{
  "artifact_type": "conference_abstract_archive",
  "created_at_utc": "2026-07-19T18:46:41+00:00",
  "source": {
    "name": "AHNS 2026 EventPilot Abstracts",
    "url": "https://eppro02.ativ.me/web/page.php?page=Media&project=AHNS26&url=urn%3Aeventpilot%3Aall%3Amedia%3Atype%3Aint%2Fhtml&title=Abstracts",
    "api_url": "https://eppro02.ativ.me/web/api.php",
    "official_meeting_url": "https://www.ahns2026.org/",
    "accessed_at_utc": "2026-07-19T16:51:27+00:00"
  },
  "meeting": {
    "name": "AHNS 12th International Conference on Head and Neck Cancer",
    "short_name": "AHNS 2026",
    "dates": "July 18-22, 2026",
    "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
    "official_url": "https://www.ahns2026.org/"
  },
  "record_count": 996,
  "source_record_count": 996,
  "extraction_summary": {
    "structured_records": 996,
    "records_with_source_images": 214,
    "source_image_count": 343,
    "presentation_types": {
      "Poster": 409,
      "Proffered Paper": 587
    },
    "topic_count": 21
  },
  "limitations": [
    "The EventPilot Abstracts section exposes full abstract HTML but no downloadable poster PDF files.",
    "Presentation type and topic are source-defined EventPilot filter fields. Each record maps to exactly one value in each field.",
    "Author and institution profiles are normalized heuristically from source HTML and should be treated as directional.",
    "Embedded figure and table images remain hosted by submitmyabstract.com and may change independently of this archive."
  ],
  "tracks": [
    {
      "name": "Reconstruction / Microvascular Surgery",
      "count": 101
    },
    {
      "name": "Oral Cavity",
      "count": 93
    },
    {
      "name": "Endocrine Surgery",
      "count": 88
    },
    {
      "name": "Oropharynx / HPV Related Disease",
      "count": 82
    },
    {
      "name": "Functional Outcomes / Quality",
      "count": 73
    },
    {
      "name": "Cancer Biology",
      "count": 69
    },
    {
      "name": "Immunotherapy / Systemic Therapy",
      "count": 68
    },
    {
      "name": "Translational Research/Science",
      "count": 54
    },
    {
      "name": "Education / Care Delivery",
      "count": 46
    },
    {
      "name": "Artificial Intelligence",
      "count": 44
    },
    {
      "name": "Salivary Gland",
      "count": 44
    },
    {
      "name": "Care Delivery Innovation",
      "count": 38
    },
    {
      "name": "Hypopharynx / Larynx",
      "count": 38
    },
    {
      "name": "Survivorship",
      "count": 35
    },
    {
      "name": "Imaging and Screening",
      "count": 30
    },
    {
      "name": "Nasopharynx / Paranasal Sinus / Skull Base",
      "count": 27
    },
    {
      "name": "Radiation / Adjuvant Treatment",
      "count": 16
    },
    {
      "name": "Skin Cancer",
      "count": 15
    },
    {
      "name": "Cancer Engineering / Technology",
      "count": 13
    },
    {
      "name": "Precision Medicine",
      "count": 13
    },
    {
      "name": "Behavioral Health",
      "count": 9
    }
  ],
  "session_types": [
    {
      "name": "Proffered Paper",
      "count": 587
    },
    {
      "name": "Poster",
      "count": 409
    }
  ],
  "author_profiles": [
    {
      "name": "Luiz P Kowalski",
      "record_count": 16,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 6
        },
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 11
        },
        {
          "name": "Poster",
          "count": 5
        }
      ],
      "abstract_uids": [
        "P136",
        "P140",
        "P259",
        "P268",
        "P432",
        "S051",
        "S069",
        "S129",
        "S228",
        "S236",
        "S358",
        "S435",
        "S451",
        "S541",
        "S542",
        "S607"
      ]
    },
    {
      "name": "Marisa R Buchakjian",
      "record_count": 15,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 11
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P333",
        "P336",
        "S076",
        "S089",
        "S116",
        "S153",
        "S154",
        "S160",
        "S285",
        "S315",
        "S413",
        "S419",
        "S492"
      ]
    },
    {
      "name": "Pratyusha Yalamanchi",
      "record_count": 15,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 5
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 11
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P333",
        "P374",
        "S076",
        "S116",
        "S153",
        "S160",
        "S244",
        "S285",
        "S288",
        "S289",
        "S413",
        "S419",
        "S430"
      ]
    },
    {
      "name": "Vishal Gupta",
      "record_count": 14,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 8
        },
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "P057",
        "P061",
        "P137",
        "P141",
        "P142",
        "P204",
        "P297",
        "P380",
        "S031",
        "S036",
        "S229",
        "S379",
        "S523",
        "S546"
      ]
    },
    {
      "name": "Kevin J Contrera",
      "record_count": 12,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 12
        }
      ],
      "abstract_uids": [
        "S015",
        "S043",
        "S089",
        "S115",
        "S155",
        "S158",
        "S178",
        "S206",
        "S268",
        "S453",
        "S479",
        "S514"
      ]
    },
    {
      "name": "Matthew E Spector",
      "record_count": 12,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 7
        },
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 11
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S015",
        "S019",
        "S115",
        "S155",
        "S158",
        "S206",
        "S302",
        "S453",
        "S479",
        "S514",
        "S555"
      ]
    },
    {
      "name": "Keith A Casper",
      "record_count": 11,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P333",
        "S076",
        "S089",
        "S116",
        "S153",
        "S160",
        "S285",
        "S413",
        "S419"
      ]
    },
    {
      "name": "Molly E Heft Neal",
      "record_count": 11,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P333",
        "P374",
        "S089",
        "S154",
        "S160",
        "S285",
        "S413",
        "S492",
        "S574"
      ]
    },
    {
      "name": "Dauren Adilbay",
      "record_count": 10,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P088",
        "P114",
        "P222",
        "P322",
        "S105",
        "S139",
        "S207",
        "S361",
        "S389",
        "S451"
      ]
    },
    {
      "name": "Mateo Useche",
      "record_count": 10,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 7
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P247",
        "P248",
        "S143",
        "S232",
        "S250",
        "S262",
        "S272",
        "S283",
        "S429",
        "S595"
      ]
    },
    {
      "name": "Nicole C Schmitt",
      "record_count": 10,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P202",
        "P207",
        "P210",
        "P429",
        "S033",
        "S273",
        "S328",
        "S378",
        "S417",
        "S592"
      ]
    },
    {
      "name": "Steven B Chinn",
      "record_count": 10,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 10
        }
      ],
      "abstract_uids": [
        "S015",
        "S089",
        "S115",
        "S153",
        "S155",
        "S158",
        "S206",
        "S453",
        "S479",
        "S514"
      ]
    },
    {
      "name": "Daniel Uralov",
      "record_count": 9,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P115",
        "P340",
        "P440",
        "S005",
        "S029",
        "S077",
        "S144",
        "S251",
        "S449"
      ]
    },
    {
      "name": "David Forner",
      "record_count": 9,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P374",
        "S089",
        "S116",
        "S134",
        "S244",
        "S413",
        "S546"
      ]
    },
    {
      "name": "David Z Allen",
      "record_count": 9,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 5
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P128",
        "S057",
        "S058",
        "S235",
        "S378",
        "S506",
        "S570",
        "S592",
        "S596"
      ]
    },
    {
      "name": "Joseph Lopez",
      "record_count": 9,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 7
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P067",
        "P076",
        "P077",
        "P079",
        "P100",
        "P390",
        "P391",
        "S049",
        "S452"
      ]
    },
    {
      "name": "Karthik Rajasekaran",
      "record_count": 9,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205",
        "S011",
        "S156",
        "S164",
        "S207",
        "S312",
        "S323",
        "S339",
        "S410"
      ]
    },
    {
      "name": "Kelly M Malloy",
      "record_count": 9,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 3
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P093",
        "P157",
        "P333",
        "P374",
        "S116",
        "S153",
        "S285",
        "S413",
        "S419"
      ]
    },
    {
      "name": "Matthew Old",
      "record_count": 9,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P200",
        "P276",
        "S085",
        "S143",
        "S195",
        "S199",
        "S214",
        "S232",
        "S595"
      ]
    },
    {
      "name": "Ryan P McSpadden",
      "record_count": 9,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 7
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P057",
        "P141",
        "P142",
        "P297",
        "P379",
        "P380",
        "P381",
        "S031",
        "S229"
      ]
    },
    {
      "name": "Theresa Guo",
      "record_count": 9,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 3
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P029",
        "P302",
        "S114",
        "S225",
        "S238",
        "S249",
        "S277",
        "S284",
        "S462"
      ]
    },
    {
      "name": "Vikas Mehta",
      "record_count": 9,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P028",
        "P176",
        "P271",
        "P442",
        "S190",
        "S217",
        "S323",
        "S348",
        "S464"
      ]
    },
    {
      "name": "William J Magner",
      "record_count": 9,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P061",
        "P137",
        "P141",
        "S031",
        "S036",
        "S229",
        "S379",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Alice Tang",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 6
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P158",
        "P220",
        "P278",
        "P332",
        "P343",
        "P366",
        "S076",
        "S191"
      ]
    },
    {
      "name": "Andrew G Shuman",
      "record_count": 8,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "S076",
        "S089",
        "S116",
        "S153",
        "S160",
        "S285"
      ]
    },
    {
      "name": "Carissa M Thomas",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P337",
        "P404",
        "P425",
        "S270",
        "S316",
        "S374",
        "S377",
        "S408"
      ]
    },
    {
      "name": "Chaz L Stucken",
      "record_count": 8,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "P374",
        "S076",
        "S160",
        "S285",
        "S413",
        "S419"
      ]
    },
    {
      "name": "Daniel G Deschler",
      "record_count": 8,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248",
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S239",
        "S401"
      ]
    },
    {
      "name": "Derrick T Lin",
      "record_count": 8,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248",
        "S032",
        "S061",
        "S065",
        "S099",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Ian Ganly",
      "record_count": 8,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P269",
        "P320",
        "S075",
        "S109",
        "S122",
        "S233",
        "S366",
        "S451"
      ]
    },
    {
      "name": "Jason Rich",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P338",
        "P351",
        "S027",
        "S303",
        "S328",
        "S383",
        "S454",
        "S473"
      ]
    },
    {
      "name": "Kimberly E Wooten",
      "record_count": 8,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 6
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P057",
        "P061",
        "P141",
        "P142",
        "P297",
        "P380",
        "S229",
        "S476"
      ]
    },
    {
      "name": "Luiz Paulo Kowalski",
      "record_count": 8,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P004",
        "P445",
        "S165",
        "S201",
        "S280",
        "S418",
        "S563",
        "S565"
      ]
    },
    {
      "name": "Lynn Sigurdson",
      "record_count": 8,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P137",
        "P142",
        "S031",
        "S036",
        "S229",
        "S379",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Neerav Goyal",
      "record_count": 8,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 4
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P111",
        "P121",
        "P201",
        "P237",
        "S052",
        "S167",
        "S185",
        "S497"
      ]
    },
    {
      "name": "Nikita Bedi",
      "record_count": 8,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 4
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P003",
        "P006",
        "P009",
        "S010",
        "S044",
        "S205",
        "S304",
        "S404"
      ]
    },
    {
      "name": "Priscilla Pichardo",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 5
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P220",
        "P278",
        "P332",
        "P343",
        "P366",
        "S024",
        "S191",
        "S258"
      ]
    },
    {
      "name": "Shaum Sridharan",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S019",
        "S020",
        "S115",
        "S302",
        "S479",
        "S514",
        "S555"
      ]
    },
    {
      "name": "Stephen Y Lai",
      "record_count": 8,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 5
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        }
      ],
      "abstract_uids": [
        "S089",
        "S169",
        "S182",
        "S242",
        "S388",
        "S579",
        "S583",
        "S597"
      ]
    },
    {
      "name": "Steven Chinn",
      "record_count": 8,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S006",
        "S019",
        "S020",
        "S124",
        "S178",
        "S302",
        "S555"
      ]
    },
    {
      "name": "Amritha Suresh",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S031",
        "S326",
        "S379",
        "S476",
        "S586",
        "S588"
      ]
    },
    {
      "name": "Brittany Barber",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S089",
        "S143",
        "S232",
        "S250",
        "S557",
        "S595"
      ]
    },
    {
      "name": "Daniel Kraft",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S274",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Daniel L Faden",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248",
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "David J Hernandez",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P174",
        "P262",
        "P389",
        "P423",
        "S133",
        "S361",
        "S524"
      ]
    },
    {
      "name": "Emily Marchiano",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S143",
        "S232",
        "S250",
        "S262",
        "S557",
        "S595"
      ]
    },
    {
      "name": "Gabriela Cendejas",
      "record_count": 7,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P067",
        "P076",
        "P077",
        "P079",
        "P390",
        "S049",
        "S452"
      ]
    },
    {
      "name": "Helena Levyn",
      "record_count": 7,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271",
        "S190",
        "S217",
        "S348",
        "S366",
        "S451",
        "S464"
      ]
    },
    {
      "name": "Jeremy D Richmon",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P069",
        "P248",
        "S032",
        "S061",
        "S065",
        "S203",
        "S401"
      ]
    },
    {
      "name": "Jose P Zevallos",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S043",
        "S115",
        "S178",
        "S268",
        "S479",
        "S514"
      ]
    },
    {
      "name": "Joseph Curry",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P201",
        "P327",
        "P337",
        "S077",
        "S144",
        "S163",
        "S251"
      ]
    },
    {
      "name": "Joshua D Smith",
      "record_count": 7,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S115",
        "S155",
        "S206",
        "S453",
        "S479",
        "S514",
        "S517"
      ]
    },
    {
      "name": "Larissa Sweeny",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P235",
        "P327",
        "P337",
        "P420",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Lori J Wirth",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S186",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Madeline Pyle",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P208",
        "P327",
        "P337",
        "P420",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Marianne Abouyared",
      "record_count": 7,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P155",
        "P274",
        "S087",
        "S172",
        "S197",
        "S425",
        "S488"
      ]
    },
    {
      "name": "Mark Wax",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 5
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P326",
        "P327",
        "P337",
        "S014",
        "S023",
        "S163",
        "S412"
      ]
    },
    {
      "name": "Neal Futran",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S143",
        "S232",
        "S250",
        "S262",
        "S557",
        "S595"
      ]
    },
    {
      "name": "Ray Y Wang",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P254",
        "P323",
        "P423",
        "S118",
        "S133",
        "S524",
        "S558"
      ]
    },
    {
      "name": "Robert M Brody",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P165",
        "P205",
        "S047",
        "S048",
        "S286",
        "S294",
        "S410"
      ]
    },
    {
      "name": "Ryan Sicard",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S180",
        "S274",
        "S432",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Sallie Long",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P014",
        "P068",
        "P337",
        "P352",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Vlad C Sandulache",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P254",
        "P423",
        "S133",
        "S182",
        "S361",
        "S519",
        "S524"
      ]
    },
    {
      "name": "William C Faquin",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S310",
        "S401"
      ]
    },
    {
      "name": "Adam S Fisch",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Allen Feng",
      "record_count": 6,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S065",
        "S203",
        "S210",
        "S305",
        "S498",
        "S527"
      ]
    },
    {
      "name": "Annie Chan",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Bayan A Alzumaili",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Caroline Bonaventure",
      "record_count": 6,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P011",
        "P327",
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Chad Zender",
      "record_count": 6,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220",
        "P278",
        "P332",
        "P343",
        "P366",
        "S191"
      ]
    },
    {
      "name": "Chirayu Patel",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Dustin Silverman",
      "record_count": 6,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220",
        "P278",
        "P332",
        "P343",
        "P366",
        "S191"
      ]
    },
    {
      "name": "Ella P Jackert",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 4
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S030",
        "S293",
        "S411",
        "S470"
      ]
    },
    {
      "name": "Eric Genden",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S180",
        "S414",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Ethan Gomez",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S180",
        "S432",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Fernando Luiz Dias",
      "record_count": 6,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P168",
        "P178",
        "P184",
        "P203",
        "S175",
        "S563"
      ]
    },
    {
      "name": "Gjystina Lumaj",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Gregory S Weinstein",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S011",
        "S047",
        "S048",
        "S164",
        "S339",
        "S410"
      ]
    },
    {
      "name": "Hlu Vang",
      "record_count": 6,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P003",
        "P006",
        "S010",
        "S044",
        "S304",
        "S404"
      ]
    },
    {
      "name": "Hosam H Alkhatib",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S250",
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Hugo F Kohler",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P259",
        "P432",
        "S129",
        "S358",
        "S435",
        "S542"
      ]
    },
    {
      "name": "Jeffrey N Myers",
      "record_count": 6,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036",
        "S137",
        "S145",
        "S279",
        "S380",
        "S519"
      ]
    },
    {
      "name": "Jin Hua Li",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P239",
        "P244",
        "P283",
        "S241",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Jonathan J Paly",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Jong C Park",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Jose G Vartanian",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P259",
        "P432",
        "S129",
        "S358",
        "S435",
        "S542"
      ]
    },
    {
      "name": "Lindsey Moses",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 4
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P373",
        "S054",
        "S076",
        "S136",
        "S257",
        "S459"
      ]
    },
    {
      "name": "Manisha J Patel",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Marita Teng",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Mark E Prince",
      "record_count": 6,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P157",
        "P333",
        "P374",
        "S153",
        "S285",
        "S419"
      ]
    },
    {
      "name": "Matthew O Old",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Merry Sebelik",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P065",
        "P429",
        "S235",
        "S378",
        "S569",
        "S570"
      ]
    },
    {
      "name": "Michael Berger",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Moni A Kuriakose",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P137",
        "S031",
        "S379",
        "S476",
        "S585",
        "S586"
      ]
    },
    {
      "name": "Nolan Seim",
      "record_count": 6,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P156",
        "P276",
        "S085",
        "S195",
        "S199",
        "S399"
      ]
    },
    {
      "name": "Peter M Sadow",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Rachel Harter",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P239",
        "P244",
        "P283",
        "S241",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Ravindra Uppaluri",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 4
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S021",
        "S025",
        "S074",
        "S148",
        "S275",
        "S305"
      ]
    },
    {
      "name": "Raymond Chai",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Ross D Merkin",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Scott Roof",
      "record_count": 6,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S180",
        "S274",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Steven B Cannady",
      "record_count": 6,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P165",
        "P205",
        "S011",
        "S294",
        "S410",
        "S412"
      ]
    },
    {
      "name": "Thomas J Roberts",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Usman Khan",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P261",
        "P286",
        "S016",
        "S323",
        "S505",
        "S546"
      ]
    },
    {
      "name": "Uttam Sinha",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 5
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S030",
        "S091",
        "S146",
        "S470"
      ]
    },
    {
      "name": "Veenadhari Kollipara",
      "record_count": 6,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 4
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P111",
        "P121",
        "P237",
        "S052",
        "S299",
        "S497"
      ]
    },
    {
      "name": "Vivian Vo",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P029",
        "S225",
        "S238",
        "S284",
        "S462",
        "S535"
      ]
    },
    {
      "name": "Zoukaa Sargi",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P026",
        "P196",
        "P214",
        "S330",
        "S397",
        "S451"
      ]
    },
    {
      "name": "Adam S Jacobson",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P301",
        "P360",
        "S481",
        "S560",
        "S571"
      ]
    },
    {
      "name": "Alexander Karabachev",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P278",
        "P332",
        "P343",
        "P366",
        "S191"
      ]
    },
    {
      "name": "Alicia Yang",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S180",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Allen L Feng",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248",
        "S032",
        "S061",
        "S239",
        "S401"
      ]
    },
    {
      "name": "Amaan Rahman",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S115",
        "S158",
        "S178",
        "S555"
      ]
    },
    {
      "name": "Amit Agrawal",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "P276",
        "S085",
        "S399"
      ]
    },
    {
      "name": "Andrew Birkeland",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403",
        "S087",
        "S172",
        "S197",
        "S488"
      ]
    },
    {
      "name": "Angela L Mazul",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S043",
        "S115",
        "S268",
        "S428"
      ]
    },
    {
      "name": "Arnaud Bewley",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274",
        "S087",
        "S172",
        "S197",
        "S488"
      ]
    },
    {
      "name": "Austin S Lam",
      "record_count": 5,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P328",
        "S062",
        "S120",
        "S264",
        "S337"
      ]
    },
    {
      "name": "Aviram Mizrachi",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P239",
        "P244",
        "P283",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Bradley A Schiff",
      "record_count": 5,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P176",
        "P442",
        "S190",
        "S348",
        "S390"
      ]
    },
    {
      "name": "Brittany R Barber",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225",
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Bruno P Duarte, Mr",
      "record_count": 5,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S292",
        "S418",
        "S563",
        "S565"
      ]
    },
    {
      "name": "Celeste Kim",
      "record_count": 5,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P065",
        "P429",
        "S248",
        "S328",
        "S569"
      ]
    },
    {
      "name": "Christine R Burton",
      "record_count": 5,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P057",
        "P141",
        "P297",
        "S229",
        "S586"
      ]
    },
    {
      "name": "Christopher Rassekh",
      "record_count": 5,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127",
        "P412",
        "S095",
        "S112"
      ]
    },
    {
      "name": "Dev Amin",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P327",
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Devraj Basu",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S011",
        "S047",
        "S048",
        "S164",
        "S312"
      ]
    },
    {
      "name": "Eitan Prisman",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S382",
        "S477",
        "S482",
        "S483",
        "S484"
      ]
    },
    {
      "name": "Enver Ozer",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "P276",
        "S085",
        "S399"
      ]
    },
    {
      "name": "Farshid Taghizadeh",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P327",
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Grayson Buning",
      "record_count": 5,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "S160",
        "S492",
        "S546"
      ]
    },
    {
      "name": "Ilya Likhterov",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141",
        "S332"
      ]
    },
    {
      "name": "Jacob Beiriger",
      "record_count": 5,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S226",
        "S259",
        "S450"
      ]
    },
    {
      "name": "Jamie P Levine",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P359",
        "P360",
        "P371",
        "S560",
        "S571"
      ]
    },
    {
      "name": "Jason Leibowitz",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P327",
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Jennifer H Gross",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P202",
        "P210",
        "S033",
        "S328",
        "S417"
      ]
    },
    {
      "name": "Jeremy Richmon",
      "record_count": 5,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S207",
        "S210",
        "S305",
        "S498",
        "S527"
      ]
    },
    {
      "name": "Joanna George",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P310",
        "S084",
        "S308",
        "S434",
        "S438"
      ]
    },
    {
      "name": "Katie M Carlson",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S043",
        "S115",
        "S268",
        "S428"
      ]
    },
    {
      "name": "Kevin Contrera",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S019",
        "S020",
        "S302",
        "S555"
      ]
    },
    {
      "name": "Krzysztof Misiukiewicz",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522"
      ]
    },
    {
      "name": "Kunal A Koka",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 4
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P111",
        "P121",
        "P237",
        "S052",
        "S497"
      ]
    },
    {
      "name": "Kunal Sindhu",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522"
      ]
    },
    {
      "name": "Kyle VanKoevering",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "S195",
        "S199",
        "S399"
      ]
    },
    {
      "name": "Lauren E Miller",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "S134",
        "S195",
        "S199"
      ]
    },
    {
      "name": "Lauren Shih",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S232",
        "S262",
        "S272",
        "S283"
      ]
    },
    {
      "name": "Linda X Yin",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S039",
        "S089",
        "S101",
        "S117",
        "S525"
      ]
    },
    {
      "name": "Luiz Kowalski",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P059",
        "P108",
        "P109",
        "P150",
        "S001"
      ]
    },
    {
      "name": "Lurdes Queimado",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P037",
        "P042",
        "P243",
        "S434",
        "S438"
      ]
    },
    {
      "name": "Maaike van Gerwen",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P032",
        "P051",
        "P104",
        "S056",
        "S432"
      ]
    },
    {
      "name": "Mary Jue Xu",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P072",
        "S040",
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Melina Windon",
      "record_count": 5,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S076",
        "S304",
        "S431",
        "S461",
        "S532"
      ]
    },
    {
      "name": "Merry Sebelik, MAMSE",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P128",
        "S058",
        "S248",
        "S506",
        "S596"
      ]
    },
    {
      "name": "Michael Li",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S087",
        "S172",
        "S197",
        "S425",
        "S488"
      ]
    },
    {
      "name": "Michelle M Chen, MHS",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053",
        "S174",
        "S301",
        "S404"
      ]
    },
    {
      "name": "Muhammad El Shatanofy",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P196",
        "P214",
        "P235",
        "S330",
        "S397"
      ]
    },
    {
      "name": "Nidal Muhanna",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362",
        "S103",
        "S331",
        "S354",
        "S554"
      ]
    },
    {
      "name": "Patrick K Ha",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141",
        "S472"
      ]
    },
    {
      "name": "Patrik Pipkorn",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S027",
        "S303",
        "S383",
        "S417",
        "S473"
      ]
    },
    {
      "name": "Peter Cooke",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S180",
        "S490",
        "S495",
        "S522",
        "S530"
      ]
    },
    {
      "name": "Richard Bakst",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S495",
        "S522"
      ]
    },
    {
      "name": "Richard V Smith",
      "record_count": 5,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P375",
        "P442",
        "S190",
        "S348",
        "S464"
      ]
    },
    {
      "name": "Richard Wong",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P269",
        "P320",
        "S349",
        "S351",
        "S366"
      ]
    },
    {
      "name": "Rocco Ferrandino",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S143",
        "S250",
        "S262",
        "S283"
      ]
    },
    {
      "name": "Rogério Aparecido Dedivitis",
      "record_count": 5,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S292",
        "S418",
        "S563",
        "S565"
      ]
    },
    {
      "name": "Sarah Drejet",
      "record_count": 5,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S226",
        "S259",
        "S450"
      ]
    },
    {
      "name": "Sarah Harrington",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P115",
        "S029",
        "S077",
        "S144",
        "S449"
      ]
    },
    {
      "name": "Seungwon Kim",
      "record_count": 5,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S020",
        "S115",
        "S176",
        "S178",
        "S479"
      ]
    },
    {
      "name": "Shriya Shukla",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210"
      ]
    },
    {
      "name": "Snehal Patel",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P269",
        "S075",
        "S122",
        "S345",
        "S451"
      ]
    },
    {
      "name": "Stephen Kang",
      "record_count": 5,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085",
        "S195",
        "S199",
        "S399"
      ]
    },
    {
      "name": "Terry Day",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P261",
        "P286",
        "S016",
        "S323",
        "S505"
      ]
    },
    {
      "name": "Tomoko Yamazaki",
      "record_count": 5,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227",
        "P232",
        "P264",
        "P298",
        "S111"
      ]
    },
    {
      "name": "Trevor G Hackman",
      "record_count": 5,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P073",
        "S098",
        "S256",
        "S362",
        "S507"
      ]
    },
    {
      "name": "Udeerna Tippabhatla",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P239",
        "P244",
        "P283",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Vivienne Au",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 5
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P239",
        "P244",
        "P283",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Aayush Unadkat",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P336",
        "P374",
        "S116",
        "S160"
      ]
    },
    {
      "name": "Abhinav Talwar",
      "record_count": 4,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418",
        "S194"
      ]
    },
    {
      "name": "Adam Luginbuhl",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S029",
        "S077",
        "S212",
        "S449"
      ]
    },
    {
      "name": "Ahmad Abubaker",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S182",
        "S388",
        "S579",
        "S597"
      ]
    },
    {
      "name": "Albert Y Han",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 3
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S293",
        "S470"
      ]
    },
    {
      "name": "Alberto Paderno",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002",
        "P003",
        "P006",
        "S010"
      ]
    },
    {
      "name": "Alessandra Ruaro",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S183",
        "S486",
        "S582"
      ]
    },
    {
      "name": "Alex F Porsani",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "Alexandra Kejner",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P267",
        "P342",
        "S018",
        "S157"
      ]
    },
    {
      "name": "Allen Khudaverdyan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S054",
        "S136",
        "S257",
        "S459"
      ]
    },
    {
      "name": "Anastasios Maniakas",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S094",
        "S231",
        "S388",
        "S597"
      ]
    },
    {
      "name": "Andreja Radevic",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S390",
        "S391",
        "S562",
        "S606"
      ]
    },
    {
      "name": "Andrew Prince",
      "record_count": 4,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P093",
        "P373",
        "S160",
        "S571"
      ]
    },
    {
      "name": "Andrey Finegersh",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221",
        "S026",
        "S174",
        "S301"
      ]
    },
    {
      "name": "Annie E Arrighi-Allisan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S286",
        "S339",
        "S410",
        "S412"
      ]
    },
    {
      "name": "Anthony Morlandt",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282",
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Anton Warshavsky",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362",
        "S103",
        "S331",
        "S354"
      ]
    },
    {
      "name": "Anurag K Singh",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P061",
        "P137",
        "P142",
        "P297"
      ]
    },
    {
      "name": "Ara A Chalian",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P119",
        "P165",
        "S011",
        "S410"
      ]
    },
    {
      "name": "Azeem S Kaka",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P202",
        "P210",
        "S033",
        "S417"
      ]
    },
    {
      "name": "Brian J Boyce",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P202",
        "P210",
        "S033",
        "S417"
      ]
    },
    {
      "name": "Brian Reisenberg",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P261",
        "P286",
        "S016",
        "S505"
      ]
    },
    {
      "name": "Catherine Haring",
      "record_count": 4,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085",
        "S195",
        "S399"
      ]
    },
    {
      "name": "Chase M Heaton",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Christine Peterson",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S220",
        "S240"
      ]
    },
    {
      "name": "Clifton Fuller",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S220",
        "S240"
      ]
    },
    {
      "name": "Cristina P Rodriguez",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Daniel Kwon",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S030",
        "S470"
      ]
    },
    {
      "name": "David Goldenberg",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 3
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P111",
        "P121",
        "S167",
        "S497"
      ]
    },
    {
      "name": "David Neskey",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P286",
        "S016",
        "S323",
        "S505"
      ]
    },
    {
      "name": "David W Forner",
      "record_count": 4,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P333",
        "S153",
        "S285",
        "S419"
      ]
    },
    {
      "name": "Dipon Das",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S203",
        "S401"
      ]
    },
    {
      "name": "Dustin Conrad",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P309",
        "P328",
        "S062",
        "S264"
      ]
    },
    {
      "name": "Eben Rosenthal",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P437",
        "S188",
        "S223",
        "S573"
      ]
    },
    {
      "name": "Edgar D Uribe Sanchez",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P045",
        "P355",
        "S062",
        "S337"
      ]
    },
    {
      "name": "Eduardo Calheiros de Moraes",
      "record_count": 4,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168",
        "P184",
        "P203",
        "S175"
      ]
    },
    {
      "name": "Eitan Prisman, MA, FRCSC",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P363",
        "S013",
        "S368",
        "S381"
      ]
    },
    {
      "name": "Elisabet Pujadas",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S490",
        "S522"
      ]
    },
    {
      "name": "Elise Krippaehne",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Eloa B Oliveira Andrade",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "Emma De Ravin",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P115",
        "P340",
        "S077",
        "S212"
      ]
    },
    {
      "name": "Emma Dunn",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P289",
        "S090",
        "S510",
        "S552"
      ]
    },
    {
      "name": "Emma Finnegan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S109",
        "S122",
        "S233",
        "S366"
      ]
    },
    {
      "name": "Eric Sokhn",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P196",
        "P214",
        "S330",
        "S397"
      ]
    },
    {
      "name": "Eun-Jae Chung",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P263",
        "P413",
        "S357",
        "S416"
      ]
    },
    {
      "name": "Evan M Graboyes",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P088",
        "P222",
        "S361",
        "S389"
      ]
    },
    {
      "name": "Fahad Rind",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P200",
        "P255",
        "P256",
        "P424"
      ]
    },
    {
      "name": "Frank Ondrey",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P031",
        "P047",
        "P265",
        "P439"
      ]
    },
    {
      "name": "Gilad Horowitz",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362",
        "S103",
        "S331",
        "S354"
      ]
    },
    {
      "name": "Harishanker Jeyarajan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P148",
        "P177",
        "P182",
        "S340"
      ]
    },
    {
      "name": "Ivan H El-Sayed",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "James Rocco",
      "record_count": 4,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085",
        "S195",
        "S399"
      ]
    },
    {
      "name": "James W Rocco",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "S073",
        "S199"
      ]
    },
    {
      "name": "Jamie JY Kwon",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P363",
        "S368",
        "S381",
        "S382"
      ]
    },
    {
      "name": "Jason G Newman",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P088",
        "P222",
        "S361",
        "S389"
      ]
    },
    {
      "name": "Jason Tasoulas",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "S077",
        "S098",
        "S144"
      ]
    },
    {
      "name": "Javier Nishikawa",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P327",
        "P337",
        "S023",
        "S163"
      ]
    },
    {
      "name": "Jeffrey Houlton",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261",
        "S016",
        "S323",
        "S505"
      ]
    },
    {
      "name": "Jenny Romero",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P061",
        "P141",
        "S031",
        "S476"
      ]
    },
    {
      "name": "Jessica H Maxwell",
      "record_count": 4,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S115",
        "S178",
        "S206",
        "S514"
      ]
    },
    {
      "name": "Jessica Maxwell",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S020",
        "S155",
        "S453",
        "S479"
      ]
    },
    {
      "name": "Joao Goncalves Filho",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P136",
        "P140",
        "P268",
        "S051"
      ]
    },
    {
      "name": "Joaquin Austerlitz",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S390",
        "S391",
        "S562",
        "S606"
      ]
    },
    {
      "name": "Jobran Mansour",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P349",
        "P362",
        "S543",
        "S554"
      ]
    },
    {
      "name": "John B Sunwoo",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221",
        "S064",
        "S375",
        "S455"
      ]
    },
    {
      "name": "Jonathan Irish",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152",
        "S134",
        "S183",
        "S394"
      ]
    },
    {
      "name": "Jonathan R George",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Jose Zevallos",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S020",
        "S027",
        "S176",
        "S517"
      ]
    },
    {
      "name": "Joseph M Curry",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440",
        "S207",
        "S212",
        "S408"
      ]
    },
    {
      "name": "Joshua E Smith",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S015",
        "S158",
        "S302",
        "S555"
      ]
    },
    {
      "name": "Joshua Smith",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S019",
        "S020",
        "S178"
      ]
    },
    {
      "name": "Julia O Parenti",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "Justin M Hintze",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P103",
        "P269",
        "S050",
        "S349"
      ]
    },
    {
      "name": "Katherine C Wai",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S040",
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Keith Richardson",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S121",
        "S213",
        "S252",
        "S271"
      ]
    },
    {
      "name": "Kendall K Tasche",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S039",
        "S071",
        "S101",
        "S525"
      ]
    },
    {
      "name": "Kevin J Kovatch",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "P155",
        "P409",
        "S346"
      ]
    },
    {
      "name": "Kim B Le",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S011",
        "S164",
        "S468",
        "S577"
      ]
    },
    {
      "name": "Kyle Polen",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S011",
        "S294",
        "S468",
        "S577"
      ]
    },
    {
      "name": "Larkin Harris",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S226",
        "S259"
      ]
    },
    {
      "name": "Leandro L Matos",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S069",
        "S165",
        "S236",
        "S541"
      ]
    },
    {
      "name": "Liyang Tang",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S030",
        "S470"
      ]
    },
    {
      "name": "Louis-Xavier Barrette",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P161",
        "S047",
        "S048",
        "S156"
      ]
    },
    {
      "name": "Luc Morris",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S050",
        "S157",
        "S349",
        "S351"
      ]
    },
    {
      "name": "Madeline Otto",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Maria Beatriz Orru",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "Mario Augusto F Castro",
      "record_count": 4,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S418",
        "S563",
        "S565"
      ]
    },
    {
      "name": "Mark Varvares",
      "record_count": 4,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P398",
        "S239",
        "S266",
        "S498"
      ]
    },
    {
      "name": "Mathilda Monaghan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P032",
        "P051",
        "P104",
        "S056"
      ]
    },
    {
      "name": "Matthew Mifsud",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S090",
        "S510",
        "S552"
      ]
    },
    {
      "name": "Matthew Spector",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S020",
        "S124",
        "S176",
        "S178"
      ]
    },
    {
      "name": "Micah K Harris",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S155",
        "S178",
        "S206",
        "S453"
      ]
    },
    {
      "name": "Michael C Topf, MSCI",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P075",
        "S391",
        "S437",
        "S562"
      ]
    },
    {
      "name": "Michael DiLeo",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P327",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Morgan Terry",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P326",
        "P337",
        "P401",
        "S023"
      ]
    },
    {
      "name": "Nader Sadeghi",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S121",
        "S252",
        "S271",
        "S396"
      ]
    },
    {
      "name": "Nathalia M Nogueira",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "Nicolaus Knight",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P327",
        "P337",
        "S023",
        "S163"
      ]
    },
    {
      "name": "Niels Kokot",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 3
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S411",
        "S470"
      ]
    },
    {
      "name": "Paul Zolkind",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S027",
        "S303",
        "S383",
        "S473"
      ]
    },
    {
      "name": "Peter S Han",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S359",
        "S439",
        "S512",
        "S605"
      ]
    },
    {
      "name": "Peter T Dziegielewski",
      "record_count": 4,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P355",
        "S062",
        "S120",
        "S337"
      ]
    },
    {
      "name": "Qin Wang",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S203",
        "S401"
      ]
    },
    {
      "name": "Quintin Pan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S276",
        "S422",
        "S578",
        "S580"
      ]
    },
    {
      "name": "Ryan Jackson",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182",
        "S027",
        "S037",
        "S383"
      ]
    },
    {
      "name": "Ryan M Carey",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205",
        "S164",
        "S468",
        "S577"
      ]
    },
    {
      "name": "Samantha Tam",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P428",
        "P430",
        "S433",
        "S587"
      ]
    },
    {
      "name": "Samuli Eldfors",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S203",
        "S401"
      ]
    },
    {
      "name": "Sara Friedman",
      "record_count": 4,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S190",
        "S348",
        "S390",
        "S464"
      ]
    },
    {
      "name": "Scharukh Jalisi",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S128",
        "S456",
        "S589",
        "S590"
      ]
    },
    {
      "name": "Scott A Roof",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217",
        "S104",
        "S216",
        "S432"
      ]
    },
    {
      "name": "Seo Young Kim",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P263",
        "P413",
        "S357",
        "S416"
      ]
    },
    {
      "name": "Sergio A Segrera",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P359",
        "P360",
        "P371",
        "S560"
      ]
    },
    {
      "name": "Shu-Yun Cheng",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P035",
        "P053",
        "S030",
        "S470"
      ]
    },
    {
      "name": "Sidharth V Puram",
      "record_count": 4,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S099",
        "S303",
        "S361",
        "S473"
      ]
    },
    {
      "name": "Soumil Prasad",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P196",
        "P214",
        "S330",
        "S397"
      ]
    },
    {
      "name": "Srivatsa Surya Vasudevan",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434",
        "S007",
        "S102",
        "S469"
      ]
    },
    {
      "name": "Sruti Tekumalla",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Stephen Lai",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S220",
        "S240"
      ]
    },
    {
      "name": "Taylor L Jamil",
      "record_count": 4,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P404",
        "P425",
        "S270",
        "S377"
      ]
    },
    {
      "name": "Thomas Hendriks, MBBS, MPhil, FRACS",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414",
        "S016",
        "S323",
        "S505"
      ]
    },
    {
      "name": "Umamaheswar Duvvuri",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301",
        "S136",
        "S257",
        "S459"
      ]
    },
    {
      "name": "Wesley L Hicks Jr",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P057",
        "P061",
        "P141",
        "S476"
      ]
    },
    {
      "name": "Yang Liu",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204",
        "S360"
      ]
    },
    {
      "name": "Yasaman Baghshomali",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Yedeh Ying",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282",
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Zain H Rizvi",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Abdullah Adil",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S089",
        "S116",
        "S430"
      ]
    },
    {
      "name": "Abdurrahman Abdurrob",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P369",
        "S433",
        "S587"
      ]
    },
    {
      "name": "Adam J Luginbuhl",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "P440",
        "S005"
      ]
    },
    {
      "name": "Adam Jacobson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P359",
        "P371",
        "P373"
      ]
    },
    {
      "name": "Akihisa Wada",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P183",
        "P227",
        "P368"
      ]
    },
    {
      "name": "Alain P Algazi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S040",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Alex Mlynarek",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S121",
        "S252",
        "S396"
      ]
    },
    {
      "name": "Alex V Vaicius",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P379",
        "P380",
        "P381"
      ]
    },
    {
      "name": "Alex Vaicius",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P061",
        "P141",
        "S523"
      ]
    },
    {
      "name": "Alexa Kacin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S128",
        "S456",
        "S589"
      ]
    },
    {
      "name": "Alexandra E Hunter",
      "record_count": 3,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S192",
        "S251"
      ]
    },
    {
      "name": "Alexandre Bezerra dos Santos",
      "record_count": 3,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S201",
        "S280"
      ]
    },
    {
      "name": "Alexis Gursky",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P359",
        "P371",
        "S481"
      ]
    },
    {
      "name": "Alice C Yu",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S360",
        "S458",
        "S466"
      ]
    },
    {
      "name": "Alice Lin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P129",
        "P238",
        "S487"
      ]
    },
    {
      "name": "Alisa Vidwans, ScM",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S090",
        "S510",
        "S552"
      ]
    },
    {
      "name": "Anandhini Narayanan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P359",
        "P371",
        "S560"
      ]
    },
    {
      "name": "Andres Bur",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274",
        "S266",
        "S412"
      ]
    },
    {
      "name": "Andrew Day",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S193",
        "S328",
        "S508"
      ]
    },
    {
      "name": "Andrew Fuson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P177",
        "S340",
        "S374"
      ]
    },
    {
      "name": "Angeline A Truong",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S113",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Anna Lee",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S168",
        "S169",
        "S173"
      ]
    },
    {
      "name": "Anthony M Sheyn",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Apostolos Christopoulos",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Ashley C Mays",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P116",
        "P117",
        "S406"
      ]
    },
    {
      "name": "Azita Khorsandi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S522"
      ]
    },
    {
      "name": "Benjamin Greene",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Beverly J Fu, MA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053",
        "S064"
      ]
    },
    {
      "name": "Bradley Schiff",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271",
        "S217",
        "S464"
      ]
    },
    {
      "name": "Brianna Brammer",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207",
        "S033",
        "S273"
      ]
    },
    {
      "name": "C T Allen",
      "record_count": 3,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S281",
        "S282",
        "S475"
      ]
    },
    {
      "name": "Carissa Thomas",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P327",
        "S023",
        "S163"
      ]
    },
    {
      "name": "Carlos L Nava",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P214",
        "S330",
        "S397"
      ]
    },
    {
      "name": "Carly Barbon",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S240"
      ]
    },
    {
      "name": "Carole Fakhry",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S287",
        "S321",
        "S383"
      ]
    },
    {
      "name": "Carolyn J Khoury",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182",
        "P217",
        "S216"
      ]
    },
    {
      "name": "Catherine Po Ling Chan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P003",
        "P187",
        "S384"
      ]
    },
    {
      "name": "Catherine T Haring",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P255",
        "P256",
        "S199"
      ]
    },
    {
      "name": "Chad A Zender",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144",
        "S024",
        "S258"
      ]
    },
    {
      "name": "Chad Brenner",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S076",
        "S154",
        "S574"
      ]
    },
    {
      "name": "Changming An",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Chareeni Kurukulasuriya",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P373",
        "S481",
        "S571"
      ]
    },
    {
      "name": "Chelsey A Witsberger",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P336",
        "S116",
        "S574"
      ]
    },
    {
      "name": "Cherie-Ann O Nathan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P170",
        "P241",
        "S469"
      ]
    },
    {
      "name": "Christie Hung",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S054",
        "S136",
        "S459"
      ]
    },
    {
      "name": "Christina Tsien",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S252",
        "S254",
        "S271"
      ]
    },
    {
      "name": "Christopher A Puchi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Cristina Rodriguez",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S143",
        "S232"
      ]
    },
    {
      "name": "D. Alexander Cronkite",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "S005",
        "S449"
      ]
    },
    {
      "name": "Daniel C Chelius",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Daniel I Kwon",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S436",
        "S521",
        "S602"
      ]
    },
    {
      "name": "Daniel L Price",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S101",
        "S525"
      ]
    },
    {
      "name": "Dante Merlino",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S011",
        "S164",
        "S410"
      ]
    },
    {
      "name": "David Cognetti",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S077",
        "S144",
        "S157"
      ]
    },
    {
      "name": "David Gorelov",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P332",
        "P343",
        "P366"
      ]
    },
    {
      "name": "David J Fei-Zhang",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "David M Routman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S101",
        "S525"
      ]
    },
    {
      "name": "David Routman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S045",
        "S079",
        "S314"
      ]
    },
    {
      "name": "Derin Caglar",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S121",
        "S252",
        "S271"
      ]
    },
    {
      "name": "Diana Bell",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S006",
        "S157",
        "S184"
      ]
    },
    {
      "name": "Diana Kirke",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201",
        "S180",
        "S522"
      ]
    },
    {
      "name": "Dustin A Silverman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144",
        "S024",
        "S258"
      ]
    },
    {
      "name": "Dustin J Conrad",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P355",
        "S120",
        "S337"
      ]
    },
    {
      "name": "Edith Filion",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S038",
        "S211"
      ]
    },
    {
      "name": "Eitan Prisman, FRCSC",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S017",
        "S162",
        "S478"
      ]
    },
    {
      "name": "Eleni M Rettig",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S021",
        "S395",
        "S494"
      ]
    },
    {
      "name": "Elizabeth Franzmann",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P063",
        "P305",
        "S493"
      ]
    },
    {
      "name": "Emre Vural",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S342",
        "S460",
        "S549"
      ]
    },
    {
      "name": "Eric Bissada",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Eric J Moore",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S117",
        "S525"
      ]
    },
    {
      "name": "Eric Lentsch",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P286",
        "S016",
        "S505"
      ]
    },
    {
      "name": "Eric Mastrolonardo",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340",
        "S077",
        "S212"
      ]
    },
    {
      "name": "Erin Kaye",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P026",
        "P208",
        "P235"
      ]
    },
    {
      "name": "Evan Graboyes",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S087",
        "S303",
        "S539"
      ]
    },
    {
      "name": "Eyal Yosefof",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S364",
        "S463"
      ]
    },
    {
      "name": "Franco Novelli",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P136",
        "P140",
        "S051"
      ]
    },
    {
      "name": "Georges Daoud",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P128",
        "S248",
        "S378"
      ]
    },
    {
      "name": "Giuseppe Facchi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002",
        "P003",
        "S010"
      ]
    },
    {
      "name": "Greg Krempl",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P310",
        "S038",
        "S084"
      ]
    },
    {
      "name": "Guillermo Flores",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S154",
        "S315",
        "S574"
      ]
    },
    {
      "name": "Hadar Gez Reder",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S109",
        "S122",
        "S233"
      ]
    },
    {
      "name": "Hailey Wyatt",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P359",
        "P371",
        "S481"
      ]
    },
    {
      "name": "Han Li",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Hannah Kenny",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440",
        "S077",
        "S212"
      ]
    },
    {
      "name": "Hengyan Zhu",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S369",
        "S371",
        "S376"
      ]
    },
    {
      "name": "Henry Diamond-Pott",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P051",
        "P104",
        "S056"
      ]
    },
    {
      "name": "Hilary McCrary",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S450"
      ]
    },
    {
      "name": "Hirohisa Iwaki",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Holly R Harris, ScD",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S429"
      ]
    },
    {
      "name": "Houda Bahig",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Imani Agard",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P332",
        "P343",
        "P366"
      ]
    },
    {
      "name": "Jacob W Rosenthal",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S057",
        "S506",
        "S592"
      ]
    },
    {
      "name": "Jamie Ku",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P433",
        "S089",
        "S147"
      ]
    },
    {
      "name": "Jarrod W Stein",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S065",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Jason Chan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S002",
        "S371",
        "S373"
      ]
    },
    {
      "name": "Jason Hunt",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S450"
      ]
    },
    {
      "name": "Jayden R Garcia",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "S160"
      ]
    },
    {
      "name": "Jeffrey C Rastatter",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Jennifer M Johnson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "S108",
        "S212"
      ]
    },
    {
      "name": "Jerome N Nashed",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S120",
        "S264",
        "S337"
      ]
    },
    {
      "name": "Jessica Wilson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S079",
        "S101"
      ]
    },
    {
      "name": "Jill N D'Souza",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Jingwei Luo",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Joel A Sercarz",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S359",
        "S439",
        "S512"
      ]
    },
    {
      "name": "John Cramer",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S060",
        "S457",
        "S608"
      ]
    },
    {
      "name": "John R de Almeida",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S134",
        "S157",
        "S318"
      ]
    },
    {
      "name": "Jonas T Johnson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S176",
        "S198",
        "S428"
      ]
    },
    {
      "name": "Jonathan Giurintano",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123",
        "P299",
        "S177"
      ]
    },
    {
      "name": "Jonathan M Hughes",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361",
        "S539"
      ]
    },
    {
      "name": "Jorge Gutierrez",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Joseph Paydarfar",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060",
        "S149",
        "S218"
      ]
    },
    {
      "name": "Joshua Hornig",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P286",
        "S016",
        "S505"
      ]
    },
    {
      "name": "Juhi J Patel",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Jumin Sunde",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S342",
        "S460",
        "S549"
      ]
    },
    {
      "name": "Justin R Shinn",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064",
        "S170",
        "S511"
      ]
    },
    {
      "name": "Justina R Varghese",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056",
        "P307",
        "S499"
      ]
    },
    {
      "name": "Katherine A Hutcheson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S169",
        "S242"
      ]
    },
    {
      "name": "Katherine Hutcheson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S168",
        "S240",
        "S427"
      ]
    },
    {
      "name": "Kathryn M Van Abel",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S101",
        "S525"
      ]
    },
    {
      "name": "Keith Casper",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374",
        "S244",
        "S492"
      ]
    },
    {
      "name": "Keith L Kirkwood",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S031",
        "S379",
        "S476"
      ]
    },
    {
      "name": "Kerol Faltas",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S011",
        "S164",
        "S294"
      ]
    },
    {
      "name": "Khashayar Esfahani",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S252",
        "S254",
        "S271"
      ]
    },
    {
      "name": "Kian Tartibi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P067",
        "P076",
        "S452"
      ]
    },
    {
      "name": "Kimya Manouchehri",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P080",
        "P164",
        "S536"
      ]
    },
    {
      "name": "Kirk Withrow",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Kirollos E Armosh",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P328",
        "S120",
        "S264"
      ]
    },
    {
      "name": "Kunal Jain",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P122",
        "S086",
        "S378"
      ]
    },
    {
      "name": "Laura Chen",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P072",
        "P090",
        "S187"
      ]
    },
    {
      "name": "Lauran K Evans",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S360",
        "S568",
        "S605"
      ]
    },
    {
      "name": "Lauren Miller",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085",
        "S399"
      ]
    },
    {
      "name": "Leandro L de Matos",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S292",
        "S563"
      ]
    },
    {
      "name": "Lin Gui",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Lisa Orloff",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P134",
        "P187",
        "S384"
      ]
    },
    {
      "name": "Louis Guertin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Luis E Cortina",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S250",
        "S262",
        "S272"
      ]
    },
    {
      "name": "Luiza Seganfredo Mainardi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168",
        "P184",
        "S175"
      ]
    },
    {
      "name": "Luke Buchmann",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S450"
      ]
    },
    {
      "name": "Mabel Kahil, CST",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S270",
        "S374",
        "S377"
      ]
    },
    {
      "name": "Maie A St",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S360",
        "S458",
        "S466"
      ]
    },
    {
      "name": "Makoto Tahara",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227",
        "S108",
        "S524"
      ]
    },
    {
      "name": "Marci L Nilsen",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S176",
        "S198",
        "S422"
      ]
    },
    {
      "name": "Marco Mascarella",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S121",
        "S213",
        "S396"
      ]
    },
    {
      "name": "Marcus M Monroe",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419",
        "S226",
        "S259"
      ]
    },
    {
      "name": "Marcus Monroe",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S450"
      ]
    },
    {
      "name": "Margaret Brandwein",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S522"
      ]
    },
    {
      "name": "Maria Polania-Sandoval",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P076",
        "P077",
        "S452"
      ]
    },
    {
      "name": "Marisa Buchakjian",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374",
        "S244",
        "S574"
      ]
    },
    {
      "name": "Mark Prince",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P093",
        "S116",
        "S244"
      ]
    },
    {
      "name": "Mark S Burke",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094",
        "P421",
        "S529"
      ]
    },
    {
      "name": "Marta M Williams",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P031",
        "P135",
        "P246"
      ]
    },
    {
      "name": "Maryanna S Owoc",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S268",
        "S428"
      ]
    },
    {
      "name": "Matheus Buissa",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P059",
        "P108",
        "P109"
      ]
    },
    {
      "name": "Matthew E Lin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S439",
        "S568",
        "S605"
      ]
    },
    {
      "name": "Maxwell Kligerman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S058",
        "S235",
        "S569"
      ]
    },
    {
      "name": "Michael Bobian",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "P222",
        "S361"
      ]
    },
    {
      "name": "Michael Pozin, MSE",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S049",
        "S413",
        "S430"
      ]
    },
    {
      "name": "Michael Singer",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P112",
        "P113",
        "S207"
      ]
    },
    {
      "name": "Michelle Mierzwa",
      "record_count": 3,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S038",
        "S492",
        "S524"
      ]
    },
    {
      "name": "Mirabelle Sajisevi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S157",
        "S189",
        "S347"
      ]
    },
    {
      "name": "Miriam N Lango",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S089",
        "S157",
        "S231"
      ]
    },
    {
      "name": "Mishek Thapa",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S359",
        "S439",
        "S512"
      ]
    },
    {
      "name": "Mitsuhiko Nakahira",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Mobeen Rahman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234",
        "S205",
        "S455"
      ]
    },
    {
      "name": "Nabil F Saba, FACP",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210",
        "S328",
        "S443"
      ]
    },
    {
      "name": "Nadia Hua",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P363",
        "S382",
        "S482"
      ]
    },
    {
      "name": "Nancy Lee",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S075",
        "S122",
        "S366"
      ]
    },
    {
      "name": "Naoki Nishio",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P183",
        "P227",
        "P368"
      ]
    },
    {
      "name": "Natalia Issaeva",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S098",
        "S144",
        "S327"
      ]
    },
    {
      "name": "Nathaniel Bouganim",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S252",
        "S254",
        "S271"
      ]
    },
    {
      "name": "Nazineen Kandahari",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019",
        "S256",
        "S507"
      ]
    },
    {
      "name": "Neal D Futran",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Neil Gildener-Leapman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292",
        "S189",
        "S531"
      ]
    },
    {
      "name": "Nicolaus D Knight",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P177",
        "S374",
        "S408"
      ]
    },
    {
      "name": "Nicole Farber",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P165",
        "S164",
        "S488"
      ]
    },
    {
      "name": "Nicole Scheff",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S006",
        "S176"
      ]
    },
    {
      "name": "Nir Tsur",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120",
        "S088",
        "S526"
      ]
    },
    {
      "name": "Nitin Pagedar",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S237",
        "S353",
        "S601"
      ]
    },
    {
      "name": "Noe Francois-Saint-Cyr",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "S160"
      ]
    },
    {
      "name": "Nofar Edri",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120",
        "S364",
        "S463"
      ]
    },
    {
      "name": "Oluwatobiloba Ayo-Ajibola",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S436",
        "S602",
        "S605"
      ]
    },
    {
      "name": "Paul Tabet",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Peter Dziegielewski",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309",
        "P328",
        "S264"
      ]
    },
    {
      "name": "Peter Horwich",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261",
        "S323",
        "S505"
      ]
    },
    {
      "name": "Peter Vo",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213",
        "S277",
        "S462"
      ]
    },
    {
      "name": "Peter W Kahng",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202",
        "P210",
        "S033"
      ]
    },
    {
      "name": "Po Ling Chan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006",
        "P009",
        "S404"
      ]
    },
    {
      "name": "Qindong Cai",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Rachel Berglas",
      "record_count": 3,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271",
        "S190",
        "S348"
      ]
    },
    {
      "name": "Rahul Patel",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292",
        "P403",
        "S221"
      ]
    },
    {
      "name": "Ramez Philips",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440",
        "S005",
        "S077"
      ]
    },
    {
      "name": "Ranee Mehra",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S157",
        "S534"
      ]
    },
    {
      "name": "Ratna Veeramachaneni",
      "record_count": 3,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260",
        "S137",
        "S279"
      ]
    },
    {
      "name": "Rex H Lee",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S040",
        "S131",
        "S141"
      ]
    },
    {
      "name": "Richard Cannon",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S083",
        "S093",
        "S450"
      ]
    },
    {
      "name": "Richard J Wong",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S075",
        "S110",
        "S215"
      ]
    },
    {
      "name": "Robert Brody",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S011",
        "S164",
        "S312"
      ]
    },
    {
      "name": "Robert Wang",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046",
        "P403",
        "S221"
      ]
    },
    {
      "name": "Rocco Ferrandino, MSCR",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S232",
        "S557",
        "S595"
      ]
    },
    {
      "name": "Rohan Birk, BASc",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S013",
        "S477",
        "S483"
      ]
    },
    {
      "name": "Ron J Karni",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P007",
        "S086",
        "S378"
      ]
    },
    {
      "name": "Ronald Ghossein",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S233",
        "S349",
        "S351"
      ]
    },
    {
      "name": "Rosh Sethi",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S021",
        "S196",
        "S305"
      ]
    },
    {
      "name": "Rui Fu",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001",
        "S096",
        "S134"
      ]
    },
    {
      "name": "Ruth N Agwaze",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S039",
        "S117",
        "S525"
      ]
    },
    {
      "name": "Ryan Carey",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P165",
        "S011",
        "S410"
      ]
    },
    {
      "name": "Ryan S Jackson",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S303",
        "S361",
        "S473"
      ]
    },
    {
      "name": "Róger Ariel Matus, Radiologist",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P138",
        "P139",
        "P143"
      ]
    },
    {
      "name": "Sagar Kansara",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011",
        "P078",
        "S076"
      ]
    },
    {
      "name": "Sandhya Kalavacherla",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P029",
        "P302",
        "S284"
      ]
    },
    {
      "name": "Sanjana Velu",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P161",
        "P205",
        "S047"
      ]
    },
    {
      "name": "Sarbani Ghosh Laskar",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S309",
        "S447",
        "S501"
      ]
    },
    {
      "name": "Satoko Matsumura",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Shady I Soliman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S359",
        "S439",
        "S512"
      ]
    },
    {
      "name": "Shao Hui Huang",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317",
        "S318",
        "S394"
      ]
    },
    {
      "name": "Shaoyan Liu",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Sharon Tzelnick",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152",
        "S161",
        "S245"
      ]
    },
    {
      "name": "Shaum J Sridharan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S015",
        "S158",
        "S178"
      ]
    },
    {
      "name": "Shaum S Sridharan",
      "record_count": 3,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S155",
        "S206",
        "S453"
      ]
    },
    {
      "name": "Shaun A Nguyen",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P114",
        "P322",
        "S139"
      ]
    },
    {
      "name": "Shimrit Sharav",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261",
        "P286",
        "S505"
      ]
    },
    {
      "name": "Sholem Hack, MBBS",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P007",
        "S086",
        "S544"
      ]
    },
    {
      "name": "Shwetabh Sinha",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S309",
        "S447",
        "S501"
      ]
    },
    {
      "name": "Sidharth Puram",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201",
        "S027",
        "S028"
      ]
    },
    {
      "name": "Simone Maistro",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150",
        "P445",
        "S280"
      ]
    },
    {
      "name": "Snehal G Patel",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S109",
        "S233",
        "S366"
      ]
    },
    {
      "name": "Sophia Linguiti",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340",
        "P440",
        "S449"
      ]
    },
    {
      "name": "Steven Frank",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S240"
      ]
    },
    {
      "name": "Subin Surendran",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S031",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Sudhanvan Iyer",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P411",
        "S440",
        "S556"
      ]
    },
    {
      "name": "Sumanth Chandrupatla",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S023",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Sumsum P Sunny",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S072",
        "S585"
      ]
    },
    {
      "name": "Sumsum Sunny, MDS",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S031",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Taisei Yasuda",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Tara Mokhtari",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S090",
        "S510"
      ]
    },
    {
      "name": "Tara P Menon",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064",
        "S260",
        "S511"
      ]
    },
    {
      "name": "Taral K Jella",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064",
        "S260",
        "S511"
      ]
    },
    {
      "name": "Tareck Ayad",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S003",
        "S034",
        "S211"
      ]
    },
    {
      "name": "Tayo Steininger",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S162",
        "S219",
        "S478"
      ]
    },
    {
      "name": "Thom R Loree",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094",
        "P421",
        "S529"
      ]
    },
    {
      "name": "Tjoson Tjoa",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188",
        "S344",
        "S524"
      ]
    },
    {
      "name": "Travis Schrank",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S144",
        "S393",
        "S520"
      ]
    },
    {
      "name": "Trevor Hackman",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019",
        "S144",
        "S520"
      ]
    },
    {
      "name": "Vanessa Stubbs",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145",
        "P147",
        "S424"
      ]
    },
    {
      "name": "Victoria N Huynh",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P014",
        "P068",
        "P352"
      ]
    },
    {
      "name": "W Greer Albergotti",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P114",
        "P222",
        "S139"
      ]
    },
    {
      "name": "Warren B Chun",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P114",
        "P322",
        "S139"
      ]
    },
    {
      "name": "Wei Keat Teo",
      "record_count": 3,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S205",
        "S444",
        "S489"
      ]
    },
    {
      "name": "Wendell G Yarbrough",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S045",
        "S314",
        "S393"
      ]
    },
    {
      "name": "Wendell Yarbrough, MMHC",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019",
        "S144",
        "S520"
      ]
    },
    {
      "name": "Wenye Song",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S168",
        "S173",
        "S240"
      ]
    },
    {
      "name": "Whitney Jin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S391",
        "S539",
        "S606"
      ]
    },
    {
      "name": "William J Benjamin",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P069",
        "S021",
        "S356"
      ]
    },
    {
      "name": "William Magner",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S546",
        "S585",
        "S588"
      ]
    },
    {
      "name": "William P Magdycz",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064",
        "S260",
        "S511"
      ]
    },
    {
      "name": "Xiaolei Wang",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Ximena Mimica",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S130",
        "S261",
        "S550"
      ]
    },
    {
      "name": "Y Robbins",
      "record_count": 3,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S281",
        "S282",
        "S475"
      ]
    },
    {
      "name": "Yazeed Alhiyari",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S360",
        "S387",
        "S466"
      ]
    },
    {
      "name": "Ye Zhang",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Yehia Elkersh",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S104",
        "S180",
        "S522"
      ]
    },
    {
      "name": "Yi Ren",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025",
        "S322",
        "S444"
      ]
    },
    {
      "name": "Yudong Ning",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Yuichiro Enoki",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Zainab Farzal",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S170",
        "S193",
        "S298"
      ]
    },
    {
      "name": "Zigui Chen",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S371",
        "S373",
        "S376"
      ]
    },
    {
      "name": "A Huynh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S282",
        "S475"
      ]
    },
    {
      "name": "Aaron W Bogan, MA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S525"
      ]
    },
    {
      "name": "Abdullah A Adil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S153",
        "S419"
      ]
    },
    {
      "name": "Abdullah A Osman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S519"
      ]
    },
    {
      "name": "Adam Beucler",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Aditya Shreenivas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023",
        "S524"
      ]
    },
    {
      "name": "Akarsh Lal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S060",
        "S457"
      ]
    },
    {
      "name": "Akina Tamaki",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P349",
        "S543"
      ]
    },
    {
      "name": "Akshay R Prabhakar, BSA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P056",
        "P307"
      ]
    },
    {
      "name": "Alaa Safia",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124",
        "S135"
      ]
    },
    {
      "name": "Alan Ho",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320",
        "S075"
      ]
    },
    {
      "name": "Alana Eagan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S366",
        "S451"
      ]
    },
    {
      "name": "Albert Li",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S436",
        "S602"
      ]
    },
    {
      "name": "Albert Y Li",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S439",
        "S512"
      ]
    },
    {
      "name": "Alec E Dallas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Alex E Kejner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Alex Z Graboyes",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127"
      ]
    },
    {
      "name": "Alexandra E Kejner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P155",
        "P222"
      ]
    },
    {
      "name": "Alexandria G Yao",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P015",
        "P285"
      ]
    },
    {
      "name": "Alexis K Gursky",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P360",
        "S560"
      ]
    },
    {
      "name": "Aliaa Sabry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S245",
        "S420"
      ]
    },
    {
      "name": "Alice A Tang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S024",
        "S258"
      ]
    },
    {
      "name": "Alice L Tang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144",
        "S323"
      ]
    },
    {
      "name": "Alicia Pellerin-Viger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048",
        "S034"
      ]
    },
    {
      "name": "Alisa Phillips",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023"
      ]
    },
    {
      "name": "Allison Rollins",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S020",
        "S479"
      ]
    },
    {
      "name": "Amanda J Bastien",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160",
        "S487"
      ]
    },
    {
      "name": "Amani Alvi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Amber Dunmire",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P411",
        "S440"
      ]
    },
    {
      "name": "Amelie Marshall, BASc",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S483",
        "S484"
      ]
    },
    {
      "name": "Ameya A",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434",
        "S007"
      ]
    },
    {
      "name": "Ameya A Jategaonkar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P179",
        "S022"
      ]
    },
    {
      "name": "Ameya Jategaonkar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S355",
        "S538"
      ]
    },
    {
      "name": "Amy C Moreno",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S169",
        "S242"
      ]
    },
    {
      "name": "Amy Moreno",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S168",
        "S173"
      ]
    },
    {
      "name": "Andrea Bonetto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425",
        "S374"
      ]
    },
    {
      "name": "Andrea Costantino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S088",
        "S526"
      ]
    },
    {
      "name": "Andrea Lopez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S223",
        "S606"
      ]
    },
    {
      "name": "Andrea M Park",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P335",
        "S405"
      ]
    },
    {
      "name": "Andrea Stoddard",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S154",
        "S574"
      ]
    },
    {
      "name": "Andressa Silva de Freitas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168",
        "S175"
      ]
    },
    {
      "name": "Andrew C Birkeland",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274",
        "S425"
      ]
    },
    {
      "name": "Andrew G Sikora",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S279"
      ]
    },
    {
      "name": "Andrew Holcomb",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S046",
        "S266"
      ]
    },
    {
      "name": "Andrew Hope",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317",
        "S183"
      ]
    },
    {
      "name": "Andrew Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P018",
        "P376"
      ]
    },
    {
      "name": "Andrew M Peterson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S104",
        "S417"
      ]
    },
    {
      "name": "Andrew T Day",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S170",
        "S298"
      ]
    },
    {
      "name": "Andrés Bur",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P015",
        "P285"
      ]
    },
    {
      "name": "Aneek Mirza",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Anela Thomas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S072"
      ]
    },
    {
      "name": "Angela Haskins",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P099",
        "P262"
      ]
    },
    {
      "name": "Angela Mazul",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S027",
        "S198"
      ]
    },
    {
      "name": "Anita Rau",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P003",
        "P006"
      ]
    },
    {
      "name": "Ann Marie Egloff",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S148",
        "S275"
      ]
    },
    {
      "name": "Anna Bottoms",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P412",
        "S112"
      ]
    },
    {
      "name": "Anna C Clements",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S262",
        "S272"
      ]
    },
    {
      "name": "Anna Xiang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P089",
        "P171"
      ]
    },
    {
      "name": "Annette E Mino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188",
        "S344"
      ]
    },
    {
      "name": "Annie R Abruzzo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S032",
        "S203"
      ]
    },
    {
      "name": "Anthony DiPalma",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S555"
      ]
    },
    {
      "name": "Anthony J Apicelli",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S303",
        "S473"
      ]
    },
    {
      "name": "Anthony Mangino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S461",
        "S532"
      ]
    },
    {
      "name": "Antoine Eskander, ScM",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S096",
        "S222"
      ]
    },
    {
      "name": "Antoine Eskander, ScM, FRCSC",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164",
        "S536"
      ]
    },
    {
      "name": "Antonio Dekhou",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P332",
        "S191"
      ]
    },
    {
      "name": "Antonio L Amelio",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S098",
        "S100"
      ]
    },
    {
      "name": "Antonio S Dekhou",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S024",
        "S258"
      ]
    },
    {
      "name": "Anuj Kumar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S447"
      ]
    },
    {
      "name": "Anushri Tiwari",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S147",
        "S372"
      ]
    },
    {
      "name": "Ara Chalian",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P161",
        "P205"
      ]
    },
    {
      "name": "Ari J Rosenberg",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S081",
        "S516"
      ]
    },
    {
      "name": "Arisa Nishikawa Kaga",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S519"
      ]
    },
    {
      "name": "Arjun G Singh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Armita Norouzi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P072",
        "P090"
      ]
    },
    {
      "name": "Aruni Areti",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P099",
        "S604"
      ]
    },
    {
      "name": "Ashish A Deshmukh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Ashley Feng",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S136",
        "S257"
      ]
    },
    {
      "name": "Ashley Heidtmann, CCCSLP",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Ashtyn McAdoo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S188",
        "S390"
      ]
    },
    {
      "name": "Atif Islam",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S552"
      ]
    },
    {
      "name": "Atif M Islam",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Austin Tautfest",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S083",
        "S093"
      ]
    },
    {
      "name": "Avanti Verma",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "S502"
      ]
    },
    {
      "name": "Avinash V Mantravadi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Aviva Mattingly",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P075",
        "S606"
      ]
    },
    {
      "name": "Bailey Balouch",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P191",
        "P192"
      ]
    },
    {
      "name": "Beatrice Manduchi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S169",
        "S242"
      ]
    },
    {
      "name": "Benjamin Sanchez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S427"
      ]
    },
    {
      "name": "Benjamin Wahle",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S303",
        "S473"
      ]
    },
    {
      "name": "Bert W O'Malley",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Beth Beadle",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S247",
        "S304"
      ]
    },
    {
      "name": "Beverly Wuertz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P265",
        "P439"
      ]
    },
    {
      "name": "Bhaskar Gurram",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S105",
        "S389"
      ]
    },
    {
      "name": "Bin Xu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S349",
        "S351"
      ]
    },
    {
      "name": "Binav Baral, MBBS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S079"
      ]
    },
    {
      "name": "Birk J Olson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Bradley Aouizerat, MAS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S374"
      ]
    },
    {
      "name": "Brandon J Dyer",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Brayden Seliger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S083",
        "S093"
      ]
    },
    {
      "name": "Brendan Dolan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P112",
        "P113"
      ]
    },
    {
      "name": "Brendan Kinney",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207",
        "S033"
      ]
    },
    {
      "name": "Brett Campbell",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S128",
        "S589"
      ]
    },
    {
      "name": "Brett Miles",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341",
        "S412"
      ]
    },
    {
      "name": "Brian Burkey",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P116",
        "P117"
      ]
    },
    {
      "name": "Brian P Cervenka",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P404",
        "P425"
      ]
    },
    {
      "name": "Brianna L Buchler",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S468",
        "S577"
      ]
    },
    {
      "name": "Brittany Beisel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P014",
        "P068"
      ]
    },
    {
      "name": "Bruna Hanauer",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P108",
        "P109"
      ]
    },
    {
      "name": "Bryan Trieu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S225",
        "S462"
      ]
    },
    {
      "name": "Caitlyn B Tomblin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Carly E A Barbon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S169",
        "S242"
      ]
    },
    {
      "name": "Carmen Marcela Quezada, Hematopathologist",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P138",
        "P143"
      ]
    },
    {
      "name": "Changxing Liu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P118",
        "S551"
      ]
    },
    {
      "name": "Charles E Robertson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S374",
        "S377"
      ]
    },
    {
      "name": "Charles J Cook",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P254",
        "P418"
      ]
    },
    {
      "name": "Chase Clark",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P094",
        "P421"
      ]
    },
    {
      "name": "Chaz Stucken",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P157",
        "S116"
      ]
    },
    {
      "name": "Chee Yit Lim, MBBS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S444",
        "S489"
      ]
    },
    {
      "name": "Chelsea Gelboin Burkhart",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S555"
      ]
    },
    {
      "name": "Chelsea Gelboin-Burkhart",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S006",
        "S124"
      ]
    },
    {
      "name": "Chi T Viet",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Chiara Pasini",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Chloe M Jones",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P191",
        "P192"
      ]
    },
    {
      "name": "Christian Gluck",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S379",
        "S586"
      ]
    },
    {
      "name": "Christian J Leonardo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S600",
        "S603"
      ]
    },
    {
      "name": "Christina Zhu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P299",
        "S177"
      ]
    },
    {
      "name": "Christine Auberle",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S303",
        "S473"
      ]
    },
    {
      "name": "Christine Dinh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P026",
        "P208"
      ]
    },
    {
      "name": "Christine H Chung",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S073",
        "S098"
      ]
    },
    {
      "name": "Christine Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Christopher J Nickel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Christopher Kopp",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S575",
        "S582"
      ]
    },
    {
      "name": "Christopher MKL Yao",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317",
        "S183"
      ]
    },
    {
      "name": "Christopher Nickel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S552"
      ]
    },
    {
      "name": "Christopher W Noel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S134",
        "S222"
      ]
    },
    {
      "name": "Christopher Yao",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P011",
        "P152"
      ]
    },
    {
      "name": "Claudia I Cabrera",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S004",
        "S547"
      ]
    },
    {
      "name": "Claudia N Gutierrez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S333",
        "S408"
      ]
    },
    {
      "name": "Claudio Cernea",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P108",
        "S451"
      ]
    },
    {
      "name": "Claudio R Cernea",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S230",
        "S236"
      ]
    },
    {
      "name": "Clifton D Fuller",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S169",
        "S242"
      ]
    },
    {
      "name": "Cody Huffman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S383",
        "S473"
      ]
    },
    {
      "name": "Colleen G Hochfelder",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374",
        "S430"
      ]
    },
    {
      "name": "Cornelius Kurten",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S017",
        "S483"
      ]
    },
    {
      "name": "Cornelius Kürten",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S381",
        "S477"
      ]
    },
    {
      "name": "Craig A Bollig",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Cristina Valero",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S366",
        "S451"
      ]
    },
    {
      "name": "Curtis Pickering",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P436",
        "S142"
      ]
    },
    {
      "name": "Daniel A Ribeiro",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S418"
      ]
    },
    {
      "name": "Daniel Clayburgh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P326",
        "S323"
      ]
    },
    {
      "name": "Daniel Deschler",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S305",
        "S498"
      ]
    },
    {
      "name": "Daniel E Bestourous",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S083",
        "S093"
      ]
    },
    {
      "name": "Daniel Faden",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S305",
        "S498"
      ]
    },
    {
      "name": "Daniel J Ma",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S101"
      ]
    },
    {
      "name": "Daniel Ledezma",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S130",
        "S550"
      ]
    },
    {
      "name": "Daniel McGrail",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S147",
        "S372"
      ]
    },
    {
      "name": "Daniel N Frank",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S374",
        "S377"
      ]
    },
    {
      "name": "Daniel Sharbel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P014",
        "P068"
      ]
    },
    {
      "name": "Danielle Bottalico",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S147",
        "S480"
      ]
    },
    {
      "name": "Danielle Scarola",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P281",
        "P341"
      ]
    },
    {
      "name": "Dante J Merlino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205",
        "S572"
      ]
    },
    {
      "name": "Daria Ivanova",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S066",
        "S493"
      ]
    },
    {
      "name": "David A Campbell",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "David Goldstein",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152",
        "S183"
      ]
    },
    {
      "name": "David Hernandez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P099",
        "P254"
      ]
    },
    {
      "name": "David I Kutler",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010",
        "S241"
      ]
    },
    {
      "name": "David Kutler",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P049",
        "S345"
      ]
    },
    {
      "name": "David L Hirsch",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331",
        "S126"
      ]
    },
    {
      "name": "David M Cognetti",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "S212"
      ]
    },
    {
      "name": "David Strum",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S256",
        "S362"
      ]
    },
    {
      "name": "David WA Forner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S160",
        "S492"
      ]
    },
    {
      "name": "Daysi Sanguano",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P108",
        "P109"
      ]
    },
    {
      "name": "De-Chen Lin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S146",
        "S151"
      ]
    },
    {
      "name": "Debbie Cohen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127"
      ]
    },
    {
      "name": "Deborah X Xie",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S022",
        "S042"
      ]
    },
    {
      "name": "Deborah Xie",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S246",
        "S538"
      ]
    },
    {
      "name": "Delaney Sheehan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Deniz C Demircioglu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S263",
        "S296"
      ]
    },
    {
      "name": "Devaprabu Abraham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Diana N Kirke, Phil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217",
        "S216"
      ]
    },
    {
      "name": "Diego Sinagra",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "Dina Modlin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S023",
        "S163"
      ]
    },
    {
      "name": "Diwakar Davar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S206",
        "S453"
      ]
    },
    {
      "name": "Donald T Weed",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S066",
        "S493"
      ]
    },
    {
      "name": "Donovan Eu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P212",
        "P408"
      ]
    },
    {
      "name": "Dorina Kallogjeri",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338",
        "S454"
      ]
    },
    {
      "name": "Douglas Adkins",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S074",
        "S303"
      ]
    },
    {
      "name": "Drake V Johnston",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P020",
        "S308"
      ]
    },
    {
      "name": "Dukagjin Blakaj",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P256",
        "S399"
      ]
    },
    {
      "name": "Dylan F Roden",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P033",
        "S343"
      ]
    },
    {
      "name": "Eben L Rosenthal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S437",
        "S562"
      ]
    },
    {
      "name": "Ebrahim Farashi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100",
        "S452"
      ]
    },
    {
      "name": "Edward S Sim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S065",
        "S275"
      ]
    },
    {
      "name": "Elisabeth R Wenneker",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P262",
        "P389"
      ]
    },
    {
      "name": "Elise Patchett",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P412",
        "S112"
      ]
    },
    {
      "name": "Elizabeth G Hill",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Elizabeth M Iype",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P131",
        "P195"
      ]
    },
    {
      "name": "Ellen P Penn",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "Emerson Bouldin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065",
        "S570"
      ]
    },
    {
      "name": "Emile Gogineni",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P256",
        "S399"
      ]
    },
    {
      "name": "Emilie de Groot",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S186",
        "S498"
      ]
    },
    {
      "name": "Emily J Marchiano",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S283",
        "S429"
      ]
    },
    {
      "name": "Emily Sagalow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046",
        "S221"
      ]
    },
    {
      "name": "Emmanuel Garcia Morales",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S136",
        "S257"
      ]
    },
    {
      "name": "Eric M Genden, MHCA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217",
        "S216"
      ]
    },
    {
      "name": "Eric Moore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S079",
        "S101"
      ]
    },
    {
      "name": "Eric Tran",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107",
        "S231"
      ]
    },
    {
      "name": "Eric V Mastrolonardo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218",
        "S005"
      ]
    },
    {
      "name": "Eric Y Du",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319",
        "S159"
      ]
    },
    {
      "name": "Erica Choe",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P123",
        "P299"
      ]
    },
    {
      "name": "Erich M Sturgis",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S118",
        "S133"
      ]
    },
    {
      "name": "Erik Vanstrum",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S359",
        "S512"
      ]
    },
    {
      "name": "Ethan Meiburg",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S353",
        "S601"
      ]
    },
    {
      "name": "Ethan Soudry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "F. Christopher Holsinger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S304",
        "S404"
      ]
    },
    {
      "name": "F. Jeffrey Lorenz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P111",
        "P237"
      ]
    },
    {
      "name": "Fabio Albuquerque Marchi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S165"
      ]
    },
    {
      "name": "Fahad Hasnain",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S060",
        "S457"
      ]
    },
    {
      "name": "Farshad N Chowdhury",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P005",
        "S291"
      ]
    },
    {
      "name": "Fatima Syed Amanullah, Dr",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105",
        "S467"
      ]
    },
    {
      "name": "Federico Marinelli",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "Felipe Porto-Gutierrez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S456",
        "S589"
      ]
    },
    {
      "name": "Fernando Dip",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "Fernando L Dias",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364",
        "S228"
      ]
    },
    {
      "name": "Forest Weir",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P014",
        "P068"
      ]
    },
    {
      "name": "Francesco Mazzola",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P339",
        "P367"
      ]
    },
    {
      "name": "Francis P Worden",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S285"
      ]
    },
    {
      "name": "Francis Worden",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S492",
        "S524"
      ]
    },
    {
      "name": "Francisco Medrano, Head and Neck Surgeon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P139",
        "P143"
      ]
    },
    {
      "name": "Frederick Dun-Dery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P001",
        "P017"
      ]
    },
    {
      "name": "Fu-Min Fang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P311",
        "S423"
      ]
    },
    {
      "name": "Fátima Solange Pasini",
      "record_count": 2,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S280"
      ]
    },
    {
      "name": "Gabriel Carrillo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "S502"
      ]
    },
    {
      "name": "Gabriel S Dayan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S003",
        "S211"
      ]
    },
    {
      "name": "Garren Low",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P089",
        "P098"
      ]
    },
    {
      "name": "Geethanjeli Mahendran",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S305",
        "S498"
      ]
    },
    {
      "name": "George Shenouda",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S252",
        "S271"
      ]
    },
    {
      "name": "Georges E Daoud",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202",
        "S417"
      ]
    },
    {
      "name": "Ghabrielle Almeida",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P116",
        "P117"
      ]
    },
    {
      "name": "Gilberto de Castro Junior",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P150",
        "P445"
      ]
    },
    {
      "name": "Gillian Michaelson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P349",
        "S543"
      ]
    },
    {
      "name": "Gintas P Krisciunas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092",
        "S150"
      ]
    },
    {
      "name": "Giulia Di Vincenzo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P367",
        "S500"
      ]
    },
    {
      "name": "Giulio Badin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Glenn J Hanna",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S395",
        "S494"
      ]
    },
    {
      "name": "Gregory Farwell",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S011",
        "S164"
      ]
    },
    {
      "name": "Hailey P Wyatt",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P360",
        "S560"
      ]
    },
    {
      "name": "Haleigh Pine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P412",
        "S112"
      ]
    },
    {
      "name": "Haluk Damgacioglu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Hamdan Pasha",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105",
        "S467"
      ]
    },
    {
      "name": "Han Lee Goh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S444",
        "S489"
      ]
    },
    {
      "name": "Harish Bharambe",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S098",
        "S100"
      ]
    },
    {
      "name": "Harley Chan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Harry Fuentes Bayne",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S079"
      ]
    },
    {
      "name": "Harry M Baddour",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202",
        "S417"
      ]
    },
    {
      "name": "Harry Quon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S095",
        "S321"
      ]
    },
    {
      "name": "Hassan Arshad",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P381",
        "P382"
      ]
    },
    {
      "name": "Hayes Stancliff",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S167",
        "S299"
      ]
    },
    {
      "name": "Henry T Hoffman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P396",
        "P397"
      ]
    },
    {
      "name": "Hidekiyo Yamaki",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Hideyuki Takahashi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041",
        "S324"
      ]
    },
    {
      "name": "Hilary C McCrary",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Hiroki Komatsuda",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Hudson Sodré",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P108",
        "P109"
      ]
    },
    {
      "name": "Hyun Song",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S190",
        "S348"
      ]
    },
    {
      "name": "Ian Kim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S439",
        "S605"
      ]
    },
    {
      "name": "Ido Amir",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "Imraan Jan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Inbar Finkel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S103",
        "S331"
      ]
    },
    {
      "name": "Isabela Firigato",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P242",
        "P258"
      ]
    },
    {
      "name": "Isabelle Jang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S168",
        "S445"
      ]
    },
    {
      "name": "Isabelle Jia Hui Jang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S173",
        "S220"
      ]
    },
    {
      "name": "Ismail M Khaderi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S256",
        "S362"
      ]
    },
    {
      "name": "Ivan Stepanek",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S026",
        "S064"
      ]
    },
    {
      "name": "Izabella Costa Santos",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P184",
        "S175"
      ]
    },
    {
      "name": "Jaafar Hadi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P036",
        "P260"
      ]
    },
    {
      "name": "Jack Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S168",
        "S240"
      ]
    },
    {
      "name": "Jacob McCoy",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S427"
      ]
    },
    {
      "name": "Jacob Parker",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S552"
      ]
    },
    {
      "name": "Jake J Lee, MSCI",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053"
      ]
    },
    {
      "name": "Jake Sims",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P369",
        "S587"
      ]
    },
    {
      "name": "Jalal Jalaly",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275",
        "S312"
      ]
    },
    {
      "name": "James A Bankson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S182",
        "S388"
      ]
    },
    {
      "name": "James R Gardner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S342",
        "S460"
      ]
    },
    {
      "name": "Jane Y Tong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Janice Farlow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405",
        "S076"
      ]
    },
    {
      "name": "Janice L Farlow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Jasmine Sze",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331",
        "S126"
      ]
    },
    {
      "name": "Jason M Warram",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Jason P Hunt",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Jason S Acheampong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P095",
        "P387"
      ]
    },
    {
      "name": "Jason Townson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S486",
        "S582"
      ]
    },
    {
      "name": "Jatin P Shah",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S366",
        "S451"
      ]
    },
    {
      "name": "Javier Ghiselli",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "Jay J Liao",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S232"
      ]
    },
    {
      "name": "Jay Mehta",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S098",
        "S100"
      ]
    },
    {
      "name": "Jazlyn Selvasingh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S260",
        "S511"
      ]
    },
    {
      "name": "Jeffrey Wolf",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Jennifer Cracchiolo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320",
        "S215"
      ]
    },
    {
      "name": "Jennifer L Harper",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Jennifer L Shah",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S285"
      ]
    },
    {
      "name": "Jenny Kim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S115",
        "S155"
      ]
    },
    {
      "name": "Jens P Klussmann",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S110",
        "S398"
      ]
    },
    {
      "name": "Jeong-Yeon Ji",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P263",
        "P304"
      ]
    },
    {
      "name": "Jerry Liu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Jessica A Yesensky",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Jiayu Wang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S006",
        "S124"
      ]
    },
    {
      "name": "Jing Wu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S383",
        "S473"
      ]
    },
    {
      "name": "Jingjing Hu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S114",
        "S284"
      ]
    },
    {
      "name": "Jiyang Tan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S369",
        "S371"
      ]
    },
    {
      "name": "Joe W Foley",
      "record_count": 2,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S322",
        "S444"
      ]
    },
    {
      "name": "Joel S Feier",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188",
        "S344"
      ]
    },
    {
      "name": "John A Ridge",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S038",
        "S157"
      ]
    },
    {
      "name": "John E Hanks",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P155",
        "P409"
      ]
    },
    {
      "name": "John Kaczmar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "John T Loree",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P421",
        "S529"
      ]
    },
    {
      "name": "Johnny R Belcher",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S263",
        "S296"
      ]
    },
    {
      "name": "Jonathan C Irish, FRCSC, FCAHS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S161",
        "S486"
      ]
    },
    {
      "name": "Jonathan D Schoenfeld, MPhil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S494",
        "S516"
      ]
    },
    {
      "name": "Jonathan Garneau",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P272",
        "P356"
      ]
    },
    {
      "name": "Jonathan R Mark",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P095",
        "P387"
      ]
    },
    {
      "name": "Joon Yong Park",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S357",
        "S416"
      ]
    },
    {
      "name": "Jorge E Arpi Palacios",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P391",
        "S231"
      ]
    },
    {
      "name": "Jose A Monteiro de Oliveira Novaes",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210",
        "S592"
      ]
    },
    {
      "name": "Joseph A Califano",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P213",
        "P353"
      ]
    },
    {
      "name": "Joseph Califano",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S114",
        "S238"
      ]
    },
    {
      "name": "Joseph Celidonio",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P033",
        "S343"
      ]
    },
    {
      "name": "Joseph Masselli",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341",
        "S126"
      ]
    },
    {
      "name": "Joshua J Kain",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173",
        "S378"
      ]
    },
    {
      "name": "Joshua K Tay, MBBS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S444",
        "S489"
      ]
    },
    {
      "name": "Joshua Teitcher, CCCSLP",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Josiah Brandt",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Judith M Skoner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Judith Varner",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P029",
        "S284"
      ]
    },
    {
      "name": "Julie Hallet",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S096",
        "S222"
      ]
    },
    {
      "name": "Jungirl Seok",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263",
        "S357"
      ]
    },
    {
      "name": "Justin Fortino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S002",
        "S040"
      ]
    },
    {
      "name": "Justine Philteos",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P069",
        "S527"
      ]
    },
    {
      "name": "Kara L Cushing-Haugen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S262",
        "S429"
      ]
    },
    {
      "name": "Karthik Rao, MCh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S407",
        "S471"
      ]
    },
    {
      "name": "Kate Hutcheson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S173",
        "S220"
      ]
    },
    {
      "name": "Katelyn S Rourk",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S117"
      ]
    },
    {
      "name": "Katharine A Price",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S101"
      ]
    },
    {
      "name": "Katherine Xu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P244",
        "P283"
      ]
    },
    {
      "name": "Kathleen Bartemes",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S045",
        "S314"
      ]
    },
    {
      "name": "Kathleen Luckett",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P049",
        "S345"
      ]
    },
    {
      "name": "Katie K Hohenberger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053"
      ]
    },
    {
      "name": "Katie Van Able",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S045",
        "S314"
      ]
    },
    {
      "name": "Kayla E Baker",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S200",
        "S528"
      ]
    },
    {
      "name": "Kazuaki Chikamatsu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041",
        "S324"
      ]
    },
    {
      "name": "Keene Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S026",
        "S064"
      ]
    },
    {
      "name": "Keisuke Nakajima",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P183",
        "P368"
      ]
    },
    {
      "name": "Kelly Bridgham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S029",
        "S212"
      ]
    },
    {
      "name": "Kelly Brigham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S077",
        "S449"
      ]
    },
    {
      "name": "Kelly L Staricha",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S302",
        "S479"
      ]
    },
    {
      "name": "Kelly Moyer",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Kenny Nguyen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S342",
        "S460"
      ]
    },
    {
      "name": "Kento Okamoto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S519"
      ]
    },
    {
      "name": "Kenzo Ohara",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Kesava Asam",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S374"
      ]
    },
    {
      "name": "Kevin Liu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S062",
        "S264"
      ]
    },
    {
      "name": "Khalil Sultanem",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S252",
        "S271"
      ]
    },
    {
      "name": "Khang Wen Pang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P212",
        "P408"
      ]
    },
    {
      "name": "Khara Sauro",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P001",
        "P017"
      ]
    },
    {
      "name": "Kirollos Armosh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S062",
        "S337"
      ]
    },
    {
      "name": "Kiyoaki Tsukahara",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P224",
        "P227"
      ]
    },
    {
      "name": "Krishnamurthi Sundaram",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300",
        "S255"
      ]
    },
    {
      "name": "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P153",
        "S249"
      ]
    },
    {
      "name": "Kumar Prabhash",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Kurtis Young",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P046",
        "P403"
      ]
    },
    {
      "name": "Kwok Seng Loh, MBBS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S444",
        "S489"
      ]
    },
    {
      "name": "Kyle M Hatten",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Kyle Mannion",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S223",
        "S562"
      ]
    },
    {
      "name": "Kyrionna M Golliday",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S390",
        "S437"
      ]
    },
    {
      "name": "Lara Dunn",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320",
        "S075"
      ]
    },
    {
      "name": "Laura J Fish",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S192"
      ]
    },
    {
      "name": "Laura Kim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P056",
        "P307"
      ]
    },
    {
      "name": "Lauren Ottenstein, CCCSLP",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P429",
        "S417"
      ]
    },
    {
      "name": "Laurent Ganry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331",
        "S126"
      ]
    },
    {
      "name": "Lawrence F Oppenheimer Vélez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P330",
        "P361"
      ]
    },
    {
      "name": "Leila J Mady",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S287",
        "S321"
      ]
    },
    {
      "name": "Li Liang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P262",
        "P389"
      ]
    },
    {
      "name": "Libby Ward Schafer",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "S502"
      ]
    },
    {
      "name": "Liliana Ein",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P208",
        "P420"
      ]
    },
    {
      "name": "Lisa A Orloff",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053"
      ]
    },
    {
      "name": "Lisa Galati",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292",
        "S189"
      ]
    },
    {
      "name": "Livia Florianova",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S252",
        "S271"
      ]
    },
    {
      "name": "Lixia Zhang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S031",
        "S476"
      ]
    },
    {
      "name": "Liyona Kampel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S103",
        "S331"
      ]
    },
    {
      "name": "Louise Davies",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S050",
        "S157"
      ]
    },
    {
      "name": "Lucas Berry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092",
        "S150"
      ]
    },
    {
      "name": "Lucas Penny",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S318",
        "S394"
      ]
    },
    {
      "name": "Lucas Takanori Sanchez Shiromizu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S427"
      ]
    },
    {
      "name": "Luciana Sartore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Luis Cortina",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S143",
        "S429"
      ]
    },
    {
      "name": "Luis Felipe Ribeiro Pinto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P178",
        "P184"
      ]
    },
    {
      "name": "Luke O Buchmann",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "M Craveiro",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S282",
        "S475"
      ]
    },
    {
      "name": "M. Elyse Moore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S105",
        "S389"
      ]
    },
    {
      "name": "Madelyn N Stevens",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378",
        "S553"
      ]
    },
    {
      "name": "Madison McElliot",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Maie St",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S387",
        "S568"
      ]
    },
    {
      "name": "Malini Patel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Mandy Salmon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "S023"
      ]
    },
    {
      "name": "Marc Anthony Pastor",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P072",
        "P090"
      ]
    },
    {
      "name": "Marcelo Bonomi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S073",
        "S399"
      ]
    },
    {
      "name": "Marci Lee Nilsen, CHPN",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S268"
      ]
    },
    {
      "name": "Marco Aurélio V Kulcsar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S563",
        "S565"
      ]
    },
    {
      "name": "Marco Ferrari",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Marco Mascarella, FRCSC",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S252",
        "S254"
      ]
    },
    {
      "name": "Maria Aparecida Azevedo Koike Folgueira",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S201"
      ]
    },
    {
      "name": "Maria J Polania-Sandoval",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P067",
        "P079"
      ]
    },
    {
      "name": "Maria Lucia Hirata Katayama",
      "record_count": 2,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S280"
      ]
    },
    {
      "name": "Marilene B Wang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S400",
        "S524"
      ]
    },
    {
      "name": "Marita S Teng",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217",
        "S216"
      ]
    },
    {
      "name": "Mark A Varvares",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248",
        "S356"
      ]
    },
    {
      "name": "Mark Swanson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S207",
        "S293"
      ]
    },
    {
      "name": "Mark Urken",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Mark Zafereo",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S231",
        "S597"
      ]
    },
    {
      "name": "Markus Blaurock",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S089",
        "S094"
      ]
    },
    {
      "name": "Matthew Krutz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S434",
        "S438"
      ]
    },
    {
      "name": "Matthew M Hanasono",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P380",
        "S412"
      ]
    },
    {
      "name": "Mauricio Moreno",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S342",
        "S549"
      ]
    },
    {
      "name": "Maxwell P Kligerman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065",
        "S057"
      ]
    },
    {
      "name": "Maxwell Y Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S375",
        "S455"
      ]
    },
    {
      "name": "Mayu Shigeyama",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P183",
        "P368"
      ]
    },
    {
      "name": "Megan S Wu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P382",
        "P384"
      ]
    },
    {
      "name": "Megha Mohanakrishnan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S024",
        "S258"
      ]
    },
    {
      "name": "Melina J Windon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346",
        "S494"
      ]
    },
    {
      "name": "Meredith Lilly",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P128",
        "S506"
      ]
    },
    {
      "name": "Michael Chow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S332",
        "S571"
      ]
    },
    {
      "name": "Michael D Henry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S154",
        "S574"
      ]
    },
    {
      "name": "Michael G Moore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Michael Groves",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P014",
        "P068"
      ]
    },
    {
      "name": "Michael Hier",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S121",
        "S396"
      ]
    },
    {
      "name": "Michael Moore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405",
        "S028"
      ]
    },
    {
      "name": "Michael P Wu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S215",
        "S239"
      ]
    },
    {
      "name": "Michael S Chow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S113",
        "S131"
      ]
    },
    {
      "name": "Michael Topf",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S127",
        "S223"
      ]
    },
    {
      "name": "Michael W Sim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Michaela Geffert",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060",
        "S218"
      ]
    },
    {
      "name": "Micheal Machiorlatti",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P020",
        "S308"
      ]
    },
    {
      "name": "Michelle Antony",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S184",
        "S198"
      ]
    },
    {
      "name": "Michelle Chen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S304"
      ]
    },
    {
      "name": "Michelle Florentine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P072",
        "S332"
      ]
    },
    {
      "name": "Michelle L Mierzwa",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S285"
      ]
    },
    {
      "name": "Michihisa Kono",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Mihir Bhayani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P145",
        "P147"
      ]
    },
    {
      "name": "Mikalin Huckeba, BHS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P116",
        "P117"
      ]
    },
    {
      "name": "Miki Takahara",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Milena Fior",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P339",
        "P367"
      ]
    },
    {
      "name": "Mina A Beshy",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Mina Eskandar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Missak Haigentz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Mitchell Victor",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405",
        "S119"
      ]
    },
    {
      "name": "Mohamad Almasri",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S153",
        "S419"
      ]
    },
    {
      "name": "Mohammed Al Ajmi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P081",
        "P399"
      ]
    },
    {
      "name": "Mohammed Khan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S490",
        "S495"
      ]
    },
    {
      "name": "Mohemmed Khan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Mohemmed N Khan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S216",
        "S548"
      ]
    },
    {
      "name": "Molly E Heft-Neal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S153",
        "S419"
      ]
    },
    {
      "name": "Molly Heft Neal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S116",
        "S244"
      ]
    },
    {
      "name": "Morgan Sandelski",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S300",
        "S303"
      ]
    },
    {
      "name": "Mudassir Mumtaz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Musaddiq Awan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S263",
        "S296"
      ]
    },
    {
      "name": "Mutsuki Kawabe",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S519"
      ]
    },
    {
      "name": "Nabil F Saba",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S033",
        "S073"
      ]
    },
    {
      "name": "Nadia Mohyuddin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P056",
        "P307"
      ]
    },
    {
      "name": "Naheed Alam",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P421",
        "S529"
      ]
    },
    {
      "name": "Nana-Hawwa Abdul-Rahman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S268"
      ]
    },
    {
      "name": "Nancy Y Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320",
        "S074"
      ]
    },
    {
      "name": "Naresh K Panda",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P198",
        "P294"
      ]
    },
    {
      "name": "Nasrin Ghesani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Natalia Swiatowiec",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S298",
        "S485"
      ]
    },
    {
      "name": "Natalie Silver",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S147",
        "S372"
      ]
    },
    {
      "name": "Nathan Farrokhian",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P285",
        "S266"
      ]
    },
    {
      "name": "Nathan Vu Pham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S359",
        "S512"
      ]
    },
    {
      "name": "Neil Panjwani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P247",
        "S232"
      ]
    },
    {
      "name": "Nghi Nguyen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S579",
        "S583"
      ]
    },
    {
      "name": "Nicholas C Purdy",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "Nicole A Cipriani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P384",
        "S081"
      ]
    },
    {
      "name": "Nicole E Becker",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P396",
        "P397"
      ]
    },
    {
      "name": "Nicole J Reynoso",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P335",
        "S405"
      ]
    },
    {
      "name": "Niels C Kokot",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S030",
        "S293"
      ]
    },
    {
      "name": "Nihal Punjabi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S457",
        "S608"
      ]
    },
    {
      "name": "Nikhil Rammohan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S303",
        "S473"
      ]
    },
    {
      "name": "Nikhil S Chari",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S579",
        "S583"
      ]
    },
    {
      "name": "Nilam D Patel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Nina D Ham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274",
        "S425"
      ]
    },
    {
      "name": "Nishant Agrawal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S081",
        "S373"
      ]
    },
    {
      "name": "Nolan B Seim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256"
      ]
    },
    {
      "name": "Noor Zaghlula",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S149",
        "S218"
      ]
    },
    {
      "name": "Nosayaba Osazuwa Peters, BDS, CHES",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S192",
        "S251"
      ]
    },
    {
      "name": "Nour Mary Aissaoui",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P072",
        "P090"
      ]
    },
    {
      "name": "Orit Gutfeld",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S103",
        "S331"
      ]
    },
    {
      "name": "Orly Coblens",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S392",
        "S556"
      ]
    },
    {
      "name": "Pamela O Soares",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S069",
        "S541"
      ]
    },
    {
      "name": "Pankaj Chaturvedi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Paolo Serafini",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S066",
        "S493"
      ]
    },
    {
      "name": "Parvesh Kumar Jr",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440",
        "S449"
      ]
    },
    {
      "name": "Patrick Tassone",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P395",
        "S125"
      ]
    },
    {
      "name": "Paul L Swiecicki",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S323"
      ]
    },
    {
      "name": "Pawan Acharya",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S434",
        "S438"
      ]
    },
    {
      "name": "Pedro Nicolau-Neto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P178",
        "P184"
      ]
    },
    {
      "name": "Pei Yuan Fong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110",
        "S445"
      ]
    },
    {
      "name": "Peter J Attia",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P033",
        "S343"
      ]
    },
    {
      "name": "Peter S Giannaris",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P281",
        "P341"
      ]
    },
    {
      "name": "Peyton Robinson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Phuc-Felix Nguyen-Tan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S003",
        "S211"
      ]
    },
    {
      "name": "Piero Nicolai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S451",
        "S486"
      ]
    },
    {
      "name": "Poonam Joshi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Poria Dorali",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Prajwal Dange, MCh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S407",
        "S471"
      ]
    },
    {
      "name": "Qing Wang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S182",
        "S388"
      ]
    },
    {
      "name": "Rachad Mhawej",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S084",
        "S438"
      ]
    },
    {
      "name": "Rachel Stemme",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S287",
        "S321"
      ]
    },
    {
      "name": "Rahul Jayaram, Mr",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P290",
        "P407"
      ]
    },
    {
      "name": "Rahul Mhaskar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334",
        "S552"
      ]
    },
    {
      "name": "Ralph Gilbert",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152",
        "S183"
      ]
    },
    {
      "name": "Ralph W Gilbert, FRCSC",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S161",
        "S486"
      ]
    },
    {
      "name": "Randy W Lesh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "Rathan Shetty",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Raul Pellini",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P339",
        "P367"
      ]
    },
    {
      "name": "Rebecca A Zasloff",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S192"
      ]
    },
    {
      "name": "Reid T Powell",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S579",
        "S583"
      ]
    },
    {
      "name": "Rene Aleman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "Revital Benvenisti",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S192"
      ]
    },
    {
      "name": "Ricardo L Carrau",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256"
      ]
    },
    {
      "name": "Ricardo Padilla",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261",
        "S144"
      ]
    },
    {
      "name": "Ricardo Pulido",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P235",
        "P327"
      ]
    },
    {
      "name": "Richard B Cannon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S226",
        "S259"
      ]
    },
    {
      "name": "Richard Bavier",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S083",
        "S093"
      ]
    },
    {
      "name": "Richard Smith",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271",
        "S217"
      ]
    },
    {
      "name": "Risa Wakisaka",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Robert B Baldwin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Robert J Lee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S468",
        "S577"
      ]
    },
    {
      "name": "Roberto Rangel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S279",
        "S380"
      ]
    },
    {
      "name": "Rocco M Ferrandino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S272",
        "S429"
      ]
    },
    {
      "name": "Rod Rezaee",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S004",
        "S547"
      ]
    },
    {
      "name": "Rodney Taylor",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Rosemary Martino",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S245",
        "S420"
      ]
    },
    {
      "name": "Rusha J Patel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P020",
        "S308"
      ]
    },
    {
      "name": "Rusha Patel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S084",
        "S566"
      ]
    },
    {
      "name": "Ryan Anderson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Ryan Halter",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060",
        "S149"
      ]
    },
    {
      "name": "Ryan Seng Hong Wong, MBBS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S068",
        "S209"
      ]
    },
    {
      "name": "Sabrina Wurzba",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106",
        "S396"
      ]
    },
    {
      "name": "Safa Kriuar, Miss",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P290",
        "P407"
      ]
    },
    {
      "name": "Sagus Sampath",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023",
        "S524"
      ]
    },
    {
      "name": "Salma Al Sheibani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P081",
        "P399"
      ]
    },
    {
      "name": "Samantha N Corman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P396",
        "P397"
      ]
    },
    {
      "name": "Samer Al-Khudari",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145",
        "S424"
      ]
    },
    {
      "name": "Samer T Elsamna",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Samuel Auger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S351",
        "S373"
      ]
    },
    {
      "name": "Samuel J Rubin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P171",
        "P277"
      ]
    },
    {
      "name": "Sara D O'Sullivan-Bakshi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P051",
        "P104"
      ]
    },
    {
      "name": "Sara E Monaco",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "Sarah R Harrington",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P340",
        "P440"
      ]
    },
    {
      "name": "Sarah Rohde",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S223",
        "S606"
      ]
    },
    {
      "name": "Sarah Sywanycz",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S468",
        "S577"
      ]
    },
    {
      "name": "Savinnie Ho",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S131",
        "S141"
      ]
    },
    {
      "name": "Scott A McLean",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P093",
        "P333"
      ]
    },
    {
      "name": "Scott C Lester",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S039",
        "S101"
      ]
    },
    {
      "name": "Scott Magnuson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S088",
        "S526"
      ]
    },
    {
      "name": "Sebastian Guadarrama-Sistos Vazquez",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P056",
        "P307"
      ]
    },
    {
      "name": "Seiya Goto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P183",
        "P368"
      ]
    },
    {
      "name": "Sepehr Shabani",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023",
        "S392"
      ]
    },
    {
      "name": "Serene Siow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S205",
        "S209"
      ]
    },
    {
      "name": "Seungjun Ahn",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P032",
        "S432"
      ]
    },
    {
      "name": "Shamir Chandarana",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P001",
        "P017"
      ]
    },
    {
      "name": "Shayanne Lajud",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P194",
        "P361"
      ]
    },
    {
      "name": "Shen Kai Ng",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S205",
        "S209"
      ]
    },
    {
      "name": "Sher-lyn Tham",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P212",
        "P408"
      ]
    },
    {
      "name": "Shivam D Patel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S206",
        "S453"
      ]
    },
    {
      "name": "Shivani M",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S072",
        "S588"
      ]
    },
    {
      "name": "Shlomo Koyfman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S038",
        "S372"
      ]
    },
    {
      "name": "Shouhao Zhou",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S167",
        "S299"
      ]
    },
    {
      "name": "Shrey Shah",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P100",
        "P175"
      ]
    },
    {
      "name": "Siddhant H Tripathi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Siddharth Sheth",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S144",
        "S520"
      ]
    },
    {
      "name": "Sina Dadafarin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P225",
        "P226"
      ]
    },
    {
      "name": "Sindhura Sridhar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S391",
        "S539"
      ]
    },
    {
      "name": "Sivraj Muralikrishnan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Smrithi Chidambaram, MSCI",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P098",
        "P277"
      ]
    },
    {
      "name": "Sobia F Khaja",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P246",
        "S545"
      ]
    },
    {
      "name": "Sofia Cortes",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S279"
      ]
    },
    {
      "name": "Sohil Singh",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S263",
        "S296"
      ]
    },
    {
      "name": "Soon-Hyun Ahn",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263",
        "S357"
      ]
    },
    {
      "name": "Soroush Ershadifar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274",
        "S425"
      ]
    },
    {
      "name": "Sreeram MP",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S407",
        "S471"
      ]
    },
    {
      "name": "Stefano Taboni",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Stepan V Pulukchu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S105",
        "S389"
      ]
    },
    {
      "name": "Stephanie Wong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P053",
        "S521"
      ]
    },
    {
      "name": "Stephen Glass",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S176",
        "S198"
      ]
    },
    {
      "name": "Stephen Nash",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P068",
        "P352"
      ]
    },
    {
      "name": "Stephen Y Kang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P255",
        "P256"
      ]
    },
    {
      "name": "Stergios Doumas",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S325",
        "S539"
      ]
    },
    {
      "name": "Steven Cannady",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P161",
        "S572"
      ]
    },
    {
      "name": "Steven Chang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S433",
        "S587"
      ]
    },
    {
      "name": "Steven Johnson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S098",
        "S144"
      ]
    },
    {
      "name": "Sudhir Nair",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S309",
        "S501"
      ]
    },
    {
      "name": "Sue S Yom",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S040",
        "S361"
      ]
    },
    {
      "name": "Suet Ying Wong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S369",
        "S376"
      ]
    },
    {
      "name": "Sumsum P Sunny, MDS",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S379",
        "S588"
      ]
    },
    {
      "name": "Sung Kim",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Supriya K",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S072"
      ]
    },
    {
      "name": "Susan D McCammon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P163",
        "S374"
      ]
    },
    {
      "name": "Susan McCammon",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Syeda Maria Ahmad Zaidi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P437",
        "S509"
      ]
    },
    {
      "name": "Taha A Mur",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Takahiro Asakage",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227",
        "S518"
      ]
    },
    {
      "name": "Takahiro Inoue",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Takumi Kumai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S278",
        "S584"
      ]
    },
    {
      "name": "Taylor E Freeman",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085"
      ]
    },
    {
      "name": "Teertha Shetty",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S407",
        "S471"
      ]
    },
    {
      "name": "Thomas Barrett",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S180",
        "S522"
      ]
    },
    {
      "name": "Thomas Hendriks",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P261",
        "P286"
      ]
    },
    {
      "name": "Thomas J Ow",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442",
        "S323"
      ]
    },
    {
      "name": "Thomas L Haupt",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357",
        "S385"
      ]
    },
    {
      "name": "Tiffany Glazer",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S179",
        "S564"
      ]
    },
    {
      "name": "Timothy L Lindemann",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "Tommy Jacob",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362",
        "S354"
      ]
    },
    {
      "name": "Tony Richa",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P071",
        "P381"
      ]
    },
    {
      "name": "Travis P Schrank",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S045",
        "S314"
      ]
    },
    {
      "name": "Trisha Wise-Draper",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220",
        "S524"
      ]
    },
    {
      "name": "Tseng-Cheng Chen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P101",
        "S123"
      ]
    },
    {
      "name": "Tsung-You Tsai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S137",
        "S519"
      ]
    },
    {
      "name": "Uttam K Sinha",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S151",
        "S524"
      ]
    },
    {
      "name": "Valentina Carducci",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S079",
        "S101"
      ]
    },
    {
      "name": "Vanessa Di Lalla",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S252",
        "S271"
      ]
    },
    {
      "name": "Vanessa Helou",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S043",
        "S514"
      ]
    },
    {
      "name": "Vasu Divi",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221",
        "S455"
      ]
    },
    {
      "name": "Vera Bzhilyanskaya",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "Veronica Sanhueza",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S130",
        "S261"
      ]
    },
    {
      "name": "Vijay Pillai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S585"
      ]
    },
    {
      "name": "Viran J Ranasinghe",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P411",
        "S440"
      ]
    },
    {
      "name": "Viran Ranasinghe",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S055",
        "S392"
      ]
    },
    {
      "name": "W. Greer Albergotti",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Wade Thorstad",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S037",
        "S303"
      ]
    },
    {
      "name": "Warren C Swegal",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P098",
        "P171"
      ]
    },
    {
      "name": "Wassim Najjar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S287",
        "S321"
      ]
    },
    {
      "name": "Wendell G Yarbrough, MMHC",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S098",
        "S327"
      ]
    },
    {
      "name": "Wesley L Hicks, Jr",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P380",
        "S379"
      ]
    },
    {
      "name": "William N Doyle",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145",
        "S552"
      ]
    },
    {
      "name": "Winston Wong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320",
        "S524"
      ]
    },
    {
      "name": "Wonjae Cha",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P263",
        "P304"
      ]
    },
    {
      "name": "Woo-Jin Jeong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P263",
        "P304"
      ]
    },
    {
      "name": "Xin Wu",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S131",
        "S141"
      ]
    },
    {
      "name": "Yang Chai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P035",
        "S470"
      ]
    },
    {
      "name": "Yarah M Haidar",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188",
        "S344"
      ]
    },
    {
      "name": "Yash Patil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Yasmin Edmonds, Miss",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P290",
        "P407"
      ]
    },
    {
      "name": "Yasuhiro Ebihara",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P232",
        "P264"
      ]
    },
    {
      "name": "Yelizaveta Semikina",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S427"
      ]
    },
    {
      "name": "Ying C Henderson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S182",
        "S388"
      ]
    },
    {
      "name": "Yonghong Huan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127"
      ]
    },
    {
      "name": "Yunyun Chen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S182",
        "S388"
      ]
    },
    {
      "name": "Yuval Avidor",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "Yvonne M Mowery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S428"
      ]
    },
    {
      "name": "Yvonne M Saenger",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S190",
        "S464"
      ]
    },
    {
      "name": "Zaelig Averch",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S190",
        "S217"
      ]
    },
    {
      "name": "Zaid Al-Qurayshi, MBChB",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P211",
        "S237"
      ]
    },
    {
      "name": "Zhenghao Wang",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P089",
        "P171"
      ]
    },
    {
      "name": "A Colaianni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "A Hammoudi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "A Kaskas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S282"
      ]
    },
    {
      "name": "A Markopoulos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "A McIntosh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "A Pearson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "A Perez-Atayde",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "A Ruaro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S575"
      ]
    },
    {
      "name": "A Tate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "A. Dimitrios Colevas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S304"
      ]
    },
    {
      "name": "A. Mlynarek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Aadel A Chaudhuri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Aadel Chaudhuri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Aakash Agarwal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P307"
      ]
    },
    {
      "name": "Aakash N Nagarapu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S092"
      ]
    },
    {
      "name": "Aaron Bliss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Aaron Ge",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "Aaron M Wieland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "Aaron Tucker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S152"
      ]
    },
    {
      "name": "Aaron Zebolsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Aastha Sharma, Otorhinolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Abdelaziz Alsharawy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S242"
      ]
    },
    {
      "name": "Abdul Abdel-Raheem",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Abdul-Rahman K Abdul-Reheem",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Abdulghafoor Alani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Abdullah Bhurgri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Abdullah Bin-Salman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Abdullah W Saleh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S256"
      ]
    },
    {
      "name": "Abdulrahman Nakshabandi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S148"
      ]
    },
    {
      "name": "Abhay Deshpande",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Abhijit Gundale",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Abhishek Mahajan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S309"
      ]
    },
    {
      "name": "Abideen O Yekinni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P086"
      ]
    },
    {
      "name": "Abiramy D/O Anathan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Achraf Shamseddine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Adam Benson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Adam Bess",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Adam Garden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Adam Hamawy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Adam Holtzman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Adam J Rosenberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Adam Raben",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Adam Rosenburg, Research Assoc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Adam S Garden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Adedamola Adeniyi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Adena Li Tyin Peh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Adham Aljariri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Adhya Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Adi Sharabi-Nov",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Aditi Kulkarni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Adriana Vélez-Avilés",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S502"
      ]
    },
    {
      "name": "Advika Sumit",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Ah Ra Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P400"
      ]
    },
    {
      "name": "Ahmad J Odeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S362"
      ]
    },
    {
      "name": "Ahmed Beydoun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Ahmed Diab",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Ahmed Tajmim Noor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Ahsan Ahmed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S289"
      ]
    },
    {
      "name": "Aidan H Coyle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S285"
      ]
    },
    {
      "name": "Aiiman Salhav",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Aimee Israel, MSW, LCSW",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Aina Brunet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P003"
      ]
    },
    {
      "name": "Aina Brunet Garcia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Ainsley Kohler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Ainul Akbar Mughal, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S467"
      ]
    },
    {
      "name": "Ajay Bezawada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "Ajay Bharathan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P077"
      ]
    },
    {
      "name": "Akari Unome",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Akhilesh Wodeyar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S374"
      ]
    },
    {
      "name": "Akihiro Homma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Akshay Dinesan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Akshay Prabhakar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Akshay Vasudevan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Akshaya Raman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S453"
      ]
    },
    {
      "name": "Ala Refai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S420"
      ]
    },
    {
      "name": "Alain Algazi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Alaina Carr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Alan L Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Alan Shattuck",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Alban J Linnenbach",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Albert C Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P423"
      ]
    },
    {
      "name": "Albert Han",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S030"
      ]
    },
    {
      "name": "Alec Vaezi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Alejandra Varela",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Alejandro Kochen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P436"
      ]
    },
    {
      "name": "Alejandro Santiago Nazario",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Alejandro Santiago-Nazario",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Alekhya Pidugu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S456"
      ]
    },
    {
      "name": "Aleksandra Ogurtsova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Alena Pauley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Alessa Colaianni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Alex Abdollahzadeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Alex Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S017"
      ]
    },
    {
      "name": "Alex Chen, BASc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Alex Dobriyan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Alex Harbison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S027"
      ]
    },
    {
      "name": "Alex Kejner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Alex Lichtl",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S023"
      ]
    },
    {
      "name": "Alex M Mlynarek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Alex Mlynarek, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Alex O Esemezie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S134"
      ]
    },
    {
      "name": "Alex Reznik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P063"
      ]
    },
    {
      "name": "Alex T Cheng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Alexa De la Fuente Hagopian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Alexander Abodllahzadeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S569"
      ]
    },
    {
      "name": "Alexander Drilon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Alexander Fairman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P127"
      ]
    },
    {
      "name": "Alexander Fish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P350"
      ]
    },
    {
      "name": "Alexander Graf",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Alexander J Langerman, SM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S562"
      ]
    },
    {
      "name": "Alexander Jones",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Alexander Kejner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Alexander Ladenheim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166"
      ]
    },
    {
      "name": "Alexander Langerman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Alexander Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Alexander Moise, MDCM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Alexander P Marston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Alexander Poulakis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P005"
      ]
    },
    {
      "name": "Alexandra E Turfe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S608"
      ]
    },
    {
      "name": "Alexandra Kejner, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Alexandra M Naicker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Alexandra Vacaru",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P376"
      ]
    },
    {
      "name": "Alexandre Santos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Alfred M Iloreta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Alfredo Saavedra, Clinical Oncologist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Ali Hosni Abdalaty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317"
      ]
    },
    {
      "name": "Ali Hosni, MBBCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "Alicia Alvarado, Pathologist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Alicia B Yang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S432"
      ]
    },
    {
      "name": "Alina Galaria",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S449"
      ]
    },
    {
      "name": "Aline P Miazaki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Alireza Mirmiran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Alisa L Phillips",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P326"
      ]
    },
    {
      "name": "Alisa Vidwans",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "Alison L Tuominen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P312"
      ]
    },
    {
      "name": "Alison M Taylor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P038"
      ]
    },
    {
      "name": "Alissa A Nolden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Alistaire D Ruggiero-Sherman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S064"
      ]
    },
    {
      "name": "Aliya Hyman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S229"
      ]
    },
    {
      "name": "Aliyah Pabani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Allen S Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Allison Ciolino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Allison H Maciver, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P070"
      ]
    },
    {
      "name": "Allison Nipper",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "Allyson R Cochran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Alok R Khandelwal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Alvaro Emilio Arteaga Guamán",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P203"
      ]
    },
    {
      "name": "Alvaro L Oliveira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S435"
      ]
    },
    {
      "name": "Alyanna Melicor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P428"
      ]
    },
    {
      "name": "Alyanna Melicor, Project Manager",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P430"
      ]
    },
    {
      "name": "Alyssa Civantos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Alyssa Heiser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P426"
      ]
    },
    {
      "name": "Alyssa Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Alyssa Steinbaum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S490"
      ]
    },
    {
      "name": "Amanda B Figueiredo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Amanda Carston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Amanda Ding",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Amanda E Dilger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P028"
      ]
    },
    {
      "name": "Amanda Karcioglu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P386"
      ]
    },
    {
      "name": "Amanda L Verzosa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S064"
      ]
    },
    {
      "name": "Amanda N Hollinger, MPA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Amanda Phipps",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S143"
      ]
    },
    {
      "name": "Amanda Psyrri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Amanda Reyes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Amanda Shen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Amanda Streeper, NP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Amanda Ting",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Amanda Wissmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S119"
      ]
    },
    {
      "name": "Amanda Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S307"
      ]
    },
    {
      "name": "Amani Kais",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P295"
      ]
    },
    {
      "name": "Amanjit Bal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Ambika Parmar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S134"
      ]
    },
    {
      "name": "Ameen Amanian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P015"
      ]
    },
    {
      "name": "Amelia Nichols, CPH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Amelie Marshall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Ameya Asarkar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P185"
      ]
    },
    {
      "name": "Amir H Safavi, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Amir Horowitz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S274"
      ]
    },
    {
      "name": "Amir Parham Pirhadi Rad, Student",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P055"
      ]
    },
    {
      "name": "Amit Joshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Amiya Agrawal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Ammaar Kazi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Amna Ramadan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S454"
      ]
    },
    {
      "name": "Amra M Vranjkovina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S317"
      ]
    },
    {
      "name": "Amrita Bonthu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S553"
      ]
    },
    {
      "name": "Amy Ann Lassig",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Amy Halter, Doctor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P021"
      ]
    },
    {
      "name": "Amy Irwin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Amy J Wagers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Amy Juliano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S356"
      ]
    },
    {
      "name": "Amy Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S399"
      ]
    },
    {
      "name": "Amy Wozniak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Ana Carolina Prado-Ribeiro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Ana Catarina Silva e Silva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168"
      ]
    },
    {
      "name": "Ana Gomes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Ana K Leite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Ana Luiza Marques",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445"
      ]
    },
    {
      "name": "Ana Luiza de Araújo Butarelli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Ana M Mercante",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Ana O Hoff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Ana Paula Lepique",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Anais A Zourelidis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Anand Devaiah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P008"
      ]
    },
    {
      "name": "Anand Ramakrishnan, MBBS, FRACS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Anandan Gerard Thiagarajah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Anandhini D Narayanan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P360"
      ]
    },
    {
      "name": "Ananya Pal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Ananya Uddanti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S011"
      ]
    },
    {
      "name": "Anas Eid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Anav Rattan, Senior Resident",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P074"
      ]
    },
    {
      "name": "Anderson Dewitt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P170"
      ]
    },
    {
      "name": "Anderson Scott",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Andre Bandiera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P059"
      ]
    },
    {
      "name": "Andrea Fung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Andrea Fung, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Andrea Gillis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Andrea L Pusic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Andrea Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Andrea Pusic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Andrea Snitchler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P277"
      ]
    },
    {
      "name": "Andres Aguirre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Andres Gempeler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Andressa T Ramos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S607"
      ]
    },
    {
      "name": "Andrew Bayley, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Andrew Blount",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S022"
      ]
    },
    {
      "name": "Andrew Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S059"
      ]
    },
    {
      "name": "Andrew C Prince",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "Andrew Coughlin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Andrew D Prince",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S419"
      ]
    },
    {
      "name": "Andrew Fong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Andrew George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Andrew Griffin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S460"
      ]
    },
    {
      "name": "Andrew Hernandez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Andrew Hong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Andrew Ibrahim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S288"
      ]
    },
    {
      "name": "Andrew J Bellas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338"
      ]
    },
    {
      "name": "Andrew J McWhorter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Andrew Larson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S487"
      ]
    },
    {
      "name": "Andrew M Harding",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Andrew M Ibrahim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S289"
      ]
    },
    {
      "name": "Andrew McPartlin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S420"
      ]
    },
    {
      "name": "Andrew Peterson, MSCI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338"
      ]
    },
    {
      "name": "Andrew R Salama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331"
      ]
    },
    {
      "name": "Andrew Salama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S126"
      ]
    },
    {
      "name": "Andrew Sikora",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Andrew Simpson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Andrew South",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Andrew T Huang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "Andrew Tassler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S345"
      ]
    },
    {
      "name": "Andrew Y Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Andrew Yousef",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Andrey Finegeresh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S404"
      ]
    },
    {
      "name": "André C Martins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "André Santos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S269"
      ]
    },
    {
      "name": "André de Souza S Potenza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Andrés M Bur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P444"
      ]
    },
    {
      "name": "Andy Jian Kai Chua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P230"
      ]
    },
    {
      "name": "Anela Thomas, BDS, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Anela Thomas, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Angela C Xie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P091"
      ]
    },
    {
      "name": "Angela D Haskins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S604"
      ]
    },
    {
      "name": "Angela J Yoon, MAMSc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S389"
      ]
    },
    {
      "name": "Angela Magri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "Angela Osmolak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Angelica Walker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P342"
      ]
    },
    {
      "name": "Angelleen Peters-Lewis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Anika Walia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S449"
      ]
    },
    {
      "name": "Anirudh Yalamanchali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Anish Ghodadra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S479"
      ]
    },
    {
      "name": "Anish K Bhattacharya, Head",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Anish Palli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Anita Pothukuchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S472"
      ]
    },
    {
      "name": "Anjali Desai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Anjali Keshavamurthy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Anjul M Bansal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P008"
      ]
    },
    {
      "name": "Ankit Chhajed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S454"
      ]
    },
    {
      "name": "Ankita Mehta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Ankur Walli, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P131"
      ]
    },
    {
      "name": "Ann Ann Scheck McAlearney, ScD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S199"
      ]
    },
    {
      "name": "Ann Kearney, CScD, CCCSLP, BCSS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Ann M Egloff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Ann Scheck McAlearney, ScD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S195"
      ]
    },
    {
      "name": "Anna Blakely, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S419"
      ]
    },
    {
      "name": "Anna Blakely, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Anna Bogursky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P415"
      ]
    },
    {
      "name": "Anna Christina Clements",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S595"
      ]
    },
    {
      "name": "Anna J Orr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Anna Miller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Anna Szombathy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S036"
      ]
    },
    {
      "name": "Anna Xinyin See, Senior Consultant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Annaliese Opran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374"
      ]
    },
    {
      "name": "Anne F Klassen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Anne Fischer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P391"
      ]
    },
    {
      "name": "Anne Grand'Maison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P421"
      ]
    },
    {
      "name": "Anne Grandmaison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Anne Kane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Anne-Renee Hartman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Anneliese Opran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Annemieke van Zante",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S472"
      ]
    },
    {
      "name": "Annie Arrighi-Allisan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S011"
      ]
    },
    {
      "name": "Annie Suctte",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Annie W Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S441"
      ]
    },
    {
      "name": "Anoushka Taneja",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Anshu Giri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Anthony E Dipalma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S158"
      ]
    },
    {
      "name": "Anthony Nichols, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Anthony Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358"
      ]
    },
    {
      "name": "Antoine Desilets",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S003"
      ]
    },
    {
      "name": "Antoine Désilets",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S211"
      ]
    },
    {
      "name": "Antoine Eskander",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S134"
      ]
    },
    {
      "name": "Antoinette R Esce",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P163"
      ]
    },
    {
      "name": "Antonello Vidiri, Radiology Specialist, Chief of the ra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S500"
      ]
    },
    {
      "name": "Antonieta Solar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Antonino Cassara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Antonino Cassarà",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Antonio Franco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S293"
      ]
    },
    {
      "name": "Antony Hodgson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Anuja Deshmukh, PROF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Anuraag S Parikh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Anusha Dabak, BSA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S055"
      ]
    },
    {
      "name": "Anusha Naik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Anushka Jetly, AB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "Anushka Pradhan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Anya Forma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145"
      ]
    },
    {
      "name": "Apar Ganti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Apar Kishor Ganti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Apoorva T Ramaswamy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P424"
      ]
    },
    {
      "name": "Apostolos Christopoulos, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Arash Abiri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Arata Horii",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Arati Bendapudi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S055"
      ]
    },
    {
      "name": "Archer Schaeffer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S339"
      ]
    },
    {
      "name": "Ardeen Nicholas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Areeb Iraqi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S598"
      ]
    },
    {
      "name": "Ari Moskowitz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Aria Jafari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Ariana Sahli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S240"
      ]
    },
    {
      "name": "Arianna Winchester",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P373"
      ]
    },
    {
      "name": "Ariel Frost",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "Arielle Thal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340"
      ]
    },
    {
      "name": "Aris Spathis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Aritra Chatterjee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Armin Namvar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Armo Derbarsegian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Arnaud F Bewley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S425"
      ]
    },
    {
      "name": "Arnav Pemmaraju",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P034"
      ]
    },
    {
      "name": "Arnoldo Corona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Aron Popovtzer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Aronpreet Atwell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Arshbir Aulakh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Aru Panwar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Arushi Gulati",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Arvind Rao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S124"
      ]
    },
    {
      "name": "Arya Amini",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Arya Bhanu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Arya Dahal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144"
      ]
    },
    {
      "name": "Aryan Safakish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S005"
      ]
    },
    {
      "name": "Asad Iqbal, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257"
      ]
    },
    {
      "name": "Asher C Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Ashish A Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Ashish Dahal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S148"
      ]
    },
    {
      "name": "Ashish V Chintakuntlawar, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Ashley H Aiken",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Ashley Jackson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Ashley M Pham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P014"
      ]
    },
    {
      "name": "Ashley Sellers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S127"
      ]
    },
    {
      "name": "Ashley Tellis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Ashley Weichmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Ashlynn Gober",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S450"
      ]
    },
    {
      "name": "Ashok R Shaha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P103"
      ]
    },
    {
      "name": "Ashok Shaha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Ashok Z Samuel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Ashton Huppert Steed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P179"
      ]
    },
    {
      "name": "Ashtyn G McAdoo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Ashwath Ashok",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Ashwini Budrukkar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Atish Gandhi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Atonanzas Lisa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Atsuko Sakanushi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Atticus Turner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Audrey Abend",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "August Culbert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Augusto César Castro, Oral Surgeon and Pathotogist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P143"
      ]
    },
    {
      "name": "Augusto González Gómez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Aundria Parkman, MLIS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Austin Lam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P355"
      ]
    },
    {
      "name": "Austin Schafer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Austin Shelton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Austin T Armstrong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S092"
      ]
    },
    {
      "name": "Avery L Richardson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S438"
      ]
    },
    {
      "name": "Avery Richardson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S434"
      ]
    },
    {
      "name": "Avigeet Gupta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P243"
      ]
    },
    {
      "name": "Avishai Wizel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Avital Fellner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Avraham Adelman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Ayesha Saleem, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257"
      ]
    },
    {
      "name": "Ayham Al Afif",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Aynharan Sinnarajah, CCFP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Ayush G Iyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "B Aouizerat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "B Luong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "Babak Shadgan, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P055"
      ]
    },
    {
      "name": "Bac A Luong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Badi El Osta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Badr Ibrahim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "Bailey Swaffar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Balaji Sadhasivam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Bamdad Tayyari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P369"
      ]
    },
    {
      "name": "Bao Luu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Bao Sciscent",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Barak Spector",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "Baran D Sumer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Barry L Wenig",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201"
      ]
    },
    {
      "name": "Barry M Berger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Bas Keizers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Basir S Mansoor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Bastien Valencia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Basu Devraj",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S045"
      ]
    },
    {
      "name": "Beatriz F",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Beatriz Fernandes de Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Beatriz Souza, Master of Science",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Becky Tsang, MSPA, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Behnoush Mortazavi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S381"
      ]
    },
    {
      "name": "Bei Jun Yap, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Ben B Levy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Ben Panizza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Ben Schiff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Ben Wahle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Benedict Neo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Benjamin Adams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S027"
      ]
    },
    {
      "name": "Benjamin Aunins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P199"
      ]
    },
    {
      "name": "Benjamin Haibe-Kains",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "Benjamin Judson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Benjamin M Wahle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S027"
      ]
    },
    {
      "name": "Benjamin Oakes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Benoît Trap",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Bernardo Peryassú",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P178"
      ]
    },
    {
      "name": "Bernice Oberman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Bert van der Vegt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Bertrand Cailliau, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Beth M Beadle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234"
      ]
    },
    {
      "name": "Beth M Beadle, FASTRO",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Beth N McLellan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Bethany Rohr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378"
      ]
    },
    {
      "name": "Bethany Sargent",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S395"
      ]
    },
    {
      "name": "Betsy Davis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S016"
      ]
    },
    {
      "name": "Beverly Garber, DNP, ANP, CORLN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S087"
      ]
    },
    {
      "name": "Beverly Garber, DNP, ANPBC, CORLN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S172"
      ]
    },
    {
      "name": "Beverly Garber, DNP, ANPC, CORLN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S197"
      ]
    },
    {
      "name": "Bezawit Kase",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261"
      ]
    },
    {
      "name": "Bharat Panuganti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Bharghabi Pau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Bhavani S Gowda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Bhinya R Jat, Senior Resident",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P294"
      ]
    },
    {
      "name": "Bhisham Chera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Bhisham S Chera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Bhumika Srinivas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Bianca Bonafont",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Bijal Amin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Bijoy Jacob Thomas Jacob Thomas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Billy Yang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "Bin Huang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S431"
      ]
    },
    {
      "name": "Bin Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Bing Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Bingcheng Wu, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S444"
      ]
    },
    {
      "name": "Bingcheng Wu, MBBS, FRCPath",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Bipin T Varghese",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P195"
      ]
    },
    {
      "name": "Boin Choi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P009"
      ]
    },
    {
      "name": "Boon Cher Goh, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Boudewijn Plaat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Bouganim Nathaniel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Boyan Hu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S146"
      ]
    },
    {
      "name": "Brad Neville",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261"
      ]
    },
    {
      "name": "Brad Strong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Bradford Gill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Bradley Aouizerat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S377"
      ]
    },
    {
      "name": "Bradley Moon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Brandee Brown, Research Manager",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Brandee T Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Branden Qi Yu Chua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P230"
      ]
    },
    {
      "name": "Brandon Gunn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S168"
      ]
    },
    {
      "name": "Brandon L Prendes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Brandon Mo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S387"
      ]
    },
    {
      "name": "Brandon Prendes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Brandon Strong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Brandon Tapasak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P068"
      ]
    },
    {
      "name": "Brant Hannahs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Brenda Villegas, EdD, CCC-SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "Brendan C Stack, Jr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Brendan Knapp",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Brendan L Kinney",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S273"
      ]
    },
    {
      "name": "Brennan G Olson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S071"
      ]
    },
    {
      "name": "Brent A Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Brett A Campbell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Brette Harding",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S593"
      ]
    },
    {
      "name": "Brian A Nuyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Brian Allen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Brian B Hughley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P372"
      ]
    },
    {
      "name": "Brian Burkey, MEd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S406"
      ]
    },
    {
      "name": "Brian Niland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P277"
      ]
    },
    {
      "name": "Brian Nussenbaum, MHCM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Brian P Swendseid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P191"
      ]
    },
    {
      "name": "Brian R Quaranto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "Brian W Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Brian Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Brianna Maniscalco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P267"
      ]
    },
    {
      "name": "Briant Fruth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Bridger Woods",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046"
      ]
    },
    {
      "name": "Bridget McLeod, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Bridget Reeves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "Bridgett Harr, CNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Brielle Raine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "Brina Emu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166"
      ]
    },
    {
      "name": "Brinda Emu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S502"
      ]
    },
    {
      "name": "Britney He",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Brittney Dickey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Brittny Tillman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Brooke Meyer, MSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S087"
      ]
    },
    {
      "name": "Bruce Daniel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S384"
      ]
    },
    {
      "name": "Bruce Davidson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P299"
      ]
    },
    {
      "name": "Bruna C Silva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Bruno Albuquerque Sousa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Bss Srinath, Mch, Surgical Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S012"
      ]
    },
    {
      "name": "Byung Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S018"
      ]
    },
    {
      "name": "Béatrice Voizard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "C B Wood",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "C Lumley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "C Orgain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P236"
      ]
    },
    {
      "name": "C Thomas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "C Tsien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "C Viet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "C. Alessandra Colaianni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "C. Burton Wood, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "C. Rene Leemans",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "C. Tsien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "CK Waite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "Caden Duffy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P211"
      ]
    },
    {
      "name": "Caglar Derin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Caia Hypatia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Caitlin McMullen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Caitlin Stone, MCD, CCCSLP, BCSS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P177"
      ]
    },
    {
      "name": "Callas Peter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Cameron C Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Cameron Galic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Cameron MacDonald",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Camila De Oliveira R Pegoraro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Can Ozturk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P380"
      ]
    },
    {
      "name": "Carine Tamamian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P302"
      ]
    },
    {
      "name": "Carine Tamanian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Carl B Clay Jr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S476"
      ]
    },
    {
      "name": "Carl H Snyderman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Carl Ren",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S382"
      ]
    },
    {
      "name": "Carleigh R Burns",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Carlo Resteghini",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Carlos Castellanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Carlos Crespo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Carlos E Ferreira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Carlos Eduardo M Nardi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S418"
      ]
    },
    {
      "name": "Carlos Eduardo R Fernandes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P432"
      ]
    },
    {
      "name": "Carlos H Pavan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Carlos Lange Nava",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P196"
      ]
    },
    {
      "name": "Carlos T Chone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Carlos X Castellanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Carly E Barbon, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016"
      ]
    },
    {
      "name": "Carmen Gomez Fernandez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "Carmen Marcela Quezada, Pathologist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P139"
      ]
    },
    {
      "name": "Carol M Bier-Laning",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Carol Rouphael",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Carolina Contador",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Caroline Curtin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P154"
      ]
    },
    {
      "name": "Caroline Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S221"
      ]
    },
    {
      "name": "Caroline R Christmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P075"
      ]
    },
    {
      "name": "Caroline Rozzo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S553"
      ]
    },
    {
      "name": "Carolyn A DeBiase",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Carolyn Debiase",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P375"
      ]
    },
    {
      "name": "Carolyn Hsu, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Carolyn Rachofsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Carolyn S Abraham, MSCCCSLP, BCSS, CLT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S355"
      ]
    },
    {
      "name": "Carrie P Flanagan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Caryn J Ha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "Casey Collet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S146"
      ]
    },
    {
      "name": "Casey Mehrhoff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "Catherine A Colaianni, MPhil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Catherine Barnett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Catherine Colaianni, MPhil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Catherine H Frenkel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Catherine J Lumley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Catherine M Chung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Catherine Rennie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Ce-Bella Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Cecelia M Hidalgo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Celeste S Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S417"
      ]
    },
    {
      "name": "Cesar Migliorati",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Cesare Piazza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Cessal T Kainickal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Chad Brenner, MSE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Chaitali Nangia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Chandler Rygalski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S127"
      ]
    },
    {
      "name": "Chandrashekar Dravid, PROF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Changsong Qi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Chanita Hughes-Halbert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Charbél Talani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Charles B Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S196"
      ]
    },
    {
      "name": "Charlotte Kuperwasser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Charmaine Tan, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Chase Heaton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Chase Hintelmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Chayce Ross",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S017"
      ]
    },
    {
      "name": "Chee Yit Lim, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Chelsea S Hamill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Cheng-Ming Hsu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P052"
      ]
    },
    {
      "name": "Cheng-Ping Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Cher An Javier Chee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Cherie-Ann O. Nathan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S007"
      ]
    },
    {
      "name": "Cheryl Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P323"
      ]
    },
    {
      "name": "Chetan S Nayak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P289"
      ]
    },
    {
      "name": "Cheyenne Corbett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Chi Viet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Chia-En Lu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Chia-Jung Busch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Chiara E Mussi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Chih-Chin Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Chih-Yen Chien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P311"
      ]
    },
    {
      "name": "Chinazo Onyema",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S602"
      ]
    },
    {
      "name": "Ching Shen Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S273"
      ]
    },
    {
      "name": "Ching-Yuan Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Chirag K Ahuja",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Chirag Raval",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Chiristi Longnecker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Chisato Shito",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Chistiana Vanni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P059"
      ]
    },
    {
      "name": "Chloe E Derocher, BSE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P179"
      ]
    },
    {
      "name": "Chloe Watkins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P305"
      ]
    },
    {
      "name": "Chor Hiang Siow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Chris B Choi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201"
      ]
    },
    {
      "name": "Chris Holsinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Chris Vugt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Christabel Oghinan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Christian Simon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "Christian Turner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S060"
      ]
    },
    {
      "name": "Christina Baik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Christina H Fang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Christina Yip",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Christine B Peterson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S169"
      ]
    },
    {
      "name": "Christine C Little",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P075"
      ]
    },
    {
      "name": "Christine G Gourin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Christophe Goncalves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S396"
      ]
    },
    {
      "name": "Christophe Le Tourneau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Christopher C Tseng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S185"
      ]
    },
    {
      "name": "Christopher F",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002"
      ]
    },
    {
      "name": "Christopher H Rassekh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S011"
      ]
    },
    {
      "name": "Christopher Holsinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "Christopher Khudari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Christopher Klem",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Christopher Kruglik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Christopher Lemmon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Christopher M Yao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "Christopher M Yao, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "Christopher Nielson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S450"
      ]
    },
    {
      "name": "Christopher Noel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Christopher P Kruglik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Christopher Pishvaian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Christopher T Wilke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S545"
      ]
    },
    {
      "name": "Christopher U Jones",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Christopher Vanison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S603"
      ]
    },
    {
      "name": "Christopher W Noel, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "Christopher Waite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403"
      ]
    },
    {
      "name": "Chuan Keng Goh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Chulwoo Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Chun-Ju Chiang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Chun-Nan Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "Chun-Wei Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Chun-Yang Hung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Chwee Ming Lim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "Chwee Ming Lim, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Chwee Ming Lim, MBBS, MRCSEdin, MMedORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "Ciaran Lane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Ciaran Powers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P156"
      ]
    },
    {
      "name": "Claire E Tolan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P386"
      ]
    },
    {
      "name": "Claire Eiden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S024"
      ]
    },
    {
      "name": "Claire Fritz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Claire Gleadhill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378"
      ]
    },
    {
      "name": "Claire M Gleadhill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S553"
      ]
    },
    {
      "name": "Clara Arrate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Clare Schilling",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Claudia Cabrera Aviles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S202"
      ]
    },
    {
      "name": "Clifford C Stephen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S579"
      ]
    },
    {
      "name": "Clifford Stephan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S583"
      ]
    },
    {
      "name": "Clovis A L Pinto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S129"
      ]
    },
    {
      "name": "Clovis A Pinto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P268"
      ]
    },
    {
      "name": "Clóvis A Lopes Pinto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Cody Sullivan, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Cole Kendall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Colette J Shen, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Colewyn D Knoblich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P215"
      ]
    },
    {
      "name": "Colin Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S054"
      ]
    },
    {
      "name": "Colin Mackay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Collin Mulcahy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Colton Ladbury",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Conall W Fitzgerald, MB, BCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Cong Fan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Connor Burns",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Connor Holmes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S484"
      ]
    },
    {
      "name": "Conrad Blunck",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Constance Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Cooper Schwartz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "Coral Karunakaran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Corrina Z Tan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "Courtney Hunter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "Courtney King",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Craig Buchman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Cristina Benites",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P328"
      ]
    },
    {
      "name": "Cristina Benites, MBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Cristina Lopez-Roman, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Cristina Verea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P407"
      ]
    },
    {
      "name": "Crystal Hattum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Crystal Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Cynthia Ogoro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "D Golden, MHPE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "D Ma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "D Neil Hayes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S027"
      ]
    },
    {
      "name": "D Neskey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "D Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "D Rajeev",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "D Weatherford",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "D Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "D'Antoni C Dennis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "D. Caglar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "D. Greg Farwell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S572"
      ]
    },
    {
      "name": "Daan Roos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Dahee Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P009"
      ]
    },
    {
      "name": "Dai Imamura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Daijuanru Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S376"
      ]
    },
    {
      "name": "Dale Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Dale H Brown, MB, BCh, BAO, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "Dalia N Mitchell, MSCI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Damian Quiroz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Dan M Fliss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Danae Alexandrou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S564"
      ]
    },
    {
      "name": "Dane Grenda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340"
      ]
    },
    {
      "name": "Dane N Fernandez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Dang-Khoa Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S460"
      ]
    },
    {
      "name": "Daniel A Otchere",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S185"
      ]
    },
    {
      "name": "Daniel Alam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Daniel Benito",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P355"
      ]
    },
    {
      "name": "Daniel Brobst",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Daniel Brungs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Daniel Bu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Daniel Bu, MPP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S527"
      ]
    },
    {
      "name": "Daniel D Bu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S356"
      ]
    },
    {
      "name": "Daniel D Bu, MPP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P069"
      ]
    },
    {
      "name": "Daniel Dohan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Daniel G Eyassu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Daniel Gilmore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S199"
      ]
    },
    {
      "name": "Daniel Gorelik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P307"
      ]
    },
    {
      "name": "Daniel Kruituk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "Daniel Krutik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S463"
      ]
    },
    {
      "name": "Daniel Krutik, BScMed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206"
      ]
    },
    {
      "name": "Daniel L Faden, . Massachusetts Eye & Ear",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Daniel L Marks",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S071"
      ]
    },
    {
      "name": "Daniel M Ramos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S292"
      ]
    },
    {
      "name": "Daniel Ma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Daniel Miller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Daniel Najafali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Daniel Price",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Daniel R Torres",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S065"
      ]
    },
    {
      "name": "Daniel S Brickman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Daniel S Shin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Daniel Stuart",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Daniel Suarez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "Daniel Sukato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357"
      ]
    },
    {
      "name": "Daniel Swanson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P299"
      ]
    },
    {
      "name": "Daniel W Scholfield, MB, ChB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S233"
      ]
    },
    {
      "name": "Daniel W Scholfield, MBChB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S366"
      ]
    },
    {
      "name": "Daniel Xiao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P122"
      ]
    },
    {
      "name": "Daniel Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P243"
      ]
    },
    {
      "name": "Daniela Castanotto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Daniele Moreira Peres",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445"
      ]
    },
    {
      "name": "Daniella Karassawa Zanoni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S366"
      ]
    },
    {
      "name": "Danielle M Bottalico",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Danielle Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Danielle Tomer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Daniyah Saleh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S382"
      ]
    },
    {
      "name": "Dannelys Perez Bello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P262"
      ]
    },
    {
      "name": "Dannielle Allen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Danny Enepekides, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Danny Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S427"
      ]
    },
    {
      "name": "Dante De Paz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S409"
      ]
    },
    {
      "name": "Daodang Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Darren Broughton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S388"
      ]
    },
    {
      "name": "Darren M Broughton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S182"
      ]
    },
    {
      "name": "Darrion L Mitchell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "David A Cronkite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "David Addison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "David Allen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S086"
      ]
    },
    {
      "name": "David B Goldston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "David Balis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "David Booth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "David Burkett, JD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "David C Shonka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P199"
      ]
    },
    {
      "name": "David Cohn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "David E Rosow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S333"
      ]
    },
    {
      "name": "David G Schlundt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S127"
      ]
    },
    {
      "name": "David Hamlar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "David Hirsch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341"
      ]
    },
    {
      "name": "David I Rosenthal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "David J Anderson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "David L Tran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "David M Neskey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "David M Weatherford",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P180"
      ]
    },
    {
      "name": "David Octeau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P433"
      ]
    },
    {
      "name": "David P Goldstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "David P Goldstein, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "David P Strum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019"
      ]
    },
    {
      "name": "David Riccio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P155"
      ]
    },
    {
      "name": "David Rule",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "David S Hong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "David Sarne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "David Shimunov",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S603"
      ]
    },
    {
      "name": "David Suster",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S343"
      ]
    },
    {
      "name": "David U Sanchez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S120"
      ]
    },
    {
      "name": "David W Forner, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "David W Hutton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S285"
      ]
    },
    {
      "name": "Davide Botta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S270"
      ]
    },
    {
      "name": "Dean C Pavlick",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Deborah J Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Deborah Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "Deema ElRufaei",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Deepa Danan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S073"
      ]
    },
    {
      "name": "Deepa Nair, PROF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Deepak Gurushanthaiah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357"
      ]
    },
    {
      "name": "Deepak Lakshmipathy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Deepak Ramsingh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Deepthi Pagidimarri, BDS, MAS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S249"
      ]
    },
    {
      "name": "Dejana Braithwaite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Denise D'Andrea, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Derek S Mann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S159"
      ]
    },
    {
      "name": "Derrick Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S498"
      ]
    },
    {
      "name": "Dervishan Sezer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Dev Mukundan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S494"
      ]
    },
    {
      "name": "Dhanam Raghupathy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Dhara Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P108"
      ]
    },
    {
      "name": "Dhara de Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P109"
      ]
    },
    {
      "name": "Dharam Vir, Associate Audiology & Speech",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P074"
      ]
    },
    {
      "name": "Di Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S144"
      ]
    },
    {
      "name": "Diana N Kirke, MPhil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Diana Oramas Mogrovejo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P135"
      ]
    },
    {
      "name": "Diana Shaari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S490"
      ]
    },
    {
      "name": "Diana Whitaker-Menezes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Diane Lorenzetti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Diane Pan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S482"
      ]
    },
    {
      "name": "Dianna Roberts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "Diego Carillo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Diego E Razura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Diego Mendez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Diego Redondo Rivera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Dieter Haemmerich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S389"
      ]
    },
    {
      "name": "Dillon Strepay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S246"
      ]
    },
    {
      "name": "Dina Modin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337"
      ]
    },
    {
      "name": "Dinesh Chhetri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Dinesh K Chhetri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Divya Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P398"
      ]
    },
    {
      "name": "Doga Demirel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Domenica Voli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S449"
      ]
    },
    {
      "name": "Domenico Russo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Dominick Rich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Domnita-Ileana Burcoveanu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Donald Anderson, Clinical",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P055"
      ]
    },
    {
      "name": "Donald Annino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Donald J Annino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Donald L Rosenstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Donald Weed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P026"
      ]
    },
    {
      "name": "Donalrey Nieva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Dongbin Ahn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S114"
      ]
    },
    {
      "name": "Donita Dyalram",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Donovan Eu, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Doreen Lam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Dorothy Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S241"
      ]
    },
    {
      "name": "Doru M Paul",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Doug Chepeha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Doungporn Rodpitaks",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Drew Hurd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Duane V Trahan, CCCSLP, BCSS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P177"
      ]
    },
    {
      "name": "Duc M Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Dustin Firmenich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Dylan Fall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P099"
      ]
    },
    {
      "name": "Dylan Roden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Dylan Z Erwin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P312"
      ]
    },
    {
      "name": "E Ostby",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P236"
      ]
    },
    {
      "name": "E Weitman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "Eben Rosenthal, Dept Chairperson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Ebrahim Chaudhry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "Ebunoluwa Morakinyo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P167"
      ]
    },
    {
      "name": "Eddy Manih, BEng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S003"
      ]
    },
    {
      "name": "Eden R Brauer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Edgar D Sanchez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S264"
      ]
    },
    {
      "name": "Edmund Howe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S092"
      ]
    },
    {
      "name": "Eduardo Aluicio Sarduy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Edward Christopher Dee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Edward J Damrose",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Edward Sim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Ege Cubuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P389"
      ]
    },
    {
      "name": "Ehab Hanna",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Eiling Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Eiman Stiffler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S202"
      ]
    },
    {
      "name": "Eladio Rodriguez-Diaz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Elaine Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Elaine Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P018"
      ]
    },
    {
      "name": "Elena Colombo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Eleni Rettig",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Elham Mohebbi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Eli Gordin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "Eli Hopkins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414"
      ]
    },
    {
      "name": "Eliav Gov-Ari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Elihu Igbinadolor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Elisa de Stanchina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Elise A Peyroux",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S118"
      ]
    },
    {
      "name": "Elise K Vong, MBBS, MRCPUK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Elizabeth A Blair",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P384"
      ]
    },
    {
      "name": "Elizabeth A Weyman, DNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S441"
      ]
    },
    {
      "name": "Elizabeth Borowiec",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Elizabeth Bradford Bell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Elizabeth Cottrill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P115"
      ]
    },
    {
      "name": "Elizabeth Cross",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S245"
      ]
    },
    {
      "name": "Elizabeth Gabitzsch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Elizabeth Gardner Grubbs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Elizabeth J Franzmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Elizabeth Klingensmith",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Elizabeth Lightbody",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Elizabeth Siciliani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Ellie Maghami",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Elliot A Asare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "Elly Arizono",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S203"
      ]
    },
    {
      "name": "Eman Ahmad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Emeil Stewart",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S493"
      ]
    },
    {
      "name": "Emil Barkovich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Emilee Ayers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S127"
      ]
    },
    {
      "name": "Emilia Wiehec, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Emilian Racila",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P246"
      ]
    },
    {
      "name": "Emilio Arteaga",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Emilio Del Torro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Emilson Freitas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P178"
      ]
    },
    {
      "name": "Emilson de Queiroz Freitas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P184"
      ]
    },
    {
      "name": "Emily Becker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P047"
      ]
    },
    {
      "name": "Emily D Cheng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Emily Evangelista",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357"
      ]
    },
    {
      "name": "Emily H Chestnut",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P086"
      ]
    },
    {
      "name": "Emily Johnson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S102"
      ]
    },
    {
      "name": "Emily K Miller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S374"
      ]
    },
    {
      "name": "Emily Kistner-Griffin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Emily M Marchiano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S272"
      ]
    },
    {
      "name": "Emily Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Emily Waselchuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Emily Wikner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P095"
      ]
    },
    {
      "name": "Emiro Caicedo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Emma A Finnegan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S235"
      ]
    },
    {
      "name": "Emma Anisman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S265"
      ]
    },
    {
      "name": "Emma C Dunn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "Emma Collier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Emma Kraus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Emma Nienaber",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P366"
      ]
    },
    {
      "name": "Emma Wilson, MLIS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Eoin F Cleere, MRCSIENT, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S106"
      ]
    },
    {
      "name": "Eran E Alon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Eri S Srivatsan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Eric A Boakye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Eric A Finkelstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Eric Adjei",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Eric Adjei Boakye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P428"
      ]
    },
    {
      "name": "Eric Adjei Boakye, Assistant Scientist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P430"
      ]
    },
    {
      "name": "Eric Bissada, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Eric Carlson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "Eric D Lamarre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Eric Dowling",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Eric Gong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Eric H Abello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188"
      ]
    },
    {
      "name": "Eric Lamarre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Eric M Genden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S104"
      ]
    },
    {
      "name": "Eric M Kraus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P154"
      ]
    },
    {
      "name": "Eric Perez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Eric Perez Perez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Eric Remer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Eric Sherman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Eric W Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Erica Kropp",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S406"
      ]
    },
    {
      "name": "Erich A Mildner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P154"
      ]
    },
    {
      "name": "Erika Ren",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Erin E Donahue",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Erin E Reardon, MFA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Ernest D Gomez, MTR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Ernest W Fu, MBBS, MRCS, MMedORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Erwan Goy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Esfahani Khashayar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Eshan S King",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P199"
      ]
    },
    {
      "name": "Esmat Najjar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "Ethan C Sage",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Ethan Kearns",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Ethan Leoni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Ethan Lewis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338"
      ]
    },
    {
      "name": "Ethan Murphy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Eugene Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "Eva Domenjo-Vila",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S283"
      ]
    },
    {
      "name": "Eva R Levin, Candidate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S252"
      ]
    },
    {
      "name": "Evan A Thomas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P157"
      ]
    },
    {
      "name": "Evan Bagley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S389"
      ]
    },
    {
      "name": "Evan Matros",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Evan Nicklas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "Evan S Walgama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Evan de Joya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P122"
      ]
    },
    {
      "name": "Evgeny Izumchenko",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Evit John",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Eyal Rubishtok",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120"
      ]
    },
    {
      "name": "Eysmar Josué Álvarez, General Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Eysmar Josué Álvarez, Surgeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P139"
      ]
    },
    {
      "name": "Ezra Cohen, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "F. Chris Holsinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "F. Christopher Holsinger, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S044"
      ]
    },
    {
      "name": "F. Christopher M Holsinger, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P003"
      ]
    },
    {
      "name": "Fabian Necker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S384"
      ]
    },
    {
      "name": "Fabiane Cristina Colunna",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Fabio Marchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S001"
      ]
    },
    {
      "name": "Faisal Al Kalbani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P081"
      ]
    },
    {
      "name": "Faizaan Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Faizan Alawi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "Fang Jugao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Fangdi Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234"
      ]
    },
    {
      "name": "Fanghui Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "Farah Karipineni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Farah Kaval",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Farhoud Faraji",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P353"
      ]
    },
    {
      "name": "Farida Nazeer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Fatih Selcukbiricik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Fatima Amanullah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S589"
      ]
    },
    {
      "name": "Fatima Pasini",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Fatima S Amanullah, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S590"
      ]
    },
    {
      "name": "Fatma Cemre Sazak Kundi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S118"
      ]
    },
    {
      "name": "Fawaz Makki, Physician",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Faye M Johnson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "Federica Rossi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P367"
      ]
    },
    {
      "name": "Federica Rossi, ENT Specialist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S500"
      ]
    },
    {
      "name": "Fei Yao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Felipe Augusto Brasileiro Vanderlei",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P108"
      ]
    },
    {
      "name": "Felipe Buscaglia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S130"
      ]
    },
    {
      "name": "Felipe Contreras",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Felipe Porto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S590"
      ]
    },
    {
      "name": "Felipe Porto - Gutierrez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S128"
      ]
    },
    {
      "name": "Felix Fernandez Penny",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Feng Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S345"
      ]
    },
    {
      "name": "Fengshen Kuo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Fernanda Goncalves, Ph, D",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P242"
      ]
    },
    {
      "name": "Fernanda T Goncalves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P258"
      ]
    },
    {
      "name": "Fernanda Vaisman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Fernando Diaz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Fernando Lopez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S427"
      ]
    },
    {
      "name": "Fleur S Kabala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S053"
      ]
    },
    {
      "name": "Floris Voskuil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Flávio C Hojaij",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "Francesco Mazzola, ENT Specialist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S500"
      ]
    },
    {
      "name": "Francis Ho, MBBS, RANZCR, FAMS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Francis Rodier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Francisca K Pereira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Francisco Araujo Dias",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P250"
      ]
    },
    {
      "name": "Francisco Garraton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Francisco Medrano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Franco DeMonte",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Franco Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Frank A Guerrero",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P162"
      ]
    },
    {
      "name": "Frank T Materia, MHS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Frankie Mulder",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P277"
      ]
    },
    {
      "name": "Franz Villaroel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Fred Baik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S384"
      ]
    },
    {
      "name": "Fred M Baik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "Frederic Kolb, MRes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P353"
      ]
    },
    {
      "name": "Fredrick R Schumacher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S422"
      ]
    },
    {
      "name": "Fudong Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Fátima Cristina M De Matos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Fátima Cristina M de Matos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "G Chengizkhan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "G Fleming",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P236"
      ]
    },
    {
      "name": "G Krempl",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "G Shenouda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "G. Shenouda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "GP Sexton, MB, BCh, BAO",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "Gabriel A Kwong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S273"
      ]
    },
    {
      "name": "Gabriel Berberi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S396"
      ]
    },
    {
      "name": "Gabriel Montclare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Gabriela S Fonseca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S270"
      ]
    },
    {
      "name": "Gabriela Sabogal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Gabriella Cote",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Gabriella Le Blanc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Gabriella San Juan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S269"
      ]
    },
    {
      "name": "Gabrielle L Wolter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "Gahie Nam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P409"
      ]
    },
    {
      "name": "Gail Jackson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Gang Zhang, Prof",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "Gangotri Siddappa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Gargi Roy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Garren M Low",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P171"
      ]
    },
    {
      "name": "Garret W Choby",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Garrett Forman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P305"
      ]
    },
    {
      "name": "Gary Patti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Gaurav Shukla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Ge Bai, CPA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Ge Zhou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036"
      ]
    },
    {
      "name": "Geena Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Genady Shendler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "Gene Huh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Genevieve Spagnuolo, MBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Genival B Carvalho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S358"
      ]
    },
    {
      "name": "Genival Carvalho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S001"
      ]
    },
    {
      "name": "Geoffrey D Young",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Geoffrey Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "George Daoud",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "George Semeniuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "George Shenouda, MBBCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Georgii Vasiukov",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P437"
      ]
    },
    {
      "name": "Georgii Vasuikov",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S573"
      ]
    },
    {
      "name": "Georgios Zenonos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Geraldine Chissoe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Gerard A Silvestri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Gerek Meinhardt, BBA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S461"
      ]
    },
    {
      "name": "Ghassan El-Haddad, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Ghayoour S Mir",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "Gianluca Savoia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Gianna Rosamilia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S086"
      ]
    },
    {
      "name": "Gideon Bachar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120"
      ]
    },
    {
      "name": "Gideon Hallum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P243"
      ]
    },
    {
      "name": "Gijs van der Sluis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Gila Weinrib",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Gina D Jefferson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P045"
      ]
    },
    {
      "name": "Gina Palma, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Giovanna L Caxeiro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S366"
      ]
    },
    {
      "name": "Giulio Sandri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002"
      ]
    },
    {
      "name": "Giuseppe Spriano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002"
      ]
    },
    {
      "name": "Glenn Bunting, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Go Ogawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S111"
      ]
    },
    {
      "name": "Golabi Nahid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Gonghao Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Gopalakrishna Ramaswamy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Gopika Pillai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Gouri Pantvaidya, PROF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Grace Amadio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P254"
      ]
    },
    {
      "name": "Grace Bryant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "Grace E Fleming",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S494"
      ]
    },
    {
      "name": "Grace Fleming",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Grace Snow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "Grace Wester",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P185"
      ]
    },
    {
      "name": "Grace Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Gracie Vargas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Greer Albergotti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Greeshma K P",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Greg A Krempl",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P280"
      ]
    },
    {
      "name": "Gregorio S Aniceto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Gregory A Grillone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Gregory Gibb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Gregory J Baker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Gregory P Marks",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Gregory Rosenblatt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Gregory W Randolph",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Gregory W Randolph, FACE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Gregory Wolf",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Guangyong Peng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Guillaume B Cardin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S034"
      ]
    },
    {
      "name": "Guillaume Cardin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Guillermo Carmona, General Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Guillermo Carmona, Surgeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P139"
      ]
    },
    {
      "name": "Guillermo Corrales",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Guojun Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "Gurel Ari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Gurleen K Tung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Gustavo Gonçalves-Silva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Gustavo Vial",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Guy Slonimsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Gyorgy B Halmos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Gyorgy Halmos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "H Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "H M Baddour",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "H Michael Baddour",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Haeun Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S603"
      ]
    },
    {
      "name": "Haia Darawshe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S599"
      ]
    },
    {
      "name": "Hallie Samuel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "Haluk Tezcan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Hamdan A Pasha, FCPS, FRCSInt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S590"
      ]
    },
    {
      "name": "Hamdan Ahmed Pasha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Hamna Bilal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Hamzah Jehanzeb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S467"
      ]
    },
    {
      "name": "Han Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Hana Seif",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Hanel Eberly",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Hania Fatima",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Hannah Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P426"
      ]
    },
    {
      "name": "Hannah Eadie, MSN, FNPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P073"
      ]
    },
    {
      "name": "Hannah L Kenny",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218"
      ]
    },
    {
      "name": "Hannah Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Hannah Q Baratz, MSMEd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Hannah Roth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S494"
      ]
    },
    {
      "name": "Hansel Comas Rojas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Hao Li, MBBS, MCI, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Haocheng Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S274"
      ]
    },
    {
      "name": "Haresh S/O Singaraju",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Hari U Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Hariz Hassan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S095"
      ]
    },
    {
      "name": "Harlan Sayles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Harman Parhar, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Harmony I Saunders",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P444"
      ]
    },
    {
      "name": "Harrison Cash",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P245"
      ]
    },
    {
      "name": "Harrison Chong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Harrison Gao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "Harry May",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Harshini Vemula",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "Haseeb Safdar Ali, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105"
      ]
    },
    {
      "name": "Hassan Baig",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Hassane M Zarour",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Hayato Imanari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Hayden Guidry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Hayley Mann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S564"
      ]
    },
    {
      "name": "Haythem Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Heath Skinner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "Heather Edwards",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Heather Starmer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S304"
      ]
    },
    {
      "name": "Heather Starmer, CCCSLP, BCSS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Heba Isaac",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P308"
      ]
    },
    {
      "name": "Heidi Kletzien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Helena Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P096"
      ]
    },
    {
      "name": "Helena T Yip",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "Hen Chaushu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S554"
      ]
    },
    {
      "name": "Hendrikus Boersma, PharmD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Henrik Huizinga, PharmD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Henry Hoffman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S095"
      ]
    },
    {
      "name": "Heping Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Hera Mukhtar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P237"
      ]
    },
    {
      "name": "Herve Sroussi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S148"
      ]
    },
    {
      "name": "Heshaam Fallah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357"
      ]
    },
    {
      "name": "Hideki Kanebako",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Hideki Tanaka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Hidenori Tanaka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S573"
      ]
    },
    {
      "name": "Hier M",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S252"
      ]
    },
    {
      "name": "Hier Michael",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Hikaru Nagao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Hillary S Sloane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S210"
      ]
    },
    {
      "name": "Hiroe Tada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Hirofumi Shibata",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Hiroshi Idogawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Hirotaka Shinomiya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Hisataka Ominato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S584"
      ]
    },
    {
      "name": "Hitomi Iwaki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Ho-Sheng Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S608"
      ]
    },
    {
      "name": "Holly Sprow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P351"
      ]
    },
    {
      "name": "Hong Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Hope Iyiewuare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Hosam Alkhatib",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S143"
      ]
    },
    {
      "name": "How Ting Ong, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Hsuan-Yu Chou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "Hua Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S146"
      ]
    },
    {
      "name": "Huaqi Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Hudson Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123"
      ]
    },
    {
      "name": "Hugh A Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "Hui Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Hui Lin Teo, MBBS, MRCPUK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Hui Nan Yeo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Hui-Ching Chuang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P043"
      ]
    },
    {
      "name": "Huiying Tsang, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S404"
      ]
    },
    {
      "name": "Humam Kadara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Humzah Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S417"
      ]
    },
    {
      "name": "Hunter Jones",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Hunter Leggett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Hunter Martin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331"
      ]
    },
    {
      "name": "Hussain Ali Lanewala, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S467"
      ]
    },
    {
      "name": "Hussein Saleh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P287"
      ]
    },
    {
      "name": "Hussien Abouzeid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P137"
      ]
    },
    {
      "name": "Hye Rhee Chi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P291"
      ]
    },
    {
      "name": "Hye-Joung Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S357"
      ]
    },
    {
      "name": "Hyeong Ahn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Hyman B Muss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Hyun Jee Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P039"
      ]
    },
    {
      "name": "Hyunseok Kang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S141"
      ]
    },
    {
      "name": "I Turgeman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "Ian Cheong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Ian Poon, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Ian Witterick",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Ibrahim Elsharabasy, MOMS, RCSEd, ABOMS, BDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P345"
      ]
    },
    {
      "name": "Ida Marie Lim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "Ifeanyi Onuh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S237"
      ]
    },
    {
      "name": "Ignacia Arteaga",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Ignatius Nip",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Ilyes Berania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "Imran A Mohammad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S064"
      ]
    },
    {
      "name": "In Gul Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S357"
      ]
    },
    {
      "name": "India Jackson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P161"
      ]
    },
    {
      "name": "Indu Elizabeth Mathew",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Ingrid Nakamuta, Master of Science",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Ingrid Plass",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Irene Eng Ai Teo, Clinical Psychology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "Irene Karam, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Irving J Bigio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Isaac Tze Yang Chow, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Isabel Cioffi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Isabella Romeo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Isabella V Schafer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P267"
      ]
    },
    {
      "name": "Isabelle Fournier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Isabelle Jia Hui Jang, Consultant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Isabelle Jia Hui Jang, MRCSGlasg, MMedORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "Isha Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S456"
      ]
    },
    {
      "name": "Ivan El-Sayed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Ivan Vegar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P018"
      ]
    },
    {
      "name": "Ivete F P S Rodrigues",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S129"
      ]
    },
    {
      "name": "Izabella Santos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Izza Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P287"
      ]
    },
    {
      "name": "J Blumberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "J George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "J Jack Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S169"
      ]
    },
    {
      "name": "J Lieberman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "J M Soffer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "J Mack",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "J Macke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P236"
      ]
    },
    {
      "name": "J O'Brien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "J P Gleysteen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "J Pugi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "J Sanclement",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "J Scott Durham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "J Townson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S575"
      ]
    },
    {
      "name": "J W Rosenthal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S378"
      ]
    },
    {
      "name": "J. Fredrick Grimmer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "J. Kenneth Byrd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P014"
      ]
    },
    {
      "name": "J. Martin Johnston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "J. Quinn Odom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "J. Reed Gardner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "J. Silvio Gutkind",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "J. Walker Rosenthal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S596"
      ]
    },
    {
      "name": "JC Irish, FRCSC, FCAHS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S575"
      ]
    },
    {
      "name": "Jaafar Al Hadi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Jack Birkenbeuel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S399"
      ]
    },
    {
      "name": "Jack Garcia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Jack J Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S173"
      ]
    },
    {
      "name": "Jack Owen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P068"
      ]
    },
    {
      "name": "Jack Y Ghannam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Jackson Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338"
      ]
    },
    {
      "name": "Jackson P Maradik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S139"
      ]
    },
    {
      "name": "Jacob B Nielsen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S608"
      ]
    },
    {
      "name": "Jacob Hoer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046"
      ]
    },
    {
      "name": "Jacob J Swan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P322"
      ]
    },
    {
      "name": "Jacob Lieberman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P042"
      ]
    },
    {
      "name": "Jacob Miller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Jacob Ruzevick",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Jacob Seals",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P180"
      ]
    },
    {
      "name": "Jacobus Boeve",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Jacqueline Minken",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S494"
      ]
    },
    {
      "name": "Jacqueline Mojica, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Jacqueline Tardif, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S214"
      ]
    },
    {
      "name": "Jacqueline Tucker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Jade Montpetit",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Jae Gardella",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Jagdish Dhingra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Jaimanti Bakshi, AND HEAD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P294"
      ]
    },
    {
      "name": "Jaimanti Bakshi, Head",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P074"
      ]
    },
    {
      "name": "Jaimanti Bakshi, and Head",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Jaime A Peña Garcia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "Jake J Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S404"
      ]
    },
    {
      "name": "Jake Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "Jake O Rammell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P351"
      ]
    },
    {
      "name": "Jakob Bakhtiari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "James A Bonner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "James A Widner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S133"
      ]
    },
    {
      "name": "James Barraclough",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "James Bowman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "James C Borders",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S242"
      ]
    },
    {
      "name": "James C Gates",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S294"
      ]
    },
    {
      "name": "James Fagin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "James Gates",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "James K Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "James O'Brien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S566"
      ]
    },
    {
      "name": "James R Barnett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "James R Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "James Rocco, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "James S Lewis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Jamie A Ku",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Jamie D Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S405"
      ]
    },
    {
      "name": "Jamie Jabalee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Jamie Kwon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S483"
      ]
    },
    {
      "name": "Jamie P Lavine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "Jan Bian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "Jan Doff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Jan-Jaap Hendrickx",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Janene Reeves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Janice Huang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P063"
      ]
    },
    {
      "name": "Janice J Chung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Janmaris Marin Fermin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Jannik Johannsen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Japnam Jassal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Jared C Dublin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Jared C Inman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P376"
      ]
    },
    {
      "name": "Jared Stewart",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S152"
      ]
    },
    {
      "name": "Jared Weiss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Jarod M Labrador",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Jarrod Stein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S203"
      ]
    },
    {
      "name": "Jaslyn Lee, MBBS, FRCPA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Jason Doherty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S092"
      ]
    },
    {
      "name": "Jason Frazier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Jason Newman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Jason W Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S040"
      ]
    },
    {
      "name": "Jason YK Chan, Prof",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S369"
      ]
    },
    {
      "name": "Jason, YK Chan, FHKAM, FRCSEdORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S376"
      ]
    },
    {
      "name": "Jatin Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P269"
      ]
    },
    {
      "name": "Javier Cher An Chee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Javier K Nishikawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S408"
      ]
    },
    {
      "name": "Javier Vila",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Jay K Ferrell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P312"
      ]
    },
    {
      "name": "Jay Ponto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282"
      ]
    },
    {
      "name": "Jayashree NP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Jaylou M Velez Torres",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P235"
      ]
    },
    {
      "name": "Jazlyn A Selvasingh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064"
      ]
    },
    {
      "name": "Jeams Richard-Costa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Jean-Nicolas Gallant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Jean-Pierre Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Jeannie Slater",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Jeffery Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P008"
      ]
    },
    {
      "name": "Jeffrey Bruce",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "Jeffrey C Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P083"
      ]
    },
    {
      "name": "Jeffrey D Huynh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Jeffrey F Lorenz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S497"
      ]
    },
    {
      "name": "Jeffrey J Chin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Jeffrey Janus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Jeffrey K. Jopling",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Jeffrey M Blumberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Jeffrey Myers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "Jeffrey P North",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S405"
      ]
    },
    {
      "name": "Jeffrey Searl",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Jeffrey W Toman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Jenna Hall, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S248"
      ]
    },
    {
      "name": "Jenna L Schaefer-Randolph",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P280"
      ]
    },
    {
      "name": "Jenna R Schwartz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S117"
      ]
    },
    {
      "name": "Jennifer Anderson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S137"
      ]
    },
    {
      "name": "Jennifer Becker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P429"
      ]
    },
    {
      "name": "Jennifer De Los Santos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Jennifer Faulkner, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P148"
      ]
    },
    {
      "name": "Jennifer Gottfried",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Jennifer Gross",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Jennifer Guo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S134"
      ]
    },
    {
      "name": "Jennifer L Anderson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "Jennifer Ma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Jennifer R Cracchiolo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S075"
      ]
    },
    {
      "name": "Jennifer R Wang, ScM, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Jennifer S Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "Jennifer Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Jennifer Sosa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S474"
      ]
    },
    {
      "name": "Jennifer Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "Jenny Zhu, PT, DPT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "Jensy Jaison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Jeon Seong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Jereme Y Gan, MBBS, MRCS, MMedORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Jereme Yijin Gan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S350"
      ]
    },
    {
      "name": "Jeremiah Alt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S450"
      ]
    },
    {
      "name": "Jeremiah Tracy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P426"
      ]
    },
    {
      "name": "Jeremy Berdugo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S211"
      ]
    },
    {
      "name": "Jeremy D Richmon, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Jeremy P Tervo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P087"
      ]
    },
    {
      "name": "Jerome Z Ong, MBBS, MRCS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Jerry T Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S104"
      ]
    },
    {
      "name": "Jesse Frija-Gruman, DCS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Jesse Qualliotine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Jesse Zaretsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Jessica Addis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Jessica Bauman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Jessica Bourbonnais",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Jessica Catarine Frutuoso Nascimento",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S580"
      ]
    },
    {
      "name": "Jessica Geiger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Jessica Hier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Jessica Islam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Jessica L Geiger, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Jessica Pham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Jessica R Bauman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Jessica R Weinberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Jessica Rosenberry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S013"
      ]
    },
    {
      "name": "Jessica Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Jessica Weinberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P028"
      ]
    },
    {
      "name": "Jhih-Hao Shen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P052"
      ]
    },
    {
      "name": "Jhoel Maldonado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "Jhonatan Elia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Ji Wei Yang, CM, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Ji-Hyun Lee, Dr, PH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Jia Jia Wee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "Jia Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Jiahao Ye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P118"
      ]
    },
    {
      "name": "Jianjun Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Jianqiang Yang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "Jiawei Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Jieru Meng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Jill Gilbert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Jill I Cameron",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S420"
      ]
    },
    {
      "name": "Jillian Blackwell, BSN, CORLN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S572"
      ]
    },
    {
      "name": "Jimmy J Caudell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Jin Zhong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Jinfeng Zou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Jing Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Jini M Rajan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P195"
      ]
    },
    {
      "name": "Jinyi Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Jiya Uttam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Jo Omata",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Joan Yanyi Lee, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Joanna W Bodmann, CNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Joanne Hu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Joanne Soo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S404"
      ]
    },
    {
      "name": "Joel B Fontanarosa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P005"
      ]
    },
    {
      "name": "Joel Badders",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P185"
      ]
    },
    {
      "name": "Joel Greenberger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "Joel Howlett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S382"
      ]
    },
    {
      "name": "Joel Howlett, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Joel Kar Heng Tang, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Joesph Dort",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Johan Carrascoza-Bolanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Johanna Inhestern",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "John Alfarone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "John B A Hanen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "John Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "John D Cramer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S307"
      ]
    },
    {
      "name": "John Dale V Trogo, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "John DeAlmeida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "John Deeken",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "John E Hayes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "John Gleysteen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P180"
      ]
    },
    {
      "name": "John Hyngstrom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "John J Caraway",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S059"
      ]
    },
    {
      "name": "John Kirkwood",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "John Lukens",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "John Lynch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "John P Gleysteen, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "John Pang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "John Paul T Arrios",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145"
      ]
    },
    {
      "name": "John Powers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "John Quadarella",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "John R De Almeida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "John R de Almeida, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "John Sunwoo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S026"
      ]
    },
    {
      "name": "John Teknos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S580"
      ]
    },
    {
      "name": "John Truelson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "John Vieth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S532"
      ]
    },
    {
      "name": "John de Almeida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Johnny Yang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S384"
      ]
    },
    {
      "name": "Jolly S Grewal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Jon Feldman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Jon Mallen-St",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P350"
      ]
    },
    {
      "name": "Jon Mallen-St.Clair",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Jon Strasser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Jonah Gonzalez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P008"
      ]
    },
    {
      "name": "Jonathan C Irish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S245"
      ]
    },
    {
      "name": "Jonathan C. Irish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Jonathan D Powell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Jonathan D Schoenfeld",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Jonathan D West",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "Jonathan E Bard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S317"
      ]
    },
    {
      "name": "Jonathan Engle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Jonathan George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Jonathan Harris",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Jonathan Irish, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "Jonathan Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Jonathan Raskin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P018"
      ]
    },
    {
      "name": "Jonathan Schoenfeld, MPhil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S395"
      ]
    },
    {
      "name": "Jonathan Wang, MSE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Jonathon O Russell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S058"
      ]
    },
    {
      "name": "Jordan Currie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Jordan Foy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Jordan Frey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "Jordan Hanson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S538"
      ]
    },
    {
      "name": "Jordan Kankam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Jordan R Salley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Jordan Sternthal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Jordyn Carroll",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P342"
      ]
    },
    {
      "name": "Jorge Sapunar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Joris Vos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Jose A Monteiro de Olivera Novaes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Jose Marie L Castro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "Jose Sanclement",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Jose Tomas Peña",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Josef Madrigal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Joseph Bendik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Joseph C. Dort",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Joseph Connors",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "Joseph Curry, D",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S023"
      ]
    },
    {
      "name": "Joseph Foley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Joseph Hoang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Joseph O Humtsoe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S472"
      ]
    },
    {
      "name": "Joseph O Johnson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Joseph R Curry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P218"
      ]
    },
    {
      "name": "Joseph Scharpf",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Joseph Smith",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Joseph Valentino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S532"
      ]
    },
    {
      "name": "Joseph Zenga",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Josette Graves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P098"
      ]
    },
    {
      "name": "Josh Egede",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P167"
      ]
    },
    {
      "name": "Josh Twigg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Joshua C Barlow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P174"
      ]
    },
    {
      "name": "Joshua Hornig, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414"
      ]
    },
    {
      "name": "Joshua K Tay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Joshua K Tay, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Joshua K Tay, MBBS, MRCS, MMed, FAMS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Joshua Lubek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Joshua R Veatch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Joshua Sorrentino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S476"
      ]
    },
    {
      "name": "Joshua Tay, MBBS, FAMS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Joshua Tay, MBBS, MRCS, MMED, FAMS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Josie Yalovitser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "José Guilherme Vartanian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "José López L López",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "José Zevallos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S124"
      ]
    },
    {
      "name": "Jovan Cheema",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S478"
      ]
    },
    {
      "name": "Jovanka Gencel-Augusto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S131"
      ]
    },
    {
      "name": "Joy Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S414"
      ]
    },
    {
      "name": "Joyce Jeong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S424"
      ]
    },
    {
      "name": "Joyce S Jeong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147"
      ]
    },
    {
      "name": "João Ricardo Signoretti Alexandre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S165"
      ]
    },
    {
      "name": "Juan A Raygoza Garay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S315"
      ]
    },
    {
      "name": "Juan C Fernandez-Miranda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234"
      ]
    },
    {
      "name": "Juan C Hernandez-Prera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Juan Sebastian Valencia Fajardo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Juda Barcellos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Judith Mwobobia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022"
      ]
    },
    {
      "name": "Julia C Maclean",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S243"
      ]
    },
    {
      "name": "Julia Meehan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S419"
      ]
    },
    {
      "name": "Julia Noel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Julia Porter, MSP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S246"
      ]
    },
    {
      "name": "Julia Toman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S090"
      ]
    },
    {
      "name": "Julian Wilson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S487"
      ]
    },
    {
      "name": "Julianna Miller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S395"
      ]
    },
    {
      "name": "Julie A Goddard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P404"
      ]
    },
    {
      "name": "Julie George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Julie Goddard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425"
      ]
    },
    {
      "name": "Julie Jang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Julie K Silver",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Julien Ghannoum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Jun Jin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S587"
      ]
    },
    {
      "name": "Jun Ma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "Jun Yuan Koo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Jun Yun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Juneko Grilley-Olson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Junhe Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Junxing Chay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Justin Choi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Justin Choi, M, Ed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Justin Dvorak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "Justin Hintze",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Justin M Soffer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Justin Moyers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Justin Shinn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S260"
      ]
    },
    {
      "name": "Justin Soffer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P180"
      ]
    },
    {
      "name": "Justina Shafik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Justine Colivas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S211"
      ]
    },
    {
      "name": "Jyue-Shi Yang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "K Bai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S281"
      ]
    },
    {
      "name": "K Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "K Paydary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "K Stenson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "K SultaneM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "K Thomas Robbins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "K van Abel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "K. Esfahani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "K. Richardson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "K. Sultanem",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Kaci Eikmann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Kaeli Samson, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Kaitlin Sclater",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S431"
      ]
    },
    {
      "name": "Kaitlynne Pak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P350"
      ]
    },
    {
      "name": "Kala K Mahen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Kalyani Sonawane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Kamel Moufarrej",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Kamila Vadell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292"
      ]
    },
    {
      "name": "Kan Kishibe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S584"
      ]
    },
    {
      "name": "Kanvar Panesar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282"
      ]
    },
    {
      "name": "Kara Jonas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Kara Jonas, BScN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Karen Tawk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S344"
      ]
    },
    {
      "name": "Karen Y Choi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "Karim Botros",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S396"
      ]
    },
    {
      "name": "Karin Roberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Karissa A Nichols",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Karl Payne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Karolina Plonowska-Hirschfeld",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Karthik Chakravarthy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P156"
      ]
    },
    {
      "name": "Karthik Rao, Mch, Head and Neck Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S012"
      ]
    },
    {
      "name": "Kasey Bowyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P129"
      ]
    },
    {
      "name": "Kasey Bowyer, AB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P238"
      ]
    },
    {
      "name": "Kassidy Collins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S502"
      ]
    },
    {
      "name": "Kate Chatfield-Reed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Kate Gillepsie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Katelyn O Stepan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Katelyn Stepan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201"
      ]
    },
    {
      "name": "Katerina Arca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Katerina Green",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Katharine Price",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Katherina Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S399"
      ]
    },
    {
      "name": "Katherine A Mozingo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Katherine Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S102"
      ]
    },
    {
      "name": "Katherine R Sterba",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Katherine W Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S417"
      ]
    },
    {
      "name": "Katherine Wai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Katherine Webb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Kathleen Dennert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Kathleen Hogg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Kathleen Yaremchuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Kathryn E Roth, MHPE, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P070"
      ]
    },
    {
      "name": "Kathryn Genoa-Obradovic, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Kathryn Hardin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Kathryn Hitchcock",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Kathryn Sinha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P014"
      ]
    },
    {
      "name": "Kathryn Van Abel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Katie Hogan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P389"
      ]
    },
    {
      "name": "Katie Humphrey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S559"
      ]
    },
    {
      "name": "Katie Mathias, RDAP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Katie S Traylor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Katrina Harrill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Katrina Harrill, MSN, BSN, OCN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Katrina Minutello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P287"
      ]
    },
    {
      "name": "Katrina Rey-McIntyre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Katrina Zaraska",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S017"
      ]
    },
    {
      "name": "Kayla E Payne, DCS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Kayla Jackson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S566"
      ]
    },
    {
      "name": "Kayla S Hopwo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Kazuchika Ohno",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Kazuo Yasuhara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S111"
      ]
    },
    {
      "name": "Kedar Kirtane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S073"
      ]
    },
    {
      "name": "Kedar S Kirtane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Keer Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Keerthi KrishnaKumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Keerthivani Balraj",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Keerthy G, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Kees Heetderks",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019"
      ]
    },
    {
      "name": "Kees-Pieter Schepman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Keethi G",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Keethi J",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Keewon Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P413"
      ]
    },
    {
      "name": "Keisuke Hamanaka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Keith Richardson, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Keivan Shifteh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Kelly Guiver",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Kelly M Maloy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S160"
      ]
    },
    {
      "name": "Kelly Magliocca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P128"
      ]
    },
    {
      "name": "Kelly R Magliocca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Kelly S Sayre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P155"
      ]
    },
    {
      "name": "Kelly Sayre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Kelsey Decker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Kelsey Karnik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S461"
      ]
    },
    {
      "name": "Kelsey Nocilla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P437"
      ]
    },
    {
      "name": "Kemberlee R Bonnet, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S127"
      ]
    },
    {
      "name": "Ken Byrd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P068"
      ]
    },
    {
      "name": "Ken Ichi Nibu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Ken Nakazawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P232"
      ]
    },
    {
      "name": "Kendall Tasche",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Kendyl Barron",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P415"
      ]
    },
    {
      "name": "Kenneth J Gollob",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Kenny Nguyen, MEd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "Kenric Tam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S075"
      ]
    },
    {
      "name": "Kerstin Stenson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145"
      ]
    },
    {
      "name": "Keseva Asam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S377"
      ]
    },
    {
      "name": "Keshav Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "Keshav Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S011"
      ]
    },
    {
      "name": "Keshav V Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S164"
      ]
    },
    {
      "name": "Keshia Mora",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "Kevin B Chandler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Kevin Cho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Kevin Harrington",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Kevin Higgins, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Kevin J Contrera, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Kevin Milligan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Kevin Min",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340"
      ]
    },
    {
      "name": "Kevin P Higgins, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P080"
      ]
    },
    {
      "name": "Kevin Scher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Kevin Sullivan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P034"
      ]
    },
    {
      "name": "Kevin Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S385"
      ]
    },
    {
      "name": "Keyon Kazempour",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S125"
      ]
    },
    {
      "name": "Khalil Sultanem, FRCP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Khanh K Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Khanh Linh Tran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Khin Chaw Yu Aung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Kian D Tartibi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P079"
      ]
    },
    {
      "name": "Kieley A Trempy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Kievan Shifteh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S190"
      ]
    },
    {
      "name": "Kimberley Liqin Kiong, MBBS, MRCSEdin, MMEDORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "Kimberley Liqin Kiong, Senior Consultant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Kimberley Olsin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P428"
      ]
    },
    {
      "name": "Kimberley S Samkoe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S496"
      ]
    },
    {
      "name": "Kimberly Benjamin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Kimberly Huynh, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "Kimberly Kennedy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P430"
      ]
    },
    {
      "name": "Kimberly Vanderveen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P057"
      ]
    },
    {
      "name": "Kimiko A Yamada, PT, DPT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "Kinga Szigeti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S036"
      ]
    },
    {
      "name": "Kinsey Bryant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S342"
      ]
    },
    {
      "name": "Kiran Devisitty, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Ko Chun Fang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P273"
      ]
    },
    {
      "name": "Kohei Minemura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Kohei Taniguchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Koichi Yoshizawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Koji Sakamoto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Konrad P Zielinski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S306"
      ]
    },
    {
      "name": "Konstantinos I Bougioukas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S242"
      ]
    },
    {
      "name": "Koushik Rameshbabu, BEng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "Kranti Khadilkar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Kripa A",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Kristen Linnemeyer-Risser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Kristi D. Graves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Kristin Schlueter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Kristina R Dahlstrom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S118"
      ]
    },
    {
      "name": "Kristofer G Andren",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P406"
      ]
    },
    {
      "name": "Kristy K Brock",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S169"
      ]
    },
    {
      "name": "Krithika Suresh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Krupal B Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Krupal Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Krzysztof J Misiukiewicsz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217"
      ]
    },
    {
      "name": "Kshitij P Sharma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Kumar Prabhash, DM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Kunal Gupta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Kunal K Sindhu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217"
      ]
    },
    {
      "name": "Kunal Koka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Kunle Odunsi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S031"
      ]
    },
    {
      "name": "Kwang Hyun Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Kwang Sung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Kwok Seng Loh, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Kyle Leonard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Kyle S Ettinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Kyle Vankoevering",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S085"
      ]
    },
    {
      "name": "Kyra Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S218"
      ]
    },
    {
      "name": "Kyrionna Golliday",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S188"
      ]
    },
    {
      "name": "Kyunghee Burkitt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "L Queimado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "L. Florianova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Labani Kole",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S501"
      ]
    },
    {
      "name": "Lady Quintero Urego, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Laila A Gharzai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Laksmi Pradeep, BDS, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Lalitha Laxhm",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Lana Kovac Bilic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P040"
      ]
    },
    {
      "name": "Larissa Fonseca Marques",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Lark Smith",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Larry Harshyne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Larry L Myers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Laura A Goguen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Laura Ann Goguen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Laura Bryne, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Laura Ebbitt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346"
      ]
    },
    {
      "name": "Laura Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Laura J Tafe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S496"
      ]
    },
    {
      "name": "Laura M Dooley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Laura M Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Laura McDavid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P291"
      ]
    },
    {
      "name": "Laura Rozek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Laura Teo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Laura V Romo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Lauren C Shih",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S429"
      ]
    },
    {
      "name": "Lauren Clubb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Lauren E Schlegel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Lauren E Wehner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Lauren G Himes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P154"
      ]
    },
    {
      "name": "Lauren Gabra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "Lauren Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S202"
      ]
    },
    {
      "name": "Lauren M Boeckermann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "Lauren Ottenstein, CCC, SLP, BCSSS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S248"
      ]
    },
    {
      "name": "Lauren Sullivan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Laurence DiNardo, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S152"
      ]
    },
    {
      "name": "Laurent Letourneau-Guillon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S003"
      ]
    },
    {
      "name": "Lauriane Eberst",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Laurie Ailles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "Laurie Wennerholm, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Lavinia Tofan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Lawrence Lam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Lawrence Leung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Lawrence Oppenheimer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Lays Silva de Azevedo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S201"
      ]
    },
    {
      "name": "Lazar Vujanovic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Leah Novenger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425"
      ]
    },
    {
      "name": "Leah Novinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S374"
      ]
    },
    {
      "name": "Leah Shriver",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Leah Yturri, PAC, MPAS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Lee Cranmer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "LeeAnn Marcello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "LeeAnn T Marcello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Lekha M Nair",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Lekha Medarametla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S334"
      ]
    },
    {
      "name": "Lekshmi Pradeep, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Lennie Sender",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Leonardo F Rios",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S541"
      ]
    },
    {
      "name": "Leonardo Freitas B Rios",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Lester J Layfield",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Leticia S Soares",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P432"
      ]
    },
    {
      "name": "Levi G Ledgerwood",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Leylah Drusbosky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Li Ann Loh, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Li Xuan Beverly Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S350"
      ]
    },
    {
      "name": "Li-Jen Liao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Liam P O'Brien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Liana Salehian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Liangliang Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Liat Appelbaum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Licy Yanes Cardozo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P045"
      ]
    },
    {
      "name": "Lijun Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S004"
      ]
    },
    {
      "name": "Lilian Boe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Lilian Neide da Silva Pereira de Almeida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S175"
      ]
    },
    {
      "name": "Lilian T Gien",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Limor Muallem Kalmovich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Lin Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P386"
      ]
    },
    {
      "name": "Lin Tan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S182"
      ]
    },
    {
      "name": "Lin Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036"
      ]
    },
    {
      "name": "Linda Yin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Lindsay Bischoff",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S606"
      ]
    },
    {
      "name": "Lindsay Boven",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Lindsay Olinde",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Lindsey Romak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Linh K Tran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S017"
      ]
    },
    {
      "name": "Linh Tran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S482"
      ]
    },
    {
      "name": "Lior Hayat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "Liri Kotz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "Lisa B Earnest-Noble",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P372"
      ]
    },
    {
      "name": "Lisa G Rosas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Lisa J Mirabello",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Lisa Licitra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Lisa M Knowlton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Litika Vermani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Livia Flornianova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "Liza Blumenfeld, MA, CCC, SLP, BCS, S",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P153"
      ]
    },
    {
      "name": "Liza S Blumenfeld",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Logan Engle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Lomesh Choudhary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Long Chi Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Lorelai Pop",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Loren Mell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Loren Mell, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Lorena Gomez Bolanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Lorenzo Di Martino",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Lori Ross, PA, C",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Loris De Cecco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S045"
      ]
    },
    {
      "name": "Lorna Merritt-Charles, Anesthesiologyst Lecturer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Louis G Abarca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P423"
      ]
    },
    {
      "name": "Louis Guertin, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Louis Jansen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Louise Cunningham, SLPD, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Lova Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Lovely Raghav",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Lovisa Farnebo, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Lu Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S379"
      ]
    },
    {
      "name": "Luana Bittencourt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P109"
      ]
    },
    {
      "name": "Luana De Araujo Bittencourt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P108"
      ]
    },
    {
      "name": "Luc GT Morris",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Lucas Axiotakis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P087"
      ]
    },
    {
      "name": "Lucas Marinho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P109"
      ]
    },
    {
      "name": "Lucas Ratiani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "Lucas Siqueira Campos Marinho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P108"
      ]
    },
    {
      "name": "Luciana M P Piotto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P432"
      ]
    },
    {
      "name": "Ludi Smeele",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Lue-Yen Tucker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Luis Alvarado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P083"
      ]
    },
    {
      "name": "Luis Avila",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Luis Boccalatte",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Luis Fernando Tintinago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Luis Garcia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Luis Martinez Ramirez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S455"
      ]
    },
    {
      "name": "Luis Marín",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Luis Raez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Luisa Pineda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Luiz G Cortes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Luiza H Crispim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Luiza Tatar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Lukasz Czerwonka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S600"
      ]
    },
    {
      "name": "Lukasz Zareba",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Luke Galloway",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Luke Higgins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Luke M O'Neil, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "Luvita Suryani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Luz E Castellanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Lynn G Feun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P208"
      ]
    },
    {
      "name": "Lívia S Eberlin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "M Arambula",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "M Bhayani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "M Chinnaiyan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "M Elyse Moore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P222"
      ]
    },
    {
      "name": "M Jelinek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "M Meyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "M Mims",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "M Nazir Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S104"
      ]
    },
    {
      "name": "M Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "M Pusztaszeri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "M S Dar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S475"
      ]
    },
    {
      "name": "M Sobieski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S579"
      ]
    },
    {
      "name": "M. Hier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "M. Pusztaszeri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Mabel Kahil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425"
      ]
    },
    {
      "name": "Mabrooka Kazi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P437"
      ]
    },
    {
      "name": "Mabrooka Kazi, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S573"
      ]
    },
    {
      "name": "Madeline Bald",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P148"
      ]
    },
    {
      "name": "Madeline Kiernan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Madeline Polson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P241"
      ]
    },
    {
      "name": "Madelyn A Krueger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064"
      ]
    },
    {
      "name": "Madelyn Bell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P332"
      ]
    },
    {
      "name": "Madelyn Stevens",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Madette Galapin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Madette Galapin, MRTT, MScHQ",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Madhavi Kambam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "Madison Ambrose, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S419"
      ]
    },
    {
      "name": "Madison Ambrose, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Magdalena Alvis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P086"
      ]
    },
    {
      "name": "Magdy Gohar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Mahima Jain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Mahmoud Awad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "Mahmoud I Awad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Maia Smith",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S055"
      ]
    },
    {
      "name": "Maie A St John",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Maie A St. John",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Maisha Rahman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S431"
      ]
    },
    {
      "name": "Makayla R Matthews",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P073"
      ]
    },
    {
      "name": "Makenna L Brown",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Makenna L Brown, CRC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Malay Sannigrahi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Malek Ajam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S197"
      ]
    },
    {
      "name": "Malek Amin, student",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Mallory G McKeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Mallory McKeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P278"
      ]
    },
    {
      "name": "Mallory Mckeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Malu M Rafi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Manaal Tariq",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Manami Tabuchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Manas P Peter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Manasvini Kala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Mandy Losiewicz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Manish Warrier, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Manju Moorthy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Manjunath Prasad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Manraj N Kaur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Mansoor Saleh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Manu Prasad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Manuel A Cespedes Araya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S130"
      ]
    },
    {
      "name": "Manuel Lora Gonzalez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S270"
      ]
    },
    {
      "name": "Manuel Mock, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Manuel Patino Galindo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Mao Tian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Maoxuan Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Mar Cotter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S106"
      ]
    },
    {
      "name": "Mara Roth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S595"
      ]
    },
    {
      "name": "Marc A Cohen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S075"
      ]
    },
    {
      "name": "Marc Chioda, Mr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Marc Cohen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Marc Fischer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Marc P Pusztaszeri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Marc Pusztaszeri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S252"
      ]
    },
    {
      "name": "Marcel Mayer, MHBA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Marcela Radtke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Marcelo Figari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Marcelo S Schalch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S292"
      ]
    },
    {
      "name": "Marci L Nilsen, CHPN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S428"
      ]
    },
    {
      "name": "Marci Nilsen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S115"
      ]
    },
    {
      "name": "Marcia S Brose",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Marco A Campioli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S133"
      ]
    },
    {
      "name": "Marco A Mascarella",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Marco Kulcsar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P059"
      ]
    },
    {
      "name": "Marcos Decnop Batista Pinheiro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P203"
      ]
    },
    {
      "name": "Marcus Balanky, CHP, CIH, CLSO",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Marcus Couey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Marcus Dantas, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "Margaret A Heller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S468"
      ]
    },
    {
      "name": "Margaret Falkovic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022"
      ]
    },
    {
      "name": "Margaret Falkovic, MSW, LCSW",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Margaret Fitch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S420"
      ]
    },
    {
      "name": "Margaret Locke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P034"
      ]
    },
    {
      "name": "Maria Abreu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Maria Aparecida Koike Folgueira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Maria Bonnani, NP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P127"
      ]
    },
    {
      "name": "Maria Cabanillas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Maria Cristina Traiano Beal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P203"
      ]
    },
    {
      "name": "Maria E Cabanillas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Maria Evasovich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P135"
      ]
    },
    {
      "name": "Maria Folgueira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Maria Iuliano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Maria J Polania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Maria José Ferreira Alves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445"
      ]
    },
    {
      "name": "Maria Katayama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Maria Kristine Gule-Monroe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Maria Lugo-Fagundo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S163"
      ]
    },
    {
      "name": "Maria P Curado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S236"
      ]
    },
    {
      "name": "Maria Polania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P390"
      ]
    },
    {
      "name": "Marianne Y Nakai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Marice Alcantara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Marika D Russell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Marina Nogueira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Mario Bilic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P040"
      ]
    },
    {
      "name": "Mark E Prince, FRSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Mark E.P. Prince",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S160"
      ]
    },
    {
      "name": "Mark EP Prince",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S413"
      ]
    },
    {
      "name": "Mark K Wax",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S408"
      ]
    },
    {
      "name": "Mark L Urken",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S104"
      ]
    },
    {
      "name": "Mark M Ong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "Mark Mims",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Mark Orland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Mark S Swanson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S344"
      ]
    },
    {
      "name": "Marlaine H Frelier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Marlene Redlich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S493"
      ]
    },
    {
      "name": "Marra Francis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Martha Lucía Gutiérrez Pérez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434"
      ]
    },
    {
      "name": "Martin Prlic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S283"
      ]
    },
    {
      "name": "Mary E Cunane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S356"
      ]
    },
    {
      "name": "Mary Falstin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S153"
      ]
    },
    {
      "name": "Mary G Robichaux",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P096"
      ]
    },
    {
      "name": "Mary Jue Xue",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Mary Katherine Henry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207"
      ]
    },
    {
      "name": "Mary Sobieski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S583"
      ]
    },
    {
      "name": "Mary Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Maryann Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Maryanna Owoc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Masahiro Rokugo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Masaki Kakumu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Masao Takahashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P232"
      ]
    },
    {
      "name": "Masaru Miyagi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Masashi Nakaishi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Masato Nagaoka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Masayoshi Takashima",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Mason A Norgard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S071"
      ]
    },
    {
      "name": "Matheus F Lourenço",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P268"
      ]
    },
    {
      "name": "Matheus G Rosenfeld",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S236"
      ]
    },
    {
      "name": "Matheus M Luna Barros",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Matin Imanguli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Matthew Adams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Matthew Aschenbrenner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Matthew Bak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P095"
      ]
    },
    {
      "name": "Matthew C Hiemenz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Matthew Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Matthew Gonzalez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S606"
      ]
    },
    {
      "name": "Matthew Hagen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Matthew Holdaway",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "Matthew J Schipper",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Matthew Pierce",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123"
      ]
    },
    {
      "name": "Matthew Rigby",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Matthew Su",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Matthew Vance",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P170"
      ]
    },
    {
      "name": "Matthew White",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S569"
      ]
    },
    {
      "name": "Matthew Witek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Matthieu Schmittbuhl",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S211"
      ]
    },
    {
      "name": "Matthijs Valstar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Matías Lavín",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Maura Campbell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Maura L Gillison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Maureen Kane",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Mauricio A Moreno",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S460"
      ]
    },
    {
      "name": "Mauro K Ikeda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P268"
      ]
    },
    {
      "name": "Max Rademaekers, student",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Max Witjes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Maxime Tarabichi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Maximilian J Bailey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S375"
      ]
    },
    {
      "name": "Maxwell Zywica",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "May Rose Dela Cruz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Maya Behrend",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P336"
      ]
    },
    {
      "name": "Maya C Downs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Mayank Rampal, RESIDENT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P198"
      ]
    },
    {
      "name": "Mayas M Arraf",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Mayil Chinnaiyan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Mayte Diaz, DNP, CRNA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S552"
      ]
    },
    {
      "name": "Mayuri A Yasuda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "MedGenome Labs, Bangalore, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Megan Applewhite",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Megan Gillespie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P395"
      ]
    },
    {
      "name": "Megan Inada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Megan L Durr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Megan Long",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Megan McLeod",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Megan Sullivan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331"
      ]
    },
    {
      "name": "Meghan T Turner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P295"
      ]
    },
    {
      "name": "Meghan Turner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S041"
      ]
    },
    {
      "name": "Meghana Nathan, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P429"
      ]
    },
    {
      "name": "Mehrdad Pournaderi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Mehri Monavarian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S026"
      ]
    },
    {
      "name": "Mei Hamada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P264"
      ]
    },
    {
      "name": "Mei Ju Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S341"
      ]
    },
    {
      "name": "Mei Xing G Zuo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Mei Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036"
      ]
    },
    {
      "name": "Mei-fan Parnes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Mekibib Altaye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S258"
      ]
    },
    {
      "name": "Melanie L Styers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Melissa A Schroder",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P073"
      ]
    },
    {
      "name": "Melissa Bouhraoua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "Melissa Ghulam-Smith",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "Melissa M Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Melissa Tucker Ponto, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P177"
      ]
    },
    {
      "name": "Melody B Eckert, BM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Melonie A Nance",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Melonie Nance",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P167"
      ]
    },
    {
      "name": "Melvin Chua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Mena M Fam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188"
      ]
    },
    {
      "name": "Meng Yee Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Menggang Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Mengyuan Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S117"
      ]
    },
    {
      "name": "Meredith A Lilly",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S057"
      ]
    },
    {
      "name": "Meredith E Tabangin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S258"
      ]
    },
    {
      "name": "Merry E Sebelik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S057"
      ]
    },
    {
      "name": "MiJin Cho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Micah Harris",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Michael A Belsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Michael A Harmon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Michael Allevato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S124"
      ]
    },
    {
      "name": "Michael B Prystowsky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Michael Bouvet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Michael C. Topf",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Michael Chang, Biology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S551"
      ]
    },
    {
      "name": "Michael DeLeo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337"
      ]
    },
    {
      "name": "Michael Dougherty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P401"
      ]
    },
    {
      "name": "Michael E Bryan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Michael Eggerstedt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145"
      ]
    },
    {
      "name": "Michael Eizyk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Michael F Gensheimer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Michael Fediw",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Michael Gorelik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Michael Graham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S353"
      ]
    },
    {
      "name": "Michael H Berger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S216"
      ]
    },
    {
      "name": "Michael Hinni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Michael Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Michael I Orestes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S059"
      ]
    },
    {
      "name": "Michael J Buck",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S317"
      ]
    },
    {
      "name": "Michael J Dennis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Michael J Persky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Michael Kallen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Michael Kokko",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060"
      ]
    },
    {
      "name": "Michael Lamb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "Michael Lasarev",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S564"
      ]
    },
    {
      "name": "Michael Luttrull",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P200"
      ]
    },
    {
      "name": "Michael Machiorlatti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S566"
      ]
    },
    {
      "name": "Michael Markiewicz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P380"
      ]
    },
    {
      "name": "Michael Nagai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "Michael P Hier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Michael P Hier, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Michael P Veve, PharmD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Michael R Markiewicz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P142"
      ]
    },
    {
      "name": "Michael R Tuttle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S233"
      ]
    },
    {
      "name": "Michael S Lawrence",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Michael Sim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S119"
      ]
    },
    {
      "name": "Michael Simons",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Michael T Starc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S075"
      ]
    },
    {
      "name": "Michael Tjong, FRCPC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Michael Topf*, MSCI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Michael Troka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "Michael Tuttle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Michael V Medina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "Michael Valic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "Michael Woolman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Michael Xie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Michael Y Nagai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Michaele Corbisiero",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S044"
      ]
    },
    {
      "name": "Micheal Daly",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Micheal Topf, Assoc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Micheal Topf, MSCI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S188"
      ]
    },
    {
      "name": "Michele Arambula, DA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Michele Ceccarelli",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "Michelle A Neben Wittich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Michelle A Worst, PharmD, BCOP, CHCP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S443"
      ]
    },
    {
      "name": "Michelle Bradbury",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S345"
      ]
    },
    {
      "name": "Michelle Chen, MHS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "Michelle K Hong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P323"
      ]
    },
    {
      "name": "Michelle M Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S375"
      ]
    },
    {
      "name": "Michelle Neben Wittich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Michelle Neben-Wittich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Michelle Pei",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P026"
      ]
    },
    {
      "name": "Michelle Ruse, MDS, FACP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S016"
      ]
    },
    {
      "name": "Michelle Tengarra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Michelle Williams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Michelle York, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Michelle York, MA, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P433"
      ]
    },
    {
      "name": "Michelle Zhu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P421"
      ]
    },
    {
      "name": "Michiko Machida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Mihai Merzianu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S476"
      ]
    },
    {
      "name": "Mihika Shinde, BDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Mihir K Bhayani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S424"
      ]
    },
    {
      "name": "Mihir Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Miho Uchida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Mikel Ruterbusch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Milan Carter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "Milan P Fehrenbach",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Milena Fior, ENT Specialist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S500"
      ]
    },
    {
      "name": "Mimi Hu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Min Kyeong Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P039"
      ]
    },
    {
      "name": "Min-Shu Hsieh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P101"
      ]
    },
    {
      "name": "Mindy C DeRouen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Ming Hann Cheah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Ming Hsien Tsai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P273"
      ]
    },
    {
      "name": "Ming Liang Oon, MBBS, FRCAPA, FRCPath, MRCSI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Ming Yann Lim, MBBS, MRCS, DOHNS, MMedORL, FAMSORL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Ming-Hsien Tsai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S063"
      ]
    },
    {
      "name": "Ming-Huei Chou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P043"
      ]
    },
    {
      "name": "Mingyang Gray",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S414"
      ]
    },
    {
      "name": "Minh P Dong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Minit Shah, DM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Minnie Jan, PT, DPT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "Minoru Gotoh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Minsheng Hou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Miriam O'Leary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Mit A Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346"
      ]
    },
    {
      "name": "Mitchell Fourman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Mitchell J Frederick",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S519"
      ]
    },
    {
      "name": "Mitchell J Mead",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S288"
      ]
    },
    {
      "name": "Mitchell J Mead, BSA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S289"
      ]
    },
    {
      "name": "Mitesh Mehta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Mitra Alikhani, BSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Mitra Mehrad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S391"
      ]
    },
    {
      "name": "Mlynarek Alex",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Moanes Awad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Mohamad Mahameed, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S598"
      ]
    },
    {
      "name": "Mohamed Abdallah Sherif Radwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S220"
      ]
    },
    {
      "name": "Mohammad Jay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Mohammed Alzamil, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P431"
      ]
    },
    {
      "name": "Moitrayee Dhar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P032"
      ]
    },
    {
      "name": "Molly Heft-Neal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Molly Henn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Molly Smeltzer, MA, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P433"
      ]
    },
    {
      "name": "Mona Sabra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Mona Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S411"
      ]
    },
    {
      "name": "Mona Yuan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S286"
      ]
    },
    {
      "name": "Monali Swain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Monet C McCalla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393"
      ]
    },
    {
      "name": "Monet McCalla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Moni A",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Moni A Kuriakose, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Moni A Kuriakose, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Moni Abraham Kuriakose",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Monica A Wagner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S422"
      ]
    },
    {
      "name": "Monica Bodd, MTS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P163"
      ]
    },
    {
      "name": "Monica H Bodd, MTS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Monica S Gorton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Monica S Trent",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S344"
      ]
    },
    {
      "name": "Monika Krzyzanowska",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Monil D Parsana, Senior Resident",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P294"
      ]
    },
    {
      "name": "Monoj K Deka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Morgan Byrd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022"
      ]
    },
    {
      "name": "Morgan C Byrd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S251"
      ]
    },
    {
      "name": "Muaaz Wajahath",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Muaz Wahid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Mudit Agarwal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S234"
      ]
    },
    {
      "name": "Muhammad Ahmed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Muhammad Faisal, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257"
      ]
    },
    {
      "name": "Muhammad Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "Muhammad S Arshad, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S590"
      ]
    },
    {
      "name": "Muhammad Seif",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Muhammad Shahzaib Arshad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S467"
      ]
    },
    {
      "name": "Muhammad Shahzaib Arshad, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105"
      ]
    },
    {
      "name": "Munenaga Nakamizo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Murad Farooqi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S022"
      ]
    },
    {
      "name": "Murat Budak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Mursalin M Anis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S333"
      ]
    },
    {
      "name": "Myiah Quach",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "Myung-Whun Sung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "N Issaeva . Dept",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "N Joshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "N Najam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "N Vasan, FRACS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "N. Bouganim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "N. Eddie Liou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "N. Sadeghi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "NCI Div",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "NR Scott-Wittenborn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "Nabil F",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "Nabil Saba",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S592"
      ]
    },
    {
      "name": "Nadeem Riaz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Nader Sadeghi, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Nadia G Mohyuddin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Naifa Busaidy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Naiwei Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Nandini Menon, DM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Naohiro Takeshita",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Naomi Kiyota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Naomi Rabinovics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Naomi Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Narin Nard Carmel-Neidermann",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "Narin Ratanaprasert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "Naseem Saleh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Naser Sadeghi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Nasir Ud Din",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "Natalia Iasaeva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S314"
      ]
    },
    {
      "name": "Natalie Coburn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Natalie Weiss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Natalya Chernichenko",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Natascha Neu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Natasha Cohen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P062"
      ]
    },
    {
      "name": "Nathalia Peres Borges dos Santos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168"
      ]
    },
    {
      "name": "Nathalie G. Coburn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Nathan Foster",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Nathan Hansen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016"
      ]
    },
    {
      "name": "Nathan Hemenway",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S492"
      ]
    },
    {
      "name": "Nathan Huey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S498"
      ]
    },
    {
      "name": "Nathan P Ward",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Nathan V Pham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Nathan W Hales",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P406"
      ]
    },
    {
      "name": "Nathaniel Baek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Nathaniel Neptune",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Nathaniel S Treister",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Natlia Isaeva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S045"
      ]
    },
    {
      "name": "Naveen B S",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Naveen Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Naveen MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Navroze Eduljee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Nayuta Tsushima",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Neal E Dunlap",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Neel Sangal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S286"
      ]
    },
    {
      "name": "Neerada Meenakshi Warrier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Neerada Warrier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Neha Rana",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P299"
      ]
    },
    {
      "name": "Neil Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S183"
      ]
    },
    {
      "name": "Neil M Woody",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Neil Mehta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S195"
      ]
    },
    {
      "name": "Neil N Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S405"
      ]
    },
    {
      "name": "Neil Woody",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Neoni Yustana, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "Nevin Yi Meng Chua, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Ngechi Nwankwoala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Ngoc B Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P171"
      ]
    },
    {
      "name": "Ngoc Bich Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P089"
      ]
    },
    {
      "name": "Nguyen-Anh Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Niall Kent, , MBChB, BDS, MRCS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Nicholas Brian Shannon, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Nicholas Bridi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317"
      ]
    },
    {
      "name": "Nicholas Correia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P072"
      ]
    },
    {
      "name": "Nicholas Elmer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "Nicholas Hutchins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S191"
      ]
    },
    {
      "name": "Nicholas R Rowan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Nicholas Van Maele",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S461"
      ]
    },
    {
      "name": "Nick Sahlollbey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P125"
      ]
    },
    {
      "name": "Nickolas Dreher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Nickolas Pudik",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S385"
      ]
    },
    {
      "name": "Nicolas F Schlecht",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Nicolas Oltean",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "Nicole Caltabellotta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Nicole Casper, DPN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Nicole H Creppel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P418"
      ]
    },
    {
      "name": "Nicole I Farber",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S011"
      ]
    },
    {
      "name": "Nicole L Jones, CCRP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S437"
      ]
    },
    {
      "name": "Nicole Rogus-Pulia, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P151"
      ]
    },
    {
      "name": "Nicole Schaen-Heacock, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P151"
      ]
    },
    {
      "name": "Nihar Rama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Nijo Jose",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Nika Darvish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S113"
      ]
    },
    {
      "name": "Nikhil C Mathur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "Nikhil Joshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147"
      ]
    },
    {
      "name": "Nikhita Santebennur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Nikita Jadhav",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Nikolina Dioufa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P126"
      ]
    },
    {
      "name": "Nilesh Vasan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "Nilesh Vasan, FRACS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S084"
      ]
    },
    {
      "name": "Nima M Taghizadeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S441"
      ]
    },
    {
      "name": "Nimish Mehta, CHCP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S443"
      ]
    },
    {
      "name": "Nimish Valvi, DrPH, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Nina Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Ning Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S431"
      ]
    },
    {
      "name": "Nir Hirshoren, MHA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Nishant Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Nithesh S",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Nivedita Chakrabarty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S309"
      ]
    },
    {
      "name": "Noa Brenner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Noah A Bloomgarden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Noah Bogart",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S460"
      ]
    },
    {
      "name": "Noah DeMoss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "Noah Earland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Noah Thornton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Noah Weaver",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "Noam Auslander",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Nobuhiro Hanai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Noga Kurman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S364"
      ]
    },
    {
      "name": "Nora Katabi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Norah Alnafea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "Norbert Sule",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S036"
      ]
    },
    {
      "name": "Noriaki Tanaka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036"
      ]
    },
    {
      "name": "Norihiro Usukura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Norman Lester",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Nosayaba Osazuwa-Peters, BDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Nosayaba Osazuwa-Peters, BDS, CHES",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022"
      ]
    },
    {
      "name": "Nour Mourra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "Noémie Villemure-Poliquin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Nuwan Dharmawardana, BMBS, FRACS, MClinSci",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S161"
      ]
    },
    {
      "name": "Obinna Nwosu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S527"
      ]
    },
    {
      "name": "Ohad Ronen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Oldrich Virag",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P121"
      ]
    },
    {
      "name": "Oleg Militsakh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Oleksandr Butskiy, Clinical Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P055"
      ]
    },
    {
      "name": "Olena Bracho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P026"
      ]
    },
    {
      "name": "Olga Gologan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S211"
      ]
    },
    {
      "name": "Olga Pasternak-Wise",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P384"
      ]
    },
    {
      "name": "Olinde Lindsay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P241"
      ]
    },
    {
      "name": "Oliver Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Oliver. Siefer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Olivia Lopes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Olivia Uchima, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Olivier Abboud",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "Omar Fernandez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Omar G Ahmed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Omar Karadaghy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S266"
      ]
    },
    {
      "name": "On behalf of OPC-SURVIVOR Research Program",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S168"
      ]
    },
    {
      "name": "Orr Dimitstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S396"
      ]
    },
    {
      "name": "Orr Raved",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362"
      ]
    },
    {
      "name": "Osamu Sakai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S203"
      ]
    },
    {
      "name": "Osman Kostek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Ousama A'Amar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Owen Hall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "P Berryman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "P Daniel Knott",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P335"
      ]
    },
    {
      "name": "P Dong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "P Putnam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "P R Ratmeyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "P Walker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "PO LING Catherine Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P134"
      ]
    },
    {
      "name": "Pabiththa Kamalraj",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Pablo Ocampo Quintana",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P250"
      ]
    },
    {
      "name": "Pallavi Dutta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P062"
      ]
    },
    {
      "name": "Pamela Sandow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Pamella Abreu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Panagiota Economopoulou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Paolo Bossi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Paolo Castelnuovo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Parag Sanghvi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S462"
      ]
    },
    {
      "name": "Parastou Gorovanchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Pardis Mohammadzadeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Parisa Abedi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Parisa Abedi, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P436"
      ]
    },
    {
      "name": "Parnaz Jafari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Parshad Suthar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S320"
      ]
    },
    {
      "name": "Parth Tagdiwala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Patricia Biondo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Patricia Castro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P262"
      ]
    },
    {
      "name": "Patricia Cerri-Droz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S600"
      ]
    },
    {
      "name": "Patricia I Diaz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S379"
      ]
    },
    {
      "name": "Patricia J Brooks",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Patricia Scott, APRNNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Patrick Galligan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S026"
      ]
    },
    {
      "name": "Patrick Ha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Patrick Hunt, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "Patrick Lizotte",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Patrick McGarrah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Patrick Sheahan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S106"
      ]
    },
    {
      "name": "Patrick Soon-Shiong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Patrick T Tassone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S159"
      ]
    },
    {
      "name": "Patrick W McGarrah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Patrick Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Patrick Youssef",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P156"
      ]
    },
    {
      "name": "Patryk Dabek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Paul A Gardner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Paul Allen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Paul Boutros",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Paul C Bryson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S334"
      ]
    },
    {
      "name": "Paul C Walker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Paul L Sweicicki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S285"
      ]
    },
    {
      "name": "Paul M Harari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Paul Sinno",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P095"
      ]
    },
    {
      "name": "Paul Tabet, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Paula Demetrio de Souza Franca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Paula Moretzsohn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Paula Villarreal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Pauline Shih",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146"
      ]
    },
    {
      "name": "Pavan M Hallur, Mr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Paveena Pithuksurachai, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P197"
      ]
    },
    {
      "name": "Pavithra C",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Pavithra Chandrashekhar, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Pawin Numthavaj, Asst Prof",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Payal Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P398"
      ]
    },
    {
      "name": "Payam Entezami",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Payton Dudley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P395"
      ]
    },
    {
      "name": "Pedro Cesar M Silveira, Mr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "Pedro Nunes Bernotavicius Araújo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P203"
      ]
    },
    {
      "name": "Peesit Leelasawatsuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Pei-Jen Lou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Pen Yuan Chu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S341"
      ]
    },
    {
      "name": "Peng Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Periklis Foukas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Perry B Hammond",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P387"
      ]
    },
    {
      "name": "Peter Angelos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Peter Berryman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Peter Brett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "Peter Clarke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Peter H Hwang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234"
      ]
    },
    {
      "name": "Peter H Shaw",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Peter H. Ahn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Peter Horwich, MEd, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S016"
      ]
    },
    {
      "name": "Peter Kahng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Peter Lancione",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Peter Opelt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Peter Protzel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331"
      ]
    },
    {
      "name": "Peter Steele",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Peter Van Loo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Peter W Larner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S226"
      ]
    },
    {
      "name": "Petr Szturz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Phatchara Ruampattana",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Phil Tseng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "Philip Brauer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Philip C Doyle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Philip Weissbrod",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Philippe Herman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Phillip Pirgousis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Philopateer Hanein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S559"
      ]
    },
    {
      "name": "Phitthawat Yingsukamol",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Phoebe Ato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123"
      ]
    },
    {
      "name": "Phuc Felix Nguyen-Tân",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Phyllis Gimotty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Piamkhun Siritantikorn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Pilkeun Jang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Pim Schreuder",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Pin Cai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Piyush B Gupta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Po Ling Catherine Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S044"
      ]
    },
    {
      "name": "Prachya Maneeprasopchoke, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P197"
      ]
    },
    {
      "name": "Prajwal Dange, Mch, Head and Neck Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S012"
      ]
    },
    {
      "name": "Prakriti Sen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Pramila Mendonca",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Praneet C Kaki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205"
      ]
    },
    {
      "name": "Prashasthi Shetty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Prathamesh Pai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Pratik Kadam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Praveen Birur, BDS, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Praveen Birur, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Praveen Rao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S320"
      ]
    },
    {
      "name": "Preethi George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Priscila Bastos de Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S201"
      ]
    },
    {
      "name": "Priscilla F Pichardo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144"
      ]
    },
    {
      "name": "Priyanka Bhateja",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S399"
      ]
    },
    {
      "name": "Punam Thakkar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Pyung hun Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Qing Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Qing Li, MMath",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Quinn A Dunlap",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346"
      ]
    },
    {
      "name": "Quynh-Thu Le",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "R Bryan Bell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "R Ferris",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "R Mhawej",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "R Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "R Philips",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "R Powszok",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "R Rahbar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "R. Alex Harbison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Rabia S Angiras",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Rachel B Fenberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S154"
      ]
    },
    {
      "name": "Rachel Elsey, PharmD, BCOP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Rachel Fenberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P336"
      ]
    },
    {
      "name": "Rachel Jia Xuan Ng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Rachel Kaye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "Rachel Paolini",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Rachel T Gonzalez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Radhika Duggal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Radhika K, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S407"
      ]
    },
    {
      "name": "Radhika Kapahtia, MCh, Plastic Reconstructive Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S012"
      ]
    },
    {
      "name": "Radhika Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S603"
      ]
    },
    {
      "name": "Rafael Araúz, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Rafael C Ortiz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Rafael De Cicco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P250"
      ]
    },
    {
      "name": "Rafael Ortiz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "Rafael Pereira De Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P250"
      ]
    },
    {
      "name": "Raghav Gupta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Rahat Malhotra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Rahul Seth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P335"
      ]
    },
    {
      "name": "Raisa Chowdhury",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Raj Malhotra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "Rajarsi Mandal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Rajeev Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Ralph W. Gilbert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Ramanakumar Agnihotram",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Ramona Dadu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Randy Wei, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Ranjani Balakrishnan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Raquel A Moyses",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S541"
      ]
    },
    {
      "name": "Raquel A Moyses . LIM-",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Raul Ramos Sanchez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P361"
      ]
    },
    {
      "name": "Ravi Kannan, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Ray McDermott",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Ray Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P099"
      ]
    },
    {
      "name": "Raymond K Tsang, FRCSEd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S444"
      ]
    },
    {
      "name": "Raymond KY Tsang, MBChB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Raymond Medina, AS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "Raymond Tsang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Raza Hussain, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257"
      ]
    },
    {
      "name": "Razan Hussein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Reba Elsa Sam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Rebecca Bartlett, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S355"
      ]
    },
    {
      "name": "Rebecca Eary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Rebecca Gao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S215"
      ]
    },
    {
      "name": "Rebecca Hofer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Rebecca Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Reena Kudchadker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Regan Bergmark",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Regina Golding",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Regina Kahnert, CNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Reid DeMass",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Reinier Hernandez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "Rejnish R Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Ren Yi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Renan B Lira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S607"
      ]
    },
    {
      "name": "Renata Mahmoud",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P109"
      ]
    },
    {
      "name": "Renata O Ferrarotto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Renato Capuzzo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Renee Moadel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Reshmi Parameswaran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Rhea Shetty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Rhiannon Sutch, BSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Ric Carrau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S195"
      ]
    },
    {
      "name": "Ricardo Aulet",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P415"
      ]
    },
    {
      "name": "Ricardo Carrau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S085"
      ]
    },
    {
      "name": "Ricardo Gama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Ricardo R Gama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "Richard A Harbison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Richard Chan W Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "Richard D Hammer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Richard Harvey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Richard Hausman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Richard Hayden",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Richard J Lu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S075"
      ]
    },
    {
      "name": "Richard J Payne, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Richard L Bakst",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217"
      ]
    },
    {
      "name": "Richard Sullivan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S501"
      ]
    },
    {
      "name": "Richard Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Rinku Sutradhar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Rishi Malhotra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Rishi Mittal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Ritesh Tapkire, Mch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Ritu V Bhalerao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S022"
      ]
    },
    {
      "name": "Rizwan Aslam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Rob Lindau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Robert E Africa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S440"
      ]
    },
    {
      "name": "Robert Ferris",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Robert Haddad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Robert Hart",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P125"
      ]
    },
    {
      "name": "Robert I Haddad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Robert J Sinard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S562"
      ]
    },
    {
      "name": "Robert Saddawi-Konefka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Robert Schnoll",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Robert Sinard",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Robert Soriano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Roberto Ortega Platt, Gynecologic oncologist",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Robi Mitra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Robin Higashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Robin Humphryes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Robin Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S073"
      ]
    },
    {
      "name": "Robin W Davis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Rod P Rezaee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S553"
      ]
    },
    {
      "name": "Rodney Schlosser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Rodolfo Arozarena Fundora",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Rodrigo Bayon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P308"
      ]
    },
    {
      "name": "Roee Domany",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S554"
      ]
    },
    {
      "name": "Rohan Minocha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S196"
      ]
    },
    {
      "name": "Rohini Bahethi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P033"
      ]
    },
    {
      "name": "Rohit Bhargava",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Ronald Horswell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Ronald N Cohen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Ronaldo Toledo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Rongguang Liang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Roni Ochakovski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Rony Aouad",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S461"
      ]
    },
    {
      "name": "Roopali Kulkarni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P275"
      ]
    },
    {
      "name": "Rosanne Schoonbeek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Rosh K Sethi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Rosimeire Aparecida Ruela",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Rossana López",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Rounik T",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Roy Frye",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P277"
      ]
    },
    {
      "name": "Roy W Qu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P376"
      ]
    },
    {
      "name": "Ruben Miranda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S130"
      ]
    },
    {
      "name": "Ruby Nguyen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Rui Fu, PStat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Rui Jennifer Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Rukmini Prabhu, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Rula Mualla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Rupal P Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S306"
      ]
    },
    {
      "name": "Rushil Dang, BDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S587"
      ]
    },
    {
      "name": "Russel Kahmke, MMCi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Ruud Schreurs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Ryan Bowman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S593"
      ]
    },
    {
      "name": "Ryan C Higgins",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Ryan Chung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S293"
      ]
    },
    {
      "name": "Ryan Daniel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P317"
      ]
    },
    {
      "name": "Ryan Elvis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P068"
      ]
    },
    {
      "name": "Ryan Goepfert",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S173"
      ]
    },
    {
      "name": "Ryan Griswold",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Ryan H",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Ryan Hellums",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P401"
      ]
    },
    {
      "name": "Ryan I Instrum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S349"
      ]
    },
    {
      "name": "Ryan Instrum",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Ryan J Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Ryan K Orosco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Ryan K Stepp",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Ryan Kong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S255"
      ]
    },
    {
      "name": "Ryan Lanning",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425"
      ]
    },
    {
      "name": "Ryan M Mitchell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Ryan Mackay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434"
      ]
    },
    {
      "name": "Ryan Osborne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393"
      ]
    },
    {
      "name": "Ryan T Judd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S214"
      ]
    },
    {
      "name": "Ryan Winters",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Ryder Grantham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Ryo Kawaura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Ryosuke Kitoh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Ryosuke Sato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S584"
      ]
    },
    {
      "name": "Ryosuke Takahashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Ryu Dom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S036"
      ]
    },
    {
      "name": "Ryuhei Okada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Ryuichi Hayashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Ryung S Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Ryusuke Shodo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Ryutaro Onaga",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Róger Padilla, Maxilofacial and Prosthetic Surgeon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P143"
      ]
    },
    {
      "name": "S Alkhudari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "S Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "S Norberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S281"
      ]
    },
    {
      "name": "S Turgeman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "S. Ahmed Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P155"
      ]
    },
    {
      "name": "S. Danielle MacNeil, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P070"
      ]
    },
    {
      "name": "ST Parambil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "Saad Ahmed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Sabrina Bernardo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Sacha Moufarrej, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P353"
      ]
    },
    {
      "name": "Sadra Khosravi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P055"
      ]
    },
    {
      "name": "Safina Suratwala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Sahar Assi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Sahin Laçin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Sai Ramani Choudari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P038"
      ]
    },
    {
      "name": "Sai Y Panidarapu, MBT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P125"
      ]
    },
    {
      "name": "Said Turfe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S406"
      ]
    },
    {
      "name": "Sailesh S Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Saketh Bathula",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "Sally Long",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P327"
      ]
    },
    {
      "name": "Salma Ahsanuddin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Salma Ramadan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S454"
      ]
    },
    {
      "name": "Sam Auger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S349"
      ]
    },
    {
      "name": "Samad Farashi Bonab",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Samantha Lloyd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Samarpita Mohanty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Samarprita Mohanty",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S309"
      ]
    },
    {
      "name": "Sameer Alvi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P382"
      ]
    },
    {
      "name": "Samip M Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Samip Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Samir H Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Samir S Khariwala",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Samntha Tam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Samuel Angel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Samuel D Cloyd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Samuel Kadoury",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S003"
      ]
    },
    {
      "name": "Samuel O Poore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "Samuel Rubin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P089"
      ]
    },
    {
      "name": "Samyukta Mallick",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P038"
      ]
    },
    {
      "name": "San Chu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Sana D Karam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Sana Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "Sandeep Reddy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Sandhya Ganesan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Sandra LIop Serna",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Sanjana Balachandra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Sanjana Kaza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Sara A Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S073"
      ]
    },
    {
      "name": "Sara Armstrong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P015"
      ]
    },
    {
      "name": "Sara B Strauss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Sara Forastieri Vicente",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Sara Jasper",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261"
      ]
    },
    {
      "name": "Sara Kochanny",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Sara O'Sullivan-Bakshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S056"
      ]
    },
    {
      "name": "Sara Piva, PT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "Sarah Adams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Sarah C Nyirjesy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Sarah Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Sarah E Ridge",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378"
      ]
    },
    {
      "name": "Sarah G Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378"
      ]
    },
    {
      "name": "Sarah Hamidi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Sarah Hamilton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Sarah Honjo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S472"
      ]
    },
    {
      "name": "Sarah L Rohde, MMHC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S562"
      ]
    },
    {
      "name": "Sarah Nyirjesy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Sarah Toti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S461"
      ]
    },
    {
      "name": "Sarah Zadeh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Saral Mehra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Sarina Piha-Paul",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Saroj K Basak",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Sasha Mallya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Satish Govindaraj",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Satoshi Kano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Satrajit Sinha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S474"
      ]
    },
    {
      "name": "Saurin R Popat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Savannah A Zimmerman, BSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Saveli Goldberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S441"
      ]
    },
    {
      "name": "Sayaka Yokoi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P368"
      ]
    },
    {
      "name": "Sayuri Miyauchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Scharukh M Jalisi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Scott Bratman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S318"
      ]
    },
    {
      "name": "Scott Fuller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S197"
      ]
    },
    {
      "name": "Scott Lester",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S079"
      ]
    },
    {
      "name": "Scott McLean",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S160"
      ]
    },
    {
      "name": "Scott Troob",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P087"
      ]
    },
    {
      "name": "Scott V Bratman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Se Heon Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Sean Barber",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Sean Maroongroge",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Sean McBride",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Sean T Massa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S092"
      ]
    },
    {
      "name": "Sebastiaan de Visscher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Sebastian Guadarrama-Sistos-Vazquez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Sebastián Sepúlveda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Sefik Hosal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P240"
      ]
    },
    {
      "name": "Seka Lazare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Selda Samakoglu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Selena M White",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Semma Kacker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Seneca Williams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S340"
      ]
    },
    {
      "name": "Seo Y Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Septimiu Salcudean",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S381"
      ]
    },
    {
      "name": "Serdar Ozer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Serena Pu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Serene C Siow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S444"
      ]
    },
    {
      "name": "Serge Atherwood",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Sergio Goncalves",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Seth Kaplan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P281"
      ]
    },
    {
      "name": "Seth Zwillenberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P291"
      ]
    },
    {
      "name": "Seungwon W Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Seyed Ziaeddin Rasihashemi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Shaan Bhullar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P245"
      ]
    },
    {
      "name": "Shaan M Raza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Shahaf Shilo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S103"
      ]
    },
    {
      "name": "Shahid Nimjee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P156"
      ]
    },
    {
      "name": "Shahme Farook, MBChB, BDS, Hons, MRCS, MFDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P169"
      ]
    },
    {
      "name": "Shahruhk R Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S440"
      ]
    },
    {
      "name": "Shahzada Ahmed",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Shama Karanth, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Shannon M Hall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P390"
      ]
    },
    {
      "name": "Shannon M Poti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Shannon S Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P221"
      ]
    },
    {
      "name": "Shanthi Velusamy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S471"
      ]
    },
    {
      "name": "Sharika Kumar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S298"
      ]
    },
    {
      "name": "Shashikala Balanna",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Shaun Edalati",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Shauna Brodie, FNP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Shauna R Campbell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Shaunak Dalal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S185"
      ]
    },
    {
      "name": "Shawn Newlands",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S291"
      ]
    },
    {
      "name": "Shayanne Lajud Guerrero",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Shaylan Bera",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P245"
      ]
    },
    {
      "name": "Shaynie Segal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P375"
      ]
    },
    {
      "name": "Shea Fincher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S406"
      ]
    },
    {
      "name": "Shelley Machuta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Sheng Liang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Shenouda George",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Sherrie L Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "Shethal Bearelly",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P162"
      ]
    },
    {
      "name": "Shigeru Hirano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Shigeru Kondo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Shih-yu Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Shikha Shikha Jha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Shiqi Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Shireen Gohari, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S498"
      ]
    },
    {
      "name": "Shireen S Gohari, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Shirley Lewis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Shirley X Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Shirly Y Su",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Shivakumar Thiagarajan, PROF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S224"
      ]
    },
    {
      "name": "Shivani K Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Shivani L Lotlikar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S556"
      ]
    },
    {
      "name": "Shivaprasad K S",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Shiven Sharma, JD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Shiyu Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Shlomo Merchavy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Shlomo Merchavy, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S135"
      ]
    },
    {
      "name": "Shmuel Wechsler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Shorook Naara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Shota Sugaya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Shradha Sreeprakash",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S557"
      ]
    },
    {
      "name": "Shreni Shah",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P267"
      ]
    },
    {
      "name": "Shreya Arun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S152"
      ]
    },
    {
      "name": "Shreya Jain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P389"
      ]
    },
    {
      "name": "Shreyans A Udani, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Shreyas Anil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Shriraam P Mahadevan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Shriya Airen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P083"
      ]
    },
    {
      "name": "Shuai Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Shubha G",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Shubha Gurudath, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Shubham Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Shunji Takahashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Shusuke Ohshima",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Shyam Rao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S087"
      ]
    },
    {
      "name": "Si Ying Julienne Keong, MRCSGlasg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "Sid Puram",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Sida Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S557"
      ]
    },
    {
      "name": "Siddhant Kansal, Mr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P169"
      ]
    },
    {
      "name": "Siddharth V Puram",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Siddhi Patil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Sidney Fels",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Sienna Nanji, MHA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Silvio Bicciato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "Simo Kraguljac",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S049"
      ]
    },
    {
      "name": "Simon Ellington",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019"
      ]
    },
    {
      "name": "Simon Müller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Sindhura Popuri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S105"
      ]
    },
    {
      "name": "Sing Cheer Kwek",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Siqi Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Siti Radhziah Binte Sudirman, Senior Consultant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Sivaporn Kiatthanabumrung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Siyeon Jin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Slyn Uaroon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S315"
      ]
    },
    {
      "name": "Smrithi Chidambaram",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P171"
      ]
    },
    {
      "name": "Sofia Beseth, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S547"
      ]
    },
    {
      "name": "Sofia Leusch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S347"
      ]
    },
    {
      "name": "Sofiya Yusina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Soichiro Matsuo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P183"
      ]
    },
    {
      "name": "Solaiman Juman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Solymar Torres Maldonado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S018"
      ]
    },
    {
      "name": "Somya Shankar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P165"
      ]
    },
    {
      "name": "Sonam Patel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Song Hon Hwang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S387"
      ]
    },
    {
      "name": "Sonia del Rincon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S396"
      ]
    },
    {
      "name": "Soo Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S462"
      ]
    },
    {
      "name": "Soo Yeon Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Sook-Bin Woo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S148"
      ]
    },
    {
      "name": "Sophia Tang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Sophia Z Shalhout",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Sophie A Lloyd",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Sophie Jabban",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S257"
      ]
    },
    {
      "name": "Sophie Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Soraya Fereydooni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Soren McLeod",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "Soumik Purkayastha, MStat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S043"
      ]
    },
    {
      "name": "Soumya Vijaya Kuma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "Sowmya C",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Spencer Dennis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046"
      ]
    },
    {
      "name": "Spencer G Shumway",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P243"
      ]
    },
    {
      "name": "Spencer H Short",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P289"
      ]
    },
    {
      "name": "Spenser S Souza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Sri Vemulamanda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S327"
      ]
    },
    {
      "name": "Srikar Ganapathiraju",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Srinivas Saladi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "Srinivasa R Chandra, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S559"
      ]
    },
    {
      "name": "Srivatsa S Vasudevan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P241"
      ]
    },
    {
      "name": "Srivatsa Vasudevan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P170"
      ]
    },
    {
      "name": "Sruthi Suprapaneni",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Stacy Hooker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Stacy Stewart, BSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S361"
      ]
    },
    {
      "name": "Stanislav Drapela",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Stefanie Pena",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P235"
      ]
    },
    {
      "name": "Stelby Augustine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Stella Ghevondyan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P302"
      ]
    },
    {
      "name": "Stephanie Chiodini",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261"
      ]
    },
    {
      "name": "Stephanie Fish",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Stephen Li",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Stephen P Naber",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Stephen Schoenberger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Stephenie Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S146"
      ]
    },
    {
      "name": "Steve Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P018"
      ]
    },
    {
      "name": "Steven B Cannady, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Steven Hong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Steven J Frank",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S169"
      ]
    },
    {
      "name": "Steven J Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "Steven Waguespack",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Stewart Lyman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Stuart Corr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Subir Goyal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Subramania Iyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Subramanian Kannan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Suimin Qiu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Sujan Dhar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Sujan K Dhar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Sujith Baliga",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S399"
      ]
    },
    {
      "name": "Sukhkaran Aulakh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "Sulfath Thottungal Parambil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P042"
      ]
    },
    {
      "name": "Sultanem Khalil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Sumanth Chandrpatla",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337"
      ]
    },
    {
      "name": "Sumita Trivedi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Sumiyo Saburi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Sung J Park",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Sunny K Ennis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P114"
      ]
    },
    {
      "name": "Supratik Mukhopadhyay",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Supriya Atta",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S360"
      ]
    },
    {
      "name": "Susan M Sereika",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "Susanne Flach",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Susumu Okano",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Suthida Sujaritsrichaikul",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P197"
      ]
    },
    {
      "name": "Suvranu De",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Swati Jain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Syamantak Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S320"
      ]
    },
    {
      "name": "Sydney Butts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Syed Ahmed Ali",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P369"
      ]
    },
    {
      "name": "Syed Shahzeb Hasan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S414"
      ]
    },
    {
      "name": "Syeda Maria Ahmad Zaidi, Research Fellow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S581"
      ]
    },
    {
      "name": "Sylvie Mrug",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S374"
      ]
    },
    {
      "name": "Syndey Coleman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "T Day",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "T Hackman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "T Wilson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S035"
      ]
    },
    {
      "name": "T. Wayne Matthews",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Ta'ir Rocker",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Tagharid Marhoon Al Riyami",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P081"
      ]
    },
    {
      "name": "Taghreed Al Riyami",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P399"
      ]
    },
    {
      "name": "Taha Mur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Taha Shaikh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Taiji Koyama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Taimur Kahlid",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046"
      ]
    },
    {
      "name": "Taisei Nagahisa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Tajinder Kainth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S579"
      ]
    },
    {
      "name": "Tajinder S Kainth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S583"
      ]
    },
    {
      "name": "Takaaki Sato",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Takahiro Fukuhara",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Takahiro Tsujikawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Takayoshi Suzuki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Takenori Ogawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Takeshi Shinozaki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Takeshi Takahashi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Tal Marom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Talitha K Lewis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P409"
      ]
    },
    {
      "name": "Tam Ramsey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Tamar Kotz, CCCSLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S216"
      ]
    },
    {
      "name": "Tamara A Sussman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Tamara Vesel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Tammy B Pham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S238"
      ]
    },
    {
      "name": "Tammy Pham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S249"
      ]
    },
    {
      "name": "Tammy Sussman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S372"
      ]
    },
    {
      "name": "Tan X",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "Tanner Frahm",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S548"
      ]
    },
    {
      "name": "Tara Coreanu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S364"
      ]
    },
    {
      "name": "Tara Mokhrari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S552"
      ]
    },
    {
      "name": "Tara Moore-Medlin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Tareck Ayad, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Tatiana Natasha Toporcov",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S201"
      ]
    },
    {
      "name": "Tatsuya Furukawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Tatyana Voloshchuk",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S016"
      ]
    },
    {
      "name": "Taylor Hall",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282"
      ]
    },
    {
      "name": "Taylor Kring",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P305"
      ]
    },
    {
      "name": "Taylor Osborne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393"
      ]
    },
    {
      "name": "Taylor Redding",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P278"
      ]
    },
    {
      "name": "Ted Kuke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Teena Sura",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Tejas Patil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Terence Pires de Farias",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P203"
      ]
    },
    {
      "name": "Teresa Alnemri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Teresa Jewell, MLIS, AHIP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S272"
      ]
    },
    {
      "name": "Teresa Lyden, CCC, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S419"
      ]
    },
    {
      "name": "Teresa Lyden, SLP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Tetsuya Ogawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Theodoros Teknos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Theophilus Hong Qiu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S350"
      ]
    },
    {
      "name": "TheraCUES Innovations Pvt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Theresa Tharakan, MSCI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S037"
      ]
    },
    {
      "name": "Theresa Yao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Thi Nguyen, RD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Thiago B Oliveira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S435"
      ]
    },
    {
      "name": "Thomas F Barrett",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S104"
      ]
    },
    {
      "name": "Thomas Gernon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Thomas Houser",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "Thomas J Gal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346"
      ]
    },
    {
      "name": "Thomas J Sorenson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "Thomas Kislinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Thomas Kwok Seng Loh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025"
      ]
    },
    {
      "name": "Thomas R O'Toole",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Thomas S Nijboer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S208"
      ]
    },
    {
      "name": "Thomas S Tilton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S151"
      ]
    },
    {
      "name": "Thomas Sorenson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "Thomas Szabo Yamashita",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S058"
      ]
    },
    {
      "name": "Thomas Zheng Jie Teng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Tien-Shew Huang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Tieying Hou",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405"
      ]
    },
    {
      "name": "Tiffany Chao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S112"
      ]
    },
    {
      "name": "Tiffany Heikel, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Timothy Cheo, MBBS, RANZCR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Timothy Eberlein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Tobias Meissner",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Todd Burus, MAS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S431"
      ]
    },
    {
      "name": "Tolani F Olonisakin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Tomer Kerman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120"
      ]
    },
    {
      "name": "Tomoaki Asamori",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Tomohiro Shimizu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S324"
      ]
    },
    {
      "name": "Tomoya Kurokawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Toni Rush",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S059"
      ]
    },
    {
      "name": "Tony Satroplus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Tonya Aaron",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P235"
      ]
    },
    {
      "name": "Tonya Wibbenmeyer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Toshimasa M Aoki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P446"
      ]
    },
    {
      "name": "Traci Buescher, APRN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Travis J Haller",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Trenton House",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S538"
      ]
    },
    {
      "name": "Trinitia Y Cannon",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S251"
      ]
    },
    {
      "name": "Trisha M Wise-Draper",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P144"
      ]
    },
    {
      "name": "Tristan Coles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Tristan Tham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S053"
      ]
    },
    {
      "name": "Troy Ejsmentewicz, M, Sc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Troy Weinstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P162"
      ]
    },
    {
      "name": "Trupti Kolur, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Tsien Christina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Tsung-Lin Yang, EMBA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "Tuan Vo-Dinh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S360"
      ]
    },
    {
      "name": "Tulika S",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Turki Almuhaimid, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P431"
      ]
    },
    {
      "name": "Twisha Kurlagunda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Tyler Gathman",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S457"
      ]
    },
    {
      "name": "Tyler J Gallagher",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S293"
      ]
    },
    {
      "name": "Tyler J Gathman, MSE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S608"
      ]
    },
    {
      "name": "Tyler Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Ubaldo E Martinez-Outschoorn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Ubaldo Martinez-Outschoorn",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Udit Nindra",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Uma Mohan, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Umaymah Uzair",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Umesh Velu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Usama Aboelkheir",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S031"
      ]
    },
    {
      "name": "Usman Khan, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414"
      ]
    },
    {
      "name": "Uzair Khan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S042"
      ]
    },
    {
      "name": "V Stubbs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S491"
      ]
    },
    {
      "name": "Va'Shayna Williams",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292"
      ]
    },
    {
      "name": "Vafa Tabatabaie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Vaishnav Vasudevan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Valentina Montanez-Azcarate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S456"
      ]
    },
    {
      "name": "Valeria F Alarcon Leiva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S130"
      ]
    },
    {
      "name": "Vanessa Chin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Vanessa Fishel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Vanessa Nwaiwu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Vanita Noronha, DM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Varsha C Yarra, BDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Varsha Manucha",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P045"
      ]
    },
    {
      "name": "Varsha Pudi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Varun Gopal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Veena Jajoo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S552"
      ]
    },
    {
      "name": "Veena Jajoo, CPH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "Veronica Ashton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Veronica Bernacchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P428"
      ]
    },
    {
      "name": "Veronica Bernacchi, Assistant",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P430"
      ]
    },
    {
      "name": "Veronica Rodriguez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S245"
      ]
    },
    {
      "name": "Veronique-Isabelle Forest",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106"
      ]
    },
    {
      "name": "Vianca Angelica Mendoza",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S172"
      ]
    },
    {
      "name": "Vicky Yau",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P375"
      ]
    },
    {
      "name": "Victor Albornoz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S102"
      ]
    },
    {
      "name": "Victor Diaz Barros",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Victor H Albornoz Alvarez",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P241"
      ]
    },
    {
      "name": "Victoria E Banuchi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S231"
      ]
    },
    {
      "name": "Victoria Kuznetsova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S493"
      ]
    },
    {
      "name": "Victoria Shaffer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Victoria Teoh, BBA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "Victoria X Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374"
      ]
    },
    {
      "name": "Vidhya Kannan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S085"
      ]
    },
    {
      "name": "Vidyabhushan R",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Vidyabhushan R, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Vijay Pillai, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Vijay Pillai, MDS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Vijayalakshmi Bhat",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Vikas Barnwal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088"
      ]
    },
    {
      "name": "Vikas Mehta*",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Vikas Sharma, RESIDENT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P294"
      ]
    },
    {
      "name": "Vikash Kansal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207"
      ]
    },
    {
      "name": "Vikram Vasan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Vimawala Swar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S436"
      ]
    },
    {
      "name": "Virginia Sun, MSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Virginia Waring, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Vivek Shetty, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Vivek Shetty, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Vivian Weiss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S606"
      ]
    },
    {
      "name": "Vivian Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Viviane Sonaglio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P432"
      ]
    },
    {
      "name": "Vlad Sandulache",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P262"
      ]
    },
    {
      "name": "Vladimir Frias",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P380"
      ]
    },
    {
      "name": "W. Craig Kemper",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P254"
      ]
    },
    {
      "name": "Wais Rahmati",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S305"
      ]
    },
    {
      "name": "Walter Fontanella",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Wan Qin Chong, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Wan-Lun Hsu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Wanwen Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S381"
      ]
    },
    {
      "name": "Wanxing Chai-Ho",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "Warren R Bacorro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "Warren Swegal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P089"
      ]
    },
    {
      "name": "Warut Pongsapich, Associate",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P197"
      ]
    },
    {
      "name": "Wayne M Koch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Wayne T. Matthews",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001"
      ]
    },
    {
      "name": "Wee Hian Tan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Wei Fu Chan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S409"
      ]
    },
    {
      "name": "Wei Sian Lim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P408"
      ]
    },
    {
      "name": "Wei Sian Lim, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Wei-Ting Chen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Weida Gong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Weifeng Zeng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "Weijia Fu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P032"
      ]
    },
    {
      "name": "Weiyi Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S095"
      ]
    },
    {
      "name": "Weiyuan Mai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P423"
      ]
    },
    {
      "name": "Wen-Chung Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Wenceslao S Llauderes, FPSNM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "Wendi O'Neill, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S580"
      ]
    },
    {
      "name": "Wendi Quinn O'Neill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Wendy Winckler",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Wenqi LU",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S376"
      ]
    },
    {
      "name": "Wesley Hicks Jr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Wesley Stepp",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P208"
      ]
    },
    {
      "name": "William A Stokes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "William C Spanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P215"
      ]
    },
    {
      "name": "William Del Fresno, PAC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "William Doyle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "William G Albergotti",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P322"
      ]
    },
    {
      "name": "William Kuhel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S345"
      ]
    },
    {
      "name": "William Lydiatt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "William Moss",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "William Ryan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "William Spanos",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "William T Andrews",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "William Weir",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S342"
      ]
    },
    {
      "name": "William Wong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Willian Silva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S001"
      ]
    },
    {
      "name": "Wisse E Haakma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S496"
      ]
    },
    {
      "name": "Wojciech Golusinski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Wojciech Mydlarz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "Worabun Romtrairut",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Wyatt A Johnson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P404"
      ]
    },
    {
      "name": "Wyatt O Wofford",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P222"
      ]
    },
    {
      "name": "Xavier M Keutgen",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Xialiu Xie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S144"
      ]
    },
    {
      "name": "Xianhong Xie",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P028"
      ]
    },
    {
      "name": "Xiao Zhao, FRCSC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "Xiao-Cheng Wu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Xiaohong I Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P389"
      ]
    },
    {
      "name": "Xiaoming Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Xingzhu Deng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "Xinni Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P408"
      ]
    },
    {
      "name": "Yadranko Ducic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Yael Reichenberg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "Yahav Bordovski",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S103"
      ]
    },
    {
      "name": "Yalon Dolev",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "Yangqiao Zheng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Yanhua Wang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P065"
      ]
    },
    {
      "name": "Yaniv Avraham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Yanna Najjar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S206"
      ]
    },
    {
      "name": "Yannet Interian",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "Yao Yu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Yarah Haidar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Yarong Wang, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Yashvi Vardhan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Yasmine Ibrahim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "Yasuhiro Ebihara, Ph",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P298"
      ]
    },
    {
      "name": "Yaw Boachie-Adjei",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P372"
      ]
    },
    {
      "name": "Yaw Chyn Lim, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Yazeed M Alhiyari",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S070"
      ]
    },
    {
      "name": "Yee Yan Sia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Yekaterina Shapiro",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P192"
      ]
    },
    {
      "name": "Yeo Eun Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Yeon Soo Kim",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P400"
      ]
    },
    {
      "name": "Yerko Leighton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S550"
      ]
    },
    {
      "name": "Yevgeniy Vinogradskiy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S005"
      ]
    },
    {
      "name": "Yi-Hsuan Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Yih-Leong Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Yilin Kuo, BSN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Ying Henderson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Ying Hitchcock",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S450"
      ]
    },
    {
      "name": "Ying Xian Chua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Ying Yu Tan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Yingchen Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Yiu Tsun Kwan, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Yjun Sun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Yocheved Halberstam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P028"
      ]
    },
    {
      "name": "Yogesh Dhoke",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Yogesh Dokhe",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Yogesh Dokhe, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Yogesh Dokhe, MCh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Yoh-ichiro Iwasa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Yoko Usami",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P232"
      ]
    },
    {
      "name": "Yong Hong Ng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110"
      ]
    },
    {
      "name": "Yong Yi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Yongdong Ouyang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P137"
      ]
    },
    {
      "name": "Yoon Woo Koh",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P009"
      ]
    },
    {
      "name": "Yoram Fleissig",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Yossef Alsabawi, BSA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P099"
      ]
    },
    {
      "name": "Yosuke Ariizumi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Yotam Drier",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Young Ho Jung",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Young Kyun Hur",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P009"
      ]
    },
    {
      "name": "Young-Gyu Eun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P039"
      ]
    },
    {
      "name": "Yu-Jin Lee",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S020"
      ]
    },
    {
      "name": "Yu-Ping Cheng",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Yu-Tsai Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P311"
      ]
    },
    {
      "name": "Yuan Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Yuan Shi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060"
      ]
    },
    {
      "name": "Yuelin Xia, MBBS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Yuh-Shin Chang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Yujie Shi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "Yujie Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Yukio Katori",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Yulun Liu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Yungan Tao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Yungpo B Su",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Yurino Nagata",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Yushi Ueki",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Yusuf Chaudhry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Yusuf Dundar",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Yusuke Yokoyama",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Yuta Hoshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Yuta Kawai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Yuta Nakatsuka",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Yvonne Mowery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "Z Gil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "Zachary A Valley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S041"
      ]
    },
    {
      "name": "Zachary Buxo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S153"
      ]
    },
    {
      "name": "Zachary E Thompson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S602"
      ]
    },
    {
      "name": "Zachary Kons",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S196"
      ]
    },
    {
      "name": "Zachary M Huttinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S525"
      ]
    },
    {
      "name": "Zachary Pierre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P356"
      ]
    },
    {
      "name": "Zachary Zumsteg",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Zaid Al-Qurayshi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P308"
      ]
    },
    {
      "name": "Zaid Nathani",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Zain Rizvi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S557"
      ]
    },
    {
      "name": "Zainab Farzal, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "Zara V Sepulveda",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Zaria Cosby",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Zeeshan Khalid, Dr",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105"
      ]
    },
    {
      "name": "Zeinab Abou Yehia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "Zeitouni Anthony",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S213"
      ]
    },
    {
      "name": "Zhao Lin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Zhen Gooi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Zhen Zhao",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Zhi Kang Chin",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Zhi Peng Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Zhibin Cui, DDSPhD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S476"
      ]
    },
    {
      "name": "Zhongping Xu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Zhu Yi Ming",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Zhuosheng Gu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Zigui Chen, Prof",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S369"
      ]
    },
    {
      "name": "Zihan Zhu",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S147"
      ]
    },
    {
      "name": "Zishan Mahmood",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037"
      ]
    },
    {
      "name": "Zoe Baxter",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Zoe Fullerton",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S304"
      ]
    },
    {
      "name": "Zoe H Fullerton, MBE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P163"
      ]
    },
    {
      "name": "Zoe Zhang",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "Zongtai Qi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S028"
      ]
    },
    {
      "name": "Zuhair Zaidi",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Zurwa M Uzun",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Zvonimir L Milas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    }
  ],
  "institution_profiles": [
    {
      "name": "Medical University of South Carolina",
      "record_count": 17,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 3
        },
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 12
        },
        {
          "name": "Poster",
          "count": 5
        }
      ],
      "abstract_uids": [
        "P088",
        "P114",
        "P155",
        "P222",
        "P267",
        "S014",
        "S018",
        "S047",
        "S048",
        "S087",
        "S105",
        "S157",
        "S207",
        "S303",
        "S361",
        "S389",
        "S539"
      ]
    },
    {
      "name": "Roswell Park Comprehensive Cancer Center",
      "record_count": 17,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 10
        },
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "P057",
        "P061",
        "P137",
        "P141",
        "P142",
        "P297",
        "P379",
        "P380",
        "P381",
        "P442",
        "S031",
        "S036",
        "S229",
        "S379",
        "S476",
        "S523",
        "S586"
      ]
    },
    {
      "name": "Stanford University",
      "record_count": 17,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 10
        },
        {
          "name": "Poster",
          "count": 7
        }
      ],
      "abstract_uids": [
        "P002",
        "P003",
        "P009",
        "P134",
        "P163",
        "P187",
        "P221",
        "S026",
        "S038",
        "S044",
        "S089",
        "S141",
        "S157",
        "S247",
        "S304",
        "S329",
        "S384"
      ]
    },
    {
      "name": "University of Michigan",
      "record_count": 16,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 13
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P093",
        "P333",
        "P336",
        "S038",
        "S089",
        "S116",
        "S124",
        "S134",
        "S153",
        "S177",
        "S285",
        "S288",
        "S289",
        "S419",
        "S546",
        "S574"
      ]
    },
    {
      "name": "Icahn School of Medicine at Mount Sinai",
      "record_count": 14,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Translational Research/Science",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 11
        },
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P032",
        "P051",
        "P104",
        "S056",
        "S104",
        "S180",
        "S274",
        "S414",
        "S432",
        "S490",
        "S495",
        "S522",
        "S530",
        "S548"
      ]
    },
    {
      "name": "University of Pittsburgh",
      "record_count": 14,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 5
        },
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 13
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P358",
        "S006",
        "S015",
        "S019",
        "S124",
        "S157",
        "S158",
        "S178",
        "S198",
        "S302",
        "S422",
        "S514",
        "S545",
        "S555"
      ]
    },
    {
      "name": "Baylor College of Medicine",
      "record_count": 13,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 7
        },
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "P099",
        "P174",
        "P262",
        "P323",
        "P389",
        "P418",
        "P423",
        "S118",
        "S133",
        "S170",
        "S361",
        "S519",
        "S604"
      ]
    },
    {
      "name": "Memorial Sloan Kettering Cancer Center",
      "record_count": 13,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 5
        }
      ],
      "abstract_uids": [
        "P103",
        "P163",
        "P269",
        "P320",
        "P442",
        "S050",
        "S075",
        "S110",
        "S122",
        "S157",
        "S215",
        "S345",
        "S349"
      ]
    },
    {
      "name": "Emory University",
      "record_count": 12,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 5
        },
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 10
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P065",
        "P128",
        "S038",
        "S057",
        "S058",
        "S073",
        "S244",
        "S273",
        "S378",
        "S506",
        "S570",
        "S596"
      ]
    },
    {
      "name": "Thomas Jefferson University",
      "record_count": 11,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P201",
        "P218",
        "P327",
        "P337",
        "S023",
        "S035",
        "S144",
        "S157",
        "S163",
        "S207",
        "S408"
      ]
    },
    {
      "name": "University of Toronto",
      "record_count": 11,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 9
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P011",
        "P317",
        "S134",
        "S157",
        "S161",
        "S183",
        "S245",
        "S318",
        "S420",
        "S575",
        "S582"
      ]
    },
    {
      "name": "Vanderbilt University Medical Center",
      "record_count": 11,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 5
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 9
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P075",
        "P437",
        "S127",
        "S188",
        "S223",
        "S310",
        "S437",
        "S509",
        "S573",
        "S581",
        "S606"
      ]
    },
    {
      "name": "The Ohio State University",
      "record_count": 10,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P200",
        "P255",
        "P256",
        "P424",
        "S073",
        "S134",
        "S195",
        "S199",
        "S214",
        "S399"
      ]
    },
    {
      "name": "University of Alabama at Birmingham",
      "record_count": 10,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 4
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "P163",
        "P177",
        "P282",
        "P327",
        "P337",
        "S163",
        "S170",
        "S340",
        "S374",
        "S408"
      ]
    },
    {
      "name": "University of Pennsylvania",
      "record_count": 10,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P161",
        "P275",
        "S011",
        "S045",
        "S095",
        "S164",
        "S207",
        "S312",
        "S468",
        "S551"
      ]
    },
    {
      "name": "University of Pittsburgh Medical Center",
      "record_count": 10,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 10
        }
      ],
      "abstract_uids": [
        "S006",
        "S020",
        "S089",
        "S115",
        "S155",
        "S184",
        "S206",
        "S428",
        "S479",
        "S517"
      ]
    },
    {
      "name": "University of Miami",
      "record_count": 9,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 5
        },
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P026",
        "P208",
        "P327",
        "P337",
        "P420",
        "S023",
        "S270",
        "S333",
        "S408"
      ]
    },
    {
      "name": "Harvard Medical School",
      "record_count": 8,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270",
        "S021",
        "S032",
        "S099",
        "S148",
        "S196",
        "S203",
        "S591"
      ]
    },
    {
      "name": "MD Anderson Cancer Center",
      "record_count": 8,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 3
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 8
        }
      ],
      "abstract_uids": [
        "S169",
        "S173",
        "S191",
        "S220",
        "S231",
        "S242",
        "S329",
        "S427"
      ]
    },
    {
      "name": "The University of Texas MD Anderson Cancer Center",
      "record_count": 8,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P016",
        "P380",
        "S137",
        "S145",
        "S157",
        "S168",
        "S519",
        "S583"
      ]
    },
    {
      "name": "University of Miami Miller School of Medicine",
      "record_count": 8,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P063",
        "P196",
        "P214",
        "P305",
        "S066",
        "S330",
        "S397",
        "S493"
      ]
    },
    {
      "name": "Henry Ford Health",
      "record_count": 7,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P112",
        "P113",
        "P155",
        "P369",
        "S207",
        "S426",
        "S433"
      ]
    },
    {
      "name": "Mayo Clinic",
      "record_count": 7,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S045",
        "S071",
        "S079",
        "S089",
        "S314",
        "S517",
        "S525"
      ]
    },
    {
      "name": "UC San Diego School of Medicine",
      "record_count": 7,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P029",
        "P088",
        "S225",
        "S238",
        "S284",
        "S462",
        "S535"
      ]
    },
    {
      "name": "University of California, San Francisco",
      "record_count": 7,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Salivary Gland",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P335",
        "S002",
        "S040",
        "S113",
        "S131",
        "S141",
        "S472"
      ]
    },
    {
      "name": "University of Colorado",
      "record_count": 7,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 7
        }
      ],
      "abstract_uids": [
        "S023",
        "S035",
        "S163",
        "S270",
        "S374",
        "S377",
        "S408"
      ]
    },
    {
      "name": "University of Iowa",
      "record_count": 7,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P211",
        "P308",
        "P396",
        "P397",
        "S095",
        "S237",
        "S601"
      ]
    },
    {
      "name": "A C Camargo Cancer Center",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P259",
        "P432",
        "S129",
        "S358",
        "S435",
        "S542"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
      "record_count": 6,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P029",
        "S225",
        "S238",
        "S284",
        "S462",
        "S535"
      ]
    },
    {
      "name": "Massachusetts General Hospital",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 6
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S203",
        "S210",
        "S401"
      ]
    },
    {
      "name": "Penn State College of Medicine",
      "record_count": 6,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 4
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P111",
        "P121",
        "P201",
        "P237",
        "S052",
        "S497"
      ]
    },
    {
      "name": "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
      "record_count": 6,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P142",
        "P380",
        "S036",
        "S229",
        "S476",
        "S586"
      ]
    },
    {
      "name": "University of British Columbia",
      "record_count": 6,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P015",
        "P055",
        "S219",
        "S482",
        "S483",
        "S484"
      ]
    },
    {
      "name": "University of Washington",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P225",
        "P247",
        "S089",
        "S143",
        "S232",
        "S250"
      ]
    },
    {
      "name": "Weill Cornell Medicine",
      "record_count": 6,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 4
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P049",
        "P244",
        "P283",
        "S241",
        "S345",
        "S546"
      ]
    },
    {
      "name": "Albert Einstein College of Medicine, Bronx, NY, USA",
      "record_count": 5,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S190",
        "S217",
        "S348",
        "S390",
        "S464"
      ]
    },
    {
      "name": "Case Western Reserve University School of Medicine",
      "record_count": 5,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P199",
        "S200",
        "S202",
        "S372",
        "S578"
      ]
    },
    {
      "name": "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P363",
        "S017",
        "S368",
        "S381",
        "S382"
      ]
    },
    {
      "name": "Faculdade de Medicina da Universidade de São Paulo",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P059",
        "P108",
        "P109",
        "P150",
        "S269"
      ]
    },
    {
      "name": "Massachusetts Eye & Ear",
      "record_count": 5,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 3
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 5
        }
      ],
      "abstract_uids": [
        "S032",
        "S061",
        "S065",
        "S210",
        "S401"
      ]
    },
    {
      "name": "NYU Grossman School of Medicine",
      "record_count": 5,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P167",
        "S054",
        "S136",
        "S257",
        "S459"
      ]
    },
    {
      "name": "Tel Aviv Sourasky Medical Center",
      "record_count": 5,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P362",
        "S103",
        "S331",
        "S354",
        "S554"
      ]
    },
    {
      "name": "University of California, San Diego",
      "record_count": 5,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149",
        "S207",
        "S249",
        "S277",
        "S329"
      ]
    },
    {
      "name": "University of Minnesota",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P047",
        "P265",
        "S156",
        "S545",
        "S591"
      ]
    },
    {
      "name": "University of Southern California",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 4
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P035",
        "S146",
        "S151",
        "S361",
        "S470"
      ]
    },
    {
      "name": "University of Utah",
      "record_count": 5,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P016",
        "P419",
        "S226",
        "S259",
        "S450"
      ]
    },
    {
      "name": "Washington University School of Medicine",
      "record_count": 5,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P351",
        "S027",
        "S099",
        "S303",
        "S517"
      ]
    },
    {
      "name": "Washington University in St. Louis",
      "record_count": 5,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P163",
        "P201",
        "S104",
        "S300",
        "S361"
      ]
    },
    {
      "name": "AC Camargo Cancer Center",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 3
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P136",
        "P268",
        "S051",
        "S607"
      ]
    },
    {
      "name": "Albert Einstein College of Medicine",
      "record_count": 4,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176",
        "P375",
        "P442",
        "S289"
      ]
    },
    {
      "name": "Brazilian National Cancer Institute",
      "record_count": 4,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P168",
        "P184",
        "P203",
        "S175"
      ]
    },
    {
      "name": "Cleveland Clinic",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P433",
        "S089",
        "S147",
        "S372"
      ]
    },
    {
      "name": "Dana-Farber Cancer Institute",
      "record_count": 4,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S025",
        "S148",
        "S395",
        "S415"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 4
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S182",
        "S388",
        "S579",
        "S597"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P115",
        "P440",
        "S077",
        "S449"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P037",
        "P310",
        "S084",
        "S434"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 4,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 2
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S190",
        "S348",
        "S390",
        "S464"
      ]
    },
    {
      "name": "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 4
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S283",
        "S429"
      ]
    },
    {
      "name": "Instituto do Câncer do Estado de São Paulo",
      "record_count": 4,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445",
        "S165",
        "S280",
        "S576"
      ]
    },
    {
      "name": "Louisiana State University",
      "record_count": 4,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P078",
        "P337",
        "S023",
        "S207"
      ]
    },
    {
      "name": "McGill University",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P106",
        "S213",
        "S252",
        "S396"
      ]
    },
    {
      "name": "Medical College of Georgia at Augusta University",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P014",
        "P068",
        "P352",
        "S417"
      ]
    },
    {
      "name": "Rutgers New Jersey Medical School",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P033",
        "P175",
        "S343",
        "S402"
      ]
    },
    {
      "name": "Santa Casa Araraquara",
      "record_count": 4,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 2
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P027",
        "P193",
        "P416",
        "P417"
      ]
    },
    {
      "name": "University of Calgary",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P001",
        "P017",
        "P125",
        "S134"
      ]
    },
    {
      "name": "University of Cincinnati College of Medicine",
      "record_count": 4,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 4
        }
      ],
      "abstract_uids": [
        "P144",
        "P220",
        "P343",
        "P366"
      ]
    },
    {
      "name": "University of Florida",
      "record_count": 4,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P355",
        "S062",
        "S337",
        "S504"
      ]
    },
    {
      "name": "University of Kentucky",
      "record_count": 4,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P346",
        "S304",
        "S431",
        "S461"
      ]
    },
    {
      "name": "University of Maryland",
      "record_count": 4,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P146",
        "S157",
        "S163",
        "S383"
      ]
    },
    {
      "name": "University of Massachusetts",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P105",
        "P415",
        "S167",
        "S467"
      ]
    },
    {
      "name": "University of Miami Hospital",
      "record_count": 4,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P214",
        "P235",
        "S330",
        "S397"
      ]
    },
    {
      "name": "University of Michigan Medical School",
      "record_count": 4,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P157",
        "S124",
        "S160",
        "S492"
      ]
    },
    {
      "name": "Wayne State University",
      "record_count": 4,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P112",
        "P113",
        "S156",
        "S307"
      ]
    },
    {
      "name": "AdventHealth Orlando",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P067",
        "P076",
        "S049"
      ]
    },
    {
      "name": "Adventhealth Orlando",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S088",
        "S452",
        "S526"
      ]
    },
    {
      "name": "Aga Khan University Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257",
        "S509",
        "S590"
      ]
    },
    {
      "name": "Augusta University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P014",
        "P337",
        "S023"
      ]
    },
    {
      "name": "Barrow Neurological Institute",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S042",
        "S246",
        "S355"
      ]
    },
    {
      "name": "Boston University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S150",
        "S242",
        "S383"
      ]
    },
    {
      "name": "Brigham and Women's Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S148",
        "S305",
        "S395"
      ]
    },
    {
      "name": "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P007",
        "S086",
        "S544"
      ]
    },
    {
      "name": "Cleveland Clinic Florida",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394",
        "S009",
        "S352"
      ]
    },
    {
      "name": "Cleveland Clinic Indian River Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P116",
        "P117",
        "S406"
      ]
    },
    {
      "name": "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182",
        "P217",
        "S216"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292",
        "S076",
        "S531"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P239",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P031",
        "P135",
        "P246"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P239",
        "S265",
        "S540"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S286",
        "S339",
        "S410"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P413",
        "S357",
        "S416"
      ]
    },
    {
      "name": "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S080",
        "S132",
        "S204"
      ]
    },
    {
      "name": "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P232",
        "P264",
        "P298"
      ]
    },
    {
      "name": "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P091",
        "P096",
        "P418"
      ]
    },
    {
      "name": "Duke University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "P372",
        "S361"
      ]
    },
    {
      "name": "Duke University School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S251",
        "S402"
      ]
    },
    {
      "name": "Emory University School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207",
        "S569",
        "S592"
      ]
    },
    {
      "name": "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S109",
        "S233",
        "S366"
      ]
    },
    {
      "name": "Instituto Oncológico Fundación Arturo López Pérez",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S130",
        "S261",
        "S550"
      ]
    },
    {
      "name": "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S360",
        "S458",
        "S466"
      ]
    },
    {
      "name": "Lakeshore Hospital, Kochi, India",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S031",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Lewis Katz School of Medicine at Temple University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P349",
        "P362",
        "S543"
      ]
    },
    {
      "name": "Louisiana State University Health Science Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P327",
        "S163",
        "S408"
      ]
    },
    {
      "name": "Mass Eye and Ear",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S305",
        "S498",
        "S527"
      ]
    },
    {
      "name": "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S031",
        "S476",
        "S586"
      ]
    },
    {
      "name": "Medical College of Georgia",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202",
        "S163",
        "S408"
      ]
    },
    {
      "name": "NYU Langone Department of Otolaryngology",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S136",
        "S257",
        "S459"
      ]
    },
    {
      "name": "National Institutes of Health",
      "record_count": 3,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S281",
        "S282",
        "S475"
      ]
    },
    {
      "name": "Northwell Health",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P034",
        "S126",
        "S383"
      ]
    },
    {
      "name": "OHSU",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337",
        "P401",
        "S023"
      ]
    },
    {
      "name": "Oregon Health & Science University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P326",
        "S071",
        "S383"
      ]
    },
    {
      "name": "Oregon Health and Science University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P327",
        "S163",
        "S408"
      ]
    },
    {
      "name": "PGIMER, Chandigarh, India",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P074",
        "P198",
        "P294"
      ]
    },
    {
      "name": "Penn State Health",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S299",
        "S379",
        "S586"
      ]
    },
    {
      "name": "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 3
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S262",
        "S272",
        "S429"
      ]
    },
    {
      "name": "Rutgers Robert Wood Johnson Medical School",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344",
        "S286",
        "S402"
      ]
    },
    {
      "name": "Salud Integral Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P138",
        "P139",
        "P143"
      ]
    },
    {
      "name": "Sarah Cannon Cancer Institute, Charleston, SC, USA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414",
        "S016",
        "S323"
      ]
    },
    {
      "name": "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S292",
        "S418",
        "S565"
      ]
    },
    {
      "name": "Singapore General Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P110",
        "S181",
        "S421"
      ]
    },
    {
      "name": "Stanford University School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S174",
        "S375",
        "S404"
      ]
    },
    {
      "name": "Tata Memorial Centre",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S224",
        "S309",
        "S501"
      ]
    },
    {
      "name": "The University of Washington",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P200",
        "P255",
        "P256"
      ]
    },
    {
      "name": "Thomas Jefferson University Hospital",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S005",
        "S212",
        "S548"
      ]
    },
    {
      "name": "Tufts University School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159",
        "S456",
        "S515"
      ]
    },
    {
      "name": "UNC School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S256",
        "S362"
      ]
    },
    {
      "name": "USF Health Morsani College of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S090",
        "S510",
        "S552"
      ]
    },
    {
      "name": "University Hospitals Seidman Cancer Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S276",
        "S578",
        "S580"
      ]
    },
    {
      "name": "University at Buffalo",
      "record_count": 3,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094",
        "P421",
        "S474"
      ]
    },
    {
      "name": "University of Alabama",
      "record_count": 3,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425",
        "S270",
        "S377"
      ]
    },
    {
      "name": "University of Arkansas for Medical Sciences",
      "record_count": 3,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S342",
        "S460",
        "S549"
      ]
    },
    {
      "name": "University of California, Irvine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 2
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P188",
        "S207",
        "S344"
      ]
    },
    {
      "name": "University of California, San Francisco School of Medicine, San Francisco, CA",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P072",
        "P090",
        "S187"
      ]
    },
    {
      "name": "University of Kansas Medical Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P015",
        "P285",
        "P444"
      ]
    },
    {
      "name": "University of Pittsburgh School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S027",
        "S115",
        "S453"
      ]
    },
    {
      "name": "University of São Paulo School of Medicine, São Paulo, Brazil",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S292",
        "S563",
        "S565"
      ]
    },
    {
      "name": "University of Texas Southwestern Medical Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 2
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P282",
        "S193",
        "S508"
      ]
    },
    {
      "name": "University of Vermont Medical Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P236",
        "S189",
        "S347"
      ]
    },
    {
      "name": "University of Virginia",
      "record_count": 3,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P199",
        "P272",
        "P356"
      ]
    },
    {
      "name": "Vanderbilt University",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S127",
        "S391",
        "S562"
      ]
    },
    {
      "name": "Virginia Tech Carilion School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        },
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P064",
        "S260",
        "S511"
      ]
    },
    {
      "name": "Wayne State University School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 3
        }
      ],
      "abstract_uids": [
        "S060",
        "S457",
        "S608"
      ]
    },
    {
      "name": "X Ray Medical Center",
      "record_count": 3,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 3
        }
      ],
      "abstract_uids": [
        "P138",
        "P139",
        "P143"
      ]
    },
    {
      "name": "Yale School of Medicine",
      "record_count": 3,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "P436",
        "S502"
      ]
    },
    {
      "name": "1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127"
      ]
    },
    {
      "name": "2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P126",
        "P127"
      ]
    },
    {
      "name": "Aditi P Singh, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Advent Health Medical Group",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S014",
        "S223"
      ]
    },
    {
      "name": "Advent Health Orlando",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P077",
        "P390"
      ]
    },
    {
      "name": "Aga Khan University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105",
        "S467"
      ]
    },
    {
      "name": "Al Nahdha Hospital",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P081",
        "P399"
      ]
    },
    {
      "name": "Albany Medical College",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292",
        "S189"
      ]
    },
    {
      "name": "Alexander Lin, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Allegheny Health Network",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P089",
        "P171"
      ]
    },
    {
      "name": "Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P098",
        "P277"
      ]
    },
    {
      "name": "Ara A Chalian, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Beth Israel Deaconess Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S561",
        "S590"
      ]
    },
    {
      "name": "Beth Israel Deaconess Medical Center - Harvard Medical School",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S128",
        "S456"
      ]
    },
    {
      "name": "Boston Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P008",
        "P155"
      ]
    },
    {
      "name": "California University of Science and Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S293",
        "S462"
      ]
    },
    {
      "name": "Carle Illinois College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P008",
        "P092"
      ]
    },
    {
      "name": "Case Western Reserve University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S147",
        "S422"
      ]
    },
    {
      "name": "Centre Hospitalier de l'Université de Montréal (CHUM)",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S003",
        "S211"
      ]
    },
    {
      "name": "Christopher H Rassekh, MD, FACS 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Dartmouth College",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S157",
        "S496"
      ]
    },
    {
      "name": "Dartmouth-Hitchcock Health",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060",
        "S218"
      ]
    },
    {
      "name": "David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S359",
        "S512"
      ]
    },
    {
      "name": "Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004",
        "S418"
      ]
    },
    {
      "name": "Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204",
        "S072"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022",
        "S251"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S200",
        "S528"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S439",
        "S512"
      ]
    },
    {
      "name": "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S080",
        "S132"
      ]
    },
    {
      "name": "Department of Hematology and Oncology at Mount Sinai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S490",
        "S495"
      ]
    },
    {
      "name": "Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S182",
        "S388"
      ]
    },
    {
      "name": "Department of Laboratory Medicine and Pathology, University of Minnesota",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P135",
        "P246"
      ]
    },
    {
      "name": "Department of Oncology – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S190",
        "S464"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P408",
        "S444"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S090",
        "S510"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Toronto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P080",
        "P164"
      ]
    },
    {
      "name": "Department of Otolaryngology at Mount Sinai",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S490",
        "S495"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P095",
        "P387"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S322",
        "S489"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P129",
        "P238"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119",
        "S053"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P072",
        "P090"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P072",
        "P090"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P118",
        "S551"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S076",
        "S316"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Michigan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P374",
        "S430"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Nagoya University Hospital",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P183",
        "P368"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S294",
        "S577"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S357",
        "S416"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P007",
        "S086"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P412",
        "S112"
      ]
    },
    {
      "name": "Department of Pathology, National University Hospital",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S068",
        "S209"
      ]
    },
    {
      "name": "Department of Pathology, University of California San Diego Health",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P029",
        "S284"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S200",
        "S528"
      ]
    },
    {
      "name": "Department of Radiology – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S190",
        "S464"
      ]
    },
    {
      "name": "Drexel University College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P089",
        "P098"
      ]
    },
    {
      "name": "Duke Cancer Institute, Duke University, Durham, NC, USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S108",
        "S192"
      ]
    },
    {
      "name": "Florida State University College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P116",
        "P117"
      ]
    },
    {
      "name": "Fox Chase Cancer Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S038",
        "S157"
      ]
    },
    {
      "name": "Georgetown University School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P123",
        "P299"
      ]
    },
    {
      "name": "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P206",
        "S463"
      ]
    },
    {
      "name": "Gregory Farwell, MD, FACS 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada",
      "record_count": 2,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443",
        "S486"
      ]
    },
    {
      "name": "Head & Neck Cancer Alliance",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S361"
      ]
    },
    {
      "name": "Henry Ford Health System",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P428",
        "P430"
      ]
    },
    {
      "name": "INCA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P178",
        "P364"
      ]
    },
    {
      "name": "Independent Research Team",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P138",
        "P139"
      ]
    },
    {
      "name": "Indiana University Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405",
        "S119"
      ]
    },
    {
      "name": "Indiana University School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P086",
        "S119"
      ]
    },
    {
      "name": "Indiana University/IU Health",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "Jason G Newman, MD, FACS 3",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S360",
        "S458"
      ]
    },
    {
      "name": "Johns Hopkins University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S095",
        "S383"
      ]
    },
    {
      "name": "Kaiser Permanente Bernard J. Tyson School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P129",
        "P238"
      ]
    },
    {
      "name": "Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Keck School of Medicine of USC",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S293",
        "S605"
      ]
    },
    {
      "name": "Keck School of Medicine, University of Southern California, Los Angeles, CA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S439",
        "S512"
      ]
    },
    {
      "name": "Lee Hartner, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Loma Lina University Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S270",
        "S377"
      ]
    },
    {
      "name": "Loma Linda University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P018",
        "S035"
      ]
    },
    {
      "name": "Lova L Sun, MD, MSCE 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Mass Eye and Ear/Harvard Medical School",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P069",
        "S186"
      ]
    },
    {
      "name": "Massachusetts Eye and Ear",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S203",
        "S239"
      ]
    },
    {
      "name": "Medical College of Wisconsin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S263",
        "S296"
      ]
    },
    {
      "name": "Michelle Gentile, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Michigan State University (MSU)",
      "record_count": 2,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P428",
        "P430"
      ]
    },
    {
      "name": "Moffitt Cancer Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S073",
        "S157"
      ]
    },
    {
      "name": "NYU Langone Hansjörg Wyss Department of Plastic Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P359",
        "P371"
      ]
    },
    {
      "name": "National University of Singapore",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P025",
        "S209"
      ]
    },
    {
      "name": "New York University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S035",
        "S270"
      ]
    },
    {
      "name": "New York-Presbyterian/Weill Cornell Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P244",
        "P283"
      ]
    },
    {
      "name": "Northwestern Medicine Department of Otolaryngology",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "Northwestern University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201",
        "S038"
      ]
    },
    {
      "name": "Northwestern University Feinberg School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P091",
        "P096"
      ]
    },
    {
      "name": "Perelman School of Medicine at the University of Pennsylvania",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P412",
        "S112"
      ]
    },
    {
      "name": "Perelman School of Medicine, University of Pennsylvania",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S294",
        "S577"
      ]
    },
    {
      "name": "Queen's University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P017",
        "P062"
      ]
    },
    {
      "name": "Rakuten Medical K.K",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224",
        "S518"
      ]
    },
    {
      "name": "Regional cancer Centre",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        },
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P131",
        "P195"
      ]
    },
    {
      "name": "Renaissance School of Medicine at Stony Brook",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P051",
        "P104"
      ]
    },
    {
      "name": "Roger B Cohen, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Rush Medical College, Rush University Medical Center, Chicago, IL 60612",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P147",
        "S424"
      ]
    },
    {
      "name": "Rush University Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P145",
        "S491"
      ]
    },
    {
      "name": "Rutgers Cancer Institute of New Jersey - Department of Medical Oncology",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "Rutgers School of Graduate Studies",
      "record_count": 2,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P318",
        "S166"
      ]
    },
    {
      "name": "SUNY - University at Stony Brook (SSO)",
      "record_count": 2,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S600",
        "S603"
      ]
    },
    {
      "name": "SUNY Downstate",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S255",
        "S499"
      ]
    },
    {
      "name": "Saint Louis University School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P351",
        "S092"
      ]
    },
    {
      "name": "Saitama Medical University International Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227",
        "S111"
      ]
    },
    {
      "name": "Sarah Cannon Cancer Institute, Charleston, SC, United States",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P286",
        "S505"
      ]
    },
    {
      "name": "Sri Shankara Cancer Hospital and Research Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S407",
        "S471"
      ]
    },
    {
      "name": "St George's Hospital",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P290",
        "P407"
      ]
    },
    {
      "name": "Steven B Cannady, MD 1",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S047",
        "S048"
      ]
    },
    {
      "name": "Temerty Faculty of Medicine, University of Toronto",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152",
        "S222"
      ]
    },
    {
      "name": "The Chinese University of Hong Kong",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S369",
        "S376"
      ]
    },
    {
      "name": "The Ohio State University Wexner Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P276",
        "S085"
      ]
    },
    {
      "name": "UConn Health",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066",
        "S346"
      ]
    },
    {
      "name": "UNC Dept. of Otolaryngology/Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S256",
        "S362"
      ]
    },
    {
      "name": "USC Caruso Department of Otolaryngology Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P053",
        "S030"
      ]
    },
    {
      "name": "UT Southwestern Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S170",
        "S298"
      ]
    },
    {
      "name": "Universidade Estadual de Pernambuco, Recife, Brazil",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S563",
        "S565"
      ]
    },
    {
      "name": "University Health Network",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S245",
        "S420"
      ]
    },
    {
      "name": "University Hospitals",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P378",
        "S202"
      ]
    },
    {
      "name": "University Hospitals Cleveland",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S004",
        "S547"
      ]
    },
    {
      "name": "University Hospitals Cleveland Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S223",
        "S553"
      ]
    },
    {
      "name": "University Medical Center Groningen",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S208",
        "S291"
      ]
    },
    {
      "name": "University Of Oklahoma College Of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P310",
        "S084"
      ]
    },
    {
      "name": "University at Buffalo School of Dental Medicine, Buffalo, NY",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S031",
        "S476"
      ]
    },
    {
      "name": "University of Arizona College of Medicine - Phoenix",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P162",
        "S538"
      ]
    },
    {
      "name": "University of Arizona College of Medicine - Tucson",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P013",
        "P162"
      ]
    },
    {
      "name": "University of Arizona College of Medicine-Phoenix",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P179",
        "S022"
      ]
    },
    {
      "name": "University of Buenos Aires",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S009",
        "S352"
      ]
    },
    {
      "name": "University of California San Francisco",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S157",
        "S361"
      ]
    },
    {
      "name": "University of California, Davis",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S172",
        "S488"
      ]
    },
    {
      "name": "University of Chicago",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P386",
        "S035"
      ]
    },
    {
      "name": "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S024",
        "S258"
      ]
    },
    {
      "name": "University of Cincinnati Department of Otolaryngology",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P343",
        "P366"
      ]
    },
    {
      "name": "University of Cincinnati Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158",
        "S191"
      ]
    },
    {
      "name": "University of Florida College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309",
        "S469"
      ]
    },
    {
      "name": "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P328",
        "S264"
      ]
    },
    {
      "name": "University of Illinois Chicago",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P016",
        "S427"
      ]
    },
    {
      "name": "University of Louisville",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S042",
        "S246"
      ]
    },
    {
      "name": "University of Maryland School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P325",
        "S534"
      ]
    },
    {
      "name": "University of Milan",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002",
        "S010"
      ]
    },
    {
      "name": "University of Missouri",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P088",
        "S465"
      ]
    },
    {
      "name": "University of North Carolina",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S045",
        "S314"
      ]
    },
    {
      "name": "University of North Carolina at Chapel Hill",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P073",
        "S144"
      ]
    },
    {
      "name": "University of Oklahoma College of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P037",
        "S566"
      ]
    },
    {
      "name": "University of Oklahoma Health Science Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P020",
        "S308"
      ]
    },
    {
      "name": "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441",
        "S268"
      ]
    },
    {
      "name": "University of Puerto Rico School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P194",
        "P361"
      ]
    },
    {
      "name": "University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P194",
        "P361"
      ]
    },
    {
      "name": "University of Rochester School of Medicine and Dentistry",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P005",
        "S291"
      ]
    },
    {
      "name": "University of South Dakota Sanford School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        },
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P215",
        "S171"
      ]
    },
    {
      "name": "University of Texas MD Anderson Cancer Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S038",
        "S089"
      ]
    },
    {
      "name": "University of Texas Medical Branch at Galveston",
      "record_count": 2,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        },
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P411",
        "S440"
      ]
    },
    {
      "name": "University of Utah Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S083",
        "S093"
      ]
    },
    {
      "name": "University of Washington School of Medicine",
      "record_count": 2,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226",
        "S557"
      ]
    },
    {
      "name": "University of Wisconsin",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        },
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393",
        "S038"
      ]
    },
    {
      "name": "Washington University in St Louis",
      "record_count": 2,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        },
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S028",
        "S037"
      ]
    },
    {
      "name": "Wellstar MCG Health Medical Center",
      "record_count": 2,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        },
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 2
        }
      ],
      "abstract_uids": [
        "P014",
        "P352"
      ]
    },
    {
      "name": "West Virginia University",
      "record_count": 2,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P295",
        "S041"
      ]
    },
    {
      "name": "Western University of Health Sciences",
      "record_count": 2,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 2
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 2
        }
      ],
      "abstract_uids": [
        "S163",
        "S408"
      ]
    },
    {
      "name": "Yale Department of Internal Medicine, Division of Infectious Diseases",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "S502"
      ]
    },
    {
      "name": "Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery",
      "record_count": 2,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        },
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        },
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166",
        "S502"
      ]
    },
    {
      "name": "12 de Octubre University Hospital, Madrid, Spain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "1The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "2The Azrieli Faculty of Medicine, Bar-Ilan University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S354"
      ]
    },
    {
      "name": "3 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P126"
      ]
    },
    {
      "name": "3 Vascular Surgery Division, Department of Surgery, University of Pennsylvania, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P127"
      ]
    },
    {
      "name": "4 Department of Otolaryngology-Head and Neck Surgery, Samson Ashdod University Hospital, Ashdod, Israel 5Faculty of Health Sciences, Ben -Gurion University of the Negev, Beer Sheva, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S227"
      ]
    },
    {
      "name": "5th Port",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "AC Camargo Cacner Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P140"
      ]
    },
    {
      "name": "ALTITUD100K SpA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S130"
      ]
    },
    {
      "name": "Adela, Inc., Foster City, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "AdventHealth Medical Group Plastic and Reconstructive Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P391"
      ]
    },
    {
      "name": "AdventHealth for Children",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P079"
      ]
    },
    {
      "name": "Aichi Cancer Center Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Albany Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Albert Einstein College of Medicine/ Montefiore Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Albert Einstein Jewish Institute for Education and Research, St. Comendador Elias Jafet, 755, São Paulo-SP Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Alberta Health Services",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P017"
      ]
    },
    {
      "name": "Alex Harbison 1 . 1 Washington University in St. Louis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "Alexandre Bezerra dos Santos, PhD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Allegheny Health Network-Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P277"
      ]
    },
    {
      "name": "Amrita Institute of Medical Sciences, Kochi, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Amritha Suresh 8 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Analytic Microscopy Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Aristotle University of Thessaloniki, Thessaloniki, Greece",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S242"
      ]
    },
    {
      "name": "Asahikawa Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S278"
      ]
    },
    {
      "name": "Asan Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Asarkar, MD, FACS 1 . 1 Louisiana State University Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434"
      ]
    },
    {
      "name": "Asarkar, MD, FACS. Louisiana State University Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S007"
      ]
    },
    {
      "name": "Assistant Professor, Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP) São Paulo, SP, Brazil. Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Atilim University, Medicana International Ankara, Ankara, Turkey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Atrium Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S378"
      ]
    },
    {
      "name": "Atrium Health - Levine Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Attiko University Hospital Athens Greece",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Avera Cancer Institute at Avera McKennan Hospital & University Health Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Avera McKennan Hospital & University Health Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S171"
      ]
    },
    {
      "name": "Avera Mckenna Hospital and University Health Center - Avera Medical Group ENT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P215"
      ]
    },
    {
      "name": "Aveta Biomics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Azienda Ospedaliera Università di Padova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "BIDMC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S589"
      ]
    },
    {
      "name": "Ball State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S504"
      ]
    },
    {
      "name": "Baqai Medical Univeristy (Assistant proffesor)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P240"
      ]
    },
    {
      "name": "Barnes Jewish Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S303"
      ]
    },
    {
      "name": "Barretos Cancer Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Barretos Cancer Hospital, São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "Barrow Neurologic Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S538"
      ]
    },
    {
      "name": "Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Bayer Pharmaceuticals, Reading, UK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Bayer S.p.A., Milan, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Baylor College of Medicine, 1 Baylor Plz, Houston, TX 77030, The United States of America",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Baylor College of Medicine, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "Baylor College of Medicine, Michael E. Debakey Veterans Affairs Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P254"
      ]
    },
    {
      "name": "Beckman Institute for Advanced Science and Technology, University of Illinois Urbana- Champaign",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S586"
      ]
    },
    {
      "name": "Beijing Cancer Center, Beijing, China",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Beijing Tongren Hospital, Beijing, China",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Belcher, MD, MPH 2 . 1 Aga Khan University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Beth Israel Deaconess Medical Center, Department of Otolayrngology-Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "Bioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S182"
      ]
    },
    {
      "name": "Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S558"
      ]
    },
    {
      "name": "Boston Medical Center/Boston University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S186"
      ]
    },
    {
      "name": "Boston University Chobanian & Avedisian School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Boston University Chobanian and Avedisian School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Brenda Iwakura Alves 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Brigham and Women's Hospital / Dana Farber Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Brigham and Women's Hosptial",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Broad Institute of Harvard and MIT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "Bundang Jesaeng General Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Burrell College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P305"
      ]
    },
    {
      "name": "Burton Wood, MD. University of Tennessee Health Science Center - Memphis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P180"
      ]
    },
    {
      "name": "Cachar Cancer Hospital and Research Centre, Silchar, Assam, India, 788015",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Calico Labs",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S383"
      ]
    },
    {
      "name": "California Health Sciences University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "California University of Science & Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S043"
      ]
    },
    {
      "name": "Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Cancer Institute of New Jersey, Rutgers",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Carey School of Business, Johns Hopkins University, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Carilion Clinic Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S260"
      ]
    },
    {
      "name": "Carilion Clinic Otolaryngology and Audiology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S511"
      ]
    },
    {
      "name": "Carle Illinois College of Medicine, University of Illinois at Urbana Champaign, Illinois",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P398"
      ]
    },
    {
      "name": "Carle-Illinois College of Medicine, University of Illinois",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S430"
      ]
    },
    {
      "name": "Caruso Department of Otolaryngology - Head and Neck Surgery, Keck SOM of USC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S411"
      ]
    },
    {
      "name": "Case Western Reserve School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S553"
      ]
    },
    {
      "name": "Case Western Reserve University School of Medicine, Cleveland, Ohio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S334"
      ]
    },
    {
      "name": "Cedars Sinai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P160"
      ]
    },
    {
      "name": "Cedars Sinai, Kaiser Permanente",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S487"
      ]
    },
    {
      "name": "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Center for Translational Cancer Research, Texas A&M Health Science Center Institute of Biosciences & Technology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S579"
      ]
    },
    {
      "name": "Centre Hospitalier de l’Université de Montréal (CHUM)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Centre de recherche du centre hospitalier de l'Université de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S034"
      ]
    },
    {
      "name": "Centre for Quality Improvement and Patient Safety, University of Toronto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Centre hospitalier de l'Université de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S034"
      ]
    },
    {
      "name": "Chairman and Professor of Head and Neck Surgery, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Head, Head and Neck Tumors Reference Canter, A C Camargo Cancer Center, São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Chan Soon-Shiong Institute for Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Chang Gung Memorial Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S409"
      ]
    },
    {
      "name": "Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P052"
      ]
    },
    {
      "name": "Chinese University of Hong Kong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Chrestos GmbH, Essen, Germany",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "ChristianaCare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P223"
      ]
    },
    {
      "name": "Christopher Holsinger, MD 1 . 1 Stanford University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S010"
      ]
    },
    {
      "name": "Christopher Holsinger, MD 2 . 1 Yonsei University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P009"
      ]
    },
    {
      "name": "Christopher Holsinger, MD, FACS 2 . 1 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Christopher Holsinger, MD. Stanford University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P006"
      ]
    },
    {
      "name": "Cincinnati Children's Hospital Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P332"
      ]
    },
    {
      "name": "Cincinnati Children's Hospital Medical Center, Department of Biostatistics and Epidemiology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S258"
      ]
    },
    {
      "name": "City University of New York School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P281"
      ]
    },
    {
      "name": "City of Hope National Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P023"
      ]
    },
    {
      "name": "Clair, MD, PhD 1 . 1 Cedars Sinai Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P350"
      ]
    },
    {
      "name": "Cleveland Clinic Foundation",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S480"
      ]
    },
    {
      "name": "Cleveland Clinic Voice Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S334"
      ]
    },
    {
      "name": "Cleveland Clinic, Cleveland, OH, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Clinica Alemana de Santiago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Clinical Translational Research, Singapore General Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "College of Medicine, Lexington, Kentucky, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "College of Medicine, University of Kentucky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S532"
      ]
    },
    {
      "name": "College of Medicine, University of Nebraska Medical Center, Omaha, NE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S438"
      ]
    },
    {
      "name": "College of Medicine, University of Oklahoma, Oklahoma City, OK, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P042"
      ]
    },
    {
      "name": "College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Coloradu University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P337"
      ]
    },
    {
      "name": "Columbia University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P038"
      ]
    },
    {
      "name": "Columbia University Irving Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P087"
      ]
    },
    {
      "name": "Columbia University Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "Community Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Complejo Hospitalario Dr. Arnulfo Arias Madrid, Caja de Seguro Social",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Computational Biology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Computational Biology, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Cooper Medical School of Rowan University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P191"
      ]
    },
    {
      "name": "Cooper Univeristy Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P192"
      ]
    },
    {
      "name": "Cooper University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P191"
      ]
    },
    {
      "name": "Corewell East Department of Plastic Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Dalhousie University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Dana Farber Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S494"
      ]
    },
    {
      "name": "Dana-Farber Cancer Institute, Boston, MA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Danan Farber Cancer Institution",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "Daniel Knott, MD. University of California, San Francisco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S405"
      ]
    },
    {
      "name": "Dartmouth College, Geisel School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Dartmouth College, Thayer School of Engineering",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Dartmouth Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S496"
      ]
    },
    {
      "name": "Dartmouth Hitchcock Medical Center, Division of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S149"
      ]
    },
    {
      "name": "Data Science Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "David Geffen School of Medicine at UCLA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "David Geffen School of Medicine, UCLA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Davidson College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P173"
      ]
    },
    {
      "name": "Dean Hosgood, PhD. Montefiore Einstein",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P028"
      ]
    },
    {
      "name": "Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340"
      ]
    },
    {
      "name": "Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Department of Biology, University of California Los Angeles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P118"
      ]
    },
    {
      "name": "Department of Biomedical Engineering, Boston University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Department of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S013"
      ]
    },
    {
      "name": "Department of Biomedical Sciences, Humanitas University, Milan, Italy, IRCCS Humanitas Research Hospital, Milan, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S043"
      ]
    },
    {
      "name": "Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland OH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Department of Biostatistics, Mayo Clinic, Rochester, MN, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Biostatistics, University of Kentucky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S532"
      ]
    },
    {
      "name": "Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Department of Children’s Surgery, Division of Pediatric Head & Neck Surgery, AdventHealth for Children, Orlando, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S452"
      ]
    },
    {
      "name": "Department of Dentistry, University of Barcelona. Member of the oral health research group at DIBELL. Medical Director of the University of Barcelona Dental Hospital (HOUB), Spain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Dermatology – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Department of Dermatology, University of Wisconsin Carbone Cancer Center, Wisconsin Institute of Medical Research, University of Wisconsin-Madison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Department of Diagnostic Radiology, BC Cancer Agency, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S381"
      ]
    },
    {
      "name": "Department of Disease Prevention, Stanford University, Palo Alto, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S439"
      ]
    },
    {
      "name": "Department of ENT and Skull Base Surgery, Barrow Neurological Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P179"
      ]
    },
    {
      "name": "Department of Electrical Engineering and Computer Science, University of Missouri-Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S320"
      ]
    },
    {
      "name": "Department of Electrical and Computer Engineering, Faculty of Applied Science, University of British Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S381"
      ]
    },
    {
      "name": "Department of Electrical and Computer Engineering, University of Houston, Houston, Texas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P307"
      ]
    },
    {
      "name": "Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Department of Endocrinology – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Department of Endocrinology, Ernakulam Medical Centre, Kochi, India, 682028",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Department of Endocrinology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Department of Epidemiology & Population Health – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S348"
      ]
    },
    {
      "name": "Department of Epidemiology and Biostatistics, University of California, San Francisco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Department of Epidemiology of the School of Public Health at the University of São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S236"
      ]
    },
    {
      "name": "Department of Epidemiology, University of Nebraska Medical Cente",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S535"
      ]
    },
    {
      "name": "Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland OH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Department of General Surgery, Florida Atlantic University, Florida, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P391"
      ]
    },
    {
      "name": "Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S438"
      ]
    },
    {
      "name": "Department of Genetics, Genomics & Cancer Biology Program, Department of Medical Oncology, Thomas Jefferson University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Department of Haematology-Oncology, National University Cancer Institute, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S109"
      ]
    },
    {
      "name": "Department of Head and Neck Oncology, Mazumdar Shaw Cancer Centre, Narayana Health City, Bangaluru, Karnataka 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S001"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery of the Hospital das Clinicas of the Faculty of Medicine, University of São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S236"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, Hospital Ana Costa, Santos, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S418"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo - Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, Institute of Science Tokyo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S518"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, National Cancer Institute, RJ - Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P036"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, University of California, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S359"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, University of Sao Paulo Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S541"
      ]
    },
    {
      "name": "Department of Head and Neck Surgery, University of São Paulo School of Medicine, São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S418"
      ]
    },
    {
      "name": "Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R.China",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S204"
      ]
    },
    {
      "name": "Department of Head and Neck and Thoracic Oncology, Division of Radiation Oncology, National Cancer Center, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, New York, 14263",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Department of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Hematology and Medical Oncology, Emory University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S528"
      ]
    },
    {
      "name": "Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "Department of Hematology-Oncology, Aga Khan University, 3rd Parklands Avenue, Nairobi, Kenya",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Department of Internal Medicine-Medical Oncology, Henry Ford Health System, Detroit, MI, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Internal Medicine-Medical Oncology, University of Michigan Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Mechanical Engineering, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Department of Mechanical Engineering, Faculty of Applied Science, University of British Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Department of Mechanical and Industrial Engineering, University of Brescia Via Branze, Brescia, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Department of Medical Education University of Florida Morsani College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Medical Oncology, Catalan, Institute of oncology (ICO, L’Hospitalet), Barcelona, Spain",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P440"
      ]
    },
    {
      "name": "Department of Medical Oncology, University of California San Francisco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Department of Medicine, Case Western Reserve University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Department of Medicine, Division of Medical Oncology, MUHC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Department of Medicine, Section of Hematology and Oncology, University of Chicago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Department of Medicine, The University of Chicago Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Department of Medicine, University of Toronto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S371"
      ]
    },
    {
      "name": "Department of Microbiology, The Chinese University of Hong Kong SAR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S579"
      ]
    },
    {
      "name": "Department of Neurosurgery, Houston Methodist, Houston, Texas, US",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Department of Oncology, McGill University, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Department of Oral Medicine and Radiology, KLE Institute of Dental Sciences, Bangaluru, 560022",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Bangalore, India, 560022",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Department of Oral and Maxillofacial Surgery, Boston Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S294"
      ]
    },
    {
      "name": "Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Department of Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Ramat Gan, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Department of Otolaryngolgoy - Head and Neck Surgery, University of California – Davis, Sacramento, California, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S425"
      ]
    },
    {
      "name": "Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S584"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery (ENT), National University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, Houston Methodist Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, John Hunter Hospital, New Lambton Heights, Australia and Tulane University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, Louisiana State University Health Sciences Center - New Orleans",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P212"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, Stanford Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, Weill Cornell Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head & Neck Surgery, Wellstar MCG Health Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P068"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S150"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Health Sciences, McGill University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P398"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P307"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas, US",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P342"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Alabama at Birmingham Heersink School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of California San Diego, La Jolla, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P302"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of California, Los Angeles, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Kansas, Kansas City, Kansas, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S425"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S159"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Oklahoma, Oklahoma City, OK, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P042"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Pennsylvania Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S453"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P182"
      ]
    },
    {
      "name": "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Arizona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Jacksonville, Florida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Otolaryngology Head and Neck Surgery Massachusetts Eye and Ear/Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S498"
      ]
    },
    {
      "name": "Department of Otolaryngology Head and Neck Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University, Songkhla, Thailand",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S251"
      ]
    },
    {
      "name": "Department of Otolaryngology and Skull Base Surgery, Barrow Neurological Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S022"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, Johns Hopkins Hospital, Baltimore, MD, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, National University Hospital, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S064"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, UNC Chapel Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head & Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Emory University, Atlanta, GA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of California, Davis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of Kansas Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of Michigan Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology – Head and Neck Surgery, University of Nevada, Las Vegas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403"
      ]
    },
    {
      "name": "Department of Otolaryngology, Baylor Scott & White All Saints Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology, Case Western Reserve University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Department of Otolaryngology, Emory University, Atlanta, GA, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S235"
      ]
    },
    {
      "name": "Department of Otolaryngology, George Washington University School of Medicine and Health Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head & Neck Surgery, Emory University, Atlanta, GA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S086"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head & Neck Surgery, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P210"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head and Neck Surgery, Northwell Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head and Neck Surgery, St. Vincent's Hospital, Darlinghurst, NSW, Australia. Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology, Head and Neck Surgical Oncology and Microvascular Reconstruction, University of California Irvine, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P273"
      ]
    },
    {
      "name": "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P311"
      ]
    },
    {
      "name": "Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology, Louisiana State University Health Shreveport",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P185"
      ]
    },
    {
      "name": "Department of Otolaryngology, Mass Eye and Ear/Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S356"
      ]
    },
    {
      "name": "Department of Otolaryngology, McGill University, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Otolaryngology, National Taiwan University BioMedical Park Hospital, Hsin-Chu, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Department of Otolaryngology, National University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Department of Otolaryngology, New York University Grossman School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "Department of Otolaryngology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Kentucky",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S532"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Michigan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S413"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Missouri-Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Nebraska Medical Center, Omaha NE",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P071"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of North Carolina-Chapel Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S043"
      ]
    },
    {
      "name": "Department of Otolaryngology, University of Texas Medical Branch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S055"
      ]
    },
    {
      "name": "Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S444"
      ]
    },
    {
      "name": "Department of Otolaryngology- Head & Neck Surgery, Boston Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P092"
      ]
    },
    {
      "name": "Department of Otolaryngology- Head & Neck Surgery, Thomas Jefferson University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S029"
      ]
    },
    {
      "name": "Department of Otolaryngology- Head and Neck Surgery, Northwell Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P281"
      ]
    },
    {
      "name": "Department of Otolaryngology- Head and Neck Surgery, Singapore General Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S445"
      ]
    },
    {
      "name": "Department of Otolaryngology- Head and Neck Surgery, University of Mississippi Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Shreveport, Shreveport, LA, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head & Neck Surgery, UHN, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head & Neck Surgery, University of Toronto",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P121"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Banner MD Anderson Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P245"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Emory School of Medicine, Atlanta, GA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P429"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Gunma Graduate School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P041"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S324"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System, Baltimore, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S436"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S386"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University, Daegu, South Korea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S114"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S196"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, OR, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S185"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Sheba Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S544"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Stanford University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P340"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, UC Irvine School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S293"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, UNC-Chapel Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of California Davis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S225"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz Medical Campus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P404"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S438"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern, Dallas, TX",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, MO",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Department of Otolaryngology-Head and Neck surgery Amsterdam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S498"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head & Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head & Neck Surgery, Mayo Clinic Arizona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head and Neck Surgery, Indiana University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P410"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S341"
      ]
    },
    {
      "name": "Department of Otolaryngology–Head and Neck Surgery, University of California, San Diego School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S114"
      ]
    },
    {
      "name": "Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology – Head and Neck Surgery – Vanderbilt University Medical Center, Nashville, TN, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P119"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology –Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S572"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P197"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Head and Neck Surgery Rush University Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S371"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong SAR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S398"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head & Neck Surgery, Boramae Medical Center, Seoul Metropolitan Government–Seoul National University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head & Neck Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P304"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S418"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S217"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P375"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P176"
      ]
    },
    {
      "name": "Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S233"
      ]
    },
    {
      "name": "Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P220"
      ]
    },
    {
      "name": "Department of Pathology at Mount Sinai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S490"
      ]
    },
    {
      "name": "Department of Pathology – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S464"
      ]
    },
    {
      "name": "Department of Pathology, Boston Children’s Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "Department of Pathology, Case Western Reserve University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S276"
      ]
    },
    {
      "name": "Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Department of Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S069"
      ]
    },
    {
      "name": "Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Pathology, KLE Institute of Dental Sciences, Yeswanthpur, Bengaluru, Karnataka 560022",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Pathology, McGill University, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Pathology, National Taiwan University Cancer Center and National University College of Medicine, Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Department of Pathology, National University Hospital, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S444"
      ]
    },
    {
      "name": "Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Department of Pathology, Stanford University School of Medicine, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Department of Pathology, The University of Chicago Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Department of Pathology, University of British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S382"
      ]
    },
    {
      "name": "Department of Pathology, University of California, San Diego School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S114"
      ]
    },
    {
      "name": "Department of Pathology, University of Missouri-Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P319"
      ]
    },
    {
      "name": "Department of Pathology, VAGLAHS, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Department of Pediatric Oncology, Dana-Farber Cancer Institute/Department of Pediatric Hematology/Oncology, Boston Children’s Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P392"
      ]
    },
    {
      "name": "Department of Physiology, University of Pennsylvania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S577"
      ]
    },
    {
      "name": "Department of Plastic Surgery, St. Joseph’s Hospital and Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S022"
      ]
    },
    {
      "name": "Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, India 221010",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Department of Preventive Oncology, NCI-AIMS, Gurgaon. India 122006",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "Department of Public Health Sciences, New Mexico State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S507"
      ]
    },
    {
      "name": "Department of Public Health, University of California, San Diego, La Jolla, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P302"
      ]
    },
    {
      "name": "Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S321"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S423"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P311"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Mayo Clinic, Arizona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Radiation Oncology, McGill University, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S366"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Rochester, Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Department of Radiation Oncology, School of Medicine, University of Missouri-Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S320"
      ]
    },
    {
      "name": "Department of Radiation Oncology, Stanford University School of Medicine, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Department of Radiation Oncology, University of California San Diego Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S462"
      ]
    },
    {
      "name": "Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Department of Radiation Oncology- University of Michigan Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S076"
      ]
    },
    {
      "name": "Department of Radiology and Nuclear Medicine – Montefiore Medical Center, Bronx, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S390"
      ]
    },
    {
      "name": "Department of Radiology, Cleveland Clinic, Cleveland OH",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S200"
      ]
    },
    {
      "name": "Department of Radiology, Mass Eye and Ear/Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S356"
      ]
    },
    {
      "name": "Department of Radiology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Department of Radiology, Weill Cornell Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P010"
      ]
    },
    {
      "name": "Department of Rehabilitation medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P413"
      ]
    },
    {
      "name": "Department of Stomatology, CHUM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Department of Surgery, Mass General Brigham, Boston, Massachusetts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Department of Surgery, Memorial Sloan Kettering Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S351"
      ]
    },
    {
      "name": "Department of Surgery, Section of Otolaryngology, University of Chicago Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Department of Surgery, The University of Chicago Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Department of Surgery, University of British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Department of Surgery, University of Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P135"
      ]
    },
    {
      "name": "Department of Surgery, VAGLAHS, Los Angeles, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S400"
      ]
    },
    {
      "name": "Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S098"
      ]
    },
    {
      "name": "Department of Veterans Affairs - Geriatric Research Education and Clinical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P151"
      ]
    },
    {
      "name": "Department of radiology, radio-oncology and nuclear medicine, Université de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Departments of Community Health Sciences, Surgery and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Dept of Biostatistics, Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "Dept of Diagnostic Pathology, Saitama Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P264"
      ]
    },
    {
      "name": "Dept of Diagnostic Radiology, International Medical Center, Saitama Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P232"
      ]
    },
    {
      "name": "Dept of Head and Neck Surgery Kaiser Oakland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P357"
      ]
    },
    {
      "name": "Dept of Head and Neck Surgery at Kaiser Oakland Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S385"
      ]
    },
    {
      "name": "Dept of Otolaryngology/Head and Neck Surgery, Mayo Clinic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "Dept of Radiation Oncology, Mayo Clinic",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "Dept of Radiology, Saitama Medical University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P232"
      ]
    },
    {
      "name": "Dimitrios Colevas 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Dimitrios Colevas, MD. Stanford University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P234"
      ]
    },
    {
      "name": "Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology Head and Neck Surgery, University of Michigan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, IL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Division of Head & Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Palo Alto, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S205"
      ]
    },
    {
      "name": "Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Division of Hematology & Oncology, Department of Medicine, University of Nebraska Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P217"
      ]
    },
    {
      "name": "Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Hematology and Oncology, Department of Medicine, University of California San Diego Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S462"
      ]
    },
    {
      "name": "Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Medical Oncology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Medical Oncology, Mayo Clinic, Arizona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Division of Medical Oncology, Rochester, Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S101"
      ]
    },
    {
      "name": "Division of Medical Oncology, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Division of Medicine, Centro de Referência para Imunobiológicos Especiais, MG - Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Division of Neuroradiology, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P429"
      ]
    },
    {
      "name": "Division of Oncology, University of North Carolina at Chapel Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P331"
      ]
    },
    {
      "name": "Division of Oral and Maxillofacial Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P375"
      ]
    },
    {
      "name": "Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "Division of Otolaryngology Head and Neck Surgery, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Division of Otolaryngology Head and Neck Surgery, University of British Columbia, Vancouver, BC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Division of Otolaryngology – Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S013"
      ]
    },
    {
      "name": "Division of Otolaryngology, Children’s Hospital of Philadelphia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S286"
      ]
    },
    {
      "name": "Division of Otolaryngology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S521"
      ]
    },
    {
      "name": "Division of Otolaryngology, Department of Surgery, Faculty of Medicine, University of British Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S478"
      ]
    },
    {
      "name": "Division of Pediatric Head & Neck Surgery, Department of Children’s Surgery, AdventHealth for Children, Orlando, FL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "Division of Plastic Surgery, Department of Surgery, University of Alabama at Birmingham, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Division of Radiation Therapy, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Division of Surgery, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Divya K 4",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Dow Medical College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S509"
      ]
    },
    {
      "name": "Dr. Kiran C Patel College of Allopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "Drexel College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P171"
      ]
    },
    {
      "name": "Droplet Biosciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S517"
      ]
    },
    {
      "name": "Duke Cancer Institute Behavioral Health and Survey Research Core",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P022"
      ]
    },
    {
      "name": "Duke University Department of Biomedical Engineering",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S360"
      ]
    },
    {
      "name": "Duke University School of Medicine, Durham, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S192"
      ]
    },
    {
      "name": "East Tennessee State University Quillen College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Eastern Virginia Medical College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S574"
      ]
    },
    {
      "name": "Eastern Virginia Medical College, Department of Molecular Physiology and Biophysics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S154"
      ]
    },
    {
      "name": "Eastern Virginia Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S202"
      ]
    },
    {
      "name": "Edward Via College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S406"
      ]
    },
    {
      "name": "Einstein Hospital Israelita",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S607"
      ]
    },
    {
      "name": "Einstein Jewish Hospital, Av. Padre Lebret - Morumbi, São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S230"
      ]
    },
    {
      "name": "Emory School of Medicine, Atlanta, GA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S328"
      ]
    },
    {
      "name": "Emory University Department of Hematology and Medical Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Emory University Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Endeavor Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P386"
      ]
    },
    {
      "name": "Endeavor Health Medical Group",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P382"
      ]
    },
    {
      "name": "Endevica Bio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S071"
      ]
    },
    {
      "name": "Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S233"
      ]
    },
    {
      "name": "Erie County Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P421"
      ]
    },
    {
      "name": "Erie County Medical Center Department of Head and Neck and Plastic Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Erie County Medical Center Department of Medical Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S529"
      ]
    },
    {
      "name": "Evaluative Clinical Sciences, Sunnybrook Research Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "FAMU-FSU College of Engineering",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "Fabio Albuquerque Marchi, PhD 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Faculdade de Medicina da USP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P445"
      ]
    },
    {
      "name": "Faculdade de Medicina, Universidade de São Paulo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S567"
      ]
    },
    {
      "name": "Faculty of Medicine of the University of São Paulo (FMUSP)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S165"
      ]
    },
    {
      "name": "Faculty of Medicine, KU Leuven, Belgium",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Faculty of Medicine, Khon Kaen University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S184"
      ]
    },
    {
      "name": "Faculty of Medicine, University of British Columbia, Vancouver, BC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S162"
      ]
    },
    {
      "name": "Federal University of Alagoas, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P364"
      ]
    },
    {
      "name": "Florida International University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Fondazione IRCCS Istituto Nazionale Dei Tumori",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S045"
      ]
    },
    {
      "name": "Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Foundation Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S465"
      ]
    },
    {
      "name": "Fox Chase Cancer Cente, Temple Health, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S554"
      ]
    },
    {
      "name": "Fox Chase Cancer Center, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Fred Hutch Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P225"
      ]
    },
    {
      "name": "Fundación Valle del Lili",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P377"
      ]
    },
    {
      "name": "Fátima Solange Pasini, PhD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Galilee Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Geisel School of Medicine, Dartmouth College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S218"
      ]
    },
    {
      "name": "Geisinger",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S346"
      ]
    },
    {
      "name": "Geisinger Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P066"
      ]
    },
    {
      "name": "General Surgery Department, University of Alabama at Birmingham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S434"
      ]
    },
    {
      "name": "Georgetown University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S177"
      ]
    },
    {
      "name": "Georgia Institute of Technology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S273"
      ]
    },
    {
      "name": "Gifu University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Graduate Curriculum in Cell Biology and Physiology, Biological and Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S100"
      ]
    },
    {
      "name": "Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "Great Neck South High School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P034"
      ]
    },
    {
      "name": "HCA Healthcare Trident Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P414"
      ]
    },
    {
      "name": "Hackensack Meridian Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S402"
      ]
    },
    {
      "name": "Hansjörg Wyss Department of Plastic Surgery, NYU Langone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P360"
      ]
    },
    {
      "name": "Hari Krishna Raju Sagiraju 5",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Harvard Medical School, Boston, Massachusetts",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S275"
      ]
    },
    {
      "name": "Harvard Stem Cell Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Harvard University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Haystack Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S210"
      ]
    },
    {
      "name": "Head and Neck Cancer Service, Memorial Sloan Kettering Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S334"
      ]
    },
    {
      "name": "Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Head and Neck Oncology, Mazumdar Shaw Medical Centre, NH, Bangalore, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Head and Neck Reference Center, AC Camargo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Head and Neck Specialists, Sarah Cannon Cancer Network",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    },
    {
      "name": "Head and Neck Specialists, Sarah Cannon Canner Network, Charleston, SC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Health Science Library, University of Washington, Seattle, Washington, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S272"
      ]
    },
    {
      "name": "HealthPartners, St Paul, MN",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Healthpartners",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P047"
      ]
    },
    {
      "name": "Heather M Starmer 2 . 1 Stanford Healthcare",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Helen F. Graham Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S297"
      ]
    },
    {
      "name": "Hennepin County Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Henry Ford Hospital - Department of Oral and Maxillofacial Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S587"
      ]
    },
    {
      "name": "Henry Ford Hospital - Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S587"
      ]
    },
    {
      "name": "Hispital Lariboisiere APHP, Paris, France",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Hokkaido University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S067"
      ]
    },
    {
      "name": "Holsinger, MD, FACS 3 . 1 Humanitas University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P002"
      ]
    },
    {
      "name": "Honor Health Scottsdale",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "Horus university, Egypt",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P345"
      ]
    },
    {
      "name": "Hospital Israelita Albert Einstein, São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Hospital Italiano de Buenos Aires, Buenos Aires, Argentina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Hospital das Clínicas FMUSP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S201"
      ]
    },
    {
      "name": "Hospital of the University of Pennsylvania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P165"
      ]
    },
    {
      "name": "Houston Methodist Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S499"
      ]
    },
    {
      "name": "Howard University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S476"
      ]
    },
    {
      "name": "Human Genomics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Humanitas Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Humanitas University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S010"
      ]
    },
    {
      "name": "Hôpital du Sacré-Cœur de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "ICESP, São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "IRCCS Regina Elena Cancer Institute of Rome",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P339"
      ]
    },
    {
      "name": "IRCSS Regina Elena Roma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P367"
      ]
    },
    {
      "name": "Illawarra Cancer Centre, Wollongong Hospital, NSW, Australia. Graduate School of Medicine, University of Wollongong, NSW, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "ImmunityBio, Inc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "Imperial College Health care NHS Trust, Charing Cross Hospital, London, UK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Imperial College London",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P169"
      ]
    },
    {
      "name": "Indiana University Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P405"
      ]
    },
    {
      "name": "Indiana University of Pennsylvania",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P021"
      ]
    },
    {
      "name": "Ingrid Kathleen Nakamuta, MSc 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Inova Schar Cancer Institute, Fairfax, VA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Institut Curie, Paris, France",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Institut Gustave Roussy, Villejuif, France",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Institut de Cancérologie de Strasbourg Europe, Strasbourg, France",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Institut du cancer de Montréal, Centre de recherche du CHUM",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Institut du cancer de Montréal, Centre de recherche du CHUM, Université de Montréal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P048"
      ]
    },
    {
      "name": "Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Institute for Computational and Data Sciences, Pennsylvania State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S185"
      ]
    },
    {
      "name": "Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P090"
      ]
    },
    {
      "name": "Institute of Chemical Engineering Convergence System, Korea University, Seoul, Republic of Korea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S357"
      ]
    },
    {
      "name": "Institute of Science Tokyo Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Instituto Nacional de Câncer, Rio de Janeiro, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Instituto Oncológico Nacional",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Instituto de Ciências Biomédicas, University of São Paulo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S280"
      ]
    },
    {
      "name": "Instituto de Câncer Dr. Arnaldo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P250"
      ]
    },
    {
      "name": "Instituto do Câncer de São Paulo Octavio Frias de Oliveira",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P150"
      ]
    },
    {
      "name": "Instituto do Câncer do Estado de São Paulo (ICESP), Sao Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S292"
      ]
    },
    {
      "name": "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S228"
      ]
    },
    {
      "name": "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Instituto do câncer Doutor Arnaldo Vieira de Carvalho, Sao Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S292"
      ]
    },
    {
      "name": "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P204"
      ]
    },
    {
      "name": "Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Istituto Fitoterapici Ospedalieri",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S500"
      ]
    },
    {
      "name": "Jacobs School of Medicine and Biomedical Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S317"
      ]
    },
    {
      "name": "Jai Research Foundation, Valvada, Vapi, Gujarat, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Jennifer Kizner 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Jichi Medical University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Jocelen Hamilton 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "John N Luken, MD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S048"
      ]
    },
    {
      "name": "John N Lukens, MD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S047"
      ]
    },
    {
      "name": "John Sealy School of Medicine, University of Texas Medical Branch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S055"
      ]
    },
    {
      "name": "John, MD, PhD 2 . 1 David Geffen School of Medicine at UCLA - Department of Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S387"
      ]
    },
    {
      "name": "John, MD, PhD 6 . 1 UCLA Department of Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "John, MD, PhD 7 . 1 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Johns Hopkins Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S387"
      ]
    },
    {
      "name": "Johns Hopkins University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "Johns Hopkins University, Whiting School of Engineering, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "Johnson & Johnson, Horsham, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Johnson & Johnson, Raritan, NJ, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Johnson & Johnson, Spring House, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Johnson & Johnson, Titusville, NJ, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Jonsson Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Jose R Reyes Memorial Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "Joslin Diabetes Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S591"
      ]
    },
    {
      "name": "Kaiser Permanente",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S487"
      ]
    },
    {
      "name": "Kaiser Permanente Division of Research",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Kaiser Permanente South Sacramento",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S295"
      ]
    },
    {
      "name": "Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P043"
      ]
    },
    {
      "name": "Kaohsiung Chang-Gung Memorial Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S063"
      ]
    },
    {
      "name": "Kasturba Medical College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S363"
      ]
    },
    {
      "name": "Keck School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S411"
      ]
    },
    {
      "name": "King Fahad Specialist Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P431"
      ]
    },
    {
      "name": "Kings Institute of Cancer Policy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S501"
      ]
    },
    {
      "name": "Kirk Kerkorian School of Medicine at UNLV",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S221"
      ]
    },
    {
      "name": "Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403"
      ]
    },
    {
      "name": "Kobe University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Kobe University Graduate School of Medicine, Kobe, Japan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Kobe University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Korea University College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P400"
      ]
    },
    {
      "name": "Kuriakose 8",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Kyung Hee Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P039"
      ]
    },
    {
      "name": "Kyung Hee Universtiy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P039"
      ]
    },
    {
      "name": "LSU Health Shreveport",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P241"
      ]
    },
    {
      "name": "La Jolla Institute of Immunology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S277"
      ]
    },
    {
      "name": "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM-40 do Hospital das Clinicas HCFMUSP, Faculdadde de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P242"
      ]
    },
    {
      "name": "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM40 do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P258"
      ]
    },
    {
      "name": "Laerte Luchini Jr. 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Lakeshore Hospital, Kocki, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S379"
      ]
    },
    {
      "name": "Lausanne University Hospital, Lausanne (CHUV)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Lee Kong Chian School of Medicine, Nanyang Technological University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Leeds Teaching Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Lehigh Valley Health Network",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P289"
      ]
    },
    {
      "name": "Lewis Katz School of Medicine, Temple University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P404"
      ]
    },
    {
      "name": "Linda Vista Medical Center Managua",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P143"
      ]
    },
    {
      "name": "Linköping University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P030"
      ]
    },
    {
      "name": "Loma Linda University Health, Department of Otolaryngology–Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P376"
      ]
    },
    {
      "name": "Loma Linda University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P376"
      ]
    },
    {
      "name": "Long Beach Memorial Medical Center, Long Beach, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Louisiana State University Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S469"
      ]
    },
    {
      "name": "Louisiana State University Health Sciences Center - New Orleans",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P011"
      ]
    },
    {
      "name": "Louisiana State University Health Sciences Center - Shreveport",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P170"
      ]
    },
    {
      "name": "Louisiana State University Health Sciences Center New Orleans",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S118"
      ]
    },
    {
      "name": "Louisiana State University Health Shreveport",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S102"
      ]
    },
    {
      "name": "Louisiana State University Health and Sciences Center School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P096"
      ]
    },
    {
      "name": "Louisiana State University Shreveport School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P185"
      ]
    },
    {
      "name": "Loyola University Chicago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Loyola University Chicago Stritch School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Loyola University Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S300"
      ]
    },
    {
      "name": "Loyola University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "Ltd., Bangalore, India, 560092",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Luiz Paulo Kowalski, PhD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "M.D. Anderson Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S403"
      ]
    },
    {
      "name": "MD Anderson",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "MD Anderson Cancer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S380"
      ]
    },
    {
      "name": "Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S326"
      ]
    },
    {
      "name": "Maria Aparecida Azevedo Koike Folgueira, PhD 1 . 1 Faculdade de Medicina da USP",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Maria Lucia Hirata Katayama, PhD 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Mascarella, MD 1 . 1 McGill University - Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "Mass Eye and Ear - Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S266"
      ]
    },
    {
      "name": "Mass Eye and Ear / Brigham and Women's Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S021"
      ]
    },
    {
      "name": "Mass General Brigham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Mass General Brigham Department of Otolaryngology-Head and Neck Surgery and Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Mass General Brigham Division of Oral Medicine and Dentistry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S415"
      ]
    },
    {
      "name": "Mass General Brigham, Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P248"
      ]
    },
    {
      "name": "Massachusetts Eye and Ear Infirmary",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "Massachusetts General Hospital, Harvard Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S441"
      ]
    },
    {
      "name": "Massachusetts Institute of Technology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "Maxillofacial Unit, Queen Victoria Hospital NHSFT, East Grinstead UK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S325"
      ]
    },
    {
      "name": "Mayo Clinic - Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S117"
      ]
    },
    {
      "name": "Mayo Clinic Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S514"
      ]
    },
    {
      "name": "Mayo Clinic Florida",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P266"
      ]
    },
    {
      "name": "Mayo Clinic, Rochester MN, USA. Department of Otolaryngology, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Mayo Clinic, Rochester MN, USA. Department of Radiation Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Mayo Clinic, Rochester MN, USA. Division of Medical Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Mayo Clinic, Scottsdale, AZ. USA. Department of Quantitative Health Sciences, Division of Biostatistics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S039"
      ]
    },
    {
      "name": "Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Bangaluru, Karnataka 560099",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S588"
      ]
    },
    {
      "name": "Mazumdar Shaw Medical Foundation",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S379"
      ]
    },
    {
      "name": "McGill Faculty of Medicine and Health Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S254"
      ]
    },
    {
      "name": "McGill University - Department of Medical Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "McGill University - Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "McGill University - Department of Radiation Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S290"
      ]
    },
    {
      "name": "McGill University, Faculty of Medicine, Montreal, QC, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S271"
      ]
    },
    {
      "name": "McGovern Medical School at UTHealth",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P122"
      ]
    },
    {
      "name": "McMaster University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S239"
      ]
    },
    {
      "name": "Mcgill University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S121"
      ]
    },
    {
      "name": "Mclaren Oakland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P287"
      ]
    },
    {
      "name": "MedStar Georgetown Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123"
      ]
    },
    {
      "name": "MedStar Washington Hospital Center Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P123"
      ]
    },
    {
      "name": "Medical College of Wisconsin, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Medical College of Wisconsin, Department of Pediatrics, Division of Pediatric Hematology and Oncology & Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P054"
      ]
    },
    {
      "name": "Medical Physics Department, BC Cancer-Vancouver, Vancouver, British Columbia, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S368"
      ]
    },
    {
      "name": "Medical University Of South Carolina",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P322"
      ]
    },
    {
      "name": "Medical University of South Carolina College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S139"
      ]
    },
    {
      "name": "Medical University of South Carolina Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S139"
      ]
    },
    {
      "name": "Medical University of South Carolina, Charleston, South Carolina, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Medscape, LLC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S443"
      ]
    },
    {
      "name": "Medstar Georgetown University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P299"
      ]
    },
    {
      "name": "Memorial Cancer Institute, Florida International University, Miami, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Memorial Sloan Kettering Cancer Center, New York, NY, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Memorial Sloan Kettering Cancer Center, New York, New York, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Merck & Co., Inc., Rahway, NJ, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S182"
      ]
    },
    {
      "name": "Methodist Estabrook Cancer Center, Nebraska Methodist Hospital, Omaha, Nebraska",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S046"
      ]
    },
    {
      "name": "Metropolitan University of Santos, Santos – Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P004"
      ]
    },
    {
      "name": "Miami Cancer Institute, Baptist Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S313"
      ]
    },
    {
      "name": "Michael G. DeGroote School of Medicine, McMaster University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Michael Gensheimer 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Michigan Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S244"
      ]
    },
    {
      "name": "Michigan State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S426"
      ]
    },
    {
      "name": "Michigan State University College of Human Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Michigan State University College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P287"
      ]
    },
    {
      "name": "Michigan State University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S433"
      ]
    },
    {
      "name": "Midwestern University, Arizona College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P219"
      ]
    },
    {
      "name": "Mie University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P024"
      ]
    },
    {
      "name": "Moffitt Cancer Center and Research Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Moffitt Cancer Center, Tampa, FL, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Montefiore Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P442"
      ]
    },
    {
      "name": "Moores Cancer Center, UC San Diego",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P213"
      ]
    },
    {
      "name": "Mount Sinai Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201"
      ]
    },
    {
      "name": "NRG Oncology Statistics and Data Management Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "NTR University of Health Sciences (NTRUHS)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S105"
      ]
    },
    {
      "name": "NUS Centre for Cancer Research (N2CR), National University of Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S322"
      ]
    },
    {
      "name": "NYU Department of Otolaryngology-Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P371"
      ]
    },
    {
      "name": "NYU Langone - Department of Otolaryngology—Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S560"
      ]
    },
    {
      "name": "NYU Langone - Hansjörg Wyss Department of Plastic Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S560"
      ]
    },
    {
      "name": "NYU Langone Department of Otolaryngology-Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P359"
      ]
    },
    {
      "name": "NYU Langone Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P373"
      ]
    },
    {
      "name": "NYU-Langone",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "NYU-Langone Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S481"
      ]
    },
    {
      "name": "Nagoya University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "National Cancer Center East Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "National Cancer Center Hospital East",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "National Cancer Center Hospital East, Kashiwa, Japan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "National Cancer Centre Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S421"
      ]
    },
    {
      "name": "National Taiwan University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "National Taiwan University Cancer Center, Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P101"
      ]
    },
    {
      "name": "National Taiwan University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P303"
      ]
    },
    {
      "name": "National Taiwan University Hospital, Department of Otolaryngology, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P101"
      ]
    },
    {
      "name": "National University Cancer Institute, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "National University Health System Diagnostics, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "National University Polyclinics, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Naveris, Inc",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S515"
      ]
    },
    {
      "name": "Nebraska Methodist Health System - Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S266"
      ]
    },
    {
      "name": "Neurosurgeons of New Jersey",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P175"
      ]
    },
    {
      "name": "New York Medical College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S163"
      ]
    },
    {
      "name": "New York Oncology Hematology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "New York University College of Dentistry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S374"
      ]
    },
    {
      "name": "New York University Grossman School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P301"
      ]
    },
    {
      "name": "New York University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S377"
      ]
    },
    {
      "name": "NewYork-Presbyterian - Columbia/Cornell",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P087"
      ]
    },
    {
      "name": "Nippon Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P209"
      ]
    },
    {
      "name": "Nishtar Medical University & Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P105"
      ]
    },
    {
      "name": "North Oaks Medical Center, Hammond, LA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P186"
      ]
    },
    {
      "name": "Northeast Ohio Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "Northeastern University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S306"
      ]
    },
    {
      "name": "Northern Arizona University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S355"
      ]
    },
    {
      "name": "Northwell Health-Department of Oral and Maxillofacial Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341"
      ]
    },
    {
      "name": "Northwell Health-Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341"
      ]
    },
    {
      "name": "Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S194"
      ]
    },
    {
      "name": "Northwick Park Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P169"
      ]
    },
    {
      "name": "Norton College of Medicine, SUNY Upstate Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P271"
      ]
    },
    {
      "name": "Nova Southeastern University College of Allopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S395"
      ]
    },
    {
      "name": "Nowon Eulji Medical Center, Eulji University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P400"
      ]
    },
    {
      "name": "Oberhavel Kliniken",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Odette Cancer Centre, Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Odette Cancer Centre, Sunnybrook Health Sciences Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S222"
      ]
    },
    {
      "name": "Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Ohio State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Ohio State University Wexner Medical Center, Columbus, OH, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "Oncology Research, Jazz Pharmaceuticals Palo Alto, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S597"
      ]
    },
    {
      "name": "Oregon Health Science University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "Ortiz-Gurdian Foundation",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P138"
      ]
    },
    {
      "name": "Osborne Head and Neck Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393"
      ]
    },
    {
      "name": "Otolaryngology University of Minnesota",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "Otolaryngology–Head & Neck Surgery, University of Puerto Rico School of Medicine, San Juan, PR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Pacific Neuroscience Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Pathnova Laboratories, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Peking University Cancer Hospital & Institute, Beijing, China",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Penn Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "Penn State University College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Pennington Biomedical Research Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P078"
      ]
    },
    {
      "name": "Philadelphia College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P291"
      ]
    },
    {
      "name": "Ponce School of Medicine and Health Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P292"
      ]
    },
    {
      "name": "Pontificia Universidad Católica de Chile",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S261"
      ]
    },
    {
      "name": "Portland Veterans Affairs Medical Center, Portland, OR, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Praveen Birur 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Praveen Birur 3",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Presage Biosciences, Inc., Seattle, WA, United States",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S323"
      ]
    },
    {
      "name": "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Princess Margaret Cancer Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S394"
      ]
    },
    {
      "name": "Princess Margaret Cancer Centre, Toronto General Hospital, Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, University Health Network, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Princess Margaret Cancer Centre, University Health Network",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P152"
      ]
    },
    {
      "name": "Princeton Plastic Surgeons",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Pritzker School of Medicine, University of Chicago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S373"
      ]
    },
    {
      "name": "Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S489"
      ]
    },
    {
      "name": "Providence",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S301"
      ]
    },
    {
      "name": "Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Qualitative Health Research Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P158"
      ]
    },
    {
      "name": "Queen Elizabeth University Hospital Glasgow",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Queen Victoria Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Queen's Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "Quynh Thu Le 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Rabin Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S364"
      ]
    },
    {
      "name": "Rabin Medical Center, Petah Tikva",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S582"
      ]
    },
    {
      "name": "Rabin Medical center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P120"
      ]
    },
    {
      "name": "Rajiv Gandhi Cancer Institute & Research Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S234"
      ]
    },
    {
      "name": "Rambam Health Care Campus",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P270"
      ]
    },
    {
      "name": "Raymond Fong 3",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S247"
      ]
    },
    {
      "name": "Regional Cancer Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P233"
      ]
    },
    {
      "name": "Renaissance School of Medicine at Stony Brook University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S056"
      ]
    },
    {
      "name": "Renown Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P419"
      ]
    },
    {
      "name": "RiboX Therapeutics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S095"
      ]
    },
    {
      "name": "Robert Larner, MD College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S189"
      ]
    },
    {
      "name": "Rosalind Franklin University of Medicine and Science",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "Rose Medical Center, Denver, Colorado",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P057"
      ]
    },
    {
      "name": "Roswell Park Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S546"
      ]
    },
    {
      "name": "Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S585"
      ]
    },
    {
      "name": "Royal Free Foundation Trust",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Rush University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S552"
      ]
    },
    {
      "name": "Rutgers New Jersey Medical School, Newark, NJ, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P100"
      ]
    },
    {
      "name": "SUNY Downstate College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P320"
      ]
    },
    {
      "name": "SUNY Downstate Health Sciences University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P300"
      ]
    },
    {
      "name": "Saba",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "San Antonio ENT",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P406"
      ]
    },
    {
      "name": "San Antonio Uniformed Services Health Education Consortium",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P406"
      ]
    },
    {
      "name": "San Diego State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P149"
      ]
    },
    {
      "name": "Sarah Cannon Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P261"
      ]
    },
    {
      "name": "School of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S477"
      ]
    },
    {
      "name": "School of Medicine, Johns Hopkins University, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S287"
      ]
    },
    {
      "name": "School of Medicine, Trinity College Dublin, Dublin, Ireland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S235"
      ]
    },
    {
      "name": "School of Nursing, David Geffen School of Medicine at UCLA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "Section Chief, OMS VA Portland, OR Consultant Surgeon, Swedish Providence Hospitals, Seattle",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S559"
      ]
    },
    {
      "name": "Section of Hematology and Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "Section of Hematology-Oncology, Baylor College of Medicine, Staff Physician at Michael E DeBakey VA Medical Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "Sengkang General Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P230"
      ]
    },
    {
      "name": "Seoul National University Bundang Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Seoul National University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P263"
      ]
    },
    {
      "name": "Sharett Cancer Institute at Hadassah Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S365"
      ]
    },
    {
      "name": "Shaukat Khan Memorial Cancer Hospital and Research Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P257"
      ]
    },
    {
      "name": "Shinshu University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Sidney Kimmel Medical College, Philadelphia, PA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S265"
      ]
    },
    {
      "name": "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S449"
      ]
    },
    {
      "name": "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P205"
      ]
    },
    {
      "name": "Simone Maistro, PhD 2",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Sinonasal and Skull Base Tumor Program, Division of Head and Neck Cancer, National Cancer Institute, National Institute of Health, Bethesda, MD, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S452"
      ]
    },
    {
      "name": "Siriraj Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "Sociedade Brasileira de Cirurgia de Cabeça e Pescoço, São Paulo, Brazil. A.C.Camargo Cancer Center, Sao Paulo, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S565"
      ]
    },
    {
      "name": "South Infirmary Victoria University Hospital, Cork, Ireland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S106"
      ]
    },
    {
      "name": "Southern Illinois University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Southern Illinois University (Emeritus)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "Southern Illinois University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S593"
      ]
    },
    {
      "name": "Southern Methodist University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "Sri Shankara Cancer Hospital and Research Centre, Bengaluru",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S012"
      ]
    },
    {
      "name": "St George Hospital, Sydney, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S243"
      ]
    },
    {
      "name": "St. George's University School of Medicine, Grenada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P137"
      ]
    },
    {
      "name": "St. Luke's University Health Network",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P083"
      ]
    },
    {
      "name": "St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Stanford Department of Pediatrics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "Stanford Health Care",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S174"
      ]
    },
    {
      "name": "Stanford Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S404"
      ]
    },
    {
      "name": "Stanford University School of Medicine, Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S455"
      ]
    },
    {
      "name": "Stanford University School of Medicine, Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S455"
      ]
    },
    {
      "name": "Sunnybrook Health Sciences Centre, Library Services",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P164"
      ]
    },
    {
      "name": "Sunnybrook Research Institute, Odette Cancer Centre & University of Toronto, Toronto, Ontario, Canada. Cancer Program, ICES, Toronto, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S096"
      ]
    },
    {
      "name": "Sutter Cancer Research Consortium",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "Sydney Ear Nose Throat Clinic, Darlinghurst, NewSouth Wales, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Tan Tock Seng Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S350"
      ]
    },
    {
      "name": "Tan Tock Seng Hospital, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S311"
      ]
    },
    {
      "name": "Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S447"
      ]
    },
    {
      "name": "Tata Memorial Hospital, Mumbai, India",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Te Aviv University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S554"
      ]
    },
    {
      "name": "Teikyo University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S111"
      ]
    },
    {
      "name": "Tel Aviv University, Sackler School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S531"
      ]
    },
    {
      "name": "Tel-Aviv University, Tel Aviv, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S536"
      ]
    },
    {
      "name": "Temple University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "Texas A&M Health Science Center Institute of Biosciences & Technology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S583"
      ]
    },
    {
      "name": "Texas A&M Medical University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Texas College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S193"
      ]
    },
    {
      "name": "Texas Institute for Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "Texas Tech University Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P107"
      ]
    },
    {
      "name": "Texas Tech University Health and Sciences Center School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P344"
      ]
    },
    {
      "name": "Thayer School of Engineering, Dartmouth College",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P060"
      ]
    },
    {
      "name": "The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P056"
      ]
    },
    {
      "name": "The Clatterbridge Cancer Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S309"
      ]
    },
    {
      "name": "The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "The Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P043"
      ]
    },
    {
      "name": "The Greater Poland Cancer Centre, Poznan, Poland",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "The Hebrew University of Jerusalem",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S099"
      ]
    },
    {
      "name": "The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "The James Graham Brown Cancer Center at University of Louisville",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "The Jewish Hospital - Mercy Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P332"
      ]
    },
    {
      "name": "The Jikei University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Sydney, NSW, Australia. School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, NSW, Australia. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "The Ohio State University- James Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P156"
      ]
    },
    {
      "name": "The Peggy and Charles Stephenson Cancer Center TSET Health Promotion Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P042"
      ]
    },
    {
      "name": "The Pennsylvania State University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "The Pennsylvania State University, College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "The Pennsylvania State University, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "The Russell Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S058"
      ]
    },
    {
      "name": "The Scripps Research Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S329"
      ]
    },
    {
      "name": "The University of Arizona Wyant College of Optical Sciecnes",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The University of Oklahoma College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P243"
      ]
    },
    {
      "name": "The University of Texas M.D. Anderson Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P260"
      ]
    },
    {
      "name": "The University of Texas MD Anderson Cancer Cente",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S240"
      ]
    },
    {
      "name": "The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "The University of Texas MD Anderson Cancer Center, Department of Thoracic-Head and Neck Medical Oncology, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S279"
      ]
    },
    {
      "name": "The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "The University of Texas Medical Branch",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S556"
      ]
    },
    {
      "name": "The University of Texas Medical Branch, Department of Institute for Translational Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The University of Texas Medical Branch, Department of Neurobiology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The University of Texas Medical Branch, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The University of Texas Medical Branch, Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The University of Texas Medical Branch, John Sealy School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S392"
      ]
    },
    {
      "name": "The West Indies University. St Augustine Campus . Trinidad and Tobago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P097"
      ]
    },
    {
      "name": "Thomas Jefferson University Department of Otolaryngology - Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "Thomas Jefferson University Hospital, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Tohoku University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "Tokyo Medical University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P224"
      ]
    },
    {
      "name": "Tokyo Medical University Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P227"
      ]
    },
    {
      "name": "Touro University Nevada College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P403"
      ]
    },
    {
      "name": "Tufts Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P426"
      ]
    },
    {
      "name": "Tufts Medical Center Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Tufts Medical Center Division of Palliative Care",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P159"
      ]
    },
    {
      "name": "Tufts University School of Medicine, Boston, MA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Tufts University School of Medicine, Boston, MA, USA, Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA, ENT Specialists, Inc., Brockton, MA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P132"
      ]
    },
    {
      "name": "Tulane University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S442"
      ]
    },
    {
      "name": "UAB",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S023"
      ]
    },
    {
      "name": "UAB Heersink School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P148"
      ]
    },
    {
      "name": "UC Davis Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P155"
      ]
    },
    {
      "name": "UC Davis Health Department of Otolaryngology, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S197"
      ]
    },
    {
      "name": "UC San Diego Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P353"
      ]
    },
    {
      "name": "UC San Diego Division of Plastic Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P353"
      ]
    },
    {
      "name": "UC San Diego Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P153"
      ]
    },
    {
      "name": "UCLA Department of Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S605"
      ]
    },
    {
      "name": "UCLA Department of Hematology Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S458"
      ]
    },
    {
      "name": "UCSF",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S571"
      ]
    },
    {
      "name": "UCSF Fresno, Division Of Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Radiation / Adjuvant Treatment",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P316"
      ]
    },
    {
      "name": "UNC Chapel Hill School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "UNC Lineberger Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S520"
      ]
    },
    {
      "name": "UPMC Hillman Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P441"
      ]
    },
    {
      "name": "USC",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S091"
      ]
    },
    {
      "name": "USC Caruso Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S293"
      ]
    },
    {
      "name": "USF Morsani College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P289"
      ]
    },
    {
      "name": "UT Health Houston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S378"
      ]
    },
    {
      "name": "UT Heath San Antonio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S508"
      ]
    },
    {
      "name": "UT MD Anderson Cancer Center, Houston, Texas, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "UTHealth Houston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S242"
      ]
    },
    {
      "name": "Uniformed Services University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S059"
      ]
    },
    {
      "name": "Unit of Otorhinolaryngology-Head and Neck Surgery, Azienda Ospedale-Università di Padova, Padova, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P443"
      ]
    },
    {
      "name": "Universidad Catolica Santiago de Guayaquil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P394"
      ]
    },
    {
      "name": "Universidad Central del Caribe, Bayamón, PR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "Universidad El Bosque",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434"
      ]
    },
    {
      "name": "Universidad de Panamá",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P228"
      ]
    },
    {
      "name": "Universidade Estadual de Campinas, Campinas, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "Universidade Metropolitana de Santos, Santos, Brazil",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S563"
      ]
    },
    {
      "name": "University College Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "University Health Network, Toronto, Ontario, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University Hospital Center Zagreb",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P040"
      ]
    },
    {
      "name": "University Hospital Cologne, Germany",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S110"
      ]
    },
    {
      "name": "University Medical Center Vaud",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "University Of Chicago",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S025"
      ]
    },
    {
      "name": "University Zurich",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "University at Buffalo School of Dental Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S379"
      ]
    },
    {
      "name": "University of Alabama at Birmingham Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P148"
      ]
    },
    {
      "name": "University of Alabama at Birmingham Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "University of Alabama in Birmingham",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "University of Amsterdam",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Engineering / Technology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S488"
      ]
    },
    {
      "name": "University of Arizona",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P008"
      ]
    },
    {
      "name": "University of Arizona College of Medicine -- Phoenix",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P245"
      ]
    },
    {
      "name": "University of Arizona, College of Medicine – Tucson, Department of Otolaryngology – Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P013"
      ]
    },
    {
      "name": "University of Arkansas for Medical Sciences College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S549"
      ]
    },
    {
      "name": "University of Birmingham, University Hospitals Birmingham, Birmingham, UK",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University of Brescia, Brescia, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University of Brescia, italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S486"
      ]
    },
    {
      "name": "University of California - Los Angeles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P393"
      ]
    },
    {
      "name": "University of California Davis School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S197"
      ]
    },
    {
      "name": "University of California Los Angeles, David Geffen School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P350"
      ]
    },
    {
      "name": "University of California San Diego School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S568"
      ]
    },
    {
      "name": "University of California San Diego, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "University of California San Diego, La Jolla, CA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "University of California San Francisco, Department of Otolaryngology Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S332"
      ]
    },
    {
      "name": "University of California, Davis - Department of Otolaryngology-Head and neck surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274"
      ]
    },
    {
      "name": "University of California, Davis Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S087"
      ]
    },
    {
      "name": "University of California, Davis School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S172"
      ]
    },
    {
      "name": "University of California, Los Angeles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S316"
      ]
    },
    {
      "name": "University of California, Los Angeles (UCLA)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S070"
      ]
    },
    {
      "name": "University of Cape Town",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S569"
      ]
    },
    {
      "name": "University of Chicago Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S031"
      ]
    },
    {
      "name": "University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S516"
      ]
    },
    {
      "name": "University of Chicago Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P382"
      ]
    },
    {
      "name": "University of Chicago Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P384"
      ]
    },
    {
      "name": "University of Chicago, Section of Hematology/Oncology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S081"
      ]
    },
    {
      "name": "University of Cincinnati College of Medicine, Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P278"
      ]
    },
    {
      "name": "University of Cincinnati Department of Otolaryngology Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P332"
      ]
    },
    {
      "name": "University of Cleveland Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "University of Colorado Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P425"
      ]
    },
    {
      "name": "University of Colorado, Denver, Aurora, CO, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "University of Connecticut Department of Otolaryngology-Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P409"
      ]
    },
    {
      "name": "University of Connecticut Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P409"
      ]
    },
    {
      "name": "University of Connecticut Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P155"
      ]
    },
    {
      "name": "University of Connecticut School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P409"
      ]
    },
    {
      "name": "University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S053"
      ]
    },
    {
      "name": "University of Florida - College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S120"
      ]
    },
    {
      "name": "University of Florida - Department of Biostatistics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "University of Florida - Department of Otolaryngology - Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S120"
      ]
    },
    {
      "name": "University of Florida - UF Health Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P309"
      ]
    },
    {
      "name": "University of Greifswald",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S089"
      ]
    },
    {
      "name": "University of Hawaii at Manoa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P249"
      ]
    },
    {
      "name": "University of IOWA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P434"
      ]
    },
    {
      "name": "University of Illinois College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P201"
      ]
    },
    {
      "name": "University of Illinois Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "University of Insubria, Varese, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University of Iowa Department of Otolaryngology - Head & Neck Cancer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S315"
      ]
    },
    {
      "name": "University of Iowa Holden Comprehensive Cancer Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S315"
      ]
    },
    {
      "name": "University of Iowa Hospital and Clinics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S574"
      ]
    },
    {
      "name": "University of Iowa Hospitals and Clinics, Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S154"
      ]
    },
    {
      "name": "University of Iowa Hosptials and Clinics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S353"
      ]
    },
    {
      "name": "University of Kansas - Department of Otolaryngology-Head and neck surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P274"
      ]
    },
    {
      "name": "University of Kansas Medical Center - Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S266"
      ]
    },
    {
      "name": "University of Maryland Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S048"
      ]
    },
    {
      "name": "University of Maryland Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S047"
      ]
    },
    {
      "name": "University of Maryland School of Medicine, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "University of Maryland School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Baltimore, MD",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S187"
      ]
    },
    {
      "name": "University of Melbourne",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "University of Miami Health System and Jackson Memorial Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P305"
      ]
    },
    {
      "name": "University of Miami, Florida, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University of Miami/Jackson Memorial Hospital",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S163"
      ]
    },
    {
      "name": "University of Michigan - Department of Otolaryngology, Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S154"
      ]
    },
    {
      "name": "University of Michigan Department of Otolaryngology - Head & Neck Cancer",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S315"
      ]
    },
    {
      "name": "University of Michigan Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P157"
      ]
    },
    {
      "name": "University of Milan, Milan, Italy",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "University of Minnesota, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "University of Mississippi Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P045"
      ]
    },
    {
      "name": "University of Missouri School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S125"
      ]
    },
    {
      "name": "University of Missouri- Columbia",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P395"
      ]
    },
    {
      "name": "University of Montreal",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P365"
      ]
    },
    {
      "name": "University of Nevada, Las Vegas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P046"
      ]
    },
    {
      "name": "University of New England College of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S395"
      ]
    },
    {
      "name": "University of New Mexico",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S207"
      ]
    },
    {
      "name": "University of North Carolina Chapel Hill",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P019"
      ]
    },
    {
      "name": "University of North Carolina School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S327"
      ]
    },
    {
      "name": "University of North Carolina, Chapel Hill, NC, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "University of Oklahoma",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S561"
      ]
    },
    {
      "name": "University of Oklahoma - Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "University of Oklahoma - Hudson College of Public Health - Department of Biostatistics and Epidemiology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P348"
      ]
    },
    {
      "name": "University of Oklahoma College Of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S434"
      ]
    },
    {
      "name": "University of Oklahoma Health Sciences Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S038"
      ]
    },
    {
      "name": "University of Oklahoma, College of Public Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "University of Oklahoma, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P435"
      ]
    },
    {
      "name": "University of Oklahoma- College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P280"
      ]
    },
    {
      "name": "University of Ottawa",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "University of Padova",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S066"
      ]
    },
    {
      "name": "University of Pennsylvania Health System",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S412"
      ]
    },
    {
      "name": "University of Pennsylvania, Philadelphia, PA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S367"
      ]
    },
    {
      "name": "University of Pittsburgh, School of Health and Rehabilitation Science",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "University of Pittsburgh, School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "University of Pittsburgh, School of Nursing",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "University of Pittsburgh, School of Public Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S176"
      ]
    },
    {
      "name": "University of Puerto Rico School of Medicine, Department of Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P194"
      ]
    },
    {
      "name": "University of Puerto Rico School of Medicine, San Juan, PR",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P330"
      ]
    },
    {
      "name": "University of Rochester",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P094"
      ]
    },
    {
      "name": "University of San Francisco",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S002"
      ]
    },
    {
      "name": "University of Santo Tomas",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P172"
      ]
    },
    {
      "name": "University of Sao Paulo",
      "record_count": 1,
      "tracks": [
        {
          "name": "Behavioral Health",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S201"
      ]
    },
    {
      "name": "University of South Carolina Greenville",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P272"
      ]
    },
    {
      "name": "University of South Florida Department of Otolaryngology and Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "University of South Florida Morsani College of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P334"
      ]
    },
    {
      "name": "University of Southern California Keck School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S602"
      ]
    },
    {
      "name": "University of São Paulo Medical School",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S001"
      ]
    },
    {
      "name": "University of Tennessee Health Science Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S027"
      ]
    },
    {
      "name": "University of Tennessee Health Science Center (UTHSC)",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S014"
      ]
    },
    {
      "name": "University of Tennessee Health Science Center: Department of Otolaryngology Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P084"
      ]
    },
    {
      "name": "University of Texas Health at San Antonio",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P312"
      ]
    },
    {
      "name": "University of Texas McGovern Medical School at Houston",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P389"
      ]
    },
    {
      "name": "University of Texas Rio Grande Valley",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P099"
      ]
    },
    {
      "name": "University of Texas at Southwestern",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S485"
      ]
    },
    {
      "name": "University of Toledo College of Medicine and Life Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P044"
      ]
    },
    {
      "name": "University of Toronto Department of Medical Biophysics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "University of Toronto, Faculty of Dentistry",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S559"
      ]
    },
    {
      "name": "University of Vermont",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S157"
      ]
    },
    {
      "name": "University of Virginia, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "University of Warsaw",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S306"
      ]
    },
    {
      "name": "University of Washington Department of Neurosurgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "University of Washington Department of Otolaryngology - Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P226"
      ]
    },
    {
      "name": "University of Washington Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S156"
      ]
    },
    {
      "name": "University of Washington, Department of Otolaryngology - Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S595"
      ]
    },
    {
      "name": "University of Washington, Division of Metabolism, Endocrinology, and Nutrition",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S595"
      ]
    },
    {
      "name": "University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "University of Western Ontario Department of Otolaryngology – Head and Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S466"
      ]
    },
    {
      "name": "University of Wisconsin - Biostatistics and Medical Informatics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S564"
      ]
    },
    {
      "name": "University of Wisconsin - Department of Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S564"
      ]
    },
    {
      "name": "University of Wisconsin - Madison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S179"
      ]
    },
    {
      "name": "University of Wisconsin School of Medicine and Public Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P085"
      ]
    },
    {
      "name": "University of Wisconsin, Madison",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S050"
      ]
    },
    {
      "name": "University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P151"
      ]
    },
    {
      "name": "Universitymedicine Greifswald",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S094"
      ]
    },
    {
      "name": "Université Libre de Bruxelles",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S145"
      ]
    },
    {
      "name": "VA Hospital, Bronx NY",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S031"
      ]
    },
    {
      "name": "VA Nebraska-Western Iowa Health Center, Omaha, NE, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S524"
      ]
    },
    {
      "name": "VAMC Minneapolis",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P439"
      ]
    },
    {
      "name": "VCU",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S152"
      ]
    },
    {
      "name": "Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S283"
      ]
    },
    {
      "name": "Vanderbilt University Medical Centre",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S539"
      ]
    },
    {
      "name": "Vanderbilt University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S223"
      ]
    },
    {
      "name": "Vanderbilt University, Nashville, TN, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Salivary Gland",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S108"
      ]
    },
    {
      "name": "Vijay Pillai 6",
      "record_count": 1,
      "tracks": [
        {
          "name": "Artificial Intelligence",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S072"
      ]
    },
    {
      "name": "Vinícius Marques Rocha, MSc 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "Wake Forest School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S170"
      ]
    },
    {
      "name": "Wake Forest University School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P154"
      ]
    },
    {
      "name": "Washington University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Skin Cancer",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S454"
      ]
    },
    {
      "name": "Washington University - St. Louis, MO",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S473"
      ]
    },
    {
      "name": "Washington University School of Medicine Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, MO, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S074"
      ]
    },
    {
      "name": "Washington University in St. Louis – Department of Otolaryngology–Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P338"
      ]
    },
    {
      "name": "Washington University in St. Louis, Department of Otolaryngology Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S417"
      ]
    },
    {
      "name": "Wayne State University, Department of Otolaryngology Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S608"
      ]
    },
    {
      "name": "West Virginia School of Osteopathic Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S299"
      ]
    },
    {
      "name": "Western University, London, Ontario, Canada",
      "record_count": 1,
      "tracks": [
        {
          "name": "Care Delivery Innovation",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P070"
      ]
    },
    {
      "name": "Winship Cancer Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S033"
      ]
    },
    {
      "name": "Winship Cancer Institute at Emory University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S248"
      ]
    },
    {
      "name": "Winship Cancer Institute of Emory University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S443"
      ]
    },
    {
      "name": "Winship Cancer Institute of Emory University - Department of Oral and Maxillofacial Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Winship Cancer Institute of Emory University - Department of Otolaryngology Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Winship Cancer Institute of Emory University - Department of Radiology and Imaging Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P202"
      ]
    },
    {
      "name": "Winship Cancer Institute of Emory University, Department of Otolaryngology Head & Neck Surgery",
      "record_count": 1,
      "tracks": [
        {
          "name": "Hypopharynx / Larynx",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S417"
      ]
    },
    {
      "name": "Winship Cancer Institute, Emory University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P207"
      ]
    },
    {
      "name": "Wistar Institute",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S312"
      ]
    },
    {
      "name": "Yale Department of Pathology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Functional Outcomes / Quality",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P166"
      ]
    },
    {
      "name": "Yale Graduate School of Arts and Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S502"
      ]
    },
    {
      "name": "Yale School of Medicine, Department of Otolaryngology",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S142"
      ]
    },
    {
      "name": "Yale School of Public Health",
      "record_count": 1,
      "tracks": [
        {
          "name": "Education / Care Delivery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S502"
      ]
    },
    {
      "name": "Yokohama City Univercity Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Cancer Biology",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P446"
      ]
    },
    {
      "name": "Yong Loo Lin School of Medicine, National University Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Imaging and Screening",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S181"
      ]
    },
    {
      "name": "Yong Loo Lin School of Medicine, National University of Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Precision Medicine",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S209"
      ]
    },
    {
      "name": "Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S068"
      ]
    },
    {
      "name": "Yong Teng . Emory",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P438"
      ]
    },
    {
      "name": "Yonsei University Health System, Seoul, South Korea",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S451"
      ]
    },
    {
      "name": "Yukon University",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S578"
      ]
    },
    {
      "name": "Ziv Medical Center",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P124"
      ]
    },
    {
      "name": "Ziv Medical Center, Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S135"
      ]
    },
    {
      "name": "Ziv Medical Center, Safad Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Immunotherapy / Systemic Therapy",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S598"
      ]
    },
    {
      "name": "Ziv medical center- Israel",
      "record_count": 1,
      "tracks": [
        {
          "name": "Endocrine Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S599"
      ]
    },
    {
      "name": "Zucker School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Reconstruction / Microvascular Surgery",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Poster",
          "count": 1
        }
      ],
      "abstract_uids": [
        "P341"
      ]
    },
    {
      "name": "de Souza, MSc 1",
      "record_count": 1,
      "tracks": [
        {
          "name": "Translational Research/Science",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S576"
      ]
    },
    {
      "name": "he Pennsylvania State University, Department of Public Health Sciences",
      "record_count": 1,
      "tracks": [
        {
          "name": "Survivorship",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S167"
      ]
    },
    {
      "name": "nstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oral Cavity",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S123"
      ]
    },
    {
      "name": "of Cancer Epidemiology & Genetics",
      "record_count": 1,
      "tracks": [
        {
          "name": "Nasopharynx / Paranasal Sinus / Skull Base",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S310"
      ]
    },
    {
      "name": "of Otolaryngology/Head and Neck Surgery, UNC School of Medicine",
      "record_count": 1,
      "tracks": [
        {
          "name": "Oropharynx / HPV Related Disease",
          "count": 1
        }
      ],
      "session_types": [
        {
          "name": "Proffered Paper",
          "count": 1
        }
      ],
      "abstract_uids": [
        "S393"
      ]
    }
  ],
  "abstracts": [
    {
      "uid": "P001",
      "content_id": "152911",
      "abstract_number": "P001",
      "poster_number": "P001",
      "title": "Identifying catastrophic health events in adults with head and neck cancer to enable AI-assisted clinical decision-making: a scoping review.",
      "summary": "Outcomes that can be determined with certainty by using routinely collected health administrative or registry databases, such as all-cause mortality and unplanned hospitalizations, are a realistic starting point for AI-based early-alert system development in HNC. Outcomes that require more clinical expertise, especially those that require patient interviews/chart reviews of EMR, may require considerably more...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152911",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Deema ElRufaei, Bsc",
      "presenter": "Deema ElRufaei, Bsc",
      "authors": "Christabel Oghinan, Bsc; Deema ElRufaei, Bsc ; Frederick Dun-Dery, PhD; Diane Lorenzetti, PhD; Khara Sauro, PhD; Andrea Fung, PhD; Sasha Mallya, PhD; Shamir Chandarana, PhD; Wayne T. Matthews, PhD; Joseph C. Dort, PhD; Rui (Ray) Fu, PhD",
      "normalized_authors": [
        "Christabel Oghinan",
        "Deema ElRufaei",
        "Frederick Dun-Dery",
        "Diane Lorenzetti",
        "Khara Sauro",
        "Andrea Fung",
        "Sasha Mallya",
        "Shamir Chandarana",
        "Wayne T. Matthews",
        "Joseph C. Dort",
        "Rui Fu"
      ],
      "affiliations": [
        "University of Calgary"
      ],
      "normalized_institutions": [
        "University of Calgary"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 514,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Christabel Oghinan, Bsc; Deema ElRufaei, Bsc ; Frederick Dun-Dery, PhD; Diane Lorenzetti, PhD; Khara Sauro, PhD; Andrea Fung, PhD; Sasha Mallya, PhD; Shamir Chandarana, PhD; Wayne T. Matthews, PhD; Joseph C. Dort, PhD; Rui (Ray) Fu, PhD",
        "Affiliations": "University of Calgary",
        "Background": "An AI-enabled early-alert system embedded in routine clinical management platforms may help healthcare providers identify patients with head and neck cancer (HNC) at risk of experiencing an adverse outcome, especially an imminent catastrophic health event. Developing such AI systems requires 1) identifying HNC-meaningful catastrophic health events, focusing on those that are detrimental yet potentially preventable, and 2) reviewing data sources and methods used to capture these events to ensure accuracy and replicability. This is an ongoing review.",
        "Methods": "In this PRISMA-guided scoping review, we worked with a medical librarian to conduct a comprehensive search using MEDLINE, Embase, CINAHL Plus, APA PsycINFO, and Cochrane CENTRAL databases for peer-reviewed, English-language journal articles published between 2015–2025. Non-trial studies documenting health outcomes of adult HNC patients labelled as “catastrophic” or a similar descriptor were included. Two reviewers independently screened all studies and extracted the data in duplicate. Any common terminology criteria for adverse events (such as the CTCAE) were excluded as we aimed to capture unstandardized outcomes with detrimental impact on HNC patients. This abstract presents the results of studies conducted in North America between 2020–2025.",
        "Results": "Our search yielded 7,025 unique citations. After title/abstract screening, 758 studies were eligible for full-text review; 143 were included in the overall study, with 16 meeting eligibility for this analysis. Of the 16 studies, 15 were conducted in the USA and 1 in Canada, representing 241,147 adults with mainly oropharyngeal or oral cavity cancer undergoing curative treatment. Three domains of catastrophic health events were reported: carotid blowout, airway compromise and other severe surgical complications (n=7, 43.8%); sudden/premature deaths (n=8, 50.0%); and other events (n=16, 100%) including clinically diagnosed depression (n=1), patient-reported severe pain/fatigue (n=2) and other symptoms from the MD Anderson Symptom Inventory (n=1), and acute care encounters including unplanned hospital admissions (n=1), readmissions (n=11) and ICU admissions (n=1). Of the 7 studies reporting severe surgical complications, 3 used electronic medical records (EMR) to capture these events, while the remaining studies used health administrative data (i.e., hospitalization records with the corresponding ICD diagnostic code) or surgical quality assurance data (e.g., the National Surgical Quality Improvement Program or NSQIP). Meanwhile, all studies documenting sudden/premature deaths or acute care encounters used routinely collected health administrative data to determine these events. Of the 3 studies reporting severe patient-reported symptoms, 2 used the EMR, and 1 used a patient questionnaire.",
        "Conclusions": "Outcomes that can be determined with certainty by using routinely collected health administrative or registry databases, such as all-cause mortality and unplanned hospitalizations, are a realistic starting point for AI-based early-alert system development in HNC. Outcomes that require more clinical expertise, especially those that require patient interviews/chart reviews of EMR, may require considerably more effort to define before using them to develop a prediction algorithm. The preliminary results of this review suggest that catastrophic health events in HNC are captured through relatively diverse data sources. These findings have actionable implications for designing clinically relevant and feasible AI-based early-alert systems for catastrophic health events in HNC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Identifying catastrophic health events in adults with head and neck cancer to enable AI-assisted clinical decision-making: a scoping review.</span>. Christabel Oghinan, Bsc; <u>Deema ElRufaei, Bsc</u>; Frederick Dun-Dery, PhD; Diane Lorenzetti, PhD; Khara Sauro, PhD; Andrea Fung, PhD; Sasha Mallya, PhD; Shamir Chandarana, PhD; Wayne T. Matthews, PhD; Joseph C. Dort, PhD; Rui (Ray) Fu, PhD. University of Calgary<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>An AI-enabled early-alert system embedded in routine clinical management platforms may help healthcare providers identify patients with head and neck cancer (HNC) at risk of experiencing an adverse outcome, especially an imminent catastrophic health event. Developing such AI systems requires 1) identifying HNC-meaningful catastrophic health events, focusing on those that are detrimental yet potentially preventable, and 2) reviewing data sources and methods used to capture these events to ensure accuracy and replicability. This is an ongoing review.</p>\n\n<p><strong>Methods:</strong> In this PRISMA-guided scoping review, we worked with a medical librarian to conduct a comprehensive search using MEDLINE, Embase, CINAHL Plus, APA PsycINFO, and Cochrane CENTRAL databases for peer-reviewed, English-language journal articles published between 2015–2025. Non-trial studies documenting health outcomes of adult HNC patients labelled as “catastrophic” or a similar descriptor were included. Two reviewers independently screened all studies and extracted the data in duplicate. Any common terminology criteria for adverse events (such as the CTCAE) were excluded as we aimed to capture unstandardized outcomes with detrimental impact on HNC patients. This abstract presents the results of studies conducted in North America between 2020–2025.</p>\n\n<p><strong>Results: </strong>Our search yielded 7,025 unique citations. After title/abstract screening, 758 studies were eligible for full-text review; 143 were included in the overall study, with 16 meeting eligibility for this analysis. Of the 16 studies, 15 were conducted in the USA and 1 in Canada, representing 241,147 adults with mainly oropharyngeal or oral cavity cancer undergoing curative treatment. Three domains of catastrophic health events were reported: carotid blowout, airway compromise and other severe surgical complications (n=7, 43.8%); sudden/premature deaths (n=8, 50.0%); and other events (n=16, 100%) including clinically diagnosed depression (n=1), patient-reported severe pain/fatigue (n=2) and other symptoms from the MD Anderson Symptom Inventory (n=1), and acute care encounters including unplanned hospital admissions (n=1), readmissions (n=11) and ICU admissions (n=1). Of the 7 studies reporting severe surgical complications, 3 used electronic medical records (EMR) to capture these events, while the remaining studies used health administrative data (i.e., hospitalization records with the corresponding ICD diagnostic code) or surgical quality assurance data (e.g., the National Surgical Quality Improvement Program or NSQIP). Meanwhile, all studies documenting sudden/premature deaths or acute care encounters used routinely collected health administrative data to determine these events. Of the 3 studies reporting severe patient-reported symptoms, 2 used the EMR, and 1 used a patient questionnaire.</p>\n\n<p><strong>Conclusions:</strong> Outcomes that can be determined with certainty by using routinely collected health administrative or registry databases, such as all-cause mortality and unplanned hospitalizations, are a realistic starting point for AI-based early-alert system development in HNC. Outcomes that require more clinical expertise, especially those that require patient interviews/chart reviews of EMR, may require considerably more effort to define before using them to develop a prediction algorithm. The preliminary results of this review suggest that catastrophic health events in HNC are captured through relatively diverse data sources. These findings have actionable implications for designing clinically relevant and feasible AI-based early-alert systems for catastrophic health events in HNC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152911--></body></html>"
    },
    {
      "uid": "P002",
      "content_id": "154597",
      "abstract_number": "P002",
      "poster_number": "P002",
      "title": "Accuracy of Large Language Model (MedGemma-4B and -27B) in Detecting Laryngeal Lesions",
      "summary": "MedGemma showed strong accuracy in detecting laryngeal lesions, achieving better performance than the deep learning model. These results support the feasibility of LLM-based image understanding in laryngology and highlight the potential for developing diagnostic captioning systems that integrate clinically meaningful descriptors such as appearance, location, and side.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154597",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alberto Paderno, MD",
      "presenter": "Alberto Paderno, MD",
      "authors": "Giulio Sandri, MD 1 ; Giuseppe Facchi 2 ; Alberto Paderno, MD 1 ; Giuseppe Spriano, MD 1 ; Christopher F",
      "normalized_authors": [
        "Giulio Sandri",
        "Giuseppe Facchi",
        "Alberto Paderno",
        "Giuseppe Spriano",
        "Christopher F"
      ],
      "affiliations": [
        "Holsinger, MD, FACS 3 . 1 Humanitas University",
        "University of Milan",
        "Stanford University"
      ],
      "normalized_institutions": [
        "Holsinger, MD, FACS 3 . 1 Humanitas University",
        "University of Milan",
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 234,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Giulio Sandri, MD 1 ; Giuseppe Facchi 2 ; Alberto Paderno, MD 1 ; Giuseppe Spriano, MD 1 ; Christopher F",
        "Affiliations": "Holsinger, MD, FACS 3 . 1 Humanitas University; 2 University of Milan; 3 Stanford University",
        "Introduction": "The role of Artificial Intelligence (AI) in clinical settings is rapidly expanding. Large Language Models (LLMs) are used daily by millions of people worldwide, and their versatility has led to the development of several topic-specific models. MedGemma (Google DeepMind©?), launched in May 2025, is an LLM fine-tuned on medical literature and clinical applications. We used MedGemma on the “Laryngoscope8” dataset to assess the accuracy and feasibility of LLMs in detecting laryngeal lesions.",
        "Methods": "We re-labeled and refined the Laryngoscope8 dataset to correct inconsistencies and resolve annotation errors, ensuring higher-quality ground truth. To rigorously evaluate model performance, we employed 5-fold cross-validation with strict patient-level separation to prevent data leakage between training and testing folds. Both MedGemma-4B and MedGemma-27B were assessed on a multiclass lesion-detection task. In addition, we explored the feasibility of future diagnostic captioning by structuring labels to include key clinical descriptors such as lesion appearance, anatomical location, and side.",
        "Results": "Across the 5-fold cross-validation, MedGemma achieved an average F1-score of 83% for lesion classification, outperforming the baseline deep learning model on the same task. The model demonstrated consistent performance across folds, confirming robustness when evaluated under patient-separated conditions.",
        "Conclusion": "MedGemma showed strong accuracy in detecting laryngeal lesions, achieving better performance than the deep learning model. These results support the feasibility of LLM-based image understanding in laryngology and highlight the potential for developing diagnostic captioning systems that integrate clinically meaningful descriptors such as appearance, location, and side."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Accuracy of Large Language Model (MedGemma-4B and -27B) in Detecting Laryngeal Lesions</span>. Giulio Sandri, MD<sup>1</sup>; Giuseppe Facchi<sup>2</sup>; <u>Alberto Paderno, MD</u><sup>1</sup>; Giuseppe Spriano, MD<sup>1</sup>; Christopher F. Holsinger, MD, FACS<sup>3</sup>. <sup>1</sup>Humanitas University; <sup>2</sup>University of Milan; <sup>3</sup>Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The role of Artificial Intelligence (AI) in clinical settings is rapidly expanding. Large Language Models (LLMs) are used daily by millions of people worldwide, and their versatility has led to the development of several topic-specific models. MedGemma (Google DeepMind©?), launched in May 2025, is an LLM fine-tuned on medical literature and clinical applications. We used MedGemma on the “Laryngoscope8” dataset to assess the accuracy and feasibility of LLMs in detecting laryngeal lesions.</p>\n\n<p><strong>Methods: </strong>We re-labeled and refined the Laryngoscope8 dataset to correct inconsistencies and resolve annotation errors, ensuring higher-quality ground truth. To rigorously evaluate model performance, we employed 5-fold cross-validation with strict patient-level separation to prevent data leakage between training and testing folds. Both MedGemma-4B and MedGemma-27B were assessed on a multiclass lesion-detection task. In addition, we explored the feasibility of future diagnostic captioning by structuring labels to include key clinical descriptors such as lesion appearance, anatomical location, and side.</p>\n\n<p><strong>Results: </strong>Across the 5-fold cross-validation, MedGemma achieved an average F1-score of 83% for lesion classification, outperforming the baseline deep learning model on the same task. The model demonstrated consistent performance across folds, confirming robustness when evaluated under patient-separated conditions.</p>\n\n<p><strong>Conclusion: </strong>MedGemma showed strong accuracy in detecting laryngeal lesions, achieving better performance than the deep learning model. These results support the feasibility of LLM-based image understanding in laryngology and highlight the potential for developing diagnostic captioning systems that integrate clinically meaningful descriptors such as appearance, location, and side.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154597--></body></html>"
    },
    {
      "uid": "P003",
      "content_id": "153640",
      "abstract_number": "P003",
      "poster_number": "P003",
      "title": "Building a Scalable Open Surgery Dataset in Head and Neck Surgery: Feasibility & Lessons Learned",
      "summary": "Large-scale acquisition and processing of SurgEV open surgical video in head and neck surgery is feasible and scalable when supported by a standardized workflow and ontology-driven annotation strategy. Our experience and resulting dataset provide a practical blueprint for institutions seeking to build similar resources and establish a foundation for multi-institutional collaboration in open surgical data science,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153640",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nikita Bedi",
      "presenter": "Nikita Bedi",
      "authors": "Nikita Bedi ; Catherine Po Ling Chan; Hlu Vang; Giuseppe Facchi; Aina Brunet; Alberto Paderno; Anita Rau; F. Christopher M Holsinger, Professor Head and Neck Surgery",
      "normalized_authors": [
        "Nikita Bedi",
        "Catherine Po Ling Chan",
        "Hlu Vang",
        "Giuseppe Facchi",
        "Aina Brunet",
        "Alberto Paderno",
        "Anita Rau",
        "F. Christopher M Holsinger, Head and Neck Surgery"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 471,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Nikita Bedi ; Catherine Po Ling Chan; Hlu Vang; Giuseppe Facchi; Aina Brunet; Alberto Paderno; Anita Rau; F. Christopher M Holsinger, Professor Head and Neck Surgery",
        "Affiliations": "Stanford University",
        "Background": "Surgical data science relies on large, diverse video datasets to develop artificial intelligence (AI) systems for automated documentation, skill assessment, and intraoperative guidance. However, there is a severe bias: open surgery remains critically underrepresented, and head and neck surgery is virtually absent from existing resources. The only open surgery video dataset (AVOS) contains 34 procedures from YouTube, with limited head and neck representation. This underrepresentation limits development of AI systems for documentation, education, and decision support in a specialty that demands precise identification of critical neurovascular and endocrine structures. We describe a comprehensive, reproducible workflow for large-scale collection and processing of open head and neck surgical videos to address this gap.",
        "Methods": "We retrospectively analyzed videos captured with a wearable 4K head-mounted camera during routine head and neck surgical procedures. These digital recordings were taken directly from the viewpoint of the operating surgeon, or the Surgeon’s-Eye View (SurgEV) -- not from an overhead camera or other optical source. Our pipeline spans the full lifecycle from capture to analysis-ready datasets: (1) equipment configuration and institutional approvals, (2) intraoperative video acquisition with minimal disruption to operating room workflow, (3) secure storage and transfer, (4) preprocessing with frame-rate standardization and stabilization, (5) compression and quality control, and (6) an annotation infrastructure. To support structured downstream tasks, we developed a thyroidectomy-specific ontology defining phases, key steps, and critical structures (e.g., recurrent laryngeal nerve, parathyroid glands) and applied it to a subset of thyroidectomy cases.",
        "Results": "We compiled 400 SurgEV recordings of open head and neck procedures, totaling 55,927 minutes (~932 hours) across 18 procedure categories—representing a 12-fold increase over existing open surgery datasets and the first large-scale resource from real clinical practice. Major categories included thyroidectomy and completion thyroidectomy (153 cases; ~398 hours), neck dissection (137; ~316 hours), parathyroidectomy (25; ~52 hours), carotid body tumor excision (17; ~45 hours), salivary gland procedures (7; ~26 hours), total laryngectomy (9; ~23 hours), tracheotomy (8; ~5 hours), oral cavity and oropharyngeal procedures (30; ~27 hours), and anterior cervical discectomy/debridement and cervical spine approaches (7; ~6 hours), with the remaining 7 procedures (~18 hours) classified as other open head and neck operations. For proof-of-concept structured analysis, 51 thyroidectomy cases (~152 hours) were fully processed and annotated into 5 phases and 10 essential steps, with explicit labeling of critical structures and key intraoperative events. Ontology-based phase annotation was feasible and reproducible, enabling alignment with standardized operative note templates.",
        "Conclusions": "Large-scale acquisition and processing of SurgEV open surgical video in head and neck surgery is feasible and scalable when supported by a standardized workflow and ontology-driven annotation strategy. Our experience and resulting dataset provide a practical blueprint for institutions seeking to build similar resources and establish a foundation for multi-institutional collaboration in open surgical data science, with direct implications for future AI tools in documentation, education, and intraoperative decision support."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Building a Scalable Open Surgery Dataset in Head and Neck Surgery: Feasibility & Lessons Learned</span>. <u>Nikita Bedi</u>; Catherine Po Ling Chan; Hlu Vang; Giuseppe Facchi; Aina Brunet; Alberto Paderno; Anita Rau; F. Christopher M Holsinger, Professor Head and Neck Surgery. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Surgical data science relies on large, diverse video datasets to develop artificial intelligence (AI) systems for automated documentation, skill assessment, and intraoperative guidance. However, there is a severe bias: open surgery remains critically underrepresented, and head and neck surgery is virtually absent from existing resources. The only open surgery video dataset (AVOS) contains 34 procedures from YouTube, with limited head and neck representation. This underrepresentation limits development of AI systems for documentation, education, and decision support in a specialty that demands precise identification of critical neurovascular and endocrine structures. We describe a comprehensive, reproducible workflow for large-scale collection and processing of open head and neck surgical videos to address this gap.</p>\n\n<p><strong>Methods: </strong>We retrospectively analyzed videos captured with a wearable 4K head-mounted camera during routine head and neck surgical procedures. These digital recordings were taken directly from the viewpoint of the operating surgeon, or the Surgeon’s-Eye View (SurgEV) -- not from an overhead camera or other optical source. Our pipeline spans the full lifecycle from capture to analysis-ready datasets: (1) equipment configuration and institutional approvals, (2) intraoperative video acquisition with minimal disruption to operating room workflow, (3) secure storage and transfer, (4) preprocessing with frame-rate standardization and stabilization, (5) compression and quality control, and (6) an annotation infrastructure. To support structured downstream tasks, we developed a thyroidectomy-specific ontology defining phases, key steps, and critical structures (e.g., recurrent laryngeal nerve, parathyroid glands) and applied it to a subset of thyroidectomy cases.</p>\n\n<p><strong>Results: </strong>We compiled 400 SurgEV recordings of open head and neck procedures, totaling 55,927 minutes (~932 hours) across 18 procedure categories—representing a 12-fold increase over existing open surgery datasets and the first large-scale resource from real clinical practice. Major categories included thyroidectomy and completion thyroidectomy (153 cases; ~398 hours), neck dissection (137; ~316 hours), parathyroidectomy (25; ~52 hours), carotid body tumor excision (17; ~45 hours), salivary gland procedures (7; ~26 hours), total laryngectomy (9; ~23 hours), tracheotomy (8; ~5 hours), oral cavity and oropharyngeal procedures (30; ~27 hours), and anterior cervical discectomy/debridement and cervical spine approaches (7; ~6 hours), with the remaining 7 procedures (~18 hours) classified as other open head and neck operations. For proof-of-concept structured analysis, 51 thyroidectomy cases (~152 hours) were fully processed and annotated into 5 phases and 10 essential steps, with explicit labeling of critical structures and key intraoperative events. Ontology-based phase annotation was feasible and reproducible, enabling alignment with standardized operative note templates.</p>\n\n<p><strong>Conclusions: </strong>Large-scale acquisition and processing of SurgEV open surgical video in head and neck surgery is feasible and scalable when supported by a standardized workflow and ontology-driven annotation strategy. Our experience and resulting dataset provide a practical blueprint for institutions seeking to build similar resources and establish a foundation for multi-institutional collaboration in open surgical data science, with direct implications for future AI tools in documentation, education, and intraoperative decision support.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153640--></body></html>"
    },
    {
      "uid": "P004",
      "content_id": "154298",
      "abstract_number": "P004",
      "poster_number": "P004",
      "title": "Large Language Models in Laryngeal Cancer Treatment: Concordance with Clinical Practice Guidelines",
      "summary": "Large Language Models demonstrated 78.6% concordance with established clinical practice guidelines for laryngeal cancer management, indicating substantial but imperfect alignment with expert consensus. While artificial intelligence shows considerable potential to support guideline development and clinical decision support, the identified discrepancies underscore the necessity for rigorous validation before...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154298",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rogério Aparecido Dedivitis, PhD, MD",
      "presenter": "Rogério Aparecido Dedivitis, PhD, MD",
      "authors": "Rogério Aparecido Dedivitis, PhD, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Leandro L de Matos, PhD, MD 3 ; Daniel A Ribeiro, PhD 4 ; Bruno P Duarte, Mr 2 ; Luiz Paulo Kowalski, PhD, MD 1",
      "normalized_authors": [
        "Rogério Aparecido Dedivitis",
        "Mario Augusto F Castro",
        "Leandro L de Matos",
        "Daniel A Ribeiro",
        "Bruno P Duarte, Mr",
        "Luiz Paulo Kowalski"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo - Brazil",
        "Metropolitan University of Santos, Santos – Brazil",
        "Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
        "Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo - Brazil",
        "Metropolitan University of Santos, Santos – Brazil",
        "Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
        "Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 406,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Rogério Aparecido Dedivitis, PhD, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Leandro L de Matos, PhD, MD 3 ; Daniel A Ribeiro, PhD 4 ; Bruno P Duarte, Mr 2 ; Luiz Paulo Kowalski, PhD, MD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo - Brazil; 2 Metropolitan University of Santos, Santos – Brazil; 3 Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil; 4 Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil",
        "Background": "The integration of artificial intelligence into clinical decision-making represents a transformative development in oncology. Large Language Models have emerged as potential tools to support clinicians in complex treatment planning. This study aimed to assess the concordance between artificial intelligence-generated responses and established clinical practice guidelines for advanced laryngeal cancer treatment decision-making. We sought to determine whether these computational tools can reliably reproduce expert consensus and identify areas where they may provide complementary or divergent information.",
        "Methods": "Seven specific recommendations from established clinical practice guidelines for advanced laryngeal cancer management were systematicallyselected based on their clinical relevance andfrequency of application in daily practice. Each recommendation was carefully formulated as a structured clinical question to ensure clarity and standardization. Four distinct Large Language Model platforms were queried independently with identical questions to assess consistency across different systems. The Claude platform was subsequently utilized to perform a systematic comparative analysis, identifying and categorizing all discrepancies between guideline recommendations and AI-generated responses. Three board-certified head and neck surgery specialists with extensive clinical experience independently evaluated each identified difference, assessing its clinical significance and potential impact on patient care. The evaluation process included qualitative assessment of content completeness, accuracy of recommendations, and alignment with current evidence-based practice.",
        "Results": "Among the 28 responses analyzed across all platforms and questions, 22 responses (78.6%) demonstrated substantial concordance with existing clinical practice guidelines, indicating general alignment in core recommendations. Two responses revealed that the established guidelines contained significantly more comprehensive and nuanced information than the AI-generated content, suggesting limitations in the depth of artificial intelligence responses for certain complex scenarios. Three responses provided additional clinically relevant information that was not explicitly present in the current guidelines, potentially reflecting more recent evidence or alternative clinical perspectives that have not yet been incorporated into formal recommendations. One response directly contradicted established guideline recommendations, representing a potentially concerning divergence that could lead to inappropriate clinical decisions if applied without critical evaluation. The pattern of concordance and divergence varied across different clinical scenarios and platforms, suggesting that performance may be context-dependent.",
        "Conclusion": "Large Language Models demonstrated 78.6% concordance with established clinical practice guidelines for laryngeal cancer management, indicating substantial but imperfect alignment with expert consensus. While artificial intelligence shows considerable potential to support guideline development and clinical decision support, the identified discrepancies underscore the necessity for rigorous validation before clinical implementation. These tools should augmentrather than substitute expert-driven protocols, serving as complementary resources that require critical oversight by experienced clinicians."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Large Language Models in Laryngeal Cancer Treatment: Concordance with Clinical Practice Guidelines</span>. <u>Rogério Aparecido Dedivitis, PhD, MD</u><sup>1</sup>; Mario Augusto F Castro, PhD, MD<sup>2</sup>; Leandro L de Matos, PhD, MD<sup>3</sup>; Daniel A Ribeiro, PhD<sup>4</sup>; Bruno P Duarte, Mr<sup>2</sup>; Luiz Paulo Kowalski, PhD, MD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo - Brazil; <sup>2</sup>Metropolitan University of Santos, Santos – Brazil; <sup>3</sup>Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil; <sup>4</sup>Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The integration of artificial intelligence into clinical decision-making represents a transformative development in oncology. Large Language Models have emerged as potential tools to support clinicians in complex treatment planning. This study aimed to assess the concordance between artificial intelligence-generated responses and established clinical practice guidelines for advanced laryngeal cancer treatment decision-making. We sought to determine whether these computational tools can reliably reproduce expert consensus and identify areas where they may provide complementary or divergent information.</p>\n\n<p><strong>Methods: </strong>Seven specific recommendations from established clinical practice guidelines for advanced laryngeal cancer management were systematicallyselected based on their clinical relevance andfrequency of application in daily practice. Each recommendation was carefully formulated as a structured clinical question to ensure clarity and standardization. Four distinct Large Language Model platforms were queried independently with identical questions to assess consistency across different systems. The Claude platform was subsequently utilized to perform a systematic comparative analysis, identifying and categorizing all discrepancies between guideline recommendations and AI-generated responses. Three board-certified head and neck surgery specialists with extensive clinical experience independently evaluated each identified difference, assessing its clinical significance and potential impact on patient care. The evaluation process included qualitative assessment of content completeness, accuracy of recommendations, and alignment with current evidence-based practice.</p>\n\n<p><strong>Results: </strong>Among the 28 responses analyzed across all platforms and questions, 22 responses (78.6%) demonstrated substantial concordance with existing clinical practice guidelines, indicating general alignment in core recommendations. Two responses revealed that the established guidelines contained significantly more comprehensive and nuanced information than the AI-generated content, suggesting limitations in the depth of artificial intelligence responses for certain complex scenarios. Three responses provided additional clinically relevant information that was not explicitly present in the current guidelines, potentially reflecting more recent evidence or alternative clinical perspectives that have not yet been incorporated into formal recommendations. One response directly contradicted established guideline recommendations, representing a potentially concerning divergence that could lead to inappropriate clinical decisions if applied without critical evaluation. The pattern of concordance and divergence varied across different clinical scenarios and platforms, suggesting that performance may be context-dependent.</p>\n\n<p><strong>Conclusion:</strong> Large Language Models demonstrated 78.6% concordance with established clinical practice guidelines for laryngeal cancer management, indicating substantial but imperfect alignment with expert consensus. While artificial intelligence shows considerable potential to support guideline development and clinical decision support, the identified discrepancies underscore the necessity for rigorous validation before clinical implementation. These tools should augmentrather than substitute expert-driven protocols, serving as complementary resources that require critical oversight by experienced clinicians.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154298--></body></html>"
    },
    {
      "uid": "P005",
      "content_id": "154750",
      "abstract_number": "P005",
      "poster_number": "P005",
      "title": "AI-Assisted Volumetric Modeling of Pharyngeal Reconstruction: A Pilot Feasibility Study",
      "summary": "This pilot demonstrates that an AI-assisted semi-automatic segmentation workflow can reliably generate longitudinal measurements of luminal circumference, area, eccentricity, flap thickness, and total flap volume at anatomically and functionally relevant levels of a reconstructed pharynx. The approach appears technically robust across CT and MR and is compatible with multi-timepoint analysis, supporting its...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154750",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexander Poulakis, MD",
      "presenter": "Alexander Poulakis, MD",
      "authors": "Alexander Poulakis, MD ; Joel B Fontanarosa, MD, PhD; Farshad N Chowdhury, MD, FACS",
      "normalized_authors": [
        "Alexander Poulakis",
        "Joel B Fontanarosa",
        "Farshad N Chowdhury"
      ],
      "affiliations": [
        "University of Rochester School of Medicine and Dentistry"
      ],
      "normalized_institutions": [
        "University of Rochester School of Medicine and Dentistry"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 407,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alexander Poulakis, MD ; Joel B Fontanarosa, MD, PhD; Farshad N Chowdhury, MD, FACS",
        "Affiliations": "University of Rochester School of Medicine and Dentistry",
        "Background": "Free tissue transfer for circumferential laryngopharyngectomy creates a neopharyngeal conduit whose geometry evolves with healing and adjuvant radiotherapy. Yet, quantitative descriptions of these changes remain limited, particularly for circumferential reconstructions. Existing head and neck free-flap series describe global volume loss and broad predictors but rarely characterize segmental lumen caliber, wall thickness, and 3D volume in a way that directly maps to dysphagia mechanisms or stricture risk. A reproducible, imaging-based workflow to extract such metrics is needed to support future multi-patient studies linking reconstruction geometry, flap type, and swallowing function.",
        "Methods": "A patient who underwent salvage laryngectomy with circumferential pharyngeal reconstruction using a tubed anterolateral thigh flap and postoperative repeat radiotherapy was selected as a pilot case. Serial CT and MR neck studies over approximately three years were segmented using semi-automatic active contour methods in ITK-SNAP, with minor manual refinement to delineate the reconstructed flap and neopharyngeal lumen. At three prespecified axial levels — the base of tongue, the narrowest cross-section within the reconstructed segment, and the distal anastomosis to native esophagus — internal luminal circumference, cross-sectional area, flap thickness, lumen eccentricity and total flap volume at each timepoint were obtained. The primary objective was to assess technical feasibility of this approach, within-patient consistency across modalities and timepoints, and the practicality of this workflow for future cohort-scale analyses, rather than to infer definitive biological trends from this single case.",
        "Results": "Semi-automatic segmentation of the reconstructed pharyngeal segment and lumen was feasible on all CT and MR studies across the follow-up interval, with minor manual refinement and consistent application of the predefined protocol. At the three axial levels of interest, internal luminal circumference, cross-sectional area, flap thickness, and lumen eccentricity were successfully obtained together with total reconstruction volume at each timepoint. CT proved advantageous for defining air–soft tissue interfaces and luminal boundaries, whereas MR improved soft-tissue contrast for tissue composition assessment.",
        "Conclusion": "This pilot demonstrates that an AI-assisted semi-automatic segmentation workflow can reliably generate longitudinal measurements of luminal circumference, area, eccentricity, flap thickness, and total flap volume at anatomically and functionally relevant levels of a reconstructed pharynx. The approach appears technically robust across CT and MR and is compatible with multi-timepoint analysis, supporting its scalability for larger clinical datasets. Future work will apply this methodology to multi-patient cohorts to characterize reconstruction remodeling patterns by flap type, quantify structural resistance-related features, and test associations with swallowing outcomes and need for dilation, with the aim of informing flap design and patient selection in pharyngeal reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AI-Assisted Volumetric Modeling of Pharyngeal Reconstruction: A Pilot Feasibility Study</span>. <u>Alexander Poulakis, MD</u>; Joel B Fontanarosa, MD, PhD; Farshad N Chowdhury, MD, FACS. University of Rochester School of Medicine and Dentistry<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Free tissue transfer for circumferential laryngopharyngectomy creates a neopharyngeal conduit whose geometry evolves with healing and adjuvant radiotherapy. Yet, quantitative descriptions of these changes remain limited, particularly for circumferential reconstructions. Existing head and neck free-flap series describe global volume loss and broad predictors but rarely characterize segmental lumen caliber, wall thickness, and 3D volume in a way that directly maps to dysphagia mechanisms or stricture risk. A reproducible, imaging-based workflow to extract such metrics is needed to support future multi-patient studies linking reconstruction geometry, flap type, and swallowing function.</p>\n\n<p><strong>Methods: </strong>A patient who underwent salvage laryngectomy with circumferential pharyngeal reconstruction using a tubed anterolateral thigh flap and postoperative repeat radiotherapy was selected as a pilot case. Serial CT and MR neck studies over approximately three years were segmented using semi-automatic active contour methods in ITK-SNAP, with minor manual refinement to delineate the reconstructed flap and neopharyngeal lumen. At three prespecified axial levels — the base of tongue, the narrowest cross-section within the reconstructed segment, and the distal anastomosis to native esophagus — internal luminal circumference, cross-sectional area, flap thickness, lumen eccentricity and total flap volume at each timepoint were obtained. The primary objective was to assess technical feasibility of this approach, within-patient consistency across modalities and timepoints, and the practicality of this workflow for future cohort-scale analyses, rather than to infer definitive biological trends from this single case.</p>\n\n<p><strong>Results: </strong>Semi-automatic segmentation of the reconstructed pharyngeal segment and lumen was feasible on all CT and MR studies across the follow-up interval, with minor manual refinement and consistent application of the predefined protocol. At the three axial levels of interest, internal luminal circumference, cross-sectional area, flap thickness, and lumen eccentricity were successfully obtained together with total reconstruction volume at each timepoint. CT proved advantageous for defining air–soft tissue interfaces and luminal boundaries, whereas MR improved soft-tissue contrast for tissue composition assessment.</p>\n\n<p><strong>Conclusion: </strong>This pilot demonstrates that an AI-assisted semi-automatic segmentation workflow can reliably generate longitudinal measurements of luminal circumference, area, eccentricity, flap thickness, and total flap volume at anatomically and functionally relevant levels of a reconstructed pharynx. The approach appears technically robust across CT and MR and is compatible with multi-timepoint analysis, supporting its scalability for larger clinical datasets. Future work will apply this methodology to multi-patient cohorts to characterize reconstruction remodeling patterns by flap type, quantify structural resistance-related features, and test associations with swallowing outcomes and need for dilation, with the aim of informing flap design and patient selection in pharyngeal reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154750--></body></html>"
    },
    {
      "uid": "P006",
      "content_id": "155601",
      "abstract_number": "P006",
      "poster_number": "P006",
      "title": "Using AI to Analyze and Annotate Thyroidectomy using Temporal Phase Recognition: Developing a Surgical Ontology",
      "summary": "The development of an open thyroid surgical ontology provides a structured framework for defining anatomical landmarks, operative actions, and workflow phases in thyroidectomy. To our knowledge, this represents one of the first ontology-based frameworks developed specifically for open thyroid surgery using egocentric operative video data. By organizing surgical knowledge in a standardized format, this approach...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155601",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Po Ling Chan, MD",
      "presenter": "Po Ling Chan, MD",
      "authors": "Po Ling Chan, MD ; Nikita Bedi, BS; Hlu Vang, BS; Anita Rau, phd; Soo Yeon Jung, MD; Tatsuya Furukawa, MD; Lisa M Knowlton, MD, MPH; Jeffrey K. Jopling, MD; Aina Brunet Garcia; Alberto Paderno, PhD; F",
      "normalized_authors": [
        "Po Ling Chan",
        "Nikita Bedi",
        "Hlu Vang",
        "Anita Rau",
        "Soo Yeon Jung",
        "Tatsuya Furukawa",
        "Lisa M Knowlton",
        "Jeffrey K. Jopling",
        "Aina Brunet Garcia",
        "Alberto Paderno"
      ],
      "affiliations": [
        "Christopher Holsinger, MD. Stanford University"
      ],
      "normalized_institutions": [
        "Christopher Holsinger, MD. Stanford University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 434,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Po Ling Chan, MD ; Nikita Bedi, BS; Hlu Vang, BS; Anita Rau, phd; Soo Yeon Jung, MD; Tatsuya Furukawa, MD; Lisa M Knowlton, MD, MPH; Jeffrey K. Jopling, MD; Aina Brunet Garcia; Alberto Paderno, PhD; F",
        "Affiliations": "Christopher Holsinger, MD. Stanford University",
        "Background": "Surgical ontologies provide structured, machine-interpretable frameworks that define key anatomical structures, surgical actions, and operative intentions during a procedure. Such structured representation enables consistent description and interpretation of surgical events for workflow analysis and AI-assisted recognition. Open surgery remains a fundamental component of clinical practice, yet unlike robotic and endoscopic procedures, the operative field is not naturally captured by camera. The use of a Cinvivo 4K head-mounted camera enables recording from the surgeon's egocentric perspective, producing high-resolution operative video from open surgical cases. Thyroidectomy was selected as the index procedure given its standardized operative sequence and critical anatomical structures — including the recurrent laryngeal nerve and parathyroid glands — requiring careful identification and preservation. This study presents the first surgical ontology and phase recognition framework for open thyroidectomy.",
        "Methods": "The ontology spanned three domains: anatomical structures (recurrent laryngeal nerve, parathyroid glands, superior laryngeal nerve, Berry's ligament), operative actions (dissection, ligation, retraction, coagulation, nerve stimulation), and procedural intention. Seven phases were defined: (1) Incision and Exposure, (2) Deep Thyroid Access, (3) Vascular Control, (4) Nerve and Parathyroid Preservation, (5) Gland Removal, (6) Nerve Monitoring, and (7) Closure. The ontology was validated through rules-based review of 2,980 operative notes across four surgical services at a single academic medical center from 2000–2025. For video-based phase recognition, five head and neck surgeons annotated temporal events from 44 operative videos, recorded from a “surgeon-eye” view. These were used to develop a few-shot CLIP-based phase classification model using ontology-derived text descriptors without procedure-specific training.",
        "Results": "Phase coverage across 2,980 operative notes ranged from 69–100%: Phase 1 (99.7%), Phase 2 (98.9%), Phase 3 (93.7%), Phase 4 (98.7%), Phase 5 (98.0%), Phase 6 (69.1%), and Phase 7 (99.4%). Lower Phase 6 coverage reflects historical variation in intraoperative nerve monitoring documentation rather than procedural omission, with adoption rising from 10% (2000–2004) to 89% (2020–2024). The framework applied consistently across hemithyroidectomy, total, and completion thyroidectomy. Few-shot CLIP-based phase classification was developed using ontology-derived text descriptors without procedure-specific training; validation is ongoing.",
        "Conclusions": "The development of an open thyroid surgical ontology provides a structured framework for defining anatomical landmarks, operative actions, and workflow phases in thyroidectomy. To our knowledge, this represents one of the first ontology-based frameworks developed specifically for open thyroid surgery using egocentric operative video data. By organizing surgical knowledge in a standardized format, this approach enables phase-based interpretation of operative videos and supports automated recognition of surgical workflow. This work represents an important step toward systematic analysis of open surgical video and future applications in artificial intelligence–assisted surgery, surgical education, and workflow modeling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Using AI to Analyze and Annotate Thyroidectomy using Temporal Phase Recognition:  Developing a Surgical Ontology</span>. <u>Po Ling Chan, MD</u>; Nikita Bedi, BS; Hlu Vang, BS; Anita Rau, phd; Soo Yeon Jung, MD; Tatsuya Furukawa, MD; Lisa M Knowlton, MD, MPH; Jeffrey K. Jopling, MD; Aina Brunet Garcia; Alberto Paderno, PhD; F. Christopher Holsinger, MD. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Surgical ontologies provide structured, machine-interpretable frameworks that define key anatomical structures, surgical actions, and operative intentions during a procedure. Such structured representation enables consistent description and interpretation of surgical events for workflow analysis and AI-assisted recognition. Open surgery remains a fundamental component of clinical practice, yet unlike robotic and endoscopic procedures, the operative field is not naturally captured by camera. The use of a Cinvivo 4K head-mounted camera enables recording from the surgeon's egocentric perspective, producing high-resolution operative video from open surgical cases. Thyroidectomy was selected as the index procedure given its standardized operative sequence and critical anatomical structures — including the recurrent laryngeal nerve and parathyroid glands — requiring careful identification and preservation. This study presents the first surgical ontology and phase recognition framework for open thyroidectomy.</p>\n\n<p><strong>Methods: </strong>The ontology spanned three domains: anatomical structures (recurrent laryngeal nerve, parathyroid glands, superior laryngeal nerve, Berry's ligament), operative actions (dissection, ligation, retraction, coagulation, nerve stimulation), and procedural intention. Seven phases were defined: (1) Incision and Exposure, (2) Deep Thyroid Access, (3) Vascular Control, (4) Nerve and Parathyroid Preservation, (5) Gland Removal, (6) Nerve Monitoring, and (7) Closure. The ontology was validated through rules-based review of 2,980 operative notes across four surgical services at a single academic medical center from 2000–2025. For video-based phase recognition, five head and neck surgeons annotated temporal events from 44 operative videos, recorded from a “surgeon-eye” view. These were used to develop a few-shot CLIP-based phase classification model using ontology-derived text descriptors without procedure-specific training.</p>\n\n<p><strong>Results:</strong> Phase coverage across 2,980 operative notes ranged from 69–100%: Phase 1 (99.7%), Phase 2 (98.9%), Phase 3 (93.7%), Phase 4 (98.7%), Phase 5 (98.0%), Phase 6 (69.1%), and Phase 7 (99.4%). Lower Phase 6 coverage reflects historical variation in intraoperative nerve monitoring documentation rather than procedural omission, with adoption rising from 10% (2000–2004) to 89% (2020–2024). The framework applied consistently across hemithyroidectomy, total, and completion thyroidectomy. Few-shot CLIP-based phase classification was developed using ontology-derived text descriptors without procedure-specific training; validation is ongoing.</p>\n\n<p><strong>Conclusions:</strong> The development of an open thyroid surgical ontology provides a structured framework for defining anatomical landmarks, operative actions, and workflow phases in thyroidectomy. To our knowledge, this represents one of the first ontology-based frameworks developed specifically for open thyroid surgery using egocentric operative video data. By organizing surgical knowledge in a standardized format, this approach enables phase-based interpretation of operative videos and supports automated recognition of surgical workflow. This work represents an important step toward systematic analysis of open surgical video and future applications in artificial intelligence–assisted surgery, surgical education, and workflow modeling.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155601--></body></html>"
    },
    {
      "uid": "P007",
      "content_id": "154333",
      "abstract_number": "P007",
      "poster_number": "P007",
      "title": "Staging the Stagers: How Otolaryngologists and Large Language Models Classify the Same Head and Neck Cancers",
      "summary": "In this interim analysis of ten real pre-operative head and neck cancer cases, we observed substantial variability in TNM and AJCC staging across otolaryngologists and LLMs. Several non-RAG frontier models demonstrated high stage-group concordance with an attending reference, while others showed frequent upstaging or broader dispersion of TNM components. N-category assignment accounted for most disagreement,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154333",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sholem Hack, MBBS",
      "presenter": "Sholem Hack, MBBS",
      "authors": "Sholem Hack, MBBS 1 ; Ron J Karni, MD 2",
      "normalized_authors": [
        "Sholem Hack, MBBS",
        "Ron J Karni"
      ],
      "affiliations": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA"
      ],
      "normalized_institutions": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 486,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sholem Hack, MBBS 1 ; Ron J Karni, MD 2",
        "Affiliations": "1 City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; 2 Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA",
        "Background": "Large language models (LLMs) are increasingly explored for oncologic decision support, yet their consistency in applying TNM classification and AJCC 8th edition staging to real-world head and neck cancer presentations is unclear. Because initial clinic evaluations rely on limited biopsy and imaging data, and no pathologic gold standard exists at this stage, staging is intrinsically rater-dependent. This abstract presents partial results from an ongoing multirater agreement study comparing staging across otolaryngologists and multiple LLM configurations.",
        "Methods": "Ten consecutive new patients from a single academic head and neck oncology practice were assembled into standardized vignettes containing clinic notes, cross-sectional imaging, and biopsy or FNA pathology. Two attending otolaryngologists and twelve LLMs (GPT-4 and GPT-5.1 with and without retrieval-augmented generation [RAG], Gemini with and without RAG, Claude, DeepSeek, Grok, Mistral, Copilot, and Perplexity) independently assigned T, N, and M categories and AJCC 8th edition stage groups using only pre-operative information. The senior attending served as a reference rater. Indeterminate outputs were treated as missing. Exact stage-group agreement and Cohen’s κ were calculated for each rater relative to the reference attending, and TNM disagreement patterns were quantified across all 14 raters.",
        "Results": "Across the ten cases, stage-group agreement with the reference attending ranged from 3/10 to 9/10 cases, corresponding to Cohen’s κ values of 0.20 to 0.86 (fair to almost perfect agreement). Highest concordance was observed for non-RAG GPT-5.1, non-RAG GPT-4, and Copilot (each 9/10 cases; κ=0.86). Intermediate agreement was seen with RAG-enabled GPT and Gemini configurations (6–7/10; κ=0.51–0.56), whereas Claude (3/10; κ=0.20) and DeepSeek (4/10; κ=0.28) showed the lowest concordance, largely due to systematic upstaging.",
        "Abstract": "Component-level analysis demonstrated that N-category disagreement was the dominant source of variation, with a median of 2 distinct N categories per case (range 1–4) and broadest dispersion in Case 6 (four different N assignments across raters). T-category variability was less pronounced but present, with a median of 2.5 distinct T values per case (range 1–6), particularly in cases involving post-radiation laryngeal changes or equivocal bone/cartilage involvement. M-category classification was highly consistent, with 9 of 10 cases showing a single unanimous M assignment. Stage-group heterogeneity reflected these patterns, with individual cases receiving 2 to 5 distinct stage groups across raters despite identical source information.",
        "Conclusions": "In this interim analysis of ten real pre-operative head and neck cancer cases, we observed substantial variability in TNM and AJCC staging across otolaryngologists and LLMs. Several non-RAG frontier models demonstrated high stage-group concordance with an attending reference, while others showed frequent upstaging or broader dispersion of TNM components. N-category assignment accounted for most disagreement, whereas M-category assignment was nearly uniform. These preliminary findings will be expanded with additional cases and multi-rater statistical analyses in the completed study, including integration of pathologic and outcome-based endpoints to more fully assess the clinical reliability of LLM-assisted staging."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Staging the Stagers: How Otolaryngologists and Large Language Models Classify the Same Head and Neck Cancers</span>. <u>Sholem Hack, MBBS</u><sup>1</sup>; Ron J Karni, MD<sup>2</sup>. <sup>1</sup>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Large language models (LLMs) are increasingly explored for oncologic decision support, yet their consistency in applying TNM classification and AJCC 8th edition staging to real-world head and neck cancer presentations is unclear. Because initial clinic evaluations rely on limited biopsy and imaging data, and no pathologic gold standard exists at this stage, staging is intrinsically rater-dependent. This abstract presents partial results from an ongoing multirater agreement study comparing staging across otolaryngologists and multiple LLM configurations.</p>\n\n<p><strong>Methods:</strong> Ten consecutive new patients from a single academic head and neck oncology practice were assembled into standardized vignettes containing clinic notes, cross-sectional imaging, and biopsy or FNA pathology. Two attending otolaryngologists and twelve LLMs (GPT-4 and GPT-5.1 with and without retrieval-augmented generation [RAG], Gemini with and without RAG, Claude, DeepSeek, Grok, Mistral, Copilot, and Perplexity) independently assigned T, N, and M categories and AJCC 8th edition stage groups using only pre-operative information. The senior attending served as a reference rater. Indeterminate outputs were treated as missing. Exact stage-group agreement and Cohen’s κ were calculated for each rater relative to the reference attending, and TNM disagreement patterns were quantified across all 14 raters.</p>\n\n<p><strong>Results: </strong>Across the ten cases, stage-group agreement with the reference attending ranged from 3/10 to 9/10 cases, corresponding to Cohen’s κ values of 0.20 to 0.86 (fair to almost perfect agreement). Highest concordance was observed for non-RAG GPT-5.1, non-RAG GPT-4, and Copilot (each 9/10 cases; κ=0.86). Intermediate agreement was seen with RAG-enabled GPT and Gemini configurations (6–7/10; κ=0.51–0.56), whereas Claude (3/10; κ=0.20) and DeepSeek (4/10; κ=0.28) showed the lowest concordance, largely due to systematic upstaging.</p>\n\n<p>Component-level analysis demonstrated that N-category disagreement was the dominant source of variation, with a median of 2 distinct N categories per case (range 1–4) and broadest dispersion in Case 6 (four different N assignments across raters). T-category variability was less pronounced but present, with a median of 2.5 distinct T values per case (range 1–6), particularly in cases involving post-radiation laryngeal changes or equivocal bone/cartilage involvement. M-category classification was highly consistent, with 9 of 10 cases showing a single unanimous M assignment. Stage-group heterogeneity reflected these patterns, with individual cases receiving 2 to 5 distinct stage groups across raters despite identical source information.</p>\n\n<p><strong>Conclusions:</strong> In this interim analysis of ten real pre-operative head and neck cancer cases, we observed substantial variability in TNM and AJCC staging across otolaryngologists and LLMs. Several non-RAG frontier models demonstrated high stage-group concordance with an attending reference, while others showed frequent upstaging or broader dispersion of TNM components. N-category assignment accounted for most disagreement, whereas M-category assignment was nearly uniform. These preliminary findings will be expanded with additional cases and multi-rater statistical analyses in the completed study, including integration of pathologic and outcome-based endpoints to more fully assess the clinical reliability of LLM-assisted staging.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154333--></body></html>"
    },
    {
      "uid": "P008",
      "content_id": "154098",
      "abstract_number": "P008",
      "poster_number": "P008",
      "title": "Otolaryngology Image and Video Datasets in Machine Learning: A Review of Resources, Strengths, and Limitations",
      "summary": "ML in ENT shows potential in education, diagnostics and surgical guidance, but is constrained by fragmented dataset quality and reporting practices. Standard guidelines emphasizing demographic reporting, annotation transparency, acquisition metadata, external validation, and open-source collaboration are essential prior to clinical implementation.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154098",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonah Gonzalez",
      "presenter": "Jonah Gonzalez",
      "authors": "Anjul M Bansal 1 ; Jeffery Li 1 ; Jonah Gonzalez 2 ; Anand Devaiah, MD 3",
      "normalized_authors": [
        "Anjul M Bansal",
        "Jeffery Li",
        "Jonah Gonzalez",
        "Anand Devaiah"
      ],
      "affiliations": [
        "Carle Illinois College of Medicine",
        "University of Arizona",
        "Boston Medical Center"
      ],
      "normalized_institutions": [
        "Carle Illinois College of Medicine",
        "University of Arizona",
        "Boston Medical Center"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 260,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Anjul M Bansal 1 ; Jeffery Li 1 ; Jonah Gonzalez 2 ; Anand Devaiah, MD 3",
        "Affiliations": "1 Carle Illinois College of Medicine; 2 University of Arizona; 3 Boston Medical Center",
        "Introduction": "Utilization of Machine Learning (ML) is increasingly common in otolaryngology (ENT), necessitated by the volume of sourced endoscopic, intraoperative, and radiologic imaging through ever increasing patient burden. While early studies demonstrate high diagnostic accuracy across classification, segmentation, and video-based tasks in the fields of anatomical and pathological detection, progress toward clinical translation remains limited by inconsistent dataset design, quality, and cost.",
        "Objective": "To identify and characterize existing publicly accessible ENT datasets, evaluate their strengths and limitations, and propose guidelines for future dataset development.",
        "Methods": "A structured review of publications from 2015–2025 was performed to identify ENT imaging datasets used in ML, netting ten unique open access datasets. For each dataset, we extracted imaging modality, dataset size, annotation type, access status, model architecture, validation methods, reporting quality, and stated limitations. Findings were mapped by dataset characteristics to appropriate ML project types, and limitations acknowledged.",
        "Results": "Most datasets (n=10) were openly accessible and comprised endoscopic still images (n=6) or intraoperative videos (n=3). Dataset size ranged from 300 to 59,240 images. Five datasets included semi-automated segmentations, while others contained raw, unannotated frames. CNN-based models (ResNet, VGGNet, and DenseNet) were the dominant architectures and achieved strong internal performance, with accuracy exceeding 95% in several classification tasks. However, external validation was rare, demographic data were inconsistently reported, and annotation standards were inconsistent.",
        "Conclusion": "ML in ENT shows potential in education, diagnostics and surgical guidance, but is constrained by fragmented dataset quality and reporting practices. Standard guidelines emphasizing demographic reporting, annotation transparency, acquisition metadata, external validation, and open-source collaboration are essential prior to clinical implementation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Otolaryngology Image and Video Datasets in Machine Learning: A Review of Resources, Strengths, and Limitations</span>. Anjul M Bansal<sup>1</sup>; Jeffery Li<sup>1</sup>; <u>Jonah Gonzalez</u><sup>2</sup>; Anand Devaiah, MD<sup>3</sup>. <sup>1</sup>Carle Illinois College of Medicine; <sup>2</sup>University of Arizona; <sup>3</sup>Boston Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Utilization of Machine Learning (ML) is increasingly common in otolaryngology (ENT), necessitated by the volume of sourced endoscopic, intraoperative, and radiologic imaging through ever increasing patient burden. While early studies demonstrate high diagnostic accuracy across classification, segmentation, and video-based tasks in the fields of anatomical and pathological detection, progress toward clinical translation remains limited by inconsistent dataset design, quality, and cost.</p>\n\n<p><strong>Objective: </strong>To identify and characterize existing publicly accessible ENT datasets, evaluate their strengths and limitations, and propose guidelines for future dataset development.</p>\n\n<p><strong>Methods: </strong>A structured review of publications from 2015–2025 was performed to identify ENT imaging datasets used in ML, netting ten unique open access datasets. For each dataset, we extracted imaging modality, dataset size, annotation type, access status, model architecture, validation methods, reporting quality, and stated limitations. Findings were mapped by dataset characteristics to appropriate ML project types, and limitations acknowledged.</p>\n\n<p><strong>Results: </strong>Most datasets (n=10) were openly accessible and comprised endoscopic still images (n=6) or intraoperative videos (n=3). Dataset size ranged from 300 to 59,240 images. Five datasets included semi-automated segmentations, while others contained raw, unannotated frames. CNN-based models (ResNet, VGGNet, and DenseNet) were the dominant architectures and achieved strong internal performance, with accuracy exceeding 95% in several classification tasks. However, external validation was rare, demographic data were inconsistently reported, and annotation standards were inconsistent.</p>\n\n<p><strong>Conclusion: </strong>ML in ENT shows potential in education, diagnostics and surgical guidance, but is constrained by fragmented dataset quality and reporting practices. Standard guidelines emphasizing demographic reporting, annotation transparency, acquisition metadata, external validation, and open-source collaboration are essential prior to clinical implementation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154098--></body></html>"
    },
    {
      "uid": "P009",
      "content_id": "155602",
      "abstract_number": "P009",
      "poster_number": "P009",
      "title": "Development of an AI Surgical Ontology for Robotic Thyroidectomy: Comparing Open to Robotic Approaches",
      "summary": "A surgical ontology for robotic thyroid surgery via the retroauricular approach enables systematic cross-platform comparison and alignment with open thyroidectomy, revealing conserved operative logic alongside approach-specific adaptations. This framework supports AI development, standardized training, and outcomes research by linking operative workflow to clinical results. It is anticipated that this study will...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155602",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Young Kyun Hur, MD",
      "presenter": "Young Kyun Hur, MD",
      "authors": "Young Kyun Hur, MD 1 ; Boin Choi, MD 1 ; Po Ling Chan, MD 2 ; Dahee Kim, MD 1 ; Yoon Woo Koh, MD 1 ; Nikita Bedi, BS 2 ; F",
      "normalized_authors": [
        "Young Kyun Hur",
        "Boin Choi",
        "Po Ling Chan",
        "Dahee Kim",
        "Yoon Woo Koh",
        "Nikita Bedi"
      ],
      "affiliations": [
        "Christopher Holsinger, MD 2 . 1 Yonsei University",
        "Stanford University"
      ],
      "normalized_institutions": [
        "Christopher Holsinger, MD 2 . 1 Yonsei University",
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 426,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Young Kyun Hur, MD 1 ; Boin Choi, MD 1 ; Po Ling Chan, MD 2 ; Dahee Kim, MD 1 ; Yoon Woo Koh, MD 1 ; Nikita Bedi, BS 2 ; F",
        "Affiliations": "Christopher Holsinger, MD 2 . 1 Yonsei University; 2 Stanford University",
        "Background": "Robotic thyroidectomy encompasses diverse approaches—including transaxillary, retroauricular, and transoral—each eliminating direct transcervical incisions while differing significantly in anatomical trajectory, instrument dynamics, and operative sequences. These variations are not merely technical; the anatomical perspective and the order of identifying critical structures diverge enough that a single framework cannot encompass all techniques. Although a validated ontology for open thyroidectomy was previously established, robotic-assisted surgery introduces unique access-phase complexities and altered spatial relationships that require dedicated ontological modeling. This study presents a modular robotic thyroidectomy ontology that extends the existing open framework to the retroauricular approach, characterizing both shared operative logic and approach-specific adaptations.",
        "Methods": "Building on the established open thyroidectomy ontology, a structured comparative analysis of operative phases and instrument-action pairs was performed for retroauricular robotic thyroidectomy using the da Vinci surgical system (Intuitive Surgical). Despite the distinct surgical approach, most anatomical structures and surgical actions are shared with open procedures; thus, the standardized vocabularies from the previous thyroid ontology were adapted. Using this framework, a phase-based interpretation algorithm was developed to recognize surgical phases from operative videos. Five head and neck surgeons experienced in robotic surgery annotated temporal events in 45 videos, which were then used to create a training dataset for phase-based categorization. Critical procedural phases—including strap muscle identification, vascular control, recurrent laryngeal nerve (RLN) identification, and gland removal—were mapped against the open ontology to identify conserved logic and platform-specific adaptations.",
        "Results": "The retroauricular approach required unique access-phase modules absent in open thyroidectomy. Despite different anatomical entry points, core procedural phases showed strong homology: vascular control, RLN identification, parathyroid preservation, and gland removal followed equivalent logical sequences. Compared to open surgery, the robotic platform offered distinct advantages for video-based AI analysis: 1) high-definition, stabilized endoscopic imaging facilitated clearer identification of anatomy and surgical actions; 2) a standardized, limited instrument set streamlined instrument recognition; and 3) the recording integrated within the robotic system ensured consistent, high-fidelity data. Furthermore, the availability of robotic kinematic data may act as a critical factor for the future development of \"physical AI\" in surgery. This mapping process ultimately enabled the identification of a unified cross-platform schema for surgical phase recognition.",
        "Conclusions": "A surgical ontology for robotic thyroid surgery via the retroauricular approach enables systematic cross-platform comparison and alignment with open thyroidectomy, revealing conserved operative logic alongside approach-specific adaptations. This framework supports AI development, standardized training, and outcomes research by linking operative workflow to clinical results. It is anticipated that this study will serve as a foundation for comparing and aligning various robotic and endoscopic approaches, such as transoral or transaxillary techniques."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development of an AI Surgical Ontology for Robotic Thyroidectomy: Comparing Open to Robotic Approaches</span>. <u>Young Kyun Hur, MD</u><sup>1</sup>; Boin Choi, MD<sup>1</sup>; Po Ling Chan, MD<sup>2</sup>; Dahee Kim, MD<sup>1</sup>; Yoon Woo Koh, MD<sup>1</sup>; Nikita Bedi, BS<sup>2</sup>; F. Christopher Holsinger, MD<sup>2</sup>. <sup>1</sup>Yonsei University; <sup>2</sup>Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Robotic thyroidectomy encompasses diverse approaches—including transaxillary, retroauricular, and transoral—each eliminating direct transcervical incisions while differing significantly in anatomical trajectory, instrument dynamics, and operative sequences. These variations are not merely technical; the anatomical perspective and the order of identifying critical structures diverge enough that a single framework cannot encompass all techniques. Although a validated ontology for open thyroidectomy was previously established, robotic-assisted surgery introduces unique access-phase complexities and altered spatial relationships that require dedicated ontological modeling. This study presents a modular robotic thyroidectomy ontology that extends the existing open framework to the retroauricular approach, characterizing both shared operative logic and approach-specific adaptations.</p>\n\n<p><strong>Methods: </strong>Building on the established open thyroidectomy ontology, a structured comparative analysis of operative phases and instrument-action pairs was performed for retroauricular robotic thyroidectomy using the da Vinci surgical system (Intuitive Surgical). Despite the distinct surgical approach, most anatomical structures and surgical actions are shared with open procedures; thus, the standardized vocabularies from the previous thyroid ontology were adapted. Using this framework, a phase-based interpretation algorithm was developed to recognize surgical phases from operative videos. Five head and neck surgeons experienced in robotic surgery annotated temporal events in 45 videos, which were then used to create a training dataset for phase-based categorization. Critical procedural phases—including strap muscle identification, vascular control, recurrent laryngeal nerve (RLN) identification, and gland removal—were mapped against the open ontology to identify conserved logic and platform-specific adaptations.</p>\n\n<p><strong>Results: </strong>The retroauricular approach required unique access-phase modules absent in open thyroidectomy. Despite different anatomical entry points, core procedural phases showed strong homology: vascular control, RLN identification, parathyroid preservation, and gland removal followed equivalent logical sequences. Compared to open surgery, the robotic platform offered distinct advantages for video-based AI analysis: 1) high-definition, stabilized endoscopic imaging facilitated clearer identification of anatomy and surgical actions; 2) a standardized, limited instrument set streamlined instrument recognition; and 3) the recording integrated within the robotic system ensured consistent, high-fidelity data. Furthermore, the availability of robotic kinematic data may act as a critical factor for the future development of \"physical AI\" in surgery. This mapping process ultimately enabled the identification of a unified cross-platform schema for surgical phase recognition.</p>\n\n<p><strong>Conclusions: </strong>A surgical ontology for robotic thyroid surgery via the retroauricular approach enables systematic cross-platform comparison and alignment with open thyroidectomy, revealing conserved operative logic alongside approach-specific adaptations. This framework supports AI development, standardized training, and outcomes research by linking operative workflow to clinical results. It is anticipated that this study will serve as a foundation for comparing and aligning various robotic and endoscopic approaches, such as transoral or transaxillary techniques.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155602--></body></html>"
    },
    {
      "uid": "P010",
      "content_id": "153303",
      "abstract_number": "P010",
      "poster_number": "P010",
      "title": "A Novel Vision Transformer-based Deep Learning Model Distinguishing Pleomorphic Adenomas from MRI",
      "summary": "This is the first Vision Transformer-based deep learning model for distinguishing PA from other salivary gland tumors utilizing only MRI images. The use of additional symmetry and ring-enhanced image channels, designed to highlight unilateral abnormalities and tumor margins within the model input, enhanced classification performance. Although further research is necessary for refining model architecture and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153303",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yeo Eun Kim, MD",
      "presenter": "Yeo Eun Kim, MD",
      "authors": "Yeo Eun Kim, MD 1 ; Sanjana Kaza, MS 2 ; Sara B Strauss, MD 3 ; David I Kutler, MD 2",
      "normalized_authors": [
        "Yeo Eun Kim",
        "Sanjana Kaza",
        "Sara B Strauss",
        "David I Kutler"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head & Neck Surgery, Houston Methodist Hospital",
        "Department of Otolaryngology - Head & Neck Surgery, Weill Cornell Medicine",
        "Department of Radiology, Weill Cornell Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head & Neck Surgery, Houston Methodist Hospital",
        "Department of Otolaryngology - Head & Neck Surgery, Weill Cornell Medicine",
        "Department of Radiology, Weill Cornell Medicine"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 377,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Yeo Eun Kim, MD 1 ; Sanjana Kaza, MS 2 ; Sara B Strauss, MD 3 ; David I Kutler, MD 2",
        "Affiliations": "1 Department of Otolaryngology - Head & Neck Surgery, Houston Methodist Hospital; 2 Department of Otolaryngology - Head & Neck Surgery, Weill Cornell Medicine; 3 Department of Radiology, Weill Cornell Medicine",
        "Introduction": "Currently, diagnosis of pleomorphic adenoma (PA) involves sequential examination, imaging, and biopsy. MRI-based deep learning (DL) models have emerged as a potential one-stop diagnostic solution that could help avoid added procedural costs and decrease time-to-treatment. However, these models mostly rely on traditional convolutional neural networks (CNNs) and report widely variable accuracy, underscoring their inconsistency and limited reliability. Compared to CNNs, which focus on local features and inherently underperform in capturing long-range dependencies, Vision Transformers (ViTs) utilize self-attention mechanisms to extract the global context of an image. Here, we use a ViT-based DL model for distinguishing PA from other benign and malignant salivary gland tumors.",
        "Methods": "Adult patients who underwent parotidectomy for unilateral parotid gland neoplasm were retrospectively identified. Clinicodemographic data and MRI were collected. A ViT-based model was trained using T1- and T2-weighted MRI as input. In addition, two derived image channels were created: (1) a symmetry channel highlighting left and right differences between parotid glands to emphasize unilateral abnormalities, and (2) a ring channel emphasizing tumor margins and rim patterns. These multi-channel images were used to classify PA vs non-PA at the patient level. Student’s t-test and Fisher’s exact testing were used to compare the cohorts’ clinicodemographic profile.",
        "Results": "A total of 103 patients were included (mean age: 57±16 years; 61 (59%) female). Forty-eight patients (47%) had histopathologically confirmed PA (mean age: 50±14 years; 28 (58%) female). Of the non-PA cohort, 24 patients (44%) had benign tumors. Although there was no significant difference in sex (33 female (59%); p=0.9340), there was a significant difference in age (63±14 years; p<0.0001) when compared to the PA cohort.",
        "Abstract": "On the held-out test set, the model achieved an F1-score of 80%, AUROC of 73%, and a precision of 66% at identifying PA at the patient level.",
        "Conclusions": "This is the first Vision Transformer-based deep learning model for distinguishing PA from other salivary gland tumors utilizing only MRI images. The use of additional symmetry and ring-enhanced image channels, designed to highlight unilateral abnormalities and tumor margins within the model input, enhanced classification performance. Although further research is necessary for refining model architecture and training strategy, the current study shows potential for accurate, non-invasive MRI-based identification of pleomorphic adenoma in patients with unilateral parotid gland tumor."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Novel Vision Transformer-based Deep Learning Model Distinguishing Pleomorphic Adenomas from MRI</span>. <u>Yeo Eun Kim, MD</u><sup>1</sup>; Sanjana Kaza, MS<sup>2</sup>; Sara B Strauss, MD<sup>3</sup>; David I Kutler, MD<sup>2</sup>. <sup>1</sup>Department of Otolaryngology - Head & Neck Surgery, Houston Methodist Hospital; <sup>2</sup>Department of Otolaryngology - Head & Neck Surgery, Weill Cornell Medicine; <sup>3</sup>Department of Radiology, Weill Cornell Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Currently, diagnosis of pleomorphic adenoma (PA) involves sequential examination, imaging, and biopsy. MRI-based deep learning (DL) models have emerged as a potential one-stop diagnostic solution that could help avoid added procedural costs and decrease time-to-treatment. However, these models mostly rely on traditional convolutional neural networks (CNNs) and report widely variable accuracy, underscoring their inconsistency and limited reliability. Compared to CNNs, which focus on local features and inherently underperform in capturing long-range dependencies, Vision Transformers (ViTs) utilize self-attention mechanisms to extract the global context of an image. Here, we use a ViT-based DL model for distinguishing PA from other benign and malignant salivary gland tumors.</p>\n\n<p><strong>Methods: </strong>Adult patients who underwent parotidectomy for unilateral parotid gland neoplasm were retrospectively identified. Clinicodemographic data and MRI were collected. A ViT-based model was trained using T1- and T2-weighted MRI as input. In addition, two derived image channels were created: (1) a symmetry channel highlighting left and right differences between parotid glands to emphasize unilateral abnormalities, and (2) a ring channel emphasizing tumor margins and rim patterns. These multi-channel images were used to classify PA vs non-PA at the patient level. Student’s t-test and Fisher’s exact testing were used to compare the cohorts’ clinicodemographic profile.</p>\n\n<p><strong>Results: </strong>A total of 103 patients were included (mean age: 57±16 years; 61 (59%) female). Forty-eight patients (47%) had histopathologically confirmed PA (mean age: 50±14 years; 28 (58%) female). Of the non-PA cohort, 24 patients (44%) had benign tumors. Although there was no significant difference in sex (33 female (59%); p=0.9340), there was a significant difference in age (63±14 years; p<0.0001) when compared to the PA cohort.</p>\n\n<p>On the held-out test set, the model achieved an F1-score of 80%, AUROC of 73%, and a precision of 66% at identifying PA at the patient level.</p>\n\n<p><strong>Conclusions: </strong>This is the first Vision Transformer-based deep learning model for distinguishing PA from other salivary gland tumors utilizing only MRI images. The use of additional symmetry and ring-enhanced image channels, designed to highlight unilateral abnormalities and tumor margins within the model input, enhanced classification performance. Although further research is necessary for refining model architecture and training strategy, the current study shows potential for accurate, non-invasive MRI-based identification of pleomorphic adenoma in patients with unilateral parotid gland tumor.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153303--></body></html>"
    },
    {
      "uid": "P011",
      "content_id": "154620",
      "abstract_number": "P011",
      "poster_number": "P011",
      "title": "A Machine Learning Model to Predict Prolonged Time to Postoperative Radiation in Head and Neck Cancer",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) remains one of the most prevalent cancers worldwide, with outcomes strongly influenced by timing of treatment. An increasing body of evidence suggests that time to postoperative radiation (TPR), the interval from surgery to completing postoperative radiation, is associated with lower survival and higher recurrence rates. Though established guidelines recommend...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154620",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caroline Bonaventure, MD",
      "presenter": "Caroline Bonaventure, MD",
      "authors": "Caroline Bonaventure, MD 1 ; Adam Bess, PhD 1 ; Michael Simons 1 ; Lark Smith 1 ; Ethan Leoni 1 ; Supratik Mukhopadhyay, PhD 1 ; Christopher Yao, MD 2 ; Sagar Kansara, MD 1",
      "normalized_authors": [
        "Caroline Bonaventure",
        "Adam Bess",
        "Michael Simons",
        "Lark Smith",
        "Ethan Leoni",
        "Supratik Mukhopadhyay",
        "Christopher Yao",
        "Sagar Kansara"
      ],
      "affiliations": [
        "Louisiana State University Health Sciences Center - New Orleans",
        "University of Toronto"
      ],
      "normalized_institutions": [
        "Louisiana State University Health Sciences Center - New Orleans",
        "University of Toronto"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Caroline Bonaventure, MD 1 ; Adam Bess, PhD 1 ; Michael Simons 1 ; Lark Smith 1 ; Ethan Leoni 1 ; Supratik Mukhopadhyay, PhD 1 ; Christopher Yao, MD 2 ; Sagar Kansara, MD 1",
        "Affiliations": "1 Louisiana State University Health Sciences Center - New Orleans; 2 University of Toronto",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) remains one of the most prevalent cancers worldwide, with outcomes strongly influenced by timing of treatment. An increasing body of evidence suggests that time to postoperative radiation (TPR), the interval from surgery to completing postoperative radiation, is associated with lower survival and higher recurrence rates. Though established guidelines recommend initiation of adjuvant radiation within six weeks of definitive surgery, variation exists across patient populations. Disparities have been linked to socioeconomic status, medical comorbidities, and access to care in prior studies using traditional statistical methods. To our knowledge, this study is among the first to apply an exploratory multivariable machine learning and clustering framework to characterize predictors of prolonged TPR and associated disease-free survival. A retrospective chart review was conducted of patients with head and neck cancer treated surgically with postoperative radiation between 2022 and 2025 at a single institution. Variables included demographic data, tumor characteristics, treatment intervals, comorbidities (including Charlson Comorbidity Index), and clinical outcomes. Time from surgery to the start and completion of adjuvant radiation was quantified. Binary endpoints were defined for prolonged TPR and disease-free survival. Multivariable machine learning models using logistic regression with cross-validation were developed to predict prolonged TPR and disease-free survival. Unsupervised clustering with HDBSCAN (hierarchical density based spatial clustering of applications with noise) was used to identify patient subgroups with similar delay patterns and outcome profiles. These analyses were selected to identify individual associations, evaluate multivariable patterns, and determine whether subgroup patterns may influence treatment delays and clinical outcomes. 151 patients were included. Average age was 64 years. 84.1% were male. 20.1% had Medicaid insurance. 89.4% had pathology squamous cell carcinoma. 71% of patients started adjuvant radiation within 42 days of surgery, with an average TPR of 42.6 days and a median TPR of 40 days. The model predicting prolonged TPR achieved a ROC-AUC of 0.54 with accuracy of 0.58, indicating limited predictive signal from baseline variables. The disease-free survival model performed better, with a ROC-AUC of 0.74 and accuracy of 0.74. Cluster analysis, based on baseline clinical characteristics, revealed distinct patient groups with differing treatment intervals and outcomes. Four clusters had short treatment package times with disease-free survival rates ranging from 57% to 92%. Three clusters showed substantially prolonged treatment package times, with mean delays ranging from 54 to 69 days and wide variability, including some very long delays. One cluster had a favorable disease-free survival rate (80%) despite long delays but included a high proportion of patients with unknown outcome status (20%). Two clusters exhibited more concerning outcomes, including both disease-related and non–disease-related mortality, suggesting these groups might represent patients with more complex clinical profiles or poorer prognoses, potentially exacerbated by longer treatment delays. This study demonstrates the use of an exploratory multivariable machine learning and clustering framework to characterize predictors of prolonged TPR and disease-free survival. The findings reveal preliminary patterns in both treatment delays and patient outcomes, identifying key variables and patient subgroups that warrant further evaluation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Machine Learning Model to Predict Prolonged Time to Postoperative Radiation in Head and Neck Cancer</span>. <u>Caroline Bonaventure, MD</u><sup>1</sup>; Adam Bess, PhD<sup>1</sup>; Michael Simons<sup>1</sup>; Lark Smith<sup>1</sup>; Ethan Leoni<sup>1</sup>; Supratik Mukhopadhyay, PhD<sup>1</sup>; Christopher Yao, MD<sup>2</sup>; Sagar Kansara, MD<sup>1</sup>. <sup>1</sup>Louisiana State University Health Sciences Center - New Orleans; <sup>2</sup>University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) remains one of the most prevalent cancers worldwide, with outcomes strongly influenced by timing of treatment. An increasing body of evidence suggests that time to postoperative radiation (TPR), the interval from surgery to completing postoperative radiation, is associated with lower survival and higher recurrence rates. Though established guidelines recommend initiation of adjuvant radiation within six weeks of definitive surgery, variation exists across patient populations. Disparities have been linked to socioeconomic status, medical comorbidities, and access to care in prior studies using traditional statistical methods. To our knowledge, this study is among the first to apply an exploratory multivariable machine learning and clustering framework to characterize predictors of prolonged TPR and associated disease-free survival.</p>\n\n<p>A retrospective chart review was conducted of patients with head and neck cancer treated surgically with postoperative radiation between 2022 and 2025 at a single institution. Variables included demographic data, tumor characteristics, treatment intervals, comorbidities (including Charlson Comorbidity Index), and clinical outcomes. Time from surgery to the start and completion of adjuvant radiation was quantified. Binary endpoints were defined for prolonged TPR and disease-free survival. Multivariable machine learning models using logistic regression with cross-validation were developed to predict prolonged TPR and disease-free survival. Unsupervised clustering with HDBSCAN (hierarchical density based spatial clustering of applications with noise) was used to identify patient subgroups with similar delay patterns and outcome profiles. These analyses were selected to identify individual associations, evaluate multivariable patterns, and determine whether subgroup patterns may influence treatment delays and clinical outcomes.</p>\n\n<p>151 patients were included. Average age was 64 years. 84.1% were male. 20.1% had Medicaid insurance. 89.4% had pathology squamous cell carcinoma. 71% of patients started adjuvant radiation within 42 days of surgery, with an average TPR of 42.6 days and a median TPR of 40 days. The model predicting prolonged TPR achieved a ROC-AUC of 0.54 with accuracy of 0.58, indicating limited predictive signal from baseline variables. The disease-free survival model performed better, with a ROC-AUC of 0.74 and accuracy of 0.74. Cluster analysis, based on baseline clinical characteristics, revealed distinct patient groups with differing treatment intervals and outcomes. Four clusters had short treatment package times with disease-free survival rates ranging from 57% to 92%. Three clusters showed substantially prolonged treatment package times, with mean delays ranging from 54 to 69 days and wide variability, including some very long delays. One cluster had a favorable disease-free survival rate (80%) despite long delays but included a high proportion of patients with unknown outcome status (20%). Two clusters exhibited more concerning outcomes, including both disease-related and non–disease-related mortality, suggesting these groups might represent patients with more complex clinical profiles or poorer prognoses, potentially exacerbated by longer treatment delays.</p>\n\n<p>This study demonstrates the use of an exploratory multivariable machine learning and clustering framework to characterize predictors of prolonged TPR and disease-free survival. The findings reveal preliminary patterns in both treatment delays and patient outcomes, identifying key variables and patient subgroups that warrant further evaluation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154620--></body></html>"
    },
    {
      "uid": "P013",
      "content_id": "152028",
      "abstract_number": "P013",
      "poster_number": "P013",
      "title": "Artificial Intelligence in Head and Neck Oncology: A Scoping Review of Clinician-Facing Applications and the Patient-Facing Gap",
      "summary": "Current AI/ML within otolaryngology concentrates on clinician-facing tasks with promising technical performance but minimal patient involvement. We found no evaluated, patient-facing AI tools. Future work should co-design and prospectively test patient-delivered interventions (interactive explainers of diagnosis and treatment tradeoffs, values-clarification modules aligned to tumor board options, and consent aids...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152028",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Phil Tseng",
      "presenter": "Phil Tseng",
      "authors": "Phil Tseng 1 ; Noah Weaver, BS 1 ; Nikhil C Mathur, BS 1 ; Helena T Yip, MD 2 ; Steven J Wang, MD 2",
      "normalized_authors": [
        "Phil Tseng",
        "Noah Weaver",
        "Nikhil C Mathur",
        "Helena T Yip",
        "Steven J Wang"
      ],
      "affiliations": [
        "University of Arizona College of Medicine - Tucson",
        "University of Arizona, College of Medicine – Tucson, Department of Otolaryngology – Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine - Tucson",
        "University of Arizona, College of Medicine – Tucson, Department of Otolaryngology – Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 418,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Phil Tseng 1 ; Noah Weaver, BS 1 ; Nikhil C Mathur, BS 1 ; Helena T Yip, MD 2 ; Steven J Wang, MD 2",
        "Affiliations": "1 University of Arizona College of Medicine - Tucson; 2 University of Arizona, College of Medicine – Tucson, Department of Otolaryngology – Head and Neck Surgery",
        "Objective": "To provide a review summarizing the current applications, patient perceptions, and clinical utility of machine learning–based (ML) and artificial intelligence (AI) decision support tools utilized in medicine and its potential applications in head and neck cancer care within otolaryngology.",
        "Methods": "A scoping literature review was conducted using PubMed with the following search strategy: (“otolaryngology” OR “head and neck”) AND (“artificial intelligence” OR “machine learning” OR “deep learning”), supplemented by targeted terms (“pediatric otolaryngology,” “radiomics,” “decision support,” “patient education,” “informed consent”). Titles and abstracts were screened for relevance. English-language clinical studies and validation studies with real-world or simulated clinical endpoints were included. Technical algorithm papers without clinical context and studies focused solely on clinician performance without patient-related outcomes were excluded.",
        "Results": "The literature review identified one hundred and eight-seven. Sixty-three underwent full text review after removal of duplicates and initial abstract review for relevance, and fifty-three were included in the final review. Identified AI/ML applications in medicine were overwhelmingly clinician-facing. Major use cases included imaging segmentation and treatment-target delineation for radiotherapy, including large language model–aided multimodal auto-delineation; plan evaluation and automated or mimicked planning workflows to improve quality and spare organs at risk; predictive modeling of toxicity (for example, xerostomia) and treatment response (for example, peritumoral CT radiomics in nasopharyngeal carcinoma); peri-treatment monitoring such as thermal imaging to anticipate radiation dermatitis; decision-support systems for complex therapy selection; and comparisons of LLM-generated recommendations with multidisciplinary tumor board decisions in primary laryngeal cancer, suggesting potential adjunctive use. Web-based prognostic tools were reported for select salivary malignancies, primarily to assist clinicians in risk communication. Across studies, internal performance metrics were frequently strong and, in some cases, externally validated. Several tools even showed concordance with expert selections or improved planning efficiency. However, outcomes that matter directly to patients, including comprehension, decisional conflict, acceptability, trust, and equity, were rarely measured. No study deployed or prospectively evaluated a patient-facing AI system to support education, shared decision-making, or informed consent in medicine and, specifically, the complexities in head and neck oncology.",
        "Conclusions": "Current AI/ML within otolaryngology concentrates on clinician-facing tasks with promising technical performance but minimal patient involvement. We found no evaluated, patient-facing AI tools. Future work should co-design and prospectively test patient-delivered interventions (interactive explainers of diagnosis and treatment tradeoffs, values-clarification modules aligned to tumor board options, and consent aids tailored to literacy and language). Studies should report patient-centered outcomes (comprehension, decisional conflict, usability, trust), evaluate equity and bias, ensure privacy and transparency, and integrate with multidisciplinary workflows to support safer, more informed care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Artificial Intelligence in Head and Neck Oncology: A Scoping Review of Clinician-Facing Applications and the Patient-Facing Gap</span>. <u>Phil Tseng</u><sup>1</sup>; Noah Weaver, BS<sup>1</sup>; Nikhil C Mathur, BS<sup>1</sup>; Helena T Yip, MD<sup>2</sup>; Steven J Wang, MD<sup>2</sup>. <sup>1</sup>University of Arizona College of Medicine - Tucson; <sup>2</sup>University of Arizona, College of Medicine – Tucson, Department of Otolaryngology – Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To provide a review summarizing the current applications, patient perceptions, and clinical utility of machine learning–based (ML) and artificial intelligence (AI) decision support tools utilized in medicine and its potential applications in head and neck cancer care within otolaryngology. </p>\n\n<p><strong>Methods: </strong>A scoping literature review was conducted using PubMed with the following search strategy: (“otolaryngology” OR “head and neck”) AND (“artificial intelligence” OR “machine learning” OR “deep learning”), supplemented by targeted terms (“pediatric otolaryngology,” “radiomics,” “decision support,” “patient education,” “informed consent”). Titles and abstracts were screened for relevance. English-language clinical studies and validation studies with real-world or simulated clinical endpoints were included. Technical algorithm papers without clinical context and studies focused solely on clinician performance without patient-related outcomes were excluded. </p>\n\n<p><strong>Results: </strong>The literature review identified one hundred and eight-seven. Sixty-three underwent full text review after removal of duplicates and initial abstract review for relevance, and fifty-three were included in the final review. Identified AI/ML applications in medicine were overwhelmingly clinician-facing. Major use cases included imaging segmentation and treatment-target delineation for radiotherapy, including large language model–aided multimodal auto-delineation; plan evaluation and automated or mimicked planning workflows to improve quality and spare organs at risk; predictive modeling of toxicity (for example, xerostomia) and treatment response (for example, peritumoral CT radiomics in nasopharyngeal carcinoma); peri-treatment monitoring such as thermal imaging to anticipate radiation dermatitis; decision-support systems for complex therapy selection; and comparisons of LLM-generated recommendations with multidisciplinary tumor board decisions in primary laryngeal cancer, suggesting potential adjunctive use. Web-based prognostic tools were reported for select salivary malignancies, primarily to assist clinicians in risk communication. Across studies, internal performance metrics were frequently strong and, in some cases, externally validated. Several tools even showed concordance with expert selections or improved planning efficiency. However, outcomes that matter directly to patients, including comprehension, decisional conflict, acceptability, trust, and equity, were rarely measured. No study deployed or prospectively evaluated a patient-facing AI system to support education, shared decision-making, or informed consent in medicine and, specifically, the complexities in head and neck oncology.</p>\n\n<p><strong>Conclusions: </strong>Current AI/ML within otolaryngology concentrates on clinician-facing tasks with promising technical performance but minimal patient involvement. We found no evaluated, patient-facing AI tools. Future work should co-design and prospectively test patient-delivered interventions (interactive explainers of diagnosis and treatment tradeoffs, values-clarification modules aligned to tumor board options, and consent aids tailored to literacy and language). Studies should report patient-centered outcomes (comprehension, decisional conflict, usability, trust), evaluate equity and bias, ensure privacy and transparency, and integrate with multidisciplinary workflows to support safer, more informed care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152028--></body></html>"
    },
    {
      "uid": "P014",
      "content_id": "154004",
      "abstract_number": "P014",
      "poster_number": "P014",
      "title": "Classification of Current Procedural Terminology Codes of Head and Neck Procedures Using Microsoft CoPilot",
      "summary": "Publicly available LLMs are a promising tool to help suggest and assign appropriate CPT codes for head and neck procedures based on de-identified operative notes. CPT codes assigned by CoPilot were congruent or partially congruent with codes assigned by the medical biller in the majority of cases. CoPilot also suggested additional potential codes in over half of cases. Future directions include reviewing codes...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154004",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Victoria N Huynh, BS",
      "presenter": "Victoria N Huynh, BS",
      "authors": "Victoria N Huynh, BS 1 ; Brittany Beisel, MD 2 ; Ashley M Pham, BS 2 ; Kathryn Sinha, PhD 3 ; J. Kenneth Byrd, MD 2 ; Daniel Sharbel, MD 1 ; Forest Weir, MD 2 ; Michael Groves, MD 2 ; Sallie Long, MD 2",
      "normalized_authors": [
        "Victoria N Huynh",
        "Brittany Beisel",
        "Ashley M Pham",
        "Kathryn Sinha",
        "J. Kenneth Byrd",
        "Daniel Sharbel",
        "Forest Weir",
        "Michael Groves",
        "Sallie Long"
      ],
      "affiliations": [
        "Medical College of Georgia at Augusta University",
        "Wellstar MCG Health Medical Center",
        "Augusta University"
      ],
      "normalized_institutions": [
        "Medical College of Georgia at Augusta University",
        "Wellstar MCG Health Medical Center",
        "Augusta University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 440,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Victoria N Huynh, BS 1 ; Brittany Beisel, MD 2 ; Ashley M Pham, BS 2 ; Kathryn Sinha, PhD 3 ; J. Kenneth Byrd, MD 2 ; Daniel Sharbel, MD 1 ; Forest Weir, MD 2 ; Michael Groves, MD 2 ; Sallie Long, MD 2",
        "Affiliations": "1 Medical College of Georgia at Augusta University; 2 Wellstar MCG Health Medical Center; 3 Augusta University",
        "Introduction": "Medical billing is a significant administrative burden that accounts for an estimated 13.4% of generated surgical revenue. CPT codes are often misunderstood and difficult to streamline, leading to incorrect coding and improper payment. Otolaryngology, in particular, has an estimated improper payment rate of 7.2%. Existing literature suggests that artificial intelligence (AI) and large language models (LLMs) are promising avenues for the future of medical billing. To date, no studies have evaluated the ability of publicly available LLMs to assign appropriate CPT codes for otolaryngological procedures. Our study assesses the ability of Microsoft CoPilot, a publicly available LLM, to generate CPT codes for head and neck procedures based on the operative note.",
        "Methods": "All head and neck procedures between January 2025 and July 2025 at a tertiary medical center were identified. Thyroidectomies, parathyroidectomies, DISEs, and hypoglossal nerve stimulator insertions were excluded due to repetitive nature of operative notes. We entered deidentified procedure indications, findings, and details, and then prompted CoPilot to “Generate the CPT code(s) that should be billed for the following operative report. Exclude codes that are not explicitly described in this operative report.” The collection of CPT codes generated were then compared to codes submitted by the medical biller and were categorized as correct, partially correct, or incorrect. Additional codes generated by CoPilot were also noted.",
        "Results": "Based on a prospective power analysis conducted to determine sample size needed to detect an effect size of 0.5 with 80% power, 296 cases spread across 5 different surgeons were analyzed. Of the 296 operative notes identified, 16.89% (n = 50) pertained to head and neck ablation and microvascular free flap reconstruction cases. Cases were, on average, 184 (9-600, ±152) minutes long. CoPilot correctly identified at least one submitted code for 61.1% (n = 181) of cases. CPT codes suggested by CoPilot were fully correct for 29.7% (n = 88) of cases, partially correct for 31.4% (n = 93) of cases, and incorrect for 38.5% (n = 114) of cases. CoPilot also suggested additional codes beyond those submitted by the medical biller for 57.8% (n = 171) of cases.",
        "Conclusion": "Publicly available LLMs are a promising tool to help suggest and assign appropriate CPT codes for head and neck procedures based on de-identified operative notes. CPT codes assigned by CoPilot were congruent or partially congruent with codes assigned by the medical biller in the majority of cases. CoPilot also suggested additional potential codes in over half of cases. Future directions include reviewing codes suggested by CoPilot and codes submitted by the medical biller for accuracy, expanding analysis to other otolaryngological sub-specialties, and comparing CPT codes suggested by other publicly available LLMs."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Classification of Current Procedural Terminology Codes of Head and Neck Procedures Using Microsoft CoPilot</span>. <u>Victoria N Huynh, BS</u><sup>1</sup>; Brittany Beisel, MD<sup>2</sup>; Ashley M Pham, BS<sup>2</sup>; Kathryn Sinha, PhD<sup>3</sup>; J. Kenneth Byrd, MD<sup>2</sup>; Daniel Sharbel, MD<sup>1</sup>; Forest Weir, MD<sup>2</sup>; Michael Groves, MD<sup>2</sup>; Sallie Long, MD<sup>2</sup>. <sup>1</sup>Medical College of Georgia at Augusta University; <sup>2</sup>Wellstar MCG Health Medical Center; <sup>3</sup>Augusta University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Medical billing is a significant administrative burden that accounts for an estimated 13.4% of generated surgical revenue. CPT codes are often misunderstood and difficult to streamline, leading to incorrect coding and improper payment. Otolaryngology, in particular, has an estimated improper payment rate of 7.2%. Existing literature suggests that artificial intelligence (AI) and large language models (LLMs) are promising avenues for the future of medical billing. To date, no studies have evaluated the ability of publicly available LLMs to assign appropriate CPT codes for otolaryngological procedures. Our study assesses the ability of Microsoft CoPilot, a publicly available LLM, to generate CPT codes for head and neck procedures based on the operative note.</p>\n\n<p><strong>Methods: </strong>All head and neck procedures between January 2025 and July 2025 at a tertiary medical center were identified. Thyroidectomies, parathyroidectomies, DISEs, and hypoglossal nerve stimulator insertions were excluded due to repetitive nature of operative notes. We entered deidentified procedure indications, findings, and details, and then prompted CoPilot to “Generate the CPT code(s) that should be billed for the following operative report. Exclude codes that are not explicitly described in this operative report.” The collection of CPT codes generated were then compared to codes submitted by the medical biller and were categorized as correct, partially correct, or incorrect. Additional codes generated by CoPilot were also noted.</p>\n\n<p><strong>Results: </strong>Based on a prospective power analysis conducted to determine sample size needed to detect an effect size of 0.5 with 80% power, 296 cases spread across 5 different surgeons were analyzed. Of the 296 operative notes identified, 16.89% (n = 50) pertained to head and neck ablation and microvascular free flap reconstruction cases. Cases were, on average, 184 (9-600, ±152) minutes long. CoPilot correctly identified at least one submitted code for 61.1% (n = 181) of cases. CPT codes suggested by CoPilot were fully correct for 29.7% (n = 88) of cases, partially correct for 31.4% (n = 93) of cases, and incorrect for 38.5% (n = 114) of cases. CoPilot also suggested additional codes beyond those submitted by the medical biller for 57.8% (n = 171) of cases.</p>\n\n<p><strong>Conclusion: </strong>Publicly available LLMs are a promising tool to help suggest and assign appropriate CPT codes for head and neck procedures based on de-identified operative notes. CPT codes assigned by CoPilot were congruent or partially congruent with codes assigned by the medical biller in the majority of cases. CoPilot also suggested additional potential codes in over half of cases. Future directions include reviewing codes suggested by CoPilot and codes submitted by the medical biller for accuracy, expanding analysis to other otolaryngological sub-specialties, and comparing CPT codes suggested by other publicly available LLMs.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154004--></body></html>"
    },
    {
      "uid": "P015",
      "content_id": "151816",
      "abstract_number": "P015",
      "poster_number": "P015",
      "title": "Evaluating Large Language Models for Clinical Trial Eligibility Assessment in Head and Neck Cancer",
      "summary": "Copilot performed well in determining clinical trial eligibility based on CC notes and shows promise in assisting clinicians by automating patient screening. Incorporating LLMs into multidisciplinary team workflows may enhance efficiency and streamline clinical trial screening, while maintaining high standards of patient care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151816",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandria G Yao, BA",
      "presenter": "Alexandria G Yao, BA",
      "authors": "Alexandria G Yao, BA 1 ; Sara Armstrong, BS 1 ; Ameen Amanian, MD 2 ; Andrés Bur, MD 1",
      "normalized_authors": [
        "Alexandria G Yao",
        "Sara Armstrong",
        "Ameen Amanian",
        "Andrés Bur"
      ],
      "affiliations": [
        "University of Kansas Medical Center",
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of Kansas Medical Center",
        "University of British Columbia"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151816/Figure%201%20-%20Prompt.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151816/Figure%201%20-%20Prompt.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151816"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/151816/Table%201%20-%20Results(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151816/Table%201%20-%20Results(1).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151816"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alexandria G Yao, BA 1 ; Sara Armstrong, BS 1 ; Ameen Amanian, MD 2 ; Andrés Bur, MD 1",
        "Affiliations": "1 University of Kansas Medical Center; 2 University of British Columbia",
        "Importance": "Multidisciplinary tumor board conferences are standard at academic institutions, providing comprehensive evaluation and treatment planning for patients with head and neck cancer (HNC). These meetings also serve as a forum to assess patients’ eligibility for active clinical trials. However, the process of matching patient data to trial eligibility criteria remains largely manual, which can lead to under identification of eligible patients and missed opportunities for enrollment. Large language models (LLMs) such as Copilot and ChatGPT have a multitude of applications, including diagnostic assistance and medical documentation. Here, we evaluate Copilot as a clinical support tool for determining head and neck clinical trial eligibility evaluation in HNC patients.",
        "Objectives": "To assess the accuracy of a LLM in evaluating patient charts for clinical trial eligibility.",
        "Methods": "Copilot was first provided with the inclusion/exclusion criteria for seven clinical trials and then prompted (Figure 1) to assess patient eligibility based on cancer conference (CC) notes. One hundred and two patients presented at multidisciplinary tumor board conference between 2014 and 2025 were selected through exhausting the list of patients with confirmed enrollment in one of the specified clinical trials (n=69) and patients presented at a tumor board meeting in 2025 without a confirmed clinical trial enrollment (n=33). For each patient, the CC note was extracted from the EMR and entered into Copilot. The LLM was then prompted to evaluate the patient based on input information, without inferring beyond the provided data. Copilot’s response was evaluated for accuracy in reasoning and whether more information was required to determine eligibility. The first three patient charts were reviewed by a head and neck surgeon, who confirmed the criteria for assessing the accuracy of LLM responses. The accuracy of Copilot’s recommendations was evaluated by comparing its determination to the clinical trial each patient was enrolled in, alongside its rationale for determining whether or not a patient was eligible.",
        "Results": "The LLM demonstrated 100% accuracy (Table 1) in assessing CC notes for clinical trial eligibility. For patients eligible and enrolled in a clinical trial, the trial in which each patient was enrolled in served as the ground truth, while the LLM’s response and explanation served as the predicted outcome. For patients who were ineligible or not enrolled in a clinical trial, Copilot’s responses were evaluated to assess accuracy. Notably, Copilot determined 89% of cases required additional information to determine eligibility. Among these cases, Copilot identified the most likely eligible trial(s) and specified what information would be required to determine eligibility. For CC notes that required additional information but had patients that were ultimately enrolled in a clinical trial, Copilot’s identified likely trial was compared with the enrolled trial, which served as ground truth alongside the LLM generated explanation.",
        "Conclusions": "Copilot performed well in determining clinical trial eligibility based on CC notes and shows promise in assisting clinicians by automating patient screening. Incorporating LLMs into multidisciplinary team workflows may enhance efficiency and streamline clinical trial screening, while maintaining high standards of patient care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating Large Language Models for Clinical Trial Eligibility Assessment in Head and Neck Cancer</span>. <u>Alexandria G Yao, BA</u><sup>1</sup>; Sara Armstrong, BS<sup>1</sup>; Ameen Amanian, MD<sup>2</sup>; Andrés Bur, MD<sup>1</sup>. <sup>1</sup>University of Kansas Medical Center; <sup>2</sup>University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance</strong>: Multidisciplinary tumor board conferences are standard at academic institutions, providing comprehensive evaluation and treatment planning for patients with head and neck cancer (HNC). These meetings also serve as a forum to assess patients’ eligibility for active clinical trials. However, the process of matching patient data to trial eligibility criteria remains largely manual, which can lead to under identification of eligible patients and missed opportunities for enrollment. Large language models (LLMs) such as Copilot and ChatGPT have a multitude of applications, including diagnostic assistance and medical documentation. Here, we evaluate Copilot as a clinical support tool for determining head and neck clinical trial eligibility evaluation in HNC patients.</p>\n\n<p><strong>Objectives</strong>: To assess the accuracy of a LLM in evaluating patient charts for clinical trial eligibility.</p>\n\n<p><strong>Methods</strong>: Copilot was first provided with the inclusion/exclusion criteria for seven clinical trials and then prompted (Figure 1) to assess patient eligibility based on cancer conference (CC) notes. One hundred and two patients presented at multidisciplinary tumor board conference between 2014 and 2025 were selected through exhausting the list of patients with confirmed enrollment in one of the specified clinical trials (n=69) and patients presented at a tumor board meeting in 2025 without a confirmed clinical trial enrollment (n=33). For each patient, the CC note was extracted from the EMR and entered into Copilot. The LLM was then prompted to evaluate the patient based on input information, without inferring beyond the provided data. Copilot’s response was evaluated for accuracy in reasoning and whether more information was required to determine eligibility. The first three patient charts were reviewed by a head and neck surgeon, who confirmed the criteria for assessing the accuracy of LLM responses. The accuracy of Copilot’s recommendations was evaluated by comparing its determination to the clinical trial each patient was enrolled in, alongside its rationale for determining whether or not a patient was eligible.</p>\n\n<p><strong>Results</strong>: The LLM demonstrated 100% accuracy (Table 1) in assessing CC notes for clinical trial eligibility. For patients eligible and enrolled in a clinical trial, the trial in which each patient was enrolled in served as the ground truth, while the LLM’s response and explanation served as the predicted outcome. For patients who were ineligible or not enrolled in a clinical trial, Copilot’s responses were evaluated to assess accuracy. Notably, Copilot determined 89% of cases required additional information to determine eligibility. Among these cases, Copilot identified the most likely eligible trial(s) and specified what information would be required to determine eligibility. For CC notes that required additional information but had patients that were ultimately enrolled in a clinical trial, Copilot’s identified likely trial was compared with the enrolled trial, which served as ground truth alongside the LLM generated explanation.</p>\n\n<p><strong>Conclusions</strong>: Copilot performed well in determining clinical trial eligibility based on CC notes and shows promise in assisting clinicians by automating patient screening. Incorporating LLMs into multidisciplinary team workflows may enhance efficiency and streamline clinical trial screening, while maintaining high standards of patient care.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151816/Figure%201%20-%20Prompt.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151816/Table%201%20-%20Results(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151816--></body></html>"
    },
    {
      "uid": "P016",
      "content_id": "154524",
      "abstract_number": "P016",
      "poster_number": "P016",
      "title": "Lingual Rehabilitation Outcomes in a Patient with Hypoglossal (CN XII) Neuropathy: Preliminary Findings and Integration of a Novel Speech Tracking Application",
      "summary": "This case demonstrates, for the first time, a lingual-focused rehabilitation program for CN XII neuropathy alongside integration of digital speech tracking. The targeted rehabilitation program directly improved and sustained lingual mobility, with automated acoustic metrics revealing articulatory gains not traditionally measured objectively in standard clinical assessment. Notably, increased F1 values objectively...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154524",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carly E Barbon, Assistant Professor",
      "presenter": "Carly E Barbon, Assistant Professor",
      "authors": "Lucas Takanori Sanchez Shiromizu 1 ; Nathan Hansen 2 ; Jacob McCoy 1 ; Yelizaveta Semikina 1 ; Katherine A Hutcheson, Professor 3 ; Benjamin Sanchez, Professor 1 ; Carly E Barbon, Assistant Professor 3",
      "normalized_authors": [
        "Lucas Takanori Sanchez Shiromizu",
        "Nathan Hansen",
        "Jacob McCoy",
        "Yelizaveta Semikina",
        "Katherine A Hutcheson",
        "Benjamin Sanchez",
        "Carly E Barbon, Assistant"
      ],
      "affiliations": [
        "University of Illinois Chicago",
        "University of Utah",
        "The University of Texas MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "University of Illinois Chicago",
        "University of Utah",
        "The University of Texas MD Anderson Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Lucas Takanori Sanchez Shiromizu 1 ; Nathan Hansen 2 ; Jacob McCoy 1 ; Yelizaveta Semikina 1 ; Katherine A Hutcheson, Professor 3 ; Benjamin Sanchez, Professor 1 ; Carly E Barbon, Assistant Professor 3",
        "Affiliations": "1 University of Illinois Chicago; 2 University of Utah; 3 The University of Texas MD Anderson Cancer Center",
        "Background": "Hypoglossal nerve (CN XII) dysfunction is a profoundly disabling late effect of head and neck cancer treatment, often resulting in persistent articulation deficits and impaired oral processing that negatively impact quality of life. Objective tracking of speech recovery is limited in standard clinical care. A patient with late-onset radiation-induced CN XII neuropathy underwent a targeted lingual rehabilitation program. Speech outcomes collected over three years were objectively analyzed with a novel application designed to extract longitudinal acoustic metrics beyond standard clinical methods.",
        "Methods": "A 70-year-old male, ten years post-chemoradiotherapy and neck dissection for T2N2b squamous cell carcinoma of the tonsil, presented with dysarthria attributed to unilateral iatrogenic CN XII neuropathy. He completed a structured lingual rehabilitation protocol focused on strengthening, endurance, and contralateral neuromotor re-education. Lingual mobility (lingual range of motion scale) and speech samples (“Rainbow Passage”) were collected during follow-up visits in 2022 (baseline), 2023 and 2024. Ratings of lingual mobility, intraoral photographs, and subjective speech clarity were obtained. Recordings were retrospectively analyzed with custom software to quantify acoustic markers of tongue mobility via F1 (vertical movement), F2 (anterior–posterior movement), and word accuracy. Speech metrics were analyzed using a two-way ANOVA with Tukey’s post hoc test for multiple comparisons. The novel rehabilitation intervention will be presented using the TIDieR (Template for Intervention Description and Replication framework) framework.",
        "Results": "After targeted rehabilitation and adherence to a home exercise program, the patient reported reduced conversational fatigue and increased communicative confidence, corroborated by improved clinician-rated speech precision. Lingual range of motion improved from 2022 (87.5/100) to 2023 (100/100) and was sustained in 2024. Objective analysis revealed a significant increase in F1 from 2022 (538.35 ± 427.27 Hz, N=5,824) and 2023 (541.96 ± 456.68 Hz, N=3,890) to 2024 (579.98 ± 440.23 Hz, N=4,131), p<0.0001. F2 and word accuracy showed no significant changes across the three years, which is attributed to limited sample size. Longitudinal speech samples from each year will be demonstrated in the results to provide audio perceptual evidence of progressive change across interventions.",
        "Conclusion": "This case demonstrates, for the first time, a lingual-focused rehabilitation program for CN XII neuropathy alongside integration of digital speech tracking. The targeted rehabilitation program directly improved and sustained lingual mobility, with automated acoustic metrics revealing articulatory gains not traditionally measured objectively in standard clinical assessment. Notably, increased F1 values objectively corresponded with enhanced vertical tongue movement, reflecting more precise articulation and better speech precision/clarity. These results highlight how digital monitoring can support individualized therapy and reliably track meaningful improvement in speech metrics. This approach offers a practical, scalable strategy to optimize care for patients with CN XII impairment and provides preliminary evidence that targeted lingual rehabilitation can improve speech and lingual function following CN XII injury, addressing a critical gap given the absence of standardized rehabilitation regimens for the increasing number of patients who develop late-onset deficits after radiotherapy. Further study is needed to validate these findings in larger cohorts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lingual Rehabilitation Outcomes in a Patient with Hypoglossal (CN XII) Neuropathy: Preliminary Findings and Integration of a Novel Speech Tracking Application</span>. Lucas Takanori Sanchez Shiromizu<sup>1</sup>; Nathan Hansen<sup>2</sup>; Jacob McCoy<sup>1</sup>; Yelizaveta Semikina<sup>1</sup>; Katherine A Hutcheson, Professor<sup>3</sup>; Benjamin Sanchez, Professor<sup>1</sup>; <u>Carly E Barbon, Assistant Professor</u><sup>3</sup>. <sup>1</sup>University of Illinois Chicago; <sup>2</sup>University of Utah; <sup>3</sup>The University of Texas MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Hypoglossal nerve (CN XII) dysfunction is a profoundly disabling late effect of head and neck cancer treatment, often resulting in persistent articulation deficits and impaired oral processing that negatively impact quality of life. Objective tracking of speech recovery is limited in standard clinical care. A patient with late-onset radiation-induced CN XII neuropathy underwent a targeted lingual rehabilitation program. Speech outcomes collected over three years were objectively analyzed with a novel application designed to extract longitudinal acoustic metrics beyond standard clinical methods.</p>\n\n<p><strong>Methods: </strong>A 70-year-old male, ten years post-chemoradiotherapy and neck dissection for T2N2b squamous cell carcinoma of the tonsil, presented with dysarthria attributed to unilateral iatrogenic CN XII neuropathy. He completed a structured lingual rehabilitation protocol focused on strengthening, endurance, and contralateral neuromotor re-education. Lingual mobility (lingual range of motion scale) and speech samples (“Rainbow Passage”) were collected during follow-up visits in 2022 (baseline), 2023 and 2024. Ratings of lingual mobility, intraoral photographs, and subjective speech clarity were obtained. Recordings were retrospectively analyzed with custom software to quantify acoustic markers of tongue mobility via F1 (vertical movement), F2 (anterior–posterior movement), and word accuracy. Speech metrics were analyzed using a two-way ANOVA with Tukey’s post hoc test for multiple comparisons. The novel rehabilitation intervention will be presented using the TIDieR (Template for Intervention Description and Replication framework) framework.</p>\n\n<p><strong>Results: </strong>After targeted rehabilitation and adherence to a home exercise program, the patient reported reduced conversational fatigue and increased communicative confidence, corroborated by improved clinician-rated speech precision. Lingual range of motion improved from 2022 (87.5/100) to 2023 (100/100) and was sustained in 2024. Objective analysis revealed a significant increase in F1 from 2022 (538.35 ± 427.27 Hz, N=5,824) and 2023 (541.96 ± 456.68 Hz, N=3,890) to 2024 (579.98 ± 440.23 Hz, N=4,131), p<0.0001. F2 and word accuracy showed no significant changes across the three years, which is attributed to limited sample size. Longitudinal speech samples from each year will be demonstrated in the results to provide audio perceptual evidence of progressive change across interventions.</p>\n\n<p><strong>Conclusion: </strong>This case demonstrates, for the first time, a lingual-focused rehabilitation program for CN XII neuropathy alongside integration of digital speech tracking. The targeted rehabilitation program directly improved and sustained lingual mobility, with automated acoustic metrics revealing articulatory gains not traditionally measured objectively in standard clinical assessment. Notably, increased F1 values objectively corresponded with enhanced vertical tongue movement, reflecting more precise articulation and better speech precision/clarity. These results highlight how digital monitoring can support individualized therapy and reliably track meaningful improvement in speech metrics. This approach offers a practical, scalable strategy to optimize care for patients with CN XII impairment and provides preliminary evidence that targeted lingual rehabilitation can improve speech and lingual function following CN XII injury, addressing a critical gap given the absence of standardized rehabilitation regimens for the increasing number of patients who develop late-onset deficits after radiotherapy. Further study is needed to validate these findings in larger cohorts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154524--></body></html>"
    },
    {
      "uid": "P017",
      "content_id": "153020",
      "abstract_number": "P017",
      "poster_number": "P017",
      "title": "Socioeconomically based disparities in the place of death for head and neck cancer: a machine learning approach",
      "summary": "More than half of our cohort of decedents with HNC died in a hospital rather than in the community. Socioeconomic variables especially sex, rurality and immigration status may be related to the risk of dying in a hospital, with rural-dwelling women who were also immigrants to Canada identified to have the highest risk. These findings have actionable implications on cancer care delivery by advocating for advanced...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153020",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shiyu Sun, MSc",
      "presenter": "Shiyu Sun, MSc",
      "authors": "Rui Fu, PhD, PStat 1 ; Frederick Dun-Dery, PhD 1 ; Shiyu Sun, MSc 1 ; Khara Sauro, PhD 1 ; Pin Cai, PhD 2 ; Andrew Fong, MSc 2 ; Andrea Fung, MD, PhD, FRCPC 1 ; Shamir Chandarana, MD, MSc 1 ; T. Wayne Matthews, MD, FRCS 1 ; Joesph Dort, MD, MSc 1 ; Patricia Biondo, PhD 1 ; Aynharan Sinnarajah, MD, MPH, CCFP 3",
      "normalized_authors": [
        "Rui Fu, PStat",
        "Frederick Dun-Dery",
        "Shiyu Sun",
        "Khara Sauro",
        "Pin Cai",
        "Andrew Fong",
        "Andrea Fung, FRCPC",
        "Shamir Chandarana",
        "T. Wayne Matthews",
        "Joesph Dort",
        "Patricia Biondo",
        "Aynharan Sinnarajah, CCFP"
      ],
      "affiliations": [
        "University of Calgary",
        "Alberta Health Services",
        "Queen's University"
      ],
      "normalized_institutions": [
        "University of Calgary",
        "Alberta Health Services",
        "Queen's University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153020/3way(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153020/3way(1).png",
          "alt": "Note: The H-statistic was used to measure the statistical strength of all 2-way (n=165) and 3-way (n=730) interactions formed by the seven socioeconomic variables for at-hospital deaths, using the validated XGBoost model. The strongest 2-way interaction effect was identified to be between immigration status and sex (H-statistic, 0.055) while the only meaningful 3-way interaction effect was between immigration status, sex, and rural living (H-statistic, 0.003). Herein we demonstrate the average predicted probability (i.e., partial dependence) of at-hospital deaths by immigration status, sex, and rural living. Overall, women, rural residents, and immigrants had a higher predicted probability of at-hospital deaths than did men, urban residents, and non-immigrants, respectively. The subgroup identified to have the highest predicted probability of at-hospital deaths (60.1%) was rural women who were also an immigrant to Canada.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153020"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 519,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Rui Fu, PhD, PStat 1 ; Frederick Dun-Dery, PhD 1 ; Shiyu Sun, MSc 1 ; Khara Sauro, PhD 1 ; Pin Cai, PhD 2 ; Andrew Fong, MSc 2 ; Andrea Fung, MD, PhD, FRCPC 1 ; Shamir Chandarana, MD, MSc 1 ; T. Wayne Matthews, MD, FRCS 1 ; Joesph Dort, MD, MSc 1 ; Patricia Biondo, PhD 1 ; Aynharan Sinnarajah, MD, MPH, CCFP 3",
        "Affiliations": "1 University of Calgary; 2 Alberta Health Services; 3 Queen's University",
        "Background": "While home is generally considered to be the preferred place of death for patients with cancer, patients with head and neck cancer (HNC) tend to die in a hospital partially due to their intensive use of hospital-based care towards the end of life. Socioeconomic status may also impact end-of-life care and subsequently, the place of death. We used an interpretable machine learning approach to identify patients with HNC at the highest risk of dying in a hospital.",
        "Methods": "In this retrospective population-based cohort study conducted in Alberta, Canada (population~5 million), individuals diagnosed with HNC at age 18 or above between January 2006 and December 2021 who later died between January 2013 and December 2021 were included. The primary outcome was location of death dichotomized as deaths in a hospital (including an emergency department or enroute) or in the community (including a hospice, a supportive living or long-term care facility, or a private residence/home). There were seven socioeconomic exposures measured at diagnosis: sex, rurality, immigration status, Chinese or South Asian ethnicity (approximated using validated surname-based algorithms), material and social deprivation quintiles, and exposure to homelessness (using validated codes in census and registry databases). Using these and 25 additional patient-level variables (such as age and HNC stage), we developed and internally validated an XGBoost (eXtreme Gradient Boosting, an open-source algorithm) model to classify patients into in-hospital vs. in-community death groups. Using the final model, we exhaustively assessed all 2-way (n=165) and 3-way (n=730) interactions formed by the socioeconomic variables to characterize the most high-risk patients for in-hospital deaths.",
        "Results": "Of 1,441 patients, 56.2% (n=810) died in a hospital and 43.8% (n=631) died in the community. Mean age at diagnosis was 65.7 (SD 13.1) years, with 26.9% women, 24.1% rural residents, 21.4% being an immigrant, 6.2% being a Chinese (4.0%) or South Asian (2.2%), and 2.0% reported to have experienced homelessness. The XGBoost achieved excellent performance (C-index 0.91), with high sensitivity (0.88), specificity (0.80), and accuracy (0.84). Of all socioeconomically based interactions assessed, the strongest 2-way interaction effect was identified to be between immigration status and sex (H-statistic, 0.055) while the only statistically meaningful 3-way interaction effect was between immigration status, sex, and rurality (H-statistic, 0.003). Specifically, women who were a rural resident and an immigrant to Canada were identified to have the highest risk of dying in a hospital (average predicted probability of in-hospital deaths, 60.1%).",
        "Conclusion": "More than half of our cohort of decedents with HNC died in a hospital rather than in the community. Socioeconomic variables especially sex, rurality and immigration status may be related to the risk of dying in a hospital, with rural-dwelling women who were also immigrants to Canada identified to have the highest risk. These findings have actionable implications on cancer care delivery by advocating for advanced care planning in HNC patients, especially those who may be at risk of dying in a hospital, to improve their chance of receiving end-of-life care and ultimately dying at the comfort of their own home/community."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Socioeconomically based disparities in the place of death for head and neck cancer: a machine learning approach</span>. Rui Fu, PhD, PStat<sup>1</sup>; Frederick Dun-Dery, PhD<sup>1</sup>; <u>Shiyu Sun, MSc</u><sup>1</sup>; Khara Sauro, PhD<sup>1</sup>; Pin Cai, PhD<sup>2</sup>; Andrew Fong, MSc<sup>2</sup>; Andrea Fung, MD, PhD, FRCPC<sup>1</sup>; Shamir Chandarana, MD, MSc<sup>1</sup>; T. Wayne Matthews, MD, FRCS<sup>1</sup>; Joesph Dort, MD, MSc<sup>1</sup>; Patricia Biondo, PhD<sup>1</sup>; Aynharan Sinnarajah, MD, MPH, CCFP<sup>3</sup>. <sup>1</sup>University of Calgary; <sup>2</sup>Alberta Health Services; <sup>3</sup>Queen's University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>While home is generally considered to be the preferred place of death for patients with cancer, patients with head and neck cancer (HNC) tend to die in a hospital partially due to their intensive use of hospital-based care towards the end of life. Socioeconomic status may also impact end-of-life care and subsequently, the place of death. We used an interpretable machine learning approach to identify patients with HNC at the highest risk of dying in a hospital.</p>\n\n<p><strong>Methods: </strong>In this retrospective population-based cohort study conducted in Alberta, Canada (population~5 million), individuals diagnosed with HNC at age 18 or above between January 2006 and December 2021 who later died between January 2013 and December 2021 were included. The primary outcome was location of death dichotomized as deaths in a hospital (including an emergency department or enroute) or in the community (including a hospice, a supportive living or long-term care facility, or a private residence/home). There were seven socioeconomic exposures measured at diagnosis: sex, rurality, immigration status, Chinese or South Asian ethnicity (approximated using validated surname-based algorithms), material and social deprivation quintiles, and exposure to homelessness (using validated codes in census and registry databases). Using these and 25 additional patient-level variables (such as age and HNC stage), we developed and internally validated an XGBoost (eXtreme Gradient Boosting, an open-source algorithm) model to classify patients into in-hospital vs. in-community death groups. Using the final model, we exhaustively assessed all 2-way (n=165) and 3-way (n=730) interactions formed by the socioeconomic variables to characterize the most high-risk patients for in-hospital deaths.</p>\n\n<p><strong>Results:</strong> Of 1,441 patients, 56.2% (n=810) died in a hospital and 43.8% (n=631) died in the community. Mean age at diagnosis was 65.7 (SD 13.1) years, with 26.9% women, 24.1% rural residents, 21.4% being an immigrant, 6.2% being a Chinese (4.0%) or South Asian (2.2%), and 2.0% reported to have experienced homelessness. The XGBoost achieved excellent performance (C-index 0.91), with high sensitivity (0.88), specificity (0.80), and accuracy (0.84). Of all socioeconomically based interactions assessed, the strongest 2-way interaction effect was identified to be between immigration status and sex (H-statistic, 0.055) while the only statistically meaningful 3-way interaction effect was between immigration status, sex, and rurality (H-statistic, 0.003). Specifically, women who were a rural resident and an immigrant to Canada were identified to have the highest risk of dying in a hospital (average predicted probability of in-hospital deaths, 60.1%).</p>\n\n<p><strong>Conclusion: </strong>More than half of our cohort of decedents with HNC died in a hospital rather than in the community. Socioeconomic variables especially sex, rurality and immigration status may be related to the risk of dying in a hospital, with rural-dwelling women who were also immigrants to Canada identified to have the highest risk. These findings have actionable implications on cancer care delivery by advocating for advanced care planning in HNC patients, especially those who may be at risk of dying in a hospital, to improve their chance of receiving end-of-life care and ultimately dying at the comfort of their own home/community.</p>\n\n<p><img alt='Note: The H-statistic was used to measure the statistical strength of all 2-way (n=165) and 3-way (n=730) interactions formed by the seven socioeconomic variables for at-hospital deaths, using the validated XGBoost model. The strongest 2-way interaction effect was identified to be between immigration status and sex (H-statistic, 0.055) while the only meaningful 3-way interaction effect was between immigration status, sex, and rural living (H-statistic, 0.003). Herein we demonstrate the average predicted probability (i.e., partial dependence) of at-hospital deaths by immigration status, sex, and rural living. Overall, women, rural residents, and immigrants had a higher predicted probability of at-hospital deaths than did men, urban residents, and non-immigrants, respectively. The subgroup identified to have the highest predicted probability of at-hospital deaths (60.1%) was rural women who were also an immigrant to Canada.' src='https://www.submitmyabstract.com/abs/images/153020/3way(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153020--></body></html>"
    },
    {
      "uid": "P018",
      "content_id": "153577",
      "abstract_number": "P018",
      "poster_number": "P018",
      "title": "Evaluating Concordance Between Tumor Board and AI Treatment Recommendations for Head and Neck Cancer Patients",
      "summary": "While both AI tools demonstrated strong accuracy in cancer staging, they frequently over-recommended imaging, diagnostic studies, and palliative care, and CG under-recommended surgery. Although AI shows promise as a supportive tool, these findings highlight the need for cautious integration to prevent potential over- or under-treatment in head and neck cancer care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153577",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan Raskin, MD",
      "presenter": "Jonathan Raskin, MD",
      "authors": "Jonathan Raskin, MD ; Andrew Lee, MD; Ivan Vegar; Elaine Sun; Steve Lee, MD",
      "normalized_authors": [
        "Jonathan Raskin",
        "Andrew Lee",
        "Ivan Vegar",
        "Elaine Sun",
        "Steve Lee"
      ],
      "affiliations": [
        "Loma Linda University"
      ],
      "normalized_institutions": [
        "Loma Linda University"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 325,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jonathan Raskin, MD ; Andrew Lee, MD; Ivan Vegar; Elaine Sun; Steve Lee, MD",
        "Affiliations": "Loma Linda University",
        "Introduction": "Artificial intelligence (AI) platforms are increasingly used to support clinical decision-making, yet their agreement with multidisciplinary tumor board (TB) recommendations—particularly in complex head and neck cancer management—remains unclear.",
        "Objective": "To compare treatment recommendations for head and neck cancer patients generated by ChatGPT (CG) and OpenEvidence (OE) with decisions made by a multidisciplinary TB.",
        "Methods": "Fifty head and neck cancer cases presented at the Loma Linda University Otolaryngology Tumor Board were reviewed. For each case, TB recommendations were recorded and compared with CG and OE outputs across multiple treatment domains, including cancer staging, surgery, radiation alone, chemotherapy alone, chemoradiation, further imaging, diagnostic studies, and palliative care. Similarity scores were calculated, and directional differences relative to TB recommendations were assessed.",
        "Results": "Overall concordance favored CG, which demonstrated greater similarity to TB recommendations than OE (mean similarity score 5.90 ± 1.37 vs 5.08 ± 1.65; p<0.001). For surgery, TB and OE recommended surgery at identical rates (24/50 each; p=1.00), while CG under-recommended surgery (14/50; p=0.031). TB recommended additional imaging in 27/50 cases, compared with significantly higher rates from OE (43/50; p=0.001) and CG (38/50; p=0.003). TB recommended diagnostic studies in 20/50 cases, whereas OE (43/50; p<0.001) and CG (33/50; p=0.002) significantly over-recommended them. Palliative care was recommended by TB in 4/50 cases, compared with substantially higher frequencies from OE (22/50; p<0.001) and CG (19/50; p<0.001). Cancer staging concordance was high, with both AI systems matching TB staging in 90% of cases and showing no significant directional differences.",
        "Conclusion": "While both AI tools demonstrated strong accuracy in cancer staging, they frequently over-recommended imaging, diagnostic studies, and palliative care, and CG under-recommended surgery. Although AI shows promise as a supportive tool, these findings highlight the need for cautious integration to prevent potential over- or under-treatment in head and neck cancer care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating Concordance Between Tumor Board and AI Treatment Recommendations for Head and Neck Cancer Patients</span>. <u>Jonathan Raskin, MD</u>; Andrew Lee, MD; Ivan Vegar; Elaine Sun; Steve Lee, MD. Loma Linda University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Artificial intelligence (AI) platforms are increasingly used to support clinical decision-making, yet their agreement with multidisciplinary tumor board (TB) recommendations—particularly in complex head and neck cancer management—remains unclear. </p>\n\n<p><strong>Objective: </strong>To compare treatment recommendations for head and neck cancer patients generated by ChatGPT (CG) and OpenEvidence (OE) with decisions made by a multidisciplinary TB.</p>\n\n<p><strong>Methods:</strong> Fifty head and neck cancer cases presented at the Loma Linda University Otolaryngology Tumor Board were reviewed. For each case, TB recommendations were recorded and compared with CG and OE outputs across multiple treatment domains, including cancer staging, surgery, radiation alone, chemotherapy alone, chemoradiation, further imaging, diagnostic studies, and palliative care. Similarity scores were calculated, and directional differences relative to TB recommendations were assessed.</p>\n\n<p><strong>Results: </strong>Overall concordance favored CG, which demonstrated greater similarity to TB recommendations than OE (mean similarity score 5.90 ± 1.37 vs 5.08 ± 1.65; p<0.001). For surgery, TB and OE recommended surgery at identical rates (24/50 each; p=1.00), while CG under-recommended surgery (14/50; p=0.031). TB recommended additional imaging in 27/50 cases, compared with significantly higher rates from OE (43/50; p=0.001) and CG (38/50; p=0.003). TB recommended diagnostic studies in 20/50 cases, whereas OE (43/50; p<0.001) and CG (33/50; p=0.002) significantly over-recommended them. Palliative care was recommended by TB in 4/50 cases, compared with substantially higher frequencies from OE (22/50; p<0.001) and CG (19/50; p<0.001). Cancer staging concordance was high, with both AI systems matching TB staging in 90% of cases and showing no significant directional differences.</p>\n\n<p><strong>Conclusion: </strong>While both AI tools demonstrated strong accuracy in cancer staging, they frequently over-recommended imaging, diagnostic studies, and palliative care, and CG under-recommended surgery. Although AI shows promise as a supportive tool, these findings highlight the need for cautious integration to prevent potential over- or under-treatment in head and neck cancer care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153577--></body></html>"
    },
    {
      "uid": "P019",
      "content_id": "154041",
      "abstract_number": "P019",
      "poster_number": "P019",
      "title": "Artificial Intelligence Platforms Versus Multidisciplinary Tumor Board Recommendations in Head and Neck Cancer: A Comparative Analysis of Decision-Making Trends",
      "summary": "MTB discussion at tertiary and quaternary medical centers provides valuable insights from a group of experienced professionals that likely adds a combination of experience and knowledge base with ongoing clinical trial participation. In today’s climate where both patients and providers are using AI to inform care decisions and streamline efficiency, it is important to recognize the limitations pertaining to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154041",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nazineen Kandahari, MD",
      "presenter": "Nazineen Kandahari, MD",
      "authors": "David P Strum, MD; Nazineen Kandahari, MD ; Kees Heetderks, BS; Simon Ellington, BS; Trevor Hackman, MD, FACS; Wendell Yarbrough, MD, MMHC, FACS",
      "normalized_authors": [
        "David P Strum",
        "Nazineen Kandahari",
        "Kees Heetderks",
        "Simon Ellington",
        "Trevor Hackman",
        "Wendell Yarbrough, MMHC"
      ],
      "affiliations": [
        "University of North Carolina Chapel Hill"
      ],
      "normalized_institutions": [
        "University of North Carolina Chapel Hill"
      ],
      "session_type": "Poster",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "David P Strum, MD; Nazineen Kandahari, MD ; Kees Heetderks, BS; Simon Ellington, BS; Trevor Hackman, MD, FACS; Wendell Yarbrough, MD, MMHC, FACS",
        "Affiliations": "University of North Carolina Chapel Hill",
        "Background": "Artificial intelligence (AI) platforms are increasingly being used by patients and clinicians to guide medical decision-making. As public trust and interest in AI-based tools continue to rise, it is unclear how these platforms interpret complex oncologic data compared to expert multidisciplinary consensus, especially in the setting of paradigm shifts in management as evidenced by immunotherapy utilization in head and neck cancer. This study aims to evaluate how commonly available AI models interpret and recommend management for head and neck cancer patients presented at a multidisciplinary tumor board (MTB) at a quaternary academic medical center.",
        "Methods": "Cases presented at a single-institution head and neck oncology multidisciplinary tumor board were retrospectively selected over a 2-month time period and deidentified. Clinical variables including patient demographics, comorbidities, tumor subsite, clinical and pathologic staging, and relevant diagnostic findings were compiled and input into ChatGPT (GPT 5.1), Google Gemini (Gemini 2.5 Flash), and OpenEvidence (OpenEvidence 2.0) with a standardized prompt requesting a management recommendation. AI-generated treatment plans were compared with the tumor board consensus. Concordance rates and qualitative differences were analyzed.",
        "Results": "A total of 83 patients were included representing multiple types of head and neck malignancies throughout different phases of the treatment course. Overall, each of the AI platforms had just over a 50% concordance rate with our institution’s MTB (ChatGPT 57.83%, Google Gemini 57.83%, OpenEvidence 54.22%). The concordance rate varied based on pathology, tumor subsite, and whether the patient presented for primary or adjuvant treatment. Most of the patients (65 out of 83) had squamous cell carcinoma, and the concordance rate of AI management to MTB recommendation for all three platforms in this group was 56.9%. Five patients had salivary malignancy, and the concordance rates with ChatGPT, OpenEvidence, and Google Gemini were 80%, 60%, and 40%, respectively. The most common subsites represented were oral cavity (29 patients) and oropharynx (20 patients). AI concordance rates for oral cavity malignancies for ChatGPT, OpenEvidence, and Google Gemini were 65.5%, 65.5%, and 51.7%, respectively. AI concordance rates for oropharynx malignancies for ChatGPT, OpenEvidence, and Google Gemini were 75%, 65%, and 75%, respectively. AI concordance rates for those presenting prior to any surgical management for ChatGPT, OpenEvidence, and Google Gemini were 72.7%, 54.5%, and 69.7%, respectively.",
        "Conclusion": "MTB discussion at tertiary and quaternary medical centers provides valuable insights from a group of experienced professionals that likely adds a combination of experience and knowledge base with ongoing clinical trial participation. In today’s climate where both patients and providers are using AI to inform care decisions and streamline efficiency, it is important to recognize the limitations pertaining to management decisions in head and neck oncology. Current popular platforms do not show a high or consistent concordance rate with the MTB in this single institutional study at a quaternary care center. This suggests cautious utilization of AI in this setting, although further research is warranted to determine the utility of AI for patient education and clinicians outside tertiary care facilities in the setting of head and neck cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Artificial Intelligence Platforms Versus Multidisciplinary Tumor Board Recommendations in Head and Neck Cancer: A Comparative Analysis of Decision-Making Trends</span>. David P Strum, MD; <u>Nazineen Kandahari, MD</u>; Kees Heetderks, BS; Simon Ellington, BS; Trevor Hackman, MD, FACS; Wendell Yarbrough, MD, MMHC, FACS. University of North Carolina Chapel Hill<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Artificial intelligence (AI) platforms are increasingly being used by patients and clinicians to guide medical decision-making. As public trust and interest in AI-based tools continue to rise, it is unclear how these platforms interpret complex oncologic data compared to expert multidisciplinary consensus, especially in the setting of paradigm shifts in management as evidenced by immunotherapy utilization in head and neck cancer. This study aims to evaluate how commonly available AI models interpret and recommend management for head and neck cancer patients presented at a multidisciplinary tumor board (MTB) at a quaternary academic medical center.</p>\n\n<p><strong>Methods: </strong>Cases presented at a single-institution head and neck oncology multidisciplinary tumor board were retrospectively selected over a 2-month time period and deidentified. Clinical variables including patient demographics, comorbidities, tumor subsite, clinical and pathologic staging, and relevant diagnostic findings were compiled and input into ChatGPT (GPT 5.1), Google Gemini (Gemini 2.5 Flash), and OpenEvidence (OpenEvidence 2.0) with a standardized prompt requesting a management recommendation. AI-generated treatment plans were compared with the tumor board consensus. Concordance rates and qualitative differences were analyzed.</p>\n\n<p><strong>Results: </strong>A total of 83 patients were included representing multiple types of head and neck malignancies throughout different phases of the treatment course. Overall, each of the AI platforms had just over a 50% concordance rate with our institution’s MTB (ChatGPT 57.83%, Google Gemini 57.83%, OpenEvidence 54.22%). The concordance rate varied based on pathology, tumor subsite, and whether the patient presented for primary or adjuvant treatment. Most of the patients (65 out of 83) had squamous cell carcinoma, and the concordance rate of AI management to MTB recommendation for all three platforms in this group was 56.9%.  Five patients had salivary malignancy, and the concordance rates with ChatGPT, OpenEvidence, and Google Gemini were 80%, 60%, and 40%, respectively. The most common subsites represented were oral cavity (29 patients) and oropharynx (20 patients). AI concordance rates for oral cavity malignancies for ChatGPT, OpenEvidence, and Google Gemini were 65.5%, 65.5%, and 51.7%, respectively.  AI concordance rates for oropharynx malignancies for ChatGPT, OpenEvidence, and Google Gemini were 75%, 65%, and 75%, respectively. AI concordance rates for those presenting prior to any surgical management for ChatGPT, OpenEvidence, and Google Gemini were 72.7%, 54.5%, and 69.7%, respectively.</p>\n\n<p><strong>Conclusion: </strong>MTB discussion at tertiary and quaternary medical centers provides valuable insights from a group of experienced professionals that likely adds a combination of experience and knowledge base with ongoing clinical trial participation. In today’s climate where both patients and providers are using AI to inform care decisions and streamline efficiency, it is important to recognize the limitations pertaining to management decisions in head and neck oncology. Current popular platforms do not show a high or consistent concordance rate with the MTB in this single institutional study at a quaternary care center. This suggests cautious utilization of AI in this setting, although further research is warranted to determine the utility of AI for patient education and clinicians outside tertiary care facilities in the setting of head and neck cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154041--></body></html>"
    },
    {
      "uid": "P020",
      "content_id": "153966",
      "abstract_number": "P020",
      "poster_number": "P020",
      "title": "Scoping Review of Complementary and Alternative Medicine Use in Head and Neck Cancer Patients",
      "summary": "The objective of this study was to evaluate published in the use of complementary and alternative medicine (CAM) among adults diagnosed with head and neck cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153966",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Drake V Johnston",
      "presenter": "Drake V Johnston",
      "authors": "Drake V Johnston ; Rusha J Patel, MD; Micheal Machiorlatti, PhD",
      "normalized_authors": [
        "Drake V Johnston",
        "Rusha J Patel",
        "Micheal Machiorlatti"
      ],
      "affiliations": [
        "University of Oklahoma Health Science Center"
      ],
      "normalized_institutions": [
        "University of Oklahoma Health Science Center"
      ],
      "session_type": "Poster",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 489,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "AIM",
        "METHODS",
        "RESULTS",
        "DISCUSSION",
        "CONCLUSION",
        "CONTRIBUTION"
      ],
      "sections": {
        "Authors": "Drake V Johnston ; Rusha J Patel, MD; Micheal Machiorlatti, PhD",
        "Affiliations": "University of Oklahoma Health Science Center",
        "BACKGROUND": "The objective of this study was to evaluate published in the use of complementary and alternative medicine (CAM) among adults diagnosed with head and neck cancer.",
        "AIM": "CAM usage has been shown to be prevalent within the head and neck cancer population; however, studies have varied in the presentation, classification of, and what constitutes CAM. The purpose of this review is to establish trends in CAM use in literature.",
        "METHODS": "Literature search following PRISMA Guideline was performed using the Ovid library, specifically within the MEDLINE(R), Pubmed, and EmBase, and Google Scholar using the search terms of “complementary and alternative medicine”, “head and neck cancer”, and “alternative medicine”. Inclusion criterion for studies involving CAM usage in adult head and neck cancer patients of any subsite.",
        "RESULTS": "44 articles were initially included by title or abstract and after screening 31 were reviewed. CAM usage varied by sex with 56.4% of men versus 43.6% of women reporting CAM usage. The majority of included studies focused on head and neck cancer patients, with 5 studies including them as part of a larger cohort. Of those that focused on head and neck cancer patients, the most common subsite was thyroid cancer. However, studies varied widely in their demographics, size, and usage percentages of CAM and alternative medicines. CAM was not defined in 65% of studies, with 86% of studies specific to head and neck cancers not specifying the pathology of malignancy associated with CAM usage. There was also variation in reporting of age, sex, a precise definition of CAM, what constitutes CAM usage with the latter including supplements, medication, and prayer. The most used CAM treatments used included supplements, followed by herbal medicines and teas. Only 2 studies were published after the COVID19 pandemic.",
        "DISCUSSION": "While CAM use is prevalent amount cancer patients, reporting on CAM use in the head and neck cancer population is inconsistent with regards to definitions of CAM, subsites studied, and detail about use practices. There are also few studies done on CAM use after the COVID19 pandemic, defined as 2020 and onwards, and past data may not reflect current CAM use practices among our study population. However, our findings do show an interest in CAM, specifically supplements both medical and herbal, among head and neck cancer patients which have high rates of use. These use patterns deserve to explored further in studies dedicated to head and neck cancer patients with well-defined CAM use and outcomes.",
        "CONCLUSION": "Patient usage of CAM has been continuous over the past 25 years and is prevalent among head and neck cancer patients. Providers should be aware of CAM use patterns among patients. Future work should be done specifically defining CAM types and use patterns in this patient cohort.",
        "CONTRIBUTION": "This study shows that CAM, particularly medical and herbal supplements, are commonly used in head and neck cancer patients. Dedicated study can rectify inconsistencies in current literature to provide a larger understanding on the subject of CAM usage."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Scoping Review of Complementary and Alternative Medicine Use in Head and Neck Cancer Patients</span>. <u>Drake V Johnston</u>; Rusha J Patel, MD; Micheal Machiorlatti, PhD. University of Oklahoma Health Science Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>The objective of this study was to evaluate published in the use of complementary and alternative medicine (CAM) among adults diagnosed with head and neck cancer.  </p>\n\n<p><strong>AIM: </strong>CAM usage has been shown to be prevalent within the head and neck cancer population; however, studies have varied in the presentation, classification of, and what constitutes CAM. The purpose of this review is to establish trends in CAM use in literature.</p>\n\n<p><strong>METHODS: </strong>Literature search following PRISMA Guideline was performed using the Ovid library, specifically within the MEDLINE(R), Pubmed, and EmBase, and Google Scholar using the search terms of “complementary and alternative medicine”, “head and neck cancer”, and “alternative medicine”. Inclusion criterion for studies involving CAM usage in adult head and neck cancer patients of any subsite.</p>\n\n<p><strong>RESULTS: </strong>44 articles were initially included by title or abstract and after screening 31 were reviewed. CAM usage varied by sex with 56.4% of men versus 43.6% of women reporting CAM usage. The majority of included studies focused on head and neck cancer patients, with 5 studies including them as part of a larger cohort. Of those that focused on head and neck cancer patients, the most common subsite was thyroid cancer. However, studies varied widely in their demographics, size, and usage percentages of CAM and alternative medicines. CAM was not defined in 65% of studies, with 86% of studies specific to head and neck cancers not specifying the pathology of malignancy associated with CAM usage. There was also variation in reporting of age, sex, a precise definition of CAM, what constitutes CAM usage with the latter including supplements, medication, and prayer. The most used CAM treatments used included supplements, followed by herbal medicines and teas. Only 2 studies were published after the COVID19 pandemic.</p>\n\n<p><strong>DISCUSSION: </strong>While CAM use is prevalent amount cancer patients, reporting on CAM use in the head and neck cancer population is inconsistent with regards to definitions of CAM, subsites studied, and detail about use practices. There are also few studies done on CAM use after the COVID19 pandemic, defined as 2020 and onwards, and past data may not reflect current CAM use practices among our study population. However, our findings do show an interest in CAM, specifically supplements both medical and herbal, among head and neck cancer patients which have high rates of use. These use patterns deserve to explored further in studies dedicated to head and neck cancer patients with well-defined CAM use and outcomes.</p>\n\n<p><strong>CONCLUSION: </strong>Patient usage of CAM has been continuous over the past 25 years and is prevalent among head and neck cancer patients. Providers should be aware of CAM use patterns among patients. Future work should be done specifically defining CAM types and use patterns in this patient cohort.</p>\n\n<p><strong>CONTRIBUTION: </strong>This study shows that CAM, particularly medical and herbal supplements, are commonly used in head and neck cancer patients. Dedicated study can rectify inconsistencies in current literature to provide a larger understanding on the subject of CAM usage.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153966--></body></html>"
    },
    {
      "uid": "P021",
      "content_id": "153557",
      "abstract_number": "P021",
      "poster_number": "P021",
      "title": "The lived experiences of family cancer caregivers and the impact of supportive services",
      "summary": "The American Cancer Society reported in 2022 there was 1,918,030 new cancer diagnoses in the United States With the increase in new cancer diagnoses, family caregivers will be called upon to support patients as they begin to navigate their cancer journey. A cancer diagnosis impacts the whole family and is often physically, emotionally, socially, and financially demanding to the informal caregiver Prior research...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153557",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amy Halter, Doctor",
      "presenter": "Amy Halter, Doctor",
      "authors": "Amy Halter, Doctor",
      "normalized_authors": [
        "Amy Halter, Doctor"
      ],
      "affiliations": [
        "Indiana University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Indiana University of Pennsylvania"
      ],
      "session_type": "Poster",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 256,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amy Halter, Doctor",
        "Affiliations": "Indiana University of Pennsylvania",
        "Abstract": "The American Cancer Society reported in 2022 there was 1,918,030 new cancer diagnoses in the United States With the increase in new cancer diagnoses, family caregivers will be called upon to support patients as they begin to navigate their cancer journey. A cancer diagnosis impacts the whole family and is often physically, emotionally, socially, and financially demanding to the informal caregiver Prior research has demonstrated the link between caregiver burden and the negative impacts on the caregiver. This qualitative, social constructivist research examined the experiences of caregivers for family members who have been diagnosed with head and neck cancer. Results included the following themes as they relate to the experiences of the cancer caregiver: impact on daily life, challenges of being a caregiver, feelings of guilt, patient relationship, need for support, and counseling services. These findings support the need for medical cancer healthcare teams to provide resources to family cancer caregivers. Further results indicated that a healthy caregiver would ensure that their loved one attends treatment, follows up with appointments and is given quality care in the home setting. Additionally, they provide insight for social workers/counselors to use when supporting caregivers, specifically the value of using the Indivisible Self Model as a tool to evaluate the cancer caregiver holistically to support them in the various domains that can suffer during caregiving. The findings point to the need for the medical team to ensure that the caregiver is seen during treatment and provided with the necessary supports. Keywords: cancer caregiver, family caregiver, caregiver burden"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The lived experiences of family cancer caregivers and the impact of supportive services</span>. <u>Amy Halter, Doctor</u>. Indiana University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The American Cancer Society reported in 2022 there was 1,918,030 new cancer diagnoses in the United States With the increase in new cancer diagnoses, family caregivers will be called upon to support patients as they begin to navigate their cancer journey. A cancer diagnosis impacts the whole family and is often physically, emotionally, socially, and financially demanding to the informal caregiver Prior research has demonstrated the link between caregiver burden and the negative impacts on the caregiver. This qualitative, social constructivist research examined the experiences of caregivers for family members who have been diagnosed with head and neck cancer. Results included the following themes as they relate to the experiences of the cancer caregiver: impact on daily life, challenges of being a caregiver, feelings of guilt, patient relationship, need for support, and counseling services. These findings support the need for medical cancer healthcare teams to provide resources to family cancer caregivers. Further results indicated that a healthy caregiver would ensure that their loved one attends treatment, follows up with appointments and is given quality care in the home setting. Additionally, they provide insight for social workers/counselors to use when supporting caregivers, specifically the value of using the Indivisible Self Model as a tool to evaluate the cancer caregiver holistically to support them in the various domains that can suffer during caregiving. The findings point to the need for the medical team to ensure that the caregiver is seen during treatment and provided with the necessary supports. </p>\n\n<p>Keywords: cancer caregiver, family caregiver, caregiver burden</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153557--></body></html>"
    },
    {
      "uid": "P022",
      "content_id": "154571",
      "abstract_number": "P022",
      "poster_number": "P022",
      "title": "From Diagnosis to Survivorship: A Qualitative Exploration of Psychological Distress Across the Head and Neck Cancer Continuum",
      "summary": "Psychological distress among patients with HNC is pervasive and evolves across the care continuum. Understanding these experiences is critical for identifying unmet psychosocial needs and informing targeted interventions that support both emotional and functional well-being among HNC patients across every stage of cancer care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154571",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES",
      "presenter": "Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES",
      "authors": "Rebecca A Zasloff, MPH 1 ; Alexandra E Hunter, BA 1 ; Judith Mwobobia 2 ; Margaret Falkovic 2 ; Revital Benvenisti 2 ; Morgan Byrd, PhD 3 ; Laura J Fish, PhD, MPH 4 ; Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES 3",
      "normalized_authors": [
        "Rebecca A Zasloff",
        "Alexandra E Hunter",
        "Judith Mwobobia",
        "Margaret Falkovic",
        "Revital Benvenisti",
        "Morgan Byrd",
        "Laura J Fish",
        "Nosayaba Osazuwa-Peters, BDS, CHES"
      ],
      "affiliations": [
        "Duke University School of Medicine",
        "Duke University",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine",
        "Duke Cancer Institute Behavioral Health and Survey Research Core"
      ],
      "normalized_institutions": [
        "Duke University School of Medicine",
        "Duke University",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine",
        "Duke Cancer Institute Behavioral Health and Survey Research Core"
      ],
      "session_type": "Poster",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154571/figure1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154571/figure1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154571"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Figure 1."
      ],
      "sections": {
        "Authors": "Rebecca A Zasloff, MPH 1 ; Alexandra E Hunter, BA 1 ; Judith Mwobobia 2 ; Margaret Falkovic 2 ; Revital Benvenisti 2 ; Morgan Byrd, PhD 3 ; Laura J Fish, PhD, MPH 4 ; Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES 3",
        "Affiliations": "1 Duke University School of Medicine; 2 Duke University; 3 Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine; 4 Duke Cancer Institute Behavioral Health and Survey Research Core",
        "Background": "Head and neck cancer (HNC) is among the most physically and psychologically challenging malignancies given its profound effect on essential functions, such as speaking and swallowing, as well as social interactions and quality of life. Compared to other cancers, patients with HNC experience disproportionately higher rates of psychosocial distress. Among survivors of HNC, history of mental health disorders, including anxiety and depression, has been linked to poorer survival outcomes, highlighting the potential impact of timely psychological interventions. Despite this, few studies have qualitatively explored the lived experiences of distress across the HNC care continuum as well as coping strategies patients rely on.",
        "Objective": "To characterize the experiences and management of psychological distress across the cancer continuum for patients with head and neck cancer.",
        "Methods": "Guided by the Consolidated Criteria for Reporting Qualitative Research (COREQ), we conducted in-depth qualitative interviews with survivors of HNC recruited from a tertiary cancer center. Eligible patients had documented “clinically significant” distress (NCCN Distress Thermometer score ≥4) within the past 6 months during a routine HNC visit. Using a semi-structured guide, interviews explored emotional challenges, treatment-related distress, and experiences with mental health and supportive services. All interviews were audio-recorded and transcribed. Using a rapid qualitative analysis approach, we identified common sources of distress for patients with HNC across multiple phases of cancer continuum as well as the strategies participants used to cope with distress. Demographic data were obtained through review of medical records.",
        "Results": "Twelve participants completed individual interviews. The cohort was 42% female, with a median age of 64 years. Most identified as White (92%), and all participants were non-Hispanic ethnicity. Two primary themes and nine subthemes emerged: (1) experiences of distress across the cancer trajectory and (2) approaches to managing distress. Participants described distress beginning at diagnosis triggered by overwhelming or insufficiently explained information about prognosis and treatment. Early encounters involving major surgical discussions contributed to fear and depressive symptoms. Distress intensified during treatment due to cumulative physical burden, daily appointments, and emotional fatigue. Participants reported fluctuating mood, persistent anxiety, and at times passive thoughts of not wanting to continue. Distress in survivorship remained significant. Long-term side effects of treatment, such as dysphagia, altered appearance, and fatigue, disrupted daily functioning and personal identity. Participants commonly reported ongoing anxiety and panic episodes emerging months after treatment. Fear of recurrence led some to withdraw socially or rely on rigid routines. Participants shared multiple coping strategies and described social support as essential. Mental health services, spirituality, information seeking, and self-advocacy served to alleviate distress. Practical supports, such as lodging and transportation, reduced distress associated with logistical burdens, especially during active treatment. Engaging in purposeful activities helped to rebuild a sense of identity in survivorship.",
        "Conclusion": "Psychological distress among patients with HNC is pervasive and evolves across the care continuum. Understanding these experiences is critical for identifying unmet psychosocial needs and informing targeted interventions that support both emotional and functional well-being among HNC patients across every stage of cancer care.",
        "Figure 1.": "Themes and Subthemes Overview"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>From Diagnosis to Survivorship: A Qualitative Exploration of Psychological Distress Across the Head and Neck Cancer Continuum</span>. Rebecca A Zasloff, MPH<sup>1</sup>; Alexandra E Hunter, BA<sup>1</sup>; Judith Mwobobia<sup>2</sup>; Margaret Falkovic<sup>2</sup>; Revital Benvenisti<sup>2</sup>; Morgan Byrd, PhD<sup>3</sup>; Laura J Fish, PhD, MPH<sup>4</sup>; <u>Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES</u><sup>3</sup>. <sup>1</sup>Duke University School of Medicine; <sup>2</sup>Duke University; <sup>3</sup>Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine; <sup>4</sup>Duke Cancer Institute Behavioral Health and Survey Research Core<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Head and neck cancer (HNC) is among the most physically and psychologically challenging malignancies given its profound effect on essential functions, such as speaking and swallowing, as well as social interactions and quality of life. Compared to other cancers, patients with HNC experience disproportionately higher rates of psychosocial distress. Among survivors of HNC, history of mental health disorders, including anxiety and depression, has been linked to poorer survival outcomes, highlighting the potential impact of timely psychological interventions. Despite this, few studies have qualitatively explored the lived experiences of distress across the HNC care continuum as well as coping strategies patients rely on. </p>\n\n<p><strong>Objective</strong>: To characterize the experiences and management of psychological distress across the cancer continuum for patients with head and neck cancer.</p>\n\n<p><strong>Methods</strong>: Guided by the Consolidated Criteria for Reporting Qualitative Research (COREQ), we conducted in-depth qualitative interviews with survivors of HNC recruited from a tertiary cancer center. Eligible patients had documented “clinically significant” distress (NCCN Distress Thermometer score ≥4) within the past 6 months during a routine HNC visit. Using a semi-structured guide, interviews explored emotional challenges, treatment-related distress, and experiences with mental health and supportive services. All interviews were audio-recorded and transcribed. Using a rapid qualitative analysis approach, we identified common sources of distress for patients with HNC across multiple phases of cancer continuum as well as the strategies participants used to cope with distress. Demographic data were obtained through review of medical records. </p>\n\n<p><strong>Results</strong>: Twelve participants completed individual interviews. The cohort was 42% female, with a median age of 64 years. Most identified as White (92%), and all participants were non-Hispanic ethnicity. Two primary themes and nine subthemes emerged: (1) experiences of distress across the cancer trajectory and (2) approaches to managing distress. Participants described distress beginning at diagnosis triggered by overwhelming or insufficiently explained information about prognosis and treatment. Early encounters involving major surgical discussions contributed to fear and depressive symptoms. Distress intensified during treatment due to cumulative physical burden, daily appointments, and emotional fatigue. Participants reported fluctuating mood, persistent anxiety, and at times passive thoughts of not wanting to continue. Distress in survivorship remained significant. Long-term side effects of treatment, such as dysphagia, altered appearance, and fatigue, disrupted daily functioning and personal identity. Participants commonly reported ongoing anxiety and panic episodes emerging months after treatment. Fear of recurrence led some to withdraw socially or rely on rigid routines. Participants shared multiple coping strategies and described social support as essential. Mental health services, spirituality, information seeking, and self-advocacy served to alleviate distress. Practical supports, such as lodging and transportation, reduced distress associated with logistical burdens, especially during active treatment. Engaging in purposeful activities helped to rebuild a sense of identity in survivorship. </p>\n\n<p><strong>Conclusion</strong>: Psychological distress among patients with HNC is pervasive and evolves across the care continuum. Understanding these experiences is critical for identifying unmet psychosocial needs and informing targeted interventions that support both emotional and functional well-being among HNC patients across every stage of cancer care.</p>\n\n<p><strong>Figure 1.</strong> Themes and Subthemes Overview</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154571/figure1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154571--></body></html>"
    },
    {
      "uid": "P023",
      "content_id": "154618",
      "abstract_number": "P023",
      "poster_number": "P023",
      "title": "Feasibility and acceptability of Virtual Reality Intervention to manage Depressive Symptoms, Anxiety and Pain in Head and Neck Cancer Patients Undergoing Chemo/Radiation",
      "summary": "The trial is in progress. We expect reduction in depressive symptoms, anxiety and pain in patients undergoing the intervention. We have recruited nearly half of our goal of patients. Our interim recruitment analysis indicate that the trial design and VR intervention is acceptable to the HNC patient-caregiver dyads.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154618",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Krupal B Patel, MD",
      "presenter": "Krupal B Patel, MD",
      "authors": "Krupal B Patel, MD ; Katerina Arca; Marice Alcantara; Daniela Castanotto, PhD; Sagus Sampath, MD; Arya Amini, MD; Sean Maroongroge, MD; Colton Ladbury, MD; George Semeniuk, MD; Lee Cranmer, MD; Amanda Reyes, MD; Ellie Maghami, MD; Thomas Gernon, MD; Sepehr Shabani, MD; Aditya Shreenivas, MD; Virginia Sun, PhD, MSN, RN",
      "normalized_authors": [
        "Krupal B Patel",
        "Katerina Arca",
        "Marice Alcantara",
        "Daniela Castanotto",
        "Sagus Sampath",
        "Arya Amini",
        "Sean Maroongroge",
        "Colton Ladbury",
        "George Semeniuk",
        "Lee Cranmer",
        "Amanda Reyes",
        "Ellie Maghami",
        "Thomas Gernon",
        "Sepehr Shabani",
        "Aditya Shreenivas",
        "Virginia Sun, MSN"
      ],
      "affiliations": [
        "City of Hope National Medical Center"
      ],
      "normalized_institutions": [
        "City of Hope National Medical Center"
      ],
      "session_type": "Poster",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Krupal B Patel, MD ; Katerina Arca; Marice Alcantara; Daniela Castanotto, PhD; Sagus Sampath, MD; Arya Amini, MD; Sean Maroongroge, MD; Colton Ladbury, MD; George Semeniuk, MD; Lee Cranmer, MD; Amanda Reyes, MD; Ellie Maghami, MD; Thomas Gernon, MD; Sepehr Shabani, MD; Aditya Shreenivas, MD; Virginia Sun, PhD, MSN, RN",
        "Affiliations": "City of Hope National Medical Center",
        "Purpose": "Head and Neck Cancer (HNC) patients undergoing chemoradiation or radiation (C/RT) can experience increased depressive symptomatology, anxiety, distress and pain that adversely impact quality of life. Virtual Reality (VR) based solutions have shown promise in non-cancer patients to reduce these symptoms, however there is limited evidence of VR use in cancer patients. Furthermore, there are no data in patients undergoing C/RT for HNC. The purpose of this study was to assess feasibility of VR to manage depressive symptoms, anxiety and pain in HNC patients undergoing C/RT. This is a trial in progress.",
        "Methods": "HNC patients ≥ 18 yrs, undergoing C/RT will be recruited. Patients will be asked to identify their primary caregivers (CG) at the time of recruitment and if CG would be interested in participation. Patient-caregiver dyads will be enrolled in the same intervention arm. Patients will be randomized 1:1 in a 3D immersive structured mindfulness VR program versus a 2D non-immersive program delivered at home via Meta Quest 3. Each arm will include 10 patients (and up to 10 caregivers). Participants will be asked to use the intervention 3x/week during active treatment and 1x/week for 4 weeks after treatment completion. Passive biometric data will be captured using Fitbit Charge 6. Electronic patient reported outcomes (ePRO) will be captured using Hamilton Anxiety and Depression Scale (HADS), Brief Pain Inventory – short form (BPI-SF), Edmonton Symptom Assessment Scale (ESAS), and FACT-HN 1x/week. Satisfaction and qualitative interviews will be conducted at the end of the study.",
        "Abstract": "Feasibility will be assessed with a priori benchmarks for recruitment (≥50% of eligible patients will agree to participate), retention (≥70% of participants will use the intervention), adherence to intervention (≥50% of participants will use the intervention), completion of ePRO (≥70% of on-treatment scheduled ePROs will be completed by each participant). Acceptability will be assessed with an a priori participant satisfaction benchmark (≥50% of participants reporting that their experience with the study was positive).",
        "Results": "The trial is ongoing. From June 26/25 – Nov 1/25, 21 patients were approached to participate. 9 patients are currently enrolled in the trial – 3 (33.3%) patients alone and 6 (66.7%) patient-caregiver dyads. Mean patient age of patients is 69 yrs (49 – 79), with 8 (88.9%) being male, 7 (77.8%) receiving CRT, 7 (77.8%) with oropharynx primary. Mean caregiver age is 58.8 yrs (42 – 73), with 5 being female. There are 6 (66.7%) patients in the mindfulness VR arm and 3 (33.3%) are in the 2D non-immersive arm.",
        "Conclusion": "The trial is in progress. We expect reduction in depressive symptoms, anxiety and pain in patients undergoing the intervention. We have recruited nearly half of our goal of patients. Our interim recruitment analysis indicate that the trial design and VR intervention is acceptable to the HNC patient-caregiver dyads."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Feasibility and acceptability of Virtual Reality Intervention to manage Depressive Symptoms, Anxiety and Pain in Head and Neck Cancer Patients Undergoing Chemo/Radiation</span>. <u>Krupal B Patel, MD</u>; Katerina Arca; Marice Alcantara; Daniela Castanotto, PhD; Sagus Sampath, MD; Arya Amini, MD; Sean Maroongroge, MD; Colton Ladbury, MD; George Semeniuk, MD; Lee Cranmer, MD; Amanda Reyes, MD; Ellie Maghami, MD; Thomas Gernon, MD; Sepehr Shabani, MD; Aditya Shreenivas, MD; Virginia Sun, PhD, MSN, RN. City of Hope National Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Head and Neck Cancer (HNC) patients undergoing chemoradiation or radiation (C/RT) can experience increased depressive symptomatology, anxiety, distress and pain that adversely impact quality of life. Virtual Reality (VR) based solutions have shown promise in non-cancer patients to reduce these symptoms, however there is limited evidence of VR use in cancer patients. Furthermore, there are no data in patients undergoing C/RT for HNC. The purpose of this study was to assess feasibility of VR to manage depressive symptoms, anxiety and pain in HNC patients undergoing C/RT. This is a trial in progress.</p>\n\n<p><strong>Methods: </strong>HNC patients ≥ 18 yrs, undergoing C/RT will be recruited. Patients will be asked to identify their primary caregivers (CG) at the time of recruitment and if CG would be interested in participation. Patient-caregiver dyads will be enrolled in the same intervention arm. Patients will be randomized 1:1 in a 3D immersive structured mindfulness VR program versus a 2D non-immersive program delivered at home via Meta Quest 3. Each arm will include 10 patients (and up to 10 caregivers). Participants will be asked to use the intervention 3x/week during active treatment and 1x/week for 4 weeks after treatment completion. Passive biometric data will be captured using Fitbit Charge 6. Electronic patient reported outcomes (ePRO) will be captured using Hamilton Anxiety and Depression Scale (HADS), Brief Pain Inventory – short form (BPI-SF), Edmonton Symptom Assessment Scale (ESAS), and FACT-HN 1x/week. Satisfaction and qualitative interviews will be conducted at the end of the study.</p>\n\n<p>Feasibility will be assessed with a priori benchmarks for recruitment (≥50% of eligible patients will agree to participate), retention (≥70% of participants will use the intervention), adherence to intervention (≥50% of participants will use the intervention), completion of ePRO (≥70% of on-treatment scheduled ePROs will be completed by each participant). Acceptability will be assessed with an a priori participant satisfaction benchmark (≥50% of participants reporting that their experience with the study was positive).</p>\n\n<p><strong>Results: </strong>The trial is ongoing. From June 26/25 – Nov 1/25, 21 patients were approached to participate. 9 patients are currently enrolled in the trial – 3 (33.3%) patients alone and 6 (66.7%) patient-caregiver dyads. Mean patient age of patients is 69 yrs (49 – 79), with 8 (88.9%) being male, 7 (77.8%) receiving CRT, 7 (77.8%) with oropharynx primary. Mean caregiver age is 58.8 yrs (42 – 73), with 5 being female. There are 6 (66.7%) patients in the mindfulness VR arm and 3 (33.3%) are in the 2D non-immersive arm.</p>\n\n<p><strong>Conclusion: </strong>The trial is in progress. We expect reduction in depressive symptoms, anxiety and pain in patients undergoing the intervention. We have recruited nearly half of our goal of patients. Our interim recruitment analysis indicate that the trial design and VR intervention is acceptable to the HNC patient-caregiver dyads.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154618--></body></html>"
    },
    {
      "uid": "P024",
      "content_id": "153579",
      "abstract_number": "P024",
      "poster_number": "P024",
      "title": "In vivo reprogramming unveils anaplastic transformation mechanism in thyroid carcinoma",
      "summary": "These findings reveal that embryonic reprogramming is a key mechanism to induce anaplastic transformation, offering a mechanistic link between plasticity and malignancy in ATC. Our study identifies in vivo reprogramming as a powerful tool to model anaplastic transformation and highlights the therapeutic potential of redifferentiation strategies in ATC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153579",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hirofumi Shibata, MD, PhD",
      "presenter": "Hirofumi Shibata, MD, PhD",
      "authors": "Hirofumi Shibata, MD, PhD 1 ; Ryo Kawaura, MD 2 ; Akari Unome, MD 2 ; Takenori Ogawa, MD, PhD 2",
      "normalized_authors": [
        "Hirofumi Shibata",
        "Ryo Kawaura",
        "Akari Unome",
        "Takenori Ogawa"
      ],
      "affiliations": [
        "Mie University",
        "Gifu University"
      ],
      "normalized_institutions": [
        "Mie University",
        "Gifu University"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 274,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Method",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Hirofumi Shibata, MD, PhD 1 ; Ryo Kawaura, MD 2 ; Akari Unome, MD 2 ; Takenori Ogawa, MD, PhD 2",
        "Affiliations": "1 Mie University; 2 Gifu University",
        "Abstract": "Anaplastic thyroid carcinomas (ATCs) are a relatively rare but highly aggressive type of thyroid carcinoma. To unveil the mechanism of anaplastic transformation, we first investigated the pluripotent gene expression profile in human ATCs. Then we aimed to use in vivo reprogramming technology to elucidate the mechanism of anaplastic transformation.",
        "Method": "Immunostaining of pluripotency-related proteins (SALL4, LIN28) was performed on a total of 31 ATC cases treated at Gifu University Hospital. Then, public gene expression data were modified to identify pluripotency-related gene groups in undifferentiated thyroid cancer. In addition, we generated TPO-Cre, LSL-Braf V600E, Rosa LSL-rtTA3, Col1a1 tetO-OSKM genetically engineered mice and overexpressed OSKM reprogramming factors using the Tet-ON system.",
        "Results": "We demonstrate that human ATC exhibits a hybrid transcriptional state resembling pluripotent stem cells, with upregulation of SOX2, MYC, LIN28B, and SALL4 in conjunction with the activation of the MAPK pathway. Using genetically engineered mouse models, we show that forced expression of reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc; OSKM) induces anaplastic transformation in thyroid epithelium, even in the absence of Tp53 mutation. This transformation is characterized by loss of the thyroid lineage marker Ttf-1, elevated Ki-67, sustained ERK activation, and pluripotency-related protein expression. Furthermore, we show that Braf mutation, combined with embryonic reprogramming, was sufficient to induce ATC formation even in the absence of TP53 mutation. Conversely, redifferentiation to ATC cells attenuates proliferation and restores differentiation features.",
        "Conclusion": "These findings reveal that embryonic reprogramming is a key mechanism to induce anaplastic transformation, offering a mechanistic link between plasticity and malignancy in ATC. Our study identifies in vivo reprogramming as a powerful tool to model anaplastic transformation and highlights the therapeutic potential of redifferentiation strategies in ATC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>In vivo reprogramming unveils anaplastic transformation mechanism in thyroid carcinoma</span>. <u>Hirofumi Shibata, MD, PhD</u><sup>1</sup>; Ryo Kawaura, MD<sup>2</sup>; Akari Unome, MD<sup>2</sup>; Takenori Ogawa, MD, PhD<sup>2</sup>. <sup>1</sup>Mie University; <sup>2</sup>Gifu University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Anaplastic thyroid carcinomas (ATCs) are a relatively rare but highly aggressive type of thyroid carcinoma. To unveil the mechanism of anaplastic transformation, we first investigated the pluripotent gene expression profile in human ATCs. Then we aimed to use in vivo reprogramming technology to elucidate the mechanism of anaplastic transformation.</p>\n\n<p><strong>Method: </strong>Immunostaining of pluripotency-related proteins (SALL4, LIN28) was performed on a total of 31 ATC cases treated at Gifu University Hospital. Then, public gene expression data were modified to identify pluripotency-related gene groups in undifferentiated thyroid cancer. In addition, we generated TPO-Cre, LSL-Braf V600E, Rosa LSL-rtTA3, Col1a1 tetO-OSKM genetically engineered mice and overexpressed OSKM reprogramming factors using the Tet-ON system.</p>\n\n<p><strong>Results: </strong>We demonstrate that human ATC exhibits a hybrid transcriptional state resembling pluripotent stem cells, with upregulation of SOX2, MYC, LIN28B, and SALL4 in conjunction with the activation of the MAPK pathway. Using genetically engineered mouse models, we show that forced expression of reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc; OSKM) induces anaplastic transformation in thyroid epithelium, even in the absence of Tp53 mutation. This transformation is characterized by loss of the thyroid lineage marker Ttf-1, elevated Ki-67, sustained ERK activation, and pluripotency-related protein expression. Furthermore, we show that Braf mutation, combined with embryonic reprogramming, was sufficient to induce ATC formation even in the absence of TP53 mutation. Conversely, redifferentiation to ATC cells attenuates proliferation and restores differentiation features.</p>\n\n<p><strong>Conclusion: </strong>These findings reveal that embryonic reprogramming is a key mechanism to induce anaplastic transformation, offering a mechanistic link between plasticity and malignancy in ATC. Our study identifies in vivo reprogramming as a powerful tool to model anaplastic transformation and highlights the therapeutic potential of redifferentiation strategies in ATC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153579--></body></html>"
    },
    {
      "uid": "P025",
      "content_id": "153406",
      "abstract_number": "P025",
      "poster_number": "P025",
      "title": "Post-Irradiation Gene Expression Profiling Reveals ALDH2 as Translational Radiosensitization Target in Nasopharyngeal Carcinoma (NPC) Cell Lines",
      "summary": "Using ClusterGVis, we identified 4159, 3661 and 3962 genes as upregulated following irradiation in C17, C666-1 and NPC43, respectively. Of these, 296 gene were consistently upregulated across all three cell lines. We then ranked genes by their mean Spearman correlation with time points after irradiation and identified TRIM22, WFDC2, and ALDH2 as the top three candidates, with mean Spearman correlation...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153406",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Cher An Javier Chee",
      "presenter": "Cher An Javier Chee",
      "authors": "Cher An Javier Chee ; Chuan Keng Goh; Yi Ren; Ce-Bella Chen; Thomas Kwok Seng Loh; Raymond Tsang; Joshua K Tay",
      "normalized_authors": [
        "Cher An Javier Chee",
        "Chuan Keng Goh",
        "Yi Ren",
        "Ce-Bella Chen",
        "Thomas Kwok Seng Loh",
        "Raymond Tsang",
        "Joshua K Tay"
      ],
      "affiliations": [
        "National University of Singapore"
      ],
      "normalized_institutions": [
        "National University of Singapore"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153406/Figure(3).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153406/Figure(3).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153406"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 422,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Cher An Javier Chee ; Chuan Keng Goh; Yi Ren; Ce-Bella Chen; Thomas Kwok Seng Loh; Raymond Tsang; Joshua K Tay",
        "Affiliations": "National University of Singapore",
        "Background": "Nasopharyngeal cancer (NPC) is endemic in Southern China and Southeast Asia. Although radiotherapy is the mainstay for NPC treatment, a significant portion of patients (~20%) experience treatment failure due to radioresistance, a leading contributor to NPC mortality. Currently, there are no reliable biomarkers to predict radioresistance or targeted therapies to counteract it. To address this gap, we investigated post-irradiation gene expression changes in NPC cell lines to identify upregulated genes. These genes can serve as potential biomarkers and targets for precision therapy to enhance radiosensitivity and improve patient outcomes.",
        "Methods": "Three NPC cell lines (C17, C666-1, NPC43) were irradiated at doses of 1 Gy for C17 and C666-1 and 2 Gy for NPC43. Total RNA were extracted at 3, 6, 12, 24, 48, and 72 hours post-irradiation. RNA sequencing was performed and gene expression patterns were identified using ClusterGVis. Among genes upregulated by irradiation, Spearman correlation coefficients were computed across the cell lines, and genes were ranked by their mean Spearman correlation.",
        "Results": "Using ClusterGVis, we identified 4159, 3661 and 3962 genes as upregulated following irradiation in C17, C666-1 and NPC43, respectively. Of these, 296 gene were consistently upregulated across all three cell lines. We then ranked genes by their mean Spearman correlation with time points after irradiation and identified TRIM22, WFDC2, and ALDH2 as the top three candidates, with mean Spearman correlation coefficients of 0.94, 0.94, and 0.93, respectively. Consistent with previous publications, TRIM22, WFDC2, and ALDH2 each have known association with cancer; notably, WFDC2 (HE4) has been associated with radioresistance in gastric cancer. Given its established role as a mitochondrial aldehyde detoxification enzyme that limits ROS-mediated damage, ALDH2 emerged as a plausible mediator of irradiation resistance in NPC cells and a potential therapeutic target. We therefore prioritized ALDH2 for translational study.",
        "Discussion": "ALDH2 activity can be antagonized by disulfiram, an existing, widely available, and affordable drug. Disulfiram has demonstrated radio-chemo-sensitizing effects in head and neck squamous cell carcinoma (HNSCC) cells line via ROS-induced cytotoxicity. Additionally, the ALDH2*2 variant – the most common single nucleotide polymorphism in Asia – confers reduced ALDH2 activity; individuals with the variant may exhibit enhanced radiosensitivity, raising the possibility of radiotherapy dose de-escalation to reduce radiotoxicity. Collectively, these features position ALDH2 a clinically actionable target for precision therapy in NPC, enabling both pharmacological radiosensitization and biomarker-guided radiotherapy dose optimization. Ongoing and future work will aim to confirm ALDH2 upregulation post-irradiation at the protein level by Western blot, evaluate the effects of ALDH2 antagonist and agonist, and ALDH2 knockdown on radiation induced-oxidative stress, DNA damage, and clonogenic survival."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Post-Irradiation Gene Expression Profiling Reveals ALDH2 as Translational Radiosensitization Target in Nasopharyngeal Carcinoma (NPC) Cell Lines</span>. <u>Cher An Javier Chee</u>; Chuan Keng Goh; Yi Ren; Ce-Bella Chen; Thomas Kwok Seng Loh; Raymond Tsang; Joshua K Tay. National University of Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Nasopharyngeal cancer (NPC) is endemic in Southern China and Southeast Asia. Although radiotherapy is the mainstay for NPC treatment, a significant portion of patients (~20%) experience treatment failure due to radioresistance, a leading contributor to NPC mortality. Currently, there are no reliable biomarkers to predict radioresistance or targeted therapies to counteract it. To address this gap, we investigated post-irradiation gene expression changes in NPC cell lines to identify upregulated genes. These genes can serve as potential biomarkers and targets for precision therapy to enhance radiosensitivity and improve patient outcomes.</p>\n\n<p><strong>Methods: </strong>Three NPC cell lines (C17, C666-1, NPC43) were irradiated at doses of 1 Gy for C17 and C666-1 and 2 Gy for NPC43. Total RNA were extracted at 3, 6, 12, 24, 48, and 72 hours post-irradiation. RNA sequencing was performed and gene expression patterns were identified using ClusterGVis. Among genes upregulated by irradiation, Spearman correlation coefficients were computed across the cell lines, and genes were ranked by their mean Spearman correlation.</p>\n\n<p><strong>Results: </strong>Using ClusterGVis, we identified 4159, 3661 and 3962 genes as upregulated following irradiation in C17, C666-1 and NPC43, respectively. Of these, 296 gene were consistently upregulated across all three cell lines. We then ranked genes by their mean Spearman correlation with time points after irradiation and identified TRIM22, WFDC2, and ALDH2 as the top three candidates, with mean Spearman correlation coefficients of 0.94, 0.94, and 0.93, respectively. Consistent with previous publications, TRIM22, WFDC2, and ALDH2 each have known association with cancer; notably, WFDC2 (HE4) has been associated with radioresistance in gastric cancer. Given its established role as a mitochondrial aldehyde detoxification enzyme that limits ROS-mediated damage, ALDH2 emerged as a plausible mediator of irradiation resistance in NPC cells and a potential therapeutic target. We therefore prioritized ALDH2 for translational study. </p>\n\n<p><strong>Discussion: </strong>ALDH2 activity can be antagonized by disulfiram, an existing, widely available, and affordable drug. Disulfiram has demonstrated radio-chemo-sensitizing effects in head and neck squamous cell carcinoma (HNSCC) cells line via ROS-induced cytotoxicity. Additionally, the ALDH2*2 variant – the most common single nucleotide polymorphism in Asia – confers reduced ALDH2 activity; individuals with the variant may exhibit enhanced radiosensitivity, raising the possibility of radiotherapy dose de-escalation to reduce radiotoxicity. Collectively, these features position ALDH2 a clinically actionable target for precision therapy in NPC, enabling both pharmacological radiosensitization and biomarker-guided radiotherapy dose optimization. Ongoing and future work will aim to confirm ALDH2 upregulation post-irradiation at the protein level by Western blot, evaluate the effects of ALDH2 antagonist and agonist, and ALDH2 knockdown on radiation induced-oxidative stress, DNA damage, and clonogenic survival. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153406/Figure(3).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153406--></body></html>"
    },
    {
      "uid": "P026",
      "content_id": "153242",
      "abstract_number": "P026",
      "poster_number": "P026",
      "title": "Reparixin Slows Cancer Cell Migration and Proliferation in Human Head and Neck Cutaneous Squamous Cell Carcinoma",
      "summary": "IL-8 is highly expressed by HNcSCC cells. In our in vitro model, inhibiting IL-8 signaling with reparixin significantly slowed cancer cell migration in all cell lines and cancer cell proliferation at a later timepoint in HNA07. Further investigation into the role of IL-8 within the tumor microenvironment may lead to a novel therapeutic approach for the treatment of cSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153242",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michelle Pei, MD",
      "presenter": "Michelle Pei, MD",
      "authors": "Michelle Pei, MD ; Olena Bracho, MBA; Erin Kaye, MD; Zoukaa Sargi, MD, MPH; Donald Weed, MD; Christine Dinh, MD",
      "normalized_authors": [
        "Michelle Pei",
        "Olena Bracho",
        "Erin Kaye",
        "Zoukaa Sargi",
        "Donald Weed",
        "Christine Dinh"
      ],
      "affiliations": [
        "University of Miami"
      ],
      "normalized_institutions": [
        "University of Miami"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Michelle Pei, MD ; Olena Bracho, MBA; Erin Kaye, MD; Zoukaa Sargi, MD, MPH; Donald Weed, MD; Christine Dinh, MD",
        "Affiliations": "University of Miami",
        "Background": "Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide with the highest disease incidence in the head and neck. Currently, surgery is the mainstay of therapy with the addition of adjuvant radiation and/or immunotherapy for aggressive disease. In recent years, there is building interest to develop targeted treatments capable of halting cSCC cancer progression and spread. A potential area to target is the tumor microenvironment, which comprise of a rich milieu of signaling molecules that promote cancer growth and invasion. Recently, our lab has shown IL-8 is highly secreted by cSCCs, and the addition of recombinant IL-8 promotes cSCC cell proliferation and migration in vitro.",
        "Purpose": "In our study, we aimed to study the effect of an IL-8 receptor inhibitor on cSCC cell proliferation and migration.",
        "Methods": "Two patient-derived head and neck cSCC cell lines (HNA07, HNA15) were developed using a previously described method from tumors obtained in the operating room at the University of Miami Hospital. HNA07, HNA15, and A431 (an established human cSCC cell line) were cultured. Culture media was harvested on day 2 and a cytokine array was performed: one highly expressed cytokine (IL-8) was chosen for further investigation. To study cell proliferation, cells were plated on a 96-well plate and 100uM of reparixin, an IL-8 receptor inhibitor, was added. CellTiter-Glo assays were performed to assess for cell viability at 0, 12, 24, and 48 hours. Two migration assays were performed: the scratch migration assay and the transwell migration assay. For the scratch migration assay, cells were placed on a 24-well plate and allowed to grow to confluency. A scratcher comb was used to make uniform gaps in the cell monolayer. Reparixin was then added to the wells and the plates were incubated in a live-imaging microscope with images taken every 4 hours for 48 hours. For the transwell migration assay, a monolayer of cells with reparixin was added to transwell inserts, which were fully submerged in media with a chemoattractant. Cells were allowed to migrate for 12, 24, or 48 hours, stained with DAPI, and counted using fluorescence microscopy.",
        "Results": "IL-8 was highly expressed by all 3 cSCC cell lines. In all cell lines, the addition of IL-8 receptor inhibitor reparixin significantly slowed the rate of gap closure on scratch migration assay and the rate of transwell cell migration when compared to the control. Reparixin had no effect on HNA07 cell viability at 12 and 24 hours, however significantly reduced viability at 48 hours; there was no effect on cell viability in A431 and HNA15 at all tested time points.",
        "Conclusion": "IL-8 is highly expressed by HNcSCC cells. In our in vitro model, inhibiting IL-8 signaling with reparixin significantly slowed cancer cell migration in all cell lines and cancer cell proliferation at a later timepoint in HNA07. Further investigation into the role of IL-8 within the tumor microenvironment may lead to a novel therapeutic approach for the treatment of cSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Reparixin Slows Cancer Cell Migration and Proliferation in Human Head and Neck Cutaneous Squamous Cell Carcinoma</span>. <u>Michelle Pei, MD</u>; Olena Bracho, MBA; Erin Kaye, MD; Zoukaa Sargi, MD, MPH; Donald Weed, MD; Christine Dinh, MD. University of Miami<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide with the highest disease incidence in the head and neck. Currently, surgery is the mainstay of therapy with the addition of adjuvant radiation and/or immunotherapy for aggressive disease. In recent years, there is building interest to develop targeted treatments capable of halting cSCC cancer progression and spread. A potential area to target is the tumor microenvironment, which comprise of a rich milieu of signaling molecules that promote cancer growth and invasion. Recently, our lab has shown IL-8 is highly secreted by cSCCs, and the addition of recombinant IL-8 promotes cSCC cell proliferation and migration in vitro.</p>\n\n<p><strong>Purpose: </strong>In our study, we aimed to study the effect of an IL-8 receptor inhibitor on cSCC cell proliferation and migration.</p>\n\n<p><strong>Methods:</strong> Two patient-derived head and neck cSCC cell lines (HNA07, HNA15) were developed using a previously described method from tumors obtained in the operating room at the University of Miami Hospital. HNA07, HNA15, and A431 (an established human cSCC cell line) were cultured. Culture media was harvested on day 2 and a cytokine array was performed: one highly expressed cytokine (IL-8) was chosen for further investigation. To study cell proliferation, cells were plated on a 96-well plate and 100uM of reparixin, an IL-8 receptor inhibitor, was added. CellTiter-Glo assays were performed to assess for cell viability at 0, 12, 24, and 48 hours. Two migration assays were performed: the scratch migration assay and the transwell migration assay. For the scratch migration assay, cells were placed on a 24-well plate and allowed to grow to confluency. A scratcher comb was used to make uniform gaps in the cell monolayer. Reparixin was then added to the wells and the plates were incubated in a live-imaging microscope with images taken every 4 hours for 48 hours. For the transwell migration assay, a monolayer of cells with reparixin was added to transwell inserts, which were fully submerged in media with a chemoattractant. Cells were allowed to migrate for 12, 24, or 48 hours, stained with DAPI, and counted using fluorescence microscopy.</p>\n\n<p><strong>Results:</strong> IL-8 was highly expressed by all 3 cSCC cell lines. In all cell lines, the addition of IL-8 receptor inhibitor reparixin significantly slowed the rate of gap closure on scratch migration assay and the rate of transwell cell migration when compared to the control. Reparixin had no effect on HNA07 cell viability at 12 and 24 hours, however significantly reduced viability at 48 hours; there was no effect on cell viability in A431 and HNA15 at all tested time points.</p>\n\n<p><strong>Conclusion:</strong> IL-8 is highly expressed by HNcSCC cells. In our <em>in vitro</em> model, inhibiting IL-8 signaling with reparixin significantly slowed cancer cell migration in all cell lines and cancer cell proliferation at a later timepoint in HNA07. Further investigation into the role of IL-8 within the tumor microenvironment may lead to a novel therapeutic approach for the treatment of cSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153242--></body></html>"
    },
    {
      "uid": "P027",
      "content_id": "153710",
      "abstract_number": "P027",
      "poster_number": "P027",
      "title": "Extramammary Myofibroblastoma of the Cervical Region: A Rare Diagnosis and the Crucial Role of Immunohistochemistry",
      "summary": "Extramammary myofibroblastoma is a rare benign neoplasm, whose recognition is vital for proper management.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153710",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex F Porsani, MD",
      "presenter": "Alex F Porsani, MD",
      "authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
      "normalized_authors": [
        "Alex F Porsani",
        "Eloa B Oliveira Andrade",
        "Julia O Parenti",
        "Maria Beatriz Orru",
        "Nathalia M Nogueira"
      ],
      "affiliations": [
        "Santa Casa Araraquara"
      ],
      "normalized_institutions": [
        "Santa Casa Araraquara"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 187,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Abstract",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
        "Affiliations": "Santa Casa Araraquara",
        "Objective": "Myofibroblastoma is a rare benign neoplasm, with extramammary occurrence even more uncommon, presenting diagnostic challenges.",
        "Abstract": "This study aims to describe a case of extramammary cervical myofibroblastoma in an elderly patient and to review the literature to improve knowledge about this rare condition. The review was conducted in PubMed, ScienceDirect, and Google Scholar, focusing on the epidemiology, clinical characteristics, diagnosis, treatment, and prognosis of extramammary myofibroblastoma. Complete surgical excision revealed a benign extramammary myofibroblastoma with clear margins. The patient had a good recovery, without recurrence of the lesion. Clinical presentation can vary, but surgical excision is the treatment of choice and is usually curative. Histopathology and immunohistochemistry are crucial for diagnostic confirmation, avoiding unnecessary interventions. This case reinforces the effectiveness of surgical excision and the importance of accurate diagnosis for a favorable prognosis.",
        "Methods": "A descriptive case report was conducted, with retrospective analysis of clinical and histopathological data from a patient.",
        "Results": "A 78-year-old male patient presented with a painful cervical nodule for six months.",
        "Discussion": "Extramammary myofibroblastoma is a rare entity that requires careful differential diagnosis.",
        "Conclusion": "Extramammary myofibroblastoma is a rare benign neoplasm, whose recognition is vital for proper management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Extramammary Myofibroblastoma of the Cervical Region: A Rare Diagnosis and the Crucial Role of Immunohistochemistry</span>. <u>Alex F Porsani, MD</u>; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira. Santa Casa Araraquara<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Myofibroblastoma is a rare benign neoplasm, with extramammary occurrence even more uncommon, presenting diagnostic challenges.</p>\n\n<p>This study aims to describe a case of extramammary cervical myofibroblastoma in an elderly patient and to review the literature to improve knowledge about this rare condition.</p>\n\n<p><strong>Methods: </strong>A descriptive case report was conducted, with retrospective analysis of clinical and histopathological data from a patient.</p>\n\n<p>The review was conducted in PubMed, ScienceDirect, and Google Scholar, focusing on the epidemiology, clinical characteristics, diagnosis, treatment, and prognosis of extramammary myofibroblastoma.</p>\n\n<p><strong>Results: </strong>A 78-year-old male patient presented with a painful cervical nodule for six months.</p>\n\n<p>Complete surgical excision revealed a benign extramammary myofibroblastoma with clear margins.</p>\n\n<p>The patient had a good recovery, without recurrence of the lesion.</p>\n\n<p><strong>Discussion: </strong>Extramammary myofibroblastoma is a rare entity that requires careful differential diagnosis.</p>\n\n<p>Clinical presentation can vary, but surgical excision is the treatment of choice and is usually curative. Histopathology and immunohistochemistry are crucial for diagnostic confirmation, avoiding unnecessary interventions.</p>\n\n<p><strong>Conclusion: </strong>Extramammary myofibroblastoma is a rare benign neoplasm, whose recognition is vital for proper management.</p>\n\n<p>This case reinforces the effectiveness of surgical excision and the importance of accurate diagnosis for a favorable prognosis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153710--></body></html>"
    },
    {
      "uid": "P028",
      "content_id": "147755",
      "abstract_number": "P028",
      "poster_number": "P028",
      "title": "Ambient Air Pollution Exposure and Survival Outcomes in Head and Neck Cancer Patients",
      "summary": "Elevated levels of ambient air pollution, including fine particulate matter less than or equal to 2.5 micrometers in diameter (PM 2.5 ), are associated with a wide range of detrimental health effects, including increased risk of cardiovascular disease, malignancy, stroke, diabetes, respiratory disease and all-cause mortality. Air pollution exposure is an independent risk factor for development of lung cancer and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147755",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Weinberg, BS",
      "presenter": "Jessica Weinberg, BS",
      "authors": "Amanda E Dilger, MD; Xianhong Xie, PhD; Jessica Weinberg, BS ; Yocheved Halberstam, MPH; Vikas Mehta, MD, MPH; H",
      "normalized_authors": [
        "Amanda E Dilger",
        "Xianhong Xie",
        "Jessica Weinberg",
        "Yocheved Halberstam",
        "Vikas Mehta"
      ],
      "affiliations": [
        "Dean Hosgood, PhD. Montefiore Einstein"
      ],
      "normalized_institutions": [
        "Dean Hosgood, PhD. Montefiore Einstein"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/147755/HNC_overall_survival_by_PM2p5.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/147755/HNC_overall_survival_by_PM2p5.png",
          "alt": "Kaplan-Meier survival curve for head and neck cancer patients exposed to low (green) versus medium to high (red) levels of fine particulate matter (p < 0.0001)",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147755"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amanda E Dilger, MD; Xianhong Xie, PhD; Jessica Weinberg, BS ; Yocheved Halberstam, MPH; Vikas Mehta, MD, MPH; H",
        "Affiliations": "Dean Hosgood, PhD. Montefiore Einstein",
        "Abstract": "Elevated levels of ambient air pollution, including fine particulate matter less than or equal to 2.5 micrometers in diameter (PM 2.5 ), are associated with a wide range of detrimental health effects, including increased risk of cardiovascular disease, malignancy, stroke, diabetes, respiratory disease and all-cause mortality. Air pollution exposure is an independent risk factor for development of lung cancer and has been classified as a Group 1 carcinogen by the International Agency for Research on Cancer. In patients with lung cancer, exposure to higher levels of PM 2.5 and other air pollutants including sulfur dioxide (SO 2 ) and nitrogen dioxide (NO 2 ) are associated with higher all-cause and disease specific mortality. Recent studies have demonstrated an association between PM 2.5 exposure and increased incidence of head and neck cancer, suggesting a role for air pollution exposure in HNC disease development similar to that of lung cancer. However, despite similar exposure mechanisms between air pollution and the upper and lower airways, the relationship between air pollution exposure and survival in head and neck cancer (HNC) patients has not yet been explored. There are also no studies to date that assess air pollution exposure as a potential contributor to outcome disparities in head and neck surgical oncology. Given the well-established increase in ambient air pollution exposure in historically disadvantaged communities and the carcinogenic properties of air pollution, we hypothesized that environmental air pollution exposure contributes to disparities in stage at presentation and survival outcomes. Here, a multivariable logistic regression model and a Cox proportional hazards model were used to assess the relationship between air pollution exposure and the stage at diagnosis and survival in 2,642 adult patients diagnosed with HNC at a single academic institution between 2004 and 2024. The stepwise model selection was used to develop the final multivariable models. Patients included were diagnosed with HNC based on International Classification of Diseases – Oncology version 3 (ICD-O-3) codes for oral cavity, oropharynx, larynx, hypopharynx, sinonasal and middle ear cancers; and patients with missing covariates and/or location data required to assess air pollution exposure were excluded. The cohort was 68.8% male, 67.1% non-White, 30.6% Hispanic/Latino and 73.9% current or former smokers. 77.6% of patients were insured by Medicaid or Medicare. The majority of HNC diagnoses involved the larynx (30.2%), oral cavity (33.0%), and oropharynx (21.4%). PM 2.5 exposure was associated with decreased overall survival even when controlling for other known prognostic factors including tobacco use, insurance status and stage at presentation [HR 1.08, 95% CI 1.03-1.12 (p = 0.001)] (Figure 1). Additionally, NO 2 exposure was positively associated with later cancer stage at diagnosis [OR 1.10, 95% CI 1.05-1.16 (p = 0.0001)]. These findings suggest that air pollution exposure may contribute to disparities in HNC survival. Further research is needed to better understand the mechanism by which air pollution impacts disease development and outcomes in HNC. Figure 1: Kaplan-Meier survival curves for overall survival in HNC patients exposed to low (green) and moderate-to-high (red) levels of PM 2.5 (p < 0.0001)."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ambient Air Pollution Exposure and Survival Outcomes in Head and Neck Cancer Patients</span>. Amanda E Dilger, MD; Xianhong Xie, PhD; <u>Jessica Weinberg, BS</u>; Yocheved Halberstam, MPH; Vikas Mehta, MD, MPH; H. Dean Hosgood, PhD. Montefiore Einstein<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Elevated levels of ambient air pollution, including fine particulate matter less than or equal to 2.5 micrometers in diameter (PM<sub>2.5</sub>), are associated with a wide range of detrimental health effects, including increased risk of cardiovascular disease, malignancy, stroke, diabetes, respiratory disease and all-cause mortality. Air pollution exposure is an independent risk factor for development of lung cancer and has been classified as a Group 1 carcinogen by the International Agency for Research on Cancer. In patients with lung cancer, exposure to higher levels of PM<sub>2.5</sub> and other air pollutants including sulfur dioxide (SO<sub>2</sub>) and nitrogen dioxide (NO<sub>2</sub>) are associated with higher all-cause and disease specific mortality. Recent studies have demonstrated an association between PM<sub>2.5</sub> exposure and increased incidence of head and neck cancer, suggesting a role for air pollution exposure in HNC disease development similar to that of lung cancer. However, despite similar exposure mechanisms between air pollution and the upper and lower airways, the relationship between air pollution exposure and survival in head and neck cancer (HNC) patients has not yet been explored. There are also no studies to date that assess air pollution exposure as a potential contributor to outcome disparities in head and neck surgical oncology.  </p>\n\n<p>Given the well-established increase in ambient air pollution exposure in historically disadvantaged communities and the carcinogenic properties of air pollution, we hypothesized that environmental air pollution exposure contributes to disparities in stage at presentation and survival outcomes. Here, a multivariable logistic regression model and a Cox proportional hazards model were used to assess the relationship between air pollution exposure and the stage at diagnosis and survival in 2,642 adult patients diagnosed with HNC at a single academic institution between 2004 and 2024. The stepwise model selection was used to develop the final multivariable models. Patients included were diagnosed with HNC based on International Classification of Diseases – Oncology version 3 (ICD-O-3) codes for oral cavity, oropharynx, larynx, hypopharynx, sinonasal and middle ear cancers; and patients with missing covariates and/or location data required to assess air pollution exposure were excluded. The cohort was 68.8% male, 67.1% non-White, 30.6% Hispanic/Latino and 73.9% current or former smokers. 77.6% of patients were insured by Medicaid or Medicare. The majority of HNC diagnoses involved the larynx (30.2%), oral cavity (33.0%), and oropharynx (21.4%). PM<sub>2.5</sub> exposure was associated with decreased overall survival even when controlling for other known prognostic factors including tobacco use, insurance status and stage at presentation [HR 1.08, 95% CI 1.03-1.12 (p = 0.001)] (Figure 1). Additionally, NO<sub>2</sub> exposure was positively associated with later cancer stage at diagnosis [OR 1.10, 95% CI 1.05-1.16 (p = 0.0001)]. These findings suggest that air pollution exposure may contribute to disparities in HNC survival. Further research is needed to better understand the mechanism by which air pollution impacts disease development and outcomes in HNC.</p>\n\n<p><img alt='Kaplan-Meier survival curve for head and neck cancer patients exposed to low (green) versus medium to high (red) levels of fine particulate matter (p < 0.0001)' src='https://www.submitmyabstract.com/abs/images/147755/HNC_overall_survival_by_PM2p5.png' /></p>\n\n<p>Figure 1: Kaplan-Meier survival curves for overall survival in HNC patients exposed to low (green) and moderate-to-high (red) levels of PM<sub>2.5 </sub>(p < 0.0001).</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147755--></body></html>"
    },
    {
      "uid": "P029",
      "content_id": "154140",
      "abstract_number": "P029",
      "poster_number": "P029",
      "title": "IL-34 as a Site-Specific Prognostic Biomarker in Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Head and neck squamous cell carcinoma (HNSC) is characterized by substantial biological heterogeneity and aggressive clinical behavior, yet reliable prognostic biomarkers remain limited. As global incidence rises, there is growing interest in identifying immunoregulatory factors that clarify mechanisms of tumor progression and refine risk stratification. Recent preclinical work has highlighted Interleukin-34...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154140",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Sandhya Kalavacherla 1 ; Judith Varner, PhD 2 ; Theresa Guo, MD 3",
      "normalized_authors": [
        "Vivian Vo",
        "Sandhya Kalavacherla",
        "Judith Varner",
        "Theresa Guo"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "Department of Pathology, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "Department of Pathology, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 436,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Sandhya Kalavacherla 1 ; Judith Varner, PhD 2 ; Theresa Guo, MD 3",
        "Affiliations": "1 UC San Diego School of Medicine; 2 Department of Pathology, University of California San Diego Health; 3 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "Head and neck squamous cell carcinoma (HNSC) is characterized by substantial biological heterogeneity and aggressive clinical behavior, yet reliable prognostic biomarkers remain limited. As global incidence rises, there is growing interest in identifying immunoregulatory factors that clarify mechanisms of tumor progression and refine risk stratification. Recent preclinical work has highlighted Interleukin-34 (IL-34), Insulin-growth factor 1 (IGF-1), and Integrin Beta 8 (ITGB8) as immunoregulatory factors of interest in solid tumors. Complementary work in other tumor types has shown differential expression of IL-34 and IGF-1 in tumor cells and macrophages, with links to survival outcomes. Based on these findings suggesting that degree of IGF-1, IL-34, and ITGB8 expression may contribute to immune modulation and tumor behavior in HNSC, we sought to characterize their associations with survival in HSNC. HNSC transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA).). The association between IGF-1, IL-34, and ITGB8 gene expression and survival were evaluated with both univariable and multivariable Cox proportional hazards models controlling for pathologic stage, HPV status, and smoking status. Gene expression levels were stratified by quartiles, and analyses compared outcomes for tumors in the upper vs. lower quartiles of expression.Parallel analyses were performed for TCGA lung, breast, and bladder cohorts. Across tumors from all HNSC subsites (N=438), only high IL34 expression was associated with improved survival in univariable models (hazard ratio (HR)=0.63, p=0.039). When stratifying the cohort by smoking status, IL-34 also demonstrated a protective association among smokers (HR=0.53, p=0.029). Within, a subset of oropharyngeal primary tumors (N=71), higher IL34 (HR=0.2, p=0.04) expression was associated with improved survival , an effect that was maintained with multivariable adjustment. There were no significant associations between any of the genes and survival in the subset of oral cavity primary tumors. Conversely, outside of HNSC, elevated IGF-1 and ITGB8 expression were associated with significantly worse overall survival in bladder cancer, underscoring the context-dependent nature of these pathways. To our knowledge, we are the first to describe IL34 as a favorable prognostic marker in oropharyngeal cancer. The favorable association of IL-34 in oropharyngeal tumors, and the absence of this effect in oral cavity tumors, supports a model in which cytokine-driven immune activation is potentiated in lymphoid-rich and HPV-associated microenvironments but blunted in carcinogen-driven and immunosuppressed tissues. The inverse associations seen in bladder cancer further highlight that these pathways can shift toward pro-tumorigenic signaling in epithelial organs that have different inflammatory baselines. Overall, these results suggest that anatomic site, immune composition, and oncogenic context jointly determine whether these immunoregulatory genes promote antitumor activity or facilitate tumor progression."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>IL-34 as a Site-Specific Prognostic Biomarker in Oropharyngeal Squamous Cell Carcinoma</span>. <u>Vivian Vo</u><sup>1</sup>; Sandhya Kalavacherla<sup>1</sup>; Judith Varner, PhD<sup>2</sup>; Theresa Guo, MD<sup>3</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>Department of Pathology, University of California San Diego Health; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSC) is characterized by substantial biological heterogeneity and aggressive clinical behavior, yet reliable prognostic biomarkers remain limited. As global incidence rises, there is growing interest in identifying immunoregulatory factors that clarify mechanisms of tumor progression and refine risk stratification. Recent preclinical work has highlighted Interleukin-34 (IL-34), Insulin-growth factor 1 (IGF-1), and Integrin Beta 8 (ITGB8) as immunoregulatory factors of interest in solid tumors. Complementary work in other tumor types has shown differential expression of IL-34 and IGF-1 in tumor cells and macrophages, with links to survival outcomes. Based on these findings suggesting that degree of IGF-1, IL-34, and ITGB8 expression may contribute to immune modulation and tumor behavior in HNSC, we sought to characterize their associations with survival in HSNC.</p>\n\n<p>HNSC transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA).). The association between IGF-1, IL-34, and ITGB8 gene expression and survival were evaluated with both univariable and multivariable Cox proportional hazards models controlling for pathologic stage, HPV status, and smoking status. Gene expression levels were stratified by quartiles, and analyses compared outcomes for tumors in the upper vs. lower quartiles of expression.Parallel analyses were performed for TCGA lung, breast, and bladder cohorts.</p>\n\n<p>Across tumors from all HNSC subsites (N=438), only high IL34 expression was associated with improved survival in univariable models (hazard ratio (HR)=0.63, p=0.039). When stratifying the cohort by smoking status, IL-34 also demonstrated a protective association among smokers (HR=0.53, p=0.029). Within, a subset of oropharyngeal primary tumors (N=71), higher IL34 (HR=0.2, p=0.04) expression was associated with improved survival , an effect that was maintained with multivariable adjustment. There were no significant associations between any of the genes and survival in the subset of oral cavity primary tumors. Conversely, outside of HNSC, elevated IGF-1 and ITGB8 expression were associated with significantly worse overall survival in bladder cancer, underscoring the context-dependent nature of these pathways.</p>\n\n<p>To our knowledge, we are the first to describe IL34 as a favorable prognostic marker in oropharyngeal cancer. The favorable association of IL-34 in oropharyngeal tumors, and the absence of this effect in oral cavity tumors, supports a model in which cytokine-driven immune activation is potentiated in lymphoid-rich and HPV-associated microenvironments but blunted in carcinogen-driven and immunosuppressed tissues. The inverse associations seen in bladder cancer further highlight that these pathways can shift toward pro-tumorigenic signaling in epithelial organs that have different inflammatory baselines. Overall, these results suggest that anatomic site, immune composition, and oncogenic context jointly determine whether these immunoregulatory genes promote antitumor activity or facilitate tumor progression.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154140--></body></html>"
    },
    {
      "uid": "P030",
      "content_id": "153526",
      "abstract_number": "P030",
      "poster_number": "P030",
      "title": "Clinical relevance of hypoxia-associated biomarkers in head and neck squamous cell carcinoma: a retrospective tissue microarray study",
      "summary": "These findings suggest that the hypoxia-associated markers HIF-1α, MCT4, and CA9 may serve as independent prognostic and predictive biomarkers of mortality and treatment outcome in HNSCC. Their combined assessment could help to identify patients at higher risk and guide more individualized therapeutic strategy approaches.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153526",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Charbél Talani, MD, PhD",
      "presenter": "Charbél Talani, MD, PhD",
      "authors": "Charbél Talani, MD, PhD ; Lovisa Farnebo, Associate Professor; Malek Amin, PhD, student; Max Rademaekers, PhD, student; Emilia Wiehec, Associate Professor; Karin Roberg, Professor",
      "normalized_authors": [
        "Charbél Talani",
        "Lovisa Farnebo, Associate",
        "Malek Amin, student",
        "Max Rademaekers, student",
        "Emilia Wiehec, Associate",
        "Karin Roberg"
      ],
      "affiliations": [
        "Linköping University"
      ],
      "normalized_institutions": [
        "Linköping University"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 309,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials and Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Charbél Talani, MD, PhD ; Lovisa Farnebo, Associate Professor; Malek Amin, PhD, student; Max Rademaekers, PhD, student; Emilia Wiehec, Associate Professor; Karin Roberg, Professor",
        "Affiliations": "Linköping University",
        "Introduction": "This retrospective study aimed to evaluate the prognostic and predictive value of multiple cancer-associated biomarkers and their relationship with clinical outcomes in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). The overarching goal was to integrate molecular and clinical parameters to enhance the accuracy of mortality and treatment response predictions, thereby supporting individualized therapeutic strategies.",
        "Materials and Methods": "A panel of biomarkers, including established markers of cancer metabolism, hypoxia, proliferation, survival and invasion (GLUT1, MCT4, CA9, HIF-1α, EGFR, pEGFR, Survivin, and MMP-9), was analysed by immunohistochemistry in 65 archived, patient-derived tumour samples assembled in a tissue microarray (TMA). Biomarker expression levels were semi-quantitatively scored based on staining intensity and distribution.",
        "Results": "High HIF-1α expression was independently associated with an increased risk of death within six months (HR43.7, p=0.019), two years (HR8.8, p<0.001), and five years (HR4.5, p=0.007). Similarly, elevated MCT4 expression was linked to higher mortality at two years (HR5.2, p=0.003) and five years (HR3.4, p=0.004). Notably, tumours co-expressing high levels of both HIF-1α and MCT4 exhibited a synergistically increased risk of mortality at five years (HR10.9, p=0.014). Furthermore, high MCT4 expression was predictive of treatment failure, defined as residual disease or recurrence (HR3.8, p=0.041), whereas high CA9 expression was associated with improved treatment response (HR0.2, p=0.008).",
        "Conclusions": "These findings suggest that the hypoxia-associated markers HIF-1α, MCT4, and CA9 may serve as independent prognostic and predictive biomarkers of mortality and treatment outcome in HNSCC. Their combined assessment could help to identify patients at higher risk and guide more individualized therapeutic strategy approaches.",
        "Abstract": "HR: Hazard Ratio MCT4: Monocarboxylase transport 4 CA9: Carbonic anhydrase 9 GLUT1: Glucose transporter 1 EGFR: Epidermal growth factor receptor pEGFR: Phosphorylated epidermal growth factor receptor HIF-1α: Hypoxia inducible factor 1 alpha MMP-9: Matrix metalloproteinase 9"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical relevance of hypoxia-associated biomarkers in head and neck squamous cell carcinoma: a retrospective tissue microarray study</span>. <u>Charbél Talani, MD, PhD</u>; Lovisa Farnebo, Associate Professor; Malek Amin, PhD, student; Max Rademaekers, PhD, student; Emilia Wiehec, Associate Professor; Karin Roberg, Professor. Linköping University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>This retrospective study aimed to evaluate the prognostic and predictive value of multiple cancer-associated biomarkers and their relationship with clinical outcomes in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). The overarching goal was to integrate molecular and clinical parameters to enhance the accuracy of mortality and treatment response predictions, thereby supporting individualized therapeutic strategies.</p>\n\n<p><strong>Materials and Methods: </strong>A panel of biomarkers, including established markers of cancer metabolism, hypoxia, proliferation, survival and invasion (GLUT1, MCT4, CA9, HIF-1α, EGFR, pEGFR, Survivin, and MMP-9), was analysed by immunohistochemistry in 65 archived, patient-derived tumour samples assembled in a tissue microarray (TMA). Biomarker expression levels were semi-quantitatively scored based on staining intensity and distribution.</p>\n\n<p><strong>Results: </strong>High HIF-1α expression was independently associated with an increased risk of death within six months (HR43.7, p=0.019), two years (HR8.8, p<0.001), and five years (HR4.5, p=0.007). Similarly, elevated MCT4 expression was linked to higher mortality at two years (HR5.2, p=0.003) and five years (HR3.4, p=0.004). Notably, tumours co-expressing high levels of both HIF-1α and MCT4 exhibited a synergistically increased risk of mortality at five years (HR10.9, p=0.014). Furthermore, high MCT4 expression was predictive of treatment failure, defined as residual disease or recurrence (HR3.8, p=0.041), whereas high CA9 expression was associated with improved treatment response (HR0.2, p=0.008).</p>\n\n<p><strong>Conclusions: </strong>These findings suggest that the hypoxia-associated markers HIF-1α, MCT4, and CA9 may serve as independent prognostic and predictive biomarkers of mortality and treatment outcome in HNSCC. Their combined assessment could help to identify patients at higher risk and guide more individualized therapeutic strategy approaches.</p>\n\n<p>HR: Hazard Ratio<br />\nMCT4: Monocarboxylase transport 4<br />\nCA9: Carbonic anhydrase 9<br />\nGLUT1: Glucose transporter 1<br />\nEGFR: Epidermal growth factor receptor<br />\npEGFR: Phosphorylated epidermal growth factor receptor<br />\nHIF-1α: Hypoxia inducible factor 1 alpha<br />\nMMP-9: Matrix metalloproteinase 9</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153526--></body></html>"
    },
    {
      "uid": "P031",
      "content_id": "153580",
      "abstract_number": "P031",
      "poster_number": "P031",
      "title": "BRCA1 Beyond Its Usual Borders: A Case Report of Oral Cavity Squamous Cell Carcinoma in a BRCA1 Mutation Carrier",
      "summary": "Head and neck cancer (HNC) is a common cancer worldwide, accounting for 7.6% of all cancers and 4.8% of cancer-related deaths.1 HNC in patients with BRCA mutations, however, is quite rare.2 While BRCA1 is classically associated with breast and ovarian malignancies, broader associations, including to uterine and pancreatic cancers are emerging. The prognostic implications and therapeutic opportunities for HNC in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153580",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marta M Williams, MD",
      "presenter": "Marta M Williams, MD",
      "authors": "Marta M Williams, MD ; Frank Ondrey, MD, PhD",
      "normalized_authors": [
        "Marta M Williams",
        "Frank Ondrey"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 463,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Abstract",
        "Discussion/Conclusions"
      ],
      "sections": {
        "Authors": "Marta M Williams, MD ; Frank Ondrey, MD, PhD",
        "Affiliations": "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
        "Introduction": "Head and neck cancer (HNC) is a common cancer worldwide, accounting for 7.6% of all cancers and 4.8% of cancer-related deaths.1 HNC in patients with BRCA mutations, however, is quite rare.2 While BRCA1 is classically associated with breast and ovarian malignancies, broader associations, including to uterine and pancreatic cancers are emerging. The prognostic implications and therapeutic opportunities for HNC in BRCA1 carriers remain underreported. Here we present a case of aggressive oral tongue SCC in a BRCA1-positive patient with a history of multiple primary malignancies.",
        "Case Presentation": "A 53-year-old nonsmoking female with a known pathogenic BRCA1 mutation presented with a persistent tongue lesion. Her oncologic history was significant for triple-negative breast cancer (treated with trimodality therapy at age 35), followed by prophylactic bilateral salpingo-oophorectomy. Thirteen years later, she developed endometrial carcinoma treated with hysterectomy.",
        "Abstract": "Less than one year after her hysterectomy, she presented with persistent tongue soreness and mass. Wide local excision revealed a 2.5 cm SCC with 5 mm depth of invasion and perineural invasion. Given the size of the mass and presence of perineural invasion, ipsilateral neck dissection was performed, with one positive ipsilateral node identified. Adjuvant radiation was then performed. Despite the use of multimodality therapy, the disease course was aggressive. Follow-up PET/CT one year post-treatment revealed contralateral neck metastasis, treated with contralateral radical neck dissection and adjuvant radiation. Three years later, she developed a new pleural effusion and breast mass (Stage IIA cT2, cN0 triple-negative breast cancer). The rapid progression and metastasis in this case support literature suggesting that BRCA1 downregulation or mutation may function as an independent prognostic marker of reduced survival and heightened aggressiveness in OSCC. 3 Genetic testing should be considered in patients such as this one with significant family history of cancer, particularly given the potential for targeted therapies to improve outcomes among patients with BRCA mutations. 1. Zhou T, Huang W, Wang X, et al. Global burden of head and neck cancers from 1990 to 2019. iScience. 2024;27(3). doi:10.1016/j.isci.2024.109282 2. Chung CH, Guthrie VB, Masica DL, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015;26(6):1216-1223. doi:10.1093/annonc/mdv109 3. Oliveira-Costa JP, Oliveira LR, Zanetti R, et al. BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma. Oncoscience. 2014;1(5):383-391. doi:10.18632/oncoscience.47",
        "Discussion/Conclusions": "Oral cavity cancer arising in a BRCA1-positive patient has been rarely reported in the literature to date. While large cohort studies have not shown a statistical increase in head and neck cancer among BRCA1 carriers, this patient’s presentation aligns with a multi-organ neoplastic syndrome. Early screening beyond breast and ovarian areas should be considered in these patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>BRCA1 Beyond Its Usual Borders: A Case Report of Oral Cavity Squamous Cell Carcinoma in a BRCA1 Mutation Carrier</span>. <u>Marta M Williams, MD</u>; Frank Ondrey, MD, PhD. Department of Otolaryngology-Head and Neck Surgery, University of Minnesota<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancer (HNC) is a common cancer worldwide, accounting for 7.6% of all cancers and 4.8% of cancer-related deaths.1 HNC in patients with BRCA mutations, however, is quite rare.2 While BRCA1 is classically associated with breast and ovarian malignancies, broader associations, including to uterine and pancreatic cancers are emerging. The prognostic implications and therapeutic opportunities for HNC in BRCA1 carriers remain underreported. Here we present a case of aggressive oral tongue SCC in a BRCA1-positive patient with a history of multiple primary malignancies.</p>\n\n<p><strong>Case Presentation: </strong>A 53-year-old nonsmoking female with a known pathogenic BRCA1 mutation presented with a persistent tongue lesion. Her oncologic history was significant for triple-negative breast cancer (treated with trimodality therapy at age 35), followed by prophylactic bilateral salpingo-oophorectomy. Thirteen years later, she developed endometrial carcinoma treated with hysterectomy.</p>\n\n<p>Less than one year after her hysterectomy, she presented with persistent tongue soreness and mass. Wide local excision revealed a 2.5 cm SCC with 5 mm depth of invasion and perineural invasion. Given the size of the mass and presence of perineural invasion, ipsilateral neck dissection was performed, with one positive ipsilateral node identified. Adjuvant radiation was then performed. Despite the use of multimodality therapy, the disease course was aggressive. Follow-up PET/CT one year post-treatment revealed contralateral neck metastasis, treated with contralateral radical neck dissection and adjuvant radiation. Three years later, she developed a new pleural effusion and breast mass (Stage IIA cT2, cN0 triple-negative breast cancer).</p>\n\n<p><strong>Discussion/Conclusions: </strong>Oral cavity cancer arising in a BRCA1-positive patient has been rarely reported in the literature to date. While large cohort studies have not shown a statistical increase in head and neck cancer among BRCA1 carriers, this patient’s presentation aligns with a multi-organ neoplastic syndrome. Early screening beyond breast and ovarian areas should be considered in these patients.</p>\n\n<p>The rapid progression and metastasis in this case support literature suggesting that BRCA1 downregulation or mutation may function as an independent prognostic marker of reduced survival and heightened aggressiveness in OSCC. 3 Genetic testing should be considered in patients such as this one with significant family history of cancer, particularly given the potential for targeted therapies to improve outcomes among patients with BRCA mutations.</p>\n\n<p>1.             Zhou T, Huang W, Wang X, et al. Global burden of head and neck cancers from 1990 to 2019. iScience. 2024;27(3). doi:10.1016/j.isci.2024.109282</p>\n\n<p>2.             Chung CH, Guthrie VB, Masica DL, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015;26(6):1216-1223. doi:10.1093/annonc/mdv109</p>\n\n<p>3.             Oliveira-Costa JP, Oliveira LR, Zanetti R, et al. BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma. Oncoscience. 2014;1(5):383-391. doi:10.18632/oncoscience.47</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153580--></body></html>"
    },
    {
      "uid": "P032",
      "content_id": "151840",
      "abstract_number": "P032",
      "poster_number": "P032",
      "title": "Associations Between 2,4-D Herbicide Exposure and Thyroid Cancer Incidence in U.S. Counties",
      "summary": "The significant positive relationships observed in rural counties suggest that geographic and agricultural context may impact exposure risk when it comes to 2,4-D usage. There is a need for further longitudinal and mechanistic studies to establish causality and explore the potential endocrine pathways underlying these associations.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151840",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Moitrayee Dhar",
      "presenter": "Moitrayee Dhar",
      "authors": "Moitrayee Dhar ; Seungjun Ahn; Weijia Fu; Mathilda Monaghan; Maaike van Gerwen",
      "normalized_authors": [
        "Moitrayee Dhar",
        "Seungjun Ahn",
        "Weijia Fu",
        "Mathilda Monaghan",
        "Maaike van Gerwen"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 275,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Moitrayee Dhar ; Seungjun Ahn; Weijia Fu; Mathilda Monaghan; Maaike van Gerwen",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Introduction": "The increasing thyroid cancer incidence rates in the United States suggest a potential role of environmental exposures such as endocrine-disrupting chemicals. 2,4-Dichlorophenoxyacetic acid (2,4-D) is a widely used herbicide with endocrine disruptive properties and potential thyroid toxicity. This ecological study investigated potential associations between county-level 2,4-D exposure and age-adjusted thyroid cancer incidence across the United States.",
        "Methods": "Age-adjusted thyroid cancer incidence rates for 2017-2021 were collected from the CDC database. County-level 2,4-D usage data was obtained from the U.S. Geological Survey and averaged over two periods: 2003-2007 (representing a 10-year lag) and 2008-2012 (representing a 5-year lag). Linear mixed model analysis design was utilised to assess associations between 2,4-D use and thyroid cancer incidence. The data was also stratified by sex and by rurality as defined by Rural-Urban Continuum Codes (RUCC 6-9). Statistical significance was defined as p < 0.05.",
        "Results": "Nationwide analyses across counties showed no significant associations in both combined (5-year lag: p=0.218; 10-year lag: p=0.276) or in sex-stratified models (males: p=0.540 and p=0.497; females: p=0.222 and p=0.353, for the 5- and 10-year lags, respectively). In analyses restricted to rural counties, 2,4-D exposure was significantly associated with higher thyroid cancer incidence for both the 5-year (p = 0.004) and 10-year (p = 0.006) lag periods for the combined population.",
        "Conclusion": "The significant positive relationships observed in rural counties suggest that geographic and agricultural context may impact exposure risk when it comes to 2,4-D usage. There is a need for further longitudinal and mechanistic studies to establish causality and explore the potential endocrine pathways underlying these associations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Associations Between 2,4-D Herbicide Exposure and Thyroid Cancer Incidence in U.S. Counties</span>. <u>Moitrayee Dhar</u>; Seungjun Ahn; Weijia Fu; Mathilda Monaghan; Maaike van Gerwen. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The increasing thyroid cancer incidence rates in the United States  suggest a potential role of environmental exposures such as endocrine-disrupting chemicals. 2,4-Dichlorophenoxyacetic acid (2,4-D) is a widely used herbicide with endocrine disruptive properties  and potential thyroid toxicity. This ecological study investigated potential associations between county-level 2,4-D exposure and age-adjusted thyroid cancer incidence across the United States.</p>\n\n<p><strong>Methods: </strong>Age-adjusted thyroid cancer incidence rates for 2017-2021 were collected from the CDC database. County-level 2,4-D usage data was obtained from the U.S. Geological Survey and averaged over two periods: 2003-2007 (representing a 10-year lag) and 2008-2012 (representing a 5-year lag).  Linear mixed model analysis design was utilised to assess associations between 2,4-D use and thyroid cancer incidence. The data was also stratified by sex and by rurality as defined by Rural-Urban Continuum Codes (RUCC 6-9). Statistical significance was defined as p < 0.05.</p>\n\n<p><strong>Results: </strong>Nationwide analyses across counties showed no significant associations in both combined (5-year lag: p=0.218; 10-year lag: p=0.276) or in sex-stratified models (males: p=0.540 and p=0.497; females: p=0.222 and p=0.353, for the 5- and 10-year lags, respectively). In analyses restricted to rural counties, 2,4-D exposure was significantly associated with higher thyroid cancer incidence for both the 5-year (p = 0.004) and 10-year (p = 0.006) lag periods for the combined population.</p>\n\n<p><strong>Conclusion: </strong>The significant positive relationships observed in rural counties suggest that geographic and agricultural context may impact exposure risk when it comes to 2,4-D usage. There is a need for further longitudinal and mechanistic studies to establish causality and explore the potential endocrine pathways underlying these associations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151840--></body></html>"
    },
    {
      "uid": "P033",
      "content_id": "153922",
      "abstract_number": "P033",
      "poster_number": "P033",
      "title": "An examination of laryngeal cancer genomics – a TCGA cohort",
      "summary": "LSCC harbors genomic alterations associated with recurrence and advanced stage. Mutations in NSD1, APOB, and ZNF804A may represent clinically meaningful biomarkers that could inform risk stratification and guide future targeted or immunologic treatment strategies. Neither TMB (KEYNOTE-158 definition) nor Poeta et al.’s disruptive TP53 classification showed prognostic relevance in LSCC. These findings underscore...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153922",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dylan F Roden, MD, MPH",
      "presenter": "Dylan F Roden, MD, MPH",
      "authors": "Peter J Attia, BA; Joseph Celidonio, MD; Rohini Bahethi, MD; Dylan F Roden, MD, MPH",
      "normalized_authors": [
        "Peter J Attia",
        "Joseph Celidonio",
        "Rohini Bahethi",
        "Dylan F Roden"
      ],
      "affiliations": [
        "Rutgers New Jersey Medical School"
      ],
      "normalized_institutions": [
        "Rutgers New Jersey Medical School"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Peter J Attia, BA; Joseph Celidonio, MD; Rohini Bahethi, MD; Dylan F Roden, MD, MPH",
        "Affiliations": "Rutgers New Jersey Medical School",
        "Objectives": "Laryngeal squamous cell carcinoma (LSCC) has an understudied genomic profile that may influence its treatment and prognosis. Genomic mutations have been known to play a role in tumor behavior, prognostication, and treatment response and/or resistance. Previous studies have aggregated head and neck squamous cell carcinomas (HNSCC) for analysis, potentially obscuring site-specific patterns that are driven by distinct risk factors and pathogenesis. This study examines the genomic profiles of patients with LSCC using The Cancer Genome Atlas (TCGA).",
        "Methods": "Using the National Cancer Institute’s Genomic Data Commons, we harmonized clinical and genomic data for patients with laryngeal squamous cell carcinoma (LSCC). Mutation Annotation Files (MAFs) were curated and used to characterize the overall mutational landscape. We then evaluated whether mutational patterns varied by tumor stage, pathological details, and by recurrence/persistence status. To contextualize findings within established genomic frameworks, we applied Poeta et al.’s disruptive vs. non-disruptive TP53 classification and stratified patients using the KEYNOTE-158 framework of tumor mutational burden (TMB), categorizing samples as TMB-high (≥10 mutations/Mb) or TMB-low (<10 mutations/Mb). Descriptive, correlation, and survival analyses were performed in R using Bioconductor, with significance set at p < 0.05.",
        "Results": "165 patients were included, with 86% being male, 78% being White non-Hispanic, a median age of 67 [IQR: 57-68], and 62% having a Stage IV diagnosis. The most frequently mutated genes include TP53 (87%), TTN (50%), CSMD3 (34%), MUC16 (27%), and LRP1B (25%). Recurrence/persistent disease was associated with lower NSD1 mutation frequency (10% vs 28%, p=0.017) and higher APOB mutation frequency (28% vs 12%, p=0.041) compared to sequencing data from patients without evidence of recurrence or persistent disease. Patients with Stage IV LSCC were more likely to harbor ZNF804A mutations compared to non-Stage IV patients (15% vs 2%, p=0.009). Patient specimens with disruptive TP53 mutations (42%) showed no differences in stage distribution (Stage IV: 61% vs 63%, p=0.9), recurrence (69% vs 79%, p=0.2), or overall survival (Cox p=0.6) compared to specimens with non-disruptive TP53 mutations. TMB-high tumors comprised 13% of cases and demonstrated similar distributions of Stage IV disease (63% vs 61%, p=0.9) and recurrence (21% vs 31%, p=0.2) compared with TMB-low tumors, with no survival difference (Cox p=0.26). TMB showed no correlation with a disruptive TP53 mutation (r = 0.04, p = 0.58).",
        "Conclusion": "LSCC harbors genomic alterations associated with recurrence and advanced stage. Mutations in NSD1, APOB, and ZNF804A may represent clinically meaningful biomarkers that could inform risk stratification and guide future targeted or immunologic treatment strategies. Neither TMB (KEYNOTE-158 definition) nor Poeta et al.’s disruptive TP53 classification showed prognostic relevance in LSCC. These findings underscore the importance of site-specific genomic characterization to advance precision oncology efforts in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>An examination of laryngeal cancer genomics – a TCGA cohort</span>. Peter J Attia, BA; Joseph Celidonio, MD; Rohini Bahethi, MD; <u>Dylan F Roden, MD, MPH</u>. Rutgers New Jersey Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> Laryngeal squamous cell carcinoma (LSCC) has an understudied genomic profile that may influence its treatment and prognosis. Genomic mutations have been known to play a role in tumor behavior, prognostication, and treatment response and/or resistance. Previous studies have aggregated head and neck squamous cell carcinomas (HNSCC) for analysis, potentially obscuring site-specific patterns that are driven by distinct risk factors and pathogenesis. This study examines the genomic profiles of patients with LSCC using The Cancer Genome Atlas (TCGA). </p>\n\n<p><strong>Methods: </strong>Using the National Cancer Institute’s Genomic Data Commons, we harmonized clinical and genomic data for patients with laryngeal squamous cell carcinoma (LSCC). Mutation Annotation Files (MAFs) were curated and used to characterize the overall mutational landscape. We then evaluated whether mutational patterns varied by tumor stage, pathological details, and by recurrence/persistence status. To contextualize findings within established genomic frameworks, we applied Poeta et al.’s disruptive vs. non-disruptive TP53 classification and stratified patients using the KEYNOTE-158 framework of tumor mutational burden (TMB), categorizing samples as TMB-high (≥10 mutations/Mb) or TMB-low (<10 mutations/Mb). Descriptive, correlation, and survival analyses were performed in R using Bioconductor, with significance set at p < 0.05. </p>\n\n<p><strong>Results:</strong> 165 patients were included, with 86% being male, 78% being White non-Hispanic, a median age of 67 [IQR: 57-68], and 62% having a Stage IV diagnosis. The most frequently mutated genes include TP53 (87%), TTN (50%), CSMD3 (34%), MUC16 (27%), and LRP1B (25%). Recurrence/persistent disease was associated with lower NSD1 mutation frequency (10% vs 28%, p=0.017) and higher APOB mutation frequency (28% vs 12%, p=0.041) compared to sequencing data from patients without evidence of recurrence or persistent disease. Patients with Stage IV LSCC were more likely to harbor ZNF804A mutations compared to non-Stage IV patients (15% vs 2%, p=0.009). Patient specimens with disruptive TP53 mutations (42%) showed no differences in stage distribution (Stage IV: 61% vs 63%, p=0.9), recurrence (69% vs 79%, p=0.2), or overall survival (Cox p=0.6) compared to specimens with non-disruptive TP53 mutations.  TMB-high tumors comprised 13% of cases and demonstrated similar distributions of Stage IV disease (63% vs 61%, p=0.9) and recurrence (21% vs 31%, p=0.2) compared with TMB-low tumors, with no survival difference (Cox p=0.26). TMB showed no correlation with a disruptive TP53 mutation (r = 0.04, p = 0.58). </p>\n\n<p><strong>Conclusion:</strong> LSCC harbors genomic alterations associated with recurrence and advanced stage. Mutations in NSD1, APOB, and ZNF804A may represent clinically meaningful biomarkers that could inform risk stratification and guide future targeted or immunologic treatment strategies. Neither TMB (KEYNOTE-158 definition) nor Poeta et al.’s disruptive TP53 classification showed prognostic relevance in LSCC. These findings underscore the importance of site-specific genomic characterization to advance precision oncology efforts in HNSCC.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153922--></body></html>"
    },
    {
      "uid": "P034",
      "content_id": "154252",
      "abstract_number": "P034",
      "poster_number": "P034",
      "title": "Genomic-Based Prognostic Classification of Head and Neck Squamous Cell Carcinoma: A cBioPortal Analysis",
      "summary": "Integrating genomic alterations into a risk-tier model refines prognostication and may guide treatment decisions in management of HNSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154252",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arnav Pemmaraju",
      "presenter": "Arnav Pemmaraju",
      "authors": "Arnav Pemmaraju 1 ; Margaret Locke, MD 2 ; Kevin Sullivan, MD 2",
      "normalized_authors": [
        "Arnav Pemmaraju",
        "Margaret Locke",
        "Kevin Sullivan"
      ],
      "affiliations": [
        "Great Neck South High School",
        "Northwell Health"
      ],
      "normalized_institutions": [
        "Great Neck South High School",
        "Northwell Health"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 244,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Arnav Pemmaraju 1 ; Margaret Locke, MD 2 ; Kevin Sullivan, MD 2",
        "Affiliations": "1 Great Neck South High School; 2 Northwell Health",
        "Background": "Current management of head and neck squamous cell carcinoma (HNSCC) has limited use of molecular information of the tumors. Since genomic drivers influence outcomes in many cancers, we aimed to define mutation-based signatures associated with survival risk using multi-cohort data from cBioPortal (TCGA-HNSC, MSK, and others).",
        "Methods": "Nine commonly altered genes ( TP53, CDKN2A, CCND1, PIK3CA, EGFR, NOTCH1, FAT1, HRAS, TERT ) were queried in cBioPortal. Python (pandas) was used to aggregate cBioPortal clinical files across cohorts and for the analysis. Patients were stratified into four risk categories, poor, unfavorable, fair, and good, using a literature-informed, rule-based scoring system that assigned weights to each alteration based on its reported prognostic significance. Kaplan-Meier analysis and log-rank tests validated survival differences across tiers.",
        "Results": "Based on 104,900 patient samples, TP53 mutations (72%) and CDKN2A loss (32%) were most frequent. Complex profiles such as TP53 mutation + CDKN2A loss + CCND1 amplification defined the poor risk group with markedly reduced overall survival (HR ≈ 1.8). TP53 mutation combined with TERT promoter mutation or CDKN2A loss indicated unfavorable risk (HR 1.4–1.6). Single TP53 mutation or isolated EGFR amplification corresponded to fair risk (HR 1.2–1.3), while tumors lacking TP53/CDKN2A alterations were good risk (HR ≈ 1.0). Isolated PIK3CA mutation conferred favorable outcomes, particularly in HPV-positive oropharyngeal SCC, whereas co-amplification with EGFR or TP53 mutation shifted prognosis toward unfavorable risk.",
        "Conclusion": "Integrating genomic alterations into a risk-tier model refines prognostication and may guide treatment decisions in management of HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Genomic-Based Prognostic Classification of Head and Neck Squamous Cell Carcinoma: A cBioPortal Analysis</span>. <u>Arnav Pemmaraju</u><sup>1</sup>; Margaret Locke, MD<sup>2</sup>; Kevin Sullivan, MD<sup>2</sup>. <sup>1</sup>Great Neck South High School; <sup>2</sup>Northwell Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Current management of head and neck squamous cell carcinoma (HNSCC) has limited use of molecular information of the tumors. Since genomic drivers influence outcomes in many cancers, we aimed to define mutation-based signatures associated with survival risk using multi-cohort data from cBioPortal (TCGA-HNSC, MSK, and others). </p>\n\n<p><strong>Methods: </strong>Nine commonly altered genes (<em>TP53, CDKN2A, CCND1, PIK3CA, EGFR, NOTCH1, FAT1, HRAS, TERT</em>) were queried in cBioPortal. Python (pandas) was used to aggregate cBioPortal clinical files across cohorts and for the analysis. Patients were stratified into four risk categories, poor, unfavorable, fair, and good, using a literature-informed, rule-based scoring system that assigned weights to each alteration based on its reported prognostic significance. Kaplan-Meier analysis and log-rank tests validated survival differences across tiers. </p>\n\n<p><strong>Results:</strong> Based on 104,900 patient samples, <em>TP53 </em>mutations (72%) and CDKN2A loss (32%) were most frequent. Complex profiles such as <em>TP53 </em>mutation + <em>CDKN2A </em>loss + <em>CCND1</em> amplification defined the poor risk group with markedly reduced overall survival (HR ≈ 1.8). <em>TP53 </em>mutation combined with <em>TERT</em> promoter mutation or <em>CDKN2A</em> loss indicated unfavorable risk (HR 1.4–1.6). Single <em>TP53 </em>mutation or isolated EGFR amplification corresponded to fair risk (HR 1.2–1.3), while tumors lacking <em>TP53/CDKN2A</em> alterations were good risk (HR ≈ 1.0). Isolated <em>PIK3CA</em> mutation conferred favorable outcomes, particularly in HPV-positive oropharyngeal SCC, whereas co-amplification with<em> EGFR </em>or <em>TP53</em> mutation shifted prognosis toward unfavorable risk. </p>\n\n<p><strong>Conclusion: </strong>Integrating genomic alterations into a risk-tier model refines prognostication and may guide treatment decisions in management of HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154252--></body></html>"
    },
    {
      "uid": "P035",
      "content_id": "154665",
      "abstract_number": "P035",
      "poster_number": "P035",
      "title": "HPV-Driven Reprogramming of Tonsil Fibroblasts Suppresses Immune-Stimulatory Signaling in Head and Neck Cancer",
      "summary": "HPV reprograms tonsil fibroblasts into a CAF state marked by diminished secretion of immune-stimulatory cytokines, a shift that may weaken local immune surveillance. To interrogate this transition, we are now using HPV-infected tonsil organoid co-cultures to test whether epithelial viral oncogene expression elevates local TGF-β signaling, drives fibroblast activation, and initiates the cytokine reprogramming that...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154665",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shu-Yun Cheng, MS",
      "presenter": "Shu-Yun Cheng, MS",
      "authors": "Shu-Yun Cheng, MS ; Ella P Jackert, BS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD",
      "normalized_authors": [
        "Shu-Yun Cheng",
        "Ella P Jackert",
        "Liyang Tang",
        "Daniel Kwon",
        "Niels Kokot",
        "Uttam Sinha",
        "Yang Chai",
        "Albert Y Han"
      ],
      "affiliations": [
        "University of Southern California"
      ],
      "normalized_institutions": [
        "University of Southern California"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Shu-Yun Cheng, MS ; Ella P Jackert, BS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD",
        "Affiliations": "University of Southern California",
        "Background": "Human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCC) frequently presents with small primary tumors and early regional metastasis. Increasing evidence suggests that this clinical pattern arises from HPV dependent remodeling of the tumor microenvironment (TME). Cancer associated fibroblasts (CAFs) are important stromal mediators of tumor progression and immune modulation, yet the mechanisms by which HPV alters fibroblast function in lymphoid tissues such as the tonsil remain poorly understood.",
        "Methods": "Two HPV positive CAF lines and two tonsil derived normal fibroblast (NF) lines were generated from fresh surgical specimens. Tissue fragments were mechanically and enzymatically dissociated, and single cell suspensions were expanded on collagen coated plates for 3 to 4 weeks. Fibroblast identity was verified by morphology, α-SMA expression using Western blot, and immunofluorescence staining with vimentin and pancytokeratin to exclude epithelial contamination. Conditioned media (CM) were collected from confluent cultures after 48 hours in serum free DMEM, cleared at 300 g for 5 minutes, aliquoted, and stored at minus 80°C. Cytokine profiling was performed using a 105-plex human cytokine array (R&D Systems ARY022B). Dot intensities were quantified using ImageJ integrated density. For each cytokine, replicate CAF measurements (n = 2 lines) were compared with replicate NF measurements (n = 2 lines) using an unpaired two tailed t test, with p < 0.05 considered significant.",
        "Results": "All four fibroblast lines displayed spindle shaped morphology. α-SMA expression confirmed activation in CAFs and absence in NFs. Cytokine array analysis demonstrated a consistent reduction in immune stimulatory cytokines in CAF CM compared with NF CM. CXCL12 levels were lower in CAFs (integrated density 1.14 and 1.97) relative to NFs (5.02 and 3.70; p = 0.0016). BAFF showed a similar pattern (CAF 0.89 and 0.94 vs NF 6.8 and 4.7; p = 0.004). PTX3 levels were also reduced (CAF 3.77 and 8.86 vs NF 9.99 and 11.99; p = 0.043). These results support a model in which tonsil NFs are primed to support local immune activation, whereas HPV associated CAFs exhibit a markedly blunted immune stimulatory secretome.",
        "Conclusion": "HPV reprograms tonsil fibroblasts into a CAF state marked by diminished secretion of immune-stimulatory cytokines, a shift that may weaken local immune surveillance. To interrogate this transition, we are now using HPV-infected tonsil organoid co-cultures to test whether epithelial viral oncogene expression elevates local TGF-β signaling, drives fibroblast activation, and initiates the cytokine reprogramming that precedes full CAF emergence."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HPV-Driven Reprogramming of Tonsil Fibroblasts Suppresses Immune-Stimulatory Signaling in Head and Neck Cancer</span>. <u>Shu-Yun Cheng, MS</u>; Ella P Jackert, BS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD. University of Southern California<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCC) frequently presents with small primary tumors and early regional metastasis. Increasing evidence suggests that this clinical pattern arises from HPV dependent remodeling of the tumor microenvironment (TME). Cancer associated fibroblasts (CAFs) are important stromal mediators of tumor progression and immune modulation, yet the mechanisms by which HPV alters fibroblast function in lymphoid tissues such as the tonsil remain poorly understood.</p>\n\n<p><strong>Methods: </strong>Two HPV positive CAF lines and two tonsil derived normal fibroblast (NF) lines were generated from fresh surgical specimens. Tissue fragments were mechanically and enzymatically dissociated, and single cell suspensions were expanded on collagen coated plates for 3 to 4 weeks. Fibroblast identity was verified by morphology, α-SMA expression using Western blot, and immunofluorescence staining with vimentin and pancytokeratin to exclude epithelial contamination. Conditioned media (CM) were collected from confluent cultures after 48 hours in serum free DMEM, cleared at 300 g for 5 minutes, aliquoted, and stored at minus 80°C. Cytokine profiling was performed using a 105-plex human cytokine array (R&D Systems ARY022B). Dot intensities were quantified using ImageJ integrated density. For each cytokine, replicate CAF measurements (n = 2 lines) were compared with replicate NF measurements (n = 2 lines) using an unpaired two tailed t test, with p < 0.05 considered significant.</p>\n\n<p><strong>Results: </strong>All four fibroblast lines displayed spindle shaped morphology. α-SMA expression confirmed activation in CAFs and absence in NFs. Cytokine array analysis demonstrated a consistent reduction in immune stimulatory cytokines in CAF CM compared with NF CM. CXCL12 levels were lower in CAFs (integrated density 1.14 and 1.97) relative to NFs (5.02 and 3.70; p = 0.0016). BAFF showed a similar pattern (CAF 0.89 and 0.94 vs NF 6.8 and 4.7; p = 0.004). PTX3 levels were also reduced (CAF 3.77 and 8.86 vs NF 9.99 and 11.99; p = 0.043). These results support a model in which tonsil NFs are primed to support local immune activation, whereas HPV associated CAFs exhibit a markedly blunted immune stimulatory secretome.</p>\n\n<p><strong>Conclusion: </strong>HPV reprograms tonsil fibroblasts into a CAF state marked by diminished secretion of immune-stimulatory cytokines, a shift that may weaken local immune surveillance. To interrogate this transition, we are now using HPV-infected tonsil organoid co-cultures to test whether epithelial viral oncogene expression elevates local TGF-β signaling, drives fibroblast activation, and initiates the cytokine reprogramming that precedes full CAF emergence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154665--></body></html>"
    },
    {
      "uid": "P036",
      "content_id": "153443",
      "abstract_number": "P036",
      "poster_number": "P036",
      "title": "Context-dependent TP53 mutation gain-of-function is correlated with its contribution to genomic instability in head and neck cancer cells",
      "summary": "As the “guardian of the genome”, TP53 is the most frequently mutated gene in head and neck squamous cell carcinoma (HNSCC). Inactivating TP53 mutations often lead to a loss-of-function and/or dorminant negative mutant p53 protein (mutp53), but can also result in oncogenic gain-of-function (GOF) of mutp53s that promote tumor development and progression. In this study, we established isogenic HNSCC UM-SCC-1 cell...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153443",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jaafar Hadi, MD",
      "presenter": "Jaafar Hadi, MD",
      "authors": "Noriaki Tanaka, DDS; Jaafar Hadi, MD ; Mei Zhao, MD; Lin Tang, MD; Jeffrey N Myers, MD, PhD; Ge Zhou, PhD",
      "normalized_authors": [
        "Noriaki Tanaka",
        "Jaafar Hadi",
        "Mei Zhao",
        "Lin Tang",
        "Jeffrey N Myers",
        "Ge Zhou"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 222,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Noriaki Tanaka, DDS; Jaafar Hadi, MD ; Mei Zhao, MD; Lin Tang, MD; Jeffrey N Myers, MD, PhD; Ge Zhou, PhD",
        "Affiliations": "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA",
        "Abstract": "As the “guardian of the genome”, TP53 is the most frequently mutated gene in head and neck squamous cell carcinoma (HNSCC). Inactivating TP53 mutations often lead to a loss-of-function and/or dorminant negative mutant p53 protein (mutp53), but can also result in oncogenic gain-of-function (GOF) of mutp53s that promote tumor development and progression. In this study, we established isogenic HNSCC UM-SCC-1 cell lines expressing mutp53 R175H or mutp53 G245D alone or in combination with constitutively active phosphoinositide 3-kinase (PI3K). We demonstrated an example of context-dependent mutp53 GOF, in which mutp53 G245D—but neither mutp53 R175H nor PI3K—gained oncogenic functions to promote UM-SCC-1 cell invasive growth in vitro and metastasis in vivo . Furthermore, we demonstrated that our “isogenic” cell lines were not truly isogenic, as mutp53 R175H and PI3K mainly impacted chromosomal number variations, whereas mutp53 G245D promoted cells to develop more qualitative genomic alterations, such as chromosome fragment insertions, deletions and translocations. The correlation of the mutp53 G245D–induced qualitative genomic alterations with the GOF activities of mutp53 G245D in UM-SCC-1 cells strongly suggests that mutp53-induced genomic alterations may be critical or responsible for the context-dependent GOF of mutp53s in UM-SCC-1 cells. Together, our results support that the acquisition of genomic alterations is one of the important mechanisms accounting for many context-dependent GOF phenotypes previously attributed to mutp53 proteins in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Context-dependent TP53 mutation gain-of-function is correlated with its contribution to genomic instability in head and neck cancer cells</span>. Noriaki Tanaka, DDS; <u>Jaafar Hadi, MD</u>; Mei Zhao, MD; Lin Tang, MD; Jeffrey N Myers, MD, PhD; Ge Zhou, PhD. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>As the “guardian of the genome”, <em>TP53</em> is the most frequently mutated gene in head and neck squamous cell carcinoma (HNSCC). Inactivating TP53 mutations often lead to a loss-of-function and/or dorminant negative mutant p53 protein (mutp53), but can also result in oncogenic gain-of-function (GOF) of mutp53s that promote tumor development and progression. In this study, we established isogenic HNSCC UM-SCC-1 cell lines expressing mutp53 R175H or mutp53 G245D alone or in combination with constitutively active phosphoinositide 3-kinase (PI3K). We demonstrated an example of context-dependent mutp53 GOF, in which mutp53 G245D—but neither mutp53 R175H nor PI3K—gained oncogenic functions to promote UM-SCC-1 cell invasive growth <em>in vitro </em>and metastasis <em>in vivo</em>. Furthermore, we demonstrated that our “isogenic” cell lines were not truly isogenic, as mutp53 R175H and PI3K mainly impacted chromosomal number variations, whereas mutp53 G245D promoted cells to develop more qualitative genomic alterations, such as chromosome fragment insertions, deletions and translocations. The correlation of the mutp53 G245D–induced qualitative genomic alterations with the GOF activities of mutp53 G245D in UM-SCC-1 cells strongly suggests that mutp53-induced genomic alterations may be critical or responsible for the context-dependent GOF of mutp53s in UM-SCC-1 cells. Together, our results support that the acquisition of genomic alterations is one of the important mechanisms accounting for many context-dependent GOF phenotypes previously attributed to mutp53 proteins in HNSCC. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153443--></body></html>"
    },
    {
      "uid": "P037",
      "content_id": "154748",
      "abstract_number": "P037",
      "poster_number": "P037",
      "title": "Urinary Biomarkers Reveal Mutagenic Activity Associated with Cannabis Combustion",
      "summary": "This is the first study to document that metabolites present in the urine of cannabis smokers exhibit high mutagenicity, suggesting high genotoxic risk from cannabis combustion. These data support other studies linking cannabis smoking to increased cancer risk. Our data suggest that cannabis and tobacco smokers excrete similar levels of mutagens able to induce base-pair substitution mutations. Additional studies...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154748",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter Berryman",
      "presenter": "Peter Berryman",
      "authors": "Peter Berryman 1 ; Raghav Gupta 1 ; Mayil Chinnaiyan, PhD 2 ; Balaji Sadhasivam 2 ; Tristan Coles, MD 2 ; Zishan Mahmood 2 ; Geraldine Chissoe 2 ; Daniel Brobst 2 ; Lurdes Queimado, MD, PhD 2",
      "normalized_authors": [
        "Peter Berryman",
        "Raghav Gupta",
        "Mayil Chinnaiyan",
        "Balaji Sadhasivam",
        "Tristan Coles",
        "Zishan Mahmood",
        "Geraldine Chissoe",
        "Daniel Brobst",
        "Lurdes Queimado"
      ],
      "affiliations": [
        "University of Oklahoma College of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma"
      ],
      "normalized_institutions": [
        "University of Oklahoma College of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Financial support"
      ],
      "sections": {
        "Authors": "Peter Berryman 1 ; Raghav Gupta 1 ; Mayil Chinnaiyan, PhD 2 ; Balaji Sadhasivam 2 ; Tristan Coles, MD 2 ; Zishan Mahmood 2 ; Geraldine Chissoe 2 ; Daniel Brobst 2 ; Lurdes Queimado, MD, PhD 2",
        "Affiliations": "1 University of Oklahoma College of Medicine; 2 Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "Background": "Cannabis use in the U.S. has risen with legalization, increasing the prevalence from 10.4% to 18.0% in the past year. Americans are increasingly viewing the substance as harmless. Yet, smoking cannabis, the most prevalent method of use in America, exposes users to carcinogens. Although cigarette smoking has well established mutagenic potential in humans, that of cannabis combustion products remains less clearly defined.",
        "Methods": "Participants were recruited via a secure online survey. Demographics and substance use details were collected via questionnaire. Eligible participants who reported 1) ≥ twice weekly cannabis smoking (CAN) for the past month, 2) daily combustible tobacco use (TOB), or 3) not using either product [Nonusers (NU)] were enrolled. Reported status was validated biochemically. Following extraction and purification of urinary metabolites, we assessed mutagenicity with an AMES bacterial reverse mutation assay with Salmonella Typhimurium strain TA100. Daily revertants were counted and group differences analyzed by t-test and Chi-squared with Yates correction.",
        "Results": "A total of 50 participants were included: 22 NU, 20 CAN, and 10 TOB. Ages were comparable across groups, with median ages of 27 (NU), 31 (CAN), and 30 (TOB), and an overall range of 18–45 years. The male-to-female distribution was balanced (~50% in each group), and more than half of participants were Caucasian. Mean smoking history was 12 ± 9 years among cannabis users and 11 ± 6 years among tobacco smokers. Median plasma THC-COOH levels among CAN users were 77 ng/mL, confirming frequent use. To detect premutagenic and mutagenic urinary metabolites, samples were tested with and without metabolic activation (± S9 liver homogenate). Presently, mutagenicity analysis has been completed for 22 NU, 5 TOB, and 6 CAN. Mutations were observed in 1 NU (1 in 33 tests), 3 CAN (3 in 6 tests), and 3 TOB (3 in 5 tests). Our data show that CAN are more likely than NU to excrete substances able to cause mutations [X2 (1, N = 39) = 7.6, p = .005]. There was no difference in urine mutagenicity between CAN and TOB users.",
        "Conclusion": "This is the first study to document that metabolites present in the urine of cannabis smokers exhibit high mutagenicity, suggesting high genotoxic risk from cannabis combustion. These data support other studies linking cannabis smoking to increased cancer risk. Our data suggest that cannabis and tobacco smokers excrete similar levels of mutagens able to induce base-pair substitution mutations. Additional studies are needed to determine the broader health implications of these findings.",
        "Financial support": "NIH/NCI (R01CA242168; P30CA225520); TSET HPRC (R23-02); PHF Bridge."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Urinary Biomarkers Reveal Mutagenic Activity Associated with Cannabis Combustion</span>. <u>Peter Berryman</u><sup>1</sup>; Raghav Gupta<sup>1</sup>; Mayil Chinnaiyan, PhD<sup>2</sup>; Balaji Sadhasivam<sup>2</sup>; Tristan Coles, MD<sup>2</sup>; Zishan Mahmood<sup>2</sup>; Geraldine Chissoe<sup>2</sup>; Daniel Brobst<sup>2</sup>; Lurdes Queimado, MD, PhD<sup>2</sup>. <sup>1</sup>University of Oklahoma College of Medicine; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cannabis use in the U.S. has risen with legalization, increasing the prevalence from 10.4% to 18.0% in the past year. Americans are increasingly viewing the substance as harmless. Yet, smoking cannabis, the most prevalent method of use in America, exposes users to carcinogens. Although cigarette smoking has well established mutagenic potential in humans, that of cannabis combustion products remains less clearly defined.</p>\n\n<p><strong>Methods: </strong>Participants were recruited via a secure online survey. Demographics and substance use details were collected via questionnaire. Eligible participants who reported 1) ≥ twice weekly cannabis smoking (CAN) for the past month, 2) daily combustible tobacco use (TOB), or 3) not using either product [Nonusers (NU)] were enrolled. Reported status was validated biochemically. Following extraction and purification of urinary metabolites, we assessed mutagenicity with an AMES bacterial reverse mutation assay with Salmonella Typhimurium strain TA100. Daily revertants were counted and group differences analyzed by t-test and Chi-squared with Yates correction.</p>\n\n<p><strong>Results:</strong> A total of 50 participants were included: 22 NU, 20 CAN, and 10 TOB. Ages were comparable across groups, with median ages of 27 (NU), 31 (CAN), and 30 (TOB), and an overall range of 18–45 years. The male-to-female distribution was balanced (~50% in each group), and more than half of participants were Caucasian. Mean smoking history was 12 ± 9 years among cannabis users and 11 ± 6 years among tobacco smokers. Median plasma THC-COOH levels among CAN users were 77 ng/mL, confirming frequent use. To detect premutagenic and mutagenic urinary metabolites, samples were tested with and without metabolic activation (± S9 liver homogenate). Presently, mutagenicity analysis has been completed for 22 NU, 5 TOB, and 6 CAN. Mutations were observed in 1 NU (1 in 33 tests), 3 CAN (3 in 6 tests), and 3 TOB (3 in 5 tests). Our data show that CAN are more likely than NU to excrete substances able to cause mutations [X2 (1, N = 39) = 7.6, p = .005]. There was no difference in urine mutagenicity between CAN and TOB users.</p>\n\n<p><strong>Conclusion:</strong> This is the first study to document that metabolites present in the urine of cannabis smokers exhibit high mutagenicity, suggesting high genotoxic risk from cannabis combustion. These data support other studies linking cannabis smoking to increased cancer risk. Our data suggest that cannabis and tobacco smokers excrete similar levels of mutagens able to induce base-pair substitution mutations. Additional studies are needed to determine the broader health implications of these findings.</p>\n\n<p><strong>Financial support:</strong> NIH/NCI (R01CA242168; P30CA225520); TSET HPRC (R23-02); PHF Bridge.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154748--></body></html>"
    },
    {
      "uid": "P038",
      "content_id": "154669",
      "abstract_number": "P038",
      "poster_number": "P038",
      "title": "Elucidating the Function of Chromosome 3p Monosomy in HPV+ and HPV- Squamous Cancer",
      "summary": "Squamous Cell Carcinoma (SCC) is an aggressive form of cancer that develops in the mucosal epithelium of the digestive and respiratory tracts, with SCC of the head and neck (HNSCC) occurring in the oral cavity, pharynx and larynx. Two major risk factors for development of HNSCC are carcinogen exposures, such as alcohol and tobacco, and Human Papillomavirus (HPV) infection. Viral- and carcinogen-driven HNSCCs have...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154669",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samyukta Mallick",
      "presenter": "Samyukta Mallick",
      "authors": "Samyukta Mallick ; Sai Ramani Choudari; Alison M Taylor",
      "normalized_authors": [
        "Samyukta Mallick",
        "Sai Ramani Choudari",
        "Alison M Taylor"
      ],
      "affiliations": [
        "Columbia University"
      ],
      "normalized_institutions": [
        "Columbia University"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 279,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Samyukta Mallick ; Sai Ramani Choudari; Alison M Taylor",
        "Affiliations": "Columbia University",
        "Abstract": "Squamous Cell Carcinoma (SCC) is an aggressive form of cancer that develops in the mucosal epithelium of the digestive and respiratory tracts, with SCC of the head and neck (HNSCC) occurring in the oral cavity, pharynx and larynx. Two major risk factors for development of HNSCC are carcinogen exposures, such as alcohol and tobacco, and Human Papillomavirus (HPV) infection. Viral- and carcinogen-driven HNSCCs have differential responses to radiation, chemotherapy, and immunotherapy, with HPV+ HNSCCs responding better to these treatments than HPV- carcinomas. SCCs are characterized by gain of chromosome arm 3q gain and loss of chromosome arm 3p. However, while HPV+ SCCs show similar rates of 3q gain, they have significantly lower rates of 3p loss, suggesting that 3p deletion and HPV infection might have overlapping roles in cancer initiation and/or progression. In analysis of data in the Cancer Genome Atlas (TCGA), we identified a strong correlation between 3p deletion and high epithelial-mesenchymal transition (EMT) gene signature across all cancer types. In addition, several genes encoding PDZ domain proteins are found on chromosome 3p, including PDZRN3 and MAGI1. It is thought that HPV E6 mediated degradation of PDZ domain proteins involved in junction formation may affect invasion. Expression of these genes is lower in cancers with 3p monosomy. In addition, we previously engineered isogenic cells with 3p monosomy; these cells have decreased levels of PDZRN3 and MAGI1 DNA, RNA and protein. Ongoing studies will identify the effect of individual gene knockdown on invasion and EMT phenotypes. Additionally, we are engineering 3p monosomy, as well as HPV oncoprotein overexpression, in normal keratinocytes to create isogenic models. With these models, we can elucidate the consequences of 3p deletion in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Elucidating the Function of Chromosome 3p Monosomy in HPV+ and HPV- Squamous Cancer</span>. <u>Samyukta Mallick</u>; Sai Ramani Choudari; Alison M Taylor. Columbia University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Squamous Cell Carcinoma (SCC) is an aggressive form of cancer that develops in the mucosal epithelium of the digestive and respiratory tracts, with SCC of the head and neck (HNSCC) occurring in the oral cavity, pharynx and larynx. Two major risk factors for development of HNSCC are carcinogen exposures, such as alcohol and tobacco, and Human Papillomavirus (HPV) infection. Viral- and carcinogen-driven HNSCCs have differential responses to radiation, chemotherapy, and immunotherapy, with HPV+ HNSCCs responding better to these treatments than HPV- carcinomas. SCCs are characterized by gain of chromosome arm 3q gain and loss of chromosome arm 3p. However, while HPV+ SCCs show similar rates of 3q gain, they have significantly lower rates of 3p loss, suggesting that 3p deletion and HPV infection might have overlapping roles in cancer initiation and/or progression.</p>\n\n<p>In analysis of data in the Cancer Genome Atlas (TCGA), we identified a strong correlation between 3p deletion and high epithelial-mesenchymal transition (EMT) gene signature across all cancer types. In addition, several genes encoding PDZ domain proteins are found on chromosome 3p, including PDZRN3 and MAGI1. It is thought that HPV E6 mediated degradation of PDZ domain proteins involved in junction formation may affect invasion. Expression of these genes is lower in cancers with 3p monosomy. In addition, we previously engineered isogenic cells with 3p monosomy; these cells have decreased levels of PDZRN3 and MAGI1 DNA, RNA and protein. Ongoing studies will identify the effect of individual gene knockdown on invasion and EMT phenotypes. Additionally, we are engineering 3p monosomy, as well as HPV oncoprotein overexpression, in normal keratinocytes to create isogenic models. With these models, we can elucidate the consequences of 3p deletion in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154669--></body></html>"
    },
    {
      "uid": "P039",
      "content_id": "153777",
      "abstract_number": "P039",
      "poster_number": "P039",
      "title": "Blocking YAP1-Liprin-?2 interaction impedes metastasis and promotes tumor suppression in head and neck squamous carcinoma",
      "summary": "Our research investigates the role of the YAP1-PPFIBP2 axis in the epithelial-mesenchymal transition (EMT) and its subsequent impact on invasion and migration in head and neck squamous cell carcinoma (HNSCC). Utilizing both in vitro assays and genomic analyses, we demonstrate that YAP1 upregulates EMT by suppressing PPFIBP2/liprin-β2 expression. This regulatory pathway contributes to enhanced invasiveness and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153777",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Young-Gyu Eun",
      "presenter": "Young-Gyu Eun",
      "authors": "Hyun Jee Lee, MD 1 ; Min Kyeong Lee, PhD 2 ; Young-Gyu Eun 2",
      "normalized_authors": [
        "Hyun Jee Lee",
        "Min Kyeong Lee",
        "Young-Gyu Eun"
      ],
      "affiliations": [
        "Kyung Hee Medical Center",
        "Kyung Hee Universtiy"
      ],
      "normalized_institutions": [
        "Kyung Hee Medical Center",
        "Kyung Hee Universtiy"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 181,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hyun Jee Lee, MD 1 ; Min Kyeong Lee, PhD 2 ; Young-Gyu Eun 2",
        "Affiliations": "1 Kyung Hee Medical Center; 2 Kyung Hee Universtiy",
        "Abstract": "Our research investigates the role of the YAP1-PPFIBP2 axis in the epithelial-mesenchymal transition (EMT) and its subsequent impact on invasion and migration in head and neck squamous cell carcinoma (HNSCC). Utilizing both in vitro assays and genomic analyses, we demonstrate that YAP1 upregulates EMT by suppressing PPFIBP2/liprin-β2 expression. This regulatory pathway contributes to enhanced invasiveness and correlates with poorer prognostic outcomes in HNSCC. We specifically knocked down YAP1 in SNU1041 and SCC9 cell lines using siRNA, resulting in reduced invasion and migration. These effects were reversed by subsequent administration of siPPFIBP2. In contrast, overexpression of YAP1 in SCC25 cells led to increased EMT marker activity and enhanced invasive behavior, supporting the functional role of this axis. Importantly, pharmacological inhibition of YAP1 using CA3 led to a notable decrease in EMT markers, invasion, and migration, suggesting that blocking the YAP1-PPFIBP2 axis may serve as an effective therapeutic strategy in HNSCC. In conclusion, our study identifies the YAP1-PPFIBP2 interaction as a crucial mediator of tumor aggressiveness in HNSCC, offering new insight into metastatic progression and highlighting a promising target for therapeutic intervention."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Blocking YAP1-Liprin-?2 interaction impedes metastasis and promotes tumor suppression in head and neck squamous carcinoma</span>. Hyun Jee Lee, MD<sup>1</sup>; Min Kyeong Lee, PhD<sup>2</sup>; <u>Young-Gyu Eun</u><sup>2</sup>. <sup>1</sup>Kyung Hee Medical Center; <sup>2</sup>Kyung Hee Universtiy<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Our research investigates the role of the YAP1-PPFIBP2 axis in the epithelial-mesenchymal transition (EMT) and its subsequent impact on invasion and migration in head and neck squamous cell carcinoma (HNSCC). Utilizing both in vitro assays and genomic analyses, we demonstrate that YAP1 upregulates EMT by suppressing PPFIBP2/liprin-β2 expression. This regulatory pathway contributes to enhanced invasiveness and correlates with poorer prognostic outcomes in HNSCC. We specifically knocked down YAP1 in SNU1041 and SCC9 cell lines using siRNA, resulting in reduced invasion and migration. These effects were reversed by subsequent administration of siPPFIBP2. In contrast, overexpression of YAP1 in SCC25 cells led to increased EMT marker activity and enhanced invasive behavior, supporting the functional role of this axis. Importantly, pharmacological inhibition of YAP1 using CA3 led to a notable decrease in EMT markers, invasion, and migration, suggesting that blocking the YAP1-PPFIBP2 axis may serve as an effective therapeutic strategy in HNSCC. In conclusion, our study identifies the YAP1-PPFIBP2 interaction as a crucial mediator of tumor aggressiveness in HNSCC, offering new insight into metastatic progression and highlighting a promising target for therapeutic intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153777--></body></html>"
    },
    {
      "uid": "P040",
      "content_id": "155287",
      "abstract_number": "P040",
      "poster_number": "P040",
      "title": "Gene Expression Profiling and Prognostic Significance of Nuclear and Membrane Progesterone Receptors in Head and Neck Squamous Cell Carcinoma",
      "summary": "The risk of developing some types of head and neck squamous cell carcinoma (HNSCC) is seven times higher in males, and such disparities may not be associated only with tobacco and alcohol consumption or HPV infection. Therefore, the endocrine microenvironment is considered another risk factor, as epidemiologic studies have unequivocally shown the protective effect of estrogen in women. This research was focused...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155287",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mario Bilic, PhD",
      "presenter": "Mario Bilic, PhD",
      "authors": "Mario Bilic, PhD ; Lana Kovac Bilic, PhD",
      "normalized_authors": [
        "Mario Bilic",
        "Lana Kovac Bilic"
      ],
      "affiliations": [
        "University Hospital Center Zagreb"
      ],
      "normalized_institutions": [
        "University Hospital Center Zagreb"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 276,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mario Bilic, PhD ; Lana Kovac Bilic, PhD",
        "Affiliations": "University Hospital Center Zagreb",
        "Abstract": "The risk of developing some types of head and neck squamous cell carcinoma (HNSCC) is seven times higher in males, and such disparities may not be associated only with tobacco and alcohol consumption or HPV infection. Therefore, the endocrine microenvironment is considered another risk factor, as epidemiologic studies have unequivocally shown the protective effect of estrogen in women. This research was focused on progesterone receptors (PRs), the least-studied sex hormone receptors in HNSCC. Our study included fresh tissue samples from 95 primary tumors, 25 metastatic lymph nodes and 40 healthy oral mucosa. Gene expression of nuclear (PGR) and seven membrane PRs (PAQR5, PAQR6, PAQR7, PAQR8, PAQR9, PGRMC1 and PGRMC2) was analyzed by qRT-PCR and associated with clinicopathological characteristics. The results showed that, compared to control tissue, PGR was increased in metastatic lymph nodes, while PAQR5, PAQR7, PAQR8 and PAQR9 were decreased in primary tumors (all p < 0.05). The expression of almost all PRs was greater in older patients and showed moderate to strong positive mutual correlations in both tumors and controls. PARQ8 and PAQR9 were increased in females and pT4 tumors (all p < 0.05). Survival analysis showed that higher PAQR5 (hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.19–6.57, p = 0.019) and PAQR7 (HR 2.0, 95% CI 1.01–3.81, p = 0.048) were associated with worse overall survival, but their independence was not proven in multivariate analysis. Although most PRs were reduced in primary tumors, an increased PAQR5 expression, also associated with tumor invasion markers, could likely mark a specific aggressive, advanced stage of primary tumors and potentially serve as a negative prognostic biomarker for HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Gene Expression Profiling and Prognostic Significance of Nuclear and Membrane Progesterone Receptors in Head and Neck Squamous Cell Carcinoma</span>. <u>Mario Bilic, PhD</u>; Lana Kovac Bilic, PhD. University Hospital Center Zagreb<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The risk of developing some types of head and neck squamous cell carcinoma (HNSCC) is seven times higher in males, and such disparities may not be associated only with tobacco and alcohol consumption or HPV infection. Therefore, the endocrine microenvironment is considered another risk factor, as epidemiologic studies have unequivocally shown the protective effect of estrogen in women. This research was focused on progesterone receptors (PRs), the least-studied sex hormone receptors in HNSCC. Our study included fresh tissue samples from 95 primary tumors, 25 metastatic lymph nodes and 40 healthy oral mucosa. Gene expression of nuclear (PGR) and seven membrane PRs (PAQR5, PAQR6, PAQR7, PAQR8, PAQR9, PGRMC1 and PGRMC2) was analyzed by qRT-PCR and associated with clinicopathological characteristics. The results showed that, compared to control tissue, PGR was increased in metastatic lymph nodes, while PAQR5, PAQR7, PAQR8 and PAQR9 were decreased in primary tumors (all p < 0.05). The expression of almost all PRs was greater in older patients and showed moderate to strong positive mutual correlations in both tumors and controls. PARQ8 and PAQR9 were increased in females and pT4 tumors (all p < 0.05). Survival analysis showed that higher PAQR5 (hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.19–6.57, p = 0.019) and PAQR7 (HR 2.0, 95% CI 1.01–3.81, p = 0.048) were associated with worse overall survival, but their independence was not proven in multivariate analysis. Although most PRs were reduced in primary tumors, an increased PAQR5 expression, also associated with tumor invasion markers, could likely mark a specific aggressive, advanced stage of primary tumors and potentially serve as a negative prognostic biomarker for HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155287--></body></html>"
    },
    {
      "uid": "P041",
      "content_id": "153508",
      "abstract_number": "P041",
      "poster_number": "P041",
      "title": "Differential prognostic roles of metastatic and non-metastatic lymph nodes in head and neck cancer",
      "summary": "Cervical lymph node metastasis is a major prognostic determinant in head and neck cancer, and comprehensive neck dissection remains standard. However, cervical lymph nodes also serve as crucial sites for the initiation of antitumor immune responses. This study examined the relationships among metastatic and non-metastatic lymph node counts, systemic immune status, and clinical outcomes in patients who underwent...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153508",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Miho Uchida",
      "presenter": "Miho Uchida",
      "authors": "Miho Uchida ; Chisato Shito; Kohei Minemura; Yurino Nagata; Hiroe Tada; Hideyuki Takahashi; Kazuaki Chikamatsu",
      "normalized_authors": [
        "Miho Uchida",
        "Chisato Shito",
        "Kohei Minemura",
        "Yurino Nagata",
        "Hiroe Tada",
        "Hideyuki Takahashi",
        "Kazuaki Chikamatsu"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Gunma Graduate School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Gunma Graduate School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 292,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Miho Uchida ; Chisato Shito; Kohei Minemura; Yurino Nagata; Hiroe Tada; Hideyuki Takahashi; Kazuaki Chikamatsu",
        "Affiliations": "Department of Otolaryngology-Head and Neck Surgery, Gunma Graduate School of Medicine",
        "Abstract": "Cervical lymph node metastasis is a major prognostic determinant in head and neck cancer, and comprehensive neck dissection remains standard. However, cervical lymph nodes also serve as crucial sites for the initiation of antitumor immune responses. This study examined the relationships among metastatic and non-metastatic lymph node counts, systemic immune status, and clinical outcomes in patients who underwent initial neck dissection between April 2015 and March 2025. Systemic immune-inflammatory and immuno-nutritional indices were derived from preoperative blood tests. Overall survival (OS) and progression-free survival (PFS) did not differ significantly between pN– and pN+ groups. However, when evaluated using the number of metastatic lymph nodes or the log odds of positive nodes (LODDS), patients with pN+ disease demonstrated significantly worse prognosis. Both the pN+ group and the high-LODDS group showed significantly lower CAR values, suggesting altered systemic inflammatory and nutritional status. Among pN+ patients, extranodal extension (ENE) was associated with significantly elevated neutrophil-to-lymphocyte ratio (NLR), and ENE-positive patients exhibited poorer PFS compared with ENE-negative cases, indicating a link between nodal aggressiveness and systemic immune dysregulation. Subgroup analyses further revealed distinct prognostic implications of non-metastatic lymph nodes. In the pN– group, a higher number of non-metastatic lymph nodes was associated with improved PFS, whereas in the pN+ group, a higher number of non-metastatic nodes correlated with worse OS. Although non-metastatic lymph node count did not remain an independent prognostic factor in multivariate analysis, these opposing trends suggest that its biological/immunological significance may vary depending on metastatic status. Taken together, the findings indicate that cervical lymph nodes have divergent oncological and immunological roles in metastatic versus non-metastatic settings. The interaction between lymph node microenvironments, systemic immune status, and clinical outcomes warrants further investigation, particularly from the standpoint of antitumor immunity and lymph node immunobiology."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Differential prognostic roles of metastatic and non-metastatic lymph nodes in head and neck cancer</span>. <u>Miho Uchida</u>; Chisato Shito; Kohei Minemura; Yurino Nagata; Hiroe Tada; Hideyuki Takahashi; Kazuaki Chikamatsu. Department of Otolaryngology-Head and Neck Surgery, Gunma Graduate School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Cervical lymph node metastasis is a major prognostic determinant in head and neck cancer, and comprehensive neck dissection remains standard. However, cervical lymph nodes also serve as crucial sites for the initiation of antitumor immune responses. This study examined the relationships among metastatic and non-metastatic lymph node counts, systemic immune status, and clinical outcomes in patients who underwent initial neck dissection between April 2015 and March 2025. Systemic immune-inflammatory and immuno-nutritional indices were derived from preoperative blood tests.</p>\n\n<p>Overall survival (OS) and progression-free survival (PFS) did not differ significantly between pN– and pN+ groups. However, when evaluated using the number of metastatic lymph nodes or the log odds of positive nodes (LODDS), patients with pN+ disease demonstrated significantly worse prognosis. Both the pN+ group and the high-LODDS group showed significantly lower CAR values, suggesting altered systemic inflammatory and nutritional status.</p>\n\n<p>Among pN+ patients, extranodal extension (ENE) was associated with significantly elevated neutrophil-to-lymphocyte ratio (NLR), and ENE-positive patients exhibited poorer PFS compared with ENE-negative cases, indicating a link between nodal aggressiveness and systemic immune dysregulation.</p>\n\n<p>Subgroup analyses further revealed distinct prognostic implications of non-metastatic lymph nodes. In the pN– group, a higher number of non-metastatic lymph nodes was associated with improved PFS, whereas in the pN+ group, a higher number of non-metastatic nodes correlated with worse OS. Although non-metastatic lymph node count did not remain an independent prognostic factor in multivariate analysis, these opposing trends suggest that its biological/immunological significance may vary depending on metastatic status.</p>\n\n<p>Taken together, the findings indicate that cervical lymph nodes have divergent oncological and immunological roles in metastatic versus non-metastatic settings. The interaction between lymph node microenvironments, systemic immune status, and clinical outcomes warrants further investigation, particularly from the standpoint of antitumor immunity and lymph node immunobiology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153508--></body></html>"
    },
    {
      "uid": "P042",
      "content_id": "154318",
      "abstract_number": "P042",
      "poster_number": "P042",
      "title": "Effects of cannabidiol on head and neck squamous cell carcinoma migration",
      "summary": "The concentration range of CBD observed in users enhanced the migration of head and neck cancer cells in vitro. Given the importance of cell migration in invasiveness, metastasis, treatment resistance, and recurrence, our findings raise concern regarding the use of CBD by head and neck cancer patients. Mechanistically, our data suggest that in UM-SCC-1 cells, CBD acts through CB2-mediated pathways: the CB2...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154318",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jacob Lieberman, BS",
      "presenter": "Jacob Lieberman, BS",
      "authors": "Jacob Lieberman, BS 1,2 ; Sulfath Thottungal Parambil 2 ; Lurdes Queimado, MD, PhD 1,2,3",
      "normalized_authors": [
        "Jacob Lieberman",
        "Sulfath Thottungal Parambil",
        "Lurdes Queimado"
      ],
      "affiliations": [
        "College of Medicine, University of Oklahoma, Oklahoma City, OK, USA",
        "Department of Otolaryngology - Head and Neck Surgery, University of Oklahoma, Oklahoma City, OK, USA",
        "The Peggy and Charles Stephenson Cancer Center TSET Health Promotion Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"
      ],
      "normalized_institutions": [
        "College of Medicine, University of Oklahoma, Oklahoma City, OK, USA",
        "Department of Otolaryngology - Head and Neck Surgery, University of Oklahoma, Oklahoma City, OK, USA",
        "The Peggy and Charles Stephenson Cancer Center TSET Health Promotion Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 431,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jacob Lieberman, BS 1,2 ; Sulfath Thottungal Parambil 2 ; Lurdes Queimado, MD, PhD 1,2,3",
        "Affiliations": "1 College of Medicine, University of Oklahoma, Oklahoma City, OK, USA; 2 Department of Otolaryngology - Head and Neck Surgery, University of Oklahoma, Oklahoma City, OK, USA; 3 The Peggy and Charles Stephenson Cancer Center TSET Health Promotion Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
        "Background": "Cannabidiol (CBD) is a phytocannabinoid that has a variety of uses including analgesia, anti-inflammation, and overall wellness, but its effects on cancer behavior remains poorly understood. Cannabinoids have been proposed to modulate cell migration in the context of wound healing, but information on its impact on cancer progression is limited and poorly defined. Based on the increasing prevalence of CBD use by cancer patients, investigating the relationship between CBD and tumor cell behavior is critical for clinical practice. We evaluated the effect of specific cannabinoids on motility in UM-SCC-1, a head and neck squamous cell carcinoma cell line.",
        "Methods": "UM-SCC1-1 cells were treated with CBD, the selective cannabinoid receptor (CB2) agonist HU-308, and the selective CB2 receptor antagonist SR144528 at concentrations ranging from 1-90nM[ST1] , based on previously reported human tissue levels of CBD. The cells were exposed to their respective treatment group for 48 hours. Manual scratch assays were conducted, in which a pipette scratch was made and imaged with light microscopy. Automated experiments were also conducted using the IncuCyte 96-well Woundmaker Tool and IncuCyte live-cell imaging. Data was analyzed by ANOVA followed by t-tests.",
        "Results": "Exposure of UM-SCC-1 cells to CBD at the lowest levels of exposure (1-9 nM) had no significant impact on cell motility. However, CBD concentrations 30nM and 90nM resulted in a significant concentration-dependent increase in cell migration, relative to control, that was measurable at 24 (p<0.05) and 48 (p<0.05) hours of exposure,[LQ2] and lead to a significant increase in wound closure (p<0.05). Exposure to HU-308 also produced a similar concentration-dependent increase in cell motility, whereas SR144528 treatment resulted in a concentration-dependent decrease in cell mobility. These results indicate that CBD agonism promotes migratory behavior of UM-SCC-1 cells, while antagonism suppresses this activity.",
        "Conclusion": "The concentration range of CBD observed in users enhanced the migration of head and neck cancer cells in vitro. Given the importance of cell migration in invasiveness, metastasis, treatment resistance, and recurrence, our findings raise concern regarding the use of CBD by head and neck cancer patients. Mechanistically, our data suggest that in UM-SCC-1 cells, CBD acts through CB2-mediated pathways: the CB2 agonist HU-308 increased cell migration relative to untreated controls, whereas the CB2 antagonist SR144528 reduced migration. Although our results do not establish a clinically relevant effect, they underscore the need for continued investigation into how CBD use may influence metastasis, treatment resistance, and prognosis. Further studies aimed at defining the specific pathways involved and evaluating the impact of prolonged CBD exposure will be essential to clarify these effects and their potential implications on cancer patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Effects of cannabidiol on head and neck squamous cell carcinoma migration</span>. <u>Jacob Lieberman, BS</u><sup>1,2</sup>; Sulfath Thottungal Parambil<sup>2</sup>; Lurdes Queimado, MD, PhD<sup>1,2,3</sup>. <sup>1</sup>College of Medicine, University of Oklahoma, Oklahoma City, OK, USA; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, University of Oklahoma, Oklahoma City, OK, USA; <sup>3</sup>The Peggy and Charles Stephenson Cancer Center TSET Health Promotion Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cannabidiol (CBD) is a phytocannabinoid that has a variety of uses including analgesia, anti-inflammation, and overall wellness, but its effects on cancer behavior remains poorly understood. Cannabinoids have been proposed to modulate cell migration in the context of wound healing, but information on its impact on cancer progression is limited and poorly defined. Based on the increasing prevalence of CBD use by cancer patients, investigating the relationship between CBD and tumor cell behavior is critical for clinical practice. We evaluated the effect of specific cannabinoids on motility in UM-SCC-1, a head and neck squamous cell carcinoma cell line.</p>\n\n<p><strong>Methods: </strong>UM-SCC1-1 cells were treated with CBD, the selective cannabinoid receptor (CB2) agonist HU-308, and the selective CB2 receptor antagonist SR144528 at concentrations ranging from 1-90nM[ST1] , based on previously reported human tissue levels of CBD. The cells were exposed to their respective treatment group for 48 hours. Manual scratch assays were conducted, in which a pipette scratch was made and imaged with light microscopy. Automated experiments were also conducted using the IncuCyte 96-well Woundmaker Tool and IncuCyte live-cell imaging. Data was analyzed by ANOVA followed by t-tests.</p>\n\n<p><strong>Results: </strong>Exposure of UM-SCC-1 cells to CBD at the lowest levels of exposure (1-9 nM) had no significant impact on cell motility. However, CBD concentrations 30nM and 90nM resulted in a significant concentration-dependent increase in cell migration, relative to control, that was measurable at 24 (p<0.05) and 48 (p<0.05) hours of exposure,[LQ2]  and lead to a significant increase in wound closure (p<0.05). Exposure to HU-308 also produced a similar concentration-dependent increase in cell motility, whereas SR144528 treatment resulted in a concentration-dependent decrease in cell mobility. These results indicate that CBD agonism promotes migratory behavior of UM-SCC-1 cells, while antagonism suppresses this activity.</p>\n\n<p><strong>Conclusion: </strong>The concentration range of CBD observed in users enhanced the migration of head and neck cancer cells in vitro. Given the importance of cell migration in invasiveness, metastasis, treatment resistance, and recurrence, our findings raise concern regarding the use of CBD by head and neck cancer patients. Mechanistically, our data suggest that in UM-SCC-1 cells, CBD acts through CB2-mediated pathways: the CB2 agonist HU-308 increased cell migration relative to untreated controls, whereas the CB2 antagonist SR144528 reduced migration. Although our results do not establish a clinically relevant effect, they underscore the need for continued investigation into how CBD use may influence metastasis, treatment resistance, and prognosis. Further studies aimed at defining the specific pathways involved and evaluating the impact of prolonged CBD exposure will be essential to clarify these effects and their potential implications on cancer patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154318--></body></html>"
    },
    {
      "uid": "P043",
      "content_id": "153841",
      "abstract_number": "P043",
      "poster_number": "P043",
      "title": "The interplay between ONC 201 and Cisplatin in promoting cell death by modulating MET signaling through triggering the mitochondrial stress response in head and neck squamous cell carcinoma",
      "summary": "Cisplatin, a platinum-based chemotherapy agent, is commonly used as a first-line treatment for head and neck squamous cell carcinoma (HNSCC) due to its potent anticancer activity. However, a significant challenge in treating patients with advanced or recurrent cancers is the development of resistance to cisplatin. ONC201 is a small molecule that has demonstrated antitumor efficacy both as monotherapy and in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153841",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hui-Ching Chuang, MD, PhD",
      "presenter": "Hui-Ching Chuang, MD, PhD",
      "authors": "Hui-Ching Chuang, MD, PhD 1 ; Ming-Huei Chou, PhD 2",
      "normalized_authors": [
        "Hui-Ching Chuang",
        "Ming-Huei Chou"
      ],
      "affiliations": [
        "Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
        "The Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan"
      ],
      "normalized_institutions": [
        "Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
        "The Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 254,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hui-Ching Chuang, MD, PhD 1 ; Ming-Huei Chou, PhD 2",
        "Affiliations": "1 Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 The Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan",
        "Abstract": "Cisplatin, a platinum-based chemotherapy agent, is commonly used as a first-line treatment for head and neck squamous cell carcinoma (HNSCC) due to its potent anticancer activity. However, a significant challenge in treating patients with advanced or recurrent cancers is the development of resistance to cisplatin. ONC201 is a small molecule that has demonstrated antitumor efficacy both as monotherapy and in combination with other treatments in phase II clinical trials across various solid tumors and hematological malignancies. This efficacy is achieved through the activation of the integrated stress response, inhibition of AKT/ERK signaling, and promotion of TRAIL-mediated apoptosis. Clinical studies in patients with HNSCC have shown that overexpression of the mesenchymal-epithelial transition factor (MET) is associated with lymph node metastasis and decreased overall survival. In our previous research, we found that ONC201 enhances the efficacy of cisplatin by activating distinct stress-mediated apoptotic pathways in HNSCC. The ability of ONC201 to overcome cisplatin resistance and its synergistic antitumor effects highlight its potential as a combination therapy candidate. In the present study, we investigate the synergistic effects of ONC201 and cisplatin in HNSCC using both in vitro and in vivo models. We aim to elucidate the underlying molecular mechanisms and assess the therapeutic potential of this combination in overcoming treatment resistance and improving outcomes in HNSCC. The preliminary results indicate that ONC201 suppresses MET signaling and decreases the levels of anti-apoptotic proteins, leading to increased cell death. Targeting the MET pathway could be a potential new strategy for cancer patients, especially those with recurrent /metastatic HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The interplay between ONC 201 and Cisplatin in promoting cell death by modulating MET signaling through triggering the mitochondrial stress response in head and neck squamous cell carcinoma</span>. <u>Hui-Ching Chuang, MD, PhD</u><sup>1</sup>; Ming-Huei Chou, PhD<sup>2</sup>. <sup>1</sup>Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; <sup>2</sup>The Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Cisplatin, a platinum-based chemotherapy agent, is commonly used as a first-line treatment for head and neck squamous cell carcinoma (HNSCC) due to its potent anticancer activity. However, a significant challenge in treating patients with advanced or recurrent cancers is the development of resistance to cisplatin. ONC201 is a small molecule that has demonstrated antitumor efficacy both as monotherapy and in combination with other treatments in phase II clinical trials across various solid tumors and hematological malignancies. This efficacy is achieved through the activation of the integrated stress response, inhibition of AKT/ERK signaling, and promotion of TRAIL-mediated apoptosis. Clinical studies in patients with HNSCC have shown that overexpression of the mesenchymal-epithelial transition factor (MET) is associated with lymph node metastasis and decreased overall survival.</p>\n\n<p>In our previous research, we found that ONC201 enhances the efficacy of cisplatin by activating distinct stress-mediated apoptotic pathways in HNSCC. The ability of ONC201 to overcome cisplatin resistance and its synergistic antitumor effects highlight its potential as a combination therapy candidate. In the present study, we investigate the synergistic effects of ONC201 and cisplatin in HNSCC using both in vitro and in vivo models. We aim to elucidate the underlying molecular mechanisms and assess the therapeutic potential of this combination in overcoming treatment resistance and improving outcomes in HNSCC. The preliminary results indicate that ONC201 suppresses MET signaling and decreases the levels of anti-apoptotic proteins, leading to increased cell death. Targeting the MET pathway could be a potential new strategy for cancer patients, especially those with recurrent /metastatic HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153841--></body></html>"
    },
    {
      "uid": "P044",
      "content_id": "154716",
      "abstract_number": "P044",
      "poster_number": "P044",
      "title": "FBXW7 mutations as important regulators of notch mediated differentiation and immune evasive programs in HPV negative Head and Neck Squamous cell carcinoma.",
      "summary": "NOTCH1-FBXW7 axis is an important therapeutic vulnerability in a subset of HNSCC to reactivate tumor immune and differentiation programs, thereby promoting patient survival in patients with HNSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154716",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Saketh Bathula",
      "presenter": "Saketh Bathula",
      "authors": "Lucas Ratiani; Saketh Bathula ; Harshini Vemula; Eric Carlson; Srinivas Saladi",
      "normalized_authors": [
        "Lucas Ratiani",
        "Saketh Bathula",
        "Harshini Vemula",
        "Eric Carlson",
        "Srinivas Saladi"
      ],
      "affiliations": [
        "University of Toledo College of Medicine and Life Sciences"
      ],
      "normalized_institutions": [
        "University of Toledo College of Medicine and Life Sciences"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 380,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Lucas Ratiani; Saketh Bathula ; Harshini Vemula; Eric Carlson; Srinivas Saladi",
        "Affiliations": "University of Toledo College of Medicine and Life Sciences",
        "Introduction": "Head and neck squamous cell carcinoma (HNSCC) accounts for the majority of head and neck cancers. Its molecular, and anatomic, heterogeneity play a role in the presentation and progression of patients with HNSCC. Despite known risk factors and development of targeted therapies, HNSCC often presents in the later stages of malignancy and is associated with a high rate of recurrence. The complex nature of HNSCC and its high morbidity highlight the importance of greater insight into the genetic characterization of the disease and carcinogenesis. NOCTH1 mutations have been reported in approximately 10 percent of HNSCC patients. However, most patients do not have a mutation in NOTCH1 or its family members (NOTCH2,3,4). NOTCH1 is shown to be regulated by FBXW7, which is a substrate recognition component of the SCF-type E3 ubiquitin ligase complex, playing a role in the proteasomal degradation of numerous oncogenes. The NOTCH family of genes are one the most mutated genes in HPV-negative HNSCC. FBXW7 is also mutated in 8 percent of HNSCC patients but the two are considered mutually exclusive, and the remaining NOTCH2, 3, 4, are less frequent. Understanding the mechanism by which NOTCH-FBXW7 axis plays a role in tumor differentiation and immune evasion will help in designing targeted therapies in patients with high NOTCH activity.",
        "Methods": "The Cancer Genome Atlas (TCGA) data for HNSCC was extracted for mutations in NOTCH1, 2, 3, 4, and FBXW7. Non-synonymous tumor mutation burden (TMB), perineural invasion, angiolymphatic invasion, differentiation programs, and immune evasive programs in HPV negative HNSCC patients were analyzed. HPV positive HNSCC patients were taken into account as well. Quantitative PCRs were performed in HNSCC cell lines to analyze the NOTCH1 target genes. HES1 HEY1, and differentiation genes and tumor immune genes were also investigated.",
        "Results": "NOTCH1 has been shown previously to cooperate with p63 and regulate differentiation program in keratinocytes and HNSCC. We observed a significant negative correlation (p<0.01) between FBXW7 and differentiation marker genes (early and late differentiation markers, Keratin 1, 10, and LORCRIN) we also observed a negative correlation between FBXW7 and two internal regulatory factor (IRF) genes. Suggesting its immune evasive mechanism in HNSCC.",
        "Conclusion": "NOTCH1-FBXW7 axis is an important therapeutic vulnerability in a subset of HNSCC to reactivate tumor immune and differentiation programs, thereby promoting patient survival in patients with HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>FBXW7 mutations as important regulators of notch mediated differentiation and immune evasive programs in HPV negative Head and Neck Squamous cell carcinoma.</span>. Lucas Ratiani; <u>Saketh Bathula</u>; Harshini Vemula; Eric Carlson; Srinivas Saladi. University of Toledo College of Medicine and Life Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Head and neck squamous cell carcinoma (HNSCC) accounts for the majority of head and neck cancers. Its molecular, and anatomic, heterogeneity play a role in the presentation and progression of patients with HNSCC. Despite known risk factors and development of targeted therapies, HNSCC often presents in the later stages of malignancy and is associated with a high rate of recurrence. The complex nature of HNSCC and its high morbidity highlight the importance of greater insight into the genetic characterization of the disease and carcinogenesis. NOCTH1 mutations have been reported in approximately 10 percent of HNSCC patients. However, most patients do not have a mutation in NOTCH1 or its family members (NOTCH2,3,4). NOTCH1 is shown to be regulated by FBXW7, which is a substrate recognition component of the SCF-type E3 ubiquitin ligase complex, playing a role in the proteasomal degradation of numerous oncogenes. The NOTCH family of genes are one the most mutated genes in HPV-negative HNSCC. FBXW7 is also mutated in 8 percent of HNSCC patients but the two are considered mutually exclusive, and the remaining NOTCH2, 3, 4, are less frequent. Understanding the mechanism by which NOTCH-FBXW7 axis plays a role in tumor differentiation and immune evasion will help in designing targeted therapies in patients with high NOTCH activity.</p>\n\n<p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) data for HNSCC was extracted for mutations in NOTCH1, 2, 3, 4, and FBXW7. Non-synonymous tumor mutation burden (TMB), perineural invasion, angiolymphatic invasion, differentiation programs, and immune evasive programs in HPV negative HNSCC patients were analyzed. HPV positive HNSCC patients were taken into account as well. Quantitative PCRs were performed in HNSCC cell lines to analyze the NOTCH1 target genes. HES1 HEY1, and differentiation genes and tumor immune genes were also investigated.</p>\n\n<p><strong>Results: </strong>NOTCH1 has been shown previously to cooperate with p63 and regulate differentiation program in keratinocytes and HNSCC. We observed a significant negative correlation (p<0.01) between FBXW7 and differentiation marker genes (early and late differentiation markers, Keratin 1, 10, and LORCRIN) we also observed a negative correlation between FBXW7 and two internal regulatory factor (IRF) genes. Suggesting its immune evasive mechanism in HNSCC.</p>\n\n<p><strong>Conclusion:  </strong>NOTCH1-FBXW7 axis is an important therapeutic vulnerability in a subset of HNSCC to reactivate tumor immune and differentiation programs, thereby promoting patient survival in patients with HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154716--></body></html>"
    },
    {
      "uid": "P045",
      "content_id": "147001",
      "abstract_number": "P045",
      "poster_number": "P045",
      "title": "A Rare Case of Metastatic Radioiodine-Refractory Follicular Thyroid Carcinoma Associated with NRAS Q61R Mutation",
      "summary": "This case highlights challenges in managing metastatic follicular thyroid carcinoma with RAI resistance. Molecular profiling identified an NRAS Q61R mutation, informing potential MEK inhibitor therapy. Early imaging and biopsy are essential, and molecular testing aids in guiding therapy. Continued research into the role of MEK inhibitors and other molecular-based treatments will be essential in optimizing patient...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147001",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Edgar D Uribe Sanchez, BA",
      "presenter": "Edgar D Uribe Sanchez, BA",
      "authors": "Edgar D Uribe Sanchez, BA ; Gina D Jefferson, MD; Licy Yanes Cardozo, MD; Varsha Manucha, MD",
      "normalized_authors": [
        "Edgar D Uribe Sanchez",
        "Gina D Jefferson",
        "Licy Yanes Cardozo",
        "Varsha Manucha"
      ],
      "affiliations": [
        "University of Mississippi Medical Center"
      ],
      "normalized_institutions": [
        "University of Mississippi Medical Center"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 414,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Postoperative Course and Management",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Edgar D Uribe Sanchez, BA ; Gina D Jefferson, MD; Licy Yanes Cardozo, MD; Varsha Manucha, MD",
        "Affiliations": "University of Mississippi Medical Center",
        "Introduction": "Follicular thyroid carcinoma can present with distant metastases at the time of diagnosis, although osseous involvement is less common. The presence of metastatic thyroid cancer in the mandible is rare and may mimic primary bone lesions or odontogenic pathology. This case illustrates an unusual presentation of metastatic follicular thyroid carcinoma and underscores the importance of multidisciplinary collaboration in both diagnosis and management.",
        "Case Presentation": "A 71-year-old male with a 25-year history as a nuclear technician presented to his dentist with a progressively enlarging lesion on the left mandibular gingiva. Referral to an oral and maxillofacial surgeon led to biopsy, which revealed metastatic thyroid carcinoma. Subsequent imaging confirmed a primary thyroid malignancy with widespread osseous metastases. A multidisciplinary treatment plan was initiated, including total thyroidectomy and segmental mandibulectomy. The patient underwent radioactive iodine (RAI) therapy through endocrine follow-up, which initially demonstrated favorable response with reduced plasma thyroglobulin levels and improved radiographic findings. Over time, however, rising thyroglobulin levels and the appearance of new, non-iodine–avid metastatic lesions indicated progression with RAI resistance. Tumoral molecular profiling identified an NRAS Q61R mutation via next-generation RNA sequencing, implicating MAPK pathway activation and impaired iodine uptake. MEK inhibitors were considered to restore iodine sensitivity, but the most recent PET-CT demonstrated stable disease, and the patient opted for surveillance.",
        "Postoperative Course and Management": "Postoperatively, the patient experienced acute respiratory failure requiring tracheostomy and hematoma evacuation. He was discharged after 13 days. RAI therapy (175 mCi I-131) in January 2021 initially lowered thyroglobulin levels (from 595 ng/mL to 78 ng/mL by July 2021). Palliative radiation was provided in March 2021. A February 2022 PET-CT showed new osseous metastases and rising thyroglobulin (219 ng/mL). A second dose of RAI (150 mCi) was administered, and subsequent imaging revealed persistent uptake in a left lower pelvic metastasis. Concurrent bloodwork demonstrated pancytopenia, necessitating referral to hematology. Serial NM PET CT whole body scans were stable until October 2024 when the PET-CT demonstrated new metastases. A diagnostic I-123 scan showed minimal iodine uptake in the left inferior pubic ramus metastasis, confirming RAI-resistance. Given increasing thyroglobulin levels (1423 ng/mL) and minimal iodine uptake, the disease was deemed as RAI-resistant metastatic thyroid cancer.",
        "Conclusion": "This case highlights challenges in managing metastatic follicular thyroid carcinoma with RAI resistance. Molecular profiling identified an NRAS Q61R mutation, informing potential MEK inhibitor therapy. Early imaging and biopsy are essential, and molecular testing aids in guiding therapy. Continued research into the role of MEK inhibitors and other molecular-based treatments will be essential in optimizing patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Rare Case of Metastatic Radioiodine-Refractory Follicular Thyroid Carcinoma Associated with NRAS Q61R Mutation</span>. <u>Edgar D Uribe Sanchez, BA</u>; Gina D Jefferson, MD; Licy Yanes Cardozo, MD; Varsha Manucha, MD. University of Mississippi Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Follicular thyroid carcinoma can present with distant metastases at the time of diagnosis, although osseous involvement is less common. The presence of metastatic thyroid cancer in the mandible is rare and may mimic primary bone lesions or odontogenic pathology. This case illustrates an unusual presentation of metastatic follicular thyroid carcinoma and underscores the importance of multidisciplinary collaboration in both diagnosis and management.</p>\n\n<p><strong>Case Presentation: </strong>A 71-year-old male with a 25-year history as a nuclear technician presented to his dentist with a progressively enlarging lesion on the left mandibular gingiva. Referral to an oral and maxillofacial surgeon led to biopsy, which revealed metastatic thyroid carcinoma. Subsequent imaging confirmed a primary thyroid malignancy with widespread osseous metastases. A multidisciplinary treatment plan was initiated, including total thyroidectomy and segmental mandibulectomy. The patient underwent radioactive iodine (RAI) therapy through endocrine follow-up, which initially demonstrated favorable response with reduced plasma thyroglobulin levels and improved radiographic findings. Over time, however, rising thyroglobulin levels and the appearance of new, non-iodine–avid metastatic lesions indicated progression with RAI resistance. Tumoral molecular profiling identified an NRAS Q61R mutation via next-generation RNA sequencing, implicating MAPK pathway activation and impaired iodine uptake. MEK inhibitors were considered to restore iodine sensitivity, but the most recent PET-CT demonstrated stable disease, and the patient opted for surveillance. </p>\n\n<p><strong>Postoperative Course and Management: </strong>Postoperatively, the patient experienced acute respiratory failure requiring tracheostomy and hematoma evacuation. He was discharged after 13 days. RAI therapy (175 mCi I-131) in January 2021 initially lowered thyroglobulin levels (from 595 ng/mL to 78 ng/mL by July 2021). Palliative radiation was provided in March 2021. A February 2022 PET-CT showed new osseous metastases and rising thyroglobulin (219 ng/mL). A second dose of RAI (150 mCi) was administered, and subsequent imaging revealed persistent uptake in a left lower pelvic metastasis. Concurrent bloodwork demonstrated pancytopenia, necessitating referral to hematology. Serial NM PET CT whole body scans were stable until October 2024 when the PET-CT demonstrated new metastases. A diagnostic I-123 scan showed minimal iodine uptake in the left inferior pubic ramus metastasis, confirming RAI-resistance. Given increasing thyroglobulin levels (1423 ng/mL) and minimal iodine uptake, the disease was deemed as RAI-resistant metastatic thyroid cancer.</p>\n\n<p><strong>Conclusion: </strong>This case highlights challenges in managing metastatic follicular thyroid carcinoma with RAI resistance. Molecular profiling identified an NRAS Q61R mutation, informing potential MEK inhibitor therapy. Early imaging and biopsy are essential, and molecular testing aids in guiding therapy. Continued research into the role of MEK inhibitors and other molecular-based treatments will be essential in optimizing patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147001--></body></html>"
    },
    {
      "uid": "P046",
      "content_id": "154688",
      "abstract_number": "P046",
      "poster_number": "P046",
      "title": "A Primary Squamous Cell Carcinoma of the Pterygopalatine Fossa: A Case Report",
      "summary": "The pterygopalatine fossa (PPF) is an anatomically complex space situated below the lateral skull base with numerous connections to surrounding regions such as the nasal cavity, nasopharynx, orbit, and infratemporal fossa. As such, tumors of the PPF are more commonly the result of metastasis or direct extension. Of all possible primary malignancies, squamous cell carcinoma (SCC) of the PPF is one of the rarer,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154688",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Spencer Dennis, BA",
      "presenter": "Spencer Dennis, BA",
      "authors": "Spencer Dennis, BA ; Bridger Woods, BS; Jacob Hoer, BS; Taimur Kahlid; Emily Sagalow, MD; Kurtis Young, MD; Robert Wang, MD",
      "normalized_authors": [
        "Spencer Dennis",
        "Bridger Woods",
        "Jacob Hoer",
        "Taimur Kahlid",
        "Emily Sagalow",
        "Kurtis Young",
        "Robert Wang"
      ],
      "affiliations": [
        "University of Nevada, Las Vegas"
      ],
      "normalized_institutions": [
        "University of Nevada, Las Vegas"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Spencer Dennis, BA ; Bridger Woods, BS; Jacob Hoer, BS; Taimur Kahlid; Emily Sagalow, MD; Kurtis Young, MD; Robert Wang, MD",
        "Affiliations": "University of Nevada, Las Vegas",
        "Abstract": "The pterygopalatine fossa (PPF) is an anatomically complex space situated below the lateral skull base with numerous connections to surrounding regions such as the nasal cavity, nasopharynx, orbit, and infratemporal fossa. As such, tumors of the PPF are more commonly the result of metastasis or direct extension. Of all possible primary malignancies, squamous cell carcinoma (SCC) of the PPF is one of the rarer, with only 3 cases documented. Here, we present a 4th case of a squamous cell carcinoma in the pterygopalatine fossa. A 59-year-old never-smoker male presented to the Otolaryngology clinic with 6 months of right-sided facial pain along the V1 distribution without decreased sensation, sinus tenderness, headache, or nasal obstruction. Magnetic resonance imaging (MRI) of the face demonstrated a polyploid soft tissue mass originating from the right PPF measuring 21 x 19 x 21 mm, involving the middle turbinate, posterior maxillary sinus wall, superior pterygoid plate, and infraorbital fissure without cavernous sinus extension. Nasal endoscopy demonstrated fullness with a purple bulge of the posterior inferior ethmoid/medial maxillary wall junction with medial displacement at the posterior aspect. Surgical resection was performed involving partial posterior maxillectomy via an endoscopic endonasal and transantral approach. Intraoperatively, the PPF was noted to be the epicenter of the mass, and no other mucosal sites were identified as potential primaries. Final pathology demonstrated p16-positive HPV-negative nonkeratinizing SCC with perineural invasion without bony invasion. The PPF is a less commonly recognized site for the development of HNSCC. However, SCC may still present in this region as it may spread through the PPF’s extensive communication with adjacent structures, including the posterior maxilla, pterygoid process, palatine bone, and pterygomaxillary fissure. It houses vital structures, including branches of the maxillary artery, the maxillary division of the trigeminal nerve (V2), and the sphenopalatine ganglion. In contrast, a primary squamous cell carcinoma (SCC) of the pterygopalatine fossa (PPF) is exceedingly rare, likely due to the absence of epithelial lining in this space. In this case, CT and MRI findings correlated closely with intraoperative findings and revealed no alternative primary site, supporting a diagnosis of primary SCC of the PPF. Symptoms of SCC of the PPF arise from mass effect. Budu et al. and Muvais et al., described patients presenting with facial numbness and pain over the cheek, consistent with compression of the V2 branch of the trigeminal nerve. Our patient also presented with right-sided facial pain; however, this was distributed over the V1 branch of the trigeminal nerve. This suggests varying degrees of symptomatology between patient presentations. Primary SCC of the PPF is extremely rare. Accurate diagnosis is contingent on multidisciplinary evaluation with imaging, surgical resection, and histopathology. In this case, the absence of a primary lesion elsewhere on imaging, focal intraoperative localization, and symptomatology suggestive of PPF involvement support the diagnosis of a primary origin. Additionally, the complex anatomy of the PPF poses unique challenges for surgical resection and, for malignancies such as SCC, may necessitate combined endoscopic and open approaches to achieve negative margins."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Primary Squamous Cell Carcinoma of the Pterygopalatine Fossa: A Case Report</span>. <u>Spencer Dennis, BA</u>; Bridger Woods, BS; Jacob Hoer, BS; Taimur Kahlid; Emily Sagalow, MD; Kurtis Young, MD; Robert Wang, MD. University of Nevada, Las Vegas<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The pterygopalatine fossa (PPF) is an anatomically complex space situated below the lateral skull base with numerous connections to surrounding regions such as the nasal cavity, nasopharynx, orbit, and infratemporal fossa. As such, tumors of the PPF are more commonly the result of metastasis or direct extension. Of all possible primary malignancies, squamous cell carcinoma (SCC) of the PPF is one of the rarer, with only 3 cases documented. Here, we present a 4th case of a squamous cell carcinoma in the pterygopalatine fossa.</p>\n\n<p>A 59-year-old never-smoker male presented to the Otolaryngology clinic with 6 months of right-sided facial pain along the V1 distribution without decreased sensation, sinus tenderness, headache, or nasal obstruction. Magnetic resonance imaging (MRI) of the face demonstrated a polyploid soft tissue mass originating from the right PPF measuring 21 x 19 x 21 mm, involving the middle turbinate, posterior maxillary sinus wall, superior pterygoid plate, and infraorbital fissure without cavernous sinus extension. Nasal endoscopy demonstrated fullness with a purple bulge of the posterior inferior ethmoid/medial maxillary wall junction with medial displacement at the posterior aspect. Surgical resection was performed involving partial posterior maxillectomy via an endoscopic endonasal and transantral approach. Intraoperatively, the PPF was noted to be the epicenter of the mass, and no other mucosal sites were identified as potential primaries. Final pathology demonstrated p16-positive HPV-negative nonkeratinizing SCC with perineural invasion without bony invasion.</p>\n\n<p>The PPF is a less commonly recognized site for the development of HNSCC. However, SCC may still present in this region as it may spread through the PPF’s extensive communication with adjacent structures, including the posterior maxilla, pterygoid process, palatine bone, and pterygomaxillary fissure. It houses vital structures, including branches of the maxillary artery, the maxillary division of the trigeminal nerve (V2), and the sphenopalatine ganglion. In contrast, a primary squamous cell carcinoma (SCC) of the pterygopalatine fossa (PPF) is exceedingly rare, likely due to the absence of epithelial lining in this space. In this case, CT and MRI findings correlated closely with intraoperative findings and revealed no alternative primary site, supporting a diagnosis of primary SCC of the PPF.</p>\n\n<p>Symptoms of SCC of the PPF arise from mass effect. Budu et al. and Muvais et al., described patients presenting with facial numbness and pain over the cheek, consistent with compression of the V2 branch of the trigeminal nerve. Our patient also presented with right-sided facial pain; however, this was distributed over the V1 branch of the trigeminal nerve. This suggests varying degrees of symptomatology between patient presentations. </p>\n\n<p>Primary SCC of the PPF is extremely rare. Accurate diagnosis is contingent on multidisciplinary evaluation with imaging, surgical resection, and histopathology. In this case, the absence of a primary lesion elsewhere on imaging, focal intraoperative localization, and symptomatology suggestive of  PPF involvement support the diagnosis of a primary origin. Additionally, the complex anatomy of the PPF poses unique challenges for surgical resection and, for malignancies such as SCC, may necessitate combined endoscopic and open approaches to achieve negative margins.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154688--></body></html>"
    },
    {
      "uid": "P047",
      "content_id": "154713",
      "abstract_number": "P047",
      "poster_number": "P047",
      "title": "Rapid growth of head and neck cancers: Example of 2 cases",
      "summary": "In our head neck cancer clinics patients will present at advanced stages of disease under high surveillance conditions. Our regional head and neck cancer and surveillance program covers a stable population of over 3 million patients at 4 tertiary head and neck cancer hospitals. Between 1200 and 1500 head and neck cancer cases are discussed yearly at tumor conferences. Over the past 5 years, there has been an...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154713",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Frank Ondrey",
      "presenter": "Frank Ondrey",
      "authors": "Emily Becker, MD 1 ; Frank Ondrey 2",
      "normalized_authors": [
        "Emily Becker",
        "Frank Ondrey"
      ],
      "affiliations": [
        "Healthpartners",
        "University of Minnesota"
      ],
      "normalized_institutions": [
        "Healthpartners",
        "University of Minnesota"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 400,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case",
        "Case 2",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emily Becker, MD 1 ; Frank Ondrey 2",
        "Affiliations": "1 Healthpartners; 2 University of Minnesota",
        "Introduction": "In our head neck cancer clinics patients will present at advanced stages of disease under high surveillance conditions. Our regional head and neck cancer and surveillance program covers a stable population of over 3 million patients at 4 tertiary head and neck cancer hospitals. Between 1200 and 1500 head and neck cancer cases are discussed yearly at tumor conferences. Over the past 5 years, there has been an emphasis on calculating tumor progression rates because of delays experienced in Covid 19. Presently we describe 2 (of several) cases where there were uncommonly uncommonly rapid growth rates. Head neck cancer is an aggressive and rapid growing malignancy with reported median growth rates of 1 1/2 to 3 1/2 percent per day portending doubling times of 19 to 50 days in several recent publications.",
        "Case": "1 73 year old non smoking female the 25 year history of oral lichen planus with several conversions to malignancy over decades. The patient developed left oral cavity pain with exam negative by two practitioners. CT scan imaging of the oral cavity showed no lesions and normal Bony structures of the mouth. Symptoms persisted over 28 days and reimaging demonstrated a 3.1 x 1.3 cm tumor of the left oral cavity invading the mandible and buccal space. Assuming 1 cm spherical limit of detection of physical exam and CT this tumor represented a 6.1%/day growth rate.",
        "Case 2": "41 year old nonsmoking female was noted on DL to have 2 lesions: Left arytenoid: 0.8 x 0.7 cm lesion and right hypopharynx: 1.6 x 0.6 cm lesion. Final pathology 16 days later revealed a left arytenoid: 1.4 x 1.1 x 0.4 cm and right hypopharynx 1.7 x 1.4 x 0.7 cm cancers. These reveal a growth rate of 9.6 and 11.6% daily growth rates.",
        "Abstract": "In our clinics we all see rapidly growing tumors, but until they jump T size they are not often calculated as being larger. Here we show the rapid development or growth of substandial tumors in 2 patients. These two example cases of many in our practice demonstrate very rapid growth of tumors, and we have had several rapid growing tumors in our clinics now that we are evaluating such patients. Rapid growth of tumors is well documented in the literature, but the rates of these tumors was quite high."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rapid growth of head and neck cancers: Example of 2 cases</span>. Emily Becker, MD<sup>1</sup>; <u>Frank Ondrey</u><sup>2</sup>. <sup>1</sup>Healthpartners; <sup>2</sup>University of Minnesota<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> In our head neck cancer clinics patients will present at advanced stages of disease under high surveillance conditions. Our regional head and neck cancer and surveillance program covers a stable population of over 3 million patients at 4 tertiary head and neck cancer hospitals. Between 1200 and 1500 head and neck cancer cases are discussed yearly at tumor conferences. Over the past 5 years, there has been an emphasis on calculating tumor progression rates because of delays experienced in Covid 19. Presently we describe 2 (of several) cases where there were uncommonly uncommonly rapid growth rates. Head neck cancer is an aggressive and rapid growing malignancy with reported median growth rates of 1 1/2 to 3 1/2 percent per day portending doubling times of 19 to 50 days in several recent publications.</p>\n\n<p><strong>Case:</strong>1 73 year old non smoking female the 25 year history of oral lichen planus with several conversions to malignancy over decades. The patient developed left oral cavity pain with exam negative by two practitioners. CT scan imaging of the oral cavity showed no lesions and normal Bony structures of the mouth. Symptoms persisted over 28 days and reimaging demonstrated a 3.1 x 1.3 cm tumor of the left oral cavity invading the mandible and buccal space. Assuming 1 cm spherical limit of detection of physical exam and CT this tumor represented a 6.1%/day growth rate.</p>\n\n<p><strong>Case 2: </strong>41 year old nonsmoking female was noted on DL to have 2 lesions: Left arytenoid: 0.8 x 0.7 cm lesion and right hypopharynx: 1.6 x 0.6 cm lesion. Final pathology 16 days later revealed a left arytenoid: 1.4 x 1.1 x 0.4 cm and right hypopharynx 1.7 x 1.4 x 0.7 cm cancers. These reveal a growth rate of 9.6 and 11.6% daily growth rates.</p>\n\n<p>In our clinics we all see rapidly growing tumors, but until they jump T size they are not often calculated as being larger. Here we show the rapid development or growth of substandial tumors in 2 patients. These two example cases of many in our practice demonstrate very rapid growth of tumors, and we have had several rapid growing tumors in our clinics now that we are evaluating such patients. Rapid growth of tumors is well documented in the literature, but the rates of these tumors was quite high.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154713--></body></html>"
    },
    {
      "uid": "P048",
      "content_id": "154384",
      "abstract_number": "P048",
      "poster_number": "P048",
      "title": "Beyond the Senescence-Associated Secretory Phenotype: How Senescent Cells Accelerate OSCC Progression",
      "summary": "Oral squamous cell carcinoma (OSCC) is the most common type of head and neck malignancy. Oral carcinogenesis involves multiple stages of transformation occurring within epithelial cells and their surrounding microenvironment. Although the genetic landscape of transformed mucosal epithelial cells has been extensively characterized, the contribution of the microenvironment remains less understood. In particular,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154384",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Bourbonnais, MSc",
      "presenter": "Jessica Bourbonnais, MSc",
      "authors": "Jessica Bourbonnais, MSc 1 ; Jade Montpetit, BSc 1 ; Guillaume Cardin, MSc 2 ; Erwan Goy, PhD 1 ; Alicia Pellerin-Viger, MSc 2 ; Julien Ghannoum, DMD 3 ; Tareck Ayad, MD, FRCSC 4 ; Louis Guertin, MD, FRCSC 4 ; Eric Bissada, MD, DMD, FRCSC 4 ; Paul Tabet, MD, MSc, FRCSC 4 ; Francis Rodier, PhD 5 ; Apostolos Christopoulos, MD, MSc, FRCSC 6",
      "normalized_authors": [
        "Jessica Bourbonnais",
        "Jade Montpetit",
        "Guillaume Cardin",
        "Erwan Goy",
        "Alicia Pellerin-Viger",
        "Julien Ghannoum",
        "Tareck Ayad, FRCSC",
        "Louis Guertin, FRCSC",
        "Eric Bissada, FRCSC",
        "Paul Tabet, FRCSC",
        "Francis Rodier",
        "Apostolos Christopoulos, FRCSC"
      ],
      "affiliations": [
        "Institut du cancer de Montréal, Centre de recherche du CHUM, Université de Montréal",
        "Institut du cancer de Montréal, Centre de recherche du CHUM",
        "Department of Stomatology, CHUM",
        "Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal",
        "Department of radiology, radio-oncology and nuclear medicine, Université de Montréal"
      ],
      "normalized_institutions": [
        "Institut du cancer de Montréal, Centre de recherche du CHUM, Université de Montréal",
        "Institut du cancer de Montréal, Centre de recherche du CHUM",
        "Department of Stomatology, CHUM",
        "Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal",
        "Department of radiology, radio-oncology and nuclear medicine, Université de Montréal"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 329,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jessica Bourbonnais, MSc 1 ; Jade Montpetit, BSc 1 ; Guillaume Cardin, MSc 2 ; Erwan Goy, PhD 1 ; Alicia Pellerin-Viger, MSc 2 ; Julien Ghannoum, DMD 3 ; Tareck Ayad, MD, FRCSC 4 ; Louis Guertin, MD, FRCSC 4 ; Eric Bissada, MD, DMD, FRCSC 4 ; Paul Tabet, MD, MSc, FRCSC 4 ; Francis Rodier, PhD 5 ; Apostolos Christopoulos, MD, MSc, FRCSC 6",
        "Affiliations": "1 Institut du cancer de Montréal, Centre de recherche du CHUM, Université de Montréal; 2 Institut du cancer de Montréal, Centre de recherche du CHUM; 3 Department of Stomatology, CHUM; 4 Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal; 5 Department of radiology, radio-oncology and nuclear medicine, Université de Montréal ; Institut du cancer de Montréal, Centre de recherche du CHUM; 6 Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal ; Institut du cancer de Montréal, Centre de recherche du CHUM",
        "Abstract": "Oral squamous cell carcinoma (OSCC) is the most common type of head and neck malignancy. Oral carcinogenesis involves multiple stages of transformation occurring within epithelial cells and their surrounding microenvironment. Although the genetic landscape of transformed mucosal epithelial cells has been extensively characterized, the contribution of the microenvironment remains less understood. In particular, the role of senescent cells in oral carcinogenesis and tumour progression has yet to be clearly defined. Cellular senescence is a stable state of proliferation arrest induced by genotoxic stress and is characterized by a profound shift in cellular phenotype, a major component of which is the senescence-associated secretory phenotype (SASP). The SASP comprises signaling molecules that can promote tumour growth, migration, and invasion, but it is also associated with immune clearance of senescent and damaged cells. Elevated p53 levels in oral mucosa adjacent to OSCC suggest the presence of senescent cells and their potential role in shaping the tumour microenvironment. To study how senescence influences oral carcinogenesis, we co-cultured OSCC cell lines with fluorescently labeled nuclei (H2B-GFP) together with senescent fibroblasts or senescent epithelial cells. OSCC cells co-cultured with senescent cells exhibited significantly increased proliferation compared wtih controls. Notably, this effect was strongest when OSCC cells were in direct proximity to senescent cells, indicating that cell-cell contact plays a more prominent role than SASP alone, which has dominated prior studies. These observations highlight an underappreciated mode of senescence and cancer communication. We also observed phenotypic changes consistent with enhanced survival, migration, and invasive potential in OSCC cells exposed to senescent cells. To uncover the signalling pathways mediating these interactions, we have generated single-cell RNA sequencing (scRNAseq) data from our co-culture model. These transcriptomic datasets are currently being analyzed, and we will present our findings, highlighting senescence responsive pathways and cell-cell interaction signatures, at the conference. Together, these results identify direct interactions with senescent and cancer cells as key modulators of OSCC progression and provide new insight into the molecular mechanisms underlying senescence driven tumour behaviour."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Beyond the Senescence-Associated Secretory Phenotype: How Senescent Cells Accelerate OSCC Progression</span>. <u>Jessica Bourbonnais, MSc</u><sup>1</sup>; Jade Montpetit, BSc<sup>1</sup>; Guillaume Cardin, MSc<sup>2</sup>; Erwan Goy, PhD<sup>1</sup>; Alicia Pellerin-Viger, MSc<sup>2</sup>; Julien Ghannoum, DMD<sup>3</sup>; Tareck Ayad, MD, FRCSC<sup>4</sup>; Louis Guertin, MD, FRCSC<sup>4</sup>; Eric Bissada, MD, DMD, FRCSC<sup>4</sup>; Paul Tabet, MD, MSc, FRCSC<sup>4</sup>; Francis Rodier, PhD<sup>5</sup>; Apostolos Christopoulos, MD, MSc, FRCSC<sup>6</sup>. <sup>1</sup>Institut du cancer de Montréal, Centre de recherche du CHUM, Université de Montréal; <sup>2</sup>Institut du cancer de Montréal, Centre de recherche du CHUM; <sup>3</sup>Department of Stomatology, CHUM; <sup>4</sup>Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal; <sup>5</sup>Department of radiology, radio-oncology and nuclear medicine, Université de Montréal ; Institut du cancer de Montréal, Centre de recherche du CHUM; <sup>6</sup>Division of Otolaryngology – Head and Neck Surgery, Center Hospitalier de l’Université de Montréal, Université de Montréal ; Institut du cancer de Montréal, Centre de recherche du CHUM<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Oral squamous cell carcinoma (OSCC) is the most common type of head and neck malignancy. Oral carcinogenesis involves multiple stages of transformation occurring within epithelial cells and their surrounding microenvironment. Although the genetic landscape of transformed mucosal epithelial cells has been extensively characterized, the contribution of the microenvironment remains less understood. In particular, the role of senescent cells in oral carcinogenesis and tumour progression has yet to be clearly defined. Cellular senescence is a stable state of proliferation arrest induced by genotoxic stress and is characterized by a profound shift in cellular phenotype, a major component of which is the senescence-associated secretory phenotype (SASP). The SASP comprises signaling molecules that can promote tumour growth, migration, and invasion, but it is also associated with immune clearance of senescent and damaged cells. Elevated p53 levels in oral mucosa adjacent to OSCC suggest the presence of senescent cells and their potential role in shaping the tumour microenvironment.</p>\n\n<p>To study how senescence influences oral carcinogenesis, we co-cultured OSCC cell lines with fluorescently labeled nuclei (H2B-GFP) together with senescent fibroblasts or senescent epithelial cells. OSCC cells co-cultured with senescent cells exhibited significantly increased proliferation compared wtih controls. Notably, this effect was strongest when OSCC cells were in direct proximity to senescent cells, indicating that cell-cell contact plays a more prominent role than SASP alone, which has dominated prior studies. These observations highlight an underappreciated mode of senescence and cancer communication.</p>\n\n<p>We also observed phenotypic changes consistent with enhanced survival, migration, and invasive potential in OSCC cells exposed to senescent cells. To uncover the signalling pathways mediating these interactions, we have generated single-cell RNA sequencing (scRNAseq) data from our co-culture model. These transcriptomic datasets are currently being analyzed, and we will present our findings, highlighting senescence responsive pathways and cell-cell interaction signatures, at the conference.</p>\n\n<p>Together, these results identify direct interactions with senescent and cancer cells as key modulators of OSCC progression and provide new insight into the molecular mechanisms underlying senescence driven tumour behaviour.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154384--></body></html>"
    },
    {
      "uid": "P049",
      "content_id": "154417",
      "abstract_number": "P049",
      "poster_number": "P049",
      "title": "Single-Cell Analysis Identifies a CD44-Associated Stem-Like Malignant Program in Papillary Thyroid Cancer",
      "summary": "CD44 has been proposed as a marker of thyroid cancer stem-like cells, yet its biology has been characterized primarily through bulk sequencing, leaving its cell-specific role in metastatic progression unclear. To address this gap, we analyzed the only two publicly available single-cell RNA-sequencing datasets in GEO that, to our knowledge, include sequenced metastatic lymph nodes or distant metastases from...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154417",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kathleen Luckett",
      "presenter": "Kathleen Luckett",
      "authors": "Kathleen Luckett ; David Kutler, MD",
      "normalized_authors": [
        "Kathleen Luckett",
        "David Kutler"
      ],
      "affiliations": [
        "Weill Cornell Medicine"
      ],
      "normalized_institutions": [
        "Weill Cornell Medicine"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 264,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kathleen Luckett ; David Kutler, MD",
        "Affiliations": "Weill Cornell Medicine",
        "Abstract": "CD44 has been proposed as a marker of thyroid cancer stem-like cells, yet its biology has been characterized primarily through bulk sequencing, leaving its cell-specific role in metastatic progression unclear. To address this gap, we analyzed the only two publicly available single-cell RNA-sequencing datasets in GEO that, to our knowledge, include sequenced metastatic lymph nodes or distant metastases from papillary thyroid cancer patients. Across these datasets—comprising 8 primary tumors, 7 normal thyroids, 9 metastatic lymph nodes, and 2 subcutaneous metastases from 12 patients—we found that malignant cells in metastatic lymph nodes exhibited higher CD44 expression than those in primary tumors, with the highest expression observed in distant subcutaneous metastases. Within malignant compartments, Spearman correlation analysis identified transcriptional programs associated with CD44 expression. Among the top ten positively correlated genes in each dataset, LRRK2 and IGFBP6 consistently emerged as conserved components of a reproducible CD44-associated module, suggesting shared regulatory features across patients and metastatic sites. To test whether CD44 marks a more dedifferentiated malignant state, we applied the 16-gene thyroid differentiation score (TDS), a transcriptional metric linked to aggressive, metastatic, and radioiodine-refractory disease. CD44-high cells consistently demonstrated lower TDS than CD44-low cells. Parallel analyses using LRRK2 and IGFBP6 revealed that IGFBP6 most strongly discriminated TDS among the three genes, showing the largest divergence between high- and low-expressing populations. Together, these findings support a stem-like malignant role for CD44 and highlight additional markers that may refine the molecular characterization of this clinically important population. More broadly, this work illustrates the power of single-cell approaches to resolve transcriptional heterogeneity that is undetectable in bulk profiling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Single-Cell Analysis Identifies a CD44-Associated Stem-Like Malignant Program in Papillary Thyroid Cancer</span>. <u>Kathleen Luckett</u>; David Kutler, MD. Weill Cornell Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>CD44 has been proposed as a marker of thyroid cancer stem-like cells, yet its biology has been characterized primarily through bulk sequencing, leaving its cell-specific role in metastatic progression unclear. To address this gap, we analyzed the only two publicly available single-cell RNA-sequencing datasets in GEO that, to our knowledge, include sequenced metastatic lymph nodes or distant metastases from papillary thyroid cancer patients. Across these datasets—comprising 8 primary tumors, 7 normal thyroids, 9 metastatic lymph nodes, and 2 subcutaneous metastases from 12 patients—we found that malignant cells in metastatic lymph nodes exhibited higher CD44 expression than those in primary tumors, with the highest expression observed in distant subcutaneous metastases. Within malignant compartments, Spearman correlation analysis identified transcriptional programs associated with CD44 expression. Among the top ten positively correlated genes in each dataset, LRRK2 and IGFBP6 consistently emerged as conserved components of a reproducible CD44-associated module, suggesting shared regulatory features across patients and metastatic sites. To test whether CD44 marks a more dedifferentiated malignant state, we applied the 16-gene thyroid differentiation score (TDS), a transcriptional metric linked to aggressive, metastatic, and radioiodine-refractory disease. CD44-high cells consistently demonstrated lower TDS than CD44-low cells. Parallel analyses using LRRK2 and IGFBP6 revealed that IGFBP6 most strongly discriminated TDS among the three genes, showing the largest divergence between high- and low-expressing populations. Together, these findings support a stem-like malignant role for CD44 and highlight additional markers that may refine the molecular characterization of this clinically important population. More broadly, this work illustrates the power of single-cell approaches to resolve transcriptional heterogeneity that is undetectable in bulk profiling.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154417--></body></html>"
    },
    {
      "uid": "P051",
      "content_id": "153575",
      "abstract_number": "P051",
      "poster_number": "P051",
      "title": "Somatic Mutation Profiles in Papillary Thyroid Carcinoma with and without Hashimoto’s Thyroiditis",
      "summary": "BRAF was the only alteration that occurred significantly more frequently in isolated PTC compared with PTC+HT. Other mutations—including NRAS, HRAS, TERT, RET, and PAX8—were observed at similar frequencies in both groups and did not differ after adjustment for clinical and demographic factors. These findings indicate that, aside from BRAF, most somatic mutations appear to occur at similar frequencies between PTC...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153575",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sara D O'Sullivan-Bakshi, BS",
      "presenter": "Sara D O'Sullivan-Bakshi, BS",
      "authors": "Sara D O'Sullivan-Bakshi, BS 1 ; Henry Diamond-Pott, BA 2 ; Maaike van Gerwen, MD, PhD 2 ; Mathilda Monaghan, MPH 2",
      "normalized_authors": [
        "Sara D O'Sullivan-Bakshi",
        "Henry Diamond-Pott",
        "Maaike van Gerwen",
        "Mathilda Monaghan"
      ],
      "affiliations": [
        "Renaissance School of Medicine at Stony Brook",
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Renaissance School of Medicine at Stony Brook",
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sara D O'Sullivan-Bakshi, BS 1 ; Henry Diamond-Pott, BA 2 ; Maaike van Gerwen, MD, PhD 2 ; Mathilda Monaghan, MPH 2",
        "Affiliations": "1 Renaissance School of Medicine at Stony Brook; 2 Icahn School of Medicine at Mount Sinai",
        "Background": "Patients with Hashimoto thyroiditis (HT) may have an increased risk of developing papillary thyroid carcinoma (PTC), and prior studies suggest that PTC arising in the setting of HT may demonstrate different clinical and molecular features than conventional PTC. Although earlier work has largely focused on individual mutations—particularly BRAF V600E—limited data exist on how the broader somatic mutation profile identified by next-generation sequencing assays differs between PTC and PTC coexisting with HT. Understanding these differences is increasingly relevant as molecular testing such as ThyroSeq plays a central role in thyroid nodule evaluation. This study sought to characterize and compare the full ThyroSeq mutational landscapes of PTC and PTC+HT.",
        "Methods": "A retrospective analysis of all adult patients with a confirmed primary diagnosis of PTC who underwent Thyroseq at a single academic center between 2018 and 2021 was performed. HT status was determined through medical history and pathology report review. We included 160 patients with PTC and 65 with PTC and HT. Baseline demographic and clinical characteristics were compared between the groups. The frequency of each ThyroSeq-reported mutation category (e.g., BRAF, NRAS, HRAS, RET, TERT, and others) in each cohort was calculated and used to define the overall mutational distribution. Mutation-specific prevalence was evaluated using Fisher’s exact tests with false-discovery-rate correction for multiple testing, followed by a chi-square test across all mutation categories. Multivariable logistic regression adjusting for demographic and clinical factors assessed independent associations between specific mutations and PTC with and without concurrent HT.",
        "Results": "There was an overall difference in mutational distributions between the two cohorts (p=0.017). BRAF (49.4% vs 24.6%), NRAS (19.4% vs 15.4%), HRAS (10.0% vs 7.7%), TERT (5.0% vs 7.7%), and RET (1.2% vs 6.2%) mutations were the most frequently observed for PTC and PTC+HT, respectively. BRAF was significantly more common in isolated PTC than in HT + PTC (49.4% vs. 24.6%; OR 2.97, 95% CI 1.83–7.42). Other mutations, including KRAS and RET, appeared more frequently in HT + PTC, though these differences did not remain significant after adjustment. In adjusted multivariable models, BRAF remained the only mutation independently associated with isolated PTC (OR 3.60, 95% CI 1.83–7.42, p = 0.00031).",
        "Conclusions": "BRAF was the only alteration that occurred significantly more frequently in isolated PTC compared with PTC+HT. Other mutations—including NRAS, HRAS, TERT, RET, and PAX8—were observed at similar frequencies in both groups and did not differ after adjustment for clinical and demographic factors. These findings indicate that, aside from BRAF, most somatic mutations appear to occur at similar frequencies between PTC and PTC+HT when evaluated with ThyroSeq. Further studies with larger cohorts are warranted to clarify whether subtle differences in mutation patterns exist between these two clinical contexts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Somatic Mutation Profiles in Papillary Thyroid Carcinoma with and without Hashimoto’s Thyroiditis</span>. <u>Sara D O'Sullivan-Bakshi, BS</u><sup>1</sup>; Henry Diamond-Pott, BA<sup>2</sup>; Maaike van Gerwen, MD, PhD<sup>2</sup>; Mathilda Monaghan, MPH<sup>2</sup>. <sup>1</sup>Renaissance School of Medicine at Stony Brook; <sup>2</sup>Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patients with Hashimoto thyroiditis (HT) may have an increased risk of developing papillary thyroid carcinoma (PTC), and prior studies suggest that PTC arising in the setting of HT may demonstrate different clinical and molecular features than conventional PTC. Although earlier work has largely focused on individual mutations—particularly BRAF V600E—limited data exist on how the broader somatic mutation profile identified by next-generation sequencing assays differs between PTC and PTC coexisting with HT. Understanding these differences is increasingly relevant as molecular testing such as ThyroSeq plays a central role in thyroid nodule evaluation. This study sought to characterize and compare the full ThyroSeq mutational landscapes of PTC and PTC+HT. </p>\n\n<p><strong>Methods: </strong>A retrospective analysis of all adult patients with a confirmed primary diagnosis of PTC who underwent Thyroseq at a single academic center between 2018 and 2021 was performed. HT status was determined through medical history and pathology report review. We included 160 patients with PTC and 65 with PTC and HT. Baseline demographic and clinical characteristics were compared between the groups. The frequency of each ThyroSeq-reported mutation category (e.g., BRAF, NRAS, HRAS, RET, TERT, and others) in each cohort was calculated and used to define the overall mutational distribution. Mutation-specific prevalence was evaluated using Fisher’s exact tests with false-discovery-rate correction for multiple testing, followed by a chi-square test across all mutation categories. Multivariable logistic regression adjusting for demographic and clinical factors assessed independent associations between specific mutations and PTC with and without concurrent HT. </p>\n\n<p><strong>Results: </strong>There was an overall difference in mutational distributions between the two cohorts (p=0.017). BRAF (49.4% vs 24.6%), NRAS (19.4% vs 15.4%), HRAS (10.0% vs 7.7%), TERT (5.0% vs 7.7%), and RET (1.2% vs 6.2%) mutations were the most frequently observed for PTC and PTC+HT, respectively. BRAF was significantly more common in isolated PTC than in HT + PTC (49.4% vs. 24.6%; OR 2.97, 95% CI 1.83–7.42). Other mutations, including KRAS and RET, appeared more frequently in HT + PTC, though these differences did not remain significant after adjustment. In adjusted multivariable models, BRAF remained the only mutation independently associated with isolated PTC (OR 3.60, 95% CI 1.83–7.42, p = 0.00031). </p>\n\n<p><strong>Conclusions: </strong>BRAF was the only alteration that occurred significantly more frequently in isolated PTC compared with PTC+HT. Other mutations—including NRAS, HRAS, TERT, RET, and PAX8—were observed at similar frequencies in both groups and did not differ after adjustment for clinical and demographic factors. These findings indicate that, aside from BRAF, most somatic mutations appear to occur at similar frequencies between PTC and PTC+HT when evaluated with ThyroSeq. Further studies with larger cohorts are warranted to clarify whether subtle differences in mutation patterns exist between these two clinical contexts. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153575--></body></html>"
    },
    {
      "uid": "P052",
      "content_id": "155443",
      "abstract_number": "P052",
      "poster_number": "P052",
      "title": "Non-acidic Pepsin Exposure as a Potent Stimulator of HNSCC Progression: The Role of Multi-pathway Signaling Activation in Laryngopharyngeal Reflux-Related Carcinogenesis",
      "summary": "Pepsin treatment significantly promoted cell proliferation in SCC4, SCC25, and FaDu cells in a dose-dependent manner, whereas no significant effect was observed in K562 cells. Flow cytometry revealed that pepsin induced a marked accumulation of epithelial cancer cells in the G2/M phase. Molecular analysis showed that pepsin exposure triggered rapid and sustained phosphorylation of EGFR and its downstream...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155443",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jhih-Hao Shen",
      "presenter": "Jhih-Hao Shen",
      "authors": "Jhih-Hao Shen ; Cheng-Ming Hsu",
      "normalized_authors": [
        "Jhih-Hao Shen",
        "Cheng-Ming Hsu"
      ],
      "affiliations": [
        "Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan"
      ],
      "normalized_institutions": [
        "Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 214,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results"
      ],
      "sections": {
        "Authors": "Jhih-Hao Shen ; Cheng-Ming Hsu",
        "Affiliations": "Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan",
        "Background": "Laryngopharyngeal reflux (LPR) and its primary marker, pepsin, are implicated in the development of head and neck squamous cell carcinoma (HNSCC). While previous studies focused on hypopharyngeal cells, the impact of pepsin on other HNSCC lineages and its concentration-dependent mechanisms remain less clear. This study investigates the effects of pepsin on cell proliferation, cell cycle progression, and signaling pathways in multiple HNSCC cell lines.",
        "Methods": "Human tongue (SCC4, SCC25) and hypopharyngeal (FaDu) SCC cell lines, along with a non-epithelial line (K562), were exposed to varying concentrations of pepsin (0.1–5 mg/mL) at pH 7.4. Cell viability was assessed via MTT assay. Cell cycle distribution was analyzed by flow cytometry. Western blotting was performed to evaluate the activation of EGFR, STAT3, AKT, NF-κB, and MAPK (p38, ERK, JNK) signaling pathways.",
        "Results": "Pepsin treatment significantly promoted cell proliferation in SCC4, SCC25, and FaDu cells in a dose-dependent manner, whereas no significant effect was observed in K562 cells. Flow cytometry revealed that pepsin induced a marked accumulation of epithelial cancer cells in the G2/M phase. Molecular analysis showed that pepsin exposure triggered rapid and sustained phosphorylation of EGFR and its downstream cascades, including STAT3, AKT, and the MAPK pathways. These effects were notably more pronounced at higher concentrations (5 mg/mL) compared to lower doses."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Non-acidic Pepsin Exposure as a Potent Stimulator of HNSCC Progression: The Role of Multi-pathway Signaling Activation in Laryngopharyngeal Reflux-Related Carcinogenesis</span>. <u>Jhih-Hao Shen</u>; Cheng-Ming Hsu. Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Laryngopharyngeal reflux (LPR) and its primary marker, pepsin, are implicated in the development of head and neck squamous cell carcinoma (HNSCC). While previous studies focused on hypopharyngeal cells, the impact of pepsin on other HNSCC lineages and its concentration-dependent mechanisms remain less clear. This study investigates the effects of pepsin on cell proliferation, cell cycle progression, and signaling pathways in multiple HNSCC cell lines.</p>\n\n<p><strong>Methods: </strong>Human tongue (SCC4, SCC25) and hypopharyngeal (FaDu) SCC cell lines, along with a non-epithelial line (K562), were exposed to varying concentrations of pepsin (0.1–5 mg/mL) at pH 7.4. Cell viability was assessed via MTT assay. Cell cycle distribution was analyzed by flow cytometry. Western blotting was performed to evaluate the activation of EGFR, STAT3, AKT, NF-κB, and MAPK (p38, ERK, JNK) signaling pathways.</p>\n\n<p><strong>Results:</strong> Pepsin treatment significantly promoted cell proliferation in SCC4, SCC25, and FaDu cells in a dose-dependent manner, whereas no significant effect was observed in K562 cells. Flow cytometry revealed that pepsin induced a marked accumulation of epithelial cancer cells in the G2/M phase. Molecular analysis showed that pepsin exposure triggered rapid and sustained phosphorylation of EGFR and its downstream cascades, including STAT3, AKT, and the MAPK pathways. These effects were notably more pronounced at higher concentrations (5 mg/mL) compared to lower doses.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155443--></body></html>"
    },
    {
      "uid": "P053",
      "content_id": "154624",
      "abstract_number": "P053",
      "poster_number": "P053",
      "title": "The Genomic Landscape of Buschke-Löwenstein Tumors",
      "summary": "Here, we report what is, to our knowledge, the first whole-genome characterization of low-risk HPV32 in Buschke-Löwenstein tumors arising in an individual with HIV. The detection of HPV32 and accompanying host genomic alterations in the setting of HIV integration highlights that even traditionally low-risk HPV types can drive substantial genomic instability. Defining these mutations and structural changes may...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154624",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ella P Jackert, BS",
      "presenter": "Ella P Jackert, BS",
      "authors": "Ella P Jackert, BS ; Stephanie Wong, MD; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Albert Y Han, MD, PhD",
      "normalized_authors": [
        "Ella P Jackert",
        "Stephanie Wong",
        "Shu-Yun Cheng",
        "Liyang Tang",
        "Daniel Kwon",
        "Niels Kokot",
        "Uttam Sinha",
        "Albert Y Han"
      ],
      "affiliations": [
        "USC Caruso Department of Otolaryngology Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "USC Caruso Department of Otolaryngology Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 396,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ella P Jackert, BS ; Stephanie Wong, MD; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Albert Y Han, MD, PhD",
        "Affiliations": "USC Caruso Department of Otolaryngology Head and Neck Surgery",
        "Introduction": "Low-risk human papillomavirus (HPV) types typically cause benign oral warts but can undergo uncontrolled growth in cases of chronic immunodeficiency such as in patients with human immunodeficiency virus (HIV). The specific molecular and biological changes in HPV pathogenesis associated with HIV are not well defined, especially the resulting genomic alteration and mutations triggered by non-6 or 11 low-risk HPV types. Here, we sought to comprehensively characterize low-risk HPV-associated genomic instability including copy number and structural variants with potential relevance for future therapeutic targeting.",
        "Methods": "Informed consent was obtained. Fresh tissue from oral lesions concerning for carcinoma and blood samples were collected intraoperatively. DNA was extracted and pathology was confirmed through histological evaluation. Tumor and normal blood specimen DNA libraries for Illumina whole genome sequencing were prepared. Data was analyzed following the Broad Institute’s Genome Analysis Toolkit pipeline. Tumor and normal sequences were aligned to a combined reference genome containing the human reference hg38 and all HPV genome sequences available on the Papillomavirus Episteme database. Structural variant calling was undergone using Manta calls for mapped paired-end sequencing reads.",
        "Results": "A 58-year-old male with a 20-year history of well-controlled HIV on antiretroviral therapy presented with multiple, longstanding oral and nasal cavity lesions. Surgical evaluation and debulking revealed condyloma acuminatum and large Buschke-Löwenstein tumors of the lip. Presence of HPV-associated disease was confirmed through histology. Concurrently, he was diagnosed with anal squamous cell carcinoma and underwent chemoradiation, after which his oral lesions progressed, becoming more extensive and symptomatic. The patient underwent multiple debulking surgeries and medical therapy trials and still has persistent oral disease.",
        "Abstract": "Whole-genome sequencing demonstrated that the patient’s tumors contained predominantly HPV32, a low-risk type typically associated with benign oral mucosal hyperplasia in immunocompetent individuals, but prior studies have reported its involvement in HPV-related oral condyloma acuminatum in immunocompromised patients. Genome analysis revealed multiple variations in adjacent coding regions and non-coding RNAs, underscoring the genomic instability associated with HPV32 pathogenesis.",
        "Conclusion": "Here, we report what is, to our knowledge, the first whole-genome characterization of low-risk HPV32 in Buschke-Löwenstein tumors arising in an individual with HIV. The detection of HPV32 and accompanying host genomic alterations in the setting of HIV integration highlights that even traditionally low-risk HPV types can drive substantial genomic instability. Defining these mutations and structural changes may help identify biomarkers that improve risk stratification and guide the development of targeted therapies for atypical HPV-associated oral disease."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Genomic Landscape of Buschke-Löwenstein Tumors</span>. <u>Ella P Jackert, BS</u>; Stephanie Wong, MD; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Albert Y Han, MD, PhD. USC Caruso Department of Otolaryngology Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Low-risk human papillomavirus (HPV) types typically cause benign oral warts but can undergo uncontrolled growth in cases of chronic immunodeficiency such as in patients with human immunodeficiency virus (HIV). The specific molecular and biological changes in HPV pathogenesis associated with HIV are not well defined, especially the resulting genomic alteration and mutations triggered by non-6 or 11 low-risk HPV types. Here, we sought to comprehensively characterize low-risk HPV-associated genomic instability including copy number and structural variants with potential relevance for future therapeutic targeting.</p>\n\n<p><strong>Methods: </strong>Informed consent was obtained. Fresh tissue from oral lesions concerning for carcinoma and blood samples were collected intraoperatively. DNA was extracted and pathology was confirmed through histological evaluation. Tumor and normal blood specimen DNA libraries for Illumina whole genome sequencing were prepared. Data was analyzed following the Broad Institute’s Genome Analysis Toolkit pipeline. Tumor and normal sequences were aligned to a combined reference genome containing the human reference hg38 and all HPV genome sequences available on the Papillomavirus Episteme database. Structural variant calling was undergone using Manta calls for mapped paired-end sequencing reads.</p>\n\n<p><strong>Results: </strong>A 58-year-old male with a 20-year history of well-controlled HIV on antiretroviral therapy presented with multiple, longstanding oral and nasal cavity lesions. Surgical evaluation and debulking revealed condyloma acuminatum and large Buschke-Löwenstein tumors of the lip. Presence of HPV-associated disease was confirmed through histology. Concurrently, he was diagnosed with anal squamous cell carcinoma and underwent chemoradiation, after which his oral lesions progressed, becoming more extensive and symptomatic. The patient underwent multiple debulking surgeries and medical therapy trials and still has persistent oral disease.</p>\n\n<p>Whole-genome sequencing demonstrated that the patient’s tumors contained predominantly HPV32, a low-risk type typically associated with benign oral mucosal hyperplasia in immunocompetent individuals, but prior studies have reported its involvement in HPV-related oral condyloma acuminatum in immunocompromised patients. Genome analysis revealed multiple variations in adjacent coding regions and non-coding RNAs, underscoring the genomic instability associated with HPV32 pathogenesis.</p>\n\n<p><strong>Conclusion: </strong>Here, we report what is, to our knowledge, the first whole-genome characterization of low-risk HPV32 in Buschke-Löwenstein tumors arising in an individual with HIV. The detection of HPV32 and accompanying host genomic alterations in the setting of HIV integration highlights that even traditionally low-risk HPV types can drive substantial genomic instability. Defining these mutations and structural changes may help identify biomarkers that improve risk stratification and guide the development of targeted therapies for atypical HPV-associated oral disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154624--></body></html>"
    },
    {
      "uid": "P054",
      "content_id": "153188",
      "abstract_number": "P054",
      "poster_number": "P054",
      "title": "Pediatric Head and Neck PEComa with Rare ZC3H4:TFE3 Fusion: A Case Report and Review of the Literature",
      "summary": "Pediatric head and neck perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with unpredictable clinical behavior, ranging from benign to highly malignant. For localized, resectable PEComa, complete surgical excision is the mainstay of treatment and offers the best chance for cure. Long-term surveillance is critical due to the risk of recurrence and metastasis, even after complete...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153188",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shreyans A Udani, MA",
      "presenter": "Shreyans A Udani, MA",
      "authors": "Shreyans A Udani, MA 1 ; Adham Aljariri, MD 1 ; Peter H Shaw, MD 2 ; Michael Gorelik, MD 1",
      "normalized_authors": [
        "Shreyans A Udani, MA",
        "Adham Aljariri",
        "Peter H Shaw",
        "Michael Gorelik"
      ],
      "affiliations": [
        "Medical College of Wisconsin, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA",
        "Medical College of Wisconsin, Department of Pediatrics, Division of Pediatric Hematology and Oncology & Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, USA"
      ],
      "normalized_institutions": [
        "Medical College of Wisconsin, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA",
        "Medical College of Wisconsin, Department of Pediatrics, Division of Pediatric Hematology and Oncology & Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, USA"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 336,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Summary",
        "Discussion"
      ],
      "sections": {
        "Authors": "Shreyans A Udani, MA 1 ; Adham Aljariri, MD 1 ; Peter H Shaw, MD 2 ; Michael Gorelik, MD 1",
        "Affiliations": "1 Medical College of Wisconsin, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA; 2 Medical College of Wisconsin, Department of Pediatrics, Division of Pediatric Hematology and Oncology & Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, USA",
        "Background": "Pediatric head and neck perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with unpredictable clinical behavior, ranging from benign to highly malignant. For localized, resectable PEComa, complete surgical excision is the mainstay of treatment and offers the best chance for cure. Long-term surveillance is critical due to the risk of recurrence and metastasis, even after complete resection. Given the rarity of this pathology in the pediatric population there is a lack of pediatric-specific prospective trials, and molecular profiling may help guide therapy in the future.",
        "Case Summary": "A two-year-old male presented with a rapidly enlarging right submandibular mass. Initial laboratory workup including CBC, ESR, and Bartonella serology was unremarkable. Ultrasound and computed tomography (CT) identified a 4-cm, well-circumscribed mass adjacent to the right submandibular gland. Positron emission tomography (PET) demonstrated high SUV uptake with involvement of the ipsilateral cervical lymph nodes without distant metastases. Fine-needle biopsy was performed, and pathology revealed a PEComa with a ZC3H4:TFE3 fusion. Wide local excision with level I-IV neck dissection was performed and required sacrifice of the marginal mandibular nerve. The patient had an uneventful postoperative course with expected marginal mandibular nerve weakness. Final pathology demonstrated negative margins with multiple metastatic lymph nodes. Multidisciplinary discussion recommended continued surveillance without adjuvant therapy. Follow-up PET imaging at 6 months post-resection has shown no evidence of recurrence or metastasis.",
        "Discussion": "Pediatric head and neck PEComas are extremely rare with fewer than 40 reported pediatric cases. Diagnosis relies on a combination of imaging findings and histopathological evaluation, including immunohistochemistry for HMB45, myoid/melanocytic markers, and molecular analysis. The ZC3H4:TFE3 fusion has been seldom reported and may confer an aggressive subtype with a higher risk of recurrence. Multidisciplinary assessment is essential, following principles outlined for pediatric head and neck tumors. Surgery remains the mainstay of treatment for resectable and local-regional disease. For unresectable, metastatic, or recurrent disease, systemic therapy with mTOR inhibitors is the preferred first-line systemic therapy. Regular surveillance remains necessary as aggressive subtypes of PEComa have been implicated in recurrence many years after diagnosis."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pediatric Head and Neck PEComa with Rare ZC3H4:TFE3 Fusion: A Case Report and Review of the Literature</span>. <u>Shreyans A Udani, MA</u><sup>1</sup>; Adham Aljariri, MD<sup>1</sup>; Peter H Shaw, MD<sup>2</sup>; Michael Gorelik, MD<sup>1</sup>. <sup>1</sup>Medical College of Wisconsin, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>2</sup>Medical College of Wisconsin, Department of Pediatrics, Division of Pediatric Hematology and Oncology & Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Pediatric head and neck perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with unpredictable clinical behavior, ranging from benign to highly malignant. For localized, resectable PEComa, complete surgical excision is the mainstay of treatment and offers the best chance for cure. Long-term surveillance is critical due to the risk of recurrence and metastasis, even after complete resection. Given the rarity of this pathology in the pediatric population there is a lack of pediatric-specific prospective trials, and molecular profiling may help guide therapy in the future. </p>\n\n<p><strong>Case Summary:</strong> A two-year-old male presented with a rapidly enlarging right submandibular mass. Initial laboratory workup including CBC, ESR, and Bartonella serology was unremarkable. Ultrasound and computed tomography (CT) identified a 4-cm, well-circumscribed mass adjacent to the right submandibular gland. Positron emission tomography (PET) demonstrated high SUV uptake with involvement of the ipsilateral cervical lymph nodes without distant metastases.  Fine-needle biopsy was performed, and pathology revealed a PEComa with a ZC3H4:TFE3 fusion. Wide local excision with level I-IV neck dissection was performed and required sacrifice of the marginal mandibular nerve. The patient had an uneventful postoperative course with expected marginal mandibular nerve weakness. Final pathology demonstrated negative margins with multiple metastatic lymph nodes. Multidisciplinary discussion recommended continued surveillance without adjuvant therapy. Follow-up PET imaging at 6 months post-resection has shown no evidence of recurrence or metastasis.  </p>\n\n<p><strong>Discussion:</strong> Pediatric head and neck PEComas are extremely rare with fewer than 40 reported pediatric cases. Diagnosis relies on a combination of imaging findings and histopathological evaluation, including immunohistochemistry for HMB45, myoid/melanocytic markers, and molecular analysis. The ZC3H4:TFE3 fusion has been seldom reported and may confer an aggressive subtype with a higher risk of recurrence.  Multidisciplinary assessment is essential, following principles outlined for pediatric head and neck tumors.  Surgery remains the mainstay of treatment for resectable and local-regional disease. For unresectable, metastatic, or recurrent disease, systemic therapy with mTOR inhibitors is the preferred first-line systemic therapy. Regular surveillance remains necessary as aggressive subtypes of PEComa have been implicated in recurrence many years after diagnosis. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153188--></body></html>"
    },
    {
      "uid": "P055",
      "content_id": "153563",
      "abstract_number": "P055",
      "poster_number": "P055",
      "title": "Free Tissue Transfer (FTT) Monitoring Using a miniaturized Near-Infrared Spectroscopy (NIRS) Sensor",
      "summary": "Head and neck cancer is the 7th most common cancer worldwide, with 660,000+ new cases and 325,000 deaths annually. Free Tissue Transfer (FTT) is the most common surgical procedure to reconstruct complex wounds caused by cancer removal. Monitoring the vitality of the transplanted tissue after surgery poses significant challenges. To address this, Near-Infrared Spectroscopy (NIRS) can be used as a non-invasive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153563",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Babak Shadgan, Associate Professor",
      "presenter": "Babak Shadgan, Associate Professor",
      "authors": "Amir Parham Pirhadi Rad, PhD, Student; Oleksandr Butskiy, Clinical Assistant Professor; Sadra Khosravi; Donald Anderson, Clinical Professor; Babak Shadgan, Associate Professor",
      "normalized_authors": [
        "Amir Parham Pirhadi Rad, Student",
        "Oleksandr Butskiy, Clinical Assistant",
        "Sadra Khosravi",
        "Donald Anderson, Clinical",
        "Babak Shadgan, Associate"
      ],
      "affiliations": [
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of British Columbia"
      ],
      "session_type": "Poster",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 257,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amir Parham Pirhadi Rad, PhD, Student; Oleksandr Butskiy, Clinical Assistant Professor; Sadra Khosravi; Donald Anderson, Clinical Professor; Babak Shadgan, Associate Professor",
        "Affiliations": "University of British Columbia",
        "Abstract": "Head and neck cancer is the 7th most common cancer worldwide, with 660,000+ new cases and 325,000 deaths annually. Free Tissue Transfer (FTT) is the most common surgical procedure to reconstruct complex wounds caused by cancer removal. Monitoring the vitality of the transplanted tissue after surgery poses significant challenges. To address this, Near-Infrared Spectroscopy (NIRS) can be used as a non-invasive optical technology that enables real-time monitoring of tissue hemodynamics. Currently, there are no commercially available NIRS systems that feature a small enough sensor probe for use in the head and neck region. 15 patients undergoing FTT surgery have been recruited with an average age of 71.7 (±17.7 SD) as a part of the clinical trial. The sensor will be placed on the flap on the head and neck region for 72 hours post-surgery on the FTT tissue, and regional tissue perfusion will be monitored postoperatively. The average TOI on the flap was reported as 60.1 (±4.4 SD). Two patients experienced venous occlusion with TOI ranging from 41 to 63.5, and one patient with full flap failure had a TOI recorded at 52. Patients and clinicians rated their experience with the FTT NIRS system on a scale of 1 to 10. The average patient discomfort level was reported as 1.7 (SD ±1.4), and interference with clinical treatment was 1.5 (SD ±0.7). The FTT NIRS system can monitor for 72 hours postoperatively following FTT surgery and can also differentiate arterial from venous occlusions with P < 0.006."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Tissue Transfer (FTT) Monitoring Using a miniaturized Near-Infrared Spectroscopy (NIRS) Sensor</span>. Amir Parham Pirhadi Rad, PhD, Student; Oleksandr Butskiy, Clinical Assistant Professor; Sadra Khosravi; Donald Anderson, Clinical Professor; <u>Babak Shadgan, Associate Professor</u>. University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck cancer is the 7th most common cancer worldwide, with 660,000+ new cases and 325,000 deaths annually. Free Tissue Transfer (FTT) is the most common surgical procedure to reconstruct complex wounds caused by cancer removal. Monitoring the vitality of the transplanted tissue after surgery poses significant challenges. To address this, Near-Infrared Spectroscopy (NIRS) can be used as a non-invasive optical technology that enables real-time monitoring of tissue hemodynamics. Currently, there are no commercially available NIRS systems that feature a small enough sensor probe for use in the head and neck region.</p>\n\n<p>15 patients undergoing FTT surgery have been recruited with an average age of 71.7 (±17.7 SD) as a part of the clinical trial. The sensor will be placed on the flap on the head and neck region for 72 hours post-surgery on the FTT tissue, and regional tissue perfusion will be monitored postoperatively. </p>\n\n<p>The average TOI on the flap was reported as 60.1 (±4.4 SD). Two patients experienced venous occlusion with TOI ranging from 41 to 63.5, and one patient with full flap failure had a TOI recorded at 52. Patients and clinicians rated their experience with the FTT NIRS system on a scale of 1 to 10. The average patient discomfort level was reported as 1.7 (SD ±1.4), and interference with clinical treatment was 1.5 (SD ±0.7).</p>\n\n<p>The FTT NIRS system can monitor for 72 hours postoperatively following FTT surgery and can also differentiate arterial from venous occlusions with P < 0.006.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153563--></body></html>"
    },
    {
      "uid": "P056",
      "content_id": "154718",
      "abstract_number": "P056",
      "poster_number": "P056",
      "title": "Virtual Surgical Planning for Transmandibular Approach to Extensive Clival Chordoma: A Case Report",
      "summary": "VSP enhances complex surgical techniques, such as our TCR approach, by enabling surgeons to predict surgical exposure limits before surgery and virtually confirm optimal access with patient-specific anatomy. Integration of emerging technologies like VSP improves preoperative planning, patient education, and outcomes for challenging cases. This technology moves surgical practice closer to performing procedures...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154718",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Akshay R Prabhakar, BSA",
      "presenter": "Akshay R Prabhakar, BSA",
      "authors": "Akshay R Prabhakar, BSA 1 ; Laura Kim, MD 1 ; Collin Mulcahy, MD 1 ; Austin Shelton, BS 2 ; Justina R Varghese, BA 1 ; Sebastian Guadarrama-Sistos Vazquez, MD 1 ; Sean Barber, MD 3 ; Stuart Corr, PhD 4 ; Nadia Mohyuddin, MD 1",
      "normalized_authors": [
        "Akshay R Prabhakar, BSA",
        "Laura Kim",
        "Collin Mulcahy",
        "Austin Shelton",
        "Justina R Varghese",
        "Sebastian Guadarrama-Sistos Vazquez",
        "Sean Barber",
        "Stuart Corr",
        "Nadia Mohyuddin"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas, US",
        "The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US",
        "Department of Neurosurgery, Houston Methodist, Houston, Texas, US",
        "1The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas, US",
        "The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US",
        "Department of Neurosurgery, Houston Methodist, Houston, Texas, US",
        "1The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US"
      ],
      "session_type": "Poster",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154718/mri_case_ahns.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154718/mri_case_ahns.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154718"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-52-52%20(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-52-52%20(1).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154718"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-44-26.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-44-26.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154718"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_15-43-27.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_15-43-27.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154718"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Surgical Planning",
        "Expected Technique",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Akshay R Prabhakar, BSA 1 ; Laura Kim, MD 1 ; Collin Mulcahy, MD 1 ; Austin Shelton, BS 2 ; Justina R Varghese, BA 1 ; Sebastian Guadarrama-Sistos Vazquez, MD 1 ; Sean Barber, MD 3 ; Stuart Corr, PhD 4 ; Nadia Mohyuddin, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas, US; 2 The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US; 3 Department of Neurosurgery, Houston Methodist, Houston, Texas, US; 4 1The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US",
        "Background": "Clival chordomas with significant prevertebral extension require wide surgical access to the craniocervical junction. Traditional transoral approaches provide limited exposure for tumors extending beyond the upper cervical spine, and transcervical approaches offer inadequate visualization of the cranio-cervical junction. The transmandibular, circumglossal, retropharyngeal (TCR) approach addresses these limitations by providing wide exposure to both midline and lateral skull base compartments. However, the complexity of this approach demands meticulous preoperative planning to navigate critical neurovascular structures. Virtual surgical planning (VSP) has emerged as a valuable tool for optimizing skull-base approaches through detailed three-dimensional anatomic visualization and precise surgical corridor mapping.",
        "Case Presentation": "A 46-year-old male with a two-year history of progressive dyspnea and muffled voice presented to the ED with acute respiratory failure, requiring emergent awake tracheostomy. Imaging demonstrated a 7.3-cm biopsy-proven chordoma centered at C2 with C1 anterior arch involvement and prevertebral and retropharyngeal extension from C1 to C5. This anatomic distribution creates significant access challenges: the vertical extent from skull base to mid-cervical spine requires multilevel exposure, while the prevertebral location requires wide anterior access for safe dissection. The tumor partially encased bilateral vertebral arteries with involvement of C2 pedicles, precluding en bloc resection.",
        "Surgical Planning": "To address the complex access requirements and critical anatomy, comprehensive VSP was performed using high-resolution maxillofacial CT in conjunction with the Elucis™ VR platform (Realize Medical Inc., Ottawa, Canada). While standard imaging reveals the multilevel tumor involvement, VSP allowed virtual manipulation of the mandible relative to the tumor to confirm adequate access would be achieved. Alternate surgical approaches were discarded after VSP analysis demonstrated the full extent of tumor in relation to anatomic confines for said approaches. VSP confirmed the decision to proceed with the TCR approach by virtually demonstrating optimal exposure for tumor resection and mapping bilateral vertebral artery trajectories relative to the planned surgical corridor, critical information for neurosurgical planning. The ability to manipulate the mandible and tumor in virtual space confirmed the mandibulotomy would achieve necessary exposure while protecting critical neurovascular structures.",
        "Expected Technique": "Stage one posterior occipitocervical fusion will establish spinal stability. Stage two will utilize VSP-guided mandibulotomy with circumglossal dissection and retropharyngeal exposure, providing wide access to the C1-C5 anterior spinal column for neurosurgical resection. Rigid mandibular fixation will be achieved with customized reconstructive plates.",
        "Conclusion": "VSP enhances complex surgical techniques, such as our TCR approach, by enabling surgeons to predict surgical exposure limits before surgery and virtually confirm optimal access with patient-specific anatomy. Integration of emerging technologies like VSP improves preoperative planning, patient education, and outcomes for challenging cases. This technology moves surgical practice closer to performing procedures virtually before entering the operating room. Surgical outcomes will be presented at the meeting.",
        "Abstract": "Image 1: Sagittal and axial CT images showing 7.3-cm mass at C2 vertebral body Image 2: Lateral view of clival chordoma (green) demonstrating anatomic relationship to carotid and vertebral arteries, spine, and mandible Image 3: Anterior view with mandible intact and tumor Image 4: Anterior view with mandibulotomy demonstrating surgical approach and access to tumor"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Virtual Surgical Planning for Transmandibular Approach to Extensive Clival Chordoma: A Case Report</span>. <u>Akshay R Prabhakar, BSA</u><sup>1</sup>; Laura Kim, MD<sup>1</sup>; Collin Mulcahy, MD<sup>1</sup>; Austin Shelton, BS<sup>2</sup>; Justina R Varghese, BA<sup>1</sup>; Sebastian Guadarrama-Sistos Vazquez, MD<sup>1</sup>; Sean Barber, MD<sup>3</sup>; Stuart Corr, PhD<sup>4</sup>; Nadia Mohyuddin, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas, US; <sup>2</sup>The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US; <sup>3</sup>Department of Neurosurgery, Houston Methodist, Houston, Texas, US; <sup>4</sup>1The Bookout Center, Houston Methodist Academic Institute, Houston, Texas, US<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Clival chordomas with significant prevertebral extension require wide surgical access to the craniocervical junction. Traditional transoral approaches provide limited exposure for tumors extending beyond the upper cervical spine, and transcervical approaches offer inadequate visualization of the cranio-cervical junction. The transmandibular, circumglossal, retropharyngeal (TCR) approach addresses these limitations by providing wide exposure to both midline and lateral skull base compartments. However, the complexity of this approach demands meticulous preoperative planning to navigate critical neurovascular structures. Virtual surgical planning (VSP) has emerged as a valuable tool for optimizing skull-base approaches through detailed three-dimensional anatomic visualization and precise surgical corridor mapping.</p>\n\n<p><strong>Case Presentation: </strong>A 46-year-old male with a two-year history of progressive dyspnea and muffled voice presented to the ED with acute respiratory failure, requiring emergent awake tracheostomy. Imaging demonstrated a 7.3-cm biopsy-proven chordoma centered at C2 with C1 anterior arch involvement and prevertebral and retropharyngeal extension from C1 to C5. This anatomic distribution creates significant access challenges: the vertical extent from skull base to mid-cervical spine requires multilevel exposure, while the prevertebral location requires wide anterior access for safe dissection. The tumor partially encased bilateral vertebral arteries with involvement of C2 pedicles, precluding en bloc resection.</p>\n\n<p><strong>Surgical Planning: </strong>To address the complex access requirements and critical anatomy, comprehensive VSP was performed using high-resolution maxillofacial CT in conjunction with the Elucis™ VR platform (Realize Medical Inc., Ottawa, Canada). While standard imaging reveals the multilevel tumor involvement, VSP allowed virtual manipulation of the mandible relative to the tumor to confirm adequate access would be achieved. Alternate surgical approaches were discarded after VSP analysis demonstrated the full extent of tumor in relation to anatomic confines for said approaches. VSP confirmed the decision to proceed with the TCR approach by virtually demonstrating optimal exposure for tumor resection and mapping bilateral vertebral artery trajectories relative to the planned surgical corridor, critical information for neurosurgical planning. The ability to manipulate the mandible and tumor in virtual space confirmed the mandibulotomy would achieve necessary exposure while protecting critical neurovascular structures.</p>\n\n<p><strong>Expected Technique: </strong>Stage one posterior occipitocervical fusion will establish spinal stability. Stage two will utilize VSP-guided mandibulotomy with circumglossal dissection and retropharyngeal exposure, providing wide access to the C1-C5 anterior spinal column for neurosurgical resection. Rigid mandibular fixation will be achieved with customized reconstructive plates.</p>\n\n<p><strong>Conclusion: </strong>VSP enhances complex surgical techniques, such as our TCR approach, by enabling surgeons to predict surgical exposure limits before surgery and virtually confirm optimal access with patient-specific anatomy. Integration of emerging technologies like VSP improves preoperative planning, patient education, and outcomes for challenging cases. This technology moves surgical practice closer to performing procedures virtually before entering the operating room. Surgical outcomes will be presented at the meeting.</p>\n\n<p>Image 1: Sagittal and axial CT images showing 7.3-cm mass at C2 vertebral body</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154718/mri_case_ahns.png' /></p>\n\n<p>Image 2: Lateral view of clival chordoma (green) demonstrating anatomic relationship to carotid and vertebral arteries, spine, and mandible</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-52-52%20(1).png' /></p>\n\n<p>Image 3: Anterior view with mandible intact and tumor</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_13-44-26.png' /></p>\n\n<p>Image 4: Anterior view with mandibulotomy demonstrating surgical approach and access to tumor</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154718/desktop_2025-12-05_15-43-27.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154718--></body></html>"
    },
    {
      "uid": "P057",
      "content_id": "155437",
      "abstract_number": "P057",
      "poster_number": "P057",
      "title": "Radar-guided Localization and Resection for Metastatic Nodal and Soft Tissue Neoplasm in the Head and Neck: A Single-Institution Retrospective Study",
      "summary": "In our practice, radar-guided localization is a safe and effective localization method for patients with recurrent or post-treatment metastatic lymph nodal disease or a single focus of non-palpable soft tissue disease in the head and neck. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph nodal retrieval. It is particularly helpful in re-operative...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155437",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christine R Burton, MD",
      "presenter": "Christine R Burton, MD",
      "authors": "Christine R Burton, MD 1 ; Kimberly Vanderveen, MD 2 ; Wesley L Hicks Jr, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1",
      "normalized_authors": [
        "Christine R Burton",
        "Kimberly Vanderveen",
        "Wesley L Hicks Jr",
        "Kimberly E Wooten",
        "Ryan P McSpadden",
        "Vishal Gupta"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "Rose Medical Center, Denver, Colorado"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "Rose Medical Center, Denver, Colorado"
      ],
      "session_type": "Poster",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 289,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Christine R Burton, MD 1 ; Kimberly Vanderveen, MD 2 ; Wesley L Hicks Jr, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 Rose Medical Center, Denver, Colorado",
        "Background": "Radar-guided localization offers a wire-free, nonradioactive surgical guidance method consisting of a small, inert, percutaneously placed radar reflector that is localized intra-operatively with a handheld probe. The study investigates the feasibility, utility, and outcomes of radar-guided localization for head and neck malignancy.",
        "Methods": "We retrospectively identified eleven patients at our cancer center who underwent radar-guided localization and resection of either a metastatic lymph node or soft tissue malignancy in the head and neck between January 2025 and January 2026. Data pertaining to patients’ cancer history, management, reflector placement, surgical intervention, and follow-up was extracted from patient charts and analyzed.",
        "Results": "Eleven radar-guided localization cases were performed in patients with metastatic lymph nodal disease or soft tissue malignancy in the head and neck. Diagnoses included nasopharyngeal SCC, esophageal SCC, papillary thyroid carcinoma, acinic cell carcinoma, lymphoma, melanoma, supraglottic SCC. Cases included index lymph node resections, selective neck dissections, and soft tissue nodal retrievals. Reflectors were located and retrieved intraoperatively in 100% of cases from a range of 0 to 148 days after placement. One reflector had migrated outside of the index lesion due to systemic treatment effect but was adjacent to the lesion. Associated index lesion removal was 11 of 11 (100%). There were no complications attributable to reflector insertion and no unexpected complications of radar-guided localization surgery.",
        "Conclusion": "In our practice, radar-guided localization is a safe and effective localization method for patients with recurrent or post-treatment metastatic lymph nodal disease or a single focus of non-palpable soft tissue disease in the head and neck. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph nodal retrieval. It is particularly helpful in re-operative nodal basins that have had adjuvant radiation where tissue planes have been obscured."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Radar-guided Localization and Resection for Metastatic Nodal and Soft Tissue Neoplasm in the Head and Neck: A Single-Institution Retrospective Study</span>. <u>Christine R Burton, MD</u><sup>1</sup>; Kimberly Vanderveen, MD<sup>2</sup>; Wesley L Hicks Jr, MD<sup>1</sup>; Kimberly E Wooten, MD<sup>1</sup>; Ryan P McSpadden, MD<sup>1</sup>; Vishal Gupta, MD<sup>1</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>Rose Medical Center, Denver, Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Radar-guided localization offers a wire-free, nonradioactive surgical guidance method consisting of a small, inert, percutaneously placed radar reflector that is localized intra-operatively with a handheld probe. The study investigates the feasibility, utility, and outcomes of radar-guided localization for head and neck malignancy.</p>\n\n<p><strong>Methods: </strong>We retrospectively identified eleven patients at our cancer center who underwent radar-guided localization and resection of either a metastatic lymph node or soft tissue malignancy in the head and neck between January 2025 and January 2026. Data pertaining to patients’ cancer history, management, reflector placement, surgical intervention, and follow-up was extracted from patient charts and analyzed.</p>\n\n<p><strong>Results:</strong> Eleven radar-guided localization cases were performed in patients with metastatic lymph nodal disease or soft tissue malignancy in the head and neck. Diagnoses included nasopharyngeal SCC, esophageal SCC, papillary thyroid carcinoma, acinic cell carcinoma, lymphoma, melanoma, supraglottic SCC. Cases included index lymph node resections, selective neck dissections, and soft tissue nodal retrievals. Reflectors were located and retrieved intraoperatively in 100% of cases from a range of 0 to 148 days after placement. One reflector had migrated outside of the index lesion due to systemic treatment effect but was adjacent to the lesion. Associated index lesion removal was 11 of 11 (100%). There were no complications attributable to reflector insertion and no unexpected complications of radar-guided localization surgery.</p>\n\n<p><strong>Conclusion:</strong> In our practice, radar-guided localization is a safe and effective localization method for patients with recurrent or post-treatment metastatic lymph nodal disease or a single focus of non-palpable soft tissue disease in the head and neck. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph nodal retrieval. It is particularly helpful in re-operative nodal basins that have had adjuvant radiation where tissue planes have been obscured.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155437--></body></html>"
    },
    {
      "uid": "P059",
      "content_id": "153935",
      "abstract_number": "P059",
      "poster_number": "P059",
      "title": "Efficacy of Robotic Versus Conventional Neck Dissection in the Treatment of Head and Neck Squamous Cell Carcinoma at a Public Teaching Hospital",
      "summary": "This study demonstrates the feasibility of robotic neck dissection, which is characterized by prolonged operative time but comparable oncological outcomes, reduced complication rates, and similar hospital stays when compared to conventional approaches. These findings support the integration of robotic techniques into head and neck surgical oncology, for appropriately selected patients. Future prospective studies...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153935",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiz Kowalski, PhD",
      "presenter": "Luiz Kowalski, PhD",
      "authors": "Matheus Buissa, MD; Chistiana Vanni, PhD; Andre Bandiera, PhD; Marco Kulcsar, PhD; Luiz Kowalski, PhD",
      "normalized_authors": [
        "Matheus Buissa",
        "Chistiana Vanni",
        "Andre Bandiera",
        "Marco Kulcsar",
        "Luiz Kowalski"
      ],
      "affiliations": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "session_type": "Poster",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 467,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Matheus Buissa, MD; Chistiana Vanni, PhD; Andre Bandiera, PhD; Marco Kulcsar, PhD; Luiz Kowalski, PhD",
        "Affiliations": "Faculdade de Medicina da Universidade de São Paulo",
        "Introduction": "Neck dissection represents an established surgical approach for managing cervical lymph node metastases and achieving accurate pathological staging in upper aerodigestive tract malignancies. First described by Crile in 1906 and subsequently refined by Martin in 1951, this procedure has demonstrated reproducible outcomes and therapeutic efficacy for over a century. Recent technological innovations in minimally invasive surgery have prompted investigation into robotic techniques as potential alternatives to optimize cosmetic outcomes while maintaining oncological adequacy.",
        "Objective": "To compare oncological and perioperative outcomes between conventional and robotic neck dissection techniques in patients with squamous cell carcinoma of the upper aerodigestive tract and lips.",
        "Methods": "This retrospective cohort study analyzed electronic medical records of 39 patients who underwent neck dissection for squamous cell carcinoma of the upper aerodigestive tract and lips at Instituto do Câncer de São Paulo (ICESP) between January 1, 2021, and March 13, 2023. Analyzed variables included surgical technique, operative duration, lymph node yield, number of metastatic nodes, postoperative hospital stay, perioperative complications (minor and major), progression-free survival, and overall survival. Exclusion criteria comprised patients requiring mandibular resection, those with primary laryngeal tumors, and cases necessitating free flap reconstruction, thereby ensuring comparable baseline characteristics between groups. The robotic approach utilized a retroauricular hairline incision with subsequent creation of a subplatysmal flap.",
        "Results": "A total of 30 patients underwent conventional neck dissections and 9 robotic retroauricular neck dissections. Preliminary analysis revealed no statistically significant differences between conventional and robotic approaches regarding patient age, respectively: (mean of 59.3 years vs 59.8 years, p= 0.92), postoperative hospital stay (mean of 5.3 days vs 3.9 days, p= .22), reoperation rates (mean of 10% vs 3.3%, p0.4423), and lymph node yield (34.2 vs 26.6, p= 012. Operative time was significantly prolonged in the robotic cohort (338.7 min vs. 270.3min, p= 0,005861). While nerve injury rates showed no significant intergroup differences (43.3% vs 20%, p= 0.43), the conventional group experienced additional neck dissection-related complications—including seroma formation (6%) and wound infection (3%)—not observed in the robotic cohort. This disparity may reflect unequal sample sizes between groups as well patient selection . Conversely, flap necrosis occurred exclusively in the robotic group (10%). There was no significant differences on disease-free survival calculated by Kaplan Meier method (27,03 vs. 25 months, p= 0.41).",
        "Conclusion": "This study demonstrates the feasibility of robotic neck dissection, which is characterized by prolonged operative time but comparable oncological outcomes, reduced complication rates, and similar hospital stays when compared to conventional approaches. These findings support the integration of robotic techniques into head and neck surgical oncology, for appropriately selected patients. Future prospective studies with larger cohorts and long-term follow-up are warranted to definitively establish the role of robotic neck dissection in optimizing both functional and aesthetic outcomes while maintaining oncological safety."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy of Robotic Versus Conventional Neck Dissection in the Treatment of Head and Neck Squamous Cell Carcinoma at a Public Teaching Hospital</span>. Matheus Buissa, MD; Chistiana Vanni, PhD; Andre Bandiera, PhD; Marco Kulcsar, PhD; <u>Luiz Kowalski, PhD</u>. Faculdade de Medicina da Universidade de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Neck dissection represents an established surgical approach for managing cervical lymph node metastases and achieving accurate pathological staging in upper aerodigestive tract malignancies. First described by Crile in 1906 and subsequently refined by Martin in 1951, this procedure has demonstrated reproducible outcomes and therapeutic efficacy for over a century. Recent technological innovations in minimally invasive surgery have prompted investigation into robotic techniques as potential alternatives to optimize cosmetic outcomes while maintaining oncological adequacy.</p>\n\n<p><strong>Objective: </strong>To compare oncological and perioperative outcomes between conventional and robotic neck dissection techniques in patients with squamous cell carcinoma of the upper aerodigestive tract and lips.</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study analyzed electronic medical records of 39 patients who underwent neck dissection for squamous cell carcinoma of the upper aerodigestive tract and lips at Instituto do Câncer de São Paulo (ICESP) between January 1, 2021, and March 13, 2023. Analyzed variables included surgical technique, operative duration, lymph node yield, number of metastatic nodes, postoperative hospital stay, perioperative complications (minor and major), progression-free survival, and overall survival. Exclusion criteria comprised patients requiring mandibular resection, those with primary laryngeal tumors, and cases necessitating free flap reconstruction, thereby ensuring comparable baseline characteristics between groups. The robotic approach utilized a retroauricular hairline incision with subsequent creation of a subplatysmal flap.</p>\n\n<p><strong>Results: </strong>A total of 30 patients underwent conventional neck dissections and 9 robotic retroauricular neck dissections. Preliminary analysis revealed no statistically significant differences between conventional and robotic approaches regarding patient age, respectively: (mean of 59.3 years vs 59.8 years, p= 0.92), postoperative hospital stay (mean of 5.3 days vs 3.9 days, p= .22), reoperation rates (mean of 10% vs 3.3%, p0.4423), and lymph node yield (34.2 vs 26.6, p= 012. Operative time was significantly prolonged in the robotic cohort (338.7 min vs. 270.3min, p= 0,005861). While nerve injury rates showed no significant intergroup differences (43.3% vs 20%, p= 0.43), the conventional group experienced additional neck dissection-related complications—including seroma formation (6%) and wound infection (3%)—not observed in the robotic cohort. This disparity may reflect unequal sample sizes between groups as well patient selection . Conversely, flap necrosis occurred exclusively in the robotic group (10%). There was no significant differences on disease-free survival calculated by Kaplan Meier method (27,03 vs. 25 months, p= 0.41). </p>\n\n<p><strong>Conclusion: </strong>This study demonstrates the feasibility of robotic neck dissection, which is characterized by prolonged operative time but comparable oncological outcomes, reduced complication rates, and similar hospital stays when compared to conventional approaches. These findings support the integration of robotic techniques into head and neck surgical oncology, for appropriately selected patients. Future prospective studies with larger cohorts and long-term follow-up are warranted to definitively establish the role of robotic neck dissection in optimizing both functional and aesthetic outcomes while maintaining oncological safety.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153935--></body></html>"
    },
    {
      "uid": "P060",
      "content_id": "153679",
      "abstract_number": "P060",
      "poster_number": "P060",
      "title": "In vivo Evaluation of a CT-Compatible Retractor for Image Guided Trans-Oral Surgery",
      "summary": "Preliminary data indicate that the polymer retractor provides IIDs equivalent to or slightly greater than those achieved with standard metal retractors, demonstrating its potential to facilitate intraoperative CT and MRI imaging. Positioning the polymer retractor currently takes 6.6 times longer than the metal retractors, highlighting an area for improvement expected to decrease with further experience. Overall,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153679",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michaela Geffert, MS",
      "presenter": "Michaela Geffert, MS",
      "authors": "Michaela Geffert, MS 1 ; Yuan Shi, PhD 2 ; Michael Kokko, PhD 2 ; Ryan Halter, PhD 2 ; Joseph Paydarfar, MD 1",
      "normalized_authors": [
        "Michaela Geffert",
        "Yuan Shi",
        "Michael Kokko",
        "Ryan Halter",
        "Joseph Paydarfar"
      ],
      "affiliations": [
        "Dartmouth-Hitchcock Health",
        "Thayer School of Engineering, Dartmouth College"
      ],
      "normalized_institutions": [
        "Dartmouth-Hitchcock Health",
        "Thayer School of Engineering, Dartmouth College"
      ],
      "session_type": "Poster",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153679/Figure%201%20-%20RetracTOR.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153679/Figure%201%20-%20RetracTOR.png",
          "alt": "Figure 1: 3D CAD Model of the retractor system.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153679"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Michaela Geffert, MS 1 ; Yuan Shi, PhD 2 ; Michael Kokko, PhD 2 ; Ryan Halter, PhD 2 ; Joseph Paydarfar, MD 1",
        "Affiliations": "1 Dartmouth-Hitchcock Health; 2 Thayer School of Engineering, Dartmouth College",
        "Introduction": "Transoral robotic surgery (TORS) is a widely deployed approach for minimally invasive management of cancers of the oropharynx. One of the challenges with the “inside-out” TORS approach is the lack of haptic feedback and inability to easily gauge tumor depth and extent based on pre-operative imaging. Image guided surgical navigation could potentially improve the safety and efficacy of TORS; however, current retractor systems are not CT/MRI compatible precluding the ability to obtain intraoperative imaging for accurate patient registration.",
        "Methods": "A CT and MRI compatible polymer retractor system was developed and fabricated using 3D printing (Figure 1) 1 . The system consists of a nylon frame with an integrated maxillary blade, along with an adjustable and interchangeable carbon fiber/onyx tongue blade for tongue retraction. A suspension system was also designed and fabricated to allow for rigid fixation of the retractor to the operative bedframe. Blade design was modified via an iterative design process based on deployment of the retractor, initially in the cadaver and subsequently in patients enrolled in the trial.",
        "Abstract": "For each patient the retractor was sterilized prior to surgery. Once nasally intubated, the standard-of-care metal FK and Crowe Davis (CD) retractors were sequentially deployed to expose the oropharynx, followed by the polymer retractor. For all three retractors, stereoendoscopic imaging of the oral cavity and oropharynx was acquired to assess surgical working volume (SWV) 2 . Inter-incisive distance (IID) was measured between the maxillary and tongue blades. With the polymer retractor, an intraoperative CT scan of the neck with intravenous administration of iohexol 350 was obtained. Positioning time for all retractors was recorded. Effectiveness of the polymer retractor was evaluated by comparing the SWV, IID, setup time, and retractor-related adverse events to the standard metal retractors (FK and CD).",
        "Results": "The polymer retractor was successfully deployed in six of eight enrolled participants (83% male; mean age 70 years). Data were unavailable for two participants due to an engineering failure prior to deployment. No device-related adverse events occurred. Mean IID was 3.3 cm with the polymer retractor versus 3.0 cm with metal retractors. Per-patient, the polymer system increased IID on average 0.42 cm relative to the FK and 0.13 cm relative to the CD. Average positioning time for the polymer retractor was 13.1 minutes, whereas the metal retractors required 2.1 minutes. SWV measurements for the polymer, FK and CD retractors are being finalized. CT images obtained with the polymer retractor were free of artifact.",
        "Conclusion": "Preliminary data indicate that the polymer retractor provides IIDs equivalent to or slightly greater than those achieved with standard metal retractors, demonstrating its potential to facilitate intraoperative CT and MRI imaging. Positioning the polymer retractor currently takes 6.6 times longer than the metal retractors, highlighting an area for improvement expected to decrease with further experience. Overall, these findings support the feasibility and safety of the polymer retractor, and continued evaluation in the full cohort will clarify its effectiveness for routine clinical use as part of an image guided surgical navigation system for TORS."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>In vivo Evaluation of a CT-Compatible Retractor for Image Guided Trans-Oral Surgery</span>. <u>Michaela Geffert, MS</u><sup>1</sup>; Yuan Shi, PhD<sup>2</sup>; Michael Kokko, PhD<sup>2</sup>; Ryan Halter, PhD<sup>2</sup>; Joseph Paydarfar, MD<sup>1</sup>. <sup>1</sup>Dartmouth-Hitchcock Health; <sup>2</sup>Thayer School of Engineering, Dartmouth College<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Transoral robotic surgery (TORS) is a widely deployed approach for minimally invasive management of cancers of the oropharynx. One of the challenges with the “inside-out” TORS approach is the lack of haptic feedback and inability to easily gauge tumor depth and extent based on pre-operative imaging. Image guided surgical navigation could potentially improve the safety and efficacy of TORS; however, current retractor systems are not CT/MRI compatible precluding the ability to obtain intraoperative imaging for accurate patient registration. </p>\n\n<p><strong>Methods: </strong>A CT and MRI compatible polymer retractor system was developed and fabricated using 3D printing (Figure 1)<sup>1</sup>. The system consists of a nylon frame with an integrated maxillary blade, along with an adjustable and interchangeable carbon fiber/onyx tongue blade for tongue retraction. A suspension system was also designed and fabricated to allow for rigid fixation of the retractor to the operative bedframe. Blade design was modified via an iterative design process based on deployment of the retractor, initially in the cadaver and subsequently in patients enrolled in the trial. </p>\n\n<p>For each patient the retractor was sterilized prior to surgery. Once nasally intubated, the standard-of-care metal FK and Crowe Davis (CD) retractors were sequentially deployed to expose the oropharynx, followed by the polymer retractor. For all three retractors, stereoendoscopic imaging of the oral cavity and oropharynx was acquired to assess surgical working volume (SWV)<sup>2</sup>. Inter-incisive distance (IID) was measured between the maxillary and tongue blades. With the polymer retractor, an intraoperative CT scan of the neck with intravenous administration of iohexol 350 was obtained. Positioning time for all retractors was recorded. Effectiveness of the polymer retractor was evaluated by comparing the SWV, IID, setup time, and retractor-related adverse events to the standard metal retractors (FK and CD).</p>\n\n<p><img alt='Figure 1: 3D CAD Model of the retractor system.' src='https://www.submitmyabstract.com/abs/images/153679/Figure%201%20-%20RetracTOR.png' /></p>\n\n<p><strong>Results: </strong>The polymer retractor was successfully deployed in six of eight enrolled participants (83% male; mean age 70 years). Data were unavailable for two participants due to an engineering failure prior to deployment. No device-related adverse events occurred. Mean IID was 3.3 cm with the polymer retractor versus 3.0 cm with metal retractors. Per-patient, the polymer system increased IID on average 0.42 cm relative to the FK and 0.13 cm relative to the CD. Average positioning time for the polymer retractor was 13.1 minutes, whereas the metal retractors required 2.1 minutes. SWV measurements for the polymer, FK and CD retractors are being finalized. CT images obtained with the polymer retractor were free of artifact.</p>\n\n<p><strong>Conclusion: </strong>Preliminary data indicate that the polymer retractor provides IIDs equivalent to or slightly greater than those achieved with standard metal retractors, demonstrating its potential to facilitate intraoperative CT and MRI imaging. Positioning the polymer retractor currently takes 6.6 times longer than the metal retractors, highlighting an area for improvement expected to decrease with further experience. Overall, these findings support the feasibility and safety of the polymer retractor, and continued evaluation in the full cohort will clarify its effectiveness for routine clinical use as part of an image guided surgical navigation system for TORS.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153679--></body></html>"
    },
    {
      "uid": "P061",
      "content_id": "155435",
      "abstract_number": "P061",
      "poster_number": "P061",
      "title": "Medicaid Expansion and Care Pathways in Oral Cavity Squamous Cell Carcinoma: An NCDB Study (2004–2022)",
      "summary": "Across nearly two decades of NCDB data, Medicaid expansion status was consistently associated with both the facility type accessed and the composition of initial treatment for tongue/oral cavity carcinoma. Expansion states, particularly early adopters, demonstrated a higher proportion of care delivered at Academic/Research centers and a shift toward combined-modality surgical management. These findings suggest...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155435",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Wesley L Hicks Jr, MD; Alex Vaicius, MD; William J Magner, PhD; Kimberly E Wooten, MD; Jenny Romero, MD; Anurag K Singh, MD; Vishal Gupta, MD",
      "normalized_authors": [
        "Wesley L Hicks Jr",
        "Alex Vaicius",
        "William J Magner",
        "Kimberly E Wooten",
        "Jenny Romero",
        "Anurag K Singh",
        "Vishal Gupta"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 540,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Wesley L Hicks Jr, MD; Alex Vaicius, MD; William J Magner, PhD; Kimberly E Wooten, MD; Jenny Romero, MD; Anurag K Singh, MD; Vishal Gupta, MD",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Background": "Medicaid expansion under the Affordable Care Act has altered insurance coverage patterns across the United States, with potential downstream effects on access to specialized oncologic care. Tongue and oral cavity squamous cell carcinomas typically require coordinated multidisciplinary management, and receipt of definitive surgery and appropriate adjuvant therapy often depends on the capabilities of the treating institution. Whether state-level Medicaid expansion status is associated with differences in facility type or initial treatment selection in this disease has not been well characterized. Using the National Cancer Database (NCDB) 2022 Participant User File, we examined the relationship between Medicaid expansion status and early care pathways in a large, contemporary national cohort.",
        "Methods": "Adults aged ≥18-years diagnosed with invasive tongue/oral cavity carcinoma between 2004 and 2022 were identified from the NCDB Tongue PUF. The exposure of interest was the NCDB Medicaid Expansion Code, categorized as: non-expansion, January-2014 expansion, late expansion, other/territorial, or suppressed. Outcomes included (1) facility type, grouped as Community, Comprehensive Community, Academic/Research, or Integrated Network Cancer Programs; and (2) initial treatment pattern, reconstructed using standardized NCDB summary treatment fields, sequencing variables, and timing indicators. Treatment categories included Surgery only, Surgery+RT, Definitive chemoradiation (CRT), Definitive RT alone, Systemic-only therapy, and Other/None. All analyses were descriptive. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis. The authors take responsibility for the integrity and full biostatistical analyses will be verified prior to presentation.",
        "Results": "The analytic cohort consisted of 186,037 adults. Medicaid expansion status was distributed as follows: non-expansion 37.7%, January-2014 expansion 29.4%, late expansion 16.5%, other/territorial 13.0%, and suppressed 3.4%. Marked differences in facility type were observed across expansion categories. In non-expansion states, 45.5% of patients received treatment at Academic/Research centers, compared with 54.8% in January-2014 expansion states and 49.6% in late-expansion states; Comprehensive Community centers accounted for 31.7%, 24.1%, and 31.1%, respectively. Integrated Network and Community programs constituted smaller shares across all groups.",
        "Abstract": "Among non-expansion states, Surgery only comprised 30.4% of cases, Surgery+RT 19.0%, CRT 33.6%, RT-only 5.4%, Systemic-only 3.9%, and Other/None 7.8%. In January-2014 expansion states, proportions were 30.7%, 21.5%, 33.6%, 4.8%, 2.8%, and 6.5%, respectively. Late-expansion states showed a similar distribution, with modestly higher Surgery+RT use (22.0%) and slightly lower CRT (31.8%). The other/territorial group mirrored these patterns. The suppressed stratum exhibited higher procedural proportions (Surgery only 47.1%, Surgery+RT 36.4%) but reflects data redaction rather than a policy-based phenomenon.",
        "Conclusions": "Across nearly two decades of NCDB data, Medicaid expansion status was consistently associated with both the facility type accessed and the composition of initial treatment for tongue/oral cavity carcinoma. Expansion states, particularly early adopters, demonstrated a higher proportion of care delivered at Academic/Research centers and a shift toward combined-modality surgical management. These findings suggest that insurance policy shapes structural access to subspecialty care in head and neck oncology. Future analyses incorporating stage, comorbidity, and socioeconomic covariates, as well as facility-level random effects, are needed to determine whether Medicaid expansion exerts an independent effect on treatment patterns beyond case-mix and regional practice norms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Medicaid Expansion and Care Pathways in Oral Cavity Squamous Cell Carcinoma: An NCDB Study (2004–2022)</span>. Wesley L Hicks Jr, MD; Alex Vaicius, MD; William J Magner, PhD; Kimberly E Wooten, MD; Jenny Romero, MD; Anurag K Singh, MD; <u>Vishal Gupta, MD</u>. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Medicaid expansion under the Affordable Care Act has altered insurance coverage patterns across the United States, with potential downstream effects on access to specialized oncologic care. Tongue and oral cavity squamous cell carcinomas typically require coordinated multidisciplinary management, and receipt of definitive surgery and appropriate adjuvant therapy often depends on the capabilities of the treating institution. Whether state-level Medicaid expansion status is associated with differences in facility type or initial treatment selection in this disease has not been well characterized. Using the National Cancer Database (NCDB) 2022 Participant User File, we examined the relationship between Medicaid expansion status and early care pathways in a large, contemporary national cohort.</p>\n\n<p><strong>Methods: </strong>Adults aged ≥18-years diagnosed with invasive tongue/oral cavity carcinoma between 2004 and 2022 were identified from the NCDB Tongue PUF. The exposure of interest was the NCDB Medicaid Expansion Code, categorized as: non-expansion, January-2014 expansion, late expansion, other/territorial, or suppressed. Outcomes included (1) facility type, grouped as Community, Comprehensive Community, Academic/Research, or Integrated Network Cancer Programs; and (2) initial treatment pattern, reconstructed using standardized NCDB summary treatment fields, sequencing variables, and timing indicators. Treatment categories included Surgery only, Surgery+RT, Definitive chemoradiation (CRT), Definitive RT alone, Systemic-only therapy, and Other/None. All analyses were descriptive. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis. The authors take responsibility for the integrity and full biostatistical analyses will be verified prior to presentation.</p>\n\n<p><strong>Results: </strong>The analytic cohort consisted of 186,037 adults. Medicaid expansion status was distributed as follows: non-expansion 37.7%, January-2014 expansion 29.4%, late expansion 16.5%, other/territorial 13.0%, and suppressed 3.4%. Marked differences in facility type were observed across expansion categories. In non-expansion states, 45.5% of patients received treatment at Academic/Research centers, compared with 54.8% in January-2014 expansion states and 49.6% in late-expansion states; Comprehensive Community centers accounted for 31.7%, 24.1%, and 31.1%, respectively. Integrated Network and Community programs constituted smaller shares across all groups.</p>\n\n<p>Among non-expansion states, Surgery only comprised 30.4% of cases, Surgery+RT 19.0%, CRT 33.6%, RT-only 5.4%, Systemic-only 3.9%, and Other/None 7.8%. In January-2014 expansion states, proportions were 30.7%, 21.5%, 33.6%, 4.8%, 2.8%, and 6.5%, respectively. Late-expansion states showed a similar distribution, with modestly higher Surgery+RT use (22.0%) and slightly lower CRT (31.8%). The other/territorial group mirrored these patterns. The suppressed stratum exhibited higher procedural proportions (Surgery only 47.1%, Surgery+RT 36.4%) but reflects data redaction rather than a policy-based phenomenon.</p>\n\n<p><strong>Conclusions: </strong>Across nearly two decades of NCDB data, Medicaid expansion status was consistently associated with both the facility type accessed and the composition of initial treatment for tongue/oral cavity carcinoma. Expansion states, particularly early adopters, demonstrated a higher proportion of care delivered at Academic/Research centers and a shift toward combined-modality surgical management. These findings suggest that insurance policy shapes structural access to subspecialty care in head and neck oncology. Future analyses incorporating stage, comorbidity, and socioeconomic covariates, as well as facility-level random effects, are needed to determine whether Medicaid expansion exerts an independent effect on treatment patterns beyond case-mix and regional practice norms.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155435--></body></html>"
    },
    {
      "uid": "P062",
      "content_id": "154348",
      "abstract_number": "P062",
      "poster_number": "P062",
      "title": "Patient Factors Associated with Same-Day Discharge versus Overnight Stay After Neck Dissection",
      "summary": "Patterns in patient characteristics indicated that current smoking status, diagnosis of SCC, and select comorbidities categories were more frequently associated with OS, leading to the conclusion that neck dissections can safely be done as outpatient procedures in the well-selected patient. The regression model further showed that risk factors such as cardiovascular, gastrointestinal, and certain other...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154348",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Pallavi Dutta",
      "presenter": "Pallavi Dutta",
      "authors": "Pallavi Dutta ; Natasha Cohen",
      "normalized_authors": [
        "Pallavi Dutta",
        "Natasha Cohen"
      ],
      "affiliations": [
        "Queen's University"
      ],
      "normalized_institutions": [
        "Queen's University"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Pallavi Dutta ; Natasha Cohen",
        "Affiliations": "Queen's University",
        "Background": "Head and neck cancers are reported to be the sixth most common type of cancer worldwide. With cervical metastases being an important prognosticating factor, neck dissections are a common procedure in the context of head and neck cancer. While neck dissections are generally considered major surgery, post-operative care has increasingly been deemed safe to deliver from home with appropriate supports. Oftentimes, current practice errs on keeping patients in hospital for overnight observation due to the post-operative complication risk of hematoma which has a less than 1% chance of occurring within the first 12-24h after a neck dissection surgery. However, with increasing pressures relating to resource management, exploring safe alternatives for post-operative care is important and some patients may be suitable for same day discharge. This study aimed to examine patient factors associated with overnight stay (OS) and same day discharge (SDD) after neck dissections.",
        "Methods": "We conducted a retrospective cohort study which included patients who underwent neck dissections at Kingston Health Sciences Centre between March 2020 and August 2024. Baseline demographic, patient factors including risk factors (smoking status, alcohol use, HPV status) and comorbidities were collected. Descriptive statistics and a logistic regression was performed to examine the impact of patient comorbidities based on pre-selected categories (including cardiovascular, pulmonary, endocrine, coagulopathies, immunosuppression, gastrointestinal and other) to identify factors associated with SDD and OS.",
        "Results": "A total of 219 patients were included in this study (Mean age=64, 69% male) with 29 SDD patients. Descriptive statistics of demographic data and risk factors demonstrated that in the SDD group, 3.4% were current smokers, versus 25.3% in OS group and were likely to be observed overnight (p-value<0.05). Patterns of baseline factors such as alcohol use, cannabis use, HPV status, sex, age, BMI and overall comorbidity status were not significantly different. In the SDD group, 39.3% of the patients has squamous cell carcinomas (SCC) while in the OS group 68% had SCC (p-value<0.05). A logistic regression model predicting SDD based on categories of comorbidities was statistically significant, X2 (8) = 39.23, p<0.01, indicating that the set of comorbidities variables reliably distinguished between SDD and OS. The model explained 30.5% of the variance in discharge status (Nagelkerke R2 = 0.305). Cardiovascular co-morbidities (OR=5.96, p<0.01), gastrointestinal co-morbidities (OR=4.04, p=0.012), and other comorbidities (OR=20.99, p=0.004) were significantly associated with increased odds of OS. The remainder of the co-morbidities did not reach statistical significance.",
        "Conclusions": "Patterns in patient characteristics indicated that current smoking status, diagnosis of SCC, and select comorbidities categories were more frequently associated with OS, leading to the conclusion that neck dissections can safely be done as outpatient procedures in the well-selected patient. The regression model further showed that risk factors such as cardiovascular, gastrointestinal, and certain other comorbidities significantly increased the likelihood of OS, underscoring the role of thorough assessment of a patient’s baseline medical complexity in guiding postoperative disposition in head and neck cancer care when neck dissections are required."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient Factors Associated with Same-Day Discharge versus Overnight Stay After Neck Dissection</span>. <u>Pallavi Dutta</u>; Natasha Cohen. Queen's University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancers are reported to be the sixth most common type of cancer worldwide. With cervical metastases being an important prognosticating factor, neck dissections are a common procedure in the context of head and neck cancer.  While neck dissections are generally considered major surgery, post-operative care has increasingly been deemed safe to deliver from home with appropriate supports. Oftentimes, current practice errs on keeping patients in hospital for overnight observation due to the post-operative complication risk of hematoma which has a less than 1% chance of occurring within the first 12-24h after a neck dissection surgery. However, with increasing pressures relating to resource management, exploring safe alternatives for post-operative care is important and some patients may be suitable for same day discharge. This study aimed to examine patient factors associated with overnight stay (OS) and same day discharge (SDD) after neck dissections.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study which included patients who underwent neck dissections at Kingston Health Sciences Centre between March 2020 and August 2024. Baseline demographic, patient factors including risk factors (smoking status, alcohol use, HPV status) and comorbidities were collected. Descriptive statistics and a logistic regression was performed to examine the impact of patient comorbidities based on pre-selected categories (including cardiovascular, pulmonary, endocrine, coagulopathies, immunosuppression, gastrointestinal and other) to identify factors associated with SDD and OS.  </p>\n\n<p><strong>Results:</strong> A total of 219 patients were included in this study (Mean age=64, 69% male) with 29 SDD patients. Descriptive statistics of demographic data and risk factors demonstrated that in the SDD group, 3.4% were current smokers, versus 25.3% in OS group and were likely to be observed overnight (p-value<0.05). Patterns of baseline factors such as alcohol use, cannabis use, HPV status, sex, age, BMI and overall comorbidity status were not significantly different. In the SDD group, 39.3% of the patients has squamous cell carcinomas (SCC) while in the OS group 68% had SCC (p-value<0.05). A logistic regression model predicting SDD based on categories of comorbidities was statistically significant, X2 (8) = 39.23, p<0.01, indicating that the set of comorbidities variables reliably distinguished between SDD and OS. The model explained 30.5% of the variance in discharge status (Nagelkerke R2 = 0.305). Cardiovascular co-morbidities (OR=5.96, p<0.01), gastrointestinal co-morbidities (OR=4.04, p=0.012), and other comorbidities (OR=20.99, p=0.004) were significantly associated with increased odds of OS. The remainder of the co-morbidities did not reach statistical significance.</p>\n\n<p><strong>Conclusions: </strong>Patterns in patient characteristics indicated that current smoking status, diagnosis of SCC, and select comorbidities categories were more frequently associated with OS, leading to the conclusion that neck dissections can safely be done as outpatient procedures in the well-selected patient. The regression model further showed that risk factors such as cardiovascular, gastrointestinal, and certain other comorbidities significantly increased the likelihood of OS, underscoring the role of thorough assessment of a patient’s baseline medical complexity in guiding postoperative disposition in head and neck cancer care when neck dissections are required.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154348--></body></html>"
    },
    {
      "uid": "P063",
      "content_id": "154243",
      "abstract_number": "P063",
      "poster_number": "P063",
      "title": "Drivers of Phase 3 Supportive Care Clinical Trial Failure in Oncology: A Matched Comparative Analysis",
      "summary": "Across Phase 3 supportive care oncology trials, including a distinct subset in head and neck cancer, recruitment is the primary barrier to completion. Unlike treatment trials, which often fail due to industry driven strategic shifts, supportive care trials fail primarily due to structural constraints of smaller, non-industry funded studies. These findings underscore a critical need for improved accrual planning,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154243",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Janice Huang",
      "presenter": "Janice Huang",
      "authors": "Janice Huang ; Alex Reznik; Elizabeth Franzmann, MD",
      "normalized_authors": [
        "Janice Huang",
        "Alex Reznik",
        "Elizabeth Franzmann"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 359,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Janice Huang ; Alex Reznik; Elizabeth Franzmann, MD",
        "Affiliations": "University of Miami Miller School of Medicine",
        "Background": "Supportive care interventions are essential for mitigating treatment related toxicities, particularly in multimodal head and neck cancer therapy. However, late phase supportive care trials frequently fail to reach completion. The specific determinants of these failures remain poorly defined, particularly when compared with completed supportive care trials and with the broader landscape of failed oncology treatment trials.",
        "Methods": "We identified Phase 3 supportive care trials on ClinicalTrials.gov that were terminated or withdrawn (“failed”) and manually classified failure reasons into six categories: administrative, efficacy, nonreported, recruitment, safety, and sponsor/funding. Patterns of failure were characterized across cancer types, with a subgroup analysis for head and neck cancer. Findings were validated using two matched cohorts: (1) completed vs failed supportive care trials (Cohort 1), and (2) a case control comparison of failed supportive care vs failed treatment focused trials (Cohort 2).",
        "Results": "We identified 48 Phase 3 failed supportive care trials. Recruitment/enrollment was the leading driver of failure, representing the most common failure mode in other solid tumors (n=12), hematologic malignancies (n=2), and head and neck cancer (2 of 6 failures). In the matched completion analysis (Cohort 1), failed supportive care trials were significantly characterized by smaller planned enrollment (OR 0.37, p < 0.001) compared to completed trials. In the case control analysis (Cohort 2), failed supportive care trials were distinct from failed treatment trials: they were overwhelmingly non-industry funded (92% vs 31%; p < 0.001), significantly smaller (median log enrollment 2.6 vs 3.7; p = 0.013), and more likely to use blinded designs (67% vs 42%; p = 0.03). Reflecting this funding difference, supportive care failures were driven by structural recruitment barriers common in academic research, whereas treatment failures frequently involved industry sponsored studies.",
        "Conclusions": "Across Phase 3 supportive care oncology trials, including a distinct subset in head and neck cancer, recruitment is the primary barrier to completion. Unlike treatment trials, which often fail due to industry driven strategic shifts, supportive care trials fail primarily due to structural constraints of smaller, non-industry funded studies. These findings underscore a critical need for improved accrual planning, streamlined eligibility, and enhanced site engagement to ensure rigorous evaluation of toxicity-mitigating interventions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Drivers of Phase 3 Supportive Care Clinical Trial Failure in Oncology: A Matched Comparative Analysis</span>. <u>Janice Huang</u>; Alex Reznik; Elizabeth Franzmann, MD. University of Miami Miller School of Medicine <hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Supportive care interventions are essential for mitigating treatment related toxicities, particularly in multimodal head and neck cancer therapy. However, late phase supportive care trials frequently fail to reach completion. The specific determinants of these failures remain poorly defined, particularly when compared with completed supportive care trials and with the broader landscape of failed oncology treatment trials.</p>\n\n<p><strong>Methods: </strong>We identified Phase 3 supportive care trials on ClinicalTrials.gov that were terminated or withdrawn (“failed”) and manually classified failure reasons into six categories: administrative, efficacy, nonreported, recruitment, safety, and sponsor/funding. Patterns of failure were characterized across cancer types, with a subgroup analysis for head and neck cancer. Findings were validated using two matched cohorts: (1) completed vs failed supportive care trials (Cohort 1), and (2) a case control comparison of failed supportive care vs failed treatment focused trials (Cohort 2).</p>\n\n<p><strong>Results: </strong>We identified 48 Phase 3 failed supportive care trials. Recruitment/enrollment was the leading driver of failure, representing the most common failure mode in other solid tumors (n=12), hematologic malignancies (n=2), and head and neck cancer (2 of 6 failures). In the matched completion analysis (Cohort 1), failed supportive care trials were significantly characterized by smaller planned enrollment (OR 0.37, p < 0.001) compared to completed trials. In the case control analysis (Cohort 2), failed supportive care trials were distinct from failed treatment trials: they were overwhelmingly non-industry funded (92% vs 31%; p < 0.001), significantly smaller (median log enrollment 2.6 vs 3.7; p = 0.013), and more likely to use blinded designs (67% vs 42%; p = 0.03). Reflecting this funding difference, supportive care failures were driven by structural recruitment barriers common in academic research, whereas treatment failures frequently involved industry sponsored studies.</p>\n\n<p><strong>Conclusions: </strong>Across Phase 3 supportive care oncology trials, including a distinct subset in head and neck cancer, recruitment is the primary barrier to completion. Unlike treatment trials, which often fail due to industry driven strategic shifts, supportive care trials fail primarily due to structural constraints of smaller, non-industry funded studies. These findings underscore a critical need for improved accrual planning, streamlined eligibility, and enhanced site engagement to ensure rigorous evaluation of toxicity-mitigating interventions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154243--></body></html>"
    },
    {
      "uid": "P064",
      "content_id": "153660",
      "abstract_number": "P064",
      "poster_number": "P064",
      "title": "Who Goes Home? Predicting Non-Home Discharge After Neck Dissection",
      "summary": "Among 1,865 patients undergoing ND, 94.9% were discharged home, and 5.1% required non-home discharge. After excluding cases with missing data, 1,616 patients were analyzed, including 89 (5.5%) non-home discharges. Patients requiring facility-based discharge were older (mean 69.4 vs. 57.2 years), had lower BMI, and demonstrated a higher prevalence of comorbidities such as diabetes, COPD, peripheral vascular...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153660",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jazlyn A Selvasingh, BA",
      "presenter": "Jazlyn A Selvasingh, BA",
      "authors": "Jazlyn A Selvasingh, BA ; Taral K Jella, BA; Madelyn A Krueger, BS; Tara P Menon, BS; Justin R Shinn, MD; William P Magdycz, MD",
      "normalized_authors": [
        "Jazlyn A Selvasingh",
        "Taral K Jella",
        "Madelyn A Krueger",
        "Tara P Menon",
        "Justin R Shinn",
        "William P Magdycz"
      ],
      "affiliations": [
        "Virginia Tech Carilion School of Medicine"
      ],
      "normalized_institutions": [
        "Virginia Tech Carilion School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Jazlyn A Selvasingh, BA ; Taral K Jella, BA; Madelyn A Krueger, BS; Tara P Menon, BS; Justin R Shinn, MD; William P Magdycz, MD",
        "Affiliations": "Virginia Tech Carilion School of Medicine",
        "Introduction": "Head and neck cancers involving the oral cavity, pharynx, and larynx represent a substantial and rising oncologic burden in the United States, driven by persistent tobacco and alcohol use and increasing rates of HPV. Cervical neck dissection (ND) remains a fundamental procedure for staging and treating these malignancies. Discharge disposition following surgery is an important indicator of functional recovery and postoperative support needs, with non-home discharge associated with delays in adjuvant therapy and greater healthcare utilization. However, existing studies often group ND with ablative or reconstructive procedures, limiting insight into predictors specific to cervical node dissections. This study uses a national surgical registry to identify demographic, clinical, and perioperative factors associated with non-home discharge following ND.",
        "Methods": "A retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) from 2011–2021. Adult patients undergoing ND were identified using CPT codes. Cases with missing or non-classifiable discharge disposition were excluded. The primary outcome was non-home discharge, defined as discharge to a skilled nursing facility, inpatient rehabilitation facility, or long-term acute care hospital. Home discharge included discharge to home with or without home-health services. Preoperative demographic and clinical characteristics, comorbidities, operative time, and procedure setting were abstracted. A multivariable logistic regression model identified independent predictors of non-home discharge. Continuous predictors were scaled (age per 10 years, BMI per 5 kg/m², operative time per 30 minutes). Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were reported, and model performance was assessed with area under the receiver operating characteristic curve (AUC).",
        "Results": "Among 1,865 patients undergoing ND, 94.9% were discharged home, and 5.1% required non-home discharge. After excluding cases with missing data, 1,616 patients were analyzed, including 89 (5.5%) non-home discharges. Patients requiring facility-based discharge were older (mean 69.4 vs. 57.2 years), had lower BMI, and demonstrated a higher prevalence of comorbidities such as diabetes, COPD, peripheral vascular disease, and chronic steroid use. In multivariable analysis (AUC = 0.8689, p < 0.001), increasing age (aOR 1.78 per decade, 95% CI 1.43–2.21), longer operative time (aOR 1.10 per 30 minutes, 95% CI 1.07–1.14), lower BMI (aOR 0.62 per 5 units, 95% CI 0.49–0.79), diabetes (aOR 2.54, 95% CI 1.42–4.55), COPD (aOR 2.61, 95% CI 1.39–4.89), and chronic steroid use (aOR 3.14, 95% CI 1.29–7.63) were independently associated with non-home discharge.",
        "Discussion": "This national analysis identifies several demographic, clinical, and operative predictors of non-home discharge following ND. Age, operative duration, frailty-related comorbidities, and chronic steroid exposure significantly increased the likelihood of requiring facility-based postoperative care, while higher BMI was protective. These findings indicate valuable factors for risk stratification in patients, particularly those with greater medical complexity or of advanced age, undergoing ND. Incorporating these predictors into perioperative workflows and early rehabilitation planning may reduce care delays, optimize resource use, and support timely initiation of adjuvant therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Who Goes Home? Predicting Non-Home Discharge After Neck Dissection</span>. <u>Jazlyn A Selvasingh, BA</u>; Taral K Jella, BA; Madelyn A Krueger, BS; Tara P Menon, BS; Justin R Shinn, MD; William P Magdycz, MD. Virginia Tech Carilion School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancers involving the oral cavity, pharynx, and larynx represent a substantial and rising oncologic burden in the United States, driven by persistent tobacco and alcohol use and increasing rates of HPV. Cervical neck dissection (ND) remains a fundamental procedure for staging and treating these malignancies. Discharge disposition following surgery is an important indicator of functional recovery and postoperative support needs, with non-home discharge associated with delays in adjuvant therapy and greater healthcare utilization. However, existing studies often group ND with ablative or reconstructive procedures, limiting insight into predictors specific to cervical node dissections. This study uses a national surgical registry to identify demographic, clinical, and perioperative factors associated with non-home discharge following ND.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) from 2011–2021. Adult patients undergoing ND were identified using CPT codes. Cases with missing or non-classifiable discharge disposition were excluded. The primary outcome was non-home discharge, defined as discharge to a skilled nursing facility, inpatient rehabilitation facility, or long-term acute care hospital. Home discharge included discharge to home with or without home-health services. Preoperative demographic and clinical characteristics, comorbidities, operative time, and procedure setting were abstracted. A multivariable logistic regression model identified independent predictors of non-home discharge. Continuous predictors were scaled (age per 10 years, BMI per 5 kg/m², operative time per 30 minutes). Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were reported, and model performance was assessed with area under the receiver operating characteristic curve (AUC).</p>\n\n<p><strong>Results: </strong>Among 1,865 patients undergoing ND, 94.9% were discharged home, and 5.1% required non-home discharge. After excluding cases with missing data, 1,616 patients were analyzed, including 89 (5.5%) non-home discharges. Patients requiring facility-based discharge were older (mean 69.4 vs. 57.2 years), had lower BMI, and demonstrated a higher prevalence of comorbidities such as diabetes, COPD, peripheral vascular disease, and chronic steroid use. In multivariable analysis (AUC = 0.8689, p < 0.001), increasing age (aOR 1.78 per decade, 95% CI 1.43–2.21), longer operative time (aOR 1.10 per 30 minutes, 95% CI 1.07–1.14), lower BMI (aOR 0.62 per 5 units, 95% CI 0.49–0.79), diabetes (aOR 2.54, 95% CI 1.42–4.55), COPD (aOR 2.61, 95% CI 1.39–4.89), and chronic steroid use (aOR 3.14, 95% CI 1.29–7.63) were independently associated with non-home discharge.</p>\n\n<p><strong>Discussion: </strong>This national analysis identifies several demographic, clinical, and operative predictors of non-home discharge following ND. Age, operative duration, frailty-related comorbidities, and chronic steroid exposure significantly increased the likelihood of requiring facility-based postoperative care, while higher BMI was protective. These findings indicate valuable factors for risk stratification in patients, particularly those with greater medical complexity or of advanced age, undergoing ND. Incorporating these predictors into perioperative workflows and early rehabilitation planning may reduce care delays, optimize resource use, and support timely initiation of adjuvant therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153660--></body></html>"
    },
    {
      "uid": "P065",
      "content_id": "153695",
      "abstract_number": "P065",
      "poster_number": "P065",
      "title": "Early Assessment of A Quality Improvement Initiative to Reduce Time to Treatment for Veterans with Head and Neck Cancer",
      "summary": "This QI initiative highlighted specific strategies to reduce delays. After implementing these QI interventions we will use control charts to monitor for statistically significant reductions in delays. This QI project may serve as a blueprint for other VAMCs to reduce time to treatment with cost free interventions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153695",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maxwell P Kligerman",
      "presenter": "Maxwell P Kligerman",
      "authors": "Maxwell P Kligerman ; Celeste Kim, MD; George Daoud, MD; Luke Galloway; Kathryn Hardin, MD; Oliver Liu, MD; Shelley Machuta, MD; Badi El Osta, MD; Nathaniel Neptune, MD; Emerson Bouldin, MD; Hope Iyiewuare, MD; Shubham Patel, MD; Mitesh Mehta, MD; Alex Abdollahzadeh; Norman Lester; Robert Soriano, MD; Yanhua Wang, PhD; Merry Sebelik, MD; Carrie P Flanagan, MD",
      "normalized_authors": [
        "Maxwell P Kligerman",
        "Celeste Kim",
        "George Daoud",
        "Luke Galloway",
        "Kathryn Hardin",
        "Oliver Liu",
        "Shelley Machuta",
        "Badi El Osta",
        "Nathaniel Neptune",
        "Emerson Bouldin",
        "Hope Iyiewuare",
        "Shubham Patel",
        "Mitesh Mehta",
        "Alex Abdollahzadeh",
        "Norman Lester",
        "Robert Soriano",
        "Yanhua Wang",
        "Merry Sebelik",
        "Carrie P Flanagan"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153695/Figure%201.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153695/Figure%201.jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153695"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153695/figure%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153695/figure%202.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153695"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153695/Table%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153695/Table%201.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153695"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Maxwell P Kligerman ; Celeste Kim, MD; George Daoud, MD; Luke Galloway; Kathryn Hardin, MD; Oliver Liu, MD; Shelley Machuta, MD; Badi El Osta, MD; Nathaniel Neptune, MD; Emerson Bouldin, MD; Hope Iyiewuare, MD; Shubham Patel, MD; Mitesh Mehta, MD; Alex Abdollahzadeh; Norman Lester; Robert Soriano, MD; Yanhua Wang, PhD; Merry Sebelik, MD; Carrie P Flanagan, MD",
        "Affiliations": "Emory University",
        "Background": "Delays in treatment of head and neck cancer (HNC) are directly associated with worse survival and functional outcomes. Patients with HNC at our 466-bed tertiary care Veteran’s Affairs Medical Center (VAMC) anecdotally face long wait times from diagnosis to treatment initiation; however, there is limited data to contextualize this claim. This quality improvement (QI) initiative aimed to 1) quantify the time from diagnosis to treatment for patients with HNC at our VAMC, 2) identify root causes of delays in time to treatment, and 3) propose cost-free interventions that would target these root causes of delay.",
        "Methods": "We performed a mixed-methods problem analysis in accordance with standard QI principles. A retrospective review of the electronic medical record was performed to quantify the number of days from diagnosis to initiation of treatment. Inclusion criteria were veterans diagnosed at a single tertiary care VAMC with mucosal or advanced cutaneous HNC between 2014 and 2023. Quantitative data was analyzed with descriptive statistics and control charts. Patients with time to treatment > 90 days were reviewed in detail with a Pareto analysis to identify specific factors contributing to the delay. Qualitative analysis was performed via semi-structured interviews with key stakeholders. Interview summaries were coded and then inductive thematic analysis was performed. Lastly, cause-and-effect brainstorming was performed with key stake holders using the above results to propose targeted, no-cost interventions.",
        "Results": "There were 214 patients that met inclusion criteria. Median time to treatment was 55 days. Figure 1 demonstrates time to treatment per quarter. Of all patients, 16% (n=34) had time to treatment >90 days. The most frequently identified contributing factors in the Pareto analysis were community care referrals (79%, n=27), social determinants of health (26%, n=9), and the veteran’s own decision to temporarily pause treatment (26%, n=9). Inductive thematic analysis highlighted six distinct themes contributing to delays including: 1) varying perceptions of timely treatment amongst members of the treatment team; 2) lack of transparency regarding the status of individual patients during the treatment pathway; 3) fragmentation of patient care due to community care referrals; 4) patient difficulty independently coordinating multidisciplinary care; 5) untimely pre-treatment appointments; 6) staffing shortages. Key stake holders selected four initial interventions targeting these root causes of delay: a) selecting an evidenced-based and shared goal for time to treatment across all service lines and tracking success in meeting this goal; b) performing social work screening and psycho-oncology screening for all newly diagnosed HNC patients; c) providing a community care training update across services lines; d) utilizing a patient treatment tracker to provide updates at weekly tumor board for all HNC patients with pending treatment.",
        "Conclusion": "This QI initiative highlighted specific strategies to reduce delays. After implementing these QI interventions we will use control charts to monitor for statistically significant reductions in delays. This QI project may serve as a blueprint for other VAMCs to reduce time to treatment with cost free interventions.",
        "Abstract": "Figure 1: Figure 2: Table 1:"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Assessment of A Quality Improvement Initiative to Reduce Time to Treatment for Veterans with Head and Neck Cancer</span>. <u>Maxwell P Kligerman</u>; Celeste Kim, MD; George Daoud, MD; Luke Galloway; Kathryn Hardin, MD; Oliver Liu, MD; Shelley Machuta, MD; Badi El Osta, MD; Nathaniel Neptune, MD; Emerson Bouldin, MD; Hope Iyiewuare, MD; Shubham Patel, MD; Mitesh Mehta, MD; Alex Abdollahzadeh; Norman Lester; Robert Soriano, MD; Yanhua Wang, PhD; Merry Sebelik, MD; Carrie P Flanagan, MD. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Delays in treatment of head and neck cancer (HNC) are directly associated with worse survival and functional outcomes. Patients with HNC at our 466-bed tertiary care Veteran’s Affairs Medical Center (VAMC) anecdotally face long wait times from diagnosis to treatment initiation; however, there is limited data to contextualize this claim. This quality improvement (QI) initiative aimed to 1) quantify the time from diagnosis to treatment for patients with HNC at our VAMC, 2) identify root causes of delays in time to treatment, and 3) propose cost-free interventions that would target these root causes of delay.</p>\n\n<p><strong>Methods: </strong>We performed a mixed-methods problem analysis in accordance with standard QI principles. A retrospective review of the electronic medical record was performed to quantify the number of days from diagnosis to initiation of treatment. Inclusion criteria were veterans diagnosed at a single tertiary care VAMC with mucosal or advanced cutaneous HNC between 2014 and 2023. Quantitative data was analyzed with descriptive statistics and control charts. Patients with time to treatment > 90 days were reviewed in detail with a Pareto analysis to identify specific factors contributing to the delay. Qualitative analysis was performed via semi-structured interviews with key stakeholders. Interview summaries were coded and then inductive thematic analysis was performed. Lastly, cause-and-effect brainstorming was performed with key stake holders using the above results to propose targeted, no-cost interventions.</p>\n\n<p><strong>Results: </strong>There were 214 patients that met inclusion criteria. Median time to treatment was 55 days. Figure 1 demonstrates time to treatment per quarter. Of all patients, 16% (n=34) had time to treatment >90 days. The most frequently identified contributing factors in the Pareto analysis were community care referrals (79%, n=27), social determinants of health (26%, n=9), and the veteran’s own decision to temporarily pause treatment (26%, n=9). Inductive thematic analysis highlighted six distinct themes contributing to delays including: 1) varying perceptions of timely treatment amongst members of the treatment team; 2) lack of transparency regarding the status of individual patients during the treatment pathway; 3) fragmentation of patient care due to community care referrals; 4) patient difficulty independently coordinating multidisciplinary care; 5) untimely pre-treatment appointments; 6) staffing shortages. Key stake holders selected four initial interventions targeting these root causes of delay: a) selecting an evidenced-based and shared goal for time to treatment across all service lines and tracking success in meeting this goal; b) performing social work screening and psycho-oncology screening for all newly diagnosed HNC patients; c) providing a community care training update across services lines; d) utilizing a patient treatment tracker to provide updates at weekly tumor board for all HNC patients with pending treatment.</p>\n\n<p><strong>Conclusion: </strong>This QI initiative highlighted specific strategies to reduce delays. After implementing these QI interventions we will use control charts to monitor for statistically significant reductions in delays. This QI project may serve as a blueprint for other VAMCs to reduce time to treatment with cost free interventions.</p>\n\n<p>Figure 1:</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153695/Figure%201.jpeg' /></p>\n\n<p>Figure 2:</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153695/figure%202.jpg' /></p>\n\n<p>Table 1:</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153695/Table%201.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153695--></body></html>"
    },
    {
      "uid": "P066",
      "content_id": "154216",
      "abstract_number": "P066",
      "poster_number": "P066",
      "title": "Management Patterns and Predictors of Non-Diagnostic In-Office FNA for Head and Neck Masses",
      "summary": "Non-diagnostic FNA biopsies remain a challenge in the evaluation and workup of head and neck masses. Management decisions should be guided by patient history, clinical context, and lesion characteristics. In selected cases, triage to settings with on-site cytology or deferring to excisional biopsy may be appropriate to improve adequacy. The observed variability in subsequent management of non-diagnostic results...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154216",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Randy W Lesh, MD",
      "presenter": "Randy W Lesh, MD",
      "authors": "Randy W Lesh, MD 1 ; Ellen P Penn, MD 1 ; Timothy L Lindemann, MD 1 ; Sara E Monaco, MD 1 ; Nicholas C Purdy, DO 1 ; Kevin J Kovatch, MD 2",
      "normalized_authors": [
        "Randy W Lesh",
        "Ellen P Penn",
        "Timothy L Lindemann",
        "Sara E Monaco",
        "Nicholas C Purdy",
        "Kevin J Kovatch"
      ],
      "affiliations": [
        "Geisinger Health System",
        "UConn Health"
      ],
      "normalized_institutions": [
        "Geisinger Health System",
        "UConn Health"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 366,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Randy W Lesh, MD 1 ; Ellen P Penn, MD 1 ; Timothy L Lindemann, MD 1 ; Sara E Monaco, MD 1 ; Nicholas C Purdy, DO 1 ; Kevin J Kovatch, MD 2",
        "Affiliations": "1 Geisinger Health System; 2 UConn Health",
        "Background": "In-office fine needle aspiration (FNA) biopsy performed by Otolaryngologists offers an efficient, accessible approach for evaluating head and neck masses. However, non-diagnostic results remain a clinical challenge and require thoughtful management to avoid delays in diagnosis. This study characterizes incidence, contributing factors, and subsequent management of non-diagnostic in-office FNAs.",
        "Methods": "A retrospective review was performed on all in-office FNAs of thyroid, parotid, and other neck masses completed from 2021–2025 at two clinical sites. Cases resulting in non-diagnostic cytology were identified, and patient-, lesion-, and management-related variables were analyzed.",
        "Results": "Of 419 total FNA biopsies, 65 (15.5%) were non-diagnostic, subsite-specific rates of 11.0% (29/255) for thyroid, 34.8% (24.69) for salivary gland, and 13.7% (13/95) for other neck masses. Cystic parotid masses accounted for the highest proportion of non-diagnostic biopsies. In 52.3% of cases, procedural documentation noted predisposing factors for a non-diagnostic result, including predominantly cystic or necrotic lesions, heavily calcified nodules, prior non-diagnostic biopsy, limited patient tolerance, or technical difficulty. Repeat FNA or core needle biopsy was recommended in 43.1% of cases; 72.7% of repeat FNA biopsies yielded diagnostic results. Core biopsy was chosen for selected cases (e.g., necrotic neck masses) where repeat FNA was felt less likely to be adequate. Observation, with or without interval imaging, was selected in 30.7% of cases. Surgical intervention was pursued in 26.2% of cases.",
        "Conclusion": "Non-diagnostic FNA biopsies remain a challenge in the evaluation and workup of head and neck masses. Management decisions should be guided by patient history, clinical context, and lesion characteristics. In selected cases, triage to settings with on-site cytology or deferring to excisional biopsy may be appropriate to improve adequacy. The observed variability in subsequent management of non-diagnostic results reflects a tailored, patient-centered approach. Clinicians identified and documented pre-procedural concern for a non-diagnostic result with fair predictive accuracy. Ongoing work focuses on (1) refining technique and workflow to improve diagnostic yield and (2) identifying objective patient and lesion factors that predict non-diagnostic results, with the aim of establishing evidence-based guidance for triage of FNAs to settings with on-site cytology versus acceptable transition to either observation (lower risk lesions) or core/excisional biopsy (higher risk lesions)."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Management Patterns and Predictors of Non-Diagnostic In-Office FNA for Head and Neck Masses</span>. <u>Randy W Lesh, MD</u><sup>1</sup>; Ellen P Penn, MD<sup>1</sup>; Timothy L Lindemann, MD<sup>1</sup>; Sara E Monaco, MD<sup>1</sup>; Nicholas C Purdy, DO<sup>1</sup>; Kevin J Kovatch, MD<sup>2</sup>. <sup>1</sup>Geisinger Health System; <sup>2</sup>UConn Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> In-office fine needle aspiration (FNA) biopsy performed by Otolaryngologists offers an efficient, accessible approach for evaluating head and neck masses. However, non-diagnostic results remain a clinical challenge and require thoughtful management to avoid delays in diagnosis. This study characterizes incidence, contributing factors, and subsequent management of non-diagnostic in-office FNAs.</p>\n\n<p><strong>Methods: </strong>A retrospective review was performed on all in-office FNAs of thyroid, parotid, and other neck masses completed from 2021–2025 at two clinical sites. Cases resulting in non-diagnostic cytology were identified, and patient-, lesion-, and management-related variables were analyzed.</p>\n\n<p><strong>Results: </strong>Of 419 total FNA biopsies, 65 (15.5%) were non-diagnostic, subsite-specific rates of 11.0% (29/255) for thyroid, 34.8% (24.69) for salivary gland, and 13.7% (13/95) for other neck masses. Cystic parotid masses accounted for the highest proportion of non-diagnostic biopsies.  In 52.3% of cases, procedural documentation noted predisposing factors for a non-diagnostic result, including predominantly cystic or necrotic lesions, heavily calcified nodules, prior non-diagnostic biopsy, limited patient tolerance, or technical difficulty. Repeat FNA or core needle biopsy was recommended in 43.1% of cases; 72.7% of repeat FNA biopsies yielded diagnostic results.  Core biopsy was chosen for selected cases (e.g., necrotic neck masses) where repeat FNA was felt less likely to be adequate. Observation, with or without interval imaging, was selected in 30.7% of cases. Surgical intervention was pursued in 26.2% of cases.</p>\n\n<p><strong>Conclusion: </strong>Non-diagnostic FNA biopsies remain a challenge in the evaluation and workup of head and neck masses. Management decisions should be guided by patient history, clinical context, and lesion characteristics. In selected cases, triage to settings with on-site cytology or deferring to excisional biopsy may be appropriate to improve adequacy. The observed variability in subsequent management of non-diagnostic results reflects a tailored, patient-centered approach. Clinicians identified and documented pre-procedural concern for a non-diagnostic result with fair predictive accuracy. Ongoing work focuses on (1) refining technique and workflow to improve diagnostic yield and (2) identifying objective patient and lesion factors that predict non-diagnostic results, with the aim of establishing evidence-based guidance for triage of FNAs to settings with on-site cytology versus acceptable transition to either observation (lower risk lesions) or core/excisional biopsy (higher risk lesions). </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154216--></body></html>"
    },
    {
      "uid": "P067",
      "content_id": "154199",
      "abstract_number": "P067",
      "poster_number": "P067",
      "title": "Mandibular Osteotomy for Carotid Body Tumor Excision: First Pediatric Case and Comparative Review of Adult Outcomes",
      "summary": "Pediatric CBTs, though rare, warrant thorough evaluation for hereditary predisposition and long-term follow-up. While mandibular osteotomy is a recognized surgical adjunct for challenging adult cases, its use in children has not been reported. This highlights a critical gap in literature and an area for further study. Documentation of surgical approaches and outcomes in pediatric CBTs—including when advanced...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154199",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joseph Lopez, MD, MBA",
      "presenter": "Joseph Lopez, MD, MBA",
      "authors": "Gabriela Cendejas, MS; Maria J Polania-Sandoval, MD; Kian Tartibi, MBA; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Gabriela Cendejas",
        "Maria J Polania-Sandoval",
        "Kian Tartibi",
        "Joseph Lopez"
      ],
      "affiliations": [
        "AdventHealth Orlando"
      ],
      "normalized_institutions": [
        "AdventHealth Orlando"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods/Case Report",
        "SDHB mutation",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Gabriela Cendejas, MS; Maria J Polania-Sandoval, MD; Kian Tartibi, MBA; Joseph Lopez, MD, MBA",
        "Affiliations": "AdventHealth Orlando",
        "Purpose": "Carotid body tumors (CBTs) are rare neuroendocrine neoplasms derived from paraganglionic tissue at the carotid bifurcation. While well-described in adults, pediatric CBTs are rare. Up to 40–50% have been found to be associated with hereditary syndromes, most often involving SDHx mutations. Pediatric presentations raise unique diagnostic and management challenges, particularly regarding genetic risk and long-term surveillance and outcomes. Here we present the first documented case of mandibular osteotomy in the treatment of a CBT in a child and review comparative adult outcomes in the literature.",
        "Methods/Case Report": "A 14-year-old boy presented with a right-sided neck swelling noted incidentally on ultrasound (US). Repeat US and CT angiography demonstrated a 5.4 × 3.2 × 6.4 cm hypervascular lesion displacing the internal and external carotid arteries, consistent with a Shamblin II carotid body tumor.",
        "SDHB mutation": "as asymptomatic, with no cranial neuropathies or catecholamine-related symptoms. Family history was notable for paragangliomas in his father (abdominal) and paternal grandmother (neck). Genetic testing confirmed a pathogenic SDHB mutation , establishing a hereditary paraganglioma–pheochromocytoma syndrome.",
        "Abstract": "Given the known indolent behavior of CBTs, close observation was initially elected. However, surgical intervention was later pursued due to documented interval growth (3 mm increase on repeat imaging), recent genetic testing that revealed increased risk of malignancy and metastasis with a SDHB mutation, as well as evidence of a new lesion in the sacrum. Preoperative planning included a balloon occlusion test and consideration of arterial embolization. The patient successfully underwent a three-part procedure that consisted of a superficial parotidectomy, IR embolization, and tumor excision via mandibular osteotomy to optimize access and exposure. Patient remained clinically stable at follow-up one month later and will continue to be monitored for dysphagia.",
        "Results": "In adults, surgery occasionally necessitates approaches such as mandibulotomy or mandibular osteotomy for adequate exposure of tumors extending to the skull base or parapharyngeal space. These approaches provide excellent surgical access but carry risks of malocclusion, mandibular nonunion, osteomyelitis, and cranial nerve injury. Current evidence shows that mandibular osteotomy in pediatric CBT surgery remains undocumented. A recent systematic review by Alanezi et al. (2024) of 29 cases reported gross surgical resection as the preferred treatment, with none involving mandibular osteotomy. Surgical resection remains the standard of care, often preceded by preoperative embolization. The absence of pediatric reports underscores both the rarity of the tumor and hesitancy to use mandibulotomy. To our knowledge, this represents the first documented pediatric use of a mandibular osteotomy for CBT excision.",
        "Conclusion": "Pediatric CBTs, though rare, warrant thorough evaluation for hereditary predisposition and long-term follow-up. While mandibular osteotomy is a recognized surgical adjunct for challenging adult cases, its use in children has not been reported. This highlights a critical gap in literature and an area for further study. Documentation of surgical approaches and outcomes in pediatric CBTs—including when advanced access techniques are necessary—will be essential for informing future management guidelines. Combining adult outcome data with this first pediatric case helps define risks and guide future surgical decision-making."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mandibular Osteotomy for Carotid Body Tumor Excision: First Pediatric Case and Comparative Review of Adult Outcomes</span>. Gabriela Cendejas, MS; Maria J Polania-Sandoval, MD; Kian Tartibi, MBA; <u>Joseph Lopez, MD, MBA</u>. AdventHealth Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Carotid body tumors (CBTs) are rare neuroendocrine neoplasms derived from paraganglionic tissue at the carotid bifurcation. While well-described in adults, pediatric CBTs are rare. Up to 40–50% have been found to be associated with hereditary syndromes, most often involving SDHx mutations. Pediatric presentations raise unique diagnostic and management challenges, particularly regarding genetic risk and long-term surveillance and outcomes. Here we present the first documented case of mandibular osteotomy in the treatment of a CBT in a child and review comparative adult outcomes in the literature.</p>\n\n<p><strong>Methods/Case Report: </strong>A 14-year-old boy presented with a right-sided neck swelling noted incidentally on ultrasound (US). Repeat US and CT angiography demonstrated a 5.4 × 3.2 × 6.4 cm hypervascular lesion displacing the internal and external carotid arteries, consistent with a Shamblin II carotid body tumor.</p>\n\n<p>The patient was asymptomatic, with no cranial neuropathies or catecholamine-related symptoms. Family history was notable for paragangliomas in his father (abdominal) and paternal grandmother (neck). Genetic testing confirmed a pathogenic <strong>SDHB mutation</strong>, establishing a hereditary paraganglioma–pheochromocytoma syndrome.</p>\n\n<p>Given the known indolent behavior of CBTs, close observation was initially elected. However, surgical intervention was later pursued due to documented interval growth (3 mm increase on repeat imaging), recent genetic testing that revealed increased risk of malignancy and metastasis with a SDHB mutation, as well as evidence of a new lesion in the sacrum. Preoperative planning included a balloon occlusion test and consideration of arterial embolization. The patient successfully underwent a three-part procedure that consisted of a superficial parotidectomy, IR embolization, and tumor excision via mandibular osteotomy to optimize access and exposure. Patient remained clinically stable at follow-up one month later and will continue to be monitored for dysphagia.</p>\n\n<p><strong>Results: </strong>In adults, surgery occasionally necessitates approaches such as mandibulotomy or mandibular osteotomy for adequate exposure of tumors extending to the skull base or parapharyngeal space. These approaches provide excellent surgical access but carry risks of malocclusion, mandibular nonunion, osteomyelitis, and cranial nerve injury. Current evidence shows that mandibular osteotomy in pediatric CBT surgery remains undocumented. A recent systematic review by Alanezi et al. (2024) of 29 cases reported gross surgical resection as the preferred treatment, with none involving mandibular osteotomy. Surgical resection remains the standard of care, often preceded by preoperative embolization. The absence of pediatric reports underscores both the rarity of the tumor and hesitancy to use mandibulotomy. To our knowledge, this represents the first documented pediatric use of a mandibular osteotomy for CBT excision.</p>\n\n<p><strong>Conclusion: </strong>Pediatric CBTs, though rare, warrant thorough evaluation for hereditary predisposition and long-term follow-up. While mandibular osteotomy is a recognized surgical adjunct for challenging adult cases, its use in children has not been reported. This highlights a critical gap in literature and an area for further study. Documentation of surgical approaches and outcomes in pediatric CBTs—including when advanced access techniques are necessary—will be essential for informing future management guidelines. Combining adult outcome data with this first pediatric case helps define risks and guide future surgical decision-making.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154199--></body></html>"
    },
    {
      "uid": "P068",
      "content_id": "153155",
      "abstract_number": "P068",
      "poster_number": "P068",
      "title": "Identifying and Evaluating Reasons for Delay in Head and Neck Free Flap Cases",
      "summary": "Of 54 cases analyzed, 39 cases (72.22%) reported reasons for transfer delay. The most reported reasons were patient-related delays (lateness, additional questions, etc.) (N = 13, 20.97%), anesthesia or anesthesia-related procedural delays (N = 8, 12.90%) and case set-up delays (large case set-up, missing equipment, etc.) (N = 8, 12.90%). On average, transfer time was 19.02 minutes (22-135, + 22.35 minutes), and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153155",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Victoria N Huynh, BS",
      "presenter": "Victoria N Huynh, BS",
      "authors": "Victoria N Huynh, BS 1 ; Stephen Nash, MD 2 ; Brandon Tapasak, MD 2 ; Brittany Beisel, MD 2 ; Ryan Elvis, MD 2 ; Jack Owen, MD 2 ; Forest Weir, MD 2 ; Ken Byrd, MD 2 ; Daniel Sharbel, MD 2 ; Michael Groves, MD 2 ; Sallie Long, MD 2",
      "normalized_authors": [
        "Victoria N Huynh",
        "Stephen Nash",
        "Brandon Tapasak",
        "Brittany Beisel",
        "Ryan Elvis",
        "Jack Owen",
        "Forest Weir",
        "Ken Byrd",
        "Daniel Sharbel",
        "Michael Groves",
        "Sallie Long"
      ],
      "affiliations": [
        "Medical College of Georgia at Augusta University",
        "Department of Otolaryngology - Head & Neck Surgery, Wellstar MCG Health Medical Center"
      ],
      "normalized_institutions": [
        "Medical College of Georgia at Augusta University",
        "Department of Otolaryngology - Head & Neck Surgery, Wellstar MCG Health Medical Center"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153155/Screenshot%202025-11-30%20at%209_53_59%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153155/Screenshot%202025-11-30%20at%209_53_59%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153155"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 443,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Victoria N Huynh, BS 1 ; Stephen Nash, MD 2 ; Brandon Tapasak, MD 2 ; Brittany Beisel, MD 2 ; Ryan Elvis, MD 2 ; Jack Owen, MD 2 ; Forest Weir, MD 2 ; Ken Byrd, MD 2 ; Daniel Sharbel, MD 2 ; Michael Groves, MD 2 ; Sallie Long, MD 2",
        "Affiliations": "1 Medical College of Georgia at Augusta University; 2 Department of Otolaryngology - Head & Neck Surgery, Wellstar MCG Health Medical Center",
        "Background": "Major head and neck cancer ablation and microvascular free flap reconstruction are complicated and time-consuming procedures that are costly for the healthcare system. Prolonged anesthesia has been associated with increased complications, including wound breakdown, fistula formation, hematoma, and additional procedures. Long surgical cases will often have at least one operating room team change, leading to communication failures up to 30% of the time. These communication failures lead to inefficiency, team tension, resource waste, and procedural error. The objective of this study is to assess average case delay for head and neck free flap cases and evaluate documented reasons for delays to identify opportunities to reduce cost and improve outcomes.",
        "Methods": "We conducted a retrospective case review of all head and neck ablation and microvascular free flap reconstruction cases at a single institution between August 2024 and August 2025, excluding November 2024 due to an institutional EMR transition. Transfer time was defined as the time between scheduled case start and patient arrival to the OR. Patient preparation time was defined as the time between patient arrival to the OR and first incision of any team involved in the case. The American Society of Anesthesiologists Physical Status Classification (ASA score) was used as a proxy for patient health. Reasons for case delay were collected via the OR record. Welch’s T-test and ANOVA analyses were conducted with SPSS.",
        "Results": "Of 54 cases analyzed, 39 cases (72.22%) reported reasons for transfer delay. The most reported reasons were patient-related delays (lateness, additional questions, etc.) (N = 13, 20.97%), anesthesia or anesthesia-related procedural delays (N = 8, 12.90%) and case set-up delays (large case set-up, missing equipment, etc.) (N = 8, 12.90%). On average, transfer time was 19.02 minutes (22-135, + 22.35 minutes), and patient preparation time was 75.11 minutes (20-132, + 25.54 minutes). Patient preparation times for patients with an ASA of IV were significantly longer than for patients with an ASA of II (46.95 ± 11.74 minutes, p = 0.02). Latissimus/scapula free flap cases had significantly longer patient preparation times than all other free flap cases (19.68 ± 12.45 minutes, p = 0.03).",
        "Discussion": "There is a substantial delay in transfer time and patient preparation time for head and neck microvascular free flap reconstruction cases. Preparation times were shorter for cases involving healthier patients and non-subscapular system free flaps. Decreasing delay time may improve cost effectiveness, efficiency, and patient outcomes. Limitations include variable quality of delay documentation and analysis of only a single institution. Improving pre-operative planning and communication with anesthesia, increasing patient instruction and education during the pre-operative visit, and establishing dedicated surgical teams are potential avenues to optimize on-time case starts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Identifying and Evaluating Reasons for Delay in Head and Neck Free Flap Cases</span>. <u>Victoria N Huynh, BS</u><sup>1</sup>; Stephen Nash, MD<sup>2</sup>; Brandon Tapasak, MD<sup>2</sup>; Brittany Beisel, MD<sup>2</sup>; Ryan Elvis, MD<sup>2</sup>; Jack Owen, MD<sup>2</sup>; Forest Weir, MD<sup>2</sup>; Ken Byrd, MD<sup>2</sup>; Daniel Sharbel, MD<sup>2</sup>; Michael Groves, MD<sup>2</sup>; Sallie Long, MD<sup>2</sup>. <sup>1</sup>Medical College of Georgia at Augusta University; <sup>2</sup>Department of Otolaryngology - Head & Neck Surgery, Wellstar MCG Health Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Major head and neck cancer ablation and microvascular free flap reconstruction are complicated and time-consuming procedures that are costly for the healthcare system. Prolonged anesthesia has been associated with increased complications, including wound breakdown, fistula formation, hematoma, and additional procedures. Long surgical cases will often have at least one operating room team change, leading to communication failures up to 30% of the time. These communication failures lead to inefficiency, team tension, resource waste, and procedural error. The objective of this study is to assess average case delay for head and neck free flap cases and evaluate documented reasons for delays to identify opportunities to reduce cost and improve outcomes.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective case review of all head and neck ablation and microvascular free flap reconstruction cases at a single institution between August 2024 and August 2025, excluding November 2024 due to an institutional EMR transition. Transfer time was defined as the time between scheduled case start and patient arrival to the OR. Patient preparation time was defined as the time between patient arrival to the OR and first incision of any team involved in the case. The American Society of Anesthesiologists Physical Status Classification (ASA score) was used as a proxy for patient health. Reasons for case delay were collected via the OR record. Welch’s T-test and ANOVA analyses were conducted with SPSS.</p>\n\n<p><strong>Results: </strong>Of 54 cases analyzed, 39 cases (72.22%) reported reasons for transfer delay. The most reported reasons were patient-related delays (lateness, additional questions, etc.) (N = 13, 20.97%), anesthesia or anesthesia-related procedural delays (N = 8, 12.90%) and case set-up delays (large case set-up, missing equipment, etc.) (N = 8, 12.90%). On average, transfer time was 19.02 minutes (22-135, + 22.35 minutes), and patient preparation time was 75.11 minutes (20-132, + 25.54 minutes). Patient preparation times for patients with an ASA of IV were significantly longer than for patients with an ASA of II (46.95 ± 11.74 minutes, p = 0.02). Latissimus/scapula free flap cases had significantly longer patient preparation times than all other free flap cases (19.68 ± 12.45 minutes, p = 0.03).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153155/Screenshot%202025-11-30%20at%209_53_59%E2%80%AFPM.png' /></p>\n\n<p><strong>Discussion: </strong>There is a substantial delay in transfer time and patient preparation time for head and neck microvascular free flap reconstruction cases. Preparation times were shorter for cases involving healthier patients and non-subscapular system free flaps. Decreasing delay time may improve cost effectiveness, efficiency, and patient outcomes. Limitations include variable quality of delay documentation and analysis of only a single institution. Improving pre-operative planning and communication with anesthesia, increasing patient instruction and education during the pre-operative visit, and establishing dedicated surgical teams are potential avenues to optimize on-time case starts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153155--></body></html>"
    },
    {
      "uid": "P069",
      "content_id": "153638",
      "abstract_number": "P069",
      "poster_number": "P069",
      "title": "Modeling the Impact of New Robotic Platforms on TORS Access for OPSCC: An Agent-Based Simulation Study",
      "summary": "In this model, introducing a second, robotic platform increased robotic adoption and TORS use among eligible OPSCC patients, When the entrant was less costly, adoption increased. When it was also clinically superior, adoption expanded further, more patients received TORS, and functional outcomes improved. These findings suggest that for new robotic platforms entering an incumbent-dominated market, price alone...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153638",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel D Bu, MD, MPP, MBA",
      "presenter": "Daniel D Bu, MD, MPP, MBA",
      "authors": "Daniel D Bu, MD, MPP, MBA ; William J Benjamin, MD, MPH; Justine Philteos, MD; Jeremy D Richmon, MD",
      "normalized_authors": [
        "Daniel D Bu, MPP",
        "William J Benjamin",
        "Justine Philteos",
        "Jeremy D Richmon"
      ],
      "affiliations": [
        "Mass Eye and Ear/Harvard Medical School"
      ],
      "normalized_institutions": [
        "Mass Eye and Ear/Harvard Medical School"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 537,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Daniel D Bu, MD, MPP, MBA ; William J Benjamin, MD, MPH; Justine Philteos, MD; Jeremy D Richmon, MD",
        "Affiliations": "Mass Eye and Ear/Harvard Medical School",
        "Background": "Transoral robotic surgery (TORS) is widely used modality for selected oropharyngeal squamous cell carcinoma (OPSCC). Multiple robotic platforms for transoral robotic surgery (TORS) are emerging, but incumbent vendors dominate the market. As additional platforms emerge, it is unclear whether slightly lower costs alone, versus lower costs coupled with better performance, will have greater impact on hospital adoption and patient access to TORS. We used an agent-based model (ABM) to explore how introduction of a second platform affects diffusion and uptake of surgical robotic platforms and use of TORS among clinically appropriate OPSCC patients.",
        "Methods": "The ABM represented 40 heterogeneous hospitals and 100 head and neck surgeons over 20 simulated years. Initially, only an incumbent robotic platform was available. Hospitals differed in OPSCC volume, innovation orientation, and decided whether to purchase the incumbent platform based on an expected margin function that included capital cost, per-use cost, and downstream oncology revenue. Surgeons varied in innovation propensity and network connectivity and offered TORS versus non-robotic modalities only when a robot was available. For each simulation, 30–60% of OPSCC cases were sampled as clinically appropriate for TORS. At year 10, a second vendor entered the market. We examined three scenarios (250 runs each): (1) Incumbent only (no entrant); (2) Lower cost entrant – entrant capital and per-use costs 25% lower than incumbent, equal performance; and (3) Lower cost-and-better entrant – 25% lower costs plus 10% higher functional rate. Primary outcome was the proportion of clinically eligible OPSCC cases treated with TORS by year 20; secondary outcomes included hospital robotic adoption and entrant market share.",
        "Results": "In the incumbent-only scenario, 46.1% (95% simulation interval [SI] 38.7–53.4%) of hospitals adopted a robot by year 20, covering 72.4% (95% SI 66.1–78.0%) of OPSCC volume; 61.3% (95% SI 55.4–66.7%) of clinically eligible cases received TORS, with mean functional score 73.4 (95% SI 72.0–74.7). In the lower-cost entrant scenario, total hospital robotic adoption rose to 55.8% (95% SI 48.3–63.0%), covering 79.3% (95% SI 73.9–84.1%) of OPSCC volume; 68.2% (95% SI 63.0–73.1%) of eligible cases received TORS, with the entrant capturing 39.7% (95% SI 31.0–48.1%) of robotic hospitals. Mean functional scores were unchanged (73.6, 95% SI 72.3–75.0). In the lower-cost and better entrant scenario, robotic adoption increased to 63.9% (95% SI 56.6–70.6%) of hospitals and 86.1% (95% SI 81.2–90.0%) of OPSCC volume; 76.5% (95% SI 71.9–80.7%) of eligible cases received TORS. The entrant captured 51.4% (95% SI 43.2–59.3%) of robotic hospitals, and mean functional score improved to 76.8 (95% SI 75.4–78.2).",
        "Conclusions": "In this model, introducing a second, robotic platform increased robotic adoption and TORS use among eligible OPSCC patients, When the entrant was less costly, adoption increased. When it was also clinically superior, adoption expanded further, more patients received TORS, and functional outcomes improved. These findings suggest that for new robotic platforms entering an incumbent-dominated market, price alone primarily shifts platform mix, whereas price plus performance gains meaningfully improve system-level access and patient benefit."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Modeling the Impact of New Robotic Platforms on TORS Access for OPSCC: An Agent-Based Simulation Study</span>. <u>Daniel D Bu, MD, MPP, MBA</u>; William J Benjamin, MD, MPH; Justine Philteos, MD; Jeremy D Richmon, MD. Mass Eye and Ear/Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral robotic surgery (TORS) is widely used modality for selected oropharyngeal squamous cell carcinoma (OPSCC). Multiple robotic platforms for transoral robotic surgery (TORS) are emerging, but incumbent vendors dominate the market. As additional platforms emerge, it is unclear whether slightly lower costs alone, versus lower costs coupled with better performance, will have greater impact on hospital adoption and patient access to TORS. We used an agent-based model (ABM) to explore how introduction of a second platform affects diffusion and uptake of surgical robotic platforms and use of TORS among clinically appropriate OPSCC patients.</p>\n\n<p><strong>Methods: </strong>The ABM represented 40 heterogeneous hospitals and 100 head and neck surgeons over 20 simulated years. Initially, only an incumbent robotic platform was available. Hospitals differed in OPSCC volume, innovation orientation, and decided whether to purchase the incumbent platform based on an expected margin function that included capital cost, per-use cost, and downstream oncology revenue. Surgeons varied in innovation propensity and network connectivity and offered TORS versus non-robotic modalities only when a robot was available. For each simulation, 30–60% of OPSCC cases were sampled as clinically appropriate for TORS. At year 10, a second vendor entered the market. We examined three scenarios (250 runs each): (1) Incumbent only (no entrant); (2) Lower cost entrant – entrant capital and per-use costs 25% lower than incumbent, equal performance; and (3) Lower cost-and-better entrant – 25% lower costs plus 10% higher functional rate. Primary outcome was the proportion of clinically eligible OPSCC cases treated with TORS by year 20; secondary outcomes included hospital robotic adoption and entrant market share.</p>\n\n<p><strong>Results: </strong>In the incumbent-only scenario, 46.1% (95% simulation interval [SI] 38.7–53.4%) of hospitals adopted a robot by year 20, covering 72.4% (95% SI 66.1–78.0%) of OPSCC volume; 61.3% (95% SI 55.4–66.7%) of clinically eligible cases received TORS, with mean functional score 73.4 (95% SI 72.0–74.7). In the lower-cost entrant scenario, total hospital robotic adoption rose to 55.8% (95% SI 48.3–63.0%), covering 79.3% (95% SI 73.9–84.1%) of OPSCC volume; 68.2% (95% SI 63.0–73.1%) of eligible cases received TORS, with the entrant capturing 39.7% (95% SI 31.0–48.1%) of robotic hospitals. Mean functional scores were unchanged (73.6, 95% SI 72.3–75.0). In the lower-cost and better entrant scenario, robotic adoption increased to 63.9% (95% SI 56.6–70.6%) of hospitals and 86.1% (95% SI 81.2–90.0%) of OPSCC volume; 76.5% (95% SI 71.9–80.7%) of eligible cases received TORS. The entrant captured 51.4% (95% SI 43.2–59.3%) of robotic hospitals, and mean functional score improved to 76.8 (95% SI 75.4–78.2).</p>\n\n<p><strong>Conclusions: </strong>In this model, introducing a second, robotic platform increased robotic adoption and TORS use among eligible OPSCC patients, When the entrant was less costly, adoption increased. When it was also clinically superior, adoption expanded further, more patients received TORS, and functional outcomes improved. These findings suggest that for new robotic platforms entering an incumbent-dominated market, price alone primarily shifts platform mix, whereas price plus performance gains meaningfully improve system-level access and patient benefit. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153638--></body></html>"
    },
    {
      "uid": "P070",
      "content_id": "153373",
      "abstract_number": "P070",
      "poster_number": "P070",
      "title": "Advancing Sentinel Node Localization in Head and Neck Melanoma Using Real-Time ICG Fluorescence Lymphatic Imaging",
      "summary": "ICG–guided SLN mapping using SpyPhi technology is feasible in head and neck melanoma and provides safe, dynamic intraoperative visualization that is concordant with Tc99m lymphoscintigraphy. Findings support further evaluation in a prospective trial comparing Tc99m alone versus Tc99m plus ICG as a logical next step to determine the clinical impact on detection accuracy and operative efficiency.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153373",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kathryn E Roth, MD, MHPE, FRCSC",
      "presenter": "Kathryn E Roth, MD, MHPE, FRCSC",
      "authors": "S. Danielle MacNeil, MD, MSc, FRCSC; Allison H Maciver, MD, MSc, FRCSC; Kathryn E Roth, MD, MHPE, FRCSC",
      "normalized_authors": [
        "S. Danielle MacNeil, FRCSC",
        "Allison H Maciver, FRCSC",
        "Kathryn E Roth, MHPE, FRCSC"
      ],
      "affiliations": [
        "Western University, London, Ontario, Canada"
      ],
      "normalized_institutions": [
        "Western University, London, Ontario, Canada"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 258,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "S. Danielle MacNeil, MD, MSc, FRCSC; Allison H Maciver, MD, MSc, FRCSC; Kathryn E Roth, MD, MHPE, FRCSC",
        "Affiliations": "Western University, London, Ontario, Canada",
        "Background": "Sentinel lymph node (SLN) biopsy in head and neck melanoma is technically challenging due to complex lymphatic drainage and small nodes. Standard mapping with Tc99m and blue dyes reliably identifies SLNs in ~95% of patients. False-negatives and failure to identify sentinel nodes can occur; and blue dyes can cause tissue staining, obscure deep margin dissection, and complicate workflow logistics. Indocyanine green (ICG) fluorescence offers real-time lymphatic visualization and may mitigate these limitations.",
        "Methods": "This study examined the feasibility and signal reliability of SLN localization using peritumoral dermal ICG injection and intraoperative fluorescence detection with the SpyPhi system. Feasibility endpoints included ICG uptake within lymphatic channels, correlation with standard Tc99m-identified nodes, and operability of SpyPhi within head and neck in comparison to groin and axilla surgical fields.",
        "Results": "ICG injection produced consistent lymphatic fluorescence, enabling real-time tracking of drainage pathways. Fluorescent nodes were detectable with SpyPhi in the majority of cases and corresponded to Tc99m-identified SLNs. No dye-related complications occurred. The technique was technically straightforward, did not interfere with standard workflows, and avoided the tissue discoloration associated with blue dyes, particularly around the anatomical sites of forehead, eyelid, and nose. These findings support the technical feasibility and potential clinical value of ICG-guided SLN localization.",
        "Conclusion": "ICG–guided SLN mapping using SpyPhi technology is feasible in head and neck melanoma and provides safe, dynamic intraoperative visualization that is concordant with Tc99m lymphoscintigraphy. Findings support further evaluation in a prospective trial comparing Tc99m alone versus Tc99m plus ICG as a logical next step to determine the clinical impact on detection accuracy and operative efficiency."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Advancing Sentinel Node Localization in Head and Neck Melanoma Using Real-Time ICG Fluorescence Lymphatic Imaging</span>. S. Danielle MacNeil, MD, MSc, FRCSC; Allison H Maciver, MD, MSc, FRCSC; <u>Kathryn E Roth, MD, MHPE, FRCSC</u>. Western University, London, Ontario, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Sentinel lymph node (SLN) biopsy in head and neck melanoma is technically challenging due to complex lymphatic drainage and small nodes. Standard mapping with Tc99m and blue dyes reliably identifies SLNs in ~95% of patients. False-negatives  and failure to identify sentinel nodes can occur; and blue dyes can cause tissue staining, obscure deep margin dissection, and complicate workflow logistics. Indocyanine green (ICG) fluorescence offers real-time lymphatic visualization and may mitigate these limitations.</p>\n\n<p><strong>Methods: </strong>This study examined the feasibility and signal reliability of SLN localization using peritumoral dermal ICG injection and intraoperative fluorescence detection with the SpyPhi system. Feasibility endpoints included ICG uptake within lymphatic channels, correlation with standard Tc99m-identified nodes, and operability of SpyPhi within head and neck in comparison to groin and axilla surgical fields.</p>\n\n<p><strong>Results: </strong>ICG injection produced consistent lymphatic fluorescence, enabling real-time tracking of drainage pathways. Fluorescent nodes were detectable with SpyPhi in the majority of cases and corresponded to Tc99m-identified SLNs. No dye-related complications occurred. The technique was technically straightforward, did not interfere with standard workflows, and avoided the tissue discoloration associated with blue dyes, particularly around the anatomical sites of forehead, eyelid, and nose. These findings support the technical feasibility and potential clinical value of ICG-guided SLN localization.</p>\n\n<p><strong>Conclusion: </strong>ICG–guided SLN mapping using SpyPhi technology is feasible in head and neck melanoma and provides safe, dynamic intraoperative visualization that is concordant with Tc99m lymphoscintigraphy. Findings support further evaluation in a prospective trial comparing Tc99m alone versus Tc99m plus ICG as a logical next step to determine the clinical impact on detection accuracy and operative efficiency.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153373--></body></html>"
    },
    {
      "uid": "P071",
      "content_id": "153342",
      "abstract_number": "P071",
      "poster_number": "P071",
      "title": "Delays to Post Operative Radiation: A Needs Assessment and Implementation of Second Touch Visits",
      "summary": "The rate of delay to PORT in this single-institution study (68%) exceeded rates reported in a recent meta-analysis which included all head and neck cancer patients (49%), underscoring the need for intervention. Program implementation demonstrated that APP involvement in dual-surgeon workflows improves patient satisfaction, may reduce PORT delays, and helps to optimize reconstructive surgeon clinic time by...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153342",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tony Satroplus, MD",
      "presenter": "Tony Satroplus, MD",
      "authors": "Tony Satroplus, MD 1 ; Ryan C Higgins, MD 1 ; Karissa A Nichols, BS 2 ; Kaeli Samson, MPH, MA 3 ; Frank T Materia, PhD, MHS 4 ; Patricia Scott, APRNNP 1 ; Elizabeth Bradford Bell, MD 1 ; Tony Richa, MD 1 ; Chelsea S Hamill, MD 1",
      "normalized_authors": [
        "Tony Satroplus",
        "Ryan C Higgins",
        "Karissa A Nichols",
        "Kaeli Samson, MA",
        "Frank T Materia, MHS",
        "Patricia Scott, APRNNP",
        "Elizabeth Bradford Bell",
        "Tony Richa",
        "Chelsea S Hamill"
      ],
      "affiliations": [
        "Department of Otolaryngology, University of Nebraska Medical Center, Omaha NE",
        "College of Medicine, University of Nebraska Medical Center, Omaha, NE",
        "Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE",
        "Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, University of Nebraska Medical Center, Omaha NE",
        "College of Medicine, University of Nebraska Medical Center, Omaha, NE",
        "Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE",
        "Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Tony Satroplus, MD 1 ; Ryan C Higgins, MD 1 ; Karissa A Nichols, BS 2 ; Kaeli Samson, MPH, MA 3 ; Frank T Materia, PhD, MHS 4 ; Patricia Scott, APRNNP 1 ; Elizabeth Bradford Bell, MD 1 ; Tony Richa, MD 1 ; Chelsea S Hamill, MD 1",
        "Affiliations": "1 Department of Otolaryngology, University of Nebraska Medical Center, Omaha NE; 2 College of Medicine, University of Nebraska Medical Center, Omaha, NE; 3 Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE; 4 Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS",
        "Background": "Timely delivery of post-operative radiation therapy (PORT) following surgical resection of head and neck cancer has been shown to improve rates of recurrence-free intervals and increase overall survival. In 2021, starting PORT within 42 days of surgery became the first quality metric in head and neck oncology. Despite this, delays remain common, with patient education identified as a contributing factor. Previous work at a single institution implemented preoperative visits with an advanced practice provider (APP) separate from their initial consultation, during which they received counseling and educational materials on their expected treatment course. Within a single-surgeon model, these “second touch” visits were shown to help reduce delays to PORT.",
        "Objectives": "This study aims to (a) characterize the need for improved timeliness of PORT at a single tertiary care institution with a dual-surgeon model, (b) describe the development and implementation of a second touch visit program informed by multidisciplinary stakeholder input, and (c) evaluate patient-reported experiences with the program.",
        "Methods": "A retrospective chart review was completed evaluating patients who underwent surgical resection and free-flap reconstruction from January 2022 to December 2024. Data collected included patient demographics, disease characteristics, surgical intervention, hospital stay, and adjuvant treatment course. Statistical analyses evaluated associations between these factors and days to PORT.",
        "Abstract": "Second touch visits were integrated into the head and neck cancer program at a tertiary care center. Stakeholders, including surgeons, APPs, nurses, and residents, collaborated through multiple meetings to streamline workflows and refine patient education materials for clarity. Patient experiences with the second touch visits were assessed using a 7-point Likert scale survey based on the Health Belief Model focusing on the visits’ helpfulness in improving understanding of treatment course and likelihood of attending future appointments.",
        "Results": "A retrospective chart review of 22 patients showed a mean age of 63.9 years. Most were retired/unemployed (68.2%), married (54.5%), non-Hispanic (95.5%), White (100%), male (72.7%), and insured through government programs (71.4%). Delays to PORT occurred in 68% (n=15), while 32% (n=7) initiated therapy within 42 days. Patients with LVI had shorter intervals to radiation (median: 42.0 days) relative to patients who did not (median: 53.0 days; p = 0.04). Trends toward delays were observed in cutaneous carcinoma and surgeries later in the week (e.g. Wednesday-Friday), though not statistically significant. Surveys revealed that patients considered the visit and associated materials to be helpful, clear, well-timed, and highly recommended for future patients, with all categories given a 7/7 (best) from 100% of patients (n = 3).",
        "Conclusion": "The rate of delay to PORT in this single-institution study (68%) exceeded rates reported in a recent meta-analysis which included all head and neck cancer patients (49%), underscoring the need for intervention. Program implementation demonstrated that APP involvement in dual-surgeon workflows improves patient satisfaction, may reduce PORT delays, and helps to optimize reconstructive surgeon clinic time by allowing patients to meet the second surgeon the day of surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Delays to Post Operative Radiation: A Needs Assessment and Implementation of Second Touch Visits</span>. <u>Tony Satroplus, MD</u><sup>1</sup>; Ryan C Higgins, MD<sup>1</sup>; Karissa A Nichols, BS<sup>2</sup>; Kaeli Samson, MPH, MA<sup>3</sup>; Frank T Materia, PhD, MHS<sup>4</sup>; Patricia Scott, APRNNP<sup>1</sup>; Elizabeth Bradford Bell, MD<sup>1</sup>; Tony Richa, MD<sup>1</sup>; Chelsea S Hamill, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, University of Nebraska Medical Center, Omaha NE; <sup>2</sup>College of Medicine, University of Nebraska Medical Center, Omaha, NE; <sup>3</sup>Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE; <sup>4</sup>Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Timely delivery of post-operative radiation therapy (PORT) following surgical resection of head and neck cancer has been shown to improve rates of recurrence-free intervals and increase overall survival. In 2021, starting PORT within 42 days of surgery became the first quality metric in head and neck oncology. Despite this, delays remain common, with patient education identified as a contributing factor. Previous work at a single institution implemented preoperative visits with an advanced practice provider (APP) separate from their initial consultation, during which they received counseling and educational materials on their expected treatment course. Within a single-surgeon model, these “second touch” visits were shown to help reduce delays to PORT.</p>\n\n<p><strong>Objectives: </strong>This study aims to (a) characterize the need for improved timeliness of PORT at a single tertiary care institution with a dual-surgeon model, (b) describe the development and implementation of a second touch visit program informed by multidisciplinary stakeholder input, and (c) evaluate patient-reported experiences with the program.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was completed evaluating patients who underwent surgical resection and free-flap reconstruction from January 2022 to December 2024.  Data collected included patient demographics, disease characteristics, surgical intervention, hospital stay, and adjuvant treatment course. Statistical analyses evaluated associations between these factors and days to PORT.</p>\n\n<p>Second touch visits were integrated into the head and neck cancer program at a tertiary care center. Stakeholders, including surgeons, APPs, nurses, and residents, collaborated through multiple meetings to streamline workflows and refine patient education materials for clarity.</p>\n\n<p>Patient experiences with the second touch visits were assessed using a 7-point Likert scale survey based on the Health Belief Model focusing on the visits’ helpfulness in improving understanding of treatment course and likelihood of attending future appointments.</p>\n\n<p><strong>Results:</strong> A retrospective chart review of 22 patients showed a mean age of 63.9 years. Most were retired/unemployed (68.2%), married (54.5%), non-Hispanic (95.5%), White (100%), male (72.7%), and insured through government programs (71.4%). Delays to PORT occurred in 68% (n=15), while 32% (n=7) initiated therapy within 42 days. Patients with LVI had shorter intervals to radiation (median: 42.0 days) relative to patients who did not (median: 53.0 days; p = 0.04). Trends toward delays were observed in cutaneous carcinoma and surgeries later in the week (e.g. Wednesday-Friday), though not statistically significant. Surveys revealed that patients considered the visit and associated materials to be helpful, clear, well-timed, and highly recommended for future patients, with all categories given a 7/7 (best) from 100% of patients (n = 3).</p>\n\n<p><strong>Conclusion: </strong>The rate of delay to PORT in this single-institution study (68%) exceeded rates reported in a recent meta-analysis which included all head and neck cancer patients (49%), underscoring the need for intervention. Program implementation demonstrated that APP involvement in dual-surgeon workflows improves patient satisfaction, may reduce PORT delays, and helps to optimize reconstructive surgeon clinic time by allowing patients to meet the second surgeon the day of surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153342--></body></html>"
    },
    {
      "uid": "P072",
      "content_id": "153613",
      "abstract_number": "P072",
      "poster_number": "P072",
      "title": "From Symptom Onset to Treatment in Head and Neck Cancer: Delays Along the Care Pathway in a Safety-Net Population",
      "summary": "Our preliminary findings highlight substantial variability and overall delays in the care pathway for patients with HNC at an urban safety-net hospital, with non-White and unstably housed patients at higher risk of experiencing delays. Future work should target social determinants of delay and develop improvement interventions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153613",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nour Mary Aissaoui, MS",
      "presenter": "Nour Mary Aissaoui, MS",
      "authors": "Nour Mary Aissaoui, MS 1 ; Michelle Florentine, MD 2 ; Marc Anthony Pastor, BS 1 ; Nicholas Correia, BA 1 ; Laura Chen, BA 1 ; Armita Norouzi, BA 3 ; Mary Jue Xu, MD 2",
      "normalized_authors": [
        "Nour Mary Aissaoui",
        "Michelle Florentine",
        "Marc Anthony Pastor",
        "Nicholas Correia",
        "Laura Chen",
        "Armita Norouzi",
        "Mary Jue Xu"
      ],
      "affiliations": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA"
      ],
      "normalized_institutions": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153613/AHNS%20Figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153613/AHNS%20Figure%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153613"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nour Mary Aissaoui, MS 1 ; Michelle Florentine, MD 2 ; Marc Anthony Pastor, BS 1 ; Nicholas Correia, BA 1 ; Laura Chen, BA 1 ; Armita Norouzi, BA 3 ; Mary Jue Xu, MD 2",
        "Affiliations": "1 University of California, San Francisco School of Medicine, San Francisco, CA ; 2 Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA; 3 Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA",
        "Introduction": "Head and neck cancer (HNC) accounts for ~15,000 deaths annually in the United States, with a 60% five-year survival 1 . Rapid treatment is critical, as a multi-center analysis of over 50,000 patients found that starting therapy more than 46–52 days after diagnosis substantially increased mortality 2 . There is limited literature identifying delays and their predictors across pre-determined time intervals throughout the cancer care timeline, especially among vulnerable populations in safety-net settings. This study describes time to care, from symptom onset through treatment completion, and identifies factors associated with delays among patients with HNC in a safety-net hospital setting.",
        "Methods": "We conducted a retrospective chart review of adults with biopsy-proven HNC diagnosed at an urban safety-net hospital between 2019 and 2024. Pre-specified predictors including age, sex, race/ethnicity, language, stage, and subsite were collected as well as clinical data regarding symptom onset, presentation, and treatment-related encounters. The primary outcomes were delays in established time intervals based on existing literature: time from symptom onset to presentation greater than 3 months 3 , time from diagnosis to treatment initiation (TTI) greater than 60 days 4 , time from surgery to adjuvant therapy greater than 6 weeks 5 , and total treatment time greater than 100 days 6 . One-, two-, and five-year survival data were also collected. Critical dates were collected through retrospective chart review and limited by data availability. Median times were reported for all intervals and univariate analysis was performed to assess for predictive factors of delay and survival.",
        "Results": "Sixty-one patients met inclusion criteria with a mean age at diagnosis of 61 ± 10 years and 67% of patients presented with stage III/IV HNC. The median time from symptom onset to presentation was 68 days (IQR 28-132), with 41% exceeding the 3-month threshold. Measured from diagnosis to treatment initiation, median TTI was 50 days (IQR 28-67), with 33% of patients facing delays. The median time from surgery to initiation of adjuvant radiotherapy or chemoradiotherapy was 63 days (IQR 53-70), and 89% experienced delays in starting adjuvant treatment. The median total treatment time, irrespective of plan type (with/without surgery) was 57 days (IQR 47-104), and 31% experienced delays in treatment completion. The one-, two-, and five-year survival rate were 79%, 70% and 61% respectively. Univariate analysis revealed that non-White patients and unstably housed patients were more likely to experience longer time from diagnosis to treatment initiation (p=0.032 and p=0.045, respectively). Advanced stage (III/IV) was associated with lower survival rate (p=0.003).",
        "Conclusion": "Our preliminary findings highlight substantial variability and overall delays in the care pathway for patients with HNC at an urban safety-net hospital, with non-White and unstably housed patients at higher risk of experiencing delays. Future work should target social determinants of delay and develop improvement interventions.",
        "Abstract": "References: 1.Connell,2020 2.Murphy,2016 3.Tromp,2004 4.Liao,2019 5.Graboyes,2017 6.Ghanem,2019"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>From Symptom Onset to Treatment in Head and Neck Cancer: Delays Along the Care Pathway in a Safety-Net Population</span>. <u>Nour Mary Aissaoui, MS</u><sup>1</sup>; Michelle Florentine, MD<sup>2</sup>; Marc Anthony Pastor, BS<sup>1</sup>; Nicholas Correia, BA<sup>1</sup>; Laura Chen, BA<sup>1</sup>; Armita Norouzi, BA<sup>3</sup>; Mary Jue Xu, MD<sup>2</sup>. <sup>1</sup>University of California, San Francisco School of Medicine, San Francisco, CA ; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA; <sup>3</sup>Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Head and neck cancer (HNC) accounts for ~15,000 deaths annually in the United States, with a 60% five-year survival<sup>1</sup>. Rapid treatment is critical, as a multi-center analysis of over 50,000 patients found that starting therapy more than 46–52 days after diagnosis substantially increased mortality<sup>2</sup>. There is limited literature identifying delays and their predictors across pre-determined time intervals throughout the cancer care timeline, especially among vulnerable populations in safety-net settings. This study describes time to care, from symptom onset through treatment completion, and identifies factors associated with delays among patients with HNC in a safety-net hospital setting. </p>\n\n<p><strong>Methods:</strong> We conducted a retrospective chart review of adults with biopsy-proven HNC diagnosed at an urban safety-net hospital between 2019 and 2024. Pre-specified predictors including age, sex, race/ethnicity, language, stage, and subsite were collected as well as clinical data regarding symptom onset, presentation, and treatment-related encounters. The primary outcomes were delays in established time intervals based on existing literature: time from symptom onset to presentation greater than 3 months<sup>3</sup>, time from diagnosis to treatment initiation (TTI) greater than 60 days<sup>4</sup>, time from surgery to adjuvant therapy greater than 6 weeks<sup>5</sup>, and total treatment time greater than 100 days<sup>6</sup>. One-, two-, and five-year survival data were also collected. Critical dates were collected through retrospective chart review and limited by data availability. Median times were reported for all intervals and univariate analysis was performed to assess for predictive factors of delay and survival.  </p>\n\n<p><strong>Results: </strong>Sixty-one patients met inclusion criteria with a mean age at diagnosis of 61 ± 10 years and 67% of patients presented with stage III/IV HNC. The median time from symptom onset to presentation was 68 days (IQR 28-132), with 41% exceeding the 3-month threshold. Measured from diagnosis to treatment initiation, median TTI was 50 days (IQR 28-67), with 33% of patients facing delays. The median time from surgery to initiation of adjuvant radiotherapy or chemoradiotherapy was 63 days (IQR 53-70), and 89% experienced delays in starting adjuvant treatment. The median total treatment time, irrespective of plan type (with/without surgery) was 57 days (IQR 47-104), and 31% experienced delays in treatment completion. The one-, two-, and five-year survival rate were 79%, 70% and 61% respectively. Univariate analysis revealed that non-White patients and unstably housed patients were more likely to experience longer time from diagnosis to treatment initiation (p=0.032 and p=0.045, respectively). Advanced stage (III/IV) was associated with lower survival rate (p=0.003). </p>\n\n<p><strong>Conclusion:</strong> Our preliminary findings highlight substantial variability and overall delays in the care pathway for patients with HNC at an urban safety-net hospital, with non-White and unstably housed patients at higher risk of experiencing delays. Future work should target social determinants of delay and develop improvement interventions. </p>\n\n<p>References: 1.Connell,2020 2.Murphy,2016 3.Tromp,2004 4.Liao,2019 5.Graboyes,2017 6.Ghanem,2019</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153613/AHNS%20Figure%201.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153613--></body></html>"
    },
    {
      "uid": "P073",
      "content_id": "154307",
      "abstract_number": "P073",
      "poster_number": "P073",
      "title": "Evaluating a Novel Nomogram in its Ability to Predict Gastrostomy Tube Placement in Head and Neck Cancer Surgery Patients",
      "summary": "These preliminary results suggest a statistically significant increased LOS for patients with a positive nomogram. Conversely, the N–/G– patient group has the shortest LOS. The data suggests that the nomogram tends to correctly identify the patients that are at high risk for requiring prolonged nutritional supplementation and would benefit from G-tube placement. This may be a helpful tool to guide clinical...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154307",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Melissa A Schroder, BS",
      "presenter": "Melissa A Schroder, BS",
      "authors": "Melissa A Schroder, BS ; Makayla R Matthews, BS; Hannah Eadie, MSN, FNPC; Trevor G Hackman, MD",
      "normalized_authors": [
        "Melissa A Schroder",
        "Makayla R Matthews",
        "Hannah Eadie, MSN, FNPC",
        "Trevor G Hackman"
      ],
      "affiliations": [
        "University of North Carolina at Chapel Hill"
      ],
      "normalized_institutions": [
        "University of North Carolina at Chapel Hill"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154307/AHNS%20G-Tube%20Figure.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154307/AHNS%20G-Tube%20Figure.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154307"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Melissa A Schroder, BS ; Makayla R Matthews, BS; Hannah Eadie, MSN, FNPC; Trevor G Hackman, MD",
        "Affiliations": "University of North Carolina at Chapel Hill",
        "Background": "Ensuring adequate nutritional support during head and neck cancer (HNC) treatment is inherently challenging due to the involvement of the aerodigestive tract. Maintaining proper nutrition is a priority for these patients because weight loss and malnutrition have been associated with adverse outcomes such as increased hospital readmissions, psychosocial stress, and mortality. Prolonged enteral nutrition via gastrostomy tube (G-tube) placement may be indicated, though consensus between reactive versus prophylactic placement has not been reached. There is also a paucity of data to guide practitioners, and thus the decision for placement is generally left to the subjective judgement of the individual provider. The properly developed nomogram may allow for better data-driven decisions, which may improve patient selection, optimize nutrition, and reduce hospitalizations. This project aims to validate a new internally developed nomogram designed to identify high-risk patients that may benefit from prolonged enteral nutrition early on in the post-operative course while minimizing unnecessary medical procedures.",
        "Methods": "Observational. Patients 18+ undergoing head and neck cancer extirpation with free flap reconstruction or laryngectomy at a tertiary care academic center from May 2025 - November 2025 (ongoing) were eligible. Oncologic and surgical data were used within the nomogram to predict individual risk of G-tube placement during primary hospitalization. Retrospective data was collected to assess for outcomes.",
        "Results": "40 patients (72.5% oral, 5% oropharyngeal, 17.5% laryngeal; 5% parotid) were included, and subcategories by nomogram (N) and G-tube (G) created: 12 N+/G+, 7 N+/G–, 4 N–/G+, 17 N–/G–. Mean age 64 years (±11.9) and pre-operative BMI 26.3 kg/m2 (±6.1). Stage breakdown: T0-T2 (30.8%), T3-T4 (64.1%), Tx (5.1%); N0-N1 (69.2%), N2-N3 (30.8%). 22.5% of patients had prior radiation therapy. Median days to G-tube placement from the index surgery was POD 7 (3-24) for the N+/G+ and POD 9 (7-9) N-/G+. Average length of stay (LOS) in days was 17.3 (±10.0) N+/G+, 12.9 (±4.5) N+/G–, 13.3 (±2.6) N–/G+, 9.6 (±3.3) N–/G– (p = 0.0136, N+/G+ versus N–/G–).",
        "Conclusions": "These preliminary results suggest a statistically significant increased LOS for patients with a positive nomogram. Conversely, the N–/G– patient group has the shortest LOS. The data suggests that the nomogram tends to correctly identify the patients that are at high risk for requiring prolonged nutritional supplementation and would benefit from G-tube placement. This may be a helpful tool to guide clinical reasoning and clinician judgement early on in the primary hospitalization, so as to more expeditiously obtain gastrostomy tube placement and reduce unnecessary lengths of stay. Further data is needed to continue to elucidate the differences between groups and guide calibration of the nomogram, including optimization of internal practitioner compliance with the nomogram recommendations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating a Novel Nomogram in its Ability to Predict Gastrostomy Tube Placement in Head and Neck Cancer Surgery Patients</span>. <u>Melissa A Schroder, BS</u>; Makayla R Matthews, BS; Hannah Eadie, MSN, FNPC; Trevor G Hackman, MD. University of North Carolina at Chapel Hill<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Ensuring adequate nutritional support during head and neck cancer (HNC) treatment is inherently challenging due to the involvement of the aerodigestive tract. Maintaining proper nutrition is a priority for these patients because weight loss and malnutrition have been associated with adverse outcomes such as increased hospital readmissions, psychosocial stress, and mortality. Prolonged enteral nutrition via gastrostomy tube (G-tube) placement may be indicated, though consensus between reactive versus prophylactic placement has not been reached. There is also a paucity of data to guide practitioners, and thus the decision for placement is generally left to the subjective judgement of the individual provider. The properly developed nomogram may allow for better data-driven decisions, which may improve patient selection, optimize nutrition, and reduce hospitalizations. This project aims to validate a new internally developed nomogram designed to identify high-risk patients that may benefit from prolonged enteral nutrition early on in the post-operative course while minimizing unnecessary medical procedures.</p>\n\n<p><strong>Methods:</strong> Observational. Patients 18+ undergoing head and neck cancer extirpation with free flap reconstruction or laryngectomy at a tertiary care academic center from May 2025 - November 2025 (ongoing) were eligible. Oncologic and surgical data were used within the nomogram to predict individual risk of G-tube placement during primary hospitalization. Retrospective data was collected to assess for outcomes.</p>\n\n<p><strong>Results: </strong>40 patients (72.5% oral, 5% oropharyngeal, 17.5% laryngeal; 5% parotid) were included, and subcategories by nomogram (N) and G-tube (G) created: 12 N+/G+, 7 N+/G–, 4 N–/G+, 17 N–/G–. Mean age 64 years (±11.9) and pre-operative BMI 26.3 kg/m2 (±6.1). Stage breakdown: T0-T2 (30.8%), T3-T4 (64.1%), Tx (5.1%); N0-N1 (69.2%), N2-N3 (30.8%). 22.5% of patients had prior radiation therapy. Median days to G-tube placement from the index surgery was POD 7 (3-24) for the N+/G+ and POD 9 (7-9) N-/G+. Average length of stay (LOS) in days was 17.3 (±10.0) N+/G+, 12.9 (±4.5) N+/G–, 13.3 (±2.6) N–/G+, 9.6 (±3.3) N–/G– (p = 0.0136, N+/G+ versus N–/G–).</p>\n\n<p><strong>Conclusions:</strong> These preliminary results suggest a statistically significant increased LOS for patients with a positive nomogram. Conversely, the N–/G– patient group has the shortest LOS. The data suggests that the nomogram tends to correctly identify the patients that are at high risk for requiring prolonged nutritional supplementation and would benefit from G-tube placement. This may be a helpful tool to guide clinical reasoning and clinician judgement early on in the primary hospitalization, so as to more expeditiously obtain gastrostomy tube placement and reduce unnecessary lengths of stay. Further data is needed to continue to elucidate the differences between groups and guide calibration of the nomogram, including optimization of internal practitioner compliance with the nomogram recommendations.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154307/AHNS%20G-Tube%20Figure.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154307--></body></html>"
    },
    {
      "uid": "P074",
      "content_id": "154769",
      "abstract_number": "P074",
      "poster_number": "P074",
      "title": "Endoscopic Management of Sinonasal Tumors: Experience from a Tertiary Care Hospital",
      "summary": "Endoscopic surgery is effective primary modality for sinonasal cancers, with reduced morbidity. Integration of adjuvant radiotherapy and multimodal therapy is essential for optimizing oncological outcomes . Careful selection and multidisciplinary management remain key.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154769",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dharam Vir, Associate Professor Audiology & Speech",
      "presenter": "Dharam Vir, Associate Professor Audiology & Speech",
      "authors": "Dharam Vir, Associate Professor Audiology & Speech ; Jaimanti Bakshi, Professor Head; Anav Rattan, Senior Resident",
      "normalized_authors": [
        "Dharam Vir, Associate Audiology & Speech",
        "Jaimanti Bakshi, Head",
        "Anav Rattan, Senior Resident"
      ],
      "affiliations": [
        "PGIMER, Chandigarh, India"
      ],
      "normalized_institutions": [
        "PGIMER, Chandigarh, India"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 177,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Aim",
        "Methodology",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Dharam Vir, Associate Professor Audiology & Speech ; Jaimanti Bakshi, Professor Head; Anav Rattan, Senior Resident",
        "Affiliations": "PGIMER, Chandigarh, India",
        "Aim": "To evaluate the spectrum, surgical outcomes, and role of adjuvant therapy in sinonasal cancers managed endoscopically at a tertiary care hospital.",
        "Methodology": "A retrospective review conducted on 21 patients with sinonasal tumors treated by endoscopic surgery. Demographic details, surgical outcomes, recurrence and use of adjuvant modalities were analyzed. Patients previously managed by open surgery were excluded.",
        "Results": "The cohort comprised 21 patients (mean age 45 years; 11 females, 10 males).",
        "Abstract": "The histology was as follows- Adenocarcinoma – 7 Adenoid cystic carcinoma – 2 Glomangiopericytoma/Hemangiopericytoma – 3 Solitary fibrous tumor – 1 Plasmacytoma – 1 Osteosarcoma – 1 Others/Inflammatory (Rosai-Dorfman, GPA, inverted papilloma ) – 6 Complete endoscopic excision was feasible in most patients with minimal complications. Adjuvant radiotherapy was administered in high-risk cases with aggressive histologies and positive or close margins. Selected patients also received chemoradiation. Early follow-up indicates favorable disease control, though recurrences were noted in a few adenocarcinoma and hemangiopericytoma cases.",
        "Conclusions": "Endoscopic surgery is effective primary modality for sinonasal cancers, with reduced morbidity. Integration of adjuvant radiotherapy and multimodal therapy is essential for optimizing oncological outcomes . Careful selection and multidisciplinary management remain key."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Endoscopic Management of Sinonasal Tumors: Experience from a Tertiary Care Hospital</span>. <u>Dharam Vir, Associate Professor Audiology & Speech</u>; Jaimanti Bakshi, Professor Head; Anav Rattan, Senior Resident. PGIMER, Chandigarh, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Aim: </strong>To evaluate the spectrum, surgical outcomes, and role of adjuvant therapy in sinonasal cancers managed endoscopically at a tertiary care hospital.</p>\n\n<p><strong>Methodology: </strong>A retrospective review conducted on 21 patients with sinonasal tumors treated by endoscopic surgery. Demographic details, surgical outcomes, recurrence and use of adjuvant modalities were analyzed. Patients previously managed by open surgery were excluded.</p>\n\n<p><strong>Results: </strong>The cohort comprised 21 patients (mean age 45 years; 11 females, 10 males).</p>\n\n<p>The histology was as follows-</p>\n\n<p>Adenocarcinoma – 7<br />\nAdenoid cystic carcinoma – 2<br />\nGlomangiopericytoma/Hemangiopericytoma – 3<br />\nSolitary fibrous tumor – 1<br />\nPlasmacytoma – 1<br />\nOsteosarcoma – 1<br />\nOthers/Inflammatory (Rosai-Dorfman, GPA, inverted papilloma ) – 6</p>\n\n<p>Complete endoscopic excision was feasible in most patients with minimal complications. Adjuvant radiotherapy was administered in high-risk cases with aggressive histologies and positive or close margins. Selected patients also received chemoradiation. Early follow-up indicates favorable disease control, though recurrences were noted in a few adenocarcinoma and hemangiopericytoma cases.</p>\n\n<p><strong>Conclusions: </strong>Endoscopic surgery is effective primary modality for sinonasal cancers, with reduced morbidity. Integration of adjuvant radiotherapy and multimodal therapy is essential for optimizing oncological outcomes . Careful selection and multidisciplinary management remain key.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154769--></body></html>"
    },
    {
      "uid": "P075",
      "content_id": "153352",
      "abstract_number": "P075",
      "poster_number": "P075",
      "title": "Safer Care for Laryngectomy Patients: Leveraging the Electronic Medical Record for Clinical Decision Support",
      "summary": "An accurate EMR notification was designed with an ongoing monitoring plan to improve care for laryngectomy patients by providing quick access to information about a patient’s airway anatomy to both otolaryngology and non-otolaryngology providers. Future updates will be made based on feedback obtained in weekly surveys sent to providers who viewed the notification to continue the process of providing safer, more...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153352",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caroline R Christmann, MD",
      "presenter": "Caroline R Christmann, MD",
      "authors": "Caroline R Christmann, MD ; Aviva Mattingly, MD; Christine C Little, MD; Michael C Topf, MD, MSCI",
      "normalized_authors": [
        "Caroline R Christmann",
        "Aviva Mattingly",
        "Christine C Little",
        "Michael C Topf, MSCI"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 380,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Caroline R Christmann, MD ; Aviva Mattingly, MD; Christine C Little, MD; Michael C Topf, MD, MSCI",
        "Affiliations": "Vanderbilt University Medical Center",
        "Introduction": "Laryngectomy stomas and tracheostomy stomas are often difficult to distinguish, particularly for non-head and neck cancer providers. This has significant implications for patient care, particularly for patients requiring urgent or emergent respiratory support. Currently, the only way to confirm airway anatomy in our institution’s electronic medical record (EMR) is by viewing recent otolaryngology notes. We have developed an EMR notification to identify patients who have had a laryngectomy based on ICD 10 and CPT codes. The goal of this quality improvement project is to allow providers to quickly determine patient’s airway anatomy in urgent and emergent scenarios to improve clinical decision-making and support.",
        "Methods": "An electronic notification was designed by a multidisciplinary team (including otolaryngologists, advanced practice providers, emergency medicine physicians, and IT staff) with text and visual components. This EMR alert informs treating providers of the patient’s surgical history with an accompanying image of the airway anatomy. Educational information is provided for the following categories: respiratory support, inhaled medications, and laryngectomy tubes. It provides suggested orders for standard laryngectomy care while in the hospital. This notification will appear when a patient's chart is opened once per encounter for physicians, advanced practice providers, nurses, and respiratory therapists. Patients are identified as having a laryngectomy based on ICD codes for a diagnosis of history of laryngectomy or CPT codes indicating prior laryngectomy.",
        "Results": "Buy-in was obtained by multidisciplinary care teams and EMR leadership. Initial review of patients who would meet inclusion criteria for the notification by ICD or CPT codes demonstrated 96% accuracy for identification of laryngectomy patients, with 429 total living laryngectomy patients identified in the institutional EMR. Surveys will be administered weekly to providers who viewed the notification to assess the utility of this notification and solicit feedback for future improvements. Additionally, the rate of laryngectomy care orders placed will be assessed for further evaluation of the utility of this component of the notification.",
        "Conclusion": "An accurate EMR notification was designed with an ongoing monitoring plan to improve care for laryngectomy patients by providing quick access to information about a patient’s airway anatomy to both otolaryngology and non-otolaryngology providers. Future updates will be made based on feedback obtained in weekly surveys sent to providers who viewed the notification to continue the process of providing safer, more efficient care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Safer Care for Laryngectomy Patients: Leveraging the Electronic Medical Record for Clinical Decision Support</span>. <u>Caroline R Christmann, MD</u>; Aviva Mattingly, MD; Christine C Little, MD; Michael C Topf, MD, MSCI. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Laryngectomy stomas and tracheostomy stomas are often difficult to distinguish, particularly for non-head and neck cancer providers. This has significant implications for patient care, particularly for patients requiring urgent or emergent respiratory support. Currently, the only way to confirm airway anatomy in our institution’s electronic medical record (EMR) is by viewing recent otolaryngology notes. We have developed an EMR notification to identify patients who have had a laryngectomy based on ICD 10 and CPT codes. The goal of this quality improvement project is to allow providers to quickly determine patient’s airway anatomy in urgent and emergent scenarios to improve clinical decision-making and support.</p>\n\n<p><strong>Methods: </strong>An electronic notification was designed by a multidisciplinary team (including otolaryngologists, advanced practice providers, emergency medicine physicians, and IT staff) with text and visual components. This EMR alert informs treating providers of the patient’s surgical history with an accompanying image of the airway anatomy. Educational information is provided for the following categories: respiratory support, inhaled medications, and laryngectomy tubes. It provides suggested orders for standard laryngectomy care while in the hospital. This notification will appear when a patient's chart is opened once per encounter for physicians, advanced practice providers, nurses, and respiratory therapists. Patients are identified as having a laryngectomy based on ICD codes for a diagnosis of history of laryngectomy or CPT codes indicating prior laryngectomy.</p>\n\n<p><strong>Results: </strong>Buy-in was obtained by multidisciplinary care teams and EMR leadership. Initial review of patients who would meet inclusion criteria for the notification by ICD or CPT codes demonstrated 96% accuracy for identification of laryngectomy patients, with 429 total living laryngectomy patients identified in the institutional EMR. Surveys will be administered weekly to providers who viewed the notification to assess the utility of this notification and solicit feedback for future improvements.  Additionally, the rate of laryngectomy care orders placed will be assessed for further evaluation of the utility of this component of the notification.</p>\n\n<p><strong>Conclusion:</strong> An accurate EMR notification was designed with an ongoing monitoring plan to improve care for laryngectomy patients by providing quick access to information about a patient’s airway anatomy to both otolaryngology and non-otolaryngology providers. Future updates will be made based on feedback obtained in weekly surveys sent to providers who viewed the notification to continue the process of providing safer, more efficient care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153352--></body></html>"
    },
    {
      "uid": "P076",
      "content_id": "154596",
      "abstract_number": "P076",
      "poster_number": "P076",
      "title": "Patient-Specific 3D-Printed Models to Improve Pediatric Head and Neck Tumor R0 Resections: A Case Series",
      "summary": "A total of 85 children with head & neck tumors were identified but only 10 patients underwent total tumor resection with 3D printed model assistance with a 6:4 male: female ratio. The average age at intervention was 11.2±6.31. 50% (5/10) of the cases were excision of an odontogenic tumor, while the rest of the tumors were an epithelioid carcinoma on the parapharyngeal space, a carotid body tumor, a mucoepidermoid...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154596",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maria Polania-Sandoval, MD",
      "presenter": "Maria Polania-Sandoval, MD",
      "authors": "Maria Polania-Sandoval, MD ; Gabriela Cendejas, MS; Kian Tartibi, MS; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Maria Polania-Sandoval",
        "Gabriela Cendejas",
        "Kian Tartibi",
        "Joseph Lopez"
      ],
      "affiliations": [
        "AdventHealth Orlando"
      ],
      "normalized_institutions": [
        "AdventHealth Orlando"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 516,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        ">Conclusion"
      ],
      "sections": {
        "Authors": "Maria Polania-Sandoval, MD ; Gabriela Cendejas, MS; Kian Tartibi, MS; Joseph Lopez, MD, MBA",
        "Affiliations": "AdventHealth Orlando",
        "Introduction": "Three-dimensional (3D) technology has expanded across multiple fields and now is recently used in medicine as a valuable tool in different specialties. These models have been proven to be useful resources for evaluating a tumor and planning resection aimed at achieving negative margin resection (R0) in various medical specialties, especially in orthopedic oncology (1,7). This tool proves its usefulness in guiding resections in anatomically delicate areas, making it particularly relevant for pediatric head and neck surgery. However, there are few studies that have described the use of 3D models as a pre- and post-surgical guide for this population. The aim of this study is to demonstrate the feasibility of 3D-printed models as a tool for achieving negative margin resection (R0) in pediatric head and neck tumors.",
        "Methods": "This is a retrospective review of children who underwent head and neck tumor resections between 2023 and 2025 with a 3D-printed model. We collected data of all surgical tumor resections performed by a single pediatric head and neck surgeon (J.L.) at a tertiary children’s hospital. The inclusion criteria were patients that underwent head and neck tumor excision between September 2023 through December 2025, patients ≤21 years old, patients with a confirmed 3D-printed model, and complete clinical history for data collection. Data collected included age, gender, principal diagnosis, procedure duration, location of the tumor, complications, reintervention rate, R0 resections achievement, remission, and relapse rates.",
        "Results": "A total of 85 children with head & neck tumors were identified but only 10 patients underwent total tumor resection with 3D printed model assistance with a 6:4 male: female ratio. The average age at intervention was 11.2±6.31. 50% (5/10) of the cases were excision of an odontogenic tumor, while the rest of the tumors were an epithelioid carcinoma on the parapharyngeal space, a carotid body tumor, a mucoepidermoid carcinoma of the parotid gland, a Langerhans cell histiocytosis, and a NUT carcinoma. 30% (3/10) of the surgeries were located on the neck, 30% (3/10) on the mandible, followed by 20% on the maxilla, 10% on the base of the skull, and 10% on the ethmoid bone. The mean length operative time was 210.2±163.51 minutes, with increased time due to a 10-hour surgery of an excision of an epithelioid carcinoma. The majority, 90% (9/10) of patients reported an R0 resection confirmed by pathology. There were no complications after surgery; only 1 patient that required reintervention due to an infection of the wound. 60% (6/10) of the patients had a remission after surgery, and no patient has had a relapse of cancer to date.",
        ">Conclusion": "The clinical utility demonstrated in our case series aligns with growing evidence supporting the role of 3D-printed models in improving oncological surgery. The surgeon in this series developed a better understanding of spatial relationships and achieved negative margin resection regardless of the type of tumor in all cases. Here we demonstrated the feasibility using 3D models for pre-operative planning and intraoperative tool for achievement of RO resections of complex pediatric tumors without immediate complications and a high rate of cancer remission."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient-Specific 3D-Printed Models to Improve Pediatric Head and Neck Tumor R0 Resections: A Case Series</span>. <u>Maria Polania-Sandoval, MD</u>; Gabriela Cendejas, MS; Kian Tartibi, MS; Joseph Lopez, MD, MBA. AdventHealth Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Three-dimensional (3D) technology has expanded across multiple fields and now is recently used in medicine as a valuable tool in different specialties. These models have been proven to be useful resources for evaluating a tumor and planning resection aimed at achieving negative margin resection (R0) in various medical specialties, especially in orthopedic oncology (1,7). This tool proves its usefulness in guiding resections in anatomically delicate areas, making it particularly relevant for pediatric head and neck surgery. However, there are few studies that have described the use of 3D models as a pre- and post-surgical guide for this population. The aim of this study is to demonstrate the feasibility of 3D-printed models as a tool for achieving negative margin resection (R0) in pediatric head and neck tumors. </p>\n\n<p><strong>Methods: </strong>This is a retrospective review of children who underwent head and neck tumor resections between 2023 and 2025 with a 3D-printed model. We collected data of all surgical tumor resections performed by a single pediatric head and neck surgeon (J.L.) at a tertiary children’s hospital. The inclusion criteria were patients that underwent head and neck tumor excision between September 2023 through December 2025, patients ≤21 years old, patients with a confirmed 3D-printed model, and complete clinical history for data collection. Data collected included age, gender, principal diagnosis, procedure duration, location of the tumor, complications, reintervention rate, R0 resections achievement, remission, and relapse rates.</p>\n\n<p><strong>Results: </strong>A total of 85 children with head & neck tumors were identified but only 10 patients underwent total tumor resection with 3D printed model assistance with a 6:4 male: female ratio. The average age at intervention was 11.2±6.31. 50% (5/10) of the cases were excision of an odontogenic tumor, while the rest of the tumors were an epithelioid carcinoma on the parapharyngeal space, a carotid body tumor, a mucoepidermoid carcinoma of the parotid gland, a Langerhans cell histiocytosis, and a NUT carcinoma. 30% (3/10) of the surgeries were located on the neck, 30% (3/10) on the mandible, followed by 20% on the maxilla, 10% on the base of the skull, and 10% on the ethmoid bone. The mean length operative time was 210.2±163.51 minutes, with increased time due to a 10-hour surgery of an excision of an epithelioid carcinoma. The majority, 90% (9/10) of patients reported an R0 resection confirmed by pathology. There were no complications after surgery; only 1 patient that required reintervention due to an infection of the wound. 60% (6/10) of the patients had a remission after surgery, and no patient has had a relapse of cancer to date. </p>\n\n<p><strong>>Conclusion: </strong>The clinical utility demonstrated in our case series aligns with growing evidence supporting the role of 3D-printed models in improving oncological surgery. The surgeon in this series developed a better understanding of spatial relationships and achieved negative margin resection regardless of the type of tumor in all cases. Here we demonstrated the feasibility using 3D models for pre-operative planning and intraoperative tool for achievement of RO resections of complex pediatric tumors without immediate complications and a high rate of cancer remission. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154596--></body></html>"
    },
    {
      "uid": "P077",
      "content_id": "154364",
      "abstract_number": "P077",
      "poster_number": "P077",
      "title": "Pediatric Parapharyngeal SMARCB1-Deficient Myoepithelial Carcinoma",
      "summary": "This case illustrates the diagnostic and surgical complexities of SMARCB1-deficient myoepithelial carcinoma in the pediatric parapharyngeal space. Early multidisciplinary collaboration and tailored multimodal therapy are critical to optimizing outcomes while preserving neurovascular function.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154364",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maria Polania-Sandoval, MD",
      "presenter": "Maria Polania-Sandoval, MD",
      "authors": "Ajay Bharathan, MS; Maria Polania-Sandoval, MD ; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Ajay Bharathan",
        "Maria Polania-Sandoval",
        "Gabriela Cendejas",
        "Joseph Lopez"
      ],
      "affiliations": [
        "Advent Health Orlando"
      ],
      "normalized_institutions": [
        "Advent Health Orlando"
      ],
      "session_type": "Poster",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 206,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Description",
        "Management/Outcome",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ajay Bharathan, MS; Maria Polania-Sandoval, MD ; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA",
        "Affiliations": "Advent Health Orlando",
        "Background": "SMARCB1 (INI-1)–deficient myoepithelial carcinoma of soft tissue is an exceptionally rare and aggressive pediatric neoplasm. Although epithelial in origin, these tumors display sarcoma-like behavior and often arise in the head and neck, where complete surgical excision can be technically challenging.",
        "Case Description": "A three-year-old girl, born prematurely at 32 weeks, presented with progressive left neck swelling initially treated as cervical lymphadenitis. Imaging demonstrated a 5.6 cm retropharyngeal mass displacing the carotid space. Excisional biopsy revealed a SMARCB1 (INI-1)–deficient myoepithelial carcinoma, confirmed through molecular testing and secondary review at a research hospital. PET-CT showed no evidence of metastatic disease.",
        "Management/Outcome": "The patient underwent six cycles of modified CHOP-based chemotherapy (vincristine, cyclophosphamide, doxorubicin) with near-complete metabolic response. Definitive management included radical resection via lip-split mandibulotomy with selective neck dissection and carotid artery resection following preoperative embolization. Tracheostomy and gastrostomy were performed concurrently. Facial, vagus, and hypoglossal nerves were preserved.",
        "Abstract": "Postoperatively, the patient maintained normal facial movement and swallow function. Adjuvant proton beam radiation is planned. Follow-up PET-CT demonstrated no evidence of residual or metastatic disease.",
        "Conclusion": "This case illustrates the diagnostic and surgical complexities of SMARCB1-deficient myoepithelial carcinoma in the pediatric parapharyngeal space. Early multidisciplinary collaboration and tailored multimodal therapy are critical to optimizing outcomes while preserving neurovascular function."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pediatric Parapharyngeal SMARCB1-Deficient Myoepithelial Carcinoma</span>. Ajay Bharathan, MS; <u>Maria Polania-Sandoval, MD</u>; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA. Advent Health Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>SMARCB1 (INI-1)–deficient myoepithelial carcinoma of soft tissue is an exceptionally rare and aggressive pediatric neoplasm. Although epithelial in origin, these tumors display sarcoma-like behavior and often arise in the head and neck, where complete surgical excision can be technically challenging.</p>\n\n<p><strong>Case Description: </strong>A three-year-old girl, born prematurely at 32 weeks, presented with progressive left neck swelling initially treated as cervical lymphadenitis. Imaging demonstrated a 5.6 cm retropharyngeal mass displacing the carotid space. Excisional biopsy revealed a SMARCB1 (INI-1)–deficient myoepithelial carcinoma, confirmed through molecular testing and secondary review at a research hospital. PET-CT showed no evidence of metastatic disease.</p>\n\n<p><strong>Management/Outcome: </strong>The patient underwent six cycles of modified CHOP-based chemotherapy (vincristine, cyclophosphamide, doxorubicin) with near-complete metabolic response. Definitive management included radical resection via lip-split mandibulotomy with selective neck dissection and carotid artery resection following preoperative embolization. Tracheostomy and gastrostomy were performed concurrently. Facial, vagus, and hypoglossal nerves were preserved.</p>\n\n<p>Postoperatively, the patient maintained normal facial movement and swallow function. Adjuvant proton beam radiation is planned. Follow-up PET-CT demonstrated no evidence of residual or metastatic disease.</p>\n\n<p><strong>Conclusion: </strong>This case illustrates the diagnostic and surgical complexities of SMARCB1-deficient myoepithelial carcinoma in the pediatric parapharyngeal space. Early multidisciplinary collaboration and tailored multimodal therapy are critical to optimizing outcomes while preserving neurovascular function.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154364--></body></html>"
    },
    {
      "uid": "P078",
      "content_id": "153160",
      "abstract_number": "P078",
      "poster_number": "P078",
      "title": "Factors Affecting Late Stage Presentation in Head and Neck Cancer in Louisiana",
      "summary": "Late-stage presentation in head and neck cancer cancers is strongly linked with age, race/ethnicity and Medicaid insurance status. These findings highlight persistent disparities in early detection and suggest a need for targeted efforts to improve early detection and access to care to reduce these inequities. Future research will focus on identifying the underlying causes of late stage presentation among...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153160",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rula Mualla, MD",
      "presenter": "Rula Mualla, MD",
      "authors": "Rula Mualla, MD 1 ; Xiao-Cheng Wu, MD, MPH 1 ; Sagar Kansara, MD 1 ; San Chu, MS 1 ; Yong Yi, PhD 1 ; Ronald Horswell, PhD 2",
      "normalized_authors": [
        "Rula Mualla",
        "Xiao-Cheng Wu",
        "Sagar Kansara",
        "San Chu",
        "Yong Yi",
        "Ronald Horswell"
      ],
      "affiliations": [
        "Louisiana State University",
        "Pennington Biomedical Research Center"
      ],
      "normalized_institutions": [
        "Louisiana State University",
        "Pennington Biomedical Research Center"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 405,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Rula Mualla, MD 1 ; Xiao-Cheng Wu, MD, MPH 1 ; Sagar Kansara, MD 1 ; San Chu, MS 1 ; Yong Yi, PhD 1 ; Ronald Horswell, PhD 2",
        "Affiliations": "1 Louisiana State University; 2 Pennington Biomedical Research Center",
        "Introduction": "Approximately two thirds of head and neck cancers present with advanced stage at diagnosis. This has remained unchanged in the last two decades despite advances in screening and imaging. Advanced stage at presentation is well known to portend worse prognosis. Although prior research has explored potential causes of late-stage diagnosis, gaps remain in understanding the underlying drivers. This study aimed to determine factors affecting late-stage presentation of head and neck cancer patients in Louisiana.",
        "Methods": "Data on head and neck cancer cases diagnosed between 2015 and 2021 was obtained from the Louisiana Tumor Board Registry. Head and neck cancer cases were subdivided into oral cavity and laryngeal cancer due to limitations in classification by other subsites in the registry. Multivariable logistic regression model was performed to assess the association of age, sex, race, insurance, and socioeconomic status with stage at diagnosis. Advanced stage was defined as AJCC stage 3 and 4. To validate model specification, insurance effects were estimated using a propensity score approach, specifically comparing Medicaid to private insurance and to Medicare.",
        "Results": "Of the 3886 patients in the study. 74% were male, 74% were non Hispanic white, and 63% were 60 or older. For larynx cancer, non- Hispanic black race, age > 70, and Medicaid insurance were associated with late-stage diagnosis. For oral cavity cancer, male, non Hispanic black race, and Medicaid insurance were associated with late-stage diagnosis.",
        "Abstract": "Regarding socioeconomic status, poverty and rural location were not significantly associated with stage at diagnosis. Those socioeconomic factors, however, are measured at the census tract (not individual) level. Propensity score stratification analysis demonstrated that Medicaid patients with larynx cancer had 80% higher odds of late-stage disease than those with private insurance (OR=1.80; 95% CI: 1.41-2.41) ) and 75% higher odds than those with Medicare (OR=1.75; 95% CI: 1.37-2.243). Similar findings were observed for oral cancer, with 85% higher odds among Medicaid patients compared with private insurance (OR=1.85, 95% CI: 1.45-2.37) and 77% higher odds compared with Medicare (OR=1.77; 95% CI: 1.34-2.34).",
        "Conclusions": "Late-stage presentation in head and neck cancer cancers is strongly linked with age, race/ethnicity and Medicaid insurance status. These findings highlight persistent disparities in early detection and suggest a need for targeted efforts to improve early detection and access to care to reduce these inequities. Future research will focus on identifying the underlying causes of late stage presentation among Medicaid patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Factors Affecting Late Stage Presentation in Head and Neck Cancer in Louisiana</span>. <u>Rula Mualla, MD</u><sup>1</sup>; Xiao-Cheng Wu, MD, MPH<sup>1</sup>; Sagar Kansara, MD<sup>1</sup>; San Chu, MS<sup>1</sup>; Yong Yi, PhD<sup>1</sup>; Ronald Horswell, PhD<sup>2</sup>. <sup>1</sup>Louisiana State University; <sup>2</sup>Pennington Biomedical Research Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Approximately two thirds of head and neck cancers present with advanced stage at diagnosis. This has remained unchanged in the last two decades despite advances in screening and imaging. Advanced stage at presentation is well known to portend worse prognosis. Although prior research has explored potential causes of late-stage diagnosis, gaps remain in understanding the underlying drivers. This study aimed to determine factors affecting late-stage presentation of head and neck cancer patients in Louisiana.</p>\n\n<p><strong>Methods: </strong>Data on head and neck cancer cases diagnosed between 2015 and 2021 was obtained from the Louisiana Tumor Board Registry. Head and neck cancer cases were subdivided into oral cavity and laryngeal cancer due to limitations in classification by other subsites in the registry. Multivariable logistic regression model was performed to assess the association of age, sex, race, insurance, and socioeconomic status with stage at diagnosis. Advanced stage was defined as AJCC stage 3 and 4. To validate model specification, insurance effects were estimated using a propensity score approach, specifically comparing Medicaid to private insurance and to Medicare.</p>\n\n<p><strong>Results: </strong>Of the 3886 patients in the study. 74% were male, 74% were non Hispanic white, and 63% were 60 or older.  For larynx cancer, non- Hispanic black race, age > 70, and Medicaid insurance were associated with late-stage diagnosis. For oral cavity cancer, male, non Hispanic black race, and Medicaid insurance were associated with late-stage diagnosis. </p>\n\n<p>Regarding socioeconomic status, poverty and rural location were not significantly associated with stage at diagnosis. Those socioeconomic factors, however, are measured at the census tract (not individual) level.</p>\n\n<p>Propensity score stratification analysis demonstrated that Medicaid patients with larynx cancer had 80% higher odds of late-stage disease than those with private insurance (OR=1.80; 95% CI: 1.41-2.41) ) and 75% higher odds than those with Medicare (OR=1.75; 95% CI: 1.37-2.243). Similar findings were observed for oral cancer, with 85% higher odds among Medicaid patients compared with private insurance (OR=1.85, 95% CI: 1.45-2.37) and 77% higher odds compared with Medicare (OR=1.77; 95% CI: 1.34-2.34).</p>\n\n<p><strong>Conclusions: </strong>Late-stage presentation in head and neck cancer cancers is strongly linked with age, race/ethnicity and Medicaid insurance status. These findings highlight persistent disparities in early detection and suggest a need for targeted efforts to improve early detection and access to care to reduce these inequities. Future research will focus on identifying the underlying causes of late stage presentation among Medicaid patients.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153160--></body></html>"
    },
    {
      "uid": "P079",
      "content_id": "155328",
      "abstract_number": "P079",
      "poster_number": "P079",
      "title": "Impact of Provider Outreach on Pediatric Head and Neck Oncology Referral Patterns: An Interrupted Time Series Analysis",
      "summary": "A structured provider outreach initiative was associated with a substantial immediate increase in pediatric head and neck oncology referrals, consistent with improved awareness of specialized services and clearer referral pathways. These findings suggest that targeted engagement with community clinicians can strengthen referral networks and facilitate timely access to multidisciplinary pediatric head and neck...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155328",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maria J Polania-Sandoval, MD",
      "presenter": "Maria J Polania-Sandoval, MD",
      "authors": "Kian D Tartibi, MBA; Maria J Polania-Sandoval, MD ; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Kian D Tartibi",
        "Maria J Polania-Sandoval",
        "Gabriela Cendejas",
        "Joseph Lopez"
      ],
      "affiliations": [
        "AdventHealth for Children"
      ],
      "normalized_institutions": [
        "AdventHealth for Children"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_02%20PM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_02%20PM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155328"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_14%20PM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_14%20PM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155328"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 339,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Kian D Tartibi, MBA; Maria J Polania-Sandoval, MD ; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA",
        "Affiliations": "AdventHealth for Children",
        "Introduction": "Timely referral to specialized pediatric head and neck oncology programs is essential for coordinated multidisciplinary cancer care. Although malignancy is typically recognized as high acuity, delays may still occur due to limited awareness of specialized services, unclear referral pathways, and variable familiarity among community clinicians with regional pediatric head and neck oncology resources. Structured provider engagement may improve referral connectivity and access to subspecialty care. This study evaluated whether a targeted provider outreach initiative influenced pediatric head and neck oncology referral patterns.",
        "Methods": "An interrupted time series analysis was performed using monthly external referral data to a pediatric head and neck oncology program from January 2021 through December 2025. The intervention, initiated in March 2023, consisted of recurring educational and networking sessions for community pediatricians, family physicians, advanced practice providers, dentists, and other referring clinicians focused on oncologic diagnoses, available multidisciplinary services, and referral processes. Segmented linear regression assessed baseline trend, immediate level change at intervention, and post-intervention slope change. Monthly referral volume over time with the intervention point is shown in Figure 1, and model coefficients are summarized in Table 1.",
        "Results": "Sixty monthly observations were analyzed with March 2023 designated as the intervention point. Prior to intervention, referrals demonstrated a significant increasing baseline trend (β = 0.27 referrals/month, p = 0.004). Following program implementation, an immediate and significant increase in referral volume was observed (level change β = 7.53, p < 0.001). No significant change in post-intervention slope was detected (β = −0.12, p = 0.26). Overall model fit was statistically significant (p < 0.001). Visual inspection demonstrated a sustained upward shift in referral volume after intervention (Figure 1).",
        "Conclusions": "A structured provider outreach initiative was associated with a substantial immediate increase in pediatric head and neck oncology referrals, consistent with improved awareness of specialized services and clearer referral pathways. These findings suggest that targeted engagement with community clinicians can strengthen referral networks and facilitate timely access to multidisciplinary pediatric head and neck cancer care. Outreach-based referral optimization represents a scalable strategy for improving access to specialized oncologic services."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Provider Outreach on Pediatric Head and Neck Oncology Referral Patterns: An Interrupted Time Series Analysis</span>. Kian D Tartibi, MBA; <u>Maria J Polania-Sandoval, MD</u>; Gabriela Cendejas, MS; Joseph Lopez, MD, MBA. AdventHealth for Children<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Timely referral to specialized pediatric head and neck oncology programs is essential for coordinated multidisciplinary cancer care. Although malignancy is typically recognized as high acuity, delays may still occur due to limited awareness of specialized services, unclear referral pathways, and variable familiarity among community clinicians with regional pediatric head and neck oncology resources. Structured provider engagement may improve referral connectivity and access to subspecialty care. This study evaluated whether a targeted provider outreach initiative influenced pediatric head and neck oncology referral patterns.</p>\n\n<p><strong>Methods: </strong>An interrupted time series analysis was performed using monthly external referral data to a pediatric head and neck oncology program from January 2021 through December 2025. The intervention, initiated in March 2023, consisted of recurring educational and networking sessions for community pediatricians, family physicians, advanced practice providers, dentists, and other referring clinicians focused on oncologic diagnoses, available multidisciplinary services, and referral processes. Segmented linear regression assessed baseline trend, immediate level change at intervention, and post-intervention slope change. Monthly referral volume over time with the intervention point is shown in Figure 1, and model coefficients are summarized in Table 1.</p>\n\n<p><strong>Results: </strong>Sixty monthly observations were analyzed with March 2023 designated as the intervention point. Prior to intervention, referrals demonstrated a significant increasing baseline trend (β = 0.27 referrals/month, p = 0.004). Following program implementation, an immediate and significant increase in referral volume was observed (level change β = 7.53, p < 0.001). No significant change in post-intervention slope was detected (β = −0.12, p = 0.26). Overall model fit was statistically significant (p < 0.001). Visual inspection demonstrated a sustained upward shift in referral volume after intervention (Figure 1).</p>\n\n<p><strong>Conclusions: </strong>A structured provider outreach initiative was associated with a substantial immediate increase in pediatric head and neck oncology referrals, consistent with improved awareness of specialized services and clearer referral pathways. These findings suggest that targeted engagement with community clinicians can strengthen referral networks and facilitate timely access to multidisciplinary pediatric head and neck cancer care. Outreach-based referral optimization represents a scalable strategy for improving access to specialized oncologic services. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_02%20PM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155328/Screenshot%202026-02-27%20at%202_15_14%20PM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155328--></body></html>"
    },
    {
      "uid": "P080",
      "content_id": "154320",
      "abstract_number": "P080",
      "poster_number": "P080",
      "title": "Tuberculosis (TB) Lymphadenitis and Persistent Paradoxical Reaction in a 23-year-old Pregnant Woman from Vietnam",
      "summary": "TB lymphadenitis remains a significant public health challenge, with rising incidence in some high-income regions. Diagnostic challenges, including variable accuracy of FNA biopsy and atypical presentations, underscore the need to re-evaluate diagnostic approaches and maintain high suspicion in patients with persistent or atypical cervical lymphadenopathy. This case illustrates how multidisciplinary coordination...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154320",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kimya Manouchehri, MD",
      "presenter": "Kimya Manouchehri, MD",
      "authors": "Kimya Manouchehri, MD ; Kevin P Higgins, MD, FRCSC",
      "normalized_authors": [
        "Kimya Manouchehri",
        "Kevin P Higgins, FRCSC"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 418,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction/Background",
        "Case Presentation",
        "Management",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kimya Manouchehri, MD ; Kevin P Higgins, MD, FRCSC",
        "Affiliations": "Department of Otolaryngology - Head and Neck Surgery, University of Toronto",
        "Introduction/Background": "Tuberculosis (TB) lymphadenitis is the most common form of extrapulmonary tuberculosis, and the diagnosis can be challenging due to variable sensitivity and specificity of biopsy modalities. Pregnancy further complicates the diagnosis and treatment of TB due to limited radiographic options and required adjustments of antimycobacterial regimens. We present a case of cervical TB lymphadenitis in early pregnancy with a challenging diagnostic course and a prolonged paradoxical reaction requiring multidisciplinary involvement.",
        "Case Presentation": "A 23-year-old Vietnamese-born woman, 8 weeks pregnant, presented with a week of painful right-sided neck swelling and fevers. Her last visit to Vietnam was 2 years prior and she had no history of exposure to TB. Ultrasound demonstrated necrotic-appearing lymphadenopathy with features of suppurative adenitis. Despite a trial of amoxicillin-clavulanate, which was guided by the Infectious Diseases team to avoid teratogenic effects, her symptoms progressed, and she re-presented with worsening neck swelling and dyspnea. Fine-needle aspiration revealed necrotic debris without diagnostic features. Two subsequent core needle biopsies with ultrasound guidance were performed, and the final specimen was positive for Mycobacterium tuberculosis complex on real-time PCR, with non-caseating granulomas on pathology. Chest imaging showed no pulmonary involvement.",
        "Management": "The patient was diagnosed with TB lymphadenitis and was started on a 6-month regimen of Isoniazid, Rifampin, Ethambutol, and Vitamin B6, with pyrazinamide withheld due to risk of teratogenic effects. During treatment, she developed a paradoxical reaction with increasing lymphadenopathy and persistent sinus tract drainage. Her pain and swelling improved by four months but plateaued. Postpartum CT, coordinated by OHNS to be performed on the same admission as her delivery, revealed calcified necrotic nodes with sinus tract formation, and she was therefore scheduled for surgical excision for symptomatic management.",
        "Discussion": "This case highlights the diagnostic complexity of TB lymphadenitis, particularly in pregnancy, where imaging and therapeutic options are more limited. It also underscores the evolving role of ultrasound-guided core biopsy, which provided the definitive diagnosis in this patient. Paradoxical reactions can occur in up to 20% of HIV-negative patients and may complicate an otherwise appropriate treatment course. Surgical excision, while not commonly indicated, may be considered for persistent, symptomatic disease after medical therapy.",
        "Conclusion": "TB lymphadenitis remains a significant public health challenge, with rising incidence in some high-income regions. Diagnostic challenges, including variable accuracy of FNA biopsy and atypical presentations, underscore the need to re-evaluate diagnostic approaches and maintain high suspicion in patients with persistent or atypical cervical lymphadenopathy. This case illustrates how multidisciplinary coordination supports timely diagnosis, safe imaging, and treatment decisions during pregnancy, as well as the individualized management of paradoxical reactions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tuberculosis (TB) Lymphadenitis and Persistent Paradoxical Reaction in a 23-year-old Pregnant Woman from Vietnam</span>. <u>Kimya Manouchehri, MD</u>; Kevin P Higgins, MD, FRCSC. Department of Otolaryngology - Head and Neck Surgery, University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction/Background:</strong> Tuberculosis (TB) lymphadenitis is the most common form of extrapulmonary tuberculosis, and the diagnosis can be challenging due to variable sensitivity and specificity of biopsy modalities. Pregnancy further complicates the diagnosis and treatment of TB due to limited radiographic options and required adjustments of antimycobacterial regimens. We present a case of cervical TB lymphadenitis in early pregnancy with a challenging diagnostic course and a prolonged paradoxical reaction requiring multidisciplinary involvement.</p>\n\n<p><strong>Case Presentation: </strong>A 23-year-old Vietnamese-born woman, 8 weeks pregnant, presented with a week of painful right-sided neck swelling and fevers. Her last visit to Vietnam was 2 years prior and she had no history of exposure to TB. Ultrasound demonstrated necrotic-appearing lymphadenopathy with features of suppurative adenitis. Despite a trial of amoxicillin-clavulanate, which was guided by the Infectious Diseases team to avoid teratogenic effects, her symptoms progressed, and she re-presented with worsening neck swelling and dyspnea. Fine-needle aspiration revealed necrotic debris without diagnostic features. Two subsequent core needle biopsies with ultrasound guidance were performed, and the final specimen was positive for Mycobacterium tuberculosis complex on real-time PCR, with non-caseating granulomas on pathology. Chest imaging showed no pulmonary involvement.</p>\n\n<p><strong>Management: </strong>The patient was diagnosed with TB lymphadenitis and was started on a 6-month regimen of Isoniazid, Rifampin, Ethambutol, and Vitamin B6, with pyrazinamide withheld due to risk of teratogenic effects. During treatment, she developed a paradoxical reaction with increasing lymphadenopathy and persistent sinus tract drainage. Her pain and swelling improved by four months but plateaued. Postpartum CT, coordinated by OHNS to be performed on the same admission as her delivery, revealed calcified necrotic nodes with sinus tract formation, and she was therefore scheduled for surgical excision for symptomatic management.</p>\n\n<p><strong>Discussion:</strong> This case highlights the diagnostic complexity of TB lymphadenitis, particularly in pregnancy, where imaging and therapeutic options are more limited. It also underscores the evolving role of ultrasound-guided core biopsy, which provided the definitive diagnosis in this patient. Paradoxical reactions can occur in up to 20% of HIV-negative patients and may complicate an otherwise appropriate treatment course. Surgical excision, while not commonly indicated, may be considered for persistent, symptomatic disease after medical therapy.</p>\n\n<p><strong>Conclusion: </strong>TB lymphadenitis remains a significant public health challenge, with rising incidence in some high-income regions. Diagnostic challenges, including variable accuracy of FNA biopsy and atypical presentations, underscore the need to re-evaluate diagnostic approaches and maintain high suspicion in patients with persistent or atypical cervical lymphadenopathy. This case illustrates how multidisciplinary coordination supports timely diagnosis, safe imaging, and treatment decisions during pregnancy, as well as the individualized management of paradoxical reactions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154320--></body></html>"
    },
    {
      "uid": "P081",
      "content_id": "153291",
      "abstract_number": "P081",
      "poster_number": "P081",
      "title": "EXIT Procedure in Neonatal Airway Obstruction: Clinical Experience and Management Algorithm",
      "summary": "The EXIT procedure represents a safe, effective, and controlled strategy for airway establishment in neonates with prenatally anticipated airway obstruction. Early involvement of a paediatric otolaryngology team is critical to optimize outcomes. Based on our experience, we present a structured management algorithm to standardize decision-making and improve perinatal airway safety in high-risk deliveries",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153291",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tagharid Marhoon Al Riyami, MD",
      "presenter": "Tagharid Marhoon Al Riyami, MD",
      "authors": "Salma Al Sheibani, MD; Faisal Al Kalbani, MD; Mohammed Al Ajmi, MD; Tagharid Marhoon Al Riyami, MD",
      "normalized_authors": [
        "Salma Al Sheibani",
        "Faisal Al Kalbani",
        "Mohammed Al Ajmi",
        "Tagharid Marhoon Al Riyami"
      ],
      "affiliations": [
        "Al Nahdha Hospital"
      ],
      "normalized_institutions": [
        "Al Nahdha Hospital"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 234,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Salma Al Sheibani, MD; Faisal Al Kalbani, MD; Mohammed Al Ajmi, MD; Tagharid Marhoon Al Riyami, MD",
        "Affiliations": "Al Nahdha Hospital",
        "Background": "The Ex-Utero Intrapartum Treatment (EXIT) procedure enables controlled establishment of a secure airway while maintaining uteroplacental circulation during delivery. It is indicated in fetuses with prenatally diagnosed congenital anomalies that pose a high risk of airway obstruction at birth.",
        "Objective": "To report our institutional series of EXIT procedures for anticipated neonatal airway obstruction due to congenital cervical masses, describe clinical outcomes, and propose a management algorithm to guide perinatal airway planning.",
        "Methods": "We conducted a retrospective chart review of seven fetuses who underwent EXIT delivery with paediatric otolaryngology involvement. Perinatal airway management prioritized endotracheal intubation; if intubation failed or was not feasible, tracheostomy was performed under uteroplacental support. Following stabilization, postnatal imaging and airway assessments guided the timing of surgical excision of the cervical mass.",
        "Results": "Histopathology revealed immature teratoma in four neonates and lymphangioma in one; two cases remain under follow-up. Five infants underwent successful mass excision during the neonatal period. In the majority of cases, postoperative airway evaluation demonstrated long-term airway patency, with favorable clinical progression and survival. There were no intraoperative mortalities, and perinatal morbidity was minimized through coordinated multidisciplinary management.",
        "Conclusion": "The EXIT procedure represents a safe, effective, and controlled strategy for airway establishment in neonates with prenatally anticipated airway obstruction. Early involvement of a paediatric otolaryngology team is critical to optimize outcomes. Based on our experience, we present a structured management algorithm to standardize decision-making and improve perinatal airway safety in high-risk deliveries"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>EXIT Procedure in Neonatal Airway Obstruction: Clinical Experience and Management Algorithm</span>. Salma Al Sheibani, MD; Faisal Al Kalbani, MD; Mohammed Al Ajmi, MD; <u>Tagharid Marhoon Al Riyami, MD</u>. Al Nahdha Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The Ex-Utero Intrapartum Treatment (EXIT) procedure enables controlled establishment of a secure airway while maintaining uteroplacental circulation during delivery. It is indicated in fetuses with prenatally diagnosed congenital anomalies that pose a high risk of airway obstruction at birth.</p>\n\n<p><strong>Objective: </strong>To report our institutional series of EXIT procedures for anticipated neonatal airway obstruction due to congenital cervical masses, describe clinical outcomes, and propose a management algorithm to guide perinatal airway planning.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective chart review of seven fetuses who underwent EXIT delivery with paediatric otolaryngology involvement. Perinatal airway management prioritized endotracheal intubation; if intubation failed or was not feasible, tracheostomy was performed under uteroplacental support. Following stabilization, postnatal imaging and airway assessments guided the timing of surgical excision of the cervical mass.</p>\n\n<p><strong>Results: </strong>Histopathology revealed immature teratoma in four neonates and lymphangioma in one; two cases remain under follow-up. Five infants underwent successful mass excision during the neonatal period. In the majority of cases, postoperative airway evaluation demonstrated long-term airway patency, with favorable clinical progression and survival. There were no intraoperative mortalities, and perinatal morbidity was minimized through coordinated multidisciplinary management.</p>\n\n<p><strong>Conclusion: </strong>The EXIT procedure represents a safe, effective, and controlled strategy for airway establishment in neonates with prenatally anticipated airway obstruction. Early involvement of a paediatric otolaryngology team is critical to optimize outcomes. Based on our experience, we present a structured management algorithm to standardize decision-making and improve perinatal airway safety in high-risk deliveries</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153291--></body></html>"
    },
    {
      "uid": "P083",
      "content_id": "154387",
      "abstract_number": "P083",
      "poster_number": "P083",
      "title": "Are mucosal head and neck cancers now seen more in rural settings?",
      "summary": "Over the last twenty years, there has been a statistically significant shift in non-HPV associated mucosal HNSCC cancers being treated in rural settings. Patients presenting with late-stage disease were statistically more likely to reside in rural areas. Travel distance to treatment increased for all groups over the last twenty years. These findings underscore the need for strategies to address geographic access...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154387",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shriya Airen, MD",
      "presenter": "Shriya Airen, MD",
      "authors": "Shriya Airen, MD ; Luis Alvarado, MS; Jeffrey C Liu, MD",
      "normalized_authors": [
        "Shriya Airen",
        "Luis Alvarado",
        "Jeffrey C Liu"
      ],
      "affiliations": [
        "St. Luke's University Health Network"
      ],
      "normalized_institutions": [
        "St. Luke's University Health Network"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 438,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Shriya Airen, MD ; Luis Alvarado, MS; Jeffrey C Liu, MD",
        "Affiliations": "St. Luke's University Health Network",
        "Background": "Over the last twenty years, the incidence of non-HPV associated mucosal squamous cell carcinoma (SCC) has steadily decreased. As cancer care has become more specialized, such care has often been delivered in concentrated, often urban, centers. Rural patients, on the other hand, face many barriers to cancer care, including longer travel distances and more limited head and neck specialist access. We hypothesized that head and neck cancer in rural settings would be associated with greater travel distances and later-stage disease, as well as represent a greater proportion of head and neck cancers treated in the United States.",
        "Methods": "Using the National Cancer Database (NCDB), 576,484 cases of mucosal HNSCC (oral cavity, larynx, hypopharynx, and oropharyngeal SCC) from 2003–2022 were analyzed. Where HPV data for oropharynx cancer was available, only HPV negative cancers were included. For descriptive travel-distance analysis, we used the standard NCDB 3-category rurality variable: Metro, Urban, and Rural. We also constructed a 2-category exposure variable (Metro vs Rural) using both Rural-Urban Continuum Codes (RUCC) and circle distance. Rurality and stage differences were assessed. Subsite-specific analyses were performed for oral cavity and larynx/hypopharynx cancers. Stage at diagnosis (I–II vs III–IV) was compared between rural and metro patients using the Mann-Whitney test.",
        "Results": "Over the 20 year cohort, rural patients represented approximately 32-33% of the population while metro patients were 66-67% of cases. The difference in metro and rural settings over time was statistically significant (p<0.05), with just over 1% difference. When further stratified by subsite, oral cavity from 2003 – 2022 (p > 0.05) and laryngeal/hypopharyngeal SCC incidence from 2003 – 2012 (p > 0.05) remained stable over time in metro vs rural populations. However, there was a statistically significant difference (p<0.05) in the incidence of laryngeal/hypopharyngeal SCC from 2013 - 2022, with a 2% increase in incidence in rural areas. Early versus late stage at diagnosis differed significantly (p<0.001) when comparing rural vs metro populations. Long-distance travel increased across all RUCC groups, with proportions nearly doubling from ~6% in 2003 to ~12% in 2022, though the rise occurred in parallel for metro, urban, and rural patients.",
        "Conclusion": "Over the last twenty years, there has been a statistically significant shift in non-HPV associated mucosal HNSCC cancers being treated in rural settings. Patients presenting with late-stage disease were statistically more likely to reside in rural areas. Travel distance to treatment increased for all groups over the last twenty years. These findings underscore the need for strategies to address geographic access challenges in head and neck cancer care, but especially in rural settings where a greater fraction of cases are being treated."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Are mucosal head and neck cancers now seen more in rural settings?</span>. <u>Shriya Airen, MD</u>; Luis Alvarado, MS; Jeffrey C Liu, MD. St. Luke's University Health Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Over the last twenty years, the incidence of non-HPV associated mucosal squamous cell carcinoma (SCC) has steadily decreased. As cancer care has become more specialized, such care has often been delivered in concentrated, often urban, centers. Rural patients, on the other hand, face many barriers to cancer care, including longer travel distances and more limited head and neck specialist access. We hypothesized that head and neck cancer in rural settings would be associated with greater travel distances and later-stage disease, as well as represent a greater proportion of head and neck cancers treated in the United States. </p>\n\n<p><strong>Methods: </strong>Using the National Cancer Database (NCDB), 576,484 cases of mucosal HNSCC (oral cavity, larynx, hypopharynx, and oropharyngeal SCC) from 2003–2022 were analyzed. Where HPV data for oropharynx cancer was available, only HPV negative cancers were included. For descriptive travel-distance analysis, we used the standard NCDB 3-category rurality variable: Metro, Urban, and Rural. We also constructed a 2-category exposure variable (Metro vs Rural) using both Rural-Urban Continuum Codes (RUCC) and circle distance. Rurality and stage differences were assessed.  Subsite-specific analyses were performed for oral cavity and larynx/hypopharynx cancers. Stage at diagnosis (I–II vs III–IV) was compared between rural and metro patients using the Mann-Whitney test.</p>\n\n<p><strong>Results: </strong>Over the 20 year cohort, rural patients represented approximately 32-33% of the population while metro patients were 66-67% of cases. The difference in metro and rural settings over time was statistically significant (p<0.05), with just over 1% difference. When further stratified by subsite, oral cavity from 2003 – 2022 (p > 0.05) and laryngeal/hypopharyngeal SCC incidence from 2003 – 2012 (p > 0.05) remained stable over time in metro vs rural populations. However, there was a statistically significant difference (p<0.05) in the incidence of laryngeal/hypopharyngeal SCC from 2013 - 2022, with a 2% increase in incidence in rural areas. Early versus late stage at diagnosis differed significantly (p<0.001) when comparing rural vs metro populations. Long-distance travel increased across all RUCC groups, with proportions nearly doubling from ~6% in 2003 to ~12% in 2022, though the rise occurred in parallel for metro, urban, and rural patients.</p>\n\n<p><strong>Conclusion: </strong>Over the last twenty years, there has been a statistically significant shift in non-HPV associated mucosal HNSCC cancers being treated in rural settings. Patients presenting with late-stage disease were statistically more likely to reside in rural areas. Travel distance to treatment increased for all groups over the last twenty years. These findings underscore the need for strategies to address geographic access challenges in head and neck cancer care, but especially in rural settings where a greater fraction of cases are being treated.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154387--></body></html>"
    },
    {
      "uid": "P084",
      "content_id": "153214",
      "abstract_number": "P084",
      "poster_number": "P084",
      "title": "Emergency Department Entry Pathways in Head and Neck Squamous Cell Carcinoma: Associations with Disease Severity, Treatment Delay, and Mortality",
      "summary": "Nearly one-quarter of HNSCC patients at our institution initially presented through the ED, substantially higher than national estimates, and this fact likely reflects the demographic and socioeconomic characteristics of our highly vulnerable catchment area. ED-presenting patients were younger, reported shorter symptom duration, and had more advanced disease driven primarily by tumor T stage, suggesting a subset...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153214",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "P R Ratmeyer, MD",
      "presenter": "P R Ratmeyer, MD",
      "authors": "P R Ratmeyer, MD ; D Weatherford, MD; J M Soffer, MD; P Putnam, MD; J P Gleysteen, MD; C B Wood, MD",
      "normalized_authors": [
        "P R Ratmeyer",
        "D Weatherford",
        "J M Soffer",
        "P Putnam",
        "J P Gleysteen",
        "C B Wood"
      ],
      "affiliations": [
        "University of Tennessee Health Science Center: Department of Otolaryngology Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Tennessee Health Science Center: Department of Otolaryngology Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 387,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "P R Ratmeyer, MD ; D Weatherford, MD; J M Soffer, MD; P Putnam, MD; J P Gleysteen, MD; C B Wood, MD",
        "Affiliations": "University of Tennessee Health Science Center: Department of Otolaryngology Head and Neck Surgery",
        "Introduction": "Head and neck cancer (HNC) remains a major cause of morbidity and mortality worldwide, and the route through which patients enter the healthcare system is critical to timely diagnosis and management. Population-based analyses indicate that roughly 7–9% of new HNC diagnoses in the United States occur in the emergency department (ED), with patients more likely to present with advanced disease, belong to racial and ethnic minority groups, and have lower socioeconomic status. However, these studies have some limitations in regards to granularity of available patient-level data. The current study aims to better characterize patients at risk for ED diagnosis of head and neck squamous cell carcinoma (HNSCC) within a single-center population.",
        "Methods": "A retrospective review was conducted of all HNSCC patients evaluated by our head and neck surgery service between January 2022 and September 2024. Patients ≥18 years with a new, biopsy-proven, HNSCC discussed at multidisciplinary tumor board were included. Patients with prior head and neck malignancy, chemotherapy, or radiation were excluded. Data were collected on presentation location, demographics, tumor stage, treatment, and oncologic outcomes. Univariate and multivariate analyses were performed.",
        "Results": "Three hundred eight patients met inclusion criteria. Sixty-eight (22%) initially presented through the ED, while 240 (78%) presented in an outpatient setting. ED presenters were more likely to be younger (p<0.001), black (p<0.001), uninsured (p=0.046), and tobacco users (p= 0.002). They had higher T stage (p<0.001) and N stage (p=0.020) despite reporting shorter symptom duration (p=0.024). ED presentation was associated with treatment delays (p<0.001) and higher mortality (p=0.005). Sex and recurrence rates were not significantly different.",
        "Conclusion": "Nearly one-quarter of HNSCC patients at our institution initially presented through the ED, substantially higher than national estimates, and this fact likely reflects the demographic and socioeconomic characteristics of our highly vulnerable catchment area. ED-presenting patients were younger, reported shorter symptom duration, and had more advanced disease driven primarily by tumor T stage, suggesting a subset with more aggressive, symptomatic, rapidly progressing tumors, or more limited access to preventative or primary health care services. Given increased treatment delays and higher mortality observed, early identification of patients likely to enter the health system through the ED and more intensive follow up strategies after ED presentation remains critical to improving HNSCC care pathways and outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Emergency Department Entry Pathways in Head and Neck Squamous Cell Carcinoma: Associations with Disease Severity, Treatment Delay, and Mortality</span>. <u>P R Ratmeyer, MD</u>; D Weatherford, MD; J M Soffer, MD; P Putnam, MD; J P Gleysteen, MD; C B Wood, MD. University of Tennessee Health Science Center: Department of Otolaryngology Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancer (HNC) remains a major cause of morbidity and mortality worldwide, and the route through which patients enter the healthcare system is critical to timely diagnosis and management. Population-based analyses indicate that roughly 7–9% of new HNC diagnoses in the United States occur in the emergency department (ED), with patients more likely to present with advanced disease, belong to racial and ethnic minority groups, and have lower socioeconomic status. However, these studies have some limitations in regards to granularity of available patient-level data. The current study aims to better characterize patients at risk for ED diagnosis of head and neck squamous cell carcinoma (HNSCC) within a single-center population.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted of all HNSCC patients evaluated by our head and neck surgery service between January 2022 and September 2024. Patients ≥18 years with a new, biopsy-proven, HNSCC discussed at multidisciplinary tumor board were included. Patients with prior head and neck malignancy, chemotherapy, or radiation were excluded. Data were collected on presentation location, demographics, tumor stage, treatment, and oncologic outcomes. Univariate and multivariate analyses were performed.</p>\n\n<p><strong>Results: </strong>Three hundred eight patients met inclusion criteria. Sixty-eight (22%) initially presented through the ED, while 240 (78%) presented in an outpatient setting. ED presenters were more likely to be younger (p<0.001), black (p<0.001), uninsured (p=0.046), and tobacco users (p= 0.002). They had higher T stage (p<0.001) and N stage (p=0.020) despite reporting shorter symptom duration (p=0.024). ED presentation was associated with treatment delays (p<0.001) and higher mortality (p=0.005). Sex and recurrence rates were not significantly different.</p>\n\n<p><strong>Conclusion: </strong>Nearly one-quarter of HNSCC patients at our institution initially presented through the ED, substantially higher than national estimates, and this fact likely reflects the demographic and socioeconomic characteristics of our highly vulnerable catchment area. ED-presenting patients were younger, reported shorter symptom duration, and had more advanced disease driven primarily by tumor T stage, suggesting a subset with more aggressive, symptomatic, rapidly progressing tumors, or more limited access to preventative or primary health care services. Given increased treatment delays and higher mortality observed, early identification of patients likely to enter the health system through the ED and more intensive follow up strategies after ED presentation remains critical to improving HNSCC care pathways and outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153214--></body></html>"
    },
    {
      "uid": "P085",
      "content_id": "155550",
      "abstract_number": "P085",
      "poster_number": "P085",
      "title": "3D-Printed Head and Neck Model for Microsurgical Training: Early Model Development Study",
      "summary": "This early model development study supports the educational value and realism of a 3D-printed model for head and neck free tissue transfer and the unique challenges encountered due to proximity to the mandible. Continued refinement of the design based on expert and trainee insight will optimize the model’s utility as a training tool, ultimately expanding access to microsurgical training.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155550",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jaime A Peña Garcia",
      "presenter": "Jaime A Peña Garcia",
      "authors": "Jaime A Peña Garcia ; Myiah Quach, BS; Weifeng Zeng, MD; Samuel O Poore, MD, PhD; Aaron M Wieland",
      "normalized_authors": [
        "Jaime A Peña Garcia",
        "Myiah Quach",
        "Weifeng Zeng",
        "Samuel O Poore",
        "Aaron M Wieland"
      ],
      "affiliations": [
        "University of Wisconsin School of Medicine and Public Health"
      ],
      "normalized_institutions": [
        "University of Wisconsin School of Medicine and Public Health"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155550/Mandible%20model%20abstract.gif",
          "source_url": "https://www.submitmyabstract.com/abs/images/155550/Mandible%20model%20abstract.gif",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155550"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jaime A Peña Garcia ; Myiah Quach, BS; Weifeng Zeng, MD; Samuel O Poore, MD, PhD; Aaron M Wieland",
        "Affiliations": "University of Wisconsin School of Medicine and Public Health",
        "Introduction": "Microsurgical free tissue transfer is a cornerstone of head and neck reconstruction and requires advanced technical skills and extensive operative training. Opportunities for trainees to develop microsurgical proficiency can be limited by operative time constraints, variability in case exposure, and the high-stakes nature of live surgery. Simulation-based training models have emerged as valuable adjuncts to traditional operative education. However, many existing models lack anatomic realism or accessibility. In particular, the proximity of the mandible with the cervical vasculature creates difficult anatomic constraints due to challenging orientations and ergonomics during microvascular anastomosis. Combination of three-dimensional (3D) printing and the validated blue-blood chicken thigh model offers a promising approach for developing an anatomically accurate simulation tool. The primary objective of this study was to evaluate the perceived educational value, realism, and utility of our 3D-printed reconstructive model for head and neck specific microsurgical training among surgical trainees and attending surgeons.",
        "Methods": "In this prospective, multi-institutional study, Otolaryngology and Plastic Surgery trainees and attending surgeons were invited to perform a single end-to-end microsurgical anastomosis on blue-blood chicken thigh femoral artery vessels integrated into a 3D-printed head and neck reconstructive model to mimic anastomoses inferior to the mandible using a binocular microscope. Because exposure to head and neck microsurgical reconstruction occurs at varying times during training, emphasis was placed on participants’ experience rather than post graduate year. Participants completed a pre-survey and post survey documenting level of experience, comfort performing the operation in humans, and upon completion assessed the model’s accuracy for head and neck microsurgical experience, ease of use, educational value, and its potential to enhance teaching capacity.",
        "Results": "Among the participants for the survey (n=11), all participants (100%) identified as having observed head and neck reconstruction, with 18.2% reporting comfort acting as the primary surgeon, 9.1% reporting comfort with all aspects of the procedure but not performing it regularly, and 18.2% reporting extensive experience with routine performance in practice.",
        "Abstract": "Of the respondents, 81.8% reported the steps performing end-to-end anastomosis to be very or extremely similar to real-life surgery. The model was rated to be very or extremely similar by 63.6% in overall anatomic similarity, 81.8% in ergonomic similarity, and 72.7% in vessel alignment. All (100%) participants reported the model to be a useful educational tool and would recommend it to be incorporated into residency microsurgical training. Additionally, 90.9% of participants reported this model would be most useful for residents in post-graduate years 3-7. Comments provided in the survey reflected overwhelmingly positive feedback, with suggestions for enhancements in a more realistic vessel length. Data collection is ongoing, and additional responses are being gathered to further validate these findings.",
        "Conclusion": "This early model development study supports the educational value and realism of a 3D-printed model for head and neck free tissue transfer and the unique challenges encountered due to proximity to the mandible. Continued refinement of the design based on expert and trainee insight will optimize the model’s utility as a training tool, ultimately expanding access to microsurgical training."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>3D-Printed Head and Neck Model for Microsurgical Training: Early Model Development Study</span>. <u>Jaime A Peña Garcia</u>; Myiah Quach, BS; Weifeng Zeng, MD; Samuel O Poore, MD, PhD; Aaron M Wieland. University of Wisconsin School of Medicine and Public Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Microsurgical free tissue transfer is a cornerstone of head and neck reconstruction and requires advanced technical skills and extensive operative training. Opportunities for trainees to develop microsurgical proficiency can be limited by operative time constraints, variability in case exposure, and the high-stakes nature of live surgery. Simulation-based training models have emerged as valuable adjuncts to traditional operative education. However, many existing models lack anatomic realism or accessibility. In particular, the proximity of the mandible with the cervical vasculature creates difficult anatomic constraints due to challenging orientations and ergonomics during microvascular anastomosis. Combination of three-dimensional (3D) printing and the validated blue-blood chicken thigh model offers a promising approach for developing an anatomically accurate simulation tool. The primary objective of this study was to evaluate the perceived educational value, realism, and utility of our 3D-printed reconstructive model for head and neck specific microsurgical training among surgical trainees and attending surgeons.</p>\n\n<p><strong>Methods: </strong>In this prospective, multi-institutional study, Otolaryngology and Plastic Surgery trainees and attending surgeons were invited to perform a single end-to-end microsurgical anastomosis on blue-blood chicken thigh femoral artery vessels integrated into a 3D-printed head and neck reconstructive model to mimic anastomoses inferior to the mandible using a binocular microscope. Because exposure to head and neck microsurgical reconstruction occurs at varying times during training, emphasis was placed on participants’ experience rather than post graduate year. Participants completed a pre-survey and post survey documenting level of experience, comfort performing the operation in humans, and upon completion assessed the model’s accuracy for head and neck microsurgical experience, ease of use, educational value, and its potential to enhance teaching capacity.</p>\n\n<p><strong>Results: </strong>Among the participants for the survey (n=11), all participants (100%) identified as having observed head and neck reconstruction, with 18.2% reporting comfort acting as the primary surgeon, 9.1% reporting comfort with all aspects of the procedure but not performing it regularly, and 18.2% reporting extensive experience with routine performance in practice.</p>\n\n<p>Of the respondents, 81.8% reported the steps performing end-to-end anastomosis to be very or extremely similar to real-life surgery. The model was rated to be very or extremely similar by 63.6% in overall anatomic similarity, 81.8% in ergonomic similarity, and 72.7% in vessel alignment.</p>\n\n<p>All (100%) participants reported the model to be a useful educational tool and would recommend it to be incorporated into residency microsurgical training. Additionally, 90.9% of participants reported this model would be most useful for residents in post-graduate years 3-7. Comments provided in the survey reflected overwhelmingly positive feedback, with suggestions for enhancements in a more realistic vessel length. Data collection is ongoing, and additional responses are being gathered to further validate these findings.</p>\n\n<p><strong>Conclusion: </strong>This early model development study supports the educational value and realism of a 3D-printed model for head and neck free tissue transfer and the unique challenges encountered due to proximity to the mandible. Continued refinement of the design based on expert and trainee insight will optimize the model’s utility as a training tool, ultimately expanding access to microsurgical training.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155550/Mandible%20model%20abstract.gif' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155550--></body></html>"
    },
    {
      "uid": "P086",
      "content_id": "153137",
      "abstract_number": "P086",
      "poster_number": "P086",
      "title": "New Onset Metastatic Papillary Thyroid Carcinoma in Pregnancy: Diagnostic Challenges and Considerations",
      "summary": "This case highlights the diagnostic challenges of thyroid cancer during pregnancy, where physiologic and hormonal changes can obscure malignancy. Imaging modalities such as ultrasound and MRI are preferred for evaluation in pregnancy, and fine-needle aspiration is the standard for cytologic diagnosis. Cervical lymph node metastases are common in papillary thyroid carcinoma and often present as cystic neck lesions...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153137",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Magdalena Alvis, BS",
      "presenter": "Magdalena Alvis, BS",
      "authors": "Emily H Chestnut, BS; Magdalena Alvis, BS ; Abideen O Yekinni, MD",
      "normalized_authors": [
        "Emily H Chestnut",
        "Magdalena Alvis",
        "Abideen O Yekinni"
      ],
      "affiliations": [
        "Indiana University School of Medicine"
      ],
      "normalized_institutions": [
        "Indiana University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 327,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Patient Case",
        "Conclusions",
        "Objective"
      ],
      "sections": {
        "Authors": "Emily H Chestnut, BS; Magdalena Alvis, BS ; Abideen O Yekinni, MD",
        "Affiliations": "Indiana University School of Medicine",
        "Background": "Papillary thyroid cancer is the most common endocrine malignancy in women of reproductive age and the second most frequent cancer diagnosed during pregnancy. Pregnancy-related hormonal changes, including elevated human chorionic gonadotropin and estrogen, transiently stimulate thyroid tissue and may accelerate the growth of adenomas. These changes are generally self-limited, and most new adenomas or hyperplastic thyroid tissue stabilize or regress postpartum. However, by an unclear pathophysiologic mechanism, some pregnant women go on to develop malignancy of the thyroid gland, even in the setting of normal thyroid laboratory values.",
        "Patient Case": "In this case, a 31-year-old female in the fifth month of pregnancy presented with the acute onset of a neck mass. Thyroid function testing revealed a normal TSH level (0.596 µIU/mL). Magnetic resonance imaging revealed a lobular cystic nodule beneath the sternocleidomastoid muscle (2.3 × 2.2 cm), contiguous with a second cystic lesion adjacent to the trachea (1.7 × 2.1 cm) that was favored to be a lymphangioma or lymphatic malformation. Subsequent CT imaging showed multiple mildly enlarged bilateral cervical lymph nodes. Fine-needle aspiration (FNA) of two cystic nodules yielded benign cyst contents; however, subsequent right neck dissection and excisional biopsy of a lymph node revealed metastatic papillary thyroid carcinoma (3.0 cm). The patient underwent total thyroidectomy with neck dissection and is scheduled to receive radioactive iodine ablation therapy.",
        "Conclusions": "This case highlights the diagnostic challenges of thyroid cancer during pregnancy, where physiologic and hormonal changes can obscure malignancy. Imaging modalities such as ultrasound and MRI are preferred for evaluation in pregnancy, and fine-needle aspiration is the standard for cytologic diagnosis. Cervical lymph node metastases are common in papillary thyroid carcinoma and often present as cystic neck lesions that mimic benign lymphatic malformations; therefore, definitive histopathology may be necessary to confirm metastatic papillary thyroid cancer.",
        "Objective": "A high index of suspicion for thyroid cancer is warranted for pregnant or post-partum patients who present with cervical lymphadenopathy or rapidly enlarging neck masses, regardless of normal thyroid studies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>New Onset Metastatic Papillary Thyroid Carcinoma in Pregnancy: Diagnostic Challenges and Considerations</span>. Emily H Chestnut, BS; <u>Magdalena Alvis, BS</u>; Abideen O Yekinni, MD. Indiana University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Papillary thyroid cancer is the most common endocrine malignancy in women of reproductive age and the second most frequent cancer diagnosed during pregnancy. Pregnancy-related hormonal changes, including elevated human chorionic gonadotropin and estrogen, transiently stimulate thyroid tissue and may accelerate the growth of adenomas. These changes are generally self-limited, and most new adenomas or hyperplastic thyroid tissue stabilize or regress postpartum. However, by an unclear pathophysiologic mechanism, some pregnant women go on to develop malignancy of the thyroid gland, even in the setting of normal thyroid laboratory values.</p>\n\n<p><strong>Patient Case:</strong> In this case, a 31-year-old female in the fifth month of pregnancy presented with the acute onset of a neck mass. Thyroid function testing revealed a normal TSH level (0.596 µIU/mL). Magnetic resonance imaging revealed a lobular cystic nodule beneath the sternocleidomastoid muscle (2.3 × 2.2 cm), contiguous with a second cystic lesion adjacent to the trachea (1.7 × 2.1 cm) that was favored to be a lymphangioma or lymphatic malformation. Subsequent CT imaging showed multiple mildly enlarged bilateral cervical lymph nodes. Fine-needle aspiration (FNA) of two cystic nodules yielded benign cyst contents; however, subsequent right neck dissection and excisional biopsy of a lymph node revealed metastatic papillary thyroid carcinoma (3.0 cm). The patient underwent total thyroidectomy with neck dissection and is scheduled to receive radioactive iodine ablation therapy.</p>\n\n<p><strong>Conclusions:</strong> This case highlights the diagnostic challenges of thyroid cancer during pregnancy, where physiologic and hormonal changes can obscure malignancy. Imaging modalities such as ultrasound and MRI are preferred for evaluation in pregnancy, and fine-needle aspiration is the standard for cytologic diagnosis. Cervical lymph node metastases are common in papillary thyroid carcinoma and often present as cystic neck lesions that mimic benign lymphatic malformations; therefore, definitive histopathology may be necessary to confirm metastatic papillary thyroid cancer.</p>\n\n<p><strong>Objective:</strong> A high index of suspicion for thyroid cancer is warranted for pregnant or post-partum patients who present with cervical lymphadenopathy or rapidly enlarging neck masses, regardless of normal thyroid studies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153137--></body></html>"
    },
    {
      "uid": "P087",
      "content_id": "154116",
      "abstract_number": "P087",
      "poster_number": "P087",
      "title": "Multidisciplinary Perioperative Management of Oral Cavity Squamous Cell Carcinoma in an Adult with Eisenmenger Syndrome: A Case Report",
      "summary": "Oral cavity cancer in patients with Eisenmenger syndrome presents unique perioperative hazards where successful outcomes depend heavily on multidisciplinary coordination of perioperative care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154116",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jeremy P Tervo, MD",
      "presenter": "Jeremy P Tervo, MD",
      "authors": "Jeremy P Tervo, MD 1 ; Lucas Axiotakis, MD 1 ; Scott Troob, MD 2",
      "normalized_authors": [
        "Jeremy P Tervo",
        "Lucas Axiotakis",
        "Scott Troob"
      ],
      "affiliations": [
        "NewYork-Presbyterian - Columbia/Cornell",
        "Columbia University Irving Medical Center"
      ],
      "normalized_institutions": [
        "NewYork-Presbyterian - Columbia/Cornell",
        "Columbia University Irving Medical Center"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 418,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Abstract",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jeremy P Tervo, MD 1 ; Lucas Axiotakis, MD 1 ; Scott Troob, MD 2",
        "Affiliations": "1 NewYork-Presbyterian - Columbia/Cornell; 2 Columbia University Irving Medical Center",
        "Introduction": "Eisenmenger syndrome represents one of the highest-risk physiologic states for noncardiac surgery due to fixed pulmonary hypertension, right-to-left shunting, and profound sensitivity to changes in systemic vascular resistance. Head and neck oncologic procedures often require controlled airway manipulation and general anesthesia, creating substantial hemodynamic risk. We present a case of oral cavity squamous cell carcinoma (SCC) in an adult with longstanding Eisenmenger physiology requiring operative intervention, highlighting the interdisciplinary coordination necessary to safely deliver cancer care.",
        "Case Presentation": "A 56-year-old man with congenital heart disease complicated by Eisenmenger syndrome (VSD-related, WHO functional class II) on continuous oxygen (3 L/min) and double pulmonary hypertension therapy (Opsynvi – macitentan/tadalafil) was referred for evaluation of a progressive tongue lesion concerning for SCC. Adult congenital cardiology deemed him optimized and cleared him for necessary surgical procedures but emphasized avoidance of hypotension, hypoxemia, and ventilatory instability.",
        "Abstract": "• Pre-induction arterial line • Central venous access • ECMO team pre-emptively placed R femoral arterial and venous catheter sheaths in case of decompensation during anesthetic induction • Continuous nebulized epoprostenol (pulmonary arterial vasodilator) in anesthesia circuit • Strict hemodynamic targets to avoid drops in SVR • Maintenance of normoxia and normocapnia • Smooth, atraumatic airway management with nasal RAE intubation via Glidescope after Afrin and nasal airway preparation • Minimized apnea time with preoxygenation to EtO2 > 90% Partial glossectomy with level I-IV neck dissection and reconstruction with submental island flap proceeded uneventfully with stable end-tidal CO2, preserved oxygenation, and no intraoperative pulmonary hypertensive events. ECMO was neither required nor initiated during the procedure. The patient was successfully extubated to humidified face tent at end of case. Postoperative disposition included planned ICU monitoring with readiness for mechanical ventilation if needed. The patient’s ICU course was notable for tapering of pressors and inotropes through POD3, after which the patient was demonstrated to be hemodynamically stable on home pulmonary hypertension medications. Post-operative nutrition was supported with feeds through nasogastric tube. SLP was engaged on POD3 to allow for healing of submental island flap and floor of mouth tunnel. The patient’s diet was subsequently advanced per guidance from SLP without complication. The patient recovered without cardiorespiratory complications.",
        "Discussion": "This case underscores that adults with Eisenmenger physiology can safely undergo head and neck oncologic procedures when an interdisciplinary approach is employed. Key elements included early cardiac anesthesiology involvement, disease-specific hemodynamic targets, airway strategies minimizing sympathetic swings, and real-time coordination with adult congenital cardiology and ICU teams.",
        "Conclusion": "Oral cavity cancer in patients with Eisenmenger syndrome presents unique perioperative hazards where successful outcomes depend heavily on multidisciplinary coordination of perioperative care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Multidisciplinary Perioperative Management of Oral Cavity Squamous Cell Carcinoma in an Adult with Eisenmenger Syndrome: A Case Report</span>. <u>Jeremy P Tervo, MD</u><sup>1</sup>; Lucas Axiotakis, MD<sup>1</sup>; Scott Troob, MD<sup>2</sup>. <sup>1</sup>NewYork-Presbyterian - Columbia/Cornell; <sup>2</sup>Columbia University Irving Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Eisenmenger syndrome represents one of the highest-risk physiologic states for noncardiac surgery due to fixed pulmonary hypertension, right-to-left shunting, and profound sensitivity to changes in systemic vascular resistance. Head and neck oncologic procedures often require controlled airway manipulation and general anesthesia, creating substantial hemodynamic risk. We present a case of oral cavity squamous cell carcinoma (SCC) in an adult with longstanding Eisenmenger physiology requiring operative intervention, highlighting the interdisciplinary coordination necessary to safely deliver cancer care.</p>\n\n<p><strong>Case Presentation: </strong>A 56-year-old man with congenital heart disease complicated by Eisenmenger syndrome (VSD-related, WHO functional class II) on continuous oxygen (3 L/min) and double pulmonary hypertension therapy (Opsynvi – macitentan/tadalafil) was referred for evaluation of a progressive tongue lesion concerning for SCC. Adult congenital cardiology deemed him optimized and cleared him for necessary surgical procedures but emphasized avoidance of hypotension, hypoxemia, and ventilatory instability.</p>\n\n<p><strong>Preoperative anesthesia planning included:</strong></p>\n\n<p>• Pre-induction arterial line</p>\n\n<p>• Central venous access</p>\n\n<p>• ECMO team pre-emptively placed R femoral arterial and venous catheter sheaths in case of decompensation during anesthetic induction</p>\n\n<p>• Continuous nebulized epoprostenol (pulmonary arterial vasodilator) in anesthesia circuit</p>\n\n<p>• Strict hemodynamic targets to avoid drops in SVR</p>\n\n<p>• Maintenance of normoxia and normocapnia</p>\n\n<p>• Smooth, atraumatic airway management with nasal RAE intubation via Glidescope after Afrin and nasal airway preparation</p>\n\n<p>• Minimized apnea time with preoxygenation to EtO2 > 90%</p>\n\n<p>Partial glossectomy with level I-IV neck dissection and reconstruction with submental island flap proceeded uneventfully with stable end-tidal CO2, preserved oxygenation, and no intraoperative pulmonary hypertensive events. ECMO was neither required nor initiated during the procedure. The patient was successfully extubated to humidified face tent at end of case. Postoperative disposition included planned ICU monitoring with readiness for mechanical ventilation if needed. The patient’s ICU course was notable for tapering of pressors and inotropes through POD3, after which the patient was demonstrated to be hemodynamically stable on home pulmonary hypertension medications. Post-operative nutrition was supported with feeds through nasogastric tube. SLP was engaged on POD3 to allow for healing of submental island flap and floor of mouth tunnel. The patient’s diet was subsequently advanced per guidance from SLP without complication. The patient recovered without cardiorespiratory complications.</p>\n\n<p><strong>Discussion: </strong>This case underscores that adults with Eisenmenger physiology can safely undergo head and neck oncologic procedures when an interdisciplinary approach is employed. Key elements included early cardiac anesthesiology involvement, disease-specific hemodynamic targets, airway strategies minimizing sympathetic swings, and real-time coordination with adult congenital cardiology and ICU teams.</p>\n\n<p><strong>Conclusion: </strong>Oral cavity cancer in patients with Eisenmenger syndrome presents unique perioperative hazards where successful outcomes depend heavily on multidisciplinary coordination of perioperative care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154116--></body></html>"
    },
    {
      "uid": "P088",
      "content_id": "155455",
      "abstract_number": "P088",
      "poster_number": "P088",
      "title": "Treatment Patterns and Oncologic Outcomes among Older Adults with HPV-Related Oropharyngeal Cancer",
      "summary": "In this cohort of older adults with HPV-OPSCC, treatment modifications prior to and during treatment were common. As many older adults with HPV-OPSCC die of non-HPV-OPSCC-related causes, our findings underscore the importance of considering competing mortality risks in this population. These findings support the need for prospective studies to guide optimal treatment for the growing population of older adults...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155455",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan M Hughes, BS",
      "presenter": "Jonathan M Hughes, BS",
      "authors": "Jonathan M Hughes, BS 1 ; Vikas Barnwal, PhD 1 ; Poria Dorali, PhD 1 ; Haluk Damgacioglu, PhD 1 ; Bhisham Chera, MD 1 ; Hyman B Muss, MD 2 ; Loren Mell, MD 3 ; Elizabeth G Hill, PhD 1 ; Gerard A Silvestri, MD, MS 1 ; John Kaczmar, MD 1 ; Dauren Adilbay, MD, PhD 1 ; W. Greer Albergotti, MD 1 ; Michael Bobian, MD 1 ; Alex E Kejner, MD 1 ; Jason G Newman, MD 1 ; Judith M Skoner, MD 1 ; Jennifer L Harper, MD 1 ; Amanda N Hollinger, MPA 4 ; Stewart Lyman, PhD 4 ; David Burkett, JD 4 ; Victoria Shaffer, PhD 5 ; Kalyani Sonawane, PhD 1 ; Ashish A Deshmukh, PhD, MPH 1 ; Evan M Graboyes, MD, MPH 1",
      "normalized_authors": [
        "Jonathan M Hughes",
        "Vikas Barnwal",
        "Poria Dorali",
        "Haluk Damgacioglu",
        "Bhisham Chera",
        "Hyman B Muss",
        "Loren Mell",
        "Elizabeth G Hill",
        "Gerard A Silvestri",
        "John Kaczmar",
        "Dauren Adilbay",
        "W. Greer Albergotti",
        "Michael Bobian",
        "Alex E Kejner",
        "Jason G Newman",
        "Judith M Skoner",
        "Jennifer L Harper",
        "Amanda N Hollinger, MPA",
        "Stewart Lyman",
        "David Burkett, JD",
        "Victoria Shaffer",
        "Kalyani Sonawane",
        "Ashish A Deshmukh",
        "Evan M Graboyes"
      ],
      "affiliations": [
        "Medical University of South Carolina",
        "UNC School of Medicine",
        "UC San Diego School of Medicine",
        "Head & Neck Cancer Alliance",
        "University of Missouri"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina",
        "UNC School of Medicine",
        "UC San Diego School of Medicine",
        "Head & Neck Cancer Alliance",
        "University of Missouri"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 537,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jonathan M Hughes, BS 1 ; Vikas Barnwal, PhD 1 ; Poria Dorali, PhD 1 ; Haluk Damgacioglu, PhD 1 ; Bhisham Chera, MD 1 ; Hyman B Muss, MD 2 ; Loren Mell, MD 3 ; Elizabeth G Hill, PhD 1 ; Gerard A Silvestri, MD, MS 1 ; John Kaczmar, MD 1 ; Dauren Adilbay, MD, PhD 1 ; W. Greer Albergotti, MD 1 ; Michael Bobian, MD 1 ; Alex E Kejner, MD 1 ; Jason G Newman, MD 1 ; Judith M Skoner, MD 1 ; Jennifer L Harper, MD 1 ; Amanda N Hollinger, MPA 4 ; Stewart Lyman, PhD 4 ; David Burkett, JD 4 ; Victoria Shaffer, PhD 5 ; Kalyani Sonawane, PhD 1 ; Ashish A Deshmukh, PhD, MPH 1 ; Evan M Graboyes, MD, MPH 1",
        "Affiliations": "1 Medical University of South Carolina; 2 UNC School of Medicine; 3 UC San Diego School of Medicine; 4 Head & Neck Cancer Alliance; 5 University of Missouri",
        "Importance": "The incidence of HPV-associated oropharynx squamous cell carcinoma (HPV-OPSCC) is rapidly rising among older adults in the United States and is projected to represent a majority of new HPV-OPSCC diagnoses by 2029. Treatment selection for older adults with HPV-OPSCC must account for their higher comorbidity burden, narrower therapeutic window, and distinct care preferences. Real-world data evaluating frailty, comorbidity, treatment patterns, and oncologic outcomes among older adults with HPV-OPSCC are limited.",
        "Objective": "To evaluate treatment patterns and oncologic outcomes among older adults with HPV-OPSCC.",
        "Methods": "We conducted a retrospective cohort study of adults age ≥65 years with index p16-positive OPSCC without distant metastases treated with curative intent at an academic center (January 2018–August 2025) with surgical-based (surgery ± adjuvant therapy) or radiation-based therapy (definitive RT/CRT). Frailty was measured using the 5-item Modified Frailty Index (MFI-5), and comorbidity with the Charlson Comorbidity Index (CCI). Treatment modifications and completion of planned therapy were described. Cumulative incidence of recurrence was estimated using competing risks methods (death as competing event). Cancer-specific survival was estimated using competing risks methods (non-cancer death as competing event). Overall survival (OS) was estimated using Kaplan–Meier methods.",
        "Results": "Among 119 older adults with HPV-OPSCC (median age 69.1 years [IQR 67.0–73.3]), 61% (72/119) had moderate or severe frailty (MFI-5 score ≥0.2) and 22% (26/119) had CCI score ≥3. Overall, 41.2% (49/119) had a >10 pack-year smoking history. Most patients had AJCC 8th edition clinical stage I disease (69%; 82/119); 45% (54/119) were cT0-T1 and 66% (79/119) were cN1. A majority (60%; 71/119) received radiation-based treatment (RT, n=9; CRT, n=62) and 40% (48/119) received surgical-based treatment (surgery, n=23; surgery + RT, n=17; surgery + CRT, n=8). Overall, 19% (22/119) of patients were treated on a therapeutic clinical trial. Among patients receiving systemic therapy, 67% (47/70) were planned for cisplatin-containing regimens, 31% (22/70) were cisplatin-ineligible due to hearing loss or kidney disease, and 1 was cisplatin-eligible but received nivolumab on trial. Alternative regimens included carboplatin (16%; 11/70), carboplatin-paclitaxel (13%; 9/70), and cetuximab (3%; 2/70). Among cisplatin recipients, 17% (8/47) required mid-course substitution due to nephrotoxicity (n=5) or ototoxicity (n=3). Among patients receiving RT, 9% (9/96) did not complete RT as planned. Median follow-up was 31.9 months (IQR 22.0–62.5), during which 18.5% of patients (22/119) experienced a recurrence (5 local, 4 regional, 7 distant, 2 local/regional, 1 local/distant, 3 regional/distant). The 2-year cumulative incidence of recurrence was 16.7% (95% CI, 10.2–24.4%). There were 18 deaths (6 due to cancer, 7 due to other causes, and 5 of unknown cause). 2-year cancer-specific survival was 96.0% (95% CI, 90.8–98.7%). 2-year OS was 89.8% (95% CI, 84.2–95.8%).",
        "Conclusions": "In this cohort of older adults with HPV-OPSCC, treatment modifications prior to and during treatment were common. As many older adults with HPV-OPSCC die of non-HPV-OPSCC-related causes, our findings underscore the importance of considering competing mortality risks in this population. These findings support the need for prospective studies to guide optimal treatment for the growing population of older adults with HPV-OPSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment Patterns and Oncologic Outcomes among Older Adults with HPV-Related Oropharyngeal Cancer</span>. <u>Jonathan M Hughes, BS</u><sup>1</sup>; Vikas Barnwal, PhD<sup>1</sup>; Poria Dorali, PhD<sup>1</sup>; Haluk Damgacioglu, PhD<sup>1</sup>; Bhisham Chera, MD<sup>1</sup>; Hyman B Muss, MD<sup>2</sup>; Loren Mell, MD<sup>3</sup>; Elizabeth G Hill, PhD<sup>1</sup>; Gerard A Silvestri, MD, MS<sup>1</sup>; John Kaczmar, MD<sup>1</sup>; Dauren Adilbay, MD, PhD<sup>1</sup>; W. Greer Albergotti, MD<sup>1</sup>; Michael Bobian, MD<sup>1</sup>; Alex E Kejner, MD<sup>1</sup>; Jason G Newman, MD<sup>1</sup>; Judith M Skoner, MD<sup>1</sup>; Jennifer L Harper, MD<sup>1</sup>; Amanda N Hollinger, MPA<sup>4</sup>; Stewart Lyman, PhD<sup>4</sup>; David Burkett, JD<sup>4</sup>; Victoria Shaffer, PhD<sup>5</sup>; Kalyani Sonawane, PhD<sup>1</sup>; Ashish A Deshmukh, PhD, MPH<sup>1</sup>; Evan M Graboyes, MD, MPH<sup>1</sup>. <sup>1</sup>Medical University of South Carolina; <sup>2</sup>UNC School of Medicine; <sup>3</sup>UC San Diego School of Medicine; <sup>4</sup>Head & Neck Cancer Alliance; <sup>5</sup>University of Missouri<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> The incidence of HPV-associated oropharynx squamous cell carcinoma (HPV-OPSCC) is rapidly rising among older adults in the United States and is projected to represent a majority of new HPV-OPSCC diagnoses by 2029. Treatment selection for older adults with HPV-OPSCC must account for their higher comorbidity burden, narrower therapeutic window, and distinct care preferences. Real-world data evaluating frailty, comorbidity, treatment patterns, and oncologic outcomes among older adults with HPV-OPSCC are limited.</p>\n\n<p><strong>Objective: </strong>To evaluate treatment patterns and oncologic outcomes among older adults with HPV-OPSCC.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study of adults age ≥65 years with index p16-positive OPSCC without distant metastases treated with curative intent at an academic center (January 2018–August 2025) with surgical-based (surgery ± adjuvant therapy) or radiation-based therapy (definitive RT/CRT). Frailty was measured using the 5-item Modified Frailty Index (MFI-5), and comorbidity with the Charlson Comorbidity Index (CCI). Treatment modifications and completion of planned therapy were described. Cumulative incidence of recurrence was estimated using competing risks methods (death as competing event). Cancer-specific survival was estimated using competing risks methods (non-cancer death as competing event). Overall survival (OS) was estimated using Kaplan–Meier methods.</p>\n\n<p><strong>Results:</strong> Among 119 older adults with HPV-OPSCC (median age 69.1 years [IQR 67.0–73.3]), 61% (72/119) had moderate or severe frailty (MFI-5 score ≥0.2) and 22% (26/119) had CCI score ≥3. Overall, 41.2% (49/119) had a >10 pack-year smoking history. Most patients had AJCC 8th edition clinical stage I disease (69%; 82/119); 45% (54/119) were cT0-T1 and 66% (79/119) were cN1. A majority (60%; 71/119) received radiation-based treatment (RT, n=9; CRT, n=62) and 40% (48/119) received surgical-based treatment (surgery, n=23; surgery + RT, n=17; surgery + CRT, n=8). Overall, 19% (22/119) of patients were treated on a therapeutic clinical trial. Among patients receiving systemic therapy, 67% (47/70) were planned for cisplatin-containing regimens, 31% (22/70) were cisplatin-ineligible due to hearing loss or kidney disease, and 1 was cisplatin-eligible but received nivolumab on trial. Alternative regimens included carboplatin (16%; 11/70), carboplatin-paclitaxel (13%; 9/70), and cetuximab (3%; 2/70). Among cisplatin recipients, 17% (8/47) required mid-course substitution due to nephrotoxicity (n=5) or ototoxicity (n=3). Among patients receiving RT, 9% (9/96) did not complete RT as planned. Median follow-up was 31.9 months (IQR 22.0–62.5), during which 18.5% of patients (22/119) experienced a recurrence (5 local, 4 regional, 7 distant, 2 local/regional, 1 local/distant, 3 regional/distant). The 2-year cumulative incidence of recurrence was 16.7% (95% CI, 10.2–24.4%). There were 18 deaths (6 due to cancer, 7 due to other causes, and 5 of unknown cause). 2-year cancer-specific survival was 96.0% (95% CI, 90.8–98.7%). 2-year OS was 89.8% (95% CI, 84.2–95.8%).</p>\n\n<p><strong>Conclusions:</strong> In this cohort of older adults with HPV-OPSCC, treatment modifications prior to and during treatment were common. As many older adults with HPV-OPSCC die of non-HPV-OPSCC-related causes, our findings underscore the importance of considering competing mortality risks in this population. These findings support the need for prospective studies to guide optimal treatment for the growing population of older adults with HPV-OPSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155455--></body></html>"
    },
    {
      "uid": "P089",
      "content_id": "154622",
      "abstract_number": "P089",
      "poster_number": "P089",
      "title": "Oncologic factors associated with increased risk of chyle leak during neck dissection in head and neck cancer patients",
      "summary": "This study demonstrates that the rate of chyle leak is approximately 2.5%-3% when comparing patients who receive primary neck dissection versus salvage neck dissection. Although there was a statistically significant difference between groups, the difference is likely not clinically meaningful. Additionally, the increased rate of chyle leak in patients with ENE is likely due to the need for more extensive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154622",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna Xiang, BS",
      "presenter": "Anna Xiang, BS",
      "authors": "Anna Xiang, BS 1 ; Zhenghao Wang, BA 1 ; Ngoc Bich Nguyen, BS 1 ; Warren Swegal, MD 2 ; Garren Low, MD 2 ; Samuel Rubin, MD, MPH 2",
      "normalized_authors": [
        "Anna Xiang",
        "Zhenghao Wang",
        "Ngoc Bich Nguyen",
        "Warren Swegal",
        "Garren Low",
        "Samuel Rubin"
      ],
      "affiliations": [
        "Drexel University College of Medicine",
        "Allegheny Health Network"
      ],
      "normalized_institutions": [
        "Drexel University College of Medicine",
        "Allegheny Health Network"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 359,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Anna Xiang, BS 1 ; Zhenghao Wang, BA 1 ; Ngoc Bich Nguyen, BS 1 ; Warren Swegal, MD 2 ; Garren Low, MD 2 ; Samuel Rubin, MD, MPH 2",
        "Affiliations": "1 Drexel University College of Medicine; 2 Allegheny Health Network",
        "Background": "Cervical chyle leak a complication that occurs in 1% to 8% of patients who undergo neck dissection. This is a complication that often requires the patients to remain on a modified diet and sometimes requires either repeat surgical intervention or interventional radiology procedures to control the chyle leak. This complication also results in increased length of stay, which can be costly to the healthcare system.",
        "Objective": "Determine oncologic factors that may be associated with increased risk of chyle leak",
        "Methods": "A retrospective study was performed using TriNetX, a global federated electronic health records database. All patients 18 years of age or older with a primary diagnosis of head and neck cancer who underwent either primary or salvage neck dissection were included in the study. The primary outcome was the rate of chyle leak in patients who received radiation therapy versus those patients who did not receive radiation therapy, prior to neck dissection. Univariate analysis was performed using a two-sample t-test for continuous variables and chi-squared test for categorical variables. Significance was determined if p was less than 0.05.",
        "Results": "A total of 51,221 were included in the study. The rate of chyle leak in the group that received radiation therapy was 2.45% (n=347) compared to the rate of leak in the non-radiated group, which was 2.93% (n=1089) (p=0.0027). Furthermore, the presence of extranodal extension (ENE) on pathology was significantly associated with rate of chyle leak (p<0.0001). No other demographic factors, including age, gender, or race, were associated with chyle leak. Furthermore, primary tumor site, overall stage, and pathologic N stage were not associated with rate of chyle leak.",
        "Conclusion": "This study demonstrates that the rate of chyle leak is approximately 2.5%-3% when comparing patients who receive primary neck dissection versus salvage neck dissection. Although there was a statistically significant difference between groups, the difference is likely not clinically meaningful. Additionally, the increased rate of chyle leak in patients with ENE is likely due to the need for more extensive dissection. Increased caution should be maintained in cases of patients with concern for ENE to minimize the risk of postoperative chyle leak."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncologic factors associated with increased risk of chyle leak during neck dissection in head and neck cancer patients</span>. <u>Anna Xiang, BS</u><sup>1</sup>; Zhenghao Wang, BA<sup>1</sup>; Ngoc Bich Nguyen, BS<sup>1</sup>; Warren Swegal, MD<sup>2</sup>; Garren Low, MD<sup>2</sup>; Samuel Rubin, MD, MPH<sup>2</sup>. <sup>1</sup>Drexel University College of Medicine; <sup>2</sup>Allegheny Health Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Cervical chyle leak a complication that occurs in 1% to 8% of patients who undergo neck dissection. This is a complication that often requires the patients to remain on a modified diet and sometimes requires either repeat surgical intervention or interventional radiology procedures to control the chyle leak. This complication also results in increased length of stay, which can be costly to the healthcare system.</p>\n\n<p><strong>Objective</strong>: Determine oncologic factors that may be associated with increased risk of chyle leak</p>\n\n<p><strong>Methods</strong>: A retrospective study was performed using TriNetX, a global federated electronic health records database. All patients 18 years of age or older with a primary diagnosis of head and neck cancer who underwent either primary or salvage neck dissection were included in the study. The primary outcome was the rate of chyle leak in patients who received radiation therapy versus those patients who did not receive radiation therapy, prior to neck dissection. Univariate analysis was performed using a two-sample t-test for continuous variables and chi-squared test for categorical variables. Significance was determined if p was less than 0.05.</p>\n\n<p><strong>Results</strong>: A total of 51,221 were included in the study. The rate of chyle leak in the group that received radiation therapy was 2.45% (n=347) compared to the rate of leak in the non-radiated group, which was 2.93% (n=1089) (p=0.0027). Furthermore, the presence of extranodal extension (ENE) on pathology was significantly associated with rate of chyle leak (p<0.0001). No other demographic factors, including age, gender, or race, were associated with chyle leak. Furthermore, primary tumor site, overall stage, and pathologic N stage were not associated with rate of chyle leak.</p>\n\n<p><strong>Conclusion</strong>: This study demonstrates that the rate of chyle leak is approximately 2.5%-3% when comparing patients who receive primary neck dissection versus salvage neck dissection. Although there was a statistically significant difference between groups, the difference is likely not clinically meaningful. Additionally, the increased rate of chyle leak in patients with ENE is likely due to the need for more extensive dissection. Increased caution should be maintained in cases of patients with concern for ENE to minimize the risk of postoperative chyle leak.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154622--></body></html>"
    },
    {
      "uid": "P090",
      "content_id": "153537",
      "abstract_number": "P090",
      "poster_number": "P090",
      "title": "Speaking Through Barriers: Language and Lived Experience in Head and Neck Cancer Care at an Urban Safety-Net Hospital",
      "summary": "In this urban safety-net setting, patient-reported delays mainly occurred prior to diagnosis and entry into subspecialty care, highlighting opportunities to improve community symptom awareness and provider education to speed evaluation and referral. Non-English speakers reported dependable interpreter access and culturally-concordant care. Finally, while timeliness remains essential, the substantial emotional...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153537",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Laura Chen, BA",
      "presenter": "Laura Chen, BA",
      "authors": "Laura Chen, BA 1 ; Armita Norouzi, BA 2 ; Ignacia Arteaga, PhD 3 ; Daniel Dohan, PhD 3 ; Nour Mary Aissaoui, MS 1 ; Marc Anthony Pastor, BS 1 ; Lori Ross, PA, C 2 ; Shauna Brodie, RN, MS, FNP 2 ; Alyssa Civantos, MD, MS 4 ; Megan L Durr, MD 2 ; Regan Bergmark, MD, MPH 5 ; Mary Jue Xue, MD 2",
      "normalized_authors": [
        "Laura Chen",
        "Armita Norouzi",
        "Ignacia Arteaga",
        "Daniel Dohan",
        "Nour Mary Aissaoui",
        "Marc Anthony Pastor",
        "Lori Ross, PA, C",
        "Shauna Brodie, FNP",
        "Alyssa Civantos",
        "Megan L Durr",
        "Regan Bergmark",
        "Mary Jue Xue"
      ],
      "affiliations": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA",
        "Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA"
      ],
      "normalized_institutions": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA",
        "Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA",
        "Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153537/AHNS_Figure%201%20(1)(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153537/AHNS_Figure%201%20(1)(1).jpg",
          "alt": "Key themes from interviews with insight statements and representative quotes.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153537"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153537/AHNS_Table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153537/AHNS_Table%201.png",
          "alt": "Table 1. Sample questions from interview guide.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153537"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Laura Chen, BA 1 ; Armita Norouzi, BA 2 ; Ignacia Arteaga, PhD 3 ; Daniel Dohan, PhD 3 ; Nour Mary Aissaoui, MS 1 ; Marc Anthony Pastor, BS 1 ; Lori Ross, PA, C 2 ; Shauna Brodie, RN, MS, FNP 2 ; Alyssa Civantos, MD, MS 4 ; Megan L Durr, MD 2 ; Regan Bergmark, MD, MPH 5 ; Mary Jue Xue, MD 2",
        "Affiliations": "1 University of California, San Francisco School of Medicine, San Francisco, CA; 2 Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA; 3 Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA; 4 Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA; 5 Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA",
        "Background": "Head and neck cancer (HNC) disproportionately affects low socioeconomic status and minority populations. 1 Patients in safety-net settings often face delays in diagnosis and treatment that worsen survival. 2,3 Patient perspectives on timely care navigation and acceptability of interventions remains underexplored. An urban safety-net hospital serving a diverse, multilingual population offers a critical context to understand HNC care experiences and surface patient-centered solutions.",
        "Methods": "With Institutional Review Board approval, we conducted semi-structured interviews with English- and Cantonese-speaking adults diagnosed with HNC at an urban safety-net hospital in California. The interview guide was informed by prior HNC literature and refined through pilot testing. It elicited barriers and facilitators throughout care navigation, as well as suggestions for interventions across the care continuum. Interviews were conducted by LC in-person or by phone with certified medical interpreters as needed and were audio-recorded, transcribed verbatim, and de-identified. Transcripts were analyzed in Dedoose using Braun and Clarke’s framework for thematic analysis. 41.66% of transcripts were double-coded with discrepancies resolved by consensus (Cohen’s Kappa > 0.8).",
        "Results": "We interviewed 12 patients (mean age 57 years [range 37-78]; 41.6% East Asian; 25% female; primary tumor sites 50% oropharynx, 25% larynx, 25% nasopharynx). Mean interview length was 48.34 minutes (SD=17.98). Eight identified English as their primary language; four were Cantonese-speaking. Ten participants were in surveillance and two were receiving chemotherapy and/or radiation; all had public insurance. Three themes emerged: 1) Symptom awareness among patients and healthcare workers was central to diagnosis delay : patients reported that recognizing cancer-related symptoms enabled timely referral; conversely, delayed recognition contributed to reported lags (“I wasn’t aware tonsil cancer even existed”; “They didn’t have an answer…it was just a lump.”) 2) Patients perceived on-site subspecialty care as timely, language-concordant, and culturally-responsive : Once referred, most described rapid, well-coordinated care (“Once I was seen the first time, everything took care of itself”), support from clinical teams and transportation resources, dependable interpreter access (“even at check-in, they can find someone to interpret”), and cultural concordance (“I was lucky enough to be taken under the wings of a doctor who's able to speak Chinese”, “It’s nice [my dietitians] are Asian too, to be cuisine-specific.”). 3) Patients emphasized the emotional toll of HNC - including isolation, fear, sadness, and the all-consuming nature of treatment - and the need for strengthened social support and proactive outreach , such as structured check-ins from patient advocates or navigators between visits (“somebody who would take me by the hand and tell me what I’m going to face”).",
        "Conclusion": "In this urban safety-net setting, patient-reported delays mainly occurred prior to diagnosis and entry into subspecialty care, highlighting opportunities to improve community symptom awareness and provider education to speed evaluation and referral. Non-English speakers reported dependable interpreter access and culturally-concordant care. Finally, while timeliness remains essential, the substantial emotional burden of HNC underscores the need to embed ongoing psychosocial and resource support beyond clinic visits to strengthen whole-person care.",
        "Abstract": "1. Massa 2019 2. Lenze 2021 3. Ioerger 2024"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Speaking Through Barriers: Language and Lived Experience in Head and Neck Cancer Care at an Urban Safety-Net Hospital</span>. <u>Laura Chen, BA</u><sup>1</sup>; Armita Norouzi, BA<sup>2</sup>; Ignacia Arteaga, PhD<sup>3</sup>; Daniel Dohan, PhD<sup>3</sup>; Nour Mary Aissaoui, MS<sup>1</sup>; Marc Anthony Pastor, BS<sup>1</sup>; Lori Ross, PA, C<sup>2</sup>; Shauna Brodie, RN, MS, FNP<sup>2</sup>; Alyssa Civantos, MD, MS<sup>4</sup>; Megan L Durr, MD<sup>2</sup>; Regan Bergmark, MD, MPH<sup>5</sup>; Mary Jue Xue, MD<sup>2</sup>. <sup>1</sup>University of California, San Francisco School of Medicine, San Francisco, CA; <sup>2</sup>Department of Otolaryngology, Head and Neck Surgery, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA; <sup>3</sup>Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA; <sup>4</sup>Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, San Francisco, CA; <sup>5</sup>Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer (HNC) disproportionately affects low socioeconomic status and minority populations.<sup>1 </sup>Patients in safety-net settings often face delays in diagnosis and treatment that worsen survival.<sup>2,3</sup> Patient perspectives on timely care navigation and acceptability of interventions remains underexplored. An urban safety-net hospital serving a diverse, multilingual population offers a critical context to understand HNC care experiences and surface patient-centered solutions.  </p>\n\n<p><strong>Methods: </strong>With Institutional Review Board approval, we conducted semi-structured interviews with English- and Cantonese-speaking adults diagnosed with HNC at an urban safety-net hospital in California. The interview guide was informed by prior HNC literature and refined through pilot testing. It elicited barriers and facilitators throughout care navigation, as well as suggestions for interventions across the care continuum. Interviews were conducted by LC in-person or by phone with certified medical interpreters as needed and were audio-recorded, transcribed verbatim, and de-identified. Transcripts were analyzed in Dedoose using Braun and Clarke’s framework for thematic analysis. 41.66% of transcripts were double-coded with discrepancies resolved by consensus (Cohen’s Kappa > 0.8).</p>\n\n<p><strong>Results: </strong>We interviewed 12 patients (mean age 57 years [range 37-78]; 41.6% East Asian; 25% female; primary tumor sites 50% oropharynx, 25% larynx, 25% nasopharynx). Mean interview length was 48.34 minutes (SD=17.98). Eight identified English as their primary language; four were Cantonese-speaking. Ten participants were in surveillance and two were receiving chemotherapy and/or radiation; all had public insurance. Three themes emerged: <strong>1) Symptom awareness among patients and healthcare workers was central to diagnosis delay</strong>: patients reported that recognizing cancer-related symptoms enabled timely referral; conversely, delayed recognition contributed to reported lags (“I wasn’t aware tonsil cancer even existed”; “They didn’t have an answer…it was just a lump.”) <strong>2) Patients perceived on-site subspecialty care as timely, language-concordant, and culturally-responsive</strong>: Once referred, most described rapid, well-coordinated care (“Once I was seen the first time, everything took care of itself”), support from clinical teams and transportation resources, dependable interpreter access (“even at check-in, they can find someone to interpret”), and cultural concordance (“I was lucky enough to be taken under the wings of a doctor who's able to speak Chinese”, “It’s nice [my dietitians] are Asian too, to be cuisine-specific.”). <strong>3) Patients emphasized the emotional toll of HNC</strong> - including isolation, fear, sadness, and the all-consuming nature of treatment -<strong> and the need for strengthened social support and proactive outreach</strong>, such as structured check-ins from patient advocates or navigators between visits (“somebody who would take me by the hand and tell me what I’m going to face”).</p>\n\n<p><strong>Conclusion:</strong> In this urban safety-net setting, patient-reported delays mainly occurred prior to diagnosis and entry into subspecialty care, highlighting opportunities to improve community symptom awareness and provider education to speed evaluation and referral. Non-English speakers reported dependable interpreter access and culturally-concordant care. Finally, while timeliness remains essential, the substantial emotional burden of HNC underscores the need to embed ongoing psychosocial and resource support beyond clinic visits to strengthen whole-person care.</p>\n\n<p><strong>Figure 1.</strong></p>\n\n<p><img alt='Key themes from interviews with insight statements and representative quotes. ' src='https://www.submitmyabstract.com/abs/images/153537/AHNS_Figure%201%20(1)(1).jpg' /></p>\n\n<p><strong>Table 1.</strong> </p>\n\n<p><img alt='Table 1. Sample questions from interview guide. ' src='https://www.submitmyabstract.com/abs/images/153537/AHNS_Table%201.png' /></p>\n\n<p><strong>References </strong></p>\n\n<p>1. Massa 2019</p>\n\n<p>2. Lenze 2021</p>\n\n<p>3. Ioerger 2024</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153537--></body></html>"
    },
    {
      "uid": "P091",
      "content_id": "153359",
      "abstract_number": "P091",
      "poster_number": "P091",
      "title": "The Impact of Digital Inequities on Head and Neck Hematologic Cancer Disparities in the US",
      "summary": "In this analysis of HNHC, increasing digital inequity was consistently associated with worse survival, advanced presentation, and poorer-prognostic treatment profiles. These results suggest detrimental trends potentially driven by delayed presentation associated with reduced access to digital care pathways and technological-structural barriers. By characterizing how digital inequity is a potentially crucial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153359",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Angela C Xie",
      "presenter": "Angela C Xie",
      "authors": "Angela C Xie 1 ; David J Fei-Zhang 2 ; Jorge Gutierrez 2 ; Abhinav Talwar 2 ; Christopher A Puchi 3 ; Jill N D'Souza 4 ; Anthony M Sheyn 5 ; Daniel C Chelius 6 ; Jeffrey C Rastatter 3",
      "normalized_authors": [
        "Angela C Xie",
        "David J Fei-Zhang",
        "Jorge Gutierrez",
        "Abhinav Talwar",
        "Christopher A Puchi",
        "Jill N D'Souza",
        "Anthony M Sheyn",
        "Daniel C Chelius",
        "Jeffrey C Rastatter"
      ],
      "affiliations": [
        "Northwestern University Feinberg School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "normalized_institutions": [
        "Northwestern University Feinberg School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 477,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Angela C Xie 1 ; David J Fei-Zhang 2 ; Jorge Gutierrez 2 ; Abhinav Talwar 2 ; Christopher A Puchi 3 ; Jill N D'Souza 4 ; Anthony M Sheyn 5 ; Daniel C Chelius 6 ; Jeffrey C Rastatter 3",
        "Affiliations": "1 Northwestern University Feinberg School of Medicine; 2 Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; 3 Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; 4 Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; 5 Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; 6 Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital",
        "Introduction": "In the modern age, the use of technology has become embedded in the care of patients from diagnosis to treatment. As disparities in access to digital resources continue to exist across the United States, these differences consequently can impact the prognostic outcomes for cancer patients with long-term care burdens, especially for those diagnosed with head & neck hematologic cancers (HNHC). Despite prior studies showing how digital disparities correlate with outcomes across many cancer types, the specific influence of digital inequity on HNHC remains seldom investigated. Thus, this study aims to evaluate the association between digital inequity and HNHC treatment and prognosis.",
        "Methods": "This retrospective cohort study assessed adult HNHC-patients between 2008–2017 in the NCI-Surveillance, Epidemiology, and End Results (SEER) database. Digital inequity was assessed using the Digital Inequity Index (DII), which was quantified using 17 census-tract level variables derived from the American Community Survey and the Federal Communications Commission, grouped into (1) digital infrastructure (i.e. electronic device ownership, broadband type, internet provider availability, income–broadband subscription ratio) and (2) sociodemographic factors (i.e. education, income, disability status). Variables were then ranked and composited into county-level DII scores encompassing both direct and indirect factors related to digital inequity. DII was matched to patients’ county of residence recorded in SEER. Multivariable Cox-hazards and logistic regression models were used to assess overall survival, early mortality (3- & 5-year), advanced staging/distal lymph node involvement, and treatment modalities across increasing DII scores.",
        "Results": "Of the 32,982 patients with HNHC identified, 65–84 years (n = 10,287, 41%), male (n = 13,713, 55%), non-Hispanic white race/ethnicity (n = 16,444, 65%) were the most represented characteristics. A majority were diagnosed with non-Hodgkin lymphoma (n=22,497, 89%). Increasing digital inequity, represented by higher overall DII scores, was significantly associated with worse survival outcomes (HR:1.08, 95% confidence interval [CI]: 1.06-1.10). Higher DII was also associated with increased advanced staging/distal lymph node occurrence (odds ratio [OR]: 1.03, 95% CI: 1.01–1.05) and increased 3-year (OR: 1.08, 95% CI: 1.06-1.10) and 5-year mortality (OR: 1.11, 95% CI: 1.08-1.13). Regarding treatment patterns, patients residing in higher-DII areas demonstrated decreased odds of receiving radiation therapy (OR: 0.97, 95% CI: 0.95-0.98) but increased odds of receiving chemotherapy (OR: 1.02, 95% CI: 1.01-1.03) and lymph-node surgical intervention (OR: 1.25, 95% CI: 1.17-1.35).",
        "Conclusions": "In this analysis of HNHC, increasing digital inequity was consistently associated with worse survival, advanced presentation, and poorer-prognostic treatment profiles. These results suggest detrimental trends potentially driven by delayed presentation associated with reduced access to digital care pathways and technological-structural barriers. By characterizing how digital inequity is a potentially crucial driver of HNHC disparities, this study identifies an actionable target for prospective investigations and interventions aimed at reducing disparities in head & neck hematologic cancer care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Impact of Digital Inequities on Head and Neck Hematologic Cancer Disparities in the US</span>. <u>Angela C Xie</u><sup>1</sup>; David J Fei-Zhang<sup>2</sup>; Jorge Gutierrez<sup>2</sup>; Abhinav Talwar<sup>2</sup>; Christopher A Puchi<sup>3</sup>; Jill N D'Souza<sup>4</sup>; Anthony M Sheyn<sup>5</sup>; Daniel C Chelius<sup>6</sup>; Jeffrey C Rastatter<sup>3</sup>. <sup>1</sup>Northwestern University Feinberg School of Medicine; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; <sup>3</sup>Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; <sup>4</sup>Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; <sup>5</sup>Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; <sup>6</sup>Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>In the modern age, the use of technology has become embedded in the care of patients from diagnosis to treatment. As disparities in access to digital resources continue to exist across the United States, these differences consequently can impact the prognostic outcomes for cancer patients with long-term care burdens, especially for those diagnosed with head & neck hematologic cancers (HNHC). Despite prior studies showing how digital disparities correlate with outcomes across many cancer types, the specific influence of digital inequity on HNHC remains seldom investigated. Thus, this study aims to evaluate the association between digital inequity and HNHC treatment and prognosis.</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study assessed adult HNHC-patients between 2008–2017 in the NCI-Surveillance, Epidemiology, and End Results (SEER) database. Digital inequity was assessed using the Digital Inequity Index (DII), which was quantified using 17 census-tract level variables derived from the American Community Survey and the Federal Communications Commission, grouped into (1) digital infrastructure (i.e. electronic device ownership, broadband type, internet provider availability, income–broadband subscription ratio) and (2) sociodemographic factors (i.e. education, income, disability status). Variables were then ranked and composited into county-level DII scores encompassing both direct and indirect factors related to digital inequity. DII was matched to patients’ county of residence recorded in SEER. Multivariable Cox-hazards and logistic regression models were used to assess overall survival, early mortality (3- & 5-year), advanced staging/distal lymph node involvement, and treatment modalities across increasing DII scores.</p>\n\n<p><strong>Results: </strong>Of the 32,982 patients with HNHC identified, 65–84 years (n = 10,287, 41%), male (n = 13,713, 55%), non-Hispanic white race/ethnicity (n = 16,444, 65%) were the most represented characteristics. A majority were diagnosed with non-Hodgkin lymphoma (n=22,497, 89%). Increasing digital inequity, represented by higher overall DII scores, was significantly associated with worse survival outcomes (HR:1.08, 95% confidence interval [CI]: 1.06-1.10). Higher DII was also associated with increased advanced staging/distal lymph node occurrence (odds ratio [OR]: 1.03, 95% CI: 1.01–1.05) and increased 3-year (OR: 1.08, 95% CI: 1.06-1.10) and 5-year mortality (OR: 1.11, 95% CI: 1.08-1.13). Regarding treatment patterns, patients residing in higher-DII areas demonstrated decreased odds of receiving radiation therapy (OR: 0.97, 95% CI: 0.95-0.98) but increased odds of receiving chemotherapy (OR: 1.02, 95% CI: 1.01-1.03) and lymph-node surgical intervention (OR: 1.25, 95% CI: 1.17-1.35).</p>\n\n<p><strong>Conclusions: </strong>In this analysis of HNHC, increasing digital inequity was consistently associated with worse survival, advanced presentation, and poorer-prognostic treatment profiles. These results suggest detrimental trends potentially driven by delayed presentation associated with reduced access to digital care pathways and technological-structural barriers. By characterizing how digital inequity is a potentially crucial driver of HNHC disparities, this study identifies an actionable target for prospective investigations and interventions aimed at reducing disparities in head & neck hematologic cancer care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153359--></body></html>"
    },
    {
      "uid": "P092",
      "content_id": "154697",
      "abstract_number": "P092",
      "poster_number": "P092",
      "title": "Social and Structural Determinants of Health as Predictors of 90 Day Readmission Following Head and Neck Cancer Surgery",
      "summary": "This study identified cumulative SSDOH vulnerability, transportation, and possibly community support systems as salient contributors to hospital readmission following HNCS. Importantly, all the examined SSDOH factors represent areas where hospital systems could potentially intervene, i.e. improving/providing transportation options for patients or ensuring patients have adequate care systems out of the hospital...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154697",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ruby Nguyen",
      "presenter": "Ruby Nguyen",
      "authors": "Varun Gopal 1 ; Ruby Nguyen 2 ; Emma Kraus 2 ; Kamel Moufarrej 2 ; Sarah Nyirjesy, MD 3 ; Lucas Berry 2 ; Gintas P Krisciunas, PhD 2",
      "normalized_authors": [
        "Varun Gopal",
        "Ruby Nguyen",
        "Emma Kraus",
        "Kamel Moufarrej",
        "Sarah Nyirjesy",
        "Lucas Berry",
        "Gintas P Krisciunas"
      ],
      "affiliations": [
        "Carle Illinois College of Medicine",
        "Boston University Chobanian & Avedisian School of Medicine",
        "Department of Otolaryngology- Head & Neck Surgery, Boston Medical Center"
      ],
      "normalized_institutions": [
        "Carle Illinois College of Medicine",
        "Boston University Chobanian & Avedisian School of Medicine",
        "Department of Otolaryngology- Head & Neck Surgery, Boston Medical Center"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Varun Gopal 1 ; Ruby Nguyen 2 ; Emma Kraus 2 ; Kamel Moufarrej 2 ; Sarah Nyirjesy, MD 3 ; Lucas Berry 2 ; Gintas P Krisciunas, PhD 2",
        "Affiliations": "1 Carle Illinois College of Medicine; 2 Boston University Chobanian & Avedisian School of Medicine; 3 Department of Otolaryngology- Head & Neck Surgery, Boston Medical Center",
        "Background": "Head and neck cancer surgeries (HNCS) are associated with a high rate of readmission, with 30-day readmission rates for HNCS reported between 11-16% and reports as high as 55% of HNCS patients having at least 1 ED visit within 90-days of discharge. Prior literature has examined associations between demographic, surgical, and medical factors and risk of readmission. Black race and low socioeconomic status have been identified as predictors of HNCS readmission, but existing research has not examined the underlying causes that drive these observed trends. It has been hypothesized that various social and structural determinants of health (SSDOH) underlie these trends, some of which may be proactively addressed or managed. We hypothesized that SSDOH factors including transportation difficulty, financial concerns (treatment, medical supply, living costs), poor out of hospital support/care systems, and housing insecurity may cause delays in a patient’s ability to seek care promptly and may cause greater rates of readmission.",
        "Methods": "This retrospective study evaluated patients who underwent HNCS at a large, urban, safety-net, teaching hospital. Patients who had a readmission from the emergency department from 4/2021 to 11/2022 within 90 days of discharge for a reason related to their HNCS were included. Patient, provider, and care coordinator medical record notes were reviewed for any noted challenges with transportation to medical appointments, financial concerns (affording treatment, supplies, cost of living), support/care systems outside of the hospital following discharge, and stable housing/living space. SSDOH data were obtained for a control group that was matched to readmitted patients based on tumor stage (prioritizing size), tumor location, age (+/-7 years), current smoking status, presence of uncontrolled diabetes mellitus on surgery day, and adjuvant chemo/radiotherapy. A cumulative SSDOH score (0-4) was also calculated for each patient by summing the number of identified SSDOH variables, with a score of 2-4 being defined as SSDOH vulnerable. Group level correlations between each SSDOH factor and readmission, and between cumulative SSDOH score and readmission, for the matched pairs, were evaluated using McNemar’s test.",
        "Results": "16 patients with HNCS related 90-day readmissions were analyzed with 16 matched non-readmissions. A cumulative SSDOH vulnerability score of 2 or greater was significantly (p=0.023) associated with a HNCS readmission. For individual SSDOH variables, transportation difficulty was significantly associated with readmission (p=0.013). There was a trend towards significance (p=0.074) for the correlation between poor out-of-hospital support systems and readmission. The remaining SSDOH variables were not significantly associated with readmission.",
        "Conclusion": "This study identified cumulative SSDOH vulnerability, transportation, and possibly community support systems as salient contributors to hospital readmission following HNCS. Importantly, all the examined SSDOH factors represent areas where hospital systems could potentially intervene, i.e. improving/providing transportation options for patients or ensuring patients have adequate care systems out of the hospital prior to discharge. A follow-up study with a larger sample size will further interrogate these relationships to identify and confirm salient and actionable SSDOH variables that could enhance surgical outcomes for vulnerable HNC patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Social and Structural Determinants of Health as Predictors of 90 Day Readmission Following Head and Neck Cancer Surgery</span>. Varun Gopal<sup>1</sup>; <u>Ruby Nguyen</u><sup>2</sup>; Emma Kraus<sup>2</sup>; Kamel Moufarrej<sup>2</sup>; Sarah Nyirjesy, MD<sup>3</sup>; Lucas Berry<sup>2</sup>; Gintas P Krisciunas, PhD<sup>2</sup>. <sup>1</sup>Carle Illinois College of Medicine; <sup>2</sup>Boston University Chobanian & Avedisian School of Medicine; <sup>3</sup>Department of Otolaryngology- Head & Neck Surgery, Boston Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer surgeries (HNCS) are associated with a high rate of readmission, with 30-day readmission rates for HNCS reported between 11-16% and reports as high as 55% of HNCS patients having at least 1 ED visit within 90-days of discharge. Prior literature has examined associations between demographic, surgical, and medical factors and risk of readmission. Black race and low socioeconomic status have been identified as predictors of HNCS readmission, but existing research has not examined the underlying causes that drive these observed trends. It has been hypothesized that various social and structural determinants of health (SSDOH) underlie these trends, some of which may be proactively addressed or managed. We hypothesized that SSDOH factors including transportation difficulty, financial concerns (treatment, medical supply, living costs), poor out of hospital support/care systems, and housing insecurity may cause delays in a patient’s ability to seek care promptly and may cause greater rates of readmission.</p>\n\n<p><strong>Methods: </strong>This retrospective study evaluated patients who underwent HNCS at a large, urban, safety-net, teaching hospital. Patients who had a readmission from the emergency department from 4/2021 to 11/2022 within 90 days of discharge for a reason related to their HNCS were included. Patient, provider, and care coordinator medical record notes were reviewed for any noted challenges with transportation to medical appointments, financial concerns (affording treatment, supplies, cost of living), support/care systems outside of the hospital following discharge, and stable housing/living space. SSDOH data were obtained for a control group that was matched to readmitted patients based on tumor stage (prioritizing size), tumor location, age (+/-7 years), current smoking status, presence of uncontrolled diabetes mellitus on surgery day, and adjuvant chemo/radiotherapy. A cumulative SSDOH score (0-4) was also calculated for each patient by summing the number of identified SSDOH variables, with a score of 2-4 being defined as SSDOH vulnerable. Group level correlations between each SSDOH factor and readmission, and between cumulative SSDOH score and readmission, for the matched pairs, were evaluated using McNemar’s test.</p>\n\n<p><strong>Results: </strong>16 patients with HNCS related 90-day readmissions were analyzed with 16 matched non-readmissions. A cumulative SSDOH vulnerability score of 2 or greater was significantly (p=0.023) associated with a HNCS readmission. For individual SSDOH variables, transportation difficulty was significantly associated with readmission (p=0.013). There was a trend towards significance (p=0.074) for the correlation between poor out-of-hospital support systems and readmission. The remaining SSDOH variables were not significantly associated with readmission.</p>\n\n<p><strong>Conclusion:</strong> This study identified cumulative SSDOH vulnerability, transportation, and possibly community support systems as salient contributors to hospital readmission following HNCS. Importantly, all the examined SSDOH factors represent areas where hospital systems could potentially intervene, i.e. improving/providing transportation options for patients or ensuring patients have adequate care systems out of the hospital prior to discharge. A follow-up study with a larger sample size will further interrogate these relationships to identify and confirm salient and actionable SSDOH variables that could enhance surgical outcomes for vulnerable HNC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154697--></body></html>"
    },
    {
      "uid": "P093",
      "content_id": "153956",
      "abstract_number": "P093",
      "poster_number": "P093",
      "title": "Length of Stay and Patient-Initiated Communications after Isolated Cutaneous Free Flap Reconstruction",
      "summary": "Early discharge after free flap reconstruction of cutaneous head and neck defects is not associated with an increase in postoperative communication or actionable clinical findings compared with later discharge. Targeted improvements in reconstruction site wound care education and clarification of normal healing trajectories may further support and enable safe early discharge practices.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153956",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Noe Francois-Saint-Cyr, BS",
      "presenter": "Noe Francois-Saint-Cyr, BS",
      "authors": "Noe Francois-Saint-Cyr, BS ; Jayden R Garcia, MD; Grayson Buning, BS; Andrew Prince, MD; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David Forner, MD, MSc",
      "normalized_authors": [
        "Noe Francois-Saint-Cyr",
        "Jayden R Garcia",
        "Grayson Buning",
        "Andrew Prince",
        "Marisa R Buchakjian",
        "Pratyusha Yalamanchi",
        "Keith A Casper",
        "Chaz L Stucken",
        "Kelly M Malloy",
        "Andrew G Shuman",
        "Mark Prince",
        "Scott A McLean",
        "Molly E Heft Neal",
        "David Forner"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Noe Francois-Saint-Cyr, BS ; Jayden R Garcia, MD; Grayson Buning, BS; Andrew Prince, MD; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David Forner, MD, MSc",
        "Affiliations": "University of Michigan",
        "Background": "Shortening postoperative hospitalization can reduce nosocomial infections, improve hospital resource burden, and improve patient satisfaction. However, the safety of earlier discharge is poorly understood. Postoperative patient-initiated communications provide a means of assessing patient concerns, the adequacy of discharge instructions, and the presentation of common postoperative complications. Evaluating the association between length of stay (LOS) and patient-initiated communications may inform strategies to facilitate earlier safe discharge by strengthening discharge education and expectations.",
        "Objective": "To characterize postoperative patient communications and assess their relationship with LOS after free flap reconstruction of cutaneous head and neck defects.",
        "Methods": "This retrospective cohort study evaluated consecutive isolated cutaneous microvascular reconstructions performed at a single academic tertiary center between 2014 and 2025. Patients requiring additional procedure(s) within the 30-day postoperative period unrelated to complications of the initial surgery were excluded. The primary exposure was postoperative LOS. The main outcome was any unplanned, patient-initiated communication within 30 days of surgery. Communications were characterized by concern type (wound concern, systemic/medical concern, supplies), required response (surgeon intervention, staff instruction, reassurance), and whether an actionable clinical finding was identified. LOS was dichotomized into early (≤5 days) and late (>5 days) discharge.",
        "Results": "Ninety-three patients (55 early, 38 late discharge) met inclusion criteria. There was no significant difference in demographics or comorbidities between groups. Fifty patients (53.8%), 33 early discharge (57%) and 17 late discharge (43%), initiated 67 postoperative communications, with no between-group difference (p=0.1454). Among those who initiated communication, late-discharge patients submitted more communications per patient (1.24 vs 1.65; p=0.045). However, regression analysis showed no significant difference in number of communications between discharge groups when adjusted for comorbidities (IRR: 1.36, p = 0.245). Overall, 79.1% of concerns were managed with staff instruction or reassurance. Wound concerns (35%), systemic concerns (15%), and wound care guidance (12.5%) were the most prevalent concerns in the early discharge group. Wound concerns at the reconstruction site were more prevalent in early discharge compared to late discharge, though low event counts resulted in an imprecise OR (OR=11.1, p=0.013). However, the presence of actionable clinical findings between discharge groups and across anatomic sites was not different (OR: 1.78, p=0.643). Staff instruction was the most frequent intervention in both LOS groups (early 47.5%, late 70.4%) and significantly more common in late discharge (OR=3.10, CI 0.983–10.752). Surgeon intervention was more common in early discharge (27.5% vs 11.1%; OR=0.335, CI 0.054–1.47). There were no post-discharge returns to the OR for flap-related complications; surgeon interventions were mainly antibiotics or unplanned clinic visits. Three early-discharge patients (5.5%) required ED visit or readmission.",
        "Conclusion": "Early discharge after free flap reconstruction of cutaneous head and neck defects is not associated with an increase in postoperative communication or actionable clinical findings compared with later discharge. Targeted improvements in reconstruction site wound care education and clarification of normal healing trajectories may further support and enable safe early discharge practices."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Length of Stay and Patient-Initiated Communications after Isolated Cutaneous Free Flap Reconstruction</span>. <u>Noe Francois-Saint-Cyr, BS</u>; Jayden R Garcia, MD; Grayson Buning, BS; Andrew Prince, MD; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David Forner, MD, MSc. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Shortening postoperative hospitalization can reduce nosocomial infections, improve hospital resource burden, and improve patient satisfaction. However, the safety of earlier discharge is poorly understood. Postoperative patient-initiated communications provide a means of assessing patient concerns, the adequacy of discharge instructions, and the presentation of common postoperative complications. Evaluating the association between length of stay (LOS) and patient-initiated communications may inform strategies to facilitate earlier safe discharge by strengthening discharge education and expectations.</p>\n\n<p><strong>Objective: </strong>To characterize postoperative patient communications and assess their relationship with LOS after free flap reconstruction of cutaneous head and neck defects.</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study evaluated consecutive isolated cutaneous microvascular reconstructions performed at a single academic tertiary center between 2014 and 2025. Patients requiring additional procedure(s) within the 30-day postoperative period unrelated to complications of the initial surgery were excluded. The primary exposure was postoperative LOS. The main outcome was any unplanned, patient-initiated communication within 30 days of surgery. Communications were characterized by concern type (wound concern, systemic/medical concern, supplies), required response (surgeon intervention, staff instruction, reassurance), and whether an actionable clinical finding was identified. LOS was dichotomized into early (≤5 days) and late (>5 days) discharge.</p>\n\n<p><strong>Results: </strong>Ninety-three patients (55 early, 38 late discharge) met inclusion criteria. There was no significant difference in demographics or comorbidities between groups. Fifty patients (53.8%), 33 early discharge (57%) and 17 late discharge (43%), initiated 67 postoperative communications, with no between-group difference (p=0.1454). Among those who initiated communication, late-discharge patients submitted more communications per patient (1.24 vs 1.65; p=0.045). However, regression analysis showed no significant difference in number of communications between discharge groups when adjusted for comorbidities (IRR: 1.36, p = 0.245). Overall, 79.1% of concerns were managed with staff instruction or reassurance. Wound concerns (35%), systemic concerns (15%), and wound care guidance (12.5%) were the most prevalent concerns in the early discharge group. Wound concerns at the reconstruction site were more prevalent in early discharge compared to late discharge, though low event counts resulted in an imprecise OR (OR=11.1, p=0.013). However, the presence of actionable clinical findings between discharge groups and across anatomic sites was not different (OR: 1.78, p=0.643). Staff instruction was the most frequent intervention in both LOS groups (early 47.5%, late 70.4%) and significantly more common in late discharge (OR=3.10, CI 0.983–10.752). Surgeon intervention was more common in early discharge (27.5% vs 11.1%; OR=0.335, CI 0.054–1.47). There were no post-discharge returns to the OR for flap-related complications; surgeon interventions were mainly antibiotics or unplanned clinic visits. Three early-discharge patients (5.5%) required ED visit or readmission.</p>\n\n<p><strong>Conclusion: </strong>Early discharge after free flap reconstruction of cutaneous head and neck defects is not associated with an increase in postoperative communication or actionable clinical findings compared with later discharge. Targeted improvements in reconstruction site wound care education and clarification of normal healing trajectories may further support and enable safe early discharge practices.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153956--></body></html>"
    },
    {
      "uid": "P094",
      "content_id": "151919",
      "abstract_number": "P094",
      "poster_number": "P094",
      "title": "Immersive Virtual Reality First-Person Perspective Video for Surgical Education: Anterolateral Thigh Free Flap Reconstruction",
      "summary": "Anterolateral thigh (ALT) free flaps are versatile and reliable options for a variety of reconstructive surgeries, including repair of head and neck defects. Mastery of complex procedures, like flap dissection, by residents and fellows takes years of training to develop. Surgical education is shifting towards advanced technologies to deliver learning experiences introducing potential for immersive virtual reality...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151919",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chase Clark",
      "presenter": "Chase Clark",
      "authors": "Chase Clark 1 ; Brian R Quaranto, MD 1 ; Brielle Raine, MD 2 ; Michael Lamb, PhD 1 ; Thom R Loree, MD 1 ; Michael Nagai, MD, DDS 1 ; Jordan Frey, MD 1 ; Mark S Burke, MD 1",
      "normalized_authors": [
        "Chase Clark",
        "Brian R Quaranto",
        "Brielle Raine",
        "Michael Lamb",
        "Thom R Loree",
        "Michael Nagai",
        "Jordan Frey",
        "Mark S Burke"
      ],
      "affiliations": [
        "University at Buffalo",
        "University of Rochester"
      ],
      "normalized_institutions": [
        "University at Buffalo",
        "University of Rochester"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151919/Figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151919/Figure%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151919"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 297,
      "section_labels": [
        "Authors",
        "Affiliations",
        "PURPOSE",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Figure 1"
      ],
      "sections": {
        "Authors": "Chase Clark 1 ; Brian R Quaranto, MD 1 ; Brielle Raine, MD 2 ; Michael Lamb, PhD 1 ; Thom R Loree, MD 1 ; Michael Nagai, MD, DDS 1 ; Jordan Frey, MD 1 ; Mark S Burke, MD 1",
        "Affiliations": "1 University at Buffalo; 2 University of Rochester",
        "PURPOSE": "Anterolateral thigh (ALT) free flaps are versatile and reliable options for a variety of reconstructive surgeries, including repair of head and neck defects. Mastery of complex procedures, like flap dissection, by residents and fellows takes years of training to develop. Surgical education is shifting towards advanced technologies to deliver learning experiences introducing potential for immersive virtual reality (VR) first-person video from the operative surgeon's perspective for teaching and learning plastic and reconstructive surgery (figure 1).",
        "METHODS": "63-year-old male with history of diabetes mellitus, hypertension, and polysubstance use diagnosed with epithelial myoepithelial carcinoma ex-pleomorphic adenoma of the parotid gland presented for ALT flap reconstruction of a facial defect after cancer resection. The entire procedure was captured in the surgeon's first-person perspective using a novel head-mounted gimbal stabilized stereoscopic camera.",
        "RESULTS": "A total of 112 minutes of 5.7K stereoscopic video demonstrating ALT flap dissection was edited to a five minute immersive VR video. Critical steps of the procedure included flap markings, separation from the rectus femoris and vastus lateralis muscles, and dissection of the vascular pedicle.",
        "CONCLUSIONS": "Learning complex visuospatial techniques demands the visual perspective of the operating surgeon. Using stereoscopy and advanced stabilization, our camera system has the potential to achieve unparalleled depth into the open operative field. This video represents one in a series of complex myocutaneous flap procedures captured using this technology at our institution. By enabling trainees to visually embody the master surgeons’ visual perspectives, the conveyance of operative skills is facilitated. Further research is being conducted on the comparative impact of immersive video to conventional video. Future research focusing on the utilization of newer technology to capture first-person surgical technique encompass the next steps for advancing this teaching modality.",
        "Figure 1": "Intra-operative photo showing the senior surgeon’s first-person perspective performing the initial steps of ALT flap dissection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immersive Virtual Reality First-Person Perspective Video for Surgical Education: Anterolateral Thigh Free Flap Reconstruction</span>. <u>Chase Clark</u><sup>1</sup>; Brian R Quaranto, MD<sup>1</sup>; Brielle Raine, MD<sup>2</sup>; Michael Lamb, PhD<sup>1</sup>; Thom R Loree, MD<sup>1</sup>; Michael Nagai, MD, DDS<sup>1</sup>; Jordan Frey, MD<sup>1</sup>; Mark S Burke, MD<sup>1</sup>. <sup>1</sup>University at Buffalo; <sup>2</sup>University of Rochester<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>PURPOSE</strong>: Anterolateral thigh (ALT) free flaps are versatile and reliable options for a variety of reconstructive surgeries, including repair of head and neck defects. Mastery of complex procedures, like flap dissection, by residents and fellows takes years of training to develop. Surgical education is shifting towards advanced technologies to deliver learning experiences introducing potential for immersive virtual reality (VR) first-person video from the operative surgeon's perspective for teaching and learning plastic and reconstructive surgery (figure 1).</p>\n\n<p><strong>METHODS</strong>: 63-year-old male with history of diabetes mellitus, hypertension, and polysubstance use diagnosed with epithelial myoepithelial carcinoma ex-pleomorphic adenoma of the parotid gland presented for ALT flap reconstruction of a facial defect after cancer resection. The entire procedure was captured in the surgeon's first-person perspective using a novel head-mounted gimbal stabilized stereoscopic camera.</p>\n\n<p><strong>RESULTS</strong>: A total of 112 minutes of 5.7K stereoscopic video demonstrating ALT flap dissection was edited to a five minute immersive VR video. Critical steps of the procedure included flap markings, separation from the rectus femoris and vastus lateralis muscles, and dissection of the vascular pedicle.</p>\n\n<p>\n<strong>CONCLUSIONS</strong>: Learning complex visuospatial techniques demands the visual perspective of the operating surgeon. Using stereoscopy and advanced stabilization, our camera system has the potential to achieve unparalleled depth into the open operative field. This video represents one in a series of complex myocutaneous flap procedures captured using this technology at our institution. By enabling trainees to visually embody the master surgeons’ visual perspectives, the conveyance of operative skills is facilitated. Further research is being conducted on the comparative impact of immersive video to conventional video. Future research focusing on the utilization of newer technology to capture first-person surgical technique encompass the next steps for advancing this teaching modality.</p>\n\n<p><strong>FIGURES</strong>:</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151919/Figure%201.png' /></p>\n\n<p><strong>Figure 1</strong>: Intra-operative photo showing the senior surgeon’s first-person perspective performing the initial steps of ALT flap dissection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151919--></body></html>"
    },
    {
      "uid": "P095",
      "content_id": "154674",
      "abstract_number": "P095",
      "poster_number": "P095",
      "title": "Prospective Trial Comparing Anesthetic Efficacy of an Intranasal Tetracaine/Oxymetazoline Foam to Cotton Pledget application for Flexible Nasolaryngoscopy",
      "summary": "Among patients undergoing nasolaryngoscopy, non-aerosolizing anesthetic topicalization appears to be as effective as the aerosolizing method, although it is associated with a worse taste profile.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154674",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jason S Acheampong, MD",
      "presenter": "Jason S Acheampong, MD",
      "authors": "Paul Sinno, MS; Jason S Acheampong, MD ; Emily Wikner, MD; Matthew Bak, MD, FACS; Jonathan R Mark, MD, FACS",
      "normalized_authors": [
        "Paul Sinno",
        "Jason S Acheampong",
        "Emily Wikner",
        "Matthew Bak",
        "Jonathan R Mark"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 213,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Paul Sinno, MS; Jason S Acheampong, MD ; Emily Wikner, MD; Matthew Bak, MD, FACS; Jonathan R Mark, MD, FACS",
        "Affiliations": "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University",
        "Introduction": "The standard method of anesthetic application during nasolaryngoscopy is aerosolized 2% tetracaine combined with 0.05% oxymetazoline delivered directly into the nasal passage. During the COVID-19 pandemic, however, anesthetic was often administered via insertion of a cotton pledget to minimize the risk of viral mobilization within the nasopharynx. Given this concern, alternative methods of nasal anesthetic application for nasolaryngoscopy should be considered.",
        "Objective": "To compare patient care outcomes between non-aerosolizing foam-based and cotton-pledget anesthetic application methods for nasolaryngoscopy.",
        "Methods": "A total of 200 patients were randomized to receive 2% tetracaine plus 0.05% oxymetazoline via either cotton-pledget placement or foam-based application prior to undergoing nasolaryngoscopy. Immediately following the procedure, patients completed a survey assessing discomfort and adverse outcomes using the Iowa Satisfaction with Anesthesia Scale (ISAS).",
        "Results": "There were minimal significant differences in ISAS scores between the foam and cotton-pledget methods, indicating that foam-based anesthetic application is as effective as the cotton-pledget technique. The only significant difference was that participants were more likely to report an unpleasant taste with the foam method, likely due to the foaming agent reaching the oropharynx. No significant differences were observed across multiple patient demographic subgroups.",
        "Conclusion": "Among patients undergoing nasolaryngoscopy, non-aerosolizing anesthetic topicalization appears to be as effective as the aerosolizing method, although it is associated with a worse taste profile."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prospective Trial Comparing Anesthetic Efficacy of an Intranasal Tetracaine/Oxymetazoline Foam to Cotton Pledget application for Flexible Nasolaryngoscopy</span>. Paul Sinno, MS; <u>Jason S Acheampong, MD</u>; Emily Wikner, MD; Matthew Bak, MD, FACS; Jonathan R Mark, MD, FACS. Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The standard method of anesthetic application during nasolaryngoscopy is aerosolized 2% tetracaine combined with 0.05% oxymetazoline delivered directly into the nasal passage. During the COVID-19 pandemic, however, anesthetic was often administered via insertion of a cotton pledget to minimize the risk of viral mobilization within the nasopharynx. Given this concern, alternative methods of nasal anesthetic application for nasolaryngoscopy should be considered.</p>\n\n<p><strong>Objective: </strong>To compare patient care outcomes between non-aerosolizing foam-based and cotton-pledget anesthetic application methods for nasolaryngoscopy.</p>\n\n<p><strong>Methods: </strong>A total of 200 patients were randomized to receive 2% tetracaine plus 0.05% oxymetazoline via either cotton-pledget placement or foam-based application prior to undergoing nasolaryngoscopy. Immediately following the procedure, patients completed a survey assessing discomfort and adverse outcomes using the Iowa Satisfaction with Anesthesia Scale (ISAS).</p>\n\n<p><strong>Results: </strong>There were minimal significant differences in ISAS scores between the foam and cotton-pledget methods, indicating that foam-based anesthetic application is as effective as the cotton-pledget technique. The only significant difference was that participants were more likely to report an unpleasant taste with the foam method, likely due to the foaming agent reaching the oropharynx. No significant differences were observed across multiple patient demographic subgroups.</p>\n\n<p><strong>Conclusion: </strong>Among patients undergoing nasolaryngoscopy, non-aerosolizing anesthetic topicalization appears to be as effective as the aerosolizing method, although it is associated with a worse taste profile.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154674--></body></html>"
    },
    {
      "uid": "P096",
      "content_id": "153706",
      "abstract_number": "P096",
      "poster_number": "P096",
      "title": "Assessments of Social Vulnerability with Pediatric Head-Neck Nervous System Cancer Prognosis in the US",
      "summary": "The summative effect of vulnerabilities across a multitude of SDoH-factors was significantly associated with detrimental prognostic trends among pediatric HNNSC, with selective correlations of HT, SES, ML-vulnerabilities underlying these overall correlations. This study not only reveals the exacerbated extent of how summative SDoH-vulnerabilities influence pediatric HNNSC outcomes but also quantifies the specific...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153706",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David J Fei-Zhang",
      "presenter": "David J Fei-Zhang",
      "authors": "Helena Kim 1 ; Mary G Robichaux 2 ; David J Fei-Zhang 3 ; Jill N D'Souza 4 ; Christopher A Puchi 5 ; Abhinav Talwar 3 ; Jorge Gutierrez 3 ; Anthony M Sheyn 6 ; Daniel C Chelius 7 ; Jeffrey C Rastatter 5",
      "normalized_authors": [
        "Helena Kim",
        "Mary G Robichaux",
        "David J Fei-Zhang",
        "Jill N D'Souza",
        "Christopher A Puchi",
        "Abhinav Talwar",
        "Jorge Gutierrez",
        "Anthony M Sheyn",
        "Daniel C Chelius",
        "Jeffrey C Rastatter"
      ],
      "affiliations": [
        "Northwestern University Feinberg School of Medicine",
        "Louisiana State University Health and Sciences Center School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "normalized_institutions": [
        "Northwestern University Feinberg School of Medicine",
        "Louisiana State University Health and Sciences Center School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "session_type": "Poster",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Helena Kim 1 ; Mary G Robichaux 2 ; David J Fei-Zhang 3 ; Jill N D'Souza 4 ; Christopher A Puchi 5 ; Abhinav Talwar 3 ; Jorge Gutierrez 3 ; Anthony M Sheyn 6 ; Daniel C Chelius 7 ; Jeffrey C Rastatter 5",
        "Affiliations": "1 Northwestern University Feinberg School of Medicine; 2 Louisiana State University Health and Sciences Center School of Medicine; 3 Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; 4 Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; 5 Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; 6 Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; 7 Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital",
        "Background": "Comprising the most common solid tumor type and leading cause of cancer mortality among children, head and neck nervous system cancers (HNNNSC) have long been studied for the clinical and non-clinical factors underlying their prevalence and poor prognoses. Among them, social drivers of health (SDoH) have played a role in shaping health outcomes for pediatric-HNNSC patients, especially those pertaining to socioeconomic status and race-ethnicity. However, beyond these traditionally understood SDoH-factors, assessments of drivers beyond them and, more importantly, their complex interplay in the real world have seldom been investigated. Using the Social Vulnerability Index (SVI), a large-data tool validated by the Centers for Disease Control and Prevention (CDC) for assessing SDoH-differences across a multitude of community-level factors, this present study aims to assess the specific and summative influences of a wide scope of SDoH-vulnerabilities with pediatric HNNSC prognostic outcomes in the United States.",
        "Methods": "This retrospective cohort study analyzed 18,630 pediatric patients (0 - 19 years) diagnosed with primary HNNSC between 1975-2017 from the Surveillance, Epidemiology, and End Results (SEER) database. SDoH-vulnerabilities were assessed based on ranked scores calculated by the SVI across 15 county-level factors grouped into categories of socioeconomic status (SES), minority-language status (ML), household composition (HC), and housing-transportation (HT), as well as a weighted, total composite across all factors. SVI/SDoH-vulnerability scores were then assigned to patients’ county of residence. Age-adjusted Cox-hazards and logistic regression models were used to assess overall survival, high grading, and advanced staging with increasing SVI scores.",
        "Results": "With increasing overall vulnerability, as measured by total SVI scores, reduced survival was observed across all HNNSC (p < 0.001), with relative survival differences ranging as high as 58.72% for “Other Glioma Malignant Tumors” (37.13 to 15.32 months) to as low as 12.2% for “Ependymal Malignant Tumors” (46.59 to 40.91 months). Comprising these overall vulnerability trends, HT and ML-vulnerabilities were the largest associative contributors. For “Diffuse Astrocytic and Oligodendroglial Malignant Tumors”, increasing overall social vulnerability was significantly associated with higher tumor grade (OR 1.25, 95% CI 1.18-1.32), with overall trends primarily contributed by vulnerabilities in SES and HT, followed by ML-factors. Increasing overall social vulnerability was also significantly associated with advanced staging for “Other Glioma Malignant Tumors” (OR 1.23, 95% CI 1.00-1.53, p=0.048), driven primarily by vulnerabilities in SES.",
        "Conclusions": "The summative effect of vulnerabilities across a multitude of SDoH-factors was significantly associated with detrimental prognostic trends among pediatric HNNSC, with selective correlations of HT, SES, ML-vulnerabilities underlying these overall correlations. This study not only reveals the exacerbated extent of how summative SDoH-vulnerabilities influence pediatric HNNSC outcomes but also quantifies the specific detriment conferred by certain SDoH-factors. Importantly, such specificity may guide targeted inquiry for prospective initiatives and investigations, especially in an environment where public health resources are limited to mitigate disparities in pediatric-HNNSC access and care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessments of Social Vulnerability with Pediatric Head-Neck Nervous System Cancer Prognosis in the US</span>. Helena Kim<sup>1</sup>; Mary G Robichaux<sup>2</sup>; <u>David J Fei-Zhang</u><sup>3</sup>; Jill N D'Souza<sup>4</sup>; Christopher A Puchi<sup>5</sup>; Abhinav Talwar<sup>3</sup>; Jorge Gutierrez<sup>3</sup>; Anthony M Sheyn<sup>6</sup>; Daniel C Chelius<sup>7</sup>; Jeffrey C Rastatter<sup>5</sup>. <sup>1</sup>Northwestern University Feinberg School of Medicine; <sup>2</sup>Louisiana State University Health and Sciences Center School of Medicine; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; <sup>4</sup>Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; <sup>5</sup>Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; <sup>6</sup>Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; <sup>7</sup>Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Comprising the most common solid tumor type and leading cause of cancer mortality among children, head and neck nervous system cancers (HNNNSC) have long been studied for the clinical and non-clinical factors underlying their prevalence and poor prognoses. Among them, social drivers of health (SDoH) have played a role in shaping health outcomes for pediatric-HNNSC patients, especially those pertaining to socioeconomic status and race-ethnicity. However, beyond these traditionally understood SDoH-factors, assessments of drivers beyond them and, more importantly, their complex interplay in the real world have seldom been investigated. Using the Social Vulnerability Index (SVI), a large-data tool validated by the Centers for Disease Control and Prevention (CDC) for assessing SDoH-differences across a multitude of community-level factors, this present study aims to assess the specific and summative influences of a wide scope of SDoH-vulnerabilities with pediatric HNNSC prognostic outcomes in the United States.</p>\n\n<p><strong>Methods</strong>: This retrospective cohort study analyzed 18,630 pediatric patients (0 - 19 years) diagnosed with primary HNNSC between 1975-2017 from the Surveillance, Epidemiology, and End Results (SEER) database. SDoH-vulnerabilities were assessed based on ranked scores calculated by the SVI across 15 county-level factors grouped into categories of socioeconomic status (SES), minority-language status (ML), household composition (HC), and housing-transportation (HT), as well as a weighted, total composite across all factors. SVI/SDoH-vulnerability scores were then assigned to patients’ county of residence. Age-adjusted Cox-hazards and logistic regression models were used to assess overall survival, high grading, and advanced staging with increasing SVI scores.</p>\n\n<p><strong>Results</strong>: With increasing overall vulnerability, as measured by total SVI scores, reduced survival was observed across all HNNSC (p < 0.001), with relative survival differences ranging as high as 58.72% for “Other Glioma Malignant Tumors” (37.13 to 15.32 months) to as low as 12.2% for “Ependymal Malignant Tumors” (46.59 to 40.91 months). Comprising these overall vulnerability trends, HT and ML-vulnerabilities were the largest associative contributors. For “Diffuse Astrocytic and Oligodendroglial Malignant Tumors”, increasing overall social vulnerability was significantly associated with higher tumor grade (OR 1.25, 95% CI 1.18-1.32), with overall trends primarily contributed by vulnerabilities in SES and HT, followed by ML-factors. Increasing overall social vulnerability was also significantly associated with advanced staging for “Other Glioma Malignant Tumors” (OR 1.23, 95% CI 1.00-1.53, p=0.048), driven primarily by vulnerabilities in SES.</p>\n\n<p><strong>Conclusions</strong>: The summative effect of vulnerabilities across a multitude of SDoH-factors was significantly associated with detrimental prognostic trends among pediatric HNNSC, with selective correlations of HT, SES, ML-vulnerabilities underlying these overall correlations. This study not only reveals the exacerbated extent of how summative SDoH-vulnerabilities influence pediatric HNNSC outcomes but also quantifies the specific detriment conferred by certain SDoH-factors. Importantly, such specificity may guide targeted inquiry for prospective initiatives and investigations, especially in an environment where public health resources are limited to mitigate disparities in pediatric-HNNSC access and care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153706--></body></html>"
    },
    {
      "uid": "P097",
      "content_id": "154029",
      "abstract_number": "P097",
      "poster_number": "P097",
      "title": "Papillary Thyroid Carcinoma associated to Carney Complex in adolescent’s Caribbean girl. Multidisciplinary Management at Single Institution of Trinidad and Tobago.",
      "summary": "Thyroid cancer in children and adolescents is an increasingly significant concern, pediatric thyroid cancer is presented with larger tumors, increased local invasion, and a higher propensity for both cervical lymph node and distant metastases, particularly in younger children (≤10 years old) Despite these aggressive features, clinical attention to thyroid cancer in children and adolescents remains insufficient,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154029",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lorna Merritt-Charles, Anesthesiologyst Lecturer",
      "presenter": "Lorna Merritt-Charles, Anesthesiologyst Lecturer",
      "authors": "Rodolfo Arozarena Fundora, MD; Solaiman Juman, MD; Deepak Ramsingh, MD; Ardeen Nicholas, MD; Lorna Merritt-Charles, Anesthesiologyst Lecturer",
      "normalized_authors": [
        "Rodolfo Arozarena Fundora",
        "Solaiman Juman",
        "Deepak Ramsingh",
        "Ardeen Nicholas",
        "Lorna Merritt-Charles, Anesthesiologyst Lecturer"
      ],
      "affiliations": [
        "The West Indies University. St Augustine Campus . Trinidad and Tobago"
      ],
      "normalized_institutions": [
        "The West Indies University. St Augustine Campus . Trinidad and Tobago"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 343,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rodolfo Arozarena Fundora, MD; Solaiman Juman, MD; Deepak Ramsingh, MD; Ardeen Nicholas, MD; Lorna Merritt-Charles, Anesthesiologyst Lecturer",
        "Affiliations": "The West Indies University. St Augustine Campus . Trinidad and Tobago",
        "Background": "Thyroid cancer in children and adolescents is an increasingly significant concern, pediatric thyroid cancer is presented with larger tumors, increased local invasion, and a higher propensity for both cervical lymph node and distant metastases, particularly in younger children (≤10 years old) Despite these aggressive features, clinical attention to thyroid cancer in children and adolescents remains insufficient, with misconceptions surrounding its management.",
        "Abstract": "Global thyroid cancer incidence among adolescent and young adults (15-39 years) increased by 150% between 1990 and 2021 according with Global Burden Disease (GBD.A gender disparities between females exhibited 2.38 per 100,000, threefold higher than males (0.88 per 100,000). Projections to 2050 the global prevalence reflect an 18% increase from 2021. The Carney Complex (CCN) is a rare disorder with a prevalence minor 1 in 1000000 habitants. It is clinically characterized by Myxoma-spotty pigmentation- endocrine overactivity syndrome. The skin pigmentation anomalies include lentigines and blue naevi. The most common endocrine gland manifestations are acromegaly, thyroid and testicular tumors, and adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD. The 15 years old adolescent was seen in clinic with a mass in the lower and anterior neck. On Physical Examination a polylobate mass of the thyroid with multiples and bilateral lymphonodes were found. The workout for diagnosis was performed including Blood screening, Thyroid Function test, Images (US and CT), Cytology of the thyroid mass and bilateral lymphonodes. The cytology shows a Papillary Thyroid Carcinoma with bilateral metastasis of the neck. No distant metastasis was detected. Total Thyroidectomy with bilateral neck dissection was proposed and accepted by patient and parents. The operation was done satisfactorily with the maximum care for bleeding (Jehovah Witness Patient). On examination hypopigmented and darks areas of the skin were detected in the right labial commissure and in the vermillion. Other hyperpigmented areas were seen in the posterior part of the trunk and legs generating the suspect of the Carney Complex. PRKART1A test for the patient and her’s parent was ordered to confirm the clinical diagnosis of Carney Complex."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Papillary Thyroid Carcinoma  associated to Carney Complex  in adolescent’s Caribbean girl. Multidisciplinary Management  at Single Institution of Trinidad and Tobago.</span>. Rodolfo Arozarena Fundora, MD; Solaiman Juman, MD; Deepak Ramsingh, MD; Ardeen Nicholas, MD; <u>Lorna Merritt-Charles, Anesthesiologyst Lecturer</u>. The West Indies University. St Augustine Campus . Trinidad and Tobago<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Thyroid cancer in children and adolescents is an increasingly significant concern, pediatric thyroid cancer is presented with larger tumors, increased local invasion, and a higher propensity for both cervical lymph node and distant metastases, particularly in younger children (≤10 years old) Despite these aggressive features, clinical attention to thyroid cancer in children and adolescents remains insufficient, with misconceptions surrounding its management.</p>\n\n<p>Global thyroid cancer incidence among adolescent and young adults (15-39 years) increased by 150% between 1990 and 2021 according with Global Burden Disease (GBD.A gender disparities between females exhibited 2.38 per 100,000, threefold higher than males (0.88 per 100,000). Projections to 2050 the global prevalence reflect an 18% increase from 2021.</p>\n\n<p>The Carney Complex (CCN) is a rare disorder with a prevalence minor 1 in 1000000 habitants. It is clinically characterized by Myxoma-spotty pigmentation- endocrine overactivity syndrome. The skin pigmentation anomalies include lentigines and blue naevi. The most common endocrine gland manifestations are acromegaly, thyroid and testicular tumors, and adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD.</p>\n\n<p>The 15 years old adolescent was seen in clinic with a mass in the lower and anterior neck. On Physical Examination a polylobate mass of the thyroid with multiples and bilateral lymphonodes were found. The workout for diagnosis was performed including Blood screening, Thyroid Function test, Images (US and CT), Cytology of the thyroid mass and bilateral lymphonodes. The cytology shows a Papillary Thyroid Carcinoma with bilateral metastasis of the neck. No distant metastasis was detected. Total Thyroidectomy with bilateral neck dissection was proposed and accepted by patient and parents. The operation was done satisfactorily with the maximum care for bleeding (Jehovah Witness Patient).</p>\n\n<p>On examination hypopigmented and darks areas of the skin were detected in the right labial commissure and in the vermillion. Other hyperpigmented areas were seen in the posterior part of the trunk and legs generating the suspect of the Carney Complex. PRKART1A test for the patient and her’s parent was ordered to confirm the clinical diagnosis of Carney Complex.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154029--></body></html>"
    },
    {
      "uid": "P098",
      "content_id": "153796",
      "abstract_number": "P098",
      "poster_number": "P098",
      "title": "Giant Cystic Parathyroid Adenoma Presenting as a Compressive Neck Mass",
      "summary": "Giant parathyroid adenomas are classified as weighing more than 3.5 g with a diameter greater than 2 cm in the greatest dimension. We encountered a novel presentation of giant, cystic parathyroid adenoma.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153796",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Smrithi Chidambaram, MD, MSCI",
      "presenter": "Smrithi Chidambaram, MD, MSCI",
      "authors": "Smrithi Chidambaram, MD, MSCI 1 ; Josette Graves, MS 2 ; Garren Low, MD, MS 1 ; Warren C Swegal, MD 1",
      "normalized_authors": [
        "Smrithi Chidambaram, MSCI",
        "Josette Graves",
        "Garren Low",
        "Warren C Swegal"
      ],
      "affiliations": [
        "Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery",
        "Drexel University College of Medicine"
      ],
      "normalized_institutions": [
        "Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery",
        "Drexel University College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153796/Screenshot%202025-12-04%20at%203_45_36%20AM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153796/Screenshot%202025-12-04%20at%203_45_36%20AM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153796"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 481,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case and Surgical Course",
        "Discussion"
      ],
      "sections": {
        "Authors": "Smrithi Chidambaram, MD, MSCI 1 ; Josette Graves, MS 2 ; Garren Low, MD, MS 1 ; Warren C Swegal, MD 1",
        "Affiliations": "1 Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery; 2 Drexel University College of Medicine",
        "Background": "Giant parathyroid adenomas are classified as weighing more than 3.5 g with a diameter greater than 2 cm in the greatest dimension. We encountered a novel presentation of giant, cystic parathyroid adenoma.",
        "Case and Surgical Course": "A 75 year-old male presented to the emergency department due to increasing right neck swelling, dysphonia, and dysphagia. Urgent otolaryngology consultation was pursued due to dysphagia and neck mass. Lab values on admission also demonstrated a serum calcium of 18.1 mg/dL with further work up showing elevated serum parathyroid hormone (PTH 891pg/ml) and ionized calcium (2.51 mg/dL). An outpatient neck ultrasound report from 2 years prior described a small left thyroid nodule (FNA-benign) and a 9.0 cm x 3.0 cm x 6.0 cm debris filled cyst within the right thyroid lobe. Patient endorsed slow growth of this mass with associated voice change and dysphagia to solids for months and his family reported progressive confusion, constipation, and weakness in the days prior to admission. CT soft tissue neck demonstrated a 6.1 cm 8 cm x 11 cm (AP x TV x CC) cystic right central neck mass extending into the retropharyngeal space with mass effect on the upper airway and lateral displacement of the carotid artery (Figure 1). The patient’s hypercalcemia was addressed with calcitonin, furosemide, fluids, and bisphosphonates by the endocrinology team. He was cleared for neck exploration with intraoperative nerve and parathyroid serum level monitoring due to concern for a parathyroid adenoma. Though presentation was not typical for carcinoma, it remained on the differential. Intraoperatively, the mass was distinct but adherent to the right thyroid lobe, necessitating removal of the right lobe with the mass. PTH dropped from 1700 pg/mL to 150 pg/mL in the operating room. Given a >90% drop from baseline, left neck exploration was deferred. Final pathology indicated lesion was a parathyroid adenoma. The patient had an uneventful post-operative course without evidence of hungry bone syndrome and displayed rapid reversal of his dysphagia, dysphonia, and altered mental status.",
        "Discussion": "This case highlights a unique presentation of giant parathyroid adenoma and is the largest reported in the literature. Other cases of giant parathyroid adenomas have been confused for thyroid nodules and identified in the setting of recurrent nephrolithiasis and parathyroid crisis. In this case, urgent otolaryngology evaluation was prompted by a palpable neck mass with compressive symptoms and radiographic demonstration of airway deviation which occurred simultaneously with symptoms and signs of parathyroid crisis. This patient also had evidence of a right cystic intrathyroidal lesion on outpatient thyroid ultrasound and serum calcium at the upper limit of normal at least 2-3 years prior to presentation. Fortunately, removal of the adenoma quickly reversed the compressive symptoms and altered mental status with an uneventful post-operative course. However, earlier recognition and diagnosis in a case like this could eliminate the need for urgent, inpatient surgery and decrease morbidity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Giant Cystic Parathyroid Adenoma Presenting as a Compressive Neck Mass</span>. <u>Smrithi Chidambaram, MD, MSCI</u><sup>1</sup>; Josette Graves, MS<sup>2</sup>; Garren Low, MD, MS<sup>1</sup>; Warren C Swegal, MD<sup>1</sup>. <sup>1</sup>Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery; <sup>2</sup>Drexel University College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Giant parathyroid adenomas are classified as weighing more than 3.5 g with a diameter greater than 2 cm in the greatest dimension. We encountered a novel presentation of giant, cystic parathyroid adenoma.</p>\n\n<p><strong>Case and Surgical Course: </strong>A 75 year-old male presented to the emergency department due to increasing right neck swelling, dysphonia, and dysphagia. Urgent otolaryngology consultation was pursued due to dysphagia and neck mass. Lab values on admission also demonstrated a serum calcium of 18.1 mg/dL with further work up showing elevated serum parathyroid hormone (PTH 891pg/ml) and ionized calcium (2.51 mg/dL). An outpatient neck ultrasound report from 2 years prior described a small left thyroid nodule (FNA-benign) and a 9.0 cm x 3.0 cm x 6.0 cm debris filled cyst within the right thyroid lobe. Patient endorsed slow growth of this mass with associated voice change and dysphagia to solids for months and his family reported progressive confusion, constipation, and weakness in the days prior to admission. CT soft tissue neck demonstrated a 6.1 cm 8 cm x 11 cm (AP x TV x CC) cystic right central neck mass extending into the retropharyngeal space with mass effect on the upper airway and lateral displacement of the carotid artery (Figure 1). The patient’s hypercalcemia was addressed with calcitonin, furosemide, fluids, and bisphosphonates by the endocrinology team. He was cleared for neck exploration with intraoperative nerve and parathyroid serum level monitoring due to concern for a parathyroid adenoma. Though presentation was not typical for carcinoma, it remained on the differential. Intraoperatively, the mass was distinct but adherent to the right thyroid lobe, necessitating removal of the right lobe with the mass. PTH dropped from 1700 pg/mL to 150 pg/mL in the operating room. Given a >90% drop from baseline, left neck exploration was deferred. Final pathology indicated lesion was a parathyroid adenoma. The patient had an uneventful post-operative course without evidence of hungry bone syndrome and displayed rapid reversal of his dysphagia, dysphonia, and altered mental status.</p>\n\n<p><strong>Discussion: </strong>This case highlights a unique presentation of giant parathyroid adenoma and is the largest reported in the literature. Other cases of giant parathyroid adenomas have been confused for thyroid nodules and identified in the setting of recurrent nephrolithiasis and parathyroid crisis.  In this case, urgent otolaryngology evaluation was prompted by a palpable neck mass with compressive symptoms and radiographic demonstration of airway deviation which occurred simultaneously with symptoms and signs of parathyroid crisis. This patient also had evidence of a right cystic intrathyroidal lesion on outpatient thyroid ultrasound and serum calcium at the upper limit of normal at least 2-3 years prior to presentation. Fortunately, removal of the adenoma quickly reversed the compressive symptoms and altered mental status with an uneventful post-operative course. However, earlier recognition and diagnosis in a case like this could eliminate the need for urgent, inpatient surgery and decrease morbidity.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153796/Screenshot%202025-12-04%20at%203_45_36%20AM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153796--></body></html>"
    },
    {
      "uid": "P099",
      "content_id": "152241",
      "abstract_number": "P099",
      "poster_number": "P099",
      "title": "Proposal of Novel Frailty Index MFI-6C as Predictor of Hypocalcemia with Extended Length of Stay After Thyroid Surgery",
      "summary": "Among all thyroidectomy patients, frailty was associated with PHSH, and our novel frailty index (mFI-6C) improved prediction of both hypocalcemia and PHSH. In hemithyroidectomy, frailty alone was a strong predictor of both adverse outcomes, while patients who were both frail and vitamin D-deficient represented a highly vulnerable subgroup at markedly increased risk. In total thyroidectomy frailty identified...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152241",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aruni Areti, BA",
      "presenter": "Aruni Areti, BA",
      "authors": "Aruni Areti, BA 1 ; Dylan Fall, MD 1 ; Yossef Alsabawi, BSA 2 ; Ray Wang, MD 1 ; David Hernandez, MD 1 ; Angela Haskins, MD 1",
      "normalized_authors": [
        "Aruni Areti",
        "Dylan Fall",
        "Yossef Alsabawi, BSA",
        "Ray Wang",
        "David Hernandez",
        "Angela Haskins"
      ],
      "affiliations": [
        "Baylor College of Medicine",
        "University of Texas Rio Grande Valley"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine",
        "University of Texas Rio Grande Valley"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Aruni Areti, BA 1 ; Dylan Fall, MD 1 ; Yossef Alsabawi, BSA 2 ; Ray Wang, MD 1 ; David Hernandez, MD 1 ; Angela Haskins, MD 1",
        "Affiliations": "1 Baylor College of Medicine; 2 University of Texas Rio Grande Valley",
        "Introduction": "The 5-item Modified Frailty Index (mFI-5) is a validated tool quantifying frailty, and higher scores are associated with increased perioperative risk following thyroidectomy; however, mFI-5 has not been evaluated for its ability to predict post-thyroidectomy hypocalcemia or prolonged hospital stay with hypocalcemia (PHSH) beyond 23-hour observation. Hypovitaminosis D has also been linked to hypocalcemia after thyroidectomy. This study aims to determine whether frailty is an independent predictor of PHSH after thyroid surgery, and to assess whether a novel frailty model incorporating vitamin D status improves predictive accuracy.",
        "Methods": "We conducted a retrospective cohort study of 214 patients having thyroid surgery at our large, safety-net county hospital. Data to calculate mFI-5 were abstracted from the electronic medical record. We created an expanded frailty model (mFI-6C), adding pre-operative hypovitaminosis D as a comorbidity. Analyses were performed on all thyroidectomy patients (n=214), in addition to patients having only hemithyroidectomy (n=72), total thyroidectomy (n=142), and completion thyroidectomy (n=35). Univariate and multivariate logistic regressions, discrimination, and a “double-hit” analyses comparing vitamin D–deficient patients with low (mFI-5=0–1) versus high frailty (mFI-5≥2) were calculated. Statistical significance was defined as two-tailed p < 0.05.",
        "Results": "Of all patients, hypocalcemia was significantly more common in total thyroidectomy compared to hemithyroidectomy and completion thyroidectomy cohorts (71.1% vs. 38.9%, OR 3.87, p < 0.001). In all patients undergoing thyroid surgery, mFI-5 was significantly associated with PHSH (OR 1.77, p = 0.001, area under the curve (AUC) 0.703) but not hypocalcemia alone (p = 0.076, AUC 0.702), while our novel index, mFI-6C, significantly predicted both hypocalcemia (OR 1.31, p = 0.046, AUC 0.711) and PHSH (OR 1.32, p = 0.029, AUC 0.666). For hemithyroidectomy, both indices independently predicted hypocalcemia (mFI-5 OR 2.07, p = 0.019, AUC 0.693; mFI-6C OR 1.59, p = 0.045, AUC 0.647) and PHSH (mFI-5 OR 2.56, p = 0.007, AUC 0.748; mFI-6C OR 2.09, p = 0.010, AUC 0.729). In total thyroidectomy, mFI-5 predicted PHSH (OR 1.57, p = 0.037, AUC 0.653), while neither index predicted hypocalcemia (p = 0.65 and p = 0.31, respectively), and mFI-6C did not predict PHSH (p = 0.36). In double-hit analyses, all patients undergoing thyroid surgery with both frailty per the mFI-5 index and hypovitaminosis D had elevated risk (hypocalcemia p = 0.006; prolonged hospitalization p = 0.060), as did those undergoing hemithyroidectomy (hypocalcemia OR 16.3, p = 0.006); PHSH (OR 15.0, p = 0.025), but not in total thyroidectomy (p = 0.087 and p = 0.34).",
        "Conclusion": "Among all thyroidectomy patients, frailty was associated with PHSH, and our novel frailty index (mFI-6C) improved prediction of both hypocalcemia and PHSH. In hemithyroidectomy, frailty alone was a strong predictor of both adverse outcomes, while patients who were both frail and vitamin D-deficient represented a highly vulnerable subgroup at markedly increased risk. In total thyroidectomy frailty identified patients likely to experience PHSH. Integrating frailty scoring and vitamin D assessment into preoperative evaluation prior to thyroid surgery may enable surgeons to better stratify risk and plan postoperative care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Proposal of Novel Frailty Index MFI-6C as Predictor of Hypocalcemia with Extended Length of Stay After Thyroid Surgery</span>. <u>Aruni Areti, BA</u><sup>1</sup>; Dylan Fall, MD<sup>1</sup>; Yossef Alsabawi, BSA<sup>2</sup>; Ray Wang, MD<sup>1</sup>; David Hernandez, MD<sup>1</sup>; Angela Haskins, MD<sup>1</sup>. <sup>1</sup>Baylor College of Medicine; <sup>2</sup>University of Texas Rio Grande Valley<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The 5-item Modified Frailty Index (mFI-5) is a validated tool quantifying frailty, and higher scores are associated with increased perioperative risk following thyroidectomy; however, mFI-5 has not been evaluated for its ability to predict post-thyroidectomy hypocalcemia or prolonged hospital stay with hypocalcemia (PHSH) beyond 23-hour observation. Hypovitaminosis D has also been linked to hypocalcemia after thyroidectomy. This study aims to determine whether frailty is an independent predictor of PHSH after thyroid surgery, and to assess whether a novel frailty model incorporating vitamin D status improves predictive accuracy.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of 214 patients having thyroid surgery at our large, safety-net county hospital. Data to calculate mFI-5 were abstracted from the electronic medical record. We created an expanded frailty model (mFI-6C), adding pre-operative hypovitaminosis D as a comorbidity. Analyses were performed on all thyroidectomy patients (n=214), in addition to patients having only hemithyroidectomy (n=72), total thyroidectomy (n=142), and completion thyroidectomy (n=35). Univariate and multivariate logistic regressions, discrimination, and a “double-hit” analyses comparing vitamin D–deficient patients with low (mFI-5=0–1) versus high frailty (mFI-5≥2) were calculated. Statistical significance was defined as two-tailed p < 0.05.</p>\n\n<p><strong>Results: </strong>Of all patients, hypocalcemia was significantly more common in total thyroidectomy compared to hemithyroidectomy and completion thyroidectomy cohorts (71.1% vs. 38.9%, OR 3.87, p < 0.001). In all patients undergoing thyroid surgery, mFI-5 was significantly associated with PHSH (OR 1.77, p = 0.001, area under the curve (AUC) 0.703) but not hypocalcemia alone (p = 0.076, AUC 0.702), while our novel index, mFI-6C, significantly predicted both hypocalcemia (OR 1.31, p = 0.046, AUC 0.711) and PHSH (OR 1.32, p = 0.029, AUC 0.666). For hemithyroidectomy, both indices independently predicted hypocalcemia (mFI-5 OR 2.07, p = 0.019, AUC 0.693; mFI-6C OR 1.59, p = 0.045, AUC 0.647) and PHSH (mFI-5 OR 2.56, p = 0.007, AUC 0.748; mFI-6C OR 2.09, p = 0.010, AUC 0.729). In total thyroidectomy, mFI-5 predicted PHSH (OR 1.57, p = 0.037, AUC 0.653), while neither index predicted hypocalcemia (p = 0.65 and p = 0.31, respectively), and mFI-6C did not predict PHSH (p = 0.36). In double-hit analyses, all patients undergoing thyroid surgery with both frailty per the mFI-5 index and hypovitaminosis D had elevated risk (hypocalcemia p = 0.006; prolonged hospitalization p = 0.060), as did those undergoing hemithyroidectomy (hypocalcemia OR 16.3, p = 0.006); PHSH (OR 15.0, p = 0.025), but not in total thyroidectomy (p = 0.087 and p = 0.34).</p>\n\n<p><strong>Conclusion: </strong>Among all thyroidectomy patients, frailty was associated with PHSH, and our novel frailty index (mFI-6C) improved prediction of both hypocalcemia and PHSH. In hemithyroidectomy, frailty alone was a strong predictor of both adverse outcomes, while patients who were both frail and vitamin D-deficient represented a highly vulnerable subgroup at markedly increased risk. In total thyroidectomy frailty identified patients likely to experience PHSH. Integrating frailty scoring and vitamin D assessment into preoperative evaluation prior to thyroid surgery may enable surgeons to better stratify risk and plan postoperative care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152241--></body></html>"
    },
    {
      "uid": "P100",
      "content_id": "155576",
      "abstract_number": "P100",
      "poster_number": "P100",
      "title": "Perineural Invasion and Histologic Subtype as Predictors of Recurrence in Papillary Thyroid Carcinoma: A Retrospective Cohort Study",
      "summary": "In this large ATA-defined cohort of patients undergoing total thyroidectomy for PTC, perineural invasion and advanced TNM stage were the dominant independent predictors of recurrence, while follicular variant histology was protective. Tumor laterality and preoperative vocal cord findings provided additional risk stratification signals. These results reinforce the central role of detailed pathologic assessment in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155576",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ebrahim Farashi, MD",
      "presenter": "Ebrahim Farashi, MD",
      "authors": "Ebrahim Farashi, MD 1 ; Tolani F Olonisakin 2 ; Armin Namvar, MD 3 ; Parastou Gorovanchi, MD 4 ; Shrey Shah, MS 5 ; Parnaz Jafari 3 ; Samad Farashi Bonab 6 ; Joseph Lopez, MD, MBA 1 ; Seyed Ziaeddin Rasihashemi, MD 3",
      "normalized_authors": [
        "Ebrahim Farashi",
        "Tolani F Olonisakin",
        "Armin Namvar",
        "Parastou Gorovanchi",
        "Shrey Shah",
        "Parnaz Jafari",
        "Samad Farashi Bonab",
        "Joseph Lopez",
        "Seyed Ziaeddin Rasihashemi"
      ],
      "affiliations": [
        "Division of Pediatric Head & Neck Surgery, Department of Children’s Surgery, AdventHealth for Children, Orlando, FL",
        "Department of Otolaryngology – Head & Neck Surgery, Johns Hopkins Hospital, Baltimore, MD, USA",
        "Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran",
        "Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran",
        "Rutgers New Jersey Medical School, Newark, NJ, USA",
        "Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"
      ],
      "normalized_institutions": [
        "Division of Pediatric Head & Neck Surgery, Department of Children’s Surgery, AdventHealth for Children, Orlando, FL",
        "Department of Otolaryngology – Head & Neck Surgery, Johns Hopkins Hospital, Baltimore, MD, USA",
        "Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran",
        "Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran",
        "Rutgers New Jersey Medical School, Newark, NJ, USA",
        "Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155576/Independent%20predictors%20of%20recurrence(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155576/Independent%20predictors%20of%20recurrence(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155576"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Keywords"
      ],
      "sections": {
        "Authors": "Ebrahim Farashi, MD 1 ; Tolani F Olonisakin 2 ; Armin Namvar, MD 3 ; Parastou Gorovanchi, MD 4 ; Shrey Shah, MS 5 ; Parnaz Jafari 3 ; Samad Farashi Bonab 6 ; Joseph Lopez, MD, MBA 1 ; Seyed Ziaeddin Rasihashemi, MD 3",
        "Affiliations": "1 Division of Pediatric Head & Neck Surgery, Department of Children’s Surgery, AdventHealth for Children, Orlando, FL; 2 Department of Otolaryngology – Head & Neck Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; 3 Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran; 4 Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 5 Rutgers New Jersey Medical School, Newark, NJ, USA; 6 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran",
        "Background": "Disease recurrence after thyroidectomy in papillary thyroid carcinoma (PTC) remains a clinically relevant and difficult-to-predict outcome. Although several clinicopathologic factors have been associated with recurrence, real-world evidence assessing their independent prognostic value within comprehensive multivariable models is limited.",
        "Methods": "We conducted a retrospective cohort study of consecutive patients with histologically confirmed PTC who underwent total thyroidectomy between April 2015 and December 2023 at a tertiary referral center. Clinicopathologic variables were collected using a standardized data abstraction protocol and defined in accordance with the 2015 American Thyroid Association (ATA) management guidelines and the American Joint Committee on Cancer (AJCC) 8th edition staging system. Tumor size was dichotomized as ≤1 cm versus >1 cm based on ATA risk stratification criteria. To ensure model stability and avoid sparse data bias, TNM stage was collapsed into stage I versus stage II–III for regression analyses. The primary outcome was disease recurrence, defined according to ATA criteria as the presence of structural and/or biochemical recurrence and confirmed by histopathological examination following reoperative surgery. All statistical analyses were performed using R software. Univariable and multivariable logistic regression analyses were conducted to identify clinicopathologic predictors of recurrence. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis.",
        "Results": "Among 678 patients, 74 (10.9%) developed disease recurrence. On unadjusted comparisons, recurrence was significantly more frequent among males (29.7% vs 15.6%, p-value=0.005), tumors >1 cm (85.1% vs 72.3%, p-value=0.017), and patients with advanced TNM stage II–III (20.3% vs 4.5%, p<0.001). Perineural invasion (14.9% vs 2.0%, p<0.001) and extrathyroidal extension (12.2% vs 5.3%, p-value=0.024) were strongly associated with recurrence. Tumor laterality/location also demonstrated a significant association with recurrence (p-value=0.029), with higher recurrence rates observed in bilateral and lobe–isthmus tumors. Abnormal right vocal cord mobility was observed more frequently among patients with recurrence (4.1% vs 0.8%, p-value=0.011), whereas left-sided vocal cord abnormalities were rare. Distant metastasis at presentation was uncommon but occurred more frequently in patients who developed recurrence (4.2% vs 0.2%, p-value=0.004). In multivariable analysis, perineural invasion emerged as the strongest independent predictor of recurrence (adjusted OR 8.56, 95% CI 2.94–24.84), followed by advanced TNM stage II–III (adjusted OR 6.18, 95% CI 2.33–16.92) and male sex (adjusted OR 2.25, 95% CI 1.23–4.02). Follicular variant histology was independently associated with lower recurrence risk (adjusted OR 0.40, 95% CI 0.16–0.86). The final model demonstrated good discriminative performance (AUC = 0.74).",
        "Conclusions": "In this large ATA-defined cohort of patients undergoing total thyroidectomy for PTC, perineural invasion and advanced TNM stage were the dominant independent predictors of recurrence, while follicular variant histology was protective. Tumor laterality and preoperative vocal cord findings provided additional risk stratification signals. These results reinforce the central role of detailed pathologic assessment in postoperative risk stratification and support intensified surveillance strategies for patients with high-risk features.",
        "Keywords": "Papillary thyroid carcinoma; Disease recurrence; Perineural invasion; Prognostic factors"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Perineural Invasion and Histologic Subtype as Predictors of Recurrence in Papillary Thyroid Carcinoma: A Retrospective Cohort Study</span>. <u>Ebrahim Farashi, MD</u><sup>1</sup>; Tolani F Olonisakin<sup>2</sup>; Armin Namvar, MD<sup>3</sup>; Parastou Gorovanchi, MD<sup>4</sup>; Shrey Shah, MS<sup>5</sup>; Parnaz Jafari<sup>3</sup>; Samad Farashi Bonab<sup>6</sup>; Joseph Lopez, MD, MBA<sup>1</sup>; Seyed Ziaeddin Rasihashemi, MD<sup>3</sup>. <sup>1</sup>Division of Pediatric Head & Neck Surgery, Department of Children’s Surgery, AdventHealth for Children, Orlando, FL; <sup>2</sup>Department of Otolaryngology – Head & Neck Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; <sup>3</sup>Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran; <sup>4</sup>Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; <sup>5</sup>Rutgers New Jersey Medical School, Newark, NJ, USA; <sup>6</sup>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Disease recurrence after thyroidectomy in papillary thyroid carcinoma (PTC) remains a clinically relevant and difficult-to-predict outcome. Although several clinicopathologic factors have been associated with recurrence, real-world evidence assessing their independent prognostic value within comprehensive multivariable models is limited.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of consecutive patients with histologically confirmed PTC who underwent total thyroidectomy between April 2015 and December 2023 at a tertiary referral center. Clinicopathologic variables were collected using a standardized data abstraction protocol and defined in accordance with the 2015 American Thyroid Association (ATA) management guidelines and the American Joint Committee on Cancer (AJCC) 8th edition staging system. Tumor size was dichotomized as ≤1 cm versus >1 cm based on ATA risk stratification criteria. To ensure model stability and avoid sparse data bias, TNM stage was collapsed into stage I versus stage II–III for regression analyses. The primary outcome was disease recurrence, defined according to ATA criteria as the presence of structural and/or biochemical recurrence and confirmed by histopathological examination following reoperative surgery. All statistical analyses were performed using R software. Univariable and multivariable logistic regression analyses were conducted to identify clinicopathologic predictors of recurrence. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis.</p>\n\n<p><strong>Results: </strong>Among 678 patients, 74 (10.9%) developed disease recurrence. On unadjusted comparisons, recurrence was significantly more frequent among males (29.7% vs 15.6%, p-value=0.005), tumors >1 cm (85.1% vs 72.3%, p-value=0.017), and patients with advanced TNM stage II–III (20.3% vs 4.5%, p<0.001). Perineural invasion (14.9% vs 2.0%, p<0.001) and extrathyroidal extension (12.2% vs 5.3%, p-value=0.024) were strongly associated with recurrence. Tumor laterality/location also demonstrated a significant association with recurrence (p-value=0.029), with higher recurrence rates observed in bilateral and lobe–isthmus tumors. Abnormal right vocal cord mobility was observed more frequently among patients with recurrence (4.1% vs 0.8%, p-value=0.011), whereas left-sided vocal cord abnormalities were rare. Distant metastasis at presentation was uncommon but occurred more frequently in patients who developed recurrence (4.2% vs 0.2%, p-value=0.004). In multivariable analysis, perineural invasion emerged as the strongest independent predictor of recurrence (adjusted OR 8.56, 95% CI 2.94–24.84), followed by advanced TNM stage II–III (adjusted OR 6.18, 95% CI 2.33–16.92) and male sex (adjusted OR 2.25, 95% CI 1.23–4.02). Follicular variant histology was independently associated with lower recurrence risk (adjusted OR 0.40, 95% CI 0.16–0.86). The final model demonstrated good discriminative performance (AUC = 0.74).</p>\n\n<p><strong>Conclusions: </strong>In this large ATA-defined cohort of patients undergoing total thyroidectomy for PTC, perineural invasion and advanced TNM stage were the dominant independent predictors of recurrence, while follicular variant histology was protective. Tumor laterality and preoperative vocal cord findings provided additional risk stratification signals. These results reinforce the central role of detailed pathologic assessment in postoperative risk stratification and support intensified surveillance strategies for patients with high-risk features.</p>\n\n<p><strong>Keywords: </strong>Papillary thyroid carcinoma; Disease recurrence; Perineural invasion; Prognostic factors</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155576/Independent%20predictors%20of%20recurrence(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155576--></body></html>"
    },
    {
      "uid": "P101",
      "content_id": "151986",
      "abstract_number": "P101",
      "poster_number": "P101",
      "title": "Preoperative Idylla™ BRAF Testing in Thyroid Nodules: High Accuracy and Clinical Utility for Surgical Decision-Making",
      "summary": "The preoperative Idylla BRAF test is a highly accurate and specific tool for detecting the BRAF V600E mutation in thyroid nodules. A positive BRAF result is strongly predictive of Papillary Thyroid Carcinoma and is associated with multiple high-risk sonographic and pathological features, including lymphatic invasion and central neck metastasis. However, clinicians should be aware that false-negative results,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151986",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tseng-Cheng Chen, MD, PhD",
      "presenter": "Tseng-Cheng Chen, MD, PhD",
      "authors": "Tseng-Cheng Chen, MD, PhD 1 ; Min-Shu Hsieh, MD, PhD 2",
      "normalized_authors": [
        "Tseng-Cheng Chen",
        "Min-Shu Hsieh"
      ],
      "affiliations": [
        "National Taiwan University Hospital, Department of Otolaryngology, Head and Neck Surgery",
        "National Taiwan University Cancer Center, Department of Pathology"
      ],
      "normalized_institutions": [
        "National Taiwan University Hospital, Department of Otolaryngology, Head and Neck Surgery",
        "National Taiwan University Cancer Center, Department of Pathology"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Tseng-Cheng Chen, MD, PhD 1 ; Min-Shu Hsieh, MD, PhD 2",
        "Affiliations": "1 National Taiwan University Hospital, Department of Otolaryngology, Head and Neck Surgery; 2 National Taiwan University Cancer Center, Department of Pathology",
        "Background": "The BRAF V600E mutation is a key molecular marker in Papillary Thyroid Carcinoma (PTC) and is associated with more aggressive clinicopathological features. The Idylla™ BRAF Mutation Test is a fully automated real-time PCR system that provides rapid results. This study aims to evaluate the diagnostic performance of the preoperative Idylla BRAF test and to analyze the correlation between its results and sonographic and postoperative pathological features.",
        "Methods": "This study included 124 patients who underwent surgery for thyroid nodules or tumors. All patients received a preoperative ultrasound-guided fine-needle aspiration (FNA) to obtain specimens for the Idylla BRAF test. We collected and analyzed patient clinical data, preoperative thyroid ultrasound characteristics, and FNA cytology results (Bethesda system). The Idylla BRAF test results were then compared with the final postoperative histopathology reports.",
        "Results": "Of the 124 patients, 49 (39.5%) tested positive for the BRAF mutation (Idylla BRAF+), while 75 (60.5%) were negative (Idylla BRAF-). When compared with the final pathological results, the Idylla BRAF test demonstrated a sensitivity of 89.09%, a specificity of 100%, a positive predictive value (PPV) of 100%, a negative predictive value (NPV) of 92.00%, and an overall accuracy of 95.16%. An analysis of the discordant cases (false negatives on the Idylla test) revealed that factors significantly associated with discordance were tumor size <1cm (OR 34.027,",
        "Abstract": "p=0.009) and the presence of macrocalcification (OR 22.07, p=0.02). While rim calcification also showed a high odds ratio for discordance (OR 50.19), it did not reach statistical significance in this cohort (p=0.07). BRAF positivity was significantly associated with several clinicopathological features. BRAF+ patients were more likely to be younger (<50 years, p=0.01). On ultrasound, BRAF+ nodules were significantly more likely to be solid in architecture (p=0.02), hypoechoic (p<0.001), associated with microcalcifications (p<0.001), featuring irregular margins (p<0.001), and taller than wide in shape (p=0.003). Pathologically, BRAF+ status was strongly correlated with a diagnosis of Papillary Carcinoma (97.96% of cases, p<0.001), lymphatic invasion (p<0.001), multicentricity (p<0.001), and metastasis to central neck lymph nodes (Level VI node+, p<0.001). On multivariate analysis, the most significant independent predictors for a BRAF+ result were the presence of microcalcifications (OR 17.06,p<0.001), an irregular margin (OR 11.18, p=0.001), and a taller-than-wide shape (OR 8.36, p=0.04).",
        "Conclusion": "The preoperative Idylla BRAF test is a highly accurate and specific tool for detecting the BRAF V600E mutation in thyroid nodules. A positive BRAF result is strongly predictive of Papillary Thyroid Carcinoma and is associated with multiple high-risk sonographic and pathological features, including lymphatic invasion and central neck metastasis. However, clinicians should be aware that false-negative results, though infrequent, are significantly associated with smaller tumor size (<1cm) and the presence of macrocalcification. Integrating this rapid molecular test into the preoperative evaluation can assist in surgical planning, risk stratification, and patient counseling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Idylla™ BRAF Testing in Thyroid Nodules: High Accuracy and Clinical Utility for Surgical Decision-Making</span>. <u>Tseng-Cheng Chen, MD, PhD</u><sup>1</sup>; Min-Shu Hsieh, MD, PhD<sup>2</sup>. <sup>1</sup>National Taiwan University Hospital, Department of Otolaryngology, Head and Neck Surgery; <sup>2</sup>National Taiwan University Cancer Center, Department of Pathology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The BRAF V600E mutation is a key molecular marker in Papillary Thyroid Carcinoma (PTC) and is associated with more aggressive clinicopathological features. The Idylla™ BRAF Mutation Test is a fully automated real-time PCR system that provides rapid results. This study aims to evaluate the diagnostic performance of the preoperative Idylla BRAF test and to analyze the correlation between its results and sonographic and postoperative pathological features.</p>\n\n<p><strong>Methods: </strong>This study included 124 patients who underwent surgery for thyroid nodules or tumors. All patients received a preoperative ultrasound-guided fine-needle aspiration (FNA) to obtain specimens for the Idylla BRAF test. We collected and analyzed patient clinical data, preoperative thyroid ultrasound characteristics, and FNA cytology results (Bethesda system). The Idylla BRAF test results were then compared with the final postoperative histopathology reports.</p>\n\n<p><strong>Results: </strong>Of the 124 patients, 49 (39.5%) tested positive for the BRAF mutation (Idylla BRAF+), while 75 (60.5%) were negative (Idylla BRAF-). When compared with the final pathological results, the Idylla BRAF test demonstrated a sensitivity of 89.09%, a specificity of 100%, a positive predictive value (PPV) of 100%, a negative predictive value (NPV) of 92.00%, and an overall accuracy of 95.16%. An analysis of the discordant cases (false negatives on the Idylla test) revealed that factors significantly associated with discordance were tumor size <1cm (OR 34.027,</p>\n\n<p>p=0.009) and the presence of macrocalcification (OR 22.07, p=0.02). While rim calcification also showed a high odds ratio for discordance (OR 50.19), it did not reach statistical significance in this cohort (p=0.07). BRAF positivity was significantly associated with several clinicopathological features. BRAF+ patients were more likely to be younger (<50 years, p=0.01). On ultrasound, BRAF+ nodules were significantly more likely to be solid in architecture (p=0.02), hypoechoic (p<0.001), associated with microcalcifications (p<0.001), featuring irregular margins (p<0.001), and taller than wide in shape (p=0.003).</p>\n\n<p>Pathologically, BRAF+ status was strongly correlated with a diagnosis of Papillary Carcinoma (97.96% of cases, p<0.001), lymphatic invasion (p<0.001), multicentricity (p<0.001), and metastasis to central neck lymph nodes (Level VI node+, p<0.001). On multivariate analysis, the most significant independent predictors for a BRAF+ result were the presence of microcalcifications (OR 17.06,p<0.001), an irregular margin (OR 11.18, p=0.001), and a taller-than-wide shape (OR 8.36, p=0.04).</p>\n\n<p><strong>Conclusion: </strong>The preoperative Idylla BRAF test is a highly accurate and specific tool for detecting the BRAF V600E mutation in thyroid nodules. A positive BRAF result is strongly predictive of Papillary Thyroid Carcinoma and is associated with multiple high-risk sonographic and pathological features, including lymphatic invasion and central neck metastasis. However, clinicians should be aware that false-negative results, though infrequent, are significantly associated with smaller tumor size (<1cm) and the presence of macrocalcification. Integrating this rapid molecular test into the preoperative evaluation can assist in surgical planning, risk stratification, and patient counseling.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151986--></body></html>"
    },
    {
      "uid": "P103",
      "content_id": "153251",
      "abstract_number": "P103",
      "poster_number": "P103",
      "title": "NIFT-P: Binary Answers to a Simple Question",
      "summary": "The histopathological diagnosis of NIFT-P requires an extensive review of the entire specimen, with specific criteria applied to make a definitive diagnosis. It is generally considered to be a benign condition; however, its premalignant potential must be recognized. It appears that we do have a binary answer to this complex entity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153251",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin M Hintze, MD",
      "presenter": "Justin M Hintze, MD",
      "authors": "Justin M Hintze, MD ; Ashok R Shaha, MD",
      "normalized_authors": [
        "Justin M Hintze",
        "Ashok R Shaha"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 230,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Material and Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Justin M Hintze, MD ; Ashok R Shaha, MD",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Introduction": "NIFT-P was first described as an encapsulated tumor in 2016. Subsequently, there has been a considerable rise in its detection. There continues to be considerable debate as to whether it is a benign or malignant lesion. It is fairly common that patients and their families seek a binary answer: benign or malignant.",
        "Material and Methods": "In an effort to get a binary answer to this complex subject, we queried 20 experts in the field of thyroid cancer with direct questions about the binary nature of NIFT-P.",
        "Results": "Of the 20 experts queried, every one of them responded within 48 hours. 80% responded within a few hours of the email. Sixteen experts classified NIFT-P as benign, while two responded as malignant. Two other experts had no clear-cut answer. We have collected all the responses in individual emails. The descriptive responses are quite interesting. Despite eight years since its description, there continues to be some confusion both in diagnosis and reporting to the patient in binary fashion. However, the majority of respondents considered it to be a benign pathology. Will discuss the vagaries to NIFT-P.",
        "Conclusion": "The histopathological diagnosis of NIFT-P requires an extensive review of the entire specimen, with specific criteria applied to make a definitive diagnosis. It is generally considered to be a benign condition; however, its premalignant potential must be recognized. It appears that we do have a binary answer to this complex entity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>NIFT-P: Binary Answers to a Simple Question</span>. <u>Justin M Hintze, MD</u>; Ashok R Shaha, MD. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>NIFT-P was first described as an encapsulated tumor in 2016. Subsequently, there has been a considerable rise in its detection. There continues to be considerable debate as to whether it is a benign or malignant lesion. It is fairly common that patients and their families seek a binary answer: benign or malignant. </p>\n\n<p><strong>Material and Methods: </strong>In an effort to get a binary answer to this complex subject, we queried 20 experts in the field of thyroid cancer with direct questions about the binary nature of NIFT-P. </p>\n\n<p><strong>Results: </strong>Of the 20 experts queried, every one of them responded within 48 hours. 80% responded within a few hours of the email. Sixteen experts classified NIFT-P as benign, while two responded as malignant. Two other experts had no clear-cut answer. We have collected all the responses in individual emails. The descriptive responses are quite interesting. Despite eight years since its description, there continues to be some confusion both in diagnosis and reporting to the patient in binary fashion. However, the majority of respondents considered it to be a benign pathology. Will discuss the vagaries to NIFT-P. </p>\n\n<p><strong>Conclusion: </strong>The histopathological diagnosis of NIFT-P requires an extensive review of the entire specimen, with specific criteria applied to make a definitive diagnosis. It is generally considered to be a benign condition; however, its premalignant potential must be recognized. It appears that we do have a binary answer to this complex entity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153251--></body></html>"
    },
    {
      "uid": "P104",
      "content_id": "154539",
      "abstract_number": "P104",
      "poster_number": "P104",
      "title": "Patient Age Does Not Predict Time to Undergo Thyroidectomy for Thyroid Cancer",
      "summary": "In this large retrospective cohort, patient age was not associated with longer time to thyroidectomy, even after adjusting for demographic and clinical factors. These findings suggest that surgical wait times were consistent across age groups within this health system indicating no age disparities. Further research is needed to confirm whether similar patterns are observed in other institutions and in specific...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154539",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sara D O'Sullivan-Bakshi, BS",
      "presenter": "Sara D O'Sullivan-Bakshi, BS",
      "authors": "Sara D O'Sullivan-Bakshi, BS 1 ; Henry Diamond-Pott, BA 2 ; Mathilda Monaghan, MPH 2 ; Maaike van Gerwen, MD, PhD 2",
      "normalized_authors": [
        "Sara D O'Sullivan-Bakshi",
        "Henry Diamond-Pott",
        "Mathilda Monaghan",
        "Maaike van Gerwen"
      ],
      "affiliations": [
        "Renaissance School of Medicine at Stony Brook",
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Renaissance School of Medicine at Stony Brook",
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 331,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sara D O'Sullivan-Bakshi, BS 1 ; Henry Diamond-Pott, BA 2 ; Mathilda Monaghan, MPH 2 ; Maaike van Gerwen, MD, PhD 2",
        "Affiliations": "1 Renaissance School of Medicine at Stony Brook; 2 Icahn School of Medicine at Mount Sinai",
        "Background": "Timeliness from diagnosis to surgery is an important component of care delivery in thyroid disease, yet it is unclear whether wait times for thyroidectomy differ by age. As the thyroid cancer population increasingly includes both younger and older adults, understanding whether age is associated with delays between diagnosis and surgery may help identify disparities in surgical timing. This study evaluated whether time from diagnosis to thyroidectomy differed across age groups within a large retrospective cohort.",
        "Methods": "We conducted a retrospective review of all adult patients diagnosed with primary thyroid cancer between 2018 and 2021 at a tertiary academic medical center (n= 922). Time-to-surgery was calculated as the number of days between diagnosis and thyroid surgery. Patients were grouped into age categories: <39, 40–64, and ≥65 years. Multivariable linear regression assessed the association between age and time to surgery, adjusting for demographic and clinical covariates. Subgroup analyses compared age groups using <39 years as the reference.",
        "Results": "Older adults (>65 years) had a higher comorbidity burden (p=0.002) and were predominantly insured through Medicare (p=0.003). BMI increased with age (p=0.01), and race distribution differed across groups (p=0.04). Despite these differences, time to thyroidectomy was consistent across age groups; 70.0 days (<39), 71.8 days (40–64), and 70.8 days (≥65) (p=0.88).",
        "Abstract": "In multivariable regression, age at diagnosis was not associated with time to surgery (beta: 0.11; 95% CI –0.66 to 0.43). Subgroup analyses also showed no significant differences for the 40–64 (p=0.997) or ≥65 groups (p=0.463) compared with patients under 39.",
        "Conclusions": "In this large retrospective cohort, patient age was not associated with longer time to thyroidectomy, even after adjusting for demographic and clinical factors. These findings suggest that surgical wait times were consistent across age groups within this health system indicating no age disparities. Further research is needed to confirm whether similar patterns are observed in other institutions and in specific thyroid disease subtypes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient Age Does Not Predict Time to Undergo Thyroidectomy for Thyroid Cancer</span>. <u>Sara D O'Sullivan-Bakshi, BS</u><sup>1</sup>; Henry Diamond-Pott, BA<sup>2</sup>; Mathilda Monaghan, MPH<sup>2</sup>; Maaike van Gerwen, MD, PhD<sup>2</sup>. <sup>1</sup>Renaissance School of Medicine at Stony Brook; <sup>2</sup>Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Timeliness from diagnosis to surgery is an important component of care delivery in thyroid disease, yet it is unclear whether wait times for thyroidectomy differ by age. As the thyroid cancer population increasingly includes both younger and older adults, understanding whether age is associated with delays between diagnosis and surgery may help identify disparities in surgical timing. This study evaluated whether time from diagnosis to thyroidectomy differed across age groups within a large retrospective cohort. </p>\n\n<p><strong>Methods: </strong>We conducted a retrospective review of all adult patients diagnosed with primary thyroid cancer between 2018 and 2021 at a tertiary academic medical center (n= 922). Time-to-surgery was calculated as the number of days between diagnosis and thyroid surgery. Patients were grouped into age categories: <39, 40–64, and ≥65 years. Multivariable linear regression assessed the association between age and time to surgery, adjusting for demographic and clinical covariates. Subgroup analyses compared age groups using <39 years as the reference. </p>\n\n<p><strong>Results: </strong>Older adults (>65 years) had a higher comorbidity burden (p=0.002) and were predominantly insured through Medicare (p=0.003). BMI increased with age (p=0.01), and race distribution differed across groups (p=0.04). Despite these differences, time to thyroidectomy was consistent across age groups; 70.0 days (<39), 71.8 days (40–64), and 70.8 days (≥65) (p=0.88). </p>\n\n<p>In multivariable regression, age at diagnosis was not associated with time to surgery (beta: 0.11; 95% CI –0.66 to 0.43). Subgroup analyses also showed no significant differences for the 40–64 (p=0.997) or ≥65 groups (p=0.463) compared with patients under 39. </p>\n\n<p><strong>Conclusions: </strong>In this large retrospective cohort, patient age was not associated with longer time to thyroidectomy, even after adjusting for demographic and clinical factors. These findings suggest that surgical wait times were consistent across age groups within this health system indicating no age disparities. Further research is needed to confirm whether similar patterns are observed in other institutions and in specific thyroid disease subtypes.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154539--></body></html>"
    },
    {
      "uid": "P105",
      "content_id": "154167",
      "abstract_number": "P105",
      "poster_number": "P105",
      "title": "Anaplastic Thyroid Carcinoma Masquerading as Tuberculous Cervical Lymphadenitis: A Case Report",
      "summary": "Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy that may present with clinical features resembling infectious or inflammatory neck disease, particularly in regions where tuberculosis remains prevalent. We describe the case of a 55-year-old woman who presented with a progressive cervical swelling associated with purulent discharge and fistulization, initially presumed to represent...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154167",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fatima Syed Amanullah, Dr",
      "presenter": "Fatima Syed Amanullah, Dr",
      "authors": "Muhammad Shahzaib Arshad, Dr 1 ; Zeeshan Khalid, Dr 2 ; Haseeb Safdar Ali, Dr 2 ; Hamdan Pasha, MD 1 ; Fatima Syed Amanullah, Dr 3",
      "normalized_authors": [
        "Muhammad Shahzaib Arshad, Dr",
        "Zeeshan Khalid, Dr",
        "Haseeb Safdar Ali, Dr",
        "Hamdan Pasha",
        "Fatima Syed Amanullah, Dr"
      ],
      "affiliations": [
        "Aga Khan University",
        "Nishtar Medical University & Hospital",
        "University of Massachusetts"
      ],
      "normalized_institutions": [
        "Aga Khan University",
        "Nishtar Medical University & Hospital",
        "University of Massachusetts"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 179,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Muhammad Shahzaib Arshad, Dr 1 ; Zeeshan Khalid, Dr 2 ; Haseeb Safdar Ali, Dr 2 ; Hamdan Pasha, MD 1 ; Fatima Syed Amanullah, Dr 3",
        "Affiliations": "1 Aga Khan University; 2 Nishtar Medical University & Hospital; 3 University of Massachusetts",
        "Abstract": "Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy that may present with clinical features resembling infectious or inflammatory neck disease, particularly in regions where tuberculosis remains prevalent. We describe the case of a 55-year-old woman who presented with a progressive cervical swelling associated with purulent discharge and fistulization, initially presumed to represent tuberculous lymphadenitis based on clinical appearance, inflammatory markers, and epidemiologic context. Despite empirical therapy, no improvement occurred, and subsequent imaging revealed a necrotic soft-tissue lesion arising from the left thyroid lobe with widespread lymphadenopathy. Fine-needle aspiration cytology and biopsy ultimately confirmed the diagnosis of ATC. This presentation illustrates how tuberculosis can be favored diagnostically in high-burden settings, leading to delayed recognition of underlying malignancy. To the best of our knowledge, this represents the first reported case from Pakistan and only the second case described in the literature of ATC masquerading as cervical tuberculosis. The report underscores the importance of maintaining a broad differential diagnosis for persistent necrotic cervical lesions and highlights the need for early and repeated cytological evaluation before initiating prolonged antimicrobial therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Anaplastic Thyroid Carcinoma Masquerading as Tuberculous Cervical Lymphadenitis: A Case  Report</span>. Muhammad Shahzaib Arshad, Dr<sup>1</sup>; Zeeshan Khalid, Dr<sup>2</sup>; Haseeb Safdar Ali, Dr<sup>2</sup>; Hamdan Pasha, MD<sup>1</sup>; <u>Fatima Syed Amanullah, Dr</u><sup>3</sup>. <sup>1</sup>Aga Khan University; <sup>2</sup>Nishtar Medical University & Hospital; <sup>3</sup>University of Massachusetts<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy that may present with clinical features resembling infectious or inflammatory neck disease, particularly in regions where tuberculosis remains prevalent. We describe the case of a 55-year-old woman who presented with a progressive cervical swelling associated with purulent discharge and fistulization, initially presumed to represent tuberculous lymphadenitis based on clinical appearance, inflammatory markers, and epidemiologic context. Despite empirical therapy, no improvement occurred, and subsequent imaging revealed a necrotic soft-tissue lesion arising from the left thyroid lobe with widespread lymphadenopathy. Fine-needle aspiration cytology and biopsy ultimately confirmed the diagnosis of ATC. This presentation illustrates how tuberculosis can be favored diagnostically in high-burden settings, leading to delayed recognition of underlying malignancy. To the best of our knowledge, this represents the first reported case from Pakistan and only the second case described in the literature of ATC masquerading as cervical tuberculosis. The report underscores the importance of maintaining a broad differential diagnosis for persistent necrotic cervical lesions and highlights the need for early and repeated cytological evaluation before initiating prolonged antimicrobial therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154167--></body></html>"
    },
    {
      "uid": "P106",
      "content_id": "154314",
      "abstract_number": "P106",
      "poster_number": "P106",
      "title": "Preoperative Molecular Testing Predicts Greater Postoperative Social Support in Patients With Bethesda V and VI Thyroid Nodules",
      "summary": "Preoperative molecular testing is associated with greater perceived postoperative social support, including higher support from physicians, friends, and family. These novel results suggest that MT may reduce diagnostic uncertainty, allowing patients and their networks to better understand and respond, thereby strengthening supportive relationships throughout the postoperative trajectory. Integrating MT into the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154314",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jesse Frija-Gruman, DCS",
      "presenter": "Jesse Frija-Gruman, DCS",
      "authors": "Jesse Frija-Gruman, DCS ; Kayla E Payne, DCS; Raisa Chowdhury, MSc; Veronique-Isabelle Forest, MD; Sabrina Wurzba, DDS, MSc, PhD; Ji Wei Yang, MD, CM, FRCPC; Richard J Payne, MD, MSc, FRCSC",
      "normalized_authors": [
        "Jesse Frija-Gruman, DCS",
        "Kayla E Payne, DCS",
        "Raisa Chowdhury",
        "Veronique-Isabelle Forest",
        "Sabrina Wurzba",
        "Ji Wei Yang, CM, FRCPC",
        "Richard J Payne, FRCSC"
      ],
      "affiliations": [
        "McGill University"
      ],
      "normalized_institutions": [
        "McGill University"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 324,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jesse Frija-Gruman, DCS ; Kayla E Payne, DCS; Raisa Chowdhury, MSc; Veronique-Isabelle Forest, MD; Sabrina Wurzba, DDS, MSc, PhD; Ji Wei Yang, MD, CM, FRCPC; Richard J Payne, MD, MSc, FRCSC",
        "Affiliations": "McGill University",
        "Introduction": "Despite the expanding use of molecular testing (MT) in the evaluation of indeterminate and malignant thyroid nodules, its impact on social support postoperatively remains understudied. Because diagnostic uncertainty can heighten anxiety, impair communication, and strain patient support systems, MT may influence how patients experience social support after surgery. This study evaluates whether MT is associated with differences in postoperative social support among patients with Bethesda V and VI thyroid nodules.",
        "Methods": "A cross-sectional study was conducted at a McGill University-affiliated hospital from June-August 2025. Adults with Bethesda V/VI nodules who underwent total or hemi-thyroidectomy between July 2022-July 2024 completed a phone survey 12-36 months after surgery. The primary outcome was perceived social support, measured using the EORTC QLQ-THY34 instrument (0-100 scale). Patients who received MT were compared with those who did not using t-tests, effect sizes, and multivariable regression controlling for various clinical factors.",
        "Results": "Patients who underwent MT reported significantly greater overall postoperative social support (p = 0.013), an association that remained significant after adjustment (β = 11.37, p = 0.041). Perceived support from physicians was higher in MT patients (95% CI –2.01 to 26.4, p = 0.046). Perceived support from healthcare professionals was higher in MT patients, though not statistically significant (95% CI –8.42 to 29.8, p = 0.134). Perceived support from friends and family was significantly higher in MT recipients (95% CI 2.33 to 30.8, p = 0.012). Final benign pathology was strongly associated with lower social support (β = –39.73, p = 0.0004).",
        "Conclusions": "Preoperative molecular testing is associated with greater perceived postoperative social support, including higher support from physicians, friends, and family. These novel results suggest that MT may reduce diagnostic uncertainty, allowing patients and their networks to better understand and respond, thereby strengthening supportive relationships throughout the postoperative trajectory. Integrating MT into the preoperative assessment of Bethesda V and VI thyroid cancer patients may therefore improve psychosocial outcomes in addition to informing clinical management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Molecular Testing Predicts Greater Postoperative Social Support in Patients With Bethesda V and VI Thyroid Nodules</span>. <u>Jesse Frija-Gruman, DCS</u>; Kayla E Payne, DCS; Raisa Chowdhury, MSc; Veronique-Isabelle Forest, MD; Sabrina Wurzba, DDS, MSc, PhD; Ji Wei Yang, MD, CM, FRCPC; Richard J Payne, MD, MSc, FRCSC. McGill University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Despite the expanding use of molecular testing (MT) in the evaluation of indeterminate and malignant thyroid nodules, its impact on social support postoperatively remains understudied. Because diagnostic uncertainty can heighten anxiety, impair communication, and strain patient support systems, MT may influence how patients experience social support after surgery. This study evaluates whether MT is associated with differences in postoperative social support among patients with Bethesda V and VI thyroid nodules.</p>\n\n<p><strong>Methods</strong>: A cross-sectional study was conducted at a McGill University-affiliated hospital from June-August 2025. Adults with Bethesda V/VI nodules who underwent total or hemi-thyroidectomy between July 2022-July 2024 completed a phone survey 12-36 months after surgery. The primary outcome was perceived social support, measured using the EORTC QLQ-THY34 instrument (0-100 scale). Patients who received MT were compared with those who did not using t-tests, effect sizes, and multivariable regression controlling for various clinical factors.</p>\n\n<p><strong>Results</strong>: Patients who underwent MT reported significantly greater overall postoperative social support (p = 0.013), an association that remained significant after adjustment (β = 11.37, p = 0.041). Perceived support from physicians was higher in MT patients (95% CI –2.01 to 26.4, p = 0.046). Perceived support from healthcare professionals was higher in MT patients, though not statistically significant (95% CI –8.42 to 29.8, p = 0.134). Perceived support from friends and family was significantly higher in MT recipients (95% CI 2.33 to 30.8, p = 0.012). Final benign pathology was strongly associated with lower social support (β = –39.73, p = 0.0004).</p>\n\n<p><strong>Conclusions</strong>: Preoperative molecular testing is associated with greater perceived postoperative social support, including higher support from physicians, friends, and family. These novel results suggest that MT may reduce diagnostic uncertainty, allowing patients and their networks to better understand and respond, thereby strengthening supportive relationships throughout the postoperative trajectory. Integrating MT into the preoperative assessment of Bethesda V and VI thyroid cancer patients may therefore improve psychosocial outcomes in addition to informing clinical management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154314--></body></html>"
    },
    {
      "uid": "P107",
      "content_id": "151826",
      "abstract_number": "P107",
      "poster_number": "P107",
      "title": "Shaving vs. Resection on Recurrent Laryngeal Nerve in Thyroid Cancer Surgeries: A Systematic Review and Meta-Analysis",
      "summary": "This systematic review favors the shaving technique over resection of the RLN in terms of functional outcomes and recurrence rates, without compromising overall survival. However, the current evidence is based entirely on retrospective chart reviews, highlighting the need for future prospective, randomized studies to validate these findings.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151826",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eric Tran, BS",
      "presenter": "Eric Tran, BS",
      "authors": "Eric Tran, BS ; Jordan Kankam, BS; Liana Salehian, BS; Harry May, BS; Daniel Stuart, PhD; Yusuf Dundar, MD",
      "normalized_authors": [
        "Eric Tran",
        "Jordan Kankam",
        "Liana Salehian",
        "Harry May",
        "Daniel Stuart",
        "Yusuf Dundar"
      ],
      "affiliations": [
        "Texas Tech University Health Sciences Center"
      ],
      "normalized_institutions": [
        "Texas Tech University Health Sciences Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 292,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eric Tran, BS ; Jordan Kankam, BS; Liana Salehian, BS; Harry May, BS; Daniel Stuart, PhD; Yusuf Dundar, MD",
        "Affiliations": "Texas Tech University Health Sciences Center",
        "Background": "The management of recurrent laryngeal nerve (RLN) invasion by thyroid malignancies remains controversial. Two primary surgical approaches have been employed: sacrificing the RLN or attempting to shave the tumor off the nerve while preserving its function. The objective of this systematic review is to analyze the oncological and/or functional outcomes of shaving versus resection techniques.",
        "Methods": "Three reviewers independently analyzed all retrieved studies in accordance with Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRIMSA) guidelines and predefined inclusion and exclusion criteria, covering the period from 1995 to 2024. PubMed, Embase, Medline, Central, and Google Scholar databases were systematically searched using keywords relevant to shaving, resection, recurrent laryngeal nerve, and thyroid cancer. The main outcomes explored were overall survival rate, disease free survival, progression free survival, recurrence rate, preservation of vocal cord function, tracheotomy requirement and other treatment related morbidities if provided.",
        "Results": "Of eighty studies, thirteen met the inclusion criteria for systematic review, with a total of 650 patients to analyze. Data were available for comparison across five categories: overall survival, recurrence rate, preservation of vocal cord mobility, tracheotomy requirement, and maximum phonation time. While overall survival and tracheotomy requirement did not significantly differ between shaving and resection, shaving technique demonstrated advantages in terms of recurrence rate (p=0.007) and preservation of vocal fold mobility (p<0.0001). Also, maximum phonation times were compared to evaluate post-surgery laryngeal function, and the Forest plot revealed a favorable outcome for the shaving technique (p=0.04).",
        "Conclusion": "This systematic review favors the shaving technique over resection of the RLN in terms of functional outcomes and recurrence rates, without compromising overall survival. However, the current evidence is based entirely on retrospective chart reviews, highlighting the need for future prospective, randomized studies to validate these findings."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Shaving vs. Resection on Recurrent Laryngeal Nerve in Thyroid Cancer Surgeries: A Systematic Review and Meta-Analysis</span>. <u>Eric Tran, BS</u>; Jordan Kankam, BS; Liana Salehian, BS; Harry May, BS; Daniel Stuart, PhD; Yusuf Dundar, MD. Texas Tech University Health Sciences Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The management of recurrent laryngeal nerve (RLN) invasion by thyroid malignancies remains controversial. Two primary surgical approaches have been employed: sacrificing the RLN or attempting to shave the tumor off the nerve while preserving its function. The objective of this systematic review is to analyze the oncological and/or functional outcomes of shaving versus resection techniques.</p>\n\n<p><strong>Methods:</strong> Three reviewers independently analyzed all retrieved studies in accordance with Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRIMSA) guidelines and predefined inclusion and exclusion criteria, covering the period from 1995 to 2024. PubMed, Embase, Medline, Central, and Google Scholar databases were systematically searched using keywords relevant to shaving, resection, recurrent laryngeal nerve, and thyroid cancer. The main outcomes explored were overall survival rate, disease free survival, progression free survival, recurrence rate, preservation of vocal cord function, tracheotomy requirement and other treatment related morbidities if provided.</p>\n\n<p><strong>Results:</strong> Of eighty studies, thirteen met the inclusion criteria for systematic review, with a total of 650 patients to analyze. Data were available for comparison across five categories: overall survival, recurrence rate, preservation of vocal cord mobility, tracheotomy requirement, and maximum phonation time. While overall survival and tracheotomy requirement did not significantly differ between shaving and resection, shaving technique demonstrated advantages in terms of recurrence rate (p=0.007) and preservation of vocal fold mobility (p<0.0001). Also, maximum phonation times were compared to evaluate post-surgery laryngeal function, and the Forest plot revealed a favorable outcome for the shaving technique (p=0.04).</p>\n\n<p><strong>Conclusion:</strong> This systematic review favors the shaving technique over resection of the RLN in terms of functional outcomes and recurrence rates, without compromising overall survival. However, the current evidence is based entirely on retrospective chart reviews, highlighting the need for future prospective, randomized studies to validate these findings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151826--></body></html>"
    },
    {
      "uid": "P108",
      "content_id": "153920",
      "abstract_number": "P108",
      "poster_number": "P108",
      "title": "Unpredictable Metastatic Patterns in Thyroglossal Duct Cyst Carcinoma: A Seven-Year Experience Challenging Classical Lymphatic Drainage Concepts",
      "summary": "These observations emphasize the biological heterogeneity of thyroglossal duct cyst carcinoma and support individualized surgical decision-making. Future prospective studies with standardized protocols are necessary to define optimal lymph-node dissection strategies and establish evidence-based management guidelines for this rare malignancy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153920",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiz Kowalski, PhD",
      "presenter": "Luiz Kowalski, PhD",
      "authors": "Luana De Araujo Bittencourt, MD; Lucas Siqueira Campos Marinho, MD; Bruna Hanauer, MD; Felipe Augusto Brasileiro Vanderlei, PhD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara Souza, MD; Luiz Kowalski, PhD ; Hudson Sodré, PhD; Claudio Cernea, PhD",
      "normalized_authors": [
        "Luana De Araujo Bittencourt",
        "Lucas Siqueira Campos Marinho",
        "Bruna Hanauer",
        "Felipe Augusto Brasileiro Vanderlei",
        "Matheus Buissa",
        "Daysi Sanguano",
        "Dhara Souza",
        "Luiz Kowalski",
        "Hudson Sodré",
        "Claudio Cernea"
      ],
      "affiliations": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 478,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Discussion",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Luana De Araujo Bittencourt, MD; Lucas Siqueira Campos Marinho, MD; Bruna Hanauer, MD; Felipe Augusto Brasileiro Vanderlei, PhD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara Souza, MD; Luiz Kowalski, PhD ; Hudson Sodré, PhD; Claudio Cernea, PhD",
        "Affiliations": "Faculdade de Medicina da Universidade de São Paulo",
        "Background": "Thyroglossal duct cyst carcinoma represents an uncommon malignancy, with papillary thyroid carcinoma accounting for the majority of cases. Although the Sistrunk procedure achieves excellent cure rates, uncertainty persists regarding cervical lymph-node management and the extent of surgical dissection required. Limited contemporary data exist describing metastatic patterns, particularly concerning lateral compartment involvement.",
        "Objectives": "This study aimed to characterize clinical presentation, pathological features, treatment approaches, and metastatic distribution patterns in patients with thyroglossal duct cyst carcinoma treated at a specialized head and neck surgery center.",
        "Methods": "This retrospective analysis included nine patients with histopathologically confirmed papillary carcinoma arising in thyroglossal duct cysts treated between 2018 and 2025 at a quaternary referral hospital in Brazil. Demographic data, histological subtypes, presence of lymphovascular and perineural invasion, patterns of locoregional extension, and cervical metastatic distribution were systematically collected from medical records. Metastases were categorized as either pericystic (typically level I) or involving other cervical compartments (levels II through VI). All patients underwent Sistrunk procedure and total thyroidectomy, though not necessarily during the same surgical session. Six patients received cervical lymph-node dissection with varying extent, ranging from super-selective (levels I-III) to modified radical procedures, including two bilateral dissections. Descriptive analysis focused primarily on metastatic occurrence and distribution, secondarily evaluating appropriate dissection strategies for this patient population.",
        "Results": "The median age was 44 years with slight female predominance (56%). Classic papillary carcinoma histology predominated (44%), while one-third displayed aggressive variant combinations including tall cell, hobnail, and columnar patterns. Synchronous papillary thyroid carcinoma occurred in 55.6% of cases, while others demonstrated benign thyroid pathology. Angiolymphatic invasion appeared in 22.2% of patients; perineural invasion was absent. Locoregional invasion affected 66.6% of cases, involving muscle, connective tissue, hyoid periosteum, or adipose tissue. Cervical metastases developed in 44.4% of patients, exceeding the frequency of pericystic metastases (33.3%). Importantly, lateral compartment involvement (levels II-VI) occurred more frequently than level I disease, with one patient developing bilateral nodal metastases. Radioiodine therapy was administered in 66.7% of cases.",
        "Discussion": "These findings reveal higher rates of aggressive histological variants, locoregional invasion, and cervical metastases than traditionally reported. The metastatic pattern demonstrated unpredictable lymphatic drainage, with lateral neck involvement exceeding pericystic spread, particularly in patients with synchronous thyroid carcinoma. This distribution challenges classical descriptions suggesting sequential spread from level I to lateral compartments, instead resembling intrathyroidal papillary carcinoma behavior. The variability in dissection strategies performed reflects current uncertainty regarding optimal surgical extent. Comprehensive preoperative cervical evaluation with ultrasound and cross-sectional imaging appears essential for appropriate surgical planning. In patients presenting aggressive histological features, extensive invasion, or suspicious lateral nodes, more comprehensive dissection may be warranted rather than limiting surgery to central compartment removal.",
        "Conclusions": "These observations emphasize the biological heterogeneity of thyroglossal duct cyst carcinoma and support individualized surgical decision-making. Future prospective studies with standardized protocols are necessary to define optimal lymph-node dissection strategies and establish evidence-based management guidelines for this rare malignancy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Unpredictable Metastatic Patterns in Thyroglossal Duct Cyst Carcinoma: A Seven-Year Experience Challenging Classical Lymphatic Drainage Concepts</span>. Luana De Araujo Bittencourt, MD; Lucas Siqueira Campos Marinho, MD; Bruna Hanauer, MD; Felipe Augusto Brasileiro Vanderlei, PhD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara Souza, MD; <u>Luiz Kowalski, PhD</u>; Hudson Sodré, PhD; Claudio Cernea, PhD. Faculdade de Medicina da Universidade de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Thyroglossal duct cyst carcinoma represents an uncommon malignancy, with papillary thyroid carcinoma accounting for the majority of cases. Although the Sistrunk procedure achieves excellent cure rates, uncertainty persists regarding cervical lymph-node management and the extent of surgical dissection required. Limited contemporary data exist describing metastatic patterns, particularly concerning lateral compartment involvement.</p>\n\n<p><strong>Objectives:</strong> This study aimed to characterize clinical presentation, pathological features, treatment approaches, and metastatic distribution patterns in patients with thyroglossal duct cyst carcinoma treated at a specialized head and neck surgery center.</p>\n\n<p><strong>Methods:</strong> This retrospective analysis included nine patients with histopathologically confirmed papillary carcinoma arising in thyroglossal duct cysts treated between 2018 and 2025 at a quaternary referral hospital in Brazil. Demographic data, histological subtypes, presence of lymphovascular and perineural invasion, patterns of locoregional extension, and cervical metastatic distribution were systematically collected from medical records. Metastases were categorized as either pericystic (typically level I) or involving other cervical compartments (levels II through VI). All patients underwent Sistrunk procedure and total thyroidectomy, though not necessarily during the same surgical session. Six patients received cervical lymph-node dissection with varying extent, ranging from super-selective (levels I-III) to modified radical procedures, including two bilateral dissections. Descriptive analysis focused primarily on metastatic occurrence and distribution, secondarily evaluating appropriate dissection strategies for this patient population.</p>\n\n<p><strong>Results:</strong> The median age was 44 years with slight female predominance (56%). Classic papillary carcinoma histology predominated (44%), while one-third displayed aggressive variant combinations including tall cell, hobnail, and columnar patterns. Synchronous papillary thyroid carcinoma occurred in 55.6% of cases, while others demonstrated benign thyroid pathology. Angiolymphatic invasion appeared in 22.2% of patients; perineural invasion was absent. Locoregional invasion affected 66.6% of cases, involving muscle, connective tissue, hyoid periosteum, or adipose tissue. Cervical metastases developed in 44.4% of patients, exceeding the frequency of pericystic metastases (33.3%). Importantly, lateral compartment involvement (levels II-VI) occurred more frequently than level I disease, with one patient developing bilateral nodal metastases. Radioiodine therapy was administered in 66.7% of cases.</p>\n\n<p><strong>Discussion:</strong> These findings reveal higher rates of aggressive histological variants, locoregional invasion, and cervical metastases than traditionally reported. The metastatic pattern demonstrated unpredictable lymphatic drainage, with lateral neck involvement exceeding pericystic spread, particularly in patients with synchronous thyroid carcinoma. This distribution challenges classical descriptions suggesting sequential spread from level I to lateral compartments, instead resembling intrathyroidal papillary carcinoma behavior. The variability in dissection strategies performed reflects current uncertainty regarding optimal surgical extent. Comprehensive preoperative cervical evaluation with ultrasound and cross-sectional imaging appears essential for appropriate surgical planning. In patients presenting aggressive histological features, extensive invasion, or suspicious lateral nodes, more comprehensive dissection may be warranted rather than limiting surgery to central compartment removal.</p>\n\n<p><strong>Conclusions:</strong> These observations emphasize the biological heterogeneity of thyroglossal duct cyst carcinoma and support individualized surgical decision-making. Future prospective studies with standardized protocols are necessary to define optimal lymph-node dissection strategies and establish evidence-based management guidelines for this rare malignancy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153920--></body></html>"
    },
    {
      "uid": "P109",
      "content_id": "153916",
      "abstract_number": "P109",
      "poster_number": "P109",
      "title": "Bilateral Calcified Cervical Lymphadenopathy as a Diagnostic Pitfall: When Endemic Paracoccidioidomycosis Masquerades as Metastatic Thyroid Carcinoma",
      "summary": "We report a case demonstrating the diagnostic pitfalls when endemic fungal infection presents with bilateral calcified cervical lymphadenopathy in a patient with concomitant thyroid enlargement, emphasizing the limitations of preoperative cytologic evaluation in differentiating benign granulomatous disease from malignancy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153916",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiz Kowalski, Phd",
      "presenter": "Luiz Kowalski, Phd",
      "authors": "Lucas Marinho, MD; Luana Bittencourt, MD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara de Souza, MD; Bruna Hanauer, MD; Hudson Sodré, MD; Renata Mahmoud, MD; Luiz Kowalski, Phd",
      "normalized_authors": [
        "Lucas Marinho",
        "Luana Bittencourt",
        "Matheus Buissa",
        "Daysi Sanguano",
        "Dhara de Souza",
        "Bruna Hanauer",
        "Hudson Sodré",
        "Renata Mahmoud",
        "Luiz Kowalski"
      ],
      "affiliations": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172107(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172107(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153916"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172325(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172325(2).jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153916"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%2004-12-2025.PNG",
          "source_url": "https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%2004-12-2025.PNG",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153916"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Case Presentation",
        "Abstract",
        "Conclusions and Recommendations"
      ],
      "sections": {
        "Authors": "Lucas Marinho, MD; Luana Bittencourt, MD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara de Souza, MD; Bruna Hanauer, MD; Hudson Sodré, MD; Renata Mahmoud, MD; Luiz Kowalski, Phd",
        "Affiliations": "Faculdade de Medicina da Universidade de São Paulo",
        "Background": "In endemic regions of Latin America, paracoccidioidomycosis presents diagnostic challenges when involving cervical lymph nodes with calcifications. The radiologic and cytologic features may closely resemble metastatic papillary thyroid carcinoma, potentially leading to unnecessary extensive surgical intervention. Recognition of this mimicry remains critical for appropriate management in areas where both conditions coexist.",
        "Objective": "We report a case demonstrating the diagnostic pitfalls when endemic fungal infection presents with bilateral calcified cervical lymphadenopathy in a patient with concomitant thyroid enlargement, emphasizing the limitations of preoperative cytologic evaluation in differentiating benign granulomatous disease from malignancy.",
        "Case Presentation": "An 18-year-old woman from suburban Bahia, Brazil, presented with progressive thyroid enlargement over two years, markedly accelerating during the preceding three months. She denied compressive symptoms or dysphonia, with no clinical evidence of thyroid dysfunction. Her medical history included levothyroxine-controlled hypothyroidism and recent pregnancy loss complicated by Twin Reversed Arterial Perfusion sequence. Physical examination revealed marked thyroid enlargement extending superiorly to the submandibular region and laterally toward both supraclavicular fossae, with the inferior margin not palpable. Preoperative computed tomography demonstrated a voluminous goiter with numerous bilateral calcified cervical lymph nodes. These imaging characteristics strongly suggested metastatic papillary thyroid carcinoma. Fine-needle aspiration of selected lymph nodes yielded cytologic findings interpreted as compatible with papillary thyroid carcinoma, reinforcing the malignancy suspicion.",
        "Abstract": "Based on these convergent findings, the patient underwent total thyroidectomy with comprehensive bilateral neck dissection (levels II-VI). Her postoperative recovery was unremarkable, with discharge on postoperative day four. Histopathologic examination revealed multinodular colloid goiter with chronic thyroiditis, characterized by follicular cell hyperplasia and hypertrophy, without evidence of malignant neoplasm. Among 70 harvested lymph nodes from bilateral dissection, none contained metastatic carcinoma. Instead, multiple nodes from right levels II-V and left levels II, III, and V demonstrated well-formed granulomatous inflammation with multinucleated giant cells, necrotic foci, and basophilic dystrophic calcifications. Fungal organisms were identified within necrotic areas. Grocott methenamine silver staining revealed yeast-like organisms with characteristic multiple narrow-based budding, morphologically consistent with Paracoccidioides brasiliensis. Ziehl-Neelsen staining for acid-fast bacilli was negative. Serologic testing for paracoccidioidomycosis yielded negative results, occasionally observed in localized or early-stage disease. Final diagnosis confirmed granulomatous fungal lymphadenitis secondary to paracoccidioidomycosis without thyroid malignancy. The convergence of suspicious imaging findings and cytologic interpretation compatible with papillary carcinoma drove the oncologic surgical approach. This experience underscores critical limitations of cytopathologic evaluation for endemic fungal infections, particularly when clinical suspicion is absent. In endemic regions, paracoccidioidomycosis must be considered in the differential diagnosis of calcified cervical lymphadenopathy, even when malignancy appears likely. The oncologic approach remained justified given the robust preoperative evidence suggesting malignancy and the substantial risks of incomplete surgical treatment for presumed thyroid cancer.",
        "Conclusions and Recommendations": "This case illustrates how paracoccidioidomycosis can convincingly simulate metastatic thyroid carcinoma when presenting with bilateral calcified cervical lymphadenopathy in endemic areas. While the extensive goiter justified thyroidectomy, the bilateral neck dissection proved retrospectively unnecessary."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Bilateral Calcified Cervical Lymphadenopathy as a Diagnostic Pitfall: When Endemic Paracoccidioidomycosis Masquerades as Metastatic Thyroid Carcinoma</span>. Lucas Marinho, MD; Luana Bittencourt, MD; Matheus Buissa, MD; Daysi Sanguano, MD; Dhara de Souza, MD; Bruna Hanauer, MD; Hudson Sodré, MD; Renata Mahmoud, MD; <u>Luiz Kowalski, Phd</u>. Faculdade de Medicina da Universidade de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In endemic regions of Latin America, paracoccidioidomycosis presents diagnostic challenges when involving cervical lymph nodes with calcifications. The radiologic and cytologic features may closely resemble metastatic papillary thyroid carcinoma, potentially leading to unnecessary extensive surgical intervention. Recognition of this mimicry remains critical for appropriate management in areas where both conditions coexist.</p>\n\n<p><strong>Objective:</strong> We report a case demonstrating the diagnostic pitfalls when endemic fungal infection presents with bilateral calcified cervical lymphadenopathy in a patient with concomitant thyroid enlargement, emphasizing the limitations of preoperative cytologic evaluation in differentiating benign granulomatous disease from malignancy.</p>\n\n<p><strong>Case Presentation:</strong> An 18-year-old woman from suburban Bahia, Brazil, presented with progressive thyroid enlargement over two years, markedly accelerating during the preceding three months. She denied compressive symptoms or dysphonia, with no clinical evidence of thyroid dysfunction. Her medical history included levothyroxine-controlled hypothyroidism and recent pregnancy loss complicated by Twin Reversed Arterial Perfusion sequence. Physical examination revealed marked thyroid enlargement extending superiorly to the submandibular region and laterally toward both supraclavicular fossae, with the inferior margin not palpable. Preoperative computed tomography demonstrated a voluminous goiter with numerous bilateral calcified cervical lymph nodes. These imaging characteristics strongly suggested metastatic papillary thyroid carcinoma. Fine-needle aspiration of selected lymph nodes yielded cytologic findings interpreted as compatible with papillary thyroid carcinoma, reinforcing the malignancy suspicion.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172107(1).jpg' /></p>\n\n<p>Based on these convergent findings, the patient underwent total thyroidectomy with comprehensive bilateral neck dissection (levels II-VI). Her postoperative recovery was unremarkable, with discharge on postoperative day four. Histopathologic examination revealed multinodular colloid goiter with chronic thyroiditis, characterized by follicular cell hyperplasia and hypertrophy, without evidence of malignant neoplasm. Among 70 harvested lymph nodes from bilateral dissection, none contained metastatic carcinoma. Instead, multiple nodes from right levels II-V and left levels II, III, and V demonstrated well-formed granulomatous inflammation with multinucleated giant cells, necrotic foci, and basophilic dystrophic calcifications. Fungal organisms were identified within necrotic areas. Grocott methenamine silver staining revealed yeast-like organisms with characteristic multiple narrow-based budding, morphologically consistent with Paracoccidioides brasiliensis. Ziehl-Neelsen staining for acid-fast bacilli was negative. Serologic testing for paracoccidioidomycosis yielded negative results, occasionally observed in localized or early-stage disease. Final diagnosis confirmed granulomatous fungal lymphadenitis secondary to paracoccidioidomycosis without thyroid malignancy.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%202025-12-04%20172325(2).jpg' /></p>\n\n<p><strong>Conclusions and Recommendations: </strong>This case illustrates how paracoccidioidomycosis can convincingly simulate metastatic thyroid carcinoma when presenting with bilateral calcified cervical lymphadenopathy in endemic areas. While the extensive goiter justified thyroidectomy, the bilateral neck dissection proved retrospectively unnecessary.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153916/Captura%20de%20tela%2004-12-2025.PNG' /></p>\n\n<p>The convergence of suspicious imaging findings and cytologic interpretation compatible with papillary carcinoma drove the oncologic surgical approach. This experience underscores critical limitations of cytopathologic evaluation for endemic fungal infections, particularly when clinical suspicion is absent. In endemic regions, paracoccidioidomycosis must be considered in the differential diagnosis of calcified cervical lymphadenopathy, even when malignancy appears likely. The oncologic approach remained justified given the robust preoperative evidence suggesting malignancy and the substantial risks of incomplete surgical treatment for presumed thyroid cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153916--></body></html>"
    },
    {
      "uid": "P110",
      "content_id": "153518",
      "abstract_number": "P110",
      "poster_number": "P110",
      "title": "Implementation of Radiofrequency Ablation for Benign Thyroid Nodules: A Phased Pilot Study and Audit in a Tertiary Head and Neck Centre",
      "summary": "In this phased pilot study and audit from a tertiary head and neck centre, RFA of Bethesda II benign thyroid nodules was associated with significant and sustained nodule volume reduction up to 12 months after treatment. Procedural duration decreased with increasing case experience, supporting the presence of a learning curve during early service implementation. These early outcomes support RFA as a feasible,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153518",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yong Hong Ng",
      "presenter": "Yong Hong Ng",
      "authors": "Yong Hong Ng ; Pei Yuan Fong; Siti Radhziah Binte Sudirman, Senior Consultant; Anna Xinyin See, Senior Consultant; Kimberley Liqin Kiong, Senior Consultant; Isabelle Jia Hui Jang, Consultant; Chwee Ming Lim, Associate Professor",
      "normalized_authors": [
        "Yong Hong Ng",
        "Pei Yuan Fong",
        "Siti Radhziah Binte Sudirman, Senior Consultant",
        "Anna Xinyin See, Senior Consultant",
        "Kimberley Liqin Kiong, Senior Consultant",
        "Isabelle Jia Hui Jang, Consultant",
        "Chwee Ming Lim, Associate"
      ],
      "affiliations": [
        "Singapore General Hospital"
      ],
      "normalized_institutions": [
        "Singapore General Hospital"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 349,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Yong Hong Ng ; Pei Yuan Fong; Siti Radhziah Binte Sudirman, Senior Consultant; Anna Xinyin See, Senior Consultant; Kimberley Liqin Kiong, Senior Consultant; Isabelle Jia Hui Jang, Consultant; Chwee Ming Lim, Associate Professor",
        "Affiliations": "Singapore General Hospital",
        "Background": "Radiofrequency ablation (RFA) is a minimally invasive alternative to surgery for selected benign thyroid nodules. While international data support its efficacy, real-world implementation data from Southeast Asian tertiary head and neck centres remain limited. We conducted a phased pilot study and audit to evaluate early outcomes of a newly implemented RFA service for benign thyroid nodules at Singapore General Hospital.",
        "Methods": "Patients with fine-needle aspiration (FNA)-proven benign thyroid nodules (Bethesda II) who were symptomatic and/or cosmetically bothered were offered ultrasound-guided RFA. All procedures were performed under real-time ultrasound guidance using a standardised technique under general anesthesia. Nodule volumes were recorded at baseline and at 3–4 months, 6 months, and 6–12 months post-ablation. Percentage volume change from baseline was calculated at each timepoint. Paired t-tests compared pre- and post-procedure volumes. Pearson correlation was used to explore associations between percentage volume reduction and procedural variables (procedure time and delivered power), and a learning-curve analysis was performed.",
        "Results": "Follow-up imaging was available for 8 nodules at 3–4 months, 9 at 6 months, and 11 at 6–12 months. Mean nodule volume decreased significantly at all timepoints after a single RFA session, with early reduction evident at 3–4 months and sustained effect up to 12 months. At 3–4 months, mean volume reduction was 41.9% ± 21.9% (p = 0.0019). At 6 months, mean reduction was 27.8% ± 18.5% (p = 0.00135). At 6–12 months, mean percentage volume reduction was 41.7% ± 18.7% (p = 0.00029), confirming a durable treatment effect. Learning-curve analysis showed a moderate negative correlation between case number and procedure duration (r = –0.38), supporting a trend toward improved procedural efficiency with experience.",
        "Conclusion": "In this phased pilot study and audit from a tertiary head and neck centre, RFA of Bethesda II benign thyroid nodules was associated with significant and sustained nodule volume reduction up to 12 months after treatment. Procedural duration decreased with increasing case experience, supporting the presence of a learning curve during early service implementation. These early outcomes support RFA as a feasible, minimally invasive option for benign thyroid nodules."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Implementation of Radiofrequency Ablation for Benign Thyroid Nodules: A Phased Pilot Study and Audit in a Tertiary Head and Neck Centre</span>. <u>Yong Hong Ng</u>; Pei Yuan Fong; Siti Radhziah Binte Sudirman, Senior Consultant; Anna Xinyin See, Senior Consultant; Kimberley Liqin Kiong, Senior Consultant; Isabelle Jia Hui Jang, Consultant; Chwee Ming Lim, Associate Professor. Singapore General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Radiofrequency ablation (RFA) is a minimally invasive alternative to surgery for selected benign thyroid nodules. While international data support its efficacy, real-world implementation data from Southeast Asian tertiary head and neck centres remain limited. We conducted a phased pilot study and audit to evaluate early outcomes of a newly implemented RFA service for benign thyroid nodules at Singapore General Hospital.</p>\n\n<p><strong>Methods: </strong>Patients with fine-needle aspiration (FNA)-proven benign thyroid nodules (Bethesda II) who were symptomatic and/or cosmetically bothered were offered ultrasound-guided RFA. All procedures were performed under real-time ultrasound guidance using a standardised technique under general anesthesia. Nodule volumes were recorded at baseline and at 3–4 months, 6 months, and 6–12 months post-ablation. Percentage volume change from baseline was calculated at each timepoint. Paired t-tests compared pre- and post-procedure volumes. Pearson correlation was used to explore associations between percentage volume reduction and procedural variables (procedure time and delivered power), and a learning-curve analysis was performed.</p>\n\n<p><strong>Results: </strong>Follow-up imaging was available for 8 nodules at 3–4 months, 9 at 6 months, and 11 at 6–12 months. Mean nodule volume decreased significantly at all timepoints after a single RFA session, with early reduction evident at 3–4 months and sustained effect up to 12 months. At 3–4 months, mean volume reduction was 41.9% ± 21.9% (p = 0.0019). At 6 months, mean reduction was 27.8% ± 18.5% (p = 0.00135). At 6–12 months, mean percentage volume reduction was 41.7% ± 18.7% (p = 0.00029), confirming a durable treatment effect. Learning-curve analysis showed a moderate negative correlation between case number and procedure duration (r = –0.38), supporting a trend toward improved procedural efficiency with experience.</p>\n\n<p><strong>Conclusion: </strong>In this phased pilot study and audit from a tertiary head and neck centre, RFA of Bethesda II benign thyroid nodules was associated with significant and sustained nodule volume reduction up to 12 months after treatment. Procedural duration decreased with increasing case experience, supporting the presence of a learning curve during early service implementation. These early outcomes support RFA as a feasible, minimally invasive option for benign thyroid nodules.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153518--></body></html>"
    },
    {
      "uid": "P111",
      "content_id": "154449",
      "abstract_number": "P111",
      "poster_number": "P111",
      "title": "Risk of Thyroid Malignancy Development in Females with Polycystic Ovary Syndrome",
      "summary": "This study shows a statistically significant 2.5-fold increase in thyroid cancer risk among females with PCOS compared to matched controls, based on the largest epidemiological sample to date. Several mechanisms may underlie this association, including elevated estrogen levels in PCOS and the well-documented link between insulin resistance and thyroid cancer. These results underscore the potential need for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154449",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Veenadhari Kollipara, BA",
      "presenter": "Veenadhari Kollipara, BA",
      "authors": "Veenadhari Kollipara, BA ; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS",
      "normalized_authors": [
        "Veenadhari Kollipara",
        "Kunal A Koka",
        "F. Jeffrey Lorenz",
        "Neerav Goyal",
        "David Goldenberg"
      ],
      "affiliations": [
        "Penn State College of Medicine"
      ],
      "normalized_institutions": [
        "Penn State College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 313,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Veenadhari Kollipara, BA ; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS",
        "Affiliations": "Penn State College of Medicine",
        "Background": "Thyroid cancer exhibits a notable female predominance, particularly during the reproductive years, suggesting a possible link between female hormones and the development of the disease. However, the evidence supporting this association is complex and not consistently robust across all reproductive factors. Polycystic Ovary Syndrome (PCOS) has been frequently associated with a higher prevalence of autoimmune thyroid disorders and increased risk of thyroid nodules. While systematic reviews have hinted at a potential connection between PCOS and thyroid cancer, the epidemiological evidence remains limited. This study aimed to further explore the relationship between PCOS and thyroid cancer.",
        "Methods": "The TriNetX Research Database was queried for females aged 18+ with PCOS from 2008 to 2018, with ≥5 years of follow-up. Exclusion criteria included those with MEN syndromes, familial adenomatous polyposis, Cowden syndrome, a family history of non-thyroid malignancies, radiation exposure, and use of estrogens, SERMs, or aromatase inhibitors. The incidence of malignant neoplasm of the thyroid gland was compared between PCOS patients and age-, race-, and ethnicity-matched controls.",
        "Results": "We identified 71,976 females with PCOS and 13,018,059 controls. The average age in the PCOS group was 32.5 years. After propensity score matching (PSM) for demographic variables, thyroid cancer was diagnosed in 0.51% of the PCOS (n = 369) cohort and 0.20% (n = 145) of the no-PCOS cohort. The risk ratio of thyroid cancer development in the PCOS versus no-PCOS cohort was 2.55 (95% confidence interval: 2.10 to 3.08, p < 0.0001).",
        "Conclusions": "This study shows a statistically significant 2.5-fold increase in thyroid cancer risk among females with PCOS compared to matched controls, based on the largest epidemiological sample to date. Several mechanisms may underlie this association, including elevated estrogen levels in PCOS and the well-documented link between insulin resistance and thyroid cancer. These results underscore the potential need for greater awareness and monitoring of thyroid health in patients with PCOS."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Risk of Thyroid Malignancy Development in Females with Polycystic Ovary Syndrome</span>. <u>Veenadhari Kollipara, BA</u>; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS. Penn State College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Thyroid cancer exhibits a notable female predominance, particularly during the reproductive years, suggesting a possible link between female hormones and the development of the disease. However, the evidence supporting this association is complex and not consistently robust across all reproductive factors. Polycystic Ovary Syndrome (PCOS) has been frequently associated with a higher prevalence of autoimmune thyroid disorders and increased risk of thyroid nodules. While systematic reviews have hinted at a potential connection between PCOS and thyroid cancer, the epidemiological evidence remains limited. This study aimed to further explore the relationship between PCOS and thyroid cancer.</p>\n\n<p><strong>Methods: </strong>The TriNetX Research Database was queried for females aged 18+ with PCOS from 2008 to 2018, with ≥5 years of follow-up. Exclusion criteria included those with MEN syndromes, familial adenomatous polyposis, Cowden syndrome, a family history of non-thyroid malignancies, radiation exposure, and use of estrogens, SERMs, or aromatase inhibitors. The incidence of malignant neoplasm of the thyroid gland was compared between PCOS patients and age-, race-, and ethnicity-matched controls.</p>\n\n<p><strong>Results: </strong>We identified 71,976 females with PCOS and 13,018,059 controls. The average age in the PCOS group was 32.5 years. After propensity score matching (PSM) for demographic variables, thyroid cancer was diagnosed in 0.51% of the PCOS (n = 369) cohort and 0.20% (n = 145) of the no-PCOS cohort. The risk ratio of thyroid cancer development in the PCOS versus no-PCOS cohort was 2.55 (95% confidence interval: 2.10 to 3.08, p < 0.0001).</p>\n\n<p><strong>Conclusions: </strong>This study shows a statistically significant 2.5-fold increase in thyroid cancer risk among females with PCOS compared to matched controls, based on the largest epidemiological sample to date. Several mechanisms may underlie this association, including elevated estrogen levels in PCOS and the well-documented link between insulin resistance and thyroid cancer. These results underscore the potential need for greater awareness and monitoring of thyroid health in patients with PCOS.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154449--></body></html>"
    },
    {
      "uid": "P112",
      "content_id": "154647",
      "abstract_number": "P112",
      "poster_number": "P112",
      "title": "Primary Hyperparathyroidism in Young, Non-Syndromic Adults",
      "summary": "From the study period, records were available for 1,015 patients with non-syndromic PHPT who underwent first-time parathyroidectomy. Seventy-six patients (7.5% of all reviewed patients) were included in this study, 26 group A and 50 group B. Cure was achieved in 25/26 group A (96.1%) and 49/50 group B (98%). In cured patients, single adenoma, double adenoma, and 4-gland hyperplasia was found in 84%, 4%, 12% of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154647",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Singer, MD",
      "presenter": "Michael Singer, MD",
      "authors": "Brendan Dolan, BS 1 ; Michael Singer, MD 2",
      "normalized_authors": [
        "Brendan Dolan",
        "Michael Singer"
      ],
      "affiliations": [
        "Wayne State University",
        "Henry Ford Health"
      ],
      "normalized_institutions": [
        "Wayne State University",
        "Henry Ford Health"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 392,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Results",
        "Conclusion/Relevance"
      ],
      "sections": {
        "Authors": "Brendan Dolan, BS 1 ; Michael Singer, MD 2",
        "Affiliations": "1 Wayne State University; 2 Henry Ford Health",
        "Importance": "Primary hyperparathyroidism (PHPT) most commonly affects older adults. Younger patients are often thought to be at greater risk of presenting with multiglandular disease (MGD). While true for patients with syndromic PHPT there is limited research specifically evaluating disease characteristics in young adults with sporadic PHPT.",
        "Objective": "The primary goal of this study is to assess the nature of PHPT in non-syndromic patients under 40 years old and to determine their rate of MGD, surgical outcomes and risk of recurrence.",
        "Design": "This is a retrospective study of patients that underwent parathyroidectomy between January 2014 and December 2023. Demographic, preoperative, intraoperative and postoperative data were collected. All included patients had first-time surgery for PHPT and had at least 6 months of follow-up data available. No patients with normocalcemic PHPT were included in this study. Patients with known or suspected syndromic disease (particularly multiple endocrine neoplasia) or who had previous parathyroidectomy were excluded. Patients were categorized as young adults if at the time of surgery they were 40 years old or younger. Cohorts were defined by age: group A (≤ 30 years) and group B (ages 31-40 years). Cure was defined as a sustained normalization of calcium levels lasting for at least 6 months after surgery.",
        "Setting": "All surgeries were performed at a tertiary, academic institution by the senior author.",
        "Results": "From the study period, records were available for 1,015 patients with non-syndromic PHPT who underwent first-time parathyroidectomy. Seventy-six patients (7.5% of all reviewed patients) were included in this study, 26 group A and 50 group B. Cure was achieved in 25/26 group A (96.1%) and 49/50 group B (98%). In cured patients, single adenoma, double adenoma, and 4-gland hyperplasia was found in 84%, 4%, 12% of group A and 92%, 2%, 6% of group B, respectively. Of patients with at least 1 year of follow-up data available, recurrences occurred in 1/24 group A (mean follow-up 771 days, range 461-3926) and 2/44 group B (mean follow-up 814 days, range 387-4067).",
        "Conclusion/Relevance": "In young adult patients with non-syndromic PHPT, the vast majority can be cured with removal of a single adenoma. Based on the data in this study, it appears that young patients undergoing parathyroidectomy can be reassured that recurrence rates are low regardless of disease severity. Additional analysis is planned to compare these results with patients older than 41 years from the same dataset."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Primary Hyperparathyroidism in Young, Non-Syndromic Adults</span>. Brendan Dolan, BS<sup>1</sup>; <u>Michael Singer, MD</u><sup>2</sup>. <sup>1</sup>Wayne State University; <sup>2</sup>Henry Ford Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Primary hyperparathyroidism (PHPT) most commonly affects older adults. Younger patients are often thought to be at greater risk of presenting with multiglandular disease (MGD). While true for patients with syndromic PHPT there is limited research specifically evaluating disease characteristics in young adults with sporadic PHPT.</p>\n\n<p><strong>Objective: </strong>The primary goal of this study is to assess the nature of PHPT in non-syndromic patients under 40 years old and to determine their rate of MGD, surgical outcomes and risk of recurrence.</p>\n\n<p><strong>Design: </strong>This is a retrospective study of patients that underwent parathyroidectomy between January 2014 and December 2023. Demographic, preoperative, intraoperative and postoperative data were collected. All included patients had first-time surgery for PHPT and had at least 6 months of follow-up data available. No patients with normocalcemic PHPT were included in this study. Patients with known or suspected syndromic disease (particularly multiple endocrine neoplasia) or who had previous parathyroidectomy were excluded. Patients were categorized as young adults if at the time of surgery they were 40 years old or younger. Cohorts were defined by age: group A (≤ 30 years) and group B (ages 31-40 years). Cure was defined as a sustained normalization of calcium levels lasting for at least 6 months after surgery.</p>\n\n<p><strong>Setting:</strong> All surgeries were performed at a tertiary, academic institution by the senior author.</p>\n\n<p><strong>Results:</strong> From the study period, records were available for 1,015 patients with non-syndromic PHPT who underwent first-time parathyroidectomy. Seventy-six patients (7.5% of all reviewed patients) were included in this study, 26 group A and 50 group B. Cure was achieved in 25/26 group A (96.1%) and 49/50 group B (98%). In cured patients, single adenoma, double adenoma, and 4-gland hyperplasia was found in 84%, 4%, 12% of group A and 92%, 2%, 6% of group B, respectively. Of patients with at least 1 year of follow-up data available, recurrences occurred in 1/24 group A (mean follow-up 771 days, range 461-3926) and 2/44 group B (mean follow-up 814 days, range 387-4067).</p>\n\n<p><strong>Conclusion/Relevance: </strong>In young adult patients with non-syndromic PHPT, the vast majority can be cured with removal of a single adenoma. Based on the data in this study, it appears that young patients undergoing parathyroidectomy can be reassured that recurrence rates are low regardless of disease severity. Additional analysis is planned to compare these results with patients older than 41 years from the same dataset.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154647--></body></html>"
    },
    {
      "uid": "P113",
      "content_id": "154662",
      "abstract_number": "P113",
      "poster_number": "P113",
      "title": "Solitary Microadenomas as the Cause of Primary Hyperparathyroidism",
      "summary": "During the study period 775 patients had curative primary parathyroidectomy for PHPT, due to a single adenoma. Eighty-three patients (10.7%) had adenomas ≤ 250 mg, 46 ≤ 200 mg, and 37 between 201-250 mg. Of these patients, 28.2% and 16.2%, respectively, presented with normohormonal PHPT. Seventy-four patients with small adenomas had at least one year of follow-up data available. Only 1 patient had a recurrence...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154662",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Singer, MD",
      "presenter": "Michael Singer, MD",
      "authors": "Brendan Dolan 1 ; Michael Singer, MD 2",
      "normalized_authors": [
        "Brendan Dolan",
        "Michael Singer"
      ],
      "affiliations": [
        "Wayne State University",
        "Henry Ford Health"
      ],
      "normalized_institutions": [
        "Wayne State University",
        "Henry Ford Health"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 292,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Results",
        "Conclusion/Relevance"
      ],
      "sections": {
        "Authors": "Brendan Dolan 1 ; Michael Singer, MD 2",
        "Affiliations": "1 Wayne State University; 2 Henry Ford Health",
        "Importance": "A single parathyroid adenoma is the cause of primary hyperparathyroidism (PHPT) in approximately 85% of patients. Prior studies have suggested that small pathologic glands can be a harbinger of potential multiglandular disease (MGD) and surgical complexity. However, surgeons should be aware that small, solitary adenomas can be the cause of a wide spectrum of PHPT disease severity.",
        "Objective": "To assess clinical characteristics and indicators of patients with PHPT caused by single, small adenomas.",
        "Design": "This is a retrospective study of patients who underwent parathyroidectomy between January 2014 and December 2023. Demographic, preoperative, intraoperative and postoperative data were collected. All included patients had curative, first-time surgery for PHPT caused by a single adenoma and had at least 6 months of follow-up data available. Exclusion criteria included normocalcemic PHPT, renal hyperparathyroidism, known or suspected syndromic disease and prior parathyroidectomy. Cure was defined as a sustained normalization of calcium levels lasting for at least 6 months after surgery.",
        "Setting": "All surgeries were performed at a tertiary, academic institution by the senior author.",
        "Results": "During the study period 775 patients had curative primary parathyroidectomy for PHPT, due to a single adenoma. Eighty-three patients (10.7%) had adenomas ≤ 250 mg, 46 ≤ 200 mg, and 37 between 201-250 mg. Of these patients, 28.2% and 16.2%, respectively, presented with normohormonal PHPT. Seventy-four patients with small adenomas had at least one year of follow-up data available. Only 1 patient had a recurrence approximately 2.5 years after initial surgery.",
        "Conclusion/Relevance": "Small, single adenomas are the cause of PHPT in a significant cohort of patients. During parathyroidectomy, surgeons should be aware that identification of a small abnormal gland is not necessarily indicative of MGD. Additional analysis is planned to compare these results with patients with single adenomas weighing ≥ 251 mg from the same dataset."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Solitary Microadenomas as the Cause of Primary Hyperparathyroidism</span>. Brendan Dolan<sup>1</sup>; <u>Michael Singer, MD</u><sup>2</sup>. <sup>1</sup>Wayne State University; <sup>2</sup>Henry Ford Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> A single parathyroid adenoma is the cause of primary hyperparathyroidism (PHPT) in approximately 85% of patients. Prior studies have suggested that small pathologic glands can be a harbinger of potential multiglandular disease (MGD) and surgical complexity. However, surgeons should be aware that small, solitary adenomas can be the cause of a wide spectrum of PHPT disease severity.</p>\n\n<p><strong>Objective: </strong>To assess clinical characteristics and indicators of patients with PHPT caused by single, small adenomas.</p>\n\n<p><strong>Design:</strong> This is a retrospective study of patients who underwent parathyroidectomy between January 2014 and December 2023. Demographic, preoperative, intraoperative and postoperative data were collected. All included patients had curative, first-time surgery for PHPT caused by a single adenoma and had at least 6 months of follow-up data available. Exclusion criteria included normocalcemic PHPT, renal hyperparathyroidism, known or suspected syndromic disease and prior parathyroidectomy. Cure was defined as a sustained normalization of calcium levels lasting for at least 6 months after surgery.</p>\n\n<p><strong>Setting: </strong>All surgeries were performed at a tertiary, academic institution by the senior author.</p>\n\n<p><strong>Results:</strong> During the study period 775 patients had curative primary parathyroidectomy for PHPT, due to a single adenoma. Eighty-three patients (10.7%) had adenomas ≤ 250 mg, 46 ≤ 200 mg, and 37 between 201-250 mg. Of these patients, 28.2% and 16.2%, respectively, presented with normohormonal PHPT. Seventy-four patients with small adenomas had at least one year of follow-up data available. Only 1 patient had a recurrence approximately 2.5 years after initial surgery.</p>\n\n<p><strong>Conclusion/Relevance: </strong>Small, single adenomas are the cause of PHPT in a significant cohort of patients. During parathyroidectomy, surgeons should be aware that identification of a small abnormal gland is not necessarily indicative of MGD. Additional analysis is planned to compare these results with patients with single adenomas weighing ≥ 251 mg from the same dataset.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154662--></body></html>"
    },
    {
      "uid": "P114",
      "content_id": "155525",
      "abstract_number": "P114",
      "poster_number": "P114",
      "title": "Preoperative Proton Pump Inhibitor Use and Postoperative Hypocalcemia Following Total Thyroidectomy",
      "summary": "Preoperative acid suppression is associated with increased postoperative hypocalcemia after total thyroidectomy, with robust effects across thyroid pathology subgroups and multiple sensitivity analyses. The absence of a difference between PPIs and H2 antagonists suggests that gastric suppression itself, rather than a PPI-specific mechanism, may underlie this risk. These findings support more vigilant...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155525",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sunny K Ennis, BS",
      "presenter": "Sunny K Ennis, BS",
      "authors": "Sunny K Ennis, BS ; Warren B Chun, MD; Shaun A Nguyen, MD; Dauren Adilbay, MD; W Greer Albergotti, MD",
      "normalized_authors": [
        "Sunny K Ennis",
        "Warren B Chun",
        "Shaun A Nguyen",
        "Dauren Adilbay",
        "W Greer Albergotti"
      ],
      "affiliations": [
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 416,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sunny K Ennis, BS ; Warren B Chun, MD; Shaun A Nguyen, MD; Dauren Adilbay, MD; W Greer Albergotti, MD",
        "Affiliations": "Medical University of South Carolina",
        "Background": "Hypocalcemia is a common complication that occurs after total thyroidectomy and is mainly caused by hypoparathyroidism. Acid-suppressive therapy, including proton pump inhibitors (PPIs), reduces gastric acidity and may impair calcium and magnesium absorption, potentially increasing hypocalcemia risk. Despite the common use of PPIs, PPI use has not been studied as a risk factor for postoperative hypocalcemia in this surgical population. This study evaluated whether preoperative PPI use is associated with postoperative hypocalcemia following total thyroidectomy.",
        "Methods": "Using the TriNetX federated health records database, patients who underwent total thyroidectomy were stratified by PPI use versus no PPI use within 90 days before surgery. Propensity score matching (1:1) balanced key demographic and clinical characteristics including age, sex, race, ethnicity, thyroid cancer diagnosis, hyperthyroidism, chronic kidney disease, vitamin D deficiency, type II diabetes mellitus, obesity, and tobacco use. The primary outcome was hypocalcemia within 30 days of surgery. Secondary outcomes included hypocalcemia within 6 months of surgery and analyses restricted to malignant versus nonmalignant thyroid pathology. Sensitivity analyses excluded patients with chronic kidney disease or vitamin D deficiency, narrowed the PPI exposure window, compared PPI use to H2 antagonist use, and stratified hypocalcemia codes. Time-to-event outcomes were analyzed with Cox proportional hazards models, reported as hazard ratios (HRs) with 95% confidence intervals (CIs).",
        "Results": "Preoperative PPI use showed an increased hazard of hypocalcemia within 30 days following total thyroidectomy (HR 1.38, 95% CI 1.26,1.51, p < 0.001) and within 6 months following surgery (HR 1.32, 95% CI 1.22,1.42, p < 0.001). Similar associations were seen in patients with malignant thyroid pathology (HR 1.30, 95% CI 1.13,1.49, p < 0.001) and nonmalignant thyroid pathology (HR 1.30, 95% CI 1.16,1.47, p < 0.001). Sensitivity analyses excluding patients with chronic kidney disease or vitamin D deficiency, narrowing the PPI exposure window, and restricting outcome codes all demonstrated consistent elevated risks (all p < 0.01). In contrast, PPI use versus H2 antagonist use did not differ significantly in hypocalcemia risk (HR 0.97, 95% CI 0.87,1.09, p = 0.55).",
        "Conclusions": "Preoperative acid suppression is associated with increased postoperative hypocalcemia after total thyroidectomy, with robust effects across thyroid pathology subgroups and multiple sensitivity analyses. The absence of a difference between PPIs and H2 antagonists suggests that gastric suppression itself, rather than a PPI-specific mechanism, may underlie this risk. These findings support more vigilant perioperative calcium management and consideration of prophylactic supplementation in thyroidectomy patients receiving acid-suppressive therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Proton Pump Inhibitor Use and Postoperative Hypocalcemia Following Total Thyroidectomy</span>. <u>Sunny K Ennis, BS</u>; Warren B Chun, MD; Shaun A Nguyen, MD; Dauren Adilbay, MD; W Greer Albergotti, MD. Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Hypocalcemia is a common complication that occurs after total thyroidectomy and is mainly caused by hypoparathyroidism. Acid-suppressive therapy, including proton pump inhibitors (PPIs), reduces gastric acidity and may impair calcium and magnesium absorption, potentially increasing hypocalcemia risk. Despite the common use of PPIs, PPI use has not been studied as a risk factor for postoperative hypocalcemia in this surgical population. This study evaluated whether preoperative PPI use is associated with postoperative hypocalcemia following total thyroidectomy.</p>\n\n<p><strong>Methods: </strong>Using the TriNetX federated health records database, patients who underwent total thyroidectomy were stratified by PPI use versus no PPI use within 90 days before surgery. Propensity score matching (1:1) balanced key demographic and clinical characteristics including age, sex, race, ethnicity, thyroid cancer diagnosis, hyperthyroidism, chronic kidney disease, vitamin D deficiency, type II diabetes mellitus, obesity, and tobacco use. The primary outcome was hypocalcemia within 30 days of surgery. Secondary outcomes included hypocalcemia within 6 months of surgery and analyses restricted to malignant versus nonmalignant thyroid pathology. Sensitivity analyses excluded patients with chronic kidney disease or vitamin D deficiency, narrowed the PPI exposure window, compared PPI use to H2 antagonist use, and stratified hypocalcemia codes. Time-to-event outcomes were analyzed with Cox proportional hazards models, reported as hazard ratios (HRs) with 95% confidence intervals (CIs).</p>\n\n<p><strong>Results: </strong>Preoperative PPI use showed an increased hazard of hypocalcemia within 30 days following total thyroidectomy (HR 1.38, 95% CI 1.26,1.51, p < 0.001) and within 6 months following surgery (HR 1.32, 95% CI 1.22,1.42, p < 0.001). Similar associations were seen in patients with malignant thyroid pathology (HR 1.30, 95% CI 1.13,1.49, p < 0.001) and nonmalignant thyroid pathology (HR 1.30, 95% CI 1.16,1.47, p < 0.001). Sensitivity analyses excluding patients with chronic kidney disease or vitamin D deficiency, narrowing the PPI exposure window, and restricting outcome codes all demonstrated consistent elevated risks (all p < 0.01). In contrast, PPI use versus H2 antagonist use did not differ significantly in hypocalcemia risk (HR 0.97, 95% CI 0.87,1.09, p = 0.55). </p>\n\n<p><strong>Conclusions: </strong>Preoperative acid suppression is associated with increased postoperative hypocalcemia after total thyroidectomy, with robust effects across thyroid pathology subgroups and multiple sensitivity analyses. The absence of a difference between PPIs and H2 antagonists suggests that gastric suppression itself, rather than a PPI-specific mechanism, may underlie this risk. These findings support more vigilant perioperative calcium management and consideration of prophylactic supplementation in thyroidectomy patients receiving acid-suppressive therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155525--></body></html>"
    },
    {
      "uid": "P115",
      "content_id": "154577",
      "abstract_number": "P115",
      "poster_number": "P115",
      "title": "Female Reproductive History and Incident Thyroid Dysfunction: Findings From a Large Real-World Database Study",
      "summary": "Menopause, parity, and abortion history were each associated with a reduced risk of hypothyroidism, and none were linked to increased risk of hyperthyroidism. These findings suggest that reproduction-related hormonal changes and adaptations may confer long-term protection against thyroid dysfunction. Prospective studies are warranted to validate these associations and elucidate underlying mechanisms.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154577",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Uralov, MD",
      "presenter": "Daniel Uralov, MD",
      "authors": "Daniel Uralov, MD ; Sarah Harrington, BA; Emma De Ravin, MD; Elizabeth Cottrill, MD",
      "normalized_authors": [
        "Daniel Uralov",
        "Sarah Harrington",
        "Emma De Ravin",
        "Elizabeth Cottrill"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 388,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Daniel Uralov, MD ; Sarah Harrington, BA; Emma De Ravin, MD; Elizabeth Cottrill, MD",
        "Affiliations": "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Introduction": "Female reproductive factors such as pregnancy-related hormonal shifts, postpartum immune rebound, and menopausal endocrine changes have been proposed to influence long-term thyroid function through interconnected hormonal and immunologic pathways. However, evidence from large, real-world populations remains limited. This study evaluated associations between menopause, parity, and abortion history with the development of hypothyroidism and hyperthyroidism in a multi-institutional electronic health-record network.",
        "Methods": "A retrospective cohort study was conducted using the TriNetX Research Network. Female patients aged ≥20 years with biochemical euthyroidism—TSH 0.32–5.06 mIU/L with normal free T4—were included if they had no prior history of thyroid disease, thyroid surgery, thyroid-active medications, or pregnancy within one year of the index date. Four age groups were examined: 20–35 years (n=245,619), 36-50 years (n=229,015), 51-65 years (n=205,899), and ≥66 years (n=284,224). Incidences of hypothyroidism and hyperthyroidism were assessed across age strata and within propensity-score–matched cohorts. Matching was performed 1:1 for age, race, ethnicity, and thyroid-stimulating immunoglobulin levels. Outcomes were assessed using Cox proportional hazards models and cumulative incidence estimates.",
        "Results": "Mean follow-up time was 5.7 years (SD: 4.4). Age was a significant predictor incident thyroid dysfunction. Cumulative incidence of hypothyroidism increased from 3.1% in women aged 20–35 to 7.9% in women aged ≥66. Conversely, cumulative incidence of hyperthyroidism decreased modestly, from 1.0% at ages 20–35 to 0.8% at ≥66 years of age. Menopause was associated with lower risk of both hyperthyroidism (HR 0.75, 95% CI 0.63–0.89) and hypothyroidism (HR 0.70, 95% CI 0.66–0.75). Prior pregnancy was not associated with hyperthyroidism (HR 0.92, 95% CI 0.63–1.36), but was significantly protective against hypothyroidism (HR 0.49, 95% CI 0.40–0.60). Abortion history showed no significant association with hyperthyroidism (HR 0.81, 95% CI 0.39–1.67) but was associated with a significantly lower risk of hypothyroidism (HR 0.53, 95% CI 0.36–0.78).",
        "Conclusions": "Menopause, parity, and abortion history were each associated with a reduced risk of hypothyroidism, and none were linked to increased risk of hyperthyroidism. These findings suggest that reproduction-related hormonal changes and adaptations may confer long-term protection against thyroid dysfunction. Prospective studies are warranted to validate these associations and elucidate underlying mechanisms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Female Reproductive History and Incident Thyroid Dysfunction: Findings From a Large Real-World Database Study</span>. <u>Daniel Uralov, MD</u>; Sarah Harrington, BA; Emma De Ravin, MD; Elizabeth Cottrill, MD. Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Female reproductive factors such as pregnancy-related hormonal shifts, postpartum immune rebound, and menopausal endocrine changes have been proposed to influence long-term thyroid function through interconnected hormonal and immunologic pathways. However, evidence from large, real-world populations remains limited. This study evaluated associations between menopause, parity, and abortion history with the development of hypothyroidism and hyperthyroidism in a multi-institutional electronic health-record network.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using the TriNetX Research Network. Female patients aged ≥20 years with biochemical euthyroidism—TSH 0.32–5.06 mIU/L with normal free T4—were included if they had no prior history of thyroid disease, thyroid surgery, thyroid-active medications, or pregnancy within one year of the index date. Four age groups were examined: 20–35 years (n=245,619), 36-50 years (n=229,015), 51-65 years (n=205,899), and ≥66 years (n=284,224). Incidences of hypothyroidism and hyperthyroidism were assessed across age strata and within propensity-score–matched cohorts. Matching was performed 1:1 for age, race, ethnicity, and thyroid-stimulating immunoglobulin levels. Outcomes were assessed using Cox proportional hazards models and cumulative incidence estimates.</p>\n\n<p><strong>Results: </strong>Mean follow-up time was 5.7 years (SD: 4.4). Age was a significant predictor incident thyroid dysfunction. Cumulative incidence of hypothyroidism increased from 3.1% in women aged 20–35 to 7.9% in women aged ≥66. Conversely, cumulative incidence of hyperthyroidism decreased modestly, from 1.0% at ages 20–35 to 0.8% at ≥66 years of age. Menopause was associated with lower risk of both hyperthyroidism (HR 0.75, 95% CI 0.63–0.89) and hypothyroidism (HR 0.70, 95% CI 0.66–0.75). Prior pregnancy was not associated with hyperthyroidism (HR 0.92, 95% CI 0.63–1.36), but was significantly protective against hypothyroidism (HR 0.49, 95% CI 0.40–0.60). Abortion history showed no significant association with hyperthyroidism (HR 0.81, 95% CI 0.39–1.67) but was associated with a significantly lower risk of hypothyroidism (HR 0.53, 95% CI 0.36–0.78).</p>\n\n<p><strong>Conclusions: </strong>Menopause, parity, and abortion history were each associated with a reduced risk of hypothyroidism, and none were linked to increased risk of hyperthyroidism. These findings suggest that reproduction-related hormonal changes and adaptations may confer long-term protection against thyroid dysfunction. Prospective studies are warranted to validate these associations and elucidate underlying mechanisms.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154577--></body></html>"
    },
    {
      "uid": "P116",
      "content_id": "153585",
      "abstract_number": "P116",
      "poster_number": "P116",
      "title": "Outcomes of Thyroid Cancer Surgery in a Community Hospital Setting",
      "summary": "Community hospitals can deliver specialized thyroid cancer care without compromising outcomes or patient safety. The only significant disparity observed was related to insurance status, which affected wait times and endocrinology follow-up; however, this indicates an issue in accessibility rather than quality",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153585",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashley C Mays, MD",
      "presenter": "Ashley C Mays, MD",
      "authors": "Mikalin Huckeba, BHS 1 ; Ghabrielle Almeida, BS 1 ; Brian Burkey, MD 2 ; Ashley C Mays, MD 2",
      "normalized_authors": [
        "Mikalin Huckeba, BHS",
        "Ghabrielle Almeida",
        "Brian Burkey",
        "Ashley C Mays"
      ],
      "affiliations": [
        "Florida State University College of Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "normalized_institutions": [
        "Florida State University College of Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mikalin Huckeba, BHS 1 ; Ghabrielle Almeida, BS 1 ; Brian Burkey, MD 2 ; Ashley C Mays, MD 2",
        "Affiliations": "1 Florida State University College of Medicine; 2 Cleveland Clinic Indian River Hospital",
        "Introduction": "Thyroid cancer is one of the most common head and neck malignancies and often requires highly specialized care traditionally concentrated in academic centers. However, an increasing number of surgeries are now performed in community hospitals, improving accessibility. Evaluating outcomes in these settings is essential to ensure that patients in the community receive care that meets the same quality standards as academic institutions.",
        "Methods": "A retrospective chart review of patients with pre or post operative diagnosis of thyroid cancer was performed at our regional community-based hospital system. Inclusion criteria were age ≥18 years and a postoperative, pathology-confirmed diagnosis of thyroid malignancy. Patients without long term follow up post op were excluded. Demographics, tumor pathology, surgery type, adjuvant therapy, and outcomes were recorded.",
        "Results": "A total of 357 patient records were analyzed. Of these, 66% were female (n = 235), 61% had private insurance (n = 217), and 35.5% had government insurance, defined as Medicaid or Medicare (n = 126). Thyroid cancer was confirmed pre-operatively in 79% of patients (n = 279); the remainder were discovered post-operatively. Pathology revealed 92% papillary carcinoma, 2.3% follicular, 2.0% NIFTP, 1.4% oncocytic, 0.8% medullary, and 0.6% anaplastic carcinoma. Overall, 38% of patients underwent hemithyroidectomy (n = 136). A total of 78 patients underwent neck dissection: 25 central, 20 lateral, and 29 combined central-lateral.Resection margins were positive in 10.9% of patients (n = 39).",
        "Abstract": "The mean time from biopsy of the thyroid to surgery was 127 days (SD = 149) and from ENT consult to surgery was 54 days (SD = 57; median = 35). Patients with government insurance had significantly longer time to treat: biopsy to surgery (p = 0.01) and consult to surgery (p = 0.03). Insurance status did not affect time to post-operative adjuvant therapy (p = 0.6). Endocrinology follow-up was documented in 88% of patients (n = 314) but differed significantly by insurance status (p = 0.01): 92% of privately insured and 82% of government-insured patients received post-operative endocrinology management. Among 2.3% of patients with recurrence (n=8), most were local (n=3) or regional (n=2). Recurrence was significantly associated with higher T stage (pT2–3 in 76%, p=0.004). All recurrences involved papillary thyroid carcinoma, and 75% were multifocal. Post-operative complications occurred in 6% of patients (n = 25), most commonly persistent hypoparathyroidism (4.48%, n = 16) and vocal cord paresis/paralysis (3.36%, n = 12). In comparison, two large-scale studies (n = 83,116) had average rates of 6.9% for hypoparathyroidism and 3.7% for vocal cord paralysis Recurrence and complication rates did not vary by demographics, insurance, or surgery type.",
        "Conclusion": "Community hospitals can deliver specialized thyroid cancer care without compromising outcomes or patient safety. The only significant disparity observed was related to insurance status, which affected wait times and endocrinology follow-up; however, this indicates an issue in accessibility rather than quality"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes of Thyroid Cancer Surgery in a Community Hospital Setting</span>. Mikalin Huckeba, BHS<sup>1</sup>; Ghabrielle Almeida, BS<sup>1</sup>; Brian Burkey, MD<sup>2</sup>; <u>Ashley C Mays, MD</u><sup>2</sup>. <sup>1</sup>Florida State University College of Medicine; <sup>2</sup>Cleveland Clinic Indian River Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Thyroid cancer is one of the most common head and neck malignancies and often requires highly specialized care traditionally concentrated in academic centers. However, an increasing number of surgeries are now performed in community hospitals, improving accessibility. Evaluating outcomes in these settings is essential to ensure that patients in the community receive care that meets the same quality standards as academic institutions.</p>\n\n<p><strong>Methods:</strong> A retrospective chart review of patients with pre or post operative diagnosis of thyroid cancer was performed at our regional community-based hospital system.  Inclusion criteria were age ≥18 years and a postoperative, pathology-confirmed diagnosis of thyroid malignancy. Patients without long term follow up post op were excluded. Demographics, tumor pathology, surgery type, adjuvant therapy, and outcomes were recorded.</p>\n\n<p><strong>Results: </strong>A total of 357 patient records were analyzed. Of these, 66% were female (n = 235), 61% had private insurance (n = 217), and 35.5% had government insurance, defined as Medicaid or Medicare (n = 126). Thyroid cancer was confirmed pre-operatively in 79% of patients (n = 279); the remainder were discovered post-operatively. Pathology revealed 92% papillary carcinoma, 2.3% follicular, 2.0% NIFTP, 1.4% oncocytic, 0.8% medullary, and 0.6% anaplastic carcinoma. Overall, 38% of patients underwent hemithyroidectomy (n = 136). A total of 78 patients underwent neck dissection: 25 central, 20 lateral, and 29 combined central-lateral.Resection margins were positive in 10.9% of patients (n = 39).</p>\n\n<p>The mean time from biopsy of the thyroid to surgery was 127 days (SD = 149) and from ENT consult to surgery was 54 days (SD = 57; median = 35). Patients with government insurance had significantly longer time to treat: biopsy to surgery (p = 0.01) and consult to surgery (p = 0.03). Insurance status did not affect time to post-operative adjuvant therapy (p = 0.6).</p>\n\n<p>Endocrinology follow-up was documented in 88% of patients (n = 314) but differed significantly by insurance status (p = 0.01): 92% of privately insured and 82% of government-insured patients received post-operative endocrinology management.</p>\n\n<p>Among 2.3% of patients with recurrence (n=8), most were local (n=3) or regional (n=2). Recurrence was significantly associated with higher T stage (pT2–3 in 76%, p=0.004). All recurrences involved papillary thyroid carcinoma, and 75% were multifocal. </p>\n\n<p>Post-operative complications  occurred in 6% of patients (n = 25), most commonly persistent hypoparathyroidism (4.48%, n = 16) and vocal cord paresis/paralysis (3.36%, n = 12). In comparison, two large-scale studies (n = 83,116) had average rates of 6.9% for hypoparathyroidism and 3.7% for vocal cord paralysis</p>\n\n<p>Recurrence and complication rates did not vary by demographics, insurance, or surgery type.</p>\n\n<p><strong>Conclusion:</strong> Community hospitals can deliver specialized thyroid cancer care without compromising outcomes or patient safety. The only significant disparity observed was related to insurance status, which affected wait times and endocrinology follow-up; however, this indicates an issue in accessibility rather than quality</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153585--></body></html>"
    },
    {
      "uid": "P117",
      "content_id": "153590",
      "abstract_number": "P117",
      "poster_number": "P117",
      "title": "Evaluating Guideline Adherent Care of Thyroid Cancer in the Community Hospital Setting",
      "summary": "In this community setting, most patients received thorough preoperative evaluation and high rates of guideline-recommended diagnostic testing. Adherence to NCCN treatment recommendations for papillary thyroid carcinoma did not differ by insurance type, race, or age. These findings suggest that socioeconomic and demographic factors did not influence whether patients received guideline-concordant care. Continued...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153590",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashley C Mays, MD",
      "presenter": "Ashley C Mays, MD",
      "authors": "Mikalin Huckeba, BHS 1 ; Ghabrielle Almeida, BS 1 ; Brian Burkey, MD 2 ; Ashley C Mays, MD 2",
      "normalized_authors": [
        "Mikalin Huckeba, BHS",
        "Ghabrielle Almeida",
        "Brian Burkey",
        "Ashley C Mays"
      ],
      "affiliations": [
        "Florida State University College of Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "normalized_institutions": [
        "Florida State University College of Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mikalin Huckeba, BHS 1 ; Ghabrielle Almeida, BS 1 ; Brian Burkey, MD 2 ; Ashley C Mays, MD 2",
        "Affiliations": "1 Florida State University College of Medicine; 2 Cleveland Clinic Indian River Hospital",
        "Introduction": "The treatment of thyroid cancer has historically been concentrated within academic centers, where patients have access to specialized surgery, multidisciplinary care, and advanced diagnostics. As thyroid cancer management increasingly expands into community hospitals, more patients can receive care locally. Thus, assessing the quality of care regarding adherence to treatment guidelines in this population is vital, particularly whether socioeconomic or demographic variables influence adherence to evidence based guidelines.",
        "Methods": "A retrospective chart review was conducted to identify all patients who underwent thyroid surgery from 2017-2025 in our regional community-based hospital system. Inclusion criteria were adults ≥18 years with postoperative pathology confirming thyroid carcinoma. Exclusion criteria included incomplete medical records. Data regarding demographics including race and demographics, preoperative work-up, tumor pathology, surgery type, adjuvant therapy and overall outcomes were logged. Adherence to NCCN guidelines for papillary thyroid carcinoma (PTC) was assessed for: extent of surgery performed (total vs hemi thyroidectomy) and neck dissection when indicated, and radioactive iodine (RAI) utilization when indicated. Due to limited sample size, treatment adherence data analysis was not performed for other cancer types.",
        "Results": "A total of 357 patients were identified with an average age of 54.6 years. Insurance status was predominantly private at 60.8% (n=217), with Medicaid/Medicare at 35.3% (n=126). Race was predominantly white at 69% (n=248).",
        "Abstract": "A total of 325 (91.0%) patients had a thyroid ultrasound prior to surgery; when indicated, 232 (78.1%) had reported TIRADS scores. Eighty seven percent received a biopsy, of which 283 (91.0%) were recommended per ultrasound. Of 163 patients whose biopsies met criteria for molecular testing, 143 (88%) received such testing. A total of 327 (91.6%) had PTC and 9 (2.5%) had PTC coexisting with another thyroid cancer. Based on NCCN guidelines 88 (26.2%) of those patients met criteria for total thyroidectomy while only 77 received such surgery. There were no statistically significant differences in compliance based on insurance type (p > 0.9), race (p = 0.5), or age (p = 0.3). NCCN guidelines stated 71 (21.1%) patients met criteria for post operative radioactive iodine ablation however only 55 were dispositioned. There were no statistically significant differences in compliance based on insurance type (p > 0.9), race (p > 0.7), or age (p >0,09).",
        "Conclusion": "In this community setting, most patients received thorough preoperative evaluation and high rates of guideline-recommended diagnostic testing. Adherence to NCCN treatment recommendations for papillary thyroid carcinoma did not differ by insurance type, race, or age. These findings suggest that socioeconomic and demographic factors did not influence whether patients received guideline-concordant care. Continued evaluation of recurrence, survival, and long-term outcomes will help clarify the effectiveness of community-based thyroid cancer management as treatment continues to expand beyond academic centers."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating Guideline Adherent Care of Thyroid Cancer in the Community Hospital Setting</span>. Mikalin Huckeba, BHS<sup>1</sup>; Ghabrielle Almeida, BS<sup>1</sup>; Brian Burkey, MD<sup>2</sup>; <u>Ashley C Mays, MD</u><sup>2</sup>. <sup>1</sup>Florida State University College of Medicine; <sup>2</sup>Cleveland Clinic Indian River Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The treatment of thyroid cancer has historically been concentrated within academic centers, where patients have access to specialized surgery, multidisciplinary care, and advanced diagnostics. As thyroid cancer management increasingly expands into community hospitals, more patients can receive care locally. Thus, assessing the quality of care regarding adherence to treatment guidelines in this population is vital, particularly whether socioeconomic or demographic variables influence adherence to evidence based guidelines.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted to identify all patients who underwent thyroid surgery from 2017-2025 in our regional community-based hospital system. Inclusion criteria were adults ≥18 years with postoperative pathology confirming thyroid carcinoma. Exclusion criteria included incomplete medical records. Data regarding demographics including race and demographics, preoperative work-up, tumor pathology, surgery type, adjuvant therapy and overall outcomes were logged. Adherence to NCCN guidelines for papillary thyroid carcinoma (PTC) was assessed for: extent of surgery performed (total vs hemi thyroidectomy) and neck dissection when indicated, and radioactive iodine (RAI) utilization when indicated. Due to limited sample size, treatment adherence data analysis was not performed for other cancer types. </p>\n\n<p><strong>Results: </strong>A total of 357 patients were identified with an average age of 54.6 years. Insurance status was predominantly private at 60.8% (n=217), with Medicaid/Medicare at 35.3% (n=126). Race was predominantly white at 69% (n=248).</p>\n\n<p>A total of 325 (91.0%) patients had a thyroid ultrasound prior to surgery; when indicated, 232 (78.1%) had reported TIRADS scores. Eighty seven percent received a biopsy, of which 283 (91.0%) were recommended per ultrasound. Of 163 patients whose biopsies met criteria for molecular testing, 143 (88%) received such testing.</p>\n\n<p>A total of 327 (91.6%) had PTC and 9 (2.5%) had PTC coexisting with another thyroid cancer. Based on NCCN guidelines 88 (26.2%) of those patients met criteria for total thyroidectomy while only 77 received such surgery. There were no statistically significant differences in compliance based on insurance type (p > 0.9), race (p = 0.5), or age (p = 0.3).</p>\n\n<p>NCCN guidelines stated 71 (21.1%) patients met criteria for post operative radioactive iodine ablation however only 55 were dispositioned. There were no statistically significant differences in compliance based on insurance type (p > 0.9), race (p > 0.7), or age (p >0,09).</p>\n\n<p><strong>Conclusion: </strong>In this community setting, most patients received thorough preoperative evaluation and high rates of guideline-recommended diagnostic testing. Adherence to NCCN treatment recommendations for papillary thyroid carcinoma did not differ by insurance type, race, or age. These findings suggest that socioeconomic and demographic factors did not influence whether patients received guideline-concordant care. Continued evaluation of recurrence, survival, and long-term outcomes will help clarify the effectiveness of community-based thyroid cancer management as treatment continues to expand beyond academic centers.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153590--></body></html>"
    },
    {
      "uid": "P118",
      "content_id": "153488",
      "abstract_number": "P118",
      "poster_number": "P118",
      "title": "Delayed metastasis of papillary thyroid cancer to the parotid gland - a case report",
      "summary": "Papillary Thyroid cancer is the most common thyroid carcinoma, and is typically characterised by slow growth, originating from follicular cells in the thyroid gland. Normally, papillary thyroid cancer primarily spreads to central and lateral cervical lymph nodes, but metastasis to the parotid gland is exceedingly rare. Here, we report a case of an 85-year-old female presenting with a previous diagnosis of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153488",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jiahao Ye",
      "presenter": "Jiahao Ye",
      "authors": "Jiahao Ye 1 ; Changxing Liu, MD 2",
      "normalized_authors": [
        "Jiahao Ye",
        "Changxing Liu"
      ],
      "affiliations": [
        "Department of Biology, University of California Los Angeles",
        "Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center"
      ],
      "normalized_institutions": [
        "Department of Biology, University of California Los Angeles",
        "Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 223,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jiahao Ye 1 ; Changxing Liu, MD 2",
        "Affiliations": "1 Department of Biology, University of California Los Angeles; 2 Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center",
        "Abstract": "Papillary Thyroid cancer is the most common thyroid carcinoma, and is typically characterised by slow growth, originating from follicular cells in the thyroid gland. Normally, papillary thyroid cancer primarily spreads to central and lateral cervical lymph nodes, but metastasis to the parotid gland is exceedingly rare. Here, we report a case of an 85-year-old female presenting with a previous diagnosis of papillary thyroid cancer that was treated with total thyroidectomy with central neck dissection. She developed a single lateral neck lymph node metastasis one year after the thyroid surgery. This was treated with neck dissection, level II-IV, with the result showing that 1 out of 35 lymph nodes was positive for metastatic papillary thyroid cancer. She had radioactive iodine treatment afterwards. Post-treatment whole-body scan did not show any other suspicious metastases. But 5 months later, she developed an ipsilateral parotid mass, for which she had fine needle aspiration done, and the result showed metastatic papillary thyroid cancer to the parotid gland. The mass grew rapidly inside her parotid gland, with extensive invasion into the overlying skin within 2 weeks, causing drainage of the gland. We performed a total parotidectomy with overlying skin resection and reconstruction with a lateral arm free flap. The surgical pathology showed aggressive metastatic papillary thyroid cancer with parotid gland invasion. Her whole-body scan did not show any other lesions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Delayed metastasis of papillary thyroid cancer to the parotid gland - a case report</span>. <u>Jiahao Ye</u><sup>1</sup>; Changxing Liu, MD<sup>2</sup>. <sup>1</sup>Department of Biology, University of California Los Angeles; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Papillary Thyroid cancer is the most common thyroid carcinoma, and is typically characterised by slow growth, originating from follicular cells in the thyroid gland. Normally, papillary thyroid cancer primarily spreads to central and lateral cervical lymph nodes, but metastasis to the parotid gland is exceedingly rare. Here, we report a case of an 85-year-old female presenting with a previous diagnosis of papillary thyroid cancer that was treated with total thyroidectomy with central neck dissection. She developed a single lateral neck lymph node metastasis one year after the thyroid surgery. This was treated with neck dissection, level II-IV, with the result showing that 1 out of 35 lymph nodes was positive for metastatic papillary thyroid cancer. She had radioactive iodine treatment afterwards. Post-treatment whole-body scan did not show any other suspicious metastases. But 5 months later, she developed an ipsilateral parotid mass, for which she had fine needle aspiration done, and the result showed metastatic papillary thyroid cancer to the parotid gland.  The mass grew rapidly inside her parotid gland, with extensive invasion into the overlying skin within 2 weeks, causing drainage of the gland. We performed a total parotidectomy with overlying skin resection and reconstruction with a lateral arm free flap. The surgical pathology showed aggressive metastatic papillary thyroid cancer with parotid gland invasion. Her whole-body scan did not show any other lesions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153488--></body></html>"
    },
    {
      "uid": "P119",
      "content_id": "154570",
      "abstract_number": "P119",
      "poster_number": "P119",
      "title": "Predictors and Outcomes of Hemithyroidectomy vs Total Thyroidectomy for Localized Medullary Thyroid Carcinoma: A Propensity Score Analysis",
      "summary": "In this national cohort of early-stage, localized medullary thyroid carcinoma, TT remained overwhelmingly common. HT was rare, but survival, which was very high, did not differ between HT and TT even on propensity score analysis. Interpretation is limited by sparse HT events, and the NCDB’s inability to distinguish hereditary from sporadic MTC, central versus lateral neck dissection and primary from completion...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154570",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beverly J Fu, BA, MA",
      "presenter": "Beverly J Fu, BA, MA",
      "authors": "Beverly J Fu, BA, MA 1 ; Michelle M Chen, MD, MHS 1 ; Katie K Hohenberger, MD 1 ; Ara A Chalian, MD 2 ; Lisa A Orloff, MD 1 ; Jake J Lee, MD, MSCI 1",
      "normalized_authors": [
        "Beverly J Fu, MA",
        "Michelle M Chen, MHS",
        "Katie K Hohenberger",
        "Ara A Chalian",
        "Lisa A Orloff",
        "Jake J Lee, MSCI"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
        "Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
        "Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154570/Fig(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154570/Fig(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154570"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 523,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Beverly J Fu, BA, MA 1 ; Michelle M Chen, MD, MHS 1 ; Katie K Hohenberger, MD 1 ; Ara A Chalian, MD 2 ; Lisa A Orloff, MD 1 ; Jake J Lee, MD, MSCI 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304; 2 Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104",
        "Objectives": "Per guidelines, standard of care for localized medullary thyroid carcinoma (MTC) entails total thyroidectomy (TT) with elective central neck dissection. However, recent studies support the judicious use of hemithyroidectomy (HT) for small, unilateral sporadic MTC without clinical nodal disease. National practice patterns and outcomes remain unclear. We aimed to characterize contemporary operative trends, identify demographic and clinical predictors of surgical extent, and evaluate whether there are survival differences between HT and TT using the National Cancer Database (NCDB).",
        "Methods": "We conducted a retrospective cohort study of patients diagnosed with MTC from 2015-2022 within the NCDB. Eligible cases included clinical T1-T2, N0, M0 tumors treated with HT or TT with curative intent. Patients with prior malignancy, incomplete staging, missing key variables, or non-definitive surgery were excluded. National trends in operative extent were evaluated over time, and predictors of HT were assessed using multivariable logistic regression. Overall survival was analyzed using Kaplan–Meier estimates, multivariable Cox proportional hazards models, and propensity score analysis using inverse probability of treatment weighting (IPTW).",
        "Results": "A total of 1,276 patients (median 58 years [SD 14.9], 885 [69.4%] female) with localized MTC met inclusion criteria. HT was uncommon (54 patients, 4.2%), whereas 1,222 (95.8%) underwent TT. At baseline, HT patients had higher comorbidity burden (p=0.020). Elective neck dissection was less common with HT (26/54, 48.1%) than TT (1024/1222, 83.8%) (difference -35.6%, 95% CI -49.1% to -22.2%), resulting in higher pNx rates (difference 30.1%, 95% CI 16.8% to 43.4%) and less nodal upstaging (difference -20.8%, 95% CI -28.3% to -13.4%). There was no difference in advanced pathologic T stage (pT3-T4) and tumor size between the two treatments.",
        "Abstract": "In multivariable analysis, higher income was associated with undergoing TT (aOR 0.27, 95% CI 0.08–0.90), whereas Charlson–Deyo ≥3 (aOR 3.56, 95% CI 1.00–12.68) and cT2 tumors (aOR 2.66, 95% CI 1.19–5.91) were associated with HT use. No meaningful associations were observed for age, sex, race, insurance, facility type, education level, tumor size, or year of diagnosis. HT survival remained 98.0% at 12, 24, and 60 months (one death) and TT survival was similarly high (12-month: 99.8%; 24-month: 99.1%; 60-month: 96.0%). After adjustment for age, cT stage, comorbidity, and pN stage, there were no differences in survival (aHR 0.27, 95% CI 0.03-2.12), with wide confidence intervals reflecting sparse events. To further reduce confounding using a propensity score model including age, income, comorbidity, cT stage, and pN status (LR χ²=45.05, p<0.001), HT was not associated with worse survival compared with TT (aHR 0.38; 95% CI 0.05–2.91).",
        "Conclusion": "In this national cohort of early-stage, localized medullary thyroid carcinoma, TT remained overwhelmingly common. HT was rare, but survival, which was very high, did not differ between HT and TT even on propensity score analysis. Interpretation is limited by sparse HT events, and the NCDB’s inability to distinguish hereditary from sporadic MTC, central versus lateral neck dissection and primary from completion thyroidectomy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors and Outcomes of Hemithyroidectomy vs Total Thyroidectomy for Localized Medullary Thyroid Carcinoma: A Propensity Score Analysis</span>. <u>Beverly J Fu, BA, MA</u><sup>1</sup>; Michelle M Chen, MD, MHS<sup>1</sup>; Katie K Hohenberger, MD<sup>1</sup>; Ara A Chalian, MD<sup>2</sup>; Lisa A Orloff, MD<sup>1</sup>; Jake J Lee, MD, MSCI<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304; <sup>2</sup>Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives</strong>: Per guidelines, standard of care for localized medullary thyroid carcinoma (MTC) entails total thyroidectomy (TT) with elective central neck dissection. However, recent studies support the judicious use of hemithyroidectomy (HT) for small, unilateral sporadic MTC without clinical nodal disease. National practice patterns and outcomes remain unclear. We aimed to characterize contemporary operative trends, identify demographic and clinical predictors of surgical extent, and evaluate whether there are survival differences between HT and TT using the National Cancer Database (NCDB).</p>\n\n<p><strong>Methods</strong>: We conducted a retrospective cohort study of patients diagnosed with MTC from 2015-2022 within the NCDB. Eligible cases included clinical T1-T2, N0, M0 tumors treated with HT or TT with curative intent. Patients with prior malignancy, incomplete staging, missing key variables, or non-definitive surgery were excluded. National trends in operative extent were evaluated over time, and predictors of HT were assessed using multivariable logistic regression. Overall survival was analyzed using Kaplan–Meier estimates, multivariable Cox proportional hazards models, and propensity score analysis using inverse probability of treatment weighting (IPTW).</p>\n\n<p><strong>Results</strong>: A total of 1,276 patients (median 58 years [SD 14.9], 885 [69.4%] female) with localized MTC met inclusion criteria. HT was uncommon (54 patients, 4.2%), whereas 1,222 (95.8%) underwent TT. At baseline, HT patients had higher comorbidity burden (p=0.020). Elective neck dissection was less common with HT (26/54, 48.1%) than TT (1024/1222, 83.8%) (difference -35.6%, 95% CI -49.1% to -22.2%), resulting in higher pNx rates (difference 30.1%, 95% CI 16.8% to 43.4%) and less nodal upstaging (difference -20.8%, 95% CI -28.3% to -13.4%). There was no difference in advanced pathologic T stage (pT3-T4) and tumor size between the two treatments.</p>\n\n<p>In multivariable analysis, higher income was associated with undergoing TT (aOR 0.27, 95% CI 0.08–0.90), whereas Charlson–Deyo ≥3 (aOR 3.56, 95% CI 1.00–12.68) and cT2 tumors (aOR 2.66, 95% CI 1.19–5.91) were associated with HT use. No meaningful associations were observed for age, sex, race, insurance, facility type, education level, tumor size, or year of diagnosis.</p>\n\n<p>HT survival remained 98.0% at 12, 24, and 60 months (one death) and TT survival was similarly high (12-month: 99.8%; 24-month: 99.1%; 60-month: 96.0%). After adjustment for age, cT stage, comorbidity, and pN stage, there were no differences in survival (aHR 0.27, 95% CI 0.03-2.12), with wide confidence intervals reflecting sparse events. To further reduce confounding using a propensity score model including age, income, comorbidity, cT stage, and pN status (LR χ²=45.05, p<0.001), HT was not associated with worse survival compared with TT (aHR 0.38; 95% CI 0.05–2.91).</p>\n\n<p><strong>Conclusion</strong>: In this national cohort of early-stage, localized medullary thyroid carcinoma, TT remained overwhelmingly common. HT was rare, but survival, which was very high, did not differ between HT and TT even on propensity score analysis. Interpretation is limited by sparse HT events, and the NCDB’s inability to distinguish hereditary from sporadic MTC, central versus lateral neck dissection and primary from completion thyroidectomy.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154570/Fig(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154570--></body></html>"
    },
    {
      "uid": "P120",
      "content_id": "152121",
      "abstract_number": "P120",
      "poster_number": "P120",
      "title": "Persistent Hyperparathyroidism After Parathyroidectomy: Predictors and Long-Term Outcomes in a Nationwide Cohort",
      "summary": "Persistent hyperparathyroidism occurred in 15% of patients following parathyroidectomy and was strongly associated with higher reoperation rates and long-term mortality. Patients requiring reoperation demonstrated particularly poor survival, suggesting a distinct high-risk phenotype. These findings underscore the importance of optimizing initial surgical cure through accurate localization, intraoperative PTH...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152121",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nir Tsur, MD",
      "presenter": "Nir Tsur, MD",
      "authors": "Nir Tsur, MD ; Nofar Edri; Tomer Kerman; Eyal Rubishtok; Gideon Bachar",
      "normalized_authors": [
        "Nir Tsur",
        "Nofar Edri",
        "Tomer Kerman",
        "Eyal Rubishtok",
        "Gideon Bachar"
      ],
      "affiliations": [
        "Rabin Medical center"
      ],
      "normalized_institutions": [
        "Rabin Medical center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 451,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions",
        "Clinical Significance"
      ],
      "sections": {
        "Authors": "Nir Tsur, MD ; Nofar Edri; Tomer Kerman; Eyal Rubishtok; Gideon Bachar",
        "Affiliations": "Rabin Medical center",
        "Background": "Parathyroidectomy is the only curative treatment for primary hyperparathyroidism (pHPT), yet a subset of patients experiences persistent disease—defined as biochemical failure to normalize calcium or parathyroid hormone (PTH) within six months postoperatively. The long-term consequences and predictors of persistence remain poorly defined in population-scale studies.",
        "Objective": "To identify clinical and biochemical predictors of persistent hyperparathyroidism after parathyroidectomy and to evaluate its long-term outcomes, including reoperation and mortality.",
        "Methods": "A retrospective nationwide cohort study was conducted using the Clalit Health Services database, encompassing all adult patients who underwent parathyroidectomy for pHPT between 2000–2023. Persistent disease was defined as postoperative hypercalcemia (>10.2 mg/dL) and/or elevated PTH (>40 pg/mL) beyond six months. Baseline variables included demographics, comorbidities (Charlson Comorbidity Index), socioeconomic status (SES), and pre- and postoperative biochemical values.",
        "Abstract": "Time-to-event analyses for reoperation and all-cause mortality were performed using Kaplan–Meier curves and Cox proportional hazards models adjusted for age, sex, and comorbidity burden. Preoperative and postoperative PTH levels were markedly elevated in the persistent group (252 vs 147 pg/mL pre-op; 322 vs 126 pg/mL post-op; both p<0.001). During a mean follow-up of 8.0 years, persistent pHPT was associated with significantly higher risks of reoperation (adjusted HR 2.33, 95% CI 1.50–3.63, p<0.001) and all-cause mortality (adjusted HR 1.60, 95% CI 1.32–1.93, p<0.001). Among those with persistent disease, 4.1% underwent reoperation, and mortality was substantially higher in this subgroup (45% vs 21%, p<0.001). Reoperation independently conferred a threefold increased mortality risk (adjusted HR 3.04, 95% CI 1.71–5.41, p<0.001).",
        "Results": "Among 4,638 patients, 716 (15.4%) had persistent pHPT. Compared with non-persistent cases, patients with persistence were more likely to be male (34% vs 25%, p<0.001), of Arab ethnicity (14% vs 9%, p<0.001), and from low SES backgrounds (16% vs 10%, p<0.001). They had higher rates of hypertension (60% vs 53%, p=0.001), cardiovascular disease (19% vs 15%, p=0.006), and higher BMI (29.3 ± 5.8 vs 28.2 ± 5.6 kg/m², p<0.001).",
        "Conclusions": "Persistent hyperparathyroidism occurred in 15% of patients following parathyroidectomy and was strongly associated with higher reoperation rates and long-term mortality. Patients requiring reoperation demonstrated particularly poor survival, suggesting a distinct high-risk phenotype. These findings underscore the importance of optimizing initial surgical cure through accurate localization, intraoperative PTH monitoring, and high-volume endocrine surgery, while ensuring long-term biochemical surveillance for early detection of persistence.",
        "Clinical Significance": "Persistent hyperparathyroidism is not merely a biochemical finding but a predictor of worse survival. Early identification of high-risk patients and avoidance of reoperation when feasible may improve long-term outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Persistent Hyperparathyroidism After Parathyroidectomy: Predictors and Long-Term Outcomes in a Nationwide Cohort</span>. <u>Nir Tsur, MD</u>; Nofar Edri; Tomer Kerman; Eyal Rubishtok; Gideon Bachar. Rabin Medical center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Parathyroidectomy is the only curative treatment for primary hyperparathyroidism (pHPT), yet a subset of patients experiences persistent disease—defined as biochemical failure to normalize calcium or parathyroid hormone (PTH) within six months postoperatively. The long-term consequences and predictors of persistence remain poorly defined in population-scale studies.</p>\n\n<p><strong>Objective: </strong>To identify clinical and biochemical predictors of persistent hyperparathyroidism after parathyroidectomy and to evaluate its long-term outcomes, including reoperation and mortality.</p>\n\n<p><strong>Methods: </strong>A retrospective nationwide cohort study was conducted using the Clalit Health Services database, encompassing all adult patients who underwent parathyroidectomy for pHPT between 2000–2023. Persistent disease was defined as postoperative hypercalcemia (>10.2 mg/dL) and/or elevated PTH (>40 pg/mL) beyond six months. Baseline variables included demographics, comorbidities (Charlson Comorbidity Index), socioeconomic status (SES), and pre- and postoperative biochemical values.</p>\n\n<p>Time-to-event analyses for reoperation and all-cause mortality were performed using Kaplan–Meier curves and Cox proportional hazards models adjusted for age, sex, and comorbidity burden.</p>\n\n<p><strong>Results: </strong>Among 4,638 patients, 716 (15.4%) had persistent pHPT. Compared with non-persistent cases, patients with persistence were more likely to be male (34% vs 25%, p<0.001), of Arab ethnicity (14% vs 9%, p<0.001), and from low SES backgrounds (16% vs 10%, p<0.001). They had higher rates of hypertension (60% vs 53%, p=0.001), cardiovascular disease (19% vs 15%, p=0.006), and higher BMI (29.3 ± 5.8 vs 28.2 ± 5.6 kg/m², p<0.001).</p>\n\n<p>Preoperative and postoperative PTH levels were markedly elevated in the persistent group (252 vs 147 pg/mL pre-op; 322 vs 126 pg/mL post-op; both p<0.001).</p>\n\n<p>During a mean follow-up of 8.0 years, persistent pHPT was associated with significantly higher risks of reoperation (adjusted HR 2.33, 95% CI 1.50–3.63, p<0.001) and all-cause mortality (adjusted HR 1.60, 95% CI 1.32–1.93, p<0.001). Among those with persistent disease, 4.1% underwent reoperation, and mortality was substantially higher in this subgroup (45% vs 21%, p<0.001). Reoperation independently conferred a threefold increased mortality risk (adjusted HR 3.04, 95% CI 1.71–5.41, p<0.001).</p>\n\n<p><strong>Conclusions: </strong>Persistent hyperparathyroidism occurred in 15% of patients following parathyroidectomy and was strongly associated with higher reoperation rates and long-term mortality. Patients requiring reoperation demonstrated particularly poor survival, suggesting a distinct high-risk phenotype. These findings underscore the importance of optimizing initial surgical cure through accurate localization, intraoperative PTH monitoring, and high-volume endocrine surgery, while ensuring long-term biochemical surveillance for early detection of persistence.</p>\n\n<p><strong>Clinical Significance: </strong>Persistent hyperparathyroidism is not merely a biochemical finding but a predictor of worse survival. Early identification of high-risk patients and avoidance of reoperation when feasible may improve long-term outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152121--></body></html>"
    },
    {
      "uid": "P121",
      "content_id": "155581",
      "abstract_number": "P121",
      "poster_number": "P121",
      "title": "Incidence of Thyroid Cancer Among Patients with Genetic Susceptibility to Breast and Ovarian Malignancies",
      "summary": "This study identified a higher risk of developing thyroid cancer in female patients with genetic susceptibility to malignant neoplasms of the breast and ovary. While an association has been identified, further research is needed to identify the specific role of individual mutations in the development and increased risk of thyroid cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155581",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Veenadhari Kollipara, BA",
      "presenter": "Veenadhari Kollipara, BA",
      "authors": "Oldrich Virag 1 ; Kunal A Koka, BS 1 ; Veenadhari Kollipara, BA 1 ; Neerav Goyal, MD, MPH, FACS 2 ; David Goldenberg, MD, FACS 2",
      "normalized_authors": [
        "Oldrich Virag",
        "Kunal A Koka",
        "Veenadhari Kollipara",
        "Neerav Goyal",
        "David Goldenberg"
      ],
      "affiliations": [
        "Penn State College of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center"
      ],
      "normalized_institutions": [
        "Penn State College of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 275,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Study Design",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Oldrich Virag 1 ; Kunal A Koka, BS 1 ; Veenadhari Kollipara, BA 1 ; Neerav Goyal, MD, MPH, FACS 2 ; David Goldenberg, MD, FACS 2",
        "Affiliations": "1 Penn State College of Medicine; 2 Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center",
        "Objectives": "Genetic susceptibility to cancer reflects an increased lifetime risk of malignancy due to inherited mutations. Thyroid cancer shares epidemiologic and hormonal risk factors with other female-predominant cancers, including breast and ovarian malignancies. Although hereditary predisposition is well established in breast and ovarian cancers, its association with thyroid cancer risk remains unclear. This study aimed to determine whether individuals with inherited susceptibility to breast or ovarian cancer have an increased risk of developing thyroid cancer.",
        "Study Design": "Retrospective cohort study.",
        "Methods": "The TriNetX Research Network was queried to identify female patients aged ≥18 years with or without a diagnosis of genetic susceptibility to breast or ovarian neoplasms, defined by ICD-10 codes Z15.01 and Z15.02. Inclusion was limited to patients with at least one healthcare encounter between 2010 and 2020 and a minimum of 5 years of follow-up. The incidence of thyroid gland malignancy was assessed, and statistical analyses were performed using the TriNetX analytics platform.",
        "Results": "We included 22,848 adult female patients with genetic susceptibility to cancer of the breast or ovary. When balanced for age at index, obesity, and the exclusion of known risk factors associated with thyroid malignancy, the genetically susceptible cohort had a 0.38% risk of thyroid malignancy, compared to a 0.17% risk for patients with no genetic susceptibility (relative risk: 2.29, 95% confidence interval: 1.54-3.40, P < .0001).",
        "Conclusions": "This study identified a higher risk of developing thyroid cancer in female patients with genetic susceptibility to malignant neoplasms of the breast and ovary. While an association has been identified, further research is needed to identify the specific role of individual mutations in the development and increased risk of thyroid cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence of Thyroid Cancer Among Patients with Genetic Susceptibility to Breast and Ovarian Malignancies</span>. Oldrich Virag<sup>1</sup>; Kunal A Koka, BS<sup>1</sup>; <u>Veenadhari Kollipara, BA</u><sup>1</sup>; Neerav Goyal, MD, MPH, FACS<sup>2</sup>; David Goldenberg, MD, FACS<sup>2</sup>. <sup>1</sup>Penn State College of Medicine; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> Genetic susceptibility to cancer reflects an increased lifetime risk of malignancy due to inherited mutations. Thyroid cancer shares epidemiologic and hormonal risk factors with other female-predominant cancers, including breast and ovarian malignancies. Although hereditary predisposition is well established in breast and ovarian cancers, its association with thyroid cancer risk remains unclear. This study aimed to determine whether individuals with inherited susceptibility to breast or ovarian cancer have an increased risk of developing thyroid cancer.</p>\n\n<p><strong>Study Design:</strong> Retrospective cohort study.</p>\n\n<p><strong>Methods:</strong> The TriNetX Research Network was queried to identify female patients aged ≥18 years with or without a diagnosis of genetic susceptibility to breast or ovarian neoplasms, defined by ICD-10 codes Z15.01 and Z15.02. Inclusion was limited to patients with at least one healthcare encounter between 2010 and 2020 and a minimum of 5 years of follow-up. The incidence of thyroid gland malignancy was assessed, and statistical analyses were performed using the TriNetX analytics platform.</p>\n\n<p><strong>Results:</strong> We included 22,848 adult female patients with genetic susceptibility to cancer of the breast or ovary. When balanced for age at index, obesity, and the exclusion of known risk factors associated with thyroid malignancy, the genetically susceptible cohort had a 0.38% risk of thyroid malignancy, compared to a 0.17% risk for patients with no genetic susceptibility (relative risk: 2.29, 95% confidence interval: 1.54-3.40, P < .0001).</p>\n\n<p><strong>Conclusions:</strong> This study identified a higher risk of developing thyroid cancer in female patients with genetic susceptibility to malignant neoplasms of the breast and ovary. While an association has been identified, further research is needed to identify the specific role of individual mutations in the development and increased risk of thyroid cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155581--></body></html>"
    },
    {
      "uid": "P122",
      "content_id": "153104",
      "abstract_number": "P122",
      "poster_number": "P122",
      "title": "Cost-Utility Analysis of Total vs Hemithyroidectomy for Low-Risk Papillary Thyroid Carcinoma: A Markov Model under 2025 CMS Assumptions",
      "summary": "Following the 2015 ATA shift in management guidelines for low-risk PTC, hemithyroidectomy remains the economically and clinically preferred approach for low-risk PTC less than 4 cm under 2025 CMS reimbursement conditions, supporting continued adoption of limited surgery in low-risk disease.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153104",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Evan de Joya, MD, MS",
      "presenter": "Evan de Joya, MD, MS",
      "authors": "Evan de Joya, MD, MS ; Daniel Xiao, BS; Kunal Jain, MD",
      "normalized_authors": [
        "Evan de Joya",
        "Daniel Xiao",
        "Kunal Jain"
      ],
      "affiliations": [
        "McGovern Medical School at UTHealth"
      ],
      "normalized_institutions": [
        "McGovern Medical School at UTHealth"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 308,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction (Background & Aim)",
        "Materials & Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Evan de Joya, MD, MS ; Daniel Xiao, BS; Kunal Jain, MD",
        "Affiliations": "McGovern Medical School at UTHealth",
        "Introduction (Background & Aim)": "In 2015, the American Thyroid Association (ATA) guidelines redefined surgical management of papillary thyroid carcinoma (PTC), recommending hemithyroidectomy (HT) as sufficient for tumors <4 cm without extrathyroidal extension or nodal disease. The change in guidelines has reduced routine upfront total thyroidectomy (TT), prompting questions about long-term cost-effectiveness. This study modeled the lifetime economic and quality-of-life tradeoffs between TT and HT for low-risk PTC under 2025 Centers for Medicare & Medicaid Services (CMS) payment assumptions.",
        "Materials & Methods": "A multi-state Markov model with a 40-year time horizon was developed in TreeAgePro 2025 with costs and utilities discounted at 3%. Costs were estimated from the payor perspective using CMS 2025 physician and facility payments. Transition probabilities were derived from the ATA-cited series and contemporary meta-analyses. TT assumed higher complication rates but lower recurrence. Health utility values were obtained from published quality-of-life studies. Outcomes included total discounted costs, QALYs, and the incremental cost-effectiveness ratio (ICER). Cost-effectiveness was determined by a willingness-to-pay threshold of $50,000/QALY. Probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations.",
        "Results": "Total thyroidectomy had an incremental benefit of 1.09 QALYs at an incremental cost of $68,833.30 compared to hemithyroidectomy, yielding an ICER of $63,334.20/QALY. Because this ICER is greater than our willingness-to-pay threshold of $50,000/QALY, hemithyroidectomy appears to be the cost-effective option for the treatment of low-risk papillary thyroid carcinoma less than 4 cm. Probabilistic sensitivity analysis reported hemithyroidectomy as the cost-effective strategy in 67.89% of Monte-Carlo simulations.",
        "Conclusions": "Following the 2015 ATA shift in management guidelines for low-risk PTC, hemithyroidectomy remains the economically and clinically preferred approach for low-risk PTC less than 4 cm under 2025 CMS reimbursement conditions, supporting continued adoption of limited surgery in low-risk disease.",
        "Abstract": "Haugen BR et al. Thyroid. 2016. Van den Heede K et al. Endocrine. 2021. CMS Physician Fee Schedule Final Rule, CY 2025."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cost-Utility Analysis of Total vs Hemithyroidectomy for Low-Risk Papillary Thyroid Carcinoma: A Markov Model under 2025 CMS Assumptions</span>. <u>Evan de Joya, MD, MS</u>; Daniel Xiao, BS; Kunal Jain, MD. McGovern Medical School at UTHealth<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction (Background & Aim): </strong>In 2015, the American Thyroid Association (ATA) guidelines redefined surgical management of papillary thyroid carcinoma (PTC), recommending hemithyroidectomy (HT) as sufficient for tumors <4 cm without extrathyroidal extension or nodal disease. The change in guidelines has reduced routine upfront total thyroidectomy (TT), prompting questions about long-term cost-effectiveness. This study modeled the lifetime economic and quality-of-life tradeoffs between TT and HT for low-risk PTC under 2025 Centers for Medicare & Medicaid Services (CMS) payment assumptions. </p>\n\n<p><strong>Materials & Methods: </strong>A multi-state Markov model with a 40-year time horizon was developed in TreeAgePro 2025 with costs and utilities discounted at 3%. Costs were estimated from the payor perspective using CMS 2025 physician and facility payments. Transition probabilities were derived from the ATA-cited series and contemporary meta-analyses. TT assumed higher complication rates but lower recurrence. Health utility values were obtained from published quality-of-life studies. Outcomes included total discounted costs, QALYs, and the incremental cost-effectiveness ratio (ICER). Cost-effectiveness was determined by a willingness-to-pay threshold of $50,000/QALY. Probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations. </p>\n\n<p><strong>Results: </strong>Total thyroidectomy had an incremental benefit of 1.09 QALYs at an incremental cost of $68,833.30 compared to hemithyroidectomy, yielding an ICER of $63,334.20/QALY. Because this ICER is greater than our willingness-to-pay threshold of $50,000/QALY, hemithyroidectomy appears to be the cost-effective option for the treatment of low-risk papillary thyroid carcinoma less than 4 cm. Probabilistic sensitivity analysis reported hemithyroidectomy as the cost-effective strategy in 67.89% of Monte-Carlo simulations. </p>\n\n<p><strong>Conclusions: </strong>Following the 2015 ATA shift in management guidelines for low-risk PTC, hemithyroidectomy remains the economically and clinically preferred approach for low-risk PTC less than 4 cm under 2025 CMS reimbursement conditions, supporting continued adoption of limited surgery in low-risk disease.</p>\n\n<p><strong>References </strong></p>\n\n<p>Haugen BR et al. Thyroid. 2016. </p>\n\n<p>Van den Heede K et al. Endocrine. 2021. </p>\n\n<p>CMS Physician Fee Schedule Final Rule, CY 2025. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153104--></body></html>"
    },
    {
      "uid": "P123",
      "content_id": "151971",
      "abstract_number": "P123",
      "poster_number": "P123",
      "title": "Thyroidectomy as an Aid to Anterior Cervical Discectomy and Fusion (ACDF): A Case Series",
      "summary": "Three total patients met inclusion criteria (two male, one female). The average age at the time of surgery was 55.3 years. Two patients underwent ACDF with neurosurgery and one with orthopedic surgery. Indication for ACDF was cervical disc protrusion with stenosis, with two patients undergoing C5-7 fusion and the third C4-7. For all patients, the indication for thyroidectomy was for obstructive goiter with...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151971",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Erica Choe, MD",
      "presenter": "Erica Choe, MD",
      "authors": "Erica Choe, MD 1 ; Phoebe Ato, BS 2 ; Hudson Liu, BS 2 ; Matthew Pierce, MD 3 ; Jonathan Giurintano, MD 1",
      "normalized_authors": [
        "Erica Choe",
        "Phoebe Ato",
        "Hudson Liu",
        "Matthew Pierce",
        "Jonathan Giurintano"
      ],
      "affiliations": [
        "MedStar Georgetown Department of Otolaryngology-Head and Neck Surgery",
        "Georgetown University School of Medicine",
        "MedStar Washington Hospital Center Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "MedStar Georgetown Department of Otolaryngology-Head and Neck Surgery",
        "Georgetown University School of Medicine",
        "MedStar Washington Hospital Center Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Erica Choe, MD 1 ; Phoebe Ato, BS 2 ; Hudson Liu, BS 2 ; Matthew Pierce, MD 3 ; Jonathan Giurintano, MD 1",
        "Affiliations": "1 MedStar Georgetown Department of Otolaryngology-Head and Neck Surgery; 2 Georgetown University School of Medicine; 3 MedStar Washington Hospital Center Department of Otolaryngology-Head and Neck Surgery",
        "Background": "Thyroidectomy as an aid in the approach for anterior cervical discectomy and fusion (ACDF) surgery is an uncommon indication for thyroid removal. While surgical complications of ACDF including dysphagia and dysphonia have been studied, no study to date has described outcomes in conjunction with concomitant thyroidectomy. This study aims to describe a series of three cases in which a thyroidectomy, either total or partial, was indicated to facilitate a safe ACDF procedure.",
        "Methods": "This was a retrospective case review of patients who underwent thyroidectomy at the time of ACDF between 2023 and 2025 at a single academic institution. Patient demographics, pre-operative and post-operative documentation and laboratory studies, pathology results, and surgical operative reports were reviewed.",
        "Results": "Three total patients met inclusion criteria (two male, one female). The average age at the time of surgery was 55.3 years. Two patients underwent ACDF with neurosurgery and one with orthopedic surgery. Indication for ACDF was cervical disc protrusion with stenosis, with two patients undergoing C5-7 fusion and the third C4-7. For all patients, the indication for thyroidectomy was for obstructive goiter with pre-operative symptoms varying from no symptoms to pill dysphagia and intermittent shortness of breath. Pre-operative symptoms varied, with one experiencing pill dysphagia, another intermittent shortness of breath, and the last was asymptomatic from a thyroid standpoint. No patient had undergone fine needle aspiration or other workup for the thyroid nodules prior to surgical intervention.",
        "Abstract": "Two patients underwent a total thyroidectomy while one underwent a lobectomy. The average size of thyroid lobe in the greatest superior-inferior dimension was 7.6cm (5-9cm). General endotracheal anesthesia with the use of a Neural Integrity Monitor EMG (NIMS) endotracheal tube was used for all three cases. At the end of the thyroidectomy portion of the case, the recurrent laryngeal nerve stimulated in all three cases. Immediate post-operative complication included hypocalcemia in one patient. No patient experienced vocal cord paralysis. Incidental finding of papillary thyroid carcinoma was noted in the final pathology for two patients. No patient had long-term complications of dysphagia or dysphonia.",
        "Discussion": "The approach for ACDF requires the exposure of the prevertebral region and medial retraction of the thyroid, esophagus, strap muscles, and trachea. The presence of anatomical variation including thyroid goiters can inhibit access to this prevertebral space in addition to increasing traction on the recurrent laryngeal nerve (RLN). This increases the risk of dysphagia and dysphonia, known complications following ACDF. In cases of thyroid goiter, concomitant thyroidectomy should be considered to allow for safer exposure and decreased traction. Thyroidectomy removal at the time of ACDF has been found to have decreased risk of dysphagia and dysphonia compared to ACDF in the setting of prior thyroidectomy. Dedicated studies on otolaryngology/co-surgeon involvement in ACDF approach are limited. Further studies are warranted to discuss the utility and complication rate of otolaryngology involvement in cases of re-operation and other anatomical variation where greater anatomical familiarity and expertise would be beneficial."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thyroidectomy as an Aid to Anterior Cervical Discectomy and Fusion (ACDF): A Case Series</span>. <u>Erica Choe, MD</u><sup>1</sup>; Phoebe Ato, BS<sup>2</sup>; Hudson Liu, BS<sup>2</sup>; Matthew Pierce, MD<sup>3</sup>; Jonathan Giurintano, MD<sup>1</sup>. <sup>1</sup>MedStar Georgetown Department of Otolaryngology-Head and Neck Surgery; <sup>2</sup>Georgetown University School of Medicine; <sup>3</sup>MedStar Washington Hospital Center Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Thyroidectomy as an aid in the approach for anterior cervical discectomy and fusion (ACDF) surgery is an uncommon indication for thyroid removal. While surgical complications of ACDF including dysphagia and dysphonia have been studied, no study to date has described outcomes in conjunction with concomitant thyroidectomy. This study aims to describe a series of three cases in which a thyroidectomy, either total or partial, was indicated to facilitate a safe ACDF procedure. </p>\n\n<p><strong>Methods</strong>: This was a retrospective case review of patients who underwent thyroidectomy at the time of ACDF between 2023 and 2025 at a single academic institution. Patient demographics, pre-operative and post-operative documentation and laboratory studies, pathology results, and surgical operative reports were reviewed. </p>\n\n<p><strong>Results</strong>: Three total patients met inclusion criteria (two male, one female). The average age at the time of surgery was 55.3 years. Two patients underwent ACDF with neurosurgery and one with orthopedic surgery. Indication for ACDF was cervical disc protrusion with stenosis, with two patients undergoing C5-7 fusion and the third C4-7. For all patients, the indication for thyroidectomy was for obstructive goiter with pre-operative symptoms varying from no symptoms to pill dysphagia and intermittent shortness of breath. Pre-operative symptoms varied, with one experiencing pill dysphagia, another intermittent shortness of breath, and the last was asymptomatic from a thyroid standpoint. No patient had undergone fine needle aspiration or other workup for the thyroid nodules prior to surgical intervention. </p>\n\n<p>Two patients underwent a total thyroidectomy while one underwent a lobectomy. The average size of thyroid lobe in the greatest superior-inferior dimension was 7.6cm (5-9cm). General endotracheal anesthesia with the use of a Neural Integrity Monitor EMG (NIMS) endotracheal tube was used for all three cases. At the end of the thyroidectomy portion of the case, the recurrent laryngeal nerve stimulated in all three cases. Immediate post-operative complication included hypocalcemia in one patient. No patient experienced vocal cord paralysis. Incidental finding of papillary thyroid carcinoma was noted in the final pathology for two patients. No patient had long-term complications of dysphagia or dysphonia. </p>\n\n<p><strong>Discussion</strong>: The approach for ACDF requires the exposure of the prevertebral region and medial retraction of the thyroid, esophagus, strap muscles, and trachea. The presence of anatomical variation including thyroid goiters can inhibit access to this prevertebral space in addition to increasing traction on the recurrent laryngeal nerve (RLN). This increases the risk of dysphagia and dysphonia, known complications following ACDF. In cases of thyroid goiter, concomitant thyroidectomy should be considered to allow for safer exposure and decreased traction. Thyroidectomy removal at the time of ACDF has been found to have decreased risk of dysphagia and dysphonia compared to ACDF in the setting of prior thyroidectomy. Dedicated studies on otolaryngology/co-surgeon involvement in ACDF approach are limited. Further studies are warranted to discuss the utility and complication rate of otolaryngology involvement in cases of re-operation and other anatomical variation where greater anatomical familiarity and expertise would be beneficial. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151971--></body></html>"
    },
    {
      "uid": "P124",
      "content_id": "151856",
      "abstract_number": "P124",
      "poster_number": "P124",
      "title": "Size Doesn't Matter - The Relationship Between Thyroid Gland Volume and the Development of Hypothyroidism after Hemithyroidectomy",
      "summary": "Neither the magnitude of resection nor the residual thyroid volume predicted the development of postoperative hypothyroidism. These findings indicate that determinants beyond structural or volumetric parameters—potentially including preoperative functional reserve, intrinsic glandular health, or individual endocrine adaptability—play a more pivotal role in maintaining postoperative thyroid homeostasis.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151856",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mayas M Arraf, MD",
      "presenter": "Mayas M Arraf, MD",
      "authors": "Mayas M Arraf, MD 1 ; Alaa Safia 1 ; Adi Sharabi-Nov 1 ; Moanes Awad 1 ; Yaniv Avraham 1 ; Ohad Ronen 2 ; Shlomo Merchavy 1",
      "normalized_authors": [
        "Mayas M Arraf",
        "Alaa Safia",
        "Adi Sharabi-Nov",
        "Moanes Awad",
        "Yaniv Avraham",
        "Ohad Ronen",
        "Shlomo Merchavy"
      ],
      "affiliations": [
        "Ziv Medical Center",
        "Galilee Medical Center"
      ],
      "normalized_institutions": [
        "Ziv Medical Center",
        "Galilee Medical Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 367,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Clinical Implications",
        "Keywords"
      ],
      "sections": {
        "Authors": "Mayas M Arraf, MD 1 ; Alaa Safia 1 ; Adi Sharabi-Nov 1 ; Moanes Awad 1 ; Yaniv Avraham 1 ; Ohad Ronen 2 ; Shlomo Merchavy 1",
        "Affiliations": "1 Ziv Medical Center; 2 Galilee Medical Center",
        "Background": "Hemithyroidectomy represents the standard surgical approach for unilateral benign thyroid disorders, including solitary nodules small malignant tumor and multinodular goiters confined to a single lobe. In recent years, hemithyroidectomy has become the most frequently performed thyroid operation, reflecting a global trend toward function-preserving and less extensive thyroid surgery. Despite its widespread adoption, the postoperative trajectory of thyroid function remains variable and difficult to predict. Post-hemithyroidectomy hypothyroidism has been reported in approximately 29% of patients; however, the relationship between thyroid gland volume, the extent of resection, and subsequent endocrine function remains controversial. The fundamental question persists—does preoperative or residual thyroid volume truly influence postoperative thyroidal function?",
        "Objective": "To determine whether the proportion of excised thyroid tissue or the residual lobe volume serves as a significant predictor of hypothyroidism following hemithyroidectomy.",
        "Methods": "A multicenter retrospective cohort study was conducted at Ziv Medical Center and Galilee Medical Center, including 134 adult patients who underwent hemithyroidectomy between 2017 and 2024. Preoperative and postoperative thyroid gland volumes, quantified via computed tomography (CT), were correlated with serum thyroid hormone profiles (T3, T4, and TSH) obtained preoperatively, and at one and six months postoperatively. Patients with pre-existing hypothyroidism or histopathological evidence of malignancy were excluded from analysis.",
        "Results": "Postoperative hypothyroidism occurred in 29.1% of patients, primarily within the first postoperative month. These patients exhibited significantly higher baseline TSH levels compared with euthyroid counterparts (3.0 vs. 1.4 μIU/mL, p<0.001). No statistically significant correlation was observed between postoperative thyroid function and total gland volume, resected lobe volume, or the residual-to-total gland volume ratio. At six months, only 12% of patients remained hypothyroid, suggesting partial restoration of functional capacity in the remaining thyroid tissue.",
        "Conclusions": "Neither the magnitude of resection nor the residual thyroid volume predicted the development of postoperative hypothyroidism. These findings indicate that determinants beyond structural or volumetric parameters—potentially including preoperative functional reserve, intrinsic glandular health, or individual endocrine adaptability—play a more pivotal role in maintaining postoperative thyroid homeostasis.",
        "Clinical Implications": "This study highlights the need to identify alternative physiological, biochemical, or molecular predictors of thyroid dysfunction following hemithyroidectomy, which may inform improved patient selection, risk stratification, and postoperative surveillance strategies.",
        "Keywords": "Hemithyroidectomy, postoperative hypothyroidism, thyroid volume, TSH, predictive factors, thyroid function recovery"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Size Doesn't Matter - The Relationship Between Thyroid Gland Volume and the Development of Hypothyroidism after Hemithyroidectomy</span>. <u>Mayas M Arraf, MD</u><sup>1</sup>; Alaa Safia<sup>1</sup>; Adi Sharabi-Nov<sup>1</sup>; Moanes Awad<sup>1</sup>; Yaniv Avraham<sup>1</sup>; Ohad Ronen<sup>2</sup>; Shlomo Merchavy<sup>1</sup>. <sup>1</sup>Ziv Medical Center; <sup>2</sup>Galilee Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Hemithyroidectomy represents the standard surgical approach for unilateral benign thyroid disorders, including solitary nodules small malignant tumor and multinodular goiters confined to a single lobe. In recent years, hemithyroidectomy has become the most frequently performed thyroid operation, reflecting a global trend toward function-preserving and less extensive thyroid surgery. Despite its widespread adoption, the postoperative trajectory of thyroid function remains variable and difficult to predict. Post-hemithyroidectomy hypothyroidism has been reported in approximately 29% of patients; however, the relationship between thyroid gland volume, the extent of resection, and subsequent endocrine function remains controversial. The fundamental question persists—does preoperative or residual thyroid volume truly influence postoperative thyroidal function?</p>\n\n<p><strong>Objective: </strong>To determine whether the proportion of excised thyroid tissue or the residual lobe volume serves as a significant predictor of hypothyroidism following hemithyroidectomy.</p>\n\n<p><strong>Methods: </strong>A multicenter retrospective cohort study was conducted at Ziv Medical Center and Galilee Medical Center, including 134 adult patients who underwent hemithyroidectomy between 2017 and 2024. Preoperative and postoperative thyroid gland volumes, quantified via computed tomography (CT), were correlated with serum thyroid hormone profiles (T3, T4, and TSH) obtained preoperatively, and at one and six months postoperatively. Patients with pre-existing hypothyroidism or histopathological evidence of malignancy were excluded from analysis.</p>\n\n<p><strong>Results: </strong>Postoperative hypothyroidism occurred in 29.1% of patients, primarily within the first postoperative month. These patients exhibited significantly higher baseline TSH levels compared with euthyroid counterparts (3.0 vs. 1.4 μIU/mL, p<0.001). No statistically significant correlation was observed between postoperative thyroid function and total gland volume, resected lobe volume, or the residual-to-total gland volume ratio. At six months, only 12% of patients remained hypothyroid, suggesting partial restoration of functional capacity in the remaining thyroid tissue.</p>\n\n<p><strong>Conclusions: </strong>Neither the magnitude of resection nor the residual thyroid volume predicted the development of postoperative hypothyroidism. These findings indicate that determinants beyond structural or volumetric parameters—potentially including preoperative functional reserve, intrinsic glandular health, or individual endocrine adaptability—play a more pivotal role in maintaining postoperative thyroid homeostasis.</p>\n\n<p><strong>Clinical Implications: </strong>This study highlights the need to identify alternative physiological, biochemical, or molecular predictors of thyroid dysfunction following hemithyroidectomy, which may inform improved patient selection, risk stratification, and postoperative surveillance strategies.</p>\n\n<p><strong>Keywords: </strong>Hemithyroidectomy, postoperative hypothyroidism, thyroid volume, TSH, predictive factors, thyroid function recovery</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151856--></body></html>"
    },
    {
      "uid": "P125",
      "content_id": "154756",
      "abstract_number": "P125",
      "poster_number": "P125",
      "title": "Ruptured parathyroid adenoma: micro case series and review of the literature",
      "summary": "These two cases illustrate the diagnostic complexity of ruptured parathyroid adenoma, particularly when presentations overlap with deep neck infection, malignancy, or complications of anticoagulation. Both patients were safely managed with vigilant airway monitoring and conservative acute measures while definitive endocrine and surgical management was arranged. When spontaneous neck ecchymosis and swelling are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154756",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sai Y Panidarapu, BSc, MBT",
      "presenter": "Sai Y Panidarapu, BSc, MBT",
      "authors": "Nick Sahlollbey; Robert Hart, MD; Sai Y Panidarapu, BSc, MBT",
      "normalized_authors": [
        "Nick Sahlollbey",
        "Robert Hart",
        "Sai Y Panidarapu, MBT"
      ],
      "affiliations": [
        "University of Calgary"
      ],
      "normalized_institutions": [
        "University of Calgary"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 476,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nick Sahlollbey; Robert Hart, MD; Sai Y Panidarapu, BSc, MBT",
        "Affiliations": "University of Calgary",
        "Background": "Ruptured parathyroid adenoma is an uncommon cause of spontaneous cervical or mediastinal hematoma that can mimic deep neck infection, thyroid pathology, or malignancy. Diagnosis is often delayed when primary hyperparathyroidism is not considered early. We report two recent cases from a Canadian tertiary head and neck centre and integrate them with a focused literature review to highlight key diagnostic, airway, and early management principles.",
        "Methods": "We retrospectively reviewed two women who presented within one month in 2025 with spontaneous neck bruising and swelling and were ultimately diagnosed with hemorrhage from a parathyroid adenoma. Clinical data and imaging were abstracted from the chart, and a targeted literature review of ruptured parathyroid adenoma was performed. Institutional and published cases were analyzed descriptively with attention to presentation, biochemical profile, imaging, airway interventions, and acute management.",
        "Results": "The first patient was a 65-year-old woman who presented with progressive anterior neck and chest ecchymosis, neck swelling, cough, and marked unintentional weight loss. CT neck and chest angiography showed a large heterogeneous mediastinal mass with inflammatory change, esophageal deviation, and tracheal displacement without active extravasation. MRI and interval imaging favoured a resolving hematoma centred on an enlarged right parathyroid gland. Biochemistry confirmed primary hyperparathyroidism with elevated parathyroid hormone and hypercalcemia. She was co-managed by otolaryngology, thoracic surgery, internal medicine, and gastroenterology, treated empirically for possible deep neck infection, and monitored closely; she remained airway stable and was discharged with plans for outpatient endocrine and surgical assessment.",
        "Abstract": "The second patient was a 70-year-old woman with metastatic colon cancer on apixaban for prior pulmonary embolism. She presented with right neck bruising and swelling extending to the upper sternum, sore throat, and exertional dyspnea but no stridor. CT neck demonstrated hemorrhage and rupture of a nodule lateral to the lower pole of the right thyroid with blood tracking into the parapharyngeal, retropharyngeal, and superior mediastinal spaces and leftward tracheal deviation without critical narrowing. Given concurrent hypercalcemia, this was felt most consistent with hemorrhage from a parathyroid adenoma rather than thyroid or metastatic disease. She underwent multidisciplinary evaluation by otolaryngology, ICU, internal medicine, and interventional radiology; there was no role for immediate surgery, and she was managed conservatively with airway observation, reversal of anticoagulation, and deferred surgical management.",
        "Conclusion": "These two cases illustrate the diagnostic complexity of ruptured parathyroid adenoma, particularly when presentations overlap with deep neck infection, malignancy, or complications of anticoagulation. Both patients were safely managed with vigilant airway monitoring and conservative acute measures while definitive endocrine and surgical management was arranged. When spontaneous neck ecchymosis and swelling are accompanied by hypercalcemia, early calcium and parathyroid hormone testing plus contrast-enhanced imaging are critical to avoid misdiagnosis, thyroid surgery, or overly aggressive emergent exploration. Our institutional experience, in conjunction with the existing literature, supports a management paradigm that prioritizes airway assessment and medical stabilization, with timing and extent of surgery tailored once the acute hemorrhagic phase has settled."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ruptured parathyroid adenoma: micro case series and review of the literature</span>. Nick Sahlollbey; Robert Hart, MD; <u>Sai Y Panidarapu, BSc, MBT</u>. University of Calgary<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Ruptured parathyroid adenoma is an uncommon cause of spontaneous cervical or mediastinal hematoma that can mimic deep neck infection, thyroid pathology, or malignancy. Diagnosis is often delayed when primary hyperparathyroidism is not considered early. We report two recent cases from a Canadian tertiary head and neck centre and integrate them with a focused literature review to highlight key diagnostic, airway, and early management principles.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed two women who presented within one month in 2025 with spontaneous neck bruising and swelling and were ultimately diagnosed with hemorrhage from a parathyroid adenoma. Clinical data and imaging were abstracted from the chart, and a targeted literature review of ruptured parathyroid adenoma was performed. Institutional and published cases were analyzed descriptively with attention to presentation, biochemical profile, imaging, airway interventions, and acute management.</p>\n\n<p><strong>Results: </strong>The first patient was a 65-year-old woman who presented with progressive anterior neck and chest ecchymosis, neck swelling, cough, and marked unintentional weight loss. CT neck and chest angiography showed a large heterogeneous mediastinal mass with inflammatory change, esophageal deviation, and tracheal displacement without active extravasation. MRI and interval imaging favoured a resolving hematoma centred on an enlarged right parathyroid gland. Biochemistry confirmed primary hyperparathyroidism with elevated parathyroid hormone and hypercalcemia. She was co-managed by otolaryngology, thoracic surgery, internal medicine, and gastroenterology, treated empirically for possible deep neck infection, and monitored closely; she remained airway stable and was discharged with plans for outpatient endocrine and surgical assessment.</p>\n\n<p>The second patient was a 70-year-old woman with metastatic colon cancer on apixaban for prior pulmonary embolism. She presented with right neck bruising and swelling extending to the upper sternum, sore throat, and exertional dyspnea but no stridor. CT neck demonstrated hemorrhage and rupture of a nodule lateral to the lower pole of the right thyroid with blood tracking into the parapharyngeal, retropharyngeal, and superior mediastinal spaces and leftward tracheal deviation without critical narrowing. Given concurrent hypercalcemia, this was felt most consistent with hemorrhage from a parathyroid adenoma rather than thyroid or metastatic disease. She underwent multidisciplinary evaluation by otolaryngology, ICU, internal medicine, and interventional radiology; there was no role for immediate surgery, and she was managed conservatively with airway observation, reversal of anticoagulation, and deferred surgical management.</p>\n\n<p><strong>Conclusion: </strong>These two cases illustrate the diagnostic complexity of ruptured parathyroid adenoma, particularly when presentations overlap with deep neck infection, malignancy, or complications of anticoagulation. Both patients were safely managed with vigilant airway monitoring and conservative acute measures while definitive endocrine and surgical management was arranged. When spontaneous neck ecchymosis and swelling are accompanied by hypercalcemia, early calcium and parathyroid hormone testing plus contrast-enhanced imaging are critical to avoid misdiagnosis, thyroid surgery, or overly aggressive emergent exploration. Our institutional experience, in conjunction with the existing literature, supports a management paradigm that prioritizes airway assessment and medical stabilization, with timing and extent of surgery tailored once the acute hemorrhagic phase has settled.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154756--></body></html>"
    },
    {
      "uid": "P126",
      "content_id": "154365",
      "abstract_number": "P126",
      "poster_number": "P126",
      "title": "Incidence of Thyroid Cancer In Those with Head and Neck Paragangliomas: A Retrospective Study",
      "summary": "Although the lifetime incidence of clinically apparent thyroid carcinoma is estimated to be approximately 1.2 %, autopsy studies have demonstrated a much higher rate of tumors <1 cm. In this single-institution cohort, the incidence of thyroid cancer among patients with head and neck paragangliomas was 3.2%, with most cases being follicular thyroid carcinomas, <1 cm in size, with frequent lymph node metastasis and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154365",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex Z Graboyes",
      "presenter": "Alex Z Graboyes",
      "authors": "Alex Z Graboyes 1 ; Debbie Cohen, MD 2 ; Nikolina Dioufa, MD, PhD 3 ; Christopher Rassekh, MD 1 ; Yonghong Huan, MD 1",
      "normalized_authors": [
        "Alex Z Graboyes",
        "Debbie Cohen",
        "Nikolina Dioufa",
        "Christopher Rassekh",
        "Yonghong Huan"
      ],
      "affiliations": [
        "1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA",
        "2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA",
        "3 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA",
        "2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA",
        "3 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alex Z Graboyes 1 ; Debbie Cohen, MD 2 ; Nikolina Dioufa, MD, PhD 3 ; Christopher Rassekh, MD 1 ; Yonghong Huan, MD 1",
        "Affiliations": "1 1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA; 2 2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA; 3 3 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA",
        "Background": "Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors with a high prevalence of germline mutations, most commonly in SDHx genes, and a propensity for multifocality and syndromic associations. An association with thyroid cancer (TC), specifically papillary thyroid carcinoma, has been proposed but only explored in two studies, with only isolated cases being reported, and only in patients with SDHx genetic alterations. These associations have been described in those with SDHB and SDHD mutations specifically.",
        "Methods": "Single-institution retrospective cohort study of all patients with HNPGL cared for between 2008-2025. Demographic, clinical and genetic data were abstracted from the electronic medical record. Descriptive statistics were performed.",
        "Results": "Among the cohort of 222 patients diagnosed with HNPGLS at our institution from 2008 to 2025, 7 had a concurrent diagnosis of TC (3.2%). All patients underwent germline genetic testing had pathological confirmation of both their TC and HNPGL. Among the cohort, 5 patients had single paraganglioma - two carotid body tumors (CBTs), one tympanic paraganglioma, one intrathyroidal paraganglioma, and one atypical lesion arising from the cerebellopontine angle, extending into the jugular foramen. All had negative genetic testing. One patient had bilateral CBTs, with negative genetic testing. Lastly, one patient had a germline pathogenic variant in SDHB with multiple paragangliomas (CBT, jugular, vagal, and thyroidal). All 7 patients were diagnosed with papillary thyroid carcinomas (follicular -60%, classic subtype 20% and NOS 20%). All tumors were <1 cm in size (formerly called microcarcinomas), 50% were multifocal and up to 66.7% were metastatic to lymph nodes either at the time of surgery or on follow up. Four patients were diagnosed with TC first, two were diagnosed at roughly the same time as HNPGL diagnosis, and one was diagnosed at least one year after HNPGL diagnosis. The mean age for first thyroid cancer diagnosis was 42 years (26-50, standard deviation 8.34) and the mean age for first HNPGL diagnosis was 53 years (43-69, standard deviation 9.35). The median age of diagnosis was 47 years for both TC (interquartile range: 8) and HNPGLs (interquartile range: 11.5).",
        "Conclusions": "Although the lifetime incidence of clinically apparent thyroid carcinoma is estimated to be approximately 1.2 %, autopsy studies have demonstrated a much higher rate of tumors <1 cm. In this single-institution cohort, the incidence of thyroid cancer among patients with head and neck paragangliomas was 3.2%, with most cases being follicular thyroid carcinomas, <1 cm in size, with frequent lymph node metastasis and occurring independently of SDHx mutations, which is a finding conflicting with the proposed theory in the literature. These findings suggest that the association between these two rare entities may be due to enhanced detection or a yet-unrecognized low-penetrance susceptibility rather than a shared underlying predisposition and highlight the need for larger multi-institutional studies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence of Thyroid Cancer In Those with Head and Neck Paragangliomas: A Retrospective Study</span>. <u>Alex Z Graboyes</u><sup>1</sup>; Debbie Cohen, MD<sup>2</sup>; Nikolina Dioufa, MD, PhD<sup>3</sup>; Christopher Rassekh, MD<sup>1</sup>; Yonghong Huan, MD<sup>1</sup>. <sup>1</sup>1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA; <sup>2</sup>2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>3 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors with a high prevalence of germline mutations, most commonly in SDHx genes, and a propensity for multifocality and syndromic associations. An association with thyroid cancer (TC), specifically papillary thyroid carcinoma, has been proposed but only explored in two studies, with only isolated cases being reported, and only in patients with SDHx genetic alterations. These associations have been described in those with SDHB and SDHD mutations specifically.</p>\n\n<p><strong>Methods:</strong> Single-institution retrospective cohort study of all patients with HNPGL cared for between 2008-2025. Demographic, clinical and genetic data were abstracted from the electronic medical record. Descriptive statistics were performed.</p>\n\n<p><strong>Results: </strong>Among the cohort of 222 patients diagnosed with HNPGLS at our institution from 2008 to 2025, 7 had a concurrent diagnosis of TC (3.2%). All patients underwent germline genetic testing had pathological confirmation of both their TC and HNPGL. Among the cohort, 5 patients had single paraganglioma - two carotid body tumors (CBTs), one tympanic paraganglioma, one intrathyroidal paraganglioma, and one atypical lesion arising from the cerebellopontine angle, extending into the jugular foramen.   All had negative genetic testing. One patient had bilateral CBTs, with negative genetic testing. Lastly, one patient had a germline pathogenic variant in SDHB with multiple paragangliomas (CBT, jugular, vagal, and thyroidal). All 7 patients were diagnosed with papillary thyroid carcinomas (follicular -60%, classic subtype 20% and NOS 20%). All tumors were <1 cm in size (formerly called microcarcinomas), 50% were multifocal and up to 66.7% were metastatic to lymph nodes either at the time of surgery or on follow up. Four patients were diagnosed with TC first, two were diagnosed at roughly the same time as HNPGL diagnosis, and one was diagnosed at least one year after HNPGL diagnosis. The mean age for first thyroid cancer diagnosis was 42 years (26-50, standard deviation 8.34) and the mean age for first HNPGL diagnosis was 53 years (43-69, standard deviation 9.35). The median age of diagnosis was 47 years for both TC (interquartile range: 8) and HNPGLs (interquartile range: 11.5).</p>\n\n<p><strong>Conclusions: </strong>Although the lifetime incidence of clinically apparent thyroid carcinoma is estimated to be approximately 1.2 %, autopsy studies have demonstrated a much higher rate of tumors <1 cm. In this single-institution cohort, the incidence of thyroid cancer among patients with head and neck paragangliomas was 3.2%, with most cases being follicular thyroid carcinomas, <1 cm in size, with frequent lymph node metastasis and occurring independently of SDHx mutations, which is a finding conflicting with the proposed theory in the literature. These findings suggest that the association between these two rare entities may be due to enhanced detection or a yet-unrecognized low-penetrance susceptibility rather than a shared underlying predisposition and highlight the need for larger multi-institutional studies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154365--></body></html>"
    },
    {
      "uid": "P127",
      "content_id": "153416",
      "abstract_number": "P127",
      "poster_number": "P127",
      "title": "Safety and Efficacy of Bilateral Carotid Body Tumor Excision: A Retrospective Review of Patients Managed at Our Institution",
      "summary": "Bilateral surgical resection can be a relatively safe and effective treatment of bilateral CBTs. Our data and a review of the literature suggest that the conventional view on avoiding bilateral CBT surgery for the risk of BRF should be revisited. We propose that single-stage surgery should be avoided in all cases and that staged surgery at least six months apart is recommended to help minimize the risk of cranial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153416",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex Z Graboyes",
      "presenter": "Alex Z Graboyes",
      "authors": "Alex Z Graboyes 1 ; Maria Bonnani, NP 2 ; Alexander Fairman, MD 3 ; Debbie Cohen, MD 2 ; Yonghong Huan, MD 2 ; Christopher Rassekh, MD 1",
      "normalized_authors": [
        "Alex Z Graboyes",
        "Maria Bonnani, NP",
        "Alexander Fairman",
        "Debbie Cohen",
        "Yonghong Huan",
        "Christopher Rassekh"
      ],
      "affiliations": [
        "1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA",
        "2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA",
        "3 Vascular Surgery Division, Department of Surgery, University of Pennsylvania, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA",
        "2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA",
        "3 Vascular Surgery Division, Department of Surgery, University of Pennsylvania, Philadelphia, PA"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alex Z Graboyes 1 ; Maria Bonnani, NP 2 ; Alexander Fairman, MD 3 ; Debbie Cohen, MD 2 ; Yonghong Huan, MD 2 ; Christopher Rassekh, MD 1",
        "Affiliations": "1 1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA; 2 2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA; 3 3 Vascular Surgery Division, Department of Surgery, University of Pennsylvania, Philadelphia, PA",
        "Background": "Carotid body tumors (CBTs) are paragangliomas (PGLs) involving carotid body. Bilateral CBTs account for approximately 3–13% of all cases and are often associated with increased risk of familial syndromes and malignancy. The management of bilateral CBTs remains challenging without a well-established standard. Although surgical resection has been considered the gold standard, it carries significant perioperative risks of neurovascular complications including baroreceptor failure (BRF), especially in bilateral CBTs. Thus, active surveillance and radiation are often used in the management of bilateral CBTs while surgery being avoided for risk of neurovascular complications including BRF.",
        "Methods": "A retrospective review was performed to examine the risks of surgical resection of bilateral CBTs based on a cohort of patients evaluated at our institution from 2007-2025 with head and neck PGLs diagnosed as early as 1974, to 2025.",
        "Results": "Among 30 patients identified with bilateral CBTs, 8 (26.6%) underwent bilateral surgical resection. Of the 8 with bilateral surgical resection, 5 had synchronous bilateral CBTs while 3 had metachronous bilateral CBTs. Those with metachronous CBTs, the mean interval between the first and second CBT diagnosis was 13.6 years (range 4-23 years). Only 1 patient had single-stage resection, 7 had two-stage resection. The 1 patient who had single-stage resection required vascular reconstruction and suffered vagal nerve injury with evidence of BRF. Among the 7 with two-stage resection, 3 had perioperative complications during the first resection while only 1 had perioperative complications during the second resection. During the first resection, 2 patients required vascular reconstruction and suffered vagal nerve injury resulting in dysphonia and dysphagia. During the second resection, only 1 patient developed BRF which was transient and required no long-term treatment. One patient also developed a mandibular nerve palsy, which resolved. The mean age at the first surgery was 33.7 years. The mean age at the second surgery was 39.9 years. 7 patients had positive genetic testing with 6 SDHD and 1 SDHB mutations, while one had negative testing. Additional PGLs as well as recurrence and/or metastasis were common in this cohort; 5 had additional PGLs, 3 had recurrence and 4 had metastasis. The 4 cases with perioperative complications had resection done between 1984 and 2007 while the 4 cases without perioperative complications had resection done between 2007 and 2025, suggesting that advancement in surgical approach and patient selection may contribute to the improved outcomes.",
        "Conclusions": "Bilateral surgical resection can be a relatively safe and effective treatment of bilateral CBTs. Our data and a review of the literature suggest that the conventional view on avoiding bilateral CBT surgery for the risk of BRF should be revisited. We propose that single-stage surgery should be avoided in all cases and that staged surgery at least six months apart is recommended to help minimize the risk of cranial nerve dysfunction and BRF. Multidisciplinary evaluation and individualized surgical planning, based on the tumor size and location as well as the characteristics of each patient are essential in optimizing the safety and long-term outcomes of surgical resection of bilateral CBTs."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Safety and Efficacy of Bilateral Carotid Body Tumor Excision: A Retrospective Review of Patients Managed at Our Institution</span>. <u>Alex Z Graboyes</u><sup>1</sup>; Maria Bonnani, NP<sup>2</sup>; Alexander Fairman, MD<sup>3</sup>; Debbie Cohen, MD<sup>2</sup>; Yonghong Huan, MD<sup>2</sup>; Christopher Rassekh, MD<sup>1</sup>. <sup>1</sup>1 Department of Otorhinolaryngology, Head and Neck Surgery - University of Pennsylvania, Philadelphia, PA; <sup>2</sup>2 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>3 Vascular Surgery Division, Department of Surgery, University of Pennsylvania, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Carotid body tumors (CBTs) are paragangliomas (PGLs) involving carotid body. Bilateral CBTs account for approximately 3–13% of all cases and are often associated with increased risk of familial syndromes and malignancy. The management of bilateral CBTs remains challenging without a well-established standard. Although surgical resection has been considered the gold standard, it carries significant perioperative risks of neurovascular complications including baroreceptor failure (BRF), especially in bilateral CBTs. Thus, active surveillance and radiation are often used in the management of bilateral CBTs while surgery being avoided for risk of neurovascular complications including BRF.</p>\n\n<p><strong>Methods: </strong>A retrospective review was performed to examine the risks of surgical resection of bilateral CBTs based on a cohort of patients evaluated at our institution from 2007-2025 with head and neck PGLs diagnosed as early as 1974, to 2025.</p>\n\n<p><strong>Results:</strong> Among 30 patients identified with bilateral CBTs, 8 (26.6%) underwent bilateral surgical resection. Of the 8 with bilateral surgical resection, 5 had synchronous bilateral CBTs while 3 had metachronous bilateral CBTs. Those with metachronous CBTs, the mean interval between the first and second CBT diagnosis was 13.6 years (range 4-23 years). Only 1 patient had single-stage resection, 7 had two-stage resection. The 1 patient who had single-stage resection required vascular reconstruction and suffered vagal nerve injury with evidence of BRF. Among the 7 with two-stage resection, 3 had perioperative complications during the first resection while only 1 had perioperative complications during the second resection. During the first resection, 2 patients required vascular reconstruction and suffered vagal nerve injury resulting in dysphonia and dysphagia. During the second resection, only 1 patient developed BRF which was transient and required no long-term treatment. One patient also developed a mandibular nerve palsy, which resolved. The mean age at the first surgery was 33.7 years. The mean age at the second surgery was 39.9 years. 7 patients had positive genetic testing with 6 SDHD and 1 SDHB mutations, while one had negative testing. Additional PGLs as well as recurrence and/or metastasis were common in this cohort; 5 had additional PGLs, 3 had recurrence and 4 had metastasis. The 4 cases with perioperative complications had resection done between 1984 and 2007 while the 4 cases without perioperative complications had resection done between 2007 and 2025, suggesting that advancement in surgical approach and patient selection may contribute to the improved outcomes.</p>\n\n<p><strong>Conclusions:</strong> Bilateral surgical resection can be a relatively safe and effective treatment of bilateral CBTs. Our data and a review of the literature suggest that the conventional view on avoiding bilateral CBT surgery for the risk of BRF should be revisited. We propose that single-stage surgery should be avoided in all cases and that staged surgery at least six months apart is recommended to help minimize the risk of cranial nerve dysfunction and BRF. Multidisciplinary evaluation and individualized surgical planning, based on the tumor size and location as well as the characteristics of each patient are essential in optimizing the safety and long-term outcomes of surgical resection of bilateral CBTs.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153416--></body></html>"
    },
    {
      "uid": "P128",
      "content_id": "153578",
      "abstract_number": "P128",
      "poster_number": "P128",
      "title": "NTRK3 Fusion–Positive Papillary Thyroid Carcinoma Treated with Neoadjuvant TRK Inhibition: A Case Report and Literature Review",
      "summary": "This case represents a rare instance of clinically aggressive PTC driven by an EML4::NTRK3 fusion and demonstrates the rationale for neoadjuvant TRK inhibition to downstage otherwise morbid, multi-compartment surgical resection. As alternate molecular drivers of PTC beyond BRAF v600e are increasingly recognized, early integrative genomic testing becomes essential for identifying patients who may benefit from a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153578",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Georges Daoud, MD",
      "presenter": "Georges Daoud, MD",
      "authors": "David Z Allen, MD; Georges Daoud, MD ; Merry Sebelik, MD, FACS, MAMSE; Kelly Magliocca, DDS, MPH; Meredith Lilly, MD",
      "normalized_authors": [
        "David Z Allen",
        "Georges Daoud",
        "Merry Sebelik, MAMSE",
        "Kelly Magliocca",
        "Meredith Lilly"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153578/rs_300x.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153578/rs_300x.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153578"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 344,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD; Georges Daoud, MD ; Merry Sebelik, MD, FACS, MAMSE; Kelly Magliocca, DDS, MPH; Meredith Lilly, MD",
        "Affiliations": "Emory University",
        "Background": "NTRK fusions represent an uncommon but actionable driver in follicular-derived thyroid carcinoma and can be upregulated in aggressive or radioiodine-refractory disease. Although TRK inhibitors produce high response rates across NTRK-rearranged malignancies, reports describing their neoadjuvant use in aggressive papillary thyroid carcinoma (PTC) remain limited.",
        "Methods": "We present the clinicopathologic, radiographic, and molecular features of a patient with locally advanced PTC harboring an EML4::NTRK3 fusion who was initiated on neoadjuvant larotrectinib following a poor response to VEGFR-targeted therapy. A focused literature review summarizes the current evidence regarding NTRK-rearranged thyroid cancer and the role of TRK inhibition.",
        "Results": "A 35-year-old woman with progressive dyspnea was found to have idiopathic subglottic stenosis and a large right thyroid mass with mediastinal extension, tracheal involvement, and metastatic cervical lymphadenopathy (cT4a). Fine-needle aspiration at an outside institution revealed papillary thyroid carcinoma (Bethesda VI). Core biopsy performed at our institution for comprehensive genomic profiling (Caris Life Sciences) to further characterize the tumor identified an EML4::NTRK3 kinase fusion. The patient demonstrated no radiographic response to lenvatinib and was transitioned to larotrectinib with the intent of neoadjuvant cytoreduction prior to total thyroidectomy, central and right lateral neck dissection, and potential tracheal resection with possible sternotomy for mediastinal disease. She will undergo interval imaging after three months of TRK inhibition to assess surgical resectability. Literature review indicates that NTRK fusions occur in less than 5% of adult differentiated thyroid carcinomas and are associated with high response rates (>60–70%) to larotrectinib or entrectinib, including in advanced or previously refractory disease.",
        "Conclusions": "This case represents a rare instance of clinically aggressive PTC driven by an EML4::NTRK3 fusion and demonstrates the rationale for neoadjuvant TRK inhibition to downstage otherwise morbid, multi-compartment surgical resection. As alternate molecular drivers of PTC beyond BRAF v600e are increasingly recognized, early integrative genomic testing becomes essential for identifying patients who may benefit from a targeted neoadjuvant approach.",
        "Abstract": "Figure 1. EML4::NTRK3 fusion papillary thyroid carcinoma with extensive follicular growth; Tumor arranged in microfollicles with colloid while demonstrating nuclear atypia, enlargement, elongation, nuclear membrane irregularity, and chromatin clearing [Hematoxylin and eosin, 300x]."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>NTRK3 Fusion–Positive Papillary Thyroid Carcinoma Treated with Neoadjuvant TRK Inhibition: A Case Report and Literature Review</span>. David Z Allen, MD; <u>Georges Daoud, MD</u>; Merry Sebelik, MD, FACS, MAMSE; Kelly Magliocca, DDS, MPH; Meredith Lilly, MD. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>NTRK fusions represent an uncommon but actionable driver in follicular-derived thyroid carcinoma and can be upregulated in aggressive or radioiodine-refractory disease. Although TRK inhibitors produce high response rates across NTRK-rearranged malignancies, reports describing their neoadjuvant use in aggressive papillary thyroid carcinoma (PTC) remain limited.</p>\n\n<p><strong>Methods: </strong>We present the clinicopathologic, radiographic, and molecular features of a patient with locally advanced PTC harboring an <em>EML4::NTRK3</em> fusion who was initiated on neoadjuvant larotrectinib following a poor response to VEGFR-targeted therapy. A focused literature review summarizes the current evidence regarding NTRK-rearranged thyroid cancer and the role of TRK inhibition.</p>\n\n<p><strong>Results: </strong>A 35-year-old woman with progressive dyspnea was found to have idiopathic subglottic stenosis and a large right thyroid mass with mediastinal extension, tracheal involvement, and metastatic cervical lymphadenopathy (cT4a). Fine-needle aspiration at an outside institution revealed papillary thyroid carcinoma (Bethesda VI). Core biopsy performed at our institution for comprehensive genomic profiling (Caris Life Sciences) to further characterize the tumor identified an <em>EML4::NTRK3</em> kinase fusion. The patient demonstrated no radiographic response to lenvatinib and was transitioned to larotrectinib with the intent of neoadjuvant cytoreduction prior to total thyroidectomy, central and right lateral neck dissection, and potential tracheal resection with possible sternotomy for mediastinal disease. She will undergo interval imaging after three months of TRK inhibition to assess surgical resectability. Literature review indicates that NTRK fusions occur in less than 5% of adult differentiated thyroid carcinomas and are associated with high response rates (>60–70%) to larotrectinib or entrectinib, including in advanced or previously refractory disease.</p>\n\n<p><strong>Conclusions: </strong>This case represents a rare instance of clinically aggressive PTC driven by an <em>EML4::NTRK3</em> fusion and demonstrates the rationale for neoadjuvant TRK inhibition to downstage otherwise morbid, multi-compartment surgical resection. As alternate molecular drivers of PTC beyond BRAF v600e are increasingly recognized, early integrative genomic testing becomes essential for identifying patients who may benefit from a targeted neoadjuvant approach.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153578/rs_300x.jpg' /></p>\n\n<p>Figure 1. EML4::NTRK3 fusion papillary thyroid carcinoma with extensive follicular growth; Tumor arranged in microfollicles with colloid while demonstrating nuclear atypia, enlargement, elongation, nuclear membrane irregularity, and chromatin clearing [Hematoxylin and eosin, 300x].</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153578--></body></html>"
    },
    {
      "uid": "P129",
      "content_id": "154001",
      "abstract_number": "P129",
      "poster_number": "P129",
      "title": "Malignant tracheoesophageal fistula after laryngopharyngectomy for BRAF-mutated poorly differentiated thyroid carcinoma with circumferential esophageal involvement",
      "summary": "This case illustrates the diagnostic delay and therapeutic complexity of locally advanced PDTC and highlights esophageal stenting as a temporizing but clinically meaningful option for malignant tracheoesophageal fistula after laryngopharyngectomy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154001",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kasey Bowyer",
      "presenter": "Kasey Bowyer",
      "authors": "Kasey Bowyer 1 ; Alice Lin, MD, FACS 2",
      "normalized_authors": [
        "Kasey Bowyer",
        "Alice Lin"
      ],
      "affiliations": [
        "Kaiser Permanente Bernard J. Tyson School of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group"
      ],
      "normalized_institutions": [
        "Kaiser Permanente Bernard J. Tyson School of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 329,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kasey Bowyer 1 ; Alice Lin, MD, FACS 2",
        "Affiliations": "1 Kaiser Permanente Bernard J. Tyson School of Medicine; 2 Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group",
        "Background": "Poorly differentiated thyroid carcinoma (PDTC) arising in the retropharyngeal esophagus presents substantial diagnostic and therapeutic challenges. These tumors are difficult to treat and often require multimodal therapy including complex airway and esophageal surgery. Recurrence after surgery is common, and while targeted and immunotherapies may provide disease control, they also carry risks, such as tracheoesophageal fistula, that can be life-threatening and difficult to manage.",
        "Methods": "We report the clinical course of a woman with BRAF-mutated PDTC with circumferential involvement of the post-cricoid esophagus who failed chemoradiation, received neoadjuvant targeted therapy, and underwent laryngopharyngectomy with free flap reconstruction. Subsequent post surgical recurrence was treated with immunotherapy and dabrafenib/trametinib. The development and management of a large tracheoesophageal fistula, including endoscopic esophageal stenting after laryngopharyngectomy, are described.",
        "Results": "After months of globus sensation and progressive dysphagia with initially negative evaluations in a woman in her late 60s, imaging revealed a retrotracheal mass with circumferential involvement of the esophagus. Core biopsy confirmed BRAF-mutated PDTC, leading to jejunostomy tube placement. After initial systemic therapy and refusal of primary surgery, the patient enrolled in a clinical trial for concurrent chemoradiation, achieving transient symptomatic improvement followed by rapid regrowth of the cancer. Neoadjuvant dabrafenib/trametinib was given followed by laryngopharyngectomy, bilateral neck dissection, and anterolateral thigh tubed free flap reconstruction when cricoid and tracheal shaves proved positive for PDTC. She developed an early carotid sheath recurrence that was managed with radical neck dissection and resumption of adjuvant dabrafenib/trametinib and immunotherapy.",
        "Abstract": "Subsequently, the patient developed a progressively enlarging tracheoesophageal fistula with aspiration through the laryngectomy stoma. Local measures and tracheoesophageal prostheses failed. Operative assessment showed a 20-mm proximal esophageal defect. Endoscopic esophageal stenting immediately eliminated leakage and aspiration and allowed tube feeds for several weeks until new, distal traceoesophageal fistulas formed at the stent edge, necessitating stent removal.",
        "Conclusion": "This case illustrates the diagnostic delay and therapeutic complexity of locally advanced PDTC and highlights esophageal stenting as a temporizing but clinically meaningful option for malignant tracheoesophageal fistula after laryngopharyngectomy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Malignant tracheoesophageal fistula after laryngopharyngectomy for BRAF-mutated poorly differentiated thyroid carcinoma with circumferential esophageal involvement</span>. <u>Kasey Bowyer</u><sup>1</sup>; Alice Lin, MD, FACS<sup>2</sup>. <sup>1</sup>Kaiser Permanente Bernard J. Tyson School of Medicine; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Poorly differentiated thyroid carcinoma (PDTC) arising in the retropharyngeal esophagus presents substantial diagnostic and therapeutic challenges. These tumors are difficult to treat and often require multimodal therapy including complex airway and esophageal surgery.  Recurrence after surgery is common, and while targeted and immunotherapies may provide disease control, they also carry risks, such as tracheoesophageal fistula, that can be life-threatening and difficult to manage.</p>\n\n<p><strong>Methods:</strong> We report the clinical course of a woman with BRAF-mutated PDTC with circumferential involvement of the post-cricoid esophagus who failed chemoradiation, received neoadjuvant targeted therapy, and underwent laryngopharyngectomy with free flap reconstruction. Subsequent post surgical recurrence was treated with immunotherapy and dabrafenib/trametinib. The development and management of a large tracheoesophageal fistula, including endoscopic esophageal stenting after laryngopharyngectomy, are described.</p>\n\n<p><strong>Results:</strong> After months of globus sensation and progressive dysphagia with initially negative evaluations in a woman in her late 60s, imaging revealed a retrotracheal mass with circumferential involvement of the esophagus. Core biopsy confirmed BRAF-mutated PDTC, leading to jejunostomy tube placement. After initial systemic therapy and refusal of primary surgery, the patient enrolled in a clinical trial for concurrent chemoradiation, achieving transient symptomatic improvement followed by rapid regrowth of the cancer. Neoadjuvant dabrafenib/trametinib was given followed by laryngopharyngectomy, bilateral neck dissection, and anterolateral thigh tubed free flap reconstruction when cricoid and tracheal shaves proved positive for PDTC. She developed an early carotid sheath recurrence that was managed with radical neck dissection and resumption of adjuvant dabrafenib/trametinib and immunotherapy. </p>\n\n<p>Subsequently, the patient developed a progressively enlarging tracheoesophageal fistula with aspiration through the laryngectomy stoma. Local measures and tracheoesophageal prostheses failed. Operative assessment showed a 20-mm proximal esophageal defect. Endoscopic esophageal stenting immediately eliminated leakage and aspiration and allowed tube feeds for several weeks until new, distal traceoesophageal fistulas formed at the stent edge, necessitating stent removal.</p>\n\n<p><strong>Conclusion: </strong>This case illustrates the diagnostic delay and therapeutic complexity of locally advanced PDTC and highlights esophageal stenting as a temporizing but clinically meaningful option for malignant tracheoesophageal fistula after laryngopharyngectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154001--></body></html>"
    },
    {
      "uid": "P131",
      "content_id": "151928",
      "abstract_number": "P131",
      "poster_number": "P131",
      "title": "LONG TERM SURVIVAL OUTCOME OF PAEDIATRIC & ADOLESCENT PAPILLARY THYROID CANCER .",
      "summary": "Being a rare malignancy, paediatric and adolescent PTCs tend to behave differently from adult",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151928",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elizabeth M Iype, PhD",
      "presenter": "Elizabeth M Iype, PhD",
      "authors": "Elizabeth M Iype, PhD ; Ankur Walli, MCh",
      "normalized_authors": [
        "Elizabeth M Iype",
        "Ankur Walli, MCh"
      ],
      "affiliations": [
        "Regional cancer Centre"
      ],
      "normalized_institutions": [
        "Regional cancer Centre"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Aim",
        "Methodology",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Elizabeth M Iype, PhD ; Ankur Walli, MCh",
        "Affiliations": "Regional cancer Centre",
        "Introduction": "Thyroid cancer accounts for approximately 1%-3% of all childhood malignancies and 7% of all paediatric head and neck tumours. Although thyroid cancer is less common in paediatrics than adult patients, the incidence of paediatric thyroid cancer has increased gradually throughout the world, with an increase between 2% to 3.8% per year as per (SEER) database. Thyroid cancer has become the fifth most common cancer in children aged 0–14 years. There are important clinical , molecular , and pathological differences in papillary thyroid cancer among children compared to adults.This intriguing disease is characterised by advanced presentation, coupled with frequent lymph nodal metastases and often pulmonary metastases. Despite extensive disease at clinical presentation, children are much less likely to die from disease.Even patients with systemic metastasis develop persistent albeit stable disease following iodine therapy.Being an unusual disease, treatment recommendations come from small cohorts, multicentre retrospective reviews and extrapolations from adult studies and guidelines.. This Study aims to analyse 10 year survival outcome of paediatric and adolescent papillary thyroid cancer patients who underwent treatment at Regional Cancer Centre, Thiruvananthapuram",
        "Aim": "This study aims to analyse long term survival outcomes (DFS, OS) of paediatric and adolescent Papillary thyroid cancer.",
        "Methodology": "Retrospective analysis of patients treated for papillary thyroid cancer in the age less than 21 years, between the years 2004-2013 , at Regional Cancer Centre , Thiruvananthapuram, Kerala ,India.",
        "Results": "There were a total of 55 patients treated in a ten year period ( 2004-2013) with an M:F ratio of 3:1 with a median age of 18 years. Thirty Seven patients (67.27%) presented with isolated thyroidal swelling,two patients (3.63%) presented with isolated nodal swelling and 13 patients (23.63%) presented with thyroidal swelling and neck lymphadenopathy. Surgery was performed on 05 Patients at other hospitals and was subsequently referred to our centre and all of them underwent completion surgery. Among the pathological variant, Classical ,follicular and tall cell variant comprised 32.72%, 25.45% , 23.63% respectively.Rare histological variant like Insular, diffuse sclerosis and solid variant found in 5.45%,3.63% and 3.63% respectively. Nodal positivity -found in 49.09% of cases , out of which 33.33% were N1a disease, and 70.37% were N1b disease. Median follow up of the study cohort was 146 months. In this period 4 patients developed nodal recurrence and one patient developed systemic metastasis. The 5 and 10 year Disease free survival were found to be 94.5% and 92.7% respectively. 10 Year Overall Survival is 96.4%.",
        "Conclusions": "Being a rare malignancy, paediatric and adolescent PTCs tend to behave differently from adult",
        "Abstract": "PTC with a seemingly aggressive clinical presentation; however, they are associated with excellent survival outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>LONG  TERM  SURVIVAL OUTCOME  OF PAEDIATRIC & ADOLESCENT  PAPILLARY THYROID CANCER .</span>. <u>Elizabeth M Iype, PhD</u>; Ankur Walli, MCh. Regional cancer Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Thyroid cancer accounts for approximately 1%-3% of all childhood malignancies and 7% of all paediatric head and neck tumours. Although thyroid cancer is less common in paediatrics than adult patients, the incidence of paediatric thyroid cancer has increased gradually throughout the world, with an increase between 2% to 3.8% per year as per (SEER) database. Thyroid cancer has become the fifth most common cancer in children aged 0–14 years. There are important clinical , molecular , and pathological differences in papillary thyroid cancer among children compared to adults.This intriguing disease is characterised by advanced presentation, coupled with frequent lymph nodal metastases and often pulmonary metastases. Despite extensive disease at clinical presentation, children are much less likely to die from disease.Even patients with systemic metastasis develop persistent albeit stable disease following iodine therapy.Being an unusual disease, treatment recommendations come from small cohorts, multicentre retrospective reviews and extrapolations from adult studies and guidelines.. This Study aims to analyse 10 year survival outcome of paediatric and adolescent papillary thyroid cancer patients who underwent treatment at Regional Cancer Centre, Thiruvananthapuram</p>\n\n<p><strong>Aim: </strong>This study aims to analyse long term survival outcomes (DFS, OS) of paediatric and adolescent Papillary thyroid cancer.</p>\n\n<p><strong>Methodology:</strong> Retrospective analysis of patients treated for papillary thyroid cancer in the age less than 21 years, between the years 2004-2013 , at Regional Cancer Centre , Thiruvananthapuram, Kerala ,India.</p>\n\n<p><strong>Results: </strong>There were a total of 55 patients treated in a ten year period ( 2004-2013) with an M:F ratio of 3:1 with a median age of 18 years. Thirty Seven patients (67.27%) presented with isolated thyroidal swelling,two patients (3.63%) presented with isolated nodal swelling and 13 patients (23.63%) presented with thyroidal swelling and neck lymphadenopathy. Surgery was performed on 05 Patients at other hospitals and was subsequently referred to our centre and all of them underwent completion surgery. Among the pathological variant, Classical ,follicular and tall cell variant comprised 32.72%, 25.45% , 23.63% respectively.Rare histological variant like Insular, diffuse sclerosis and solid variant found in 5.45%,3.63% and 3.63% respectively. Nodal positivity -found in 49.09% of cases , out of which 33.33% were N1a disease, and 70.37% were N1b disease. Median follow up of the study cohort was 146 months. In this period 4 patients developed nodal recurrence and one patient developed systemic metastasis. The 5 and 10 year Disease free survival were found to be 94.5% and 92.7% respectively. 10 Year Overall Survival is 96.4%.</p>\n\n<p><strong>Conclusions: </strong>Being a rare malignancy, paediatric and adolescent PTCs tend to behave differently from adult</p>\n\n<p>PTC with a seemingly aggressive clinical presentation; however, they are associated with excellent survival outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151928--></body></html>"
    },
    {
      "uid": "P132",
      "content_id": "154311",
      "abstract_number": "P132",
      "poster_number": "P132",
      "title": "Refining Management of Indeterminate Thyroid Nodules: A Single Center Comparative Study Between Bethesda Categories III and IV",
      "summary": "No statistical differences were found between the two Bethesda categories studied in our cohort. These findings support conservative management for all indeterminate nodules and indicate that TA can be safely offered for symptomatic Bethesda IV nodules. The present study was limited in evaluating individual genetic mutations and surgical outcomes due to low sample size. However, future work should focus on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154311",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ainsley Kohler, BS",
      "presenter": "Ainsley Kohler, BS",
      "authors": "Ainsley Kohler, BS 1 ; Genevieve Spagnuolo, MD, MBS 2 ; Jagdish Dhingra, MD 3",
      "normalized_authors": [
        "Ainsley Kohler",
        "Genevieve Spagnuolo, MBS",
        "Jagdish Dhingra"
      ],
      "affiliations": [
        "Tufts University School of Medicine, Boston, MA, USA",
        "Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA",
        "Tufts University School of Medicine, Boston, MA, USA, Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA, ENT Specialists, Inc., Brockton, MA, USA"
      ],
      "normalized_institutions": [
        "Tufts University School of Medicine, Boston, MA, USA",
        "Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA",
        "Tufts University School of Medicine, Boston, MA, USA, Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA, ENT Specialists, Inc., Brockton, MA, USA"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 353,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ainsley Kohler, BS 1 ; Genevieve Spagnuolo, MD, MBS 2 ; Jagdish Dhingra, MD 3",
        "Affiliations": "1 Tufts University School of Medicine, Boston, MA, USA; 2 Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA; 3 Tufts University School of Medicine, Boston, MA, USA, Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA, ENT Specialists, Inc., Brockton, MA, USA",
        "Background": "Cytologically Indeterminate (Bethesda III and IV) thyroid nodules that are benign on Gene Sequencing Classifier (GSC) carry a malignancy risk of < 4% and can therefore be safely managed by observation alone. Larger or symptomatic nodules may require intervention such as thermal ablation (TA). Some clinicians advocate for the use of TA only in Bethesda III nodules. The goal of this study was to compare cytologic, ultrasonographic, and molecular differences between Bethesda III and IV nodules to determine if management, including threshold for TA, should differ.",
        "Methods": "A retrospective review was completed at a single, large, community-based otolaryngology practice with a dedicated ultrasound (US) clinic. Between January 1, 2017 and December 31, 2023, a total of 2234 nodules were investigated by US-guided fine needle aspiration (FNA). Of these nodules, a total of 310 nodules (13.9%) were classified as Indeterminate, including 243 (78.4%) Bethesda III and 67 (21.6%) Bethesda IV nodules. Patient demographics, TI-RADS classification, Afirma Genomic Sequencing Classifier (GSC) molecular testing results, and surgical outcomes were compared between Bethesda III and IV nodules. Molecular results were analyzed by mutation frequency and mutation category. Comparative analyses were performed using chi-square or Fisher’s exact testing, as appropriate, with statistical significance defined as p < 0.05.",
        "Results": "Cytologic status (benign or suspicious) was significantly different between Bethesda III and IV nodules, with Bethesda IV nodules having a higher number of suspicious nodules (χ² = 24.0, df = 1, p < 0.001). However, there were no statistically significant differences between Bethesda III and IV nodules across TI-RADS scoring (χ² = 1.97, df = 3, p = 0.58), mutation frequency (χ² = 0.267, df = 1, p = 0.61), or adverse surgical outcomes (χ² = 1.33, df = 3, p = 0.25).",
        "Conclusions": "No statistical differences were found between the two Bethesda categories studied in our cohort. These findings support conservative management for all indeterminate nodules and indicate that TA can be safely offered for symptomatic Bethesda IV nodules. The present study was limited in evaluating individual genetic mutations and surgical outcomes due to low sample size. However, future work should focus on additional methods of stratifying indeterminate nodules through these methods."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Refining Management of Indeterminate Thyroid Nodules: A Single Center Comparative Study Between Bethesda Categories III and IV</span>. <u>Ainsley Kohler, BS</u><sup>1</sup>; Genevieve Spagnuolo, MD, MBS<sup>2</sup>; Jagdish Dhingra, MD<sup>3</sup>. <sup>1</sup>Tufts University School of Medicine, Boston, MA, USA; <sup>2</sup>Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA; <sup>3</sup>Tufts University School of Medicine, Boston, MA, USA, Department of Otolaryngology—Head and Neck Surgery, Tufts Medical Center, Boston, MA, ENT Specialists, Inc., Brockton, MA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Cytologically Indeterminate (Bethesda III and IV) thyroid nodules that are benign on Gene Sequencing Classifier (GSC) carry a malignancy risk of < 4% and can therefore be safely managed by observation alone. Larger or symptomatic nodules may require intervention such as thermal ablation (TA). Some clinicians advocate for the use of TA only in Bethesda III nodules. The goal of this study was to compare cytologic, ultrasonographic, and molecular differences between Bethesda III and IV nodules to determine if management, including threshold for TA, should differ.</p>\n\n<p><strong>Methods:</strong> A retrospective review was completed at a single, large, community-based otolaryngology practice with a dedicated ultrasound (US) clinic. Between January 1, 2017 and December 31, 2023, a total of 2234 nodules were investigated by US-guided fine needle aspiration (FNA). Of these nodules, a total of 310 nodules (13.9%) were classified as Indeterminate, including 243 (78.4%) Bethesda III and 67 (21.6%) Bethesda IV nodules. Patient demographics, TI-RADS classification, Afirma Genomic Sequencing Classifier (GSC) molecular testing results, and surgical outcomes were compared between Bethesda III and IV nodules. Molecular results were analyzed by mutation frequency and mutation category. Comparative analyses were performed using chi-square or Fisher’s exact testing, as appropriate, with statistical significance defined as p < 0.05.</p>\n\n<p><strong>Results:</strong> Cytologic status (benign or suspicious) was significantly different between Bethesda III and IV nodules, with Bethesda IV nodules having a higher number of suspicious nodules (χ² = 24.0, df = 1, p < 0.001). However, there were no statistically significant differences between Bethesda III and IV nodules across TI-RADS scoring (χ² = 1.97, df = 3, p = 0.58), mutation frequency (χ² = 0.267, df = 1, p = 0.61), or adverse surgical outcomes (χ² = 1.33, df = 3, p = 0.25).</p>\n\n<p><strong>Conclusions:</strong> No statistical differences were found between the two Bethesda categories studied in our cohort. These findings support conservative management for all indeterminate nodules and indicate that TA can be safely offered for symptomatic Bethesda IV nodules. The present study was limited in evaluating individual genetic mutations and surgical outcomes due to low sample size. However, future work should focus on additional methods of stratifying indeterminate nodules through these methods.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154311--></body></html>"
    },
    {
      "uid": "P134",
      "content_id": "154152",
      "abstract_number": "P134",
      "poster_number": "P134",
      "title": "What is hiding behind the painful anterior neck mass? – a case series of overlooked clinical presentation of medullary thyroid carcinoma.",
      "summary": "Medullary thyroid carcinoma remains a rare but aggressive thyroid malignancy with diverse and frequently overlooked clinical manifestations. Atypical symptoms including painful anterior neck mass, diarrhea, and paraneoplastic manifestations may contribute to delayed diagnosis and intervention. This case series underscores the importance of clinician awareness and early targeted evaluation to ensure prompt...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154152",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "PO LING Catherine Chan",
      "presenter": "PO LING Catherine Chan",
      "authors": "PO LING Catherine Chan ; Lisa Orloff",
      "normalized_authors": [
        "PO LING Catherine Chan",
        "Lisa Orloff"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 445,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction/Background",
        "Abstract",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "PO LING Catherine Chan ; Lisa Orloff",
        "Affiliations": "Stanford University",
        "Introduction/Background": "Medullary thyroid carcinoma (MTC) is an uncommon thyroid malignancy, accounting for approximately 1- 2% of all thyroid cancers. Arising from parafollicular C cells, MTC demonstrates a unique biochemical profile characterized by elevated calcitonin and carcinoembryonic antigen (CEA). Given its propensity for early regional and distant metastasis, timely diagnosis and aggressive surgical management are critical. However, MTC often presents with atypical systemic symptoms that may lead to delayed recognition.",
        "Abstract": "This case series highlights distinct and overlooked clinical manifestations that may serve as early diagnostic clues.",
        "Methods": "A retrospective case series was performed including all patients diagnosed with MTC at our institution between October 2018 and December 2025. Clinical documentation, including subjective presenting complaints, physical findings, and laboratory results, was reviewed. Atypical or non head and neck symptoms at presentation were identified. Time from first clinic visit to operative management was recorded. Surgical outcomes, postoperative complications, nodal disease status, recurrence, and survival at latest follow-up were analyzed.",
        "Results": "Twenty-three patients were identified. There were ten males and twelves females in this series with an average age of 52.5 years. One patient declined surgical intervention. Another patient was deemed inoperable and on systemic chemotherapy. Notably, 8 of 23 (34.8%) presented with anterior neck pain. Five patients (21.7%) reported chronic diarrhea, and one patient experienced constant chilling sensation around scalp region, which resolved postoperatively and recurred with disease activity. Another patient presented with suspected paraneoplastic bilateral upper limbs proximal muscle wasting, contributing to diagnostic uncertainty. Regional nodal metastasis was present in eleven patients (47.8%), necessitating lateral neck dissection. Diagnostic delays were common, particularly among patients initially evaluated for gastrointestinal or neuromuscular symptoms.",
        "Discussion": "Despite rarity, MTC demonstrates a surprisingly broad spectrum of initial symptoms that may distract primary care for extensive investigation outside the scope of thyroid disease. Painful anterior neck mass is an uncommon chief complaint in most thyroid cancers e.g. papillary thyroid carcinoma. However, it was a frequent yet underrated presenting feature in this cohort. Similarly, diarrhea and paraneoplastic phenomena often resulted in extensive non otolaryngologic workups before correct diagnosis was made. These findings highlight the need for heightened suspicion for MTC when encountering atypical presentations, especially when accompanied by biochemical abnormalities or progressive neck symptoms. Early recognition could shorten diagnostic intervals, guide appropriate investigations (including baseline calcitonin/CEA testing), and facilitate timely surgical treatment.",
        "Conclusion": "Medullary thyroid carcinoma remains a rare but aggressive thyroid malignancy with diverse and frequently overlooked clinical manifestations. Atypical symptoms including painful anterior neck mass, diarrhea, and paraneoplastic manifestations may contribute to delayed diagnosis and intervention. This case series underscores the importance of clinician awareness and early targeted evaluation to ensure prompt management and improve oncologic outcomes for medullary thyroid carcinoma."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>What is hiding behind the painful anterior neck mass? – a case series of overlooked clinical presentation of medullary thyroid carcinoma.</span>. <u>PO LING Catherine Chan</u>; Lisa Orloff. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction/Background: </strong>Medullary thyroid carcinoma (MTC) is an uncommon thyroid malignancy, accounting for approximately 1- 2% of all thyroid cancers. Arising from parafollicular C cells, MTC demonstrates a unique biochemical profile characterized by elevated calcitonin and carcinoembryonic antigen (CEA). Given its propensity for early regional and distant metastasis, timely diagnosis and aggressive surgical management are critical. However, MTC often presents with atypical systemic symptoms that may lead to delayed recognition.</p>\n\n<p>This case series highlights distinct and overlooked clinical manifestations that may serve as early diagnostic clues.</p>\n\n<p><strong>Methods: </strong>A retrospective case series was performed including all patients diagnosed with MTC at our institution between October 2018 and December 2025. Clinical documentation, including subjective presenting complaints, physical findings, and laboratory results, was reviewed. Atypical or non head and neck symptoms at presentation were identified. Time from first clinic visit to operative management was recorded. Surgical outcomes, postoperative complications, nodal disease status, recurrence, and survival at latest follow-up were analyzed.</p>\n\n<p><strong>Results: </strong>Twenty-three patients were identified. There were ten males and twelves females in this series with an average age of 52.5 years. One patient declined surgical intervention. Another patient was deemed inoperable and on systemic chemotherapy. Notably, 8 of 23 (34.8%) presented with anterior neck pain. Five patients (21.7%) reported chronic diarrhea, and one patient experienced constant chilling sensation around scalp region, which resolved postoperatively and recurred with disease activity. Another patient presented with suspected paraneoplastic bilateral upper limbs proximal muscle wasting, contributing to diagnostic uncertainty. Regional nodal metastasis was present in eleven patients (47.8%), necessitating lateral neck dissection. Diagnostic delays were common, particularly among patients initially evaluated for gastrointestinal or neuromuscular symptoms.</p>\n\n<p><strong>Discussion: </strong>Despite rarity, MTC demonstrates a surprisingly broad spectrum of initial symptoms that may distract primary care for extensive investigation outside the scope of thyroid disease. Painful anterior neck mass is an uncommon chief complaint in most thyroid cancers e.g. papillary thyroid carcinoma. However, it was a frequent yet underrated presenting feature in this cohort. Similarly, diarrhea and paraneoplastic phenomena often resulted in extensive non otolaryngologic workups before correct diagnosis was made. These findings highlight the need for heightened suspicion for MTC when encountering atypical presentations, especially when accompanied by biochemical abnormalities or progressive neck symptoms. Early recognition could shorten diagnostic intervals, guide appropriate investigations (including baseline calcitonin/CEA testing), and facilitate timely surgical treatment.</p>\n\n<p><strong>Conclusion: </strong>Medullary thyroid carcinoma remains a rare but aggressive thyroid malignancy with diverse and frequently overlooked clinical manifestations. Atypical symptoms including painful anterior neck mass, diarrhea, and paraneoplastic manifestations may contribute to delayed diagnosis and intervention. This case series underscores the importance of clinician awareness and early targeted evaluation to ensure prompt management and improve oncologic outcomes for medullary thyroid carcinoma.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154152--></body></html>"
    },
    {
      "uid": "P135",
      "content_id": "153539",
      "abstract_number": "P135",
      "poster_number": "P135",
      "title": "A Rare Tumor, A Second Appearance: Recurrent Pediatric Parathyroid Carcinoma",
      "summary": "This case highlights that parathyroid carcinoma, while classically a malignancy of middle and older age, can present in the pediatric population. A high index of suspicion should be maintained even in young patients presenting with neck masses and laboratory derangements. Vigilantlong-term surveillance is also essential given risks of recurrence, even after initial complete resection and negative margins.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153539",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marta M Williams, MD",
      "presenter": "Marta M Williams, MD",
      "authors": "Marta M Williams, MD 1 ; Maria Evasovich, MD 2 ; Diana Oramas Mogrovejo, MD 3",
      "normalized_authors": [
        "Marta M Williams",
        "Maria Evasovich",
        "Diana Oramas Mogrovejo"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
        "Department of Surgery, University of Minnesota",
        "Department of Laboratory Medicine and Pathology, University of Minnesota"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
        "Department of Surgery, University of Minnesota",
        "Department of Laboratory Medicine and Pathology, University of Minnesota"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153539/ParathyroidAdenoma.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153539/ParathyroidAdenoma.jpg",
          "alt": "Parathyroid Adenoma",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153539"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153539/ctrecurrence.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153539/ctrecurrence.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153539"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 332,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Marta M Williams, MD 1 ; Maria Evasovich, MD 2 ; Diana Oramas Mogrovejo, MD 3",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Minnesota; 2 Department of Surgery, University of Minnesota; 3 Department of Laboratory Medicine and Pathology, University of Minnesota",
        "Background": "Primary hyperparathyroidism is rare among the pediatric and adolescent population, occurring in only 2-5 cases per 100,000 and parathyroid carcinoma (PC) is even more exceptional. PC generally presents with hypercalcemia, markedly elevated parathyroid hormone (PTH), and neck mass, but a high index of suspicion is required given its rarity.",
        "Case Presentation": "A 17-year-old male presented with several weeks of right-sided neck fullness and was found to have hypercalcemia (Ca 13.1 mg/dL) and markedly elevated PTH (732 pg/mL). Thyroid ultrasound revealed a 4.3-cm heterogeneous mass deep to the right thyroid lobe concerning for parathyroid carcinoma. En bloc excision of a large right superior parathyroid tumor was performed, with postoperative hungry bone syndrome requiring replacement therapy. Pathology demonstrated parathyroid carcinoma with multiple foci of angioinvasion and immunoreactivity for GATA-3 and PTH, and negativity for TTF-1. Margins were negative.",
        "Abstract": "The patient underwent genetic testing showing no pathogenic variants in CDC73, MEN1, or other hereditary hyperparathyroidism genes, though one variant of unknown significance in the MSH3 gene was identified. The patient’s PTH values, while normal in the immediate aftermath of surgery, remained elevated but downtrending in the following months. Two years after surgery, his PTH levels began to increase again and 4D-CT demonstrated a 6.4 mm nodular lesion adjacent to the prior resection bed, prompting reoperative surgery. Right thyroid lobectomy, removal of recurrent tumor, and excision of the right inferior parathyroid gland were performed. Pathology confirmed multifocal recurrent/residual parathyroid carcinoma, a hypercellular right inferior parathyroid gland, and an incidental BRAF-positive papillary thyroid microcarcinoma in the excised lobe. Postoperatively, calcium and PTH normalized. First Image: Parathyroid Adenoma. Second Image: CT Demonstrating Parathyroid Carcinoma Recurrence.",
        "Conclusion": "This case highlights that parathyroid carcinoma, while classically a malignancy of middle and older age, can present in the pediatric population. A high index of suspicion should be maintained even in young patients presenting with neck masses and laboratory derangements. Vigilantlong-term surveillance is also essential given risks of recurrence, even after initial complete resection and negative margins."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Rare Tumor, A Second Appearance: Recurrent Pediatric Parathyroid Carcinoma</span>. <u>Marta M Williams, MD</u><sup>1</sup>; Maria Evasovich, MD<sup>2</sup>; Diana Oramas Mogrovejo, MD<sup>3</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Minnesota; <sup>2</sup>Department of Surgery, University of Minnesota; <sup>3</sup>Department of Laboratory Medicine and Pathology, University of Minnesota<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Primary hyperparathyroidism is rare among the pediatric and adolescent population, occurring in only 2-5 cases per 100,000 and parathyroid carcinoma (PC) is even more exceptional. PC generally presents with hypercalcemia, markedly elevated parathyroid hormone (PTH), and neck mass, but a high index of suspicion is required given its rarity. </p>\n\n<p><strong>Case Presentation: </strong>A 17-year-old male presented with several weeks of right-sided neck fullness and was found to have hypercalcemia (Ca 13.1 mg/dL) and markedly elevated PTH (732 pg/mL). Thyroid ultrasound revealed a 4.3-cm heterogeneous mass deep to the right thyroid lobe concerning for parathyroid carcinoma. En bloc excision of a large right superior parathyroid tumor was performed, with postoperative hungry bone syndrome requiring replacement therapy. Pathology demonstrated parathyroid carcinoma with multiple foci of angioinvasion and immunoreactivity for GATA-3 and PTH, and negativity for TTF-1. Margins were negative.</p>\n\n<p>The patient underwent genetic testing showing no pathogenic variants in CDC73, MEN1, or other hereditary hyperparathyroidism genes, though one variant of unknown significance in the MSH3 gene was identified. The patient’s PTH values, while normal in the immediate aftermath of surgery, remained elevated but downtrending in the following months. Two years after surgery, his PTH levels began to increase again and 4D-CT demonstrated a 6.4 mm nodular lesion adjacent to the prior resection bed, prompting reoperative surgery. Right thyroid lobectomy, removal of recurrent tumor, and excision of the right inferior parathyroid gland were performed. Pathology confirmed multifocal recurrent/residual parathyroid carcinoma, a hypercellular right inferior parathyroid gland, and an incidental BRAF-positive papillary thyroid microcarcinoma in the excised lobe. Postoperatively, calcium and PTH normalized.</p>\n\n<p><strong>Conclusion: </strong>This case highlights that parathyroid carcinoma, while classically a malignancy of middle and older age, can present in the pediatric population. A high index of suspicion should be maintained even in young patients presenting with neck masses and laboratory derangements. Vigilantlong-term surveillance is also essential given risks of recurrence, even after initial complete resection and negative margins.</p>\n\n<p><img alt='Parathyroid Adenoma' src='https://www.submitmyabstract.com/abs/images/153539/ParathyroidAdenoma.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153539/ctrecurrence.png' /></p>\n\n<p>First Image: Parathyroid Adenoma. Second Image: CT Demonstrating Parathyroid Carcinoma Recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153539--></body></html>"
    },
    {
      "uid": "P136",
      "content_id": "154743",
      "abstract_number": "P136",
      "poster_number": "P136",
      "title": "Predicting Posterior Triangle Involvement in Papillary Thyroid Carcinoma: Clinical and Pathological Determinants of Level V Metastasis in Therapeutic Lateral Neck Dissection",
      "summary": "Although level V metastasis occurred in 12% of therapeutic lateral neck dissections, specific high-risk features reliably predict posterior triangle involvement. Extrathyroidal extension, elevated nodal burden, high metastatic lymph node ratio, and particularly simultaneous multilevel involvement across levels II, III, and IV represent significant predictors of level V metastasis. These findings support selective...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154743",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joao Goncalves Filho",
      "presenter": "Joao Goncalves Filho",
      "authors": "Joao Goncalves Filho ; Franco Novelli, MD; Luiz P Kowalski, PhD",
      "normalized_authors": [
        "Joao Goncalves Filho",
        "Franco Novelli",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "AC Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "AC Camargo Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 434,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Joao Goncalves Filho ; Franco Novelli, MD; Luiz P Kowalski, PhD",
        "Affiliations": "AC Camargo Cancer Center",
        "Background": "Lateral neck dissection is fundamental for papillary thyroid carcinoma with cervical lymph node metastasis, yet the necessity of routinely including level V (posterior triangle) remains controversial. Level V dissection carries additional morbidity, including potential spinal accessory nerve injury and shoulder dysfunction. Understanding risk profiles for posterior triangle metastasis could inform selective dissection strategies, reducing unnecessary surgical morbidity while maintaining oncological adequacy.",
        "Objective": "This study aimed to determine the incidence of level V lymph node metastasis and identify specific clinical and pathological risk factors predictive of posterior triangle involvement in patients with papillary thyroid carcinoma undergoing therapeutic lateral neck dissection.",
        "Methods": "We performed a retrospective analysis of 238 consecutive patients who underwent therapeutic lateral neck dissection encompassing levels II through V for previously untreated papillary thyroid carcinoma between 2014 and 2023. All patients underwent dissection for clinically evident lateral neck metastasis confirmed by preoperative imaging and fine-needle aspiration. Detailed pathological examination documented lymph node yield and metastatic involvement by cervical level. Statistical analyses identified significant associations between clinicopathological variables and level V metastasis, with emphasis on multilevel disease patterns and quantitative nodal burden indicators.",
        "Results": "The cohort comprised 264 therapeutic lateral neck dissections in 238 patients, with ipsilateral dissection in 212 patients (60% right side) and bilateral procedures in 26 patients. Lymph node yield per dissection ranged from 23 to 106 nodes (median 38). Pathological analysis identified 2,561 metastatic lymph nodes among all examined nodes, yielding an overall metastatic rate of 19%. Level V examination revealed 1,633 lymph nodes dissected from the posterior triangle, of which 62 harbored metastatic disease, corresponding to a level-specific metastatic rate of 3.8%. Level V metastasis was identified in approximately 12% of all neck dissections. Multivariate analysis demonstrated that level V involvement was significantly associated with extrathyroidal extension of the primary tumor, which emerged as the strongest independent predictor. Quantitative nodal disease parameters including absolute number of positive lymph nodes and lymph node metastatic ratio also showed significant correlation. Simultaneous involvement of multiple anterior and central lateral levels (II, III, and IV) was a powerful predictor of posterior triangle metastasis, with sequential multilevel disease conferring substantially elevated risk for level V involvement (p<0.05 for all associations).",
        "Conclusions": "Although level V metastasis occurred in 12% of therapeutic lateral neck dissections, specific high-risk features reliably predict posterior triangle involvement. Extrathyroidal extension, elevated nodal burden, high metastatic lymph node ratio, and particularly simultaneous multilevel involvement across levels II, III, and IV represent significant predictors of level V metastasis. These findings support selective level V dissection for patients demonstrating these high-risk characteristics, potentially reducing surgical morbidity while ensuring oncological completeness in high-risk cases."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predicting Posterior Triangle Involvement in Papillary Thyroid Carcinoma: Clinical and Pathological Determinants of Level V Metastasis in Therapeutic Lateral Neck Dissection</span>. <u>Joao Goncalves Filho</u>; Franco Novelli, MD; Luiz P Kowalski, PhD. AC Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Lateral neck dissection is fundamental for papillary thyroid carcinoma with cervical lymph node metastasis, yet the necessity of routinely including level V (posterior triangle) remains controversial. Level V dissection carries additional morbidity, including potential spinal accessory nerve injury and shoulder dysfunction. Understanding risk profiles for posterior triangle metastasis could inform selective dissection strategies, reducing unnecessary surgical morbidity while maintaining oncological adequacy.</p>\n\n<p><strong>Objective: </strong>This study aimed to determine the incidence of level V lymph node metastasis and identify specific clinical and pathological risk factors predictive of posterior triangle involvement in patients with papillary thyroid carcinoma undergoing therapeutic lateral neck dissection.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective analysis of 238 consecutive patients who underwent therapeutic lateral neck dissection encompassing levels II through V for previously untreated papillary thyroid carcinoma between 2014 and 2023. All patients underwent dissection for clinically evident lateral neck metastasis confirmed by preoperative imaging and fine-needle aspiration. Detailed pathological examination documented lymph node yield and metastatic involvement by cervical level. Statistical analyses identified significant associations between clinicopathological variables and level V metastasis, with emphasis on multilevel disease patterns and quantitative nodal burden indicators.</p>\n\n<p><strong>Results: </strong>The cohort comprised 264 therapeutic lateral neck dissections in 238 patients, with ipsilateral dissection in 212 patients (60% right side) and bilateral procedures in 26 patients. Lymph node yield per dissection ranged from 23 to 106 nodes (median 38). Pathological analysis identified 2,561 metastatic lymph nodes among all examined nodes, yielding an overall metastatic rate of 19%. Level V examination revealed 1,633 lymph nodes dissected from the posterior triangle, of which 62 harbored metastatic disease, corresponding to a level-specific metastatic rate of 3.8%. Level V metastasis was identified in approximately 12% of all neck dissections. Multivariate analysis demonstrated that level V involvement was significantly associated with extrathyroidal extension of the primary tumor, which emerged as the strongest independent predictor. Quantitative nodal disease parameters including absolute number of positive lymph nodes and lymph node metastatic ratio also showed significant correlation. Simultaneous involvement of multiple anterior and central lateral levels (II, III, and IV) was a powerful predictor of posterior triangle metastasis, with sequential multilevel disease conferring substantially elevated risk for level V involvement (p<0.05 for all associations).</p>\n\n<p><strong>Conclusions: </strong>Although level V metastasis occurred in 12% of therapeutic lateral neck dissections, specific high-risk features reliably predict posterior triangle involvement. Extrathyroidal extension, elevated nodal burden, high metastatic lymph node ratio, and particularly simultaneous multilevel involvement across levels II, III, and IV represent significant predictors of level V metastasis. These findings support selective level V dissection for patients demonstrating these high-risk characteristics, potentially reducing surgical morbidity while ensuring oncological completeness in high-risk cases.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154743--></body></html>"
    },
    {
      "uid": "P137",
      "content_id": "155539",
      "abstract_number": "P137",
      "poster_number": "P137",
      "title": "Lymph Node Ratio Independently Predicts Survival in Medullary Thyroid Cancer: A National Cancer Database Analysis",
      "summary": "As one of the largest studies of its kind, this NCDB analysis reinforces the importance of quantitatively assessing nodal burden using lymph node ratio (LNR), as suggested by prior smaller studies. It also supports the importance of adequate lymph node evaluation, and may help guide postoperative risk stratification in the future.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155539",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Hussien Abouzeid, BSc 1 ; Yongdong Ouyang, PhD 2 ; William J Magner, PhD 2 ; Lynn Sigurdson, PhD 2 ; Anurag K Singh, MD 2 ; Moni A Kuriakose, MD 2 ; Vishal Gupta, MD 2",
      "normalized_authors": [
        "Hussien Abouzeid",
        "Yongdong Ouyang",
        "William J Magner",
        "Lynn Sigurdson",
        "Anurag K Singh",
        "Moni A Kuriakose",
        "Vishal Gupta"
      ],
      "affiliations": [
        "St. George's University School of Medicine, Grenada",
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "St. George's University School of Medicine, Grenada",
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Hussien Abouzeid, BSc 1 ; Yongdong Ouyang, PhD 2 ; William J Magner, PhD 2 ; Lynn Sigurdson, PhD 2 ; Anurag K Singh, MD 2 ; Moni A Kuriakose, MD 2 ; Vishal Gupta, MD 2",
        "Affiliations": "1 St. George's University School of Medicine, Grenada; 2 Roswell Park Comprehensive Cancer Center",
        "Background": "Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor with early lymphatic spread to the cervical lymph nodes. Lymph node ratio (LNR), defined as positive lymph nodes divided by total nodes examined (lymph node yield- LNY), has demonstrated prognostic value in multiple malignancies. However, the prognostic significance of LNR in MTC has been poorly studied. Given the lack of quantitative assessment in the current AJCC staging system (8th edition), which has led to its criticism in the past, this study aims to evaluate the association between LNR and overall survival (OS) in MTC using the National Cancer Database.",
        "Methods": "5,182 adult patients undergoing surgery with lymph node evaluation with complete information were identified using NCDB (2004-2023). The primary outcome studied was OS, using Kaplan-Meier (KM) survival analysis, and multivariable cox proportional hazards modeling (adjusting for age, sex, Charlson-Deyo comorbidity score, Pathologic T stage, and surgical margin status). All statistical analyses were performed using R 4.5.0, and statistical significance was defined as a two-sided p-value <0.05.",
        "Results": "KM analyses (Figures 1 and 2) have both LNR and the number of lymph nodes positive for MTC having a significant negative association with survival (log-rank p < 0.0001). For example, the median survival was 234 months for patients with 1–10 positive nodes, compared to 133 months for those with ≥21 positive nodes.",
        "Abstract": "On multivariable Cox proportional hazards analysis, increasing LNR was independently associated with worse overall survival. Compared with LNR 0%, LNR 26–50% (HR 1.35, 95% CI 1.11–1.65; p=0.003) and LNR 51–100% (HR 2.13, 95% CI 1.76–2.57; p<0.001) were significantly associated with increased mortality, while LNR 1–25% did not reach statistical significance. Sensitivity analysis restricted to patients with pre-specified >6 lymph nodes examined demonstrated a strengthened association across all nonzero LNR categories, including LNR 1–25% (HR 1.30, p=0.020), 26–50% (HR 1.50, p=0.001), and 51–100% (HR 2.39, p<0.001). Across both models, older age, male sex, higher Charlson–Deyo comorbidity score, and positive surgical margins were also independently associated with worse overall survival.",
        "Conclusion": "As one of the largest studies of its kind, this NCDB analysis reinforces the importance of quantitatively assessing nodal burden using lymph node ratio (LNR), as suggested by prior smaller studies. It also supports the importance of adequate lymph node evaluation, and may help guide postoperative risk stratification in the future."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lymph Node Ratio Independently Predicts Survival in Medullary Thyroid Cancer: A National Cancer Database Analysis</span>. Hussien Abouzeid, BSc<sup>1</sup>; Yongdong Ouyang, PhD<sup>2</sup>; William J Magner, PhD<sup>2</sup>; Lynn Sigurdson, PhD<sup>2</sup>; Anurag K Singh, MD<sup>2</sup>; Moni A Kuriakose, MD<sup>2</sup>; <u>Vishal Gupta, MD</u><sup>2</sup>. <sup>1</sup>St. George's University School of Medicine, Grenada; <sup>2</sup>Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor with early lymphatic spread to the cervical lymph nodes. Lymph node ratio (LNR), defined as positive lymph nodes divided by total nodes examined (lymph node yield- LNY), has demonstrated prognostic value in multiple malignancies. However, the prognostic significance of LNR in MTC has been poorly studied. Given the lack of quantitative assessment in the current AJCC staging system (8th edition), which has led to its criticism in the past, this study aims to evaluate the association between LNR and overall survival (OS) in MTC using the National Cancer Database.</p>\n\n<p><strong>Methods: </strong>5,182 adult patients undergoing surgery with lymph node evaluation with complete information were identified using NCDB (2004-2023). The primary outcome studied was OS, using Kaplan-Meier (KM) survival analysis, and multivariable cox proportional hazards modeling (adjusting for age, sex, Charlson-Deyo comorbidity score, Pathologic T stage, and surgical margin status). All statistical analyses were performed using R 4.5.0, and statistical significance was defined as a two-sided p-value <0.05.</p>\n\n<p><strong>Results: </strong>KM analyses (Figures 1 and 2) have both LNR and the number of lymph nodes positive for MTC having a significant negative association with survival (log-rank p < 0.0001). For example, the median survival was 234 months for patients with 1–10 positive nodes, compared to 133 months for those with ≥21 positive nodes.</p>\n\n<p>On multivariable Cox proportional hazards analysis, increasing LNR was independently associated with worse overall survival. Compared with LNR 0%, LNR 26–50% (HR 1.35, 95% CI 1.11–1.65; p=0.003) and LNR 51–100% (HR 2.13, 95% CI 1.76–2.57; p<0.001) were significantly associated with increased mortality, while LNR 1–25% did not reach statistical significance. Sensitivity analysis restricted to patients with pre-specified >6 lymph nodes examined demonstrated a strengthened association across all nonzero LNR categories, including LNR 1–25% (HR 1.30, p=0.020), 26–50% (HR 1.50, p=0.001), and 51–100% (HR 2.39, p<0.001). Across both models, older age, male sex, higher Charlson–Deyo comorbidity score, and positive surgical margins were also independently associated with worse overall survival.</p>\n\n<p><strong>Conclusion: </strong> As one of the largest studies of its kind, this NCDB analysis reinforces the importance of quantitatively assessing nodal burden using lymph node ratio (LNR), as suggested by prior smaller studies. It also supports the importance of adequate lymph node evaluation, and may help guide postoperative risk stratification in the future.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155539--></body></html>"
    },
    {
      "uid": "P138",
      "content_id": "153553",
      "abstract_number": "P138",
      "poster_number": "P138",
      "title": "Thyroid Cancer and Breast Cancer: What Do These Patients Have in Common? A case series 2010-2025, Oncology Program, Salud Integral Hospital, Managua, Nicaragua",
      "summary": "The relationship between thyroid cancer (TC) and breast cancer (BC) has been debated for decades. Studies have reported contradictory non reproducible results. Nevertheless, many patients develop both malignancies sharing some common heterogenetic elements. The objective of the study was to identify common clinical, pathological, and epidemiological features among patients who developed both malignancies. A...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153553",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Francisco Medrano",
      "presenter": "Francisco Medrano",
      "authors": "Francisco Medrano 1 ; Roberto Ortega Platt, Gynecologic oncologist 1 ; Alicia Alvarado, Pathologist 1 ; Alfredo Saavedra, Clinical Oncologist 2 ; Carmen Marcela Quezada, Hematopathologist 1 ; Róger Ariel Matus, Radiologist 3 ; Guillermo Carmona, General Surgery 1 ; Eysmar Josué Álvarez, General Surgery 4 ; Julio Lacayo, Medical doctor 4",
      "normalized_authors": [
        "Francisco Medrano",
        "Roberto Ortega Platt, Gynecologic oncologist",
        "Alicia Alvarado, Pathologist",
        "Alfredo Saavedra, Clinical Oncologist",
        "Carmen Marcela Quezada, Hematopathologist",
        "Róger Ariel Matus, Radiologist",
        "Guillermo Carmona, General Surgery",
        "Eysmar Josué Álvarez, General Surgery"
      ],
      "affiliations": [
        "Salud Integral Hospital",
        "Ortiz-Gurdian Foundation",
        "X Ray Medical Center",
        "Independent Research Team"
      ],
      "normalized_institutions": [
        "Salud Integral Hospital",
        "Ortiz-Gurdian Foundation",
        "X Ray Medical Center",
        "Independent Research Team"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Francisco Medrano 1 ; Roberto Ortega Platt, Gynecologic oncologist 1 ; Alicia Alvarado, Pathologist 1 ; Alfredo Saavedra, Clinical Oncologist 2 ; Carmen Marcela Quezada, Hematopathologist 1 ; Róger Ariel Matus, Radiologist 3 ; Guillermo Carmona, General Surgery 1 ; Eysmar Josué Álvarez, General Surgery 4 ; Julio Lacayo, Medical doctor 4",
        "Affiliations": "1 Salud Integral Hospital; 2 Ortiz-Gurdian Foundation; 3 X Ray Medical Center; 4 Independent Research Team",
        "Abstract": "The relationship between thyroid cancer (TC) and breast cancer (BC) has been debated for decades. Studies have reported contradictory non reproducible results. Nevertheless, many patients develop both malignancies sharing some common heterogenetic elements. The objective of the study was to identify common clinical, pathological, and epidemiological features among patients who developed both malignancies. A retrospective, descriptive case series was conducted through a review of medical records of patients who underwent thyroidectomy for TC between 2010 and 2025. Cases were included when BC occurred as the index tumor or as a second primary tumor, according to Warren and Gates. Clinical variables included family history of cancer, hormone replacement therapy, thyroid disease, climacteric status based on WHO 2024, radiation exposure and the interval between both primary tumors. BC pathology and biomarker profiles were assessed following the 2024–2025 College of American Pathologists (CAP), while TC histopathology followed CAP 2021 with risk stratification through the AGES system. Treatments were evaluated according to the 2015 American Thyroid Association. Statistical analysis consisted of frequencies and percentages, processed using Microsoft Excel 2019. A total of 450 patients with TC, five (1%) met the criteria for coexistence with BC. Three patients (60%) presented BC as the index tumor, and four (80%) developed TC as a second primary cancer. Two cases were synchronous and three metachronous. One patient with a history of ovarian cancer developed synchronous BC and TC (papillary and medullary variants), while another sequential case involved a prior inguinal sarcoma followed by TC and subsequently BC. The age at BC diagnosis ranged from 47 to 64 years mean 57, and age at TC diagnosis from 49 to 64 years mean 60. The interval between diagnoses varied from 3 months to 8 years, with an average of 3 years. Four patients 80% were postmenopausal, and one received hormone replacement therapy. Two (40%) had previous radiation exposure, and all remained euthyroid during follow-up. Regarding BC, the subtype was invasive ductal carcinoma (60%), followed by lobular and mucinous carcinomas (20% each). Most were well-differentiated tumors (Grade I, 80%). Estrogen receptor positivity was high (80%), while progesterone receptor positivity was 40%. HER2 overexpression and Ki-67 positivity were each observed in 20%. All tumors presented as localized disease. For TC, the classic papillary variant predominated (80%), followed by follicular (20%) and papillary/medullary case. 60% were classified as low-risk tumors and 2 (40%) intermedial risk. Four patients (80%) underwent total thyroidectomy, one hemithyroidectomy and one total thryroidectomy plus radical modificate neck disection, two received I-131 therapy. Follow-up from the index tumor ranged from 2 to 22 years mean 9, with 100% overall and disease-free survival. In conclusion, although the biological relationship between BC and TC remains controversial, this study confirms that coexistence of both malignancies is infrequent. However, close follow-up of the index tumor has enabled earlier diagnosis of the second primary cancer, translating into excellent survival and disease-free outcomes"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thyroid Cancer and Breast Cancer: What Do These Patients Have in Common? A case series 2010-2025, Oncology Program, Salud Integral Hospital, Managua, Nicaragua</span>. <u>Francisco Medrano</u><sup>1</sup>; Roberto Ortega Platt, Gynecologic oncologist<sup>1</sup>; Alicia Alvarado, Pathologist<sup>1</sup>; Alfredo Saavedra, Clinical Oncologist<sup>2</sup>; Carmen Marcela Quezada, Hematopathologist<sup>1</sup>; Róger Ariel Matus, Radiologist<sup>3</sup>; Guillermo Carmona, General Surgery<sup>1</sup>; Eysmar Josué Álvarez, General Surgery<sup>4</sup>; Julio Lacayo, Medical doctor<sup>4</sup>. <sup>1</sup>Salud  Integral Hospital; <sup>2</sup>Ortiz-Gurdian Foundation; <sup>3</sup>X Ray Medical Center; <sup>4</sup>Independent Research Team<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The relationship between thyroid cancer (TC) and breast cancer (BC) has been debated for decades. Studies have reported contradictory non reproducible results. Nevertheless, many patients develop both malignancies sharing some common heterogenetic elements. The objective of the study was to identify common clinical, pathological, and epidemiological features among patients who developed both malignancies.</p>\n\n<p>A retrospective, descriptive case series was conducted through a review of medical records of patients who underwent thyroidectomy for TC between 2010 and 2025. Cases were included when BC occurred as the index tumor or as a second primary tumor, according to Warren and Gates. Clinical variables included family history of cancer, hormone replacement therapy, thyroid disease, climacteric status based on WHO 2024, radiation exposure and the interval between both primary tumors. BC pathology and biomarker profiles were assessed following the 2024–2025 College of American Pathologists (CAP), while TC histopathology followed CAP 2021 with risk stratification through the AGES system. Treatments were evaluated according to the 2015 American Thyroid Association. Statistical analysis consisted of frequencies and percentages, processed using Microsoft Excel 2019.</p>\n\n<p>A total of 450 patients with TC, five (1%) met the criteria for coexistence with BC. Three patients (60%) presented BC as the index tumor, and four (80%) developed TC as a second primary cancer. Two cases were synchronous and three metachronous. One patient with a history of ovarian cancer developed synchronous BC and TC (papillary and medullary variants), while another sequential case involved a prior inguinal sarcoma followed by TC and subsequently BC. The age at BC diagnosis ranged from 47 to 64 years mean 57, and age at TC diagnosis from 49 to 64 years mean 60. The interval between diagnoses varied from 3 months to 8 years, with an average of 3 years. Four patients 80% were postmenopausal, and one received hormone replacement therapy. Two (40%) had previous radiation exposure, and all remained euthyroid during follow-up.</p>\n\n<p>Regarding BC, the subtype was invasive ductal carcinoma (60%), followed by lobular and mucinous carcinomas (20% each). Most were well-differentiated tumors (Grade I, 80%). Estrogen receptor positivity was high (80%), while progesterone receptor positivity was 40%. HER2 overexpression and Ki-67 positivity were each observed in 20%. All tumors presented as localized disease. For TC, the classic papillary variant predominated (80%), followed by follicular (20%) and papillary/medullary case. 60% were classified as low-risk tumors and 2 (40%) intermedial risk. Four patients (80%) underwent total thyroidectomy, one hemithyroidectomy and one total thryroidectomy plus radical modificate neck disection, two received I-131 therapy. Follow-up from the index tumor ranged from 2 to 22 years mean 9, with 100% overall and disease-free survival.</p>\n\n<p>In conclusion, although the biological relationship between BC and TC remains controversial, this study confirms that coexistence of both malignancies is infrequent. However, close follow-up of the index tumor has enabled earlier diagnosis of the second primary cancer, translating into excellent survival and disease-free outcomes</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153553--></body></html>"
    },
    {
      "uid": "P139",
      "content_id": "153067",
      "abstract_number": "P139",
      "poster_number": "P139",
      "title": "Thyroid cancer in low risk patients, impact of I-131 therapy, oncologic program, Salud Integral Hospital Managua, Nicaragua, January 2010-2023",
      "summary": "The findings suggest that, in low-risk TC patients, I-131 therapy does not significantly impact recurrence rates, overall survival, or disease-free survival. These results align with international data supporting a more conservative approach in managing low-risk thyroid cancer",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153067",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Francisco Medrano, Head and Neck Surgeon",
      "presenter": "Francisco Medrano, Head and Neck Surgeon",
      "authors": "Francisco Medrano, Head and Neck Surgeon 1 ; Eysmar Josué Álvarez, Surgeon 2 ; Róger Ariel Matus, Radiologist 3 ; Carmen Marcela Quezada, Pathologist 1 ; Guillermo Carmona, Surgeon 1",
      "normalized_authors": [
        "Francisco Medrano, Head and Neck Surgeon",
        "Eysmar Josué Álvarez, Surgeon",
        "Róger Ariel Matus, Radiologist",
        "Carmen Marcela Quezada, Pathologist",
        "Guillermo Carmona, Surgeon"
      ],
      "affiliations": [
        "Salud Integral Hospital",
        "Independent Research Team",
        "X Ray Medical Center"
      ],
      "normalized_institutions": [
        "Salud Integral Hospital",
        "Independent Research Team",
        "X Ray Medical Center"
      ],
      "session_type": "Poster",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 444,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Francisco Medrano, Head and Neck Surgeon 1 ; Eysmar Josué Álvarez, Surgeon 2 ; Róger Ariel Matus, Radiologist 3 ; Carmen Marcela Quezada, Pathologist 1 ; Guillermo Carmona, Surgeon 1",
        "Affiliations": "1 Salud Integral Hospital; 2 Independent Research Team; 3 X Ray Medical Center",
        "Abstract": "Thyroid cancer (TC) is the most common endocrine malignancy, and current clinical guidelines favor less aggressive therapeutic approaches, especially for low-risk patients. This study aimed to evaluate the impact of radioactive iodine (I-131) therapy in patients classified as low-risk. The follow-up period ranged from 4 to 13 years, with a mean duration of 7.5 years in both groups. Recurrence occurred in 3 patients (5%): one in Group A and two in Group B, all involving cervical lymph node levels III–IV. There were three deaths: one in Group A due to systemic lupus erythematosus (SLE), and two in Group B (one from SLE and one from a second primary tumor). Overall survival was similar between the two groups, with a mean of 6.5 years in Group A and 7.0 years in Group B All remaining patients were disease-free at the end of follow-up.",
        "Methods": "A descriptive, retrospective cohort study was conducted, including 80 patients who underwent thyroidectomy between January 2010 and January 2023. Of these, 55 patients were identified as low-risk according to the AGES stratification system and were divided into two groups: Group A (no I-131 therapy) and Group B (received I-131 therapy).",
        "Results": "The study included 55 patients. The distribution by sex was 48 female (87%) and 7 male (13%). The patient age ranged from 24 to 48 years, with an average of 39 years. Regarding the histological type of thyroid cancer, the most frequent was papillary thyroid carcinoma , specifically the classical variant, accounting for 51 cases (93%). Follicular thyroid carcinoma was found in 3 cases (5%), and oncocytic carcinoma in 1 case (2%). The pattern of tumor involvement was predominantly unifocal, observed in 29 patients (53%), while multifocal disease was present in 26 patients (47%). Tumor invasion were identified in 20 patients (36%) the most frequent pattern of spread was nodal metastasis, observed in 10 cases (50%). Other forms of local invasion included lymphatic invasion in 6 patients (30%), vascular invasion in 2 patients (10%), and both perineural invasion and extrathyroidal extension in 1 patient each (5%). Group A included 26 patients (21 females, 5 males) with a mean age of 49, all diagnosed with classic papillary TC. Group B included 29 patients (27 females, 2 males) with a mean age of 46. The vast majority (96%) received a single dose of I-131, the ranges was 30-200 mCi with an average of 130 mCi, although 52% lacked a documented indication for the therapy.",
        "Conclusion": "The findings suggest that, in low-risk TC patients, I-131 therapy does not significantly impact recurrence rates, overall survival, or disease-free survival. These results align with international data supporting a more conservative approach in managing low-risk thyroid cancer"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thyroid cancer in low risk patients, impact of I-131 therapy, oncologic program,  Salud Integral Hospital  Managua, Nicaragua,  January 2010-2023</span>. <u>Francisco Medrano, Head and Neck Surgeon</u><sup>1</sup>; Eysmar Josué Álvarez, Surgeon<sup>2</sup>; Róger Ariel Matus, Radiologist<sup>3</sup>; Carmen Marcela Quezada, Pathologist<sup>1</sup>; Guillermo Carmona, Surgeon<sup>1</sup>. <sup>1</sup>Salud  Integral Hospital; <sup>2</sup>Independent Research Team; <sup>3</sup>X Ray Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Thyroid cancer (TC) is the most common endocrine malignancy, and current clinical guidelines favor less aggressive therapeutic approaches, especially for low-risk patients. This study aimed to evaluate the impact of radioactive iodine (I-131) therapy in patients classified as low-risk.</p>\n\n<p><strong>Methods:</strong> A descriptive, retrospective cohort study was conducted, including 80 patients who underwent thyroidectomy between January 2010 and January 2023. Of these, 55 patients were identified as low-risk according to the AGES stratification  system and were divided into two groups: Group A (no I-131 therapy) and Group B (received I-131 therapy).</p>\n\n<p><strong>Results: </strong>The study included 55 patients. The distribution by sex was 48 female (87%) and 7 male (13%). The patient age ranged from 24 to 48 years, with an average of 39 years. Regarding the histological type of thyroid cancer, the most frequent was papillary thyroid carcinoma , specifically the classical variant, accounting for 51 cases (93%). Follicular thyroid carcinoma  was found in 3 cases (5%), and oncocytic carcinoma in 1 case (2%). The pattern of tumor involvement was predominantly unifocal, observed in 29 patients (53%), while multifocal disease was present in 26 patients (47%). Tumor invasion were identified in 20 patients (36%) the most frequent pattern of spread was nodal metastasis, observed in 10 cases (50%). Other forms of local invasion included lymphatic invasion in 6 patients (30%), vascular invasion in 2 patients (10%), and both perineural invasion and extrathyroidal extension in 1 patient each (5%). Group A included 26 patients (21 females, 5 males) with a mean age of 49, all diagnosed with classic papillary TC.  Group B included 29 patients (27 females, 2 males) with a mean age of 46.  The vast majority (96%) received a single dose of I-131, the ranges  was 30-200 mCi  with an average of 130 mCi, although 52% lacked a documented indication for the therapy.</p>\n\n<p>The follow-up period ranged from 4 to 13 years, with a mean duration of 7.5 years in both groups.</p>\n\n<p>Recurrence occurred in 3 patients (5%): one in Group A and two in Group B, all involving cervical lymph node levels III–IV. There were three deaths: one in Group A due to systemic lupus erythematosus (SLE), and two in Group B (one from SLE and one from a second primary tumor). Overall survival was similar between the two groups, with a mean of 6.5 years in Group A and 7.0 years in Group B All remaining patients were disease-free at the end of follow-up.</p>\n\n<p><strong>Conclusion: </strong>The findings suggest that, in low-risk TC patients, I-131 therapy does not significantly impact recurrence rates, overall survival, or disease-free survival. These results align with international data supporting a more conservative approach in managing low-risk thyroid cancer</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153067--></body></html>"
    },
    {
      "uid": "P140",
      "content_id": "154726",
      "abstract_number": "P140",
      "poster_number": "P140",
      "title": "Shoulder Dysfunction After Lateral Neck Dissection for Papillary Thyroid Carcinoma: The Hidden Cost of Level V Dissection",
      "summary": "Level V neck dissection in patients with papillary thyroid carcinoma is associated with substantial shoulder morbidity, manifesting as pain, restricted active range of motion with particular limitation in abduction, and spinal accessory nerve dysfunction. These findings underscore the functional consequences of lateral neck dissection and highlight the need for careful consideration of the extent of nodal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154726",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joao Goncalves Filho, PhD",
      "presenter": "Joao Goncalves Filho, PhD",
      "authors": "Franco Novelli, MD; Joao Goncalves Filho, PhD ; Luiz P Kowalski, PhD",
      "normalized_authors": [
        "Franco Novelli",
        "Joao Goncalves Filho",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "AC Camargo Cacner Center"
      ],
      "normalized_institutions": [
        "AC Camargo Cacner Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 351,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Franco Novelli, MD; Joao Goncalves Filho, PhD ; Luiz P Kowalski, PhD",
        "Affiliations": "AC Camargo Cacner Center",
        "Introduction": "Thyroid neoplasms represent common endocrine malignancies, with papillary thyroid carcinoma accounting for the majority of cases. Approximately 15% of patients require lateral neck dissection for management of regional metastases. Despite routine preservation of the spinal accessory nerve during these procedures, shoulder dysfunction remains the predominant source of postoperative morbidity, significantly impacting patient quality of life.",
        "Objective": "To investigate the association between Level V neck dissection and shoulder morbidity, specifically evaluating pain and range of motion limitations in patients undergoing lateral neck dissection for metastatic papillary thyroid carcinoma.",
        "Methods": "We analyzed patients with papillary thyroid carcinoma and lateral cervical metastases who underwent neck dissection (Levels IIa through Vb) between 2014 and 2019. All patients received standardized physiotherapy assessment, including objective measurements of shoulder muscle strength against resistance and active range of motion. Specific parameters evaluated included shoulder flexion and abduction angles.",
        "Results": "Among 106 patients referred for physiotherapy evaluation due to procedure-related complaints, 77 (72.6%) demonstrated significant shoulder dysfunction on the operated side. An initial cohort of 63 patients was selected to assess the impact of Level V dissection; however, seven patients with bilateral neck dissection were excluded to ensure accurate comparison. The final analysis included 56 patients (29 right-sided, 27 left-sided procedures). Shoulder flexion was significantly diminished on the operated side compared to the contralateral side (p<0.001). Mean shoulder abduction on the operated side measured 114.9° ± 48.8°, representing a statistically significant reduction compared to the non-operated side (p<0.001). Both internal and external rotation demonstrated significant impairment on the operative side (p=0.005). Shoulder pain showed a strong association with spinal accessory nerve dysfunction (p<0.001).",
        "Conclusion": "Level V neck dissection in patients with papillary thyroid carcinoma is associated with substantial shoulder morbidity, manifesting as pain, restricted active range of motion with particular limitation in abduction, and spinal accessory nerve dysfunction. These findings underscore the functional consequences of lateral neck dissection and highlight the need for careful consideration of the extent of nodal dissection balanced against oncologic necessity. Further investigation into nerve-sparing techniques and enhanced rehabilitation protocols may help mitigate these complications and improve postoperative functional outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Shoulder Dysfunction After Lateral Neck Dissection for Papillary Thyroid Carcinoma: The Hidden Cost of Level V Dissection</span>. Franco Novelli, MD; <u>Joao Goncalves Filho, PhD</u>; Luiz P Kowalski, PhD. AC Camargo Cacner Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Thyroid neoplasms represent common endocrine malignancies, with papillary thyroid carcinoma accounting for the majority of cases. Approximately 15% of patients require lateral neck dissection for management of regional metastases. Despite routine preservation of the spinal accessory nerve during these procedures, shoulder dysfunction remains the predominant source of postoperative morbidity, significantly impacting patient quality of life.</p>\n\n<p><strong>Objective:</strong> To investigate the association between Level V neck dissection and shoulder morbidity, specifically evaluating pain and range of motion limitations in patients undergoing lateral neck dissection for metastatic papillary thyroid carcinoma.</p>\n\n<p><strong>Methods: </strong>We analyzed patients with papillary thyroid carcinoma and lateral cervical metastases who underwent neck dissection (Levels IIa through Vb) between 2014 and 2019. All patients received standardized physiotherapy assessment, including objective measurements of shoulder muscle strength against resistance and active range of motion. Specific parameters evaluated included shoulder flexion and abduction angles.</p>\n\n<p><strong>Results: </strong>Among 106 patients referred for physiotherapy evaluation due to procedure-related complaints, 77 (72.6%) demonstrated significant shoulder dysfunction on the operated side. An initial cohort of 63 patients was selected to assess the impact of Level V dissection; however, seven patients with bilateral neck dissection were excluded to ensure accurate comparison. The final analysis included 56 patients (29 right-sided, 27 left-sided procedures). Shoulder flexion was significantly diminished on the operated side compared to the contralateral side (p<0.001). Mean shoulder abduction on the operated side measured 114.9° ± 48.8°, representing a statistically significant reduction compared to the non-operated side (p<0.001). Both internal and external rotation demonstrated significant impairment on the operative side (p=0.005). Shoulder pain showed a strong association with spinal accessory nerve dysfunction (p<0.001).</p>\n\n<p><strong>Conclusion: </strong>Level V neck dissection in patients with papillary thyroid carcinoma is associated with substantial shoulder morbidity, manifesting as pain, restricted active range of motion with particular limitation in abduction, and spinal accessory nerve dysfunction. These findings underscore the functional consequences of lateral neck dissection and highlight the need for careful consideration of the extent of nodal dissection balanced against oncologic necessity. Further investigation into nerve-sparing techniques and enhanced rehabilitation protocols may help mitigate these complications and improve postoperative functional outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154726--></body></html>"
    },
    {
      "uid": "P141",
      "content_id": "155434",
      "abstract_number": "P141",
      "poster_number": "P141",
      "title": "Determinants of Neck Evaluation Quality in Early-Stage Oral Cavity Cancer: Influence of Facility Type, Travel Distance, and System-Level Referral Patterns in a National Cohort",
      "summary": "Neck-evaluation quality in early-stage OSCC is shaped by both facility type and the travel patterns that determine where patients receive care. Shorter travel and treatment in lower-volume community settings are associated with markedly higher omission, while longer-distance referral to Academic centers yields more consistent, guideline-concordant nodal assessment. Strengthening referral pathways may reduce...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155434",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Vishal Gupta, MD ; Alex Vaicius, MD; Ryan P McSpadden, MD; William J Magner, PhD; Christine R Burton, MD; Jenny Romero, MD; Kimberly E Wooten, MD; Wesley L Hicks Jr, MD",
      "normalized_authors": [
        "Vishal Gupta",
        "Alex Vaicius",
        "Ryan P McSpadden",
        "William J Magner",
        "Christine R Burton",
        "Jenny Romero",
        "Kimberly E Wooten",
        "Wesley L Hicks Jr"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 368,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Vishal Gupta, MD ; Alex Vaicius, MD; Ryan P McSpadden, MD; William J Magner, PhD; Christine R Burton, MD; Jenny Romero, MD; Kimberly E Wooten, MD; Wesley L Hicks Jr, MD",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Background": "Elective neck evaluation is a fundamental component of guideline-concordant care for early-stage oral cavity squamous cell carcinoma (OSCC), yet national practice patterns show substantial variation in whether lymph nodes are pathologically assessed. System-level determinants—including facility type and patient travel distance—may influence treatment quality, but their relationships remain incompletely described.",
        "Methods": "We analyzed a multi-subsite National Cancer Database (NCDB) cohort by merging three Participant User Files for oral tongue, floor of mouth, and gum/other mouth cancers. Early-stage disease was defined using the Analytic Stage Group (Stages I–II). Surgery was restricted to resections only (RX_SUMM_SURG_PRIM_SITE codes 20–80), excluding biopsies. Neck evaluation was measured using the number of regional lymph nodes examined, and travel distance using the CROWFLY great-circle metric. Facility type designations followed Commission on Cancer designations. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.",
        "Results": "Across the multi-subsite cohort (N?=?305,837), 112,069 patients had early-stage disease and 77.4% underwent resection. Negative margins were achieved in 91.1% of evaluable cases. Neck-evaluation omission was common: 50.5% of resected early-stage patients had no regional nodes examined, and those evaluated had a median of 24 nodes removed. Omission rates varied substantially by facility type—highest in Community (62.4%) and Comprehensive Community programs (59.3%), and lowest in Academic/Research centers (45.1%).",
        "Abstract": "Travel distance strongly correlated with facility type. Academic centers treated the majority of long-travel patients (nearly 70% of those traveling more than 35 miles), whereas Community programs predominantly cared for patients living nearby. This pattern paralleled a decline in neck-evaluation omission across travel quartiles, from 58.4% in the shortest-travel group to 43.6% in the longest.",
        "Conclusions": "Neck-evaluation quality in early-stage OSCC is shaped by both facility type and the travel patterns that determine where patients receive care. Shorter travel and treatment in lower-volume community settings are associated with markedly higher omission, while longer-distance referral to Academic centers yields more consistent, guideline-concordant nodal assessment. Strengthening referral pathways may reduce avoidable variation in care quality."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Determinants of Neck Evaluation Quality in Early-Stage Oral Cavity Cancer: Influence of Facility Type, Travel Distance, and System-Level Referral Patterns in a National Cohort</span>. <u>Vishal Gupta, MD</u>; Alex Vaicius, MD; Ryan P McSpadden, MD; William J Magner, PhD; Christine R Burton, MD; Jenny Romero, MD; Kimberly E Wooten, MD; Wesley L Hicks Jr, MD. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Elective neck evaluation is a fundamental component of guideline-concordant care for early-stage oral cavity squamous cell carcinoma (OSCC), yet national practice patterns show substantial variation in whether lymph nodes are pathologically assessed. System-level determinants—including facility type and patient travel distance—may influence treatment quality, but their relationships remain incompletely described.</p>\n\n<p><strong>Methods: </strong>We analyzed a multi-subsite National Cancer Database (NCDB) cohort by merging three Participant User Files for oral tongue, floor of mouth, and gum/other mouth cancers. Early-stage disease was defined using the Analytic Stage Group (Stages I–II). Surgery was restricted to resections only (RX_SUMM_SURG_PRIM_SITE codes 20–80), excluding biopsies. Neck evaluation was measured using the number of regional lymph nodes examined, and travel distance using the CROWFLY great-circle metric. Facility type designations followed Commission on Cancer designations. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.</p>\n\n<p><strong>Results: </strong>Across the multi-subsite cohort (N?=?305,837), 112,069 patients had early-stage disease and 77.4% underwent resection. Negative margins were achieved in 91.1% of evaluable cases. Neck-evaluation omission was common: 50.5% of resected early-stage patients had no regional nodes examined, and those evaluated had a median of 24 nodes removed. Omission rates varied substantially by facility type—highest in Community (62.4%) and Comprehensive Community programs (59.3%), and lowest in Academic/Research centers (45.1%).</p>\n\n<p>Travel distance strongly correlated with facility type. Academic centers treated the majority of long-travel patients (nearly 70% of those traveling more than 35 miles), whereas Community programs predominantly cared for patients living nearby. This pattern paralleled a decline in neck-evaluation omission across travel quartiles, from 58.4% in the shortest-travel group to 43.6% in the longest.</p>\n\n<p><strong>Conclusions: </strong>Neck-evaluation quality in early-stage OSCC is shaped by both facility type and the travel patterns that determine where patients receive care. Shorter travel and treatment in lower-volume community settings are associated with markedly higher omission, while longer-distance referral to Academic centers yields more consistent, guideline-concordant nodal assessment. Strengthening referral pathways may reduce avoidable variation in care quality.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155434--></body></html>"
    },
    {
      "uid": "P142",
      "content_id": "155424",
      "abstract_number": "P142",
      "poster_number": "P142",
      "title": "COVID?19 Testing, Positivity, and Timeliness of Care in Tongue/Oral Cavity Cancer: An NCDB Study (2020–2021)",
      "summary": "During 2020–2021, COVID-19 positivity was associated with a consistent prolongation of treatment intervals, most prominently for surgery, and with a modest shift toward CRT and RT-only primary management. While median delays were small, the increased proportion of patients experiencing extended, clinically relevant postponements underscores the impact of infection-related operational barriers. Facility-type...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155424",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Vishal Gupta, MD 1 ; Lynn Sigurdson, PhD 1 ; Michael R Markiewicz, MD, DDS 2 ; Anurag K Singh, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1",
      "normalized_authors": [
        "Vishal Gupta",
        "Lynn Sigurdson",
        "Michael R Markiewicz",
        "Anurag K Singh",
        "Kimberly E Wooten",
        "Ryan P McSpadden"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Vishal Gupta, MD 1 ; Lynn Sigurdson, PhD 1 ; Michael R Markiewicz, MD, DDS 2 ; Anurag K Singh, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Background": "The COVID-19 pandemic disrupted surgical and multidisciplinary workflows across health systems, raising concerns about delayed initiation of therapy for time-sensitive malignancies. Tongue and oral cavity cancers typically require prompt surgical management and sequenced adjuvant therapy. Beginning in 2020, the National Cancer Database (NCDB) incorporated SARS-CoV-2 testing, positivity indicators, and day-level treatment timing fields, enabling direct assessment of pandemic-era treatment intervals. We sought to characterize the association of COVID-19 testing and positivity with time-to-treatment and initial management patterns for tongue/oral cavity squamous cell carcinoma.",
        "Methods": "Using the NCDB 2022 Tongue Participant User File, we identified adults diagnosed with invasive tongue/oral cavity carcinoma in 2020–2021. Exposures included documented SARS-CoV-2 testing and test positivity. Outcomes were time to first surgery, time to initial radiation therapy, and time to systemic therapy, obtained from NCDB days-from-diagnosis fields. Initial treatment category was reconstructed using NCDB summary treatment variables and sequencing codes (Surgery only; Surgery+RT; Definitive chemoradiation [CRT]; RT-only; Systemic-only; Other/None). All analyses were descriptive. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.",
        "Results": "Of 25,921 pandemic-era patients, 15,351 underwent testing and 1,044 tested positive (6.8% of those tested). COVID-positive patients experienced consistently longer intervals before treatment initiation. Median time-to-surgery was 34 days (IQR 16–50) among COVID-positive individuals versus 30 days (13–46.5) among COVID-negative patients. Median time-to-radiation was 65 days (45–92) versus 61 days (41–89), and time-to-systemic therapy was 56 days (39–80.3) versus 50 days (36–74), respectively. Although the absolute median differences were modest, the delay distributions were right-shifted among COVID-positive patients, indicating that a greater proportion exceeded commonly accepted institutional thresholds for timely initiation of surgery and adjuvant therapy.",
        "Abstract": "Treatment patterns differed by COVID status. In COVID-negative patients, management included Surgery only (32.1%), Surgery+RT (23.6%), CRT (31.7%), RT-only (4.6%), and Systemic-only (2.6%). Among COVID-positive patients, CRT usage increased (37.8%), RT-only was modestly higher (6.0%), while Surgery-only decreased (22.8%); Surgery+RT comprised 25.9%. These differences suggest a shift toward non-operative or multimodality approaches in the context of active infection. Facility-type distribution among tested individuals was similar in COVID-positive and COVID-negative groups (Academic/Research 57.1% vs 55.3%), indicating that infection-related perioperative constraints, rather than changes in referral or access patterns, primarily contributed to observed delays.",
        "Conclusions": "During 2020–2021, COVID-19 positivity was associated with a consistent prolongation of treatment intervals, most prominently for surgery, and with a modest shift toward CRT and RT-only primary management. While median delays were small, the increased proportion of patients experiencing extended, clinically relevant postponements underscores the impact of infection-related operational barriers. Facility-type similarity across COVID strata further supports the interpretation that delays reflected pandemic-era workflow and perioperative restrictions, rather than differential access to specialized centers. These findings highlight the need for resilient perioperative systems capable of preserving timely head and neck cancer care during infectious surges."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>COVID?19 Testing, Positivity, and Timeliness of Care in Tongue/Oral Cavity Cancer: An NCDB Study (2020–2021)</span>. <u>Vishal Gupta, MD</u><sup>1</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Michael R Markiewicz, MD, DDS<sup>2</sup>; Anurag K Singh, MD<sup>1</sup>; Kimberly E Wooten, MD<sup>1</sup>; Ryan P McSpadden, MD<sup>1</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The COVID-19 pandemic disrupted surgical and multidisciplinary workflows across health systems, raising concerns about delayed initiation of therapy for time-sensitive malignancies. Tongue and oral cavity cancers typically require prompt surgical management and sequenced adjuvant therapy. Beginning in 2020, the National Cancer Database (NCDB) incorporated SARS-CoV-2 testing, positivity indicators, and day-level treatment timing fields, enabling direct assessment of pandemic-era treatment intervals. We sought to characterize the association of COVID-19 testing and positivity with time-to-treatment and initial management patterns for tongue/oral cavity squamous cell carcinoma.</p>\n\n<p><strong>Methods: </strong>Using the NCDB 2022 Tongue Participant User File, we identified adults diagnosed with invasive tongue/oral cavity carcinoma in 2020–2021. Exposures included documented SARS-CoV-2 testing and test positivity. Outcomes were time to first surgery, time to initial radiation therapy, and time to systemic therapy, obtained from NCDB days-from-diagnosis fields. Initial treatment category was reconstructed using NCDB summary treatment variables and sequencing codes (Surgery only; Surgery+RT; Definitive chemoradiation [CRT]; RT-only; Systemic-only; Other/None). All analyses were descriptive. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.</p>\n\n<p><strong>Results: </strong>Of 25,921 pandemic-era patients, 15,351 underwent testing and 1,044 tested positive (6.8% of those tested). COVID-positive patients experienced consistently longer intervals before treatment initiation. Median time-to-surgery was 34 days (IQR 16–50) among COVID-positive individuals versus 30 days (13–46.5) among COVID-negative patients. Median time-to-radiation was 65 days (45–92) versus 61 days (41–89), and time-to-systemic therapy was 56 days (39–80.3) versus 50 days (36–74), respectively. Although the absolute median differences were modest, the delay distributions were right-shifted among COVID-positive patients, indicating that a greater proportion exceeded commonly accepted institutional thresholds for timely initiation of surgery and adjuvant therapy.</p>\n\n<p>Treatment patterns differed by COVID status. In COVID-negative patients, management included Surgery only (32.1%), Surgery+RT (23.6%), CRT (31.7%), RT-only (4.6%), and Systemic-only (2.6%). Among COVID-positive patients, CRT usage increased (37.8%), RT-only was modestly higher (6.0%), while Surgery-only decreased (22.8%); Surgery+RT comprised 25.9%. These differences suggest a shift toward non-operative or multimodality approaches in the context of active infection. Facility-type distribution among tested individuals was similar in COVID-positive and COVID-negative groups (Academic/Research 57.1% vs 55.3%), indicating that infection-related perioperative constraints, rather than changes in referral or access patterns, primarily contributed to observed delays.</p>\n\n<p><strong>Conclusions: </strong>During 2020–2021, COVID-19 positivity was associated with a consistent prolongation of treatment intervals, most prominently for surgery, and with a modest shift toward CRT and RT-only primary management. While median delays were small, the increased proportion of patients experiencing extended, clinically relevant postponements underscores the impact of infection-related operational barriers. Facility-type similarity across COVID strata further supports the interpretation that delays reflected pandemic-era workflow and perioperative restrictions, rather than differential access to specialized centers. These findings highlight the need for resilient perioperative systems capable of preserving timely head and neck cancer care during infectious surges.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155424--></body></html>"
    },
    {
      "uid": "P143",
      "content_id": "153097",
      "abstract_number": "P143",
      "poster_number": "P143",
      "title": "Prosthetic rehabilitation: a successful alternative to preserve the quality of life in head and neck cancer patients in low-income country. January 2010 to July 2025 Oncologic Program, Salud Inte",
      "summary": "Immediate and definitive prosthetic rehabilitation offers a cost-effective, functional, and aesthetic solution for patients undergoing oncologic resections in the maxillofacial region. It preserves vital functions, enables oncologic surveillance, and is especially valuable in resource-limited setting",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153097",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Francisco Medrano, Head and Neck Surgeon",
      "presenter": "Francisco Medrano, Head and Neck Surgeon",
      "authors": "Francisco Medrano, Head and Neck Surgeon 1 ; Róger Padilla, Maxilofacial and Prosthetic Surgeon 1 ; Augusto César Castro, Oral Surgeon and Pathotogist 2 ; Carmen Marcela Quezada, Hematopathologist 1 ; Róger Ariel Matus, Radiologist 3",
      "normalized_authors": [
        "Francisco Medrano, Head and Neck Surgeon",
        "Róger Padilla, Maxilofacial and Prosthetic Surgeon",
        "Augusto César Castro, Oral Surgeon and Pathotogist",
        "Carmen Marcela Quezada, Hematopathologist",
        "Róger Ariel Matus, Radiologist"
      ],
      "affiliations": [
        "Salud Integral Hospital",
        "Linda Vista Medical Center Managua",
        "X Ray Medical Center"
      ],
      "normalized_institutions": [
        "Salud Integral Hospital",
        "Linda Vista Medical Center Managua",
        "X Ray Medical Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 257,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Francisco Medrano, Head and Neck Surgeon 1 ; Róger Padilla, Maxilofacial and Prosthetic Surgeon 1 ; Augusto César Castro, Oral Surgeon and Pathotogist 2 ; Carmen Marcela Quezada, Hematopathologist 1 ; Róger Ariel Matus, Radiologist 3",
        "Affiliations": "1 Salud Integral Hospital; 2 Linda Vista Medical Center Managua; 3 X Ray Medical Center",
        "Abstract": "Tumors affecting the maxillofacial region often compromise vital functions such as speech, mastication, swallowing, and facial aesthetics. While microvascular free flap reconstruction remains a gold standard, its limitations in low-resource settings highlight the relevance of prosthetic rehabilitation as a viable alternative.",
        "Objective": "To evaluate the functional and aesthetic outcomes of patients with maxillary and mandibular tumors who underwent oncologic resection followed by immediate and definitive prosthetic rehabilitation.",
        "Methods": "A retrospective review was conducted of 450 patients diagnosed with head and neck tumors from January 2010 to July 2025. Ten patients meeting inclusion criteria (maxillary or mandibular tumor, prosthetic rehabilitation) were analyzed. Tumors were classified per WHO 5th edition (2023). Surgical approaches included total or infrastructure maxillectomy and segmental or total mandibulectomy. Titanium plates and screws were used in all reconstructions. Functional outcomes were assessed using speech intelligibility (Plank test), oral function parameters (Usui criteria), and facial symmetry (Chatrath method).",
        "Results": "The cohort included five maxillary and five mandibular tumor cases, with equal gender distribution and a mean age of 37 years. Maxillary pathologies included sarcoma, cylindroma, and mucoepidermoid carcinoma; mandibular tumors were predominantly multicystic ameloblastomas. All patients achieved 100% speech intelligibility with both obturator and definitive prosthesis. No fluid leakage, mastication, or swallowing disorders were reported. Mandibular reconstructions maintained >4 cm oral opening without deviation. facial symmetry was preserved in all patients, facilitating psychosocial reintegration.",
        "Conclusion": "Immediate and definitive prosthetic rehabilitation offers a cost-effective, functional, and aesthetic solution for patients undergoing oncologic resections in the maxillofacial region. It preserves vital functions, enables oncologic surveillance, and is especially valuable in resource-limited setting"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prosthetic rehabilitation: a successful alternative to preserve the quality of life in head and neck cancer patients in low-income country. January 2010 to July 2025 Oncologic Program, Salud Integral Hospital, Managua, Nicaragua</span>. <u>Francisco Medrano, Head and Neck Surgeon</u><sup>1</sup>; Róger Padilla, Maxilofacial and Prosthetic Surgeon<sup>1</sup>; Augusto César Castro, Oral Surgeon and Pathotogist<sup>2</sup>; Carmen Marcela Quezada, Hematopathologist<sup>1</sup>; Róger Ariel Matus, Radiologist<sup>3</sup>. <sup>1</sup>Salud  Integral Hospital; <sup>2</sup>Linda Vista Medical Center Managua; <sup>3</sup>X Ray Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Tumors affecting the maxillofacial region often compromise vital functions such as speech, mastication, swallowing, and facial aesthetics. While microvascular free flap reconstruction remains a gold standard, its limitations in low-resource settings highlight the relevance of prosthetic rehabilitation as a viable alternative.</p>\n\n<p><strong>Objective: </strong>To evaluate the functional and aesthetic outcomes of patients with maxillary and mandibular tumors who underwent oncologic resection followed by immediate and definitive prosthetic rehabilitation.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted of 450 patients diagnosed with head and neck tumors from January 2010 to July 2025. Ten patients meeting inclusion criteria (maxillary or mandibular tumor, prosthetic rehabilitation) were analyzed. Tumors were classified per WHO 5th edition (2023). Surgical approaches included total or infrastructure maxillectomy and segmental or total mandibulectomy. Titanium plates and screws were used in all reconstructions. Functional outcomes were assessed using speech intelligibility (Plank test), oral function parameters (Usui criteria), and facial symmetry (Chatrath method).</p>\n\n<p><strong>Results: </strong>The cohort included five maxillary and five mandibular tumor cases, with equal gender distribution and a mean age of 37 years. Maxillary pathologies included sarcoma, cylindroma, and mucoepidermoid carcinoma; mandibular tumors were predominantly multicystic ameloblastomas. All patients achieved 100% speech intelligibility with both obturator and definitive prosthesis. No fluid leakage, mastication, or swallowing disorders were reported. Mandibular reconstructions maintained >4 cm oral opening without deviation. facial symmetry was preserved in all patients, facilitating psychosocial reintegration.</p>\n\n<p><strong>Conclusion: </strong>Immediate and definitive prosthetic rehabilitation offers a cost-effective, functional, and aesthetic solution for patients undergoing oncologic resections in the maxillofacial region. It preserves vital functions, enables oncologic surveillance, and is especially valuable in resource-limited setting</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153097--></body></html>"
    },
    {
      "uid": "P144",
      "content_id": "153808",
      "abstract_number": "P144",
      "poster_number": "P144",
      "title": "Gender Differences in Outcomes Following Neoadjuvant Pembrolizumab in Head and Neck Cancer Surgery",
      "summary": "In this cohort, female patients had shorter intervals to death despite longer intervals to recurrence, and a greater proportion of female deaths were preceded by cancer recurrence compared with males. These trends suggest that mortality in female patients may be more strongly linked to recurrent disease. Although these associations were not statistically significant after age adjustment and high-risk status, the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153808",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arya Dahal, PhD",
      "presenter": "Arya Dahal, PhD",
      "authors": "Arya Dahal, PhD ; Priscilla F Pichardo, DO; Dustin A Silverman, MD; Chad A Zender, MD; Alice L Tang, MD; Trisha M Wise-Draper, MD, PhD",
      "normalized_authors": [
        "Arya Dahal",
        "Priscilla F Pichardo",
        "Dustin A Silverman",
        "Chad A Zender",
        "Alice L Tang",
        "Trisha M Wise-Draper"
      ],
      "affiliations": [
        "University of Cincinnati College of Medicine"
      ],
      "normalized_institutions": [
        "University of Cincinnati College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Arya Dahal, PhD ; Priscilla F Pichardo, DO; Dustin A Silverman, MD; Chad A Zender, MD; Alice L Tang, MD; Trisha M Wise-Draper, MD, PhD",
        "Affiliations": "University of Cincinnati College of Medicine",
        "Introduction": "Gender disparities have been reported in survival outcomes for head and neck cancer. Although some studies suggest better survival in women, these sex-based differences are often not significant in matched-pair analyses. Recent studies have also shown improved event free survival in advanced stage head and neck cancer patients treated with neoadjuvant immunotherapy. We evaluated sex-based differences in baseline characteristics and clinical outcomes, including cancer recurrence and death, in treatment naïve patients with head and neck squamous cell carcinoma receiving neoadjuvant immunotherapy.",
        "Methods": "A retrospective review was performed of patients with resectable HPV-negative squamous cell carcinoma of the oral cavity, larynx, hypopharynx or oropharynx who received neoadjuvant pembrolizumab followed by surgery from 2016-2020. All patients received adjuvant radiation as well as concurrent cisplatin for those with high-risk pathological features. Recurrence and death rates, as well as intervals from diagnosis, surgery, and end of treatment to recurrence or death, were compared using Chi-square and Wilcoxon rank-sum tests. Generalized linear models incorporating age and high-risk stratification were used when applicable.",
        "Results": "Seventy-five patients were included in the study, 23 (30.7%) were female and 52 (69.3%) were male. At initial diagnosis, females were older (median age of 60 years, IQR: 55-70.5) than males (median age of 55 years, IQR: 47-62.2). Other baseline characteristics including race, ethnicity, extensive smoking and alcohol exposures, primary site of disease, histological grade, high-risk stratification and programmed death-ligand 1 (PD-L1) combined positivity scores were similar between groups.",
        "Abstract": "Males had a longer interval from diagnosis to surgery (46 days vs 33 days). Recurrence occurred in 9 females (39.1%) and 13 males (25%). Among patients who recurred, females showed a trend toward longer intervals from diagnosis, surgery, and end of treatment to recurrence. Eight females (34.8%) and 21 males (40.4%) died during the follow-up period. Of the 8 female deaths, 7 (87.5%) were associated with prior recurrence, compared with 11 of 21 male deaths (52.4%). Among patients who died, females showed a trend toward consistently shorter intervals from diagnosis, surgery and end of treatment to death than males. Disease-free and overall survival did not differ significantly between sexes.",
        "Conclusion": "In this cohort, female patients had shorter intervals to death despite longer intervals to recurrence, and a greater proportion of female deaths were preceded by cancer recurrence compared with males. These trends suggest that mortality in female patients may be more strongly linked to recurrent disease. Although these associations were not statistically significant after age adjustment and high-risk status, the patterns observed may help identify female patients at increased risk for earlier mortality. Further investigation into the biological or clinical drivers of these sex-based differences and validation in a larger cohort is warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Gender Differences in Outcomes Following Neoadjuvant Pembrolizumab in Head and Neck Cancer Surgery</span>. <u>Arya Dahal, PhD</u>; Priscilla F Pichardo, DO; Dustin A Silverman, MD; Chad A Zender, MD; Alice L Tang, MD; Trisha M Wise-Draper, MD, PhD. University of Cincinnati College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Gender disparities have been reported in survival outcomes for head and neck cancer. Although some studies suggest better survival in women, these sex-based differences are often not significant in matched-pair analyses. Recent studies have also shown improved event free survival in advanced stage head and neck cancer patients treated with neoadjuvant immunotherapy.  We evaluated sex-based differences in baseline characteristics and clinical outcomes, including cancer recurrence and death, in treatment naïve patients with head and neck squamous cell carcinoma receiving neoadjuvant immunotherapy.  </p>\n\n<p><strong>Methods</strong>: A retrospective review was performed of patients with resectable HPV-negative squamous cell carcinoma of the oral cavity, larynx, hypopharynx or oropharynx who received neoadjuvant pembrolizumab followed by surgery from 2016-2020. All patients received adjuvant radiation as well as concurrent cisplatin for those with high-risk pathological features. Recurrence and death rates, as well as intervals from diagnosis, surgery, and end of treatment to recurrence or death, were compared using Chi-square and Wilcoxon rank-sum tests. Generalized linear models incorporating age and high-risk stratification were used when applicable. </p>\n\n<p><strong>Results</strong>: Seventy-five patients were included in the study, 23 (30.7%) were female and 52 (69.3%) were male. At initial diagnosis, females were older (median age of 60 years, IQR: 55-70.5) than males (median age of 55 years, IQR: 47-62.2). Other baseline characteristics including race, ethnicity, extensive smoking and alcohol exposures, primary site of disease, histological grade, high-risk stratification and programmed death-ligand 1 (PD-L1) combined positivity scores were similar between groups.  </p>\n\n<p>Males had a longer interval from diagnosis to surgery (46 days vs 33 days). Recurrence occurred in 9 females (39.1%) and 13 males (25%). Among patients who recurred, females showed a trend toward longer intervals from diagnosis, surgery, and end of treatment to recurrence. </p>\n\n<p>Eight females (34.8%) and 21 males (40.4%) died during the follow-up period. Of the 8 female deaths, 7 (87.5%) were associated with prior recurrence, compared with 11 of 21 male deaths (52.4%). Among patients who died, females showed a trend toward consistently shorter intervals from diagnosis, surgery and end of treatment to death than males. Disease-free and overall survival did not differ significantly between sexes. </p>\n\n<p><strong>Conclusion</strong>: In this cohort, female patients had shorter intervals to death despite longer intervals to recurrence, and a greater proportion of female deaths were preceded by cancer recurrence compared with males. These trends suggest that mortality in female patients may be more strongly linked to recurrent disease. Although these associations were not statistically significant after age adjustment and high-risk status, the patterns observed may help identify female patients at increased risk for earlier mortality. Further investigation into the biological or clinical drivers of these sex-based differences and validation in a larger cohort is warranted.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153808--></body></html>"
    },
    {
      "uid": "P145",
      "content_id": "154239",
      "abstract_number": "P145",
      "poster_number": "P145",
      "title": "Submental Island vs. Radial Forearm Free Flap for Hemiglossectomy Reconstruction: A Comparative Analysis of Postoperative Function",
      "summary": "The submental island flap and RFFF are both suitable options for hemiglossectomy reconstruction. It appears that patients reconstructed with submental island flaps initially experience less feeding tube dependence than those reconstructed with RFFF. This trend diminishes at 1-year post-surgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154239",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "William N Doyle, MD",
      "presenter": "William N Doyle, MD",
      "authors": "William N Doyle, MD ; John Paul T Arrios, BS; Anya Forma, BS; Vanessa Stubbs, MD; Michael Eggerstedt, MD; Kerstin Stenson, MD; Mihir Bhayani, MD; Samer Al-Khudari, MD",
      "normalized_authors": [
        "William N Doyle",
        "John Paul T Arrios",
        "Anya Forma",
        "Vanessa Stubbs",
        "Michael Eggerstedt",
        "Kerstin Stenson",
        "Mihir Bhayani",
        "Samer Al-Khudari"
      ],
      "affiliations": [
        "Rush University Medical Center"
      ],
      "normalized_institutions": [
        "Rush University Medical Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "",
          "rows": [
            [
              "",
              "Submental Island",
              "RFFF",
              "p-value"
            ],
            [
              "30-day Complications"
            ],
            [
              "Bleeding requiring OR",
              "1(9.1%)",
              "0",
              "p=1.000"
            ],
            [
              "Dehiscence",
              "1(9.1%)",
              "2(18.2%)",
              "p=0.6071"
            ],
            [
              "Pharyngocutaneous Fistula",
              "0",
              "1(9.1%)",
              "p=1.000"
            ],
            [
              "Return to OR",
              "2(18.2%)",
              "1(9.1%)",
              "p=0.6071"
            ],
            [
              "Flap Loss",
              "1(9.1%)",
              "0",
              "p=1.000"
            ],
            [
              "ICU Admission",
              "3(27.3%)",
              "11(100%)",
              "p=0.0010*"
            ],
            [
              "LOS",
              "8.1",
              "10.3",
              "p=0.2012"
            ],
            [
              "Inpatient Nutrition"
            ],
            [
              "Prophylactic PEG",
              "1(9.1%)",
              "4(36.4%)",
              "p=0.3108"
            ],
            [
              "PO Resumed during admission",
              "10(90.9%)",
              "8(72.7%)",
              "p=0.5865"
            ],
            [
              "POD# of PO Resumption",
              "5.0",
              "6.1",
              "p=0.0966"
            ],
            [
              "Discharge PO Status"
            ],
            [
              "PO",
              "9(81.8%)",
              "3(27.3%)",
              "p=0.0357*"
            ],
            [
              "PO + Enteral Supplementation",
              "1(9.1%)",
              "3(27.3%)"
            ],
            [
              "NPO",
              "1(9.1%)",
              "5(45.5%)"
            ],
            [
              "Post-RT"
            ],
            [
              "PO",
              "7(100%)",
              "1(14.3%)",
              "p=0.0052*"
            ],
            [
              "PO + Enteral Supplementation",
              "0",
              "5(71.4%)"
            ],
            [
              "NPO",
              "0",
              "1(14.3%)"
            ],
            [
              "1-year Post-surgery"
            ],
            [
              "PO",
              "8(88.9%)",
              "6(60%)",
              "p=0.2762"
            ],
            [
              "PO + Enteral Supplementation",
              "0",
              "2(20%)"
            ],
            [
              "NPO",
              "1(11.1%)",
              "2(20%)"
            ],
            [
              "Reactive G-Tube Placed",
              "2(20%)",
              "4(57.1%)",
              "p=0.1618"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 261,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "William N Doyle, MD ; John Paul T Arrios, BS; Anya Forma, BS; Vanessa Stubbs, MD; Michael Eggerstedt, MD; Kerstin Stenson, MD; Mihir Bhayani, MD; Samer Al-Khudari, MD",
        "Affiliations": "Rush University Medical Center",
        "Background": "Reconstruction of tongue defects can be performed with a variety of locoregional and free flaps. Flap selection depends on defect size, nodal disease burden, patient comorbidities, and surgeon preference. Additional studies are needed to understand how glossectomy reconstruction impacts swallowing and function.",
        "Objective": "Present postoperative and functional outcomes in oral tongue cancer patients who underwent hemiglossectomy and immediate reconstruction with either submental island flap or radial forearm free flap (RFFF).",
        "Methods": "A retrospective chart review between 2015 and 2024 was performed. Outcomes of interest include complications, diet advancement, and enteral feeding dependence. Chi-square (or Fisher’s exact) and student’s t-test were used to compare variables.",
        "Results": "22 patients met inclusion criteria. 11 underwent submental island flap and 11 underwent RFFF. RFFF patients had significantly longer operative times (536.5 minutes vs. 232.3, p<0.0001), more tracheostomies (45.5% vs. 0%, p=0.0175), and more ICU admissions (100% vs. 27.3%, p=0.0010). Complication rates were similar (Table). Oral intake was resumed at similar timepoints, however, RFFF patients were more likely to require enteral feeding at discharge. During adjuvant radiotherapy, RFFF patients were more likely to require enteral nutrition. At one year postoperatively, each cohort had similar oral intake statuses. Reactive gastrostomy tube placement rates were statistically similar between RFF and submental island patients (57.1% vs. 20%, p=0.1618).",
        "Conclusions": "The submental island flap and RFFF are both suitable options for hemiglossectomy reconstruction. It appears that patients reconstructed with submental island flaps initially experience less feeding tube dependence than those reconstructed with RFFF. This trend diminishes at 1-year post-surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Submental Island vs. Radial Forearm Free Flap for Hemiglossectomy Reconstruction: A Comparative Analysis of Postoperative Function</span>. <u>William N Doyle, MD</u>; John Paul T Arrios, BS; Anya Forma, BS; Vanessa Stubbs, MD; Michael Eggerstedt, MD; Kerstin Stenson, MD; Mihir Bhayani, MD; Samer Al-Khudari, MD. Rush University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Reconstruction of tongue defects can be performed with a variety of locoregional and free flaps. Flap selection depends on defect size, nodal disease burden, patient comorbidities, and surgeon preference. Additional studies are needed to understand how glossectomy reconstruction impacts swallowing and function.</p>\n\n<p><strong>Objective: </strong>Present postoperative and functional outcomes in oral tongue cancer patients who underwent hemiglossectomy and immediate reconstruction with either submental island flap or radial forearm free flap (RFFF).</p>\n\n<p><strong>Methods: </strong>A retrospective chart review between 2015 and 2024 was performed. Outcomes of interest include complications, diet advancement, and enteral feeding dependence. Chi-square (or Fisher’s exact) and student’s t-test were used to compare variables.</p>\n\n<p><strong>Results: </strong>22 patients met inclusion criteria. 11 underwent submental island flap and 11 underwent RFFF. RFFF patients had significantly longer operative times (536.5 minutes vs. 232.3, p<0.0001), more tracheostomies (45.5% vs. 0%, p=0.0175), and more ICU admissions (100% vs. 27.3%, p=0.0010). Complication rates were similar (Table). Oral intake was resumed at similar timepoints, however, RFFF patients were more likely to require enteral feeding at discharge. During adjuvant radiotherapy, RFFF patients were more likely to require enteral nutrition. At one year postoperatively, each cohort had similar oral intake statuses. Reactive gastrostomy tube placement rates were statistically similar between RFF and submental island patients (57.1% vs. 20%, p=0.1618). </p>\n\n<p><strong>Conclusions: </strong>The submental island flap and RFFF are both suitable options for hemiglossectomy reconstruction. It appears that patients reconstructed with submental island flaps initially experience less feeding tube dependence than those reconstructed with RFFF. This trend diminishes at 1-year post-surgery.</p>\n\n<table align='center' border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption> </caption>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td> </td>\n\t\t\t<td>Submental Island</td>\n\t\t\t<td>RFFF</td>\n\t\t\t<td>p-value</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan='4'><strong>30-day Complications</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Bleeding requiring OR</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>0</td>\n\t\t\t<td>p=1.000</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Dehiscence</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>2(18.2%)</td>\n\t\t\t<td>p=0.6071</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Pharyngocutaneous Fistula</td>\n\t\t\t<td>0</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>p=1.000</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Return to OR</td>\n\t\t\t<td>2(18.2%)</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>p=0.6071</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Flap Loss </td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>0</td>\n\t\t\t<td>p=1.000</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>ICU Admission</td>\n\t\t\t<td>3(27.3%)</td>\n\t\t\t<td>11(100%)</td>\n\t\t\t<td><strong>p=0.0010*</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>LOS </td>\n\t\t\t<td>8.1</td>\n\t\t\t<td>10.3</td>\n\t\t\t<td>p=0.2012</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan='4'><strong>Inpatient Nutrition</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Prophylactic PEG</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>4(36.4%)</td>\n\t\t\t<td>p=0.3108</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO Resumed during admission</td>\n\t\t\t<td>10(90.9%)</td>\n\t\t\t<td>8(72.7%)</td>\n\t\t\t<td>p=0.5865</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>POD# of PO Resumption</td>\n\t\t\t<td>5.0</td>\n\t\t\t<td>6.1</td>\n\t\t\t<td>p=0.0966</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan='4'><em>Discharge PO Status</em></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO</td>\n\t\t\t<td>9(81.8%)</td>\n\t\t\t<td>3(27.3%)</td>\n\t\t\t<td colspan='1' rowspan='3'><strong>p=0.0357*</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO + Enteral Supplementation</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>3(27.3%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>NPO</td>\n\t\t\t<td>1(9.1%)</td>\n\t\t\t<td>5(45.5%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan='4'><strong>Post-RT</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO</td>\n\t\t\t<td>7(100%)</td>\n\t\t\t<td>1(14.3%)</td>\n\t\t\t<td colspan='1' rowspan='3'><strong>p=0.0052*</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO + Enteral Supplementation</td>\n\t\t\t<td>0</td>\n\t\t\t<td>5(71.4%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>NPO</td>\n\t\t\t<td>0</td>\n\t\t\t<td>1(14.3%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan='4'><strong>1-year Post-surgery</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO</td>\n\t\t\t<td>8(88.9%)</td>\n\t\t\t<td>6(60%)</td>\n\t\t\t<td colspan='1' rowspan='3'>p=0.2762</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>PO + Enteral Supplementation</td>\n\t\t\t<td>0</td>\n\t\t\t<td>2(20%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>NPO</td>\n\t\t\t<td>1(11.1%)</td>\n\t\t\t<td>2(20%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Reactive G-Tube Placed</td>\n\t\t\t<td>2(20%)</td>\n\t\t\t<td>4(57.1%)</td>\n\t\t\t<td>p=0.1618</td>\n\t\t</tr>\n\t</tbody>\n</table><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154239--></body></html>"
    },
    {
      "uid": "P146",
      "content_id": "154025",
      "abstract_number": "P146",
      "poster_number": "P146",
      "title": "Sarcomas of the head and neck: An institutional review of clinicopathologic features and outcomes analysis",
      "summary": "During the study period there were 43 subjects that met inclusion criteria. The cohort had a mean age of 53.8 years, was 79% male, and 67% White. Hard tissue sarcomas accounted for 51% of tumors, including 21 osteosarcomas. The mandible was the most common site (44%), and most subjects were treated for T1 disease (55.8%). Clear margins were achieved in 70% of cases. At latest follow-up, 13 subjects (30.2%)...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154025",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aaron Bliss, DMD",
      "presenter": "Aaron Bliss, DMD",
      "authors": "Cameron C Lee, MD, DDS; Aaron Bliss, DMD ; Pauline Shih, MD; Donita Dyalram, MD, DDS; Michael Kallen, MD; Joshua Lubek, MD, DDS",
      "normalized_authors": [
        "Cameron C Lee",
        "Aaron Bliss",
        "Pauline Shih",
        "Donita Dyalram",
        "Michael Kallen",
        "Joshua Lubek"
      ],
      "affiliations": [
        "University of Maryland"
      ],
      "normalized_institutions": [
        "University of Maryland"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting, and Participants",
        "Main Outcome and Measures",
        "Results",
        "Conclusions and Relevance"
      ],
      "sections": {
        "Authors": "Cameron C Lee, MD, DDS; Aaron Bliss, DMD ; Pauline Shih, MD; Donita Dyalram, MD, DDS; Michael Kallen, MD; Joshua Lubek, MD, DDS",
        "Affiliations": "University of Maryland",
        "Importance": "Head and neck sarcomas are rare malignancies with limited contemporary data describing patterns of recurrence and survival, particularly in surgically managed cohorts.",
        "Objective": "To characterize clinicopathologic features and evaluate factors associated with time to recurrence and death in patients undergoing surgical resection for head and neck sarcoma.",
        "Design, Setting, and Participants": "Retrospective cohort study of consecutive patients with primary head and neck sarcoma treated with curative-intent surgery at a tertiary care academic center between 2010 and 2023.",
        "Main Outcome and Measures": "Primary outcomes were time to recurrence and time to death. Univariate Cox proportional hazards models were used to identify associations between covariates and outcomes. Kaplan-Meier analysis was used to estimate survival distributions. Study covariates included demographic characteristics, tumor location, histology, surgical margins, treatment modality, staging, reconstructive modality, and percent tumor necrosis.",
        "Results": "During the study period there were 43 subjects that met inclusion criteria. The cohort had a mean age of 53.8 years, was 79% male, and 67% White. Hard tissue sarcomas accounted for 51% of tumors, including 21 osteosarcomas. The mandible was the most common site (44%), and most subjects were treated for T1 disease (55.8%). Clear margins were achieved in 70% of cases. At latest follow-up, 13 subjects (30.2%) developed recurrence and 7 (16.3%) died. On univariate analysis, increasing age was associated with shorter time to recurrence (HR 1.04 per year, 95% CI 1.01 – 1.08, p = 0.027). Subjects treated with surgery plus neoadjuvant and adjuvant therapy also demonstrated shorter time to recurrence compared to surgery alone (HR 12.7, 95% CI 1.32 – 123, p = 0.028). Higher T stage and positive margins had higher odds of recurrence but did not reach statistical significance. For overall survival, stage 3 disease (HR 25.9, 95% CI 2.34 – 287, p = 0.008) was associated with shorter time to death. Percent tumor necrosis was not associated with recurrence or overall survival. In the subgroup of osteosarcomas (n = 22), no covariates were significantly associated with recurrence or death in univariate analysis. Surgery in conjunction with neoadjuvant and adjuvant therapy showed a large but non-significant effect size for recurrence (HR 7.84, 95% CI 0.81 – 75.9, p = 0.07) compared to surgery alone, likely suggesting selection for biologically aggressive tumors.",
        "Conclusions and Relevance": "In this cohort of surgically treated head and neck sarcomas, recurrence and mortality remained substantial. Older age and treatment modality were associated with earlier recurrence, while advanced stage and nodal involvement were associated with worse survival. These findings highlight the need for larger, multi-institutional studies to better define prognostic factors and optimize patient specific risk-stratified treatment strategies for this rare group of malignancies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sarcomas of the head and neck: An institutional review of clinicopathologic features and outcomes analysis</span>. Cameron C Lee, MD, DDS; <u>Aaron Bliss, DMD</u>; Pauline Shih, MD; Donita Dyalram, MD, DDS; Michael Kallen, MD; Joshua Lubek, MD, DDS. University of Maryland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>Head and neck sarcomas are rare malignancies with limited contemporary data describing patterns of recurrence and survival, particularly in surgically managed cohorts.</p>\n\n<p><strong>Objective: </strong>To characterize clinicopathologic features and evaluate factors associated with time to recurrence and death in patients undergoing surgical resection for head and neck sarcoma.</p>\n\n<p><strong>Design, Setting, and Participants: </strong>Retrospective cohort study of consecutive patients with primary head and neck sarcoma treated with curative-intent surgery at a tertiary care academic center between 2010 and 2023.</p>\n\n<p><strong>Main Outcome and Measures: </strong>Primary outcomes were time to recurrence and time to death. Univariate Cox proportional hazards models were used to identify associations between covariates and outcomes. Kaplan-Meier analysis was used to estimate survival distributions. Study covariates included demographic characteristics, tumor location, histology, surgical margins, treatment modality, staging, reconstructive modality, and percent tumor necrosis.</p>\n\n<p><strong>Results: </strong>During the study period there were 43 subjects that met inclusion criteria. The cohort had a mean age of 53.8 years, was 79% male, and 67% White. Hard tissue sarcomas accounted for 51% of tumors, including 21 osteosarcomas. The mandible was the most common site (44%), and most subjects were treated for T1 disease (55.8%). Clear margins were achieved in 70% of cases. At latest follow-up, 13 subjects (30.2%) developed recurrence and 7 (16.3%) died. On univariate analysis, increasing age was associated with shorter time to recurrence (HR 1.04 per year, 95% CI 1.01 – 1.08, p = 0.027). Subjects treated with surgery plus neoadjuvant and adjuvant therapy also demonstrated shorter time to recurrence compared to surgery alone (HR 12.7, 95% CI 1.32 – 123, p = 0.028). Higher T stage and positive margins had higher odds of recurrence but did not reach statistical significance. For overall survival, stage 3 disease (HR 25.9, 95% CI 2.34 – 287, p = 0.008) was associated with shorter time to death. Percent tumor necrosis was not associated with recurrence or overall survival. In the subgroup of osteosarcomas (n = 22), no covariates were significantly associated with recurrence or death in univariate analysis. Surgery in conjunction with neoadjuvant and adjuvant therapy showed a large but non-significant effect size for recurrence (HR 7.84, 95% CI 0.81 – 75.9, p = 0.07) compared to surgery alone, likely suggesting selection for biologically aggressive tumors.</p>\n\n<p><strong>Conclusions and Relevance:</strong> In this cohort of surgically treated head and neck sarcomas, recurrence and mortality remained substantial. Older age and treatment modality were associated with earlier recurrence, while advanced stage and nodal involvement were associated with worse survival. These findings highlight the need for larger, multi-institutional studies to better define prognostic factors and optimize patient specific risk-stratified treatment strategies for this rare group of malignancies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154025--></body></html>"
    },
    {
      "uid": "P147",
      "content_id": "154292",
      "abstract_number": "P147",
      "poster_number": "P147",
      "title": "Impact of Neighborhood Deprivation on Early Post-Treatment Swallowing Outcomes in Head and Neck Cancer",
      "summary": "Neighborhood socioeconomic disadvantage is significantly associated with substantially poorer swallowing outcomes following chemoradiation, independent of recurrence, survival, or SLP care recommendations. Although overall dietary status distributions were not statistically different across quartiles, the observed increase in full tube-dependent patients in the more disadvantaged groups underscores a potential...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154292",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joyce S Jeong, BS",
      "presenter": "Joyce S Jeong, BS",
      "authors": "Joyce S Jeong, BS 1 ; Amani Alvi, BA 2 ; Aneek Mirza, BS 1 ; Joshua Teitcher, MS, CCCSLP 3 ; Ashley Heidtmann, MS, CCCSLP 3 ; Vanessa Stubbs, MD 2 ; Nikhil Joshi, MD 3 ; Mihir Bhayani, MD 2",
      "normalized_authors": [
        "Joyce S Jeong",
        "Amani Alvi",
        "Aneek Mirza",
        "Joshua Teitcher, CCCSLP",
        "Ashley Heidtmann, CCCSLP",
        "Vanessa Stubbs",
        "Nikhil Joshi",
        "Mihir Bhayani"
      ],
      "affiliations": [
        "Rush Medical College, Rush University Medical Center, Chicago, IL 60612",
        "Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612",
        "Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612"
      ],
      "normalized_institutions": [
        "Rush Medical College, Rush University Medical Center, Chicago, IL 60612",
        "Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612",
        "Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 439,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Joyce S Jeong, BS 1 ; Amani Alvi, BA 2 ; Aneek Mirza, BS 1 ; Joshua Teitcher, MS, CCCSLP 3 ; Ashley Heidtmann, MS, CCCSLP 3 ; Vanessa Stubbs, MD 2 ; Nikhil Joshi, MD 3 ; Mihir Bhayani, MD 2",
        "Affiliations": "1 Rush Medical College, Rush University Medical Center, Chicago, IL 60612; 2 Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612; 3 Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612",
        "Background": "Socioeconomic disadvantage influences outcomes across cancer care, but its relationship to swallowing recovery after chemoradiation remains understudied. This study evaluated whether neighborhood deprivation, measured by the Area Deprivation Index (ADI), is associated with post-treatment swallowing outcomes in patients referred for speech language pathology (SLP) services.",
        "Methods": "A retrospective cohort of 596 adult patients with a history of head and neck cancer who received SLP care for dysphagia during and/or after chemoradiation from 2019-2024 were identified. National level ADI quartiles (Q1 = top 25%, least deprived; Q4 = bottom 25%, most deprived) served as the primary exposure. Functional Oral Intake Scale (FOIS) scores, a validated 7-point measure of oral intake ranging from tube dependence to full oral diet, at the first post-treatment SLP visit served as the primary outcome. Differences across quartiles were assessed using the Kruskal-Wallis test with Dunn post-hoc correction, and chi-square tests were used to compare categorical nutritional and clinical outcomes.",
        "Results": "The preliminary data included a total of 130 patients (mean age 65.95 ± 10.98 years; 70.7% male; 73.1% White; mean ADI 46.36 ± 23.41). FOIS scores differed significantly across ADI quartiles (χ2(3) = 9.95, p = .019). Median post-treatment FOIS scores demonstrated a monotonic, stepwise decline with increasing neighborhood deprivation, with patients in the least deprived quartile (Q1) showing the highest intake levels (median FOIS = 6), and those in the most deprived quartile (Q4) showing substantially poorer intake (median FOIS = 3). Post-hoc Dunn testing confirmed a statistically significant difference between Q1 and Q4, highlighting a significant socioeconomic disparity in early post-treatment swallowing recovery. ADI was not significantly associated with pre-treatment dietary status, SLP attendance, cancer recurrence, or vital status. Although post-treatment dietary status categories (PO/NPO/tube dependent) did not differ significantly across ADI quartiles (χ²(6) = 5.56, p = .47), a trend toward increased tube-dependence was observed as ADI increased.",
        "Conclusion": "Neighborhood socioeconomic disadvantage is significantly associated with substantially poorer swallowing outcomes following chemoradiation, independent of recurrence, survival, or SLP care recommendations. Although overall dietary status distributions were not statistically different across quartiles, the observed increase in full tube-dependent patients in the more disadvantaged groups underscores a potential clinically meaningful trend. Patients from more deprived neighborhoods may face lower health literacy, reduced familiarity with complex dysphagia management instructions, and barriers to implementing compensatory swallowing strategies at home. These factors could contribute to poorer early oral intake following chemoradiation therapy. Additionally, higher baseline risk of malnutrition and limited access to nutrition resources in disadvantaged areas may lead to more conservative management decisions, including prolonged reliance on enteral feeding. These findings highlight the importance of incorporating social risk factors into dysphagia recovery pathways and survivorship planning."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Neighborhood Deprivation on Early Post-Treatment Swallowing Outcomes in Head and Neck Cancer</span>. <u>Joyce S Jeong, BS</u><sup>1</sup>; Amani Alvi, BA<sup>2</sup>; Aneek Mirza, BS<sup>1</sup>; Joshua Teitcher, MS, CCCSLP<sup>3</sup>; Ashley Heidtmann, MS, CCCSLP<sup>3</sup>; Vanessa Stubbs, MD<sup>2</sup>; Nikhil Joshi, MD<sup>3</sup>; Mihir Bhayani, MD<sup>2</sup>. <sup>1</sup>Rush Medical College, Rush University Medical Center, Chicago, IL 60612; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612; <sup>3</sup>Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Socioeconomic disadvantage influences outcomes across cancer care, but its relationship to swallowing recovery after chemoradiation remains understudied. This study evaluated whether neighborhood deprivation, measured by the Area Deprivation Index (ADI), is associated with post-treatment swallowing outcomes in patients referred for speech language pathology (SLP) services.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of 596 adult patients with a history of head and neck cancer who received SLP care for dysphagia during and/or after chemoradiation from 2019-2024 were identified. National level ADI quartiles (Q1 = top 25%, least deprived; Q4 = bottom 25%, most deprived) served as the primary exposure. Functional Oral Intake Scale (FOIS) scores, a validated 7-point measure of oral intake ranging from tube dependence to full oral diet, at the first post-treatment SLP visit served as the primary outcome. Differences across quartiles were assessed using the Kruskal-Wallis test with Dunn post-hoc correction, and chi-square tests were used to compare categorical nutritional and clinical outcomes.</p>\n\n<p><strong>Results: </strong>The preliminary data included a total of 130 patients (mean age 65.95 ± 10.98 years; 70.7% male; 73.1% White; mean ADI 46.36 ± 23.41). FOIS scores differed significantly across ADI quartiles (χ2(3) = 9.95, p = .019). Median post-treatment FOIS scores demonstrated a monotonic, stepwise decline with increasing neighborhood deprivation, with patients in the least deprived quartile (Q1) showing the highest intake levels (median FOIS = 6), and those in the most deprived quartile (Q4) showing substantially poorer intake (median FOIS = 3). Post-hoc Dunn testing confirmed a statistically significant difference between Q1 and Q4, highlighting a significant socioeconomic disparity in early post-treatment swallowing recovery. ADI was not significantly associated with pre-treatment dietary status, SLP attendance, cancer recurrence, or vital status. Although post-treatment dietary status categories (PO/NPO/tube dependent) did not differ significantly across ADI quartiles (χ²(6) = 5.56, p = .47), a trend toward increased tube-dependence was observed as ADI increased.</p>\n\n<p><strong>Conclusion: </strong>Neighborhood socioeconomic disadvantage is significantly associated with substantially poorer swallowing outcomes following chemoradiation, independent of recurrence, survival, or SLP care recommendations. Although overall dietary status distributions were not statistically different across quartiles, the observed increase in full tube-dependent patients in the more disadvantaged groups underscores a potential clinically meaningful trend. Patients from more deprived neighborhoods may face lower health literacy, reduced familiarity with complex dysphagia management instructions, and barriers to implementing compensatory swallowing strategies at home. These factors could contribute to poorer early oral intake following chemoradiation therapy. Additionally, higher baseline risk of malnutrition and limited access to nutrition resources in disadvantaged areas may lead to more conservative management decisions, including prolonged reliance on enteral feeding. These findings highlight the importance of incorporating social risk factors into dysphagia recovery pathways and survivorship planning.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154292--></body></html>"
    },
    {
      "uid": "P148",
      "content_id": "154640",
      "abstract_number": "P148",
      "poster_number": "P148",
      "title": "Tracheostomy Clinic Impact on Readmission and Emergency Room Visit Rates",
      "summary": "Patients receiving care at the tracheostomy outpatient clinic had an overall reduction in ER visits and tracheostomy related hospital admissions in the six months following the visit. Additionally, patients were able to undergo tracheoscopy, which is not offered as a standard in other specialty clinics such as pulmonary. The addition of the outpatient tracheostomy clinic serves as an excellent resource for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154640",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madeline Bald, BS",
      "presenter": "Madeline Bald, BS",
      "authors": "Madeline Bald, BS 1 ; Jennifer Faulkner, PA 2 ; Harishanker Jeyarajan, MD 2",
      "normalized_authors": [
        "Madeline Bald",
        "Jennifer Faulkner, PA",
        "Harishanker Jeyarajan"
      ],
      "affiliations": [
        "UAB Heersink School of Medicine",
        "University of Alabama at Birmingham Hospital"
      ],
      "normalized_institutions": [
        "UAB Heersink School of Medicine",
        "University of Alabama at Birmingham Hospital"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 521,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Madeline Bald, BS 1 ; Jennifer Faulkner, PA 2 ; Harishanker Jeyarajan, MD 2",
        "Affiliations": "1 UAB Heersink School of Medicine; 2 University of Alabama at Birmingham Hospital",
        "Introduction": "Tracheostomy is commonly performed in critically ill patients or those undergoing head and neck surgery, with inpatient mortality rates reported between 25% and 60%1. Up to 30% of patients experience tracheostomy-related adverse events, with long-term harm persisting in 60-70%1,2. Tracheostomy care imposes a substantial economic burden, with estimated annual costs exceeding $300,000 per patient in the United States3.",
        "Abstract": "Multidisciplinary tracheostomy teams have been shown to improve outcomes through standardized care protocols 4,5,6. Studies have demonstrated significant reductions in morbidity, mortality, and length of stay, alongside enhanced care coordination and family education 3,7,8,9. The Iowa “Trach-Trail” program similarly reported improved staff training, decreased ICU and overall hospital stay, and greater efficiency in patient management10. Intraoperative complications remain relatively uncommon and are closely linked to surgical experience, while late airway complications are more prevalent among obese patients and those with prolonged intubation especially with tubes larger than 7.511,12. Collectively, these findings underscore the importance of structured, multidisciplinary tracheostomy care in optimizing patient outcomes and resource utilization.",
        "Methods": "A single-site retrospective chart review was conducted of patients who received care from the outpatient clinic during January of 2024 to June of 2025. Background data collected included reason for visit, procedures performed, referral source, supplies ordered, and need for tracheostomy education. Data including the number of emergency room(ER) visits and tracheostomy related hospital admissions were recorded in both the six months prior to the tracheostomy clinic visit and the six months following.",
        "Results": "200 patient appointments were recorded from January 2024 to July of 2025. 62.2% of patients seen in clinic had been followed by the tracheostomy team while they were inpatient, and 37.8% of patients were referred from outside providers. 32.4% of patients were seen for evaluation of decannulation, 26.2% were chronic tracheostomy patients establishing care with the tracheostomy team, 26.9% were seen for routine tracheostomy changes, 11% were there post-discharge, and 2.8% came from pediatrics(Figure 1). 60.3% of patients underwent a tracheostomy exchange at their visit, 56.2% underwent a tracheoscopy, 19% underwent a laryngoscopy, and 13.2% underwent silver nitrate application. Only 3.3% underwent a percutaneous endoscopic gastrostomy(PEG) exchange, and only 2.5% had a stoma dilation(Figure 2). 39.9% of patients required supplies to be ordered at the clinic visit due to failure to receive supplies after discharge, difficulty communicating with supply companies, and/or providers’ lack of knowledge of required supplies. Overall, when comparing the number of ER visits and hospital admissions in the six months prior and post tracheostomy clinic visit, a 44.8% and 60% reduction was observed respectively.",
        "Conclusion": "Patients receiving care at the tracheostomy outpatient clinic had an overall reduction in ER visits and tracheostomy related hospital admissions in the six months following the visit. Additionally, patients were able to undergo tracheoscopy, which is not offered as a standard in other specialty clinics such as pulmonary. The addition of the outpatient tracheostomy clinic serves as an excellent resource for patients and a way to reduce overall healthcare costs. Larger prospective studies are necessary for further evaluation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tracheostomy Clinic Impact on Readmission and Emergency Room Visit Rates</span>. <u>Madeline Bald, BS</u><sup>1</sup>; Jennifer Faulkner, PA<sup>2</sup>; Harishanker Jeyarajan, MD<sup>2</sup>. <sup>1</sup>UAB Heersink School of Medicine; <sup>2</sup>University of Alabama at Birmingham Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Tracheostomy is commonly performed in critically ill patients or those undergoing head and neck surgery, with inpatient mortality rates reported between 25% and 60%1. Up to 30% of patients experience tracheostomy-related adverse events, with long-term harm persisting in 60-70%1,2. Tracheostomy care imposes a substantial economic burden, with estimated annual costs exceeding $300,000 per patient in the United States3.</p>\n\n<p>Multidisciplinary tracheostomy teams have been shown to improve outcomes through standardized care protocols 4,5,6. Studies have demonstrated significant reductions in morbidity, mortality, and length of stay, alongside enhanced care coordination and family education 3,7,8,9. The Iowa “Trach-Trail” program similarly reported improved staff training, decreased ICU and overall hospital stay, and greater efficiency in patient management10.</p>\n\n<p>Intraoperative complications remain relatively uncommon and are closely linked to surgical experience, while late airway complications are more prevalent among obese patients and those with prolonged intubation especially with tubes larger than 7.511,12. Collectively, these findings underscore the importance of structured, multidisciplinary tracheostomy care in optimizing patient outcomes and resource utilization.</p>\n\n<p><strong>Methods: </strong>A single-site retrospective chart review was conducted of patients who received care from the outpatient clinic during January of 2024 to June of 2025. Background data collected included reason for visit, procedures performed, referral source, supplies ordered, and need for tracheostomy education. Data including the number of emergency room(ER) visits and tracheostomy related hospital admissions were recorded in both the six months prior to the tracheostomy clinic visit and the six months following.</p>\n\n<p><strong>Results: </strong>200 patient appointments were recorded from January 2024 to July of 2025. 62.2% of patients seen in clinic had been followed by the tracheostomy team while they were inpatient, and 37.8% of patients were referred from outside providers. 32.4% of patients were seen for evaluation of decannulation, 26.2% were chronic tracheostomy patients establishing care with the tracheostomy team, 26.9% were seen for routine tracheostomy changes, 11% were there post-discharge, and 2.8% came from pediatrics(Figure 1). 60.3% of patients underwent a tracheostomy exchange at their visit, 56.2% underwent a tracheoscopy, 19% underwent a laryngoscopy, and 13.2% underwent silver nitrate application. Only 3.3% underwent a percutaneous endoscopic gastrostomy(PEG) exchange, and only 2.5% had a stoma dilation(Figure 2). 39.9% of patients required supplies to be ordered at the clinic visit due to failure to receive supplies after discharge, difficulty communicating with supply companies, and/or providers’ lack of knowledge of required supplies. Overall, when comparing the number of ER visits and hospital admissions in the six months prior and post tracheostomy clinic visit, a 44.8% and 60% reduction was observed respectively.</p>\n\n<p><strong>Conclusion: </strong>Patients receiving care at the tracheostomy outpatient clinic had an overall reduction in ER visits and tracheostomy related hospital admissions in the six months following the visit. Additionally, patients were able to undergo tracheoscopy, which is not offered as a standard in other specialty clinics such as pulmonary. The addition of the outpatient tracheostomy clinic serves as an excellent resource for patients and a way to reduce overall healthcare costs. Larger prospective studies are necessary for further evaluation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154640--></body></html>"
    },
    {
      "uid": "P149",
      "content_id": "153685",
      "abstract_number": "P149",
      "poster_number": "P149",
      "title": "The role of tumor burden and radiation therapy on speech production in patients with oropharyngeal cancer",
      "summary": "Reduced tongue path distances and slower tongue speeds align with decreased speech intelligibility in both patients recently diagnosed with HNC (pre-RT) and those who have completed RT (e.g., Rinkel et al., 2016). However, patients who have completed RT rely more on jaw movements to produce speech movements. These findings suggest that although both tumor burden and RT may negatively impact tongue movements...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153685",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Liza S Blumenfeld",
      "presenter": "Liza S Blumenfeld",
      "authors": "Liza S Blumenfeld 1 ; Kristen Linnemeyer-Risser 1 ; Ignatius Nip 2 ; Syndey Coleman 2 ; Andrew Yousef 1 ; Philip Weissbrod 1",
      "normalized_authors": [
        "Liza S Blumenfeld",
        "Kristen Linnemeyer-Risser",
        "Ignatius Nip",
        "Syndey Coleman",
        "Andrew Yousef",
        "Philip Weissbrod"
      ],
      "affiliations": [
        "University of California, San Diego",
        "San Diego State University"
      ],
      "normalized_institutions": [
        "University of California, San Diego",
        "San Diego State University"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153685/Tongue%20Path%20Distance(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153685/Tongue%20Path%20Distance(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153685"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Participants",
        "Design",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Liza S Blumenfeld 1 ; Kristen Linnemeyer-Risser 1 ; Ignatius Nip 2 ; Syndey Coleman 2 ; Andrew Yousef 1 ; Philip Weissbrod 1",
        "Affiliations": "1 University of California, San Diego; 2 San Diego State University",
        "Introduction": "Many patients with head and neck cancer (HNC) have reduced speech intelligibility (Rinkel et al., 2016), leading to diminished quality of life (Meyer et al., 2004). Approximately 80% of HNC patients undergo radiation therapy (RT) as a primary or adjuvant therapy (Borras et al., 2015). Radiation may cause acute and/or chronic damage to neighboring uninvolved tissues (Bentzen, 2006), affecting speech movements and intelligibility. Tumor location also accounts for reduced intelligibility (Stelzle et al., 2018) prior to RT in some patients (McKinstry & Perry, 2003). Therefore, tumor burden and RT may impact speech movements (Tienkamp et al., 2023) for differing reasons. Understanding the role of tumor burden and RT in the mechanism of speech intelligibility could guide personalized, targeted rehabilitation strategies (e.g., Blyth et al., 2016).",
        "Objective": "A preliminary observational cross-sectional study was conducted to quantify articulatory movement differences due to the tumor burden and due to RT-associated damage of uninvolved tissues.",
        "Participants": "Two patient groups were studied, including patients recently diagnosed with oropharyngeal cancer but who had not yet received treatment (pre-RT) (n = 7; 6 males, mean age = 62.0 years) and patients who completed definitive RT (n = 5, 5 males, mean age = 59.2 years). A group of 25 healthy, young adults (n = 25; 2 males, mean age = 21.98 years) served as the control group.",
        "Design": "Electromagnetic articulography (WAVE system; Northern Digital) was used to record tongue and jaw movements. Sensors were placed on the tongue tip and on the mandible below the lower central incisors using FDA-approved dental glue (Peri-Acyl). One sensor was placed on a rigid eyeglass frame to create an anatomically-based coordinate system. Participants produced 10 repetitions of two sentences at their habitual rate and loudness. Custom Matlab R2015a (Mathworks, 2015) algorithms (Green et al., 2013) were used to obtain the duration, path distance, and average speed of tongue and jaw movements. Separate mixed models with participants on the random statement were used to evaluate the effect of Group (healthy controls, patients after DX, patients after RT) on the dependent variables in SAS 9.4 (SAS).",
        "Results": "Both patient groups had reduced tongue path distances [F(2, 363) = 83.56, p < .0001] (see attached image) and slower tongue speeds [F(2, 363) = 108.19, p < .0001] in comparison to healthy controls. The patient group who completed RT had larger jaw path distances [F(1, 88) = 9.89, p < .01] and faster jaw speeds [F(1, 88) = 9.01, p < .01] than those recently diagnosed with HNC.",
        "Conclusion": "Reduced tongue path distances and slower tongue speeds align with decreased speech intelligibility in both patients recently diagnosed with HNC (pre-RT) and those who have completed RT (e.g., Rinkel et al., 2016). However, patients who have completed RT rely more on jaw movements to produce speech movements. These findings suggest that although both tumor burden and RT may negatively impact tongue movements during speech, RT may affect lingual mobility as reflected by greater compensatory jaw movements."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The role of tumor burden and radiation therapy on speech production in patients with oropharyngeal cancer</span>. <u>Liza S Blumenfeld</u><sup>1</sup>; Kristen Linnemeyer-Risser<sup>1</sup>; Ignatius Nip<sup>2</sup>; Syndey Coleman<sup>2</sup>; Andrew Yousef<sup>1</sup>; Philip Weissbrod<sup>1</sup>. <sup>1</sup>University of California, San Diego; <sup>2</sup>San Diego State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Many patients with head and neck cancer (HNC) have reduced speech intelligibility (Rinkel et al., 2016), leading to diminished quality of life (Meyer et al., 2004). Approximately 80% of HNC patients undergo radiation therapy (RT) as a primary or adjuvant therapy (Borras et al., 2015). Radiation may cause acute and/or chronic damage to neighboring uninvolved tissues (Bentzen, 2006), affecting speech movements and intelligibility. Tumor location also accounts for reduced intelligibility (Stelzle et al., 2018) prior to RT in some patients (McKinstry & Perry, 2003). Therefore, tumor burden and RT may impact speech movements (Tienkamp et al., 2023) for differing reasons. Understanding the role of tumor burden and RT in the mechanism of speech intelligibility could guide personalized, targeted rehabilitation strategies (e.g., Blyth et al., 2016).</p>\n\n<p><strong>Objective: </strong>A preliminary observational cross-sectional study was conducted to quantify articulatory movement differences due to the tumor burden and due to RT-associated damage of uninvolved tissues.</p>\n\n<p><strong>Participants: </strong>Two patient groups were studied, including patients recently diagnosed with oropharyngeal cancer but who had not yet received treatment (pre-RT) (n = 7; 6 males, mean age = 62.0 years) and patients who completed definitive RT (n = 5, 5 males, mean age = 59.2 years). A group of 25 healthy, young adults (n = 25; 2 males, mean age = 21.98 years) served as the control group.</p>\n\n<p><strong>Design: </strong>Electromagnetic articulography (WAVE system; Northern Digital) was used to record tongue and jaw movements. Sensors were placed on the tongue tip and on the mandible below the lower central incisors using FDA-approved dental glue (Peri-Acyl). One sensor was placed on a rigid eyeglass frame to create an anatomically-based coordinate system. Participants produced 10 repetitions of two sentences at their habitual rate and loudness. Custom Matlab R2015a (Mathworks, 2015) algorithms (Green et al., 2013) were used to obtain the duration, path distance, and average speed of tongue and jaw movements. Separate mixed models with participants on the random statement were used to evaluate the effect of Group (healthy controls, patients after DX, patients after RT) on the dependent variables in SAS 9.4 (SAS).</p>\n\n<p><strong>Results:</strong> Both patient groups had reduced tongue path distances [F(2, 363) = 83.56, p < .0001] (see attached image) and slower tongue speeds [F(2, 363) = 108.19, p < .0001] in comparison to healthy controls. The patient group who completed RT had larger jaw path distances [F(1, 88) = 9.89, p < .01] and faster jaw speeds [F(1, 88) = 9.01, p < .01] than those recently diagnosed with HNC.</p>\n\n<p><strong>Conclusion: </strong>Reduced tongue path distances and slower tongue speeds align with decreased speech intelligibility in both patients recently diagnosed with HNC (pre-RT) and those who have completed RT (e.g., Rinkel et al., 2016). However, patients who have completed RT rely more on jaw movements to produce speech movements. These findings suggest that although both tumor burden and RT may negatively impact tongue movements during speech, RT may affect lingual mobility as reflected by greater compensatory jaw movements.</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153685/Tongue%20Path%20Distance(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153685--></body></html>"
    },
    {
      "uid": "P150",
      "content_id": "154557",
      "abstract_number": "P150",
      "poster_number": "P150",
      "title": "Quality of Life Before and After Treatment in Young and Never-Smoker, Never-Drinker Patients with Head and Neck Squamous Cell Carcinoma",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) is uncommon among young (aged up to 40 years) and never-smoker, never-drinker (NSND) individuals. Younger patients may experience a disproportionate and long-lasting decline in quality of life (QoL), as treatment commonly occurs during critical phases of social, educational, and professional development. Despite growing interest in these distinct epidemiological...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154557",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beatriz Souza, Master of Science",
      "presenter": "Beatriz Souza, Master of Science",
      "authors": "Beatriz Souza, Master of Science 1 ; Ingrid Nakamuta, Master of Science 1 ; Rossana López, PhD 2 ; Alexandre Santos, phD 1 ; Maria Katayama, PhD 1 ; Simone Maistro, PhD 2 ; Fatima Pasini, phD 1 ; Gilberto de Castro Junior, PhD 1 ; Luiz Kowalski, PhD 1 ; Maria Folgueira, PhD 1",
      "normalized_authors": [
        "Beatriz Souza, Master of Science",
        "Ingrid Nakamuta, Master of Science",
        "Rossana López",
        "Alexandre Santos",
        "Maria Katayama",
        "Simone Maistro",
        "Fatima Pasini",
        "Gilberto de Castro Junior",
        "Luiz Kowalski",
        "Maria Folgueira"
      ],
      "affiliations": [
        "Faculdade de Medicina da Universidade de São Paulo",
        "Instituto do Câncer de São Paulo Octavio Frias de Oliveira"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da Universidade de São Paulo",
        "Instituto do Câncer de São Paulo Octavio Frias de Oliveira"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 511,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Beatriz Souza, Master of Science 1 ; Ingrid Nakamuta, Master of Science 1 ; Rossana López, PhD 2 ; Alexandre Santos, phD 1 ; Maria Katayama, PhD 1 ; Simone Maistro, PhD 2 ; Fatima Pasini, phD 1 ; Gilberto de Castro Junior, PhD 1 ; Luiz Kowalski, PhD 1 ; Maria Folgueira, PhD 1",
        "Affiliations": "1 Faculdade de Medicina da Universidade de São Paulo; 2 Instituto do Câncer de São Paulo Octavio Frias de Oliveira",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) is uncommon among young (aged up to 40 years) and never-smoker, never-drinker (NSND) individuals. Younger patients may experience a disproportionate and long-lasting decline in quality of life (QoL), as treatment commonly occurs during critical phases of social, educational, and professional development. Despite growing interest in these distinct epidemiological subgroups, longitudinal QoL outcomes in young and NSND patients remain insufficiently characterized. This study aimed to evaluate QoL trajectories from patients diagnosed with HNSCC by comparing baseline QoL scores with those obtained during treatment and three months after completion. Patients treated at the Head and Neck Surgery Department of the Cancer Institute of the State of São Paulo were invited to complete the EORTC QLQ-C30 and QLQ-H&N43 questionnaires. Young patients were defined as individuals aged 18 to 40 years at diagnosis, while NSND were defined as individuals who had never smoked or had smoked fewer than 100 cigarettes in their lifetime (never smoker), and whose alcohol consumption did not exceed 12 drinks over their lifetime (Lifetime abstainer). All participants received standard therapy, including surgery and radiotherapy or chemotherapy when indicated. QoL questionnaires were administered at four time points: prior to treatment initiation, three to five weeks after surgery, three to five weeks after adjuvant treatment, and three months after the final treatment session. A total of twenty-five patients, 16 females and 9 males, were enrolled between July 2023 and March 2025, comprising nineteen NSND patients and six young individuals. The tongue was the most common primary tumor site, present in 64% of cases. Most patients,60%, presented with advanced stage III or IV disease. The most frequent TNM category was T2N0, observed in twenty-eight percent of participants. All tumors tested were HPV-negative. The median BMI was 26.7 among NSND individuals and 25.5 among young patients. Median age at diagnosis was 53.4 years (min: 20; max: 82), with mean ages of 34.5 years and 59.4 years in the young and NSND groups, respectively. Baseline global health status was good, with mean scores of 71 for young patients and 80 for NSND individuals. Mean and median score values for functional scales were all above 70, indicating high/good physical, role, emotional, cognitive, and social functionings. Although some patients reported very high scores for the functional scales and global health status (100), others presented severe impairments, including scores of zero in emotional and social functioning and global health. Cognitive functioning showed the highest scores in both groups (91.27 for young and 87.96 for NSND), followed by physical functioning (84,13 for young; 80,65 NSND). After surgery, social functioning showed a slight decline before recovering. Both groups experienced increased nausea and vomiting (p=0.002), decreased pain (p<0,001), and reduced appetite loss after surgery, while insomnia increased specifically among young patients (p=0,008). Fear of disease progression was the most troubling symptom across both groups. Young patients additionally reported concerns related to coughing, speech difficulties, body image, swallowing issues, and sensory problems, emphasizing the need for psychological support."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Quality of Life Before and After Treatment in Young and Never-Smoker, Never-Drinker Patients with Head and Neck Squamous Cell Carcinoma</span>. <u>Beatriz Souza, Master of Science</u><sup>1</sup>; Ingrid Nakamuta, Master of Science<sup>1</sup>; Rossana López, PhD<sup>2</sup>; Alexandre Santos, phD<sup>1</sup>; Maria Katayama, PhD<sup>1</sup>; Simone Maistro, PhD<sup>2</sup>; Fatima Pasini, phD<sup>1</sup>; Gilberto de Castro Junior, PhD<sup>1</sup>; Luiz Kowalski, PhD<sup>1</sup>; Maria Folgueira, PhD<sup>1</sup>. <sup>1</sup>Faculdade de Medicina da Universidade de São Paulo; <sup>2</sup>Instituto do Câncer de São Paulo Octavio Frias de Oliveira<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) is uncommon among young (aged up to 40 years) and never-smoker, never-drinker (NSND) individuals. Younger patients may experience a disproportionate and long-lasting decline in quality of life (QoL), as treatment commonly occurs during critical phases of social, educational, and professional development. Despite growing interest in these distinct epidemiological subgroups, longitudinal QoL outcomes in young and NSND patients remain insufficiently characterized. This study aimed to evaluate QoL trajectories from patients diagnosed with HNSCC by comparing baseline QoL scores with those obtained during treatment and three months after completion. Patients treated at the Head and Neck Surgery Department of the Cancer Institute of the State of São Paulo were invited to complete the EORTC QLQ-C30 and QLQ-H&N43 questionnaires. Young patients were defined as individuals aged 18 to 40 years at diagnosis, while NSND were defined as individuals who had never smoked or had smoked fewer than 100 cigarettes in their lifetime (never smoker), and whose alcohol consumption did not exceed 12 drinks over their lifetime (Lifetime abstainer). All participants received standard therapy, including surgery and radiotherapy or chemotherapy when indicated. QoL questionnaires were administered at four time points: prior to treatment initiation, three to five weeks after surgery, three to five weeks after adjuvant treatment, and three months after the final treatment session. A total of twenty-five patients, 16 females and 9 males, were enrolled between July 2023 and March 2025, comprising nineteen NSND patients and six young individuals. The tongue was the most common primary tumor site, present in 64%  of cases. Most patients,60%, presented with advanced stage III or IV disease. The most frequent TNM category was T2N0, observed in twenty-eight percent of participants. All tumors tested were HPV-negative. The median BMI was 26.7 among NSND individuals and 25.5 among young patients. Median age at diagnosis was 53.4 years (min: 20; max: 82), with mean ages of 34.5 years and 59.4 years in the young and NSND groups, respectively. Baseline global health status was good, with mean scores of 71 for young patients and 80 for NSND individuals. Mean and median score values for functional scales were all above 70, indicating high/good physical, role, emotional, cognitive, and social functionings.  Although some patients reported very high scores for the functional scales and global health status (100), others presented severe impairments, including scores of zero in emotional and social functioning and global health. Cognitive functioning showed the highest scores in both groups (91.27 for young and 87.96 for NSND), followed by physical functioning (84,13 for young; 80,65 NSND). After surgery, social functioning showed a slight decline before recovering. Both groups experienced increased nausea and vomiting (p=0.002), decreased pain (p<0,001), and reduced appetite loss after surgery, while insomnia increased specifically among young patients (p=0,008). Fear of disease progression was the most troubling symptom across both groups. Young patients additionally reported concerns related to coughing, speech difficulties, body image, swallowing issues, and sensory problems, emphasizing the need for psychological support.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154557--></body></html>"
    },
    {
      "uid": "P151",
      "content_id": "153876",
      "abstract_number": "P151",
      "poster_number": "P151",
      "title": "Ongoing influences of radiation on salivary function, oral health, and patient quality of life 6 months following treatment for head and neck cancer",
      "summary": "Radiation results in detrimental impacts on salivary function, oral health, and quality of life, persisting beyond the acute phase of treatment. Increases in pain and reduced salivary function have significant impacts on patient quality of life, contribute to decreased functional swallowing, and necessitate proactive and ongoing intervention to manage symptom burden from such toxicities. Examination of changes...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153876",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nicole Schaen-Heacock, PhD, CCC, SLP",
      "presenter": "Nicole Schaen-Heacock, PhD, CCC, SLP",
      "authors": "Nicole Schaen-Heacock, PhD, CCC, SLP 1 ; Nicole Rogus-Pulia, PhD, CCC, SLP 2",
      "normalized_authors": [
        "Nicole Schaen-Heacock, CCC, SLP",
        "Nicole Rogus-Pulia, CCC, SLP"
      ],
      "affiliations": [
        "Department of Veterans Affairs - Geriatric Research Education and Clinical Center",
        "University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology"
      ],
      "normalized_institutions": [
        "Department of Veterans Affairs - Geriatric Research Education and Clinical Center",
        "University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 379,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Nicole Schaen-Heacock, PhD, CCC, SLP 1 ; Nicole Rogus-Pulia, PhD, CCC, SLP 2",
        "Affiliations": "1 Department of Veterans Affairs - Geriatric Research Education and Clinical Center; University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology; 2 University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology; Department of Veterans Affairs - Geriatric Research Education and Clinical Center",
        "Purpose": "Patients receiving radiation treatment for head and neck cancer (HNC) often experience significant, detrimental sequelae impacting swallow function with resulting deficits to health status and quality of life (QOL). Chief among these are mucositis, hyposalivation (reduced salivary function), and xerostomia (sensation of dry mouth). These sequelae make oral intake extremely difficult, painful, and increase the risk of airway invasion. While often identified in the acute phase of treatment administration, these sequelae can persist well beyond cessation of treatment. However, less exploration has been devoted to markers of hyposalivation, xerostomia, mucositis, and related impacts to patients’ quality of life 6 months post-treatment. Thus, this study aimed to assess radiation-induced changes to salivary function, oral health, and related impacts to QOL 6 months following treatment for HNC. Our hypotheses were: radiation would decrease salivary flow rate, Residual Mucosal Saliva (RMS) on oral structures (marker of hyposalivation and related xerostomia), increase mucositis, and decrease patient-reported outcomes 6 months post-treatment.",
        "Methods": "9 participants who completed a 6-month follow-up were included for analysis. Paired t-tests were used to compare change between baseline and 6 months-post treatment for the following validated measures: salivary flow rate (unstimulated and stimulated samples); RMS (anterior hard palate, anterior tongue, lower labial surface, and buccal mucosa); Brief Oral Health Status Exam (BOHSE); Oral Mucositis Assessment; Eating Assessment Tool (EAT)-10; Xerostomia Quality of Life Scale. An alpha level of 0.05 indicated significance.",
        "Results": "While no significant differences were appreciated for RMS measures or unstimulated salivary flow rate, stimulated salivary flow rate significantly decreased 6 months post-radiation (p=0.02). Oral health and QOL measures were also significant. Patients experienced a significant increase (worsening) in BOHSE (p=0.02) and Oral Mucositis scores (p=0.004), and a significant increase (worsening) of Xerostomia QOL questionnaire scores (p=0.02). EAT-10 ratings were not significant.",
        "Conclusions": "Radiation results in detrimental impacts on salivary function, oral health, and quality of life, persisting beyond the acute phase of treatment. Increases in pain and reduced salivary function have significant impacts on patient quality of life, contribute to decreased functional swallowing, and necessitate proactive and ongoing intervention to manage symptom burden from such toxicities. Examination of changes beyond the acute post-treatment phase are critical in understanding ongoing sequelae and related impacts to both functional status and overall survivorship."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ongoing influences of radiation on salivary function, oral health, and patient quality of life 6 months following treatment for head and neck cancer</span>. <u>Nicole Schaen-Heacock, PhD, CCC, SLP</u><sup>1</sup>; Nicole Rogus-Pulia, PhD, CCC, SLP<sup>2</sup>. <sup>1</sup>Department of Veterans Affairs - Geriatric Research Education and Clinical Center; University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology; <sup>2</sup>University of Wisconsin-Madison - Department of Medicine, Division of Geriatrics and Gerontology; Department of Veterans Affairs - Geriatric Research Education and Clinical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> Patients receiving radiation treatment for head and neck cancer (HNC) often experience significant, detrimental sequelae impacting swallow function with resulting deficits to health status and quality of life (QOL). Chief among these are mucositis, hyposalivation (reduced salivary function), and xerostomia (sensation of dry mouth). These sequelae make oral intake extremely difficult, painful, and increase the risk of airway invasion. While often identified in the acute phase of treatment administration, these sequelae can persist well beyond cessation of treatment. However, less exploration has been devoted to markers of hyposalivation, xerostomia, mucositis, and related impacts to patients’ quality of life 6 months post-treatment. Thus, this study aimed to assess radiation-induced changes to salivary function, oral health, and related impacts to QOL 6 months following treatment for HNC. Our hypotheses were: radiation would decrease salivary flow rate, Residual Mucosal Saliva (RMS) on oral structures (marker of hyposalivation and related xerostomia), increase mucositis, and decrease patient-reported outcomes 6 months post-treatment.</p>\n\n<p><strong>Methods: </strong>9 participants who completed a 6-month follow-up were included for analysis. Paired t-tests were used to compare change between baseline and 6 months-post treatment for the following validated measures: salivary flow rate (unstimulated and stimulated samples); RMS (anterior hard palate, anterior tongue, lower labial surface, and buccal mucosa); Brief Oral Health Status Exam (BOHSE); Oral Mucositis Assessment; Eating Assessment Tool (EAT)-10; Xerostomia Quality of Life Scale. An alpha level of 0.05 indicated significance.</p>\n\n<p><strong>Results: </strong>While no significant differences were appreciated for RMS measures or unstimulated salivary flow rate, stimulated salivary flow rate significantly decreased 6 months post-radiation (p=0.02). Oral health and QOL measures were also significant. Patients experienced a significant increase (worsening) in BOHSE (p=0.02) and Oral Mucositis scores (p=0.004), and a significant increase (worsening) of Xerostomia QOL questionnaire scores (p=0.02). EAT-10 ratings were not significant.</p>\n\n<p><strong>Conclusions: </strong>Radiation results in detrimental impacts on salivary function, oral health, and quality of life, persisting beyond the acute phase of treatment. Increases in pain and reduced salivary function have significant impacts on patient quality of life, contribute to decreased functional swallowing, and necessitate proactive and ongoing intervention to manage symptom burden from such toxicities. Examination of changes beyond the acute post-treatment phase are critical in understanding ongoing sequelae and related impacts to both functional status and overall survivorship.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153876--></body></html>"
    },
    {
      "uid": "P152",
      "content_id": "153463",
      "abstract_number": "P152",
      "poster_number": "P152",
      "title": "Impact of Preoperative Iron Infusion on Postoperative Transfusions in Head and Neck Free Flap Reconstruction: A Retrospective Cohort Study",
      "summary": "Our cohort study of HNC patients who underwent free flap reconstruction found that preoperative iron infusion was not associated with reduced postoperative RBC transfusion. Transfusion risk was primarily driven by tumor stage, anticoagulant use, and preoperative hemoglobin. These findings build a foundation for further research into earlier and/or more selectively targeted iron optimization strategies. Future...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153463",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ben B Levy",
      "presenter": "Ben B Levy",
      "authors": "Ben B Levy 1 ; Anushka Pradhan 2 ; Lomesh Choudhary 3 ; Christopher Noel 4 ; John de Almeida 4 ; David Goldstein 4 ; Ralph Gilbert 4 ; Jonathan Irish 4 ; Dale Brown 4 ; Christopher Yao 4 ; Sharon Tzelnick 4",
      "normalized_authors": [
        "Ben B Levy",
        "Anushka Pradhan",
        "Lomesh Choudhary",
        "Christopher Noel",
        "John de Almeida",
        "David Goldstein",
        "Ralph Gilbert",
        "Jonathan Irish",
        "Dale Brown",
        "Christopher Yao",
        "Sharon Tzelnick"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head & Neck Surgery, University of Toronto",
        "Temerty Faculty of Medicine, University of Toronto",
        "Michael G. DeGroote School of Medicine, McMaster University",
        "Princess Margaret Cancer Centre, University Health Network"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head & Neck Surgery, University of Toronto",
        "Temerty Faculty of Medicine, University of Toronto",
        "Michael G. DeGroote School of Medicine, McMaster University",
        "Princess Margaret Cancer Centre, University Health Network"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 533,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ben B Levy 1 ; Anushka Pradhan 2 ; Lomesh Choudhary 3 ; Christopher Noel 4 ; John de Almeida 4 ; David Goldstein 4 ; Ralph Gilbert 4 ; Jonathan Irish 4 ; Dale Brown 4 ; Christopher Yao 4 ; Sharon Tzelnick 4",
        "Affiliations": "1 Department of Otolaryngology-Head & Neck Surgery, University of Toronto; 2 Temerty Faculty of Medicine, University of Toronto; 3 Michael G. DeGroote School of Medicine, McMaster University; 4 Princess Margaret Cancer Centre, University Health Network",
        "Background": "Patients with head and neck cancer (HNC) frequently present with anemia due to a combination of chronic disease-related inflammation and nutritional deficiencies. Major intraoperative blood loss during reconstructive surgery often necessitates postoperative allogenic red blood cell (RBC) transfusion, which carries risks including transfusion reactions, infection, and possible free flap compromise. Iron infusion therapy has emerged as a potential strategy to optimize hemoglobin and reduce postoperative transfusion requirements for patients with low transferrin saturation.",
        "Methods": "We conducted a retrospective cohort study at a tertiary care center (Toronto, Canada) to evaluate the association between preoperative iron infusion and postoperative RBC transfusion. Patients who underwent free flap reconstruction for treatment of HNC (January 2022–May 2025) were included. As part of a quality improvement initiative which began in June 2022, patients with baseline hemoglobin <120 g/L underwent routine preoperative transferrin saturation testing. Demographic and clinical variables including anemia and chronic kidney disease (CKD) history, body mass index (BMI), oral iron supplementation, anticoagulant use, preoperative hemoglobin, and iron studies were collected. The primary outcome was postoperative RBC transfusion (dichotomous variable); transfusions were administered per established hospital guidelines/protocol. Univariate analysis compared patients by receipt of preoperative iron infusion using independent samples t-tests and chi-squared (or Fisher’s exact) tests. Multivariable logistic regression was completed and adjusted for relevant covariates identified in univariate testing.",
        "Results": "We included 327 patients (mean age 64.3 years, SD=12.3). Most patients were treated for oral cavity cancer (n=292, 89%), and the largest proportion had T4 disease (n=143, 44%). Median preoperative hemoglobin was 132 g/L (IQR: 120–144) and was collected 7 days pre-surgery (IQR: 4–11); hemoglobin was <120 g/L in 73 patients (22%). Transferrin saturation data were available for 187 patients (57%), of whom 28 (15%) had low preoperative levels (<10%). Iron infusion occurred a median of 6 days preoperatively (IQR: 2–12) and RBC transfusion occurred a median of 2 days postoperatively (IQR: 1–4). Thirteen of 33 patients who received preoperative iron (39%) were administered ≥1 postoperative RBC transfusion(s). In multivariable analysis, preoperative iron infusion was not associated with postoperative RBC transfusion (adjusted OR [aOR] 1.07, 95% CI: 0.40–2.86, p =0.89). Higher preoperative hemoglobin was significantly protective (aOR 0.95 per g/L, 95% CI: 0.93–0.98, p <0.001). Advanced T stage (T3–T4) significantly increased transfusion risk (aOR 3.18, 95% CI: 1.31–7.71, p =0.011), as did anticoagulant use (aOR 2.57, 95% CI: 1.19–5.59, p =0.017). No significant associations were observed with sex, anemia history, CKD, oral iron supplementation, or prior head and neck surgery or radiation.",
        "Conclusions": "Our cohort study of HNC patients who underwent free flap reconstruction found that preoperative iron infusion was not associated with reduced postoperative RBC transfusion. Transfusion risk was primarily driven by tumor stage, anticoagulant use, and preoperative hemoglobin. These findings build a foundation for further research into earlier and/or more selectively targeted iron optimization strategies. Future work will be directed at clarifying optimal timing, dosing, and patient selection criteria to determine if preoperative iron infusion may have a meaningful role for this population in the appropriate clinical context."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Preoperative Iron Infusion on Postoperative Transfusions in Head and Neck Free Flap Reconstruction: A Retrospective Cohort Study</span>. <u>Ben B Levy</u><sup>1</sup>; Anushka Pradhan<sup>2</sup>; Lomesh Choudhary<sup>3</sup>; Christopher Noel<sup>4</sup>; John de Almeida<sup>4</sup>; David Goldstein<sup>4</sup>; Ralph Gilbert<sup>4</sup>; Jonathan Irish<sup>4</sup>; Dale Brown<sup>4</sup>; Christopher Yao<sup>4</sup>; Sharon Tzelnick<sup>4</sup>. <sup>1</sup>Department of Otolaryngology-Head & Neck Surgery, University of Toronto; <sup>2</sup>Temerty Faculty of Medicine, University of Toronto; <sup>3</sup>Michael G. DeGroote School of Medicine, McMaster University; <sup>4</sup>Princess Margaret Cancer Centre, University Health Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Patients with head and neck cancer (HNC) frequently present with anemia due to a combination of chronic disease-related inflammation and nutritional deficiencies. Major intraoperative blood loss during reconstructive surgery often necessitates postoperative allogenic red blood cell (RBC) transfusion, which carries risks including transfusion reactions, infection, and possible free flap compromise. Iron infusion therapy has emerged as a potential strategy to optimize hemoglobin and reduce postoperative transfusion requirements for patients with low transferrin saturation.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study at a tertiary care center (Toronto, Canada) to evaluate the association between preoperative iron infusion and postoperative RBC transfusion. Patients who underwent free flap reconstruction for treatment of HNC (January 2022–May 2025) were included. As part of a quality improvement initiative which began in June 2022, patients with baseline hemoglobin <120 g/L underwent routine preoperative transferrin saturation testing. Demographic and clinical variables including anemia and chronic kidney disease (CKD) history, body mass index (BMI), oral iron supplementation, anticoagulant use, preoperative hemoglobin, and iron studies were collected. The primary outcome was postoperative RBC transfusion (dichotomous variable); transfusions were administered per established hospital guidelines/protocol. Univariate analysis compared patients by receipt of preoperative iron infusion using independent samples t-tests and chi-squared (or Fisher’s exact) tests. Multivariable logistic regression was completed and adjusted for relevant covariates identified in univariate testing.</p>\n\n<p><strong>Results:</strong> We included 327 patients (mean age 64.3 years, SD=12.3). Most patients were treated for oral cavity cancer (n=292, 89%), and the largest proportion had T4 disease (n=143, 44%). Median preoperative hemoglobin was 132 g/L (IQR: 120–144) and was collected 7 days pre-surgery (IQR: 4–11); hemoglobin was <120 g/L in 73 patients (22%). Transferrin saturation data were available for 187 patients (57%), of whom 28 (15%) had low preoperative levels (<10%). Iron infusion occurred a median of 6 days preoperatively (IQR: 2–12) and RBC transfusion occurred a median of 2 days postoperatively (IQR: 1–4). Thirteen of 33 patients who received preoperative iron (39%) were administered ≥1 postoperative RBC transfusion(s). In multivariable analysis, preoperative iron infusion was not associated with postoperative RBC transfusion (adjusted OR [aOR] 1.07, 95% CI: 0.40–2.86, <em>p</em>=0.89). Higher preoperative hemoglobin was significantly protective (aOR 0.95 per g/L, 95% CI: 0.93–0.98, <em>p</em><0.001). Advanced T stage (T3–T4) significantly increased transfusion risk (aOR 3.18, 95% CI: 1.31–7.71, <em>p</em>=0.011), as did anticoagulant use (aOR 2.57, 95% CI: 1.19–5.59, <em>p</em>=0.017). No significant associations were observed with sex, anemia history, CKD, oral iron supplementation, or prior head and neck surgery or radiation.</p>\n\n<p><strong>Conclusions:</strong> Our cohort study of HNC patients who underwent free flap reconstruction found that preoperative iron infusion was not associated with reduced postoperative RBC transfusion. Transfusion risk was primarily driven by tumor stage, anticoagulant use, and preoperative hemoglobin. These findings build a foundation for further research into earlier and/or more selectively targeted iron optimization strategies. Future work will be directed at clarifying optimal timing, dosing, and patient selection criteria to determine if preoperative iron infusion may have a meaningful role for this population in the appropriate clinical context.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153463--></body></html>"
    },
    {
      "uid": "P153",
      "content_id": "152016",
      "abstract_number": "P153",
      "poster_number": "P153",
      "title": "Effective Management of Repetitive TEP Deglutition: A case study",
      "summary": "Tracheoesophageal voice puncture and prosthesis (TEP) is the most common form of voice restoration following total laryngectomy (TL) (Luu et al, 2018). A variety of complications are associated with TEPs which requires timely intervention. One complication is TEP dislodgement. Lost or missing TEPs are either 1) aspirated, 2) swallowed into the digestive tract, or 3) expelled (Ottenstein et al, 2025). Limited data...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152016",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
      "presenter": "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
      "authors": "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S ; Liza Blumenfeld, MA, CCC, SLP, BCS, S",
      "normalized_authors": [
        "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
        "Liza Blumenfeld, MA, CCC, SLP, BCS, S"
      ],
      "affiliations": [
        "UC San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego Health"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152016/Table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152016/Table%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152016"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/152016/Figure%201(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152016/Figure%201(1).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152016"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/152016/Figure%202(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152016/Figure%202(1).png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152016"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Description",
        "Discussion"
      ],
      "sections": {
        "Authors": "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S ; Liza Blumenfeld, MA, CCC, SLP, BCS, S",
        "Affiliations": "UC San Diego Health",
        "Introduction": "Tracheoesophageal voice puncture and prosthesis (TEP) is the most common form of voice restoration following total laryngectomy (TL) (Luu et al, 2018). A variety of complications are associated with TEPs which requires timely intervention. One complication is TEP dislodgement. Lost or missing TEPs are either 1) aspirated, 2) swallowed into the digestive tract, or 3) expelled (Ottenstein et al, 2025). Limited data exists regarding TEP dislodgement into the digestive tract. The Blom-Singer large esophageal and tracheal flange voice prosthesis (Blom-Singer LF) is commonly known to alleviate peri-prosthetic leakage (Choussy et al, 2012). We present a case in which the Blom-Singer LF mitigated repeated spontaneous voice prosthesis deglutition. To our knowledge, the use of this prosthesis for repeated dislodgement into the digestive tract has not been previously discussed.",
        "Case Description": "M.L. is a 70-year-old male with a history of chemoradiation for Stage III T2N1M0 larynx squamous cell carcinoma (SCCA) in 2018. In July 2019, he was diagnosed with Stage III recurrent larynx SCCA and a second primary of Stage III base of tongue (BOT) SCCA. In September 2019, he underwent TL, left base of tongue resection, and bilateral radical neck dissections as well as an ALT free flap for complex oropharyngeal reconstruction. He completed adjuvant chemoradiation in January of 2020. M.L. underwent a secondary TEP placement on 7/29/20. Over the next 31 months, M.L. swallowed five TEPs (Table 1). In April of 2021, M.L. presented to the emergency department with a missing TEP. He reported that he coughed while cleaning the TEP and swallowed it. The TEP was found in the right upper quadrant of the stomach (Figure 1). Four out of six subsequent TEP changes were due to prosthesis deglutition (2/6 were due to central leakage). In March 2023, a Blom-Singer LF was placed, with the hope that the enlarged tracheal flange would prevent the TEP from dislodging posteriorly into the esophagus (Figure 2). M.L. has not swallowed a TEP since using the Blom-Singer LF prosthesis. The average life span of his TEPs is now 289 days.",
        "Discussion": "TEP dislodgment poses a substantial risk since it can cause airway or esophageal obstruction. To combat this, TEPs are designed with soft flanges that firmly seat after insertion and successfully do so in over 99% of inserted prostheses (Cleveland & Mau, 2019). Azar et al, 2021 reviewed causes and rates of TEP failure. In 4928 patients, TEP dislodgement was the etiology of TEP failure 10.6% of the time. Imre et al, 2013 reviewed TEP complications and found that 20 out of 47 (42.5%) patients had complications, and out of those 20, 6 patients experienced prosthesis deglutition (12.7%). This case study highlights the management of prosthesis deglutition. More cases are needed to determine the utility of the Blom-Singer LF. TEP failure or inadvertent dislodgement has detrimental consequences on patient QoL and health care resources. Research is needed to identify contributors to voice prosthesis deglutition, as prevention begins with identifying patients at risk."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Effective Management of Repetitive TEP Deglutition: A case study</span>. <u>Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S</u>; Liza Blumenfeld, MA, CCC, SLP, BCS, S. UC San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tracheoesophageal voice puncture and prosthesis (TEP) is the most common form of voice restoration following total laryngectomy (TL) (Luu et al, 2018). A variety of complications are associated with TEPs which requires timely intervention. One complication is TEP dislodgement. Lost or missing TEPs are either 1) aspirated, 2) swallowed into the digestive tract, or 3) expelled (Ottenstein et al, 2025). Limited data exists regarding TEP dislodgement into the digestive tract. The Blom-Singer large esophageal and tracheal flange voice prosthesis (Blom-Singer LF) is commonly known to alleviate peri-prosthetic leakage (Choussy et al, 2012). We present a case in which the Blom-Singer LF mitigated repeated spontaneous voice prosthesis deglutition. To our knowledge, the use of this prosthesis for repeated dislodgement into the digestive tract has not been previously discussed.</p>\n\n<p><strong>Case Description: </strong>M.L. is a 70-year-old male with a history of chemoradiation for Stage III T2N1M0 larynx squamous cell carcinoma (SCCA) in 2018. In July 2019, he was diagnosed with Stage III recurrent larynx SCCA and a second primary of Stage III base of tongue (BOT) SCCA. In September 2019, he underwent TL, left base of tongue resection, and bilateral radical neck dissections as well as an ALT free flap for complex oropharyngeal reconstruction. He completed adjuvant chemoradiation in January of 2020. M.L. underwent a secondary TEP placement on 7/29/20. Over the next 31 months, M.L. swallowed five TEPs (Table 1). In April of 2021, M.L. presented to the emergency department with a missing TEP. He reported that he coughed while cleaning the TEP and swallowed it. The TEP was found in the right upper quadrant of the stomach (Figure 1). Four out of six subsequent TEP changes were due to prosthesis deglutition (2/6 were due to central leakage). In March 2023, a Blom-Singer LF was placed, with the hope that the enlarged tracheal flange would prevent the TEP from dislodging posteriorly into the esophagus (Figure 2). M.L. has not swallowed a TEP since using the Blom-Singer LF prosthesis. The average life span of his TEPs is now 289 days.</p>\n\n<p><strong>Discussion: </strong>TEP dislodgment poses a substantial risk since it can cause airway or esophageal obstruction. To combat this, TEPs are designed with soft flanges that firmly seat after insertion and successfully do so in over 99% of inserted prostheses (Cleveland & Mau, 2019). Azar et al, 2021 reviewed causes and rates of TEP failure. In 4928 patients, TEP dislodgement was the etiology of TEP failure 10.6% of the time. Imre et al, 2013 reviewed TEP complications and found that 20 out of 47 (42.5%) patients had complications, and out of those 20, 6 patients experienced prosthesis deglutition (12.7%). This case study highlights the management of prosthesis deglutition. More cases are needed to determine the utility of the Blom-Singer LF. TEP failure or inadvertent dislodgement has detrimental consequences on patient QoL and health care resources. Research is needed to identify contributors to voice prosthesis deglutition, as prevention begins with identifying patients at risk.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152016/Table%201.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152016/Figure%201(1).png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152016/Figure%202(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152016--></body></html>"
    },
    {
      "uid": "P154",
      "content_id": "155418",
      "abstract_number": "P154",
      "poster_number": "P154",
      "title": "Primary Solitary Plasmacytoma of the Temporal Bone: Two Adult Cases with Treatment Recommendations",
      "summary": "Primary, solitary bone plasmacytomas occurring in the temporal bone are exceedingly rare resulting in a paucity of literature describing the disease process and treatment recommendations. Our report describes two adult patients, a 64-year-old male (Patient A) and a 49-year-old female (Patient B) with different presentations and treatment of solitary bone plasmacytoma of the left temporal bone. Detailed...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155418",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caroline Curtin, BS",
      "presenter": "Caroline Curtin, BS",
      "authors": "Erich A Mildner, BS; Caroline Curtin, BS ; Lauren G Himes, MD; Eric M Kraus, MD",
      "normalized_authors": [
        "Erich A Mildner",
        "Caroline Curtin",
        "Lauren G Himes",
        "Eric M Kraus"
      ],
      "affiliations": [
        "Wake Forest University School of Medicine"
      ],
      "normalized_institutions": [
        "Wake Forest University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 315,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Erich A Mildner, BS; Caroline Curtin, BS ; Lauren G Himes, MD; Eric M Kraus, MD",
        "Affiliations": "Wake Forest University School of Medicine",
        "Abstract": "Primary, solitary bone plasmacytomas occurring in the temporal bone are exceedingly rare resulting in a paucity of literature describing the disease process and treatment recommendations. Our report describes two adult patients, a 64-year-old male (Patient A) and a 49-year-old female (Patient B) with different presentations and treatment of solitary bone plasmacytoma of the left temporal bone. Detailed presentations and examinations, preoperative diagnostic testing, intraoperative findings, permanent pathologic analysis, and postoperative decision making and management are discussed for solitary plasmacytoma of the temporal bone in comparison to multiple myeloma. Our case series highlights the importance of: (1) obtaining an intraoperative frozen section biopsy when encountering tissue that does not look like fibro-reactive/granulation tissue or cholesteatoma, (2) surgical debulking versus meticulous excision, (3) the importance of performing a postoperative work-up in order to differentiate between extramedullary, solitary bone plasmacytoma and multiple myeloma, (4) treatment options, and (5) surveillance for potential future progression to multiple myeloma. We would like to emphasize that the possibility of primary, solitary bone plasmacytoma of the temporal bones was not entertained in either patient preoperatively but has now been added to our preoperative differential diagnoses for aggressive lesions of the temporal bone as well as cases thought to be secondary to chronic otitis media and mastoiditis. To our knowledge, only a few primary solitary plasmacytomas arising from the temporal bone have been described. Our case report emphasizes the need to include solitary plasmacytomas in the differential diagnosis for aggressive lesions of the temporal bone. We describe the work-up and treatment for extramedullary solitary bone plasmacytoma in comparison to multiple myeloma. Our series highlights the importance of: (1) obtaining an intraoperative frozen section biopsy when encountering tumor, (2) surgical debulking versus complete excision, (3) performing a postoperative work-up to differentiate between solitary bone plasmacytoma and multiple myeloma, (4) treatment options, and (5) the need for surveillance for potential future progression to multiple myeloma."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Primary Solitary Plasmacytoma of the Temporal Bone: Two Adult Cases with Treatment Recommendations</span>. Erich A Mildner, BS; <u>Caroline Curtin, BS</u>; Lauren G Himes, MD; Eric M Kraus, MD. Wake Forest University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Primary, solitary bone plasmacytomas occurring in the temporal bone are exceedingly rare resulting in a paucity of literature describing the disease process and treatment recommendations. </p>\n\n<p>Our report describes two adult patients, a 64-year-old male (Patient A) and a 49-year-old female (Patient B) with different presentations and treatment of solitary bone plasmacytoma of the left temporal bone. Detailed presentations and examinations, preoperative diagnostic testing, intraoperative findings, permanent pathologic analysis, and postoperative decision making and management are discussed for solitary plasmacytoma of the temporal bone in comparison to multiple myeloma.</p>\n\n<p>Our case series highlights the importance of: (1) obtaining an intraoperative frozen section biopsy when encountering tissue that does not look like fibro-reactive/granulation tissue or cholesteatoma, (2) surgical debulking versus meticulous excision, (3) the importance of performing a postoperative work-up in order to differentiate between extramedullary, solitary bone plasmacytoma and multiple myeloma, (4) treatment options, and (5) surveillance for potential future progression to multiple myeloma.</p>\n\n<p>We would like to emphasize that the possibility of primary, solitary bone plasmacytoma of the temporal bones was not entertained in either patient preoperatively but has now been added to our preoperative differential diagnoses for aggressive lesions of the temporal bone as well as cases thought to be secondary to chronic otitis media and mastoiditis.</p>\n\n<p>To our knowledge, only a few primary solitary plasmacytomas arising from the temporal bone have been described. Our case report emphasizes the need to include solitary plasmacytomas in the differential diagnosis for aggressive lesions of the temporal bone. We describe the work-up and treatment for extramedullary solitary bone plasmacytoma in comparison to multiple myeloma. Our series highlights the importance of: (1) obtaining an intraoperative frozen section biopsy when encountering tumor, (2) surgical debulking versus complete excision, (3) performing a postoperative work-up to differentiate between solitary bone plasmacytoma and multiple myeloma, (4) treatment options, and (5) the need for surveillance for potential future progression to multiple myeloma.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155418--></body></html>"
    },
    {
      "uid": "P155",
      "content_id": "153587",
      "abstract_number": "P155",
      "poster_number": "P155",
      "title": "Topical Manuka Honey: Simple, Effective, Patient-Administered Management of Free Flap Donor Site Tendon Exposure in Head and Neck Reconstruction",
      "summary": "Conservative superficial tendinous debridement followed by patient-administered manuka honey ointment is a swift, effective, inexpensive, and simple ambulatory treatment for post-operative tendon exposure after RFFF or FFF harvest. While further study is needed, drastically shorter healing times of affected donor sites were observed in this small series compared to historically published wound regimens lasting up...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153587",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Riccio, MD",
      "presenter": "David Riccio, MD",
      "authors": "David Riccio, MD 1 ; Kevin J Kovatch, MD 1 ; Kelly S Sayre, MD, DMD 2 ; S. Ahmed Ali, MD 3 ; Alexandra E Kejner, MD 4 ; Marianne Abouyared, MD 5 ; John E Hanks, MD 1",
      "normalized_authors": [
        "David Riccio",
        "Kevin J Kovatch",
        "Kelly S Sayre",
        "S. Ahmed Ali",
        "Alexandra E Kejner",
        "Marianne Abouyared",
        "John E Hanks"
      ],
      "affiliations": [
        "University of Connecticut Health",
        "Boston Medical Center",
        "Henry Ford Health",
        "Medical University of South Carolina",
        "UC Davis Health"
      ],
      "normalized_institutions": [
        "University of Connecticut Health",
        "Boston Medical Center",
        "Henry Ford Health",
        "Medical University of South Carolina",
        "UC Davis Health"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153587/Figure%201A.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153587/Figure%201A.jpg",
          "alt": "Figure 1: A) Initial diagnosis of tendon exposure after FFF; B) Exposed tendon after surgeon performed superficial dissection of exposed peroneus tendon to punctate bleeding; C) Robust granulation formation over the exposed tendon; D) Final healing",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153587"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153587/Figure%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153587/Figure%202.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153587"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153587/Patient%20Outcomes.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153587/Patient%20Outcomes.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153587"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Riccio, MD 1 ; Kevin J Kovatch, MD 1 ; Kelly S Sayre, MD, DMD 2 ; S. Ahmed Ali, MD 3 ; Alexandra E Kejner, MD 4 ; Marianne Abouyared, MD 5 ; John E Hanks, MD 1",
        "Affiliations": "1 University of Connecticut Health; 2 Boston Medical Center; 3 Henry Ford Health; 4 Medical University of South Carolina; 5 UC Davis Health",
        "Introduction": "Fibula free flaps (FFF) and radial forearm free flaps (RFFF) are modern head and neck (HN) reconstructive workhorses. Numerous RFFF and FFF harvest site closure techniques and post-operative regimens aim to prevent tendon exposure, yet no dominant alternative to skin grafting has emerged, while tendon exposure remains common at both sites. Tendon exposure traditionally obligates patients to reoperation and/or prolonged, onerous wound care regimens. Manuka honey is a monofloral honey produced by bees via pollen of the manuka tree ( Leptospermum scoparium ) endemic to New Zealand and Southeast Australia. Given its antibacterial/anti-biofilm properties and its ability to promote wound granulation, manuka honey has been employed as a healing agent for millennia. We have found that it represents an effective, straightforward RFFF and FFF donor site tendon exposure treatment when applied to exposed tendons after sharp superficial dissection.",
        "Methods": "6 patients sustained post-operative tendon exposure following RFFF (n=5) or FFF (n=1) harvest for HN reconstruction from 2020 to 2024. All patients underwent conservative wound care. Upon detection of tendon exposure, the surgeon performed superficial sharp dissection of affected tendons to punctate bleeding at bedside or in clinic. Affected tendons were found to be insensate, and no local or topical anesthetic was required in this series but was available as needed. TID patient-administered manuka honey-impregnated ointment application was then initiated and continued until healing was complete (Figures 1 & 2). Healing time, subjective donor site cosmesis, and patient-reported extremity function were recorded.",
        "Results": "Mean harvested free flap skin paddle area was 72.8 cm^2 (Range 50 cm^2 to 99 cm ^2; Std 17.4 cm^2), and mean percentage of donor site skin graft loss was 60.8% (Range 25% to 100%; Std 30.1%). Mean healing time was 67.8 days (range 49-95 days, Std 15.7 days). Ultimate donor site cosmesis was acceptable or excellent in all patients at last follow-up, no extremity dysfunction was reported, no oncologic treatment delays were required on account of any donor site wound, and no return to the OR was required in any patient to address tendon exposure (Table 1).",
        "Conclusion": "Conservative superficial tendinous debridement followed by patient-administered manuka honey ointment is a swift, effective, inexpensive, and simple ambulatory treatment for post-operative tendon exposure after RFFF or FFF harvest. While further study is needed, drastically shorter healing times of affected donor sites were observed in this small series compared to historically published wound regimens lasting up to 6 months. Moreover, harvest site cosmesis and reported ipsilateral wrist function was favorable in all patients, and no resultant delays in oncologic treatment occurred.",
        "Abstract": "Figure 1: A) Initial diagnosis of tendon exposure after FFF; B) Exposed tendon after surgeon performed superficial dissection of exposed peroneus tendon to punctate bleeding; C) Robust granulation formation over the exposed tendon; D) Final healing Figure 2: A) Initial diagnosis of brachioradialis, FCR, and palmaris tendon exposure after RFFF; B) Exposed tendon after surgeon performed a second superficial dissection of exposed tendon in clinic; C) Robust granulation formation over the exposed tendon; D) Final healing Table 1: Patient demographics and outcomes"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Topical Manuka Honey: Simple, Effective, Patient-Administered Management of Free Flap Donor Site Tendon Exposure in Head and Neck Reconstruction</span>. <u>David Riccio, MD</u><sup>1</sup>; Kevin J Kovatch, MD<sup>1</sup>; Kelly S Sayre, MD, DMD<sup>2</sup>; S. Ahmed Ali, MD<sup>3</sup>; Alexandra E Kejner, MD<sup>4</sup>; Marianne Abouyared, MD<sup>5</sup>; John E Hanks, MD<sup>1</sup>. <sup>1</sup>University of Connecticut Health; <sup>2</sup>Boston Medical Center; <sup>3</sup>Henry Ford Health; <sup>4</sup>Medical University of South Carolina; <sup>5</sup>UC Davis Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Fibula free flaps (FFF) and radial forearm free flaps (RFFF) are modern head and neck (HN) reconstructive workhorses. Numerous RFFF and FFF harvest site closure techniques and post-operative regimens aim to prevent tendon exposure, yet no dominant alternative to skin grafting has emerged, while tendon exposure remains common at both sites. Tendon exposure traditionally obligates patients to reoperation and/or prolonged, onerous wound care regimens. Manuka honey is a monofloral honey produced by bees via pollen of the manuka tree (<em>Leptospermum scoparium</em>) endemic to New Zealand and Southeast Australia. Given its antibacterial/anti-biofilm properties and its ability to promote wound granulation, manuka honey has been employed as a healing agent for millennia. We have found that it represents an effective, straightforward RFFF and FFF donor site tendon exposure treatment when applied to exposed tendons after sharp superficial dissection.</p>\n\n<p><strong>Methods:</strong> 6 patients sustained post-operative tendon exposure following RFFF (n=5) or FFF (n=1) harvest for HN reconstruction from 2020 to 2024. All patients underwent conservative wound care. Upon detection of tendon exposure, the surgeon performed superficial sharp dissection of affected tendons to punctate bleeding at bedside or in clinic. Affected tendons were found to be insensate, and no local or topical anesthetic was required in this series but was available as needed. TID patient-administered manuka honey-impregnated ointment application was then initiated and continued until healing was complete (Figures 1 & 2).  Healing time, subjective donor site cosmesis, and patient-reported extremity function were recorded.</p>\n\n<p><strong>Results: </strong>Mean harvested free flap skin paddle area was 72.8 cm^2 (Range 50 cm^2 to 99 cm ^2; Std 17.4 cm^2), and mean percentage of donor site skin graft loss was 60.8% (Range 25% to 100%; Std 30.1%). Mean healing time was 67.8 days (range 49-95 days, Std 15.7 days). Ultimate donor site cosmesis was acceptable or excellent in all patients at last follow-up, no extremity dysfunction was reported, no oncologic treatment delays were required on account of any donor site wound, and no return to the OR was required in any patient to address tendon exposure (Table 1).</p>\n\n<p><strong>Conclusion:</strong> Conservative superficial tendinous debridement followed by patient-administered manuka honey ointment is a swift, effective, inexpensive, and simple ambulatory treatment for post-operative tendon exposure after RFFF or FFF harvest. While further study is needed, drastically shorter healing times of affected donor sites were observed in this small series compared to historically published wound regimens lasting up to 6 months. Moreover, harvest site cosmesis and reported ipsilateral wrist function was favorable in all patients, and no resultant delays in oncologic treatment occurred.</p>\n\n<p><img alt='Figure 1: A) Initial diagnosis of tendon exposure after FFF; B) Exposed tendon after surgeon performed superficial dissection of exposed peroneus tendon to punctate bleeding; C) Robust granulation formation over the exposed tendon; D) Final healing' src='https://www.submitmyabstract.com/abs/images/153587/Figure%201A.jpg' /></p>\n\n<p>Figure 1: A) Initial diagnosis of tendon exposure after FFF; B) Exposed tendon after surgeon performed superficial dissection of exposed peroneus tendon to punctate bleeding; C) Robust granulation formation over the exposed tendon; D) Final healing<img alt='' src='https://www.submitmyabstract.com/abs/images/153587/Figure%202.jpg' /></p>\n\n<p>Figure 2: A) Initial diagnosis of brachioradialis, FCR, and palmaris tendon exposure after RFFF; B) Exposed tendon after surgeon performed a second superficial dissection of exposed tendon in clinic; C) Robust granulation formation over the exposed tendon; D) Final healing</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153587/Patient%20Outcomes.jpg' /></p>\n\n<p>Table 1: Patient demographics and outcomes</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153587--></body></html>"
    },
    {
      "uid": "P156",
      "content_id": "154595",
      "abstract_number": "P156",
      "poster_number": "P156",
      "title": "Evaluating carotid blowout syndrome outcomes post head and neck surgery using negative CTA",
      "summary": "Based on the initial data we have investigated for this study, it appears that in the context of predicting outcomes related to mortality and rebleeding, the negative CTA finding did not offer significant predictability over positive CTA based on the Cox-proportional model. However, this may indicate that there is a larger value in further evaluating a negative CTA using additional factors including other...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154595",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karthik Chakravarthy",
      "presenter": "Karthik Chakravarthy",
      "authors": "Karthik Chakravarthy ; Ciaran Powers, MD, PhD; Patrick Youssef, MD; Shahid Nimjee, MD, PhD; Nolan Seim",
      "normalized_authors": [
        "Karthik Chakravarthy",
        "Ciaran Powers",
        "Patrick Youssef",
        "Shahid Nimjee",
        "Nolan Seim"
      ],
      "affiliations": [
        "The Ohio State University- James Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "The Ohio State University- James Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 504,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Karthik Chakravarthy ; Ciaran Powers, MD, PhD; Patrick Youssef, MD; Shahid Nimjee, MD, PhD; Nolan Seim",
        "Affiliations": "The Ohio State University- James Comprehensive Cancer Center",
        "Background": "For patients experiencing complications after undergoing head and neck surgery, carotid blowout syndrome (CBS) presents a serious neurovascular scenario that poses a significant risk to recovery and post-operative status. The efficacy of current methods involving either reconstructive and deconstructive protocols to manage ENT hemorrhaging can depend on accurate prediction and identification of existing vascular bleeds based on radiographic imaging. The common metric of identifying complications involving CBS consists of obtaining and assessing a computed tomography angiogram (CTA). However, in certain cases, CTA can prove to lack predictive value and either result in mismanagement or require additional imaging studies to validate, thus resulting in delay of care. One factor limiting this accurate prediction via CTA is the relatively low number of studies investigating CBS management outcomes in the context of a negative CTA, resulting in the lack of a well-defined treatment plan for such cases leading to failures and salvage surgeries. We aimed to identify whether a negative CTA finding in patients admitted would provide differences in outcomes after subsequent embolization of admitted patients related to either improvements in morbidity/mortality or management of these vascular complications in head and neck cancer patients.",
        "Methods": "We conducted a retrospective cohort study consisting of patients seen at The Ohio State University Wexner Medical Center and James Cancer Center and Solove Research Institute (n=103). We included patients who underwent head and neck surgical procedures with subsequent endovascular interventions for CBS emergency that resulted in hospital admissions. Variables of interest in this population included performed/evaluated CTA finding, duration of surgery to discharge, history of bleeding, prior head and neck procedures, radiation treatment, CBS details, wound/infection in region, necrosis or fistula, and tumor details. The key data variables were obtained through the efforts of the Department of Neurosurgery Cerebrovascular Team consisting of physicians who evaluated and operated on these patients.",
        "Results": "For our approach for identifying the utility of negative CTA in predicting outcomes from CBS, we performed an assessment on survivorship and mortality on the cohort assembled, particularly related to outcomes of rebleeding or death. Our analysis included determining duration between endovascular intervention and significant event, and conducting a cox-proportional hazards model to generate a survival curve and statistic for comparison between groups with positive (n=37) and negative (n=66) CTA finding. Our assessment revealed no significant difference between the two groups, with a p-value of 0.12 and a C-index of 0.5. The survival curve revealed no significant trend or differences between the two population curves as well.",
        "Conclusions": "Based on the initial data we have investigated for this study, it appears that in the context of predicting outcomes related to mortality and rebleeding, the negative CTA finding did not offer significant predictability over positive CTA based on the Cox-proportional model. However, this may indicate that there is a larger value in further evaluating a negative CTA using additional factors including other treatments and patient histories, both surgical and medical, to improve the predictive nature and develop a robust model for evaluating CBS outcomes post-endovascular intervention."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating carotid blowout syndrome outcomes post head and neck surgery using negative CTA</span>. <u>Karthik Chakravarthy</u>; Ciaran Powers, MD, PhD; Patrick Youssef, MD; Shahid Nimjee, MD, PhD; Nolan Seim. The Ohio State University- James Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>For patients experiencing complications after undergoing head and neck surgery, carotid blowout syndrome (CBS) presents a serious neurovascular scenario that poses a significant risk to recovery and post-operative status. The efficacy of current methods involving either reconstructive and deconstructive protocols to manage ENT hemorrhaging can depend on accurate prediction and identification of existing vascular bleeds based on radiographic imaging. The common metric of identifying complications involving CBS consists of obtaining and assessing a computed tomography angiogram (CTA). However, in certain cases, CTA can prove to lack predictive value and either result in mismanagement or require additional imaging studies to validate, thus resulting in delay of care. One factor limiting this accurate prediction via CTA is the relatively low number of studies investigating CBS management outcomes in the context of a negative CTA, resulting in the lack of a well-defined treatment plan for such cases leading to failures and salvage surgeries. We aimed to identify whether a negative CTA finding in patients admitted would provide differences in outcomes after subsequent embolization of admitted patients related to either improvements in morbidity/mortality or management of these vascular complications in head and neck cancer patients.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study consisting of patients seen at The Ohio State University Wexner Medical Center and James Cancer Center and Solove Research Institute (n=103). We included patients who underwent head and neck surgical procedures with subsequent endovascular interventions for CBS emergency that resulted in hospital admissions. Variables of interest in this population included performed/evaluated CTA finding, duration of surgery to discharge, history of bleeding, prior head and neck procedures, radiation treatment, CBS details, wound/infection in region, necrosis or fistula, and tumor details. The key data variables were obtained through the efforts of the Department of Neurosurgery Cerebrovascular Team consisting of physicians who evaluated and operated on these patients.</p>\n\n<p><strong>Results: </strong>For our approach for identifying the utility of negative CTA in predicting outcomes from CBS, we performed an assessment on survivorship and mortality on the cohort assembled, particularly related to outcomes of rebleeding or death. Our analysis included determining duration between endovascular intervention and significant event, and conducting a cox-proportional hazards model to generate a survival curve and statistic for comparison between groups with positive (n=37) and negative (n=66) CTA finding. Our assessment revealed no significant difference between the two groups, with a p-value of 0.12 and a C-index of 0.5. The survival curve revealed no significant trend or differences between the two population curves as well.</p>\n\n<p><strong>Conclusions: </strong>Based on the initial data we have investigated for this study, it appears that in the context of predicting outcomes related to mortality and rebleeding, the negative CTA finding did not offer significant predictability over positive CTA based on the Cox-proportional model. However, this may indicate that there is a larger value in further evaluating a negative CTA using additional factors including other treatments and patient histories, both surgical and medical, to improve the predictive nature and develop a robust model for evaluating CBS outcomes post-endovascular intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154595--></body></html>"
    },
    {
      "uid": "P157",
      "content_id": "153263",
      "abstract_number": "P157",
      "poster_number": "P157",
      "title": "Feasibility of Dental Implantation in Scapular Tip Free Flaps for Maxillary Reconstruction",
      "summary": "This case-series demonstrates the feasibility and success of dental implantation into scapular tip free flaps for maxillary defects. Although adjuvant procedures were required for all patients prior to implantation, all patients achieved successful osseointegration and prosthodontic success, with restoration of key functions such as mastication, deglutition, and speech. These findings suggest viability of the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153263",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Evan A Thomas, BS",
      "presenter": "Evan A Thomas, BS",
      "authors": "Evan A Thomas, BS 1 ; David Forner, MD, MSc 2 ; Molly E Heft Neal, MD 2 ; Keith A Casper, MD 2 ; Pratyusha Yalamanchi, MD, MBA 2 ; Marisa R Buchakjian, MD, PhD 2 ; Kelly M Malloy, MD, MBA 2 ; Mark E Prince, MD 2 ; Chaz Stucken, MD 2",
      "normalized_authors": [
        "Evan A Thomas",
        "David Forner",
        "Molly E Heft Neal",
        "Keith A Casper",
        "Pratyusha Yalamanchi",
        "Marisa R Buchakjian",
        "Kelly M Malloy",
        "Mark E Prince",
        "Chaz Stucken"
      ],
      "affiliations": [
        "University of Michigan Medical School",
        "University of Michigan Department of Otolaryngology - Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Michigan Medical School",
        "University of Michigan Department of Otolaryngology - Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 463,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Evan A Thomas, BS 1 ; David Forner, MD, MSc 2 ; Molly E Heft Neal, MD 2 ; Keith A Casper, MD 2 ; Pratyusha Yalamanchi, MD, MBA 2 ; Marisa R Buchakjian, MD, PhD 2 ; Kelly M Malloy, MD, MBA 2 ; Mark E Prince, MD 2 ; Chaz Stucken, MD 2",
        "Affiliations": "1 University of Michigan Medical School; 2 University of Michigan Department of Otolaryngology - Head and Neck Surgery",
        "Background": "Maxillary defects following oncologic resection present significant challenges for functional dental rehabilitation. The scapular tip free flap is a versatile reconstructive option, offering ample soft tissue, adaptable geometry, a long vascular pedicle, as well as minimal donor site morbidity. However, concerns regarding the flap’s bone thickness have historically discouraged its utilization for dental implant-supported reconstruction compared to other workhorse osseous flaps. In this case-series, we aim to evaluate clinical and prosthodontic outcomes of dental implantation following scapular tip free flap reconstruction of maxillary defects.",
        "Methods": "In this retrospective case-series, six patients with maxillary defects underwent scapular tip free flap reconstruction at a single tertiary academic center between 2012-2016. After flap success was ensured, all patients underwent endosseus dental implant placement. Clinicodemographic and descriptive functional outcome data were abstracted from patient charts.",
        "Results": "All six patients underwent successful maxillary reconstruction with scapular tip free flaps. The cohort included three males and three females, with a median age of 51 years (range, 14-80). Four patients underwent maxillectomy due to malignant tumors, while two were benign. One patient received neoadjuvant chemotherapy, and one patient required adjuvant radiation therapy.",
        "Abstract": "Patients required a median of 4 adjuvant procedures (range, 3-7) prior to implantation. All six patients required additional soft tissue procedures for vestibuloplasty. Two patients required additional bone grafting due to initial bone stock loss, which was harvested from the iliac. A total of 20 initial implants were placed into the neo-maxilla (range, 2-6 implants per patient). Implantation occurred a median of 27 months (range, 3-51) after reconstruction. Implants were placed into a median length of 40.8 mm scapula (range, 30-49.4), with a median bone thickness of 12.3 mm (range, 9.6-14.6). Three implants into the scapula failed among two separate patients at 6 and 42 months. At removal, peri-implantitis was deemed causal for both patients; the former patient had received adjuvant radiotherapy. The latter patient had two additional dental implants placed into the scapula after initial failure. All patients underwent successful prosthodontic rehabilitation with either fixed (2) or removable (4) prostheses. Success was defined as consistent use of dental prosthesis at longitudinal follow-up. At a median follow-up of 81.5 months (range, 17-96) after implantation, all functioning implants remained stable without evidence of infection or mechanical failure. All patients exhibited restoration of normal mastication, swallowing, and speech function as compared to pre-implantation functionality.",
        "Conclusion": "This case-series demonstrates the feasibility and success of dental implantation into scapular tip free flaps for maxillary defects. Although adjuvant procedures were required for all patients prior to implantation, all patients achieved successful osseointegration and prosthodontic success, with restoration of key functions such as mastication, deglutition, and speech. These findings suggest viability of the scapular tip free flap for implant-based reconstruction, with larger studies needed to better characterize optimal patient selection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Feasibility of Dental Implantation in Scapular Tip Free Flaps for Maxillary Reconstruction</span>. <u>Evan A Thomas, BS</u><sup>1</sup>; David Forner, MD, MSc<sup>2</sup>; Molly E Heft Neal, MD<sup>2</sup>; Keith A Casper, MD<sup>2</sup>; Pratyusha Yalamanchi, MD, MBA<sup>2</sup>; Marisa R Buchakjian, MD, PhD<sup>2</sup>; Kelly M Malloy, MD, MBA<sup>2</sup>; Mark E Prince, MD<sup>2</sup>; Chaz Stucken, MD<sup>2</sup>. <sup>1</sup>University of Michigan Medical School; <sup>2</sup>University of Michigan Department of Otolaryngology - Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Maxillary defects following oncologic resection present significant challenges for functional dental rehabilitation. The scapular tip free flap is a versatile reconstructive option, offering ample soft tissue, adaptable geometry, a long vascular pedicle, as well as minimal donor site morbidity. However, concerns regarding the flap’s bone thickness have historically discouraged its utilization for dental implant-supported reconstruction compared to other workhorse osseous flaps. In this case-series, we aim to evaluate clinical and prosthodontic outcomes of dental implantation following scapular tip free flap reconstruction of maxillary defects. </p>\n\n<p><strong>Methods:</strong> In this retrospective case-series, six patients with maxillary defects underwent scapular tip free flap reconstruction at a single tertiary academic center between 2012-2016. After flap success was ensured, all patients underwent endosseus dental implant placement. Clinicodemographic and descriptive functional outcome data were abstracted from patient charts. </p>\n\n<p><strong>Results: </strong>All six patients underwent successful maxillary reconstruction with scapular tip free flaps. The cohort included three males and three females, with a median age of 51 years (range, 14-80). Four patients underwent maxillectomy due to malignant tumors, while two were benign. One patient received neoadjuvant chemotherapy, and one patient required adjuvant radiation therapy. </p>\n\n<p>Patients required a median of 4 adjuvant procedures (range, 3-7) prior to implantation. All six patients required additional soft tissue procedures for vestibuloplasty. Two patients required additional bone grafting due to initial bone stock loss, which was harvested from the iliac. </p>\n\n<p>A total of 20 initial implants were placed into the neo-maxilla (range, 2-6 implants per patient). Implantation occurred a median of 27 months (range, 3-51) after reconstruction. Implants were placed into a median length of 40.8 mm scapula (range, 30-49.4), with a median bone thickness of 12.3 mm (range, 9.6-14.6). Three implants into the scapula failed among two separate patients at 6 and 42 months. At removal, peri-implantitis was deemed causal for both patients; the former patient had received adjuvant radiotherapy. The latter patient had two additional dental implants placed into the scapula after initial failure.</p>\n\n<p>All patients underwent successful prosthodontic rehabilitation with either fixed (2) or removable (4) prostheses. Success was defined as consistent use of dental prosthesis at longitudinal follow-up. At a median follow-up of 81.5 months (range, 17-96) after implantation, all functioning implants remained stable without evidence of infection or mechanical failure. All patients exhibited restoration of normal mastication, swallowing, and speech function as compared to pre-implantation functionality. </p>\n\n<p><strong>Conclusion: </strong>This case-series demonstrates the feasibility and success of dental implantation into scapular tip free flaps for maxillary defects. Although adjuvant procedures were required for all patients prior to implantation, all patients achieved successful osseointegration and prosthodontic success, with restoration of key functions such as mastication, deglutition, and speech. These findings suggest viability of the scapular tip free flap for implant-based reconstruction, with larger studies needed to better characterize optimal patient selection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153263--></body></html>"
    },
    {
      "uid": "P158",
      "content_id": "154563",
      "abstract_number": "P158",
      "poster_number": "P158",
      "title": "Patient experience with swallow therapy during head and neck cancer treatment",
      "summary": "Swallow therapy is an important component of multidisciplinary care for patients with HNC. While barriers persist, most patients deeply value their relationship with SLP, which uniquely empowers them to be an active member of their care team. Larger issues around the financial impact may be challenging, but targeted SLP follow-up both improves clinical outcomes and supports patient engagement in HNC treatment.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154563",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mallory G McKeon, MD",
      "presenter": "Mallory G McKeon, MD",
      "authors": "Mallory G McKeon, MD 1 ; Grace Zhang 1 ; Madeline Kiernan 2 ; Amy Irwin 2 ; Sarah Adams 1 ; Armo Derbarsegian 1 ; Cameron MacDonald 2 ; Farah Kaval 1 ; David Rule 1 ; Alice Tang 1",
      "normalized_authors": [
        "Mallory G McKeon",
        "Grace Zhang",
        "Madeline Kiernan",
        "Amy Irwin",
        "Sarah Adams",
        "Armo Derbarsegian",
        "Cameron MacDonald",
        "Farah Kaval",
        "David Rule",
        "Alice Tang"
      ],
      "affiliations": [
        "University of Cincinnati Medical Center",
        "Qualitative Health Research Center"
      ],
      "normalized_institutions": [
        "University of Cincinnati Medical Center",
        "Qualitative Health Research Center"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 306,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Mallory G McKeon, MD 1 ; Grace Zhang 1 ; Madeline Kiernan 2 ; Amy Irwin 2 ; Sarah Adams 1 ; Armo Derbarsegian 1 ; Cameron MacDonald 2 ; Farah Kaval 1 ; David Rule 1 ; Alice Tang 1",
        "Affiliations": "1 University of Cincinnati Medical Center; 2 Qualitative Health Research Center",
        "Background": "Dysphagia is a common long-term impairment in patients with head and neck cancer (HNC), particularly those treated with radiation therapy. Despite evidence that speech-language pathology (SLP) interventions improve swallowing outcomes, many patients face barriers to fully engaging in therapy. Resulting dysphagia, odynophagia, and malnutrition contribute to substantial medical and psychosocial morbidity.",
        "Objective": "To identify patient reported factors impeding participation in swallow therapy and better understand the role of SLP in HNC treatment.",
        "Methods": "Semi-structured qualitative interviewed were conducted with patients who had completed treatment for HNC. Interviews focused on experiences through diagnosis and treatment with a particular interest in swallow therapy and eating. Quantitative assessments were collected including the CHLT-30 health literacy test, the Cost- FACIT, and objective socioeconomic data from the Neighborhood Atlas. Interviews and survey data were transcribed and analyzed for thematic saturation. Descriptive statistics are reported.",
        "Results": "Seventeen patients were recruited; 14 had radiation as primary or adjuvant treatment. Participants were predominantly low-income (65%), white (82%) males living in non-rural areas (65%) insured through Medicaid (41%). Patients generally reported positive experiences with swallow therapy and expressed strong confidence in their SLP. While participants reliably attended outpatient visits, adherence to prescribed home exercises was variable. Notably, those who were diligent with home exercises reported great subjective outcomes. Conversely, those who were not reported decisional regret and swallowing difficulty. The time burden or treatments and travel to appointments were frequently cited barriers. Coordinated scheduling substantially reduced this concern for many. Only two patients reported high out-of-pocket costs.",
        "Conclusions": "Swallow therapy is an important component of multidisciplinary care for patients with HNC. While barriers persist, most patients deeply value their relationship with SLP, which uniquely empowers them to be an active member of their care team. Larger issues around the financial impact may be challenging, but targeted SLP follow-up both improves clinical outcomes and supports patient engagement in HNC treatment."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient experience with swallow therapy during head and neck cancer treatment</span>. <u>Mallory G McKeon, MD</u><sup>1</sup>; Grace Zhang<sup>1</sup>; Madeline Kiernan<sup>2</sup>; Amy Irwin<sup>2</sup>; Sarah Adams<sup>1</sup>; Armo Derbarsegian<sup>1</sup>; Cameron MacDonald<sup>2</sup>; Farah Kaval<sup>1</sup>; David Rule<sup>1</sup>; Alice Tang<sup>1</sup>. <sup>1</sup>University of Cincinnati Medical Center; <sup>2</sup>Qualitative Health Research Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Dysphagia is a common long-term impairment in patients with head and neck cancer (HNC), particularly those treated with radiation therapy. Despite evidence that speech-language pathology (SLP) interventions improve swallowing outcomes, many patients face barriers to fully engaging in therapy. Resulting dysphagia, odynophagia, and malnutrition contribute to substantial medical and psychosocial morbidity.</p>\n\n<p><strong>Objective: </strong>To identify patient reported factors impeding participation in swallow therapy and better understand the role of SLP in HNC treatment.</p>\n\n<p><strong>Methods: </strong>Semi-structured qualitative interviewed were conducted with patients who had completed treatment for HNC. Interviews focused on experiences through diagnosis and treatment with a particular interest in swallow therapy and eating. Quantitative assessments were collected including the CHLT-30 health literacy test, the Cost- FACIT, and objective socioeconomic data from the Neighborhood Atlas. Interviews and survey data were transcribed and analyzed for thematic saturation. Descriptive statistics are reported.</p>\n\n<p><strong>Results:</strong> Seventeen patients were recruited; 14 had radiation as primary or adjuvant treatment. Participants were predominantly low-income (65%), white (82%) males living in non-rural areas (65%) insured through Medicaid (41%). Patients generally reported positive experiences with swallow therapy and expressed strong confidence in their SLP. While participants reliably attended outpatient visits, adherence to prescribed home exercises was variable. Notably, those who were diligent with home exercises reported great subjective outcomes. Conversely, those who were not reported decisional regret and swallowing difficulty. The time burden or treatments and travel to appointments were frequently cited barriers. Coordinated scheduling substantially reduced this concern for many. Only two patients reported high out-of-pocket costs.</p>\n\n<p><strong>Conclusions:</strong> Swallow therapy is an important component of multidisciplinary care for patients with HNC. While barriers persist, most patients deeply value their relationship with SLP, which uniquely empowers them to be an active member of their care team. Larger issues around the financial impact may be challenging, but targeted SLP follow-up both improves clinical outcomes and supports patient engagement in HNC treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154563--></body></html>"
    },
    {
      "uid": "P159",
      "content_id": "154289",
      "abstract_number": "P159",
      "poster_number": "P159",
      "title": "Early Integration of Embedded Palliative Care in Treatment of Head and Neck Cancer",
      "summary": "Embedded palliative care for patients with head and neck cancer was frequently initiated in the setting of active disease and was associated with age- and sex-related differences in symptom documentation, but we did not detect significant differences in primary outcomes between early and late referral. Inclusion of additional patients may show significant differences for early integration of palliative care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154289",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Monica S Gorton, MD, MS",
      "presenter": "Monica S Gorton, MD, MS",
      "authors": "Monica S Gorton, MD, MS 1 ; Michael Eizyk, MD 2 ; Olivia Lopes, BS 3 ; Tamara Vesel, MD 2 ; Miriam O'Leary, MD 1",
      "normalized_authors": [
        "Monica S Gorton",
        "Michael Eizyk",
        "Olivia Lopes",
        "Tamara Vesel",
        "Miriam O'Leary"
      ],
      "affiliations": [
        "Tufts Medical Center Department of Otolaryngology",
        "Tufts Medical Center Division of Palliative Care",
        "Tufts University School of Medicine"
      ],
      "normalized_institutions": [
        "Tufts Medical Center Department of Otolaryngology",
        "Tufts Medical Center Division of Palliative Care",
        "Tufts University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction/Background",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Monica S Gorton, MD, MS 1 ; Michael Eizyk, MD 2 ; Olivia Lopes, BS 3 ; Tamara Vesel, MD 2 ; Miriam O'Leary, MD 1",
        "Affiliations": "1 Tufts Medical Center Department of Otolaryngology; 2 Tufts Medical Center Division of Palliative Care; 3 Tufts University School of Medicine",
        "Introduction/Background": "Head and neck cancer and treatment side effects can cause a significant symptom burden 1,2 . Palliative care is recommended by the American Society of Clinical Oncology guidelines 3 . The goal of this study is to analyze differences between early and late integration of palliative care in an embedded palliative care and head and neck surgery clinic. We hypothesize that early integration of palliative care will be associated with decreased healthcare utilization, increased breadth of symptoms addressed, and fewer hospital deaths.",
        "Methods": "A retrospective chart review was conducted using a single institution’s electronic medical record. Patients who had their first head and neck surgery visit and an embedded clinic visit between April 2022 and September 2025 were included. Patients were placed in either the early integration (early) group or the late integration (late) group. Patients in the early group had eight weeks or less between their first head and neck surgery visit and their first palliative care visit 4 . Univariate (chi-square analysis and t-test) and multivariate (multiple linear regression) analyses were performed (alpha=0.05).",
        "Results": "A total of 52 patients were included (early, n=37; late, n=15). Univariate analysis revealed significantly more patients with active diagnoses in the early group (p=0.007). On multivariate analysis, independent of age and early vs. late palliative care, there was 23.54% lower probability of dysphagia for males (p=0.034). Independent of sex and early vs. late palliative care, there was 4.27% lower probability of ED visits (p=0.027), 0.77% greater probability of having a documented goals of care conversation (p=0.0034), and 0.50% greater probability of dysphonia for older age at diagnosis. There was no significant difference between the early and late groups for primary outcome variables on multivariate analysis.",
        "Discussion": "There may have been more patients with active diagnoses in the early group because of more recent diagnoses upon integration of palliative care. Patients more often utilized palliative care only during, or died with, active disease. Higher probability of dysphagia in males contrasts with community-based data showing similar or higher dysphagia reporting in females, and warrants further investigation 5,6 . Older age was associated with dysphonia and documented goals-of-care discussions, consistent with age-related voice changes and greater receptivity to advance care planning in older adults. The lower probability of ED visits in older patients diverges from national trends and may reflect unmeasured confounders or incomplete capture of outside encounters 7 . This study is limited by a small sample size and a single-center design. Routine intensive and acute care admissions for free-flap surgery may also blunt differences in health care utilization.",
        "Conclusion": "Embedded palliative care for patients with head and neck cancer was frequently initiated in the setting of active disease and was associated with age- and sex-related differences in symptom documentation, but we did not detect significant differences in primary outcomes between early and late referral. Inclusion of additional patients may show significant differences for early integration of palliative care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Integration of Embedded Palliative Care in Treatment of Head and Neck Cancer</span>. <u>Monica S Gorton, MD, MS</u><sup>1</sup>; Michael Eizyk, MD<sup>2</sup>; Olivia Lopes, BS<sup>3</sup>; Tamara Vesel, MD<sup>2</sup>; Miriam O'Leary, MD<sup>1</sup>. <sup>1</sup>Tufts Medical Center Department of Otolaryngology; <sup>2</sup>Tufts Medical Center Division of Palliative Care; <sup>3</sup>Tufts University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction/Background: </strong>Head and neck cancer and treatment side effects can cause a significant symptom burden<sup>1,2</sup>. Palliative care is recommended by the American Society of Clinical Oncology guidelines<sup>3</sup>. The goal of this study is to analyze differences between early and late integration of palliative care in an embedded palliative care and head and neck surgery clinic. We hypothesize that early integration of palliative care will be associated with decreased healthcare utilization, increased breadth of symptoms addressed, and fewer hospital deaths. </p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted using a single institution’s electronic medical record. Patients who had their first head and neck surgery visit and an embedded clinic visit between April 2022 and September 2025 were included. Patients were placed in either the early integration (early) group or the late integration (late) group. Patients in the early group had eight weeks or less between their first head and neck surgery visit and their first palliative care visit<sup>4</sup>. Univariate (chi-square analysis and t-test) and multivariate (multiple linear regression) analyses were performed (alpha=0.05). </p>\n\n<p><strong>Results:</strong> A total of 52 patients were included (early, n=37; late, n=15). Univariate analysis revealed significantly more patients with active diagnoses in the early group (p=0.007). On multivariate analysis, independent of age and early vs. late palliative care, there was 23.54% lower probability of dysphagia for males (p=0.034). Independent of sex and early vs. late palliative care, there was 4.27% lower probability of ED visits (p=0.027), 0.77% greater probability of having a documented goals of care conversation (p=0.0034), and 0.50% greater probability of dysphonia for older age at diagnosis. There was no significant difference between the early and late groups for primary outcome variables on multivariate analysis. </p>\n\n<p><strong>Discussion: </strong>There may have been more patients with active diagnoses in the early group because of more recent diagnoses upon integration of palliative care. Patients more often utilized palliative care only during, or died with, active disease. Higher probability of dysphagia in males contrasts with community-based data showing similar or higher dysphagia reporting in females, and warrants further investigation<sup>5,6</sup>. Older age was associated with dysphonia and documented goals-of-care discussions, consistent with age-related voice changes and greater receptivity to advance care planning in older adults. The lower probability of ED visits in older patients diverges from national trends and may reflect unmeasured confounders or incomplete capture of outside encounters<sup>7</sup>. This study is limited by a small sample size and a single-center design. Routine intensive and acute care admissions for free-flap surgery may also blunt differences in health care utilization. </p>\n\n<p><strong>Conclusion:</strong> Embedded palliative care for patients with head and neck cancer was frequently initiated in the setting of active disease and was associated with age- and sex-related differences in symptom documentation, but we did not detect significant differences in primary outcomes between early and late referral. Inclusion of additional patients may show significant differences for early integration of palliative care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154289--></body></html>"
    },
    {
      "uid": "P160",
      "content_id": "153149",
      "abstract_number": "P160",
      "poster_number": "P160",
      "title": "Dental prosthetic rehabilitation and associated quality of life following mandibular reconstruction with free fibula flap",
      "summary": "This ongoing study highlights high patient reported quality of life following mandibular reconstruction and simultaneous dental rehabilitation for both cosmetic and functional outcomes. Despite reported high quality of life, decision regret was variable which may be associated with high out of pocket cost. Further research is ongoing.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153149",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amanda J Bastien",
      "presenter": "Amanda J Bastien",
      "authors": "Amanda J Bastien ; Arash Abiri; Kevin Scher; Justin Moyers; Julie Jang; Zachary Zumsteg; Allen S Ho; Evan S Walgama; Jon Mallen-St.Clair",
      "normalized_authors": [
        "Amanda J Bastien",
        "Arash Abiri",
        "Kevin Scher",
        "Justin Moyers",
        "Julie Jang",
        "Zachary Zumsteg",
        "Allen S Ho",
        "Evan S Walgama",
        "Jon Mallen-St.Clair"
      ],
      "affiliations": [
        "Cedars Sinai"
      ],
      "normalized_institutions": [
        "Cedars Sinai"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153149/qol(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153149/qol(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153149"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Amanda J Bastien ; Arash Abiri; Kevin Scher; Justin Moyers; Julie Jang; Zachary Zumsteg; Allen S Ho; Evan S Walgama; Jon Mallen-St.Clair",
        "Affiliations": "Cedars Sinai",
        "Introduction": "Despite research supporting success of implant supported dental prosthetic rehabilitation (DPR) after mandibular reconstruction with fibula free flaps (FFF), follow-up dental services are historically not covered by insurance. Understanding patient-reported financial toxicity, quality of life, and decision regret is critical for informing health policy and for survivorship care planning. The objective of this study was to investigate both the patient perception of their DPR as well as the patient reported dollar amounts for their final prosthesis following FFF.",
        "Methods": "This is an ongoing prospective study of patients who underwent FFF and dental prosthetic rehabilitation after jaw reconstruction for both cancer and noncancerous etiologies between September 2017 and January 2024 with at least 6 months follow-up at a single institution. Consented participants completed a modified University of Washington Quality of Life Questionnaire with “cancer” replaced with “fibula free flap” and The Decision Regret Scale. Patients also completed a series of focused questions related to their dental rehabilitation and related expenses.",
        "Results": "In total 66% of eligible patients responded (N=20). Patients exempt from the study include eight patients who died before survey follow-up, one with cancer recurrence delaying final prosthesis, and one with neurocognitive impairment.",
        "Abstract": "Of the 20 patients, 65% patients endorsed moderate to severe decision regret. Patient, sex, etiology, adjuvant therapy (radiation ± chemotherapy) and quality of life scores was not associated with patient decision regret on linear regression analysis. However, this patient cohort demonstrated notably high post-FFF quality of life (Table 1). The median overall patient reported quality of life being 80 out of 100 (SD 22.4, range 40-100). In total, fifteen patients self-reported financial information related to their dental rehabilitation. 86.6% paid out of pocket for their final prosthesis with no assistance from medical or dental insurance. For patients who received insurance coverage, coverage was variable with one patient reporting over 2.5 years appealing their denial to receive 50% insurance coverage. The median out of pocket cost for their dental rehabilitation was $33,000 (SD: $18,811 range: $10,745- $75,025).",
        "Discussion": "Prior to 1988 breast reconstruction after mastectomy was recognized as solely cosmetic until the Women’s Health and Cancer Rights Act required insurance companies to cover breast reconstruction following mastectomies and its related complications. In 2024, Centers for Medicare & Medicaid Services clarified that certain dental services are covered including treatment of dental complications after cancer therapy (radiation, chemotherapy, surgery) in head and neck cancer. Further research is needed including the impact of these policy changes on the head and neck cancer population and whether dental rehabilitation is included as it may assist in the financial burden patients currently experience in their dental rehabilitation despite the good quality of life outcomes associated with it.",
        "Conclusion": "This ongoing study highlights high patient reported quality of life following mandibular reconstruction and simultaneous dental rehabilitation for both cosmetic and functional outcomes. Despite reported high quality of life, decision regret was variable which may be associated with high out of pocket cost. Further research is ongoing."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Dental prosthetic rehabilitation and associated quality of life following mandibular reconstruction with free fibula flap</span>. <u>Amanda J Bastien</u>; Arash Abiri; Kevin Scher; Justin Moyers; Julie Jang; Zachary Zumsteg; Allen S Ho; Evan S Walgama; Jon Mallen-St.Clair. Cedars Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Despite research supporting success of implant supported dental prosthetic rehabilitation (DPR) after mandibular reconstruction with fibula free flaps (FFF), follow-up dental services are historically not covered by insurance. Understanding patient-reported financial toxicity, quality of life, and decision regret is critical for informing health policy and for survivorship care planning. The objective of this study was to investigate both the patient perception of their DPR as well as the patient reported dollar amounts for their final prosthesis following FFF.</p>\n\n<p><strong>Methods: </strong>This is an ongoing prospective study of patients who underwent FFF and dental prosthetic rehabilitation after jaw reconstruction for both cancer and noncancerous etiologies between September 2017 and January 2024 with at least 6 months follow-up at a single institution. Consented participants completed a modified University of Washington Quality of Life Questionnaire with “cancer” replaced with “fibula free flap” and The Decision Regret Scale. Patients also completed a series of focused questions related to their dental rehabilitation and related expenses.</p>\n\n<p><strong>Results: </strong>In total 66% of eligible patients responded (N=20). Patients exempt from the study include eight patients who died before survey follow-up, one with cancer recurrence delaying final prosthesis, and one with neurocognitive impairment.</p>\n\n<p>Of the 20 patients, 65% patients endorsed moderate to severe decision regret. Patient, sex, etiology, adjuvant therapy (radiation ± chemotherapy) and quality of life scores was not associated with patient decision regret on linear regression analysis. However, this patient cohort demonstrated notably high post-FFF quality of life (Table 1). The median overall patient reported quality of life being 80 out of 100 (SD 22.4, range 40-100).</p>\n\n<p>In total, fifteen patients self-reported financial information related to their dental rehabilitation. 86.6% paid out of pocket for their final prosthesis with no assistance from medical or dental insurance. For patients who received insurance coverage, coverage was variable with one patient reporting over 2.5 years appealing their denial to receive 50% insurance coverage. The median out of pocket cost for their dental rehabilitation was $33,000 (SD: $18,811 range: $10,745- $75,025).</p>\n\n<p><strong>Discussion: </strong>Prior to 1988 breast reconstruction after mastectomy was recognized as solely cosmetic until the Women’s Health and Cancer Rights Act required insurance companies to cover breast reconstruction following mastectomies and its related complications. In 2024, Centers for Medicare & Medicaid Services clarified that certain dental services are covered including treatment of dental complications after cancer therapy (radiation, chemotherapy, surgery) in head and neck cancer. Further research is needed including the impact of these policy changes on the head and neck cancer population and whether dental rehabilitation is included as it may assist in the financial burden patients currently experience in their dental rehabilitation despite the good quality of life outcomes associated with it.</p>\n\n<p><strong>Conclusion: </strong>This ongoing study highlights high patient reported quality of life following mandibular reconstruction and simultaneous dental rehabilitation for both cosmetic and functional outcomes. Despite reported high quality of life, decision regret was variable which may be associated with high out of pocket cost. Further research is ongoing.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153149/qol(2).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153149--></body></html>"
    },
    {
      "uid": "P161",
      "content_id": "155596",
      "abstract_number": "P161",
      "poster_number": "P161",
      "title": "Defining and Quantifying Postoperative Bleeding in Otolaryngology Using ACS-NSQIP: A Multicohort Analysis",
      "summary": "RTO variables alone underestimate postoperative bleeding burden in otolaryngology. A composite definition incorporating both operative and nonoperative bleeding events provides a more complete and clinically meaningful estimate of complication rates. Establishing a standardized bleeding definition enables accurate benchmarking and supports otolaryngology-specific quality improvement initiatives.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155596",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "India Jackson, BS",
      "presenter": "India Jackson, BS",
      "authors": "India Jackson, BS ; Sanjana Velu; Louis-Xavier Barrette, MD; Ara Chalian, MD; Steven Cannady, MD",
      "normalized_authors": [
        "India Jackson",
        "Sanjana Velu",
        "Louis-Xavier Barrette",
        "Ara Chalian",
        "Steven Cannady"
      ],
      "affiliations": [
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of Pennsylvania"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 321,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "India Jackson, BS ; Sanjana Velu; Louis-Xavier Barrette, MD; Ara Chalian, MD; Steven Cannady, MD",
        "Affiliations": "University of Pennsylvania",
        "Introduction": "Postoperative bleeding in otolaryngology lacks a standardized national definition, limiting benchmarking and quality improvement efforts. Return to operating room (RTO) variables capture severe events but fail to account for clinically significant bleeding managed nonoperatively. We aimed to define a comprehensive postoperative bleeding cohort within ACS-NSQIP and quantify the overall bleeding burden across ENT procedures.",
        "Methods": "ACS-NSQIP data from 2020 to 2024 were queried for otolaryngology cases. A total of 115,820 ENT procedures were identified, including 3,062 unplanned RTO events. Postoperative bleeding was defined using a composite of finalized RTO-related CPT and ICD-10 codes, complemented by non-RTO postoperative diagnostic codes capturing bleeding managed without operative intervention. This approach generated two subcohorts: bleeding requiring RTO and bleeding not requiring RTO. Procedure-specific bleeding rates were calculated using the finalized bleeding definition. Multivariable logistic regression was performed to evaluate associations between preoperative comorbidities and postoperative bleeding.",
        "Results": "Using this definition, 1,495 total postoperative bleeding events were identified among 115,820 ENT cases, corresponding to an overall ENT bleeding rate of 1.29%. Of these events, 90.8% required RTO and 9.2% were managed without operative intervention. The RTO-only bleeding rate was 1.17%, while the non-RTO bleeding rate was 0.12%. The most frequent RTO bleeding-related CPT codes included 35800 and 10140, and the most common ICD-10 code was J95.830. Procedure-specific bleeding rates ranged from 0.14% to 9.68%, with the highest rate observed in CPT code 42960. Multivariable analysis found six variables (age, smoking, COPD, hypertension on medication, bleeding disorder, and sepsis) independently associated with postoperative bleeding, with preoperative SIRS demonstrating the strongest independent association (OR 1.86, 95% CI 1.17-2.95, p = 0.0088).",
        "Conclusion": "RTO variables alone underestimate postoperative bleeding burden in otolaryngology. A composite definition incorporating both operative and nonoperative bleeding events provides a more complete and clinically meaningful estimate of complication rates. Establishing a standardized bleeding definition enables accurate benchmarking and supports otolaryngology-specific quality improvement initiatives."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Defining and Quantifying Postoperative Bleeding in Otolaryngology Using ACS-NSQIP: A Multicohort Analysis</span>. <u>India Jackson, BS</u>; Sanjana Velu; Louis-Xavier Barrette, MD; Ara Chalian, MD; Steven Cannady, MD. University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Postoperative bleeding in otolaryngology lacks a standardized national definition, limiting benchmarking and quality improvement efforts. Return to operating room (RTO) variables capture severe events but fail to account for clinically significant bleeding managed nonoperatively. We aimed to define a comprehensive postoperative bleeding cohort within ACS-NSQIP and quantify the overall bleeding burden across ENT procedures.</p>\n\n<p><strong>Methods:</strong> ACS-NSQIP data from 2020 to 2024 were queried for otolaryngology cases. A total of 115,820 ENT procedures were identified, including 3,062 unplanned RTO events. Postoperative bleeding was defined using a composite of finalized RTO-related CPT and ICD-10 codes, complemented by non-RTO postoperative diagnostic codes capturing bleeding managed without operative intervention. This approach generated two subcohorts: bleeding requiring RTO and bleeding not requiring RTO. Procedure-specific bleeding rates were calculated using the finalized bleeding definition. Multivariable logistic regression was performed to evaluate associations between preoperative comorbidities and postoperative bleeding.</p>\n\n<p><strong>Results:</strong> Using this definition, 1,495 total postoperative bleeding events were identified among 115,820 ENT cases, corresponding to an overall ENT bleeding rate of 1.29%. Of these events, 90.8% required RTO and 9.2% were managed without operative intervention. The RTO-only bleeding rate was 1.17%, while the non-RTO bleeding rate was 0.12%. The most frequent RTO bleeding-related CPT codes included 35800 and 10140, and the most common ICD-10 code was J95.830. Procedure-specific bleeding rates ranged from 0.14% to 9.68%, with the highest rate observed in CPT code 42960. Multivariable analysis found six variables (age, smoking, COPD, hypertension on medication, bleeding disorder, and sepsis) independently associated with postoperative bleeding, with preoperative SIRS demonstrating the strongest independent association (OR 1.86, 95% CI 1.17-2.95, p = 0.0088).</p>\n\n<p><strong>Conclusion: </strong>RTO variables alone underestimate postoperative bleeding burden in otolaryngology. A composite definition incorporating both operative and nonoperative bleeding events provides a more complete and clinically meaningful estimate of complication rates. Establishing a standardized bleeding definition enables accurate benchmarking and supports otolaryngology-specific quality improvement initiatives. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155596--></body></html>"
    },
    {
      "uid": "P162",
      "content_id": "153602",
      "abstract_number": "P162",
      "poster_number": "P162",
      "title": "Evaluating the Effect of Patient Language Preference on Treatment and Oncologic Outcomes in Head and Neck Cancer",
      "summary": "Language preference was not associated with delays in presentation, complications, or readmissions. However, non-English speaking patients demonstrated significantly higher recurrence rates in the full cohort and within non-surgical treatment group. These findings suggest that language barriers may contribute to disparities in oncologic outcomes, particularly among patients managed with chemotherapy and radiotherapy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153602",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Frank A Guerrero",
      "presenter": "Frank A Guerrero",
      "authors": "Frank A Guerrero 1 ; Troy Weinstein 2 ; Shethal Bearelly, MD 2",
      "normalized_authors": [
        "Frank A Guerrero",
        "Troy Weinstein",
        "Shethal Bearelly"
      ],
      "affiliations": [
        "University of Arizona College of Medicine - Phoenix",
        "University of Arizona College of Medicine - Tucson"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine - Phoenix",
        "University of Arizona College of Medicine - Tucson"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 538,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Educational Objective",
        "Objectives",
        "Study Design",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Frank A Guerrero 1 ; Troy Weinstein 2 ; Shethal Bearelly, MD 2",
        "Affiliations": "1 University of Arizona College of Medicine - Phoenix; 2 University of Arizona College of Medicine - Tucson",
        "Educational Objective": "Participants will be able to interpret how patient language preference influences diagnostic timelines and post-treatment outcomes among individuals with head and neck cancer.",
        "Objectives": "To examine whether patient language preference is associated with symptom duration prior to presentation, treatment modality received, postoperative complications, unplanned readmissions, and oncologic outcomes in head and neck cancer patients.",
        "Study Design": "Retrospective cohort of 645 patients.",
        "Results": "Of the 645 patients, 603 (93.5%) were English-speaking, and 42 (6.5%) were non-English-speaking. 18.4% (119/645) were Hispanic, while 80.6% (520/645) were non-Hispanic. Among non-English speakers, the majority were Spanish speakers; one spoke Nepali, and two spoke Vietnamese. Across the 645 tumors, the most common subsites were oropharynx (39.1%) and oral cavity (25.0%), followed by larynx (16.0%), salivary glands (5.9%), nasal cavity (4.7%), and paranasal sinuses (4.5%). Tumor histology was most represented by squamous cell carcinoma (85.6%), Other/Unknown (8.4%), adenoid cystic carcinoma (2.3%), and adenocarcinoma (1.9%). Overall, 316 patients (49.0%) underwent surgery with or without chemotherapy or radiation, and 329 (51.0%) were managed non-surgically with chemotherapy and/or radiation.",
        "Abstract": "In the full cohort, mean symptom duration before presentation was similar between groups (English 6.95 ± 8.61 months vs non-English 6.73 ± 7.56 months; p = 0.884). Recurrence occurred in 31.0% (198/638) of patients and was more frequent among non-English-speaking patients (47.6%, 20/42) than English-speaking patients (29.9%, 178/596; p = 0.016). When restricted to surgically treated patients, recurrence rates did not differ significantly between non-English and English-speaking patients (42.9% [12/28] vs 33.5% [95/284], p = 0.317). When restricted to non-surgically treated patients, recurrence rates did differ significantly between non-English and English-speaking patients (57.1% [8/14] vs 26.6% [83/312], p = 0.027). Across English-speaking patients, T-stage was T0 (0.5%), T1 (11.6%), T2 (18.6%), T3 (18.4%), T4 (15.3%), with 17.6% missing. For non-English-speaking patients, T-stage was T0 (0%), T1 (9.5%), T2 (11.9%), T3 (11.9%), T4 (11.9%), with 31.0% missing. Clinical T, N, and M staging were recoded into binary early (0) vs. advanced (1) categories, and chi-square testing demonstrated no significant differences in T stage (p = 0.979), N stage (p = 0.679), or M stage (p = 0.390) between English-speaking and non-English-speaking patients, indicating that baseline tumor stage was comparable across groups. Among surgical patients, unplanned 30-day readmission occurred in 15.4% (45/293) and did not differ significantly between English-speaking (14.7%, 39/266) and non-English-speaking patients (22.2%, 6/27; p = 0.299). Overall, postoperative complications were uncommon and identical by language (7.4% in both groups; 20/270 English vs. 2/27 non-English; p = 1.000). Individual complication types: including salivary leak, pneumonia, pulmonary embolus, and surgical-site infection, each occurred infrequently (≤5% in either group), with no significant differences between English and non-English-speaking patients.",
        "Conclusion": "Language preference was not associated with delays in presentation, complications, or readmissions. However, non-English speaking patients demonstrated significantly higher recurrence rates in the full cohort and within non-surgical treatment group. These findings suggest that language barriers may contribute to disparities in oncologic outcomes, particularly among patients managed with chemotherapy and radiotherapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating the Effect of Patient Language Preference on Treatment and Oncologic Outcomes in Head and Neck Cancer</span>. <u>Frank A Guerrero</u><sup>1</sup>; Troy Weinstein<sup>2</sup>; Shethal Bearelly, MD<sup>2</sup>. <sup>1</sup>University of Arizona College of Medicine - Phoenix; <sup>2</sup>University of Arizona College of Medicine - Tucson<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Educational Objective</strong>: Participants will be able to interpret how patient language preference influences diagnostic timelines and post-treatment outcomes among individuals with head and neck cancer.</p>\n\n<p><strong>Objectives</strong>: To examine whether patient language preference is associated with symptom duration prior to presentation, treatment modality received, postoperative complications, unplanned readmissions, and oncologic outcomes in head and neck cancer patients.</p>\n\n<p><strong>Study Design</strong>: Retrospective cohort of 645 patients.</p>\n\n<p><strong>Results</strong>: Of the 645 patients, 603 (93.5%) were English-speaking, and 42 (6.5%) were non-English-speaking. 18.4% (119/645) were Hispanic, while 80.6% (520/645) were non-Hispanic. Among non-English speakers, the majority were Spanish speakers; one spoke Nepali, and two spoke Vietnamese. Across the 645 tumors, the most common subsites were oropharynx (39.1%) and oral cavity (25.0%), followed by larynx (16.0%), salivary glands (5.9%), nasal cavity (4.7%), and paranasal sinuses (4.5%). Tumor histology was most represented by squamous cell carcinoma (85.6%), Other/Unknown (8.4%), adenoid cystic carcinoma (2.3%), and adenocarcinoma (1.9%). Overall, 316 patients (49.0%) underwent surgery with or without chemotherapy or radiation, and 329 (51.0%) were managed non-surgically with chemotherapy and/or radiation.</p>\n\n<p>In the full cohort, mean symptom duration before presentation was similar between groups (English 6.95 ± 8.61 months vs non-English 6.73 ± 7.56 months; p = 0.884). Recurrence occurred in 31.0% (198/638) of patients and was more frequent among non-English-speaking patients (47.6%, 20/42) than English-speaking patients (29.9%, 178/596; p = 0.016). When restricted to surgically treated patients, recurrence rates did not differ significantly between non-English and English-speaking patients (42.9% [12/28] vs 33.5% [95/284], p = 0.317). When restricted to non-surgically treated patients, recurrence rates did differ significantly between non-English and English-speaking patients (57.1% [8/14] vs 26.6% [83/312], p = 0.027).</p>\n\n<p>Across English-speaking patients, T-stage was T0 (0.5%), T1 (11.6%), T2 (18.6%), T3 (18.4%), T4 (15.3%), with 17.6% missing. For non-English-speaking patients, T-stage was T0 (0%), T1 (9.5%), T2 (11.9%), T3 (11.9%), T4 (11.9%), with 31.0% missing. Clinical T, N, and M staging were recoded into binary early (0) vs. advanced (1) categories, and chi-square testing demonstrated no significant differences in T stage (p = 0.979), N stage (p = 0.679), or M stage (p = 0.390) between English-speaking and non-English-speaking patients, indicating that baseline tumor stage was comparable across groups.</p>\n\n<p>Among surgical patients, unplanned 30-day readmission occurred in 15.4% (45/293) and did not differ significantly between English-speaking (14.7%, 39/266) and non-English-speaking patients (22.2%, 6/27; p = 0.299). Overall, postoperative complications were uncommon and identical by language (7.4% in both groups; 20/270 English vs. 2/27 non-English; p = 1.000). Individual complication types: including salivary leak, pneumonia, pulmonary embolus, and surgical-site infection, each occurred infrequently (≤5% in either group), with no significant differences between English and non-English-speaking patients.</p>\n\n<p><strong>Conclusion</strong>: Language preference was not associated with delays in presentation, complications, or readmissions. However, non-English speaking patients demonstrated significantly higher recurrence rates in the full cohort and within non-surgical treatment group. These findings suggest that language barriers may contribute to disparities in oncologic outcomes, particularly among patients managed with chemotherapy and radiotherapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153602--></body></html>"
    },
    {
      "uid": "P163",
      "content_id": "152630",
      "abstract_number": "P163",
      "poster_number": "P163",
      "title": "Historical trends in the use of palliative surgery in head and neck cancer",
      "summary": "Prior to 1980, the literature focused on radical surgery as the presumed best treatment for locoregional control, with the implied goal of either alleviating symptoms now, or preventing or delaying future symptoms and disability. Yet there was still debate in the field about what constituted effective palliation: “Physicians speak glibly about palliative surgery without critical analysis as to whether it truly...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152630",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Monica Bodd, MD, MTS",
      "presenter": "Monica Bodd, MD, MTS",
      "authors": "Antoinette R Esce, MD 1 ; Monica Bodd, MD, MTS 2 ; Susan D McCammon, MD, PhD 3 ; Zoe H Fullerton, MD, MBE 4",
      "normalized_authors": [
        "Antoinette R Esce",
        "Monica Bodd, MTS",
        "Susan D McCammon",
        "Zoe H Fullerton, MBE"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center",
        "Stanford University",
        "University of Alabama at Birmingham",
        "Washington University in St. Louis"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center",
        "Stanford University",
        "University of Alabama at Birmingham",
        "Washington University in St. Louis"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "Abstract",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Antoinette R Esce, MD 1 ; Monica Bodd, MD, MTS 2 ; Susan D McCammon, MD, PhD 3 ; Zoe H Fullerton, MD, MBE 4",
        "Affiliations": "1 Memorial Sloan Kettering Cancer Center; 2 Stanford University; 3 University of Alabama at Birmingham; 4 Washington University in St. Louis",
        "INTRODUCTION": "The term “palliative surgery” has heterogeneous usage in the literature, representing a spectrum of ideas including surgery done specifically to improve symptoms and surgery done without curative intent, either because of biological factors or the inability of the surgery to resect all macroscopic or microscopic disease (Kopecky 2024). These definitions are informed by a historical surgical perspective, the evolution of oncologic therapies, and changes in palliative medical care. An appreciation of these concepts and their interactions within the field of head and neck surgery is vital to understanding how patients are advised and counseled in the present moment.",
        "METHODS": "A scoping review of the literature on palliative surgery in head and neck cancer (HNC) was undertaken using four electronic databases and included peer-reviewed articles published between January 1945 and March 2025. Two independent reviewers screened studies, and three reviewers performed a full text review. Thematic analysis was performed with attention to historical themes.",
        "RESULTS": "Over time, the mention of “palliative surgery” in the HNC literature has become increasingly common, with a 17-fold increase in the number of articles per year across the period of review. Discussions consistently center on the critical importance of locoregional control for symptom management and the high morbidity of both HNC and its treatments, with tension between definitions of “palliative surgery” as a surgery that will be unsuccessful at achieving cure versus a surgery that will be successful treating symptoms.",
        "Abstract": "Prior to 1980, the literature focused on radical surgery as the presumed best treatment for locoregional control, with the implied goal of either alleviating symptoms now, or preventing or delaying future symptoms and disability. Yet there was still debate in the field about what constituted effective palliation: “Physicians speak glibly about palliative surgery without critical analysis as to whether it truly helps the patient (Gaisford 1972).” Nearly every article across the period of review relied on physician assessments of palliation or function as outcome measures. These were often poorly defined or abstract. Only 4% percent (9/234) of articles meeting criteria for full text analysis reported use of validated quality-of life instruments. All of these were published between 2008 and 2023. Many papers demonstrated the effectiveness of interventions like photodynamic therapy, radiofrequency ablation, or superficial laser treatments to help with tumor bulk, bleeding, or wound care, but these techniques have not gained widespread traction in the literature. Many evolving therapies, such as endoscopic or laser surgeries, were initially called “palliative” since they were not the standard of care for cure. Kopecky KE, Monton O, Arbaugh C, et al. The language of palliative surgery: A scoping review. Surgical Oncology Insight. 2024;1(2). doi:10.1016/j.soi.2024.100053 Gaisford JC. Palliative surgery. JAMA. 1972;221(1):83-84.",
        "CONCLUSION": "Definitions, approaches, and norms surrounding palliative surgery have evolved over the decades. As treatment options expand for patients with advanced, recurrent head and neck cancer, understanding historical trends in palliative surgery can help guide future discussions about the definition and usage of these terms, which may support efforts toward patient-centered decision-making."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Historical trends in the use of palliative surgery in head and neck cancer</span>. Antoinette R Esce, MD<sup>1</sup>; <u>Monica Bodd, MD, MTS</u><sup>2</sup>; Susan D McCammon, MD, PhD<sup>3</sup>; Zoe H Fullerton, MD, MBE<sup>4</sup>. <sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>Stanford University; <sup>3</sup>University of Alabama at Birmingham; <sup>4</sup>Washington University in St. Louis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION</strong>: The term “palliative surgery” has heterogeneous usage in the literature, representing a spectrum of ideas including surgery done specifically to improve symptoms and surgery done without curative intent, either because of biological factors or the inability of the surgery to resect all macroscopic or microscopic disease (Kopecky 2024). These definitions are informed by a historical surgical perspective, the evolution of oncologic therapies, and changes in palliative medical care. An appreciation of these concepts and their interactions within the field of head and neck surgery is vital to understanding how patients are advised and counseled in the present moment.</p>\n\n<p><strong>METHODS</strong>: A scoping review of the literature on palliative surgery in head and neck cancer (HNC) was undertaken using four electronic databases and included peer-reviewed articles published between January 1945 and March 2025. Two independent reviewers screened studies, and three reviewers performed a full text review. Thematic analysis was performed with attention to historical themes.</p>\n\n<p><strong>RESULTS</strong>: Over time, the mention of “palliative surgery” in the HNC literature has become increasingly common, with a 17-fold increase in the number of articles per year across the period of review. Discussions consistently center on the critical importance of locoregional control for symptom management and the high morbidity of both HNC and its treatments, with tension between definitions of “palliative surgery” as a surgery that will be unsuccessful at achieving cure versus a surgery that will be successful treating symptoms.</p>\n\n<p>Prior to 1980, the literature focused on radical surgery as the presumed best treatment for locoregional control, with the implied goal of either alleviating symptoms now, or preventing or delaying future symptoms and disability. Yet there was still debate in the field about what constituted effective palliation: “Physicians speak glibly about palliative surgery without critical analysis as to whether it truly helps the patient (Gaisford 1972).”</p>\n\n<p>Nearly every article across the period of review relied on physician assessments of palliation or function as outcome measures. These were often poorly defined or abstract. Only 4% percent (9/234) of articles meeting criteria for full text analysis reported use of validated quality-of life instruments. All of these were published between 2008 and 2023.</p>\n\n<p>Many papers demonstrated the effectiveness of interventions like photodynamic therapy, radiofrequency ablation, or superficial laser treatments to help with tumor bulk, bleeding, or wound care, but these techniques have not gained widespread traction in the literature. Many evolving therapies, such as endoscopic or laser surgeries, were initially called “palliative” since they were not the standard of care for cure.</p>\n\n<p><strong>CONCLUSION</strong>: Definitions, approaches, and norms surrounding palliative surgery have evolved over the decades. As treatment options expand for patients with advanced, recurrent head and neck cancer, understanding historical trends in palliative surgery can help guide future discussions about the definition and usage of these terms, which may support efforts toward patient-centered decision-making.</p>\n\n<p><strong>REFERENCES</strong>:</p>\n\n<p>Kopecky KE, Monton O, Arbaugh C, et al. The language of palliative surgery: A scoping review. Surgical Oncology Insight. 2024;1(2). doi:10.1016/j.soi.2024.100053<br />\nGaisford JC. Palliative surgery. JAMA. 1972;221(1):83-84.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152630--></body></html>"
    },
    {
      "uid": "P164",
      "content_id": "153295",
      "abstract_number": "P164",
      "poster_number": "P164",
      "title": "Prognostic Impact of Extranodal Extension in Oral Cavity and HPV-Positive Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis",
      "summary": "Macroscopic ENE appears to confer worse prognosis than microscopic ENE, particularly regarding disease recurrence. However, current evidence is limited by small study numbers and heterogeneous definitions. Final analyses incorporating additional studies and adjusted hazard ratios will provide more precise estimates to clarify the prognostic impact of ENE extent and strengthen its potential role in staging...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153295",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kimya Manouchehri, MD",
      "presenter": "Kimya Manouchehri, MD",
      "authors": "Kimya Manouchehri, MD 1 ; Mohammad Jay, MD 2 ; Alyssa Li, MD 1 ; Elizabeth Siciliani 1 ; Emma Wilson, MLIS 3 ; Antoine Eskander, MD, ScM, FRCSC 1",
      "normalized_authors": [
        "Kimya Manouchehri",
        "Mohammad Jay",
        "Alyssa Li",
        "Elizabeth Siciliani",
        "Emma Wilson, MLIS",
        "Antoine Eskander, ScM, FRCSC"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto",
        "Department of Medicine, University of Toronto",
        "Sunnybrook Health Sciences Centre, Library Services"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto",
        "Department of Medicine, University of Toronto",
        "Sunnybrook Health Sciences Centre, Library Services"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 337,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background/Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Kimya Manouchehri, MD 1 ; Mohammad Jay, MD 2 ; Alyssa Li, MD 1 ; Elizabeth Siciliani 1 ; Emma Wilson, MLIS 3 ; Antoine Eskander, MD, ScM, FRCSC 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Toronto; 2 Department of Medicine, University of Toronto; 3 Sunnybrook Health Sciences Centre, Library Services",
        "Background/Objective": "Extranodal extension (ENE) is an established adverse prognostic factor in head and neck squamous cell carcinoma (HNSCC), yet the prognostic significance of ENE extent remains unclear. We aimed to synthesize the evidence on how the degree of ENE impacts survival and disease recurrence in oral cavity (OCSCC) and HPV-positive oropharyngeal SCC (OPSCC).",
        "Methods": "A systematic review and meta-analysis were conducted and reported in accordance with PRISMA guidelines. Protocol was registered in PROSPERO (CRD420251119747). MEDLINE (Ovid), Embase, Cochrane CENTRAL, Cochrane Database of Systematic Reviews, and Epistemonikos were searched from inception until July 2025. Eligible studies reported ENE extent and survival outcomes including overall survival (OS), disease-free survival (DFS), and/or recurrence in patients with OCSCC or HPV-positive OPSCC. Risk of bias was assessed using QUIPS, and certainty of evidence was evaluated with GRADE for prognostic research.",
        "Results": "Four retrospective cohort studies (3 oral cavity; 1 oropharynx), including 4596 patients (median age 51.5 years [IQR 49–54.8]), were identified. The majority were male (77.5%), and 36.3% were ENE positive overall. Three studies classified ENE as microscopic (ENEmi ≤2mm) versus macroscopic (ENEma >2mm), and one used a four-grade system dichotomized into ENEmi (grades 1–2) versus ENEma (grades 3–4). ENEma was associated with a higher risk of recurrence compared with ENEmi (RR 1.27; 95% CI 0.90–1.80; I²=0%; two studies). Mortality analyses similarly suggested increased risk with ENEma (RR 1.40; 95% CI 0.88–2.23; I²=0%; three studies), though effect estimates varied due to differences in ENE definitions and follow-up intervals. Certainty of evidence was rated low for both recurrence and mortality, primarily due to risk of bias and imprecision.",
        "Conclusions": "Macroscopic ENE appears to confer worse prognosis than microscopic ENE, particularly regarding disease recurrence. However, current evidence is limited by small study numbers and heterogeneous definitions. Final analyses incorporating additional studies and adjusted hazard ratios will provide more precise estimates to clarify the prognostic impact of ENE extent and strengthen its potential role in staging refinements and adjuvant treatment decisions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Impact of Extranodal Extension in Oral Cavity and HPV-Positive Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis</span>. <u>Kimya Manouchehri, MD</u><sup>1</sup>; Mohammad Jay, MD<sup>2</sup>; Alyssa Li, MD<sup>1</sup>; Elizabeth Siciliani<sup>1</sup>; Emma Wilson, MLIS<sup>3</sup>; Antoine Eskander, MD, ScM, FRCSC<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Toronto; <sup>2</sup>Department of Medicine, University of Toronto; <sup>3</sup>Sunnybrook Health Sciences Centre, Library Services<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background/Objective: </strong>Extranodal extension (ENE) is an established adverse prognostic factor in head and neck squamous cell carcinoma (HNSCC), yet the prognostic significance of ENE extent remains unclear. We aimed to synthesize the evidence on how the degree of ENE impacts survival and disease recurrence in oral cavity (OCSCC) and HPV-positive oropharyngeal SCC (OPSCC).</p>\n\n<p><strong>Methods: </strong>A systematic review and meta-analysis were conducted and reported in accordance with PRISMA guidelines. Protocol was registered in PROSPERO (CRD420251119747). MEDLINE (Ovid), Embase, Cochrane CENTRAL, Cochrane Database of Systematic Reviews, and Epistemonikos were searched from inception until July 2025. Eligible studies reported ENE extent and survival outcomes including overall survival (OS), disease-free survival (DFS), and/or recurrence in patients with OCSCC or HPV-positive OPSCC. Risk of bias was assessed using QUIPS, and certainty of evidence was evaluated with GRADE for prognostic research.</p>\n\n<p><strong>Results: </strong>Four retrospective cohort studies (3 oral cavity; 1 oropharynx), including 4596 patients (median age 51.5 years [IQR 49–54.8]), were identified. The majority were male (77.5%), and 36.3% were ENE positive overall. Three studies classified ENE as microscopic (ENEmi ≤2mm) versus macroscopic (ENEma >2mm), and one used a four-grade system dichotomized into ENEmi (grades 1–2) versus ENEma (grades 3–4). ENEma was associated with a higher risk of recurrence compared with ENEmi (RR 1.27; 95% CI 0.90–1.80; I²=0%; two studies). Mortality analyses similarly suggested increased risk with ENEma (RR 1.40; 95% CI 0.88–2.23; I²=0%; three studies), though effect estimates varied due to differences in ENE definitions and follow-up intervals. Certainty of evidence was rated low for both recurrence and mortality, primarily due to risk of bias and imprecision.</p>\n\n<p><strong>Conclusions: </strong>Macroscopic ENE appears to confer worse prognosis than microscopic ENE, particularly regarding disease recurrence. However, current evidence is limited by small study numbers and heterogeneous definitions. Final analyses incorporating additional studies and adjusted hazard ratios will provide more precise estimates to clarify the prognostic impact of ENE extent and strengthen its potential role in staging refinements and adjuvant treatment decisions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153295--></body></html>"
    },
    {
      "uid": "P165",
      "content_id": "155520",
      "abstract_number": "P165",
      "poster_number": "P165",
      "title": "Soft Tissue Free Flap Reconstruction for Radiation-Induced Trismus: A Four-Patient Case Series",
      "summary": "Four patients who underwent free flap reconstruction for correction of radiation-associated trismus were included. All four patients demonstrated postoperative improvement in mouth opening, mandibular excursion, speech, oral intake, and overall function. In one representative case, preoperative trismus of less than one fingerbreadth improved to greater than three fingerbreadths following reconstruction. No flap...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155520",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Somya Shankar, MD",
      "presenter": "Somya Shankar, MD",
      "authors": "Somya Shankar, MD ; Nicole Farber, MD; Ryan Carey, MD; Steven B Cannady, MD; Ara A Chalian, MD; Robert M Brody, MD",
      "normalized_authors": [
        "Somya Shankar",
        "Nicole Farber",
        "Ryan Carey",
        "Steven B Cannady",
        "Ara A Chalian",
        "Robert M Brody"
      ],
      "affiliations": [
        "Hospital of the University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Hospital of the University of Pennsylvania"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 493,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion/Conclusion"
      ],
      "sections": {
        "Authors": "Somya Shankar, MD ; Nicole Farber, MD; Ryan Carey, MD; Steven B Cannady, MD; Ara A Chalian, MD; Robert M Brody, MD",
        "Affiliations": "Hospital of the University of Pennsylvania",
        "Introduction": "Radiation-associated trismus is a late consequence of head and neck cancer treatment with significant implications. Trismus results in impairment of oral intake, speech, and overall quality of life. Initial management involves jaw-stretching exercises in conjunction with speech therapy. However, a subset of patients can develop severe trismus refractory to conservative management. In many cases, surgical scar release alone is insufficient in treating severe trismus due to the risk of recurrent fibrosis in the irradiated field as well as extensive contracture along the lateral pterygoid extending close to the condylar head within the glenoid fossa. Resection of the condylar head, coronoid process, and ramus followed by reconstruction with vascularized soft tissue transfer can improve the durability of surgical correction by introducing healthy, nonirradiated tissue. We describe a four-patient case series evaluating soft tissue free flap reconstruction for the palliation of severe radiation-induced trismus.",
        "Methods": "A retrospective chart review was performed of patients undergoing surgery for radiation-induced trismus at a tertiary academic head and neck center. Inclusion criteria were a history of head and neck malignancy treated with radiation, severe refractory trismus, and reconstruction after scar release with a soft tissue free flap. Surgical management consisted of release or resection of the fibrotic scar by excision of the mandible inferior to the sigmoid notch in the axial plane. This resection allowed for the extirpation of all pterygoid attachments with preservation of the mandibular angle and inferior ramus with the intent of releasing all scar attachments to the skull base while limiting the resultant crossbite deformity. This resection was then followed by reconstruction with an anterolateral thigh (ALT) to provide adequate skin along the buccal space and soft tissue within the infratemporal fossa. Primary outcomes were postoperative oral opening and functional improvement in oral intake, speech, and oral hygiene. Flap-related complications were also assessed.",
        "Results": "Four patients who underwent free flap reconstruction for correction of radiation-associated trismus were included. All four patients demonstrated postoperative improvement in mouth opening, mandibular excursion, speech, oral intake, and overall function. In one representative case, preoperative trismus of less than one fingerbreadth improved to greater than three fingerbreadths following reconstruction. No flap losses occurred. Postoperative morbidity was acceptable in this complex population, and patients were maintained on adjunctive jaw-stretching therapy postoperatively to preserve gains in oral opening.",
        "Discussion/Conclusion": "Radiation-induced trismus is a complex and challenging late complication of head and neck cancer treatment. In this limited case series, soft tissue free flap reconstruction after scar release for refractory trismus was associated with improved post-operative mouth opening and improved functional outcomes. It should be considered that performing free flap surgery in post-radiated fields can present challenges in identifying healthy recipient vasculature for vessel anastomosis, which can increase the risk of free flap failure. In this series, no patients suffered from flap-related complications. Our findings suggest that vascularized free flap reconstruction may reduce the risk of recurrent fibrosis, improve the durability of surgical correction, and is a valuable treatment strategy in patients with severe post-radiation trismus."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Soft Tissue Free Flap Reconstruction for Radiation-Induced Trismus: A Four-Patient Case Series</span>. <u>Somya Shankar, MD</u>; Nicole Farber, MD; Ryan Carey, MD; Steven B Cannady, MD; Ara A Chalian, MD; Robert M Brody, MD. Hospital of the University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Radiation-associated trismus is a late consequence of head and neck cancer treatment with significant implications. Trismus results in impairment of oral intake, speech, and overall quality of life. Initial management involves jaw-stretching exercises in conjunction with speech therapy. However, a subset of patients can develop severe trismus refractory to conservative management. In many cases, surgical scar release alone is insufficient in treating severe trismus due to the risk of recurrent fibrosis in the irradiated field as well as extensive contracture along the lateral pterygoid extending close to the condylar head within the glenoid fossa. Resection of the condylar head, coronoid process, and ramus followed by reconstruction with vascularized soft tissue transfer can improve the durability of surgical correction by introducing healthy, nonirradiated tissue. We describe a four-patient case series evaluating soft tissue free flap reconstruction for the palliation of severe radiation-induced trismus.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was performed of patients undergoing surgery for radiation-induced trismus at a tertiary academic head and neck center. Inclusion criteria were a history of head and neck malignancy treated with radiation, severe refractory trismus, and reconstruction after scar release with a soft tissue free flap. Surgical management consisted of release or resection of the fibrotic scar by excision of the mandible inferior to the sigmoid notch in the axial plane. This resection allowed for the extirpation of all pterygoid attachments with preservation of the mandibular angle and inferior ramus with the intent of releasing all scar attachments to the skull base while limiting the resultant crossbite deformity. This resection was then followed by reconstruction with an anterolateral thigh (ALT) to provide adequate skin along the buccal space and soft tissue within the infratemporal fossa. Primary outcomes were postoperative oral opening and functional improvement in oral intake, speech, and oral hygiene. Flap-related complications were also assessed.</p>\n\n<p><strong>Results: </strong>Four patients who underwent free flap reconstruction for correction of radiation-associated trismus were included. All four patients demonstrated postoperative improvement in mouth opening, mandibular excursion, speech, oral intake, and overall function. In one representative case, preoperative trismus of less than one fingerbreadth improved to greater than three fingerbreadths following reconstruction. No flap losses occurred. Postoperative morbidity was acceptable in this complex population, and patients were maintained on adjunctive jaw-stretching therapy postoperatively to preserve gains in oral opening.</p>\n\n<p><strong>Discussion/Conclusion: </strong>Radiation-induced trismus is a complex and challenging late complication of head and neck cancer treatment. In this limited case series, soft tissue free flap reconstruction after scar release for refractory trismus was associated with improved post-operative mouth opening and improved functional outcomes. It should be considered that performing free flap surgery in post-radiated fields can present challenges in identifying healthy recipient vasculature for vessel anastomosis, which can increase the risk of free flap failure. In this series, no patients suffered from flap-related complications. Our findings suggest that vascularized free flap reconstruction may reduce the risk of recurrent fibrosis, improve the durability of surgical correction, and is a valuable treatment strategy in patients with severe post-radiation trismus.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155520--></body></html>"
    },
    {
      "uid": "P166",
      "content_id": "154653",
      "abstract_number": "P166",
      "poster_number": "P166",
      "title": "Biomarker Profiles of Head and Neck Squamous Cell Carcinoma in Patients with HIV",
      "summary": "Preliminary findings highlight substantial gaps in biomarker assessment and clinically significant treatment-related immunosuppression among PWH with HNSCC. Variable p16, HPV, and PD-L1 testing limits the applicability of current prognostic frameworks derived from HIV-negative populations. Most p16 testing was performed for oral cavity tumors despite current recommendations only for oropharyngeal HNSCC....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154653",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriel Carrillo, BS",
      "presenter": "Gabriel Carrillo, BS",
      "authors": "Gabriel Carrillo, BS 1 ; Libby Ward Schafer, MD 2 ; Alexander Ladenheim, MD 3 ; Brina Emu, MD 4 ; Avanti Verma, MD 2",
      "normalized_authors": [
        "Gabriel Carrillo",
        "Libby Ward Schafer",
        "Alexander Ladenheim",
        "Brina Emu",
        "Avanti Verma"
      ],
      "affiliations": [
        "Yale School of Medicine",
        "Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery",
        "Yale Department of Pathology",
        "Yale Department of Internal Medicine, Division of Infectious Diseases"
      ],
      "normalized_institutions": [
        "Yale School of Medicine",
        "Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery",
        "Yale Department of Pathology",
        "Yale Department of Internal Medicine, Division of Infectious Diseases"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Gabriel Carrillo, BS 1 ; Libby Ward Schafer, MD 2 ; Alexander Ladenheim, MD 3 ; Brina Emu, MD 4 ; Avanti Verma, MD 2",
        "Affiliations": "1 Yale School of Medicine; 2 Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery; 3 Yale Department of Pathology; 4 Yale Department of Internal Medicine, Division of Infectious Diseases",
        "Background": "People with HIV (PWH) are 1.5-4 times more likely to develop head and neck squamous cell carcinoma (HNSCC) than people without HIV and have reduced survival even after adjusting for stage and treatment. Treatment is complicated by immunosuppression, comorbidities, and antiretroviral therapy interactions. PWH may not receive standard HNSCC therapy, such as chemoradiation, due to concerns for harm and toxicity. Despite this, PWH remain underrepresented in clinical research, and most biomarker-based guidelines are extrapolated from HIV-negative populations. Programmed death ligand 1 (PD-L1) and p16—key biomarkers for immunotherapy eligibility and Human papillomavirus (HPV)-mediated prognosis—are well studied in the general population but poorly characterized in PWH. Preliminary institutional data revealed diagnostic delays, inconsistent biomarker testing, and significant treatment-related immunosuppression in PWH with HNSCC, suggesting that current diagnostics and therapies may not be optimized for this population. This study aims to characterize biomarker expression in archived tumor samples from PWH with HNSCC and integrate these results with retrospective clinical data to assess how commonly tested biomarkers apply to PWH and identify areas for diagnostic or treatment modification.",
        "Methods": "This ongoing retrospective, single-center study evaluates PD-L1 and p16 expression, along with HPV testing, in archived HNSCC tumor samples from PWH treated from 2000-2025. Eighty cases have been identified, and their biopsied tumor samples are undergoing immunohistochemical analysis. Biomarker results are being integrated with chart review data, including primary site, stage, CD4 count, treatment modalities, recurrence, and survival.",
        "Results": "Among 80 unique cases of mucosal HNSCC, primary sites included oral cavity (48.8%), oropharynx (27.4%), larynx (21.3%), and nasal cavity (2.5%). Testing rates were 66.3% for p16, 31.3% for HPV, and 11.3% for PD-L1. Of 53 cases tested for p16, most arose in the oral cavity (54.7%) and oropharynx (30.2%). In oropharyngeal HNSCC (n=22), 72.7% were tested for p16, 50% were p16-positive, and 45.5% lacked HPV testing. All stage I/II HPV-mediated oropharyngeal cancers presented with local nodal, but not distant, metastasis. Among oral cavity cancers (n=37), 75.6% were tested for p16, 16.2% were p16-positive, and 8.1% were HPV-positive. Although many were stage III/IV, 80% presented without evidence of nodal or distant metastasis. CD4 counts declined markedly during treatment, reaching as low as 7% of baseline during radiation therapy.",
        "Conclusions": "Preliminary findings highlight substantial gaps in biomarker assessment and clinically significant treatment-related immunosuppression among PWH with HNSCC. Variable p16, HPV, and PD-L1 testing limits the applicability of current prognostic frameworks derived from HIV-negative populations. Most p16 testing was performed for oral cavity tumors despite current recommendations only for oropharyngeal HNSCC. Significant CD4 decline underscores the need to evaluate treatment tolerance more systematically in PWH. Ongoing analysis will differentiate PD-L1 testing patterns between initial and recurrent/metastatic settings given recent changes in guidelines. It will also contextualize results before and after 2010 given changes in understanding of HPV-mediated HNSCC around this time. Continued characterization will clarify standard biomarker relevance in this population, assess their correlation with outcomes, and potentially inform more tailored diagnostic and therapeutic approaches for PWH."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biomarker Profiles of Head and Neck Squamous Cell Carcinoma in Patients with HIV</span>. <u>Gabriel Carrillo, BS</u><sup>1</sup>; Libby Ward Schafer, MD<sup>2</sup>; Alexander Ladenheim, MD<sup>3</sup>; Brina Emu, MD<sup>4</sup>; Avanti Verma, MD<sup>2</sup>. <sup>1</sup>Yale School of Medicine; <sup>2</sup>Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery; <sup>3</sup>Yale Department of Pathology; <sup>4</sup>Yale Department of Internal Medicine, Division of Infectious Diseases<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>People with HIV (PWH) are 1.5-4 times more likely to develop head and neck squamous cell carcinoma (HNSCC) than people without HIV and have reduced survival even after adjusting for stage and treatment. Treatment is complicated by immunosuppression, comorbidities, and antiretroviral therapy interactions. PWH may not receive standard HNSCC therapy, such as chemoradiation, due to concerns for harm and toxicity. Despite this, PWH remain underrepresented in clinical research, and most biomarker-based guidelines are extrapolated from HIV-negative populations. Programmed death ligand 1 (PD-L1) and p16—key biomarkers for immunotherapy eligibility and Human papillomavirus (HPV)-mediated prognosis—are well studied in the general population but poorly characterized in PWH. Preliminary institutional data revealed diagnostic delays, inconsistent biomarker testing, and significant treatment-related immunosuppression in PWH with HNSCC, suggesting that current diagnostics and therapies may not be optimized for this population. This study aims to characterize biomarker expression in archived tumor samples from PWH with HNSCC and integrate these results with retrospective clinical data to assess how commonly tested biomarkers apply to PWH and identify areas for diagnostic or treatment modification. </p>\n\n<p><strong>Methods: </strong>This ongoing retrospective, single-center study evaluates PD-L1 and p16 expression, along with HPV testing, in archived HNSCC tumor samples from PWH treated from 2000-2025. Eighty cases have been identified, and their biopsied tumor samples are undergoing immunohistochemical analysis. Biomarker results are being integrated with chart review data, including primary site, stage, CD4 count, treatment modalities, recurrence, and survival. </p>\n\n<p><strong>Results: </strong>Among 80 unique cases of mucosal HNSCC, primary sites included oral cavity (48.8%), oropharynx (27.4%), larynx (21.3%), and nasal cavity (2.5%). Testing rates were 66.3% for p16, 31.3% for HPV, and 11.3% for PD-L1. Of 53 cases tested for p16, most arose in the oral cavity (54.7%) and oropharynx (30.2%). In oropharyngeal HNSCC (n=22), 72.7% were tested for p16, 50% were p16-positive, and 45.5% lacked HPV testing. All stage I/II HPV-mediated oropharyngeal cancers presented with local nodal, but not distant, metastasis. Among oral cavity cancers (n=37), 75.6% were tested for p16, 16.2% were p16-positive, and 8.1% were HPV-positive. Although many were stage III/IV, 80% presented without evidence of nodal or distant metastasis. CD4 counts declined markedly during treatment, reaching as low as 7% of baseline during radiation therapy. </p>\n\n<p><strong>Conclusions:</strong> Preliminary findings highlight substantial gaps in biomarker assessment and clinically significant treatment-related immunosuppression among PWH with HNSCC. Variable p16, HPV, and PD-L1 testing limits the applicability of current prognostic frameworks derived from HIV-negative populations. Most p16 testing was performed for oral cavity tumors despite current recommendations only for oropharyngeal HNSCC. Significant CD4 decline underscores the need to evaluate treatment tolerance more systematically in PWH. Ongoing analysis will differentiate PD-L1 testing patterns between initial and recurrent/metastatic settings given recent changes in guidelines. It will also contextualize results before and after 2010 given changes in understanding of HPV-mediated HNSCC around this time. Continued characterization will clarify standard biomarker relevance in this population, assess their correlation with outcomes, and potentially inform more tailored diagnostic and therapeutic approaches for PWH.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154653--></body></html>"
    },
    {
      "uid": "P167",
      "content_id": "154693",
      "abstract_number": "P167",
      "poster_number": "P167",
      "title": "The Diagnosis is Clear, But What’s the Treatment?: Strategies to Address Health Disparities in Head and Neck Cancer, A Systematized Review",
      "summary": "We found there was a diverse collection of recommendations with a variety of overarching themes. While most recommendations clustered in patient education, screening expansion, and access-to-care strategies, critical drivers of equitable outcomes—multidisciplinary coordination and diversity initiatives—were rarely addressed. We used these quantitative patterns to construct a data-derived framework to inform the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154693",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ebunoluwa Morakinyo",
      "presenter": "Ebunoluwa Morakinyo",
      "authors": "Josh Egede; Ebunoluwa Morakinyo ; Melonie Nance, MD",
      "normalized_authors": [
        "Josh Egede",
        "Ebunoluwa Morakinyo",
        "Melonie Nance"
      ],
      "affiliations": [
        "NYU Grossman School of Medicine"
      ],
      "normalized_institutions": [
        "NYU Grossman School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 352,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Josh Egede; Ebunoluwa Morakinyo ; Melonie Nance, MD",
        "Affiliations": "NYU Grossman School of Medicine",
        "Background": "A significant body of research has shown disparities in oncologic outcomes associated with head and neck (HNC) mucosal malignancies. Race, ethnicity, and socioeconomic status have been identified as strong predictors of stage at presentation, treatment decision making, and survival. To date, medical literature centers on the detection of disparities in HNC, with minimal study of novel interventions to reduce inequity. This review synthesizes existing disparity-mitigation strategies aimed at reducing disparities and offers a framework for future action.",
        "Methods": "A search of PubMed, Ovid Embase, Cochrane, and Scopus identified U.S.-based primary research studies evaluating racial, ethnic, or socioeconomic disparities in adult mucosal/squamous cell head and neck cancer. The primary outcome was the presence and category of disparity-mitigation strategies in Discussion or Conclusion sections. A disparity-mitigation strategies was defined as an explicit, directive suggestion that bridges the gap between the disparities discussed in the paper to improved clinical practice/patient outcomes. Strategies were grouped by thematic category.",
        "Results": "Among 223 included studies, 115 (51.6%) contained disparity-mitigation strategies. Articles were categorized into nine groups: Patient Education/Counseling, Access to Care, Screening Expansion, Physician-Directed Changes, Multidisciplinary Care Coordination, Socioeconomic/Policy Changes, Diversity Enriching Initiatives, Preventative Measures/Risk Factor Management, and Mixed (for articles that provided combination of recommendations). Across 201 total strategies, most addressed patient education (n = 42, 20.9%), screening expansion (n = 32, 15.9%), access to care (n = 32, 15.9%), policy change (n = 29, 14.4%), and physician-directed strategies (n = 28, 13.9%). Less frequently cited were strategies centered on multidisciplinary coordination (n = 18, 9.0%), preventative approaches (n = 11, 5.5%), and diversity enriching initiatives (n = 9, 4.5%).",
        "Conclusion": "We found there was a diverse collection of recommendations with a variety of overarching themes. While most recommendations clustered in patient education, screening expansion, and access-to-care strategies, critical drivers of equitable outcomes—multidisciplinary coordination and diversity initiatives—were rarely addressed. We used these quantitative patterns to construct a data-derived framework to inform the direction of future interventions, immediate patient care, and multidisciplinary efforts. This study emphasizes how diversity-enhancing efforts are essential to improving access, representation, and ultimately patient outcomes in HNC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Diagnosis is Clear, But What’s the Treatment?: Strategies to Address Health Disparities in Head and Neck Cancer, A Systematized Review</span>. Josh Egede; <u>Ebunoluwa Morakinyo</u>; Melonie Nance, MD. NYU Grossman School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>A significant body of research has shown disparities in oncologic outcomes associated with head and neck (HNC) mucosal malignancies. Race, ethnicity, and socioeconomic status have been identified as strong predictors of stage at presentation, treatment decision making, and survival. To date, medical literature centers on the detection of disparities in HNC, with minimal study of novel interventions to reduce inequity. This review synthesizes existing disparity-mitigation strategies aimed at reducing disparities and offers a framework for future action.</p>\n\n<p><strong>Methods: </strong>A search of PubMed, Ovid Embase, Cochrane, and Scopus identified U.S.-based primary research studies evaluating racial, ethnic, or socioeconomic disparities in adult mucosal/squamous cell head and neck cancer. The primary outcome was the presence and category of disparity-mitigation strategies in Discussion or Conclusion sections. A disparity-mitigation strategies was defined as an explicit, directive suggestion that bridges the gap between the disparities discussed in the paper to improved clinical practice/patient outcomes. Strategies were grouped by thematic category.</p>\n\n<p><strong>Results: </strong>Among 223 included studies, 115 (51.6%) contained disparity-mitigation strategies. Articles were categorized into nine groups: Patient Education/Counseling, Access to Care, Screening Expansion, Physician-Directed Changes, Multidisciplinary Care Coordination, Socioeconomic/Policy Changes, Diversity Enriching Initiatives, Preventative Measures/Risk Factor Management, and Mixed (for articles that provided combination of recommendations). Across 201 total strategies, most addressed patient education (n = 42, 20.9%), screening expansion (n = 32, 15.9%), access to care (n = 32, 15.9%), policy change (n = 29, 14.4%), and physician-directed strategies (n = 28, 13.9%). Less frequently cited were strategies centered on multidisciplinary coordination (n = 18, 9.0%), preventative approaches (n = 11, 5.5%), and diversity enriching initiatives (n = 9, 4.5%).</p>\n\n<p><strong>Conclusion: </strong>We found there was a diverse collection of recommendations with a variety of overarching themes. While most recommendations clustered in patient education, screening expansion, and access-to-care strategies, critical drivers of equitable outcomes—multidisciplinary coordination and diversity initiatives—were rarely addressed. We used these quantitative patterns to construct a data-derived framework to inform the direction of future interventions, immediate patient care, and multidisciplinary efforts. This study emphasizes how diversity-enhancing efforts are essential to improving access, representation, and ultimately patient outcomes in HNC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154693--></body></html>"
    },
    {
      "uid": "P168",
      "content_id": "154548",
      "abstract_number": "P168",
      "poster_number": "P168",
      "title": "FUNCTIONAL OUTCOMES AFTER ORGAN PRESERVATION TREATMENT FOR LARYNGEAL CANCER",
      "summary": "Laryngeal carcinoma is one of the most prevalent malignancies in the head and neck region, significantly affecting vital functions such as breathing, phonation, and swallowing. Radiotherapy is considered an organ-preserving treatment; however, post-treatment laryngeal function is often not fully restored, resulting in meaningful long-term functional impairment. Dysphagia, one of the most severe and debilitating...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154548",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiza Seganfredo Mainardi",
      "presenter": "Luiza Seganfredo Mainardi",
      "authors": "Eduardo Calheiros de Moraes; Luiza Seganfredo Mainardi ; Nathalia Peres Borges dos Santos; Andressa Silva de Freitas; Ana Catarina Silva e Silva; Fernando Luiz Dias",
      "normalized_authors": [
        "Eduardo Calheiros de Moraes",
        "Luiza Seganfredo Mainardi",
        "Nathalia Peres Borges dos Santos",
        "Andressa Silva de Freitas",
        "Ana Catarina Silva e Silva",
        "Fernando Luiz Dias"
      ],
      "affiliations": [
        "Brazilian National Cancer Institute"
      ],
      "normalized_institutions": [
        "Brazilian National Cancer Institute"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 298,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "OBJECTIVES",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Eduardo Calheiros de Moraes; Luiza Seganfredo Mainardi ; Nathalia Peres Borges dos Santos; Andressa Silva de Freitas; Ana Catarina Silva e Silva; Fernando Luiz Dias",
        "Affiliations": "Brazilian National Cancer Institute",
        "INTRODUCTION": "Laryngeal carcinoma is one of the most prevalent malignancies in the head and neck region, significantly affecting vital functions such as breathing, phonation, and swallowing. Radiotherapy is considered an organ-preserving treatment; however, post-treatment laryngeal function is often not fully restored, resulting in meaningful long-term functional impairment. Dysphagia, one of the most severe and debilitating late complications, can substantially compromise patients’ quality of life. Affected individuals may develop malnutrition, require enteral nutritional support, and experience an increased risk of pulmonary aspiration and pneumonia, along with psychosocial and social-interaction difficulties.",
        "OBJECTIVES": "To evaluate survival and functional outcomes in patients undergoing chemoradiotherapy for laryngeal carcinoma and to identify patterns that may guide more effective therapeutic interventions.",
        "MATERIALS AND METHODS": "Patients over 18 years of age treated with radiotherapy—either alone or in combination with chemotherapy—between 2015 and 2019 and without evidence of active disease were included. Swallowing function was assessed using the MDADI questionnaire and videofluoroscopy, enabling detailed evaluation of oropharyngeal biomechanics.",
        "RESULTS": "Of the 565 patients initially screened, 153 met the eligibility criteria. Among them, 123 had died, and 25 were alive at the time of analysis. The mean age was 64 years, with a predominance of male patients (80%), smokers (92%), and alcohol consumers (80%). The prevalence of dysphagia was 63%; 53% required temporary enteral nutrition, and 19% progressed to permanent gastrostomy. Additionally, 69% underwent tracheostomy, and 51% presented significant dysphonia. Among surviving patients, 61.5% had dysphonia and 38.5% had dysphagia.",
        "CONCLUSION": "The findings highlight the significant late functional impact of organ-preserving treatment for laryngeal cancer, particularly regarding swallowing and vocal quality. Videofluoroscopy and the MDADI scale proved to be essential tools for identifying specific patterns of functional impairment. These results reinforce the need for structured, multidisciplinary follow-up and rehabilitation protocols aimed at optimizing functional recovery and improving patients’ quality of life."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>FUNCTIONAL OUTCOMES AFTER ORGAN PRESERVATION TREATMENT FOR LARYNGEAL CANCER</span>. Eduardo Calheiros de Moraes; <u>Luiza Seganfredo Mainardi</u>; Nathalia Peres Borges dos Santos; Andressa Silva de Freitas; Ana Catarina Silva e Silva; Fernando Luiz Dias. Brazilian National Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION:</strong> Laryngeal carcinoma is one of the most prevalent malignancies in the head and neck region, significantly affecting vital functions such as breathing, phonation, and swallowing. Radiotherapy is considered an organ-preserving treatment; however, post-treatment laryngeal function is often not fully restored, resulting in meaningful long-term functional impairment. Dysphagia, one of the most severe and debilitating late complications, can substantially compromise patients’ quality of life. Affected individuals may develop malnutrition, require enteral nutritional support, and experience an increased risk of pulmonary aspiration and pneumonia, along with psychosocial and social-interaction difficulties.</p>\n\n<p><strong>OBJECTIVES:</strong> To evaluate survival and functional outcomes in patients undergoing chemoradiotherapy for laryngeal carcinoma and to identify patterns that may guide more effective therapeutic interventions.</p>\n\n<p><strong>MATERIALS AND METHODS:</strong> Patients over 18 years of age treated with radiotherapy—either alone or in combination with chemotherapy—between 2015 and 2019 and without evidence of active disease were included. Swallowing function was assessed using the MDADI questionnaire and videofluoroscopy, enabling detailed evaluation of oropharyngeal biomechanics.</p>\n\n<p><strong>RESULTS:</strong> Of the 565 patients initially screened, 153 met the eligibility criteria. Among them, 123 had died, and 25 were alive at the time of analysis. The mean age was 64 years, with a predominance of male patients (80%), smokers (92%), and alcohol consumers (80%). The prevalence of dysphagia was 63%; 53% required temporary enteral nutrition, and 19% progressed to permanent gastrostomy. Additionally, 69% underwent tracheostomy, and 51% presented significant dysphonia. Among surviving patients, 61.5% had dysphonia and 38.5% had dysphagia.</p>\n\n<p><strong>CONCLUSION: </strong>The findings highlight the significant late functional impact of organ-preserving treatment for laryngeal cancer, particularly regarding swallowing and vocal quality. Videofluoroscopy and the MDADI scale proved to be essential tools for identifying specific patterns of functional impairment. These results reinforce the need for structured, multidisciplinary follow-up and rehabilitation protocols aimed at optimizing functional recovery and improving patients’ quality of life.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154548--></body></html>"
    },
    {
      "uid": "P169",
      "content_id": "154502",
      "abstract_number": "P169",
      "poster_number": "P169",
      "title": "Use of Facial Nerve Monitoring During Neck Dissection to Reduce Marginal Mandibular Nerve Injury: A Retrospective Audit",
      "summary": "Neck dissection commonly places the marginal mandibular branch of the facial nerve at risk. Temporary or permanent dysfunction of this nerve can compromise oral competence, smile symmetry and overall patient satisfaction. Facial nerve monitors are well established in parotidectomies, but their translational use in neck dissection is under-explored. Early signals or stimulation feedback may help avoid traction or...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154502",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Siddhant Kansal, Mr",
      "presenter": "Siddhant Kansal, Mr",
      "authors": "Siddhant Kansal, Mr 1 ; Shahme Farook, MBChB, BDS, BSc, Hons, MRCS, MFDS, FRCS 2",
      "normalized_authors": [
        "Siddhant Kansal, Mr",
        "Shahme Farook, MBChB, BDS, Hons, MRCS, MFDS"
      ],
      "affiliations": [
        "Imperial College London",
        "Northwick Park Hospital"
      ],
      "normalized_institutions": [
        "Imperial College London",
        "Northwick Park Hospital"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 293,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Expected Impact"
      ],
      "sections": {
        "Authors": "Siddhant Kansal, Mr 1 ; Shahme Farook, MBChB, BDS, BSc, Hons, MRCS, MFDS, FRCS 2",
        "Affiliations": "1 Imperial College London; 2 Northwick Park Hospital",
        "Background": "Neck dissection commonly places the marginal mandibular branch of the facial nerve at risk. Temporary or permanent dysfunction of this nerve can compromise oral competence, smile symmetry and overall patient satisfaction. Facial nerve monitors are well established in parotidectomies, but their translational use in neck dissection is under-explored. Early signals or stimulation feedback may help avoid traction or thermal injury, but there is limited evidence to advocate or dismiss routine monitoring in this setting. We therefore propose a retrospective audit to assess whether the use of a facial nerve monitor introduced for parotid dissection reduces marginal mandibular nerve dysfunction during neck dissection.",
        "Abstract": "(i) Determine whether routine facial nerve monitoring during neck dissection educes the incidence of postoperative dysfunction of the marginal mandibular nerve We hypothesise use of monitoring will reduce incidence and severity of nerve weakness compared to cases without the use of the monitor. Primary Outcome: Incidence of marginal mandibular nerve dysfunction. Secondary Outcome: Data such as age, indication, neck dissection type and any relevant intraoperative events will be collected Proportional Comparisons will be made between groups, mean differences and multivariable adjustments will be made.",
        "Methods": "A retrospective audit will be conducted at a major acute-care teaching hospital. Patients having undergone neck dissections with or without the nerve monitoring will be selected, as the intervention and control groups respectively. A functional assessment will be conducted on all patients to ascertain their facial nerve status. Data such as age, indication, neck dissection type and any relevant intraoperative events will be collected. The audit will be formally registered at the host hospital.",
        "Expected Impact": "We expect to determine whether facial nerve monitoring offers measurable benefit during neck dissection. Results may inform operative planning, justify routine adoption, or clarify its role when dissecting close to the marginal branch."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Facial Nerve Monitoring During Neck Dissection to Reduce Marginal Mandibular Nerve Injury: A Retrospective Audit</span>. <u>Siddhant Kansal, Mr</u><sup>1</sup>; Shahme Farook, MBChB, BDS, BSc, Hons, MRCS, MFDS, FRCS<sup>2</sup>. <sup>1</sup>Imperial College London; <sup>2</sup>Northwick Park Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neck dissection commonly places the marginal mandibular branch of the facial nerve at risk. Temporary or permanent dysfunction of this nerve can compromise oral competence, smile symmetry and overall patient satisfaction. Facial nerve monitors are well established in parotidectomies, but their translational use in neck dissection is under-explored. Early signals or stimulation feedback may help avoid traction or thermal injury, but there is limited evidence to advocate or dismiss routine monitoring in this setting. We therefore propose a retrospective audit to assess whether the use of a facial nerve monitor introduced for parotid dissection reduces marginal mandibular nerve dysfunction during neck dissection.</p>\n\n<p><strong>Objective:</strong></p>\n\n<p>(i) Determine whether routine facial nerve monitoring during neck dissection educes the incidence of postoperative dysfunction of the marginal mandibular nerve</p>\n\n<p>We hypothesise use of monitoring will reduce incidence and severity of nerve weakness compared to cases without the use of the monitor.</p>\n\n<p><strong>Methods: </strong>A retrospective audit will be conducted at a major acute-care teaching hospital. Patients having undergone neck dissections with or without the nerve monitoring will be selected, as the intervention and control groups respectively. A functional assessment will be conducted on all patients to ascertain their facial nerve status. Data such as age, indication, neck dissection type and any relevant intraoperative events will be collected. The audit will be formally registered at the host hospital.</p>\n\n<p><strong>Outcomes and Measures:</strong></p>\n\n<p>Primary Outcome: Incidence of marginal mandibular nerve dysfunction.</p>\n\n<p>Secondary Outcome: Data such as age, indication, neck dissection type and any relevant intraoperative events will be collected</p>\n\n<p>Proportional Comparisons will be made between groups, mean differences and multivariable adjustments will be made.</p>\n\n<p><strong>Expected Impact: </strong>We expect to determine whether facial nerve monitoring offers measurable benefit during neck dissection. Results may inform operative planning, justify routine adoption, or clarify its role when dissecting close to the marginal branch.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154502--></body></html>"
    },
    {
      "uid": "P170",
      "content_id": "154510",
      "abstract_number": "P170",
      "poster_number": "P170",
      "title": "Predictors of Prolonged Length of Stay in Patients Undergoing Head and Neck Cancer Surgery: A Systematic Review and Meta-analysis",
      "summary": "In HNC surgical patients, increasing age, longer operative times, and the need for return to the operating room and revision surgery are key drivers of prolonged LOS, whereas most baseline demographic and oncologic factors are not. Targeted perioperative optimization to reduce complications and reoperations may substantially shorten LOS in this high-risk population.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154510",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Matthew Vance, MS, BS",
      "presenter": "Matthew Vance, MS, BS",
      "authors": "Matthew Vance, MS, BS ; Srivatsa Vasudevan, MD, MS; Anderson Dewitt, BS; Cherie-Ann O Nathan, MD, FACS",
      "normalized_authors": [
        "Matthew Vance",
        "Srivatsa Vasudevan",
        "Anderson Dewitt",
        "Cherie-Ann O Nathan"
      ],
      "affiliations": [
        "Louisiana State University Health Sciences Center - Shreveport"
      ],
      "normalized_institutions": [
        "Louisiana State University Health Sciences Center - Shreveport"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 295,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Matthew Vance, MS, BS ; Srivatsa Vasudevan, MD, MS; Anderson Dewitt, BS; Cherie-Ann O Nathan, MD, FACS",
        "Affiliations": "Louisiana State University Health Sciences Center - Shreveport",
        "Background": "Prolonged length of stay (LOS) after head and neck cancer (HNC) surgery increases healthcare costs, resource use, and patient morbidity. However, data on consistent predictors of extended LOS in this population remain heterogeneous. We aimed to identify clinical, oncologic, and perioperative factors associated with prolonged LOS in HNC patients.",
        "Methods": "PubMed, Embase, Web of Science, and ScienceDirect were searched from January 2000 to October 15, 2025, for studies evaluating predictors of prolonged or extended LOS after HNC surgery. Pooled multivariate ORs with 95% confidence intervals (CI) were calculated using random-effects meta-analysis.",
        "Results": "Of 1,762 articles, 32 studies comprising 30,233 HNC patients were analyzed. Increasing age as a continuous variable was significantly associated with prolonged LOS (OR 1.03, 95% CI 1.01–1.05, p = 0.01), but age as a categorical variable (≥65 vs <65 years) was not significant. Longer operative time was associated with increased odds of prolonged LOS (OR 1.08, 95% CI 1.00–1.17, p = 0.04). Return to the operating room (OR 4.80, 95% CI 3.38–6.83, p<0.0001) and revision surgery (OR 7.48, 95% CI 1.28–43.74, p = 0.03) were the strongest predictors of extended LOS. Sex, stage (early vs late), flap type (bony vs soft tissue), tracheostomy, diabetes, smoking, insurance type (Medicare, Medicaid, or other government vs private), previous radiation, immediate postoperative complications and intraoperative transfusion were not significantly associated with LOS (all p>0.05)",
        "Conclusion": "In HNC surgical patients, increasing age, longer operative times, and the need for return to the operating room and revision surgery are key drivers of prolonged LOS, whereas most baseline demographic and oncologic factors are not. Targeted perioperative optimization to reduce complications and reoperations may substantially shorten LOS in this high-risk population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors of Prolonged Length of Stay in Patients Undergoing Head and Neck Cancer Surgery: A Systematic Review and Meta-analysis</span>. <u>Matthew Vance, MS, BS</u>; Srivatsa Vasudevan, MD, MS; Anderson Dewitt, BS; Cherie-Ann O Nathan, MD, FACS. Louisiana State University Health Sciences Center - Shreveport<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Prolonged length of stay (LOS) after head and neck cancer (HNC) surgery increases healthcare costs, resource use, and patient morbidity. However, data on consistent predictors of extended LOS in this population remain heterogeneous. We aimed to identify clinical, oncologic, and perioperative factors associated with prolonged LOS in HNC patients.</p>\n\n<p><strong>Methods: </strong>PubMed, Embase, Web of Science, and ScienceDirect were searched from January 2000 to October 15, 2025, for studies evaluating predictors of prolonged or extended LOS after HNC surgery. Pooled multivariate ORs with 95% confidence intervals (CI) were calculated using random-effects meta-analysis.</p>\n\n<p><strong>Results: </strong>Of 1,762 articles, 32 studies comprising 30,233 HNC patients were analyzed. Increasing age as a continuous variable was significantly associated with prolonged LOS (OR 1.03, 95% CI 1.01–1.05, p = 0.01), but age as a categorical variable (≥65 vs <65 years) was not significant. Longer operative time was associated with increased odds of prolonged LOS (OR 1.08, 95% CI 1.00–1.17, p = 0.04). Return to the operating room (OR 4.80, 95% CI 3.38–6.83, p<0.0001) and revision surgery (OR 7.48, 95% CI 1.28–43.74, p = 0.03) were the strongest predictors of extended LOS. Sex, stage (early vs late), flap type (bony vs soft tissue), tracheostomy, diabetes, smoking, insurance type (Medicare, Medicaid, or other government vs private), previous radiation, immediate postoperative complications and intraoperative transfusion were not significantly associated with LOS (all p>0.05)</p>\n\n<p><strong>Conclusion: </strong>In HNC surgical patients, increasing age, longer operative times, and the need for return to the operating room and revision surgery are key drivers of prolonged LOS, whereas most baseline demographic and oncologic factors are not. Targeted perioperative optimization to reduce complications and reoperations may substantially shorten LOS in this high-risk population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154510--></body></html>"
    },
    {
      "uid": "P171",
      "content_id": "154084",
      "abstract_number": "P171",
      "poster_number": "P171",
      "title": "Cannabis use increases the likelihood that head and neck surgery patients receive postoperative opiate pain medications.",
      "summary": "There has been substantial increase in cannabis use nationally, and many surgical patients do not report use to their treating surgeon. While it is used widely for pain control, it is unclear how pre-operative cannabis use affects pain management in the postoperative period. This is due to variability in the current literature in dosing, study populations, and follow-up periods. As research on how cannabis...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154084",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ngoc B Nguyen, BS",
      "presenter": "Ngoc B Nguyen, BS",
      "authors": "Ngoc B Nguyen, BS 1 ; Zhenghao Wang, BA 1 ; Anna Xiang, BS 1 ; Smrithi Chidambaram, MD 2 ; Warren C Swegal 2 ; Samuel J Rubin, MD, MPH 2 ; Garren M Low, MS, MD 2",
      "normalized_authors": [
        "Ngoc B Nguyen",
        "Zhenghao Wang",
        "Anna Xiang",
        "Smrithi Chidambaram",
        "Warren C Swegal",
        "Samuel J Rubin",
        "Garren M Low"
      ],
      "affiliations": [
        "Drexel College of Medicine",
        "Allegheny Health Network"
      ],
      "normalized_institutions": [
        "Drexel College of Medicine",
        "Allegheny Health Network"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 450,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ngoc B Nguyen, BS 1 ; Zhenghao Wang, BA 1 ; Anna Xiang, BS 1 ; Smrithi Chidambaram, MD 2 ; Warren C Swegal 2 ; Samuel J Rubin, MD, MPH 2 ; Garren M Low, MS, MD 2",
        "Affiliations": "1 Drexel College of Medicine; 2 Allegheny Health Network",
        "Abstract": "There has been substantial increase in cannabis use nationally, and many surgical patients do not report use to their treating surgeon. While it is used widely for pain control, it is unclear how pre-operative cannabis use affects pain management in the postoperative period. This is due to variability in the current literature in dosing, study populations, and follow-up periods. As research on how cannabis affects medical care is in its infancy, administrative data sets can be beneficial to evaluate trends at the population level. In this study, a retrospective cohort was generated using the TriNetX research network, a global federated electronic health records database. The study compares two cohorts of patients, those with a documented history of cannabis use and those with no history of cannabis use who underwent common head and neck surgery procedures (neck dissection, parathyroidectomy, thyroidectomy, and parotidectomy). The incidence of postoperative high-potency opioid prescriptions (oxycodone, morphine, oxymorphone, hydromorphone, tapentadol, fentanyl) was compared between the cohorts during two time points: postoperative day (POD) 0 and the first week following surgery POD 1–7. Propensity score matching (1:1) was conducted for age, sex, ethnicity, body mass index, and preoperative analgesic use. A total of 291,553 non-users and 2,619 users were identified, resulting in 2,614 well-balanced pairs post-matching. All matched covariates achieve balance with non-significance between group differences (p>0.05). On POD 0, opiate prescriptions in cannabis users were found to be slightly (4.09%) more likely than those with no history of cannabis use (p=0.007), but prescriptions of opiates in the week after surgery were found to be twice as likely (RR 2.06, 95% CI 1.77-2.40). When the data were stratified by type of surgery, this trend of increased prescriptions during postoperative week 1 persisted in patients specifically undergoing neck dissection (RR 1.43, 95% CI 1.22,1.68), parathyroidectomy (RR 2.08, 95% CI 1.30,3.30), parotidectomy (RR 1.85, 95% CI 1.16,2.82), and thyroidectomy (RR 1.63, 95% CI 1.25, 2.11). In each of these procedure groups, there was a minimally increased risk of opiate prescription on POD 0. Our findings demonstrate that cannabis users are more likely to require additional opiate pain medication prescriptions in the immediate post-operative period (one week). These findings may help guide more individualized postoperative pain management, particularly for patients who use cannabis. Future studies are needed to understand how to optimize perioperative pain strategies in cannabis users, including tailoring multimodal pain management to this specific patient population, evaluating whether specific analgesic regimens can reduce their need for high-potency opioids after surgery, and improving counseling around preoperative cannabis use in the outpatient setting."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cannabis use increases the likelihood that head and neck surgery patients receive postoperative opiate pain medications.</span>. <u>Ngoc B Nguyen, BS</u><sup>1</sup>; Zhenghao Wang, BA<sup>1</sup>; Anna Xiang, BS<sup>1</sup>; Smrithi Chidambaram, MD<sup>2</sup>; Warren C Swegal<sup>2</sup>; Samuel J Rubin, MD, MPH<sup>2</sup>; Garren M Low, MS, MD<sup>2</sup>. <sup>1</sup>Drexel College of Medicine; <sup>2</sup>Allegheny Health Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>There has been substantial increase in cannabis use nationally, and many surgical patients do not report use to their treating surgeon. While it is used widely for pain control, it is unclear how pre-operative cannabis use affects pain management in the postoperative period. This is due to variability in the current literature in dosing, study populations, and follow-up periods. As research on how cannabis affects medical care is in its infancy, administrative data sets can be beneficial to evaluate trends at the population level. In this study, a retrospective cohort was generated using the TriNetX research network, a global federated electronic health records database. The study compares two cohorts of patients, those with a documented history of cannabis use and those with no history of cannabis use who underwent common head and neck surgery procedures (neck dissection, parathyroidectomy, thyroidectomy, and parotidectomy). The incidence of postoperative high-potency opioid prescriptions (oxycodone, morphine, oxymorphone, hydromorphone, tapentadol, fentanyl) was compared between the cohorts during two time points:  postoperative day (POD) 0 and the first week following surgery POD 1–7. Propensity score matching (1:1) was conducted for age, sex, ethnicity, body mass index, and preoperative analgesic use. A total of 291,553 non-users and 2,619 users were identified, resulting in 2,614 well-balanced pairs post-matching. All matched covariates achieve balance with non-significance between group differences (p>0.05).</p>\n\n<p>On POD 0, opiate prescriptions in cannabis users were found to be slightly (4.09%) more likely than those with no history of cannabis use (p=0.007), but prescriptions of opiates in the week after surgery were found to be twice as likely (RR 2.06, 95% CI 1.77-2.40). When the data were stratified by type of surgery, this trend of increased prescriptions during postoperative week 1 persisted in patients specifically undergoing neck dissection (RR 1.43, 95% CI 1.22,1.68), parathyroidectomy (RR 2.08, 95% CI 1.30,3.30), parotidectomy (RR 1.85, 95% CI 1.16,2.82), and thyroidectomy (RR 1.63, 95% CI 1.25, 2.11). In each of these procedure groups, there was a minimally increased risk of opiate prescription on POD 0.</p>\n\n<p>Our findings demonstrate that cannabis users are more likely to require additional opiate pain medication prescriptions in the immediate post-operative period (one week). These findings may help guide more individualized postoperative pain management, particularly for patients who use cannabis. Future studies are needed to understand how to optimize perioperative pain strategies in cannabis users, including tailoring multimodal pain management to this specific patient population, evaluating whether specific analgesic regimens can reduce their need for high-potency opioids after surgery, and improving counseling around preoperative cannabis use in the outpatient setting.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154084--></body></html>"
    },
    {
      "uid": "P172",
      "content_id": "154150",
      "abstract_number": "P172",
      "poster_number": "P172",
      "title": "Translation and Validation of the MD Anderson Symptom Inventory – Thyroid (MDASI-Thy-F): Monitoring the quality of life of Filipino thyroid cancer patients",
      "summary": "Thyroid cancer ranks 7th with a 5 year prevalence of 24,694 based on the 2022 Globocan Philippines, with a noted increase in incidence and recurrence in a systematic review by San Juan ,et al. Although the prognosis of well differentiated thyroid cancer is generally good with above 95% survival based on international data, there are studies which show that thyroid cancer in Filipinos have high risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154150",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ida Marie Lim",
      "presenter": "Ida Marie Lim",
      "authors": "Ida Marie Lim 1 ; Wenceslao S Llauderes, MD, FPSNM 1 ; Warren R Bacorro, MD 2 ; Jose Marie L Castro, MD 1 ; John Dale V Trogo, MA 2",
      "normalized_authors": [
        "Ida Marie Lim",
        "Wenceslao S Llauderes, FPSNM",
        "Warren R Bacorro",
        "Jose Marie L Castro",
        "John Dale V Trogo, MA"
      ],
      "affiliations": [
        "Jose R Reyes Memorial Medical Center",
        "University of Santo Tomas"
      ],
      "normalized_institutions": [
        "Jose R Reyes Memorial Medical Center",
        "University of Santo Tomas"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 302,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Result and Conclusion"
      ],
      "sections": {
        "Authors": "Ida Marie Lim 1 ; Wenceslao S Llauderes, MD, FPSNM 1 ; Warren R Bacorro, MD 2 ; Jose Marie L Castro, MD 1 ; John Dale V Trogo, MA 2",
        "Affiliations": "1 Jose R Reyes Memorial Medical Center; 2 University of Santo Tomas",
        "Background": "Thyroid cancer ranks 7th with a 5 year prevalence of 24,694 based on the 2022 Globocan Philippines, with a noted increase in incidence and recurrence in a systematic review by San Juan ,et al. Although the prognosis of well differentiated thyroid cancer is generally good with above 95% survival based on international data, there are studies which show that thyroid cancer in Filipinos have high risk characteristics (lymph node metastases and multifocality) and aggressive biologic behavior. Thus, prospective studies with active long-term follow-up is essential to detect any changes in the outcomes among Filipinos. Monitoring of disease status necessitate the use of standard tests such as neck ultrasound and serum thyroglobulin. However, there no clinical tool used to evaluate for symptoms and quality of life . Assessment tools for patient- reported outcomes may be useful to achieve this purpose such as the MD Anderson MDASI -Thy which has been developed to assess the severity of symptoms and interference with daily living among thyroid cancer patients. A valid and reliable Filipino translation of MDASI-Thy may be useful in evaluating symptoms among thyroid cancer patients for better symptom management, quality of life and compliance to treatment . This study aims to develop a valid and reliable Filipino translation of the MDASI- Thy using the previously validated MDASI core – F.",
        "Methods": "This is part one of a two part study which focuses on the Filipino translation of the six questions specific for thyroid cancer of the MDASI -Thy since the MDASI core has already been translated into Filipino. The translation process will follow the guide provided by MD Anderson Department of Symptom Research Linguistic Validation Instructions.",
        "Result and Conclusion": "The approved Filipino translation of the MDASI Thyroid questionnaire will be used in the long term surveillance of thyroid cancer patients in support of the institution’s Advanced Cancer Center mission."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Translation and Validation of the MD Anderson Symptom Inventory – Thyroid (MDASI-Thy-F): Monitoring the quality of life of Filipino thyroid cancer patients</span>. <u>Ida Marie Lim</u><sup>1</sup>; Wenceslao S Llauderes, MD, FPSNM<sup>1</sup>; Warren R Bacorro, MD<sup>2</sup>; Jose Marie L Castro, MD<sup>1</sup>; John Dale V Trogo, MA<sup>2</sup>. <sup>1</sup>Jose R Reyes Memorial Medical Center; <sup>2</sup>University of Santo Tomas<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Thyroid cancer ranks 7th with a 5 year prevalence of 24,694 based on the 2022 Globocan Philippines, with a noted increase in incidence and recurrence in a systematic review by San Juan ,et al. Although the prognosis of well differentiated thyroid cancer is generally good with above 95% survival based on international data, there are studies which show that thyroid cancer in Filipinos have high risk characteristics (lymph node metastases and multifocality) and aggressive biologic behavior. Thus, prospective studies with active long-term follow-up is essential to detect any changes in the outcomes among Filipinos. Monitoring of disease status necessitate the use of standard tests such as neck ultrasound and serum thyroglobulin. However, there no clinical tool used to evaluate for symptoms and quality of life . Assessment tools for patient- reported outcomes may be useful to achieve this purpose such as the MD Anderson MDASI -Thy which has been developed to assess the severity of symptoms and interference with daily living among thyroid cancer patients. A valid and reliable Filipino translation of MDASI-Thy may be useful in evaluating symptoms among thyroid cancer patients for better symptom management, quality of life and compliance to treatment . This study aims to develop a valid and reliable Filipino translation of the MDASI- Thy using the previously validated MDASI core – F.</p>\n\n<p><strong>Methods:</strong> This is part one of a two part study which focuses on the Filipino translation of the six questions specific for thyroid cancer of the MDASI -Thy since the MDASI core has already been translated into Filipino. The translation process will follow the guide provided by MD Anderson Department of Symptom Research Linguistic Validation Instructions.</p>\n\n<p><strong>Result and Conclusion:</strong> The approved Filipino translation of the MDASI Thyroid questionnaire will be used in the long term surveillance of thyroid cancer patients in support of the institution’s Advanced Cancer Center mission.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154150--></body></html>"
    },
    {
      "uid": "P173",
      "content_id": "153653",
      "abstract_number": "P173",
      "poster_number": "P173",
      "title": "Exploring the complex web of surgical quality and social vulnerability in head and neck cancer patients who require major ablative surgery with free flap reconstruction.",
      "summary": "After major ablative and reconstructive surgery for HNC, SES adversely impacts LOS. SES likely drives the adverse impact of SVI on ERAS quality metric compliance. Innovative strategies to support socioeconomically disadvantaged advanced HNC patients in the perioperative setting should be explored to optimize downstream individual and healthcare system benefits.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153653",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdullah Bin-Salman",
      "presenter": "Abdullah Bin-Salman",
      "authors": "Catherine H Frenkel, MD, FACS 1 ; Allyson R Cochran, PhD 1 ; Abdullah Bin-Salman 2 ; Erin E Donahue, PhD 1 ; Steven Hong, MD 1 ; Joshua J Kain, MD 1 ; Daniel S Brickman, MD 1 ; Zvonimir L Milas, MD 1",
      "normalized_authors": [
        "Catherine H Frenkel",
        "Allyson R Cochran",
        "Abdullah Bin-Salman",
        "Erin E Donahue",
        "Steven Hong",
        "Joshua J Kain",
        "Daniel S Brickman",
        "Zvonimir L Milas"
      ],
      "affiliations": [
        "Atrium Health - Levine Cancer Institute",
        "Davidson College"
      ],
      "normalized_institutions": [
        "Atrium Health - Levine Cancer Institute",
        "Davidson College"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "The Effect of Social Factors on Length of Stay",
          "rows": [
            [
              "Effect",
              "Estimate",
              "SE",
              "95% CI",
              "p"
            ],
            [
              "Intercept",
              "10.8",
              "1.6",
              "7.6, 14.0",
              "0.00*"
            ],
            [
              "ERAS",
              "-1.4",
              "1.3",
              "-4.0, 1.2",
              "0.30"
            ],
            [
              "Socioeconomic status percentile",
              "7.7",
              "3.8",
              "0.12, 15.2",
              "0.05"
            ],
            [
              "Household characteristics percentile",
              "-1.8",
              "3.2",
              "-8.1, 4.5",
              "0.57"
            ],
            [
              "Racial status percentile",
              "1.6",
              "2.6",
              "-3.5, 6.8",
              "0.53"
            ],
            [
              "Housing & transportation percentile",
              "-3.5",
              "1.6",
              "-7.9, 0.9",
              "0.11"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 384,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Catherine H Frenkel, MD, FACS 1 ; Allyson R Cochran, PhD 1 ; Abdullah Bin-Salman 2 ; Erin E Donahue, PhD 1 ; Steven Hong, MD 1 ; Joshua J Kain, MD 1 ; Daniel S Brickman, MD 1 ; Zvonimir L Milas, MD 1",
        "Affiliations": "1 Atrium Health - Levine Cancer Institute; 2 Davidson College",
        "Importance": "Enhanced recovery after surgery (ERAS) programs have improved quality outcomes for several surgical subspecialties. In head and neck cancer (HNC), however, the drivers of surgical quality outcomes are unclear.",
        "Objective": "This study analyzes the impact of socioeconomic status (SES), social vulnerability index (SVI, a composite score that considers SES, household composition/disability, minority status, housing and transportation) on ERAS compliance and length of stay (LOS) for patients with HNC of the aerodigestive tract who require ablative surgery with free flap reconstruction.",
        "Methods": "A cohort of patients undergoing larynx, pharynx or oral cavity major resection and free flap reconstruction and adjuvant treatment at a single tertiary referral cancer institute was analyzed. Patients in an ERAS program for larynx cancer from 2018 and oral cavity/pharynx cancer in 2019 through 2020 (n=85) were analyzed with respect to a pre-ERAS group (n=35). Pearson's chi-square and Fisher's exact tests were used to examine associations between treatment group categorical variables. Wilcoxon rank-sum test was used for continuous variables. Univariable and multivariable logistic regression models were employed. Analyses were performed in SAS v9.4 with a significance level of 0.05. Complications and readmissions in this cohort have been previously reported.",
        "Results": "Median patient age was 66 years. Most patients were caucasian (87.5%), with private or government insurance (93.3%), T3 or 4 cancer (n=70.8%). Median socioeconomic percentile was 35.0 and 46.4 in the pre-ERAS and ERAS cohorts respectively, p =0.44. In our regression model, we found that for every 10-unit increase in SES percentile, LOS increased by 0.8 days when ERAS and the other SVI composite elements were controlled for, p =0.05. ERAS implementation did not have a significant interaction effect with SES on LOS, p =0.48. SVI percentile was not associated with prolonged LOS, p =0.22, and the ERAS interaction did not significantly change this relationship. Review of ERAS quality metric compliance revealed that metric compliance improved by 17% when either SES or SVI were controlled for ( p =0.00*).",
        "Conclusions": "After major ablative and reconstructive surgery for HNC, SES adversely impacts LOS. SES likely drives the adverse impact of SVI on ERAS quality metric compliance. Innovative strategies to support socioeconomically disadvantaged advanced HNC patients in the perioperative setting should be explored to optimize downstream individual and healthcare system benefits."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Exploring the complex web of surgical quality and social vulnerability in head and neck cancer patients who require major ablative surgery with free flap reconstruction.</span>. Catherine H Frenkel, MD, FACS<sup>1</sup>; Allyson R Cochran, PhD<sup>1</sup>; <u>Abdullah Bin-Salman</u><sup>2</sup>; Erin E Donahue, PhD<sup>1</sup>; Steven Hong, MD<sup>1</sup>; Joshua J Kain, MD<sup>1</sup>; Daniel S Brickman, MD<sup>1</sup>; Zvonimir L Milas, MD<sup>1</sup>. <sup>1</sup>Atrium Health - Levine Cancer Institute; <sup>2</sup>Davidson College<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Enhanced recovery after surgery (ERAS) programs have improved quality outcomes for several surgical subspecialties. In head and neck cancer (HNC), however, the drivers of surgical quality outcomes are unclear.</p>\n\n<p><strong>Objective: </strong>This study analyzes the impact of socioeconomic status (SES), social vulnerability index (SVI, a composite score that considers SES, household composition/disability, minority status, housing and transportation) on ERAS compliance and length of stay (LOS) for patients with HNC of the aerodigestive tract who require ablative surgery with free flap reconstruction.</p>\n\n<p><strong>Methods: </strong>A cohort of patients undergoing larynx, pharynx or oral cavity major resection and free flap reconstruction and adjuvant treatment at a single tertiary referral cancer institute was analyzed. Patients in an ERAS program for larynx cancer from 2018 and oral cavity/pharynx cancer in 2019 through 2020 (n=85) were analyzed with respect to a pre-ERAS group (n=35). Pearson's chi-square and Fisher's exact tests were used to examine associations between treatment group categorical variables. Wilcoxon rank-sum test was used for continuous variables. Univariable and multivariable logistic regression models were employed. Analyses were performed in SAS v9.4 with a significance level of 0.05. Complications and readmissions in this cohort have been previously reported.</p>\n\n<p><strong>Results: </strong>Median patient age was 66 years. Most patients were caucasian (87.5%), with private or government insurance (93.3%), T3 or 4 cancer (n=70.8%). Median socioeconomic percentile was 35.0 and 46.4 in the pre-ERAS and ERAS cohorts respectively, <em>p</em>=0.44. In our regression model, we found that for every 10-unit increase in SES percentile, LOS increased by 0.8 days when ERAS and the other SVI composite elements were controlled for, <em>p</em>=0.05. ERAS implementation did not have a significant interaction effect with SES on LOS, <em>p</em>=0.48. SVI percentile was not associated with prolonged LOS, <em>p</em>=0.22, and the ERAS interaction did not significantly change this relationship. Review of ERAS quality metric compliance revealed that metric compliance improved by 17% when either SES or SVI were controlled for (<em>p</em>=0.00*).</p>\n\n<table border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption>The Effect of Social Factors on Length of Stay</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope='col'>Effect</th>\n\t\t\t<th scope='col'>Estimate</th>\n\t\t\t<th scope='col'><em>SE</em></th>\n\t\t\t<th scope='col'>95% CI</th>\n\t\t\t<th scope='col'><em>p</em></th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>Intercept</td>\n\t\t\t<td>10.8</td>\n\t\t\t<td>1.6</td>\n\t\t\t<td>7.6, 14.0</td>\n\t\t\t<td>0.00*</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>ERAS</td>\n\t\t\t<td>-1.4</td>\n\t\t\t<td>1.3</td>\n\t\t\t<td>-4.0, 1.2 </td>\n\t\t\t<td>0.30</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Socioeconomic status percentile</td>\n\t\t\t<td>7.7</td>\n\t\t\t<td>3.8</td>\n\t\t\t<td>0.12, 15.2</td>\n\t\t\t<td>0.05</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Household characteristics percentile</td>\n\t\t\t<td>-1.8</td>\n\t\t\t<td>3.2</td>\n\t\t\t<td>-8.1, 4.5</td>\n\t\t\t<td>0.57</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Racial status percentile</td>\n\t\t\t<td>1.6</td>\n\t\t\t<td>2.6</td>\n\t\t\t<td>-3.5, 6.8</td>\n\t\t\t<td>0.53</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Housing & transportation percentile</td>\n\t\t\t<td>-3.5</td>\n\t\t\t<td>1.6</td>\n\t\t\t<td>-7.9, 0.9</td>\n\t\t\t<td>0.11</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Conclusions:</strong> After major ablative and reconstructive surgery for HNC, SES adversely impacts LOS. SES likely drives the adverse impact of SVI on ERAS quality metric compliance. Innovative strategies to support socioeconomically disadvantaged advanced HNC patients in the perioperative setting should be explored to optimize downstream individual and healthcare system benefits.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153653--></body></html>"
    },
    {
      "uid": "P174",
      "content_id": "154645",
      "abstract_number": "P174",
      "poster_number": "P174",
      "title": "Outcomes Following Total Glossectomy and Total Laryngectomy for HNSCC at a Safety Net Hospital",
      "summary": "Patients with locally advanced OC and OP disease involving the mandible or significant oral structures are often inadequately treated with non-surgical modalities. Despite TGTL’s morbidity, many patients are already tracheostomy and G-tube-dependent with little hope of liberation from these devices. Thus, there remains a role for TGTL in the salvage and primary setting for oral and oropharyngeal SCC, and its...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154645",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joshua C Barlow, BS",
      "presenter": "Joshua C Barlow, BS",
      "authors": "Joshua C Barlow, BS ; David J Hernandez, MD",
      "normalized_authors": [
        "Joshua C Barlow",
        "David J Hernandez"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 453,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Joshua C Barlow, BS ; David J Hernandez, MD",
        "Affiliations": "Baylor College of Medicine",
        "Introduction": "Treatment of squamous cell carcinoma of the head and neck (HNSCC) can be extremely taxing. Advanced tumors involving multiple aerodigestive structures may require radical approaches with therapeutic or palliative intent. Total glossectomy with total laryngectomy (TGTL) is a rarely performed surgery used in select patients with locoregional spread or treatment-resistant malignancies. These interventions carry morbid complications that permanently alter quality of life, particularly oral feeding and speech. This study evaluates patient outcomes following TGTL in a county safety-net hospital system.",
        "Methods": "We included all patients who underwent TGTL for HNSCC within Harris Health System from 2020–2025. Both primary TGTL and salvage resections were analyzed. Data included demographics, comorbidities, oncologic history, tumor characteristics, prescribed therapy, and outcomes, all obtained from electronic health records.",
        "Results": "11 patients underwent TGTL over 5 years (5 female, 6 male; mean age 55.3). 6 (55%) were Hispanic, 3 (27%) were Black, and 2 (18%) were White. 9 patients (82%) were uninsured but qualified for county financial assistance. 8 (73%) had a smoking history (median 26 pack-years). 6 patients had oropharyngeal (OP) primaries (1 HPV+), with the remaining 5 tumors occurring in the oral cavity (OC). All but one had T4 tumors; 6 (55%) had N2–3 disease. 5 (45%) had received prior radiotherapy; 6 underwent TGTL as primary therapy. 7 (64%) had pre-op tracheostomy; 10 (91%) had gastrostomy tubes. 8 (73%) required mandibulectomy; 8 (73%) needed double or chimeric flaps for reconstruction. None of the patients had positive margins, though 2 (18%) had close margins (<1 mm). 4 patients (36%) had >2 mm extranodal extension (ENE); 1 had <2 mm ENE. 2 (18%) developed a pharyngocutaneous fistula requiring additional surgery; 1 flap failure occurred. Postoperatively, 8 patients received adjuvant radiotherapy (7 completed; 2 re-irradiated); 4 received concurrent platinum-based chemotherapy. 4 individuals (36%) had disease recurrence within 1 year, 1 each with local or distant recurrence and 2 with both. 2 of these had chemo-radiation post-TGTL; 2 had no adjuvant therapy. 3 (27%) patients are deceased (2 within a year of TGTL); 2 patients were admitted to hospice, and 1 was lost to follow-up. During recovery, 10/11 patients (91%) remained G-tube dependent; 6 achieved some oral intake for pleasure, and 1 discontinued G-tube after adequate PO nutrition. All patients were incapable of speech post-TGTL.",
        "Conclusion": "Patients with locally advanced OC and OP disease involving the mandible or significant oral structures are often inadequately treated with non-surgical modalities. Despite TGTL’s morbidity, many patients are already tracheostomy and G-tube-dependent with little hope of liberation from these devices. Thus, there remains a role for TGTL in the salvage and primary setting for oral and oropharyngeal SCC, and its outcomes need to be studied further in all patient populations to better counsel patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes Following Total Glossectomy and Total Laryngectomy for HNSCC at a Safety Net Hospital</span>. <u>Joshua C Barlow, BS</u>; David J Hernandez, MD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Treatment of squamous cell carcinoma of the head and neck (HNSCC) can be extremely taxing. Advanced tumors involving multiple aerodigestive structures may require radical approaches with therapeutic or palliative intent. Total glossectomy with total laryngectomy (TGTL) is a rarely performed surgery used in select patients with locoregional spread or treatment-resistant malignancies. These interventions carry morbid complications that permanently alter quality of life, particularly oral feeding and speech. This study evaluates patient outcomes following TGTL in a county safety-net hospital system. </p>\n\n<p><strong>Methods: </strong>We included all patients who underwent TGTL for HNSCC within Harris Health System from 2020–2025. Both primary TGTL and salvage resections were analyzed. Data included demographics, comorbidities, oncologic history, tumor characteristics, prescribed therapy, and outcomes, all obtained from electronic health records. </p>\n\n<p><strong>Results: </strong>11 patients underwent TGTL over 5 years (5 female, 6 male; mean age 55.3). 6 (55%) were Hispanic, 3 (27%) were Black, and 2 (18%) were White. 9 patients (82%) were uninsured but qualified for county financial assistance. 8 (73%) had a smoking history (median 26 pack-years). 6 patients had oropharyngeal (OP) primaries (1 HPV+), with the remaining 5 tumors occurring in the oral cavity (OC). All but one had T4 tumors; 6 (55%) had N2–3 disease. 5 (45%) had received prior radiotherapy; 6 underwent TGTL as primary therapy. 7 (64%) had pre-op tracheostomy; 10 (91%) had gastrostomy tubes. 8 (73%) required mandibulectomy; 8 (73%) needed double or chimeric flaps for reconstruction. None of the patients had positive margins, though 2 (18%) had close margins (<1 mm). 4 patients (36%) had >2 mm extranodal extension (ENE); 1 had <2 mm ENE. 2 (18%) developed a pharyngocutaneous fistula requiring additional surgery; 1 flap failure occurred. Postoperatively, 8 patients received adjuvant radiotherapy (7 completed; 2 re-irradiated); 4 received concurrent platinum-based chemotherapy. 4 individuals (36%) had disease recurrence within 1 year, 1 each with local or distant recurrence and 2 with both. 2 of these had chemo-radiation post-TGTL; 2 had no adjuvant therapy. 3 (27%) patients are deceased (2 within a year of TGTL); 2 patients were admitted to hospice, and 1 was lost to follow-up. During recovery, 10/11 patients (91%) remained G-tube dependent; 6 achieved some oral intake for pleasure, and 1 discontinued G-tube after adequate PO nutrition. All patients were incapable of speech post-TGTL. </p>\n\n<p><strong>Conclusion: </strong>Patients with locally advanced OC and OP disease involving the mandible or significant oral structures are often inadequately treated with non-surgical modalities. Despite TGTL’s morbidity, many patients are already tracheostomy and G-tube-dependent with little hope of liberation from these devices. Thus, there remains a role for TGTL in the salvage and primary setting for oral and oropharyngeal SCC, and its outcomes need to be studied further in all patient populations to better counsel patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154645--></body></html>"
    },
    {
      "uid": "P175",
      "content_id": "154111",
      "abstract_number": "P175",
      "poster_number": "P175",
      "title": "Microsurgical “Onion-Peeling” Technique for Resection of Carotid Body Paragangliomas: Outcomes from a Consecutive Case Series",
      "summary": "The “onion-peeling” technique for CBT resection allows for a high rate of GTR with preservation of the involved and surrounding neurovascular structures, particularly the carotid artery and lower cranial nerves. Functional outcomes were positive overall, with quick recovery of voice and swallowing in the patients who encountered dysphonia and dysphagia. These surgical and functional outcomes demonstrate the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154111",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Raj Malhotra",
      "presenter": "Raj Malhotra",
      "authors": "Raj Malhotra 1 ; Caryn J Ha 1 ; Shrey Shah 1 ; Rachel Kaye 1 ; Ghayoour S Mir 1 ; James K Liu 2 ; Richard Chan W Park 1",
      "normalized_authors": [
        "Raj Malhotra",
        "Caryn J Ha",
        "Shrey Shah",
        "Rachel Kaye",
        "Ghayoour S Mir",
        "James K Liu",
        "Richard Chan W Park"
      ],
      "affiliations": [
        "Rutgers New Jersey Medical School",
        "Neurosurgeons of New Jersey"
      ],
      "normalized_institutions": [
        "Rutgers New Jersey Medical School",
        "Neurosurgeons of New Jersey"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 428,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Raj Malhotra 1 ; Caryn J Ha 1 ; Shrey Shah 1 ; Rachel Kaye 1 ; Ghayoour S Mir 1 ; James K Liu 2 ; Richard Chan W Park 1",
        "Affiliations": "1 Rutgers New Jersey Medical School; 2 Neurosurgeons of New Jersey",
        "Background": "Carotid body tumors (CBTs) are a type of paraganglioma that arises from the paraganglia cell body at the carotid artery bifurcation. While gross total resection can be curative, it often carries the risk of vascular injury, cranial neuropathies, and functional morbidity. In the microsurgical “onion-peeling” technique, the fibrovascular connective tissue surrounding the tumor capsule is carefully peeled off the true tumor capsule. The dissection plane is carried between the true tumor capsule and the fibrovascular connective tissue so that the cranial nerves are outside of this connective tissue layer. This technique facilitates preservation of cranial nerves and surrounding neurovascular structures. We review our clinical outcomes of microsurgical resection of CBTs using this onion-peeling technique.",
        "Methods": "A retrospective review of consecutive CBT resections performed by a single surgeon using the “onion-peeling” technique from 2015-2025 was conducted. Demographics, tumor characteristics, surgical details, and postoperative outcomes were collected. Functional outcomes, including swallow function and vocal fold mobility, were recorded.",
        "Results": "Eighteen patients (19 CBT resections) were included with a mean age of 44.11 years and were mostly female at 72%. Six patients had multiple paragangliomas, four of whom had an ipsilateral second paraganglioma (jugulotympanic or vagal origin) that was resected during the same operation. Genetic mutations were seen in 39% of patients, most commonly succinate dehydrogenase (SDH-D) mutations. 17% of patients had a catecholamine-secreting tumor. Gross total resection was achieved in 94.7% of patients. All cranial nerves were anatomically preserved, and one patient had a tumor invading the ICA, which required excision and interpositional grafting. Mean hospitalization time was 6.74 days. One patient had a subtotal resection because the tumor was very fibrous and engulfed the lower cranial nerves, which were functional. Two patients required a temporary PEG tube for nutritional supplementation due to postoperative dysphagia that was maintained at discharge; however, all patients tolerated oral nutrition by six months post-operation. Injection laryngoplasty for vocal fold paresis or paralysis was needed in 6 patients (31.5%), with two patients eventually requiring medialization laryngoplasty. Postoperative complications included Horner’s syndrome (26%), first-bite syndrome (11%), hematoma (5%), and pulmonary embolism (5%).",
        "Conclusions": "The “onion-peeling” technique for CBT resection allows for a high rate of GTR with preservation of the involved and surrounding neurovascular structures, particularly the carotid artery and lower cranial nerves. Functional outcomes were positive overall, with quick recovery of voice and swallowing in the patients who encountered dysphonia and dysphagia. These surgical and functional outcomes demonstrate the “onion-peeling” technique as a safe microsurgical approach to CBT resection that preserves the function of the lower cranial nerves and enables gross tumor removal."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Microsurgical “Onion-Peeling” Technique for Resection of Carotid Body Paragangliomas: Outcomes from a Consecutive Case Series</span>. <u>Raj Malhotra</u><sup>1</sup>; Caryn J Ha<sup>1</sup>; Shrey Shah<sup>1</sup>; Rachel Kaye<sup>1</sup>; Ghayoour S Mir<sup>1</sup>; James K Liu<sup>2</sup>; Richard Chan W Park<sup>1</sup>. <sup>1</sup>Rutgers New Jersey Medical School; <sup>2</sup>Neurosurgeons of New Jersey<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Carotid body tumors (CBTs) are a type of paraganglioma that arises from the paraganglia cell body at the carotid artery bifurcation. While gross total resection can be curative, it often carries the risk of vascular injury, cranial neuropathies, and functional morbidity. In the microsurgical “onion-peeling” technique, the fibrovascular connective tissue surrounding the tumor capsule is carefully peeled off the true tumor capsule. The dissection plane is carried between the true tumor capsule and the fibrovascular connective tissue so that the cranial nerves are outside of this connective tissue layer. This technique facilitates preservation of cranial nerves and surrounding neurovascular structures. We review our clinical outcomes of microsurgical resection of CBTs using this onion-peeling technique.</p>\n\n<p><strong>Methods: </strong>A retrospective review of consecutive CBT resections performed by a single surgeon using the “onion-peeling” technique from 2015-2025 was conducted. Demographics, tumor characteristics, surgical details, and postoperative outcomes were collected. Functional outcomes, including swallow function and vocal fold mobility, were recorded.</p>\n\n<p><strong>Results: </strong>Eighteen patients (19 CBT resections) were included with a mean age of 44.11 years and were mostly female at 72%. Six patients had multiple paragangliomas, four of whom had an ipsilateral second paraganglioma (jugulotympanic or vagal origin) that was resected during the same operation. Genetic mutations were seen in 39% of patients, most commonly succinate dehydrogenase (SDH-D) mutations. 17% of patients had a catecholamine-secreting tumor. Gross total resection was achieved in 94.7% of patients. All cranial nerves were anatomically preserved, and one patient had a tumor invading the ICA, which required excision and interpositional grafting. Mean hospitalization time was 6.74 days. One patient had a subtotal resection because the tumor was very fibrous and engulfed the lower cranial nerves, which were functional. Two patients required a temporary PEG tube for nutritional supplementation due to postoperative dysphagia that was maintained at discharge; however, all patients tolerated oral nutrition by six months post-operation. Injection laryngoplasty for vocal fold paresis or paralysis was needed in 6 patients (31.5%), with two patients eventually requiring medialization laryngoplasty. Postoperative complications included Horner’s syndrome (26%), first-bite syndrome (11%), hematoma (5%), and pulmonary embolism (5%).</p>\n\n<p><strong>Conclusions:</strong> The “onion-peeling” technique for CBT resection allows for a high rate of GTR with preservation of the involved and surrounding neurovascular structures, particularly the carotid artery and lower cranial nerves. Functional outcomes were positive overall, with quick recovery of voice and swallowing in the patients who encountered dysphonia and dysphagia. These surgical and functional outcomes demonstrate the “onion-peeling” technique as a safe microsurgical approach to CBT resection that preserves the function of the lower cranial nerves and enables gross tumor removal.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154111--></body></html>"
    },
    {
      "uid": "P176",
      "content_id": "153550",
      "abstract_number": "P176",
      "poster_number": "P176",
      "title": "Impact of Total Thyroidectomy on Graves’ Orbitopathy Progression: A Prospective Cohort Study",
      "summary": "Our results demonstrate that total thyroidectomy may improve the severity and symptomatology of GO. Most patients experienced symptomatic improvement within one month postoperatively, with improvements largely maintained at 6 months. These benefits may reflect reduced autoimmune activity following surgery. A minority of patients developed new ocular symptoms at 6 months post-thyroidectomy, highlighting the need...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153550",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica R Weinberg, BS",
      "presenter": "Jessica R Weinberg, BS",
      "authors": "Jessica R Weinberg, BS 1 ; Geena Jung, BA 1 ; Elizabeth Borowiec, MD 2 ; Vikas Mehta, MD 2 ; Carolyn A DeBiase, MD 2 ; Bradley A Schiff, MD 2 ; Christina H Fang, MD 2",
      "normalized_authors": [
        "Jessica R Weinberg",
        "Geena Jung",
        "Elizabeth Borowiec",
        "Vikas Mehta",
        "Carolyn A DeBiase",
        "Bradley A Schiff",
        "Christina H Fang"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine",
        "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine",
        "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jessica R Weinberg, BS 1 ; Geena Jung, BA 1 ; Elizabeth Borowiec, MD 2 ; Vikas Mehta, MD 2 ; Carolyn A DeBiase, MD 2 ; Bradley A Schiff, MD 2 ; Christina H Fang, MD 2",
        "Affiliations": "1 Albert Einstein College of Medicine; 2 Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine",
        "Introduction": "Graves’ orbitopathy (GO) is a rare extrathyroidal manifestation of Graves’ disease driven by autoantibodies targeting the thyrotropic receptor which activate orbital fibroblasts. Patients with GO often present with proptosis, eyelid retraction, and extraocular muscle dysfunction leading to symptoms of dryness, diplopia, photophobia, and ocular pain. While moderate to severe GO is recognized as an indication for total thyroidectomy, surgery is typically reserved for definitive management in patients who have failed medical management. Data describing the effect of thyroidectomy on orbitopathy is conflicting and limited to objective measurements. This study aims to elucidate and quantify changes in GO and its associated clinical symptoms following thyroidectomy.",
        "Methods": "This is a prospective study at Montefiore Medical Center of adult Graves patients with documented ocular involvement undergoing thyroidectomy. Patients with history of eye surgery or teprotumumab usage were excluded. Primary outcomes include degree of exophthalmos, lid retraction, and thyroid stimulating immunoglobulin (TSI) levels, measured pre-operatively, at 1 month, and at 6 months post-operatively. Secondary outcomes include symptoms of pain, redness, swelling, and vision changes at the same time points.",
        "Results": "13 patients were enrolled. 12/13 (92.3%) of the patients were female, with a mean age of 41.4 years, and 10/12 (83.3%) identified as African American. Preoperatively, the most common symptoms were eyelid swelling (76.9%), pain (61.5%), vision disturbances (61.5%), and eye redness (53.8%). Mean preoperative exophthalmos was 21.8mm (OS) and 22.2mm (OD) and mean eyelid retraction (palpebral fissure height) was 10.8mm (OS) and 11.5mm (OD). At 1 month follow-up (n=10), 40% of patients had an objective, clinical improvement in their exophthalmos ( ≥2mm), with mean reductions of 1.1mm (OS) and 1.6mm (OD). Eyelid retraction decreased by an average of 1mm in both eyes. Among patients with preoperative ocular symptoms, pain and swelling resolved in 100% of the patients by the 1 month post-op visit, vision disturbances improved in 83.3%, and eyelid swelling improved in 71.4%. For those without any preoperative symptoms, new onset pain and redness were reported in 10% of patients at 1 month. At 6-month follow-up (n = 8), a majority of patients maintained their 1-month improvements without further change. However, three patients developed new symptoms: two experienced pain with associated swelling, redness, and vision changes, and one reported swelling alone. Of note, one of these patients had been fully non-compliant with their thyroid supplementation. Among those with objective measurements recorded at the second post-operative visit (n=5), two patients had new-onset improvement in exophthalmos (≥2mm), while three patients experienced worsening compared to their preoperative measurements. One patient demonstrated worsening eyelid retraction.",
        "Conclusions": "Our results demonstrate that total thyroidectomy may improve the severity and symptomatology of GO. Most patients experienced symptomatic improvement within one month postoperatively, with improvements largely maintained at 6 months. These benefits may reflect reduced autoimmune activity following surgery. A minority of patients developed new ocular symptoms at 6 months post-thyroidectomy, highlighting the need for continued long-term monitoring to identify late disease activity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Total Thyroidectomy on Graves’ Orbitopathy Progression: A Prospective Cohort Study</span>. <u>Jessica R Weinberg, BS</u><sup>1</sup>; Geena Jung, BA<sup>1</sup>; Elizabeth Borowiec, MD<sup>2</sup>; Vikas Mehta, MD<sup>2</sup>; Carolyn A DeBiase, MD<sup>2</sup>; Bradley A Schiff, MD<sup>2</sup>; Christina H Fang, MD<sup>2</sup>. <sup>1</sup>Albert Einstein College of Medicine; <sup>2</sup>Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center, The University Hospital of Albert Einstein College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Graves’ orbitopathy (GO) is a rare extrathyroidal manifestation of Graves’ disease driven by autoantibodies targeting the thyrotropic receptor which activate orbital fibroblasts. Patients with GO often present with proptosis, eyelid retraction, and extraocular muscle dysfunction leading to symptoms of dryness, diplopia, photophobia, and ocular pain. While moderate to severe GO is recognized as an indication for total thyroidectomy, surgery is typically reserved for definitive management in patients who have failed medical management. Data describing the effect of thyroidectomy on orbitopathy is conflicting and limited to objective measurements. This study aims to elucidate and quantify changes in GO and its associated clinical symptoms following thyroidectomy. </p>\n\n<p><strong>Methods</strong>: This is a prospective study at Montefiore Medical Center of adult Graves patients with documented ocular involvement undergoing thyroidectomy.  Patients with history of eye surgery or teprotumumab usage were excluded.  Primary outcomes include degree of exophthalmos, lid retraction, and thyroid stimulating immunoglobulin (TSI) levels, measured pre-operatively, at 1 month, and at 6 months post-operatively. Secondary outcomes include symptoms of pain, redness, swelling, and vision changes at the same time points. </p>\n\n<p><strong>Results</strong>: 13 patients were enrolled. 12/13 (92.3%) of the patients were female, with a mean age of 41.4 years, and 10/12 (83.3%) identified as African American. Preoperatively, the most common symptoms were eyelid swelling (76.9%), pain (61.5%), vision disturbances (61.5%), and eye redness (53.8%). Mean preoperative exophthalmos was 21.8mm (OS) and 22.2mm (OD) and mean eyelid retraction (palpebral fissure height) was 10.8mm (OS) and 11.5mm (OD). At 1 month follow-up (n=10), 40% of patients had an objective, clinical improvement in their exophthalmos ( ≥2mm), with mean reductions of 1.1mm (OS) and 1.6mm (OD). Eyelid retraction decreased by an average of 1mm in both eyes. Among patients with preoperative ocular symptoms, pain and swelling resolved in 100% of the patients by the 1 month post-op visit, vision disturbances improved in 83.3%, and eyelid swelling improved in 71.4%. For those without any preoperative symptoms, new onset pain and redness were reported in 10% of patients at 1 month. At 6-month follow-up (n = 8), a majority of patients maintained their 1-month improvements without further change. However, three patients developed new symptoms: two experienced pain with associated swelling, redness, and vision changes, and one reported swelling alone. Of note, one of these patients had been fully non-compliant with their thyroid supplementation. Among those with objective measurements recorded at the second post-operative visit (n=5), two patients had new-onset improvement in exophthalmos (≥2mm), while three patients experienced worsening compared to their preoperative measurements. One patient demonstrated worsening eyelid retraction.</p>\n\n<p><strong>Conclusions</strong>: Our results demonstrate that total thyroidectomy may improve the severity and symptomatology of GO. Most patients experienced symptomatic improvement within one month postoperatively, with improvements largely maintained at 6 months. These benefits may reflect reduced autoimmune activity following surgery.  A minority of patients developed new ocular symptoms at 6 months post-thyroidectomy, highlighting the need for continued long-term monitoring to identify late disease activity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153550--></body></html>"
    },
    {
      "uid": "P177",
      "content_id": "153705",
      "abstract_number": "P177",
      "poster_number": "P177",
      "title": "Communication and Swallowing Outcomes in Transoral Robotic-Assisted Total Laryngectomy",
      "summary": "TORS-assisted total laryngectomy may provide superior voicing outcomes and comparable swallowing function to traditional open salvage TL at 6 months postoperatively, with fewer observed shoulder and lymphedema complications. These early results suggest potential functional advantages of the transoral robotic approach, warranting further evaluation in larger cohorts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153705",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Melissa Tucker Ponto, MS, CCCSLP",
      "presenter": "Melissa Tucker Ponto, MS, CCCSLP",
      "authors": "Melissa Tucker Ponto, MS, CCCSLP ; Duane V Trahan, MS, CCCSLP, BCSS; Caitlin Stone, MCD, CCCSLP, BCSS; Nicolaus D Knight, MS; Andrew Fuson, MD; Harishanker Jeyarajan, MD",
      "normalized_authors": [
        "Melissa Tucker Ponto, CCCSLP",
        "Duane V Trahan, CCCSLP, BCSS",
        "Caitlin Stone, MCD, CCCSLP, BCSS",
        "Nicolaus D Knight",
        "Andrew Fuson",
        "Harishanker Jeyarajan"
      ],
      "affiliations": [
        "University of Alabama at Birmingham"
      ],
      "normalized_institutions": [
        "University of Alabama at Birmingham"
      ],
      "session_type": "Poster",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 397,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Melissa Tucker Ponto, MS, CCCSLP ; Duane V Trahan, MS, CCCSLP, BCSS; Caitlin Stone, MCD, CCCSLP, BCSS; Nicolaus D Knight, MS; Andrew Fuson, MD; Harishanker Jeyarajan, MD",
        "Affiliations": "University of Alabama at Birmingham",
        "Background": "Transoral robotic-assisted total laryngectomy (TORSaTL) is a recently developed technique, and limited data exist regarding postoperative voice and swallowing outcomes. This study compared functional communication and swallowing outcomes between patients undergoing TORSaTL for functional indications or endolaryngeal, N0 recurrent disease and matched patients who underwent traditional open salvage total laryngectomy (TL).",
        "Methods": "We conducted a prospective, concurrent cohort study of 8 TORSaTL and 8 open TL patients treated from 2024–2025 at our institution. Of 12 patients who underwent TORSaTL during the study period, 2 were excluded due to death and 2 due to late-stage ALS. Two control TL patients were excluded due to death. Functional outcomes were assessed preoperatively and at 3 and 6 months postoperatively using the Performance Status Scale for Head and Neck Cancer (PSS-HN). In patients receiving a tracheoesophageal prosthesis (TEP), we assessed voice quality and self-care using the Harrison–Robillard–Shultz TEP Rating Scale (HRS-TEP). Clinicians recorded presence or absence of lymphedema and shoulder weakness. For continuous data (scale 0–100), descriptive statistics (mean, SD) were calculated, and independent-samples t-tests compared group means, with unequal variance correction where appropriate. Statistical significance was defined as α = 0.05. Analyses were conducted in R version 4.4.3 (2025-02-28 ucrt).",
        "Results": "Baseline PSS-HN Normalcy of Diet, Eating in Public, and Intelligibility of Speech scores were comparable between groups. At 6 months postoperatively, PSS-HN Diet scores were mean 65.0 (SD 27.8) for TORSaTL and 71.7 (SD 24.0) for TL. Eating in Public scores were 75.0 (SD 32.7) and 66.7 (SD 34.2), respectively. On the Speech subscale, which considers both TEP and electrolarynx speech, TORSaTL patients demonstrated greater intelligibility than open TL controls (mean 75.0 [SD 23.2] vs 45.8 [SD 18.8]; p = 0.023). Among patients with a TEP (TORSaTL n = 3; TL n = 4), initial HRS-TEP scores averaged 11.7 out of 15 possible points (SD 1.3) and 8.5 (SD 1.8), respectively. Shoulder weakness was observed in 0/8 TORSaTL and 2/8 TL patients. Lymphedema occurred in 3/8 TORSaTL and 8/8 TL patients.",
        "Conclusion": "TORS-assisted total laryngectomy may provide superior voicing outcomes and comparable swallowing function to traditional open salvage TL at 6 months postoperatively, with fewer observed shoulder and lymphedema complications. These early results suggest potential functional advantages of the transoral robotic approach, warranting further evaluation in larger cohorts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Communication and Swallowing Outcomes in Transoral Robotic-Assisted Total Laryngectomy</span>. <u>Melissa Tucker Ponto, MS, CCCSLP</u>; Duane V Trahan, MS, CCCSLP, BCSS; Caitlin Stone, MCD, CCCSLP, BCSS; Nicolaus D Knight, MS; Andrew Fuson, MD; Harishanker Jeyarajan, MD. University of Alabama at Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral robotic-assisted total laryngectomy (TORSaTL) is a recently developed technique, and limited data exist regarding postoperative voice and swallowing outcomes. This study compared functional communication and swallowing outcomes between patients undergoing TORSaTL for functional indications or endolaryngeal, N0 recurrent disease and matched patients who underwent traditional open salvage total laryngectomy (TL). </p>\n\n<p><strong>Methods: </strong>We conducted a prospective, concurrent cohort study of 8 TORSaTL and 8 open TL patients treated from 2024–2025 at our institution. Of 12 patients who underwent TORSaTL during the study period, 2 were excluded due to death and 2 due to late-stage ALS. Two control TL patients were excluded due to death. Functional outcomes were assessed preoperatively and at 3 and 6 months postoperatively using the Performance Status Scale for Head and Neck Cancer (PSS-HN). In patients receiving a tracheoesophageal prosthesis (TEP), we assessed voice quality and self-care using the Harrison–Robillard–Shultz TEP Rating Scale (HRS-TEP). Clinicians recorded presence or absence of lymphedema and shoulder weakness. For continuous data (scale 0–100), descriptive statistics (mean, SD) were calculated, and independent-samples t-tests compared group means, with unequal variance correction where appropriate. Statistical significance was defined as α = 0.05. Analyses were conducted in R version 4.4.3 (2025-02-28 ucrt). </p>\n\n<p><strong>Results: </strong>Baseline PSS-HN Normalcy of Diet, Eating in Public, and Intelligibility of Speech scores were comparable between groups. At 6 months postoperatively, PSS-HN Diet scores were mean 65.0 (SD 27.8) for TORSaTL and 71.7 (SD 24.0) for TL. Eating in Public scores were 75.0 (SD 32.7) and 66.7 (SD 34.2), respectively. On the Speech subscale, which considers both TEP and electrolarynx speech, TORSaTL patients demonstrated greater intelligibility than open TL controls (mean 75.0 [SD 23.2] vs 45.8 [SD 18.8]; p = 0.023). Among patients with a TEP (TORSaTL n = 3; TL n = 4), initial HRS-TEP scores averaged 11.7 out of 15 possible points (SD 1.3) and 8.5 (SD 1.8), respectively. Shoulder weakness was observed in 0/8 TORSaTL and 2/8 TL patients. Lymphedema occurred in 3/8 TORSaTL and 8/8 TL patients. </p>\n\n<p><strong>Conclusion: </strong>TORS-assisted total laryngectomy may provide superior voicing outcomes and comparable swallowing function to traditional open salvage TL at 6 months postoperatively, with fewer observed shoulder and lymphedema complications. These early results suggest potential functional advantages of the transoral robotic approach, warranting further evaluation in larger cohorts. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153705--></body></html>"
    },
    {
      "uid": "P178",
      "content_id": "153422",
      "abstract_number": "P178",
      "poster_number": "P178",
      "title": "ALCAM arises as a biomarker of cervical occult metastasis in glottic laryngeal squamous cell carcinoma",
      "summary": "Glottic cancer is a tumor emerging from the vocal cords, the most prevalent laryngeal cancer site, with the laryngeal squamous cell carcinoma (LSCC) being the most prevalent histological type. Glottic LSCC tends to be diagnosed at an early stage due to early symptoms, allowing curative treatment and a good prognosis. The glottic site has sparse lymph node chains compared to other laryngeal or head-and-neck sites,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153422",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Bernardo Peryassú, MD, MsC",
      "presenter": "Bernardo Peryassú, MD, MsC",
      "authors": "Bernardo Peryassú, MD, MsC ; Pedro Nicolau-Neto, PhD; Emilson Freitas, MD, MsC; Fernando Luiz Dias, MD, PhD; Luis Felipe Ribeiro Pinto, PhD",
      "normalized_authors": [
        "Bernardo Peryassú",
        "Pedro Nicolau-Neto",
        "Emilson Freitas",
        "Fernando Luiz Dias",
        "Luis Felipe Ribeiro Pinto"
      ],
      "affiliations": [
        "INCA"
      ],
      "normalized_institutions": [
        "INCA"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Bernardo Peryassú, MD, MsC ; Pedro Nicolau-Neto, PhD; Emilson Freitas, MD, MsC; Fernando Luiz Dias, MD, PhD; Luis Felipe Ribeiro Pinto, PhD",
        "Affiliations": "INCA",
        "Abstract": "Glottic cancer is a tumor emerging from the vocal cords, the most prevalent laryngeal cancer site, with the laryngeal squamous cell carcinoma (LSCC) being the most prevalent histological type. Glottic LSCC tends to be diagnosed at an early stage due to early symptoms, allowing curative treatment and a good prognosis. The glottic site has sparse lymph node chains compared to other laryngeal or head-and-neck sites, which is associated with a low frequency of cervical metastasis. Nevertheless, cervical occult metastasis, a clinically negative (cN0) and pathologically positive (pN+) lymph node, is an important prognostic factor for LSCC, and its frequency ranges from 0% to 25.2% in glottic LSCC. Consequently, there is a need to improve the identification of glottic LSCC with cervical occult metastasis, aiming to increase treatment efficacy and the survival rates. High levels of the Activated Leukocyte Cell Adhesion Molecule (ALCAM) protein were associated with cervical metastasis and worse survival rates. This transmembrane glycoprotein is associated with cell–cell adhesion, epithelial and endothelial interactions, and immune response regulation. Therefore, this study evaluates ALCAM levels as a biomarker of cervical occult metastasis in glottic LSCC patients from the Head and Neck Surgery Division of the Instituto Nacional de Câncer (Brazil), and associates this protein levels with clinical and pathological features and patient outcomes. This study included 111 glottic LSCC patients cN0, cT2/T3, who underwent surgery with curative intent with neck dissection. All patients were followed for at least five years. The Institutional Ethics Committee approved the study. At diagnosis, 82% of patients showed impaired vocal cords, with clinical TNM stages distributed as 40.54% cT2 and 59.46% cT3. All underwent primary surgical therapy, achieving negative margins in 83.78% of cases. Postoperative findings classified tumors as pT1 (7.21%), pT2 (23.42%), pT3 (52.25%), and pT4 (17.12%); 68.47% were pTNM stage III or IV, and 85.59% were moderately differentiated. Anterior commissure involvement was found in 59.46% of cases, supraglottic extension in 45.05%, and thyroid cartilage invasion in 21.62%. Occult lymph node metastases were observed in 18.92% of patients, and 36% showed high ALCAM levels. Tumor recurrence occurred in 13 patients (11.71%), including seven local, three regional, and three distant relapses. The median overall survival was 74.4 months. Cervical occult metastasis was associated with high ALCAM levels (p=0.00063), and subglottic involvement remained significantly associated with occult metastasis (p=0.015). Overall survival analyses showed that high ALCAM levels (p=0.023), cervical occult metastasis (p<0.001), age ≥61 years (p=0.007), impaired vocal cords (p=0.003), pT3/4 classification (p=0.04), tumor stage III/IV (p=0.04), supraglottic involvement (p=0.034), subglottic involvement (p=0.021), and transglottic tumor presence (p=0.009) were associated with worse prognosis. In our study, we found that high ALCAM level is a biomarker of cervical occult metastasis in glottic LSCC and affects patients' prognosis."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>ALCAM arises as a biomarker of cervical occult metastasis in glottic laryngeal squamous cell carcinoma</span>. <u>Bernardo Peryassú, MD, MsC</u>; Pedro Nicolau-Neto, PhD; Emilson Freitas, MD, MsC; Fernando Luiz Dias, MD, PhD; Luis Felipe Ribeiro Pinto, PhD. INCA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Glottic cancer is a tumor emerging from the vocal cords, the most prevalent laryngeal cancer site, with the laryngeal squamous cell carcinoma (LSCC) being the most prevalent histological type. Glottic LSCC tends to be diagnosed at an early stage due to early symptoms, allowing curative treatment and a good prognosis. The glottic site has sparse lymph node chains compared to other laryngeal or head-and-neck sites, which is associated with a low frequency of cervical metastasis. Nevertheless, cervical occult metastasis, a clinically negative (cN0) and pathologically positive (pN+) lymph node, is an important prognostic factor for LSCC, and its frequency ranges from 0% to 25.2% in glottic LSCC. Consequently, there is a need to improve the identification of glottic LSCC with cervical occult metastasis, aiming to increase treatment efficacy and the survival rates. High levels of the Activated Leukocyte Cell Adhesion Molecule (ALCAM) protein were associated with cervical metastasis and worse survival rates. This transmembrane glycoprotein is associated with cell–cell adhesion, epithelial and endothelial interactions, and immune response regulation. Therefore, this study evaluates ALCAM levels as a biomarker of cervical occult metastasis in glottic LSCC patients from the Head and Neck Surgery Division of the Instituto Nacional de Câncer (Brazil), and associates this protein levels with clinical and pathological features and patient outcomes. This study included 111 glottic LSCC patients cN0, cT2/T3, who underwent surgery with curative intent with neck dissection. All patients were followed for at least five years. The Institutional Ethics Committee approved the study. At diagnosis, 82% of patients showed impaired vocal cords, with clinical TNM stages distributed as 40.54% cT2 and 59.46% cT3. All underwent primary surgical therapy, achieving negative margins in 83.78% of cases. Postoperative findings classified tumors as pT1 (7.21%), pT2 (23.42%), pT3 (52.25%), and pT4 (17.12%); 68.47% were pTNM stage III or IV, and 85.59% were moderately differentiated. Anterior commissure involvement was found in 59.46% of cases, supraglottic extension in 45.05%, and thyroid cartilage invasion in 21.62%. Occult lymph node metastases were observed in 18.92% of patients, and 36% showed high ALCAM levels. Tumor recurrence occurred in 13 patients (11.71%), including seven local, three regional, and three distant relapses. The median overall survival was 74.4 months. Cervical occult metastasis was associated with high ALCAM levels (p=0.00063), and subglottic involvement remained significantly associated with occult metastasis (p=0.015). Overall survival analyses showed that high ALCAM levels (p=0.023), cervical occult metastasis (p<0.001), age ≥61 years (p=0.007), impaired vocal cords (p=0.003), pT3/4 classification (p=0.04), tumor stage III/IV (p=0.04), supraglottic involvement (p=0.034), subglottic involvement (p=0.021), and transglottic tumor presence (p=0.009) were associated with worse prognosis. In our study, we found that high ALCAM level is a biomarker of cervical occult metastasis in glottic LSCC and affects patients' prognosis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153422--></body></html>"
    },
    {
      "uid": "P179",
      "content_id": "154341",
      "abstract_number": "P179",
      "poster_number": "P179",
      "title": "Clinical Behavior and Treatment Patterns of Moderately Differentiated Laryngeal Neuroendocrine Carcinoma: A Systematic Review",
      "summary": "Neuroendocrine carcinomas of the larynx represent a rare malignancy that can be aggressive. In this pooled cohort of MDNECL cases, treatment approaches varied considerably, and mortality differed significantly by treatment modality. The increased mortality in patients treated with adjuvant or salvage chemoradiation likely reflects more advanced disease burden at the time of treatment. Although the optimal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154341",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chloe E Derocher, BSE",
      "presenter": "Chloe E Derocher, BSE",
      "authors": "Ashton Huppert Steed, BS 1 ; Chloe E Derocher, BSE 1 ; Ameya A Jategaonkar, MD 2",
      "normalized_authors": [
        "Ashton Huppert Steed",
        "Chloe E Derocher, BSE",
        "Ameya A Jategaonkar"
      ],
      "affiliations": [
        "University of Arizona College of Medicine-Phoenix",
        "Department of ENT and Skull Base Surgery, Barrow Neurological Institute"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine-Phoenix",
        "Department of ENT and Skull Base Surgery, Barrow Neurological Institute"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 372,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ashton Huppert Steed, BS 1 ; Chloe E Derocher, BSE 1 ; Ameya A Jategaonkar, MD 2",
        "Affiliations": "1 University of Arizona College of Medicine-Phoenix; 2 Department of ENT and Skull Base Surgery, Barrow Neurological Institute",
        "Introduction": "Neuroendocrine carcinomas of the larynx are rare malignancies, and available literature consists largely of small case series and isolated reports. Within this group, the intermediate-grade subtype known historically as atypical carcinoid and more recently as moderately differentiated neuroendocrine carcinoma (MDNECL) remains particularly understudied, with limited guidance on optimal management. Primary surgical resection is generally favored when feasible, although the use of adjuvant chemoradiation varies widely. This systematic review aims to consolidate reported clinical features, treatment approaches, and outcomes to better characterize contemporary practice patterns for MDNECL.",
        "Methods": "A PRISMA-guided literature search identified studies reporting histopathologically confirmed atypical carcinoid/MDNECL. Studies lacking treatment or outcome data, those involving non-laryngeal tumors, or reporting alternative neuroendocrine subtypes were excluded. Two independent reviewers screened 687 abstracts and 107 full texts, yielding 39 studies for inclusion. Descriptive statistics and comparative analyses were performed using chi-square and Fisher’s exact tests.",
        "Results": "A total of 120 patients with MDNECL were identified. The mean age was 61.4 years, 69.2% were male, and 81.1% had a smoking history. Common presenting symptoms included hoarseness, dysphagia, globus sensation, sore throat, and odynophagia. Treatment modalities included primary surgery alone (n=41), surgery with adjuvant chemoradiation (n=38), primary chemoradiation (n=23), and initial surgery with subsequent chemoradiation for recurrence or metastasis (n=17). Mortality differed significantly by treatment approach: primary chemoradiation demonstrated the highest mortality (65.2%), which was significantly worse than primary surgery alone (24.4%, p=0.003). Surgery with adjuvant chemoradiation showed a 47.4% mortality rate, also significantly worse than surgery alone (p=0.04), while salvage chemoradiation following initial surgery had a mortality rate of 52.9%. Overall mortality across the cohort was 43.3%. The most frequently reported metastatic sites were cervical lymph nodes, skin or subcutaneous tissue, lungs, liver, and bone",
        "Conclusion": "Neuroendocrine carcinomas of the larynx represent a rare malignancy that can be aggressive. In this pooled cohort of MDNECL cases, treatment approaches varied considerably, and mortality differed significantly by treatment modality. The increased mortality in patients treated with adjuvant or salvage chemoradiation likely reflects more advanced disease burden at the time of treatment. Although the optimal treatment regimen remains unclear, these findings reinforce that early surgical management may offer more favorable outcomes for MDNECL."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Behavior and Treatment Patterns of Moderately Differentiated Laryngeal Neuroendocrine Carcinoma: A Systematic Review</span>. Ashton Huppert Steed, BS<sup>1</sup>; <u>Chloe E Derocher, BSE</u><sup>1</sup>; Ameya A Jategaonkar, MD<sup>2</sup>. <sup>1</sup>University of Arizona College of Medicine-Phoenix; <sup>2</sup>Department of ENT and Skull Base Surgery, Barrow Neurological Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Neuroendocrine carcinomas of the larynx are rare malignancies, and available literature consists largely of small case series and isolated reports. Within this group, the intermediate-grade subtype known historically as atypical carcinoid and more recently as moderately differentiated neuroendocrine carcinoma (MDNECL) remains particularly understudied, with limited guidance on optimal management. Primary surgical resection is generally favored when feasible, although the use of adjuvant chemoradiation varies widely. This systematic review aims to consolidate reported clinical features, treatment approaches, and outcomes to better characterize contemporary practice patterns for MDNECL.</p>\n\n<p><strong>Methods: </strong>A PRISMA-guided literature search identified studies reporting histopathologically confirmed atypical carcinoid/MDNECL. Studies lacking treatment or outcome data, those involving non-laryngeal tumors, or reporting alternative neuroendocrine subtypes were excluded. Two independent reviewers screened 687 abstracts and 107 full texts, yielding 39 studies for inclusion. Descriptive statistics and comparative analyses were performed using chi-square and Fisher’s exact tests.</p>\n\n<p><strong>Results: </strong>A total of 120 patients with MDNECL were identified. The mean age was 61.4 years, 69.2% were male, and 81.1% had a smoking history. Common presenting symptoms included hoarseness, dysphagia, globus sensation, sore throat, and odynophagia. Treatment modalities included primary surgery alone (n=41), surgery with adjuvant chemoradiation (n=38), primary chemoradiation (n=23), and initial surgery with subsequent chemoradiation for recurrence or metastasis (n=17). Mortality differed significantly by treatment approach: primary chemoradiation demonstrated the highest mortality (65.2%), which was significantly worse than primary surgery alone (24.4%, p=0.003). Surgery with adjuvant chemoradiation showed a 47.4% mortality rate, also significantly worse than surgery alone (p=0.04), while salvage chemoradiation following initial surgery had a mortality rate of 52.9%. Overall mortality across the cohort was 43.3%. The most frequently reported metastatic sites were cervical lymph nodes, skin or subcutaneous tissue, lungs, liver, and bone</p>\n\n<p><strong>Conclusion: </strong>Neuroendocrine carcinomas of the larynx represent a rare malignancy that can be aggressive. In this pooled cohort of MDNECL cases, treatment approaches varied considerably, and mortality differed significantly by treatment modality. The increased mortality in patients treated with adjuvant or salvage chemoradiation likely reflects more advanced disease burden at the time of treatment. Although the optimal treatment regimen remains unclear, these findings reinforce that early surgical management may offer more favorable outcomes for MDNECL.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154341--></body></html>"
    },
    {
      "uid": "P180",
      "content_id": "154330",
      "abstract_number": "P180",
      "poster_number": "P180",
      "title": "Aggressive Neck Recurrence Following Narrow Field Radiation Treatment in Early Stage Glottic Cancer: A Single Institution Report",
      "summary": "Unlike the typical failure pattern in early stage glottic SCC, the patients described here experienced rapid and aggressive regional metastasis despite initial primary-site control. Such early disease progression following definitive RT is exceedingly rare in this population and represents a distinct clinical phenotype with salvage potential. These cases underscore the importance of heightened vigilance during...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154330",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David M Weatherford, MD",
      "presenter": "David M Weatherford, MD",
      "authors": "David M Weatherford, MD ; Justin Soffer, MD; Jacob Seals, BS; John Gleysteen, MD; C",
      "normalized_authors": [
        "David M Weatherford",
        "Justin Soffer",
        "Jacob Seals",
        "John Gleysteen"
      ],
      "affiliations": [
        "Burton Wood, MD. University of Tennessee Health Science Center - Memphis"
      ],
      "normalized_institutions": [
        "Burton Wood, MD. University of Tennessee Health Science Center - Memphis"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case 1",
        "Case 2",
        "Case 3",
        "Conclusion"
      ],
      "sections": {
        "Authors": "David M Weatherford, MD ; Justin Soffer, MD; Jacob Seals, BS; John Gleysteen, MD; C",
        "Affiliations": "Burton Wood, MD. University of Tennessee Health Science Center - Memphis",
        "Introduction": "Early-stage glottic squamous cell carcinoma (SCC) has an excellent prognosis when treated with definitive radiotherapy (RT) or transoral microsurgery, with both modalities achieving comparable overall survival rates, excellent local control, and low rates of regional or distant metastasis. Most treatment failures occur at the primary site, and nodal involvement is particularly uncommon in T1–T2N0 disease such that elective neck management is generally not indicated. When neck recurrence does arise, it may present insidiously, progress rapidly, and limit opportunities for salvage. This case series describes three patients representing the small but clinically important subset of early stage glottic SCC who developed bulky, aggressive neck disease following laryngeal radiation.",
        "Case 1": "A 58-year-old former smoker with T2N0M0 glottic SCC completed definitive RT with an initial complete response. Five months later, he developed right parotid/upper neck swelling initially attributed to sialadenitis by his primary ENT. The swelling progressed, and subsequent FNA revealed SCC within the right neck. He was referred to clinic but ultimately presented to the ED with rapidly progressive neck disease that led to extrinsic compression of the airway. Radical neck dissection was attempted but aborted intra-operatively secondary to diffuse soft tissue metastasis throughout the right neck and near circumferential involvement of the carotid. Laryngoscopy showed no evidence of disease in the larynx. The patient started systemic therapy but continued to progress prompting awake tracheostomy. He is currently enrolled in an immunotherapeutic clinical trial with complete clinical response.",
        "Case 2": "A 63-year-old patient with cT1bN0M0 glottic SCC developed a new right neck mass with worsening dysphagia several months after competing definitive RT. FNA confirmed p16-negative metastatic SCC prompting a salvage radical neck dissection with pathology revealing significant extranodal extension and nodal replacement by tumor. Adjuvant neck chemoradiation was recommended, but the patient did not attend recommended follow up visits. Within weeks he developed recurrent necrotic right-sided lymphadenopathy, again confirmed as SCC on presentation to the ED for progressive dysphagia. Examination revealed new glottic and vallecular lesions suspicious for multi-site mucosal recurrence. Due to rapid, widespread progression, he elected hospice care.",
        "Case 3": "A 69-year-old male with multiple prior cutaneous SCCs was treated with RT for T1bN0M0 glottic SCC. Post-treatment PET/CT showed good primary-site response but revealed a new left level III nodal metastasis. He underwent left modified radical neck dissection with pectoralis flap reconstruction followed by reirradiation. Subsequent PET/CT demonstrated hypermetabolic bilateral pulmonary nodules, though multiple lung biopsies were non-diagnostic. Surveillance laryngoscopy showed substantial but benign-appearing arytenoid edema, without evidence of recurrent tumor at the primary site. He is currently engaged in close surveillance with short interval imaging.",
        "Conclusion": "Unlike the typical failure pattern in early stage glottic SCC, the patients described here experienced rapid and aggressive regional metastasis despite initial primary-site control. Such early disease progression following definitive RT is exceedingly rare in this population and represents a distinct clinical phenotype with salvage potential. These cases underscore the importance of heightened vigilance during early post-treatment surveillance, recognizing that even early stage glottic tumors can demonstrate unexpectedly aggressive behavior."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Aggressive Neck Recurrence Following Narrow Field Radiation Treatment in Early Stage Glottic Cancer: A Single Institution Report</span>. <u>David M Weatherford, MD</u>; Justin Soffer, MD; Jacob Seals, BS; John Gleysteen, MD; C. Burton Wood, MD. University of Tennessee Health Science Center - Memphis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Early-stage glottic squamous cell carcinoma (SCC) has an excellent prognosis when treated with definitive radiotherapy (RT) or transoral microsurgery, with both modalities achieving comparable overall survival rates, excellent local control, and low rates of regional or distant metastasis. Most treatment failures occur at the primary site, and nodal involvement is particularly uncommon in T1–T2N0 disease such that elective neck management is generally not indicated. When neck recurrence does arise, it may present insidiously, progress rapidly, and limit opportunities for salvage. This case series describes three patients representing the small but clinically important subset of early stage glottic SCC who developed bulky, aggressive neck disease following laryngeal radiation. </p>\n\n<p><strong>Case 1:</strong> A 58-year-old former smoker with T2N0M0 glottic SCC completed definitive RT with an initial complete response. Five months later, he developed right parotid/upper neck swelling initially attributed to sialadenitis by his primary ENT. The swelling progressed, and subsequent FNA revealed SCC within the right neck. He was referred to clinic but ultimately presented to the ED with rapidly progressive neck disease that led to extrinsic compression of the airway. Radical neck dissection was attempted but aborted intra-operatively secondary to diffuse soft tissue metastasis throughout the right neck and near circumferential involvement of the carotid. Laryngoscopy showed no evidence of disease in the larynx. The patient started systemic therapy but continued to progress prompting awake tracheostomy. He is currently enrolled in an immunotherapeutic clinical trial with complete clinical response. </p>\n\n<p><strong>Case 2:</strong> A 63-year-old patient with cT1bN0M0 glottic SCC developed a new right neck mass with worsening dysphagia several months after competing definitive RT. FNA confirmed p16-negative metastatic SCC prompting a salvage radical neck dissection with pathology revealing significant extranodal extension and nodal replacement by tumor. Adjuvant neck chemoradiation was recommended, but the patient did not attend recommended follow up visits. Within weeks he developed recurrent necrotic right-sided lymphadenopathy, again confirmed as SCC on presentation to the ED for progressive dysphagia. Examination revealed new glottic and vallecular lesions suspicious for multi-site mucosal recurrence. Due to rapid, widespread progression, he elected hospice care. </p>\n\n<p><strong>Case 3:</strong> A 69-year-old male with multiple prior cutaneous SCCs was treated with RT for T1bN0M0 glottic SCC. Post-treatment PET/CT showed good primary-site response but revealed a new left level III nodal metastasis. He underwent left modified radical neck dissection with pectoralis flap reconstruction followed by reirradiation. Subsequent PET/CT demonstrated hypermetabolic bilateral pulmonary nodules, though multiple lung biopsies were non-diagnostic. Surveillance laryngoscopy showed substantial but benign-appearing arytenoid edema, without evidence of recurrent tumor at the primary site. He is currently engaged in close surveillance with short interval imaging. </p>\n\n<p><strong>Conclusion:</strong> Unlike the typical failure pattern in early stage glottic SCC, the patients described here experienced rapid and aggressive regional metastasis despite initial primary-site control. Such early disease progression following definitive RT is exceedingly rare in this population and represents a distinct clinical phenotype with salvage potential. These cases underscore the importance of heightened vigilance during early post-treatment surveillance, recognizing that even early stage glottic tumors can demonstrate unexpectedly aggressive behavior. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154330--></body></html>"
    },
    {
      "uid": "P182",
      "content_id": "154707",
      "abstract_number": "P182",
      "poster_number": "P182",
      "title": "Transoral Robotic Surgery in the Glottis & Subglottis: A Scoping Review",
      "summary": "This scoping review evaluates the literature on the use of TORS in the glottis and subglottis, and in doing so characterizes the state of the field. Although endolaryngeal TORS is feasible, safe, and effective, ergonomic constraints of multi-port systems and high cost of adoption limit implementation. Future research should prioritize larger cohort studies, direct comparisons with conventional surgical modalities...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154707",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carolyn J Khoury, BA",
      "presenter": "Carolyn J Khoury, BA",
      "authors": "Carolyn J Khoury, BA 1 ; Serena Pu, MD 1 ; Ted Kuke, BS 1 ; Bharat Panuganti, MD 2 ; Harishanker Jeyarajan, MD 3 ; Ryan Jackson, MD 2 ; Diana N Kirke, MD, MPhil 1",
      "normalized_authors": [
        "Carolyn J Khoury",
        "Serena Pu",
        "Ted Kuke",
        "Bharat Panuganti",
        "Harishanker Jeyarajan",
        "Ryan Jackson",
        "Diana N Kirke, MPhil"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of Alabama at Birmingham Heersink School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of Alabama at Birmingham Heersink School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 487,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Carolyn J Khoury, BA 1 ; Serena Pu, MD 1 ; Ted Kuke, BS 1 ; Bharat Panuganti, MD 2 ; Harishanker Jeyarajan, MD 3 ; Ryan Jackson, MD 2 ; Diana N Kirke, MD, MPhil 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai; 2 Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine; 3 Department of Otolaryngology - Head and Neck Surgery, University of Alabama at Birmingham Heersink School of Medicine",
        "Introduction": "Transoral robotic surgery (TORS) is an established minimally invasive approach for upper airway surgery. Most literature on TORS focuses on oropharyngeal applications, though hypopharyngeal and supraglottic applications are also well-described. TORS has been successfully employed in the treatment of glottic and subglottic lesions, though these most distal applications of TORS are not widely studied. This scoping review characterizes the size and scope of the body of literature on the use of TORS in the glottis and subglottis.",
        "Methods": "This review followed the PRISMA-ScR guidelines for scoping review. Eligible studies included peer-reviewed English publications which reference TORS in relation to the larynx, glottis, or subglottis. Literature discussing the supraglottis without reference to glottis or subglottis were excluded. A search string was developed accordingly and reviewed by a medical librarian. Electronic databases searched include Medline, Embase, Scopus, and Web of Science. References were imported to Covidence, where two independent study members reviewed each article and a third reviewer resolved any discrepancies.",
        "Results": "100 publications met inclusion criteria, encompassing preclinical robot development, feasibility studies, case series, retrospective cohort studies, and review articles. The earliest and most commonly used robots for endolaryngeal TORS were the da Vinci Si, X, and Xi systems. More recent platforms, such as the da Vinci SP and the now defunct Medrobotics Flex, improved ergonomics for the confined upper airway through single-port access. Across studies, both platforms were reported as feasible, safe, and effective for the resection of glottic and subglottic lesions. Parallel to these advances, several groups have developed flexible continuum robots aimed at distal laryngeal access, though none progressed beyond preclinical testing.",
        "Abstract": "A wide variety of benign and malignant laryngeal pathologies have been treated with TORS across pediatric, adult, and elderly populations without unique complications. Strong oncologic and functional outcomes are reported for early (T1-T2) glottic cancers, including anterior commissure involvement, as well as more advanced tumors (T3-T4). Operative exposure assessment with the FK retractor have become standard in determining TORS candidacy however there were still limitations secondary to base of tongue and epiglottic prolapse necessitating at times partial epiglottic resection and thus increasing morbidity. Most transoral procedures were completed successfully, though some procedures required conversion to open due to poor exposure. Large-cohort high-powered studies comparing endolaryngeal TORS to the standard-of-care remain scarce, and existing clinical cohorts are generally small, limiting the ability to draw definitive comparisons between robotic and non-robotic techniques. Furthermore, learning-curve effects may cause early or short-term studies to underestimate the efficiency and effectiveness of TORS.",
        "Conclusions": "This scoping review evaluates the literature on the use of TORS in the glottis and subglottis, and in doing so characterizes the state of the field. Although endolaryngeal TORS is feasible, safe, and effective, ergonomic constraints of multi-port systems and high cost of adoption limit implementation. Future research should prioritize larger cohort studies, direct comparisons with conventional surgical modalities and improvements in access, to establish more robust evidence on the role of TORS in the glottis and subglottis."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transoral Robotic Surgery in the Glottis & Subglottis: A Scoping Review</span>. <u>Carolyn J Khoury, BA</u><sup>1</sup>; Serena Pu, MD<sup>1</sup>; Ted Kuke, BS<sup>1</sup>; Bharat Panuganti, MD<sup>2</sup>; Harishanker Jeyarajan, MD<sup>3</sup>; Ryan Jackson, MD<sup>2</sup>; Diana N Kirke, MD, MPhil<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine; <sup>3</sup>Department of Otolaryngology - Head and Neck Surgery, University of Alabama at Birmingham Heersink School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Transoral robotic surgery (TORS) is an established minimally invasive approach for upper airway surgery. Most literature on TORS focuses on oropharyngeal applications, though hypopharyngeal and supraglottic applications are also well-described. TORS has been successfully employed in the treatment of glottic and subglottic lesions, though these most distal applications of TORS are not widely studied. This scoping review characterizes the size and scope of the body of literature on the use of TORS in the glottis and subglottis.</p>\n\n<p><strong>Methods: </strong>This review followed the PRISMA-ScR guidelines for scoping review. Eligible studies included peer-reviewed English publications which reference TORS in relation to the larynx, glottis, or subglottis. Literature discussing the supraglottis without reference to glottis or subglottis were excluded. A search string was developed accordingly and reviewed by a medical librarian. Electronic databases searched include Medline, Embase, Scopus, and Web of Science. References were imported to Covidence, where two independent study members reviewed each article and a third reviewer resolved any discrepancies.</p>\n\n<p><strong>Results:</strong> 100 publications met inclusion criteria, encompassing preclinical robot development, feasibility studies, case series, retrospective cohort studies, and review articles. The earliest and most commonly used robots for endolaryngeal TORS were the da Vinci Si, X, and Xi systems. More recent platforms, such as the da Vinci SP and the now defunct Medrobotics Flex, improved ergonomics for the confined upper airway through single-port access. Across studies, both platforms were reported as feasible, safe, and effective for the resection of glottic and subglottic lesions. Parallel to these advances, several groups have developed flexible continuum robots aimed at distal laryngeal access, though none progressed beyond preclinical testing. </p>\n\n<p>A wide variety of benign and malignant laryngeal pathologies have been treated with TORS across pediatric, adult, and elderly populations without unique complications. Strong oncologic and functional outcomes are reported for early (T1-T2) glottic cancers, including anterior commissure involvement, as well as more advanced tumors (T3-T4). Operative exposure assessment with the FK retractor have become standard in determining TORS candidacy however there were still limitations secondary to base of tongue and epiglottic prolapse necessitating at times partial epiglottic resection and thus increasing morbidity. Most transoral procedures were completed successfully, though some procedures required conversion to open due to poor exposure.</p>\n\n<p>Large-cohort high-powered studies comparing endolaryngeal TORS to the standard-of-care remain scarce, and existing clinical cohorts are generally small, limiting the ability to draw definitive comparisons between robotic and non-robotic techniques. Furthermore, learning-curve effects may cause early or short-term studies to underestimate the efficiency and effectiveness of TORS.</p>\n\n<p><strong>Conclusions:</strong> This scoping review evaluates the literature on the use of TORS in the glottis and subglottis, and in doing so characterizes the state of the field. Although endolaryngeal TORS is feasible, safe, and effective, ergonomic constraints of multi-port systems and high cost of adoption limit implementation. Future research should prioritize larger cohort studies, direct comparisons with conventional surgical modalities and improvements in access, to establish more robust evidence on the role of TORS in the glottis and subglottis. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154707--></body></html>"
    },
    {
      "uid": "P183",
      "content_id": "153624",
      "abstract_number": "P183",
      "poster_number": "P183",
      "title": "Successful Treatment of Carotid Blowout Syndrome Secondary to Radiation Necrosis of the Hypopharynx: A Case Report",
      "summary": "Chemoradiotherapy is a commonly used and highly effective treatment for head and neck cancer. Despite its success in treating the primary tumor and metastatic lymph nodes, high-dose radiation therapy often leads to destructive side effects in the surrounding tissues, known as radiation necrosis. To date, only a few cases of radiation necrosis of the hypopharynx have been reported in the literature. Even more...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153624",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Keisuke Nakajima",
      "presenter": "Keisuke Nakajima",
      "authors": "Keisuke Nakajima ; Akihisa Wada; Soichiro Matsuo; Mayu Shigeyama; Seiya Goto; Naoki Nishio",
      "normalized_authors": [
        "Keisuke Nakajima",
        "Akihisa Wada",
        "Soichiro Matsuo",
        "Mayu Shigeyama",
        "Seiya Goto",
        "Naoki Nishio"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology, Nagoya University Hospital"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology, Nagoya University Hospital"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 338,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case",
        "Discussion"
      ],
      "sections": {
        "Authors": "Keisuke Nakajima ; Akihisa Wada; Soichiro Matsuo; Mayu Shigeyama; Seiya Goto; Naoki Nishio",
        "Affiliations": "Department of Otorhinolaryngology, Nagoya University Hospital",
        "Background": "Chemoradiotherapy is a commonly used and highly effective treatment for head and neck cancer. Despite its success in treating the primary tumor and metastatic lymph nodes, high-dose radiation therapy often leads to destructive side effects in the surrounding tissues, known as radiation necrosis. To date, only a few cases of radiation necrosis of the hypopharynx have been reported in the literature. Even more rarely documented is the coexistence of carotid blowout syndrome (CBS) with radiation necrosis of the hypopharynx.",
        "Case": "A 77-year-old male presented with cT2N2bM0 left hypopharyngeal squamous cell carcinoma and was treated with definitive cisplatin-based chemoradiotherapy (total cisplatin dose of 240 mg/m², radiotherapy 70 Gy in 35 fractions). Six months after completing chemoradiotherapy, the patient developed a sore throat and worsening dysphagia. Flexible fiberoptic endoscopy revealed mucosal edema and an ulcer in the hypopharynx. Biopsy showed severe mucosal inflammation without evidence of malignancy. Subsequently, the patient experienced severe dyspnea and swallowing dysfunction, necessitating emergent tracheotomy and gastrostomy tube placement. Given the suspicion of radiation-induced necrosis of the hypopharynx, hyperbaric oxygen therapy was initiated. During follow-up, the patient was referred to our hospital due to oral bleeding and was admitted on day X. On the morning of day X+1, the patient suffered a critical and massive oral bleeding. Contrast-enhanced CT revealed a pseudoaneurysm and rupture of the left common carotid artery. The diagnosis was CBS secondary to radiation necrosis of the hypopharynx. The patient was transferred to the operating room with adequate carotid artery compression and underwent stent graft insertion by vascular surgeons. On day X+10, local debridement of necrotic tissue and total pharyngolaryngoesophagostomy with free jejunum transfer were performed. Final pathology demonstrated severe inflammation and necrosis without malignancy. The postoperative course was uneventful. On day X+43, the patient resumed oral intake and is currently undergoing swallowing rehabilitation.",
        "Discussion": "In cases of critical complications, such as CBS related to radiation necrosis, it is essential to promptly share the treatment history within a multidisciplinary team and to perform appropriate surgical interventions, including flap transfer when necessary."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Successful Treatment of Carotid Blowout Syndrome Secondary to Radiation Necrosis of the Hypopharynx: A Case Report</span>. <u>Keisuke Nakajima</u>; Akihisa Wada; Soichiro Matsuo; Mayu Shigeyama; Seiya Goto; Naoki Nishio. Department of Otorhinolaryngology, Nagoya University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Chemoradiotherapy is a commonly used and highly effective treatment for head and neck cancer. Despite its success in treating the primary tumor and metastatic lymph nodes, high-dose radiation therapy often leads to destructive side effects in the surrounding tissues, known as radiation necrosis. To date, only a few cases of radiation necrosis of the hypopharynx have been reported in the literature. Even more rarely documented is the coexistence of carotid blowout syndrome (CBS) with radiation necrosis of the hypopharynx. </p>\n\n<p><strong>Case: </strong>A 77-year-old male presented with cT2N2bM0 left hypopharyngeal squamous cell carcinoma and was treated with definitive cisplatin-based chemoradiotherapy (total cisplatin dose of 240 mg/m², radiotherapy 70 Gy in 35 fractions). Six months after completing chemoradiotherapy, the patient developed a sore throat and worsening dysphagia. Flexible fiberoptic endoscopy revealed mucosal edema and an ulcer in the hypopharynx. Biopsy showed severe mucosal inflammation without evidence of malignancy. Subsequently, the patient experienced severe dyspnea and swallowing dysfunction, necessitating emergent tracheotomy and gastrostomy tube placement. Given the suspicion of radiation-induced necrosis of the hypopharynx, hyperbaric oxygen therapy was initiated. During follow-up, the patient was referred to our hospital due to oral bleeding and was admitted on day X. On the morning of day X+1, the patient suffered a critical and massive oral bleeding. Contrast-enhanced CT revealed a pseudoaneurysm and rupture of the left common carotid artery. The diagnosis was CBS secondary to radiation necrosis of the hypopharynx. The patient was transferred to the operating room with adequate carotid artery compression and underwent stent graft insertion by vascular surgeons. On day X+10, local debridement of necrotic tissue and total pharyngolaryngoesophagostomy with free jejunum transfer were performed. Final pathology demonstrated severe inflammation and necrosis without malignancy. The postoperative course was uneventful. On day X+43, the patient resumed oral intake and is currently undergoing swallowing rehabilitation. </p>\n\n<p><strong>Discussion: </strong>In cases of critical complications, such as CBS related to radiation necrosis, it is essential to promptly share the treatment history within a multidisciplinary team and to perform appropriate surgical interventions, including flap transfer when necessary. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153624--></body></html>"
    },
    {
      "uid": "P184",
      "content_id": "154520",
      "abstract_number": "P184",
      "poster_number": "P184",
      "title": "PROGNOSTIC FACTORS FOR STAGE T3N0M0 GLOTTIC SQUAMOUS CELL CARCINOMA TREATED EXCLUSIVELY BY TYPE IIA OPEN PARTIAL HORIZONTAL LARYNGECTOMY",
      "summary": "Infiltrative/ulcerative tumors and high ALCAM expression were associated with aggressive behavior in T3N0M0 glottic CCEL tumors treated exclusively with type IIa OPHL.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154520",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emilson de Queiroz Freitas",
      "presenter": "Emilson de Queiroz Freitas",
      "authors": "Eduardo Calheiros de Moraes; Emilson de Queiroz Freitas ; Luiza Seganfredo Mainardi; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Izabella Costa Santos; Fernando Luiz Dias",
      "normalized_authors": [
        "Eduardo Calheiros de Moraes",
        "Emilson de Queiroz Freitas",
        "Luiza Seganfredo Mainardi",
        "Pedro Nicolau-Neto",
        "Luis Felipe Ribeiro Pinto",
        "Izabella Costa Santos",
        "Fernando Luiz Dias"
      ],
      "affiliations": [
        "Brazilian National Cancer Institute"
      ],
      "normalized_institutions": [
        "Brazilian National Cancer Institute"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 237,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eduardo Calheiros de Moraes; Emilson de Queiroz Freitas ; Luiza Seganfredo Mainardi; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Izabella Costa Santos; Fernando Luiz Dias",
        "Affiliations": "Brazilian National Cancer Institute",
        "Introduction": "The curative treatment for advanced glottic squamous cell carcinoma (SCC) is total laryngectomy, but this results in functional loss. Open type IIa partial horizontal laryngectomy (OPHL type IIa) preserves function in selected cases of advanced squamous cell carcinoma of the larynx (SCLC) (T3), with disease-free survival of 70-80% at five years and recurrence of 20-30%. Overexpression of the ALCAM (Activated Leukocyte Cell Adhesion Molecule) protein is considered an independent biomarker of poor prognosis.",
        "Objectives": "To evaluate prognostic factors in patients with T3N0M0 glottic SCLC treated exclusively with OPHL IIa.",
        "Methods": "Retrospective observational study to evaluate demographic, clinical, pathological factors, and ALCAM expression in patients with T3N0M0 glottic SCC undergoing exclusively type IIa OPHL therapy at INCA (1995 to 2019), without radiotherapy. Fifty-nine patients were included, with viable immunohistochemical analysis in 50.",
        "Results": "Twenty-eight patients (56%) showed ALCAM expression. Considering the cutoff point of 20% ALCAM protein in tumor cells, according to a study published by the National Cancer Institute (INCA, RJ-Brazil) by NICOLAU-NETO et al., 2020, 30 patients (60%) showed low/no expression and 20 (40%) showed high expression. Infiltrative/ulcerated tumors (HR=5.48, p=0.018) and high ALCAM expression (HR=4.71, p=0.036) were factors associated with a worse prognosis. Overall and disease-free survival at 5 years were 84% and 89%, respectively.",
        "Conclusion": "Infiltrative/ulcerative tumors and high ALCAM expression were associated with aggressive behavior in T3N0M0 glottic CCEL tumors treated exclusively with type IIa OPHL."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>PROGNOSTIC FACTORS FOR STAGE T3N0M0 GLOTTIC SQUAMOUS CELL CARCINOMA TREATED EXCLUSIVELY BY TYPE IIA OPEN PARTIAL HORIZONTAL LARYNGECTOMY</span>. Eduardo Calheiros de Moraes; <u>Emilson de Queiroz Freitas</u>; Luiza Seganfredo Mainardi; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Izabella Costa Santos; Fernando Luiz Dias. Brazilian National Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> The curative treatment for advanced glottic squamous cell carcinoma (SCC) is total laryngectomy, but this results in functional loss. Open type IIa partial horizontal laryngectomy (OPHL type IIa) preserves function in selected cases of advanced squamous cell carcinoma of the larynx (SCLC) (T3), with disease-free survival of 70-80% at five years and recurrence of 20-30%. Overexpression of the ALCAM (Activated Leukocyte Cell Adhesion Molecule) protein is considered an independent biomarker of poor prognosis.</p>\n\n<p><strong>Objectives: </strong>To evaluate prognostic factors in patients with T3N0M0 glottic SCLC treated exclusively with OPHL IIa.</p>\n\n<p><strong>Methods:</strong> Retrospective observational study to evaluate demographic, clinical, pathological factors, and ALCAM expression in patients with T3N0M0 glottic SCC undergoing exclusively type IIa OPHL therapy at INCA (1995 to 2019), without radiotherapy. Fifty-nine patients were included, with viable immunohistochemical analysis in 50.</p>\n\n<p><strong>Results:</strong> Twenty-eight patients (56%) showed ALCAM expression. Considering the cutoff point of 20% ALCAM protein in tumor cells, according to a study published by the National Cancer Institute (INCA, RJ-Brazil) by NICOLAU-NETO et al., 2020, 30 patients (60%) showed low/no expression and 20 (40%) showed high expression. Infiltrative/ulcerated tumors (HR=5.48, p=0.018) and high ALCAM expression (HR=4.71, p=0.036) were factors associated with a worse prognosis. Overall and disease-free survival at 5 years were 84% and 89%, respectively.</p>\n\n<p><strong>Conclusion:</strong> Infiltrative/ulcerative tumors and high ALCAM expression were associated with aggressive behavior in T3N0M0 glottic CCEL tumors treated exclusively with type IIa OPHL.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154520--></body></html>"
    },
    {
      "uid": "P185",
      "content_id": "151850",
      "abstract_number": "P185",
      "poster_number": "P185",
      "title": "Rosai-Dorfman Disease Presenting as a Subglottic Mass",
      "summary": "In conclusion we present a 59-year-old female with worsening airway symptoms who was shown to have Rosai-Dorfman Disease with isolated subglottic involvement. Her symptoms improved following debulking surgery, and she was discharged home in good condition. She was decannulated one month after discharge.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151850",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ameya Asarkar, MD",
      "presenter": "Ameya Asarkar, MD",
      "authors": "Grace Wester, BS 1 ; Joel Badders, MD 2 ; Ameya Asarkar, MD 2",
      "normalized_authors": [
        "Grace Wester",
        "Joel Badders",
        "Ameya Asarkar"
      ],
      "affiliations": [
        "Louisiana State University Shreveport School of Medicine",
        "Department of Otolaryngology, Louisiana State University Health Shreveport"
      ],
      "normalized_institutions": [
        "Louisiana State University Shreveport School of Medicine",
        "Department of Otolaryngology, Louisiana State University Health Shreveport"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151850/Screen%20Shot%202025-10-18%20at%2010_48_07%20AM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151850/Screen%20Shot%202025-10-18%20at%2010_48_07%20AM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151850"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 412,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Search Methods & Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Grace Wester, BS 1 ; Joel Badders, MD 2 ; Ameya Asarkar, MD 2",
        "Affiliations": "1 Louisiana State University Shreveport School of Medicine; 2 Department of Otolaryngology, Louisiana State University Health Shreveport",
        "Introduction": "Rosai-Dorfman Disease (RDD) is an uncommon benign lymphoproliferative disorder of sinus histiocytes, usually causing massive lymphadenopathy (1). Most cases present in childhood and young adulthood (2). Approximately 50% of patients will have extranodal involvement, with the most common sites being skin, nasal cavity, bone, orbital tissue, and the central nervous system, salivary glands, and tracheobronchial tree (1,3). We present an unusual case of Rosai-Dorfman Disease presenting with isolated subglottic involvement.",
        "Case Presentation": "A 59-year-old African American female presented to the ED from the clinic for concerns of worsening dyspnea and biphasic stridor. She had a months-long history of worsening shortness of breath, dyspnea on exertion, and stridor. The patient was being followed by pulmonology, where she was prescribed Symbicort and Albuterol as needed. Upon arrival at the emergency department, she was given Prednisone, Duonebs, and racemic epinephrine nebulization with minimal improvement. ENT was consulted, and flexible laryngoscopy showed an exophytic subglottic mass obstructing greater than 50% of the subglottis (Figure 1). She was rush-rolled to the OR for awake tracheostomy, panendoscopy with biopsies, and mass debulking. The post-operative course was complicated by hospital-acquired pneumonia and Ogilvie syndrome. The pathology results came back positive for Rosai-Dorfman Disease. She was deemed stable and discharged home on daily nebulized budesonide and as-needed DuoNebs. She was subsequently decannulated one month after discharge from the hospital.",
        "Search Methods & Results": "A literature review was performed on PubMed using the terms “Rosai-Dorfman” AND “subglottis OR larynx”. Extranodal Rosai-Dorfman disease isolated to the subglottis is a very uncommon presentation of the disease, with only six reported cases in the literature of isolated subglottic involvement. There are only 16 cases reporting involvement of the subglottis with glottic or supraglottic involvement.",
        "Discussion": "Isolated subglottic Rosai-Dorfman Disease is difficult to diagnose, as it can mimic a laryngeal carcinoma or lymphoma in both radiographic and direct visualization. Patients with isolated laryngeal involvement tend to present with dyspnea, stridor, and shortness of breath. There is no consensus on treatment for the disease. In the case of our patient, the risk for airway deterioration was high, necessitating a tracheostomy placement for airway stabilization. However, some cases may show spontaneous regression, but treatments that have been shown to improve symptoms are surgery, steroids, radiation, chemotherapy, Sirolimus, and immunomodulators (2).",
        "Conclusion": "In conclusion we present a 59-year-old female with worsening airway symptoms who was shown to have Rosai-Dorfman Disease with isolated subglottic involvement. Her symptoms improved following debulking surgery, and she was discharged home in good condition. She was decannulated one month after discharge."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rosai-Dorfman Disease Presenting as a Subglottic Mass</span>. Grace Wester, BS<sup>1</sup>; Joel Badders, MD<sup>2</sup>; <u>Ameya Asarkar, MD</u><sup>2</sup>. <sup>1</sup>Louisiana State University Shreveport School of Medicine; <sup>2</sup>Department of Otolaryngology, Louisiana State University Health Shreveport<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Rosai-Dorfman Disease (RDD) is an uncommon benign lymphoproliferative disorder of sinus histiocytes, usually causing massive lymphadenopathy (1). Most cases present in childhood and young adulthood (2). Approximately 50% of patients will have extranodal involvement, with the most common sites being skin, nasal cavity, bone, orbital tissue, and the central nervous system, salivary glands, and tracheobronchial tree (1,3). We present an unusual case of Rosai-Dorfman Disease presenting with isolated subglottic involvement. </p>\n\n<p><strong>Case Presentation:</strong> A 59-year-old African American female presented to the ED from the clinic for concerns of worsening dyspnea and biphasic stridor. She had a months-long history of worsening shortness of breath, dyspnea on exertion, and stridor. The patient was being followed by pulmonology, where she was prescribed Symbicort and Albuterol as needed. Upon arrival at the emergency department, she was given Prednisone, Duonebs, and racemic epinephrine nebulization with minimal improvement. ENT was consulted, and flexible laryngoscopy showed an exophytic subglottic mass obstructing greater than 50% of the subglottis (Figure 1). She was rush-rolled to the OR for awake tracheostomy, panendoscopy with biopsies, and mass debulking. The post-operative course was complicated by hospital-acquired pneumonia and Ogilvie syndrome. The pathology results came back positive for Rosai-Dorfman Disease. She was deemed stable and discharged home on daily nebulized budesonide and as-needed DuoNebs. She was subsequently decannulated one month after discharge from the hospital.</p>\n\n<p><strong>Search Methods & Results:</strong> A literature review was performed on PubMed using the terms “Rosai-Dorfman” AND “subglottis OR larynx”. Extranodal Rosai-Dorfman disease isolated to the subglottis is a very uncommon presentation of the disease, with only six reported cases in the literature of isolated subglottic involvement. There are only 16 cases reporting involvement of the subglottis with glottic or supraglottic involvement. </p>\n\n<p><strong>Discussion:</strong> Isolated subglottic Rosai-Dorfman Disease is difficult to diagnose, as it can mimic a laryngeal carcinoma or lymphoma in both radiographic and direct visualization. Patients with isolated laryngeal involvement tend to present with dyspnea, stridor, and shortness of breath. There is no consensus on treatment for the disease. In the case of our patient, the risk for airway deterioration was high, necessitating a tracheostomy placement for airway stabilization. However, some cases may show spontaneous regression, but treatments that have been shown to improve symptoms are surgery, steroids, radiation, chemotherapy, Sirolimus, and immunomodulators (2). </p>\n\n<p><strong>Conclusion:</strong> In conclusion we present a 59-year-old female with worsening airway symptoms who was shown to have Rosai-Dorfman Disease with isolated subglottic involvement. Her symptoms improved following debulking surgery, and she was discharged home in good condition. She was decannulated one month after discharge.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151850/Screen%20Shot%202025-10-18%20at%2010_48_07%20AM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151850--></body></html>"
    },
    {
      "uid": "P186",
      "content_id": "153904",
      "abstract_number": "P186",
      "poster_number": "P186",
      "title": "Esophageal synovial cell sarcoma presenting as acute airway obstruction",
      "summary": "At the first postoperative visit, a repeat flexible laryngoscopy was performed, but curiously, the mass was no longer visible in the hypopharynx. A repeat CT of the neck was performed, which demonstrated the mass located more caudally below the cricopharyngeus. At this point, final pathology returned with immunostaining positive for SS18-SSX fusion protein, which is a pathognomonic mutation for synovial sarcoma....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153904",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samuel D Cloyd, MD",
      "presenter": "Samuel D Cloyd, MD",
      "authors": "Samuel D Cloyd, MD 1 ; Selena M White, BS 2 ; Gregory P Marks, MD 1 ; D'Antoni C Dennis, MD 2 ; Andrew J McWhorter, MD 1",
      "normalized_authors": [
        "Samuel D Cloyd",
        "Selena M White",
        "Gregory P Marks",
        "D'Antoni C Dennis",
        "Andrew J McWhorter"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head & Neck Surgery, Louisiana State University Health Sciences Center - New Orleans",
        "North Oaks Medical Center, Hammond, LA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head & Neck Surgery, Louisiana State University Health Sciences Center - New Orleans",
        "North Oaks Medical Center, Hammond, LA"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153904/78414923082__313eb52b-a259-489b-aec3-9f0b454e85ec.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153904/78414923082__313eb52b-a259-489b-aec3-9f0b454e85ec.jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153904"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_11_25T13_00_25_616(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_11_25T13_00_25_616(1).jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153904"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_12_05T15_22_05_454.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_12_05T15_22_05_454.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153904"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "CASE REPORT",
        "Abstract",
        "DISCUSSION"
      ],
      "sections": {
        "Authors": "Samuel D Cloyd, MD 1 ; Selena M White, BS 2 ; Gregory P Marks, MD 1 ; D'Antoni C Dennis, MD 2 ; Andrew J McWhorter, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head & Neck Surgery, Louisiana State University Health Sciences Center - New Orleans; 2 North Oaks Medical Center, Hammond, LA",
        "INTRODUCTION": "Synovial cell sarcoma is a rare malignant soft tissue neoplasm, typically found near joint capsules and tendon sheaths in the extremities. Less commonly, these tumors can arise within the head and neck, mediastinum, and aerodigestive tract. We present a rare case of upper esophageal synovial sarcoma presenting as an obstructive mass within the laryngeal inlet, necessitating emergent tracheostomy. To our knowledge, fewer than 15 cases of esophageal synovial sarcoma have been reported in the literature, and this case is likely the first description of such a tumor resulting in acute upper airway obstruction.",
        "CASE REPORT": "A 59-year-old male initially presented to an external otolaryngologist with intermittent, progressively worsening dysphagia of one year's duration. During the course of his workup, he presented to the ED with complaints of acute-onset SOB after coughing up fleshy tissue. CT of the neck was performed, which demonstrated a 5.2 x 3.3 x 3.8 cm soft tissue mass in the hypopharynx, with initial concern that the mass was arising from the larynx. He became increasingly dyspneic and was taken for an emergent tracheostomy and direct laryngoscopy. On initial direct laryngoscopy, the mass appeared to arise from the arytenoid/postcricoid region and was obstructing the laryngeal inlet. Biopsies were performed and tumor obstructing the glottis was debulked.",
        "Abstract": "At the first postoperative visit, a repeat flexible laryngoscopy was performed, but curiously, the mass was no longer visible in the hypopharynx. A repeat CT of the neck was performed, which demonstrated the mass located more caudally below the cricopharyngeus. At this point, final pathology returned with immunostaining positive for SS18-SSX fusion protein, which is a pathognomonic mutation for synovial sarcoma. The patient was then referred to our head and neck oncology clinic for further evaluation. Given the unusual presentation of his malignancy, he was taken to the operating room again for panendoscopy and repeat biopsies of the tumor. Direct laryngoscopy revealed a normal larynx without evidence of any mass or lesion. Flexible esophagoscopy was next performed, which located the mass approximately 2 cm below the cricopharyngeal sphincter. The partially necrotic mass appeared to be pedunculated, based off the anterior and right lateral walls of the upper esophagus. Finally, under rigid esophagoscopy, the majority of the tumor was sharply debulked. Pathology again confirmed synovial sarcoma.",
        "DISCUSSION": "Synovial cell sarcoma of the esophagus is an extremely rare entity. Mediastinal synovial sarcomas have been reported to present with airway obstruction due to mass effect on the distal trachea. However, the case we have described may be the first reported instance of esophageal synovial sarcoma resulting in acute airway obstruction. In this case, it is hypothesized that the pedunculated nature of the patient's upper esophageal tumor caused a ball-valve effect, allowing the mass to pass through the cricopharyngeal sphincter and into the laryngeal inlet. This likely explains the patient's initial complaints of coughing up fleshy tissue, followed by acute airway obstruction. This could also explain the obscure clinical findings of a normal-appearing larynx and hypopharynx on repeat laryngoscopy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Esophageal synovial cell sarcoma presenting as acute airway obstruction</span>. <u>Samuel D Cloyd, MD</u><sup>1</sup>; Selena M White, BS<sup>2</sup>; Gregory P Marks, MD<sup>1</sup>; D'Antoni C Dennis, MD<sup>2</sup>; Andrew J McWhorter, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head & Neck Surgery, Louisiana State University Health Sciences Center - New Orleans; <sup>2</sup>North Oaks Medical Center, Hammond, LA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION: </strong>Synovial cell sarcoma is a rare malignant soft tissue neoplasm, typically found near joint capsules and tendon sheaths in the extremities. Less commonly, these tumors can arise within the head and neck, mediastinum, and aerodigestive tract. We present a rare case of upper esophageal synovial sarcoma presenting as an obstructive mass within the laryngeal inlet, necessitating emergent tracheostomy. To our knowledge, fewer than 15 cases of esophageal synovial sarcoma have been reported in the literature, and this case is likely the first description of such a tumor resulting in acute upper airway obstruction.</p>\n\n<p><strong>CASE REPORT: </strong>A 59-year-old male initially presented to an external otolaryngologist with intermittent, progressively worsening dysphagia of one year's duration. During the course of his workup, he presented to the ED with complaints of acute-onset SOB after coughing up fleshy tissue. CT of the neck was performed, which demonstrated a 5.2 x 3.3 x 3.8 cm soft tissue mass in the hypopharynx, with initial concern that the mass was arising from the larynx. He became increasingly dyspneic and was taken for an emergent tracheostomy and direct laryngoscopy. On initial direct laryngoscopy, the mass appeared to arise from the arytenoid/postcricoid region and was obstructing the laryngeal inlet. Biopsies were performed and tumor obstructing the glottis was debulked.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153904/78414923082__313eb52b-a259-489b-aec3-9f0b454e85ec.jpeg' /></p>\n\n<p>At the first postoperative visit, a repeat flexible laryngoscopy was performed, but curiously, the mass was no longer visible in the hypopharynx. A repeat CT of the neck was performed, which demonstrated the mass located more caudally below the cricopharyngeus. At this point, final pathology returned with immunostaining positive for SS18-SSX fusion protein, which is a pathognomonic mutation for synovial sarcoma.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_11_25T13_00_25_616(1).jpg' /></p>\n\n<p>The patient was then referred to our head and neck oncology clinic for further evaluation. Given the unusual presentation of his malignancy, he was taken to the operating room again for panendoscopy and repeat biopsies of the tumor. Direct laryngoscopy revealed a normal larynx without evidence of any mass or lesion. Flexible esophagoscopy was next performed, which located the mass approximately 2 cm below the cricopharyngeal sphincter. The partially necrotic mass appeared to be pedunculated, based off the anterior and right lateral walls of the upper esophagus. Finally, under rigid esophagoscopy, the majority of the tumor was sharply debulked. Pathology again confirmed synovial sarcoma.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153904/Screenshot_2025_12_05T15_22_05_454.jpg' /></p>\n\n<p><strong>DISCUSSION: </strong>Synovial cell sarcoma of the esophagus is an extremely rare entity. Mediastinal synovial sarcomas have been reported to present with airway obstruction due to mass effect on the distal trachea. However, the case we have described may be the first reported instance of esophageal synovial sarcoma resulting in acute airway obstruction. In this case, it is hypothesized that the pedunculated nature of the patient's upper esophageal tumor caused a ball-valve effect, allowing the mass to pass through the cricopharyngeal sphincter and into the laryngeal inlet. This likely explains the patient's initial complaints of coughing up fleshy tissue, followed by acute airway obstruction. This could also explain the obscure clinical findings of a normal-appearing larynx and hypopharynx on repeat laryngoscopy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153904--></body></html>"
    },
    {
      "uid": "P187",
      "content_id": "153666",
      "abstract_number": "P187",
      "poster_number": "P187",
      "title": "'Valley Fever' does strike on a young healthy Caucasian - A Rare Manifestation of Disseminated Coccidioidomycosis Presenting with severe head and neck sequalaes",
      "summary": "This case illustrates an atypical but aggressive manifestation of disseminated coccidioidomycosis with extensive cervical osteomyelitis and large multiloculated retropharyngeal and epidural abscesses in a healthy immunocompetent young Caucasian man. Multidisciplinary evaluation and timely surgical drainage, combined with systemic antifungal therapy, are essential to successful management of this rare and complex...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153666",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Catherine Po Ling Chan",
      "presenter": "Catherine Po Ling Chan",
      "authors": "Catherine Po Ling Chan ; Lisa Orloff",
      "normalized_authors": [
        "Catherine Po Ling Chan",
        "Lisa Orloff"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 480,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Case Presentation",
        "Operative Intervention",
        "Postoperative management",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Catherine Po Ling Chan ; Lisa Orloff",
        "Affiliations": "Stanford University",
        "Background": "Coccidioidomycosis, as known as “Valley Fever”, is a unique endemic disease at the southwestern United States and South America. Commonly, patients develop febrile illness and pneumonia, rarely disseminate beyond the pulmonary system. Approximately 0.5-1.0% infected patients develop extrapulmonary disseminated coccidioidomycosis, involving central nervous and musculoskeletal system. Retropharyngeal abscess secondary to Coccidioides infection has only been described in isolated cases in literature with non-Caucasian ethnicity.",
        "Abstract": "This report describes a young, otherwise healthy Caucasian man with multifocal atypical manifestation of disseminated coccidioidomycosis involving spine, neck and wrist abscesses. MRI and CT revealed extensive multifocal osteomyelitis from C2 to C7 with erosive involvement of the dens and multiple vertebral collapse. Large multiloculated retropharyngeal and prevertebral abscesses extended from C1–T2, measuring up to 6.6 cm craniocaudally. Ventral epidural phlegmon/abscess from C2 to C7/T1 contributed to moderate spinal stenosis. The abscesses displaced both V1 vertebral arteries and caused moderate–severe narrowing of the oropharyngeal airway. Multidisciplinary discussion involving OHNS, Neurosurgery, and Infectious Diseases, bilateral cervical exploration, incision and drainage under general anaesthesia was recommended. Neurosurgery suggested conservative management with soft collars regarding the cervical spine osteomyelitis. Infectious disease team suggested a total of 4-week course of amphotericin B and lifelong itraconazole therapy.",
        "Case Presentation": "A 27-year-old Caucasian healthy non-smoker man, resided in Central Valley, presented with progressive dysphagia for three weeks after recovery from a recent diagnosis of coccidioidal septic arthritis and osteomyelitis of the left wrist, which required incision and drainage and itraconazole treatment. He attended emergency department in our hospital due to worsening swallowing symptoms and intolerable to solid and fluid diet. He denied odynophagia and hoarseness of voice. ENT was consulted, revealing long segment posterior pharyngeal wall mass, yielded 10 cc of purulence from needle aspiration, with cultures growing Coccidioides immitis/posadasii.",
        "Operative Intervention": "The patient underwent bilateral transcervical incision and drainage of retropharyngeal and prevertebral abscesses with intraoperative ultrasound guidance for incision and surgical planning. Extensive necrotic tissue and purulence were encountered and debrided from the oropharyngeal to hypopharynx levels. Bilateral Penrose drains were placed. No intraoperative airway instability occurred.",
        "Postoperative management": "Postoperatively, patient had bilateral symmetrical vocal cords mobility and intact sensation and motor functions of upper and lower limbs. Feeding tube was taken off on post operation day 2 after evaluation by speech language pathologist. Penrose drains were off on day 3 and wounds were all healed on day 14.",
        "Discussion": "Fungal retropharyngeal abscesses are extremely rare. This case highlights the need for high suspicion for extrapulmonary disseminated Coccidioidomycosis in endemic regions as presented with combined cervical osteomyelitis, epidural and retropharyngeal abscess representing a uniquely severe disease phenotype.",
        "Conclusion": "This case illustrates an atypical but aggressive manifestation of disseminated coccidioidomycosis with extensive cervical osteomyelitis and large multiloculated retropharyngeal and epidural abscesses in a healthy immunocompetent young Caucasian man. Multidisciplinary evaluation and timely surgical drainage, combined with systemic antifungal therapy, are essential to successful management of this rare and complex disease entity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>'Valley Fever' does strike on a young healthy Caucasian - A Rare Manifestation of Disseminated Coccidioidomycosis Presenting with severe head and neck sequalaes</span>. <u>Catherine Po Ling Chan</u>; Lisa Orloff. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Coccidioidomycosis, as known as “Valley Fever”, is a unique endemic disease at the southwestern United States and South America. Commonly, patients develop febrile illness and pneumonia, rarely disseminate beyond the pulmonary system. Approximately 0.5-1.0% infected patients develop extrapulmonary disseminated coccidioidomycosis, involving central nervous and musculoskeletal system. Retropharyngeal abscess secondary to Coccidioides infection has only been described in isolated cases in literature with non-Caucasian ethnicity.</p>\n\n<p>This report describes a young, otherwise healthy Caucasian man with multifocal atypical manifestation of disseminated coccidioidomycosis involving spine, neck and wrist abscesses. </p>\n\n<p><strong>Case Presentation: </strong>A 27-year-old Caucasian healthy non-smoker man, resided in Central Valley, presented with progressive dysphagia for three weeks after recovery from a recent diagnosis of coccidioidal septic arthritis and osteomyelitis of the left wrist, which required incision and drainage and itraconazole treatment. He attended emergency department in our hospital due to worsening swallowing symptoms and intolerable to solid and fluid diet. He denied odynophagia and hoarseness of voice. ENT was consulted, revealing long segment posterior pharyngeal wall mass, yielded 10 cc of purulence from needle aspiration, with cultures growing Coccidioides immitis/posadasii. </p>\n\n<p>MRI and CT revealed extensive multifocal osteomyelitis from C2 to C7 with erosive involvement of the dens and multiple vertebral collapse. Large multiloculated retropharyngeal and prevertebral abscesses extended from C1–T2, measuring up to 6.6 cm craniocaudally. Ventral epidural phlegmon/abscess from C2 to C7/T1 contributed to moderate spinal stenosis. The abscesses displaced both V1 vertebral arteries and caused moderate–severe narrowing of the oropharyngeal airway.</p>\n\n<p>Multidisciplinary discussion involving OHNS, Neurosurgery, and Infectious Diseases, bilateral cervical exploration, incision and drainage under general anaesthesia was recommended.</p>\n\n<p><strong>Operative Intervention: </strong>The patient underwent bilateral transcervical incision and drainage of retropharyngeal and prevertebral abscesses with intraoperative ultrasound guidance for incision and surgical planning. Extensive necrotic tissue and purulence were encountered and debrided from the oropharyngeal to hypopharynx levels. Bilateral Penrose drains were placed. No intraoperative airway instability occurred.</p>\n\n<p><strong>Postoperative management: </strong>Postoperatively, patient had bilateral symmetrical vocal cords mobility and intact sensation and motor functions of upper and lower limbs. Feeding tube was taken off on post operation day 2 after evaluation by speech language pathologist. Penrose drains were off on day 3 and wounds were all healed on day 14.</p>\n\n<p>Neurosurgery suggested conservative management with soft collars regarding the cervical spine osteomyelitis. Infectious disease team suggested a total of 4-week course of amphotericin B and lifelong itraconazole therapy.</p>\n\n<p><strong>Discussion: </strong>Fungal retropharyngeal abscesses are extremely rare. This case highlights the need for high suspicion for extrapulmonary disseminated Coccidioidomycosis in endemic regions as presented with combined cervical osteomyelitis, epidural and retropharyngeal abscess representing a uniquely severe disease phenotype. </p>\n\n<p><strong>Conclusion: </strong>This case illustrates an atypical but aggressive manifestation of disseminated coccidioidomycosis with extensive cervical osteomyelitis and large multiloculated retropharyngeal and epidural abscesses in a healthy immunocompetent young Caucasian man. Multidisciplinary evaluation and timely surgical drainage, combined with systemic antifungal therapy, are essential to successful management of this rare and complex disease entity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153666--></body></html>"
    },
    {
      "uid": "P188",
      "content_id": "153787",
      "abstract_number": "P188",
      "poster_number": "P188",
      "title": "Effect of Free Flap Reconstruction and Tracheoesophageal Puncture Timing on Outcomes After Total Laryngectomy",
      "summary": "FF reconstruction was associated with higher rates of postoperative fistula, infection, and long-term TEP complications. This contrasts with most TL literature, which describes FF reconstruction as protective against fistula formation. A possible explanation is that FF patients were inherently more complex than non-FF patients, predisposing them to complications. However, cohorts were propensity matched for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153787",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annette E Mino, BS",
      "presenter": "Annette E Mino, BS",
      "authors": "Annette E Mino, BS ; Mena M Fam, BS; Joel S Feier, MD; Eric H Abello, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD",
      "normalized_authors": [
        "Annette E Mino",
        "Mena M Fam",
        "Joel S Feier",
        "Eric H Abello",
        "Yarah M Haidar",
        "Tjoson Tjoa"
      ],
      "affiliations": [
        "University of California, Irvine"
      ],
      "normalized_institutions": [
        "University of California, Irvine"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 386,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Study Design",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Annette E Mino, BS ; Mena M Fam, BS; Joel S Feier, MD; Eric H Abello, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD",
        "Affiliations": "University of California, Irvine",
        "Objectives": "To assess the impact of free flap (FF) reconstruction and tracheoesophageal puncture (TEP) timing on total laryngectomy (TL) outcomes using real-world data.",
        "Study Design": "Multi-institutional retrospective cohort study.",
        "Methods": "Adult patients undergoing TL were identified in the TriNetX global network and stratified by TEP timing and FF reconstruction status. Cohorts were 1:1 propensity-matched for demographics, comorbidities, chemotherapy and radiation history, and AJCC TNM classification. Outcomes were grouped as acute postoperative complications within 30 days (fistula, neck infection, aspiration pneumonia, dysphagia, intraoperative hemorrhage, and flap failure) and long-term TEP-related outcomes after 30 days (fistula, neck infection, aspiration pneumonia, dysphagia, TEP leakage, prosthesis revision, stoma revision, fibrosis, percutaneous endoscopic gastrostomy dependence, and prosthesis infection). Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.",
        "Results": "TriNetX identified 6,450 TL patients. After propensity matching, 2,180 patients remained in each arm (FF vs. no FF). Compared with non-FF patients, FF reconstruction patients had a higher risk of fistula (RR 2.13, 95% CI 1.72–2.65) and neck infection (RR 1.42, 95% CI 1.03–1.96), but a lower risk of aspiration pneumonia (RR 0.63, 95% CI 0.44–0.92).",
        "Abstract": "In the FF reconstruction subset, primary vs secondary TEP (390 per arm) was not associated with differences in most outcomes, although primary TEP carried a greater risk of neck infection (RR 2.72, 95% CI 1.34–5.51) and fibrosis (RD 0.03, 95% CI 0.01–0.04). When restricting analysis to primary TEP patients (443 per arm), FF reconstruction was again associated with long-term complications, including higher risk of fistula (RR 2.59, 95% CI 1.57–4.28) and infection (RR 2.23, 95% CI 1.12–4.46).",
        "Conclusions": "FF reconstruction was associated with higher rates of postoperative fistula, infection, and long-term TEP complications. This contrasts with most TL literature, which describes FF reconstruction as protective against fistula formation. A possible explanation is that FF patients were inherently more complex than non-FF patients, predisposing them to complications. However, cohorts were propensity matched for chemotherapy, radiation, TNM classification, and comorbidities, so differences in baseline complexity may not fully explain these findings. Future studies should examine this discrepancy more closely. As expected, TEP timing had minimal overall impact on outcomes, although primary TEP was associated with increased fibrosis and neck infection in FF patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Effect of Free Flap Reconstruction and Tracheoesophageal Puncture Timing on Outcomes After Total Laryngectomy</span>. <u>Annette E Mino, BS</u>; Mena M Fam, BS; Joel S Feier, MD; Eric H Abello, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD. University of California, Irvine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>To assess the impact of free flap (FF) reconstruction and tracheoesophageal puncture (TEP) timing on total laryngectomy (TL) outcomes using real-world data.</p>\n\n<p><strong>Study Design: </strong>Multi-institutional retrospective cohort study.</p>\n\n<p><strong>Methods: </strong>Adult patients undergoing TL were identified in the TriNetX global network and stratified by TEP timing and FF reconstruction status. Cohorts were 1:1 propensity-matched for demographics, comorbidities, chemotherapy and radiation history, and AJCC TNM classification. Outcomes were grouped as acute postoperative complications within 30 days (fistula, neck infection, aspiration pneumonia, dysphagia, intraoperative hemorrhage, and flap failure) and long-term TEP-related outcomes after 30 days (fistula, neck infection, aspiration pneumonia, dysphagia, TEP leakage, prosthesis revision, stoma revision, fibrosis, percutaneous endoscopic gastrostomy dependence, and prosthesis infection). Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.</p>\n\n<p><strong>Results: </strong>TriNetX identified 6,450 TL patients. After propensity matching, 2,180 patients remained in each arm (FF vs. no FF). Compared with non-FF patients, FF reconstruction patients had a higher risk of fistula (RR 2.13, 95% CI 1.72–2.65) and neck infection (RR 1.42, 95% CI 1.03–1.96), but a lower risk of aspiration pneumonia (RR 0.63, 95% CI 0.44–0.92).</p>\n\n<p>In the FF reconstruction subset, primary vs secondary TEP (390 per arm) was not associated with differences in most outcomes, although primary TEP carried a greater risk of neck infection (RR 2.72, 95% CI 1.34–5.51) and fibrosis (RD 0.03, 95% CI 0.01–0.04).</p>\n\n<p>When restricting analysis to primary TEP patients (443 per arm), FF reconstruction was again associated with long-term complications, including higher risk of fistula (RR 2.59, 95% CI 1.57–4.28) and infection (RR 2.23, 95% CI 1.12–4.46).</p>\n\n<p><strong>Conclusions: </strong>FF reconstruction was associated with higher rates of postoperative fistula, infection, and long-term TEP complications. This contrasts with most TL literature, which describes FF reconstruction as protective against fistula formation. A possible explanation is that FF patients were inherently more complex than non-FF patients, predisposing them to complications. However, cohorts were propensity matched for chemotherapy, radiation, TNM classification, and comorbidities, so differences in baseline complexity may not fully explain these findings. Future studies should examine this discrepancy more closely. As expected, TEP timing had minimal overall impact on outcomes, although primary TEP was associated with increased fibrosis and neck infection in FF patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153787--></body></html>"
    },
    {
      "uid": "P191",
      "content_id": "154123",
      "abstract_number": "P191",
      "poster_number": "P191",
      "title": "Pharyngocutaneous Fistula Outcomes After Salvage Total Laryngectomy with Primary Closure",
      "summary": "While PCF rate is higher in salvage TL with primary closure, the overall outcomes are similar to those of primary TL and most PCFs were successfully managed conservatively. Surgeons should weigh the risk of PCF in a particular patient to the additional operative time and surgical risk associated with free flap reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154123",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Bailey Balouch, MD",
      "presenter": "Bailey Balouch, MD",
      "authors": "Bailey Balouch, MD 1 ; Chloe M Jones 2 ; Brian P Swendseid, MD 1",
      "normalized_authors": [
        "Bailey Balouch",
        "Chloe M Jones",
        "Brian P Swendseid"
      ],
      "affiliations": [
        "Cooper University Hospital",
        "Cooper Medical School of Rowan University"
      ],
      "normalized_institutions": [
        "Cooper University Hospital",
        "Cooper Medical School of Rowan University"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 313,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Bailey Balouch, MD 1 ; Chloe M Jones 2 ; Brian P Swendseid, MD 1",
        "Affiliations": "1 Cooper University Hospital; 2 Cooper Medical School of Rowan University",
        "Abstract": "Publications have advocated for free tissue transfer to decrease rates of pharyngocutaneous fistula (PCF) in salvage total laryngectomy (TL), compared to primary closure. PCF is often treated as binary, without much description of the actual severity or implications of said PCFs. We aim to assess the actual outcomes and impact of PCFs in patients treated with primary closure for salvage TL",
        "Methods": "Retrospective review of salvage TL patients, all treated with primary closure.",
        "Results": "There were 31 salvage TLs included, with 11 (35.5%) developing PCF. Of the patients with PCFs, hospital length-of-stay was an average of 18.5±13.4 days. PO diet was resumed by 9 (81.8%) patients and the majority (54.5%) resumed PO within 40 days after surgery. 3/6 (50.0%) of patients without an existing gastrostomy tube underwent PEG placement after PCF. One patient (9.1%) required operative intervention for PCF while 10 (90.9%) were successfully managed conservatively. There were no instances of carotid blowout in this series and no patients required secondary regional flap or free tissue transfer. Compared to published literature on patients undergoing free flap reconstruction following salvage TL, our cohort had a 5-day longer average length-of-stay, but a higher proportion of patients resuming a PO diet and similar rates of PEG-dependence. We then compared outcomes to an internal sample of 83 radiation-naïve patients who underwent primary TL with primary closure. Hospital length of stay, PO intake, and need for PEG did not differ significantly. However, patients in the salvage TL group resumed PO intake significantly later than patients after primary TL.",
        "Conclusion": "While PCF rate is higher in salvage TL with primary closure, the overall outcomes are similar to those of primary TL and most PCFs were successfully managed conservatively. Surgeons should weigh the risk of PCF in a particular patient to the additional operative time and surgical risk associated with free flap reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pharyngocutaneous Fistula Outcomes After Salvage Total Laryngectomy with Primary Closure</span>. <u>Bailey Balouch, MD</u><sup>1</sup>; Chloe M Jones<sup>2</sup>; Brian P Swendseid, MD<sup>1</sup>. <sup>1</sup>Cooper University Hospital; <sup>2</sup>Cooper Medical School of Rowan University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Publications have advocated for free tissue transfer to decrease rates of pharyngocutaneous fistula (PCF) in salvage total laryngectomy (TL), compared to primary closure. PCF is often treated as binary, without much description of the actual severity or implications of said PCFs. We aim to assess the actual outcomes and impact of PCFs in patients treated with primary closure for salvage TL</p>\n\n<p><strong>Methods: </strong>Retrospective review of salvage TL patients, all treated with primary closure.</p>\n\n<p><strong>Results: </strong>There were 31 salvage TLs included, with 11 (35.5%) developing PCF. Of the patients with PCFs, hospital length-of-stay was an average of 18.5±13.4 days. PO diet was resumed by 9 (81.8%) patients and the majority (54.5%) resumed PO within 40 days after surgery. 3/6 (50.0%) of patients without an existing gastrostomy tube underwent PEG placement after PCF. One patient (9.1%) required operative intervention for PCF while 10 (90.9%) were successfully managed conservatively. There were no instances of carotid blowout in this series and no patients required secondary regional flap or free tissue transfer. Compared to published literature on patients undergoing free flap reconstruction following salvage TL, our cohort had a 5-day longer average length-of-stay, but a higher proportion of patients resuming a PO diet and similar rates of PEG-dependence. We then compared outcomes to an internal sample of 83 radiation-naïve patients who underwent primary TL with primary closure. Hospital length of stay, PO intake, and need for PEG did not differ significantly. However, patients in the salvage TL group resumed PO intake significantly later than patients after primary TL.</p>\n\n<p><strong>Conclusion: </strong>While PCF rate is higher in salvage TL with primary closure, the overall outcomes are similar to those of primary TL and most PCFs were successfully managed conservatively.  Surgeons should weigh the risk of PCF in a particular patient to the additional operative time and surgical risk associated with free flap reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154123--></body></html>"
    },
    {
      "uid": "P192",
      "content_id": "153470",
      "abstract_number": "P192",
      "poster_number": "P192",
      "title": "Drain Fluid Amylase Level as a Predictor for Pharyngocutaneous Fistula following Total Laryngectomy",
      "summary": "Drain amylase is a noninvasive laboratory study that can facilitate early detection of PCF after total laryngectomy while maintaining NPO status.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153470",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Bailey Balouch, MD",
      "presenter": "Bailey Balouch, MD",
      "authors": "Bailey Balouch, MD ; Chloe M Jones, BS; Yekaterina Shapiro, MD",
      "normalized_authors": [
        "Bailey Balouch",
        "Chloe M Jones",
        "Yekaterina Shapiro"
      ],
      "affiliations": [
        "Cooper Univeristy Hospital"
      ],
      "normalized_institutions": [
        "Cooper Univeristy Hospital"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 258,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Bailey Balouch, MD ; Chloe M Jones, BS; Yekaterina Shapiro, MD",
        "Affiliations": "Cooper Univeristy Hospital",
        "Abstract": "Pharyngocutaneous fistula (PCF) is a well-known and potentially devastating complication following total laryngectomy. PCF can be detected by clinical evaluation of the cervical wounds and drain contents, bedside procedures, such as dye-test, and radiographically via esophagram. However, all of these modalities require the patient to be PO challenged to facilitate identification of the site of the leak. The purpose of this study was to quantify the drain fluid amylase level and to establish a protocol for the use of drain fluid amylase level to detect PCF after laryngectomy.",
        "Methods": "Retrospective chart review of patients who had documented amylase level collected from their Jackson-Pratt drain (JP) following total laryngectomy. PCF was confirmed radiographically with modified water-soluble esophagram. Sensitivity and specificity were calculated for various amylase cutoff values.",
        "Results": "Amylase level was available from 44 drains from 25 patients. Of these, there were 19 (43.2%) confirmed instances of PCF. JP amylase level ranged from 9 to 137,040 U/L. Amylase level differed significantly between patients with confirmed PCF (19,413 ± 35,848 U/L) and those without evidence of PCF (88 ± 77 U/L, p = 0.010). A receiver operating characteristic curve was plotted for sensitivity versus 1-specificity at various amylase cutoff values (AUC = 0.840 [0.708-0.972]) and an optimal cutoff value of 345 U/L was identified using Youden’s index (sensitivity = 68.4%, specificity = 100.0%, positive predictive value = 100.0%, negative-predictive value = 80.6%).",
        "Conclusion": "Drain amylase is a noninvasive laboratory study that can facilitate early detection of PCF after total laryngectomy while maintaining NPO status."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Drain Fluid Amylase Level as a Predictor for Pharyngocutaneous Fistula following Total Laryngectomy</span>. <u>Bailey Balouch, MD</u>; Chloe M Jones, BS; Yekaterina Shapiro, MD. Cooper Univeristy Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Pharyngocutaneous fistula (PCF) is a well-known and potentially devastating complication following total laryngectomy. PCF can be detected by clinical evaluation of the cervical wounds and drain contents, bedside procedures, such as dye-test, and radiographically via esophagram. However, all of these modalities require the patient to be PO challenged to facilitate identification of the site of the leak. The purpose of this study was to quantify the drain fluid amylase level and to establish a protocol for the use of drain fluid amylase level to detect PCF after laryngectomy.</p>\n\n<p><strong>Methods: </strong>Retrospective chart review of patients who had documented amylase level collected from their Jackson-Pratt drain (JP) following total laryngectomy. PCF was confirmed radiographically with modified water-soluble esophagram. Sensitivity and specificity were calculated for various amylase cutoff values.</p>\n\n<p><strong>Results: </strong>Amylase level was available from 44 drains from 25 patients. Of these, there were 19 (43.2%) confirmed instances of PCF. JP amylase level ranged from 9 to 137,040 U/L. Amylase level differed significantly between patients with confirmed PCF (19,413 ± 35,848 U/L) and those without evidence of PCF (88 ± 77 U/L, p = 0.010). A receiver operating characteristic curve was plotted for sensitivity versus 1-specificity at various amylase cutoff values (AUC = 0.840 [0.708-0.972]) and an optimal cutoff value of 345 U/L was identified using Youden’s index (sensitivity = 68.4%, specificity = 100.0%, positive predictive value = 100.0%, negative-predictive value = 80.6%).</p>\n\n<p><strong>Conclusion: </strong>Drain amylase is a noninvasive laboratory study that can facilitate early detection of PCF after total laryngectomy while maintaining NPO status.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153470--></body></html>"
    },
    {
      "uid": "P193",
      "content_id": "153702",
      "abstract_number": "P193",
      "poster_number": "P193",
      "title": "Laryngeal Amyloidosis: A Challenge in the Differential Diagnosis of Benign Laryngeal Lesions",
      "summary": "Localized laryngeal amyloidosis, although rare, should be considered in the differential diagnosis of laryngeal lesions, especially in patients with progressive dysphonia. Early diagnosis and appropriate treatment are fundamental for preserving vocal function and preventing respiratory complications.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153702",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex F Porsani, MD",
      "presenter": "Alex F Porsani, MD",
      "authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
      "normalized_authors": [
        "Alex F Porsani",
        "Eloa B Oliveira Andrade",
        "Julia O Parenti",
        "Maria Beatriz Orru",
        "Nathalia M Nogueira"
      ],
      "affiliations": [
        "Santa Casa Araraquara"
      ],
      "normalized_institutions": [
        "Santa Casa Araraquara"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 233,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Objective",
        "Method",
        "Case report",
        "Results and Discussion",
        "Conclusion",
        "Keywords"
      ],
      "sections": {
        "Authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
        "Affiliations": "Santa Casa Araraquara",
        "Abstract": "Laryngeal amyloidosis is a rare condition characterized by the extracellular deposition of insoluble fibrillar proteins in laryngeal tissues, representing approximately 0.2-1.2% of benign laryngeal tumors.",
        "Objective": "To report a case of laryngeal amyloidosis in a 65-year-old female patient with dysphonia for 6 months and mild dyspnea, who underwent surgical treatment, discussing clinical, diagnostic, and therapeutic aspects in light of current scientific literature.",
        "Method": "Descriptive case report study, following CARE guidelines. A review of the scientific literature on laryngeal amyloidosis was conducted in the PubMed/MEDLINE, SciELO, and LILACS databases.",
        "Case report": "A 65-year-old female patient presented with progressive dysphonia for 6 months and mild dyspnea on exertion. Videolaryngoscopy revealed a yellowish, nodular submucosal lesion in the right vestibular fold. Computed tomography revealed a well-defined lesion, without signs of invasion. Histopathological examination with Congo red staining confirmed the diagnosis of amyloidosis. The patient underwent endoscopic excision with CO2 laser, with favorable evolution and no recurrence after 12 months.",
        "Results and Discussion": "The clinical presentation, anatomical location, and histopathological findings are consistent with the literature. Endoscopic surgical treatment with CO2 laser is considered the approach of choice, with a favorable prognosis, although recurrences may occur in 15-33% of cases.",
        "Conclusion": "Localized laryngeal amyloidosis, although rare, should be considered in the differential diagnosis of laryngeal lesions, especially in patients with progressive dysphonia. Early diagnosis and appropriate treatment are fundamental for preserving vocal function and preventing respiratory complications.",
        "Keywords": "Amyloidosis; Larynx; Dysphonia; Case report."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Laryngeal Amyloidosis: A Challenge in the Differential Diagnosis of Benign Laryngeal Lesions</span>. <u>Alex F Porsani, MD</u>; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira. Santa Casa Araraquara<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Laryngeal amyloidosis is a rare condition characterized by the extracellular deposition of insoluble fibrillar proteins in laryngeal tissues, representing approximately 0.2-1.2% of benign laryngeal tumors.</p>\n\n<p><strong>Objective: </strong>To report a case of laryngeal amyloidosis in a 65-year-old female patient with dysphonia for 6 months and mild dyspnea, who underwent surgical treatment, discussing clinical, diagnostic, and therapeutic aspects in light of current scientific literature.</p>\n\n<p><strong>Method: </strong>Descriptive case report study, following CARE guidelines. A review of the scientific literature on laryngeal amyloidosis was conducted in the PubMed/MEDLINE, SciELO, and LILACS databases.</p>\n\n<p><strong>Case report: </strong>A 65-year-old female patient presented with progressive dysphonia for 6 months and mild dyspnea on exertion. Videolaryngoscopy revealed a yellowish, nodular submucosal lesion in the right vestibular fold. Computed tomography revealed a well-defined lesion, without signs of invasion. Histopathological examination with Congo red staining confirmed the diagnosis of amyloidosis. The patient underwent endoscopic excision with CO2 laser, with favorable evolution and no recurrence after 12 months.</p>\n\n<p><strong>Results and Discussion:</strong> The clinical presentation, anatomical location, and histopathological findings are consistent with the literature. Endoscopic surgical treatment with CO2 laser is considered the approach of choice, with a favorable prognosis, although recurrences may occur in 15-33% of cases.</p>\n\n<p><strong>Conclusion: </strong>Localized laryngeal amyloidosis, although rare, should be considered in the differential diagnosis of laryngeal lesions, especially in patients with progressive dysphonia. Early diagnosis and appropriate treatment are fundamental for preserving vocal function and preventing respiratory complications.</p>\n\n<p><strong>Keywords:</strong> Amyloidosis; Larynx; Dysphonia; Case report.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153702--></body></html>"
    },
    {
      "uid": "P194",
      "content_id": "154404",
      "abstract_number": "P194",
      "poster_number": "P194",
      "title": "Transcervical Excision of a Supraglottic Paraganglioma: A Rare Neuroendocrine Tumor of the Larynx",
      "summary": "Supraglottic paragangliomas are exceptionally rare, with fewer than 200 cases reported and historical reviews recognizing only approximately 100 laryngeal cases. While head and neck paragangliomas account for 65–70% of all paragangliomas, they represent only approximately 0.6% of all head and neck malignancies, with an estimated incidence of 0.3–1 per 100,000. The majority arise from the carotid body or...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154404",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lawrence Oppenheimer, MD",
      "presenter": "Lawrence Oppenheimer, MD",
      "authors": "Lawrence Oppenheimer, MD 1 ; Francisco Garraton, MD 1 ; Eric Perez, BS 2 ; Luis Garcia, MD 3 ; Bianca Bonafont, MD 3 ; Rafael Ortiz, BS 2 ; Shayanne Lajud, MD 1",
      "normalized_authors": [
        "Lawrence Oppenheimer",
        "Francisco Garraton",
        "Eric Perez",
        "Luis Garcia",
        "Bianca Bonafont",
        "Rafael Ortiz",
        "Shayanne Lajud"
      ],
      "affiliations": [
        "University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery",
        "University of Puerto Rico School of Medicine",
        "University of Puerto Rico School of Medicine, Department of Surgery"
      ],
      "normalized_institutions": [
        "University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery",
        "University of Puerto Rico School of Medicine",
        "University of Puerto Rico School of Medicine, Department of Surgery"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 347,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lawrence Oppenheimer, MD 1 ; Francisco Garraton, MD 1 ; Eric Perez, BS 2 ; Luis Garcia, MD 3 ; Bianca Bonafont, MD 3 ; Rafael Ortiz, BS 2 ; Shayanne Lajud, MD 1",
        "Affiliations": "1 University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery; 2 University of Puerto Rico School of Medicine; 3 University of Puerto Rico School of Medicine, Department of Surgery",
        "Abstract": "Supraglottic paragangliomas are exceptionally rare, with fewer than 200 cases reported and historical reviews recognizing only approximately 100 laryngeal cases. While head and neck paragangliomas account for 65–70% of all paragangliomas, they represent only approximately 0.6% of all head and neck malignancies, with an estimated incidence of 0.3–1 per 100,000. The majority arise from the carotid body or jugulotympanic and vagal paraganglia; therefore, primary tumors of the upper aerodigestive tract, particularly the supraglottis, remain scarce. We report a 53-year-old woman presenting with progressive dysphagia, exertional dyspnea, and severe supraglottic obstruction. MRI demonstrated a well-circumscribed, hyperenhancing 2.8 × 1.4 × 3.6 cm left aryepiglottic fold mass on T2-weighted images, correlating with flexible laryngoscopy findings of marked airway compromise from a hypervascular supraglottic submucosal lesion. Given the degree of obstruction and atypical presentation, an awake tracheostomy and direct laryngoscopy with biopsy were performed. Histopathology confirmed paraganglioma, and negative plasma and urine metanephrines supported a non-secretory lesion. Although multiple surgical approaches have been described, this case represents the first documented transcervical excision of a supraglottic paraganglioma in Puerto Rico. Resection was achieved via a left lateral laryngotomy. The superior laryngeal nerve was preserved, and the superior laryngeal vascular pedicle was ligated for hemostasis. Removal of the upper third of the thyroid ala, while preserving both perichondrial layers, provided controlled access to the supraglottic compartment. Capsular dissection was performed for complete en bloc excision while preserving the arytenoid cartilage. The tumor was peeled from the false vocal fold mucosa. A small quadrangular membrane defect at the adherent previous biopsy site was appreciated and was repaired with 3-0 Vicryl in a Connell fashion. A closed suction drain was placed, and the patient was discharged on postoperative day 3, tolerating an oral diet with planned outpatient decannulation. This case expands the anatomic spectrum of reported supraglottic paragangliomas and emphasizes the diagnostic challenge posed by submucosal laryngeal masses where carcinoma is often suspected. A successful outcome in this patient underscores the importance of early airway control, high-resolution imaging, and meticulous transcervical exposure when managing highly vascular supraglottic tumors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transcervical Excision of a Supraglottic Paraganglioma: A Rare Neuroendocrine Tumor of the Larynx</span>. <u>Lawrence Oppenheimer, MD</u><sup>1</sup>; Francisco Garraton, MD<sup>1</sup>; Eric Perez, BS<sup>2</sup>; Luis Garcia, MD<sup>3</sup>; Bianca Bonafont, MD<sup>3</sup>; Rafael Ortiz, BS<sup>2</sup>; Shayanne Lajud, MD<sup>1</sup>. <sup>1</sup>University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery; <sup>2</sup>University of Puerto Rico School of Medicine; <sup>3</sup>University of Puerto Rico School of Medicine, Department of Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Supraglottic paragangliomas are exceptionally rare, with fewer than 200 cases reported and historical reviews recognizing only approximately 100 laryngeal cases. While head and neck paragangliomas account for 65–70% of all paragangliomas, they represent only approximately 0.6% of all head and neck malignancies, with an estimated incidence of 0.3–1 per 100,000. The majority arise from the carotid body or jugulotympanic and vagal paraganglia; therefore, primary tumors of the upper aerodigestive tract, particularly the supraglottis, remain scarce. We report a 53-year-old woman presenting with progressive dysphagia, exertional dyspnea, and severe supraglottic obstruction. MRI demonstrated a well-circumscribed, hyperenhancing 2.8 × 1.4 × 3.6 cm left aryepiglottic fold mass on T2-weighted images, correlating with flexible laryngoscopy findings of marked airway compromise from a hypervascular supraglottic submucosal lesion. Given the degree of obstruction and atypical presentation, an awake tracheostomy and direct laryngoscopy with biopsy were performed. Histopathology confirmed paraganglioma, and negative plasma and urine metanephrines supported a non-secretory lesion.</p>\n\n<p>Although multiple surgical approaches have been described, this case represents the first documented transcervical excision of a supraglottic paraganglioma in Puerto Rico. Resection was achieved via a left lateral laryngotomy. The superior laryngeal nerve was preserved, and the superior laryngeal vascular pedicle was ligated for hemostasis. Removal of the upper third of the thyroid ala, while preserving both perichondrial layers, provided controlled access to the supraglottic compartment. Capsular dissection was performed for complete en bloc excision while preserving the arytenoid cartilage. The tumor was peeled from the false vocal fold mucosa. A small quadrangular membrane defect at the adherent previous biopsy site was appreciated and was repaired with 3-0 Vicryl in a Connell fashion. A closed suction drain was placed, and the patient was discharged on postoperative day 3, tolerating an oral diet with planned outpatient decannulation. This case expands the anatomic spectrum of reported supraglottic paragangliomas and emphasizes the diagnostic challenge posed by submucosal laryngeal masses where carcinoma is often suspected. A successful outcome in this patient underscores the importance of early airway control, high-resolution imaging, and meticulous transcervical exposure when managing highly vascular supraglottic tumors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154404--></body></html>"
    },
    {
      "uid": "P195",
      "content_id": "151960",
      "abstract_number": "P195",
      "poster_number": "P195",
      "title": "Oncological outcome of salvage open conservation laryngeal surgery",
      "summary": "Traditionally total laryngectomy is done for all laryngeal cancers following the failure of radiation therapy.In selected early recurrent cases open conservation laryngeal procedures can be done to avoid the significant functional morbidity caused by the total removal of larynx.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151960",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elizabeth M Iype, PhD",
      "presenter": "Elizabeth M Iype, PhD",
      "authors": "Elizabeth M Iype, PhD ; Jini M Rajan, MS; Bipin T Varghese, PhD",
      "normalized_authors": [
        "Elizabeth M Iype",
        "Jini M Rajan",
        "Bipin T Varghese"
      ],
      "affiliations": [
        "Regional cancer Centre"
      ],
      "normalized_institutions": [
        "Regional cancer Centre"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 247,
      "section_labels": [
        "Authors",
        "Affiliations",
        "ABSTRACT SUMMARY",
        "OBJECTIVE",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Elizabeth M Iype, PhD ; Jini M Rajan, MS; Bipin T Varghese, PhD",
        "Affiliations": "Regional cancer Centre",
        "ABSTRACT SUMMARY": "Traditionally total laryngectomy is done for all laryngeal cancers following the failure of radiation therapy.In selected early recurrent cases open conservation laryngeal procedures can be done to avoid the significant functional morbidity caused by the total removal of larynx.",
        "OBJECTIVE": "The primary aim of this study was to assess the oncological outcome of patients who had undergone open conservation laryngeal surgery after the failure of radiotherapy and the secondary aim was to estimate the local control rate, disease free survival and overall survival of those patients at the end of two years.",
        "MATERIALS AND METHODS": "This is a retrospective review of case records of 20 patients who underwent open conservation laryngeal procedures during the period between 2010 to 2021 for recurrence after failure of radiation therapy.",
        "RESULTS": "Among 20 patients with carcinoma larynx who underwent conservation laryngeal surgery, 13 procedures were variations of vertical partial laryngectomy (VPL), 3 were supracricoid partial laryngectomy with cricohyoidoepiglottopexy (SCPL+CHEP) and 4 were near total laryngectomy (NTL). 13 patients were decannulated with a mean decannulation period of 28 days. Two patients were dependent on nasogastric tubes due to aspiration. Completion laryngectomy was required in 3 patients due to recurrence. Local control rate at the end of 24 months was 70%. At the end of 2 years, disease free survival rate was 73.9% and overall survival rate was 89.7% with laryngectomy free survival of 85%.",
        "CONCLUSION": "In carefully selected patients open conservation laryngeal surgeries found to have comparable local control rate with preservation of functions"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncological outcome of salvage open conservation laryngeal surgery</span>. <u>Elizabeth M Iype, PhD</u>; Jini M Rajan, MS; Bipin T Varghese, PhD. Regional cancer Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>ABSTRACT SUMMARY: </strong>Traditionally total laryngectomy is done for all laryngeal cancers following the failure of radiation therapy.In selected early recurrent cases open conservation laryngeal procedures can be done to avoid the significant functional morbidity caused by the total removal of larynx.</p>\n\n<p><strong>OBJECTIVE:</strong> The primary aim of this study was to assess the oncological outcome of patients who had undergone open conservation laryngeal surgery after the failure of radiotherapy and the secondary aim was to estimate the local control rate, disease free survival and overall survival of those patients at the end of two years.</p>\n\n<p><strong>MATERIALS AND METHODS: </strong>This is a retrospective review of case records of 20 patients who underwent open conservation laryngeal procedures during the period between 2010 to 2021 for recurrence after failure of radiation therapy.</p>\n\n<p><strong>RESULTS: </strong>Among 20 patients with carcinoma larynx who underwent conservation laryngeal surgery, 13 procedures were variations of vertical partial laryngectomy (VPL), 3 were supracricoid partial laryngectomy with cricohyoidoepiglottopexy (SCPL+CHEP) and 4 were near total laryngectomy (NTL). 13 patients were decannulated with a mean decannulation period of 28 days. Two patients were dependent on nasogastric tubes due to aspiration. Completion laryngectomy was required in 3 patients due to recurrence. Local control rate at the end of 24 months was 70%. At the end of 2 years, disease free survival rate was 73.9% and overall survival rate was 89.7% with laryngectomy free survival of 85%.</p>\n\n<p><strong>CONCLUSION:</strong> In carefully selected patients open conservation laryngeal surgeries found to have comparable local control rate with preservation of functions </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151960--></body></html>"
    },
    {
      "uid": "P196",
      "content_id": "154069",
      "abstract_number": "P196",
      "poster_number": "P196",
      "title": "Outcomes Following Salvage Total Laryngectomy in Recurrent Laryngeal Cancer",
      "summary": "In this cohort, salvage total laryngectomy did not independently improve survival after recurrence. Advanced AJCC stage showed a clinically meaningful trend toward worse survival but lacked statistical significance due to limited sample size. These findings suggest that treatment decisions for recurrent laryngeal cancer should consider functional goals and patient priorities, as salvage modality alone may not...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154069",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carlos Lange Nava, BS",
      "presenter": "Carlos Lange Nava, BS",
      "authors": "Carlos Lange Nava, BS ; Muhammad El Shatanofy, MD; Eric Sokhn, BS; Soumil Prasad, BS; Zoukaa Sargi, MD, MPH",
      "normalized_authors": [
        "Carlos Lange Nava",
        "Muhammad El Shatanofy",
        "Eric Sokhn",
        "Soumil Prasad",
        "Zoukaa Sargi"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154069/image002.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154069/image002.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154069"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154069/image003.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154069/image003.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154069"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions",
        "Figure 1",
        "Figure 2"
      ],
      "sections": {
        "Authors": "Carlos Lange Nava, BS ; Muhammad El Shatanofy, MD; Eric Sokhn, BS; Soumil Prasad, BS; Zoukaa Sargi, MD, MPH",
        "Affiliations": "University of Miami Miller School of Medicine",
        "Background": "Salvage total laryngectomy (STL) is the standard of care for resectable recurrences of laryngeal cancer. Studies suggest that salvage total laryngectomy provides strong local control but is associated with significant morbidity, particularly in the setting of prior radiation. The objective of this study was to investigate recurrence patterns, treatment modalities, and survival outcomes for patients with recurrent laryngeal cancer.",
        "Methods": "A retrospective review of 99 patients with recurrent laryngeal cancer (2015–2023) was performed. Variables included age, sex, time to recurrence, AJCC recurrence stage, and salvage treatment modality (STL vs. nonsurgical salvage). Post-recurrence overall survival was calculated from recurrence to death or last follow-up. Kaplan–Meier analysis with log-rank testing assessed survival differences. A multivariable Cox proportional hazards model evaluated whether STL independently predicted survival after adjusting for time to recurrence and AJCC stage.",
        "Results": "Ninety-nine patients were included in the analytic cohort. Across the full institutional population (n = 164), the mean age at recurrence was 65.0 years (range 37–89), and most patients were male (87.2%). During follow-up, 81 patients (49.4%) died and 83 (50.6%) remained alive, yielding an approximately 1:1 mortality ratio. Among the 72 patients with available AJCC recurrence staging, 54.2% had advanced-stage recurrence (IVA–IVC).",
        "Abstract": "Post-recurrence survival (n = 142 with available data) had a median of 228.5 days and a mean of 670.1 days. Time to recurrence (n = 99) had a median of 482 days and a mean of 843.8 days. Forty-five patients (45.5%) in the analytic cohort underwent STL at recurrence. Median post-recurrence survival was 3.4 years for patients who underwent STL and 2.7 years for those treated nonsurgically. Kaplan–Meier analysis showed no significant difference in survival between STL and nonsurgical salvage (log-rank p = 0.825). The Cox proportional hazards model (n = 43 with complete data) demonstrated that STL was not associated with improved survival (HR 1.969, 95% CI 0.863–4.493, p = 0.108). Time to recurrence was not independently predictive (HR 1.000, 95% CI 0.999–1.000, p = 0.475), and AJCC recurrence group showed no significant association with survival (HR 1.600, 95% CI 0.719–3.561, p = 0.250). Wide confidence intervals reflected limited model power.",
        "Conclusions": "In this cohort, salvage total laryngectomy did not independently improve survival after recurrence. Advanced AJCC stage showed a clinically meaningful trend toward worse survival but lacked statistical significance due to limited sample size. These findings suggest that treatment decisions for recurrent laryngeal cancer should consider functional goals and patient priorities, as salvage modality alone may not determine post-recurrence survival. STL remains essential for local control and airway preservation but may not confer a survival advantage on its own.",
        "Figure 1": ". Post-recurrence survival by AJCC recurrence stage (I–III vs. IVA–IVC). Early-stage recurrence demonstrated longer survival, though not statistically significant..",
        "Figure 2": ". No significant difference in post-recurrence survival between patients undergoing STL and those managed nonsurgically."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes Following Salvage Total Laryngectomy in Recurrent Laryngeal Cancer</span>. <u>Carlos Lange Nava, BS</u>; Muhammad El Shatanofy, MD; Eric Sokhn, BS; Soumil Prasad, BS; Zoukaa Sargi, MD, MPH. University of Miami Miller School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salvage total laryngectomy (STL) is the standard of care for resectable recurrences of laryngeal cancer. Studies suggest that salvage total laryngectomy provides strong local control but is associated with significant morbidity, particularly in the setting of prior radiation. The objective of this study was to investigate recurrence patterns, treatment modalities, and survival outcomes for patients with recurrent laryngeal cancer.</p>\n\n<p><strong>Methods:</strong> A retrospective review of 99 patients with recurrent laryngeal cancer (2015–2023) was performed. Variables included age, sex, time to recurrence, AJCC recurrence stage, and salvage treatment modality (STL vs. nonsurgical salvage). Post-recurrence overall survival was calculated from recurrence to death or last follow-up. Kaplan–Meier analysis with log-rank testing assessed survival differences. A multivariable Cox proportional hazards model evaluated whether STL independently predicted survival after adjusting for time to recurrence and AJCC stage.</p>\n\n<p><strong>Results: </strong>Ninety-nine patients were included in the analytic cohort. Across the full institutional population (n = 164), the mean age at recurrence was 65.0 years (range 37–89), and most patients were male (87.2%). During follow-up, 81 patients (49.4%) died and 83 (50.6%) remained alive, yielding an approximately 1:1 mortality ratio. Among the 72 patients with available AJCC recurrence staging, 54.2% had advanced-stage recurrence (IVA–IVC).</p>\n\n<p>Post-recurrence survival (n = 142 with available data) had a median of 228.5 days and a mean of 670.1 days. Time to recurrence (n = 99) had a median of 482 days and a mean of 843.8 days. Forty-five patients (45.5%) in the analytic cohort underwent STL at recurrence. Median post-recurrence survival was 3.4 years for patients who underwent STL and 2.7 years for those treated nonsurgically. Kaplan–Meier analysis showed no significant difference in survival between STL and nonsurgical salvage (log-rank p = 0.825).</p>\n\n<p>The Cox proportional hazards model (n = 43 with complete data) demonstrated that STL was not associated with improved survival (HR 1.969, 95% CI 0.863–4.493, p = 0.108). Time to recurrence was not independently predictive (HR 1.000, 95% CI 0.999–1.000, p = 0.475), and AJCC recurrence group showed no significant association with survival (HR 1.600, 95% CI 0.719–3.561, p = 0.250). Wide confidence intervals reflected limited model power.</p>\n\n<p><strong>Conclusions</strong>: In this cohort, salvage total laryngectomy did not independently improve survival after recurrence. Advanced AJCC stage showed a clinically meaningful trend toward worse survival but lacked statistical significance due to limited sample size. These findings suggest that treatment decisions for recurrent laryngeal cancer should consider functional goals and patient priorities, as salvage modality alone may not determine post-recurrence survival. STL remains essential for local control and airway preservation but may not confer a survival advantage on its own.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154069/image002.png' /></p>\n\n<p><strong>Figure 1</strong>. Post-recurrence survival by AJCC recurrence stage (I–III vs. IVA–IVC). Early-stage recurrence demonstrated longer survival, though not statistically significant..</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154069/image003.png' /></p>\n\n<p><strong>Figure 2</strong>. No significant difference in post-recurrence survival between patients undergoing STL and those managed nonsurgically.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154069--></body></html>"
    },
    {
      "uid": "P197",
      "content_id": "154036",
      "abstract_number": "P197",
      "poster_number": "P197",
      "title": "Real-World Performance of the ThyroidPrint Gene Classifier in Indeterminate Thyroid Nodules: Correlation with Final Pathology",
      "summary": "Our real-world findings confirmed the intended clinical utility of the ThyroidPrint Assay as a rule-out test, demonstrating a robust Negative Predictive Value of 85.37%. This high NPV supports its potential to safely reduce unnecessary diagnostic thyroid surgeries. However, the observed accuracy metrics (Sensitivity and Specificity) were notably lower than those reported in the initial validation studies. This...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154036",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Suthida Sujaritsrichaikul, MD",
      "presenter": "Suthida Sujaritsrichaikul, MD",
      "authors": "Warut Pongsapich, Associate Professor, MD; Prachya Maneeprasopchoke, Assistant Professor, MD; Paveena Pithuksurachai, Assistant Professor, MD; Suthida Sujaritsrichaikul, MD",
      "normalized_authors": [
        "Warut Pongsapich, Associate",
        "Prachya Maneeprasopchoke, Assistant",
        "Paveena Pithuksurachai, Assistant",
        "Suthida Sujaritsrichaikul"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Warut Pongsapich, Associate Professor, MD; Prachya Maneeprasopchoke, Assistant Professor, MD; Paveena Pithuksurachai, Assistant Professor, MD; Suthida Sujaritsrichaikul, MD",
        "Affiliations": "Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand",
        "Background": "According to the American Thyroid Association (ATA) guidelines, molecular testing is a crucial adjunct for managing indeterminate thyroid nodules (ITNs). The performance metrics—specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV)—of these molecular tests are highly dependent on the pre-test probability (incidence of malignancy) within the targeted patient population. Per the 2023 Bethesda System for Reporting Thyroid Cytopathology, ITNs Category III and IV are the groups that benefit most from molecular stratification to guide surgical decision-making.The ThyroidPrint Assay, a ten-gene molecular classifier, is designed as a rule-out test to stratify ITNs into high- or low-risk categories. The assay was initially developed in Chile (2013) and launched in Latin America (2018). Preliminary performance data based on 132 samples reported high initial metrics: sensitivity of 92%, specificity of 82%, PPV of 66%, and NPV of 96%. Due to the variability in performance across different populations, real-world data is essential.",
        "Objectives": "This study aimed to evaluate the real-world clinical performance of the ThyroidPrint ten-gene classifier in a prospective cohort of patients with Bethesda III or IV ITNs who had already elected to undergo thyroid surgery. The assay results were correlated with the gold standard of the final post-operative surgical pathology report.",
        "Methods": "We prospectively enrolled 39 consecutive patients with ITNs (Bethesda III or IV) who underwent thyroid surgery between November 2024 and October 2025 at a single academic tertiary medical center in Thailand. To reduce confounders, patients with pre-existing suspicious cervical adenopathy confirmed by imaging or fine-needle aspiration were excluded. Intraoperative ThyroidPrint Assay results were obtained and compared against the definitive pathological diagnosis to calculate diagnostic accuracy metrics, including sensitivity, specificity, PPV, and NPV.",
        "Results": "The median patient age was 55 years, 82% of patients were female, and the median nodule size was 1.9 cm. The overall malignancy rate for the study cohort was 41% (16 malignant cases out of 39). The assay classified 43% (15 of 35) of Bethesda III nodules and 25% (1 of 4) of Bethesda IV nodules as low-risk.",
        "Abstract": "The calculated diagnostic accuracy metrics were: Sensitivity: 71.43% (95% CI: 47.82% to 88.72%) Specificity: 55.56% (95% CI: 30.76% to 78.47%) Positive Predictive Value (PPV): 34.88% Negative Predictive Value (NPV): 85.37% Analysis of false-positive cases (n=8) revealed heterogeneous pathology, including six benign follicular nodules, one follicular-derived tumor with undetermined malignancy, and one oncocytic adenoma.",
        "Conclusions": "Our real-world findings confirmed the intended clinical utility of the ThyroidPrint Assay as a rule-out test, demonstrating a robust Negative Predictive Value of 85.37%. This high NPV supports its potential to safely reduce unnecessary diagnostic thyroid surgeries. However, the observed accuracy metrics (Sensitivity and Specificity) were notably lower than those reported in the initial validation studies. This discrepancy is attributed to the inherent selection bias of our specific surgical cohort, which resulted in a significantly higher pre-test risk of malignancy (41%) compared to the general ITN population targeted for rule-out testing. These results underscore the critical importance of applying molecular classifiers within their distinct clinical context to ensure optimal performance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-World Performance of the ThyroidPrint Gene Classifier in Indeterminate Thyroid Nodules: Correlation with Final Pathology</span>. Warut Pongsapich, Associate Professor, MD; Prachya Maneeprasopchoke, Assistant Professor, MD; Paveena Pithuksurachai, Assistant Professor, MD; <u>Suthida Sujaritsrichaikul, MD</u>. Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>According to the American Thyroid Association (ATA) guidelines, molecular testing is a crucial adjunct for managing indeterminate thyroid nodules (ITNs). The performance metrics—specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV)—of these molecular tests are highly dependent on the pre-test probability (incidence of malignancy) within the targeted patient population. Per the 2023 Bethesda System for Reporting Thyroid Cytopathology, ITNs Category III and IV  are the groups that benefit most from molecular stratification to guide surgical decision-making.The ThyroidPrint Assay, a ten-gene molecular classifier, is designed as a rule-out test to stratify ITNs into high- or low-risk categories. The assay was initially developed in Chile (2013) and launched in Latin America (2018). Preliminary performance data based on 132 samples reported high initial metrics: sensitivity of 92%, specificity of 82%, PPV of 66%, and NPV of 96%. Due to the variability in performance across different populations, real-world data is essential.</p>\n\n<p><strong>Objectives: </strong>This study aimed to evaluate the real-world clinical performance of the ThyroidPrint ten-gene classifier in a prospective cohort of patients with Bethesda III or IV ITNs who had already elected to undergo thyroid surgery. The assay results were correlated with the gold standard of the final post-operative surgical pathology report.</p>\n\n<p><strong>Methods: </strong>We prospectively enrolled 39 consecutive patients with ITNs (Bethesda III or IV) who underwent thyroid surgery between November 2024 and October 2025 at a single academic tertiary medical center in Thailand. To reduce confounders, patients with pre-existing suspicious cervical adenopathy confirmed by imaging or fine-needle aspiration were excluded. Intraoperative ThyroidPrint Assay results were obtained and compared against the definitive pathological diagnosis to calculate diagnostic accuracy metrics, including sensitivity, specificity, PPV, and NPV.</p>\n\n<p><strong>Results: </strong>The median patient age was 55 years, 82% of patients were female, and the median nodule size was 1.9 cm. The overall malignancy rate for the study cohort was 41% (16 malignant cases out of 39). The assay classified 43% (15 of 35) of Bethesda III nodules and 25% (1 of 4) of Bethesda IV nodules as low-risk.</p>\n\n<p>The calculated diagnostic accuracy metrics were:</p>\n\n<p>Sensitivity: 71.43% (95% CI: 47.82% to 88.72%)</p>\n\n<p>Specificity: 55.56% (95% CI: 30.76% to 78.47%)</p>\n\n<p>Positive Predictive Value (PPV): 34.88%</p>\n\n<p>Negative Predictive Value (NPV): 85.37%</p>\n\n<p>Analysis of false-positive cases (n=8) revealed heterogeneous pathology, including six benign follicular nodules, one follicular-derived tumor with undetermined malignancy, and one oncocytic adenoma.</p>\n\n<p><strong>Conclusions: </strong>Our real-world findings confirmed the intended clinical utility of the ThyroidPrint Assay as a rule-out test, demonstrating a robust Negative Predictive Value of 85.37%. This high NPV supports its potential to safely reduce unnecessary diagnostic thyroid surgeries. However, the observed accuracy metrics (Sensitivity and Specificity) were notably lower than those reported in the initial validation studies. This discrepancy is attributed to the inherent selection bias of our specific surgical cohort, which resulted in a significantly higher pre-test risk of malignancy (41%) compared to the general ITN population targeted for rule-out testing. These results underscore the critical importance of applying molecular classifiers within their distinct clinical context to ensure optimal performance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154036--></body></html>"
    },
    {
      "uid": "P198",
      "content_id": "154768",
      "abstract_number": "P198",
      "poster_number": "P198",
      "title": "Comparing the efficacy of Narrow Band Imaging and Storz Professional Image Enhancement System guided tumour resection versus Conventional tumour resection in the management of early stage oral an",
      "summary": "Obtaining tumour-free margins at the final histological examination is the primary aim of any surgical resection and is presently the gold standard in oncologic surgery. Narrow band imaging (NBI) has been at the forefront in widely demonstrating its efficacy in detecting superficial mucosal lesions of the oral and oropharyngeal mucosa. Storz Professional Image Enhancement System (SPIES) works similar to NBI...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154768",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aastha Sharma, MS Otorhinolaryngology",
      "presenter": "Aastha Sharma, MS Otorhinolaryngology",
      "authors": "Jaimanti Bakshi, Professor and Head; Mayank Rampal, RESIDENT; Naresh K Panda, PROFESSOR; Amanjit Bal, PROFESSOR; Anish K Bhattacharya, Professor Head; Chirag K Ahuja, PROFESSOR; Aastha Sharma, MS Otorhinolaryngology",
      "normalized_authors": [
        "Jaimanti Bakshi, and Head",
        "Mayank Rampal, RESIDENT",
        "Naresh K Panda",
        "Amanjit Bal",
        "Anish K Bhattacharya, Head",
        "Chirag K Ahuja",
        "Aastha Sharma, Otorhinolaryngology"
      ],
      "affiliations": [
        "PGIMER, Chandigarh, India"
      ],
      "normalized_institutions": [
        "PGIMER, Chandigarh, India"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 477,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "AIMS",
        "MATERIALS AND METHOD",
        "RESULTS",
        "CONCLUSIONS",
        "KEYWORDS"
      ],
      "sections": {
        "Authors": "Jaimanti Bakshi, Professor and Head; Mayank Rampal, RESIDENT; Naresh K Panda, PROFESSOR; Amanjit Bal, PROFESSOR; Anish K Bhattacharya, Professor Head; Chirag K Ahuja, PROFESSOR; Aastha Sharma, MS Otorhinolaryngology",
        "Affiliations": "PGIMER, Chandigarh, India",
        "INTRODUCTION": "Obtaining tumour-free margins at the final histological examination is the primary aim of any surgical resection and is presently the gold standard in oncologic surgery. Narrow band imaging (NBI) has been at the forefront in widely demonstrating its efficacy in detecting superficial mucosal lesions of the oral and oropharyngeal mucosa. Storz Professional Image Enhancement System (SPIES) works similar to NBI imaging by enhancing superficial changes of neo-angiogenesis of the tumour lesions thus helping in the recognition of the tumour.",
        "AIMS": "To assess the efficacy of NBI and intraoperative SPIES in exact tumour mapping and for defining tumour margins versus conventional tumour resection for early-stage oral and oropharyngeal cancer. Early detection of recurrence of oral and oropharyngeal cancer with Narrow Band Imaging in follow-up after surgery.",
        "MATERIALS AND METHOD": "This pilot observational study was done in the Department of Otolaryngology, Head and Neck Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in . The study duration was from July 2020 to December 2021. Prior approval from the institutional ethics committee was obtained. 20 patients with biopsy-proven squamous cell carcinoma of the oral cavity and being planned for surgical resection were included. Group 1 underwent primary tumour resection using preop NBI and intraop SPIES. Group 2 underwent conventional tumour resection. Both groups were compared using postop histopathological examination and were followed up for a maximum of 6 months. NBI was done at 3 months and 6 months follow-ups in both groups for local recurrence.",
        "RESULTS": "Group 1 had only 10% close margins in comparison to group 2 where 50 % close margins were seen. TNM tumour stage was upstaged to T3 stage on postop HPE, due to depth of invasion of more than 10 mm in 30% of participants in group 1 and 20% of participants in group 2. Also, group 1 consisted of 40% participants in the T1 stage and 30% participants in the T2 stage. Whereas, group 2 consisted of 20 % participants in the T1 stage and 60% participants in the T2 stage. In group 1 only 10% of the participant had to undergo postoperative RT due to the close margin in comparison with group 2 where 50% of participants received postoperative RT due to close margins. No complications of surgery in both groups during the course of the study. Functional outcomes were similar in both groups.",
        "CONCLUSIONS": "The use of preop NBI and intraop SPIES helps in almost exact tumour mapping and for defining tumour margins in oral cavity carcinoma patients in the early stage compared to the conventional method of tumour resection. However, Oncological and functional outcomes were similar in both groups. Patients undergoing conventional surgery were more exposed to Postop radiotherapy and its adverse effects owing to close margins in comparison to patients with NBI and SPIES guided resection.",
        "KEYWORDS": "Head and neck oncology, Oral cavity carcinoma, Tumour margin, Narrow Band Imaging, Storz Professional Image Enhancement System, Tumour follow-up."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparing the efficacy of Narrow Band Imaging and Storz Professional Image Enhancement System guided tumour resection versus Conventional tumour resection in the management of early stage oral and oropharyngeal cancer</span>. Jaimanti Bakshi, Professor and Head; Mayank Rampal, RESIDENT; Naresh K Panda, PROFESSOR; Amanjit Bal, PROFESSOR; Anish K Bhattacharya, Professor Head; Chirag K Ahuja, PROFESSOR; <u>Aastha Sharma, MS Otorhinolaryngology</u>. PGIMER, Chandigarh, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION:</strong> Obtaining tumour-free margins at the final histological examination is the primary aim of any surgical resection and is presently the gold standard in oncologic surgery. Narrow band imaging (NBI) has been at the forefront in widely demonstrating its efficacy in detecting superficial mucosal lesions of the oral and oropharyngeal mucosa. Storz Professional Image Enhancement System (SPIES) works similar to NBI imaging by enhancing superficial changes of neo-angiogenesis of the tumour lesions thus helping in the recognition of the tumour.</p>\n\n<p><strong>AIMS:</strong> To assess the efficacy of NBI and intraoperative SPIES in exact tumour mapping and for defining tumour margins versus conventional tumour resection for early-stage oral and oropharyngeal cancer. Early detection of recurrence of oral and oropharyngeal cancer with Narrow Band Imaging in follow-up after surgery.</p>\n\n<p><strong>MATERIALS AND METHOD:</strong> This pilot observational study was done in the Department of Otolaryngology, Head and Neck Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in . The study duration was from July 2020 to December 2021. Prior approval from the institutional ethics committee was obtained. 20 patients with biopsy-proven squamous cell carcinoma of the oral cavity and being planned for surgical resection were included. Group 1 underwent primary tumour resection using preop NBI and intraop SPIES. Group 2 underwent conventional tumour resection. Both groups were compared using postop histopathological examination and were followed up for a maximum of 6 months. NBI was done at 3 months and 6 months follow-ups in both groups for local recurrence.</p>\n\n<p><strong>RESULTS:</strong> Group 1 had only 10% close margins in comparison to group 2 where 50 % close margins were seen. TNM tumour stage was upstaged to T3 stage on postop HPE, due to depth of invasion of more than 10 mm in 30% of participants in group 1 and 20% of participants in group 2. Also, group 1 consisted of 40% participants in the T1 stage and 30% participants in the T2 stage. Whereas, group 2 consisted of 20 % participants in the T1 stage and 60% participants in the T2 stage. In group 1 only 10% of the participant had to undergo postoperative RT due to the close margin in comparison with group 2 where 50% of participants received postoperative RT due to close margins. No complications of surgery in both groups during the course of the study. Functional outcomes were similar in both groups.</p>\n\n<p><strong>CONCLUSIONS: </strong>The use of preop NBI and intraop SPIES helps in almost exact tumour mapping and for defining tumour margins in oral cavity carcinoma patients in the early stage compared to the conventional method of tumour resection. However, Oncological and functional outcomes were similar in both groups. Patients undergoing conventional surgery were more exposed to Postop radiotherapy and its adverse effects owing to close margins in comparison to patients with NBI and SPIES guided resection.</p>\n\n<p><strong>KEYWORDS: </strong>Head and neck oncology, Oral cavity carcinoma, Tumour margin, Narrow Band Imaging, Storz Professional Image Enhancement System, Tumour follow-up.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154768--></body></html>"
    },
    {
      "uid": "P199",
      "content_id": "153361",
      "abstract_number": "P199",
      "poster_number": "P199",
      "title": "Factors determining innominate artery identification on pre-operative ultrasound in thyroid and parathyroid surgery",
      "summary": "Pre-operative ultrasonography is considered standard of care for the pre-operative workup for primary hyperparathyroidism and for the initial workup of thyroid nodules. In addition to elucidating thyroid and parathyroid anatomy, ultrasound can identify important vascular anatomy. An aberrant subclavian artery is associated with a nonrecurrent right laryngeal nerve and an increased risk of associated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153361",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Benjamin Aunins, MD",
      "presenter": "Benjamin Aunins, MD",
      "authors": "Benjamin Aunins, MD 1 ; Eshan S King, PhD 2 ; David C Shonka, MD 1",
      "normalized_authors": [
        "Benjamin Aunins",
        "Eshan S King",
        "David C Shonka"
      ],
      "affiliations": [
        "University of Virginia",
        "Case Western Reserve University School of Medicine"
      ],
      "normalized_institutions": [
        "University of Virginia",
        "Case Western Reserve University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153361/Innominate.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153361/Innominate.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153361"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 402,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Benjamin Aunins, MD 1 ; Eshan S King, PhD 2 ; David C Shonka, MD 1",
        "Affiliations": "1 University of Virginia; 2 Case Western Reserve University School of Medicine",
        "Abstract": "Pre-operative ultrasonography is considered standard of care for the pre-operative workup for primary hyperparathyroidism and for the initial workup of thyroid nodules. In addition to elucidating thyroid and parathyroid anatomy, ultrasound can identify important vascular anatomy. An aberrant subclavian artery is associated with a nonrecurrent right laryngeal nerve and an increased risk of associated intraoperative nerve injury, so pre-operative identification of this aberrant anatomy is critical for avoidance of complications. The purpose of this study was to identify predictive factors in visualization of normal innominate artery anatomy on ultrasound. It was hypothesized that increased BMI and increased thyroid size would be associated with decreased likelihood of visualization of the innominate artery. This was designed as a single-center single-surgeon prospective cohort of 37 consecutive adult patients undergoing thyroid or parathyroid surgery from October to November 2025, with each patient undergoing ultrasound in the operating room prior to incision. In 33 of 37 patients (89%), normal innominate arterial anatomy was identified, with abnormal anatomy in 1 of 37 (3%) and no visualization in 3 of 37 (8%). On multivariate logistic regression analysis, the dependent variable was innominate artery identification, with predictor variables of age, sex, BMI, and total thyroid volume. Only BMI was found to be predictive of innominate artery identification, with increasing BMI significantly associated with decreased innominate artery visualization (OR 0.82, CI 0.66 – 0.95, p 0.019) (Figure 1). Of note, BMI was significant even though the lowest BMI patient without normal visualized anatomy had a history of an aberrant right subclavian s/p repair for dysphagia lusoria. No other aberrant subclavian artery was noted on ultrasound or intraoperatively. While this study was limited by a relatively small sample size at a tertiary care institution, multiple conclusions can be drawn. This is the first study to report the frequency of visualization of innominate anatomy on ultrasound and shows that this anatomy can be visualized in most patients on pre-operative ultrasound for thyroid/parathyroid surgery. Additionally, this study identifies larger body habitus as a risk factor for more difficulty in pre-operative visualization of innominate artery anatomy. The results of this study can better prepare the physician to pre-operatively identify an essential anatomic relationship to avoid complications in thyroid and parathyroid surgery. Figure 1. Innominate visualization as a function of BMI. Red dots represent individual patient data. The teal line represents likelihood of normal innominate anatomic visualization for a given BMI."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Factors determining innominate artery identification on pre-operative ultrasound in thyroid and parathyroid surgery</span>. <u>Benjamin Aunins, MD</u><sup>1</sup>; Eshan S King, PhD<sup>2</sup>; David C Shonka, MD<sup>1</sup>. <sup>1</sup>University of Virginia; <sup>2</sup>Case Western Reserve University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Pre-operative ultrasonography is considered standard of care for the pre-operative workup for primary hyperparathyroidism and for the initial workup of thyroid nodules. In addition to elucidating thyroid and parathyroid anatomy, ultrasound can identify important vascular anatomy.   An aberrant subclavian artery is associated with a nonrecurrent right laryngeal nerve and an increased risk of associated intraoperative nerve injury, so pre-operative identification of this aberrant anatomy is critical for avoidance of complications. The purpose of this study was to identify predictive factors in visualization of normal innominate artery anatomy on ultrasound. It was hypothesized that increased BMI and increased thyroid size would be associated with decreased likelihood of visualization of the innominate artery. This was designed as a single-center single-surgeon prospective cohort of 37 consecutive adult patients undergoing thyroid or parathyroid surgery from October to November 2025, with each patient undergoing ultrasound in the operating room prior to incision. In 33 of 37 patients (89%), normal innominate arterial anatomy was identified, with abnormal anatomy in 1 of 37 (3%) and no visualization in 3 of 37 (8%). On multivariate logistic regression analysis, the dependent variable was innominate artery identification, with predictor variables of age, sex, BMI, and total thyroid volume. Only BMI was found to be predictive of innominate artery identification, with increasing BMI significantly associated with decreased innominate artery visualization (OR 0.82, CI 0.66 – 0.95, p 0.019) (Figure 1). Of note, BMI was significant even though the lowest BMI patient without normal visualized anatomy had a history of an aberrant right subclavian s/p repair for dysphagia lusoria. No other aberrant subclavian artery was noted on ultrasound or intraoperatively. While this study was limited by a relatively small sample size at a tertiary care institution, multiple conclusions can be drawn. This is the first study to report the frequency of visualization of innominate anatomy on ultrasound and shows that this anatomy can be visualized in most patients on pre-operative ultrasound for thyroid/parathyroid surgery. Additionally, this study identifies larger body habitus as a risk factor for more difficulty in pre-operative visualization of innominate artery anatomy. The results of this study can better prepare the physician to pre-operatively identify an essential anatomic relationship to avoid complications in thyroid and parathyroid surgery.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153361/Innominate.jpg' /></p>\n\n<p>Figure 1. Innominate visualization as a function of BMI. Red dots represent individual patient data. The teal line represents likelihood of normal innominate anatomic visualization for a given BMI.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153361--></body></html>"
    },
    {
      "uid": "P200",
      "content_id": "155599",
      "abstract_number": "P200",
      "poster_number": "P200",
      "title": "Stylohyoid anatomy and headache syndromes",
      "summary": "Cluster headaches may be associated with the distinct morphologic trend of increasingly lateralization in the stylohyoid anatomy. This finding may serve to improve our understanding of neurovascular headache syndromes and skullbase anatomy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155599",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Rind, MD",
      "presenter": "Fahad Rind, MD",
      "authors": "Fahad Rind, MD 1 ; Michael Luttrull, MD 1 ; Matthew Old, MD 2",
      "normalized_authors": [
        "Fahad Rind",
        "Michael Luttrull",
        "Matthew Old"
      ],
      "affiliations": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "normalized_institutions": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 274,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Fahad Rind, MD 1 ; Michael Luttrull, MD 1 ; Matthew Old, MD 2",
        "Affiliations": "1 The Ohio State University; 2 The University of Washington",
        "Introduction": "The styloid process is a projection from the temporal bone that normally measures 20–30 mm and lies near several critical neurovascular structures. When elongated or calcified, it may compress these structures and cause symptoms such as dysphagia, neck pain, and headache, though many individuals remain asymptomatic. This study aims to examine variations in stylohyoid anatomy in patinets with headache syndromes.",
        "Methods": "An IRB-approved bioinformatic search was conducted to find the demopgarically propensity matched patients with no headache diagnosis, migraine diagnoses or cluster headaches; these patients had to have CT scans conducted during the inclusion period. CT scans were studied to document the morphology of styloid processes. Documented variables included mediolateral angulation, anteroposterior angulation, length of styloid process, diameter of styloid process, calcification, and distance from styloid process to the lateral process of the first cervial spine. Statistical analysis was conducted using Mann–Whitney U tests to test for significance of difference between radiologic measurements.",
        "Results": "In total 121 patients were included i.e. 49 controls, 47 patients with migraine history and 25 patients with history of cluster headaches. Overall, patients with cluster headaches had styloid processes with greater mediolateral angles, this was significantly more than both control (Control 72.69° vs Cluster 75.80°; p=0.02) and migraine groups (Migraine 72.71° vs Cluster 75.80°; p=0.01). No significant difference was seen between cohorts when measuring anteroposterior angulation, length of styloid process and distance from C1 to the styloid process.",
        "Conclusion": "Cluster headaches may be associated with the distinct morphologic trend of increasingly lateralization in the stylohyoid anatomy. This finding may serve to improve our understanding of neurovascular headache syndromes and skullbase anatomy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Stylohyoid anatomy and headache syndromes</span>. <u>Fahad Rind, MD</u><sup>1</sup>; Michael Luttrull, MD<sup>1</sup>; Matthew Old, MD<sup>2</sup>. <sup>1</sup>The Ohio State University; <sup>2</sup>The University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: The styloid process is a projection from the temporal bone that normally measures 20–30 mm and lies near several critical neurovascular structures. When elongated or calcified, it may compress these structures and cause symptoms such as dysphagia, neck pain, and headache, though many individuals remain asymptomatic. This study aims to examine variations in stylohyoid anatomy in patinets with headache syndromes.</p>\n\n<p><strong>Methods</strong>: An IRB-approved bioinformatic search was conducted to find the demopgarically propensity matched patients with no headache diagnosis, migraine diagnoses or cluster headaches; these patients had to have CT scans conducted during the inclusion period. CT scans were studied to document the morphology of styloid processes. Documented variables included mediolateral angulation, anteroposterior angulation, length of styloid process, diameter of styloid process, calcification, and distance from styloid process to the lateral process of the first cervial spine. Statistical analysis was conducted using Mann–Whitney U tests to test for significance of difference between radiologic measurements.</p>\n\n<p><strong>Results</strong>: In total 121 patients were included i.e. 49 controls, 47 patients with migraine history and 25 patients with history of cluster headaches. Overall, patients with cluster headaches had styloid processes with greater mediolateral angles, this was significantly more than both control (Control 72.69° vs Cluster 75.80°; p=0.02) and migraine groups (Migraine 72.71° vs Cluster 75.80°; p=0.01). No significant difference was seen between cohorts when measuring anteroposterior angulation, length of styloid process and distance from C1 to the styloid process.</p>\n\n<p><strong>Conclusion</strong>: Cluster headaches may be associated with the distinct morphologic trend of increasingly lateralization in the stylohyoid anatomy. This finding may serve to improve our understanding of neurovascular headache syndromes and skullbase anatomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155599--></body></html>"
    },
    {
      "uid": "P201",
      "content_id": "153460",
      "abstract_number": "P201",
      "poster_number": "P201",
      "title": "Delayed Diagnosis of Head and Neck Cancer During COVID-19",
      "summary": "Although the aggregated multi-institution cohort did not show a statistically significant shift in stage distribution during the COVID-19 pandemic, several centers demonstrated significant increases in advanced tumor or nodal burden and substantial reductions in early-stage disease, suggesting localized diagnostic delays. These findings highlight important health-system–level heterogeneity, likely reflecting...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153460",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chris B Choi, MD",
      "presenter": "Chris B Choi, MD",
      "authors": "Chris B Choi, MD 1 ; Diana Kirke, MD 1 ; Katelyn Stepan, MD 2 ; Joseph Curry, MD 3 ; Sidharth Puram, MD 4 ; Neerav Goyal, MD 5 ; Barry L Wenig, MD 6",
      "normalized_authors": [
        "Chris B Choi",
        "Diana Kirke",
        "Katelyn Stepan",
        "Joseph Curry",
        "Sidharth Puram",
        "Neerav Goyal",
        "Barry L Wenig"
      ],
      "affiliations": [
        "Mount Sinai Hospital",
        "Northwestern University",
        "Thomas Jefferson University",
        "Washington University in St. Louis",
        "Penn State College of Medicine",
        "University of Illinois College of Medicine"
      ],
      "normalized_institutions": [
        "Mount Sinai Hospital",
        "Northwestern University",
        "Thomas Jefferson University",
        "Washington University in St. Louis",
        "Penn State College of Medicine",
        "University of Illinois College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Chris B Choi, MD 1 ; Diana Kirke, MD 1 ; Katelyn Stepan, MD 2 ; Joseph Curry, MD 3 ; Sidharth Puram, MD 4 ; Neerav Goyal, MD 5 ; Barry L Wenig, MD 6",
        "Affiliations": "1 Mount Sinai Hospital; 2 Northwestern University; 3 Thomas Jefferson University; 4 Washington University in St. Louis; 5 Penn State College of Medicine; 6 University of Illinois College of Medicine",
        "Background": "The COVID-19 pandemic caused widespread disruptions to healthcare delivery, raising concerns that reductions in in-person visits, diagnostic procedures, and referral pathways may have delayed cancer diagnosis. Head and neck squamous cell carcinoma (HNSCC), which relies on early symptom recognition and timely evaluation, may be particularly vulnerable to such delays. Although emerging reports suggest a shift toward more advanced disease during the pandemic, large multi-institutional analyses remain limited.",
        "Objective": "To determine whether the COVID-19 pandemic was associated with delayed diagnosis and a shift toward more advanced tumor (T), nodal (N), metastatic (M), and overall stage presentation across five major U.S. cancer centers.",
        "Methods": "We performed a retrospective cohort study using oncology data from Miami Cancer Institute, Northwestern University, Penn State University, Thomas Jefferson University, and Washington University St. Louis. Patients diagnosed from May 2018–February 2020 were classified as pre-COVID, and those from April 2020–January 2022 as post-COVID. Multiple analytic windows (22, 12, 6, and 3 months) were examined using chi-square tests. A total of 2953 patients were included in the primary analysis.",
        "Results": "In the combined multi-site dataset, overall stage distributions did not change significantly in the 22-month comparison (stage IV: 30.6% pre-COVID vs 32.9% post-COVID, p=0.173), and no significant shifts were observed in tumor stage, nodal stage, or metastatic status (all p>0.10). However, site-specific analyses revealed several statistically significant changes consistent with delayed diagnosis. At Miami Cancer Institute, stage I disease decreased substantially from 39.2% to 24.0% (22-month comparison, p=0.010) and from 51.5% to 24.4% in the 6-month comparison (p=0.016), indicating a marked decline in early-stage presentation. Northwestern University demonstrated a significant rise in T2 tumors from 24.9% to 34.7% (p=0.018) and a decline in stage III disease from 16.2% to 8.6% (p=0.012) in the 22-month analysis. Penn State University showed a significant reduction in stage I disease (32.7% to 19.3%, p=0.037) and a corresponding increase in stage IV disease (28.8% to 44.3%, p=0.026) in the 12-month comparison. Thomas Jefferson University exhibited significantly higher N3 nodal disease in both the 22-month (6.8% to 11.3%, p=0.026) and 6-month intervals (3.3% to 11.0%, p=0.024). Washington University St. Louis demonstrated a significant increase in T2 tumors (24.2% to 30.3%, p=0.046) in the 22-month analysis.",
        "Conclusions": "Although the aggregated multi-institution cohort did not show a statistically significant shift in stage distribution during the COVID-19 pandemic, several centers demonstrated significant increases in advanced tumor or nodal burden and substantial reductions in early-stage disease, suggesting localized diagnostic delays. These findings highlight important health-system–level heterogeneity, likely reflecting differences in pandemic burden, access disruption, and institutional referral pathways. Strengthening referral mechanisms, telehealth systems, and proactive community outreach will be essential to maintaining timely cancer diagnosis during future healthcare disruptions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Delayed Diagnosis of Head and Neck Cancer During COVID-19</span>. <u>Chris B Choi, MD</u><sup>1</sup>; Diana Kirke, MD<sup>1</sup>; Katelyn Stepan, MD<sup>2</sup>; Joseph Curry, MD<sup>3</sup>; Sidharth Puram, MD<sup>4</sup>; Neerav Goyal, MD<sup>5</sup>; Barry L Wenig, MD<sup>6</sup>. <sup>1</sup>Mount Sinai Hospital; <sup>2</sup>Northwestern University; <sup>3</sup>Thomas Jefferson University; <sup>4</sup>Washington University in St. Louis; <sup>5</sup>Penn State College of Medicine; <sup>6</sup>University of Illinois College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The COVID-19 pandemic caused widespread disruptions to healthcare delivery, raising concerns that reductions in in-person visits, diagnostic procedures, and referral pathways may have delayed cancer diagnosis. Head and neck squamous cell carcinoma (HNSCC), which relies on early symptom recognition and timely evaluation, may be particularly vulnerable to such delays. Although emerging reports suggest a shift toward more advanced disease during the pandemic, large multi-institutional analyses remain limited.</p>\n\n<p><strong>Objective:</strong> To determine whether the COVID-19 pandemic was associated with delayed diagnosis and a shift toward more advanced tumor (T), nodal (N), metastatic (M), and overall stage presentation across five major U.S. cancer centers.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study using oncology data from Miami Cancer Institute, Northwestern University, Penn State University, Thomas Jefferson University, and Washington University St. Louis. Patients diagnosed from May 2018–February 2020 were classified as pre-COVID, and those from April 2020–January 2022 as post-COVID. Multiple analytic windows (22, 12, 6, and 3 months) were examined using chi-square tests. A total of 2953 patients were included in the primary analysis.</p>\n\n<p><strong>Results: </strong>In the combined multi-site dataset, overall stage distributions did not change significantly in the 22-month comparison (stage IV: 30.6% pre-COVID vs 32.9% post-COVID, p=0.173), and no significant shifts were observed in tumor stage, nodal stage, or metastatic status (all p>0.10). However, site-specific analyses revealed several statistically significant changes consistent with delayed diagnosis. At Miami Cancer Institute, stage I disease decreased substantially from 39.2% to 24.0% (22-month comparison, p=0.010) and from 51.5% to 24.4% in the 6-month comparison (p=0.016), indicating a marked decline in early-stage presentation. Northwestern University demonstrated a significant rise in T2 tumors from 24.9% to 34.7% (p=0.018) and a decline in stage III disease from 16.2% to 8.6% (p=0.012) in the 22-month analysis. Penn State University showed a significant reduction in stage I disease (32.7% to 19.3%, p=0.037) and a corresponding increase in stage IV disease (28.8% to 44.3%, p=0.026) in the 12-month comparison. Thomas Jefferson University exhibited significantly higher N3 nodal disease in both the 22-month (6.8% to 11.3%, p=0.026) and 6-month intervals (3.3% to 11.0%, p=0.024). Washington University St. Louis demonstrated a significant increase in T2 tumors (24.2% to 30.3%, p=0.046) in the 22-month analysis.</p>\n\n<p><strong>Conclusions: </strong>Although the aggregated multi-institution cohort did not show a statistically significant shift in stage distribution during the COVID-19 pandemic, several centers demonstrated significant increases in advanced tumor or nodal burden and substantial reductions in early-stage disease, suggesting localized diagnostic delays. These findings highlight important health-system–level heterogeneity, likely reflecting differences in pandemic burden, access disruption, and institutional referral pathways. Strengthening referral mechanisms, telehealth systems, and proactive community outreach will be essential to maintaining timely cancer diagnosis during future healthcare disruptions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153460--></body></html>"
    },
    {
      "uid": "P202",
      "content_id": "153365",
      "abstract_number": "P202",
      "poster_number": "P202",
      "title": "Seeing Is Believing: MRI Accuracy in Diagnosis and Pre-operative Planning for Parotid Gland Malignancies",
      "summary": "Parotid salivary gland malignancies encompass numerous histopathological types. While some are inherently high grade such as salivary duct carcinoma, most others require pathologic grading. Treatment strategies differ between high-grade and low-to-intermediate-grade tumors, making accurate classification essential for appropriate management. Preoperative diagnosis typically relies on fine-needle aspiration (FNA)...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153365",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Georges E Daoud, MD",
      "presenter": "Georges E Daoud, MD",
      "authors": "Georges E Daoud, MD 1 ; Ethan Kearns, BS 2 ; Peter W Kahng, MD 1 ; Harry M Baddour, MD 1 ; Azeem S Kaka, MD 1 ; Brian J Boyce, MD 1 ; Jennifer H Gross, MD 1 ; Kelly R Magliocca, DDS 3 ; Ashley H Aiken, MD 4 ; Nicole C Schmitt, MD 1",
      "normalized_authors": [
        "Georges E Daoud",
        "Ethan Kearns",
        "Peter W Kahng",
        "Harry M Baddour",
        "Azeem S Kaka",
        "Brian J Boyce",
        "Jennifer H Gross",
        "Kelly R Magliocca",
        "Ashley H Aiken",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Winship Cancer Institute of Emory University - Department of Otolaryngology Head & Neck Surgery",
        "Medical College of Georgia",
        "Winship Cancer Institute of Emory University - Department of Oral and Maxillofacial Pathology",
        "Winship Cancer Institute of Emory University - Department of Radiology and Imaging Sciences"
      ],
      "normalized_institutions": [
        "Winship Cancer Institute of Emory University - Department of Otolaryngology Head & Neck Surgery",
        "Medical College of Georgia",
        "Winship Cancer Institute of Emory University - Department of Oral and Maxillofacial Pathology",
        "Winship Cancer Institute of Emory University - Department of Radiology and Imaging Sciences"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 357,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Georges E Daoud, MD 1 ; Ethan Kearns, BS 2 ; Peter W Kahng, MD 1 ; Harry M Baddour, MD 1 ; Azeem S Kaka, MD 1 ; Brian J Boyce, MD 1 ; Jennifer H Gross, MD 1 ; Kelly R Magliocca, DDS 3 ; Ashley H Aiken, MD 4 ; Nicole C Schmitt, MD 1",
        "Affiliations": "1 Winship Cancer Institute of Emory University - Department of Otolaryngology Head & Neck Surgery; 2 Medical College of Georgia; 3 Winship Cancer Institute of Emory University - Department of Oral and Maxillofacial Pathology; 4 Winship Cancer Institute of Emory University - Department of Radiology and Imaging Sciences",
        "BACKGROUND": "Parotid salivary gland malignancies encompass numerous histopathological types. While some are inherently high grade such as salivary duct carcinoma, most others require pathologic grading. Treatment strategies differ between high-grade and low-to-intermediate-grade tumors, making accurate classification essential for appropriate management. Preoperative diagnosis typically relies on fine-needle aspiration (FNA) and imaging, particularly MRI; however, distinguishing tumor grade prior to surgery remains challenging. This project aims to evaluate the accuracy of MRI in distinguishing high- and low-to-intermediate grade parotid gland malignancies.",
        "METHODS": "This retrospective cohort study examined 315 patients who underwent parotidectomy for malignancy from 2015 to 2025 at a tertiary care center. Only patients who had a preoperative MRI interpreted by a neuroradiologist were included. For each patient, the MRI interpretation, FNA, frozen section (FS) evaluation, and final histopathologic data were collected and analyzed. Data were stratified by high- and low to intermediate- grade pathologic diagnosis and cohorts were examined independently. Comparative statistical analyses were performed using the Chi-squared test.",
        "RESULTS": "Seventy-four patients met inclusion criteria, divided into pathologically high-grade (n=38), and pathologically low- or intermediate- grade (n=36) parotid malignancies. For low- or intermediate- grade malignancies confirmed by final pathology, pre-operative FNA suspected malignancy in only 54.5% of cases, which was significantly less than FS (85.3%, p=0.01) and trended towards significantly less when compared with MRI alone (77.8%, p=0.06). Moreover, there was no significant difference in detecting malignancy between MRI and FS alone (77.8% vs. 85.3%, p=0.42). For high-grade malignancy confirmed by final pathology, suspicion for high-grade malignancy specifically was much higher for all diagnostics tests: 96.4% with FS, 86.8% with MRI, and 70.6% with FNA. As expected, detection of high-grade malignancy was superior with FS (p=0.03), but there was no significant difference in detection rates between MRI and FNA (p=0.28).",
        "CONCLUSION": "In tertiary referral centers with neuroradiology expertise, pre-operative MRI with intraoperative FS is an oncologically responsible option and may be sufficient for surgical planning and pre-operative patient counseling on extent of surgery and need for neck dissection. This approach potentially obviates the need for pre-operative FNA for suspected parotid malignancies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Seeing Is Believing: MRI Accuracy in Diagnosis and Pre-operative Planning for Parotid Gland Malignancies</span>. <u>Georges E Daoud, MD</u><sup>1</sup>; Ethan Kearns, BS<sup>2</sup>; Peter W Kahng, MD<sup>1</sup>; Harry M Baddour, MD<sup>1</sup>; Azeem S Kaka, MD<sup>1</sup>; Brian J Boyce, MD<sup>1</sup>; Jennifer H Gross, MD<sup>1</sup>; Kelly R Magliocca, DDS<sup>3</sup>; Ashley H Aiken, MD<sup>4</sup>; Nicole C Schmitt, MD<sup>1</sup>. <sup>1</sup>Winship Cancer Institute of Emory University - Department of Otolaryngology Head & Neck Surgery; <sup>2</sup>Medical College of Georgia; <sup>3</sup>Winship Cancer Institute of Emory University - Department of Oral and Maxillofacial Pathology; <sup>4</sup>Winship Cancer Institute of Emory University - Department of Radiology and Imaging Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Parotid salivary gland malignancies encompass numerous histopathological types. While some are inherently high grade such as salivary duct carcinoma, most others require pathologic grading. Treatment strategies differ between high-grade and low-to-intermediate-grade tumors, making accurate classification essential for appropriate management. Preoperative diagnosis typically relies on fine-needle aspiration (FNA) and imaging, particularly MRI; however, distinguishing tumor grade prior to surgery remains challenging. This project aims to evaluate the accuracy of MRI in distinguishing high- and low-to-intermediate grade parotid gland malignancies.</p>\n\n<p><strong>METHODS: </strong>This retrospective cohort study examined 315 patients who underwent parotidectomy for malignancy from 2015 to 2025 at a tertiary care center. Only patients who had a preoperative MRI interpreted by a neuroradiologist were included. For each patient, the MRI interpretation, FNA, frozen section (FS) evaluation, and final histopathologic data were collected and analyzed. Data were stratified by high- and low to intermediate- grade pathologic diagnosis and cohorts were examined independently. Comparative statistical analyses were performed using the Chi-squared test.</p>\n\n<p><strong>RESULTS: </strong>Seventy-four patients met inclusion criteria, divided into pathologically high-grade (n=38), and pathologically low- or intermediate- grade (n=36) parotid malignancies. For low- or intermediate- grade malignancies confirmed by final pathology, pre-operative FNA suspected malignancy in only 54.5% of cases, which was significantly less than FS (85.3%, p=0.01) and trended towards significantly less when compared with MRI alone (77.8%, p=0.06). Moreover, there was no significant difference in detecting malignancy between MRI and FS alone (77.8% vs. 85.3%, p=0.42). For high-grade malignancy confirmed by final pathology, suspicion for high-grade malignancy specifically was much higher for all diagnostics tests: 96.4% with FS, 86.8% with MRI, and 70.6% with FNA. As expected, detection of high-grade malignancy was superior with FS (p=0.03), but there was no significant difference in detection rates between MRI and FNA (p=0.28).</p>\n\n<p><strong>CONCLUSION: </strong>In tertiary referral centers with neuroradiology expertise, pre-operative MRI with intraoperative FS is an oncologically responsible option and may be sufficient for surgical planning and pre-operative patient counseling on extent of surgery and need for neck dissection. This approach potentially obviates the need for pre-operative FNA for suspected parotid malignancies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153365--></body></html>"
    },
    {
      "uid": "P203",
      "content_id": "154514",
      "abstract_number": "P203",
      "poster_number": "P203",
      "title": "MAGNETIC RESONANCE IMAGING (MRI) USING ADC (APPARENT DIFFUSION COEFFICIENT) MAP: A TOOL FOR DIFFERENTIATING BETWEEN LYMPHOMAS AND ORBITAL LESIONS",
      "summary": "The orbit is a small anatomical space containing several important structures. Diagnosing orbital masses can be challenging, due to the numerous possible etiologies, their threat to vision and their relation to the skull base. Magnetic resonance imaging (MRI) assumes an essential role because of its high accuracy in tissue contrast differentiation, lack of irradiation and the use of techniques that can reflect...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154514",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alvaro Emilio Arteaga Guamán",
      "presenter": "Alvaro Emilio Arteaga Guamán",
      "authors": "Alvaro Emilio Arteaga Guamán ; Eduardo Calheiros de Moraes; Marcos Decnop Batista Pinheiro; Pedro Nunes Bernotavicius Araújo; Maria Cristina Traiano Beal; Terence Pires de Farias; Fernando Luiz Dias",
      "normalized_authors": [
        "Alvaro Emilio Arteaga Guamán",
        "Eduardo Calheiros de Moraes",
        "Marcos Decnop Batista Pinheiro",
        "Pedro Nunes Bernotavicius Araújo",
        "Maria Cristina Traiano Beal",
        "Terence Pires de Farias",
        "Fernando Luiz Dias"
      ],
      "affiliations": [
        "Brazilian National Cancer Institute"
      ],
      "normalized_institutions": [
        "Brazilian National Cancer Institute"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 345,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alvaro Emilio Arteaga Guamán ; Eduardo Calheiros de Moraes; Marcos Decnop Batista Pinheiro; Pedro Nunes Bernotavicius Araújo; Maria Cristina Traiano Beal; Terence Pires de Farias; Fernando Luiz Dias",
        "Affiliations": "Brazilian National Cancer Institute",
        "Abstract": "The orbit is a small anatomical space containing several important structures. Diagnosing orbital masses can be challenging, due to the numerous possible etiologies, their threat to vision and their relation to the skull base. Magnetic resonance imaging (MRI) assumes an essential role because of its high accuracy in tissue contrast differentiation, lack of irradiation and the use of techniques that can reflect the biochemical features of masses. Diffusion-weighted imaging (DWI) is a technique based on MRI which uses the diffusivity of moving water protons in different tissues to produce image contrast. A quantitative DW-MRI measure widely used in clinical practice, called apparent diffusion coefficient (ADC), can be easily acquired from MRI images once they are calculated automatically by a software and displayed as a parametric map. There is a correlation betwen the absolute ADC value and tumour cellularity, which can improve the diagnosis of orbital masses. Malignant lesions demonstrate restricted diffusion due to their higher cellularity and nuclear-cytoplasmic ratio within the cells. Previous studies showed that lymphomas have the lowest mean ADC values compared to other masses located in the head and neck, such as squamous cell carcinomas (SCC) and inflammatory lesions. Furthermore, the relative ADC (rADC), calculated by dividing ADC value of the orbital lesion by that of the adjacent periorbital parenchyma, can be used to optimize ADC value. The aim of this study is to evaluate the absolute and relative ADC values of orbital lymphomas and compare them with values from orbital masses of different etiologies, such as SCC metastases and inflammatory lesions. MRI images of twenty-nine patients with orbital masses were analysed, in which 51% were orbital lymphomas and 49% were other lesions. In addition to this, their absolute and relative ADC values were measured and compared. In this setting, there are few studies in the literature evaluating the role of absolute and relative ADC values in differentiating orbital lymphomas from other orbital masses of different etiologies. This is an important quantitative and non-invasive tool that can enhance conventional MRI and can be helpful for the characterization and differentiation of orbital lymphomas."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>MAGNETIC RESONANCE IMAGING (MRI) USING ADC (APPARENT DIFFUSION COEFFICIENT) MAP: A TOOL FOR DIFFERENTIATING BETWEEN LYMPHOMAS AND ORBITAL LESIONS</span>. <u>Alvaro Emilio Arteaga Guamán</u>; Eduardo Calheiros de Moraes; Marcos Decnop Batista Pinheiro; Pedro Nunes Bernotavicius Araújo; Maria Cristina Traiano Beal; Terence Pires de Farias; Fernando Luiz Dias. Brazilian National Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The orbit is a small anatomical space containing several important structures. Diagnosing orbital masses can be challenging, due to the numerous possible etiologies, their threat to vision and their relation to the skull base. Magnetic resonance imaging (MRI) assumes an essential role because of its high accuracy in tissue contrast differentiation, lack of irradiation and the use of techniques that can reflect the biochemical features of masses. Diffusion-weighted imaging (DWI) is a technique based on MRI which uses the diffusivity of moving water protons in different tissues to produce image contrast. A quantitative DW-MRI measure widely used in clinical practice, called apparent diffusion coefficient (ADC), can be easily acquired from MRI images once they are calculated automatically by a software and displayed as a parametric map. There is a correlation betwen the absolute ADC value and tumour cellularity, which can improve the diagnosis of orbital masses. Malignant lesions demonstrate restricted diffusion due to their higher cellularity and nuclear-cytoplasmic ratio within the cells.  Previous studies showed that lymphomas have the lowest mean ADC values compared to other masses located in the head and neck, such as squamous cell carcinomas (SCC) and inflammatory lesions. Furthermore, the relative ADC (rADC), calculated by dividing ADC value of the orbital lesion by that of the adjacent periorbital parenchyma, can be used to optimize ADC value. The aim of this study is to evaluate the absolute and relative ADC values of orbital lymphomas and compare them with values from orbital masses of different etiologies, such as SCC metastases and inflammatory lesions. MRI images of twenty-nine patients with orbital masses were analysed, in which 51% were orbital lymphomas and 49% were other lesions. In addition to this, their absolute and relative ADC values were measured and compared. In this setting, there are few studies in the literature evaluating the role of absolute and relative ADC values in differentiating orbital lymphomas from other orbital masses of different etiologies. This is an important quantitative and non-invasive tool that can enhance conventional MRI and can be helpful for the characterization and differentiation of orbital lymphomas.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154514--></body></html>"
    },
    {
      "uid": "P204",
      "content_id": "155511",
      "abstract_number": "P204",
      "poster_number": "P204",
      "title": "Semi-supervised deep-learning of USG images for risk-stratification of indeterminate thyroid nodules- a multicentric validation in Indian Population",
      "summary": "We present a multicentre-validated deep-learning framework that integrates attention-guided segmentation (achieving 100% nodule detection in validation videos). The study addresses cytology-indeterminate nodules, which improves malignancy risk stratification in the most clinically challenging subgroup and may support more appropriate decision-making for USG-FNAC/B and active surveillance.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155511",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Moni Abraham Kuriakose",
      "presenter": "Moni Abraham Kuriakose",
      "authors": "Sumsum P Sunny 1 ; Anela Thomas 1 ; Greeshma K P 2 ; Supriya K 2 ; Kunal Gupta 3 ; Manas P Peter 4 ; Shivaprasad K S 5 ; Kranti Khadilkar 5 ; Yogesh Dhoke 6 ; Jensy Jaison 7 ; Vishal Gupta 8 ; Bijoy Jacob Thomas Jacob Thomas 4 ; Moni Abraham Kuriakose 9 ; Indu Elizabeth Mathew 5 ; Shriraam P Mahadevan 4 ; Vijay Pillai 6 ; Amritha Suresh 9 ; Subramanian Kannan 10",
      "normalized_authors": [
        "Sumsum P Sunny",
        "Anela Thomas",
        "Greeshma K P",
        "Supriya K",
        "Kunal Gupta",
        "Manas P Peter",
        "Shivaprasad K S",
        "Kranti Khadilkar",
        "Yogesh Dhoke",
        "Jensy Jaison",
        "Vishal Gupta",
        "Bijoy Jacob Thomas Jacob Thomas",
        "Moni Abraham Kuriakose",
        "Indu Elizabeth Mathew",
        "Shriraam P Mahadevan",
        "Vijay Pillai",
        "Amritha Suresh",
        "Subramanian Kannan"
      ],
      "affiliations": [
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099",
        "Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Endocrinology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
        "Department of Endocrinology, Ernakulam Medical Centre, Kochi, India, 682028",
        "Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Radiology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
        "Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203"
      ],
      "normalized_institutions": [
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099",
        "Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Endocrinology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
        "Department of Endocrinology, Ernakulam Medical Centre, Kochi, India, 682028",
        "Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Radiology, Sri Ramachandra Medical Centre, Chennai, India, 600116",
        "Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203"
      ],
      "session_type": "Poster",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155511/workflow.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155511/workflow.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155511"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sumsum P Sunny 1 ; Anela Thomas 1 ; Greeshma K P 2 ; Supriya K 2 ; Kunal Gupta 3 ; Manas P Peter 4 ; Shivaprasad K S 5 ; Kranti Khadilkar 5 ; Yogesh Dhoke 6 ; Jensy Jaison 7 ; Vishal Gupta 8 ; Bijoy Jacob Thomas Jacob Thomas 4 ; Moni Abraham Kuriakose 9 ; Indu Elizabeth Mathew 5 ; Shriraam P Mahadevan 4 ; Vijay Pillai 6 ; Amritha Suresh 9 ; Subramanian Kannan 10",
        "Affiliations": "1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 2 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; 3 Department of Endocrinology, Sri Ramachandra Medical Centre, Chennai, India, 600116; 4 Department of Endocrinology, Ernakulam Medical Centre, Kochi, India, 682028; 5 Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 6 Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 7 Department of Radiology, Sri Ramachandra Medical Centre, Chennai, India, 600116; 8 Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203; 9 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203; 10 Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Background": "Ultrasonography-Guided Fine-Needle Aspiration Cytology/Biopsy (USG-FNAC/B), followed by the Bethesda classification system, is the current standard-of-care for risk-stratification of thyroid nodules. However, approximately 40% of nodules are classified as non-conclusive (indeterminate), often leading to surgery to establish a definitive diagnosis. Accurate malignant stratification during live USG imaging could assist clinicians in determining appropriate management strategies, including targeted USG-FNAC/B or active surveillance. Although advances in machine-learning have enabled the development of highly accurate image-based classification models, these approaches typically require large datasets with reliable ground-truth labels. Obtaining such labels for indeterminate nodules remains challenging. In the present study, we developed a deep-learning–based classification model that leverages unlabelled images (absence of ground-truth labels) to improve stratification of indeterminate thyroid nodules.",
        "Methods": "USG images and videos were collected from three tertiary care hospitals after ethics committee approval and written informed consent. The analysis followed a two-step approach: first identifying thyroid nodules on ultrasound images and then classifying them as benign or malignant. A total of 2,498 images from 260 nodules and 160 images from 20 normal glands were labelled by radiologist. In addition, 466 publicly available images from the Kaggle dataset were included for developing the nodule detection. Segmentation models, including modified U-Nets, were used to identify nodules, and performance was evaluated using Intersection over Union (IoU).",
        "Abstract": "Initial classification (small CNN) models were trained using nodules with confirmed diagnoses based on cytology and/or histopathology, including benign (5,682 images from 265 nodules) and malignant nodules (2,892 images from 135 nodules). Because relatively few indeterminate nodules (n=38) had surgical confirmation, a semi-supervised learning approach was used, allowing the model to learn from both labelled and unlabelled images (1,534 images from 202 nodules- absence of ground-truth labels). Model performance was assessed using sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Validation was performed using independent datasets from participating institutions (108 benign and 10 malignant nodules) and ultrasound video recordings (56 benign and 51 malignant cases) where diagnosis was available.",
        "Results": "Atrous U-Net demonstrated the best performance for nodule segmentation on the independent test dataset (n = 250 images), achieving a IoU of 0.91. The model also achieved 100% accuracy in detecting nodules in validation ultrasound video recordings (n=107). A baseline classifier trained on definitively benign and malignant nodules achieved AUC of 0.83 but showed poor performance for indeterminate nodules (AUC 0.57). Incorporation of uncertainty-guided semi-supervised learning, which included unlabelled indeterminate nodules, significantly improved classification of Bethesda III/IV nodules, achieving a sensitivity of 84% (16/19) and specificity of 70% (12/17), with an AUC of 0.75. This approach outperformed the naïve supervised model. External validation using datasets from participating institutions demonstrated sustained diagnostic performance, with a sensitivity of 80% (8/10) and specificity of 75.9% (82/108).",
        "Conclusions": "We present a multicentre-validated deep-learning framework that integrates attention-guided segmentation (achieving 100% nodule detection in validation videos). The study addresses cytology-indeterminate nodules, which improves malignancy risk stratification in the most clinically challenging subgroup and may support more appropriate decision-making for USG-FNAC/B and active surveillance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Semi-supervised deep-learning of USG images for risk-stratification of indeterminate thyroid nodules- a multicentric validation in Indian Population</span>. Sumsum P Sunny<sup>1</sup>; Anela Thomas<sup>1</sup>; Greeshma K P<sup>2</sup>; Supriya K<sup>2</sup>; Kunal Gupta<sup>3</sup>; Manas P Peter<sup>4</sup>; Shivaprasad K S<sup>5</sup>; Kranti Khadilkar<sup>5</sup>; Yogesh Dhoke<sup>6</sup>; Jensy Jaison<sup>7</sup>; Vishal Gupta<sup>8</sup>; Bijoy Jacob Thomas Jacob Thomas<sup>4</sup>; <u>Moni Abraham Kuriakose</u><sup>9</sup>; Indu Elizabeth Mathew<sup>5</sup>; Shriraam P Mahadevan<sup>4</sup>; Vijay Pillai<sup>6</sup>; Amritha Suresh<sup>9</sup>; Subramanian Kannan<sup>10</sup>. <sup>1</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; <sup>2</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; <sup>3</sup>Department of Endocrinology, Sri Ramachandra Medical Centre, Chennai, India, 600116; <sup>4</sup>Department of Endocrinology, Ernakulam Medical Centre, Kochi, India, 682028; <sup>5</sup>Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; <sup>6</sup>Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; <sup>7</sup>Department of Radiology, Sri Ramachandra Medical Centre, Chennai, India, 600116; <sup>8</sup>Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203; <sup>9</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203; <sup>10</sup>Department of Head and Neck Oncology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099;  Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Ultrasonography-Guided Fine-Needle Aspiration Cytology/Biopsy (USG-FNAC/B), followed by the Bethesda classification system, is the current standard-of-care for risk-stratification of thyroid nodules. However, approximately 40% of nodules are classified as non-conclusive (indeterminate), often leading to surgery to establish a definitive diagnosis. Accurate malignant stratification during live USG imaging could assist clinicians in determining appropriate management strategies, including targeted USG-FNAC/B or active surveillance. Although advances in machine-learning have enabled the development of highly accurate image-based classification models, these approaches typically require large datasets with reliable ground-truth labels. Obtaining such labels for indeterminate nodules remains challenging. In the present study, we developed a deep-learning–based classification model that leverages unlabelled images (absence of ground-truth labels) to improve stratification of indeterminate thyroid nodules.</p>\n\n<p><strong>Methods:</strong> USG images and videos were collected from three tertiary care hospitals after ethics committee approval and written informed consent. The analysis followed a two-step approach: first identifying thyroid nodules on ultrasound images and then classifying them as benign or malignant. A total of 2,498 images from 260 nodules and 160 images from 20 normal glands were labelled by radiologist. In addition, 466 publicly available images from the Kaggle dataset were included for developing the nodule detection. Segmentation models, including modified U-Nets, were used to identify nodules, and performance was evaluated using Intersection over Union (IoU).</p>\n\n<p>Initial classification (small CNN) models were trained using nodules with confirmed diagnoses based on cytology and/or histopathology, including benign (5,682 images from 265 nodules) and malignant nodules (2,892 images from 135 nodules). Because relatively few indeterminate nodules (n=38) had surgical confirmation, a semi-supervised learning approach was used, allowing the model to learn from both labelled and unlabelled images (1,534 images from 202 nodules- absence of ground-truth labels). Model performance was assessed using sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Validation was performed using independent datasets from participating institutions (108 benign and 10 malignant nodules) and ultrasound video recordings (56 benign and 51 malignant cases) where diagnosis was available.</p>\n\n<p><strong>Results:</strong> Atrous U-Net demonstrated the best performance for nodule segmentation on the independent test dataset (n = 250 images), achieving a IoU of 0.91. The model also achieved 100% accuracy in detecting nodules in validation ultrasound video recordings (n=107). A baseline classifier trained on definitively benign and malignant nodules achieved AUC of 0.83 but showed poor performance for indeterminate nodules (AUC 0.57). Incorporation of uncertainty-guided semi-supervised learning, which included unlabelled indeterminate nodules, significantly improved classification of Bethesda III/IV nodules, achieving a sensitivity of 84% (16/19) and specificity of 70% (12/17), with an AUC of 0.75. This approach outperformed the naïve supervised model. External validation using datasets from participating institutions demonstrated sustained diagnostic performance, with a sensitivity of 80% (8/10) and specificity of 75.9% (82/108).</p>\n\n<p><strong>Conclusions:</strong> We present a multicentre-validated deep-learning framework that integrates attention-guided segmentation (achieving 100% nodule detection in validation videos). The study addresses cytology-indeterminate nodules, which improves malignancy risk stratification in the most clinically challenging subgroup and may support more appropriate decision-making for USG-FNAC/B and active surveillance.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155511/workflow.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155511--></body></html>"
    },
    {
      "uid": "P205",
      "content_id": "153038",
      "abstract_number": "P205",
      "poster_number": "P205",
      "title": "Effects of Induction Immunotherapy via Pembrolizumab on Postoperative Outcomes Following Free Flap Reconstruction of Head and Neck Cancer",
      "summary": "Patients undergoing induction ICI prior to surgical excision with FFR demonstrated no significant differences in healing, complications, and other postoperative outcomes compared to those who did not receive ICI, although trending higher rates of discharge with tracheostomy. Our findings suggest that induction ICI with pembrolizumab may represent a feasible and generally safe approach for management of locally...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153038",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sanjana Velu",
      "presenter": "Sanjana Velu",
      "authors": "Sanjana Velu 1 ; Praneet C Kaki, BS 2 ; Dante J Merlino, MD, PhD 1 ; Robert M Brody, MD 1 ; Ryan M Carey, MD 1 ; Ara Chalian, MD 1 ; Karthik Rajasekaran, MD, FACS 1 ; Steven B Cannady, MD 1",
      "normalized_authors": [
        "Sanjana Velu",
        "Praneet C Kaki",
        "Dante J Merlino",
        "Robert M Brody",
        "Ryan M Carey",
        "Ara Chalian",
        "Karthik Rajasekaran",
        "Steven B Cannady"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
        "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA",
        "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sanjana Velu 1 ; Praneet C Kaki, BS 2 ; Dante J Merlino, MD, PhD 1 ; Robert M Brody, MD 1 ; Ryan M Carey, MD 1 ; Ara Chalian, MD 1 ; Karthik Rajasekaran, MD, FACS 1 ; Steven B Cannady, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA",
        "Introduction": "Pembrolizumab is an immune checkpoint inhibitor (ICI) that received FDA approval in June 2025 for resectable, locally advanced head and neck squamous cell carcinoma with PD-L1 expression. Approval was based on trials showing that pembrolizumab administration before, during, and after standard surgical treatment increased tumor shrinkage and improved event-free survival.",
        "Abstract": "Due to the recent approval of pembrolizumab as an induction therapy in this setting, little is known about its impact on subsequent surgical outcomes, especially in patient populations such as those undergoing microvascular free flap reconstruction (FFR) for large complex defects. ICI patients trended toward a higher rate of discharge with tracheostomy tube in place (59% vs 35%; p=0.085). Rates of vascular compromise (5.9% vs 2.9%), flap loss (0% vs 2.9%), hemorrhage (0% vs 5.9%), blood transfusions (47% vs 30%), return to OR (12% vs 5.9%), and readmission within 30 days (13% vs 18%) were similar between groups. There were no significant differences in other post-operative outcomes including donor site complications, recipient site complications, neck infection, salivary leak, ICU stay, return to ventilation, DVT/PE, pneumonia, UTI, cardiac events, delirium, CVA, systemic anticoagulation, feeding tube requirement at discharge, discharge disposition, and length of stay.",
        "Methods": "A retrospective cohort study of head and neck cancer (HNC) patients who underwent FFR between 2019-2025 and received induction pembrolizumab (ICI) within 90 days of surgery was conducted. Patient cohorts were defined as ICI and no ICI (nICI). A 1:2 propensity score match (PSM) was performed to match for age, race, gender, smoking status, flap type, pathology, and primary site. Data pertaining to postoperative outcomes were extracted for comparison between groups. Statistical analysis was performed using R Studio.",
        "Results": "51 patients met inclusion criteria (65.2 years, 78% White, 69% male), with 17 (33%) receiving ICI and 34 (67%) not receiving ICI. Among the whole cohort, 23 (45%) were former or current smokers, 21 (41%) received a radial forearm flap, 39 (76%) had squamous cell carcinoma, and 18 (35%) had primary disease of the oral cavity. Post-PSM, there were no significant differences in age, sex, race, smoking status, pathology, and primary site between ICI and nICI cohorts.",
        "Conclusions": "Patients undergoing induction ICI prior to surgical excision with FFR demonstrated no significant differences in healing, complications, and other postoperative outcomes compared to those who did not receive ICI, although trending higher rates of discharge with tracheostomy. Our findings suggest that induction ICI with pembrolizumab may represent a feasible and generally safe approach for management of locally advanced HNC requiring microvascular reconstructions compared to standard treatment regimens without ICI. However, the novelty of pembrolizumab usage in this context and the limited sample size of our study restricts our ability to draw definitive conclusions. As the usage of induction ICI expands in the management of HNC, larger, longitudinal prospective studies will be essential to verify and expand upon our findings to better delineate the long-term risks and benefits of this new treatment paradigm."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Effects of Induction Immunotherapy via Pembrolizumab on Postoperative Outcomes Following Free Flap Reconstruction of Head and Neck Cancer</span>. <u>Sanjana Velu</u><sup>1</sup>; Praneet C Kaki, BS<sup>2</sup>; Dante J Merlino, MD, PhD<sup>1</sup>; Robert M Brody, MD<sup>1</sup>; Ryan M Carey, MD<sup>1</sup>; Ara Chalian, MD<sup>1</sup>; Karthik Rajasekaran, MD, FACS<sup>1</sup>; Steven B Cannady, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA; <sup>2</sup>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Pembrolizumab is an immune checkpoint inhibitor (ICI) that received FDA approval in June 2025 for resectable, locally advanced head and neck squamous cell carcinoma with PD-L1 expression. Approval was based on trials showing that pembrolizumab administration before, during, and after standard surgical treatment increased tumor shrinkage and improved event-free survival.</p>\n\n<p>Due to the recent approval of pembrolizumab as an induction therapy in this setting, little is known about its impact on subsequent surgical outcomes, especially in patient populations such as those undergoing microvascular free flap reconstruction (FFR) for large complex defects.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of head and neck cancer (HNC) patients who underwent FFR between 2019-2025 and received induction pembrolizumab (ICI) within 90 days of surgery was conducted. Patient cohorts were defined as ICI and no ICI (nICI). A 1:2 propensity score match (PSM) was performed to match for age, race, gender, smoking status, flap type, pathology, and primary site. Data pertaining to postoperative outcomes were extracted for comparison between groups. Statistical analysis was performed using R Studio.</p>\n\n<p><strong>Results: </strong>51 patients met inclusion criteria (65.2 years, 78% White, 69% male), with 17 (33%) receiving ICI and 34 (67%) not receiving ICI. Among the whole cohort, 23 (45%) were former or current smokers, 21 (41%) received a radial forearm flap, 39 (76%) had squamous cell carcinoma, and 18 (35%) had primary disease of the oral cavity. Post-PSM, there were no significant differences in age, sex, race, smoking status, pathology, and primary site between ICI and nICI cohorts.</p>\n\n<p>ICI patients trended toward a higher rate of discharge with tracheostomy tube in place (59% vs 35%; p=0.085). Rates of vascular compromise (5.9% vs 2.9%), flap loss (0% vs 2.9%), hemorrhage (0% vs 5.9%), blood transfusions (47% vs 30%), return to OR (12% vs 5.9%), and readmission within 30 days (13% vs 18%) were similar between groups. There were no significant differences in other post-operative outcomes including donor site complications, recipient site complications, neck infection, salivary leak, ICU stay, return to ventilation, DVT/PE, pneumonia, UTI, cardiac events, delirium, CVA, systemic anticoagulation, feeding tube requirement at discharge, discharge disposition, and length of stay.</p>\n\n<p><strong>Conclusions: </strong>Patients undergoing induction ICI prior to surgical excision with FFR demonstrated no significant differences in healing, complications, and other postoperative outcomes compared to those who did not receive ICI, although trending higher rates of discharge with tracheostomy. Our findings suggest that induction ICI with pembrolizumab may represent a feasible and generally safe approach for management of locally advanced HNC requiring microvascular reconstructions compared to standard treatment regimens without ICI. However, the novelty of pembrolizumab usage in this context and the limited sample size of our study restricts our ability to draw definitive conclusions. As the usage of induction ICI expands in the management of HNC, larger, longitudinal prospective studies will be essential to verify and expand upon our findings to better delineate the long-term risks and benefits of this new treatment paradigm.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153038--></body></html>"
    },
    {
      "uid": "P206",
      "content_id": "154160",
      "abstract_number": "P206",
      "poster_number": "P206",
      "title": "Prognostic Significance of Early Eosinophil Dynamics and Baseline Neutrophil-to-Lymphocyte Ratio in Pembrolizumab-Treated Advanced Head and Neck Squamous Cell Carcinoma",
      "summary": "Among patients with advanced HNSCC treated with pembrolizumab, an early eosinophil count increase was associated with improved progression-free survival, suggesting that early peripheral eosinophil count increases may represent a robust treatment-related immunologic activity. In contrast, baseline NLR provided no prognostic insight. These findings support the potential value of eosinophil kinetics as an...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154160",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ido Amir, MD",
      "presenter": "Ido Amir, MD",
      "authors": "Ido Amir, MD 1 ; Eyal Yosefof, MD 2 ; Yuval Avidor, MD 1 ; Daniel Krutik, BScMed 3 ; Ethan Soudry, MD 1",
      "normalized_authors": [
        "Ido Amir",
        "Eyal Yosefof",
        "Yuval Avidor",
        "Daniel Krutik, BScMed",
        "Ethan Soudry"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel",
        "Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel",
        "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel",
        "Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel",
        "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 456,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ido Amir, MD 1 ; Eyal Yosefof, MD 2 ; Yuval Avidor, MD 1 ; Daniel Krutik, BScMed 3 ; Ethan Soudry, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel; 2 Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "Background": "Pembrolizumab is an established treatment option for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Practical biomarkers that may assist in assessing treatment outcomes are an area of active investigation. Peripheral inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR) and eosinophil count dynamics during therapy have been suggested as potential indicators of systemic immune activity during treatment with immune checkpoint inhibitors for various types of malignancies. This study evaluates whether baseline NLR and early eosinophil count dynamics are associated with survival outcomes in pembrolizumab-treated HNSCC patients.",
        "Methods": "A retrospective cohort of patients with recurrent or metastatic HNSCC treated with pembrolizumab at a single tertiary academic center between March 2018 and January 2024 was analyzed. Primary tumor sites included the oral cavity, oropharynx, larynx or supraglottis, hypopharynx, nasopharynx, the sinonasal tract, and unknown primary SCC. Complete blood counts (CBC) were obtained prior to the first three treatment cycles and again at 3 months and 6 months after treatment initiation. A high baseline NLR was defined as >3. An eosinophil surge was defined as an absolute eosinophil count >500 cells/µL at baseline or a ≥3-fold increase within 6 months of treatment initiation. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Cox proportional hazards modeling with multivariable adjustment for demographic, disease-specific, and treatment-related covariates, including age at treatment initiation, Eastern Cooperative Oncology Group (ECOG) performance status, distant metastases, tumor grade and prior treatment modalities. Proportional hazards assumptions and model discrimination were evaluated using standard diagnostics.",
        "Results": "A total of 71 patients were included in our cohort. The median age at pembrolizumab initiation was 67.5. The most common primary tumor site was the oral cavity (45%), followed by the larynx or supraglottis (18.3%), oropharynx (16.9%), hypopharynx (8.4%), nasopharynx (7%), the sinonasal tract (2.8%) and unknown primary SCC (1.4%). An eosinophil surge was observed in 14.1% of patients. In multivariable analysis, eosinophil surge was independently associated with improved PFS (HR 0.39, p=0.043). No significant association was detected between eosinophil surge and OS. High baseline NLR (>3), present in 73.2% of the cohort, did not predict OS or PFS in univariate or multivariable analyses. All Cox models met proportional hazards assumptions, and concordance indices demonstrated a modest predictive capability.",
        "Conclusions": "Among patients with advanced HNSCC treated with pembrolizumab, an early eosinophil count increase was associated with improved progression-free survival, suggesting that early peripheral eosinophil count increases may represent a robust treatment-related immunologic activity. In contrast, baseline NLR provided no prognostic insight. These findings support the potential value of eosinophil kinetics as an accessible, clinically meaningful early biomarker of immunotherapy response. Prospective validation in larger, multi-institutional cohorts is warranted to define the clinical utility of eosinophil-based monitoring strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Significance of Early Eosinophil Dynamics and Baseline Neutrophil-to-Lymphocyte Ratio in Pembrolizumab-Treated Advanced Head and Neck Squamous Cell Carcinoma</span>. <u>Ido Amir, MD</u><sup>1</sup>; Eyal Yosefof, MD<sup>2</sup>; Yuval Avidor, MD<sup>1</sup>; Daniel Krutik, BScMed<sup>3</sup>; Ethan Soudry, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel; <sup>2</sup>Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; <sup>3</sup>Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pembrolizumab is an established treatment option for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Practical biomarkers that may assist in assessing treatment outcomes are an area of active investigation. Peripheral inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR) and eosinophil count dynamics during therapy have been suggested as potential indicators of systemic immune activity during treatment with immune checkpoint inhibitors for various types of malignancies. This study evaluates whether baseline NLR and early eosinophil count dynamics are associated with survival outcomes in pembrolizumab-treated HNSCC patients.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of patients with recurrent or metastatic HNSCC treated with pembrolizumab at a single tertiary academic center between March 2018 and January 2024 was analyzed. Primary tumor sites included the oral cavity, oropharynx, larynx or supraglottis, hypopharynx, nasopharynx, the sinonasal tract, and unknown primary SCC. Complete blood counts (CBC) were obtained prior to the first three treatment cycles and again at 3 months and 6 months after treatment initiation. A high baseline NLR was defined as >3. An eosinophil surge was defined as an absolute eosinophil count >500 cells/µL at baseline or a ≥3-fold increase within 6 months of treatment initiation. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Cox proportional hazards modeling with multivariable adjustment for demographic, disease-specific, and treatment-related covariates, including age at treatment initiation, Eastern Cooperative Oncology Group (ECOG) performance status, distant metastases, tumor grade and prior treatment modalities. Proportional hazards assumptions and model discrimination were evaluated using standard diagnostics.</p>\n\n<p><strong>Results: </strong>A total of 71 patients were included in our cohort. The median age at pembrolizumab initiation was 67.5. The most common primary tumor site was the oral cavity (45%), followed by the larynx or supraglottis (18.3%), oropharynx (16.9%), hypopharynx (8.4%), nasopharynx (7%), the sinonasal tract (2.8%) and unknown primary SCC (1.4%). An eosinophil surge was observed in 14.1% of patients. In multivariable analysis, eosinophil surge was independently associated with improved PFS (HR 0.39, p=0.043). No significant association was detected between eosinophil surge and OS. High baseline NLR (>3), present in 73.2% of the cohort, did not predict OS or PFS in univariate or multivariable analyses. All Cox models met proportional hazards assumptions, and concordance indices demonstrated a modest predictive capability.</p>\n\n<p><strong>Conclusions: </strong>Among patients with advanced HNSCC treated with pembrolizumab, an early eosinophil count increase was associated with improved progression-free survival, suggesting that early peripheral eosinophil count increases may represent a robust treatment-related immunologic activity. In contrast, baseline NLR provided no prognostic insight. These findings support the potential value of eosinophil kinetics as an accessible, clinically meaningful early biomarker of immunotherapy response. Prospective validation in larger, multi-institutional cohorts is warranted to define the clinical utility of eosinophil-based monitoring strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154160--></body></html>"
    },
    {
      "uid": "P207",
      "content_id": "153911",
      "abstract_number": "P207",
      "poster_number": "P207",
      "title": "SHP2 Inhibition Enhances Responses to Anti-PD1 Immunotherapy in Head and Neck Cancer Models",
      "summary": "These results suggest further study into the use of SHP099 as a drug that may enhance responses to PD-1 immunotherapies. Furthermore, our in vitro results suggest that increases in APM afforded by this drug may be limited, and further studies into the mechanisms of SHP099, including direct activation of T cells, should be explored.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153911",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mary Katherine Henry",
      "presenter": "Mary Katherine Henry",
      "authors": "Mary Katherine Henry 1 ; Brendan Kinney, MS 2 ; Vikash Kansal, PhD 2 ; Brianna Brammer, BS 1 ; Nicole C Schmitt 3",
      "normalized_authors": [
        "Mary Katherine Henry",
        "Brendan Kinney",
        "Vikash Kansal",
        "Brianna Brammer",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Emory University School of Medicine",
        "Winship Cancer Institute, Emory University",
        "Department of Otolaryngology – Head and Neck Surgery, Emory University, Atlanta, GA"
      ],
      "normalized_institutions": [
        "Emory University School of Medicine",
        "Winship Cancer Institute, Emory University",
        "Department of Otolaryngology – Head and Neck Surgery, Emory University, Atlanta, GA"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 302,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Mary Katherine Henry 1 ; Brendan Kinney, MS 2 ; Vikash Kansal, PhD 2 ; Brianna Brammer, BS 1 ; Nicole C Schmitt 3",
        "Affiliations": "1 Emory University School of Medicine; 2 Winship Cancer Institute, Emory University; 3 Department of Otolaryngology – Head and Neck Surgery, Emory University, Atlanta, GA",
        "Background": "Anti-PD-1/PD-L1 immunotherapies are the gold standard for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), but response among patients remains low. Lack of response may be attributed to a lack of major histocompatibility complex (MHC) class I expression for presentation of antigen to T cells by tumor cells, which is largely dependent on interferon (IFN) induced STAT1 expression and phosphorylation. SHP2 has been shown to have a role in pathways relevant to HNSCC, including STAT1 induced upregulation of antigen processing machinery (APM) expression, PI3K pathways, CD8+ T cell activation, and angiogenesis. Previous research indicates that SHP2 inhibitors, such as SHP099, may enhance the effects of PD-1 immune checkpoint blockade (ICB) in colon and lung cancer models. We hypothesized that SHP2 inhibition would upregulate APM expression, enhance the efficacy of immunotherapy, and delay tumor growth in HNSCC.",
        "Methods": "In vitro, SHP099 was given to mouse oral carcinoma (MOC1) cells and a MOC1 variant expressing the model antigen ovalbumin (MOC1-OVA). In vivo, MOC1 tumor bearing mice were treated with SHP099 by oral gavage alone or in combination with anti-PD-1 treatment.",
        "Results": "Using flow cytometry, we found that SHP099 treatment in combination with IFNγ increased STAT1 expression in MOC1 cells without resulting in significant differences in expression of MHC class I (H2kb/H2kb-SINFEKL). In our MOC1 tumor bearing mice, we found that oral dosing of SHP099 six times weekly for two weeks in combination with anti-PD-1 treatment significantly delayed tumor growth in comparison with doses of SHP099 or anti-PD-1 alone.",
        "Conclusions": "These results suggest further study into the use of SHP099 as a drug that may enhance responses to PD-1 immunotherapies. Furthermore, our in vitro results suggest that increases in APM afforded by this drug may be limited, and further studies into the mechanisms of SHP099, including direct activation of T cells, should be explored."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>SHP2 Inhibition Enhances Responses to Anti-PD1 Immunotherapy in Head and Neck Cancer Models</span>. <u>Mary Katherine Henry</u><sup>1</sup>; Brendan Kinney, MS<sup>2</sup>; Vikash Kansal, PhD<sup>2</sup>; Brianna Brammer, BS<sup>1</sup>; Nicole C Schmitt<sup>3</sup>. <sup>1</sup>Emory University School of Medicine; <sup>2</sup>Winship Cancer Institute, Emory University; <sup>3</sup>Department of Otolaryngology – Head and Neck Surgery, Emory University, Atlanta, GA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Anti-PD-1/PD-L1 immunotherapies are the gold standard for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), but response among patients remains low. Lack of response may be attributed to a lack of major histocompatibility complex (MHC) class I expression for presentation of antigen to T cells by tumor cells, which is largely dependent on interferon (IFN) induced STAT1 expression and phosphorylation. SHP2 has been shown to have a role in pathways relevant to HNSCC, including STAT1 induced upregulation of antigen processing machinery (APM) expression, PI3K pathways, CD8+ T cell activation, and angiogenesis. Previous research indicates that SHP2 inhibitors, such as SHP099, may enhance the effects of PD-1 immune checkpoint blockade (ICB) in colon and lung cancer models. We hypothesized that SHP2 inhibition would upregulate APM expression, enhance the efficacy of immunotherapy, and delay tumor growth in HNSCC.</p>\n\n<p><strong>Methods:</strong> In vitro, SHP099 was given to mouse oral carcinoma (MOC1) cells and a MOC1 variant expressing the model antigen ovalbumin (MOC1-OVA). In vivo, MOC1 tumor bearing mice were treated with SHP099 by oral gavage alone or in combination with anti-PD-1 treatment.</p>\n\n<p><strong>Results: </strong>Using flow cytometry, we found that SHP099 treatment in combination with IFNγ increased STAT1 expression in MOC1 cells without resulting in significant differences in expression of MHC class I (H2kb/H2kb-SINFEKL). In our MOC1 tumor bearing mice, we found that oral dosing of SHP099 six times weekly for two weeks in combination with anti-PD-1 treatment significantly delayed tumor growth in comparison with doses of SHP099 or anti-PD-1 alone.</p>\n\n<p><strong>Conclusions:</strong> These results suggest further study into the use of SHP099 as a drug that may enhance responses to PD-1 immunotherapies. Furthermore, our in vitro results suggest that increases in APM afforded by this drug may be limited, and further studies into the mechanisms of SHP099, including direct activation of T cells, should be explored.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153911--></body></html>"
    },
    {
      "uid": "P208",
      "content_id": "154658",
      "abstract_number": "P208",
      "poster_number": "P208",
      "title": "Complete Pathologic Response After Neoadjuvant Cetuximab in Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",
      "summary": "This case demonstrates a complete pathologic response to Cetuximab, including elimination of perineural invasion of the facial nerve, in a patient with locoregionally advanced recurrent unresectable cSCC of the left parotid. In this case, it was used as second-line immunotherapy in combination with chemotherapy after rapid tumor progression on Cemiplimab. The complete response suggests that Cetuximab may have...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154658",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madeline Pyle, MD",
      "presenter": "Madeline Pyle, MD",
      "authors": "Madeline Pyle, MD ; Wesley Stepp, MD, PhD; Liliana Ein, MD; Christine Dinh, MD; Lynn G Feun, MD; Erin Kaye, MD",
      "normalized_authors": [
        "Madeline Pyle",
        "Wesley Stepp",
        "Liliana Ein",
        "Christine Dinh",
        "Lynn G Feun",
        "Erin Kaye"
      ],
      "affiliations": [
        "University of Miami"
      ],
      "normalized_institutions": [
        "University of Miami"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 417,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Description",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Madeline Pyle, MD ; Wesley Stepp, MD, PhD; Liliana Ein, MD; Christine Dinh, MD; Lynn G Feun, MD; Erin Kaye, MD",
        "Affiliations": "University of Miami",
        "Introduction": "For locoregionally advanced unresectable cutaneous squamous cell carcinoma (cSCC) treatment options are primary radiation and systemic therapy. Recent clinical trials have shown promising response to anti–programmed cell death 1 (PD-1) monoclonal antibodies in advanced cSCC and a small number of low powered, non-randomized studies have also demonstrated response to epidermal-like growth factory antibody inhibitors (EGFRi); however, currently no systemic therapy has been proven as a curative or neoadjuvant option in unresectable disease. Below is a case report of unresectable locoregionally advanced recurrent cSCC involving the skull base with perineural invasion that demonstrated complete pathologic response after receiving cetuximab as second-line therapy.",
        "Case Description": "71-year-old male with history of shave biopsy for a left temple cSCC with positive margins who was lost to follow up. Two years later he presented with left facial paralysis, jaw pain, and rapidly growing preauricular mass. CT scan showed a 4.4cm rim-enhancing hypodense lesion of the left parotid gland with invasion of the pterygoid and masticator space, mandible, and external auditory canal. MRI showed extension to the skull base along the auriculotemporal nerve with enhancement of the foramen rotundum. A fine needle aspiration was positive for cSCC. He received one cycle of Cemiplimab (PD-1 inhibitor) but was admitted for rapid tumor growth now measuring 8cm on CT. He received inpatient palliative radiation (5 fractions of 20Gy) and started Carboplatin/Taxol with weekly Cetuximab (EGFRi) for 10 cycles. During treatment facial paralysis progressed to House-Brackman 6/6 and MRI showed enhancement of the facial nerve. He had an excellent response to therapy with significant tumor shrinkage on imaging and minimal remaining PET avidity. Based on the imaging response, he underwent modified surgery without skull base resection including left parotidectomy with facial nerve sacrifice, neck dissection, mastoidectomy with facial nerve resection, submental island rotational flap, and facial nerve reanimation. Final pathology showed no residual carcinoma in the specimen or in the facial nerve at the proximal mastoid segment.",
        "Conclusion": "This case demonstrates a complete pathologic response to Cetuximab, including elimination of perineural invasion of the facial nerve, in a patient with locoregionally advanced recurrent unresectable cSCC of the left parotid. In this case, it was used as second-line immunotherapy in combination with chemotherapy after rapid tumor progression on Cemiplimab. The complete response suggests that Cetuximab may have utility in treating cSCC in the neoadjuvant setting as a second line immunotherapy for patients who fail PD-1 antibodies, especially given that it may have played a role in eliminating tumor with perineural invasion and allowed for modified surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Complete Pathologic Response After Neoadjuvant Cetuximab in Locoregionally Advanced Cutaneous Squamous Cell Carcinoma</span>. <u>Madeline Pyle, MD</u>; Wesley Stepp, MD, PhD; Liliana Ein, MD; Christine Dinh, MD; Lynn G Feun, MD; Erin Kaye, MD. University of Miami<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>For locoregionally advanced unresectable cutaneous squamous cell carcinoma (cSCC) treatment options are primary radiation and systemic therapy. Recent clinical trials have shown promising response to anti–programmed cell death 1 (PD-1) monoclonal antibodies in advanced cSCC and a small number of low powered, non-randomized studies have also demonstrated response to epidermal-like growth factory antibody inhibitors (EGFRi); however, currently no systemic therapy has been proven as a curative or neoadjuvant option in unresectable disease. Below is a case report of unresectable locoregionally advanced recurrent cSCC involving the skull base with perineural invasion that demonstrated complete pathologic response after receiving cetuximab as second-line therapy.</p>\n\n<p><strong>Case Description:</strong> 71-year-old male with history of shave biopsy for a left temple cSCC with positive margins who was lost to follow up. Two years later he presented with left facial paralysis, jaw pain, and rapidly growing preauricular mass. CT scan showed a 4.4cm rim-enhancing hypodense lesion of the left parotid gland with invasion of the pterygoid and masticator space, mandible, and external auditory canal. MRI showed extension to the skull base along the auriculotemporal nerve with enhancement of the foramen rotundum. A fine needle aspiration was positive for cSCC. He received one cycle of Cemiplimab (PD-1 inhibitor) but was admitted for rapid tumor growth now measuring 8cm on CT. He received inpatient palliative radiation (5 fractions of 20Gy) and started Carboplatin/Taxol with weekly Cetuximab (EGFRi) for 10 cycles. During treatment facial paralysis progressed to House-Brackman 6/6 and MRI showed enhancement of the facial nerve. He had an excellent response to therapy with significant tumor shrinkage on imaging and minimal remaining PET avidity. Based on the imaging response, he underwent modified surgery without skull base resection including left parotidectomy with facial nerve sacrifice, neck dissection, mastoidectomy with facial nerve resection, submental island rotational flap, and facial nerve reanimation. Final pathology showed no residual carcinoma in the specimen or in the facial nerve at the proximal mastoid segment.</p>\n\n<p><strong>Conclusion:</strong> This case demonstrates a complete pathologic response to Cetuximab, including elimination of perineural invasion of the facial nerve, in a patient with locoregionally advanced recurrent unresectable cSCC of the left parotid. In this case, it was used as second-line immunotherapy in combination with chemotherapy after rapid tumor progression on Cemiplimab. The complete response suggests that Cetuximab may have utility in treating cSCC in the neoadjuvant setting as a second line immunotherapy for patients who fail PD-1 antibodies, especially given that it may have played a role in eliminating tumor with perineural invasion and allowed for modified surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154658--></body></html>"
    },
    {
      "uid": "P209",
      "content_id": "155320",
      "abstract_number": "P209",
      "poster_number": "P209",
      "title": "Development of Intra arterial Photoimmunotherapy for Recurrent or Metastatic Head and Neck Cancer",
      "summary": "Molecular targeted drugs and immune checkpoint inhibitors (ICIs) are designed to act specifically on tumor-target molecules. However, systemic intravenous (IV) administration delivers these agents to non-target organs, leading to systemic adverse events and increased healthcare costs. To address these issues, we advocate for the clinical superiority of intra-arterial (IA) administration via tumor-feeding arteries.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155320",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tetsuya Ogawa",
      "presenter": "Tetsuya Ogawa",
      "authors": "Tetsuya Ogawa ; Masashi Nakaishi; Atsuko Sakanushi; Koji Sakamoto; Norihiro Usukura; Keisuke Hamanaka; Yuta Nakatsuka; Yuta Kawai; Kohei Taniguchi; Munenaga Nakamizo; Minoru Gotoh",
      "normalized_authors": [
        "Tetsuya Ogawa",
        "Masashi Nakaishi",
        "Atsuko Sakanushi",
        "Koji Sakamoto",
        "Norihiro Usukura",
        "Keisuke Hamanaka",
        "Yuta Nakatsuka",
        "Yuta Kawai",
        "Kohei Taniguchi",
        "Munenaga Nakamizo",
        "Minoru Gotoh"
      ],
      "affiliations": [
        "Nippon Medical School"
      ],
      "normalized_institutions": [
        "Nippon Medical School"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 330,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Basic Research",
        "Abstract",
        "Clinical Research"
      ],
      "sections": {
        "Authors": "Tetsuya Ogawa ; Masashi Nakaishi; Atsuko Sakanushi; Koji Sakamoto; Norihiro Usukura; Keisuke Hamanaka; Yuta Nakatsuka; Yuta Kawai; Kohei Taniguchi; Munenaga Nakamizo; Minoru Gotoh",
        "Affiliations": "Nippon Medical School",
        "Introduction": "Molecular targeted drugs and immune checkpoint inhibitors (ICIs) are designed to act specifically on tumor-target molecules. However, systemic intravenous (IV) administration delivers these agents to non-target organs, leading to systemic adverse events and increased healthcare costs. To address these issues, we advocate for the clinical superiority of intra-arterial (IA) administration via tumor-feeding arteries.",
        "Basic Research": "Local Administration of Nivolumab",
        "Abstract": "Using mice bearing head and neck cancer cell lines, we evaluated the anti-tumor immunological effects of three groups: (1) saline control, (2) systemic administration of 100 µg Nivolumab, and (3) local administration of 10 µg Nivolumab. Both (2) and (3) showed significant tumor growth inhibition compared to (1). Notably, (3) demonstrated non-inferiority to (2). Furthermore, the infiltration of CD8+ T cells in (3) was same of (2), demonstrating the efficacy of low-dose local Nivolumab administration (JP Patent 2024-102980; Anticancer Res. 2022; KAKENHI 19K19214, 22K10181, 23K09382). We conducted a clinical trial of IA immunotherapy (jRCTs041220157), preceding a prospective Advanced Medicine B study by the Ministry of Health, Labour and Welfare. The patient was 67-year-old female with p16-positive oropharyngeal cancer (T4N2M1) who had previously treated with Pembrolizumab. A catheter was inserted via the superficial temporal artery into the tumor-feeding artery, and IA Nivolumab (20 mg × 2 doses) was administered. The binding of Nivolumab to tumor-infiltrating lymphocytes even at the 20 mg IA dose was seen (Patent Pending 2024-102980). Following additional treatment, the patient achieved a complete response (CR). Development of Intra-arterial Photoimmunotherapy (PIT) The current approved protocol for Cetuximab Sarotalocan Sodium (Akalux®) requires an IV infusion of 640 mg/m² over 24 hours, followed by laser irradiation under general anesthesia the next day. Refined protocol involves IA administration of Akalux® at 1/100 to 1/10 of the standard dose, followed immediately laser irradiation under local anesthesia, with subsequent outpatient IV Pembrolizumab seven days later. This innovative method reached an agreement with PMDA(Japanese government), and an investigator-initiated clinical trial is approved by AMED(Japanese government) for Phase I/II.",
        "Clinical Research": "First-in-Human Trial of Intra-arterial Nivolumab"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development of Intra arterial Photoimmunotherapy for Recurrent or Metastatic Head and Neck Cancer</span>. <u>Tetsuya Ogawa</u>; Masashi Nakaishi; Atsuko Sakanushi; Koji Sakamoto; Norihiro Usukura; Keisuke Hamanaka; Yuta Nakatsuka; Yuta Kawai; Kohei Taniguchi; Munenaga Nakamizo; Minoru Gotoh. Nippon Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Molecular targeted drugs and immune checkpoint inhibitors (ICIs) are designed to act specifically on tumor-target molecules. However, systemic intravenous (IV) administration delivers these agents to non-target organs, leading to systemic adverse events and increased healthcare costs. To address these issues, we advocate for the clinical superiority of intra-arterial (IA) administration via tumor-feeding arteries.</p>\n\n<p><strong>Basic Research:</strong> Local Administration of Nivolumab</p>\n\n<p>Using mice bearing head and neck cancer cell lines, we evaluated the anti-tumor immunological effects of three groups: (1) saline control, (2) systemic administration of 100 µg Nivolumab, and (3) local administration of 10 µg Nivolumab. Both (2) and (3) showed significant tumor growth inhibition compared to (1). Notably, (3) demonstrated non-inferiority to (2). Furthermore, the infiltration of CD8+ T cells in (3) was same of (2), demonstrating the efficacy of low-dose local Nivolumab administration (JP Patent 2024-102980; Anticancer Res. 2022; KAKENHI 19K19214, 22K10181, 23K09382).</p>\n\n<p><strong>Clinical Research:</strong> First-in-Human Trial of Intra-arterial Nivolumab</p>\n\n<p>We conducted a clinical trial of IA immunotherapy (jRCTs041220157), preceding a prospective Advanced Medicine B study by the Ministry of Health, Labour and Welfare. The patient was 67-year-old female with p16-positive oropharyngeal cancer (T4N2M1) who had previously treated with Pembrolizumab. A catheter was inserted via the superficial temporal artery into the tumor-feeding artery, and IA Nivolumab (20 mg × 2 doses) was administered. The binding of Nivolumab to tumor-infiltrating lymphocytes even at the 20 mg IA dose was seen (Patent Pending 2024-102980). Following additional treatment, the patient achieved a complete response (CR).</p>\n\n<p>Development of Intra-arterial Photoimmunotherapy (PIT)</p>\n\n<p>The current approved protocol for Cetuximab Sarotalocan Sodium (Akalux®) requires an IV infusion of 640 mg/m² over 24 hours, followed by laser irradiation under general anesthesia the next day. Refined protocol involves IA administration of Akalux® at 1/100 to 1/10 of the standard dose, followed immediately laser irradiation under local anesthesia, with subsequent outpatient IV Pembrolizumab seven days later. This innovative method reached an agreement with PMDA(Japanese government), and an investigator-initiated clinical trial is approved by AMED(Japanese government) for Phase I/II.</p>\n\n<p><strong>Expected Outcomes</strong></p>\n<ol>\n<li>A photoimmunotherapy is expected to efficiently present tumor antigens, thereby maximizing the systemic anti-tumor immune response triggered by pembrolizumab.</li></br>\n<li>By reducing the IA dose to less than 1/10th of the IV concentration (specifically 100 mg, 20 mg, or 10 mg), we expect reduction patient physical burden, adverse events, medical expenses.</li></br>\n<li>This protocol aims to establish a new cancer immunotherapy that can be performed by IVR physicians. We anticipate the widespread adoption and standardization of IA immunotherapy, positioning it as a novel, Japan-originated treatment for the global market.</li></br>\n<li>Through the analysis of \"Immune Signatures\" in tumor tissues before and after IA administration in the same patient, we expect to identify true predictive factors for therapeutic efficacy. Furthermore, this project is expected to contribute to academia-industry collaboration, new pharmaceuticals tailored for IA therapy and the advancement of the medical catheter industry.</li>\n</ol><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155320--></body></html>"
    },
    {
      "uid": "P210",
      "content_id": "154050",
      "abstract_number": "P210",
      "poster_number": "P210",
      "title": "Real-world, single-institution series of neoadjuvant pembrolizumab for head and neck cancer in the first year after Keynote-689",
      "summary": "On June 12, 2025, the addition of neoadjuvant pembrolizumab (pembro) with adjuvant pembro to the standard of care for resectable locally advanced head and neck squamous cell carcinoma (HNSCC) was the first significant treatment advancement in over two decades. The foundation for this approval is based on the landmark study Keynote-689, which showed significantly improved event-free survival in the group treated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154050",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sherrie L Wang, MD",
      "presenter": "Sherrie L Wang, MD",
      "authors": "Sherrie L Wang, MD 1 ; Nour Mourra, BS, BA 1 ; Brian J Boyce, MD, FACS 2 ; Azeem S Kaka, MD 2 ; Peter W Kahng, MD 2 ; H M Baddour, MD 2 ; Nabil F Saba, MD, FACP 3 ; Jose A Monteiro de Oliveira Novaes, MD 3 ; Jennifer H Gross, MD 2 ; Nicole C Schmitt, MD, FACS 2",
      "normalized_authors": [
        "Sherrie L Wang",
        "Nour Mourra",
        "Brian J Boyce",
        "Azeem S Kaka",
        "Peter W Kahng",
        "H M Baddour",
        "Nabil F Saba, FACP",
        "Jose A Monteiro de Oliveira Novaes",
        "Jennifer H Gross",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Department of Otolaryngology, Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA",
        "Department of Otolaryngology, Head & Neck Surgery, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA",
        "Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA",
        "Department of Otolaryngology, Head & Neck Surgery, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA",
        "Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 278,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sherrie L Wang, MD 1 ; Nour Mourra, BS, BA 1 ; Brian J Boyce, MD, FACS 2 ; Azeem S Kaka, MD 2 ; Peter W Kahng, MD 2 ; H M Baddour, MD 2 ; Nabil F Saba, MD, FACP 3 ; Jose A Monteiro de Oliveira Novaes, MD 3 ; Jennifer H Gross, MD 2 ; Nicole C Schmitt, MD, FACS 2",
        "Affiliations": "1 Department of Otolaryngology, Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA; 2 Department of Otolaryngology, Head & Neck Surgery, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA; 3 Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA",
        "Abstract": "On June 12, 2025, the addition of neoadjuvant pembrolizumab (pembro) with adjuvant pembro to the standard of care for resectable locally advanced head and neck squamous cell carcinoma (HNSCC) was the first significant treatment advancement in over two decades. The foundation for this approval is based on the landmark study Keynote-689, which showed significantly improved event-free survival in the group treated with neoadjuvant and adjuvant pembro in addition to standard of care surgery followed by adjuvant radiotherapy/chemoradiotherapy versus the standard of care control group. However, details about rates of minor pathologic response and progression were not included in the study. The objective of this prospective study is to provide an in-depth evaluation of the first year of experience with this novel standard regimen at a high-volume Southeast American metropolitan academic institution. Patients receiving neoadjuvant and adjuvant pembro in addition to standard of care surgery followed by adjuvant radiation/chemoradiation are prospectively tracked from July 1, 2025, at the outset of the FDA approval. Included patients are over the age of 18, have a newly diagnosedand untreated primary resectable locally advanced HNSCC without evidence of distant metastasis, and a CPS score of ≥1; all in concordance with the FDA approval. Approximately 3-4 patients per month have been included. Short-term endpoints include pathologic response rates (including minor responses), progression rates (including pathologic upstaging), and subsequent alterations to surgeries performed. Univariate and multivariate analyses of the relationships between these endpoints and clinicopathologic variables will be presented, with oncologic outcomes as a future direction. Logistic barriers, complications, and other insights gathered from this first year of experience after early adoption of this regimen at a high-volume center will also be summarized."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-world, single-institution series of neoadjuvant pembrolizumab for head and neck cancer in the first year after Keynote-689</span>. <u>Sherrie L Wang, MD</u><sup>1</sup>; Nour Mourra, BS, BA<sup>1</sup>; Brian J Boyce, MD, FACS<sup>2</sup>; Azeem S Kaka, MD<sup>2</sup>; Peter W Kahng, MD<sup>2</sup>; H M Baddour, MD<sup>2</sup>; Nabil F Saba, MD, FACP<sup>3</sup>; Jose A Monteiro de Oliveira Novaes, MD<sup>3</sup>; Jennifer H Gross, MD<sup>2</sup>; Nicole C Schmitt, MD, FACS<sup>2</sup>. <sup>1</sup>Department of Otolaryngology, Head & Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA; <sup>2</sup>Department of Otolaryngology, Head & Neck Surgery, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA; <sup>3</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>On June 12, 2025, the addition of neoadjuvant pembrolizumab (pembro) with adjuvant pembro to the standard of care for resectable locally advanced head and neck squamous cell carcinoma (HNSCC) was the first significant treatment advancement in over two decades. The foundation for this approval is based on the landmark study Keynote-689, which showed significantly improved event-free survival in the group treated with neoadjuvant and adjuvant pembro in addition to standard of care surgery followed by adjuvant radiotherapy/chemoradiotherapy versus the standard of care control group. However, details about rates of minor pathologic response and progression were not included in the study.</p>\n\n<p>The objective of this prospective study is to provide an in-depth evaluation of the first year of experience with this novel standard regimen at a high-volume Southeast American metropolitan academic institution. </p>\n\n<p>Patients receiving neoadjuvant and adjuvant pembro in addition to standard of care surgery followed by adjuvant radiation/chemoradiation are prospectively tracked from July 1, 2025, at the outset of the FDA approval. Included patients are over the age of 18, have a newly diagnosedand untreated primary resectable locally advanced HNSCC without evidence of distant metastasis, and a CPS score of ≥1; all in concordance with the FDA approval. Approximately 3-4 patients per month have been included. Short-term endpoints include pathologic response rates (including minor responses), progression rates (including pathologic upstaging), and subsequent alterations to surgeries performed. Univariate and multivariate analyses of the relationships between these endpoints and clinicopathologic variables will be presented, with oncologic outcomes as a future direction. Logistic barriers, complications, and other insights gathered from this first year of experience after early adoption of this regimen at a high-volume center will also be summarized.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154050--></body></html>"
    },
    {
      "uid": "P211",
      "content_id": "155304",
      "abstract_number": "P211",
      "poster_number": "P211",
      "title": "Trends in Timing of Neoadjuvant Immunotherapy for Head and Neck Cancer Patients",
      "summary": "Our results show that since 2015, there has been an increasing delay in the timing from diagnosis to receiving neoadjuvant immunotherapy for head and neck cancer. Several factors could explain this result. Among these include the increasing demand for immunotherapy and a shortage of providers who can administer it. Another contributor could be an increase in administrative and financial burdens for getting...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155304",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caden Duffy, MD",
      "presenter": "Caden Duffy, MD",
      "authors": "Caden Duffy, MD ; Zaid Al-Qurayshi, MBChB, MPH",
      "normalized_authors": [
        "Caden Duffy",
        "Zaid Al-Qurayshi, MBChB"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155304/Picture1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155304/Picture1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155304"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155304/Picture2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155304/Picture2.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155304"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155304/Picture3.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155304/Picture3.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155304"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 386,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Caden Duffy, MD ; Zaid Al-Qurayshi, MBChB, MPH",
        "Affiliations": "University of Iowa",
        "Introduction": "Since the initial approval by the FDA for the use of nivolumab and pembrolizumab in 2016, the number of patients receiving immunotherapy for head and neck cancers has greatly increased. In June 2025, pembrolizumab was approved in the United States for neoadjuvant therapy in patients with locally advanced, resectable disease. Given the expanded eligibility for neoadjuvant immunotherapy, we sought to identify trends in the timing from initial encounter to the onset of receiving immunotherapy for patients who will undergo primary surgical treatment for head and neck cancers.",
        "Methods": "A data query from the National Cancer Database was performed, with records extracted from 2015-2023. Patients with unknown or missing values in the dataset for each analysis were excluded. Neoadjuvant therapy was defined by immunotherapy treatment starting prior to definitive surgical treatment. Linear regression was performed based on median counts for each year. Distance to treating facility was filtered for outliers further than 500 miles and changed to log distance to account for distance proximity skew. All data filtering and analysis steps were performed in R.",
        "Results": "1308 patients were identified who had undergone neoadjuvant immunotherapy for head and neck cancer. Linear regression modeling of yearly median time to neoadjuvant immunotherapy showed an increased delay, with a change from approximately 31 days in 2015 to 40 days in 2023 (β = 1.62; p=0.02). Box plot (left) and linear regression (right) are shown below.",
        "Abstract": "This increase was seen across both private and government insured patients. Increasing travel distance was not significantly associated with time to receive neoadjuvant immunotherapy (β = 0.25 days per log10 mile increase, p = 0.89). Further areas to explore include understanding the clinical impact of this delay since the National Cancer Database does not include data on long term outcomes or recurrence. The specific medication used in immunotherapy are also not recorded in the database, which could be analyzed to look for further differences in their specific timing of administration.",
        "Conclusion": "Our results show that since 2015, there has been an increasing delay in the timing from diagnosis to receiving neoadjuvant immunotherapy for head and neck cancer. Several factors could explain this result. Among these include the increasing demand for immunotherapy and a shortage of providers who can administer it. Another contributor could be an increase in administrative and financial burdens for getting approval for immunotherapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in Timing of Neoadjuvant Immunotherapy for Head and Neck Cancer Patients</span>. <u>Caden Duffy, MD</u>; Zaid Al-Qurayshi, MBChB, MPH. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Since the initial approval by the FDA for the use of nivolumab and pembrolizumab in 2016, the number of patients receiving immunotherapy for head and neck cancers has greatly increased. In June 2025, pembrolizumab was approved in the United States for neoadjuvant therapy in patients with locally advanced, resectable disease. Given the expanded eligibility for neoadjuvant immunotherapy, we sought to identify trends in the timing from initial encounter to the onset of receiving immunotherapy for patients who will undergo primary surgical treatment for head and neck cancers.</p>\n\n<p><strong>Methods: </strong>A data query from the National Cancer Database was performed, with records extracted from 2015-2023. Patients with unknown or missing values in the dataset for each analysis were excluded. Neoadjuvant therapy was defined by immunotherapy treatment starting prior to definitive surgical treatment. Linear regression was performed based on median counts for each year. Distance to treating facility was filtered for outliers further than 500 miles and changed to log distance to account for distance proximity skew. All data filtering and analysis steps were performed in R.</p>\n\n<p><strong>Results: </strong>1308 patients were identified who had undergone neoadjuvant immunotherapy for head and neck cancer. Linear regression modeling of yearly median time to neoadjuvant immunotherapy showed an increased delay, with a change from approximately 31 days in 2015 to 40 days in 2023 (β = 1.62; p=0.02). Box plot (left) and linear regression (right) are shown below.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155304/Picture1.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155304/Picture2.png' /></p>\n\n<p>This increase was seen across both private and government insured patients. Increasing travel distance was not significantly associated with time to receive neoadjuvant immunotherapy (β = 0.25 days per log10 mile increase, p = 0.89).             </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155304/Picture3.png' /></p>\n\n<p><strong>Conclusion: </strong>Our results show that since 2015, there has been an increasing delay in the timing from diagnosis to receiving neoadjuvant immunotherapy for head and neck cancer. Several factors could explain this result. Among these include the increasing demand for immunotherapy and a shortage of providers who can administer it. Another contributor could be an increase in administrative and financial burdens for getting approval for immunotherapy.</p>\n\n<p>Further areas to explore include understanding the clinical impact of this delay since the National Cancer Database does not include data on long term outcomes or recurrence. The specific medication used in immunotherapy are also not recorded in the database, which could be analyzed to look for further differences in their specific timing of administration.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155304--></body></html>"
    },
    {
      "uid": "P212",
      "content_id": "153833",
      "abstract_number": "P212",
      "poster_number": "P212",
      "title": "Evolution of anaplastic thyroid carcinoma management: A tertiary center’s experience in Singapore",
      "summary": "Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumour with poor prognosis. The management pillars of ATC focus on addressing acute symptoms, obtaining the diagnosis quickly, and staging the disease to establish goals of care and to institute treatment or palliation. Historically, surgery, whenever feasible, has been the preferred option for improved disease-free survival. However, many are inoperable...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153833",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sher-lyn Tham",
      "presenter": "Sher-lyn Tham",
      "authors": "Sher-lyn Tham ; Khang Wen Pang; Donovan Eu",
      "normalized_authors": [
        "Sher-lyn Tham",
        "Khang Wen Pang",
        "Donovan Eu"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 471,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sher-lyn Tham ; Khang Wen Pang; Donovan Eu",
        "Affiliations": "Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore",
        "Abstract": "Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumour with poor prognosis. The management pillars of ATC focus on addressing acute symptoms, obtaining the diagnosis quickly, and staging the disease to establish goals of care and to institute treatment or palliation. Historically, surgery, whenever feasible, has been the preferred option for improved disease-free survival. However, many are inoperable at diagnosis and 50% have distant metastases. Traditional chemotherapy failed to demonstrate improved survival, while radiation was mainly reserved for local control or palliation. The advent of targeted therapy and immunotherapy changed the landscape, with the ROAR trial establishing a new treatment backbone with BRAF/MEK targeted therapy (Dabrafenib/Trametinib) for BRAF-mutants, while the ATLEP trial provided a non-BRAF option with TKI and immunotherapy (Lenvatinib/Pembrolizumab). The 2021 ATA Guidelines support molecular profiling in order to detect actionable mutations, recognizing the role of targeted therapy in unresectable ATC BRAF-mutants. Our tertiary centre saw 25 ATC patients over 15 years. In the first 10 years (2011-2021), 14 patients were diagnosed with ATC. 60% were treated with palliative intent with best supportive care, limited chemotherapy or radiation. Only 6/14 patients underwent definitive surgery and they had a longer mean survival rate at 4.47 months compared to those without at 1.93 months. Overall, outcomes were dismal as the mean survival rate was 3.0 months with 100% mortality within a year. In the next 5 years after the introduction of targeted therapy (2021-2025), 55% (6/11) of patients with ATC received systemic therapy. 30% (4/11) opted for best supportive care due to comorbidities and advanced disease. Only 1/11 underwent surgery, with ATC being a postoperative finding after hemithyroidectomy. Survival outcomes were also better after 2021 as mean survival rate more than doubled, reaching 8.0 months. Patients treated with upfront systemic treatment had better survival outcomes at 15.3 months, far exceeding those without at 0.4 months. Only 16% (1/6) of patients who received systemic therapy was BRAF-positive and received Dabrafenib/Trametinib. In contrast, elevated PD-L1 expression was seen in more than 50%. This made the remaining BRAF-negative patients amenable for combination Lenvatinib/Pembrolizumab. Overall, our institution’s data from the past 15 years highlights a lower incidence of BRAF-mutants at 12.5% compared to 33-40% quoted in current literature. Consequently, this emphasises the role of combined TKI and immunotherapy as an important alternative for non-BRAF mutants. Our data also suggests that the incidence of ATCs in general has increased from 1.4 to 2.2 patients per year While outcomes with systemic therapy appear promising, we recognize that our sample size is small and that limitations do exist with molecular testing, including financial costs, turnaround time and heterogeneity in testing. With more work, the landscape of ATC management will continue to evolve in both diagnostic and therapeutic interventions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evolution of anaplastic thyroid carcinoma management: A tertiary center’s experience in Singapore</span>. <u>Sher-lyn Tham</u>; Khang Wen Pang; Donovan Eu. Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumour with poor prognosis. The management pillars of ATC focus on addressing acute symptoms, obtaining the diagnosis quickly, and staging the disease to establish goals of care and to institute treatment or palliation. Historically, surgery, whenever feasible, has been the preferred option for improved disease-free survival. However, many are inoperable at diagnosis and 50% have distant metastases. Traditional chemotherapy failed to demonstrate improved survival, while radiation was mainly reserved for local control or palliation. The advent of targeted therapy and immunotherapy changed the landscape, with the ROAR trial establishing a new treatment backbone with BRAF/MEK targeted therapy (Dabrafenib/Trametinib) for BRAF-mutants, while the ATLEP trial provided a non-BRAF option with TKI and immunotherapy (Lenvatinib/Pembrolizumab). The 2021 ATA Guidelines support molecular profiling in order to detect actionable mutations, recognizing the role of targeted therapy in unresectable ATC BRAF-mutants. </p>\n\n<p>Our tertiary centre saw 25 ATC patients over 15 years. In the first 10 years (2011-2021), 14 patients were diagnosed with ATC. 60% were treated with palliative intent with best supportive care, limited chemotherapy or radiation. Only 6/14 patients underwent definitive surgery and they had a longer mean survival rate at 4.47 months compared to those without at 1.93 months. Overall, outcomes were dismal as the mean survival rate was 3.0 months with 100% mortality within a year. </p>\n\n<p>In the next 5 years after the introduction of targeted therapy (2021-2025), 55% (6/11) of patients with ATC received systemic therapy. 30% (4/11) opted for best supportive care due to comorbidities and advanced disease. Only 1/11 underwent surgery, with ATC being a postoperative finding after hemithyroidectomy. Survival outcomes were also better after 2021 as mean survival rate more than doubled, reaching 8.0 months. Patients treated with upfront systemic treatment had better survival outcomes at 15.3 months, far exceeding those without at 0.4 months. </p>\n\n<p>Only 16% (1/6) of patients who received systemic therapy was BRAF-positive and received Dabrafenib/Trametinib. In contrast, elevated PD-L1 expression was seen in more than 50%. This made the remaining BRAF-negative patients amenable for combination Lenvatinib/Pembrolizumab. </p>\n\n<p>Overall, our institution’s data from the past 15 years highlights a lower incidence of BRAF-mutants at 12.5% compared to 33-40% quoted in current literature. Consequently, this emphasises the role of combined TKI and immunotherapy as an important alternative for non-BRAF mutants. Our data also suggests that the incidence of ATCs in general has increased from 1.4 to 2.2 patients per year</p>\n\n<p>While outcomes with systemic therapy appear promising, we recognize that our sample size is small and that limitations do exist with molecular testing, including financial costs, turnaround time and heterogeneity in testing. With more work, the landscape of ATC management will continue to evolve in both diagnostic and therapeutic interventions. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153833--></body></html>"
    },
    {
      "uid": "P213",
      "content_id": "153981",
      "abstract_number": "P213",
      "poster_number": "P213",
      "title": "Preclinical Rationale for Perioperative Cannabidiol with PD-1 Blockade: Evidence of Immune Mobilization and Survival Extension in HNSCC",
      "summary": "Immunotherapy for head and neck squamous cell carcinoma (HNSCC) has advanced with the clinical application of PD-1 inhibitors; however, there is opportunity to enhance therapeutic efficacy. Cannabidiol (CBD) has recently gained attention for its immunomodulatory and antitumor properties. With its FDA-approved use in epilepsy and well-established safety profile, CBD represents a promising candidate for oncologic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153981",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tomoya Kurokawa",
      "presenter": "Tomoya Kurokawa",
      "authors": "Tomoya Kurokawa ; Prakriti Sen; Anais A Zourelidis; Pardis Mohammadzadeh; Kelsey Decker; Sayuri Miyauchi; Peter Vo; Joseph A Califano",
      "normalized_authors": [
        "Tomoya Kurokawa",
        "Prakriti Sen",
        "Anais A Zourelidis",
        "Pardis Mohammadzadeh",
        "Kelsey Decker",
        "Sayuri Miyauchi",
        "Peter Vo",
        "Joseph A Califano"
      ],
      "affiliations": [
        "Moores Cancer Center, UC San Diego"
      ],
      "normalized_institutions": [
        "Moores Cancer Center, UC San Diego"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "DISCUSSION"
      ],
      "sections": {
        "Authors": "Tomoya Kurokawa ; Prakriti Sen; Anais A Zourelidis; Pardis Mohammadzadeh; Kelsey Decker; Sayuri Miyauchi; Peter Vo; Joseph A Califano",
        "Affiliations": "Moores Cancer Center, UC San Diego",
        "INTRODUCTION": "Immunotherapy for head and neck squamous cell carcinoma (HNSCC) has advanced with the clinical application of PD-1 inhibitors; however, there is opportunity to enhance therapeutic efficacy. Cannabidiol (CBD) has recently gained attention for its immunomodulatory and antitumor properties. With its FDA-approved use in epilepsy and well-established safety profile, CBD represents a promising candidate for oncologic applications, including HNSCC. This study evaluated whether combining CBD with PD-1 blockade could potentiate antitumor efficacy by leveraging CBD-mediated immune modulation.",
        "METHODS": "A syngeneic orthotopic HNSCC mouse model (4MOSC1) was used to assess the effects of CBD and anti-mouse PD-1 antibody on tumor growth and survival. Immune profiling was performed via flow cytometry and multiplex immunohistochemistry (mIHC) using tumor tissue and sentinel lymph nodes (SLN) identified by lymph-node mapping to elucidate immune dynamics during treatment.",
        "RESULTS": "Combination treatment with CBD and PD-1 inhibitors resulted in significantly greater tumor shrinkage and improved survival compared with either CBD alone (p < .01) or PD-1 inhibition alone (p < .05). Immune analysis of samples collected prior to measurable tumor regression demonstrated that CBD addition markedly increased intratumoral immune infiltration, characterized by T-cell dominant accumulation (p < .01). Within the T-cell compartment, CD4T-cell abundance was particularly elevated (p < .01), and dendritic cell numbers were also significantly increased in the tumor (p < .01). mIHC corroborated these findings. Concomitantly, SLNs exhibited a pronounced reduction in T-cell density (p < .001), suggesting mobilization of lymph-node–resident immune cells into the tumor microenvironment.",
        "DISCUSSION": "CBD has previously been reported to enhance T-cell activation and reshape immune dynamics, and synergistic benefit with PD-1 blockade has been demonstrated in mouse models of breast and colorectal cancer. To our knowledge, this is the first demonstration of augmented antitumor efficacy achieved by combining CBD with PD-1 checkpoint inhibition in HNSCC. Mechanistically, our findings indicate that CBD facilitates immune cell redistribution—driving T cell influx from SLNs and enhancing dendritic cell activation—rather than acting via conventional PD-1-mediated rescue from T cell exhaustion. Prior reports indicate that interaction among CD4T cells, CD8T cells, and antigen-presenting cells forms a tripartite immune network that supports CD8T-cell antitumor function, and the present results suggest a comparable mechanism in HNSCC. In summary, CBD is a promising therapeutic candidate for immune therapy in HNSCC, particularly in combination with PD-1 inhibition. The recent KEYNOTE-689 study demonstrated clinical benefit of perioperative pembrolizumab, supporting the application of immune checkpoint inhibitors in a neoadjuvant setting. Given that CBD-enhanced antitumor activity appears to require the mobilization of immune cells from regional lymph nodes, incorporating CBD with neoadjuvant checkpoint therapy in the presence of intact lymphatic drainage may be particularly advantageous in HNSCC, where lymph node involvement is common. Based on these preclinical data, a Phase I/II clinical trial is being planned to evaluate the tolerability, safety, and efficacy of adding CBD to PD-1 inhibitors in a neoadjuvant setting."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preclinical Rationale for Perioperative Cannabidiol with PD-1 Blockade: Evidence of Immune Mobilization and Survival Extension in HNSCC</span>. <u>Tomoya Kurokawa</u>; Prakriti Sen; Anais A Zourelidis; Pardis Mohammadzadeh; Kelsey Decker; Sayuri Miyauchi; Peter Vo; Joseph A Califano. Moores Cancer Center, UC San Diego<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION</strong> Immunotherapy for head and neck squamous cell carcinoma (HNSCC) has advanced with the clinical application of PD-1 inhibitors; however, there is opportunity to enhance therapeutic efficacy. Cannabidiol (CBD) has recently gained attention for its immunomodulatory and antitumor properties. With its FDA-approved use in epilepsy and well-established safety profile, CBD represents a promising candidate for oncologic applications, including HNSCC. This study evaluated whether combining CBD with PD-1 blockade could potentiate antitumor efficacy by leveraging CBD-mediated immune modulation.</p>\n\n<p><strong>METHODS </strong>A syngeneic orthotopic HNSCC mouse model (4MOSC1) was used to assess the effects of CBD and anti-mouse PD-1 antibody on tumor growth and survival. Immune profiling was performed via flow cytometry and multiplex immunohistochemistry (mIHC) using tumor tissue and sentinel lymph nodes (SLN) identified by lymph-node mapping to elucidate immune dynamics during treatment.</p>\n\n<p><strong>RESULTS</strong> Combination treatment with CBD and PD-1 inhibitors resulted in significantly greater tumor shrinkage and improved survival compared with either CBD alone (p < .01) or PD-1 inhibition alone (p < .05). Immune analysis of samples collected prior to measurable tumor regression demonstrated that CBD addition markedly increased intratumoral immune infiltration, characterized by T-cell dominant accumulation (p < .01). Within the T-cell compartment, CD4T-cell abundance was particularly elevated (p < .01), and dendritic cell numbers were also significantly increased in the tumor (p < .01). mIHC corroborated these findings. Concomitantly, SLNs exhibited a pronounced reduction in T-cell density (p < .001), suggesting mobilization of lymph-node–resident immune cells into the tumor microenvironment.</p>\n\n<p><strong>DISCUSSION </strong>CBD has previously been reported to enhance T-cell activation and reshape immune dynamics, and synergistic benefit with PD-1 blockade has been demonstrated in mouse models of breast and colorectal cancer. To our knowledge, this is the first demonstration of augmented antitumor efficacy achieved by combining CBD with PD-1 checkpoint inhibition in HNSCC. Mechanistically, our findings indicate that CBD facilitates immune cell redistribution—driving T cell influx from SLNs and enhancing dendritic cell activation—rather than acting via conventional PD-1-mediated rescue from T cell exhaustion. Prior reports indicate that interaction among CD4T cells, CD8T cells, and antigen-presenting cells forms a tripartite immune network that supports CD8T-cell antitumor function, and the present results suggest a comparable mechanism in HNSCC. In summary, CBD is a promising therapeutic candidate for immune therapy in HNSCC, particularly in combination with PD-1 inhibition. The recent KEYNOTE-689 study demonstrated clinical benefit of perioperative pembrolizumab, supporting the application of immune checkpoint inhibitors in a neoadjuvant setting. Given that CBD-enhanced antitumor activity appears to require the mobilization of immune cells from regional lymph nodes, incorporating CBD with neoadjuvant checkpoint therapy in the presence of intact lymphatic drainage may be particularly advantageous in HNSCC, where lymph node involvement is common. Based on these preclinical data, a Phase I/II clinical trial is being planned to evaluate the tolerability, safety, and efficacy of adding CBD to PD-1 inhibitors in a neoadjuvant setting.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153981--></body></html>"
    },
    {
      "uid": "P214",
      "content_id": "154110",
      "abstract_number": "P214",
      "poster_number": "P214",
      "title": "A retrospective study on outcomes of recurrent head and neck mucosal squamous cell carcinoma",
      "summary": "Recurrent head and neck carcinoma carries a poor prognosis with disease specific mortality was 49% within the follow up period. In particular subsites such as the oral cavity, our data supports that immunotherapy can help improve progression free survival in the recurrent setting. Despite the relative success of immunotherapy, further research is required to improve risk stratification, prediction of treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154110",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Muhammad El Shatanofy, MD",
      "presenter": "Muhammad El Shatanofy, MD",
      "authors": "Muhammad El Shatanofy, MD 1 ; Eric Sokhn, BS 2 ; Soumil Prasad, BS 2 ; Carlos L Nava, BS 2 ; Zoukaa Sargi, MD, MPH 1",
      "normalized_authors": [
        "Muhammad El Shatanofy",
        "Eric Sokhn",
        "Soumil Prasad",
        "Carlos L Nava",
        "Zoukaa Sargi"
      ],
      "affiliations": [
        "University of Miami Hospital",
        "University of Miami Miller School of Medicine"
      ],
      "normalized_institutions": [
        "University of Miami Hospital",
        "University of Miami Miller School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Muhammad El Shatanofy, MD 1 ; Eric Sokhn, BS 2 ; Soumil Prasad, BS 2 ; Carlos L Nava, BS 2 ; Zoukaa Sargi, MD, MPH 1",
        "Affiliations": "1 University of Miami Hospital; 2 University of Miami Miller School of Medicine",
        "Background": "Head and neck cancer is the seventh most prevalent cancer worldwide. Treatment typically involves one or more of the following: surgery, chemotherapy, radiation, or immunotherapy. Despite advances in treatment modalities, a subset of patients inevitably develops recurrences that are aggressive and treatment resistant. Few studies have investigated underlying factors that make head and neck squamous cell carcinomas more prone to recurrence and treatment failure. The objective of this study was to retrospectively review a cohort of patients with recurrent head and neck carcinoma to identify trends in patient demographics, tumor characteristics, and treatment resistances.",
        "Methods": "Our institution's tumor registry was queried to identify a cohort of patients diagnosed with recurrent head and neck squamous cell carcinoma between the year 2015 and 2023. Descriptive data included age at diagnosis, sex comorbidities, recurrence timing, number of recurrences, pathologic data, and carcinoma staging based on the American Joint Committee on carcinoma (AJCC) 8th edition. Multivariable analysis was performed to identify independent prognostic factors associated with an increased risk of recurrence. Survival analysis was performed using Kaplan-Meier analysis and the Cox proportional hazards model.",
        "Results": "620 patients with recurrent head and neck carcinoma were included in this study. A majority of patients were men (72.3%, p<0.05) and self-identified as white (89.2%, p<0.05). The most commonly involved sites were oropharynx (34.0%) followed by oral cavity (24.8%) and larynx (21.1%), and most recurrences were local recurrences (46.8%). 147 (23.7%) of patients in this cohort received immunotherapy, of which 11.5% were treated with palliative intent. The overall mortality rate during the follow up period was 49%. Within a subset of patients with oral cavity carcinoma, immunotherapy was associated with a significantly improved 2-year progression free survival when compared to those who were not treated with immunotherapy (HR 1.60, 1.09-2.35, p<0.05). There was no survival benefit among those who received immunotherapy within either the HPV related oropharyngeal carcinoma group or the HPV-negative oropharyngeal group. Further survival analyses for the entire cohort are pending.",
        "Conclusions": "Recurrent head and neck carcinoma carries a poor prognosis with disease specific mortality was 49% within the follow up period. In particular subsites such as the oral cavity, our data supports that immunotherapy can help improve progression free survival in the recurrent setting. Despite the relative success of immunotherapy, further research is required to improve risk stratification, prediction of treatment responses, and prognostic evaluations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A retrospective study on outcomes of recurrent head and neck mucosal squamous cell carcinoma</span>. <u>Muhammad El Shatanofy, MD</u><sup>1</sup>; Eric Sokhn, BS<sup>2</sup>; Soumil Prasad, BS<sup>2</sup>; Carlos L Nava, BS<sup>2</sup>; Zoukaa Sargi, MD, MPH<sup>1</sup>. <sup>1</sup>University of Miami Hospital; <sup>2</sup>University of Miami Miller School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer is the seventh most prevalent cancer worldwide. Treatment typically involves one or more of the following: surgery, chemotherapy, radiation, or immunotherapy. Despite advances in treatment modalities, a subset of patients inevitably develops recurrences that are aggressive and treatment resistant. Few studies have investigated underlying factors that make head and neck squamous cell carcinomas more prone to recurrence and treatment failure. The objective of this study was to retrospectively review a cohort of patients with recurrent head and neck carcinoma to identify trends in patient demographics, tumor characteristics, and treatment resistances.</p>\n\n<p><strong>Methods: </strong>Our institution's tumor registry was queried to identify a cohort of patients diagnosed with recurrent head and neck squamous cell carcinoma between the year 2015 and 2023. Descriptive data included age at diagnosis, sex comorbidities, recurrence timing, number of recurrences, pathologic data, and carcinoma staging based on the American Joint Committee on carcinoma (AJCC) 8th edition. Multivariable analysis was performed to identify independent prognostic factors associated with an increased risk of recurrence. Survival analysis was performed using Kaplan-Meier analysis and the Cox proportional hazards model.</p>\n\n<p><strong>Results:</strong> 620 patients with recurrent head and neck carcinoma were included in this study. A majority of patients were men (72.3%, p<0.05) and self-identified as white (89.2%, p<0.05). The most commonly involved sites were oropharynx (34.0%) followed by oral cavity (24.8%) and larynx (21.1%), and most recurrences were local recurrences (46.8%). 147 (23.7%) of patients in this cohort received immunotherapy, of which 11.5% were treated with palliative intent. The overall mortality rate during the follow up period was 49%. Within a subset of patients with oral cavity carcinoma, immunotherapy was associated with a significantly improved 2-year progression free survival when compared to those who were not treated with immunotherapy (HR 1.60, 1.09-2.35, p<0.05). There was no survival benefit among those who received immunotherapy within either the HPV related oropharyngeal carcinoma group or the HPV-negative oropharyngeal group. Further survival analyses for the entire cohort are pending.</p>\n\n<p><strong>Conclusions:</strong> Recurrent head and neck carcinoma carries a poor prognosis with disease specific mortality was 49% within the follow up period. In particular subsites such as the oral cavity, our data supports that immunotherapy can help improve progression free survival in the recurrent setting. Despite the relative success of immunotherapy, further research is required to improve risk stratification, prediction of treatment responses, and prognostic evaluations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154110--></body></html>"
    },
    {
      "uid": "P215",
      "content_id": "154377",
      "abstract_number": "P215",
      "poster_number": "P215",
      "title": "Nutritional and Inflammatory Status as Predictors of Immune Checkpoint Inhibitor Response in Head and Neck Squamous Cell Carcinoma",
      "summary": "We found that lower prognositc nutritional index was associated with lower OS and PFS in patients with HNSCC treated with ICI. Additionally, several parameters for inflammation were associated with OS and PFS. These results indicate that nutritional and inflammatory status have prognostic value in ICI therapy in HNSCC patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154377",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Colewyn D Knoblich, MS",
      "presenter": "Colewyn D Knoblich, MS",
      "authors": "Colewyn D Knoblich, MS 1 ; William C Spanos, MD, FACS 2",
      "normalized_authors": [
        "Colewyn D Knoblich",
        "William C Spanos"
      ],
      "affiliations": [
        "University of South Dakota Sanford School of Medicine",
        "Avera Mckenna Hospital and University Health Center - Avera Medical Group ENT"
      ],
      "normalized_institutions": [
        "University of South Dakota Sanford School of Medicine",
        "Avera Mckenna Hospital and University Health Center - Avera Medical Group ENT"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 427,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Colewyn D Knoblich, MS 1 ; William C Spanos, MD, FACS 2",
        "Affiliations": "1 University of South Dakota Sanford School of Medicine; 2 Avera Mckenna Hospital and University Health Center - Avera Medical Group ENT",
        "Introduction": "Tumors arising from the head and neck are typically of the squamous mucosa that line the upper aerodigestive tract. Head and neck squamous cell carcinoma (HNSCC) accounts for roughly 90% of all head and neck cancers. Major anatomical sites include areas such as the oral cavity and oropharynx which affect swallowing and nutrition. Patients diagnosed with HNSCC commonly present with locally advanced disease and will require multimodal therapy. Immune checkpoint inhibitors (ICI) have transformed the treatment of many solid tumors including HNSCC. They were first approved for second line metastatic settings but are now used as first line metastatic therapy in HNSCC alongside standard chemotherapy. Despite this, many patients will have unfavorable response to ICI therapy. In the context of nutritional deficiencies, cancer induced cachexia and inflammation are events that are known to impact other types of cancer treatments, but their impact on ICI therapy is incompletely understood. This study aims to identify if nutritional and inflammatory status in patients with HNSCC can be predictors of response to ICIs.",
        "Methods": "Patients who were diagnosed with HNSCC and treated with an ICI at least once were included. We generated a query from SlicerDicer using electronic medical records (EMRs) from patients who met inclusion criteria. Both the query and EMRs were then manually reviewed. Prognostic nutritional index was used as a parameter for nutritional status. Neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were used as parameters for inflammatory status. Overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), stable disease (SD), and disease progression (DP) were measured to characterize response to ICI therapy.",
        "Results": "The relationship between nutritional and inflammatory status and OS and PFS were examined. A majority of patients had HNSCC of the tongue base and presented with stage 3 and 4A tumors at time of diagnosis. A majority of patients received ICIs as first-line metastatic treatment alongside standard treatment, with pembrolizumab being the most frequently used ICI for both locally aggressive and recurrent disease. A low prognostic nutritional index was associated with lower OS and PFS. Several of the parameters for inflammatory status such as MLR, NLR, CRP, CAR were associated with OS and PFS.",
        "Conclusion": "We found that lower prognositc nutritional index was associated with lower OS and PFS in patients with HNSCC treated with ICI. Additionally, several parameters for inflammation were associated with OS and PFS. These results indicate that nutritional and inflammatory status have prognostic value in ICI therapy in HNSCC patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Nutritional and Inflammatory Status as Predictors of Immune Checkpoint Inhibitor Response in Head and Neck Squamous Cell Carcinoma</span>. <u>Colewyn D Knoblich, MS</u><sup>1</sup>; William C Spanos, MD, FACS<sup>2</sup>. <sup>1</sup>University of South Dakota Sanford School of Medicine; <sup>2</sup>Avera Mckenna Hospital and University Health Center - Avera Medical Group ENT<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tumors arising from the head and neck are typically of the squamous mucosa that line the upper aerodigestive tract. Head and neck squamous cell carcinoma (HNSCC) accounts for roughly 90% of all head and neck cancers. Major anatomical sites include areas such as the oral cavity and oropharynx which affect swallowing and nutrition. Patients diagnosed with HNSCC commonly present with locally advanced disease and will require multimodal therapy. Immune checkpoint inhibitors (ICI) have transformed the treatment of many solid tumors including HNSCC. They were first approved for second line metastatic settings but are now used as first line metastatic therapy in HNSCC alongside standard chemotherapy. Despite this, many patients will have unfavorable response to ICI therapy.  In the context of nutritional deficiencies, cancer induced cachexia and inflammation are events that are known to impact other types of cancer treatments, but their impact on ICI therapy is incompletely understood.  This study aims to identify if nutritional and inflammatory status in patients with HNSCC can be predictors of response to ICIs.</p>\n\n<p><strong>Methods:</strong> Patients who were diagnosed with HNSCC and treated with an ICI at least once were included. We generated a query from SlicerDicer using electronic medical records (EMRs) from patients who met inclusion criteria. Both the query and EMRs were then manually reviewed. Prognostic nutritional index was used as a parameter for nutritional status. Neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were used as parameters for inflammatory status. Overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), stable disease (SD), and disease progression (DP) were measured to characterize response to ICI therapy.</p>\n\n<p><strong>Results: </strong>The relationship between nutritional and inflammatory status and OS and PFS were examined. A majority of patients had HNSCC of the tongue base and presented with stage 3 and 4A tumors at time of diagnosis. A majority of patients received ICIs as first-line metastatic treatment alongside standard treatment, with pembrolizumab being the most frequently used ICI for both locally aggressive and recurrent disease. A low prognostic nutritional index was associated with lower OS and PFS. Several of the parameters for inflammatory status such as MLR, NLR, CRP, CAR were associated with OS and PFS.</p>\n\n<p><strong>Conclusion: </strong>We found that lower prognositc nutritional index was associated with lower OS and PFS in patients with HNSCC treated with ICI. Additionally, several parameters for inflammation were associated with OS and PFS. These results indicate that nutritional and inflammatory status have prognostic value in ICI therapy in HNSCC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154377--></body></html>"
    },
    {
      "uid": "P217",
      "content_id": "154714",
      "abstract_number": "P217",
      "poster_number": "P217",
      "title": "Single-Institution Experience Using Neoadjuvant Chemo-Immunotherapy in the Treatment of Locally Advanced Laryngeal Squamous Cell Carcinoma",
      "summary": "Treatment with neoadjuvant chemo-immunotherapy (NAIC) followed by chemoradiotherapy demonstrated rapid and clinically meaningful reductions in laryngeal tumor size with zero patients experiencing tumor progression, recurrence, metastasis, or death since induction and none requiring a laryngectomy. However, functional improvement was variable, and several patients experienced significant local reactions...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154714",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carolyn J Khoury, BA",
      "presenter": "Carolyn J Khoury, BA",
      "authors": "Carolyn J Khoury, BA 1 ; Kunal K Sindhu, MD 2 ; Richard L Bakst, MD 2 ; Eric M Genden, MD, MHCA, FACS 1 ; Marita S Teng, MD 1 ; Scott A Roof, MD, MS 1 ; Krzysztof J Misiukiewicsz, MD 3 ; Diana N Kirke, MD, Phil 1",
      "normalized_authors": [
        "Carolyn J Khoury",
        "Kunal K Sindhu",
        "Richard L Bakst",
        "Eric M Genden, MHCA",
        "Marita S Teng",
        "Scott A Roof",
        "Krzysztof J Misiukiewicsz",
        "Diana N Kirke, Phil"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
        "Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai",
        "Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
        "Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai",
        "Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Carolyn J Khoury, BA 1 ; Kunal K Sindhu, MD 2 ; Richard L Bakst, MD 2 ; Eric M Genden, MD, MHCA, FACS 1 ; Marita S Teng, MD 1 ; Scott A Roof, MD, MS 1 ; Krzysztof J Misiukiewicsz, MD 3 ; Diana N Kirke, MD, Phil 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai; 2 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai; 3 Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai",
        "Introduction": "Recent clinical trials marked an inflection point in the treatment of head and neck squamous cell carcinoma (HNSCC), with KEYNOTE-689 leading to the approval of Pembrolizumab as neoadjuvant and adjuvant treatment for locally advanced HNSCC in June 2025. Still, laryngeal squamous cell carcinoma (LSCC) remains underrepresented in published cohorts, and data on oncologic outcomes are limited. We present a case series of five patients treated with neoadjuvant chemo-immunotherapy (NAIC) for locally advanced LSCC.",
        "Methods": "Patients treated at Mount Sinai Hospital with NAIC for locally advanced LSCC were identified. Data regarding patient presentation prior to induction were collected including cTNM stage, imaging, histopathology, p16 status, PD-L1 status, and combined positive score (CPS). The primary endpoint was oncologic outcome, represented by post-induction imaging results, time to radiographic response, recurrence events, metastasis events, and deaths. The secondary endpoint was functional outcome which encompassed pre-and post-treatment VHI-10, EAT-10, and diet, as well as relevant adverse events following induction.",
        "Results": "Five patients found to have locally advanced LSCC were treated with NAIC. This comprised of two cycles of induction immunotherapy with pembrolizumab plus a taxane (docetaxel or paclitaxel) and a platinum agent (cisplatin or carboplatin). This was then followed by chemoradiotherapy if the patient responded to initial treatment. Median age was 69 years (SD=11 years). Follow up period for all cases was approximately 5 months—the period since FDA approval of pembrolizumab for locally advanced disease. One patient (20%) was p16+ and all patients (100%) were PD-L1+. One patient (20%) had CPS 1-20, two (40%) had CPS 20-50, and two (33%) lacked documented CPS. Radiographic response occurred in 100% of patients with a mean response time of 3.6 weeks (range 2-4 weeks). Most notably, zero patients experienced tumor progression, recurrence, metastasis, or death since induction and none have required a laryngectomy.",
        "Abstract": "Functional adverse effects were notable. One patient (20%) with CPS 20-50 experienced dyspnea with subsequent reactive swelling and expansion of the laryngeal lesion to the point of moderate-to-serve airway obstruction requiring emergent intubation and subsequent tracheostomy. Two patients (40%) reported dysphagia; one (20%) reported odynophagia. While EAT-10 data was only available pre-treatment, comparison between pre-induction and post-induction diet show diet improvement in one patient (20%), diet remaining stable in two patients (40%), and diet worsening in two patients (40%) who are currently G-tube-dependent. Pre- and post-treatment VHI-10 scores were available for one patient, with score improvement from 34 to 26.",
        "Conclusions": "Treatment with neoadjuvant chemo-immunotherapy (NAIC) followed by chemoradiotherapy demonstrated rapid and clinically meaningful reductions in laryngeal tumor size with zero patients experiencing tumor progression, recurrence, metastasis, or death since induction and none requiring a laryngectomy. However, functional improvement was variable, and several patients experienced significant local reactions compromising airway or swallow function. Interestingly, the patient with substantial reactive airway obstruction had a relatively higher CPS (20-50), possibly suggesting a more severe local immunogenic reaction with increased PD-L1 expression. Longer follow-up periods and larger cohorts of patients with locally advanced LSCC are needed to clarify oncologic and functional trajectories and to optimize peri-therapeutic management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Single-Institution Experience Using Neoadjuvant Chemo-Immunotherapy in the Treatment of Locally Advanced Laryngeal Squamous Cell Carcinoma</span>. <u>Carolyn J Khoury, BA</u><sup>1</sup>; Kunal K Sindhu, MD<sup>2</sup>; Richard L Bakst, MD<sup>2</sup>; Eric M Genden, MD, MHCA, FACS<sup>1</sup>; Marita S Teng, MD<sup>1</sup>; Scott A Roof, MD, MS<sup>1</sup>; Krzysztof J Misiukiewicsz, MD<sup>3</sup>; Diana N Kirke, MD, Phil<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai; <sup>2</sup>Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai; <sup>3</sup>Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Recent clinical trials marked an inflection point in the treatment of head and neck squamous cell carcinoma (HNSCC), with KEYNOTE-689 leading to the approval of Pembrolizumab as neoadjuvant and adjuvant treatment for locally advanced HNSCC in June 2025. Still, laryngeal squamous cell carcinoma (LSCC) remains underrepresented in published cohorts, and data on oncologic outcomes are limited. We present a case series of five patients treated with neoadjuvant chemo-immunotherapy (NAIC) for locally advanced LSCC.</p>\n\n<p><strong>Methods: </strong>Patients treated at Mount Sinai Hospital with NAIC for locally advanced LSCC were identified. Data regarding patient presentation prior to induction were collected including cTNM stage, imaging, histopathology, p16 status, PD-L1 status, and combined positive score (CPS). The primary endpoint was oncologic outcome, represented by post-induction imaging results, time to radiographic response, recurrence events, metastasis events, and deaths. The secondary endpoint was functional outcome which encompassed pre-and post-treatment VHI-10, EAT-10, and diet, as well as relevant adverse events following induction.</p>\n\n<p><strong>Results: </strong>Five patients found to have locally advanced LSCC were treated with NAIC. This comprised of two cycles of induction immunotherapy with pembrolizumab plus a taxane (docetaxel or paclitaxel) and a platinum agent (cisplatin or carboplatin). This was then followed by chemoradiotherapy if the patient responded to initial treatment. Median age was 69 years (SD=11 years). Follow up period for all cases was approximately 5 months—the period since FDA approval of pembrolizumab for locally advanced disease. One patient (20%) was p16+ and all patients (100%) were PD-L1+. One patient (20%) had CPS 1-20, two (40%) had CPS 20-50, and two (33%) lacked documented CPS. Radiographic response occurred in 100% of patients with a mean response time of 3.6 weeks (range 2-4 weeks). Most notably, zero patients experienced tumor progression, recurrence, metastasis, or death since induction and none have required a laryngectomy.</p>\n\n<p>Functional adverse effects were notable. One patient (20%) with CPS 20-50 experienced dyspnea with subsequent reactive swelling and expansion of the laryngeal lesion to the point of moderate-to-serve airway obstruction requiring emergent intubation and subsequent tracheostomy. Two patients (40%) reported dysphagia; one (20%) reported odynophagia. While EAT-10 data was only available pre-treatment, comparison between pre-induction and post-induction diet show diet improvement in one patient (20%), diet remaining stable in two patients (40%), and diet worsening in two patients (40%) who are currently G-tube-dependent. Pre- and post-treatment VHI-10 scores were available for one patient, with score improvement from 34 to 26.</p>\n\n<p><strong>Conclusions:</strong> Treatment with neoadjuvant chemo-immunotherapy (NAIC) followed by chemoradiotherapy demonstrated rapid and clinically meaningful reductions in laryngeal tumor size with zero patients experiencing tumor progression, recurrence, metastasis, or death since induction and none requiring a laryngectomy. However, functional improvement was variable, and several patients experienced significant local reactions compromising airway or swallow function. Interestingly, the patient with substantial reactive airway obstruction had a relatively higher CPS (20-50), possibly suggesting a more severe local immunogenic reaction with increased PD-L1 expression. Longer follow-up periods and larger cohorts of patients with locally advanced LSCC are needed to clarify oncologic and functional trajectories and to optimize peri-therapeutic management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154714--></body></html>"
    },
    {
      "uid": "P218",
      "content_id": "154278",
      "abstract_number": "P218",
      "poster_number": "P218",
      "title": "Targeted therapy with trastuzumab-deruxtecan (T-DXd) in recurrent or metastatic salivary duct carcinoma: a single institution experience",
      "summary": "A small sample of patients with metastatic HER2+ SDCs at a single institution were treated with T-Dxd; the regimen was safe, with no grade 3 or higher adverse events, and stable disease was achieved in the majority of patients. Notably our patient cohort had a much improved survival compared to previous studies on SGC. In addition to the limitations of a small sample size and the retrospective nature of this...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154278",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jason Tasoulas, MD, DMD, PhD",
      "presenter": "Jason Tasoulas, MD, DMD, PhD",
      "authors": "Jason Tasoulas, MD, DMD, PhD ; Hannah L Kenny, MD; Eric V Mastrolonardo, MD; D. Alexander Cronkite, MD; Adam J Luginbuhl, MD; David M Cognetti, MD; Joseph R Curry, MD; Jennifer M Johnson, MD, PhD",
      "normalized_authors": [
        "Jason Tasoulas",
        "Hannah L Kenny",
        "Eric V Mastrolonardo",
        "D. Alexander Cronkite",
        "Adam J Luginbuhl",
        "David M Cognetti",
        "Joseph R Curry",
        "Jennifer M Johnson"
      ],
      "affiliations": [
        "Thomas Jefferson University"
      ],
      "normalized_institutions": [
        "Thomas Jefferson University"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 459,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Patients and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jason Tasoulas, MD, DMD, PhD ; Hannah L Kenny, MD; Eric V Mastrolonardo, MD; D. Alexander Cronkite, MD; Adam J Luginbuhl, MD; David M Cognetti, MD; Joseph R Curry, MD; Jennifer M Johnson, MD, PhD",
        "Affiliations": "Thomas Jefferson University",
        "Introduction": "Salivary duct carcinoma (SDC) is a rare salivary gland cancer (SGC) accounting for ~1-3% of all SGCs. SDC is frequently associated with perineural invasion, lymphovascular invasion, and regional metastasis at diagnosis and carries a poor prognosis (5-year overall survival -OS: 41-54%, progression free survival PFS: 42-44mo). The tumor expresses HER2/NEU in ~20-40% of cases. Trastuzumab deruxtecan-nxki (T-DXd) is FDA-approved for unresectable or metastatic HER2+ solid tumors based on the the DESTINY-PanTumor 02 Phase II Trial. Further, the MYTHOS trial also demonstrated high objective response rate (ORR: 68.4, 95%CI 43.4-87.4) and a median PFS of 15.9 months. This study sought to review real world data outcomes associated with T-DXd for treatment of patients with SDCs at a single institution.",
        "Patients and Methods": "A retrospective chart review between 2015 and 2025 was performed at a single institution to identify patients with SDCs that received T-DXd. Demographic, clinical, treatment, and survival data (OS, PFS) were extracted. Descriptive statistics were used for data analysis and interpretation. Statistical analysis was performed using Stata 17.1 (StataCorp LP, College Station, TX, USA).",
        "Results": "Six patients with SDCs were identified, including 3 originating from pleomorphic adenomas and 1 high-grade ductal adenocarcinoma. Male-to-female ratio was 2:1 with a mean age of 70 (66-77). HER2/NEU expression was evaluated with immunohistochemistry in all patients (3+ in 5 patients; 2+ in 1). Five patients were treated for metastatic disease and one was treated for local recurrence. The median duration of follow up was 32 months. Patients underwent an average of 18 treatment cycles (3-37) with 33% reporting no adverse events (AEs), with the remaining patients reporting grade 1 and 2 AEs by chart review. Five patients were considered by the treating physician as having stable disease as their best response. At the time of this submission 3 patients were still on therapy, 1 had discontinued due to disease progression and 2 due to non-treatment related issues (trauma and subsequent deconditioning, insurance barriers). In our single institution cohort, OS was 32 months (7-51) and PFS was 25 months (7-51).",
        "Conclusions": "A small sample of patients with metastatic HER2+ SDCs at a single institution were treated with T-Dxd; the regimen was safe, with no grade 3 or higher adverse events, and stable disease was achieved in the majority of patients. Notably our patient cohort had a much improved survival compared to previous studies on SGC. In addition to the limitations of a small sample size and the retrospective nature of this study, it is important to note that all patients in this cohort were treated in the palliative setting; with the recent approval of T-Dxd for HER2+ metastatic solid cancers, further study will be imperative to elucidate the potential role of T-Dxd earlier in treatment for this disease entity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Targeted therapy with trastuzumab-deruxtecan (T-DXd) in recurrent or metastatic salivary duct carcinoma: a single institution experience</span>. <u>Jason Tasoulas, MD, DMD, PhD</u>; Hannah L Kenny, MD; Eric V Mastrolonardo, MD; D. Alexander Cronkite, MD; Adam J Luginbuhl, MD; David M Cognetti, MD; Joseph R Curry, MD; Jennifer M Johnson, MD, PhD. Thomas Jefferson University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Salivary duct carcinoma (SDC) is a rare salivary gland cancer (SGC) accounting for ~1-3% of all SGCs. SDC is frequently associated with perineural invasion, lymphovascular invasion, and regional metastasis at diagnosis and carries a poor prognosis (5-year overall survival -OS: 41-54%, progression free survival PFS: 42-44mo). The tumor expresses HER2/NEU in ~20-40% of cases. Trastuzumab deruxtecan-nxki (T-DXd) is FDA-approved for unresectable or metastatic HER2+ solid tumors based on the the DESTINY-PanTumor 02 Phase II Trial. Further, the MYTHOS trial also demonstrated high objective response rate (ORR: 68.4, 95%CI 43.4-87.4) and a median PFS of 15.9 months. This study sought to review real world data outcomes associated with T-DXd for treatment of patients with SDCs at a single institution.</p>\n\n<p><strong>Patients and Methods: </strong>A retrospective chart review between 2015 and 2025 was performed at a single institution to identify patients with SDCs that received T-DXd. Demographic, clinical, treatment, and survival data (OS, PFS) were extracted. Descriptive statistics were used for data analysis and interpretation. Statistical analysis was performed using Stata 17.1 (StataCorp LP, College Station, TX, USA). </p>\n\n<p><strong>Results:</strong> Six patients with SDCs were identified, including 3 originating from pleomorphic adenomas and 1 high-grade ductal adenocarcinoma. Male-to-female ratio was 2:1 with a mean age of 70 (66-77). HER2/NEU expression was evaluated with immunohistochemistry in all patients (3+ in 5 patients; 2+ in 1). Five patients were treated for metastatic disease and one  was treated for  local recurrence.  The median duration of follow up was 32 months.  Patients underwent an average of 18 treatment cycles (3-37) with 33% reporting no adverse events (AEs), with the remaining patients reporting grade 1 and 2 AEs by chart review. Five patients were considered by the treating physician as having stable disease as their best response.  At the time of this submission 3 patients were still on therapy, 1 had discontinued due to disease progression and 2 due to non-treatment related issues (trauma and subsequent deconditioning, insurance barriers). In our single institution cohort, OS was 32 months (7-51) and PFS was 25 months (7-51).</p>\n\n<p><strong>Conclusions:</strong> A small sample of patients with metastatic HER2+ SDCs at a single institution were treated with T-Dxd; the regimen was safe, with no grade 3 or higher adverse events, and stable disease was achieved in the majority of patients. Notably our patient cohort had a much improved survival compared to previous studies on SGC. In addition to the limitations of a small sample size and the retrospective nature of this study, it is important to note that all patients in this cohort were treated in the palliative setting; with the recent approval of T-Dxd for HER2+ metastatic solid cancers, further study will be imperative to elucidate the potential role of T-Dxd earlier in treatment for this disease entity.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154278--></body></html>"
    },
    {
      "uid": "P219",
      "content_id": "154078",
      "abstract_number": "P219",
      "poster_number": "P219",
      "title": "Neoadjuvant Immunotherapy in Head and Neck Squamous Cell Carcinoma: Early Evidence and Surgical Implications",
      "summary": "Neoadjuvant immunotherapy has emerged as a promising approach in the management of resectable head and neck squamous cell carcinoma (HNSCC), complementing traditional surgical and adjuvant treatment strategies. While surgery and chemoradiation remain the current standards of care, limitations related to morbidity, functional impairment, and oncologic heterogeneity have prompted the exploration of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154078",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Patrick Hunt, MA, BS",
      "presenter": "Patrick Hunt, MA, BS",
      "authors": "Patrick Hunt, MA, BS 1 ; Kimberly Huynh, MA, BS 1 ; David Addison, BS 1 ; Ajay Bezawada, BS 2",
      "normalized_authors": [
        "Patrick Hunt, MA",
        "Kimberly Huynh, MA",
        "David Addison",
        "Ajay Bezawada"
      ],
      "affiliations": [
        "Midwestern University, Arizona College of Osteopathic Medicine",
        "Honor Health Scottsdale"
      ],
      "normalized_institutions": [
        "Midwestern University, Arizona College of Osteopathic Medicine",
        "Honor Health Scottsdale"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 245,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Patrick Hunt, MA, BS 1 ; Kimberly Huynh, MA, BS 1 ; David Addison, BS 1 ; Ajay Bezawada, BS 2",
        "Affiliations": "1 Midwestern University, Arizona College of Osteopathic Medicine; 2 Honor Health Scottsdale",
        "Abstract": "Neoadjuvant immunotherapy has emerged as a promising approach in the management of resectable head and neck squamous cell carcinoma (HNSCC), complementing traditional surgical and adjuvant treatment strategies. While surgery and chemoradiation remain the current standards of care, limitations related to morbidity, functional impairment, and oncologic heterogeneity have prompted the exploration of immunotherapeutic interventions delivered prior to definitive operative management. This review evaluates emerging evidence on neoadjuvant checkpoint blockade and explores its implications for surgical planning, margin control, and organ-preservation strategies. Recent phase I–II trials investigating PD-1 and PD-L1 inhibitors as monotherapy and in combination regimens demonstrate encouraging rates of radiographic tumor reduction and meaningful pathologic responses, including major and complete responses in a subset of patients. These findings suggest the potential for decreased tumor burden at the time of surgery, improved resectability, and, in select cases, facilitate more conservative postoperative radiation strategies. Additional advances in biomarker-driven selection, PD-L1 expression, HPV status, tumor mutational burden, and immune gene signatures, further support the development of personalized neoadjuvant treatment algorithms. Despite recent advances, several challenges remain, including variability in response, limited long-term survival data, uncertainty surrounding ideal patient selection, and logistical considerations regarding timing, toxicity monitoring, and surgical delays. This review identifies current gaps in evidence and highlights the need for multicenter randomized trials, standardized response criteria, and integrated multidisciplinary approaches. By aligning immunologic advances with operative strategy, neoadjuvant immunotherapy has the potential to redefine future surgical paradigms and improve both oncologic and functional outcomes in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant Immunotherapy in Head and Neck Squamous Cell Carcinoma: Early Evidence and Surgical Implications</span>. <u>Patrick Hunt, MA, BS</u><sup>1</sup>; Kimberly Huynh, MA, BS<sup>1</sup>; David Addison, BS<sup>1</sup>; Ajay Bezawada, BS<sup>2</sup>. <sup>1</sup>Midwestern University, Arizona College of Osteopathic Medicine; <sup>2</sup>Honor Health Scottsdale<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Neoadjuvant immunotherapy has emerged as a promising approach in the management of resectable head and neck squamous cell carcinoma (HNSCC), complementing traditional surgical and adjuvant treatment strategies. While surgery and chemoradiation remain the current standards of care, limitations related to morbidity, functional impairment, and oncologic heterogeneity have prompted the exploration of immunotherapeutic interventions delivered prior to definitive operative management. This review evaluates emerging evidence on neoadjuvant checkpoint blockade and explores its implications for surgical planning, margin control, and organ-preservation strategies.</p>\n\n<p>Recent phase I–II trials investigating PD-1 and PD-L1 inhibitors as monotherapy and in combination regimens demonstrate encouraging rates of radiographic tumor reduction and meaningful pathologic responses, including major and complete responses in a subset of patients. These findings suggest the potential for decreased tumor burden at the time of surgery, improved resectability, and, in select cases, facilitate more conservative postoperative radiation strategies. Additional advances in biomarker-driven selection, PD-L1 expression, HPV status, tumor mutational burden, and immune gene signatures, further support the development of personalized neoadjuvant treatment algorithms.</p>\n\n<p>Despite recent advances, several challenges remain, including variability in response, limited long-term survival data, uncertainty surrounding ideal patient selection, and logistical considerations regarding timing, toxicity monitoring, and surgical delays. This review identifies current gaps in evidence and highlights the need for multicenter randomized trials, standardized response criteria, and integrated multidisciplinary approaches. By aligning immunologic advances with operative strategy, neoadjuvant immunotherapy has the potential to redefine future surgical paradigms and improve both oncologic and functional outcomes in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154078--></body></html>"
    },
    {
      "uid": "P220",
      "content_id": "153858",
      "abstract_number": "P220",
      "poster_number": "P220",
      "title": "Early Implementation of Neoadjuvant Immunotherapy at a Single Academic Institution",
      "summary": "Early implementation of neoadjuvant pembrolizumab for LAHNSCC was feasible but frequently associated with delays that extended beyond the intended 8-week timeline. Although not statistically significant, these delays reflect substantial logistical challenges in integrating this newly approved therapy into routine care. High rates of disease progression, treatment modification, and immune-related toxicities...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153858",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jarod M Labrador, BS",
      "presenter": "Jarod M Labrador, BS",
      "authors": "Priscilla Pichardo, DO 1 ; Jarod M Labrador, BS 2 ; Sabrina Bernardo, MD 1 ; Katrina Harrill, MSN, BSN, OCN 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Trisha Wise-Draper, MD, PhD 3 ; Christopher Lemmon, MD 3 ; Matthew Hagen, MD, PhD 4 ; Chad Zender, MD 1",
      "normalized_authors": [
        "Priscilla Pichardo",
        "Jarod M Labrador",
        "Sabrina Bernardo",
        "Katrina Harrill, MSN, BSN, OCN",
        "Dustin Silverman",
        "Alice Tang",
        "Trisha Wise-Draper",
        "Christopher Lemmon",
        "Matthew Hagen",
        "Chad Zender"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio",
        "University of Cincinnati College of Medicine",
        "Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio",
        "Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio",
        "University of Cincinnati College of Medicine",
        "Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio",
        "Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 487,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Priscilla Pichardo, DO 1 ; Jarod M Labrador, BS 2 ; Sabrina Bernardo, MD 1 ; Katrina Harrill, MSN, BSN, OCN 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Trisha Wise-Draper, MD, PhD 3 ; Christopher Lemmon, MD 3 ; Matthew Hagen, MD, PhD 4 ; Chad Zender, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio; 2 University of Cincinnati College of Medicine; 3 Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio; 4 Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio",
        "Introduction": "Neoadjuvant pembrolizumab for locally advanced head and neck squamous cell carcinoma (LAHNSCC) was recently granted FDA approval for use in resectable disease, marking a significant shift in the treatment landscape. As this approach enters clinical practice, its integration into routine head and neck oncology care remains incompletely characterized. Implementing a newly established immunotherapy-based standard of care introduces practical, logistical, and clinical challenges for healthcare systems. The phase 3 KEYNOTE-689 trial demonstrated improved event-free survival with neoadjuvant pembrolizumab compared with standard therapy. Given these considerations, the purpose of this study was to describe the real-world implementation and delivery of neoadjuvant pembrolizumab for patients with LAHNSCC and to evaluate surgical, oncologic, and toxicity-related outcomes.",
        "Methods": "Our institution developed a standardized treatment protocol based on the KEYNOTE-689 trial to mitigate logistical barriers. The protocol included Head and Neck surgeon consultation with biopsy for CPS score evaluation, referral to medical oncology within seven days, and multidisciplinary tumor board review. The target was to initiate immunotherapy within two weeks of the initial visit. Operating room time was tentatively scheduled eight weeks from consultation, with the intent to complete two neoadjuvant pembrolizumab doses preoperatively, with imaging and clinical evaluation after the second dose. Patients then proceeded to surgical resection, and clinical outcomes were assessed. Eligible patients were adults >18 years with biopsy-confirmed locally advanced HNSCC and PD-L1 CPS ≥1 who received at least one neoadjuvant pembrolizumab dose. Data were collected retrospectively through chart review.",
        "Results": "During the study period, 333 new cancer patients were seen within the Head and Neck Cancer Division from June 1, 2025 to September 30, 2025, of whom eight were eligible and suitable for this pathway. The interval from surgical oncology consultation to medical oncology evaluation averaged 10.5 days, not significantly different from the target of seven days (p = 0.15). One patient remains on immunotherapy and has not yet undergone surgery. Among the seven who completed surgery, the median time from consultation to operation was 72 days (mean 79.0; SD 27.7), exceeding the planned 8-week (56-day) goal by an average of 23 days (t=2.20, p=0.07; 95% CI –2.6 to 48.6). CPS scores ranged from 1–90 (median 10). Factors impacting delays were insurance denials, disease progression/additional therapy, and socioeconomic factors. Four of seven patients experienced disease progression while on immunotherapy. Two patients had no clinical response and required changes in treatment after the first pembrolizumab dose. Immune-related complications occurred in two patients, including one grade 4 drug-induced pneumonitis.",
        "Conclusion": "Early implementation of neoadjuvant pembrolizumab for LAHNSCC was feasible but frequently associated with delays that extended beyond the intended 8-week timeline. Although not statistically significant, these delays reflect substantial logistical challenges in integrating this newly approved therapy into routine care. High rates of disease progression, treatment modification, and immune-related toxicities further underscore the need for refined workflows, careful patient selection, and larger studies to better define real-world safety, effectiveness, and system-level demands."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Implementation of Neoadjuvant Immunotherapy at a Single Academic Institution</span>. Priscilla Pichardo, DO<sup>1</sup>; <u>Jarod M Labrador, BS</u><sup>2</sup>; Sabrina Bernardo, MD<sup>1</sup>; Katrina Harrill, MSN, BSN, OCN<sup>1</sup>; Dustin Silverman, MD<sup>1</sup>; Alice Tang, MD<sup>1</sup>; Trisha Wise-Draper, MD, PhD<sup>3</sup>; Christopher Lemmon, MD<sup>3</sup>; Matthew Hagen, MD, PhD<sup>4</sup>; Chad Zender, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio; <sup>2</sup>University of Cincinnati College of Medicine; <sup>3</sup>Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio; <sup>4</sup>Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Neoadjuvant pembrolizumab for locally advanced head and neck squamous cell carcinoma (LAHNSCC) was recently granted FDA approval for use in resectable disease, marking a significant shift in the treatment landscape.  As this approach enters clinical practice, its integration into routine head and neck oncology care remains incompletely characterized. Implementing a newly established immunotherapy-based standard of care introduces practical, logistical, and clinical challenges for healthcare systems. The phase 3 KEYNOTE-689 trial demonstrated improved event-free survival with neoadjuvant pembrolizumab compared with standard therapy. Given these considerations, the purpose of this study was to describe the real-world implementation and delivery of neoadjuvant pembrolizumab for patients with LAHNSCC and to evaluate surgical, oncologic, and toxicity-related outcomes.</p>\n\n<p><strong>Methods: </strong>Our institution developed a standardized treatment protocol based on the KEYNOTE-689 trial to mitigate logistical barriers. The protocol included Head and Neck surgeon consultation with biopsy for CPS score evaluation, referral to medical oncology within seven days, and multidisciplinary tumor board review. The target was to initiate immunotherapy within two weeks of the initial visit. Operating room time was tentatively scheduled eight weeks from consultation, with the intent to complete two neoadjuvant pembrolizumab doses preoperatively, with imaging and clinical evaluation after the second dose. Patients then proceeded to surgical resection, and clinical outcomes were assessed. Eligible patients were adults >18 years with biopsy-confirmed locally advanced HNSCC and PD-L1 CPS ≥1 who received at least one neoadjuvant pembrolizumab dose. Data were collected retrospectively through chart review.</p>\n\n<p><strong>Results: </strong>During the study period, 333 new cancer patients were seen within the Head and Neck Cancer Division from June 1, 2025 to September 30, 2025, of whom eight were eligible and suitable for this pathway. The interval from surgical oncology consultation to medical oncology evaluation averaged 10.5 days, not significantly different from the target of seven days (p = 0.15). One patient remains on immunotherapy and has not yet undergone surgery. Among the seven who completed surgery, the median time from consultation to operation was 72 days (mean 79.0; SD 27.7), exceeding the planned 8-week (56-day) goal by an average of 23 days (t=2.20, p=0.07; 95% CI –2.6 to 48.6). CPS scores ranged from 1–90 (median 10). Factors impacting delays were insurance denials, disease progression/additional therapy, and socioeconomic factors.  Four of seven patients experienced disease progression while on immunotherapy. Two patients had no clinical response and required changes in treatment after the first pembrolizumab dose. Immune-related complications occurred in two patients, including one grade 4 drug-induced pneumonitis.</p>\n\n<p><strong>Conclusion: </strong>Early implementation of neoadjuvant pembrolizumab for LAHNSCC was feasible but frequently associated with delays that extended beyond the intended 8-week timeline. Although not statistically significant, these delays reflect substantial logistical challenges in integrating this newly approved therapy into routine care. High rates of disease progression, treatment modification, and immune-related toxicities further underscore the need for refined workflows, careful patient selection, and larger studies to better define real-world safety, effectiveness, and system-level demands.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153858--></body></html>"
    },
    {
      "uid": "P221",
      "content_id": "155413",
      "abstract_number": "P221",
      "poster_number": "P221",
      "title": "Cervical lymph node management and immunotherapy outcomes in head and neck squamous cell carcinoma",
      "summary": "Among 336 patients with HNC receiving immunotherapy, those who underwent prior ND had worse OS compared to those without prior ND, whereas prior radiation therapy and chemotherapy were not associated with OS. The negative association between prior ND and OS was more pronounced among patients with CPS≥1 than among CPS<1. The total lymph node count was not associated with OS, suggesting that more limited neck...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155413",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shannon S Wu, MD",
      "presenter": "Shannon S Wu, MD",
      "authors": "Shannon S Wu, MD ; Anushka Jetly, AB; John B Sunwoo, MD; F. Chris Holsinger, MD; Andrey Finegersh, MD, PhD; Michelle Chen, MD, MHS, FACS; Jake Lee, MD; Fred M Baik, MD; Vasu Divi, MD",
      "normalized_authors": [
        "Shannon S Wu",
        "Anushka Jetly, AB",
        "John B Sunwoo",
        "F. Chris Holsinger",
        "Andrey Finegersh",
        "Michelle Chen, MHS",
        "Jake Lee",
        "Fred M Baik",
        "Vasu Divi"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155413/Figure1(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155413/Figure1(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155413"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 548,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Shannon S Wu, MD ; Anushka Jetly, AB; John B Sunwoo, MD; F. Chris Holsinger, MD; Andrey Finegersh, MD, PhD; Michelle Chen, MD, MHS, FACS; Jake Lee, MD; Fred M Baik, MD; Vasu Divi, MD",
        "Affiliations": "Stanford University",
        "Background": "Cervical lymphadenectomy has been a cornerstone of oncologic management in head and neck squamous cell carcinoma (HNSCC) for both elective and therapeutic indications. However, emerging preclinical and clinical data in the immunotherapy era suggest that cervical lymph nodal basins may serve as key sites of antitumor immune activation. This raises the possibility that neck dissection (ND) preceding immunotherapy may interfere with immune priming and potentially diminish treatment efficacy. This study aimed to assess the impact of preceding neck treatments on survival outcomes among patients with HNSCC who received immunotherapy.",
        "Methods": "This retrospective study assessed patients with HNSCC who received immunotherapy at a tertiary-level institution between 1/1/2015-7/31/2025. Demographics, tumor characteristics, PD-L1 Combined Positive Score (CPS), treatment characteristics, and overall survival (OS) were recorded. Cox univariable and multivariable proportional hazards models and Kaplan-Meier survival analysis were performed.",
        "Results": "336 patients were included: median age 68 years, 72.3% male, 49.7% current/former smokers. Primary tumor site was 38.1% oral cavity, 32.7% oropharynx, 8.9% nasopharynx, 6.0% larynx, 6.0% salivary, 5.1% sinonasal, 3.3% hypopharynx. Pembrolizumab was most commonly used, for indications of recurrent disease (50.6%), metastatic disease (31.0%), or unresectable locally advanced disease (18.5%). Treatments received before immunotherapy included: radiation therapy (69.7%), chemotherapy (57.7%), neck dissection (42.6%), and surgical resection (64.0%). Of 245 patients with available p16 testing, 97 (39.6%) were p16-positive and 148 (60.1%) were p16-negative. Of 216 patients with available PD-L1 testing, CPS scores were: <1 in 24 (11.1%), 1-49 in 121 (56.0%), and 50-100 in 71 (32.9%). On Kaplan-Meier analysis, patients with ND (median OS: 13.0 months [95%CI 9.4-17.2]) had significantly worse OS compared to those without ND (median OS 22.2 months [95%CI 16.8-32.8]) (p=0.016). Among patients who had ND, total lymph node count (ρ=0.001, p=0.99) did not correlate with OS. There was no difference in OS based on ≤18 versus >18 lymph nodes removed (p=0.46). OS was not different based on prior radiation therapy (p=0.52) or chemotherapy (p=0.30). Patients whose tumors demonstrating CPS<1 had worse OS compared to CPS≥1 (p=0.007). Among patients with CPS<1, neck treatment was not associated with OS differences, whereas in patients with CPS≥1, having no prior ND conferred superior OS compared to ND. On multivariable Cox analysis, prior ND, chemotherapy, and radiation therapy were not associated with OS, whereas oral cavity primary site (adjusted HR 2.4 [95%CI 1.3-4.4]) and CPS<1 (adjusted HR 2.05 [95%CI 1.2-3.4]) were independently associated with worse OS.",
        "Conclusion": "Among 336 patients with HNC receiving immunotherapy, those who underwent prior ND had worse OS compared to those without prior ND, whereas prior radiation therapy and chemotherapy were not associated with OS. The negative association between prior ND and OS was more pronounced among patients with CPS≥1 than among CPS<1. The total lymph node count was not associated with OS, suggesting that more limited neck dissections did not mitigate the effect of prior neck surgery on immunotherapy efficacy. Future studies are needed to characterize the impact of cervical lymph node removal on immunotherapy efficacy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cervical lymph node management and immunotherapy outcomes in head and neck squamous cell carcinoma</span>. <u>Shannon S Wu, MD</u>; Anushka Jetly, AB; John B Sunwoo, MD; F. Chris Holsinger, MD; Andrey Finegersh, MD, PhD; Michelle Chen, MD, MHS, FACS; Jake Lee, MD; Fred M Baik, MD; Vasu Divi, MD. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cervical lymphadenectomy has been a cornerstone of oncologic management in head and neck squamous cell carcinoma (HNSCC) for both elective and therapeutic indications. However, emerging preclinical and clinical data in the immunotherapy era suggest that cervical lymph nodal basins may serve as key sites of antitumor immune activation. This raises the possibility that neck dissection (ND) preceding immunotherapy may interfere with immune priming and potentially diminish treatment efficacy. This study aimed to assess the impact of preceding neck treatments on survival outcomes among patients with HNSCC who received immunotherapy.</p>\n\n<p><strong>Methods: </strong>This retrospective study assessed patients with HNSCC who received immunotherapy at a tertiary-level institution between 1/1/2015-7/31/2025. Demographics, tumor characteristics, PD-L1 Combined Positive Score (CPS), treatment characteristics, and overall survival (OS) were recorded. Cox univariable and multivariable proportional hazards models and Kaplan-Meier survival analysis were performed.</p>\n\n<p><strong>Results: </strong>336 patients were included: median age 68 years, 72.3% male, 49.7% current/former smokers. Primary tumor site was 38.1% oral cavity, 32.7% oropharynx, 8.9% nasopharynx, 6.0% larynx, 6.0% salivary, 5.1% sinonasal, 3.3% hypopharynx. Pembrolizumab was most commonly used, for indications of recurrent disease (50.6%), metastatic disease (31.0%), or unresectable locally advanced disease (18.5%). Treatments received before immunotherapy included: radiation therapy (69.7%), chemotherapy (57.7%), neck dissection (42.6%), and surgical resection (64.0%). Of 245 patients with available p16 testing, 97 (39.6%) were p16-positive and 148 (60.1%) were p16-negative. Of 216 patients with available PD-L1 testing, CPS scores were: <1 in 24 (11.1%), 1-49 in 121 (56.0%), and 50-100 in 71 (32.9%). On Kaplan-Meier analysis, patients with ND (median OS: 13.0 months [95%CI 9.4-17.2]) had significantly worse OS compared to those without ND (median OS 22.2 months [95%CI 16.8-32.8]) (p=0.016). Among patients who had ND, total lymph node count (ρ=0.001, p=0.99) did not correlate with OS. There was no difference in OS based on ≤18 versus >18 lymph nodes removed (p=0.46). OS was not different based on prior radiation therapy (p=0.52) or chemotherapy (p=0.30). Patients whose tumors demonstrating CPS<1 had worse OS compared to CPS≥1 (p=0.007). Among patients with CPS<1, neck treatment was not associated with OS differences, whereas in patients with CPS≥1, having no prior ND conferred superior OS compared to ND. On multivariable Cox analysis, prior ND, chemotherapy, and radiation therapy were not associated with OS, whereas oral cavity primary site (adjusted HR 2.4 [95%CI 1.3-4.4]) and CPS<1 (adjusted HR 2.05 [95%CI 1.2-3.4]) were independently associated with worse OS.</p>\n\n<p><strong>Conclusion: </strong>Among 336 patients with HNC receiving immunotherapy, those who underwent prior ND had worse OS compared to those without prior ND, whereas prior radiation therapy and chemotherapy were not associated with OS. The negative association between prior ND and OS was more pronounced among patients with CPS≥1 than among CPS<1. The total lymph node count was not associated with OS, suggesting that more limited neck dissections did not mitigate the effect of prior neck surgery on immunotherapy efficacy. Future studies are needed to characterize the impact of cervical lymph node removal on immunotherapy efficacy.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155413/Figure1(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155413--></body></html>"
    },
    {
      "uid": "P222",
      "content_id": "153764",
      "abstract_number": "P222",
      "poster_number": "P222",
      "title": "Response Heterogeneity After Neoadjuvant Immunotherapy in Oral Cavity SCC: A Multi-Case Series",
      "summary": "This case series highlights early evidence of heterogeneous responses in OCSCC after neoadjuvant IO captured by serial imaging, revealing patterns of tumoral and nodal changes of uncertain clinical significance. Although these radiographic findings did not alter surgical management, they posed interpretive challenges. Interestingly, findings such as primary tumor regression, new nodal abnormalities, or stable...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153764",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Wyatt O Wofford, BS",
      "presenter": "Wyatt O Wofford, BS",
      "authors": "Wyatt O Wofford, BS ; M Elyse Moore, BS; W Greer Albergotti, MD; Alexandra E Kejner, MD; Michael Bobian, MD; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD",
      "normalized_authors": [
        "Wyatt O Wofford",
        "M Elyse Moore",
        "W Greer Albergotti",
        "Alexandra E Kejner",
        "Michael Bobian",
        "Evan M Graboyes",
        "Jason G Newman",
        "Dauren Adilbay"
      ],
      "affiliations": [
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 475,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Wyatt O Wofford, BS ; M Elyse Moore, BS; W Greer Albergotti, MD; Alexandra E Kejner, MD; Michael Bobian, MD; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD",
        "Affiliations": "Medical University of South Carolina",
        "Background": "Neoadjuvant immunotherapy (IO) is increasingly incorporated into the management of locally advanced oral cavity squamous cell carcinoma (OCSCC). Neoadjuvant IO adds a new time interval between diagnostic workup and surgery. Importantly, not all patients respond to IO uniformly, and there can even be variability by cancer subsite and/or primary and nodal disease in the same patient. Such heterogeneity creates uncertainty for head and neck surgeons, as no IO-specific framework currently exists to guide the interpretation of mixed response patterns.",
        "Methods": "We conducted a retrospective chart review of four patients with locally advanced OCSCC who received standardized neoadjuvant IO and subsequent surgery at a single academic center. Case #1 involved the left anterior floor of mouth (CPS 3), case #2 involved the midline anterior floor of mouth (CPS 100), case #3 involved the buccal/retromolar trigone space (CPS 90), and case #4 involved the left lateral posterior tongue (CPS of >50). All patients underwent baseline CT imaging and post-IO preoperative imaging, allowing assessment of interval radiographic evolution during neoadjuvant IO. Clinical, radiologic, operative, and histopathologic data were extracted to describe patterns of heterogeneous response.",
        "Results": "Across cases, we observed divergent response patterns. Case #1 demonstrated interval reduction in primary tumor volume and ipsilateral lymphadenopathy. Final pathology revealed invasive carcinoma at the deep margin and multiple positive lymph nodes (6/38) with ENE in level II/III nodes. ENE was not detected on preoperative imaging. Case #2 showed no interval change in the primary tumor volume, but decreased ipsilateral level I, II, and V lymphadenopathy, excluding a stable enlarged level VI node. Final pathology demonstrated no evidence of carcinoma in the primary specimen, but multiple positive lymph nodes were identified bilaterally (6/66). Case #3 demonstrated no interval changes in primary tumor volume or bilateral lymphadenopathy. Final pathology showed no adverse features and no positive lymph nodes (0/50) despite intraoperative and imaging suspicion for nodal involvement. Case #4 showed an interval reduction in primary tumor volume and ipsilateral lymphadenopathy, but also newly increased contralateral lymphadenopathy. Final pathology for this case is pending and will be disclosed in the presentation; intraoperative findings included significant bilateral nodal disease. No patient experienced delayed surgery or unexpected morbidity attributable to neoadjuvant IO.",
        "Conclusion": "This case series highlights early evidence of heterogeneous responses in OCSCC after neoadjuvant IO captured by serial imaging, revealing patterns of tumoral and nodal changes of uncertain clinical significance. Although these radiographic findings did not alter surgical management, they posed interpretive challenges. Interestingly, findings such as primary tumor regression, new nodal abnormalities, or stable disease trajectories do not correlate cleanly with final pathology. This case series highlights real-world variability, underscoring the need for standardized response criteria and multidisciplinary, IO-specific guidelines to support consistent, evidence-based decision-making within the surgical workflow. As neoadjuvant IO becomes more widely adopted, clarifying these relationships will be essential for optimizing oncologic safety and functional outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Response Heterogeneity After Neoadjuvant Immunotherapy in Oral Cavity SCC: A Multi-Case Series</span>. <u>Wyatt O Wofford, BS</u>; M Elyse Moore, BS; W Greer Albergotti, MD; Alexandra E Kejner, MD; Michael Bobian, MD; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD. Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant immunotherapy (IO) is increasingly incorporated into the management of locally advanced oral cavity squamous cell carcinoma (OCSCC). Neoadjuvant IO adds a new time interval between diagnostic workup and surgery. Importantly, not all patients respond to IO uniformly, and there can even be variability by cancer subsite and/or primary and nodal disease in the same patient. Such heterogeneity creates uncertainty for head and neck surgeons, as no IO-specific framework currently exists to guide the interpretation of mixed response patterns.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective chart review of four patients with locally advanced OCSCC who received standardized neoadjuvant IO and subsequent surgery at a single academic center. Case #1 involved the left anterior floor of mouth (CPS 3), case #2 involved the midline anterior floor of mouth (CPS 100), case #3 involved the buccal/retromolar trigone space (CPS 90), and case #4 involved the left lateral posterior tongue (CPS of >50). All patients underwent baseline CT imaging and post-IO preoperative imaging, allowing assessment of interval radiographic evolution during neoadjuvant IO. Clinical, radiologic, operative, and histopathologic data were extracted to describe patterns of heterogeneous response.</p>\n\n<p><strong>Results: </strong>Across cases, we observed divergent response patterns. Case #1 demonstrated interval reduction in primary tumor volume and ipsilateral lymphadenopathy. Final pathology revealed invasive carcinoma at the deep margin and multiple positive lymph nodes (6/38) with ENE in level II/III nodes. ENE was not detected on preoperative imaging. Case #2  showed no interval change in the primary tumor volume, but decreased ipsilateral level I, II, and V lymphadenopathy, excluding a stable enlarged level VI node. Final pathology demonstrated no evidence of carcinoma in the primary specimen, but multiple positive lymph nodes were identified bilaterally (6/66). Case #3 demonstrated no interval changes in primary tumor volume or bilateral lymphadenopathy. Final pathology showed no adverse features and no positive lymph nodes (0/50) despite intraoperative and imaging suspicion for nodal involvement. Case #4 showed an interval reduction in primary tumor volume and ipsilateral lymphadenopathy, but also newly increased contralateral lymphadenopathy. Final pathology for this case is pending and will be disclosed in the presentation; intraoperative findings included significant bilateral nodal disease. No patient experienced delayed surgery or unexpected morbidity attributable to neoadjuvant IO.</p>\n\n<p><strong>Conclusion:</strong> This case series highlights early evidence of heterogeneous responses in OCSCC after neoadjuvant IO captured by serial imaging, revealing patterns of tumoral and nodal changes of uncertain clinical significance. Although these radiographic findings did not alter surgical management, they posed interpretive challenges. Interestingly, findings such as primary tumor regression, new nodal abnormalities, or stable disease trajectories do not correlate cleanly with final pathology. This case series highlights real-world variability, underscoring the need for standardized response criteria and multidisciplinary, IO-specific guidelines to support consistent, evidence-based decision-making within the surgical workflow. As neoadjuvant IO becomes more widely adopted, clarifying these relationships will be essential for optimizing oncologic safety and functional outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153764--></body></html>"
    },
    {
      "uid": "P223",
      "content_id": "153108",
      "abstract_number": "P223",
      "poster_number": "P223",
      "title": "Treatment Refractory Immune-Mediated Myasthenia Gravis",
      "summary": "Immune checkpoint inhibitors (ICI) have become the standard of care as monotherapy or adjunct therapy for several different types of cancers. ICIs have significantly improved survival rates and long-term remission periods. While ICIs are beneficial, serious toxicities caused by off-target inflammatory and autoimmune responses have also been demonstrated. Neurologic immune-related adverse events are uncommon and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153108",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Addis, DO",
      "presenter": "Jessica Addis, DO",
      "authors": "Jessica Addis, DO ; Elizabeth Klingensmith, MD; Dannielle Allen, DO; Amanda Streeper, NP; Atish Gandhi, DO",
      "normalized_authors": [
        "Jessica Addis",
        "Elizabeth Klingensmith",
        "Dannielle Allen",
        "Amanda Streeper, NP",
        "Atish Gandhi"
      ],
      "affiliations": [
        "ChristianaCare"
      ],
      "normalized_institutions": [
        "ChristianaCare"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Report",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Jessica Addis, DO ; Elizabeth Klingensmith, MD; Dannielle Allen, DO; Amanda Streeper, NP; Atish Gandhi, DO",
        "Affiliations": "ChristianaCare",
        "Introduction": "Immune checkpoint inhibitors (ICI) have become the standard of care as monotherapy or adjunct therapy for several different types of cancers. ICIs have significantly improved survival rates and long-term remission periods. While ICIs are beneficial, serious toxicities caused by off-target inflammatory and autoimmune responses have also been demonstrated. Neurologic immune-related adverse events are uncommon and can present broadly, affecting the neuroaxis, neuromuscular junction, peripheral nervous system, and central nervous system. Immune-related myasthenia gravis (irMG) is an uncommon presentation of immune related adverse reaction but carries a high rate of morbidity and mortality. This case highlights a 75-year-old female being treated with pembrolizumab who developed treatment refractory irMG.",
        "Case Report": "A 75-year-old female with a history of stage IVa, T4a N2b M0 oral cavity squamous cell carcinoma undergoing palliative therapy with quad shot radiation and pembrolizumab presented to the hospital with progressive left facial droop, bilateral diplopia, and dysphagia. CT head, CTA brain, and CTA neck were unremarkable. An MRI brain was not done due to respiratory distress. Acetylcholine receptor antibody (ACHR) and Muscle Specific Kinase (MUSK) levels for myasthenia gravis were negative, however, due to ongoing symptoms, she was initiated on treatment for checkpoint-inhibitor induced myasthenia gravis with steroids, pyridostigmine, and IVIG for 5 days with symptom improvement and subsequent discharged.",
        "Abstract": "Three weeks later she presented again for failure to thrive and need for parenteral nutrition from progressive dysphagia. She had worsening cranial neuropathies with dysarthria, nasal hypophonic voice and smooth right forehead. This heightened concern for possible brainstem lesions versus CNS carcinomatosis. MRI was delayed due to risk of intubation and need for a tracheostomy; however, she eventually tolerated imaging. MRI was negative. It was felt she had refractory irMG and PLEX was initiated, improving her symptoms. Unfortunately, the patient had an episode of vomiting and aspiration prior to completing all PLEX sessions and passed soon after. This patient initially improved with appropriate treatment however her symptoms remitted several weeks later. This lead to doubting her original diagnosis, making a brain MRI essential. Her risk was increased for intubation/tracheostomy placement in order to safely proceed with MRI. Later when PLEX was initiated, her symptoms improved, however she unfortunately passed from aspiration. This case highlights the treatment and management difficulties related to this rare medication adverse reaction.",
        "Discussion": "IrMG is an uncommon presentation of immune-related adverse reactions but carries a high rate of morbidity and mortality. Previous studies have proposed that early intervention with IVIG or PLEX may lead to better patient outcomes than treatment with steroids alone. Considering non-immune related myasthenia gravis, treatment with IVIG or PLEX has similar outcomes. Similarly, a study done in 2019 looked at patients with irMG found that early treatment with IVIG or PLEX as a first line treatment resulted in improvement of symptoms compared to patients who received IVIG or PLEX as a second line therapy due to progression to respiratory failure. A better understanding of how irMG clinically progresses is necessary to optimize initial treatment modalities."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment Refractory Immune-Mediated Myasthenia Gravis</span>. <u>Jessica Addis, DO</u>; Elizabeth Klingensmith, MD; Dannielle Allen, DO; Amanda Streeper, NP; Atish Gandhi, DO. ChristianaCare<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICI) have become the standard of care as monotherapy or adjunct therapy for several different types of cancers. ICIs have significantly improved survival rates and long-term remission periods. While ICIs are beneficial, serious toxicities caused by off-target inflammatory and autoimmune responses have also been demonstrated. Neurologic immune-related adverse events are uncommon and can present broadly, affecting the neuroaxis, neuromuscular junction, peripheral nervous system, and central nervous system. Immune-related myasthenia gravis (irMG) is an uncommon presentation of immune related adverse reaction but carries a high rate of morbidity and mortality. This case highlights a 75-year-old female being treated with pembrolizumab who developed treatment refractory irMG. </p>\n\n<p><strong>Case Report: </strong>A 75-year-old female with a history of stage IVa, T4a N2b M0 oral cavity squamous cell carcinoma undergoing palliative therapy with quad shot radiation and pembrolizumab presented to the hospital with progressive left facial droop, bilateral diplopia, and dysphagia. CT head, CTA brain, and CTA neck were unremarkable. An MRI brain was not done due to respiratory distress. Acetylcholine receptor antibody (ACHR) and Muscle Specific Kinase (MUSK) levels for myasthenia gravis were negative, however, due to ongoing symptoms, she was initiated on treatment for checkpoint-inhibitor induced myasthenia gravis with steroids, pyridostigmine, and IVIG for 5 days with symptom improvement and subsequent discharged. </p>\n\n<p>Three weeks later she presented again for failure to thrive and need for parenteral nutrition from progressive dysphagia. She had worsening cranial neuropathies with dysarthria, nasal hypophonic voice and smooth right forehead. This heightened concern for possible brainstem lesions versus CNS carcinomatosis. </p>\n\n<p>MRI was delayed due to risk of intubation and need for a tracheostomy; however, she eventually tolerated imaging. MRI was negative. It was felt she had refractory irMG and PLEX was initiated, improving her symptoms. Unfortunately, the patient had an episode of vomiting and aspiration prior to completing all PLEX sessions and passed soon after. </p>\n\n<p><strong>Discussion: </strong>IrMG is an uncommon presentation of immune-related adverse reactions but carries a high rate of morbidity and mortality. Previous studies have proposed that early intervention with IVIG or PLEX may lead to better patient outcomes than treatment with steroids alone. Considering non-immune related myasthenia gravis, treatment with IVIG or PLEX has similar outcomes. Similarly, a study done in 2019 looked at patients with irMG found that early treatment with IVIG or PLEX as a first line treatment resulted in improvement of symptoms compared to patients who received IVIG or PLEX as a second line therapy due to progression to respiratory failure. A better understanding of how irMG clinically progresses is necessary to optimize initial treatment modalities. </p>\n\n<p>This patient initially improved with appropriate treatment however her symptoms remitted several weeks later. This lead to doubting her original diagnosis, making a brain MRI essential. Her risk was increased for intubation/tracheostomy placement in order to safely proceed with MRI. Later when PLEX was initiated, her symptoms improved, however she unfortunately passed from aspiration. This case highlights the treatment and management difficulties related to this rare medication adverse reaction. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153108--></body></html>"
    },
    {
      "uid": "P224",
      "content_id": "153823",
      "abstract_number": "P224",
      "poster_number": "P224",
      "title": "Investigation of treatment procedure to optimize photoimmunotherapy for head and neck cancer",
      "summary": "It is important to illuminate the entire lesion to maximize the efficacy of PIT.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153823",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nobuhiro Hanai",
      "presenter": "Nobuhiro Hanai",
      "authors": "Nobuhiro Hanai 1 ; Kiyoaki Tsukahara 2 ; Takeshi Shinozaki 3 ; Ryuichi Hayashi 3 ; Hirotaka Shinomiya 4 ; Dai Imamura 5 ; Manami Tabuchi 5",
      "normalized_authors": [
        "Nobuhiro Hanai",
        "Kiyoaki Tsukahara",
        "Takeshi Shinozaki",
        "Ryuichi Hayashi",
        "Hirotaka Shinomiya",
        "Dai Imamura",
        "Manami Tabuchi"
      ],
      "affiliations": [
        "Aichi Cancer Center Hospital",
        "Tokyo Medical University",
        "National Cancer Center Hospital East",
        "Kobe University",
        "Rakuten Medical K.K"
      ],
      "normalized_institutions": [
        "Aichi Cancer Center Hospital",
        "Tokyo Medical University",
        "National Cancer Center Hospital East",
        "Kobe University",
        "Rakuten Medical K.K"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 406,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nobuhiro Hanai 1 ; Kiyoaki Tsukahara 2 ; Takeshi Shinozaki 3 ; Ryuichi Hayashi 3 ; Hirotaka Shinomiya 4 ; Dai Imamura 5 ; Manami Tabuchi 5",
        "Affiliations": "1 Aichi Cancer Center Hospital; 2 Tokyo Medical University; 3 National Cancer Center Hospital East; 4 Kobe University; 5 Rakuten Medical K.K",
        "Introduction": "Photoimmunotherapy (PIT), using cetuximab sarotalocan sodium and 690 nm laser light, is a treatment for unresectable locally advanced or recurrent head and neck cancer. The drug and devices were approved in Japan in 2020 under the conditional early approval system. It is important to consider treatment approaches from anatomical and functional perspectives to reduce treatment-related risks and improve effective implementation as information regarding treatment procedures obtained from clinical trials is limited. To optimize PIT, we investigated treatment procedures, that may affect anti-tumor effects and the incidence of treatment-related adverse events (TRAE).",
        "Methods": "A multi-center, non-interventional, observational study was conducted targeting patients who initiated PIT between January 2021 and September 2022 under clinical practice in Japan and were enrolled in this research.",
        "Abstract": "The Data Review Board (DRB), comprising principal investigators and sub-investigators of this study, assessed whether the illumination of this treatment adequately covered whole lesions theoretically by reviewing the illustration of treatment procedure plan, imaging data, and CRF data. The presence of the risk for treatment-related adverse events of special interest (TRAESI) that could lead to a serious outcome, for illumination lesions was assessed by reviewing imaging data at baseline. Among the TRAESI, the risk of occurrence that required consideration by DRB was defined as airway obstruction, fistula, bleeding from major blood vessels, and proximity to vital organs (dura mater, orbit). Efficacy was evaluated as a volume reduction rate of illuminated lesions and anti-tumor effect based on RECIST v.1.1 by central image assessment. Safety was assessed for the incidence of TRAE. For the 76 subjects, the occurrence of TRAESI considered by the DRB was bleeding 1 (1.3%), airway stenosis 6 (7.9%) and fistula 5 (6.5%). Among these, considered as low risk of occurrence by DRB based on imaging data at baseline were bleeding 1 (1.3%), airway stenosis 2 (2.6%), and fistula 3 (3.9%). Close monitoring and appropriate procedures are required because TRAESI may occur despite adequate pre-treatment risk assessment.",
        "Results": "A total number of illuminated lesions was 75. In 29 lesions that were theoretically covered entire lesions by illumination throughout all cycles, CR 17 (58.6%), PR 6 (20.7%), SD 5 (17.2%), PD 0 (0%), and NE 1 (3.4%). In the other 46 lesions, CR 11 (23.9 %), PR 11 (23.9 %), SD 21 (45.7 %), PD 3 (6.5 %), NE 0 (0 %).",
        "Conclusion": "It is important to illuminate the entire lesion to maximize the efficacy of PIT."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Investigation of treatment procedure to optimize photoimmunotherapy for head and neck cancer</span>. <u>Nobuhiro Hanai</u><sup>1</sup>; Kiyoaki Tsukahara<sup>2</sup>; Takeshi Shinozaki<sup>3</sup>; Ryuichi Hayashi<sup>3</sup>; Hirotaka Shinomiya<sup>4</sup>; Dai Imamura<sup>5</sup>; Manami Tabuchi<sup>5</sup>. <sup>1</sup>Aichi Cancer Center Hospital; <sup>2</sup>Tokyo Medical University; <sup>3</sup>National Cancer Center Hospital East; <sup>4</sup>Kobe University; <sup>5</sup>Rakuten Medical K.K.<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Photoimmunotherapy (PIT), using cetuximab sarotalocan sodium and 690 nm laser light, is a treatment for unresectable locally advanced or recurrent head and neck cancer. The drug and devices were approved in Japan in 2020 under the conditional early approval system. It is important to consider treatment approaches from anatomical and functional perspectives to reduce treatment-related risks and improve effective implementation as information regarding treatment procedures obtained from clinical trials is limited. To optimize PIT, we investigated treatment procedures, that may affect anti-tumor effects and the incidence of treatment-related adverse events (TRAE).</p>\n\n<p><strong>Methods:</strong> A multi-center, non-interventional, observational study was conducted targeting patients who initiated PIT between January 2021 and September 2022 under clinical practice in Japan and were enrolled in this research.</p>\n\n<p>The Data Review Board (DRB), comprising principal investigators and sub-investigators of this study, assessed whether the illumination of this treatment adequately covered whole lesions theoretically by reviewing the illustration of treatment procedure plan, imaging data, and CRF data. The presence of the risk for treatment-related adverse events of special interest (TRAESI) that could lead to a serious outcome, for illumination lesions was assessed by reviewing imaging data at baseline. Among the TRAESI, the risk of occurrence that required consideration by DRB was defined as airway obstruction, fistula, bleeding from major blood vessels, and proximity to vital organs (dura mater, orbit).</p>\n\n<p>Efficacy was evaluated as a volume reduction rate of illuminated lesions and anti-tumor effect based on RECIST v.1.1 by central image assessment. Safety was assessed for the incidence of TRAE.</p>\n\n<p><strong>Results:</strong> A total number of illuminated lesions was 75. In 29 lesions that were theoretically covered entire lesions by illumination throughout all cycles, CR 17 (58.6%), PR 6 (20.7%), SD 5 (17.2%), PD 0 (0%), and NE 1 (3.4%). In the other 46 lesions, CR 11 (23.9 %), PR 11 (23.9 %), SD 21 (45.7 %), PD 3 (6.5 %), NE 0 (0 %).</p>\n\n<p>For the 76 subjects, the occurrence of TRAESI considered by the DRB was bleeding 1 (1.3%), airway stenosis 6 (7.9%) and fistula 5 (6.5%). Among these, considered as low risk of occurrence by DRB based on imaging data at baseline were bleeding 1 (1.3%), airway stenosis 2 (2.6%), and fistula 3 (3.9%).</p>\n\n<p><strong>Conclusion:</strong> It is important to illuminate the entire lesion to maximize the efficacy of PIT.</p>\n\n<p>Close monitoring and appropriate procedures are required because TRAESI may occur despite adequate pre-treatment risk assessment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153823--></body></html>"
    },
    {
      "uid": "P225",
      "content_id": "152352",
      "abstract_number": "P225",
      "poster_number": "P225",
      "title": "Therapeutically Relevant Class II Restricted T-Cell Receptors Targeting HPV Antigens",
      "summary": "The incidence of HPV-driven oropharyngeal squamous cell carcinoma (OPSCC) has sharply risen over the past 2 decades despite the widespread availability of HPV vaccines. Mortality from OPSCC is largely driven by metastatic progression or locoregional recurrence after definitive resection or chemoradiation. Inhibiting negative regulatory pathways on T cells through antibodies that block PD-1 leads to responses in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152352",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sina Dadafarin, MD, PhD",
      "presenter": "Sina Dadafarin, MD, PhD",
      "authors": "Sina Dadafarin, MD, PhD 1 ; Cole Kendall 1 ; Maria Iuliano 1 ; Kayla S Hopwo 1 ; Jakob Bakhtiari 1 ; Gargi Roy, PhD 1 ; Mikel Ruterbusch, PhD 1 ; Brittany R Barber, MD 2 ; Joshua R Veatch, MD, PhD 1",
      "normalized_authors": [
        "Sina Dadafarin",
        "Cole Kendall",
        "Maria Iuliano",
        "Kayla S Hopwo",
        "Jakob Bakhtiari",
        "Gargi Roy",
        "Mikel Ruterbusch",
        "Brittany R Barber",
        "Joshua R Veatch"
      ],
      "affiliations": [
        "Fred Hutch Cancer Center",
        "University of Washington"
      ],
      "normalized_institutions": [
        "Fred Hutch Cancer Center",
        "University of Washington"
      ],
      "session_type": "Poster",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sina Dadafarin, MD, PhD 1 ; Cole Kendall 1 ; Maria Iuliano 1 ; Kayla S Hopwo 1 ; Jakob Bakhtiari 1 ; Gargi Roy, PhD 1 ; Mikel Ruterbusch, PhD 1 ; Brittany R Barber, MD 2 ; Joshua R Veatch, MD, PhD 1",
        "Affiliations": "1 Fred Hutch Cancer Center; 2 University of Washington",
        "Abstract": "The incidence of HPV-driven oropharyngeal squamous cell carcinoma (OPSCC) has sharply risen over the past 2 decades despite the widespread availability of HPV vaccines. Mortality from OPSCC is largely driven by metastatic progression or locoregional recurrence after definitive resection or chemoradiation. Inhibiting negative regulatory pathways on T cells through antibodies that block PD-1 leads to responses in less than 20% in patients who fail first line therapy despite the presence of immunogenic viral antigens from the HPV16 genome. Previous clinical trials leveraged the ubiquitous presence of HPV16 viral antigens to developed cellular therapies with either adoptive transfer of ex-vivo expanded tumor infiltrating lymphocytes (TILs) or engineered CD8+ T cells that express E6 or E7-specific T-cell receptors (TCR); however, tumor response rates were limited by diverse immune suppressive mechanisms, including loss of antigen expression and presentation to T cells, or reprogramming of innate immune cells in the tumor microenvironment (TME) to suppress T cell function. We therefore investigated an alternate approach using TCR transgenic CD4+ T cells that may overcome the well-characterized limitations of CD8+ cell transfer. In contrast to CD8+ and chimeric antigen receptor (CAR)-T cells, CD4+ helper T cells indirectly recognize tumor antigens presented on class II major histocompatibility proteins (MHC II) by APC. Furthermore, CD4+ T cells can reprogram otherwise suppressive tumor-associated APCs to marshal numerous immune mediators against tumors. Using our experience in isolating tumor antigen specific CD4+ T cells and their TCR from metastatic melanoma and Merkel cell carcinoma, we developed a pipeline for identification of TCR specific to HPV antigens from CD4+ T cells expanded from OPSCC patient tumors. We successfully isolated 17 TCRs with targets across HPV16 E1, E2, E6 and E7 proteins. Most notably, we have isolated a high avidity TCR specific to an HPV16 E6 epitope presented by HLA-DP0401 and DP0402 which is compatible to use in 50-60% of patients of the U.S. population. Furthermore, this TCR demonstrated no alloreactivity to a panel of cell lines expressing HLA types present in 95% of the population. We further characterized the phenotype of HPV-specific CD4+ cells with targeted single cell sequencing on patients tumors with observed E6 and E7 reactive CD4+ T cells. These cells develop a Tfh-like phenotype in OPSCC primary tumors and lymph nodes, defined by expression of CXCL13. Examining bulk RNA-sequencing from a the Cancer Genome Atlas cohort, we found that CXCL13 expression significantly correlated with improved overall survival among head and neck cancer patients, supporting the concept that infiltration of tumor-specific CD4+ T cells reflects a more robust immunoreactive TME. Ongoing efforts aim to develop a library of candidate TCRs for HPV-related disease, test combination therapies and strategies to enhance transgenic T-cell differentiation, and evaluate the efficacy of adoptive transfer of HPV-specific CD4+ T cells in preclinical in vivo models."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Therapeutically Relevant Class II Restricted T-Cell Receptors Targeting HPV Antigens</span>. <u>Sina Dadafarin, MD, PhD</u><sup>1</sup>; Cole Kendall<sup>1</sup>; Maria Iuliano<sup>1</sup>; Kayla S Hopwo<sup>1</sup>; Jakob Bakhtiari<sup>1</sup>; Gargi Roy, PhD<sup>1</sup>; Mikel Ruterbusch, PhD<sup>1</sup>; Brittany R Barber, MD<sup>2</sup>; Joshua R Veatch, MD, PhD<sup>1</sup>. <sup>1</sup>Fred Hutch Cancer Center; <sup>2</sup>University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The incidence of HPV-driven oropharyngeal squamous cell carcinoma (OPSCC) has sharply risen over the past 2 decades despite the widespread availability of HPV vaccines. Mortality from OPSCC is largely driven by metastatic progression or locoregional recurrence after definitive resection or chemoradiation. Inhibiting negative regulatory pathways on T cells through antibodies that block PD-1 leads to responses in less than 20% in patients who fail first line therapy despite the presence of immunogenic viral antigens from the HPV16 genome. Previous clinical trials leveraged the ubiquitous presence of HPV16 viral antigens to developed cellular therapies with either adoptive transfer of ex-vivo expanded tumor infiltrating lymphocytes (TILs) or engineered CD8+ T cells that express E6 or E7-specific T-cell receptors (TCR); however, tumor response rates were limited by diverse immune suppressive mechanisms, including loss of antigen expression  and presentation to T cells, or reprogramming of innate immune cells in the tumor microenvironment (TME) to suppress T cell function. We therefore investigated an alternate approach using TCR transgenic CD4+ T cells that may overcome the well-characterized limitations of CD8+ cell transfer. In contrast to CD8+ and chimeric antigen receptor (CAR)-T cells, CD4+ helper T cells indirectly recognize tumor antigens presented on class II major histocompatibility proteins (MHC II) by APC. Furthermore, CD4+ T cells can reprogram otherwise suppressive tumor-associated APCs to marshal numerous immune mediators against tumors. Using our experience in isolating tumor antigen specific CD4+ T cells and their TCR from metastatic melanoma and Merkel cell carcinoma, we developed a pipeline for identification of TCR specific to HPV antigens from CD4+ T cells expanded from OPSCC patient tumors.</p>\n\n<p>We successfully isolated 17 TCRs with targets across HPV16 E1, E2, E6 and E7 proteins. Most notably, we have isolated a high avidity TCR specific to an HPV16 E6 epitope presented by HLA-DP0401 and DP0402 which is compatible to use in 50-60% of patients of the U.S. population. Furthermore, this TCR demonstrated no alloreactivity to a panel of cell lines expressing HLA types present in 95% of the population.</p>\n\n<p>We further characterized the phenotype of HPV-specific CD4+ cells with targeted single cell sequencing on patients tumors with observed E6 and E7 reactive CD4+ T cells. These cells develop a Tfh-like phenotype in OPSCC primary tumors and lymph nodes, defined by expression of CXCL13. Examining bulk RNA-sequencing from a the Cancer Genome Atlas cohort, we found that CXCL13 expression significantly correlated with improved overall survival among head and neck cancer patients, supporting the concept that infiltration of tumor-specific CD4+ T cells reflects a more robust immunoreactive TME.  Ongoing efforts aim to develop a library of candidate TCRs for HPV-related disease, test combination therapies and strategies to enhance transgenic T-cell differentiation, and evaluate the efficacy of adoptive transfer of HPV-specific CD4+ T cells in preclinical in vivo models.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152352--></body></html>"
    },
    {
      "uid": "P226",
      "content_id": "154028",
      "abstract_number": "P226",
      "poster_number": "P226",
      "title": "Distinct Psychosocial Profiles in Sinonasal Tumors: Associations Between Health Mindset, Optimism, and Disease Type",
      "summary": "Patients with benign sinonasal tumors demonstrated significantly lower dispositional optimism and trended toward lower growth-oriented health mindset compared to those with malignancies. This unexpected pattern suggests that benign disease presents meaningful psychological burden, potentially driven by prolonged surveillance, diagnostic ambiguity, or perceptions of an indolent course. Conversely, patients with...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154028",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sina Dadafarin, MD",
      "presenter": "Sina Dadafarin, MD",
      "authors": "Luke M O'Neil, MBBS 1 ; Sina Dadafarin, MD 1 ; Ethan C Sage, BS 2 ; Abdullah Bhurgri, BS 2 ; Katherine A Mozingo, BA 2 ; Jacob Ruzevick, MD 3 ; Aria Jafari, MD 1",
      "normalized_authors": [
        "Luke M O'Neil, MBBS",
        "Sina Dadafarin",
        "Ethan C Sage",
        "Abdullah Bhurgri",
        "Katherine A Mozingo",
        "Jacob Ruzevick",
        "Aria Jafari"
      ],
      "affiliations": [
        "University of Washington Department of Otolaryngology - Head & Neck Surgery",
        "University of Washington School of Medicine",
        "University of Washington Department of Neurosurgery"
      ],
      "normalized_institutions": [
        "University of Washington Department of Otolaryngology - Head & Neck Surgery",
        "University of Washington School of Medicine",
        "University of Washington Department of Neurosurgery"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154028/lotr.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154028/lotr.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154028"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Luke M O'Neil, MBBS 1 ; Sina Dadafarin, MD 1 ; Ethan C Sage, BS 2 ; Abdullah Bhurgri, BS 2 ; Katherine A Mozingo, BA 2 ; Jacob Ruzevick, MD 3 ; Aria Jafari, MD 1",
        "Affiliations": "1 University of Washington Department of Otolaryngology - Head & Neck Surgery; 2 University of Washington School of Medicine; 3 University of Washington Department of Neurosurgery",
        "Background": "Health mindset and optimism are psychosocial factors that influence recovery and well-being. In other health fields, a growth health mindset—belief that health outcomes improve with effort and adaptive behaviors—has been associated with resilience and greater treatment engagement. Similarly, dispositional optimism has been linked to improved surgical recovery, and better therapy adherence, whereas a fixed mindset views health as largely immutable. Despite these relationships being well-established in other clinical settings, their role in patients with sinonasal tumors remains unexplored. Understanding relationships between mindset, optimism, and symptom burden may guide individualized perioperative communication and psychosocial support, potentially impacting clinical outcomes. This pilot study evaluated health mindset, optimism, self-efficacy, health literacy, and symptom burden in patients undergoing sinus surgery for benign and malignant sinonasal tumors.",
        "Methods": "Adult patients with sinonasal tumors presenting to a tertiary rhinology clinic were included and classified as having sinonasal malignancies (SNM) or benign sinonasal tumors (BSNT). Patients with pituitary or hematologic malignancies were excluded. Psychometric measures included optimism (Revised Life Orientation Test, LOT-R), health mindset (Health Mindset Scale, HM), self-efficacy (Perceived Health Competence Scale, HSE), and health literacy (Brief Health Literacy Screen, HL). Baseline symptom burden was assessed using the SNOT-22. Higher LOT-R, HM, HSE, and HL scores reflect greater optimism, growth mindset, self-efficacy, and health literacy, respectively; higher SNOT-22 scores indicate greater symptom burden. Analyses were performed using parametric t-tests.",
        "Results": "Seventeen patients were enrolled (SNM n=9; BSNT n=8). Sinonasal malignancies included squamous cell carcinoma (n=3), mucosal melanoma (n=2), undifferentiated carcinoma (n=2), NUT carcinoma (n=1), and HPV-related multiphenotypic carcinoma (n=1). Benign sinonasal tumors included inverted papilloma (n=8) and osteoma (n=1). Mean age was 61.7 ± 14.4 years. Mean SNOT-22 was 20.5 ± 22.0. No group differences were observed in SNOT-22, HSE, or HL scores (p = 0.20; 0.10; 0.37). The BSNT group demonstrated significantly lower LOT-R scores than the SNM group (11.12 ± 4.30 vs. 18.33 ± 4.66; p < 0.005) and trended toward lower HM scores (12.38 ± 2.62 vs. 14.78 ± 2.20; p = 0.06). Across the cohort, female patients exhibited lower LOT-R scores than males (11.25 ± 2.99 vs. 16.10 ± 5.94; p = 0.05), with no other gender-based differences.",
        "Conclusion": "Patients with benign sinonasal tumors demonstrated significantly lower dispositional optimism and trended toward lower growth-oriented health mindset compared to those with malignancies. This unexpected pattern suggests that benign disease presents meaningful psychological burden, potentially driven by prolonged surveillance, diagnostic ambiguity, or perceptions of an indolent course. Conversely, patients with malignancy may benefit from clearer prognostic information and comprehensive, multidisciplinary support with structured counseling, contributing to increased optimism. Furthermore, the observation that female patients exhibited significantly lower optimism, despite comparable scores in other psychosocial instruments, highlights a possible gender-related vulnerability. Incorporating validated assessments of mindset and optimism into sinonasal malignancy care may help identify patients who would benefit from targeted counseling and support. Future longitudinal studies are warranted to evaluate whether fostering adaptive mindset can meaningfully improve recovery and quality of life in patients with sinonasal tumors both benign and malignant."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Distinct Psychosocial Profiles in Sinonasal Tumors: Associations Between Health Mindset, Optimism, and Disease Type</span>. Luke M O'Neil, MBBS<sup>1</sup>; <u>Sina Dadafarin, MD</u><sup>1</sup>; Ethan C Sage, BS<sup>2</sup>; Abdullah Bhurgri, BS<sup>2</sup>; Katherine A Mozingo, BA<sup>2</sup>; Jacob Ruzevick, MD<sup>3</sup>; Aria Jafari, MD<sup>1</sup>. <sup>1</sup>University of Washington Department of Otolaryngology - Head & Neck Surgery; <sup>2</sup>University of Washington School of Medicine; <sup>3</sup>University of Washington Department of Neurosurgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Health mindset and optimism are psychosocial factors that influence recovery and well-being. In other health fields, a growth health mindset—belief that health outcomes improve with effort and adaptive behaviors—has been associated with resilience and greater treatment engagement. Similarly, dispositional optimism has been linked to improved surgical recovery, and better therapy adherence, whereas a fixed mindset views health as largely immutable. Despite these relationships being well-established in other clinical settings, their role in patients with sinonasal tumors remains unexplored. Understanding relationships between mindset, optimism, and symptom burden may guide individualized perioperative communication and psychosocial support, potentially impacting clinical outcomes. This pilot study evaluated health mindset, optimism, self-efficacy, health literacy, and symptom burden in patients undergoing sinus surgery for benign and malignant sinonasal tumors.</p>\n\n<p><strong>Methods: </strong>Adult patients with sinonasal tumors presenting to a tertiary rhinology clinic were included and classified as having sinonasal malignancies (SNM) or benign sinonasal tumors (BSNT). Patients with pituitary or hematologic malignancies were excluded. Psychometric measures included optimism (Revised Life Orientation Test, LOT-R), health mindset (Health Mindset Scale, HM), self-efficacy (Perceived Health Competence Scale, HSE), and health literacy (Brief Health Literacy Screen, HL). Baseline symptom burden was assessed using the SNOT-22. Higher LOT-R, HM, HSE, and HL scores reflect greater optimism, growth mindset, self-efficacy, and health literacy, respectively; higher SNOT-22 scores indicate greater symptom burden. Analyses were performed using parametric t-tests.</p>\n\n<p><strong>Results: </strong>Seventeen patients were enrolled (SNM n=9; BSNT n=8). Sinonasal malignancies included squamous cell carcinoma (n=3), mucosal melanoma (n=2), undifferentiated carcinoma (n=2), NUT carcinoma (n=1), and HPV-related multiphenotypic carcinoma (n=1). Benign sinonasal tumors included inverted papilloma (n=8) and osteoma (n=1). Mean age was 61.7 ± 14.4 years. Mean SNOT-22 was 20.5 ± 22.0. No group differences were observed in SNOT-22, HSE, or HL scores (p = 0.20; 0.10; 0.37). The BSNT group demonstrated significantly lower LOT-R scores than the SNM group (11.12 ± 4.30 vs. 18.33 ± 4.66; p < 0.005) and trended toward lower HM scores (12.38 ± 2.62 vs. 14.78 ± 2.20; p = 0.06). Across the cohort, female patients exhibited lower LOT-R scores than males (11.25 ± 2.99 vs. 16.10 ± 5.94; p = 0.05), with no other gender-based differences.</p>\n\n<p><strong>Conclusion: </strong>Patients with benign sinonasal tumors demonstrated significantly lower dispositional optimism and trended toward lower growth-oriented health mindset compared to those with malignancies. This unexpected pattern suggests that benign disease presents meaningful psychological burden, potentially driven by prolonged surveillance, diagnostic ambiguity, or perceptions of an indolent course. Conversely, patients with malignancy may benefit from clearer prognostic information and comprehensive, multidisciplinary support with structured counseling, contributing to increased optimism. Furthermore, the observation that female patients exhibited significantly lower optimism, despite comparable scores in other psychosocial instruments, highlights a possible gender-related vulnerability. Incorporating validated assessments of mindset and optimism into sinonasal malignancy care may help identify patients who would benefit from targeted counseling and support. Future longitudinal studies are warranted to evaluate whether fostering adaptive mindset can meaningfully improve recovery and quality of life in patients with sinonasal tumors both benign and malignant.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154028/lotr.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154028--></body></html>"
    },
    {
      "uid": "P227",
      "content_id": "153392",
      "abstract_number": "P227",
      "poster_number": "P227",
      "title": "A Phase 2, single-arm, clinical trial evaluating nivolumab in recurrent/metastatic olfactory neuroblastoma (Orion trial).",
      "summary": "Olfactory neuroblastoma (ONB) is a rare malignancy arising from the olfactory neuroepithelium. Due to its rarity, evidence for systemic therapy is limited, particularly for recurrent or metastatic (R/M) ONB. We previously reported an objective response rate (ORR) of 33.3% in six patients with R/M ONB treated with anti–PD-1 antibodies monotherapy (nivolumab or pembrolizumab)1. Although this finding suggests...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153392",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yuta Hoshi, MD",
      "presenter": "Yuta Hoshi, MD",
      "authors": "Yuta Hoshi, MD 1 ; Susumu Okano 1 ; Naomi Kiyota 2 ; Taiji Koyama 2 ; Tomoko Yamazaki 3 ; Takahiro Fukuhara 4 ; Ryutaro Onaga 4 ; Ryosuke Kitoh 5 ; Yoh-ichiro Iwasa 5 ; Kiyoaki Tsukahara 6 ; Hideki Tanaka 6 ; Takahiro Asakage 7 ; Yosuke Ariizumi 7 ; Masato Nagaoka 8 ; Naohiro Takeshita 8 ; Naoki Nishio 9 ; Akihisa Wada 9 ; Makoto Tahara 1",
      "normalized_authors": [
        "Yuta Hoshi",
        "Susumu Okano",
        "Naomi Kiyota",
        "Taiji Koyama",
        "Tomoko Yamazaki",
        "Takahiro Fukuhara",
        "Ryutaro Onaga",
        "Ryosuke Kitoh",
        "Yoh-ichiro Iwasa",
        "Kiyoaki Tsukahara",
        "Hideki Tanaka",
        "Takahiro Asakage",
        "Yosuke Ariizumi",
        "Masato Nagaoka",
        "Naohiro Takeshita",
        "Naoki Nishio",
        "Akihisa Wada",
        "Makoto Tahara"
      ],
      "affiliations": [
        "National Cancer Center East Hospital",
        "Kobe University Hospital",
        "Saitama Medical University International Medical Center",
        "Jichi Medical University Hospital",
        "Shinshu University Hospital",
        "Tokyo Medical University Hospital",
        "Institute of Science Tokyo Hospital",
        "The Jikei University Hospital",
        "Nagoya University Hospital"
      ],
      "normalized_institutions": [
        "National Cancer Center East Hospital",
        "Kobe University Hospital",
        "Saitama Medical University International Medical Center",
        "Jichi Medical University Hospital",
        "Shinshu University Hospital",
        "Tokyo Medical University Hospital",
        "Institute of Science Tokyo Hospital",
        "The Jikei University Hospital",
        "Nagoya University Hospital"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 392,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Clinical trial information",
        "Research Sponsor"
      ],
      "sections": {
        "Authors": "Yuta Hoshi, MD 1 ; Susumu Okano 1 ; Naomi Kiyota 2 ; Taiji Koyama 2 ; Tomoko Yamazaki 3 ; Takahiro Fukuhara 4 ; Ryutaro Onaga 4 ; Ryosuke Kitoh 5 ; Yoh-ichiro Iwasa 5 ; Kiyoaki Tsukahara 6 ; Hideki Tanaka 6 ; Takahiro Asakage 7 ; Yosuke Ariizumi 7 ; Masato Nagaoka 8 ; Naohiro Takeshita 8 ; Naoki Nishio 9 ; Akihisa Wada 9 ; Makoto Tahara 1",
        "Affiliations": "1 National Cancer Center East Hospital; 2 Kobe University Hospital; 3 Saitama Medical University International Medical Center; 4 Jichi Medical University Hospital; 5 Shinshu University Hospital; 6 Tokyo Medical University Hospital; 7 Institute of Science Tokyo Hospital; 8 The Jikei University Hospital; 9 Nagoya University Hospital",
        "Background": "Olfactory neuroblastoma (ONB) is a rare malignancy arising from the olfactory neuroepithelium. Due to its rarity, evidence for systemic therapy is limited, particularly for recurrent or metastatic (R/M) ONB. We previously reported an objective response rate (ORR) of 33.3% in six patients with R/M ONB treated with anti–PD-1 antibodies monotherapy (nivolumab or pembrolizumab)1. Although this finding suggests potential activity of anti–PD-1 therapy in R/M ONB, the evidence remains inconclusive because of the small sample size and retrospective study design. Therefore, we initiated a prospective clinical trial to evaluate the efficacy of nivolumab in patients with R/M ONB.",
        "Methods": "This is a multi-center, single-arm, open-label clinical trial evaluating nivolumab monotherapy in patients with R/M ONB. Key eligibility criteria include: (1) histologically confirmed ONB; (2) patients must not be candidates for curative local therapy; (3) histologic confirmation must be obtained from recurrent or metastatic lesions; if histologic confirmation is not feasible, FDG uptake in recurrent/metastatic sites on PET-CT is acceptable; (4) disease progression following platinum-based therapy for ONB; (5) ECOG performance status 0–1; and (6) at least one measurable lesion per RECIST v1.1. Patients receive nivolumab monotherapy, administered either at 240 mg on Days 1 and 15 or 480 mg on Day 1 of each 28-day cycle, with treatment schedule modification permitted at the investigator’s discretion. Treatment continues until radiologic disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria are met. The primary endpoint is ORR. Secondary endpoints include safety and tolerability, progression-free survival, and overall survival. Exploratory analyses may include biomarker studies focusing on the tumor microenvironment using tumor tissue specimens and peripheral blood samples, depending on local resources and assay availability. Given the absence of an established standard systemic therapy for R/M ONB, the null hypothesis ORR was set at 5% as a clinically negligible response rate. Based on our retrospective data demonstrating an ORR of 33.3% with anti–PD-1 therapy, the alternative hypothesis ORR was set at 33%. Using a one-sided alpha level of 0.05 and a statistical power of 80%, a sample size of 12 evaluable patients was required according to an exact binomial design. To account for potential ineligibility or dropout, the total planned enrollment was set at 14 patients.",
        "Abstract": "1. Hoshi Y, et al. Front Oncol. 2024 May 23;14:1379013.",
        "Clinical trial information": "NCT07100704.",
        "Research Sponsor": "None."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Phase 2, single-arm, clinical trial evaluating nivolumab in recurrent/metastatic olfactory neuroblastoma (Orion trial).</span>. <u>Yuta Hoshi, MD</u><sup>1</sup>; Susumu Okano<sup>1</sup>; Naomi Kiyota<sup>2</sup>; Taiji Koyama<sup>2</sup>; Tomoko Yamazaki<sup>3</sup>; Takahiro Fukuhara<sup>4</sup>; Ryutaro Onaga<sup>4</sup>; Ryosuke Kitoh<sup>5</sup>; Yoh-ichiro Iwasa<sup>5</sup>; Kiyoaki Tsukahara<sup>6</sup>; Hideki Tanaka<sup>6</sup>; Takahiro Asakage<sup>7</sup>; Yosuke Ariizumi<sup>7</sup>; Masato Nagaoka<sup>8</sup>; Naohiro Takeshita<sup>8</sup>; Naoki Nishio<sup>9</sup>; Akihisa Wada<sup>9</sup>; Makoto Tahara<sup>1</sup>. <sup>1</sup>National Cancer Center East Hospital; <sup>2</sup>Kobe University Hospital; <sup>3</sup>Saitama Medical University International Medical Center; <sup>4</sup>Jichi Medical University Hospital; <sup>5</sup>Shinshu University Hospital; <sup>6</sup>Tokyo Medical University Hospital; <sup>7</sup>Institute of Science Tokyo Hospital; <sup>8</sup>The Jikei University Hospital; <sup>9</sup>Nagoya University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Olfactory neuroblastoma (ONB) is a rare malignancy arising from the olfactory neuroepithelium. Due to its rarity, evidence for systemic therapy is limited, particularly for recurrent or metastatic (R/M) ONB. We previously reported an objective response rate (ORR) of 33.3% in six patients with R/M ONB treated with anti–PD-1 antibodies monotherapy (nivolumab or pembrolizumab)1. Although this finding suggests potential activity of anti–PD-1 therapy in R/M ONB, the evidence remains inconclusive because of the small sample size and retrospective study design. Therefore, we initiated a prospective clinical trial to evaluate the efficacy of nivolumab in patients with R/M ONB.</p>\n\n<p><strong>Methods: </strong>This is a multi-center, single-arm, open-label clinical trial evaluating nivolumab monotherapy in patients with R/M ONB. Key eligibility criteria include: (1) histologically confirmed ONB; (2) patients must not be candidates for curative local therapy; (3) histologic confirmation must be obtained from recurrent or metastatic lesions; if histologic confirmation is not feasible, FDG uptake in recurrent/metastatic sites on PET-CT is acceptable; (4) disease progression following platinum-based therapy for ONB; (5) ECOG performance status 0–1; and (6) at least one measurable lesion per RECIST v1.1. Patients receive nivolumab monotherapy, administered either at 240 mg on Days 1 and 15 or 480 mg on Day 1 of each 28-day cycle, with treatment schedule modification permitted at the investigator’s discretion. Treatment continues until radiologic disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria are met. The primary endpoint is ORR. Secondary endpoints include safety and tolerability, progression-free survival, and overall survival. Exploratory analyses may include biomarker studies focusing on the tumor microenvironment using tumor tissue specimens and peripheral blood samples, depending on local resources and assay availability. Given the absence of an established standard systemic therapy for R/M ONB, the null hypothesis ORR was set at 5% as a clinically negligible response rate. Based on our retrospective data demonstrating an ORR of 33.3% with anti–PD-1 therapy, the alternative hypothesis ORR was set at 33%. Using a one-sided alpha level of 0.05 and a statistical power of 80%, a sample size of 12 evaluable patients was required according to an exact binomial design. To account for potential ineligibility or dropout, the total planned enrollment was set at 14 patients.</p>\n\n<p>1. Hoshi Y, et al. Front Oncol. 2024 May 23;14:1379013.</p>\n\n<p><strong>Clinical trial information:</strong> NCT07100704.</p>\n\n<p><strong>Research Sponsor:</strong> None.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153392--></body></html>"
    },
    {
      "uid": "P228",
      "content_id": "153255",
      "abstract_number": "P228",
      "poster_number": "P228",
      "title": "Diagnostic Delay in Extranodal NK/T-Cell Lymphoma, Nasal Type: A Scoping Review on Misdiagnosis and Survival Outcomes",
      "summary": "The diagnostic delay remains a critical barrier to timely treatment and improved outcome. Misdiagnosis as common inflammatory conditions such as sinusitis or cellulitis were frequent, particularly in non-endemic regions, and most patients did not undergo upfront biopsy. Most cases were diagnosed only after failed empirical therapy, often at advanced stages, contributing to poor survival. These findings underscore...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153255",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sebastián Sepúlveda",
      "presenter": "Sebastián Sepúlveda",
      "authors": "Sebastián Sepúlveda 1 ; Alejandra Varela 1 ; Guillermo Corrales 1 ; Diego Mendez 1 ; Rafael Araúz, Dr 2 ; Manuel Mock, Dr 3",
      "normalized_authors": [
        "Sebastián Sepúlveda",
        "Alejandra Varela",
        "Guillermo Corrales",
        "Diego Mendez",
        "Rafael Araúz, Dr",
        "Manuel Mock, Dr"
      ],
      "affiliations": [
        "Universidad de Panamá",
        "Instituto Oncológico Nacional",
        "Complejo Hospitalario Dr. Arnulfo Arias Madrid, Caja de Seguro Social"
      ],
      "normalized_institutions": [
        "Universidad de Panamá",
        "Instituto Oncológico Nacional",
        "Complejo Hospitalario Dr. Arnulfo Arias Madrid, Caja de Seguro Social"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Data Sources",
        "Review Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sebastián Sepúlveda 1 ; Alejandra Varela 1 ; Guillermo Corrales 1 ; Diego Mendez 1 ; Rafael Araúz, Dr 2 ; Manuel Mock, Dr 3",
        "Affiliations": "1 Universidad de Panamá; 2 Instituto Oncológico Nacional; 3 Complejo Hospitalario Dr. Arnulfo Arias Madrid, Caja de Seguro Social",
        "Objective": "Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT), is a highly aggressive, rare malignancy with a poor prognosis often worsened by therapeutic delays. The paucity of literature consolidating its mimetic features, particularly in non-endemic regions, contributes to high rates of misdiagnosis as common inflammatory or infectious processes. The purpose of this scoping review is to synthesize the available studies and categorize findings.",
        "Data Sources": "PubMed and Google Scholar were searched for articles addressing misdiagnosis in patients with ENKTL-NT between 2008 and August of 2025.",
        "Review Methods": "Databases were systematically searched. Two reviewers independently screened records and assessed full texts for eligibility, with disagreements resolved by consensus with external reviewers. Extracted data included general publication details (year, author, and country), type of article, sample size, patient’s sex and age, time between the correct diagnosis and death or last follow-up, time between the wrong diagnosis and the correct one, stage of the disease following the Ann Arbor classification, location of the lymphoma, initial misdiagnoses, initial symptoms, type of treatment and if the failure of the diagnosis was clinical or by pathology.",
        "Results": "A total of 401 records were imported for screening, and 29 studies met inclusion criteria. Most (86%) were case reports and the remainder case series, encompassing 35 patients (20 males, 15 females; mean age 45.9 ± 20 years). Out of the 35 patients, 20 (57.1%) of the initial misdiagnosis were sinusitis, 4 (11.4%) were orbital cellulitis and 2 (5.7%) conjunctivitis. Of the 29 studies 11 (38%) were from North America, 10 (35%) from Asia, 7 (24%) from Europe and 1 (3%) from Oceania. Only 9 (25.7%) underwent upfront biopsy; the rest were diagnosed after failed empirical treatment. At final diagnosis, 22 (62.9%) were stage I–II, 10 (28.6%) stage IV of the Ann Arbor classification, and 3 (8.6%) unstaged due to deferred treatment. Most of the lymphomas were located in the nasal sinuses 16 (44.4%), nasal and orbital 10 (27.8%), orbital 8 (22.2%) and other locations 2 (5.6%). Treatments included chemotherapy 16 (45.7%), chemoradiotherapy 13 (37.1%), radiotherapy alone 2 (5.7%), and immunotherapy 1 (2.9%). Mean time from the diagnosis to reported death was 5.6 months in 26 (74%) patients and 14.5 months last follow up in 9 (26%).",
        "Conclusions": "The diagnostic delay remains a critical barrier to timely treatment and improved outcome. Misdiagnosis as common inflammatory conditions such as sinusitis or cellulitis were frequent, particularly in non-endemic regions, and most patients did not undergo upfront biopsy. Most cases were diagnosed only after failed empirical therapy, often at advanced stages, contributing to poor survival. These findings underscore the need for more studies, heightened clinical suspicion, early biopsy, and improved awareness of ENKTL-NT’s mimetic features among clinicians."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic Delay in Extranodal NK/T-Cell Lymphoma, Nasal Type: A Scoping Review on Misdiagnosis and Survival Outcomes</span>. <u>Sebastián Sepúlveda</u><sup>1</sup>; Alejandra Varela<sup>1</sup>; Guillermo Corrales<sup>1</sup>; Diego Mendez<sup>1</sup>; Rafael Araúz, Dr<sup>2</sup>; Manuel Mock, Dr<sup>3</sup>. <sup>1</sup>Universidad de Panamá; <sup>2</sup>Instituto Oncológico Nacional; <sup>3</sup>Complejo Hospitalario Dr. Arnulfo Arias Madrid, Caja de Seguro Social<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT), is a highly aggressive, rare malignancy with a poor prognosis often worsened by therapeutic delays. The paucity of literature consolidating its mimetic features, particularly in non-endemic regions, contributes to high rates of misdiagnosis as common inflammatory or infectious processes. The purpose of this scoping review is to synthesize the available studies and categorize findings. </p>\n\n<p><strong>Data Sources: </strong>PubMed and Google Scholar were searched for articles addressing misdiagnosis in patients with ENKTL-NT between 2008 and August of 2025.</p>\n\n<p><strong>Review Methods: </strong>Databases were systematically searched. Two reviewers independently screened records and assessed full texts for eligibility, with disagreements resolved by consensus with external reviewers. Extracted data included general publication details (year, author, and country), type of article, sample size, patient’s sex and age, time between the correct diagnosis and death or last follow-up, time between the wrong diagnosis and the correct one, stage of the disease following the Ann Arbor classification, location of the lymphoma, initial misdiagnoses, initial symptoms, type of treatment and if the failure of the diagnosis was clinical or by pathology.</p>\n\n<p><strong>Results: </strong>A total of 401 records were imported for screening, and 29 studies met inclusion criteria. Most (86%) were case reports and the remainder case series, encompassing 35 patients (20 males, 15 females; mean age 45.9 ± 20 years). Out of the 35 patients, 20 (57.1%) of the initial misdiagnosis were sinusitis, 4 (11.4%) were orbital cellulitis and 2 (5.7%) conjunctivitis. Of the 29 studies 11 (38%) were from North America, 10 (35%) from Asia, 7 (24%) from Europe and 1 (3%) from Oceania. Only 9 (25.7%) underwent upfront biopsy; the rest were diagnosed after failed empirical treatment. At final diagnosis, 22 (62.9%) were stage I–II, 10 (28.6%) stage IV of the Ann Arbor classification, and 3 (8.6%) unstaged due to deferred treatment. Most of the lymphomas were located in the nasal sinuses 16 (44.4%), nasal and orbital 10 (27.8%), orbital 8 (22.2%) and other locations 2 (5.6%). Treatments included chemotherapy 16 (45.7%), chemoradiotherapy 13 (37.1%), radiotherapy alone 2 (5.7%), and immunotherapy 1 (2.9%). Mean time from the diagnosis to reported death was 5.6 months in 26 (74%) patients and 14.5 months last follow up in 9 (26%).</p>\n\n<p><strong>Conclusions: </strong>The diagnostic delay remains a critical barrier to timely treatment and improved outcome. Misdiagnosis as common inflammatory conditions such as sinusitis or cellulitis were frequent, particularly in non-endemic regions, and most patients did not undergo upfront biopsy. Most cases were diagnosed only after failed empirical therapy, often at advanced stages, contributing to poor survival. These findings underscore the need for more studies, heightened clinical suspicion, early biopsy, and improved awareness of ENKTL-NT’s mimetic features among clinicians. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153255--></body></html>"
    },
    {
      "uid": "P230",
      "content_id": "153870",
      "abstract_number": "P230",
      "poster_number": "P230",
      "title": "Inflammatory sinonasal pseudotumor with lacrimal involvement mimicking malignancy: A Case Report",
      "summary": "Inflammatory pseudotumors (IPT) are a rare pathology that uncommonly affect the sinonasal region. We report a unique case of sinonasal mass with lacrimal duct and sac involvement resembling a malignant process, only to be found later to be an IPT. To the best of our knowledge, this is the first reported case of sinonasal IPT involving the lacrimal system.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153870",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Branden Qi Yu Chua",
      "presenter": "Branden Qi Yu Chua",
      "authors": "Branden Qi Yu Chua ; Andy Jian Kai Chua",
      "normalized_authors": [
        "Branden Qi Yu Chua",
        "Andy Jian Kai Chua"
      ],
      "affiliations": [
        "Sengkang General Hospital"
      ],
      "normalized_institutions": [
        "Sengkang General Hospital"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 313,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Description",
        "Discussion"
      ],
      "sections": {
        "Authors": "Branden Qi Yu Chua ; Andy Jian Kai Chua",
        "Affiliations": "Sengkang General Hospital",
        "Background": "Inflammatory pseudotumors (IPT) are a rare pathology that uncommonly affect the sinonasal region. We report a unique case of sinonasal mass with lacrimal duct and sac involvement resembling a malignant process, only to be found later to be an IPT. To the best of our knowledge, this is the first reported case of sinonasal IPT involving the lacrimal system.",
        "Case Description": "A 42-year-old Chinese male presented with a 6-year history of right sided nasal obstruction. Nasoendoscopy showed a right nasal mass inferior to the inferior turbinate extending beyond the posterior choanae to the contralateral nasal cavity. An in-office punch biopsy returned as inflammatory polyp-type changes. Contrasted computed tomography (CT) scan showed a faintly enhancing soft tissue lesion measuring 6.5 x 2.7 x 3.3 cm. The inferior meatus was widened, with scalloping of the medial wall of the right maxillary sinus. Contrasted magnetic resonance imaging (MRI) additionally showed the mass occupying and expanding the right nasolacrimal duct. Lacrimal syringing was done by Oculoplastics which revealed partial obstruction of the lacrimal system. Under general anesthesia, the nasal aspect of the tumor was divided in the inferior meatus. An endoscopic modified medial maxillectomy was performed along with a wide dacryocystorhinostomy (DCR). Intra-operative frozen-section showed chronic inflammatory infiltrate with no evidence of malignancy. A joint decision was made to avoid the morbidity of a dacryocystectomy in the absence of evidence of malignancy. The mass was excised by retracting and amputating it sharply from its proximal attachment. Crawford stents were inserted and placed in the middle meatus. Subsequent histological analysis confirmed the diagnosis of an IPT. Till date his lacrimal system remains patent with no evidence of disease recurrence.",
        "Discussion": "Key factors that enabled our patient to achieve favourable outcomes included a multi-disciplinary team approach with Oculoplastics and the availability of reliable intraoperative frozen section analysis, which played a key role in decision making regarding extent of surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Inflammatory sinonasal pseudotumor with lacrimal involvement mimicking malignancy: A Case Report</span>. <u>Branden Qi Yu Chua</u>; Andy Jian Kai Chua. Sengkang General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Inflammatory pseudotumors (IPT) are a rare pathology that uncommonly affect the sinonasal region. We report a unique case of sinonasal mass with lacrimal duct and sac involvement resembling a malignant process, only to be found later to be an IPT. To the best of our knowledge, this is the first reported case of sinonasal IPT involving the lacrimal system.</p>\n\n<p><strong>Case Description:</strong> A 42-year-old Chinese male presented with a 6-year history of right sided nasal obstruction. Nasoendoscopy showed a right nasal mass inferior to the inferior turbinate extending beyond the posterior choanae to the contralateral nasal cavity. An in-office punch biopsy returned as inflammatory polyp-type changes. Contrasted computed tomography (CT) scan showed a faintly enhancing soft tissue lesion measuring 6.5 x 2.7 x 3.3 cm. The inferior meatus was widened, with scalloping of the medial wall of the right maxillary sinus. Contrasted magnetic resonance imaging (MRI) additionally showed the mass occupying and expanding the right nasolacrimal duct. Lacrimal syringing was done by Oculoplastics which revealed partial obstruction of the lacrimal system. Under general anesthesia, the nasal aspect of the tumor was divided in the inferior meatus. An endoscopic modified medial maxillectomy was performed along with a wide dacryocystorhinostomy (DCR). Intra-operative frozen-section showed chronic inflammatory infiltrate with no evidence of malignancy. A joint decision was made to avoid the morbidity of a dacryocystectomy in the absence of evidence of malignancy. The mass was excised by retracting and amputating it sharply from its proximal attachment. Crawford stents were inserted and placed in the middle meatus. Subsequent histological analysis confirmed the diagnosis of an IPT. Till date his lacrimal system remains patent with no evidence of disease recurrence.</p>\n\n<p><strong>Discussion:</strong> Key factors that enabled our patient to achieve favourable outcomes included a multi-disciplinary team approach with Oculoplastics and the availability of reliable intraoperative frozen section analysis, which played a key role in decision making regarding extent of surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153870--></body></html>"
    },
    {
      "uid": "P232",
      "content_id": "152606",
      "abstract_number": "P232",
      "poster_number": "P232",
      "title": "Salvage Extended Maxillectomy for Recurrent Maxillary Sinus Carcinoma After RADPLAT: A Case Series of Five Patients",
      "summary": "Salvage extended maxillectomy after recurrence following RADPLAT can provide durable control in selected patients. Four of five cases achieved long-term CR, supporting salvage surgery as an important curative option for recurrent maxillary sinus carcinoma after RADPLAT.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152606",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hirohisa Iwaki, MD, PhD",
      "presenter": "Hirohisa Iwaki, MD, PhD",
      "authors": "Hirohisa Iwaki, MD, PhD 1 ; Yasuhiro Ebihara, MD, PhD 1 ; Taisei Yasuda, MD 1 ; Yuichiro Enoki, DDS, PhD 1 ; Satoko Matsumura, MD 1 ; Tomoko Yamazaki, MD, DDS, PhD 1 ; Mitsuhiko Nakahira, MD, PhD 1 ; Masao Takahashi, MD, PhD 2 ; Yoko Usami, MD, PhD 3 ; Ken Nakazawa, MD, PhD 3",
      "normalized_authors": [
        "Hirohisa Iwaki",
        "Yasuhiro Ebihara",
        "Taisei Yasuda",
        "Yuichiro Enoki",
        "Satoko Matsumura",
        "Tomoko Yamazaki",
        "Mitsuhiko Nakahira",
        "Masao Takahashi",
        "Yoko Usami",
        "Ken Nakazawa"
      ],
      "affiliations": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
        "Dept of Radiology, Saitama Medical University Hospital",
        "Dept of Diagnostic Radiology, International Medical Center, Saitama Medical University"
      ],
      "normalized_institutions": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
        "Dept of Radiology, Saitama Medical University Hospital",
        "Dept of Diagnostic Radiology, International Medical Center, Saitama Medical University"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Hirohisa Iwaki, MD, PhD 1 ; Yasuhiro Ebihara, MD, PhD 1 ; Taisei Yasuda, MD 1 ; Yuichiro Enoki, DDS, PhD 1 ; Satoko Matsumura, MD 1 ; Tomoko Yamazaki, MD, DDS, PhD 1 ; Mitsuhiko Nakahira, MD, PhD 1 ; Masao Takahashi, MD, PhD 2 ; Yoko Usami, MD, PhD 3 ; Ken Nakazawa, MD, PhD 3",
        "Affiliations": "1 Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University; 2 Dept of Radiology, Saitama Medical University Hospital; 3 Dept of Diagnostic Radiology, International Medical Center, Saitama Medical University",
        "Background": "In advanced maxillary sinus squamous cell carcinoma (T3 or higher), treatment selection depends on tumor resectability, orbital invasion, and functional preservation. For resectable T3–T4a lesions, total maxillectomy followed by postoperative radiotherapy (60–66 Gy) is standard and provides the highest local control. Postoperative chemoradiotherapy is recommended for high-risk features such as positive margins, perineural invasion, or nodal metastasis. For unresectable T4b disease or patients unfit for surgery, cisplatin-based chemoradiotherapy (CRT) is indicated, although outcomes for T3–T4a remain inferior.",
        "Abstract": "Superselective intra-arterial chemoradiotherapy (RADPLAT), combining high-dose cisplatin with IMRT, is an organ-preserving option for T3–T4a cases requiring ocular preservation and selected T4b cases in which extensive surgery should be avoided. While favorable outcomes have been reported in Japan, international evidence remains limited. Case 1: A 69-year-old man (T4aN1M0) underwent TPF induction chemotherapy followed by RT 60 Gy plus four intra-arterial infusions. Seven years later, a recurrent tumor (rT4a) involving the entire left maxilla with orbital and pterygopalatine invasion was detected. Extended maxillectomy and rectus abdominis (RA) flap reconstruction were performed. A second recurrence (rT2) in the anterior palate appeared four months later and was resected. He has remained in complete remission (CR) for five years. Case 2: A 74-year-old man (T4aN0M0) developed a recurrent tumor (rT3) from the anterior maxillary wall to the orbital floor five months after RT 60 Gy plus six intra-arterial infusions. Extended maxillectomy with RA flap reconstruction was performed, and he has maintained CR for five years. Case 3: A 67-year-old man (T4aN1M0) developed a similar rT3 recurrence six months after RT 60 Gy plus six intra-arterial treatments and underwent extended maxillectomy with RA flap reconstruction. He has maintained CR for five years. Case 4: A 61-year-old man (T4aN2bM0) developed a recurrent tumor (rT3) in the right anterior maxillary wall to the orbital floor one year and eight months after RT 70 Gy plus six intra-arterial infusions. Extended maxillectomy, hemimandibulectomy, and RA flap reconstruction were performed. Recurrent disease (rT4b) appeared 11 months later, and he died one year and two months postoperatively. Case 5: A 50-year-old man (T4aN2bM0) developed a recurrent tumor (rT3) from the left lateral maxillary wall to the orbital floor one year and six months after RT 70 Gy plus seven intra-arterial infusions. Extended maxillectomy with scapular–latissimus dorsi flap reconstruction was performed. He has remained recurrence-free for six months.",
        "Methods": "At our institution, RADPLAT is used as initial therapy for patients with T3 or more advanced maxillary sinus carcinoma who decline surgery or are inoperable. Some patients subsequently develop local recurrence. Salvage surgery is chosen according to the extent of recurrent tumor invasion. We report five cases treated with salvage extended maxillectomy and reconstructive surgery after recurrence following RADPLAT to assess its therapeutic value.",
        "Conclusion": "Salvage extended maxillectomy after recurrence following RADPLAT can provide durable control in selected patients. Four of five cases achieved long-term CR, supporting salvage surgery as an important curative option for recurrent maxillary sinus carcinoma after RADPLAT."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Salvage Extended Maxillectomy for Recurrent Maxillary Sinus Carcinoma After RADPLAT: A Case Series of Five Patients</span>. <u>Hirohisa Iwaki, MD, PhD</u><sup>1</sup>; Yasuhiro Ebihara, MD, PhD<sup>1</sup>; Taisei Yasuda, MD<sup>1</sup>; Yuichiro Enoki, DDS, PhD<sup>1</sup>; Satoko Matsumura, MD<sup>1</sup>; Tomoko Yamazaki, MD, DDS, PhD<sup>1</sup>; Mitsuhiko Nakahira, MD, PhD<sup>1</sup>; Masao Takahashi, MD, PhD<sup>2</sup>; Yoko Usami, MD, PhD<sup>3</sup>; Ken Nakazawa, MD, PhD<sup>3</sup>. <sup>1</sup>Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University; <sup>2</sup>Dept of Radiology, Saitama Medical University Hospital; <sup>3</sup>Dept of Diagnostic Radiology, International Medical Center, Saitama Medical University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In advanced maxillary sinus squamous cell carcinoma (T3 or higher), treatment selection depends on tumor resectability, orbital invasion, and functional preservation. For resectable T3–T4a lesions, total maxillectomy followed by postoperative radiotherapy (60–66 Gy) is standard and provides the highest local control. Postoperative chemoradiotherapy is recommended for high-risk features such as positive margins, perineural invasion, or nodal metastasis. For unresectable T4b disease or patients unfit for surgery, cisplatin-based chemoradiotherapy (CRT) is indicated, although outcomes for T3–T4a remain inferior.</p>\n\n<p>Superselective intra-arterial chemoradiotherapy (RADPLAT), combining high-dose cisplatin with IMRT, is an organ-preserving option for T3–T4a cases requiring ocular preservation and selected T4b cases in which extensive surgery should be avoided. While favorable outcomes have been reported in Japan, international evidence remains limited.</p>\n\n<p><strong>Methods: </strong>At our institution, RADPLAT is used as initial therapy for patients with T3 or more advanced maxillary sinus carcinoma who decline surgery or are inoperable. Some patients subsequently develop local recurrence. Salvage surgery is chosen according to the extent of recurrent tumor invasion. We report five cases treated with salvage extended maxillectomy and reconstructive surgery after recurrence following RADPLAT to assess its therapeutic value.</p>\n\n<p><strong>Results:</strong></p>\n\n<p>Case 1: A 69-year-old man (T4aN1M0) underwent TPF induction chemotherapy followed by RT 60 Gy plus four intra-arterial infusions. Seven years later, a recurrent tumor (rT4a) involving the entire left maxilla with orbital and pterygopalatine invasion was detected. Extended maxillectomy and rectus abdominis (RA) flap reconstruction were performed. A second recurrence (rT2) in the anterior palate appeared four months later and was resected. He has remained in complete remission (CR) for five years.</p>\n\n<p>Case 2: A 74-year-old man (T4aN0M0) developed a recurrent tumor (rT3) from the anterior maxillary wall to the orbital floor five months after RT 60 Gy plus six intra-arterial infusions. Extended maxillectomy with RA flap reconstruction was performed, and he has maintained CR for five years.</p>\n\n<p>Case 3: A 67-year-old man (T4aN1M0) developed a similar rT3 recurrence six months after RT 60 Gy plus six intra-arterial treatments and underwent extended maxillectomy with RA flap reconstruction. He has maintained CR for five years.</p>\n\n<p>Case 4: A 61-year-old man (T4aN2bM0) developed a recurrent tumor (rT3) in the right anterior maxillary wall to the orbital floor one year and eight months after RT 70 Gy plus six intra-arterial infusions. Extended maxillectomy, hemimandibulectomy, and RA flap reconstruction were performed. Recurrent disease (rT4b) appeared 11 months later, and he died one year and two months postoperatively.</p>\n\n<p>Case 5: A 50-year-old man (T4aN2bM0) developed a recurrent tumor (rT3) from the left lateral maxillary wall to the orbital floor one year and six months after RT 70 Gy plus seven intra-arterial infusions. Extended maxillectomy with scapular–latissimus dorsi flap reconstruction was performed. He has remained recurrence-free for six months.</p>\n\n<p><strong>Conclusion: </strong>Salvage extended maxillectomy after recurrence following RADPLAT can provide durable control in selected patients. Four of five cases achieved long-term CR, supporting salvage surgery as an important curative option for recurrent maxillary sinus carcinoma after RADPLAT. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152606--></body></html>"
    },
    {
      "uid": "P233",
      "content_id": "153402",
      "abstract_number": "P233",
      "poster_number": "P233",
      "title": "Clinical Profile and Treatment Outcomes in Patients Treated with Intensity-Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx: A retrospective analysis from a non-endemic area",
      "summary": "IMRT for nasopharyngeal carcinoma provides favorable long-term survival outcomes with excellent distant metastasis control and acceptable locoregional control across all stages. These results further establish IMRT combined with appropriate chemotherapy as an effective and reliable standard treatment approach for NPC in real-world clinical practice.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153402",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Cessal T Kainickal, MD",
      "presenter": "Cessal T Kainickal, MD",
      "authors": "Cessal T Kainickal, MD ; Farida Nazeer, MD; Rejnish R Kumar, MD; Malu M Rafi, MD; Lekha M Nair, MD; Nijo Jose, MD; Arya Bhanu; Preethi George, PhD",
      "normalized_authors": [
        "Cessal T Kainickal",
        "Farida Nazeer",
        "Rejnish R Kumar",
        "Malu M Rafi",
        "Lekha M Nair",
        "Nijo Jose",
        "Arya Bhanu",
        "Preethi George"
      ],
      "affiliations": [
        "Regional Cancer Centre"
      ],
      "normalized_institutions": [
        "Regional Cancer Centre"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 415,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Cessal T Kainickal, MD ; Farida Nazeer, MD; Rejnish R Kumar, MD; Malu M Rafi, MD; Lekha M Nair, MD; Nijo Jose, MD; Arya Bhanu; Preethi George, PhD",
        "Affiliations": "Regional Cancer Centre",
        "Background": "Intensity-modulated radiotherapy (IMRT) has become the standard of care for nasopharyngeal carcinoma (NPC) due to its superior dose conformity and improved sparing of critical normal structures, leading to better tumor control and reduced treatment-related toxicity. This study evaluates the long-term clinical outcomes of patients with NPC treated with IMRT at a tertiary cancer centre in Kerala, South India.",
        "Methods": "A retrospective analysis was conducted on patients with biopsy-proven carcinoma of the nasopharynx treated with radical IMRT with or without chemotherapy between January 2011 and July 2016. Patients with metastatic disease at presentation, recurrent disease, or those treated with palliative intent were excluded. Clinical staging was done according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system. IMRT was delivered using a simultaneous integrated boost (SIB) technique, with doses of 66 Gy in 30 fractions to the high-risk planning target volume (PTV), 60 Gy in 30 fractions to the intermediate-risk PTV, and 54 Gy in 30 fractions to the low-risk PTV. Stage II patients were treated with concurrent chemoradiation, while Stage III and IVa patients were treated with either concurrent chemoradiation alone or induction chemotherapy followed by concurrent chemoradiation. The primary endpoints were disease-free survival (DFS) and overall survival (OS), while secondary endpoints included locoregional control (LRC) and distant metastasis-free survival (DMFS). Survival outcomes were calculated using the Kaplan–Meier method.",
        "Results": "The Total number of patients included in the study was 134. The median follow-up duration was 78.7 months. All patients completed the planned radical radiotherapy without treatment interruption. The median age at diagnosis was 45 years, with a male predominance (70.1%). Stage distribution was as follows: Stage I – 4.4%, Stage II – 19.3%, Stage III – 37.8%, and Stage IV – 37.8%. Residual disease after treatment completion was observed in 5.8% of patients. Disease relapse occurred in 29.1% of patients, with distant metastasis being the most common pattern of failure. The five-year DFS, OS, DMFS, and LRC were 64.8%, 70.6%, 85.5%, and 64.2%, respectively. Stage-wise five-year OS rates for Stage I–IV were 83.3%, 76.9%, 71.9%, and 64.5%, respectively, while five-year DFS rates were 83.3%, 76.9%, 62.5%, and 58.7%, respectively.",
        "Conclusion": "IMRT for nasopharyngeal carcinoma provides favorable long-term survival outcomes with excellent distant metastasis control and acceptable locoregional control across all stages. These results further establish IMRT combined with appropriate chemotherapy as an effective and reliable standard treatment approach for NPC in real-world clinical practice."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Profile and Treatment Outcomes in Patients Treated with Intensity-Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx: A retrospective analysis from a non-endemic area</span>. <u>Cessal T Kainickal, MD</u>; Farida Nazeer, MD; Rejnish R Kumar, MD; Malu M Rafi, MD; Lekha M Nair, MD; Nijo Jose, MD; Arya Bhanu; Preethi George, PhD. Regional Cancer Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Intensity-modulated radiotherapy (IMRT) has become the standard of care for nasopharyngeal carcinoma (NPC) due to its superior dose conformity and improved sparing of critical normal structures, leading to better tumor control and reduced treatment-related toxicity. This study evaluates the long-term clinical outcomes of patients with NPC treated with IMRT at a tertiary cancer centre in Kerala, South India.</p>\n\n<p><strong>Methods: </strong>A retrospective analysis was conducted on patients with biopsy-proven carcinoma of the nasopharynx treated with radical IMRT  with or without chemotherapy between January 2011 and July 2016. Patients with metastatic disease at presentation, recurrent disease, or those treated with palliative intent were excluded. Clinical staging was done according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system. IMRT was delivered using a simultaneous integrated boost (SIB) technique, with doses of 66 Gy in 30 fractions to the high-risk planning target volume (PTV), 60 Gy in 30 fractions to the intermediate-risk PTV, and 54 Gy in 30 fractions to the low-risk PTV. Stage II patients were treated with concurrent chemoradiation, while Stage III and IVa patients were treated with either concurrent chemoradiation alone or induction chemotherapy followed by concurrent chemoradiation. The primary endpoints were disease-free survival (DFS) and overall survival (OS), while secondary endpoints included locoregional control (LRC) and distant metastasis-free survival (DMFS). Survival outcomes were calculated using the Kaplan–Meier method.</p>\n\n<p><strong>Results: </strong>The Total number of patients included in the study was 134. The median follow-up duration was 78.7 months. All patients completed the planned radical radiotherapy without treatment interruption. The median age at diagnosis was 45 years, with a male predominance (70.1%). Stage distribution was as follows: Stage I – 4.4%, Stage II – 19.3%, Stage III – 37.8%, and Stage IV – 37.8%. Residual disease after treatment completion was observed in 5.8% of patients. Disease relapse occurred in 29.1% of patients, with distant metastasis being the most common pattern of failure. The five-year DFS, OS, DMFS, and LRC were 64.8%, 70.6%, 85.5%, and 64.2%, respectively. Stage-wise five-year OS rates for Stage I–IV were 83.3%, 76.9%, 71.9%, and 64.5%, respectively, while five-year DFS rates were 83.3%, 76.9%, 62.5%, and 58.7%, respectively.</p>\n\n<p><strong>Conclusion:</strong> IMRT for nasopharyngeal carcinoma provides favorable long-term survival outcomes with excellent distant metastasis control and acceptable locoregional control across all stages. These results further establish IMRT combined with appropriate chemotherapy as an effective and reliable standard treatment approach for NPC in real-world clinical practice.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153402--></body></html>"
    },
    {
      "uid": "P234",
      "content_id": "153116",
      "abstract_number": "P234",
      "poster_number": "P234",
      "title": "Multimodality Management of Non-Intestinal-Type Sinonasal Adenocarcinoma with Intracranial Extension: A Case Report and Literature Review",
      "summary": "Non-intestinal-type adenocarcinoma (non-ITAC) is a rare subtype of primary sinonasal malignancy that remains a diagnosis of exclusion, characterized by glandular differentiation without defining features of intestinal-type differentiation or salivary gland neoplasia. Sinonasal non-ITAC are further subdivided into low-grade and high-grade categories, with the latter characterized by more aggressive clinical...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153116",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fangdi Sun, MD",
      "presenter": "Fangdi Sun, MD",
      "authors": "Fangdi Sun, MD ; Mobeen Rahman, MD; Peter H Hwang, MD; Beth M Beadle, MD; Juan C Fernandez-Miranda, MD; A",
      "normalized_authors": [
        "Fangdi Sun",
        "Mobeen Rahman",
        "Peter H Hwang",
        "Beth M Beadle",
        "Juan C Fernandez-Miranda"
      ],
      "affiliations": [
        "Dimitrios Colevas, MD. Stanford University"
      ],
      "normalized_institutions": [
        "Dimitrios Colevas, MD. Stanford University"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153116/nITAC%20abstract%20figure.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153116/nITAC%20abstract%20figure.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153116"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 384,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Report",
        "Discussion/Conclusion"
      ],
      "sections": {
        "Authors": "Fangdi Sun, MD ; Mobeen Rahman, MD; Peter H Hwang, MD; Beth M Beadle, MD; Juan C Fernandez-Miranda, MD; A",
        "Affiliations": "Dimitrios Colevas, MD. Stanford University",
        "Introduction": "Non-intestinal-type adenocarcinoma (non-ITAC) is a rare subtype of primary sinonasal malignancy that remains a diagnosis of exclusion, characterized by glandular differentiation without defining features of intestinal-type differentiation or salivary gland neoplasia. Sinonasal non-ITAC are further subdivided into low-grade and high-grade categories, with the latter characterized by more aggressive clinical features including local invasion.",
        "Case Report": "An otherwise healthy 48-year-old man presented with two months of nasal obstruction and increased forgetfulness. MRI showed a large mass centered in the left nasal cavity with intracranial extension into the anterior and middle cranial fossae, associated with midline shift and early herniation (Stage IVB, cT4bN0M0). Biopsy demonstrated sinonasal non-ITAC, at least intermediate grade, favoring a seromucinous origin due to focal SOX10 and S100 positivity. NGS was notable for ATM loss-of-function alteration. He received 4 cycles of docetaxel/cisplatin/5-fluorouracil with partial response, course complicated by seizure during cycle one as well as sensory neuropathy. He underwent endoscopic and transbasal combined surgical resection, with residual involvement of the meninges and frontal brain (ypT4b). There was evidence of systemic treatment effect as demonstrated by lower-grade pathologic features on the resection specimen, however margin status could not be determined due to multiple unoriented edges of frontal brain fragments. He was then dispositioned to adjuvant chemoradiation (60 Gy in 30 fractions) with concurrent weekly cisplatin. He remains with no evidence of disease, now 16 months since initial diagnosis and 10 months since completion of treatment.",
        "Discussion/Conclusion": "There are no established risk factors or molecular phenotypes for sinonasal non-ITAC. Older case series may misclassify newer provisional entities as non-ITAC, particularly those defined by characteristic molecular features, including SWI/SNF complex-deficient sinonasal carcinoma. Numerous studies aggregate clinical outcomes for low- and high-grade non-ITAC, which are biologically and clinically quite distinct. We identified sixteen existing cases of high-grade sinonasal non-ITAC with associated clinical history in the literature. All except for a one case (94%) were managed with up-front surgery, and most patients received adjuvant radiotherapy (n=12, 75%). In a single case, a patient with orbital infiltration received initial chemotherapy followed by orbit-sparing surgery, adjuvant proton therapy, and concurrent cisplatin, however no post-treatment follow-up was reported. To our knowledge, this case represents the first report of locally advanced sinonasal non-ITAC treated with induction systemic therapy followed by surgery and adjuvant chemoradiation with both ongoing clinical and radiographic follow-up."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Multimodality Management of Non-Intestinal-Type Sinonasal Adenocarcinoma with Intracranial Extension: A Case Report and Literature Review</span>. <u>Fangdi Sun, MD</u>; Mobeen Rahman, MD; Peter H Hwang, MD; Beth M Beadle, MD; Juan C Fernandez-Miranda, MD; A. Dimitrios Colevas, MD. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Non-intestinal-type adenocarcinoma (non-ITAC) is a rare subtype of primary sinonasal malignancy that remains a diagnosis of exclusion, characterized by glandular differentiation without defining features of intestinal-type differentiation or salivary gland neoplasia. Sinonasal non-ITAC are further subdivided into low-grade and high-grade categories, with the latter characterized by more aggressive clinical features including local invasion.</p>\n\n<p><strong>Case Report</strong>: An otherwise healthy 48-year-old man presented with two months of nasal obstruction and increased forgetfulness. MRI showed a large mass centered in the left nasal cavity with intracranial extension into the anterior and middle cranial fossae, associated with midline shift and early herniation (Stage IVB, cT4bN0M0). Biopsy demonstrated sinonasal non-ITAC, at least intermediate grade, favoring a seromucinous origin due to focal SOX10 and S100 positivity. NGS was notable for ATM loss-of-function alteration. He received 4 cycles of docetaxel/cisplatin/5-fluorouracil with partial response, course complicated by seizure during cycle one as well as sensory neuropathy. He underwent endoscopic and transbasal combined surgical resection, with residual involvement of the meninges and frontal brain (ypT4b). There was evidence of systemic treatment effect as demonstrated by lower-grade pathologic features on the resection specimen, however margin status could not be determined due to multiple unoriented edges of frontal brain fragments. He was then dispositioned to adjuvant chemoradiation (60 Gy in 30 fractions) with concurrent weekly cisplatin. He remains with no evidence of disease, now 16 months since initial diagnosis and 10 months since completion of treatment.</p>\n\n<p><strong>Discussion/Conclusion</strong>: There are no established risk factors or molecular phenotypes for sinonasal non-ITAC. Older case series may misclassify newer provisional entities as non-ITAC, particularly those defined by characteristic molecular features, including SWI/SNF complex-deficient sinonasal carcinoma. Numerous studies aggregate clinical outcomes for low- and high-grade non-ITAC, which are biologically and clinically quite distinct. We identified sixteen existing cases of high-grade sinonasal non-ITAC with associated clinical history in the literature. All except for a one case (94%) were managed with up-front surgery, and most patients received adjuvant radiotherapy (n=12, 75%). In a single case, a patient with orbital infiltration received initial chemotherapy followed by orbit-sparing surgery, adjuvant proton therapy, and concurrent cisplatin, however no post-treatment follow-up was reported. To our knowledge, this case represents the first report of locally advanced sinonasal non-ITAC treated with induction systemic therapy followed by surgery and adjuvant chemoradiation with both ongoing clinical and radiographic follow-up.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153116/nITAC%20abstract%20figure.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153116--></body></html>"
    },
    {
      "uid": "P235",
      "content_id": "154126",
      "abstract_number": "P235",
      "poster_number": "P235",
      "title": "A unique case of rapidly progressive recurrent DEK-AFF2 fusion-associated papillary squamous cell carcinoma in pregnancy",
      "summary": "DEK::AFF2 fusion–associated carcinoma is exceedingly rare and prone to misdiagnosis. This case illustrates the diagnostic challenges encountered at both initial and recurrent presentation and highlights a dramatic acceleration of tumor growth during pregnancy. Hormonal influences on head and neck SCC are complex and existing studies suggest that estrogen and progesterone may exert tumor-promoting effects. This...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154126",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tonya Aaron, MD",
      "presenter": "Tonya Aaron, MD",
      "authors": "Muhammad El Shatanofy, MD; Stefanie Pena, MD; Tonya Aaron, MD ; Ricardo Pulido, MD; Jaylou M Velez Torres, MD; Larissa Sweeny, MD; Erin Kaye, MD",
      "normalized_authors": [
        "Muhammad El Shatanofy",
        "Stefanie Pena",
        "Tonya Aaron",
        "Ricardo Pulido",
        "Jaylou M Velez Torres",
        "Larissa Sweeny",
        "Erin Kaye"
      ],
      "affiliations": [
        "University of Miami Hospital"
      ],
      "normalized_institutions": [
        "University of Miami Hospital"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154126/Screenshot%202025-12-05%20at%2012_32_33%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154126/Screenshot%202025-12-05%20at%2012_32_33%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154126"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Muhammad El Shatanofy, MD; Stefanie Pena, MD; Tonya Aaron, MD ; Ricardo Pulido, MD; Jaylou M Velez Torres, MD; Larissa Sweeny, MD; Erin Kaye, MD",
        "Affiliations": "University of Miami Hospital",
        "Background": "DEK::AFF2 fusion–associated carcinoma is a newly recognized subtype of non-keratinizing squamous cell carcinoma in the WHO classification. Fewer than 100 cases have been reported, and true prevalence is likely higher due to its deceptively bland histology and resemblance to inverted papilloma and other benign sinonasal lesions. Diagnosis is frequently delayed because confirmation requires send-out molecular testing. Because DEK is upregulated by estrogen-receptor signaling—a known proliferative driver in ER-positive breast cancer—pregnancy may influence tumor growth. We present the first reported case of a rapidly progressive, suspected pregnancy-associated recurrent sinonasal carcinoma harboring a DEK::AFF2 fusion.",
        "Case": "A 39-year-old G1P0 at 29 weeks’ gestation presented with a month of worsening pain and swelling of the left nasal ala. She had previously undergone a medial maxillectomy in 2023 for a sinonasal lesion initially presumed to be a hemangioma but ultimately diagnosed as DEK::AFF2 papillary squamous cell carcinoma (SCC). She was lost to follow-up and now re-presented during pregnancy. MRI revealed a 2.9-cm heterogeneous mass concerning for tumor recurrence.",
        "Abstract": "Bedside FNA was negative, but persistent clinical concern prompted an open biopsy, which confirmed recurrent DEK::AFF2 papillary SCC. Initial tumor board recommendation was to proceed with surgery after full term delivery. However, the mass enlarged substantially over the next 4 weeks, with extension into the nasal cavity and fixation of the overlying skin. She was urgently re-presented at tumor board and at a multidisciplinary conference with maternal–fetal medicine. Given rapid progression, the team elected to induce labor at 37 weeks, followed by definitive surgery one week postpartum. Postpartum imaging demonstrated near doubling of the tumor to 4.5 cm over six weeks. She subsequently underwent a left medial maxillectomy with radical resection of the nasal ala and cheek soft tissue and reconstruction using a left osteocutaneous forearm flap. Final pathology confirmed DEK::AFF2 papillary SCC, pT4aN1, with lymphovascular invasion, no perineural invasion, negative margins, and one positive lymph node without extranodal extension. Post-operative course was uncomplicated and she was discharged on post-op day 10 with plans for adjuvant radiation therapy. Figure 1. Primary and recurrent intranasal papillary SCC. A.Pre-operative contrast-enhanced CT face (2022) showing a large nasal cavity mass with extensive bony remodeling B.Post-operative non-contrast CT face (2023) showing postsurgical changes without gross residual disease C.Non-contrast MRI (2025) revealing a 2.9 cm mass involving the left nasolabial fold/nasal ala and left nasal vestibule concerning for recurrence D.Post-delivery contrast-enhanced MRI (2025) showing enlarged 4.5 cm tumor centered at the left nasal vestibule with extensions along the alveolar rim of the maxilla.",
        "Conclusion": "DEK::AFF2 fusion–associated carcinoma is exceedingly rare and prone to misdiagnosis. This case illustrates the diagnostic challenges encountered at both initial and recurrent presentation and highlights a dramatic acceleration of tumor growth during pregnancy. Hormonal influences on head and neck SCC are complex and existing studies suggest that estrogen and progesterone may exert tumor-promoting effects. This case underscores the importance of early recognition, close surveillance, timely management of this uncommon entity, and suggests pregnancy as a potential variable of disease behavior worthy of further study."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A unique case of rapidly progressive recurrent DEK-AFF2 fusion-associated papillary squamous cell carcinoma in pregnancy</span>. Muhammad El Shatanofy, MD; Stefanie Pena, MD; <u>Tonya Aaron, MD</u>; Ricardo Pulido, MD; Jaylou M Velez Torres, MD; Larissa Sweeny, MD; Erin Kaye, MD. University of Miami Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>DEK::AFF2 fusion–associated carcinoma is a newly recognized subtype of non-keratinizing squamous cell carcinoma in the WHO classification. Fewer than 100 cases have been reported, and true prevalence is likely higher due to its deceptively bland histology and resemblance to inverted papilloma and other benign sinonasal lesions. Diagnosis is frequently delayed because confirmation requires send-out molecular testing. Because DEK is upregulated by estrogen-receptor signaling—a known proliferative driver in ER-positive breast cancer—pregnancy may influence tumor growth. We present the first reported case of a rapidly progressive, suspected pregnancy-associated recurrent sinonasal carcinoma harboring a DEK::AFF2 fusion.</p>\n\n<p><strong>Case: </strong>A 39-year-old G1P0 at 29 weeks’ gestation presented with a month of worsening pain and swelling of the left nasal ala. She had previously undergone a medial maxillectomy in 2023 for a sinonasal lesion initially presumed to be a hemangioma but ultimately diagnosed as DEK::AFF2 papillary squamous cell carcinoma (SCC). She was lost to follow-up and now re-presented during pregnancy. MRI revealed a 2.9-cm heterogeneous mass concerning for tumor recurrence.</p>\n\n<p>Bedside FNA was negative, but persistent clinical concern prompted an open biopsy, which confirmed recurrent DEK::AFF2 papillary SCC. Initial tumor board recommendation was to proceed with surgery after full term delivery. However, the mass enlarged substantially over the next 4 weeks, with extension into the nasal cavity and fixation of the overlying skin. She was urgently re-presented at tumor board and at a multidisciplinary conference with maternal–fetal medicine. Given rapid progression, the team elected to induce labor at 37 weeks, followed by definitive surgery one week postpartum.</p>\n\n<p>Postpartum imaging demonstrated near doubling of the tumor to 4.5 cm over six weeks. She subsequently underwent a left medial maxillectomy with radical resection of the nasal ala and cheek soft tissue and reconstruction using a left osteocutaneous forearm flap. Final pathology confirmed DEK::AFF2 papillary SCC, pT4aN1, with lymphovascular invasion, no perineural invasion, negative margins, and one positive lymph node without extranodal extension. Post-operative course was uncomplicated and she was discharged on post-op day 10 with plans for adjuvant radiation therapy.</p>\n\n<p><strong>Conclusion: </strong>DEK::AFF2 fusion–associated carcinoma is exceedingly rare and prone to misdiagnosis. This case illustrates the diagnostic challenges encountered at both initial and recurrent presentation and highlights a dramatic acceleration of tumor growth during pregnancy. Hormonal influences on head and neck SCC are complex and existing studies suggest that estrogen and progesterone may exert tumor-promoting effects. This case underscores the importance of early recognition, close surveillance, timely management of this uncommon entity, and suggests pregnancy as a potential variable of disease behavior worthy of further study.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154126/Screenshot%202025-12-05%20at%2012_32_33%E2%80%AFAM.png' /></p>\n\n<p>Figure 1. Primary and recurrent intranasal papillary SCC. A.Pre-operative contrast-enhanced CT face (2022) showing a large nasal cavity mass with extensive bony remodeling B.Post-operative non-contrast CT face (2023) showing postsurgical changes without gross residual disease C.Non-contrast MRI (2025) revealing a 2.9 cm mass involving the left nasolabial fold/nasal ala and left nasal vestibule concerning for recurrence D.Post-delivery contrast-enhanced MRI (2025) showing enlarged 4.5 cm tumor centered at the left nasal vestibule with extensions along the alveolar rim of the maxilla.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154126--></body></html>"
    },
    {
      "uid": "P236",
      "content_id": "153170",
      "abstract_number": "P236",
      "poster_number": "P236",
      "title": "De Novo Primary Sinonasal Salivary Duct Carcinoma: Expanding the Literature on a Rare Aggressive Salivary Gland Tumor in an Uncommon Anatomical Site",
      "summary": "Salivary duct carcinoma (SDC) is an uncommon but highly aggressive salivary gland malignancy and carries one of the worst prognoses among salivary cancer subtypes. Typically, SDC arises most commonly in the parotid glands of older males, with a small minority originating in the submandibular or minor salivary glands. Although the sinonasal mucosa lacks true salivary glands, its submucosal epithelium contains...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153170",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "J Macke",
      "presenter": "J Macke",
      "authors": "J Macke ; G Fleming; E Ostby; C Orgain",
      "normalized_authors": [
        "J Macke",
        "G Fleming",
        "E Ostby",
        "C Orgain"
      ],
      "affiliations": [
        "University of Vermont Medical Center"
      ],
      "normalized_institutions": [
        "University of Vermont Medical Center"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 463,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "J Macke ; G Fleming; E Ostby; C Orgain",
        "Affiliations": "University of Vermont Medical Center",
        "Abstract": "Salivary duct carcinoma (SDC) is an uncommon but highly aggressive salivary gland malignancy and carries one of the worst prognoses among salivary cancer subtypes. Typically, SDC arises most commonly in the parotid glands of older males, with a small minority originating in the submandibular or minor salivary glands. Although the sinonasal mucosa lacks true salivary glands, its submucosal epithelium contains glandular acini and ducts from which salivary gland tumors, including SDC, can arise. We present a rare case of de novo primary sinonasal SDC to expand the existing understanding of this pathology and highlight the importance of including SDC in the differential diagnosis of sinonasal masses. An 80-year-old male with a past medical history of cerebrovascular disease, coronary artery disease (status post three-vessel CABG), aortic stenosis, left ventricular hypertrophy, type 2 diabetes, obesity, and tobacco use presented to the emergency department with a one-year history of right-sided headache and congestion, as well as new symptoms of right eye diplopia, ptosis, and abducens palsy. CT and MR imaging demonstrated a 5 × 4 × 6.5 cm enhancing mass with bony erosion of the ethmoid septa, medial wall of the right maxillary sinus, medial right orbital wall, and cribriform plate. A small component extended into the floor of the anterior cranial fossa with associated dural thickening, although there was no gross parenchymal involvement. At follow-up, nasal endoscopy demonstrated a large, vascular mass filling the right nasal cavity adjacent to the middle turbinate. Biopsy showed invasive nests of tumor cells forming glandular structures with focal areas of comedonecrosis and lymphovascular invasion. Immunohistochemical (IHC) staining demonstrated positivity for androgen receptor (AR), cytokeratin, CK7, and GATA3. HER2/neu expression was also positive, albeit weakly. The IHC profile was consistent with SDC, and he was subsequently diagnosed with stage IVB (cT4bN0M0) poorly differentiated sinonasal SDC. Given his age and comorbidities, high-dose induction systemic therapy was not recommended. He underwent cisplatin-based concurrent chemoradiation therapy for six weeks. Unfortunately, three weeks after completing chemoradiation, he presented to the emergency department with an acute decline in mental status, dysphagia, and poor oral intake in the setting of a fall. Imaging demonstrated a subdural hematoma. The family ultimately opted for comfort measures, and the patient passed away one week later. Prior literature has identified only three genuine cases of primary sinonasal SDC, with just one arising de novo, making this, to our knowledge, only the second reported de novo primary sinonasal SDC. This rarity underscores the need for clinicians to maintain a broad differential diagnosis that includes uncommon but highly aggressive neoplasms such as SDC, where timely recognition is critical. Furthermore, the characteristic immunohistochemical profile of SDC carries significant therapeutic implications, as targeted approaches—including androgen deprivation therapy, trastuzumab-based regimens, and systemic chemotherapy—may complement surgical management and optimize patient outcomes when clinically appropriate."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>De Novo Primary Sinonasal Salivary Duct Carcinoma: Expanding the Literature on a Rare Aggressive Salivary Gland Tumor in an Uncommon Anatomical Site</span>. <u>J Macke</u>; G Fleming; E Ostby; C Orgain. University of Vermont Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Salivary duct carcinoma (SDC) is an uncommon but highly aggressive salivary gland malignancy and carries one of the worst prognoses among salivary cancer subtypes. Typically, SDC arises most commonly in the parotid glands of older males, with a small minority originating in the submandibular or minor salivary glands. Although the sinonasal mucosa lacks true salivary glands, its submucosal epithelium contains glandular acini and ducts from which salivary gland tumors, including SDC, can arise. We present a rare case of de novo primary sinonasal SDC to expand the existing understanding of this pathology and highlight the importance of including SDC in the differential diagnosis of sinonasal masses.</p>\n\n<p>An 80-year-old male with a past medical history of cerebrovascular disease, coronary artery disease (status post three-vessel CABG), aortic stenosis, left ventricular hypertrophy, type 2 diabetes, obesity, and tobacco use presented to the emergency department with a one-year history of right-sided headache and congestion, as well as new symptoms of right eye diplopia, ptosis, and abducens palsy. CT and MR imaging demonstrated a 5 × 4 × 6.5 cm enhancing mass with bony erosion of the ethmoid septa, medial wall of the right maxillary sinus, medial right orbital wall, and cribriform plate. A small component extended into the floor of the anterior cranial fossa with associated dural thickening, although there was no gross parenchymal involvement. At follow-up, nasal endoscopy demonstrated a large, vascular mass filling the right nasal cavity adjacent to the middle turbinate.</p>\n\n<p>Biopsy showed invasive nests of tumor cells forming glandular structures with focal areas of comedonecrosis and lymphovascular invasion. Immunohistochemical (IHC) staining demonstrated positivity for androgen receptor (AR), cytokeratin, CK7, and GATA3. HER2/neu expression was also positive, albeit weakly. The IHC profile was consistent with SDC, and he was subsequently diagnosed with stage IVB (cT4bN0M0) poorly differentiated sinonasal SDC. Given his age and comorbidities, high-dose induction systemic therapy was not recommended. He underwent cisplatin-based concurrent chemoradiation therapy for six weeks. Unfortunately, three weeks after completing chemoradiation, he presented to the emergency department with an acute decline in mental status, dysphagia, and poor oral intake in the setting of a fall. Imaging demonstrated a subdural hematoma. The family ultimately opted for comfort measures, and the patient passed away one week later.</p>\n\n<p>Prior literature has identified only three genuine cases of primary sinonasal SDC, with just one arising de novo, making this, to our knowledge, only the second reported de novo primary sinonasal SDC. This rarity underscores the need for clinicians to maintain a broad differential diagnosis that includes uncommon but highly aggressive neoplasms such as SDC, where timely recognition is critical. Furthermore, the characteristic immunohistochemical profile of SDC carries significant therapeutic implications, as targeted approaches—including androgen deprivation therapy, trastuzumab-based regimens, and systemic chemotherapy—may complement surgical management and optimize patient outcomes when clinically appropriate.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153170--></body></html>"
    },
    {
      "uid": "P237",
      "content_id": "154422",
      "abstract_number": "P237",
      "poster_number": "P237",
      "title": "Rates of Cerebrospinal Fluid Leaks in Patients with Ehlers Danlos Syndrome",
      "summary": "Patients with EDS have a significantly elevated risk, almost 18 times higher, of developing CSF leaks compared to the general population. Our findings support the hypothesized association between connective tissue fragility and spontaneous CSF leak development. Management guidelines of EDS should include consideration of CSF leaks in these patients, especially in those presenting with orthostatic headaches.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154422",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Veenadhari Kollipara, BA",
      "presenter": "Veenadhari Kollipara, BA",
      "authors": "Veenadhari Kollipara, BA ; Hera Mukhtar, BS; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS",
      "normalized_authors": [
        "Veenadhari Kollipara",
        "Hera Mukhtar",
        "Kunal A Koka",
        "F. Jeffrey Lorenz",
        "Neerav Goyal"
      ],
      "affiliations": [
        "Penn State College of Medicine"
      ],
      "normalized_institutions": [
        "Penn State College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 327,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Veenadhari Kollipara, BA ; Hera Mukhtar, BS; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS",
        "Affiliations": "Penn State College of Medicine",
        "Background": "Spontaneous cerebrospinal fluid (CSF) leaks are a rare but potentially debilitating neurological complication which has been associated with Ehlers-Danlos syndrome (EDS) and other hypermobile connective tissue disorders (CTDs). The pathogenesis of spontaneous CSF leaks in patients with EDS is not completely understood, however, the increased dural fragility due to connective tissue abnormalities is a leading hypothesis. Population level data to quantify the risk of CSF leak development in patients with CTDs, specifically EDS, is lacking. The objective of this study is to determine rates of CSF leaks in patients with EDS.",
        "Methods": "Patients diagnosed with EDS with a visit from 2009 to 2018 with ≥5 years of follow up, were queried in the TriNetX Research Network. Exclusion criteria included patients with: benign intracranial hypertension, Marfan syndrome, intracranial injuries, skull and facial bone fractures, spinal cord and nerve injuries, and benign and malignant neoplasms of the meninges and brain. The primary outcome was the rates of CSF leaks in patients with EDS versus patients who did not have EDS.",
        "Results": "We identified 51,608 patients in the EDS cohort and 41,311,637 patients in the no-EDS cohort. The average age of the EDS cohort was 25.3 years. Females made up 82.4% (n = 42,523) of the EDS cohort, with males making up 16.41% (n = 8,470). The risk of developing a CSF leak in the EDS cohort was 1.09% (n = 560) and 0.06% (n = 25,616) in the no-EDS cohort. The risk ratio of the EDS cohort developing a CSF leak compared with the no-EDS cohort was 17.68 (95% CI: 16.10 - 19.02, p < 0.0001).",
        "Conclusions": "Patients with EDS have a significantly elevated risk, almost 18 times higher, of developing CSF leaks compared to the general population. Our findings support the hypothesized association between connective tissue fragility and spontaneous CSF leak development. Management guidelines of EDS should include consideration of CSF leaks in these patients, especially in those presenting with orthostatic headaches."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rates of Cerebrospinal Fluid Leaks in Patients with Ehlers Danlos Syndrome</span>. <u>Veenadhari Kollipara, BA</u>; Hera Mukhtar, BS; Kunal A Koka, BS; F. Jeffrey Lorenz, MD; Neerav Goyal, MD, MPH, FACS. Penn State College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Spontaneous cerebrospinal fluid (CSF) leaks are a rare but potentially debilitating neurological complication which has been associated with Ehlers-Danlos syndrome (EDS) and other hypermobile connective tissue disorders (CTDs). The pathogenesis of spontaneous CSF leaks in patients with EDS is not completely understood, however, the increased dural fragility due to connective tissue abnormalities is a leading hypothesis. Population level data to quantify the risk of CSF leak development in patients with CTDs, specifically EDS, is lacking. The objective of this study is to determine rates of CSF leaks in patients with EDS.</p>\n\n<p><strong>Methods</strong>: Patients diagnosed with EDS with a visit from 2009 to 2018 with ≥5 years of follow up, were queried in the TriNetX Research Network. Exclusion criteria included patients with: benign intracranial hypertension, Marfan syndrome, intracranial injuries, skull and facial bone fractures, spinal cord and nerve injuries, and benign and malignant neoplasms of the meninges and brain. The primary outcome was the rates of CSF leaks in patients with EDS versus patients who did not have EDS.</p>\n\n<p><strong>Results</strong>: We identified 51,608 patients in the EDS cohort and 41,311,637 patients in the no-EDS cohort. The average age of the EDS cohort was 25.3 years. Females made up 82.4% (n = 42,523) of the EDS cohort, with males making up 16.41% (n = 8,470). The risk of developing a CSF leak in the EDS cohort was 1.09% (n = 560) and 0.06% (n = 25,616) in the no-EDS cohort. The risk ratio of the EDS cohort developing a CSF leak compared with the no-EDS cohort was 17.68 (95% CI: 16.10 - 19.02, p < 0.0001).</p>\n\n<p><strong>Conclusions</strong>: Patients with EDS have a significantly elevated risk, almost 18 times higher, of developing CSF leaks compared to the general population. Our findings support the hypothesized association between connective tissue fragility and spontaneous CSF leak development. Management guidelines of EDS should include consideration of CSF leaks in these patients, especially in those presenting with orthostatic headaches.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154422--></body></html>"
    },
    {
      "uid": "P238",
      "content_id": "153995",
      "abstract_number": "P238",
      "poster_number": "P238",
      "title": "Atypical Presentation of Eagle syndrome with Styloid Process Protrusion through Tongue Base",
      "summary": "This is the first reported case of Eagle syndrome with styloid process protrusion through the pharyngeal wall leading to secondary infection and parapharyngeal abscess. This case highlights the importance of considering Eagle syndrome in the differential diagnosis of unexplained tongue deviation, dysarthria, or apparent tongue-base masses, and emphasizes transoral robotic styloidectomy as an effective, minimally...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153995",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alice Lin, MD, FACS",
      "presenter": "Alice Lin, MD, FACS",
      "authors": "Kasey Bowyer, AB 1 ; Alice Lin, MD, FACS 2",
      "normalized_authors": [
        "Kasey Bowyer, AB",
        "Alice Lin"
      ],
      "affiliations": [
        "Kaiser Permanente Bernard J. Tyson School of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group"
      ],
      "normalized_institutions": [
        "Kaiser Permanente Bernard J. Tyson School of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group"
      ],
      "session_type": "Poster",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 288,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kasey Bowyer, AB 1 ; Alice Lin, MD, FACS 2",
        "Affiliations": "1 Kaiser Permanente Bernard J. Tyson School of Medicine; 2 Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group",
        "Background": "Eagle syndrome, caused by elongation of the styloid process or calcification of the stylohyoid ligament, can irritate or compress adjacent neurovascular structures and typically presents with cervicofacial pain, dysphagia, or otalgia. Cranial nerve involvement is uncommon, and protrusion of the styloid process into the oropharynx with secondary infection has not previously been reported.",
        "Methods": "We report a case of Eagle syndrome with an atypical neurologic presentation, styloid process protrusion into the oropharynx mimicking a tongue-based mass, and subsequent parapharyngeal abscess, managed with transoral robotic-assisted bilateral tonsillectomy and styloidectomy.",
        "Results": "A 49-year-old woman presented with tongue deviation, intermittent dysarthria, and oropharyngeal discomfort. Initial neurologic evaluation, brain imaging, and electromyography testing were unrevealing, leading to a diagnosis of functional neurologic disorder. Otolaryngolic examination identified left tongue atrophy and a vallecular/tonsillar mass. Biopsy initially suggested a hamartoma. Subsequent evaluation of neck CT demonstrated bilateral elongated, calcified stylohyoid ligaments with the left styloid tip protruding through the pharyngeal wall, later complicated by a parapharyngeal abscess. After resolution of the infection, the patient underwent transoral robotic-assisted bilateral tonsillectomy and styloidectomy. Intraoperatively, the left styloid process was fractured with the distal segment protruding into the tongue base and the proximal segment measuring over 5 cm in length and 8 mm in thickness. The contralateral styloid was similarly elongated. Postoperatively, tongue deviation and dysarthria resolved, and repeat electromyography confirmed normal hypoglossal function.",
        "Conclusion": "This is the first reported case of Eagle syndrome with styloid process protrusion through the pharyngeal wall leading to secondary infection and parapharyngeal abscess. This case highlights the importance of considering Eagle syndrome in the differential diagnosis of unexplained tongue deviation, dysarthria, or apparent tongue-base masses, and emphasizes transoral robotic styloidectomy as an effective, minimally invasive approach that can prevent misdiagnosis and infectious complications."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Atypical Presentation of Eagle syndrome with Styloid Process Protrusion through Tongue Base</span>. Kasey Bowyer, AB<sup>1</sup>; <u>Alice Lin, MD, FACS</u><sup>2</sup>. <sup>1</sup>Kaiser Permanente Bernard J. Tyson School of Medicine; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Southern California Medical Group<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Eagle syndrome, caused by elongation of the styloid process or calcification of the stylohyoid ligament, can irritate or compress adjacent neurovascular structures and typically presents with cervicofacial pain, dysphagia, or otalgia. Cranial nerve involvement is uncommon, and protrusion of the styloid process into the oropharynx with secondary infection has not previously been reported.</p>\n\n<p><strong>Methods:</strong> We report a case of Eagle syndrome with an atypical neurologic presentation, styloid process protrusion into the oropharynx mimicking a tongue-based mass, and subsequent parapharyngeal abscess, managed with transoral robotic-assisted bilateral tonsillectomy and styloidectomy.</p>\n\n<p><strong>Results:</strong> A 49-year-old woman presented with tongue deviation, intermittent dysarthria, and oropharyngeal discomfort. Initial neurologic evaluation, brain imaging, and electromyography testing were unrevealing, leading to a diagnosis of functional neurologic disorder. Otolaryngolic examination identified left tongue atrophy and a vallecular/tonsillar mass. Biopsy initially suggested a hamartoma. Subsequent evaluation of neck CT demonstrated bilateral elongated, calcified stylohyoid ligaments with the left styloid tip protruding through the pharyngeal wall, later complicated by a parapharyngeal abscess. After resolution of the infection, the patient underwent transoral robotic-assisted bilateral tonsillectomy and styloidectomy. Intraoperatively, the left styloid process was fractured with the distal segment protruding into the tongue base and the proximal segment measuring over 5 cm in length and 8 mm in thickness. The contralateral styloid was similarly elongated. Postoperatively, tongue deviation and dysarthria resolved, and repeat electromyography confirmed normal hypoglossal function.  </p>\n\n<p><strong>Conclusion:</strong> This is the first reported case of Eagle syndrome with styloid process protrusion through the pharyngeal wall leading to secondary infection and parapharyngeal abscess. This case highlights the importance of considering Eagle syndrome in the differential diagnosis of unexplained tongue deviation, dysarthria, or apparent tongue-base masses, and emphasizes transoral robotic styloidectomy as an effective, minimally invasive approach that can prevent misdiagnosis and infectious complications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153995--></body></html>"
    },
    {
      "uid": "P239",
      "content_id": "154547",
      "abstract_number": "P239",
      "poster_number": "P239",
      "title": "Metastatic Nodal Burden, Not Lymph Node Yield or Ratio, Predicts Recurrence After Elective Neck Dissection for Oral cavity Squamous Cell Carcinoma",
      "summary": "In END-treated OCSCC, LNY and LNR did not independently predict DFS, whereas metastatic nodal burden (≥2 positive nodes) and ECE were the dominant determinants of recurrence. These findings challenge the clinical utility of fixed nodal yield thresholds and support prioritizing biology-driven risk factors and intensified early surveillance for patients with multiple metastatic nodes or ECE.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154547",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Udeerna Tippabhatla",
      "presenter": "Udeerna Tippabhatla",
      "authors": "Udeerna Tippabhatla 1 ; Jin Hua Li 1 ; Rachel Harter 1 ; Vivienne Au 2 ; Aviram Mizrachi 1",
      "normalized_authors": [
        "Udeerna Tippabhatla",
        "Jin Hua Li",
        "Rachel Harter",
        "Vivienne Au",
        "Aviram Mizrachi"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 329,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Udeerna Tippabhatla 1 ; Jin Hua Li 1 ; Rachel Harter 1 ; Vivienne Au 2 ; Aviram Mizrachi 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; 2 Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA",
        "Background": "Lymph node yield (LNY) and lymph node ratio (LNR) are frequently used as surgical quality and prognostic metrics after elective neck dissection (END) for oral cavity squamous cell carcinoma (OCSCC), but their independent prognostic value remains unclear. Metastatic nodal burden and adverse pathologic features may offer more biologically relevant risk stratification. This study evaluated the prognostic relevance of LNY, LNR, and metastatic nodal burden in a contemporary END cohort.",
        "Methods": "A retrospective review was performed of 53 consecutive OCSCC patients undergoing END with available follow-up. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up. LNR performance for 3-year DFS was assessed with time-dependent ROC analysis. Kaplan–Meier and Cox proportional hazards models evaluated LNY (≤13, ≤18), continuous and categorical LNR (cutoff 0.024), tumor depth, extranodal extension (ECE), perineural invasion (PNI), lymphovascular invasion (LVI), adjuvant radiotherapy, and metastatic nodal burden (≥2 positive nodes).",
        "Results": "Fifteen patients (28%) developed recurrence, predominantly locoregional, with a median time to recurrence of 1.0 year. LNY did not associate with DFS using 13- or 18-node thresholds (log-rank p=0.3-0.6), and LNY did not differ between recurrence and non-recurrence groups (p=0.49). LNR showed poor discrimination for 3-year DFS (AUC 0.54) and was not prognostic as a continuous or dichotomized variable (log-rank p=0.50; Cox p=0.88). Higher LNR values, however, correlated with aggressive pathology, including greater depth of invasion, ECE, PNI, and use of adjuvant radiotherapy. Patients with ≥2 positive nodes had nearly fourfold higher recurrence risk (HR 3.86, 95% CI 1.06–14.1, p=0.04), and ECE conferred markedly elevated risk (HR 35.0, p<0.001).",
        "Conclusions": "In END-treated OCSCC, LNY and LNR did not independently predict DFS, whereas metastatic nodal burden (≥2 positive nodes) and ECE were the dominant determinants of recurrence. These findings challenge the clinical utility of fixed nodal yield thresholds and support prioritizing biology-driven risk factors and intensified early surveillance for patients with multiple metastatic nodes or ECE."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Metastatic Nodal Burden, Not Lymph Node Yield or Ratio, Predicts Recurrence After Elective Neck Dissection for Oral cavity Squamous Cell Carcinoma</span>. <u>Udeerna Tippabhatla</u><sup>1</sup>; Jin Hua Li<sup>1</sup>; Rachel Harter<sup>1</sup>; Vivienne Au<sup>2</sup>; Aviram Mizrachi<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Lymph node yield (LNY) and lymph node ratio (LNR) are frequently used as surgical quality and prognostic metrics after elective neck dissection (END) for oral cavity squamous cell carcinoma (OCSCC), but their independent prognostic value remains unclear. Metastatic nodal burden and adverse pathologic features may offer more biologically relevant risk stratification. This study evaluated the prognostic relevance of LNY, LNR, and metastatic nodal burden in a contemporary END cohort.</p>\n\n<p><strong>Methods: </strong>A retrospective review was performed of 53 consecutive OCSCC patients undergoing END with available follow-up. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up. LNR performance for 3-year DFS was assessed with time-dependent ROC analysis. Kaplan–Meier and Cox proportional hazards models evaluated LNY (≤13, ≤18), continuous and categorical LNR (cutoff 0.024), tumor depth, extranodal extension (ECE), perineural invasion (PNI), lymphovascular invasion (LVI), adjuvant radiotherapy, and metastatic nodal burden (≥2 positive nodes).</p>\n\n<p><strong>Results: </strong>Fifteen patients (28%) developed recurrence, predominantly locoregional, with a median time to recurrence of 1.0 year. LNY did not associate with DFS using 13- or 18-node thresholds (log-rank p=0.3-0.6), and LNY did not differ between recurrence and non-recurrence groups (p=0.49). LNR showed poor discrimination for 3-year DFS (AUC 0.54) and was not prognostic as a continuous or dichotomized variable (log-rank p=0.50; Cox p=0.88). Higher LNR values, however, correlated with aggressive pathology, including greater depth of invasion, ECE, PNI, and use of adjuvant radiotherapy. Patients with ≥2 positive nodes had nearly fourfold higher recurrence risk (HR 3.86, 95% CI 1.06–14.1, p=0.04), and ECE conferred markedly elevated risk (HR 35.0, p<0.001).</p>\n\n<p><strong>Conclusions:</strong> In END-treated OCSCC, LNY and LNR did not independently predict DFS, whereas metastatic nodal burden (≥2 positive nodes) and ECE were the dominant determinants of recurrence. These findings challenge the clinical utility of fixed nodal yield thresholds and support prioritizing biology-driven risk factors and intensified early surveillance for patients with multiple metastatic nodes or ECE.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154547--></body></html>"
    },
    {
      "uid": "P240",
      "content_id": "154773",
      "abstract_number": "P240",
      "poster_number": "P240",
      "title": "To evaluate the mean change in health-related quality of life (HRQoL) in oral cancer patients by comparing preoperative and postoperative scores following primary surgical treatment in a Tertiary",
      "summary": "A highly significant improvement in HRQoL was noted following primary surgical treatment of oral cancer. Postoperative HRQoL scores were markedly better than preoperative scores, demonstrating the positive impact of surgery on patient quality of life. Significant differences were also found between different surgical resection types.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154773",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe",
      "presenter": "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe",
      "authors": "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe",
      "normalized_authors": [
        "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe"
      ],
      "affiliations": [
        "Baqai Medical Univeristy (Assistant proffesor)"
      ],
      "normalized_institutions": [
        "Baqai Medical Univeristy (Assistant proffesor)"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 255,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Duration",
        "Subjects and Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe",
        "Affiliations": "Baqai Medical Univeristy (Assistant proffesor)",
        "Objective": "To evaluate the mean change in health-related quality of life (HRQoL) in oral cancer patients by comparing preoperative and postoperative scores following primary surgical treatment in tertiary care hospital",
        "Study Design": "Quasi-experimental study.",
        "Setting": "Department of Oral and Maxillofacial Surgery, Abbasi Shaheed Hospital, Karachi.",
        "Duration": "One year",
        "Subjects and Methods": "All patients meeting the inclusion criteria and presenting to the department during the study period were enrolled. Informed consent was obtained after explaining the procedure, risks, and benefits. HRQoL was assessed using the University of Washington Quality of Life (UW-QOL) questionnaire. Scores ranged from 10 (normal function) to 50 (greatest dysfunction), with lower scores indicating better quality of life. Preoperative and postoperative scores were recorded and analyzed. Data were documented on a structured proforma.",
        "Results": "A total of 60 patients were included, with a mean age of 51.93 ± 13.84 years. Of these, 48 (80%) were male and 12 (20%) were female. The mean preoperative HRQoL score was 32.25 ± 19.13, while the mean postoperative score was 15.16 ± 21.67. The mean change in HRQoL was 17.08 ± 9.04, with a 95% confidence interval of 14.74–19.24, indicating a highly significant improvement (P = 0.0001). A statistically significant difference in HRQoL was also observed between patients undergoing marginal versus segmental mandibular resection.",
        "Conclusion": "A highly significant improvement in HRQoL was noted following primary surgical treatment of oral cancer. Postoperative HRQoL scores were markedly better than preoperative scores, demonstrating the positive impact of surgery on patient quality of life. Significant differences were also found between different surgical resection types."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>To evaluate the mean change in health-related quality of life (HRQoL) in oral cancer patients by comparing preoperative and postoperative scores following primary surgical treatment in a Tertiary Care Hospital</span>. <u>Seherish Khan Abbasi, BDS, Gold Medalist, Fcps, chpe</u>. Baqai Medical Univeristy (Assistant proffesor)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate the mean change in health-related quality of life (HRQoL) in oral cancer patients by comparing preoperative and postoperative scores following primary surgical treatment in tertiary care hospital</p>\n\n<p><strong>Study Design: </strong>Quasi-experimental study.</p>\n\n<p><strong>Setting: </strong>Department of Oral and Maxillofacial Surgery, Abbasi Shaheed Hospital, Karachi.</p>\n\n<p><strong>Duration: </strong>One year</p>\n\n<p><strong>Subjects and Methods: </strong>All patients meeting the inclusion criteria and presenting to the department during the study period were enrolled. Informed consent was obtained after explaining the procedure, risks, and benefits. HRQoL was assessed using the University of Washington Quality of Life (UW-QOL) questionnaire. Scores ranged from 10 (normal function) to 50 (greatest dysfunction), with lower scores indicating better quality of life. Preoperative and postoperative scores were recorded and analyzed. Data were documented on a structured proforma.</p>\n\n<p><strong>Results: </strong>A total of 60 patients were included, with a mean age of 51.93 ± 13.84 years. Of these, 48 (80%) were male and 12 (20%) were female. The mean preoperative HRQoL score was 32.25 ± 19.13, while the mean postoperative score was 15.16 ± 21.67. The mean change in HRQoL was 17.08 ± 9.04, with a 95% confidence interval of 14.74–19.24, indicating a highly significant improvement (P = 0.0001). A statistically significant difference in HRQoL was also observed between patients undergoing marginal versus segmental mandibular resection.</p>\n\n<p><strong>Conclusion: </strong>A highly significant improvement in HRQoL was noted following primary surgical treatment of oral cancer. Postoperative HRQoL scores were markedly better than preoperative scores, demonstrating the positive impact of surgery on patient quality of life. Significant differences were also found between different surgical resection types.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154773--></body></html>"
    },
    {
      "uid": "P241",
      "content_id": "154363",
      "abstract_number": "P241",
      "poster_number": "P241",
      "title": "Prevalence and predictors of enteral nutrition following curative resection of oral cavity squamous cell carcinoma: systematic review and meta-analysis",
      "summary": "EN use is common in patients with oral cavity cancer, particularly older patients following multimodal treatment and in those with higher tumor stage or extensive tongue resection.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154363",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Victor H Albornoz Alvarez, MD",
      "presenter": "Victor H Albornoz Alvarez, MD",
      "authors": "Victor H Albornoz Alvarez, MD ; Srivatsa S Vasudevan, MD; Madeline Polson, BS, MS; Cherie-Ann O Nathan, MD, FACS; Olinde Lindsay, MD",
      "normalized_authors": [
        "Victor H Albornoz Alvarez",
        "Srivatsa S Vasudevan",
        "Madeline Polson",
        "Cherie-Ann O Nathan",
        "Olinde Lindsay"
      ],
      "affiliations": [
        "LSU Health Shreveport"
      ],
      "normalized_institutions": [
        "LSU Health Shreveport"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 341,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Victor H Albornoz Alvarez, MD ; Srivatsa S Vasudevan, MD; Madeline Polson, BS, MS; Cherie-Ann O Nathan, MD, FACS; Olinde Lindsay, MD",
        "Affiliations": "LSU Health Shreveport",
        "Objective": "To evaluate the prevalence, duration, and key predictors of enteral nutrition (EN) use in patients treated surgically for oral cavity cancer.",
        "Study Design": "Systematic review and meta-analysis.",
        "Methods": "A comprehensive literature search was conducted to identify studies reporting rates and predictors of EN in patients with oral cavity squamous cell carcinoma treated surgically. Prevalence of EN at various time points, as well as by treatment modality, was pooled using a random-effects model. Predictors of EN incidence were analyzed using pooled odds ratios. Meta-regression was performed to identify patient and treatment factors associated with overall EN prevalence.",
        "Results": "A total of 27 studies comprising 13,759 patients with oral cavity cancer were included, with a mean age of 58.4 years (SD 4.46). The pooled prevalence of overall EN was 25.0% (95% CI: 16.8-35.5%). EN prevalence declined over time, with 18.5% (95% CI: 13.2-25.4%) of patients requiring EN at 6 months and 9.1% (95% CI: 3.9-20.1%) at 12 months post-treatment. Subgroup analysis showed EN prevalence rates of 5.2% (95% CI: 4.2-6.3%) following surgery alone, 15.0% (95% CI: 5.1-36.8%) for surgery with radiotherapy, and 35.6% (95% CI: 6.8-80.8%) for surgery with chemoradiotherapy. The prevalence of EN at the tongue subsite was 30.5% (95% CI: 13.1-56.2%. Advanced tumor stage (T3/T4 vs T1/T2) significantly increased the risk of requiring EN (OR: 5.2, 95% CI: 2.7-9.9, p<0.0001), as did resection of more than 50% of the tongue (OR: 3.8, 95% CI: 1.4-10.3, p=0.01). On meta-regression, increasing age had a significant impact on EN prevalence (p=0.04; coefficient: 0.0004, 95% CI: 0.0001-0.0008), while sex, year of publication, salvage surgery status, use of free flaps, mean follow-up duration, and mandibulectomy were not significantly associated with EN prevalence.",
        "Conclusion": "EN use is common in patients with oral cavity cancer, particularly older patients following multimodal treatment and in those with higher tumor stage or extensive tongue resection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prevalence and predictors of enteral nutrition following curative resection of oral cavity squamous cell carcinoma: systematic review and meta-analysis</span>. <u>Victor H Albornoz Alvarez, MD</u>; Srivatsa S Vasudevan, MD; Madeline Polson, BS, MS; Cherie-Ann O Nathan, MD, FACS; Olinde Lindsay, MD. LSU Health Shreveport<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate the prevalence, duration, and key predictors of enteral nutrition (EN) use in patients treated surgically for oral cavity cancer.</p>\n\n<p><strong>Study Design: </strong>Systematic review and meta-analysis.</p>\n\n<p><strong>Methods: </strong>A comprehensive literature search was conducted to identify studies reporting rates and predictors of EN in patients with oral cavity squamous cell carcinoma treated surgically. Prevalence of EN at various time points, as well as by treatment modality, was pooled using a random-effects model. Predictors of EN incidence were analyzed using pooled odds ratios. Meta-regression was performed to identify patient and treatment factors associated with overall EN prevalence.</p>\n\n<p><strong>Results: </strong>A total of 27 studies comprising 13,759 patients with oral cavity cancer were included, with a mean age of 58.4 years (SD 4.46). The pooled prevalence of overall EN was 25.0% (95% CI: 16.8-35.5%). EN prevalence declined over time, with 18.5% (95% CI: 13.2-25.4%) of patients requiring EN at 6 months and 9.1% (95% CI: 3.9-20.1%) at 12 months post-treatment. Subgroup analysis showed EN prevalence rates of 5.2% (95% CI: 4.2-6.3%) following surgery alone, 15.0% (95% CI: 5.1-36.8%) for surgery with radiotherapy, and 35.6% (95% CI: 6.8-80.8%) for surgery with chemoradiotherapy. The prevalence of EN at the tongue subsite was 30.5% (95% CI: 13.1-56.2%. Advanced tumor stage (T3/T4 vs T1/T2) significantly increased the risk of requiring EN (OR: 5.2, 95% CI: 2.7-9.9, p<0.0001), as did resection of more than 50% of the tongue (OR: 3.8, 95% CI: 1.4-10.3, p=0.01). On meta-regression, increasing age had a significant impact on EN prevalence (p=0.04; coefficient: 0.0004, 95% CI: 0.0001-0.0008), while sex, year of publication, salvage surgery status, use of free flaps, mean follow-up duration, and mandibulectomy were not significantly associated with EN prevalence.</p>\n\n<p><strong>Conclusion: </strong>EN use is common in patients with oral cavity cancer, particularly older patients following multimodal treatment and in those with higher tumor stage or extensive tongue resection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154363--></body></html>"
    },
    {
      "uid": "P242",
      "content_id": "153628",
      "abstract_number": "P242",
      "poster_number": "P242",
      "title": "The Dark Side of Head and Neck Squamous Cell Carcinoma",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) is a malignancy typically associated with smoking cigarettes and alcohol consumption among males who are above 50 years-old. However, there are distinct HNSCC cases that are out of sight, including etiologic factors and treatment approaches. The understanding of this fraction of HNSCC cases starts with the description of patients’ characteristics. Then, this study...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153628",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Isabela Firigato, MSc",
      "presenter": "Isabela Firigato, MSc",
      "authors": "Isabela Firigato, MSc ; Fernanda Goncalves, Ph, D",
      "normalized_authors": [
        "Isabela Firigato",
        "Fernanda Goncalves, Ph, D"
      ],
      "affiliations": [
        "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM-40 do Hospital das Clinicas HCFMUSP, Faculdadde de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR"
      ],
      "normalized_institutions": [
        "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM-40 do Hospital das Clinicas HCFMUSP, Faculdadde de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 519,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Isabela Firigato, MSc ; Fernanda Goncalves, Ph, D",
        "Affiliations": "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM-40 do Hospital das Clinicas HCFMUSP, Faculdadde de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) is a malignancy typically associated with smoking cigarettes and alcohol consumption among males who are above 50 years-old. However, there are distinct HNSCC cases that are out of sight, including etiologic factors and treatment approaches. The understanding of this fraction of HNSCC cases starts with the description of patients’ characteristics. Then, this study aimed to describe the profile of unusual HNSCC patients comparing retrospective and prospective groups. A hospital-based longitudinal study was performed that HNSCC patients were enrolled in 2000-2011 and 2023-2025, each period of time from two public health institutions at São Paulo city. Two cohorts were composed: I) Young HNSCC patients that included participants who were from 18 to 40 years-old with a HNSCC HPV (human papillomavirus)-negative diagnosis; II) Non-exposed HNSCC patients that included participants above 40 years-old without exposition to tobacco, alcohol, and virus infection. Comparison between the two periods of time was carried out about frequency and proportion. Young HNSCC patients. A total of 21 retrospective and 13 prospective patients were included, which showed an increased proportion of early-onset HNSCC that occurred 1.1 cases/year from 2000 to 2011, while a total of 10.5 cases/year during the period of 2023-2025. The majority of participants were males from both groups (80.9% and 76.9%, respectively) with a mean age of 36.6 (4.7) years-old. Cigarette smoking was more prevalent among retrospective young HNSCC patients that was observed 2/3 of smokers in comparison to 1/4 smokers among prospective patients. On the other hand, the never smokers were prevalent among prospective HNSCC patients, over 9/10 than 1/10 of retrospective ones. About the alcohol consumption, young drinker patients were observed in similar frequencies between retrospective and prospective participants (47.6% and 53.8%, respectively) as long as never drinking patients from both generations (28.6% and 38.5%, respectively). The anatomic site most affected by the malignancy was the oral cavity that was diagnosed in 69.2% of prospective young HNSCC patients and 61.9% of retrospective ones. Non-exposed HNSCC patients. A total of 17 retrospective and 34 prospective participants were included, which also indicates the proportion increase over years: from 1.7 cases/year during 2000-2011 to 11.3 cases/year over 2023-2025. There was a shift in the sex of patients over generations that retrospective non-exposed HNSCC patients were composed of 58.8% of males, but 73.5% of prospective ones were females, which resulted in a ratio of 1 man to 2 women during 2023-2025. Moreover, the mean age was similar between the two periods of time that was 62.5 (11.1) years-old for retrospective non-exposed HNSCC patients and 61.2 (12.2) years-old for prospective ones. The oral cavity was also the main anatomic area where the malignancy was detected in both groups: 70.5% of retrospective and 85.3% of prospective cases. The dark side of HNSCC includes unusual cases that have been hidden by the most frequent HNSCC cases. However, the prevalence of these distinct HNSCC cases is increasing at least in São Paulo, Brazil."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Dark Side of Head and Neck Squamous Cell Carcinoma</span>. <u>Isabela Firigato, MSc</u>; Fernanda Goncalves, Ph, D. Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM-40 do Hospital das Clinicas HCFMUSP, Faculdadde de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) is a malignancy typically associated with smoking cigarettes and alcohol consumption among males who are above 50 years-old. However, there are distinct HNSCC cases that are out of sight, including etiologic factors and treatment approaches. The understanding of this fraction of HNSCC cases starts with the description of patients’ characteristics.  Then, this study aimed to describe the profile of unusual HNSCC patients comparing retrospective and prospective groups.</p>\n\n<p>A hospital-based longitudinal study was performed that HNSCC patients were enrolled in 2000-2011 and 2023-2025, each period of time from two public health institutions at São Paulo city. Two cohorts were composed: I) Young HNSCC patients that included participants who were from 18 to 40 years-old with a HNSCC HPV (human papillomavirus)-negative diagnosis; II) Non-exposed HNSCC patients that included participants above 40 years-old without exposition to tobacco, alcohol, and virus infection. Comparison between the two periods of time was carried out about frequency and proportion.</p>\n\n<p>Young HNSCC patients. A total of 21 retrospective and 13 prospective patients were included, which showed an increased proportion of early-onset HNSCC that occurred 1.1 cases/year from 2000 to 2011, while a total of 10.5 cases/year during the period of 2023-2025. The majority of participants were males from both groups (80.9% and 76.9%, respectively) with a mean age of 36.6 (4.7) years-old. Cigarette smoking was more prevalent among retrospective young HNSCC patients that was observed 2/3 of smokers in comparison to 1/4 smokers among prospective patients. On the other hand, the never smokers were prevalent among prospective HNSCC patients, over 9/10 than 1/10 of retrospective ones. About the alcohol consumption, young drinker patients were observed in similar frequencies between retrospective and prospective participants (47.6% and 53.8%, respectively) as long as never drinking patients from both generations (28.6% and 38.5%, respectively). The anatomic site most affected by the malignancy was the oral cavity that was diagnosed in 69.2% of prospective young HNSCC patients and 61.9% of retrospective ones.</p>\n\n<p>Non-exposed HNSCC patients. A total of 17 retrospective and 34 prospective participants were included, which also indicates the proportion increase over years: from 1.7 cases/year during 2000-2011 to 11.3 cases/year over 2023-2025. There was a shift in the sex of patients over generations that retrospective non-exposed HNSCC patients were composed of 58.8% of males, but 73.5% of prospective ones were females, which resulted in a ratio of 1 man to 2 women during 2023-2025. Moreover, the mean age was similar between the two periods of time that was 62.5 (11.1) years-old for retrospective non-exposed HNSCC patients and 61.2 (12.2) years-old for prospective ones. The oral cavity was also the main anatomic area where the malignancy was detected in both groups: 70.5% of retrospective and 85.3% of prospective cases.</p>\n\n<p>The dark side of HNSCC includes unusual cases that have been hidden by the most frequent HNSCC cases. However, the prevalence of these distinct HNSCC cases is increasing at least in São Paulo, Brazil.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153628--></body></html>"
    },
    {
      "uid": "P243",
      "content_id": "154582",
      "abstract_number": "P243",
      "poster_number": "P243",
      "title": "Oral Cavity Basaloid Squamous Cell Carcinoma: A Rare Subtype with Comparable Outcomes to Squamous Cell Carcinoma",
      "summary": "In contrast to historical reports describing basaloid morphology as an inherently aggressive variant, this large site-specific analysis demonstrates that oral cavity BSCC does not confer worse survival than conventional SCC. HPV association, early detection and aggressive treatment might contribute to the similar prognosis of BSCC. These findings suggest that the adverse prognosis previously attributed to BSCC...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154582",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Spencer G Shumway, BS",
      "presenter": "Spencer G Shumway, BS",
      "authors": "Spencer G Shumway, BS ; Avigeet Gupta, MD; Gideon Hallum, MS; Daniel Zhao, PhD; Lurdes Queimado, MD, PhD",
      "normalized_authors": [
        "Spencer G Shumway",
        "Avigeet Gupta",
        "Gideon Hallum",
        "Daniel Zhao",
        "Lurdes Queimado"
      ],
      "affiliations": [
        "The University of Oklahoma College of Medicine"
      ],
      "normalized_institutions": [
        "The University of Oklahoma College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Financial support"
      ],
      "sections": {
        "Authors": "Spencer G Shumway, BS ; Avigeet Gupta, MD; Gideon Hallum, MS; Daniel Zhao, PhD; Lurdes Queimado, MD, PhD",
        "Affiliations": "The University of Oklahoma College of Medicine",
        "Background": "Basaloid squamous cell carcinoma (BSCC) of the oral cavity is traditionally described as an aggressive histologic variant of squamous cell carcinoma (SCC), although there is no consensus in the field. To clarify site-specific behavior, we analyzed demographic, tumor characteristics, and prognosis between oral cavity BSCC and SCC via review of the Surveillance, Epidemiology, and End Results (SEER) database.",
        "Methods": "Using the SEER database, we identified patients diagnosed with oral cavity BSCC or SCC from 2000–2019. A total of 29,647 patients met inclusion criteria: n = 221 BSCC and n = 29,426 SCC. Demographics, tumor characteristics, treatment patterns, and survival outcomes were compared using univariate analyses. Multivariate and univariate regression was performed including age, sex, race, stage, TNM classification, treatment modality, and prior cancer history to determine the independent effect of histology on survival. Hazard ratios and survival outcomes were calculated using SPSS 28.0.",
        "Results": "BSCC comprised only 0.7% of oral cavity cancers. Compared with SCC, BSCC patients were more often male (77.8% vs 59.8%, p < 0.001), Black (10.4% vs 5.9%, p < 0.001) and diagnosed with local (41% vs 32%, p = 0.002) and distant metastasis (4% vs 1%, p < 0.001), but had similar age distribution, and tumor stage. Patients with BSCC were less frequently treated with surgery alone (49% vs 51%, p = 0.03). On univariate analysis, overall survival did not differ significantly between BSCC and SCC. In multivariate analysis adjusting for all clinical and demographic variables, tumor histology (BSCC vs SCC) was not an independent predictor of survival (HR 0.88, 95% CI 0.74–1.06; p = 0.177). Established prognostic factors including advanced TNM classification, advanced stage, older age, and metastatic disease remained strongly associated with increased mortality in both BSCC and SCC.",
        "Conclusion": "In contrast to historical reports describing basaloid morphology as an inherently aggressive variant, this large site-specific analysis demonstrates that oral cavity BSCC does not confer worse survival than conventional SCC. HPV association, early detection and aggressive treatment might contribute to the similar prognosis of BSCC. These findings suggest that the adverse prognosis previously attributed to BSCC may not apply within the oral cavity and highlight the importance of site-specific evaluation when counseling patients and planning treatment strategies.",
        "Financial support": "This work was supported in part by the National Cancer Institute (NCI) of the National Institutes of Health (R01CA242168), and the Oklahoma Tobacco Settlement Endowment Trust Health Promotion Research Center (HPRC). NIH/NCI (R01CA242168; P30CA225520); TSET HPRC (R23-02); PHF CTGA"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oral Cavity Basaloid Squamous Cell Carcinoma: A Rare Subtype with Comparable Outcomes to Squamous Cell Carcinoma</span>. <u>Spencer G Shumway, BS</u>; Avigeet Gupta, MD; Gideon Hallum, MS; Daniel Zhao, PhD; Lurdes Queimado, MD, PhD. The University of Oklahoma College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Basaloid squamous cell carcinoma (BSCC) of the oral cavity is traditionally described as an aggressive histologic variant of squamous cell carcinoma (SCC), although there is no consensus in the field. To clarify site-specific behavior, we analyzed demographic, tumor characteristics, and prognosis between oral cavity BSCC and SCC via review of the Surveillance, Epidemiology, and End Results (SEER) database.</p>\n\n<p><strong>Methods: </strong>Using the SEER database, we identified patients diagnosed with oral cavity BSCC or SCC from 2000–2019. A total of 29,647 patients met inclusion criteria: n = 221 BSCC and n = 29,426 SCC. Demographics, tumor characteristics, treatment patterns, and survival outcomes were compared using univariate analyses. Multivariate and univariate regression was performed including age, sex, race, stage, TNM classification, treatment modality, and prior cancer history to determine the independent effect of histology on survival. Hazard ratios and survival outcomes were calculated using SPSS 28.0.</p>\n\n<p><strong>Results: </strong>BSCC comprised only 0.7% of oral cavity cancers. Compared with SCC, BSCC patients were more often male (77.8% vs 59.8%, p < 0.001), Black (10.4% vs 5.9%, p < 0.001) and diagnosed with local (41% vs 32%, p = 0.002) and distant metastasis (4% vs 1%, p < 0.001), but had similar age distribution, and tumor stage. Patients with BSCC were less frequently treated with surgery alone (49% vs 51%, p = 0.03). On univariate analysis, overall survival did not differ significantly between BSCC and SCC. In multivariate analysis adjusting for all clinical and demographic variables, tumor histology (BSCC vs SCC) was not an independent predictor of survival (HR 0.88, 95% CI 0.74–1.06; p = 0.177). Established prognostic factors including advanced TNM classification, advanced stage, older age, and metastatic disease remained strongly associated with increased mortality in both BSCC and SCC.</p>\n\n<p><strong>Conclusion: </strong>In contrast to historical reports describing basaloid morphology as an inherently aggressive variant, this large site-specific analysis demonstrates that oral cavity BSCC does not confer worse survival than conventional SCC. HPV association, early detection and aggressive treatment might contribute to the similar prognosis of BSCC. These findings suggest that the adverse prognosis previously attributed to BSCC may not apply within the oral cavity and highlight the importance of site-specific evaluation when counseling patients and planning treatment strategies.</p>\n\n<p><strong>Financial support: </strong>This work was supported in part by the National Cancer Institute (NCI) of the National Institutes of Health (R01CA242168), and the Oklahoma Tobacco Settlement Endowment Trust Health Promotion Research Center (HPRC). NIH/NCI (R01CA242168; P30CA225520); TSET HPRC (R23-02); PHF CTGA</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154582--></body></html>"
    },
    {
      "uid": "P244",
      "content_id": "154257",
      "abstract_number": "P244",
      "poster_number": "P244",
      "title": "Prognostic Value of Minor Adverse Pathologic Features in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Adverse pathologic features were associated with more advanced disease and need for more aggressive treatment, but did not independently predict recurrence or DFS after adjustment for other prognostic factors.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154257",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katherine Xu, MD",
      "presenter": "Katherine Xu, MD",
      "authors": "Vivienne Au 1 ; Jin Hua Li 2 ; Katherine Xu, MD 1 ; Rachel Harter 2 ; Udeerna Tippabhatla 2 ; Aviram Mizrachi 2",
      "normalized_authors": [
        "Vivienne Au",
        "Jin Hua Li",
        "Katherine Xu",
        "Rachel Harter",
        "Udeerna Tippabhatla",
        "Aviram Mizrachi"
      ],
      "affiliations": [
        "New York-Presbyterian/Weill Cornell Medical Center",
        "Weill Cornell Medicine"
      ],
      "normalized_institutions": [
        "New York-Presbyterian/Weill Cornell Medical Center",
        "Weill Cornell Medicine"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 340,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Vivienne Au 1 ; Jin Hua Li 2 ; Katherine Xu, MD 1 ; Rachel Harter 2 ; Udeerna Tippabhatla 2 ; Aviram Mizrachi 2",
        "Affiliations": "1 New York-Presbyterian/Weill Cornell Medical Center; 2 Weill Cornell Medicine",
        "Introduction": "Minor adverse pathologic features, including non-keratinizing histology, poor differentiation, lymphovascular invasion (LVI) and perineural invasion (PNI), are associated with more biologically aggressive oral cavity squamous cell carcinoma (OCSCC). This study aimed to evaluate the clinical impact of these factors on patient survival outcomes.",
        "Methods": "Adult patients with oral cavity squamous cell carcinoma who presented at a single institution between 2007 and 2024 were identified. Demographics, risk factors for OCSCC, clinical and pathological tumor characteristics, staging, treatment modalities, recurrence patterns, and survival outcomes were collected for 163 patients. Baseline characteristics were compared between patients with and without adverse features. Predictors of recurrence were assessed with univariate and multivariate logistic regression. Kaplan-Meier models and Cox Proportional hazard models were used to identify independent predictors of disease-free survival (DFS).",
        "Results": "Seventy-four patients (45%) had at least one adverse pathologic feature. These patients presented with more advanced pathologic stage (p<0.001), increased rate of clinical cervical nodes (p<0.001) and requiring more aggressive treatment such as neck dissection (p<0.001), free flap reconstruction (p<0.001), and adjuvant radiation therapy and chemotherapy (p<0.001; p=0.012). Among the patients with pathologic features, 23 (31%) developed recurrence, the rate of recurrence was not statistically different from the patients without pathologic features.",
        "Abstract": "On multivariable analysis, none of the adverse features but bony invasion (p=0.039), free flap reconstruction (p=0.046), and margin positivity (p=0.042) independently predicted recurrence. In Kaplan-Meier analysis, LVI (p=0.001), PNI (p<0.001) and need for free flap reconstruction (p=0.008) were associated with reduced DFS. However, in multivariable Cox models, only free flap reconstruction (HR 4.66, 95% CI 1.04-20.9, p=0.045) and adjuvant chemotherapy (HR 34.9, 95% CI 1.22-996, p=0.038) were independent predictors of decreased DFS, whereas none of the adverse pathologic features were significant.",
        "Conclusion": "Adverse pathologic features were associated with more advanced disease and need for more aggressive treatment, but did not independently predict recurrence or DFS after adjustment for other prognostic factors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Value of Minor Adverse Pathologic Features in Oral Cavity Squamous Cell Carcinoma</span>. Vivienne Au<sup>1</sup>; Jin Hua Li<sup>2</sup>; <u>Katherine Xu, MD</u><sup>1</sup>; Rachel Harter<sup>2</sup>; Udeerna Tippabhatla<sup>2</sup>; Aviram Mizrachi<sup>2</sup>. <sup>1</sup>New York-Presbyterian/Weill Cornell Medical Center; <sup>2</sup>Weill Cornell Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Minor adverse pathologic features, including non-keratinizing histology, poor differentiation, lymphovascular invasion (LVI) and perineural invasion (PNI), are associated with more biologically aggressive oral cavity squamous cell carcinoma (OCSCC). This study aimed to evaluate the clinical impact of these factors on patient survival outcomes. </p>\n\n<p><strong>Methods: </strong>Adult patients with oral cavity squamous cell carcinoma who presented at a single institution between 2007 and 2024 were identified. Demographics, risk factors for OCSCC, clinical and pathological tumor characteristics, staging, treatment modalities, recurrence patterns, and survival outcomes were collected for 163 patients. Baseline characteristics were compared between patients with and without adverse features. Predictors of recurrence were assessed with univariate and multivariate logistic regression. Kaplan-Meier models and Cox Proportional hazard models were used to identify independent predictors of disease-free survival (DFS). </p>\n\n<p><strong>Results: </strong>Seventy-four patients (45%) had at least one adverse pathologic feature. These patients presented with more advanced pathologic stage (p<0.001), increased rate of clinical cervical nodes (p<0.001) and requiring more aggressive treatment such as neck dissection (p<0.001), free flap reconstruction (p<0.001), and adjuvant radiation therapy and chemotherapy (p<0.001; p=0.012). Among the patients with pathologic features, 23 (31%) developed recurrence, the rate of recurrence was not statistically different from the patients without pathologic features. </p>\n\n<p>On multivariable analysis, none of the adverse features but bony invasion (p=0.039), free flap reconstruction (p=0.046), and margin positivity (p=0.042) independently predicted recurrence. In Kaplan-Meier analysis, LVI (p=0.001), PNI (p<0.001) and need for free flap reconstruction (p=0.008) were associated with reduced DFS. However, in multivariable Cox models, only free flap reconstruction (HR 4.66, 95% CI 1.04-20.9, p=0.045) and adjuvant chemotherapy (HR 34.9, 95% CI 1.22-996, p=0.038) were independent predictors of decreased DFS, whereas none of the adverse pathologic features were significant. </p>\n\n<p><strong>Conclusion: </strong>Adverse pathologic features were associated with more advanced disease and need for more aggressive treatment, but did not independently predict recurrence or DFS after adjustment for other prognostic factors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154257--></body></html>"
    },
    {
      "uid": "P245",
      "content_id": "153766",
      "abstract_number": "P245",
      "poster_number": "P245",
      "title": "Orocutaneous Fistula After Head and Neck Oncologic Surgery: A National Comparison of Primary and Salvage Procedures",
      "summary": "In this large, contemporary national cohort, salvage surgery after prior radiation did not increase the risk of postoperative OCF compared with primary head and neck oncologic surgery. This finding remained stable across unmatched comparisons, postoperative timelines, propensity-matched analyses, and multivariable regression. Although male sex, comorbidity burden, and tobacco use appeared associated with OCF...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153766",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shaan Bhullar, BS",
      "presenter": "Shaan Bhullar, BS",
      "authors": "Shaan Bhullar, BS 1 ; Shaylan Bera, BS 1 ; Harrison Cash, MD, MS 2",
      "normalized_authors": [
        "Shaan Bhullar",
        "Shaylan Bera",
        "Harrison Cash"
      ],
      "affiliations": [
        "University of Arizona College of Medicine -- Phoenix",
        "Department of Otolaryngology-Head and Neck Surgery, Banner MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine -- Phoenix",
        "Department of Otolaryngology-Head and Neck Surgery, Banner MD Anderson Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 480,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion",
        "Keywords"
      ],
      "sections": {
        "Authors": "Shaan Bhullar, BS 1 ; Shaylan Bera, BS 1 ; Harrison Cash, MD, MS 2",
        "Affiliations": "1 University of Arizona College of Medicine -- Phoenix; 2 Department of Otolaryngology-Head and Neck Surgery, Banner MD Anderson Cancer Center",
        "Objective": "To compare rates of orocutaneous fistula (OCF) following primary versus salvage head and neck oncologic surgery in a large national cohort, and to assess whether prior radiation is an independent risk factor for postoperative fistula formation across multiple postoperative intervals. Secondary aims included identifying additional comorbidities associated with OCF development.",
        "Methods": "A retrospective cohort study was performed using the PearlDiver national insurance claims database (2010–2023). Adult patients undergoing major head and neck oncologic resections—including pharyngectomy, laryngectomy, mandibulectomy, and floor-of-mouth resection—were identified using CPT codes. Primary surgery was defined as first-time resection without preceding radiation. Salvage surgery was defined as surgery performed within five years of radiation therapy. OCF was identified using postoperative ICD codes and evaluated at 15, 30, 60, and 90 days after surgery. Initial comparisons were made in an unmatched cohort, followed by 1:2 propensity score matching to control for demographic and clinical variables. Multivariable logistic regression (unmatched and matched) assessed independent predictors of OCF, including age, sex, tobacco use, diabetes, and Charlson Comorbidity Index (CCI).",
        "Results": "A total of 5,190 patients met inclusion criteria (1,168 salvage; 4,022 primary). In the unmatched cohort, OCF incidence was low and did not differ significantly between salvage and primary surgery at any postoperative interval (15, 30, 60, or 90 days; all P > 0.05). After propensity matching (1,168 salvage; 2,336 primary), OCF rates again remained similar between groups, with no significant differences at any time point (all P > 0.05).",
        "Abstract": "In unmatched multivariable logistic regression, male sex (OR = 1.70, P = 0.04), increasing CCI (OR = 1.05 per point, P = 0.01), and tobacco use (OR = 2.02, P = 0.002) were associated with higher odds of OCF formation. Salvage status, however, was not a significant predictor (OR = 1.27, P = 0.18). In the propensity-matched regression model, none of these factors—including tobacco use, CCI, age, or sex—remained statistically significant, and salvage status again showed no association with OCF risk (OR = 1.11, P = 0.57). Across all analyses—unmatched, matched, and time-stratified—salvage surgery consistently demonstrated no increased likelihood of postoperative OCF.",
        "Conclusion": "In this large, contemporary national cohort, salvage surgery after prior radiation did not increase the risk of postoperative OCF compared with primary head and neck oncologic surgery. This finding remained stable across unmatched comparisons, postoperative timelines, propensity-matched analyses, and multivariable regression. Although male sex, comorbidity burden, and tobacco use appeared associated with OCF formation in the unmatched model, these relationships were not sustained after matching, suggesting that fistula development may reflect a multifactorial interplay of patient and treatment. These results indicate that the relationship between salvage surgery and fistula formation may be less straightforward than traditionally assumed and highlight the importance of considering broader perioperative and patient-specific factors—particularly smoking—when assessing risk.",
        "Keywords": "orocutaneous fistula, salvage surgery, primary surgery, head and neck cancer, postoperative complications, radiation therapy, PearlDiver"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Orocutaneous Fistula After Head and Neck Oncologic Surgery: A National Comparison of Primary and Salvage Procedures</span>. <u>Shaan Bhullar, BS</u><sup>1</sup>; Shaylan Bera, BS<sup>1</sup>; Harrison Cash, MD, MS<sup>2</sup>. <sup>1</sup>University of Arizona College of Medicine -- Phoenix; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Banner MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> To compare rates of orocutaneous fistula (OCF) following primary versus salvage head and neck oncologic surgery in a large national cohort, and to assess whether prior radiation is an independent risk factor for postoperative fistula formation across multiple postoperative intervals. Secondary aims included identifying additional comorbidities associated with OCF development.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort study was performed using the PearlDiver national insurance claims database (2010–2023). Adult patients undergoing major head and neck oncologic resections—including pharyngectomy, laryngectomy, mandibulectomy, and floor-of-mouth resection—were identified using CPT codes. Primary surgery was defined as first-time resection without preceding radiation. Salvage surgery was defined as surgery performed within five years of radiation therapy. OCF was identified using postoperative ICD codes and evaluated at 15, 30, 60, and 90 days after surgery. Initial comparisons were made in an unmatched cohort, followed by 1:2 propensity score matching to control for demographic and clinical variables. Multivariable logistic regression (unmatched and matched) assessed independent predictors of OCF, including age, sex, tobacco use, diabetes, and Charlson Comorbidity Index (CCI).</p>\n\n<p><strong>Results:</strong> A total of 5,190 patients met inclusion criteria (1,168 salvage; 4,022 primary). In the unmatched cohort, OCF incidence was low and did not differ significantly between salvage and primary surgery at any postoperative interval (15, 30, 60, or 90 days; all P > 0.05). After propensity matching (1,168 salvage; 2,336 primary), OCF rates again remained similar between groups, with no significant differences at any time point (all P > 0.05).</p>\n\n<p>In unmatched multivariable logistic regression, male sex (OR = 1.70, P = 0.04), increasing CCI (OR = 1.05 per point, P = 0.01), and tobacco use (OR = 2.02, P = 0.002) were associated with higher odds of OCF formation. Salvage status, however, was not a significant predictor (OR = 1.27, P = 0.18). In the propensity-matched regression model, none of these factors—including tobacco use, CCI, age, or sex—remained statistically significant, and salvage status again showed no association with OCF risk (OR = 1.11, P = 0.57). Across all analyses—unmatched, matched, and time-stratified—salvage surgery consistently demonstrated no increased likelihood of postoperative OCF.</p>\n\n<p><strong>Conclusion:</strong> In this large, contemporary national cohort, salvage surgery after prior radiation did not increase the risk of postoperative OCF compared with primary head and neck oncologic surgery. This finding remained stable across unmatched comparisons, postoperative timelines, propensity-matched analyses, and multivariable regression. Although male sex, comorbidity burden, and tobacco use appeared associated with OCF formation in the unmatched model, these relationships were not sustained after matching, suggesting that fistula development may reflect a multifactorial interplay of patient and treatment. These results indicate that the relationship between salvage surgery and fistula formation may be less straightforward than traditionally assumed and highlight the importance of considering broader perioperative and patient-specific factors—particularly smoking—when assessing risk.</p>\n\n<p><strong>Keywords:</strong> orocutaneous fistula, salvage surgery, primary surgery, head and neck cancer, postoperative complications, radiation therapy, PearlDiver</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153766--></body></html>"
    },
    {
      "uid": "P246",
      "content_id": "153597",
      "abstract_number": "P246",
      "poster_number": "P246",
      "title": "Rapid-Onset Radiation-Induced Malignant Peripheral Nerve Sheath Tumor",
      "summary": "This case highlights the potential for radiation-induced MPNST to develop with a surprisingly short latency interval, defying the classic prolonged latency period for most radiation-induced secondary malignancies. Distinguishing MPNST from SCC recurrence, or tumor-induced pathologic fracture from advanced ORN can be challenging. In this case immunostaining was critical for diagnosis. Surgeons must maintain a high...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153597",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marta M Williams, MD",
      "presenter": "Marta M Williams, MD",
      "authors": "Marta M Williams, MD 1 ; Emilian Racila, MD 2 ; Sobia F Khaja, MD 1",
      "normalized_authors": [
        "Marta M Williams",
        "Emilian Racila",
        "Sobia F Khaja"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
        "Department of Laboratory Medicine and Pathology, University of Minnesota"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Minnesota",
        "Department of Laboratory Medicine and Pathology, University of Minnesota"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 394,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Marta M Williams, MD 1 ; Emilian Racila, MD 2 ; Sobia F Khaja, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Minnesota; 2 Department of Laboratory Medicine and Pathology, University of Minnesota",
        "Introduction": "Radiation-induced malignant peripheral nerve sheath tumors (MPNST) of the head and neck are rare, aggressive secondary malignancies, classically presenting with a long latency period (median >10 years).1 Oral cavity radiation-induced MPNSTs are particularly rare. Histologic diagnosis of these tumors is challenging, as is clinical diagnosis given that the presentation of these tumors often mimics osteoradionecrosis (ORN) or recurrent squamous cell carcinoma.",
        "Methods": "Here we report a case of radiation-induced MPNST of the oral cavity arising four years after radiation treatment.",
        "Results": "A 60-year-old man with a history of a T2N2b squamous cell carcinoma (SCC) of the left oropharynx, treated with definitive chemoradiation (7000 cGy) and subsequent resolved exposed bone, presented four years following treatment with a new left oral cavity mass. He reported intraoral mass, a \"crunching\" sensation with eating consistent with a pathologic mandible fracture, and progressive facial swelling. CT imaging revealed a 5.1 cm mass of the oral cavity and mandible with a pathologic fracture, initially presumed to represent a T4a recurrence of SCC. A biopsy was obtained which demonstrated high-grade malignant spindle cell neoplasm. The patient underwent segmental mandibulectomy with skin resection, neck dissection and fibula free flap reconstruction. Final pathology identified a high-grade malignant spindle cell neoplasm consistent with a radiation induced sarcoma. Immunohistochemistry demonstrated positive staining for vimentin, and negative staining for cytokeratin, S100, desmin, P40, P63, Melan-A, CD68, and SMA staining. H3k27me3 immunostain demonstrated loss of expression in the tumor cells, confirming radiation-induced MPNST. His 3 month post-treatment PET demonstrated multi-focal recurrence (mandible, soft tissue along the hyoid, parotid, and spine), with salvage treatment attempted with chemoimmunotherapy. He ultimately died of disease 17 months post-surgery.",
        "Conclusions": "This case highlights the potential for radiation-induced MPNST to develop with a surprisingly short latency interval, defying the classic prolonged latency period for most radiation-induced secondary malignancies. Distinguishing MPNST from SCC recurrence, or tumor-induced pathologic fracture from advanced ORN can be challenging. In this case immunostaining was critical for diagnosis. Surgeons must maintain a high index of suspicion for MPNST in patients with new masses, pathologic fractures, or worsening symptoms even in the early post-radiation years. Early detection is critical given the aggressive nature of these malignancies and potential for rapid recurrence even after resection.",
        "Abstract": "1. Struckmeier AK, Gosau M, Smeets R. Radiation-induced sarcomas of the craniofacial region: A systematic review. Oral Oncol. 2025;164:107282. doi:10.1016/j.oraloncology.2025.107282"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rapid-Onset Radiation-Induced Malignant Peripheral Nerve Sheath Tumor</span>. <u>Marta M Williams, MD</u><sup>1</sup>; Emilian Racila, MD<sup>2</sup>; Sobia F Khaja, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Minnesota; <sup>2</sup>Department of Laboratory Medicine and Pathology, University of Minnesota<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Radiation-induced malignant peripheral nerve sheath tumors (MPNST) of the head and neck are rare, aggressive secondary malignancies, classically presenting with a long latency period (median >10 years).1 Oral cavity radiation-induced MPNSTs are particularly rare. Histologic diagnosis of these tumors is challenging, as is clinical diagnosis given that the presentation of these tumors often mimics osteoradionecrosis (ORN) or recurrent squamous cell carcinoma. </p>\n\n<p><strong>Methods: </strong>Here we report a case of radiation-induced MPNST of the oral cavity arising four years after radiation treatment. </p>\n\n<p><strong>Results:</strong> A 60-year-old man with a history of a T2N2b squamous cell carcinoma (SCC) of the left oropharynx, treated with definitive chemoradiation (7000 cGy) and subsequent resolved exposed bone, presented four years following treatment with a new left oral cavity mass. He reported intraoral mass, a \"crunching\" sensation with eating consistent with a pathologic mandible fracture, and progressive facial swelling. CT imaging revealed a 5.1 cm mass of the oral cavity and mandible with a pathologic fracture, initially presumed to represent a T4a recurrence of SCC. A biopsy was obtained which demonstrated high-grade malignant spindle cell neoplasm. The patient underwent segmental mandibulectomy with skin resection, neck dissection and fibula free flap reconstruction. Final pathology identified a high-grade malignant spindle cell neoplasm consistent with a radiation induced sarcoma. Immunohistochemistry demonstrated positive staining for vimentin, and negative staining for cytokeratin, S100, desmin, P40, P63, Melan-A, CD68, and SMA staining.  H3k27me3 immunostain demonstrated loss of expression in the tumor cells, confirming radiation-induced MPNST. His 3 month post-treatment PET demonstrated  multi-focal recurrence (mandible, soft tissue along the hyoid, parotid, and spine), with salvage treatment attempted with chemoimmunotherapy. He ultimately died of disease 17 months post-surgery.</p>\n\n<p><strong>Conclusions:</strong> This case highlights the potential for radiation-induced MPNST to develop with a surprisingly short latency interval, defying the classic prolonged latency period for most radiation-induced secondary malignancies. Distinguishing MPNST from SCC recurrence, or tumor-induced pathologic fracture from advanced ORN can be challenging. In this case immunostaining was critical for diagnosis. Surgeons must maintain a high index of suspicion for MPNST in patients with new masses, pathologic fractures, or worsening symptoms even in the early post-radiation years. Early detection is critical given the aggressive nature of these malignancies and potential for rapid recurrence even after resection.</p>\n\n<p>1.    Struckmeier AK, Gosau M, Smeets R. Radiation-induced sarcomas of the craniofacial region: A systematic review. Oral Oncol. 2025;164:107282. doi:10.1016/j.oraloncology.2025.107282</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153597--></body></html>"
    },
    {
      "uid": "P247",
      "content_id": "154424",
      "abstract_number": "P247",
      "poster_number": "P247",
      "title": "Racial and Ethnic Survival Disparities in Oral Cavity Squamous Cell Carcinoma in the U.S.",
      "summary": "Among U.S. patients with OCSCC, NHAPI and Hispanic groups demonstrated superior OS compared with NHW patients, even after adjustment for clinical and socioeconomic factors. Although NHB patients experienced significantly worse survival in crude analysis, this disparity was attenuated when controlling for access to care, insurance type, disease burden and therapeutic interventions. These findings highlight that...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154424",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mateo Useche, MD, MPH",
      "presenter": "Mateo Useche, MD, MPH",
      "authors": "Mateo Useche, MD, MPH ; Hosam H Alkhatib, MD; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Emily Marchiano, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MS",
      "normalized_authors": [
        "Mateo Useche",
        "Hosam H Alkhatib",
        "Lauren Shih",
        "Cristina Rodriguez",
        "Jay J Liao",
        "Neil Panjwani",
        "Neal Futran",
        "Emily Marchiano",
        "Brittany Barber",
        "Rocco Ferrandino"
      ],
      "affiliations": [
        "University of Washington"
      ],
      "normalized_institutions": [
        "University of Washington"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154424/5%20year%20OS%20by%20race-ethn.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154424/5%20year%20OS%20by%20race-ethn.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154424"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 557,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mateo Useche, MD, MPH ; Hosam H Alkhatib, MD; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Emily Marchiano, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MS",
        "Affiliations": "University of Washington",
        "Introduction": "Racial and ethnic disparities in oral cavity squamous cell carcinoma (OCSCC) outcomes remain a persistent public health concern in the United States. Prior literature has focused on differences between non-Hispanic White (NHW) and Black patients, while disparities across other racial/ethnic groups remain understudied. This study evaluates survival differences among five racial/ethnic groups and examines whether sociodemographic factors attenuate these disparities.",
        "Methods": "A retrospective cohort study was performed using the National Cancer Database (NCDB) from 2004–2022. Adult patients diagnosed with OCSCC were included and categorized as Non-Hispanic White (NHW), Non-Hispanic Asian/Pacific Islander (NHAPI), Non-Hispanic Black (NHB), Hispanic, or Other. Overall survival (OS) was estimated using Kaplan–Meier curves. A multivariable Cox proportional hazards model evaluated the association between race/ethnicity and 5-year OS after adjusting for age, sex, insurance, comorbidity burden, facility type, income, education, distance to treatment center, tumor site, pathologic T/N stage, surgical margins, time to surgery, and adjuvant therapy.",
        "Results": "A total of 105,450 patients were included: 82.4% NHW (n=86,897), 4.2% NHAPI (n=4,403), 6.2% NHB (n=6,548), 4.8% Hispanic (n=5,099), and 2.4% Other (n=2,503). NHB individuals were more frequently uninsured or Medicaid insured (31.1%), resided more often in lower-income communities (46%), and had a higher proportion of non-tongue tumors (62%; p<0.001) compared to other groups. NHW were less frequently treated in academic/research programs (53%) and were more likely to live >50 miles away from treatment center (33%; p<0.001). Hispanic patients had the highest proportion of individuals with low educational attainment (56%; p<0.001). NHAPI and Hispanic patients had a higher distribution of individuals living in metropolitan areas (95% and 93%, respectively, p<0.001).",
        "Abstract": "Five-year OS differed significantly by race/ethnicity, with rates of 66.7% for NHAPIs, 59.7% for Hispanics, 58.7% for NHW, 62.9% for Other, and 44.7% for NHB patients. After multivariable adjustment, NHAPI (HR 0.81, 95% CI 0.75–0.87; p<0.001) and Hispanic patients (HR 0.82, 95% CI 0.77–0.88; p<0.001) demonstrated a survival benefit compared to NHW. NHB was not significantly associated with poorer survival after controlling for covariates (HR 1.04, 95% CI 0.99–1.10; p=0.13). Other independent predictors of worse survival included Male sex (HR 1.14, 95% CI 1.10–1.17; p<0.001) lack of insurance (HR 1.45, 95% CI 1.35–1.55; p<0.001), higher comorbidity burden (HR 1.41, 95% CI 1.35–1.48; p<0.001), and positive surgical margins (HR 1.51, 95% CI 1.46–1.57; p<0.001). Highest education (HR 0.91, 95% CI 0.86–0.96) and income quartiles (HR 0.85, 95% CI 0.81–0.89) were associated with better OS.",
        "Conclusion": "Among U.S. patients with OCSCC, NHAPI and Hispanic groups demonstrated superior OS compared with NHW patients, even after adjustment for clinical and socioeconomic factors. Although NHB patients experienced significantly worse survival in crude analysis, this disparity was attenuated when controlling for access to care, insurance type, disease burden and therapeutic interventions. These findings highlight that measured structural determinants explain some racial/ethnic disparities in OCSCC survival, while persistent advantages in NHAPI and Hispanics warrant further investigation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Racial and Ethnic Survival Disparities in Oral Cavity Squamous Cell Carcinoma in the U.S.</span>. <u>Mateo Useche, MD, MPH</u>; Hosam H Alkhatib, MD; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Emily Marchiano, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MS. University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Racial and ethnic disparities in oral cavity squamous cell carcinoma (OCSCC) outcomes remain a persistent public health concern in the United States. Prior literature has focused on differences between non-Hispanic White (NHW) and Black patients, while disparities across other racial/ethnic groups remain understudied. This study evaluates survival differences among five racial/ethnic groups and examines whether sociodemographic factors attenuate these disparities.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed using the National Cancer Database (NCDB) from 2004–2022. Adult patients diagnosed with OCSCC were included and categorized as Non-Hispanic White (NHW), Non-Hispanic Asian/Pacific Islander (NHAPI), Non-Hispanic Black (NHB), Hispanic, or Other. Overall survival (OS) was estimated using Kaplan–Meier curves. A multivariable Cox proportional hazards model evaluated the association between race/ethnicity and 5-year OS after adjusting for age, sex, insurance, comorbidity burden, facility type, income, education, distance to treatment center, tumor site, pathologic T/N stage, surgical margins, time to surgery, and adjuvant therapy.</p>\n\n<p><strong>Results: </strong>A total of 105,450 patients were included: 82.4% NHW (n=86,897), 4.2% NHAPI (n=4,403), 6.2% NHB (n=6,548), 4.8% Hispanic (n=5,099), and 2.4% Other (n=2,503). NHB individuals were more frequently uninsured or Medicaid insured (31.1%), resided more often in lower-income communities (46%), and had a higher proportion of non-tongue tumors (62%; p<0.001) compared to other groups. NHW were less frequently treated in academic/research programs (53%) and were more likely to live >50 miles away from treatment center (33%; p<0.001). Hispanic patients had the highest proportion of individuals with low educational attainment (56%; p<0.001). NHAPI and Hispanic patients had a higher distribution of individuals living in metropolitan areas (95% and 93%, respectively, p<0.001).</p>\n\n<p>Five-year OS differed significantly by race/ethnicity, with rates of 66.7% for NHAPIs, 59.7% for Hispanics, 58.7% for NHW, 62.9% for Other, and 44.7% for NHB patients. After multivariable adjustment, NHAPI (HR 0.81, 95% CI 0.75–0.87; p<0.001) and Hispanic patients (HR 0.82, 95% CI 0.77–0.88; p<0.001) demonstrated a survival benefit compared to NHW. NHB was not significantly associated with poorer survival after controlling for covariates (HR 1.04, 95% CI 0.99–1.10; p=0.13). Other independent predictors of worse survival included Male sex (HR 1.14, 95% CI 1.10–1.17; p<0.001) lack of insurance (HR 1.45, 95% CI 1.35–1.55; p<0.001), higher comorbidity burden (HR 1.41, 95% CI 1.35–1.48; p<0.001), and positive surgical margins (HR 1.51, 95% CI 1.46–1.57; p<0.001). Highest education (HR 0.91, 95% CI 0.86–0.96) and income quartiles (HR 0.85, 95% CI 0.81–0.89) were associated with better OS.</p>\n\n<p><strong>Conclusion: </strong>Among U.S. patients with OCSCC, NHAPI and Hispanic groups demonstrated superior OS compared with NHW patients, even after adjustment for clinical and socioeconomic factors. Although NHB patients experienced significantly worse survival in crude analysis, this disparity was attenuated when controlling for access to care, insurance type, disease burden and therapeutic interventions. These findings highlight that measured structural determinants explain some racial/ethnic disparities in OCSCC survival, while persistent advantages in NHAPI and Hispanics warrant further investigation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154424/5%20year%20OS%20by%20race-ethn.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154424--></body></html>"
    },
    {
      "uid": "P248",
      "content_id": "154378",
      "abstract_number": "P248",
      "poster_number": "P248",
      "title": "Clinical Relevance of Average Margins in Tongue Squamous Cell Carcinoma: A Pilot Study.",
      "summary": "In this pilot analysis of tongue SCC, a single close margin (1–5 mm) did not confer additional risk when the average circumferential margin was ≥7 mm. Positive closest margins were the only margin category associated with worse overall survival. These findings suggest that overall circumferential clearance may be clinically relevant and warrant validation in larger, multi-institutional cohorts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154378",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mateo Useche, MD, MPH",
      "presenter": "Mateo Useche, MD, MPH",
      "authors": "Mateo Useche, MD, MPH ; Daniel L Faden, MD, FACS; Allen L Feng, MD; Jeremy D Richmon, MD; Derrick T Lin, MD, FACS; Daniel G Deschler, MD, FACS; Mark A Varvares, MD, FACS",
      "normalized_authors": [
        "Mateo Useche",
        "Daniel L Faden",
        "Allen L Feng",
        "Jeremy D Richmon",
        "Derrick T Lin",
        "Daniel G Deschler",
        "Mark A Varvares"
      ],
      "affiliations": [
        "Mass General Brigham, Harvard Medical School"
      ],
      "normalized_institutions": [
        "Mass General Brigham, Harvard Medical School"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mateo Useche, MD, MPH ; Daniel L Faden, MD, FACS; Allen L Feng, MD; Jeremy D Richmon, MD; Derrick T Lin, MD, FACS; Daniel G Deschler, MD, FACS; Mark A Varvares, MD, FACS",
        "Affiliations": "Mass General Brigham, Harvard Medical School",
        "Background": "The optimal definition of an adequate surgical margin in tongue squamous cell carcinoma (SCC) remains controversial. We evaluated whether average margin width provides prognostic value beyond the closest margin and whether close margins (1–5 mm) confer increased risk of recurrence or death compared with negative margins.",
        "Methods": "We retrospectively analyzed patients who underwent primary surgical resection for tongue SCC at single institution that had complete histopathologic margin measurements from 2007 to 2015. Average margin was calculated as the mean of anterior, posterior, medial, and lateral margins. Closest margin categories were defined as negative (≥5 mm), close (1–5 mm), and positive (<1 mm). ROC curves and DeLong tests assessed the discriminatory ability of closest vs average margin; Cox proportional hazards models examined associations with disease-free survival (DFS) and overall survival (OS); and four-group interaction models (average × closest-margin status) assessed whether a wide overall circumferential margin mitigates the effect of a close margin. Local recurrence was analyzed with logistic regression in the subset with complete recurrence-site data.",
        "Results": "The cohort included 164 patients, mean age 65 ± 15 years, and 54% male. Most tumors were pT1 (32%) or pT2 (40%), with lymphovascular and perineural invasion present in 23% and 39%, respectively. Negative closest margin (≥5mm) was present in 30% of the cohort while 18% had positive closest margin (<1mm). Overall, 52 patients (32%) recurred and 16% died during follow-up. Average and closest margins demonstrated limited discriminatory ability for recurrence (AUC 0.56 vs 0.55; DeLong p=0.86) and mortality (AUC 0.56 vs 0.64; p=0.31). ROC-derived Youden optimization identified cut points of 7 mm as the average-margin threshold for categorical analyses. In Cox models for DFS, a single close margin was not associated with recurrence (HR 0.95 per mm, 95% CI 0.86–1.06, p = 0.39), and average margin was similarly not significant (HR 0.97 per mm, 95% CI 0.89–1.04, p = 0.37). Positive closest margins (≤1mm) showed a nonsignificant trend toward higher recurrence (HR 1.60, p=0.23) but were significantly associated with worse OS (HR 3.71, p=0.037). Among patients with average margins ≥7 mm, a single close margin (1-5 mm) did not increase DFS (HR 0.83, p = 0.64) or local recurrence (OR = 1.07, p = 0.94) risk. Further threshold analyses within this subgroup showed no closest-margin cutoff (≤2, ≤3, ≤4, or ≤5 mm) associated with higher recurrence risk (HR range 0.64–1.14; all p ≥ 0.26), and a ≤2 mm closest margin similarly failed to predict local recurrence (HR 1.09, 95% CI 0.41–2.95; p = 0.86).",
        "Conclusion": "In this pilot analysis of tongue SCC, a single close margin (1–5 mm) did not confer additional risk when the average circumferential margin was ≥7 mm. Positive closest margins were the only margin category associated with worse overall survival. These findings suggest that overall circumferential clearance may be clinically relevant and warrant validation in larger, multi-institutional cohorts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Relevance of Average Margins in Tongue Squamous Cell Carcinoma: A Pilot Study.</span>. <u>Mateo Useche, MD, MPH</u>; Daniel L Faden, MD, FACS; Allen L Feng, MD; Jeremy D Richmon, MD; Derrick T Lin, MD, FACS; Daniel G Deschler, MD, FACS; Mark A Varvares, MD, FACS. Mass General Brigham, Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The optimal definition of an adequate surgical margin in tongue squamous cell carcinoma (SCC) remains controversial. We evaluated whether average margin width provides prognostic value beyond the closest margin and whether close margins (1–5 mm) confer increased risk of recurrence or death compared with negative margins.</p>\n\n<p><strong>Methods: </strong>We retrospectively analyzed patients who underwent primary surgical resection for tongue SCC at single institution that had complete histopathologic margin measurements from 2007 to 2015. Average margin was calculated as the mean of anterior, posterior, medial, and lateral margins. Closest margin categories were defined as negative (≥5 mm), close (1–5 mm), and positive (<1 mm). ROC curves and DeLong tests assessed the discriminatory ability of closest vs average margin; Cox proportional hazards models examined associations with disease-free survival (DFS) and overall survival (OS); and four-group interaction models (average × closest-margin status) assessed whether a wide overall circumferential margin mitigates the effect of a close margin. Local recurrence was analyzed with logistic regression in the subset with complete recurrence-site data.</p>\n\n<p><strong>Results: </strong>The cohort included 164 patients, mean age 65 ± 15 years, and 54% male. Most tumors were pT1 (32%) or pT2 (40%), with lymphovascular and perineural invasion present in 23% and 39%, respectively. Negative closest margin (≥5mm) was present in 30% of the cohort while 18% had positive closest margin (<1mm). Overall, 52 patients (32%) recurred and 16% died during follow-up. Average and closest margins demonstrated limited discriminatory ability for recurrence (AUC 0.56 vs 0.55; DeLong p=0.86) and mortality (AUC 0.56 vs 0.64; p=0.31). ROC-derived Youden optimization identified cut points of 7 mm as the average-margin threshold for categorical analyses. In Cox models for DFS, a single close margin was not associated with recurrence (HR 0.95 per mm, 95% CI 0.86–1.06, p = 0.39), and average margin was similarly not significant (HR 0.97 per mm, 95% CI 0.89–1.04, p = 0.37). Positive closest margins (≤1mm) showed a nonsignificant trend toward higher recurrence (HR 1.60, p=0.23) but were significantly associated with worse OS (HR 3.71, p=0.037). Among patients with average margins ≥7 mm, a single close margin (1-5 mm) did not increase DFS (HR 0.83, p = 0.64) or local recurrence (OR = 1.07, p = 0.94) risk. Further threshold analyses within this subgroup showed no closest-margin cutoff (≤2, ≤3, ≤4, or ≤5 mm) associated with higher recurrence risk (HR range 0.64–1.14; all p ≥ 0.26), and a ≤2 mm closest margin similarly failed to predict local recurrence (HR 1.09, 95% CI 0.41–2.95; p = 0.86).</p>\n\n<p><strong>Conclusion: </strong>In this pilot analysis of tongue SCC, a single close margin (1–5 mm) did not confer additional risk when the average circumferential margin was ≥7 mm. Positive closest margins were the only margin category associated with worse overall survival. These findings suggest that overall circumferential clearance may be clinically relevant and warrant validation in larger, multi-institutional cohorts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154378--></body></html>"
    },
    {
      "uid": "P249",
      "content_id": "152760",
      "abstract_number": "P249",
      "poster_number": "P249",
      "title": "Oral Cavity Cancer: A Growing Concern among Micronesians in Hawai‘i",
      "summary": "The total study population comprised of 432 patients: 198 Asian (median (IQR) age at presentation, 70 (58, 79) years)), 72 Micronesian (47 (38, 58) years)), 52 Other Pacific Islander (61 (52, 71) years)), and 110 White (66 (57, 75) years)) individuals. The Micronesian cohort had the greatest proportion of those on Medicaid (81%) in comparison to White (18%), Asian (12%), and Other Pacific Islander (23%)....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152760",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Olivia Uchima, PhD, SLP",
      "presenter": "Olivia Uchima, PhD, SLP",
      "authors": "Olivia Uchima, PhD, SLP 1 ; Hyeong Ahn, PhD 2 ; Noa Brenner 2 ; Megan Inada 2 ; May Rose Dela Cruz 2 ; Zhen Gooi 1 ; Daniel Alam 1 ; Christopher Klem 1",
      "normalized_authors": [
        "Olivia Uchima, SLP",
        "Hyeong Ahn",
        "Noa Brenner",
        "Megan Inada",
        "May Rose Dela Cruz",
        "Zhen Gooi",
        "Daniel Alam",
        "Christopher Klem"
      ],
      "affiliations": [
        "Queen's Medical Center",
        "University of Hawaii at Manoa"
      ],
      "normalized_institutions": [
        "Queen's Medical Center",
        "University of Hawaii at Manoa"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Design, Setting, and Participants",
        "Main Outcomes and Measures",
        "Results"
      ],
      "sections": {
        "Authors": "Olivia Uchima, PhD, SLP 1 ; Hyeong Ahn, PhD 2 ; Noa Brenner 2 ; Megan Inada 2 ; May Rose Dela Cruz 2 ; Zhen Gooi 1 ; Daniel Alam 1 ; Christopher Klem 1",
        "Affiliations": "1 Queen's Medical Center; 2 University of Hawaii at Manoa",
        "Introduction": "Oral cavity cancer (OCC) remains a significant health burden on the population of the United States with 27,570 recorded cases in 2022 and an age-standardized incidence rate of 4.6 per 100,000. Micronesia is a vast region of the Northwestern Pacific comprising of over 2,000 islands and a population of over 500,000. The age-adjusted incidence per 100,000 population for oral cavity cancer has been shown to be significantly higher for various islands in Micronesia ranging from 20.6-98.4. The United States (US) retains close historical and cultural links with numerous Micronesian territories and this is especially apparent for Hawai‘i given that it is the closest US state to the Micronesian region. The Micronesian population within Hawai‘i has increased by 296% from 2010-2020 with a good proportion relocating for medical care. Epidemiologic and outcomes data on OCC for the Micronesian population within Hawai‘i is lacking and there is a strong need to determine if this community would benefit from targeted health interventions.",
        "Design, Setting, and Participants": "This was a retrospective population-based cohort study using a Hawai'i based oncology database, which collects patient data for those receiving oncologic care at the largest cancer facility in Hawai'i. Asian, Other Pacific Islander, Micronesian, and non-Hispanic White adult patients diagnosed in 2014 through 2023 with OCC were included; any patient whose record was missing data on disease, treatment status, demographic information, and those with synchronous cancers were excluded.",
        "Main Outcomes and Measures": "Cancer stage at presentation was compared among Asian, Other Pacific Islander, Micronesian, and non-Hispanic White patients using a multivariable logistic regression model. Survival outcomes will be compared among these ethnic groups using Cox regression models and Kaplan-Meier with Log Rank analysis. Data analyses started September 2025 and are expected to be completed by February 2026.",
        "Results": "The total study population comprised of 432 patients: 198 Asian (median (IQR) age at presentation, 70 (58, 79) years)), 72 Micronesian (47 (38, 58) years)), 52 Other Pacific Islander (61 (52, 71) years)), and 110 White (66 (57, 75) years)) individuals. The Micronesian cohort had the greatest proportion of those on Medicaid (81%) in comparison to White (18%), Asian (12%), and Other Pacific Islander (23%). Micronesian patients also had the highest proportion of individuals presenting with Stage III/IV cancers (83%) compared to Asian (42%), Other Pacific Islander (65%), and White (46%) with p-value <0.001; T3/T4 classification (82%) compared to Asian (34%), Other Pacific Islander (63%), and White (44%) with p-value <0.001; and N3 nodal staging (21%) compared to Asian (11%), Other Pacific Islander (5.8%), and White (5.5%) with p-value <0.001. The association between ethnicity and advanced disease stage and survival outcomes are still being performed. However, given the high proportion of Micronesian patients presenting with late-stage disease, it is hypothesized they are more likely to have reduced survival, highlighting the need for identifying barriers to care and earlier detection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oral Cavity Cancer: A Growing Concern among Micronesians in Hawai‘i</span>. <u>Olivia Uchima, PhD, SLP</u><sup>1</sup>; Hyeong Ahn, PhD<sup>2</sup>; Noa Brenner<sup>2</sup>; Megan Inada<sup>2</sup>; May Rose Dela Cruz<sup>2</sup>; Zhen Gooi<sup>1</sup>; Daniel Alam<sup>1</sup>; Christopher Klem<sup>1</sup>. <sup>1</sup>Queen's Medical Center; <sup>2</sup>University of Hawaii at Manoa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Oral cavity cancer (OCC) remains a significant health burden on the population of the United States with 27,570 recorded cases in 2022 and an age-standardized incidence rate of 4.6 per 100,000.  Micronesia is a vast region of the Northwestern Pacific comprising of over 2,000 islands and a population of over 500,000. The age-adjusted incidence per 100,000 population for oral cavity cancer has been shown to be significantly higher for various islands in Micronesia ranging from 20.6-98.4. The United States (US) retains close historical and cultural links with numerous Micronesian territories and this is especially apparent for Hawai‘i given that it is the closest US state to the Micronesian region. The Micronesian population within Hawai‘i has increased by 296% from 2010-2020 with a good proportion relocating for medical care. Epidemiologic and outcomes data on OCC for the Micronesian population within Hawai‘i is lacking and there is a strong need to determine if this community would benefit from targeted health interventions.</p>\n\n<p><strong>Design, Setting, and Participants: </strong>This was a retrospective population-based cohort study using a Hawai'i based oncology database, which collects patient data for those receiving oncologic care at the largest cancer facility in Hawai'i. Asian, Other Pacific Islander, Micronesian, and non-Hispanic White adult patients diagnosed in 2014 through 2023 with OCC were included; any patient whose record was missing data on disease, treatment status, demographic information, and those with synchronous cancers were excluded.</p>\n\n<p><strong>Main Outcomes and Measures:</strong> Cancer stage at presentation was compared among Asian, Other Pacific Islander, Micronesian, and non-Hispanic White patients using a multivariable logistic regression model. Survival outcomes will be compared among these ethnic groups using Cox regression models and Kaplan-Meier with Log Rank analysis. Data analyses started September 2025 and are expected to be completed by February 2026.</p>\n\n<p><strong>Results: </strong>The total study population comprised of 432 patients: 198 Asian (median (IQR) age at presentation, 70 (58, 79) years)), 72 Micronesian (47 (38, 58) years)), 52 Other Pacific Islander (61 (52, 71) years)), and 110 White (66 (57, 75) years)) individuals. The Micronesian cohort had the greatest proportion of those on Medicaid (81%) in comparison to White (18%), Asian (12%), and Other Pacific Islander (23%). Micronesian patients also had the highest proportion of individuals presenting with Stage III/IV cancers (83%) compared to Asian (42%), Other Pacific Islander (65%), and White (46%) with p-value <0.001; T3/T4 classification (82%) compared to Asian (34%), Other Pacific Islander (63%), and White (44%) with p-value <0.001; and N3 nodal staging (21%) compared to Asian (11%), Other Pacific Islander (5.8%), and White (5.5%) with p-value <0.001. The association between ethnicity and advanced disease stage and survival outcomes are still being performed. However, given the high proportion of Micronesian patients presenting with late-stage disease, it is hypothesized they are more likely to have reduced survival, highlighting the need for identifying barriers to care and earlier detection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152760--></body></html>"
    },
    {
      "uid": "P250",
      "content_id": "154370",
      "abstract_number": "P250",
      "poster_number": "P250",
      "title": "Prevalence of Metastatic Lymph Nodes at Cervical Level IIb in Oral Cavity Squamous Cell Carcinomas: A Retrospective Study",
      "summary": "The low prevalence of metastases at Level IIb, consistent with literature, provides a strong rationale to adoption more selective surgical approaches in OCSCC. It is crucial to differentiate between the overall Level II (which can have a prevalence of up to 20%) and its specific sublevel IIb, given that Level IIa substantially contributes to the overall positivity rate of Level II. The positive correlation...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154370",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rafael De Cicco",
      "presenter": "Rafael De Cicco",
      "authors": "Pablo Ocampo Quintana, MD; Francisco Araujo Dias; Rafael Pereira De Souza; Rafael De Cicco",
      "normalized_authors": [
        "Pablo Ocampo Quintana",
        "Francisco Araujo Dias",
        "Rafael Pereira De Souza",
        "Rafael De Cicco"
      ],
      "affiliations": [
        "Instituto de Câncer Dr. Arnaldo"
      ],
      "normalized_institutions": [
        "Instituto de Câncer Dr. Arnaldo"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Pablo Ocampo Quintana, MD; Francisco Araujo Dias; Rafael Pereira De Souza; Rafael De Cicco",
        "Affiliations": "Instituto de Câncer Dr. Arnaldo",
        "Introduction": "Oral Cavity Squamous Cell Carcinoma (OCSCC) is a highly prevalent malignancy where lymphatic dissemination serves as critical prognostic factor. Oncological control, it frequently leads to significant morbidities, in Level IIb. This clinical dilemma underscores the need to balance therapeutic efficacy with the preservation of patient quality of life. Although Level II is commonly involved in OCSCC metastasis, the isolated prevalence of metastases within its sublevel IIb remains a subject of controversy. This study was designed to ascertain the prevalence of metastatic lymph nodes at Level IIb in OCSCC patients and correlate these findings with clinicopathological factors, as well as survival and recurrence outcomes.",
        "Methods": "This investigation comprised a retrospective and observational cohort study. Analyzed 172 patients diagnosed with oral cavity OCSCC who underwent cervical dissection at Dr. Arnaldo Cancer Institute between 2014 to 2020. Inclusion criteria: histological diagnosis of OCSCC, curative-intent surgical intervention, and a minimum follow-up of 18 months. Cervical Level IIb was meticulously dissected and subjected to independent anatomopathological evaluation. Statistical analyses included Chi-Square tests for assessing associations between categorical variables and simple linear regression to explore correlation between Level IIb positivity and total nodal burden. A p-value of < 0.05 was predetermined as the threshold for statistical significance.",
        "Results": "The overall prevalence of metastatic lymph nodes at Level IIb was found to be 6.98% (12/172 patients). Within the subgroup of patients with confirmed positive lymph nodes (N+), the positivity rate specifically at Level IIb reached 15%. Linear regression analysis demonstrated a positive and statistically significant correlation between Level IIb positivity and the total burden of compromised lymph nodes (coefficient = 1.5654, p < 0.001). No statistically significant was observed with overall survival (p = 0.2540). However, a discernible statistical trend (p = 0.0688) indicated a higher rate of locoregional recurrence in the Level IIb positive group (41.7%) compared to Level IIb negative group (16.3%).",
        "Conclusion": "The low prevalence of metastases at Level IIb, consistent with literature, provides a strong rationale to adoption more selective surgical approaches in OCSCC. It is crucial to differentiate between the overall Level II (which can have a prevalence of up to 20%) and its specific sublevel IIb, given that Level IIa substantially contributes to the overall positivity rate of Level II. The positive correlation between Level IIb positivity and a higher total nodal burden suggests that, although infrequent, involvement of Level IIb signifies a more aggressive disease phenotype. The noted trend towards increased locoregional recurrence in Level IIb positive patients, despite not achieving full statistical significance, carries relevant clinical implications, indicating an elevated risk of regional failure. Preserving Level IIb, by mitigating shoulder dysfunction, offers substantial benefits to patients' quality of life. The prevalence of metastatic lymph nodes at Level IIb in OCSCC is reduced, particularly in early disease stages, thereby supporting more conservative cervical dissections to optimize accessory nerve function and patient quality of life. Nevertheless, the association of Level IIb positivity with more extensive nodal disease and a trend toward higher locoregional recurrence mandates differentiated clinical attention when present."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prevalence of Metastatic Lymph Nodes at Cervical Level IIb in Oral Cavity Squamous Cell Carcinomas: A Retrospective Study</span>. Pablo Ocampo Quintana, MD; Francisco Araujo Dias; Rafael Pereira De Souza; <u>Rafael De Cicco</u>. Instituto de Câncer Dr. Arnaldo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oral Cavity Squamous Cell Carcinoma (OCSCC) is a highly prevalent malignancy where lymphatic dissemination serves as critical prognostic factor. Oncological control, it frequently leads to significant morbidities, in Level IIb. This clinical dilemma underscores the need to balance therapeutic efficacy with the preservation of patient quality of life. Although Level II is commonly involved in OCSCC metastasis, the isolated prevalence of metastases within its sublevel IIb remains a subject of controversy. This study was designed to ascertain the prevalence of metastatic lymph nodes at Level IIb in OCSCC patients and correlate these findings with clinicopathological factors, as well as survival and recurrence outcomes.</p>\n\n<p><strong>Methods: </strong>This investigation comprised a retrospective and observational cohort study. Analyzed 172 patients diagnosed with oral cavity OCSCC who underwent cervical dissection at Dr. Arnaldo Cancer Institute between 2014 to 2020. Inclusion criteria: histological diagnosis of OCSCC, curative-intent surgical intervention, and a minimum follow-up of 18 months. Cervical Level IIb was meticulously dissected and subjected to independent anatomopathological evaluation. Statistical analyses included Chi-Square tests for assessing associations between categorical variables and simple linear regression to explore correlation between Level IIb positivity and total nodal burden. A p-value of < 0.05 was predetermined as the threshold for statistical significance.</p>\n\n<p><strong>Results: </strong>The overall prevalence of metastatic lymph nodes at Level IIb was found to be 6.98% (12/172 patients). Within the subgroup of patients with confirmed positive lymph nodes (N+), the positivity rate specifically at Level IIb reached 15%. Linear regression analysis demonstrated a positive and statistically significant correlation between Level IIb positivity and the total burden of compromised lymph nodes (coefficient = 1.5654, p < 0.001). No statistically significant was observed with overall survival (p = 0.2540). However, a discernible statistical trend (p = 0.0688) indicated a higher rate of locoregional recurrence in the Level IIb positive group (41.7%) compared to Level IIb negative group (16.3%).</p>\n\n<p><strong>Conclusion: </strong>The low prevalence of metastases at Level IIb, consistent with literature, provides a strong rationale to adoption more selective surgical approaches in OCSCC. It is crucial to differentiate between the overall Level II (which can have a prevalence of up to 20%) and its specific sublevel IIb, given that Level IIa substantially contributes to the overall positivity rate of Level II. The positive correlation between Level IIb positivity and a higher total nodal burden suggests that, although infrequent, involvement of Level IIb signifies a more aggressive disease phenotype. The noted trend towards increased locoregional recurrence in Level IIb positive patients, despite not achieving full statistical significance, carries relevant clinical implications, indicating an elevated risk of regional failure. Preserving Level IIb, by mitigating shoulder dysfunction, offers substantial benefits to patients' quality of life. The prevalence of metastatic lymph nodes at Level IIb in OCSCC is reduced, particularly in early disease stages, thereby supporting more conservative cervical dissections to optimize accessory nerve function and patient quality of life. Nevertheless, the association of Level IIb positivity with more extensive nodal disease and a trend toward higher locoregional recurrence mandates differentiated clinical attention when present.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154370--></body></html>"
    },
    {
      "uid": "P254",
      "content_id": "151908",
      "abstract_number": "P254",
      "poster_number": "P254",
      "title": "A Tale of Two Hospitals: Differences in Presentation, Treatment, and Outcomes in Oral Cavity Cancer between a Veterans Affairs Medical Center and County Hospital",
      "summary": "Patient cohorts at a VAMC and county hospital diagnosed with primary oral cavity cancer differed significantly in demographics, clinical presentation, treatment, and outcomes. Special care should be taken to increase the odds of early diagnosis and improve time from surgery to radiation in underserved populations.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151908",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Grace Amadio, MD",
      "presenter": "Grace Amadio, MD",
      "authors": "W. Craig Kemper, MD; Grace Amadio, MD ; Charles J Cook, BA; David Hernandez, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD",
      "normalized_authors": [
        "W. Craig Kemper",
        "Grace Amadio",
        "Charles J Cook",
        "David Hernandez",
        "Vlad C Sandulache",
        "Ray Y Wang"
      ],
      "affiliations": [
        "Baylor College of Medicine, Michael E. Debakey Veterans Affairs Medical Center"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine, Michael E. Debakey Veterans Affairs Medical Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 532,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Subjects/Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "W. Craig Kemper, MD; Grace Amadio, MD ; Charles J Cook, BA; David Hernandez, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD",
        "Affiliations": "Baylor College of Medicine, Michael E. Debakey Veterans Affairs Medical Center",
        "Objective": "To compare demographics, tumor characteristics, and survival for patients with oral cavity cancer in underserved populations in a tertiary referral veterans affairs medical center (VAMC) versus a tertiary referral county hospital in the same city.",
        "Study Design": "Retrospective cohort study",
        "Setting": "Tertiary referral VAMC, tertiary care county hospital",
        "Subjects/Methods": "Retrospective analysis of patients with a primary diagnosis of oral cavity cancer diagnosed and treated from 2010 to 2023. Categorical variables were compared with chi square analysis. Logistic and Cox regression analyses were performed in Stata.",
        "Results": "138 subjects at the VAMC and 154 at the county hospital were included. The mean age at the VAMC was 67 versus 55 at the county hospital (p<0.0001). The VAMC cohort had more males than the county hospital (99% vs 75%, p<0.01). Race differed with 83% white patients in the VAMC cohort versus 42% white patients in the county hospital (p<0.01) while the county hospital had more Hispanic patients compared to the VAMC (30% vs 2%, p<0.01). Patients at VAMC were more likely to smoke (85% vs 69%) and had more extensive smoking history (55 pack-years versus 19.05 pack-years, p<0.01). VAMC patients were more likely to have a prior history of head and neck cancer (15 vs 3%, p<0.01). Patients at the county hospital were more likely to present with advanced local (58% vs 36%, p <0.01) or regional (39% vs 20%, p < 0.01) disease. All patients were treated with definitive surgery; veterans were significantly more likely to be treated with surgery alone (50% vs 25%, p<0.01). A greater portion of patients at the county hospital underwent bony resection (48% vs 29%, p<0.01) and bilateral neck dissection (49% vs 25%, p<0.01) There were no differences in rates of positive margins, lymphovascular invasion, or perineural invasion, but extranodal extension was more prevalent at the county hospital (38% vs 14%, p<0.01). Time to surgery did not differ between sites, but patients at the county hospital were more likely to start radiation >42 days after surgery when compared to patients at the VAMC (p<0.01). The county hospital saw a greater burden of recurrence (37% vs 24%, p=0.02). Factors associated with increased risk of recurrence on logistic regression were N2 (HR 5.15, CI 1.48 - 17.97) or N3 (HR 4.91, CI 1.06 - 22.70) status for the county hospital, and T4b (HR 18.12, CI 2.37 - 138.37), N1 (HR 6.20, CI 1.06 - 36.36), and N2 (HR 10.21, CI 1.28 - 81.68) status for the VAMC. There was no significant difference in overall survival at the county hospital compared to VAMC (HR 0.73; CI 0.52 - 1.03; p = 0.07), but there was a significant decrease in disease free survival (HR 1.64; CI 1.01 - 2.65; p = 0.04).",
        "Conclusion": "Patient cohorts at a VAMC and county hospital diagnosed with primary oral cavity cancer differed significantly in demographics, clinical presentation, treatment, and outcomes. Special care should be taken to increase the odds of early diagnosis and improve time from surgery to radiation in underserved populations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Tale of Two Hospitals: Differences in Presentation, Treatment, and Outcomes in Oral Cavity Cancer between a Veterans Affairs Medical Center and County Hospital</span>. W. Craig Kemper, MD; <u>Grace Amadio, MD</u>; Charles J Cook, BA; David Hernandez, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD. Baylor College of Medicine, Michael E. Debakey Veterans Affairs Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To compare demographics, tumor characteristics, and survival for patients with oral cavity cancer in underserved populations in a tertiary referral veterans affairs medical center (VAMC) versus a tertiary referral county hospital in the same city. </p>\n\n<p><strong>Study Design: </strong>Retrospective cohort study </p>\n\n<p><strong>Setting:</strong> Tertiary referral VAMC, tertiary care county hospital </p>\n\n<p><strong>Subjects/Methods:</strong> Retrospective analysis of patients with a primary diagnosis of oral cavity cancer diagnosed and treated from 2010 to 2023. Categorical variables were compared with chi square analysis. Logistic and Cox regression analyses were performed in Stata.</p>\n\n<p><strong>Results:</strong> 138 subjects at the VAMC and 154 at the county hospital were included. The mean age at the VAMC was 67 versus 55 at the county hospital (p<0.0001). The VAMC cohort had more males than the county hospital (99% vs 75%, p<0.01). Race differed with 83% white patients in the VAMC cohort versus 42% white patients in the county hospital (p<0.01) while the county hospital had more Hispanic patients compared to the VAMC (30% vs 2%, p<0.01). Patients at VAMC were more likely to smoke (85% vs 69%) and had more extensive smoking history (55 pack-years versus 19.05 pack-years, p<0.01). VAMC patients were more likely to have a prior history of head and neck cancer (15 vs 3%, p<0.01). Patients at the county hospital were more likely to present with advanced local (58% vs 36%, p <0.01) or regional (39% vs 20%, p < 0.01) disease. All patients were treated with definitive surgery; veterans were significantly more likely to be treated with surgery alone (50% vs 25%, p<0.01). A greater portion of patients at the county hospital underwent bony resection (48% vs 29%, p<0.01) and bilateral neck dissection (49% vs 25%, p<0.01) There were no differences in rates of positive margins, lymphovascular invasion, or perineural invasion, but extranodal extension was more prevalent at the county hospital (38% vs 14%, p<0.01). Time to surgery did not differ between sites, but patients at the county hospital were more likely to start radiation >42 days after surgery when compared to patients at the VAMC (p<0.01). The county hospital saw a greater burden of recurrence (37% vs 24%, p=0.02). Factors associated with increased risk of recurrence on logistic regression were N2 (HR 5.15, CI 1.48 - 17.97) or N3 (HR 4.91, CI 1.06 - 22.70) status for the county hospital, and T4b (HR 18.12, CI 2.37 - 138.37), N1 (HR 6.20, CI 1.06 - 36.36), and N2 (HR 10.21, CI 1.28 - 81.68) status for the VAMC. There was no significant difference in overall survival at the county hospital compared to VAMC (HR 0.73; CI 0.52 - 1.03; p = 0.07), but there was a significant decrease in disease free survival (HR 1.64; CI 1.01 - 2.65; p = 0.04).</p>\n\n<p><strong>Conclusion: </strong>Patient cohorts at a VAMC and county hospital diagnosed with primary oral cavity cancer differed significantly in demographics, clinical presentation, treatment, and outcomes. Special care should be taken to increase the odds of early diagnosis and improve time from surgery to radiation in underserved populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151908--></body></html>"
    },
    {
      "uid": "P255",
      "content_id": "155584",
      "abstract_number": "P255",
      "poster_number": "P255",
      "title": "The Effect of Alcohol Use Disorder on Overall Survival in Early-Stage Oral Cavity Squamous Cell Carcinoma",
      "summary": "Alcohol use disorder is significantly associated with worsened overall survival in patients with a history of ES-OCSCC. This finding may serve to highlight the need for medical and psychosocial optimizations in achieving survival after treatment for early stage head and neck cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155584",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Rind, MD",
      "presenter": "Fahad Rind, MD",
      "authors": "Fahad Rind, MD 1 ; Enver Ozer, MD 1 ; Kyle VanKoevering, MD 1 ; Catherine T Haring, MD, PhD 1 ; James W Rocco, MD, PhD 1 ; Amit Agrawal, MD 1 ; Stephen Y Kang, MD 1 ; Ricardo L Carrau, MD, MBA 1 ; Lauren E Miller, MD, MBA 1 ; Matthew O Old, MD 2 ; Nolan B Seim, MD, MBA 1",
      "normalized_authors": [
        "Fahad Rind",
        "Enver Ozer",
        "Kyle VanKoevering",
        "Catherine T Haring",
        "James W Rocco",
        "Amit Agrawal",
        "Stephen Y Kang",
        "Ricardo L Carrau",
        "Lauren E Miller",
        "Matthew O Old",
        "Nolan B Seim"
      ],
      "affiliations": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "normalized_institutions": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155584/KM%20curve.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155584/KM%20curve.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155584"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 362,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Fahad Rind, MD 1 ; Enver Ozer, MD 1 ; Kyle VanKoevering, MD 1 ; Catherine T Haring, MD, PhD 1 ; James W Rocco, MD, PhD 1 ; Amit Agrawal, MD 1 ; Stephen Y Kang, MD 1 ; Ricardo L Carrau, MD, MBA 1 ; Lauren E Miller, MD, MBA 1 ; Matthew O Old, MD 2 ; Nolan B Seim, MD, MBA 1",
        "Affiliations": "1 The Ohio State University; 2 The University of Washington",
        "Introduction": "Early stage (cT1-2N0M0) oral cavity squamous cell carcinoma (ES-OCSCC) represents a relatively treatable section of head and neck cancer. In the absence of nodal metastases, there are clinical and pathological variable with which to prognosticate patients. The risk imposed by alcohol and smoking history is well established in advanced stage oral cavity, however, it’s effect on long term survival is less understood in the ES-OCSCC cohort. This study aims to investigate the prognostic effect of alcohol use disorder (AUD) in early-stage OCSCC patients.",
        "Methods": "A retrospective chart review was conducted of ES-OCSCC patients between 2015 and 2019 inclusive, undergoing curative intent surgery. Alcohol use disorder (AUD+) was defined as lifetime occurrence of AUD or alcohol intake of 14 or more drinks per week. Continuous variables were compared with T-test and categorical variables were compared with regression analysis. Survival analysis was graphically displayed as Kaplan-Meier curves and multivariate survival analysis modelling was presented as hazard ratios (HR) with 95% confidence intervals (CI).",
        "Results": "In total, 183 patients were included of which 104 were male (56.8%) with a mean age of 61.9 years. The rate of 5-year recurrence was 12% (22/183). Patients in the AUD+ cohort suffered a worsened overall survival compared with patients without AUD i.e. median survival was 102 vs 90 months. Overall survival was also significantly affected by patient age, pT stage, lymphovascular invasion (LVI), perineural invasion, AUD (HR 1.695, 95% CI 1.006 to 2.857, p=0.048), and depth of invasion (DOI). In a multivariate model controlling for covariates, the significant negative effect of AUD on OS persisted i.e. HR 2.055, 95% CI 1.181 to 3.575), p = 0.011. AUD did not significantly affect the locoregional disease free survival (HR 1.593, 95% CI 0.950 to 2.673, p=0.078) as a univariate outcome. Postop adjuvant radiation did not have a significant effect on overall survival.",
        "Conclusion": "Alcohol use disorder is significantly associated with worsened overall survival in patients with a history of ES-OCSCC. This finding may serve to highlight the need for medical and psychosocial optimizations in achieving survival after treatment for early stage head and neck cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Effect of Alcohol Use Disorder on Overall Survival in Early-Stage Oral Cavity Squamous Cell Carcinoma</span>. <u>Fahad Rind, MD</u><sup>1</sup>; Enver Ozer, MD<sup>1</sup>; Kyle VanKoevering, MD<sup>1</sup>; Catherine T Haring, MD, PhD<sup>1</sup>; James W Rocco, MD, PhD<sup>1</sup>; Amit Agrawal, MD<sup>1</sup>; Stephen Y Kang, MD<sup>1</sup>; Ricardo L Carrau, MD, MBA<sup>1</sup>; Lauren E Miller, MD, MBA<sup>1</sup>; Matthew O Old, MD<sup>2</sup>; Nolan B Seim, MD, MBA<sup>1</sup>. <sup>1</sup>The Ohio State University; <sup>2</sup>The University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Early stage (cT1-2N0M0) oral cavity squamous cell carcinoma (ES-OCSCC) represents a relatively treatable section of head and neck cancer. In the absence of nodal metastases, there are clinical and pathological variable with which to prognosticate patients. The risk imposed by alcohol and smoking history is well established in advanced stage oral cavity, however, it’s effect on long term survival is less understood in the ES-OCSCC cohort. This study aims to investigate the prognostic effect of alcohol use disorder (AUD) in early-stage OCSCC patients.</p>\n\n<p><strong>Methods:</strong> A retrospective chart review was conducted of ES-OCSCC patients between 2015 and 2019 inclusive, undergoing curative intent surgery. Alcohol use disorder (AUD+) was defined as lifetime occurrence of AUD or alcohol intake of 14 or more drinks per week. Continuous variables were compared with T-test and categorical variables were compared with regression analysis. Survival analysis was graphically displayed as Kaplan-Meier curves and multivariate survival analysis modelling was presented as hazard ratios (HR) with 95% confidence intervals (CI).</p>\n\n<p><strong>Results:</strong> In total, 183 patients were included of which 104 were male (56.8%) with a mean age of 61.9 years. The rate of 5-year recurrence was 12% (22/183). Patients in the AUD+ cohort suffered a worsened overall survival compared with patients without AUD i.e. median survival was 102 vs 90 months. Overall survival was also significantly affected by patient age, pT stage, lymphovascular invasion (LVI), perineural invasion, AUD (HR 1.695, 95% CI 1.006 to 2.857, p=0.048), and depth of invasion (DOI). In a multivariate model controlling for covariates, the significant negative effect of AUD on OS persisted i.e. HR 2.055, 95% CI 1.181 to 3.575), p = 0.011. AUD did not significantly affect the locoregional disease free survival (HR 1.593, 95% CI 0.950 to 2.673, p=0.078) as a univariate outcome. Postop adjuvant radiation did not have a significant effect on overall survival.</p>\n\n<p><strong>Conclusion:</strong> Alcohol use disorder is significantly associated with worsened overall survival in patients with a history of ES-OCSCC. This finding may serve to highlight the need for medical and psychosocial optimizations in achieving survival after treatment for early stage head and neck cancer. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155584/KM%20curve.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155584--></body></html>"
    },
    {
      "uid": "P256",
      "content_id": "155592",
      "abstract_number": "P256",
      "poster_number": "P256",
      "title": "Outcomes with Adjuvant Radiation Therapy in Early-Stage Oral Cavity Squamous Cell Carcinoma",
      "summary": "The NCCN guidelines recommend consideration for adjuvant radiation therapy in early stage OCSCC with the presence of PNI, LVI, and positive margins. Our findings suggest a role of radiation in PNI+ cases but without apparent benefit of radiation therapy in AUD and high grade tumors; despite their poor prognostic outcomes. These findings warrant further investigation and consideration for additional treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155592",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Rind, MD",
      "presenter": "Fahad Rind, MD",
      "authors": "Fahad Rind, MD 1 ; Stephen Y Kang, MD 1 ; Amit Agrawal, MD 1 ; Kyle VanKoevering, MD 1 ; Enver Ozer, MD 1 ; Dukagjin Blakaj, MD, PhD 1 ; Emile Gogineni, MD 1 ; Catherine T Haring, MD, PhD 1 ; Lauren E Miller, MD, MBA 1 ; James W Rocco, MD, PhD 1 ; Ricardo L Carrau, MD, MBA 1 ; Matthew O Old, MD 2 ; Nolan B Seim, MD, MBA 1",
      "normalized_authors": [
        "Fahad Rind",
        "Stephen Y Kang",
        "Amit Agrawal",
        "Kyle VanKoevering",
        "Enver Ozer",
        "Dukagjin Blakaj",
        "Emile Gogineni",
        "Catherine T Haring",
        "Lauren E Miller",
        "James W Rocco",
        "Ricardo L Carrau",
        "Matthew O Old",
        "Nolan B Seim"
      ],
      "affiliations": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "normalized_institutions": [
        "The Ohio State University",
        "The University of Washington"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155592/Radiation%20and%20high%20risk%20prognostics%20crossplots.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155592/Radiation%20and%20high%20risk%20prognostics%20crossplots.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155592"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 319,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Fahad Rind, MD 1 ; Stephen Y Kang, MD 1 ; Amit Agrawal, MD 1 ; Kyle VanKoevering, MD 1 ; Enver Ozer, MD 1 ; Dukagjin Blakaj, MD, PhD 1 ; Emile Gogineni, MD 1 ; Catherine T Haring, MD, PhD 1 ; Lauren E Miller, MD, MBA 1 ; James W Rocco, MD, PhD 1 ; Ricardo L Carrau, MD, MBA 1 ; Matthew O Old, MD 2 ; Nolan B Seim, MD, MBA 1",
        "Affiliations": "1 The Ohio State University; 2 The University of Washington",
        "Introduction": "Early-stage oral cavity squamous cell carcinoma (OCSCC) has meaningfully better survival outcomes compared to advanced oral cavity (OCSCC). The National Comprehensive Cancer Network Head and Neck guidelines provide the option of adjuvant radiation when pathology exhibits high-risk features.",
        "Methods": "This single institution, retrospective study includes patients with pT1-3 pN0 M0 OCSCC included and sub-stratified into early stage (ES) T1-2 and T3 only cohorts. Predictors of receiving radiation therapy and its effect on overall survival (OS) and locoregional disease-free survival (LRDFS) were investigated using univariable and multivariable cox-proportional hazards-models reported as hazard ratios (HR) with a 95% confidence interval.",
        "Results": "285 patients with pathologic staging T1-3 N0 M0 were included. This was subdivided into 235 ES cases and 51 T3 only cases. In our cohort, 18.2% (n=52) of OCSCC patients received adjuvant radiation, 29.1% suffered all-cause mortality within 5 years (n=83), and 34.4% suffered a recurrence or died within 5 years (n=98). Patients receiving adjuvant radiation were more likely to have tumors with greater size & depth invasion, and exhibit perineural invasion (PNI; p<0.05).",
        "Abstract": "In the total cohort, overall survival was associated with alcohol use disorder, LVI, PNI & tumor grade and locoregional survival was associated with age, alcohol use disorder (AUD), PNI & tumor grade (p<0.05). In the early stage cohort, worsened OS and worsened LRDFS was associated with age, AUD, LVI, PNI & tumor grade (p<0.05). Adjuvant radiation therapy was not associated with a significant effect on survival outcomes in any studied cohort.",
        "Conclusion": "The NCCN guidelines recommend consideration for adjuvant radiation therapy in early stage OCSCC with the presence of PNI, LVI, and positive margins. Our findings suggest a role of radiation in PNI+ cases but without apparent benefit of radiation therapy in AUD and high grade tumors; despite their poor prognostic outcomes. These findings warrant further investigation and consideration for additional treatment strategies for patients with non-metastatic OCSCC with high-risk features."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes with Adjuvant Radiation Therapy in Early-Stage Oral Cavity Squamous Cell Carcinoma</span>. <u>Fahad Rind, MD</u><sup>1</sup>; Stephen Y Kang, MD<sup>1</sup>; Amit Agrawal, MD<sup>1</sup>; Kyle VanKoevering, MD<sup>1</sup>; Enver Ozer, MD<sup>1</sup>; Dukagjin Blakaj, MD, PhD<sup>1</sup>; Emile Gogineni, MD<sup>1</sup>; Catherine T Haring, MD, PhD<sup>1</sup>; Lauren E Miller, MD, MBA<sup>1</sup>; James W Rocco, MD, PhD<sup>1</sup>; Ricardo L Carrau, MD, MBA<sup>1</sup>; Matthew O Old, MD<sup>2</sup>; Nolan B Seim, MD, MBA<sup>1</sup>. <sup>1</sup>The Ohio State University; <sup>2</sup>The University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/155592/Radiation%20and%20high%20risk%20prognostics%20crossplots.png' /></p>\n\n<p><strong>Introduction:</strong> Early-stage oral cavity squamous cell carcinoma (OCSCC) has meaningfully better survival outcomes compared to advanced oral cavity (OCSCC). The National Comprehensive Cancer Network Head and Neck guidelines provide the option of adjuvant radiation when pathology exhibits high-risk features.</p>\n\n<p><strong>Methods: </strong>This single institution, retrospective study includes patients with pT1-3 pN0 M0 OCSCC included and sub-stratified into early stage (ES) T1-2 and T3 only cohorts. Predictors of receiving radiation therapy and its effect on overall survival (OS) and locoregional disease-free survival (LRDFS) were investigated using univariable and multivariable cox-proportional hazards-models reported as hazard ratios (HR) with a 95% confidence interval.</p>\n\n<p><strong>Results: </strong>285 patients with pathologic staging T1-3 N0 M0 were included. This was subdivided into 235 ES cases and 51 T3 only cases. In our cohort, 18.2% (n=52) of OCSCC patients received adjuvant radiation, 29.1% suffered all-cause mortality within 5 years (n=83), and 34.4% suffered a recurrence or died within 5 years (n=98). Patients receiving adjuvant radiation were more likely to have tumors with greater size & depth invasion, and  exhibit perineural invasion (PNI; p<0.05).</p>\n\n<p>In the total cohort, overall survival was associated with alcohol use disorder, LVI, PNI & tumor grade  and locoregional survival was associated with age, alcohol use disorder (AUD), PNI & tumor grade (p<0.05). In the early stage cohort, worsened OS and worsened LRDFS was associated with age, AUD, LVI, PNI & tumor grade (p<0.05). Adjuvant radiation therapy was not associated with a significant effect on survival outcomes in any studied cohort.</p>\n\n<p><strong>Conclusion:</strong> The NCCN guidelines recommend consideration for adjuvant radiation therapy in early stage OCSCC with the presence of PNI, LVI, and positive margins. Our findings suggest a role of radiation in PNI+ cases but without apparent benefit of radiation therapy in AUD and high grade tumors; despite their poor prognostic outcomes. These findings warrant further investigation and consideration for additional treatment strategies for patients with non-metastatic OCSCC with high-risk features.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155592--></body></html>"
    },
    {
      "uid": "P257",
      "content_id": "154736",
      "abstract_number": "P257",
      "poster_number": "P257",
      "title": "Association of Clinical (cT) Tumor size with Pathological Depth of Invasion (DOI) in oral cavity (Lower-Alveolus) Squamous Cell Carcinoma",
      "summary": "The findings of this study demonstrated that Clinical Tumor Stage (cT) is a significant predictor of Pathological Depth of Invasion (DOI) in patients with lower alveolus squamous cell carcinoma, with 95% confidence intervals indicating a strong positive linear association. Additionally, the Total Number of Positive Lymph Nodes(pN) also showed a significant positive association with DOI. These results suggest that...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154736",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Asad Iqbal, Dr",
      "presenter": "Asad Iqbal, Dr",
      "authors": "Asad Iqbal, Dr 1 ; Ayesha Saleem, Dr 1 ; Muhammad Faisal, Dr 2 ; Raza Hussain, Dr 2",
      "normalized_authors": [
        "Asad Iqbal, Dr",
        "Ayesha Saleem, Dr",
        "Muhammad Faisal, Dr",
        "Raza Hussain, Dr"
      ],
      "affiliations": [
        "Aga Khan University Hospital",
        "Shaukat Khan Memorial Cancer Hospital and Research Centre"
      ],
      "normalized_institutions": [
        "Aga Khan University Hospital",
        "Shaukat Khan Memorial Cancer Hospital and Research Centre"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Research Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Asad Iqbal, Dr 1 ; Ayesha Saleem, Dr 1 ; Muhammad Faisal, Dr 2 ; Raza Hussain, Dr 2",
        "Affiliations": "1 Aga Khan University Hospital; 2 Shaukat Khan Memorial Cancer Hospital and Research Centre",
        "Background": "Oral cavity squamous cell carcinoma (OCSCC) demonstrates aggressive behavior, predominantly influenced by the degree of tissue invasion. Although clinical tumour size (cT) is routinely used for staging, it does not reliably predict biological aggressiveness or cervical nodal involvement. Pathological depth of invasion (DOI) has been shown to be a more accurate prognostic indicator; however, its relationship with cT remains under-investigated in specific anatomical subsites such as the lower alveolus, where early bone and soft-tissue infiltration complicate pre-operative assessment.",
        "Research Objective": "The objective of the study is to determine whether clinical (cT) Tumor Size predicts pathological depth of invasion in lower-alveolus Squamous Cell Carcinoma.",
        "Methods": "A retrospective cohort study was conducted using hospital records of 156 patients with lower-alveolus SCC, of which 114 were included after data cleaning. Non-probability consecutive sampling was used. Data was collected from Shaukat Khanum Memorial Hospital and Research Centre.Descriptive statistics were calculated, followed by univariate screening. Variables meeting criteria were assessed for multicollinearity, followed by stepwise multivariable linear regression. Model adequacy was evaluated using normal probability plots, residual diagnostics, and influential observation assessment (Leverage, Cook’s distance, DFBETA, DFIT, Studentized residuals). A transformation model and robust regression were also tested for comparison.",
        "Results": "In univariate analysis, cT stage, pathological tumour size, total number of positive lymph nodes, cN stage, and tumor grade showed associations with DOI. After correlation assessment, three variables (cT, total nodes positive, tumor grade) were included in multivariable modelling. Stepwise regression retained only cT and total positive nodes as significant predictors. The final model, selected after removal of influential outliers, met all assumptions of linearity, normality, independence, and homoscedasticity. In the final model, increasing positive lymph nodes were associated with a 0.5688 mm increase in DOI per node. Compared with cT1, patients in higher clinical stages had significantly greater pathological depth of invasion: cT2 tumours were, on average, 3.15 mm deeper, cT3 tumours were 4.67 mm deeper, and cT4 tumours were 4.66 mm deeper.",
        "Conclusion": "The findings of this study demonstrated that Clinical Tumor Stage (cT) is a significant predictor of Pathological Depth of Invasion (DOI) in patients with lower alveolus squamous cell carcinoma, with 95% confidence intervals indicating a strong positive linear association. Additionally, the Total Number of Positive Lymph Nodes(pN) also showed a significant positive association with DOI. These results suggest that larger clinical tumor size is associated with greater depth of invasion, which is a well-established risk factor for regional lymph node metastasis. Therefore, clinical tumor stage can be considered a reliable marker for predicting more advanced pathological behavior. Incorporating these predictors into clinical assessment may support more accurate risk stratification and guide surgical decision-making, including the need for elective neck dissection in selected patients. Because DOI strongly predicts nodal metastasis and prognosis, integrating clinical tumor stage into routine assessment can enable earlier intervention, improve treatment decisions, and enhance oral cancer outcomes by identifying high-risk patients sooner and optimizing resource allocation in high-incidence settings."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Clinical (cT) Tumor size with Pathological Depth of Invasion (DOI) in oral cavity (Lower-Alveolus) Squamous Cell Carcinoma</span>. <u>Asad Iqbal, Dr</u><sup>1</sup>; Ayesha Saleem, Dr<sup>1</sup>; Muhammad Faisal, Dr<sup>2</sup>; Raza Hussain, Dr<sup>2</sup>. <sup>1</sup>Aga Khan University Hospital; <sup>2</sup>Shaukat Khan Memorial Cancer Hospital and Research Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Oral cavity squamous cell carcinoma (OCSCC) demonstrates aggressive behavior, predominantly influenced by the degree of tissue invasion. Although clinical tumour size (cT) is routinely used for staging, it does not reliably predict biological aggressiveness or cervical nodal involvement. Pathological depth of invasion (DOI) has been shown to be a more accurate prognostic indicator; however, its relationship with cT remains under-investigated in specific anatomical subsites such as the lower alveolus, where early bone and soft-tissue infiltration complicate pre-operative assessment.</p>\n\n<p><strong>Research Objective: </strong>The objective of the study is to determine whether clinical (cT) Tumor Size predicts pathological depth of invasion in lower-alveolus Squamous Cell Carcinoma.</p>\n\n<p><strong>Methods</strong>: A retrospective cohort study was conducted using hospital records of 156 patients with lower-alveolus SCC, of which 114 were included after data cleaning. Non-probability consecutive sampling was used. Data was collected from Shaukat Khanum Memorial Hospital and  Research Centre.Descriptive statistics were calculated, followed by univariate screening. Variables meeting criteria were assessed for multicollinearity, followed by stepwise multivariable linear regression. Model adequacy was evaluated using normal probability plots, residual diagnostics, and influential observation assessment (Leverage, Cook’s distance, DFBETA, DFIT, Studentized residuals). A transformation model and robust regression were also tested for comparison.</p>\n\n<p><strong>Results</strong>: In univariate analysis, cT stage, pathological tumour size, total number of positive lymph nodes, cN stage, and tumor grade showed associations with DOI. After correlation assessment, three variables (cT, total nodes positive, tumor grade) were included in multivariable modelling. Stepwise regression retained only cT and total positive nodes as significant predictors. The final model, selected after removal of influential outliers, met all assumptions of linearity, normality, independence, and homoscedasticity. In the final model, increasing positive lymph nodes were associated with a 0.5688 mm increase in DOI per node. Compared with cT1, patients in higher clinical stages had significantly greater pathological depth of invasion: cT2 tumours were, on average, 3.15 mm deeper, cT3 tumours were 4.67 mm deeper, and cT4 tumours were 4.66 mm deeper.</p>\n\n<p><strong>Conclusion: </strong>The findings of this study demonstrated that Clinical Tumor Stage (cT) is a significant predictor of Pathological Depth of Invasion (DOI) in patients with lower alveolus squamous cell carcinoma, with 95% confidence intervals indicating a strong positive linear association. Additionally, the Total Number of Positive Lymph Nodes(pN) also showed a significant positive association with DOI. These results suggest that larger clinical tumor size is associated with greater depth of invasion, which is a well-established risk factor for regional lymph node metastasis. Therefore, clinical tumor stage can be considered a reliable marker for predicting more advanced pathological behavior. Incorporating these predictors into clinical assessment may support more accurate risk stratification and guide surgical decision-making, including the need for elective neck dissection in selected patients. Because DOI strongly predicts nodal metastasis and prognosis, integrating clinical tumor stage into routine assessment can enable earlier intervention, improve treatment decisions, and enhance oral cancer outcomes by identifying high-risk patients sooner and optimizing resource allocation in high-incidence settings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154736--></body></html>"
    },
    {
      "uid": "P258",
      "content_id": "153101",
      "abstract_number": "P258",
      "poster_number": "P258",
      "title": "Two sounds great, but one is better: one copy of GSTM1 decreased the death risk between OSCC mainstay treatment approaches",
      "summary": "Our findings suggest that the CNV of GSTM1 might be a predictor of OSCC treatment response that 1 copy of the gene was related to the better prognostic of surgery alone or combined with the chemoradiotherapy. These results may aid the application of the best treatment approach for each patient according to his endogenous detoxification capacity, which might improve the therapy efficacy and the quality of life of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153101",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fernanda T Goncalves, PhD",
      "presenter": "Fernanda T Goncalves, PhD",
      "authors": "Fernanda T Goncalves, PhD ; Isabela Firigato, MSc",
      "normalized_authors": [
        "Fernanda T Goncalves",
        "Isabela Firigato"
      ],
      "affiliations": [
        "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM40 do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo"
      ],
      "normalized_institutions": [
        "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM40 do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 377,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Fernanda T Goncalves, PhD ; Isabela Firigato, MSc",
        "Affiliations": "Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM40 do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo",
        "Background": "High and stable mortality rates of oral squamous cell carcinoma (OSCC) is also supported by the failure of mainstay treatment approaches as surgery, radiotherapy, and chemotherapy. The identification of predictors for the therapy response might optimize the treatment efficacy that molecules related to the metabolization of risk factors and therapy compounds may be a promising target. Among them is the copy number variation (CNV) of the gene GSTM1 that promotes the range from 0 (gene deletion) to 2 copies and yields a dose-dependent relationship with the level of the enzyme GSTM1. The CNV of GSTM1 was investigated whether it impacts OSCC overall survival (OS) according to the treatment approach.",
        "Methods": "A total of 234 OSCC patients were recruited from a public Hospital at São Paulo, Brazil, and were followed-up from 2000 to 2019. CNV of GSTM1 was determined by TaqMan qPCR. OS was evaluated according to the interaction between the CNV of GSTM1 and surgery, surgery and chemoradiotherapy, and chemoradiotherapy throughout the Kaplan-Meier method with the Log-rank test and Cox Regression with Hazard Ratio (HR) and 95% of confidence interval (CI).",
        "Results": "OSCC patients that had one copy of GSTM1 and were treated by surgery alone presented the decreased death risk of 62% (HR 0.38; 95% CI 0.21-0.63) while the interaction between one copy of GSTM1 and surgery combined with chemoradiotherapy showed a decreased death risk of 47% (HR 0.53; 95%CI 0.29-0.98). Additionally, OSCC patients with two copies of GSTM1 that underwent to surgery alone showed a 5-year OS of 78%, but among the chemoradiotherapy approach OSCC patients with one copy of GSTM1 showed highest OS probabilities: a 5-year OS of 49% for chemoradiotherapy combined with surgery and a 5-year OS of 44% for chemoradiotherapy alone. On the other hand, zero copies of GSTM1 showed worst OS probabilities for each treatment approach.",
        "Conclusions": "Our findings suggest that the CNV of GSTM1 might be a predictor of OSCC treatment response that 1 copy of the gene was related to the better prognostic of surgery alone or combined with the chemoradiotherapy. These results may aid the application of the best treatment approach for each patient according to his endogenous detoxification capacity, which might improve the therapy efficacy and the quality of life of the patient."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Two sounds great, but one is better: one copy of GSTM1 decreased the death risk between OSCC mainstay treatment approaches</span>. <u>Fernanda T Goncalves, PhD</u>; Isabela Firigato, MSc. Laboratorio de Genetica e Biologia Molecular, Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao, LIM40 do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>High and stable mortality rates of oral squamous cell carcinoma (OSCC) is also supported by the failure of mainstay treatment approaches as surgery, radiotherapy, and chemotherapy. The identification of predictors for the therapy response might optimize the treatment efficacy that molecules related to the metabolization of risk factors and therapy compounds may be a promising target. Among them is the copy number variation (CNV) of the gene <em>GSTM1</em> that promotes the range from 0 (gene deletion) to 2 copies and yields a dose-dependent relationship with the level of the enzyme GSTM1. The CNV of <em>GSTM1</em> was investigated whether it impacts OSCC overall survival (OS) according to the treatment approach.</p>\n\n<p><strong>Methods:</strong> A total of 234 OSCC patients were recruited from a public Hospital at São Paulo, Brazil, and were followed-up from 2000 to 2019. CNV of <em>GSTM1</em> was determined by TaqMan qPCR. OS was evaluated according to the interaction between the CNV of <em>GSTM1</em> and surgery, surgery and chemoradiotherapy, and chemoradiotherapy throughout the Kaplan-Meier method with the Log-rank test and Cox Regression with Hazard Ratio (HR) and 95% of confidence interval (CI).</p>\n\n<p><strong>Results: </strong>OSCC patients that had one copy of <em>GSTM1</em> and were treated by surgery alone presented the decreased death risk of 62% (HR 0.38; 95% CI 0.21-0.63) while the interaction between one copy of <em>GSTM1</em> and surgery combined with chemoradiotherapy showed a decreased death risk of 47% (HR 0.53; 95%CI 0.29-0.98). Additionally, OSCC patients with two copies of <em>GSTM1</em> that underwent to surgery alone showed a 5-year OS of 78%, but among the chemoradiotherapy approach OSCC patients with one copy of <em>GSTM1</em> showed highest OS probabilities: a 5-year OS of 49% for chemoradiotherapy combined with surgery and a 5-year OS of 44% for chemoradiotherapy alone. On the other hand, zero copies of <em>GSTM1</em> showed worst OS probabilities for each treatment approach.</p>\n\n<p><strong>Conclusions:</strong> Our findings suggest that the CNV of <em>GSTM1</em> might be a predictor of OSCC treatment response that 1 copy of the gene was related to the better prognostic of surgery alone or combined with the chemoradiotherapy. These results may aid the application of the best treatment approach for each patient according to his endogenous detoxification capacity, which might improve the therapy efficacy and the quality of life of the patient.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153101--></body></html>"
    },
    {
      "uid": "P259",
      "content_id": "154472",
      "abstract_number": "P259",
      "poster_number": "P259",
      "title": "Selective Neck Dissection in cN+ Oral Cancer: Does Imaging Modality and Dissection Extent Affect Survival Outcomes?",
      "summary": "Selective neck dissection achieves oncologic outcomes equivalent to more extensive dissection in cN+ OSCC patients, with both NRFS and DSS being independent of dissection extent. The declining positive predictive value of clinical staging reflects improved imaging technology detecting subclinical disease rather than true diagnostic impairment. These findings support treatment de-escalation in appropriately...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154472",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Jose G Vartanian, MD, PhD ; Hugo F Kohler, MD; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Jose G Vartanian",
        "Hugo F Kohler",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 417,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jose G Vartanian, MD, PhD ; Hugo F Kohler, MD; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "Background": "Therapeutic neck dissection effectively controls cervical metastases in oral squamous cell carcinoma. However, the role of selective neck dissection versus radical approaches in clinically node-positive disease remains controversial, with ongoing debate regarding oncologic safety versus functional preservation. Although the diagnostic accuracy of various preoperative imaging modalities has been extensively discussed in the literature, their impact on long-term oncologic outcomes remains largely unexamined.",
        "Objective": "To evaluate the impact of preoperative imaging modalities on neck staging accuracy and compare oncologic outcomes between selective neck dissection (SND) and modified/radical neck dissection (M/RND) in patients with clinically node-positive oral squamous cell carcinoma (OSCC).",
        "Methods": "This retrospective cohort study included treatment-naive patients with cN1-2 OSCC. Primary endpoints were neck recurrence-free survival (NRFS) and disease-specific survival (DSS). Survival analysis employed log-rank testing and Cox proportional hazards models. Propensity score matching addressed selection bias between treatment groups. Temporal trends in imaging modality utilization and diagnostic accuracy were analyzed across the study period.",
        "Results": "Among 600 consecutive patients, 186 (31.0%) underwent SND and 414 (69.0%) received M/RND. Preoperative staging methodology evolved significantly during the study period, with increasing adoption of cross-sectional imaging (CT/MRI) replacing physical examination and ultrasonography. This transition corresponded with declining positive predictive value from 63% to 31%, reflecting stage migration and improved detection of occult nodal disease.",
        "Abstract": "Neck recurrence occurred in 14 SND patients (7.5%) versus 51 M/RND patients (12.3%). Multivariate Cox regression demonstrated SND was associated with improved DSS compared to M/RND (p<0.05), though NRFS showed no significant difference. Propensity score-matched analysis confirmed the DSS advantage for SND while maintaining comparable NRFS. Among pathologically node-positive (pN+) patients, dissection extent did not significantly influence NRFS, a finding that persisted after propensity score matching. Similarly, nodal metastatic burden showed no correlation with neck recurrence rates. Even in the pN2-3 subset, NRFS remained statistically equivalent between SND and M/RND groups. Comparative analysis across time periods and staging modalities revealed no differences in either NRFS or DSS.",
        "Conclusion": "Selective neck dissection achieves oncologic outcomes equivalent to more extensive dissection in cN+ OSCC patients, with both NRFS and DSS being independent of dissection extent. The declining positive predictive value of clinical staging reflects improved imaging technology detecting subclinical disease rather than true diagnostic impairment. These findings support treatment de-escalation in appropriately selected patients, potentially reducing surgical morbidity without compromising oncologic safety. Future investigations should focus on integrating advanced imaging to refine patient selection for selective dissection and identify subgroups where nodal metastatic patterns might warrant extended resection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Selective Neck Dissection in cN+ Oral Cancer: Does Imaging Modality and Dissection Extent Affect Survival Outcomes?</span>. <u>Jose G Vartanian, MD, PhD</u>; Hugo F Kohler, MD; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Therapeutic neck dissection effectively controls cervical metastases in oral squamous cell carcinoma. However, the role of selective neck dissection versus radical approaches in clinically node-positive disease remains controversial, with ongoing debate regarding oncologic safety versus functional preservation. Although the diagnostic accuracy of various preoperative imaging modalities has been extensively discussed in the literature, their impact on long-term oncologic outcomes remains largely unexamined.</p>\n\n<p><strong>Objective: </strong>To evaluate the impact of preoperative imaging modalities on neck staging accuracy and compare oncologic outcomes between selective neck dissection (SND) and modified/radical neck dissection (M/RND) in patients with clinically node-positive oral squamous cell carcinoma (OSCC).</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study included treatment-naive patients with cN1-2 OSCC. Primary endpoints were neck recurrence-free survival (NRFS) and disease-specific survival (DSS). Survival analysis employed log-rank testing and Cox proportional hazards models. Propensity score matching addressed selection bias between treatment groups. Temporal trends in imaging modality utilization and diagnostic accuracy were analyzed across the study period.</p>\n\n<p><strong>Results: </strong>Among 600 consecutive patients, 186 (31.0%) underwent SND and 414 (69.0%) received M/RND. Preoperative staging methodology evolved significantly during the study period, with increasing adoption of cross-sectional imaging (CT/MRI) replacing physical examination and ultrasonography. This transition corresponded with declining positive predictive value from 63% to 31%, reflecting stage migration and improved detection of occult nodal disease.</p>\n\n<p>Neck recurrence occurred in 14 SND patients (7.5%) versus 51 M/RND patients (12.3%). Multivariate Cox regression demonstrated SND was associated with improved DSS compared to M/RND (p<0.05), though NRFS showed no significant difference. Propensity score-matched analysis confirmed the DSS advantage for SND while maintaining comparable NRFS.</p>\n\n<p>Among pathologically node-positive (pN+) patients, dissection extent did not significantly influence NRFS, a finding that persisted after propensity score matching. Similarly, nodal metastatic burden showed no correlation with neck recurrence rates. Even in the pN2-3 subset, NRFS remained statistically equivalent between SND and M/RND groups. Comparative analysis across time periods and staging modalities revealed no differences in either NRFS or DSS.</p>\n\n<p><strong>Conclusion:</strong> Selective neck dissection achieves oncologic outcomes equivalent to more extensive dissection in cN+ OSCC patients, with both NRFS and DSS being independent of dissection extent. The declining positive predictive value of clinical staging reflects improved imaging technology detecting subclinical disease rather than true diagnostic impairment. These findings support treatment de-escalation in appropriately selected patients, potentially reducing surgical morbidity without compromising oncologic safety. Future investigations should focus on integrating advanced imaging to refine patient selection for selective dissection and identify subgroups where nodal metastatic patterns might warrant extended resection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154472--></body></html>"
    },
    {
      "uid": "P260",
      "content_id": "153868",
      "abstract_number": "P260",
      "poster_number": "P260",
      "title": "Cigarette Smoking Is Not Associated with Recurrence Risk in Oral Tongue Squamous Cell Carcinoma",
      "summary": "When considered alongside the previously reported similar genomic profiles of SCCOT arising in smokers and never-smokers, these results suggest that the determinants of recurrence in SCCOT may lie less in tobacco exposure itself and other potential tumor-intrinsic- and microenvironment related genomic and epigenomic factors may exist within these cancers. Therefore, larger, well-designed prospective studies are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153868",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jaafar Hadi, MD",
      "presenter": "Jaafar Hadi, MD",
      "authors": "Jaafar Hadi, MD ; Guojun Li; Jennifer Wang; Bridget Reeves; Ratna Veeramachaneni; Dianna Roberts; Jeffrey Myers",
      "normalized_authors": [
        "Jaafar Hadi",
        "Guojun Li",
        "Jennifer Wang",
        "Bridget Reeves",
        "Ratna Veeramachaneni",
        "Dianna Roberts",
        "Jeffrey Myers"
      ],
      "affiliations": [
        "The University of Texas M.D. Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "The University of Texas M.D. Anderson Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 402,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Impact"
      ],
      "sections": {
        "Authors": "Jaafar Hadi, MD ; Guojun Li; Jennifer Wang; Bridget Reeves; Ratna Veeramachaneni; Dianna Roberts; Jeffrey Myers",
        "Affiliations": "The University of Texas M.D. Anderson Cancer Center",
        "Background": "Prior molecular profiling studies have demonstrated that oral tongue squamous cell carcinomas (SCCOT) arising in never-smokers and smokers have similar genomic profiles, suggesting that tobacco exposure may not be the dominant driver of tumor biology at this site. Whether this genomic convergence translates into comparable clinical behavior, however, remains uncertain.",
        "Methods": "We analyzed disease-free survival (DFS) in two SCCOT cohorts: a discovery cohort of 86 patients and a validation cohort of 424 patients, both treated and followed at MD Anderson Cancer Center with detailed smoking histories and comprehensive demographic, epidemiological, clinical, and pathologic information. The risk for recurrence was assessed using univariate and multivariable Cox regression models adjusting for several important prognostic factors. Smoking was evaluated as (1) ever-smoker vs. never-smoker and (2) high vs. low cumulative exposure (>15 vs. ≤15 pack-years, when available).",
        "Results": "Overall, in both cohorts, neither smoking status nor cumulative pack-year exposure was significantly associated with DFS and risk of recurrence. Specifically, in the discovery cohort, DFS did not differ between never-smokers and ever-smokers (log-rank: p > 0.05) and between high vs. low cumulative exposure groups (log-rank: p > 0.05), and both smoking status and cumulative exposure were not significantly associated with increased recurrence risk (aHR, 0.78, 95% CI, 0.32-1.86 for smoking status and aHR, 0.56, 95% CI, 0.21-1.48 for cumulative exposure, respectively). These findings were confirmed in the validation cohort (log-rank: P > 0.05 for smoking status; P> 0.05 for cumulative exposure; aHR 1.12, 95% CI 0.70–1.77 for smoking status; and aHR 1.10, 95% CI 0.68–1.80 for cumulative exposure, respectively).",
        "Conclusions": "When considered alongside the previously reported similar genomic profiles of SCCOT arising in smokers and never-smokers, these results suggest that the determinants of recurrence in SCCOT may lie less in tobacco exposure itself and other potential tumor-intrinsic- and microenvironment related genomic and epigenomic factors may exist within these cancers. Therefore, larger, well-designed prospective studies are required to validate these findings and further research is needed to explore those genomic and transcriptomic profiles on clinical behavior in this specific subgroup of head and neck SCC (HNSCC), which may help better define the biology of high risk tumors, and provide biomarkers for appropriate personalized treatment of SCCOT.",
        "Impact": "Our findings directly link molecular convergence to clinical behavior, challenging long-standing assumptions that SCCOT represents a distinct or inherently less aggressive disease subtype from other tumor sites of HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cigarette Smoking Is Not Associated with Recurrence Risk in Oral Tongue Squamous Cell Carcinoma</span>. <u>Jaafar Hadi, MD</u>; Guojun Li; Jennifer Wang; Bridget Reeves; Ratna Veeramachaneni; Dianna Roberts; Jeffrey Myers. The University of Texas M.D. Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Prior molecular profiling studies have demonstrated that oral tongue squamous cell carcinomas (SCCOT) arising in never-smokers and smokers have similar genomic profiles, suggesting that tobacco exposure may not be the dominant driver of tumor biology at this site. Whether this genomic convergence translates into comparable clinical behavior, however, remains uncertain.</p>\n\n<p><strong>Methods: </strong>We analyzed disease-free survival (DFS) in two SCCOT cohorts: a discovery cohort of 86 patients and a validation cohort of 424 patients, both treated and followed at MD Anderson Cancer Center with detailed smoking histories and comprehensive demographic, epidemiological, clinical, and pathologic information. The risk for recurrence was assessed using univariate and multivariable Cox regression models adjusting for several important prognostic factors. Smoking was evaluated as (1) ever-smoker vs. never-smoker and (2) high vs. low cumulative exposure (>15 vs. ≤15 pack-years, when available).</p>\n\n<p><strong>Results: </strong>Overall, in both cohorts, neither smoking status nor cumulative pack-year exposure was significantly associated with DFS and risk of recurrence. Specifically, in the discovery cohort, DFS did not differ between never-smokers and ever-smokers (log-rank: p > 0.05) and between high vs. low cumulative exposure groups (log-rank: p > 0.05), and both smoking status and cumulative exposure were not significantly associated with increased recurrence risk (aHR, 0.78, 95% CI, 0.32-1.86 for smoking status and aHR,  0.56, 95% CI, 0.21-1.48 for cumulative exposure, respectively). These findings were confirmed in the validation cohort (log-rank: P > 0.05 for smoking status; P> 0.05 for cumulative exposure; aHR 1.12, 95% CI 0.70–1.77 for smoking status; and aHR 1.10, 95% CI 0.68–1.80 for cumulative exposure, respectively).</p>\n\n<p><strong>Conclusions:</strong> When considered alongside the previously reported similar genomic profiles of SCCOT arising in smokers and never-smokers, these results suggest that the determinants of recurrence in SCCOT may lie less in tobacco exposure itself and other potential tumor-intrinsic- and microenvironment related genomic and epigenomic factors may exist within these cancers. Therefore, larger, well-designed prospective studies are required to validate these findings and further research is needed to explore  those genomic and transcriptomic profiles on clinical behavior in this specific subgroup of head and neck SCC (HNSCC), which may help better define the biology of high risk tumors, and provide biomarkers for appropriate personalized treatment of SCCOT.</p>\n\n<p><strong>Impact: </strong>Our findings directly link molecular convergence to clinical behavior, challenging long-standing assumptions that SCCOT represents a distinct or inherently less aggressive disease subtype from other tumor sites of HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153868--></body></html>"
    },
    {
      "uid": "P261",
      "content_id": "154310",
      "abstract_number": "P261",
      "poster_number": "P261",
      "title": "Trends in Oral Cavity Squamous Cell Carcinoma: A 25 Year Analysis of the South Carolina Cancer Registry",
      "summary": "Overall trends demonstrate an increase in the incidence of OCSCC. African American race or unmarried status was a predictor of advanced stage presentation. Reporting on smoking and smokeless tobacco is limited in the OCSCC patient cohort and is an area for improvement in data acquisition and reporting. Further analysis and considerations of data abstracting and early detection prevention programs for oral cancer...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154310",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas Hendriks",
      "presenter": "Thomas Hendriks",
      "authors": "Usman Khan; Thomas Hendriks ; Shimrit Sharav; Brian Reisenberg; Ricardo Padilla; Brad Neville; Sara Jasper; Jeffrey Houlton; Peter Horwich; Bezawit Kase; Stephanie Chiodini; Terry Day",
      "normalized_authors": [
        "Usman Khan",
        "Thomas Hendriks",
        "Shimrit Sharav",
        "Brian Reisenberg",
        "Ricardo Padilla",
        "Brad Neville",
        "Sara Jasper",
        "Jeffrey Houlton",
        "Peter Horwich",
        "Bezawit Kase",
        "Stephanie Chiodini",
        "Terry Day"
      ],
      "affiliations": [
        "Sarah Cannon Cancer Institute"
      ],
      "normalized_institutions": [
        "Sarah Cannon Cancer Institute"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 476,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Usman Khan; Thomas Hendriks ; Shimrit Sharav; Brian Reisenberg; Ricardo Padilla; Brad Neville; Sara Jasper; Jeffrey Houlton; Peter Horwich; Bezawit Kase; Stephanie Chiodini; Terry Day",
        "Affiliations": "Sarah Cannon Cancer Institute",
        "Background": "South Carolina has been ranked historically as one of the states with the highest per capita incidence and mortality with significant racial disparities for oral cancer. During the past 25 year, US and state efforts have focused upon education of medical and dental professionals along with public advocacy efforts. These have resulted in improved awareness, dental exams, reduced tobacco use and improved health care access. Statewide data on OCSCC has not been reported for over two decades in South Carolina. We report on overall trends of OCSCC, with a subgroup analysis on socioeconomic and demographic factors that predict presentation at localized, regional, or distant stages of disease.",
        "Methods": "All patients with OCSCC in the South Carolina cancer registry from 1996 to 2023 were identified. Overall trends on available demographic, socioeconomic and oncologic variables were extrapolated. Patients were also grouped by stage at initial presentation as localized, regional metastatic, or distant metastatic disease. Chi-square tests and Welch two-sample t-tests were used to assess statistical significance. Binary logistic regression model was used to identify independent predictors of stage of presentation.",
        "Results": "A total of 4,405 patients met inclusion criteria. The overall incidence of OCSCC has increased from 1996 to 2023. More males were diagnosed with OCSCC than females, and most patients were diagnosed between the ages of 50 to 69 (mean 63-65 since 1996). Smoking status and tobbaco use was underreported (95% not reported). Urban versus rural residence did not significantly influence clinical stage at diagnosis (p > 0.001). A total of 2,568 (58%) presented with localized disease, 1,358 (31%) with regional metastasis, and 479 (11%) with distant metastasis. However, certain variables did influence presentation at more advanced stages of disease over the full time periods studied. Female patients were less likely to present with regional metastatic disease when compared to males. Patients presenting with localized disease were more commonly Caucasian and married (p < 0.001). A total of 1,112 patients (25%) presented with clinical N0 disease. A total of 1,558 (35%) patients ultimately received radiation treatment. A total of 1,031 (23%) patients received chemotherapy. African Americans (OR= 2.06, p<0.001) and unmarried status (OR=1.25, p=0.001) independently predict advanced-stage presentation, with race showing the strongest effect on logistical regression analysis. Correlation with national and state prevention factors, treatment and survival data will be presented. Additionally, data registries include certain terminology that does not clearly specify oral cavity vs oropharyngeal subsites.",
        "Conclusion": "Overall trends demonstrate an increase in the incidence of OCSCC. African American race or unmarried status was a predictor of advanced stage presentation. Reporting on smoking and smokeless tobacco is limited in the OCSCC patient cohort and is an area for improvement in data acquisition and reporting. Further analysis and considerations of data abstracting and early detection prevention programs for oral cancer in the US may be warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in Oral Cavity Squamous Cell Carcinoma: A 25 Year Analysis of the South Carolina Cancer Registry</span>. Usman Khan; <u>Thomas Hendriks</u>; Shimrit Sharav; Brian Reisenberg; Ricardo Padilla; Brad Neville; Sara Jasper; Jeffrey Houlton; Peter Horwich; Bezawit Kase; Stephanie Chiodini; Terry Day. Sarah Cannon Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>South Carolina has been ranked historically as one of the states with the highest per capita incidence and mortality with significant racial disparities for oral cancer. During the past 25 year, US and state efforts have focused upon education of medical and dental professionals along with public advocacy efforts. These have resulted in improved awareness, dental exams, reduced tobacco use and improved health care access. Statewide data on OCSCC has not been reported for over two decades in South Carolina. We report on overall trends of OCSCC, with a subgroup analysis on socioeconomic and demographic factors that predict presentation at localized, regional, or distant stages of disease.</p>\n\n<p><strong>Methods: </strong>All patients with OCSCC in the South Carolina cancer registry from 1996 to 2023 were identified. Overall trends on available demographic, socioeconomic and oncologic variables were extrapolated. Patients were also grouped by stage at initial presentation as localized, regional metastatic, or distant metastatic disease. Chi-square tests and Welch two-sample t-tests were used to assess statistical significance. Binary logistic regression model was used to identify independent predictors of stage of presentation.</p>\n\n<p><strong>Results: </strong>A total of 4,405 patients met inclusion criteria. The overall incidence of OCSCC has increased from 1996 to 2023. More males were diagnosed with OCSCC than females, and most patients were diagnosed between the ages of 50 to 69 (mean 63-65 since 1996). Smoking status and tobbaco use was underreported (95% not reported). Urban versus rural residence did not significantly influence clinical stage at diagnosis (p > 0.001). A total of 2,568 (58%) presented with localized disease, 1,358 (31%) with regional metastasis, and 479 (11%) with distant metastasis. However, certain variables did influence presentation at more advanced stages of disease over the full time periods studied. Female patients were less likely to present with regional metastatic disease when compared to males. Patients presenting with localized disease were more commonly Caucasian and married (p < 0.001). A total of 1,112 patients (25%) presented with clinical N0 disease. A total of 1,558 (35%) patients ultimately received radiation treatment. A total of 1,031 (23%) patients received chemotherapy. African Americans (OR= 2.06, p<0.001) and unmarried status (OR=1.25, p=0.001) independently predict advanced-stage presentation, with race showing the strongest effect on logistical regression analysis. Correlation with national and state prevention factors, treatment and survival data will be presented. Additionally, data registries include certain terminology that does not clearly specify oral cavity vs oropharyngeal subsites.</p>\n\n<p><strong>Conclusion: </strong>Overall trends demonstrate an increase in the incidence of OCSCC. African American race or unmarried status was a predictor of advanced stage presentation. Reporting on smoking and smokeless tobacco is limited in the OCSCC patient cohort and is an area for improvement in data acquisition and reporting. Further analysis and considerations of data abstracting and early detection prevention programs for oral cancer in the US may be warranted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154310--></body></html>"
    },
    {
      "uid": "P262",
      "content_id": "154056",
      "abstract_number": "P262",
      "poster_number": "P262",
      "title": "Beta-human chorionic gonadotropin (Beta-hCG) expression in head and neck squamous cell carcinoma",
      "summary": "Oral cavity samples exhibited the highest rate of immunostaining for β-hCG. Some literature suggests that in non-placental tissues, the anti-β-hCG antibody may bind other glycoproteins. Therefore, given the focal staining pattern, the current data cannot conclusively be interpreted as reflective of true β-hCG levels for these tumors. Future investigations to compare the immunohistochemical findings with in-situ...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154056",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elisabeth R Wenneker, MD",
      "presenter": "Elisabeth R Wenneker, MD",
      "authors": "Elisabeth R Wenneker, MD ; Li Liang, MD, PhD; Patricia Castro, PhD; Dannelys Perez Bello, PhD; Angela Haskins, MD; David J Hernandez, MD; Vlad Sandulache, MD, PhD",
      "normalized_authors": [
        "Elisabeth R Wenneker",
        "Li Liang",
        "Patricia Castro",
        "Dannelys Perez Bello",
        "Angela Haskins",
        "David J Hernandez",
        "Vlad Sandulache"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154056/Table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154056/Table%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154056"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154056/Beta-hCG%20expression.jpg.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154056/Beta-hCG%20expression.jpg.jpeg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154056"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 461,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Table 1.",
        "Figure 1.",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Elisabeth R Wenneker, MD ; Li Liang, MD, PhD; Patricia Castro, PhD; Dannelys Perez Bello, PhD; Angela Haskins, MD; David J Hernandez, MD; Vlad Sandulache, MD, PhD",
        "Affiliations": "Baylor College of Medicine",
        "Background": "Biomarkers play an important role in many types of malignancy. β-human chorionic gonadotropin (β-hCG) is a glycoprotein primarily produced by the placenta. It is also an established marker of both germ cell and trophoblastic tumors. Currently, the limited data on β-hCG expression in head and neck squamous cell carcinoma (HNSCC) suggests it is a marker of aggressive disease. The purpose of this study is to describe the immunohistochemical expression of β-hCG in HNSCC.",
        "Methods": "Tissue microarrays (TMAs) including archival tissue from a retrospective cohort of patients with oral cavity, oropharynx, and larynx SCC who received curative treatment from 1997 to 2018 were tested for β-hCG expression by immunohistochemistry (IHC) with two anti-β-hCG antibodies (PA0014-U, Leica Biosystems, Deer Park, IL; GA508, Agilent, Santa Clara, CA). Human placenta stained with and without the same primary antibodies served as positive and negative controls.",
        "Abstract": "For each tumor site, three TMA cores exhibiting β-hCG expression and three without β-hCG expression were selected to further evaluate by staining the whole tissue section from which they were derived. The pattern and percentage of positive tumor cells and the intensity of β-hCG expression were evaluated and compared. Because the TMA represents small samples of the overall tumors and given the focal staining pattern on the TMAs, whole tissue sections from three positively and three negatively scored TMA cores from each site were stained for β-hCG (18 total). The sections derived from positively stained oral cavity TMA cores showed rare or focal β-hCG expression, all less than 50% tumor cell positivity with a range of intensities (Figure 1). The negative oral cavity samples also showed rare expression in the tumor cells. Of the six oropharynx whole tissue sections, one positive sample exhibited β-hCG expression. The positive larynx samples all showed focal β-hCG expression with ranging intensities; none of the negative samples exhibited β-hCG expression. In many cases, the β-hCG staining was localized to the peripheral tumor cells at the stromal epithelial interface.",
        "Results": "Oral cavity tumors had the highest rate of β-hCG expression, 37% of tumor samples showed at least focal positivity, followed by oropharynx with 15%, and larynx with 9% (Table 1). Expression was variable from focal to patchy on the TMA cores. The two antibodies showed similar results.",
        "Table 1.": "Rate of β-hCG expression by tumor site on TMAs.",
        "Figure 1.": "Example of oral cavity whole tissue section with focal β-hCG expression.",
        "Conclusion": "Oral cavity samples exhibited the highest rate of immunostaining for β-hCG. Some literature suggests that in non-placental tissues, the anti-β-hCG antibody may bind other glycoproteins. Therefore, given the focal staining pattern, the current data cannot conclusively be interpreted as reflective of true β-hCG levels for these tumors. Future investigations to compare the immunohistochemical findings with in-situ hybridization or RNA sequencing are needed to validate the β-hCG IHC staining and expression in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Beta-human chorionic gonadotropin (Beta-hCG) expression in head and neck squamous cell carcinoma</span>. <u>Elisabeth R Wenneker, MD</u>; Li Liang, MD, PhD; Patricia Castro, PhD; Dannelys Perez Bello, PhD; Angela Haskins, MD; David J Hernandez, MD; Vlad Sandulache, MD, PhD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Biomarkers play an important role in many types of malignancy. β-human chorionic gonadotropin (β-hCG) is a glycoprotein primarily produced by the placenta. It is also an established marker of both germ cell and trophoblastic tumors. Currently, the limited data on β-hCG expression in head and neck squamous cell carcinoma (HNSCC) suggests it is a marker of aggressive disease. The purpose of this study is to describe the immunohistochemical expression of β-hCG in HNSCC.</p>\n\n<p><strong>Methods: </strong>Tissue microarrays (TMAs) including archival tissue from a retrospective cohort of patients with oral cavity, oropharynx, and larynx SCC who received curative treatment from 1997 to 2018 were tested for β-hCG expression by immunohistochemistry (IHC) with two anti-β-hCG antibodies (PA0014-U, Leica Biosystems, Deer Park, IL; GA508, Agilent, Santa Clara, CA). Human placenta stained with and without the same primary antibodies served as positive and negative controls.</p>\n\n<p>For each tumor site, three TMA cores exhibiting β-hCG expression and three without β-hCG expression were selected to further evaluate by staining the whole tissue section from which they were derived. The pattern and percentage of positive tumor cells and the intensity of β-hCG expression were evaluated and compared.</p>\n\n<p><strong>Results: </strong>Oral cavity tumors had the highest rate of β-hCG expression, 37% of tumor samples showed at least focal positivity, followed by oropharynx with 15%, and larynx with 9% (Table 1). Expression was variable from focal to patchy on the TMA cores. The two antibodies showed similar results.</p>\n\n<p>Because the TMA represents small samples of the overall tumors and given the focal staining pattern on the TMAs, whole tissue sections from three positively and three negatively scored TMA cores from each site were stained for β-hCG (18 total). The sections derived from positively stained oral cavity TMA cores showed rare or focal β-hCG expression, all less than 50% tumor cell positivity with a range of intensities (Figure 1). The negative oral cavity samples also showed rare expression in the tumor cells. Of the six oropharynx whole tissue sections, one positive sample exhibited β-hCG expression. The positive larynx samples all showed focal β-hCG expression with ranging intensities; none of the negative samples exhibited β-hCG expression. In many cases, the β-hCG staining was localized to the peripheral tumor cells at the stromal epithelial interface.</p>\n\n<p><strong>Table 1.</strong> Rate of β-hCG expression by tumor site on TMAs.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154056/Table%201.png' /></p>\n\n<p> </p>\n\n<p><strong>Figure 1. </strong>Example of oral cavity whole tissue section with focal β-hCG expression.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154056/Beta-hCG%20expression.jpg.jpeg' /></p>\n\n<p><strong>Conclusion: </strong>Oral cavity samples exhibited the highest rate of immunostaining for β-hCG. Some literature suggests that in non-placental tissues, the anti-β-hCG antibody may bind other glycoproteins. Therefore, given the focal staining pattern, the current data cannot conclusively be interpreted as reflective of true β-hCG levels for these tumors. Future investigations to compare the immunohistochemical findings with in-situ hybridization or RNA sequencing are needed to validate the β-hCG IHC staining and expression in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154056--></body></html>"
    },
    {
      "uid": "P263",
      "content_id": "153203",
      "abstract_number": "P263",
      "poster_number": "P263",
      "title": "Differential Efficacy of Neoadjuvant Chemotherapy in Oral Cavity Versus Oropharyngeal Squamous Cell Carcinoma: Subsite and Clinical Implications",
      "summary": "NACT showed lower response rates in oral cavity SCC compared to oropharyngeal SCC. Oral cavity cancers located in the posterolateral part seem to respond more favorably to NACT than those in the anteromedial part. For the patients with oral cavity cancer, NACT should be applied cautiously only in selected cases.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153203",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Wonjae Cha, MD, PhD",
      "presenter": "Wonjae Cha, MD, PhD",
      "authors": "Wonjae Cha, MD, PhD 1 ; Pilkeun Jang, MD 2 ; Jeon Seong, MD 1 ; Seo Young Kim, MD 2 ; Jeong-Yeon Ji, MD 1 ; Jungirl Seok, MD, PhD 2 ; Eun-Jae Chung, MD, PhD 2 ; Young Ho Jung, MD, PhD 3 ; Soon-Hyun Ahn, MD, PhD 2 ; Myung-Whun Sung, MD, PhD 2 ; Kwang Hyun Kim, MD, PhD 4 ; Woo-Jin Jeong, MD, PhD 1",
      "normalized_authors": [
        "Wonjae Cha",
        "Pilkeun Jang",
        "Jeon Seong",
        "Seo Young Kim",
        "Jeong-Yeon Ji",
        "Jungirl Seok",
        "Eun-Jae Chung",
        "Young Ho Jung",
        "Soon-Hyun Ahn",
        "Myung-Whun Sung",
        "Kwang Hyun Kim",
        "Woo-Jin Jeong"
      ],
      "affiliations": [
        "Seoul National University Bundang Hospital",
        "Seoul National University Hospital",
        "Asan Medical Center",
        "Bundang Jesaeng General Hospital"
      ],
      "normalized_institutions": [
        "Seoul National University Bundang Hospital",
        "Seoul National University Hospital",
        "Asan Medical Center",
        "Bundang Jesaeng General Hospital"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Wonjae Cha, MD, PhD 1 ; Pilkeun Jang, MD 2 ; Jeon Seong, MD 1 ; Seo Young Kim, MD 2 ; Jeong-Yeon Ji, MD 1 ; Jungirl Seok, MD, PhD 2 ; Eun-Jae Chung, MD, PhD 2 ; Young Ho Jung, MD, PhD 3 ; Soon-Hyun Ahn, MD, PhD 2 ; Myung-Whun Sung, MD, PhD 2 ; Kwang Hyun Kim, MD, PhD 4 ; Woo-Jin Jeong, MD, PhD 1",
        "Affiliations": "1 Seoul National University Bundang Hospital; 2 Seoul National University Hospital; 3 Asan Medical Center; 4 Bundang Jesaeng General Hospital",
        "Purpose": "Neoadjuvant chemotherapy (NACT) has emerged as a promising approach in the management of head and neck cancers. Its role is relatively well established in hypopharyngeal and oropharyngeal squamous cell carcinoma (SCC), whereas its benefit for patients with oral cavity SCC remains controversial. This study aimed to evaluate the therapeutic response to NACT in oral cavity SCC, compared to its established role in oropharyngeal SCC, and to identify tumor or patient characteristics that contribute to a favorable outcome.",
        "Methods": "This retrospective study included 54 patients with oral cavity (n=14) or oropharyngeal cancers (n=40) who underwent NACT followed by definitive treatment at a same given period at a single tertiary referral center. Demographics, tumor subsite, clinical stage, HPV status, NACT regimen and number of cycles were collected. The response to NACT was evaluated according to RECIST v1.1. Laboratory results, including hemoglobin, neutrophil, lymphocyte, monocyte and albumin, were collected to calculate the H-index and neutrophil-to-lymphocyte ratio (NLR). Definitive treatment modalities and recurrence patterns were analyzed.",
        "Results": "The proportion of patients achieving complete or partial response (responder) after NACT was significantly higher in the oropharynx cancers (33/40, 82.5%) than in the oral cavity cancers (4/14, 28.6%) ( p <0.001). The pre-NACT H-index (4.98 vs. 2.44, p =0.263) and NLR (3.38 vs. 2.22, p =0.282) tended to be higher in the oral cavity cancers than in the oropharynx. Within the oral cavity cancers, tumors in the posterolateral part (gingiva, retromolar trigone, and buccal mucosa) demonstrated a better response (responder 50.0% vs. 12.5%, p =0.245) to NACT than those in anteromedial part (tongue, floor of mouth). Tumors with an early clinical N stage (N0-N1) showed a higher, though not statistically significant, response rate compared to those with an advanced N stage (N2-N3) (60.0% vs. 11.1%, p =0.094).",
        "Abstract": "Among the 40 patients with a follow-up duration of at least 12 months (oral cavity, n=9; oropharynx, n=31), subgroup analyses revealed no significant differences in demographic characteristics (age, sex), clinical stage, pre-NACT H-index, or NLR between patients with recurrence and those without recurrence within each cancer. Patients who responded to NACT showed a non-significant trend toward lower recurrence rates compared to non-responders (75.0% vs. 20.0%, p =0.206). Two-year recurrence-free survival was significantly better in the oropharynx cancers (80.1% vs. 41.7%, p =0.017) compared to the oral cavity cancers.",
        "Conclusion": "NACT showed lower response rates in oral cavity SCC compared to oropharyngeal SCC. Oral cavity cancers located in the posterolateral part seem to respond more favorably to NACT than those in the anteromedial part. For the patients with oral cavity cancer, NACT should be applied cautiously only in selected cases."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Differential Efficacy of Neoadjuvant Chemotherapy in Oral Cavity Versus Oropharyngeal Squamous Cell Carcinoma: Subsite and Clinical Implications</span>. <u>Wonjae Cha, MD, PhD</u><sup>1</sup>; Pilkeun Jang, MD<sup>2</sup>; Jeon Seong, MD<sup>1</sup>; Seo Young Kim, MD<sup>2</sup>; Jeong-Yeon Ji, MD<sup>1</sup>; Jungirl Seok, MD, PhD<sup>2</sup>; Eun-Jae Chung, MD, PhD<sup>2</sup>; Young Ho Jung, MD, PhD<sup>3</sup>; Soon-Hyun Ahn, MD, PhD<sup>2</sup>; Myung-Whun Sung, MD, PhD<sup>2</sup>; Kwang Hyun Kim, MD, PhD<sup>4</sup>; Woo-Jin Jeong, MD, PhD<sup>1</sup>. <sup>1</sup>Seoul National University Bundang Hospital; <sup>2</sup>Seoul National University Hospital; <sup>3</sup>Asan Medical Center; <sup>4</sup>Bundang Jesaeng General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> Neoadjuvant chemotherapy (NACT) has emerged as a promising approach in the management of head and neck cancers. Its role is relatively well established in hypopharyngeal and oropharyngeal squamous cell carcinoma (SCC), whereas its benefit for patients with oral cavity SCC remains controversial. This study aimed to evaluate the therapeutic response to NACT in oral cavity SCC, compared to its established role in oropharyngeal SCC, and to identify tumor or patient characteristics that contribute to a favorable outcome.</p>\n\n<p><strong>Methods:</strong> This retrospective study included 54 patients with oral cavity (n=14) or oropharyngeal cancers (n=40) who underwent NACT followed by definitive treatment at a same given period at a single tertiary referral center. Demographics, tumor subsite, clinical stage, HPV status, NACT regimen and number of cycles were collected. The response to NACT was evaluated according to RECIST v1.1. Laboratory results, including hemoglobin, neutrophil, lymphocyte, monocyte and albumin, were collected to calculate the H-index and neutrophil-to-lymphocyte ratio (NLR). Definitive treatment modalities and recurrence patterns were analyzed.</p>\n\n<p><strong>Results:</strong> The proportion of patients achieving complete or partial response (responder) after NACT was significantly higher in the oropharynx cancers (33/40, 82.5%) than in the oral cavity cancers (4/14, 28.6%) (<em>p</em><0.001). The pre-NACT H-index (4.98 vs. 2.44, <em>p</em>=0.263) and NLR (3.38 vs. 2.22, <em>p</em>=0.282) tended to be higher in the oral cavity cancers than in the oropharynx. Within the oral cavity cancers, tumors in the posterolateral part (gingiva, retromolar trigone, and buccal mucosa) demonstrated a better response (responder 50.0% vs. 12.5%, <em>p</em>=0.245) to NACT than those in anteromedial part (tongue, floor of mouth). Tumors with an early clinical N stage (N0-N1) showed a higher, though not statistically significant, response rate compared to those with an advanced N stage (N2-N3) (60.0% vs. 11.1%, <em>p</em>=0.094).</p>\n\n<p>Among the 40 patients with a follow-up duration of at least 12 months (oral cavity, n=9; oropharynx, n=31), subgroup analyses revealed no significant differences in demographic characteristics (age, sex), clinical stage, pre-NACT H-index, or NLR between patients with recurrence and those without recurrence within each cancer. Patients who responded to NACT showed a non-significant trend toward lower recurrence rates compared to non-responders (75.0% vs. 20.0%, <em>p</em>=0.206). Two-year recurrence-free survival was significantly better in the oropharynx cancers (80.1% vs. 41.7%, <em>p</em>=0.017) compared to the oral cavity cancers.</p>\n\n<p><strong>Conclusion:</strong> NACT showed lower response rates in oral cavity SCC compared to oropharyngeal SCC. Oral cavity cancers located in the posterolateral part seem to respond more favorably to NACT than those in the anteromedial part. For the patients with oral cavity cancer, NACT should be applied cautiously only in selected cases.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153203--></body></html>"
    },
    {
      "uid": "P264",
      "content_id": "153322",
      "abstract_number": "P264",
      "poster_number": "P264",
      "title": "Pathological prognostic factor from primary lesion of cT1/2 tongue squamous cell carcinoma",
      "summary": "DOI was identified as the most influential prognostic factor for DSS in early-stage tongue SCC. The widely used cutoff of DOI 5 mm for distinguishing between T1 and T2 tumors was strongly supported by the present findings and may be valuable for risk stratification and determining appropriate treatment strategies.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153322",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yasuhiro Ebihara, MD, PhD",
      "presenter": "Yasuhiro Ebihara, MD, PhD",
      "authors": "Yasuhiro Ebihara, MD, PhD 1 ; Yuichiro Enoki, DDS, PhD 1 ; Hirohisa Iwaki, MD, PhD 1 ; Taisei Yasuda, MD 1 ; Satoko Matsumura, MD 1 ; Tomoko Yamazaki, MD, DDS, PhD 1 ; Mitsuhiko Nakahira, MD, PhD 1 ; Mei Hamada, DDS, PhD 2",
      "normalized_authors": [
        "Yasuhiro Ebihara",
        "Yuichiro Enoki",
        "Hirohisa Iwaki",
        "Taisei Yasuda",
        "Satoko Matsumura",
        "Tomoko Yamazaki",
        "Mitsuhiko Nakahira",
        "Mei Hamada"
      ],
      "affiliations": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
        "Dept of Diagnostic Pathology, Saitama Medical University"
      ],
      "normalized_institutions": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
        "Dept of Diagnostic Pathology, Saitama Medical University"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 444,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Yasuhiro Ebihara, MD, PhD 1 ; Yuichiro Enoki, DDS, PhD 1 ; Hirohisa Iwaki, MD, PhD 1 ; Taisei Yasuda, MD 1 ; Satoko Matsumura, MD 1 ; Tomoko Yamazaki, MD, DDS, PhD 1 ; Mitsuhiko Nakahira, MD, PhD 1 ; Mei Hamada, DDS, PhD 2",
        "Affiliations": "1 Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University; 2 Dept of Diagnostic Pathology, Saitama Medical University",
        "Objective": "In early-stage tongue squamous cell carcinoma (SCC; T1/2), factors associated with neck lymph node metastasis and disease-specific survival (DSS) remain insufficiently understood. Depth of invasion (DOI) has been incorporated into the T-classification of the UICC/AJCC 8th edition due to its prognostic importance. Meanwhile, in colorectal cancer, “budding”—small clusters of 1–4 tumor cells at the invasive front—serves as a strong predictor of lymph node metastasis. This study investigated prognostic factors derived from primary tumor pathology in tongue SCC, with particular emphasis on DOI and tumor budding grade (TBG).",
        "Methods": "We retrospectively analyzed 56 patients with tongue SCC who underwent initial treatment at our institution between 2007 and 2016. All cases had primary tumors evaluable by MRI and were reclassified as cT1/2 according to the UICC/AJCC 8th edition. TBG was assessed following the Japanese colorectal cancer guidelines, defining budding as clusters composed of fewer than five cancer cells located at the invasive front. Tumor budding was classified as TBG1 (0–4 buds), TBG2 (5–9 buds), or TBG3 (≥10 buds). DSS was evaluated using Kaplan–Meier analysis and log-rank tests, while prognostic factors were assessed via univariate and multivariate Cox proportional hazards models. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff value for pDOI.",
        "Results": "Of the 56 patients included (24 men, 32 women; median age 63 years), clinical T classification comprised 15 cT1 and 41 cT2 lesions. Pathologically, 36 tumors were classified as pT1 and 20 as pT2. Cervical lymph node status included 35 pN(–) and 21 pN(+). The median pathological tumor diameter was 18 mm (range 6–38 mm), and the median DOI was 5 mm (range 0–25 mm). Pathological risk factors were distributed as follows: ly(–/+) 51/5, v(–/+) 46/10, neu(–/+) 48/8, and BD grade 1/2/3: 40/6/10. DSS did not differ significantly between T1 and T2 tumors (log-rank p = 0.644), indicating that tumor biology may have a stronger prognostic impact than tumor size. In univariate Cox analysis, DOI was a significant prognostic factor, with each 1-mm increase associated with a 16% rise in mortality risk (HR 1.16, p = 0.035). In multivariate analysis, DOI remained an independent predictor of DSS (HR 1.20, p = 0.023). ROC analysis identified an optimal cutoff of 5 mm for DOI (sensitivity 0.875, specificity 0.521, AUC 0.698).",
        "Conclusions": "DOI was identified as the most influential prognostic factor for DSS in early-stage tongue SCC. The widely used cutoff of DOI 5 mm for distinguishing between T1 and T2 tumors was strongly supported by the present findings and may be valuable for risk stratification and determining appropriate treatment strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pathological prognostic factor from primary lesion of cT1/2 tongue squamous cell carcinoma</span>. <u>Yasuhiro Ebihara, MD, PhD</u><sup>1</sup>; Yuichiro Enoki, DDS, PhD<sup>1</sup>; Hirohisa Iwaki, MD, PhD<sup>1</sup>; Taisei Yasuda, MD<sup>1</sup>; Satoko Matsumura, MD<sup>1</sup>; Tomoko Yamazaki, MD, DDS, PhD<sup>1</sup>; Mitsuhiko Nakahira, MD, PhD<sup>1</sup>; Mei Hamada, DDS, PhD<sup>2</sup>. <sup>1</sup>Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University; <sup>2</sup>Dept of Diagnostic Pathology, Saitama Medical University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>In early-stage tongue squamous cell carcinoma (SCC; T1/2), factors associated with neck lymph node metastasis and disease-specific survival (DSS) remain insufficiently understood. Depth of invasion (DOI) has been incorporated into the T-classification of the UICC/AJCC 8th edition due to its prognostic importance. Meanwhile, in colorectal cancer, “budding”—small clusters of 1–4 tumor cells at the invasive front—serves as a strong predictor of lymph node metastasis. This study investigated prognostic factors derived from primary tumor pathology in tongue SCC, with particular emphasis on DOI and tumor budding grade (TBG).</p>\n\n<p><strong>Methods: </strong>We retrospectively analyzed 56 patients with tongue SCC who underwent initial treatment at our institution between 2007 and 2016. All cases had primary tumors evaluable by MRI and were reclassified as cT1/2 according to the UICC/AJCC 8th edition. TBG was assessed following the Japanese colorectal cancer guidelines, defining budding as clusters composed of fewer than five cancer cells located at the invasive front. Tumor budding was classified as TBG1 (0–4 buds), TBG2 (5–9 buds), or TBG3 (≥10 buds). DSS was evaluated using Kaplan–Meier analysis and log-rank tests, while prognostic factors were assessed via univariate and multivariate Cox proportional hazards models. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff value for pDOI.</p>\n\n<p><strong>Results: </strong>Of the 56 patients included (24 men, 32 women; median age 63 years), clinical T classification comprised 15 cT1 and 41 cT2 lesions. Pathologically, 36 tumors were classified as pT1 and 20 as pT2. Cervical lymph node status included 35 pN(–) and 21 pN(+). The median pathological tumor diameter was 18 mm (range 6–38 mm), and the median DOI was 5 mm (range 0–25 mm). Pathological risk factors were distributed as follows: ly(–/+) 51/5, v(–/+) 46/10, neu(–/+) 48/8, and BD grade 1/2/3: 40/6/10. DSS did not differ significantly between T1 and T2 tumors (log-rank p = 0.644), indicating that tumor biology may have a stronger prognostic impact than tumor size. In univariate Cox analysis, DOI was a significant prognostic factor, with each 1-mm increase associated with a 16% rise in mortality risk (HR 1.16, p = 0.035). In multivariate analysis, DOI remained an independent predictor of DSS (HR 1.20, p = 0.023). ROC analysis identified an optimal cutoff of 5 mm for DOI (sensitivity 0.875, specificity 0.521, AUC 0.698).</p>\n\n<p><strong>Conclusions:</strong> DOI was identified as the most influential prognostic factor for DSS in early-stage tongue SCC. The widely used cutoff of DOI 5 mm for distinguishing between T1 and T2 tumors was strongly supported by the present findings and may be valuable for risk stratification and determining appropriate treatment strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153322--></body></html>"
    },
    {
      "uid": "P265",
      "content_id": "155562",
      "abstract_number": "P265",
      "poster_number": "P265",
      "title": "Pioglitazone/Metformin treatment of oral preneoplasia: a Phase IIa study",
      "summary": "As of February 2026, there have been 19 screens performed and 12 subjects enrolled. An important feature of chemoprevention agents is tolerability and thus far there have been zero dose limiting toxicities at the CTCAE 2 or less. There has been 1 subject requiring dose reduction for the second half of the trial. There are no subjects with progressive disease. All of the accruals have occurred at the primary...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155562",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Frank Ondrey, MD, PhD",
      "presenter": "Frank Ondrey, MD, PhD",
      "authors": "Frank Ondrey, MD, PhD ; Beverly Wuertz, BA",
      "normalized_authors": [
        "Frank Ondrey",
        "Beverly Wuertz"
      ],
      "affiliations": [
        "University of Minnesota"
      ],
      "normalized_institutions": [
        "University of Minnesota"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 421,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Frank Ondrey, MD, PhD ; Beverly Wuertz, BA",
        "Affiliations": "University of Minnesota",
        "Introduction": "It is estimated that over 1% of the US population harbors oral preneoplasia, which has a substantial risk of becoming oral cancer. There are currently no effective chemoprevention agents for aerodigestive precancerous lesion treatment or field cancerization. To achieve aerodigestive cancer prevention, strategies that antagonize inflammation or force cellular differentiation are highly compelling in the clinic. In the current trial we are examining the use of combination metformin and pioglitazone in oral preneoplasia in a 12 week study of patients with high risk leukoplakia.",
        "Methods": "In the study we are seeking to enroll 25-35 subjects with dysplastic oral leukoplakia or hyperplasia of high risk oral cavity sites (tongue/floor of mouth). Patients will be screened for health conditions under typical chemoprevention study criteria. Patients will be required to have a biopsy proven diagnosis in a lesion of 28 mm squared to qualify. Subjects will be administered metformin and pioglitazone in combination for 12 weeks. Hypothesis driven biomarkers as well as RNA seq is being employed on the lesions and surrounding normal appearing mucosa before and after treatment to examine effects on the Milieu as well as the lesion biology. Patient responses will be examined for improvement in histology as well as decrease in lesion size to derive a response. A unique feature of the trial that we are conducting this study at 4 institutions in the state for more rapid accrual.",
        "Results": "As of February 2026, there have been 19 screens performed and 12 subjects enrolled. An important feature of chemoprevention agents is tolerability and thus far there have been zero dose limiting toxicities at the CTCAE 2 or less. There has been 1 subject requiring dose reduction for the second half of the trial. There are no subjects with progressive disease. All of the accruals have occurred at the primary institution over the first 12 months of enrollment. It was felt that we could achieve an opening of the trial in less than the 220 days that many of the trial take to open at our institution. We found that with complex IRB processes at 4 hospitals that this took almost 18 months for finalization of all documents.",
        "Discussion": "We found it is feasible to perform a multi institutional leukoplakia trial within our academic system that ostensibly covers 60% of our regions population. The drugs, in combination are safe and do not cause hypoglycemia in non diabetic patients. We expect that complete accrual of the trial will occur by the end of 2026, despite a sluggish period at the beginning of the grant."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pioglitazone/Metformin treatment of  oral preneoplasia: a Phase IIa study</span>. <u>Frank Ondrey, MD, PhD</u>; Beverly Wuertz, BA. University of Minnesota<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>It is estimated that over 1% of the US population harbors oral preneoplasia, which has a substantial risk of becoming oral cancer. There are currently no effective chemoprevention agents for aerodigestive precancerous lesion treatment or field cancerization. To achieve aerodigestive cancer prevention, strategies that antagonize inflammation  or force cellular differentiation are highly compelling in the clinic. In the current trial we are examining the use of combination metformin and pioglitazone in oral preneoplasia in a 12 week study of patients with high risk leukoplakia.</p>\n\n<p><strong>Methods: </strong>In the study we are seeking to enroll 25-35 subjects with dysplastic oral leukoplakia or hyperplasia of high risk oral cavity sites (tongue/floor of mouth). Patients will be screened for health conditions under typical chemoprevention study criteria. Patients will be required to have a biopsy proven diagnosis in a lesion of 28 mm squared to qualify. Subjects will be administered metformin and pioglitazone in combination for 12 weeks. Hypothesis driven biomarkers as well as RNA seq is being employed on the lesions and surrounding normal appearing mucosa before and after treatment to examine effects on the Milieu as well as the lesion biology. Patient responses will be examined for improvement in histology as well as decrease in lesion size to derive a response. A unique feature of the trial that we are conducting this study at 4 institutions in the state for more rapid accrual.  </p>\n\n<p><strong>Results: </strong>As of February 2026, there have been 19 screens performed and 12 subjects enrolled. An important feature of chemoprevention agents is tolerability and thus far there have been zero dose limiting toxicities at the CTCAE  2 or less. There has been 1 subject requiring dose reduction for the second half of the trial. There are no subjects with progressive disease. All of the accruals have occurred at the primary institution over the first 12 months of enrollment.  It was felt that we could achieve an opening of the trial in less than the 220 days that many  of the trial take to open at our institution. We found that with complex IRB processes at 4 hospitals that this took almost 18 months for finalization of all documents.</p>\n\n<p><strong>Discussion: </strong>We found it is feasible to perform a multi institutional leukoplakia trial within our academic system that ostensibly covers 60% of our regions population. The drugs, in combination are safe and do not cause hypoglycemia in non diabetic patients. We expect that complete accrual of the trial will occur by the end of 2026, despite a sluggish period at the beginning of the grant.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155562--></body></html>"
    },
    {
      "uid": "P266",
      "content_id": "155331",
      "abstract_number": "P266",
      "poster_number": "P266",
      "title": "Oral Tongue Reconstruction with Porcine Small Intestine Xenograft: A Case Series",
      "summary": "Biodesign is a viable reconstructive option for small to mid-sized oral tongue defects. It provides tissue protection, facilitates granulation tissue ingrowth and prevents mucosal wound contracture. It avoids need for secondary surgical sites and subjectively reducing post-operative pain and promotes tissue regeneration that improves functional recovery. Further prospective studies with objective measures are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155331",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katerina Green, MD",
      "presenter": "Katerina Green, MD",
      "authors": "Katerina Green, MD ; Bastien Valencia, MD; Natalie Weiss, MD; Phillip Pirgousis, MD; Samip Patel, MD",
      "normalized_authors": [
        "Katerina Green",
        "Bastien Valencia",
        "Natalie Weiss",
        "Phillip Pirgousis",
        "Samip Patel"
      ],
      "affiliations": [
        "Mayo Clinic Florida"
      ],
      "normalized_institutions": [
        "Mayo Clinic Florida"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 306,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Katerina Green, MD ; Bastien Valencia, MD; Natalie Weiss, MD; Phillip Pirgousis, MD; Samip Patel, MD",
        "Affiliations": "Mayo Clinic Florida",
        "Objective": "Evaluate the feasibility and clinical outcomes of Biodesign, an extracellular matrix graft, for reconstructing small and mid-sized oral tongue defects following partial glossectomy.",
        "Study Design": "This retrospective case series reviewed patients who underwent partial glossectomy with Biodesign reconstruction at a single institution from January 2022 to August 2025.",
        "Setting": "The study was conducted at a tertiary center.",
        "Methods": "Patients undergoing partial glossectomy with Biodesign reconstruction were identified through retrospective chart review. Biodesign reconstruction was performed in a standardized fashion, with the graft custom-cut to the defect and secured to surrounding mucosa and musculature using 3-0 Vicryl sutures, with pie-crust incisions and tacking sutures. No additional dressings or bolsters were used. Data on pre-operative diagnosis, lesion size, intraoperative details, and post-operative outcomes were collected. Outcomes included healing progress, complications, pain control, and functional recovery. Long-term functional outcomes were measured with questions from the EAT-10 and Speech Handicap Index questionnaires",
        "Results": "Twenty patients were included, with a mean age of 63.2 ± 14.7 years (range 35-87). Biodesign was used for reconstructing defects ranging from 6 to 28 cm², (mean 13.8 cm²). At the first post-operative visit (POV1), all patients showed either healing granulation tissue or completely healed oral mucosa was seen in all patients. All patients tolerated an oral diet by post-operative day one. Post-operative complications included two cases of bleeding requiring intervention. Eighty-five percent of patients (n=17) were seen for POV1 within 14 days of surgery. Patient-reported outcomes at POV1 included swallowing difficulties, speech issues and post-operative pain.",
        "Conclusion": "Biodesign is a viable reconstructive option for small to mid-sized oral tongue defects. It provides tissue protection, facilitates granulation tissue ingrowth and prevents mucosal wound contracture. It avoids need for secondary surgical sites and subjectively reducing post-operative pain and promotes tissue regeneration that improves functional recovery. Further prospective studies with objective measures are needed to validate these findings and optimize outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oral Tongue Reconstruction with Porcine Small Intestine Xenograft: A Case Series</span>. <u>Katerina Green, MD</u>; Bastien Valencia, MD; Natalie Weiss, MD; Phillip Pirgousis, MD; Samip Patel, MD. Mayo Clinic Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Evaluate the feasibility and clinical outcomes of Biodesign, an extracellular matrix graft, for reconstructing small and mid-sized oral tongue defects following partial glossectomy.</p>\n\n<p><strong>Study Design: </strong>This retrospective case series reviewed patients who underwent partial glossectomy with Biodesign reconstruction at a single institution from January 2022 to August 2025.</p>\n\n<p><strong>Setting: </strong>The study was conducted at a tertiary center.</p>\n\n<p><strong>Methods: </strong>Patients undergoing partial glossectomy with Biodesign reconstruction were identified through retrospective chart review. Biodesign reconstruction was performed in a standardized fashion, with the graft custom-cut to the defect and secured to surrounding mucosa and musculature using 3-0 Vicryl sutures, with pie-crust incisions and tacking sutures. No additional dressings or bolsters were used. Data on pre-operative diagnosis, lesion size, intraoperative details, and post-operative outcomes were collected. Outcomes included healing progress, complications, pain control, and functional recovery. Long-term functional outcomes were measured with questions from the EAT-10 and Speech Handicap Index questionnaires</p>\n\n<p><strong>Results: </strong>Twenty patients were included, with a mean age of 63.2 ± 14.7 years (range 35-87). Biodesign was used for reconstructing defects ranging from 6 to 28 cm², (mean 13.8 cm²). At the first post-operative visit (POV1), all patients showed either healing granulation tissue or completely healed oral mucosa was seen in all patients. All patients tolerated an oral diet by post-operative day one. Post-operative complications included two cases of bleeding requiring intervention. Eighty-five percent of patients (n=17) were seen for POV1 within 14 days of surgery. Patient-reported outcomes at POV1 included swallowing difficulties, speech issues and post-operative pain.</p>\n\n<p><strong>Conclusion: </strong>Biodesign is a viable reconstructive option for small to mid-sized oral tongue defects.  It provides tissue protection, facilitates granulation tissue ingrowth and prevents mucosal wound contracture. It avoids need for secondary surgical sites and subjectively reducing post-operative pain and promotes tissue regeneration that improves functional recovery. Further prospective studies with objective measures are needed to validate these findings and optimize outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155331--></body></html>"
    },
    {
      "uid": "P267",
      "content_id": "153421",
      "abstract_number": "P267",
      "poster_number": "P267",
      "title": "Use of Custom Dental Guards to Reduce Soft Tissue Trauma After Oral Cancer Surgery: A Case Series",
      "summary": "Across the available literature, removable intraoral devices consistently demonstrate the ability to shield vulnerable soft tissues, prevent repetitive trauma, maintain occlusal stability, and improve functional outcomes in patients with postoperative oral cavity vulnerability or altered occlusal dynamics. Although direct studies in postoperative oral cancer patients are scarce, the evidence from our descriptive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153421",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brianna Maniscalco, MD",
      "presenter": "Brianna Maniscalco, MD",
      "authors": "Isabella V Schafer, BA; Brianna Maniscalco, MD ; Shreni Shah, MD; Alexandra Kejner, MD",
      "normalized_authors": [
        "Isabella V Schafer",
        "Brianna Maniscalco",
        "Shreni Shah",
        "Alexandra Kejner"
      ],
      "affiliations": [
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Isabella V Schafer, BA; Brianna Maniscalco, MD ; Shreni Shah, MD; Alexandra Kejner, MD",
        "Affiliations": "Medical University of South Carolina",
        "Introduction": "Oral cancer resection and subsequent flap reconstruction frequently result in complex functional and anatomical deficits, including impaired mastication, speech, and swallowing, as well as sequelae of trismus and xerostomia. Postoperative complication rates following ablative and reconstructive surgery range from 30-50%, with wound dehiscence and flap failure being the most common events. Given this high complication burden, dental guards are proposed as cost-effective, protective, and rehabilitative adjuncts to minimize trauma, maintain occlusal alignment, and support early healing of ablative sites or reconstructed flaps.",
        "Abstract": "Despite extensive literature on prosthetic devices and oral cancer rehabilitation, there is a striking lack of published research that directly investigates the role of dental guards in the postoperative recovery of patients with oral cancer. Therefore, this case series aims to synthesize relevant literature and present patient-reported outcomes to characterize early experiences with custom postoperative dental guards. Through identifying perceived benefits and limitations of use, this work hopes to provide a rationale and theoretical foundation to explore the clinical use of dental guards in reducing mechanical soft tissue trauma, improving patient comfort, and decreasing complication rates during postoperative recovery. Five patients described clear benefits from using the custom dental appliance, including protection of swollen tissues from biting or scraping, prevention of nocturnal tongue or cheek trauma, reduction of jaw clenching, and improved comfort during the early stages of healing. Two patients specifically stated that receiving the guard immediately during the postoperative hospitalization would have further supported recovery. Three patients continue with nighttime use and report good tolerance. The other three patients discontinued long-term use due to discomfort, heightened gag sensitivity, or the need for self-adjustment of the device. Other reported issues with the guard were minor but included dry mouth and device-related discomfort. No patient experienced new oral cavity lesions at follow-up.",
        "Methods": "Patient-reported outcomes were collected from postoperative oral cancer patients who received a custom dental guard as part of their standard clinical care. Survey items assessed device use, diet advancement, perceived benefits, challenges, and overall satisfaction.",
        "Results": "Six postoperative oral cancer patients (7-24 months post-surgery) completed the survey regarding use of a custom dental guard. All six patients reported using the device during the at-home postoperative period, with two patients wearing it continuously and the remaining four using it primarily at night. Diet advancement following surgery ranged between 5 to 120 days, though all patients ultimately returned to a regular diet.",
        "Conclusion": "Across the available literature, removable intraoral devices consistently demonstrate the ability to shield vulnerable soft tissues, prevent repetitive trauma, maintain occlusal stability, and improve functional outcomes in patients with postoperative oral cavity vulnerability or altered occlusal dynamics. Although direct studies in postoperative oral cancer patients are scarce, the evidence from our descriptive case series suggests that custom dental guards may offer meaningful protection during the early healing period, improve patient comfort, and serve as a feasible adjunctive tool in postoperative rehabilitation. Further prospective studies are needed to clarify ideal timing, optimize device design, and evaluate long-term clinical impact."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Custom Dental Guards to Reduce Soft Tissue Trauma After Oral Cancer Surgery: A Case Series</span>. Isabella V Schafer, BA; <u>Brianna Maniscalco, MD</u>; Shreni Shah, MD; Alexandra Kejner, MD. Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oral cancer resection and subsequent flap reconstruction frequently result in complex functional and anatomical deficits, including impaired mastication, speech, and swallowing, as well as sequelae of trismus and xerostomia. Postoperative complication rates following ablative and reconstructive surgery range from 30-50%, with wound dehiscence and flap failure being the most common events. Given this high complication burden, dental guards are proposed as cost-effective, protective, and rehabilitative adjuncts to minimize trauma, maintain occlusal alignment, and support early healing of ablative sites or reconstructed flaps.</p>\n\n<p>Despite extensive literature on prosthetic devices and oral cancer rehabilitation, there is a striking lack of published research that directly investigates the role of dental guards in the postoperative recovery of patients with oral cancer. Therefore, this case series aims to synthesize relevant literature and present patient-reported outcomes to characterize early experiences with custom postoperative dental guards. Through identifying perceived benefits and limitations of use, this work hopes to provide a rationale and theoretical foundation to explore the clinical use of dental guards in reducing mechanical soft tissue trauma, improving patient comfort, and decreasing complication rates during postoperative recovery.</p>\n\n<p><strong>Methods: </strong>Patient-reported outcomes were collected from postoperative oral cancer patients who received a custom dental guard as part of their standard clinical care. Survey items assessed device use, diet advancement, perceived benefits, challenges, and overall satisfaction.</p>\n\n<p><strong>Results: </strong>Six postoperative oral cancer patients (7-24 months post-surgery) completed the survey regarding use of a custom dental guard. All six patients reported using the device during the at-home postoperative period, with two patients wearing it continuously and the remaining four using it primarily at night. Diet advancement following surgery ranged between 5 to 120 days, though all patients ultimately returned to a regular diet.</p>\n\n<p>Five patients described clear benefits from using the custom dental appliance, including protection of swollen tissues from biting or scraping, prevention of nocturnal tongue or cheek trauma, reduction of jaw clenching, and improved comfort during the early stages of healing. Two patients specifically stated that receiving the guard immediately during the postoperative hospitalization would have further supported recovery.</p>\n\n<p>Three patients continue with nighttime use and report good tolerance. The other three patients discontinued long-term use due to discomfort, heightened gag sensitivity, or the need for self-adjustment of the device. Other reported issues with the guard were minor but included dry mouth and device-related discomfort. No patient experienced new oral cavity lesions at follow-up.</p>\n\n<p><strong>Conclusion: </strong>Across the available literature, removable intraoral devices consistently demonstrate the ability to shield vulnerable soft tissues, prevent repetitive trauma, maintain occlusal stability, and improve functional outcomes in patients with postoperative oral cavity vulnerability or altered occlusal dynamics. Although direct studies in postoperative oral cancer patients are scarce, the evidence from our descriptive case series suggests that custom dental guards may offer meaningful protection during the early healing period, improve patient comfort, and serve as a feasible adjunctive tool in postoperative rehabilitation. Further prospective studies are needed to clarify ideal timing, optimize device design, and evaluate long-term clinical impact.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153421--></body></html>"
    },
    {
      "uid": "P268",
      "content_id": "154730",
      "abstract_number": "P268",
      "poster_number": "P268",
      "title": "Long-Term Survival in Oral Cavity Minor Salivary Gland Malignancies: A 22-Year Institutional Experience",
      "summary": "Minor salivary gland malignancies of the oral cavity represent uncommon neoplasms with distinct clinical characteristics. This series demonstrates limited histological diversity, with only three subtypes identified despite the theoretical potential for varied histopathology. Mucoepidermoid carcinoma emerged as the predominant malignancy, showing a predilection for female patients and the hard palate. The...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154730",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joao Goncalves Filho",
      "presenter": "Joao Goncalves Filho",
      "authors": "Matheus F Lourenço; Mauro K Ikeda, PhD; Luiz P Kowalski, PhD; Clovis A Pinto, PHd; Joao Goncalves Filho",
      "normalized_authors": [
        "Matheus F Lourenço",
        "Mauro K Ikeda",
        "Luiz P Kowalski",
        "Clovis A Pinto",
        "Joao Goncalves Filho"
      ],
      "affiliations": [
        "AC Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "AC Camargo Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 340,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Matheus F Lourenço; Mauro K Ikeda, PhD; Luiz P Kowalski, PhD; Clovis A Pinto, PHd; Joao Goncalves Filho",
        "Affiliations": "AC Camargo Cancer Center",
        "Introduction": "Malignant neoplasms of the minor salivary glands in the oral cavity represent rare entities in head and neck oncology. The palate constitutes the most frequent anatomical site for these tumors. Prognosis is primarily determined by histological subtype and disease stage at presentation. Despite their clinical significance, few contemporary series addressing these malignancies have been reported in the recent literature.",
        "Objective": "To evaluate treatment outcomes and characterize the clinical and pathological features of patients diagnosed with malignant minor salivary gland tumors of the oral cavity.",
        "Methods": "We conducted a retrospective review of medical records from patients treated at the Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Cancer Center, during a 22-year period (2000-2022). Clinical, pathological, and survival data were analyzed.",
        "Results": "Fifty-one patients with malignant minor salivary gland neoplasms were identified. The cohort demonstrated a female predominance (71%, n=36) with a mean age of 48 years (range 15-78 years). Three histological subtypes were observed: mucoepidermoid carcinoma represented the majority (71.4%), followed by adenoid cystic carcinoma (14.3%) and adenocarcinoma (14.3%). A favorable tumor grade distribution was noted, with 82% classified as low-grade malignancies. Anatomically, the hard palate served as the primary site in half of all cases (50%), with the buccal mucosa accounting for 25% of tumors. Additional sites included the tongue, lips, and retromolar trigone. Most patients presented with localized disease, as 71.4% had early-stage tumors (T1-T2) without regional lymph node involvement. Treatment consisted of surgical resection in all cases, with adjuvant radiotherapy delivered to 81% of patients (n=41). Survival outcomes were excellent, with 5-year and 10-year overall survival rates of 100% and 87%, respectively.",
        "Conclusion": "Minor salivary gland malignancies of the oral cavity represent uncommon neoplasms with distinct clinical characteristics. This series demonstrates limited histological diversity, with only three subtypes identified despite the theoretical potential for varied histopathology. Mucoepidermoid carcinoma emerged as the predominant malignancy, showing a predilection for female patients and the hard palate. The favorable stage distribution at presentation, combined with multimodality treatment approaches, contributed to long-term survival outcomes in this patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Long-Term Survival in Oral Cavity Minor Salivary Gland Malignancies: A 22-Year Institutional Experience</span>. Matheus F Lourenço; Mauro K Ikeda, PhD; Luiz P Kowalski, PhD; Clovis A Pinto, PHd; <u>Joao Goncalves Filho</u>. AC Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Malignant neoplasms of the minor salivary glands in the oral cavity represent rare entities in head and neck oncology. The palate constitutes the most frequent anatomical site for these tumors. Prognosis is primarily determined by histological subtype and disease stage at presentation. Despite their clinical significance, few contemporary series addressing these malignancies have been reported in the recent literature.</p>\n\n<p><strong>Objective:</strong> To evaluate treatment outcomes and characterize the clinical and pathological features of patients diagnosed with malignant minor salivary gland tumors of the oral cavity.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective review of medical records from patients treated at the Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Cancer Center, during a 22-year period (2000-2022). Clinical, pathological, and survival data were analyzed.</p>\n\n<p><strong>Results: </strong>Fifty-one patients with malignant minor salivary gland neoplasms were identified. The cohort demonstrated a female predominance (71%, n=36) with a mean age of 48 years (range 15-78 years). Three histological subtypes were observed: mucoepidermoid carcinoma represented the majority (71.4%), followed by adenoid cystic carcinoma (14.3%) and adenocarcinoma (14.3%). A favorable tumor grade distribution was noted, with 82% classified as low-grade malignancies. Anatomically, the hard palate served as the primary site in half of all cases (50%), with the buccal mucosa accounting for 25% of tumors. Additional sites included the tongue, lips, and retromolar trigone. Most patients presented with localized disease, as 71.4% had early-stage tumors (T1-T2) without regional lymph node involvement. Treatment consisted of surgical resection in all cases, with adjuvant radiotherapy delivered to 81% of patients (n=41). Survival outcomes were excellent, with 5-year and 10-year overall survival rates of 100% and 87%, respectively.</p>\n\n<p><strong>Conclusion: </strong>Minor salivary gland malignancies of the oral cavity represent uncommon neoplasms with distinct clinical characteristics. This series demonstrates limited histological diversity, with only three subtypes identified despite the theoretical potential for varied histopathology. Mucoepidermoid carcinoma emerged as the predominant malignancy, showing a predilection for female patients and the hard palate. The favorable stage distribution at presentation, combined with multimodality treatment approaches, contributed to long-term survival outcomes in this patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154730--></body></html>"
    },
    {
      "uid": "P269",
      "content_id": "154668",
      "abstract_number": "P269",
      "poster_number": "P269",
      "title": "Oncological outcomes of elderly nonsmoking women with oral cavity Squamous Cell Carcinoma",
      "summary": "In this elderly, female cohort with OCSCC, smoking history did not independently influence OS or DSS. Prognosis was shaped predominantly by nodal stage, margin status, and PNI. These findings demonstrate that elderly non-smoking females with oral cancer, who constitute a growing demographic, experience survival outcomes driven primarily by tumor biology and anatomic subsite rather than behavioral history.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154668",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin M Hintze, MD",
      "presenter": "Justin M Hintze, MD",
      "authors": "Justin M Hintze, MD ; Jatin Shah, MD; Richard Wong, MD; Snehal Patel, MD; Ian Ganly, MD",
      "normalized_authors": [
        "Justin M Hintze",
        "Jatin Shah",
        "Richard Wong",
        "Snehal Patel",
        "Ian Ganly"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Justin M Hintze, MD ; Jatin Shah, MD; Richard Wong, MD; Snehal Patel, MD; Ian Ganly, MD",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Introduction": "The incidence of oral cavity squamous cell carcinoma (OCSCC) has been rising, with data from the United States showing an average annual percentage change of 1.8%. The greatest change in incidence was in cancers of the oral tongue and in women. Data from France has demonstrated a 72% increase in oral cavity SCC in women above 70 over the last 30 years, with population growth, smoking and alcohol intake not accounting for this increase alone. Some have suggested that elderly non-smoking women are a distinct subgroup of patients. Their tumors more commonly occur on the lateral tongue, and pathogenesis may be related to areas of dental trauma. The purpose of the present study was to examine the clinic-pathological features and outcomes of oral cavity SCC in non-smoking, women over the age of 70 at Memorial Sloan Kettering Cancer Center from 1985-2015.",
        "Methods": "From a dataset of 2073 OCSCC patients treated with primary surgery between 1985-2015 at Memorial Sloan Kettering Cancer Center, 14.4% (n=300), were women over the age of 70. Patients were categorized into smokers or ex-smokers (n=148) and never smokers (n=152). Patient demographics, comorbidities according to the Washington University Head and Neck Comorbidity Index, oral cavity subsite, T- and N-staging according to the 8th edition of the AJCC, pathological features (margin status, perineural invasion, lymphovascular invasion) were collected. Factors predictive of DSS and OS were determined by univariable and multivariable analyses using the Cox proportional hazard method. Disease-specific (DSS) and overall survival (OS) were calculated using the Kaplan-Meier method.",
        "Results": "Non-smokers had a higher prevalence of oral tongue tumors, whereas smokers demonstrated increased proportion of floor-of-mouth and retromolar trigone tumors. (p<0.001). Stage distribution did not differ substantially between the groups.",
        "Abstract": "On multivariable analysis, factors predictive of OS were N2- and N3-stage (HR 2.07, 2.80, p=0.007, <0.001 respectively), and involved margins (HR 2.26, p=0.002). Factors predictive of DSS were N3-stage (HR 2.65, p=0.015), involved margins (HR 3.53, p=0.002), and PNI (HR 2.65, p=0.002), whereas smoking status was not associated with higher risk for DSS (p=0.457). On Kaplan–Meier analysis, elderly nonsmoking females with oral cancer had similar OS (5 year 49.3% in non-smokers vs 48.0% in smokers, p=0.61) and DSS (5 year 70.8% in non-smokers vs 65.8% in smokers, p=0.76) to smoking patients.",
        "Conclusions": "In this elderly, female cohort with OCSCC, smoking history did not independently influence OS or DSS. Prognosis was shaped predominantly by nodal stage, margin status, and PNI. These findings demonstrate that elderly non-smoking females with oral cancer, who constitute a growing demographic, experience survival outcomes driven primarily by tumor biology and anatomic subsite rather than behavioral history."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncological outcomes of elderly nonsmoking women with oral cavity Squamous Cell Carcinoma</span>. <u>Justin M Hintze, MD</u>; Jatin Shah, MD; Richard Wong, MD; Snehal Patel, MD; Ian Ganly, MD. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The incidence of oral cavity squamous cell carcinoma (OCSCC) has been rising, with data from the United States showing an average annual percentage change of 1.8%. The greatest change in incidence was in cancers of the oral tongue and in women. Data from France has demonstrated a 72% increase in oral cavity SCC in women above 70 over the last 30 years, with population growth, smoking and alcohol intake not accounting for this increase alone. Some have suggested that elderly non-smoking women are a distinct subgroup of patients. Their tumors more commonly occur on the lateral tongue, and pathogenesis may be related to areas of dental trauma. The purpose of the present study was to examine the clinic-pathological features and outcomes of oral cavity SCC in non-smoking,  women over the age of 70 at Memorial Sloan Kettering Cancer Center from 1985-2015.</p>\n\n<p><strong>Methods: </strong>From a dataset of 2073 OCSCC patients treated with primary surgery between 1985-2015 at Memorial Sloan Kettering Cancer Center, 14.4% (n=300), were women over the age of 70. Patients were categorized into smokers or ex-smokers (n=148) and never smokers (n=152). Patient demographics, comorbidities according to the Washington University Head and Neck Comorbidity Index, oral cavity subsite, T- and N-staging according to the 8th edition of the AJCC, pathological features (margin status, perineural invasion, lymphovascular invasion) were collected. Factors predictive of DSS and OS were determined by univariable and multivariable analyses using the Cox proportional hazard method. Disease-specific (DSS) and overall survival (OS) were calculated using the Kaplan-Meier method.</p>\n\n<p><strong>Results: </strong>Non-smokers had a higher prevalence of oral tongue tumors, whereas smokers demonstrated increased proportion of floor-of-mouth and retromolar trigone tumors. (p<0.001). Stage distribution did not differ substantially between the groups.</p>\n\n<p>On multivariable analysis, factors predictive of OS were N2- and N3-stage (HR 2.07, 2.80, p=0.007, <0.001 respectively), and involved margins (HR 2.26, p=0.002). Factors predictive of DSS were N3-stage (HR 2.65, p=0.015), involved margins (HR 3.53, p=0.002), and PNI (HR 2.65, p=0.002), whereas smoking status was not associated with higher risk for DSS (p=0.457). </p>\n\n<p>On Kaplan–Meier analysis, elderly nonsmoking females with oral cancer had similar OS (5 year 49.3% in non-smokers vs 48.0% in smokers, p=0.61) and DSS (5 year 70.8% in non-smokers vs 65.8% in smokers, p=0.76) to smoking patients.  </p>\n\n<p><strong>Conclusions: </strong>In this elderly, female cohort with OCSCC, smoking history did not independently influence OS or DSS. Prognosis was shaped predominantly by nodal stage, margin status, and PNI. These findings demonstrate that elderly non-smoking females with oral cancer, who constitute a growing demographic, experience survival outcomes driven primarily by tumor biology and anatomic subsite rather than behavioral history. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154668--></body></html>"
    },
    {
      "uid": "P270",
      "content_id": "155390",
      "abstract_number": "P270",
      "poster_number": "P270",
      "title": "Surgical Burden and Deliverability of Adjuvant Therapy in Oral Cavity Cancer: A Real-World Pathway and Landmark Analysis",
      "summary": "Greater surgical burden was associated with delayed initiation of adjuvant therapy and may influence outcomes through disruption of multimodal treatment pathways. These findings suggest operative complexity affects survival primarily through its impact on timely delivery of adjuvant therapy rather than surgery itself. Optimizing perioperative pathways and preoperative risk stratification may help align operative...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155390",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "S Turgeman",
      "presenter": "S Turgeman",
      "authors": "S Turgeman 1 ; I Turgeman 2 ; E Weitman 3 ; Z Gil 1",
      "normalized_authors": [
        "S Turgeman",
        "I Turgeman",
        "E Weitman",
        "Z Gil"
      ],
      "affiliations": [
        "Rambam Health Care Campus",
        "Danan Farber Cancer Institution",
        "Harvard Medical School"
      ],
      "normalized_institutions": [
        "Rambam Health Care Campus",
        "Danan Farber Cancer Institution",
        "Harvard Medical School"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "S Turgeman 1 ; I Turgeman 2 ; E Weitman 3 ; Z Gil 1",
        "Affiliations": "1 Rambam Health Care Campus; 2 Danan Farber Cancer Institution; 3 Harvard Medical School",
        "Background": "Surgical resection is the cornerstone of curative treatment for oral cavity squamous cell carcinoma (OCSCC), with adjuvant radiotherapy (RT) or chemoradiotherapy recommended for high-risk disease. Advances in operative and reconstructive techniques have expanded resectability, however, their impact on timely delivery of adjuvant therapy remains unclear. We evaluated how surgical burden influences treatment pathways, delivery of adjuvant therapy, and outcomes in a real-world cohort.",
        "Methods": "We conducted a retrospective cohort study of patients with OCSCC treated at a single center between 2000 and 2023. Surgical complexity was categorized as tumor resection alone (R), tumor resection with unilateral neck dissection (R+UNI), free flap reconstruction with unilateral neck dissection (FF+UNI), and free flap reconstruction with bilateral neck dissection (FF+BLT). Treatment pathways from surgery to adjuvant therapy were reconstructed using procedural and treatment records. The primary endpoint was delivery of adjuvant RT within 90 days of surgery. A two-stage analysis evaluated factors associated with (1) receipt of adjuvant RT and (2) early initiation (≤42 days) among treated patients. Multivariable models included age, sex, population group, tumor subsite, HPV status, and surgical burden. Overall survival (OS) was assessed using a 90-day landmark analysis among patients alive who initiated adjuvant RT.",
        "Results": "Among 521 patients, the median age was 65.8 years; 58.9% were male, 44.1% had tongue primaries, and 8.3% were HPV positive. Definitive surgery was performed in 41% of patients, while the remainder received non-surgical management including definitive chemoradiation or systemic or palliative therapy. Within the surgical cohort (n = 215), neck dissection was performed in 81.4% and free flap reconstruction in 37.2%. Overall, 29.8% of surgical patients received postoperative RT within 180 days and 25.6% within 90 days. Increasing surgical complexity was associated with progressively longer time to RT initiation, with median RT intervals of 36, 64, 69, and 73 days across the R, R+UNI, FF+UNI, and FF+BLT groups, respectively, indicating a stepwise delay with increasing operative burden. The proportion initiating RT within the 42-day benchmark declined across groups (28.6%, 28.2%, 22.9%, and 16.7%, respectively). Younger age (HR 0.96 per year), male sex, tongue primary, and non-minority population group were associated with earlier RT initiation. In a 90-day landmark analysis (n = 52), delayed RT initiation (43–90 days) was associated with a higher hazard of death compared with early RT (HR 1.61, 95% CI 0.65–3.98). Among patients with delayed RT initiation (>42 days), older age was associated with a higher risk of death. In an exploratory age-adjusted model, each additional year of age was associated with increased mortality (OR, 1.05; 95% CI, 1.02–1.09; p = 0.0015).",
        "Conclusions": "Greater surgical burden was associated with delayed initiation of adjuvant therapy and may influence outcomes through disruption of multimodal treatment pathways. These findings suggest operative complexity affects survival primarily through its impact on timely delivery of adjuvant therapy rather than surgery itself. Optimizing perioperative pathways and preoperative risk stratification may help align operative strategy with timely completion of multimodal therapy and improve outcomes through coordinated multidisciplinary care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Burden and Deliverability of Adjuvant Therapy in Oral Cavity Cancer: A Real-World Pathway and Landmark Analysis</span>. <u>S Turgeman</u><sup>1</sup>; I Turgeman<sup>2</sup>; E Weitman<sup>3</sup>; Z Gil<sup>1</sup>. <sup>1</sup>Rambam Health Care Campus; <sup>2</sup>Danan Farber Cancer Institution; <sup>3</sup>Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Surgical resection is the cornerstone of curative treatment for oral cavity squamous cell carcinoma (OCSCC), with adjuvant radiotherapy (RT) or chemoradiotherapy recommended for high-risk disease. Advances in operative and reconstructive techniques have expanded resectability, however, their impact on timely delivery of adjuvant therapy remains unclear. We evaluated how surgical burden influences treatment pathways, delivery of adjuvant therapy, and outcomes in a real-world cohort.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of patients with OCSCC treated at a single center between 2000 and 2023. Surgical complexity was categorized as tumor resection alone (R), tumor resection with unilateral neck dissection (R+UNI), free flap reconstruction with unilateral neck dissection (FF+UNI), and free flap reconstruction with bilateral neck dissection (FF+BLT). Treatment pathways from surgery to adjuvant therapy were reconstructed using procedural and treatment records. The primary endpoint was delivery of adjuvant RT within 90 days of surgery. A two-stage analysis evaluated factors associated with (1) receipt of adjuvant RT and (2) early initiation (≤42 days) among treated patients. Multivariable models included age, sex, population group, tumor subsite, HPV status, and surgical burden. Overall survival (OS) was assessed using a 90-day landmark analysis among patients alive who initiated adjuvant RT.</p>\n\n<p><strong>Results: </strong>Among 521 patients, the median age was 65.8 years; 58.9% were male, 44.1% had tongue primaries, and 8.3% were HPV positive. Definitive surgery was performed in 41% of patients, while the remainder received non-surgical management including definitive chemoradiation or systemic or palliative therapy. Within the surgical cohort (n = 215), neck dissection was performed in 81.4% and free flap reconstruction in 37.2%. Overall, 29.8% of surgical patients received postoperative RT within 180 days and 25.6% within 90 days. Increasing surgical complexity was associated with progressively longer time to RT initiation, with median RT intervals of 36, 64, 69, and 73 days across the R, R+UNI, FF+UNI, and FF+BLT groups, respectively, indicating a stepwise delay with increasing operative burden. The proportion initiating RT within the 42-day benchmark declined across groups (28.6%, 28.2%, 22.9%, and 16.7%, respectively). Younger age (HR 0.96 per year), male sex, tongue primary, and non-minority population group were associated with earlier RT initiation. In a 90-day landmark analysis (n = 52), delayed RT initiation (43–90 days) was associated with a higher hazard of death compared with early RT (HR 1.61, 95% CI 0.65–3.98). Among patients with delayed RT initiation (>42 days), older age was associated with a higher risk of death. In an exploratory age-adjusted model, each additional year of age was associated with increased mortality (OR, 1.05; 95% CI, 1.02–1.09; p = 0.0015).</p>\n\n<p><strong>Conclusions: </strong>Greater surgical burden was associated with delayed initiation of adjuvant therapy and may influence outcomes through disruption of multimodal treatment pathways. These findings suggest operative complexity affects survival primarily through its impact on timely delivery of adjuvant therapy rather than surgery itself. Optimizing perioperative pathways and preoperative risk stratification may help align operative strategy with timely completion of multimodal therapy and improve outcomes through coordinated multidisciplinary care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155390--></body></html>"
    },
    {
      "uid": "P271",
      "content_id": "154065",
      "abstract_number": "P271",
      "poster_number": "P271",
      "title": "A Newly Recognized Phenomenon: Acquired Macroglossia in Post-Stroke Patients - A Systematic Review",
      "summary": "Post-stroke macroglossia is a rare but profoundly debilitating complication. Increasing awareness of this condition, particularly among African American women, is essential to improving patient quality of life. Steroids and antihistamines are commonly used as first-line therapies, but little evidence exists to support their efficacy in the post-stroke setting. For patients with persistent macroglossia, timely...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154065",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rachel Berglas, BS",
      "presenter": "Rachel Berglas, BS",
      "authors": "Vanessa Nwaiwu, DO 1 ; John Alfarone, BS 2 ; Rachel Berglas, BS 1 ; Vikas Mehta, MD 1 ; Richard Smith, MD 1 ; Bradley Schiff, MD 1 ; Rishi Malhotra, MD 1 ; Ari Moskowitz, MD 1 ; Gina Palma, SLP 1 ; Laura Bryne, SLP 1 ; Helena Levyn, MD 1",
      "normalized_authors": [
        "Vanessa Nwaiwu",
        "John Alfarone",
        "Rachel Berglas",
        "Vikas Mehta",
        "Richard Smith",
        "Bradley Schiff",
        "Rishi Malhotra",
        "Ari Moskowitz",
        "Gina Palma, SLP",
        "Laura Bryne, SLP",
        "Helena Levyn"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine/ Montefiore Medical Center",
        "Norton College of Medicine, SUNY Upstate Medical University"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine/ Montefiore Medical Center",
        "Norton College of Medicine, SUNY Upstate Medical University"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 388,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Vanessa Nwaiwu, DO 1 ; John Alfarone, BS 2 ; Rachel Berglas, BS 1 ; Vikas Mehta, MD 1 ; Richard Smith, MD 1 ; Bradley Schiff, MD 1 ; Rishi Malhotra, MD 1 ; Ari Moskowitz, MD 1 ; Gina Palma, SLP 1 ; Laura Bryne, SLP 1 ; Helena Levyn, MD 1",
        "Affiliations": "1 Albert Einstein College of Medicine/ Montefiore Medical Center; 2 Norton College of Medicine, SUNY Upstate Medical University",
        "Background": "Macroglossia, defined as abnormal enlargement of the tongue extending beyond the alveolar ridge, may be congenital or acquired. In this systematic review, we describe an underrecognized phenomenon of acquired macroglossia in post-stroke patients. This condition can impede speech, breathing, and swallowing, significantly diminishing quality of life. By highlighting this entity, we aim to raise clinical awareness and propose surgical intervention for cases of prolonged macroglossia that fail to respond to medical therapy.",
        "Methods": "A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they reported macroglossia following stroke or neurosurgical intervention related to stroke. Exclusion criteria included macroglossia secondary to trauma, genetic syndromes, medication, or other identifiable causes unrelated to stroke. Only published peer-reviewed articles were included in the systematic review; conference abstracts were excluded.",
        "Results": "Of 360 studies screened, 4 met the inclusion criteria, encompassing a total of 9 patients (2 males and 7 females). The mean age was 45.2 years, and all seven female patients were African American. All cases occurred following an ischemic or hemorrhagic stroke, with reported time of onset of macroglossia ranging from 3 to 31 days following the neurologic event. Initial medical management consisted of IV steroids (n=4,44%) and antihistamines (n=2,22%), which led to the resolution of macroglossia in two patients. The remaining 7 patients required tracheostomy and percutaneous gastrostomy tubes given the persistence of macroglossia. All seven patients ultimately underwent surgical management, most commonly the anterior wedge glossectomy (n=4, 57%), as well as the keyhole resection technique (n=1, 14%), resulting in a marked decrease in tongue size. Surgical management with partial glossectomy achieved sufficient tongue reduction to permit complete intraoral position in all patients. Subsequently, 5/7 (71%) patients were successfully decannulated, and 4/7 (57%) were able to resume an oral diet as early as one month after surgery.",
        "Conclusion": "Post-stroke macroglossia is a rare but profoundly debilitating complication. Increasing awareness of this condition, particularly among African American women, is essential to improving patient quality of life. Steroids and antihistamines are commonly used as first-line therapies, but little evidence exists to support their efficacy in the post-stroke setting. For patients with persistent macroglossia, timely referral for surgical evaluation is recommended to facilitate recovery of fundamental functions, including speech, oral intake, and airway patency."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Newly Recognized Phenomenon: Acquired Macroglossia in Post-Stroke Patients - A Systematic Review</span>. Vanessa Nwaiwu, DO<sup>1</sup>; John Alfarone, BS<sup>2</sup>; <u>Rachel Berglas, BS</u><sup>1</sup>; Vikas Mehta, MD<sup>1</sup>; Richard Smith, MD<sup>1</sup>; Bradley Schiff, MD<sup>1</sup>; Rishi Malhotra, MD<sup>1</sup>; Ari Moskowitz, MD<sup>1</sup>; Gina Palma, SLP<sup>1</sup>; Laura Bryne, SLP<sup>1</sup>; Helena Levyn, MD<sup>1</sup>. <sup>1</sup>Albert Einstein College of Medicine/ Montefiore Medical Center; <sup>2</sup>Norton College of Medicine, SUNY Upstate Medical University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Macroglossia, defined as abnormal enlargement of the tongue extending beyond the alveolar ridge, may be congenital or acquired. In this systematic review, we describe an underrecognized phenomenon of acquired macroglossia in post-stroke patients. This condition can impede speech, breathing, and swallowing, significantly diminishing quality of life. By highlighting this entity, we aim to raise clinical awareness and propose surgical intervention for cases of prolonged macroglossia that fail to respond to medical therapy.</p>\n\n<p><strong>Methods:</strong> A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they reported macroglossia following stroke or neurosurgical intervention related to stroke. Exclusion criteria included macroglossia secondary to trauma, genetic syndromes, medication, or other identifiable causes unrelated to stroke. Only published peer-reviewed articles were included in the systematic review; conference abstracts were excluded.</p>\n\n<p><strong>Results: </strong>Of 360 studies screened, 4 met the inclusion criteria, encompassing a total of 9 patients (2 males and 7 females). The mean age was 45.2 years, and all seven female patients were African American. All cases occurred following an ischemic or hemorrhagic stroke, with reported time of onset of macroglossia ranging from 3 to 31 days following the neurologic event. Initial medical management consisted of IV steroids (n=4,44%) and antihistamines (n=2,22%), which led to the resolution of macroglossia in two patients. The remaining 7 patients required tracheostomy and percutaneous gastrostomy tubes given the persistence of macroglossia. All seven patients ultimately underwent surgical management, most commonly the anterior wedge glossectomy (n=4, 57%), as well as the keyhole resection technique (n=1, 14%), resulting in a marked decrease in tongue size. Surgical management with partial glossectomy achieved sufficient tongue reduction to permit complete intraoral position in all patients. Subsequently, 5/7 (71%) patients were successfully decannulated, and 4/7 (57%) were able to resume an oral diet as early as one month after surgery.</p>\n\n<p><strong>Conclusion: </strong>Post-stroke macroglossia is a rare but profoundly debilitating complication. Increasing awareness of this condition, particularly among African American women, is essential to improving patient quality of life. Steroids and antihistamines are commonly used as first-line therapies, but little evidence exists to support their efficacy in the post-stroke setting. For patients with persistent macroglossia, timely referral for surgical evaluation is recommended to facilitate recovery of fundamental functions, including speech, oral intake, and airway patency.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154065--></body></html>"
    },
    {
      "uid": "P272",
      "content_id": "154764",
      "abstract_number": "P272",
      "poster_number": "P272",
      "title": "Clinical and Pathological Feature of Early On-set Oral Cavity Squamous Cell Carcinoma",
      "summary": "Our results suggest that early-onset oral cavity cancer has higher rates of nodal involvement at presentation. In addition, despite younger age and lower rates of traditional risk factors, TNM stage and histologic adverse risk factors were not significant different between age groups. Of note, early on-set patients may tend to have higher incidence of WPOI 5 and elevated rates of recurrence. Our results suggest...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154764",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan Garneau, MD",
      "presenter": "Jonathan Garneau, MD",
      "authors": "Katherine Webb, MD 1 ; Ryan K Stepp, BS 2 ; Sarah Zadeh, MD 1 ; Britney He, BS 1 ; Noah Thornton, BS 3 ; Sonam Patel, BS 1 ; Eric Dowling, MD 1 ; Jonathan Garneau, MD 1",
      "normalized_authors": [
        "Katherine Webb",
        "Ryan K Stepp",
        "Sarah Zadeh",
        "Britney He",
        "Noah Thornton",
        "Sonam Patel",
        "Eric Dowling",
        "Jonathan Garneau"
      ],
      "affiliations": [
        "University of Virginia",
        "University of South Carolina Greenville",
        "Temple University"
      ],
      "normalized_institutions": [
        "University of Virginia",
        "University of South Carolina Greenville",
        "Temple University"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 365,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Katherine Webb, MD 1 ; Ryan K Stepp, BS 2 ; Sarah Zadeh, MD 1 ; Britney He, BS 1 ; Noah Thornton, BS 3 ; Sonam Patel, BS 1 ; Eric Dowling, MD 1 ; Jonathan Garneau, MD 1",
        "Affiliations": "1 University of Virginia; 2 University of South Carolina Greenville; 3 Temple University",
        "Background": "Patients with early on-set (< 45 years) oral-cavity squamous-cell carcinoma (OCSCC) can present at advanced stages and have an unusually aggressive clinical course despite younger age and lack of traditional risk factors. The focus of this study is to compare clinical and pathologic features between two broad age groups with inclusion of “worst pattern of invasion (WPOI),” a known histologic predictor of adverse clinical outcomes.",
        "Methods": "A retrospective review of consecutive OCSCC cases treated at the University of Virginia Medical Center between 2013-2023 was conducted. Patients were grouped as early-onset (< 45 years, n=59) or control (> 45 years, n=59). Fisher’s exact, Chi-Square, and Wilcoxon testing were used for statistical analysis.",
        "Results": "Patients with early on-set OC had higher incidence of nodal involvement and increased number of nodes involved when compared to the control group (p=0.004). However, TNM staging was similar in both groups, aside from T3 lesions being over-represented in the early on set cohort (p=0.02). In terms of pathology, the rates of known adverse features such as LVI, PNI and ENE were similar in both groups and not statistically different. However, higher WPOI grades (grade 5) were higher in the early on-set group; 19 (43%) compared to 11 (23%) in control group, but this did not reach significant difference (p=0.06). Recurrence rate between groups were not statistically significant (p=0.054) despite a significant decrease in traditional risk factors of smoking or increased alcohol consumption in the early on-set group (p = 0.03). Measurable survival outcomes were similar in both groups.",
        "Conclusion": "Our results suggest that early-onset oral cavity cancer has higher rates of nodal involvement at presentation. In addition, despite younger age and lower rates of traditional risk factors, TNM stage and histologic adverse risk factors were not significant different between age groups. Of note, early on-set patients may tend to have higher incidence of WPOI 5 and elevated rates of recurrence. Our results suggest treatment of early on-set patients should favor elective nodal treatment, adherence to standard of care adjuvant therapy based on risk factors, and frequent surveillance. Future studies are needed to elucidate the use of immunotherapy in this population and the exploration of non-traditional risk factors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and Pathological Feature of Early On-set Oral Cavity Squamous Cell Carcinoma</span>. Katherine Webb, MD<sup>1</sup>; Ryan K Stepp, BS<sup>2</sup>; Sarah Zadeh, MD<sup>1</sup>; Britney He, BS<sup>1</sup>; Noah Thornton, BS<sup>3</sup>; Sonam Patel, BS<sup>1</sup>; Eric Dowling, MD<sup>1</sup>; <u>Jonathan Garneau, MD</u><sup>1</sup>. <sup>1</sup>University of Virginia; <sup>2</sup>University of South Carolina Greenville; <sup>3</sup>Temple University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patients with early on-set (< 45 years) oral-cavity squamous-cell carcinoma (OCSCC) can present at advanced stages and have an unusually aggressive clinical course despite younger age and lack of traditional risk factors. The focus of this study is to compare clinical and pathologic features between two broad age groups with inclusion of “worst pattern of invasion (WPOI),” a known histologic predictor of adverse clinical outcomes.</p>\n\n<p><strong>Methods: </strong>A retrospective review of consecutive OCSCC cases treated at the University of Virginia Medical Center between 2013-2023 was conducted. Patients were grouped as early-onset (< 45 years, n=59) or control (> 45 years, n=59). Fisher’s exact, Chi-Square, and Wilcoxon testing were used for statistical analysis.</p>\n\n<p><strong>Results:</strong> Patients with early on-set OC had higher incidence of nodal involvement and increased number of nodes involved when compared to the control group (p=0.004). However, TNM staging was similar in both groups, aside from T3 lesions being over-represented in the early on set cohort (p=0.02). In terms of pathology, the rates of known adverse features such as LVI, PNI and ENE were similar in both groups and not statistically different. However, higher WPOI grades (grade 5) were higher in the early on-set group; 19 (43%) compared to 11 (23%) in control group, but this did not reach significant difference (p=0.06). Recurrence rate between groups were not statistically significant (p=0.054) despite a significant decrease in traditional risk factors of smoking or increased alcohol consumption in the early on-set group (p = 0.03). Measurable survival outcomes were similar in both groups.  </p>\n\n<p><strong>Conclusion: </strong>Our results suggest that early-onset oral cavity cancer has higher rates of nodal involvement at presentation. In addition, despite younger age and lower rates of traditional risk factors, TNM stage and histologic adverse risk factors were not significant different between age groups. Of note, early on-set patients may tend to have higher incidence of WPOI 5 and elevated rates of recurrence. Our results suggest treatment of early on-set patients should favor elective nodal treatment, adherence to standard of care adjuvant therapy based on risk factors, and frequent surveillance. Future studies are needed to elucidate the use of immunotherapy in this population and the exploration of non-traditional risk factors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154764--></body></html>"
    },
    {
      "uid": "P273",
      "content_id": "151841",
      "abstract_number": "P273",
      "poster_number": "P273",
      "title": "Low Margin-to-Depth of Invasion Ratio Combined with N1 Status Identifies Poor Prognosis in Surgically Treated Low-Risk Stage I–III Oral Cancer",
      "summary": "Low MDR and N1 status are independent adverse prognostic factors in pathologically low-risk OSCC. Patients exhibiting both risk factors may benefit from adjuvant therapy to improve survival outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151841",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ko Chun Fang, MD",
      "presenter": "Ko Chun Fang, MD",
      "authors": "Ko Chun Fang, MD ; Ming Hsien Tsai, MD",
      "normalized_authors": [
        "Ko Chun Fang",
        "Ming Hsien Tsai"
      ],
      "affiliations": [
        "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 277,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods and Materials",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ko Chun Fang, MD ; Ming Hsien Tsai, MD",
        "Affiliations": "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan",
        "Background": "This study investigated the prognostic significance of the margin-to-depth of invasion ratio (MDR) combined with N classification in patients with stage I–III oral squamous cell carcinoma (OSCC) considered pathologically low risk and treated with surgery alone.",
        "Methods and Materials": "We retrospectively analyzed 820 patients with pathological T1–3N0–1 OSCC who underwent radical surgery without adjuvant therapy between 2007 and 2017. The optimal MDR cutoff for predicting survival was determined using Youden’s index and validated with 1,000 bootstrap resampling iterations. Cox proportional hazards models were applied to identify factors associated with cancer-specific survival (CSS) and relapse-free survival (RFS).",
        "Results": "The optimal MDR cutoff was 0.92. Patients with MDR ≥ 0.92 had significantly better 5-year CSS (96.8% vs. 90.0%, p < 0.001) and RFS (88.6% vs. 81.5%, p = 0.001) than those with MDR < 0.92. Both low MDR and N1 status independently predicted poorer CSS and RFS (p < 0.05). When combined, patients with low MDR and N1 classification showed the worst outcomes, with 5-year CSS and RFS rates of 56.3% and 37.5%, respectively, compared with 97.0%/89.9% (high MDR + N0), 92.1%/84.0% (low MDR + N0), and 88.2%/76.5% (high MDR + N1) (p < 0.001). Multivariate analysis, adjusted for clinicopathological factors, confirmed lower mortality for high MDR + N1 or low MDR + N0 (CSS HR = 0.055; RFS HR = 0.108) and for high MDR + N0 (CSS HR = 0.152; RFS HR = 0.179; all p < 0.001).",
        "Conclusion": "Low MDR and N1 status are independent adverse prognostic factors in pathologically low-risk OSCC. Patients exhibiting both risk factors may benefit from adjuvant therapy to improve survival outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Low Margin-to-Depth of Invasion Ratio Combined with N1 Status Identifies Poor Prognosis in Surgically Treated Low-Risk Stage I–III Oral Cancer</span>. <u>Ko Chun Fang, MD</u>; Ming Hsien Tsai, MD. Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>This study investigated the prognostic significance of the margin-to-depth of invasion ratio (MDR) combined with N classification in patients with stage I–III oral squamous cell carcinoma (OSCC) considered pathologically low risk and treated with surgery alone.</p>\n\n<p><strong>Methods and Materials:</strong> We retrospectively analyzed 820 patients with pathological T1–3N0–1 OSCC who underwent radical surgery without adjuvant therapy between 2007 and 2017. The optimal MDR cutoff for predicting survival was determined using Youden’s index and validated with 1,000 bootstrap resampling iterations. Cox proportional hazards models were applied to identify factors associated with cancer-specific survival (CSS) and relapse-free survival (RFS).</p>\n\n<p><strong>Results:</strong> The optimal MDR cutoff was 0.92. Patients with MDR ≥ 0.92 had significantly better 5-year CSS (96.8% vs. 90.0%, p < 0.001) and RFS (88.6% vs. 81.5%, p = 0.001) than those with MDR < 0.92. Both low MDR and N1 status independently predicted poorer CSS and RFS (p < 0.05). When combined, patients with low MDR and N1 classification showed the worst outcomes, with 5-year CSS and RFS rates of 56.3% and 37.5%, respectively, compared with 97.0%/89.9% (high MDR + N0), 92.1%/84.0% (low MDR + N0), and 88.2%/76.5% (high MDR + N1) (p < 0.001). Multivariate analysis, adjusted for clinicopathological factors, confirmed lower mortality for high MDR + N1 or low MDR + N0 (CSS HR = 0.055; RFS HR = 0.108) and for high MDR + N0 (CSS HR = 0.152; RFS HR = 0.179; all p < 0.001).</p>\n\n<p><strong>Conclusion:</strong> Low MDR and N1 status are independent adverse prognostic factors in pathologically low-risk OSCC. Patients exhibiting both risk factors may benefit from adjuvant therapy to improve survival outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151841--></body></html>"
    },
    {
      "uid": "P274",
      "content_id": "153856",
      "abstract_number": "P274",
      "poster_number": "P274",
      "title": "Prognostic Significance of Tumor Growth Rates (TGR) in Oral Cavity Cancer",
      "summary": "Preliminary findings suggest that TGR may be a clinically meaningful prognostic marker in oral cavity cancer, especially in tongue squamous cell carcinoma. Further studies with larger sample sizes are needed to validate these observations. Preliminary results of our study show promising data for utilizing imaging segmentation and its use to identify high risk tumors which could affect treatment decision making.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153856",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Soroush Ershadifar, MD",
      "presenter": "Soroush Ershadifar, MD",
      "authors": "Soroush Ershadifar, MD 1 ; Nina D Ham, BA 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2 ; Andres Bur, MD 1 ; Andrew C Birkeland, MD 2",
      "normalized_authors": [
        "Soroush Ershadifar",
        "Nina D Ham",
        "Arnaud Bewley",
        "Marianne Abouyared",
        "Andres Bur",
        "Andrew C Birkeland"
      ],
      "affiliations": [
        "University of Kansas - Department of Otolaryngology-Head and neck surgery",
        "University of California, Davis - Department of Otolaryngology-Head and neck surgery"
      ],
      "normalized_institutions": [
        "University of Kansas - Department of Otolaryngology-Head and neck surgery",
        "University of California, Davis - Department of Otolaryngology-Head and neck surgery"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 481,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Soroush Ershadifar, MD 1 ; Nina D Ham, BA 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2 ; Andres Bur, MD 1 ; Andrew C Birkeland, MD 2",
        "Affiliations": "1 University of Kansas - Department of Otolaryngology-Head and neck surgery; 2 University of California, Davis - Department of Otolaryngology-Head and neck surgery",
        "Background": "Head and neck cancer, particularly oral cavity squamous cell carcinoma (OCSCC), remains a challenging disease to treat. Diagnosis at later stages and delays in treatment initiation contribute to upstaging and potentially poorer survival outcomes. Additionally, tumors can exhibit different rates of growth, with prior studies showing faster growing laryngeal tumors to be associated with worse survival and increased risk of recurrence while HPV-related tumors’ growth rate have shown to have unclear prognostic impact. Despite recognition of variable tumor and nodal growth rates (TGR and NGR, respectively), limited data exist regarding their prognostic significance in oral cavity cancer. This study aims to characterize TGR in OCSCC patients and assess its prognostic significance on survival and recurrence.",
        "Methods": "We conducted a retrospective review of patients with biopsy-proven OCSCC referred for treatment between 2015 and 2025. Inclusion criteria were histologically confirmed OCSCC and the availability of both diagnostic and follow-up CT or PET-CT imaging prior to definitive treatment. Exclusion criteria included prior head and neck cancer treatment, previous radiotherapy to the head and neck, and insufficient medical records. Tumor volumes were quantified through manual segmentation using Visage software by two authors, with independent review by a senior author. TGR was defined as the relative volume increase per unit time and calculated using the formula: TGR = ln (Volume 2 - Volume 1 )/(t 2 - t 1 )Survival analysis was subsequently conducted using log-rank test and cox-proportional hazard ratio.",
        "Results": "A total of 59 patients met inclusion criteria; most were male (n = 34, 57%), former or current tobacco users (n = 41, 70%), or had a history of alcohol use disorder (n = 15, 25%). The most common tumor subsite was the tongue (n = 30, 51%), followed by the alveolar ridge (n = 14, 25%), floor of mouth (n = 8, 14%), and hard palate (n = 5, 8%). Mean initial and final tumor volumes were 16.6 cm³ (SD = 20.5) and 26.5 cm³ (SD = 35.5), respectively. The average interval between scans was 29 days (SD = 28). No statistically significant difference in TGR was observed across tumor subsites (p > 0.05). The top 25th percentile of TGR values was used to classify tumors as fast- vs. slow-growing (n = 15 fast-growing). Survival analysis using log-rank and Cox proportional hazards models showed no significant difference based on TGR alone. However, fast-growing tumors were associated with higher odds of recurrence compared to slow-growing tumors. Among tongue tumors specifically, univariate and multivariate analysis controlling for age, sex, smoking status, and stage revealed fast-growing tumors to be associated with significantly reduced overall survival (p < 0.05).",
        "Conclusion": "Preliminary findings suggest that TGR may be a clinically meaningful prognostic marker in oral cavity cancer, especially in tongue squamous cell carcinoma. Further studies with larger sample sizes are needed to validate these observations. Preliminary results of our study show promising data for utilizing imaging segmentation and its use to identify high risk tumors which could affect treatment decision making."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Significance of Tumor Growth Rates (TGR) in Oral Cavity Cancer</span>. <u>Soroush Ershadifar, MD</u><sup>1</sup>; Nina D Ham, BA<sup>2</sup>; Arnaud Bewley, MD<sup>2</sup>; Marianne Abouyared, MD<sup>2</sup>; Andres Bur, MD<sup>1</sup>; Andrew C Birkeland, MD<sup>2</sup>. <sup>1</sup>University of Kansas -  Department of Otolaryngology-Head and neck surgery; <sup>2</sup>University of California, Davis - Department of Otolaryngology-Head and neck surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Head and neck cancer, particularly oral cavity squamous cell carcinoma (OCSCC), remains a challenging disease to treat. Diagnosis at later stages and delays in treatment initiation contribute to upstaging and potentially poorer survival outcomes. Additionally, tumors can exhibit different rates of growth, with prior studies showing faster growing laryngeal tumors to be associated with worse survival and increased risk of recurrence while HPV-related tumors’ growth rate have shown to have unclear prognostic impact. Despite recognition of variable tumor and nodal growth rates (TGR and NGR, respectively), limited data exist regarding their prognostic significance in oral cavity cancer. This study aims to characterize TGR in OCSCC patients and assess its prognostic significance on survival and recurrence.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective review of patients with biopsy-proven OCSCC referred for treatment between 2015 and 2025. Inclusion criteria were histologically confirmed OCSCC and the availability of both diagnostic and follow-up CT or PET-CT imaging prior to definitive treatment. Exclusion criteria included prior head and neck cancer treatment, previous radiotherapy to the head and neck, and insufficient medical records. Tumor volumes were quantified through manual segmentation using Visage software by two authors, with independent review by a senior author. TGR was defined as the relative volume increase per unit time and calculated using the formula: TGR = ln (Volume<sub>2</sub> - Volume<sub>1</sub>)/(t<sub>2</sub> - t<sub>1</sub>)Survival analysis was subsequently conducted using log-rank test and cox-proportional hazard ratio.</p>\n\n<p><strong>Results: </strong>A total of 59 patients met inclusion criteria; most were male (n = 34, 57%), former or current tobacco users (n = 41, 70%), or had a history of alcohol use disorder (n = 15, 25%). The most common tumor subsite was the tongue (n = 30, 51%), followed by the alveolar ridge (n = 14, 25%), floor of mouth (n = 8, 14%), and hard palate (n = 5, 8%). Mean initial and final tumor volumes were 16.6 cm³ (SD = 20.5) and 26.5 cm³ (SD = 35.5), respectively. The average interval between scans was 29 days (SD = 28). No statistically significant difference in TGR was observed across tumor subsites (p > 0.05). The top 25th percentile of TGR values was used to classify tumors as fast- vs. slow-growing (n = 15 fast-growing). Survival analysis using log-rank and Cox proportional hazards models showed no significant difference based on TGR alone. However, fast-growing tumors were associated with higher odds of recurrence compared to slow-growing tumors. Among tongue tumors specifically, univariate and multivariate analysis controlling for age, sex, smoking status, and stage revealed fast-growing tumors to be associated with significantly reduced overall survival (p < 0.05).</p>\n\n<p><strong>Conclusion: </strong>Preliminary findings suggest that TGR may be a clinically meaningful prognostic marker in oral cavity cancer, especially in tongue squamous cell carcinoma. Further studies with larger sample sizes are needed to validate these observations. Preliminary results of our study show promising data for utilizing imaging segmentation and its use to identify high risk tumors which could affect treatment decision making.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153856--></body></html>"
    },
    {
      "uid": "P275",
      "content_id": "153046",
      "abstract_number": "P275",
      "poster_number": "P275",
      "title": "Biomarker Assisted Clinical Management of Oral Precancerous Lesions",
      "summary": "Currently, there are no widely validated biomarkers to predict malignant transformation and aid in the clinical management of oral precancerous lesions. Here, we examine a panel of biomarkers, p53, Ki-67 and H2AX for use as adjuncts to clinical and histologic exam. Increased staining intensity and pattern of expression of these markers has been shown to correlate with severity of oral dysplasia. (Chou, Suwasini)...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153046",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "James Gates, DMD, MD",
      "presenter": "James Gates, DMD, MD",
      "authors": "James Gates, DMD, MD ; Cooper Schwartz, MD; Keshia Mora, MD; Michael Troka, BA; Faizan Alawi, DDS; Roopali Kulkarni, DMD, MPH; Jalal Jalaly, MD",
      "normalized_authors": [
        "James Gates",
        "Cooper Schwartz",
        "Keshia Mora",
        "Michael Troka",
        "Faizan Alawi",
        "Roopali Kulkarni",
        "Jalal Jalaly"
      ],
      "affiliations": [
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of Pennsylvania"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153046/Table%201(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153046/Table%201(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153046"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 321,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "James Gates, DMD, MD ; Cooper Schwartz, MD; Keshia Mora, MD; Michael Troka, BA; Faizan Alawi, DDS; Roopali Kulkarni, DMD, MPH; Jalal Jalaly, MD",
        "Affiliations": "University of Pennsylvania",
        "Abstract": "Currently, there are no widely validated biomarkers to predict malignant transformation and aid in the clinical management of oral precancerous lesions. Here, we examine a panel of biomarkers, p53, Ki-67 and H2AX for use as adjuncts to clinical and histologic exam. Increased staining intensity and pattern of expression of these markers has been shown to correlate with severity of oral dysplasia. (Chou, Suwasini) In fact, H2AX a marker of DNA damage, has been shown to be more predictive of malignant transformation than grade of dysplasia alone.(Leung) Our initial results show the ability of Ki-67, p53 and H2Ax to support histologic diagnosis and differentiate clinically indistinguishable lesions. For example, both patients 1 and 3 had innocuous appearing, thin, white lesions (Table 1). Histology showed high grade dysplasia for patient 1 and low grade for patient 3. IHC for Ki-67, p53 and H2Ax was completed on both specimens. Results showed increased strength of staining and pattern in patient 1 vs patient 3. These findings confirmed and supported the H&E diagnosis. The patient whose lesion showed high grade dysplasia had their lesion excised with a 5mm margin under general anesthesia in the operating room. Meanwhile, the patient with low grade dysplasia is a candidate for close clinical surveillance. In this instance, IHC helps to support the histologic diagnosis, and justify the risk and cost in performing wide excision under general anesthesia. Interobserver variability occurs in the grading of oral dysplasia.(de Freitas Silva, Batista et al. 2021, Sperandio, Warnakulasuriya et al. 2023) Here we demonstrate the ability of Ki-67, p53 and H2Ax to validate histologic diagnosis, aiding to risk stratify patients and support clinical management and intervention. This study is ongoing, and we aim to determine if this panel is helpful in risk stratifying those with indeterminate or equivocal grades of dysplasia. Continued investigation of this biomarker panel is also needed to determine its ability to predict malignant transformation of oral precancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biomarker Assisted Clinical Management of Oral Precancerous Lesions</span>. <u>James Gates, DMD, MD</u>; Cooper Schwartz, MD; Keshia Mora, MD; Michael Troka, BA; Faizan Alawi, DDS; Roopali Kulkarni, DMD, MPH; Jalal Jalaly, MD. University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Currently, there are no widely validated biomarkers to predict malignant transformation and aid in the clinical management of oral precancerous lesions. Here, we examine a panel of biomarkers, p53, Ki-67 and H2AX for use as adjuncts to clinical and histologic exam. Increased staining intensity and pattern of expression of these markers has been shown to correlate with severity of oral dysplasia. (Chou, Suwasini) In fact, H2AX a marker of DNA damage, has been shown to be more predictive of malignant transformation than grade of dysplasia alone.(Leung) </p>\n\n<p>Our initial results show the ability of Ki-67, p53 and H2Ax to support histologic diagnosis and differentiate clinically indistinguishable lesions. For example, both patients 1 and 3 had innocuous appearing, thin, white lesions (Table 1). Histology showed high grade dysplasia for patient 1 and low grade for patient 3. IHC for Ki-67, p53 and H2Ax was completed on both specimens. Results showed increased strength of staining and pattern in patient 1 vs patient 3. These findings confirmed and supported the H&E diagnosis. The patient whose lesion showed high grade dysplasia had their lesion excised with a 5mm margin under general anesthesia in the operating room. Meanwhile, the patient with low grade dysplasia is a candidate for close clinical surveillance. In this instance, IHC helps to support the histologic diagnosis, and justify the risk and cost in performing wide excision under general anesthesia. </p>\n\n<p>Interobserver variability occurs in the grading of oral dysplasia.(de Freitas Silva, Batista et al. 2021, Sperandio, Warnakulasuriya et al. 2023) Here we demonstrate the ability of Ki-67, p53 and H2Ax to validate histologic diagnosis, aiding to risk stratify patients and support clinical management and intervention. This study is ongoing, and we aim to determine if this panel is helpful in risk stratifying those with indeterminate or equivocal grades of dysplasia. Continued investigation of this biomarker panel is also needed to determine its ability to predict malignant transformation of oral precancer.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153046/Table%201(2).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153046--></body></html>"
    },
    {
      "uid": "P276",
      "content_id": "153546",
      "abstract_number": "P276",
      "poster_number": "P276",
      "title": "Surgical Timing and Positive Nodal Disease in Oral Tongue Squamous Cell Carcinoma",
      "summary": "Nodal involvement is a poor prognostic factor in patients with OCSCC. Our study suggests that increased TTS, particularly over 18 days, is associated with increased odds of pathologic nodal disease in a cohort of OCSCC patients that are N0 at presentation. This information may provide key insight into a potentially modifiable risk factor and opportunity for quality improvement initiatives.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153546",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taylor E Freeman, MD",
      "presenter": "Taylor E Freeman, MD",
      "authors": "Taylor E Freeman, MD ; Enver Ozer, MD; Amit Agrawal, MD; Catherine Haring, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Lauren Miller, MD, MBA",
      "normalized_authors": [
        "Taylor E Freeman",
        "Enver Ozer",
        "Amit Agrawal",
        "Catherine Haring",
        "Nolan Seim",
        "Stephen Kang",
        "Matthew Old",
        "James Rocco",
        "Lauren Miller"
      ],
      "affiliations": [
        "The Ohio State University Wexner Medical Center"
      ],
      "normalized_institutions": [
        "The Ohio State University Wexner Medical Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 342,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose/Objectives",
        "Materials/Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Taylor E Freeman, MD ; Enver Ozer, MD; Amit Agrawal, MD; Catherine Haring, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Lauren Miller, MD, MBA",
        "Affiliations": "The Ohio State University Wexner Medical Center",
        "Purpose/Objectives": "Patients with oral cavity squamous cell carcinoma (OCSCC) often harbor occult lymph node metastases. Extended time to surgery (TTS) has been linked to a higher incidence of occult nodal disease across various cancer types and is a modifiable component of patient care delivery. We sought to investigate the relationship between TTS and nodal involvement in patients with OCSCC and clinically negative neck disease on presentation.",
        "Materials/Methods": "The National Cancer Database (NCDB) was queried for patients with OCSCC from 2004-2017. Specifically, we collected patients with oral tongue SCC with a clinically N0 neck who underwent primary surgery including elective neck dissection. Demographic and tumor information were obtained. The primary outcome was rate of pathologic nodal disease as a variable of TTS. Uni- and multi-variate logistic regression results were reported using odds ratio (OR) with a 95% confidence interval (CI).",
        "Results": "We identified 15,696 patients in the NCDB that met our inclusion criteria. Most patients had T1 (n=8,940) or T2 (n=5,006) disease. After surgery, 22.1% of patients, who were clinically N0 at presentation, had at least pN1 disease. Median days to surgery was 32 days for those without and 34 days for those with positive nodal disease (p<0.001). On multivariate analysis, TTS was significantly associated with presence of pathologic nodal disease (OR 1.03, CI 1.001-1.01, p=0.005). An adjusted cubic spline demonstrated the largest increase in positive nodal disease between 18 and 29 days to surgery (OR 0.95-1.30; 37.0% increase). Other factors significantly associated with nodal positivity included tumor stage T3-4, Medicaid insurance, positive surgical margins, and positive LVI. Tumor location on the ventral tongue was negatively associated with positive nodal disease.",
        "Conclusion": "Nodal involvement is a poor prognostic factor in patients with OCSCC. Our study suggests that increased TTS, particularly over 18 days, is associated with increased odds of pathologic nodal disease in a cohort of OCSCC patients that are N0 at presentation. This information may provide key insight into a potentially modifiable risk factor and opportunity for quality improvement initiatives."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Timing and Positive Nodal Disease in Oral Tongue Squamous Cell Carcinoma</span>. <u>Taylor E Freeman, MD</u>; Enver Ozer, MD; Amit Agrawal, MD; Catherine Haring, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Lauren Miller, MD, MBA. The Ohio State University Wexner Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose/Objectives: </strong>Patients with oral cavity squamous cell carcinoma (OCSCC) often harbor occult lymph node metastases. Extended time to surgery (TTS) has been linked to a higher incidence of occult nodal disease across various cancer types and is a modifiable component of patient care delivery. We sought to investigate the relationship between TTS and nodal involvement in patients with OCSCC and clinically negative neck disease on presentation.</p>\n\n<p><strong>Materials/Methods: </strong>The National Cancer Database (NCDB) was queried for patients with OCSCC from 2004-2017.  Specifically, we collected patients with oral tongue SCC with a clinically N0 neck who underwent primary surgery including elective neck dissection. Demographic and tumor information were obtained.  The primary outcome was rate of pathologic nodal disease as a variable of TTS. Uni- and multi-variate logistic regression results were reported using odds ratio (OR) with a 95% confidence interval (CI). </p>\n\n<p><strong>Results: </strong>We identified 15,696 patients in the NCDB that met our inclusion criteria. Most patients had T1 (n=8,940) or T2 (n=5,006) disease. After surgery, 22.1% of patients, who were clinically N0 at presentation, had at least pN1 disease. Median days to surgery was 32 days for those without and 34 days for those with positive nodal disease (p<0.001). On multivariate analysis, TTS was significantly associated with presence of pathologic nodal disease (OR 1.03, CI 1.001-1.01, p=0.005). An adjusted cubic spline demonstrated the largest increase in positive nodal disease between 18 and 29 days to surgery (OR 0.95-1.30; 37.0% increase). Other factors significantly associated with nodal positivity included tumor stage T3-4, Medicaid insurance, positive surgical margins, and positive LVI. Tumor location on the ventral tongue was negatively associated with positive nodal disease. </p>\n\n<p><strong>Conclusion: </strong>Nodal involvement is a poor prognostic factor in patients with OCSCC. Our study suggests that increased TTS, particularly over 18 days, is associated with increased odds of pathologic nodal disease in a cohort of OCSCC patients that are N0 at presentation. This information may provide key insight into a potentially modifiable risk factor and opportunity for quality improvement initiatives.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153546--></body></html>"
    },
    {
      "uid": "P277",
      "content_id": "153788",
      "abstract_number": "P277",
      "poster_number": "P277",
      "title": "A Case of Carcinoma Cuniculatum of the Head and Neck: A Rare and Underrecognized Pathology",
      "summary": "Given the rarity and well-differentiated nature of this deeply invasive entity, superficial biopsies can yield erroneous negative results and delay treatment. Recognition of the characteristic features of this histopathology are critical in providing an accurate and timely diagnosis and appropriate pathology-directed treatment. Delays in diagnosis could contribute to need for more extensive resection at the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153788",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Smrithi Chidambaram, MD, MSCI",
      "presenter": "Smrithi Chidambaram, MD, MSCI",
      "authors": "Smrithi Chidambaram, MD, MSCI 1 ; Brian Niland, DO 2 ; Frankie Mulder, DO 2 ; Roy Frye, MD 2 ; Andrea Snitchler, DO 2 ; Samuel J Rubin, MD, MPH 1",
      "normalized_authors": [
        "Smrithi Chidambaram, MSCI",
        "Brian Niland",
        "Frankie Mulder",
        "Roy Frye",
        "Andrea Snitchler",
        "Samuel J Rubin"
      ],
      "affiliations": [
        "Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery",
        "Allegheny Health Network-Department of Pathology"
      ],
      "normalized_institutions": [
        "Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery",
        "Allegheny Health Network-Department of Pathology"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153788/CC%20final%20(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153788/CC%20final%20(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153788"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 416,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation, Histopathology, and Treatment",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Smrithi Chidambaram, MD, MSCI 1 ; Brian Niland, DO 2 ; Frankie Mulder, DO 2 ; Roy Frye, MD 2 ; Andrea Snitchler, DO 2 ; Samuel J Rubin, MD, MPH 1",
        "Affiliations": "1 Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery; 2 Allegheny Health Network-Department of Pathology",
        "Background": "Carcinoma cuniculatum is a rare type of well-differentiated squamous cell carcinoma with a deeply infiltrative pattern of growth that features vertically oriented, infiltrating cavities filled with keratinaceous debris that are said to be reminiscent of “rabbit burrows”. There have been less than 60 cases of carcinoma cuniculatum of the oral cavity reported in the literature. We describe the clinicopathologic findings of a unique case of oral carcinoma cuniculatum.",
        "Case Presentation, Histopathology, and Treatment": "A 47-year-old male presented to head and neck clinic with a large ulcerative lesion of the left lower lip covering both the skin and mucosal surfaces, which he attributed initially to a cigar burn. Computed tomography imaging revealed an ulcerative soft tissue lesion measuring 2.6cm x 6.5cm x 2.3cm (AP x TV x CC) as well as mildly enlarged left level IIA lymph nodes. Two outpatient superficial biopsies were performed that both reported atypical squamous proliferations. Neither reported high-grade dysplasia, carcinoma in-situ, or overt squamous cell carcinoma. Subsequently, the patient was taken to the operating room for excisional biopsy and intraoperative frozen section for diagnosis and pathology-directed treatment. The frozen section yielded a well-differentiated squamous cell carcinoma (Figure 1A). The patient then underwent primary resection with full thickness excision of the left lower lip including the left oral commissure, left modified radical neck dissection (Levels I-IV), and reconstruction with a Karapanzic flap. The final pathology revealed a 4.5 cm lesion with the unique, deeply endophytic morphology of carcinoma cuniculatum (Figure 1B). Final pathologic stage was determined to be pT3N0 with negative margins, no lymphovascular invasion, and no perineural invasion. The patient received adjuvant radiotherapy. The patient then presented 5 months after completion of adjuvant radiation therapy with an aggressive local recurrence necessitating further extensive surgical resection including a segmental mandibulectomy, bilateral neck dissection, and osteo-cutaneous forearm free flap reconstruction followed by adjuvant immunotherapy.",
        "Conclusions": "Given the rarity and well-differentiated nature of this deeply invasive entity, superficial biopsies can yield erroneous negative results and delay treatment. Recognition of the characteristic features of this histopathology are critical in providing an accurate and timely diagnosis and appropriate pathology-directed treatment. Delays in diagnosis could contribute to need for more extensive resection at the primary site and worse functional outcomes for the patient. In the existing literature, the most common sites of this oral cavity histopathology are the mandibular and maxillary gingiva, with buccal mucosal and lip sites being exceedingly rare. Further work is needed to better understand recurrence patterns and rates within this histopathological subset of oral cavity cancers."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Case of Carcinoma Cuniculatum of the Head and Neck: A Rare and Underrecognized Pathology</span>. <u>Smrithi Chidambaram, MD, MSCI</u><sup>1</sup>; Brian Niland, DO<sup>2</sup>; Frankie Mulder, DO<sup>2</sup>; Roy Frye, MD<sup>2</sup>; Andrea Snitchler, DO<sup>2</sup>; Samuel J Rubin, MD, MPH<sup>1</sup>. <sup>1</sup>Allegheny Health Network-Division of Otolaryngology-Head and Neck Surgery; <sup>2</sup>Allegheny Health Network-Department of Pathology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Carcinoma cuniculatum is a rare type of well-differentiated squamous cell carcinoma with a deeply infiltrative pattern of growth that features vertically oriented, infiltrating cavities filled with keratinaceous debris that are said to be reminiscent of “rabbit burrows”.  There have been less than 60 cases of carcinoma cuniculatum of the oral cavity reported in the literature.  We describe the clinicopathologic findings of a unique case of oral carcinoma cuniculatum.</p>\n\n<p><strong>Case Presentation, Histopathology, and Treatment: </strong>A 47-year-old male presented to head and neck clinic with a large ulcerative lesion of the left lower lip covering both the skin and mucosal surfaces, which he attributed initially to a cigar burn.  Computed tomography imaging revealed an ulcerative soft tissue lesion measuring 2.6cm x 6.5cm x 2.3cm (AP x TV x CC) as well as mildly enlarged left level IIA lymph nodes. Two outpatient superficial biopsies were performed that both reported atypical squamous proliferations. Neither reported high-grade dysplasia, carcinoma in-situ, or overt squamous cell carcinoma. Subsequently, the patient was taken to the operating room for excisional biopsy and intraoperative frozen section for diagnosis and pathology-directed treatment. The frozen section yielded a well-differentiated squamous cell carcinoma (Figure 1A). The patient then underwent primary resection with full thickness excision of the left lower lip including the left oral commissure, left modified radical neck dissection (Levels I-IV), and reconstruction with a Karapanzic flap. The final pathology revealed a 4.5 cm lesion with the unique, deeply endophytic morphology of carcinoma cuniculatum (Figure 1B). Final pathologic stage was determined to be pT3N0 with negative margins, no lymphovascular invasion, and no perineural invasion. The patient received adjuvant radiotherapy. The patient then presented 5 months after completion of adjuvant radiation therapy with an aggressive local recurrence necessitating further extensive surgical resection including a segmental mandibulectomy, bilateral neck dissection, and osteo-cutaneous forearm free flap reconstruction followed by adjuvant immunotherapy. </p>\n\n<p><strong>Conclusions: </strong>Given the rarity and well-differentiated nature of this deeply invasive entity, superficial biopsies can yield erroneous negative results and delay treatment. Recognition of the characteristic features of this histopathology are critical in providing an accurate and timely diagnosis and appropriate pathology-directed treatment. Delays in diagnosis could contribute to need for more extensive resection at the primary site and worse functional outcomes for the patient. In the existing literature, the most common sites of this oral cavity histopathology are the mandibular and maxillary gingiva, with buccal mucosal and lip sites being exceedingly rare.  Further work is needed to better understand recurrence patterns and rates within this histopathological subset of oral cavity cancers. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153788/CC%20final%20(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153788--></body></html>"
    },
    {
      "uid": "P278",
      "content_id": "154479",
      "abstract_number": "P278",
      "poster_number": "P278",
      "title": "Early Recurrence of Oral Cavity Cancer in Patients with Reassuring Depth of Invasion",
      "summary": "It is well established that tumor depth of invasion (DOI) ≥4 millimeters is a valuable prognostic predictor in oral cavity cancer and warrants empiric neck dissection. However, early locoregional recurrence rates remain high even in patients with reassuring depth of invasion. Thus, surgeons are increasingly evaluating additional adverse pathologic features (APF) to combat early locoregional recurrence of oral...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154479",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mallory McKeon, MD",
      "presenter": "Mallory McKeon, MD",
      "authors": "Mallory McKeon, MD ; Priscilla Pichardo, DO; Taylor Redding, MD; Alexander Karabachev, MD; Dustin Silverman, MD; Alice Tang, MD; Chad Zender, MD",
      "normalized_authors": [
        "Mallory McKeon",
        "Priscilla Pichardo",
        "Taylor Redding",
        "Alexander Karabachev",
        "Dustin Silverman",
        "Alice Tang",
        "Chad Zender"
      ],
      "affiliations": [
        "University of Cincinnati College of Medicine, Department of Otolaryngology - Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Cincinnati College of Medicine, Department of Otolaryngology - Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 431,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "OBJECTIVE",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS"
      ],
      "sections": {
        "Authors": "Mallory McKeon, MD ; Priscilla Pichardo, DO; Taylor Redding, MD; Alexander Karabachev, MD; Dustin Silverman, MD; Alice Tang, MD; Chad Zender, MD",
        "Affiliations": "University of Cincinnati College of Medicine, Department of Otolaryngology - Head and Neck Surgery",
        "BACKGROUND": "It is well established that tumor depth of invasion (DOI) ≥4 millimeters is a valuable prognostic predictor in oral cavity cancer and warrants empiric neck dissection. However, early locoregional recurrence rates remain high even in patients with reassuring depth of invasion. Thus, surgeons are increasingly evaluating additional adverse pathologic features (APF) to combat early locoregional recurrence of oral cavity cancer.?",
        "OBJECTIVE": "To characterize the clinical and pathologic features associated with early recurrence of oral cavity cancer, particularly comparing patients with and without favorable depth of invasion (<4mm).?",
        "METHODS": "A retrospective review of an institutional database was queried from October 1, 2018 to February 1, 2025 to identify surgical patients treated for oral cavity cancer. Clinical variables were collected, including several APF and disease recurrence. Patients were stratified by DOI ≥4 or DOI <4. Categorical variables, such as, margin status, presence of perineural or lymphovascular invasion (LVI), and extranodal extension were compared using Fisher’s exact test analysis. Age, sex, smoking history, and alcohol use were also assessed.?",
        "RESULTS": "Among 271 patients with oral cavity carcinoma, 70 patients developed oral cavity recurrence. Recurrence occurred in 16 of 19 (84.2%) with DOI <4 mm and 35 of 42 (83.3%) with DOI ≥4 mm (Fisher p = 1.00). When analyzing DOI in <4 mm cohort, DOI values range from?0.3 to 3.0 mm, demonstrating that recurrence occurred?across the full spectrum?of low DOI.? Further analysis revealed that in the DOI <4 mm subgroup none of the primary tumors demonstrated PNI, and that recurrence was not associated with margin status (Fisher p = 0.40), LVI, histologic grade, smoking, alcohol exposure, or T-stage (all p > 0.40). The most common oral cavity subsite to develop recurrence was the oral tongue which accounted for greater than 87% of the recurrent cases. In a multivariable logistic regression model, no variable emerged as an independent predictor of recurrence (overall model p = 0.41) after controlling for DOI, PNI, margin status, and neck dissection.",
        "CONCLUSIONS": "In this cohort, there was no significant difference in recurrence rates between patients with and without favorable DOI. Further, patients with DOI <4 mm did not demonstrate other APF which could potentially explain their outcomes. These findings exhibit a critical gap in the current knowledge and stress the need to refine predictive models to incorporate additional clinical and pathologic features to better assess for oral cancer recurrence. The current study’s findings emphasize that even in the absence of classic evidence-based risk factors, vigilant surveillance must be maintained. Ongoing analyses with expanded data will further evaluate determinants of recurrence in this clinically challenging subset."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Recurrence of Oral Cavity Cancer in Patients with Reassuring Depth of Invasion</span>. <u>Mallory McKeon, MD</u>; Priscilla Pichardo, DO; Taylor Redding, MD; Alexander Karabachev, MD; Dustin Silverman, MD; Alice Tang, MD; Chad Zender, MD. University of Cincinnati College of Medicine, Department of Otolaryngology - Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> It is well established that tumor depth of invasion (DOI) ≥4 millimeters is a valuable prognostic predictor in oral cavity cancer and warrants empiric neck dissection. However, early locoregional recurrence rates remain high even in patients with reassuring depth of invasion. Thus, surgeons are increasingly evaluating additional adverse pathologic features (APF) to combat early locoregional recurrence of oral cavity cancer.? </p>\n\n<p><strong>OBJECTIVE: </strong>To characterize the clinical and pathologic features associated with early recurrence of oral cavity cancer, particularly comparing patients with and without favorable depth of invasion (<4mm).? </p>\n\n<p><strong>METHODS:</strong> A retrospective review of an institutional database was queried from October 1, 2018 to February 1, 2025 to identify surgical patients treated for oral cavity cancer. Clinical variables were collected, including several APF and disease recurrence. Patients were stratified by DOI ≥4 or DOI <4. Categorical variables, such as, margin status, presence of perineural or lymphovascular invasion (LVI), and extranodal extension were compared using Fisher’s exact test analysis. Age, sex, smoking history, and alcohol use were also assessed.? </p>\n\n<p><strong>RESULTS: </strong>Among 271 patients with oral cavity carcinoma, 70 patients developed oral cavity recurrence. Recurrence occurred in 16 of 19 (84.2%) with DOI <4 mm and 35 of 42 (83.3%) with DOI ≥4 mm (Fisher p = 1.00). When analyzing DOI in <4 mm cohort, DOI values range from?0.3 to 3.0 mm, demonstrating that recurrence occurred?across the full spectrum?of low DOI.? Further analysis revealed that in the DOI <4 mm subgroup none of the primary tumors demonstrated PNI, and that recurrence was not associated with margin status (Fisher p = 0.40), LVI, histologic grade, smoking, alcohol exposure, or T-stage (all p > 0.40). The most common oral cavity subsite to develop recurrence was the oral tongue which accounted for greater than 87% of the recurrent cases. In a multivariable logistic regression model, no variable emerged as an independent predictor of recurrence (overall model p = 0.41) after controlling for DOI, PNI, margin status, and neck dissection. </p>\n\n<p><strong>CONCLUSIONS: </strong>In this cohort, there was no significant difference in recurrence rates between patients with and without favorable DOI. Further, patients with DOI <4 mm did not demonstrate other APF which could potentially explain their outcomes. These findings exhibit a critical gap in the current knowledge and stress the need to refine predictive models to incorporate additional clinical and pathologic features to better assess for oral cancer recurrence. The current study’s findings emphasize that even in the absence of classic evidence-based risk factors, vigilant surveillance must be maintained. Ongoing analyses with expanded data will further evaluate determinants of recurrence in this clinically challenging subset. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154479--></body></html>"
    },
    {
      "uid": "P280",
      "content_id": "153779",
      "abstract_number": "P280",
      "poster_number": "P280",
      "title": "A GLI1-Driven Tongue Tumor Masquerading as Hemangioma: A Diagnostic Pitfall and Treatment Challenge",
      "summary": "When a vascular lesion that appears to histologically/radiographically be a hemangioma in the head & neck but has an atypical presentation and doesn’t respond to traditional therapy one should maintain suspicion of other entities such as GLI1-altered tumors. Early biopsy with molecular characterization is critical to identify this uncommon tumor and ensure appropriate surgical management.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153779",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jenna L Schaefer-Randolph, BS",
      "presenter": "Jenna L Schaefer-Randolph, BS",
      "authors": "Jenna L Schaefer-Randolph, BS ; Greg A Krempl, MD, FACS",
      "normalized_authors": [
        "Jenna L Schaefer-Randolph",
        "Greg A Krempl"
      ],
      "affiliations": [
        "University of Oklahoma- College of Medicine"
      ],
      "normalized_institutions": [
        "University of Oklahoma- College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 276,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Backgrounds",
        "Case Presentation",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jenna L Schaefer-Randolph, BS ; Greg A Krempl, MD, FACS",
        "Affiliations": "University of Oklahoma- College of Medicine",
        "Backgrounds": "GLI1-altered mesenchymal tumors are rare soft-tissue neoplasms with predilection for the head and neck, particularly the tongue. Their multinodular architecture and rich vascular network can mimic benign vascular lesions, such as hemangiomas, leading to delayed diagnosis and inappropriate therapy.",
        "Case Presentation": "We report the case of a 61-year-old female with a three-year history of a progressively enlarging, vascular-appearing right anterior tongue mass. Initial biopsy suggested hemangioma which was collaborated initially by CT scan with contrast and then a CT Angiogram. Standard therapies, including propranolol, itraconazole, and endovascular embolization were used but failed to shrink the tumor and symptoms progressed. She underwent partial glossectomy with radial forearm free flap reconstruction. Histopathology showed a monomorphic spindle and round cell neoplasm arranged in nests with prominent capillaries, diffuse CD56 positivity, and variable S100 staining. Molecular testing identified a MALAT1::GLI1 fusion, confirming a GLI1-altered mesenchymal tumor",
        "Discussion": "The lesion’s superficial vascularity, red-blue coloration, initial histological appearance and radiographic imaging all mimicked a hemangioma. Her age and clinical presentation were atypical for this; however, the pathology was initially considered the best diagnosis, illustrating the diagnostic challenges of GLI1 tumors in the oral cavity. Surgical excision is the treatment of choice for these tumors, and ideally molecular testing of initially biopsies is essential to establish the correct diagnosis and guide definitive management of this exceedingly rare tumor.",
        "Conclusion": "When a vascular lesion that appears to histologically/radiographically be a hemangioma in the head & neck but has an atypical presentation and doesn’t respond to traditional therapy one should maintain suspicion of other entities such as GLI1-altered tumors. Early biopsy with molecular characterization is critical to identify this uncommon tumor and ensure appropriate surgical management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A GLI1-Driven Tongue Tumor Masquerading as Hemangioma: A Diagnostic Pitfall and Treatment Challenge</span>. <u>Jenna L Schaefer-Randolph, BS</u>; Greg A Krempl, MD, FACS. University of Oklahoma- College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Backgrounds:</strong> GLI1-altered mesenchymal tumors are rare soft-tissue neoplasms with predilection for the head and neck, particularly the tongue. Their multinodular architecture and rich vascular network can mimic benign vascular lesions, such as hemangiomas, leading to delayed diagnosis and inappropriate therapy.</p>\n\n<p><strong>Case Presentation:</strong> We report the case of a 61-year-old female with a three-year history of a progressively enlarging, vascular-appearing right anterior tongue mass. Initial biopsy suggested hemangioma which was collaborated initially by CT scan with contrast and then a CT Angiogram. Standard therapies, including propranolol, itraconazole, and endovascular embolization were used but failed to shrink the tumor and symptoms progressed. She underwent partial glossectomy with radial forearm free flap reconstruction. Histopathology showed a monomorphic spindle and round cell neoplasm arranged in nests with prominent capillaries, diffuse CD56 positivity, and variable S100 staining. Molecular testing identified a MALAT1::GLI1 fusion, confirming a GLI1-altered mesenchymal tumor</p>\n\n<p><strong>Discussion: </strong>The lesion’s superficial vascularity, red-blue coloration, initial histological appearance and radiographic imaging all mimicked a hemangioma. Her age and clinical presentation were atypical for this; however, the pathology was initially considered the best diagnosis, illustrating the diagnostic challenges of GLI1 tumors in the oral cavity. Surgical excision is the treatment of choice for these tumors, and ideally molecular testing of initially biopsies is essential to establish the correct diagnosis and guide definitive management of this exceedingly rare tumor. </p>\n\n<p><strong>Conclusion: </strong>When a vascular lesion that appears to histologically/radiographically be a hemangioma in the head & neck but has an atypical presentation and doesn’t respond to traditional therapy one should maintain suspicion of other entities such as GLI1-altered tumors. Early biopsy with molecular characterization is critical to identify this uncommon tumor and ensure appropriate surgical management. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153779--></body></html>"
    },
    {
      "uid": "P281",
      "content_id": "152155",
      "abstract_number": "P281",
      "poster_number": "P281",
      "title": "Malignant Seeding to the Trachea and Tracheostomy Site After Head and Neck Cancer Resection: A Literature Review and Case Report",
      "summary": "Malignant seeding to the trachea or tracheostomy is an uncommon yet devastating clinical diagnosis with poor prognosis. Preventive measures include delayed tracheostomy placement, use of separate sterile instruments, and consideration of prophylactic stoma radiation in high-risk patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152155",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Danielle Scarola, MD",
      "presenter": "Danielle Scarola, MD",
      "authors": "Peter S Giannaris, BS 1 ; Danielle Scarola, MD 2 ; Seth Kaplan, MD 2",
      "normalized_authors": [
        "Peter S Giannaris",
        "Danielle Scarola",
        "Seth Kaplan"
      ],
      "affiliations": [
        "City University of New York School of Medicine",
        "Department of Otolaryngology- Head and Neck Surgery, Northwell Health"
      ],
      "normalized_institutions": [
        "City University of New York School of Medicine",
        "Department of Otolaryngology- Head and Neck Surgery, Northwell Health"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 474,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Report",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Peter S Giannaris, BS 1 ; Danielle Scarola, MD 2 ; Seth Kaplan, MD 2",
        "Affiliations": "1 City University of New York School of Medicine; 2 Department of Otolaryngology- Head and Neck Surgery, Northwell Health",
        "Background": "Malignant seeding of the trachea after resection of head and neck cancer is a rare but clinically significant complication, often associated with advanced-stage squamous cell carcinoma (SCC) with nodal involvement. Temporary tracheostomy is a common intervention for airway management in these patients and implantation of tumor cells at the stoma or tracheal lumen represents an underrecognized complication with substantial morbidity. Therefore, we present a case of malignant seeding of SCC to the tracheostomy site as well as provide a comprehensive review of all known cases to identify patterns in presentation, management, outcomes, and potential risk factors.",
        "Case Report": "We report a case of an 83-year-old woman with mandibular SCC (cT2N2cM0, stage IVA) that underwent segmental mandibulectomy with anterolateral thigh free flap reconstruction with temporary tracheostomy. She returned at nineteen months postoperatively with cough, dyspnea, and subglottic narrowing; biopsy revealed well-to-moderately differentiated keratinizing SCC, and PET-CT demonstrated disease at the tracheostomy site with bilateral cervical nodal metastases. Ultimately, she declined further surgery and elected for comfort care.",
        "Methods": "We conducted a literature review on PubMed, Embase, and Scopus to identify all reported cases of malignant seeding to the trachea or tracheostomy site. Inclusion criteria consisted of histologically confirmed cases of malignancy at the tracheal or tracheostomy site with sufficient clinical details including tumor characteristics, staging and outcomes. Studies documenting stomal recurrence after total laryngectomy were excluded.",
        "Results": "Twenty-eight cases including our institutional case were identified. The mean age of the cohort was 57.4 years (range 21-85), with 64.3% (n=18) male patients. Squamous cell carcinoma accounted for 92.9% (n=26) of cases; the remaining tumors were osteosarcoma (n=1) and adenoid cystic carcinoma (n=1). The most common primary site was the oral cavity (67.9%, n=19) followed by the oropharynx (17.9%, n=5), supraglottis (7.1%, n=2), glottis (3.6%, n=1), and maxillary sinus (3.6%, n=1). Positive lymph nodes were present in 71.4% (n=20) of patients, with extracapsular spread in 3 cases. Median latency from primary surgery to seeding was approximately 6 months (range, 1-96 months); with early seeding (<3 months) in 21.4% (n=6), intermediate (3-6 months) in 31.1% (n=9), and late (>6 months) in 46.4% (n=13). Postoperative radiation therapy (RT) was administered in 57.1% (n=16) of primary tumors, though stoma coverage was inconsistent. Treatment for the tracheal seeding included surgical intervention with or without RT or chosen palliative care. At last follow-up, sixteen patients died of disease and two patients died due to postoperative complications while seven patients were alive without evidence of disease and two patients were alive with disease",
        "Conclusion": "Malignant seeding to the trachea or tracheostomy is an uncommon yet devastating clinical diagnosis with poor prognosis. Preventive measures include delayed tracheostomy placement, use of separate sterile instruments, and consideration of prophylactic stoma radiation in high-risk patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Malignant Seeding to the Trachea and Tracheostomy Site After Head and Neck Cancer Resection: A Literature Review and Case Report</span>. Peter S Giannaris, BS<sup>1</sup>; <u>Danielle Scarola, MD</u><sup>2</sup>; Seth Kaplan, MD<sup>2</sup>. <sup>1</sup>City University of New York School of Medicine; <sup>2</sup>Department of Otolaryngology- Head and Neck Surgery, Northwell Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Malignant seeding of the trachea after resection of head and neck cancer is a rare but clinically significant complication, often associated with advanced-stage squamous cell carcinoma (SCC) with nodal involvement. Temporary tracheostomy is a common intervention for airway management in these patients and implantation of tumor cells at the stoma or tracheal lumen represents an underrecognized complication with substantial morbidity.  Therefore, we present a case of malignant seeding of SCC to the tracheostomy site as well as provide a comprehensive review of all known cases to identify patterns in presentation, management, outcomes, and potential risk factors.</p>\n\n<p><strong>Case Report:</strong> We report a case of an 83-year-old woman with mandibular SCC  (cT2N2cM0, stage IVA) that underwent segmental mandibulectomy with anterolateral thigh free flap reconstruction with temporary tracheostomy. She returned at nineteen months postoperatively with cough, dyspnea, and subglottic narrowing; biopsy revealed well-to-moderately differentiated keratinizing SCC, and PET-CT demonstrated disease at the tracheostomy site with bilateral cervical nodal metastases. Ultimately, she declined further surgery and elected for comfort care.</p>\n\n<p><strong>Methods:</strong> We conducted a literature review on PubMed, Embase, and Scopus to identify all reported cases of malignant seeding to the trachea or tracheostomy site.  Inclusion criteria consisted of histologically confirmed cases of malignancy at the tracheal or tracheostomy site with sufficient clinical details including tumor characteristics, staging and outcomes. Studies documenting stomal recurrence after total laryngectomy were excluded.</p>\n\n<p><strong>Results: </strong>Twenty-eight cases including our institutional case were identified. The mean age of the cohort was 57.4 years (range 21-85), with 64.3% (n=18) male patients. Squamous cell carcinoma accounted for 92.9% (n=26) of cases; the remaining tumors were osteosarcoma (n=1) and adenoid cystic carcinoma (n=1). The most common primary site was the oral cavity (67.9%, n=19) followed by the oropharynx (17.9%, n=5), supraglottis (7.1%, n=2), glottis (3.6%, n=1), and maxillary sinus (3.6%, n=1). Positive lymph nodes were present in 71.4% (n=20) of patients, with extracapsular spread in 3 cases. Median latency from primary surgery to seeding was approximately 6 months (range, 1-96 months); with early seeding (<3 months) in 21.4% (n=6), intermediate (3-6 months) in 31.1% (n=9), and late (>6 months) in 46.4% (n=13). Postoperative radiation therapy (RT) was administered in 57.1% (n=16) of primary tumors, though stoma coverage was inconsistent. Treatment for the tracheal seeding included surgical intervention with or without RT or chosen palliative care. At last follow-up, sixteen patients died of disease and two patients died due to postoperative complications while seven patients were alive without evidence of disease and two patients were alive with disease</p>\n\n<p><strong>Conclusion: </strong>Malignant seeding to the trachea or tracheostomy is an uncommon yet devastating clinical diagnosis with poor prognosis. Preventive measures include delayed tracheostomy placement, use of separate sterile instruments, and consideration of prophylactic stoma radiation in high-risk patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152155--></body></html>"
    },
    {
      "uid": "P282",
      "content_id": "153874",
      "abstract_number": "P282",
      "poster_number": "P282",
      "title": "Pattern of Bone Invasion around Dental Implants versus Teeth in Gingival Squamous Cell Carcinoma",
      "summary": "In this single-institution cohort, mg-OSCC adjacent to dental implants demonstrated no cases of cortical bone invasion, in contrast to high invasion rates among dentate tumors. While limited by small implant sample size, these findings suggest differing patterns of tumor behavior and raise the possibility that peri-implant carcinomas may follow a less locally aggressive osseous trajectory than dentate-associated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153874",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taylor Hall, DDS",
      "presenter": "Taylor Hall, DDS",
      "authors": "Kanvar Panesar, DDS, MS, MD 1 ; Taylor Hall, DDS 2 ; Yedeh Ying, DMD, MD 2 ; Anthony Morlandt, DDS, MD 2 ; Jay Ponto, DDS, MBA, MD 2",
      "normalized_authors": [
        "Kanvar Panesar",
        "Taylor Hall",
        "Yedeh Ying",
        "Anthony Morlandt",
        "Jay Ponto"
      ],
      "affiliations": [
        "University of Texas Southwestern Medical Center",
        "University of Alabama at Birmingham"
      ],
      "normalized_institutions": [
        "University of Texas Southwestern Medical Center",
        "University of Alabama at Birmingham"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 378,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kanvar Panesar, DDS, MS, MD 1 ; Taylor Hall, DDS 2 ; Yedeh Ying, DMD, MD 2 ; Anthony Morlandt, DDS, MD 2 ; Jay Ponto, DDS, MBA, MD 2",
        "Affiliations": "1 University of Texas Southwestern Medical Center; 2 University of Alabama at Birmingham",
        "Objective": "This study aimed to compare patterns of mandibular bone invasion in primary mandibular gingival squamous cell carcinoma (mg-OSCC) occurring adjacent to dental implants versus natural dentition. Specifically, we examined whether tumors arising around implants exhibit similar rates of cortical bone invasion compared to dentate cases.",
        "Methods": "A retrospective cohort study was performed including adults treated between 2023–2025 with biopsy-confirmed primary mg-OSCC. Subjects were excluded if they had other OSCC subtypes, history of head and neck cancer, or documentation that did not state biopsy site. Subjects were stratified into two exposure groups: implant-associated versus dentate-associated tumors. Cases involving both implants and teeth were grouped with the dentate cohort. The primary predictor was presence of dental implants. The primary outcome was cortical bone invasion (CI), defined as bony penetration beyond the superficial/cortical margin, compared against no/superficial bone invasion (SBI). Continuous variables were summarized as mean ± SD with 95% CI, whereas categorical variables were reported as frequency and proportion. Between-group comparisons utilized Mann-Whitney U, Chi-square, or Fisher exact testing. Effect size was expressed using Risk Difference (RD) with 95% confidence intervals.",
        "Results": "Sixty-eight patients met inclusion criteria, of whom 5 (7.4%) had implant-associated mg-OSCC and 63 (92.6%) were dentate. Baseline features, including age, BMI, tumor size, depth of invasion (DOI), ASA class, tobacco and alcohol exposure, pN status, perineural invasion (PNI), lymphovascular invasion (LVI), and use of postoperative adjuvant therapy (PORT), were similar across groups. Cortical invasion was observed in 41/63 dentate tumors (65.1%), compared with 0/5 implant-associated cases (0%). This corresponded to an absolute risk difference of –65.1% (95% CI: –75.7% to –9.3%) with Fisher’s exact p = 0.008. T-staging (pT1–T4a) demonstrated strong correlation with cortical invasion (p < 0.001, Chi-square). Multivariable regression was not feasible due to small sample size.",
        "Conclusion": "In this single-institution cohort, mg-OSCC adjacent to dental implants demonstrated no cases of cortical bone invasion, in contrast to high invasion rates among dentate tumors. While limited by small implant sample size, these findings suggest differing patterns of tumor behavior and raise the possibility that peri-implant carcinomas may follow a less locally aggressive osseous trajectory than dentate-associated mg-OSCC. Larger, multi-center datasets are needed to validate these findings and explore potential biomechanical or microenvironmental mechanisms underlying the observed difference."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pattern of Bone Invasion around Dental Implants versus Teeth in Gingival Squamous Cell Carcinoma</span>. Kanvar Panesar, DDS, MS, MD<sup>1</sup>; <u>Taylor Hall, DDS</u><sup>2</sup>; Yedeh Ying, DMD, MD<sup>2</sup>; Anthony Morlandt, DDS, MD<sup>2</sup>; Jay Ponto, DDS, MBA, MD<sup>2</sup>. <sup>1</sup>University of Texas Southwestern Medical Center; <sup>2</sup>University of Alabama at Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>This study aimed to compare patterns of mandibular bone invasion in primary mandibular gingival squamous cell carcinoma (mg-OSCC) occurring adjacent to dental implants versus natural dentition. Specifically, we examined whether tumors arising around implants exhibit similar rates of cortical bone invasion compared to dentate cases.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed including adults treated between 2023–2025 with biopsy-confirmed primary mg-OSCC. Subjects were excluded if they had other OSCC subtypes, history of head and neck cancer, or documentation that did not state biopsy site. Subjects were stratified into two exposure groups: implant-associated versus dentate-associated tumors. Cases involving both implants and teeth were grouped with the dentate cohort. The primary predictor was presence of dental implants. The primary outcome was cortical bone invasion (CI), defined as bony penetration beyond the superficial/cortical margin, compared against no/superficial bone invasion (SBI). Continuous variables were summarized as mean ± SD with 95% CI, whereas categorical variables were reported as frequency and proportion. Between-group comparisons utilized Mann-Whitney U, Chi-square, or Fisher exact testing. Effect size was expressed using Risk Difference (RD) with 95% confidence intervals.</p>\n\n<p><strong>Results: </strong>Sixty-eight patients met inclusion criteria, of whom 5 (7.4%) had implant-associated mg-OSCC and 63 (92.6%) were dentate. Baseline features, including age, BMI, tumor size, depth of invasion (DOI), ASA class, tobacco and alcohol exposure, pN status, perineural invasion (PNI), lymphovascular invasion (LVI), and use of postoperative adjuvant therapy (PORT), were similar across groups. Cortical invasion was observed in 41/63 dentate tumors (65.1%), compared with 0/5 implant-associated cases (0%). This corresponded to an absolute risk difference of –65.1% (95% CI: –75.7% to –9.3%) with Fisher’s exact p = 0.008. T-staging (pT1–T4a) demonstrated strong correlation with cortical invasion (p < 0.001, Chi-square). Multivariable regression was not feasible due to small sample size.</p>\n\n<p><strong>Conclusion: </strong>In this single-institution cohort, mg-OSCC adjacent to dental implants demonstrated no cases of cortical bone invasion, in contrast to high invasion rates among dentate tumors. While limited by small implant sample size, these findings suggest differing patterns of tumor behavior and raise the possibility that peri-implant carcinomas may follow a less locally aggressive osseous trajectory than dentate-associated mg-OSCC. Larger, multi-center datasets are needed to validate these findings and explore potential biomechanical or microenvironmental mechanisms underlying the observed difference.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153874--></body></html>"
    },
    {
      "uid": "P283",
      "content_id": "154256",
      "abstract_number": "P283",
      "poster_number": "P283",
      "title": "Reappraising Age as a Prognostic Factor in Oral Cavity Cancer: A ROC-Derived Threshold and Survival Analysis",
      "summary": "An age cutoff of 79 years derived from ROC analysis identified patients with worse DFS and OS, although age alone demonstrated limited predictive value for mortality. While older age correlates with poorer outcomes, ECOG performance status was identified as an independent predictor for DFS.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154256",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katherine Xu, MD",
      "presenter": "Katherine Xu, MD",
      "authors": "Vivienne Au, MD 1 ; Jin Hua Li 2 ; Katherine Xu, MD 1 ; Rachel Harter 2 ; Udeerna Tippabhatla 2 ; Aviram Mizrachi 2",
      "normalized_authors": [
        "Vivienne Au",
        "Jin Hua Li",
        "Katherine Xu",
        "Rachel Harter",
        "Udeerna Tippabhatla",
        "Aviram Mizrachi"
      ],
      "affiliations": [
        "New York-Presbyterian/Weill Cornell Medical Center",
        "Weill Cornell Medicine"
      ],
      "normalized_institutions": [
        "New York-Presbyterian/Weill Cornell Medical Center",
        "Weill Cornell Medicine"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 360,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Vivienne Au, MD 1 ; Jin Hua Li 2 ; Katherine Xu, MD 1 ; Rachel Harter 2 ; Udeerna Tippabhatla 2 ; Aviram Mizrachi 2",
        "Affiliations": "1 New York-Presbyterian/Weill Cornell Medical Center; 2 Weill Cornell Medicine",
        "Introduction": "The prognosis of oral cavity squamous cell carcinoma (OCSCC) is influenced by various clinical and pathological factors, and more recently, there has been new literature exploring the relationship between age and OCSCC prognosis, but the results thus far have been inconsistent. While some studies have found no differences in outcomes by age, other studies have identified specific age cutoffs associated with worse mortality. Therefore, the aim of this present study is to further elucidate whether age is a true independent prognostic factor for OCSCC outcome.",
        "Methods": "Adult patients with oral cavity squamous cell carcinoma who presented at a single institution between 2007 and 2024 were identified using CPT codes corresponding to glossectomy, mandibulectomy, alveolectomy, floor-of-mouth resection, and wide local excision. Demographics, risk factors for OCSCC, clinical and pathological tumor characteristics, staging, treatment modalities, recurrence patterns, and survival outcomes were collected. A Receiver Operating Characteristic (ROC) curve analysis was conducted to determine the cutoff age for disease-specific mortality prediction. Patients were then grouped into two cohorts based on the cutoff age and survival data were analyzed for the two groups.",
        "Results": "A hundred and sixty-three patients were included with a median age of 67 (range 19-94). Median follow-up was 52 months (range 1.3-180), during which 8 patients (5%) died of OCSCC. Based on a ROC curve analysis of age for prediction of mortality, an area under the curve (AUC) with potential prognostic value was identified (AUC = 0.529; 95% CI 0.267-0.792). A 79-year cutoff age was determined to predict mortality based on Youden’s index (sensitivity 37.5% and specificity 88.4%). On univariable Cox analysis, ECOG performance status, age ≥79 years and bony involvement were predictors of disease-free survival (DFS); however, only ECOG remained significant in multivariable analysis. For overall survival (OS), although multiple variables including age ≥79 years were found to be significant predictors, none of those variables retained their significance in multivariable analysis.",
        "Conclusion": "An age cutoff of 79 years derived from ROC analysis identified patients with worse DFS and OS, although age alone demonstrated limited predictive value for mortality. While older age correlates with poorer outcomes, ECOG performance status was identified as an independent predictor for DFS."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Reappraising Age as a Prognostic Factor in Oral Cavity Cancer: A ROC-Derived Threshold and Survival Analysis</span>. Vivienne Au, MD<sup>1</sup>; Jin Hua Li<sup>2</sup>; <u>Katherine Xu, MD</u><sup>1</sup>; Rachel Harter<sup>2</sup>; Udeerna Tippabhatla<sup>2</sup>; Aviram Mizrachi<sup>2</sup>. <sup>1</sup>New York-Presbyterian/Weill Cornell Medical Center; <sup>2</sup>Weill Cornell Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The prognosis of oral cavity squamous cell carcinoma (OCSCC) is influenced by various clinical and pathological factors, and more recently, there has been new literature exploring the relationship between age and OCSCC prognosis, but the results thus far have been inconsistent. While some studies have found no differences in outcomes by age, other studies have identified specific age cutoffs associated with worse mortality. Therefore, the aim of this present study is to further elucidate whether age is a true independent prognostic factor for OCSCC outcome.</p>\n\n<p><strong>Methods:</strong> Adult patients with oral cavity squamous cell carcinoma who presented at a single institution between 2007 and 2024 were identified using CPT codes corresponding to glossectomy, mandibulectomy, alveolectomy, floor-of-mouth resection, and wide local excision. Demographics, risk factors for OCSCC, clinical and pathological tumor characteristics, staging, treatment modalities, recurrence patterns, and survival outcomes were collected. A Receiver Operating Characteristic (ROC) curve analysis was conducted to determine the cutoff age for disease-specific mortality prediction. Patients were then grouped into two cohorts based on the cutoff age and survival data were analyzed for the two groups. </p>\n\n<p><strong>Results: </strong>A hundred and sixty-three patients were included with a median age of 67 (range 19-94). Median follow-up was 52 months (range 1.3-180), during which 8 patients (5%) died of OCSCC. Based on a ROC curve analysis of age for prediction of mortality, an area under the curve (AUC) with potential prognostic value was identified (AUC = 0.529; 95% CI 0.267-0.792). A 79-year cutoff age was determined to predict mortality based on Youden’s index (sensitivity 37.5% and specificity 88.4%). On univariable Cox analysis, ECOG performance status, age ≥79 years and bony involvement were predictors of disease-free survival (DFS); however, only ECOG remained significant in multivariable analysis. For overall survival (OS), although multiple variables including age ≥79 years were found to be significant predictors, none of those variables retained their significance in multivariable analysis. </p>\n\n<p><strong>Conclusion: </strong>An age cutoff of 79 years derived from ROC analysis identified patients with worse DFS and OS, although age alone demonstrated limited predictive value for mortality. While older age correlates with poorer outcomes, ECOG performance status was identified as an independent predictor for DFS.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154256--></body></html>"
    },
    {
      "uid": "P285",
      "content_id": "154632",
      "abstract_number": "P285",
      "poster_number": "P285",
      "title": "Patterns of Recurrence In Early Oral Cavity Squamous Cell Carcinoma (OSCC)",
      "summary": "A total of 510 patients were included (Figure 1). Of this cohort, 408 (80%) patients did not develop any recurrence, 59 (12%) developed local recurrence, 59 (12%) developed regional recurrence, 15 (3%) developed both local and regional recurrence, and 21 (4%) patients developed distant metastasis. Among the 430 (84%) patients with the following relevant clinical characteristics (Figure 2), 390 (91%) patients had...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154632",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandria G Yao, BA",
      "presenter": "Alexandria G Yao, BA",
      "authors": "Alexandria G Yao, BA ; Nathan Farrokhian, MD; Andrés Bur, MD",
      "normalized_authors": [
        "Alexandria G Yao",
        "Nathan Farrokhian",
        "Andrés Bur"
      ],
      "affiliations": [
        "University of Kansas Medical Center"
      ],
      "normalized_institutions": [
        "University of Kansas Medical Center"
      ],
      "session_type": "Poster",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154632/eoscc%20ahns%20figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154632/eoscc%20ahns%20figure%201.png",
          "alt": "Figure 1 - Recurrence and Adjuvant Therapy Distribution",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154632"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154632/EOSCC%20AHNS%20Figure%202a.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154632/EOSCC%20AHNS%20Figure%202a.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154632"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 386,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions and Relevance",
        "Figure 1"
      ],
      "sections": {
        "Authors": "Alexandria G Yao, BA ; Nathan Farrokhian, MD; Andrés Bur, MD",
        "Affiliations": "University of Kansas Medical Center",
        "Importance": "Oral Cavity Squamous Cell Carcinoma (OSCC) has a significant and increasing impact on global health, increasing to approximately 389,485 cases and 188,230 deaths reported in 2022. Although patients with early oral cancers overall have a favorable prognosis, around 20% still develop recurrence and the current scheme leads to over treatment for some patients, and under treatment for others.",
        "Objectives": "To characterize recurrence patterns in early OSCC following guideline-concordant primary surgical management and pathology-driven adjuvant therapy, with the goal of optimizing treatment selection and improve oncologic outcomes.",
        "Methods": "This retrospective cohort study included adults (≥18 years) with previously nonrecurrent, nonmetastatic, clinical T1-2, N0 OSCC who underwent primary surgical resection, followed by pathology-driven adjuvant therapy, at four tertiary medical centers (University of Kansas, Massachusetts Eye & Ear Infirmary, Nebraska Methodist Hospital, and University of Iowa) from 2003 to 2020. Patient demographics, clinical care, tumor characteristics, treatment details, and recurrence patterns were collated from electronic medical records and aggregated for analysis.",
        "Results": "A total of 510 patients were included (Figure 1). Of this cohort, 408 (80%) patients did not develop any recurrence, 59 (12%) developed local recurrence, 59 (12%) developed regional recurrence, 15 (3%) developed both local and regional recurrence, and 21 (4%) patients developed distant metastasis. Among the 430 (84%) patients with the following relevant clinical characteristics (Figure 2), 390 (91%) patients had <5 mm closest margin; 89 (21%) had nodal involvement; 126 (29%) had perineural invasion (PNI); 71 (17%) had lymphovascular invasion (LVI); and 8 (2%) were upstaged to pT3. Of this group, 297 (69%) did not receive adjuvant therapy and 91 (21%) developed recurrence of any type. Among patients who did not receive adjuvant therapy, 208 (70%) patients had a closest margin of <5mm as their sole adverse pathologic feature. Recurrence occurred in 86 (22%) of patients with closest margins <5mm. Notably, among all patients with closest margins <5 mm (n=390), the closest margin was the only relevant clinical feature in 228 (58%), while 102 (26%) had both PNI and margin <5 mm.",
        "Conclusions and Relevance": "Nearly 70% of patients with closest margins <5mm did not receive adjuvant therapy; however, >20% developed recurrence. These findings highlight the need for more nuanced investigation into these patterns of recurrence, specifically with respect to the closest margin, to optimize adjuvant therapy decisions and improve early OSCC patient outcomes.",
        "Figure 1": "- Recurrence and Adjuvant Therapy Distribution"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patterns of Recurrence In Early Oral Cavity Squamous Cell Carcinoma (OSCC)</span>. <u>Alexandria G Yao, BA</u>; Nathan Farrokhian, MD; Andrés Bur, MD. University of Kansas Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance</strong>: Oral Cavity Squamous Cell Carcinoma (OSCC) has a significant and increasing impact on global health, increasing to approximately 389,485 cases and 188,230 deaths reported in 2022. Although patients with early oral cancers overall have a favorable prognosis, around 20% still develop recurrence and the current scheme leads to over treatment for some patients, and under treatment for others.</p>\n\n<p><strong>Objectives</strong>: To characterize recurrence patterns in early OSCC following guideline-concordant primary surgical management and pathology-driven adjuvant therapy, with the goal of optimizing treatment selection and improve oncologic outcomes.</p>\n\n<p><strong>Methods</strong>: This retrospective cohort study included adults (≥18 years) with previously nonrecurrent, nonmetastatic, clinical T1-2, N0 OSCC who underwent primary surgical resection, followed by pathology-driven adjuvant therapy, at four tertiary medical centers (University of Kansas, Massachusetts Eye & Ear Infirmary, Nebraska Methodist Hospital, and University of Iowa) from 2003 to 2020. Patient demographics, clinical care, tumor characteristics, treatment details, and recurrence patterns were collated from electronic medical records and aggregated for analysis.</p>\n\n<p><strong>Results</strong>: A total of 510 patients were included (Figure 1). Of this cohort, 408 (80%) patients did not develop any recurrence, 59 (12%) developed local recurrence, 59 (12%) developed regional recurrence, 15 (3%) developed both local and regional recurrence, and 21 (4%) patients developed distant metastasis. Among the 430 (84%) patients with the following relevant clinical characteristics (Figure 2), 390 (91%) patients had <5 mm closest margin; 89 (21%) had nodal involvement; 126 (29%) had perineural invasion (PNI); 71 (17%) had lymphovascular invasion (LVI); and 8 (2%) were upstaged to pT3. Of this group, 297 (69%) did not receive adjuvant therapy and 91 (21%) developed recurrence of any type. Among patients who did not receive adjuvant therapy, 208 (70%) patients had a closest margin of <5mm as their sole adverse pathologic feature. Recurrence occurred in 86 (22%) of patients with closest margins <5mm. Notably, among all patients with closest margins <5 mm (n=390), the closest margin was the only relevant clinical feature in 228 (58%), while 102 (26%) had both PNI and margin <5 mm.</p>\n\n<p><strong>Conclusions and Relevance:</strong> Nearly 70% of patients with closest margins <5mm did not receive adjuvant therapy; however, >20% developed recurrence. These findings highlight the need for more nuanced investigation into these patterns of recurrence, specifically with respect to the closest margin, to optimize adjuvant therapy decisions and improve early OSCC patient outcomes.</p>\n\n<p><strong>Figure 1</strong> - <em><strong>Recurrence and Adjuvant Therapy Distribution</strong></em></p>\n\n<p><img alt='Figure 1 - Recurrence and Adjuvant Therapy Distribution' src='https://www.submitmyabstract.com/abs/images/154632/eoscc%20ahns%20figure%201.png' /></p>\n\n<p><strong>Figure 2 - <em>Adjuvant Therapy Clinical Characteristics Overlap</em></strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154632/EOSCC%20AHNS%20Figure%202a.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154632--></body></html>"
    },
    {
      "uid": "P286",
      "content_id": "154418",
      "abstract_number": "P286",
      "poster_number": "P286",
      "title": "Oropharyngeal Squamous Cell Carcinoma: Trends Over the Past Two Decades in South Carolina",
      "summary": "Oropharyngeal squamous cell carcinoma incidence continues to rise in the state of SC presumably driven by HPV infection. Fortunately stage of presentation remains fairly consistent with most patients presenting with loco-regionally advanced disease rather than distant metastases. State cancer databases may need updated analysis due to the changing landscape of oropharyngeal cancer especially since the change in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154418",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brian Reisenberg",
      "presenter": "Brian Reisenberg",
      "authors": "Thomas Hendriks; Usman Khan; Brian Reisenberg ; David Neskey; Eric Lentsch; Shimrit Sharav; Joshua Hornig; Terry Day",
      "normalized_authors": [
        "Thomas Hendriks",
        "Usman Khan",
        "Brian Reisenberg",
        "David Neskey",
        "Eric Lentsch",
        "Shimrit Sharav",
        "Joshua Hornig",
        "Terry Day"
      ],
      "affiliations": [
        "Sarah Cannon Cancer Institute, Charleston, SC, United States"
      ],
      "normalized_institutions": [
        "Sarah Cannon Cancer Institute, Charleston, SC, United States"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Thomas Hendriks; Usman Khan; Brian Reisenberg ; David Neskey; Eric Lentsch; Shimrit Sharav; Joshua Hornig; Terry Day",
        "Affiliations": "Sarah Cannon Cancer Institute, Charleston, SC, United States",
        "Introduction": "The incidence of oropharyngeal squamous cell carcinoma (OPSCC) continues to rise and has surpassed oral cavity squamous cell carcinoma (OCSCC) with regards to overall incidence and total mortality. This is largely driven by human papillomavirus (HPV) infection, which now accounts for the most common HPV-related cancer in the United States of America, suprassing that of cervical cancer. Trends over time in South Carolina (SC) and in particular since the introduction of HPV vaccination, have been poorly described and so we endeavoured to describe and report on the trends over the past two decades on OPSCC in SC.",
        "Methods": "We examined patients diagnosed with OPSCC between 1996 and 2023. A retrospective analysis of over 5,000 patients utilising a statewide cancer registry in South Carolina was conducted. Baseline demographics, stage of presentation, marital status, geographic location, histology, grade, insurance status and treatment details were assessed and analysed. Chi-square tests and Welch two-sample t-tests were used to assess statistical significance. Binary logistic regression model was used to identify independent predictors of stage of presentation.",
        "Results": "6481 patients met the inclusion criteria of being diagnosed with OPSCC during the study period in SC. Analysis of the whole cohort demonstrated a mean age of 60.9 years at diagnosis and male gender accounted for the majority of cases (81.9%). Of note, age at diagnosis appeared to increase over time from a mean age of 58 between 1996-2000, compared with 64, between 2021-2023. Almost two-thirds of patients presented with regional disease (60.2%). Overall the incidence of OPSCC increased over the past 25 years in SC with stable survival rates. Stage at diagnosis for OPSCC also appeared to remain stable over this time period although there was a trend (not statistically significant) towards a greater proportion of patients presenting with regional disease during the last decade which is likely a relfection of the concurrent increase in overall incidence. Racial disparities previously reported in SC have changed due to the changing landscape of HPV vs. tobacco in OPSCC with a higher incidence in Caucasians and a lower incidence in African Americans, particularly beyond the year 2010. African Americans (OR= 1.83, p<0.001) and unmarried status (OR=1.45, p<0.001) were independent predictors of advanced-stage presentation, with race showing the strongest effect on logistical regression analysis. Rural areas continue to be disparate in stage at diagnosis in SC although this did not meet statistical significance. Reporting on tobacco smoking and HPV was inconsistent and so not available to study as a risk factor in this dataset.",
        "Conclusions": "Oropharyngeal squamous cell carcinoma incidence continues to rise in the state of SC presumably driven by HPV infection. Fortunately stage of presentation remains fairly consistent with most patients presenting with loco-regionally advanced disease rather than distant metastases. State cancer databases may need updated analysis due to the changing landscape of oropharyngeal cancer especially since the change in AJCC staging in 2018, in addition to reporting on HPV status, which presents an opportunity for improvement among US state databases."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oropharyngeal Squamous Cell Carcinoma: Trends Over the Past Two Decades in South Carolina</span>. Thomas Hendriks; Usman Khan; <u>Brian Reisenberg</u>; David Neskey; Eric Lentsch; Shimrit Sharav; Joshua Hornig; Terry Day. Sarah Cannon Cancer Institute, Charleston, SC, United States<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The incidence of oropharyngeal squamous cell carcinoma (OPSCC) continues to rise and has surpassed oral cavity squamous cell carcinoma (OCSCC) with regards to overall incidence and total mortality. This is largely driven by human papillomavirus (HPV) infection, which now accounts for the most common HPV-related cancer in the United States of America, suprassing that of cervical cancer. Trends over time in South Carolina (SC) and in particular since the introduction of HPV vaccination, have been poorly described and so we endeavoured to describe and report on the trends over the past two decades on OPSCC in SC.</p>\n\n<p><strong>Methods: </strong>We examined patients diagnosed with OPSCC between 1996 and 2023. A retrospective analysis of over 5,000 patients utilising a statewide cancer registry in South Carolina was conducted. Baseline demographics, stage of presentation, marital status, geographic location, histology, grade, insurance status and treatment details were assessed and analysed. Chi-square tests and Welch two-sample t-tests were used to assess statistical significance. Binary logistic regression model was used to identify independent predictors of stage of presentation.</p>\n\n<p><strong>Results: </strong>6481 patients met the inclusion criteria of being diagnosed with OPSCC during the study period in SC. Analysis of the whole cohort demonstrated a mean age of 60.9 years at diagnosis and male gender accounted for the majority of cases (81.9%). Of note, age at diagnosis appeared to increase over time from a mean age of 58 between 1996-2000, compared with 64, between 2021-2023. Almost two-thirds of patients presented with regional disease (60.2%). Overall the incidence of OPSCC increased over the past 25 years in SC with stable survival rates. Stage at diagnosis for OPSCC also appeared to remain stable over this time period although there was a trend (not statistically significant) towards a greater proportion of patients presenting with regional disease during the last decade which is likely a relfection of the concurrent increase in overall incidence. Racial disparities previously reported in SC have changed due to the changing landscape of HPV vs. tobacco in OPSCC with a higher incidence in Caucasians and a lower incidence in African Americans, particularly beyond the year 2010. African Americans (OR= 1.83, p<0.001) and unmarried status (OR=1.45, p<0.001) were independent predictors of advanced-stage presentation, with race showing the strongest effect on logistical regression analysis. Rural areas continue to be disparate in stage at diagnosis in SC although this did not meet statistical significance. Reporting on tobacco smoking and HPV was inconsistent and so not available to study as a risk factor in this dataset.</p>\n\n<p><strong>Conclusions: </strong>Oropharyngeal squamous cell carcinoma incidence continues to rise in the state of SC presumably driven by HPV infection. Fortunately stage of presentation remains fairly consistent with most patients presenting with loco-regionally advanced disease rather than distant metastases. State cancer databases may need updated analysis due to the changing landscape of oropharyngeal cancer especially since the change in AJCC staging in 2018, in addition to reporting on HPV status, which presents an opportunity for improvement among US state databases.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154418--></body></html>"
    },
    {
      "uid": "P287",
      "content_id": "154428",
      "abstract_number": "P287",
      "poster_number": "P287",
      "title": "Frailty Risk Model for Readmission after Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma",
      "summary": "This study aims to address an essential gap in the understanding of short-term complications, associated risk factors, and the role of social determinants of health in patients with oropharyngeal squamous cell carcinoma undergoing transoral robotic surgery. It is anticipated that clinical factors such as diabetes, obesity, bleeding disorders, and other comorbid conditions will be linked with a higher likelihood...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154428",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hussein Saleh, BS",
      "presenter": "Hussein Saleh, BS",
      "authors": "Hussein Saleh, BS 1 ; Izza Ali, BS 1 ; Katrina Minutello, DO 2",
      "normalized_authors": [
        "Hussein Saleh",
        "Izza Ali",
        "Katrina Minutello"
      ],
      "affiliations": [
        "Michigan State University College of Osteopathic Medicine",
        "Mclaren Oakland"
      ],
      "normalized_institutions": [
        "Michigan State University College of Osteopathic Medicine",
        "Mclaren Oakland"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Objectives",
        "Methods",
        "Expected Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Hussein Saleh, BS 1 ; Izza Ali, BS 1 ; Katrina Minutello, DO 2",
        "Affiliations": "1 Michigan State University College of Osteopathic Medicine; 2 Mclaren Oakland",
        "Background": "Transoral robotic surgery (TORS) is a minimally invasive surgical technique that emerged as a treatment modality for select oropharyngeal malignancies, most commonly oropharyngeal squamous cell carcinoma (OPSCC). Its utility in the management of early-stage head and neck cancers is increasing, and compared to open surgical approaches, it is associated with improved oncologic outcomes and functional outcomes, specifically a reduced need for tracheostomy, shorter recovery period, quicker return of swallowing function, and overall cost of care.",
        "Abstract": "While oncologic and functional outcomes after TORS are well-established, short-term complications and whether racial disparities exist after adjustment for comorbidities are less clear. This study aims to identify specific patient cardiopulmonary and metabolic risk factors associated with increased risk of early (30-day) complications after resection of OPSCC. Furthermore, it seeks to investigate whether race, ethnicity, and insurance status are independently associated with short-term complications.",
        "Objectives": "Determine the rate of short-term (30-day) complications after TORS for oropharyngeal squamous cell carcinoma, and specific patient-related factors - comorbidities, race, insurance status - associated with these complications.",
        "Methods": "A retrospective cross-sectional analysis of patient data collected from the American College of Surgeons National Surgical Quality Improvement Program database will be conducted from January 1, 2014 to December 31, 2024. The ACS-NSQIP-P database will be queried using current procedural technology (CPT) codes for partial removal of the tongue (41130), lingual tonsil (42870) and pharynx (42890) with the additional code indicating surgical technique requiring use of robotic surgical system (S2900). We will evaluate short-term postoperative complications such as hemorrhage, infection, and dysphagia, and assess whether specific patient-related factors are associated with higher rates of these outcomes. In addition, the study will examine social determinants of health, including race, economic status, and insurance status, to understand their influence on overall postoperative complications.",
        "Expected Results": "There will likely be individual cardiopulmonary and social comorbidities attributed to an increased rate of short-term complications within 30 days after transoral robotic surgery. Although data on the impact of social determinants of health on complication rates is limited, we believe patients without insurance and of lower economic status will be at increased risk of short-term complications. This could be attributed to the inaccessibility of medical care and to a primary care physician's lack of management of comorbid conditions.",
        "Conclusion": "This study aims to address an essential gap in the understanding of short-term complications, associated risk factors, and the role of social determinants of health in patients with oropharyngeal squamous cell carcinoma undergoing transoral robotic surgery. It is anticipated that clinical factors such as diabetes, obesity, bleeding disorders, and other comorbid conditions will be linked with a higher likelihood of postoperative complications. When outcomes are evaluated by race, insurance status, and socioeconomic status, patients from low socioeconomic status are also anticipated to be associated with an increased risk of adverse events. Our analysis aims to identify modifiable perioperative and socio-demographic contributors to early postoperative morbidity and suggests targeted strategies to reduce disparities in perioperative outcomes following TORS for OPSCC patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Frailty Risk Model for Readmission after Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma</span>. <u>Hussein Saleh, BS</u><sup>1</sup>; Izza Ali, BS<sup>1</sup>; Katrina Minutello, DO<sup>2</sup>. <sup>1</sup>Michigan State University College of Osteopathic Medicine; <sup>2</sup>Mclaren Oakland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral robotic surgery (TORS) is a minimally invasive surgical technique that emerged as a treatment modality for select oropharyngeal malignancies, most commonly oropharyngeal squamous cell carcinoma (OPSCC). Its utility in the management of early-stage head and neck cancers is increasing, and compared to open surgical approaches, it is associated with improved oncologic outcomes and functional outcomes, specifically a reduced need for tracheostomy, shorter recovery period, quicker return of swallowing function, and overall cost of care.</p>\n\n<p>While oncologic and functional outcomes after TORS are well-established, short-term complications and whether racial disparities exist after adjustment for comorbidities are less clear. This study aims to identify specific patient cardiopulmonary and metabolic risk factors associated with increased risk of early (30-day) complications after resection of OPSCC. Furthermore, it seeks to investigate whether race, ethnicity, and insurance status are independently associated with short-term complications. </p>\n\n<p><strong>Objectives: </strong>Determine the rate of short-term (30-day) complications after TORS for oropharyngeal squamous cell carcinoma, and specific patient-related factors - comorbidities, race, insurance status - associated with these complications.</p>\n\n<p><strong>Methods: </strong>A retrospective cross-sectional analysis of patient data collected from the American College of Surgeons National Surgical Quality Improvement Program database will be conducted from January 1, 2014 to December 31, 2024. The ACS-NSQIP-P database will be queried using current procedural technology (CPT) codes for partial removal of the tongue (41130), lingual tonsil (42870) and pharynx (42890) with the additional code indicating surgical technique requiring use of robotic surgical system (S2900).  We will evaluate short-term postoperative complications such as hemorrhage, infection, and dysphagia, and assess whether specific patient-related factors are associated with higher rates of these outcomes. In addition, the study will examine social determinants of health, including race, economic status, and insurance status, to understand their influence on overall postoperative complications. </p>\n\n<p><strong>Expected Results: </strong>There will likely be individual cardiopulmonary and social comorbidities attributed to an increased rate of short-term complications within 30 days after transoral robotic surgery. Although data on the impact of social determinants of health on complication rates is limited, we believe patients without insurance and of lower economic status will be at increased risk of short-term complications. This could be attributed to the inaccessibility of medical care and to a primary care physician's lack of management of comorbid conditions. </p>\n\n<p><strong>Conclusion: </strong>This study aims to address an essential gap in the understanding of short-term complications, associated risk factors, and the role of social determinants of health in patients with oropharyngeal squamous cell carcinoma undergoing transoral robotic surgery. It is anticipated that clinical factors such as diabetes, obesity, bleeding disorders, and other comorbid conditions will be linked with a higher likelihood of postoperative complications. When outcomes are evaluated by race, insurance status, and socioeconomic status, patients from low socioeconomic status are also anticipated to be associated with an increased risk of adverse events. Our analysis aims to identify modifiable perioperative and socio-demographic contributors to early postoperative morbidity and suggests targeted strategies to reduce disparities in perioperative outcomes following TORS for OPSCC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154428--></body></html>"
    },
    {
      "uid": "P289",
      "content_id": "152794",
      "abstract_number": "P289",
      "poster_number": "P289",
      "title": "Incidence of First Bite Syndrome following Transoral Robotic Surgery with Neck Dissection for Oropharyngeal Cancer: A Single-Institution Retrospective Analysis.",
      "summary": "FBS is a rare complication following TORS with ND, with an incidence of 3% when suspected cases are included and no FBS cases under strict diagnostic criteria. Parapharyngeal exposure is routinely encountered in TORS and this alone does not appear sufficient to cause FBS. Ligation of ECA branches may play a greater role in its development. Standardized diagnostic criteria and systematic postoperative evaluation...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152794",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Spencer H Short, MD",
      "presenter": "Spencer H Short, MD",
      "authors": "Spencer H Short, MD 1 ; Emma Dunn 2 ; Chetan S Nayak, MD 1",
      "normalized_authors": [
        "Spencer H Short",
        "Emma Dunn",
        "Chetan S Nayak"
      ],
      "affiliations": [
        "Lehigh Valley Health Network",
        "USF Morsani College of Medicine"
      ],
      "normalized_institutions": [
        "Lehigh Valley Health Network",
        "USF Morsani College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 417,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Spencer H Short, MD 1 ; Emma Dunn 2 ; Chetan S Nayak, MD 1",
        "Affiliations": "1 Lehigh Valley Health Network; 2 USF Morsani College of Medicine",
        "Background": "First bite syndrome (FBS) is characterized by sharp pain in the parotid region that occurs with the first bite of food and diminishes with subsequent bites. Although this complication is well-documented after open parapharyngeal approaches, its occurrence following transoral robotic surgery (TORS) with neck dissections (ND) remains an area of debate. Two recent studies differ on the incidence of FBS following TORS with ND (2% vs 8%), as well as the underlying cause of FBS in patients. One study hypothesized that FBS is due to dissection into the parapharyngeal space alone, while the other supports FBS developing from sympathetic denervation during ligation of external carotid artery (ECA) branches during the ND instead.",
        "Objective": "To determine the incidence of FBS among patients undergoing TORS with ND for OPSCC at a single institution and evaluate potential contributing factors, including parapharyngeal space manipulation and ligation of ECA branches.",
        "Methods": "We conducted a retrospective review of all patients who underwent TORS with ND (N=67) for OPSCC between January 2017 and February 2025 at a tertiary academic institution. Descriptive statistics were obtained for patients who underwent neck dissection (ND) without TORS (N=370), serving as a control cohort representing cases without parapharyngeal fat manipulation. Operative reports were analyzed to determine whether ECA branches (facial, lingual, and superior thyroid arteries) were ligated and whether parapharyngeal fat was manipulated. Each FBS case with suspected symptoms underwent individual review to confirm diagnosis and document treatment response.",
        "Results": "67 patients underwent TORS with ND during the study period. Ligation of at least one ECA branch was performed in 91% (n=61). Parapharyngeal fat was routinely visualized during tonsillar resections, though only 11 patients (16%) had manipulation beyond expected exposure. Only 2 patients out of 370 who had a ND without TORS had FBS (0.5%). Two TORS with ND patients (3%) reported transient FBS-like symptoms, but both had confounding factors: one with temporomandibular joint dysfunction and another who underwent concurrent parotidectomy for neurofibromas. Both patients' symptoms resolved with conservative management. No other TORS with ND patients developed confirmed FBS postoperatively.",
        "Conclusions": "FBS is a rare complication following TORS with ND, with an incidence of 3% when suspected cases are included and no FBS cases under strict diagnostic criteria. Parapharyngeal exposure is routinely encountered in TORS and this alone does not appear sufficient to cause FBS. Ligation of ECA branches may play a greater role in its development. Standardized diagnostic criteria and systematic postoperative evaluation are needed to ensure accurate incidence reporting and guide surgical counseling regarding this uncommon complication."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence of First Bite Syndrome following Transoral Robotic Surgery with Neck Dissection for Oropharyngeal Cancer: A Single-Institution Retrospective Analysis.</span>. <u>Spencer H Short, MD</u><sup>1</sup>; Emma Dunn<sup>2</sup>; Chetan S Nayak, MD<sup>1</sup>. <sup>1</sup>Lehigh Valley Health Network; <sup>2</sup>USF Morsani College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>First bite syndrome (FBS) is characterized by sharp pain in the parotid region that occurs with the first bite of food and diminishes with subsequent bites. Although this complication is well-documented after open parapharyngeal approaches, its occurrence following transoral robotic surgery (TORS) with neck dissections (ND) remains an area of debate. Two recent studies differ on the incidence of FBS following TORS with ND (2% vs 8%), as well as the underlying cause of FBS in patients. One study hypothesized that FBS is due to dissection into the parapharyngeal space alone, while the other supports FBS developing from sympathetic denervation during ligation of external carotid artery (ECA) branches during the ND instead.</p>\n\n<p><strong>Objective: </strong>To determine the incidence of FBS among patients undergoing TORS with ND for OPSCC at a single institution and evaluate potential contributing factors, including parapharyngeal space manipulation and ligation of ECA branches.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective review of all patients who underwent TORS with ND (N=67) for OPSCC between January 2017 and February 2025 at a tertiary academic institution. Descriptive statistics were obtained for patients who underwent neck dissection (ND) without TORS (N=370), serving as a control cohort representing cases without parapharyngeal fat manipulation. Operative reports were analyzed to determine whether ECA branches (facial, lingual, and superior thyroid arteries) were ligated and whether parapharyngeal fat was manipulated. Each FBS case with suspected symptoms underwent individual review to confirm diagnosis and document treatment response.</p>\n\n<p><strong>Results:</strong> 67 patients underwent TORS with ND during the study period. Ligation of at least one ECA branch was performed in 91% (n=61). Parapharyngeal fat was routinely visualized during tonsillar resections, though only 11 patients (16%) had manipulation beyond expected exposure. Only 2 patients out of 370 who had a ND without TORS had FBS (0.5%).  Two TORS with ND patients (3%) reported transient FBS-like symptoms, but both had confounding factors: one with temporomandibular joint dysfunction and another who underwent concurrent parotidectomy for neurofibromas. Both patients' symptoms resolved with conservative management. No other TORS with ND patients developed confirmed FBS postoperatively.</p>\n\n<p><strong>Conclusions:</strong> FBS is a rare complication following TORS with ND, with an incidence of 3% when suspected cases are included and no FBS cases under strict diagnostic criteria. Parapharyngeal exposure is routinely encountered in TORS and this alone does not appear sufficient to cause FBS. Ligation of ECA branches may play a greater role in its development. Standardized diagnostic criteria and systematic postoperative evaluation are needed to ensure accurate incidence reporting and guide surgical counseling regarding this uncommon complication.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152794--></body></html>"
    },
    {
      "uid": "P290",
      "content_id": "154173",
      "abstract_number": "P290",
      "poster_number": "P290",
      "title": "A Rare Presentation of Salmonella Infection: Submandibular Abscess with an Atypical Infection",
      "summary": "Salmonella infections are predominantly associated with gastrointestinal diseases; in rare instances they present as an extra-intestinal manifestation. In this unusual case, a Salmonella infection caused a submandibular neck infection in a patient with undiagnosed diabetes mellitus (DM). The atypical presentation and clinical findings made it challenging to diagnosis initially. We report an unusual case, that...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154173",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yasmin Edmonds, Miss",
      "presenter": "Yasmin Edmonds, Miss",
      "authors": "Rahul Jayaram, Mr; Yasmin Edmonds, Miss ; Safa Kriuar, Miss",
      "normalized_authors": [
        "Rahul Jayaram, Mr",
        "Yasmin Edmonds, Miss",
        "Safa Kriuar, Miss"
      ],
      "affiliations": [
        "St George's Hospital"
      ],
      "normalized_institutions": [
        "St George's Hospital"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 478,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Investigations",
        "Differential Diagnosis",
        "Management",
        "Outcome",
        "Discussion"
      ],
      "sections": {
        "Authors": "Rahul Jayaram, Mr; Yasmin Edmonds, Miss ; Safa Kriuar, Miss",
        "Affiliations": "St George's Hospital",
        "Background": "Salmonella infections are predominantly associated with gastrointestinal diseases; in rare instances they present as an extra-intestinal manifestation. In this unusual case, a Salmonella infection caused a submandibular neck infection in a patient with undiagnosed diabetes mellitus (DM). The atypical presentation and clinical findings made it challenging to diagnosis initially. We report an unusual case, that highlights the importance of taking into consideration atypical pathogens as part of differential diagnosis of neck abscess.",
        "Case Presentation": "A 21-year-old female of Eastern Asian origin with a medical history of undiagnosed and poorly controlled type II diabetes mellitus (DMII), presented with progressive left-sided neck swelling. On examination, there was a 7x8cm large submandibular and submental swelling, with no signs of any airway compromise. The blood test results showed raised infection markers with mild leukocytosis, raised CRP and Hb1Ac.",
        "Investigations": "Initial investigations included taking a pus swab for MCS, of which confirmed the growth of Salmonella intrities. Although tested for, no growth of MRSA, EBV, HIV and HepB/C was identified, in addition CMV IgI was levels was consistent with past EBV infection. A contrast-enhanced CT scan of the neck was carried out which revealed a large well-defined collection within the submandibular space and level II reactive lymph node. The Orthopantogram (OPG) and CXR were unremarkable, ruling out potential odontogenic and tuberculosis (TB) causes, respectively. Based on the microbiological culture results and imaging a diagnosis of Salmonella-induced submandibular abscess was established.",
        "Differential Diagnosis": "The most common differential diagnoses for neck swelling include odontogenic, sialogenous, deep neck spaced infections, lymphadenitis (including TB and atypical mycobacteria) and neoplasm. Uncommon differentials include fungal infections (e.g., Coccidioides), syphilis, and Bartonella henselae. Consideration of Salmonella infection was not originally included as a differential.",
        "Management": "The initial management involved intravenous broad-spectrum antibiotics. Given, the size and location of the collection an incision and drainage and placement of drains was conducted under general anaesthesia, with successful gradual resolution of symptoms postoperatively. A stoma bag was placed to monitor drainage output. In addition, hypoglycaemic medication was prescribed to achieve hypoglycaemic control. Complete resolution of the abscess was confirmed on a 4-week post-operative CT scan.",
        "Outcome": "On discharge, oral amoxicillin was given to complete a 4-week course. At their outpatient follow-up appointment, the patient has improved clinically with no signs of recurrence. The patient was started on a regime to ensue glycaemic control and follow-up arranged locally with their general practitioner.",
        "Discussion": "This case highlights an atypical, rare presentation of a Salmonella-associated submandibular abscess; as Salmonella is a common gastrointestinal pathogen. The diagnostic challenge in this instance was identifying the causative agent, as majority of submandibular abscess referred to OMFS have odontogenic or salivary gland origins; this highlights the importance of clinicians considering broad differentials including systemic infection. Within the literature, there are a limited case of Salmonella- associated neck abscess in diabetic patients. This case demonstrated the importance of early diagnosis, treatment and surgical intervention to prevent complications."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Rare Presentation of Salmonella Infection: Submandibular Abscess with an Atypical Infection</span>. Rahul Jayaram, Mr; <u>Yasmin Edmonds, Miss</u>; Safa Kriuar, Miss. St George's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salmonella infections are predominantly associated with gastrointestinal diseases; in rare instances they present as an extra-intestinal manifestation. In this unusual case, a Salmonella infection caused a submandibular neck infection in a patient with undiagnosed diabetes mellitus (DM). The atypical presentation and clinical findings made it challenging to diagnosis initially. We report an unusual case, that highlights the importance of taking into consideration atypical pathogens as part of differential diagnosis of neck abscess.</p>\n\n<p><strong>Case Presentation: </strong>A 21-year-old female of Eastern Asian origin with a medical history of undiagnosed and poorly controlled type II diabetes mellitus (DMII), presented with progressive left-sided neck swelling. On examination, there was a 7x8cm large submandibular and submental swelling, with no signs of any airway compromise. The blood test results showed raised infection markers with mild leukocytosis, raised CRP and Hb1Ac.</p>\n\n<p><strong>Investigations: </strong>Initial investigations included taking a pus swab for MCS, of which confirmed the growth of Salmonella intrities. Although tested for, no growth of MRSA, EBV, HIV and HepB/C was identified, in addition CMV IgI was levels was consistent with past EBV infection. A contrast-enhanced CT scan of the neck was carried out which revealed a large well-defined collection within the submandibular space and level II reactive lymph node. The Orthopantogram (OPG) and CXR were unremarkable, ruling out potential odontogenic and tuberculosis (TB) causes, respectively. Based on the microbiological culture results and imaging a diagnosis of Salmonella-induced submandibular abscess was established.</p>\n\n<p><strong>Differential Diagnosis: </strong>The most common differential diagnoses for neck swelling include odontogenic, sialogenous, deep neck spaced infections, lymphadenitis (including TB and atypical mycobacteria) and neoplasm. Uncommon differentials include fungal infections (e.g., Coccidioides), syphilis, and Bartonella henselae. Consideration of Salmonella infection was not originally included as a differential.</p>\n\n<p><strong>Management: </strong>The initial management involved intravenous broad-spectrum antibiotics. Given, the size and location of the collection an incision and drainage and placement of drains was conducted under general anaesthesia, with successful gradual resolution of symptoms postoperatively. A stoma bag was placed to monitor drainage output. In addition, hypoglycaemic medication was prescribed to achieve hypoglycaemic control. Complete resolution of the abscess was confirmed on a 4-week post-operative CT scan.</p>\n\n<p><strong>Outcome: </strong>On discharge, oral amoxicillin was given to complete a 4-week course. At their outpatient follow-up appointment, the patient has improved clinically with no signs of recurrence. The patient was started on a regime to ensue glycaemic control and follow-up arranged locally with their general practitioner.</p>\n\n<p><strong>Discussion: </strong>This case highlights an atypical, rare presentation of a Salmonella-associated submandibular abscess; as Salmonella is a common gastrointestinal pathogen. The diagnostic challenge in this instance was identifying the causative agent, as majority of submandibular abscess referred to OMFS have odontogenic or salivary gland origins; this highlights the importance of clinicians considering broad differentials including systemic infection. Within the literature, there are a limited case of Salmonella- associated neck abscess in diabetic patients. This case demonstrated the importance of early diagnosis, treatment and surgical intervention to prevent complications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154173--></body></html>"
    },
    {
      "uid": "P291",
      "content_id": "147157",
      "abstract_number": "P291",
      "poster_number": "P291",
      "title": "Synchronous primary cancer of the head and neck",
      "summary": "Head and neck cancer ranks as the seventh most prevalent malignancy worldwide (1). However, synchronous primary malignancies within the head and neck region are rarely documented in the literature. The unique therapeutic approaches and the associated morbidity introduce significant diagnostic challenges and complexities in managing multiple primary malignancies. This report details two cases of synchronous head...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147157",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hye Rhee Chi, DO",
      "presenter": "Hye Rhee Chi, DO",
      "authors": "Hye Rhee Chi, DO ; Laura McDavid, DO; Seth Zwillenberg, MD",
      "normalized_authors": [
        "Hye Rhee Chi",
        "Laura McDavid",
        "Seth Zwillenberg"
      ],
      "affiliations": [
        "Philadelphia College of Osteopathic Medicine"
      ],
      "normalized_institutions": [
        "Philadelphia College of Osteopathic Medicine"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case 1 Description",
        "Abstract",
        "Case 2 Description",
        "Discussion"
      ],
      "sections": {
        "Authors": "Hye Rhee Chi, DO ; Laura McDavid, DO; Seth Zwillenberg, MD",
        "Affiliations": "Philadelphia College of Osteopathic Medicine",
        "Introduction": "Head and neck cancer ranks as the seventh most prevalent malignancy worldwide (1). However, synchronous primary malignancies within the head and neck region are rarely documented in the literature. The unique therapeutic approaches and the associated morbidity introduce significant diagnostic challenges and complexities in managing multiple primary malignancies. This report details two cases of synchronous head and neck cancer.",
        "Case 1 Description": "An 84-year-old male presented with a several-month history of progressively worsening right sided otalgia and difficulty tolerating solid diet. The patient had a history of alcohol use disorder, now in remission, and a two-pack-year smoking history. Head and neck examination revealed subtle tonsillar asymmetry, and a 4 cm by 3 cm soft, mobile, and nontender lymphadenopathy at right cervical levels 1B and 2. Laryngoscopy showed fullness of the right posterior tonsillar region, right base of tongue, and right vallecula, with a smooth mucosal surface. The larynx appeared intact, with symmetric and mobile bilateral vocal folds.",
        "Abstract": "A CT scan of the neck demonstrated a relatively well-circumscribed soft tissue mass in the right base of tongue and right tonsillar enlargement involving the right glossotonsillar sulcus. Intraoperative biopsies of the right tonsil and right base of tongue identified large B-cell lymphoma and p16 positive SCC, respectively. Subsequent in-office biopsy of the right cervical lymphadenopathy confirmed p16 positive SCC. Multidisciplinary discussion among medical oncology, radiation oncology and otolaryngology determined that chemotherapeutic agents for diffuse large B cell lymphoma and P16+ SCC could not be administered concurrently, and treatment for SCC should precede lymphoma. The patient ultimately requested transfer of care for continued chemoradiation therapy. The patient subsequently underwent panendoscopy with biopsy and right hemithyroidectomy, yielding a diagnosis of a T1aN0M0 left glottic invasive SCC and T3N0M0 encapsulated angioinvasive oncocytic carcinoma of the right thyroid gland measuring 4 cm. Treatment included external beam radiotherapy to 6300 cGy to the larynx. At three-month follow-up post-radiation therapy, the patient showed no evidence of recurrence. Multidisciplinary discussion among medical oncology, radiation oncology and otolaryngology determined that completion thyroidectomy should be avoided in this patient following radiation therapy for the SCC of the glottis.",
        "Case 2 Description": "A 74-year-old male presented with two-month history of dysphonia, characterized by a low-pitched, raspy voice and reduced vocal projection. The patient had 30 pack-year smoking history, having ceased smoking 30 years prior. Flexible laryngoscopy revealed a polypoid mass on left anterior true vocal fold, causing incomplete glottic closure with possible anterior commissure involvement. CT neck demonstrated nodularity along the anterior left vocal cord and incidental finding of an enlarged, multinodular thyroid gland, with dominant right nodule measuring 3.2 cm craniocaudally. Fine needle aspiration (FNA) of the right thyroid nodule performed under ultrasound guidance returned Bethesda IV, suspicious for follicular cell-derived neoplasm.",
        "Discussion": "Synchronous primary cancer presents diagnostic and therapeutic complexities requiring comprehensive evaluation and individualized multimodal treatment planning. Although synchronous primary cancers in the head and neck region are rare, this case series highlights the importance of maintaining a high index of suspicion for possible coexisting malignancies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Synchronous primary cancer of the head and neck</span>. <u>Hye Rhee Chi, DO</u>; Laura McDavid, DO; Seth Zwillenberg, MD. Philadelphia College of Osteopathic Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancer ranks as the seventh most prevalent malignancy worldwide (1). However, synchronous primary malignancies within the head and neck region are rarely documented in the literature. The unique therapeutic approaches and the associated morbidity introduce significant diagnostic challenges and complexities in managing multiple primary malignancies. This report details two cases of synchronous head and neck cancer.</p>\n\n<p><strong>Case 1 Description: </strong>An 84-year-old male presented with a several-month history of progressively worsening right sided otalgia and difficulty tolerating solid diet. The patient had a history of alcohol use disorder, now in remission, and a two-pack-year smoking history. Head and neck examination revealed subtle tonsillar asymmetry, and a 4 cm by 3 cm soft, mobile, and nontender lymphadenopathy at right cervical levels 1B and 2. Laryngoscopy showed fullness of the right posterior tonsillar region, right base of tongue, and right vallecula, with a smooth mucosal surface. The larynx appeared intact, with symmetric and mobile bilateral vocal folds.</p>\n\n<p>A CT scan of the neck demonstrated a relatively well-circumscribed soft tissue mass in the right base of tongue and right tonsillar enlargement involving the right glossotonsillar sulcus. Intraoperative biopsies of the right tonsil and right base of tongue identified large B-cell lymphoma and p16 positive SCC, respectively. Subsequent in-office biopsy of the right cervical lymphadenopathy confirmed p16 positive SCC. Multidisciplinary discussion among medical oncology, radiation oncology and otolaryngology determined that chemotherapeutic agents for diffuse large B cell lymphoma and P16+ SCC could not be administered concurrently, and treatment for SCC should precede lymphoma. The patient ultimately requested transfer of care for continued chemoradiation therapy. </p>\n\n<p><strong>Case 2 Description: </strong>A 74-year-old male presented with two-month history of dysphonia, characterized by a low-pitched, raspy voice and reduced vocal projection. The patient had 30 pack-year smoking history, having ceased smoking 30 years prior. Flexible laryngoscopy revealed a polypoid mass on left anterior true vocal fold, causing incomplete glottic closure with possible anterior commissure involvement. CT neck demonstrated nodularity along the anterior left vocal cord and incidental finding of an enlarged, multinodular thyroid gland, with dominant right nodule measuring 3.2 cm craniocaudally. Fine needle aspiration (FNA) of the right thyroid nodule performed under ultrasound guidance returned Bethesda IV, suspicious for follicular cell-derived neoplasm.</p>\n\n<p>The patient subsequently underwent panendoscopy with biopsy and right hemithyroidectomy, yielding a diagnosis of a T1aN0M0 left glottic invasive SCC and T3N0M0 encapsulated angioinvasive oncocytic carcinoma of the right thyroid gland measuring 4 cm. Treatment included external beam radiotherapy to 6300 cGy to the larynx. At three-month follow-up post-radiation therapy, the patient showed no evidence of recurrence. Multidisciplinary discussion among medical oncology, radiation oncology and otolaryngology determined that completion thyroidectomy should be avoided in this patient following radiation therapy for the SCC of the glottis. </p>\n\n<p><strong>Discussion: </strong>Synchronous primary cancer presents diagnostic and therapeutic complexities requiring comprehensive evaluation and individualized multimodal treatment planning. Although synchronous primary cancers in the head and neck region are rare, this case series highlights the importance of maintaining a high index of suspicion for possible coexisting malignancies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147157--></body></html>"
    },
    {
      "uid": "P292",
      "content_id": "154568",
      "abstract_number": "P292",
      "poster_number": "P292",
      "title": "Addressing Barriers in Head and Neck Cancer Clinical Trial Participation in Women",
      "summary": "Findings of this study may clarify the barriers of clinical trial participation for women with Head and Neck Cancer and inform us of strategies to enhance equitable recruitment practices to improve representation.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154568",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Va'Shayna Williams, MS",
      "presenter": "Va'Shayna Williams, MS",
      "authors": "Va'Shayna Williams, MS 1 ; Rahul Patel, MD 2 ; Kamila Vadell 3 ; Neil Gildener-Leapman, MD 2 ; Lisa Galati, MD 2",
      "normalized_authors": [
        "Va'Shayna Williams",
        "Rahul Patel",
        "Kamila Vadell",
        "Neil Gildener-Leapman",
        "Lisa Galati"
      ],
      "affiliations": [
        "Albany Medical College",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
        "Ponce School of Medicine and Health Sciences"
      ],
      "normalized_institutions": [
        "Albany Medical College",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
        "Ponce School of Medicine and Health Sciences"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Va'Shayna Williams, MS 1 ; Rahul Patel, MD 2 ; Kamila Vadell 3 ; Neil Gildener-Leapman, MD 2 ; Lisa Galati, MD 2",
        "Affiliations": "1 Albany Medical College; 2 Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center; 3 Ponce School of Medicine and Health Sciences",
        "Introduction": "Head and Neck Cancer (HNC) is a heterogeneous malignancy arising from the oral cavity, nasal cavity, tongue, larynx, hypopharynx, oropharynx, nasopharynx, pharynx, and salivary glands. The genetic and clinical complexity of HNC emphasizes the need for exploring targeted and effective therapy through clinical trials. Disparities in clinical trial enrollment may be impacted by a multitude of barriers experienced by a patient population. While approximately 26.2% of HNC patients are women, and the incidence ratio of HNC being 3:1 men to women, women account for only 17% of trial participants [1,2]. Disparities in enrollment between women and men are persistently seen in clinical trials. Understanding disease variability and treatment susceptibility [2] differences between sexes is vital to reducing Head and Neck Cancer incidence among both men and women. This study aims to investigate the reasons associated with women’s disproportionate representation in HNC Clinical trials.",
        "Methods": "A 15-question survey study was designed to assess variables that impact men’s and women’s decisions when considering participation in HNC clinical trial research. The survey contains questions assessing household responsibility, financial limitations, employment status, education level, travel constraints, and personal beliefs, utilizing a Likert scale. The survey is currently deployed at two Otolaryngology clinics: Albany Medical Center and Dartmouth Hitchcock Medical Center. The inclusion criteria include individuals who identify as male or female, have had or currently have an HNC diagnosis, are above the age of 18, and individuals who have or have not participated in a Head and Neck clinical trial. Patients who do not have Head and Neck Cancer or who did not complete the survey to its entirety will be excluded from the study. The study results are currently pending, as the power analysis predicts that the necessary number of patients to reach conclusive results is 200-240. Data collection is ongoing.",
        "Conclusion": "Findings of this study may clarify the barriers of clinical trial participation for women with Head and Neck Cancer and inform us of strategies to enhance equitable recruitment practices to improve representation.",
        "Abstract": "[1] Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncol. 2019 Jul;94:32-40. doi: 10.1016/j.oraloncology.2019.05.009. Epub 2019 May 14. PMID: 31178210. [2] Gaeta, A., Tagliabue, M., D’Ecclesiis, O. et al. Are sex and gender considered in head and neck cancer clinical studies?. npj Precis. Onc. 7, 84 (2023). https://doi.org/10.1038/s41698-023-00439-z [3] Labots G, Jones A, de Visser SJ, Rissmann R, Burggraaf J. Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharmacol. 2018 Apr;84(4):700-707. doi: 10.1111/bcp.13497. Epub 2018 Feb 12. PMID: 29293280; PMCID: PMC5867082"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Addressing Barriers in Head and Neck Cancer Clinical Trial Participation in Women</span>. <u>Va'Shayna Williams, MS</u><sup>1</sup>; Rahul Patel, MD<sup>2</sup>; Kamila Vadell<sup>3</sup>; Neil Gildener-Leapman, MD<sup>2</sup>; Lisa Galati, MD<sup>2</sup>. <sup>1</sup>Albany Medical College; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center; <sup>3</sup>Ponce School of Medicine and Health Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Head and Neck Cancer (HNC) is a heterogeneous malignancy arising from the oral cavity, nasal cavity, tongue, larynx, hypopharynx, oropharynx, nasopharynx, pharynx, and salivary glands. The genetic and clinical complexity of HNC emphasizes the need for exploring targeted and effective therapy through clinical trials. Disparities in clinical trial enrollment may be impacted by a multitude of barriers experienced by a patient population. While approximately 26.2% of HNC patients are women, and the incidence ratio of HNC being 3:1 men to women, women account for only 17% of trial participants [1,2]. Disparities in enrollment between women and men are persistently seen in clinical trials. Understanding disease variability and treatment susceptibility [2] differences between sexes is vital to reducing Head and Neck Cancer incidence among both men and women. This study aims to investigate the reasons associated with women’s disproportionate representation in HNC Clinical trials.</p>\n\n<p><strong>Methods:</strong> A 15-question survey study was designed to assess variables that impact men’s and women’s decisions when considering participation in HNC clinical trial research. The survey contains questions assessing household responsibility, financial limitations, employment status, education level,  travel constraints, and personal beliefs, utilizing a Likert scale. The survey is currently deployed at two Otolaryngology clinics: Albany Medical Center and Dartmouth Hitchcock Medical Center. The inclusion criteria include individuals who identify as male or female, have had or currently have an HNC diagnosis, are above the age of 18, and individuals who have or have not participated in a Head and Neck clinical trial. Patients who do not have Head and Neck Cancer or who did not complete the survey to its entirety will be excluded from the study. The study results are currently pending, as the power analysis predicts that the necessary number of patients to reach conclusive results is 200-240. Data collection is ongoing.</p>\n\n<p><strong>Conclusion: </strong>Findings of this study may clarify the barriers of clinical trial participation for women with Head and Neck Cancer and inform us of strategies to enhance equitable recruitment practices to improve representation.</p>\n\n<p><strong>References:</strong></p>\n\n<p>[1] Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncol. 2019 Jul;94:32-40. doi: 10.1016/j.oraloncology.2019.05.009. Epub 2019 May 14. PMID: 31178210.</p>\n\n<p>[2] Gaeta, A., Tagliabue, M., D’Ecclesiis, O. et al. Are sex and gender considered in head and neck cancer clinical studies?. npj Precis. Onc. 7, 84 (2023). https://doi.org/10.1038/s41698-023-00439-z</p>\n\n<p>[3] Labots G, Jones A, de Visser SJ, Rissmann R, Burggraaf J. Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharmacol. 2018 Apr;84(4):700-707. doi: 10.1111/bcp.13497. Epub 2018 Feb 12. PMID: 29293280; PMCID: PMC5867082</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154568--></body></html>"
    },
    {
      "uid": "P294",
      "content_id": "154767",
      "abstract_number": "P294",
      "poster_number": "P294",
      "title": "ROLE OF TRANSORAL ROBOTIC SURGERY FOR PARAPHARYNGEAL SPACE TUMORS- OUR EXPERIENCE",
      "summary": "TORS is a safe and feasible approach for selected benign PPS tumors, offering excellent local control and a low rate of surgical complications. It represents a valuable minimally invasive alternative for managing appropriately selected lesions of the parapharyngeal space.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154767",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jaimanti Bakshi, PROFESSOR AND HEAD",
      "presenter": "Jaimanti Bakshi, PROFESSOR AND HEAD",
      "authors": "Jaimanti Bakshi, PROFESSOR AND HEAD ; Naresh K Panda, PROFESSOR; Vikas Sharma, RESIDENT; Monil D Parsana, Senior Resident; Bhinya R Jat, Senior Resident",
      "normalized_authors": [
        "Jaimanti Bakshi, AND HEAD",
        "Naresh K Panda",
        "Vikas Sharma, RESIDENT",
        "Monil D Parsana, Senior Resident",
        "Bhinya R Jat, Senior Resident"
      ],
      "affiliations": [
        "PGIMER, Chandigarh, India"
      ],
      "normalized_institutions": [
        "PGIMER, Chandigarh, India"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 199,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Materials and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jaimanti Bakshi, PROFESSOR AND HEAD ; Naresh K Panda, PROFESSOR; Vikas Sharma, RESIDENT; Monil D Parsana, Senior Resident; Bhinya R Jat, Senior Resident",
        "Affiliations": "PGIMER, Chandigarh, India",
        "Objective": "To evaluate the outcomes of patients with parapharyngeal space (PPS) tumors managed using a transoral robotic surgery (TORS) approach in a tertiary care academic and research center.",
        "Materials and Methods": "A retrospective review was conducted of patients who underwent TORS for benign, well-circumscribed PPS tumors between 2018 and 2025 using the da Vinci Si surgical system. Inclusion criteria consisted of tumors accessible via the oropharynx without evidence of carotid artery encasement or bony erosion. Outcome measures included technical feasibility, local tumor control, and postoperative complication rates.",
        "Results": "A total of 10 patients with diagnosis of pleomorphic adenoma underwent TORS during the study period, with a mean follow-up ranging from 2 to 80 months. All procedures were completed successfully without the need for conversion. Operative time and blood loss were within acceptable limits. There were no major complications such as hemorrhage, infection, or trismus. Tumor spillage occurred in 3 cases. Among 7 patients diagnosed with pleomorphic adenoma, local control was achieved in all cases (100%).",
        "Conclusions": "TORS is a safe and feasible approach for selected benign PPS tumors, offering excellent local control and a low rate of surgical complications. It represents a valuable minimally invasive alternative for managing appropriately selected lesions of the parapharyngeal space."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>ROLE OF TRANSORAL ROBOTIC SURGERY FOR PARAPHARYNGEAL SPACE TUMORS- OUR EXPERIENCE</span>. <u>Jaimanti Bakshi, PROFESSOR AND HEAD</u>; Naresh K Panda, PROFESSOR; Vikas Sharma, RESIDENT; Monil D Parsana, Senior Resident; Bhinya R Jat, Senior Resident. PGIMER, Chandigarh, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate the outcomes of patients with parapharyngeal space (PPS) tumors managed using a transoral robotic surgery (TORS) approach in a tertiary care academic and research center.</p>\n\n<p><strong>Materials and Methods: </strong>A retrospective review was conducted of patients who underwent TORS for benign, well-circumscribed PPS tumors between 2018 and 2025 using the da Vinci Si surgical system. Inclusion criteria consisted of tumors accessible via the oropharynx without evidence of carotid artery encasement or bony erosion. Outcome measures included technical feasibility, local tumor control, and postoperative complication rates.</p>\n\n<p><strong>Results: </strong>A total of 10 patients with diagnosis of pleomorphic adenoma underwent TORS during the study period, with a mean follow-up ranging from 2 to 80 months. All procedures were completed successfully without the need for conversion. Operative time and blood loss were within acceptable limits. There were no major complications such as hemorrhage, infection, or trismus. Tumor spillage occurred in 3 cases. Among 7 patients diagnosed with pleomorphic adenoma, local control was achieved in all cases (100%).</p>\n\n<p><strong>Conclusions: </strong>TORS is a safe and feasible approach for selected benign PPS tumors, offering excellent local control and a low rate of surgical complications. It represents a valuable minimally invasive alternative for managing appropriately selected lesions of the parapharyngeal space.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154767--></body></html>"
    },
    {
      "uid": "P295",
      "content_id": "151788",
      "abstract_number": "P295",
      "poster_number": "P295",
      "title": "The Effect of BMI on Outcomes after Robotic Head and Neck Surgery – a Database Study.",
      "summary": "BMI was not associated with increased postoperative mortality or complications rates within 90 days. There was a greater risk of emergent tracheostomy in class I, II, and III obesity. Elevated BMI may not be a contraindication to TORS.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151788",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amani Kais, MD",
      "presenter": "Amani Kais, MD",
      "authors": "Amani Kais, MD ; Meghan T Turner, MD",
      "normalized_authors": [
        "Amani Kais",
        "Meghan T Turner"
      ],
      "affiliations": [
        "West Virginia University"
      ],
      "normalized_institutions": [
        "West Virginia University"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 398,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Materials and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Amani Kais, MD ; Meghan T Turner, MD",
        "Affiliations": "West Virginia University",
        "Purpose": "Elevated body mass index (BMI) is regarded as a relative contraindication for robotic head and neck surgery (RHNS). However, the basis of this is largely expert opinion. The goal of this study is to examine the effect of BMI on complications using a large, public database.",
        "Materials and Methods": "The TriNetX US Research Database was accessed to perform a retrospective database study. ICD-10CM and ICD-10PCS diagnostic and billing codes were used to select the study population. Patients 18 or older who underwent RHNS (ICD-10PCS, 8E09XCZ, 8E090CZ, 8E093CZ, 8E094CZ, 8E097CZ, 8E098CZ) and who had information on BMI (ICD-10 Z68.20-Z68.42) were included. The primary outcomes of interest death and complications rates within 90 days of RHNS. Secondary outcomes were rates of emergency intubation, emergency tracheostomy, planned tracheostomy, postoperative pneumonia, emergency room visits, and emergency hospitalization within 90 days of RHNS. Statistical analyses were performed using the TriNetX platform’s integrated software.",
        "Results": "The search yielded 3,511patients from 50 HCOs who underwent RHNS and had information on BMI from 2010-2024. The average patient age at the time of RHNS was 57.5 years (SD 14.1). Most patients were male (59.7%), Caucasian (74.8%), and from the south (42%). Planned tracheostomy was performed in 3.47% of patients prior to or at the time of TORS with significantly more being done in the normal BMI group (p=<0.00001). The overall 90-day mortality rate and complication rates after RHNS were 0.97% and 7.36%. Emergency intubation, emergency tracheostomy, unplanned tracheostomy, and postoperative pneumonia, occurred at rates of 1.18%, <0.285%, 0.73%, and 2.87%. There were no emergency room (ER) or hospital readmissions. Comparing patients with BMI 20-24.9 to those with classifications as overweight, class I obesity, class II obesity, and class III obesity, there was no increase in the odds of perioperative mortality or complications. There was a significantly greater risk of emergency tracheostomy in those patients consider to be overweight or those having class I and II obesity (p=0.002 for all). There was a significantly greater risk of pneumonia in patients with normal BMI compared to patients who were overweight or having Class I obesity.",
        "Conclusions": "BMI was not associated with increased postoperative mortality or complications rates within 90 days. There was a greater risk of emergent tracheostomy in class I, II, and III obesity. Elevated BMI may not be a contraindication to TORS."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Effect of BMI on Outcomes after Robotic Head and Neck Surgery – a Database Study.</span>. <u>Amani Kais, MD</u>; Meghan T Turner, MD. West Virginia University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Elevated body mass index (BMI) is regarded as a relative contraindication for robotic head and neck surgery (RHNS). However, the basis of this is largely expert opinion. The goal of this study is to examine the effect of BMI on complications using a large, public database.</p>\n\n<p><strong>Materials and Methods: </strong>The TriNetX US Research Database was accessed to perform a retrospective database study. ICD-10CM and ICD-10PCS diagnostic and billing codes were used to select the study population. Patients 18 or older who underwent RHNS (ICD-10PCS, 8E09XCZ, 8E090CZ, 8E093CZ, 8E094CZ, 8E097CZ, 8E098CZ) and who had information on BMI (ICD-10 Z68.20-Z68.42) were included. The primary outcomes of interest death and complications rates within 90 days of RHNS. Secondary outcomes were rates of emergency intubation, emergency tracheostomy, planned tracheostomy, postoperative pneumonia, emergency room visits, and emergency hospitalization within 90 days of RHNS. Statistical analyses were performed using the TriNetX platform’s integrated software.</p>\n\n<p><strong>Results:</strong> The search yielded 3,511patients from 50 HCOs who underwent RHNS and had information on BMI from 2010-2024. The average patient age at the time of RHNS was 57.5 years (SD 14.1). Most patients were male (59.7%), Caucasian (74.8%), and from the south (42%). Planned tracheostomy was performed in 3.47% of patients prior to or at the time of TORS with significantly more being done in the normal BMI group (p=<0.00001). The overall 90-day mortality rate and complication rates after RHNS were 0.97% and 7.36%. Emergency intubation, emergency tracheostomy, unplanned tracheostomy, and postoperative pneumonia, occurred at rates of 1.18%, <0.285%, 0.73%, and 2.87%. There were no emergency room (ER) or hospital readmissions. Comparing patients with BMI 20-24.9 to those with classifications as overweight, class I obesity, class II obesity, and class III obesity, there was no increase in the odds of perioperative mortality or complications. There was a significantly greater risk of emergency tracheostomy in those patients consider to be overweight or those having class I and II obesity (p=0.002 for all). There was a significantly greater risk of pneumonia in patients with normal BMI compared to patients who were overweight or having Class I obesity.</p>\n\n<p><strong>Conclusions: </strong>BMI was not associated with increased postoperative mortality or complications rates within 90 days. There was a greater risk of emergent tracheostomy in class I, II, and III obesity. Elevated BMI may not be a contraindication to TORS.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151788--></body></html>"
    },
    {
      "uid": "P297",
      "content_id": "155439",
      "abstract_number": "P297",
      "poster_number": "P297",
      "title": "Timing of Neck Dissection in TORS Tonsil Surgery: National Patterns and Stage Distribution in the NCDB (2004–2022)",
      "summary": "Most TORS tonsil surgeries with available data incorporate same-day ND, reflecting prevailing hemostatic strategy aimed at minimizing life-threatening postoperative hemorrhage through early arterial control. Although prophylactic ligation does not lower overall hemorrhage rates, evidence suggests a reduction in severe events, supporting coordinated surgical timing. These national patterns may inform institutional...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155439",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Vishal Gupta, MD ; Christine R Burton, MD; Anurag K Singh, MD; Kimberly E Wooten, MD; Ryan P McSpadden, MD",
      "normalized_authors": [
        "Vishal Gupta",
        "Christine R Burton",
        "Anurag K Singh",
        "Kimberly E Wooten",
        "Ryan P McSpadden"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 336,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Vishal Gupta, MD ; Christine R Burton, MD; Anurag K Singh, MD; Kimberly E Wooten, MD; Ryan P McSpadden, MD",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Background": "Post-TORS (Transoral Robotic Surgery) oropharyngeal hemorrhage is an uncommon but potentially catastrophic complication. Contemporary studies indicate that prophylactic ligation of external carotid artery branches does not reduce overall hemorrhage incidence but may decrease the severity of bleeding events. This has led many centers to coordinate neck dissection (ND) with TORS tonsil surgery to control arterial inflow to the tonsillar bed.",
        "Methods": "We analyzed the NCDB 2022 Tonsil site file (ICD-O-3 C09.*). TORS cases were defined as robotic approach at the reporting facility (RX_HOSP_SURG_APPR_2010=1) combined with definitive primary-site surgery performed at the reporting facility (RX_HOSP_SURG_PRIM_SITE codes 30–52). Destruction/ablation procedures (10–15) and diagnostic excision/polypectomy (27/26) were excluded. Neck dissection timing was computed using days to regional lymph node dissection minus days to definitive surgery and categorized as same-day (0), staged-before (<0), or staged-after (>0). Stage distribution was based on Analytic Stage Group. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.",
        "Results": "Among 7,238 TORS tonsil cases, ND timing was known for 3,068 (42.4%). Among those with known timing, same-day ND occurred in 84.8%, staged-before in 11.3%, and staged-after in 3.9%, with a median difference of 0 days. Tonsillectomy-specific cases (code 31) showed the same pattern. Overall stage distribution in TORS cases was Stage I 43.5%, Stage II 12.9%, Stage III 10.8%, and Stage IV 29.3%, consistent with early-stage selection for transoral approaches.",
        "Conclusions": "Most TORS tonsil surgeries with available data incorporate same-day ND, reflecting prevailing hemostatic strategy aimed at minimizing life-threatening postoperative hemorrhage through early arterial control. Although prophylactic ligation does not lower overall hemorrhage rates, evidence suggests a reduction in severe events, supporting coordinated surgical timing. These national patterns may inform institutional protocols and guide future studies examining ND strategy, vessel ligation techniques, and postoperative outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Timing of Neck Dissection in TORS Tonsil Surgery: National Patterns and Stage Distribution in the NCDB (2004–2022)</span>. <u>Vishal Gupta, MD</u>; Christine R Burton, MD; Anurag K Singh, MD; Kimberly E Wooten, MD; Ryan P McSpadden, MD. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Post-TORS (Transoral Robotic Surgery) oropharyngeal hemorrhage is an uncommon but potentially catastrophic complication. Contemporary studies indicate that prophylactic ligation of external carotid artery branches does not reduce overall hemorrhage incidence but may decrease the severity of bleeding events. This has led many centers to coordinate neck dissection (ND) with TORS tonsil surgery to control arterial inflow to the tonsillar bed.</p>\n\n<p><strong>Methods:</strong> We analyzed the NCDB 2022 Tonsil site file (ICD-O-3 C09.*). TORS cases were defined as robotic approach at the reporting facility (RX_HOSP_SURG_APPR_2010=1) combined with definitive primary-site surgery performed at the reporting facility (RX_HOSP_SURG_PRIM_SITE codes 30–52). Destruction/ablation procedures (10–15) and diagnostic excision/polypectomy (27/26) were excluded. Neck dissection timing was computed using days to regional lymph node dissection minus days to definitive surgery and categorized as same-day (0), staged-before (<0), or staged-after (>0). Stage distribution was based on Analytic Stage Group. Microsoft Copilot (M365, built on GPT-5 chat model, accessed 2/20/2026) was used to assist with data analysis and the proofreading of this abstract. The authors take responsibility for the integrity of the content submitted and full biostatistical analyses will be verified prior to presentation.</p>\n\n<p><strong>Results: </strong>Among 7,238 TORS tonsil cases, ND timing was known for 3,068 (42.4%). Among those with known timing, same-day ND occurred in 84.8%, staged-before in 11.3%, and staged-after in 3.9%, with a median difference of 0 days. Tonsillectomy-specific cases (code 31) showed the same pattern. Overall stage distribution in TORS cases was Stage I 43.5%, Stage II 12.9%, Stage III 10.8%, and Stage IV 29.3%, consistent with early-stage selection for transoral approaches.</p>\n\n<p><strong>Conclusions:</strong> Most TORS tonsil surgeries with available data incorporate same-day ND, reflecting prevailing hemostatic strategy aimed at minimizing life-threatening postoperative hemorrhage through early arterial control. Although prophylactic ligation does not lower overall hemorrhage rates, evidence suggests a reduction in severe events, supporting coordinated surgical timing. These national patterns may inform institutional protocols and guide future studies examining ND strategy, vessel ligation techniques, and postoperative outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155439--></body></html>"
    },
    {
      "uid": "P298",
      "content_id": "153767",
      "abstract_number": "P298",
      "poster_number": "P298",
      "title": "Diagnostic Pathways, HPV/p16 Status, and Clinical Outcomes in Cervical Cancer of Unknown Primary: A Retrospective Study of 17 Patients",
      "summary": "Cervical CUP showed favorable long-term outcomes, particularly in p16-positive patients treated with CRT. Despite the limited number of cases and the absence of statistical significance, p16-positive CUP showed a trend toward similar overall survival to that of cases with p16-positive oropharyngeal cancer. These findings highlight the importance of p16/HPV profiling, optimized radiation strategies, and early...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153767",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taisei Yasuda, MD",
      "presenter": "Taisei Yasuda, MD",
      "authors": "Taisei Yasuda, MD ; Yasuhiro Ebihara, MD, Ph; Yuichiro Enoki, DDS, PhD; Hirohisa Iwaki, MD, PhD; Satoko Matsumura, MD; Tomoko Yamazaki, MD, DDS, PhD; Mitsuhiko Nakahira, MD, PhD",
      "normalized_authors": [
        "Taisei Yasuda",
        "Yasuhiro Ebihara, Ph",
        "Yuichiro Enoki",
        "Hirohisa Iwaki",
        "Satoko Matsumura",
        "Tomoko Yamazaki",
        "Mitsuhiko Nakahira"
      ],
      "affiliations": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University"
      ],
      "normalized_institutions": [
        "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 427,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Taisei Yasuda, MD ; Yasuhiro Ebihara, MD, Ph; Yuichiro Enoki, DDS, PhD; Hirohisa Iwaki, MD, PhD; Satoko Matsumura, MD; Tomoko Yamazaki, MD, DDS, PhD; Mitsuhiko Nakahira, MD, PhD",
        "Affiliations": "Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University",
        "Objectives": "This study aimed to review diagnostic pathways used for cervical cancer of unknown primary (CUP) in our institution, evaluate endoscopic, radiologic, and surgical diagnostic performance, assess clinical and pathological factors associated with primary-site estimation—particularly HPV/p16 status—and analyze treatment patterns and long-term outcomes.",
        "Methods": "A retrospective review was conducted on 17 patients presenting with cervical lymph node metastasis from CUP between January 1, 2015, and December 31, 2022, at the Department of Otolaryngology–Head and Neck Surgery, Saitama Medical University International Medical Center. Variables collected included staging, diagnostic modalities, biopsy results, nodal characteristics, extranodal extension, HPV/p16 and EBER status, treatment types, and oncologic outcomes.",
        "Results": "Patients ranged from 45–83 years (median 67), with a male–female ratio of 14:3. All underwent NBI endoscopy, CT, and PET-CT; MRI was performed in 13 cases. In the UICC/AJCC 7th and 8th edition classification for p16-negative cases or cases without p16 staining, clinical N classification was N1 (n=3), N2 (n=6), and N3 (n=8). Tonsillar biopsy was performed in 5 patients, direct transoral tonsillectomy in 10, and base-of-tongue biopsy in 1. Examination under anesthesia identified the primary site in 5 cases (4 oropharyngeal, 1 laryngeal), while 12 remained CUP. Neck dissection was performed in 15 patients (Level1-4 → 4cases, Level 1-5 → 5 cases, Level 2-4 → 3 cases, Level 2-5 → 2 cases, Level 1b → 1 case). All patients received postoperative radiation therapy. Among irradiated cases, 9 received RT alone (60–70 Gy), and 6 received concurrent chemoradiotherapy (CRT) with cisplatin (64–70 Gy); one patient received systemic chemotherapy alone. Recurrence occurred in both groups: RT patients developed lung metastases in 2 cases, and CRT patients developed lung metastases in 2 cases, brain metastasis in 1 case, and distant lymph node metastasis in 1 case. Among neck dissection cases, final pathology demonstrated p16 positivity in 7 cases and EBER positivity in 1. Median OS was approximately 50 months. Overall survival was 76%; among these survivors, one patient remained alive with disease, while the others were disease-free. And 4 deaths occurred (2 disease-related). Among patients with identified primaries, survival was 80%. In patients initially classified as CUP who were later confirmed as p16-positive after neck dissection (n=4), survival was 100%.",
        "Conclusion": "Cervical CUP showed favorable long-term outcomes, particularly in p16-positive patients treated with CRT. Despite the limited number of cases and the absence of statistical significance, p16-positive CUP showed a trend toward similar overall survival to that of cases with p16-positive oropharyngeal cancer. These findings highlight the importance of p16/HPV profiling, optimized radiation strategies, and early definitive management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic Pathways, HPV/p16 Status, and Clinical Outcomes in Cervical Cancer of Unknown Primary: A Retrospective Study of 17 Patients</span>. <u>Taisei Yasuda, MD</u>; Yasuhiro Ebihara, MD, Ph; Yuichiro Enoki, DDS, PhD; Hirohisa Iwaki, MD, PhD; Satoko Matsumura, MD; Tomoko Yamazaki, MD, DDS, PhD; Mitsuhiko Nakahira, MD, PhD. Dept of Head and Neck Surgery, International Medical Center, Saitama Medical University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>This study aimed to review diagnostic pathways used for cervical cancer of unknown primary (CUP) in our institution, evaluate endoscopic, radiologic, and surgical diagnostic performance, assess clinical and pathological factors associated with primary-site estimation—particularly HPV/p16 status—and analyze treatment patterns and long-term outcomes.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted on 17 patients presenting with cervical lymph node metastasis from CUP between January 1, 2015, and December 31, 2022, at the Department of Otolaryngology–Head and Neck Surgery, Saitama Medical University International Medical Center. Variables collected included staging, diagnostic modalities, biopsy results, nodal characteristics, extranodal extension, HPV/p16 and EBER status, treatment types, and oncologic outcomes.</p>\n\n<p><strong>Results: </strong>Patients ranged from 45–83 years (median 67), with a male–female ratio of 14:3. All underwent NBI endoscopy, CT, and PET-CT; MRI was performed in 13 cases. In the UICC/AJCC 7th and 8th edition classification for p16-negative cases or cases without p16 staining, clinical N classification was N1 (n=3), N2 (n=6), and N3 (n=8). Tonsillar biopsy was performed in 5 patients, direct transoral tonsillectomy in 10, and base-of-tongue biopsy in 1. Examination under anesthesia identified the primary site in 5 cases (4 oropharyngeal, 1 laryngeal), while 12 remained CUP. Neck dissection was performed in 15 patients (Level1-4 → 4cases, Level 1-5 → 5 cases, Level 2-4 → 3 cases, Level 2-5 → 2 cases, Level 1b → 1 case). All patients received postoperative radiation therapy. Among irradiated cases, 9 received RT alone (60–70 Gy), and 6 received concurrent chemoradiotherapy (CRT) with cisplatin (64–70 Gy); one patient received systemic chemotherapy alone. Recurrence occurred in both groups: RT patients developed lung metastases in 2 cases, and CRT patients developed lung metastases in 2 cases, brain metastasis in 1 case, and distant lymph node metastasis in 1 case. Among neck dissection cases, final pathology demonstrated p16 positivity in 7 cases and EBER positivity in 1. Median OS was approximately 50 months. Overall survival was 76%; among these survivors, one patient remained alive with disease, while the others were disease-free. And 4 deaths occurred (2 disease-related). Among patients with identified primaries, survival was 80%. In patients initially classified as CUP who were later confirmed as p16-positive after neck dissection (n=4), survival was 100%.</p>\n\n<p><strong>Conclusion: </strong>Cervical CUP showed favorable long-term outcomes, particularly in p16-positive patients treated with CRT. Despite the limited number of cases and the absence of statistical significance, p16-positive CUP showed a trend toward similar overall survival to that of cases with p16-positive oropharyngeal cancer. These findings highlight the importance of p16/HPV profiling, optimized radiation strategies, and early definitive management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153767--></body></html>"
    },
    {
      "uid": "P299",
      "content_id": "153233",
      "abstract_number": "P299",
      "poster_number": "P299",
      "title": "Patient Presentation, Tumor Characteristics, and Lateral Neck Disease in Endophytic Base of Tongue Tumors",
      "summary": "Our cohort shows that patients with endophytic BOT tumors commonly present with throat, ear, or tongue pain, and many experience delayed diagnosis. In fact, nearly half of our patients’ diagnoses were missed by community Otolaryngologists, underscoring the diagnostic challenge these endophytic tumors pose. Endophytic BOT tumors in our series were more frequently staged as T4 at diagnosis and appeared more likely...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153233",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Swanson, MD",
      "presenter": "Daniel Swanson, MD",
      "authors": "Daniel Swanson, MD 1 ; Christina Zhu, BS 2 ; Neha Rana, BA 2 ; Erica Choe, MD 1 ; Bruce Davidson, MD 1 ; Jonathan Giurintano, MD 1",
      "normalized_authors": [
        "Daniel Swanson",
        "Christina Zhu",
        "Neha Rana",
        "Erica Choe",
        "Bruce Davidson",
        "Jonathan Giurintano"
      ],
      "affiliations": [
        "Medstar Georgetown University Hospital",
        "Georgetown University School of Medicine"
      ],
      "normalized_institutions": [
        "Medstar Georgetown University Hospital",
        "Georgetown University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 460,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Study Design",
        "Data Extraction",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel Swanson, MD 1 ; Christina Zhu, BS 2 ; Neha Rana, BA 2 ; Erica Choe, MD 1 ; Bruce Davidson, MD 1 ; Jonathan Giurintano, MD 1",
        "Affiliations": "1 Medstar Georgetown University Hospital; 2 Georgetown University School of Medicine",
        "Introduction": "Tumors arising from the base of the tongue (BOT) may grow exophytically, projecting into the oropharynx, or endophytically, infiltrating into the tongue musculature. However, no distinction between these two patterns of tumor growth are currently described in the literature. The literature does show that rates of lateral neck disease in HPV-related oropharyngeal squamous cell carcinoma is very high and can approach even 90-95% (1). We define endophytic BOT tumors as those lacking a clear exophytic mass on clinical exam or flexible fiberoptic laryngoscopy, but showing clear evidence of tumor growth into tongue musculature on imaging.",
        "Objective": "To describe endophytic base of tongue tumors as a clinical entity and evaluate differences in tumor characteristics and lateral neck disease compared with traditional exophytic base of tongue tumors.",
        "Study Design": "Retrospective cohort study",
        "Data Extraction": "Three independent reviewers (CZ, DS, EC) reviewed cases of BOT tumors presented at our multidisciplinary tumor board in the last five years (2020-2025). They identified patients with endophytic BOT tumors and extracted data on demographics, clinical presentation, tumor characteristics, neck disease, treatments, and current treatment response.",
        "Results": "The research team identified eleven patients with endophytic BOT tumors. Most presented with sore throat and/or odynophagia (10/11; 91%), followed by otalgia (9/11; 82%), and tongue pain (3/11; 27%). Five patients (46%) had been previously evaluated by an otolaryngologist with the diagnosis missed; all had unremarkable flexible fiberoptic laryngoscopy, and MRI established the diagnosis in each case. The average time from symptom onset to diagnosis was 4.25 months. Nine tumors (82%) were HPV positive for p16. Most (10/11; 91%) were staged T4 for extrinsic tongue musculature invasion, with nodal staging of N0 in three patients (27%), N1 in four (36%), and N2 in four (36%). One patient (9%) had metastatic disease at presentation. Treatment included definitive chemoradiation at our institution (8/11; 73%), surgical resection (2/11; 18%), or definitive chemoradiation at a different facility (1/11; 9%). At last follow-up, eight patients (73%) were disease free, two (18%) had recurrent disease, and information was unavailable for one (9%).",
        "Conclusions": "Our cohort shows that patients with endophytic BOT tumors commonly present with throat, ear, or tongue pain, and many experience delayed diagnosis. In fact, nearly half of our patients’ diagnoses were missed by community Otolaryngologists, underscoring the diagnostic challenge these endophytic tumors pose. Endophytic BOT tumors in our series were more frequently staged as T4 at diagnosis and appeared more likely to present with an N0 neck compared with reported rates for HPV+ base of tongue tumors.",
        "Abstract": "Chera BS, et al. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res. 2019 Aug 1;25(15):4682-4690. doi: 10.1158/1078-0432.CCR-19-0211. Epub 2019 May 14. PMID: 31088830."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient Presentation, Tumor Characteristics, and Lateral Neck Disease in Endophytic Base of Tongue Tumors</span>. <u>Daniel Swanson, MD</u><sup>1</sup>; Christina Zhu, BS<sup>2</sup>; Neha Rana, BA<sup>2</sup>; Erica Choe, MD<sup>1</sup>; Bruce Davidson, MD<sup>1</sup>; Jonathan Giurintano, MD<sup>1</sup>. <sup>1</sup>Medstar Georgetown University Hospital; <sup>2</sup>Georgetown University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tumors arising from the base of the tongue (BOT) may grow exophytically, projecting into the oropharynx, or endophytically, infiltrating into the tongue musculature. However, no distinction between these two patterns of tumor growth are currently described in the literature. The literature does show that rates of lateral neck disease in HPV-related oropharyngeal squamous cell carcinoma is very high and can approach even 90-95% (1). We define endophytic BOT tumors as those lacking a clear exophytic mass on clinical exam or flexible fiberoptic laryngoscopy, but showing clear evidence of tumor growth into tongue musculature on imaging. </p>\n\n<p><strong>Objective: </strong>To describe endophytic base of tongue tumors as a clinical entity and evaluate differences in tumor characteristics and lateral neck disease compared with traditional exophytic base of tongue tumors. </p>\n\n<p><strong>Study Design: </strong>Retrospective cohort study</p>\n\n<p><strong>Data Extraction: </strong>Three independent reviewers (CZ, DS, EC) reviewed cases of BOT tumors presented at our multidisciplinary tumor board in the last five years (2020-2025). They identified patients with endophytic BOT tumors and extracted data on demographics, clinical presentation, tumor characteristics, neck disease, treatments, and current treatment response. </p>\n\n<p><strong>Results: </strong>The research team identified eleven patients with endophytic BOT tumors. Most presented with sore throat and/or odynophagia (10/11; 91%), followed by otalgia (9/11; 82%), and tongue pain (3/11; 27%). Five patients (46%) had been previously evaluated by an otolaryngologist with the diagnosis missed; all had unremarkable flexible fiberoptic laryngoscopy, and MRI established the diagnosis in each case. The average time from symptom onset to diagnosis was 4.25 months. Nine tumors (82%) were HPV positive for p16. Most (10/11; 91%) were staged T4 for extrinsic tongue musculature invasion, with nodal staging of N0 in three patients (27%), N1 in four (36%), and N2 in four (36%). One patient (9%) had metastatic disease at presentation. Treatment included definitive chemoradiation at our institution (8/11; 73%), surgical resection (2/11; 18%),  or definitive chemoradiation at a different facility (1/11; 9%). At last follow-up, eight patients (73%) were disease free, two (18%) had recurrent disease, and information was unavailable for one (9%). </p>\n\n<p><strong>Conclusions:</strong> Our cohort shows that patients with endophytic BOT tumors commonly present with throat, ear, or tongue pain, and many experience delayed diagnosis. In fact, nearly half of our patients’ diagnoses were missed by community Otolaryngologists, underscoring the diagnostic challenge these endophytic tumors pose. Endophytic BOT tumors in our series were more frequently staged as T4 at diagnosis and appeared more likely to present with an N0 neck compared with reported rates for HPV+ base of tongue tumors. </p>\n\n<p><strong>References: </strong></p>\n\n<p>Chera BS, et al. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res. 2019 Aug 1;25(15):4682-4690. doi: 10.1158/1078-0432.CCR-19-0211. Epub 2019 May 14. PMID: 31088830.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153233--></body></html>"
    },
    {
      "uid": "P300",
      "content_id": "153606",
      "abstract_number": "P300",
      "poster_number": "P300",
      "title": "Examining HPV- and HPV Vaccine-Related Cognitions and Acceptability in Immigrant Communities",
      "summary": "Our study revealed significant heterogeneity in an urban immigrant population’s understanding of HPV infection complications and HPV vaccine effectiveness in preventing oropharyngeal cancer. Drivers of vaccination hesitancy may include reduced awareness, poor understanding, and variable beliefs surrounding provider and vaccine availability, affordability, and government mistrust. Community-based education and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153606",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Melody B Eckert, BM",
      "presenter": "Melody B Eckert, BM",
      "authors": "Melody B Eckert, BM ; LeeAnn T Marcello, BS; Justin Choi, M, Ed; Matthew Adams, MD; Alexander Graf, MD; Jennifer Gottfried, MD; Sydney Butts, MD; Mahmoud I Awad, MD; Krishnamurthi Sundaram, MD; Natalya Chernichenko, MD",
      "normalized_authors": [
        "Melody B Eckert, BM",
        "LeeAnn T Marcello",
        "Justin Choi, M, Ed",
        "Matthew Adams",
        "Alexander Graf",
        "Jennifer Gottfried",
        "Sydney Butts",
        "Mahmoud I Awad",
        "Krishnamurthi Sundaram",
        "Natalya Chernichenko"
      ],
      "affiliations": [
        "SUNY Downstate Health Sciences University"
      ],
      "normalized_institutions": [
        "SUNY Downstate Health Sciences University"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Educational Objectives",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Melody B Eckert, BM ; LeeAnn T Marcello, BS; Justin Choi, M, Ed; Matthew Adams, MD; Alexander Graf, MD; Jennifer Gottfried, MD; Sydney Butts, MD; Mahmoud I Awad, MD; Krishnamurthi Sundaram, MD; Natalya Chernichenko, MD",
        "Affiliations": "SUNY Downstate Health Sciences University",
        "Educational Objectives": "Assess patient awareness of the Human Papillomavirus (HPV) vaccine’s potential to prevent head and neck cancer; understand the key drivers of HPV vaccination hesitancy; propose interventions to improve awareness of the HPV vaccine’s oropharyngeal cancer prevention potential; mitigate other drivers of vaccination hesitancy unveiled in this study.",
        "Background": "HPV is the most common sexually transmitted infection (STI) and a well-known cause of cancer. Associations have been established between HPV and oropharyngeal squamous cell carcinoma tumorigenesis, with over 70% of new oropharyngeal cancers attributable to HPV infection. Three recently developed, highly effective vaccines (nine-valent Gardasil, quadra-valent Gardasil, and Ceravix) are supported by the CDC and professional primary care organizations for the prevention of HPV-related infections and disease. While the HPV vaccine is widely accepted for preventing anogenital disease, its impact on head and neck cancer prevention is less understood. Urban underserved populations are at particularly high risk for poor vaccine adoption. We hypothesized that poor understanding of HPV vaccine effectiveness for head and neck cancer prevention is the primary driver of HPV vaccination hesitancy.",
        "Methods": "We administered a cross-sectional survey to adults (18-45 years) at two clinics in an urban academic medical center with a large underserved, immigrant population. Survey questions encompassed demographics, medical information, and knowledge and attitudes surrounding the HPV vaccine. Data was collected via Redcap software. Descriptive statistics were used for data analysis.",
        "Results": "From April-November 2025, 77 surveys were obtained. Demographics included: mean age of 32 years (range 19-45); 66% female (n=51); 57% Black/African American (n=44); 44% immigrants (n=34); 66% have health insurance (n=51); 9.09% use tobacco (n=7, 11 cigarettes/day mean, range 1-30); 45.45% consume alcohol (n=35, 3 drinks/week mean, range 1-20); 27% received HPV vaccination (n=21), 45% have not (n=35), 27% were unsure (n=21).",
        "Abstract": "Of the total respondents, 64% had heard of the HPV vaccine or had discussed it with a healthcare provider; however, 43% agreed that it prevents STIs, 27% disagreed, 30% were unsure. While 68% of respondents agreed that alcohol and tobacco use increase oropharyngeal cancer risk, 42% reported HPV infection as a risk factor and 43% were unsure. Regarding the vaccine’s effectiveness, many respondents were unsure about its ability to prevent oropharyngeal cancer (66%), cervical cancer (52%), and genital warts (65%). Respondents were also unsure about the HPV vaccine’s safety (38%) and potential to cause short-term problems such as fever or discomfort (48%) and lasting health problems (55%). Additionally, respondents were unsure about provider accessibility (29%), provider availability (34%), vaccine availability (40%), and vaccine affordability (38%). Lastly, respondents were unsure if other community members are vaccinating their children (73%) and if they should delay vaccinating their children due to recent FDA approval (32%).",
        "Conclusions": "Our study revealed significant heterogeneity in an urban immigrant population’s understanding of HPV infection complications and HPV vaccine effectiveness in preventing oropharyngeal cancer. Drivers of vaccination hesitancy may include reduced awareness, poor understanding, and variable beliefs surrounding provider and vaccine availability, affordability, and government mistrust. Community-based education and interventions may improve awareness, facilitate understanding, and reduce hesitancy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Examining HPV- and HPV Vaccine-Related Cognitions and Acceptability in Immigrant Communities</span>. <u>Melody B Eckert, BM</u>; LeeAnn T Marcello, BS; Justin Choi, M, Ed; Matthew Adams, MD; Alexander Graf, MD; Jennifer Gottfried, MD; Sydney Butts, MD; Mahmoud I Awad, MD; Krishnamurthi Sundaram, MD; Natalya Chernichenko, MD. SUNY Downstate Health Sciences University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Educational Objectives:</strong> Assess patient awareness of the Human Papillomavirus (HPV) vaccine’s potential to prevent head and neck cancer; understand the key drivers of HPV vaccination hesitancy; propose interventions to improve awareness of the HPV vaccine’s oropharyngeal cancer prevention potential; mitigate other drivers of vaccination hesitancy unveiled in this study. </p>\n\n<p><strong>Background: </strong>HPV is the most common sexually transmitted infection (STI) and a well-known cause of cancer. Associations have been established between HPV and oropharyngeal squamous cell carcinoma tumorigenesis, with over 70% of new oropharyngeal cancers attributable to HPV infection. Three recently developed, highly effective vaccines (nine-valent Gardasil, quadra-valent Gardasil, and Ceravix) are supported by the CDC and professional primary care organizations for the prevention of HPV-related infections and disease. While the HPV vaccine is widely accepted for preventing anogenital disease, its impact on head and neck cancer prevention is less understood. Urban underserved populations are at particularly high risk for poor vaccine adoption. We hypothesized that poor understanding of HPV vaccine effectiveness for head and neck cancer prevention is the primary driver of HPV vaccination hesitancy. </p>\n\n<p><strong>Methods:</strong> We administered a cross-sectional survey to adults (18-45 years) at two clinics in an urban academic medical center with a large underserved, immigrant population. Survey questions encompassed demographics, medical information, and knowledge and attitudes surrounding the HPV vaccine. Data was collected via Redcap software. Descriptive statistics were used for data analysis. </p>\n\n<p><strong>Results:</strong> From April-November 2025, 77 surveys were obtained. Demographics included: mean age of 32 years (range 19-45); 66% female (n=51); 57% Black/African American (n=44); 44% immigrants (n=34); 66% have health insurance (n=51); 9.09% use tobacco (n=7, 11 cigarettes/day mean, range 1-30); 45.45% consume alcohol (n=35, 3 drinks/week mean, range 1-20); 27% received HPV vaccination (n=21), 45% have not (n=35), 27% were unsure (n=21). </p>\n\n<p>Of the total respondents, 64% had heard of the HPV vaccine or had discussed it with a healthcare provider; however, 43% agreed that it prevents STIs, 27% disagreed, 30% were unsure. While 68% of respondents agreed that alcohol and tobacco use increase oropharyngeal cancer risk, 42% reported HPV infection as a risk factor and 43% were unsure. Regarding the vaccine’s effectiveness, many respondents were unsure about its ability to prevent oropharyngeal cancer (66%), cervical cancer (52%), and genital warts (65%). Respondents were also unsure about the HPV vaccine’s safety (38%) and potential to cause short-term problems such as fever or discomfort (48%) and lasting health problems (55%). Additionally, respondents were unsure about provider accessibility (29%), provider availability (34%), vaccine availability (40%), and vaccine affordability (38%). Lastly, respondents were unsure if other community members are vaccinating their children (73%) and if they should delay vaccinating their children due to recent FDA approval (32%). </p>\n\n<p><strong>Conclusions:</strong> Our study revealed significant heterogeneity in an urban immigrant population’s understanding of HPV infection complications and HPV vaccine effectiveness in preventing oropharyngeal cancer. Drivers of vaccination hesitancy may include reduced awareness, poor understanding, and variable beliefs surrounding provider and vaccine availability, affordability, and government mistrust. Community-based education and interventions may improve awareness, facilitate understanding, and reduce hesitancy. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153606--></body></html>"
    },
    {
      "uid": "P301",
      "content_id": "153762",
      "abstract_number": "P301",
      "poster_number": "P301",
      "title": "Trends in Lymphedema Following Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma",
      "summary": "In OPSCC patients treated with TORS, mild lymphedema persisted throughout the early postoperative period. These findings suggest that laryngeal edema should be anticipated during early recovery after TORS and that postoperative dysphagia likely reflects multiple contributors, including edema, pain, and altered anatomy. Prospective studies are needed to define the early trajectory of lymphedema and to determine...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153762",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Matthew Su, BS",
      "presenter": "Matthew Su, BS",
      "authors": "Jared C Dublin, MD 1 ; Sofiya Yusina, BS 2 ; Matthew Su, BS 2 ; Melonie A Nance, MD 1 ; Adam S Jacobson, MD 1 ; Alec Vaezi, MD, PhD 1 ; Michael J Persky, MD 1 ; Jacqueline Mojica, SLP 1 ; Laurie Wennerholm, SLP 1 ; Umamaheswar Duvvuri, MD, PhD 1",
      "normalized_authors": [
        "Jared C Dublin",
        "Sofiya Yusina",
        "Matthew Su",
        "Melonie A Nance",
        "Adam S Jacobson",
        "Alec Vaezi",
        "Michael J Persky",
        "Jacqueline Mojica, SLP",
        "Laurie Wennerholm, SLP",
        "Umamaheswar Duvvuri"
      ],
      "affiliations": [
        "Department of Otolaryngology, New York University Grossman School of Medicine",
        "New York University Grossman School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, New York University Grossman School of Medicine",
        "New York University Grossman School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 436,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials/Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jared C Dublin, MD 1 ; Sofiya Yusina, BS 2 ; Matthew Su, BS 2 ; Melonie A Nance, MD 1 ; Adam S Jacobson, MD 1 ; Alec Vaezi, MD, PhD 1 ; Michael J Persky, MD 1 ; Jacqueline Mojica, SLP 1 ; Laurie Wennerholm, SLP 1 ; Umamaheswar Duvvuri, MD, PhD 1",
        "Affiliations": "1 Department of Otolaryngology, New York University Grossman School of Medicine; 2 New York University Grossman School of Medicine",
        "Background": "Transoral robotic surgery (TORS) is a preferred minimally invasive approach for appropriately selected oropharyngeal squamous cell carcinoma (OPSCC). Despite its reduced morbidity compared with open approaches, many patients undergo concurrent neck dissection and adjuvant radiotherapy (RT), which are associated with cervical lymphedema and dysphagia. The onset and evolution of lymphedema in the early postoperative period after TORS are not well defined. This study evaluated trends in early postoperative lymphedema before the initiation of any adjuvant therapy.",
        "Materials/Methods": "All adults with OPSCC treated with TORS between December 2023 and July 2025 at a single institution were reviewed. Demographics, pathology, treatment details, Patterson edema scores, and diet tolerance were recorded. Flexible laryngoscopy was performed preoperatively, during the inpatient period (POD1–3), and at postoperative visits (POD6–41). Edema was scored using the 2021 Patterson system, and overall severity was assessed using a sum-score approach by summing ratings across all Patterson subsites not involved in the primary resection. Only patients with at least two edema scores were included. Diet tolerance was assessed either by speech-language pathology evaluation or by clinical assessment from the treating physician. Within-patient changes in edema scores were analyzed using paired Wilcoxon signed-rank tests.",
        "Results": "Thirty-eight patients (29 male; median age 63.5 years, range 45–83) were identified. Most tumors were HPV-related (35, 92%) and arose in the palatine tonsil (25, 65.8%) or tongue base (10, 26.3%); three were unknown primaries. Preoperatively, 84% (32) reported no dysphagia, and all patients had Patterson scores of 0. The majority had early-stage disease (pT1: 16, 42%; pT2: 19, 50%) and underwent unilateral neck dissection (34, 89%). Postoperative edema scores were recorded at POD1–3 (median 7, n=27, IQR 5.5), POD6–19 (median 5, n=21, IQR 5), and POD22–41 (median 4, n=11, IQR 6). Among patients with paired data (n=27), scores increased from preoperative 0 to a median of 4 at POD6–41 (p < .001). Paired comparisons showed no significant change between POD1–3 and POD6–41 (median 8 vs 4.5, n=20; p=0.18) or between POD1–3 and POD22–41 (median 8 vs 4, n=8; p=0.67). Forty-two percent (n=16) tolerated a normal diet by POD41.",
        "Conclusion": "In OPSCC patients treated with TORS, mild lymphedema persisted throughout the early postoperative period. These findings suggest that laryngeal edema should be anticipated during early recovery after TORS and that postoperative dysphagia likely reflects multiple contributors, including edema, pain, and altered anatomy. Prospective studies are needed to define the early trajectory of lymphedema and to determine the extent to which HPV status, neck dissection, and adjuvant RT influence its course."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in Lymphedema Following Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma</span>. Jared C Dublin, MD<sup>1</sup>; Sofiya Yusina, BS<sup>2</sup>; <u>Matthew Su, BS</u><sup>2</sup>; Melonie A Nance, MD<sup>1</sup>; Adam S Jacobson, MD<sup>1</sup>; Alec Vaezi, MD, PhD<sup>1</sup>; Michael J Persky, MD<sup>1</sup>; Jacqueline Mojica, SLP<sup>1</sup>; Laurie Wennerholm, SLP<sup>1</sup>; Umamaheswar Duvvuri, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, New York University Grossman School of Medicine; <sup>2</sup>New York University Grossman School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral robotic surgery (TORS) is a preferred minimally invasive approach for appropriately selected oropharyngeal squamous cell carcinoma (OPSCC). Despite its reduced morbidity compared with open approaches, many patients undergo concurrent neck dissection and adjuvant radiotherapy (RT), which are associated with cervical lymphedema and dysphagia. The onset and evolution of lymphedema in the early postoperative period after TORS are not well defined. This study evaluated trends in early postoperative lymphedema before the initiation of any adjuvant therapy.</p>\n\n<p><strong>Materials/Methods: </strong>All adults with OPSCC treated with TORS between December 2023 and July 2025 at a single institution were reviewed. Demographics, pathology, treatment details, Patterson edema scores, and diet tolerance were recorded. Flexible laryngoscopy was performed preoperatively, during the inpatient period (POD1–3), and at postoperative visits (POD6–41). Edema was scored using the 2021 Patterson system, and overall severity was assessed using a sum-score approach by summing ratings across all Patterson subsites not involved in the primary resection. Only patients with at least two edema scores were included. Diet tolerance was assessed either by speech-language pathology evaluation or by clinical assessment from the treating physician. Within-patient changes in edema scores were analyzed using paired Wilcoxon signed-rank tests.</p>\n\n<p><strong>Results: </strong>Thirty-eight patients (29 male; median age 63.5 years, range 45–83) were identified. Most tumors were HPV-related (35, 92%) and arose in the palatine tonsil (25, 65.8%) or tongue base (10, 26.3%); three were unknown primaries. Preoperatively, 84% (32) reported no dysphagia, and all patients had Patterson scores of 0. The majority had early-stage disease (pT1: 16, 42%; pT2: 19, 50%) and underwent unilateral neck dissection (34, 89%). Postoperative edema scores were recorded at POD1–3 (median 7, n=27, IQR 5.5), POD6–19 (median 5, n=21, IQR 5), and POD22–41 (median 4, n=11, IQR 6). Among patients with paired data (n=27), scores increased from preoperative 0 to a median of 4 at POD6–41 (p < .001). Paired comparisons showed no significant change between POD1–3 and POD6–41 (median 8 vs 4.5, n=20; p=0.18) or between POD1–3 and POD22–41 (median 8 vs 4, n=8; p=0.67). Forty-two percent (n=16) tolerated a normal diet by POD41.</p>\n\n<p><strong>Conclusion: </strong>In OPSCC patients treated with TORS, mild lymphedema persisted throughout the early postoperative period. These findings suggest that laryngeal edema should be anticipated during early recovery after TORS and that postoperative dysphagia likely reflects multiple contributors, including edema, pain, and altered anatomy. Prospective studies are needed to define the early trajectory of lymphedema and to determine the extent to which HPV status, neck dissection, and adjuvant RT influence its course.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153762--></body></html>"
    },
    {
      "uid": "P302",
      "content_id": "153748",
      "abstract_number": "P302",
      "poster_number": "P302",
      "title": "Understanding HPV-Associated Oropharyngeal Cancer: Knowledge Gaps Among Undergraduate Students",
      "summary": "In one of the first large-scale assessments of OPSCC-related understanding in young adults, we demonstrate substantial deficits in awareness of HPV-associated head and neck cancers among undergraduates, even within a large public research university. Despite moderate overall HPV familiarity and higher literacy among women in several domains, OPSCC-specific knowledge was uniformly low. These gaps represent a key...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153748",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carine Tamamian, BS",
      "presenter": "Carine Tamamian, BS",
      "authors": "Sandhya Kalavacherla, BS 1 ; Carine Tamamian, BS 1 ; Stella Ghevondyan 2 ; Theresa Guo, MD 1",
      "normalized_authors": [
        "Sandhya Kalavacherla",
        "Carine Tamamian",
        "Stella Ghevondyan",
        "Theresa Guo"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of California San Diego, La Jolla, CA",
        "Department of Public Health, University of California, San Diego, La Jolla, CA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of California San Diego, La Jolla, CA",
        "Department of Public Health, University of California, San Diego, La Jolla, CA"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 449,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sandhya Kalavacherla, BS 1 ; Carine Tamamian, BS 1 ; Stella Ghevondyan 2 ; Theresa Guo, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of California San Diego, La Jolla, CA; 2 Department of Public Health, University of California, San Diego, La Jolla, CA",
        "Background": "HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is the most common HPV-related malignancy in the United States, yet public awareness is low. As most prior work centers on cervical cancer literacy, little is known about what young adults within the optimal vaccination window know about HPV-associated head and neck cancers. Few studies have quantified these perceptions in large student populations. The University of California San Diego (UCSD), a large and diverse public university, provides an ideal setting to evaluate these gaps. We assessed baseline HPV literacy among UCSD undergraduates, with a specific focus on head and neck cancer awareness, to inform the development of targeted educational interventions.",
        "Methods": "An anonymous campus-wide survey was distributed in partnership with the Moores Cancer Center, UCSD Department of Otolaryngology, and undergraduate public health organizations. The survey assessed awareness of all HPV-related cancers, transmission routes, perceived susceptibility, vaccine awareness, comfort discussing HPV, and demographic characteristics. Recruitment occurred through classroom announcements, flyers, newsletters, and social media. Findings from this baseline assessment will aid in the development of OPSCC-focused programs designed to address misconceptions and connect students with vaccination resources.",
        "Results": "The survey included 272 students (median age 20); 50% were female, and the cohort was 29% White, 31% Asian, 11% Black, and 19% non-White Hispanic, with 31% first-generation college students and 23% studying biology/public health-related majors. Most students recognized HPV’s association with anogenital cancers (e.g. cervical 71%), whereas awareness of head and neck risk was low: only 20% identified throat cancer as HPV-related. Students also commonly misattributed HPV to non-HPV cancers (e.g., liver 15%); very few selected all cancer options, indicating minimal indiscriminate selection. Women were more likely than men to identify cervical (p=0.026) and anal (p=0.036) cancer associations, though no sociodemographic differences were seen for head and neck cancer knowledge. Regarding perceived demographic risk, women more often endorsed that everyone is equally at risk (p=0.01). Gaps in transmission knowledge were observed: 61% correctly identified sexual contact as primary, while nearly one-third believed HPV spreads via respiratory droplets. Vaccine familiarity varied with 47% reporting receiving at least one dose, and only 38% felt comfortable discussing HPV with a physician.",
        "Conclusion": "In one of the first large-scale assessments of OPSCC-related understanding in young adults, we demonstrate substantial deficits in awareness of HPV-associated head and neck cancers among undergraduates, even within a large public research university. Despite moderate overall HPV familiarity and higher literacy among women in several domains, OPSCC-specific knowledge was uniformly low. These gaps represent a key barrier to primary prevention. Future work will use these findings to inform targeted educational strategies that strengthen OPSCC knowledge, clarify HPV transmission, and ultimately support broader HPV prevention efforts in this population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Understanding HPV-Associated Oropharyngeal Cancer: Knowledge Gaps Among Undergraduate Students</span>. Sandhya Kalavacherla, BS<sup>1</sup>; <u>Carine Tamamian, BS</u><sup>1</sup>; Stella Ghevondyan<sup>2</sup>; Theresa Guo, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of California San Diego, La Jolla, CA; <sup>2</sup>Department of Public Health, University of California, San Diego, La Jolla, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is the most common HPV-related malignancy in the United States, yet public awareness is low. As most prior work centers on cervical cancer literacy, little is known about what young adults within the optimal vaccination window know about HPV-associated head and neck cancers. Few studies have quantified these perceptions in large student populations. The University of California San Diego (UCSD), a large and diverse public university, provides an ideal setting to evaluate these gaps. We assessed baseline HPV literacy among UCSD undergraduates, with a specific focus on head and neck cancer awareness, to inform the development of targeted educational interventions.</p>\n\n<p><strong>Methods: </strong>An anonymous campus-wide survey was distributed in partnership with the Moores Cancer Center, UCSD Department of Otolaryngology, and undergraduate public health organizations. The survey assessed awareness of all HPV-related cancers, transmission routes, perceived susceptibility, vaccine awareness, comfort discussing HPV, and demographic characteristics. Recruitment occurred through classroom announcements, flyers, newsletters, and social media. Findings from this baseline assessment will aid in the development of OPSCC-focused programs designed to address misconceptions and connect students with vaccination resources.</p>\n\n<p><strong>Results: </strong>The survey included 272 students (median age 20); 50% were female, and the cohort was 29% White, 31% Asian, 11% Black, and 19% non-White Hispanic, with 31% first-generation college students and 23% studying biology/public health-related majors. Most students recognized HPV’s association with anogenital cancers (e.g. cervical 71%), whereas awareness of head and neck risk was low: only 20% identified throat cancer as HPV-related. Students also commonly misattributed HPV to non-HPV cancers (e.g., liver 15%); very few selected all cancer options, indicating minimal indiscriminate selection. Women were more likely than men to identify cervical (p=0.026) and anal (p=0.036) cancer associations, though no sociodemographic differences were seen for head and neck cancer knowledge. Regarding perceived demographic risk, women more often endorsed that everyone is equally at risk (p=0.01). Gaps in transmission knowledge were observed: 61% correctly identified sexual contact as primary, while nearly one-third believed HPV spreads via respiratory droplets. Vaccine familiarity varied with 47% reporting receiving at least one dose, and only 38% felt comfortable discussing HPV with a physician.</p>\n\n<p><strong>Conclusion: </strong>In one of the first large-scale assessments of OPSCC-related understanding in young adults, we demonstrate substantial deficits in awareness of HPV-associated head and neck cancers among undergraduates, even within a large public research university. Despite moderate overall HPV familiarity and higher literacy among women in several domains, OPSCC-specific knowledge was uniformly low. These gaps represent a key barrier to primary prevention. Future work will use these findings to inform targeted educational strategies that strengthen OPSCC knowledge, clarify HPV transmission, and ultimately support broader HPV prevention efforts in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153748--></body></html>"
    },
    {
      "uid": "P303",
      "content_id": "151725",
      "abstract_number": "P303",
      "poster_number": "P303",
      "title": "Application of transoral ultrasound-guided core biopsy for tissue sampling of tongue base cancer",
      "summary": "Accurate histopathological diagnosis is essential for treatment stratification and prognosis prediction in patients with tongue base tumors. Conventional approaches, such as endoscopic or open incisional biopsy, are often limited by restricted access, procedural morbidity, and insufficient sampling in cases with submucosal tumor spread. Ultrasound-guided core biopsy (USCB) has been performed via transcervical or...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151725",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tsung-Lin Yang, MD, PhD, EMBA",
      "presenter": "Tsung-Lin Yang, MD, PhD, EMBA",
      "authors": "Hsuan-Yu Chou, MD 1 ; Chun-Nan Chen, MD, PhD 1 ; Jyue-Shi Yang 2 ; Tsung-Lin Yang, MD, PhD, EMBA 3",
      "normalized_authors": [
        "Hsuan-Yu Chou",
        "Chun-Nan Chen",
        "Jyue-Shi Yang",
        "Tsung-Lin Yang, EMBA"
      ],
      "affiliations": [
        "National Taiwan University Hospital",
        "Massachusetts Institute of Technology",
        "National Taiwan University"
      ],
      "normalized_institutions": [
        "National Taiwan University Hospital",
        "Massachusetts Institute of Technology",
        "National Taiwan University"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 215,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hsuan-Yu Chou, MD 1 ; Chun-Nan Chen, MD, PhD 1 ; Jyue-Shi Yang 2 ; Tsung-Lin Yang, MD, PhD, EMBA 3",
        "Affiliations": "1 National Taiwan University Hospital; 2 Massachusetts Institute of Technology; 3 National Taiwan University",
        "Abstract": "Accurate histopathological diagnosis is essential for treatment stratification and prognosis prediction in patients with tongue base tumors. Conventional approaches, such as endoscopic or open incisional biopsy, are often limited by restricted access, procedural morbidity, and insufficient sampling in cases with submucosal tumor spread. Ultrasound-guided core biopsy (USCB) has been performed via transcervical or non–ultrasound-guided transoral routes, but these techniques remain invasive or less reliable in securing adequate tissue. Moreover, most transoral core biopsies have focused on oral cavity lesions, with limited evidence supporting its use for deeper sites such as the tongue base. This study reports our institutional experience with transoral USCB specifically for tongue base tumors, emphasizing its feasibility, diagnostic yield, and safety. Patients with tongue base lesions underwent transoral USCB, and clinical, procedural, and pathological data were retrospectively reviewed. Adequate tissue was successfully obtained in all cases, enabling accurate histopathological diagnosis and ancillary molecular testing when indicated. No major complications were observed; minor bleeding occurred in a few cases and was effectively managed with local compression. These findings demonstrate that transoral USCB extends the utility of minimally invasive ultrasound-guided biopsy to the anatomically challenging tongue base, offering reliable tissue acquisition with minimal morbidity. Incorporating this approach into diagnostic pathways may reduce reliance on invasive surgical biopsies, and enable timely, individualized treatment planning."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Application of transoral ultrasound-guided core biopsy for tissue sampling of tongue base cancer</span>. Hsuan-Yu Chou, MD<sup>1</sup>; Chun-Nan Chen, MD, PhD<sup>1</sup>; Jyue-Shi Yang<sup>2</sup>; <u>Tsung-Lin Yang, MD, PhD, EMBA</u><sup>3</sup>. <sup>1</sup>National Taiwan University Hospital; <sup>2</sup>Massachusetts Institute of Technology; <sup>3</sup>National Taiwan University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Accurate histopathological diagnosis is essential for treatment stratification and prognosis prediction in patients with tongue base tumors. Conventional approaches, such as endoscopic or open incisional biopsy, are often limited by restricted access, procedural morbidity, and insufficient sampling in cases with submucosal tumor spread. Ultrasound-guided core biopsy (USCB) has been performed via transcervical or non–ultrasound-guided transoral routes, but these techniques remain invasive or less reliable in securing adequate tissue. Moreover, most transoral core biopsies have focused on oral cavity lesions, with limited evidence supporting its use for deeper sites such as the tongue base. This study reports our institutional experience with transoral USCB specifically for tongue base tumors, emphasizing its feasibility, diagnostic yield, and safety. Patients with tongue base lesions underwent transoral USCB, and clinical, procedural, and pathological data were retrospectively reviewed. Adequate tissue was successfully obtained in all cases, enabling accurate histopathological diagnosis and ancillary molecular testing when indicated. No major complications were observed; minor bleeding occurred in a few cases and was effectively managed with local compression. These findings demonstrate that transoral USCB extends the utility of minimally invasive ultrasound-guided biopsy to the anatomically challenging tongue base, offering reliable tissue acquisition with minimal morbidity. Incorporating this approach into diagnostic pathways may reduce reliance on invasive surgical biopsies, and enable timely, individualized treatment planning.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151725--></body></html>"
    },
    {
      "uid": "P304",
      "content_id": "154156",
      "abstract_number": "P304",
      "poster_number": "P304",
      "title": "Clinical analysis of HPV-positive oropharyngeal squamous cell cancer according to HPV type",
      "summary": "In our cohort of HPV-positive OPSCC, there was a marked male predominance, and non-HPV-16 genotypes accounted for approximately 25% of cases. These findings support the need for 9-valent, gender-neutral vaccination as a preventive strategy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154156",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gene Huh, MD",
      "presenter": "Gene Huh, MD",
      "authors": "Gene Huh, MD 1 ; Siyeon Jin, MD 2 ; Sung J Park, MD 3 ; Jinyi Lee, RN 2 ; Seo Y Kim, MD 2 ; Jeong-Yeon Ji, MD 2 ; Woo-Jin Jeong, MD, PhD 2 ; Wonjae Cha, MD, PhD 2",
      "normalized_authors": [
        "Gene Huh",
        "Siyeon Jin",
        "Sung J Park",
        "Jinyi Lee",
        "Seo Y Kim",
        "Jeong-Yeon Ji",
        "Woo-Jin Jeong",
        "Wonjae Cha"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology-Head & Neck Surgery, Boramae Medical Center, Seoul Metropolitan Government–Seoul National University",
        "Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine",
        "Department of Otorhinolaryngology-Head & Neck Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology-Head & Neck Surgery, Boramae Medical Center, Seoul Metropolitan Government–Seoul National University",
        "Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine",
        "Department of Otorhinolaryngology-Head & Neck Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 308,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Gene Huh, MD 1 ; Siyeon Jin, MD 2 ; Sung J Park, MD 3 ; Jinyi Lee, RN 2 ; Seo Y Kim, MD 2 ; Jeong-Yeon Ji, MD 2 ; Woo-Jin Jeong, MD, PhD 2 ; Wonjae Cha, MD, PhD 2",
        "Affiliations": "1 Department of Otorhinolaryngology-Head & Neck Surgery, Boramae Medical Center, Seoul Metropolitan Government–Seoul National University; 2 Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine; 3 Department of Otorhinolaryngology-Head & Neck Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine",
        "Introduction": "Oropharyngeal squamous cell carcinoma (OPSCC) has undergone an epidemiologic shift, with high-risk human papillomavirus (HPV) emerging as the major cause and HPV-16 comprising most HPV-positive cases worldwide. The clinical features and prognostic impact of non-HPV-16 genotypes remain unclear, with inconsistent evidence and limited data from Asian cohorts. This study examined genotype distribution and survival outcomes in a single-institution cohort of HPV-positive OPSCC to clarify the prognostic significance of HPV genotype variation.",
        "Methods": "We conducted a retrospective review of patients who underwent treatment for HPV-related OPSCC at Seoul National University Bundang Hospital from 2003 to 2023. Medical records, including imaging studies for staging and pathologic reports (p16 staining and HPV DNA tests), were analyzed. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan-Meier method and compared using the log-rank test.",
        "Results": "Among 254 patients with OPSCC, 177 were HPV-positive and 77 were HPV-negative. Of the HPV genotype-specific cases (n=174), HPV-16 was the most prevalent (n=130). Non-HPV-16 groups included HPV-33 (n=11), HPV-35 (n=8), HPV-58 (n=6), HPV-18 (n=6), other high-risk HPV (n=11), and HPV-not otherwise specified (n=2). Both HPV-16 and non-HPV-16 groups showed marked male predominance. However, HPV-16 patients were significantly younger and had better performance status (P=0.019 and 0.024, respectively).",
        "Abstract": "Clinical staging based on the AJCC 8th edition was similar between HPV-16 and non-HPV-16 groups, though HPV-33 cases showed significantly higher nodal stage (P=0.009). No significant differences in disease-free survival (DFS) were observed across genotypes. However, overall survival (OS) varied significantly (P=0.005), with HPV-35 and other hrHPV showing worse OS compared to HPV-16 (P=0.002 and 0.014, respectively).",
        "Conclusion": "In our cohort of HPV-positive OPSCC, there was a marked male predominance, and non-HPV-16 genotypes accounted for approximately 25% of cases. These findings support the need for 9-valent, gender-neutral vaccination as a preventive strategy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical analysis of HPV-positive oropharyngeal squamous cell cancer according to HPV type</span>. <u>Gene Huh, MD</u><sup>1</sup>; Siyeon Jin, MD<sup>2</sup>; Sung J Park, MD<sup>3</sup>; Jinyi Lee, RN<sup>2</sup>; Seo Y Kim, MD<sup>2</sup>; Jeong-Yeon Ji, MD<sup>2</sup>; Woo-Jin Jeong, MD, PhD<sup>2</sup>; Wonjae Cha, MD, PhD<sup>2</sup>. <sup>1</sup>Department of Otorhinolaryngology-Head & Neck Surgery, Boramae Medical Center, Seoul Metropolitan Government–Seoul National University; <sup>2</sup>Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine; <sup>3</sup>Department of Otorhinolaryngology-Head & Neck Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oropharyngeal squamous cell carcinoma (OPSCC) has undergone an epidemiologic shift, with high-risk human papillomavirus (HPV) emerging as the major cause and HPV-16 comprising most HPV-positive cases worldwide. The clinical features and prognostic impact of non-HPV-16 genotypes remain unclear, with inconsistent evidence and limited data from Asian cohorts. This study examined genotype distribution and survival outcomes in a single-institution cohort of HPV-positive OPSCC to clarify the prognostic significance of HPV genotype variation.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective review of patients who underwent treatment for HPV-related OPSCC at Seoul National University Bundang Hospital from 2003 to 2023. Medical records, including imaging studies for staging and pathologic reports (p16 staining and HPV DNA tests), were analyzed. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan-Meier method and compared using the log-rank test.</p>\n\n<p><strong>Results:</strong> Among 254 patients with OPSCC, 177 were HPV-positive and 77 were HPV-negative. Of the HPV genotype-specific cases (n=174), HPV-16 was the most prevalent (n=130). Non-HPV-16 groups included HPV-33 (n=11), HPV-35 (n=8), HPV-58 (n=6), HPV-18 (n=6), other high-risk HPV (n=11), and HPV-not otherwise specified (n=2). Both HPV-16 and non-HPV-16 groups showed marked male predominance. However, HPV-16 patients were significantly younger and had better performance status (P=0.019 and 0.024, respectively).</p>\n\n<p>Clinical staging based on the AJCC 8th edition was similar between HPV-16 and non-HPV-16 groups, though HPV-33 cases showed significantly higher nodal stage (P=0.009). No significant differences in disease-free survival (DFS) were observed across genotypes. However, overall survival (OS) varied significantly (P=0.005), with HPV-35 and other hrHPV showing worse OS compared to HPV-16 (P=0.002 and 0.014, respectively).</p>\n\n<p><strong>Conclusion:</strong> In our cohort of HPV-positive OPSCC, there was a marked male predominance, and non-HPV-16 genotypes accounted for approximately 25% of cases. These findings support the need for 9-valent, gender-neutral vaccination as a preventive strategy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154156--></body></html>"
    },
    {
      "uid": "P305",
      "content_id": "153726",
      "abstract_number": "P305",
      "poster_number": "P305",
      "title": "Emergence of Second Primary HPV-Negative Oral-Pharyngeal Squamous Cell Carcinoma in Patients with Prior HPV-Positive Oral-Pharyngeal Squamous Cell Carcinoma",
      "summary": "Our goal is to characterize and stratify the risk of developing a second primary HPV-negative SCC following an initial HPV-positive OPSCC by comparing this group to HPV-positive squamous cell carcinoma patients treated with surgery only. These findings may inform surveillance strategies and support ongoing efforts in radiation de-escalation.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153726",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taylor Kring",
      "presenter": "Taylor Kring",
      "authors": "Taylor Kring 1 ; Chloe Watkins 2 ; Garrett Forman 1 ; Elizabeth Franzmann, MD 3",
      "normalized_authors": [
        "Taylor Kring",
        "Chloe Watkins",
        "Garrett Forman",
        "Elizabeth Franzmann"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine",
        "Burrell College of Osteopathic Medicine",
        "University of Miami Health System and Jackson Memorial Hospital"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine",
        "Burrell College of Osteopathic Medicine",
        "University of Miami Health System and Jackson Memorial Hospital"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 277,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Taylor Kring 1 ; Chloe Watkins 2 ; Garrett Forman 1 ; Elizabeth Franzmann, MD 3",
        "Affiliations": "1 University of Miami Miller School of Medicine; 2 Burrell College of Osteopathic Medicine ; 3 University of Miami Health System and Jackson Memorial Hospital",
        "Background": "Through recent anecdotal clinical observations, we have identified 7 patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) who subsequently developed a second primary in-field HPV-negative squamous cell carcinoma. Reported rates of radiation-induced second primary SCC (SPSCC) range from 0.5% to 15%. Svärd et al. reported a median latency of 7.9 years following treatment for nasopharyngeal cancer. Patients with HPV-positive OPSCC who undergo radiation therapy may therefore carry an increased risk of developing an in-field HPV-negative SPSCC. Understanding the factors associated with this transformation is critical, including tumor biomarkers, traditional carcinogenic exposures (tobacco, alcohol), and radiation dose.",
        "Methods": "We are conducting a retrospective chart review of patients treated at the University of Miami Hospital between 2005 and 2025. Inclusion criteria were: (1) histologically confirmed HPV-positive OPSCC, and (2) subsequent development of a second primary in-field HPV-negative SCC within 15 years of the initial diagnosis. Data extracted included demographics (age, sex, smoking and alcohol history), tumor characteristics (site, stage, pathology, DNA/HPV testing), treatment parameters (radiation dose, chemotherapy regimen), and follow-up outcomes (interval between diagnoses, survival).",
        "Results": "Following initial data extraction and filtering for patients with multiple pathology reports containing HPV or p16 status, so far 6 additional eligible patients were identified through the EPIC institutional data brokers. We will continue to identify eligible patients. All identified cases originated from a single academic medical center, the University of Miami Health System.",
        "Conclusion": "Our goal is to characterize and stratify the risk of developing a second primary HPV-negative SCC following an initial HPV-positive OPSCC by comparing this group to HPV-positive squamous cell carcinoma patients treated with surgery only. These findings may inform surveillance strategies and support ongoing efforts in radiation de-escalation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Emergence of Second Primary HPV-Negative Oral-Pharyngeal Squamous Cell Carcinoma in Patients with Prior HPV-Positive Oral-Pharyngeal Squamous Cell Carcinoma</span>. <u>Taylor Kring</u><sup>1</sup>; Chloe Watkins<sup>2</sup>; Garrett Forman<sup>1</sup>; Elizabeth Franzmann, MD<sup>3</sup>. <sup>1</sup>University of Miami Miller School of Medicine; <sup>2</sup>Burrell College of Osteopathic Medicine ; <sup>3</sup>University of Miami Health System and Jackson Memorial Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Through recent anecdotal clinical observations, we have identified 7 patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) who subsequently developed a second primary in-field HPV-negative squamous cell carcinoma. Reported rates of radiation-induced second primary SCC (SPSCC) range from 0.5% to 15%. Svärd et al. reported a median latency of 7.9 years following treatment for nasopharyngeal cancer. Patients with HPV-positive OPSCC who undergo radiation therapy may therefore carry an increased risk of developing an in-field HPV-negative SPSCC. Understanding the factors associated with this transformation is critical, including tumor biomarkers, traditional carcinogenic exposures (tobacco, alcohol), and radiation dose. </p>\n\n<p><strong>Methods: </strong>We are conducting a retrospective chart review of patients treated at the University of Miami Hospital between 2005 and 2025. Inclusion criteria were: (1) histologically confirmed HPV-positive OPSCC, and (2) subsequent development of a second primary in-field HPV-negative SCC within 15 years of the initial diagnosis. Data extracted included demographics (age, sex, smoking and alcohol history), tumor characteristics (site, stage, pathology, DNA/HPV testing), treatment parameters (radiation dose, chemotherapy regimen), and follow-up outcomes (interval between diagnoses, survival).</p>\n\n<p><strong>Results: </strong>Following initial data extraction and filtering for patients with multiple pathology reports containing HPV or p16 status, so far 6 additional eligible patients were identified through the EPIC institutional data brokers. We will continue to identify eligible patients. All identified cases originated from a single academic medical center, the University of Miami Health System. </p>\n\n<p><strong>Conclusion: </strong>Our goal is to characterize and stratify the risk of developing a second primary HPV-negative SCC following an initial HPV-positive OPSCC by comparing this group to HPV-positive squamous cell carcinoma patients treated with surgery only. These findings may inform surveillance strategies and support ongoing efforts in radiation de-escalation. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153726--></body></html>"
    },
    {
      "uid": "P307",
      "content_id": "154699",
      "abstract_number": "P307",
      "poster_number": "P307",
      "title": "The role of the COVID-19 pandemic on disparities in HPV vaccination rates in the United States: A population study",
      "summary": "Increased vaccination rates likely reflect 2018 FDA approval expansion to adults aged 27-45 years and pandemic-era catch-up efforts. However, critical disparities emerged or intensified. Males remain half as likely to initiate vaccination despite comparable cancer risk. Black individuals faced new barriers post-pandemic, while insurance-related disparities intensified. As head and neck surgeons increasingly...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154699",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Akshay R Prabhakar, BSA",
      "presenter": "Akshay R Prabhakar, BSA",
      "authors": "Akshay R Prabhakar, BSA 1 ; Daniel Gorelik, MD 1 ; Justina R Varghese, BA 1 ; Aakash Agarwal, MS 2 ; Sebastian Guadarrama-Sistos Vazquez, MD 1 ; Nadia Mohyuddin, MD 1 ; Laura Kim, MD 1",
      "normalized_authors": [
        "Akshay R Prabhakar, BSA",
        "Daniel Gorelik",
        "Justina R Varghese",
        "Aakash Agarwal",
        "Sebastian Guadarrama-Sistos Vazquez",
        "Nadia Mohyuddin",
        "Laura Kim"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas",
        "Department of Electrical and Computer Engineering, University of Houston, Houston, Texas"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas",
        "Department of Electrical and Computer Engineering, University of Houston, Houston, Texas"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Akshay R Prabhakar, BSA 1 ; Daniel Gorelik, MD 1 ; Justina R Varghese, BA 1 ; Aakash Agarwal, MS 2 ; Sebastian Guadarrama-Sistos Vazquez, MD 1 ; Nadia Mohyuddin, MD 1 ; Laura Kim, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas; 2 Department of Electrical and Computer Engineering, University of Houston, Houston, Texas",
        "Introduction": "Despite strong evidence supporting human papillomavirus (HPV) vaccination in preventing HPV-related cancers, U.S. vaccination rates remain suboptimal. Social determinants of health, including race, gender, insurance status, and socioeconomic factors, contribute to preventive care disparities, yet their impact on HPV vaccination remains unclear. We examined a nationally representative sample to identify sociodemographic factors associated with vaccine initiation and series completion, comparing pre-pandemic and post-pandemic periods.",
        "Methods": "We analyzed data from the National Health and Nutrition Examination Survey. Individuals ages 9-45 were assessed via questionnaire data to determine HPV vaccine initiation and completion of series over two time periods, January 2017 - March 2020 and August 2021 - August 2023. Vaccine initiation was defined as receipt of at least one HPV dose. Series completion followed ACIP guidelines: two doses for those initiating before age 15, three doses for those initiating at 15 or older. Multivariable logistic regression assessed associations between vaccination outcomes and sociodemographic factors including age, gender, race/ethnicity, insurance coverage, poverty income ratio, birth country, and behavioral factors. Education was analyzed only among adults aged 18 and older.",
        "Results": "A total of 9,932 individuals were included in the study period. 4,211 (42.4%) individuals were surveyed after the start of the COVID-19 pandemic.Overall vaccination rates post-pandemic exceeded pre-pandemic rates (initiation: 22% to 38%, p<0.001; completion: 11% to 16%,p<0.001), with the largest increase among adults aged 26-45 years (initiation: 12% to 29%,p<0.001). Males had approximately half the odds of both initiation (OR 0.53, 95% CI 0.47-0.61) and completion (OR 0.46,0.38-0.55) compared to females. Black individuals showed no initiation disparity pre-pandemic (OR 1.00,p=0.98) but faced significant barriers since the start of the pandemic (OR 0.66, 0.54-0.81,p<0.001). Hispanic ethnicity emerged as a positive predictor since the pandemic (OR 1.33,1.06-1.67). The protective effect of insurance nearly doubled for initiation (pre: OR 1.60 vs since: OR 2.65,p<0.001). Among adults, educational attainment predicted vaccination across both periods, with college graduates initiating at 37% compared to 8% among those with less than ninth-grade education in the period since the pandemic (OR 1.55,95% CI 1.13-2.10). The target age group of 10-12 years had the lowest vaccination rates in both periods, with adolescents aged 13-17 demonstrating substantially higher rates (since-pandemic initiation: 58% vs. 31%,p<0.001; completion: 33% vs. 11%,p<0.001).",
        "Conclusion": "Increased vaccination rates likely reflect 2018 FDA approval expansion to adults aged 27-45 years and pandemic-era catch-up efforts. However, critical disparities emerged or intensified. Males remain half as likely to initiate vaccination despite comparable cancer risk. Black individuals faced new barriers post-pandemic, while insurance-related disparities intensified. As head and neck surgeons increasingly encounter HPV-related malignancies, these findings identify where additional prevention efforts are needed. Targeted interventions addressing insurance access, male vaccination, and culturally tailored outreach to Black communities are essential to achieve equitable HPV vaccination coverage."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The role of the COVID-19 pandemic on disparities in HPV vaccination rates in the United States: A population study</span>. <u>Akshay R Prabhakar, BSA</u><sup>1</sup>; Daniel Gorelik, MD<sup>1</sup>; Justina R Varghese, BA<sup>1</sup>; Aakash Agarwal, MS<sup>2</sup>; Sebastian Guadarrama-Sistos Vazquez, MD<sup>1</sup>; Nadia Mohyuddin, MD<sup>1</sup>; Laura Kim, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Houston Methodist, Houston, Texas; <sup>2</sup>Department of Electrical and Computer Engineering, University of Houston, Houston, Texas<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Despite strong evidence supporting human papillomavirus (HPV) vaccination in preventing HPV-related cancers, U.S. vaccination rates remain suboptimal. Social determinants of health, including race, gender, insurance status, and socioeconomic factors, contribute to preventive care disparities, yet their impact on HPV vaccination remains unclear. We examined a nationally representative sample to identify sociodemographic factors associated with vaccine initiation and series completion, comparing pre-pandemic and post-pandemic periods.</p>\n\n<p><strong>Methods: </strong>We analyzed data from the National Health and Nutrition Examination Survey. Individuals ages 9-45 were assessed via questionnaire data to determine HPV vaccine initiation and completion of series over two time periods, January 2017 - March 2020 and August 2021 - August 2023. Vaccine initiation was defined as receipt of at least one HPV dose. Series completion followed ACIP guidelines: two doses for those initiating before age 15, three doses for those initiating at 15 or older. Multivariable logistic regression assessed associations between vaccination outcomes and sociodemographic factors including age, gender, race/ethnicity, insurance coverage, poverty income ratio, birth country, and behavioral factors. Education was analyzed only among adults aged 18 and older.</p>\n\n<p><strong>Results: </strong>A total of 9,932 individuals were included in the study period. 4,211 (42.4%) individuals were surveyed after the start of the COVID-19 pandemic.Overall vaccination rates post-pandemic exceeded pre-pandemic rates (initiation: 22% to 38%, p<0.001; completion: 11% to 16%,p<0.001), with the largest increase among adults aged 26-45 years (initiation: 12% to 29%,p<0.001). Males had approximately half the odds of both initiation (OR 0.53, 95% CI 0.47-0.61) and completion (OR 0.46,0.38-0.55) compared to females. Black individuals showed no initiation disparity pre-pandemic (OR 1.00,p=0.98) but faced significant barriers since the start of the pandemic (OR 0.66, 0.54-0.81,p<0.001). Hispanic ethnicity emerged as a positive predictor since the pandemic (OR 1.33,1.06-1.67). The protective effect of insurance nearly doubled for initiation (pre: OR 1.60 vs since: OR 2.65,p<0.001). Among adults, educational attainment predicted vaccination across both periods, with college graduates initiating at 37% compared to 8% among those with less than ninth-grade education in the period since the pandemic (OR 1.55,95% CI 1.13-2.10). The target age group of 10-12 years had the lowest vaccination rates in both periods, with adolescents aged 13-17 demonstrating substantially higher rates (since-pandemic initiation: 58% vs. 31%,p<0.001; completion: 33% vs. 11%,p<0.001). </p>\n\n<p><strong>Conclusion: </strong>Increased vaccination rates likely reflect 2018 FDA approval expansion to adults aged 27-45 years and pandemic-era catch-up efforts. However, critical disparities emerged or intensified. Males remain half as likely to initiate vaccination despite comparable cancer risk. Black individuals faced new barriers post-pandemic, while insurance-related disparities intensified. As head and neck surgeons increasingly encounter HPV-related malignancies, these findings identify where additional prevention efforts are needed. Targeted interventions addressing insurance access, male vaccination, and culturally tailored outreach to Black communities are essential to achieve equitable HPV vaccination coverage.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154699--></body></html>"
    },
    {
      "uid": "P308",
      "content_id": "154761",
      "abstract_number": "P308",
      "poster_number": "P308",
      "title": "Impact of Surgical Margins on Recurrence and Survival in P16+ Oropharyngeal Squamous Cell Carcinoma Treated with Transoral Robotic Surgery.",
      "summary": "Patients with P16+ OPSCC patients treated with TORS have low recurrence rates and excellent OS and DFS independent of margin status or margin clearance group. These findings suggest that margin status is not a predictor of recurrence risk in with P16+ OPSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154761",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Heba Isaac, MD",
      "presenter": "Heba Isaac, MD",
      "authors": "Heba Isaac, MD ; Rodrigo Bayon, MD; Zaid Al-Qurayshi, MD",
      "normalized_authors": [
        "Heba Isaac",
        "Rodrigo Bayon",
        "Zaid Al-Qurayshi"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 445,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Heba Isaac, MD ; Rodrigo Bayon, MD; Zaid Al-Qurayshi, MD",
        "Affiliations": "University of Iowa",
        "Abstract": "The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen within the last two decades. The association of HPV with OPSCC portends two distinct entities of p16+ and p16- OPSCC which are now regarded as separate disease processes with different genetic behavior and clinical implications. P16+ OPSCC has an overall favorable prognosis. However, the prognosticating value of surgical margins towards disease recurrence and survival remain unclear. A cohort of P16+ OPSCC cases (n = 152) treated with transoral robotic surgery (TORS) at a single tertiary care center between 2012 and 2024 was analyzed for association of margin status with local recurrence (LR), overall survival (OS) and disease-free survival (DFS). Patients were stratified into 4 groups based on margin clearance status: Group A: negative frozen section (FS) and permanent specimen (PS) margins (n=119); Group B: FS positive, PS negative (n=3); Group C: FS negative, PS positive (n=4); Group D: positive FS and PS margins (n=4). LR rate based on margin status and margin clearance was analyzed, as well as association between margin status and 5-year OS and DFS. There was no significant association between LR rates and margin status or margin clearance group. LR rates based on FS margin status were 8.9% in negative FS and 0% in positive FS. LR rates based on PS margin status were 9% in negative PS and 0% in positive FS. No odds ratio available due to zero events reported. Similarly, LR rates based on margin clearance status group was 9.2% in group A and 0% in groups B, C, & D. Again, no odds ratio calculated due to zero events of recurrence identified. There was excellent OS and DFS regardless of frozen section margin status (Positive FS: 100% OS, 100% DFS; Negative FS: 87% OS & 96% DFS). OS and DFS were also not associated with PS margin status (Positive PS: 87% OS, 100% DFS; Negative PS: 87% OS, 96% DFS). Over a period of 10 years, there was no significant difference in OS and DFS between groups (OS p=0.088, DFS, p=0.96)",
        "Results": "Average age was 60 years with higher incidence in males (n=135, 88%) and whites (n=114, 96%). 90% of patients (n=136) presented at stage I. Most common primary subsites included tonsil (47%) and base of tongue (46%). Majority of patients were former smokers (n= 56, 51%), with light alcohol consumption (0-1 drink/day, n=116, 92%).",
        "Conclusion": "Patients with P16+ OPSCC patients treated with TORS have low recurrence rates and excellent OS and DFS independent of margin status or margin clearance group. These findings suggest that margin status is not a predictor of recurrence risk in with P16+ OPSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Surgical Margins on Recurrence and Survival in P16+ Oropharyngeal Squamous Cell Carcinoma Treated with Transoral Robotic Surgery.</span>. <u>Heba Isaac, MD</u>; Rodrigo Bayon, MD; Zaid Al-Qurayshi, MD. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen within the last two decades. The association of HPV with OPSCC portends two distinct entities of p16+ and p16- OPSCC which are now regarded as separate disease processes with different genetic behavior and clinical implications. P16+ OPSCC has an overall favorable prognosis. However, the prognosticating value of surgical margins towards disease recurrence and survival remain unclear. A cohort of P16+ OPSCC cases (n = 152) treated with transoral robotic surgery (TORS) at a single tertiary care center between 2012 and 2024 was analyzed for association of margin status with local recurrence (LR), overall survival (OS) and disease-free survival (DFS). Patients were stratified into 4 groups based on margin clearance status: Group A: negative frozen section (FS) and permanent specimen (PS) margins (n=119); Group B: FS positive, PS negative (n=3); Group C: FS negative, PS positive (n=4); Group D: positive FS and PS margins (n=4). LR rate based on margin status and margin clearance was analyzed, as well as association between margin status and 5-year OS and DFS.</p>\n\n<p><strong>Results</strong>: Average age was 60 years with higher incidence in males (n=135, 88%) and whites (n=114, 96%). 90% of patients (n=136) presented at stage I. Most common primary subsites included tonsil (47%) and base of tongue (46%). Majority of patients were former smokers (n= 56, 51%), with light alcohol consumption (0-1 drink/day, n=116, 92%).</p>\n\n<p>There was no significant association between LR rates and margin status or margin clearance group. LR rates based on FS margin status were 8.9% in negative FS and 0% in positive FS. LR rates based on PS margin status were 9% in negative PS and 0% in positive FS. No odds ratio available due to zero events reported. Similarly, LR rates based on margin clearance status group was 9.2% in group A and 0% in groups B, C, & D. Again, no odds ratio calculated due to zero events of recurrence identified.</p>\n\n<p>There was excellent OS and DFS regardless of frozen section margin status (Positive FS: 100% OS, 100% DFS; Negative FS: 87% OS & 96% DFS). OS and DFS were also not associated with PS margin status (Positive PS: 87% OS, 100% DFS; Negative PS: 87% OS, 96% DFS). Over a period of 10 years, there was no significant difference in OS and DFS between groups (OS p=0.088, DFS, p=0.96)</p>\n\n<p><strong>Conclusion</strong>: Patients with P16+ OPSCC patients treated with TORS have low recurrence rates and excellent OS and DFS independent of margin status or margin clearance group. These findings suggest that margin status is not a predictor of recurrence risk in with P16+ OPSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154761--></body></html>"
    },
    {
      "uid": "P309",
      "content_id": "152079",
      "abstract_number": "P309",
      "poster_number": "P309",
      "title": "Oropharyngeal vs Oral Cavity Squamous Cell Carcinoma: Demographic Correlates and p16 Status",
      "summary": "OPSCC was more common among males, aged 45-64, Black individuals and those who were divorced/separated with significant demographic disparities in HPV-associated (p16+) tumors. Females and Hispanic patients were less likely to have OPSCC. Black and Hispanic patients, as well as females, had significantly lower odds of p16-positive OPSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152079",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samuel Angel, BS",
      "presenter": "Samuel Angel, BS",
      "authors": "Cristina Benites, MBS 1 ; Chirag Raval, BS 2 ; Jeams Richard-Costa, BS 2 ; Samuel Angel, BS 3 ; Avraham Adelman, BS 1 ; Gonghao Liu, MS 4 ; Ji-Hyun Lee, Dr, PH 4 ; Dustin Conrad, MD 1 ; Peter Dziegielewski, MD 1",
      "normalized_authors": [
        "Cristina Benites, MBS",
        "Chirag Raval",
        "Jeams Richard-Costa",
        "Samuel Angel",
        "Avraham Adelman",
        "Gonghao Liu",
        "Ji-Hyun Lee, Dr, PH",
        "Dustin Conrad",
        "Peter Dziegielewski"
      ],
      "affiliations": [
        "University of Florida - UF Health Otolaryngology",
        "Dr. Kiran C Patel College of Allopathic Medicine",
        "University of Florida College of Medicine",
        "University of Florida - Department of Biostatistics"
      ],
      "normalized_institutions": [
        "University of Florida - UF Health Otolaryngology",
        "Dr. Kiran C Patel College of Allopathic Medicine",
        "University of Florida College of Medicine",
        "University of Florida - Department of Biostatistics"
      ],
      "session_type": "Poster",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 256,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Cristina Benites, MBS 1 ; Chirag Raval, BS 2 ; Jeams Richard-Costa, BS 2 ; Samuel Angel, BS 3 ; Avraham Adelman, BS 1 ; Gonghao Liu, MS 4 ; Ji-Hyun Lee, Dr, PH 4 ; Dustin Conrad, MD 1 ; Peter Dziegielewski, MD 1",
        "Affiliations": "1 University of Florida - UF Health Otolaryngology; 2 Dr. Kiran C Patel College of Allopathic Medicine; 3 University of Florida College of Medicine; 4 University of Florida - Department of Biostatistics",
        "Objective": "To determine whether demographic factors predict oropharyngeal squamous cell carcinoma (OPSCC) versus oral cavity squamous cell carcinoma (OCSCC). In a prespecified sub-analysis limited to years with available biomarker data, evaluate demographic factors associated with p16 status among OPSCC cases.",
        "Study Design": "A retrospective database study.",
        "Abstract": "Setting:The SEER Research Plus Limited-Field Data was used",
        "Methods": "Adult patients with OPSCC and OCSCC diagnosed between 2000-2021 were identified. Demographic and socioeconomic variables included age, sex, race, Hispanic ethnicity, marital status, income and geographic location. The primary outcome was demographic differences between OPSCC and OCSCC. The secondary outcome was the demographic differences among the OPSCC cohort stratified by p16 status. The p16 sub-analysis was restricted to 2018–2021 when p16 reporting was available. Descriptive analysis and a multivariable logistic regression analysis were done.",
        "Results": "29,793 cases of OPSCC or OCSCC were analyzed. 44% had OPSCC and 56% had OCSCC. Male sex, age 45–64, Black race and divorced/separated marital status were associated with increased OPSCC risk (p<0.001). Household income and geographic location were not associated with OPSCC. A sub analysis of p16(+/-) patients revealed that 56% were p16(+). Male sex, White, non-Hispanic ethnicity and being married or partnered were associated with higher odds of having p16-positive OPSCC (p<0.001).",
        "Conclusion": "OPSCC was more common among males, aged 45-64, Black individuals and those who were divorced/separated with significant demographic disparities in HPV-associated (p16+) tumors. Females and Hispanic patients were less likely to have OPSCC. Black and Hispanic patients, as well as females, had significantly lower odds of p16-positive OPSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oropharyngeal vs Oral Cavity Squamous Cell Carcinoma: Demographic Correlates and p16 Status</span>. Cristina Benites, MBS<sup>1</sup>; Chirag Raval, BS<sup>2</sup>; Jeams Richard-Costa, BS<sup>2</sup>; <u>Samuel Angel, BS</u><sup>3</sup>; Avraham Adelman, BS<sup>1</sup>; Gonghao Liu, MS<sup>4</sup>; Ji-Hyun Lee, Dr, PH<sup>4</sup>; Dustin Conrad, MD<sup>1</sup>; Peter Dziegielewski, MD<sup>1</sup>. <sup>1</sup>University of Florida - UF Health Otolaryngology; <sup>2</sup>Dr. Kiran C Patel College of Allopathic Medicine; <sup>3</sup>University of Florida College of Medicine; <sup>4</sup>University of Florida - Department of Biostatistics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> To determine whether demographic factors predict oropharyngeal squamous cell carcinoma (OPSCC) versus oral cavity squamous cell carcinoma (OCSCC). In a prespecified sub-analysis limited to years with available biomarker data, evaluate demographic factors associated with p16 status among OPSCC cases.</p>\n\n<p><strong>Study Design:</strong> A retrospective database study.</p>\n\n<p>Setting:The SEER Research Plus Limited-Field Data was used</p>\n\n<p><strong>Methods:</strong> Adult patients with OPSCC and OCSCC diagnosed between 2000-2021 were identified. Demographic and socioeconomic variables included age, sex, race, Hispanic ethnicity, marital status, income and geographic location. The primary outcome was demographic differences between OPSCC and OCSCC. The secondary outcome was the demographic differences among the OPSCC cohort stratified by p16 status. The p16 sub-analysis was restricted to 2018–2021 when p16 reporting was available. Descriptive analysis and a multivariable logistic regression analysis were done.</p>\n\n<p><strong>Results: </strong>29,793 cases of OPSCC or OCSCC were analyzed. 44% had OPSCC and 56% had OCSCC. Male sex, age 45–64, Black race and divorced/separated marital status were associated with increased OPSCC risk (p<0.001). Household income and geographic location were not associated with OPSCC. A sub analysis of p16(+/-) patients revealed that 56% were p16(+). Male sex, White, non-Hispanic ethnicity and being married or partnered were associated with higher odds of having p16-positive OPSCC (p<0.001).</p>\n\n<p><strong>Conclusion:</strong> OPSCC was more common among males, aged 45-64, Black individuals and those who were divorced/separated with significant demographic disparities in HPV-associated (p16+) tumors. Females and Hispanic patients were less likely to have OPSCC. Black and Hispanic patients, as well as females, had significantly lower odds of p16-positive OPSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152079--></body></html>"
    },
    {
      "uid": "P310",
      "content_id": "154661",
      "abstract_number": "P310",
      "poster_number": "P310",
      "title": "Using Purified Exosome Product To Heal a Soft Tissue Radionecrotic Wound",
      "summary": "PEP showed promise as a regenerative therapy for wound healing in a heavily treated refractory case of soft tissue radionecrosis. While this requires significant commitment/time for treatment the results were impressive and offer a potential novel option for others with similar complex soft tissue wounds.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154661",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joanna George, BS",
      "presenter": "Joanna George, BS",
      "authors": "Greg Krempl, MD, FACS 1 ; Joanna George, BS 2",
      "normalized_authors": [
        "Greg Krempl",
        "Joanna George"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "University Of Oklahoma College Of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "University Of Oklahoma College Of Medicine"
      ],
      "session_type": "Poster",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154661/%E0%B4%B8%E0%B5%8D%E0%B4%95%E0%B5%8D%E0%B4%B0%E0%B5%80%E0%B5%BB%E0%B4%B7%E0%B5%8B%E0%B4%9F%E0%B5%8D%E0%B4%9F%E0%B5%8D%202025-12-05%20152920(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154661/%E0%B4%B8%E0%B5%8D%E0%B4%95%E0%B5%8D%E0%B4%B0%E0%B5%80%E0%B5%BB%E0%B4%B7%E0%B5%8B%E0%B4%9F%E0%B5%8D%E0%B4%9F%E0%B5%8D%202025-12-05%20152920(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154661"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 403,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Treatment Procedure",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Greg Krempl, MD, FACS 1 ; Joanna George, BS 2",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma; 2 University Of Oklahoma College Of Medicine",
        "Background": "A 77-year old male who was treated for base of tongue cancer in 1990 and recurred in 1994 both of which were treated with external beam radiation. He recurred in 2005 and underwent 2 cycles of chemotherapy followed by a partial glossectomy/laryngectomy followed by 3 additional cycles of chemotherapy. In March 2023 he spontaneously developed a small ulcer on his neck that expanded despite multiple therapies including hyperbaric oxygen treatments. He unfortunately did not show signs of healing after 15 months of attempts at all traditional healing avenues.",
        "Abstract": "Purified Exosome Product (PEP) manufactured by RION is a novel, investigational regenerative product consisting of a lyophilized powder/powder-cake derived from leukocyte depleted U.S. sourced apheresed platelets that contains platelet-derived extracellular vesicles. These vesicles contain proteins, nucleic acids, and lipids that inherently promote tissue repair. It is being investigated in multiple arenas of regenerative medicine but has not been used to date in soft tissue radionecrosis. This is the first report of the use of PEP to successfully treat a chronic ulcer/soft tissue radionecrosis which was refractory to traditional modalities. The effect of this regenerative product on this non-healing wound, which was progressing over a 15-month period, was remarkable with 24 weeks on this novel investigational therapy.",
        "Treatment Procedure": "Under the oversight of an individual IND, the patient received PEP treatment weekly with 24 treatments from 10/18/24 through 4/25/25 with no adverse events. For each treatment the wound was debrided, PEP was reconstituted in a fibrin sealant and loaded into a dual barrel syringe for topical application. PEP was squirted into all areas of exposed tissue and covered with xeroform and a Band-Aid. Throughout the study, some order/drainage issues were identified. He had been on multiple courses of antibiotics and these were continued for the initial treatment period however were able to be discontinued during the course of therapy.",
        "Discussion": "An overall 95% improvement in the wound is seen (Figures 1 & 2). The wound, which was originally deeper than 7mm, filled in with soft tissue and epithelialized although at 6 months follow up there still is a soft tissue defect with a depressed area.",
        "Conclusion": "PEP showed promise as a regenerative therapy for wound healing in a heavily treated refractory case of soft tissue radionecrosis. While this requires significant commitment/time for treatment the results were impressive and offer a potential novel option for others with similar complex soft tissue wounds."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Using Purified Exosome Product To Heal a Soft Tissue Radionecrotic Wound</span>. Greg Krempl, MD, FACS<sup>1</sup>; <u>Joanna George, BS</u><sup>2</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma; <sup>2</sup>University Of Oklahoma College Of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>A 77-year old male who was treated for base of tongue cancer in 1990 and recurred in 1994 both of which were treated with external beam radiation. He recurred in 2005 and underwent 2 cycles of chemotherapy followed by a partial glossectomy/laryngectomy followed by 3 additional cycles of chemotherapy. In March 2023 he spontaneously developed a small ulcer on his neck that expanded despite multiple therapies including hyperbaric oxygen treatments. He unfortunately did not show signs of healing after 15 months of attempts at all traditional healing avenues.</p>\n\n<p>Purified Exosome Product (PEP) manufactured by RION is a novel, investigational regenerative product consisting of a lyophilized powder/powder-cake derived from leukocyte depleted U.S. sourced apheresed platelets that contains platelet-derived extracellular vesicles. These vesicles contain proteins, nucleic acids, and lipids that inherently promote tissue repair. It is being investigated in multiple arenas of regenerative medicine but has not been used to date in soft tissue radionecrosis.</p>\n\n<p><strong>Treatment Procedure: </strong>Under the oversight of an individual IND, the patient received PEP treatment weekly with 24 treatments from 10/18/24 through 4/25/25 with no adverse events. For each treatment the wound was debrided, PEP was reconstituted in a fibrin sealant and loaded into a dual barrel syringe for topical application. PEP was squirted into all areas of exposed tissue and covered with xeroform and a Band-Aid. Throughout the study, some order/drainage issues were identified. He had been on multiple courses of antibiotics and these were continued for the initial treatment period however were able to be discontinued during the course of therapy.</p>\n\n<p><strong>Discussion: </strong>An overall 95% improvement in the wound is seen (Figures 1 & 2). The wound, which was originally deeper than 7mm, filled in with soft tissue and epithelialized although at 6 months follow up there still is a soft tissue defect with a depressed area.</p>\n\n<p>This is the first report of the use of PEP to successfully treat a chronic ulcer/soft tissue radionecrosis which was refractory to traditional modalities. The effect of this regenerative product on this non-healing wound, which was progressing over a 15-month period, was remarkable with 24 weeks on this novel investigational therapy.</p>\n\n<p><strong>Conclusion: </strong>PEP showed promise as a regenerative therapy for wound healing in a heavily treated refractory case of soft tissue radionecrosis. While this requires significant commitment/time for treatment the results were impressive and offer a potential novel option for others with similar complex soft tissue wounds.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154661/%E0%B4%B8%E0%B5%8D%E0%B4%95%E0%B5%8D%E0%B4%B0%E0%B5%80%E0%B5%BB%E0%B4%B7%E0%B5%8B%E0%B4%9F%E0%B5%8D%E0%B4%9F%E0%B5%8D%202025-12-05%20152920(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154661--></body></html>"
    },
    {
      "uid": "P311",
      "content_id": "154124",
      "abstract_number": "P311",
      "poster_number": "P311",
      "title": "Prognostic Significance of EMT Marker in Nasopharyngeal Carcinoma: A Retrospective Study",
      "summary": "These findings indicate that elevated expression of EMT markers, particularly Vimentin and Snail, is associated with advanced nodal involvement and poorer survival outcomes in NPC. These markers may therefore serve as potential prognostic indicators of disease progression.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154124",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yu-Tsai Lin, MD",
      "presenter": "Yu-Tsai Lin, MD",
      "authors": "Yu-Tsai Lin, MD 1 ; Fu-Min Fang, MD, PhD 2 ; Chih-Yen Chien, MD 1",
      "normalized_authors": [
        "Yu-Tsai Lin",
        "Fu-Min Fang",
        "Chih-Yen Chien"
      ],
      "affiliations": [
        "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
        "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
        "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"
      ],
      "session_type": "Poster",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 229,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Yu-Tsai Lin, MD 1 ; Fu-Min Fang, MD, PhD 2 ; Chih-Yen Chien, MD 1",
        "Affiliations": "1 Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
        "Background": "Nasopharyngeal carcinoma (NPC) arises from the epithelial cells lining the nasopharynx and is characterized by early lymph node spread and distant metastasis, contributing to its poor prognosis. Epithelial-mesenchymal transition (EMT) enables epithelial cells to acquire mesenchymal properties, enhancing the migratory and invasive capabilities of cancer cells. This retrospective study investigated the association between EMT markers and disease progression in NPC.",
        "Methods": "A total of 108 patients with NPC were analyzed, including 50 who died during follow-up (failure group) and 58 who remained alive (non-failure group). Clinical data were collected, and immunohistochemical analyses were performed to assess the expression of EMT markers, including E-cadherin, Vimentin, and Snail.",
        "Results": "The two groups showed no significant differences in gender, T stage, WHO histological type, or medical history. However, N stage distribution differed significantly (p < 0.01). Immunohistochemical analyses revealed that Vimentin and Snail expression levels were higher in N1–N3 stages compared with N0 across both groups. Quantitative assessment further demonstrated significantly lower Vimentin expression at N2 (p < 0.01) and lower Snail expression at N1 (p < 0.05) in the non-failure group.In contrast, there was no significant difference in E-cadherin expression between the two groups.",
        "Conclusion": "These findings indicate that elevated expression of EMT markers, particularly Vimentin and Snail, is associated with advanced nodal involvement and poorer survival outcomes in NPC. These markers may therefore serve as potential prognostic indicators of disease progression."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Significance of EMT Marker in Nasopharyngeal Carcinoma: A Retrospective Study</span>. <u>Yu-Tsai Lin, MD</u><sup>1</sup>; Fu-Min Fang, MD, PhD<sup>2</sup>; Chih-Yen Chien, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; <sup>2</sup>Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Nasopharyngeal carcinoma (NPC) arises from the epithelial cells lining the nasopharynx and is characterized by early lymph node spread and distant metastasis, contributing to its poor prognosis. Epithelial-mesenchymal transition (EMT) enables epithelial cells to acquire mesenchymal properties, enhancing the migratory and invasive capabilities of cancer cells. This retrospective study investigated the association between EMT markers and disease progression in NPC.</p>\n\n<p><strong>Methods:</strong> A total of 108 patients with NPC were analyzed, including 50 who died during follow-up (failure group) and 58 who remained alive (non-failure group). Clinical data were collected, and immunohistochemical analyses were performed to assess the expression of EMT markers, including E-cadherin, Vimentin, and Snail.</p>\n\n<p><strong>Results:</strong> The two groups showed no significant differences in gender, T stage, WHO histological type, or medical history. However, N stage distribution differed significantly (p < 0.01). Immunohistochemical analyses revealed that Vimentin and Snail expression levels were higher in N1–N3 stages compared with N0 across both groups. Quantitative assessment further demonstrated significantly lower Vimentin expression at N2 (p < 0.01) and lower Snail expression at N1 (p < 0.05) in the non-failure group.In contrast, there was no significant difference in E-cadherin expression between the two groups.</p>\n\n<p><strong>Conclusion:</strong> These findings indicate that elevated expression of EMT markers, particularly Vimentin and Snail, is associated with advanced nodal involvement and poorer survival outcomes in NPC. These markers may therefore serve as potential prognostic indicators of disease progression.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154124--></body></html>"
    },
    {
      "uid": "P312",
      "content_id": "153541",
      "abstract_number": "P312",
      "poster_number": "P312",
      "title": "Practical Experience with Probe-Based Near Infrared Autofluorescence",
      "summary": "Through this early, preliminary data, our results suggest that the probe-based NIRAF PTeye detection system is a useful adjunct in focused parathyroidectomy surgery and may be utilized in lieu of frozen section analysis or ioPTH in select cases with localizing preoperative imaging.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153541",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alison L Tuominen, MD",
      "presenter": "Alison L Tuominen, MD",
      "authors": "Dylan Z Erwin, MD; Alison L Tuominen, MD ; Jay K Ferrell",
      "normalized_authors": [
        "Dylan Z Erwin",
        "Alison L Tuominen",
        "Jay K Ferrell"
      ],
      "affiliations": [
        "University of Texas Health at San Antonio"
      ],
      "normalized_institutions": [
        "University of Texas Health at San Antonio"
      ],
      "session_type": "Poster",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 414,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Dylan Z Erwin, MD; Alison L Tuominen, MD ; Jay K Ferrell",
        "Affiliations": "University of Texas Health at San Antonio",
        "Introduction": "Focused parathyroidectomy is the most common surgical approach for the management of primary hyperparathyroidism. This technique is predicated on localizing preoperative imaging combined with the use of intraoperative PTH (ioPTH) as per the Miami Criteria. However, the result time for ioPTH can vary significantly across institutions and often results in prolonged operative times. Furthermore, this approach may limit the operative settings in which parathyroid surgery is performed such as outpatient surgical facilities which lack ioPTH and/or frozen section pathology capabilities. PTeye is a probe-based near infrared autofluorescence (NIRAF) detection system which is designed to detect parathyroid tissue through the ratio of NIRAF in suspected parathyroid tissue to baseline thyroid NIRAF levels. While the utility of this technology has been studied in thyroidectomy, studies on its efficacy as a tool in focused parathyroidectomy are limited. In the present study, we describe our preliminary experience and the efficacy of utilizing NIRAF in lieu of intraoperative PTH or frozen section analysis for patients with primary hyperparathyroidism and localizing preoperative imaging.",
        "Methods": "We reviewed data in a prospective observational cohort of patients undergoing focused parathyroidectomy augmented by the PTeye NIRAF detection system. Selection criteria for this modified surgical approach included: primary hyperparathyroidism diagnosis, distinct localized adenoma on preoperative parathyroid imaging, surgeon performed ultrasound which concurred with preoperative imaging, and intraoperative confirmation of the suspected parathyroid adenoma with intraoperative NIRAF detection. Baseline autofluorescence levels (BL), maximum autofluorescence detection levels (DL), and autofluorescence detection ratios (DR) were recorded. A positive NIRAF parathyroid signal was defined as a DR of >1.2 (maximum DL/BL). Pre-incision PTH levels were obtained and compared to postoperative PTH levels to evaluate the overall rate of biochemical cure and surgical success.",
        "Results": "Our analysis included four female patients (mean age 67 years, range 61–78). All patients presented with primary hyperparathyroidism and had localized adenomas identified on preoperative imaging, which were confirmed with preoperative surgeon-performed ultrasound. In each case, a single parathyroid adenoma was identified intraoperatively and demonstrated NIRAF with a mean maximum DL of 573 (range 150–750) and a mean DR of 13.5 (range 6–21.8). All patients demonstrated biochemical cure based on appropriately decreased and normalized postoperative PTH levels. There were no significant surgical complications among this patient cohort.",
        "Conclusion": "Through this early, preliminary data, our results suggest that the probe-based NIRAF PTeye detection system is a useful adjunct in focused parathyroidectomy surgery and may be utilized in lieu of frozen section analysis or ioPTH in select cases with localizing preoperative imaging."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Practical Experience with Probe-Based Near Infrared Autofluorescence</span>. Dylan Z Erwin, MD; <u>Alison L Tuominen, MD</u>; Jay K Ferrell. University of Texas Health at San Antonio<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Focused parathyroidectomy is the most common surgical approach for the management of primary hyperparathyroidism. This technique is predicated on localizing preoperative imaging combined with the use of intraoperative PTH (ioPTH) as per the Miami Criteria. However, the result time for ioPTH can vary significantly across institutions and often results in prolonged operative times. Furthermore, this approach may limit the operative settings in which parathyroid surgery is performed such as outpatient surgical facilities which lack ioPTH and/or frozen section pathology capabilities. PTeye is a probe-based near infrared autofluorescence (NIRAF) detection system which is designed to detect parathyroid tissue through the ratio of NIRAF in suspected parathyroid tissue to baseline thyroid NIRAF levels. While the utility of this technology has been studied in thyroidectomy, studies on its efficacy as a tool in focused parathyroidectomy are limited. In the present study, we describe our preliminary experience and the efficacy of utilizing NIRAF in lieu of intraoperative PTH or frozen section analysis for patients with primary hyperparathyroidism and localizing preoperative imaging.</p>\n\n<p><strong>Methods:</strong> We reviewed data in a prospective observational cohort of patients undergoing focused parathyroidectomy augmented by the PTeye NIRAF detection system. Selection criteria for this modified surgical approach included: primary hyperparathyroidism diagnosis, distinct localized adenoma on preoperative parathyroid imaging, surgeon performed ultrasound which concurred with preoperative imaging, and intraoperative confirmation of the suspected parathyroid adenoma with intraoperative NIRAF detection. Baseline autofluorescence levels (BL), maximum autofluorescence detection levels (DL), and autofluorescence detection ratios (DR) were recorded. A positive NIRAF parathyroid signal was defined as a DR of >1.2 (maximum DL/BL). Pre-incision PTH levels were obtained and compared to postoperative PTH levels to evaluate the overall rate of biochemical cure and surgical success.</p>\n\n<p><strong>Results:</strong> Our analysis included four female patients (mean age 67 years, range 61–78). All patients presented with primary hyperparathyroidism and had localized adenomas identified on preoperative imaging, which were confirmed with preoperative surgeon-performed ultrasound. In each case, a single parathyroid adenoma was identified intraoperatively and demonstrated NIRAF with a mean maximum DL of 573 (range 150–750) and a mean DR of 13.5 (range 6–21.8). All patients demonstrated biochemical cure based on appropriately decreased and normalized postoperative PTH levels. There were no significant surgical complications among this patient cohort.</p>\n\n<p><strong>Conclusion: </strong>Through this early, preliminary data, our results suggest that the probe-based NIRAF PTeye detection system is a useful adjunct in focused parathyroidectomy surgery and may be utilized in lieu of frozen section analysis or ioPTH in select cases with localizing preoperative imaging.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153541--></body></html>"
    },
    {
      "uid": "P316",
      "content_id": "154558",
      "abstract_number": "P316",
      "poster_number": "P316",
      "title": "From Surgery to Radiation: Why the Journey Takes Too Long for Head and Neck Cancer Patients in the Central Valley",
      "summary": "Postoperative complications were associated with longer treatment intervals (mean 80 vs. 54 days) and a higher proportion of delays beyond 8 weeks (67% vs. 25%), although statistical significance was limited by the small sample (p=0.03). Patients requiring SNF placement demonstrated a similar trend, with longer intervals (mean 90 vs. 60 days) and more frequent delays exceeding 8 weeks (67% vs. 36%). Feeding tube...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154558",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jeffrey W Toman, BS",
      "presenter": "Jeffrey W Toman, BS",
      "authors": "Jeffrey W Toman, BS 1 ; Alexandra M Naicker, BA 2 ; Jiya Uttam 3 ; Farah Karipineni, MD, MPH, FACS 4",
      "normalized_authors": [
        "Jeffrey W Toman",
        "Alexandra M Naicker",
        "Jiya Uttam",
        "Farah Karipineni"
      ],
      "affiliations": [
        "Northeast Ohio Medical University",
        "California Health Sciences University",
        "Community Health System",
        "UCSF Fresno, Division Of Surgery"
      ],
      "normalized_institutions": [
        "Northeast Ohio Medical University",
        "California Health Sciences University",
        "Community Health System",
        "UCSF Fresno, Division Of Surgery"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "Abstract",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Jeffrey W Toman, BS 1 ; Alexandra M Naicker, BA 2 ; Jiya Uttam 3 ; Farah Karipineni, MD, MPH, FACS 4",
        "Affiliations": "1 Northeast Ohio Medical University; 2 California Health Sciences University; 3 Community Health System; 4 UCSF Fresno, Division Of Surgery",
        "INTRODUCTION": "In head and neck cancer care, timely initiation of postoperative radiation therapy (RT) is essential to optimize locoregional control. National Comprehensive Cancer Network guidelines recommend beginning adjuvant RT within 6 weeks after surgery. However, delays remain common, particularly in rural and medically underserved regions. In California’s Central Valley, access to specialized oncologic services may be limited, which can contribute to prolonged postoperative treatment intervals. This study aimed to determine the prevalence of delayed RT initiation in this regional patient population and to identify clinical, workflow, and sociodemographic factors that may be associated with treatment delay.",
        "METHODS": "A retrospective chart review was conducted of 36 patients with head and neck cancer who underwent curative-intent surgery followed by adjuvant RT at regional medical centers between 2021 and 2024. Extracted variables included key treatment dates, radiation oncology referral patterns, postoperative complications, feeding tube placement and timing, PET timing, use of skilled nursing facilities (SNFs), and insurance type. The primary outcome was delay, defined as more than 42 days from surgery to the start of RT. Fisher’s exact tests assessed associations between categorical predictors and delay. PET timing was analyzed as a continuous interval.",
        "RESULTS": "Among the 36 patients, 33 (91.7%) began RT more than 42 days after surgery. The median surgery-to-RT interval was 50 days (mean 63 days; range 37–174). Preoperative referral to radiation oncology did not reduce delays (92.9% delayed with referral vs. 87.5% without, p=0.33), and postoperative referral showed a similar pattern (95.7% vs. 90.0%, p=0.52).",
        "Abstract": "Postoperative complications were associated with longer treatment intervals (mean 80 vs. 54 days) and a higher proportion of delays beyond 8 weeks (67% vs. 25%), although statistical significance was limited by the small sample (p=0.03). Patients requiring SNF placement demonstrated a similar trend, with longer intervals (mean 90 vs. 60 days) and more frequent delays exceeding 8 weeks (67% vs. 36%). Feeding tube presence, feeding tube timing, and PET timing were not significantly associated with delay (all p>0.20). Insurance types showed meaningful differences in delays. Commercially insured patients had the shortest median interval from surgery to RT (46 days) and the lowest proportion of delays beyond 8 weeks (25%). Medi-Cal and dual-eligible patients had longer median intervals (56 and 59 days, respectively) and higher rates of delays exceeding 8 weeks (46–50%). Medicare patients fell between these groups. These patterns suggest a potential influence of payer type on timely access to adjuvant therapy, although no category reached statistical significance.",
        "CONCLUSION": "Delays in initiating adjuvant RT were widespread, with more than 90% of patients exceeding guideline-recommended timelines. Although referral patterns, PET scheduling, feeding tube placement, postoperative complications, SNF stay, and insurance type all showed trends toward longer treatment intervals, none reliably predicted delay because delays were pervasive across all groups. Future work should include prospective mapping of care pathways and the use of larger, multi-institutional cohorts to identify modifiable barriers and guide interventions that improve timely access to postoperative RT in underserved regions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>From Surgery to Radiation: Why the Journey Takes Too Long for Head and Neck Cancer Patients in the Central Valley</span>. <u>Jeffrey W Toman, BS</u><sup>1</sup>; Alexandra M Naicker, BA<sup>2</sup>; Jiya Uttam<sup>3</sup>; Farah Karipineni, MD, MPH, FACS<sup>4</sup>. <sup>1</sup>Northeast Ohio Medical University; <sup>2</sup>California Health Sciences University; <sup>3</sup>Community Health System; <sup>4</sup>UCSF Fresno, Division Of Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION: </strong>In head and neck cancer care, timely initiation of postoperative radiation therapy (RT) is essential to optimize locoregional control. National Comprehensive Cancer Network guidelines recommend beginning adjuvant RT within 6 weeks after surgery. However, delays remain common, particularly in rural and medically underserved regions. In California’s Central Valley, access to specialized oncologic services may be limited, which can contribute to prolonged postoperative treatment intervals. This study aimed to determine the prevalence of delayed RT initiation in this regional patient population and to identify clinical, workflow, and sociodemographic factors that may be associated with treatment delay.</p>\n\n<p><strong>METHODS: </strong>A retrospective chart review was conducted of 36 patients with head and neck cancer who underwent curative-intent surgery followed by adjuvant RT at regional medical centers between 2021 and 2024. Extracted variables included key treatment dates, radiation oncology referral patterns, postoperative complications, feeding tube placement and timing, PET timing, use of skilled nursing facilities (SNFs), and insurance type. The primary outcome was delay, defined as more than 42 days from surgery to the start of RT. Fisher’s exact tests assessed associations between categorical predictors and delay. PET timing was analyzed as a continuous interval.</p>\n\n<p><strong>RESULTS: </strong>Among the 36 patients, 33 (91.7%) began RT more than 42 days after surgery. The median surgery-to-RT interval was 50 days (mean 63 days; range 37–174). Preoperative referral to radiation oncology did not reduce delays (92.9% delayed with referral vs. 87.5% without, p=0.33), and postoperative referral showed a similar pattern (95.7% vs. 90.0%, p=0.52).</p>\n\n<p>Postoperative complications were associated with longer treatment intervals (mean 80 vs. 54 days) and a higher proportion of delays beyond 8 weeks (67% vs. 25%), although statistical significance was limited by the small sample (p=0.03). Patients requiring SNF placement demonstrated a similar trend, with longer intervals (mean 90 vs. 60 days) and more frequent delays exceeding 8 weeks (67% vs. 36%). Feeding tube presence, feeding tube timing, and PET timing were not significantly associated with delay (all p>0.20).</p>\n\n<p>Insurance types showed meaningful differences in delays. Commercially insured patients had the shortest median interval from surgery to RT (46 days) and the lowest proportion of delays beyond 8 weeks (25%). Medi-Cal and dual-eligible patients had longer median intervals (56 and 59 days, respectively) and higher rates of delays exceeding 8 weeks (46–50%). Medicare patients fell between these groups. These patterns suggest a potential influence of payer type on timely access to adjuvant therapy, although no category reached statistical significance.</p>\n\n<p><strong>CONCLUSION: </strong>Delays in initiating adjuvant RT were widespread, with more than 90% of patients exceeding guideline-recommended timelines. Although referral patterns, PET scheduling, feeding tube placement, postoperative complications, SNF stay, and insurance type all showed trends toward longer treatment intervals, none reliably predicted delay because delays were pervasive across all groups. Future work should include prospective mapping of care pathways and the use of larger, multi-institutional cohorts to identify modifiable barriers and guide interventions that improve timely access to postoperative RT in underserved regions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154558--></body></html>"
    },
    {
      "uid": "P317",
      "content_id": "153390",
      "abstract_number": "P317",
      "poster_number": "P317",
      "title": "Catastrophic Bleeding in Head and Neck Squamous Cell Carcinoma: Institutional Review",
      "summary": "In our case series, we present 11 cases of carotid blowout requiring endovascular intervention at our tertiary care institution to bolster the current literature in this area and assist interdisciplinary teams in guiding care in these difficult but rare clinical scenarios.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153390",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Daniel, MD",
      "presenter": "Ryan Daniel, MD",
      "authors": "Ryan Daniel, MD ; Nicholas Bridi, BSc; Shao Hui Huang, MD; Ali Hosni Abdalaty, MD; Andrew Hope, MD; Christopher MKL Yao, MD",
      "normalized_authors": [
        "Ryan Daniel",
        "Nicholas Bridi",
        "Shao Hui Huang",
        "Ali Hosni Abdalaty",
        "Andrew Hope",
        "Christopher MKL Yao"
      ],
      "affiliations": [
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University of Toronto"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ryan Daniel, MD ; Nicholas Bridi, BSc; Shao Hui Huang, MD; Ali Hosni Abdalaty, MD; Andrew Hope, MD; Christopher MKL Yao, MD",
        "Affiliations": "University of Toronto",
        "Introduction": "Carotid Blowout is a rare but devastating complication for patients with head and neck squamous cell carcinoma. Prior radiation, oropharynx cancer, and recurrent disease are significant risk factors for these events. Given the rarity of this complication there is a need for further literature to better describe this patient population, presentation and treatment pathway.",
        "Methods": "An institutional review of recent cases of head and neck squamous cell carcinoma with carotid blowout requiring endovascular intervention was conducted between Jan 1 2019 and Dec 21 2024.",
        "Results": "We identified 11 cases overall that met criteria. The median age at diagnosis was 62.3 years old and 27.3% (3/11) were female. The majority of patients had a history of smoking (9/11). Oropharynx was the most common cancer subsite (9/11) and of these patients 55.6% had HPV positive histology. The vast majority of patients had Stage IVA disease at presentation (10/11). All patients received radiation as part of their definitive treatment with a median dose of 70 Gy and 36.4% received concurrent chemotherapy. In terms of the carotid blowout events, 2/11 occurred during active treatment and 9/11 occurred during active surveillance. The majority had a sentinel bleeding event (8/11) and 5/11 were taking antiplatelet or anticoagulant medications. The median time from diagnosis and completion of radiation treatment to carotid blowout was 175 days (range; 22-1017 days) and 112 days (range; 27-898 days) respectively. In terms of the type of blowout, 6/11 patients had Type 2 and 5/11 had Type 3 blowouts. In terms of the cause of blowout, 6/11 were due to active or persistent disease and 5/11 were due to radiation induced necrosis. The vast majority were due to bleeding for branches of the external carotid artery (10/11) with the lingual artery being the most common culprit vessel (5/11). All patients underwent endovascular intervention with coil or glue embolization and all patients survived the initial intervention. The majority of patients did not have a repeat bleeding event (8/11), however, 2/11 patients had catastrophic repeat bleeding events leading to death. In terms of survival 3/11 patients are still alive at the most recent follow up. Overall, when looking at our institutional head and neck radiation oncology database, we calculated a prevalence of 1% (9/878) of patients with oropharynx head and neck squamous cell carcinoma treated with definitive radiation will have a carotid blowout requiring endovascular intervention.",
        "Conclusions": "In our case series, we present 11 cases of carotid blowout requiring endovascular intervention at our tertiary care institution to bolster the current literature in this area and assist interdisciplinary teams in guiding care in these difficult but rare clinical scenarios."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Catastrophic Bleeding in Head and Neck Squamous Cell Carcinoma: Institutional Review</span>. <u>Ryan Daniel, MD</u>; Nicholas Bridi, BSc; Shao Hui Huang, MD; Ali Hosni Abdalaty, MD; Andrew Hope, MD; Christopher MKL Yao, MD. University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Carotid Blowout is a rare but devastating complication for patients with head and neck squamous cell carcinoma. Prior radiation, oropharynx cancer, and recurrent disease are significant risk factors for these events. Given the rarity of this complication there is a need for further literature to better describe this patient population, presentation and treatment pathway.</p>\n\n<p><strong>Methods: </strong>An institutional review of recent cases of head and neck squamous cell carcinoma with carotid blowout requiring endovascular intervention was conducted between Jan 1 2019 and Dec 21 2024.</p>\n\n<p><strong>Results: </strong>We identified 11 cases overall that met criteria. The median age at diagnosis was 62.3 years old and 27.3% (3/11) were female. The majority of patients had a history of smoking (9/11). Oropharynx was the most common cancer subsite (9/11) and of these patients 55.6% had HPV positive histology.  The vast majority of patients had Stage IVA disease at presentation (10/11). All patients received radiation as part of their definitive treatment with a median dose of 70 Gy and 36.4% received concurrent chemotherapy. In terms of the carotid blowout events, 2/11 occurred during active treatment and 9/11 occurred during active surveillance. The majority had a sentinel bleeding event (8/11) and 5/11 were taking antiplatelet or anticoagulant medications. The median time from diagnosis and completion of radiation treatment to carotid blowout was 175 days (range; 22-1017 days) and 112 days (range; 27-898 days) respectively.  In terms of the type of blowout, 6/11 patients had Type 2 and 5/11 had Type 3 blowouts. In terms of the cause of blowout, 6/11 were due to active or persistent disease and 5/11 were due to radiation induced necrosis. The vast majority were due to bleeding for branches of the external carotid artery (10/11) with the lingual artery being the most common culprit vessel (5/11). All patients underwent endovascular intervention with coil or glue embolization and all patients survived the initial intervention. The majority of patients did not have a repeat bleeding event (8/11), however, 2/11 patients had catastrophic repeat bleeding events leading to death.  In terms of survival 3/11 patients are still alive at the most recent follow up. Overall, when looking at our institutional head and neck radiation oncology database, we calculated a prevalence of 1% (9/878) of patients with oropharynx head and neck squamous cell carcinoma treated with definitive radiation will have a carotid blowout requiring endovascular intervention.</p>\n\n<p><strong>Conclusions: </strong>In our case series, we present 11 cases of carotid blowout requiring endovascular intervention at our tertiary care institution to bolster the current literature in this area and assist interdisciplinary teams in guiding care in these difficult but rare clinical scenarios.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153390--></body></html>"
    },
    {
      "uid": "P318",
      "content_id": "153467",
      "abstract_number": "P318",
      "poster_number": "P318",
      "title": "Clinical Factors Associated with Delays in Adjuvant Treatment in Head and Neck Cancer",
      "summary": "Overall, this study demonstrates the potential for expedited radiation oncology consultations in ensuring that radiation therapy starts on-time. Additionally, it shows an independent correlation between the primary surgeon and the odds of starting radiation therapy on-time, indicating the importance of collaboration between surgeons and radiation oncologists.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153467",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mina Eskandar, BA",
      "presenter": "Mina Eskandar, BA",
      "authors": "Mina A Beshy, BA 1 ; Mina Eskandar, BA 2 ; Missak Haigentz, MD 3 ; Malini Patel, MD 3 ; Sivraj Muralikrishnan, MD 3 ; Taha A Mur, MD 1 ; Imraan Jan, MD 4 ; Sung Kim, MD 4 ; Craig A Bollig, MD 1",
      "normalized_authors": [
        "Mina A Beshy",
        "Mina Eskandar",
        "Missak Haigentz",
        "Malini Patel",
        "Sivraj Muralikrishnan",
        "Taha A Mur",
        "Imraan Jan",
        "Sung Kim",
        "Craig A Bollig"
      ],
      "affiliations": [
        "Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences",
        "Rutgers School of Graduate Studies",
        "Rutgers Cancer Institute of New Jersey - Department of Medical Oncology",
        "Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology"
      ],
      "normalized_institutions": [
        "Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences",
        "Rutgers School of Graduate Studies",
        "Rutgers Cancer Institute of New Jersey - Department of Medical Oncology",
        "Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 306,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mina A Beshy, BA 1 ; Mina Eskandar, BA 2 ; Missak Haigentz, MD 3 ; Malini Patel, MD 3 ; Sivraj Muralikrishnan, MD 3 ; Taha A Mur, MD 1 ; Imraan Jan, MD 4 ; Sung Kim, MD 4 ; Craig A Bollig, MD 1",
        "Affiliations": "1 Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences; 2 Rutgers School of Graduate Studies; 3 Rutgers Cancer Institute of New Jersey - Department of Medical Oncology; 4 Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology",
        "Objective": "Initiating post-operative radiation therapy by 6 weeks of surgery for patients with head and neck cancer has become a national benchmark. Delays beyond this are associated with increased mortality. In this study, we aim to identify clinical variables that are associated with successful start of post-operative radiation therapy (RT) within this timeframe.",
        "Study Design": "Retrospective cohort study",
        "Setting": "Tertiary care academic medical center.",
        "Methods": "Patient demographics and cancer characteristics were recorded in patients with head and neck cancer who had surgery at our institution between 2021-2025 and received adjuvant RT. The time from surgery to the start of RT was recorded. Delays were defined as initiation of RT after week 6 from surgery. Clinical variables associated with RT start by week 6 were identified using univariable and multivariable logistic regression. Odds Ratios (OR) with 95% Confidence Intervals (CI) were calculated. Statistical significance was defined as p <0.05.",
        "Results": "177 total patients were included in our study, of which 138 (78.0%) started post-operative radiation therapy by 6 weeks of surgery, while 39 (22.0%) were delayed. Expedited radiation oncology consults were associated with on-time radiation therapy start (97.8%, p <0.001). Interestingly, there were significant differences in the rate of timely administration of RT among surgeons (range: 35.3% to 91.8%, p <0.001). In the multivariable model expedited radiation oncology consult and operative surgeon were independently associated with increased odds of on-time start. Among the factors that were not significantly associated with on time start were in-patient dental consults, 30d readmission, postoperative complication, hospital length of stay, or RT treatment facility.",
        "Conclusion": "Overall, this study demonstrates the potential for expedited radiation oncology consultations in ensuring that radiation therapy starts on-time. Additionally, it shows an independent correlation between the primary surgeon and the odds of starting radiation therapy on-time, indicating the importance of collaboration between surgeons and radiation oncologists."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Factors Associated with Delays in Adjuvant Treatment in Head and Neck Cancer</span>. Mina A Beshy, BA<sup>1</sup>; <u>Mina Eskandar, BA</u><sup>2</sup>; Missak Haigentz, MD<sup>3</sup>; Malini Patel, MD<sup>3</sup>; Sivraj Muralikrishnan, MD<sup>3</sup>; Taha A Mur, MD<sup>1</sup>; Imraan Jan, MD<sup>4</sup>; Sung Kim, MD<sup>4</sup>; Craig A Bollig, MD<sup>1</sup>. <sup>1</sup>Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences; <sup>2</sup>Rutgers School of Graduate Studies; <sup>3</sup>Rutgers Cancer Institute of New Jersey - Department of Medical Oncology; <sup>4</sup>Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Initiating post-operative radiation therapy by 6 weeks of surgery for patients with head and neck cancer has become a national benchmark. Delays beyond this are associated with increased mortality. In this study, we aim to identify clinical variables that are associated with successful start of post-operative radiation therapy (RT) within this timeframe. </p>\n\n<p><strong>Study Design:</strong> Retrospective cohort study </p>\n\n<p><strong>Setting:</strong> Tertiary care academic medical center. </p>\n\n<p><strong>Methods:</strong> Patient demographics and cancer characteristics were recorded in patients with head and neck cancer who had surgery at our institution between 2021-2025 and received adjuvant RT. The time from surgery to the start of RT was recorded. Delays were defined as initiation of RT after week 6 from surgery. Clinical variables associated with RT start by week 6 were identified using univariable and multivariable logistic regression. Odds Ratios (OR) with 95% Confidence Intervals (CI) were calculated. Statistical significance was defined as p <0.05. </p>\n\n<p><strong>Results:</strong> 177 total patients were included in our study, of which 138 (78.0%) started post-operative radiation therapy by 6 weeks of surgery, while 39 (22.0%) were delayed. Expedited radiation oncology consults were associated with on-time radiation therapy start (97.8%, p <0.001). Interestingly, there were significant differences in the rate of timely administration of RT among surgeons (range: 35.3% to 91.8%, p <0.001). In the multivariable model expedited radiation oncology consult and operative surgeon were independently associated with increased odds of on-time start. Among the factors that were not significantly associated with on time start were in-patient dental consults, 30d readmission, postoperative complication, hospital length of stay, or RT treatment facility. </p>\n\n<p><strong>Conclusion:</strong> Overall, this study demonstrates the potential for expedited radiation oncology consultations in ensuring that radiation therapy starts on-time. Additionally, it shows an independent correlation between the primary surgeon and the odds of starting radiation therapy on-time, indicating the importance of collaboration between surgeons and radiation oncologists. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153467--></body></html>"
    },
    {
      "uid": "P319",
      "content_id": "154374",
      "abstract_number": "P319",
      "poster_number": "P319",
      "title": "Novel presentation of pediatric carotid sheath epithelioid sarcoma with rare EWSR1::CREM fusion",
      "summary": "Multidisciplinary, multi-institution discussion was utilized. From an Otolaryngologic perspective, the tumor was not deemed to be a favorable resection candidate due to encasement of the carotid artery. Therefore, concurrent radiation therapy and systemic therapy were pursued. The patient was started on pazopanib, a multiple kinase inhibitor utilized in targeting vascular endothelial growth factor receptor among...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154374",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna J Orr, MD",
      "presenter": "Anna J Orr, MD",
      "authors": "Kieley A Trempy, BS 1 ; Anna J Orr, MD 1 ; Eric Y Du, MD 1 ; Lester J Layfield, MD 2 ; Eliav Gov-Ari, MD 1",
      "normalized_authors": [
        "Kieley A Trempy",
        "Anna J Orr",
        "Eric Y Du",
        "Lester J Layfield",
        "Eliav Gov-Ari"
      ],
      "affiliations": [
        "Department of Otolaryngology, University of Missouri-Columbia",
        "Department of Pathology, University of Missouri-Columbia"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, University of Missouri-Columbia",
        "Department of Pathology, University of Missouri-Columbia"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Patient Presentation",
        "Diagnostics & Treatment",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Kieley A Trempy, BS 1 ; Anna J Orr, MD 1 ; Eric Y Du, MD 1 ; Lester J Layfield, MD 2 ; Eliav Gov-Ari, MD 1",
        "Affiliations": "1 Department of Otolaryngology, University of Missouri-Columbia; 2 Department of Pathology, University of Missouri-Columbia",
        "Patient Presentation": "An otherwise healthy 14-year-old female presented with a 2-month history of a growing right-sided neck, fatigue, night sweats, and unexplained weight loss. The mass was nontender and palpable in right levels 2 and 3. There was no maternal family history of lymphoma or leukemia, childhood cancers, or head and neck cancers, but paternal family history was unknown. No significant environmental exposures.",
        "Diagnostics & Treatment": "CT neck showed 3.3 x 3.5 x 7.0 cm fusiform hypoenhancing mass, encasing the right common/internal and external carotid. PET/CT showed no distant metastases with FDG avidity isolated to the neck mass (Figure 1). Fine needle aspiration was unable to fully assess the lesion but did favor a malignancy due to markedly atypical cells, with enlarged nuclei, prominent nucleoli, scant to moderate amount of cytoplasm. Therefore she was taken to the operating room for an incisional biopsy. Pathologic evaluation of the specimen revealed nests and cords of moderately pleomorphic epithelioid tumor cells with desmoplastic/fibromyxoid stroma (Figure 2). Immunohistochemical staining was not typical for any well-defined diagnosis but was reported to most closely resemble epithelioid fibrosarcoma and hyalinizing clear-cell carcinoma. Genetic sequencing did reveal a EWSR1-CREM fusion.",
        "Abstract": "Multidisciplinary, multi-institution discussion was utilized. From an Otolaryngologic perspective, the tumor was not deemed to be a favorable resection candidate due to encasement of the carotid artery. Therefore, concurrent radiation therapy and systemic therapy were pursued. The patient was started on pazopanib, a multiple kinase inhibitor utilized in targeting vascular endothelial growth factor receptor among others to inhibit angiogenesis. The patient had significant shrinkage of disease after completion of radiation and 5 months of systemic therapy with tumor size of 2.5 x 2.0 x 2.5 cm. Systemic imaging has not demonstrated any regional or distant metastases. cAMP responsive element modulator (CREM) is another member of the CREB family, with rare reports of EWSR1-CREM fusions. However, instead of the usual association with clear cell sarcoma, these isolated reports of EWSR1-CREM fusions have diverse associations, most often as intracranial mesenchymal tumors, and ranging from clear cell sarcomas, round cell sarcomas, angiomatoid fibrous histiocytomas, cystic hamartomas, and epithelioid neoplasms. Interestingly, despite the various morphologies of previous reports of EWSR1-CREM fusion malignancies, there are similarities in anatomical location of the tumors, most often reported as intracranial, as well as in the deep tissues of the extremities, and peritoneal. As the patient has demonstrated a positive response to radiation and chemotherapy with a smaller tumor size, the role of salvage resection is worth exploring. Permission was obtained by the patient and guardian to report this case.",
        "Discussion": "Ewing Sarcoma RNA Binding Protein 1 (EWSR1), hence the name, is a gene and protein product implicated in various sarcomas given its involvement in the regulation of transcription and RNA processing. Most commonly, fusions of EWSR1 occur with Fli-1 proto-oncogene (FLI1), in its namesake Ewing sarcoma."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Novel presentation of pediatric carotid sheath epithelioid sarcoma with rare EWSR1::CREM fusion</span>. Kieley A Trempy, BS<sup>1</sup>; <u>Anna J Orr, MD</u><sup>1</sup>; Eric Y Du, MD<sup>1</sup>; Lester J Layfield, MD<sup>2</sup>; Eliav Gov-Ari, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, University of Missouri-Columbia; <sup>2</sup>Department of Pathology, University of Missouri-Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Patient Presentation:</strong> An otherwise healthy 14-year-old female presented with a 2-month history of a growing right-sided neck, fatigue, night sweats, and unexplained weight loss. The mass was nontender and palpable in right levels 2 and 3. There was no maternal family history of lymphoma or leukemia, childhood cancers, or head and neck cancers, but paternal family history was unknown. No significant environmental exposures. </p>\n\n<p><strong>Diagnostics & Treatment:</strong> CT neck showed 3.3 x 3.5 x 7.0 cm fusiform hypoenhancing mass, encasing the right common/internal and external carotid. PET/CT showed no distant metastases with FDG avidity isolated to the neck mass (Figure 1). Fine needle aspiration was unable to fully assess the lesion but did favor a malignancy due to markedly atypical cells, with enlarged nuclei, prominent nucleoli, scant to moderate amount of cytoplasm.  Therefore she was taken to the operating room for an incisional biopsy. Pathologic evaluation of the specimen revealed nests and cords of moderately pleomorphic epithelioid tumor cells with desmoplastic/fibromyxoid stroma (Figure 2). Immunohistochemical staining was not typical for any well-defined diagnosis but was reported to most closely resemble epithelioid fibrosarcoma and hyalinizing clear-cell carcinoma. Genetic sequencing did reveal a EWSR1-CREM fusion. </p>\n\n<p>Multidisciplinary, multi-institution discussion was utilized. From an Otolaryngologic perspective, the tumor was not deemed to be a favorable resection candidate due to encasement of the carotid artery. Therefore, concurrent radiation therapy and systemic therapy were pursued. The patient was started on pazopanib, a multiple kinase inhibitor utilized in targeting vascular endothelial growth factor receptor among others to inhibit angiogenesis. The patient had significant shrinkage of disease after completion of radiation and 5 months of systemic therapy with tumor size of 2.5 x 2.0 x 2.5 cm. Systemic imaging has not demonstrated any regional or distant metastases. </p>\n\n<p><strong>Discussion:</strong> Ewing Sarcoma RNA Binding Protein 1 (EWSR1), hence the name, is a gene and protein product implicated in various sarcomas given its involvement in the regulation of transcription and RNA processing. Most commonly, fusions of EWSR1 occur with Fli-1 proto-oncogene (FLI1), in its namesake Ewing sarcoma. </p>\n\n<p>cAMP responsive element modulator (CREM) is another member of the CREB family, with rare reports of EWSR1-CREM fusions. However, instead of the usual association with clear cell sarcoma, these isolated reports of EWSR1-CREM fusions have diverse associations, most often as intracranial mesenchymal tumors, and ranging from clear cell sarcomas, round cell sarcomas, angiomatoid fibrous histiocytomas, cystic hamartomas, and epithelioid neoplasms. </p>\n\n<p>Interestingly, despite the various morphologies of previous reports of EWSR1-CREM fusion malignancies, there are similarities in anatomical location of the tumors, most often reported as intracranial, as well as in the deep tissues of the extremities, and peritoneal. As the patient has demonstrated a positive response to radiation and chemotherapy with a smaller tumor size, the role of salvage resection is worth exploring. Permission was obtained by the patient and guardian to report this case. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154374--></body></html>"
    },
    {
      "uid": "P320",
      "content_id": "152203",
      "abstract_number": "P320",
      "poster_number": "P320",
      "title": "Selective Field Reduction Lowers Toxicity Without Compromising Locoregional Control in Differentiated Thyroid Cancer",
      "summary": "RT field reduction in recurrent or high-risk DTC significantly decreases selected acute and late toxicities without compromising LRC. These findings support selective field limitation as a safe and effective strategy for appropriately staged patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152203",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shuai Wang",
      "presenter": "Shuai Wang",
      "authors": "Justin Choi 1 ; Shuai Wang 2 ; Eric Sherman 2 ; Edward Christopher Dee 2 ; Achraf Shamseddine 2 ; Yao Yu 2 ; Jennifer Ma 2 ; Nadeem Riaz 2 ; Sean McBride 2 ; Zeinab Abou Yehia 2 ; Alan Ho 2 ; Lara Dunn 2 ; Winston Wong 2 ; Michael Tuttle 2 ; James Fagin 2 ; Mona Sabra 2 ; Stephanie Fish 2 ; Jennifer Cracchiolo 2 ; Ian Ganly 2 ; Ashok Shaha 2 ; Richard Wong 2 ; Nancy Y Lee 2",
      "normalized_authors": [
        "Justin Choi",
        "Shuai Wang",
        "Eric Sherman",
        "Edward Christopher Dee",
        "Achraf Shamseddine",
        "Yao Yu",
        "Jennifer Ma",
        "Nadeem Riaz",
        "Sean McBride",
        "Zeinab Abou Yehia",
        "Alan Ho",
        "Lara Dunn",
        "Winston Wong",
        "Michael Tuttle",
        "James Fagin",
        "Mona Sabra",
        "Stephanie Fish",
        "Jennifer Cracchiolo",
        "Ian Ganly",
        "Ashok Shaha",
        "Richard Wong",
        "Nancy Y Lee"
      ],
      "affiliations": [
        "SUNY Downstate College of Medicine",
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "SUNY Downstate College of Medicine",
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152203/LRC%20By%20RT%20Field%20Coverage(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152203/LRC%20By%20RT%20Field%20Coverage(1).png",
          "alt": "Locoregional Control (LRC) by RT Field Coverage",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152203"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Justin Choi 1 ; Shuai Wang 2 ; Eric Sherman 2 ; Edward Christopher Dee 2 ; Achraf Shamseddine 2 ; Yao Yu 2 ; Jennifer Ma 2 ; Nadeem Riaz 2 ; Sean McBride 2 ; Zeinab Abou Yehia 2 ; Alan Ho 2 ; Lara Dunn 2 ; Winston Wong 2 ; Michael Tuttle 2 ; James Fagin 2 ; Mona Sabra 2 ; Stephanie Fish 2 ; Jennifer Cracchiolo 2 ; Ian Ganly 2 ; Ashok Shaha 2 ; Richard Wong 2 ; Nancy Y Lee 2",
        "Affiliations": "1 SUNY Downstate College of Medicine; 2 Memorial Sloan Kettering Cancer Center",
        "Introduction": "External beam radiotherapy (RT) is used for upfront high risk, gross residual, unresected or recurrent differentiated thyroid cancer (DTC) when further surgery or targeted therapies are not recommended. Although RT can improve locoregional control (LRC), head and neck RT toxicities remain a concern. De-escalation of RT fields is therefore an attractive option for DTC as it can potentially mitigate toxicities. Whether field reduction can lessen toxicity while maintaining tumor control in advanced DTC has not been defined. We evaluated a large single institution cohort of DTC that underwent RT to assess the impact of smaller RT fields on toxicity and LRC.",
        "Methods": "RT plans that were available for 275 consecutive patients treated from 1999–2023 for upfront high risk, gross residual, unresected, or recurrent DTC were retrospectively reviewed. Treatment fields were classified as: (1) Comprehensive – bilateral central compartment and bilateral necks; (2) Ipsilateral – central compartment plus ipsilateral neck; or (3) Central – central compartment only. All patients received IMRT; median dose to gross disease was 70 Gy (IQR: 60-70 Gy) given over a median 33 fractions. There were 136 patients (49.5%) that received concurrent chemotherapy, which did not differ across field types. Acute toxicities were defined as worst grade within 90 days of RT start (CTCAE criteria) and late toxicities were those thereafter (RTOG criteria), grouping grades 0-1 versus grades 2+ and compared across field types using chi-square tests in SAS 9.4. LRC within the treatment field was assessed using the Kaplan–Meier method.",
        "Results": "Among 275 patients, 102 (37%) received comprehensive, 112 (41%) ipsilateral, and 61 (22%) central fields. Group differences in acute grade 2+ toxicities were observed in xerostomia (36% comprehensive, 18% ipsilateral, 13% central, p = .001), dysphagia (58% comprehensive, 47% ipsilateral, 37% central, p = .03), voice changes (39% comprehensive, 22% ipsilateral, 28% central, p = .03) and fatigue (41% comprehensive, 28% ipsilateral, 22% central, p = .02). Other acute toxicities of dermatitis, nausea/vomiting, mucositis, and dysgeusia did not differ.",
        "Abstract": "Group differences in late grade 2+ toxicities were observed in xerostomia (16% comprehensive, 6% ipsilateral, 7% central, p = .04) and dysphagia (22% comprehensive, 6% ipsilateral, 9% central, p = .001). Other late toxicities of voice changes, taste changes, laryngeal edema, or fibrosis did not differ. The overall 5- and 10-year LRC rates were 90.9% and 81.8% respectively. Twenty-seven patients experienced in-field failure at a median of 22.2 months (range 1.2–121.0). Median follow-up for surviving patients was 71.8 months. In-field failure rates were 12/102 (11.8%) for comprehensive, 10/112 (8.9%) for ipsilateral, and 5/61 (8.2%) for central fields, with no difference in LRC across groups (p = .50). Additional to the 5 in-field central compartment failures were 4 out-of-field regional failures, including 3 lateral neck recurrences successfully salvaged with neck dissections.",
        "Conclusion": "RT field reduction in recurrent or high-risk DTC significantly decreases selected acute and late toxicities without compromising LRC. These findings support selective field limitation as a safe and effective strategy for appropriately staged patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Selective Field Reduction Lowers Toxicity Without Compromising Locoregional Control in Differentiated Thyroid Cancer</span>. Justin Choi<sup>1</sup>; <u>Shuai Wang</u><sup>2</sup>; Eric Sherman<sup>2</sup>; Edward Christopher Dee<sup>2</sup>; Achraf Shamseddine<sup>2</sup>; Yao Yu<sup>2</sup>; Jennifer Ma<sup>2</sup>; Nadeem Riaz<sup>2</sup>; Sean McBride<sup>2</sup>; Zeinab Abou Yehia<sup>2</sup>; Alan Ho<sup>2</sup>; Lara Dunn<sup>2</sup>; Winston Wong<sup>2</sup>; Michael Tuttle<sup>2</sup>; James Fagin<sup>2</sup>; Mona Sabra<sup>2</sup>; Stephanie Fish<sup>2</sup>; Jennifer Cracchiolo<sup>2</sup>; Ian Ganly<sup>2</sup>; Ashok Shaha<sup>2</sup>; Richard Wong<sup>2</sup>; Nancy Y Lee<sup>2</sup>. <sup>1</sup>SUNY Downstate College of Medicine; <sup>2</sup>Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>External beam radiotherapy (RT) is used for upfront high risk, gross residual, unresected or recurrent differentiated thyroid cancer (DTC) when further surgery or targeted therapies are not recommended. Although RT can improve locoregional control (LRC), head and neck RT toxicities remain a concern. De-escalation of RT fields is therefore an attractive option for DTC as it can potentially mitigate toxicities. Whether field reduction can lessen toxicity while maintaining tumor control in advanced DTC has not been defined. We evaluated a large single institution cohort of DTC that underwent RT to assess the impact of smaller RT fields on toxicity and LRC.</p>\n\n<p><strong>Methods: </strong>RT plans that were available for 275 consecutive patients treated from 1999–2023 for upfront high risk, gross residual, unresected, or recurrent DTC were retrospectively reviewed. Treatment fields were classified as: (1) Comprehensive – bilateral central compartment and bilateral necks; (2) Ipsilateral – central compartment plus ipsilateral neck; or (3) Central – central compartment only. All patients received IMRT; median dose to gross disease was 70 Gy (IQR: 60-70 Gy) given over a median 33 fractions. There were 136 patients (49.5%) that received concurrent chemotherapy, which did not differ across field types. Acute toxicities were defined as worst grade within 90 days of RT start (CTCAE criteria) and late toxicities were those thereafter (RTOG criteria), grouping grades 0-1 versus grades 2+ and compared across field types using chi-square tests in SAS 9.4. LRC within the treatment field was assessed using the Kaplan–Meier method.</p>\n\n<p><strong>Results: </strong>Among 275 patients, 102 (37%) received comprehensive, 112 (41%) ipsilateral, and 61 (22%) central fields. Group differences in acute grade 2+ toxicities were observed in xerostomia (36% comprehensive, 18% ipsilateral, 13% central, p = .001), dysphagia (58% comprehensive, 47% ipsilateral, 37% central, p = .03), voice changes (39% comprehensive, 22% ipsilateral, 28% central, p = .03) and fatigue (41% comprehensive, 28% ipsilateral, 22% central, p = .02). Other acute toxicities of dermatitis, nausea/vomiting, mucositis, and dysgeusia did not differ.</p>\n\n<p>Group differences in late grade 2+ toxicities were observed in xerostomia (16% comprehensive, 6% ipsilateral, 7% central, p = .04) and dysphagia (22% comprehensive, 6% ipsilateral, 9% central, p = .001). Other late toxicities of voice changes, taste changes, laryngeal edema, or fibrosis did not differ.</p>\n\n<p>The overall 5- and 10-year LRC rates were 90.9% and 81.8% respectively. Twenty-seven patients experienced in-field failure at a median of 22.2 months (range 1.2–121.0). Median follow-up for surviving patients was 71.8 months. In-field failure rates were 12/102 (11.8%) for comprehensive, 10/112 (8.9%) for ipsilateral, and 5/61 (8.2%) for central fields, with no difference in LRC across groups (p = .50). Additional to the 5 in-field central compartment failures were 4 out-of-field regional failures, including 3 lateral neck recurrences successfully salvaged with neck dissections.</p>\n\n<p><strong>Conclusion: </strong>RT field reduction in recurrent or high-risk DTC significantly decreases selected acute and late toxicities without compromising LRC. These findings support selective field limitation as a safe and effective strategy for appropriately staged patients.</p>\n\n<p><img alt='Locoregional Control (LRC) by RT Field Coverage' src='https://www.submitmyabstract.com/abs/images/152203/LRC%20By%20RT%20Field%20Coverage(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152203--></body></html>"
    },
    {
      "uid": "P322",
      "content_id": "155572",
      "abstract_number": "P322",
      "poster_number": "P322",
      "title": "Incidence of Carotid Artery Stenosis Following Radiotherapy for Head and Neck Cancer: A Propensity Score-Matched TriNetX Cohort Study",
      "summary": "Head and neck radiotherapy was associated with a substantially increased incidence of carotid artery stenosis and other thromboembolic and vascular complications in this large real-world cohort. These findings underscore the need for long-term vascular surveillance and risk-factor optimization in HNC survivors treated with radiotherapy and support multidisciplinary strategies to mitigate late vascular toxicity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155572",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jacob J Swan",
      "presenter": "Jacob J Swan",
      "authors": "Jacob J Swan ; Warren B Chun; Shaun A Nguyen; Dauren Adilbay; William G Albergotti",
      "normalized_authors": [
        "Jacob J Swan",
        "Warren B Chun",
        "Shaun A Nguyen",
        "Dauren Adilbay",
        "William G Albergotti"
      ],
      "affiliations": [
        "Medical University Of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University Of South Carolina"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 429,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background/Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jacob J Swan ; Warren B Chun; Shaun A Nguyen; Dauren Adilbay; William G Albergotti",
        "Affiliations": "Medical University Of South Carolina",
        "Background/Objective": "Radiation therapy for head and neck cancer (HNC) has been associated with long term vascular complications, likely driven by radiation-induced endothelial injury. However, large-scale population-based data on carotid artery stenosis following HNC radiotherapy remain limited. This study aimed to determine the incidence of carotid artery stenosis among patients receiving HNC radiotherapy, compared to propensity-matched patients without radiation exposure.",
        "Methods": "This is a retrospective cohort study using TriNetX’s global collaborative network, a real-world database containing secure, de-identified patient data from 171 healthcare organizations. Adult patients (≥18 years old) with HNC were identified and stratified into cohorts exposed versus not exposed to head and neck radiotherapy; both cohorts required baseline treatment with surgery and chemotherapy. Propensity score matching (1:1) was used to balance baseline characteristics including age, race, sex, TNM designation, malignancy stage, hypertensive diseases, chronic kidney disease, atherosclerotic disease, diabetes, hyperlipidemia, BMI, nicotine dependence, malignancy location, antiplatelet medications, HMG CoA reductase inhibitors, and other cardiovascular medications. Outcomes were assessed beginning 1 year after the index event and continued through the available follow-up period. The primary outcome was incident carotid artery stenosis; secondary outcomes included myocardial infarction, deep venous thrombosis, pulmonary embolism, and vascular dementia. Measures of association and Kaplan-Meier analyses were used to compare the hazard and survival probability between cohorts, with effect estimates reported as hazard ratios (HRs) and 95% confidence intervals (CIs). Absolute risks and risk differences (RDs) with 95% CIs were also calculated for each outcome.",
        "Results": "Propensity score matching yielded 19,884 patients in both the radiotherapy and no-radiotherapy cohorts. Patients receiving radiotherapy had a significantly higher incidence of carotid artery stenosis (7.96% vs. 4.42%; RD 3.55%, 95% CI 3.07%-4.02%, p < .0001). At the end of follow-up, survival probability free of carotid stenosis was 69.94% in the radiotherapy cohort versus 79.65% in controls (HR 1.81, 95% CI 1.67-1.97, p < .0001). Secondary analyses showed higher risks of myocardial infarction (HR 1.99, 95% CI 1.75-2.25, p = 0.004), deep venous thrombosis (HR 2.06, 95% CI 1.72-2.48, p = .01), pulmonary embolism (HR 2.53, 95% CI 2.08-3.08, p = 0.007), and vascular dementia (HR 1.54, 95% CI 1.09-2.17, p = 0.03) among radiotherapy-exposed patients.",
        "Conclusion": "Head and neck radiotherapy was associated with a substantially increased incidence of carotid artery stenosis and other thromboembolic and vascular complications in this large real-world cohort. These findings underscore the need for long-term vascular surveillance and risk-factor optimization in HNC survivors treated with radiotherapy and support multidisciplinary strategies to mitigate late vascular toxicity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence of Carotid Artery Stenosis Following Radiotherapy for Head and Neck Cancer: A Propensity Score-Matched TriNetX Cohort Study</span>. <u>Jacob J Swan</u>; Warren B Chun; Shaun A Nguyen; Dauren Adilbay; William G Albergotti. Medical University Of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background/Objective:</strong> Radiation therapy for head and neck cancer (HNC) has been associated with long term vascular complications, likely driven by radiation-induced endothelial injury. However, large-scale population-based data on carotid artery stenosis following HNC radiotherapy remain limited. This study aimed to determine the incidence of carotid artery stenosis among patients receiving HNC radiotherapy, compared to propensity-matched patients without radiation exposure. </p>\n\n<p><strong>Methods:</strong> This is a retrospective cohort study using TriNetX’s global collaborative network, a real-world database containing secure, de-identified patient data from 171 healthcare organizations. Adult patients (≥18 years old) with HNC were identified and stratified into cohorts exposed versus not exposed to head and neck radiotherapy; both cohorts required baseline treatment with surgery and chemotherapy. Propensity score matching (1:1) was used to balance baseline characteristics including age, race, sex, TNM designation, malignancy stage, hypertensive diseases, chronic kidney disease, atherosclerotic disease, diabetes, hyperlipidemia, BMI, nicotine dependence, malignancy location, antiplatelet medications, HMG CoA reductase inhibitors, and other cardiovascular medications. Outcomes were assessed beginning 1 year after the index event and continued through the available follow-up period. The primary outcome was incident carotid artery stenosis; secondary outcomes included myocardial infarction, deep venous thrombosis, pulmonary embolism, and vascular dementia. Measures of association and Kaplan-Meier analyses were used to compare the hazard and survival probability between cohorts, with effect estimates reported as hazard ratios (HRs) and 95% confidence intervals (CIs). Absolute risks and risk differences (RDs) with 95% CIs were also calculated for each outcome.</p>\n\n<p><strong>Results:</strong><em><strong> </strong></em>Propensity score matching yielded 19,884 patients in both the radiotherapy and no-radiotherapy cohorts. Patients receiving radiotherapy had a significantly higher incidence of carotid artery stenosis (7.96% vs. 4.42%; RD 3.55%, 95% CI 3.07%-4.02%, p < .0001). At the end of follow-up, survival probability free of carotid stenosis was 69.94% in the radiotherapy cohort versus 79.65% in controls (HR 1.81, 95% CI 1.67-1.97, p < .0001). Secondary analyses showed higher risks of myocardial infarction (HR 1.99, 95% CI 1.75-2.25, p = 0.004), deep venous thrombosis (HR 2.06, 95% CI 1.72-2.48, p = .01), pulmonary embolism (HR 2.53, 95% CI 2.08-3.08, p = 0.007), and vascular dementia (HR 1.54, 95% CI 1.09-2.17, p = 0.03) among radiotherapy-exposed patients.</p>\n\n<p><strong>Conclusion:</strong> Head and neck radiotherapy was associated with a substantially increased incidence of carotid artery stenosis and other thromboembolic and vascular complications in this large real-world cohort. These findings underscore the need for long-term vascular surveillance and risk-factor optimization in HNC survivors treated with radiotherapy and support multidisciplinary strategies to mitigate late vascular toxicity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155572--></body></html>"
    },
    {
      "uid": "P323",
      "content_id": "155566",
      "abstract_number": "P323",
      "poster_number": "P323",
      "title": "Hypothyroidism Following Narrow Field Radiation Treatment of Laryngeal Squamous Cell Carcinoma",
      "summary": "In this veteran cohort, narrow-beam radiation for early-stage laryngeal SCC results in a 5-year cumulative incidence of hypothyroidism of 38.1%, which is consistent with current literature rates. The median time to developing hypothyroidism in patients who did not undergo TL was 17 months. This suggests that patients who have undergone radiation treatment of laryngeal cancer should continue to be monitored for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155566",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michelle K Hong, MD",
      "presenter": "Michelle K Hong, MD",
      "authors": "Michelle K Hong, MD ; Cheryl Yu, MD; Ray Y Wang, MD",
      "normalized_authors": [
        "Michelle K Hong",
        "Cheryl Yu",
        "Ray Y Wang"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 315,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Michelle K Hong, MD ; Cheryl Yu, MD; Ray Y Wang, MD",
        "Affiliations": "Baylor College of Medicine",
        "Introduction": "It is well-known that patients with laryngeal squamous cell carcinoma (SCC) treated with radiation have a significant risk of hypothyroidism due to incidental exposure of the thyroid gland during treatment, with modern estimates of incidence reaching 40-50%. This study investigates the incidence and timing of hypothyroidism in a veteran population receiving narrow beam radiation for early-stage laryngeal SCC.",
        "Methods": "This a retrospective study of a patient cohort at a tertiary Veteran Affairs medical center treated with narrow field radiation for T1-T2 laryngeal SCC. Patients who had pre-existing hypothyroidism and patients that did not have a post-radiation TSH value were excluded from analysis. Cumulative incidence of hypothyroidism was performed using the Kaplan-Meier method.",
        "Results": "121 patients met the inclusion criteria with a median follow-up of 60 months. The median dose of radiation was 66Gy. 49 patients developed hypothyroidism after radiation (40%). The 5-year cumulative incidence of hypothyroidism for the entire cohort was 38.1% (95% CI: 27.4-47.3%). 23 patients underwent salvage total laryngectomy (TL) for disease recurrence and of these, 20 patients (87%) developed hypothyroidism. Cumulative incidence of hypothyroidism was lower at 33.4% (95% CI: 21.2-43.8%) at 5 years for those without TL compared to 56.5% (95% CI: 30.7-72.7%) for patients requiring TL. The median time to developing hypothyroidism in patients who did not undergo TL was 17 months.",
        "Conclusions": "In this veteran cohort, narrow-beam radiation for early-stage laryngeal SCC results in a 5-year cumulative incidence of hypothyroidism of 38.1%, which is consistent with current literature rates. The median time to developing hypothyroidism in patients who did not undergo TL was 17 months. This suggests that patients who have undergone radiation treatment of laryngeal cancer should continue to be monitored for hypothyroidism for an extended period after radiation. Additionally, the combination of surgical trauma and radiation exposure to the thyroid gland in TL patients significantly increases the incidence of hypothyroidism."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Hypothyroidism Following Narrow Field Radiation Treatment of Laryngeal Squamous Cell Carcinoma</span>. <u>Michelle K Hong, MD</u>; Cheryl Yu, MD; Ray Y Wang, MD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> It is well-known that patients with laryngeal squamous cell carcinoma (SCC) treated with radiation have a significant risk of hypothyroidism due to incidental exposure of the thyroid gland during treatment, with modern estimates of incidence reaching 40-50%. This study investigates the incidence and timing of hypothyroidism in a veteran population receiving narrow beam radiation for early-stage laryngeal SCC.</p>\n\n<p><strong>Methods: </strong>This a retrospective study of a patient cohort at a tertiary Veteran Affairs medical center treated with narrow field radiation for T1-T2 laryngeal SCC. Patients who had pre-existing hypothyroidism and patients that did not have a post-radiation TSH value were excluded from analysis. Cumulative incidence of hypothyroidism was performed using the Kaplan-Meier method.</p>\n\n<p><strong>Results: </strong>121 patients met the inclusion criteria with a median follow-up of 60 months. The median dose of radiation was 66Gy. 49 patients developed hypothyroidism after radiation (40%). The 5-year cumulative incidence of hypothyroidism for the entire cohort was 38.1% (95% CI: 27.4-47.3%). 23 patients underwent salvage total laryngectomy (TL) for disease recurrence and of these, 20 patients (87%) developed hypothyroidism. Cumulative incidence of hypothyroidism was lower at 33.4% (95% CI: 21.2-43.8%) at 5 years for those without TL compared to 56.5% (95% CI: 30.7-72.7%) for patients requiring TL. The median time to developing hypothyroidism in patients who did not undergo TL was 17 months.</p>\n\n<p><strong>Conclusions:</strong> In this veteran cohort, narrow-beam radiation for early-stage laryngeal SCC results in a 5-year cumulative incidence of hypothyroidism of 38.1%, which is consistent with current literature rates. The median time to developing hypothyroidism in patients who did not undergo TL was 17 months. This suggests that patients who have undergone radiation treatment of laryngeal cancer should continue to be monitored for hypothyroidism for an extended period after radiation. Additionally, the combination of surgical trauma and radiation exposure to the thyroid gland in TL patients significantly increases the incidence of hypothyroidism.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155566--></body></html>"
    },
    {
      "uid": "P325",
      "content_id": "153992",
      "abstract_number": "P325",
      "poster_number": "P325",
      "title": "Impact of Nurse Navigation on Time to Adjuvant Radiation Therapy after TORS for Oropharyngeal Squamous Cell Cancer",
      "summary": "Introduction of an oncology nurse navigator was associated with a statistically significant reduction in time from TORS to initiation of adjuvant RT for OPSCC. This improvement extended across affiliated hospitals within our hospital system, demonstrating the efficacy of these interventions in optimizing adjuvant treatment care coordination and reducing treatment delays.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153992",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vera Bzhilyanskaya, BS",
      "presenter": "Vera Bzhilyanskaya, BS",
      "authors": "Vera Bzhilyanskaya, BS ; Jane Y Tong, MD; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD",
      "normalized_authors": [
        "Vera Bzhilyanskaya",
        "Jane Y Tong",
        "Kelly Moyer",
        "Jeffrey Wolf",
        "Rodney Taylor",
        "Ranee Mehra",
        "Kyle M Hatten"
      ],
      "affiliations": [
        "University of Maryland School of Medicine"
      ],
      "normalized_institutions": [
        "University of Maryland School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 482,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Vera Bzhilyanskaya, BS ; Jane Y Tong, MD; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD",
        "Affiliations": "University of Maryland School of Medicine",
        "Objective": "Timely initiation of adjuvant radiation therapy (RT) following surgical resection for head and neck cancer is associated with improved oncologic outcomes. Guidelines recommend initiating postoperative RT within six weeks, however many barriers to timely initiation exist. Prior studies have shown that multidisciplinary tumor boards and oncology nurse navigators can reduce treatment delays by improving care coordination. This study evaluates the impact of these interventions at our tertiary academic medical center on time to initiation of adjuvant RT following transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC).",
        "Study Design": "Retrospective cohort study of patients treated with TORS and adjuvant therapy from January 2016 to December 2024 at a tertiary academic medical center.",
        "Methods": "Patient demographics, oncologic treatment course, and disease characteristics were extracted from electronic medical records. Time from TORS to initiation of adjuvant therapy was compared between patients treated before (2016-2019) and after (2020-2024) introduction of a virtual multidisciplinary tumor board and oncology nurse navigator.",
        "Results": "Ninety-nine patients were included. Thirty-seven were treated from 2016 to 2019, and 62 from 2020 to 2024. Median age was 60 years. Most patients were male (85.9%) and White (88.9%). The most common pathological tumor stage was pT1 (57.6%). Adjuvant treatment consisted of RT alone in 60.6% and chemoradiation in 39.4%. Proton beam therapy (PBT) was used in 50.5% of patients and photon-based radiation therapy was used in 49.5%. Most (76.8%) patients received adjuvant treatment within our hospital system. With median follow-up of 3.1 years, 10.1% had locoregional recurrence, 9.1% had distant metastases, and 7.1% had died.",
        "Abstract": "Implementation of an oncology nurse navigator was associated with a significant reduction in time from surgical resection to initiation of adjuvant RT. Patients treated from 2016 to 2019 experienced significantly greater delay than those treated from 2020 to 2024 (2016 to 2019: 49 days, 2020 to 2024: 44 days, p = 0.045). On subgroup analysis, this finding persisted among patients treated within our hospital system (2016 to 2019: 49 days, 2020 to 2024: 43.5 days, p = 0.047), however no significant difference was observed in patients treated at outside medical centers (2016 to 2019: 46 days, 2020 to 2024: 45 days, p = 0.54). When stratified by radiation modality, patients treated with PBT experienced a significant reduction in time to RT (2016 - 2019: 49 days, 2020 - 2024: 44 days, p = 0.008). Notably, adherence to the recommended six-week timeframe for initiation of adjuvant RT also improved among patients treated with PBT, increasing from 0% in 2016 to 2019 to 36.8% in 2020 to 2024 ( p = 0.013).",
        "Conclusion": "Introduction of an oncology nurse navigator was associated with a statistically significant reduction in time from TORS to initiation of adjuvant RT for OPSCC. This improvement extended across affiliated hospitals within our hospital system, demonstrating the efficacy of these interventions in optimizing adjuvant treatment care coordination and reducing treatment delays."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Nurse Navigation on Time to Adjuvant Radiation Therapy after TORS for Oropharyngeal Squamous Cell Cancer</span>. <u>Vera Bzhilyanskaya, BS</u>; Jane Y Tong, MD; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD. University of Maryland School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Timely initiation of adjuvant radiation therapy (RT) following surgical resection for head and neck cancer is associated with improved oncologic outcomes. Guidelines recommend initiating postoperative RT within six weeks, however many barriers to timely initiation exist. Prior studies have shown that multidisciplinary tumor boards and oncology nurse navigators can reduce treatment delays by improving care coordination. This study evaluates the impact of these interventions at our tertiary academic medical center on time to initiation of adjuvant RT following transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC).</p>\n\n<p><strong>Study Design: </strong>Retrospective cohort study of patients treated with TORS and adjuvant therapy from January 2016 to December 2024 at a tertiary academic medical center.</p>\n\n<p><strong>Methods:</strong> Patient demographics, oncologic treatment course, and disease characteristics were extracted from electronic medical records. Time from TORS to initiation of adjuvant therapy was compared between patients treated before (2016-2019) and after (2020-2024) introduction of a virtual multidisciplinary tumor board and oncology nurse navigator.</p>\n\n<p><strong>Results: </strong>Ninety-nine patients were included. Thirty-seven were treated from 2016 to 2019, and 62 from 2020 to 2024. Median age was 60 years. Most patients were male (85.9%) and White (88.9%). The most common pathological tumor stage was pT1 (57.6%). Adjuvant treatment consisted of RT alone in 60.6% and chemoradiation in 39.4%. Proton beam therapy (PBT) was used in 50.5% of patients and photon-based radiation therapy was used in 49.5%. Most (76.8%) patients received adjuvant treatment within our hospital system. With median follow-up of 3.1 years, 10.1% had locoregional recurrence, 9.1% had distant metastases, and 7.1% had died.</p>\n\n<p>Implementation of an oncology nurse navigator was associated with a significant reduction in time from surgical resection to initiation of adjuvant RT. Patients treated from 2016 to 2019 experienced significantly greater delay than those treated from 2020 to 2024 (2016 to 2019: 49 days, 2020 to 2024: 44 days, <em>p</em> = 0.045). On subgroup analysis, this finding persisted among patients treated within our hospital system (2016 to 2019: 49 days, 2020 to 2024: 43.5 days, <em>p</em> = 0.047), however no significant difference was observed in patients treated at outside medical centers (2016 to 2019: 46 days, 2020 to 2024: 45 days, <em>p</em> = 0.54). When stratified by radiation modality, patients treated with PBT experienced a significant reduction in time to RT (2016 - 2019: 49 days, 2020 - 2024: 44 days, <em>p</em> = 0.008). Notably, adherence to the recommended six-week timeframe for initiation of adjuvant RT also improved among patients treated with PBT, increasing from 0% in 2016 to 2019 to 36.8% in 2020 to 2024 (<em>p</em> = 0.013).</p>\n\n<p><strong>Conclusion</strong>: Introduction of an oncology nurse navigator was associated with a statistically significant reduction in time from TORS to initiation of adjuvant RT for OPSCC. This improvement extended across affiliated hospitals within our hospital system, demonstrating the efficacy of these interventions in optimizing adjuvant treatment care coordination and reducing treatment delays.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153992--></body></html>"
    },
    {
      "uid": "P326",
      "content_id": "153445",
      "abstract_number": "P326",
      "poster_number": "P326",
      "title": "Use of Extracorporeal Membrane Oxygenation (ECMO) to Facilitate Tracheostomy in a High-Risk Airway: A Case-Based Approach and Review of the Literature",
      "summary": "ECMO can serve as a life-saving adjunct in performing tracheostomy in patients with high-risk airways. Successful outcomes depend on the identification of airway risk, multidisciplinary coordination, and meticulous perioperative planning.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153445",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alisa L Phillips, MD, MSc",
      "presenter": "Alisa L Phillips, MD, MSc",
      "authors": "Alisa L Phillips, MD, MSc ; Morgan Terry, MD; Mark Wax, MD; Daniel Clayburgh, MD, PhD",
      "normalized_authors": [
        "Alisa L Phillips",
        "Morgan Terry",
        "Mark Wax",
        "Daniel Clayburgh"
      ],
      "affiliations": [
        "Oregon Health & Science University"
      ],
      "normalized_institutions": [
        "Oregon Health & Science University"
      ],
      "session_type": "Poster",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 435,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alisa L Phillips, MD, MSc ; Morgan Terry, MD; Mark Wax, MD; Daniel Clayburgh, MD, PhD",
        "Affiliations": "Oregon Health & Science University",
        "Background": "Tracheostomy in patients with compromised airways—such as those with severe upper airway obstruction, distorted anatomy, or high oxygen requirements—pose significant perioperative challenges. Conventional airway management techniques such as awake tracheostomy or awake fiberoptic intubation may fail or carry unacceptable risks of hypoxia and hemodynamic instability. Extracorporeal membrane oxygenation (ECMO) has emerged as a potential adjunct to safely secure the airway in these rare complex scenarios.",
        "Methods": "We present a 36-year-old with severe upper airway obstruction secondary to metastatic neuroendocrine tumor with anticipated loss of airway upon induction of anesthesia.",
        "Abstract": "In 2013, the patient was diagnosed with a low-grade lung carcinoid neuroendocrine tumor. Metastatic disease was identified in 2018, with subsequent progression to the left thyroid lobe in 2021 requiring hemithyroidectomy, and to the left parotid gland in 2022 requiring left parotidectomy. In March 2025, imaging revealed a paratracheal mass causing tracheal compression, resulting in a stenosis measuring 5mm at its narrowest point. A debulking procedure was performed in August 2025. Airway management required a fiberoptic awake intubation with a 5.0 endotracheal tube (ETT). During the procedure, intermittent obstruction of the ETT occurred, placing the patient at risk for airway compromise. Tracheostomy was avoided due to the tumor’s location and concern for invasion. Following the procedure, the patient was able to maintain his active lifestyle until initiation of palliative radiation therapy. In October, he underwent two rounds of palliative radiation and subsequently presented with acute-onset upper airway obstruction. Simulation imaging obtained for radiation demonstrated progressive tracheal narrowing compared to imaging prior to the debulking procedure. Based on these findings, it was determined that securing the airway using a standard awake fiberoptic intubation approach would be unsafe. They underwent successful tracheostomy under veno-venous ECMO support. A multidisciplinary team (otolaryngology, anesthesia, and critical care specialists) coordinated perioperative management. He experienced immediate relief post-operatively and was able to complete his palliative radiation therapy and initiate palliative chemotherapy.",
        "Results": "ECMO provided adequate oxygenation and ventilation throughout the tracheostomy, allowing for a controlled and hemodynamically stable procedure without hypoxic events. The tumor invaded the trachea, narrowing the lumen significantly. The additional time afforded by ECMO allowed the appropriate tracheostomy tube to be passed beyond tumor and perform intraoperative bronchoscopy to confirm placement. The patient was decannulated from ECMO postoperatively without complications. Review of published cases supports ECMO as a viable bridge to airway stabilization that should be considered in select high-risk patients when conventional methods are unsafe or infeasible.",
        "Conclusion": "ECMO can serve as a life-saving adjunct in performing tracheostomy in patients with high-risk airways. Successful outcomes depend on the identification of airway risk, multidisciplinary coordination, and meticulous perioperative planning."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Extracorporeal Membrane Oxygenation (ECMO) to Facilitate Tracheostomy in a High-Risk Airway: A Case-Based Approach and Review of the Literature</span>. <u>Alisa L Phillips, MD, MSc</u>; Morgan Terry, MD; Mark Wax, MD; Daniel Clayburgh, MD, PhD. Oregon Health & Science University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Tracheostomy in patients with compromised airways—such as those with severe upper airway obstruction, distorted anatomy, or high oxygen requirements—pose significant perioperative challenges. Conventional airway management techniques such as awake tracheostomy or awake fiberoptic intubation may fail or carry unacceptable risks of hypoxia and hemodynamic instability. Extracorporeal membrane oxygenation (ECMO) has emerged as a potential adjunct to safely secure the airway in these rare complex scenarios. </p>\n\n<p><strong>Methods: </strong>We present a 36-year-old with severe upper airway obstruction secondary to metastatic neuroendocrine tumor with anticipated loss of airway upon induction of anesthesia. </p>\n\n<p>In 2013, the patient was diagnosed with a low-grade lung carcinoid neuroendocrine tumor. Metastatic disease was identified in 2018, with subsequent progression to the left thyroid lobe in 2021 requiring hemithyroidectomy, and to the left parotid gland in 2022 requiring left parotidectomy. </p>\n\n<p>In March 2025, imaging revealed a paratracheal mass causing tracheal compression, resulting in a stenosis measuring 5mm at its narrowest point. A debulking procedure was performed in August 2025. Airway management required a fiberoptic awake intubation with a 5.0 endotracheal tube (ETT). During the procedure, intermittent obstruction of the ETT occurred, placing the patient at risk for airway compromise. Tracheostomy was avoided due to the tumor’s location and concern for invasion. Following the procedure, the patient was able to maintain his active lifestyle until initiation of palliative radiation therapy. </p>\n\n<p>In October, he underwent two rounds of palliative radiation and subsequently presented with acute-onset upper airway obstruction. Simulation imaging obtained for radiation demonstrated progressive tracheal narrowing compared to imaging prior to the debulking procedure. Based on these findings, it was determined that securing the airway using a standard awake fiberoptic intubation approach would be unsafe. </p>\n\n<p>They underwent successful tracheostomy under veno-venous ECMO support. A multidisciplinary team (otolaryngology, anesthesia, and critical care specialists) coordinated perioperative management. He experienced immediate relief post-operatively and was able to complete his palliative radiation therapy and initiate palliative chemotherapy. </p>\n\n<p><strong>Results: </strong>ECMO provided adequate oxygenation and ventilation throughout the tracheostomy, allowing for a controlled and hemodynamically stable procedure without hypoxic events. The tumor invaded the trachea, narrowing the lumen significantly. The additional time afforded by ECMO allowed the appropriate tracheostomy tube to be passed beyond tumor and perform intraoperative bronchoscopy to confirm placement. The patient was decannulated from ECMO postoperatively without complications. Review of published cases supports ECMO as a viable bridge to airway stabilization that should be considered in select high-risk patients when conventional methods are unsafe or infeasible. </p>\n\n<p><strong>Conclusion: </strong>ECMO can serve as a life-saving adjunct in performing tracheostomy in patients with high-risk airways. Successful outcomes depend on the identification of airway risk, multidisciplinary coordination, and meticulous perioperative planning. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153445--></body></html>"
    },
    {
      "uid": "P327",
      "content_id": "153073",
      "abstract_number": "P327",
      "poster_number": "P327",
      "title": "Vessel Selection and Predictors of Complications in Free Flap Surgery",
      "summary": "Our retrospective study demonstrated that there was an association of increased arterial compromise with certain arteries when compared to one another. The results of this association should be evaluated further, however ultimately vessel selection is limited to the individual patient and available vessels. The results of these findings may allow for appropriate consoling regarding predictions of flap compromise...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153073",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ricardo Pulido, MD",
      "presenter": "Ricardo Pulido, MD",
      "authors": "Ricardo Pulido, MD 1 ; Madeline Pyle, MD 1 ; Mark Wax, MD 2 ; Nicolaus Knight, MS 3 ; Jason Leibowitz, MD 1 ; Carissa Thomas, MD, PhD 3 ; Javier Nishikawa, BS 3 ; Caroline Bonaventure, MD 4 ; Michael DiLeo, MD 4 ; Joseph Curry, MD 5 ; Dev Amin, MD 5 ; Farshid Taghizadeh, MD 2 ; Larissa Sweeny, MD 1 ; Sally Long, MD 1",
      "normalized_authors": [
        "Ricardo Pulido",
        "Madeline Pyle",
        "Mark Wax",
        "Nicolaus Knight",
        "Jason Leibowitz",
        "Carissa Thomas",
        "Javier Nishikawa",
        "Caroline Bonaventure",
        "Michael DiLeo",
        "Joseph Curry",
        "Dev Amin",
        "Farshid Taghizadeh",
        "Larissa Sweeny",
        "Sally Long"
      ],
      "affiliations": [
        "University of Miami",
        "Oregon Health and Science University",
        "University of Alabama at Birmingham",
        "Louisiana State University Health Science Center",
        "Thomas Jefferson University"
      ],
      "normalized_institutions": [
        "University of Miami",
        "Oregon Health and Science University",
        "University of Alabama at Birmingham",
        "Louisiana State University Health Science Center",
        "Thomas Jefferson University"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ricardo Pulido, MD 1 ; Madeline Pyle, MD 1 ; Mark Wax, MD 2 ; Nicolaus Knight, MS 3 ; Jason Leibowitz, MD 1 ; Carissa Thomas, MD, PhD 3 ; Javier Nishikawa, BS 3 ; Caroline Bonaventure, MD 4 ; Michael DiLeo, MD 4 ; Joseph Curry, MD 5 ; Dev Amin, MD 5 ; Farshid Taghizadeh, MD 2 ; Larissa Sweeny, MD 1 ; Sally Long, MD 1",
        "Affiliations": "1 University of Miami; 2 Oregon Health and Science University; 3 University of Alabama at Birmingham; 4 Louisiana State University Health Science Center; 5 Thomas Jefferson University",
        "Introduction": "Free flap failures are devastating complications that are complex and subjugated to multiple factors such as patient comorbidities, intraoperative factors, and postoperative course. Given this, prior studies specifically looking at recipient vessels and free flap failures have been challenging to study and currently lack any conclusive data. The primary aim of this retrospective study is to determine if specific recipient arterial vessels can predict complications in free flap patients. Secondary aims are to determine what preoperative, intraoperative, or postoperative variables correlate with flap complications. Complications were defined as need for pedicle revision, flap compromise, and flap failure.",
        "Methods": "A multi-institutional retrospective study was performed between the years of 2019 and 2025 for a total of 2920 patients. Preoperative, intraoperative, and postoperative factors were examined which included patient demographics, history of cardiac disease, history of prior head and neck radiation, history of prior chemotherapy, pedicle revision intraoperatively, intraoperative thrombectomy, postoperative medical complications (thromboembolism, stroke, transition back to intensive care unit (ICU), and sepsis), donor tissue used for reconstruction, recipient venous and arterial vessel selected. This data was then stratified and controlled.",
        "Results": "There was increased association for arterial vessel compromise when the lingual artery was used compared to the facial artery (OR 3.04; 95% CI, 0.07 – 0.90; p = 0.003). There was increased association for arterial vessel compromise when the superior thyroid artery (OR 5.27; 95% CI, 1.08 – 25.55; p = 0.04), terminal external carotid (OR 7.98; 95% CI, 1.85 – 34.46; p = 0.005), transverse cervical (OR 16.99; 95% CI, 3.49 – 82.65; p = 0.001), and lingual artery (OR 9.59; 95% CI, 2.10 – 43.83; p = 0.004) were used compared to the superficial temporal artery. Pedicle revision was associated with increased flap failures (OR 5.39; 95% CI, 3.88 – 7.50, p < 0.001). Intraoperative thrombectomy was associated with increased flap failure (OR 16.77; 95% CI 11.11 – 25.32, p < 0.001). Postoperative hematoma was associated with increased flap failure (OR 2.27; 95% CI, 1.48 – 3.50, p = 0.003). Transition back to ICU during hospitalization was associated with increased flap failure (OR 4.20; 95% CI, 2.71-6.49, p < 0.001). Postoperative stroke was associated with increased flap failure (OR 2.81; 95% CI, 1.17 – 6.69, p = 0.029). Postoperative sepsis was associated with increased flap failure (OR 1.85; 95% CI, 1.01 – 3.39, p = 0.04).",
        "Conclusion": "Our retrospective study demonstrated that there was an association of increased arterial compromise with certain arteries when compared to one another. The results of this association should be evaluated further, however ultimately vessel selection is limited to the individual patient and available vessels. The results of these findings may allow for appropriate consoling regarding predictions of flap compromise postoperatively. The additional intraoperative and postoperative variables that appeared associated with increased flap failure rates were intraoperative thrombectomy and pedicle revision, postoperative stroke, transition back to ICU, and postoperative sepsis which needs to be studied in the future."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Vessel Selection and Predictors of Complications in Free Flap Surgery</span>. <u>Ricardo Pulido, MD</u><sup>1</sup>; Madeline Pyle, MD<sup>1</sup>; Mark Wax, MD<sup>2</sup>; Nicolaus Knight, MS<sup>3</sup>; Jason Leibowitz, MD<sup>1</sup>; Carissa Thomas, MD, PhD<sup>3</sup>; Javier Nishikawa, BS<sup>3</sup>; Caroline Bonaventure, MD<sup>4</sup>; Michael DiLeo, MD<sup>4</sup>; Joseph Curry, MD<sup>5</sup>; Dev Amin, MD<sup>5</sup>; Farshid Taghizadeh, MD<sup>2</sup>; Larissa Sweeny, MD<sup>1</sup>; Sally Long, MD<sup>1</sup>. <sup>1</sup>University of Miami; <sup>2</sup>Oregon Health and Science University; <sup>3</sup>University of Alabama at Birmingham; <sup>4</sup>Louisiana State University Health Science Center; <sup>5</sup>Thomas Jefferson University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Free flap failures are devastating complications that are complex and subjugated to multiple factors such as patient comorbidities, intraoperative factors, and postoperative course. Given this, prior studies specifically looking at recipient vessels and free flap failures have been challenging to study and currently lack any conclusive data.  The primary aim of this retrospective study is to determine if specific recipient arterial vessels can predict complications in free flap patients. Secondary aims are to determine what preoperative, intraoperative, or postoperative variables correlate with flap complications. Complications were defined as need for pedicle revision, flap compromise, and flap failure.</p>\n\n<p><strong>Methods: </strong>A multi-institutional retrospective study was performed between the years of 2019 and 2025 for a total of 2920 patients.  Preoperative, intraoperative, and postoperative factors were examined which included patient demographics, history of cardiac disease, history of prior head and neck radiation, history of prior chemotherapy, pedicle revision intraoperatively, intraoperative thrombectomy, postoperative medical complications (thromboembolism, stroke, transition back to intensive care unit (ICU), and sepsis), donor tissue used for reconstruction, recipient venous and arterial vessel selected. This data was then stratified and controlled.</p>\n\n<p><strong>Results: </strong>There was increased association for arterial vessel compromise when the lingual artery was used compared to the facial artery (OR 3.04; 95% CI, 0.07 – 0.90; p = 0.003). There was increased association for arterial vessel compromise when the superior thyroid artery (OR 5.27; 95% CI, 1.08 – 25.55; p = 0.04), terminal external carotid (OR 7.98; 95% CI, 1.85 – 34.46; p = 0.005), transverse cervical (OR 16.99; 95% CI, 3.49 – 82.65; p = 0.001), and lingual artery (OR 9.59; 95% CI, 2.10 – 43.83; p = 0.004) were used compared to the superficial temporal artery. Pedicle revision was associated with increased flap failures (OR 5.39; 95% CI, 3.88 – 7.50, p < 0.001). Intraoperative thrombectomy was associated with increased flap failure (OR 16.77; 95% CI 11.11 – 25.32, p < 0.001). Postoperative hematoma was associated with increased flap failure (OR 2.27; 95% CI, 1.48 – 3.50, p = 0.003). Transition back to ICU during hospitalization was associated with increased flap failure (OR 4.20; 95% CI, 2.71-6.49, p < 0.001). Postoperative stroke was associated with increased flap failure (OR 2.81; 95% CI, 1.17 – 6.69, p = 0.029). Postoperative sepsis was associated with increased flap failure (OR 1.85; 95% CI, 1.01 – 3.39, p = 0.04).</p>\n\n<p><strong>Conclusion: </strong>Our retrospective study demonstrated that there was an association of increased arterial compromise with certain arteries when compared to one another. The results of this association should be evaluated further, however ultimately vessel selection is limited to the individual patient and available vessels. The results of these findings may allow for appropriate consoling regarding predictions of flap compromise postoperatively. The additional intraoperative and postoperative variables that appeared associated with increased flap failure rates were intraoperative thrombectomy and pedicle revision, postoperative stroke, transition back to ICU, and postoperative sepsis which needs to be studied in the future.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153073--></body></html>"
    },
    {
      "uid": "P328",
      "content_id": "153651",
      "abstract_number": "P328",
      "poster_number": "P328",
      "title": "Jaw in a Day for Mandibular IMT: A Case Report and Literature Review",
      "summary": "Cases of an IMT are not well documented in the literature and thus present a unique clinical challenge. The standard treatment strategy for IMTs involves complete surgical resection with negative margins. This case highlights the feasibility of single-stage surgical resection and reconstruction using the JIAD approach for IMTs in anatomically challenging regions of the head and neck. For unresectable or relapsed...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153651",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kirollos E Armosh, BS",
      "presenter": "Kirollos E Armosh, BS",
      "authors": "Kirollos E Armosh, BS ; Cristina Benites, MS; Dustin Conrad, MD; Austin S Lam, MD; Peter Dziegielewski, MD",
      "normalized_authors": [
        "Kirollos E Armosh",
        "Cristina Benites",
        "Dustin Conrad",
        "Austin S Lam",
        "Peter Dziegielewski"
      ],
      "affiliations": [
        "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA"
      ],
      "normalized_institutions": [
        "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 437,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kirollos E Armosh, BS ; Cristina Benites, MS; Dustin Conrad, MD; Austin S Lam, MD; Peter Dziegielewski, MD",
        "Affiliations": "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA",
        "Introduction": "Inflammatory Myofibroblastic Tumors (IMT) are a heterogeneous group of rare neoplasms composed of myofibroblastic and fibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and/or eosinophils. IMTs primarily develop in the lungs, liver, and abdominal regions. IMTs in the head and neck regions are an atypical presentation but can affect the aero-digestive tract and major salivary glands. Extremely few cases have been observed in the mandible. Diagnosis is made through biopsy and histopathological analysis, which typically displays ALK positivity. Standard treatment is surgical resection with wide margins. Alternative treatments include ALK inhibitors.",
        "Methods": "A 15-year-old patient presented with a 9-month history of progressive mandibular pain, paresthesia, and swelling. Imaging revealed a mandibular lesion, and biopsy confirmed IMT with ALK positivity. The patient underwent composite resection and immediate reconstruction using the \"Jaw in a Day\" (JIAD) procedure. A systematic review of the literature was conducted using PubMed, Web of Science, and Embase through Preferred Reporting Items for Systematic Review and Meta-analyses guidelines (PRISMA). Search terms included were “Inflammatory Myofibroblastic Tumor” or “IMT” and “Head and Neck” or “Mandible”. 11 cases of IMTs with mandibular presentation were reviewed.",
        "Results": "Postoperatively, the patient was transferred to the ICU for monitoring and discharged on day 7 without complications.? At the 12-month follow-up, she underwent dental prosthetic adjustments and is disease-free. A systematic review demonstrated 11 cases of IMTs with mandibular presentation. The mean age was 36 years (range:11-82), and the majority of patients were female. Tumor sizes were reported in 8 cases, averaging 4.2 cm x 3.8 cm. 64% of tumors reported were in the posterior mandible area, and no recurrence was found in 9 cases. Tumor resection was performed with clear margins in most cases, with no indications of metastases or aggressive local behavior on follow-up.",
        "Conclusion": "Cases of an IMT are not well documented in the literature and thus present a unique clinical challenge. The standard treatment strategy for IMTs involves complete surgical resection with negative margins. This case highlights the feasibility of single-stage surgical resection and reconstruction using the JIAD approach for IMTs in anatomically challenging regions of the head and neck. For unresectable or relapsed cases, systemic therapy is used. Many IMTs exhibit ALK gene dysregulation, which can be targeted therapeutically. Markers, including SMA, vimentin, and ALK-1, differentiate IMTs from other spindle cell tumors. Crizotinib was found to be the most frequently prescribed agent. In crizotinib-resistant cases, second and third-generation inhibitors were successful at shrinking these tumors. These ALK inhibitors have shown efficacy for resistant tumors in both adult and pediatric patients. In the future, genomic profiling could help guide personalized treatment plans."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Jaw in a Day for Mandibular IMT: A Case Report and Literature Review</span>. <u>Kirollos E Armosh, BS</u>; Cristina Benites, MS; Dustin Conrad, MD; Austin S Lam, MD; Peter Dziegielewski, MD. University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Inflammatory Myofibroblastic Tumors (IMT) are a heterogeneous group of rare neoplasms composed of myofibroblastic and fibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and/or eosinophils. IMTs primarily develop in the lungs, liver, and abdominal regions. IMTs in the head and neck regions are an atypical presentation but can affect the aero-digestive tract and major salivary glands. Extremely few cases have been observed in the mandible. Diagnosis is made through biopsy and histopathological analysis, which typically displays ALK positivity. Standard treatment is surgical resection with wide margins. Alternative treatments include ALK inhibitors.</p>\n\n<p><strong>Methods: </strong>A 15-year-old patient presented with a 9-month history of progressive mandibular pain, paresthesia, and swelling. Imaging revealed a mandibular lesion, and biopsy confirmed IMT with ALK positivity. The patient underwent composite resection and immediate reconstruction using the \"Jaw in a Day\" (JIAD) procedure. A systematic review of the literature was conducted using PubMed, Web of Science, and Embase through Preferred Reporting Items for Systematic Review and Meta-analyses guidelines (PRISMA). Search terms included were “Inflammatory Myofibroblastic Tumor” or “IMT” and “Head and Neck” or “Mandible”. 11 cases of IMTs with mandibular presentation were reviewed.</p>\n\n<p><strong>Results: </strong>Postoperatively, the patient was transferred to the ICU for monitoring and discharged on day 7 without complications.? At the 12-month follow-up, she underwent dental prosthetic adjustments and is disease-free. A systematic review demonstrated 11 cases of IMTs with mandibular presentation. The mean age was 36 years (range:11-82), and the majority of patients were female. Tumor sizes were reported in 8 cases, averaging 4.2 cm x 3.8 cm. 64% of tumors reported were in the posterior mandible area, and no recurrence was found in 9 cases. Tumor resection was performed with clear margins in most cases, with no indications of metastases or aggressive local behavior on follow-up.</p>\n\n<p><strong>Conclusion: </strong>Cases of an IMT are not well documented in the literature and thus present a unique clinical challenge. The standard treatment strategy for IMTs involves complete surgical resection with negative margins. This case highlights the feasibility of single-stage surgical resection and reconstruction using the JIAD approach for IMTs in anatomically challenging regions of the head and neck. For unresectable or relapsed cases, systemic therapy is used. Many IMTs exhibit ALK gene dysregulation, which can be targeted therapeutically. Markers, including SMA, vimentin, and ALK-1, differentiate IMTs from other spindle cell tumors. Crizotinib was found to be the most frequently prescribed agent. In crizotinib-resistant cases, second and third-generation inhibitors were successful at shrinking these tumors. These ALK inhibitors have shown efficacy for resistant tumors in both adult and pediatric patients. In the future, genomic profiling could help guide personalized treatment plans.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153651--></body></html>"
    },
    {
      "uid": "P330",
      "content_id": "153681",
      "abstract_number": "P330",
      "poster_number": "P330",
      "title": "Submental Island Flap for Lateral Facial Reconstruction: Analysis of Outcomes in Case Series of Traumatic and Oncologic Defects",
      "summary": "The SIF is a reliable and versatile reconstructive option for lateral facial defects across varied etiologies and age groups. Its ease of harvest, low donor-site morbidity, and lack of need for microsurgical resources make it particularly advantageous in high-demand, resource-limited environments. Although the SIF has been described for lateral facial reconstruction for more than three decades, this case series...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153681",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lawrence F Oppenheimer Vélez, MD",
      "presenter": "Lawrence F Oppenheimer Vélez, MD",
      "authors": "Alejandro Santiago-Nazario, MD 1 ; Sara Forastieri Vicente, BA 2 ; Augusto González Gómez, BS 3 ; Diego Redondo Rivera, BS 2 ; Lawrence F Oppenheimer Vélez, MD 1 ; Shayanne Lajud Guerrero, MD 1",
      "normalized_authors": [
        "Alejandro Santiago-Nazario",
        "Sara Forastieri Vicente",
        "Augusto González Gómez",
        "Diego Redondo Rivera",
        "Lawrence F Oppenheimer Vélez",
        "Shayanne Lajud Guerrero"
      ],
      "affiliations": [
        "Otolaryngology–Head & Neck Surgery, University of Puerto Rico School of Medicine, San Juan, PR",
        "University of Puerto Rico School of Medicine, San Juan, PR",
        "Universidad Central del Caribe, Bayamón, PR"
      ],
      "normalized_institutions": [
        "Otolaryngology–Head & Neck Surgery, University of Puerto Rico School of Medicine, San Juan, PR",
        "University of Puerto Rico School of Medicine, San Juan, PR",
        "Universidad Central del Caribe, Bayamón, PR"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 266,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Study Objective",
        "Design Type",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alejandro Santiago-Nazario, MD 1 ; Sara Forastieri Vicente, BA 2 ; Augusto González Gómez, BS 3 ; Diego Redondo Rivera, BS 2 ; Lawrence F Oppenheimer Vélez, MD 1 ; Shayanne Lajud Guerrero, MD 1",
        "Affiliations": "1 Otolaryngology–Head & Neck Surgery, University of Puerto Rico School of Medicine, San Juan, PR; 2 University of Puerto Rico School of Medicine, San Juan, PR; 3 Universidad Central del Caribe, Bayamón, PR",
        "Background": "Reconstruction of complex lateral facial defects requires a balance between functional restoration, aesthetic outcomes, and donor-site morbidity. The submental island flap (SIF) offers a versatile regional option with reduced use of resources compared to free tissue transfer.",
        "Study Objective": "To evaluate the efficacy of the submental island flap (SIF) for lateral facial reconstruction in traumatic and oncologic defects treated within a resource-limited setting.",
        "Design Type": "Retrospective case series follows four patients who underwent reconstruction using SIF between 2023-2024.",
        "Methods": "Three of the patients had oncologic defects following parotidectomy for squamous cell carcinoma; one sustained traumatic injury. SIF was performed on these patients as a regionally available and adequate volume flap in a setting with limited free tissue transfer resources. Demographics, defect characteristics, surgical technique, complications, and postoperative outcomes were analyzed.",
        "Results": "The mean patient age was 64.25 years (range 29-88). All donor sites were closed primarily. The mean hospital stay was 9.75 days. All flaps demonstrated 100% survival with no major inpatient or follow-up complications over a mean follow-up period of 8 months.",
        "Conclusions": "The SIF is a reliable and versatile reconstructive option for lateral facial defects across varied etiologies and age groups. Its ease of harvest, low donor-site morbidity, and lack of need for microsurgical resources make it particularly advantageous in high-demand, resource-limited environments. Although the SIF has been described for lateral facial reconstruction for more than three decades, this case series underscores its continued relevance as a practical and effective alternative to microvascular free flaps, especially in settings such as the Puerto Rico Medical Center where increasing surgical demand and limited resources may constrain the feasibility of microsurgical reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Submental Island Flap for Lateral Facial Reconstruction: Analysis of Outcomes in Case Series of Traumatic and Oncologic Defects</span>. Alejandro Santiago-Nazario, MD<sup>1</sup>; Sara Forastieri Vicente, BA<sup>2</sup>; Augusto González Gómez, BS<sup>3</sup>; Diego Redondo Rivera, BS<sup>2</sup>; <u>Lawrence F Oppenheimer Vélez, MD</u><sup>1</sup>; Shayanne Lajud Guerrero, MD<sup>1</sup>. <sup>1</sup>Otolaryngology–Head & Neck Surgery, University of Puerto Rico School of Medicine, San Juan, PR; <sup>2</sup>University of Puerto Rico School of Medicine, San Juan, PR; <sup>3</sup>Universidad Central del Caribe, Bayamón, PR<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Reconstruction of complex lateral facial defects requires a balance between functional restoration, aesthetic outcomes, and donor-site morbidity. The submental island flap (SIF) offers a versatile regional option with reduced use of resources compared to free tissue transfer.</p>\n\n<p><strong>Study Objective: </strong>To evaluate the efficacy of the submental island flap (SIF) for lateral facial reconstruction in traumatic and oncologic defects treated within a resource-limited setting.</p>\n\n<p><strong>Design Type: </strong>Retrospective case series follows four patients who underwent reconstruction using SIF between 2023-2024.</p>\n\n<p><strong>Methods: </strong>Three of the patients had oncologic defects following parotidectomy for squamous cell carcinoma; one sustained traumatic injury. SIF was performed on these patients as a regionally available and adequate volume flap in a setting with limited free tissue transfer resources. Demographics, defect characteristics, surgical technique, complications, and postoperative outcomes were analyzed.</p>\n\n<p><strong>Results: </strong>The mean patient age was 64.25 years (range 29-88). All donor sites were closed primarily. The mean hospital stay was 9.75 days. All flaps demonstrated 100% survival with no major inpatient or follow-up complications over a mean follow-up period of 8 months.</p>\n\n<p><strong>Conclusions: </strong>The SIF is a reliable and versatile reconstructive option for lateral facial defects across varied etiologies and age groups. Its ease of harvest, low donor-site morbidity, and lack of need for microsurgical resources make it particularly advantageous in high-demand, resource-limited environments. Although the SIF has been described for lateral facial reconstruction for more than three decades, this case series underscores its continued relevance as a practical and effective alternative to microvascular free flaps, especially in settings such as the Puerto Rico Medical Center where increasing surgical demand and limited resources may constrain the feasibility of microsurgical reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153681--></body></html>"
    },
    {
      "uid": "P331",
      "content_id": "147443",
      "abstract_number": "P331",
      "poster_number": "P331",
      "title": "Advances in Oral Cavity Cancer Reconstruction: One single large osseous free flap can rule the majority of defects",
      "summary": "Reconstruction of extensive oral cavity defects following oncologic resection remains one of the most complex challenges in head and neck surgery. These cases are inherently high-risk, often compounded by severe denutrition, previous treatments, distorted anatomy, and compromised vascularity. Traditionally, large composite defects have been addressed using double free flaps or staged reconstructions. However, the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147443",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jasmine Sze, DDS, MD",
      "presenter": "Jasmine Sze, DDS, MD",
      "authors": "Jasmine Sze, DDS, MD ; Laurent Ganry, MD, MSc; Andrew R Salama, MD, DDS, FACS; Megan Sullivan, MD, DMD; Peter Protzel, MD, DDS; Hunter Martin, MD, DDS, FACS; David L Hirsch, MD, DDS, FACS",
      "normalized_authors": [
        "Jasmine Sze",
        "Laurent Ganry",
        "Andrew R Salama",
        "Megan Sullivan",
        "Peter Protzel",
        "Hunter Martin",
        "David L Hirsch"
      ],
      "affiliations": [
        "Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY, USA"
      ],
      "normalized_institutions": [
        "Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY, USA"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 195,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jasmine Sze, DDS, MD ; Laurent Ganry, MD, MSc; Andrew R Salama, MD, DDS, FACS; Megan Sullivan, MD, DMD; Peter Protzel, MD, DDS; Hunter Martin, MD, DDS, FACS; David L Hirsch, MD, DDS, FACS",
        "Affiliations": "Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY, USA",
        "Abstract": "Reconstruction of extensive oral cavity defects following oncologic resection remains one of the most complex challenges in head and neck surgery. These cases are inherently high-risk, often compounded by severe denutrition, previous treatments, distorted anatomy, and compromised vascularity. Traditionally, large composite defects have been addressed using double free flaps or staged reconstructions. However, the use of a single, well-designed osseous free flap - \"mega\" flap - has emerged as a viable, efficient, and often superior alternative in our team. This abstract discusses the clinical rationale, surgical technique, and reconstructive versatility of the mega Fibula Free Flap (mFFF) and mega Scapula Free Flap (mSFF). Both can be harvested to provide extensive bone stock, soft tissue bulk, and skin paddle surface, addressing composite defects in a single-stage reconstruction. The mega flap approach minimizes operative time, reduces microvascular anastomosis demands, and lowers the complexity associated with dual-flap reconstructions. In the setting of complex oral cavity oncologic defects, we propose that a single, large, strategically planned osseous free flap can often achieve oncologic, functional, and aesthetic goals while mitigating the risks and resource demands associated with double free flaps. This paradigm shift prioritizes reliability and surgical economy without compromising reconstructive outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Advances in Oral Cavity Cancer Reconstruction: One single large osseous free flap can rule the majority of defects</span>. <u>Jasmine Sze, DDS, MD</u>; Laurent Ganry, MD, MSc; Andrew R Salama, MD, DDS, FACS; Megan Sullivan, MD, DMD; Peter Protzel, MD, DDS; Hunter Martin, MD, DDS, FACS; David L Hirsch, MD, DDS, FACS. Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Reconstruction of extensive oral cavity defects following oncologic resection remains one of the most complex challenges in head and neck surgery. These cases are inherently high-risk, often compounded by severe denutrition, previous treatments, distorted anatomy, and compromised vascularity. Traditionally, large composite defects have been addressed using double free flaps or staged reconstructions. However, the use of a single, well-designed osseous free flap - \"mega\" flap - has emerged as a viable, efficient, and often superior alternative in our team.</p>\n\n<p>This abstract discusses the clinical rationale, surgical technique, and reconstructive versatility of the mega Fibula Free Flap (mFFF) and mega Scapula Free Flap (mSFF). Both can be harvested to provide extensive bone stock, soft tissue bulk, and skin paddle surface, addressing composite defects in a single-stage reconstruction. The mega flap approach minimizes operative time, reduces microvascular anastomosis demands, and lowers the complexity associated with dual-flap reconstructions.</p>\n\n<p>In the setting of complex oral cavity oncologic defects, we propose that a single, large, strategically planned osseous free flap can often achieve oncologic, functional, and aesthetic goals while mitigating the risks and resource demands associated with double free flaps. This paradigm shift prioritizes reliability and surgical economy without compromising reconstructive outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147443--></body></html>"
    },
    {
      "uid": "P332",
      "content_id": "153890",
      "abstract_number": "P332",
      "poster_number": "P332",
      "title": "Supraclavicular Artery Island Flap for Pharyngeal Reconstruction After Resection of Recurrent Cervical Malignant Ectomesenchymoma in a 7-Month-Old Infant",
      "summary": "This case illustrates the substantial diagnostic, oncologic, and surgical challenges posed by cervical MEM in infancy, particularly when complicated by airway compromise, treatment-resistant disease and upper aerodigestive tract reconstruction. Management required coordinated multidisciplinary oversight, timely recognition of disease progression, and definitive surgical resection with advanced reconstructive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153890",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Antonio Dekhou, MD",
      "presenter": "Antonio Dekhou, MD",
      "authors": "David Gorelov, MD 1 ; Imani Agard, BS 2 ; Madelyn Bell, RN 3 ; Alexander Karabachev, MD 2 ; Antonio Dekhou, MD 2 ; Priscilla Pichardo, DO 2 ; Dustin Silverman, MD 2 ; Alice Tang, MD 2 ; Chad Zender, MD 2",
      "normalized_authors": [
        "David Gorelov",
        "Imani Agard",
        "Madelyn Bell",
        "Alexander Karabachev",
        "Antonio Dekhou",
        "Priscilla Pichardo",
        "Dustin Silverman",
        "Alice Tang",
        "Chad Zender"
      ],
      "affiliations": [
        "The Jewish Hospital - Mercy Health",
        "University of Cincinnati Department of Otolaryngology Head and Neck Surgery",
        "Cincinnati Children's Hospital Medical Center"
      ],
      "normalized_institutions": [
        "The Jewish Hospital - Mercy Health",
        "University of Cincinnati Department of Otolaryngology Head and Neck Surgery",
        "Cincinnati Children's Hospital Medical Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 375,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "David Gorelov, MD 1 ; Imani Agard, BS 2 ; Madelyn Bell, RN 3 ; Alexander Karabachev, MD 2 ; Antonio Dekhou, MD 2 ; Priscilla Pichardo, DO 2 ; Dustin Silverman, MD 2 ; Alice Tang, MD 2 ; Chad Zender, MD 2",
        "Affiliations": "1 The Jewish Hospital - Mercy Health; 2 University of Cincinnati Department of Otolaryngology Head and Neck Surgery; 3 Cincinnati Children's Hospital Medical Center",
        "Introduction": "Malignant ectomesenchymoma (MEM) is an exceptionally rare pediatric malignancy characterized by biphenotypic mesenchymal and neuroectodermal differentiation, with fewer than one hundred cases reported. Cervical presentations in the neonatal period are exceedingly uncommon and present unique diagnostic and therapeutic challenges. In advanced or treatment refractory cases, extensive surgical management may be required including composite pharyngeal resection when the aerodigestive tract is extensively involved. Such resections in infants demand careful planning to preserve airway stability and swallowing function, necessitating reconstructive approaches that provide thin, pliable tissue with reliable vascularity. This report describes the perinatal through postoperative course of an infant with recurrent cervical MEM, emphasizing the diagnostic complexity, surgical strategy, reconstructive considerations, and implications for multidisciplinary care.",
        "Methods": "A comprehensive case review was performed, including clinical documentation, operative reports, radiologic studies, pathology evaluations, and next-generation sequencing (NGS) data.",
        "Results": "A term male infant presented at birth with inspiratory stridor and a left cervical mass. Patient underwent transcervical debulking and open biopsy at two months of age, which confirmed Stage I, clinical group II MEM. Despite chemotherapy treatment disease progression occurred. Restaging MRI revealed an enhancing retropharyngeal and hypopharyngeal mass concerning for residual disease. Biopsy confirmed recurrent MEM. Given the progression of symptoms and radiologic evidence of treatment-resistant disease, definitive surgical resection was recommended. At 7 months, the patient underwent an extensive cervical approach including right pharyngectomy with sacrifice of cranial nerve X and the external carotid artery. Thin pliable tissue with moderate bulk was needed so reconstruction of the pharyngectomy defect was completed using a supraclavicular artery island flap. The procedure went well without complication and a tracheostomy was not necessary . Following recovery from surgery, proton therapy was completed followed by 1 year of adjuvant chemotherapy. The patient continues to undergo interval direct laryngoscopy for surveillance.",
        "Conclusion": "This case illustrates the substantial diagnostic, oncologic, and surgical challenges posed by cervical MEM in infancy, particularly when complicated by airway compromise, treatment-resistant disease and upper aerodigestive tract reconstruction. Management required coordinated multidisciplinary oversight, timely recognition of disease progression, and definitive surgical resection with advanced reconstructive techniques tailored to the pediatric airway. This case contributes meaningful insight into the biology and management of MEM and underscore the need for continued collaborative research to inform evidence-based care for rare pediatric head and neck malignancies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Supraclavicular Artery Island Flap for Pharyngeal Reconstruction After Resection of Recurrent Cervical Malignant Ectomesenchymoma in a 7-Month-Old Infant</span>. David Gorelov, MD<sup>1</sup>; Imani Agard, BS<sup>2</sup>; Madelyn Bell, RN<sup>3</sup>; Alexander Karabachev, MD<sup>2</sup>; <u>Antonio Dekhou, MD</u><sup>2</sup>; Priscilla Pichardo, DO<sup>2</sup>; Dustin Silverman, MD<sup>2</sup>; Alice Tang, MD<sup>2</sup>; Chad Zender, MD<sup>2</sup>. <sup>1</sup>The Jewish Hospital - Mercy Health; <sup>2</sup>University of Cincinnati Department of Otolaryngology Head and Neck Surgery; <sup>3</sup>Cincinnati Children's Hospital Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Malignant ectomesenchymoma (MEM) is an exceptionally rare pediatric malignancy characterized by biphenotypic mesenchymal and neuroectodermal differentiation, with fewer than one hundred cases reported. Cervical presentations in the neonatal period are exceedingly uncommon and present unique diagnostic and therapeutic challenges. In advanced or treatment refractory cases, extensive surgical management may be required including composite pharyngeal resection when the aerodigestive tract is extensively involved. Such resections in infants demand careful planning to preserve airway stability and swallowing function, necessitating reconstructive approaches that provide thin, pliable tissue with reliable vascularity. This report describes the perinatal through postoperative course of an infant with recurrent cervical MEM, emphasizing the diagnostic complexity, surgical strategy, reconstructive considerations, and implications for multidisciplinary care.</p>\n\n<p><strong>Methods: </strong>A comprehensive case review was performed, including clinical documentation, operative reports, radiologic studies, pathology evaluations, and next-generation sequencing (NGS) data.</p>\n\n<p><strong>Results: </strong>A term male infant presented at birth with inspiratory stridor and a left cervical mass. Patient underwent transcervical debulking and open biopsy at two months of age, which confirmed Stage I, clinical group II MEM. Despite chemotherapy treatment disease progression occurred. Restaging MRI revealed an enhancing retropharyngeal and hypopharyngeal mass concerning for residual disease. Biopsy confirmed recurrent MEM.  Given the progression of symptoms and radiologic evidence of treatment-resistant disease, definitive surgical resection was recommended. At 7 months, the patient underwent an extensive cervical approach including right pharyngectomy with sacrifice of cranial nerve X and the external carotid artery.  Thin pliable tissue with moderate bulk was needed so reconstruction of the pharyngectomy defect was completed using a supraclavicular artery island flap. The procedure went well without complication and a tracheostomy was not necessary . Following recovery from surgery, proton therapy was completed followed by 1 year of adjuvant chemotherapy. The patient continues to undergo interval direct laryngoscopy for surveillance.</p>\n\n<p><strong>Conclusion: </strong>This case illustrates the substantial diagnostic, oncologic, and surgical challenges posed by cervical MEM in infancy, particularly when complicated by airway compromise, treatment-resistant disease and upper aerodigestive tract reconstruction. Management required coordinated multidisciplinary oversight, timely recognition of disease progression, and definitive surgical resection with advanced reconstructive techniques tailored to the pediatric airway. This case contributes meaningful insight into the biology and management of MEM and underscore the need for continued collaborative research to inform evidence-based care for rare pediatric head and neck malignancies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153890--></body></html>"
    },
    {
      "uid": "P333",
      "content_id": "153305",
      "abstract_number": "P333",
      "poster_number": "P333",
      "title": "Early Discharge in Cutaneous Free Flap Reconstruction: Are We Keeping Patients Too Long?",
      "summary": "Cutaneous head and neck free flap patients experienced low flap failure rates and few complications, most of which occurred within 48 hours postoperatively. Early discharge was not associated with increased healthcare utilization after discharge. Risk stratification and selection of patients eligible for earlier discharges is a viable strategy to explore further.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153305",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jayden R Garcia, MD",
      "presenter": "Jayden R Garcia, MD",
      "authors": "Jayden R Garcia, MD ; Noe Francois-Saint-Cyr, BS; Grayson Buning, BS; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark E Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David W Forner, MD, MSc",
      "normalized_authors": [
        "Jayden R Garcia",
        "Noe Francois-Saint-Cyr",
        "Grayson Buning",
        "Marisa R Buchakjian",
        "Pratyusha Yalamanchi",
        "Keith A Casper",
        "Chaz L Stucken",
        "Kelly M Malloy",
        "Andrew G Shuman",
        "Mark E Prince",
        "Scott A McLean",
        "Molly E Heft Neal",
        "David W Forner"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jayden R Garcia, MD ; Noe Francois-Saint-Cyr, BS; Grayson Buning, BS; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark E Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David W Forner, MD, MSc",
        "Affiliations": "University of Michigan",
        "Background": "Free tissue reconstruction of isolated cutaneous defects of the head and neck typically do not require the intensive airway and functional rehabilitation inherent to reconstruction of aerodigestive mucosal defects. However, many such patients experience prolonged hospitalizations as part of standard microsurgical post-operative protocols which impose substantial physical, emotional, and logistical burdens on patients, families, and health systems. There is a paucity of evidence on the safety and feasibility of early discharge for patients undergoing free tissue reconstruction of isolated cutaneous head and neck defects.",
        "Objective": "To describe and stratify perioperative outcomes in patients undergoing isolated cutaneous head and neck free flap reconstruction.",
        "Methods": "This was a retrospective cohort study based upon a prospective clinical database at a single academic tertiary center from 2014 to 2025. The population included adults undergoing isolated cutaneous head and neck free flap reconstruction. Demographic and perioperative details were abstracted. The exposure of interest was post-operative length of stay (LOS). Primary outcomes included emergency department (ED) visits and hospital readmissions within 30 days whereas secondary outcomes focused on flap and donor site complications. Primary analyses compared categorical LOS (≤5 vs >5 days) using Fisher’s exact tests, with secondary Wilcoxon rank-sum analyses evaluating LOS as a continuous measure.",
        "Results": "A total of 98 patients met inclusion criteria. The mean age was 65?years and 81% were male. Most common reconstructions included soft tissue defects following radical parotidectomy (42%) and anterior facial defects (27%). There were 20 flap and donor site complications (21%), with no difference between early and late discharge groups (19% vs 23%, p=0.61). One patient (1%) experienced flap compromise which was salvaged on post-operative day 1, and two patients developed late partial flap loss requiring operative debridement on POD 19 and POD 23. Six patients (6%) developed hematomas, all of which were safely evacuated within the first 48 hours of surgery. There were no perioperative deaths.",
        "Abstract": "Mean LOS was 6?±?4?days; 40% of patients remained in hospital ≥6?days. There was no difference in combined unplanned hospital encounters between the early (≤5 days) and late (>5 days) discharge groups (10.3% vs. 15.8%, p = 0.53). In contrast, treating LOS as a continuous measure revealed that longer hospital stays were associated with a greater likelihood of ED return or readmission (mean LOS 9.0 days vs. 5.5 days, p = 0.037). Considered individually, the trends for ED visits (7.1 vs. 5.8, p = 0.083) and readmissions (10.6 vs. 5.5, p = 0.066) were not significant.",
        "Conclusion": "Cutaneous head and neck free flap patients experienced low flap failure rates and few complications, most of which occurred within 48 hours postoperatively. Early discharge was not associated with increased healthcare utilization after discharge. Risk stratification and selection of patients eligible for earlier discharges is a viable strategy to explore further."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Discharge in Cutaneous Free Flap Reconstruction: Are We Keeping Patients Too Long?</span>. <u>Jayden R Garcia, MD</u>; Noe Francois-Saint-Cyr, BS; Grayson Buning, BS; Marisa R Buchakjian, MD, PhD; Pratyusha Yalamanchi, MD, MBA; Keith A Casper, MD; Chaz L Stucken, MD; Kelly M Malloy, MD, MBA; Andrew G Shuman, MD; Mark E Prince, MD; Scott A McLean, MD, PhD; Molly E Heft Neal, MD; David W Forner, MD, MSc. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Free tissue reconstruction of isolated cutaneous defects of the head and neck typically do not require the intensive airway and functional rehabilitation inherent to reconstruction of aerodigestive mucosal defects. However, many such patients experience prolonged hospitalizations as part of standard microsurgical post-operative protocols which impose substantial physical, emotional, and logistical burdens on patients, families, and health systems. There is a paucity of evidence on the safety and feasibility of early discharge for patients undergoing free tissue reconstruction of isolated cutaneous head and neck defects. </p>\n\n<p><strong>Objective: </strong>To describe and stratify perioperative outcomes in patients undergoing isolated cutaneous head and neck free flap reconstruction. </p>\n\n<p><strong>Methods: </strong>This was a retrospective cohort study based upon a prospective clinical database at a single academic tertiary center from 2014 to 2025. The population included adults undergoing isolated cutaneous head and neck free flap reconstruction. Demographic and perioperative details were abstracted. The exposure of interest was post-operative length of stay (LOS). Primary outcomes included emergency department (ED) visits and hospital readmissions within 30 days whereas secondary outcomes focused on flap and donor site complications. Primary analyses compared categorical LOS (≤5 vs >5 days) using Fisher’s exact tests, with secondary Wilcoxon rank-sum analyses evaluating LOS as a continuous measure.</p>\n\n<p><strong>Results: </strong>A total of 98 patients met inclusion criteria. The mean age was 65?years and 81% were male. Most common reconstructions included soft tissue defects following radical parotidectomy (42%) and anterior facial defects (27%). There were 20 flap and donor site complications (21%), with no difference between early and late discharge groups (19% vs 23%, p=0.61). One patient (1%) experienced flap compromise which was salvaged on post-operative day 1, and two patients developed late partial flap loss requiring operative debridement on POD 19 and POD 23. Six patients (6%) developed hematomas, all of which were safely evacuated within the first 48 hours of surgery. There were no perioperative deaths. </p>\n\n<p>Mean LOS was 6?±?4?days; 40% of patients remained in hospital ≥6?days. There was no difference in combined unplanned hospital encounters between the early (≤5 days) and late (>5 days) discharge groups (10.3% vs. 15.8%, p = 0.53). In contrast, treating LOS as a continuous measure revealed that longer hospital stays were associated with a greater likelihood of ED return or readmission (mean LOS 9.0 days vs. 5.5 days, p = 0.037). Considered individually, the trends for ED visits (7.1 vs. 5.8, p = 0.083) and readmissions (10.6 vs. 5.5, p = 0.066) were not significant. </p>\n\n<p><strong>Conclusion: </strong>Cutaneous head and neck free flap patients experienced low flap failure rates and few complications, most of which occurred within 48 hours postoperatively. Early discharge was not associated with increased healthcare utilization after discharge. Risk stratification and selection of patients eligible for earlier discharges is a viable strategy to explore further. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153305--></body></html>"
    },
    {
      "uid": "P334",
      "content_id": "153755",
      "abstract_number": "P334",
      "poster_number": "P334",
      "title": "Association of Intraoperative and Postoperative Transfusion With Flap Outcomes and Complications in Head and Neck Microvascular Reconstruction",
      "summary": "In this cohort, PO RBC transfusion was associated with higher rates of flap loss, wound complications, and reoperation compared with no PO transfusion, while IO transfusion demonstrated similar but less pronounced trends. These findings suggest that transfusion timing may be related to postoperative outcomes; however, unadjusted analyses and potential confounding necessitate cautious interpretation. Prospective...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153755",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma C Dunn, BS",
      "presenter": "Emma C Dunn, BS",
      "authors": "Emma C Dunn, BS 1 ; Alisa Vidwans, BS 1 ; Jacob Parker, BS 1 ; Atif Islam, BS 1 ; William Doyle, MD 2 ; Veena Jajoo, MPH, CPH 3 ; Rahul Mhaskar, PhD 3 ; Tara Mokhtari, MD 4 ; Christopher Nickel, MD 4 ; Matthew Mifsud, MD 4",
      "normalized_authors": [
        "Emma C Dunn",
        "Alisa Vidwans",
        "Jacob Parker",
        "Atif Islam",
        "William Doyle",
        "Veena Jajoo, CPH",
        "Rahul Mhaskar",
        "Tara Mokhtari",
        "Christopher Nickel",
        "Matthew Mifsud"
      ],
      "affiliations": [
        "University of South Florida Morsani College of Medicine",
        "Department of Otorhinolaryngology, Head and Neck Surgery Rush University Medical Center",
        "Department of Medical Education University of Florida Morsani College of Medicine",
        "University of South Florida Department of Otolaryngology and Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of South Florida Morsani College of Medicine",
        "Department of Otorhinolaryngology, Head and Neck Surgery Rush University Medical Center",
        "Department of Medical Education University of Florida Morsani College of Medicine",
        "University of South Florida Department of Otolaryngology and Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Emma C Dunn, BS 1 ; Alisa Vidwans, BS 1 ; Jacob Parker, BS 1 ; Atif Islam, BS 1 ; William Doyle, MD 2 ; Veena Jajoo, MPH, CPH 3 ; Rahul Mhaskar, PhD 3 ; Tara Mokhtari, MD 4 ; Christopher Nickel, MD 4 ; Matthew Mifsud, MD 4",
        "Affiliations": "1 University of South Florida Morsani College of Medicine; 2 Department of Otorhinolaryngology, Head and Neck Surgery Rush University Medical Center; 3 Department of Medical Education University of Florida Morsani College of Medicine; 4 University of South Florida Department of Otolaryngology and Head and Neck Surgery",
        "Background": "Microvascular free-flap reconstruction is essential for restoration of form and function following head and neck cancer resection. Despite advances in technique, wound complications, flap loss, and unplanned reoperation remain clinically important challenges. Transfusion practices vary widely, in part due to uncertainty regarding whether red blood cell (RBC) transfusion timing or dose is associated with adverse outcomes. A clearer understanding of these relationships may help inform perioperative management strategies.",
        "Objective": "To evaluate whether intraoperative (IO) and postoperative (PO) RBC transfusions, as well as total RBC units transfused, are associated with flap loss and postoperative complications after head and neck free-flap reconstruction.",
        "Methods": "A retrospective cohort study was performed at Tampa General Hospital between 2017–2023. Exposures included IO transfusion (yes/no), PO transfusion (yes/no), and total RBC units transfused. Outcomes were flap loss (partial or total) and neck-wound complications (dehiscence, culture-confirmed infection, or pharyngocutaneous fistula). Prespecified covariates included age, body mass index (BMI), Charlson Comorbidity Index (CCI), preoperative and intraoperative hemoglobin, estimated blood loss (EBL), operative time, cancer site, and prior oncologic treatment. Group comparisons were conducted using Pearson’s Chi-Square or Fisher’s Exact tests for categorical variables and Mann–Whitney U tests for continuous variables. Associations between total RBC units and outcomes were evaluated with Spearman’s Rho and Mann–Whitney U testing. All analyses were unadjusted, with statistical significance defined as p < 0.05.",
        "Results": "Among 301 patients, 47 (15.6%) received PO transfusion. Compared with non-transfused patients, those receiving PO transfusion demonstrated lower hematologic values and greater EBL and experienced significantly longer hospitalization (14.7 ± 9.1 vs. 7.9 ± 5.0 days, p < 0.001). Overall postoperative complications were more frequent in the PO transfusion cohort (31.9% vs. 11.5%, p < 0.001), including higher rates of wound complications such as dehiscence or pharyngocutaneous fistula (p = 0.001).",
        "Abstract": "Flap outcomes differed by transfusion status: PO-transfused patients had higher overall flap loss (21.3% vs. 2.0%, p < 0.001), including total flap loss (19.1% vs. 1.2%, p < 0.001). Return to the operating room was also more common (34.0% vs. 7.9%, p < 0.001). IO transfusion displayed similar patterns of lower hemoglobin, higher EBL, and longer hospitalization, although associations with flap loss were less pronounced. Total RBC units transfused were not associated with flap loss (2.42 ± 1.62 vs. 3.07 ± 2.17 units, p = 0.272). However, patients without wound complications received more units than those with complications (3.27 ± 2.28 vs. 2.26 ± 1.41 units, p = 0.043). These relationships may reflect differences in case complexity, anemia, or perioperative physiology, and causality cannot be inferred.",
        "Conclusion": "In this cohort, PO RBC transfusion was associated with higher rates of flap loss, wound complications, and reoperation compared with no PO transfusion, while IO transfusion demonstrated similar but less pronounced trends. These findings suggest that transfusion timing may be related to postoperative outcomes; however, unadjusted analyses and potential confounding necessitate cautious interpretation. Prospective and risk-adjusted studies are needed to further clarify these associations and guide transfusion strategy in free-flap reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Intraoperative and Postoperative Transfusion With Flap Outcomes and Complications in Head and Neck Microvascular Reconstruction</span>. <u>Emma C Dunn, BS</u><sup>1</sup>; Alisa Vidwans, BS<sup>1</sup>; Jacob Parker, BS<sup>1</sup>; Atif Islam, BS<sup>1</sup>; William Doyle, MD<sup>2</sup>; Veena Jajoo, MPH, CPH<sup>3</sup>; Rahul Mhaskar, PhD<sup>3</sup>; Tara Mokhtari, MD<sup>4</sup>; Christopher Nickel, MD<sup>4</sup>; Matthew Mifsud, MD<sup>4</sup>. <sup>1</sup>University of South Florida Morsani College of Medicine; <sup>2</sup>Department of Otorhinolaryngology, Head and Neck Surgery Rush University Medical Center; <sup>3</sup>Department of Medical Education University of Florida Morsani College of Medicine; <sup>4</sup>University of South Florida Department of Otolaryngology and Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Microvascular free-flap reconstruction is essential for restoration of form and function following head and neck cancer resection. Despite advances in technique, wound complications, flap loss, and unplanned reoperation remain clinically important challenges. Transfusion practices vary widely, in part due to uncertainty regarding whether red blood cell (RBC) transfusion timing or dose is associated with adverse outcomes. A clearer understanding of these relationships may help inform perioperative management strategies.</p>\n\n<p><strong>Objective: </strong>To evaluate whether intraoperative (IO) and postoperative (PO) RBC transfusions, as well as total RBC units transfused, are associated with flap loss and postoperative complications after head and neck free-flap reconstruction.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed at Tampa General Hospital between 2017–2023. Exposures included IO transfusion (yes/no), PO transfusion (yes/no), and total RBC units transfused. Outcomes were flap loss (partial or total) and neck-wound complications (dehiscence, culture-confirmed infection, or pharyngocutaneous fistula). Prespecified covariates included age, body mass index (BMI), Charlson Comorbidity Index (CCI), preoperative and intraoperative hemoglobin, estimated blood loss (EBL), operative time, cancer site, and prior oncologic treatment. Group comparisons were conducted using Pearson’s Chi-Square or Fisher’s Exact tests for categorical variables and Mann–Whitney U tests for continuous variables. Associations between total RBC units and outcomes were evaluated with Spearman’s Rho and Mann–Whitney U testing. All analyses were unadjusted, with statistical significance defined as p < 0.05.</p>\n\n<p><strong>Results: </strong>Among 301 patients, 47 (15.6%) received PO transfusion. Compared with non-transfused patients, those receiving PO transfusion demonstrated lower hematologic values and greater EBL and experienced significantly longer hospitalization (14.7 ± 9.1 vs. 7.9 ± 5.0 days, p < 0.001). Overall postoperative complications were more frequent in the PO transfusion cohort (31.9% vs. 11.5%, p < 0.001), including higher rates of wound complications such as dehiscence or pharyngocutaneous fistula (p = 0.001).</p>\n\n<p>Flap outcomes differed by transfusion status: PO-transfused patients had higher overall flap loss (21.3% vs. 2.0%, p < 0.001), including total flap loss (19.1% vs. 1.2%, p < 0.001). Return to the operating room was also more common (34.0% vs. 7.9%, p < 0.001). IO transfusion displayed similar patterns of lower hemoglobin, higher EBL, and longer hospitalization, although associations with flap loss were less pronounced.</p>\n\n<p>Total RBC units transfused were not associated with flap loss (2.42 ± 1.62 vs. 3.07 ± 2.17 units, p = 0.272). However, patients without wound complications received more units than those with complications (3.27 ± 2.28 vs. 2.26 ± 1.41 units, p = 0.043). These relationships may reflect differences in case complexity, anemia, or perioperative physiology, and causality cannot be inferred.</p>\n\n<p><strong>Conclusion: </strong>In this cohort, PO RBC transfusion was associated with higher rates of flap loss, wound complications, and reoperation compared with no PO transfusion, while IO transfusion demonstrated similar but less pronounced trends. These findings suggest that transfusion timing may be related to postoperative outcomes; however, unadjusted analyses and potential confounding necessitate cautious interpretation. Prospective and risk-adjusted studies are needed to further clarify these associations and guide transfusion strategy in free-flap reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153755--></body></html>"
    },
    {
      "uid": "P335",
      "content_id": "154667",
      "abstract_number": "P335",
      "poster_number": "P335",
      "title": "Reconstructive Outcomes in Premaxillary Reconstruction",
      "summary": "Premaxillary reconstruction after maxillectomy is associated with substantial morbidity in this small series, including high rates of oral incompetence, trismus, fistula formation, and flap-related complications. Ocular sequelae and midface contour changes were also common. The diversity of flap types used, including radial forearm, fibula, and ALT, reflects the heterogeneity of defects encountered. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154667",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nicole J Reynoso",
      "presenter": "Nicole J Reynoso",
      "authors": "Nicole J Reynoso ; Andrea M Park, MD; Rahul Seth, MD; P Daniel Knott, MD",
      "normalized_authors": [
        "Nicole J Reynoso",
        "Andrea M Park",
        "Rahul Seth",
        "P Daniel Knott"
      ],
      "affiliations": [
        "University of California, San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 380,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Nicole J Reynoso ; Andrea M Park, MD; Rahul Seth, MD; P Daniel Knott, MD",
        "Affiliations": "University of California, San Francisco",
        "Background": "Premaxillary reconstruction following partial or total maxillectomy remains technically challenging due to the complex three-dimensional contour of the midface and the need to restore or preserve critical functions including oral competence, nasal projection, and mastication. High rates of wound-healing issues and flap-related complications have been reported, yet literature describing complication patterns specific to premaxillary reconstruction remains limited. The complexity of maxillary reconstruction becomes even more challenging when the premaxilla is involved. This study characterizes reconstructive approaches and associated outcomes in a contemporary cohort of patients undergoing maxillectomy with premaxillary reconstruction at a tertiary academic center.",
        "Methods": "A retrospective review was performed of n=10 patients who underwent premaxillary reconstruction. Demographic, oncologic, operative, and postoperative variables were collected, including maxillectomy extent, reconstructive technique, and functional and flap-related complications. Outcomes included midface contour changes, ocular complications, oral competence, trismus, fistula formation, and flap morbidity.",
        "Results": "Among patients undergoing maxillectomy with premaxillary reconstruction, most defects were reconstructed with free flaps (9/10, 90%) and split-thickness skin grafts (9/10, 90%). The reconstructive burden in this cohort was substantial, with many patients requiring staged procedures utilizing both osteocutaneous and soft-tissue free flaps to address complex premaxillary and midface defects. Maxillectomy extent included partial (40%), subtotal (30%), total (20%), and extended partial (10%) resections. Many patients required complex, staged reconstruction, often employing multiple flaps, including combinations of osteocutaneous and soft-tissue microvascular flaps, to address the magnitude and three-dimensional contour of their defects.",
        "Abstract": "Midface and periocular morbidity was substantial, with midface contraction observed in 3 patients (30%), ectropion in 2 (20%), lagophthalmos in 1 (10%), keratopathy in 2 (20%), chemosis in 2 (20%), oral incompetence in 6 (60%), and trismus in 5 (50%). Fistula formation was also prevalent, including pre-existing fistulae in 4 patients (40%) and reconstruction-related fistulae in 8 (80%). Partial flap loss was observed in 2 patients (20%).",
        "Conclusions": "Premaxillary reconstruction after maxillectomy is associated with substantial morbidity in this small series, including high rates of oral incompetence, trismus, fistula formation, and flap-related complications. Ocular sequelae and midface contour changes were also common. The diversity of flap types used, including radial forearm, fibula, and ALT, reflects the heterogeneity of defects encountered. These findings highlight the reconstructive complexity of premaxillary defects and underscore the need for further study to refine patient selection, flap choice, and perioperative management strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Reconstructive Outcomes in Premaxillary Reconstruction</span>. <u>Nicole J Reynoso</u>; Andrea M Park, MD; Rahul Seth, MD; P Daniel Knott, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Premaxillary reconstruction following partial or total maxillectomy remains technically challenging due to the complex three-dimensional contour of the midface and the need to restore or preserve critical functions including oral competence, nasal projection, and mastication. High rates of wound-healing issues and flap-related complications have been reported, yet literature describing complication patterns specific to premaxillary reconstruction remains limited. The complexity of maxillary reconstruction becomes even more challenging when the premaxilla is involved. This study characterizes reconstructive approaches and associated outcomes in a contemporary cohort of patients undergoing maxillectomy with premaxillary reconstruction at a tertiary academic center.</p>\n\n<p><strong>Methods:</strong> A retrospective review was performed of n=10 patients who underwent premaxillary reconstruction. Demographic, oncologic, operative, and postoperative variables were collected, including maxillectomy extent, reconstructive technique, and functional and flap-related complications. Outcomes included midface contour changes, ocular complications, oral competence, trismus, fistula formation, and flap morbidity.</p>\n\n<p><strong>Results: </strong>Among patients undergoing maxillectomy with premaxillary reconstruction, most defects were reconstructed with free flaps (9/10, 90%) and split-thickness skin grafts (9/10, 90%). The reconstructive burden in this cohort was substantial, with many patients requiring staged procedures utilizing both osteocutaneous and soft-tissue free flaps to address complex premaxillary and midface defects. Maxillectomy extent included partial (40%), subtotal (30%), total (20%), and extended partial (10%) resections. Many patients required complex, staged reconstruction, often employing multiple flaps, including combinations of osteocutaneous and soft-tissue microvascular flaps, to address the magnitude and three-dimensional contour of their defects.</p>\n\n<p>Midface and periocular morbidity was substantial, with midface contraction observed in 3 patients (30%), ectropion in 2 (20%), lagophthalmos in 1 (10%), keratopathy in 2 (20%), chemosis in 2 (20%), oral incompetence in 6 (60%), and trismus in 5 (50%). Fistula formation was also prevalent, including pre-existing fistulae in 4 patients (40%) and reconstruction-related fistulae in 8 (80%). Partial flap loss was observed in 2 patients (20%).</p>\n\n<p><strong>Conclusions:</strong> Premaxillary reconstruction after maxillectomy is associated with substantial morbidity in this small series, including high rates of oral incompetence, trismus, fistula formation, and flap-related complications. Ocular sequelae and midface contour changes were also common. The diversity of flap types used, including radial forearm, fibula, and ALT, reflects the heterogeneity of defects encountered. These findings highlight the reconstructive complexity of premaxillary defects and underscore the need for further study to refine patient selection, flap choice, and perioperative management strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154667--></body></html>"
    },
    {
      "uid": "P336",
      "content_id": "154572",
      "abstract_number": "P336",
      "poster_number": "P336",
      "title": "Workforce Trends and Career Trajectories of Fellowship-Trained Head and Neck Microvascular Surgeons",
      "summary": "There is strong academic retention and leadership progression among fellowship trained head and neck microvascular surgeons. Many are promoted to prominent institutional roles within a few years of graduation. While there is a wide variability in the private sector with no consistent practice model or pathway, many microvascular surgeons find themselves in a private practice setting. Research engagment after...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154572",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maya Behrend, BS",
      "presenter": "Maya Behrend, BS",
      "authors": "Maya Behrend, BS ; Chelsey A Witsberger, MD, MSc; Rachel Fenberg, MD; Aayush Unadkat, BS; Marisa R Buchakjian, MD, PhD",
      "normalized_authors": [
        "Maya Behrend",
        "Chelsey A Witsberger",
        "Rachel Fenberg",
        "Aayush Unadkat",
        "Marisa R Buchakjian"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 339,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Maya Behrend, BS ; Chelsey A Witsberger, MD, MSc; Rachel Fenberg, MD; Aayush Unadkat, BS; Marisa R Buchakjian, MD, PhD",
        "Affiliations": "University of Michigan",
        "Background": "Fellowship training in head and neck microvascular surgery has become the main pathway for building a surgical oncologic practice in otolaryngology. However, data on career trajectories after fellowship remains limited. Variability in job availability and private practice structure plus academic burnout all contribute to uncertainty when providing job counseling to otolaryngology trainees. Understanding workforce distribution and career outcomes of fellowship trained surgeons can help elucidate themes to assist with career planning.",
        "Objective": "To characterize the workforce of fellowship trained head and neck microvascular surgeons in North America with a focus on practice setting, leadership roles, and research productivity.",
        "Methods": "We developed a workforce database of 150 fellowship trained head and neck microvacular surgeons from 2012-2025. Data was obtained using publicly available data from institutional websites, directories, PubMed, LinkedIn, and Doximity. Key information obtained included current position, prior positions, practice type, geographic region, academic title, leadership roles, and research activity.",
        "Results": "Of the 150 surgeons analyzed, 67% were in academic practice, 26% private practice, and 7% in a hybrid setting. Leadership roles were common within 5-7 years post-fellowship. 21% held titles such as Division Chief, Residency Program Director, or Department Chair. Research engagement was high with 38% holding active research or participating in clinical trials and 10% serving as PIs or NIH-funded investigators. Private practice structures were variable with some in larger health systems, smaller specialty groups, or ENT-owned practices. Geographic distribution skewed toward urban academic hubs. Women represented approximately 40% of the cohort and approximately 20% held leadership or director-level positions.",
        "Conclusions": "There is strong academic retention and leadership progression among fellowship trained head and neck microvascular surgeons. Many are promoted to prominent institutional roles within a few years of graduation. While there is a wide variability in the private sector with no consistent practice model or pathway, many microvascular surgeons find themselves in a private practice setting. Research engagment after fellowship remains high and gender representation in leadership is improving. These findings provide valuable insight for residency and fellowship programs and serve as a framework for more personalized and data-backed career counseling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Workforce Trends and Career Trajectories of Fellowship-Trained Head and Neck Microvascular Surgeons</span>. <u>Maya Behrend, BS</u>; Chelsey A Witsberger, MD, MSc; Rachel Fenberg, MD; Aayush Unadkat, BS; Marisa R Buchakjian, MD, PhD. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Fellowship training in head and neck microvascular surgery has become the main pathway for building a surgical oncologic practice in otolaryngology. However, data on career trajectories after fellowship remains limited. Variability in job availability and private practice structure plus academic burnout all contribute to uncertainty when providing job counseling to otolaryngology trainees. Understanding workforce distribution and career outcomes of fellowship trained surgeons can help elucidate themes to assist with career planning.</p>\n\n<p><strong>Objective: </strong>To characterize the workforce of fellowship trained head and neck microvascular surgeons in North America with a focus on practice setting, leadership roles, and research productivity.</p>\n\n<p><strong>Methods: </strong>We developed a workforce database of 150 fellowship trained head and neck microvacular surgeons from 2012-2025. Data was obtained using publicly available data from institutional websites, directories, PubMed, LinkedIn, and Doximity.  Key information obtained included current position, prior positions, practice type, geographic region, academic title, leadership roles, and research activity.</p>\n\n<p><strong>Results: </strong>Of the 150 surgeons analyzed, 67% were in academic practice, 26% private practice, and 7% in a hybrid setting. Leadership roles were common within 5-7 years post-fellowship. 21% held titles such as Division Chief, Residency Program Director, or Department Chair. Research engagement was high with 38% holding active research or participating in clinical trials and 10% serving as PIs or NIH-funded investigators. Private practice structures were variable with some in larger health systems, smaller specialty groups, or ENT-owned practices. Geographic distribution skewed toward urban academic hubs. Women represented approximately 40% of the cohort and approximately 20% held leadership or director-level positions.</p>\n\n<p><strong>Conclusions: </strong>There is strong academic retention and leadership progression among fellowship trained head and neck microvascular surgeons. Many are promoted to prominent institutional roles within a few years of graduation. While there is a wide variability in the private sector with no consistent practice model or pathway, many microvascular surgeons find themselves in a private practice setting. Research engagment after fellowship remains high and gender representation in leadership is improving. These findings provide valuable insight for residency and fellowship programs and serve as a framework for more personalized and data-backed career counseling.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154572--></body></html>"
    },
    {
      "uid": "P337",
      "content_id": "154015",
      "abstract_number": "P337",
      "poster_number": "P337",
      "title": "Thirty-day mortality following free tissue transfer for head and neck cancer",
      "summary": "Thirty-day mortality following free tissue transfer for head and neck cancer reconstruction is driven predominantly by postoperative complications rather than baseline demographics or operative factors. Advanced physiologic vulnerability: renal dysfunction, dialysis dependence, diabetes, elevated TSH, and extreme age (≥90 years) — substantially increases risk. Postoperative complications: DVT, pulmonary events,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154015",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mandy Salmon, MD",
      "presenter": "Mandy Salmon, MD",
      "authors": "Mandy Salmon, MD 1 ; Morgan Terry 1 ; Alisa Phillips 1 ; Madeline Pyle, MD 2 ; Mark Wax, MD 1 ; Joseph Curry, MD 3 ; Carissa M Thomas, MD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 1 ; Dina Modin, BS 2 ; Jason Leibowitz, MD 2 ; Michael DeLeo, MD 6 ; Nicolaus Knight, MS 4 ; Elise Krippaehne, BS 1 ; Javier Nishikawa, BS 4 ; Yasaman Baghshomali, BS 7 ; Madeline Otto, BS 1 ; Sruti Tekumalla, BA 3 ; Sumanth Chandrpatla, BS 4 ; Larissa Sweeny, MD 2",
      "normalized_authors": [
        "Mandy Salmon",
        "Morgan Terry",
        "Alisa Phillips",
        "Madeline Pyle",
        "Mark Wax",
        "Joseph Curry",
        "Carissa M Thomas",
        "Sallie Long",
        "Dev Amin",
        "Caroline Bonaventure",
        "Farshid Taghizadeh",
        "Dina Modin",
        "Jason Leibowitz",
        "Michael DeLeo",
        "Nicolaus Knight",
        "Elise Krippaehne",
        "Javier Nishikawa",
        "Yasaman Baghshomali",
        "Madeline Otto",
        "Sruti Tekumalla",
        "Sumanth Chandrpatla",
        "Larissa Sweeny"
      ],
      "affiliations": [
        "OHSU",
        "University of Miami",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Augusta University",
        "Louisiana State University",
        "Coloradu University"
      ],
      "normalized_institutions": [
        "OHSU",
        "University of Miami",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Augusta University",
        "Louisiana State University",
        "Coloradu University"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154015/Screenshot%202025-12-04%20at%206_47_29%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154015/Screenshot%202025-12-04%20at%206_47_29%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154015"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 363,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mandy Salmon, MD 1 ; Morgan Terry 1 ; Alisa Phillips 1 ; Madeline Pyle, MD 2 ; Mark Wax, MD 1 ; Joseph Curry, MD 3 ; Carissa M Thomas, MD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 1 ; Dina Modin, BS 2 ; Jason Leibowitz, MD 2 ; Michael DeLeo, MD 6 ; Nicolaus Knight, MS 4 ; Elise Krippaehne, BS 1 ; Javier Nishikawa, BS 4 ; Yasaman Baghshomali, BS 7 ; Madeline Otto, BS 1 ; Sruti Tekumalla, BA 3 ; Sumanth Chandrpatla, BS 4 ; Larissa Sweeny, MD 2",
        "Affiliations": "1 OHSU; 2 University of Miami; 3 Thomas Jefferson University; 4 University of Alabama at Birmingham; 5 Augusta University; 6 Louisiana State University; 7 Coloradu University",
        "Background": "Thirty-day mortality following free tissue transfer for head and neck (H&N) cancer reconstruction is uncommon but represents a critical safety endpoint. Identifying patient and perioperative-level predictors of early postoperative death may guide risk stratification, optimization, and perioperative surveillance. This study evaluated demographic, comorbidity, operative, and postoperative variables associated with 30-day mortality after microvascular reconstruction for H&N malignancies.",
        "Methods": "Multi-institutional retrospective review 2010-2024 in adult patients who underwent a free tissue transfer for reconstruction of a H&N cancer ablation and had a mortality within 30 days of procedure. Demographics, nutritional markers, perioperative events, and postoperative complications were analyzed using t-tests, odds ratios (OR), and likelihood ratio testing where appropriate.",
        "Results": "There were 2,947 patients who underwent free tissue transfer, 104 (3.53%) died within 30 days of their free tissue reconstruction with variables examined for positive predictors (Table 1). Mortality was higher in patients >75 years with similar but borderline findings for >80 years. In contrast, age >85 years showed no significant effect, while the very small cohort of patients ≥90 years had markedly elevated mortality. Males trended toward higher mortality.",
        "Abstract": "Operative duration (defined as <10hrs or >10hrs) did not predict mortality (p=0.235). Some comorbidities (cardiac disease, hypertension, pulmonary disease, COPD, tobacco use, prior radiation, and prior chemotherapy) also did not predict mortality. Positive predictors included: diabetes, renal disease, and dialysis. Elevated TSH was the only laboratory marker associated with mortality (p=0.0027). Postoperative complications that predicted 30-day mortality, included return to the operating room, flap compromise, fistula or salivary leak, wound dehiscence, postoperative wound complications, and composite postoperative complications. Severe Clavien–Dindo IV complications were strongly associated. ICU escalation and postoperative pulmonary complications were significant predictors. Notably, deep venous thrombosis showed a strong association, whereas pulmonary embolism did not. Postoperative sepsis and 30-day readmission were also highly predictive.",
        "Conclusion": "Thirty-day mortality following free tissue transfer for head and neck cancer reconstruction is driven predominantly by postoperative complications rather than baseline demographics or operative factors. Advanced physiologic vulnerability: renal dysfunction, dialysis dependence, diabetes, elevated TSH, and extreme age (≥90 years) — substantially increases risk. Postoperative complications: DVT, pulmonary events, sepsis, and need for return to the operating room — also increases mortality."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thirty-day mortality following free tissue transfer for head and neck cancer</span>. <u>Mandy Salmon, MD</u><sup>1</sup>; Morgan Terry<sup>1</sup>; Alisa Phillips<sup>1</sup>; Madeline Pyle, MD<sup>2</sup>; Mark Wax, MD<sup>1</sup>; Joseph Curry, MD<sup>3</sup>; Carissa M Thomas, MD<sup>4</sup>; Sallie Long, MD<sup>5</sup>; Dev Amin, MD<sup>3</sup>; Caroline Bonaventure, MD<sup>6</sup>; Farshid Taghizadeh, MD<sup>1</sup>; Dina Modin, BS<sup>2</sup>; Jason Leibowitz, MD<sup>2</sup>; Michael DeLeo, MD<sup>6</sup>; Nicolaus Knight, MS<sup>4</sup>; Elise Krippaehne, BS<sup>1</sup>; Javier Nishikawa, BS<sup>4</sup>; Yasaman Baghshomali, BS<sup>7</sup>; Madeline Otto, BS<sup>1</sup>; Sruti Tekumalla, BA<sup>3</sup>; Sumanth Chandrpatla, BS<sup>4</sup>; Larissa Sweeny, MD<sup>2</sup>. <sup>1</sup>OHSU; <sup>2</sup>University of Miami; <sup>3</sup>Thomas Jefferson University; <sup>4</sup>University of Alabama at Birmingham; <sup>5</sup>Augusta University; <sup>6</sup>Louisiana State University; <sup>7</sup>Coloradu University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Thirty-day mortality following free tissue transfer for head and neck (H&N) cancer reconstruction is uncommon but represents a critical safety endpoint. Identifying patient and perioperative-level predictors of early postoperative death may guide risk stratification, optimization, and perioperative surveillance. This study evaluated demographic, comorbidity, operative, and postoperative variables associated with 30-day mortality after microvascular reconstruction for H&N malignancies.</p>\n\n<p><strong>Methods: </strong>Multi-institutional retrospective review 2010-2024 in adult patients who underwent a free tissue transfer for reconstruction of a H&N cancer ablation and had a mortality within 30 days of procedure. Demographics, nutritional markers, perioperative events, and postoperative complications were analyzed using t-tests, odds ratios (OR), and likelihood ratio testing where appropriate.</p>\n\n<p><strong>Results: </strong>There were 2,947 patients who underwent free tissue transfer, 104 (3.53%) died within 30 days of their free tissue reconstruction with variables examined for positive predictors (Table 1). Mortality was higher in patients >75 years with similar but borderline findings for >80 years. In contrast, age >85 years showed no significant effect, while the very small cohort of patients ≥90 years had markedly elevated mortality. Males trended toward higher mortality.  </p>\n\n<p>Operative duration (defined as <10hrs or >10hrs) did not predict mortality (p=0.235). Some comorbidities (cardiac disease, hypertension, pulmonary disease, COPD, tobacco use, prior radiation, and prior chemotherapy) also did not predict mortality. Positive predictors included: diabetes, renal disease, and dialysis. Elevated TSH was the only laboratory marker associated with mortality (p=0.0027).</p>\n\n<p>Postoperative complications that predicted 30-day mortality, included return to the operating room, flap compromise, fistula or salivary leak, wound dehiscence, postoperative wound complications, and composite postoperative complications. Severe Clavien–Dindo IV complications were strongly associated. ICU escalation and postoperative pulmonary complications were significant predictors. Notably, deep venous thrombosis showed a strong association, whereas pulmonary embolism did not. Postoperative sepsis and 30-day readmission were also highly predictive. </p>\n\n<p><strong>Conclusion: </strong>Thirty-day mortality following free tissue transfer for head and neck cancer reconstruction is driven predominantly by postoperative complications rather than baseline demographics or operative factors. Advanced physiologic vulnerability: renal dysfunction, dialysis dependence, diabetes, elevated TSH, and extreme age (≥90 years) — substantially increases risk. Postoperative complications: DVT, pulmonary events, sepsis, and need for return to the operating room — also increases mortality. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154015/Screenshot%202025-12-04%20at%206_47_29%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154015--></body></html>"
    },
    {
      "uid": "P338",
      "content_id": "154686",
      "abstract_number": "P338",
      "poster_number": "P338",
      "title": "Local vs Free Flaps for Cutaneous Head and Neck Cancer: Evaluating Differences in Complication Profiles and Treatment Burden",
      "summary": "Local flaps are associated with a lower treatment burden compared to free flaps and have similar complication profiles and acceptable outcomes. Local flaps may be a preferred choice when feasible for cutaneous reconstruction in the head and neck, especially in older patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154686",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Andrew J Bellas, BS",
      "presenter": "Andrew J Bellas, BS",
      "authors": "Andrew J Bellas, BS ; Ethan Lewis, BS; Jackson Brown, BS; Andrew Peterson, MD, MSCI; Dorina Kallogjeri, MD, MPH; Jason Rich, MD, FACS",
      "normalized_authors": [
        "Andrew J Bellas",
        "Ethan Lewis",
        "Jackson Brown",
        "Andrew Peterson, MSCI",
        "Dorina Kallogjeri",
        "Jason Rich"
      ],
      "affiliations": [
        "Washington University in St. Louis – Department of Otolaryngology–Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "Washington University in St. Louis – Department of Otolaryngology–Head & Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 478,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Andrew J Bellas, BS ; Ethan Lewis, BS; Jackson Brown, BS; Andrew Peterson, MD, MSCI; Dorina Kallogjeri, MD, MPH; Jason Rich, MD, FACS",
        "Affiliations": "Washington University in St. Louis – Department of Otolaryngology–Head & Neck Surgery",
        "Background": "With the growing incidence of head and neck cutaneous malignancies, head and neck surgeons are increasingly required to provide adequate cutaneous reconstruction. As the reliability, speed, and comfort level of performing microvascular free flaps has improved, many surgeons are drawn to performing free flaps over local flaps to reconstruct cutaneous defects. However, the complication rates and treatment burden differences between free flaps and local flaps for cutaneous defects are unknown. Since most skin cancers occur in older patients, it is imperative to have more complete data on these outcomes to better counsel patients in a shared decision-making process.",
        "Objective": "This study aims to compare the complication profiles and treatment burden in patients with cutaneous head and neck malignancies undergoing either local flap or free flap reconstruction.",
        "Methods": "This is a retrospective cohort study of patients undergoing local flaps (LF) or free flaps (FF) for reconstruction of cutaneous malignancy defects ≥ 5 cm on major and minor axis at a single academic center from 1/1/2024 to 8/1/2024. Extracted variables included demographic characteristics, intra-op time (IOT), pathological and clinical characteristics, comorbidities, and length of hospitalization (LOS). Flap-site infection, dehiscence, or necrosis <50% with no unexpected wound care at 30-days post-operatively were defined as minor wound complications (MiWC). Unexpected and continued wound care at 30 days postoperatively, ≥50% flap necrosis, or complete flap failure were defined as major wound complications (MaWC). Complications including heart attack, stroke, pneumonia, DVT, etc., transfer to a higher level of care, re-admission, death, or functional decline within 90 days of surgery were defined as medical complications (MC).",
        "Results": "LF patients (n=25) were older than their FF (n=13) counterparts (75 years (±13.5) vs 66 (±11.5), mean difference 9.1, 95% CI: 0.1-18.1). Median (range) of largest dimension of defect size for LF was 6 cm (5-9) and for FF was 10 cm (6-17). LF took a median of 4.8 hours less IOT (95% CI: 3.9-6.0) than FF with median (range) 2.5 hours (0.9-4.9) for LF and 7.4 hours (5.3-10.9) for FF. The LOS differed markedly with a median (range) LOS of 0 days (0-1) for LF and 6 days (3-8) for FF. MiWC rates were higher in the LF (n=6, 25%) compared to FF (n=2, 16.7%), for a difference of 8.3% (95% CI: -22%-33%). MaWC was seen in 1 patient in each group. There was 1 FF patient that experienced MC. For those requiring adjuvant radiation (n=13), median (range) time to radiation for LF was 6 weeks (4-10) and 7 weeks (4-12) for FF.",
        "Conclusion": "Local flaps are associated with a lower treatment burden compared to free flaps and have similar complication profiles and acceptable outcomes. Local flaps may be a preferred choice when feasible for cutaneous reconstruction in the head and neck, especially in older patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Local vs Free Flaps for Cutaneous Head and Neck Cancer: Evaluating Differences in Complication Profiles and Treatment Burden</span>. <u>Andrew J Bellas, BS</u>; Ethan Lewis, BS; Jackson Brown, BS; Andrew Peterson, MD, MSCI; Dorina Kallogjeri, MD, MPH; Jason Rich, MD, FACS. Washington University in St. Louis – Department of Otolaryngology–Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>With the growing incidence of head and neck cutaneous malignancies, head and neck surgeons are increasingly required to provide adequate cutaneous reconstruction. As the reliability, speed, and comfort level of performing microvascular free flaps has improved, many surgeons are drawn to performing free flaps over local flaps to reconstruct cutaneous defects. However, the complication rates and treatment burden differences between free flaps and local flaps for cutaneous defects are unknown. Since most skin cancers occur in older patients, it is imperative to have more complete data on these outcomes to better counsel patients in a shared decision-making process.</p>\n\n<p><strong>Objective: </strong>This study aims to compare the complication profiles and treatment burden in patients with cutaneous head and neck malignancies undergoing either local flap or free flap reconstruction.</p>\n\n<p><strong>Methods: </strong>This is a retrospective cohort study of patients undergoing local flaps (LF) or free flaps (FF) for reconstruction of cutaneous malignancy defects ≥ 5 cm on major and minor axis at a single academic center from 1/1/2024 to 8/1/2024. Extracted variables included demographic characteristics, intra-op time (IOT), pathological and clinical characteristics, comorbidities, and length of hospitalization (LOS). Flap-site infection, dehiscence, or necrosis <50% with no unexpected wound care at 30-days post-operatively were defined as minor wound complications (MiWC). Unexpected and continued wound care at 30 days postoperatively, ≥50% flap necrosis, or complete flap failure were defined as major wound complications (MaWC). Complications including heart attack, stroke, pneumonia, DVT, etc., transfer to a higher level of care, re-admission, death, or functional decline within 90 days of surgery were defined as medical complications (MC).</p>\n\n<p><strong>Results: </strong>LF patients (n=25) were older than their FF (n=13) counterparts (75 years (±13.5) vs 66 (±11.5), mean difference 9.1, 95% CI: 0.1-18.1). Median (range) of largest dimension of defect size for LF was 6 cm (5-9) and for FF was 10 cm (6-17). LF took a median of 4.8 hours less IOT (95% CI: 3.9-6.0) than FF with median (range) 2.5 hours (0.9-4.9) for LF and 7.4 hours (5.3-10.9) for FF. The LOS differed markedly with a median (range) LOS of 0 days (0-1) for LF and 6 days (3-8) for FF. MiWC rates were higher in the LF (n=6, 25%) compared to FF (n=2, 16.7%), for a difference of 8.3% (95% CI: -22%-33%). MaWC was seen in 1 patient in each group. There was 1 FF patient that experienced MC. For those requiring adjuvant radiation (n=13), median (range) time to radiation for LF was 6 weeks (4-10) and 7 weeks (4-12) for FF.</p>\n\n<p><strong>Conclusion: </strong>Local flaps are associated with a lower treatment burden compared to free flaps and have similar complication profiles and acceptable outcomes. Local flaps may be a preferred choice when feasible for cutaneous reconstruction in the head and neck, especially in older patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154686--></body></html>"
    },
    {
      "uid": "P339",
      "content_id": "154192",
      "abstract_number": "P339",
      "poster_number": "P339",
      "title": "The Deep Femoral Vascular System: main perforator flaps in microvascular reconstruction after oncological head and neck surgery",
      "summary": "This study analyzes the perforator flaps that can be harvested from the deep femoral vascular system as a convenient and versatile option for a wide range of oncological head and neck defects. We describe the vascular anatomy of the deep femoral system, its principal variants, and the main reconstructive options—from the most established (ALT flap) to emerging ones (PAP flap, anteromedial thigh flap, tensor...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154192",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Milena Fior",
      "presenter": "Milena Fior",
      "authors": "Milena Fior ; Francesco Mazzola; Raul Pellini",
      "normalized_authors": [
        "Milena Fior",
        "Francesco Mazzola",
        "Raul Pellini"
      ],
      "affiliations": [
        "IRCCS Regina Elena Cancer Institute of Rome"
      ],
      "normalized_institutions": [
        "IRCCS Regina Elena Cancer Institute of Rome"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 151,
      "section_labels": [
        "Authors",
        "Affiliations",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSIONS"
      ],
      "sections": {
        "Authors": "Milena Fior ; Francesco Mazzola; Raul Pellini",
        "Affiliations": "IRCCS Regina Elena Cancer Institute of Rome",
        "MATERIALS AND METHODS": "This study analyzes the perforator flaps that can be harvested from the deep femoral vascular system as a convenient and versatile option for a wide range of oncological head and neck defects. We describe the vascular anatomy of the deep femoral system, its principal variants, and the main reconstructive options—from the most established (ALT flap) to emerging ones (PAP flap, anteromedial thigh flap, tensor fascia lata flap)—using illustrative material and surgical videos.",
        "RESULTS": "We reviewed surgical techniques, anatomical variations, indications, complications, and functional outcomes associated with the major thigh perforator flaps. Both lateral and medial approaches allow the harvest of different perforator flaps with a simultaneous two-team approach, relatively consistent anatomy, low complication rates, and good functional results.",
        "CONCLUSIONS": "In the era of contemporary microvascular reconstruction, a new generation of thigh perforator flaps can be integrated into the reconstructive surgeon’s armamentarium for the management of complex head and neck defects"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Deep Femoral Vascular System: main perforator flaps in microvascular reconstruction after oncological head and neck surgery</span>. <u>Milena Fior</u>; Francesco Mazzola; Raul Pellini. IRCCS Regina Elena Cancer Institute of Rome<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>MATERIALS AND METHODS: </strong>This study analyzes the perforator flaps that can be harvested from the deep femoral vascular system as a convenient and versatile option for a wide range of oncological head and neck defects. We describe the vascular anatomy of the deep femoral system, its principal variants, and the main reconstructive options—from the most established (ALT flap) to emerging ones (PAP flap, anteromedial thigh flap, tensor fascia lata flap)—using illustrative material and surgical videos.</p>\n\n<p><strong>RESULTS: </strong>We reviewed surgical techniques, anatomical variations, indications, complications, and functional outcomes associated with the major thigh perforator flaps. Both lateral and medial approaches allow the harvest of different perforator flaps with a simultaneous two-team approach, relatively consistent anatomy, low complication rates, and good functional results.</p>\n\n<p><strong>CONCLUSIONS: </strong>In the era of contemporary microvascular reconstruction, a new generation of thigh perforator flaps can be integrated into the reconstructive surgeon’s armamentarium for the management of complex head and neck defects</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154192--></body></html>"
    },
    {
      "uid": "P340",
      "content_id": "154392",
      "abstract_number": "P340",
      "poster_number": "P340",
      "title": "Impact of a goal-directed hemodynamic anesthesia protocol: a prospective observational study on perioperative outcomes in head and neck free flap reconstruction",
      "summary": "Implementation of a standardized goal-directed hemodynamic protocol reduced intraoperative transfusion rates and increased vasopressor use without adversely affecting major 30-day outcomes in free flap reconstruction. The increased wound infection rate requires further investigation, and prospective studies are necessary to validate and refine protocol-based hemodynamic management.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154392",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sarah R Harrington, BA",
      "presenter": "Sarah R Harrington, BA",
      "authors": "Sarah R Harrington, BA 1 ; Daniel Uralov, MD 1 ; Sophia Linguiti, BA 1 ; Eric Mastrolonardo, MD 1 ; Emma De Ravin, MD 1 ; Kevin Min, MD 2 ; Dane Grenda, DO 2 ; Arielle Thal, MD 1",
      "normalized_authors": [
        "Sarah R Harrington",
        "Daniel Uralov",
        "Sophia Linguiti",
        "Eric Mastrolonardo",
        "Emma De Ravin",
        "Kevin Min",
        "Dane Grenda",
        "Arielle Thal"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA",
        "Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA",
        "Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sarah R Harrington, BA 1 ; Daniel Uralov, MD 1 ; Sophia Linguiti, BA 1 ; Eric Mastrolonardo, MD 1 ; Emma De Ravin, MD 1 ; Kevin Min, MD 2 ; Dane Grenda, DO 2 ; Arielle Thal, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA; 2 Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA",
        "Introduction": "Fluid and hemodynamic management in microvascular free flap procedures pose significant challenges for the surgical and anesthesia teams. While adequate perfusion must be maintained to prevent flap thrombosis, traditional fluid-based approaches to treating perioperative hypotension can lead to fluid overload, contributing to higher complication and flap failure rates. Blood transfusion has historically served an alternative strategy; however, perioperative transfusion in head and neck free flap reconstruction is consistently associated with higher rates of wound complications, flap related morbidity, and a dose-dependent increase in cancer recurrence and mortality. In contrast, goal-directed hemodynamic strategies that incorporate vasopressor support—demonstrated to be safe in free flap patients—help maintain perfusion pressure while minimizing excessive fluid burden. To improve consistency in intraoperative care and reduce unnecessary transfusions, our institution implemented a standardized hemodynamic protocol emphasizing perfusion-pressure support, judicious fluid administration, and restrictive transfusion criteria. This study evaluates the protocol’s impact on 30-day surgical and medical outcomes, as well as associated changes in intraoperative hemodynamic practices.",
        "Methods": "We conducted a prospective observational trial of adult patients undergoing head and neck microvascular free flap reconstruction at a tertiary academic center. A standardized intraoperative hemodynamic protocol was implemented that targeted a mean arterial pressure (MAP) ≥65 mmHg) and incorporated a stepwise algorithm for assessing fluid responsiveness with pulse pressure variation (PPV). Phenylephrine was designated as the first-line vasopressor for pressure support. Transfusion thresholds were standardized to a restrictive hemoglobin of <7 g/dL, or <7.5 g/dL in patients with known coronary artery disease. Demographic, operative, intraoperative, and postoperative variables were obtained through chart review. Primary endpoints included 30-day free flap related postoperative outcomes (flap failure, need for salvage surgery, primary and donor-site complications), systemic complications, need for PEG tube placement or tracheostomy, unplanned healthcare utilization, and postoperative transfusion. Secondary endpoints included rate of intraoperative vasopressor use, fluid administration, and intraoperative transfusion.",
        "Results": "A total of 170 patients were included (pre-protocol n=85, ; post-protocol n=85). Intraoperative transfusion decreased from 21.2% to 12.2% (p=0.148) following protocol administration. Intraoperative vasopressor use increased significantly (32.9% to 67.5%, p<0.001). Total crystalloid administration showed no significant difference between cohorts. (5.0±1.7 L vs 4.6±1.5 L). 30-day primary outcomes were similar between cohorts. Rates of flap failure, return to the operating room, donor-site complications, and systemic complications did not differ. Postoperative wound infection rates were higher in the post-protocol cohort (6.1% vs 16.5%, p=0.049), however group analyses showed no association with intraoperative fluid volume, vasopressor use, or transfusion. No significant differences were observed in ED visits, readmissions, airway or nutrition outcomes, or length of stay.",
        "Conclusion": "Implementation of a standardized goal-directed hemodynamic protocol reduced intraoperative transfusion rates and increased vasopressor use without adversely affecting major 30-day outcomes in free flap reconstruction. The increased wound infection rate requires further investigation, and prospective studies are necessary to validate and refine protocol-based hemodynamic management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of a goal-directed hemodynamic anesthesia protocol: a prospective observational study on perioperative outcomes in head and neck free flap reconstruction</span>. <u>Sarah R Harrington, BA</u><sup>1</sup>; Daniel Uralov, MD<sup>1</sup>; Sophia Linguiti, BA<sup>1</sup>; Eric Mastrolonardo, MD<sup>1</sup>; Emma De Ravin, MD<sup>1</sup>; Kevin Min, MD<sup>2</sup>; Dane Grenda, DO<sup>2</sup>; Arielle Thal, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA; <sup>2</sup>Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Fluid and hemodynamic management in microvascular free flap procedures pose significant challenges for the surgical and anesthesia teams. While adequate perfusion must be maintained to prevent flap thrombosis, traditional fluid-based approaches to treating perioperative hypotension can lead to fluid overload, contributing to higher complication and flap failure rates. Blood transfusion has historically served an alternative strategy; however, perioperative transfusion in head and neck free flap reconstruction is consistently associated with higher rates of wound complications, flap related morbidity, and a dose-dependent increase in cancer recurrence and mortality. In contrast, goal-directed hemodynamic strategies that incorporate vasopressor support—demonstrated to be safe in free flap patients—help maintain perfusion pressure while minimizing excessive fluid burden. To improve consistency in intraoperative care and reduce unnecessary transfusions, our institution implemented a standardized hemodynamic protocol emphasizing perfusion-pressure support, judicious fluid administration, and restrictive transfusion criteria. This study evaluates the protocol’s impact on 30-day surgical and medical outcomes, as well as associated changes in intraoperative hemodynamic practices.</p>\n\n<p><strong>Methods: </strong>We conducted a prospective observational trial of adult patients undergoing head and neck microvascular free flap reconstruction at a tertiary academic center. A standardized intraoperative hemodynamic protocol was implemented that targeted a mean arterial pressure (MAP) ≥65 mmHg) and incorporated a stepwise algorithm for assessing fluid responsiveness with pulse pressure variation (PPV). Phenylephrine was designated as the first-line vasopressor for pressure support. Transfusion thresholds were standardized to a restrictive hemoglobin of <7 g/dL, or <7.5 g/dL in patients with known coronary artery disease. Demographic, operative, intraoperative, and postoperative variables were obtained through chart review. Primary endpoints included 30-day free flap related postoperative outcomes (flap failure, need for salvage surgery, primary and donor-site complications), systemic complications, need for PEG tube placement or tracheostomy, unplanned healthcare utilization, and postoperative transfusion. Secondary endpoints included rate of intraoperative vasopressor use, fluid administration, and intraoperative transfusion.</p>\n\n<p><strong>Results: </strong>A total of 170 patients were included (pre-protocol n=85, ; post-protocol n=85). Intraoperative transfusion decreased from 21.2% to 12.2% (p=0.148) following protocol administration. Intraoperative vasopressor use increased significantly (32.9% to 67.5%, p<0.001). Total crystalloid administration showed no significant difference between cohorts. (5.0±1.7 L vs 4.6±1.5 L). 30-day primary outcomes were similar between cohorts. Rates of flap failure, return to the operating room, donor-site complications, and systemic complications did not differ. Postoperative wound infection rates were higher in the post-protocol cohort (6.1% vs 16.5%, p=0.049), however group analyses showed no association with intraoperative fluid volume, vasopressor use, or transfusion. No significant differences were observed in ED visits, readmissions, airway or nutrition outcomes, or length of stay.</p>\n\n<p><strong>Conclusion: </strong>Implementation of a standardized goal-directed hemodynamic protocol reduced intraoperative transfusion rates and increased vasopressor use without adversely affecting major 30-day outcomes in free flap reconstruction. The increased wound infection rate requires further investigation, and prospective studies are necessary to validate and refine protocol-based hemodynamic management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154392--></body></html>"
    },
    {
      "uid": "P341",
      "content_id": "155586",
      "abstract_number": "P341",
      "poster_number": "P341",
      "title": "Are Single-Shot Popliteal Nerve Blocks Effective for Opioid Reduction in Fibular Free Flap Reconstruction?",
      "summary": "Single-shot popliteal nerve blocks with ropivacaine were not associated with reduced postoperative opioid consumption following fibular free flap reconstruction. Opioid use trended higher among patients receiving nerve blocks, particularly during the 24–48 hour postoperative period corresponding to block resolution, suggesting possible rebound analgesia. These findings suggest that single-shot blocks alone may be...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155586",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joseph Masselli, MD, DDS",
      "presenter": "Joseph Masselli, MD, DDS",
      "authors": "Peter S Giannaris, BS 1 ; Joseph Masselli, MD, DDS 2 ; Jake Do 3 ; Danielle Scarola, MD 1 ; David Hirsch, MD, DDS 2 ; Brett Miles, MD, DDS 1",
      "normalized_authors": [
        "Peter S Giannaris",
        "Joseph Masselli",
        "Danielle Scarola",
        "David Hirsch",
        "Brett Miles"
      ],
      "affiliations": [
        "Northwell Health-Department of Otolaryngology-Head and Neck Surgery",
        "Northwell Health-Department of Oral and Maxillofacial Surgery",
        "Zucker School of Medicine"
      ],
      "normalized_institutions": [
        "Northwell Health-Department of Otolaryngology-Head and Neck Surgery",
        "Northwell Health-Department of Oral and Maxillofacial Surgery",
        "Zucker School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 413,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Peter S Giannaris, BS 1 ; Joseph Masselli, MD, DDS 2 ; Jake Do 3 ; Danielle Scarola, MD 1 ; David Hirsch, MD, DDS 2 ; Brett Miles, MD, DDS 1",
        "Affiliations": "1 Northwell Health-Department of Otolaryngology-Head and Neck Surgery; 2 Northwell Health-Department of Oral and Maxillofacial Surgery; 3 Zucker School of Medicine",
        "Background": "Postoperative opioid consumption remains a significant concern in head and neck reconstructive surgery, with fibular free flap (FFF) patients at risk for prolonged opioid use due to donor site pain. Regional anesthesia techniques, including popliteal nerve blocks, have been proposed as opioid-sparing measures. However, single-shot blocks typically provide only 12–24 hours of analgesia, which may be insufficient for the prolonged recovery associated with FFF surgery. Data evaluating the efficacy of single-shot popliteal nerve blocks in this population remain limited.",
        "Objective": "To evaluate the association between single-shot popliteal nerve block with ropivacaine and postoperative opioid consumption, pain scores, and length of stay among patients undergoing FFF reconstruction.",
        "Methods": "A retrospective cohort study of consecutive patients undergoing tumor resection with fibular free flap (FFF) reconstruction at our institution between 2020 and 2024 was performed. Patients who received an ultrasound-guided single-shot popliteal nerve block with ropivacaine were compared with those who did not receive a regional block. Primary outcomes included total postoperative opioid consumption measured in morphine milligram equivalents (MME), hospital length of stay, and maximum pain scores. Comparisons between groups were performed using Mann–Whitney U tests, with statistical significance defined as p < 0.05.",
        "Results": "Twenty-nine patients undergoing tumor resection with fibular free flap reconstruction were included; 13 received a popliteal nerve block and 16 comprised the no-block cohort. Baseline characteristics were similar between groups, although there was a trend toward higher BMI in the block cohort (30.1±5.7 vs. 26.2±6.4 kg/m², p = 0.056). No statistically significant differences were observed in total postoperative opioid consumption, hospital length of stay, or postoperative day-one maximum pain scores. Across all postoperative time intervals, opioid consumption trended higher among patients receiving nerve blocks. During the 24–48 hour postoperative interval, corresponding to expected block resolution, opioid consumption approached statistical significance (52.3±39.9 vs. 35.0±61.9 MME, p = 0.056). Higher opioid use in the block cohort persisted through 120 hours postoperatively.",
        "Conclusion": "Single-shot popliteal nerve blocks with ropivacaine were not associated with reduced postoperative opioid consumption following fibular free flap reconstruction. Opioid use trended higher among patients receiving nerve blocks, particularly during the 24–48 hour postoperative period corresponding to block resolution, suggesting possible rebound analgesia. These findings suggest that single-shot blocks alone may be insufficient for sustained donor-site pain control after FFF reconstruction, and bridging analgesic strategies may be necessary following block resolution. Larger prospective studies are needed to better define the role of regional anesthesia in this population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Are Single-Shot Popliteal Nerve Blocks Effective for Opioid Reduction in Fibular Free Flap Reconstruction?</span>. Peter S Giannaris, BS<sup>1</sup>; <u>Joseph Masselli, MD, DDS</u><sup>2</sup>; Jake Do<sup>3</sup>; Danielle Scarola, MD<sup>1</sup>; David Hirsch, MD, DDS<sup>2</sup>; Brett Miles, MD, DDS<sup>1</sup>. <sup>1</sup>Northwell Health-Department of Otolaryngology-Head and Neck Surgery; <sup>2</sup>Northwell Health-Department of Oral and Maxillofacial Surgery; <sup>3</sup>Zucker School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Postoperative opioid consumption remains a significant concern in head and neck reconstructive surgery, with fibular free flap (FFF) patients at risk for prolonged opioid use due to donor site pain. Regional anesthesia techniques, including popliteal nerve blocks, have been proposed as opioid-sparing measures. However, single-shot blocks typically provide only 12–24 hours of analgesia, which may be insufficient for the prolonged recovery associated with FFF surgery. Data evaluating the efficacy of single-shot popliteal nerve blocks in this population remain limited.</p>\n\n<p><strong>Objective: </strong>To evaluate the association between single-shot popliteal nerve block with ropivacaine and postoperative opioid consumption, pain scores, and length of stay among patients undergoing FFF reconstruction.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of consecutive patients undergoing tumor resection with fibular free flap (FFF) reconstruction at our institution between 2020 and 2024 was performed. Patients who received an ultrasound-guided single-shot popliteal nerve block with ropivacaine were compared with those who did not receive a regional block. Primary outcomes included total postoperative opioid consumption measured in morphine milligram equivalents (MME), hospital length of stay, and maximum pain scores. Comparisons between groups were performed using Mann–Whitney U tests, with statistical significance defined as p < 0.05.</p>\n\n<p><strong>Results: </strong>Twenty-nine patients undergoing tumor resection with fibular free flap reconstruction were included; 13 received a popliteal nerve block and 16 comprised the no-block cohort. Baseline characteristics were similar between groups, although there was a trend toward higher BMI in the block cohort (30.1±5.7 vs. 26.2±6.4 kg/m², p = 0.056). No statistically significant differences were observed in total postoperative opioid consumption, hospital length of stay, or postoperative day-one maximum pain scores. Across all postoperative time intervals, opioid consumption trended higher among patients receiving nerve blocks. During the 24–48 hour postoperative interval, corresponding to expected block resolution, opioid consumption approached statistical significance (52.3±39.9 vs. 35.0±61.9 MME, p = 0.056). Higher opioid use in the block cohort persisted through 120 hours postoperatively.</p>\n\n<p><strong>Conclusion: </strong>Single-shot popliteal nerve blocks with ropivacaine were not associated with reduced postoperative opioid consumption following fibular free flap reconstruction. Opioid use trended higher among patients receiving nerve blocks, particularly during the 24–48 hour postoperative period corresponding to block resolution, suggesting possible rebound analgesia. These findings suggest that single-shot blocks alone may be insufficient for sustained donor-site pain control after FFF reconstruction, and bridging analgesic strategies may be necessary following block resolution. Larger prospective studies are needed to better define the role of regional anesthesia in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155586--></body></html>"
    },
    {
      "uid": "P342",
      "content_id": "153438",
      "abstract_number": "P342",
      "poster_number": "P342",
      "title": "Tissue Plasminogen Activator in Acute Microvascular Venous Compromise Shows Immediate improvement in near infrared spectroscopic readings",
      "summary": "Microvascular free tissue transfer has become standard for head and neck cancer reconstruction. Pedicle thrombosis is a rare but critical complication that remains a leading cause of flap compromise, with most events occurring postoperatively within the first 72 hours. Prophylactic anti-coagulation with low-molecular-weight heparin is commonly used, however its efficacy has not been proven. Potential utilization...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153438",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandra Kejner, MD",
      "presenter": "Alexandra Kejner, MD",
      "authors": "Angelica Walker, BS; Jordyn Carroll, BS; Alexandra Kejner, MD",
      "normalized_authors": [
        "Angelica Walker",
        "Jordyn Carroll",
        "Alexandra Kejner"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 493,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Angelica Walker, BS; Jordyn Carroll, BS; Alexandra Kejner, MD",
        "Affiliations": "Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina",
        "Introduction": "Microvascular free tissue transfer has become standard for head and neck cancer reconstruction. Pedicle thrombosis is a rare but critical complication that remains a leading cause of flap compromise, with most events occurring postoperatively within the first 72 hours. Prophylactic anti-coagulation with low-molecular-weight heparin is commonly used, however its efficacy has not been proven. Potential utilization of intravascular thrombolytics, such as tissue plasminogen activator (tPA), have been explored for select cases when surgical revision alone is insufficient. Few studies exist describing benefit of tPA utilization as a salvage procedure for flaps after vascular compromise.",
        "Case Presentation": "A 75-year-old female with a history of rheumatoid arthritis (RA) on leflunomide and previous diagnosis of pulmonary embolus on apixaban and also status post inferior vena cava filter placement presented to clinic with a cT4aN0M0 squamous cell carcinoma of the hard palate. The patient underwent a bilateral maxillectomy with a level I-III neck dissection followed by zygomatic implant perforated flap reconstruction.",
        "Abstract": "During flap harvest, it was noted that the ulnar pedicle was position sensitive with just mild geometric manipulation leading to mild congestion that improved with gentle re-draping. The pedicle was ligated, flushed with heparinized saline, and the patient was started on a weight-based heparin (WBH) drip. Microvascular anastomosis was to the facial vessels demonstrated immediate flow and excellent implantable doppler signal. Vioptix (Vioptix Inc.) near infrared spectroscopy (NIRS), utilized to measure the proportion of de-oxygenated to oxygenated hemoglobin, demonstrated initial StO2 readings in the 70s. However, upon inset completion, the flap was noted to be congested and ruddy in appearance, with an StO2 dropping into the lower 50’s. The anastomosis of venae comitantes with 2.0 mm couplers improved flap appearance and StO2 readings into the 70s. However, after 10 minutes, perfusion again decreased. SPY angiography identified a non-perfused skin segment, which was excised, and increasing heparin drip restored StO2 values rose into the 80s. Remaining incisions were then closed, and the patient was transferred to the STICU for further monitoring. A continuous WBH drip was maintained for 72 hours. On POD 1, supratherapeutic PTT led to discontinuation of heparin, after which congestion recurred. Subcutaneous tPA 2mg was administered, improving StO2 from 43 to 89%. A subsequent dose was held due to mild oozing from the intraoral suture line, and on POD 2 the patient required return to the OR for hemostasis. The flap was noted to be viable. That afternoon, recurrent congestion was managed with a 1mg injection of tPA, improving perfusion, and the patient was transitioned to enoxaparin. StO2 remained stable (70s to 90s) thereafter. Despite flap viability and improved perfusion, the patient later elected for palliative care and was discharged to hospice.",
        "Discussion": "Free tissue transfer remains essential for maxillofacial reconstruction, though venous congestion continues to threaten flap viability despite meticulous technique. This case adds to the growing body of evidence supporting the use of tPA as a salvage strategy in selected free flap reconstructions and underscores the ability of NIRS to detect microvascular compromise."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tissue Plasminogen Activator in Acute Microvascular Venous Compromise Shows Immediate improvement in near infrared spectroscopic readings</span>. Angelica Walker, BS; Jordyn Carroll, BS; <u>Alexandra Kejner, MD</u>. Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Microvascular free tissue transfer has become standard for head and neck cancer reconstruction. Pedicle thrombosis is a rare but critical complication that remains a leading cause of flap compromise, with most events occurring postoperatively within the first 72 hours. Prophylactic anti-coagulation with low-molecular-weight heparin is commonly used, however its efficacy has not been proven. Potential utilization of intravascular thrombolytics, such as tissue plasminogen activator (tPA), have been explored for select cases when surgical revision alone is insufficient. Few studies exist describing benefit of tPA utilization as a salvage procedure for flaps after vascular compromise.</p>\n\n<p><strong>Case Presentation:</strong> A 75-year-old female with a history of rheumatoid arthritis (RA) on leflunomide and previous diagnosis of pulmonary embolus on apixaban and also status post inferior vena cava filter placement presented to clinic with a cT4aN0M0 squamous cell carcinoma of the hard palate. The patient underwent a bilateral maxillectomy with a level I-III neck dissection followed by zygomatic implant perforated flap reconstruction.</p>\n\n<p>During flap harvest, it was noted that the ulnar pedicle was position sensitive with just mild geometric manipulation leading to mild congestion that improved with gentle re-draping. The pedicle was ligated, flushed with heparinized saline, and the patient was started on a weight-based heparin (WBH) drip.</p>\n\n<p>Microvascular anastomosis was to the facial vessels demonstrated immediate flow and excellent  implantable doppler signal. Vioptix (Vioptix Inc.) near infrared spectroscopy (NIRS), utilized to measure the proportion of de-oxygenated to oxygenated hemoglobin, demonstrated initial StO2 readings in the 70s. However, upon inset completion, the flap was noted to be congested and ruddy in appearance, with an StO2 dropping into the lower 50’s. The anastomosis of venae comitantes with 2.0 mm couplers improved flap appearance and StO2 readings into the 70s. However, after 10 minutes, perfusion again decreased. SPY angiography identified a non-perfused skin segment, which was excised, and increasing heparin drip restored StO2 values rose into the 80s. Remaining incisions were then closed, and the patient was transferred to the STICU for further monitoring.</p>\n\n<p>A continuous WBH drip was maintained for 72 hours. On POD 1, supratherapeutic PTT  led to discontinuation of heparin, after which congestion recurred. Subcutaneous tPA 2mg was administered, improving StO2 from 43 to 89%. A subsequent dose was held due to mild oozing from the intraoral suture line, and on POD 2 the patient required return to the OR for hemostasis.  The flap was noted to be viable. That afternoon, recurrent congestion was managed with a 1mg injection of tPA, improving perfusion, and the patient was transitioned to enoxaparin. StO2 remained stable (70s to 90s) thereafter. Despite flap viability and improved perfusion, the patient later elected for palliative care and was discharged to hospice.</p>\n\n<p><strong>Discussion:</strong> Free tissue transfer remains essential for maxillofacial reconstruction, though venous congestion continues to threaten flap viability despite meticulous technique. This case adds to the growing body of evidence supporting the use of tPA as a salvage strategy in selected free flap reconstructions and underscores the ability of NIRS to detect microvascular compromise.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153438--></body></html>"
    },
    {
      "uid": "P343",
      "content_id": "153481",
      "abstract_number": "P343",
      "poster_number": "P343",
      "title": "Preoperative Malnutrition Predicts Inpatient Length of Stay After Head and Neck Free Flap Reconstruction",
      "summary": "In this cohort, preoperative hypoalbuminemia was associated with a greater comorbidity burden and more complex index procedures, and independently predicted prolonged hospital stay. However, albumin did not predict flap failure or two-year survival. These findings suggest that serum albumin functions as a marker of perioperative frailty and resource utilization rather than microvascular risk or long-term...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153481",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madison McElliot",
      "presenter": "Madison McElliot",
      "authors": "Siddhant H Tripathi, MD 1 ; Madison McElliot 2 ; Josiah Brandt, MD 1 ; Alexander Karabachev, MD 1 ; Adam Beucler 2 ; Christine Lee 2 ; Imani Agard 2 ; David Gorelov 2 ; Priscilla Pichardo, DO 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Yash Patil, MD 3 ; Chad Zender, MD 1",
      "normalized_authors": [
        "Siddhant H Tripathi",
        "Madison McElliot",
        "Josiah Brandt",
        "Alexander Karabachev",
        "Adam Beucler",
        "Christine Lee",
        "Imani Agard",
        "David Gorelov",
        "Priscilla Pichardo",
        "Dustin Silverman",
        "Alice Tang",
        "Yash Patil",
        "Chad Zender"
      ],
      "affiliations": [
        "University of Cincinnati Department of Otolaryngology",
        "University of Cincinnati College of Medicine",
        "Northwestern Medicine Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "University of Cincinnati Department of Otolaryngology",
        "University of Cincinnati College of Medicine",
        "Northwestern Medicine Department of Otolaryngology"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 455,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Siddhant H Tripathi, MD 1 ; Madison McElliot 2 ; Josiah Brandt, MD 1 ; Alexander Karabachev, MD 1 ; Adam Beucler 2 ; Christine Lee 2 ; Imani Agard 2 ; David Gorelov 2 ; Priscilla Pichardo, DO 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Yash Patil, MD 3 ; Chad Zender, MD 1",
        "Affiliations": "1 University of Cincinnati Department of Otolaryngology; 2 University of Cincinnati College of Medicine; 3 Northwestern Medicine Department of Otolaryngology",
        "Objective": "Preoperative hypoalbuminemia is commonly used as a surrogate for malnutrition. Although multicenter analyses have linked malnutrition to worse outcomes following head and neck free flap reconstruction, it remains unclear whether albumin independently predicts outcomes within a standardized surgical environment. This study evaluated the association between preoperative serum albumin and postoperative outcomes, including flap survival and length of stay (LOS), in a large cohort of head and neck free flap reconstructions.",
        "Methods": "Consecutive adults undergoing microvascular free flap reconstruction from 2008–2023 were identified. Preoperative serum albumin measured within 30 days of surgery was classified as hypoalbuminemia (<3.5 g/dL) or normal (≥3.5 g/dL). Primary outcomes were prolonged hospital length of stay (LOS ≥10 days) and flap failure. Secondary outcomes included ICU LOS, death during the index hospitalization, 30-day readmission, and 2-year overall survival. Covariates included age, sex, BMI, smoking history, COPD, hypertension, diabetes, peripheral vascular disease, hypothyroidism, total laryngectomy, and tracheostomy. Group comparisons were performed with χ², Fisher’s exact, and Wilcoxon rank-sum tests. Multivariable logistic regression assessed the association between albumin level and prolonged LOS, flap failure, and two-year survival, reporting adjusted odds ratios (aOR) with 95% confidence intervals (CI).",
        "Results": "A total of 405 patients met inclusion criteria; 124 (30.6%) had hypoalbuminemia and 281 (69.4%) had normal albumin. Compared with the normal albumin cohort, patients with hypoalbuminemia more frequently had COPD (32.3% vs 19.6%), peripheral vascular disease (8.1% vs 3.6%), hypothyroidism (28.2% vs 20.3%), and underwent total laryngectomy (25.8% vs 13.9%), whereas normal albumin patients had slightly higher BMI (median 23.7 vs 23.2 kg/m²). Median LOS was similar (7 vs 7 days), but mean LOS was significantly longer in the hypoalbuminemia group (12.3 vs 7.8 days, p<0.001), reflecting a right-shifted utilization pattern. Prolonged LOS (≥10 days) occurred in 38.7% of patients with hypoalbuminemia vs 19.9% with normal albumin (p=0.0001). On multivariable analysis, hypoalbuminemia remained independently associated with prolonged LOS (aOR 2.14, 95% CI 1.31–3.50, p=0.002) but was not associated with flap failure (aOR 1.48, 95% CI 0.36–6.06, p=0.59) or two-year survival (aOR 1.06, 95% CI 0.67–1.68, p=0.79).",
        "Conclusions": "In this cohort, preoperative hypoalbuminemia was associated with a greater comorbidity burden and more complex index procedures, and independently predicted prolonged hospital stay. However, albumin did not predict flap failure or two-year survival. These findings suggest that serum albumin functions as a marker of perioperative frailty and resource utilization rather than microvascular risk or long-term oncologic outcome. Incorporating albumin-based risk stratification may enhance preoperative planning and highlight opportunities for targeted nutritional optimization in this vulnerable population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Malnutrition Predicts Inpatient Length of Stay After Head and Neck Free Flap Reconstruction</span>. Siddhant H Tripathi, MD<sup>1</sup>; <u>Madison McElliot</u><sup>2</sup>; Josiah Brandt, MD<sup>1</sup>; Alexander Karabachev, MD<sup>1</sup>; Adam Beucler<sup>2</sup>; Christine Lee<sup>2</sup>; Imani Agard<sup>2</sup>; David Gorelov<sup>2</sup>; Priscilla Pichardo, DO<sup>1</sup>; Dustin Silverman, MD<sup>1</sup>; Alice Tang, MD<sup>1</sup>; Yash Patil, MD<sup>3</sup>; Chad Zender, MD<sup>1</sup>. <sup>1</sup>University of Cincinnati Department of Otolaryngology; <sup>2</sup>University of Cincinnati College of Medicine; <sup>3</sup>Northwestern Medicine Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Preoperative hypoalbuminemia is commonly used as a surrogate for malnutrition. Although multicenter analyses have linked malnutrition to worse outcomes following head and neck free flap reconstruction, it remains unclear whether albumin independently predicts outcomes within a standardized surgical environment. This study evaluated the association between preoperative serum albumin and postoperative outcomes, including flap survival and length of stay (LOS), in a large cohort of head and neck free flap reconstructions.</p>\n\n<p><strong>Methods: </strong>Consecutive adults undergoing microvascular free flap reconstruction from 2008–2023 were identified. Preoperative serum albumin measured within 30 days of surgery was classified as hypoalbuminemia (<3.5 g/dL) or normal (≥3.5 g/dL). Primary outcomes were prolonged hospital length of stay (LOS ≥10 days) and flap failure. Secondary outcomes included ICU LOS, death during the index hospitalization, 30-day readmission, and 2-year overall survival. Covariates included age, sex, BMI, smoking history, COPD, hypertension, diabetes, peripheral vascular disease, hypothyroidism, total laryngectomy, and tracheostomy. Group comparisons were performed with χ², Fisher’s exact, and Wilcoxon rank-sum tests. Multivariable logistic regression assessed the association between albumin level and prolonged LOS, flap failure, and two-year survival, reporting adjusted odds ratios (aOR) with 95% confidence intervals (CI).</p>\n\n<p><strong>Results: </strong>A total of 405 patients met inclusion criteria; 124 (30.6%) had hypoalbuminemia and 281 (69.4%) had normal albumin. Compared with the normal albumin cohort, patients with hypoalbuminemia more frequently had COPD (32.3% vs 19.6%), peripheral vascular disease (8.1% vs 3.6%), hypothyroidism (28.2% vs 20.3%), and underwent total laryngectomy (25.8% vs 13.9%), whereas normal albumin patients had slightly higher BMI (median 23.7 vs 23.2 kg/m²). Median LOS was similar (7 vs 7 days), but mean LOS was significantly longer in the hypoalbuminemia group (12.3 vs 7.8 days, p<0.001), reflecting a right-shifted utilization pattern. Prolonged LOS (≥10 days) occurred in 38.7% of patients with hypoalbuminemia vs 19.9% with normal albumin (p=0.0001). On multivariable analysis, hypoalbuminemia remained independently associated with prolonged LOS (aOR 2.14, 95% CI 1.31–3.50, p=0.002) but was not associated with flap failure (aOR 1.48, 95% CI 0.36–6.06, p=0.59) or two-year survival (aOR 1.06, 95% CI 0.67–1.68, p=0.79).</p>\n\n<p><strong>Conclusions: </strong>In this cohort, preoperative hypoalbuminemia was associated with a greater comorbidity burden and more complex index procedures, and independently predicted prolonged hospital stay. However, albumin did not predict flap failure or two-year survival. These findings suggest that serum albumin functions as a marker of perioperative frailty and resource utilization rather than microvascular risk or long-term oncologic outcome. Incorporating albumin-based risk stratification may enhance preoperative planning and highlight opportunities for targeted nutritional optimization in this vulnerable population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153481--></body></html>"
    },
    {
      "uid": "P344",
      "content_id": "153035",
      "abstract_number": "P344",
      "poster_number": "P344",
      "title": "A Blueprint to Advanced Maxillofacial Oncologic and Reconstructive Surgery in a Resource-Limited Environment: A Consecutive Cohort Study of 20 High-Complexity Cases from Nablus",
      "summary": "This series demonstrates that high-complexity maxillofacial oncologic and reconstructive procedures can be executed safely in resource-limited environments using a structured anatomic workflow, standardized documentation, and shared postoperative stewardship with local clinicians. The cross-domain reproducibility, spanning maxillectomy, deep-lobe parotidectomy, multilayer palate reconstruction, and structural...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153035",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Razan Hussein",
      "presenter": "Razan Hussein",
      "authors": "Razan Hussein 1 ; Muaaz Wajahath 2 ; Adam Hamawy, MD 3 ; Taha Mur, MD 4",
      "normalized_authors": [
        "Razan Hussein",
        "Muaaz Wajahath",
        "Adam Hamawy",
        "Taha Mur"
      ],
      "affiliations": [
        "Texas Tech University Health and Sciences Center School of Medicine",
        "Michigan State University College of Human Medicine",
        "Princeton Plastic Surgeons",
        "Rutgers Robert Wood Johnson Medical School"
      ],
      "normalized_institutions": [
        "Texas Tech University Health and Sciences Center School of Medicine",
        "Michigan State University College of Human Medicine",
        "Princeton Plastic Surgeons",
        "Rutgers Robert Wood Johnson Medical School"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 453,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Razan Hussein 1 ; Muaaz Wajahath 2 ; Adam Hamawy, MD 3 ; Taha Mur, MD 4",
        "Affiliations": "1 Texas Tech University Health and Sciences Center School of Medicine; 2 Michigan State University College of Human Medicine; 3 Princeton Plastic Surgeons; 4 Rutgers Robert Wood Johnson Medical School",
        "Introduction": "Advanced maxillofacial pathology commonly involves significant anatomic distortion and functional loss requiring carefully planned exposure, safe resection, and reliable reconstruction. Although the global literature is extensive, detailed reporting of high-complexity oncologic and reconstructive cases from developing surgical systems remains limited. Most reports focus on primary cleft procedures or lower-acuity soft tissue operations, and there is little documentation of hemimaxillectomy, neck dissection, deep-lobe parotidectomy, multilayer palatal–pharyngeal closure, temporalis muscle transfer, or secondary cleft nasal reconstruction involving autologous cartilage grafts. Extending structured operative frameworks to environments with developing surgical capacity offers an opportunity to document reproducible oncologic and reconstructive workflows. This study reports a consecutive cohort of twenty high-acuity maxillofacial operations using a standardized operative template, perioperative monitoring, and collaborative management model.",
        "Methods": "A prospective observational cohort was conducted during a structured surgical mission in Nablus, Palestine during November 2025 across two regional referral hospitals. Consecutive patients requiring oncologic resection, complex reconstruction, or correction of congenital/acquired deformity were included. A unified workflow guided preoperative evaluation, exposure, anatomical checkpoints, and reconstruction, emphasizing reproducible facial nerve identification landmarks, maxillary osteotomy design, and layered palatal closure strategies. A standardized operative template captured indications, resection extent and techniques, graft/flap use, estimated blood loss, anatomic modifications, and postoperative course. Primary outcomes were feasibility and intraoperative safety; secondary endpoints included reconstructive stability and 30-day complication rates.",
        "Results": "All 20 operations were completed without conversion, unplanned airway intervention, hemodynamic instability, or return to the operating room. Case spectrum included hemimaxillectomy with levels I–III neck dissection and temporalis muscle transfer using coronoidectomy and zygomatic arch mobilization to increase arc of rotation; recurrent parapharyngeal pleomorphic adenoma excision with trilaminar palatal/pharyngeal closure using palatal flap, buccal fat pad, and mucosal advancement; seven parotidectomies (six superficial, one deep lobe) with 100% facial nerve preservation; four secondary cleft lip revisions restoring philtral symmetry; four advanced cleft rhinoplasties with septal or costal cartilage grafting (columellar struts, dorsal onlay, alar rim grafts); von Langenbeck palatoplasty with levator sling re-orientation; masseteric venous malformation excision; transcervical styloidectomy; and surgical rhinophyma reduction. Estimated blood loss averaged 80–250 mL with no transfusions. All flaps and grafts demonstrated immediate perfusion and no hematoma, seroma, salivary leak, wound dehiscence, infection, airway difficulty, or neurologic deficit occurred within 30 days.",
        "Conclusion": "This series demonstrates that high-complexity maxillofacial oncologic and reconstructive procedures can be executed safely in resource-limited environments using a structured anatomic workflow, standardized documentation, and shared postoperative stewardship with local clinicians. The cross-domain reproducibility, spanning maxillectomy, deep-lobe parotidectomy, multilayer palate reconstruction, and structural cleft rhinoplasty, suggests that reliability stems from disciplined operative sequencing rather than resource intensity. This framework provides a scalable blueprint for expanding advanced surgical capacity in developing systems, with ongoing follow-up needed to evaluate long-term functional and oncologic outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Blueprint to Advanced Maxillofacial Oncologic and Reconstructive Surgery in a Resource-Limited Environment: A Consecutive Cohort Study of 20 High-Complexity Cases from Nablus</span>. <u>Razan Hussein</u><sup>1</sup>; Muaaz Wajahath<sup>2</sup>; Adam Hamawy, MD<sup>3</sup>; Taha Mur, MD<sup>4</sup>. <sup>1</sup>Texas Tech University Health and Sciences Center School of Medicine; <sup>2</sup>Michigan State University College of Human Medicine; <sup>3</sup>Princeton Plastic Surgeons; <sup>4</sup>Rutgers Robert Wood Johnson Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advanced maxillofacial pathology commonly involves significant anatomic distortion and functional loss requiring carefully planned exposure, safe resection, and reliable reconstruction. Although the global literature is extensive, detailed reporting of high-complexity oncologic and reconstructive cases from developing surgical systems remains limited. Most reports focus on primary cleft procedures or lower-acuity soft tissue operations, and there is little documentation of hemimaxillectomy, neck dissection, deep-lobe parotidectomy, multilayer palatal–pharyngeal closure, temporalis muscle transfer, or secondary cleft nasal reconstruction involving autologous cartilage grafts. Extending structured operative frameworks to environments with developing surgical capacity offers an opportunity to document reproducible oncologic and reconstructive workflows. This study reports a consecutive cohort of twenty high-acuity maxillofacial operations using a standardized operative template, perioperative monitoring, and collaborative management model.</p>\n\n<p><strong>Methods: </strong>A prospective observational cohort was conducted during a structured surgical mission in Nablus, Palestine during November 2025 across two regional referral hospitals. Consecutive patients requiring oncologic resection, complex reconstruction, or correction of congenital/acquired deformity were included. A unified workflow guided preoperative evaluation, exposure, anatomical checkpoints, and reconstruction, emphasizing reproducible facial nerve identification landmarks, maxillary osteotomy design, and layered palatal closure strategies. A standardized operative template captured indications, resection extent and techniques, graft/flap use, estimated blood loss, anatomic modifications, and postoperative course. Primary outcomes were feasibility and intraoperative safety; secondary endpoints included reconstructive stability and 30-day complication rates.</p>\n\n<p><strong>Results: </strong>All 20 operations were completed without conversion, unplanned airway intervention, hemodynamic instability, or return to the operating room. Case spectrum included hemimaxillectomy with levels I–III neck dissection and temporalis muscle transfer using coronoidectomy and zygomatic arch mobilization to increase arc of rotation; recurrent parapharyngeal pleomorphic adenoma excision with trilaminar palatal/pharyngeal closure using palatal flap, buccal fat pad, and mucosal advancement; seven parotidectomies (six superficial, one deep lobe) with 100% facial nerve preservation; four secondary cleft lip revisions restoring philtral symmetry; four advanced cleft rhinoplasties with septal or costal cartilage grafting (columellar struts, dorsal onlay, alar rim grafts); von Langenbeck palatoplasty with levator sling re-orientation; masseteric venous malformation excision; transcervical styloidectomy; and surgical rhinophyma reduction. Estimated blood loss averaged 80–250 mL with no transfusions. All flaps and grafts demonstrated immediate perfusion and no hematoma, seroma, salivary leak, wound dehiscence, infection, airway difficulty, or neurologic deficit occurred within 30 days.</p>\n\n<p><strong>Conclusion: </strong>This series demonstrates that high-complexity maxillofacial oncologic and reconstructive procedures can be executed safely in resource-limited environments using a structured anatomic workflow, standardized documentation, and shared postoperative stewardship with local clinicians. The cross-domain reproducibility, spanning maxillectomy, deep-lobe parotidectomy, multilayer palate reconstruction, and structural cleft rhinoplasty, suggests that reliability stems from disciplined operative sequencing rather than resource intensity. This framework provides a scalable blueprint for expanding advanced surgical capacity in developing systems, with ongoing follow-up needed to evaluate long-term functional and oncologic outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153035--></body></html>"
    },
    {
      "uid": "P345",
      "content_id": "153785",
      "abstract_number": "P345",
      "poster_number": "P345",
      "title": "Optimizing Mid-face Reconstruction: The Layered Free Fibular Flap technique.",
      "summary": "Although layering technique of free fibular flap considered complex and difficult surgical maneuver, it enhances three-dimensional restoration of the mid-face complex. It provides a reliable foundation for functional and esthetic rehabilitation and improve outcomes in complex reconstructions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153785",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ibrahim Elsharabasy, PhD, MOMS, RCSEd, ABOMS, MSc, BDS",
      "presenter": "Ibrahim Elsharabasy, PhD, MOMS, RCSEd, ABOMS, MSc, BDS",
      "authors": "Ibrahim Elsharabasy, PhD, MOMS, RCSEd, ABOMS, MSc, BDS",
      "normalized_authors": [
        "Ibrahim Elsharabasy, MOMS, RCSEd, ABOMS, BDS"
      ],
      "affiliations": [
        "Horus university, Egypt"
      ],
      "normalized_institutions": [
        "Horus university, Egypt"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 372,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Objective",
        "Method",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ibrahim Elsharabasy, PhD, MOMS, RCSEd, ABOMS, MSc, BDS",
        "Affiliations": "Horus university, Egypt",
        "Abstract": "Introduction: Mid-face reconstruction using the free fibular flap is a well-established technique providing both bone and soft tissue components. However, optimizing functional and esthetic outcomes remains a surgical challenge, especially in complex three-dimensional defects such as brown class III and IV. The layering technique using free fibular flap offers a better approach to better mimic native anatomical contour and facilitate dental rehabilitation.",
        "Objective": "The objective of this study was to evaluate the aesthetic and clinical outcomes in addition to virtual surgical planning accuracy of using the free fibular flap in layered fashion in the mid-face reconstruction. It's a complex surgical approach that involves meticulous planning to restore both esthetic and function.",
        "Method": "A retrospective study was performed on 28 patients between 2019 and 2024, including mid-face defects resulting from oncologic resection and trauma injuries. All the patients were reconstructed by free fibular flap in a layered fashion. The virtual surgical planning and computer-guided reconstruction were utilized in all patients. The approach involved reconstruction by free fibular flap in a layered fashion through intra-operative cutting guides and patient specific plates. Osteotomies with multilevel placement of fibular bone segments in double parallel fashion to reconstruct multiple angles, curvatures, and complex structures of the midface regarding anatomic subunits of inferior orbital rim, lateral orbital rim, malar eminence, zygomatic arch and the maxilla. All these were in combination with soft tissue positioning to enhance intraoral lining and extraoral contour.",
        "Results": "28 patients of complex mid- defects categorized as the following: 11 brown class III defects, 17 brown class IV defects. There were 10 females and 18 males. All of the defects were post tumor resection. 9 of the patients were exposed to radiotherapy. One of the cases showed compromised vascularity of the most distal segment. One of the cases received hyperbaric oxygen therapy. The recipient artery of anastomosis was the facial artery in 20 patients, the external carotid artery in 3 patients, and the superior thyroid in 5 patients. Accuracy after superimposition between preoperative virtual planning with immediate postoperative CT was 93%.",
        "Conclusion": "Although layering technique of free fibular flap considered complex and difficult surgical maneuver, it enhances three-dimensional restoration of the mid-face complex. It provides a reliable foundation for functional and esthetic rehabilitation and improve outcomes in complex reconstructions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Optimizing Mid-face Reconstruction: The Layered Free Fibular Flap technique.</span>. <u>Ibrahim Elsharabasy, PhD, MOMS, RCSEd, ABOMS, MSc, BDS</u>. Horus university, Egypt<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Introduction: Mid-face reconstruction using the free fibular flap is a well-established technique providing both bone and soft tissue components. However, optimizing functional and esthetic outcomes remains a surgical challenge, especially in complex three-dimensional defects such as brown class III and IV. The layering technique using free fibular flap offers a better approach to better mimic native anatomical contour and facilitate dental rehabilitation.</p>\n\n<p><strong>Objective:</strong> The objective of this study was to evaluate the aesthetic and clinical outcomes in addition to virtual surgical planning accuracy of using the free fibular flap in layered fashion in the mid-face reconstruction. It's a complex surgical approach that involves meticulous planning to restore both esthetic and function.</p>\n\n<p><strong>Method: </strong>A retrospective study was performed on 28 patients between 2019 and 2024, including mid-face defects resulting from oncologic resection and trauma injuries. All the patients were reconstructed by free fibular flap in a layered fashion. The virtual surgical planning and computer-guided reconstruction were utilized in all patients. The approach involved reconstruction by free fibular flap in a layered fashion through intra-operative cutting guides and patient specific plates. Osteotomies with multilevel placement of fibular bone segments in double parallel fashion to reconstruct multiple angles, curvatures, and complex structures of the midface regarding anatomic subunits of inferior orbital rim, lateral orbital rim, malar eminence, zygomatic arch and the maxilla. All these were in combination with soft tissue positioning to enhance intraoral lining and extraoral contour.</p>\n\n<p><strong>Results:</strong> 28 patients of complex mid- defects categorized as the following: 11 brown class III defects, 17 brown class IV defects. There were 10 females and 18 males. All of the defects were post tumor resection. 9 of the patients were exposed to radiotherapy. One of the cases showed compromised vascularity of the most distal segment. One of the cases received hyperbaric oxygen therapy. The recipient artery of anastomosis was the facial artery in 20 patients, the external carotid artery in 3 patients, and the superior thyroid in 5 patients. Accuracy after superimposition between preoperative virtual planning with immediate postoperative CT was 93%.</p>\n\n<p><strong>Conclusion:</strong> Although layering technique of free fibular flap considered complex and difficult surgical maneuver, it enhances three-dimensional restoration of the mid-face complex. It provides a reliable foundation for functional and esthetic rehabilitation and improve outcomes in complex reconstructions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153785--></body></html>"
    },
    {
      "uid": "P346",
      "content_id": "154410",
      "abstract_number": "P346",
      "poster_number": "P346",
      "title": "Bivalirudin Therapy for Venous Congestion of Head and Neck Reconstructive Flaps: A Case Series",
      "summary": "Bivalirudin is a safe adjunct or primary therapy for venous congestion of head and neck reconstructive flaps, and in some cases can prevent the need for major revision reconstructive surgery. Our case series represents the third case series reported for this indication. Further prospective studies are needed to understand the optimal dose, injection technique, timing of initiation, and efficacy of bivalirudin...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154410",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mit A Patel",
      "presenter": "Mit A Patel",
      "authors": "Mit A Patel ; Quinn A Dunlap; Thomas J Gal; Laura Ebbitt; Melina J Windon",
      "normalized_authors": [
        "Mit A Patel",
        "Quinn A Dunlap",
        "Thomas J Gal",
        "Laura Ebbitt",
        "Melina J Windon"
      ],
      "affiliations": [
        "University of Kentucky"
      ],
      "normalized_institutions": [
        "University of Kentucky"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 383,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mit A Patel ; Quinn A Dunlap; Thomas J Gal; Laura Ebbitt; Melina J Windon",
        "Affiliations": "University of Kentucky",
        "Objectives": "Venous congestion and flap loss can be a devastating complication in head and neck surgery, often causing infection, high-risk wounds with exposed vessels, and fluid shifts. Patients with flap loss often undergo multiple surgeries including a second free flap and prolonged hospitalizations. Venous congestion refractory to flap revision has historically been managed with leech therapy. Bivalirudin, a direct thrombin inhibitor, has recently emerged as a synthetic alternative with advantages including avoidance of the infection risk and psychological trauma associated with leech therapy. As there is a paucity of literature describing associated outcomes with bivalirudin, we sought to describe our institutional experience.",
        "Methods": "A retrospective chart review of patients with acute postoperative venous congestion of head and neck reconstructive flaps who underwent bivalirudin therapy at a single institution from September 1, 2023 to September 26, 2025 was performed. All patients were treated with cruciate skin paddle incision with intradermal bivalirudin injection (0.3mg/kg/dose) every 6 hours for a variable number of doses based on clinical course.",
        "Results": "A total of ten patients underwent bivalirudin therapy for both locoregional and free flap reconstructions (3 anterolateral thigh free flaps, 2 cervicofacial advancement flaps, 1 fibula osseocutaneous free flap, 1 radial forearm free flap, 1 latissimus dorsi free flap, 1 paramedian flap, 1 submental island). The mean age was 64.2 years with sixty percent of patients being male. The mean number of doses was 12.8 (range 3-19) administered over a mean duration of 4.4 days (range 1 to 7 days). Two patients required surgical exploration with revision of venous anastomosis before initiating bivalirudin treatment. Three patients did not require any additional interventions before or after the treatment. Partial flap necrosis was noted in five patients (3 free flap, 2 locoregional flap), of which four underwent surgical debridement and additional reconstructions with locoregional flaps and/or skin grafts. Four patients required blood transfusions during the treatment, and there were no bivalirudin-related adverse reactions.",
        "Conclusion": "Bivalirudin is a safe adjunct or primary therapy for venous congestion of head and neck reconstructive flaps, and in some cases can prevent the need for major revision reconstructive surgery. Our case series represents the third case series reported for this indication. Further prospective studies are needed to understand the optimal dose, injection technique, timing of initiation, and efficacy of bivalirudin therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Bivalirudin Therapy for Venous Congestion of Head and Neck Reconstructive Flaps: A Case Series</span>. <u>Mit A Patel</u>; Quinn A Dunlap; Thomas J Gal; Laura Ebbitt; Melina J Windon. University of Kentucky<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> Venous congestion and flap loss can be a devastating complication in head and neck surgery, often causing infection, high-risk wounds with exposed vessels, and fluid shifts. Patients with flap loss often undergo multiple surgeries including a second free flap and prolonged hospitalizations. Venous congestion refractory to flap revision has historically been managed with leech therapy. Bivalirudin, a direct thrombin inhibitor, has recently emerged as a synthetic alternative with advantages including avoidance of the infection risk and psychological trauma associated with leech therapy. As there is a paucity of literature describing associated outcomes with bivalirudin, we sought to describe our institutional experience. </p>\n\n<p><strong>Methods:</strong> A retrospective chart review of patients with acute postoperative venous congestion of head and neck reconstructive flaps who underwent bivalirudin therapy at a single institution from September 1, 2023 to September 26, 2025 was performed. All patients were treated with cruciate skin paddle incision with intradermal bivalirudin injection (0.3mg/kg/dose) every 6 hours for a variable number of doses based on clinical course. </p>\n\n<p><strong>Results: </strong>A total of ten patients underwent bivalirudin therapy for both locoregional and free flap reconstructions (3 anterolateral thigh free flaps, 2 cervicofacial advancement flaps, 1 fibula osseocutaneous free flap, 1 radial forearm free flap, 1 latissimus dorsi free flap, 1 paramedian flap, 1 submental island). The mean age was 64.2 years with sixty percent of patients being male. The mean number of doses was 12.8 (range 3-19) administered over a mean duration of 4.4 days (range 1 to 7 days). Two patients required surgical exploration with revision of venous anastomosis before initiating bivalirudin treatment. Three patients did not require any additional interventions before or after the treatment. Partial flap necrosis was noted in five patients (3 free flap, 2 locoregional flap), of which four underwent surgical debridement and additional reconstructions with locoregional flaps and/or skin grafts. Four patients required blood transfusions during the treatment, and there were no bivalirudin-related adverse reactions. </p>\n\n<p><strong>Conclusion: </strong>Bivalirudin is a safe adjunct or primary therapy for venous congestion of head and neck reconstructive flaps, and in some cases can prevent the need for major revision reconstructive surgery. Our case series represents the third case series reported for this indication. Further prospective studies are needed to understand the optimal dose, injection technique, timing of initiation, and efficacy of bivalirudin therapy. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154410--></body></html>"
    },
    {
      "uid": "P348",
      "content_id": "155557",
      "abstract_number": "P348",
      "poster_number": "P348",
      "title": "Biochemically Validated Cannabis and Tobacco Use and Their Impact on Wound Healing: Early Findings from a Prospective Cohort",
      "summary": "Tobacco and/or cannabis use was associated with increased early local wound complications—particularly dehiscence—after head and neck oncologic reconstruction. Potential mechanisms include reduced tissue perfusion, heightened inflammatory signaling, and altered immune response. Ongoing follow-up will help clarify the specific contribution of cannabis and its underlying mechanisms.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155557",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "J Lieberman, BS",
      "presenter": "J Lieberman, BS",
      "authors": "J Lieberman, BS 1 ; M Chinnaiyan, PhD 1 ; ST Parambil, PhD 1 ; G Chengizkhan, PhD 1 ; A Hammoudi, PhD 1 ; J George, BS 1 ; N Najam, BS 1 ; P Berryman, BS 1 ; CK Waite, BS 1 ; J O'Brien, BS 1 ; R Patel, MD 1 ; R Mhawej, MD 1 ; J Sanclement, MD 1 ; NR Scott-Wittenborn, MD 1 ; N Vasan, MD, FRACS 1 ; D Zhao, PhD 2 ; G Krempl, MD, FACS 1 ; M Mims, MD 1 ; L Queimado, MD, PhD 1",
      "normalized_authors": [
        "J Lieberman",
        "M Chinnaiyan",
        "ST Parambil",
        "G Chengizkhan",
        "A Hammoudi",
        "J George",
        "N Najam",
        "P Berryman",
        "CK Waite",
        "J O'Brien",
        "R Patel",
        "R Mhawej",
        "J Sanclement",
        "NR Scott-Wittenborn",
        "N Vasan, FRACS",
        "D Zhao",
        "G Krempl",
        "M Mims",
        "L Queimado"
      ],
      "affiliations": [
        "University of Oklahoma - Department of Otolaryngology - Head and Neck Surgery",
        "University of Oklahoma - Hudson College of Public Health - Department of Biostatistics and Epidemiology"
      ],
      "normalized_institutions": [
        "University of Oklahoma - Department of Otolaryngology - Head and Neck Surgery",
        "University of Oklahoma - Hudson College of Public Health - Department of Biostatistics and Epidemiology"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "J Lieberman, BS 1 ; M Chinnaiyan, PhD 1 ; ST Parambil, PhD 1 ; G Chengizkhan, PhD 1 ; A Hammoudi, PhD 1 ; J George, BS 1 ; N Najam, BS 1 ; P Berryman, BS 1 ; CK Waite, BS 1 ; J O'Brien, BS 1 ; R Patel, MD 1 ; R Mhawej, MD 1 ; J Sanclement, MD 1 ; NR Scott-Wittenborn, MD 1 ; N Vasan, MD, FRACS 1 ; D Zhao, PhD 2 ; G Krempl, MD, FACS 1 ; M Mims, MD 1 ; L Queimado, MD, PhD 1",
        "Affiliations": "1 University of Oklahoma - Department of Otolaryngology - Head and Neck Surgery; 2 University of Oklahoma - Hudson College of Public Health - Department of Biostatistics and Epidemiology",
        "Background": "Cannabis use is rising in the United States, with nearly 15% of adults reporting current use—now exceeding tobacco use. Among cancer patients, prevalance is even higher, with rates reaching up to 80% among those also using tobacco. Despite widespread adoption, the perioperative effects of cannabis remain poorly understood. Evidence suggests cannabis may impair wound healing and increase postoperative complications, but data for head and neck surgery are lacking. Cannabis is most often smoked, producing oral tissue delta-9-tetrahydrocannabinol (THC) levels roughly tenfold higher than plasma, making its effects particularly relevant in head and neck oncologic reconstruction. Prior studies are largely retrospective, rely on self-reporting, and do not account for route, frequency, or biochemical verification. To address these gaps, we conducted the first prospective study evaluating cannabis and surgical wound-healing outcomes.",
        "Methods": "Participants were prospectively recruited beginning in October 2025 from our clinic at an NCI-Designated Cancer Center. At enrollment, participants completed detailed REDCap questionnaires capturing demographics and cannabis, tobacco, e-cigarette, and alcohol use. Blood, urine, and saliva samples were collected to biochemically validate cannabis and tobacco exposure. Patients were categorized as exclusive cannabis users, exclusive tobacco users, co-users, or non-users. Baseline clinical data—including medical history, comorbidities, wound-healing risk factors, and medications—were extracted from the electronic health record. Postoperative outcomes were recorded as early (<30 days) or late (>30 days) complications, and patient satisfaction with reconstruction was assessed using a Likert scale. Group differences in wound-healing complications was evaluated using one-way analysis of variance (ANOVA).",
        "Results": "Fifty-four head and neck cancer patients undergoing surgery were enrolled (median age 70 years, mean 68 ± 13), with 32 (59%) male. Sixteen participants (30%) reported current use (≥1 time/week in the past month) of tobacco (n=4), cannabis (n=7), or both (n=5). Cannabis was most commonly smoked (82%), followed by vaping (13%) and edibles (6%), and 60% of users held a medical marijuana card. Cannabis-exclusive (57±11) and co-users (56±14) were younger than non-users (70±13, p=0.008), and female:male ratio was higher among cannabis users. Other baseline demographics, clinical characteristics, reconstruction type, and closure method did not differ between groups. At 30-day follow-up, wound dehiscence was the most frequent complication, occurring in 33% of tobacco users, 33% of cannabis-only users, 25% of co-users, and 4% of non-users. Overall, participants using tobacco and/or cannabis had higher rates of local complications (dehiscence, infection, flap failure) compared to non-users (p=0.02), whereas systemic complication rates did not differ.",
        "Conclusion": "Tobacco and/or cannabis use was associated with increased early local wound complications—particularly dehiscence—after head and neck oncologic reconstruction. Potential mechanisms include reduced tissue perfusion, heightened inflammatory signaling, and altered immune response. Ongoing follow-up will help clarify the specific contribution of cannabis and its underlying mechanisms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biochemically Validated Cannabis and Tobacco Use and Their Impact on Wound Healing: Early Findings from a Prospective Cohort</span>. <u>J Lieberman, BS</u><sup>1</sup>; M Chinnaiyan, PhD<sup>1</sup>; ST Parambil, PhD<sup>1</sup>; G Chengizkhan, PhD<sup>1</sup>; A Hammoudi, PhD<sup>1</sup>; J George, BS<sup>1</sup>; N Najam, BS<sup>1</sup>; P Berryman, BS<sup>1</sup>; CK Waite, BS<sup>1</sup>; J O'Brien, BS<sup>1</sup>; R Patel, MD<sup>1</sup>; R Mhawej, MD<sup>1</sup>; J Sanclement, MD<sup>1</sup>; NR Scott-Wittenborn, MD<sup>1</sup>; N Vasan, MD, FRACS<sup>1</sup>; D Zhao, PhD<sup>2</sup>; G Krempl, MD, FACS<sup>1</sup>; M Mims, MD<sup>1</sup>; L Queimado, MD, PhD<sup>1</sup>. <sup>1</sup>University of Oklahoma - Department of Otolaryngology - Head and Neck Surgery; <sup>2</sup>University of Oklahoma - Hudson College of Public Health - Department of Biostatistics and Epidemiology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cannabis use is rising in the United States, with nearly 15% of adults reporting current use—now exceeding tobacco use. Among cancer patients, prevalance is even higher, with rates reaching up to 80% among those also using tobacco. Despite widespread adoption, the perioperative effects of cannabis remain poorly understood. Evidence suggests cannabis may impair wound healing and increase postoperative complications, but data for head and neck surgery are lacking. Cannabis is most often smoked, producing oral tissue delta-9-tetrahydrocannabinol (THC) levels roughly tenfold higher than plasma, making its effects particularly relevant in head and neck oncologic reconstruction. Prior studies are largely retrospective, rely on self-reporting, and do not account for route, frequency, or biochemical verification. To address these gaps, we conducted the first prospective study evaluating cannabis and surgical wound-healing outcomes.</p>\n\n<p><strong>Methods: </strong>Participants were prospectively recruited beginning in October 2025 from our clinic at an NCI-Designated Cancer Center. At enrollment, participants completed detailed REDCap questionnaires capturing demographics and cannabis, tobacco, e-cigarette, and alcohol use. Blood, urine, and saliva samples were collected to biochemically validate cannabis and tobacco exposure. Patients were categorized as exclusive cannabis users, exclusive tobacco users, co-users, or non-users. Baseline clinical data—including medical history, comorbidities, wound-healing risk factors, and medications—were extracted from the electronic health record. Postoperative outcomes were recorded as early (<30 days) or late (>30 days) complications, and patient satisfaction with reconstruction was assessed using a Likert scale. Group differences in wound-healing complications was evaluated using one-way analysis of variance (ANOVA).</p>\n\n<p><strong>Results: </strong>Fifty-four head and neck cancer patients undergoing surgery were enrolled (median age 70 years, mean 68 ± 13), with 32 (59%) male. Sixteen participants (30%) reported current use (≥1 time/week in the past month) of tobacco (n=4), cannabis (n=7), or both (n=5). Cannabis was most commonly smoked (82%), followed by vaping (13%) and edibles (6%), and 60% of users held a medical marijuana card. Cannabis-exclusive (57±11) and co-users (56±14) were younger than non-users (70±13, p=0.008), and female:male ratio was higher among cannabis users. Other baseline demographics, clinical characteristics, reconstruction type, and closure method did not differ between groups. At 30-day follow-up, wound dehiscence was the most frequent complication, occurring in 33% of tobacco users, 33% of cannabis-only users, 25% of co-users, and 4% of non-users. Overall, participants using tobacco and/or cannabis had higher rates of local complications (dehiscence, infection, flap failure) compared to non-users (p=0.02), whereas systemic complication rates did not differ.</p>\n\n<p><strong>Conclusion: </strong>Tobacco and/or cannabis use was associated with increased early local wound complications—particularly dehiscence—after head and neck oncologic reconstruction. Potential mechanisms include reduced tissue perfusion, heightened inflammatory signaling, and altered immune response. Ongoing follow-up will help clarify the specific contribution of cannabis and its underlying mechanisms.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155557--></body></html>"
    },
    {
      "uid": "P349",
      "content_id": "151802",
      "abstract_number": "P349",
      "poster_number": "P349",
      "title": "The Impact of Supplemental Thiamine on Post-Operative Electrolyte Stability Among Head and Neck Cancer Free Flap Patients: A Retrospective Analysis",
      "summary": "Despite recommendations to administer thiamine in patients at high-risk of refeeding syndrome, this study shows that this approach is currently only employed for a small percentage of HNC patients, particularly those with more unstable baseline health status indicated by their lower starting lab values. Even with this initial difference, supplemental thiamine appeared to have a positive impact as, after post-op...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151802",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gillian Michaelson",
      "presenter": "Gillian Michaelson",
      "authors": "Gillian Michaelson ; Akina Tamaki, MD; Jobran Mansour, MD",
      "normalized_authors": [
        "Gillian Michaelson",
        "Akina Tamaki",
        "Jobran Mansour"
      ],
      "affiliations": [
        "Lewis Katz School of Medicine at Temple University"
      ],
      "normalized_institutions": [
        "Lewis Katz School of Medicine at Temple University"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151802/Abstract%20Table%201(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/151802/Abstract%20Table%201(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151802"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Gillian Michaelson ; Akina Tamaki, MD; Jobran Mansour, MD",
        "Affiliations": "Lewis Katz School of Medicine at Temple University",
        "Introduction": "Advanced stage head and neck cancer (HNC) patients often present in a poor nutritional status due to large tumors leading to increased metabolic demand, mechanical obstruction and caloric deprivation. This increases the risk of postoperative electrolyte derangements or refeeding syndrome upon initiation of enteral feeding leading to complications and prolonged hospitalizations. To help mitigate this risk, The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends supplementing thiamine prior to feeding and for 5-7 days afterwards for high-risk patients. Despite this guidance, thiamine use among HNC patients has not been investigated. This study examines the prevalence of postoperative thiamine supplementation in HNC patients undergoing ablation procedures with free flap reconstruction and its impact on outcomes.",
        "Methods": "A retrospective cohort study was conducted using de-identified data from the last 20 years using the TriNetX global database. Relevant, adult patients were identified via Current Procedural Terminology (CPT) codes for large HNC ablation procedures with free flap reconstruction including microvascular anastomosis. Patients were placed in the thiamine positive group if they received thiamine on the day of surgery or one day after and in the thiamine negative group if they did not. TriNetX analytics tools were used to compare lab values and repletion rates for key electrolytes with a focus on phosphorous, a primary indicator of refeeding syndrome.",
        "Results": "10,295 free flap HNC patients were identified. 11% (1,167) were thiamine positive and 89% (9,128) were thiamine negative. Thiamine positive patients were more likely to have a documented alcohol use disorder (16% vs 6%, p<0.001) and to have overall lower post-op day one lab values (Phosphorous: 2.67 vs 3.09, p<0.001; Potassium: 3.83 vs 4.00, p<0.001; Calcium: 8.09 vs 8.15, p=0.001). Despite this initial difference, from post-op day two through post-op day five, the thiamine positive group had a significantly higher average phosphorous lab value than the thiamine negative group (p≤0.0001) and thiamine positive patients were not more likely to have their phosphorous repleted (p=0.104-0.978) (Table 1).",
        "Conclusions": "Despite recommendations to administer thiamine in patients at high-risk of refeeding syndrome, this study shows that this approach is currently only employed for a small percentage of HNC patients, particularly those with more unstable baseline health status indicated by their lower starting lab values. Even with this initial difference, supplemental thiamine appeared to have a positive impact as, after post-op day one, the average phosphorous level in the thiamine positive group was consistently higher than that of the thiamine negative group, indicating a more stable response to increased post-operative nutrition. To our knowledge, this is the first study to assess postoperative use of supplemental thiamine in HNC patients. It reveals an important opportunity to improve post-operative HNC patient electrolyte stability via thiamine supplementation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Impact of Supplemental Thiamine on Post-Operative Electrolyte Stability Among Head and Neck Cancer Free Flap Patients: A Retrospective Analysis</span>. <u>Gillian Michaelson</u>; Akina Tamaki, MD; Jobran Mansour, MD. Lewis Katz School of Medicine at Temple University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advanced stage head and neck cancer (HNC) patients often present in a poor nutritional status due to large tumors leading to increased metabolic demand, mechanical obstruction and caloric deprivation. This increases the risk of postoperative electrolyte derangements or refeeding syndrome upon initiation of enteral feeding leading to complications and prolonged hospitalizations. To help mitigate this risk, The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends supplementing thiamine prior to feeding and for 5-7 days afterwards for high-risk patients. Despite this guidance, thiamine use among HNC patients has not been investigated. This study examines the prevalence of postoperative thiamine supplementation in HNC patients undergoing ablation procedures with free flap reconstruction and its impact on outcomes.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using de-identified data from the last 20 years using the TriNetX global database. Relevant, adult patients were identified via Current Procedural Terminology (CPT) codes for large HNC ablation procedures with free flap reconstruction including microvascular anastomosis. Patients were placed in the thiamine positive group if they received thiamine on the day of surgery or one day after and in the thiamine negative group if they did not. TriNetX analytics tools were used to compare lab values and repletion rates for key electrolytes with a focus on phosphorous, a primary indicator of refeeding syndrome.</p>\n\n<p><strong>Results: </strong>10,295 free flap HNC patients were identified. 11% (1,167) were thiamine positive and 89% (9,128) were thiamine negative. Thiamine positive patients were more likely to have a documented alcohol use disorder (16% vs 6%, p<0.001) and to have overall lower post-op day one lab values (Phosphorous: 2.67 vs 3.09, p<0.001; Potassium: 3.83 vs 4.00, p<0.001; Calcium: 8.09 vs 8.15, p=0.001). Despite this initial difference, from post-op day two through post-op day five, the thiamine positive group had a significantly higher average phosphorous lab value than the thiamine negative group (p≤0.0001) and thiamine positive patients were not more likely to have their phosphorous repleted (p=0.104-0.978) (Table 1).</p>\n\n<p><strong>Conclusions: </strong>Despite recommendations to administer thiamine in patients at high-risk of refeeding syndrome, this study shows that this approach is currently only employed for a small percentage of HNC patients, particularly those with more unstable baseline health status indicated by their lower starting lab values. Even with this initial difference, supplemental thiamine appeared to have a positive impact as, after post-op day one, the average phosphorous level in the thiamine positive group was consistently higher than that of the thiamine negative group, indicating a more stable response to increased post-operative nutrition. To our knowledge, this is the first study to assess postoperative use of supplemental thiamine in HNC patients. It reveals an important opportunity to improve post-operative HNC patient electrolyte stability via thiamine supplementation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151802/Abstract%20Table%201(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151802--></body></html>"
    },
    {
      "uid": "P350",
      "content_id": "151828",
      "abstract_number": "P350",
      "poster_number": "P350",
      "title": "Locoregional Flaps for Osteonecrosis Management in the Head and Neck: A Clinical Perspective",
      "summary": "This study demonstrates how locoregional flaps are a safe and effective treatment option for intermediate stage ORN/MRON, especially for patients who are older and have greater comorbidities.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151828",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jon Mallen-St. Clair, MD, PhD",
      "presenter": "Jon Mallen-St. Clair, MD, PhD",
      "authors": "Kaitlynne Pak, MD 1 ; Alexander Fish, BSc 2 ; Jon Mallen-St",
      "normalized_authors": [
        "Kaitlynne Pak",
        "Alexander Fish",
        "Jon Mallen-St"
      ],
      "affiliations": [
        "Clair, MD, PhD 1 . 1 Cedars Sinai Medical Center",
        "University of California Los Angeles, David Geffen School of Medicine"
      ],
      "normalized_institutions": [
        "Clair, MD, PhD 1 . 1 Cedars Sinai Medical Center",
        "University of California Los Angeles, David Geffen School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 237,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kaitlynne Pak, MD 1 ; Alexander Fish, BSc 2 ; Jon Mallen-St",
        "Affiliations": "Clair, MD, PhD 1 . 1 Cedars Sinai Medical Center; 2 University of California Los Angeles, David Geffen School of Medicine",
        "Introduction": "Osteonecrosis of the head and neck is a prevalent and difficult to treat condition that is associated with high morbidity. Treatment options are limited and depend on the stage of disease. Typically, early-stage disease is managed with medications that increase blood flow to the mandible or hyperbaric oxygen, whereas late stage disease is treated with resection of involved bone followed by free tissue transfer. Here, we review our institutional experience treating intermediate or advanced stage osteonecrosis with debridement and local flap reconstruction.",
        "Methods": "We performed a retrospective chart review of patients at our institution who underwent local flap reconstruction as the treatment of osteonecrosis. Patient demographics, clinical history, immediate, and long-term outcomes were recorded.",
        "Results": "Six patients were included in this study and the average age was 65.3 years. There were 7 total cases of reconstruction: 3 for osteoradionecrosis (ORN) and 4 for medication-related osteonecrosis (MRON). The average defect size was 15.7 cm² (range: 3–54 cm²). The utilized flaps included the buccal fat flap (n=4), superficial temporal artery flap (n=2), and supraclavicular artery flap (n=1). The one patient with advanced ORN eventually required a larger reconstruction with a free flap due to disease burden. Otherwise, all patients with local flap reconstruction did well without complications.",
        "Conclusion": "This study demonstrates how locoregional flaps are a safe and effective treatment option for intermediate stage ORN/MRON, especially for patients who are older and have greater comorbidities."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Locoregional Flaps for Osteonecrosis Management in the Head and Neck: A Clinical Perspective</span>. Kaitlynne Pak, MD<sup>1</sup>; Alexander Fish, BSc<sup>2</sup>; <u>Jon Mallen-St. Clair, MD, PhD</u><sup>1</sup>. <sup>1</sup>Cedars Sinai Medical Center; <sup>2</sup>University of California Los Angeles, David Geffen School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Osteonecrosis of the head and neck is a prevalent and difficult to treat condition that is associated with high morbidity. Treatment options are limited and depend on the stage of disease. Typically, early-stage disease is managed with medications that increase blood flow to the mandible or hyperbaric oxygen, whereas late stage disease is treated with resection of involved bone followed by free tissue transfer.  Here, we review our institutional experience treating intermediate or advanced stage osteonecrosis with debridement and local flap reconstruction.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective chart review of patients at our institution who underwent local flap reconstruction as the treatment of osteonecrosis.  Patient demographics, clinical history, immediate, and long-term outcomes were recorded.</p>\n\n<p><strong>Results: </strong>Six patients were included in this study and the average age was 65.3 years. There were 7 total cases of reconstruction: 3 for osteoradionecrosis (ORN) and 4 for medication-related osteonecrosis (MRON). The average defect size was 15.7 cm² (range: 3–54 cm²). The utilized flaps included the buccal fat flap (n=4), superficial temporal artery flap (n=2), and supraclavicular artery flap (n=1). The one patient with advanced ORN eventually required a larger reconstruction with a free flap due to disease burden. Otherwise, all patients with local flap reconstruction did well without complications.</p>\n\n<p><strong>Conclusion: </strong>This study demonstrates how locoregional flaps are a safe and effective treatment option for intermediate stage ORN/MRON, especially for patients who are older and have greater comorbidities.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151828--></body></html>"
    },
    {
      "uid": "P351",
      "content_id": "154044",
      "abstract_number": "P351",
      "poster_number": "P351",
      "title": "Rediscovering the Webster Modification of the Bernard-von Burow Technique for Lower Lip Reconstruction and a Systematic Review",
      "summary": "The WMBB is an effective technique for lower lip reconstruction by creating additional lip length. The WMBB has been the most studied technique, yet is still underutilized. The WMBB can be used unilaterally or bilaterally as needed. While there is a multiplicity of published lower lip reconstructive techniques, there is still a lack of standardized, objective, and meaningful outcomes to define and measure...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154044",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Holly Sprow, MD",
      "presenter": "Holly Sprow, MD",
      "authors": "Holly Sprow, MD 1 ; Jake O Rammell, BS 2 ; Jason Rich, MD 1",
      "normalized_authors": [
        "Holly Sprow",
        "Jake O Rammell",
        "Jason Rich"
      ],
      "affiliations": [
        "Washington University School of Medicine",
        "Saint Louis University School of Medicine"
      ],
      "normalized_institutions": [
        "Washington University School of Medicine",
        "Saint Louis University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 436,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Holly Sprow, MD 1 ; Jake O Rammell, BS 2 ; Jason Rich, MD 1",
        "Affiliations": "1 Washington University School of Medicine; 2 Saint Louis University School of Medicine",
        "Background": "Reconstruction of large lower lip defects remains exceptionally challenging and controversial. Patients often struggle with microstomia, oral incompetence, and poor cosmesis after surgery. Despite many varied surgical techniques, there is a glaring lack of standardized, objective and meaningful outcomes to define and measure successful lower lip reconstruction. The Webster Modification of the Bernard-von Burow (WMBB) technique for lower lip reconstruction is a unique and effective procedure that creates both additional cutaneous and mucosal lip length by advancing full-thickness cheek flaps. Yet, the WMBB is relatively unknown and underutilized.",
        "Objectives": "1) Describe the surgical and functional outcomes of the WMBB technique for lower lip reconstruction. 2) Compare the outcomes of different reconstructive techniques of large lower lip defects by performing a systematic review of the current literature.",
        "Methods": "A retrospective cohort study of patients undergoing WMBB for lower lip reconstruction at a single academic center between 2008-2025 was performed. A systematic review analyzing outcomes of diverse reconstructive techniques for large lower lip defects was performed using PRISMA guidelines.",
        "Results": "The WMBB was performed on 30 patients for lower lip reconstruction. 14 patients underwent bilateral WMBB and 16 underwent unilateral WMBB. 40% of patients in this cohort had pre-existing microstomia from prior lip resections. Ablative lip defects ranged from 28% to 100%. Unilateral WMBB created an average of 2.8 cm new lip length (range 2 - 4.5 cm), and bilateral WMBB created an average of 4.75 cm new lip length (range 2 - 7 cm). Only 14% of patients were noted to have subjective post-operative microstomia. Drooling was the most common complaint, noted in 64% patients, yet the majority of these patients (61%) maintained oral competence with eating and drinking. For the systematic review, 19 case report studies met eligibility criteria. Techniques that only mobilized existing lip tissue resulted in microstomia. The WMBB was the most common technique that created new lip length and was analyzed with the greatest rigor. Fasciocutaneous free flaps trended towards worse oral competence, function, and cosmetic outcomes compared to local flaps. Due to small numbers, variability of outcome measures, lack of objective outcomes, and a high risk of bias of all studies, no comparative conclusions could be made between reconstructive techniques and a meta-analysis could not be performed.",
        "Conclusions": "The WMBB is an effective technique for lower lip reconstruction by creating additional lip length. The WMBB has been the most studied technique, yet is still underutilized. The WMBB can be used unilaterally or bilaterally as needed. While there is a multiplicity of published lower lip reconstructive techniques, there is still a lack of standardized, objective, and meaningful outcomes to define and measure successful lower lip reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rediscovering the Webster Modification of the Bernard-von Burow Technique for Lower Lip Reconstruction and a Systematic Review</span>. <u>Holly Sprow, MD</u><sup>1</sup>; Jake O Rammell, BS<sup>2</sup>; Jason Rich, MD<sup>1</sup>. <sup>1</sup>Washington University School of Medicine; <sup>2</sup>Saint Louis University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Reconstruction of large lower lip defects remains exceptionally challenging and controversial. Patients often struggle with microstomia, oral incompetence, and poor cosmesis after surgery. Despite many varied surgical techniques, there is a glaring lack of standardized, objective and meaningful outcomes to define and measure successful lower lip reconstruction. The Webster Modification of the Bernard-von Burow (WMBB) technique for lower lip reconstruction is a unique and effective procedure that creates both additional cutaneous and mucosal lip length by advancing full-thickness cheek flaps. Yet, the WMBB is relatively unknown and underutilized.</p>\n\n<p><strong>Objectives: </strong>1) Describe the surgical and functional outcomes of the WMBB technique for lower lip reconstruction. 2) Compare the outcomes of different reconstructive techniques of large lower lip defects by performing a systematic review of the current literature.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of patients undergoing WMBB for lower lip reconstruction at a single academic center between 2008-2025 was performed. A systematic review analyzing outcomes of diverse reconstructive techniques for large lower lip defects was performed using PRISMA guidelines.</p>\n\n<p><strong>Results: </strong>The WMBB was performed on 30 patients for lower lip reconstruction. 14 patients underwent bilateral WMBB and 16 underwent unilateral WMBB. 40% of patients in this cohort had pre-existing microstomia from prior lip resections. Ablative lip defects ranged from 28% to 100%. Unilateral WMBB created an average of 2.8 cm new lip length (range 2 - 4.5 cm), and bilateral WMBB created an average of 4.75 cm new lip length (range 2 - 7 cm). Only 14% of patients were noted to have subjective post-operative microstomia. Drooling was the most common complaint, noted in 64% patients, yet the majority of these patients (61%) maintained oral competence with eating and drinking. For the systematic review, 19 case report studies met eligibility criteria. Techniques that only mobilized existing lip tissue resulted in microstomia. The WMBB was the most common technique that created new lip length and was analyzed with the greatest rigor. Fasciocutaneous free flaps trended towards worse oral competence, function, and cosmetic outcomes compared to local flaps. Due to small numbers, variability of outcome measures, lack of objective outcomes, and a high risk of bias of all studies, no comparative conclusions could be made between reconstructive techniques and a meta-analysis could not be performed.</p>\n\n<p><strong>Conclusions: </strong>The WMBB is an effective technique for lower lip reconstruction by creating additional lip length. The WMBB has been the most studied technique, yet is still underutilized. The WMBB can be used unilaterally or bilaterally as needed. While there is a multiplicity of published lower lip reconstructive techniques, there is still a lack of standardized, objective, and meaningful outcomes to define and measure successful lower lip reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154044--></body></html>"
    },
    {
      "uid": "P352",
      "content_id": "153983",
      "abstract_number": "P352",
      "poster_number": "P352",
      "title": "Use of Acellular Dermal Matrices for Reconstruction of a Complex Scalp Defect with Exposed Dura: A Case Report",
      "summary": "Full-thickness scalp defects with loss of calvarium and exposed dura present a challenge for reconstructive surgeons due to scalp anatomy and limited scalp tissue mobility. Acellular dermal matrices (ADM) are biologically derived products with a basement membrane and layer of acellular dermal collagen that have been widely studied as a scaffold to promote neovascularization and epithelialization. The successful...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153983",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Victoria N Huynh, BS",
      "presenter": "Victoria N Huynh, BS",
      "authors": "Victoria N Huynh, BS 1 ; Stephen Nash, MD 2 ; Sallie Long, MD 2",
      "normalized_authors": [
        "Victoria N Huynh",
        "Stephen Nash",
        "Sallie Long"
      ],
      "affiliations": [
        "Medical College of Georgia at Augusta University",
        "Wellstar MCG Health Medical Center"
      ],
      "normalized_institutions": [
        "Medical College of Georgia at Augusta University",
        "Wellstar MCG Health Medical Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153983/ACM%20Case%20Report%20Photos_final.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153983/ACM%20Case%20Report%20Photos_final.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153983"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 426,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Description",
        "Discussion"
      ],
      "sections": {
        "Authors": "Victoria N Huynh, BS 1 ; Stephen Nash, MD 2 ; Sallie Long, MD 2",
        "Affiliations": "1 Medical College of Georgia at Augusta University; 2 Wellstar MCG Health Medical Center",
        "Introduction": "Full-thickness scalp defects with loss of calvarium and exposed dura present a challenge for reconstructive surgeons due to scalp anatomy and limited scalp tissue mobility. Acellular dermal matrices (ADM) are biologically derived products with a basement membrane and layer of acellular dermal collagen that have been widely studied as a scaffold to promote neovascularization and epithelialization. The successful application of ADMs in the reconstruction of soft tissue defects of the scalp has been well documented in the literature. However, these studies typically evaluate placement of ADMs above the periosteum or directly on exposed calvaria. We present a case of reconstruction of a complex scalp defect following craniectomy for osteoradionecrosis and recurrence of cutaneous squamous cell carcinoma (cSCC) facilitated by placing ADMs directly onto exposed dura.",
        "Case Description": "The patient is a 78-year-old male with a history of SCC of the scalp treated with multiple prior procedures including a craniectomy with several local flap reconstructions and radiation. He developed a non-healing wound with exposed dura and was referred to the otolaryngology—head and neck surgery service. A craniectomy and latissimus free flap reconstruction was performed in conjunction with neurosurgery however recurrent carcinoma was unable to be cleared at the midline bone margin due to proximity to the sagittal sinus. He was discharged on postoperative day 10 at which time there was no sign of free flap nonviability. At his second post operative visit, approximately one month after surgery, he was found to have partial flap necrosis and was taken to the OR for debridement. Approximately 6x2.5cm of the latissimus flap was debrided, leaving dura exposed. Subsequently, a series of synthetic and biologic substitute materials, primarily Surgical Extra Advanced Collagen (ACM) and Biodegradable Temporizing Matrix (BTM), were utilized directly over the dura. He was treated with immunotherapy during this time as well as long term antibiotics. The outer layer of BTM was left in place for 7 weeks. This resulted in complete coverage of his previously exposed dura at approximately 5 months following his original free flap surgery without need for any additional trips to the OR. A STSG was placed at the time of a wide local excision performed at a separate scalp site for an independent carcinoma that developed while on immunotherapy.",
        "Discussion": "ADMs serve as a scaffold for neovascularization and epithelization in chronic wounds. This case is an example that these materials can be used successfully in select scenarios even when placed directly over exposed dura. This may be useful in complex scalp reconstruction cases, particularly for patients in whom the goal is avoidance of additional surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Acellular Dermal Matrices for Reconstruction of a Complex Scalp Defect with Exposed Dura: A Case Report</span>. <u>Victoria N Huynh, BS</u><sup>1</sup>; Stephen Nash, MD<sup>2</sup>; Sallie Long, MD<sup>2</sup>. <sup>1</sup>Medical College of Georgia at Augusta University; <sup>2</sup>Wellstar MCG Health Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Full-thickness scalp defects with loss of calvarium and exposed dura present a challenge for reconstructive surgeons due to scalp anatomy and limited scalp tissue mobility. Acellular dermal matrices (ADM) are biologically derived products with a basement membrane and layer of acellular dermal collagen that have been widely studied as a scaffold to promote neovascularization and epithelialization. The successful application of ADMs in the reconstruction of soft tissue defects of the scalp has been well documented in the literature. However, these studies typically evaluate placement of ADMs above the periosteum or directly on exposed calvaria. We present a case of reconstruction of a complex scalp defect following craniectomy for osteoradionecrosis and recurrence of cutaneous squamous cell carcinoma (cSCC) facilitated by placing ADMs directly onto exposed dura.</p>\n\n<p><strong>Case Description: </strong>The patient is a 78-year-old male with a history of SCC of the scalp treated with multiple prior procedures including a craniectomy with several local flap reconstructions and radiation. He developed a non-healing wound with exposed dura and was referred to the otolaryngology—head and neck surgery service. A craniectomy and latissimus free flap reconstruction was performed in conjunction with neurosurgery however recurrent carcinoma was unable to be cleared at the midline bone margin due to proximity to the sagittal sinus. He was discharged on postoperative day 10 at which time there was no sign of free flap nonviability. At his second post operative visit, approximately one month after surgery, he was found to have partial flap necrosis and was taken to the OR for debridement. Approximately 6x2.5cm of the latissimus flap was debrided, leaving dura exposed. Subsequently, a series of synthetic and biologic substitute materials, primarily Surgical Extra Advanced Collagen (ACM) and Biodegradable Temporizing Matrix (BTM), were utilized directly over the dura. He was treated with immunotherapy during this time as well as long term antibiotics. The outer layer of BTM was left in place for 7 weeks. This resulted in complete coverage of his previously exposed dura at approximately 5 months following his original free flap surgery without need for any additional trips to the OR. A STSG was placed at the time of a wide local excision performed at a separate scalp site for an independent carcinoma that developed while on immunotherapy.</p>\n\n<p><strong>Discussion: </strong>ADMs serve as a scaffold for neovascularization and epithelization in chronic wounds. This case is an example that these materials can be used successfully in select scenarios even when placed directly over exposed dura. This may be useful in complex scalp reconstruction cases, particularly for patients in whom the goal is avoidance of additional surgery.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153983/ACM%20Case%20Report%20Photos_final.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153983--></body></html>"
    },
    {
      "uid": "P353",
      "content_id": "154118",
      "abstract_number": "P353",
      "poster_number": "P353",
      "title": "Submental Perforator Island Flaps: An Effective and Underutilized Reconstructive Technique for Cutaneous Chin Defects",
      "summary": "This case report demonstrates the effectiveness of a biaxial submental perforator island flap for cutaneous chin reconstruction, showcasing that this technique has unique advantages over other established approaches, including reliable vascularity, a wider area of available donor tissue, effective aesthetic tissue matching, and appropriate access for a concurrent neck dissection in oncology patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154118",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sacha Moufarrej, MA",
      "presenter": "Sacha Moufarrej, MA",
      "authors": "Sacha Moufarrej, MA 1 ; Farhoud Faraji, MD, PhD 1 ; Joseph A Califano, MD 1 ; Frederic Kolb, MD, MS, MRes 2",
      "normalized_authors": [
        "Sacha Moufarrej, MA",
        "Farhoud Faraji",
        "Joseph A Califano",
        "Frederic Kolb, MRes"
      ],
      "affiliations": [
        "UC San Diego Department of Otolaryngology-Head and Neck Surgery",
        "UC San Diego Division of Plastic Surgery"
      ],
      "normalized_institutions": [
        "UC San Diego Department of Otolaryngology-Head and Neck Surgery",
        "UC San Diego Division of Plastic Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 381,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sacha Moufarrej, MA 1 ; Farhoud Faraji, MD, PhD 1 ; Joseph A Califano, MD 1 ; Frederic Kolb, MD, MS, MRes 2",
        "Affiliations": "1 UC San Diego Department of Otolaryngology-Head and Neck Surgery; 2 UC San Diego Division of Plastic Surgery",
        "Background": "The rising prevalence of skin cancer has made post-excisional facial defects an increasingly common reconstructive challenge. This is particularly true of the chin, an anatomical site posing unique difficulties due to its contours, skin thickness, and high visibility requiring aesthetic tissue matching. While local random flap and free flap techniques are well-documented approaches to reconstruction of lower facial cutaneous defects, there remains a dearth of literature on the effectiveness of submental perforator flaps, which, though underutilized, may pose unique vascular and aesthetic benefits.",
        "Methods": "A case report describing the preoperative planning, surgery, and post-operative outcomes of a patient with an ulcerated melanoma of the chin requiring full-thickness wide local excision and subsequent reconstruction.",
        "Results": "A 65-year-old male with history of right cheek basal cell carcinoma presented with a 0.5 x 0.5 cm left paramedian chin ulcerated melanoma with Breslow’s depth of 0.86 mm as diagnosed via shave biopsy, requiring further management with wide local excision (WLE) and sentinel lymph node biopsy (SLNB). Excision of the melanoma with adequate margins yielded a full-thickness circular cutaneous chin defect 2.6 cm in diameter, which favored a submental perforator island flap over a local skin advancement flap approach given the larger area requiring reconstruction. After ultrasound identification of two large intact submental perforator arteries bilaterally, dissection of the superior border of the flap was initiated medially to laterally on each side along the anterior digastric bellies, with preservation of the terminal submental perforators. The inferior border was freed prior to the reconstructive stage to allow for concurrent neck dissection and SNLB at right level III and left level I. After de-epithelialization of the two ends, the freed flap was transposed through the tunneled inferior border of the chin defect above the mentalis muscle plane and secured, and the submental donor site was advanced for closure under the mandible. Post-operative follow-up demonstrated that the patient’s flap healed with no complications and with aesthetic appearance that matched the native skin.",
        "Conclusions": "This case report demonstrates the effectiveness of a biaxial submental perforator island flap for cutaneous chin reconstruction, showcasing that this technique has unique advantages over other established approaches, including reliable vascularity, a wider area of available donor tissue, effective aesthetic tissue matching, and appropriate access for a concurrent neck dissection in oncology patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Submental Perforator Island Flaps: An Effective and Underutilized Reconstructive Technique for Cutaneous Chin Defects</span>. <u>Sacha Moufarrej, MA</u><sup>1</sup>; Farhoud Faraji, MD, PhD<sup>1</sup>; Joseph A Califano, MD<sup>1</sup>; Frederic Kolb, MD, MS, MRes<sup>2</sup>. <sup>1</sup>UC San Diego Department of Otolaryngology-Head and Neck Surgery; <sup>2</sup>UC San Diego Division of Plastic Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The rising prevalence of skin cancer has made post-excisional facial defects an increasingly common reconstructive challenge. This is particularly true of the chin, an anatomical site posing unique difficulties due to its contours, skin thickness, and high visibility requiring aesthetic tissue matching. While local random flap and free flap techniques are well-documented approaches to reconstruction of lower facial cutaneous defects, there remains a dearth of literature on the effectiveness of submental perforator flaps, which, though underutilized, may pose unique vascular and aesthetic benefits.</p>\n\n<p><strong>Methods:</strong> A case report describing the preoperative planning, surgery, and post-operative outcomes of a patient with an ulcerated melanoma of the chin requiring full-thickness wide local excision and subsequent reconstruction.</p>\n\n<p><strong>Results:</strong> A 65-year-old male with history of right cheek basal cell carcinoma presented with a 0.5 x 0.5 cm left paramedian chin ulcerated melanoma with Breslow’s depth of 0.86 mm as diagnosed via shave biopsy, requiring further management with wide local excision (WLE) and sentinel lymph node biopsy (SLNB). Excision of the melanoma with adequate margins yielded a full-thickness circular cutaneous chin defect 2.6 cm in diameter, which favored a submental perforator island flap over a local skin advancement flap approach given the larger area requiring reconstruction. After ultrasound identification of two large intact submental perforator arteries bilaterally, dissection of the superior border of the flap was initiated medially to laterally on each side along the anterior digastric bellies, with preservation of the terminal submental perforators. The inferior border was freed prior to the reconstructive stage to allow for concurrent neck dissection and SNLB at right level III and left level I. After de-epithelialization of the two ends, the freed flap was transposed through the tunneled inferior border of the chin defect above the mentalis muscle plane and secured, and the submental donor site was advanced for closure under the mandible. Post-operative follow-up demonstrated that the patient’s flap healed with no complications and with aesthetic appearance that matched the native skin.</p>\n\n<p><strong>Conclusions:</strong> This case report demonstrates the effectiveness of a biaxial submental perforator island flap for cutaneous chin reconstruction, showcasing that this technique has unique advantages over other established approaches, including reliable vascularity, a wider area of available donor tissue, effective aesthetic tissue matching, and appropriate access for a concurrent neck dissection in oncology patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154118--></body></html>"
    },
    {
      "uid": "P355",
      "content_id": "155591",
      "abstract_number": "P355",
      "poster_number": "P355",
      "title": "Modified Virtual Surgical Planning for Osteocutaneous Radial Forearm Free Flap Maxillofacial Reconstruction: Long-Term Outcomes",
      "summary": "In this expanded institutional series, virtual surgical planning facilitates reliable OCRFFF reconstruction with excellent flap survival and low complication rates, supporting its use as an effective reconstructive option in appropriately selected patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155591",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Edgar D Uribe Sanchez, BA",
      "presenter": "Edgar D Uribe Sanchez, BA",
      "authors": "Edgar D Uribe Sanchez, BA ; Daniel Benito, MD; Austin Lam, MD; Dustin J Conrad, MD; Peter T Dziegielewski,, MD",
      "normalized_authors": [
        "Edgar D Uribe Sanchez",
        "Daniel Benito",
        "Austin Lam",
        "Dustin J Conrad",
        "Peter T Dziegielewski"
      ],
      "affiliations": [
        "University of Florida"
      ],
      "normalized_institutions": [
        "University of Florida"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 345,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Edgar D Uribe Sanchez, BA ; Daniel Benito, MD; Austin Lam, MD; Dustin J Conrad, MD; Peter T Dziegielewski,, MD",
        "Affiliations": "University of Florida",
        "Introduction": "Advances in computer-assisted planning have transformed complex maxillofacial reconstruction, enabling precise osteotomies and improved skeletal alignment. Virtual surgical planning (VSP) has become widely adopted for fibular free flap reconstruction of the mandible and midface. In contrast, the use of VSP in osteocutaneous radial forearm free flap (OCRFFF) reconstruction has received comparatively little attention despite the flap’s unique advantages, including shorter harvest time, reliable vascular anatomy, and suitability for patients who may not tolerate longer operations. This study evaluates utilizing VSP to facilitate OCRFFF reconstruction of maxillofacial defects.",
        "Methods": "We performed a retrospective review of patients undergoing OCRFFF reconstruction with VSP guidance at a tertiary academic center between 2016 and 2024. Patient demographics, disease characteristics, and operative details were recorded. Perioperative outcomes including operative duration, hospital length of stay, flap survival, osseous healing, and donor-site complications were evaluated.",
        "Results": "Twenty-four patients undergoing osteocutaneous radial forearm free flap (OCRFFF) reconstruction with virtual surgical planning (VSP) were identified. The average age at surgery was 74.5 years, and 18 (75%) patients were male. Most cases were performed for oncologic resection of oral cavity squamous cell carcinoma, while three (12.5%) cases were performed for traumatic defects. Seventeen (72%) patients had mandibular defects, while seven (28%) involved midface reconstruction.",
        "Abstract": "All reconstructions utilized VSP with cutting guides and patient-specific reconstruction planning. The average radial bone segment length harvested for reconstruction was 8.9 cm (range 5–11.5 cm). All wrists were plated by orthopedic surgery. Twelve (50%) patients required a single osteotomy, while twelve (50%) underwent single-segment reconstruction without additional osteotomies. Microvascular reconstruction was successful in all cases. There were no partial or total flap failures. The average length of stay was 7.6 days. Four patients (16.7%) developed minor wound complications, including two cases of wound dehiscence managed conservatively and two cases of transient salivary leak that resolved without intervention. No patients experienced radial bone fractures.",
        "Conclusions": "In this expanded institutional series, virtual surgical planning facilitates reliable OCRFFF reconstruction with excellent flap survival and low complication rates, supporting its use as an effective reconstructive option in appropriately selected patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Modified Virtual Surgical Planning for Osteocutaneous Radial Forearm Free Flap Maxillofacial Reconstruction: Long-Term Outcomes</span>. <u>Edgar D Uribe Sanchez, BA</u>; Daniel Benito, MD; Austin Lam, MD; Dustin J Conrad, MD; Peter T Dziegielewski,, MD. University of Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advances in computer-assisted planning have transformed complex maxillofacial reconstruction, enabling precise osteotomies and improved skeletal alignment. Virtual surgical planning (VSP) has become widely adopted for fibular free flap reconstruction of the mandible and midface. In contrast, the use of VSP in osteocutaneous radial forearm free flap (OCRFFF) reconstruction has received comparatively little attention despite the flap’s unique advantages, including shorter harvest time, reliable vascular anatomy, and suitability for patients who may not tolerate longer operations. This study evaluates utilizing VSP to facilitate OCRFFF reconstruction of maxillofacial defects.  </p>\n\n<p><strong>Methods: </strong>We performed a retrospective review of patients undergoing OCRFFF reconstruction with VSP guidance at a tertiary academic center between 2016 and 2024. Patient demographics, disease characteristics, and operative details were recorded. Perioperative outcomes including operative duration, hospital length of stay, flap survival, osseous healing, and donor-site complications were evaluated.  </p>\n\n<p><strong>Results: </strong>Twenty-four patients undergoing osteocutaneous radial forearm free flap (OCRFFF) reconstruction with virtual surgical planning (VSP) were identified. The average age at surgery was 74.5 years, and 18 (75%) patients were male. Most cases were performed for oncologic resection of oral cavity squamous cell carcinoma, while three (12.5%) cases were performed for traumatic defects. Seventeen (72%) patients had mandibular defects, while seven (28%) involved midface reconstruction.</p>\n\n<p>All reconstructions utilized VSP with cutting guides and patient-specific reconstruction planning. The average radial bone segment length harvested for reconstruction was 8.9 cm (range 5–11.5 cm). All wrists were plated by orthopedic surgery. Twelve (50%) patients required a single osteotomy, while twelve (50%) underwent single-segment reconstruction without additional osteotomies. Microvascular reconstruction was successful in all cases. There were no partial or total flap failures. The average length of stay was 7.6 days. Four patients (16.7%) developed minor wound complications, including two cases of wound dehiscence managed conservatively and two cases of transient salivary leak that resolved without intervention. No patients experienced radial bone fractures.</p>\n\n<p><strong>Conclusions: </strong>In this expanded institutional series, virtual surgical planning facilitates reliable OCRFFF reconstruction with excellent flap survival and low complication rates, supporting its use as an effective reconstructive option in appropriately selected patients. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155591--></body></html>"
    },
    {
      "uid": "P356",
      "content_id": "153957",
      "abstract_number": "P356",
      "poster_number": "P356",
      "title": "The Lateral Arm Flap in Modern Head and Neck Reconstruction: A Six-Case Series Highlighting the Proximal-Deltoid Technique for Pedicle-Extension",
      "summary": "The Proximal-Deltoid technique is a safe and reproducible method for creating a longer pedicle that broadens the reconstructive capabilities of the LAF. This modification improves pedicle length and flexibility - enabling safer inset and more consistent vascular performance - making it a valuable technique for head and neck reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153957",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan Garneau, MD",
      "presenter": "Jonathan Garneau, MD",
      "authors": "Zachary Pierre, BA; Jonathan Garneau, MD",
      "normalized_authors": [
        "Zachary Pierre",
        "Jonathan Garneau"
      ],
      "affiliations": [
        "University of Virginia"
      ],
      "normalized_institutions": [
        "University of Virginia"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 376,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Zachary Pierre, BA; Jonathan Garneau, MD",
        "Affiliations": "University of Virginia",
        "Background": "The lateral arm flap (LAF) is a reliable fasciocutaneous option in microsurgical reconstruction, first described by Song et al. in 1982 as a septocutaneous flap based on the posterior radial collateral artery (PRCA). Its thin tissue and vascular anatomy have made it useful for a range of reconstructive indications. Subsequent developments - including the Extended Lateral Arm Flap (ELAF), which extends distally toward the proximal forearm - demonstrated the benefits of accessing thinner skin and increasing pedicle length. Building upon these refinements, we present the Proximal-Deltoid technique, a novel pedicle-extension method achieved through deltoid-adjacent dissection toward the profunda brachii origin. This modification increases pedicle length without compromising flap thinness, which can improve inset geometry, and increase recipient-vessel flexibility. This case series evaluates outcomes in six patients undergoing head and neck reconstruction using this technique.",
        "Methods": "Six patients undergoing oncologic resection and microvascular reconstruction with the LAF were included. All patients consented to video recording and free flap reconstruction. Patient demographics, tumor characteristics, flap dimensions, defect type, operative details, and postoperative outcomes were documented. In all patients the LAF was harvested using a standardized technique.",
        "Results": "All six flaps were successfully harvested and transferred using the Proximal-Deltoid technique. Pedicle lengthening provided increased reach and improved inset orientation across a wide range of reconstructive sites, including oral cavity, oropharyngeal, sinonasal, midface, and composite facial defects. No postoperative complications occurred. All flaps remained viable without venous congestion, arterial insufficiency, or partial necrosis. Donor sites were closed primarily with no significant sensory deficits, wound complications, or upper-extremity functional impairment. Pedicle extension facilitated vessel selection in previously irradiated or surgically altered necks and improved inset geometry in deep or posterior defects.",
        "Discussion": "Compared with the anterolateral thigh (ALT) flap, and the radial forearm flap (RFF), the LAF provides a proportionate paddle without excess bulk, while avoiding major arterial sacrifice and permitting primary closure, reducing donor-site morbidity. The addition of proximal pedicle extension enhances the LAF’s utility by minimizing tension and kinking, and allowing greater flexibility in recipient-vessel choice.",
        "Conclusion": "The Proximal-Deltoid technique is a safe and reproducible method for creating a longer pedicle that broadens the reconstructive capabilities of the LAF. This modification improves pedicle length and flexibility - enabling safer inset and more consistent vascular performance - making it a valuable technique for head and neck reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Lateral Arm Flap in Modern Head and Neck Reconstruction: A Six-Case Series Highlighting the Proximal-Deltoid Technique for Pedicle-Extension</span>. Zachary Pierre, BA; <u>Jonathan Garneau, MD</u>. University of Virginia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The lateral arm flap (LAF) is a reliable fasciocutaneous option in microsurgical reconstruction, first described by Song et al. in 1982 as a septocutaneous flap based on the posterior radial collateral artery (PRCA). Its thin tissue and vascular anatomy have made it useful for a range of reconstructive indications. Subsequent developments - including the Extended Lateral Arm Flap (ELAF), which extends distally toward the proximal forearm - demonstrated the benefits of accessing thinner skin and increasing pedicle length. Building upon these refinements, we present the Proximal-Deltoid technique, a novel pedicle-extension method achieved through deltoid-adjacent dissection toward the profunda brachii origin. This modification increases pedicle length without compromising flap thinness, which can improve inset geometry, and increase recipient-vessel flexibility. This case series evaluates outcomes in six patients undergoing head and neck reconstruction using this technique. </p>\n\n<p><strong>Methods:</strong> Six patients undergoing oncologic resection and microvascular reconstruction with the LAF were included. All patients consented to video recording and free flap reconstruction. Patient demographics, tumor characteristics, flap dimensions, defect type, operative details, and postoperative outcomes were documented. In all patients the LAF was harvested using a standardized technique.</p>\n\n<p><strong>Results: </strong>All six flaps were successfully harvested and transferred using the Proximal-Deltoid technique. Pedicle lengthening provided increased reach and improved inset orientation across a wide range of reconstructive sites, including oral cavity, oropharyngeal, sinonasal, midface, and composite facial defects. No postoperative complications occurred. All flaps remained viable without venous congestion, arterial insufficiency, or partial necrosis. Donor sites were closed primarily with no significant sensory deficits, wound complications, or upper-extremity functional impairment. Pedicle extension facilitated vessel selection in previously irradiated or surgically altered necks and improved inset geometry in deep or posterior defects. </p>\n\n<p><strong>Discussion:</strong> Compared with the anterolateral thigh (ALT) flap, and the radial forearm flap (RFF), the LAF provides a proportionate paddle without excess bulk, while avoiding major arterial sacrifice and permitting primary closure, reducing donor-site morbidity. The addition of proximal pedicle extension enhances the LAF’s utility by minimizing tension and kinking, and allowing greater flexibility in recipient-vessel choice. </p>\n\n<p><strong>Conclusion: </strong>The Proximal-Deltoid technique is a safe and reproducible method for creating a longer pedicle that broadens the reconstructive capabilities of the LAF. This modification improves pedicle length and flexibility - enabling safer inset and more consistent vascular performance - making it a valuable technique for head and neck reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153957--></body></html>"
    },
    {
      "uid": "P357",
      "content_id": "153967",
      "abstract_number": "P357",
      "poster_number": "P357",
      "title": "JIAD",
      "summary": "JIAD reconstruction provided reliable single-stage osseous reconstruction with predictable perioperative performance, timely adjuvant therapy, and 100% flap survival. Limitations in final prosthetic restoration were largely related to oncologic treatment, recurrence, and radiation-associated morbidity. Further study with larger cohorts is needed to refine patient selection and optimize perioperative and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153967",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas L Haupt, MD",
      "presenter": "Thomas L Haupt, MD",
      "authors": "Thomas L Haupt, MD ; Emily Evangelista, MD; Daniel Sukato, MD; Heshaam Fallah, DDS, MD; Deepak Gurushanthaiah, MD",
      "normalized_authors": [
        "Thomas L Haupt",
        "Emily Evangelista",
        "Daniel Sukato",
        "Heshaam Fallah",
        "Deepak Gurushanthaiah"
      ],
      "affiliations": [
        "Dept of Head and Neck Surgery Kaiser Oakland"
      ],
      "normalized_institutions": [
        "Dept of Head and Neck Surgery Kaiser Oakland"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 326,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Thomas L Haupt, MD ; Emily Evangelista, MD; Daniel Sukato, MD; Heshaam Fallah, DDS, MD; Deepak Gurushanthaiah, MD",
        "Affiliations": "Dept of Head and Neck Surgery Kaiser Oakland",
        "Objective": "To evaluate the feasibility, perioperative outcomes, complication burden, dental rehabilitation success, and oncologic safety of single-stage Jaw-In-A-Day (JIAD) mandibular reconstruction.",
        "Methods": "A retrospective case series was conducted including all consecutive patients who underwent JIAD mandibular reconstruction from 2024–2025 at a single tertiary academic center within an integrated health care system. Extracted variables included demographics, diagnosis, operative duration, ischemia time, length of stay, and reconstructive characteristics (fibula segments and implant count). For malignant cases, receipt and timing of postoperative radiation therapy were recorded. Descriptive statistical analyses characterized perioperative performance and oncologic treatment intervals.",
        "Results": "Twelve patients underwent JIAD reconstruction (mean age 66.2 years, SD 17.3; 58.3% male). Malignant pathology accounted for 75% of cases, predominantly squamous cell carcinoma; 25% were benign (ameloblastoma or medication-related osteonecrosis of the jaw). Reconstructions utilized a mean of 2.0 fibula segments (range 1–3) and 3 implants (range 1–5). Mean operative duration was 11.2 hours (SD 1.4), mean ischemia time was 147.8 minutes (SD 31.4), and mean length of stay was 7.6 days (SD 2.7). Median follow-up was 5.8 months (IQR 4.4–10.8). Among malignant cases, the median interval to postoperative radiation therapy initiation was 6.0 weeks. Nine patients (75%) had ≥4 months of follow-up, among whom 3 (33%) achieved final prosthetic restoration (mean 9.4 months, median 10.4). Flap survival was 100%. The overall reconstruction-related complication rate was approximately 42%. Major complications included neck hematoma, infection with hardware exposure, and osteoradionecrosis. Minor complications included Clostridioides difficile infection during perioperative antibiotic use, tongue ulceration, and prosthesis intolerance. Cancer-related mortality was 22.2%.",
        "Conclusion": "JIAD reconstruction provided reliable single-stage osseous reconstruction with predictable perioperative performance, timely adjuvant therapy, and 100% flap survival. Limitations in final prosthetic restoration were largely related to oncologic treatment, recurrence, and radiation-associated morbidity. Further study with larger cohorts is needed to refine patient selection and optimize perioperative and rehabilitation protocols to improve long-term functional outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>JIAD</span>. <u>Thomas L Haupt, MD</u>; Emily Evangelista, MD; Daniel Sukato, MD; Heshaam Fallah, DDS, MD; Deepak Gurushanthaiah, MD. Dept of Head and Neck Surgery Kaiser Oakland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate the feasibility, perioperative outcomes, complication burden, dental rehabilitation success, and oncologic safety of single-stage Jaw-In-A-Day (JIAD) mandibular reconstruction.</p>\n\n<p><strong>Methods: </strong>A retrospective case series was conducted including all consecutive patients who underwent JIAD mandibular reconstruction from 2024–2025 at a single tertiary academic center within an integrated health care system. Extracted variables included demographics, diagnosis, operative duration, ischemia time, length of stay, and reconstructive characteristics (fibula segments and implant count). For malignant cases, receipt and timing of postoperative radiation therapy were recorded. Descriptive statistical analyses characterized perioperative performance and oncologic treatment intervals.</p>\n\n<p><strong>Results:</strong> Twelve patients underwent JIAD reconstruction (mean age 66.2 years, SD 17.3; 58.3% male). Malignant pathology accounted for 75% of cases, predominantly squamous cell carcinoma; 25% were benign (ameloblastoma or medication-related osteonecrosis of the jaw). Reconstructions utilized a mean of 2.0 fibula segments (range 1–3) and 3 implants (range 1–5). Mean operative duration was 11.2 hours (SD 1.4), mean ischemia time was 147.8 minutes (SD 31.4), and mean length of stay was 7.6 days (SD 2.7). Median follow-up was 5.8 months (IQR 4.4–10.8). Among malignant cases, the median interval to postoperative radiation therapy initiation was 6.0 weeks. Nine patients (75%) had ≥4 months of follow-up, among whom 3 (33%) achieved final prosthetic restoration (mean 9.4 months, median 10.4). Flap survival was 100%. The overall reconstruction-related complication rate was approximately 42%. Major complications included neck hematoma, infection with hardware exposure, and osteoradionecrosis. Minor complications included Clostridioides difficile infection during perioperative antibiotic use, tongue ulceration, and prosthesis intolerance. Cancer-related mortality was 22.2%.</p>\n\n<p><strong>Conclusion: </strong>JIAD reconstruction provided reliable single-stage osseous reconstruction with predictable perioperative performance, timely adjuvant therapy, and 100% flap survival. Limitations in final prosthetic restoration were largely related to oncologic treatment, recurrence, and radiation-associated morbidity. Further study with larger cohorts is needed to refine patient selection and optimize perioperative and rehabilitation protocols to improve long-term functional outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153967--></body></html>"
    },
    {
      "uid": "P358",
      "content_id": "154436",
      "abstract_number": "P358",
      "poster_number": "P358",
      "title": "Surgical end time predicts postoperative complications in head and neck microvascular reconstructive surgery",
      "summary": "Patients who finish surgery after 6pm are at an increased risk of returning to the OR and a number of postoperative complications after accounting for comorbidities. A higher charleston comorbidity index also increases risk of a patient having any postoperative complication. Later operating finishes typically involve multiple hand offs to the surgical and nursing night teams that may account for these findings....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154436",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amaan Rahman, BS",
      "presenter": "Amaan Rahman, BS",
      "authors": "Chelsea Gelboin Burkhart, MD; Anthony DiPalma, BS; Amaan Rahman, BS ; Anthony Tang, BS; Joshua Smith, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Steven Chinn, MD; Matthew E Spector, MD",
      "normalized_authors": [
        "Chelsea Gelboin Burkhart",
        "Anthony DiPalma",
        "Amaan Rahman",
        "Anthony Tang",
        "Joshua Smith",
        "Kevin Contrera",
        "Shaum Sridharan",
        "Steven Chinn",
        "Matthew E Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 512,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Chelsea Gelboin Burkhart, MD; Anthony DiPalma, BS; Amaan Rahman, BS ; Anthony Tang, BS; Joshua Smith, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Steven Chinn, MD; Matthew E Spector, MD",
        "Affiliations": "University of Pittsburgh",
        "Introduction": "Advances in head and neck microvascular surgery have allowed for increased efficiency with reduced OR times allowing for earlier end of surgery. The literature suggests that prolonged OR time is associated with increased complication rates, however the relationship between time of day of surgery completion and complication rate is unknown. The objective of this study was to correlate perioperative patient outcomes and complications with surgical end time and total intraoperative OR time.",
        "Methods": "Retrospective data was collected on patients undergoing head and neck reconstructive surgery in an academic tertiary medical center. A total of 818 patients were included from November 2017 until May 2025.",
        "Abstract": "Patient data collected included age, sex, Charleston comorbidity index (CCI), tumor stage, history of chemotherapy or radiation. Outcomes measures included surgical end time, intraoperative time, length of stay and length of ICU stay, and postoperative complication rates. Complications recorded included return to OR rates, partial or total flap failure, dehiscence, wound infection, fistula and hematoma or seroma. When adjusting for CCI, Patients whose surgery ended after 6pm were about twice as likely to require a return to the OR compared with earlier cases (OR 2.14, 95% CI 1.465-3.134). This is a much larger effect than total OR time, which only had a slight increased risk of returning to the OR (OR 1.001, 95% CI 1.001-1.003). Cases ending after 6pm were also associated with increased risk of fistula/salivary leak (OR 2.37, 95% CI 1.335-4.352), postoperative wound infection (OR 3.44, 95% CI 1.87-6.69), Partial or total flap loss (OR 2.812, 95% CI 1.11- 8.033) and dehiscence (OR 2.12, 95% CI 1.4-3.224). A high comorbidity index however, was the strongest predictor of having any postoperative complication when pooled (OR 1.122, 95% CI 1.02-1.24). Late OR time had no effect on hematoma/seroma rate. Neither late T stage nor CCI had an increased risk of returning to the OR.",
        "Results": "Among a total of 815 patients, 443 patients completed surgery prior to 6pm and 374 patients completed surgery after 6pm. Median age was 64 (range 16-91) and 69% were male. Median CCI was 2, with high CCI (>3) in 49% of patients. 20% of patients had prior radiation and or chemotherapy treatment. Of those with current head and neck cancer, 19% were early stage (T1/T2) and 58% of patients were late stage (T3/T4).",
        "Conclusion": "Patients who finish surgery after 6pm are at an increased risk of returning to the OR and a number of postoperative complications after accounting for comorbidities. A higher charleston comorbidity index also increases risk of a patient having any postoperative complication. Later operating finishes typically involve multiple hand offs to the surgical and nursing night teams that may account for these findings. While there is likely some confounding due to a correlation with surgical time, the effect of late surgical complication was higher than surgical length. Earlier surgical end time may allow for increased postoperative monitoring with higher nursing ratios, earlier mobilization, and more frequent resident rounding."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical end time predicts postoperative complications in head and neck microvascular reconstructive surgery</span>. Chelsea Gelboin Burkhart, MD; Anthony DiPalma, BS; <u>Amaan Rahman, BS</u>; Anthony Tang, BS; Joshua Smith, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Steven Chinn, MD; Matthew E Spector, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advances in head and neck microvascular surgery have allowed for increased efficiency with reduced OR times allowing for earlier end of surgery. The literature suggests that prolonged OR time is associated with increased complication rates, however the relationship between time of day of surgery completion and complication rate is unknown. The objective of this study was to correlate perioperative patient outcomes and complications with surgical end time and total intraoperative OR time.</p>\n\n<p><strong>Methods: </strong>Retrospective data was collected on patients undergoing head and neck reconstructive surgery in an academic tertiary medical center. A total of 818 patients were included from November 2017 until May 2025.</p>\n\n<p>Patient data collected included age, sex, Charleston comorbidity index (CCI), tumor stage, history of chemotherapy or radiation. Outcomes measures included surgical end time, intraoperative time, length of stay and length of ICU stay, and postoperative complication rates. Complications recorded included return to OR rates, partial or total flap failure, dehiscence, wound infection, fistula and hematoma or seroma.</p>\n\n<p><strong>Results:</strong> Among a total of 815 patients, 443 patients completed surgery prior to 6pm and 374 patients completed surgery after 6pm. Median age was 64 (range 16-91) and 69% were male. Median CCI was 2, with high CCI (>3) in 49% of patients. 20% of patients had prior radiation and or chemotherapy treatment. Of those with current head and neck cancer, 19% were early stage (T1/T2) and 58% of patients were late stage (T3/T4).</p>\n\n<p>When adjusting for CCI, Patients whose surgery ended after 6pm were about twice as likely to require a return to the OR compared with earlier cases (OR 2.14, 95% CI 1.465-3.134). This is a much larger effect than total OR time, which only had a slight increased risk of returning to the OR (OR 1.001, 95% CI 1.001-1.003). Cases ending after 6pm were also associated with increased risk of fistula/salivary leak (OR 2.37, 95% CI 1.335-4.352), postoperative wound infection (OR 3.44, 95% CI 1.87-6.69), Partial or total flap loss (OR 2.812, 95% CI 1.11- 8.033) and dehiscence (OR 2.12, 95% CI 1.4-3.224). A high comorbidity index however, was the strongest predictor of having any postoperative complication when pooled (OR 1.122, 95% CI 1.02-1.24). Late OR time had no effect on hematoma/seroma rate. Neither late T stage nor CCI had an increased risk of returning to the OR.</p>\n\n<p><strong>Conclusion: </strong>Patients who finish surgery after 6pm are at an increased risk of returning to the OR and a number of postoperative complications after accounting for comorbidities. A higher charleston comorbidity index also increases risk of a patient having any postoperative complication. Later operating finishes typically involve multiple hand offs to the surgical and nursing night teams that may account for these findings. While there is likely some confounding due to a correlation with surgical time, the effect of late surgical complication was higher than surgical length. Earlier surgical end time may allow for increased postoperative monitoring with higher nursing ratios, earlier mobilization, and more frequent resident rounding.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154436--></body></html>"
    },
    {
      "uid": "P359",
      "content_id": "155345",
      "abstract_number": "P359",
      "poster_number": "P359",
      "title": "Antidepressants and Microsurgery: Associations Between SSRI/SNRI Use and Complications in Head & Neck Free-Flap Reconstruction",
      "summary": "Across a multi-institutional cohort of head and neck free-flap reconstructions,?recent SSRI/SNRI exposure was associated with a higher early postoperative complication burden, driven primarily by bleeding-related and wound-healing events. Although absolute risks remained?modest, the relative increase has practical implications for preoperative counseling and postoperative monitoring in microsurgical head and neck...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155345",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sergio A Segrera, MS",
      "presenter": "Sergio A Segrera, MS",
      "authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis Gursky, BS 1 ; Hailey Wyatt, MD 1 ; Adam Jacobson, MD 2 ; Jamie P Levine, MD 1",
      "normalized_authors": [
        "Sergio A Segrera",
        "Anandhini Narayanan",
        "Alexis Gursky",
        "Hailey Wyatt",
        "Adam Jacobson",
        "Jamie P Levine"
      ],
      "affiliations": [
        "NYU Langone Hansjörg Wyss Department of Plastic Surgery",
        "NYU Langone Department of Otolaryngology-Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "NYU Langone Hansjörg Wyss Department of Plastic Surgery",
        "NYU Langone Department of Otolaryngology-Head & Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 561,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis Gursky, BS 1 ; Hailey Wyatt, MD 1 ; Adam Jacobson, MD 2 ; Jamie P Levine, MD 1",
        "Affiliations": "1 NYU Langone Hansjörg Wyss Department of Plastic Surgery; 2 NYU Langone Department of Otolaryngology-Head & Neck Surgery",
        "Purpose": "A significant number of head and neck cancer patients present for microvascular reconstruction while taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These have been shown to potentially increase platelet dysfunction, bleeding, and downstream wound complications, though evidence in plastic surgery is limited. Given the microvascular complexity of head and neck free-flap reconstruction, we used a large, multi-institutional electronic health record network to quantify the association between preoperative SSRI/SNRI exposure and early postoperative complications after head and neck reconstruction.",
        "Methods": "We conducted a retrospective cohort study using the TriNetX Research Network, including adults who underwent head and neck free-flap reconstruction. To ensure anatomic specificity, index cases were required to have same-day head/neck ablative codes and were additionally anchored with head/neck malignancy diagnoses. Preoperative SSRI/SNRI exposure was defined as a record within 90 days of the index procedure; comparators had no SSRI/SNRI record within 6 months. We used 1:1 nearest-neighbor propensity-score matching (logistic regression within TriNetX) with a prespecified balance threshold of standardized mean difference (SMD) <0.1 across covariates: age, race/ethnicity, procedure type, cancer site and treatment, obesity, diabetes, hypertension, tobacco and alcohol use, anemia, coagulopathy, obstructive sleep apnea, chronic kidney disease, and liver disease. Outcomes were analyzed on the TriNetX platform with risk ratios (RRs) and 95% confidence intervals; significance was set at p <0.05. The primary endpoint was a bleeding/hematoma composite (postprocedural hemorrhage/hematoma, hematoma evacuation, or transfusion) assessed at 7, 15, and 30 days. Secondary endpoints were flap complications, surgical-site infection, and wound dehiscence at the same time points.",
        "Results": "Across 58 health systems, 35,309 patients met inclusion criteria; 4,898 had preoperative SSRI/SNRI exposure and 30,411 served as comparators. After matching, 4,726 exposed and 4,726 unexposed patients achieved covariate balance. At 7 days, exposed patients had higher risk of bleeding/hematoma (15.85% vs 14.35%; RR 1.1; p<0.05) There was also an increased risk of infection (10.67% vs 7.97%; RR 1.34; p<0.0001) and wound dehiscence (7.4% vs 5.45%; RR 1.36; p<0.0002), with no significant difference in flap complications. At 15 days, there was an increased risk of all postoperative complications: bleeding/hematoma (17.9% vs 15.79%; RR 1.13; p<0.006), infection (15.17% vs 13.2%; RR 1.15; p<0.006), wound dehiscence (10.31% vs 8.46%; RR 1.22; p<0.002), and flap complications (4.02% vs 3.24%; RR 1.24; p<0.04). Similarly, by 30 days, the risks were significantly higher for the exposed cohort: bleeding/hematoma (19.3% vs 17.14%; RR 1.12; p<0.008), infection (20.48% vs 18.18%; RR 1.13; p<0.005), wound dehiscence (13.58% vs 11.79%; RR 1.15; p<0.008), and flap complications (5.18% vs 4.3%; RR 1.21; p<0.04).",
        "Conclusions": "Across a multi-institutional cohort of head and neck free-flap reconstructions,?recent SSRI/SNRI exposure was associated with a higher early postoperative complication burden, driven primarily by bleeding-related and wound-healing events. Although absolute risks remained?modest, the relative increase has practical implications for preoperative counseling and postoperative monitoring in microsurgical head and neck reconstruction. Prospective studies are warranted to refine risk stratification and evaluate standardized perioperative protocols for patients on serotonergic antidepressants."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Antidepressants and Microsurgery: Associations Between SSRI/SNRI Use and Complications in Head & Neck Free-Flap Reconstruction</span>. <u>Sergio A Segrera, MS</u><sup>1</sup>; Anandhini Narayanan, MD<sup>1</sup>; Alexis Gursky, BS<sup>1</sup>; Hailey Wyatt, MD<sup>1</sup>; Adam Jacobson, MD<sup>2</sup>; Jamie P Levine, MD<sup>1</sup>. <sup>1</sup>NYU Langone Hansjörg Wyss Department of Plastic Surgery; <sup>2</sup>NYU Langone Department of Otolaryngology-Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>A significant number of head and neck cancer patients present for microvascular reconstruction while taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These have been shown to potentially increase platelet dysfunction, bleeding, and downstream wound complications, though evidence in plastic surgery is limited. Given the microvascular complexity of head and neck free-flap reconstruction, we used a large, multi-institutional electronic health record network to quantify the association between preoperative SSRI/SNRI exposure and early postoperative complications after head and neck reconstruction. </p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study using the TriNetX Research Network, including adults who underwent head and neck free-flap reconstruction. To ensure anatomic specificity, index cases were required to have same-day head/neck ablative codes and were additionally anchored with head/neck malignancy diagnoses. Preoperative SSRI/SNRI exposure was defined as a record within 90 days of the index procedure; comparators had no SSRI/SNRI record within 6 months. We used 1:1 nearest-neighbor propensity-score matching (logistic regression within TriNetX) with a prespecified balance threshold of standardized mean difference (SMD) <0.1 across covariates: age, race/ethnicity, procedure type, cancer site and treatment, obesity, diabetes, hypertension, tobacco and alcohol use, anemia, coagulopathy, obstructive sleep apnea, chronic kidney disease, and liver disease. Outcomes were analyzed on the TriNetX platform with risk ratios (RRs) and 95% confidence intervals; significance was set at p <0.05. The primary endpoint was a bleeding/hematoma composite (postprocedural hemorrhage/hematoma, hematoma evacuation, or transfusion) assessed at 7, 15, and 30 days. Secondary endpoints were flap complications, surgical-site infection, and wound dehiscence at the same time points. </p>\n\n<p><strong>Results: </strong>Across 58 health systems, 35,309 patients met inclusion criteria; 4,898 had preoperative SSRI/SNRI exposure and 30,411 served as comparators. After matching, 4,726 exposed and 4,726 unexposed patients achieved covariate balance. At 7 days, exposed patients had higher risk of bleeding/hematoma (15.85% vs 14.35%; RR 1.1; p<0.05) There was also an increased risk of infection (10.67% vs 7.97%; RR 1.34; p<0.0001) and wound dehiscence (7.4% vs 5.45%; RR 1.36; p<0.0002), with no significant difference in flap complications. At 15 days, there was an increased risk of all postoperative complications: bleeding/hematoma (17.9% vs 15.79%; RR 1.13; p<0.006), infection (15.17% vs 13.2%; RR 1.15; p<0.006), wound dehiscence (10.31% vs 8.46%; RR 1.22; p<0.002), and flap complications (4.02% vs 3.24%; RR 1.24; p<0.04). Similarly, by 30 days, the risks were significantly higher for the exposed cohort: bleeding/hematoma (19.3% vs 17.14%; RR 1.12; p<0.008), infection (20.48% vs 18.18%; RR 1.13; p<0.005), wound dehiscence (13.58% vs 11.79%; RR 1.15; p<0.008), and flap complications (5.18% vs 4.3%; RR 1.21; p<0.04). </p>\n\n<p><strong>Conclusions:</strong> Across a multi-institutional cohort of head and neck free-flap reconstructions,?recent SSRI/SNRI exposure was associated with a higher early postoperative complication burden, driven primarily by bleeding-related and wound-healing events. Although absolute risks remained?modest, the relative increase has practical implications for preoperative counseling and postoperative monitoring in microsurgical head and neck reconstruction. Prospective studies are warranted to refine risk stratification and evaluate standardized perioperative protocols for patients on serotonergic antidepressants. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155345--></body></html>"
    },
    {
      "uid": "P360",
      "content_id": "155347",
      "abstract_number": "P360",
      "poster_number": "P360",
      "title": "Modified Frailty Index-5 Predicts Complications After Fibula Free Flap Reconstruction for Head and Neck Cancer",
      "summary": "Complications occurred in nearly half of patients, highlighting the morbidity of fibula free flap maxillomandibular reconstruction. Higher mFI-5 scores independently predicted complications and reoperations, supporting its use for risk stratification, preoperative optimization, and shared decision-making.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155347",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sergio A Segrera, MS",
      "presenter": "Sergio A Segrera, MS",
      "authors": "Alexis K Gursky, BS; Hailey P Wyatt, MD; Sergio A Segrera, MS ; Anandhini D Narayanan, MD; Adam S Jacobson; Jamie P Levine, MD",
      "normalized_authors": [
        "Alexis K Gursky",
        "Hailey P Wyatt",
        "Sergio A Segrera",
        "Anandhini D Narayanan",
        "Adam S Jacobson",
        "Jamie P Levine"
      ],
      "affiliations": [
        "Hansjörg Wyss Department of Plastic Surgery, NYU Langone"
      ],
      "normalized_institutions": [
        "Hansjörg Wyss Department of Plastic Surgery, NYU Langone"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 265,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alexis K Gursky, BS; Hailey P Wyatt, MD; Sergio A Segrera, MS ; Anandhini D Narayanan, MD; Adam S Jacobson; Jamie P Levine, MD",
        "Affiliations": "Hansjörg Wyss Department of Plastic Surgery, NYU Langone",
        "Background": "Maxillomandibular reconstruction with fibula free flap carries significant morbidity. Accurate preoperative risk stratification is essential. This study assessed the predictive value of the 5-item modified frailty index (mFI-5) for postoperative complications in head and neck cancer reconstruction.",
        "Methods": "A retrospective NSQIP analysis (2013–2023) identified patients with head and neck malignancies undergoing fibula free flap maxillomandibular reconstruction. Demographics, comorbidities, and outcomes were collected. mFI-5 was calculated from diabetes, congestive heart failure, COPD, hypertension, and dependent functional status. Outcomes included overall complications, wound complications, and reoperation. Multivariate logistic regression evaluated the predictive value of mFI-5, adjusting for demographic and clinical covariates.",
        "Results": "Over 11 years, 1,139 patients underwent fibula free flap reconstruction. The mFI-5 score distribution was 0 (44.6%), 1 (44.6%), 2 (13.3%), and 3 (1.7%), with an overall complication rate of 49.4%. Multivariate regression demonstrated that higher mFI-5 scores were independently associated with overall complications (OR 1.31, 95% CI 1.07–1.61, p = 0.008). wound complications (OR 1.27, 95% CI 1.00–1.61, p = 0.050), and reoperations (OR 1.31, 95% CI 1.03–1.66, p = 0.027). Outcome-specific analysis revealed that higher mFI-5 scores were associated with increased risk of dehiscence (OR 1.43, 95% CI 1.00–2.03, p = 0.047) and postoperative transfusion (OR 1.56, 95% CI 1.01–2.41, p = 0.044).",
        "Conclusion": "Complications occurred in nearly half of patients, highlighting the morbidity of fibula free flap maxillomandibular reconstruction. Higher mFI-5 scores independently predicted complications and reoperations, supporting its use for risk stratification, preoperative optimization, and shared decision-making."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Modified Frailty Index-5 Predicts Complications After Fibula Free Flap Reconstruction for Head and Neck Cancer</span>. Alexis K Gursky, BS; Hailey P Wyatt, MD; <u>Sergio A Segrera, MS</u>; Anandhini D Narayanan, MD; Adam S Jacobson; Jamie P Levine, MD. Hansjörg Wyss Department of Plastic Surgery, NYU Langone<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Maxillomandibular reconstruction with fibula free flap carries significant morbidity. Accurate preoperative risk stratification is essential. This study assessed the predictive value of the 5-item modified frailty index (mFI-5) for postoperative complications in head and neck cancer reconstruction.</p>\n\n<p><strong>Methods</strong>: A retrospective NSQIP analysis (2013–2023) identified patients with head and neck malignancies undergoing fibula free flap maxillomandibular reconstruction. Demographics, comorbidities, and outcomes were collected. mFI-5 was calculated from diabetes, congestive heart failure, COPD, hypertension, and dependent functional status. Outcomes included overall complications, wound complications, and reoperation. Multivariate logistic regression evaluated the predictive value of mFI-5, adjusting for demographic and clinical covariates. </p>\n\n<p><strong>Results</strong>: Over 11 years, 1,139 patients underwent fibula free flap reconstruction. The mFI-5 score distribution was 0 (44.6%), 1 (44.6%), 2 (13.3%), and 3 (1.7%), with an overall complication rate of 49.4%. Multivariate regression demonstrated that higher mFI-5 scores were independently associated with overall complications (OR 1.31, 95% CI 1.07–1.61, p = 0.008). wound complications (OR 1.27, 95% CI 1.00–1.61, p = 0.050), and reoperations (OR 1.31, 95% CI 1.03–1.66, p = 0.027). Outcome-specific analysis revealed that higher mFI-5 scores were associated with increased risk of dehiscence (OR 1.43, 95% CI 1.00–2.03, p = 0.047) and postoperative transfusion (OR 1.56, 95% CI 1.01–2.41, p = 0.044).</p>\n\n<p><strong>Conclusion</strong>: Complications occurred in nearly half of patients, highlighting the morbidity of fibula free flap maxillomandibular reconstruction. Higher mFI-5 scores independently predicted complications and reoperations, supporting its use for risk stratification, preoperative optimization, and shared decision-making.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155347--></body></html>"
    },
    {
      "uid": "P361",
      "content_id": "154373",
      "abstract_number": "P361",
      "poster_number": "P361",
      "title": "Establishing a Head and Neck Free Flap Program in a Public Tertiary Hospital in Puerto Rico: Early Outcomes Within an ERAS-Guided Framework",
      "summary": "Establishing a free flap program within a resource-limited public tertiary hospital in Puerto Rico was feasible and safe, producing flap survival and perioperative outcomes comparable to those of high-volume centers. Integration of targeted ERAS principles likely contributed to efficient recovery metrics and low medical complication rates. This initiative expands equitable access to advanced reconstruction and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154373",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lawrence F Oppenheimer Vélez, MD",
      "presenter": "Lawrence F Oppenheimer Vélez, MD",
      "authors": "Alejandro Santiago Nazario, MD 1 ; Raul Ramos Sanchez, MD 1 ; Eric Perez Perez, BS 2 ; Pamella Abreu, BS 2 ; Carlos Crespo, BS 2 ; Javier Vila, BS 2 ; Lawrence F Oppenheimer Vélez, MD 1 ; Shayanne Lajud, MD 1",
      "normalized_authors": [
        "Alejandro Santiago Nazario",
        "Raul Ramos Sanchez",
        "Eric Perez Perez",
        "Pamella Abreu",
        "Carlos Crespo",
        "Javier Vila",
        "Lawrence F Oppenheimer Vélez",
        "Shayanne Lajud"
      ],
      "affiliations": [
        "University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery",
        "University of Puerto Rico School of Medicine"
      ],
      "normalized_institutions": [
        "University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery",
        "University of Puerto Rico School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alejandro Santiago Nazario, MD 1 ; Raul Ramos Sanchez, MD 1 ; Eric Perez Perez, BS 2 ; Pamella Abreu, BS 2 ; Carlos Crespo, BS 2 ; Javier Vila, BS 2 ; Lawrence F Oppenheimer Vélez, MD 1 ; Shayanne Lajud, MD 1",
        "Affiliations": "1 University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery; 2 University of Puerto Rico School of Medicine",
        "Background": "Microvascular free tissue transfer is essential for reconstruction in major head and neck surgery, yet access to this service in publicly funded hospitals serving U.S. territories is limited. Although isolated head and neck free flaps had been performed previously in Puerto Rico, a formal and structured microsurgical program had not been established. In 2024, an otolaryngology–head and neck surgery service established the first comprehensive free flap program at a public tertiary hospital in Puerto Rico. This study describes its early reconstructive and perioperative outcomes, developed within a care pathway that incorporates selected enhanced recovery after surgery (ERAS) principles.",
        "Methods": "A retrospective review was conducted of consecutive free flap reconstructions performed from February 2024 to September 2025. Demographics, comorbidities, tumor characteristics, flap type, perioperative course, and complications were recorded in a prospectively maintained database. All patients were managed under a standardized postoperative protocol emphasizing early mobilization and judicious antibiotic use. Except for one case, all reconstructions were performed by two head and neck surgeons working together. Primary outcomes were flap survival and need for re-exploration; secondary outcomes included length of stay (LOS), ICU stay, time to oral intake, and donor- and recipient-site complications.",
        "Results": "Sixteen patients (median age 63; 62.5% male) underwent reconstruction, most for malignant disease (81%). Flap types included fasciocutaneous flaps—radial forearm (37.5%), anterolateral thigh (18.8%), and medial sural artery perforator (6.3%), subscapular system flaps (25%), and osteocutaneous fibula flaps (12.5%). Flap survival was 100%. Two patients (12.5%) required neck re-exploration, both successfully salvaged. Median hospital LOS was 11 days, and median ICU stay was 5 days, consistent with reported ERAS-associated efficiencies. Median time to oral intake was 7 days, except in two complex hypopharyngeal or pharyngolaryngeal cases with fistula development. Thirty-day complications consisted primarily of donor-site issues, wound dehiscence, or minor recipient-site breakdowns; one pharyngocutaneous fistula occurred. Additional free flap cases have been performed successfully within the program; however, they were not included in this analysis because they have not yet completed the minimum postoperative follow-up required for study inclusion.",
        "Conclusions": "Establishing a free flap program within a resource-limited public tertiary hospital in Puerto Rico was feasible and safe, producing flap survival and perioperative outcomes comparable to those of high-volume centers. Integration of targeted ERAS principles likely contributed to efficient recovery metrics and low medical complication rates. This initiative expands equitable access to advanced reconstruction and demonstrates a sustainable, residency-integrated microsurgical model for an underserved population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Establishing a Head and Neck Free Flap Program in a Public Tertiary Hospital in Puerto Rico: Early Outcomes Within an ERAS-Guided Framework</span>. Alejandro Santiago Nazario, MD<sup>1</sup>; Raul Ramos Sanchez, MD<sup>1</sup>; Eric Perez Perez, BS<sup>2</sup>; Pamella Abreu, BS<sup>2</sup>; Carlos Crespo, BS<sup>2</sup>; Javier Vila, BS<sup>2</sup>; <u>Lawrence F Oppenheimer Vélez, MD</u><sup>1</sup>; Shayanne Lajud, MD<sup>1</sup>. <sup>1</sup>University of Puerto Rico School of Medicine, Department of Otolaryngology - Head & Neck Surgery; <sup>2</sup>University of Puerto Rico School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Microvascular free tissue transfer is essential for reconstruction in major head and neck surgery, yet access to this service in publicly funded hospitals serving U.S. territories is limited. Although isolated head and neck free flaps had been performed previously in Puerto Rico, a formal and structured microsurgical program had not been established. In 2024, an otolaryngology–head and neck surgery service established the first comprehensive free flap program at a public tertiary hospital in Puerto Rico. This study describes its early reconstructive and perioperative outcomes, developed within a care pathway that incorporates selected enhanced recovery after surgery (ERAS) principles.</p>\n\n<p><strong>Methods:</strong> A retrospective review was conducted of consecutive free flap reconstructions performed from February 2024 to September 2025. Demographics, comorbidities, tumor characteristics, flap type, perioperative course, and complications were recorded in a prospectively maintained database. All patients were managed under a standardized postoperative protocol emphasizing early mobilization and judicious antibiotic use. Except for one case, all reconstructions were performed by two head and neck surgeons working together. Primary outcomes were flap survival and need for re-exploration; secondary outcomes included length of stay (LOS), ICU stay, time to oral intake, and donor- and recipient-site complications.</p>\n\n<p><strong>Results: </strong>Sixteen patients (median age 63; 62.5% male) underwent reconstruction, most for malignant disease (81%). Flap types included fasciocutaneous flaps—radial forearm (37.5%), anterolateral thigh (18.8%), and medial sural artery perforator (6.3%), subscapular system flaps (25%), and osteocutaneous fibula flaps (12.5%). Flap survival was 100%. Two patients (12.5%) required neck re-exploration, both successfully salvaged. Median hospital LOS was 11 days, and median ICU stay was 5 days, consistent with reported ERAS-associated efficiencies. Median time to oral intake was 7 days, except in two complex hypopharyngeal or pharyngolaryngeal cases with fistula development. Thirty-day complications consisted primarily of donor-site issues, wound dehiscence, or minor recipient-site breakdowns; one pharyngocutaneous fistula occurred. Additional free flap cases have been performed successfully within the program; however, they were not included in this analysis because they have not yet completed the minimum postoperative follow-up required for study inclusion.</p>\n\n<p><strong>Conclusions:</strong> Establishing a free flap program within a resource-limited public tertiary hospital in Puerto Rico was feasible and safe, producing flap survival and perioperative outcomes comparable to those of high-volume centers. Integration of targeted ERAS principles likely contributed to efficient recovery metrics and low medical complication rates. This initiative expands equitable access to advanced reconstruction and demonstrates a sustainable, residency-integrated microsurgical model for an underserved population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154373--></body></html>"
    },
    {
      "uid": "P362",
      "content_id": "154650",
      "abstract_number": "P362",
      "poster_number": "P362",
      "title": "Postoperative Thiamine Supplementation and Electrolyte Stability in Patients at Risk for Refeeding Syndrome Following Composite Resection and Reconstruction for Head and Neck Cancer",
      "summary": "Postoperative thiamine supplementation is safe, well tolerated, and associated with favorable biochemical trends. Although underpowered, this pilot cohort suggests a potential metabolic benefit that warrants evaluation in larger studies designed to assess clinically meaningful reductions in RFS-related morbidity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154650",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tommy Jacob, MD, MPH",
      "presenter": "Tommy Jacob, MD, MPH",
      "authors": "Tommy Jacob, MD, MPH 1 ; Orr Raved 1 ; Anton Warshavsky, MD 1 ; Gilad Horowitz, MD, MPH 1 ; Nidal Muhanna, MD, PhD 1 ; Jobran Mansour, MD 2",
      "normalized_authors": [
        "Tommy Jacob",
        "Orr Raved",
        "Anton Warshavsky",
        "Gilad Horowitz",
        "Nidal Muhanna",
        "Jobran Mansour"
      ],
      "affiliations": [
        "Tel Aviv Sourasky Medical Center",
        "Lewis Katz School of Medicine at Temple University"
      ],
      "normalized_institutions": [
        "Tel Aviv Sourasky Medical Center",
        "Lewis Katz School of Medicine at Temple University"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 340,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Tommy Jacob, MD, MPH 1 ; Orr Raved 1 ; Anton Warshavsky, MD 1 ; Gilad Horowitz, MD, MPH 1 ; Nidal Muhanna, MD, PhD 1 ; Jobran Mansour, MD 2",
        "Affiliations": "1 Tel Aviv Sourasky Medical Center; 2 Lewis Katz School of Medicine at Temple University",
        "Background": "Patients undergoing composite resection and reconstruction for head and neck cancer, commonly present with malnutrition and require early postoperative enteral feeding, placing them at risk for electrolyte shifts consistent with Refeeding Syndrome (RFS). Thiamine is essential for oxidative metabolism, and insufficient availability during refeeding may contribute to postoperative electrolyte instability. Evidence regarding its role in surgical oncology is limited. This study aimed to evaluate whether perioperative thiamine supplementation is associated with improved electrolyte trends and fewer RFS-related clinical manifestations in nutritionally vulnerable patients.",
        "Methods": "A prospective cohort of 34 patients undergoing composite resection (2023–2024) was analyzed; 15 received a standardized postoperative thiamine regimen (100 mg IV daily for 3 days), and 19 did not. Serum phosphate, magnesium, potassium, calcium, and albumin levels were assessed from baseline to postoperative nadirs. Electrolyte supplementation requirements and complications potentially related to RFS were recorded. Given the modest sample size, emphasis was placed on effect direction rather than statistical significance.",
        "Results": "Thiamine-treated patients demonstrated more favorable biochemical trajectories, particularly for phosphate. From baseline to postoperative nadir, the median percentage decline in phosphate was smaller with thiamine (−42.8% [IQR −60.7 to −34.2]) than without thiamine (−56.7% [IQR −64.0 to −36.4]; p = 0.326), with a slightly higher phosphate nadir (1.88 vs 1.77 mmol/L; p = 0.756). Potassium and calcium showed similar modest trends (ΔK −18.7% vs −21.6%, p = 0.709; ΔCa −12.5% vs −11.4%, p = 0.616), while magnesium changes were somewhat less favorable in the thiamine group (ΔMg −9.9% vs −3.3%, p = 0.110; nadir 1.64 vs 1.72 mmol/L, p = 0.254). Rates of electrolyte repletion and postoperative complications potentially related to RFS were similar, with numerically fewer events in the thiamine cohort, and no thiamine-related adverse effects were observed.",
        "Conclusion": "Postoperative thiamine supplementation is safe, well tolerated, and associated with favorable biochemical trends. Although underpowered, this pilot cohort suggests a potential metabolic benefit that warrants evaluation in larger studies designed to assess clinically meaningful reductions in RFS-related morbidity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Postoperative Thiamine Supplementation and Electrolyte Stability in Patients at Risk for Refeeding Syndrome Following Composite Resection and Reconstruction for Head and Neck Cancer</span>. <u>Tommy Jacob, MD, MPH</u><sup>1</sup>; Orr Raved<sup>1</sup>; Anton Warshavsky, MD<sup>1</sup>; Gilad Horowitz, MD, MPH<sup>1</sup>; Nidal Muhanna, MD, PhD<sup>1</sup>; Jobran Mansour, MD<sup>2</sup>. <sup>1</sup>Tel Aviv Sourasky Medical Center; <sup>2</sup>Lewis Katz School of Medicine at Temple University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patients undergoing composite resection and reconstruction for head and neck cancer, commonly present with malnutrition and require early postoperative enteral feeding, placing them at risk for electrolyte shifts consistent with Refeeding Syndrome (RFS). Thiamine is essential for oxidative metabolism, and insufficient availability during refeeding may contribute to postoperative electrolyte instability. Evidence regarding its role in surgical oncology is limited. This study aimed to evaluate whether perioperative thiamine supplementation is associated with improved electrolyte trends and fewer RFS-related clinical manifestations in nutritionally vulnerable patients.</p>\n\n<p><strong>Methods: </strong>A prospective cohort of 34 patients undergoing composite resection (2023–2024) was analyzed; 15 received a standardized postoperative thiamine regimen (100 mg IV daily for 3 days), and 19 did not. Serum phosphate, magnesium, potassium, calcium, and albumin levels were assessed from baseline to postoperative nadirs. Electrolyte supplementation requirements and complications potentially related to RFS were recorded. Given the modest sample size, emphasis was placed on effect direction rather than statistical significance.</p>\n\n<p><strong>Results: </strong>Thiamine-treated patients demonstrated more favorable biochemical trajectories, particularly for phosphate. From baseline to postoperative nadir, the median percentage decline in phosphate was smaller with thiamine (−42.8% [IQR −60.7 to −34.2]) than without thiamine (−56.7% [IQR −64.0 to −36.4]; p = 0.326), with a slightly higher phosphate nadir (1.88 vs 1.77 mmol/L; p = 0.756). Potassium and calcium showed similar modest trends (ΔK −18.7% vs −21.6%, p = 0.709; ΔCa −12.5% vs −11.4%, p = 0.616), while magnesium changes were somewhat less favorable in the thiamine group (ΔMg −9.9% vs −3.3%, p = 0.110; nadir 1.64 vs 1.72 mmol/L, p = 0.254). Rates of electrolyte repletion and postoperative complications potentially related to RFS were similar, with numerically fewer events in the thiamine cohort, and no thiamine-related adverse effects were observed.</p>\n\n<p><strong>Conclusion: </strong>Postoperative thiamine supplementation is safe, well tolerated, and associated with favorable biochemical trends. Although underpowered, this pilot cohort suggests a potential metabolic benefit that warrants evaluation in larger studies designed to assess clinically meaningful reductions in RFS-related morbidity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154650--></body></html>"
    },
    {
      "uid": "P363",
      "content_id": "154576",
      "abstract_number": "P363",
      "poster_number": "P363",
      "title": "Predictors of free flap complications in patients with osteoradionecrosis",
      "summary": "In this study, we demonstrate that a non-VSP approach, greater number of bony segments, and smoking status trended towards higher complication rates in patients undergoing free tissue reconstruction for MORN. Prospective work correlating the benefits of VSP based on the preoperative mandibular isodose for treatment of MORN is required to validate VSP-guided reconstruction for MORN, and is currently being undertaken.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154576",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nadia Hua, MD",
      "presenter": "Nadia Hua, MD",
      "authors": "Nadia Hua, MD ; Jamie JY Kwon, MS; Eitan Prisman, MD, MA, FRCSC",
      "normalized_authors": [
        "Nadia Hua",
        "Jamie JY Kwon",
        "Eitan Prisman, MA, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nadia Hua, MD ; Jamie JY Kwon, MS; Eitan Prisman, MD, MA, FRCSC",
        "Affiliations": "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Background": "Mandibular osteoradionecrosis (MORN) is a devastating late complication of radiation therapy (RT) for head and neck cancer. For advanced MORN, surgical resection with microvascular osseous free tissue reconstruction may be required. However, in the setting of irradiated tissue, patients with MORN have a higher rate of flap failure, fistula, and nonunion. With the recent emergence of virtual surgical planning (VSP), a few studies have reported the benefits of VSP for MORN, including planning mandibular resection beyond the preoperative 50G isodose margin to the mandible; however, these studies remain small and have fewer than 5 patients. As such, this study aims to identify preoperative risk factors, including utilization of VSP and radiation dosimetrics, that may contribute to postoperative complications for patients undergoing surgical reconstruction for MORN.",
        "Objective": "To identify patient characteristics and preoperative risk factors that may contribute to postoperative complications for patients undergoing surgical reconstruction for MORN.",
        "Methods": "This is a combined retrospective and prospective cohort study of adult patients over 18 years old who were treated with surgical resection and free tissue reconstruction for MORN between 2015 and 2021 at a tertiary care center. Patients who had routine postoperative CT scans taken at least 6 months after reconstruction were included. Preoperative clinical and radiotherapeutic variables were collected, in addition to operative and follow-up data. Preoperative parameters were analyzed in univariate and multivariable Cox proportional hazards regression models to identify risk factors of postoperative complications.",
        "Results": "A total of 32 patients treated for MORN with available dosimetry data and at least one 6-month postoperative CT scan were included. The mean age at presentation was 64 (range 45-78), and the mean time to development of MORN was 8.8 years (range 0-28). Of 32 patients, 20 (63%) underwent VSP reconstruction, where surgical resection considered the preoperative radiation dose. 15% of patients received ≥70 Gy of radiation to the mandible preoperatively. Post-operatively, four flap failures occurred, requiring salvage reconstruction, and two patients developed plate exposure. On univariate analysis, higher complication rates were associated with non-VSP surgeries (P = 0.047) and smoking history (P = 0.032). There was a trend towards significance for the number of free flap segments used for reconstruction with VSP (P = 0.10). On multivariate analysis, non-VSP approach (HR 0.64, 95%CI 0.25-1.60), higher pack-years (HR 1.11, 95%CI 0.98-1.03), and a greater number of bony segments used for reconstruction of the defect (HR 1.73, 95%CI 0.93-3.23) remained as predictive factors for postoperative complications following surgery for MORN. Notably, resecting beyond the 50Gy isodose margin did not play a role in predicting post-operative complications.",
        "Conclusion": "In this study, we demonstrate that a non-VSP approach, greater number of bony segments, and smoking status trended towards higher complication rates in patients undergoing free tissue reconstruction for MORN. Prospective work correlating the benefits of VSP based on the preoperative mandibular isodose for treatment of MORN is required to validate VSP-guided reconstruction for MORN, and is currently being undertaken."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors of free flap complications in patients with osteoradionecrosis</span>. <u>Nadia Hua, MD</u>; Jamie JY Kwon, MS; Eitan Prisman, MD, MA, FRCSC. Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Mandibular osteoradionecrosis (MORN) is a devastating late complication of radiation therapy (RT) for head and neck cancer. For advanced MORN, surgical resection with microvascular osseous free tissue reconstruction may be required. However, in the setting of irradiated tissue, patients with MORN have a higher rate of flap failure, fistula, and nonunion. With the recent emergence of virtual surgical planning (VSP), a few studies have reported the benefits of VSP for MORN, including planning mandibular resection beyond the preoperative 50G isodose margin to the mandible; however, these studies remain small and have fewer than 5 patients. As such, this study aims to identify preoperative risk factors, including utilization of VSP and radiation dosimetrics, that may contribute to postoperative complications for patients undergoing surgical reconstruction for MORN.</p>\n\n<p><strong>Objective: </strong>To identify patient characteristics and preoperative risk factors that may contribute to postoperative complications for patients undergoing surgical reconstruction for MORN.</p>\n\n<p><strong>Methods: </strong>This is a combined retrospective and prospective cohort study of adult patients over 18 years old who were treated with surgical resection and free tissue reconstruction for MORN between 2015 and 2021 at a tertiary care center. Patients who had routine postoperative CT scans taken at least 6 months after reconstruction were included. Preoperative clinical and radiotherapeutic variables were collected, in addition to operative and follow-up data. Preoperative parameters were analyzed in univariate and multivariable Cox proportional hazards regression models to identify risk factors of postoperative complications.</p>\n\n<p><strong>Results:</strong> A total of 32 patients treated for MORN with available dosimetry data and at least one 6-month postoperative CT scan were included. The mean age at presentation was 64 (range 45-78), and the mean time to development of MORN was 8.8 years (range 0-28). Of 32 patients, 20 (63%) underwent VSP reconstruction, where surgical resection considered the preoperative radiation dose. 15% of patients received ≥70 Gy of radiation to the mandible preoperatively. Post-operatively, four flap failures occurred, requiring salvage reconstruction, and two patients developed plate exposure. On univariate analysis, higher complication rates were associated with non-VSP surgeries (P = 0.047) and smoking history (P = 0.032). There was a trend towards significance for the number of free flap segments used for reconstruction with VSP (P = 0.10). On multivariate analysis, non-VSP approach (HR 0.64, 95%CI 0.25-1.60), higher pack-years (HR 1.11, 95%CI 0.98-1.03), and a greater number of bony segments used for reconstruction of the defect (HR 1.73, 95%CI 0.93-3.23) remained as predictive factors for postoperative complications following surgery for MORN. Notably, resecting beyond the 50Gy isodose margin did not play a role in predicting post-operative complications.</p>\n\n<p><strong>Conclusion: </strong>In this study, we demonstrate that a non-VSP approach, greater number of bony segments, and smoking status trended towards higher complication rates in patients undergoing free tissue reconstruction for MORN. Prospective work correlating the benefits of VSP based on the preoperative mandibular isodose for treatment of MORN is required to validate VSP-guided reconstruction for MORN, and is currently being undertaken.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154576--></body></html>"
    },
    {
      "uid": "P364",
      "content_id": "153799",
      "abstract_number": "P364",
      "poster_number": "P364",
      "title": "Comparative Analysis of Two-Stage Versus Three-Stage Paramedian Forehead Flap for Nasal Reconstruction: A Systematic Review and Meta-Analysis",
      "summary": "The choice between a two-stage and three-stage paramedian forehead flap should be tailored to the individual patient rather than standardized. For less complex nasal defects, the two-stage technique remains a reliable and efficient option. Although our pooled analysis showed no significant statistical advantage for the three-stage method, the intermediate stage may still offer safety and aesthetic benefits in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153799",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emilio Arteaga, MD",
      "presenter": "Emilio Arteaga, MD",
      "authors": "Sailesh S Kumar, MD 1 ; Bruno Albuquerque Sousa, MD, MSC, FACS 2 ; Matheus M Luna Barros, MD 3 ; Lorenzo Di Martino, MD 4 ; Bertrand Cailliau, MBBS 5 ; Emilio Arteaga, MD 6 ; Fernando L Dias, MD, PHD, FACS 2 ; Paula Moretzsohn, MD 2",
      "normalized_authors": [
        "Sailesh S Kumar",
        "Bruno Albuquerque Sousa",
        "Matheus M Luna Barros",
        "Lorenzo Di Martino",
        "Bertrand Cailliau, MBBS",
        "Emilio Arteaga",
        "Fernando L Dias",
        "Paula Moretzsohn"
      ],
      "affiliations": [
        "Division of Plastic Surgery, Department of Surgery, University of Alabama at Birmingham, USA",
        "Department of Head and Neck Surgery, National Cancer Institute, RJ - Brazil",
        "Federal University of Alagoas, Brazil",
        "Division of Medicine, Centro de Referência para Imunobiológicos Especiais, MG - Brazil",
        "Faculty of Medicine, KU Leuven, Belgium",
        "INCA"
      ],
      "normalized_institutions": [
        "Division of Plastic Surgery, Department of Surgery, University of Alabama at Birmingham, USA",
        "Department of Head and Neck Surgery, National Cancer Institute, RJ - Brazil",
        "Federal University of Alagoas, Brazil",
        "Division of Medicine, Centro de Referência para Imunobiológicos Especiais, MG - Brazil",
        "Faculty of Medicine, KU Leuven, Belgium",
        "INCA"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 349,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sailesh S Kumar, MD 1 ; Bruno Albuquerque Sousa, MD, MSC, FACS 2 ; Matheus M Luna Barros, MD 3 ; Lorenzo Di Martino, MD 4 ; Bertrand Cailliau, MBBS 5 ; Emilio Arteaga, MD 6 ; Fernando L Dias, MD, PHD, FACS 2 ; Paula Moretzsohn, MD 2",
        "Affiliations": "1 Division of Plastic Surgery, Department of Surgery, University of Alabama at Birmingham, USA; 2 Department of Head and Neck Surgery, National Cancer Institute, RJ - Brazil; 3 Federal University of Alagoas, Brazil; 4 Division of Medicine, Centro de Referência para Imunobiológicos Especiais, MG - Brazil; 5 Faculty of Medicine, KU Leuven, Belgium; 6 INCA",
        "Background": "The paramedian forehead flap remains the gold standard for complex nasal reconstruction. Traditionally performed in two stages, a three-stage modification has been proposed to improve vascular reliability and contouring. However, its relative benefit compared with the standard two-stage approach remains unclear. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of two-stage versus three-stage paramedian forehead flaps in nasal reconstruction.",
        "Methods": "Following PRISMA 2020 and Cochrane guidance, we systematically searched PubMed, Embase, Scopus, and Google Scholar through August 2025. Eligible studies compared two-stage (2S) and three-stage (3S) forehead flaps. Primary outcomes were infection, wound breakdown, and flap necrosis; secondary outcomes included revision surgery and patient satisfaction. Risk of bias was assessed with ROBINS-I and certainty of evidence with GRADE. Pooled risk ratios (RR) or standardized mean differences (SMD) were estimated using random-effects models. The protocol was registered in PROSPERO.",
        "Results": "Seven retrospective cohort studies including 428 patients (207 3S, 221 2S) met inclusion criteria. Meta-analysis demonstrated no significant differences between 3S and 2S techniques for infection (RR 1.55, 95% CI 0.50–4.83), wound breakdown (RR 1.20, 95% CI 0.41–3.52), flap necrosis (RR 1.25, 95% CI 0.52–3.02), or revision surgery (RR 1.28, 95% CI 0.67–2.43). Patient satisfaction did not differ significantly (SMD 0.38, 95% CI –0.78 to 1.53), though heterogeneity was high (I² = 81%). Egger’s test showed no publication bias for necrosis (p = 0.823). GRADE certainty was low for all outcomes and very low for satisfaction.",
        "Conclusions": "The choice between a two-stage and three-stage paramedian forehead flap should be tailored to the individual patient rather than standardized. For less complex nasal defects, the two-stage technique remains a reliable and efficient option. Although our pooled analysis showed no significant statistical advantage for the three-stage method, the intermediate stage may still offer safety and aesthetic benefits in selected case, particularly, in patients with notable comorbidities or in reconstructions of large or multi-subunit defects. Both approaches are effective, and future prospective studies are needed to identify which patients benefit most from each technique."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Analysis of Two-Stage Versus Three-Stage Paramedian Forehead Flap for Nasal Reconstruction: A Systematic Review and Meta-Analysis</span>. Sailesh S Kumar, MD<sup>1</sup>; Bruno Albuquerque Sousa, MD, MSC, FACS<sup>2</sup>; Matheus M Luna Barros, MD<sup>3</sup>; Lorenzo Di Martino, MD<sup>4</sup>; Bertrand Cailliau, MBBS<sup>5</sup>; <u>Emilio  Arteaga, MD</u><sup>6</sup>; Fernando L Dias, MD, PHD, FACS<sup>2</sup>; Paula Moretzsohn, MD<sup>2</sup>. <sup>1</sup>Division of Plastic Surgery, Department of Surgery, University of Alabama at Birmingham, USA; <sup>2</sup>Department of Head and Neck Surgery, National Cancer Institute, RJ - Brazil; <sup>3</sup>Federal University of Alagoas, Brazil; <sup>4</sup>Division of Medicine, Centro de Referência para Imunobiológicos Especiais, MG - Brazil; <sup>5</sup>Faculty of Medicine, KU Leuven, Belgium; <sup>6</sup>INCA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The paramedian forehead flap remains the gold standard for complex nasal reconstruction. Traditionally performed in two stages, a three-stage modification has been proposed to improve vascular reliability and contouring. However, its relative benefit compared with the standard two-stage approach remains unclear. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of two-stage versus three-stage paramedian forehead flaps in nasal reconstruction.</p>\n\n<p><strong>Methods: </strong>Following PRISMA 2020 and Cochrane guidance, we systematically searched PubMed, Embase, Scopus, and Google Scholar through August 2025. Eligible studies compared two-stage (2S) and three-stage (3S) forehead flaps. Primary outcomes were infection, wound breakdown, and flap necrosis; secondary outcomes included revision surgery and patient satisfaction. Risk of bias was assessed with ROBINS-I and certainty of evidence with GRADE. Pooled risk ratios (RR) or standardized mean differences (SMD) were estimated using random-effects models. The protocol was registered in PROSPERO.</p>\n\n<p><strong>Results:</strong> Seven retrospective cohort studies including 428 patients (207 3S, 221 2S) met inclusion criteria. Meta-analysis demonstrated no significant differences between 3S and 2S techniques for infection (RR 1.55, 95% CI 0.50–4.83), wound breakdown (RR 1.20, 95% CI 0.41–3.52), flap necrosis (RR 1.25, 95% CI 0.52–3.02), or revision surgery (RR 1.28, 95% CI 0.67–2.43). Patient satisfaction did not differ significantly (SMD 0.38, 95% CI –0.78 to 1.53), though heterogeneity was high (I² = 81%). Egger’s test showed no publication bias for necrosis (p = 0.823). GRADE certainty was low for all outcomes and very low for satisfaction.</p>\n\n<p><strong>Conclusions:</strong> The choice between a two-stage and three-stage paramedian forehead flap should be tailored to the individual patient rather than standardized. For less complex nasal defects, the two-stage technique remains a reliable and efficient option. Although our pooled analysis showed no significant statistical advantage for the three-stage method, the intermediate stage may still offer safety and aesthetic benefits in selected case, particularly, in patients with notable comorbidities or in reconstructions of large or multi-subunit defects. Both approaches are effective, and future prospective studies are needed to identify which patients benefit most from each technique.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153799--></body></html>"
    },
    {
      "uid": "P365",
      "content_id": "146717",
      "abstract_number": "P365",
      "poster_number": "P365",
      "title": "Versatility of Superficial Temporal Artery–Based Flaps for Head And Neck Reconstruction: Case Series and Literature Review",
      "summary": "STA-based flaps are reliable and effective reconstructive tools for various head and neck defects. In comparison to the current literature, our results demonstrate consistent outcomes, high success rates, and low morbidity. The functional and aesthetic outcomes in our case series are promising, In conclusion, the use of STA based flaps represent versatile, effective, and cosmetically favorable options in head and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146717",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Melissa Bouhraoua",
      "presenter": "Melissa Bouhraoua",
      "authors": "Melissa Bouhraoua 1 ; Badr Ibrahim, MD 2 ; Olivier Abboud, MD 2 ; Yalon Dolev, MD 2 ; Béatrice Voizard, MD 2 ; Ilyes Berania, MD 2",
      "normalized_authors": [
        "Melissa Bouhraoua",
        "Badr Ibrahim",
        "Olivier Abboud",
        "Yalon Dolev",
        "Béatrice Voizard",
        "Ilyes Berania"
      ],
      "affiliations": [
        "University of Montreal",
        "Hôpital du Sacré-Cœur de Montréal"
      ],
      "normalized_institutions": [
        "University of Montreal",
        "Hôpital du Sacré-Cœur de Montréal"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 376,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Melissa Bouhraoua 1 ; Badr Ibrahim, MD 2 ; Olivier Abboud, MD 2 ; Yalon Dolev, MD 2 ; Béatrice Voizard, MD 2 ; Ilyes Berania, MD 2",
        "Affiliations": "1 University of Montreal; 2 Hôpital du Sacré-Cœur de Montréal",
        "Introduction": "Oncological surgical defect reconstruction following head neck cancer resection requires the use of versatile and reliable flaps. Flaps based on the superficial temporal artery (STA) have emerged as valuable options for the reconstruction of specific defects in the head and neck region.",
        "Objectives": "The main goal of this study is to describe the functional and aesthetic outcomes of patients who underwent cervicofacial reconstruction using superficial temporal artery (STA) based flaps, such as the temporoparietal fascial flap (TPF), the temporal artery posterior auricular skin free flap (TAPAS), or the helix flap. By reporting our institutional experience, we aimed to highlight the indications, technical considerations, and postoperative evolution associated with these flaps. A secondary objective to perform a comprehensive literature review on the current use of STA-based flaps in head and neck reconstruction.",
        "Methods": "We performed a retrospective review of patients who underwent head and neck reconstruction using STA-based flaps between February 8, 2022, and February 3, 2025. All procedures were performed by a single surgeon. Demographic data, type of defect, flap selection, operative time, need for adjuvant therapy, complications, and functional and aesthetic outcomes were also assessed. A comprehensive literature review was conducted using specific key words to include all relevant articles describing the TPF, TAPAS, and helix flaps.",
        "Results": "Eleven patients were included in our study, with a mean age of 61.7 years (range: 34–97 years old). The majority (n=8) presented with parotid defects requiring TPF flap reconstruction. Two patients were managed using a pedicled TAPAS flap, for auricular reconstruction and for a temporal defect closure. One patient underwent a helix free flap for nasal reconstruction. The mean operative time was 3,8 hours, and the mean postoperative follow-up period was 4,8 months. One patient required adjuvant radiotherapy. Postoperative functional and aesthetic outcomes were satisfactory for all patients. No major complications were observed in the described cohort, and donor site morbidity was minimal.",
        "Conclusion": "STA-based flaps are reliable and effective reconstructive tools for various head and neck defects. In comparison to the current literature, our results demonstrate consistent outcomes, high success rates, and low morbidity. The functional and aesthetic outcomes in our case series are promising, In conclusion, the use of STA based flaps represent versatile, effective, and cosmetically favorable options in head and neck reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Versatility of Superficial Temporal Artery–Based Flaps for Head And Neck Reconstruction: Case Series and Literature Review</span>. <u>Melissa Bouhraoua</u><sup>1</sup>; Badr Ibrahim, MD<sup>2</sup>; Olivier Abboud, MD<sup>2</sup>; Yalon Dolev, MD<sup>2</sup>; Béatrice Voizard, MD<sup>2</sup>; Ilyes Berania, MD<sup>2</sup>. <sup>1</sup>University of Montreal; <sup>2</sup>Hôpital du Sacré-Cœur de Montréal<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oncological surgical defect reconstruction following head neck cancer resection requires the use of versatile and reliable flaps. Flaps based on the superficial temporal artery (STA) have emerged as valuable options for the reconstruction of specific defects in the head and neck region.</p>\n\n<p><strong>Objectives: </strong>The main goal of this study is to describe the functional and aesthetic outcomes of patients who underwent cervicofacial reconstruction using superficial temporal artery (STA) based flaps, such as the temporoparietal fascial flap (TPF), the temporal artery posterior auricular skin free flap (TAPAS), or the helix flap. By reporting our institutional experience, we aimed to highlight the indications, technical considerations, and postoperative evolution associated with these flaps. A secondary objective to perform a comprehensive literature review on the current use of STA-based flaps in head and neck reconstruction.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective review of patients who underwent head and neck reconstruction using STA-based flaps between February 8, 2022, and February 3, 2025. All procedures were performed by a single surgeon. Demographic data, type of defect, flap selection, operative time, need for adjuvant therapy, complications, and functional and aesthetic outcomes were also assessed. A comprehensive literature review was conducted using specific key words to include all relevant articles describing the TPF, TAPAS, and helix flaps.</p>\n\n<p><strong>Results: </strong>Eleven patients were included in our study, with a mean age of 61.7 years (range: 34–97 years old). The majority (n=8) presented with parotid defects requiring TPF flap reconstruction. Two patients were managed using a pedicled TAPAS flap, for auricular reconstruction and for a temporal defect closure. One patient underwent a helix free flap for nasal reconstruction. The mean operative time was 3,8 hours, and the mean postoperative follow-up period was 4,8 months. One patient required adjuvant radiotherapy. Postoperative functional and aesthetic outcomes were satisfactory for all patients. No major complications were observed in the described cohort, and donor site morbidity was minimal.</p>\n\n<p><strong>Conclusion: </strong>STA-based flaps are reliable and effective reconstructive tools for various head and neck defects. In comparison to the current literature, our results demonstrate consistent outcomes, high success rates, and low morbidity. The functional and aesthetic outcomes in our case series are promising, In conclusion, the use of STA based flaps represent versatile, effective, and cosmetically favorable options in head and neck reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146717--></body></html>"
    },
    {
      "uid": "P366",
      "content_id": "154030",
      "abstract_number": "P366",
      "poster_number": "P366",
      "title": "Association of Charlson Comorbidity Index with Outcomes After Head and Neck Free Flap Reconstruction",
      "summary": "In this large single-institution experience, increasing age-adjusted CCI was associated with higher-risk perioperative profiles, including greater odds of 30-day readmission and reduced 2-year survival after head and neck free flap reconstruction. Among individual CCI components, COPD was the strongest predictor of postoperative pneumonia, while CAD showed an association with late flap failure in univariate...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154030",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madison McElliot",
      "presenter": "Madison McElliot",
      "authors": "David Gorelov, MD 1 ; Siddhant H Tripathi, MD 2 ; Imani Agard 1 ; Josiah Brandt, MD 2 ; Alexander Karabachev, MD 2 ; Adam Beucler 1 ; Christine Lee 1 ; Emma Nienaber 1 ; Madison McElliot 1 ; Priscilla Pichardo, DO 2 ; Dustin Silverman, MD 2 ; Alice Tang, MD 2 ; Yash Patil, MD 3 ; Chad Zender, MD 2",
      "normalized_authors": [
        "David Gorelov",
        "Siddhant H Tripathi",
        "Imani Agard",
        "Josiah Brandt",
        "Alexander Karabachev",
        "Adam Beucler",
        "Christine Lee",
        "Emma Nienaber",
        "Madison McElliot",
        "Priscilla Pichardo",
        "Dustin Silverman",
        "Alice Tang",
        "Yash Patil",
        "Chad Zender"
      ],
      "affiliations": [
        "University of Cincinnati College of Medicine",
        "University of Cincinnati Department of Otolaryngology",
        "Northwestern Medicine Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "University of Cincinnati College of Medicine",
        "University of Cincinnati Department of Otolaryngology",
        "Northwestern Medicine Department of Otolaryngology"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 424,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "David Gorelov, MD 1 ; Siddhant H Tripathi, MD 2 ; Imani Agard 1 ; Josiah Brandt, MD 2 ; Alexander Karabachev, MD 2 ; Adam Beucler 1 ; Christine Lee 1 ; Emma Nienaber 1 ; Madison McElliot 1 ; Priscilla Pichardo, DO 2 ; Dustin Silverman, MD 2 ; Alice Tang, MD 2 ; Yash Patil, MD 3 ; Chad Zender, MD 2",
        "Affiliations": "1 University of Cincinnati College of Medicine; 2 University of Cincinnati Department of Otolaryngology; 3 Northwestern Medicine Department of Otolaryngology",
        "Objective": "The age-adjusted Charlson Comorbidity Index (CCI) quantifies overall comorbidity burden and predicts mortality, but its ability to risk stratify patients undergoing head and neck free flap reconstruction remains poorly defined. This study evaluated whether age-adjusted CCI and its constituent comorbidities are associated with postoperative complications, readmission, flap failure, and survival following head and neck free flap reconstruction.",
        "Methods": "Consecutive adults undergoing microvascular free flap reconstruction at a single institution from 2008–2023 were identified. Age-adjusted CCI was calculated for each patient. Exposures of interest included (1) age-adjusted CCI as a continuous score and (2) individual CCI component comorbidities (e.g., chronic obstructive pulmonary disease [COPD], coronary artery disease [CAD], diabetes, etc.). Primary outcomes were free flap failure (during index admission or after discharge), 30-day readmission, and 2-year overall survival. Secondary outcomes included postoperative pneumonia, reoperation during index hospitalization, recurrence-free survival, and length of stay. Univariate analyses (Fisher’s exact and Mann–Whitney U) were performed, and multivariable logistic regression and Cox proportional hazards models quantified independent associations between comorbidity burden and outcomes.",
        "Results": "On univariate analysis, COPD was significantly associated with postoperative pneumonia (p<0.01), hypertension with 30-day readmission (p<0.03), and CAD with flap failure after discharge (p<0.04). On multivariable analysis, higher age-adjusted CCI was independently associated with increased odds of 30-day readmission (adjusted odds ratio [aOR] 1.18; 95% confidence interval [CI] 1.03–1.36; p=0.02) and decreased 2-year survival (hazard ratio [HR] 1.25; 95% CI 1.05–1.45; p=0.01). COPD remained an independent predictor of postoperative pneumonia (aOR 2.7; 95% CI 1.4–5.2; p=0.003). CAD showed increased unadjusted risk of late flap failure, though this association did not consistently persist after adjusting for global comorbidity burden. Kaplan–Meier survival analysis demonstrated significantly lower 2-year survival in patients with higher age-adjusted CCI and in those with active cancer at the time of surgery (both p<0.01). Other CCI comorbidities were not independently associated with adverse events on multivariable analysis.",
        "Conclusions": "In this large single-institution experience, increasing age-adjusted CCI was associated with higher-risk perioperative profiles, including greater odds of 30-day readmission and reduced 2-year survival after head and neck free flap reconstruction. Among individual CCI components, COPD was the strongest predictor of postoperative pneumonia, while CAD showed an association with late flap failure in univariate testing. These findings support the use of age-adjusted CCI as a practical preoperative risk-stratification tool and suggest that comorbidity-driven optimization strategies may enhance perioperative planning and postoperative surveillance for patients undergoing complex microvascular reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Charlson Comorbidity Index with Outcomes After Head and Neck Free Flap Reconstruction</span>. David Gorelov, MD<sup>1</sup>; Siddhant H Tripathi, MD<sup>2</sup>; Imani Agard<sup>1</sup>; Josiah Brandt, MD<sup>2</sup>; Alexander Karabachev, MD<sup>2</sup>; Adam Beucler<sup>1</sup>; Christine Lee<sup>1</sup>; Emma Nienaber<sup>1</sup>; <u>Madison McElliot</u><sup>1</sup>; Priscilla Pichardo, DO<sup>2</sup>; Dustin Silverman, MD<sup>2</sup>; Alice Tang, MD<sup>2</sup>; Yash Patil, MD<sup>3</sup>; Chad Zender, MD<sup>2</sup>. <sup>1</sup>University of Cincinnati College of Medicine; <sup>2</sup>University of Cincinnati Department of Otolaryngology; <sup>3</sup>Northwestern Medicine Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The age-adjusted Charlson Comorbidity Index (CCI) quantifies overall comorbidity burden and predicts mortality, but its ability to risk stratify patients undergoing head and neck free flap reconstruction remains poorly defined. This study evaluated whether age-adjusted CCI and its constituent comorbidities are associated with postoperative complications, readmission, flap failure, and survival following head and neck free flap reconstruction.</p>\n\n<p><strong>Methods: </strong>Consecutive adults undergoing microvascular free flap reconstruction at a single institution from 2008–2023 were identified. Age-adjusted CCI was calculated for each patient. Exposures of interest included (1) age-adjusted CCI as a continuous score and (2) individual CCI component comorbidities (e.g., chronic obstructive pulmonary disease [COPD], coronary artery disease [CAD], diabetes, etc.). Primary outcomes were free flap failure (during index admission or after discharge), 30-day readmission, and 2-year overall survival. Secondary outcomes included postoperative pneumonia, reoperation during index hospitalization, recurrence-free survival, and length of stay. Univariate analyses (Fisher’s exact and Mann–Whitney U) were performed, and multivariable logistic regression and Cox proportional hazards models quantified independent associations between comorbidity burden and outcomes.</p>\n\n<p><strong>Results: </strong>On univariate analysis, COPD was significantly associated with postoperative pneumonia (p<0.01), hypertension with 30-day readmission (p<0.03), and CAD with flap failure after discharge (p<0.04). On multivariable analysis, higher age-adjusted CCI was independently associated with increased odds of 30-day readmission (adjusted odds ratio [aOR] 1.18; 95% confidence interval [CI] 1.03–1.36; p=0.02) and decreased 2-year survival (hazard ratio [HR] 1.25; 95% CI 1.05–1.45; p=0.01). COPD remained an independent predictor of postoperative pneumonia (aOR 2.7; 95% CI 1.4–5.2; p=0.003). CAD showed increased unadjusted risk of late flap failure, though this association did not consistently persist after adjusting for global comorbidity burden. Kaplan–Meier survival analysis demonstrated significantly lower 2-year survival in patients with higher age-adjusted CCI and in those with active cancer at the time of surgery (both p<0.01). Other CCI comorbidities were not independently associated with adverse events on multivariable analysis.</p>\n\n<p><strong>Conclusions: </strong>In this large single-institution experience, increasing age-adjusted CCI was associated with higher-risk perioperative profiles, including greater odds of 30-day readmission and reduced 2-year survival after head and neck free flap reconstruction. Among individual CCI components, COPD was the strongest predictor of postoperative pneumonia, while CAD showed an association with late flap failure in univariate testing. These findings support the use of age-adjusted CCI as a practical preoperative risk-stratification tool and suggest that comorbidity-driven optimization strategies may enhance perioperative planning and postoperative surveillance for patients undergoing complex microvascular reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154030--></body></html>"
    },
    {
      "uid": "P367",
      "content_id": "155560",
      "abstract_number": "P367",
      "poster_number": "P367",
      "title": "Venous End-to-Side Anastomosis in Head and Neck Microsurgery: Evaluation of the Modified Parachute Technique",
      "summary": "Although the MPETS technique is not widely adopted in H&N microsurgery, its implementation may offer several advantages, including shorter operative time, improved reliability in complex cases, facilitation of microsurgical procedures when operating without assistance, and a reduced risk of back-wall suturing errors. Wider adoption of this technique may therefore represent a valuable addition to the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155560",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Federica Rossi",
      "presenter": "Federica Rossi",
      "authors": "Federica Rossi ; Francesco Mazzola; Milena Fior; Giulia Di Vincenzo; Raul Pellini",
      "normalized_authors": [
        "Federica Rossi",
        "Francesco Mazzola",
        "Milena Fior",
        "Giulia Di Vincenzo",
        "Raul Pellini"
      ],
      "affiliations": [
        "IRCSS Regina Elena Roma"
      ],
      "normalized_institutions": [
        "IRCSS Regina Elena Roma"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 385,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Federica Rossi ; Francesco Mazzola; Milena Fior; Giulia Di Vincenzo; Raul Pellini",
        "Affiliations": "IRCSS Regina Elena Roma",
        "Introduction": "Microvascular venous anastomosis represents a critical step in free flap reconstruction in head and neck (H&N) surgery, where venous thrombosis remains one of the main causes of flap failure. End-to-side (ETS) anastomosis is particularly useful in cases of vessel size discrepancy and when large recipient veins, such as the internal jugular vein, are used. However, ETS anastomosis is technically more demanding than end-to-end techniques, especially in complex clinical scenarios such as previously irradiated necks, prior surgery, or radical neck dissection, where vessels may be scarred, shortened, or affected by intimal fibrosis. The modified parachute end-to-side (MPETS) technique has been proposed to facilitate ETS anastomosis by allowing continuous visualization of the vessel lumen during suturing and reducing the risk of technical errors. Previous studies have suggested that the parachute technique may reduce anastomosis time compared with conventional ETS methods.",
        "Materials and Methods": "A prospective study was conducted to evaluate the execution time of venous anastomoses performed during free flap reconstruction in head and neck (H&N) surgery. Venous anastomoses were performed using either the conventional end-to-side (ETS) technique or the modified parachute end-to-side (MPETS) technique. Recipient veins with a diameter of at least 2 mm were considered eligible for inclusion. A total of 30 venous anastomoses were analyzed, including 15 performed with the ETS technique and 15 using the MPETS technique. The time required to complete each venous anastomosis was recorded, measuring the interval from placement of the first suture to removal of the vascular clamp.",
        "Results": "The MPETS technique showed several technical advantages, including easier vesselotomy through a wide-slit venotomy, reduced risk of anastomotic narrowing, and safer suturing of the donor vessel heel. Continuous visualization of the vessel lumen during suturing also minimized the risk of back-wall stitches and reduced manipulation of the vessel ends. In our series, the MPETS technique was associated with a significantly shorter execution time compared with the conventional ETS technique (7.1 ± 3.1 vs. 9.2 ± 3.6 minutes; P < 0.05).",
        "Conclusions": "Although the MPETS technique is not widely adopted in H&N microsurgery, its implementation may offer several advantages, including shorter operative time, improved reliability in complex cases, facilitation of microsurgical procedures when operating without assistance, and a reduced risk of back-wall suturing errors. Wider adoption of this technique may therefore represent a valuable addition to the reconstructive surgeon’s armamentarium."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Venous End-to-Side Anastomosis in Head and Neck Microsurgery: Evaluation of the Modified Parachute Technique</span>. <u>Federica Rossi</u>; Francesco Mazzola; Milena Fior; Giulia Di Vincenzo; Raul Pellini. IRCSS Regina Elena Roma<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Microvascular venous anastomosis represents a critical step in free flap reconstruction in head and neck (H&N) surgery, where venous thrombosis remains one of the main causes of flap failure. End-to-side (ETS) anastomosis is particularly useful in cases of vessel size discrepancy and when large recipient veins, such as the internal jugular vein, are used. However, ETS anastomosis is technically more demanding than end-to-end techniques, especially in complex clinical scenarios such as previously irradiated necks, prior surgery, or radical neck dissection, where vessels may be scarred, shortened, or affected by intimal fibrosis. The modified parachute end-to-side (MPETS) technique has been proposed to facilitate ETS anastomosis by allowing continuous visualization of the vessel lumen during suturing and reducing the risk of technical errors. Previous studies have suggested that the parachute technique may reduce anastomosis time compared with conventional ETS methods.</p>\n\n<p><strong>Materials and Methods: </strong>A prospective study was conducted to evaluate the execution time of venous anastomoses performed during free flap reconstruction in head and neck (H&N) surgery. Venous anastomoses were performed using either the conventional end-to-side (ETS) technique or the modified parachute end-to-side (MPETS) technique. Recipient veins with a diameter of at least 2 mm were considered eligible for inclusion. A total of 30 venous anastomoses were analyzed, including 15 performed with the ETS technique and 15 using the MPETS technique. The time required to complete each venous anastomosis was recorded, measuring the interval from placement of the first suture to removal of the vascular clamp.</p>\n\n<p><strong>Results: </strong>The MPETS technique showed several technical advantages, including easier vesselotomy through a wide-slit venotomy, reduced risk of anastomotic narrowing, and safer suturing of the donor vessel heel. Continuous visualization of the vessel lumen during suturing also minimized the risk of back-wall stitches and reduced manipulation of the vessel ends. In our series, the MPETS technique was associated with a significantly shorter execution time compared with the conventional ETS technique (7.1 ± 3.1 vs. 9.2 ± 3.6 minutes; P < 0.05).</p>\n\n<p><strong>Conclusions: </strong>Although the MPETS technique is not widely adopted in H&N microsurgery, its implementation may offer several advantages, including shorter operative time, improved reliability in complex cases, facilitation of microsurgical procedures when operating without assistance, and a reduced risk of back-wall suturing errors. Wider adoption of this technique may therefore represent a valuable addition to the reconstructive surgeon’s armamentarium.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155560--></body></html>"
    },
    {
      "uid": "P368",
      "content_id": "153619",
      "abstract_number": "P368",
      "poster_number": "P368",
      "title": "Management of Near-Infrared Photoimmunotherapy-Induced Skin Injury Using Pedicled Flap Transfer: A Case Report",
      "summary": "Pedicled flap transfer for skin injuries following NIR-PIT is a safe and effective treatment option. With appropriate case selection and surgical technique, high success rates and favorable functional and cosmetic outcomes can be achieved.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153619",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mayu Shigeyama",
      "presenter": "Mayu Shigeyama",
      "authors": "Mayu Shigeyama ; Akihisa Wada; Keisuke Nakajima; Seiya Goto; Sayaka Yokoi; Naoki Nishio",
      "normalized_authors": [
        "Mayu Shigeyama",
        "Akihisa Wada",
        "Keisuke Nakajima",
        "Seiya Goto",
        "Sayaka Yokoi",
        "Naoki Nishio"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology, Nagoya University Hospital"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology, Nagoya University Hospital"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 389,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mayu Shigeyama ; Akihisa Wada; Keisuke Nakajima; Seiya Goto; Sayaka Yokoi; Naoki Nishio",
        "Affiliations": "Department of Otorhinolaryngology, Nagoya University Hospital",
        "Background": "Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that combines an antibody-photoabsorber conjugate and NIR light. Currently, this therapy is approved only in Japan for unresectable, locally recurrent head and neck cancers. Despite its successful clinical application, NIR-PIT often causes severe and prolonged complications, including skin injury and pharyngocutaneous fistula, which can significantly reduce patients' quality of life (QOL). Here, we report a case of NIR-PIT-induced severe skin injury around the anterior neck that was successfully managed with a pedicled flap transfer.",
        "Case": "A 71-year-old male was diagnosed as locally advanced tongue squamous cell carcinoma (T4aN2cM0). Four years prior (year X-4), he underwent total tongue resection, bilateral neck dissection, laryngeal elevation, and free flap transfer using a rectus abdominis musculocutaneous flap. One year after treatment, a local recurrence was detected near the mandibular region, and chemoradiation therapy was administered. During follow-up, a local recurrence occurred at the same site. Following multidisciplinary team discussion, NIR-PIT was selected due to concerns about his moderate swallowing dysfunction, and was performed one year prior (year X-1). Postoperatively, a NIR-PIT-induced skin injury developed, exposing the mandible and hyoid bone. Additionally, six months after NIR-PIT, metastasis in the left axillary lymph nodes was detected and treated with surgical resection. In year X, after confirming no recurrence, the skin injury was debrided and covered with a pectoralis major musculocutaneous flap (PMMF) transfer. The postoperative course was uneventful. His swallowing function improved, the risk of wound infection was eliminated, he reported high satisfaction, and a marked improvement in QOL was observed.",
        "Discussion": "Severe treatment complications, such as skin injury or fistula formation, are frequently encountered following PIT. Currently, there is no strong evidence regarding the optimal timing and methods for treating NIR-PIT-induced skin injuries. Generally, the surgical indications for flap transfer include: (1) absence of local recurrence, (2) a clean wound condition following infection control, and (3) good overall health. In our case, the NIR-PIT-induced skin injury exhibited pathophysiological characteristics similar to those observed in radiation-induced or photodynamic therapy (PDT)-induced tissue damage. The patient presented with left axillary lymph node metastasis; however, no other metastases were detected, and effective local tumor control was achieved.",
        "Conclusion": "Pedicled flap transfer for skin injuries following NIR-PIT is a safe and effective treatment option. With appropriate case selection and surgical technique, high success rates and favorable functional and cosmetic outcomes can be achieved."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Management of Near-Infrared Photoimmunotherapy-Induced Skin Injury Using Pedicled Flap Transfer: A Case Report</span>. <u>Mayu Shigeyama</u>; Akihisa Wada; Keisuke Nakajima; Seiya Goto; Sayaka Yokoi; Naoki Nishio. Department of Otorhinolaryngology, Nagoya University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that combines an antibody-photoabsorber conjugate and NIR light. Currently, this therapy is approved only in Japan for unresectable, locally recurrent head and neck cancers. Despite its successful clinical application, NIR-PIT often causes severe and prolonged complications, including skin injury and pharyngocutaneous fistula, which can significantly reduce patients' quality of life (QOL). Here, we report a case of NIR-PIT-induced severe skin injury around the anterior neck that was successfully managed with a pedicled flap transfer.</p>\n\n<p><strong>Case: </strong>A 71-year-old male was diagnosed as locally advanced tongue squamous cell carcinoma (T4aN2cM0). Four years prior (year X-4), he underwent total tongue resection, bilateral neck dissection, laryngeal elevation, and free flap transfer using a rectus abdominis musculocutaneous flap. One year after treatment, a local recurrence was detected near the mandibular region, and chemoradiation therapy was administered. During follow-up, a local recurrence occurred at the same site. Following multidisciplinary team discussion, NIR-PIT was  selected due to concerns about his moderate swallowing dysfunction, and was performed one year prior (year X-1). Postoperatively, a NIR-PIT-induced skin injury developed, exposing the mandible and hyoid bone. Additionally, six months after NIR-PIT, metastasis in the left axillary lymph nodes was detected and treated with surgical resection. In year X, after confirming no recurrence, the skin injury was debrided and covered with a pectoralis major musculocutaneous flap (PMMF) transfer. The postoperative course was uneventful. His swallowing function improved, the risk of wound infection was eliminated, he reported high satisfaction, and a marked improvement in QOL was observed.</p>\n\n<p><strong>Discussion: </strong>Severe treatment complications, such as skin injury or fistula formation, are frequently encountered following PIT. Currently, there is no strong evidence regarding the optimal timing and methods for treating NIR-PIT-induced skin injuries. Generally, the surgical indications for flap transfer include: (1) absence of local recurrence, (2) a clean wound condition following infection control, and (3) good overall health. In our case, the NIR-PIT-induced skin injury exhibited pathophysiological characteristics similar to those observed in radiation-induced or photodynamic therapy (PDT)-induced tissue damage. The patient presented with left axillary lymph node metastasis; however, no other metastases were detected, and effective local tumor control was achieved.</p>\n\n<p><strong>Conclusion: </strong>Pedicled flap transfer for skin injuries following NIR-PIT is a safe and effective treatment option. With appropriate case selection and surgical technique, high success rates and favorable functional and cosmetic outcomes can be achieved.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153619--></body></html>"
    },
    {
      "uid": "P369",
      "content_id": "153417",
      "abstract_number": "P369",
      "poster_number": "P369",
      "title": "Temporalis muscle flap for reconstruction of the oropharynx for velopharyngeal insufficiency",
      "summary": "The patient’s preoperative VELO score was 112/115. She underwent a left temporalis flap for reconstruction of the left soft palate and tracheostomy for correction of velopharyngeal insufficiency on 01/28/2025. She was decannulated during the admission and discharged from the hospital on 02/04/25 (POD 7). She was seen post-operatively at one month with significant subjective improvement in voice and nasal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153417",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdurrahman Abdurrob, MD, MS",
      "presenter": "Abdurrahman Abdurrob, MD, MS",
      "authors": "Abdurrahman Abdurrob, MD, MS ; Bamdad Tayyari; Jake Sims, DO; Syed Ahmed Ali, MD",
      "normalized_authors": [
        "Abdurrahman Abdurrob",
        "Bamdad Tayyari",
        "Jake Sims",
        "Syed Ahmed Ali"
      ],
      "affiliations": [
        "Henry Ford Health"
      ],
      "normalized_institutions": [
        "Henry Ford Health"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Abdurrahman Abdurrob, MD, MS ; Bamdad Tayyari; Jake Sims, DO; Syed Ahmed Ali, MD",
        "Affiliations": "Henry Ford Health",
        "Background": "Surgical resection of head and neck cancer requires consideration for both cosmetic and functional concerns. Palate and oropharyngeal reconstruction pose a significant challenge because of their involvement in swallowing, speech, and respiration. Therefore, reconstruction of defect sites in this region is an area of high interest. The use of various flaps, from regional or distant sites, has been the cornerstone of surgical reconstruction in the head and neck. Since its first use after resection of the condylar neck for temporomandibular joint ankylosis in 1985, the temporalis flap has been widely used in head and neck reconstruction. Although the temporalis flap has been previously described in primary reconstruction following resection of neoplasms, cleft palate, and trauma, its use for correcting velopharyngeal insufficiency (VPI) has not been described. This report presents the first published use of the temporalis muscle flap for reconstruction of the soft palate for velopharyngeal insufficiency (VPI).",
        "Methods": "This case report describes a single patient from one academic institution. The patient is a 57-year-old female with a history of Stage II, p16+ pT3N0M0 SCC of the left tonsil status post left transoral robotic radical tonsillectomy and left selective neck dissection followed by adjuvant chemoradiation. Significant VPI complicated the post-operative course.",
        "Results": "The patient’s preoperative VELO score was 112/115. She underwent a left temporalis flap for reconstruction of the left soft palate and tracheostomy for correction of velopharyngeal insufficiency on 01/28/2025. She was decannulated during the admission and discharged from the hospital on 02/04/25 (POD 7). She was seen post-operatively at one month with significant subjective improvement in voice and nasal regurgitation. She was g-tube dependent before surgery, but now tolerates diet completely by mouth, and her post-operative VELO score was improved to 23/115.",
        "Discussion": "VPI is commonly associated with surgical resection of the palate and oropharyngeal cancers. It can cause significant distress to patients by affecting speech and swallowing. The temporalis flap offers a sleek and flexible myofascial flap that can be used to reconstruct medium to large defect sites. Due to its proximity to the regions of interest, it can further reduce operating times and the need for additional operative sites such as the forearm or the anterolateral thigh. The temporalis muscle use for the correction of velopharyngeal insufficiency in this patient population has not been reported. As a single case, the use of the temporalis muscle flap for correction of VPI warrants careful consideration, but given the excellent outcome for this patient, it should be investigated further in the appropriate patient selection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Temporalis muscle flap for reconstruction of the oropharynx for velopharyngeal insufficiency</span>. <u>Abdurrahman Abdurrob, MD, MS</u>; Bamdad Tayyari; Jake Sims, DO; Syed Ahmed Ali, MD. Henry Ford Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Surgical resection of head and neck cancer requires consideration for both cosmetic and functional concerns. Palate and oropharyngeal reconstruction pose a significant challenge because of their involvement in swallowing, speech, and respiration. Therefore, reconstruction of defect sites in this region is an area of high interest. The use of various flaps, from regional or distant sites, has been the cornerstone of surgical reconstruction in the head and neck. Since its first use after resection of the condylar neck for temporomandibular joint ankylosis in 1985, the temporalis flap has been widely used in head and neck reconstruction. Although the temporalis flap has been previously described in primary reconstruction following resection of neoplasms, cleft palate, and trauma, its use for correcting velopharyngeal insufficiency (VPI) has not been described. This report presents the first published use of the temporalis muscle flap for reconstruction of the soft palate for velopharyngeal insufficiency (VPI). </p>\n\n<p><strong>Methods: </strong>This case report describes a single patient from one academic institution. The patient is a 57-year-old female with a history of Stage II, p16+ pT3N0M0 SCC of the left tonsil status post left transoral robotic radical tonsillectomy and left selective neck dissection followed by adjuvant chemoradiation. Significant VPI complicated the post-operative course. </p>\n\n<p><strong>Results: </strong>The patient’s preoperative VELO score was 112/115. She underwent a left temporalis flap for reconstruction of the left soft palate and tracheostomy for correction of velopharyngeal insufficiency on 01/28/2025. She was decannulated during the admission and discharged from the hospital on 02/04/25 (POD 7). She was seen post-operatively at one month with significant subjective improvement in voice and nasal regurgitation. She was g-tube dependent before surgery, but now tolerates diet completely by mouth, and her post-operative VELO score was improved to 23/115. </p>\n\n<p><strong>Discussion: </strong>VPI is commonly associated with surgical resection of the palate and oropharyngeal cancers. It can cause significant distress to patients by affecting speech and swallowing. The temporalis flap offers a sleek and flexible myofascial flap that can be used to reconstruct medium to large defect sites. Due to its proximity to the regions of interest, it can further reduce operating times and the need for additional operative sites such as the forearm or the anterolateral thigh. The temporalis muscle use for the correction of velopharyngeal insufficiency in this patient population has not been reported. As a single case, the use of the temporalis muscle flap for correction of VPI warrants careful consideration, but given the excellent outcome for this patient, it should be investigated further in the appropriate patient selection. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153417--></body></html>"
    },
    {
      "uid": "P371",
      "content_id": "155344",
      "abstract_number": "P371",
      "poster_number": "P371",
      "title": "Preoperative Antibiotic Exposure and Early Postoperative Outcomes in Head and Neck Free-Flap Reconstruction",
      "summary": "In this large multi-institutional cohort, preoperative antibiotic exposure was associated with significantly worse early outcomes after head and neck free-flap reconstruction, including higher rates of SSI, wound dehiscence, return to OR, and flap complications through 30 days. Recent antibiotic exposure may represent an underrecognized preoperative risk marker and should be considered in counseling and risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155344",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sergio A Segrera, MS",
      "presenter": "Sergio A Segrera, MS",
      "authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis Gursky, BS 1 ; Hailey Wyatt, MD 1 ; Adam Jacobson, MD 2 ; Jamie P Levine, MD 1",
      "normalized_authors": [
        "Sergio A Segrera",
        "Anandhini Narayanan",
        "Alexis Gursky",
        "Hailey Wyatt",
        "Adam Jacobson",
        "Jamie P Levine"
      ],
      "affiliations": [
        "NYU Langone Hansjörg Wyss Department of Plastic Surgery",
        "NYU Department of Otolaryngology-Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "NYU Langone Hansjörg Wyss Department of Plastic Surgery",
        "NYU Department of Otolaryngology-Head & Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 564,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis Gursky, BS 1 ; Hailey Wyatt, MD 1 ; Adam Jacobson, MD 2 ; Jamie P Levine, MD 1",
        "Affiliations": "1 NYU Langone Hansjörg Wyss Department of Plastic Surgery; 2 NYU Department of Otolaryngology-Head & Neck Surgery",
        "Purpose": "Head and neck free-flap reconstruction is the standard reconstructive approach for complex oncologic defects, but postoperative complications remain common. Despite routine perioperative prophylaxis, patients often present to surgery with recent antibiotic exposure for unrelated or preexisting infections. Prior literature in reconstructive surgery has raised concern that recent antibiotic use may be associated with worse postoperative outcomes, potentially through effects on microbial resistance or microbiome disruption. Given the complexity and complication burden of head and neck reconstruction, we evaluated whether preoperative antibiotic exposure is associated with increased early postoperative complications after head and neck free-flap surgery.",
        "Methods": "We performed a retrospective cohort study within the TriNetX Research Network including adult patients who underwent head and neck free-flap reconstruction paired with same-day ablative surgery and linked to head and neck malignancy diagnoses. Preoperative antibiotic exposure was defined as any documented systemic antibacterial therapy within 30 days before surgery, excluding routine day-of-surgery prophylaxis. Patients without any antibiotic record in the 30 days before surgery served as the comparator group. Cohorts were matched 1:1 using nearest-neighbor propensity-score matching based on logistic regression, with a prespecified balance target of standardized mean difference <0.1. Covariates included demographics, procedure type, cancer site and treatment, obesity, diabetes, hypertension, tobacco and alcohol use, chronic kidney disease, liver disease, and other relevant comorbidities. Outcomes were evaluated at 7, 15, and 30 days after surgery and included surgical-site infection (SSI), wound dehiscence, return to the operating room (OR), and flap complications. Associations were reported as risk ratios (RRs) with 95% confidence intervals, with significance defined as p<0.05.",
        "Results": "Across 53 health systems, 28,642 patients met inclusion criteria; 8,343 had preoperative antibiotic exposure and 20,299 served as comparators. After matching, 7,598 exposed and 7,598 unexposed patients achieved covariate balance. At 7 days, exposed patients had higher risk of SSI (11.12% vs 7.05%; RR 1.58; p<0.0001). There was also an increased risk of wound dehiscence (7.59% vs 5.21%; RR 1.46; p<0.0001), return to OR (3.94% vs 2.38%; RR 1.65; p<0.0001), and flap complications (4.09% vs 2.62%; RR 1.56; p<0.0001). At 15 days, there was an increased risk of all postoperative complications: SSI (15.69% vs 10.63%; RR 1.48; p<0.0001), wound dehiscence (10.36% vs 7.59%; RR 1.36; p<0.0001), return to OR (6.36% vs 3.88%; RR 1.64; p<0.0001), and flap complications (5.05% vs 3.15%; RR 1.61; p<0.0001). Similarly, by 30 days, the risks were significantly higher for the exposed cohort: SSI (20.66% vs 15.01%; RR 1.38; p<0.0001), wound dehiscence (14.28% vs 10.24%; RR 1.40; p<0.0001), return to OR (8.56% vs 5.50%; RR 1.56; p<0.0001), and flap complications (6.33% vs 4.16%; RR 1.52; p<0.0001).",
        "Conclusions": "In this large multi-institutional cohort, preoperative antibiotic exposure was associated with significantly worse early outcomes after head and neck free-flap reconstruction, including higher rates of SSI, wound dehiscence, return to OR, and flap complications through 30 days. Recent antibiotic exposure may represent an underrecognized preoperative risk marker and should be considered in counseling and risk stratification. Future studies should evaluate antibiotic indication, class, and timing to clarify causality and mechanisms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Antibiotic Exposure and Early Postoperative Outcomes in Head and Neck Free-Flap Reconstruction</span>. <u>Sergio A Segrera, MS</u><sup>1</sup>; Anandhini Narayanan, MD<sup>1</sup>; Alexis Gursky, BS<sup>1</sup>; Hailey Wyatt, MD<sup>1</sup>; Adam Jacobson, MD<sup>2</sup>; Jamie P Levine, MD<sup>1</sup>. <sup>1</sup>NYU Langone Hansjörg Wyss Department of Plastic Surgery; <sup>2</sup>NYU Department of Otolaryngology-Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Head and neck free-flap reconstruction is the standard reconstructive approach for complex oncologic defects, but postoperative complications remain common. Despite routine perioperative prophylaxis, patients often present to surgery with recent antibiotic exposure for unrelated or preexisting infections. Prior literature in reconstructive surgery has raised concern that recent antibiotic use may be associated with worse postoperative outcomes, potentially through effects on microbial resistance or microbiome disruption. Given the complexity and complication burden of head and neck reconstruction, we evaluated whether preoperative antibiotic exposure is associated with increased early postoperative complications after head and neck free-flap surgery. </p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study within the TriNetX Research Network including adult patients who underwent head and neck free-flap reconstruction paired with same-day ablative surgery and linked to head and neck malignancy diagnoses. Preoperative antibiotic exposure was defined as any documented systemic antibacterial therapy within 30 days before surgery, excluding routine day-of-surgery prophylaxis. Patients without any antibiotic record in the 30 days before surgery served as the comparator group. Cohorts were matched 1:1 using nearest-neighbor propensity-score matching based on logistic regression, with a prespecified balance target of standardized mean difference <0.1. Covariates included demographics, procedure type, cancer site and treatment, obesity, diabetes, hypertension, tobacco and alcohol use, chronic kidney disease, liver disease, and other relevant comorbidities. Outcomes were evaluated at 7, 15, and 30 days after surgery and included surgical-site infection (SSI), wound dehiscence, return to the operating room (OR), and flap complications. Associations were reported as risk ratios (RRs) with 95% confidence intervals, with significance defined as p<0.05. </p>\n\n<p><strong>Results:</strong> Across 53 health systems, 28,642 patients met inclusion criteria; 8,343 had preoperative antibiotic exposure and 20,299 served as comparators. After matching, 7,598 exposed and 7,598 unexposed patients achieved covariate balance. At 7 days, exposed patients had higher risk of SSI (11.12% vs 7.05%; RR 1.58; p<0.0001). There was also an increased risk of wound dehiscence (7.59% vs 5.21%; RR 1.46; p<0.0001), return to OR (3.94% vs 2.38%; RR 1.65; p<0.0001), and flap complications (4.09% vs 2.62%; RR 1.56; p<0.0001). At 15 days, there was an increased risk of all postoperative complications: SSI (15.69% vs 10.63%; RR 1.48; p<0.0001), wound dehiscence (10.36% vs 7.59%; RR 1.36; p<0.0001), return to OR (6.36% vs 3.88%; RR 1.64; p<0.0001), and flap complications (5.05% vs 3.15%; RR 1.61; p<0.0001). Similarly, by 30 days, the risks were significantly higher for the exposed cohort: SSI (20.66% vs 15.01%; RR 1.38; p<0.0001), wound dehiscence (14.28% vs 10.24%; RR 1.40; p<0.0001), return to OR (8.56% vs 5.50%; RR 1.56; p<0.0001), and flap complications (6.33% vs 4.16%; RR 1.52; p<0.0001). </p>\n\n<p><strong>Conclusions: </strong>In this large multi-institutional cohort, preoperative antibiotic exposure was associated with significantly worse early outcomes after head and neck free-flap reconstruction, including higher rates of SSI, wound dehiscence, return to OR, and flap complications through 30 days. Recent antibiotic exposure may represent an underrecognized preoperative risk marker and should be considered in counseling and risk stratification. Future studies should evaluate antibiotic indication, class, and timing to clarify causality and mechanisms. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155344--></body></html>"
    },
    {
      "uid": "P372",
      "content_id": "154058",
      "abstract_number": "P372",
      "poster_number": "P372",
      "title": "Advancing Reconstruction: A New Technique Combining Cadaveric Bone Grafting and Prophylactic Plating in Osteocutaneous Radial Forearm Free Flaps",
      "summary": "Osteocutaneous radial forearm free flaps (OCRFFF) remain a versatile and reliable reconstructive option for head and neck oncologic defects. Donor-site radius fractures historically limited the safe harvest of bone length and circumference; however, prophylactic radial plating has substantially reduced these complications. The widespread adoption of plating was influenced by a retrospective study that paired...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154058",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lisa B Earnest-Noble, MD, PhD",
      "presenter": "Lisa B Earnest-Noble, MD, PhD",
      "authors": "Lisa B Earnest-Noble, MD, PhD ; Yaw Boachie-Adjei, MD; Brian B Hughley, MD, FACS",
      "normalized_authors": [
        "Lisa B Earnest-Noble",
        "Yaw Boachie-Adjei",
        "Brian B Hughley"
      ],
      "affiliations": [
        "Duke University"
      ],
      "normalized_institutions": [
        "Duke University"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 169,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lisa B Earnest-Noble, MD, PhD ; Yaw Boachie-Adjei, MD; Brian B Hughley, MD, FACS",
        "Affiliations": "Duke University",
        "Abstract": "Osteocutaneous radial forearm free flaps (OCRFFF) remain a versatile and reliable reconstructive option for head and neck oncologic defects. Donor-site radius fractures historically limited the safe harvest of bone length and circumference; however, prophylactic radial plating has substantially reduced these complications. The widespread adoption of plating was influenced by a retrospective study that paired plating with autologous iliac crest bone grafting, though subsequent practice demonstrated that plating alone was sufficient to markedly lower fracture rates. To date, no direct comparison has evaluated plating alone versus the combination of bone grafting and prophylactic plating. We describe a novel technique that integrates cadaveric fibula allograft with prophylactic radial plating, developed in collaboration with Orthopedic Surgery to enhance donor-site stability during OCRFFF reconstruction. A retrospective review comparing outcomes from this case series with those of previously plated donor sites will be presented. Our aim is to assess complication rates and demonstrate the feasibility and potential advantages of incorporating cadaveric bone grafting to further strengthen the radial donor site and improve patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Advancing Reconstruction: A New Technique Combining Cadaveric Bone Grafting and Prophylactic Plating in Osteocutaneous Radial Forearm Free Flaps</span>. <u>Lisa B Earnest-Noble, MD, PhD</u>; Yaw Boachie-Adjei, MD; Brian B Hughley, MD, FACS. Duke University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Osteocutaneous radial forearm free flaps (OCRFFF) remain a versatile and reliable reconstructive option for head and neck oncologic defects. Donor-site radius fractures historically limited the safe harvest of bone length and circumference; however, prophylactic radial plating has substantially reduced these complications. The widespread adoption of plating was influenced by a retrospective study that paired plating with autologous iliac crest bone grafting, though subsequent practice demonstrated that plating alone was sufficient to markedly lower fracture rates. To date, no direct comparison has evaluated plating alone versus the combination of bone grafting and prophylactic plating. We describe a novel technique that integrates cadaveric fibula allograft with prophylactic radial plating, developed in collaboration with Orthopedic Surgery to enhance donor-site stability during OCRFFF reconstruction. A retrospective review comparing outcomes from this case series with those of previously plated donor sites will be presented. Our aim is to assess complication rates and demonstrate the feasibility and potential advantages of incorporating cadaveric bone grafting to further strengthen the radial donor site and improve patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154058--></body></html>"
    },
    {
      "uid": "P373",
      "content_id": "155452",
      "abstract_number": "P373",
      "poster_number": "P373",
      "title": "Paradigm Change in Open Airway Surgery: A Case Report of Repair of an Enlarging Tracheo-esophageal Fistula Utilizing a Microvascular Free Flap and Extracorporeal Membrane Oxygenation",
      "summary": "A scoping review is ongoing to characterize the use of ECMO in head and neck cancer and free flap reconstruction cases. ECMO has been described in several studies as a bridge to ensure oxygenation in patients with obstruction secondary to malignant head and neck tumors extending into the mediastinum until a surgical airway is established. Additionally, its use for flap rescue applications is described in the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155452",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chareeni Kurukulasuriya, MD",
      "presenter": "Chareeni Kurukulasuriya, MD",
      "authors": "Chareeni Kurukulasuriya, MD ; Arianna Winchester, MD; Andrew Prince, MD; Lindsey Moses, MD; Adam Jacobson, MD",
      "normalized_authors": [
        "Chareeni Kurukulasuriya",
        "Arianna Winchester",
        "Andrew Prince",
        "Lindsey Moses",
        "Adam Jacobson"
      ],
      "affiliations": [
        "NYU Langone Health"
      ],
      "normalized_institutions": [
        "NYU Langone Health"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155452/Figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155452/Figure%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155452"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Results"
      ],
      "sections": {
        "Authors": "Chareeni Kurukulasuriya, MD ; Arianna Winchester, MD; Andrew Prince, MD; Lindsey Moses, MD; Adam Jacobson, MD",
        "Affiliations": "NYU Langone Health",
        "Introduction": "Tracheo-esophageal fistula (TEF) is a serious complication of radiation in the setting of a total laryngectomy. This can cause chronic aspiration of saliva and food, putting vulnerable patients at risk for pneumonia and airway obstruction. Open surgical treatment is indicated for persistent or enlarging fistulas that fail conservative management; larger fistulas not suitable for primary closure may require microvascular free flap reconstruction. Here we describe a novel multidisciplinary approach for repair of a very large TEF, which was entirely substernal, utilizing venovenous extracorporeal membrane oxygenation (VV-ECMO) cannulation, sternotomy, and a radial forearm free flap reconstruction. While ECMO has been described in pediatric airway reconstruction cases and thoracic repair of TEF with stenting, its use in conjunction with sternotomy for free flap reconstruction in the head and neck cancer population has not been previously documented.",
        "Case Presentation": "The patient is a 78-year-old female with a history of T4aN2c laryngeal squamous cell carcinoma status post total laryngectomy, bilateral neck dissections, and radial forearm free flap pharyngeal reconstruction with primary tracheoesophageal puncture in 2024. The patient had adjuvant chemoradiation. Her course was complicated by complaints of oral feed intolerance, weight loss, and leakage from her TEP site. She was found to have an enlarging TEF approximately 5x1 cm extending to just above the carina. Additionally, she had severe pharyngeal stenosis. Given the substernal extent of the fistula, access to repair the fistula transcervically was not feasible. A combined approach to the fistula via open sternotomy and oxygenation via VV-ECMO was planned. The common party wall defect and proximal pharyngeal stenosis were repaired with a radial forearm free flap. The patient remained on ECMO postoperatively with a tracheostomy tube in the laryngectomy stoma to allow the reconstruction to formalize. She was successfully weaned from ECMO on postoperative day 9.",
        "Results": "A scoping review is ongoing to characterize the use of ECMO in head and neck cancer and free flap reconstruction cases. ECMO has been described in several studies as a bridge to ensure oxygenation in patients with obstruction secondary to malignant head and neck tumors extending into the mediastinum until a surgical airway is established. Additionally, its use for flap rescue applications is described in the literature for ischemic or congested flaps secondary to inadequate recipient vessels or emergent conditions resulting in prolonged ischemia. However, our review has only yielded one case series detailing a total of 3 patients who underwent ECMO to aid in free flap repair of TEF. The series describes the repair of persistent tracheoesophageal fistulas with bi-paddled radial forearm and latissimus dorsi muscle free flaps in conjunction with ECMO. Our case describes a novel approach to TEF reconstruction utilizing VV-ECMO, emphasizing the importance of collaboration with other surgical and medical teams to manage complex aerodigestive tract reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Paradigm Change in Open Airway Surgery: A Case Report of Repair of an Enlarging Tracheo-esophageal Fistula Utilizing a Microvascular Free Flap and Extracorporeal Membrane Oxygenation</span>. <u>Chareeni Kurukulasuriya, MD</u>; Arianna Winchester, MD; Andrew Prince, MD; Lindsey Moses, MD; Adam Jacobson, MD. NYU Langone Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Tracheo-esophageal fistula (TEF) is a serious complication of radiation in the setting of a total laryngectomy. This can cause chronic aspiration of saliva and food, putting vulnerable patients at risk for pneumonia and airway obstruction.  Open surgical treatment is indicated for persistent or enlarging fistulas that fail conservative management; larger fistulas not suitable for primary closure may require microvascular free flap reconstruction. Here we describe a novel multidisciplinary approach for repair of a very large TEF, which was entirely substernal, utilizing venovenous extracorporeal membrane oxygenation (VV-ECMO) cannulation, sternotomy, and a radial forearm free flap reconstruction.  While ECMO has been described in pediatric airway reconstruction cases and thoracic repair of TEF with stenting, its use in conjunction with sternotomy for free flap reconstruction in the head and neck cancer population has not been previously documented.  </p>\n\n<p><strong>Case Presentation: </strong>The patient is a 78-year-old female with a history of T4aN2c laryngeal squamous cell carcinoma status post total laryngectomy, bilateral neck dissections, and radial forearm free flap pharyngeal reconstruction with primary tracheoesophageal puncture in 2024. The patient had adjuvant chemoradiation. Her course was complicated by complaints of oral feed intolerance, weight loss, and leakage from her TEP site. She was found to have an enlarging TEF approximately 5x1 cm extending to just above the carina.  Additionally, she had severe pharyngeal stenosis. Given the substernal extent of the fistula, access to repair the fistula transcervically was not feasible. A combined approach to the fistula via open sternotomy and oxygenation via VV-ECMO was planned. The common party wall defect and proximal pharyngeal stenosis were repaired with a radial forearm free flap. The patient remained on ECMO postoperatively with a tracheostomy tube in the laryngectomy stoma to allow the reconstruction to formalize. She was successfully weaned from ECMO on postoperative day 9.  </p>\n\n<p><strong>Results:</strong> A scoping review is ongoing to characterize the use of ECMO in head and neck cancer and free flap reconstruction cases. ECMO has been described in several studies as a bridge to ensure oxygenation in patients with obstruction secondary to malignant head and neck tumors extending into the mediastinum until a surgical airway is established. Additionally, its use for flap rescue applications is described in the literature for ischemic or congested flaps secondary to inadequate recipient vessels or emergent conditions resulting in prolonged ischemia.  However, our review has only yielded one case series detailing a total of 3 patients who underwent ECMO to aid in free flap repair of TEF. The series describes the repair of persistent tracheoesophageal fistulas with bi-paddled radial forearm and latissimus dorsi muscle free flaps in conjunction with ECMO. Our case describes a novel approach to TEF reconstruction utilizing VV-ECMO,  emphasizing the importance of collaboration with other surgical and medical teams to manage complex aerodigestive tract reconstruction. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155452/Figure%201.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155452--></body></html>"
    },
    {
      "uid": "P374",
      "content_id": "154066",
      "abstract_number": "P374",
      "poster_number": "P374",
      "title": "Retrospective review finds no difference in patient outcomes with use of internal mammary artery or transverse cervical artery in a cohort of radiated, vessel-deplete necks.",
      "summary": "The IMA and TCA offer viable options for recipient vessels in a salvage neck setting. Neither venous coupler use nor size corresponded with free flap failure or take back.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154066",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aayush Unadkat, BS",
      "presenter": "Aayush Unadkat, BS",
      "authors": "Colleen G Hochfelder, MD; Victoria X Yu, MD; Aayush Unadkat, BS ; Annaliese Opran, BA; David Forner, MD; Chaz L Stucken, MD; Kelly M Malloy, MD; Keith Casper, MD; Mark E Prince, MD; Marisa Buchakjian, MD, PhD; Molly E Heft Neal, MD; Pratyusha Yalamanchi, MD",
      "normalized_authors": [
        "Colleen G Hochfelder",
        "Victoria X Yu",
        "Aayush Unadkat",
        "Annaliese Opran",
        "David Forner",
        "Chaz L Stucken",
        "Kelly M Malloy",
        "Keith Casper",
        "Mark E Prince",
        "Marisa Buchakjian",
        "Molly E Heft Neal",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Michigan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Michigan"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Colleen G Hochfelder, MD; Victoria X Yu, MD; Aayush Unadkat, BS ; Annaliese Opran, BA; David Forner, MD; Chaz L Stucken, MD; Kelly M Malloy, MD; Keith Casper, MD; Mark E Prince, MD; Marisa Buchakjian, MD, PhD; Molly E Heft Neal, MD; Pratyusha Yalamanchi, MD",
        "Affiliations": "Department of Otolaryngology-Head and Neck Surgery, University of Michigan",
        "Introduction": "Microvascular reconstruction of the head and neck remains a technical challenge in the salvage and reoperative settings due to the challenge of identifying reliable vessels in patients with a history of prior surgery and radiation therapy. The internal mammary artery (IMA) and transverse cervical artery (TCA) offer regional recipient vessels often spared by radiation fields and prior dissection.",
        "Methods": "Retrospective cohort study of free flaps from 2018 until 2022 was performed. Data was collected on patient demographics, type of free flap, and indications including staging, medical comorbidities, and clinical outcomes. Outcomes were assessed with respect to free flap donor site, vessel selection, and surgical techniques used. Logistic regression was used to explore associations between characteristics and binary outcomes.",
        "Results": "Among the 848 free flaps performed, there were 340 (40.1%) flaps performed for patients with a prior history of radiation and an additional 110 (13.0%) who had previously had surgical resections. There were 66 free flap take backs (6.96%) and 34 free flap losses (3.59%). Most reconstructions used typical recipient vessels 488 (57.5%) used facial artery, and 147 (17.3%) used superficial thyroid artery. There were 21 IMA-based flaps, 18 of which had a history of radiation. Of the 66 TCA-based flaps, 49 of them had a history of radiation. There was no difference in free flap loss with IMA (OR 1.23, 95% CI 0.16-9.48, p=0.84) or TCA use (OR 0.75, 95% CI 0.18-3.21, p=0.70). Similarly, there was no difference in free flap take back rate with IMA (OR 2.04, 95% CI 0.59-7.14, p=0.60) or TCA (OR 0.76, 95% CI 0.27-2.15, p=0.81). Comparing “atypical” artery use (either IMA or TC) to all other vessels found no difference in free flap loss (OR 0.86, 95% CI 0.26-2.90, p= 0.701) or take backs (OR 1.05, 95% CI 0.47-2.39, p=0.813) on logistic regression. Most venous anastomoses were accomplished using a coupler. There were 16 venous anastomoses that were handsewn, with no difference in flap failure rate (OR 0.27, 95% CI 0.06-1.23, p=0.09). Coupler size did not correspond with free flap loss as a continuous variable (OR 0.70, 95% CI 0.37-1.32, p=0.271) or as a binary variable divided at the median of 3.0 mm coupler (OR 0.82, 95% CI 0.36-1.89, p = 0.650). There were only 5 patients with end to side anastomoses and no flap failures or take backs among these. There was no association between type of flap and free flap loss (OR 0.97, 95% CI 0.90-1.05, p=0.508), or flap take back (OR 1.01, 95% CI 0.99-1.04, p=0.288).",
        "Conclusions": "The IMA and TCA offer viable options for recipient vessels in a salvage neck setting. Neither venous coupler use nor size corresponded with free flap failure or take back."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Retrospective review finds no difference in patient outcomes with use of internal mammary artery or transverse cervical artery in a cohort of radiated, vessel-deplete necks.</span>. Colleen G Hochfelder, MD; Victoria X Yu, MD; <u>Aayush Unadkat, BS</u>; Annaliese Opran, BA; David Forner, MD; Chaz L Stucken, MD; Kelly M Malloy, MD; Keith Casper, MD; Mark E Prince, MD; Marisa Buchakjian, MD, PhD; Molly E Heft Neal, MD; Pratyusha Yalamanchi, MD. Department of Otolaryngology-Head and Neck Surgery, University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Microvascular reconstruction of the head and neck remains a technical challenge in the salvage and reoperative settings due to the challenge of identifying reliable vessels in patients with a history of prior surgery and radiation therapy. The internal mammary artery (IMA) and transverse cervical artery (TCA) offer regional recipient vessels often spared by radiation fields and prior dissection. </p>\n\n<p><strong>Methods: </strong>Retrospective cohort study of free flaps from 2018 until 2022 was performed. Data was collected on patient demographics, type of free flap, and indications including staging, medical comorbidities, and clinical outcomes. Outcomes were assessed with respect to free flap donor site, vessel selection, and surgical techniques used. Logistic regression was used to explore associations between characteristics and binary outcomes. </p>\n\n<p><strong>Results: </strong>Among the 848 free flaps performed, there were 340 (40.1%) flaps performed for patients with a prior history of radiation and an additional 110 (13.0%) who had previously had surgical resections. There were 66 free flap take backs (6.96%) and 34 free flap losses (3.59%). Most reconstructions used typical recipient vessels 488 (57.5%) used facial artery, and 147 (17.3%) used superficial thyroid artery. There were 21 IMA-based flaps, 18 of which had a history of radiation. Of the 66 TCA-based flaps, 49 of them had a history of radiation. There was no difference in free flap loss with IMA (OR 1.23, 95% CI 0.16-9.48, p=0.84) or TCA use (OR 0.75, 95% CI 0.18-3.21, p=0.70). Similarly, there was no difference in free flap take back rate with IMA (OR 2.04, 95% CI 0.59-7.14, p=0.60) or TCA (OR 0.76, 95% CI 0.27-2.15, p=0.81). Comparing “atypical” artery use (either IMA or TC) to all other vessels found no difference in free flap loss (OR 0.86, 95% CI 0.26-2.90, p= 0.701) or take backs (OR 1.05, 95% CI 0.47-2.39, p=0.813) on logistic regression. Most venous anastomoses were accomplished using a coupler. There were 16 venous anastomoses that were handsewn, with no difference in flap failure rate (OR 0.27, 95% CI 0.06-1.23, p=0.09). Coupler size did not correspond with free flap loss as a continuous variable (OR 0.70, 95% CI 0.37-1.32, p=0.271) or as a binary variable divided at the median of 3.0 mm coupler (OR 0.82, 95% CI 0.36-1.89, p = 0.650).  There were only 5 patients with end to side anastomoses and no flap failures or take backs among these. There was no association between type of flap and free flap loss (OR 0.97, 95% CI 0.90-1.05, p=0.508), or flap take back (OR 1.01, 95% CI 0.99-1.04, p=0.288).</p>\n\n<p><strong>Conclusions:</strong> The IMA and TCA offer viable options for recipient vessels in a salvage neck setting. Neither venous coupler use nor size corresponded with free flap failure or take back.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154066--></body></html>"
    },
    {
      "uid": "P375",
      "content_id": "155498",
      "abstract_number": "P375",
      "poster_number": "P375",
      "title": "Skin Color Match Assessment Following Head and Neck Flap Reconstruction: A Systematic Review",
      "summary": "Assessment of postoperative skin color match in head and neck reconstruction remains methodologically heterogeneous, with most of the evidence limited to retrospective designs and unvalidated subjective scales. No study combines a high-level study design with validated objective colorimetry. Portable handheld colorimetry and standardized ΔE2000 reporting offer the most promising path toward reproducible,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155498",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shaynie Segal, BA",
      "presenter": "Shaynie Segal, BA",
      "authors": "Shaynie Segal, BA 1 ; Vicky Yau, DDS 2 ; Carolyn Debiase, MD 3 ; Richard V Smith, MD 3",
      "normalized_authors": [
        "Shaynie Segal",
        "Vicky Yau",
        "Carolyn Debiase",
        "Richard V Smith"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine",
        "Division of Oral and Maxillofacial Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai",
        "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine",
        "Division of Oral and Maxillofacial Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai",
        "Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Shaynie Segal, BA 1 ; Vicky Yau, DDS 2 ; Carolyn Debiase, MD 3 ; Richard V Smith, MD 3",
        "Affiliations": "1 Albert Einstein College of Medicine; 2 Division of Oral and Maxillofacial Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai; 3 Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center",
        "Background": "Skin color mismatch between transferred tissue and native skin is a major aesthetic concern following head and neck reconstruction with externally visible flaps, and even technically successful reconstruction may appear visually discordant. Despite increasing interest in objective colorimetric assessment, no standardized approach for postoperative color match evaluation exists. This systematic review synthesizes evidence on color match evaluation methods, predictors of discrepancy, and methodological quality.",
        "Materials and Methods": "A systematic review was conducted following PRISMA 2020 guidelines and prospectively registered on PROSPERO (CRD420251114775). PubMed, Embase, and Web of Science were searched through December 2025 for studies reporting color match assessment between transferred flap tissue and recipient-site skin following head and neck reconstruction. Eligible studies included local, regional, or free flaps with externally visible skin and used a defined measurement method with quantitative outcomes. Studies were classified according to assessment methodology as objective (instrument-based colorimetry or digital photographic analysis with CIE L*a*b* color space and ΔE calculation) or subjective (clinician-rated scales, expert panels, or patient-reported outcomes). Study quality was rated using the JAMA Quality Rating Scheme. Data were synthesized narratively following SWiM guidelines due to methodological heterogeneity.",
        "Results": "Of 893 records identified, 14 studies met inclusion criteria, encompassing 790 patients published between 2007 and 2024 across nine countries. Three studies were rated quality level 2 (prospective comparative cohort), nine level 3 (retrospective cohort), and two level 4 (cross-sectional or case series); no study achieved level 1. Six studies (42.9%) used objective measurement methods, including digital photographic analysis (n=4) and handheld colorimetry (n=2, Nix Pro 2). Eight studies (57.1%) used subjective assessment, including clinician-rated scales (n=3), expert panels (n=4), and patient-reported outcomes (n=1). Fitzpatrick skin type was reported in five studies (35.7%), and racial or ethnic distribution in three (21.4%). Among objective studies reporting ΔE color difference values, local and cervicofacial flaps consistently achieved the best color match (ΔE 4.7-5.9), radial forearm flaps demonstrated intermediate results (ΔE 3.2-7.7), and anterolateral thigh flaps the worst (ΔE 10.9-11.6; P = .001). Three consistent predictors of color match were identified: flap origin (local superior to distant), the split-thickness skin graft technique over de-epithelialized free flaps (ΔE 3.4 vs 6.5, P < .0001), and skin pigmentation with lighter-skinned patients experiencing significantly greater color discrepancy at distant donor sites (ALT ΔE 7.6 vs 5.3 for White vs non-White patients, P = 0.005). Color match improved significantly by six months. Only one study correlated objective and subjective methods (r = 0.61), and only one reported inter-rater reliability for subjective assessment (ICC = 0.818).",
        "Conclusions": "Assessment of postoperative skin color match in head and neck reconstruction remains methodologically heterogeneous, with most of the evidence limited to retrospective designs and unvalidated subjective scales. No study combines a high-level study design with validated objective colorimetry. Portable handheld colorimetry and standardized ΔE2000 reporting offer the most promising path toward reproducible, examiner-independent assessment. Prospective studies integrating objective measurement with patient-reported outcomes across diverse skin tones are needed to establish evidence-based standards for color match evaluation in head and neck reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Skin Color Match Assessment Following Head and Neck Flap Reconstruction: A Systematic Review</span>. <u>Shaynie Segal, BA</u><sup>1</sup>; Vicky Yau, DDS<sup>2</sup>; Carolyn Debiase, MD<sup>3</sup>; Richard V Smith, MD<sup>3</sup>. <sup>1</sup>Albert Einstein College of Medicine; <sup>2</sup>Division of Oral and Maxillofacial Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai; <sup>3</sup>Department of Otorhinolaryngology—Head and Neck Surgery, Montefiore Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Skin color mismatch between transferred tissue and native skin is a major aesthetic concern following head and neck reconstruction with externally visible flaps, and even technically successful reconstruction may appear visually discordant. Despite increasing interest in objective colorimetric assessment, no standardized approach for postoperative color match evaluation exists. This systematic review synthesizes evidence on color match evaluation methods, predictors of discrepancy, and methodological quality.</p>\n\n<p><strong>Materials and Methods: </strong>A systematic review was conducted following PRISMA 2020 guidelines and prospectively registered on PROSPERO (CRD420251114775). PubMed, Embase, and Web of Science were searched through December 2025 for studies reporting color match assessment between transferred flap tissue and recipient-site skin following head and neck reconstruction. Eligible studies included local, regional, or free flaps with externally visible skin and used a defined measurement method with quantitative outcomes. Studies were classified according to assessment methodology as objective (instrument-based colorimetry or digital photographic analysis with CIE L*a*b* color space and ΔE calculation) or subjective (clinician-rated scales, expert panels, or patient-reported outcomes). Study quality was rated using the JAMA Quality Rating Scheme. Data were synthesized narratively following SWiM guidelines due to methodological heterogeneity.</p>\n\n<p><strong>Results: </strong>Of 893 records identified, 14 studies met inclusion criteria, encompassing 790 patients published between 2007 and 2024 across nine countries. Three studies were rated quality level 2 (prospective comparative cohort), nine level 3 (retrospective cohort), and two level 4 (cross-sectional or case series); no study achieved level 1. Six studies (42.9%) used objective measurement methods, including digital photographic analysis (n=4) and handheld colorimetry (n=2, Nix Pro 2). Eight studies (57.1%) used subjective assessment, including clinician-rated scales (n=3), expert panels (n=4), and patient-reported outcomes (n=1). Fitzpatrick skin type was reported in five studies (35.7%), and racial or ethnic distribution in three (21.4%). Among objective studies reporting ΔE color difference values, local and cervicofacial flaps consistently achieved the best color match (ΔE 4.7-5.9), radial forearm flaps demonstrated intermediate results (ΔE 3.2-7.7), and anterolateral thigh flaps the worst (ΔE 10.9-11.6; P = .001). Three consistent predictors of color match were identified: flap origin (local superior to distant), the split-thickness skin graft technique over de-epithelialized free flaps (ΔE 3.4 vs 6.5, P < .0001), and skin pigmentation with lighter-skinned patients experiencing significantly greater color discrepancy at distant donor sites (ALT ΔE 7.6 vs 5.3 for White vs non-White patients, P = 0.005). Color match improved significantly by six months. Only one study correlated objective and subjective methods (r = 0.61), and only one reported inter-rater reliability for subjective assessment (ICC = 0.818).</p>\n\n<p><strong>Conclusions: </strong>Assessment of postoperative skin color match in head and neck reconstruction remains methodologically heterogeneous, with most of the evidence limited to retrospective designs and unvalidated subjective scales. No study combines a high-level study design with validated objective colorimetry. Portable handheld colorimetry and standardized ΔE2000 reporting offer the most promising path toward reproducible, examiner-independent assessment. Prospective studies integrating objective measurement with patient-reported outcomes across diverse skin tones are needed to establish evidence-based standards for color match evaluation in head and neck reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155498--></body></html>"
    },
    {
      "uid": "P376",
      "content_id": "154610",
      "abstract_number": "P376",
      "poster_number": "P376",
      "title": "Postoperative Outcomes in Patients 80 Years and Older Undergoing Head and Neck Free Flap Reconstruction: A 10-Year Single-Institution Cohort",
      "summary": "Ninety-six patients ≥80 years and 573 <80 years were analyzed after exclusion and matching. Rates of OR return were comparable between age groups (27.08% vs 27.05%, p = 1.00), and 30-day readmission similarly showed no significant difference (8.33% vs 12.74%, p = 0.309). Thirty-day mortality did not differ significantly between groups (2.08% vs 0.35%, p = 0.101). Hospital length of stay was comparable between...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154610",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Andrew Lee, MD",
      "presenter": "Andrew Lee, MD",
      "authors": "Alexandra Vacaru, BS 1 ; Roy W Qu, MD 2 ; Andrew Lee, MD 2 ; Jared C Inman, MD 2",
      "normalized_authors": [
        "Alexandra Vacaru",
        "Roy W Qu",
        "Andrew Lee",
        "Jared C Inman"
      ],
      "affiliations": [
        "Loma Linda University School of Medicine",
        "Loma Linda University Health, Department of Otolaryngology–Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "Loma Linda University School of Medicine",
        "Loma Linda University Health, Department of Otolaryngology–Head and Neck Surgery"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 286,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Alexandra Vacaru, BS 1 ; Roy W Qu, MD 2 ; Andrew Lee, MD 2 ; Jared C Inman, MD 2",
        "Affiliations": "1 Loma Linda University School of Medicine; 2 Loma Linda University Health, Department of Otolaryngology–Head and Neck Surgery",
        "Introduction": "Head and neck free flap surgery is a critical reconstructive modality after cancer resection, yet advanced age is often perceived as a negative prognosticator of outcomes, which makes some decision participants hesitant to recommend surgery. This perception, in part, skews outcome data for patients aged ≥80 years as it remains limited. This study evaluates OR return, 30-day readmission, 30-day mortality, and hospital length of stay in this population at a single tertiary care institution.",
        "Methods": "A single-center retrospective review was performed on patients who underwent head and neck free flap reconstruction for T3/T4 non-cutaneous originating squamous cell cancer surgery between 2014 and 2024. Patients were stratified by age (≥80 years vs <80 years). Postoperative outcomes included OR return, 30-day readmission, 30-day mortality, and hospital length of stay.",
        "Results": "Ninety-six patients ≥80 years and 573 <80 years were analyzed after exclusion and matching. Rates of OR return were comparable between age groups (27.08% vs 27.05%, p = 1.00), and 30-day readmission similarly showed no significant difference (8.33% vs 12.74%, p = 0.309). Thirty-day mortality did not differ significantly between groups (2.08% vs 0.35%, p = 0.101). Hospital length of stay was comparable between groups, with a mean stay of 10.9 ± 5.4 days in patients <80 years and 9.4 ± 5.0 days in patients ≥80 years (p = 0.458).",
        "Discussion": "Advanced age (≥80 years) was not associated with differences in OR return, 30-day readmission, 30-day mortality, or hospital length of stay, indicating that chronological age alone is not a determinant of early postoperative complications. These findings highlight the importance of individualized risk stratification and preoperative planning for older patients undergoing head and neck free flap surgery in this growing patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Postoperative Outcomes in Patients 80 Years and Older Undergoing Head and Neck Free Flap Reconstruction: A 10-Year Single-Institution Cohort</span>. Alexandra Vacaru, BS<sup>1</sup>; Roy W Qu, MD<sup>2</sup>; <u>Andrew Lee, MD</u><sup>2</sup>; Jared C Inman, MD<sup>2</sup>. <sup>1</sup>Loma Linda University School of Medicine; <sup>2</sup>Loma Linda University Health, Department of Otolaryngology–Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck free flap surgery is a critical reconstructive modality after cancer resection, yet advanced age is often perceived as a negative prognosticator of outcomes, which makes some decision participants hesitant to recommend surgery.  This perception, in part, skews outcome data for patients aged ≥80 years as it remains limited. This study evaluates OR return, 30-day readmission, 30-day mortality, and hospital length of stay in this population at a single tertiary care institution.</p>\n\n<p><strong>Methods: </strong>A single-center retrospective review was performed on patients who underwent head and neck free flap reconstruction for T3/T4 non-cutaneous originating squamous cell cancer surgery between 2014 and 2024. Patients were stratified by age (≥80 years vs <80 years). Postoperative outcomes included OR return, 30-day readmission, 30-day mortality, and hospital length of stay. </p>\n\n<p><strong>Results: </strong>Ninety-six patients ≥80 years and 573 <80 years were analyzed after exclusion and matching. Rates of OR return were comparable between age groups (27.08% vs 27.05%, p = 1.00), and 30-day readmission similarly showed no significant difference (8.33% vs 12.74%, p = 0.309). Thirty-day mortality did not differ significantly between groups (2.08% vs 0.35%, p = 0.101). Hospital length of stay was comparable between groups, with a mean stay of 10.9 ± 5.4 days in patients <80 years and 9.4 ± 5.0 days in patients ≥80 years (p = 0.458). </p>\n\n<p><strong>Discussion: </strong>Advanced age (≥80 years) was not associated with differences in OR return, 30-day readmission, 30-day mortality, or hospital length of stay, indicating that chronological age alone is not a determinant of early postoperative complications. These findings highlight the importance of individualized risk stratification and preoperative planning for older patients undergoing head and neck free flap surgery in this growing patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154610--></body></html>"
    },
    {
      "uid": "P377",
      "content_id": "155454",
      "abstract_number": "P377",
      "poster_number": "P377",
      "title": "Free Jejunal and Ileal Flaps for Pharyngoesophageal Reconstruction: a case series",
      "summary": "Free jejunal and ileal flaps represent a safe and effective option for circumferential pharyngoesophageal defect reconstruction, allowing satisfactory functional restoration with acceptable morbidity in carefully selected patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155454",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Juan Sebastian Valencia Fajardo",
      "presenter": "Juan Sebastian Valencia Fajardo",
      "authors": "Damian Quiroz; Luisa Pineda; Luis Fernando Tintinago; Juan Sebastian Valencia Fajardo ; Andres Gempeler",
      "normalized_authors": [
        "Damian Quiroz",
        "Luisa Pineda",
        "Luis Fernando Tintinago",
        "Juan Sebastian Valencia Fajardo",
        "Andres Gempeler"
      ],
      "affiliations": [
        "Fundación Valle del Lili"
      ],
      "normalized_institutions": [
        "Fundación Valle del Lili"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 231,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Damian Quiroz; Luisa Pineda; Luis Fernando Tintinago; Juan Sebastian Valencia Fajardo ; Andres Gempeler",
        "Affiliations": "Fundación Valle del Lili",
        "Background": "Pharyngoesophageal reconstruction after total laryngopharyngectomy represents a major surgical challenge, particularly in patients with a history of cervical surgery and radiotherapy. This study describes the experience of a high-complexity center in Colombia using free microvascular jejunal and ileal flaps, a technique that provides anatomical and functional advantages for restoration of the upper digestive tract.",
        "Methods": "Retrospective case series that included patients older than 18 years, that required reconstruction with a free microvascular jejunal/ileal flap after laryngopharyngectomy, between 2014 and 2024 in a tertiary care university hospital. We did not apply exclusion criteria. Summary statistics were used to describe variables.",
        "Results": "Patients undergoing total laryngopharyngectomy for advanced malignancies, mainly laryngeal and thyroid cancer (n=21), were included. Most had prior neck surgery (57.1%), previous radiotherapy (47.6%), and moderate functional impairment. Early complications included fistulas (19%) and surgical site infections (9.5%). Late complications were mainly stenosis (17%) and swallowing dysfunction (25%).",
        "Abstract": "All patients required reconstruction with a free jejunal or ileal flap. No flap losses or reoperations due to reconstructive failure occurred. Most patients achieved exclusive oral intake recovery (85%) and maintained adequate functional status at 180 days (ECOG 1–2: 75%). Complication rates were comparable or lower than those reported in the literature.",
        "Conclusion": "Free jejunal and ileal flaps represent a safe and effective option for circumferential pharyngoesophageal defect reconstruction, allowing satisfactory functional restoration with acceptable morbidity in carefully selected patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Jejunal and Ileal Flaps for Pharyngoesophageal Reconstruction: a case series</span>. Damian Quiroz; Luisa Pineda; Luis Fernando Tintinago; <u>Juan Sebastian Valencia Fajardo</u>; Andres Gempeler. Fundación Valle del Lili<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pharyngoesophageal reconstruction after total laryngopharyngectomy represents a major surgical challenge, particularly in patients with a history of cervical surgery and radiotherapy. This study describes the experience of a high-complexity center in Colombia using free microvascular jejunal and ileal flaps, a technique that provides anatomical and functional advantages for restoration of the upper digestive tract.</p>\n\n<p><strong>Methods:</strong> Retrospective case series that included patients older than 18 years, that required reconstruction with a free microvascular jejunal/ileal flap after laryngopharyngectomy, between 2014 and 2024 in a tertiary care university hospital. We did not apply exclusion criteria.  Summary statistics were used to describe variables. </p>\n\n<p><strong>Results: </strong>Patients undergoing total laryngopharyngectomy for advanced malignancies, mainly laryngeal and thyroid cancer (n=21), were included. Most had prior neck surgery (57.1%), previous radiotherapy (47.6%), and moderate functional impairment. Early complications included fistulas (19%) and surgical site infections (9.5%). Late complications were mainly stenosis (17%) and swallowing dysfunction (25%). </p>\n\n<p>All patients required reconstruction with a free jejunal or ileal flap. No flap losses or reoperations due to reconstructive failure occurred. Most patients achieved exclusive oral intake recovery (85%) and maintained adequate functional status at 180 days (ECOG 1–2: 75%). Complication rates were comparable or lower than those reported in the literature.</p>\n\n<p><strong>Conclusion: </strong>Free jejunal and ileal flaps represent a safe and effective option for circumferential pharyngoesophageal defect reconstruction, allowing satisfactory functional restoration with acceptable morbidity in carefully selected patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155454--></body></html>"
    },
    {
      "uid": "P378",
      "content_id": "153151",
      "abstract_number": "P378",
      "poster_number": "P378",
      "title": "Free Flap Management in Patients with Uncontrolled Psoriasis: Insights from a Case Series",
      "summary": "Here, we present three patients with inadequately controlled psoriasis who underwent successful free tissue transfer with no adverse surgical site or free flap outcomes, suggesting the inflammatory state due to psoriasis is not a contraindication to proceeding with this surgery. This does highlight the need for careful peri-operative management and patient counseling, as well as multi-disciplinary care including...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153151",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madelyn N Stevens, MD",
      "presenter": "Madelyn N Stevens, MD",
      "authors": "Sarah G Yu, MD; Sarah E Ridge; Claire Gleadhill, MD; Bethany Rohr, MD; Madelyn N Stevens, MD",
      "normalized_authors": [
        "Sarah G Yu",
        "Sarah E Ridge",
        "Claire Gleadhill",
        "Bethany Rohr",
        "Madelyn N Stevens"
      ],
      "affiliations": [
        "University Hospitals"
      ],
      "normalized_institutions": [
        "University Hospitals"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_1.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153151"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_2.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_2.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153151"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153151/1764846477981-058b113e-291b-4434-8777-813a7d0fbdbd_3.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153151/1764846477981-058b113e-291b-4434-8777-813a7d0fbdbd_3.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153151"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 398,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sarah G Yu, MD; Sarah E Ridge; Claire Gleadhill, MD; Bethany Rohr, MD; Madelyn N Stevens, MD",
        "Affiliations": "University Hospitals",
        "Background": "Psoriasis is a dermatologic disorder characterized by a chronic inflammatory state and has been associated with post-surgical complications, including increased risk of infection, delayed wound healing, and the potential development of new psoriatic lesions at surgical sites (Koebner phenomenon). Free tissue transfer, often utilizing a skin paddle from the donor site, is the mainstay of complex head and neck reconstruction. While there has been some data suggesting avoiding free tissue transfer in patients with active psoriasis due to concerns for cutaneous compromise and a heightened inflammatory state, there is a paucity of literature addressing the impact of uncontrolled psoriasis on reconstruction in this population.",
        "Methods": "This is a retrospective review, at a single institution, of head and neck cancer patients with psoriasis who underwent surgical resection for malignancy and free tissue transfer for reconstruction. Chart review was performed for relevant demographics, psoriasis history and treatment, cancer history and treatment, and surgical details. Institutional Review Board exemption was obtained.",
        "Results": "Three consecutive patients with a history of uncontrolled psoriasis undergoing free flap reconstruction with a skin paddle were included. All underwent oral cavity resection for squamous cell carcinoma, reconstructed with anterolateral thigh (n=1), fibula free flap with skin paddle (n=2) and pectoralis flap (n=1). No patients were receiving treatment for psoriasis at the time of surgery, and two patients were having an active psoriasis flare (Subject 1 and 3). Dermatology was consulted while inpatient, and treatment with high-dose steroids to the affected sites was initiated for all three patients. One patient started Spesolimab infusions after being discharged from the hospital (Subject 3) with complete resolution of symptoms. Another patient experienced psoriasis symptoms at their surgical donor sites (lower leg and chest) approximately 4-6 weeks post-operatively; he was treated with topical steroids and dermatology referral (patient declined due to improvement with steroids alone) (Subject 2). No wound breakdown, infection, or free flap compromise was experienced by any patient, as well as no unexpected 30 day readmission or return to the operating room.",
        "Conclusions": "Here, we present three patients with inadequately controlled psoriasis who underwent successful free tissue transfer with no adverse surgical site or free flap outcomes, suggesting the inflammatory state due to psoriasis is not a contraindication to proceeding with this surgery. This does highlight the need for careful peri-operative management and patient counseling, as well as multi-disciplinary care including involvement of dermatology colleagues for acute and long-term management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Flap Management in Patients with Uncontrolled Psoriasis: Insights from a Case Series</span>. Sarah G Yu, MD; Sarah E Ridge; Claire Gleadhill, MD; Bethany Rohr, MD; <u>Madelyn N Stevens, MD</u>. University Hospitals<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_1.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153151/1764846152888-0a6bfc1c-4dd0-4795-b75f-fd9bc00f6291_2.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153151/1764846477981-058b113e-291b-4434-8777-813a7d0fbdbd_3.jpg' /></p>\n\n<p><strong>Background: </strong>Psoriasis is a dermatologic disorder characterized by a chronic inflammatory state and has been associated with post-surgical complications, including increased risk of infection, delayed wound healing, and the potential development of new psoriatic lesions at surgical sites (Koebner phenomenon). Free tissue transfer, often utilizing a skin paddle from the donor site, is the mainstay of complex head and neck reconstruction. While there has been some data suggesting avoiding free tissue transfer in patients with active psoriasis due to concerns for cutaneous compromise and a heightened inflammatory state, there is a paucity of literature addressing the impact of uncontrolled psoriasis on reconstruction in this population.</p>\n\n<p><strong>Methods:</strong> This is a retrospective review, at a single institution, of head and neck cancer patients with psoriasis who underwent surgical resection for malignancy and free tissue transfer for reconstruction. Chart review was performed for relevant demographics, psoriasis history and treatment, cancer history and treatment, and surgical details. Institutional Review Board exemption was obtained.</p>\n\n<p><strong>Results: </strong>Three consecutive patients with a history of uncontrolled psoriasis undergoing free flap reconstruction with a skin paddle were included. All underwent oral cavity resection for squamous cell carcinoma, reconstructed with anterolateral thigh (n=1), fibula free flap with skin paddle (n=2) and pectoralis flap (n=1). No patients were receiving treatment for psoriasis at the time of surgery, and two patients were having an active psoriasis flare (Subject 1 and 3). Dermatology was consulted while inpatient, and treatment with high-dose steroids to the affected sites was initiated for all three patients. One patient started Spesolimab infusions after being discharged from the hospital (Subject 3) with complete resolution of symptoms. Another patient experienced psoriasis symptoms at their surgical donor sites (lower leg and chest) approximately 4-6 weeks post-operatively; he was treated with topical steroids and dermatology referral (patient declined due to improvement with steroids alone) (Subject 2). No wound breakdown, infection, or free flap compromise was experienced by any patient, as well as no unexpected 30 day readmission or return to the operating room.</p>\n\n<p><strong>Conclusions: </strong>Here, we present three patients with inadequately controlled psoriasis who underwent successful free tissue transfer with no adverse surgical site or free flap outcomes, suggesting the inflammatory state due to psoriasis is not a contraindication to proceeding with this surgery. This does highlight the need for careful peri-operative management and patient counseling, as well as multi-disciplinary care including involvement of dermatology colleagues for acute and long-term management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153151--></body></html>"
    },
    {
      "uid": "P379",
      "content_id": "155568",
      "abstract_number": "P379",
      "poster_number": "P379",
      "title": "Simulation-Based Bench Study of Motion Parallax and Early Performance with a 3D Exoscope Versus Optical Microscope in Microvascular Tasks",
      "summary": "This controlled bench study is designed to provide mechanistic evidence regarding the early exoscope learning curve. If Orbeye-dither improves objective performance and/or perceived depth compared with Orbeye-static, the findings would support targeted setup and training strategies to accelerate safe adoption of 3D exoscope visualization in microsurgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155568",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex V Vaicius, MD",
      "presenter": "Alex V Vaicius, MD",
      "authors": "Alex V Vaicius, MD ; Ryan P McSpadden, MD",
      "normalized_authors": [
        "Alex V Vaicius",
        "Ryan P McSpadden"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 287,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex V Vaicius, MD ; Ryan P McSpadden, MD",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Background": "Digital 3D exoscopes provide ergonomic and team-visualization advantages, yet early adoption has been associated with a performance “learning curve” compared with optical microscopes. One proposed mechanism is reduced depth cues from diminished motion parallax and limited accommodation under camera-based visualization.",
        "Objective": "To quantify microvascular task performance under an optical microscope (OM) versus a 3D exoscope (Orbeye), and to test the hypothesis that reintroducing motion parallax during exoscope use improves early performance compared with standard (static) exoscope visualization.",
        "Methods": "Single-institution, within-subject randomized crossover bench study enrolling ~16–20 surgical participants (attendings, fellows, and senior residents). Each participant completes a standardized end-to-end microvascular anastomosis on a non-living vessel model under three visualization conditions: (1) OM (control), (2) static 3D exoscope visualization (fixed camera), and (3) exoscope-dither (controlled micro-pan/tilt oscillation designed to reintroduce motion parallax through low-amplitude, periodic camera motion). Primary outcomes are task time, video-derived motion and precision metrics (e.g., bite placement/spacing error, needle angle error, instrument path length/inefficiency, tremor), and functional performance via post-procedure leak testing (leak onset pressure/rate, patency). Secondary outcomes are perceived depth, visual fatigue/simulator sickness, and ergonomics. Test results are compared using mixed-effects models with participant random effects and adjustment for order effects; the primary mechanistic contrast is exoscope-dither versus static 3D exoscope visualization.",
        "Results": "Enrollment and data collection are underway. The planned analysis will test whether Orbeye-static differs from OM across accuracy, efficiency, and leak metrics, and whether Orbeye-dither improves performance relative to Orbeye-static.",
        "Conclusion": "This controlled bench study is designed to provide mechanistic evidence regarding the early exoscope learning curve. If Orbeye-dither improves objective performance and/or perceived depth compared with Orbeye-static, the findings would support targeted setup and training strategies to accelerate safe adoption of 3D exoscope visualization in microsurgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Simulation-Based Bench Study of Motion Parallax and Early Performance with a 3D Exoscope Versus Optical Microscope in Microvascular Tasks</span>. <u>Alex V Vaicius, MD</u>; Ryan P McSpadden, MD. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Digital 3D exoscopes provide ergonomic and team-visualization advantages, yet early adoption has been associated with a performance “learning curve” compared with optical microscopes. One proposed mechanism is reduced depth cues from diminished motion parallax and limited accommodation under camera-based visualization.</p>\n\n<p><strong>Objective:</strong> To quantify microvascular task performance under an optical microscope (OM) versus a 3D exoscope (Orbeye), and to test the hypothesis that reintroducing motion parallax during exoscope use improves early performance compared with standard (static) exoscope visualization.</p>\n\n<p><strong>Methods: </strong>Single-institution, within-subject randomized crossover bench study enrolling ~16–20 surgical participants (attendings, fellows, and senior residents). Each participant completes a standardized end-to-end microvascular anastomosis on a non-living vessel model under three visualization conditions: (1) OM (control), (2) static 3D exoscope visualization (fixed camera), and (3) exoscope-dither (controlled micro-pan/tilt oscillation designed to reintroduce motion parallax through low-amplitude, periodic camera motion). Primary outcomes are task time, video-derived motion and precision metrics (e.g., bite placement/spacing error, needle angle error, instrument path length/inefficiency, tremor), and functional performance via post-procedure leak testing (leak onset pressure/rate, patency). Secondary outcomes are perceived depth, visual fatigue/simulator sickness, and ergonomics. Test results are compared using mixed-effects models with participant random effects and adjustment for order effects; the primary mechanistic contrast is exoscope-dither versus static 3D exoscope visualization.</p>\n\n<p><strong>Results:</strong> Enrollment and data collection are underway. The planned analysis will test whether Orbeye-static differs from OM across accuracy, efficiency, and leak metrics, and whether Orbeye-dither improves performance relative to Orbeye-static.</p>\n\n<p><strong>Conclusion: </strong>This controlled bench study is designed to provide mechanistic evidence regarding the early exoscope learning curve. If Orbeye-dither improves objective performance and/or perceived depth compared with Orbeye-static, the findings would support targeted setup and training strategies to accelerate safe adoption of 3D exoscope visualization in microsurgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155568--></body></html>"
    },
    {
      "uid": "P380",
      "content_id": "155583",
      "abstract_number": "P380",
      "poster_number": "P380",
      "title": "Immediate Implant Placement During Index Mandibular Reconstruction: Impact on Dental Rehabilitation Completion and Oncologic Treatment Timelines",
      "summary": "Immediate implant placement at index mandibular reconstruction increases functional dental rehabilitation by 12–24 months and shortens time to a functioning prosthesis, improving patient-centered oral function and quality of life after treatment. Pre-adjuvant (pre-radiation and/or chemotherapy) implant placement improves rehabilitation efficiency and implant-related outcomes, without delaying initiation of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155583",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex V Vaicius, MD",
      "presenter": "Alex V Vaicius, MD",
      "authors": "Alex V Vaicius, MD 1 ; Michael Markiewicz, MD, DDS 2 ; Can Ozturk, MD 1 ; Vladimir Frias, DDS 1 ; Matthew M Hanasono, MD, FACS 3 ; Wesley L Hicks, Jr, MD 1 ; Vishal Gupta, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1",
      "normalized_authors": [
        "Alex V Vaicius",
        "Michael Markiewicz",
        "Can Ozturk",
        "Vladimir Frias",
        "Matthew M Hanasono",
        "Wesley L Hicks, Jr",
        "Vishal Gupta",
        "Kimberly E Wooten",
        "Ryan P McSpadden"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "The University of Texas MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "The University of Texas MD Anderson Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 225,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex V Vaicius, MD 1 ; Michael Markiewicz, MD, DDS 2 ; Can Ozturk, MD 1 ; Vladimir Frias, DDS 1 ; Matthew M Hanasono, MD, FACS 3 ; Wesley L Hicks, Jr, MD 1 ; Vishal Gupta, MD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo Jacobs School of Medicine and Biomedical Sciences; 3 The University of Texas MD Anderson Cancer Center",
        "Background": "Dental rehabilitation after oncologic mandibular reconstruction is frequently delayed and inconsistently achieved, particularly when adjuvant radiotherapy is required and implant-to-prosthesis pathways are not integrated. Immediate implant placement at index reconstruction may improve rehabilitation completion and shorten time to functional dentition while preserving oncologic treatment timelines and flap safety.",
        "Methods": "Multi-institutional retrospective cohort study of oncologic mandibular reconstruction with osseous free flaps. Primary outcomes are (1) functional dental rehabilitation achieved by 12–24 months and (2) time from index surgery to delivery of a functioning prosthesis. Secondary outcomes include time to initiation of adjuvant radiotherapy, flap complications (takeback, partial/total loss, major wound complications, plate exposure/infection), implant survival, and osteoradionecrosis or major bony complications when definable. Comparison groups include immediate implants at index reconstruction versus no immediate implants; a delayed-implant arm will be included where data permit.",
        "Results": "We identified 24 eligible cases over 4 years comprising ~90 implants, with 33% receiving immediate implants at index reconstruction and 67% undergoing delayed implant placement. Similar non-radiotherapy free-flap cases are available for exploratory analyses.",
        "Conclusion": "Immediate implant placement at index mandibular reconstruction increases functional dental rehabilitation by 12–24 months and shortens time to a functioning prosthesis, improving patient-centered oral function and quality of life after treatment. Pre-adjuvant (pre-radiation and/or chemotherapy) implant placement improves rehabilitation efficiency and implant-related outcomes, without delaying initiation of adjuvant radiotherapy or increasing flap complications."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immediate Implant Placement During Index Mandibular Reconstruction: Impact on Dental Rehabilitation Completion and Oncologic Treatment Timelines</span>. <u>Alex V Vaicius, MD</u><sup>1</sup>; Michael Markiewicz, MD, DDS<sup>2</sup>; Can Ozturk, MD<sup>1</sup>; Vladimir Frias, DDS<sup>1</sup>; Matthew M Hanasono, MD, FACS<sup>3</sup>; Wesley L Hicks, Jr, MD<sup>1</sup>; Vishal Gupta, MD<sup>1</sup>; Kimberly E Wooten, MD<sup>1</sup>; Ryan P McSpadden, MD<sup>1</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences; <sup>3</sup>The University of Texas MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Dental rehabilitation after oncologic mandibular reconstruction is frequently delayed and inconsistently achieved, particularly when adjuvant radiotherapy is required and implant-to-prosthesis pathways are not integrated. Immediate implant placement at index reconstruction may improve rehabilitation completion and shorten time to functional dentition while preserving oncologic treatment timelines and flap safety.</p>\n\n<p><strong>Methods: </strong>Multi-institutional retrospective cohort study of oncologic mandibular reconstruction with osseous free flaps. Primary outcomes are (1) functional dental rehabilitation achieved by 12–24 months and (2) time from index surgery to delivery of a functioning prosthesis. Secondary outcomes include time to initiation of adjuvant radiotherapy, flap complications (takeback, partial/total loss, major wound complications, plate exposure/infection), implant survival, and osteoradionecrosis or major bony complications when definable. Comparison groups include immediate implants at index reconstruction versus no immediate implants; a delayed-implant arm will be included where data permit.</p>\n\n<p><strong>Results: </strong>We identified 24 eligible cases over 4 years comprising ~90 implants, with 33% receiving immediate implants at index reconstruction and 67% undergoing delayed implant placement. Similar non-radiotherapy free-flap cases are available for exploratory analyses. </p>\n\n<p><strong>Conclusion:</strong> Immediate implant placement at index mandibular reconstruction increases functional dental rehabilitation by 12–24 months and shortens time to a functioning prosthesis, improving patient-centered oral function and quality of life after treatment. Pre-adjuvant (pre-radiation and/or chemotherapy) implant placement improves rehabilitation efficiency and implant-related outcomes, without delaying initiation of adjuvant radiotherapy or increasing flap complications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155583--></body></html>"
    },
    {
      "uid": "P381",
      "content_id": "155579",
      "abstract_number": "P381",
      "poster_number": "P381",
      "title": "3D Exoscope–Assisted Microvascular Anastomosis in Head and Neck Free Flap Reconstruction: A Single-Institution Feasibility Series",
      "summary": "3D exoscope visualization supported completion of head and neck free flap microvascular anastomoses without exoscope-attributed adverse events or need for anastomotic revision, with acceptable ischemia times and expected reconstructive complications. Ongoing accrual through 2018-2025 is underway to increase sample size and enable more robust evaluation, including objective and subjective measures of ergonomics...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155579",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex V Vaicius, MD",
      "presenter": "Alex V Vaicius, MD",
      "authors": "Alex V Vaicius, MD ; Hassan Arshad, MD; Tony Richa, MD; Ryan P McSpadden, MD",
      "normalized_authors": [
        "Alex V Vaicius",
        "Hassan Arshad",
        "Tony Richa",
        "Ryan P McSpadden"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 301,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alex V Vaicius, MD ; Hassan Arshad, MD; Tony Richa, MD; Ryan P McSpadden, MD",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Background": "Digital 3D exoscopes offer potential ergonomic and educational advantages over conventional operating microscopes for microsurgery, but feasibility and early outcomes during microvascular anastomosis in head and neck free flap reconstruction remain incompletely characterized.",
        "Objective": "To assess feasibility, defined as completion of microvascular anastomosis under 3D exoscope visualization without conversion or anastomotic revision, and early perioperative outcomes of performing arterial and venous microvascular anastomoses using a 4K 3D exoscope platform during head and neck free flap reconstruction.",
        "Methods": "Retrospective review of adult patients undergoing head and neck free tissue transfer in whom microvascular arterial and venous anastomoses were performed using a 4K 3D exoscope for visualization. Data collected included demographics, flap type, ischemia time, exoscope-related intraoperative events, takeback for flap compromise, and flap outcomes.",
        "Results": "Thirteen consecutive free flap reconstructions were completed with the 3D exoscope used exclusively for microvascular anastomoses. Mean ischemia time was 138 minutes (range 60-180), and average docking time was <5 minutes. No adverse perioperative events were attributed to exoscope use, and no microvascular anastomosis revisions were required. Three patients returned to the operating room: two for partial flap loss requiring debridement and one for late flap failure requiring debridement and regional flap reconstruction. Reported advantages included improved degrees of freedom for visualization and improved surgeon-assistant ergonomics; noted limitations included monitor line-of-sight constraints in smaller rooms and a learning curve related to fixed depth of field and parallax. Accrual is ongoing and the series is being expanded to include cases from 2018-2025, inclusive, to increase sample size.",
        "Conclusions": "3D exoscope visualization supported completion of head and neck free flap microvascular anastomoses without exoscope-attributed adverse events or need for anastomotic revision, with acceptable ischemia times and expected reconstructive complications. Ongoing accrual through 2018-2025 is underway to increase sample size and enable more robust evaluation, including objective and subjective measures of ergonomics and workflow."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>3D Exoscope–Assisted Microvascular Anastomosis in Head and Neck Free Flap Reconstruction: A Single-Institution Feasibility Series</span>. <u>Alex V Vaicius, MD</u>; Hassan Arshad, MD; Tony Richa, MD; Ryan P McSpadden, MD. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Digital 3D exoscopes offer potential ergonomic and educational advantages over conventional operating microscopes for microsurgery, but feasibility and early outcomes during microvascular anastomosis in head and neck free flap reconstruction remain incompletely characterized.</p>\n\n<p><strong>Objective:</strong> To assess feasibility, defined as completion of microvascular anastomosis under 3D exoscope visualization without conversion or anastomotic revision, and early perioperative outcomes of performing arterial and venous microvascular anastomoses using a 4K 3D exoscope platform during head and neck free flap reconstruction.</p>\n\n<p><strong>Methods:</strong> Retrospective review of adult patients undergoing head and neck free tissue transfer in whom microvascular arterial and venous anastomoses were performed using a 4K 3D exoscope for visualization. Data collected included demographics, flap type, ischemia time, exoscope-related intraoperative events, takeback for flap compromise, and flap outcomes.</p>\n\n<p><strong>Results:</strong> Thirteen consecutive free flap reconstructions were completed with the 3D exoscope used exclusively for microvascular anastomoses. Mean ischemia time was 138 minutes (range 60-180), and average docking time was <5 minutes. No adverse perioperative events were attributed to exoscope use, and no microvascular anastomosis revisions were required. Three patients returned to the operating room: two for partial flap loss requiring debridement and one for late flap failure requiring debridement and regional flap reconstruction. Reported advantages included improved degrees of freedom for visualization and improved surgeon-assistant ergonomics; noted limitations included monitor line-of-sight constraints in smaller rooms and a learning curve related to fixed depth of field and parallax. Accrual is ongoing and the series is being expanded to include cases from 2018-2025, inclusive, to increase sample size.</p>\n\n<p><strong>Conclusions:</strong> 3D exoscope visualization supported completion of head and neck free flap microvascular anastomoses without exoscope-attributed adverse events or need for anastomotic revision, with acceptable ischemia times and expected reconstructive complications. Ongoing accrual through 2018-2025 is underway to increase sample size and enable more robust evaluation, including objective and subjective measures of ergonomics and workflow.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155579--></body></html>"
    },
    {
      "uid": "P382",
      "content_id": "153599",
      "abstract_number": "P382",
      "poster_number": "P382",
      "title": "Use of Restrata Synthetic Matrix for Oral Cavity Defect Repair: A Case Series and Review of Early Clinical Outcomes",
      "summary": "Restrata appears to be a safe and effective option for oral cavity defect repair after resection of early oral cavity cancer. The synthetic matrix facilitates rapid mucosalization in 2-4 weeks across a variety of defect sizes and oral cavity subsites without donor-site morbidity. Minor complications included transient mandibular bone exposure and post-op bleeding requiring holding blood-thinners. Individualized...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153599",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Megan S Wu, MD",
      "presenter": "Megan S Wu, MD",
      "authors": "Megan S Wu, MD 1 ; Sameer Alvi, MD 2 ; Hassan Arshad, MD 1",
      "normalized_authors": [
        "Megan S Wu",
        "Sameer Alvi",
        "Hassan Arshad"
      ],
      "affiliations": [
        "University of Chicago Medical Center",
        "Endeavor Health Medical Group"
      ],
      "normalized_institutions": [
        "University of Chicago Medical Center",
        "Endeavor Health Medical Group"
      ],
      "session_type": "Poster",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 378,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Megan S Wu, MD 1 ; Sameer Alvi, MD 2 ; Hassan Arshad, MD 1",
        "Affiliations": "1 University of Chicago Medical Center; 2 Endeavor Health Medical Group",
        "Background": "Reconstruction of oral cavity defects after tumor ablation poses unique challenges due to the region’s complex anatomy, constant mechanical stress from speech and mastication, and patient co-morbidities which impair wound healing. Traditional methods, including autologous grafts and local flaps, can be associated with donor-site morbidity and prolonged recovery. Restrata, a fully synthetic resorbable matrix designed to promote vascularized tissue regeneration, offers a potential alternative for oral cavity reconstruction. We aim to characterize post-operative outcomes in patients undergoing reconstruction with Restrata after ablation of dysplastic and early malignant oral cavity lesions.",
        "Methods": "This case series includes 9 patients who underwent oral cavity defect repair using Restrata following ablation between January and October 2025. Defect locations include the tongue, buccal mucosa, mandibular gingiva, hard palate, and floor of mouth. Restrata was applied as a standalone graft in all cases. Demographic variables, comorbidities (tobacco use, anticoagulant use, diabetes), indication for surgery, defect size, anatomic location, healing time, and postoperative complications were recorded. Healing time was defined as complete mucosalization on clinical exam.",
        "Results": "Patient ages ranged from 45 to 83 years old. Indications included invasive squamous cell carcinoma (50%), in situ carcinoma or dysplasia (40%), and adenoid cystic carcinoma (10%). Defect sizes ranged from 2x2 cm to 5x5cm. Tongue defects demonstrate the fastest healing time (2-3 weeks), followed by buccal mucosa, palate, mandibular gingiva, and floor of mouth which all healed around 4 weeks. Patients progressed from a soft diet for 2 weeks post-operatively to a regular diet by 4 weeks. Two patients experienced mild bleeding in the immediate post-operative period requiring temporary cessation of anticoagulation therapy, and two patients experienced transient exposed mandibular bone that resolved with conservative management. There were no infections, readmissions, or major wound breakdowns.",
        "Conclusions": "Restrata appears to be a safe and effective option for oral cavity defect repair after resection of early oral cavity cancer. The synthetic matrix facilitates rapid mucosalization in 2-4 weeks across a variety of defect sizes and oral cavity subsites without donor-site morbidity. Minor complications included transient mandibular bone exposure and post-op bleeding requiring holding blood-thinners. Individualized perioperative anticoagulation management may help reduce the incidence of minor bleeding events in anticoagulated patients. Future studies with larger cohorts, longer follow-up, and comparative analysis against traditional reconstruction methods are warranted to further define long-term outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Restrata Synthetic Matrix for Oral Cavity Defect Repair: A Case Series and Review of Early Clinical Outcomes</span>. <u>Megan S Wu, MD</u><sup>1</sup>; Sameer Alvi, MD<sup>2</sup>; Hassan Arshad, MD<sup>1</sup>. <sup>1</sup>University of Chicago Medical Center; <sup>2</sup>Endeavor Health Medical Group<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Reconstruction of oral cavity defects after tumor ablation poses unique challenges due to the region’s complex anatomy, constant mechanical stress from speech and mastication, and patient co-morbidities which impair wound healing. Traditional methods, including autologous grafts and local flaps, can be associated with donor-site morbidity and prolonged recovery. Restrata, a fully synthetic resorbable matrix designed to promote vascularized tissue regeneration, offers a potential alternative for oral cavity reconstruction. We aim to characterize post-operative outcomes in patients undergoing reconstruction with Restrata after ablation of dysplastic and early malignant oral cavity lesions.</p>\n\n<p><strong>Methods:</strong> This case series includes 9 patients who underwent oral cavity defect repair using Restrata following ablation between January and October 2025. Defect locations include the tongue, buccal mucosa, mandibular gingiva, hard palate, and floor of mouth. Restrata was applied as a standalone graft in all cases. Demographic variables, comorbidities (tobacco use, anticoagulant use, diabetes), indication for surgery, defect size, anatomic location, healing time, and postoperative complications were recorded. Healing time was defined as complete mucosalization on clinical exam.</p>\n\n<p><strong>Results:</strong> Patient ages ranged from 45 to 83 years old. Indications included invasive squamous cell carcinoma (50%), in situ carcinoma or dysplasia (40%), and adenoid cystic carcinoma (10%). Defect sizes ranged from 2x2 cm to 5x5cm. Tongue defects demonstrate the fastest healing time (2-3 weeks), followed by buccal mucosa, palate, mandibular gingiva, and floor of mouth which all healed around 4 weeks. Patients progressed from a soft diet for 2 weeks post-operatively to a regular diet by 4 weeks. Two patients experienced mild bleeding in the immediate post-operative period requiring temporary cessation of anticoagulation therapy, and two patients experienced transient exposed mandibular bone that resolved with conservative management. There were no infections, readmissions, or major wound breakdowns.</p>\n\n<p><strong>Conclusions:</strong> Restrata appears to be a safe and effective option for oral cavity defect repair after resection of early oral cavity cancer. The synthetic matrix facilitates rapid mucosalization in 2-4 weeks across a variety of defect sizes and oral cavity subsites without donor-site morbidity. Minor complications included transient mandibular bone exposure and post-op bleeding requiring holding blood-thinners. Individualized perioperative anticoagulation management may help reduce the incidence of minor bleeding events in anticoagulated patients. Future studies with larger cohorts, longer follow-up, and comparative analysis against traditional reconstruction methods are warranted to further define long-term outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153599--></body></html>"
    },
    {
      "uid": "P384",
      "content_id": "154749",
      "abstract_number": "P384",
      "poster_number": "P384",
      "title": "Tumor Seeding After Core Biopsy of Pleomorphic Adenoma: A Case Report",
      "summary": "This case illustrates a rare instance of pleomorphic adenoma implantation following core needle biopsy. Awareness of this potential complication may inform diagnostic decision-making and surgical planning, especially in otherwise benign parotid gland tumors.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154749",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Megan S Wu, MD",
      "presenter": "Megan S Wu, MD",
      "authors": "Megan S Wu, MD ; Nicole A Cipriani, MD; Olga Pasternak-Wise, MD; Elizabeth A Blair, MD",
      "normalized_authors": [
        "Megan S Wu",
        "Nicole A Cipriani",
        "Olga Pasternak-Wise",
        "Elizabeth A Blair"
      ],
      "affiliations": [
        "University of Chicago Medicine"
      ],
      "normalized_institutions": [
        "University of Chicago Medicine"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 399,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Megan S Wu, MD ; Nicole A Cipriani, MD; Olga Pasternak-Wise, MD; Elizabeth A Blair, MD",
        "Affiliations": "University of Chicago Medicine",
        "Background": "Pleomorphic adenoma is the most common benign salivary gland tumor, typically arising in the parotid gland. Although fine-needle aspiration (FNA) is widely regarded as safe and effective, core needle biopsy offers larger tissue samples to improve diagnostic yield. Tumor seeding along the biopsy tract is a well-described risk in certain malignancies but is exceedingly rare in pleomorphic adenoma. We present a case of presumed iatrogenic seeding of a pleomorphic adenoma following core needle biopsy.",
        "Case Presentation": "A 44-year-old woman underwent ultrasound-guided FNA and core needle biopsy of a 1.8 cm mobile mass within the tail of the right parotid gland that was causing her discomfort. Pathology results showed epithelial neoplasm, favoring pleomorphic adenoma. The patient subsequently underwent superficial right parotidectomy, and the mass was removed without violating the tumor capsule with facial nerve preservation. Surgical pathology confirmed pleomorphic adenoma with clear margins. 10 years later, the patient presented to the clinic with a palpable and tender firm mobile mass inferior to the right parotid gland along the anterior border of the SCM. The lesion was notably located superior to the prior incision. MRI imaging demonstrated a 1.4 cm subcutaneous nodule overlying the right parotid tail with additional smaller prominent nodules lying between the skin and platysma, consistent with biopsy-tract implantation. Ultrasound-guided FNA showed recurrent pleomorphic adenoma. The multiple subcutaneous nodules were resected en bloc with the overlying skin, fat, platysma, down to the parotid gland including adjacent cervical lymph nodes. Surgical pathology showed multifocal pleomorphic adenoma with clear margins.",
        "Discussion": "While pleomorphic adenoma has potential for pseudopodial extension and multifocal recurrence, the distinct anatomical separation of the recurrent lesions, situated between the skin and platysma rather than within the parotid bed, supports biopsy-tract seeding as the most plausible etiology. Needle-tract seeding of pleomorphic adenoma is exceedingly rare, yet this case underscores the theoretical risk associated with core needle biopsy of salivary gland tumors—particularly in mobile, superficial lesions where transcutaneous traversal may deposit epithelial-myoepithelial components along the needle tract. If core needle biopsy is pursued, clinicians should consider limiting passes and ensuring tract excision during definitive surgery when feasible. Given the potential for long-latency recurrence, pleomorphic adenomas that were core biopsied warrants prolonged (beyond 5-10 years) surveillance.",
        "Conclusion": "This case illustrates a rare instance of pleomorphic adenoma implantation following core needle biopsy. Awareness of this potential complication may inform diagnostic decision-making and surgical planning, especially in otherwise benign parotid gland tumors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tumor Seeding After Core Biopsy of Pleomorphic Adenoma: A Case Report</span>. <u>Megan S Wu, MD</u>; Nicole A Cipriani, MD; Olga Pasternak-Wise, MD; Elizabeth A Blair, MD. University of Chicago Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pleomorphic adenoma is the most common benign salivary gland tumor, typically arising in the parotid gland. Although fine-needle aspiration (FNA) is widely regarded as safe and effective, core needle biopsy offers larger tissue samples to improve diagnostic yield. Tumor seeding along the biopsy tract is a well-described risk in certain malignancies but is exceedingly rare in pleomorphic adenoma. We present a case of presumed iatrogenic seeding of a pleomorphic adenoma following core needle biopsy.</p>\n\n<p><strong>Case Presentation: </strong>A 44-year-old woman underwent ultrasound-guided FNA and core needle biopsy of a 1.8 cm mobile mass within the tail of the right parotid gland that was causing her discomfort. Pathology results showed epithelial neoplasm, favoring pleomorphic adenoma. The patient subsequently underwent superficial right parotidectomy, and the mass was removed without violating the tumor capsule with facial nerve preservation. Surgical pathology confirmed pleomorphic adenoma with clear margins. 10 years later, the patient presented to the clinic with a palpable and tender firm mobile mass inferior to the right parotid gland along the anterior border of the SCM. The lesion was notably located superior to the prior incision. MRI imaging demonstrated a 1.4 cm subcutaneous nodule overlying the right parotid tail with additional smaller prominent nodules lying between the skin and platysma, consistent with biopsy-tract implantation. Ultrasound-guided FNA showed recurrent pleomorphic adenoma. The multiple subcutaneous nodules were resected en bloc with the overlying skin, fat, platysma, down to the parotid gland including adjacent cervical lymph nodes. Surgical pathology showed multifocal pleomorphic adenoma with clear margins.</p>\n\n<p><strong>Discussion: </strong>While pleomorphic adenoma has potential for pseudopodial extension and multifocal recurrence, the distinct anatomical separation of the recurrent lesions, situated between the skin and platysma rather than within the parotid bed, supports biopsy-tract seeding as the most plausible etiology. Needle-tract seeding of pleomorphic adenoma is exceedingly rare, yet this case underscores the theoretical risk associated with core needle biopsy of salivary gland tumors—particularly in mobile, superficial lesions where transcutaneous traversal may deposit epithelial-myoepithelial components along the needle tract. If core needle biopsy is pursued, clinicians should consider limiting passes and ensuring tract excision during definitive surgery when feasible. Given the potential for long-latency recurrence, pleomorphic adenomas that were core biopsied warrants prolonged (beyond 5-10 years) surveillance.  </p>\n\n<p><strong>Conclusion: </strong>This case illustrates a rare instance of pleomorphic adenoma implantation following core needle biopsy. Awareness of this potential complication may inform diagnostic decision-making and surgical planning, especially in otherwise benign parotid gland tumors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154749--></body></html>"
    },
    {
      "uid": "P386",
      "content_id": "152915",
      "abstract_number": "P386",
      "poster_number": "P386",
      "title": "Benign Lymphoepithelial Cyst: An Unexpected Diagnosis for Immunocompetent Patients",
      "summary": "The diagnosis of benign lymphoepithelial cyst (BLEC) is most commonly associated with immunocompromised individuals and can be an early sign of HIV infection. In this patient population, the typical presentation is bilateral parotid enlargement with imaging showing unilocular cystic structure; however, they can be multilocular or mixed solid/cystic. These cysts are typically in the parotid gland but have been...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152915",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claire E Tolan, MD",
      "presenter": "Claire E Tolan, MD",
      "authors": "Claire E Tolan, MD 1 ; Lin Liu, MD 2 ; Amanda Karcioglu 2",
      "normalized_authors": [
        "Claire E Tolan",
        "Lin Liu",
        "Amanda Karcioglu"
      ],
      "affiliations": [
        "University of Chicago",
        "Endeavor Health"
      ],
      "normalized_institutions": [
        "University of Chicago",
        "Endeavor Health"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 397,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Case 1",
        "Case 2",
        "Case 3",
        "Discussion"
      ],
      "sections": {
        "Authors": "Claire E Tolan, MD 1 ; Lin Liu, MD 2 ; Amanda Karcioglu 2",
        "Affiliations": "1 University of Chicago; 2 Endeavor Health",
        "Introduction": "The diagnosis of benign lymphoepithelial cyst (BLEC) is most commonly associated with immunocompromised individuals and can be an early sign of HIV infection. In this patient population, the typical presentation is bilateral parotid enlargement with imaging showing unilocular cystic structure; however, they can be multilocular or mixed solid/cystic. These cysts are typically in the parotid gland but have been reported in the submandibular gland and pancreas. Unilateral cysts have been reported in individuals without HIV, though rare.",
        "Abstract": "Histologically, these lesions are characterized by cystic structures with benign epithelial lining that includes mixed inflammatory cells with germinal centers. Their exact origin is unknown, with speculation that they originate from the branchial apparatus or develop as an inclusion of salivary tissue within the intra-parotid lymph nodes. Surgical resection via parotidectomy is recommended in patients who are symptomatic or have resulting cosmetic deformity. Herein, we present 3 cases of HIV negative individuals who presented with parotid masses who underwent parotidectomy with final pathology demonstrating benign lymphoepithelial cyst. One-time HIV screening is recommended by the CDC for all patients aged 13 to 64. Two of our three patients agreed to post-operative testing given the diagnosis, but clinicians may wish to consider pre-operative screening in patients with cystic parotid lesions to circumvent potentially uncomfortable post-operative conversations.",
        "Case 1": "71M with noncontributory past medical history presenting with right facial mass with CT demonstrating 4 cm cystic mass in the tail of the right parotid gland. FNA of the lesion was ultimately deferred due indication for surgery based on size",
        "Case 2": "64F with history of limited scleroderma resulting in secondary Sjogren’s syndrome, who presents with an enlarging left parotid mass. MRI performed demonstrating 3.5 cm T2 hyper-enhancing lesion in the superficial left parotid gland and three incidentally found 1 cm lesions in the right parotid gland.",
        "Case 3": "53M with noncontributory past medical history presenting with 3.3 cm T2-enhancing right parotid mass. Outside FNA reviewed and was consistent with cyst contents but deemed nondiagnostic.",
        "Discussion": "Otolaryngologists may reflexively link BLEC of the parotid gland to the diagnosis of HIV; however, as these cases illustrate, the diagnosis is possible in the absence of HIV. In these cases, fine needle aspiration did not provide clarity of the diagnosis; however, samples were taken and analyzed at two different institutions, the University of Chicago and Endeavor Health (NorthShore). Histopathologic diagnosis following surgical resection remains the gold standard for these lesions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Benign Lymphoepithelial Cyst: An Unexpected Diagnosis for Immunocompetent Patients</span>. <u>Claire E Tolan, MD</u><sup>1</sup>; Lin Liu, MD<sup>2</sup>; Amanda Karcioglu<sup>2</sup>. <sup>1</sup>University of Chicago; <sup>2</sup>Endeavor Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>:  The diagnosis of benign lymphoepithelial cyst (BLEC) is most commonly associated with immunocompromised individuals and can be an early sign of HIV infection. In this patient population, the typical presentation is bilateral parotid enlargement with imaging showing unilocular cystic structure; however, they can be multilocular or mixed solid/cystic. These cysts are typically in the parotid gland but have been reported in the submandibular gland and pancreas. Unilateral cysts have been reported in individuals without HIV, though rare.</p>\n\n<p>Histologically, these lesions are characterized by cystic structures with benign epithelial lining that includes mixed inflammatory cells with germinal centers. Their exact origin is unknown, with speculation that they originate from the branchial apparatus or develop as an inclusion of salivary tissue within the intra-parotid lymph nodes. Surgical resection via parotidectomy is recommended in patients who are symptomatic or have resulting cosmetic deformity. Herein, we present 3 cases of HIV negative individuals who presented with parotid masses who underwent parotidectomy with final pathology demonstrating benign lymphoepithelial cyst.</p>\n\n<p><strong>Case 1</strong>: 71M with noncontributory past medical history presenting with right facial mass with CT demonstrating 4 cm cystic mass in the tail of the right parotid gland. FNA of the lesion was ultimately deferred due indication for surgery based on size</p>\n\n<p><strong>Case 2:</strong> 64F with history of limited scleroderma resulting in secondary Sjogren’s syndrome, who presents with an enlarging left parotid mass. MRI performed demonstrating 3.5 cm T2 hyper-enhancing lesion in the superficial left parotid gland and three incidentally found 1 cm lesions in the right parotid gland.</p>\n\n<p><strong>Case 3:</strong> 53M with noncontributory past medical history presenting with 3.3 cm T2-enhancing right parotid mass. Outside FNA reviewed and was consistent with cyst contents but deemed nondiagnostic.</p>\n\n<p><strong>Discussion</strong>: Otolaryngologists may reflexively link BLEC of the parotid gland to the diagnosis of HIV; however, as these cases illustrate, the diagnosis is possible in the absence of HIV. In these cases, fine needle aspiration did not provide clarity of the diagnosis; however, samples were taken and analyzed at two different institutions, the University of Chicago and Endeavor Health (NorthShore). Histopathologic diagnosis following surgical resection remains the gold standard for these lesions.</p>\n\n<p>One-time HIV screening is recommended by the CDC for all patients aged 13 to 64. Two of our three patients agreed to post-operative testing given the diagnosis, but clinicians may wish to consider pre-operative screening in patients with cystic parotid lesions to circumvent potentially uncomfortable post-operative conversations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152915--></body></html>"
    },
    {
      "uid": "P387",
      "content_id": "154319",
      "abstract_number": "P387",
      "poster_number": "P387",
      "title": "Work Type II First Branchial Cleft Anomaly with Myoepithelial Carcinoma of the Parotid: A Case Report",
      "summary": "The patient underwent successful surgical management and at 5-year postoperative follow-up showed no evidence of recurrence or new primary tumors. This case illustrates the diagnostic complexity of suspected BCCC and reinforces the need for careful evaluation when branchial cleft anomalies coexist with salivary gland neoplasms.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154319",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jason S Acheampong, MD",
      "presenter": "Jason S Acheampong, MD",
      "authors": "Perry B Hammond, MD; Jason S Acheampong, MD ; Jonathan R Mark, MD, FACS",
      "normalized_authors": [
        "Perry B Hammond",
        "Jason S Acheampong",
        "Jonathan R Mark"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20BCA.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20BCA.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154319"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20AXI%20Resize%20BCA.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20AXI%20Resize%20BCA.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154319"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154319/3D%20recon%20resize%20BCA.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154319/3D%20recon%20resize%20BCA.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154319"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154319/Surgical%20photo%20Resized.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154319/Surgical%20photo%20Resized.jpg",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154319"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 415,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Abstract",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Perry B Hammond, MD; Jason S Acheampong, MD ; Jonathan R Mark, MD, FACS",
        "Affiliations": "Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University",
        "Introduction": "Branchial cleft cyst carcinoma (BCCC) is a rare squamous cell carcinoma arising from the epithelial lining of a preexisting branchial cleft anomaly. Its status as a true clinicopathologic entity remains debated because of anatomic overlap with metastatic occult primary head and neck tumors and the clinical similarity to degenerating cystic metastatic lymph nodes. Fewer than 40 confirmed cases meeting strict diagnostic criteria have been reported.",
        "Case Presentation": "A 42-year-old nonsmoking female was transferred from an outside hospital for recurrent right facial swelling and infra-auricular purulent drainage concerning for a branchial cleft anomaly. CT imaging demonstrated a congenital lesion consistent with a Work type II first branchial cleft anomaly, given parotid gland involvement with a superimposed abscess. Needle aspiration was performed, and the patient was briefly hospitalized for intravenous antibiotics before being discharged with plans for excision.",
        "Abstract": "Three months later, she re-presented with similar symptoms and new spontaneously draining tracts. CT soft-tissue neck imaging and a CT fistulogram were obtained to better characterize the lesions due to more extensive skin involvement and again demonstrated the known Work type II first branchial cleft anomaly, along with a separate mass within the ipsilateral parotid gland. In the outpatient setting, the patient underwent excision of the right first branchial cleft anomaly, superficial parotidectomy, selective neck dissection (levels I–II), excision of associated skin lesions, and reconstruction of the defect with a supraclavicular flap. Initial diagnostic considerations included BCCC; however, histopathologic evaluation demonstrated two distinct lesions: a benign branchial cleft anomaly and a concurrent myoepithelial carcinoma of the parotid. Although the lesion met the anatomic criterion for BCCC, histopathology did not demonstrate the required transition zone. Instead, findings supported two separate entities: a Work type II first branchial cleft anomaly and a concurrent epithelial/myoepithelial carcinoma of the parotid. Given the absence of histologic evidence and ongoing debate about the existence of true BCCC, a diagnosis of synchronous but distinct lesions was favored.",
        "Discussion": "The diagnosis of BCCC remains controversial, as many reported cases likely represent cystic metastases from occult head and neck primaries. Despite established criteria by Martin and Khafif, diagnostic tools such as cytology, immunohistochemistry, HPV testing, and imaging have limitations, and definitive diagnosis requires a clear histologic transition from benign cyst lining to malignant cells.",
        "Conclusion": "The patient underwent successful surgical management and at 5-year postoperative follow-up showed no evidence of recurrence or new primary tumors. This case illustrates the diagnostic complexity of suspected BCCC and reinforces the need for careful evaluation when branchial cleft anomalies coexist with salivary gland neoplasms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Work Type II First Branchial Cleft Anomaly with Myoepithelial Carcinoma of the Parotid: A Case Report</span>. Perry B Hammond, MD; <u>Jason S Acheampong, MD</u>; Jonathan R Mark, MD, FACS. Department of Otolaryngology – Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences at Old Dominion University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Branchial cleft cyst carcinoma (BCCC) is a rare squamous cell carcinoma arising from the epithelial lining of a preexisting branchial cleft anomaly. Its status as a true clinicopathologic entity remains debated because of anatomic overlap with metastatic occult primary head and neck tumors and the clinical similarity to degenerating cystic metastatic lymph nodes. Fewer than 40 confirmed cases meeting strict diagnostic criteria have been reported.</p>\n\n<p><strong>Case Presentation: </strong>A 42-year-old nonsmoking female was transferred from an outside hospital for recurrent right facial swelling and infra-auricular purulent drainage concerning for a branchial cleft anomaly. CT imaging demonstrated a congenital lesion consistent with a Work type II first branchial cleft anomaly, given parotid gland involvement with a superimposed abscess. Needle aspiration was performed, and the patient was briefly hospitalized for intravenous antibiotics before being discharged with plans for excision.</p>\n\n<p>Three months later, she re-presented with similar symptoms and new spontaneously draining tracts. CT soft-tissue neck imaging and a CT fistulogram were obtained to better characterize the lesions due to more extensive skin involvement and again demonstrated the known Work type II first branchial cleft anomaly, along with a separate mass within the ipsilateral parotid gland.</p>\n\n<p>In the outpatient setting, the patient underwent excision of the right first branchial cleft anomaly, superficial parotidectomy, selective neck dissection (levels I–II), excision of associated skin lesions, and reconstruction of the defect with a supraclavicular flap. Initial diagnostic considerations included BCCC; however, histopathologic evaluation demonstrated two distinct lesions: a benign branchial cleft anomaly and a concurrent myoepithelial carcinoma of the parotid.</p>\n\n<p><strong>Discussion:</strong> The diagnosis of BCCC remains controversial, as many reported cases likely represent cystic metastases from occult head and neck primaries. Despite established criteria by Martin and Khafif, diagnostic tools such as cytology, immunohistochemistry, HPV testing, and imaging have limitations, and definitive diagnosis requires a clear histologic transition from benign cyst lining to malignant cells.</p>\n\n<p>Although the lesion met the anatomic criterion for BCCC, histopathology did not demonstrate the required transition zone. Instead, findings supported two separate entities: a Work type II first branchial cleft anomaly and a concurrent epithelial/myoepithelial carcinoma of the parotid. Given the absence of histologic evidence and ongoing debate about the existence of true BCCC, a diagnosis of synchronous but distinct lesions was favored.</p>\n\n<p><strong>Conclusion:</strong> The patient underwent successful surgical management and at 5-year postoperative follow-up showed no evidence of recurrence or new primary tumors. This case illustrates the diagnostic complexity of suspected BCCC and reinforces the need for careful evaluation when branchial cleft anomalies coexist with salivary gland neoplasms.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20BCA.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154319/Fistulogram%20AXI%20Resize%20BCA.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154319/3D%20recon%20resize%20BCA.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154319/Surgical%20photo%20Resized.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154319--></body></html>"
    },
    {
      "uid": "P389",
      "content_id": "146581",
      "abstract_number": "P389",
      "poster_number": "P389",
      "title": "Head and Neck Clear Cell Carcinomas Harboring EWSR1 Rearrangement: a case series and review of the literature",
      "summary": "HCCC and CCOC are rare tumors with nearly identical morphologic and molecular findings that are likely underrecognized in clinical practice. More published data regarding patient outcomes is needed to determine the optimal management of these similar diseases.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146581",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elisabeth R Wenneker, MD",
      "presenter": "Elisabeth R Wenneker, MD",
      "authors": "Elisabeth R Wenneker, MD 1 ; Ege Cubuk, MD 1 ; Katie Hogan, MD 1 ; Shreya Jain, BA 1 ; Xiaohong I Wang, MD, PhD 2 ; Li Liang, MD, PhD 1 ; David J Hernandez, MD 1",
      "normalized_authors": [
        "Elisabeth R Wenneker",
        "Ege Cubuk",
        "Katie Hogan",
        "Shreya Jain",
        "Xiaohong I Wang",
        "Li Liang",
        "David J Hernandez"
      ],
      "affiliations": [
        "Baylor College of Medicine",
        "University of Texas McGovern Medical School at Houston"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine",
        "University of Texas McGovern Medical School at Houston"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/146581/Table%201%2011_28(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/146581/Table%201%2011_28(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146581"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/146581/Patient%201_tumor%20abutting%20the%20laryngeal%20cartilage%20PNG.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/146581/Patient%201_tumor%20abutting%20the%20laryngeal%20cartilage%20PNG.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146581"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/146581/Patient%203_tumor%20H%26E%20PNG.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/146581/Patient%203_tumor%20H%26E%20PNG.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146581"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/146581/patient%201%20ct%20saggital%20and%20coronal.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/146581/patient%201%20ct%20saggital%20and%20coronal.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146581"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Elisabeth R Wenneker, MD 1 ; Ege Cubuk, MD 1 ; Katie Hogan, MD 1 ; Shreya Jain, BA 1 ; Xiaohong I Wang, MD, PhD 2 ; Li Liang, MD, PhD 1 ; David J Hernandez, MD 1",
        "Affiliations": "1 Baylor College of Medicine; 2 University of Texas McGovern Medical School at Houston",
        "Background": "Primary head and neck malignant neoplasms with predominantly clear cells are uncommon and present a diagnostic dilemma. Salivary gland hyalinizing clear cell carcinoma (HCCC) and clear cell odontogenic carcinoma (CCOC) have identical morphologic and molecular features, differentiated by extraosseous versus intraosseous location. While HCCC is found anywhere within the upper aerodigestive tract, CCOC is within the jaw. Both are rare tumors, first reported in the 1980s.",
        "Abstract": "Histologically, they are composed of sheets, cords, nests, or trabeculae of monotonous epithelial cells with variably clear to eosinophilic cytoplasm within loose to densely hyalinized stroma. The tumors exhibit squamous differentiation and commonly express squamous markers such as cytokeratin 5/6, p40, and p63. HCCC can be misclassified as nonkeratinizing squamous cell carcinoma or mucoepidermoid carcinoma. The focal presence of clear cell morphology, hyalinized stroma, and absence of mucosal surface involvement or dysplasia should raise suspicion for HCCC or CCOC and prompt molecular testing for Ewing Sarcoma RNA-binding protein 1 ( EWSR1 ) gene rearrangement. We present six cases of clear cell carcinomas of the head and neck, their clinicopathologic characteristics, management, and outcomes. Table1. Patient demographics and clinicopathologic data. No evidence of disease (NED). The mean age of patients was 44 years, four males and two females. Our cohort consisted of four Hispanic patients, one black patient, and one white patient. Two had CCOC and four had HCCC. All tumors demonstrated an EWSR1 translocation. Rearrangements were detected by fluorescence in situ hybridization (FISH) with a dual-color break-apart probe in four cases. Three cases underwent next-generation sequencing, which identified EWSR1::CREM and EWSR1::ATF1 fusions, representing a rare and a common fusion partner. Patient 6’s initial biopsy was interpreted as mucoepidermoid carcinoma, final pathology revealed HCCC. Three patients were treated with surgery and adjuvant radiation, one of whom received neo-adjuvant chemotherapy. Patient 2 underwent surgery alone with negative margins and pT3N0M0 staging so adjuvant therapy was not recommended. All four had durable disease control. Patients 3 and 5 had distant metastases on presentation, both received palliative chemotherapy, patient 3 also underwent radiation. Figure1. Patient 1, hematoxylin and eosin (H&E) stain of HCCC with cords and small nests of bland clear cells embedded in a sclerotic stroma, demonstrating an infiltrative growth pattern adjacent to laryngeal cartilage. Figure2. Patient 4, H&E stain of CCOC demonstrating short and long cords, interconnecting trabeculae, and nests of clear and eosinophilic cells within a hyalinized stroma and adjacent fibrous stroma. Figure3. Patient 1, computed tomography soft tissue neck with submucosal base of tongue tumor and bilateral cervical lymphadenopathy, (A)sagittal, (B)coronal.",
        "Methods": "We reviewed the electronic medical records of six patients diagnosed with HCCC or CCOC from three hospitals in a large academic medical center that serves underprivileged and underinsured patients who received treatment between 2020 and 2025. Clinicopathologic data was compared.",
        "Conclusion": "HCCC and CCOC are rare tumors with nearly identical morphologic and molecular findings that are likely underrecognized in clinical practice. More published data regarding patient outcomes is needed to determine the optimal management of these similar diseases."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Head and Neck Clear Cell Carcinomas Harboring EWSR1 Rearrangement: a case series and review of the literature</span>. <u>Elisabeth R Wenneker, MD</u><sup>1</sup>; Ege Cubuk, MD<sup>1</sup>; Katie Hogan, MD<sup>1</sup>; Shreya Jain, BA<sup>1</sup>; Xiaohong I Wang, MD, PhD<sup>2</sup>; Li Liang, MD, PhD<sup>1</sup>; David J Hernandez, MD<sup>1</sup>. <sup>1</sup>Baylor College of Medicine; <sup>2</sup>University of Texas McGovern Medical School at Houston<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Primary head and neck malignant neoplasms with predominantly clear cells are uncommon and present a diagnostic dilemma. Salivary gland hyalinizing clear cell carcinoma (HCCC) and clear cell odontogenic carcinoma (CCOC) have identical morphologic and molecular features, differentiated by extraosseous versus intraosseous location. While HCCC is found anywhere within the upper aerodigestive tract, CCOC is within the jaw. Both are rare tumors, first reported in the 1980s.</p>\n\n<p>Histologically, they are composed of sheets, cords, nests, or trabeculae of monotonous epithelial cells with variably clear to eosinophilic cytoplasm within loose to densely hyalinized stroma. The tumors exhibit squamous differentiation and commonly express squamous markers such as cytokeratin 5/6, p40, and p63. HCCC can be misclassified as nonkeratinizing squamous cell carcinoma or mucoepidermoid carcinoma. The focal presence of clear cell morphology, hyalinized stroma, and absence of mucosal surface involvement or dysplasia should raise suspicion for HCCC or CCOC and prompt molecular testing for Ewing Sarcoma RNA-binding protein 1 (<em>EWSR1</em>) gene rearrangement. </p>\n\n<p>We present six cases of clear cell carcinomas of the head and neck, their clinicopathologic characteristics, management, and outcomes.</p>\n\n<p><strong>Methods: </strong>We reviewed the electronic medical records of six patients diagnosed with HCCC or CCOC from three hospitals in a large academic medical center that serves underprivileged and underinsured patients who received treatment between 2020 and 2025. Clinicopathologic data was compared.</p>\n\n<p><strong>Results:</strong></p>\n\n<p><em>Table1. </em>Patient demographics and clinicopathologic data.<br />\nNo evidence of disease (NED).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/146581/Table%201%2011_28(1).png' /></p>\n\n<p>The mean age of patients was 44 years, four males and two females. Our cohort consisted of four Hispanic patients, one black patient, and one white patient. Two had CCOC and four had HCCC. All tumors demonstrated an <em>EWSR1</em> translocation. Rearrangements were detected by fluorescence in situ hybridization (FISH) with a dual-color break-apart probe in four cases. Three cases underwent next-generation sequencing, which identified <em>EWSR1::CREM</em> and<em> EWSR1::ATF1 </em>fusions, representing a rare and a common fusion partner. Patient 6’s initial biopsy was interpreted as mucoepidermoid carcinoma, final pathology revealed HCCC.</p>\n\n<p>Three patients were treated with surgery and adjuvant radiation, one of whom received neo-adjuvant chemotherapy. Patient 2 underwent surgery alone with negative margins and pT3N0M0 staging so adjuvant therapy was not recommended. All four had durable disease control. Patients 3 and 5 had distant metastases on presentation, both received palliative chemotherapy, patient 3 also underwent radiation.</p>\n\n<p><em>Figure1.</em> Patient 1, hematoxylin and eosin (H&E) stain of HCCC with cords and small nests of bland clear cells embedded in a sclerotic stroma, demonstrating an infiltrative growth pattern adjacent to laryngeal cartilage.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/146581/Patient%201_tumor%20abutting%20the%20laryngeal%20cartilage%20PNG.png' /></p>\n\n<p><em>Figure2. </em>Patient 4, H&E stain of CCOC demonstrating short and long cords, interconnecting trabeculae, and nests of clear and eosinophilic cells within a hyalinized stroma and adjacent fibrous stroma.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/146581/Patient%203_tumor%20H%26E%20PNG.png' /></p>\n\n<p><em>Figure3. </em>Patient 1, computed tomography soft tissue neck with submucosal base of tongue tumor and bilateral cervical lymphadenopathy, (A)sagittal, (B)coronal.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/146581/patient%201%20ct%20saggital%20and%20coronal.png' /></p>\n\n<p><strong>Conclusion: </strong>HCCC and CCOC are rare tumors with nearly identical morphologic and molecular findings that are likely underrecognized in clinical practice. More published data regarding patient outcomes is needed to determine the optimal management of these similar diseases.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146581--></body></html>"
    },
    {
      "uid": "P390",
      "content_id": "154540",
      "abstract_number": "P390",
      "poster_number": "P390",
      "title": "Surprise Salivary Malignant Tumor During Parotid Mass Resection: A Novel Intraoperative Technique Utilizing Suture to Identify Resection Margins and Cadaveric Skin to Provide a Biologic Barrier",
      "summary": "This case illustrates a novel staged surgical strategy using biologic allograft and suture mapping to safely manage an indeterminate parotid lesion later confirmed as malignancy. This technique provides both an oncologic barrier and precise orientation for delayed definitive resection, representing a practical, reproducible approach when intraoperative pathology raises concern for malignancy in an otherwise...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154540",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shannon M Hall, MD",
      "presenter": "Shannon M Hall, MD",
      "authors": "Shannon M Hall, MD ; Gabriela Cendejas, MS; Maria Polania; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Shannon M Hall",
        "Gabriela Cendejas",
        "Maria Polania",
        "Joseph Lopez"
      ],
      "affiliations": [
        "Advent Health Orlando"
      ],
      "normalized_institutions": [
        "Advent Health Orlando"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 308,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Conclusion",
        "Keywords"
      ],
      "sections": {
        "Authors": "Shannon M Hall, MD ; Gabriela Cendejas, MS; Maria Polania; Joseph Lopez, MD, MBA",
        "Affiliations": "Advent Health Orlando",
        "Background": "Acinic cell carcinoma (ACC) of the parotid gland is a rare pediatric salivary malignancy that often presents with benign imaging characteristics, leading to diagnostic uncertainty. This diagnostic ambiguity poses challenges for pre-operative planning and intra-operative decision making, as standard imaging modalities may not be reliable in distinguishing ACC from benign pathologies. Intraoperative discovery of possible malignancy requires safe and effective surgical decision-making to balance oncologic safety and preservation of normal structures.",
        "Case Presentation": "We describe a 14-year-old female with a right parotid lesion initially presumed to represent a vascular malformation or branchial cleft cyst based on MRI and CT imaging. Intraoperatively, a firm solid mass was encountered, and frozen section analysis suggested a possible low-grade malignancy. To avoid premature extensive resection before definitive diagnosis, a novel intraoperative technique was employed: placement of an acellular dermal matrix (ADM) patch as a biologic barrier over the tumor bed, combined with 5-0 Prolene sutures marking 1-cm potential oncologic margins. Permanent pathology later confirmed acinic cell carcinoma, prompting a planned second-stage definitive resection. During reoperation, the ADM and suture markings enabled precise identification of the prior tumor bed and margins, facilitating complete oncologic excision with negative frozen and permanent margins. The marginal mandibular branch of the facial nerve, found to be involved by the tumor, was repaired with nerve allograft. The patient recovered well without residual nerve deficits or recurrence on follow-up imaging.",
        "Conclusion": "This case illustrates a novel staged surgical strategy using biologic allograft and suture mapping to safely manage an indeterminate parotid lesion later confirmed as malignancy. This technique provides both an oncologic barrier and precise orientation for delayed definitive resection, representing a practical, reproducible approach when intraoperative pathology raises concern for malignancy in an otherwise presumed benign parotid mass.",
        "Keywords": "Acinic cell carcinoma, parotid gland, pediatric salivary gland tumor, salivary gland malignancy, acellular dermal matrix, cadaveric skin, frozen section, staged resection, surgical innovation"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surprise Salivary Malignant Tumor During Parotid Mass Resection: A Novel Intraoperative Technique Utilizing Suture to Identify Resection Margins and Cadaveric Skin to Provide a Biologic Barrier</span>. <u>Shannon M Hall, MD</u>; Gabriela Cendejas, MS; Maria Polania; Joseph Lopez, MD, MBA. Advent Health Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Acinic cell carcinoma (ACC) of the parotid gland is a rare pediatric salivary malignancy that often presents with benign imaging characteristics, leading to diagnostic uncertainty. This diagnostic ambiguity poses challenges for pre-operative planning and intra-operative decision making, as standard imaging modalities may not be reliable in distinguishing ACC from benign pathologies. Intraoperative discovery of possible malignancy requires safe and effective surgical decision-making to balance oncologic safety and preservation of normal structures.</p>\n\n<p><strong>Case Presentation: </strong>We describe a 14-year-old female with a right parotid lesion initially presumed to represent a vascular malformation or branchial cleft cyst based on MRI and CT imaging. Intraoperatively, a firm solid mass was encountered, and frozen section analysis suggested a possible low-grade malignancy. To avoid premature extensive resection before definitive diagnosis, a novel intraoperative technique was employed: placement of an acellular dermal matrix (ADM) patch as a biologic barrier over the tumor bed, combined with 5-0 Prolene sutures marking 1-cm potential oncologic margins. Permanent pathology later confirmed acinic cell carcinoma, prompting a planned second-stage definitive resection. During reoperation, the ADM and suture markings enabled precise identification of the prior tumor bed and margins, facilitating complete oncologic excision with negative frozen and permanent margins. The marginal mandibular branch of the facial nerve, found to be involved by the tumor, was repaired with nerve allograft. The patient recovered well without residual nerve deficits or recurrence on follow-up imaging.</p>\n\n<p><strong>Conclusion: </strong>This case illustrates a novel staged surgical strategy using biologic allograft and suture mapping to safely manage an indeterminate parotid lesion later confirmed as malignancy. This technique provides both an oncologic barrier and precise orientation for delayed definitive resection, representing a practical, reproducible approach when intraoperative pathology raises concern for malignancy in an otherwise presumed benign parotid mass.</p>\n\n<p><strong>Keywords: </strong>Acinic cell carcinoma, parotid gland, pediatric salivary gland tumor, salivary gland malignancy, acellular dermal matrix, cadaveric skin, frozen section, staged resection, surgical innovation</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154540--></body></html>"
    },
    {
      "uid": "P391",
      "content_id": "154691",
      "abstract_number": "P391",
      "poster_number": "P391",
      "title": "Unexpected Presentation of Pilomatricoma in a Parotid Gland Region: A Case Report and A Review of the Literature",
      "summary": "This case represents a unique presentation given the patient's age, tumor size, and location. Furthermore, this was an atypical tumor’s presentation over the parotid region with a rapid progression, highlighting the importance of Pilomatricoma as a differential diagnosis of a salivary gland tumor, and it must be considered in patients presenting with a progressively enlarging mass, particularly in the pediatric...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154691",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jorge E Arpi Palacios",
      "presenter": "Jorge E Arpi Palacios",
      "authors": "Jorge E Arpi Palacios 1 ; Anne Fischer, MD, PhD 1 ; Joseph Lopez, MD, MBA 2",
      "normalized_authors": [
        "Jorge E Arpi Palacios",
        "Anne Fischer",
        "Joseph Lopez"
      ],
      "affiliations": [
        "Department of General Surgery, Florida Atlantic University, Florida, USA",
        "AdventHealth Medical Group Plastic and Reconstructive Surgery"
      ],
      "normalized_institutions": [
        "Department of General Surgery, Florida Atlantic University, Florida, USA",
        "AdventHealth Medical Group Plastic and Reconstructive Surgery"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 395,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Case Presentation",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jorge E Arpi Palacios 1 ; Anne Fischer, MD, PhD 1 ; Joseph Lopez, MD, MBA 2",
        "Affiliations": "1 Department of General Surgery, Florida Atlantic University, Florida, USA; 2 AdventHealth Medical Group Plastic and Reconstructive Surgery",
        "Background": "Pilomatricoma is a rare benign adnexal skin tumor with an incidence rate of 0.5% - 1.6%. Also known as Pilamatrixoma or Malherbe's tumor, it commonly presents in the head and neck region and exhibits a bimodal age distribution across both pediatric and elderly populations. The parotid gland region represents an uncommon site for pilomatricoma presentation and may mimic salivary gland tumors. Therefore, such atypical locations can pose a significant diagnostic challenge. We present a case report and a literature review of pediatric patients with pilomatricoma involving the parotid region.",
        "Methods": "We conducted a review of the literature on pilomatricoma over the last 10 years and subsequently identified only those cases presenting in the parotid region. Of these seven reported cases, only three involved pediatric patients.",
        "Case Presentation": "A 14-year-old female patient developed painless right facial swelling in the pre-auricular region, which progressively and gradually worsened over time. After 6 months of initial presentation, the patient was evaluated by a dentist, who ruled out dental disease. Approximately 8 months after initial presentation, the patient was referred to dermatology for further evaluation. Despite clinical evaluation, swelling increased in size and was associated with pain. Two months later, the patient presented to the ED with worsening of right facial swelling, accompanied by intermittent moderate sharp pain associated with on-and-off overlying bruising. On workup, a CT scan of the face demonstrated a 2.9 x 2.8 x 2.2 cm solitary, well-delineated, oval-shaped mass in the right parotid region. Imaging showed no neck abnormalities. One month later, the patient noted a rapid increase in tumor size to 4.7 cm, prompting referral to plastic surgery for evaluation and management. Following initial evaluation by plastic surgery, an excisional biopsy was performed through the oral cavity, and pathologic findings were consistent with a pilomatricoma. The patient underwent a wide local excision through an intraoral approach and is currently under surveillance.",
        "Conclusion": "This case represents a unique presentation given the patient's age, tumor size, and location. Furthermore, this was an atypical tumor’s presentation over the parotid region with a rapid progression, highlighting the importance of Pilomatricoma as a differential diagnosis of a salivary gland tumor, and it must be considered in patients presenting with a progressively enlarging mass, particularly in the pediatric population. This benign tumor has low malignant potential; timely treatment helps limit disease progression and reduces the complexity of surgical intervention."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Unexpected Presentation of Pilomatricoma in a Parotid Gland Region: A Case Report and A Review of the Literature</span>. <u>Jorge E Arpi Palacios</u><sup>1</sup>; Anne Fischer, MD, PhD<sup>1</sup>; Joseph Lopez, MD, MBA<sup>2</sup>. <sup>1</sup>Department of General Surgery, Florida Atlantic University, Florida, USA; <sup>2</sup>AdventHealth Medical Group Plastic and Reconstructive Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pilomatricoma is a rare benign adnexal skin tumor with an incidence rate of 0.5% - 1.6%. Also known as Pilamatrixoma or Malherbe's tumor, it commonly presents in the head and neck region and exhibits a bimodal age distribution across both pediatric and elderly populations. The parotid gland region represents an uncommon site for pilomatricoma presentation and may mimic salivary gland tumors. Therefore, such atypical locations can pose a significant diagnostic challenge. We present a case report and a literature review of pediatric patients with pilomatricoma involving the parotid region.</p>\n\n<p><strong>Methods: </strong>We conducted a review of the literature on pilomatricoma over the last 10 years and subsequently identified only those cases presenting in the parotid region. Of these seven reported cases, only three involved pediatric patients.</p>\n\n<p><strong>Case Presentation: </strong>A 14-year-old female patient developed painless right facial swelling in the pre-auricular region, which progressively and gradually worsened over time. After 6 months of initial presentation, the patient was evaluated by a dentist, who ruled out dental disease. Approximately 8 months after initial presentation, the patient was referred to dermatology for further evaluation. Despite clinical evaluation, swelling increased in size and was associated with pain.  Two months later, the patient presented to the ED with worsening of right facial swelling, accompanied by intermittent moderate sharp pain associated with on-and-off overlying bruising. On workup, a CT scan of the face demonstrated a 2.9 x 2.8 x 2.2 cm solitary, well-delineated, oval-shaped mass in the right parotid region. Imaging showed no neck abnormalities. One month later, the patient noted a rapid increase in tumor size to 4.7 cm, prompting referral to plastic surgery for evaluation and management. Following initial evaluation by plastic surgery, an excisional biopsy was performed through the oral cavity, and pathologic findings were consistent with a pilomatricoma. The patient underwent a wide local excision through an intraoral approach and is currently under surveillance.</p>\n\n<p><strong>Conclusion: </strong>This case represents a unique presentation given the patient's age, tumor size, and location. Furthermore, this was an atypical tumor’s presentation over the parotid region with a rapid progression, highlighting the importance of Pilomatricoma as a differential diagnosis of a salivary gland tumor, and it must be considered in patients presenting with a progressively enlarging mass, particularly in the pediatric population. This benign tumor has low malignant potential; timely treatment helps limit disease progression and reduces the complexity of surgical intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154691--></body></html>"
    },
    {
      "uid": "P392",
      "content_id": "153664",
      "abstract_number": "P392",
      "poster_number": "P392",
      "title": "Management of pediatric head and neck mucoepidermoid carcinoma – 30 years of data with a systematic review & meta-analysis",
      "summary": "MEC is a rare diagnosis in children for which surgery is first line therapy. Parotidectomy is the approach of choice for parotid MEC, with superficial parotidectomy a reasonable option for low grade disease. Facial nerve sacrifice and maxillectomy are rarely indicated and adjuvant therapy can often be safely withheld in low grade disease. There is no proven role for elective neck dissection. Chemotherapy should...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153664",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "GP Sexton, MB, BCh, BAO",
      "presenter": "GP Sexton, MB, BCh, BAO",
      "authors": "GP Sexton, MB, BCh, BAO 1 ; D Rajeev 1 ; J Pugi, MD 1 ; H Kim, PhD 1 ; J Mack, MD, MPH 2 ; A Perez-Atayde, MD, PhD 3 ; R Rahbar, DMD, MD 1",
      "normalized_authors": [
        "GP Sexton, MB, BCh, BAO",
        "D Rajeev",
        "J Pugi",
        "H Kim",
        "J Mack",
        "A Perez-Atayde",
        "R Rahbar"
      ],
      "affiliations": [
        "Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital",
        "Department of Pediatric Oncology, Dana-Farber Cancer Institute/Department of Pediatric Hematology/Oncology, Boston Children’s Hospital",
        "Department of Pathology, Boston Children’s Hospital"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital",
        "Department of Pediatric Oncology, Dana-Farber Cancer Institute/Department of Pediatric Hematology/Oncology, Boston Children’s Hospital",
        "Department of Pathology, Boston Children’s Hospital"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 352,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "GP Sexton, MB, BCh, BAO 1 ; D Rajeev 1 ; J Pugi, MD 1 ; H Kim, PhD 1 ; J Mack, MD, MPH 2 ; A Perez-Atayde, MD, PhD 3 ; R Rahbar, DMD, MD 1",
        "Affiliations": "1 Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital; 2 Department of Pediatric Oncology, Dana-Farber Cancer Institute/Department of Pediatric Hematology/Oncology, Boston Children’s Hospital; 3 Department of Pathology, Boston Children’s Hospital",
        "Introduction": "Salivary gland mucoepidermoid carcinoma (MEC) is a rare diagnosis in children. The evidence for management is currently limited to observational data.",
        "Objective": "To determine the optimal approach to management of pediatric salivary gland MEC.",
        "Methods": "A single-center review of pediatric primary salivary gland MEC from 1994-2024 combined with a systematic review according to PRISMA guidelines. Case reports, case series, and cohort studies of MEC in patients aged 21 years or younger were considered if they included details of surgical management. PubMed, Embase, and Scopus were searched and articles assessed with the Newcastle Ottawa Scale.",
        "Results": "Records from 38 patients were available and combined with data from 95 published articles for a total of 424. Female sex (60.3%), parotid disease (76.9%), and early T-stage (78.1%) predominated. Parotidectomy was the most common management for parotid disease (93.3%); 20.6% underwent superficial parotidectomy. Of 75 superficial parotidectomies, 56% required no further management and 17% required adjuvant radiotherapy only. Wide local excision was performed for 90.2% of palate disease; no further management was performed for 76.5%. Overall revision surgery and recurrence rates were 13.7% and 11.1%. Neck dissection with primary ablation was performed in 21.2% with a nodal yield of 30%. Adjuvant radiotherapy was given in 31.1%. Complete/partial facial nerve sacrifice occurred in 10.7%. Multivariate regression demonstrated no significant change in mortality due to extent of parotidectomy, requirement for revision surgery, neck dissection, adjuvant radiotherapy, or facial nerve sacrifice. No patient undergoing maxillectomy died due to their disease. Higher disease grade and recurrence were strongly predictive of disease-specific mortality (p=0.001). Chemotherapy was exclusively used for high grade disease (2.1%).",
        "Conclusion": "MEC is a rare diagnosis in children for which surgery is first line therapy. Parotidectomy is the approach of choice for parotid MEC, with superficial parotidectomy a reasonable option for low grade disease. Facial nerve sacrifice and maxillectomy are rarely indicated and adjuvant therapy can often be safely withheld in low grade disease. There is no proven role for elective neck dissection. Chemotherapy should be reserved for high grade disease as part of multimodal therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Management of pediatric head and neck mucoepidermoid carcinoma – 30 years of data with a systematic review & meta-analysis</span>. <u>GP Sexton, MB, BCh, BAO</u><sup>1</sup>; D Rajeev<sup>1</sup>; J Pugi, MD<sup>1</sup>; H Kim, PhD<sup>1</sup>; J Mack, MD, MPH<sup>2</sup>; A Perez-Atayde, MD, PhD<sup>3</sup>; R Rahbar, DMD, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital; <sup>2</sup>Department of Pediatric Oncology, Dana-Farber Cancer Institute/Department of Pediatric Hematology/Oncology, Boston Children’s Hospital; <sup>3</sup>Department of Pathology, Boston Children’s Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Salivary gland mucoepidermoid carcinoma (MEC) is a rare diagnosis in children. The evidence for management is currently limited to observational data.</p>\n\n<p><strong>Objective: </strong>To determine the optimal approach to management of pediatric salivary gland MEC.</p>\n\n<p><strong>Methods: </strong>A single-center review of pediatric primary salivary gland MEC from 1994-2024 combined with a systematic review according to PRISMA guidelines. Case reports, case series, and cohort studies of MEC in patients aged 21 years or younger were considered if they included details of surgical management. PubMed, Embase, and Scopus were searched and articles assessed with the Newcastle Ottawa Scale.</p>\n\n<p><strong>Results: </strong>Records from 38 patients were available and combined with data from 95 published articles for a total of 424. Female sex (60.3%), parotid disease (76.9%), and early T-stage (78.1%) predominated. Parotidectomy was the most common management for parotid disease (93.3%); 20.6% underwent superficial parotidectomy. Of 75 superficial parotidectomies, 56% required no further management and 17% required adjuvant radiotherapy only. Wide local excision was performed for 90.2% of palate disease; no further management was performed for 76.5%. Overall revision surgery and recurrence rates were 13.7% and 11.1%. Neck dissection with primary ablation was performed in 21.2% with a nodal yield of 30%. Adjuvant radiotherapy was given in 31.1%. Complete/partial facial nerve sacrifice occurred in 10.7%. Multivariate regression demonstrated no significant change in mortality due to extent of parotidectomy, requirement for revision surgery, neck dissection, adjuvant radiotherapy, or facial nerve sacrifice. No patient undergoing maxillectomy died due to their disease. Higher disease grade and recurrence were strongly predictive of disease-specific mortality (p=0.001). Chemotherapy was exclusively used for high grade disease (2.1%).</p>\n\n<p><strong>Conclusion: </strong>MEC is a rare diagnosis in children for which surgery is first line therapy. Parotidectomy is the approach of choice for parotid MEC, with superficial parotidectomy a reasonable option for low grade disease. Facial nerve sacrifice and maxillectomy are rarely indicated and adjuvant therapy can often be safely withheld in low grade disease. There is no proven role for elective neck dissection. Chemotherapy should be reserved for high grade disease as part of multimodal therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153664--></body></html>"
    },
    {
      "uid": "P393",
      "content_id": "155472",
      "abstract_number": "P393",
      "poster_number": "P393",
      "title": "Sialendoscopy-Assisted Management of Accessory Parotid Gland Tumors: A Case Series",
      "summary": "Accessory parotid tumor excision can be successfully performed using alternative approaches to the traditional modified Blair incision. Preoperative sialendoscopy provides valuable information regarding Stensen's duct involvement and facilitates surgical planning. Distal surgical approaches, including transoral excision for benign tumors and direct transcutaneous excision for malignant lesions, reduce the risk of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155472",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Monet C McCalla, DO",
      "presenter": "Monet C McCalla, DO",
      "authors": "Monet C McCalla, DO 1 ; Taylor Osborne, BS 2 ; Ryan Osborne, MD 3",
      "normalized_authors": [
        "Monet C McCalla",
        "Taylor Osborne",
        "Ryan Osborne"
      ],
      "affiliations": [
        "University of Wisconsin",
        "University of California - Los Angeles",
        "Osborne Head and Neck Institute"
      ],
      "normalized_institutions": [
        "University of Wisconsin",
        "University of California - Los Angeles",
        "Osborne Head and Neck Institute"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 453,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Monet C McCalla, DO 1 ; Taylor Osborne, BS 2 ; Ryan Osborne, MD 3",
        "Affiliations": "1 University of Wisconsin; 2 University of California - Los Angeles; 3 Osborne Head and Neck Institute",
        "Introduction": "Neoplasms of the accessory parotid gland represent approximately 1-8% of all parotid tumors and typically present as anterior midfacial masses. While the modified Blair incision remains a standard approach, it is associated with significant morbidity including extensive scarring, facial nerve injury risk, and Frey's syndrome. Alternative minimally invasive approaches, including transoral and direct transcutaneous techniques, offer potential advantages in selected patients. Contemporary literature predominantly describes endoscope-assisted transoral excision for these lesions. This case series presents an alternative surgical strategy utilizing preoperative sialendoscopy to assess Stensen's duct involvement, followed by either transoral or direct transcutaneous excision without concurrent endoscopic assistance.",
        "Objective": "To evaluate the feasibility and outcomes of accessory parotid tumor excision using preoperative sialendoscopy for surgical planning, followed by either transoral or direct transcutaneous approaches without endoscopic assistance.",
        "Methods": "Three patients underwent surgical excision of accessory parotid tumors with sizes ranging from 1.5 to 4.5 cm. All patients underwent preoperative sialendoscopy to assess Stensen's duct involvement and determine appropriate surgical margins. Surgical approach selection was based on tumor pathology: transoral excision for benign lesions and direct transcutaneous incision for malignant pathology. Standard instrumentation included a dental molt elevator, tongue retractor, and soft tissue instruments. Continuous facial nerve monitoring was employed in all cases. Preoperative, intraoperative, and postoperative documentation was obtained for all patients.",
        "Results": "A 34-year-old woman underwent uneventful resection of a 3.5 cm benign tumor. The immediate postoperative course was complicated by hematoma and seroma requiring return to the operating room for buccal artery ligation. The patient remains disease-free without facial nerve injury at over 20 years of follow-up. A second patient, a 20-year-old woman, underwent uncomplicated resection of a 4.5 cm benign lesion with preservation of Stensen's duct. A third patient, an 84-year-old man, presented with early malignant disease on histopathology and imaging. Preoperative sialendoscopy demonstrated ductal involvement. The tumor was resected with appropriate margins, and the duct was primarily reanastomosed. Five months later, this patient returned for a salvage resection due to tumor recurrence. This patient then remained without subsequent recurrence at last follow-up. No patients experienced permanent or transient facial nerve dysfunction. Normal diet was resumed on postoperative day zero in all cases, with avoidance of acidic foods recommended.",
        "Conclusion": "Accessory parotid tumor excision can be successfully performed using alternative approaches to the traditional modified Blair incision. Preoperative sialendoscopy provides valuable information regarding Stensen's duct involvement and facilitates surgical planning. Distal surgical approaches, including transoral excision for benign tumors and direct transcutaneous excision for malignant lesions, reduce the risk of complete facial nerve paralysis, reduce the incidence of Frey's syndrome, and avoid extensive external incisions while achieving adequate oncologic resection in the majority of cases. These techniques represent viable alternatives in appropriately selected patients with accessory parotid gland neoplasms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sialendoscopy-Assisted Management of Accessory Parotid Gland Tumors: A Case Series</span>. <u>Monet C McCalla, DO</u><sup>1</sup>; Taylor Osborne, BS<sup>2</sup>; Ryan Osborne, MD<sup>3</sup>. <sup>1</sup>University of Wisconsin; <sup>2</sup>University of California - Los Angeles; <sup>3</sup>Osborne Head and Neck Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Neoplasms of the accessory parotid gland represent approximately 1-8% of all parotid tumors and typically present as anterior midfacial masses. While the modified Blair incision remains a standard approach, it is associated with significant morbidity including extensive scarring, facial nerve injury risk, and Frey's syndrome. Alternative minimally invasive approaches, including transoral and direct transcutaneous techniques, offer potential advantages in selected patients. Contemporary literature predominantly describes endoscope-assisted transoral excision for these lesions. This case series presents an alternative surgical strategy utilizing preoperative sialendoscopy to assess Stensen's duct involvement, followed by either transoral or direct transcutaneous excision without concurrent endoscopic assistance. </p>\n\n<p><strong>Objective: </strong>To evaluate the feasibility and outcomes of accessory parotid tumor excision using preoperative sialendoscopy for surgical planning, followed by either transoral or direct transcutaneous approaches without endoscopic assistance. </p>\n\n<p><strong>Methods: </strong>Three patients underwent surgical excision of accessory parotid tumors with sizes ranging from 1.5 to 4.5 cm. All patients underwent preoperative sialendoscopy to assess Stensen's duct involvement and determine appropriate surgical margins. Surgical approach selection was based on tumor pathology: transoral excision for benign lesions and direct transcutaneous incision for malignant pathology. Standard instrumentation included a dental molt elevator, tongue retractor, and soft tissue instruments. Continuous facial nerve monitoring was employed in all cases. Preoperative, intraoperative, and postoperative documentation was obtained for all patients. </p>\n\n<p><strong>Results: </strong>A 34-year-old woman underwent uneventful resection of a 3.5 cm benign tumor. The immediate postoperative course was complicated by hematoma and seroma requiring return to the operating room for buccal artery ligation. The patient remains disease-free without facial nerve injury at over 20 years of follow-up. A second patient, a 20-year-old woman, underwent uncomplicated resection of a 4.5 cm benign lesion with preservation of Stensen's duct. A third patient, an 84-year-old man, presented with early malignant disease on histopathology and imaging. Preoperative sialendoscopy demonstrated ductal involvement. The tumor was resected with appropriate margins, and the duct was primarily reanastomosed. Five months later, this patient returned for a salvage resection due to tumor recurrence. This patient then remained without subsequent recurrence at last follow-up. No patients experienced permanent or transient facial nerve dysfunction. Normal diet was resumed on postoperative day zero in all cases, with avoidance of acidic foods recommended. </p>\n\n<p><strong>Conclusion: </strong>Accessory parotid tumor excision can be successfully performed using alternative approaches to the traditional modified Blair incision. Preoperative sialendoscopy provides valuable information regarding Stensen's duct involvement and facilitates surgical planning. Distal surgical approaches, including transoral excision for benign tumors and direct transcutaneous excision for malignant lesions, reduce the risk of complete facial nerve paralysis, reduce the incidence of Frey's syndrome, and avoid extensive external incisions while achieving adequate oncologic resection in the majority of cases. These techniques represent viable alternatives in appropriately selected patients with accessory parotid gland neoplasms. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155472--></body></html>"
    },
    {
      "uid": "P394",
      "content_id": "152777",
      "abstract_number": "P394",
      "poster_number": "P394",
      "title": "Use of a Synthetic Biodegradable Dermal Substitute (MTX (R)) for Parotidectomy Defect Reconstruction: A Case Series",
      "summary": "Reconstruction of parotidectomy defects using a synthetic biodegradable dermal matrix offers an effective, safe, and esthetically alternative to traditional methods. This demonstrated excellent contour restoration, minimal complications, and cost savings compared to previously described methods. These findings support its use as an alternative for post-parotidectmy reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152777",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jhoel Maldonado, MD",
      "presenter": "Jhoel Maldonado, MD",
      "authors": "Michael V Medina, MD 1 ; Jhoel Maldonado, MD 2 ; William Del Fresno, PAC 3 ; Marcus Dantas, PAC 3",
      "normalized_authors": [
        "Michael V Medina",
        "Jhoel Maldonado",
        "William Del Fresno, PAC",
        "Marcus Dantas, PAC"
      ],
      "affiliations": [
        "Texas Institute for Surgery",
        "Universidad Catolica Santiago de Guayaquil",
        "Cleveland Clinic Florida"
      ],
      "normalized_institutions": [
        "Texas Institute for Surgery",
        "Universidad Catolica Santiago de Guayaquil",
        "Cleveland Clinic Florida"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Michael V Medina, MD 1 ; Jhoel Maldonado, MD 2 ; William Del Fresno, PAC 3 ; Marcus Dantas, PAC 3",
        "Affiliations": "1 Texas Institute for Surgery; 2 Universidad Catolica Santiago de Guayaquil; 3 Cleveland Clinic Florida",
        "Background": "Parotidectomy is a standard surgical approach for managing benign and malignant parotid tumors. However, the resulting soft-tissue defect often produces preauricular depression, facial asymmetry, and functional issues such as Frey syndrome. Various reconstructive options have been described, including local muscle flaps, fat grafts, and allograft materials, but each presents disadvantages such as donor-site morbidity, increased surgical time, and increased cost. A synthetic biodegradable dermal matrix (MTX), was recently developed as a reliable and biocompatible alternative for soft-tissue restoration. This study presents a new series of parotidectomy cases reconstructed with MTX, emphasizing esthetic and functional outcomes and the absence of postoperative complications.",
        "Methods": "This is a case series of patients with benign parotid disease who underwent lateral parotidectomy followed by immediate reconstruction with a synthetic dermal matrix. All cases were performed at a tetiary medical center. After tumor resection, folded sheets of MTX (R), synthetic degradable biomatrix dermal substitute were used to fill the parotid bed and restore contour. The graft was anchored to adjacent anatomic landmarks. Drains were placed routinely and removed after 7 days. Postoperative follow-up included clinical evaluation, photographic analysis, and assessment for Frey syndrome.",
        "Results": "The series included three patients aged 35 to 68 years (mean 51). All patients achieved excellent restoration of facial contour with symmetric results. No cases of hematoma, or graft extrusion were observed. Patients reported high satisfaction with postoperative appearance and minimal pain or scar contracture.",
        "Discussion": "Reconstruction of post parotid defects has been described previously using acellular dermis, free dermal fat grafts , among others. The goal is to minimize the resultant cosmetic deformity and limit the development of Frey syndrome. A synthetic biodegradable dermal substitute (MTX(R)) was recently developed for soft tissue coverage and to fill in soft tissue defects. We describe our initial experience using this as an interpositional and contour-restoring matrix after parotidectomy. This reconstruction method provided stable, natural results without donor-site morbidity. Compared with autologous flaps, the technique is simpler, less invasive, and significantly reduces operative time. Compared to acellular dermal matrix this provided significant cost savings. The absence of immunologic reactions or extrusion supports its long-term biocompatibility. Follow up is needed to determine if it also acts as a protective barrier to reduce the risk of Frey syndrome. This is the first reported series in the use of a synthetic biodegradable dermal matrix for parotidectomy reconstruction.",
        "Conclusion": "Reconstruction of parotidectomy defects using a synthetic biodegradable dermal matrix offers an effective, safe, and esthetically alternative to traditional methods. This demonstrated excellent contour restoration, minimal complications, and cost savings compared to previously described methods. These findings support its use as an alternative for post-parotidectmy reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of a Synthetic Biodegradable Dermal Substitute (MTX (R)) for Parotidectomy Defect Reconstruction: A Case Series</span>. Michael V Medina, MD<sup>1</sup>; <u>Jhoel Maldonado, MD</u><sup>2</sup>; William Del Fresno, PAC<sup>3</sup>; Marcus Dantas, PAC<sup>3</sup>. <sup>1</sup>Texas Institute for Surgery; <sup>2</sup>Universidad Catolica Santiago de Guayaquil; <sup>3</sup>Cleveland Clinic Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Parotidectomy is a standard surgical approach for managing benign and malignant parotid tumors. However, the resulting soft-tissue defect often produces preauricular depression, facial asymmetry, and functional issues such as Frey syndrome. Various reconstructive options have been described, including local muscle flaps, fat grafts, and allograft materials, but each presents disadvantages such as donor-site morbidity, increased surgical time, and increased cost. A synthetic biodegradable dermal matrix (MTX), was recently developed as a reliable and biocompatible alternative for soft-tissue restoration. This study presents a new series of parotidectomy cases reconstructed with MTX, emphasizing esthetic and functional outcomes and the absence of postoperative complications.</p>\n\n<p><strong>Methods: </strong>This is a case series of patients with benign parotid disease who underwent lateral parotidectomy followed by immediate reconstruction with a synthetic dermal matrix.  All cases were performed at a tetiary medical center. After tumor resection, folded sheets of MTX (R), synthetic degradable biomatrix dermal substitute were used to fill the parotid bed and restore contour. The graft was anchored to adjacent anatomic landmarks. Drains were placed routinely and removed after 7 days. Postoperative follow-up included clinical evaluation, photographic analysis, and assessment for Frey syndrome.</p>\n\n<p><strong>Results: </strong>The series included three patients aged 35 to 68 years (mean 51). All patients achieved excellent restoration of facial contour with symmetric results. No cases of hematoma, or graft extrusion were observed. Patients reported high satisfaction with postoperative appearance and minimal pain or scar contracture. </p>\n\n<p><strong>Discussion: </strong>Reconstruction of post parotid defects has been described previously using acellular dermis, free dermal fat grafts , among others.  The goal is to minimize the resultant cosmetic deformity and limit the development of Frey syndrome. A synthetic biodegradable dermal substitute (MTX(R)) was recently developed for soft tissue coverage and to fill in soft tissue defects. We describe our initial experience using this as an interpositional and contour-restoring matrix after parotidectomy.  This reconstruction method provided stable, natural results without donor-site morbidity. Compared with autologous flaps, the technique is simpler, less invasive, and significantly reduces operative time.  Compared to acellular dermal matrix this provided significant cost savings. The absence of immunologic reactions or extrusion supports its long-term biocompatibility. Follow up is needed to determine if it also acts as a protective barrier to reduce the risk of Frey syndrome. This is the first reported series in the use of a synthetic biodegradable dermal matrix for parotidectomy reconstruction.</p>\n\n<p><strong>Conclusion: </strong>Reconstruction of parotidectomy defects using a synthetic biodegradable dermal matrix offers an effective, safe, and esthetically alternative to traditional methods. This demonstrated excellent contour restoration, minimal complications, and cost savings compared to previously described methods. These findings support its use as an alternative for post-parotidectmy reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152777--></body></html>"
    },
    {
      "uid": "P395",
      "content_id": "153164",
      "abstract_number": "P395",
      "poster_number": "P395",
      "title": "Comparison of Extracapsular Dissection and Main Trunk Identification on Surgical Outcomes in Modified Facelift Parotidectomy",
      "summary": "Main trunk and extracapsular dissection facial nerve identification techniques demonstrated comparable rates of postoperative facial weakness and overall complications in the setting of a facelift incision. Appropriately selected patients had similar outcomes regardless of which approach to facial nerve management was used.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153164",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Payton Dudley, BS",
      "presenter": "Payton Dudley, BS",
      "authors": "Payton Dudley, BS ; Megan Gillespie; Patrick Tassone",
      "normalized_authors": [
        "Payton Dudley",
        "Megan Gillespie",
        "Patrick Tassone"
      ],
      "affiliations": [
        "University of Missouri- Columbia"
      ],
      "normalized_institutions": [
        "University of Missouri- Columbia"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 230,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Payton Dudley, BS ; Megan Gillespie; Patrick Tassone",
        "Affiliations": "University of Missouri- Columbia",
        "Background": "Both extracapsular dissection and main facial nerve trunk identification are accepted strategies for parotidectomy. Differences in their use when performing facelift incision approach are understudied. Here, we present a series of patients undergoing parotidectomy via facelift incision to examine differences between extracapsular dissection and main trunk identification.",
        "Methods": "A retrospective cohort study of patients undergoing parotidectomy via facelift incision. The study populations included patients with benign or malignant parotid tumors who were treated by a single surgeon at a tertiary care referral center. Each case was categorized based on facial nerve identification technique: main trunk identification versus extracapsular dissection. Group comparisons were examined by Chi-squared and Fisher exact test.",
        "Results": "A total of 26 patients underwent parotidectomy via facelift incision: 15 patients had main trunk identification, and 11 patients had extracapsular dissection. There were no significant differences between groups in age, tumor dimensions, tumor volume, postoperative facial weakness, duration of weakness, hematoma, seroma, or recurrence rates (all p > 0.05). The only difference between groups was the used of post-operative drains which were more common in cases of main trunk identification (11 main trunk vs. 3 extracapsular, p = 0.020).",
        "Conclusions": "Main trunk and extracapsular dissection facial nerve identification techniques demonstrated comparable rates of postoperative facial weakness and overall complications in the setting of a facelift incision. Appropriately selected patients had similar outcomes regardless of which approach to facial nerve management was used."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparison of Extracapsular Dissection and Main Trunk Identification on Surgical Outcomes in Modified Facelift Parotidectomy</span>. <u>Payton Dudley, BS</u>; Megan Gillespie; Patrick Tassone. University of Missouri- Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Both extracapsular dissection and main facial nerve trunk identification are accepted strategies for parotidectomy. Differences in their use when performing facelift incision approach are understudied. Here, we present a series of patients undergoing parotidectomy via facelift incision to examine differences between extracapsular dissection and main trunk identification.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of patients undergoing parotidectomy via facelift incision. The study populations included patients with benign or malignant parotid tumors who were treated by a single surgeon at a tertiary care referral center. Each case was categorized based on facial nerve identification technique: main trunk identification versus extracapsular dissection. Group comparisons were examined by Chi-squared and Fisher exact test.</p>\n\n<p><strong>Results: </strong>A total of 26 patients underwent parotidectomy via facelift incision: 15 patients had main trunk identification, and 11 patients had extracapsular dissection. There were no significant differences between groups in age, tumor dimensions, tumor volume, postoperative facial weakness, duration of weakness, hematoma, seroma, or recurrence rates (all p > 0.05). The only difference between groups was the used of post-operative drains which were more common in cases of main trunk identification (11 main trunk vs. 3 extracapsular, p = 0.020).</p>\n\n<p><strong>Conclusions: </strong>Main trunk and extracapsular dissection facial nerve identification techniques demonstrated comparable rates of postoperative facial weakness and overall complications in the setting of a facelift incision. Appropriately selected patients had similar outcomes regardless of which approach to facial nerve management was used. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153164--></body></html>"
    },
    {
      "uid": "P396",
      "content_id": "153741",
      "abstract_number": "P396",
      "poster_number": "P396",
      "title": "Ultrasound Correlates to Histopathology of Parotid Oncocytoma",
      "summary": "Parotid oncocytomas are rare, benign tumors believed to arise from compensatory mitochondrial hyperplasia. Although definitive diagnosis of salivary gland masses relies on histopathologic evaluation, ultrasound remains the standard first-line imaging modality in the initial assessment of parotid lesions. However, the role of ultrasound in the characterization of parotid gland oncocytomas has not been...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153741",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samantha N Corman",
      "presenter": "Samantha N Corman",
      "authors": "Samantha N Corman ; Nicole E Becker, MD; Henry T Hoffman, MD",
      "normalized_authors": [
        "Samantha N Corman",
        "Nicole E Becker",
        "Henry T Hoffman"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153741/Oncocytoma%20Fig1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153741/Oncocytoma%20Fig1.jpg",
          "alt": "Figure 1: (A) B-mode ultrasound of the left parotid lesion. (B) Color Doppler ultrasound demonstrating intratumoral vessels. (C) Color Doppler ultrasound demonstrating a spoke-wheel intratumoral vascular pattern.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153741"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 196,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Samantha N Corman ; Nicole E Becker, MD; Henry T Hoffman, MD",
        "Affiliations": "University of Iowa",
        "Abstract": "Parotid oncocytomas are rare, benign tumors believed to arise from compensatory mitochondrial hyperplasia. Although definitive diagnosis of salivary gland masses relies on histopathologic evaluation, ultrasound remains the standard first-line imaging modality in the initial assessment of parotid lesions. However, the role of ultrasound in the characterization of parotid gland oncocytomas has not been comprehensively explored. Prior literature in salivary gland and renal imaging has described the classic sonographic features of oncocytomas, yet few published works have translated these findings into clinical practice. We present the case of a 74-year-old woman with a unilateral, painless facial mass whose initial ultrasound demonstrated a characteristic spoke-wheel vascular pattern with a possible central stellate scar. Histologic analysis of the excised lesion revealed a central scar surrounded by oncocytes, confirmed by their abundant acidophilic granular cytoplasm and bland nuclei with regular nuclear contours. This case highlights a classic ultrasound appearance of parotid oncocytoma with its histologic correlates and supports the potential utility of ultrasound for early, noninvasive prediction of this benign salivary gland tumor. Figure 1: (A) B-mode ultrasound of the left parotid lesion. (B) Color Doppler ultrasound demonstrating intratumoral vessels. (C) Color Doppler ultrasound demonstrating a spoke-wheel intratumoral vascular pattern."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ultrasound Correlates to Histopathology of Parotid Oncocytoma</span>. <u>Samantha N Corman</u>; Nicole E Becker, MD; Henry T Hoffman, MD. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Parotid oncocytomas are rare, benign tumors believed to arise from compensatory mitochondrial hyperplasia. Although definitive diagnosis of salivary gland masses relies on histopathologic evaluation, ultrasound remains the standard first-line imaging modality in the initial assessment of parotid lesions. However, the role of ultrasound in the characterization of parotid gland oncocytomas has not been comprehensively explored. Prior literature in salivary gland and renal imaging has described the classic sonographic features of oncocytomas, yet few published works have translated these findings into clinical practice. We present the case of a 74-year-old woman with a unilateral, painless facial mass whose initial ultrasound demonstrated a characteristic spoke-wheel vascular pattern with a possible central stellate scar. Histologic analysis of the excised lesion revealed a central scar surrounded by oncocytes, confirmed by their abundant acidophilic granular cytoplasm and bland nuclei with regular nuclear contours. This case highlights a classic ultrasound appearance of parotid oncocytoma with its histologic correlates and supports the potential utility of ultrasound for early, noninvasive prediction of this benign salivary gland tumor. </p>\n\n<p><img alt='Figure 1: (A) B-mode ultrasound of the left parotid lesion. (B) Color Doppler ultrasound demonstrating intratumoral vessels. (C) Color Doppler ultrasound demonstrating a spoke-wheel intratumoral vascular pattern. ' src='https://www.submitmyabstract.com/abs/images/153741/Oncocytoma%20Fig1.jpg' /></p>\n\n<p>Figure 1: (A) B-mode ultrasound of the left parotid lesion. (B) Color Doppler ultrasound demonstrating intratumoral vessels. (C) Color Doppler ultrasound demonstrating a spoke-wheel intratumoral vascular pattern.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153741--></body></html>"
    },
    {
      "uid": "P397",
      "content_id": "153132",
      "abstract_number": "P397",
      "poster_number": "P397",
      "title": "Ranula Associated with Papillary Cystadenoma",
      "summary": "Ranulas are typically diagnosed clinically, with diagnostic confirmation aided by the presence of elevated amylase levels in aspirated fluid. Although prior case reports have described neoplasms that clinically mimicked ranulas, none, to our knowledge, have documented a tumor presenting in association with a true ranula validated by amylase fluid analysis. We report the case of a 68-year-old man with a history of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153132",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samantha N Corman, BS",
      "presenter": "Samantha N Corman, BS",
      "authors": "Samantha N Corman, BS ; Nicole E Becker, MD; Henry T Hoffman, MD",
      "normalized_authors": [
        "Samantha N Corman",
        "Nicole E Becker",
        "Henry T Hoffman"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153132/Fig1%20Ranula.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153132/Fig1%20Ranula.jpg",
          "alt": "Figure 1. Histology supportive of diagnosis of ranula. Granulation tissue is present diffusely through this sample. There is no consistent epithelial lining appreciated on the lower half of this slide, consistent with ranula presentation.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153132"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153132/Fig2%20Pap%20Cystad.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153132/Fig2%20Pap%20Cystad.jpg",
          "alt": "Figure 2. Histology supportive of diagnosis of papillary cystadenoma. Epithelial lining with a mix of morphologies including simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, and focal papillary projections.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153132"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 300,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Samantha N Corman, BS ; Nicole E Becker, MD; Henry T Hoffman, MD",
        "Affiliations": "University of Iowa",
        "Abstract": "Ranulas are typically diagnosed clinically, with diagnostic confirmation aided by the presence of elevated amylase levels in aspirated fluid. Although prior case reports have described neoplasms that clinically mimicked ranulas, none, to our knowledge, have documented a tumor presenting in association with a true ranula validated by amylase fluid analysis. We report the case of a 68-year-old man with a history of prior submandibular gland surgery who was found to have an amylase-positive simple ranula associated with a sublingual papillary cystadenoma. The patient presented with a painful, left-sided sublingual mass. Ultrasound and CT imaging demonstrated a 30.9 × 17.4 mm hypoechoic lesion in the region of the left sublingual gland. The patient underwent left sublingual gland resection with decompression of the cyst and fluid analysis for amylase. Histopathologic evaluation revealed a mixed picture of ranula and papillary cystadenoma. Portions of the cyst wall lacked an epithelial lining and demonstrated abundant granulation tissue, consistent with a ranula (Figure 1). Other areas showed features consistent with papillary cystadenoma, including an epithelial lining with varied morphologies such as simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, pseudostratified epithelium with goblet cells, and focal papillary projections (Figure 2). The amylase level of the cyst fluid measured 36,542 U/L. To our knowledge, this is the first report demonstrating an elevated amylase level that definitively corroborates the presence of a true ranula in association with a histologically confirmed papillary cystadenoma. Figure 1. Histology supportive of diagnosis of ranula. Granulation tissue is present diffusely through this sample. There is no consistent epithelial lining appreciated on the lower half of this slide, consistent with ranula presentation. Figure 2. Histology supportive of diagnosis of papillary cystadenoma. Epithelial lining with a mix of morphologies including simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, and focal papillary projections."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ranula Associated with Papillary Cystadenoma</span>. <u>Samantha N Corman, BS</u>; Nicole E Becker, MD; Henry T Hoffman, MD. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Ranulas are typically diagnosed clinically, with diagnostic confirmation aided by the presence of elevated amylase levels in aspirated fluid. Although prior case reports have described neoplasms that clinically mimicked ranulas, none, to our knowledge, have documented a tumor presenting in association with a true ranula validated by amylase fluid analysis. We report the case of a 68-year-old man with a history of prior submandibular gland surgery who was found to have an amylase-positive simple ranula associated with a sublingual papillary cystadenoma. The patient presented with a painful, left-sided sublingual mass. Ultrasound and CT imaging demonstrated a 30.9 × 17.4 mm hypoechoic lesion in the region of the left sublingual gland. The patient underwent left sublingual gland resection with decompression of the cyst and fluid analysis for amylase. Histopathologic evaluation revealed a mixed picture of ranula and papillary cystadenoma. Portions of the cyst wall lacked an epithelial lining and demonstrated abundant granulation tissue, consistent with a ranula (Figure 1). Other areas showed features consistent with papillary cystadenoma, including an epithelial lining with varied morphologies such as simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, pseudostratified epithelium with goblet cells, and focal papillary projections (Figure 2). The amylase level of the cyst fluid measured 36,542 U/L. To our knowledge, this is the first report demonstrating an elevated amylase level that definitively corroborates the presence of a true ranula in association with a histologically confirmed papillary cystadenoma.</p>\n\n<p><img alt='Figure 1. Histology supportive of diagnosis of ranula. Granulation tissue is present diffusely through this sample. There is no consistent epithelial lining appreciated on the lower half of this slide, consistent with ranula presentation.  ' src='https://www.submitmyabstract.com/abs/images/153132/Fig1%20Ranula.jpg' /></p>\n\n<p>Figure 1. Histology supportive of diagnosis of ranula. Granulation tissue is present diffusely through this sample. There is no consistent epithelial lining appreciated on the lower half of this slide, consistent with ranula presentation.</p>\n\n<p><img alt='Figure 2. Histology supportive of diagnosis of papillary cystadenoma. Epithelial lining with a mix of morphologies including simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, and focal papillary projections. ' src='https://www.submitmyabstract.com/abs/images/153132/Fig2%20Pap%20Cystad.jpg' /></p>\n\n<p>Figure 2. Histology supportive of diagnosis of papillary cystadenoma. Epithelial lining with a mix of morphologies including simple cuboidal cells, multilayered cells with eosinophilic cytoplasm, and focal papillary projections.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153132--></body></html>"
    },
    {
      "uid": "P398",
      "content_id": "153940",
      "abstract_number": "P398",
      "poster_number": "P398",
      "title": "The Role of Surgical Margins and Postoperative Radiotherapy in Adenoid Cystic Carcinoma of the Major Salivary Glands: A Systematic Review",
      "summary": "Our findings suggest that incomplete resection is common in major salivary gland ACC, likely due to perineural invasion and irregular tumor borders. Positive surgical margins appear to signal unfavorable prognosis with the benefit of adjuvant RT not appearing to substantially improve survival outcomes. The planned meta-analysis will quantify the role of margin status and postoperative RT on major salivary gland...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153940",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Divya Patel",
      "presenter": "Divya Patel",
      "authors": "Divya Patel 1 ; Payal Patel 1 ; Mark Varvares, MD, FACS 2",
      "normalized_authors": [
        "Divya Patel",
        "Payal Patel",
        "Mark Varvares"
      ],
      "affiliations": [
        "Carle Illinois College of Medicine, University of Illinois at Urbana Champaign, Illinois",
        "Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"
      ],
      "normalized_institutions": [
        "Carle Illinois College of Medicine, University of Illinois at Urbana Champaign, Illinois",
        "Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Divya Patel 1 ; Payal Patel 1 ; Mark Varvares, MD, FACS 2",
        "Affiliations": "1 Carle Illinois College of Medicine, University of Illinois at Urbana Champaign, Illinois; 2 Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts",
        "Introduction": "Adenoid cystic carcinoma (ACC) is a rare malignancy of the head and neck region, comprising approximately 10% of major salivary gland tumors and most often originating in the parotid gland. Despite its indolent presentation, ACC is characterized by slow, infiltrative growth with prominent perineural invasion, contributing to poor long-term prognosis and high recurrence and distant metastasis rates. Surgical resection with negative margins remains the primary treatment; however, anatomic constraints and infiltrative tumor patterns often prevent complete excision. Compromised surgical margins are associated with reduced survival, emphasizing their prognostic significance. Adjuvant radiotherapy (RT) is frequently utilized in margin-positive cases to reduce local recurrence, though its benefit relative to margin status remains unclear. We conducted a systematic review to evaluate the impact of surgical margin status and postoperative RT on disease outcomes in major salivary gland ACC.",
        "Methods": "A systemic review was conducted in Medline, Embase, Web of Science and Cochrane Library databases in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines through June 2025. Eligible studies reported margin status of clinically diagnosed cases of ACC of the major salivary glands. Outcome measures were patient demographics, tumor site, and surgical margin status, as well as local recurrence, distant metastasis and mortality rates stratified by margin status and treatment modality (surgery alone versus surgery with adjuvant RT).",
        "Results": "Our search screened 715 abstracts, of which 114 papers that reported major salivary gland tumor margin status underwent full-text review. A total of 28 unique studies were included for qualitative synthesis, representing a total of 775 patients with ACC of the major salivary glands. Most tumors arose in the parotid gland (n = 408, 53%), followed by the submandibular (n = 321, 41%) and sublingual glands (n = 46, 6%). Across these studies, 44% of patients had positive surgical margins, 53% had negative margins and 3% had unclear margin status.",
        "Abstract": "Eleven studies detailed margin status and then stratified patients by treatment modality, reporting oncologic outcomes for each subgroup, allowing for analysis of the benefit of adjuvant RT in positive versus negative margins. Within these studies, 36% of patients with positive margins underwent surgery alone and 64% received surgery with adjuvant RT, with no evidence of disease (NED) reported in 61% and 46% of cases, respectively. Among patients with negative margins, 20% underwent surgery alone and 80% received surgery with adjuvant RT, with NED in 63% of cases for both treatment regimens.",
        "Conclusion": "Our findings suggest that incomplete resection is common in major salivary gland ACC, likely due to perineural invasion and irregular tumor borders. Positive surgical margins appear to signal unfavorable prognosis with the benefit of adjuvant RT not appearing to substantially improve survival outcomes. The planned meta-analysis will quantify the role of margin status and postoperative RT on major salivary gland ACC recurrence, metastasis and survival rates. Gland-specific stratification of outcomes will further clarify the impact of anatomic factors on resection status, ultimately supporting the development of evidence-based treatment strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Role of Surgical Margins and Postoperative Radiotherapy in Adenoid Cystic Carcinoma of the Major Salivary Glands: A Systematic Review</span>. <u>Divya Patel</u><sup>1</sup>; Payal Patel<sup>1</sup>; Mark Varvares, MD, FACS<sup>2</sup>. <sup>1</sup>Carle Illinois College of Medicine, University of Illinois at Urbana Champaign, Illinois; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Adenoid cystic carcinoma (ACC) is a rare malignancy of the head and neck region, comprising approximately 10% of major salivary gland tumors and most often originating in the parotid gland. Despite its indolent presentation, ACC is characterized by slow, infiltrative growth with prominent perineural invasion, contributing to poor long-term prognosis and high recurrence and distant metastasis rates. Surgical resection with negative margins remains the primary treatment; however, anatomic constraints and infiltrative tumor patterns often prevent complete excision. Compromised surgical margins are associated with reduced survival, emphasizing their prognostic significance. Adjuvant radiotherapy (RT) is frequently utilized in margin-positive cases to reduce local recurrence, though its benefit relative to margin status remains unclear. We conducted a systematic review to evaluate the impact of surgical margin status and postoperative RT on disease outcomes in major salivary gland ACC.</p>\n\n<p><strong>Methods:</strong> A systemic review was conducted in Medline, Embase, Web of Science and Cochrane Library databases in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines through June 2025. Eligible studies reported margin status of clinically diagnosed cases of ACC of the major salivary glands. Outcome measures were patient demographics, tumor site, and surgical margin status, as well as local recurrence, distant metastasis and mortality rates stratified by margin status and treatment modality (surgery alone versus surgery with adjuvant RT). </p>\n\n<p><strong>Results:</strong> Our search screened 715 abstracts, of which 114 papers that reported major salivary gland tumor margin status underwent full-text review. A total of 28 unique studies were included for qualitative synthesis, representing a total of 775 patients with ACC of the major salivary glands. Most tumors arose in the parotid gland (n = 408, 53%), followed by the submandibular (n = 321, 41%) and sublingual glands (n = 46, 6%). Across these studies, 44% of patients had positive surgical margins, 53% had negative margins and 3% had unclear margin status. </p>\n\n<p>Eleven studies detailed margin status and then stratified patients by treatment modality, reporting oncologic outcomes for each subgroup, allowing for analysis of the benefit of adjuvant RT in positive versus negative margins. Within these studies, 36% of patients with positive margins underwent surgery alone and 64% received surgery with adjuvant RT, with no evidence of disease (NED) reported in 61% and 46% of cases, respectively. Among patients with negative margins, 20% underwent surgery alone and 80% received surgery with adjuvant RT, with NED in 63% of cases for both treatment regimens. </p>\n\n<p><strong>Conclusion: </strong>Our findings suggest that incomplete resection is common in major salivary gland ACC, likely due to perineural invasion and irregular tumor borders. Positive surgical margins appear to signal unfavorable prognosis with the benefit of adjuvant RT not appearing to substantially improve survival outcomes. The planned meta-analysis will quantify the role of margin status and postoperative RT on major salivary gland ACC recurrence, metastasis and survival rates. Gland-specific stratification of outcomes will further clarify the impact of anatomic factors on resection status, ultimately supporting the development of evidence-based treatment strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153940--></body></html>"
    },
    {
      "uid": "P399",
      "content_id": "153292",
      "abstract_number": "P399",
      "poster_number": "P399",
      "title": "Not Every Stone Is a Stone: Vascular Anomalies Mimicking Major Salivary Gland Sialolithiasis — A Case Series",
      "summary": "Vascular anomalies should be considered when radiopaque cheek or salivary-region lesions are not clearly associated with meal-related symptoms or when imaging reveals extraglandular calcifications. Incorporating MRI in the diagnostic workup may prevent misdiagnosis and avoid invasive interventions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153292",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taghreed Al Riyami",
      "presenter": "Taghreed Al Riyami",
      "authors": "Salma Al Sheibani, MD; Mohammed Al Ajmi, MD; Taghreed Al Riyami",
      "normalized_authors": [
        "Salma Al Sheibani",
        "Mohammed Al Ajmi",
        "Taghreed Al Riyami"
      ],
      "affiliations": [
        "Al Nahdha Hospital"
      ],
      "normalized_institutions": [
        "Al Nahdha Hospital"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 175,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Salma Al Sheibani, MD; Mohammed Al Ajmi, MD; Taghreed Al Riyami",
        "Affiliations": "Al Nahdha Hospital",
        "Background": "Vascular anomalies such as hemangiomas and arteriovenous malformations (AVMs) may contain phleboliths, appearing as radiopaque lesions similar to salivary calculi. This can lead to misdiagnosis and unnecessary sialendoscopic interventions.",
        "Objective": "To present five cases of vascular anomalies involving major salivary gland regions initially misdiagnosed as sialolithiasis and highlight key diagnostic features that differentiate these conditions.",
        "Methods": "A retrospective review was conducted of five patients evaluated in our sialendoscopy clinic over seven years (2018–2025), presenting with cheek or submandibular swelling and radiodense lesions. Clinical examination, CT, MRI, and sialendoscopy findings were analyzed. Management and outcomes were recorded.",
        "Results": "All cases demonstrated phlebolith-forming vascular anomalies, including two AVMs and two hemangiomas involving the parotid region, and one venolymphatic malformation affecting the submandibular gland. Classic obstructive symptoms were absent or inconsistent. Three cases underwent surgical excision with favorable outcomes; two opted for observation.",
        "Conclusion": "Vascular anomalies should be considered when radiopaque cheek or salivary-region lesions are not clearly associated with meal-related symptoms or when imaging reveals extraglandular calcifications. Incorporating MRI in the diagnostic workup may prevent misdiagnosis and avoid invasive interventions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Not Every Stone Is a Stone: Vascular Anomalies Mimicking Major Salivary Gland Sialolithiasis — A Case Series</span>. Salma Al Sheibani, MD; Mohammed Al Ajmi, MD; <u>Taghreed Al Riyami</u>. Al Nahdha Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Vascular anomalies such as hemangiomas and arteriovenous malformations (AVMs) may contain phleboliths, appearing as radiopaque lesions similar to salivary calculi. This can lead to misdiagnosis and unnecessary sialendoscopic interventions.</p>\n\n<p><strong>Objective: </strong>To present five cases of vascular anomalies involving major salivary gland regions initially misdiagnosed as sialolithiasis and highlight key diagnostic features that differentiate these conditions.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted of five patients evaluated in our sialendoscopy clinic over seven years (2018–2025), presenting with cheek or submandibular swelling and radiodense lesions. Clinical examination, CT, MRI, and sialendoscopy findings were analyzed. Management and outcomes were recorded.</p>\n\n<p><strong>Results: </strong>All cases demonstrated phlebolith-forming vascular anomalies, including two AVMs and two hemangiomas involving the parotid region, and one venolymphatic malformation affecting the submandibular gland. Classic obstructive symptoms were absent or inconsistent. Three cases underwent surgical excision with favorable outcomes; two opted for observation.</p>\n\n<p><strong>Conclusion: </strong>Vascular anomalies should be considered when radiopaque cheek or salivary-region lesions are not clearly associated with meal-related symptoms or when imaging reveals extraglandular calcifications. Incorporating MRI in the diagnostic workup may prevent misdiagnosis and avoid invasive interventions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153292--></body></html>"
    },
    {
      "uid": "P400",
      "content_id": "155317",
      "abstract_number": "P400",
      "poster_number": "P400",
      "title": "Survival Benefit of Elective Neck Dissection for Clinically N0 Salivary Gland Carcinoma: A Systematic Review and Meta-analysis",
      "summary": "This meta-analysis suggests that END may be beneficial in patients with high-grade tumors in terms of survival outcomes. These findings indicate that patient selection based on tumor grade is an important consideration in optimizing neck management strategies for SGCs.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155317",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ah Ra Jung",
      "presenter": "Ah Ra Jung",
      "authors": "Yeon Soo Kim 1 ; Ah Ra Jung 2",
      "normalized_authors": [
        "Yeon Soo Kim",
        "Ah Ra Jung"
      ],
      "affiliations": [
        "Korea University College of Medicine",
        "Nowon Eulji Medical Center, Eulji University School of Medicine"
      ],
      "normalized_institutions": [
        "Korea University College of Medicine",
        "Nowon Eulji Medical Center, Eulji University School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 240,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Materials and Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Yeon Soo Kim 1 ; Ah Ra Jung 2",
        "Affiliations": "1 Korea University College of Medicine; 2 Nowon Eulji Medical Center, Eulji University School of Medicine",
        "Objectives": "Salivary gland carcinomas (SGCs) are a heterogeneous group of malignancies, and the role of elective neck dissection (END) in patients with clinically node-negative (cN0) disease remains controversial. This study is the first systematic review and meta-analysis to quantify the survival benefit of END in this patient population, with a particular focus on the impact in high-grade tumors.",
        "Materials and Methods": "A systematic literature search was conducted across the Medline, Embase, and Cochrane Library databases. Studies that compared survival outcomes between END and observation in patients with cN0 SGC were included. A meta-analysis was performed using a random-effects model to calculate pooled odds ratios (OR) for overall survival (OS) and disease-free survival (DFS).",
        "Results": "For the overall cN0 SGC cohort, END was not associated with a statistically significant improvement in DFS (OR 1.46, 95% CI 0.85-2.52, p=0.168) or OS (OR 1.32, 95% CI 0.86-2.03, p=0.203). However, in the pre-planned subgroup analysis of patients with high-grade SGCs, END demonstrated a strong trend toward improved DFS (OR 2.37, 95% CI 0.93-6.06, p=0.072) and was associated with a statistically significant improvement in OS (OR 2.05, 95% CI 1.06-3.94, p=0.032).",
        "Conclusions": "This meta-analysis suggests that END may be beneficial in patients with high-grade tumors in terms of survival outcomes. These findings indicate that patient selection based on tumor grade is an important consideration in optimizing neck management strategies for SGCs."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Survival Benefit of Elective Neck Dissection for Clinically N0 Salivary Gland Carcinoma: A Systematic Review and Meta-analysis</span>. Yeon Soo Kim<sup>1</sup>; <u>Ah Ra Jung</u><sup>2</sup>. <sup>1</sup>Korea University College of Medicine; <sup>2</sup>Nowon Eulji Medical Center, Eulji University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> Salivary gland carcinomas (SGCs) are a heterogeneous group of malignancies, and the role of elective neck dissection (END) in patients with clinically node-negative (cN0) disease remains controversial. This study is the first systematic review and meta-analysis to quantify the survival benefit of END in this patient population, with a particular focus on the impact in high-grade tumors.</p>\n\n<p><strong>Materials and Methods: </strong>A systematic literature search was conducted across the Medline, Embase, and Cochrane Library databases. Studies that compared survival outcomes between END and observation in patients with cN0 SGC were included. A meta-analysis was performed using a random-effects model to calculate pooled odds ratios (OR) for overall survival (OS) and disease-free survival (DFS).</p>\n\n<p><strong>Results:</strong> For the overall cN0 SGC cohort, END was not associated with a statistically significant improvement in DFS (OR 1.46, 95% CI 0.85-2.52, p=0.168) or OS (OR 1.32, 95% CI 0.86-2.03, p=0.203). However, in the pre-planned subgroup analysis of patients with high-grade SGCs, END demonstrated a strong trend toward improved DFS (OR 2.37, 95% CI 0.93-6.06, p=0.072) and was associated with a statistically significant improvement in OS (OR 2.05, 95% CI 1.06-3.94, p=0.032).</p>\n\n<p><strong>Conclusions: </strong>This meta-analysis suggests that END may be beneficial in patients with high-grade tumors in terms of survival outcomes. These findings indicate that patient selection based on tumor grade is an important consideration in optimizing neck management strategies for SGCs.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155317--></body></html>"
    },
    {
      "uid": "P401",
      "content_id": "154007",
      "abstract_number": "P401",
      "poster_number": "P401",
      "title": "Sternocleidomastoid Muscle Rotational Flap for Repair of a Persistent Post-Parotidectomy Salivary Fistula: A Case Report",
      "summary": "The SCM rotational flap provides a reliable, well-vascularized, and straightforward option for closure of persistent salivary fistula after parotidectomy. Its proximity to the defect, minimal donor site morbidity, and ability to obliterate dead space make it an excellent reconstructive choice in selected patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154007",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Morgan Terry, MD",
      "presenter": "Morgan Terry, MD",
      "authors": "Morgan Terry, MD ; Michael Dougherty, MD; Ryan Hellums, DO",
      "normalized_authors": [
        "Morgan Terry",
        "Michael Dougherty",
        "Ryan Hellums"
      ],
      "affiliations": [
        "OHSU"
      ],
      "normalized_institutions": [
        "OHSU"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 192,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Presentation",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Morgan Terry, MD ; Michael Dougherty, MD; Ryan Hellums, DO",
        "Affiliations": "OHSU",
        "Introduction": "Salivary fistula is an uncommon but frustrating complication after parotidectomy, often resulting in delayed wound healing and patient discomfort. While conservative management is typically successful, persistent fistulas may require surgical repair. This case illustrates the successful use of a local sternocleidomastoid (SCM) rotational flap to achieve durable closure after failed medical management.",
        "Case Presentation": "A 34-year-old woman presented with persistent salivary fistula one year following a superficial parotidectomy for pleomorphic adenoma. Conservative measures, including pressure dressings, botulism toxin injections, and anticholinergic therapy failed to resolve the leak. Surgical exploration revealed a small, well-defined fistulous tract within the parotid bed that was able to be probed and ligated. The superiorly based SCM flap was elevated through the existing incision, rotated medially to fill the defect, and inset over the leak site to provide vascularized muscle coverage.",
        "Results": "Postoperatively, the patient recovered well without recurrence of the salivary fistula. There were no flap-related complications.",
        "Conclusion": "The SCM rotational flap provides a reliable, well-vascularized, and straightforward option for closure of persistent salivary fistula after parotidectomy. Its proximity to the defect, minimal donor site morbidity, and ability to obliterate dead space make it an excellent reconstructive choice in selected patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sternocleidomastoid Muscle Rotational Flap for Repair of a Persistent Post-Parotidectomy Salivary Fistula: A Case Report</span>. <u>Morgan Terry, MD</u>; Michael Dougherty, MD; Ryan Hellums, DO. OHSU<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Salivary fistula is an uncommon but frustrating complication after parotidectomy, often resulting in delayed wound healing and patient discomfort. While conservative management is typically successful, persistent fistulas may require surgical repair. This case illustrates the successful use of a local sternocleidomastoid (SCM) rotational flap to achieve durable closure after failed medical management.</p>\n\n<p><strong>Case Presentation: </strong>A 34-year-old woman presented with persistent salivary fistula one year following a superficial parotidectomy for pleomorphic adenoma. Conservative measures, including pressure dressings, botulism toxin injections, and anticholinergic therapy failed to resolve the leak. Surgical exploration revealed a small, well-defined fistulous tract within the parotid bed that was able to be probed and ligated. The superiorly based SCM flap was elevated through the existing incision, rotated medially to fill the defect, and inset over the leak site to provide vascularized muscle coverage.</p>\n\n<p><strong>Results: </strong>Postoperatively, the patient recovered well without recurrence of the salivary fistula. There were no flap-related complications.</p>\n\n<p><strong>Conclusion: </strong>The SCM rotational flap provides a reliable, well-vascularized, and straightforward option for closure of persistent salivary fistula after parotidectomy. Its proximity to the defect, minimal donor site morbidity, and ability to obliterate dead space make it an excellent reconstructive choice in selected patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154007--></body></html>"
    },
    {
      "uid": "P403",
      "content_id": "154556",
      "abstract_number": "P403",
      "poster_number": "P403",
      "title": "Occult Nodal Metastasis in Intermediate-Grade Mucoepidermoid Carcinoma of the Major Salivary Glands and the Role of Elective Neck Dissection: A Systematic Review",
      "summary": "The overall occult nodal metastasis rate remains below traditional thresholds for recommending END, however limited long-term follow-up in existing studies may underestimate the true impact of delayed nodal disease. Further research is needed to clarify whether any subgroup of intermediate-grade MEC patients may benefit from elective neck management.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154556",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rahul Patel, BS",
      "presenter": "Rahul Patel, BS",
      "authors": "Rahul Patel, BS 1 ; Kenny Do, BS 2 ; Christopher Waite, BS 1 ; Kurtis Young, MD 3 ; Robert Wang, MD 3 ; Andrew Birkeland, MD 4",
      "normalized_authors": [
        "Rahul Patel",
        "Christopher Waite",
        "Kurtis Young",
        "Robert Wang",
        "Andrew Birkeland"
      ],
      "affiliations": [
        "Touro University Nevada College of Osteopathic Medicine",
        "Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas",
        "Department of Otolaryngology – Head and Neck Surgery, University of Nevada, Las Vegas",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, Davis"
      ],
      "normalized_institutions": [
        "Touro University Nevada College of Osteopathic Medicine",
        "Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas",
        "Department of Otolaryngology – Head and Neck Surgery, University of Nevada, Las Vegas",
        "Department of Otolaryngology – Head and Neck Surgery, University of California, Davis"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 350,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Data sources",
        "Study selection",
        "Data extraction",
        "Data synthesis",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Rahul Patel, BS 1 ; Kenny Do, BS 2 ; Christopher Waite, BS 1 ; Kurtis Young, MD 3 ; Robert Wang, MD 3 ; Andrew Birkeland, MD 4",
        "Affiliations": "1 Touro University Nevada College of Osteopathic Medicine; 2 Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas; 3 Department of Otolaryngology – Head and Neck Surgery, University of Nevada, Las Vegas; 4 Department of Otolaryngology – Head and Neck Surgery, University of California, Davis",
        "Objective": "The optimal management of the cN0 neck in intermediate-grade mucoepidermoid carcinoma (MEC) is unclear. High-grade MEC often calls for elective neck dissection (END) due to a substantial risk of occult nodal metastasis, while low-grade MEC rarely metastasizes and is often managed with observation. Intermediate-grade tumors are less defined, and current guidelines do not clarify whether END is beneficial. The current study aims to determine the risk of occult cervical metastasis in cN0 intermediate-grade MEC of the major salivary glands and evaluate whether END improves survival outcomes.",
        "Data sources": "Pubmed, Embase, and Scopus databases were systematically searched in all languages without restriction of publication dates.",
        "Study selection": "Studies reporting data on outcomes for cN0 patients with intermediate-grade MEC of the major salivary glands and providing data on treatment modality, pathologic N-staging, or survival outcomes were included.",
        "Data extraction": "Included studies were evaluated through full text review and data on occult metastasis rates and survival outcomes in patients stratified by END status were analyzed.",
        "Data synthesis": "Data were qualitatively synthesized, with pooled values calculated for applicable variables.",
        "Results": "The rate of occult cervical metastases in cN0 intermediate-grade MEC of the major salivary glands was 13.03%. This value falls between the 3-9% and 25-35% estimated risk for low and high-grade MEC respectively. Larger database studies involving NCDB and SEER databases reported low occult nodal rates (roughly 5-8%), comparable to low-grade MEC, whereas smaller institutional series with more selective END usage found higher occult nodal positivity (22-29%).",
        "Abstract": "The 10-year OS for intermediate-grade parotid MEC was virtually identical whether or not END was performed. No OS/DFS benefit to END in intermediate-grade cases was found, even when a high occult metastasis rate of ~27% was reported. Importantly, even in higher-risk subsets, no definitive survival benefit from END was observed. Advanced primary tumor stage and adverse pathological features were consistently correlated with higher occult nodal risk.",
        "Conclusion": "The overall occult nodal metastasis rate remains below traditional thresholds for recommending END, however limited long-term follow-up in existing studies may underestimate the true impact of delayed nodal disease. Further research is needed to clarify whether any subgroup of intermediate-grade MEC patients may benefit from elective neck management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Occult Nodal Metastasis in Intermediate-Grade Mucoepidermoid Carcinoma of the Major Salivary Glands and the Role of Elective Neck Dissection: A Systematic Review</span>. <u>Rahul Patel, BS</u><sup>1</sup>; Kenny Do, BS<sup>2</sup>; Christopher Waite, BS<sup>1</sup>; Kurtis Young, MD<sup>3</sup>; Robert Wang, MD<sup>3</sup>; Andrew Birkeland, MD<sup>4</sup>. <sup>1</sup>Touro University Nevada College of Osteopathic Medicine; <sup>2</sup>Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas; <sup>3</sup>Department of Otolaryngology – Head and Neck Surgery, University of Nevada, Las Vegas; <sup>4</sup>Department of Otolaryngology – Head and Neck Surgery, University of California, Davis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The optimal management of the cN0 neck in intermediate-grade mucoepidermoid carcinoma (MEC) is unclear. High-grade MEC often calls for elective neck dissection (END) due to a substantial risk of occult nodal metastasis, while low-grade MEC rarely metastasizes and is often managed with observation. Intermediate-grade tumors are less defined, and current guidelines do not clarify whether END is beneficial. The current study aims to determine the risk of occult cervical metastasis in cN0 intermediate-grade MEC of the major salivary glands and evaluate whether END improves survival outcomes.</p>\n\n<p><strong>Data sources: </strong>Pubmed, Embase, and Scopus databases were systematically searched in all languages without restriction of publication dates.</p>\n\n<p><strong>Study selection: </strong>Studies reporting data on outcomes for cN0 patients with intermediate-grade MEC of the major salivary glands and providing data on treatment modality, pathologic N-staging, or survival outcomes were included.</p>\n\n<p><strong>Data extraction: </strong>Included studies were evaluated through full text review and data on occult metastasis rates and survival outcomes in patients stratified by END status were analyzed.</p>\n\n<p><strong>Data synthesis: </strong>Data were qualitatively synthesized, with pooled values calculated for applicable variables.</p>\n\n<p><strong>Results: </strong>The rate of occult cervical metastases in cN0 intermediate-grade MEC of the major salivary glands was 13.03%. This value falls between the 3-9% and 25-35% estimated risk for low and high-grade MEC respectively. Larger database studies involving NCDB and SEER databases reported low occult nodal rates (roughly 5-8%), comparable to low-grade MEC, whereas smaller institutional series with more selective END usage found higher occult nodal positivity (22-29%).</p>\n\n<p>The 10-year OS for intermediate-grade parotid MEC was virtually identical whether or not END was performed. No OS/DFS benefit to END in intermediate-grade cases was found, even when a high occult metastasis rate of ~27% was reported. Importantly, even in higher-risk subsets, no definitive survival benefit from END was observed. Advanced primary tumor stage and adverse pathological features were consistently correlated with higher occult nodal risk.</p>\n\n<p><strong>Conclusion: </strong>The overall occult nodal metastasis rate remains below traditional thresholds for recommending END, however limited long-term follow-up in existing studies may underestimate the true impact of delayed nodal disease. Further research is needed to clarify whether any subgroup of intermediate-grade MEC patients may benefit from elective neck management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154556--></body></html>"
    },
    {
      "uid": "P404",
      "content_id": "154573",
      "abstract_number": "P404",
      "poster_number": "P404",
      "title": "Rurality Differences in Parotid Malignancy Presentation, Management, and Survival",
      "summary": "Metropolitan populations had higher proportions of early-stage disease, indicating earlier presentation, which likely resulted in slower time to treatment due to less urgency. They additionally had more advanced cancer patients with metastatic disease, surgical facial nerve sacrifice, and adjuvant therapy, which may result from longer survival. Higher rates of chemotherapy, less surgical resection, and less...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154573",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Wyatt A Johnson, BA",
      "presenter": "Wyatt A Johnson, BA",
      "authors": "Wyatt A Johnson, BA 1 ; Taylor L Jamil, MD, MPH 2 ; Julie A Goddard, MD 2 ; Brian P Cervenka, MD 2 ; Carissa M Thomas, MD, PhD 2",
      "normalized_authors": [
        "Wyatt A Johnson",
        "Taylor L Jamil",
        "Julie A Goddard",
        "Brian P Cervenka",
        "Carissa M Thomas"
      ],
      "affiliations": [
        "Lewis Katz School of Medicine, Temple University",
        "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz Medical Campus"
      ],
      "normalized_institutions": [
        "Lewis Katz School of Medicine, Temple University",
        "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz Medical Campus"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 569,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Wyatt A Johnson, BA 1 ; Taylor L Jamil, MD, MPH 2 ; Julie A Goddard, MD 2 ; Brian P Cervenka, MD 2 ; Carissa M Thomas, MD, PhD 2",
        "Affiliations": "1 Lewis Katz School of Medicine, Temple University; 2 Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz Medical Campus",
        "Background": "Parotid malignancies make up 3-6% of head and neck cancers; yet comprise 73% of salivary gland malignancies, with increasing incidence over the past few decades. Prior studies indicate rural areas have worse overall survival for oropharyngeal cancer and longer treatment delays; however, no prior study has broadly examined rurality in parotid cancer to direct improvement in care by elucidating whether disease burden differences exist.",
        "Methods": "A retrospective database review was performed utilizing the Surveillance, Epidemiology, and End Results (SEER) Program database (2000-2022). The influence of rurality on demographics, presentation, treatment, and survival was evaluated in patients with parotid malignancies. Since patients likely travel to metropolitan areas for treatment, rurality was categorized by metropolitan counties, non-metropolitan counties adjacent to metropolitan counties (suburban), and rural counties using rural-urban continuum codes. Chi-square tests were used for categorical variables, and a multi-way ANOVA with a Tukey’s correction was used for numerical variables with RStudio (Version 2024.04.2+764). A multinomial regression was performed, and Kaplan-Meier curves for cause-specific survival were generated.",
        "Results": "There were 24,070 recorded cases between 2000-2022, with 87.9% in metropolitan areas. Most cases were seen in patients 60 years and older, with higher proportions of 60–79-year-olds in rural (572, 46.5%) versus metropolitan areas (9,041, 42.7%) (p<0.001). There were more males (67.7%) in rural compared with metropolitan areas (56.6%) (p<0.005). Patients in metropolitan areas presented more at stage 1 (27.9% vs 21.3%) and stage 2 (27.1% vs 21.3%), while rural areas were more at stage 4a (16.7% vs 24.2%) and 4b (9.9% vs 12.3%) (p<0.005). Time to treatment was longer in metropolitan (22.1 +/- 28.2 days) compared to rural areas (19.8 +/- 35.7 days) (p<0.005). The odds of metastatic disease in suburban/rural areas were 95% less (OR: 0.05, CI: 0.05-0.06 p<0.005), chemotherapy was higher in rural areas (OR: 9.04, 95% CI: 7.6-10.8, p<0.005), systemic adjuvant (OR: 1.24e-6, 95% CI: 1.24e-6-1.24e-6, p<0.005) and neoadjuvant (OR: 2.45e-7, 95% CI: 2.43e-7-2.43e-7, p<0.005) therapy was lower in rural areas, and facial nerve sacrifice was lower in suburban (OR: 0.6, 95% CI: 0.5-0.6, p<0.005) and rural (OR: 0.78, 95% CI: 0.67-0.91, p<0.005) areas. There were fewer surgical resections in suburban (OR: 0.06, 95% CI: 0.05-0.06, P<0.005) but not rural areas (OR:1.01, 95% CI: 0.87-1.16, p=0.888). Metropolitan areas experienced better survival (79% 5-year survival, 95% CI: 78.40%-79.70%) compared to suburban (73.7% 5-year survival, 95% CI: 70.9%-76.3%) and rural (74.1% 5-year survival, 95% CI: 70.9%-77.0%) areas.",
        "Conclusions": "Metropolitan populations had higher proportions of early-stage disease, indicating earlier presentation, which likely resulted in slower time to treatment due to less urgency. They additionally had more advanced cancer patients with metastatic disease, surgical facial nerve sacrifice, and adjuvant therapy, which may result from longer survival. Higher rates of chemotherapy, less surgical resection, and less systemic adjuvant therapy in suburban and rural areas indicate more palliative treatment. These differences likely reflect differences in access, diagnosis, and treatment options, which should be studied in depth prospectively to understand care disparities and opportunities for intervention."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rurality Differences in Parotid Malignancy Presentation, Management, and Survival</span>. <u>Wyatt A Johnson, BA</u><sup>1</sup>; Taylor L Jamil, MD, MPH<sup>2</sup>; Julie A Goddard, MD<sup>2</sup>; Brian P Cervenka, MD<sup>2</sup>; Carissa M Thomas, MD, PhD<sup>2</sup>. <sup>1</sup>Lewis Katz School of Medicine, Temple University; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz Medical Campus<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Parotid malignancies make up 3-6% of head and neck cancers; yet comprise 73% of salivary gland malignancies, with increasing incidence over the past few decades. Prior studies indicate rural areas have worse overall survival for oropharyngeal cancer and longer treatment delays; however, no prior study has broadly examined rurality in parotid cancer to direct improvement in care by elucidating whether disease burden differences exist.</p>\n\n<p><strong>Methods: </strong>A retrospective database review was performed utilizing the Surveillance, Epidemiology, and End Results (SEER) Program database (2000-2022). The influence of rurality on demographics, presentation, treatment, and survival was evaluated in patients with parotid malignancies. Since patients likely travel to metropolitan areas for treatment, rurality was categorized by metropolitan counties, non-metropolitan counties adjacent to metropolitan counties (suburban), and rural counties using rural-urban continuum codes. Chi-square tests were used for categorical variables, and a multi-way ANOVA with a Tukey’s correction was used for numerical variables with RStudio (Version 2024.04.2+764). A multinomial regression was performed, and Kaplan-Meier curves for cause-specific survival were generated.</p>\n\n<p><strong>Results: </strong>There were 24,070 recorded cases between 2000-2022, with 87.9% in metropolitan areas. Most cases were seen in patients 60 years and older, with higher proportions of 60–79-year-olds in rural (572, 46.5%) versus metropolitan areas (9,041, 42.7%) (p<0.001). There were more males (67.7%) in rural compared with metropolitan areas (56.6%) (p<0.005). Patients in metropolitan areas presented more at stage 1 (27.9% vs 21.3%) and stage 2 (27.1% vs 21.3%), while rural areas were more at stage 4a (16.7% vs 24.2%) and 4b (9.9% vs 12.3%) (p<0.005). Time to treatment was longer in metropolitan (22.1 +/- 28.2 days) compared to rural areas (19.8 +/- 35.7 days) (p<0.005). The odds of metastatic disease in suburban/rural areas were 95% less (OR: 0.05, CI: 0.05-0.06 p<0.005), chemotherapy was higher in rural areas (OR: 9.04, 95% CI: 7.6-10.8, p<0.005), systemic adjuvant (OR: 1.24e-6, 95% CI: 1.24e-6-1.24e-6, p<0.005) and neoadjuvant (OR: 2.45e-7, 95% CI: 2.43e-7-2.43e-7, p<0.005) therapy was lower in rural areas, and facial nerve sacrifice was lower in suburban (OR: 0.6, 95% CI: 0.5-0.6, p<0.005) and rural (OR: 0.78, 95% CI: 0.67-0.91, p<0.005) areas. There were fewer surgical resections in suburban (OR: 0.06, 95% CI: 0.05-0.06, P<0.005) but not rural areas (OR:1.01, 95% CI: 0.87-1.16, p=0.888). Metropolitan areas experienced better survival (79% 5-year survival, 95% CI: 78.40%-79.70%) compared to suburban (73.7% 5-year survival, 95% CI: 70.9%-76.3%) and rural (74.1% 5-year survival, 95% CI: 70.9%-77.0%) areas.</p>\n\n<p><strong>Conclusions:</strong> Metropolitan populations had higher proportions of early-stage disease, indicating earlier presentation, which likely resulted in slower time to treatment due to less urgency. They additionally had more advanced cancer patients with metastatic disease, surgical facial nerve sacrifice, and adjuvant therapy, which may result from longer survival. Higher rates of chemotherapy, less surgical resection, and less systemic adjuvant therapy in suburban and rural areas indicate more palliative treatment. These differences likely reflect differences in access, diagnosis, and treatment options, which should be studied in depth prospectively to understand care disparities and opportunities for intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154573--></body></html>"
    },
    {
      "uid": "P405",
      "content_id": "153479",
      "abstract_number": "P405",
      "poster_number": "P405",
      "title": "Surgical Management and Outcomes in Salivary Duct Carcinoma: A 15-year Single-center Review",
      "summary": "Thirty-five cases met inclusion criteria. Median age was 70 years [IQR: 54-75]. Thirty (86%) were male and 31 (89%) were of white ethnicity. Median follow up was 29 months [19-45]. Twenty-nine (83%) cases were of parotid gland origin. Of patients with parotid tumors, 8 (29%) presented with complete facial paralysis.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153479",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mitchell Victor, MD",
      "presenter": "Mitchell Victor, MD",
      "authors": "Mitchell Victor, MD 1 ; Michael Moore, MD 1 ; Tieying Hou, MD, PhD 2 ; Janice Farlow, MD 1",
      "normalized_authors": [
        "Mitchell Victor",
        "Michael Moore",
        "Tieying Hou",
        "Janice Farlow"
      ],
      "affiliations": [
        "Indiana University Department of Otolaryngology-Head and Neck Surgery",
        "Indiana University Department of Pathology"
      ],
      "normalized_institutions": [
        "Indiana University Department of Otolaryngology-Head and Neck Surgery",
        "Indiana University Department of Pathology"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "",
          "rows": [
            [
              "ENE-",
              "19",
              "18",
              "18",
              "15",
              "15"
            ],
            [
              "ENE+",
              "14",
              "13",
              "7",
              "3",
              "1"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153479/km_ene_rfs.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153479/km_ene_rfs.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153479"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Significance",
        "Methods",
        "Results",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Mitchell Victor, MD 1 ; Michael Moore, MD 1 ; Tieying Hou, MD, PhD 2 ; Janice Farlow, MD 1",
        "Affiliations": "1 Indiana University Department of Otolaryngology-Head and Neck Surgery; 2 Indiana University Department of Pathology",
        "Significance": "Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy. We describe a single high-volume academic institution’s experience with SDC.",
        "Methods": "Retrospective review of cases of parotid or submandibular gland SDC treated with primary surgery at a single academic institution between 2010-2025 with ≥6 months follow-up. Patients with prior treatment or distant metastasis at presentation were excluded.",
        "Results": "Thirty-five cases met inclusion criteria. Median age was 70 years [IQR: 54-75]. Thirty (86%) were male and 31 (89%) were of white ethnicity. Median follow up was 29 months [19-45]. Twenty-nine (83%) cases were of parotid gland origin. Of patients with parotid tumors, 8 (29%) presented with complete facial paralysis.",
        "Abstract": "Radical parotidectomy with facial nerve sacrifice was performed in 15 (52%) cases. Six patients underwent lateral temporal bone resection, and an additional six underwent cortical mastoidectomy. 54% and 40% of cases were ≥pT4a and pN3b. Notably, 7/13 (54%) cN0 cases had occult nodal disease, 5 of which were ≥pN2b. Lymphovascular and perineural invasion were present in 74% and 76% of cases. Fifteen cases (43%) had extranodal extension (ENE). Median lymph node ratio (LNR) was 0.10 [0.03-0.46]. Positive surgical margins were present in 24% of cases. Immunohistochemistry showed androgen receptor positivity in 89% and HER2/ERBB2 positivity in 29%. Thirteen (37%) cases were tested for PD-1 expression, for which median CPS was 15 [0-60]. Twenty percent of cases were carcinoma ex pleomorphic adenoma, none of which had ENE (53.6% vs 0%, Fisher's Exact p=0.01). Following ablation, 11 patients underwent free flap reconstruction. Simultaneous facial nerve reconstruction was performed in 10 cases. Thirty (86%) patients received adjuvant radiation and 15 (43%) received adjuvant systemic therapy. Of the 13 patients with systemic therapy data, 10 received cisplatin monotherapy, two received carboplatin and paclitaxel (one also with trastuzumab), and one received trastuzumab and pertuzumab without cytotoxic therapy. Anti-androgen therapy was only used in the salvage setting. Twelve (34%) patients experienced disease recurrence, with median time to recurrence of 10 months [6.5-32.5]. Of those, 50% had ENE at time of surgery. On Kaplan-Meier analysis, ENE was associated with reduced recurrence-free survival (RFS) (median RFS: 11 vs 24.75 months; Log Rank p=0.044). An association between LNR >0.10 and poorer RFS approached significance (Log Rank p=0.08). Margin status and pT stage were not associated with RFS (Log Rank p>0.3). Recurrence was most frequently to the lung (n=6), skeleton (n=5), or mediastinum/hilar lymph nodes (n=4). Median overall survival was 20 months in patients with ENE compared to 36.5 months in those without (Log Rank p=0.067).",
        "Discussion": "Patients with SDC at our institution present with locally advanced disease and a high burden of occult nodal metastasis and adverse pathologic features. ENE was associated with increased risk of recurrence on univariable analysis. These findings support aggressive surgical management of the primary and neck dissection and consideration of intensified multimodal adjuvant therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Management and Outcomes in Salivary Duct Carcinoma: A 15-year Single-center Review</span>. <u>Mitchell Victor, MD</u><sup>1</sup>; Michael Moore, MD<sup>1</sup>; Tieying Hou, MD, PhD<sup>2</sup>; Janice Farlow, MD<sup>1</sup>. <sup>1</sup>Indiana University Department of Otolaryngology-Head and Neck Surgery; <sup>2</sup>Indiana University Department of Pathology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Significance:</strong> Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy. We describe a single high-volume academic institution’s experience with SDC.</p>\n\n<p><strong>Methods:</strong> Retrospective review of cases of parotid or submandibular gland SDC treated with primary surgery at a single academic institution between 2010-2025 with ≥6 months follow-up. Patients with prior treatment or distant metastasis at presentation were excluded.</p>\n\n<p><strong>Results:</strong> Thirty-five cases met inclusion criteria. Median age was 70 years [IQR: 54-75]. Thirty (86%) were male and 31 (89%) were of white ethnicity. Median follow up was 29 months [19-45]. Twenty-nine (83%) cases were of parotid gland origin. Of patients with parotid tumors, 8 (29%) presented with complete facial paralysis.</p>\n\n<p>Radical parotidectomy with facial nerve sacrifice was performed in 15 (52%) cases. Six patients underwent lateral temporal bone resection, and an additional six underwent cortical mastoidectomy. 54% and 40% of cases were ≥pT4a and pN3b. Notably, 7/13 (54%) cN0 cases had occult nodal disease, 5 of which were ≥pN2b. Lymphovascular and perineural invasion were present in 74% and 76% of cases. Fifteen cases (43%) had extranodal extension (ENE). Median lymph node ratio (LNR) was 0.10 [0.03-0.46]. Positive surgical margins were present in 24% of cases. Immunohistochemistry showed androgen receptor positivity in 89% and HER2/ERBB2 positivity in 29%. Thirteen (37%) cases were tested for PD-1 expression, for which median CPS was 15 [0-60]. Twenty percent of cases were carcinoma ex pleomorphic adenoma, none of which had ENE (53.6% vs 0%, Fisher's Exact p=0.01).</p>\n\n<p>Following ablation, 11 patients underwent free flap reconstruction. Simultaneous facial nerve reconstruction was performed in 10 cases. Thirty (86%) patients received adjuvant radiation and 15 (43%) received adjuvant systemic therapy. Of the 13 patients with systemic therapy data, 10 received cisplatin monotherapy, two received carboplatin and paclitaxel (one also with trastuzumab), and one received trastuzumab and pertuzumab without cytotoxic therapy.  Anti-androgen therapy was only used in the salvage setting.</p>\n\n<p>Twelve (34%) patients experienced disease recurrence, with median time to recurrence of 10 months [6.5-32.5]. Of those, 50% had ENE at time of surgery. On Kaplan-Meier analysis, ENE was associated with reduced recurrence-free survival (RFS) (median RFS: 11 vs 24.75 months; Log Rank p=0.044). An association between LNR >0.10 and poorer RFS approached significance (Log Rank p=0.08). Margin status and pT stage were not associated with RFS (Log Rank p>0.3).  Recurrence was most frequently to the lung (n=6), skeleton (n=5), or mediastinum/hilar lymph nodes (n=4). Median overall survival was 20 months in patients with ENE compared to 36.5 months in those without (Log Rank p=0.067).</p>\n\n<p><strong>Discussion:</strong> Patients with SDC at our institution present with locally advanced disease and a high burden of occult nodal metastasis and adverse pathologic features. ENE was associated with increased risk of recurrence on univariable analysis. These findings support aggressive surgical management of the primary and neck dissection and consideration of intensified multimodal adjuvant therapy.</p>\n\n<table align='left' border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption> </caption>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>ENE-</td>\n\t\t\t<td>19</td>\n\t\t\t<td>18</td>\n\t\t\t<td>18</td>\n\t\t\t<td>15</td>\n\t\t\t<td>15</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>ENE+</td>\n\t\t\t<td>14</td>\n\t\t\t<td>13</td>\n\t\t\t<td>7</td>\n\t\t\t<td>3</td>\n\t\t\t<td>1</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153479/km_ene_rfs.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153479--></body></html>"
    },
    {
      "uid": "P406",
      "content_id": "153534",
      "abstract_number": "P406",
      "poster_number": "P406",
      "title": "Rare Case of Bilateral Cervical Metastasis in Mucoepidermoid Carcinoma with Unknown Primary",
      "summary": "The literature is sparse on MEC with unknown primary, with no current reports of bilateral cervical disease at time of presentation. Cervical metastatic rates for MEC with a known primary are approximately 10%, with 1% of patients presenting with bilateral cervical metastases. Low grade lesions can be easily misdiagnosed. Complete surgical excision is recommended as first line therapy for most salivary gland...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153534",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kristofer G Andren, DO",
      "presenter": "Kristofer G Andren, DO",
      "authors": "Kristofer G Andren, DO 1 ; Nathan W Hales, MD, FACS 2",
      "normalized_authors": [
        "Kristofer G Andren",
        "Nathan W Hales"
      ],
      "affiliations": [
        "San Antonio Uniformed Services Health Education Consortium",
        "San Antonio ENT"
      ],
      "normalized_institutions": [
        "San Antonio Uniformed Services Health Education Consortium",
        "San Antonio ENT"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 293,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case Description",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kristofer G Andren, DO 1 ; Nathan W Hales, MD, FACS 2",
        "Affiliations": "1 San Antonio Uniformed Services Health Education Consortium; 2 San Antonio ENT",
        "Introduction": "Mucoepidermoid carcinoma (MEC) is the most common malignancy of the salivary glands, typically arising from the major salivary glands or intraoral minor salivary glands. However, MEC with an unknown primary site is exceedingly rare, and it is even more rare to present as bilateral cervical metastases with an unknown primary. We present a case of MEC metastatic to bilateral cervical lymph nodes with an unknown primary site and discuss diagnosis and management.",
        "Case Description": "A 50-year-old male presented with large bilateral cystic neck masses. Multiple ultrasound guided fine needle aspirations were nondiagnostic on both sides. Given compressive symptoms and concern for malignancy, a right modified radical neck dissection (MRND) was subsequently performed. Pathology was reported as a benign lymphoepithelial cyst. A staged left sided MRND was subsequently performed. Pathology demonstrated low grade MEC with negative margins and no evidence of submandibular or parotid gland involvement. Re-review of the right MRND pathology was consistent with the same (low grade MEC). No primary lesion was identified on MRI neck and PET/CT. The patient was observed without adjuvant therapy and remains disease free after 1 year of ongoing follow up.",
        "Conclusion": "The literature is sparse on MEC with unknown primary, with no current reports of bilateral cervical disease at time of presentation. Cervical metastatic rates for MEC with a known primary are approximately 10%, with 1% of patients presenting with bilateral cervical metastases. Low grade lesions can be easily misdiagnosed. Complete surgical excision is recommended as first line therapy for most salivary gland malignancies and has been effective in published case reports in MEC with unknown primary. Adjuvant radiotherapy remains an option in the presence of high grade disease or high risk pathological features, however low-grade tumors may be treated successfully with surgical resection and appropriate clinical surveillance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rare Case of Bilateral Cervical Metastasis in Mucoepidermoid Carcinoma with Unknown Primary</span>. <u>Kristofer G Andren, DO</u><sup>1</sup>; Nathan W Hales, MD, FACS<sup>2</sup>. <sup>1</sup>San Antonio Uniformed Services Health Education Consortium; <sup>2</sup>San Antonio ENT<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Mucoepidermoid carcinoma (MEC) is the most common malignancy of the salivary glands, typically arising from the major salivary glands or intraoral minor salivary glands. However, MEC with an unknown primary site is exceedingly rare, and it is even more rare to present as bilateral cervical metastases with an unknown primary. We present a case of MEC metastatic to bilateral cervical lymph nodes with an unknown primary site and discuss diagnosis and management.</p>\n\n<p><strong>Case Description: </strong>A 50-year-old male presented with large bilateral cystic neck masses. Multiple ultrasound guided fine needle aspirations were nondiagnostic on both sides. Given compressive symptoms and concern for malignancy, a right modified radical neck dissection (MRND) was subsequently performed. Pathology was reported as a benign lymphoepithelial cyst. A staged left sided MRND was subsequently performed. Pathology demonstrated low grade MEC with negative margins and no evidence of submandibular or parotid gland involvement. Re-review of the right MRND pathology was consistent with the same (low grade MEC). No primary lesion was identified on MRI neck and PET/CT. The patient was observed without adjuvant therapy and remains disease free after 1 year of ongoing follow up.</p>\n\n<p><strong>Conclusion: </strong>The literature is sparse on MEC with unknown primary, with no current reports of bilateral cervical disease at time of presentation. Cervical metastatic rates for MEC with a known primary are approximately 10%, with 1% of patients presenting with bilateral cervical metastases. Low grade lesions can be easily misdiagnosed. Complete surgical excision is recommended as first line therapy for most salivary gland malignancies and has been effective in published case reports in MEC with unknown primary. Adjuvant radiotherapy remains an option in the presence of high grade disease or high risk pathological features, however low-grade tumors may be treated successfully with surgical resection and appropriate clinical surveillance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153534--></body></html>"
    },
    {
      "uid": "P407",
      "content_id": "154171",
      "abstract_number": "P407",
      "poster_number": "P407",
      "title": "Acute Bilateral Swelling: An Unusual Presentation of Sarcoidosis",
      "summary": "Sarcoidosis is a granulomatous disorder, that uncommonly presents in the head and neck region without systemic signs. This case underscores the importance of considering sarcoidosis as a cause of bilateral parotid swelling in a young patient with unusual symptomatology. Early diagnosis and treatment can prevent disease progression and improve the quality of life with adequate symptom control.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154171",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Safa Kriuar, Miss",
      "presenter": "Safa Kriuar, Miss",
      "authors": "Rahul Jayaram, Mr; Safa Kriuar, Miss ; Cristina Verea; Yasmin Edmonds, Miss",
      "normalized_authors": [
        "Rahul Jayaram, Mr",
        "Safa Kriuar, Miss",
        "Cristina Verea",
        "Yasmin Edmonds, Miss"
      ],
      "affiliations": [
        "St George's Hospital"
      ],
      "normalized_institutions": [
        "St George's Hospital"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Case Presentation",
        "Clinical Findings and Investigations",
        "Treatment and Management",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Rahul Jayaram, Mr; Safa Kriuar, Miss ; Cristina Verea; Yasmin Edmonds, Miss",
        "Affiliations": "St George's Hospital",
        "Background": "Sarcoidosis is a chronic granulomatous inflammatory disease. It is characterised by enlargement of lymph nodes and presence of granulomas from the reticuloendothelial system. Most common areas affected are the lungs, lymph nodes and skin; involvement in the head and neck region is rare. This case reports the presentation of bilateral parotid swelling in a young male with sarcoidosis, without any systemic symptoms.",
        "Case Presentation": "A 29-year-old Afro-Caribbean male with a medical history of an absent pulmonary valve syndrome and atrial septal defect (ASD), had their lower left wisdom tooth extracted under local anaesthetic. Subsequently, developed persistent bilateral parotid and submandibular swelling. The patient also presented with intermittent pain on LR side, initially believed it be caused by dental caries on LR8, as well as suggestive sicca symptoms of dry eyes and xerostomia. The patient denied having the more common advanced symptoms of sarcoidosis e.g., malaise, weight loss and night sweats.",
        "Clinical Findings and Investigations": "On examination, the patient had bilateral firm parotid and submandibular palpable masses as well as on their right eyebrow, supraorbital region and lacrimal glands. Imaging raised suspicious of sarcoidosis, as it revealed bilateral salivary gland enlargement and peri-lymphatic nodules in the lungs. Further investigations identified elevated serum ACE levels, negative autoimmune screen and negative IgG4 levels. A US FNA biopsy of the inguinal lymph nodes confirmed non-necrotising granulomas, consistent with sarcoidosis. In addition, a CT thorax revealed mediastinal and hilar lymphadenopathy and diffuse pulmonary nodules, characteristic of sarcoidosis.",
        "Treatment and Management": "The oral sicca symptoms with reduced saliva increases their susceptibility to oral candidiasis, a course of oral nystatin was initiated, and oral hygiene advise given. For dry mouth symptom management, hydroxychloroquine was given to provide symptomatic relief and reduce autoimmune related inflammation. Chest imaging, lung function tests as well as blood tests to monitor vitamin D levels were arranged. The decision was made to continue hydroxychloroquine as the mainstay of treatment, as the patient initially responded well to corticosteroid with reduced parotid swelling, however after six weeks it was discontinued and parotid swelling reemerged.",
        "Discussion": "This case highlights the importance of considering sarcoidosis as a differential diagnosis for bilateral parotid gland swelling, even in the absence of systemic symptoms. The clinical presentation in this instance mimicked more common conditions e.g., Sjögren's syndrome or IgG4-related disease, however the histopathology of non- necrotising granulomas confirmed the pathophysiology of sarcoidosis. Although, typical symptoms of joint, skin or ocular involvement were not identified, pulmonary involvement and elevated ACE levels were, which are consistent with the diagnosis of sarcoidosis. A multidisciplinary approach is required in this case, including rheumatology, respiratory, and haematology, for ongoing monitoring of disease progression and symptom control.",
        "Conclusion": "Sarcoidosis is a granulomatous disorder, that uncommonly presents in the head and neck region without systemic signs. This case underscores the importance of considering sarcoidosis as a cause of bilateral parotid swelling in a young patient with unusual symptomatology. Early diagnosis and treatment can prevent disease progression and improve the quality of life with adequate symptom control."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Acute Bilateral Swelling: An Unusual Presentation of Sarcoidosis</span>. Rahul Jayaram, Mr; <u>Safa Kriuar, Miss</u>; Cristina Verea; Yasmin Edmonds, Miss. St George's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Sarcoidosis is a chronic granulomatous inflammatory disease. It is characterised by enlargement of lymph nodes and presence of granulomas from the reticuloendothelial system. Most common areas affected are the lungs, lymph nodes and skin; involvement in the head and neck region is rare. This case reports the presentation of bilateral parotid swelling in a young male with sarcoidosis, without any systemic symptoms.</p>\n\n<p><strong>Case Presentation: </strong>A 29-year-old Afro-Caribbean male with a medical history of an absent pulmonary valve syndrome and atrial septal defect (ASD), had their lower left wisdom tooth extracted under local anaesthetic. Subsequently, developed persistent bilateral parotid and submandibular swelling. The patient also presented with intermittent pain on LR side, initially believed it be caused by dental caries on LR8, as well as suggestive sicca symptoms of dry eyes and xerostomia. The patient denied having the more common advanced symptoms of sarcoidosis e.g., malaise, weight loss and night sweats.</p>\n\n<p><strong>Clinical Findings and Investigations: </strong>On examination, the patient had bilateral firm parotid and submandibular palpable masses as well as on their right eyebrow, supraorbital region and lacrimal glands. Imaging raised suspicious of sarcoidosis, as it revealed bilateral salivary gland enlargement and peri-lymphatic nodules in the lungs. Further investigations identified elevated serum ACE levels, negative autoimmune screen and negative IgG4 levels. A US FNA biopsy of the inguinal lymph nodes confirmed non-necrotising granulomas, consistent with sarcoidosis. In addition, a CT thorax revealed mediastinal and hilar lymphadenopathy and diffuse pulmonary nodules, characteristic of sarcoidosis.</p>\n\n<p><strong>Treatment and Management: </strong>The oral sicca symptoms with reduced saliva increases their susceptibility to oral candidiasis, a course of oral nystatin was initiated, and oral hygiene advise given. For dry mouth symptom management, hydroxychloroquine was given to provide symptomatic relief and reduce autoimmune related inflammation. Chest imaging, lung function tests as well as blood tests to monitor vitamin D levels were arranged. The decision was made to continue hydroxychloroquine as the mainstay of treatment, as the patient initially responded well to corticosteroid with reduced parotid swelling, however after six weeks it was discontinued and parotid swelling reemerged.</p>\n\n<p><strong>Discussion: </strong>This case highlights the importance of considering sarcoidosis as a differential diagnosis for bilateral parotid gland swelling, even in the absence of systemic symptoms. The clinical presentation in this instance mimicked more common conditions e.g., Sjögren's syndrome or IgG4-related disease, however the histopathology of non- necrotising granulomas confirmed the pathophysiology of sarcoidosis. Although, typical symptoms of joint, skin or ocular involvement were not identified, pulmonary involvement and elevated ACE levels were, which are consistent with the diagnosis of sarcoidosis. A multidisciplinary approach is required in this case, including rheumatology, respiratory, and haematology, for ongoing monitoring of disease progression and symptom control.</p>\n\n<p><strong>Conclusion: </strong>Sarcoidosis is a granulomatous disorder, that uncommonly presents in the head and neck region without systemic signs. This case underscores the importance of considering sarcoidosis as a cause of bilateral parotid swelling in a young patient with unusual symptomatology. Early diagnosis and treatment can prevent disease progression and improve the quality of life with adequate symptom control.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154171--></body></html>"
    },
    {
      "uid": "P408",
      "content_id": "153349",
      "abstract_number": "P408",
      "poster_number": "P408",
      "title": "Chronic otitis media with effusion as an unusual presentation of a soft palate mucoepidermoid carcinoma: A case report",
      "summary": "Unilateral otitis media with effusion (OME) in adults can portend a sinister etiology and must be thoroughly investigated. While majority of adult OME cases are due to non-neoplastic causes, approximately 5% of them are due to head and neck tumours. Of these tumours, nasopharyngeal carcinoma is the commonest, amounting to as high as 90% in endemic regions. Other neoplasms causing OME include temporal bone, skull...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sher-lyn Tham",
      "presenter": "Sher-lyn Tham",
      "authors": "Sher-lyn Tham ; Xinni Xu; Khang Wen Pang; Donovan Eu; Wei Sian Lim",
      "normalized_authors": [
        "Sher-lyn Tham",
        "Xinni Xu",
        "Khang Wen Pang",
        "Donovan Eu",
        "Wei Sian Lim"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153349/Palate%20Ulcer(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153349/Palate%20Ulcer(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153349/Resection%20specimen.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153349/Resection%20specimen.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153349/Borders.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153349/Borders.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153349/MRI%20Axial.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153349/MRI%20Axial.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153349/mri%20coronal.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153349/mri%20coronal.png",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153349"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sher-lyn Tham ; Xinni Xu; Khang Wen Pang; Donovan Eu; Wei Sian Lim",
        "Affiliations": "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore",
        "Abstract": "Unilateral otitis media with effusion (OME) in adults can portend a sinister etiology and must be thoroughly investigated. While majority of adult OME cases are due to non-neoplastic causes, approximately 5% of them are due to head and neck tumours. Of these tumours, nasopharyngeal carcinoma is the commonest, amounting to as high as 90% in endemic regions. Other neoplasms causing OME include temporal bone, skull base and parapharyngeal space lesions but these are uncommon and reported as mainly case reports or small series. OME occurs through a variety of mechanisms, most frequently due to obstruction, direct compression or invasion of the Eustachian tube mucosa or muscles. Functionally, disrupted ciliary function of the Eustachian tube or secondary inflammatory changes can also lead to OME. Our case describes a 47-year-old female presenting with isolated unilateral chronic OME from a submucosal soft palate mucoepidermoid carcinoma (MEC) with parapharyngeal extension. To our knowledge, this is the first case report describing an oropharyngeal cancer presenting with persistent unilateral OME as the sole complaint. The patient first came to our institution for a persistently blocked left ear. Clinical examination and nasoendoscopy were normal. Myringotomy and grommet tube insertion was performed to good relief. When the grommet self-extruded, her OME reaccumulated. A repeat nasoendoscopy was unremarkable. Finally, cross sectional imaging was done in view of her intractable OME. CT and MRI showed a 3.6cm lesion in her left soft palate, extending into the deep nasopharynx, parapharyngeal space, and eroding the posterior hard palate. By that time, the patient had developed a 5mm ulcer at the junction of the left hard and soft palate but remained asymptomatic. Transoral biopsy of the tumour was done and this was eventually staged as cT4aN0M0 Stage IV left soft palate MEC. Subsequently, our patient underwent a transoral and endoscopic transpterygoid excision of the left soft palate tumour with left inferior maxillectomy, selective neck dissection (I-III), reconstruction with nasoseptal flap, buccal fat pad flap and free radial forearm flap. Final histology returned as low-to-intermediate grade MEC with perineural invasion and one out of thirty-one lymph nodes was involved with extranodal extension. In view of positive margins, she was referred for adjuvant chemoradiation. This case emphasises that a normal clinical examination and nasoendoscopy in the setting of persistent unilateral OME in an adult does not preclude a head and neck neoplasm. In these patients, the role of imaging with a CT or MRI should be considered to detect occult or submucosal lesions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Chronic otitis media with effusion as an unusual presentation of a soft palate mucoepidermoid carcinoma: A case report</span>. <u>Sher-lyn Tham</u>; Xinni Xu; Khang Wen Pang; Donovan Eu; Wei Sian Lim. Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Unilateral otitis media with effusion (OME) in adults can portend a sinister etiology and must be thoroughly investigated. While majority of adult OME cases are due to non-neoplastic causes, approximately 5% of them are due to head and neck tumours. Of these tumours, nasopharyngeal carcinoma is the commonest, amounting to as high as 90% in endemic regions. Other neoplasms causing OME include temporal bone, skull base and parapharyngeal space lesions but these are uncommon and reported as mainly case reports or small series. OME occurs through a variety of mechanisms, most frequently due to obstruction, direct compression or invasion of the Eustachian tube mucosa or muscles. Functionally, disrupted ciliary function of the Eustachian tube or secondary inflammatory changes can also lead to OME. </p>\n\n<p>Our case describes a 47-year-old female presenting with isolated unilateral chronic OME from a submucosal soft palate mucoepidermoid carcinoma (MEC) with parapharyngeal extension. To our knowledge, this is the first case report describing an oropharyngeal cancer presenting with persistent unilateral OME as the sole complaint. The patient first came to our institution for a persistently blocked left ear. Clinical examination and nasoendoscopy were normal. Myringotomy and grommet tube insertion was performed to good relief. When the grommet self-extruded, her OME reaccumulated. A repeat nasoendoscopy was unremarkable.</p>\n\n<p>Finally, cross sectional imaging was done in view of her intractable OME. CT and MRI showed a 3.6cm lesion in her left soft palate, extending into the deep nasopharynx, parapharyngeal space, and eroding the posterior hard palate. By that time, the patient had developed a 5mm ulcer at the junction of the left hard and soft palate but remained asymptomatic. Transoral biopsy of the tumour was done and this was eventually staged as cT4aN0M0 Stage IV left soft palate MEC. </p>\n\n<p>Subsequently, our patient underwent a transoral and endoscopic transpterygoid excision of the left soft palate tumour with left inferior maxillectomy, selective neck dissection (I-III), reconstruction with nasoseptal flap, buccal fat pad flap and free radial forearm flap. Final histology returned as low-to-intermediate grade MEC with perineural invasion and one out of thirty-one lymph nodes was involved with extranodal extension. In view of positive margins, she was referred for adjuvant chemoradiation. </p>\n\n<p>This case emphasises that a normal clinical examination and nasoendoscopy in the setting of persistent unilateral OME in an adult does not preclude a head and neck neoplasm. In these patients, the role of imaging with a CT or MRI should be considered to detect occult or submucosal lesions. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153349/Palate%20Ulcer(1).png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153349/Resection%20specimen.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153349/Borders.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153349/MRI%20Axial.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153349/mri%20coronal.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153349--></body></html>"
    },
    {
      "uid": "P409",
      "content_id": "153832",
      "abstract_number": "P409",
      "poster_number": "P409",
      "title": "Neurofibroma of the Greater Auricular Nerve Presenting as a Parotid Tail Mass",
      "summary": "Neurofibromas arising from the greater auricular nerve (GAN) are exceptionally rare, with only isolated case reports described in the literature. Given location, distal GAN lesions may clinically present as parotid tail masses and can be clinically or radiographically indistinguishable from salivary gland neoplasms or lymph nodes. Higher rates of nondiagnostic fine needle aspiration biopsy (FNA) are observed for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kevin J Kovatch, MD, FACS",
      "presenter": "Kevin J Kovatch, MD, FACS",
      "authors": "Talitha K Lewis, MD, MBA 1 ; John E Hanks, MD 2 ; Gahie Nam, MD 3 ; Kevin J Kovatch, MD, FACS 2",
      "normalized_authors": [
        "Talitha K Lewis",
        "John E Hanks",
        "Gahie Nam",
        "Kevin J Kovatch"
      ],
      "affiliations": [
        "University of Connecticut School of Medicine",
        "University of Connecticut Department of Otolaryngology-Head and Neck Surgery",
        "University of Connecticut Department of Pathology"
      ],
      "normalized_institutions": [
        "University of Connecticut School of Medicine",
        "University of Connecticut Department of Otolaryngology-Head and Neck Surgery",
        "University of Connecticut Department of Pathology"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/Ultrasound(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/Ultrasound(1).jpg",
          "alt": "Ultrasound demonstrating parotid tail mass at time of fine needle aspiration",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/CT.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/CT.jpg",
          "alt": "CT scan demonstrating a 1.3 x 1.2 x 1.8 cm low-attenuation nodule appearing to be within the posterior parotid tail",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%201.jpg",
          "alt": "Intraoperative photo demonstrating mass",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%202.jpg",
          "alt": "Intraoperative photo demonstrating mass dissected from greater auricular nerve branches",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%203.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%203.jpg",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153832/Pathology.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153832/Pathology.jpg",
          "alt": "H&E staining, x40x",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153832"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 380,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case",
        "Discussion/Conclusion"
      ],
      "sections": {
        "Authors": "Talitha K Lewis, MD, MBA 1 ; John E Hanks, MD 2 ; Gahie Nam, MD 3 ; Kevin J Kovatch, MD, FACS 2",
        "Affiliations": "1 University of Connecticut School of Medicine; 2 University of Connecticut Department of Otolaryngology-Head and Neck Surgery; 3 University of Connecticut Department of Pathology",
        "Introduction": "Neurofibromas arising from the greater auricular nerve (GAN) are exceptionally rare, with only isolated case reports described in the literature. Given location, distal GAN lesions may clinically present as parotid tail masses and can be clinically or radiographically indistinguishable from salivary gland neoplasms or lymph nodes. Higher rates of nondiagnostic fine needle aspiration biopsy (FNA) are observed for neurogenic tumors. This report highlights a rare GAN neurofibroma initially presumed to be a parotid lesion and emphasizes the use of intraoperative findings to guide management and excisional technique, in this case a largely nerve sparing excision.",
        "Case": "A 66-year-old woman with a history of breast cancer and monoclonal gammopathy of undetermined significance presented with a slowly enlarging 1.8cm left parotid tail mass. Both initial and repeat ultrasound-guided FNA biopsies were non-diagnostic. CT imaging showed a 1.3 x 1.2 x 1.8 cm low-attenuation nodule appearing to be within the posterior parotid tail, with differential diagnosis including cystic or necrotic lymph node versus salivary gland neoplasm. Given persistent non-diagnostic biopsy, the patient elected for excisional biopsy. Dissection revealed a well-circumscribed mass overlying the sternocleidomastoid muscle and abutting the deep and posterior aspect of the parotid tail fascia. Initial approach identifying the external jugular vein and GAN inferior to the mass revealed a mass intimately involved with distal greater auricular nerve branches and features suggestive of a nerve-sheath tumor. Two nerve branches overlying the capsule were freed and preserved, while one anterior branch entering the capsule was divided to free the tumor. Pathology demonstrated a 2.6 x 1.4 x 1.2cm neurofibroma, positive for S-100, SOX-10, and CD34, EMA negative, with MIB1<1%.",
        "Discussion/Conclusion": "GAN neurofibromas are extremely rare tumors that can closely mimic parotid tail tumors when involving the distal nerve branches. Lack of reliable distinguishing imaging features and high rates of non-diagnostic or non-specific FNA features seen in neurogenic tumors contribute to diagnostic challenges. Surgical excision provides definitive diagnosis and is best approached with careful identification and preservation of GAN branches, when possible, to avoid sensory deficits. Awareness of this entity helps avoid unnecessary parotidectomy and guides appropriate surgical planning. Surgeons should consider neurogenic tumors based on location and when FNAs are repeatedly nondiagnostic. Thoughtful intraoperative decision making and meticulous dissection facilitate nerve preservation while achieving complete excision."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neurofibroma of the Greater Auricular Nerve Presenting as a Parotid Tail Mass</span>. Talitha K Lewis, MD, MBA<sup>1</sup>; John E Hanks, MD<sup>2</sup>; Gahie Nam, MD<sup>3</sup>; <u>Kevin J Kovatch, MD, FACS</u><sup>2</sup>. <sup>1</sup>University of Connecticut School of Medicine; <sup>2</sup>University of Connecticut Department of Otolaryngology-Head and Neck Surgery; <sup>3</sup>University of Connecticut Department of Pathology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Neurofibromas arising from the greater auricular nerve (GAN) are exceptionally rare, with only isolated case reports described in the literature. Given location, distal GAN lesions may clinically present as parotid tail masses and can be clinically or radiographically indistinguishable from salivary gland neoplasms or lymph nodes. Higher rates of nondiagnostic fine needle aspiration biopsy (FNA) are observed for neurogenic tumors. This report highlights a rare GAN neurofibroma initially presumed to be a parotid lesion and emphasizes the use of intraoperative findings to guide management and excisional technique, in this case a largely nerve sparing excision.</p>\n\n<p><strong>Case: </strong>A 66-year-old woman with a history of breast cancer and monoclonal gammopathy of undetermined significance presented with a slowly enlarging 1.8cm left parotid tail mass. Both initial and repeat ultrasound-guided FNA biopsies were non-diagnostic. CT imaging showed a 1.3 x 1.2 x 1.8 cm low-attenuation nodule appearing to be within the posterior parotid tail, with differential diagnosis including cystic or necrotic lymph node versus salivary gland neoplasm. Given persistent non-diagnostic biopsy, the patient elected for excisional biopsy. Dissection revealed a well-circumscribed mass overlying the sternocleidomastoid muscle and abutting the deep and posterior aspect of the parotid tail fascia. Initial approach identifying the external jugular vein and GAN inferior to the mass revealed a mass intimately involved with distal greater auricular nerve branches and features suggestive of a nerve-sheath tumor. Two nerve branches overlying the capsule were freed and preserved, while one anterior branch entering the capsule was divided to free the tumor. Pathology demonstrated a 2.6 x 1.4 x 1.2cm neurofibroma, positive for S-100, SOX-10, and CD34, EMA negative, with MIB1<1%.</p>\n\n<p><strong>Discussion/Conclusion:</strong> GAN neurofibromas are extremely rare tumors that can closely mimic parotid tail tumors when involving the distal nerve branches. Lack of reliable distinguishing imaging features and high rates of non-diagnostic or non-specific FNA features seen in neurogenic tumors contribute to diagnostic challenges. Surgical excision provides definitive diagnosis and is best approached with careful identification and preservation of GAN branches, when possible, to avoid sensory deficits. Awareness of this entity helps avoid unnecessary parotidectomy and guides appropriate surgical planning. Surgeons should consider neurogenic tumors based on location and when FNAs are repeatedly nondiagnostic. Thoughtful intraoperative decision making and meticulous dissection facilitate nerve preservation while achieving complete excision.</p>\n\n<p><img alt='Ultrasound demonstrating parotid tail mass at time of fine needle aspiration' src='https://www.submitmyabstract.com/abs/images/153832/Ultrasound(1).jpg' /></p>\n\n<p><img alt='CT scan demonstrating a 1.3 x 1.2 x 1.8 cm low-attenuation nodule appearing to be within the posterior parotid tail' src='https://www.submitmyabstract.com/abs/images/153832/CT.jpg' /></p>\n\n<p><img alt='Intraoperative photo demonstrating mass' src='https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%201.jpg' /></p>\n\n<p><img alt='Intraoperative photo demonstrating mass dissected from greater auricular nerve branches ' src='https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%202.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153832/Intraop%20image%203.jpg' /></p>\n\n<p><img alt='H&E staining, x40x ' src='https://www.submitmyabstract.com/abs/images/153832/Pathology.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153832--></body></html>"
    },
    {
      "uid": "P410",
      "content_id": "153382",
      "abstract_number": "P410",
      "poster_number": "P410",
      "title": "Treatment strategy for parotid lymph node metastasis from eyelid sebaceous carcinoma: a single-institution case series and pooled analysis of the literature",
      "summary": "Combined institutional and pooled literature data suggest that total parotidectomy provides superior local control compared with more limited parotid surgery for PLM from eyelid sebaceous carcinoma. Unlike surgery for primary parotid tumors, the management of PLM should be planned with an emphasis on comprehensive removal of the intraparotid lymphatic tissue. PORT was associated with a lower rate of parotid...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153382",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Takeshi Takahashi",
      "presenter": "Takeshi Takahashi",
      "authors": "Takeshi Takahashi ; Shusuke Ohshima, MD; Jo Omata; Yusuke Yokoyama; Ryusuke Shodo; Yushi Ueki; Arata Horii",
      "normalized_authors": [
        "Takeshi Takahashi",
        "Shusuke Ohshima",
        "Jo Omata",
        "Yusuke Yokoyama",
        "Ryusuke Shodo",
        "Yushi Ueki",
        "Arata Horii"
      ],
      "affiliations": [
        "Department of Otolaryngology–Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology–Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Takeshi Takahashi ; Shusuke Ohshima, MD; Jo Omata; Yusuke Yokoyama; Ryusuke Shodo; Yushi Ueki; Arata Horii",
        "Affiliations": "Department of Otolaryngology–Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences",
        "Background": "Parotid lymph node metastasis (PLM) from sebaceous carcinoma of the eyelid is rare, and the optimal management—particularly the extent of parotidectomy, the role of neck dissection, and indications for postoperative radiotherapy (PORT)—remains unclear. We aimed to propose a treatment strategy by integrating data from a single-institution case series and a pooled analysis of published cases.",
        "Methods": "We retrospectively reviewed 7 patients with PLM from eyelid sebaceous carcinoma treated at our institution between 1999 and 2024, collecting data on demographics, timing and pattern of metastasis, surgical procedures, PORT, recurrence, and survival. We also conducted a systematic review of the literature and identified eight case series that described surgical procedures and the use of PORT; one report with insufficient detail on recurrence sites was excluded from the pooled analysis. In total, 51 patients (7 from our institution and 44 from the literature) with available data on parotid recurrence were included. Parotidectomy was categorized as total versus non-total (partial, superficial, or unspecified), and patients were grouped according to whether they received PORT. Parotid recurrence rates were compared between groups using Fisher’s exact test.",
        "Results": "In our institutional cohort (median age 67 years; 4 men and 3 women), 1 patient had PLM at the time of primary eyelid tumor resection, and 6 patients developed subsequent PLM following primary surgery (median interval, 9 months; range, 1–31 months). Four patients also had neck lymph node metastasis. Parotid surgery consisted of total parotidectomy in 3 patients and partial parotidectomy in 4. Neck dissection was performed in 4 patients. PORT was administered in 6 patients. During a median follow-up of 74 months, parotid recurrence occurred in 2 patients, both of whom had initially undergone partial parotidectomy and were successfully salvaged surgically; neck nodal recurrence developed in 2 patients.",
        "Abstract": "In the pooled analysis of 51 patients, parotid recurrence occurred in 10 of 28 patients (35.7%) treated with non-total parotidectomy and in 1 of 23 (4.3%) treated with total parotidectomy, indicating a significantly lower recurrence rate with total parotidectomy (p = 0.007). Regarding PORT, parotid recurrence occurred in 7 of 19 patients (36.8%) without PORT and in 4 of 32 (12.5%) with PORT, showing a trend toward reduced recurrence in patients who received PORT (p = 0.075).",
        "Conclusions": "Combined institutional and pooled literature data suggest that total parotidectomy provides superior local control compared with more limited parotid surgery for PLM from eyelid sebaceous carcinoma. Unlike surgery for primary parotid tumors, the management of PLM should be planned with an emphasis on comprehensive removal of the intraparotid lymphatic tissue. PORT was associated with a lower rate of parotid recurrence and should be strongly considered, particularly in patients at high risk of recurrence."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment strategy for parotid lymph node metastasis from eyelid sebaceous carcinoma: a single-institution case series and pooled analysis of the literature</span>. <u>Takeshi Takahashi</u>; Shusuke Ohshima, MD; Jo Omata; Yusuke Yokoyama; Ryusuke Shodo; Yushi Ueki; Arata Horii. Department of Otolaryngology–Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Parotid lymph node metastasis (PLM) from sebaceous carcinoma of the eyelid is rare, and the optimal management—particularly the extent of parotidectomy, the role of neck dissection, and indications for postoperative radiotherapy (PORT)—remains unclear. We aimed to propose a treatment strategy by integrating data from a single-institution case series and a pooled analysis of published cases.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed 7 patients with PLM from eyelid sebaceous carcinoma treated at our institution between 1999 and 2024, collecting data on demographics, timing and pattern of metastasis, surgical procedures, PORT, recurrence, and survival. We also conducted a systematic review of the literature and identified eight case series that described surgical procedures and the use of PORT; one report with insufficient detail on recurrence sites was excluded from the pooled analysis. In total, 51 patients (7 from our institution and 44 from the literature) with available data on parotid recurrence were included. Parotidectomy was categorized as total versus non-total (partial, superficial, or unspecified), and patients were grouped according to whether they received PORT. Parotid recurrence rates were compared between groups using Fisher’s exact test.</p>\n\n<p><strong>Results: </strong>In our institutional cohort (median age 67 years; 4 men and 3 women), 1 patient had PLM at the time of primary eyelid tumor resection, and 6 patients developed subsequent PLM following primary surgery (median interval, 9 months; range, 1–31 months). Four patients also had neck lymph node metastasis. Parotid surgery consisted of total parotidectomy in 3 patients and partial parotidectomy in 4. Neck dissection was performed in 4 patients. PORT was administered in 6 patients. During a median follow-up of 74 months, parotid recurrence occurred in 2 patients, both of whom had initially undergone partial parotidectomy and were successfully salvaged surgically; neck nodal recurrence developed in 2 patients.</p>\n\n<p>In the pooled analysis of 51 patients, parotid recurrence occurred in 10 of 28 patients (35.7%) treated with non-total parotidectomy and in 1 of 23 (4.3%) treated with total parotidectomy, indicating a significantly lower recurrence rate with total parotidectomy (p = 0.007). Regarding PORT, parotid recurrence occurred in 7 of 19 patients (36.8%) without PORT and in 4 of 32 (12.5%) with PORT, showing a trend toward reduced recurrence in patients who received PORT (p = 0.075).</p>\n\n<p><strong>Conclusions: </strong>Combined institutional and pooled literature data suggest that total parotidectomy provides superior local control compared with more limited parotid surgery for PLM from eyelid sebaceous carcinoma. Unlike surgery for primary parotid tumors, the management of PLM should be planned with an emphasis on comprehensive removal of the intraparotid lymphatic tissue. PORT was associated with a lower rate of parotid recurrence and should be strongly considered, particularly in patients at high risk of recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153382--></body></html>"
    },
    {
      "uid": "P411",
      "content_id": "154276",
      "abstract_number": "P411",
      "poster_number": "P411",
      "title": "Silent Threats: Chronic Sialadenitis as a Risk Factor for Salivary Gland Malignancy",
      "summary": "Our findings suggest that chronic sialadenitis is associated with a significantly increased risk of developing salivary gland malignancies, particularly in the parotid and submandibular glands. This relationship may reflect carcinogenesis that is driven by chronic inflammation and marked by repeated epithelial injury, immune dysregulation, and glandular remodeling.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154276",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amber Dunmire, MD",
      "presenter": "Amber Dunmire, MD",
      "authors": "Sudhanvan Iyer; Amber Dunmire, MD ; Viran J Ranasinghe, MD",
      "normalized_authors": [
        "Sudhanvan Iyer",
        "Amber Dunmire",
        "Viran J Ranasinghe"
      ],
      "affiliations": [
        "University of Texas Medical Branch at Galveston"
      ],
      "normalized_institutions": [
        "University of Texas Medical Branch at Galveston"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sudhanvan Iyer; Amber Dunmire, MD ; Viran J Ranasinghe, MD",
        "Affiliations": "University of Texas Medical Branch at Galveston",
        "Introduction": "Chronic sialadenitis is a recurrent inflammatory condition of the salivary glands, but its chronic implications, such as later malignant changes, are poorly defined. This study aims to investigate whether chronic sialadenitis is associated with an increased risk of developing salivary gland cancers and whether certain autoimmune conditions can increase the likelihood of developing chronic sialadenitis and subsequent salivary gland malignancy.",
        "Methods": "A retrospective cohort study was conducted using the TriNetX research network, analyzing patients with and without a history of chronic sialadenitis. Propensity score matching was performed on 14 variables, including demographics, diabetes, BMI, radiation exposure, alcohol use, nicotine dependence, and cannabis use.",
        "Abstract": "Secondary analyses compared autoimmune cohorts (Sjogren’s syndrome, SLE, and RA) with matched controls to determine if there was an association between any of these conditions and the subsequent development of chronic sialadenitis. Among patients who later developed chronic sialadenitis, further analyses examined the risk of developing salivary gland cancer. Deceased patients and those with prior salivary gland cancer diagnoses were excluded from all cohorts. Primary outcomes included overall salivary gland cancer, parotid gland cancer, and submandibular gland cancer. Outcomes were assessed starting one day after the index event, with follow-up extending up to 20 years. Risk ratios (RR) with corresponding 95% confidence intervals (CI) were calculated. While autoimmune patients demonstrated a significantly increased risk of developing chronic sialadenitis (Sjogren’s syndrome (RR = 4.63; 95% CI 3.94–5.44), SLE (RR = 2.29; 95% CI 1.75–3.00), and RA (RR = 1.49; 95% CI 1.34–1.66)), there was no significant difference in the development of any salivary gland cancers among the Sjogren’s, SLE, and RA cohorts. Additionally, the increased risk of chronic sialadenitis in patients with Sjogren’s syndrome, SLE, and RA supports the role of autoimmune-mediated glandular inflammation, a process that may also contribute to malignant transformation. However, because salivary gland cancers were extremely rare within the autoimmune cohorts, our data cannot determine whether autoimmune-driven sialadenitis significantly affects cancer risk. These findings highlight the importance of increased clinical surveillance in patients with chronic sialadenitis or related autoimmune conditions and support further investigation into potential preventive strategies.",
        "Results": "The matched chronic sialadenitis and control cohorts each included 40,813 patients, with median follow-up of 1319 and 1187 days, respectively. Chronic sialadenitis was strongly associated with increased risk of salivary gland cancer overall (RR = 0.294; 95% CI: 0.210–0.411; p < 0.001), parotid gland cancer (RR = 0.112; 95% CI: 0.077–0.163; p < 0.001), and submandibular cancer (RR = 0.400; 95% CI: 0.192–0.832; p = 0.011). Kaplan-Meier analysis also demonstrated a lower survival probability in the chronic sialadenitis group across all outcomes.",
        "Conclusions": "Our findings suggest that chronic sialadenitis is associated with a significantly increased risk of developing salivary gland malignancies, particularly in the parotid and submandibular glands. This relationship may reflect carcinogenesis that is driven by chronic inflammation and marked by repeated epithelial injury, immune dysregulation, and glandular remodeling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Silent Threats: Chronic Sialadenitis as a Risk Factor for Salivary Gland Malignancy</span>. Sudhanvan Iyer; <u>Amber Dunmire, MD</u>; Viran J Ranasinghe, MD. University of Texas Medical Branch at Galveston<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Chronic sialadenitis is a recurrent inflammatory condition of the salivary glands, but its chronic implications, such as later malignant changes, are poorly defined. This study aims to investigate whether chronic sialadenitis is associated with an increased risk of developing salivary gland cancers and whether certain autoimmune conditions can increase the likelihood of developing chronic sialadenitis and subsequent salivary gland malignancy.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using the TriNetX research network, analyzing patients with and without a history of chronic sialadenitis. Propensity score matching was performed on 14 variables, including demographics, diabetes, BMI, radiation exposure, alcohol use, nicotine dependence, and cannabis use.</p>\n\n<p>Secondary analyses compared autoimmune cohorts (Sjogren’s syndrome, SLE, and RA) with matched controls to determine if there was an association between any of these conditions and the subsequent development of chronic sialadenitis. Among patients who later developed chronic sialadenitis, further analyses examined the risk of developing salivary gland cancer. Deceased patients and those with prior salivary gland cancer diagnoses were excluded from all cohorts. Primary outcomes included overall salivary gland cancer, parotid gland cancer, and submandibular gland cancer. Outcomes were assessed starting one day after the index event, with follow-up extending up to 20 years. Risk ratios (RR) with corresponding 95% confidence intervals (CI) were calculated.</p>\n\n<p><strong>Results: </strong>The matched chronic sialadenitis and control cohorts each included 40,813 patients, with median follow-up of 1319 and 1187 days, respectively. Chronic sialadenitis was strongly associated with increased risk of salivary gland cancer overall (RR = 0.294; 95% CI: 0.210–0.411; p < 0.001), parotid gland cancer (RR = 0.112; 95% CI: 0.077–0.163; p < 0.001), and submandibular cancer (RR = 0.400; 95% CI: 0.192–0.832; p = 0.011). Kaplan-Meier analysis also demonstrated a lower survival probability in the chronic sialadenitis group across all outcomes.</p>\n\n<p>While autoimmune patients demonstrated a significantly increased risk of developing chronic sialadenitis (Sjogren’s syndrome (RR = 4.63; 95% CI 3.94–5.44), SLE (RR = 2.29; 95% CI 1.75–3.00), and RA (RR = 1.49; 95% CI 1.34–1.66)), there was no significant difference in the development of any salivary gland cancers among the Sjogren’s, SLE, and RA cohorts.</p>\n\n<p><strong>Conclusions: </strong>Our findings suggest that chronic sialadenitis is associated with a significantly increased risk of developing salivary gland malignancies, particularly in the parotid and submandibular glands. This relationship may reflect carcinogenesis that is driven by chronic inflammation and marked by repeated epithelial injury, immune dysregulation, and glandular remodeling.</p>\n\n<p>Additionally, the increased risk of chronic sialadenitis in patients with Sjogren’s syndrome, SLE, and RA supports the role of autoimmune-mediated glandular inflammation, a process that may also contribute to malignant transformation. However, because salivary gland cancers were extremely rare within the autoimmune cohorts, our data cannot determine whether autoimmune-driven sialadenitis significantly affects cancer risk. These findings highlight the importance of increased clinical surveillance in patients with chronic sialadenitis or related autoimmune conditions and support further investigation into potential preventive strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154276--></body></html>"
    },
    {
      "uid": "P412",
      "content_id": "154433",
      "abstract_number": "P412",
      "poster_number": "P412",
      "title": "Malignant Salivary Gland Neoplasms Mimicking Inflammatory Disease: A Retrospective Series",
      "summary": "Salivary gland neoplasms can present with symptoms and imaging findings suggestive of inflammatory disease, leading to diagnostic challenges. Careful evaluation of persistent pain, swelling, and heterogeneous or cystic lesions on imaging is critical, as early recognition allows timely surgical management. Despite variable histologies and occasional high-risk features, outcomes in this series were favorable with...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154433",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Haleigh Pine, BS",
      "presenter": "Haleigh Pine, BS",
      "authors": "Haleigh Pine, BS 1 ; Elise Patchett 2 ; Anna Bottoms 2 ; Christopher Rassekh, MD 2",
      "normalized_authors": [
        "Haleigh Pine",
        "Elise Patchett",
        "Anna Bottoms",
        "Christopher Rassekh"
      ],
      "affiliations": [
        "Perelman School of Medicine at the University of Pennsylvania",
        "Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Perelman School of Medicine at the University of Pennsylvania",
        "Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 476,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Haleigh Pine, BS 1 ; Elise Patchett 2 ; Anna Bottoms 2 ; Christopher Rassekh, MD 2",
        "Affiliations": "1 Perelman School of Medicine at the University of Pennsylvania; 2 Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania",
        "Background": "Salivary gland neoplasms are rare and often present with non-specific symptoms (facial pain, swelling, mass), diverse histologies, and imaging features, such as ductal dilatation or cystic lesions, that mimic chronic inflammation. Early recognition is essential for timely surgical intervention. Few studies have systematically described patients whose salivary tumors initially present as inflammatory disease, underscoring the need for improved awareness and evaluation strategies.",
        "Methods": "We retrospectively reviewed patients presenting to a tertiary academic center with salivary gland neoplasms mimicking inflammatory disease between 2011 and 2024. Data on demographics, clinical presentation, imaging, prior salivary interventions, surgical management, pathology, adjuvant therapy, and outcomes were extracted. Imaging (CT, MRI, US) was assessed for gland asymmetry, ductal dilatation, and lesion features. Tumor size, histology, stage, perineural or lymphovascular invasion, and chronic sialadenitis were recorded. Descriptive statistics summarized findings and follow-up for recurrence and persistent symptoms.",
        "Results": "Between 2011 and 2022, seven patients presented with salivary neoplasms initially masquerading as inflammatory disease (mean age 58.7). Most tumors arose in the parotid gland (86%) with one sublingual lesion involving the floor of the mouth. All patients reported facial pain, and most had swelling (71%), a palpable mass (57%), and TMJ or postauricular pain (57.1%), with a minority (28.6%) reporting dry mouth and eyes with negative Sjogren’s. One patient had a prior parotid adenoma, and two with parotid malignancy had preceding gland pain and swelling, with one having undergone sialendoscopy and steroid injection. Imaging commonly demonstrated asymmetric gland enlargement, ductal dilatation, and heterogeneous or cystic lesions, with several showing ill-defined enhancement concerning for neoplasm. Pathology revealed mucoepidermoid carcinoma in four patients (three low grade (one oncocytic variant), one high grade), along with one p16+ poorly differentiated squamous cell carcinoma, one adenoid cystic carcinoma with cribriform, and one carcinoma ex pleomorphic adenoma (p63 and EMA+). All patients underwent surgical resection, and 57% received adjuvant radiotherapy for perineural invasion, close margins or capsular invasion. The average tumor size was 2.51 cm (SD 2.63), with four tumors <2 cm; the largest was a 7.8-cm high-grade mucoepidermoid carcinoma, which had perineural invasion (T4a). All others were early stage (T1N0M0), except the squamous cell carcinoma (T2), and none showed lymphovascular invasion. No recurrences occurred over a mean 7.4-year disease-free interval (SD:5.0). Post-treatment dry mouth occurred in three of four radiated patients and one non-radiated patient. Three patients (42.9%) reported persistent but mild pain. One patient with an oncocytic-variant mucoepidermoid carcinoma later developed a contralateral Warthin’s tumor despite no smoking history.",
        "Conclusion": "Salivary gland neoplasms can present with symptoms and imaging findings suggestive of inflammatory disease, leading to diagnostic challenges. Careful evaluation of persistent pain, swelling, and heterogeneous or cystic lesions on imaging is critical, as early recognition allows timely surgical management. Despite variable histologies and occasional high-risk features, outcomes in this series were favorable with no recurrences over long-term follow-up."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Malignant Salivary Gland Neoplasms Mimicking Inflammatory Disease: A Retrospective Series</span>. <u>Haleigh Pine, BS</u><sup>1</sup>; Elise Patchett<sup>2</sup>; Anna Bottoms<sup>2</sup>; Christopher Rassekh, MD<sup>2</sup>. <sup>1</sup>Perelman School of Medicine at the University of Pennsylvania; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salivary gland neoplasms are rare and often present with non-specific symptoms (facial pain, swelling, mass), diverse histologies, and imaging features, such as ductal dilatation or cystic lesions, that mimic chronic inflammation. Early recognition is essential for timely surgical intervention. Few studies have systematically described patients whose salivary tumors initially present as inflammatory disease, underscoring the need for improved awareness and evaluation strategies. </p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed patients presenting to a tertiary academic center with salivary gland neoplasms mimicking inflammatory disease between 2011 and 2024. Data on demographics, clinical presentation, imaging, prior salivary interventions, surgical management, pathology, adjuvant therapy, and outcomes were extracted. Imaging (CT, MRI, US) was assessed for gland asymmetry, ductal dilatation, and lesion features. Tumor size, histology, stage, perineural or lymphovascular invasion, and chronic sialadenitis were recorded. Descriptive statistics summarized findings and follow-up for recurrence and persistent symptoms.</p>\n\n<p><strong>Results: </strong>Between 2011 and 2022, seven patients presented with salivary neoplasms initially masquerading as inflammatory disease (mean age 58.7). Most tumors arose in the parotid gland (86%) with one sublingual lesion involving the floor of the mouth. All patients reported facial pain, and most had swelling (71%), a palpable mass (57%), and TMJ or postauricular pain (57.1%), with a minority (28.6%) reporting dry mouth and eyes with negative Sjogren’s. One patient had a prior parotid adenoma, and two with parotid malignancy had preceding gland pain and swelling, with one having undergone sialendoscopy and steroid injection. Imaging commonly demonstrated asymmetric gland enlargement, ductal dilatation, and heterogeneous or cystic lesions, with several showing ill-defined enhancement concerning for neoplasm. Pathology revealed mucoepidermoid carcinoma in four patients (three low grade (one oncocytic variant), one high grade), along with one p16+ poorly differentiated squamous cell carcinoma, one adenoid cystic carcinoma with cribriform, and one carcinoma ex pleomorphic adenoma (p63 and EMA+). All patients underwent surgical resection, and 57% received adjuvant radiotherapy for perineural invasion, close margins or capsular invasion. The average tumor size was 2.51 cm (SD 2.63), with four tumors <2 cm; the largest was a 7.8-cm high-grade mucoepidermoid carcinoma, which had perineural invasion (T4a). All others were early stage (T1N0M0), except the squamous cell carcinoma (T2), and none showed lymphovascular invasion. No recurrences occurred over a mean 7.4-year disease-free interval (SD:5.0). Post-treatment dry mouth occurred in three of four radiated patients and one non-radiated patient. Three patients (42.9%) reported persistent but mild pain. One patient with an oncocytic-variant mucoepidermoid carcinoma later developed a contralateral Warthin’s tumor despite no smoking history.</p>\n\n<p><strong>Conclusion: </strong>Salivary gland neoplasms can present with symptoms and imaging findings suggestive of inflammatory disease, leading to diagnostic challenges. Careful evaluation of persistent pain, swelling, and heterogeneous or cystic lesions on imaging is critical, as early recognition allows timely surgical management. Despite variable histologies and occasional high-risk features, outcomes in this series were favorable with no recurrences over long-term follow-up.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154433--></body></html>"
    },
    {
      "uid": "P413",
      "content_id": "153483",
      "abstract_number": "P413",
      "poster_number": "P413",
      "title": "Electrophysiological Outcomes One Year After Single-Stage Dual/Triple Facial Nerve Reanimation Performed During Radical Parotidectomy: A Single-Institution Case Series of 15 Patients",
      "summary": "Electrophysiological outcomes provide valuable insights into the success of facial nerve reanimation surgery. This case series highlights the importance of integrating objective nerve function assessments alongside clinical evaluations to guide postoperative management and improve patient outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153483",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eun-Jae Chung",
      "presenter": "Eun-Jae Chung",
      "authors": "Eun-Jae Chung 1 ; Seo Young Kim 1 ; Keewon Kim 2",
      "normalized_authors": [
        "Eun-Jae Chung",
        "Seo Young Kim",
        "Keewon Kim"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Department of Rehabilitation medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Department of Rehabilitation medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"
      ],
      "session_type": "Poster",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 196,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eun-Jae Chung 1 ; Seo Young Kim 1 ; Keewon Kim 2",
        "Affiliations": "1 Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; 2 Department of Rehabilitation medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Background": "Facial nerve reanimation surgery aims to restore function and improve quality of life for patients with facial paralysis. While the clinical outcomes are often evaluated, the electrophysiological aspects remain underreported, especially in smaller case series.",
        "Objective": "To evaluate the electrophysiological outcomes following facial nerve reanimation surgery in a single-institute case series of 15 patients.",
        "Methods": "This retrospective study analyzed 15 cases of facial nerve reanimation surgery performed at our institution from 2021 to 2024. Electrophysiological assessments, including nerve conduction studies and electromyography (EMG), were conducted post-operatively to evaluate nerve function and muscle reinnervation. Clinical data, surgical techniques, and patient demographics were also collected and analyzed.",
        "Results": "Of the 15 patients, 8 underwent triple reinnervation, 7 underwent dual reinnervation. Postoperative assessments showed significant improvement in nerve conduction latency and EMG activity. Clinically, patients demonstrated changes after 1 year of surgery. Needle EMG results showed increased MUAP polyphasity and discrete interference pattern after nerve reinnervation. Especially nerve reinnervation to orbicularis oculi muscle showed best improvement.",
        "Conclusion": "Electrophysiological outcomes provide valuable insights into the success of facial nerve reanimation surgery. This case series highlights the importance of integrating objective nerve function assessments alongside clinical evaluations to guide postoperative management and improve patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Electrophysiological Outcomes One Year After Single-Stage Dual/Triple Facial Nerve Reanimation Performed During Radical Parotidectomy: A Single-Institution Case Series of 15 Patients</span>. <u>Eun-Jae Chung</u><sup>1</sup>; Seo Young Kim<sup>1</sup>; Keewon Kim<sup>2</sup>. <sup>1</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; <sup>2</sup>Department of Rehabilitation medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Facial nerve reanimation surgery aims to restore function and improve quality of life for patients with facial paralysis. While the clinical outcomes are often evaluated, the electrophysiological aspects remain underreported, especially in smaller case series. </p>\n\n<p><strong>Objective: </strong>To evaluate the electrophysiological outcomes following facial nerve reanimation surgery in a single-institute case series of 15 patients. </p>\n\n<p><strong>Methods:</strong> This retrospective study analyzed 15 cases of facial nerve reanimation surgery performed at our institution from 2021 to 2024. Electrophysiological assessments, including nerve conduction studies and electromyography (EMG), were conducted post-operatively to evaluate nerve function and muscle reinnervation. Clinical data, surgical techniques, and patient demographics were also collected and analyzed. </p>\n\n<p><strong>Results:</strong> Of the 15 patients, 8 underwent triple reinnervation, 7 underwent dual reinnervation. Postoperative assessments showed significant improvement in nerve conduction latency and EMG activity. Clinically, patients demonstrated changes after 1 year of surgery. Needle EMG results showed increased MUAP polyphasity and discrete interference pattern after nerve reinnervation. Especially nerve reinnervation to orbicularis oculi muscle showed best improvement. </p>\n\n<p><strong>Conclusion: </strong>Electrophysiological outcomes provide valuable insights into the success of facial nerve reanimation surgery. This case series highlights the importance of integrating objective nerve function assessments alongside clinical evaluations to guide postoperative management and improve patient outcomes. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153483--></body></html>"
    },
    {
      "uid": "P414",
      "content_id": "153246",
      "abstract_number": "P414",
      "poster_number": "P414",
      "title": "Squamous Cell Carcinoma Arising From Within Syringocystadenoma Papilliferum of the Scalp: A Rare Entity",
      "summary": "SCAP is capable of presenting in a variety of forms, making biopsy essential for any lesion with suspicious or progressive features. Once the diagnosis is established histologically, the clinician should be inclined to treat with complete surgical excision due to the documented potential for malignant transformation and concurrent carcinoma.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153246",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eli Hopkins, DO",
      "presenter": "Eli Hopkins, DO",
      "authors": "Eli Hopkins, DO 1 ; Thomas Hendriks, MBBS, MPhil, FRACS 2 ; Usman Khan, MD, MSc, FRCSC 2 ; Joshua Hornig, MD, FRCSC 2",
      "normalized_authors": [
        "Eli Hopkins",
        "Thomas Hendriks, MBBS, MPhil, FRACS",
        "Usman Khan, FRCSC",
        "Joshua Hornig, FRCSC"
      ],
      "affiliations": [
        "HCA Healthcare Trident Hospital",
        "Sarah Cannon Cancer Institute, Charleston, SC, USA"
      ],
      "normalized_institutions": [
        "HCA Healthcare Trident Hospital",
        "Sarah Cannon Cancer Institute, Charleston, SC, USA"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153246/IMG_0815%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153246/IMG_0815%202.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153246"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case",
        "Abstract",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eli Hopkins, DO 1 ; Thomas Hendriks, MBBS, MPhil, FRACS 2 ; Usman Khan, MD, MSc, FRCSC 2 ; Joshua Hornig, MD, FRCSC 2",
        "Affiliations": "1 HCA Healthcare Trident Hospital; 2 Sarah Cannon Cancer Institute, Charleston, SC, USA",
        "Introduction": "Syringocystadenoma papilliferum (SCAP) is a rare hamartomatous adnexal neoplasm first described by John Stokes in 1917, typically of apocrine differentiation, and most commonly present at birth. Its clinical presentation can vary widely, with three distinct clinical variants having been previously described. The lesion itself is benign; however, it carries a risk of malignant transformation. SCAP most commonly transforms into a basal cell carcinoma, and rarely, squamous cell carcinoma (SCC). Due to its risk of malignant transformation, these lesions should be closely followed and clinicians should have a low threshold for surgical excision. Here, we present an exceptionally rare case of SCC arising within SCAP of the scalp.",
        "Case": "A 54-year-old female was referred to our clinic for a biopsy proven right parietal scalp SCAP. She reported that the lesion has been present for over 30 years following drainage of an abscess in the same location, with subsequent growth in the preceding 1-2 years. Examination revealed a 3x3cm exophytic, verrucous mass at the right superior parietal scalp (see figure 1). Surgical management entailed wide local excision with staged reconstruction using local tissue rearrangement with the final pathology demonstrating a well-differentiated invasive SCC arising from SCAP, clear of margins and without adverse pathological features",
        "Abstract": "Figure 1: exophytic SCAP of the scalp Although SCAP is benign, it can undergo malignant transformation, with basal cell carcinoma seen in up to 10% of cases. Alternatively, SCC arising within SCAP is extremely uncommon. Several mechanisms could explain our patient’s lesion including possible origination from an unrecognized nevus sebaceous, present in up to 40% of SCAPs, or from a long-standing lesion initially mistaken for an abscess. Sporadic SCAP has also been linked to BRAF and HRAS mutations and to HPV, all of which play a role in cutaneous SCC. Finally, although SCAP arising within scars is infrequently reported, it is possible the lesion developed within scar tissue from her prior abscess drainage. While the exact pathogenesis is uncertain, the resulting SCC within SCAP has been rarely described in the literature to date.",
        "Discussion": "SCAP is an exceptionally rare tumor but most often found in the head and neck region. It is believed to arise from pluripotent adnexal stem cells capable of apocrine or eccrine differentiation, with a tendency toward apocrine features. About half of SCAPs are present at birth, a third appear in early childhood, and the remainder develop later in life. Three clinical types exist: plaque, linear, and solitary nodular. Plaque-type lesions typically present at birth as hairless plaques that become verrucous around puberty, the linear form appears as multiple umbilicated papules on the head and neck, and the solitary nodular type generally presents as a small domed nodule on the trunk or axilla.",
        "Conclusion": "SCAP is capable of presenting in a variety of forms, making biopsy essential for any lesion with suspicious or progressive features. Once the diagnosis is established histologically, the clinician should be inclined to treat with complete surgical excision due to the documented potential for malignant transformation and concurrent carcinoma."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Squamous Cell Carcinoma Arising From Within Syringocystadenoma Papilliferum of the Scalp: A Rare Entity</span>. <u>Eli Hopkins, DO</u><sup>1</sup>; Thomas Hendriks, MBBS, MPhil, FRACS<sup>2</sup>; Usman Khan, MD, MSc, FRCSC<sup>2</sup>; Joshua Hornig, MD, FRCSC<sup>2</sup>. <sup>1</sup>HCA Healthcare Trident Hospital; <sup>2</sup>Sarah Cannon Cancer Institute, Charleston, SC, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Syringocystadenoma papilliferum (SCAP) is a rare hamartomatous adnexal neoplasm first described by John Stokes in 1917, typically of apocrine differentiation, and most commonly present at birth. Its clinical presentation can vary widely, with three distinct clinical variants having been previously described. The lesion itself is benign; however, it carries a risk of malignant transformation. SCAP most commonly transforms into a basal cell carcinoma, and rarely, squamous cell carcinoma (SCC). Due to its risk of malignant transformation, these lesions should be closely followed and clinicians should have a low threshold for surgical excision. Here, we present an exceptionally rare case of SCC arising within SCAP of the scalp.</p>\n\n<p><strong>Case: </strong>A 54-year-old female was referred to our clinic for a biopsy proven right parietal scalp SCAP. She reported that the lesion has been present for over 30 years following drainage of an abscess in the same location, with subsequent growth in the preceding 1-2 years. Examination revealed a 3x3cm exophytic, verrucous mass at the right superior parietal scalp (see figure 1). Surgical management entailed wide local excision with staged reconstruction using local tissue rearrangement with the final pathology demonstrating a well-differentiated invasive SCC arising from SCAP, clear of margins and without adverse pathological features</p>\n\n<p>Figure 1: exophytic SCAP of the scalp</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153246/IMG_0815%202.jpg' /></p>\n\n<p><strong>Discussion: </strong>SCAP is an exceptionally rare tumor but most often found in the head and neck region. It is believed to arise from pluripotent adnexal stem cells capable of apocrine or eccrine differentiation, with a tendency toward apocrine features. About half of SCAPs are present at birth, a third appear in early childhood, and the remainder develop later in life. Three clinical types exist: plaque, linear, and solitary nodular. Plaque-type lesions typically present at birth as hairless plaques that become verrucous around puberty, the linear form appears as multiple umbilicated papules on the head and neck, and the solitary nodular type generally presents as a small domed nodule on the trunk or axilla.</p>\n\n<p>Although SCAP is benign, it can undergo malignant transformation, with basal cell carcinoma seen in up to 10% of cases. Alternatively, SCC arising within SCAP is extremely uncommon. Several mechanisms could explain our patient’s lesion including possible origination from an unrecognized nevus sebaceous, present in up to 40% of SCAPs, or from a long-standing lesion initially mistaken for an abscess. Sporadic SCAP has also been linked to BRAF and HRAS mutations and to HPV, all of which play a role in cutaneous SCC. Finally, although SCAP arising within scars is infrequently reported, it is possible the lesion developed within scar tissue from her prior abscess drainage. While the exact pathogenesis is uncertain, the resulting SCC within SCAP has been rarely described in the literature to date.</p>\n\n<p><strong>Conclusion: </strong>SCAP is capable of presenting in a variety of forms, making biopsy essential for any lesion with suspicious or progressive features. Once the diagnosis is established histologically, the clinician should be inclined to treat with complete surgical excision due to the documented potential for malignant transformation and concurrent carcinoma.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153246--></body></html>"
    },
    {
      "uid": "P415",
      "content_id": "153283",
      "abstract_number": "P415",
      "poster_number": "P415",
      "title": "Regional Intraneural Metastases from Squamous Cell Skin Cancer of the Head and Neck",
      "summary": "Perineural invasion (PNI) is a known and clinically significant feature of head and neck squamous cell carcinoma (HNSCC). It is defined as tumor cell presence within the nerve sheath or encasing more than 33% of the nerve. PNI in HNSCC is associated with higher risk of recurrences and worse overall survival. Involvement of nerves with increased caliber or depth from the dermis is further associated with poor...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153283",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kendyl Barron, MD",
      "presenter": "Kendyl Barron, MD",
      "authors": "Kendyl Barron, MD ; Anna Bogursky, BA; Ricardo Aulet, MD, MBA",
      "normalized_authors": [
        "Kendyl Barron",
        "Anna Bogursky",
        "Ricardo Aulet"
      ],
      "affiliations": [
        "University of Massachusetts"
      ],
      "normalized_institutions": [
        "University of Massachusetts"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 350,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kendyl Barron, MD ; Anna Bogursky, BA; Ricardo Aulet, MD, MBA",
        "Affiliations": "University of Massachusetts",
        "Abstract": "Perineural invasion (PNI) is a known and clinically significant feature of head and neck squamous cell carcinoma (HNSCC). It is defined as tumor cell presence within the nerve sheath or encasing more than 33% of the nerve. PNI in HNSCC is associated with higher risk of recurrences and worse overall survival. Involvement of nerves with increased caliber or depth from the dermis is further associated with poor outcomes. Involvement of named nerves or symptomatic neuralgia is also a poor prognostic indicator. There is limited information in the literature about regional intraneural metastases. We present two such cases of head and neck squamous cell skin cancer which presented as painful neck masses. In one case, a patient had a history of supraclavicular squamous cell carcinoma (SCC) for which he underwent surgical excision and post-operative radiation. Months later he presented with sharp, shooting neck and shoulder pain which persisted despite cortisone injection. He was found to have a palpable nodule above the clavicle and no distant metastasis on further imaging. His PET scan showed a curvilinear FDG avid lesion extending down to the cervical spine. He underwent excision of this nodule which revealed tumor deposits within the cervical rootlet. The tumor was followed down to the foramen where the nerve was ligated. Pathology showed SCC within the nerve, no lymph node tissue, and a positive nerve margin at the foramen. The second patient, who had a history of multiple squamous cell carcinomas of the scalp and face, presented with a painful superficial right neck mass, which radiated to his ear. Ultrasound showed a nodule over the SCM posterior to the jugular vein. Intraoperatively a mass was found within the greater auricular nerve. This was excised back to grossly normal nerve proximally and distally. Pathology confirmed SCC within the nerve. He later presented with a second painful neck mass more inferiorly that was excised and showed an additional nerve with a metastatic deposit. Both the presentation of these tumors and their location were atypical for SCC. Head and neck surgeons should be aware of the possibility of regional intraneural metastasis of skin SCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Regional Intraneural Metastases from Squamous Cell Skin Cancer of the Head and Neck</span>. <u>Kendyl Barron, MD</u>; Anna Bogursky, BA; Ricardo Aulet, MD, MBA. University of Massachusetts<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Perineural invasion (PNI) is a known and clinically significant feature of head and neck squamous cell carcinoma (HNSCC). It is defined as tumor cell presence within the nerve sheath or encasing more than 33% of the nerve. PNI in HNSCC is associated with higher risk of recurrences and worse overall survival. Involvement of nerves with increased caliber or depth from the dermis is further associated with poor outcomes. Involvement of named nerves or symptomatic neuralgia is also a poor prognostic indicator. There is limited information in the literature about regional intraneural metastases. We present two such cases of head and neck squamous cell skin cancer which presented as painful neck masses. In one case, a patient had a history of supraclavicular squamous cell carcinoma (SCC) for which he underwent surgical excision and post-operative radiation. Months later he presented with sharp, shooting neck and shoulder pain which persisted despite cortisone injection. He was found to have a palpable nodule above the clavicle and no distant metastasis on further imaging. His PET scan showed a curvilinear FDG avid lesion extending down to the cervical spine. He underwent excision of this nodule which revealed tumor deposits within the cervical rootlet. The tumor was followed down to the foramen where the nerve was ligated. Pathology showed SCC within the nerve, no lymph node tissue, and a positive nerve margin at the foramen. The second patient, who had a history of multiple squamous cell carcinomas of the scalp and face, presented with a painful superficial right neck mass, which radiated to his ear. Ultrasound showed a nodule over the SCM posterior to the jugular vein. Intraoperatively a mass was found within the greater auricular nerve. This was excised back to grossly normal nerve proximally and distally. Pathology confirmed SCC within the nerve. He later presented with a second painful neck mass more inferiorly that was excised and showed an additional nerve with a metastatic deposit. Both the presentation of these tumors and their location were atypical for SCC. Head and neck surgeons should be aware of the possibility of regional intraneural metastasis of skin SCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153283--></body></html>"
    },
    {
      "uid": "P416",
      "content_id": "153724",
      "abstract_number": "P416",
      "poster_number": "P416",
      "title": "Proliferating Trichilemmal Tumor: When Histopathology Overcomes Imaging in the Diagnosis of Rare Cutaneous Neoplasms",
      "summary": "Trichilemmal proliferative tumor, although rare and with varied presentations, has surgical excision as its effective treatment.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153724",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex F Porsani, MD",
      "presenter": "Alex F Porsani, MD",
      "authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
      "normalized_authors": [
        "Alex F Porsani",
        "Eloa B Oliveira Andrade",
        "Julia O Parenti",
        "Maria Beatriz Orru",
        "Nathalia M Nogueira"
      ],
      "affiliations": [
        "Santa Casa Araraquara"
      ],
      "normalized_institutions": [
        "Santa Casa Araraquara"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 222,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Abstract",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
        "Affiliations": "Santa Casa Araraquara",
        "Objective": "Trichilemmal proliferative tumor is a rare benign cutaneous neoplasm originating from the hair follicle, most common on the scalp of elderly women.",
        "Abstract": "This work aims to describe the clinical, pathological, and therapeutic aspects of trichilemmal proliferative tumor, based on the literature and an atypical case report. A clinical case of a 22-year-old male patient with a posterior cervical nodule and pain on palpation is presented. Initial investigation by cervical ultrasound did not define the etiology, and complete surgical excision with subsequent anatomopathological diagnosis was indicated. Complete surgical excision is fundamental for treatment and prevention of recurrences, with an excellent prognosis. Documentation of atypical cases contributes to the knowledge and management of this condition, emphasizing the importance of definitive histopathological diagnosis.",
        "Methods": "A review of the scientific literature (PubMed, SciELO, Google Scholar) on trichilemmal proliferative tumor was conducted.",
        "Results": "The literature confirms trichilemmal proliferative tumor as benign, with surgical excision as curative treatment. The reported case, atypical in location and age, demonstrated that surgical excision led to a definitive diagnosis and resolution of symptoms, with good postoperative evolution. Ultrasonography was not diagnostic, highlighting the importance of histopathology.",
        "Discussion": "The atypical presentation of trichilemmal proliferative tumor requires high clinical suspicion. The nonspecificity of imaging exams reinforces the need for anatomopathological confirmation.",
        "Conclusion": "Trichilemmal proliferative tumor, although rare and with varied presentations, has surgical excision as its effective treatment."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Proliferating Trichilemmal Tumor: When Histopathology Overcomes Imaging in the Diagnosis of Rare Cutaneous Neoplasms</span>. <u>Alex F Porsani, MD</u>; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira. Santa Casa Araraquara<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Trichilemmal proliferative tumor is a rare benign cutaneous neoplasm originating from the hair follicle, most common on the scalp of elderly women.</p>\n\n<p>This work aims to describe the clinical, pathological, and therapeutic aspects of trichilemmal proliferative tumor, based on the literature and an atypical case report.</p>\n\n<p><strong>Methods: </strong>A review of the scientific literature (PubMed, SciELO, Google Scholar) on trichilemmal proliferative tumor was conducted.</p>\n\n<p>A clinical case of a 22-year-old male patient with a posterior cervical nodule and pain on palpation is presented. Initial investigation by cervical ultrasound did not define the etiology, and complete surgical excision with subsequent anatomopathological diagnosis was indicated.</p>\n\n<p><strong>Results: </strong>The literature confirms trichilemmal proliferative tumor as benign, with surgical excision as curative treatment. The reported case, atypical in location and age, demonstrated that surgical excision led to a definitive diagnosis and resolution of symptoms, with good postoperative evolution. Ultrasonography was not diagnostic, highlighting the importance of histopathology.</p>\n\n<p><strong>Discussion: </strong>The atypical presentation of trichilemmal proliferative tumor requires high clinical suspicion. The nonspecificity of imaging exams reinforces the need for anatomopathological confirmation.</p>\n\n<p>Complete surgical excision is fundamental for treatment and prevention of recurrences, with an excellent prognosis.</p>\n\n<p><strong>Conclusion: </strong>Trichilemmal proliferative tumor, although rare and with varied presentations, has surgical excision as its effective treatment.</p>\n\n<p>Documentation of atypical cases contributes to the knowledge and management of this condition, emphasizing the importance of definitive histopathological diagnosis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153724--></body></html>"
    },
    {
      "uid": "P417",
      "content_id": "153716",
      "abstract_number": "P417",
      "poster_number": "P417",
      "title": "Cervical Pilomatricoma: The Challenge of Clinical Diagnosis and Histopathological Confirmation with Ghost Cells",
      "summary": "This report reinforces the importance of knowing the characteristics of pilomatricoma, its inclusion in the differential diagnosis of cervical subcutaneous nodules, and the need for complete surgical excision for diagnosis and complementation.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153716",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex F Porsani, MD",
      "presenter": "Alex F Porsani, MD",
      "authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
      "normalized_authors": [
        "Alex F Porsani",
        "Eloa B Oliveira Andrade",
        "Julia O Parenti",
        "Maria Beatriz Orru",
        "Nathalia M Nogueira"
      ],
      "affiliations": [
        "Santa Casa Araraquara"
      ],
      "normalized_institutions": [
        "Santa Casa Araraquara"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 219,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Abstract",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Keywords"
      ],
      "sections": {
        "Authors": "Alex F Porsani, MD ; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira",
        "Affiliations": "Santa Casa Araraquara",
        "Objective": "Pilomatricoma is a benign cutaneous neoplasm derived from the matrix cells of the hair follicle, representing approximately 1% of benign cutaneous tumors.",
        "Abstract": "This study aims to report a case of pilomatricoma in an 18-year-old male patient with a posterior cervical lesion, discussing clinical and therapeutic aspects. The patient presented with a 2.3 cm posterior cervical nodule with an 8-month evolution. Complete surgical excision was performed with histopathological analysis. A literature review was conducted in the PubMed/MEDLINE and SciELO databases. Histopathological examination revealed dermal neoplasia with basaloid cells in the periphery, ghost cells in the center, and areas of calcification, confirming the diagnosis of pilomatricoma. Favorable postoperative evolution, with no recurrence after one year. The correct preoperative clinical diagnosis differs in the literature, which indicates diagnostic accuracy between 12.5-55.5%. Complete surgical excision is the treatment of choice, with low recurrence rates.",
        "Methods": "Descriptive study, case report type, following CARE guidelines.",
        "Results": "On physical examination, a single, well-defined subcutaneous nodule was observed, with slightly bluish overlying skin, and a positive \"tent sign\".",
        "Discussion": "The case presents typical characteristics regarding age, location, and histopathology.",
        "Conclusion": "This report reinforces the importance of knowing the characteristics of pilomatricoma, its inclusion in the differential diagnosis of cervical subcutaneous nodules, and the need for complete surgical excision for diagnosis and complementation.",
        "Keywords": "pilomatricoma, cutaneous neoplasms, case report."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cervical Pilomatricoma: The Challenge of Clinical Diagnosis and Histopathological Confirmation with Ghost Cells</span>. <u>Alex F Porsani, MD</u>; Eloa B Oliveira Andrade; Julia O Parenti; Maria Beatriz Orru; Nathalia M Nogueira. Santa Casa Araraquara<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Pilomatricoma is a benign cutaneous neoplasm derived from the matrix cells of the hair follicle, representing approximately 1% of benign cutaneous tumors.</p>\n\n<p>This study aims to report a case of pilomatricoma in an 18-year-old male patient with a posterior cervical lesion, discussing clinical and therapeutic aspects.</p>\n\n<p><strong>Methods: </strong>Descriptive study, case report type, following CARE guidelines.</p>\n\n<p>The patient presented with a 2.3 cm posterior cervical nodule with an 8-month evolution. Complete surgical excision was performed with histopathological analysis. A literature review was conducted in the PubMed/MEDLINE and SciELO databases.</p>\n\n<p><strong>Results: </strong>On physical examination, a single, well-defined subcutaneous nodule was observed, with slightly bluish overlying skin, and a positive \"tent sign\".</p>\n\n<p>Histopathological examination revealed dermal neoplasia with basaloid cells in the periphery, ghost cells in the center, and areas of calcification, confirming the diagnosis of pilomatricoma.</p>\n\n<p>Favorable postoperative evolution, with no recurrence after one year.</p>\n\n<p><strong>Discussion: </strong>The case presents typical characteristics regarding age, location, and histopathology.</p>\n\n<p>The correct preoperative clinical diagnosis differs in the literature, which indicates diagnostic accuracy between 12.5-55.5%.</p>\n\n<p>Complete surgical excision is the treatment of choice, with low recurrence rates.</p>\n\n<p><strong>Conclusion: </strong>This report reinforces the importance of knowing the characteristics of pilomatricoma, its inclusion in the differential diagnosis of cervical subcutaneous nodules, and the need for complete surgical excision for diagnosis and complementation.</p>\n\n<p><strong>Keywords:</strong> pilomatricoma, cutaneous neoplasms, case report.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153716--></body></html>"
    },
    {
      "uid": "P418",
      "content_id": "153362",
      "abstract_number": "P418",
      "poster_number": "P418",
      "title": "Associations of Food Environment Impact on Early- and Later-Onset Head and Neck Melanoma Prognosis in the United States",
      "summary": "Across a majority of cancer types, epidemiologic studies have observed rising cancer incidence among younger patient populations. In particular, early-onset malignancies of the head and neck have exhibited similar trends, such as head-neck melanomas (HNM) demonstrating overall annual incidence increases of 5%. With these observations, growing investigations and public interest in the clinical and biological...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153362",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David J Fei-Zhang",
      "presenter": "David J Fei-Zhang",
      "authors": "Charles J Cook 1 ; David J Fei-Zhang 2 ; Nicole H Creppel 2 ; Jorge Gutierrez 2 ; Abhinav Talwar 2 ; Christopher A Puchi 3 ; Jeffrey C Rastatter 3 ; Anthony M Sheyn 4 ; Jill N D'Souza 5 ; Daniel C Chelius 6",
      "normalized_authors": [
        "Charles J Cook",
        "David J Fei-Zhang",
        "Nicole H Creppel",
        "Jorge Gutierrez",
        "Abhinav Talwar",
        "Christopher A Puchi",
        "Jeffrey C Rastatter",
        "Anthony M Sheyn",
        "Jill N D'Souza",
        "Daniel C Chelius"
      ],
      "affiliations": [
        "Baylor College of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine",
        "Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago",
        "Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital",
        "Division of Pediatric Otolaryngology, Children's Hospital of New Orleans",
        "Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Charles J Cook 1 ; David J Fei-Zhang 2 ; Nicole H Creppel 2 ; Jorge Gutierrez 2 ; Abhinav Talwar 2 ; Christopher A Puchi 3 ; Jeffrey C Rastatter 3 ; Anthony M Sheyn 4 ; Jill N D'Souza 5 ; Daniel C Chelius 6",
        "Affiliations": "1 Baylor College of Medicine; 2 Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; 3 Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; 4 Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; 5 Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; 6 Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital",
        "INTRODUCTION": "Across a majority of cancer types, epidemiologic studies have observed rising cancer incidence among younger patient populations. In particular, early-onset malignancies of the head and neck have exhibited similar trends, such as head-neck melanomas (HNM) demonstrating overall annual incidence increases of 5%. With these observations, growing investigations and public interest in the clinical and biological mechanisms behind these detrimental patterns have been prompted. However, efforts to assess the non-clinical factors, such as those pertaining to social, infrastructural, and environmental influences, have been seldom inquired, especially among those diagnosed with head-neck melanomas at earlier ages. Comprising overlapping aspects of these non-clinical themes, the food environment and its effects on oncologic outcomes have become growing fields of interest that comprise aspects of food availability, government subsidy access, public policy, and other traditional social drivers of health (SDoH). Utilizing the Food and Drug Administration’s Food Environment Atlas (FEA), an epidemiologic, geospatial tool that comprehensively assesses over 280 food environment-related sociodemographic factors, this present study sought to characterize the interactive associations between the food environment and HNM prognostic outcomes among younger patients compared to older ones.",
        "METHODS": "This retrospective cohort study analyzed HNM patients from the NCI-Surveillance-Epidemiology-End Results (SEER) program database from 2000-2017. FEA-scores were generated based on 282 county-level variables related to availability of local foods/grocery stores, food and nutrition assistance programs, nutrition affordability, and traditional SDoH-factors, and were then assigned to patients based on county-of-residence. Multivariate logistic regression and Cox-proportional hazards models were performed to assess the association between increasing FEA scores and outcomes of overall survival and tumor staging. These models were stratified by younger (20-44 years) and older (45+) age categories set per the conventions of national epidemiology and cancer statistics studies.",
        "RESULTS": "Among 86,902 patients, worse food environments were independently associated with a greater risk of overall mortality in patients, with younger patients demonstrating a greater increase in risk (HR 1.18, 95% CI 1.06-1.31) than their older counterparts (1.04, 1.02-1.05). Younger patients also experienced exacerbated associations between worse food environments and early mortality, with higher 1-year (OR 1.18, 95% CI 1.01-1.39) and 3-year (1.15, 1.03-1.30) mortality occurrence compared to older patients (1-year: 1.07, 1.04-1.10 | 3-year: 1.04, 1.01-1.06). However, increasing food vulnerability was associated with advanced-stage diagnosis in the older age group (OR 1.06, 95% CI 1.03-1.10) but not with younger patients (1.08, 0.97-1.10).",
        "CONCLUSION": "Associations of a worse food environment with overall and early mortality were exacerbated among early-onset HNM patients compared to their older counterparts. However, only older patients showed higher occurrences of advanced-stage diagnosis. These results contextualize significant differences in how certain non-clinical drivers correlate with prognostic outcomes through jointly assessing a multitude of social, environmental, and infrastructural factors comprising the food environment. In turn, they showcase specific, actionable targets for which prospective investigations and initiatives can strategically focus in order to combat increasing cancer burdens among younger patient populations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Associations of Food Environment Impact on Early- and Later-Onset Head and Neck Melanoma Prognosis in the United States</span>. Charles J Cook<sup>1</sup>; <u>David J Fei-Zhang</u><sup>2</sup>; Nicole H Creppel<sup>2</sup>; Jorge Gutierrez<sup>2</sup>; Abhinav Talwar<sup>2</sup>; Christopher A Puchi<sup>3</sup>; Jeffrey C Rastatter<sup>3</sup>; Anthony M Sheyn<sup>4</sup>; Jill N D'Souza<sup>5</sup>; Daniel C Chelius<sup>6</sup>. <sup>1</sup>Baylor College of Medicine; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine; <sup>3</sup>Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago; <sup>4</sup>Department of Pediatric Otolaryngology, St. Jude Children's Research Hospital; <sup>5</sup>Division of Pediatric Otolaryngology, Children's Hospital of New Orleans; <sup>6</sup>Department of Otolaryngology-Head and Neck Surgery, Texas Children's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION</strong>: Across a majority of cancer types, epidemiologic studies have observed rising cancer incidence among younger patient populations. In particular, early-onset malignancies of the head and neck have exhibited similar trends, such as head-neck melanomas (HNM) demonstrating overall annual incidence increases of 5%. With these observations, growing investigations and public interest in the clinical and biological mechanisms behind these detrimental patterns have been prompted. However, efforts to assess the non-clinical factors, such as those pertaining to social, infrastructural, and environmental influences, have been seldom inquired, especially among those diagnosed with head-neck melanomas at earlier ages. Comprising overlapping aspects of these non-clinical themes, the food environment and its effects on oncologic outcomes have become growing fields of interest that comprise aspects of food availability, government subsidy access, public policy, and other traditional social drivers of health (SDoH). Utilizing the Food and Drug Administration’s Food Environment Atlas (FEA), an epidemiologic, geospatial tool that comprehensively assesses over 280 food environment-related sociodemographic factors, this present study sought to characterize the interactive associations between the food environment and HNM prognostic outcomes among younger patients compared to older ones.</p>\n\n<p><strong>METHODS</strong>: This retrospective cohort study analyzed HNM patients from the NCI-Surveillance-Epidemiology-End Results (SEER) program database from 2000-2017. FEA-scores were generated based on 282 county-level variables related to availability of local foods/grocery stores, food and nutrition assistance programs, nutrition affordability, and traditional SDoH-factors, and were then assigned to patients based on county-of-residence. Multivariate logistic regression and Cox-proportional hazards models were performed to assess the association between increasing FEA scores and outcomes of overall survival and tumor staging. These models were stratified by younger (20-44 years) and older (45+) age categories set per the conventions of national epidemiology and cancer statistics studies.</p>\n\n<p><strong>RESULTS</strong>: Among 86,902 patients, worse food environments were independently associated with a greater risk of overall mortality in patients, with younger patients demonstrating a greater increase in risk (HR 1.18, 95% CI 1.06-1.31) than their older counterparts (1.04, 1.02-1.05). Younger patients also experienced exacerbated associations between worse food environments and early mortality, with higher 1-year (OR 1.18, 95% CI 1.01-1.39) and 3-year (1.15, 1.03-1.30) mortality occurrence compared to older patients (1-year: 1.07, 1.04-1.10 | 3-year: 1.04, 1.01-1.06). However, increasing food vulnerability was associated with advanced-stage diagnosis in the older age group (OR 1.06, 95% CI 1.03-1.10) but not with younger patients (1.08, 0.97-1.10).</p>\n\n<p><strong>CONCLUSION</strong>: Associations of a worse food environment with overall and early mortality were exacerbated among early-onset HNM patients compared to their older counterparts. However, only older patients showed higher occurrences of advanced-stage diagnosis. These results contextualize significant differences in how certain non-clinical drivers correlate with prognostic outcomes through jointly assessing a multitude of social, environmental, and infrastructural factors comprising the food environment. In turn, they showcase specific, actionable targets for which prospective investigations and initiatives can strategically focus in order to combat increasing cancer burdens among younger patient populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153362--></body></html>"
    },
    {
      "uid": "P419",
      "content_id": "153120",
      "abstract_number": "P419",
      "poster_number": "P419",
      "title": "AGGRESSIVE REGIONAL RECURRENCE OF AN ALK FUSION POSITIVE PEDIATRIC SPITZOID MELANOMA: A CAUTIONARY TALE IN FORGOING COMPLETION LYMPHADENECTOMY",
      "summary": "Despite lack of high-risk alterations, aggressive LR is possible in pediatric SM. Heightened surveillance may be needed in cases with positive SLN to ensure early detection of recurrence; and in certain cases, CLND should be considered.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153120",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lauren M Boeckermann, MD, MPH",
      "presenter": "Lauren M Boeckermann, MD, MPH",
      "authors": "Lauren M Boeckermann, MD, MPH 1 ; John Hyngstrom, MD 1 ; Elliot A Asare, MD, MS 1 ; J. Fredrick Grimmer, MD 1 ; J. Martin Johnston, MD 2 ; Casey Mehrhoff, DO 1 ; Marcus M Monroe, MD 1",
      "normalized_authors": [
        "Lauren M Boeckermann",
        "John Hyngstrom",
        "Elliot A Asare",
        "J. Fredrick Grimmer",
        "J. Martin Johnston",
        "Casey Mehrhoff",
        "Marcus M Monroe"
      ],
      "affiliations": [
        "University of Utah",
        "Renown Health"
      ],
      "normalized_institutions": [
        "University of Utah",
        "Renown Health"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 254,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Lauren M Boeckermann, MD, MPH 1 ; John Hyngstrom, MD 1 ; Elliot A Asare, MD, MS 1 ; J. Fredrick Grimmer, MD 1 ; J. Martin Johnston, MD 2 ; Casey Mehrhoff, DO 1 ; Marcus M Monroe, MD 1",
        "Affiliations": "1 University of Utah; 2 Renown Health",
        "Objectives": "Completion lymphadenectomy (CLND) is not routinely performed in pediatric patients with Spitzoid melanoma (SM) whose sentinel lymph nodes (SLN) are positive due to low likelihood of locoregional recurrence (LR) and distant metastases in the absence of high-risk molecular alterations (BRAF/TERT). We present a case of aggressive LR of SM without high-risk molecular alterations after initial positive SLN biopsy to illustrate the need for heightened surveillance in this patient cohort.",
        "Methods": "Case report of a 3 year-old male presenting aggressive LR of SM following initial excision and SLN biopsy.",
        "Results": "A 3 years old male had a pre-referral excisional biopsy of a right auricular melanocytic lesion demonstrating SM (ulcerative, Breslow thickness 5.7mm (T4b), mitotic count 7/mm2). He underwent a partial auriculectomy and SLNB with final pathology showing 2/11 SLNs and no residual melanoma in the primary specimen. Molecular analysis demonstrated a ZEB2/ALK fusion, notably lacking BRAF/TERT alterations. Given the lack of high-risk molecular alterations, serial observation was recommended. He developed a large LR involving skin, sternocleidomastoid muscle, and parotid; he started neoadjuvant anti-PD-1 therapy which was discontinued after 2 of 3 cycles due to disease progression. Parotidectomy, neck dissection, and cervicofacial advancement flap was performed with pathology demonstrating 8/75 lymph nodes involved (largest of 5.8 cm with extranodal extension). Adjuvant radiation was administered.",
        "Conclusions": "Despite lack of high-risk alterations, aggressive LR is possible in pediatric SM. Heightened surveillance may be needed in cases with positive SLN to ensure early detection of recurrence; and in certain cases, CLND should be considered."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AGGRESSIVE REGIONAL RECURRENCE OF AN ALK FUSION POSITIVE PEDIATRIC SPITZOID MELANOMA: A CAUTIONARY TALE IN FORGOING COMPLETION LYMPHADENECTOMY</span>. <u>Lauren M Boeckermann, MD, MPH</u><sup>1</sup>; John Hyngstrom, MD<sup>1</sup>; Elliot A Asare, MD, MS<sup>1</sup>; J. Fredrick Grimmer, MD<sup>1</sup>; J. Martin Johnston, MD<sup>2</sup>; Casey Mehrhoff, DO<sup>1</sup>; Marcus M Monroe, MD<sup>1</sup>. <sup>1</sup>University of Utah; <sup>2</sup>Renown Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>Completion lymphadenectomy (CLND) is not routinely performed in pediatric patients with Spitzoid melanoma (SM) whose sentinel lymph nodes (SLN) are positive due to low likelihood of locoregional recurrence (LR) and distant metastases in the absence of high-risk molecular alterations (BRAF/TERT). We present a case of aggressive LR of SM without high-risk molecular alterations after initial positive SLN biopsy to illustrate the need for heightened surveillance in this patient cohort.</p>\n\n<p><strong>Methods: </strong>Case report of a 3 year-old male presenting aggressive LR of SM following initial excision and SLN biopsy.</p>\n\n<p><strong>Results: </strong>A 3 years old male had a pre-referral excisional biopsy of a right auricular melanocytic lesion demonstrating SM (ulcerative, Breslow thickness 5.7mm (T4b), mitotic count 7/mm2). He underwent a partial auriculectomy and SLNB with final pathology showing 2/11 SLNs and no residual melanoma in the primary specimen. Molecular analysis demonstrated a ZEB2/ALK fusion, notably lacking BRAF/TERT alterations. Given the lack of high-risk molecular alterations, serial observation was recommended. He developed a large LR involving skin, sternocleidomastoid muscle, and parotid; he started neoadjuvant anti-PD-1 therapy which was discontinued after 2 of 3 cycles due to disease progression. Parotidectomy, neck dissection, and cervicofacial advancement flap was performed with pathology demonstrating 8/75 lymph nodes involved (largest of 5.8 cm with extranodal extension). Adjuvant radiation was administered. </p>\n\n<p><strong>Conclusions: </strong>Despite lack of high-risk alterations, aggressive LR is possible in pediatric SM. Heightened surveillance may be needed in cases with positive SLN to ensure early detection of recurrence; and in certain cases, CLND should be considered.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153120--></body></html>"
    },
    {
      "uid": "P420",
      "content_id": "154720",
      "abstract_number": "P420",
      "poster_number": "P420",
      "title": "Simultaneous facial nerve exploration, biopsy, and facial nerve reanimation for diagnosis and management of facial nerve paralysis secondary to undiagnosed perineural invasion from skin cancer",
      "summary": "This series demonstrates that patients with remote skin cancer histories who present with atypical, slowly progressive facial paralysis warrant high suspicion for PNI. Red-flag features include lack of improvement to facial tone over time, partial or progressive paralysis, and disproportionate facial pain. Subspecialty radiologic review with repeat MRI and nerve biopsy are critical for diagnosis. Simultaneous...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154720",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madeline Pyle, MD",
      "presenter": "Madeline Pyle, MD",
      "authors": "Madeline Pyle, MD ; Larissa Sweeny, MD; Liliana Ein, MD",
      "normalized_authors": [
        "Madeline Pyle",
        "Larissa Sweeny",
        "Liliana Ein"
      ],
      "affiliations": [
        "University of Miami"
      ],
      "normalized_institutions": [
        "University of Miami"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Madeline Pyle, MD ; Larissa Sweeny, MD; Liliana Ein, MD",
        "Affiliations": "University of Miami",
        "Introduction": "Facial nerve palsy resulting from perineural invasion (PNI) of cutaneous malignancies presents a challenging diagnostic scenario. These patients frequently experience significant delays in diagnosis with worse oncologic outcomes than those with microscopic PNI and limited facial nerve recovery. This case series highlights key clinical red flags, emphasizes the importance of repeat imaging and subspecialty radiologic review, and illustrates surgical strategies combining facial nerve exploration, biopsy, and immediate facial nerve reanimation.",
        "Methods": "A four-year case series of four patients presenting with slowly progressive facial paralysis to a facial nerve specialist was reviewed. All patients were ultimately diagnosed with PNI secondary to cutaneous skin malignancies and underwent facial nerve exploration with simultaneous biopsy and reanimation procedures.",
        "Results": "All four patients initially lacked visible skin lesions and were misdiagnosed with Bell’s palsy with one patient who underwent evaluation for autoimmune disease. Presenting features inconsistent with Bell’s palsy included slowly progressive facial weakness, incomplete paralysis, persistent or worsening poor facial tone beyond six months, and facial pain. Diagnostic delays ranged from 5 to 16 months. Prior outside CT and MRI scans failed to reveal PNI.",
        "Abstract": "Two patients underwent static suspension with fascia lata, eyelid weight, and lateral tarsal strip following biopsy-confirmed carcinoma. One patient received static suspension with cross-face nerve grafting, followed two years later by dual-innervated gracilis transfer. Another patient with PNI within the parotid, stylomastoid, and mastoid segments of the facial nerve without internal auditory canal involvement underwent radical parotidectomy and mastoidectomy. Cable grafting from the mastoid stump of their facial nerve to the upper division and masseteric nerve transfer to a distal smile facial nerve branch was performed immediately following resection with negative margins and plan for post-operative radiation. Three patients with PNI of the facial nerve within the internal auditory canal and skull were treated with immunotherapy following biopsy, with two receiving concurrent radiation and achieving no evidence of disease and one patient declined radiation and died of advanced disease.",
        "Conclusion": "This series demonstrates that patients with remote skin cancer histories who present with atypical, slowly progressive facial paralysis warrant high suspicion for PNI. Red-flag features include lack of improvement to facial tone over time, partial or progressive paralysis, and disproportionate facial pain. Subspecialty radiologic review with repeat MRI and nerve biopsy are critical for diagnosis. Simultaneous facial nerve exploration, biopsy, and tailored reanimation ranging from static suspension to nerve grafting and gracilis muscle transfer provide an effective framework for diagnosis and initial functional management in this complex patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Simultaneous facial nerve exploration, biopsy, and facial nerve reanimation for diagnosis and management of facial nerve paralysis secondary to undiagnosed perineural invasion from skin cancer</span>. <u>Madeline Pyle, MD</u>; Larissa Sweeny, MD; Liliana Ein, MD. University of Miami<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Facial nerve palsy resulting from perineural invasion (PNI) of cutaneous malignancies presents a challenging diagnostic scenario. These patients frequently experience significant delays in diagnosis with worse oncologic outcomes than those with microscopic PNI and limited facial nerve recovery. This case series highlights key clinical red flags, emphasizes the importance of repeat imaging and subspecialty radiologic review, and illustrates surgical strategies combining facial nerve exploration, biopsy, and immediate facial nerve reanimation.</p>\n\n<p><strong>Methods: </strong>A four-year case series of four patients presenting with slowly progressive facial paralysis to a facial nerve specialist was reviewed. All patients were ultimately diagnosed with PNI secondary to cutaneous skin malignancies and underwent facial nerve exploration with simultaneous biopsy and reanimation procedures.</p>\n\n<p><strong>Results: </strong>All four patients initially lacked visible skin lesions and were misdiagnosed with Bell’s palsy with one patient who underwent evaluation for autoimmune disease. Presenting features inconsistent with Bell’s palsy included slowly progressive facial weakness, incomplete paralysis, persistent or worsening poor facial tone beyond six months, and facial pain. Diagnostic delays ranged from 5 to 16 months. Prior outside CT and MRI scans failed to reveal PNI.</p>\n\n<p>Two patients underwent static suspension with fascia lata, eyelid weight, and lateral tarsal strip following biopsy-confirmed carcinoma. One patient received static suspension with cross-face nerve grafting, followed two years later by dual-innervated gracilis transfer. Another patient with PNI within the parotid, stylomastoid, and mastoid segments of the facial nerve without internal auditory canal involvement underwent radical parotidectomy and mastoidectomy. Cable grafting from the mastoid stump of their facial nerve to the upper division and masseteric nerve transfer to a distal smile facial nerve branch was performed immediately following resection with negative margins and plan for post-operative radiation.  Three patients with PNI of the facial nerve within the internal auditory canal and skull were treated with immunotherapy following biopsy, with two receiving concurrent radiation and achieving no evidence of disease and one patient declined radiation and died of advanced disease.</p>\n\n<p><strong>Conclusion: </strong>This series demonstrates that patients with remote skin cancer histories who present with atypical, slowly progressive facial paralysis warrant high suspicion for PNI. Red-flag features include lack of improvement to facial tone over time, partial or progressive paralysis, and disproportionate facial pain. Subspecialty radiologic review with repeat MRI and nerve biopsy are critical for diagnosis. Simultaneous facial nerve exploration, biopsy, and tailored reanimation ranging from static suspension to nerve grafting and gracilis muscle transfer provide an effective framework for diagnosis and initial functional management in this complex patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154720--></body></html>"
    },
    {
      "uid": "P421",
      "content_id": "150263",
      "abstract_number": "P421",
      "poster_number": "P421",
      "title": "Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma",
      "summary": "Advanced cutaneous squamous cell carcinoma (aCSCC) affects elderly adults and is typically treated through surgical resection. Patients with contraindications to surgery or goals outside of large reconstruction are left with few to no options. Cemiplimab is approved for treatment but has limited published outcomes data. This study evaluates outcomes of aCSCC treated with cemiplimab.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=150263",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chase Clark",
      "presenter": "Chase Clark",
      "authors": "Chase Clark 1 ; Michelle Zhu 2 ; Naheed Alam 2 ; Anne Grand'Maison 2 ; John T Loree 2 ; Thom R Loree 1 ; Mark S Burke 1",
      "normalized_authors": [
        "Chase Clark",
        "Michelle Zhu",
        "Naheed Alam",
        "Anne Grand'Maison",
        "John T Loree",
        "Thom R Loree",
        "Mark S Burke"
      ],
      "affiliations": [
        "University at Buffalo",
        "Erie County Medical Center"
      ],
      "normalized_institutions": [
        "University at Buffalo",
        "Erie County Medical Center"
      ],
      "session_type": "Poster",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "Table 1: Clinical course and outcomes",
          "rows": [
            [
              "Case",
              "Area before Treatment (cm 2 )",
              "Area after Treatment (cm 2 )",
              "Total Doses (quantity)",
              "Treatment Timeline (months)",
              "Tumor Outcome"
            ],
            [
              "1",
              "56",
              "4",
              "17",
              "ongoing",
              "PR"
            ],
            [
              "2",
              "0.5",
              "0",
              "2",
              "1.4",
              "NED"
            ],
            [
              "3",
              "2.5",
              "1.9",
              "4",
              "2.0",
              "PR"
            ],
            [
              "4",
              "120",
              "45",
              "4",
              "2.0",
              "PR"
            ],
            [
              "5",
              "8.3",
              "0",
              "4",
              "2.2",
              "NED"
            ],
            [
              "6",
              "30",
              "18",
              "4",
              "4.2",
              "PR"
            ],
            [
              "7",
              "35",
              "4",
              "4",
              "2.0",
              "PR"
            ],
            [
              "8",
              "1",
              "0",
              "4",
              "1.9",
              "NED"
            ],
            [
              "9",
              "2.8",
              "0",
              "7",
              "2.7",
              "NED"
            ],
            [
              "10",
              "22.4",
              "0",
              "5",
              "3.3",
              "NED"
            ],
            [
              "11",
              "4",
              "0",
              "3",
              "1.9",
              "NED"
            ],
            [
              "12",
              "72",
              "95",
              "4",
              "13.8",
              "Progressed"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 288,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chase Clark 1 ; Michelle Zhu 2 ; Naheed Alam 2 ; Anne Grand'Maison 2 ; John T Loree 2 ; Thom R Loree 1 ; Mark S Burke 1",
        "Affiliations": "1 University at Buffalo; 2 Erie County Medical Center",
        "Background": "Advanced cutaneous squamous cell carcinoma (aCSCC) affects elderly adults and is typically treated through surgical resection. Patients with contraindications to surgery or goals outside of large reconstruction are left with few to no options. Cemiplimab is approved for treatment but has limited published outcomes data. This study evaluates outcomes of aCSCC treated with cemiplimab.",
        "": "Methods: Retrospective review from May 2021 through August 2025 was performed. Patients with head and neck (HAN) aCSCC treated with cemiplimab were included. Patients with concomitant chemotherapy or undocumented tumor size were excluded. Demographic and clinical data were collected. Results: Twelve patients, mostly White males, were included. Mean age and BMI were 77 ± 10 years and 30.95 ± 12.24 kg/m2, respectively. Ten tumors were stage T3, one T2, and one undocumented. Mean tumor area before treatment was 29.5 ± 36.9 cm 2 and after was 14.0 ± 28.7 cm 2 (Table 1). Mean number of cemiplimab doses and treatment timelines was 5 ± 4 doses over 3.4 ± 3.5 months. Six patients demonstrated no evidence of disease (NED) after treatment, while four experienced partial resolution followed by surgical resection with clear margins. One patient experienced increasing tumor size requiring alternative treatment. Conclusions: Cemiplimab for HAN aCSCC demonstrates encouraging responses for patients with surgical contraindications and otherwise have no treatment options. Additionally, patients who are surgical candidates but do not desire an invasive reconstruction may benefit from an initial cemiplimab course followed by a less invasive surgery to decrease burden. Most patients had NED after cemiplimab treatment, but longer follow up intervals are needed to assess curative capacity. Cemiplimab was not effective in only one case suggesting most patients can benefit from treatment.",
        "Abstract": "PR, partial resolution; NED, no evidence of disease"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma</span>. <u>Chase Clark</u><sup>1</sup>; Michelle Zhu<sup>2</sup>; Naheed Alam<sup>2</sup>; Anne Grand'Maison<sup>2</sup>; John T Loree<sup>2</sup>; Thom R Loree<sup>1</sup>; Mark S Burke<sup>1</sup>. <sup>1</sup>University at Buffalo; <sup>2</sup>Erie County Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Advanced cutaneous squamous cell carcinoma (aCSCC) affects elderly adults and is typically treated through surgical resection. Patients with contraindications to surgery or goals outside of large reconstruction are left with few to no options. Cemiplimab is approved for treatment but has limited published outcomes data. This study evaluates outcomes of aCSCC treated with cemiplimab.</p>\n\n<p><strong> </strong><strong>Methods: </strong>Retrospective review from May 2021 through August 2025 was performed. Patients with head and neck (HAN) aCSCC treated with cemiplimab were included. Patients with concomitant chemotherapy or undocumented tumor size were excluded. Demographic and clinical data were collected.</p>\n\n<p><strong> </strong><strong>Results: </strong>Twelve patients, mostly White males, were included. Mean age and BMI were 77 ± 10 years and 30.95 ± 12.24 kg/m2, respectively. Ten tumors were stage T3, one T2, and one undocumented. Mean tumor area before treatment was 29.5 ± 36.9 cm<sup>2</sup> and after was 14.0 ± 28.7 cm<sup>2</sup> (Table 1). Mean number of cemiplimab doses and treatment timelines was 5 ± 4 doses over 3.4 ± 3.5 months. Six patients demonstrated no evidence of disease (NED) after treatment, while four experienced partial resolution followed by surgical resection with clear margins. One patient experienced increasing tumor size requiring alternative treatment.</p>\n\n<p><strong> </strong><strong>Conclusions: </strong>Cemiplimab for HAN aCSCC demonstrates encouraging responses for patients with surgical contraindications and otherwise have no treatment options. Additionally, patients who are surgical candidates but do not desire an invasive reconstruction may benefit from an initial cemiplimab course followed by a less invasive surgery to decrease burden. Most patients had NED after cemiplimab treatment, but longer follow up intervals are needed to assess curative capacity. Cemiplimab was not effective in only one case suggesting most patients can benefit from treatment. </p>\n\n<table border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption><strong>Table 1: Clinical course and outcomes</strong></caption>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Case</strong></td>\n\t\t\t<td><strong>Area before Treatment (cm<sup>2</sup>)</strong></td>\n\t\t\t<td><strong>Area after Treatment (cm<sup>2</sup>)</strong></td>\n\t\t\t<td><strong>Total Doses (quantity)</strong></td>\n\t\t\t<td><strong>Treatment Timeline (months)</strong></td>\n\t\t\t<td><strong>Tumor Outcome</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>1</td>\n\t\t\t<td>56</td>\n\t\t\t<td>4</td>\n\t\t\t<td>17</td>\n\t\t\t<td>ongoing</td>\n\t\t\t<td>PR</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>2</td>\n\t\t\t<td>0.5</td>\n\t\t\t<td>0</td>\n\t\t\t<td>2</td>\n\t\t\t<td>1.4</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>3</td>\n\t\t\t<td>2.5</td>\n\t\t\t<td>1.9</td>\n\t\t\t<td>4</td>\n\t\t\t<td>2.0</td>\n\t\t\t<td>PR</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>4</td>\n\t\t\t<td>120</td>\n\t\t\t<td>45</td>\n\t\t\t<td>4</td>\n\t\t\t<td>2.0</td>\n\t\t\t<td>PR</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>5</td>\n\t\t\t<td>8.3</td>\n\t\t\t<td>0</td>\n\t\t\t<td>4</td>\n\t\t\t<td>2.2</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>6</td>\n\t\t\t<td>30</td>\n\t\t\t<td>18</td>\n\t\t\t<td>4</td>\n\t\t\t<td>4.2</td>\n\t\t\t<td>PR</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>7</td>\n\t\t\t<td>35</td>\n\t\t\t<td>4</td>\n\t\t\t<td>4</td>\n\t\t\t<td>2.0</td>\n\t\t\t<td>PR</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>8</td>\n\t\t\t<td>1</td>\n\t\t\t<td>0</td>\n\t\t\t<td>4</td>\n\t\t\t<td>1.9</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>9</td>\n\t\t\t<td>2.8</td>\n\t\t\t<td>0</td>\n\t\t\t<td>7</td>\n\t\t\t<td>2.7</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>10</td>\n\t\t\t<td>22.4</td>\n\t\t\t<td>0</td>\n\t\t\t<td>5</td>\n\t\t\t<td>3.3</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>11</td>\n\t\t\t<td>4</td>\n\t\t\t<td>0</td>\n\t\t\t<td>3</td>\n\t\t\t<td>1.9</td>\n\t\t\t<td>NED</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>12</td>\n\t\t\t<td>72</td>\n\t\t\t<td>95</td>\n\t\t\t<td>4</td>\n\t\t\t<td>13.8</td>\n\t\t\t<td>Progressed</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p>PR, partial resolution; NED, no evidence of disease </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 150263--></body></html>"
    },
    {
      "uid": "P423",
      "content_id": "151843",
      "abstract_number": "P423",
      "poster_number": "P423",
      "title": "Head and Neck Squamous Cell Carcinoma – Recurrence Patterns in a Veteran Population",
      "summary": "While overall recurrence and survival rates in Veterans are comparable to those seen in civilian populations, the timing and pattern of recurrence differ by subsite. Veterans exhibited earlier recurrence onset and metastatic distributions, underscoring the influence of distinct exposure profiles and comorbidities within this population. Oropharyngeal primary tumors tended to occur at a higher rate than in the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151843",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Louis G Abarca, BA",
      "presenter": "Louis G Abarca, BA",
      "authors": "Louis G Abarca, BA ; David J Hernandez, MD; Albert C Chen, MD, PhD; Weiyuan Mai, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD",
      "normalized_authors": [
        "Louis G Abarca",
        "David J Hernandez",
        "Albert C Chen",
        "Weiyuan Mai",
        "Vlad C Sandulache",
        "Ray Y Wang"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Louis G Abarca, BA ; David J Hernandez, MD; Albert C Chen, MD, PhD; Weiyuan Mai, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD",
        "Affiliations": "Baylor College of Medicine",
        "Introduction": "Head and neck squamous cell carcinomas (HNSCC) accounts for up to 3% of all cancers in the United States. Veterans represent a population with distinct environmental exposure patterns, including higher rates of tobacco and alcohol use compared to civilians. Prior studies have linked these differential exposure to oncologic outcomes, potentially altering patterns of treatment failure and disease recurrences. Recognizing these shifts enables multi-disciplinary teams to adjust treatment and optimize surveillance to appropriately service US Veterans. We plan to describe a cohort of Veterans with HNSCC with a focus on assessment of recurrence patterns by anatomic subsite.",
        "Methods": "This retrospective cohort study included Veterans diagnosed with HNSCC and treated at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) between May 2015 and November 2024, examining tumor characteristics, treatment patterns and oncologic outcomes. Patients presenting with recurrent disease, incomplete recommended treatment, or primary treatment outside the VA system were excluded. Descriptive analyses were conducted using Microsoft Excel and survival analysis was completed using the Kaplan Meier method.",
        "Results": "A total of 366 Veterans (mean age 67; 98% male; 67% white) were included. The median follow-up time was 29 months. Oropharynx (38%, 80% p16+), larynx (32%), and oral cavity (19%) were the most common primary sites. Among p16+ oropharyngeal tumors, 60% had at least a 10 pack-year smoking history, whereas 93% of HPV– cases had >10 pack-years.",
        "Abstract": "Treatment patterns varied by subsite. All patients with oral cavity primaries were treated with primary surgery while 73% of patients with oropharyngeal primaries were treated with primary radiation +/- chemotherapy. Laryngeal cancers showed a relatively balanced distribution, with 59% treated with primary radiation and 42% managed surgically. 5-year disease-free survival was similar across sites (37% for oral cavity, 41% for oropharynx, and 41% for laryngeal primaries), but patterns of recurrence varied. Laryngeal primaries were most likely to recur locally, often in a delayed fashion, while oropharyngeal primaries were most likely to recur distantly. Notably, 19% of distant metastases in oropharyngeal cancers occurred in the liver. p16- oropharyngeal cancers recurred earlier than p16+ oropharyngeal cancers (4 months vs 8 months, p = 0.01). Restricted mean survival time analysis demonstrated worse distant control for oropharyngeal primaries compared to laryngeal primaries at 2 years. Salvage treatment of locoregional recurrence was least likely to be successful in oral cavity primaries (17%), and median survival after locoregional (7 months) and distant (4 months) recurrence was shortest in oral cavity primaries compared with oropharyngeal or laryngeal primaries.",
        "Conclusion": "While overall recurrence and survival rates in Veterans are comparable to those seen in civilian populations, the timing and pattern of recurrence differ by subsite. Veterans exhibited earlier recurrence onset and metastatic distributions, underscoring the influence of distinct exposure profiles and comorbidities within this population. Oropharyngeal primary tumors tended to occur at a higher rate than in the civilian population, likely due in part to the high tobacco exposure in our cohort. Future studies should focus on larger databases to further refine risk stratification and optimize Veteran head and neck oncologic care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Head and Neck Squamous Cell Carcinoma – Recurrence Patterns in a Veteran Population</span>. <u>Louis G Abarca, BA</u>; David J Hernandez, MD; Albert C Chen, MD, PhD; Weiyuan Mai, MD; Vlad C Sandulache, MD, PhD; Ray Y Wang, MD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck squamous cell carcinomas (HNSCC) accounts for up to 3% of all cancers in the United States. Veterans represent a population with distinct environmental exposure patterns, including higher rates of tobacco and alcohol use compared to civilians. Prior studies have linked these differential exposure to oncologic outcomes, potentially altering patterns of treatment failure and disease recurrences. Recognizing these shifts enables multi-disciplinary teams to adjust treatment and optimize surveillance to appropriately service US Veterans. We plan to describe a cohort of Veterans with HNSCC with a focus on assessment of recurrence patterns by anatomic subsite.</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study included Veterans diagnosed with HNSCC and treated at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) between May 2015 and November 2024, examining tumor characteristics, treatment patterns and oncologic outcomes. Patients presenting with recurrent disease, incomplete recommended treatment, or primary treatment outside the VA system were excluded. Descriptive analyses were conducted using Microsoft Excel and survival analysis was completed using the Kaplan Meier method. </p>\n\n<p><strong>Results: </strong>A total of 366 Veterans (mean age 67; 98% male; 67% white) were included. The median follow-up time was 29 months. Oropharynx (38%, 80% p16+), larynx (32%), and oral cavity (19%) were the most common primary sites. Among p16+ oropharyngeal tumors, 60% had at least a 10 pack-year smoking history, whereas 93% of HPV– cases had >10 pack-years. </p>\n\n<p>Treatment patterns varied by subsite. All patients with oral cavity primaries were treated with primary surgery while 73% of patients with oropharyngeal primaries were treated with primary radiation +/- chemotherapy. Laryngeal cancers showed a relatively balanced distribution, with 59% treated with primary radiation and 42% managed surgically. </p>\n\n<p>5-year disease-free survival was similar across sites (37% for oral cavity, 41% for oropharynx, and 41% for laryngeal primaries), but patterns of recurrence varied. Laryngeal primaries were most likely to recur locally, often in a delayed fashion, while oropharyngeal primaries were most likely to recur distantly. Notably, 19% of distant metastases in oropharyngeal cancers occurred in the liver. p16- oropharyngeal cancers recurred earlier than p16+ oropharyngeal cancers (4 months vs 8 months, p = 0.01). Restricted mean survival time analysis demonstrated worse distant control for oropharyngeal primaries compared to laryngeal primaries at 2 years. Salvage treatment of locoregional recurrence was least likely to be successful in oral cavity primaries (17%), and median survival after locoregional (7 months) and distant (4 months) recurrence was shortest in oral cavity primaries compared with oropharyngeal or laryngeal primaries. </p>\n\n<p><strong>Conclusion: </strong>While overall recurrence and survival rates in Veterans are comparable to those seen in civilian populations, the timing and pattern of recurrence differ by subsite. Veterans exhibited earlier recurrence onset and metastatic distributions, underscoring the influence of distinct exposure profiles and comorbidities within this population. Oropharyngeal primary tumors tended to occur at a higher rate than in the civilian population, likely due in part to the high tobacco exposure in our cohort. Future studies should focus on larger databases to further refine risk stratification and optimize Veteran head and neck oncologic care. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151843--></body></html>"
    },
    {
      "uid": "P424",
      "content_id": "155588",
      "abstract_number": "P424",
      "poster_number": "P424",
      "title": "The Effect of Balloon Dilation Therapy on Overall Survival in Head and Neck Cancer Survivors",
      "summary": "Patient-reported improvement in dysphagia is associated with longer overall survival in head and neck cancer survivors receiving pharyngoesophageal balloon dilation.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155588",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Rind, MD",
      "presenter": "Fahad Rind, MD",
      "authors": "Fahad Rind, MD ; Apoorva T Ramaswamy, MD",
      "normalized_authors": [
        "Fahad Rind",
        "Apoorva T Ramaswamy"
      ],
      "affiliations": [
        "The Ohio State University"
      ],
      "normalized_institutions": [
        "The Ohio State University"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155588/Survival%20after%20dysphagia%20treatment.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155588/Survival%20after%20dysphagia%20treatment.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155588"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 277,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Fahad Rind, MD ; Apoorva T Ramaswamy, MD",
        "Affiliations": "The Ohio State University",
        "Introduction": "Dysphagia is a debilitating complication in head and neck cancer survivors that significantly affect nutrition and quality of life. This study aims to investigate the effect of dysphagia therapy balloon dilation on overall survival in head and neck cancer survivors.",
        "Methods": "A retrospective chart review was conducted of head and cancer survivors with dysphagia who underwent balloon dilation procedures. Severity of dysphagia was measured using the Eating Assessment Tool-10 (EAT-10) patient-reported outcome measure before and after treatment with balloon dilation procedures. Responders were defined as patients with a categorical reduction in their EAT-10 scores. Overall survival was defined as time from initial dysphagia office visit to time of mortality or last contact (censored cases). Cox-proportional hazard-modelling was utilized for survival analysis.",
        "Results": "A total of 61 dysphagia patients were included and had a mean age of 67.3 yrs (standard deviation 10.2 years). In total, 43 patients endorsed improvement in EAT-10 scores (68.9%). Responders were more likely to be younger (Odds ratio: 0.918, 95% confidence interval [CI] 0.853 to 0.989, p = 0.025), though there was no significant association with sex (p=0.315) and time since treatment (p=0.554). The overall survival rate among responders was 69% (29/42) and among non-responders was 42% (8/19). Lack of improvement in EAT-10 scores was associated with a greater risk of mortality (Hazard ratio [HR] 2.476, 95% CI 1.103 to 5.556, p = 0.022). Overall survival was not associated with age, sex, treatment history, and time since treatment (p>0.05).",
        "Conclusions": "Patient-reported improvement in dysphagia is associated with longer overall survival in head and neck cancer survivors receiving pharyngoesophageal balloon dilation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Effect of Balloon Dilation Therapy on Overall Survival in Head and Neck Cancer Survivors</span>. <u>Fahad Rind, MD</u>; Apoorva T Ramaswamy, MD. The Ohio State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/155588/Survival%20after%20dysphagia%20treatment.jpg' /></p>\n\n<p><strong>Introduction: </strong>Dysphagia is a debilitating complication in head and neck cancer survivors that significantly affect nutrition and quality of life. This study aims to investigate the effect of dysphagia therapy balloon dilation on overall survival in head and neck cancer survivors.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted of head and cancer survivors with dysphagia who underwent balloon dilation procedures. Severity of dysphagia was measured using the Eating Assessment Tool-10 (EAT-10) patient-reported outcome measure before and after treatment with balloon dilation procedures. Responders were defined as patients with a categorical reduction in their EAT-10 scores. Overall survival was defined as time from initial dysphagia office visit to time of mortality or last contact (censored cases). Cox-proportional hazard-modelling was utilized for survival analysis.</p>\n\n<p><strong>Results: </strong>A total of 61 dysphagia patients were included and had a mean age of 67.3 yrs (standard deviation 10.2 years). In total, 43 patients endorsed improvement in EAT-10 scores (68.9%). Responders were more likely to be younger (Odds ratio: 0.918, 95% confidence interval [CI] 0.853 to 0.989, p = 0.025), though there was no significant association with sex (p=0.315) and time since treatment (p=0.554). The overall survival rate among responders was 69% (29/42) and among non-responders was 42% (8/19). Lack of improvement in EAT-10 scores was associated with a greater risk of mortality (Hazard ratio [HR] 2.476, 95% CI 1.103 to 5.556, p = 0.022). Overall survival was not associated with age, sex, treatment history, and time since treatment (p>0.05).</p>\n\n<p><strong>Conclusions:</strong> Patient-reported improvement in dysphagia is associated with longer overall survival in head and neck cancer survivors receiving pharyngoesophageal balloon dilation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155588--></body></html>"
    },
    {
      "uid": "P425",
      "content_id": "154774",
      "abstract_number": "P425",
      "poster_number": "P425",
      "title": "Wound Complications in Cachectic Patients with Oral Cavity Squamous Cell Carcinoma",
      "summary": "In this retrospective cohort of 31 patients with OSCC, pre-treatment NLR was linked to wound infection rates, indicating that preoperative impaired immunity related to nutritional status could affect future wound healing. Larger tumors were also associated with higher nutrition-related scores, likely due to larger resections that resulted in less function preservation and increased pain. Nutrition-related scores...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154774",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mabel Kahil",
      "presenter": "Mabel Kahil",
      "authors": "Mabel Kahil 1 ; Taylor L Jamil, MD, MPH 2 ; Ryan Lanning, MD, PhD 2 ; Brian P Cervenka 2 ; Leah Novenger 1 ; Andrea Bonetto 1 ; Julie Goddard, MD 2 ; Carissa M Thomas, MD, PhD, FACS 1",
      "normalized_authors": [
        "Mabel Kahil",
        "Taylor L Jamil",
        "Ryan Lanning",
        "Brian P Cervenka",
        "Leah Novenger",
        "Andrea Bonetto",
        "Julie Goddard",
        "Carissa M Thomas"
      ],
      "affiliations": [
        "University of Alabama",
        "University of Colorado Otolaryngology"
      ],
      "normalized_institutions": [
        "University of Alabama",
        "University of Colorado Otolaryngology"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 534,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mabel Kahil 1 ; Taylor L Jamil, MD, MPH 2 ; Ryan Lanning, MD, PhD 2 ; Brian P Cervenka 2 ; Leah Novenger 1 ; Andrea Bonetto 1 ; Julie Goddard, MD 2 ; Carissa M Thomas, MD, PhD, FACS 1",
        "Affiliations": "1 University of Alabama; 2 University of Colorado Otolaryngology",
        "Background": "Cachexia is common in patients with oral squamous cell carcinoma (OSCC) and contributes to sarcopenia, impaired immunity, and delayed wound healing. Postoperative complications, including infection, wound dehiscence, and fistula formation, may occur more often in cachectic patients. Despite the clinical relevance of these complications, the association between pre-treatment cachexia, systemic inflammation, and postoperative wound outcomes in OSCC remains poorly understood.",
        "Methods": "A single institution, retrospective study was conducted in patients with primary OSCC treated with ablation and free flap reconstruction between 2014-2021. Patient demographics, smoking status, OSCC subsite, TNM stage, pathologic features, comorbidities relevant to wound healing (e.g. diabetes), and body mass index (BMI) were collected. Pre-surgical lymphocyte and neutrophil absolute number (109/L) and percentage, respectively, albumin (g/L), and platelet count (109/L) values were collected to assess cachexia via the Systemic Immune-Immune Inflammation Index (SII), Nutritional Risk Index (NRI), Geriatric Nutritional Risk Index (GNRI), and neutrophil-to-lymphocyte ratio (NLR). Wound-related outcomes postoperatively included infections, wound dehiscence, fistula formation, and surgery needed for complications. Logistic regression analysis was used to identify how cachexia was associated with each complication in RStudio (2024.04.2+764).",
        "Results": "Thirty-one patients were included in the study with 61.3% male and 93.5% were non-Hispanic White. OSCC of the tongue was most common (N:11, 35.5%), followed by floor of mouth (N:6, 19.4%). 3 patients were positive for human papilloma virus. 51.6% were T4 stage and 42% were N2 stage and higher. 45.2% were Stage 4 (American Joint Committee on Cancer 7th edition). 1 patient had a pre-treatment gastrostomy tube (GT) and 45.2% of patients required post-treatment GT. 48.4% presented with perineural invasion (PNI) and 9.7% presented with lymphovascular invasion. 58.1% of patients had a former smoking history and 2 patients used tobacco at the time of surgery. 10 patients (32.3%) experienced a wound infection, 9.6% experienced a fistula, 35.5% experienced a dehiscence. 22.6% of patients returned to the operating room for their respective complication. Mean BMI was 27.7 kg/m2. Age was not associated with any cachexia model (p>0.05) nor was insurance (p>0.05). PNI was not associated with any nutrition-related score (p>0.05). Higher SII values correlated with T3 (beta: 2.6, p:0.018) and T4 (beta: 2.31, p: 0.034) tumors, but not nodal stage (P>0.05). This was also true for NRI and GRNI (T3: beta: 2.6, p:0.018, T4: 2.30, p: 0.033) but not for the NLR (p>0.05). A higher pre-treatment NLR was associated with post-operative wound infections (beta: 2.01, p: 0.046).",
        "Conclusion": "In this retrospective cohort of 31 patients with OSCC, pre-treatment NLR was linked to wound infection rates, indicating that preoperative impaired immunity related to nutritional status could affect future wound healing. Larger tumors were also associated with higher nutrition-related scores, likely due to larger resections that resulted in less function preservation and increased pain. Nutrition-related scores involving body weight were not significantly correlated with wound complications, possibly because of the smaller sample size. These findings suggest that incorporating inflammatory biomarkers like NLR may enhance preoperative risk assessment for postoperative complications in OSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Wound Complications in Cachectic Patients with Oral Cavity Squamous Cell Carcinoma</span>. <u>Mabel Kahil</u><sup>1</sup>; Taylor L Jamil, MD, MPH<sup>2</sup>; Ryan Lanning, MD, PhD<sup>2</sup>; Brian P Cervenka<sup>2</sup>; Leah Novenger<sup>1</sup>; Andrea Bonetto<sup>1</sup>; Julie Goddard, MD<sup>2</sup>; Carissa M Thomas, MD, PhD, FACS<sup>1</sup>. <sup>1</sup>University of Alabama; <sup>2</sup>University of Colorado Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Cachexia is common in patients with oral squamous cell carcinoma (OSCC) and contributes to sarcopenia, impaired immunity, and delayed wound healing. Postoperative complications, including infection, wound dehiscence, and fistula formation, may occur more often in cachectic patients. Despite the clinical relevance of these complications, the association between pre-treatment cachexia, systemic inflammation, and postoperative wound outcomes in OSCC remains poorly understood.</p>\n\n<p><strong>Methods</strong>: A single institution, retrospective study was conducted in patients with primary OSCC treated with ablation and free flap reconstruction between 2014-2021. Patient demographics, smoking status, OSCC subsite, TNM stage, pathologic features, comorbidities relevant to wound healing (e.g. diabetes), and body mass index (BMI) were collected. Pre-surgical lymphocyte and neutrophil absolute number (109/L) and percentage, respectively, albumin (g/L), and platelet count (109/L) values were collected to assess cachexia via the Systemic Immune-Immune Inflammation Index (SII), Nutritional Risk Index (NRI), Geriatric Nutritional Risk Index (GNRI), and neutrophil-to-lymphocyte ratio (NLR). Wound-related outcomes postoperatively included infections, wound dehiscence, fistula formation, and surgery needed for complications. Logistic regression analysis was used to identify how cachexia was associated with each complication in RStudio (2024.04.2+764).</p>\n\n<p><strong>Results</strong>: Thirty-one patients were included in the study with 61.3% male and 93.5% were non-Hispanic White. OSCC of the tongue was most common (N:11, 35.5%), followed by floor of mouth (N:6, 19.4%). 3 patients were positive for human papilloma virus. 51.6% were T4 stage and 42% were N2 stage and higher. 45.2% were Stage 4 (American Joint Committee on Cancer 7th edition). 1 patient had a pre-treatment gastrostomy tube (GT) and 45.2% of patients required post-treatment GT. 48.4% presented with perineural invasion (PNI) and 9.7% presented with lymphovascular invasion. 58.1% of patients had a former smoking history and 2 patients used tobacco at the time of surgery. 10 patients (32.3%) experienced a wound infection, 9.6% experienced a fistula, 35.5% experienced a dehiscence. 22.6% of patients returned to the operating room for their respective complication. Mean BMI was 27.7 kg/m2. Age was not associated with any cachexia model (p>0.05) nor was insurance (p>0.05). PNI was not associated with any nutrition-related score (p>0.05). Higher SII values correlated with T3 (beta: 2.6, p:0.018) and T4 (beta: 2.31, p: 0.034) tumors, but not nodal stage (P>0.05). This was also true for NRI and GRNI (T3: beta: 2.6, p:0.018, T4: 2.30, p: 0.033) but not for the NLR (p>0.05). A higher pre-treatment NLR was associated with post-operative wound infections (beta: 2.01, p: 0.046).</p>\n\n<p><strong>Conclusion</strong>: In this retrospective cohort of 31 patients with OSCC, pre-treatment NLR was linked to wound infection rates, indicating that preoperative impaired immunity related to nutritional status could affect future wound healing. Larger tumors were also associated with higher nutrition-related scores, likely due to larger resections that resulted in less function preservation and increased pain. Nutrition-related scores involving body weight were not significantly correlated with wound complications, possibly because of the smaller sample size. These findings suggest that incorporating inflammatory biomarkers like NLR may enhance preoperative risk assessment for postoperative complications in OSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154774--></body></html>"
    },
    {
      "uid": "P426",
      "content_id": "154022",
      "abstract_number": "P426",
      "poster_number": "P426",
      "title": "Cumulative Effect of Delays in Surgery and Postoperative Radiation Therapy (PORT) in Patients with Head and Neck Squamous Cell Carcinoma: A National Cancer Data Base Analysis",
      "summary": "Cumulative delays across both surgical and PORT intervals do not appear to worsen OS beyond that associated with delays in a single treatment phase, suggesting a potential plateau effect in survival outcomes of treatment timing. These findings may help inform multidisciplinary care and resource prioritization in patients with HNSCC who require complex treatment coordination.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154022",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hannah Chen, MD",
      "presenter": "Hannah Chen, MD",
      "authors": "Hannah Chen, MD ; Alyssa Heiser, MD; Jeremiah Tracy, MD",
      "normalized_authors": [
        "Hannah Chen",
        "Alyssa Heiser",
        "Jeremiah Tracy"
      ],
      "affiliations": [
        "Tufts Medical Center"
      ],
      "normalized_institutions": [
        "Tufts Medical Center"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154022/figure1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154022/figure1.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154022"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 430,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hannah Chen, MD ; Alyssa Heiser, MD; Jeremiah Tracy, MD",
        "Affiliations": "Tufts Medical Center",
        "Background": "Timeliness of treatment is an important determinant of survival outcomes in head and neck squamous cell carcinoma (HNSCC). Delay from diagnosis to definitive surgery, as well as prolonged interval between surgery and initiation of postoperative radiation therapy (PORT) have independently been associated with worse survival. However, the cumulative impact of combined delays across both surgical and adjuvant radiation treatment has not been comprehensively investigated.",
        "Methods": "The National Cancer Data Base (NCDB) was queried to identify patients with HNSCC treated with primary surgical resection followed by adjuvant PORT between 2004 and 2022. Timely surgery was defined as operative intervention within 67 days of diagnosis and timely PORT as initiation of radiation treatment within 6 weeks of surgery. Overall survival (OS) was compared across four treatment cohorts including timely surgery/timely PORT, delayed surgery/timely PORT, timely surgery/delayed PORT, and delayed surgery/timely PORT using Kaplan-Meier analysis. Univariate and multivariate analyses were performed using Cox proportional hazards model.",
        "Results": "Among 50,081 patients, 12,398 (24.8%) underwent both timely surgery and timely PORT. Kaplan Meier analysis demonstrated significantly decreased OS among patients who underwent delayed surgery and delayed PORT compared to those who underwent delayed surgery/timely PORT (log rank p=0.003), and timely surgery/delayed PORT (log rank p<0.001; Figure 1). On multivariate Cox proportional hazards analysis controlling for age, sex, race, insurance status, facility type, zip code, level education/income, Charlson comorbidity score, cancer subsite, HPV status, staging, surgical margins, lymphovascular invasion, and radiation dose, delayed surgery/timely PORT (HR 1.16; 95% CI 1.03-1.30; p=0.017), timely surgery/delayed PORT (HR 1.12; 95% CI 1.07-1.17; p<0.001), and delayed surgery/delayed PORT (HR 1.18, 95% CI 1.09-1.27; p<0.001) were associated with significantly worse OS compared to timely surgery/timely PORT. Cumulative delay across both surgery and PORT were not associated with worse OS compared to delay in a single treatment modality.",
        "Conclusion": "Cumulative delays across both surgical and PORT intervals do not appear to worsen OS beyond that associated with delays in a single treatment phase, suggesting a potential plateau effect in survival outcomes of treatment timing. These findings may help inform multidisciplinary care and resource prioritization in patients with HNSCC who require complex treatment coordination.",
        "Figure 1.": "Kaplan Meier analysis comparing overall survival (OS) between timely surgery/timely PORT, delayed surgery/timely PORT, timely surgery/delayed PORT, and delayed surgery/delayed PORT among patients with head and neck squamous cell carcinoma (HNSCC) treated with primary surgery followed by adjuvant postoperative radiation.",
        "Abstract": "Abbreviations: PORT=postoperative radiation therapy"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cumulative Effect of Delays in Surgery and Postoperative Radiation Therapy (PORT) in Patients with Head and Neck Squamous Cell Carcinoma: A National Cancer Data Base Analysis</span>. <u>Hannah Chen, MD</u>; Alyssa Heiser, MD; Jeremiah Tracy, MD. Tufts Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Timeliness of treatment is an important determinant of survival outcomes in head and neck squamous cell carcinoma (HNSCC). Delay from diagnosis to definitive surgery, as well as prolonged interval between surgery and initiation of postoperative radiation therapy (PORT) have independently been associated with worse survival. However, the cumulative impact of combined delays across both surgical and adjuvant radiation treatment has not been comprehensively investigated.</p>\n\n<p><strong>Methods:</strong> The National Cancer Data Base (NCDB) was queried to identify patients with HNSCC treated with primary surgical resection followed by adjuvant PORT between 2004 and 2022. Timely surgery was defined as operative intervention within 67 days of diagnosis and timely PORT as initiation of radiation treatment within 6 weeks of surgery. Overall survival (OS) was compared across four treatment cohorts including timely surgery/timely PORT, delayed surgery/timely PORT, timely surgery/delayed PORT, and delayed surgery/timely PORT using Kaplan-Meier analysis. Univariate and multivariate analyses were performed using Cox proportional hazards model.</p>\n\n<p><strong>Results:</strong> Among 50,081 patients, 12,398 (24.8%) underwent both timely surgery and timely PORT. Kaplan Meier analysis demonstrated significantly decreased OS among patients who underwent delayed surgery and delayed PORT compared to those who underwent delayed surgery/timely PORT (log rank p=0.003), and timely surgery/delayed PORT (log rank p<0.001; Figure 1). On multivariate Cox proportional hazards analysis controlling for age, sex, race, insurance status, facility type, zip code, level education/income, Charlson comorbidity score, cancer subsite, HPV status, staging, surgical margins, lymphovascular invasion, and radiation dose, delayed surgery/timely PORT (HR 1.16; 95% CI 1.03-1.30; p=0.017), timely surgery/delayed PORT (HR 1.12; 95% CI 1.07-1.17; p<0.001), and delayed surgery/delayed PORT (HR 1.18, 95% CI 1.09-1.27; p<0.001) were associated with significantly worse OS compared to timely surgery/timely PORT. Cumulative delay across both surgery and PORT were not associated with worse OS compared to delay in a single treatment modality.</p>\n\n<p><strong>Conclusion:</strong> Cumulative delays across both surgical and PORT intervals do not appear to worsen OS beyond that associated with delays in a single treatment phase, suggesting a potential plateau effect in survival outcomes of treatment timing. These findings may help inform multidisciplinary care and resource prioritization in patients with HNSCC who require complex treatment coordination.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154022/figure1.jpg' /></p>\n\n<p><strong>Figure 1.</strong> Kaplan Meier analysis comparing overall survival (OS) between timely surgery/timely PORT, delayed surgery/timely PORT, timely surgery/delayed PORT, and delayed surgery/delayed PORT among patients with head and neck squamous cell carcinoma (HNSCC) treated with primary surgery followed by adjuvant postoperative radiation.</p>\n\n<p>Abbreviations: PORT=postoperative radiation therapy</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154022--></body></html>"
    },
    {
      "uid": "P428",
      "content_id": "153889",
      "abstract_number": "P428",
      "poster_number": "P428",
      "title": "Utilization and Clinical Efficacy of Supportive Care Intervention for Head and Neck Cancer Patients with a Tracheostomy/Feeding Tube",
      "summary": "Preliminary findings suggest Intervention high to moderate utilization among family caregivers, and preliminary clinical efficacy. These findings will guide refinement of educational materials with the potential to enhance clinical outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153889",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Minerva So, Medical Student",
      "presenter": "Minerva So, Medical Student",
      "authors": "Minerva So, Medical Student 1 ; Alyanna Melicor 2 ; Samantha Tam 2 ; Kimberley Olsin 2 ; Eric Adjei Boakye 2 ; Veronica Bernacchi 1",
      "normalized_authors": [
        "Alyanna Melicor",
        "Samantha Tam",
        "Kimberley Olsin",
        "Eric Adjei Boakye",
        "Veronica Bernacchi"
      ],
      "affiliations": [
        "Michigan State University (MSU)",
        "Henry Ford Health System"
      ],
      "normalized_institutions": [
        "Michigan State University (MSU)",
        "Henry Ford Health System"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 309,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Minerva So, Medical Student 1 ; Alyanna Melicor 2 ; Samantha Tam 2 ; Kimberley Olsin 2 ; Eric Adjei Boakye 2 ; Veronica Bernacchi 1",
        "Affiliations": "1 Michigan State University (MSU); 2 Henry Ford Health System",
        "Introduction": "Family caregivers of post-operative head and neck cancer (HNC) patients with a tracheostomy and/or feeding tube report they do not receive the training or support needed to safely manage medical equipment at home. To provide support to family caregivers of post-operative HNC patients, we developed the Symptom Management Toolkit (SMT), a paper binder containing educational modules on tracheostomy/feeding tube care and symptom management. The purpose of this ongoing study is to test utilization and preliminary efficacy of the SMT.",
        "Methods": "We conducted a one group, pre-and-post test quasi-experimental study that occurred over 6 weeks. HNC patients with a new tracheostomy and/or feeding tube, along with their primary family caregiver, received the SMT prior to discharge home. Utilization was measured using weekly weeksheets monitoring who was performing medical care tasks, which medical care modules were being used, and which symptom management modules were being used. Symptom burden among HNC patients was measured pre- and post- intervention with the FACT-HN survey. Weekly worksheets and surveys were administered via secure RedCap links to participant emails, and HNC patients and family caregivers were asked to complete the weekly worksheet together, as a dyad, while only the HNC patient completed the FACT-HN survey.",
        "Results": "We have recruited (n=11) dyads at this time. Utilization findings indicate high engagement by family caregivers (n=10 family caregivers). Family caregivers report daily use of the intervention in the first 1-2 weeks post-discharge, then transitioning to as-needed use. Family caregivers report highest utilization of the tracheostomy and feeding tube care modules, and lowest utilization of symptom management modules. FACT-HN scores indicate a clinical reduction in patient symptom burden from pre-intervention (mean=12) to post-intervention (mean=9.2).",
        "Conclusion": "Preliminary findings suggest Intervention high to moderate utilization among family caregivers, and preliminary clinical efficacy. These findings will guide refinement of educational materials with the potential to enhance clinical outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Utilization and Clinical Efficacy of Supportive Care Intervention for Head and Neck Cancer Patients with a Tracheostomy/Feeding Tube</span>. <u>Minerva So, Medical Student</u><sup>1</sup>; Alyanna Melicor<sup>2</sup>; Samantha Tam<sup>2</sup>; Kimberley Olsin<sup>2</sup>; Eric Adjei Boakye<sup>2</sup>; Veronica Bernacchi<sup>1</sup>. <sup>1</sup>Michigan State University (MSU); <sup>2</sup>Henry Ford Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Family caregivers of post-operative head and neck cancer (HNC) patients with a tracheostomy and/or feeding tube report they do not receive the training or support needed to safely manage medical equipment at home. To provide support to family caregivers of post-operative HNC patients, we developed the Symptom Management Toolkit (SMT), a paper binder containing educational modules on tracheostomy/feeding tube care and symptom management. The purpose of this ongoing study is to test utilization and preliminary efficacy of the SMT.    </p>\n\n<p><strong>Methods: </strong>We conducted a one group, pre-and-post test quasi-experimental study that occurred over 6 weeks. HNC patients with a new tracheostomy and/or feeding tube, along with their primary family caregiver, received the SMT prior to discharge home. Utilization was measured using weekly weeksheets monitoring who was performing medical care tasks, which medical care modules were being used, and which symptom management modules were being used. Symptom burden among HNC patients was measured pre- and post- intervention with the FACT-HN survey. Weekly worksheets and surveys were administered via secure RedCap links to participant emails, and HNC patients and family caregivers were asked to complete the weekly worksheet together, as a dyad, while only the HNC patient completed the FACT-HN survey.</p>\n\n<p><strong>Results: </strong>We have recruited (n=11) dyads at this time. Utilization findings indicate high engagement by family caregivers (n=10 family caregivers). Family caregivers report daily use of the intervention in the first 1-2 weeks post-discharge, then transitioning to as-needed use. Family caregivers report highest utilization of the tracheostomy and feeding tube care modules, and lowest utilization of symptom management modules. FACT-HN scores indicate a clinical reduction in patient symptom burden from pre-intervention (mean=12) to post-intervention (mean=9.2). </p>\n\n<p><strong>Conclusion: </strong>Preliminary findings suggest Intervention high to moderate utilization among family caregivers, and preliminary clinical efficacy. These findings will guide refinement of educational materials with the potential to enhance clinical outcomes.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153889--></body></html>"
    },
    {
      "uid": "P429",
      "content_id": "154119",
      "abstract_number": "P429",
      "poster_number": "P429",
      "title": "Clinical and Radiographic Correlations with Tracheoesophageal Prosthesis Outcomes",
      "summary": "Laryngeal cancer is one of the most common subsites of head and neck cancer, and mortality rates within this patient population have decreased nationally over the past decade. With this increase in survival, optimization of alaryngeal speech is paramount for long-term quality of life. Utilization of a tracheoesophageal prosthesis (TEP) is considered the mainstay for vocal functional rehabilitation for those who...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154119",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Celeste Kim, MD",
      "presenter": "Celeste Kim, MD",
      "authors": "Celeste Kim, MD 1 ; Meghana Nathan, CCCSLP 1 ; Jennifer Becker, MD 2 ; Nicole C Schmitt, MD, FACS 1 ; Merry Sebelik, MD, FACS 1 ; Lauren Ottenstein, CCCSLP 1",
      "normalized_authors": [
        "Celeste Kim",
        "Meghana Nathan, CCCSLP",
        "Jennifer Becker",
        "Nicole C Schmitt",
        "Merry Sebelik",
        "Lauren Ottenstein, CCCSLP"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA",
        "Division of Neuroradiology, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA",
        "Division of Neuroradiology, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 467,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Celeste Kim, MD 1 ; Meghana Nathan, CCCSLP 1 ; Jennifer Becker, MD 2 ; Nicole C Schmitt, MD, FACS 1 ; Merry Sebelik, MD, FACS 1 ; Lauren Ottenstein, CCCSLP 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA; 2 Division of Neuroradiology, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA",
        "INTRODUCTION": "Laryngeal cancer is one of the most common subsites of head and neck cancer, and mortality rates within this patient population have decreased nationally over the past decade. With this increase in survival, optimization of alaryngeal speech is paramount for long-term quality of life. Utilization of a tracheoesophageal prosthesis (TEP) is considered the mainstay for vocal functional rehabilitation for those who have undergone a total laryngectomy, but there are potential associated complications, including leaking, dislodgement, and embedding, that can lead to poor functional outcomes and possibly require TEP removal in up to 50% of patients. The goal of this study is to better delineate patient and TEP factors, both clinical and radiographic, and their effects on TEP outcomes.",
        "METHODS": "This is a single-institution, retrospective study on the outcomes of secondary placement of tracheoesophageal prosthesis. Inclusion criteria included secondary TEP placement after formal review by an institutional TEP Board, which determines TEP candidacy based on specific anatomical, physiological, medical, and psychosocial factors. Radiographic measurements were made of the “parti-wall” (tracheoesophageal) thickness as well as the angle between the horizontal vector of the prosthesis in relation to the vertical neopharyngeal wall. These measures were obtained on pre-TEP imaging, with post-TEP images being used as a reference for subsequent actual TEP location (when imaging available). Details regarding TEP outcomes were also recorded, including the incidence of Speech-Language Pathology (SLP) clinic visits that addressed specific prosthesis complications, as well as any procedural interventions undertaken to address these complications. Bivariate analyses, including Pearson’s and Spearman’s Correlation were performed to identify significant relationships between clinical/radiographic factors and TEP outcomes.",
        "RESULTS": "A total of 26 patients met the inclusion criteria, with mean age of 65, and majority of patients were male (73%) and Caucasian (81%). Majority (62%) had undergone free flap reconstruction, with a mean of 684 days from laryngectomy to TEP. The average (range) parti-wall thickness was 5.74 (2-10) mm, and the average (range) TEP angle was 85 (64.7-130.2) degrees. Preliminary statistical analyses demonstrated multiple significant (p<0.05) correlative relationships, including a negative relationship between parti-wall thickness and incidence of sizing issues, as well as positive relationships between prosthesis angle and incidence of central leaks and number of TEP changes required. Of the 26 total patients, 7 (27%) patients ultimately had the TEP removed.",
        "CONCLUSION": "Our data postulates that there is a significant inverse relationship between parti-wall thickness and incidence of sizing issues. Additionally, more obtuse angles between the prosthesis and neopharyngeal wall are associated with higher incidences of central leaks and the number of TEP changes required. To our knowledge, the aforementioned prosthetic angle has not been previously characterized or correlated with TEP outcomes in this manner. Awareness of these correlative relationships may help set expectations regarding long-term prosthesis outcomes for both clinical care teams and patients alike."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and Radiographic Correlations with Tracheoesophageal Prosthesis Outcomes</span>. <u>Celeste Kim, MD</u><sup>1</sup>; Meghana Nathan, CCCSLP<sup>1</sup>; Jennifer Becker, MD<sup>2</sup>; Nicole C Schmitt, MD, FACS<sup>1</sup>; Merry Sebelik, MD, FACS<sup>1</sup>; Lauren Ottenstein, CCCSLP<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA; <sup>2</sup>Division of Neuroradiology, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION: </strong>Laryngeal cancer is one of the most common subsites of head and neck cancer, and mortality rates within this patient population have decreased nationally over the past decade. With this increase in survival, optimization of alaryngeal speech is paramount for long-term quality of life. Utilization of a tracheoesophageal prosthesis (TEP) is considered the mainstay for vocal functional rehabilitation for those who have undergone a total laryngectomy, but there are potential associated complications, including leaking, dislodgement, and embedding, that can lead to poor functional outcomes and possibly require TEP removal in up to 50% of patients. The goal of this study is to better delineate patient and TEP factors, both clinical and radiographic, and their effects on TEP outcomes.</p>\n\n<p><strong>METHODS: </strong>This is a single-institution, retrospective study on the outcomes of secondary placement of tracheoesophageal prosthesis. Inclusion criteria included secondary TEP placement after formal review by an institutional TEP Board, which determines TEP candidacy based on specific anatomical, physiological, medical, and psychosocial factors. Radiographic measurements were made of the “parti-wall” (tracheoesophageal) thickness as well as the angle between the horizontal vector of the prosthesis in relation to the vertical neopharyngeal wall. These measures were obtained on pre-TEP imaging, with post-TEP images being used as a reference for subsequent actual TEP location (when imaging available). Details regarding TEP outcomes were also recorded, including the incidence of Speech-Language Pathology (SLP) clinic visits that addressed specific prosthesis complications, as well as any procedural interventions undertaken to address these complications. Bivariate analyses, including Pearson’s and Spearman’s Correlation were performed to identify significant relationships between clinical/radiographic factors and TEP outcomes.</p>\n\n<p><strong>RESULTS: </strong>A total of 26 patients met the inclusion criteria, with mean age of 65, and majority of patients were male (73%) and Caucasian (81%). Majority (62%) had undergone free flap reconstruction, with a mean of 684 days from laryngectomy to TEP. The average (range) parti-wall thickness was 5.74 (2-10) mm, and the average (range) TEP angle was 85 (64.7-130.2) degrees. Preliminary statistical analyses demonstrated multiple significant (p<0.05) correlative relationships, including a negative relationship between parti-wall thickness and incidence of sizing issues, as well as positive relationships between prosthesis angle and incidence of central leaks and number of TEP changes required. Of the 26 total patients, 7 (27%) patients ultimately had the TEP removed.</p>\n\n<p><strong>CONCLUSION: </strong>Our data postulates that there is a significant inverse relationship between parti-wall thickness and incidence of sizing issues. Additionally, more obtuse angles between the prosthesis and neopharyngeal wall are associated with higher incidences of central leaks and the number of TEP changes required. To our knowledge, the aforementioned prosthetic angle has not been previously characterized or correlated with TEP outcomes in this manner. Awareness of these correlative relationships may help set expectations regarding long-term prosthesis outcomes for both clinical care teams and patients alike. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154119--></body></html>"
    },
    {
      "uid": "P430",
      "content_id": "153888",
      "abstract_number": "P430",
      "poster_number": "P430",
      "title": "Patient and Family Caregiver Perspectives on a Supportive Care Intervention for Tracheostomy and Feeding Tube Care",
      "summary": "The Symptom Management Toolkit is a supportive care intervention that enables family caregivers to provide life-sustaining care for HNC patients, but the intervention would be improved by the addition of visual images and videos depicting the written instructions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153888",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kimberly Kennedy",
      "presenter": "Kimberly Kennedy",
      "authors": "Veronica Bernacchi, Assistant Professor 1 ; Minerva So, Medical Student 2 ; Alyanna Melicor, Project Manager 2 ; Kimberly Kennedy 2 ; Eric Adjei Boakye, Assistant Scientist 2 ; Samantha Tam, MD 2",
      "normalized_authors": [
        "Veronica Bernacchi, Assistant",
        "Alyanna Melicor, Project Manager",
        "Kimberly Kennedy",
        "Eric Adjei Boakye, Assistant Scientist",
        "Samantha Tam"
      ],
      "affiliations": [
        "Michigan State University (MSU)",
        "Henry Ford Health System"
      ],
      "normalized_institutions": [
        "Michigan State University (MSU)",
        "Henry Ford Health System"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 318,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Veronica Bernacchi, Assistant Professor 1 ; Minerva So, Medical Student 2 ; Alyanna Melicor, Project Manager 2 ; Kimberly Kennedy 2 ; Eric Adjei Boakye, Assistant Scientist 2 ; Samantha Tam, MD 2",
        "Affiliations": "1 Michigan State University (MSU); 2 Henry Ford Health System",
        "Introduction": "Approximately 30% of head and neck cancer (HNC) patients require life-altering surgical treatment that results in a tracheostomy to breathe and feeding tube to maintain nutrition. If these equipment are not managed, then HNC patients experience potentially life-threatening symptoms such as difficulty breathing. Family caregivers are largely responsible for maintaining these equipment immediately post-surgery. However, family caregivers report that they do not receive adequate education on the management of tracheostomies and feeding tubes. To begin addressing this critical resource gap, we have conducted a quasi-experimental feasibility study with a novel supportive care tool, the Symptom Management Toolkit, for family caregiver-HNC patient dyads, tailored to the medical care needs of HNC patients. An aim of this study was to qualitatively investigate patient and family caregivers’ perceptions about the content, delivery, and impact of the Symptom Management Toolkit.",
        "Methods": "We purposefully recruited a subsample of HNC patient-family caregiver dyads from the larger feasibility study. We conducted 45-minute, qualitative interviews via telephone or HIPAA-compliant videoconferencing pending participant preference to inquire about participant perceptions of the Symptom Management Toolkit content, delivery method, and impact on the patient and family caregiver’s ability to manage life-saving medical equipment and related symptoms. Interviews were recorded, transcribed verbatim, and inductively analyzed using the framework method.",
        "Results": "At this time, n=5 HNC patient-family caregiver dyads have been interviewed. Three main themes have developed; 1) family caregivers would feel more comfortable providing medical care with picturesand videos to go along with the written instructions, 2) Dyads prefer the delivery format to be a paper binder rather than virtual-based, and 3) the Symptom Management Toolkit has supported family caregivers in providing critical care to HNC patients when life-sustaining medical equipment malfunctions.",
        "Conclusion": "The Symptom Management Toolkit is a supportive care intervention that enables family caregivers to provide life-sustaining care for HNC patients, but the intervention would be improved by the addition of visual images and videos depicting the written instructions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient and Family Caregiver Perspectives on a Supportive Care Intervention for Tracheostomy and Feeding Tube Care</span>. Veronica Bernacchi, Assistant Professor<sup>1</sup>; Minerva So, Medical Student<sup>2</sup>; Alyanna Melicor, Project Manager<sup>2</sup>; <u>Kimberly Kennedy</u><sup>2</sup>; Eric Adjei Boakye, Assistant Scientist<sup>2</sup>; Samantha Tam, MD<sup>2</sup>. <sup>1</sup>Michigan State University (MSU); <sup>2</sup>Henry Ford Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Approximately 30% of head and neck cancer (HNC) patients require life-altering surgical treatment that results in a tracheostomy to breathe and feeding tube to maintain nutrition. If these equipment are not managed, then HNC patients experience potentially life-threatening symptoms such as difficulty breathing. Family caregivers are largely responsible for maintaining these equipment immediately post-surgery. However, family caregivers report that they do not receive adequate education on the management of tracheostomies and feeding tubes. To begin addressing this critical resource gap, we have conducted a quasi-experimental feasibility study with a novel supportive care tool, the Symptom Management Toolkit, for family caregiver-HNC patient dyads, tailored to the medical care needs of HNC patients. An aim of this study was to qualitatively investigate patient and family caregivers’ perceptions about the content, delivery, and impact of the Symptom Management Toolkit.</p>\n\n<p><strong>Methods:</strong> We purposefully recruited a subsample of HNC patient-family caregiver dyads from the larger feasibility study. We conducted 45-minute, qualitative interviews via telephone or HIPAA-compliant videoconferencing pending participant preference to inquire about participant perceptions of the Symptom Management Toolkit content, delivery method, and impact on the patient and family caregiver’s ability to manage life-saving medical equipment and related symptoms. Interviews were recorded, transcribed verbatim, and inductively analyzed using the framework method.</p>\n\n<p><strong>Results: </strong>At this time, n=5 HNC patient-family caregiver dyads have been interviewed. Three main themes have developed; 1) family caregivers would feel more comfortable providing medical care with picturesand videos to go along with the written instructions, 2) Dyads prefer the delivery format to be a paper binder rather than virtual-based, and 3) the Symptom Management Toolkit has supported family caregivers in providing critical care to HNC patients when life-sustaining medical equipment malfunctions.</p>\n\n<p><strong>Conclusion: </strong>The Symptom Management Toolkit is a supportive care intervention that enables family caregivers to provide life-sustaining care for HNC patients, but the intervention would be improved by the addition of visual images and videos depicting the written instructions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153888--></body></html>"
    },
    {
      "uid": "P431",
      "content_id": "153514",
      "abstract_number": "P431",
      "poster_number": "P431",
      "title": "A TEN-YEAR REVIEW AND SURVIVAL ANALYSIS OF HEAD AND NECK CANCERS IN A TERTIARY CENTER IN SAUDI ARABIA",
      "summary": "This study provides a comprehensive overview of head and neck cancer trends in the region over the past decade, emphasizing the value of long-term institutional data in guiding clinical and research priorities. The findings highlight the importance of maintaining robust cancer registries, strengthening early detection programs, and optimizing multidisciplinary management strategies. By identifying local disease...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153514",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mohammed Alzamil, MBBS",
      "presenter": "Mohammed Alzamil, MBBS",
      "authors": "Mohammed Alzamil, MBBS ; Turki Almuhaimid, MBBS",
      "normalized_authors": [
        "Mohammed Alzamil, MBBS",
        "Turki Almuhaimid, MBBS"
      ],
      "affiliations": [
        "King Fahad Specialist Hospital"
      ],
      "normalized_institutions": [
        "King Fahad Specialist Hospital"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 517,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Method",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mohammed Alzamil, MBBS ; Turki Almuhaimid, MBBS",
        "Affiliations": "King Fahad Specialist Hospital",
        "Introduction": "Head and neck cancers comprise approximately 4% of all cancers diagnosed in the United States and rank as the seventh most prevalent cancer worldwide, contributing to around 5% of global cancer fatalities?. Over the past decade, there has been a concerning uptick in the incidence of these cancers, yet survival rates have stagnated, resulting in a rising mortality trend?. This surge in incidence can be attributed to several factors, notably the increased prevalence of risky behaviors linked to head and neck cancers. Key risk factors such as tobacco use, alcohol consumption, oral hygiene practices, and HPV infection will be pivotal focal points in this study, aiming to elucidate their role and significance among affected individuals. Conducted within one of the nation's premier tertiary hospitals, renowned for its expertise in head and neck oncology, this research aims to enrich the current literature by delineating the evolving trends and patterns of head and neck cancers over the recent decade.",
        "Method": "This retrospective cohort study was conducted at King Fahad Specialist Hospital, Dammam, and included all patients diagnosed with primary head and neck cancers between January 2013 and January 2023. Data were retrieved from the hospital’s system following ethical guidelines. The study aimed to assess the incidence, clinical characteristics, treatment approaches, and outcomes of head and neck cancer cases over the ten-year period. Data were analyzed with emphasis on descriptive summaries of demographic, clinical, and outcome variables. Although limited by its retrospective single-center design, the study provides a valuable overview of the epidemiologic, treatment, and survival trends of head and neck cancers in the Eastern Province.",
        "Results": "A total of 600 patients with head and neck cancers were identified over ten years. The cohort showed a male predominance (62.7%), with most patients residing in Dammam (32.7%) and Ahsa (24.5%). The most common age group was 40–59 years (46.3%). Squamous cell carcinoma accounted for over half of all tumors, followed by carcinoma NOS and diffuse large B-cell lymphoma. The most frequent sites were the nasopharynx (34.3%), parotid gland (10.8%), oral tongue (10.2%), and tonsillar region (7.3%). Localized and regional stages were most common (73.4%), while 19.8% had distant disease. Surgery was performed in 37.8% and chemotherapy in 49.8% of cases. Distant metastasis occurred in 19.8%, mainly to lung and bone. Recurrence occurred in 8.2%, predominantly local. The 1-, 2-, and 3-year overall survival rates were 81.8%, 69.9%, and 61.9%, respectively. These findings highlight a predominance of middle-aged males with squamous histology and regional-stage disease.",
        "Conclusion": "This study provides a comprehensive overview of head and neck cancer trends in the region over the past decade, emphasizing the value of long-term institutional data in guiding clinical and research priorities. The findings highlight the importance of maintaining robust cancer registries, strengthening early detection programs, and optimizing multidisciplinary management strategies. By identifying local disease patterns and treatment practices, this work supports evidence-based planning, enhances regional understanding of disease behavior, and contributes to improving future oncologic outcomes and healthcare delivery for patients with head and neck cancer in Saudi Arabia."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A TEN-YEAR REVIEW AND SURVIVAL ANALYSIS OF HEAD AND NECK CANCERS IN A TERTIARY CENTER IN SAUDI ARABIA</span>. <u>Mohammed Alzamil, MBBS</u>; Turki Almuhaimid, MBBS. King Fahad Specialist Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancers comprise approximately 4% of all cancers diagnosed in the United States and rank as the seventh most prevalent cancer worldwide, contributing to around 5% of global cancer fatalities?. Over the past decade, there has been a concerning uptick in the incidence of these cancers, yet survival rates have stagnated, resulting in a rising mortality trend?. This surge in incidence can be attributed to several factors, notably the increased prevalence of risky behaviors linked to head and neck cancers. Key risk factors such as tobacco use, alcohol consumption, oral hygiene practices, and HPV infection will be pivotal focal points in this study, aiming to elucidate their role and significance among affected individuals. Conducted within one of the nation's premier tertiary hospitals, renowned for its expertise in head and neck oncology, this research aims to enrich the current literature by delineating the evolving trends and patterns of head and neck cancers over the recent decade.</p>\n\n<p><strong>Method: </strong>This retrospective cohort study was conducted at King Fahad Specialist Hospital, Dammam, and included all patients diagnosed with primary head and neck cancers between January 2013 and January 2023. Data were retrieved from the hospital’s system following ethical guidelines. The study aimed to assess the incidence, clinical characteristics, treatment approaches, and outcomes of head and neck cancer cases over the ten-year period. Data were analyzed with emphasis on descriptive summaries of demographic, clinical, and outcome variables. Although limited by its retrospective single-center design, the study provides a valuable overview of the epidemiologic, treatment, and survival trends of head and neck cancers in the Eastern Province.</p>\n\n<p><strong>Results: </strong>A total of 600 patients with head and neck cancers were identified over ten years. The cohort showed a male predominance (62.7%), with most patients residing in Dammam (32.7%) and Ahsa (24.5%). The most common age group was 40–59 years (46.3%). Squamous cell carcinoma accounted for over half of all tumors, followed by carcinoma NOS and diffuse large B-cell lymphoma. The most frequent sites were the nasopharynx (34.3%), parotid gland (10.8%), oral tongue (10.2%), and tonsillar region (7.3%). Localized and regional stages were most common (73.4%), while 19.8% had distant disease. Surgery was performed in 37.8% and chemotherapy in 49.8% of cases. Distant metastasis occurred in 19.8%, mainly to lung and bone. Recurrence occurred in 8.2%, predominantly local. The 1-, 2-, and 3-year overall survival rates were 81.8%, 69.9%, and 61.9%, respectively. These findings highlight a predominance of middle-aged males with squamous histology and regional-stage disease.</p>\n\n<p><strong>Conclusion: </strong>This study provides a comprehensive overview of head and neck cancer trends in the region over the past decade, emphasizing the value of long-term institutional data in guiding clinical and research priorities. The findings highlight the importance of maintaining robust cancer registries, strengthening early detection programs, and optimizing multidisciplinary management strategies. By identifying local disease patterns and treatment practices, this work supports evidence-based planning, enhances regional understanding of disease behavior, and contributes to improving future oncologic outcomes and healthcare delivery for patients with head and neck cancer in Saudi Arabia.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153514--></body></html>"
    },
    {
      "uid": "P432",
      "content_id": "154178",
      "abstract_number": "P432",
      "poster_number": "P432",
      "title": "EPIDEMIOLOGICAL PATTERNS, TREATMENT OUTCOMES, AND AGE-SPECIFIC PROGNOSTIC FACTORS IN PEDIATRIC HEAD AND NECK MALIGNANCIES: A POPULATION-BASED ANALYSIS OF 3,707 BRAZILIAN PATIENTS",
      "summary": "Head and neck malignancies represent a significant proportion of pediatric cancers, accounting for 12% of all childhood malignancies in population-based registries. Despite reported incidence rates of 4.48 per 100,000 children in developed countries, comprehensive treatment outcomes at the population level remain poorly documented. This study aimed to characterize the epidemiological profile, therapeutic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154178",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Hugo F Kohler, MD; Viviane Sonaglio, MD; Jose G Vartanian, MD, PhD ; Carlos Eduardo R Fernandes, MD; Luciana M P Piotto, MD; Leticia S Soares, MD; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Hugo F Kohler",
        "Viviane Sonaglio",
        "Jose G Vartanian",
        "Carlos Eduardo R Fernandes",
        "Luciana M P Piotto",
        "Leticia S Soares",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Hugo F Kohler, MD; Viviane Sonaglio, MD; Jose G Vartanian, MD, PhD ; Carlos Eduardo R Fernandes, MD; Luciana M P Piotto, MD; Leticia S Soares, MD; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "BACKGROUND": "Head and neck malignancies represent a significant proportion of pediatric cancers, accounting for 12% of all childhood malignancies in population-based registries. Despite reported incidence rates of 4.48 per 100,000 children in developed countries, comprehensive treatment outcomes at the population level remain poorly documented. This study aimed to characterize the epidemiological profile, therapeutic approaches, and survival outcomes of pediatric head and neck cancers in a large Brazilian cohort.",
        "MATERIALS AND METHODS": "We conducted a retrospective analysis of a public healthcare database encompassing all pediatric cancer patients treated in São Paulo State, Brazil. Inclusion criteria comprised patients younger than 18 years at diagnosis with non-hematologic head and neck malignancies. Statistical analyses employed R software, utilizing Student t-test for mean comparisons, Tukey test for multiple pairwise comparisons, Kaplan-Meier estimator for survival function calculation, and Cox proportional hazards regression for multivariate survival analysis. Log-rank tests assessed survival differences between groups.",
        "RESULTS": "Among 29,141 pediatric patients diagnosed with cancer, 3,707 (12.7%) presented non-hematologic head and neck malignancies. Mean age at diagnosis was 7.14 years (range 0.0-17.9 years), demonstrating distinct age-specific patterns across anatomical sites and histologies. Orbital tumors occurred earliest (mean 1.9 years), while thyroid carcinomas presented latest (mean 14.8 years). Histologically, blastomas affected the youngest patients (mean 1.5 years), whereas carcinomas (mean 13.9 years) and melanomas (mean 11.8 years) predominantly affected adolescents. Treatment modalities included surgery in 1,972 patients (53.2%), chemotherapy in 1,950 (52.6%), and radiotherapy in 772 (20.8%), with multimodal therapy administered to 1,366 patients (36.8%). After median follow-up of 54.3 months (range 0.03-280.2), clinical outcomes comprised 2,518 disease-free patients (67.9%), 674 with active disease (18.2%), 438 disease-related deaths (11.8%), and 77 deaths from other causes (2.1%). Thyroid carcinomas and non-melanoma skin cancers demonstrated superior disease-specific survival, contrasting sharply with rhabdomyosarcomas and other sarcomas. Nasosinusal and soft tissue primaries exhibited the poorest disease-free survival rates. Univariate analysis identified gender (p<0.001), primary site (p<0.001), histological type (p<0.001), metastatic disease at presentation (p<0.001), and treatment modality (p<0.001) as significant prognostic factors for disease-specific survival. Multivariate Cox regression confirmed histological type, presence of metastases, and primary anatomical site as independent predictors of survival outcomes.",
        "CONCLUSION": "Pediatric head and neck malignancies demonstrate marked heterogeneity across age groups, with distinct epidemiological patterns determining clinical presentation and prognosis. The bimodal age distribution reflects fundamentally different biological entities: embryonal tumors predominate in early childhood, while epithelial malignancies emerge during adolescence. Histological classification, metastatic status, and anatomical location constitute the primary determinants of long-term survival, superseding treatment modality as prognostic indicators. The favorable outcomes observed in thyroid carcinomas contrast dramatically with the aggressive behavior of rhabdomyosarcomas, underscoring the critical importance of histology-driven risk stratification. These population-level findings provide essential benchmarks for evaluating institutional performance and identifying opportunities for therapeutic optimization. Future research should prioritize molecular characterization of age-specific tumor subtypes, development of biology-guided therapeutic protocols, and establishment of multicenter collaborative networks to facilitate prospective clinical trials in this heterogeneous patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>EPIDEMIOLOGICAL PATTERNS, TREATMENT OUTCOMES, AND AGE-SPECIFIC PROGNOSTIC FACTORS IN PEDIATRIC HEAD AND NECK MALIGNANCIES: A POPULATION-BASED ANALYSIS OF 3,707 BRAZILIAN PATIENTS</span>. Hugo F Kohler, MD; Viviane Sonaglio, MD; <u>Jose G Vartanian, MD, PhD</u>; Carlos Eduardo R Fernandes, MD; Luciana M P Piotto, MD; Leticia S Soares, MD; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Head and neck malignancies represent a significant proportion of pediatric cancers, accounting for 12% of all childhood malignancies in population-based registries. Despite reported incidence rates of 4.48 per 100,000 children in developed countries, comprehensive treatment outcomes at the population level remain poorly documented. This study aimed to characterize the epidemiological profile, therapeutic approaches, and survival outcomes of pediatric head and neck cancers in a large Brazilian cohort.</p>\n\n<p><strong>MATERIALS AND METHODS: </strong>We conducted a retrospective analysis of a public healthcare database encompassing all pediatric cancer patients treated in São Paulo State, Brazil. Inclusion criteria comprised patients younger than 18 years at diagnosis with non-hematologic head and neck malignancies. Statistical analyses employed R software, utilizing Student t-test for mean comparisons, Tukey test for multiple pairwise comparisons, Kaplan-Meier estimator for survival function calculation, and Cox proportional hazards regression for multivariate survival analysis. Log-rank tests assessed survival differences between groups.</p>\n\n<p><strong>RESULTS: </strong>Among 29,141 pediatric patients diagnosed with cancer, 3,707 (12.7%) presented non-hematologic head and neck malignancies. Mean age at diagnosis was 7.14 years (range 0.0-17.9 years), demonstrating distinct age-specific patterns across anatomical sites and histologies. Orbital tumors occurred earliest (mean 1.9 years), while thyroid carcinomas presented latest (mean 14.8 years). Histologically, blastomas affected the youngest patients (mean 1.5 years), whereas carcinomas (mean 13.9 years) and melanomas (mean 11.8 years) predominantly affected adolescents. Treatment modalities included surgery in 1,972 patients (53.2%), chemotherapy in 1,950 (52.6%), and radiotherapy in 772 (20.8%), with multimodal therapy administered to 1,366 patients (36.8%). After median follow-up of 54.3 months (range 0.03-280.2), clinical outcomes comprised 2,518 disease-free patients (67.9%), 674 with active disease (18.2%), 438 disease-related deaths (11.8%), and 77 deaths from other causes (2.1%). Thyroid carcinomas and non-melanoma skin cancers demonstrated superior disease-specific survival, contrasting sharply with rhabdomyosarcomas and other sarcomas. Nasosinusal and soft tissue primaries exhibited the poorest disease-free survival rates. Univariate analysis identified gender (p<0.001), primary site (p<0.001), histological type (p<0.001), metastatic disease at presentation (p<0.001), and treatment modality (p<0.001) as significant prognostic factors for disease-specific survival. Multivariate Cox regression confirmed histological type, presence of metastases, and primary anatomical site as independent predictors of survival outcomes.</p>\n\n<p><strong>CONCLUSION: </strong>Pediatric head and neck malignancies demonstrate marked heterogeneity across age groups, with distinct epidemiological patterns determining clinical presentation and prognosis. The bimodal age distribution reflects fundamentally different biological entities: embryonal tumors predominate in early childhood, while epithelial malignancies emerge during adolescence. Histological classification, metastatic status, and anatomical location constitute the primary determinants of long-term survival, superseding treatment modality as prognostic indicators. The favorable outcomes observed in thyroid carcinomas contrast dramatically with the aggressive behavior of rhabdomyosarcomas, underscoring the critical importance of histology-driven risk stratification. These population-level findings provide essential benchmarks for evaluating institutional performance and identifying opportunities for therapeutic optimization. Future research should prioritize molecular characterization of age-specific tumor subtypes, development of biology-guided therapeutic protocols, and establishment of multicenter collaborative networks to facilitate prospective clinical trials in this heterogeneous patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154178--></body></html>"
    },
    {
      "uid": "P433",
      "content_id": "153484",
      "abstract_number": "P433",
      "poster_number": "P433",
      "title": "T-PROSE: Impact of Tongue Proactive Strengthening Exercise Program on Speech and Swallowing Outcomes Following Partial/hemiglossectomy and Reconstruction",
      "summary": "Dysarthria and dysphagia are major survivorship issues following tongue cancer surgery, causing significant quality of life impairment. Despite advances in reconstructive techniques, including microvascular free flap reconstruction, many patients experience persistent speech and swallowing difficulties. Early intervention studies suggest that postoperative exercises may improve functional outcomes, though optimal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153484",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Octeau, MD, MSc",
      "presenter": "David Octeau, MD, MSc",
      "authors": "David Octeau, MD, MSc ; Michelle York, MA, CCCSLP; Molly Smeltzer, MA, CCCSLP; Jamie Ku, MD, FACS",
      "normalized_authors": [
        "David Octeau",
        "Michelle York, MA, CCCSLP",
        "Molly Smeltzer, MA, CCCSLP",
        "Jamie Ku"
      ],
      "affiliations": [
        "Cleveland Clinic"
      ],
      "normalized_institutions": [
        "Cleveland Clinic"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153484/schema%20tprose.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153484/schema%20tprose.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153484"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 338,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "ClinicalTrials.gov registration"
      ],
      "sections": {
        "Authors": "David Octeau, MD, MSc ; Michelle York, MA, CCCSLP; Molly Smeltzer, MA, CCCSLP; Jamie Ku, MD, FACS",
        "Affiliations": "Cleveland Clinic",
        "Introduction": "Dysarthria and dysphagia are major survivorship issues following tongue cancer surgery, causing significant quality of life impairment. Despite advances in reconstructive techniques, including microvascular free flap reconstruction, many patients experience persistent speech and swallowing difficulties. Early intervention studies suggest that postoperative exercises may improve functional outcomes, though optimal timing, type, and delivery of rehabilitation remain unclear. In addition, many of the trials investigating this topic have been limited to patients undergoing radiation and excluded surgical patients. Most institutions offer speech-language pathology (SLP) services reactively rather than proactively, and evidence supporting device-based biofeedback tongue strengthening in this population is limited. We hypothesize that a proactive, biofeedback-driven tongue strengthening exercise program will improve speech and swallowing outcomes compared to standard postoperative care.",
        "Methods": "This is a prospective, single-center, randomized controlled pilot trial at Cleveland Clinic. Adults (≥18 years) with tongue cancer undergoing partial or hemiglossectomy (≤50% tongue resection) with reconstruction are eligible. Exclusion criteria include prior head and neck cancer, prior radiation, distant metastasis, mandibulectomy, or previous speech-language pathology treatment for dysphagia/dysarthria. Participants are stratified by reconstruction type (free flap vs. non-free flap) and adjuvant radiation status, then randomized 1:1 to two arms: (1) standard postoperative care with routine range-of-motion exercises, or (2) standard care plus a 10-week home tongue strengthening exercise program using the Tongueometer biofeedback device. The intervention arm performs daily exercises including anterior/posterior tongue compressions and isometric holds at 70% maximum tongue strength with Q2-week check-in visits with a SLP.",
        "Abstract": "The primary endpoint is the Speech Handicap Index (SHI) at 6 months post-treatment. Secondary endpoint is the MD Anderson Dysphagia Inventory (MDADI) at 6 months. Exploratory endpoints include objective measures (FDA-2 intelligibility, MBSImP, DIGEST), symptom burden (MDASI-HN), diet level (PSS-HN, FOIS), tongue strength changes, weight loss, feeding tube dependence, and hospitalizations at 3, 6, and 12 months. Sample size of 40 patients (20 per arm) provides 80% power to detect a clinically significant 19.1-point difference in SHI scores. Analysis will use ANCOVA adjusting for baseline scores and stratification variables.",
        "ClinicalTrials.gov registration": "[NCT#: NCT07110142]. Enrollment status: Enrolling"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>T-PROSE: Impact of Tongue Proactive Strengthening Exercise Program on Speech and Swallowing Outcomes Following Partial/hemiglossectomy and Reconstruction</span>. <u>David Octeau, MD, MSc</u>; Michelle York, MA, CCCSLP; Molly Smeltzer, MA, CCCSLP; Jamie Ku, MD, FACS. Cleveland Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Dysarthria and dysphagia are major survivorship issues following tongue cancer surgery, causing significant quality of life impairment. Despite advances in reconstructive techniques, including microvascular free flap reconstruction, many patients experience persistent speech and swallowing difficulties. Early intervention studies suggest that postoperative exercises may improve functional outcomes, though optimal timing, type, and delivery of rehabilitation remain unclear. In addition, many of the trials investigating this topic have been limited to patients undergoing radiation and excluded surgical patients. Most institutions offer speech-language pathology (SLP) services reactively rather than proactively, and evidence supporting device-based biofeedback tongue strengthening in this population is limited. We hypothesize that a proactive, biofeedback-driven tongue strengthening exercise program will improve speech and swallowing outcomes compared to standard postoperative care.</p>\n\n<p><strong>Methods: </strong>This is a prospective, single-center, randomized controlled pilot trial at Cleveland Clinic. Adults (≥18 years) with tongue cancer undergoing partial or hemiglossectomy (≤50% tongue resection) with reconstruction are eligible. Exclusion criteria include prior head and neck cancer, prior radiation, distant metastasis, mandibulectomy, or previous speech-language pathology treatment for dysphagia/dysarthria. Participants are stratified by reconstruction type (free flap vs. non-free flap) and adjuvant radiation status, then randomized 1:1 to two arms: (1) standard postoperative care with routine range-of-motion exercises, or (2) standard care plus a 10-week home tongue strengthening exercise program using the Tongueometer biofeedback device. The intervention arm performs daily exercises including anterior/posterior tongue compressions and isometric holds at 70% maximum tongue strength with Q2-week check-in visits with a SLP.</p>\n\n<p>The primary endpoint is the Speech Handicap Index (SHI) at 6 months post-treatment. Secondary endpoint is the MD Anderson Dysphagia Inventory (MDADI) at 6 months. Exploratory endpoints include objective measures (FDA-2 intelligibility, MBSImP, DIGEST), symptom burden (MDASI-HN), diet level (PSS-HN, FOIS), tongue strength changes, weight loss, feeding tube dependence, and hospitalizations at 3, 6, and 12 months. Sample size of 40 patients (20 per arm) provides 80% power to detect a clinically significant 19.1-point difference in SHI scores. Analysis will use ANCOVA adjusting for baseline scores and stratification variables.</p>\n\n<p><strong>ClinicalTrials.gov registration:</strong> [NCT#: NCT07110142]. Enrollment status: Enrolling</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153484/schema%20tprose.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153484--></body></html>"
    },
    {
      "uid": "P434",
      "content_id": "154775",
      "abstract_number": "P434",
      "poster_number": "P434",
      "title": "Progression, Recurrence, and Survival in Carcinoma ex Pleomorphic Adenoma: A Systematic Review and Meta-analysis",
      "summary": "This meta-analysis shows that approximately 1 in 13 pleomorphic adenomas progresses to CXPA. Established CXPA demonstrates substantial distant failure and only moderate 5-year survival. These results support vigilant follow-up of pleomorphic adenoma and aggressive, risk-adapted management of CXPA to optimize tumor control and survival.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154775",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Srivatsa Surya Vasudevan, MD, MS",
      "presenter": "Srivatsa Surya Vasudevan, MD, MS",
      "authors": "Srivatsa Surya Vasudevan, MD, MS 1 ; Martha Lucía Gutiérrez Pérez, MD 2 ; Ryan Mackay, MD, PhD 3 ; Ameya A",
      "normalized_authors": [
        "Srivatsa Surya Vasudevan",
        "Martha Lucía Gutiérrez Pérez",
        "Ryan Mackay",
        "Ameya A"
      ],
      "affiliations": [
        "Asarkar, MD, FACS 1 . 1 Louisiana State University Health Sciences Center",
        "Universidad El Bosque",
        "University of IOWA"
      ],
      "normalized_institutions": [
        "Asarkar, MD, FACS 1 . 1 Louisiana State University Health Sciences Center",
        "Universidad El Bosque",
        "University of IOWA"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 274,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Srivatsa Surya Vasudevan, MD, MS 1 ; Martha Lucía Gutiérrez Pérez, MD 2 ; Ryan Mackay, MD, PhD 3 ; Ameya A",
        "Affiliations": "Asarkar, MD, FACS 1 . 1 Louisiana State University Health Sciences Center; 2 Universidad El Bosque; 3 University of IOWA",
        "Background": "Carcinoma ex pleomorphic adenoma (CXPA) arises from benign pleomorphic adenoma and carries substantial risks of recurrence and disease-related mortality. Robust pooled estimates for progression, recurrence patterns, and survival are limited. We aimed to quantify the rate of progression to CXPA, recurrence patterns, and long-term survival/tumor control.",
        "Methods": "PubMed, Embase, Web of Science, and ScienceDirect were searched from January 2000 to November 10, 2025, for studies reporting malignant transformation of pleomorphic adenoma to CXPA, recurrence outcomes, and survival. Pooled event rates with 95% confidence intervals (CI) were calculated using a random-effects meta-analysis.",
        "Results": "Of 1,095 records, 41 studies including 3,492 patients with CXPA were analyzed. The pooled transformation rate from pleomorphic adenoma to CXPA was 7.7% (95% CI, 4.2–13.8). Among patients with CXPA, pooled recurrence rates were: local recurrence 14.8% (10.6–20.3), regional recurrence 10.1% (3.8–24.2), locoregional recurrence 7.5% (3.3–16.2), and distant metastasis 20.5% (15.1–27.1). Pooled 2-year overall survival (OS) was 80.7% (68.6–88.9), declining to 67.2% (58.1–75.2) at 5 years. Two-year disease-free survival (DFS) was 71.9% (45.1–88.8) and 5-year DFS was 71.1% (57.4–81.8). Two-year disease-specific survival (DSS) was 86.6% (79.1–91.7), decreasing to 72.9% (64.6–79.8) at 5 years.",
        "Conclusion": "This meta-analysis shows that approximately 1 in 13 pleomorphic adenomas progresses to CXPA. Established CXPA demonstrates substantial distant failure and only moderate 5-year survival. These results support vigilant follow-up of pleomorphic adenoma and aggressive, risk-adapted management of CXPA to optimize tumor control and survival."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Progression, Recurrence, and Survival in Carcinoma ex Pleomorphic Adenoma: A Systematic Review and Meta-analysis</span>. <u>Srivatsa Surya Vasudevan, MD, MS</u><sup>1</sup>; Martha Lucía Gutiérrez Pérez, MD<sup>2</sup>; Ryan Mackay, MD, PhD<sup>3</sup>; Ameya A. Asarkar, MD, FACS<sup>1</sup>. <sup>1</sup>Louisiana State University Health Sciences Center; <sup>2</sup>Universidad El Bosque; <sup>3</sup>University of IOWA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Carcinoma ex pleomorphic adenoma (CXPA) arises from benign pleomorphic adenoma and carries substantial risks of recurrence and disease-related mortality. Robust pooled estimates for progression, recurrence patterns, and survival are limited. We aimed to quantify the rate of progression to CXPA, recurrence patterns, and long-term survival/tumor control.</p>\n\n<p><strong>Methods: </strong>PubMed, Embase, Web of Science, and ScienceDirect were searched from January 2000 to November 10, 2025, for studies reporting malignant transformation of pleomorphic adenoma to CXPA, recurrence outcomes, and survival. Pooled event rates with 95% confidence intervals (CI) were calculated using a random-effects meta-analysis.</p>\n\n<p><strong>Results: </strong>Of 1,095 records, 41 studies including 3,492 patients with CXPA were analyzed. The pooled transformation rate from pleomorphic adenoma to CXPA was 7.7% (95% CI, 4.2–13.8). Among patients with CXPA, pooled recurrence rates were: local recurrence 14.8% (10.6–20.3), regional recurrence 10.1% (3.8–24.2), locoregional recurrence 7.5% (3.3–16.2), and distant metastasis 20.5% (15.1–27.1). Pooled 2-year overall survival (OS) was 80.7% (68.6–88.9), declining to 67.2% (58.1–75.2) at 5 years. Two-year disease-free survival (DFS) was 71.9% (45.1–88.8) and 5-year DFS was 71.1% (57.4–81.8). Two-year disease-specific survival (DSS) was 86.6% (79.1–91.7), decreasing to 72.9% (64.6–79.8) at 5 years.</p>\n\n<p><strong>Conclusion: </strong>This meta-analysis shows that approximately 1 in 13 pleomorphic adenomas progresses to CXPA. Established CXPA demonstrates substantial distant failure and only moderate 5-year survival. These results support vigilant follow-up of pleomorphic adenoma and aggressive, risk-adapted management of CXPA to optimize tumor control and survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154775--></body></html>"
    },
    {
      "uid": "P435",
      "content_id": "153356",
      "abstract_number": "P435",
      "poster_number": "P435",
      "title": "The Impact of Masking on Quality of Life in Head and Neck Cancer Patients",
      "summary": "Head and neck cancer (HNC) patients are more likely to experience persistent emotional distress due to their diagnosis when compared to other forms of cancer. These patients are also more susceptible to social stigma due to facial disfigurement as a result of their treatment, leading to reduced quality-of-life (QOL). With the advent of masking due to the COVID-19 pandemic, anecdotal evidence indicates that...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153356",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jan Bian, MD",
      "presenter": "Jan Bian, MD",
      "authors": "Jan Bian, MD 1 ; Noah DeMoss 1 ; Evan Nicklas, MD 1 ; Justin Dvorak, PhD 2 ; Nilesh Vasan, MD 1",
      "normalized_authors": [
        "Jan Bian",
        "Noah DeMoss",
        "Evan Nicklas",
        "Justin Dvorak",
        "Nilesh Vasan"
      ],
      "affiliations": [
        "University of Oklahoma, Department of Otolaryngology",
        "University of Oklahoma, College of Public Health"
      ],
      "normalized_institutions": [
        "University of Oklahoma, Department of Otolaryngology",
        "University of Oklahoma, College of Public Health"
      ],
      "session_type": "Poster",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 413,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jan Bian, MD 1 ; Noah DeMoss 1 ; Evan Nicklas, MD 1 ; Justin Dvorak, PhD 2 ; Nilesh Vasan, MD 1",
        "Affiliations": "1 University of Oklahoma, Department of Otolaryngology; 2 University of Oklahoma, College of Public Health",
        "Abstract": "Head and neck cancer (HNC) patients are more likely to experience persistent emotional distress due to their diagnosis when compared to other forms of cancer. These patients are also more susceptible to social stigma due to facial disfigurement as a result of their treatment, leading to reduced quality-of-life (QOL). With the advent of masking due to the COVID-19 pandemic, anecdotal evidence indicates that self-confidence and quality of life have improved in patients with HNC. This cross-sectional study evaluates the impact of masking during the COVID-19 pandemic on the quality of life and mental health of HNC patients. Patients who were diagnosed with HNC and completed treatment before March 2020 were selected to participate in this study. Patients who were seen for general otolaryngologic complaints were enrolled in the control group if they had no prior history of HNC. Participants were asked to complete an anonymous modified version of the University of Washington Quality of Life survey assessing their self-confidence, QOL and mental health prior to and during the COVID-19 pandemic. Fifty-one patients were included in this study, with 26 HNC patients and 25 control patients. The majority of HNC patients reported that their surgical scar could be covered by a standard face mask (65%). Compared to controls, HNC patients were significantly more likely to report a negative change in their appearance after treatment (p = 0.0013). HNC patients were both more likely to believe that masking is effective (p = 0.0099) and were more likely to wear a mask outside their home (p = 0.046). Interestingly, HNC patients reported improvement in all QOL factors examined including recreation, shopping, social activity, mood and anxiety, while control patients reported a slight decrease in QOL when comparing pre- and post-COVID time periods; however, these trends were not statistically significant. When asked if masking had any impact on participants’ self-confidence, there was no significant difference between HNC patients and controls. There is no current literature evaluating the impact of masking on QOL or mental health in survivors of HNC. While HNC patients were more likely to wear masks for personal health reasons, our findings indicate that masking does not play a major role in their self-esteem. This small, single site study highlights the nuanced experiences of HNC patients during the COVID-19 pandemic. While this study focused primarily on how changes in appearance can affect the quality of life of HNC survivors, further research into other QOL factors potentially impacted by head and neck cancer treatment is warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Impact of Masking on Quality of Life in Head and Neck Cancer Patients</span>. <u>Jan Bian, MD</u><sup>1</sup>; Noah DeMoss<sup>1</sup>; Evan Nicklas, MD<sup>1</sup>; Justin Dvorak, PhD<sup>2</sup>; Nilesh Vasan, MD<sup>1</sup>. <sup>1</sup>University of Oklahoma, Department of Otolaryngology; <sup>2</sup>University of Oklahoma, College of Public Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck cancer (HNC) patients are more likely to experience persistent emotional distress due to their diagnosis when compared to other forms of cancer. These patients are also more susceptible to social stigma due to facial disfigurement as a result of their treatment, leading to reduced quality-of-life (QOL). With the advent of masking due to the COVID-19 pandemic, anecdotal evidence indicates that self-confidence and quality of life have improved in patients with HNC. This cross-sectional study evaluates the impact of masking during the COVID-19 pandemic on the quality of life and mental health of HNC patients.</p>\n\n<p>Patients who were diagnosed with HNC and completed treatment before March 2020 were selected to participate in this study. Patients who were seen for general otolaryngologic complaints were enrolled in the control group if they had no prior history of HNC. Participants were asked to complete an anonymous modified version of the University of Washington Quality of Life survey assessing their self-confidence, QOL and mental health prior to and during the COVID-19 pandemic.</p>\n\n<p>Fifty-one patients were included in this study, with 26 HNC patients and 25 control patients. The majority of HNC patients reported that their surgical scar could be covered by a standard face mask (65%). Compared to controls, HNC patients were significantly more likely to report a negative change in their appearance after treatment (p = 0.0013). HNC patients were both more likely to believe that masking is effective (p = 0.0099) and were more likely to wear a mask outside their home (p = 0.046). Interestingly, HNC patients reported improvement in all QOL factors examined including recreation, shopping, social activity, mood and anxiety, while control patients reported a slight decrease in QOL when comparing pre- and post-COVID time periods; however, these trends were not statistically significant. When asked if masking had any impact on participants’ self-confidence, there was no significant difference between HNC patients and controls.</p>\n\n<p>There is no current literature evaluating the impact of masking on QOL or mental health in survivors of HNC. While HNC patients were more likely to wear masks for personal health reasons, our findings indicate that masking does not play a major role in their self-esteem. This small, single site study highlights the nuanced experiences of HNC patients during the COVID-19 pandemic. While this study focused primarily on how changes in appearance can affect the quality of life of HNC survivors, further research into other QOL factors potentially impacted by head and neck cancer treatment is warranted. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153356--></body></html>"
    },
    {
      "uid": "P436",
      "content_id": "154518",
      "abstract_number": "P436",
      "poster_number": "P436",
      "title": "Treatment with Interferon-beta (IFNB) reduces viability and activates immunologic pathways in HNSCC cell lines",
      "summary": "Our study found that IFNB treatment drives anti-tumor effects in epithelial HNSCC, consistent with established IFN type I biology. We have shown that IFNB reduced short-term cell viability and long-term cell proliferation in both human and murine squamous cell carcinoma models. These effects are accompanied by strong activation of p-STAT1, MX1 and cytokine secretion, indicating engagement of IFN-stimulated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154518",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alejandro Kochen",
      "presenter": "Alejandro Kochen",
      "authors": "Alejandro Kochen ; Parisa Abedi, Dr; Curtis Pickering, PhD",
      "normalized_authors": [
        "Alejandro Kochen",
        "Parisa Abedi, Dr",
        "Curtis Pickering"
      ],
      "affiliations": [
        "Yale School of Medicine"
      ],
      "normalized_institutions": [
        "Yale School of Medicine"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 453,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alejandro Kochen ; Parisa Abedi, Dr; Curtis Pickering, PhD",
        "Affiliations": "Yale School of Medicine",
        "Background": "Type I interferon responses exhibit dual anti-tumor activity by both directly targeting epithelial cells and influencing the tumor microenvironment, resulting in reduced proliferation, induction of apoptosis, and secretion of inflammatory cytokines and chemokines. A key mediator of the interferon-beta (IFNB, a Type I interferon) signaling cascade is STAT1, which upon activation induces proapoptotic proteins and caspase-dependent cell death, and concurrently modulates immunogenic responses by inducing interferon-stimulated genes such as CXCL10, a chemokine associated with inflammatory signaling. IFNB exposure can also drive cell-cycle arrest by increasing CDK inhibitors via a STAT1-dependent mechanism. Most of these cellular phenotypes can occur across epithelial and immune cells; however, while the effects of IFN-β on immune cells have been documented, its effects on epithelial cells of the head and neck remain incompletely understood.",
        "Methods": "Human HNSCC cell lines (HN31, HN5, SCC6) and murine HNSCC cell lines (MOC1, MOC2) were treated with recombinant IFNB (0-1000 U/ml) for 24-72 hours. Cell viability was measured using the CellTiter assay. IFN pathway activation was assessed by Western Blotting. Cytokine secretion was quantified by sandwich ELISA. Long-term cell proliferation was assessed via standard clonogenic assay.",
        "Results": "IFNB caused a consistent reduction in cell viability across human and murine HNSCC models in vitro. By 72 hours, the average decrease in viability across human cell lines was approximately 30-40%. Additionally, caspase cleavage was observed, consistent with IFNB’s cytostatic and cytotoxic effects. Murine cell lines displayed a similar dose–response pattern, with viability decreasing by 30% in MOC1 and 10% in MOC2. Western blotting confirmed a robust STAT1 pathway activation, with increased p-STAT1 and MX1 induction across both dosage and time points. CXCL10 induction also showed a potent dose-dependent response to IFNB, showing a 50-100-fold rise over control samples. Standard clonogenic assays demonstrated a more dramatic IFNB dose-response than shorter-term assays. Colony formation was reduced by 60-90% at 100 U/ml and reached complete loss at 1000 U/ml across HN31, HN5 and SCC6.",
        "Conclusion": "Our study found that IFNB treatment drives anti-tumor effects in epithelial HNSCC, consistent with established IFN type I biology. We have shown that IFNB reduced short-term cell viability and long-term cell proliferation in both human and murine squamous cell carcinoma models. These effects are accompanied by strong activation of p-STAT1, MX1 and cytokine secretion, indicating engagement of IFN-stimulated apoptotic, cytostatic, and immunogenic responses. The marked loss of clonogenic activity following IFNB exposure in head and neck epithelial cells suggests a durable biologic effect beyond short-term cytotoxicity. While systemic IFNB treatment of HNSCC may have toxicity and efficacy concerns, intralesional treatment or treatment of oral premalignancy may be clinically viable. Further studies are required to better characterize effects of IFNB in HNSCC models and to determine the viability of targeting these pathways therapeutically."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment with Interferon-beta (IFNB) reduces viability and activates immunologic pathways in HNSCC cell lines</span>. <u>Alejandro Kochen</u>; Parisa Abedi, Dr; Curtis Pickering, PhD. Yale School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Type I interferon responses exhibit dual anti-tumor activity by both directly targeting epithelial cells and influencing the tumor microenvironment, resulting in reduced proliferation, induction of apoptosis, and secretion of inflammatory cytokines and chemokines. A key mediator of the interferon-beta (IFNB, a Type I interferon) signaling cascade is STAT1, which upon activation induces proapoptotic proteins and caspase-dependent cell death, and concurrently modulates immunogenic responses by inducing interferon-stimulated genes such as CXCL10, a chemokine associated with inflammatory signaling. IFNB exposure can also drive cell-cycle arrest by increasing CDK inhibitors via a STAT1-dependent mechanism. Most of these cellular phenotypes can occur across epithelial and immune cells; however, while the effects of IFN-β on immune cells have been documented, its effects on epithelial cells of the head and neck remain incompletely understood.</p>\n\n<p><strong>Methods: </strong>Human HNSCC cell lines (HN31, HN5, SCC6) and murine HNSCC cell lines (MOC1, MOC2) were treated with recombinant IFNB (0-1000 U/ml) for 24-72 hours. Cell viability was measured using the CellTiter assay. IFN pathway activation was assessed by Western Blotting. Cytokine secretion was quantified by sandwich ELISA. Long-term cell proliferation was assessed via standard clonogenic assay.</p>\n\n<p><strong>Results: </strong>IFNB caused a consistent reduction in cell viability across human and murine HNSCC models in vitro. By 72 hours, the average decrease in viability across human cell lines was approximately 30-40%. Additionally, caspase cleavage was observed, consistent with IFNB’s cytostatic and cytotoxic effects. Murine cell lines displayed a similar dose–response pattern, with viability decreasing by 30% in MOC1 and 10% in MOC2. Western blotting confirmed a robust STAT1 pathway activation, with increased p-STAT1 and MX1 induction across both dosage and time points. CXCL10 induction also showed a potent dose-dependent response to IFNB, showing a 50-100-fold rise over control samples. Standard clonogenic assays demonstrated a more dramatic IFNB dose-response than shorter-term assays. Colony formation was reduced by 60-90% at 100 U/ml and reached complete loss at 1000 U/ml across HN31, HN5 and SCC6.</p>\n\n<p><strong>Conclusion: </strong>Our study found that IFNB treatment drives anti-tumor effects in epithelial HNSCC, consistent with established IFN type I biology. We have shown that IFNB reduced short-term cell viability and long-term cell proliferation in both human and murine squamous cell carcinoma models. These effects are accompanied by strong activation of p-STAT1, MX1 and cytokine secretion, indicating engagement of IFN-stimulated apoptotic, cytostatic, and immunogenic responses. The marked loss of clonogenic activity following IFNB exposure in head and neck epithelial cells suggests a durable biologic effect beyond short-term cytotoxicity. While systemic IFNB treatment of HNSCC may have toxicity and efficacy concerns, intralesional treatment or treatment of oral premalignancy may be clinically viable. Further studies are required to better characterize effects of IFNB in HNSCC models and to determine the viability of targeting these pathways therapeutically.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154518--></body></html>"
    },
    {
      "uid": "P437",
      "content_id": "153898",
      "abstract_number": "P437",
      "poster_number": "P437",
      "title": "In the Pursuit of Novel Biomarkers: Cytotoxic Efficacy of Anti-HER2 Antibody Drug Conjugates in HER2-Low and Ultra-Low Head and Neck Squmaous Cell Carcinoma",
      "summary": "Although, HNSCC exhibit low HER2 expression, release of cytotoxic payload from uptake in surrounding tissues induces significant cytotoxicity. This is likely through the Fc portion mediated uptake of the drug via immune cells.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153898",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Syeda Maria Ahmad Zaidi, MD",
      "presenter": "Syeda Maria Ahmad Zaidi, MD",
      "authors": "Syeda Maria Ahmad Zaidi, MD ; Kelsey Nocilla; Mabrooka Kazi, MD; Georgii Vasiukov, MD, PhD; Eben Rosenthal, MD",
      "normalized_authors": [
        "Syeda Maria Ahmad Zaidi",
        "Kelsey Nocilla",
        "Mabrooka Kazi",
        "Georgii Vasiukov",
        "Eben Rosenthal"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 397,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Syeda Maria Ahmad Zaidi, MD ; Kelsey Nocilla; Mabrooka Kazi, MD; Georgii Vasiukov, MD, PhD; Eben Rosenthal, MD",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "Classically anti-HER2 therapy has demonstrated little to no efficacy in head and neck squamous cell carcinomas (HNSCC). Nevertheless, due to the expression of low levels of HER2 protein, anti-HER2 agents can be leveraged in the management of HNSCC. Notably, HER2 targeting antibody-drug conjugates (ADCs) have demonstrated clinical benefit in low and ultra-low HER2 expressing malignancies. This preclinical trial data establishes therapeutic benefit of trastuzumab-deruxtecan (T-DXd), an anti-HER2 ADC, in HNSCC.",
        "Methods": "Using a conventional murine xenografts model, animals were treated with increasing doses (25-100µg) of trastuzumab-deruxtecan (T-DXd) and assessed for reduction in tumor volume. The isotype matched monoclonal antibody (mAb), trastuzumab, served as control. Mice were dosed once on day zero and followed until day 21. Formalin fixed paraffin embedded (FFPE) blocks of the resected tumors were prepared, and multiplex immunostaining was performed on 5µm sections for anti-gamma H2A.X (histone), anti-Rad51 (DNA damage) and anti-53BP1 (impaired DNA repair pathways) to determine downstream cytotoxicity. Addtionally, xenografts were dosed at comparable doses of trastuzumab and IgG, conjugated to IRdye800, to assess for anti-HER2 drug accumulation in tumor and stromal components and determine drug specificity. All specimens were scanned on the Olympus VS200 system.",
        "Results": "We conducted in-vivo studies to determine if low or ultra-low HNSCC xenografts are susceptible to the cytotoxic effects of T-DXd. Therapeutic administration of the ADC demonstrated significant reduction in tumor volumes over a 21 day observation period (p<0.01). Significant tumor cytotoxicity could be detected in the T-DXd treated antimals in the 50µg (p=0.050) and 100µg (p=0.025) treatment groups compared to trastuzumab. Quanitative measure of the DNA damage from T-DXd was detected for gamma H2A.X (0.858 vs 0.186, p<0.001), Rad51 (2.453 vs 0.852, p<0.001) and 53BP1 (1.529 vs 0.309, p<0.001) compared to trastuzumab respectively. This signifies that DNA damage from the cytotoxic effects of T-DXd were obvious even after a singular dose of the ADC in HER2-low HNSCC. Using fluorescently labeled drug, we demosntrated that most of the drug resided in non-tumor, stromal and immune, compartements in HER2-low malignancies. This implies that T-DXd can exhibit potent cytotxocity and cellular killing through non-specific uptake in HNSCC.",
        "Conclusion": "Although, HNSCC exhibit low HER2 expression, release of cytotoxic payload from uptake in surrounding tissues induces significant cytotoxicity. This is likely through the Fc portion mediated uptake of the drug via immune cells."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>In the Pursuit of Novel Biomarkers: Cytotoxic Efficacy of Anti-HER2 Antibody Drug Conjugates in HER2-Low and Ultra-Low Head and Neck Squmaous Cell Carcinoma</span>. <u>Syeda Maria Ahmad Zaidi, MD</u>; Kelsey Nocilla; Mabrooka Kazi, MD; Georgii Vasiukov, MD, PhD; Eben Rosenthal, MD. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong><strong> </strong>Classically anti-HER2 therapy has demonstrated little to no efficacy in head and neck squamous cell carcinomas (HNSCC). Nevertheless, due to the expression of low levels of HER2 protein, anti-HER2 agents can be leveraged in the management of HNSCC. Notably, HER2 targeting antibody-drug conjugates (ADCs) have demonstrated clinical benefit in low and ultra-low HER2 expressing malignancies. This preclinical trial data establishes therapeutic benefit of trastuzumab-deruxtecan (T-DXd), an anti-HER2 ADC, in HNSCC. </p>\n\n<p><strong>Methods:</strong><strong> </strong>Using a conventional murine xenografts model, animals were treated with increasing doses (25-100µg) of trastuzumab-deruxtecan (T-DXd) and assessed for reduction in tumor volume. The isotype matched monoclonal antibody (mAb), trastuzumab, served as control. Mice were dosed once on day zero and followed until day 21. Formalin fixed paraffin embedded (FFPE) blocks of the resected tumors were prepared, and multiplex immunostaining was performed on 5µm sections for anti-gamma H2A.X (histone), anti-Rad51 (DNA damage) and anti-53BP1 (impaired DNA repair pathways) to determine downstream cytotoxicity. Addtionally, xenografts were dosed at comparable doses of trastuzumab and IgG, conjugated to IRdye800, to assess for anti-HER2 drug accumulation in tumor and stromal components and determine drug specificity. All specimens were scanned on the Olympus VS200 system.  </p>\n\n<p><strong>Results:</strong> We conducted in-vivo studies to determine if low or ultra-low HNSCC xenografts are susceptible to the cytotoxic effects of T-DXd. Therapeutic administration of the ADC demonstrated significant reduction in tumor volumes over a 21 day observation period (p<0.01). Significant tumor cytotoxicity could be detected in the T-DXd treated antimals in the 50µg (p=0.050) and 100µg (p=0.025) treatment groups compared to trastuzumab. Quanitative measure of the DNA damage from T-DXd was detected for gamma H2A.X (0.858 vs 0.186, p<0.001), Rad51 (2.453 vs 0.852, p<0.001) and 53BP1 (1.529 vs 0.309, p<0.001) compared to trastuzumab respectively. This signifies that DNA damage from the cytotoxic effects of T-DXd were obvious even after a singular dose of the ADC in HER2-low HNSCC.  Using fluorescently labeled drug, we demosntrated that most of the drug resided in non-tumor, stromal and immune, compartements in HER2-low malignancies.  This implies that T-DXd can exhibit potent cytotxocity and cellular killing through non-specific uptake in HNSCC. </p>\n\n<p><strong>Conclusion:</strong> Although, HNSCC exhibit low HER2 expression, release of cytotoxic payload from uptake in surrounding tissues induces significant cytotoxicity. This is likely through the Fc portion mediated uptake of the drug via immune cells.   </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153898--></body></html>"
    },
    {
      "uid": "P438",
      "content_id": "150663",
      "abstract_number": "P438",
      "poster_number": "P438",
      "title": "PGK1 promotes angiogenesis in head and neck cancer through a non-glycolytic mechanism",
      "summary": "Phosphoglycerate kinase 1 (PGK1) is a central enzyme in glycolysis, catalyzing the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP to generate ATP. Beyond its well-established metabolic role, increasing evidence suggests that PGK1 may also participate in non-glycolytic processes; however, the extent to which these non-metabolic functions contribute to cancer initiation and progression...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=150663",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yong Teng",
      "presenter": "Yong Teng",
      "authors": "Jianqiang Yang; Soumya Vijaya Kuma; Fanghui Chen; Nabil F",
      "normalized_authors": [
        "Jianqiang Yang",
        "Soumya Vijaya Kuma",
        "Fanghui Chen",
        "Nabil F"
      ],
      "affiliations": [
        "Saba",
        "Yong Teng . Emory"
      ],
      "normalized_institutions": [
        "Saba",
        "Yong Teng . Emory"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 188,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jianqiang Yang; Soumya Vijaya Kuma; Fanghui Chen; Nabil F",
        "Affiliations": "Saba; Yong Teng . Emory",
        "Abstract": "Phosphoglycerate kinase 1 (PGK1) is a central enzyme in glycolysis, catalyzing the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP to generate ATP. Beyond its well-established metabolic role, increasing evidence suggests that PGK1 may also participate in non-glycolytic processes; however, the extent to which these non-metabolic functions contribute to cancer initiation and progression remains poorly understood. In this study, we uncover a novel, non-glycolytic function of PGK1 in driving angiogenesis through blocking the secretion of Serum Amyloid A1 (SAA1), an inflammatory mediator implicated in tumor development. Using head and neck squamous cell carcinoma (HNSCC) cell models and RNA sequencing analysis, we identified SAA1 as the most significantly downregulated gene following PGK1 knockdown. Mechanistically, PGK1 knockdown reduces SAA1 expression at the transcriptional level via suppression of the transcription factor interferon regulatory factor 1 (IRF1). This transcriptional downregulation leads to decreased SAA1 secretion, which in turn impairs cancer cell-induced angiogenesis, as evidenced by reduced endothelial cell proliferation, migration, and tube formation. These findings reveal a previously unrecognized PGK1-IRF1-SAA1 axis that contributes to tumor-driven angiogenesis and suggest PGK1 as a promising therapeutic target in head and neck cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>PGK1 promotes angiogenesis in head and neck cancer through a non-glycolytic mechanism</span>. Jianqiang Yang; Soumya Vijaya Kuma; Fanghui Chen; Nabil F. Saba; <u>Yong Teng</u>. Emory<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Phosphoglycerate kinase 1 (PGK1) is a central enzyme in glycolysis, catalyzing the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP to generate ATP. Beyond its well-established metabolic role, increasing evidence suggests that PGK1 may also participate in non-glycolytic processes; however, the extent to which these non-metabolic functions contribute to cancer initiation and progression remains poorly understood. In this study, we uncover a novel, non-glycolytic function of PGK1 in driving angiogenesis through blocking the secretion of Serum Amyloid A1 (SAA1), an inflammatory mediator implicated in tumor development. Using head and neck squamous cell carcinoma (HNSCC) cell models and RNA sequencing analysis, we identified SAA1 as the most significantly downregulated gene following PGK1 knockdown. Mechanistically, PGK1 knockdown reduces SAA1 expression at the transcriptional level via suppression of the transcription factor interferon regulatory factor 1 (IRF1). This transcriptional downregulation leads to decreased SAA1 secretion, which in turn impairs cancer cell-induced angiogenesis, as evidenced by reduced endothelial cell proliferation, migration, and tube formation. These findings reveal a previously unrecognized PGK1-IRF1-SAA1 axis that contributes to tumor-driven angiogenesis and suggest PGK1 as a promising therapeutic target in head and neck cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 150663--></body></html>"
    },
    {
      "uid": "P439",
      "content_id": "154588",
      "abstract_number": "P439",
      "poster_number": "P439",
      "title": "Pioglitazone/Metformin (MN PioMet): A Phase IIa consortia trial for oral preneoplasia",
      "summary": "We have been able to accrue at our university site for nearly 12 months and more recently at both safety net hospitals. We experienced an 18 month period until we could start the clinical trial accrual phase, which was delayed by almost a year over anticipated. This was a new issue because of the multi-institutional model. We were successful in getting clinical trial infrastructure set up at all four hospitals...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154588",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Frank Ondrey, MD, PhD",
      "presenter": "Frank Ondrey, MD, PhD",
      "authors": "Frank Ondrey, MD, PhD 1 ; Emily Waselchuk, MD 2 ; David Hamlar, MD 2 ; Amy Ann Lassig, MD 3 ; Emiro Caicedo, MD, MS 4 ; Beverly Wuertz 1",
      "normalized_authors": [
        "Frank Ondrey",
        "Emily Waselchuk",
        "David Hamlar",
        "Amy Ann Lassig",
        "Emiro Caicedo",
        "Beverly Wuertz"
      ],
      "affiliations": [
        "Otolaryngology University of Minnesota",
        "HealthPartners, St Paul, MN",
        "Hennepin County Medical Center",
        "VAMC Minneapolis"
      ],
      "normalized_institutions": [
        "Otolaryngology University of Minnesota",
        "HealthPartners, St Paul, MN",
        "Hennepin County Medical Center",
        "VAMC Minneapolis"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 476,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion/Conclusions"
      ],
      "sections": {
        "Authors": "Frank Ondrey, MD, PhD 1 ; Emily Waselchuk, MD 2 ; David Hamlar, MD 2 ; Amy Ann Lassig, MD 3 ; Emiro Caicedo, MD, MS 4 ; Beverly Wuertz 1",
        "Affiliations": "1 Otolaryngology University of Minnesota; 2 HealthPartners, St Paul, MN; 3 Hennepin County Medical Center; 4 VAMC Minneapolis",
        "Background": "There are no effective treatments for oral preneoplasia that reduce cancer risk. We have been performing NCI sponsored oral preneoplasia clinical trials at the University of Minnesota for 20+ years. Since it is traditionally difficult to accrue patients rapidly, we decided to form a regional consortium to improve screening and access for diverse oral preneoplasia patients under many different insurance plans. The consortium was designed to be maximally inclusive of all regional payors.",
        "Methods": "Our practice catchment is minimally 3 Million patients (50% of the state) for head and neck cancer and surveillance. We chose 2 agents of high NCI interest for oral cancer prevention (pioglitazone and Metformin) for this R-01 funded trial. The study is powered for a 50% response rate. With a screening program with approximately 3000 patients undersurveillance we felt this would form the foundation for clinical trial screening. With R 01 clinical trial funding through the National Cancer Institute we were able to construct a consortium and all attendant infrastructure (pathology scanning, genomics, biomarkers, etc.) . The HealthPartners system in Saint Paul, the Regional VA medical system in Minneapolis, and Hennepin County Medical Center safety net hospital in Minneapolis, and the University of Minnesota (Central Institution) form the consortium. Patients with leukoplakia and Dysplasia or hyperplasia (in high risk sites) are eligible.",
        "Results": "We have been able to accrue at our university site for nearly 12 months and more recently at both safety net hospitals. We experienced an 18 month period until we could start the clinical trial accrual phase, which was delayed by almost a year over anticipated. This was a new issue because of the multi-institutional model. We were successful in getting clinical trial infrastructure set up at all four hospitals but await accrual to start at the VAMC. We are anticipating a demographic make up of accrual that matches our states demographics. At our University we have hit 45% of accrual (11/25 subjects) within a year. We are funded for a total of 36 patients, which if met, will establish a RNA sequenome for dysplastic leukoplakia, and all enough specimens to calculate sample sizes for smokers and all principal ethnic groups in our catchment, but socioeconomic data is not collected. We have established all specimen collection and shipping within early detection and resource network clinical trial standards (NCI). To improve efficiency we established monthly meetings to address ongoing barriers. WE have had a 100% completion rate for the first set of subjects.",
        "Discussion/Conclusions": "At the conclusion of this trial we will collect the necessary data to 1) prove efficient efficacy for the trial to proceed as a randomized trial through the NCI or NCI Cooperative groups 2) establish an RNA Sequenom for preneoplasia consistent with Precancer genome atlas guidelines (as per NCI) and 3) provide basic information on all potential gene sets that could be used to stratify risks for future trials."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pioglitazone/Metformin (MN PioMet): A Phase IIa consortia trial for oral preneoplasia</span>. <u>Frank Ondrey, MD, PhD</u><sup>1</sup>; Emily Waselchuk, MD<sup>2</sup>; David Hamlar, MD<sup>2</sup>; Amy Ann Lassig, MD<sup>3</sup>; Emiro Caicedo, MD, MS<sup>4</sup>; Beverly Wuertz<sup>1</sup>. <sup>1</sup>Otolaryngology University of Minnesota; <sup>2</sup>HealthPartners, St Paul, MN; <sup>3</sup>Hennepin County Medical Center; <sup>4</sup>VAMC Minneapolis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>There are no effective treatments for oral preneoplasia that reduce cancer risk. We have been performing NCI sponsored oral preneoplasia clinical trials at the University of Minnesota for 20+ years. Since it is traditionally difficult to accrue patients rapidly, we decided to form a regional consortium to improve screening and access for diverse oral preneoplasia patients under many different insurance plans. The consortium was designed to be maximally inclusive of all regional payors.</p>\n\n<p><strong>Methods:</strong> Our practice catchment is minimally 3 Million patients (50% of the state) for head and neck cancer and surveillance. We chose 2 agents of high NCI interest for oral cancer prevention (pioglitazone and Metformin) for this R-01 funded trial. The study is powered for a 50% response rate. With a screening program with approximately 3000 patients undersurveillance we felt this would form the foundation for clinical trial screening. With R 01 clinical trial funding through the National Cancer Institute we were able to construct a consortium and all attendant infrastructure (pathology scanning, genomics, biomarkers, etc.) . The HealthPartners system in Saint Paul, the Regional VA medical system in Minneapolis, and Hennepin County Medical Center safety net hospital in Minneapolis, and the University of Minnesota (Central Institution) form the consortium. Patients with leukoplakia and Dysplasia or hyperplasia (in high risk sites) are eligible.</p>\n\n<p><strong>Results: </strong>We have been able to accrue at our university site for nearly 12 months and more recently at both safety net hospitals. We experienced an 18 month period until we could start the clinical trial accrual phase, which was delayed by almost a year over anticipated. This was a new issue because of the multi-institutional model. We were successful in getting clinical trial infrastructure set up at all four hospitals but await accrual to start at the VAMC. We are anticipating a demographic make up of accrual that matches our states demographics. At our University we have hit 45% of accrual (11/25 subjects) within a year. We are funded for a total of 36 patients, which if met, will establish a RNA sequenome for dysplastic leukoplakia, and all enough specimens to calculate sample sizes for smokers and all principal ethnic groups in our catchment, but socioeconomic data is not collected. We have established all specimen collection and shipping within early detection and resource network clinical trial standards (NCI). To improve efficiency we established monthly meetings to address ongoing barriers. WE have had a 100% completion rate for the first set of subjects.</p>\n\n<p><strong>Discussion/Conclusions: </strong>At the conclusion of this trial we will collect the necessary data to 1) prove efficient efficacy for the trial to proceed as a randomized trial through the NCI or NCI Cooperative groups 2) establish an RNA Sequenom for preneoplasia consistent with Precancer genome atlas guidelines (as per NCI) and 3) provide basic information on all potential gene sets that could be used to stratify risks for future trials.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154588--></body></html>"
    },
    {
      "uid": "P440",
      "content_id": "154683",
      "abstract_number": "P440",
      "poster_number": "P440",
      "title": "Autophagy-high expression paradoxically predicts poor survival in immune-enriched head and neck squamous cell carcinoma",
      "summary": "Understanding aPD1 ICI resistance is critical to addressing unmet therapeutic needs. Cell-death pathway activity distinguishes prognostic sub populations within TME phenotypes in both HNSCC HPV cohorts, suggesting phenotype-specific vulnerabilities with potential for biomarkers of risk stratification and therapeutic targeting.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154683",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sarah R Harrington, BA",
      "presenter": "Sarah R Harrington, BA",
      "authors": "Sarah R Harrington, BA 1 ; Daniel Uralov, MD 1 ; Hannah Kenny, MD 1 ; Sophia Linguiti, BA 1 ; Parvesh Kumar Jr., BA 1 ; Larry Harshyne, PhD 2 ; Zhao Lin, PhD 2 ; Adam J Luginbuhl, MD 1 ; Ramez Philips, MD 1 ; Ubaldo E Martinez-Outschoorn, MD 2 ; Teresa Alnemri, PhD 3 ; Alban J Linnenbach, PhD 1 ; Joseph M Curry, MD 1",
      "normalized_authors": [
        "Sarah R Harrington",
        "Daniel Uralov",
        "Hannah Kenny",
        "Sophia Linguiti",
        "Parvesh Kumar Jr",
        "Larry Harshyne",
        "Zhao Lin",
        "Adam J Luginbuhl",
        "Ramez Philips",
        "Ubaldo E Martinez-Outschoorn",
        "Teresa Alnemri",
        "Alban J Linnenbach",
        "Joseph M Curry"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA",
        "Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA",
        "Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sarah R Harrington, BA 1 ; Daniel Uralov, MD 1 ; Hannah Kenny, MD 1 ; Sophia Linguiti, BA 1 ; Parvesh Kumar Jr., BA 1 ; Larry Harshyne, PhD 2 ; Zhao Lin, PhD 2 ; Adam J Luginbuhl, MD 1 ; Ramez Philips, MD 1 ; Ubaldo E Martinez-Outschoorn, MD 2 ; Teresa Alnemri, PhD 3 ; Alban J Linnenbach, PhD 1 ; Joseph M Curry, MD 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 2 Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA; 3 Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA",
        "Introduction": "Anti–programmed death (aPD-1) immune checkpoint inhibition (ICI) has resulted in a paradigm shift in the treatment of head and neck squamous cell carcinoma (HNSCC). However, only a fraction of patients respond to single-agent ICI therapy, and the mechanisms of resistance remain poorly understood. Efforts to classify the tumor microenvironment (TME) aim to improve our understanding of both disease biology and variable treatment responses, yet our current knowledge of the considerable tumor heterogeneity influencing therapeutic outcomes remains limited. To gain insights into this heterogeneity, we conducted a study examining cell death–related tumor heterogeneity within established TME phenotypes using HNSCC samples from TCGA.",
        "Methods": "We analyzed RNA-sequencing data from the TCGA HNSCC database (n= 94 HPV- and 415 HPV+). Using established methods (Bagaev et al.), tumors were classified by TME phenotype as depleted (D), fibrotic (F), immune-enriched (IE), or immune-enriched fibrotic (IEF). We performed supervised Gene Set Variation Analysis (GSVA) using curated cell death pathways (n=111) from Molecular Signatures Database. Prognostic associations with overall survival (OS) and progression-free survival (PFS) were evaluated using Cox proportional hazards models and stratified by HPV status, using significantly enriched gene sets. Hazard ratios represent survival differences within each TME phenotype, and only statistically significant associations (p<0.05) are reported.",
        "Results": "HPV+ tumors revealed differential enrichment of cell-death pathways across TME phenotypes for both survival endpoints. For OS, D tumors had 40 protective pathways (HRs: 0.21–0.58), involving apoptosis-, senescence-, and phagocytosis-related themes. F tumors had 5 adverse pathways, with metabolic stress and senescence biology (HRs: 2.9-6.0). IE tumors had 7 protective pathways (HRs: 0.3-0.4), involving apoptosis regulation and mitophagy-related signaling. IEF tumors had no significant OS pathways. For PFS, D tumors demonstrated 38 protective (HRs: 0.3-0.6) and 2 adverse pathways (mean HR=2.0). F tumors had 1 adverse pathway (HR=2.7) and 1 protective pathway (HR=0.4). IE tumors had 6 protective pathways (HRs = 0.15-0.45), reflecting regulated necrosis, intrinsic apoptosis, and mitochondrial maintenance. IEF tumors again showed no significant findings.",
        "Abstract": "In HPV- tumors, OS analyses showed that D tumors had 4 significant pathways (HR range 0.3-4.0), across apoptosis, senescence, and immune-clearance themes. F tumors had 5 adverse pathways linked to autophagy- and metabolic stress (HRs: 2.3–6.3). IE tumors had 20 significant pathways (HR range 0.36-40.0), spanning autophagy, apoptosis, and necrosis themes. IEF tumors had 9 adverse pathways (HR range 3.8-9.1), spanning autophagy- and metabolic-stress themes. For PFS, D tumors had 4 significant pathways (HRs: 0.17-2.45). F tumors had 6 adverse autophagy- and metabolic-stress related pathways (HRs: 3.6–11.1). IE tumors had 6 adverse pathways showing multiple autophagy-, apoptosis-, and necrosis-related themes (HRs: 3.3- 30.4). IEF tumors revealed 1 adverse, autophagy-associated pathway (HR= 9.4).",
        "Conclusions": "Understanding aPD1 ICI resistance is critical to addressing unmet therapeutic needs. Cell-death pathway activity distinguishes prognostic sub populations within TME phenotypes in both HNSCC HPV cohorts, suggesting phenotype-specific vulnerabilities with potential for biomarkers of risk stratification and therapeutic targeting."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Autophagy-high expression paradoxically predicts poor survival in immune-enriched head and neck squamous cell carcinoma</span>. <u>Sarah R Harrington, BA</u><sup>1</sup>; Daniel Uralov, MD<sup>1</sup>; Hannah Kenny, MD<sup>1</sup>; Sophia  Linguiti, BA<sup>1</sup>; Parvesh  Kumar Jr., BA<sup>1</sup>; Larry Harshyne, PhD<sup>2</sup>; Zhao Lin, PhD<sup>2</sup>; Adam J Luginbuhl, MD<sup>1</sup>; Ramez Philips, MD<sup>1</sup>; Ubaldo E Martinez-Outschoorn, MD<sup>2</sup>; Teresa Alnemri, PhD<sup>3</sup>; Alban J Linnenbach, PhD<sup>1</sup>; Joseph M Curry, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; <sup>2</sup>Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA; <sup>3</sup>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Anti–programmed death (aPD-1) immune checkpoint inhibition (ICI) has resulted in a paradigm shift in the treatment of head and neck squamous cell carcinoma (HNSCC). However, only a fraction of patients respond to single-agent ICI therapy, and the mechanisms of resistance remain poorly understood. Efforts to classify the tumor microenvironment (TME) aim to improve our understanding of both disease biology and variable treatment responses, yet our current knowledge of the considerable tumor heterogeneity influencing therapeutic outcomes remains limited. To gain insights into this heterogeneity, we conducted a study examining cell death–related tumor heterogeneity within established TME phenotypes using HNSCC samples from TCGA.</p>\n\n<p><strong>Methods: </strong>We analyzed RNA-sequencing data from the TCGA HNSCC database (n= 94 HPV- and 415 HPV+). Using established methods (Bagaev et al.), tumors were classified by TME phenotype as depleted (D), fibrotic (F), immune-enriched (IE), or immune-enriched fibrotic (IEF). We performed supervised Gene Set Variation Analysis (GSVA) using curated cell death pathways (n=111) from Molecular Signatures Database. Prognostic associations with overall survival (OS) and progression-free survival (PFS) were evaluated using Cox proportional hazards models and stratified by HPV status, using significantly enriched gene sets. Hazard ratios represent survival differences within each TME phenotype, and only statistically significant associations (p<0.05) are reported.</p>\n\n<p><strong>Results: </strong>HPV+ tumors revealed differential enrichment of cell-death pathways across TME phenotypes for both survival endpoints. For OS, D tumors had 40 protective pathways (HRs: 0.21–0.58), involving apoptosis-, senescence-, and phagocytosis-related themes. F tumors had 5 adverse pathways, with metabolic stress and senescence biology (HRs: 2.9-6.0). IE tumors had 7 protective pathways (HRs: 0.3-0.4), involving apoptosis regulation and mitophagy-related signaling. IEF tumors had no significant OS pathways. For PFS, D tumors demonstrated 38 protective (HRs: 0.3-0.6) and 2 adverse pathways (mean HR=2.0). F tumors had 1 adverse pathway (HR=2.7) and 1 protective pathway (HR=0.4). IE tumors had 6 protective pathways (HRs = 0.15-0.45), reflecting regulated necrosis, intrinsic apoptosis, and mitochondrial maintenance. IEF tumors again showed no significant findings.</p>\n\n<p>In HPV- tumors, OS analyses showed that D tumors had 4 significant pathways (HR range 0.3-4.0), across apoptosis, senescence, and immune-clearance themes. F tumors had 5 adverse pathways linked to autophagy- and metabolic stress (HRs: 2.3–6.3). IE tumors had 20 significant pathways (HR range 0.36-40.0), spanning autophagy, apoptosis, and necrosis themes. IEF tumors had 9 adverse pathways (HR range 3.8-9.1), spanning autophagy- and metabolic-stress themes. For PFS, D tumors had 4 significant pathways (HRs: 0.17-2.45). F tumors had 6 adverse autophagy- and metabolic-stress related pathways (HRs: 3.6–11.1). IE tumors had 6 adverse pathways showing multiple autophagy-, apoptosis-, and necrosis-related themes (HRs: 3.3- 30.4). IEF tumors revealed 1 adverse, autophagy-associated pathway (HR= 9.4).</p>\n\n<p><strong>Conclusions: </strong>Understanding aPD1 ICI resistance is critical to addressing unmet therapeutic needs. Cell-death pathway activity distinguishes prognostic sub populations within TME phenotypes in both HNSCC HPV cohorts, suggesting phenotype-specific vulnerabilities with potential for biomarkers of risk stratification and therapeutic targeting.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154683--></body></html>"
    },
    {
      "uid": "P441",
      "content_id": "154628",
      "abstract_number": "P441",
      "poster_number": "P441",
      "title": "Clinical and socioeconomic factors associated with allostatic load in head and neck cancer patients",
      "summary": "Living in areas with greater socioeconomic deprivation, being of male sex, and having no history of alcohol use are independently associated with higher cumulative physiologic stress in HNC patients. Future research and interventions should focus on improving psychosocial support and promoting stress management for male HNC patients and those living in lower resourced areas.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154628",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katie M Carlson, MPH",
      "presenter": "Katie M Carlson, MPH",
      "authors": "Nana-Hawwa Abdul-Rahman, MS 1 ; Katie M Carlson, MPH 1 ; Maryanna S Owoc, MD, PhD 1 ; Marci Lee Nilsen, PhD, RN, CHPN 1 ; Yvonne M Mowery, MD, PhD 2 ; Nicole Scheff, PhD 2 ; Jose P Zevallos, MD, MPH 1 ; Angela L Mazul, PhD, MPH 1",
      "normalized_authors": [
        "Nana-Hawwa Abdul-Rahman",
        "Katie M Carlson",
        "Maryanna S Owoc",
        "Marci Lee Nilsen, CHPN",
        "Yvonne M Mowery",
        "Nicole Scheff",
        "Jose P Zevallos",
        "Angela L Mazul"
      ],
      "affiliations": [
        "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery",
        "UPMC Hillman Cancer Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery",
        "UPMC Hillman Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154628/ADI%20violin%20plot(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154628/ADI%20violin%20plot(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154628"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154628/ADI%20AL%20map.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154628/ADI%20AL%20map.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154628"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Figure 1.",
        "Figure 2."
      ],
      "sections": {
        "Authors": "Nana-Hawwa Abdul-Rahman, MS 1 ; Katie M Carlson, MPH 1 ; Maryanna S Owoc, MD, PhD 1 ; Marci Lee Nilsen, PhD, RN, CHPN 1 ; Yvonne M Mowery, MD, PhD 2 ; Nicole Scheff, PhD 2 ; Jose P Zevallos, MD, MPH 1 ; Angela L Mazul, PhD, MPH 1",
        "Affiliations": "1 University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery; 2 UPMC Hillman Cancer Center",
        "Background": "Allostasis is the bidirectional regulatory feedback pathway in response to stress. Dysregulation of this process, termed allostatic load (AL), is linked to socioenvironmental stressors, psychiatric disorders, and worse survival outcomes in both cancer and non-cancer populations. The Area Deprivation Index (ADI) is a validated measure of neighborhood socioeconomic deprivation, and higher ADI values have been associated with poor outcomes in cancer patients. However, the relationship between ADI and AL is unknown. This study investigated the associations between clinical and socioeconomic factors, including ADI, and AL in a cohort of head and neck cancer (HNC) patients.",
        "Methods": "Our study included 1,038 patients with HNC who underwent definitive surgery at our institution from May 2014 to December 2024. Patient addresses were geocoded and matched to corresponding ADI national percentile scores. AL composite scores were calculated using values for nine biomarkers that were measured within one month prior to surgery. Points were assigned for values ≥75th percentile for systolic and diastolic blood pressure, pulse, albumin, alkaline phosphatase, body mass index, creatinine, blood urea nitrogen, and white blood cell count and ≤25th percentile for albumin. Clinical and sociodemographic covariates were age at diagnosis, race, sex, smoking status, alcohol use, pathologic T and N stages, and primary cancer site. The median ADI values for each AL quartile were compared using Kruskal-Wallis and Dunn’s test. Linear regression was used to investigate factors associated with AL.",
        "Results": "Among 1038 HNC patients (78.0% male, 92.1% White), the median ADI was 72 (IQR: 55 - 86) and the median AL was 2 (IQR: 1 - 3). The median ADI values differed significantly for the lowest and highest AL quartiles (70 vs. 74, respectively; p=0.01). Univariate linear regression revealed that for every 10-unit increase in the national ADI value, the AL value increased by 0.084 (p<0.001). On multivariable linear regression, male sex (ß= 0.4, p<0.001), no history of alcohol use (ß= 0.29, p= 0.015), and higher ADI (ß= 0.096, p<0.001) were independently associated with higher AL.",
        "Conclusion": "Living in areas with greater socioeconomic deprivation, being of male sex, and having no history of alcohol use are independently associated with higher cumulative physiologic stress in HNC patients. Future research and interventions should focus on improving psychosocial support and promoting stress management for male HNC patients and those living in lower resourced areas.",
        "Figure 1.": "Violin plot comparing area deprivation index values by allostatic load quartiles.",
        "Figure 2.": "Map of patient residences denoted by dots, with darker shading representing higher allostatic load, and ADI rankings by census tract, with darker shading corresponding to greater socioeconomic deprivation."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and socioeconomic factors associated with allostatic load in head and neck cancer patients</span>. Nana-Hawwa Abdul-Rahman, MS<sup>1</sup>; <u>Katie M Carlson, MPH</u><sup>1</sup>; Maryanna S Owoc, MD, PhD<sup>1</sup>; Marci Lee Nilsen, PhD, RN, CHPN<sup>1</sup>; Yvonne M Mowery, MD, PhD<sup>2</sup>; Nicole Scheff, PhD<sup>2</sup>; Jose P Zevallos, MD, MPH<sup>1</sup>; Angela L Mazul, PhD, MPH<sup>1</sup>. <sup>1</sup>University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery; <sup>2</sup>UPMC Hillman Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Allostasis is the bidirectional regulatory feedback pathway in response to stress. Dysregulation of this process, termed allostatic load (AL), is linked to socioenvironmental stressors, psychiatric disorders, and worse survival outcomes in both cancer and non-cancer populations. The Area Deprivation Index (ADI) is a validated measure of neighborhood socioeconomic deprivation, and higher ADI values have been associated with poor outcomes in cancer patients. However, the relationship between ADI and AL is unknown. This study investigated the associations between clinical and socioeconomic factors, including ADI, and AL in a cohort of head and neck cancer (HNC) patients.</p>\n\n<p><strong>Methods: </strong>Our study included 1,038 patients with HNC who underwent definitive surgery at our institution from May 2014 to December 2024. Patient addresses were geocoded and matched to corresponding ADI national percentile scores. AL composite scores were calculated using values for nine biomarkers that were measured within one month prior to surgery. Points were assigned for values ≥75th percentile for systolic and diastolic blood pressure, pulse, albumin, alkaline phosphatase, body mass index, creatinine, blood urea nitrogen, and white blood cell count and ≤25th percentile for albumin. Clinical and sociodemographic covariates were age at diagnosis, race, sex, smoking status, alcohol use, pathologic T and N stages, and primary cancer site. The median ADI values for each AL quartile were compared using Kruskal-Wallis and Dunn’s test. Linear regression was used to investigate factors associated with AL.</p>\n\n<p><strong>Results: </strong>Among 1038 HNC patients (78.0% male, 92.1% White), the median ADI was 72 (IQR: 55 - 86) and the median AL was 2 (IQR: 1 - 3). The median ADI values differed significantly for the lowest and highest AL quartiles (70 vs. 74, respectively; p=0.01). Univariate linear regression revealed that for every 10-unit increase in the national ADI value, the AL value increased by 0.084 (p<0.001). On multivariable linear regression, male sex (ß= 0.4, p<0.001), no history of alcohol use (ß= 0.29, p= 0.015), and higher ADI (ß= 0.096, p<0.001) were independently associated with higher AL.</p>\n\n<p><strong>Conclusion: </strong>Living in areas with greater socioeconomic deprivation, being of male sex, and having no history of alcohol use are independently associated with higher cumulative physiologic stress in HNC patients. Future research and interventions should focus on improving psychosocial support and promoting stress management for male HNC patients and those living in lower resourced areas.</p>\n\n<p><strong>Figure 1.</strong> Violin plot comparing area deprivation index values by allostatic load quartiles.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154628/ADI%20violin%20plot(1).png' /></p>\n\n<p><strong>Figure 2.</strong> Map of patient residences denoted by dots, with darker shading representing higher allostatic load, and ADI rankings by census tract, with darker shading corresponding to greater socioeconomic deprivation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154628/ADI%20AL%20map.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154628--></body></html>"
    },
    {
      "uid": "P442",
      "content_id": "153931",
      "abstract_number": "P442",
      "poster_number": "P442",
      "title": "The Association of Systemic Inflammation and Tumor Microenvironment Inflammatory Expression, Distant Metastases Development and Prognosis",
      "summary": "A high SII can predict which patients are at risk for worse overall survival. We will be analyzing the association with distant metastases, locoregional recurrence and the local tumor immune landscape to further elucidate the mechanism by which global immune dysregulation impacts head and neck cancer outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153931",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Danielle Tomer",
      "presenter": "Danielle Tomer",
      "authors": "Danielle Tomer 1 ; Justina Shafik 2 ; Thomas J Ow 3 ; James R Barnett 2 ; Han Yu 4 ; Michael B Prystowsky 2 ; Richard V Smith 2 ; Bradley A Schiff 2 ; Gregory Rosenblatt 1 ; Nicolas F Schlecht 4 ; Vikas Mehta 2",
      "normalized_authors": [
        "Danielle Tomer",
        "Justina Shafik",
        "Thomas J Ow",
        "James R Barnett",
        "Han Yu",
        "Michael B Prystowsky",
        "Richard V Smith",
        "Bradley A Schiff",
        "Gregory Rosenblatt",
        "Nicolas F Schlecht",
        "Vikas Mehta"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine",
        "Montefiore Medical Center",
        "Memorial Sloan Kettering Cancer Center",
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine",
        "Montefiore Medical Center",
        "Memorial Sloan Kettering Cancer Center",
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153931/Figure%201(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153931/Figure%201(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153931"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1"
      ],
      "sections": {
        "Authors": "Danielle Tomer 1 ; Justina Shafik 2 ; Thomas J Ow 3 ; James R Barnett 2 ; Han Yu 4 ; Michael B Prystowsky 2 ; Richard V Smith 2 ; Bradley A Schiff 2 ; Gregory Rosenblatt 1 ; Nicolas F Schlecht 4 ; Vikas Mehta 2",
        "Affiliations": "1 Albert Einstein College of Medicine; 2 Montefiore Medical Center; 3 Memorial Sloan Kettering Cancer Center; 4 Roswell Park Comprehensive Cancer Center",
        "Background": "Despite advances in cancer therapy, patients with metastatic head and neck malignancies have poor survival and prognosis. In addition, cancer patients with immune dysregulation often have poor responses to therapies and worse outcomes. Systemic immune-inflammation index (SII) is a metric using neutrophil, lymphocyte, and platelet counts to reflect the body’s overall level of inflammation. While the prognostication of SII with survival is well established, our objective was to analyze the association of a pre-treatment SII with the development and timing of distant metastases in patients with head and neck squamous cell carcinoma (HNSCC), as well as assess the correlation of SII with the tumor immune microenvironment.",
        "Methods": "This is a retrospective cohort study of patients treated for HNSCC at Montefiore Medical Center from 2003 to 2022. Patient demographics, clinical characteristics, and tumor and treatment variables were summarized. SII scores were calculated from complete blood count lab values, using the following formula: (Neutrophils x Platelets) / Lymphocytes. Median SII was used as a cut-off value between high and low SII groups. Univariate and multivariate analyses were used to evaluate the associations between variables of interest and survival outcomes, and association with tumor immune microenvironment gene expression.",
        "Results": "Among our cohort of 297 patients, the median age was 62 (interquartile range 55 – 68) and subjects were predominantly male (72%). Our population was diverse, with 32% of the cohort identifying as African American and 35% identifying as Hispanic. Most patients reported smoking in the past (82%), with a smaller subset reporting current smoking (4.5%). Non-Hispanic patients had better overall survival compared to Hispanic patients (HR=0.66, 95% CI: 0.45-0.96), and HIV positive patients had worse survival (HR=2.28, 95% CI: 1.20-4.34). Higher SII at time of diagnosis was associated with poorer overall survival with the risk of death increasing 22% with each doubling of SII score (HR=1.22, 95% CI: 1.03-1.44 for each log2 increase). When stratified by median SII score, patients in the lower SII group had significantly better survival outcomes than those who were in the high SII group in the multivariable analysis (HR=0.62, 95% CI: 0.45-0.84). Additionally, we are assessing the cohort for the association of SII with distant metastases and specific immune markers in the tumor microenvironment that have shown prognostic potential in previous studies with the TCGA and our institutional cohorts.",
        "Conclusions": "A high SII can predict which patients are at risk for worse overall survival. We will be analyzing the association with distant metastases, locoregional recurrence and the local tumor immune landscape to further elucidate the mechanism by which global immune dysregulation impacts head and neck cancer outcomes.",
        "Figure 1": "Survival of head and neck cancer patients by inflammatory status"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Association of Systemic Inflammation and Tumor Microenvironment Inflammatory Expression, Distant Metastases Development and Prognosis</span>. <u>Danielle Tomer</u><sup>1</sup>; Justina Shafik<sup>2</sup>; Thomas J Ow<sup>3</sup>; James R Barnett<sup>2</sup>; Han Yu<sup>4</sup>; Michael B Prystowsky<sup>2</sup>; Richard V Smith<sup>2</sup>; Bradley A Schiff<sup>2</sup>; Gregory Rosenblatt<sup>1</sup>; Nicolas F Schlecht<sup>4</sup>; Vikas Mehta<sup>2</sup>. <sup>1</sup>Albert Einstein College of Medicine; <sup>2</sup>Montefiore Medical Center; <sup>3</sup>Memorial Sloan Kettering Cancer Center; <sup>4</sup>Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Despite advances in cancer therapy, patients with metastatic head and neck malignancies have poor survival and prognosis. In addition, cancer patients with immune dysregulation often have poor responses to therapies and worse outcomes. Systemic immune-inflammation index (SII) is a metric using neutrophil, lymphocyte, and platelet counts to reflect the body’s overall level of inflammation. While the prognostication of SII with survival is well established, our objective was to analyze the association of a pre-treatment SII with the development and timing of distant metastases in patients with head and neck squamous cell carcinoma (HNSCC), as well as assess the correlation of SII with the tumor immune microenvironment.</p>\n\n<p><strong>Methods:</strong> This is a retrospective cohort study of patients treated for HNSCC at Montefiore Medical Center from 2003 to 2022. Patient demographics, clinical characteristics, and tumor and treatment variables were summarized. SII scores were calculated from complete blood count lab values, using the following formula: (Neutrophils x Platelets) / Lymphocytes. Median SII was used as a cut-off value between high and low SII groups. Univariate and multivariate analyses were used to evaluate the associations between variables of interest and survival outcomes, and association with tumor immune microenvironment gene expression.</p>\n\n<p><strong>Results:</strong> Among our cohort of 297 patients, the median age was 62 (interquartile range 55 – 68) and subjects were predominantly male (72%). Our population was diverse, with 32% of the cohort identifying as African American and 35% identifying as Hispanic. Most patients reported smoking in the past (82%), with a smaller subset reporting current smoking (4.5%). Non-Hispanic patients had better overall survival compared to Hispanic patients (HR=0.66, 95% CI: 0.45-0.96), and HIV positive patients had worse survival (HR=2.28, 95% CI: 1.20-4.34). Higher SII at time of diagnosis was associated with poorer overall survival with the risk of death increasing 22% with each doubling of SII score (HR=1.22, 95% CI: 1.03-1.44 for each log2 increase). When stratified by median SII score, patients in the lower SII group had significantly better survival outcomes than those who were in the high SII group in the multivariable analysis (HR=0.62, 95% CI: 0.45-0.84). Additionally, we are assessing the cohort for the association of SII with distant metastases and specific immune markers in the tumor microenvironment that have shown prognostic potential in previous studies with the TCGA and our institutional cohorts.</p>\n\n<p><strong>Conclusions: </strong>A high SII can predict which patients are at risk for worse overall survival. We will be analyzing the association with distant metastases, locoregional recurrence and the local tumor immune landscape to further elucidate the mechanism by which global immune dysregulation impacts head and neck cancer outcomes. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153931/Figure%201(1).png' /></p>\n\n<p><strong>Figure 1:</strong> Survival of head and neck cancer patients by inflammatory status</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153931--></body></html>"
    },
    {
      "uid": "P443",
      "content_id": "154682",
      "abstract_number": "P443",
      "poster_number": "P443",
      "title": "CO-CULTURE OF MESENCHYMAL STEM CELLS AND ENDOTHELIAL PROGENITOR CELLS TO ENHANCE VASCULARIZATION OF 3D SCAFFOLDS FOR BONE TISSUE ENGINEERING: AN IN VIVO STUDY USING A RABBIT MODEL OF CRITICAL SIZ",
      "summary": "Insufficient vascularization of bioengineered scaffolds is a well-known limiting factor hindering the clinical translation of bone tissue–engineering strategies for the repair of large bone defects. Large 3D scaffolds often exhibit poor cellular viability, particularly at the core, due to inadequate exchange of nutrients and oxygen, ultimately leading to central necrosis and graft failure. Several approaches have...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154682",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Antonino Cassara",
      "presenter": "Antonino Cassara",
      "authors": "Antonino Cassara 1 ; Harley Chan 1 ; Giulio Badin 1 ; Alessandra Ruaro 2 ; Stefano Taboni 2 ; Chiara Pasini 3 ; Luciana Sartore 3 ; Marco Ferrari 2 ; Ralph W. Gilbert 4 ; Jonathan C. Irish 4",
      "normalized_authors": [
        "Antonino Cassara",
        "Harley Chan",
        "Giulio Badin",
        "Alessandra Ruaro",
        "Stefano Taboni",
        "Chiara Pasini",
        "Luciana Sartore",
        "Marco Ferrari",
        "Ralph W. Gilbert",
        "Jonathan C. Irish"
      ],
      "affiliations": [
        "Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada",
        "Unit of Otorhinolaryngology-Head and Neck Surgery, Azienda Ospedale-Università di Padova, Padova, Italy",
        "Department of Mechanical and Industrial Engineering, University of Brescia Via Branze, Brescia, Italy",
        "Princess Margaret Cancer Centre, Toronto General Hospital, Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, University Health Network, Toronto, ON, Canada"
      ],
      "normalized_institutions": [
        "Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada",
        "Unit of Otorhinolaryngology-Head and Neck Surgery, Azienda Ospedale-Università di Padova, Padova, Italy",
        "Department of Mechanical and Industrial Engineering, University of Brescia Via Branze, Brescia, Italy",
        "Princess Margaret Cancer Centre, Toronto General Hospital, Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, University Health Network, Toronto, ON, Canada"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154682/Schermata%202025-12-05%20alle%2022_48_49.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154682/Schermata%202025-12-05%20alle%2022_48_49.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154682"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154682/30%20w1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154682/30%20w1.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154682"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 406,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Antonino Cassara 1 ; Harley Chan 1 ; Giulio Badin 1 ; Alessandra Ruaro 2 ; Stefano Taboni 2 ; Chiara Pasini 3 ; Luciana Sartore 3 ; Marco Ferrari 2 ; Ralph W. Gilbert 4 ; Jonathan C. Irish 4",
        "Affiliations": "1 Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada; 2 Unit of Otorhinolaryngology-Head and Neck Surgery, Azienda Ospedale-Università di Padova, Padova, Italy; 3 Department of Mechanical and Industrial Engineering, University of Brescia Via Branze, Brescia, Italy; 4 Princess Margaret Cancer Centre, Toronto General Hospital, Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, University Health Network, Toronto, ON, Canada",
        "BACKGROUND": "Insufficient vascularization of bioengineered scaffolds is a well-known limiting factor hindering the clinical translation of bone tissue–engineering strategies for the repair of large bone defects. Large 3D scaffolds often exhibit poor cellular viability, particularly at the core, due to inadequate exchange of nutrients and oxygen, ultimately leading to central necrosis and graft failure. Several approaches have been investigated to enhance neovascularization within tissue-engineered constructs. Among these, co-culturing mesenchymal stem cells (MSCs) with a “vascular stem cell” population, i.e. endothelial progenitor cells (EPCs), appears to be a promising strategy. In the present study, we evaluated in vivo the performance of a bioengineered PLA–hydrogel core–shell scaffold for the reconstruction of a critical-size bone defect in a rabbit model of marginal mandibulectomy. We investigated whether co-culturing MSCs and EPCs could improve scaffold vascularization and subsequently enhance new bone formation.",
        "METHODS": "A unilateral 10 × 5 × 5 mm critical-size defect was created at the inferior border of the mandible in adult New Zealand White rabbits. Defects were reconstructed using 3D-printed polylactic acid (PLA)–hydrogel core–shell scaffolds seeded with different combinations of stem cells. A total of 20 rabbits have been used for this study and divided into 5 groups, including controls: non-reconstructed (n = 3), unseeded scaffold (n = 3), scaffold seeded with human bone marrow MSCs (hMSCs) (n = 5), scaffold seeded with rabbit bone marrow MSCs (rMSCs) (n = 5), scaffold seeded with rMSCs and peripheral blood-derived EPCs (rMSCs + rEPCs) (n = 4). Animals were monitored for 16 weeks post-operatively. The primary endpoint was new bone formation at the defect site, assessed by serial CT scans and by histological analysis.",
        "RESULTS": "All animals survived surgery and recovered within a few days, with no complications observed. Preliminary results showed a discrete amount of new bone formation at the edge of the defect, but very poor regeneration at the core. The amount of total new bone formation in the monoculture groups (hMSC-seeded or rMSC-seeded scaffolds) was significantly higher than in the control groups (non-reconstructed and unseeded scaffold). Data from the co-culture group (rMSCs + rEPCs) are still being collected; however, early findings indicate promising performance.",
        "CONCLUSION": "This study demonstrates a feasible and promising strategy for reconstructing critical-size bone defects. Additional data are required to determine whether the MSC–EPC co-culture system outperforms MSC monocultures, in term of new bone formation at the core of the defect. These findings lay the groundwork for future advancements in the field of bone tissue engineering, angiogenesis, and regenerative medicine."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>CO-CULTURE OF MESENCHYMAL STEM CELLS AND ENDOTHELIAL PROGENITOR CELLS TO ENHANCE VASCULARIZATION OF 3D SCAFFOLDS FOR BONE TISSUE ENGINEERING: AN IN VIVO STUDY USING A RABBIT MODEL OF CRITICAL SIZE MANDIBULAR DEFECT</span>. <u>Antonino Cassara</u><sup>1</sup>; Harley Chan<sup>1</sup>; Giulio Badin<sup>1</sup>; Alessandra Ruaro<sup>2</sup>; Stefano Taboni<sup>2</sup>; Chiara Pasini<sup>3</sup>; Luciana Sartore<sup>3</sup>; Marco Ferrari<sup>2</sup>; Ralph W. Gilbert<sup>4</sup>; Jonathan C. Irish<sup>4</sup>. <sup>1</sup>Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada; <sup>2</sup>Unit of Otorhinolaryngology-Head and Neck Surgery, Azienda Ospedale-Università di Padova, Padova, Italy; <sup>3</sup>Department of Mechanical and Industrial Engineering, University of Brescia Via Branze, Brescia, Italy; <sup>4</sup>Princess Margaret Cancer Centre, Toronto General Hospital, Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, University Health Network, Toronto, ON, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> Insufficient vascularization of bioengineered scaffolds is a well-known limiting factor hindering the clinical translation of bone tissue–engineering strategies for the repair of large bone defects. Large 3D scaffolds often exhibit poor cellular viability, particularly at the core, due to inadequate exchange of nutrients and oxygen, ultimately leading to central necrosis and graft failure. Several approaches have been investigated to enhance neovascularization within tissue-engineered constructs. Among these, co-culturing mesenchymal stem cells (MSCs) with a “vascular stem cell” population, i.e. endothelial progenitor cells (EPCs), appears to be a promising strategy. In the present study, we evaluated<em> in vivo</em> the performance of a bioengineered PLA–hydrogel core–shell scaffold for the reconstruction of a critical-size bone defect in a rabbit model of marginal mandibulectomy. We investigated whether co-culturing MSCs and EPCs could improve scaffold vascularization and subsequently enhance new bone formation.</p>\n\n<p><strong>METHODS:</strong> A unilateral 10 × 5 × 5 mm critical-size defect was created at the inferior border of the mandible in adult New Zealand White rabbits. Defects were reconstructed using 3D-printed polylactic acid (PLA)–hydrogel core–shell scaffolds seeded with different combinations of stem cells. A total of 20 rabbits have been used for this study and divided into 5 groups, including controls: non-reconstructed (n = 3), unseeded scaffold (n = 3), scaffold seeded with human bone marrow MSCs (hMSCs) (n = 5), scaffold seeded with rabbit bone marrow MSCs (rMSCs) (n = 5), scaffold seeded with rMSCs and peripheral blood-derived EPCs (rMSCs + rEPCs) (n = 4). Animals were monitored for 16 weeks post-operatively. The primary endpoint was new bone formation at the defect site, assessed by serial CT scans and by histological analysis.</p>\n\n<p><strong>RESULTS: </strong>All animals survived surgery and recovered within a few days, with no complications observed. Preliminary results showed a discrete amount of new bone formation at the edge of the defect, but very poor regeneration at the core. The amount of total new bone formation in the monoculture groups (hMSC-seeded or rMSC-seeded scaffolds) was significantly higher than in the control groups (non-reconstructed and unseeded scaffold). Data from the co-culture group (rMSCs + rEPCs) are still being collected; however, early findings indicate promising performance.</p>\n\n<p><strong>CONCLUSION: </strong>This study demonstrates a feasible and promising strategy for reconstructing critical-size bone defects. Additional data are required to determine whether the MSC–EPC co-culture system outperforms MSC monocultures, in term of new bone formation at the core of the defect. These findings lay the groundwork for future advancements in the field of bone tissue engineering, angiogenesis, and regenerative medicine.</p>\n\n<p><strong>Fig. 1. Example of a rabbit belonging to the rMSCs group at week 12</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154682/Schermata%202025-12-05%20alle%2022_48_49.png' /></p>\n\n<p> </p>\n\n<p><strong>Fig. 2. Example of the same rabbit at week 1<img alt='' src='https://www.submitmyabstract.com/abs/images/154682/30%20w1.png' /></strong></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154682--></body></html>"
    },
    {
      "uid": "P444",
      "content_id": "154064",
      "abstract_number": "P444",
      "poster_number": "P444",
      "title": "Brown adipose gene signature defines distinct tumor microenvironment in HNSCC",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) has been extensively studied for its rich tumor microenvironment (TME) in search of better targeted therapies and prognostic indicators. Although several r metabolic signature. As a specialized adipose tissue, it is dense in mitochondrial content for mediating the process of thermogenesis. Although studies are limited, BAT has been proposed as a driver of cachexia in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154064",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Harmony I Saunders, PhD",
      "presenter": "Harmony I Saunders, PhD",
      "authors": "Harmony I Saunders, PhD ; Andrés M Bur, MD",
      "normalized_authors": [
        "Harmony I Saunders",
        "Andrés M Bur"
      ],
      "affiliations": [
        "University of Kansas Medical Center"
      ],
      "normalized_institutions": [
        "University of Kansas Medical Center"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 428,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Research Goal",
        "Methods",
        "Expected Outcomes and results",
        "Impact"
      ],
      "sections": {
        "Authors": "Harmony I Saunders, PhD ; Andrés M Bur, MD",
        "Affiliations": "University of Kansas Medical Center",
        "Research Goal": "Head and neck squamous cell carcinoma (HNSCC) has been extensively studied for its rich tumor microenvironment (TME) in search of better targeted therapies and prognostic indicators. Although several r metabolic signature. As a specialized adipose tissue, it is dense in mitochondrial content for mediating the process of thermogenesis. Although studies are limited, BAT has been proposed as a driver of cachexia in other tumor types. Located in the neck and supraclavicular region, BAT may play a role in HNSCC progression or microenvironment. In this study we use publicly available data to generate a BAT gene score and applied it to HNSCC data sets to investigate the impact of BAT in HNSCC.",
        "Methods": "To date, there is no gene signature to define active BAT, however, a proposed set of 61 genes were previously generated through analysis of human sequencing associated with a well-established marker Uncoupling Protein 1 (UCP1). We tested this proposed list as a viable starting point to establish a “BAT score” using The Cancer Genome Atlas (TCGA) HNSCC sequencing data which contains 528 patient samples and clinical data. Using R studio, the gene list was optimized for principal component analysis (PCA) on pheochromocytoma TCGA data, a tumor type with biologically active BAT. Scree analysis was ran on the PCA BAT score, and the generated BAT score was then applied to HNSCC sequencing data. ESTIMATE analysis was performed to assess for any tumor microenvironment trends. MCP Counter Tool was used to analyze proposed immune cell content based on BAT score. BAT score was analyzed across samples for any correlation with clinical metrics. BAThi and BATlo were generated by assessing the range of BAT scores, then assigning BAThi as 75th percentile and above, and BATlo as 25th percentile and below. Groups were compared using paired T test and Wilcoxon signed-ranked test.",
        "Expected Outcomes and results": "We expected HNSCC BAT score to impact the molecular profile of HNSCC tumors and therefore influence clinical outcomes such as tumor stage, nodal status, tumor site, overall survival, or progression free survival. We found that there was no-significant difference in tumor stage, nodal status, tumor site, OS, PFS, however, patients with perineural invasion had a significantly higher BAT score in HPV- HNSCC (p=0.047). Additionally, the tumor microenvironment of BAThi versus BATlo tumors was significantly different with marked reduction in immune cell gene score and in HPV+ an increased stromal TME.",
        "Impact": "Defining a new molecular signature that separates HNSCC patients’ immune environment may guide therapeutic recommendations. The novel BAT score generated in this study could be applied to other cancer types for future investigation of BAT in cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Brown adipose gene signature defines distinct tumor microenvironment in HNSCC</span>. <u>Harmony I Saunders, PhD</u>; Andrés M Bur, MD. University of Kansas Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Research Goal:</strong> Head and neck squamous cell carcinoma (HNSCC) has been extensively studied for its rich tumor microenvironment (TME) in search of better targeted therapies and prognostic indicators. Although several r metabolic signature. As a specialized adipose tissue, it is dense in mitochondrial content for mediating the process of thermogenesis. Although studies are limited, BAT has been proposed as a driver of cachexia in other tumor types. Located in the neck and supraclavicular region, BAT may play a role in HNSCC progression or microenvironment. In this study we use publicly available data to generate a BAT gene score and applied it to HNSCC data sets to investigate the impact of BAT in HNSCC.  </p>\n\n<p><strong>Methods:</strong> To date, there is no gene signature to define active BAT, however, a proposed set of 61 genes were previously generated through analysis of human sequencing associated with a well-established marker Uncoupling Protein 1 (UCP1). We tested this proposed list as a viable starting point to establish a “BAT score” using The Cancer Genome Atlas (TCGA) HNSCC sequencing data which contains 528 patient samples and clinical data. Using R studio, the gene list was optimized for principal component analysis (PCA) on pheochromocytoma TCGA data, a tumor type with biologically active BAT. Scree analysis was ran on the PCA BAT score, and the generated BAT score was then applied to HNSCC sequencing data. ESTIMATE analysis was performed to assess for any tumor microenvironment trends. MCP Counter Tool was used to analyze proposed immune cell content based on BAT score. BAT score was analyzed across samples for any correlation with clinical metrics. BAThi and BATlo were generated by assessing the range of BAT scores, then assigning BAThi as 75th percentile and above, and BATlo as 25th percentile and below. Groups were compared using paired T test and Wilcoxon signed-ranked test.  </p>\n\n<p><strong>Expected Outcomes and results:</strong> We expected HNSCC BAT score to impact the molecular profile of HNSCC tumors and therefore influence clinical outcomes such as tumor stage, nodal status, tumor site, overall survival, or progression free survival. We found that there was no-significant difference in tumor stage, nodal status, tumor site, OS, PFS, however, patients with perineural invasion had a significantly higher BAT score in HPV- HNSCC (p=0.047). Additionally, the tumor microenvironment of BAThi versus BATlo tumors was significantly different with marked reduction in immune cell gene score and in HPV+ an increased stromal TME.  </p>\n\n<p><strong>Impact: </strong>Defining a new molecular signature that separates HNSCC patients’ immune environment may guide therapeutic recommendations. The novel BAT score generated in this study could be applied to other cancer types for future investigation of BAT in cancer.   </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154064--></body></html>"
    },
    {
      "uid": "P445",
      "content_id": "154623",
      "abstract_number": "P445",
      "poster_number": "P445",
      "title": "Differential Gene Expression and Pathway Analysis in HNSCC: New Insights into Tumor Biology and Prognostic Markers",
      "summary": "A total of 3682 differentially expressed genes (DEGs) were identified comparing tumor tissue with adjacent mucosa (AM), GO analysis found protein localization to kinetochore and type I interferon-mediated signaling pathway as the most enriched biological process in tumors, however ATP synthesis coupled electron transport and signal transduction by p53 class mediator were enriched in AM. Pathway analysis...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154623",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandre Bezerra dos Santos, PhD",
      "presenter": "Alexandre Bezerra dos Santos, PhD",
      "authors": "Fátima Solange Pasini, PhD 1 ; Simone Maistro, PhD 2 ; Fabio Albuquerque Marchi, PhD 1 ; Maria José Ferreira Alves, MSc 2 ; Maria Lucia Hirata Katayama, PhD 1 ; Daniele Moreira Peres 2 ; Ana Luiza Marques 2 ; Gilberto de Castro Junior, PhD 2 ; Alexandre Bezerra dos Santos, PhD 2 ; Luiz Paulo Kowalski, PhD 1 ; Maria Aparecida Azevedo Koike Folgueira, PhD 1",
      "normalized_authors": [
        "Fátima Solange Pasini",
        "Simone Maistro",
        "Fabio Albuquerque Marchi",
        "Maria José Ferreira Alves",
        "Maria Lucia Hirata Katayama",
        "Daniele Moreira Peres",
        "Ana Luiza Marques",
        "Gilberto de Castro Junior",
        "Alexandre Bezerra dos Santos",
        "Luiz Paulo Kowalski",
        "Maria Aparecida Azevedo Koike Folgueira"
      ],
      "affiliations": [
        "Faculdade de Medicina da USP",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da USP",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "session_type": "Poster",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 373,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results"
      ],
      "sections": {
        "Authors": "Fátima Solange Pasini, PhD 1 ; Simone Maistro, PhD 2 ; Fabio Albuquerque Marchi, PhD 1 ; Maria José Ferreira Alves, MSc 2 ; Maria Lucia Hirata Katayama, PhD 1 ; Daniele Moreira Peres 2 ; Ana Luiza Marques 2 ; Gilberto de Castro Junior, PhD 2 ; Alexandre Bezerra dos Santos, PhD 2 ; Luiz Paulo Kowalski, PhD 1 ; Maria Aparecida Azevedo Koike Folgueira, PhD 1",
        "Affiliations": "1 Faculdade de Medicina da USP; 2 Instituto do Câncer do Estado de São Paulo",
        "Introduction": "head and neck cancer is the sixth most common cancer worldwide, with tobacco as the leading cause. However, the number of cases among non-drinkers and non-smokers (NSND) is increasing and the molecular mechanism underlying the pathogenesis of these HNSCC remains poorly understood.",
        "Methods": "here, we analyzed gene expression signatures associated to prognostic factors by using next generation RNA-sequencing (RNA-seq) data obtained from 15 HNSCC NSND patients (5 adjacent mucosa and 15 tumor tissue). Differential gene expression, pathway enrichment, and protein-protein network analyses were performed using DESeq2 (by using DRAGEN Differential Expression v4.3.7), PANTHER/Reactome, and String v12.0, respectively.",
        "Results": "A total of 3682 differentially expressed genes (DEGs) were identified comparing tumor tissue with adjacent mucosa (AM), GO analysis found protein localization to kinetochore and type I interferon-mediated signaling pathway as the most enriched biological process in tumors, however ATP synthesis coupled electron transport and signal transduction by p53 class mediator were enriched in AM. Pathway analysis identified Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA and MET interacts with TNS proteins pathways enriched in tumors whereas Synthesis of Lipoxins (LX) was enriched in AM. Analyzing the main prognostic factors in HNSCC, in tumor tissue from pN+ (N=7) as compared to pN0 (N=7) patients, 468 DEGs were identified, whereby, the tissue development and immune response biological process were the most enrichment in pN+ comparison. Pathway analysis identified Cytochrome P450 - arranged by substrate type (CYP4F2, CYP4F22 and CYP4F11) and keratinization pathways enriched in pN0, whereas hydrolysis of LPC (PLA2G4F, PLA2G4B, PLA2G4D) and Advanced glycosylation endproduct receptor signaling pathway (S100B, MAPK3, S100A12)were more enriched in pN+ patients. Considering the pathological TNM stage, 152 DEGS were observed (31 down and 121 upregulated) in advanced tumor tissue (III/V stage). The enrichment analysis was possible only with upregulated DEGS by using STRING database, that identified extracellular matrix as functional enrichments in the network. This study reveals distinct gene expression profiles and enriched pathways in HNSCC, with tumor tissues showing alterations in immune response, tissue development, and key signaling pathways. Additionally, advanced tumor stages were associated with upregulated genes linked to extracellular matrix remodeling. These findings provide new insights into HNSCC NSND pathogenesis and highlight potential molecular markers for prognosis and therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Differential Gene Expression and Pathway Analysis in HNSCC: New Insights into Tumor Biology and Prognostic Markers</span>. Fátima Solange Pasini, PhD<sup>1</sup>; Simone Maistro, PhD<sup>2</sup>; Fabio Albuquerque Marchi, PhD<sup>1</sup>; Maria José Ferreira Alves, MSc<sup>2</sup>; Maria Lucia Hirata Katayama, PhD<sup>1</sup>; Daniele Moreira Peres<sup>2</sup>; Ana Luiza Marques<sup>2</sup>; Gilberto de Castro Junior, PhD<sup>2</sup>; <u>Alexandre Bezerra dos Santos, PhD</u><sup>2</sup>; Luiz Paulo Kowalski, PhD<sup>1</sup>; Maria Aparecida Azevedo Koike Folgueira, PhD<sup>1</sup>. <sup>1</sup>Faculdade de Medicina da USP; <sup>2</sup>Instituto do Câncer do Estado de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>head and neck cancer is the sixth most common cancer worldwide, with tobacco as the leading cause. However, the number of cases among non-drinkers and non-smokers (NSND) is increasing and the molecular mechanism underlying the pathogenesis of these HNSCC remains poorly understood.</p>\n\n<p><strong>Methods:</strong> here, we analyzed gene expression signatures associated to prognostic factors by using next generation RNA-sequencing (RNA-seq) data obtained from 15 HNSCC NSND patients (5 adjacent mucosa and 15 tumor tissue).  Differential gene expression, pathway enrichment, and protein-protein network analyses were performed using DESeq2 (by using DRAGEN Differential Expression v4.3.7), PANTHER/Reactome, and String v12.0, respectively.</p>\n\n<p><strong>Results: </strong>A total of 3682 differentially expressed genes (DEGs) were identified comparing tumor tissue with adjacent mucosa (AM), GO analysis found protein localization to kinetochore and type I interferon-mediated signaling pathway as the most enriched biological process in tumors, however ATP synthesis coupled electron transport and signal transduction by p53 class mediator were enriched in AM. Pathway analysis identified Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA and MET interacts with TNS proteins pathways enriched in tumors whereas Synthesis of Lipoxins (LX) was enriched in AM. Analyzing the main prognostic factors in HNSCC, in tumor tissue from pN+ (N=7) as compared to pN0 (N=7) patients, 468 DEGs were identified, whereby, the tissue development and immune response biological process were the most enrichment in pN+ comparison. Pathway analysis identified Cytochrome P450 - arranged by substrate type (CYP4F2, CYP4F22 and CYP4F11) and keratinization pathways enriched in pN0, whereas hydrolysis of LPC (PLA2G4F, PLA2G4B, PLA2G4D) and Advanced glycosylation endproduct receptor signaling pathway (S100B, MAPK3, S100A12)were more enriched in pN+ patients. Considering the pathological TNM stage, 152 DEGS were observed (31 down and 121 upregulated) in advanced tumor tissue (III/V stage).  The enrichment analysis was possible only with upregulated DEGS by using STRING database, that identified extracellular matrix as functional enrichments in the network. This study reveals distinct gene expression profiles and enriched pathways in HNSCC, with tumor tissues showing alterations in immune response, tissue development, and key signaling pathways. Additionally, advanced tumor stages were associated with upregulated genes linked to extracellular matrix remodeling. These findings provide new insights into HNSCC NSND pathogenesis and highlight potential molecular markers for prognosis and therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154623--></body></html>"
    },
    {
      "uid": "P446",
      "content_id": "154162",
      "abstract_number": "P446",
      "poster_number": "P446",
      "title": "The Role of Podoplanin in Surgical Margin Evaluation in Pharyngeal Cancer",
      "summary": "This study suggests that Podoplanin may play an important role in surgical margin assessment in transoral resection of pharyngeal cancer. Its strong association with invasive carcinoma highlights the need for further clinical investigation, and margin evaluation based on Podoplanin expression may contribute to reducing local recurrence and improving treatment outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154162",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Toshimasa M Aoki",
      "presenter": "Toshimasa M Aoki",
      "authors": "Toshimasa M Aoki",
      "normalized_authors": [
        "Toshimasa M Aoki"
      ],
      "affiliations": [
        "Yokohama City Univercity Medical Center"
      ],
      "normalized_institutions": [
        "Yokohama City Univercity Medical Center"
      ],
      "session_type": "Poster",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 338,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Patients and Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Toshimasa M Aoki",
        "Affiliations": "Yokohama City Univercity Medical Center",
        "Background": "Advances in endoscopic techniques and surgical devices have greatly expanded the indications for transoral surgery in the treatment of pharyngeal malignancies. Although establishing appropriate surgical margins is crucial during tumor resection, postoperative pathological margin positivity and its association with local recurrence have not been sufficiently investigated. Several molecular markers related to cancer invasion at surgical margins have been reported. This study aimed to examine the relationships between these molecular markers and margin status.",
        "Patients and Methods": "A total of 37 cases of hypopharyngeal cancer and 23 cases of oropharyngeal cancer treated in our department from 2019 to 2024 were included. Surgical procedures consisted of Endoscopic Laryngo-Pharyngeal Surgery (ELPS) in 41 cases, Transoral Video Surgery (TOVS) in 6 cases, and Transoral Robotic Surgery (TORS) in 13 cases. Permanent pathological specimens were evaluated immunohistochemically for various molecular markers associated with head and neck cancer invasion.",
        "Results": "In the ELPS group, horizontal margin positivity was observed in 16 of 44 cases. In the TOVS group, although intraoperative frozen-section analysis showed negative margins in all cases, permanent pathology revealed margin positivity in 2 of 9 cases. In the TORS group, 1 of 4 cases showed a positive margin. Importantly, none of the patients developed local recurrence, and no postoperative adjuvant therapy, including radiotherapy, was required. Although the ELPS group demonstrated a relatively high rate of horizontal margin positivity, evaluation was often complicated by electrocautery-induced artifacts; nonetheless, no local recurrence was observed.",
        "Abstract": "Immunohistochemical analysis revealed strong Podoplanin expression in invasive carcinoma, particularly at the invasive front. These findings suggest that podoplanin may serve as a valuable indicator for determining safe surgical margins. In cases where preoperative biopsy specimens show high Podoplanin expression at the tumor edge, wider resection margins and more intensive postoperative surveillance may be warranted.",
        "Conclusion": "This study suggests that Podoplanin may play an important role in surgical margin assessment in transoral resection of pharyngeal cancer. Its strong association with invasive carcinoma highlights the need for further clinical investigation, and margin evaluation based on Podoplanin expression may contribute to reducing local recurrence and improving treatment outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Role of Podoplanin in Surgical Margin Evaluation in Pharyngeal Cancer</span>. <u>Toshimasa M Aoki</u>. Yokohama City Univercity Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Advances in endoscopic techniques and surgical devices have greatly expanded the indications for transoral surgery in the treatment of pharyngeal malignancies. Although establishing appropriate surgical margins is crucial during tumor resection, postoperative pathological margin positivity and its association with local recurrence have not been sufficiently investigated. Several molecular markers related to cancer invasion at surgical margins have been reported. This study aimed to examine the relationships between these molecular markers and margin status.</p>\n\n<p><strong>Patients and Methods: </strong>A total of 37 cases of hypopharyngeal cancer and 23 cases of oropharyngeal cancer treated in our department from 2019 to 2024 were included. Surgical procedures consisted of Endoscopic Laryngo-Pharyngeal Surgery (ELPS) in 41 cases, Transoral Video Surgery (TOVS) in 6 cases, and Transoral Robotic Surgery (TORS) in 13 cases. Permanent pathological specimens were evaluated immunohistochemically for various molecular markers associated with head and neck cancer invasion.</p>\n\n<p><strong>Results: </strong>In the ELPS group, horizontal margin positivity was observed in 16 of 44 cases. In the TOVS group, although intraoperative frozen-section analysis showed negative margins in all cases, permanent pathology revealed margin positivity in 2 of 9 cases. In the TORS group, 1 of 4 cases showed a positive margin. Importantly, none of the patients developed local recurrence, and no postoperative adjuvant therapy, including radiotherapy, was required. Although the ELPS group demonstrated a relatively high rate of horizontal margin positivity, evaluation was often complicated by electrocautery-induced artifacts; nonetheless, no local recurrence was observed.</p>\n\n<p>Immunohistochemical analysis revealed strong Podoplanin expression in invasive carcinoma, particularly at the invasive front. These findings suggest that podoplanin may serve as a valuable indicator for determining safe surgical margins. In cases where preoperative biopsy specimens show high Podoplanin expression at the tumor edge, wider resection margins and more intensive postoperative surveillance may be warranted.</p>\n\n<p><strong>Conclusion: </strong>This study suggests that Podoplanin may play an important role in surgical margin assessment in transoral resection of pharyngeal cancer. Its strong association with invasive carcinoma highlights the need for further clinical investigation, and margin evaluation based on Podoplanin expression may contribute to reducing local recurrence and improving treatment outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154162--></body></html>"
    },
    {
      "uid": "S001",
      "content_id": "154296",
      "abstract_number": "S001",
      "poster_number": "",
      "title": "AI-based early prediction of hospital length of stay after head and neck cancer surgery in a 20,540-patient cohort from a Brazilian cancer center",
      "summary": "In one of the largest head and neck surgical cohorts reported, this AI-based predictive framework identified strong determinants of prolonged postoperative LOS. Operative duration, tumor site, surgical complexity, comorbidity burden, and expected ICU requirement were the most informative features. These findings support the feasibility of AI-driven decision-support tools to improve surgical scheduling and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154296",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Willian Silva",
      "presenter": "Willian Silva",
      "authors": "Willian Silva 1 ; Fabio Marchi, PhD 1 ; Genival Carvalho, PhD 2 ; Luiz Kowalski, PhD 1",
      "normalized_authors": [
        "Willian Silva",
        "Fabio Marchi",
        "Genival Carvalho",
        "Luiz Kowalski"
      ],
      "affiliations": [
        "University of São Paulo Medical School",
        "Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "University of São Paulo Medical School",
        "Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Willian Silva 1 ; Fabio Marchi, PhD 1 ; Genival Carvalho, PhD 2 ; Luiz Kowalski, PhD 1",
        "Affiliations": "1 University of São Paulo Medical School; 2 Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center",
        "Background": "Predicting postoperative length of stay (LOS) in head and neck cancer surgery is critical for bed management, resource allocation, and reducing surgical wait times in the Brazilian public health system (SUS). Although procedure complexity, comorbidities, and tumor site are known determinants of LOS, no large-scale Brazilian studies or AI-based tools currently support LOS prediction. This study aimed to develop and evaluate an artificial intelligence framework to predict LOS using routinely collected clinical and surgical data from a major cancer center.",
        "Methods": "A retrospective cohort analysis of 20,540 consecutive patients who underwent head and neck surgical procedures at a Brazilian tertiary cancer center was performed. LOS was categorized into five levels (0, 1, 2, 3–5, ≥6 days), and binary endpoints were created, including a primary outcome of prolonged LOS (≥6 vs <6 days). Variables included demographics, comorbidities, tumor topography, planned surgical procedure, reconstruction type, and operative time (<2, 2–4, >4 hours). Associations were assessed using univariate tests and logistic regression models. A univariate machine-learning pipeline (linear SVM, k-nearest neighbors, XGBoost) quantified the isolated predictive ability of each variable using stratified train–test splits, reporting accuracy, sensitivity, specificity, and area under the ROC curve (AUC). Multinomial logistic regression quantified shifts across the five-level LOS distribution.",
        "Results": "Substantial variation in LOS was observed across tumor site, surgical complexity, comorbidities, and operative duration. Operative duration showed a clear dose–response relationship with LOS: procedures lasting >4 hours increased the odds of LOS ≥6 days 65-fold (OR 65.2; 95% CI 55.7–76.3), and those lasting 3–4 hours increased risk 35-fold (OR 35.7). Tumor topography also strongly influenced LOS: oral cavity resections markedly increased the probability of prolonged hospitalization (OR 8.6), while thyroid surgery was protective (OR 0.04). High-complexity procedures followed expected risk gradients, with maxillectomy (OR 7.3) and glossectomy (OR 3.9) associated with substantially extended LOS. Among comorbidities, renal insufficiency (OR 4.23) and COPD (OR 3.85) were the strongest predictors of prolonged stay, whereas absence of comorbidities was protective (OR 0.52). In the machine-learning analysis expected need for immediate postoperative ICU care emerged as the most accurate isolated predictor of LOS ≥6 days (AUC 0.846; specificity >95%), outperforming all other variables. Operative duration category, reconstruction type, and tumor site also demonstrated consistent discriminative ability (AUCs >0.75), reinforcing their clinical relevance in identifying patients at risk for prolonged hospitalization.",
        "Conclusion": "In one of the largest head and neck surgical cohorts reported, this AI-based predictive framework identified strong determinants of prolonged postoperative LOS. Operative duration, tumor site, surgical complexity, comorbidity burden, and expected ICU requirement were the most informative features. These findings support the feasibility of AI-driven decision-support tools to improve surgical scheduling and optimize inpatient resource utilization in the Brazilian public health system.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AI-based early prediction of hospital length of stay after head and neck cancer surgery in a 20,540-patient cohort from a Brazilian cancer center</span>. <u>Willian Silva</u><sup>1</sup>; Fabio Marchi, PhD<sup>1</sup>; Genival Carvalho, PhD<sup>2</sup>; Luiz Kowalski, PhD<sup>1</sup>. <sup>1</sup>University of São Paulo Medical School; <sup>2</sup>Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Predicting postoperative length of stay (LOS) in head and neck cancer surgery is critical for bed management, resource allocation, and reducing surgical wait times in the Brazilian public health system (SUS). Although procedure complexity, comorbidities, and tumor site are known determinants of LOS, no large-scale Brazilian studies or AI-based tools currently support LOS prediction. This study aimed to develop and evaluate an artificial intelligence framework to predict LOS using routinely collected clinical and surgical data from a major cancer center.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort analysis of 20,540 consecutive patients who underwent head and neck surgical procedures at a Brazilian tertiary cancer center was performed. LOS was categorized into five levels (0, 1, 2, 3–5, ≥6 days), and binary endpoints were created, including a primary outcome of prolonged LOS (≥6 vs <6 days). Variables included demographics, comorbidities, tumor topography, planned surgical procedure, reconstruction type, and operative time (<2, 2–4, >4 hours). Associations were assessed using univariate tests and logistic regression models. A univariate machine-learning pipeline (linear SVM, k-nearest neighbors, XGBoost) quantified the isolated predictive ability of each variable using stratified train–test splits, reporting accuracy, sensitivity, specificity, and area under the ROC curve (AUC). Multinomial logistic regression quantified shifts across the five-level LOS distribution.</p>\n\n<p><strong>Results:</strong> Substantial variation in LOS was observed across tumor site, surgical complexity, comorbidities, and operative duration. Operative duration showed a clear dose–response relationship with LOS: procedures lasting >4 hours increased the odds of LOS ≥6 days 65-fold (OR 65.2; 95% CI 55.7–76.3), and those lasting 3–4 hours increased risk 35-fold (OR 35.7). Tumor topography also strongly influenced LOS: oral cavity resections markedly increased the probability of prolonged hospitalization (OR 8.6), while thyroid surgery was protective (OR 0.04). High-complexity procedures followed expected risk gradients, with maxillectomy (OR 7.3) and glossectomy (OR 3.9) associated with substantially extended LOS. Among comorbidities, renal insufficiency (OR 4.23) and COPD (OR 3.85) were the strongest predictors of prolonged stay, whereas absence of comorbidities was protective (OR 0.52). In the machine-learning analysis expected need for immediate postoperative ICU care emerged as the most accurate isolated predictor of LOS ≥6 days (AUC 0.846; specificity >95%), outperforming all other variables. Operative duration category, reconstruction type, and tumor site also demonstrated consistent discriminative ability (AUCs >0.75), reinforcing their clinical relevance in identifying patients at risk for prolonged hospitalization.</p>\n\n<p><strong>Conclusion:</strong> In one of the largest head and neck surgical cohorts reported, this AI-based predictive framework identified strong determinants of prolonged postoperative LOS. Operative duration, tumor site, surgical complexity, comorbidity burden, and expected ICU requirement were the most informative features. These findings support the feasibility of AI-driven decision-support tools to improve surgical scheduling and optimize inpatient resource utilization in the Brazilian public health system.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154296--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S002",
      "content_id": "154032",
      "abstract_number": "S002",
      "poster_number": "",
      "title": "A Deep Learning Model for ED Visit Prediction in Locally Advanced Head and Neck Cancer",
      "summary": "ED visit risk in HNC patients is highly patient-specific and evolves over time. Incorporating unstructured physician notes into an LSTM framework enables dynamic, trajectory-aware risk stratification. This approach may facilitate earlier identification of vulnerable patients and support targeted post-treatment interventions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154032",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arushi Gulati, MD",
      "presenter": "Arushi Gulati, MD",
      "authors": "Arushi Gulati, MD 1 ; Bhumika Srinivas 1 ; Justin Fortino, BS 1 ; Shreyas Anil, MS 1 ; Benedict Neo, MS 1 ; Yannet Interian, PhD 2 ; Andrea Park, MD 1 ; Jason Chan, MD 1 ; Hui Lin, PhD 1",
      "normalized_authors": [
        "Arushi Gulati",
        "Bhumika Srinivas",
        "Justin Fortino",
        "Shreyas Anil",
        "Benedict Neo",
        "Yannet Interian",
        "Andrea Park",
        "Jason Chan",
        "Hui Lin"
      ],
      "affiliations": [
        "University of California, San Francisco",
        "University of San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco",
        "University of San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 526,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Arushi Gulati, MD 1 ; Bhumika Srinivas 1 ; Justin Fortino, BS 1 ; Shreyas Anil, MS 1 ; Benedict Neo, MS 1 ; Yannet Interian, PhD 2 ; Andrea Park, MD 1 ; Jason Chan, MD 1 ; Hui Lin, PhD 1",
        "Affiliations": "1 University of California, San Francisco; 2 University of San Francisco",
        "Introduction": "Emergency department (ED) visits are common in late-stage head and neck cancer (HNC) patients due to disease-related impairment and treatment morbidity, resulting in treatment interruptions, poorer oncologic outcomes, and increased healthcare costs. Prior studies have leveraged structured electronic health record (EHR) data to identify demographic and treatment-related drivers of ED utilization. However, this approach does not account for clinical trajectories or subjective factors captured in unstructured EHR notes.",
        "Objective": "To develop a Long Short-Term Memory (LSTM) neural network to analyze unstructured EHR data and predict ED visits in HNC patients undergoing microvascular free tissue transfer (MFTT).",
        "Methods": "All clinical notes for HNC patients who underwent MFTT from 2011-2023 were extracted from the EHR. Large language models (GPT-4o and LLaMA 3.0) were used to identify treatment completion dates, including adjuvant (chemo)radiation therapy if indicated, and ED visits. Results were validated by manual review.",
        "Abstract": "Notes were converted into numerical embeddings using a transformer-based language model (Jina Embeddings v3) optimized to capture semantic meaning. Embeddings were grouped into three sequential units: T0 (notes prior to treatment completion), T1 (0–3 months post-treatment), and T2 (4–6 months post-treatment). An LSTM model was then developed to predict ED visit occurrence within the 6-month post-treatment period. Key architectural features included two LSTM layers of 137 and 72 units, respectively, with batch normalization after the first layer for training stability and dropout to prevent overfitting. The final output was a fully connected linear layer estimating visit probability. Performance metrics assessed included model accuracy and area under the receiver operating characteristic curve (AUC). Shapley Additive Explanations (SHAP)-based analysis was performed to identify specific note content that influenced ED visit predictions. The LSTM model’s performance in predicting ED visits improved with inclusion of post-treatment data. Model accuracy improved from 70.3±1% with pre-treatment (T0) notes alone to 76.8±2% when including notes up to 6 months post-treatment (T0-T2). Model AUC similarly increased when including all notes from all time periods (0.80) compared to any period alone (T0: 0.70, T1: 0.72, T2: 0.72), indicating the importance of longitudinal clinical context. Text analysis of post-treatment notes demonstrated that description of metastatic disease progression, falls, and medication complications increased ED visit risk while uncomplicated ICU stays, stable chronic conditions, and consistent home care were protective. View in Agenda and Add to Schedule",
        "Results": "203,899 physician notes were identified from 1,091 patients. Of these, 246 (22.5%) had an ED visit within 6 months post-treatment. To obtain a more balanced cohort for model training, random undersampling was used to obtain a subset of 481 patients, including 154 (32.0%) with ED visits, that was divided into training (n=336, 70%) and test (n=145, 30%) groups. Included patients had an average age of 62.6±14.3 years, and a majority were male (65.5%), had stage T3-4 primary tumors (75.3%), and underwent adjuvant radiation treatment (60.2%).",
        "Conclusions": "ED visit risk in HNC patients is highly patient-specific and evolves over time. Incorporating unstructured physician notes into an LSTM framework enables dynamic, trajectory-aware risk stratification. This approach may facilitate earlier identification of vulnerable patients and support targeted post-treatment interventions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Deep Learning Model for ED Visit Prediction in Locally Advanced Head and Neck Cancer</span>. <u>Arushi Gulati, MD</u><sup>1</sup>; Bhumika Srinivas<sup>1</sup>; Justin Fortino, BS<sup>1</sup>; Shreyas Anil, MS<sup>1</sup>; Benedict Neo, MS<sup>1</sup>; Yannet Interian, PhD<sup>2</sup>; Andrea Park, MD<sup>1</sup>; Jason Chan, MD<sup>1</sup>; Hui Lin, PhD<sup>1</sup>. <sup>1</sup>University of California, San Francisco; <sup>2</sup>University of San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Emergency department (ED) visits are common in late-stage head and neck cancer (HNC) patients due to disease-related impairment and treatment morbidity, resulting in treatment interruptions, poorer oncologic outcomes, and increased healthcare costs. Prior studies have leveraged structured electronic health record (EHR) data to identify demographic and treatment-related drivers of ED utilization. However, this approach does not account for clinical trajectories or subjective factors captured in unstructured EHR notes.</p>\n\n<p><strong>Objective: </strong>To develop a Long Short-Term Memory (LSTM) neural network to analyze unstructured EHR data and predict ED visits in HNC patients undergoing microvascular free tissue transfer (MFTT).</p>\n\n<p><strong>Methods: </strong>All clinical notes for HNC patients who underwent MFTT from 2011-2023 were extracted from the EHR. Large language models (GPT-4o and LLaMA 3.0) were used to identify treatment completion dates, including adjuvant (chemo)radiation therapy if indicated, and ED visits. Results were validated by manual review.</p>\n\n<p>Notes were converted into numerical embeddings using a transformer-based language model (Jina Embeddings v3) optimized to capture semantic meaning. Embeddings were grouped into three sequential units: T0 (notes prior to treatment completion), T1 (0–3 months post-treatment), and T2 (4–6 months post-treatment). </p>\n\n<p>An LSTM model was then developed to predict ED visit occurrence within the 6-month post-treatment period. Key architectural features included two LSTM layers of 137 and 72 units, respectively, with batch normalization after the first layer for training stability and dropout to prevent overfitting. The final output was a fully connected linear layer estimating visit probability. Performance metrics assessed included model accuracy and area under the receiver operating characteristic curve (AUC). Shapley Additive Explanations (SHAP)-based analysis was performed to identify specific note content that influenced ED visit predictions.</p>\n\n<p><strong>Results: </strong>203,899 physician notes were identified from 1,091 patients. Of these, 246 (22.5%) had an ED visit within 6 months post-treatment. To obtain a more balanced cohort for model training, random undersampling was used to obtain a subset of 481 patients, including 154 (32.0%) with ED visits, that was divided into training (n=336, 70%) and test (n=145, 30%) groups. Included patients had an average age of 62.6±14.3 years, and a majority were male (65.5%), had stage T3-4 primary tumors (75.3%), and underwent adjuvant radiation treatment (60.2%).</p>\n\n<p>The LSTM model’s performance in predicting ED visits improved with inclusion of post-treatment data. Model accuracy improved from 70.3±1% with pre-treatment (T0) notes alone to 76.8±2% when including notes up to 6 months post-treatment (T0-T2). Model AUC similarly increased when including all notes from all time periods (0.80) compared to any period alone (T0: 0.70, T1: 0.72, T2: 0.72), indicating the importance of longitudinal clinical context.</p>\n\n<p>Text analysis of post-treatment notes demonstrated that description of metastatic disease progression, falls, and medication complications increased ED visit risk while uncomplicated ICU stays, stable chronic conditions, and consistent home care were protective.</p>\n\n<p><strong>Conclusions: </strong>ED visit risk in HNC patients is highly patient-specific and evolves over time. Incorporating unstructured physician notes into an LSTM framework enables dynamic, trajectory-aware risk stratification. This approach may facilitate earlier identification of vulnerable patients and support targeted post-treatment interventions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154032--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S003",
      "content_id": "154448",
      "abstract_number": "S003",
      "poster_number": "",
      "title": "Development and validation of an AI-driven multimodal model integrating clinical and tomodensitometric features for pretreatment risk stratification in HPV-associated oropharyngeal cancer",
      "summary": "An AI-driven multimodal model integrating pretreatment clinical variables with CT-based radiomic features from the primary tumor and involved lymph nodes stratified patients with HPV-associated OPSCC into clinically distinct recurrence and survival risk groups prior to therapy, with a low rate of events in the AI-defined low-risk group. Ongoing work includes external and prospective validation and calibration...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154448",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriel S Dayan, MD",
      "presenter": "Gabriel S Dayan, MD",
      "authors": "Gabriel S Dayan, MD ; Eddy Manih, BEng; Apostolos Christopoulos, MD, MSc; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Tareck Ayad, MD; Eric Bissada, MD, DMD; Paul Tabet, MD, MSc; Louis Guertin, MD; Antoine Desilets, MD, MSc; Laurent Letourneau-Guillon, MD, MSc; Samuel Kadoury, PhD; Houda Bahig, MD, PhD",
      "normalized_authors": [
        "Gabriel S Dayan",
        "Eddy Manih, BEng",
        "Apostolos Christopoulos",
        "Edith Filion",
        "Phuc-Felix Nguyen-Tan",
        "Tareck Ayad",
        "Eric Bissada",
        "Paul Tabet",
        "Louis Guertin",
        "Antoine Desilets",
        "Laurent Letourneau-Guillon",
        "Samuel Kadoury",
        "Houda Bahig"
      ],
      "affiliations": [
        "Centre Hospitalier de l'Université de Montréal (CHUM)"
      ],
      "normalized_institutions": [
        "Centre Hospitalier de l'Université de Montréal (CHUM)"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154448/KM%20curve%20AI%20pred%20HPV(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154448/KM%20curve%20AI%20pred%20HPV(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154448"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriel S Dayan, MD ; Eddy Manih, BEng; Apostolos Christopoulos, MD, MSc; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Tareck Ayad, MD; Eric Bissada, MD, DMD; Paul Tabet, MD, MSc; Louis Guertin, MD; Antoine Desilets, MD, MSc; Laurent Letourneau-Guillon, MD, MSc; Samuel Kadoury, PhD; Houda Bahig, MD, PhD",
        "Affiliations": "Centre Hospitalier de l'Université de Montréal (CHUM)",
        "Background": "The favorable prognosis of HPV–associated oropharyngeal squamous cell carcinoma (OPSCC) has fueled numerous treatment de-escalation efforts. Yet, all phase III trials to date have failed, reporting inferior disease control compared with standard treatment arms. A key unmet need remains pretreatment recurrence risk stratification to distinguish patients who may safely undergo de-intensified therapy from those who require standard regimens. Artificial intelligence (AI) offers powerful tools to address this challenge and enable more precise, individualized risk prediction.",
        "Objectives": "To develop and validate an AI-based multimodal model using an attention-based architecture that integrates primary tumor and nodal radiomic features with pretreatment clinical variables to predict recurrence and survival in HPV-associated OPSCC.",
        "Methods": "We conducted a multicenter study of HPV-associated OPSCC treated with definitive chemo(radiation) at two high-volume Canadian centers (2007–2023). Primary tumor contours (GTV-P) were obtained from treatment planning, while nodal volumes (GTV-LN) were generated using a previously validated automated lymph node segmentation model. Radiomic features were extracted from GTV-P and the largest involved node, and total nodal volume was included as an additional variable. Clinical variables included age, sex, pack-years, and AJCC 8th TNM stage. We developed a multimodal attention-based deep learning model with modality-specific encoders and multi-head attention fusion to predict 2-year recurrence-free survival (RFS) and overall survival (OS). Five-fold cross-validation was performed, with discrimination assessed by mean AUROC. To prevent data leakage, feature scaling and hyperparameter tuning were confined to the training data within each cross-validation fold. In each fold, risk scores were dichotomized using a threshold chosen on the training partition to achieve ≥90% sensitivity for 2-year outcomes. Kaplan–Meier and Cox analyses were performed to compare groups.",
        "Results": "Among 799 included patients, the cohort consisted of 643 males (80%) with a mean age of 62.3±9.6 years. All patients received definitive upfront radiation therapy, and 510 (64%) received concurrent chemotherapy. Two-year RFS and OS for the overall cohort were 85% and 89%, respectively. Mean cross-validated test set AUROC for predicting 2-year outcomes was 0.76±0.04 for both RFS and OS, compared to the clinical-only model, which had AUROC of 0.69±0.03 and 0.67±0.03, respectively. After dichotomization, 410 patients were classified as AI-predicted high risk and 389 as low risk. AI-predicted high-risk was associated with significantly worse RFS (77% vs 93% at 2-years; P<0.001; HR 2.44, 95% CI 1.66–3.59) and OS (86% vs 96% at 2-years; P<0.001; HR 2.77, 95% CI 1.73–4.42) (Figure 1). CT retrieval is ongoing, with approximately 400 additional pretreatment planning CT scans expected for inclusion in subsequent analyses.",
        "Conclusions": "An AI-driven multimodal model integrating pretreatment clinical variables with CT-based radiomic features from the primary tumor and involved lymph nodes stratified patients with HPV-associated OPSCC into clinically distinct recurrence and survival risk groups prior to therapy, with a low rate of events in the AI-defined low-risk group. Ongoing work includes external and prospective validation and calibration within our institution, with the longer-term objective of using model-guided risk stratification to support individualized treatment intensity and inform de-escalation protocols.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development and validation of an AI-driven multimodal model integrating clinical and tomodensitometric features for pretreatment risk stratification in HPV-associated oropharyngeal cancer</span>. <u>Gabriel S Dayan, MD</u>; Eddy Manih, BEng; Apostolos Christopoulos, MD, MSc; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Tareck Ayad, MD; Eric Bissada, MD, DMD; Paul Tabet, MD, MSc; Louis Guertin, MD; Antoine Desilets, MD, MSc; Laurent Letourneau-Guillon, MD, MSc; Samuel Kadoury, PhD; Houda Bahig, MD, PhD. Centre Hospitalier de l'Université de Montréal (CHUM)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: The favorable prognosis of HPV–associated oropharyngeal squamous cell carcinoma (OPSCC) has fueled numerous treatment de-escalation efforts. Yet, all phase III trials to date have failed, reporting inferior disease control compared with standard treatment arms. A key unmet need remains pretreatment recurrence risk stratification to distinguish patients who may safely undergo de-intensified therapy from those who require standard regimens. Artificial intelligence (AI) offers powerful tools to address this challenge and enable more precise, individualized risk prediction.</p>\n\n<p><strong>Objectives</strong>: To develop and validate an AI-based multimodal model using an attention-based architecture that integrates primary tumor and nodal radiomic features with pretreatment clinical variables to predict recurrence and survival in HPV-associated OPSCC.</p>\n\n<p><strong>Methods</strong>: We conducted a multicenter study of HPV-associated OPSCC treated with definitive chemo(radiation) at two high-volume Canadian centers (2007–2023). Primary tumor contours (GTV-P) were obtained from treatment planning, while nodal volumes (GTV-LN) were generated using a previously validated automated lymph node segmentation model. Radiomic features were extracted from GTV-P and the largest involved node, and total nodal volume was included as an additional variable. Clinical variables included age, sex, pack-years, and AJCC 8th TNM stage. We developed a multimodal attention-based deep learning model with modality-specific encoders and multi-head attention fusion to predict 2-year recurrence-free survival (RFS) and overall survival (OS). Five-fold cross-validation was performed, with discrimination assessed by mean AUROC. To prevent data leakage, feature scaling and hyperparameter tuning were confined to the training data within each cross-validation fold. In each fold, risk scores were dichotomized using a threshold chosen on the training partition to achieve ≥90% sensitivity for 2-year outcomes. Kaplan–Meier and Cox analyses were performed to compare groups.</p>\n\n<p><strong>Results</strong>: Among 799 included patients, the cohort consisted of 643 males (80%) with a mean age of 62.3±9.6 years. All patients received definitive upfront radiation therapy, and 510 (64%) received concurrent chemotherapy. Two-year RFS and OS for the overall cohort were 85% and 89%, respectively. Mean cross-validated test set AUROC for predicting 2-year outcomes was 0.76±0.04 for both RFS and OS, compared to the clinical-only model, which had AUROC of 0.69±0.03 and 0.67±0.03, respectively. After dichotomization, 410 patients were classified as AI-predicted high risk and 389 as low risk. AI-predicted high-risk was associated with significantly worse RFS (77% vs 93% at 2-years; P<0.001; HR 2.44, 95% CI 1.66–3.59) and OS (86% vs 96% at 2-years; P<0.001; HR 2.77, 95% CI 1.73–4.42) (Figure 1). CT retrieval is ongoing, with approximately 400 additional pretreatment planning CT scans expected for inclusion in subsequent analyses.</p>\n\n<p><strong>Conclusions</strong>: An AI-driven multimodal model integrating pretreatment clinical variables with CT-based radiomic features from the primary tumor and involved lymph nodes stratified patients with HPV-associated OPSCC into clinically distinct recurrence and survival risk groups prior to therapy, with a low rate of events in the AI-defined low-risk group. Ongoing work includes external and prospective validation and calibration within our institution, with the longer-term objective of using model-guided risk stratification to support individualized treatment intensity and inform de-escalation protocols.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154448/KM%20curve%20AI%20pred%20HPV(2).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154448--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S004",
      "content_id": "154212",
      "abstract_number": "S004",
      "poster_number": "",
      "title": "Enhancing Prognostic Accuracy in Oropharyngeal Cancer with HPV-Stratified Machine Learning Models",
      "summary": "Machine learning models, particularly leveraging ensemble approaches, can substantially improve survival prediction in OPC patients, especially when stratified by HPV status. The integration of clinical, treatment, and socioeconomic variables enables more accurate risk stratification, supporting personalized treatment planning and enhanced shared decision-making. These findings highlight the value of data-driven...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154212",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claudia I Cabrera, MD, MS",
      "presenter": "Claudia I Cabrera, MD, MS",
      "authors": "Claudia I Cabrera, MD, MS ; Rod Rezaee, MD; Lijun Zhang, PhD",
      "normalized_authors": [
        "Claudia I Cabrera",
        "Rod Rezaee",
        "Lijun Zhang"
      ],
      "affiliations": [
        "University Hospitals Cleveland"
      ],
      "normalized_institutions": [
        "University Hospitals Cleveland"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154212/Model%20Performance.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154212/Model%20Performance.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154212"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154212/Variable%20importance.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154212/Variable%20importance.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154212"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 384,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Study Design & Methodology",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Claudia I Cabrera, MD, MS ; Rod Rezaee, MD; Lijun Zhang, PhD",
        "Affiliations": "University Hospitals Cleveland",
        "Background": "Oropharyngeal cancer (OPC) represents a growing public health concern with increasing incidence globally, particularly in HPV-associated cases. Human papillomavirus (HPV) status is a key prognostic factor, with HPV-positive patients exhibiting improved survival compared to their HPV-negative counterparts. However, current prognostic tools often fall short in capturing complex interactions among demographic, clinical, treatment-related, and socioeconomic factors that influence survival outcomes in OPC patients.To develop and evaluate machine learning (ML) models for survival prediction in OPC patients, stratified by HPV status, using a comprehensive clinical dataset from the National Cancer Database (NCDB).",
        "Study Design & Methodology": "We analyzed 3,806 OPC cases diagnosed between 2010 and 2016 with known HPV status (HPV-positive: 1,864; HPV-negative: 1,942). Key variables included demographics, tumor stage, treatment modalities (surgery, radiation, chemotherapy), Charlson-Deyo comorbidity scores, and socioeconomic indicators (income, education, insurance status). Missing data were handled using Multiple Imputation by Chained Equations (MICE), excluding the outcome and HPV status.",
        "Abstract": "We developed four predictive models: Cox proportional hazards regression, Random Survival Forest (RSF), XGBoost survival, and a stacked Ensemble model using logistic regression as the meta-learner. Models were trained and evaluated separately for HPV-positive and HPV-negative subgroups. Performance was assessed using area under the ROC curve (AUC), precision, recall, and F1-score. SHAP (SHapley Additive exPlanations) analysis was used to interpret feature importance. SHAP analysis revealed that survival time, age, time to treatment initiation (surgery, radiation, chemotherapy), comorbidity score, insurance type, and socioeconomic status were among the most influential features. Feature importance patterns differed subtly between HPV subgroups, underscoring the heterogeneity in disease dynamics. View in Agenda and Add to Schedule",
        "Results": "The Ensemble model outperformed all others across both subgroups. For HPV-positive patients, the Ensemble model achieved the highest AUC (0.80), followed by XGBoost (0.79), RSF (0.76), and Cox PH (0.69). For HPV-negative patients, Ensemble again led with an AUC of 0.76, followed by XGBoost (0.75), RSF (0.72), and Cox PH (0.65).",
        "Conclusion": "Machine learning models, particularly leveraging ensemble approaches, can substantially improve survival prediction in OPC patients, especially when stratified by HPV status. The integration of clinical, treatment, and socioeconomic variables enables more accurate risk stratification, supporting personalized treatment planning and enhanced shared decision-making. These findings highlight the value of data-driven models in advancing precision oncology and underscore the importance of considering HPV status in prognostic modeling."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Enhancing Prognostic Accuracy in Oropharyngeal Cancer with HPV-Stratified Machine Learning Models</span>. <u>Claudia I Cabrera, MD, MS</u>; Rod Rezaee, MD; Lijun Zhang, PhD. University Hospitals Cleveland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oropharyngeal cancer (OPC) represents a growing public health concern with increasing incidence globally, particularly in HPV-associated cases. Human papillomavirus (HPV) status is a key prognostic factor, with HPV-positive patients exhibiting improved survival compared to their HPV-negative counterparts. However, current prognostic tools often fall short in capturing complex interactions among demographic, clinical, treatment-related, and socioeconomic factors that influence survival outcomes in OPC patients.To develop and evaluate machine learning (ML) models for survival prediction in OPC patients, stratified by HPV status, using a comprehensive clinical dataset from the National Cancer Database (NCDB).</p>\n\n<p><strong>Study Design & Methodology: </strong>We analyzed 3,806 OPC cases diagnosed between 2010 and 2016 with known HPV status (HPV-positive: 1,864; HPV-negative: 1,942). Key variables included demographics, tumor stage, treatment modalities (surgery, radiation, chemotherapy), Charlson-Deyo comorbidity scores, and socioeconomic indicators (income, education, insurance status). Missing data were handled using Multiple Imputation by Chained Equations (MICE), excluding the outcome and HPV status.</p>\n\n<p>We developed four predictive models: Cox proportional hazards regression, Random Survival Forest (RSF), XGBoost survival, and a stacked Ensemble model using logistic regression as the meta-learner. Models were trained and evaluated separately for HPV-positive and HPV-negative subgroups. Performance was assessed using area under the ROC curve (AUC), precision, recall, and F1-score. SHAP (SHapley Additive exPlanations) analysis was used to interpret feature importance.</p>\n\n<p><strong>Results: </strong>The Ensemble model outperformed all others across both subgroups. For HPV-positive patients, the Ensemble model achieved the highest AUC (0.80), followed by XGBoost (0.79), RSF (0.76), and Cox PH (0.69). For HPV-negative patients, Ensemble again led with an AUC of 0.76, followed by XGBoost (0.75), RSF (0.72), and Cox PH (0.65).</p>\n\n<p>SHAP analysis revealed that survival time, age, time to treatment initiation (surgery, radiation, chemotherapy), comorbidity score, insurance type, and socioeconomic status were among the most influential features. Feature importance patterns differed subtly between HPV subgroups, underscoring the heterogeneity in disease dynamics.</p>\n\n<p><strong>Conclusion: </strong>Machine learning models, particularly leveraging ensemble approaches, can substantially improve survival prediction in OPC patients, especially when stratified by HPV status. The integration of clinical, treatment, and socioeconomic variables enables more accurate risk stratification, supporting personalized treatment planning and enhanced shared decision-making. These findings highlight the value of data-driven models in advancing precision oncology and underscore the importance of considering HPV status in prognostic modeling.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154212/Model%20Performance.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154212/Variable%20importance.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154212--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S005",
      "content_id": "153297",
      "abstract_number": "S005",
      "poster_number": "",
      "title": "CT-derived radiomics predict pathologic response to neoadjuvant immunotherapy in head and neck squamous cell carcinoma",
      "summary": "A total of 78 pre-treatment CT scans were included for analysis. Of these, 38 (48.7%) patients achieved PPR (≥50% pathologic response). The mRMR algorithm identified two radiomic features in >95% of training folds, suggesting they represent robust and potentially generalizable predictors: NGTDM Busyness and GLSZM Size-Zone Non-Uniformity Normalized (both of which measure aspects of intratumoral heterogeneity)....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153297",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eric V Mastrolonardo, MD",
      "presenter": "Eric V Mastrolonardo, MD",
      "authors": "Eric V Mastrolonardo, MD ; Daniel Uralov, MD; Aryan Safakish, PhD; D. Alexander Cronkite, MD; Ramez Philips, MD; Yevgeniy Vinogradskiy, PhD; Adam J Luginbuhl, MD",
      "normalized_authors": [
        "Eric V Mastrolonardo",
        "Daniel Uralov",
        "Aryan Safakish",
        "D. Alexander Cronkite",
        "Ramez Philips",
        "Yevgeniy Vinogradskiy",
        "Adam J Luginbuhl"
      ],
      "affiliations": [
        "Thomas Jefferson University Hospital"
      ],
      "normalized_institutions": [
        "Thomas Jefferson University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Eric V Mastrolonardo, MD ; Daniel Uralov, MD; Aryan Safakish, PhD; D. Alexander Cronkite, MD; Ramez Philips, MD; Yevgeniy Vinogradskiy, PhD; Adam J Luginbuhl, MD",
        "Affiliations": "Thomas Jefferson University Hospital",
        "Introduction": "Phase III data from KEYNOTE-689 provides the first rationale to incorporate neoadjuvant immunotherapy into the standard of care for head and neck squamous cell carcinoma (HNSCC). Previous data from Phase II trials further demonstrate that achieving a partial pathologic response (PPR, ≥50% pathologic response) following neoadjuvant immunotherapy is associated with improved disease-free survival. However, non-invasive methods to predict pathologic response are lacking. Radiomics, the high-throughput extraction of quantitative features from medical imaging, offers a noninvasive approach to characterize tumor tissue. The purpose of this work was to derive a novel radiomics-based predictor of pathologic response for HNSCC patients receiving neoadjuvant immunotherapy.",
        "Methods": "Patients at Thomas Jefferson University Hospital with resectable HNSCC and treated with neaodjuvant immunotherapy were retrospectively identified (n=101). Radiomic features were extracted from primary tumors on pre-treatment contrast-enhanced CT imaging using PyRadiomics, an open-source python package, which extracts standardized quantitative features from medical images. Radiomic features were used to train machine learning classifiers to build predictive models. Models were trained using leave one out cross validation (LOOCV) using LASSO, XGBoost (XGB), SVM, and Random Forrest (RF) classifiers using 1-7 radiomics features. Feature selection was performed with the minimum-Redundancy Maximum-Relevance (mRMR) method on inner training folds. Ten hyperparameter configurations were evaluated globally for each algorithm, yielding a single parameter set applied across all folds to ensure consistent generalizability. Optimal hyperparameters were assessed based on AUC. Model performance was assessed for prediction of PPR using area under the curve (AUC), accuracy, sensitivity, precision, and F1-score.",
        "Results": "A total of 78 pre-treatment CT scans were included for analysis. Of these, 38 (48.7%) patients achieved PPR (≥50% pathologic response). The mRMR algorithm identified two radiomic features in >95% of training folds, suggesting they represent robust and potentially generalizable predictors: NGTDM Busyness and GLSZM Size-Zone Non-Uniformity Normalized (both of which measure aspects of intratumoral heterogeneity). The best performing model for predicting PPR was a 5-feature XGB model with 72% accuracy, 68% sensitivity, 72% precision, F1-score of 0.702 and AUC of 0.780.",
        "Conclusions and Relevance": "This study is the first to apply CT-based radiomic analysis to predict pathologic response in patients with HNSCC treated with neoadjuvant immunotherapy. We identified two radiomic features, both related to intratumoral heterogeneity, to be the most informative in predicting PPR. In the push for precision oncology, these data lay the initial groundwork for critical, noninvasive means to optimize patient selection for neoadjuvant immunotherapy to treat HNSCC. Validation with external datasets are required.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>CT-derived radiomics predict pathologic response to neoadjuvant immunotherapy in head and neck squamous cell carcinoma</span>. <u>Eric V Mastrolonardo, MD</u>; Daniel Uralov, MD; Aryan Safakish, PhD; D. Alexander Cronkite, MD; Ramez Philips, MD; Yevgeniy Vinogradskiy, PhD; Adam J Luginbuhl, MD. Thomas Jefferson University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Phase III data from KEYNOTE-689 provides the first rationale to incorporate neoadjuvant immunotherapy into the standard of care for head and neck squamous cell carcinoma (HNSCC). Previous data from Phase II trials further demonstrate that achieving a partial pathologic response (PPR, ≥50% pathologic response) following neoadjuvant immunotherapy is associated with improved disease-free survival. However, non-invasive methods to predict pathologic response are lacking. Radiomics, the high-throughput extraction of quantitative features from medical imaging, offers a noninvasive approach to characterize tumor tissue. The purpose of this work was to derive a novel radiomics-based predictor of pathologic response for HNSCC patients receiving neoadjuvant immunotherapy.</p>\n\n<p><strong>Methods: </strong>Patients at Thomas Jefferson University Hospital with resectable HNSCC and treated with neaodjuvant immunotherapy were retrospectively identified (n=101). Radiomic features were extracted from primary tumors on pre-treatment contrast-enhanced CT imaging using PyRadiomics, an open-source python package, which extracts standardized quantitative features from medical images. Radiomic features were used to train machine learning classifiers to build predictive models. Models were trained using leave one out cross validation (LOOCV) using LASSO, XGBoost (XGB), SVM, and Random Forrest (RF) classifiers using 1-7 radiomics features. Feature selection was performed with the minimum-Redundancy Maximum-Relevance (mRMR) method on inner training folds. Ten hyperparameter configurations were evaluated globally for each algorithm, yielding a single parameter set applied across all folds to ensure consistent generalizability. Optimal hyperparameters were assessed based on AUC.  Model performance was assessed for prediction of PPR using area under the curve (AUC), accuracy, sensitivity, precision, and F1-score.</p>\n\n<p><strong>Results: </strong>A total of 78 pre-treatment CT scans were included for analysis. Of these, 38 (48.7%) patients achieved PPR (≥50% pathologic response). The mRMR algorithm identified two radiomic features in >95% of training folds, suggesting they represent robust and potentially generalizable predictors: NGTDM Busyness and GLSZM Size-Zone Non-Uniformity Normalized (both of which measure aspects of intratumoral heterogeneity). The best performing model for predicting PPR was a 5-feature XGB model with 72% accuracy, 68% sensitivity, 72% precision, F1-score of 0.702 and AUC of 0.780.</p>\n\n<p><strong>Conclusions and Relevance: </strong>This study is the first to apply CT-based radiomic analysis to predict pathologic response in patients with HNSCC treated with neoadjuvant immunotherapy. We identified two radiomic features, both related to intratumoral heterogeneity, to be the most informative in predicting PPR. In the push for precision oncology, these data lay the initial groundwork for critical, noninvasive means to optimize patient selection for neoadjuvant immunotherapy to treat HNSCC. Validation with external datasets are required.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153297--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S006",
      "content_id": "154323",
      "abstract_number": "S006",
      "poster_number": "",
      "title": "Artificial Intelligence-Enabled Quantification of Perineural Invasion and Tumor–Nerve–Immune Interactions in Head and Neck Squamous Cell Carcinoma",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) is among the ten most common cancers worldwide and accounts for approximately 4% of all cancers in the United States. Despite advances in immunotherapy, clinical outcomes remain suboptimal, reflecting a limited understanding of tumor–host interactions, incomplete diagnostic tools, and substantial heterogeneity in therapeutic response. An emerging body of evidence...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154323",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jiayu Wang, PhD",
      "presenter": "Jiayu Wang, PhD",
      "authors": "Jiayu Wang, PhD 1 ; Chelsea Gelboin-Burkhart, MD 1 ; Diana Bell, MD 2 ; Nicole Scheff, PhD 1 ; Steven Chinn, MD, MPH, FACS 1",
      "normalized_authors": [
        "Jiayu Wang",
        "Chelsea Gelboin-Burkhart",
        "Diana Bell",
        "Nicole Scheff",
        "Steven Chinn"
      ],
      "affiliations": [
        "University of Pittsburgh",
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh",
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154323/Figure1%20for%20AHNS%202026_Jiayu%20Wang%20PNI_v2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154323/Figure1%20for%20AHNS%202026_Jiayu%20Wang%20PNI_v2.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154323"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "FIGURE 1",
        "FIGURE 1."
      ],
      "sections": {
        "Authors": "Jiayu Wang, PhD 1 ; Chelsea Gelboin-Burkhart, MD 1 ; Diana Bell, MD 2 ; Nicole Scheff, PhD 1 ; Steven Chinn, MD, MPH, FACS 1",
        "Affiliations": "1 University of Pittsburgh; 2 University of Pittsburgh Medical Center",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) is among the ten most common cancers worldwide and accounts for approximately 4% of all cancers in the United States. Despite advances in immunotherapy, clinical outcomes remain suboptimal, reflecting a limited understanding of tumor–host interactions, incomplete diagnostic tools, and substantial heterogeneity in therapeutic response. An emerging body of evidence highlights the nervous system as a key regulator of the tumor immune microenvironment (TIME). In particular, perineural invasion (PNI)—a common pathological feature in HNSCC—is strongly associated with aggressive disease behavior, increased recurrence, and poor survival. Yet, routine assessment of PNI remains hampered by biological complexity, inconsistent interpretation, and the lack of scalable quantitative approaches. Building on this capability, our next phase will map tumor-infiltrating lymphocytes (TILs) relative to nerve structures to define how immune cells are spatially organized in PNI-positive versus PNI-negative regions. We will test the hypothesis that PNI disrupts local immune surveillance and contributes to diminished responsiveness to immunotherapy. Quantitative spatial metrics will be correlated with survival and treatment outcomes to determine their clinical relevance. Complementary bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics analyses will elucidate molecular pathways linking PNI, immune evasion, and therapeutic resistance. Together, these integrated approaches will establish an AI-enabled framework for detecting PNI, characterizing nerve–immune interactions, and identifying biomarkers that may guide precision immunotherapy in HNSCC. View in Agenda and Add to Schedule",
        "FIGURE 1": "ss this gap, we have developed a dedicated artificial intelligence (AI)–based PNI caller that operates directly on routine hematoxylin and eosin (H&E) slides. Using integrated machine-learning and deep-learning methods, our system automatically detects nerves, identifies tumor–nerve interactions, and quantifies PNI burden with high fidelity. ( FIGURE 1 ) This platform establishes a standardized, objective, and reproducible approach for PNI scoring and provides a foundation for deeper investigation into the spatial ecology of the TIME.",
        "FIGURE 1.": "Representative images from the same tissue region showing: A. Immunohistochemistry staining for βIII-tubulin, with nerve regions highlighted in brown; B. the corresponding H&E slide; C. the same H&E slide annotated by a machine-learning based pixel classifier to highlight nerve regions (green), and a deep-learning based object classifier to identify tumor cells (red) and lymphoid cells (light blue). D. Spatial map showing annotated nerve regions (green) with tumor cells (red) and lymphoid cells (blue). E. A 100?μm buffer was generated around nerve regions (light green), with tumor cells (red) and lymphoid cells (blue) highlighted in these buffer areas. Spatial maps were produced in R using extracted coordinates from the annotated H&E slide."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Artificial Intelligence-Enabled Quantification of Perineural Invasion and Tumor–Nerve–Immune Interactions in Head and Neck Squamous Cell Carcinoma</span>. <u>Jiayu Wang, PhD</u><sup>1</sup>; Chelsea Gelboin-Burkhart, MD<sup>1</sup>; Diana Bell, MD<sup>2</sup>; Nicole Scheff, PhD<sup>1</sup>; Steven Chinn, MD, MPH, FACS<sup>1</sup>. <sup>1</sup>University of Pittsburgh; <sup>2</sup>University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) is among the ten most common cancers worldwide and accounts for approximately 4% of all cancers in the United States. Despite advances in immunotherapy, clinical outcomes remain suboptimal, reflecting a limited understanding of tumor–host interactions, incomplete diagnostic tools, and substantial heterogeneity in therapeutic response. An emerging body of evidence highlights the nervous system as a key regulator of the tumor immune microenvironment (TIME). In particular, perineural invasion (PNI)—a common pathological feature in HNSCC—is strongly associated with aggressive disease behavior, increased recurrence, and poor survival. Yet, routine assessment of PNI remains hampered by biological complexity, inconsistent interpretation, and the lack of scalable quantitative approaches.</p>\n\n<p>To address this gap, we have developed a dedicated artificial intelligence (AI)–based PNI caller that operates directly on routine hematoxylin and eosin (H&E) slides. Using integrated machine-learning and deep-learning methods, our system automatically detects nerves, identifies tumor–nerve interactions, and quantifies PNI burden with high fidelity. (<strong>FIGURE 1</strong>) This platform establishes a standardized, objective, and reproducible approach for PNI scoring and provides a foundation for deeper investigation into the spatial ecology of the TIME.</p>\n\n<p>Building on this capability, our next phase will map tumor-infiltrating lymphocytes (TILs) relative to nerve structures to define how immune cells are spatially organized in PNI-positive versus PNI-negative regions. We will test the hypothesis that PNI disrupts local immune surveillance and contributes to diminished responsiveness to immunotherapy. Quantitative spatial metrics will be correlated with survival and treatment outcomes to determine their clinical relevance. Complementary bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics analyses will elucidate molecular pathways linking PNI, immune evasion, and therapeutic resistance.</p>\n\n<p>Together, these integrated approaches will establish an AI-enabled framework for detecting PNI, characterizing nerve–immune interactions, and identifying biomarkers that may guide precision immunotherapy in HNSCC.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154323/Figure1%20for%20AHNS%202026_Jiayu%20Wang%20PNI_v2.png' /></p>\n\n<p><strong>FIGURE 1.</strong> Representative images from the same tissue region showing: A. Immunohistochemistry staining for βIII-tubulin, with nerve regions highlighted in brown; B. the corresponding H&E slide; C. the same H&E slide annotated by a machine-learning based pixel classifier to highlight nerve regions (green), and a deep-learning based object classifier to identify tumor cells (red) and lymphoid cells (light blue). D. Spatial map showing annotated nerve regions (green) with tumor cells (red) and lymphoid cells (blue). E. A 100?μm buffer was generated around nerve regions (light green), with tumor cells (red) and lymphoid cells (blue) highlighted in these buffer areas. Spatial maps were produced in R using extracted coordinates from the annotated H&E slide.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154323--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S007",
      "content_id": "154776",
      "abstract_number": "S007",
      "poster_number": "",
      "title": "Artificial Intelligence-Assisted Systematic Review and Meta-analysis in Head and Neck Cancer: Impact on Speed Efficiency and Accuracy",
      "summary": "AI substantially improves the efficiency of systematic review and meta-analysis workflows in HNC, with marked reductions in time for search strategy development, screening, and data extraction, alongside improved extraction accuracy. Integrating AI into evidence synthesis pipelines can accelerate high-quality HNC meta-analyses and may help teams deliver timely, rigorous data to guide clinical decision-making....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154776",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Srivatsa Surya Vasudevan, MD, MS",
      "presenter": "Srivatsa Surya Vasudevan, MD, MS",
      "authors": "Srivatsa Surya Vasudevan, MD, MS ; Cherie-Ann O. Nathan, MD, FACS; Ameya A",
      "normalized_authors": [
        "Srivatsa Surya Vasudevan",
        "Cherie-Ann O. Nathan",
        "Ameya A"
      ],
      "affiliations": [
        "Asarkar, MD, FACS. Louisiana State University Health Sciences Center"
      ],
      "normalized_institutions": [
        "Asarkar, MD, FACS. Louisiana State University Health Sciences Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 310,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Srivatsa Surya Vasudevan, MD, MS ; Cherie-Ann O. Nathan, MD, FACS; Ameya A",
        "Affiliations": "Asarkar, MD, FACS. Louisiana State University Health Sciences Center",
        "Background": "Systematic reviews and meta-analyses in head and neck cancer (HNC) are time- and labor-intensive, particularly for search strategy development, screening, and data extraction. Artificial intelligence (AI) tools may streamline these steps, but quantitative evidence on efficiency gains is limited. We aimed to evaluate the effect of AI assistance on the speed and accuracy of the key stages in HNC systematic reviews and meta-analysis.",
        "Methods": "We compared conventional (non-AI) workflows with AI-assisted workflows for systematic reviews and meta-analyses in HNC, focusing on three stages: search strategy development, title/abstract screening, and data extraction. For each stage, we recorded total person-hours and calculated relative time savings in the AI assisted group. Data extraction accuracy was assessed by discrepancy rates between extracted values and a reference standard.",
        "Results": "A total of 12 meta-analyses were analyzed (6 were AI-assisted and 6 non-AI). AI-assisted search strategy development was completed in 12.5% of the time required for conventional search formulation. AI-assisted screening reduced the screening duration to 20% of that required by non-AI screening (60-300 minutes/ project in AI-assisted vs 300-600 minutes/ project in non-AI-assisted). For data extraction, AI assistance reduced the required time by 50% compared with conventional extraction (180-360 minutes/ project in AI-assisted vs 360-720 minutes in non-AI-assisted). In addition, AI-assisted extraction decreased the overall error margin by 15% relative to the non-AI workflow.",
        "Conclusion": "AI substantially improves the efficiency of systematic review and meta-analysis workflows in HNC, with marked reductions in time for search strategy development, screening, and data extraction, alongside improved extraction accuracy. Integrating AI into evidence synthesis pipelines can accelerate high-quality HNC meta-analyses and may help teams deliver timely, rigorous data to guide clinical decision-making. However, ethical use of AI in systematic reviews requires transparent disclosure of AI-assisted steps and standardization of AI workflows and reporting practices to ensure reproducibility and maintain trust in published findings.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Artificial Intelligence-Assisted Systematic Review and Meta-analysis in Head and Neck Cancer: Impact on Speed Efficiency and Accuracy</span>. <u>Srivatsa Surya Vasudevan, MD, MS</u>; Cherie-Ann O. Nathan, MD, FACS; Ameya A. Asarkar, MD, FACS. Louisiana State University Health Sciences Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Systematic reviews and meta-analyses in head and neck cancer (HNC) are time- and labor-intensive, particularly for search strategy development, screening, and data extraction. Artificial intelligence (AI) tools may streamline these steps, but quantitative evidence on efficiency gains is limited. We aimed to evaluate the effect of AI assistance on the speed and accuracy of the key stages in HNC systematic reviews and meta-analysis.</p>\n\n<p><strong>Methods: </strong>We compared conventional (non-AI) workflows with AI-assisted workflows for systematic reviews and meta-analyses in HNC, focusing on three stages: search strategy development, title/abstract screening, and data extraction. For each stage, we recorded total person-hours and calculated relative time savings in the AI assisted group. Data extraction accuracy was assessed by discrepancy rates between extracted values and a reference standard.</p>\n\n<p><strong>Results: </strong>A total of 12 meta-analyses were analyzed (6 were AI-assisted and 6 non-AI). AI-assisted search strategy development was completed in 12.5% of the time required for conventional search formulation. AI-assisted screening reduced the screening duration to 20% of that required by non-AI screening (60-300 minutes/ project in AI-assisted vs 300-600 minutes/ project in non-AI-assisted). For data extraction, AI assistance reduced the required time by 50% compared with conventional extraction (180-360 minutes/ project in AI-assisted vs 360-720 minutes in non-AI-assisted). In addition, AI-assisted extraction decreased the overall error margin by 15% relative to the non-AI workflow.</p>\n\n<p><strong>Conclusion: </strong>AI substantially improves the efficiency of systematic review and meta-analysis workflows in HNC, with marked reductions in time for search strategy development, screening, and data extraction, alongside improved extraction accuracy. Integrating AI into evidence synthesis pipelines can accelerate high-quality HNC meta-analyses and may help teams deliver timely, rigorous data to guide clinical decision-making. However, ethical use of AI in systematic reviews requires transparent disclosure of AI-assisted steps and standardization of AI workflows and reporting practices to ensure reproducibility and maintain trust in published findings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154776--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S009",
      "content_id": "154491",
      "abstract_number": "S009",
      "poster_number": "",
      "title": "AI-Enhanced Near-Ultraviolet Fluorescence for Quantitative Mapping of Facial Nerve Trajectories and Anatomic Variability",
      "summary": "AI-driven structural analysis demonstrates that NUV autofluorescence reliably captures the major architectural trajectories of the facial nerve, with quantitative correspondence to known anatomic variability despite expected loss of fine arborization. These findings affirm that fluorescence imaging—when paired with AI interpretation—functions as a powerful visual adjunct, supporting intraoperative decision-making...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154491",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fernando Dip, MD, FACS",
      "presenter": "Fernando Dip, MD, FACS",
      "authors": "Fernando Dip, MD, FACS 1 ; Rene Aleman, MD 2 ; Federico Marinelli, MD 1 ; Javier Ghiselli, MD 1 ; Diego Sinagra, MD 1",
      "normalized_authors": [
        "Fernando Dip",
        "Rene Aleman",
        "Federico Marinelli",
        "Javier Ghiselli",
        "Diego Sinagra"
      ],
      "affiliations": [
        "University of Buenos Aires",
        "Cleveland Clinic Florida"
      ],
      "normalized_institutions": [
        "University of Buenos Aires",
        "Cleveland Clinic Florida"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154491/NUV_heat_volume_3D.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154491/NUV_heat_volume_3D.png",
          "alt": "3D heat volume showing how often each nerve voxel appears across the anatomical control and NUV images. Higher points and warmer colors indicate regions where nerve trajectories were consistently detected; lower points reflect variable or image-specific anatomy.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154491"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 439,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Clinical Implications",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fernando Dip, MD, FACS 1 ; Rene Aleman, MD 2 ; Federico Marinelli, MD 1 ; Javier Ghiselli, MD 1 ; Diego Sinagra, MD 1",
        "Affiliations": "1 University of Buenos Aires; 2 Cleveland Clinic Florida",
        "Background": "Preservation of the facial nerve is central to oncologic safety and postoperative function in parotid and lateral skull base surgery. Near-ultraviolet (NUV) autofluorescence has emerged as a visual adjunct capable of highlighting major nerve pathways, yet its ability to portray true anatomic variability remains incompletely characterized. Artificial intelligence (AI)–assisted image analysis offers a quantitative framework for interpreting fluorescence-derived nerve topography, supporting but not replacing surgical judgment. This study evaluates NUV fluorescence against a reference anatomy map using AI-driven structural metrics, including branching complexity, literature-aligned variability indices, and angularity of nerve trajectories.",
        "Methods": "A descriptive anatomy chart (control) and five intraoperative NUV captures (experimental) were analyzed. For each NUV image, the fluorescing left panel was contrast-normalized, segmented, and skeletonized. Quantitative metrics included connected nerve components, skeleton length, branchpoints, endpoints, plexiformity index, angularity profiles, and structural similarity (SSIM) to the anatomical control. Variability metrics were grounded in established facial nerve branching classifications (Davis Types I–V) and known human variability ranges.",
        "Results": "The anatomical control demonstrated a densely arborizing plexiform pattern (530 components, 149,152 px skeleton length, 7,954 branchpoints). NUV images exhibited expected attenuation of fine branches (65–153 components; 36,787–87,798 px skeleton length) but retained major trunk trajectories, as reflected by consistently high skeleton-level SSIM values (0.70–0.76). Branching variability aligned with previously reported human anatomic ranges: Case 5 demonstrated the richest plexiform representation (normalized complexity 0.53), while case 3 reflected a linear variant (0.19) despite achieving the highest directional similarity (SSIM 0.759). Angularity measures showed greater segmental deviation in NUV images (mean 4.7–10.4° vs. 2.7° of the control), indicating selective fluorescence of thicker, serpentine fascicles. Across all images, NUV successfully preserved dominant nerve pathways while underrepresenting tertiary twigs.",
        "Conclusions": "AI-driven structural analysis demonstrates that NUV autofluorescence reliably captures the major architectural trajectories of the facial nerve, with quantitative correspondence to known anatomic variability despite expected loss of fine arborization. These findings affirm that fluorescence imaging—when paired with AI interpretation—functions as a powerful visual adjunct, supporting intraoperative decision-making without supplanting the surgeon’s anatomical expertise. Such combined modalities hold promise for real-time trajectory mapping, variability recognition, and operative safety enhancement in head and neck oncologic surgery.",
        "Clinical Implications": "AI-enhanced fluorescence analysis may standardize nerve visualization, provide interpretable metrics for real-time feedback, and reinforce safe dissection strategies, particularly in anatomically variant or surgically distorted fields.",
        "Abstract": "3D heat volume showing how often each nerve voxel appears across the anatomical control and NUV images. Higher points and warmer colors indicate regions where nerve trajectories were consistently detected; lower points reflect variable or image-specific anatomy. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AI-Enhanced Near-Ultraviolet Fluorescence for Quantitative Mapping of Facial Nerve Trajectories and Anatomic Variability</span>. <u>Fernando Dip, MD, FACS</u><sup>1</sup>; Rene Aleman, MD<sup>2</sup>; Federico Marinelli, MD<sup>1</sup>; Javier Ghiselli, MD<sup>1</sup>; Diego Sinagra, MD<sup>1</sup>. <sup>1</sup>University of Buenos Aires; <sup>2</sup>Cleveland Clinic Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Preservation of the facial nerve is central to oncologic safety and postoperative function in parotid and lateral skull base surgery. Near-ultraviolet (NUV) autofluorescence has emerged as a visual adjunct capable of highlighting major nerve pathways, yet its ability to portray true anatomic variability remains incompletely characterized. Artificial intelligence (AI)–assisted image analysis offers a quantitative framework for interpreting fluorescence-derived nerve topography, supporting but not replacing surgical judgment. This study evaluates NUV fluorescence against a reference anatomy map using AI-driven structural metrics, including branching complexity, literature-aligned variability indices, and angularity of nerve trajectories.</p>\n\n<p><strong>Methods: </strong>A descriptive anatomy chart (control) and five intraoperative NUV captures (experimental) were analyzed. For each NUV image, the fluorescing left panel was contrast-normalized, segmented, and skeletonized. Quantitative metrics included connected nerve components, skeleton length, branchpoints, endpoints, plexiformity index, angularity profiles, and structural similarity (SSIM) to the anatomical control. Variability metrics were grounded in established facial nerve branching classifications (Davis Types I–V) and known human variability ranges.</p>\n\n<p><strong>Results: </strong>The anatomical control demonstrated a densely arborizing plexiform pattern (530 components, 149,152 px skeleton length, 7,954 branchpoints). NUV images exhibited expected attenuation of fine branches (65–153 components; 36,787–87,798 px skeleton length) but retained major trunk trajectories, as reflected by consistently high skeleton-level SSIM values (0.70–0.76). Branching variability aligned with previously reported human anatomic ranges: Case 5 demonstrated the richest plexiform representation (normalized complexity 0.53), while case 3 reflected a linear variant (0.19) despite achieving the highest directional similarity (SSIM 0.759). Angularity measures showed greater segmental deviation in NUV images (mean 4.7–10.4° vs. 2.7° of the control), indicating selective fluorescence of thicker, serpentine fascicles. Across all images, NUV successfully preserved dominant nerve pathways while underrepresenting tertiary twigs.</p>\n\n<p><strong>Conclusions: </strong>AI-driven structural analysis demonstrates that NUV autofluorescence reliably captures the major architectural trajectories of the facial nerve, with quantitative correspondence to known anatomic variability despite expected loss of fine arborization. These findings affirm that fluorescence imaging—when paired with AI interpretation—functions as a powerful visual adjunct, supporting intraoperative decision-making without supplanting the surgeon’s anatomical expertise. Such combined modalities hold promise for real-time trajectory mapping, variability recognition, and operative safety enhancement in head and neck oncologic surgery.</p>\n\n<p><strong>Clinical Implications: </strong>AI-enhanced fluorescence analysis may standardize nerve visualization, provide interpretable metrics for real-time feedback, and reinforce safe dissection strategies, particularly in anatomically variant or surgically distorted fields.</p>\n\n<p><img alt='3D heat volume showing how often each nerve voxel appears across the anatomical control and NUV images. Higher points and warmer colors indicate regions where nerve trajectories were consistently detected; lower points reflect variable or image-specific anatomy.' src='https://www.submitmyabstract.com/abs/images/154491/NUV_heat_volume_3D.png' /></p>\n\n<p>3D heat volume showing how often each nerve voxel appears across the anatomical control and NUV images. Higher points and warmer colors indicate regions where nerve trajectories were consistently detected; lower points reflect variable or image-specific anatomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154491--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S010",
      "content_id": "154711",
      "abstract_number": "S010",
      "poster_number": "",
      "title": "Video-Based Tumor Tracking in Oropharyngeal Cancer Using Segment Anything Model 3: The SCOPE-HN-v1 Dataset",
      "summary": "SCOPE-HN-v1 is the first publicly available OPC video dataset with expert annotations. Pilot results demonstrate SAM-3's promise (best Dice 0.972) but variable performance (mean 0.593) across OPC presentations, underscoring need for domain-specific refinement.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154711",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nikita Bedi, BSc",
      "presenter": "Nikita Bedi, BSc",
      "authors": "Nikita Bedi, BSc 1 ; Hlu Vang, Bsc 1 ; Giuseppe Facchi 2 ; Alberto Paderno, MD, PhD 3 ; F",
      "normalized_authors": [
        "Nikita Bedi",
        "Hlu Vang",
        "Giuseppe Facchi",
        "Alberto Paderno"
      ],
      "affiliations": [
        "Christopher Holsinger, MD 1 . 1 Stanford University",
        "University of Milan",
        "Humanitas University"
      ],
      "normalized_institutions": [
        "Christopher Holsinger, MD 1 . 1 Stanford University",
        "University of Milan",
        "Humanitas University"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 319,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nikita Bedi, BSc 1 ; Hlu Vang, Bsc 1 ; Giuseppe Facchi 2 ; Alberto Paderno, MD, PhD 3 ; F",
        "Affiliations": "Christopher Holsinger, MD 1 . 1 Stanford University; 2 University of Milan; 3 Humanitas University",
        "Background": "Oropharyngeal cancer (OPC) incidence has risen dramatically, driven by HPV-associated disease. Flexible endoscopy is central to OPC diagnosis and surveillance, yet practice depends on subjective interpretation with substantial inter-observer variability. Although endoscopic video recording is routine and often required for quality metrics, frame-by-frame annotation is prohibitively time-intensive. Existing head and neck video datasets focus on laryngoscopy, leaving a gap for OPC where tumors are anatomically complex and obscured by normal structures. Foundation models like Segment Anything Model 3 (SAM-3) may reduce annotation burden by propagating expert masks across videos, but performance in OPC endoscopy is unknown. We previously released SCOPE-HN, an open MICCAI 2025 dataset of 942 expert-annotated images from 106 OPC patients. Here, we introduce SCOPE-HN-v1, the first publicly available OPC video dataset, and evaluate SAM-3 for tumor propagation from minimal supervision.",
        "Methods": "SCOPE-HN-v1 comprises 104 diagnostic OPC videos from 106 patients, each linked to SCOPE-HN screenshots with pixel-level tumor masks. We automatically matched video frames to screenshots by minimizing mean squared error, then derived normalized bounding boxes as visual prompts. SAM-3 sessions tested (1) text-only prompts and (2) bounding box prompts, propagating segmentations bidirectionally. Accuracy was assessed using Dice coefficient and IoU on ground-truth frames.",
        "Results": "Pilot analysis of 32/104 videos yielded 5,818 decimated frames (stride=10). Text prompting failed. Bounding box prompts initialized tracking successfully, producing masks in 661/5,818 frames (11.4%)—consistent with diagnostic endoscopy where most frames show normal anatomy. Performance varied substantially: best-case achieved near-perfect agreement (Dice 0.972, IoU 0.895), while mean performance was Dice 0.593, IoU 0.421. SAM-3 succeeded on stable videos with exophytic tumors but struggled with motion blur, saliva, and submucosal tumors.",
        "Conclusions": "SCOPE-HN-v1 is the first publicly available OPC video dataset with expert annotations. Pilot results demonstrate SAM-3's promise (best Dice 0.972) but variable performance (mean 0.593) across OPC presentations, underscoring need for domain-specific refinement.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Video-Based Tumor Tracking in Oropharyngeal Cancer Using Segment Anything Model 3: The SCOPE-HN-v1 Dataset</span>. <u>Nikita Bedi, BSc</u><sup>1</sup>; Hlu Vang, Bsc<sup>1</sup>; Giuseppe Facchi<sup>2</sup>; Alberto Paderno, MD, PhD<sup>3</sup>; F. Christopher Holsinger, MD<sup>1</sup>. <sup>1</sup>Stanford University; <sup>2</sup>University of Milan; <sup>3</sup>Humanitas University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oropharyngeal cancer (OPC) incidence has risen dramatically, driven by HPV-associated disease. Flexible endoscopy is central to OPC diagnosis and surveillance, yet practice depends on subjective interpretation with substantial inter-observer variability. Although endoscopic video recording is routine and often required for quality metrics, frame-by-frame annotation is prohibitively time-intensive. Existing head and neck video datasets focus on laryngoscopy, leaving a gap for OPC where tumors are anatomically complex and obscured by normal structures. Foundation models like Segment Anything Model 3 (SAM-3) may reduce annotation burden by propagating expert masks across videos, but performance in OPC endoscopy is unknown. We previously released SCOPE-HN, an open MICCAI 2025 dataset of 942 expert-annotated images from 106 OPC patients. Here, we introduce SCOPE-HN-v1, the first publicly available OPC video dataset, and evaluate SAM-3 for tumor propagation from minimal supervision.</p>\n\n<p><strong>Methods:</strong> SCOPE-HN-v1 comprises 104 diagnostic OPC videos from 106 patients, each linked to SCOPE-HN screenshots with pixel-level tumor masks. We automatically matched video frames to screenshots by minimizing mean squared error, then derived normalized bounding boxes as visual prompts. SAM-3 sessions tested (1) text-only prompts and (2) bounding box prompts, propagating segmentations bidirectionally. Accuracy was assessed using Dice coefficient and IoU on ground-truth frames.</p>\n\n<p><strong>Results: </strong>Pilot analysis of 32/104 videos yielded 5,818 decimated frames (stride=10). Text prompting failed. Bounding box prompts initialized tracking successfully, producing masks in 661/5,818 frames (11.4%)—consistent with diagnostic endoscopy where most frames show normal anatomy. Performance varied substantially: best-case achieved near-perfect agreement (Dice 0.972, IoU 0.895), while mean performance was Dice 0.593, IoU 0.421. SAM-3 succeeded on stable videos with exophytic tumors but struggled with motion blur, saliva, and submucosal tumors.</p>\n\n<p><strong>Conclusions:</strong> SCOPE-HN-v1 is the first publicly available OPC video dataset with expert annotations. Pilot results demonstrate SAM-3's promise (best Dice 0.972) but variable performance (mean 0.593) across OPC presentations, underscoring need for domain-specific refinement.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154711--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S011",
      "content_id": "154601",
      "abstract_number": "S011",
      "poster_number": "",
      "title": "Validating the Use of Artificial Intelligence in Electronic Medical Record Data Abstraction for Head and Neck Cancer Patients",
      "summary": "These data show that LLM-based tools can perform several head and neck oncology abstraction tasks with variable but generally high accuracy above 80%, with particularly high accuracy for structured or binary data elements. Future evaluation will incorporate more reviewers and larger cohorts to further validate these LLM functions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154601",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dante Merlino, MD",
      "presenter": "Dante Merlino, MD",
      "authors": "Nicole I Farber, MD; Kyle Polen, BS; Annie Arrighi-Allisan, MD; Keshav Shah, BS; Kim B Le, BS; Kerol Faltas, BA; Ananya Uddanti; Karthik Rajasekaran, MD; Devraj Basu, MD; Christopher H Rassekh, MD; Ara A Chalian, MD; Steven B Cannady, MD; Gregory Farwell, MD; Gregory S Weinstein, MD; Ryan Carey, MD; Robert Brody, MD; Dante Merlino, MD",
      "normalized_authors": [
        "Nicole I Farber",
        "Kyle Polen",
        "Annie Arrighi-Allisan",
        "Keshav Shah",
        "Kim B Le",
        "Kerol Faltas",
        "Ananya Uddanti",
        "Karthik Rajasekaran",
        "Devraj Basu",
        "Christopher H Rassekh",
        "Ara A Chalian",
        "Steven B Cannady",
        "Gregory Farwell",
        "Gregory S Weinstein",
        "Ryan Carey",
        "Robert Brody",
        "Dante Merlino"
      ],
      "affiliations": [
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 531,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nicole I Farber, MD; Kyle Polen, BS; Annie Arrighi-Allisan, MD; Keshav Shah, BS; Kim B Le, BS; Kerol Faltas, BA; Ananya Uddanti; Karthik Rajasekaran, MD; Devraj Basu, MD; Christopher H Rassekh, MD; Ara A Chalian, MD; Steven B Cannady, MD; Gregory Farwell, MD; Gregory S Weinstein, MD; Ryan Carey, MD; Robert Brody, MD; Dante Merlino, MD",
        "Affiliations": "University of Pennsylvania",
        "Background": "Recent advances in artificial intelligence (AI) and large language models (LLMs) have dramatically improved data retrieval efficiency. In medicine, the electronic medical record (EMR) is poised for LLM application, as valuable clinical data is often hidden within non-tabular fields such as operative reports, pathology studies, and clinic notes. As EMR data increases in complexity, AI offers a unique solution for data abstraction, particularly for quality assessment in head and neck cancer. Despite clear use cases, there is a paucity of peer-reviewed research validating these systems in head and neck oncology. We utilized a head and neck cancer cohort to describe and validate an AI data abstraction system using the Databricks platform across three distinct clinical use cases.",
        "Methods": "We conducted a nonblinded, cross-sectional analysis at a single academic medical center using data from 2016 to 2025. Three Databricks functions were tested (\"Query,\" \"Extract,\" and \"Generate\") using the open-source LLM model databricks-meta-llama-3-3-70b-instruct. These results were compared against human review to determine accuracy. The study evaluated three datasets:",
        "Abstract": "1. Readmission Consults: Three reviewers evaluated 98 postoperative readmission/emergency department notes. The 88 cases where all three reviewers achieved unanimous consensus on the reason for admission were used for analysis. 2. Pathology Reports: 17 data points were extracted from 100 surgical pathology notes (including HPV status, Final Diagnosis, Tumor Size, Margins, Extranodal Extension, Grade, Invasion, etc.). The performance of the AI functions in abstracting these specific data points was assessed by reviewers. 3. Re-operative Notes: Reviewers evaluated 132 operative notes for patients returning to the operating room within 14 days of Transoral Robotic Surgery (TORS) (subsequent cases containing CPT codes 35800, 35860, or 35820). View in Agenda and Add to Schedule",
        "Results": "In the readmission cohort (n=88), the AI system classified reasons for readmission (bleeding, infection, nasogastric tube, other) with varying accuracy across the three functions: \"Query\" (74/88; 87.2%), \"Extract\" (69/88; 81.4%), and \"Generate\" (78/88; 90.7%). Confidence values were highest for \"Query\" (0.88 ±0.052) and \"Generate\" (0.87 ±0.05) compared to \"Extract\" (0.83 ±0.20). Incorrect categorizations were largely attributed to records with limited provider documentation. In the re-operative note cohort (n=132), the \"Query\" function outperformed other models, correctly identifying the reason for reoperation in 111/132 cases. Performance for \"Generate\" and \"Extract\" was inconsistent, with responses failing to match requested categories in 102/132 and 61/132 cases, respectively. Across 97 pathology reports, all models demonstrated near-full accurate extraction of binary variables such as laterality (100%), lymphovascular invasion (100%), perineural invasion (100%), and HPV status (99-100%). Every model performed with above 90% accuracy in other variables aside from AI “Extract” with final diagnosis (87/97; 89.7%) and “Query” with margin status (86/97; 88.7%). The greatest inaccuracy was seen with margin distance, which saw “Extract” (84/97; 86.6%) perform better than “Query” (57/97; 58.8%) and “Generate” (78/97; 80.4%).",
        "Conclusion": "These data show that LLM-based tools can perform several head and neck oncology abstraction tasks with variable but generally high accuracy above 80%, with particularly high accuracy for structured or binary data elements. Future evaluation will incorporate more reviewers and larger cohorts to further validate these LLM functions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Validating the Use of Artificial Intelligence in Electronic Medical Record Data Abstraction for Head and Neck Cancer Patients</span>. Nicole I Farber, MD; Kyle Polen, BS; Annie Arrighi-Allisan, MD; Keshav Shah, BS; Kim B Le, BS; Kerol Faltas, BA; Ananya Uddanti; Karthik Rajasekaran, MD; Devraj Basu, MD; Christopher H Rassekh, MD; Ara A Chalian, MD; Steven B Cannady, MD; Gregory Farwell, MD; Gregory S Weinstein, MD; Ryan Carey, MD; Robert Brody, MD; <u>Dante Merlino, MD</u>. University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Recent advances in artificial intelligence (AI) and large language models (LLMs) have dramatically improved data retrieval efficiency. In medicine, the electronic medical record (EMR) is poised for LLM application, as valuable clinical data is often hidden within non-tabular fields such as operative reports, pathology studies, and clinic notes. As EMR data increases in complexity, AI offers a unique solution for data abstraction, particularly for quality assessment in head and neck cancer. Despite clear use cases, there is a paucity of peer-reviewed research validating these systems in head and neck oncology. We utilized a head and neck cancer cohort to describe and validate an AI data abstraction system using the Databricks platform across three distinct clinical use cases.</p>\n\n<p><strong>Methods: </strong>We conducted a nonblinded, cross-sectional analysis at a single academic medical center using data from 2016 to 2025. Three Databricks functions were tested (\"Query,\" \"Extract,\" and \"Generate\") using the open-source LLM model databricks-meta-llama-3-3-70b-instruct. These results were compared against human review to determine accuracy. The study evaluated three datasets:</p>\n\n<p>1. Readmission Consults: Three reviewers evaluated 98 postoperative readmission/emergency department notes. The 88 cases where all three reviewers achieved unanimous consensus on the reason for admission were used for analysis.</p>\n\n<p>2. Pathology Reports: 17 data points were extracted from 100 surgical pathology notes (including HPV status, Final Diagnosis, Tumor Size, Margins, Extranodal Extension, Grade, Invasion, etc.). The performance of the AI functions in abstracting these specific data points was assessed by reviewers.</p>\n\n<p>3. Re-operative Notes: Reviewers evaluated 132 operative notes for patients returning to the operating room within 14 days of Transoral Robotic Surgery (TORS) (subsequent cases containing CPT codes 35800, 35860, or 35820).</p>\n\n<p><strong>Results: </strong>In the readmission cohort (n=88), the AI system classified reasons for readmission (bleeding, infection, nasogastric tube, other) with varying accuracy across the three functions: \"Query\" (74/88; 87.2%), \"Extract\" (69/88; 81.4%), and \"Generate\" (78/88; 90.7%). Confidence values were highest for \"Query\" (0.88 ±0.052) and \"Generate\" (0.87 ±0.05) compared to \"Extract\" (0.83 ±0.20). Incorrect categorizations were largely attributed to records with limited provider documentation. In the re-operative note cohort (n=132), the \"Query\" function outperformed other models, correctly identifying the reason for reoperation in 111/132 cases. Performance for \"Generate\" and \"Extract\" was inconsistent, with responses failing to match requested categories in 102/132 and 61/132 cases, respectively. Across 97 pathology reports, all models demonstrated near-full accurate extraction of binary variables such as laterality (100%), lymphovascular invasion (100%), perineural invasion (100%), and HPV status (99-100%). Every model performed with above 90% accuracy in other variables aside from AI “Extract” with final diagnosis (87/97; 89.7%) and “Query” with margin status (86/97; 88.7%). The greatest inaccuracy was seen with margin distance, which saw “Extract” (84/97; 86.6%) perform better than “Query” (57/97; 58.8%) and “Generate” (78/97; 80.4%).</p>\n\n<p><strong>Conclusion: </strong>These data show that LLM-based tools can perform several head and neck oncology abstraction tasks with variable but generally high accuracy above 80%, with particularly high accuracy for structured or binary data elements. Future evaluation will incorporate more reviewers and larger cohorts to further validate these LLM functions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154601--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S012",
      "content_id": "154168",
      "abstract_number": "S012",
      "poster_number": "",
      "title": "Machine-Learning-Based Prediction of Re-exploration in Microvascular Free Flap Reconstruction for Head and Neck Cancer: A CatBoost Model with a Clinically Applicable Scoring System",
      "summary": "A CatBoost-based machine-learning model demonstrated good discriminatory performance for predicting re-exploration after microvascular reconstruction. Extent of resection, intraoperative MAP, and operative duration emerged as dominant risk contributors. The derived scoring system offers a practical, point-based tool to support intraoperative and early postoperative decision-making. Prospective validation is...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154168",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260113",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karthik Rao, Mch, Head and Neck Oncology",
      "presenter": "Karthik Rao, Mch, Head and Neck Oncology",
      "authors": "Radhika Kapahtia, MCh, Plastic Reconstructive Surgery; Karthik Rao, Mch, Head and Neck Oncology ; Prajwal Dange, Mch, Head and Neck Oncology; Bss Srinath, Mch, Surgical Oncology",
      "normalized_authors": [
        "Radhika Kapahtia, MCh, Plastic Reconstructive Surgery",
        "Karthik Rao, Mch, Head and Neck Oncology",
        "Prajwal Dange, Mch, Head and Neck Oncology",
        "Bss Srinath, Mch, Surgical Oncology"
      ],
      "affiliations": [
        "Sri Shankara Cancer Hospital and Research Centre, Bengaluru"
      ],
      "normalized_institutions": [
        "Sri Shankara Cancer Hospital and Research Centre, Bengaluru"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 345,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Radhika Kapahtia, MCh, Plastic Reconstructive Surgery; Karthik Rao, Mch, Head and Neck Oncology ; Prajwal Dange, Mch, Head and Neck Oncology; Bss Srinath, Mch, Surgical Oncology",
        "Affiliations": "Sri Shankara Cancer Hospital and Research Centre, Bengaluru",
        "Background": "Early identification of patients at risk for microvascular re-exploration remains critical in head and neck reconstructive surgery. Traditional predictors often underestimate dynamic intraoperative factors such as perfusion fluctuations and extent of resection. This study aimed to develop and validate a machine-learning model capable of predicting re-exploration, and to translate key predictors into a simplified clinical scoring system.",
        "Methods": "A retrospective analysis of 150 patients undergoing free flap reconstruction for head and neck malignancies was performed. Twenty-one perioperative variables were assessed. A CatBoost classifier was trained using 5-fold stratified cross-validation. Model performance was evaluated using AUC-ROC, sensitivity, specificity, positive and negative predictive values (PPV, NPV), and Youden’s J at the optimal threshold. Feature importance was derived using both model-based (CatBoost gain scores) and SHAP values. A 387-point risk score was generated by proportionally scaling top predictor weights.",
        "Results": "The event rate of re-exploration was 8.7% (n=13). The CatBoost model demonstrated an AUC-ROC of 0.724, with a sensitivity of 53.8%, specificity of 80.3%, PPV 20.6%, NPV 94.8%, and Youden’s J 0.341.",
        "Abstract": "Model-based feature importance identified the following top predictors: Extent of resection (17.4%), Average intraoperative mean arterial pressure (9.3%), Reconstruction time (8.4%), Comorbidities (7.4%), Subsite (7.2%). SHAP analysis demonstrated consistent ranking, with intraoperative MAP and extent of resection remaining the strongest contributors to flap failure risk. These variables were incorporated into a 387-point scoring system, with the highest individual weights assigned to: Extent of resection (52 points) Intraoperative MAP (39 points) Reconstruction time (30 points) Comorbidities (26 points) Age (25 points) Score calibration showed increasing predicted probability of re-exploration with higher aggregate scores, supporting the model’s clinical interpretability. View in Agenda and Add to Schedule",
        "Conclusion": "A CatBoost-based machine-learning model demonstrated good discriminatory performance for predicting re-exploration after microvascular reconstruction. Extent of resection, intraoperative MAP, and operative duration emerged as dominant risk contributors. The derived scoring system offers a practical, point-based tool to support intraoperative and early postoperative decision-making. Prospective validation is warranted to confirm its applicability across diverse head and neck oncologic populations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Machine-Learning-Based Prediction of Re-exploration in Microvascular Free Flap Reconstruction for Head and Neck Cancer: A CatBoost Model with a Clinically Applicable Scoring System</span>. Radhika Kapahtia, MCh, Plastic Reconstructive Surgery; <u>Karthik Rao, Mch, Head and Neck Oncology</u>; Prajwal Dange, Mch, Head and Neck Oncology; Bss Srinath, Mch, Surgical Oncology. Sri Shankara Cancer Hospital and Research Centre, Bengaluru<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Early identification of patients at risk for microvascular re-exploration remains critical in head and neck reconstructive surgery. Traditional predictors often underestimate dynamic intraoperative factors such as perfusion fluctuations and extent of resection. This study aimed to develop and validate a machine-learning model capable of predicting re-exploration, and to translate key predictors into a simplified clinical scoring system.</p>\n\n<p><strong>Methods: </strong>A retrospective analysis of 150 patients undergoing free flap reconstruction for head and neck malignancies was performed. Twenty-one perioperative variables were assessed. A CatBoost classifier was trained using 5-fold stratified cross-validation. Model performance was evaluated using AUC-ROC, sensitivity, specificity, positive and negative predictive values (PPV, NPV), and Youden’s J at the optimal threshold. Feature importance was derived using both model-based (CatBoost gain scores) and SHAP values. A 387-point risk score was generated by proportionally scaling top predictor weights.</p>\n\n<p><strong>Results: </strong>The event rate of re-exploration was 8.7% (n=13). The CatBoost model demonstrated an AUC-ROC of 0.724, with a sensitivity of 53.8%, specificity of 80.3%, PPV 20.6%, NPV 94.8%, and Youden’s J 0.341.</p>\n\n<p>Model-based feature importance identified the following top predictors:</p>\n\n<p>Extent of resection (17.4%),</p>\n\n<p>Average intraoperative mean arterial pressure (9.3%),</p>\n\n<p>Reconstruction time (8.4%),</p>\n\n<p>Comorbidities (7.4%),</p>\n\n<p>Subsite (7.2%).</p>\n\n<p>SHAP analysis demonstrated consistent ranking, with intraoperative MAP and extent of resection remaining the strongest contributors to flap failure risk. These variables were incorporated into a 387-point scoring system, with the highest individual weights assigned to:</p>\n\n<p>Extent of resection (52 points)</p>\n\n<p>Intraoperative MAP (39 points)</p>\n\n<p>Reconstruction time (30 points)</p>\n\n<p>Comorbidities (26 points)</p>\n\n<p>Age (25 points)</p>\n\n<p>Score calibration showed increasing predicted probability of re-exploration with higher aggregate scores, supporting the model’s clinical interpretability.</p>\n\n<p><strong>Conclusion: </strong>A CatBoost-based machine-learning model demonstrated good discriminatory performance for predicting re-exploration after microvascular reconstruction. Extent of resection, intraoperative MAP, and operative duration emerged as dominant risk contributors. The derived scoring system offers a practical, point-based tool to support intraoperative and early postoperative decision-making. Prospective validation is warranted to confirm its applicability across diverse head and neck oncologic populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154168--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260113' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S013",
      "content_id": "153474",
      "abstract_number": "S013",
      "poster_number": "",
      "title": "How does an osseous free flap change over time: Morphologic changes of mandibular reconstruction using Scapular and Fibular free flaps.",
      "summary": "The mandible undergoes significant morphological changes as the bone adapts to new force distributions after segmental mandibulectomy and reconstruction. This study shows that there are changes to both the native mandible and the flap, as well as to the density of the bone. This knowledge will allow for reconstructions to be better planned for desired outcomes potentially including cosmetic outcomes, dental...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153474",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Rosenberry",
      "presenter": "Jessica Rosenberry",
      "authors": "Jessica Rosenberry 1 ; Rohan Birk, BASc 1 ; Eitan Prisman, MD, MA, FRCSC 2",
      "normalized_authors": [
        "Jessica Rosenberry",
        "Rohan Birk, BASc",
        "Eitan Prisman, MA, FRCSC"
      ],
      "affiliations": [
        "Department of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
        "Division of Otolaryngology – Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Department of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
        "Division of Otolaryngology – Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153474/spaghetti_plot(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153474/spaghetti_plot(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153474"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jessica Rosenberry 1 ; Rohan Birk, BASc 1 ; Eitan Prisman, MD, MA, FRCSC 2",
        "Affiliations": "1 Department of Biomedical Engineering, Faculty of Applied Science, University of British Columbia; 2 Division of Otolaryngology – Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada",
        "Background": "There is little knowledge of the extent of osseous changes of both the native mandible and osseous free tissue after mandibular reconstruction. Appreciating these changes may improve reconstructive planning to better optimize outcomes and avoid possible complications.",
        "Objective": "The objective of this study is to quantify the morphological and bone density changes between the mandibular reconstruction as assessed at the CT scan on post operative day 5 (POD5) and the CT scan at one year.",
        "Methods": "66 patients who underwent mandibular reconstruction with osseous free flaps had CT scans at 5 days post-op and 1-year post-op. Scans were segmented into 3D models using 3D Slicer software. Cephalometric measurements were taken at various locations on the native and reconstructed mandible, and the heights of each segment were recorded. Bone density was determined using normalized Hounsfield units; the mean, median, 5th percentile, and 95th percentile Hounsfield units were calculated for each reconstructed segment at POD5 and at 1 year.",
        "Results": "Several morphological features were observed between the POD5 and 1 year CT scan. Of the 66 patients, 20 received scapula free flap and 46 received fibula free flap. The average number of segments for fibula and scapula were 2.2 and 1.3, respectively. For all reconstructions, the height of the reconstructed segments decreased on average by 1.26 ± 2.05 mm from POD5 to 1 year. There were statistically significant (p < 0.05) increases in the intercondylar angle and ramus height on the healthy side, and significant decreases in intercondylar distance, intergonial distance, ramus height on the diseased side, and segment height up to 2 segments. The cephalometric changes were not significantly different between patients with a fibula or scapula donors. Across all reconstructions the bone density, measured by Hounsfield units, decreased significantly (p < 0.001) between day 5 and year 1. When comparing bone density changes between fibula and scapula no significant difference was observed, although it trends close to significance (p = 0.08761)",
        "Conclusions": "The mandible undergoes significant morphological changes as the bone adapts to new force distributions after segmental mandibulectomy and reconstruction. This study shows that there are changes to both the native mandible and the flap, as well as to the density of the bone. This knowledge will allow for reconstructions to be better planned for desired outcomes potentially including cosmetic outcomes, dental implantability and functional outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>How does an osseous free flap change over time: Morphologic changes of mandibular reconstruction using Scapular and Fibular free flaps.</span>. <u>Jessica Rosenberry</u><sup>1</sup>; Rohan Birk, BASc<sup>1</sup>; Eitan Prisman, MD, MA, FRCSC<sup>2</sup>. <sup>1</sup>Department of Biomedical Engineering, Faculty of Applied Science, University of British Columbia; <sup>2</sup>Division of Otolaryngology – Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> There is little knowledge of the extent of osseous changes of both the native mandible and osseous free tissue after mandibular reconstruction. Appreciating these changes may improve reconstructive planning to better optimize outcomes and avoid possible complications.</p>\n\n<p><strong>Objective:</strong> The objective of this study is to quantify the morphological and bone density changes between the mandibular reconstruction as assessed at the CT scan on post operative day 5 (POD5) and the CT scan at one year.</p>\n\n<p><strong>Methods: </strong>66 patients who underwent mandibular reconstruction with osseous free flaps had CT scans at 5 days post-op and 1-year post-op. Scans were segmented into 3D models using 3D Slicer software. Cephalometric measurements were taken at various locations on the native and reconstructed mandible, and the heights of each segment were recorded. Bone density was determined using normalized Hounsfield units; the mean, median, 5th percentile, and 95th percentile Hounsfield units were calculated for each reconstructed segment at POD5 and at 1 year.</p>\n\n<p><strong>Results: </strong>Several morphological features were observed between the POD5 and 1 year CT scan. Of the 66 patients, 20 received scapula free flap and 46 received fibula free flap. The average number of segments for fibula and scapula were 2.2 and 1.3, respectively. For all reconstructions, the height of the reconstructed segments decreased on average by 1.26 ± 2.05 mm from POD5 to 1 year. There were statistically significant (p < 0.05) increases in the intercondylar angle and ramus height on the healthy side, and significant decreases in intercondylar distance, intergonial distance, ramus height on the diseased side, and segment height up to 2 segments. The cephalometric changes were not significantly different between patients with a fibula or scapula donors. Across all reconstructions the bone density, measured by Hounsfield units, decreased significantly (p < 0.001) between day 5 and year 1. When comparing bone density changes between fibula and scapula no significant difference was observed, although it trends close to significance (p = 0.08761) </p>\n\n<p><strong>Conclusions:</strong> The mandible undergoes significant morphological changes as the bone adapts to new force distributions after segmental mandibulectomy and reconstruction. This study shows that there are changes to both the native mandible and the flap, as well as to the density of the bone. This knowledge will allow for reconstructions to be better planned for desired outcomes potentially including cosmetic outcomes, dental implantability and functional outcomes. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153474/spaghetti_plot(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153474--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S014",
      "content_id": "154286",
      "abstract_number": "S014",
      "poster_number": "",
      "title": "Practice Patterns, Infrastructure, and Barriers to Jaw-in-a-Day Reconstruction: A Multicenter Cross-Sectional Analysis",
      "summary": "JIAD adoption remains concentrated in resource-rich academic centers with established digital workflows and prosthodontic collaboration. Non-adopting institutions most often cited lack of prosthodontist support, reimbursement challenges, and limited training. Despite these obstacles, most clinicians expressed readiness to adopt JIAD if barriers were addressed. Findings highlight the need for standardized training...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154286",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin M Soffer, MD",
      "presenter": "Justin M Soffer, MD",
      "authors": "Justin M Soffer, MD 1 ; Joanne Hu, BS 1 ; Aaron Zebolsky, MD 1 ; John P Gleysteen, Associate Professor, MD 1 ; Fawaz Makki, Physician, MD 2 ; C. Burton Wood, Assistant Professor, MD 1 ; Alexandra Kejner, Associate Professor, MD 3 ; Mark Wax, Professor, MD 4 ; Anas Eid, MD 1",
      "normalized_authors": [
        "Justin M Soffer",
        "Joanne Hu",
        "Aaron Zebolsky",
        "John P Gleysteen, Associate",
        "Fawaz Makki, Physician",
        "C. Burton Wood, Assistant",
        "Alexandra Kejner, Associate",
        "Mark Wax",
        "Anas Eid"
      ],
      "affiliations": [
        "University of Tennessee Health Science Center (UTHSC)",
        "Advent Health Medical Group",
        "Medical University of South Carolina",
        "Oregon Health Science University"
      ],
      "normalized_institutions": [
        "University of Tennessee Health Science Center (UTHSC)",
        "Advent Health Medical Group",
        "Medical University of South Carolina",
        "Oregon Health Science University"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 530,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Justin M Soffer, MD 1 ; Joanne Hu, BS 1 ; Aaron Zebolsky, MD 1 ; John P Gleysteen, Associate Professor, MD 1 ; Fawaz Makki, Physician, MD 2 ; C. Burton Wood, Assistant Professor, MD 1 ; Alexandra Kejner, Associate Professor, MD 3 ; Mark Wax, Professor, MD 4 ; Anas Eid, MD 1",
        "Affiliations": "1 University of Tennessee Health Science Center (UTHSC); 2 Advent Health Medical Group; 3 Medical University of South Carolina; 4 Oregon Health Science University",
        "Background": "Jaw-in-a-Day (JIAD) reconstruction—combining osseous free-flap reconstruction, dental implant placement, and prosthesis delivery within a single operation—offers near-immediate restoration of form and function but requires extensive coordination, digital-planning expertise, and institutional resources. Contemporary data describing institutional practice patterns and barriers remain limited. This cross-sectional study characterizes JIAD resources, adoption, and perceived challenges across institutions performing head and neck microvascular reconstruction.",
        "Methods": "An IRB-exempt, REDCap-based survey was distributed to surgeons in otolaryngology (OHNS), oral and maxillofacial surgery (OMFS), plastic surgery, and prosthodontics through professional societies and investigator networks. The 45-item instrument assessed institutional characteristics, prosthodontic and virtual surgical planning (VSP) resources, JIAD activity, training exposure, and perceived barriers. Only complete responses were analyzed descriptively.",
        "Results": "The present analysis includes 88 verified responses (90% U.S., 2% Canada, 8% international). Fifty institutions (58%) reported performing JIAD and 36 (42%) did not. Respondents were primarily OHNS (68.8%), followed by OMFS (18.6%), plastic surgeons (7%), and prosthodontists (3.5%). Most practiced in academic or tertiary-care centers (82.6%).",
        "Abstract": "Prosthodontic collaboration was available at 61.3% of institutions overall but was significantly more common among JIAD centers (76%) than non-JIAD centers (41.7%; p=0.001). VSP access was nearly universal (96.5%), and in-house VSP capability was more common among JIAD centers (16.0% vs 8.3%; p=0.021). Formal JIAD training was reported by 55.8% overall but was markedly more common among JIAD institutions (72.0% vs 33.3%, p<0.001) Common barriers included reimbursement limitations (45.4%), lack of prosthodontic support (34.9%), planning cost (20.9%), surgical complexity (16.3%), preference for staged rehabilitation (16.3%), and limited training (16.3%). Non-JIAD centers more frequently cited lack of prosthodontist (58.3% vs 18.0%, p < 0.001) and inadequate JIAD training (30.6% vs 6.0%, p=0.002). Both factors were independent predictors of belonging to the non-JIAD cohort on multivariate analysis (p<0.001 and p=0.002, respectively). Among JIAD-performing institutions, the median annual case volume was 4 (range 0–200). Leading indications included benign tumors (53.4%), osteoradionecrosis (28.4%), malignancy (27.3%), and trauma (20.5%). Institutional leadership varied among OMFS (35.4%), OHNS (29.2%), and joint/shared teams (29.6%). 39.%% reported having encountered a JIAD complication, and 47.7% described changing their workflow to reduce the risk of similar complications. Attitudes were generally positive: 77.9% agreed that JIAD improves functional outcomes; however, 65.2% agreed it adds significant operative complexity, and 63.9% believed risks currently outweigh benefits. If barriers were mitigated, 79.5% indicated willingness to initiate or expand JIAD. Educational programs were viewed favorably, with 60.7% agreeing workshops would improve institutional JIAD capability. View in Agenda and Add to Schedule",
        "Conclusion": "JIAD adoption remains concentrated in resource-rich academic centers with established digital workflows and prosthodontic collaboration. Non-adopting institutions most often cited lack of prosthodontist support, reimbursement challenges, and limited training. Despite these obstacles, most clinicians expressed readiness to adopt JIAD if barriers were addressed. Findings highlight the need for standardized training pathways, expanded prosthodontic integration, and institutional investment to broaden access to single-stage jaw reconstruction. Ongoing international dissemination will further define global variation in JIAD practice."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Practice Patterns, Infrastructure, and Barriers to Jaw-in-a-Day Reconstruction: A Multicenter Cross-Sectional Analysis</span>. <u>Justin M Soffer, MD</u><sup>1</sup>; Joanne Hu, BS<sup>1</sup>; Aaron Zebolsky, MD<sup>1</sup>; John P Gleysteen, Associate Professor, MD<sup>1</sup>; Fawaz Makki, Physician, MD<sup>2</sup>; C. Burton Wood, Assistant Professor, MD<sup>1</sup>; Alexandra Kejner, Associate Professor, MD<sup>3</sup>; Mark Wax, Professor, MD<sup>4</sup>; Anas Eid, MD<sup>1</sup>. <sup>1</sup>University of Tennessee Health Science Center (UTHSC); <sup>2</sup>Advent Health Medical Group; <sup>3</sup>Medical University of South Carolina; <sup>4</sup>Oregon Health Science University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Jaw-in-a-Day (JIAD) reconstruction—combining osseous free-flap reconstruction, dental implant placement, and prosthesis delivery within a single operation—offers near-immediate restoration of form and function but requires extensive coordination, digital-planning expertise, and institutional resources. Contemporary data describing institutional practice patterns and barriers remain limited. This cross-sectional study characterizes JIAD resources, adoption, and perceived challenges across institutions performing head and neck microvascular reconstruction.</p>\n\n<p><strong>Methods: </strong>An IRB-exempt, REDCap-based survey was distributed to surgeons in otolaryngology (OHNS), oral and maxillofacial surgery (OMFS), plastic surgery, and prosthodontics through professional societies and investigator networks. The 45-item instrument assessed institutional characteristics, prosthodontic and virtual surgical planning (VSP) resources, JIAD activity, training exposure, and perceived barriers. Only complete responses were analyzed descriptively.</p>\n\n<p><strong>Results: </strong>The present analysis includes 88 verified responses (90% U.S., 2% Canada, 8% international). Fifty institutions (58%) reported performing JIAD and 36 (42%) did not. Respondents were primarily OHNS (68.8%), followed by OMFS (18.6%), plastic surgeons (7%), and prosthodontists (3.5%). Most practiced in academic or tertiary-care centers (82.6%).</p>\n\n<p>Prosthodontic collaboration was available at 61.3% of institutions overall but was significantly more common among JIAD centers (76%) than non-JIAD centers (41.7%; p=0.001). VSP access was nearly universal (96.5%), and in-house VSP capability was more common among JIAD centers (16.0% vs 8.3%; p=0.021). Formal JIAD training was reported by 55.8% overall but was markedly more common among JIAD institutions (72.0% vs 33.3%, p<0.001)</p>\n\n<p>Common barriers included reimbursement limitations (45.4%), lack of prosthodontic support (34.9%), planning cost (20.9%), surgical complexity (16.3%), preference for staged rehabilitation (16.3%), and limited training (16.3%). Non-JIAD centers more frequently cited lack of prosthodontist (58.3% vs 18.0%, p < 0.001) and inadequate JIAD training (30.6% vs 6.0%, p=0.002). Both factors were independent predictors of belonging to the non-JIAD cohort  on multivariate analysis (p<0.001 and p=0.002, respectively).</p>\n\n<p>Among JIAD-performing institutions, the median annual case volume was 4 (range 0–200). Leading indications included benign tumors (53.4%), osteoradionecrosis (28.4%), malignancy (27.3%), and trauma (20.5%). Institutional leadership varied among OMFS (35.4%), OHNS (29.2%), and joint/shared teams (29.6%). 39.%% reported having encountered a JIAD complication, and 47.7% described changing their workflow to reduce the risk of similar complications.</p>\n\n<p>Attitudes were generally positive: 77.9% agreed that JIAD improves functional outcomes; however, 65.2% agreed it adds significant operative complexity, and 63.9% believed risks currently outweigh benefits.  If barriers were mitigated, 79.5% indicated willingness to initiate or expand JIAD. Educational programs were viewed favorably, with 60.7% agreeing workshops would improve institutional JIAD capability.</p>\n\n<p><strong>Conclusion: </strong>JIAD adoption remains concentrated in resource-rich academic centers with established digital workflows and prosthodontic collaboration. Non-adopting institutions most often cited lack of prosthodontist support, reimbursement challenges, and limited training. Despite these obstacles, most clinicians expressed readiness to adopt JIAD if barriers were addressed. Findings highlight the need for standardized training pathways, expanded prosthodontic integration, and institutional investment to broaden access to single-stage jaw reconstruction. Ongoing international dissemination will further define global variation in JIAD practice.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154286--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S015",
      "content_id": "154474",
      "abstract_number": "S015",
      "poster_number": "",
      "title": "The high fibula free flap: A transformative approach that improves donor site morbidity for reconstruction of complex maxillomandibular defects",
      "summary": "A “high fibula” osseous free flap for reconstruction of composite maxillomandibular defects reduces donor site morbidity compared to traditional fibula free flap harvest. This novel harvest technique has the potential to transform donor site considerations in patients with composite maxillomandibular defects.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154474",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Matthew E Spector, MD",
      "presenter": "Matthew E Spector, MD",
      "authors": "Matthew E Spector, MD ; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD",
      "normalized_authors": [
        "Matthew E Spector",
        "Joshua E Smith",
        "Steven B Chinn",
        "Kevin J Contrera",
        "Shaum J Sridharan"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154474/high%20fibula%20biorender.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154474/high%20fibula%20biorender.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154474"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 539,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Matthew E Spector, MD ; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD",
        "Affiliations": "University of Pittsburgh",
        "Background": "While vascularized fibula free flaps are the workhorse of reconstruction for composite maxillomandibular defects, morbidity is often considerable with over a 1/3rd of patients experiencing wound healing complications, chronic pain, lymphedema, gait disturbance, and poor cosmesis related to skin grafting. Here, we describe a novel “high fibula” osseous free flap technique for reconstruction of composite maxillomandibular defects that spares the flexor hallucis longus and avoids donor site skin grafting.",
        "Methods": "This was a prospective study of patients undergoing composite mandibulectomy or maxillectomy with free flap reconstruction. A “high fibula” harvest technique was developed in which the proximal osteotomy is made five centimeters distal to the fibular head and after templating the defect, the length of bone harvested includes an additional 3cm to account for pedicle length (FIGURE 1). A second free flap was harvested for mucosal and/or cutaneous defects, as guided by the extirpative surgery and tailored to the patient’s body habitus, occupation, hobbies, and goals. All patients were fully weight bearing as tolerated POD 1 without the need for a controlled ankle motion (CAM) boot. Peri-operative outcomes were collected and 6-month postoperative lower extremity functional outcomes, (validated Foot and Ankle Outcome Score [FAOS]) were compared to historical controls who underwent traditional fibula free flaps.",
        "Results": "The high fibula group included 60 patients (75% male) with a mean age of 61 years and the historical control group included 38 patients(80% male, mean age 62 years) treated in the same time period. Indications for composite resection included squamous cell carcinoma(47), sarcoma(3), osteoradionecrosis(5), ameloblastoma(3), and trauma(2). The mean (range) length of fibula harvested per patient was 7(4 – 12) cm. There were no differences in surgical indications (P=0.3) nor osteotomy number (P=0.2) between groups. A second flap was included in 57 (95%) patients with the high fibula reconstruction, and included anterolateral thigh (27), parascapular (20), latissimus (4), radial forearm (3), lateral arm (2) and DIEP (1) flaps. SPY angiography confirmed vascularity of the high fibular bone. Radiologic review of CT imaging showed an average of 7.1 cm of bone available without any FHL sacrifice. All high fibular donor sites were closed primarily.",
        "Abstract": "The average operating time, fluid administration and length of stay were lower in the high fibula group (474 vs 614 min, P<0.001, 7.5 vs 11.0 P<0.001; 8.4 vs 11.3 days, P=0.01). There was 1 (1.6 %) partial soft tissue flap loss in the high fibula group that required reoperation, and 2 (5.2%) fibula skin paddle losses in the control group requiring reoperation. Three (8%) patients in the traditional fibula group underwent leg debridement for skin graft loss, compared to none in the high fibula group. Compared to historical controls FAOS surveys at 6 months showed improved pain scores(P=0.03), gait stability(P=0.04), chronic wound healing issues(P<0.001), and cosmesis(P=0.008). View in Agenda and Add to Schedule",
        "Conclusions": "A “high fibula” osseous free flap for reconstruction of composite maxillomandibular defects reduces donor site morbidity compared to traditional fibula free flap harvest. This novel harvest technique has the potential to transform donor site considerations in patients with composite maxillomandibular defects."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The high fibula free flap:  A transformative approach that improves donor site morbidity for reconstruction of complex maxillomandibular defects</span>. <u>Matthew E Spector, MD</u>; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>While vascularized fibula free flaps are the workhorse of reconstruction for composite maxillomandibular defects, morbidity is often considerable with over a 1/3rd of patients experiencing wound healing complications, chronic pain, lymphedema, gait disturbance, and poor cosmesis related to skin grafting. Here, we describe a novel “high fibula” osseous free flap technique for reconstruction of composite maxillomandibular defects that spares the flexor hallucis longus and avoids donor site skin grafting.</p>\n\n<p><strong>Methods: </strong>This was a prospective study of patients undergoing composite mandibulectomy or maxillectomy with free flap reconstruction. A “high fibula” harvest technique was developed in which the proximal osteotomy is made five centimeters distal to the fibular head and after templating the defect, the length of bone harvested includes an additional 3cm to account for pedicle length (FIGURE 1). A second free flap was harvested for mucosal and/or cutaneous defects, as guided by the extirpative surgery and tailored to the patient’s body habitus, occupation, hobbies, and goals. All patients were fully weight bearing as tolerated POD 1 without the need for a controlled ankle motion (CAM) boot. Peri-operative outcomes were collected and 6-month postoperative lower extremity functional outcomes, (validated Foot and Ankle Outcome Score [FAOS]) were compared to historical controls who underwent traditional fibula free flaps.</p>\n\n<p><strong>Results: </strong>The high fibula group included 60 patients (75% male) with a mean age of 61 years and the historical control group included 38 patients(80% male, mean age 62 years) treated in the same time period.  Indications for composite resection included squamous cell carcinoma(47), sarcoma(3), osteoradionecrosis(5), ameloblastoma(3), and trauma(2). The mean (range) length of fibula harvested per patient was 7(4 – 12) cm. There were no differences in surgical indications (P=0.3) nor osteotomy number (P=0.2) between groups.  A second flap was included in 57 (95%) patients with the high fibula reconstruction, and included anterolateral thigh (27), parascapular (20), latissimus (4), radial forearm (3), lateral arm (2) and DIEP (1) flaps. SPY angiography confirmed vascularity of the high fibular bone. Radiologic review of CT imaging showed an average of 7.1 cm of bone available without any FHL sacrifice. All high fibular donor sites were closed primarily.</p>\n\n<p>The average operating time, fluid administration and length of stay were lower in the high fibula group (474 vs 614 min, P<0.001, 7.5 vs 11.0 P<0.001; 8.4 vs 11.3 days, P=0.01).  There was 1 (1.6 %) partial soft tissue flap loss in the high fibula group that required reoperation, and 2 (5.2%) fibula skin paddle losses in the control group requiring reoperation. Three (8%) patients in the traditional fibula group underwent leg debridement for skin graft loss, compared to none in the high fibula group. Compared to historical controls FAOS surveys at 6 months showed improved pain scores(P=0.03), gait stability(P=0.04), chronic wound healing issues(P<0.001), and cosmesis(P=0.008).   </p>\n\n<p><strong>Conclusions: </strong>A “high fibula” osseous free flap for reconstruction of composite maxillomandibular defects reduces donor site morbidity compared to traditional fibula free flap harvest. This novel harvest technique has the potential to transform donor site considerations in patients with composite maxillomandibular defects.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154474/high%20fibula%20biorender.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154474--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S016",
      "content_id": "153558",
      "abstract_number": "S016",
      "poster_number": "",
      "title": "Outcomes and time to prosthesis following endosseous implantation in free fibular flap oral cavity reconstruction: A single center experience",
      "summary": "In this single-center cohort, over half of patients receiving endosseous implants into free fibular flap reconstructions achieved prosthetic loading, typically within nine months. Prior radiation exposure and post-operative radiotherapy requirements as expected were the strongest predictors of not achieving prosthetic rehabilitation. Implant related complications were infrequent. Our outcomes compare favorably...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153558",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michelle Ruse, DDS, MDS, FACP",
      "presenter": "Michelle Ruse, DDS, MDS, FACP",
      "authors": "Thomas Hendriks, MBBS, MPhil, FRACS; Michelle Ruse, DDS, MDS, FACP ; Betsy Davis, DMD, MS; Usman Khan; Tatyana Voloshchuk; Brian Reisenberg, PhD, MBA; David Neskey; Terry Day; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich, BSc, MEd, MD, FRCSC",
      "normalized_authors": [
        "Thomas Hendriks, MBBS, MPhil, FRACS",
        "Michelle Ruse, MDS, FACP",
        "Betsy Davis",
        "Usman Khan",
        "Tatyana Voloshchuk",
        "Brian Reisenberg",
        "David Neskey",
        "Terry Day",
        "Eric Lentsch",
        "Jeffrey Houlton",
        "Joshua Hornig",
        "Peter Horwich, MEd, FRCSC"
      ],
      "affiliations": [
        "Sarah Cannon Cancer Institute, Charleston, SC, USA"
      ],
      "normalized_institutions": [
        "Sarah Cannon Cancer Institute, Charleston, SC, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 512,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Thomas Hendriks, MBBS, MPhil, FRACS; Michelle Ruse, DDS, MDS, FACP ; Betsy Davis, DMD, MS; Usman Khan; Tatyana Voloshchuk; Brian Reisenberg, PhD, MBA; David Neskey; Terry Day; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich, BSc, MEd, MD, FRCSC",
        "Affiliations": "Sarah Cannon Cancer Institute, Charleston, SC, USA",
        "Introduction": "Free fibular flap (FFF) reconstruction is a workhorse for reconstructing defects of the maxilla and mandible providing a bony platform for endosseous dental implantation either simultaneously or following ablative surgery. However, despite advances in microvascular surgery and dental implantation technology, a minority of patients actually receive dental rehabilitation. We sought to describe our institutional experience and outcomes with endosseous dental implantation in patients with FFF reconstruction of the oral cavity and assess the factors that influence patients ability to receive a prosthesis.",
        "Methods": "A retrospective cohort study was conducted over a two-year period (November 2023 – November 2025) at our institution, of 24 patients whom underwent endosseous implantation into FFF reconstructions of the maxilla or mandible. Data collected included baseline patient demographics, risk factors, disease characteristics, treatment details, time to prosthetic loading, implant complications and functional oral intake status (FOIS). This study was conducted under the HCA Healthcare Research Institute's OncED_Reg02 Master Regulatory Protocol, which was approved for a waiver of authorization for use and disclosure of protected health information by the WCG IRB. Statistical analyses utilizing Wilcoxon rank sum and Fisher’s exact testing was performed.",
        "Results": "Twenty-four patients underwent endosseous implantation into FFF reconstructions. Four patients had a pre-existing FFF in place prior to the study period so underwent delayed endosseous implantation, whereas the remaining 20 underwent FFF reconstruction with immediate endosseous implantation. Three patients received immediate prosthetic loading via a jaw in a day (JIAD) approach. At analysis, 13 patients (54%) had achieved prosthetic loading and 11 (46%) had not. Median time from implant placement to prosthetic loading was 8.6 months (Q1–Q3: 0.0, 10). The median age of the overall cohort was 67 years, with a trend toward younger age among those who achieved prosthetic loading (60 vs. 70 years). The cohort included 16 males and 8 females. Insurance status, smoking history, and diabetes were not associated with the ability to receive a prosthesis. Malignant pathology (predominately squamous cell carcinoma) was the most common indication (n=16), but diagnosis did not significantly affect time to prosthesis. Radiation therapy prior to endosseous implantation was strongly associated with failure to achieve prosthetic loading (p=0.013) and the requirement for post-operative radiotherapy (due to adverse pathological features) was similarly, associated with failure to achieve prosthetic loading (p=0.007). Higher FOIS scores correlated positively in patients that had obtained prosthetic loading (p=0.009). Implant related complications were rare; one JIAD patient experienced dysfunction and extrusion of two of four implants due to failed osseointegration.",
        "Conclusions": "In this single-center cohort, over half of patients receiving endosseous implants into free fibular flap reconstructions achieved prosthetic loading, typically within nine months. Prior radiation exposure and post-operative radiotherapy requirements as expected were the strongest predictors of not achieving prosthetic rehabilitation. Implant related complications were infrequent. Our outcomes compare favorably with the published literature, with time to prosthesis and prosthetic completion rates meeting or exceeding commonly reported benchmarks and suggest that our institutional approach achieves rehabilitation outcomes at least equivalent to, and in some cases better than, current standards.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes and time to prosthesis following endosseous implantation in free fibular flap oral cavity reconstruction: A single center experience</span>. Thomas Hendriks, MBBS, MPhil, FRACS; <u>Michelle Ruse, DDS, MDS, FACP</u>; Betsy Davis, DMD, MS; Usman Khan; Tatyana Voloshchuk; Brian Reisenberg, PhD, MBA; David Neskey; Terry Day; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich, BSc, MEd, MD, FRCSC. Sarah Cannon Cancer Institute, Charleston, SC, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Free fibular flap (FFF) reconstruction is a workhorse for reconstructing defects of the maxilla and mandible providing a bony platform for endosseous dental implantation either simultaneously or following ablative surgery. However, despite advances in microvascular surgery and dental implantation technology, a minority of patients actually receive dental rehabilitation. We sought to describe our institutional experience and outcomes with endosseous dental implantation in patients with FFF reconstruction of the oral cavity and assess the factors that influence patients ability to receive a prosthesis.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted over a two-year period (November 2023 – November 2025) at our institution, of 24 patients whom underwent endosseous implantation into FFF reconstructions of the maxilla or mandible. Data collected included baseline patient demographics, risk factors, disease characteristics, treatment details, time to prosthetic loading, implant complications and functional oral intake status (FOIS). This study was conducted under the HCA Healthcare Research Institute's OncED_Reg02 Master Regulatory Protocol, which was approved for a waiver of authorization for use and disclosure of protected health information by the WCG IRB. Statistical analyses utilizing Wilcoxon rank sum and Fisher’s exact testing was performed.</p>\n\n<p><strong>Results: </strong>Twenty-four patients underwent endosseous implantation into FFF reconstructions. Four patients had a pre-existing FFF in place prior to the study period so underwent delayed endosseous implantation, whereas the remaining 20 underwent FFF reconstruction with immediate endosseous implantation. Three patients received immediate prosthetic loading via a jaw in a day (JIAD) approach. At analysis, 13 patients (54%) had achieved prosthetic loading and 11 (46%) had not. Median time from implant placement to prosthetic loading was 8.6 months (Q1–Q3: 0.0, 10). The median age of the overall cohort was 67 years, with a trend toward younger age among those who achieved prosthetic loading (60 vs. 70 years). The cohort included 16 males and 8 females. Insurance status, smoking history, and diabetes were not associated with the ability to receive a prosthesis. Malignant pathology (predominately squamous cell carcinoma) was the most common indication (n=16), but diagnosis did not significantly affect time to prosthesis. Radiation therapy prior to endosseous implantation was strongly associated with failure to achieve prosthetic loading (p=0.013) and the requirement for post-operative radiotherapy (due to adverse pathological features) was similarly, associated with failure to achieve prosthetic loading (p=0.007). Higher FOIS scores correlated positively in patients that had obtained prosthetic loading (p=0.009). Implant related complications were rare; one JIAD patient experienced dysfunction and extrusion of two of four implants due to failed osseointegration.</p>\n\n<p><strong>Conclusions: </strong>In this single-center cohort, over half of patients receiving endosseous implants into free fibular flap reconstructions achieved prosthetic loading, typically within nine months. Prior radiation exposure and post-operative radiotherapy requirements as expected were the strongest predictors of not achieving prosthetic rehabilitation. Implant related complications were infrequent. Our outcomes compare favorably with the published literature, with time to prosthesis and prosthetic completion rates meeting or exceeding commonly reported benchmarks and suggest that our institutional approach achieves rehabilitation outcomes at least equivalent to, and in some cases better than, current standards.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153558--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S017",
      "content_id": "154379",
      "abstract_number": "S017",
      "poster_number": "",
      "title": "'Tip' Top Maxillary Reconstructions: A Virtual Analysis of Ipsilateral and Contralateral Scapula Free Flap Orientations for Total Maxillectomy Reconstruction",
      "summary": "Virtual surgical planning is a useful tool for surgeons to plan and compare clinically relevant metrics, including structural accuracy, bony contact, and dental implant suitability, across different orientations of the ipsilateral and contralateral scapula for total maxillectomy. Our analysis suggests that the ipsilateral scapula remains a good, and when considering bony contact, if not superior choice for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154379",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Linh K Tran",
      "presenter": "Linh K Tran",
      "authors": "Linh K Tran ; Cornelius Kurten, MD; Chayce Ross; Alex Chen; Katrina Zaraska; Eitan Prisman, MD, FRCSC",
      "normalized_authors": [
        "Linh K Tran",
        "Cornelius Kurten",
        "Chayce Ross",
        "Alex Chen",
        "Katrina Zaraska",
        "Eitan Prisman, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154379/fig1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154379/fig1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154379"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154379/fig2(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154379/fig2(1).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154379"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154379/fig3.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154379/fig3.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154379"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Abstract",
        "aterials and Methods",
        "Figure 1.",
        "Results",
        "Figure 2.",
        "Figure 3.",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Linh K Tran ; Cornelius Kurten, MD; Chayce Ross; Alex Chen; Katrina Zaraska; Eitan Prisman, MD, FRCSC",
        "Affiliations": "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Objectives": "The scapula free flap is a versatile and robust option for complex total maxillectomy reconstruction, a challenging procedure requiring restoration of anatomical integrity and function (eating, speech, vision). The unique three-dimensional geometry and bilateral symmetry of the scapula introduce variability in donor site (ipsilateral vs. contralateral) and orientation (tip medial vs. tip lateral). While the contralateral approach is often logistically more challenging for two-team simultaneous surgery, some papers suggest that the contralateral scapula may yield a superior reconstructive outcome.",
        "Abstract": "Virtual surgical planning (VSP) offers a potent, preoperative method to compare these reconstructive strategies and optimize patient-specific outcomes. Therefore, this study performs a virtual analysis to compare the different orientations of the ipsilateral and contralateral scapula free flaps for total maxillectomy across three critical metrics: structural accuracy, bony contact, and dental implantability. Reconstructions with the tip oriented laterally supported the greatest number of feasible dental implants, though there was no difference in dental implantability between ipsilateral and contralateral scapula. This is primarily explained by the difference in scapula thickness between the tip and further along the lateral border. View in Agenda and Add to Schedule",
        "aterials and Methods": "s: Thirteen maxilla and patient-specific scapula models were segmented from CT scans of patients without oromaxillofacial or upper body trauma. Right-sided total maxillectomy extending from the zygoma to the maxilla midline was created on each model. Four reconstructions are created for each model: ipsilateral and contralateral scapulas with the tip oriented both laterally and medially, for 52 reconstructions in total. Volumetric DICE score, Hausdorff distances (95th percentile and average), and bony contact are collected. In addition, each reconstruction model was assessed for dental implantability and number of feasible implants based on previously published criteria.",
        "Figure 1.": "Orientations of scapulae used in reconstructions.",
        "Results": "While the analysis found no significant difference (One-Way ANOVA with Tukey comparison) among the four flap choices/orientations when assessing volume overlap (DICE) or Hausdorff distances, a clear distinction was observed for bony contact. Specifically, the Ipsilateral scapula with the tip oriented medially performed best, achieving significantly superior bony contact compared to the Ipsilateral-Lateral (p<0.01) and Contralateral-Medial orientations (p<0.01).",
        "Figure 2.": "Similarity metrics for orientations and choices of scapulae.",
        "Figure 3.": "The number of implantable locations based on the direction of the scapula.",
        "Conclusion": "Virtual surgical planning is a useful tool for surgeons to plan and compare clinically relevant metrics, including structural accuracy, bony contact, and dental implant suitability, across different orientations of the ipsilateral and contralateral scapula for total maxillectomy. Our analysis suggests that the ipsilateral scapula remains a good, and when considering bony contact, if not superior choice for reconstruction of a total right side maxillectomy. Moreover, for cases where maximizing dental implant suitability is the primary goal, the data supports orienting the flap with the tip directed medially, regardless of which side the scapula was harvested."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>'Tip' Top Maxillary Reconstructions: A Virtual Analysis of Ipsilateral and Contralateral Scapula Free Flap Orientations for Total Maxillectomy Reconstruction</span>. <u>Linh K Tran</u>; Cornelius Kurten, MD; Chayce Ross; Alex Chen; Katrina Zaraska; Eitan Prisman, MD, FRCSC. Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>The scapula free flap is a versatile and robust option for complex total maxillectomy reconstruction, a challenging procedure requiring restoration of anatomical integrity and function (eating, speech, vision). The unique three-dimensional geometry and bilateral symmetry of the scapula introduce variability in donor site (ipsilateral vs. contralateral) and orientation (tip medial vs. tip lateral). While the contralateral approach is often logistically more challenging for two-team simultaneous surgery, some papers suggest that the contralateral scapula may yield a superior reconstructive outcome.</p>\n\n<p>Virtual surgical planning (VSP) offers a potent, preoperative method to compare these reconstructive strategies and optimize patient-specific outcomes. Therefore, this study performs a virtual analysis to compare the different orientations of the ipsilateral and contralateral scapula free flaps for total maxillectomy across three critical metrics: structural accuracy, bony contact, and dental implantability.</p>\n\n<p>M<strong>aterials and Methods: </strong>Thirteen maxilla and patient-specific scapula models were segmented from CT scans of patients without oromaxillofacial or upper body trauma. Right-sided total maxillectomy extending from the zygoma to the maxilla midline was created on each model. Four reconstructions are created for each model: ipsilateral and contralateral scapulas with the tip oriented both laterally and medially, for 52 reconstructions in total. Volumetric DICE score, Hausdorff distances (95th percentile and average), and bony contact are collected. In addition, each reconstruction model was assessed for dental implantability and number of feasible implants based on previously published criteria.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154379/fig1.png' /></p>\n\n<p><strong>Figure 1.</strong> Orientations of scapulae used in reconstructions.</p>\n\n<p><strong>Results: </strong>While the analysis found no significant difference (One-Way ANOVA with Tukey comparison) among the four flap choices/orientations when assessing volume overlap (DICE) or Hausdorff distances, a clear distinction was observed for bony contact. Specifically, the Ipsilateral scapula with the tip oriented medially performed best, achieving significantly superior bony contact compared to the Ipsilateral-Lateral (p<0.01) and Contralateral-Medial orientations (p<0.01).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154379/fig2(1).png' /></p>\n\n<p><strong>Figure 2.</strong> Similarity metrics for orientations and choices of scapulae.</p>\n\n<p>Reconstructions with the tip oriented laterally supported the greatest number of feasible dental implants, though there was no difference in dental implantability between ipsilateral and contralateral scapula. This is primarily explained by the difference in scapula thickness between the tip and further along the lateral border.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154379/fig3.png' /><br />\n<strong>Figure 3.</strong> The number of implantable locations based on the direction of the scapula.</p>\n\n<p><strong>Conclusion: </strong>Virtual surgical planning is a useful tool for surgeons to plan and compare clinically relevant metrics, including structural accuracy, bony contact, and dental implant suitability, across different orientations of the ipsilateral and contralateral scapula for total maxillectomy. Our analysis suggests that the ipsilateral scapula remains a good, and when considering bony contact, if not superior choice for reconstruction of a total right side maxillectomy. Moreover, for cases where maximizing dental implant suitability is the primary goal, the data supports orienting the flap with the tip directed medially, regardless of which side the scapula was harvested.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154379--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S018",
      "content_id": "154478",
      "abstract_number": "S018",
      "poster_number": "",
      "title": "Dental Restoration in Scapula Osteocutaneous Free Flap Reconstruction - does density matter?",
      "summary": "The scapula osteocutaneous free flap provides a highly reliable platform for dental restoration, regardless of patient age or scapula bone density. Implants can be reliably placed in the primary or secondary setting. Identifying high-risk patients for implant failure allows for more accurate preoperative counseling.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154478",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Solymar Torres Maldonado, MD",
      "presenter": "Solymar Torres Maldonado, MD",
      "authors": "Solymar Torres Maldonado, MD ; Byung Lee, DDS; Alexandra Kejner, MD",
      "normalized_authors": [
        "Solymar Torres Maldonado",
        "Byung Lee",
        "Alexandra Kejner"
      ],
      "affiliations": [
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 301,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Solymar Torres Maldonado, MD ; Byung Lee, DDS; Alexandra Kejner, MD",
        "Affiliations": "Medical University of South Carolina",
        "Objectives": "The scapula osteocutaneous free flap (SOFF) is a versatile option for maxillomandibular reconstruction, with low donor site morbidity and high-quality bone stock. However, achieving functional dental rehabilitation remains the ultimate metric of success. While flap survival rates are well-documented, data regarding long-term dental restoration remains limited. This study aims to identify patient and surgical factors, including scapula bone density, that predict successful dental rehabilitation and functional prosthetic use in patients undergoing SOFF reconstruction.",
        "Methods": "A single-institution retrospective cohort study was conducted on all patients undergoing SOFF for maxillary or mandibular defects between July 2022 and December 2024. Patients were excluded if their planned dental restoration did not include scapula implants. Data collection included patient demographics, radiation history (pre- or postoperative), bone segment density, and timing of implant placement (primary/immediate vs. secondary/delayed). Scapula bone density was quantitatively assessed using Hounsfield Units (HU). The primary endpoint was successful dental restoration, defined as the active use of an implant-retained prosthesis. Multivariate logistic regression was utilized to identify independent predictors of implant failure.",
        "Results": "The cohort consisted of 14 patients. The overall flap survival rate was 100%. The scapula implant success rate was 90.6% (29/32). The rate of successful dental restoration was 85% (11/13) with one patient lost to follow up. On univariate and multivariate analysis, older age, lower bone density and delayed placement was not associated with increased implant failure (p > 0.05%). Primary implant placement followed by adjuvant radiation could be associated with a low rate of implant failure.",
        "Conclusions": "The scapula osteocutaneous free flap provides a highly reliable platform for dental restoration, regardless of patient age or scapula bone density. Implants can be reliably placed in the primary or secondary setting. Identifying high-risk patients for implant failure allows for more accurate preoperative counseling.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Dental Restoration in Scapula Osteocutaneous Free Flap Reconstruction - does density matter?</span>. <u>Solymar Torres Maldonado, MD</u>; Byung Lee, DDS; Alexandra Kejner, MD. Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>The scapula osteocutaneous free flap (SOFF) is a versatile option for maxillomandibular reconstruction, with low donor site morbidity and high-quality bone stock. However, achieving functional dental rehabilitation remains the ultimate metric of success. While flap survival rates are well-documented, data regarding long-term dental restoration remains limited. This study aims to identify patient and surgical factors, including scapula bone density, that predict successful dental rehabilitation and functional prosthetic use in patients undergoing SOFF reconstruction.</p>\n\n<p><strong>Methods:</strong> A single-institution retrospective cohort study was conducted on all patients undergoing SOFF for maxillary or mandibular defects between July 2022 and December 2024. Patients were excluded if their planned dental restoration did not include scapula implants. Data collection included patient demographics, radiation history (pre- or postoperative), bone segment density, and timing of implant placement (primary/immediate vs. secondary/delayed). Scapula bone density was quantitatively assessed using Hounsfield Units (HU). The primary endpoint was successful dental restoration, defined as the active use of an implant-retained prosthesis. Multivariate logistic regression was utilized to identify independent predictors of implant failure.</p>\n\n<p><strong>Results: </strong>The cohort consisted of 14 patients. The overall flap survival rate was 100%. The scapula implant success rate was 90.6% (29/32). The rate of successful dental restoration was 85% (11/13) with one patient lost to follow up. On univariate and multivariate analysis, older age, lower bone density and delayed placement was not associated with increased implant failure (p > 0.05%). Primary implant placement followed by adjuvant radiation could be associated with a low rate of implant failure.</p>\n\n<p><strong>Conclusions: </strong>The scapula osteocutaneous free flap provides a highly reliable platform for dental restoration, regardless of patient age or scapula bone density. Implants can be reliably placed in the primary or secondary setting. Identifying high-risk patients for implant failure allows for more accurate preoperative counseling.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154478--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S019",
      "content_id": "154466",
      "abstract_number": "S019",
      "poster_number": "",
      "title": "Flow through flaps as a next-generation reconstructive paradigm for complex composite maxillomandibular defects",
      "summary": "Double flap reconstructions utilizing flow through vessels for composite maxillomandibular defects are feasible and effective, permitting personalized and versatile reconstructions. Chimeric vascular anastomoses assuage any concerns regarding vessel-depleted necks and/or flap pedicle length. Novel reconstructive techniques such as this may form the backbone of next-generation microvascular reconstructive surgery...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154466",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joshua Smith, MD",
      "presenter": "Joshua Smith, MD",
      "authors": "Joshua Smith, MD ; Kevin Contrera, MD; Steven Chinn, MD; Shaum Sridharan, MD; Matthew E Spector",
      "normalized_authors": [
        "Joshua Smith",
        "Kevin Contrera",
        "Steven Chinn",
        "Shaum Sridharan",
        "Matthew E Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154466/Doubledouble(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154466/Doubledouble(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154466"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 405,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joshua Smith, MD ; Kevin Contrera, MD; Steven Chinn, MD; Shaum Sridharan, MD; Matthew E Spector",
        "Affiliations": "University of Pittsburgh",
        "Background": "Reconstruction of composite maxillomandibular defects demands a highly personalized approach for each patient to maximize form and function as well as minimize donor site morbidity. Single-stage reconstruction with multiple free flaps, guided by the individual patient’s anatomic defect, body habitus, occupation, and goals, permits versatility and optimization in such reconstructive scenarios. Here, we describe our recent experience with double flap reconstructions utilizing chimeric flow through flaps to reconstruct composite maxillomandibular defects and propose our technique as a next-generation reconstructive paradigm for such scenarios.",
        "Methods": "This was a retrospective study of patients undergoing composite mandibulectomy or maxillectomy with free flap reconstruction. Prior to surgery, patients were counseled on plan for single versus double flap reconstructions and potential donor sites were selected based on anticipated extirpative defects and individual body habitus, occupation, hobbies, and goals. A scapular tip free flap sparing most of the teres muscles and preserving partial insertion of the serratus anterior or “high fibula” free flap, harvested without skin and sparing the FHL muscle insertion, was used for bony restoration. Parascapular, latissimus, radial forearm, or anterolateral thigh flaps were harvested as a second fasciocutaneous flap for restoration of mucosal and/or cutaneous defects. Peri-operative outcomes were collected and reported, including operative time, flap harvest sites, vascular anastomoses, and post-operative complications.",
        "Results": "The study included 41 patients (73 % male) with a mean (range) age of 63 (38 – 81) years. Extirpative defects were for malignancy (33) or osteoradionecrosis (8). A fibula or scapular tip free flap was harvested in 36 (88 %) and 5 (12 %) patients, respectively. Sites of second free flap with associated anastomotic vessel for the boney flap included parascapular (thoracodorsal artery, 18) anterolateral thigh (descending branch of circumflex femoral artery, 18), latissimus dorsi (artery to serratus, 4) and radial forearm (radial artery, 1). Mean (range) operative time using an integrated, two-team approach was 473 mins, with an average fluid administration of 7.1 liters, and average length of stay of 8.1 days. There was one partial flap loss requiring reoperation and there were no donor site wound infections or hematomas requiring reoperation.",
        "Conclusions": "Double flap reconstructions utilizing flow through vessels for composite maxillomandibular defects are feasible and effective, permitting personalized and versatile reconstructions. Chimeric vascular anastomoses assuage any concerns regarding vessel-depleted necks and/or flap pedicle length. Novel reconstructive techniques such as this may form the backbone of next-generation microvascular reconstructive surgery for complex head and neck defects.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Flow through flaps as a next-generation reconstructive paradigm for complex composite maxillomandibular defects</span>. <u>Joshua Smith, MD</u>; Kevin Contrera, MD; Steven Chinn, MD; Shaum Sridharan, MD; Matthew E Spector. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Reconstruction of composite maxillomandibular defects demands a highly personalized approach for each patient to maximize form and function as well as minimize donor site morbidity. Single-stage reconstruction with multiple free flaps, guided by the individual patient’s anatomic defect, body habitus, occupation, and goals, permits versatility and optimization in such reconstructive scenarios. Here, we describe our recent experience with double flap reconstructions utilizing chimeric flow through flaps to reconstruct composite maxillomandibular defects and propose our technique as a next-generation reconstructive paradigm for such scenarios.    </p>\n\n<p><strong>Methods: </strong>This was a retrospective study of patients undergoing composite mandibulectomy or maxillectomy with free flap reconstruction. Prior to surgery, patients were counseled on plan for single versus double flap reconstructions and potential donor sites were selected based on anticipated extirpative defects and individual body habitus, occupation, hobbies, and goals. A scapular tip free flap sparing most of the teres muscles and preserving partial insertion of the serratus anterior or “high fibula” free flap, harvested without skin and sparing the FHL muscle insertion, was used for bony restoration. Parascapular, latissimus, radial forearm, or anterolateral thigh flaps were harvested as a second fasciocutaneous flap for restoration of mucosal and/or cutaneous defects. Peri-operative outcomes were collected and reported, including operative time, flap harvest sites, vascular anastomoses, and post-operative complications.</p>\n\n<p><strong>Results: </strong>The study included 41 patients (73 % male) with a mean (range) age of 63 (38 – 81) years. Extirpative defects were for malignancy (33) or osteoradionecrosis (8).  A fibula or scapular tip free flap was harvested in 36 (88 %) and 5 (12 %) patients, respectively. Sites of second free flap with associated anastomotic vessel for the boney flap included parascapular (thoracodorsal artery, 18) anterolateral thigh (descending branch of circumflex femoral artery, 18), latissimus dorsi (artery to serratus, 4) and radial forearm (radial artery, 1). Mean (range) operative time using an integrated, two-team approach was 473 mins, with an average fluid administration of 7.1 liters, and average length of stay of 8.1 days. There was one partial flap loss requiring reoperation and there were no donor site wound infections or hematomas requiring reoperation.</p>\n\n<p><strong>Conclusions: </strong>Double flap reconstructions utilizing flow through vessels for composite maxillomandibular defects are feasible and effective, permitting personalized and versatile reconstructions. Chimeric vascular anastomoses assuage any concerns regarding vessel-depleted necks and/or flap pedicle length. Novel reconstructive techniques such as this may form the backbone of next-generation microvascular reconstructive surgery for complex head and neck defects.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154466/Doubledouble(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154466--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S020",
      "content_id": "152186",
      "abstract_number": "S020",
      "poster_number": "",
      "title": "Free Flap Reconstruction and Margin Status in Early T-Stage Oral Tongue Cancer",
      "summary": "Planned free flap reconstruction after partial glossectomy for cT1-2N0 oral tongue SCC was associated with significantly greater superficial, deep, and overall surgical margins. However, this did not translate into detectable DFS or DSS benefit in our single-institution cohort. Multi-institutional studies with enhanced power to detect recurrence and survival differences are needed.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152186",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Allison Rollins, MD",
      "presenter": "Allison Rollins, MD",
      "authors": "Allison Rollins, MD ; Yu-Jin Lee, MD; Joshua Smith, MD; Shaum Sridharan, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin Contrera, MD; Steven Chinn, MD; Jose Zevallos, MD, MPH; Matthew Spector, MD",
      "normalized_authors": [
        "Allison Rollins",
        "Yu-Jin Lee",
        "Joshua Smith",
        "Shaum Sridharan",
        "Jessica Maxwell",
        "Seungwon Kim",
        "Kevin Contrera",
        "Steven Chinn",
        "Jose Zevallos",
        "Matthew Spector"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152186/Table_ANHS.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152186/Table_ANHS.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152186"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials and Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Allison Rollins, MD ; Yu-Jin Lee, MD; Joshua Smith, MD; Shaum Sridharan, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin Contrera, MD; Steven Chinn, MD; Jose Zevallos, MD, MPH; Matthew Spector, MD",
        "Affiliations": "University of Pittsburgh Medical Center",
        "Background": "Close or positive surgical margins after resection of oral cavity squamous cell carcinoma (SCC) significantly increases risk of recurrence and mortality. In addition to intrinsic tumor behavior and growth patterns, surgical technique and decision-making are critical determinants of margin status. Early T category (i.e., T1-2) tongue cancers are treated with partial glossectomy with or without free flap reconstruction. Here, we hypothesized that planned free flap reconstruction of such ablative defects would permit wider surgical margins and, consequently, reduce locoregional recurrence in oral tongue SCC.",
        "Materials and Methods": "This was a single-institution cohort study including all patients with primary, untreated, cT1-2N0 oral tongue SCC treated with partial glossectomy with or without free flap reconstruction from 1/2021 to 2/2024. Primary independent variables included closest superficial margin, closest deep margin, and closest overall margin as determined by detailed review of operative and pathology reports. We compared clinicodemographic and pathologic variables, including margin status, between patients with and without free flap reconstruction with univariate and multivariate statistics. We then assessed the impact of free flap reconstruction on disease-free (DFS) and disease-specific (DSS) survival, controlling for T- and N-category, with the Kaplan-Meier method and Cox models.",
        "Results": "Our cohort comprised 115 patients (Table). Patients who underwent free flap reconstruction of ablative tongue defects were younger and more likely to be male. As expected, there was a higher proportion of cT2 tumors in this group (Table). Closest superficial margin (1.0 vs 0.6 cm, p < 0.001), closest deep margin (0.6 vs 0.5, p = 0.01), and closest overall margin (0.6 vs 0.4 cm, p = 0.01) were all significantly greater in patients undergoing free flap reconstruction, independent of T category. The overall rate of locoregional recurrence did not differ significantly between patients undergoing free flap reconstruction versus those not (13.9 % vs 15.2 %, p = 0.86). Pathologic T category did not associate with DFS or DSS in our cohort. Pathologic N+ tumors were associated with significantly worse DFS (HR: 6.3 [95 % CI 1.9 – 21.3] p < 0.01) and DSS (HR: 14.9 [95 % CI 3.3 – 67.9] p < 0.001). Free flap reconstruction was not associated with DFS or DSS alone or when controlling for pathologic T or N category.",
        "Conclusions": "Planned free flap reconstruction after partial glossectomy for cT1-2N0 oral tongue SCC was associated with significantly greater superficial, deep, and overall surgical margins. However, this did not translate into detectable DFS or DSS benefit in our single-institution cohort. Multi-institutional studies with enhanced power to detect recurrence and survival differences are needed.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Flap Reconstruction and Margin Status in Early T-Stage Oral Tongue Cancer</span>. <u>Allison Rollins, MD</u>; Yu-Jin Lee, MD; Joshua Smith, MD; Shaum Sridharan, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin Contrera, MD; Steven Chinn, MD; Jose Zevallos, MD, MPH; Matthew Spector, MD. University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Close or positive surgical margins after resection of oral cavity squamous cell carcinoma (SCC) significantly increases risk of recurrence and mortality. In addition to intrinsic tumor behavior and growth patterns, surgical technique and decision-making are critical determinants of margin status. Early T category (i.e., T1-2) tongue cancers are treated with partial glossectomy with or without free flap reconstruction. Here, we hypothesized that planned free flap reconstruction of such ablative defects would permit wider surgical margins and, consequently, reduce locoregional recurrence in oral tongue SCC.</p>\n\n<p><strong>Materials and Methods: </strong>This was a single-institution cohort study including all patients with primary, untreated, cT1-2N0 oral tongue SCC treated with partial glossectomy with or without free flap reconstruction from 1/2021 to 2/2024. Primary independent variables included closest superficial margin, closest deep margin, and closest overall margin as determined by detailed review of operative and pathology reports. We compared clinicodemographic and pathologic variables, including margin status, between patients with and without free flap reconstruction with univariate and multivariate statistics. We then assessed the impact of free flap reconstruction on disease-free (DFS) and disease-specific (DSS) survival, controlling for T- and N-category, with the Kaplan-Meier method and Cox models.</p>\n\n<p><strong>Results: </strong>Our cohort comprised 115 patients (Table). Patients who underwent free flap reconstruction of ablative tongue defects were younger and more likely to be male. As expected, there was a higher proportion of cT2 tumors in this group (Table). Closest superficial margin (1.0 vs 0.6 cm, p < 0.001), closest deep margin (0.6 vs 0.5, p = 0.01), and closest overall margin (0.6 vs 0.4 cm, p = 0.01) were all significantly greater in patients undergoing free flap reconstruction, independent of T category.  The overall rate of locoregional recurrence did not differ significantly between patients undergoing free flap reconstruction versus those not (13.9 % vs 15.2 %, p = 0.86). Pathologic T category did not associate with DFS or DSS in our cohort. Pathologic N+ tumors were associated with significantly worse DFS (HR: 6.3 [95 % CI 1.9 – 21.3] p < 0.01) and DSS (HR: 14.9 [95 % CI 3.3 – 67.9] p < 0.001). Free flap reconstruction was not associated with DFS or DSS alone or when controlling for pathologic T or N category.</p>\n\n<p><strong>Conclusions: </strong>Planned free flap reconstruction after partial glossectomy for cT1-2N0 oral tongue SCC was associated with significantly greater superficial, deep, and overall surgical margins. However, this did not translate into detectable DFS or DSS benefit in our single-institution cohort. Multi-institutional studies with enhanced power to detect recurrence and survival differences are needed.  </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152186/Table_ANHS.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152186--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S021",
      "content_id": "153684",
      "abstract_number": "S021",
      "poster_number": "",
      "title": "Comparison of free flap donor-site morbidity between single-stage split-thickness skin graft versus two-stage integra followed by split-thickness skin graft repair.",
      "summary": "We describe a staged approach to RFFF and FFF donor site coverage that was significantly associated with lower rates of tendon exposure in this retrospective single-institution study, particularly amongst FFF patients. While our results suggest that this technique may decrease donor site morbidity, any donor-site benefits should be weighed against the considerations of a second surgical procedure in a complex...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153684",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "MiJin Cho, BA",
      "presenter": "MiJin Cho, BA",
      "authors": "MiJin Cho, BA 1 ; William J Benjamin, MD, MPH 2 ; Daniel Bu, MD 2 ; Ravindra Uppaluri, MD, PhD 3 ; Laura A Goguen, MD 3 ; Donald J Annino, MD, DMD 3 ; Rosh Sethi, MD, MPH 3 ; Eleni M Rettig, MD 3",
      "normalized_authors": [
        "MiJin Cho",
        "William J Benjamin",
        "Daniel Bu",
        "Ravindra Uppaluri",
        "Laura A Goguen",
        "Donald J Annino",
        "Rosh Sethi",
        "Eleni M Rettig"
      ],
      "affiliations": [
        "Harvard Medical School",
        "Mass Eye and Ear / Brigham and Women's Hospital",
        "Brigham and Women's Hospital / Dana Farber Cancer Institute"
      ],
      "normalized_institutions": [
        "Harvard Medical School",
        "Mass Eye and Ear / Brigham and Women's Hospital",
        "Brigham and Women's Hospital / Dana Farber Cancer Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "MiJin Cho, BA 1 ; William J Benjamin, MD, MPH 2 ; Daniel Bu, MD 2 ; Ravindra Uppaluri, MD, PhD 3 ; Laura A Goguen, MD 3 ; Donald J Annino, MD, DMD 3 ; Rosh Sethi, MD, MPH 3 ; Eleni M Rettig, MD 3",
        "Affiliations": "1 Harvard Medical School; 2 Mass Eye and Ear / Brigham and Women's Hospital; 3 Brigham and Women's Hospital / Dana Farber Cancer Institute",
        "Introduction": "Radial forearm (RFFF) and fibular (FFF) free flaps are commonly used options for head and neck reconstruction. The donor site defect from these flaps often requires split-thickness skin grafting (STSG) for appropriate soft tissue coverage, which is often completed at the time of the initial free flap operation. STSG breakdown, often with tendon exposure and requiring prolonged wound care, is a common and vexing donor site complication. Our group has trialed a staged donor site repair using an engineered skin substitute (Integra® Bilayer Wound Matrix) followed by a staged STSG several weeks later, in an attempt to decrease donor site morbidity. This study aims to assess differences in donor site outcomes between patients treated with a two-staged donor site reconstruction with Integra then STSG, and those who received an upfront STSG.",
        "Methods": "A retrospective cohort study of patients receiving either RFFF or FFF for head and neck reconstruction at a large, tertiary care hospital between 2020 and 2024 was completed. Donor sites were reconstructed with either a single-stage STSG at the time of free flap surgery (‘STSG’ group), or a two-stage approach with Integra placement followed by subsequent outpatient STSG approximately 3 weeks following free flap surgery (‘Integra’ group). Our primary outcome was donor site tendon exposure. Secondary donor site outcomes included infection, granulation tissue overgrowth, and keloid formation.",
        "Results": "152 free flaps were included in this analysis, including 104 RFFF and 48 FFF. There were 98 STSG and 54 Integra patients. 27 patients developed tendon exposure overall (17.7%), including 12/48 (25%) of FFFs and 15/104 (14.4%) of RFFFs. Integra was associated with a significantly lower frequency of tendon exposure overall, occurring in just 7.4% (4/54) of Integra patients compared with 23.5% (23/98) of STSG patients (p=0.01). When stratified by flap type, Integra was associated with a lower frequency of tendon exposure for both flap donor sites, but this was statistically significant only for FFFs (FFFs: 8.3% vs. 41.7%, p=0.007; RFFFs: 6.7% vs. 17.6%, p=0.15). In multivariable models adjusting for flap type, STSG utilization was associated with 5 times the odds of tendon exposure compared with Integra (OR: 5.0 [1.5-16.1, p=0.007). There were no significant differences noted between Integra and STSG regarding donor site infections (11.1% vs. 11.2%, p=0.98[CM1] ), granulation tissue overgrowth (5.6% vs. 15.3%, p=0.08), or keloid formation (5.6% vs. 10.2%, p=0.33). There were no major complications related to a second surgical procedure among the Integra group.",
        "Conclusion": "We describe a staged approach to RFFF and FFF donor site coverage that was significantly associated with lower rates of tendon exposure in this retrospective single-institution study, particularly amongst FFF patients. While our results suggest that this technique may decrease donor site morbidity, any donor-site benefits should be weighed against the considerations of a second surgical procedure in a complex patient population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparison of free flap donor-site morbidity between single-stage split-thickness skin graft versus two-stage integra followed by split-thickness skin graft repair.</span>. <u>MiJin Cho, BA</u><sup>1</sup>; William J Benjamin, MD, MPH<sup>2</sup>; Daniel Bu, MD<sup>2</sup>; Ravindra Uppaluri, MD, PhD<sup>3</sup>; Laura A Goguen, MD<sup>3</sup>; Donald J Annino, MD, DMD<sup>3</sup>; Rosh Sethi, MD, MPH<sup>3</sup>; Eleni M Rettig, MD<sup>3</sup>. <sup>1</sup>Harvard Medical School; <sup>2</sup>Mass Eye and Ear / Brigham and Women's Hospital; <sup>3</sup>Brigham and Women's Hospital / Dana Farber Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Radial forearm (RFFF) and fibular (FFF) free flaps are commonly used options for head and neck reconstruction. The donor site defect from these flaps often requires split-thickness skin grafting (STSG) for appropriate soft tissue coverage, which is often completed at the time of the initial free flap operation. STSG breakdown, often with tendon exposure and requiring prolonged wound care, is a common and vexing donor site complication. Our group has trialed a staged donor site repair using an engineered skin substitute (Integra® Bilayer Wound Matrix) followed by a staged STSG several weeks later, in an attempt to decrease donor site morbidity. This study aims to assess differences in donor site outcomes between patients treated with a two-staged donor site reconstruction with Integra then STSG, and those who received an upfront STSG.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of patients receiving either RFFF or FFF for head and neck reconstruction at a large, tertiary care hospital between 2020 and 2024 was completed. Donor sites were reconstructed with either a single-stage STSG at the time of free flap surgery (‘STSG’ group), or a two-stage approach with Integra placement followed by subsequent outpatient STSG approximately 3 weeks following free flap surgery (‘Integra’ group). Our primary outcome was donor site tendon exposure. Secondary donor site outcomes included infection, granulation tissue overgrowth, and keloid formation.</p>\n\n<p><strong>Results:</strong> 152 free flaps were included in this analysis, including 104 RFFF and 48 FFF. There were 98 STSG and 54 Integra patients. 27 patients developed tendon exposure overall (17.7%), including 12/48 (25%) of FFFs and 15/104 (14.4%) of RFFFs. Integra was associated with a significantly lower frequency of tendon exposure overall, occurring in just 7.4% (4/54) of Integra patients compared with 23.5% (23/98) of STSG patients (p=0.01). When stratified by flap type, Integra was associated with a lower frequency of tendon exposure for both flap donor sites, but this was statistically significant only for FFFs (FFFs: 8.3% vs. 41.7%, p=0.007; RFFFs: 6.7% vs. 17.6%, p=0.15). In multivariable models adjusting for flap type, STSG utilization was associated with 5 times the odds of tendon exposure compared with Integra (OR: 5.0 [1.5-16.1, p=0.007). There were no significant differences noted between Integra and STSG regarding donor site infections (11.1% vs. 11.2%, p=0.98[CM1] ), granulation tissue overgrowth (5.6% vs. 15.3%, p=0.08), or keloid formation (5.6% vs. 10.2%, p=0.33). There were no major complications related to a second surgical procedure among the Integra group.</p>\n\n<p><strong>Conclusion: </strong>We describe a staged approach to RFFF and FFF donor site coverage that was significantly associated with lower rates of tendon exposure in this retrospective single-institution study, particularly amongst FFF patients. While our results suggest that this technique may decrease donor site morbidity, any donor-site benefits should be weighed against the considerations of a second surgical procedure in a complex patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153684--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S022",
      "content_id": "153880",
      "abstract_number": "S022",
      "poster_number": "",
      "title": "Evaluating Outcomes in Revision Cranioplasty with Vascularized Tissue Reconstruction: A Systematic Review",
      "summary": "Our review sheds light on otherwise challenging cases of cranioplasty revision and cranial reconstruction. We have identified significant differences in outcomes between patients who underwent free flap versus non-free flap reconstructions during their first revision cranioplasty. Notably, patients receiving non-free flap reconstructions had higher rates of subsequent revisions, with many ultimately requiring a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153880",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ritu V Bhalerao, MS",
      "presenter": "Ritu V Bhalerao, MS",
      "authors": "Ritu V Bhalerao, MS 1 ; Murad Farooqi, BS 1 ; Andrew Blount, MD 2 ; Deborah X Xie, MD 3 ; Ameya A Jategaonkar, MD 3",
      "normalized_authors": [
        "Ritu V Bhalerao",
        "Murad Farooqi",
        "Andrew Blount",
        "Deborah X Xie",
        "Ameya A Jategaonkar"
      ],
      "affiliations": [
        "University of Arizona College of Medicine-Phoenix",
        "Department of Plastic Surgery, St. Joseph’s Hospital and Medical Center",
        "Department of Otolaryngology and Skull Base Surgery, Barrow Neurological Institute"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine-Phoenix",
        "Department of Plastic Surgery, St. Joseph’s Hospital and Medical Center",
        "Department of Otolaryngology and Skull Base Surgery, Barrow Neurological Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ritu V Bhalerao, MS 1 ; Murad Farooqi, BS 1 ; Andrew Blount, MD 2 ; Deborah X Xie, MD 3 ; Ameya A Jategaonkar, MD 3",
        "Affiliations": "1 University of Arizona College of Medicine-Phoenix; 2 Department of Plastic Surgery, St. Joseph’s Hospital and Medical Center; 3 Department of Otolaryngology and Skull Base Surgery, Barrow Neurological Institute",
        "Introduction": "Revision cranioplasty in the setting of complex wound complications often necessitates free flap reconstruction to achieve soft tissue coverage and reduce the risk of implant failure. While many of these reconstructive techniques have become common practice, there is relatively limited data guiding optimal surgical strategy regarding the use of free flaps for revision cases. This study evaluates published cases of revision cranioplasty involving vascularized tissue reconstruction, analyzing flap type, revision timing, and outcomes to better inform decision-making regarding reconstructive strategy and timing.",
        "Methods": "We performed a systematic review of the literature (PubMed, Embase, Cochrane Library, and Web of Science databases) from 2003-2023 according to PRISMA guidelines. Studies documenting revision cranioplasty procedures involving vascularized flap reconstruction were identified. All included patients had undergone at least two cranioplasty surgeries - one initial cranioplasty and one revision. Thus, for the purposes of this study, the first included surgical event was defined as the first revision of the initial cranioplasty. A two-proportion z-test was used to compare outcomes between cohorts when appropriate.",
        "Results": "Seventeen studies met inclusion criteria, encompassing 79 total patient cases. Patients were stratified into two cohorts based on reconstruction methods at first revision surgery: those receiving free flap reconstruction (n=36) and those receiving non-free flap reconstruction techniques such as local or advancement flaps (n=43). Etiology of the initial cranial defect was reported in 31 free flap and 34 non-free flap cases, with trauma being the most common cause in both groups (61% and 38%, respectively).",
        "Abstract": "In the free flap cohort, five patients (14%) underwent simultaneous cranioplasty implant revision along with free flap reconstruction. Twenty-five patients (69%) had a staged revision, meaning the implant was revised in a later surgery after the free flap reconstruction. In the non-free flap cohort, 14 patients (33%) underwent implant revision in addition to flap reconstruction, and none of these were staged. Further revision surgeries were uncommon in the free flap group; six patients underwent minor soft tissue revisions, and only one patient required an additional flap reconstruction. In the non-free flap cohort, 26 patients (60%) required at least one subsequent repeat flap revision, including 19 who ultimately required a free flap and six who underwent more than two total revision procedures. The overall rate of re-revision was thus 19% in the free flap group and 60% in the non-free flap group (z = -3.68, p < 0.01). View in Agenda and Add to Schedule",
        "Conclusion": "Our review sheds light on otherwise challenging cases of cranioplasty revision and cranial reconstruction. We have identified significant differences in outcomes between patients who underwent free flap versus non-free flap reconstructions during their first revision cranioplasty. Notably, patients receiving non-free flap reconstructions had higher rates of subsequent revisions, with many ultimately requiring a free flap in future surgeries. These findings suggest that early free flap reconstruction in the first revision surgery, with a staged approach to the hardware, may be associated with reduced need for reoperation. Larger cohort studies are warranted to confirm optimal staging and flap selection strategies in revision cranioplasty."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating Outcomes in Revision Cranioplasty with Vascularized Tissue Reconstruction: A Systematic Review</span>. <u>Ritu V Bhalerao, MS</u><sup>1</sup>; Murad Farooqi, BS<sup>1</sup>; Andrew Blount, MD<sup>2</sup>; Deborah X Xie, MD<sup>3</sup>; Ameya A Jategaonkar, MD<sup>3</sup>. <sup>1</sup>University of Arizona College of Medicine-Phoenix; <sup>2</sup>Department of Plastic Surgery, St. Joseph’s Hospital and Medical Center; <sup>3</sup>Department of Otolaryngology and Skull Base Surgery, Barrow Neurological Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Revision cranioplasty in the setting of complex wound complications often necessitates free flap reconstruction to achieve soft tissue coverage and reduce the risk of implant failure. While many of these reconstructive techniques have become common practice, there is relatively limited data guiding optimal surgical strategy regarding the use of free flaps for revision cases. This study evaluates published cases of revision cranioplasty involving vascularized tissue reconstruction, analyzing flap type, revision timing, and outcomes to better inform decision-making regarding reconstructive strategy and timing.</p>\n\n<p><strong>Methods: </strong>We performed a systematic review of the literature (PubMed, Embase, Cochrane Library, and Web of Science databases) from 2003-2023 according to PRISMA guidelines. Studies documenting revision cranioplasty procedures involving vascularized flap reconstruction were identified. All included patients had undergone at least two cranioplasty surgeries - one initial cranioplasty and one revision. Thus, for the purposes of this study, the first included surgical event was defined as the first revision of the initial cranioplasty. A two-proportion z-test was used to compare outcomes between cohorts when appropriate.</p>\n\n<p><strong>Results: </strong>Seventeen studies met inclusion criteria, encompassing 79 total patient cases. Patients were stratified into two cohorts based on reconstruction methods at first revision surgery: those receiving free flap reconstruction (n=36) and those receiving non-free flap reconstruction techniques such as local or advancement flaps (n=43). Etiology of the initial cranial defect was reported in 31 free flap and 34 non-free flap cases, with trauma being the most common cause in both groups (61% and 38%, respectively).</p>\n\n<p>In the free flap cohort, five patients (14%) underwent simultaneous cranioplasty implant revision along with free flap reconstruction. Twenty-five patients (69%) had a staged revision, meaning the implant was revised in a later surgery after the free flap reconstruction. In the non-free flap cohort, 14 patients (33%) underwent implant revision in addition to flap reconstruction, and none of these were staged.</p>\n\n<p>Further revision surgeries were uncommon in the free flap group; six patients underwent minor soft tissue revisions, and only one patient required an additional flap reconstruction. In the non-free flap cohort, 26 patients (60%) required at least one subsequent repeat flap revision, including 19 who ultimately required a free flap and six who underwent more than two total revision procedures. The overall rate of re-revision was thus 19% in the free flap group and 60% in the non-free flap group (z = -3.68, p < 0.01).</p>\n\n<p><strong>Conclusion: </strong>Our review sheds light on otherwise challenging cases of cranioplasty revision and cranial reconstruction. We have identified significant differences in outcomes between patients who underwent free flap versus non-free flap reconstructions during their first revision cranioplasty. Notably, patients receiving non-free flap reconstructions had higher rates of subsequent revisions, with many ultimately requiring a free flap in future surgeries. These findings suggest that early free flap reconstruction in the first revision surgery, with a staged approach to the hardware, may be associated with reduced need for reoperation. Larger cohort studies are warranted to confirm optimal staging and flap selection strategies in revision cranioplasty.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153880--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S023",
      "content_id": "154074",
      "abstract_number": "S023",
      "poster_number": "",
      "title": "Impact of prior chemotherapy on free tissue transfer outcomes",
      "summary": "Prior chemotherapy is associated with worse nutritional status and increased perioperative morbidity following H&N free tissue transfer, including higher rates of flap-related complications, thromboembolic events, sepsis, prolonged hospitalization, and readmission.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154074",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex Lichtl, MD",
      "presenter": "Alex Lichtl, MD",
      "authors": "Alex Lichtl, MD 1 ; Mandy Salmon, MD 1 ; Morgan Terry, MD 1 ; Alisa Phillips, MD 1 ; Madeline Pyle, MD 2 ; Mark Wax, MD 1 ; Joseph Curry, D 3 ; Carissa Thomas, MD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 1 ; Dina Modlin, BS 2 ; Jason Leibowitz, MD 2 ; Michael DiLeo, MD 6 ; Nicolaus Knight, MS 4 ; Elise Krippaehne, BS 1 ; Javier Nishikawa, BS 4 ; Yasaman Baghshomali, BS 7 ; Madeline Otto, BS 1 ; Sruti Tekumalla, BA 3 ; Sumanth Chandrupatla, BS 4 ; Larissa Sweeny, MD 2",
      "normalized_authors": [
        "Alex Lichtl",
        "Mandy Salmon",
        "Morgan Terry",
        "Alisa Phillips",
        "Madeline Pyle",
        "Mark Wax",
        "Joseph Curry, D",
        "Carissa Thomas",
        "Sallie Long",
        "Dev Amin",
        "Caroline Bonaventure",
        "Farshid Taghizadeh",
        "Dina Modlin",
        "Jason Leibowitz",
        "Michael DiLeo",
        "Nicolaus Knight",
        "Elise Krippaehne",
        "Javier Nishikawa",
        "Yasaman Baghshomali",
        "Madeline Otto",
        "Sruti Tekumalla",
        "Sumanth Chandrupatla",
        "Larissa Sweeny"
      ],
      "affiliations": [
        "OHSU",
        "University of Miami",
        "Thomas Jefferson University",
        "UAB",
        "Augusta University",
        "Louisiana State University",
        "University of Colorado"
      ],
      "normalized_institutions": [
        "OHSU",
        "University of Miami",
        "Thomas Jefferson University",
        "UAB",
        "Augusta University",
        "Louisiana State University",
        "University of Colorado"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154074/Screenshot%202025-12-04%20at%207_25_21%E2%80%AFPM(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154074/Screenshot%202025-12-04%20at%207_25_21%E2%80%AFPM(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154074"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 236,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex Lichtl, MD 1 ; Mandy Salmon, MD 1 ; Morgan Terry, MD 1 ; Alisa Phillips, MD 1 ; Madeline Pyle, MD 2 ; Mark Wax, MD 1 ; Joseph Curry, D 3 ; Carissa Thomas, MD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 1 ; Dina Modlin, BS 2 ; Jason Leibowitz, MD 2 ; Michael DiLeo, MD 6 ; Nicolaus Knight, MS 4 ; Elise Krippaehne, BS 1 ; Javier Nishikawa, BS 4 ; Yasaman Baghshomali, BS 7 ; Madeline Otto, BS 1 ; Sruti Tekumalla, BA 3 ; Sumanth Chandrupatla, BS 4 ; Larissa Sweeny, MD 2",
        "Affiliations": "1 OHSU; 2 University of Miami; 3 Thomas Jefferson University; 4 UAB; 5 Augusta University; 6 Louisiana State University; 7 University of Colorado",
        "Background": "Free tissue transfer (FTT) remains the optimal way to replace composite tissue after oncologic ablation. As multimodality therapy expands, the impact of prior chemotherapy on postoperative outcomes remains unclear. This study evaluates the association between preoperative chemotherapy and perioperative morbidity in patients undergoing H&N FTT.",
        "Methods": "A multi-institutional retrospective analysis compared patients with and without prior chemotherapy undergoing H&N free tissue transfer 2010-2024. Demographics, nutritional markers, perioperative events, and postoperative complications were analyzed using t-tests, odds ratios (OR), and likelihood ratio testing where appropriate.",
        "Results": "There were 2,707 patients who underwent free tissue transfer, 634 (23.42%) had prior chemotherapy. Patients with chemotherapy exposure were slightly younger (62.03 vs 63.73 years, p=0.0035). Chemotherapy was associated with lower BMI (24.38 vs 26.22, p=0.0001), reduced prealbumin (15.85 vs 17.35, p=0.0244), and elevated TSH (5.27 vs 3.33, p=0.0134). The perioperative complications that were significantly associated with prior chemotherapy exposure are outlined in Table 1.",
        "Abstract": "Chemotherapy was not associated with differences in T stage, operative time (<10 hours vs >10hours), thrombectomy, flap salvage, survival, cardiopulmonary events, stroke, delirium, discharge disposition, or overall length of stay. View in Agenda and Add to Schedule",
        "Conclusion": "Prior chemotherapy is associated with worse nutritional status and increased perioperative morbidity following H&N free tissue transfer, including higher rates of flap-related complications, thromboembolic events, sepsis, prolonged hospitalization, and readmission."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of prior chemotherapy on free tissue transfer outcomes</span>. <u>Alex Lichtl, MD</u><sup>1</sup>; Mandy Salmon, MD<sup>1</sup>; Morgan Terry, MD<sup>1</sup>; Alisa Phillips, MD<sup>1</sup>; Madeline Pyle, MD<sup>2</sup>; Mark Wax, MD<sup>1</sup>; Joseph Curry, D<sup>3</sup>; Carissa Thomas, MD<sup>4</sup>; Sallie Long, MD<sup>5</sup>; Dev Amin, MD<sup>3</sup>; Caroline Bonaventure, MD<sup>6</sup>; Farshid Taghizadeh, MD<sup>1</sup>; Dina Modlin, BS<sup>2</sup>; Jason Leibowitz, MD<sup>2</sup>; Michael DiLeo, MD<sup>6</sup>; Nicolaus Knight, MS<sup>4</sup>; Elise Krippaehne, BS<sup>1</sup>; Javier Nishikawa, BS<sup>4</sup>; Yasaman Baghshomali, BS<sup>7</sup>; Madeline Otto, BS<sup>1</sup>; Sruti Tekumalla, BA<sup>3</sup>; Sumanth Chandrupatla, BS<sup>4</sup>; Larissa Sweeny, MD<sup>2</sup>. <sup>1</sup>OHSU; <sup>2</sup>University of Miami; <sup>3</sup>Thomas Jefferson University; <sup>4</sup>UAB; <sup>5</sup>Augusta University; <sup>6</sup>Louisiana State University; <sup>7</sup>University of Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Free tissue transfer (FTT) remains the optimal way to replace composite tissue after oncologic ablation. As multimodality therapy expands, the impact of prior chemotherapy on postoperative outcomes remains unclear. This study evaluates the association between preoperative chemotherapy and perioperative morbidity in patients undergoing H&N FTT.</p>\n\n<p><strong>Methods: </strong>A multi-institutional retrospective analysis compared patients with and without prior chemotherapy undergoing H&N free tissue transfer 2010-2024. Demographics, nutritional markers, perioperative events, and postoperative complications were analyzed using t-tests, odds ratios (OR), and likelihood ratio testing where appropriate.</p>\n\n<p><strong>Results: </strong>There were 2,707 patients who underwent free tissue transfer, 634 (23.42%) had prior chemotherapy. Patients with chemotherapy exposure were slightly younger (62.03 vs 63.73 years, p=0.0035). Chemotherapy was associated with lower BMI (24.38 vs 26.22, p=0.0001), reduced prealbumin (15.85 vs 17.35, p=0.0244), and elevated TSH (5.27 vs 3.33, p=0.0134). The perioperative complications that were significantly associated with prior chemotherapy exposure are outlined in Table 1. </p>\n\n<p>Chemotherapy was not associated with differences in T stage, operative time (<10 hours vs >10hours), thrombectomy, flap salvage, survival, cardiopulmonary events, stroke, delirium, discharge disposition, or overall length of stay. </p>\n\n<p><strong>Conclusion: </strong>Prior chemotherapy is associated with worse nutritional status and increased perioperative morbidity following H&N free tissue transfer, including higher rates of flap-related complications, thromboembolic events, sepsis, prolonged hospitalization, and readmission. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154074/Screenshot%202025-12-04%20at%207_25_21%E2%80%AFPM(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154074--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S024",
      "content_id": "154283",
      "abstract_number": "S024",
      "poster_number": "",
      "title": "Outcomes Following Use of a Prior Microvascular Pedicle in Secondary Free Flap Reconstruction: A Single-Center Experience",
      "summary": "The current study provides one of the largest reviews of prior microvascular pedicle anastomosis outcomes to date. In the VDN, use of a previously used free flap pedicle remains a viable reconstructive option with a high rate of flap success.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154283",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260114",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claire Eiden, BS",
      "presenter": "Claire Eiden, BS",
      "authors": "Claire Eiden, BS ; Antonio S Dekhou, MD; Megha Mohanakrishnan; Priscilla Pichardo, DO; Alice A Tang, MD; Chad A Zender, MD; Dustin A Silverman, MD",
      "normalized_authors": [
        "Claire Eiden",
        "Antonio S Dekhou",
        "Megha Mohanakrishnan",
        "Priscilla Pichardo",
        "Alice A Tang",
        "Chad A Zender",
        "Dustin A Silverman"
      ],
      "affiliations": [
        "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Claire Eiden, BS ; Antonio S Dekhou, MD; Megha Mohanakrishnan; Priscilla Pichardo, DO; Alice A Tang, MD; Chad A Zender, MD; Dustin A Silverman, MD",
        "Affiliations": "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery",
        "Background": "The availability and quality of recipient vessels in head and neck microvascular reconstruction is critical to the success and viability of free tissue transfers. Patients with a history of a previously treated neck with surgery, radiation, chemotherapy, or combination of these modalities often have altered cervical anatomy with adverse and sometimes extreme tissue effects; this may render patients’ necks depleted of suitable recipient vessels. While a variety of vascular options remain available in the vessel-depleted neck (VDN), outcomes following reuse of a prior vascular pedicle are not well described. The primary study objective was to assess perioperative outcomes and success following secondary free flap reconstructions with use of a prior vascular pedicle for microvascular anastomosis.",
        "Methods": "A retrospective analysis of patients who required a secondary head and neck free flap reconstruction at the University of Cincinnati Medical Center during the years 2009 – 2024 was performed. Cases in which the first and second recipient artery were identical were selected for further review. Numerous patient demographic, clinicopathologic, and surgical characteristics were tabulated. Descriptive statistics were used to assess microvascular flap success and perioperative outcomes among the cohort.",
        "Results": "211 patients who required secondary free flap reconstruction were identified. The majority of patients were male (N = 28, 70.0%) with a mean age at first diagnosis of 62.0 years (± 10.5 years). The most common indications for a second free flap surgery were osteoradionecrosis/osteomyelitis (N = 13, 33.0%), recurrent malignancy (N = 11, 27.5%), and development of a fistula or nonfunctional larynx (N = 4, 10.0%). Adjuvant therapy was administered to 77.5% of patients following initial microvascular reconstruction, with 9 (22.5%) and 19 (47.5%) patients undergoing radiation therapy alone and chemoradiation therapy, respectively. A total of 20.0% of patients had a history of diabetes mellitus. Of 211 patients, 40 (19.0%) reconstructions utilized a prior vascular pedicle in which the same recipient artery was selected for both the primary and secondary free flap microvascular anastomosis. A previously used ipsilateral facial artery served as the recipient artery for the second free flap in 80% of cases (N = 32). The prior donor radial artery was utilized in two cases. A prior recipient vein was selected in 17 (42.5%) cases, with the facial (N = 6) and external jugular vein (N = 6) being most common. The average hospital length of stay (LOS) was 7.7 days (range 4-30 days). The 30-day and 60-day complication rates were 25.0% and 12.5%, respectively, with 35.0% characterized as non-surgical in nature. Return to the OR within 30 days occurred in 7 (17.5%) patients, most commonly for partial/total flap failure. Rates of total (N = 1) and partial (N = 1) flap failure were each 2.5% for an overall flap success rate of 97.5%.",
        "Conclusion": "The current study provides one of the largest reviews of prior microvascular pedicle anastomosis outcomes to date. In the VDN, use of a previously used free flap pedicle remains a viable reconstructive option with a high rate of flap success.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes Following Use of a Prior Microvascular Pedicle in Secondary Free Flap Reconstruction: A Single-Center Experience</span>. <u>Claire Eiden, BS</u>; Antonio S Dekhou, MD; Megha Mohanakrishnan; Priscilla Pichardo, DO; Alice A Tang, MD; Chad A Zender, MD; Dustin A Silverman, MD. University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: The availability and quality of recipient vessels in head and neck microvascular reconstruction is critical to the success and viability of free tissue transfers. Patients with a history of a previously treated neck with surgery, radiation, chemotherapy, or combination of these modalities often have altered cervical anatomy with adverse and sometimes extreme tissue effects; this may render patients’ necks depleted of suitable recipient vessels. While a variety of vascular options remain available in the vessel-depleted neck (VDN), outcomes following reuse of a prior vascular pedicle are not well described. The primary study objective was to assess perioperative outcomes and success following secondary free flap reconstructions with use of a prior vascular pedicle for microvascular anastomosis.</p>\n\n<p><strong>Methods</strong>: A retrospective analysis of patients who required a secondary head and neck free flap reconstruction at the University of Cincinnati Medical Center during the years 2009 – 2024 was performed. Cases in which the first and second recipient artery were identical were selected for further review. Numerous patient demographic, clinicopathologic, and surgical characteristics were tabulated. Descriptive statistics were used to assess microvascular flap success and perioperative outcomes among the cohort.</p>\n\n<p><strong>Results</strong>: 211 patients who required secondary free flap reconstruction were identified. The majority of patients were male (N = 28, 70.0%) with a mean age at first diagnosis of 62.0 years (± 10.5 years). The most common indications for a second free flap surgery were osteoradionecrosis/osteomyelitis (N = 13, 33.0%), recurrent malignancy (N = 11, 27.5%), and development of a fistula or nonfunctional larynx (N = 4, 10.0%). Adjuvant therapy was administered to 77.5% of patients following initial microvascular reconstruction, with 9 (22.5%) and 19 (47.5%) patients undergoing radiation therapy alone and chemoradiation therapy, respectively. A total of 20.0% of patients had a history of diabetes mellitus. Of 211 patients, 40 (19.0%) reconstructions utilized a prior vascular pedicle in which the same recipient artery was selected for both the primary and secondary free flap microvascular anastomosis. A previously used ipsilateral facial artery served as the recipient artery for the second free flap in 80% of cases (N = 32). The prior donor radial artery was utilized in two cases. A prior recipient vein was selected in 17 (42.5%) cases, with the facial (N = 6) and external jugular vein (N = 6) being most common. The average hospital length of stay (LOS) was 7.7 days (range 4-30 days). The 30-day and 60-day complication rates were 25.0% and 12.5%, respectively, with 35.0% characterized as non-surgical in nature. Return to the OR within 30 days occurred in 7 (17.5%) patients, most commonly for partial/total flap failure. Rates of total (N = 1) and partial (N = 1) flap failure were each 2.5% for an overall flap success rate of 97.5%.</p>\n\n<p><strong>Conclusion</strong>: The current study provides one of the largest reviews of prior microvascular pedicle anastomosis outcomes to date. In the VDN, use of a previously used free flap pedicle remains a viable reconstructive option with a high rate of flap success.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154283--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260114' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S025",
      "content_id": "154517",
      "abstract_number": "S025",
      "poster_number": "",
      "title": "Investigating the role of tumor-intrinsic STAT3 hyperactivation through genetically engineered organoid models of head and neck squamous cell carcinoma",
      "summary": "By integrating human tumor analyses with a newly established genetically engineered organoid model, we identify tumor-intrinsic STAT3 hyperactivation as a key driver of immune “cold” tumors in HPV-unrelated HNSCC. STAT3 suppressed cancer cell antigen presentation and disrupted antigen-specific T-cell priming, thereby promoting immune exclusion. These findings highlight STAT3-dependent pathways as essential...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154517",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Masahiro Rokugo",
      "presenter": "Masahiro Rokugo",
      "authors": "Masahiro Rokugo 1 ; Long Chi Nguyen 2 ; Edward Sim 3 ; John Quadarella 3 ; Patrick Lizotte 3 ; Ann M Egloff 3 ; Yukio Katori 1 ; Ravindra Uppaluri 3",
      "normalized_authors": [
        "Masahiro Rokugo",
        "Long Chi Nguyen",
        "Edward Sim",
        "John Quadarella",
        "Patrick Lizotte",
        "Ann M Egloff",
        "Yukio Katori",
        "Ravindra Uppaluri"
      ],
      "affiliations": [
        "Tohoku University",
        "University Of Chicago",
        "Dana-Farber Cancer Institute"
      ],
      "normalized_institutions": [
        "Tohoku University",
        "University Of Chicago",
        "Dana-Farber Cancer Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 358,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Masahiro Rokugo 1 ; Long Chi Nguyen 2 ; Edward Sim 3 ; John Quadarella 3 ; Patrick Lizotte 3 ; Ann M Egloff 3 ; Yukio Katori 1 ; Ravindra Uppaluri 3",
        "Affiliations": "1 Tohoku University; 2 University Of Chicago; 3 Dana-Farber Cancer Institute",
        "Introduction": "While immune checkpoint inhibitor (ICI) therapy in head and neck squamous cell carcinoma (HNSCC) has profoundly improved patient outcomes, responses are limited and defining determinants of resistance remains a key objective. Response to ICIs has been correlated with increased immune cell infiltration. Herein, we hypothesized that tumor-intrinsic genomic features regulate immune infiltration and that modeling these altered pathways can help define platforms for therapeutic approaches.",
        "Methods": "First, through single-cell RNA sequencing (scRNA-seq) of human HNSCC tumors, we identified STAT3 as a major cancer cell-intrinsic regulator of poor immune infiltration. Then, we developed the PCS mouse, a genetically engineered mouse model ( Trp53 LSL-R172H/+ Cdkn2a fl/fl Rosa26R LSL-Sox2-IRES-GFP/LSL-Sox2-IRES-GFP ) to reflect key genomic alterations in human papillomavirus (HPV)-unrelated HNSCC. Organoids generated from the oral epithelium of PCS mice were transfected ex vivo to express Cre recombinase with (SIIN+) or without (SIIN-), the SIINFEKL model antigen. These organoids were subsequently transfected with STAT3C, a mutated, constitutively active STAT3 allele to model tumor cell-intrinsic STAT3 hyperactivation. Organoids were orthotopically implanted and developing tumors assessed for immune composition by flow cytometry, tumor-specific T cell responses by interferon-g enzyme-linked immunosorbent assay (ELISA), and tumor growth by digital caliper.",
        "Results": "SIIN+ organoid-initiated orthotopic tumors elicited strong antigen-specific immune responses and were eliminated in immunocompetent mice, whereas SIIN– tumors escaped immune clearance. STAT3C expression converted otherwise immunogenic SIIN+ tumors into immune-evasive tumors. STAT3C SIIN+ tumors showed marked reductions in CD8+ tumor-infiltrating lymphocytes, SIINFEKL-specific T cells, and IFN-γ production in tumor-draining lymph nodes compared to SIIN+ tumors without STAT3C. ScRNA-seq analyses of STAT3C tumor-infiltrating T cells revealed downregulation of interferon gamma and alpha response pathways. Cancer cell-specific transcriptional programs demonstrated suppression of MHC class I antigen-presentation genes and enrichment of chromatin-remodeling pathways.",
        "Conclusion": "By integrating human tumor analyses with a newly established genetically engineered organoid model, we identify tumor-intrinsic STAT3 hyperactivation as a key driver of immune “cold” tumors in HPV-unrelated HNSCC. STAT3 suppressed cancer cell antigen presentation and disrupted antigen-specific T-cell priming, thereby promoting immune exclusion. These findings highlight STAT3-dependent pathways as essential targets to overcome ICI resistance and provide a novel platform to evaluate new therapeutic approaches in HNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Investigating the role of tumor-intrinsic STAT3 hyperactivation through genetically engineered organoid models of head and neck squamous cell carcinoma</span>. <u>Masahiro Rokugo</u><sup>1</sup>; Long Chi Nguyen<sup>2</sup>; Edward Sim<sup>3</sup>; John Quadarella<sup>3</sup>; Patrick Lizotte<sup>3</sup>; Ann M Egloff<sup>3</sup>; Yukio Katori<sup>1</sup>; Ravindra Uppaluri<sup>3</sup>. <sup>1</sup>Tohoku University; <sup>2</sup>University Of Chicago; <sup>3</sup>Dana-Farber Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: While immune checkpoint inhibitor (ICI) therapy in head and neck squamous cell carcinoma (HNSCC) has profoundly improved patient outcomes, responses are limited and defining determinants of resistance remains a key objective. Response to ICIs has been correlated with increased immune cell infiltration. Herein, we hypothesized that tumor-intrinsic genomic features regulate immune infiltration and that modeling these altered pathways can help define platforms for therapeutic approaches.</p>\n\n<p><strong>Methods</strong>: First, through single-cell RNA sequencing (scRNA-seq) of human HNSCC tumors, we identified STAT3 as a major cancer cell-intrinsic regulator of poor immune infiltration. Then, we developed the PCS mouse, a genetically engineered mouse model (<em>Trp53<sup>LSL-R172H/+</sup>Cdkn2a<sup>fl/fl</sup>Rosa26R<sup>LSL-Sox2-IRES-GFP/LSL-Sox2-IRES-GFP</sup></em>) to reflect key genomic alterations in human papillomavirus (HPV)-unrelated HNSCC. Organoids generated from the oral epithelium of PCS mice were transfected ex vivo to express Cre recombinase with (SIIN+) or without (SIIN-), the SIINFEKL model antigen. These organoids were subsequently transfected with STAT3C, a mutated, constitutively active STAT3 allele to model tumor cell-intrinsic STAT3 hyperactivation. Organoids were orthotopically implanted and developing tumors assessed for immune composition by flow cytometry, tumor-specific T cell responses by interferon-g enzyme-linked immunosorbent assay (ELISA), and tumor growth by digital caliper.</p>\n\n<p><strong>Results</strong>: SIIN+ organoid-initiated orthotopic tumors elicited strong antigen-specific immune responses and were eliminated in immunocompetent mice, whereas SIIN– tumors escaped immune clearance. STAT3C expression converted otherwise immunogenic SIIN+ tumors into immune-evasive tumors. STAT3C SIIN+ tumors showed marked reductions in CD8+ tumor-infiltrating lymphocytes, SIINFEKL-specific T cells, and IFN-γ production in tumor-draining lymph nodes compared to SIIN+ tumors without STAT3C. ScRNA-seq analyses of STAT3C tumor-infiltrating T cells revealed downregulation of interferon gamma and alpha response pathways. Cancer cell-specific transcriptional programs demonstrated suppression of MHC class I antigen-presentation genes and enrichment of chromatin-remodeling pathways.</p>\n\n<p><strong>Conclusion</strong>: By integrating human tumor analyses with a newly established genetically engineered organoid model, we identify tumor-intrinsic STAT3 hyperactivation as a key driver of immune “cold” tumors in HPV-unrelated HNSCC. STAT3 suppressed cancer cell antigen presentation and disrupted antigen-specific T-cell priming, thereby promoting immune exclusion. These findings highlight STAT3-dependent pathways as essential targets to overcome ICI resistance and provide a novel platform to evaluate new therapeutic approaches in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154517--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S026",
      "content_id": "154240",
      "abstract_number": "S026",
      "poster_number": "",
      "title": "ACTL6A regulates tumor-intrinsic immune signaling by potentiating SWI/SNF chromatin occupancy",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154240",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Andrey Finegersh",
      "presenter": "Andrey Finegersh",
      "authors": "Mehri Monavarian; Keene Lee; Patrick Galligan; Ivan Stepanek; John Sunwoo; Andrey Finegersh",
      "normalized_authors": [
        "Mehri Monavarian",
        "Keene Lee",
        "Patrick Galligan",
        "Ivan Stepanek",
        "John Sunwoo",
        "Andrey Finegersh"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mehri Monavarian; Keene Lee; Patrick Galligan; Ivan Stepanek; John Sunwoo; Andrey Finegersh",
        "Affiliations": "Stanford University",
        "BACKGROUND": "ACTL6A is a subunit of the SWI/SNF chromatin remodeling complex whose expression levels regulate its chromatin occupancy. ACTL6A over-expression occurs in the vast majority of head and neck squamous cell carcinomas (HNSCC), where it contributes to oncogenic phenotypes. We have discovered that ACTL6A expression is strongly negatively correlated with infiltration of HNSCC tumors and identify the SWI/SNF complex as a critical mediator of tumor-intrinsic interferon-gamma (IFNG) signaling.",
        "METHODS": "We leverage a multi-omics approach to mechanistically link SWI/SNF with tumor-immune interactions in HNSCC, including analysis of TCGA RNA-seq using tumor cell deconvolution, single cell spatial biology using the Nanostring CosMx platform, HNSCC organoid models, RNA-seq, and CUT&RUN.",
        "RESULTS": "Using deconvolution of TCGA RNA-seq data, we found that ACTL6A expression has a strong negative correlation with CD8+ T cell, NK cell, and anti-tumor cytokine gene signatures (p < 0.001). We then used a tissue microarray containing cores from 10 patients with HNSCC, which was stained for ACTL6A using immunofluorescence and run on the CosMx spatial molecular imager to generate single cell transcriptomic data. Spatial biology confirmed that tumors with high ACTL6A expression have significantly decreased infiltration of CD8+ T cells and proliferating T cells. We used CUT&RUN for ACTL6A occupancy and used a SWI/SNF PROTAC degrader (AU-15330) to show that SWI/SNF depletion blunts ACTL6A occupancy at key immune-related genes. We then performed RNA-seq on FaDu cells after AU-15330 treatment and found that IFNG gene sets were the most strongly down-regulated pathways. We tested whether AU-15330 could alter tumor-immune interactions using an HNSCC organoid and T cell co-culture, where AU-15330 led to a significant increase in T cell infiltration of organoids (p < 0.001). We then used an OT-1/SIINFEKL antigen-specific co-culture with mouse T cells and MOC2 cells and found that AU-15330 also significantly increased T cell mediated cytotoxicity (p<0.01). We also found that AU-15330 significantly reduces IFNG mediated up-regulation of PD-L1 in FaDu and SCC1 cells (p<0.001). Based on these results, we hypothesized that SWI/SNF regulates transcription of IFNG stimulated genes. We performed RNA-seq on FaDu cells treated with 10 nM IFNG, 1 uM AU-15330, or combination and found that AU-15330 nearly completely blocked expression of genes induced by IFNG.",
        "CONCLUSIONS": "These results define epigenetic regulation of tumor-intrinsic signaling in HNSCC, specifically that SWI/SNF regulates chromatin accessibility at key immune response genes to epigenetically prime IFNG stimulated gene expression. SWI/SNF activation through ACTL6A leads to an immune cold tumor phenotype in human HNSCC tumors. As chronic IFNG stimulation is emerging as a key mechanism of immune escape and immunotherapy resistance in HNSCC, these results develop mechanistic insight into gene regulation and provide a possible treatment avenue via SWI/SNF inhibition.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>ACTL6A regulates tumor-intrinsic immune signaling by potentiating SWI/SNF chromatin occupancy</span>. Mehri Monavarian; Keene Lee; Patrick Galligan; Ivan Stepanek; John Sunwoo; <u>Andrey Finegersh</u>. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>ACTL6A is a subunit of the SWI/SNF chromatin remodeling complex whose expression levels regulate its chromatin occupancy. ACTL6A over-expression occurs in the vast majority of head and neck squamous cell carcinomas (HNSCC), where it contributes to oncogenic phenotypes. We have discovered that ACTL6A expression is strongly negatively correlated with infiltration of HNSCC tumors and identify the SWI/SNF complex as a critical mediator of tumor-intrinsic interferon-gamma (IFNG) signaling.</p>\n\n<p><strong>METHODS: </strong>We leverage a multi-omics approach to mechanistically link SWI/SNF with tumor-immune interactions in HNSCC, including analysis of TCGA RNA-seq using tumor cell deconvolution, single cell spatial biology using the Nanostring CosMx platform, HNSCC organoid models, RNA-seq, and CUT&RUN.</p>\n\n<p><strong>RESULTS: </strong>Using deconvolution of TCGA RNA-seq data, we found that ACTL6A expression has a strong negative correlation with CD8+ T cell, NK cell, and anti-tumor cytokine gene signatures (p < 0.001). We then used a tissue microarray containing cores from 10 patients with HNSCC, which was stained for ACTL6A using immunofluorescence and run on the CosMx spatial molecular imager to generate single cell transcriptomic data. Spatial biology confirmed that tumors with high ACTL6A expression have significantly decreased infiltration of CD8+ T cells and proliferating T cells. We used CUT&RUN for ACTL6A occupancy and used a SWI/SNF PROTAC degrader (AU-15330) to show that SWI/SNF depletion blunts ACTL6A occupancy at key immune-related genes. We then performed RNA-seq on FaDu cells after AU-15330 treatment and found that IFNG gene sets were the most strongly down-regulated pathways. We tested whether AU-15330 could alter tumor-immune interactions using an HNSCC organoid and T cell co-culture, where AU-15330 led to a significant increase in T cell infiltration of organoids (p < 0.001). We then used an OT-1/SIINFEKL antigen-specific co-culture with mouse T cells and MOC2 cells and found that AU-15330 also significantly increased T cell mediated cytotoxicity (p<0.01). We also found that AU-15330 significantly reduces IFNG mediated up-regulation of PD-L1 in FaDu and SCC1 cells (p<0.001). Based on these results, we hypothesized that SWI/SNF regulates transcription of IFNG stimulated genes. We performed RNA-seq on FaDu cells treated with 10 nM IFNG, 1 uM AU-15330, or combination and found that AU-15330 nearly completely blocked expression of genes induced by IFNG.</p>\n\n<p><strong>CONCLUSIONS: </strong>These results define epigenetic regulation of tumor-intrinsic signaling in HNSCC, specifically that SWI/SNF regulates chromatin accessibility at key immune response genes to epigenetically prime IFNG stimulated gene expression. SWI/SNF activation through ACTL6A leads to an immune cold tumor phenotype in human HNSCC tumors. As chronic IFNG stimulation is emerging as a key mechanism of immune escape and immunotherapy resistance in HNSCC, these results develop mechanistic insight into gene regulation and provide a possible treatment avenue via SWI/SNF inhibition.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154240--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S027",
      "content_id": "154207",
      "abstract_number": "S027",
      "poster_number": "",
      "title": "APOBEC Dominant Mutational Signature Defines A Molecularly and Clinically Distinct Oral Cavity Cancer Subgroup",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154207",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Benjamin M Wahle",
      "presenter": "Benjamin M Wahle",
      "authors": "Benjamin M Wahle 1 ; Benjamin Adams 1 ; Alex Harbison 1 ; Ryan Jackson 1 ; Patrik Pipkorn 1 ; Jason Rich 1 ; Paul Zolkind 1 ; Angela Mazul 2 ; Jose Zevallos 2 ; D Neil Hayes 3 ; Sidharth Puram 1",
      "normalized_authors": [
        "Benjamin M Wahle",
        "Benjamin Adams",
        "Alex Harbison",
        "Ryan Jackson",
        "Patrik Pipkorn",
        "Jason Rich",
        "Paul Zolkind",
        "Angela Mazul",
        "Jose Zevallos",
        "D Neil Hayes",
        "Sidharth Puram"
      ],
      "affiliations": [
        "Washington University School of Medicine",
        "University of Pittsburgh School of Medicine",
        "University of Tennessee Health Science Center"
      ],
      "normalized_institutions": [
        "Washington University School of Medicine",
        "University of Pittsburgh School of Medicine",
        "University of Tennessee Health Science Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154207/hm_edited.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154207/hm_edited.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154207"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 482,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Benjamin M Wahle 1 ; Benjamin Adams 1 ; Alex Harbison 1 ; Ryan Jackson 1 ; Patrik Pipkorn 1 ; Jason Rich 1 ; Paul Zolkind 1 ; Angela Mazul 2 ; Jose Zevallos 2 ; D Neil Hayes 3 ; Sidharth Puram 1",
        "Affiliations": "1 Washington University School of Medicine; 2 University of Pittsburgh School of Medicine; 3 University of Tennessee Health Science Center",
        "BACKGROUND": "Up to 25% of oral cavity squamous cell carcinoma (OCSCC) cases have no significant exposure to tobacco and alcohol. Compared to the rest of the OCSCC population, these cases tend to be older, more female, and display distinct patterns of oral cavity subsite dominance. The underlying molecular pathophysiology in atypical OCSCC cases remains poorly defined. We hypothesized that analysis of OCSCC whole genomes using mutational signatures, which computationally discern the influence of discrete mutational processes, would reveal discrete subgroups within the OCSCC population.",
        "METHODS": "We performed an exploratory genomics study using oral cavity cases with available whole genome sequencing (WGS) data from The Cancer Genome Atlas (TCGA). Single base substitution (SBS), double base substitution (DBS), and insertion-deletion (ID) signatures were generated using python packages SigProfilerMatrixGenerator and SigProfilerAssignment with COSMIC SBS Signatures V3.4 as the reference. APOBEC-dominant cases were defined as those where SBS2 and SBS13 accounted for the greatest proportion of mutations relative to the tumor’s total mutational burden.",
        "RESULTS": "A total of 246 OCSCC cases were included. Of these, 161 (65.4%) showed some degree of ABPOEC-related mutational burden, and in 38 (15.4%) cases APOBEC was the dominant mutational process. Compared to the rest of the OCSCC population, APOBEC-dominant cases were older in age (mean difference 7.57 years, 95% CI 3.32-11.8, T-test P<0.001), were more female (47.3% vs 30.8%, OR 2.01, 95% CI 0.93-4.33), and had a significantly lower rate of tobacco use (Kruskal-Wallis P=0.004). APOBEC mutational burden varied by oral cavity subsite (Kruskal-Wallis P = P<0.001), with alveolar ridge and hard palate tumors being most APOBEC-dominant (51.5% and 50.0%, respectively) and floor of mouth tumors showing the lowest rate of APOBEC-dominance (5.89%). APOBEC-dominant cases showed greater SBS mutational burden (median difference 2.74 mutations/MB, Wilcoxon P<0.001). APOBEC-dominant cases showed a greater degree of mutations in CASP8, TGFBR2, HRAS, EPHA2, and NOTCH1 (FDR corrected P <0.1). In contrast, APOBEC-dominant tumors had significantly lower fraction of genome altered (Wilcox P<0.001), with significantly lower rates of both broad and focal copy number alterations.",
        "CONCLUSION": "The APOBEC-dominant mutational signature represents an organizing biologic feature, defining a subgroup of OCSCC cases that differ in somatic mutational profile, copy number alterations, and clinical features. ABPOEC-dominant OCSCC genomes show greater somatic mutational burden and fewer alterations in copy number. Intriguingly, the clinical features of APOBEC-dominant cases show enrichment for older age, lower rates of tobacco use, female sex, and occur disproportionately at the alveolar ridge, hard palate, and buccal mucosa. However, APOBEC-dominance was not exclusive to any clinical characteristic, highlighting the importance of reproducible molecular class labels in understanding population heterogeneity in OCSCC. Further investigation focused on induction of APOBEC in OCSCC is warranted and may elucidate the pathophysiology of oral cavity cancer beyond tobacco and alcohol exposure.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>APOBEC Dominant Mutational Signature Defines A Molecularly and Clinically Distinct Oral Cavity Cancer Subgroup</span>. <u>Benjamin M Wahle</u><sup>1</sup>; Benjamin Adams<sup>1</sup>; Alex Harbison<sup>1</sup>; Ryan Jackson<sup>1</sup>; Patrik Pipkorn<sup>1</sup>; Jason Rich<sup>1</sup>; Paul Zolkind<sup>1</sup>; Angela Mazul<sup>2</sup>; Jose Zevallos<sup>2</sup>; D Neil Hayes<sup>3</sup>; Sidharth Puram<sup>1</sup>. <sup>1</sup>Washington University School of Medicine; <sup>2</sup>University of Pittsburgh School of Medicine; <sup>3</sup>University of Tennessee Health Science Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/154207/hm_edited.jpg' /></p>\n\n<p><strong>BACKGROUND:</strong> Up to 25% of oral cavity squamous cell carcinoma (OCSCC) cases have no significant exposure to tobacco and alcohol. Compared to the rest of the OCSCC population, these cases tend to be older, more female, and display distinct patterns of oral cavity subsite dominance. The underlying molecular pathophysiology in atypical OCSCC cases remains poorly defined. We hypothesized that analysis of OCSCC whole genomes using mutational signatures, which computationally discern the influence of discrete mutational processes, would reveal discrete subgroups within the OCSCC population.</p>\n\n<p><strong>METHODS: </strong>We performed an exploratory genomics study using oral cavity cases with available whole genome sequencing (WGS) data from The Cancer Genome Atlas (TCGA). Single base substitution (SBS), double base substitution (DBS), and insertion-deletion (ID) signatures were generated using python packages SigProfilerMatrixGenerator and SigProfilerAssignment with COSMIC SBS Signatures V3.4 as the reference. APOBEC-dominant cases were defined as those where SBS2 and SBS13 accounted for the greatest proportion of mutations relative to the tumor’s total mutational burden.</p>\n\n<p><strong>RESULTS: </strong>A total of 246 OCSCC cases were included. Of these, 161 (65.4%) showed some degree of ABPOEC-related mutational burden, and in 38 (15.4%) cases APOBEC was the dominant mutational process. Compared to the rest of the OCSCC population, APOBEC-dominant cases were older in age (mean difference 7.57 years, 95% CI 3.32-11.8, T-test P<0.001), were more female (47.3% vs 30.8%, OR 2.01, 95% CI 0.93-4.33), and had a significantly lower rate of tobacco use (Kruskal-Wallis P=0.004). APOBEC mutational burden varied by oral cavity subsite (Kruskal-Wallis P = P<0.001), with alveolar ridge and hard palate tumors being most APOBEC-dominant (51.5% and 50.0%, respectively) and floor of mouth tumors showing the lowest rate of APOBEC-dominance (5.89%). APOBEC-dominant cases showed greater SBS mutational burden (median difference 2.74 mutations/MB, Wilcoxon P<0.001). APOBEC-dominant cases showed a greater degree of mutations in CASP8, TGFBR2, HRAS, EPHA2, and NOTCH1 (FDR corrected P <0.1). In contrast, APOBEC-dominant tumors had significantly lower fraction of genome altered (Wilcox P<0.001), with significantly lower rates of both broad and focal copy number alterations.</p>\n\n<p><strong>CONCLUSION: </strong>The APOBEC-dominant mutational signature represents an organizing biologic feature, defining a subgroup of OCSCC cases that differ in somatic mutational profile, copy number alterations, and clinical features. ABPOEC-dominant OCSCC genomes show greater somatic mutational burden and fewer alterations in copy number. Intriguingly, the clinical features of APOBEC-dominant cases show enrichment for older age, lower rates of tobacco use, female sex, and occur disproportionately at the alveolar ridge, hard palate, and buccal mucosa. However, APOBEC-dominance was not exclusive to any clinical characteristic, highlighting the importance of reproducible molecular class labels in understanding population heterogeneity in OCSCC. Further investigation focused on induction of APOBEC in OCSCC is warranted and may elucidate the pathophysiology of oral cavity cancer beyond tobacco and alcohol exposure.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154207--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S028",
      "content_id": "153938",
      "abstract_number": "S028",
      "poster_number": "",
      "title": "Mapping SNAI2-regulated Hybrid-E/M Circuitry Reveals Low-Toxicity Anti-Metastatic Vulnerabilities in HNSCC",
      "summary": "In nearly all solid tumors, metastatic progression remains the major barrier to long-term disease control and is the most common reason for death. Current anticancer agents largely target proliferation, causing toxicity in normal proliferating cells and limiting their utility as long-term adjuvant therapies to suppress metastatic dissemination. Notably, no FDA-approved therapy selectively blocks tumor invasion...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153938",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ananya Pal",
      "presenter": "Ananya Pal",
      "authors": "Ananya Pal ; Fudong Wang; Michael Moore; Zongtai Qi; Yi-Hsuan Chang; Marina Nogueira; Rachel Paolini; Robi Mitra; Sidharth Puram",
      "normalized_authors": [
        "Ananya Pal",
        "Fudong Wang",
        "Michael Moore",
        "Zongtai Qi",
        "Yi-Hsuan Chang",
        "Marina Nogueira",
        "Rachel Paolini",
        "Robi Mitra",
        "Sidharth Puram"
      ],
      "affiliations": [
        "Washington University in St Louis"
      ],
      "normalized_institutions": [
        "Washington University in St Louis"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 373,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ananya Pal ; Fudong Wang; Michael Moore; Zongtai Qi; Yi-Hsuan Chang; Marina Nogueira; Rachel Paolini; Robi Mitra; Sidharth Puram",
        "Affiliations": "Washington University in St Louis",
        "Abstract": "In nearly all solid tumors, metastatic progression remains the major barrier to long-term disease control and is the most common reason for death. Current anticancer agents largely target proliferation, causing toxicity in normal proliferating cells and limiting their utility as long-term adjuvant therapies to suppress metastatic dissemination. Notably, no FDA-approved therapy selectively blocks tumor invasion without impairing normal cell viability, underscoring a major unmet need in metastasis-directed treatment. In head and neck squamous cell carcinoma (HNSCC), invasion and metastasis are driven by hybrid epithelial–mesenchymal (E/M) states, yet the upstream regulatory circuitry governing these states remains poorly defined and therapeutically unaddressed. Here, through comprehensive correlative and loss-of-function analyses of the six canonical EMT transcription factors (TFs), we identify SNAI2 (encoding Snail2) as the dominant EMT-TF regulating hybrid-E/M states in HNSCC. Functional assays across multiple models demonstrate that SNAI2 is both necessary and sufficient to drive invasion and metastasis. To uncover Snail2 targets amenable to anti-metastatic intervention, we mapped genome-wide binding sites of Snail2 (via Calling Cards) and integrated this with RNA-seq to uncover the first genome-scale direct Snail2 regulon in hybrid-E/M cells. To determine which of these direct targets act as effectors for its metastatic phenotypes, we performed a large-scale functional screen to identify invasion-specific vulnerabilities and nominate druggable nodes. Remarkably, 21 of the 48 direct Snail2 targets we analyzed (43%) function as bona fide invasion drivers across multiple models, establishing the first systematic delineation of the upstream transcriptional architecture governing the hybrid-E/M invasive phenotype in HNSCC. Importantly, we identify two key downstream effectors, NID1 (basement membrane glycoprotein) and BNC2 (zinc-finger transcription factor) as actionable therapeutic targets. Pharmacologic inhibition of NID1 and BNC2 markedly reduces invasion in vitro and suppresses metastasis in vivo at doses ~10-fold lower than those associated with toxicity. Notably, BNC2 activates SNAI2 expression, forming a reinforcing SNAI2-BNC2 positive feedback transcriptional circuit that sustains the hybrid-E/M invasive program. Together, these findings position SNAI2 at the apex of the hybrid-E/M transcriptional network in HNSCC and expose selective, drug-vulnerable anti-metastatic nodes with high translational potential. This work establishes a blueprint for developing the first generation of long-term, low-toxicity anti-metastatic therapies deployable in the adjuvant setting to prevent metastatic progression. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mapping SNAI2-regulated Hybrid-E/M Circuitry Reveals Low-Toxicity Anti-Metastatic Vulnerabilities in HNSCC</span>. <u>Ananya Pal</u>; Fudong Wang; Michael Moore; Zongtai Qi; Yi-Hsuan Chang; Marina Nogueira; Rachel Paolini; Robi Mitra; Sidharth Puram. Washington University in St Louis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>In nearly all solid tumors, metastatic progression remains the major barrier to long-term disease control and is the most common reason for death. Current anticancer agents largely target proliferation, causing toxicity in normal proliferating cells and limiting their utility as long-term adjuvant therapies to suppress metastatic dissemination. Notably, no FDA-approved therapy selectively blocks tumor invasion without impairing normal cell viability, underscoring a major unmet need in metastasis-directed treatment. In head and neck squamous cell carcinoma (HNSCC), invasion and metastasis are driven by hybrid epithelial–mesenchymal (E/M) states, yet the upstream regulatory circuitry governing these states remains poorly defined and therapeutically unaddressed. Here, through comprehensive correlative and loss-of-function analyses of the six canonical EMT transcription factors (TFs), we identify SNAI2 (encoding Snail2) as the dominant EMT-TF regulating hybrid-E/M states in HNSCC. Functional assays across multiple models demonstrate that SNAI2 is both necessary and sufficient to drive invasion and metastasis. To uncover Snail2 targets amenable to anti-metastatic intervention, we mapped genome-wide binding sites of Snail2 (via Calling Cards) and integrated this with RNA-seq to uncover the first genome-scale direct Snail2 regulon in hybrid-E/M cells. To determine which of these direct targets act as effectors for its metastatic phenotypes, we performed a large-scale functional screen to identify invasion-specific vulnerabilities and nominate druggable nodes. Remarkably, 21 of the 48 direct Snail2 targets we analyzed (43%) function as bona fide invasion drivers across multiple models, establishing the first systematic delineation of the upstream transcriptional architecture governing the hybrid-E/M invasive phenotype in HNSCC. Importantly, we identify two key downstream effectors, NID1 (basement membrane glycoprotein) and BNC2 (zinc-finger transcription factor) as actionable therapeutic targets. Pharmacologic inhibition of NID1 and BNC2 markedly reduces invasion in vitro and suppresses metastasis in vivo at doses ~10-fold lower than those associated with toxicity.  Notably, BNC2 activates SNAI2 expression, forming a reinforcing SNAI2-BNC2 positive feedback transcriptional circuit that sustains the hybrid-E/M invasive program. Together, these findings position SNAI2 at the apex of the hybrid-E/M transcriptional network in HNSCC and expose selective, drug-vulnerable anti-metastatic nodes with high translational potential.  This work establishes a blueprint for developing the first generation of long-term, low-toxicity anti-metastatic therapies deployable in the adjuvant setting to prevent metastatic progression.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153938--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S029",
      "content_id": "153951",
      "abstract_number": "S029",
      "poster_number": "",
      "title": "Osteopontin Drives an Aggressive Tumor Phenotype and Promotes Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma",
      "summary": "OPN overexpression results in more rapid tumor growth in a murine model of HNSCC, indicating that OPN promotes a more aggressive tumor phenotype. Early results demonstrate that OPN is a node of checkpoint immunotherapy resistance in our murine model and patient cohort. This research supports further investigation into OPN blockade as a therapeutic approach to immune escape.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153951",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kelly Bridgham, MD",
      "presenter": "Kelly Bridgham, MD",
      "authors": "Kelly Bridgham, MD 1 ; Daniel Uralov, MD 1 ; Sarah Harrington, BA 1 ; Pyung hun Park, PhD 2 ; Victor Diaz Barros, MS 3 ; Diana Whitaker-Menezes 3 ; Ubaldo Martinez-Outschoorn, PhD 3 ; Andrew South, PhD 4 ; Adam Luginbuhl, MD 1",
      "normalized_authors": [
        "Kelly Bridgham",
        "Daniel Uralov",
        "Sarah Harrington",
        "Pyung hun Park",
        "Victor Diaz Barros",
        "Diana Whitaker-Menezes",
        "Ubaldo Martinez-Outschoorn",
        "Andrew South",
        "Adam Luginbuhl"
      ],
      "affiliations": [
        "Department of Otolaryngology- Head & Neck Surgery, Thomas Jefferson University",
        "Department of Hematology and Medical Oncology, Emory University School of Medicine",
        "Department of Genetics, Genomics & Cancer Biology Program, Department of Medical Oncology, Thomas Jefferson University",
        "Department of Dermatology, University of Wisconsin Carbone Cancer Center, Wisconsin Institute of Medical Research, University of Wisconsin-Madison"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology- Head & Neck Surgery, Thomas Jefferson University",
        "Department of Hematology and Medical Oncology, Emory University School of Medicine",
        "Department of Genetics, Genomics & Cancer Biology Program, Department of Medical Oncology, Thomas Jefferson University",
        "Department of Dermatology, University of Wisconsin Carbone Cancer Center, Wisconsin Institute of Medical Research, University of Wisconsin-Madison"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kelly Bridgham, MD 1 ; Daniel Uralov, MD 1 ; Sarah Harrington, BA 1 ; Pyung hun Park, PhD 2 ; Victor Diaz Barros, MS 3 ; Diana Whitaker-Menezes 3 ; Ubaldo Martinez-Outschoorn, PhD 3 ; Andrew South, PhD 4 ; Adam Luginbuhl, MD 1",
        "Affiliations": "1 Department of Otolaryngology- Head & Neck Surgery, Thomas Jefferson University; 2 Department of Hematology and Medical Oncology, Emory University School of Medicine; 3 Department of Genetics, Genomics & Cancer Biology Program, Department of Medical Oncology, Thomas Jefferson University; 4 Department of Dermatology, University of Wisconsin Carbone Cancer Center, Wisconsin Institute of Medical Research, University of Wisconsin-Madison",
        "Introduction": "Osteopontin (OPN) is a tumor-associated protein that has been linked to tumor progression, metastases, and poor oncologic outcomes in head and neck squamous cell carcinoma (HNSCC). In our analysis of non-responding patients enrolled in neoadjuvant immunotherapy as well as our tumor microenvironment systems modeling, OPN was identified as a potential driver of immunosuppression driving treatment resistance. This study aims to evaluate if OPN abundance is a node of resistance to PD-1 checkpoint inhibition in a murine model of HNSCC.",
        "Methods": "The mouse E6/E7/h-RAS (mEER) cell line was transduced to overexpress OPN. OPN-overexpressing (OPN OE) and vehicle control (VC) cells were injected into OPN knockout (KO) and wild type (WT) mice in a 1:1 ratio with Matrigel® Matrix. Tumor size was measured every 3 days for 21 days and compared across three groups: WT/OPN OE (N=16), OPN KO/OPN OE (N=16), WT/VC (N=16). Tumor growth was compared using a linear mixed-effects model. On day 21, each of the three groups were injected with either anti-PD-1 therapy (N=8 per group, total N=24) or IgG control (N=8 per group, total N=24). Injections were administered every four days for a total of four doses and tumor growth was measured. The OPN gene, SPP1, was measured through bulk RNA sequence in responders and non-responders of neoadjuvant immune checkpoint inhibition (ICI) clinical trial.",
        "Results": "WT/OE and KO/OE mice demonstrated rapid tumor growth indicating that tumor OPN overexpression promotes tumor growth regardless of mouse genotype. WT/OE and KO/OE tumors were significantly larger than WT/VC at days 12-21 (p ≤ 0.02). WT/OE and KO/OE tumors grew approximately 12-14 units/day higher than WT/VC (p< 2x10-11). Tumor growth rate did not differ significantly between WT/OE and KO/OE at any timepoint. After treatment, WT/OE and KO/OE continued to have rapid tumor growth in both the anti-PD-1 and IgG control groups, suggesting that OPN overexpression may drive resistance to PD-1 inhibition. In contrast, 7 out of 8 WT/VC mice receiving anti-PD-1 therapy had a reduction in tumor size. Corroborative analysis of patients from our neoadjuvant ICI trials have identified high levels of OPN (bulk RNA seq SPP1) in the tumor compartment of ICI non-responders compared with responders (p<0.05).",
        "Conclusion": "OPN overexpression results in more rapid tumor growth in a murine model of HNSCC, indicating that OPN promotes a more aggressive tumor phenotype. Early results demonstrate that OPN is a node of checkpoint immunotherapy resistance in our murine model and patient cohort. This research supports further investigation into OPN blockade as a therapeutic approach to immune escape.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Osteopontin Drives an Aggressive Tumor Phenotype and Promotes Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma</span>. <u>Kelly Bridgham, MD</u><sup>1</sup>; Daniel Uralov, MD<sup>1</sup>; Sarah Harrington, BA<sup>1</sup>; Pyung hun Park, PhD<sup>2</sup>; Victor Diaz Barros, MS<sup>3</sup>; Diana Whitaker-Menezes<sup>3</sup>; Ubaldo Martinez-Outschoorn, PhD<sup>3</sup>; Andrew South, PhD<sup>4</sup>; Adam Luginbuhl, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology- Head & Neck Surgery, Thomas Jefferson University; <sup>2</sup>Department of Hematology and Medical Oncology, Emory University School of Medicine; <sup>3</sup>Department of Genetics, Genomics & Cancer Biology Program, Department of Medical Oncology, Thomas Jefferson University; <sup>4</sup>Department of Dermatology, University of Wisconsin Carbone Cancer Center, Wisconsin Institute of Medical Research, University of Wisconsin-Madison<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Osteopontin (OPN) is a tumor-associated protein that has been linked to tumor progression, metastases, and poor oncologic outcomes in head and neck squamous cell carcinoma (HNSCC). In our analysis of non-responding patients enrolled in neoadjuvant immunotherapy as well as our tumor microenvironment systems modeling, OPN was identified as a potential driver of immunosuppression driving treatment resistance. This study aims to evaluate if OPN abundance is a node of resistance to PD-1 checkpoint inhibition in a murine model of HNSCC.</p>\n\n<p><strong>Methods: </strong>The mouse E6/E7/h-RAS (mEER) cell line was transduced to overexpress OPN. OPN-overexpressing (OPN OE) and vehicle control (VC) cells were injected into OPN knockout (KO) and wild type (WT) mice in a 1:1 ratio with Matrigel® Matrix. Tumor size was measured every 3 days for 21 days and compared across three groups: WT/OPN OE (N=16), OPN KO/OPN OE (N=16), WT/VC (N=16). Tumor growth was compared using a linear mixed-effects model. On day 21, each of the three groups were injected with either anti-PD-1 therapy (N=8 per group, total N=24) or IgG control (N=8 per group, total N=24). Injections were administered every four days for a total of four doses and tumor growth was measured. The OPN gene, SPP1, was measured through bulk RNA sequence in responders and non-responders of neoadjuvant immune checkpoint inhibition (ICI) clinical trial.</p>\n\n<p><strong>Results: </strong>WT/OE and KO/OE mice demonstrated rapid tumor growth indicating that tumor OPN overexpression promotes tumor growth regardless of mouse genotype. WT/OE and KO/OE tumors were significantly larger than WT/VC at days 12-21 (p ≤ 0.02). WT/OE and KO/OE tumors grew approximately 12-14 units/day higher than WT/VC (p< 2x10-11). Tumor growth rate did not differ significantly between WT/OE and KO/OE at any timepoint. After treatment, WT/OE and KO/OE continued to have rapid tumor growth in both the anti-PD-1 and IgG control groups, suggesting that OPN overexpression may drive resistance to PD-1 inhibition. In contrast, 7 out of 8 WT/VC mice receiving anti-PD-1 therapy had a reduction in tumor size. Corroborative analysis of patients from our neoadjuvant ICI trials have identified high levels of OPN (bulk RNA seq SPP1) in the tumor compartment of ICI non-responders compared with responders (p<0.05).</p>\n\n<p><strong>Conclusion: </strong>OPN overexpression results in more rapid tumor growth in a murine model of HNSCC, indicating that OPN promotes a more aggressive tumor phenotype. Early results demonstrate that OPN is a node of checkpoint immunotherapy resistance in our murine model and patient cohort. This research supports further investigation into OPN blockade as a therapeutic approach to immune escape.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153951--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S030",
      "content_id": "154407",
      "abstract_number": "S030",
      "poster_number": "",
      "title": "Metabolic Targeting of Nicotinamide Salvage Pathway in HPV-associated Head and Neck Cancer",
      "summary": "This study suggests the presence of a distinct metabolic vulnerability in HPV-positive tumors driven by increased reliance on nicotinamide salvage pathways. This metabolic sensitivity provides insight into HPV-driven carcinogenesis, in which viral oncogenes reshape metabolic programs and may create a dependence on NAD+ regeneration for sustained cancer cell proliferation and survival. Targeting nicotinamide...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154407",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ella P Jackert, BS",
      "presenter": "Ella P Jackert, BS",
      "authors": "Ella P Jackert, BS ; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels C Kokot, MD; Uttam Sinha, MD; Albert Han, MD, PhD",
      "normalized_authors": [
        "Ella P Jackert",
        "Shu-Yun Cheng",
        "Liyang Tang",
        "Daniel Kwon",
        "Niels C Kokot",
        "Uttam Sinha",
        "Albert Han"
      ],
      "affiliations": [
        "USC Caruso Department of Otolaryngology Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "USC Caruso Department of Otolaryngology Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 425,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ella P Jackert, BS ; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels C Kokot, MD; Uttam Sinha, MD; Albert Han, MD, PhD",
        "Affiliations": "USC Caruso Department of Otolaryngology Head and Neck Surgery",
        "Introduction": "Head and neck squamous cell carcinoma (HNSCC) exhibits significant metabolic reprogramming that supports tumor growth and therapy resistance. Human papillomavirus (HPV)-positive HNSCC may possess distinct metabolic dependencies. One emerging target is nicotinamide metabolism, which fuels NAD? production essential for cancer cell proliferation, stress resistance, and DNA repair. Nicotinamide-metabolism inhibitors are being evaluated in clinical trials, often in combination with standard chemotherapy, to disrupt these survival pathways. This study investigates the metabolic vulnerabilities in HNSCC using 3D spheroid models to more accurately capture tumor architecture identify metabolism-based therapeutic opportunities.",
        "Methods": "Two HPV-positive (SCC47, SCC104) and two HPV-negative (SCC9, Detroit562) HNSCC cell lines were cultured under standard DMEM + 10% FBS conditions. At 80–90% confluence, 2,000 cells per well were seeded in ultra–low-adhesion round-bottom plates to generate spheroids in triplicates. After confirming spheroid formation at 24 hours, spheroids were treated with 0 nM, 7.8 nM (½ IC50, low-dose), or 15.6 nM (IC50, high-dose) of the NAMPT inhibitor CHS828, which targets nicotinamide salvage metabolism. After 48 hours of treatment, NAD/NADH levels were quantified using a bioluminescent assay. Differences in spheroid growth and relative NAD+ depletion were compared between HPV-positive and HPV-negative cell lines.",
        "Results": "Spheroids were successfully generated from all four cell lines. Treatment with CHS828 caused marked disruption of spheroid architecture, with complete dissociation observed under high-dose conditions and thus spheroid diameter was not measurable. Under low-dose CHS828 conditions, spheroid size decreased across all cell lines compared to controls, with SCC47 spheroids showing a statistically significant reduction in diameter (p = 0.003). Additionally, low-dose CHS828-treated SCC47 spheroids exhibited significantly smaller diameters compared to SCC9 (p = 0.008) and Detroit562 (p = 0.004), whereas no differences were observed among control spheroids. SCC47 and SCC104 HPV-positive HNSCC spheroids displayed significantly greater NAD+ depletion under both high and low dose CHS828 treatments compared to HPV-negative spheroids (p < 0.03 for all comparisons). Together, these results show that HPV-positive HNSCC spheroids show heightened sensitivity to nicotinamide-metabolism inhibition, reflected by pronounced NAD/NADH depletion and greater disruption of spheroid integrity.",
        "Conclusion": "This study suggests the presence of a distinct metabolic vulnerability in HPV-positive tumors driven by increased reliance on nicotinamide salvage pathways. This metabolic sensitivity provides insight into HPV-driven carcinogenesis, in which viral oncogenes reshape metabolic programs and may create a dependence on NAD+ regeneration for sustained cancer cell proliferation and survival. Targeting nicotinamide metabolism may represent a promising therapeutic strategy for HPV-positive HNSCC, with potential application as a single agent or in combination with standard therapies to exploit HPV-specific metabolic dependencies.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Metabolic Targeting of Nicotinamide Salvage Pathway in HPV-associated Head and Neck Cancer</span>. <u>Ella P Jackert, BS</u>; Shu-Yun Cheng, MS; Liyang Tang, MD; Daniel Kwon, MD; Niels C Kokot, MD; Uttam Sinha, MD; Albert Han, MD, PhD. USC Caruso Department of Otolaryngology Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) exhibits significant metabolic reprogramming that supports tumor growth and therapy resistance. Human papillomavirus (HPV)-positive HNSCC may possess distinct metabolic dependencies. One emerging target is nicotinamide metabolism, which fuels NAD? production essential for cancer cell proliferation, stress resistance, and DNA repair. Nicotinamide-metabolism inhibitors are being evaluated in clinical trials, often in combination with standard chemotherapy, to disrupt these survival pathways. This study investigates the metabolic vulnerabilities in HNSCC using 3D spheroid models to more accurately capture tumor architecture identify metabolism-based therapeutic opportunities.</p>\n\n<p><strong>Methods:</strong> Two HPV-positive (SCC47, SCC104) and two HPV-negative (SCC9, Detroit562) HNSCC cell lines were cultured under standard DMEM + 10% FBS conditions. At 80–90% confluence, 2,000 cells per well were seeded in ultra–low-adhesion round-bottom plates to generate spheroids in triplicates. After confirming spheroid formation at 24 hours, spheroids were treated with 0 nM, 7.8 nM (½ IC50, low-dose), or 15.6 nM (IC50, high-dose) of the NAMPT inhibitor CHS828, which targets nicotinamide salvage metabolism. After 48 hours of treatment, NAD/NADH levels were quantified using a bioluminescent assay. Differences in spheroid growth and relative NAD+ depletion were compared between HPV-positive and HPV-negative cell lines.</p>\n\n<p><strong>Results: </strong>Spheroids were successfully generated from all four cell lines. Treatment with CHS828 caused marked disruption of spheroid architecture, with complete dissociation observed under high-dose conditions and thus spheroid diameter was not measurable. Under low-dose CHS828 conditions, spheroid size decreased across all cell lines compared to controls, with SCC47 spheroids showing a statistically significant reduction in diameter (p = 0.003). Additionally, low-dose CHS828-treated SCC47 spheroids exhibited significantly smaller diameters compared to SCC9 (p = 0.008) and Detroit562 (p = 0.004), whereas no differences were observed among control spheroids. SCC47 and SCC104 HPV-positive HNSCC spheroids displayed significantly greater NAD+ depletion under both high and low dose CHS828 treatments compared to HPV-negative spheroids (p < 0.03 for all comparisons). Together, these results show that HPV-positive HNSCC spheroids show heightened sensitivity to nicotinamide-metabolism inhibition, reflected by pronounced NAD/NADH depletion and greater disruption of spheroid integrity.</p>\n\n<p><strong>Conclusion: </strong>This study suggests the presence of a distinct metabolic vulnerability in HPV-positive tumors driven by increased reliance on nicotinamide salvage pathways. This metabolic sensitivity provides insight into HPV-driven carcinogenesis, in which viral oncogenes reshape metabolic programs and may create a dependence on NAD+ regeneration for sustained cancer cell proliferation and survival. Targeting nicotinamide metabolism may represent a promising therapeutic strategy for HPV-positive HNSCC, with potential application as a single agent or in combination with standard therapies to exploit HPV-specific metabolic dependencies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154407--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S031",
      "content_id": "155436",
      "abstract_number": "S031",
      "poster_number": "",
      "title": "Detection of NY-ESO-1 Antigen in Oral Premalignant Disorders, Malignant Tumors, and Patient-Derived Xenograft Models",
      "summary": "Our analysis demonstrates that NY-ESO-1 is significantly upregulated in high-risk dysplastic stages and OSCC. This association identifies NY-ESO-1 as a potentially important prognostic biomarker. These new data indicate that NY-ESO-1-targeted immunotherapeutics may benefit OPMD and OSCC patients. Establishing NY-ESO-1 expression in OSCC PDX models provides a robust and reliable preclinical platform for testing...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155436",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Subin Surendran, PhD",
      "presenter": "Subin Surendran, PhD",
      "authors": "Subin Surendran, PhD 1 ; Usama Aboelkheir, MD 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Keith L Kirkwood, DDS, PhD 3 ; Lixia Zhang, PhD 3 ; Amritha Suresh, PhD 4 ; Sumsum Sunny, MDS, PhD 4 ; Jenny Romero 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1 ; Kunle Odunsi, MD, PhD 5 ; Moni A Kuriakose, MD 6",
      "normalized_authors": [
        "Subin Surendran",
        "Usama Aboelkheir",
        "William J Magner",
        "Lynn Sigurdson",
        "Keith L Kirkwood",
        "Lixia Zhang",
        "Amritha Suresh",
        "Sumsum Sunny, MDS",
        "Jenny Romero",
        "Ryan P McSpadden",
        "Vishal Gupta",
        "Kunle Odunsi",
        "Moni A Kuriakose"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "VA Hospital, Bronx NY",
        "University at Buffalo School of Dental Medicine, Buffalo, NY",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "University of Chicago Comprehensive Cancer Center",
        "Lakeshore Hospital, Kochi, India"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "VA Hospital, Bronx NY",
        "University at Buffalo School of Dental Medicine, Buffalo, NY",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "University of Chicago Comprehensive Cancer Center",
        "Lakeshore Hospital, Kochi, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 423,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Subin Surendran, PhD 1 ; Usama Aboelkheir, MD 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Keith L Kirkwood, DDS, PhD 3 ; Lixia Zhang, PhD 3 ; Amritha Suresh, PhD 4 ; Sumsum Sunny, MDS, PhD 4 ; Jenny Romero 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1 ; Kunle Odunsi, MD, PhD 5 ; Moni A Kuriakose, MD 6",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 VA Hospital, Bronx NY; 3 University at Buffalo School of Dental Medicine, Buffalo, NY; 4 Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; 5 University of Chicago Comprehensive Cancer Center; 6 Lakeshore Hospital, Kochi, India",
        "Background": "Oral Squamous Cell Carcinoma (OSCC) remains a global health challenge with stagnant survival rates, underscoring the need for novel therapies. Oral Potentially Malignant Disorders (OPMD) represent a critical public health challenge, as they serve as the visible precursors for over 80% of OSCC. The cancer-testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is highly immunogenic and capable of inducing robust immune responses. We hypothesize that NY-ESO-1 expression may provide a therapeutic target in oral premalignant and malignant disorders. To characterize NY-ESO-1 expression in OPMD and OSCC, we evaluated a clinical cohort representing oral carcinogenesis, from non-dysplastic, through mild, moderate and severe dysplasia to OSCC. We also assessed expression in four NCI-validated OSCC Patient-Derived Xenograft (PDX) models.",
        "Methods": "For clinical evaluation, 284 formalin-fixed paraffin-embedded (FFPE) patient samples pathologically defined as non-dysplastic, mild, moderate, severe dysplasia, and carcinoma were stained for NY-ESO-1 by immunohistochemistry (IHC). We also established four NCI-validated OSCC PDX models in NSG-SGM3 mice and evaluated their NY-ESO-1 expression. NY-ESO-1 expression in PDX and human tissues was quantified using the H-score method, yielding a score ranging from 0 to 300. Statistical analyses were performed using IBM SPSS v25 or GraphPad Prism. The association between NY-ESO-1 H-score and histopathological grade was evaluated via Kruskal-Wallis and Spearman correlation tests (p < 0.05).",
        "Results": "The frequency of NY-ESO-1 expression was 48.6% and mean staining intensity H-scores ranged from 27.2 to 92.9. The human clinical cohort demonstrated NY-ESO-1 upregulation in moderate and severe dysplasia as well as OSCC (p<0.001). Mean H-scores and frequencies of expression were significantly elevated in moderate dysplasia (81.1±14.1; 90.5%), severe dysplasia (92.9 ± 13.7; 85.7%), and OSCC (62.2 ± 11.9; 72%), compared to non-dysplastic (27.2 ± 4.0; 33.6%) and mild dysplastic (27.2 ± 5.2; 38.6%) tissues. Kruskal-Wallis testing confirmed a statistically significant positive correlation between elevated NY-ESO-1 H-score and progressive histopathological grading (p < 0.001). Despite this strong correlation with progression, NY-ESO-1 expression was variable within each diagnostic category. Similarly, the four OSCC PDX models showed a range of NY-ESO-1 levels (H scores 30-163). These PDX models demonstrated some heterogeneity with 69-100% NY-ESO-1 positive cells.",
        "Conclusions": "Our analysis demonstrates that NY-ESO-1 is significantly upregulated in high-risk dysplastic stages and OSCC. This association identifies NY-ESO-1 as a potentially important prognostic biomarker. These new data indicate that NY-ESO-1-targeted immunotherapeutics may benefit OPMD and OSCC patients. Establishing NY-ESO-1 expression in OSCC PDX models provides a robust and reliable preclinical platform for testing targeted immunotherapies.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Detection of NY-ESO-1 Antigen in Oral Premalignant Disorders, Malignant Tumors, and Patient-Derived Xenograft Models</span>. <u>Subin Surendran, PhD</u><sup>1</sup>; Usama Aboelkheir, MD<sup>2</sup>; William J Magner, PhD<sup>1</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Keith L Kirkwood, DDS, PhD<sup>3</sup>; Lixia Zhang, PhD<sup>3</sup>; Amritha Suresh, PhD<sup>4</sup>; Sumsum Sunny, MDS, PhD<sup>4</sup>; Jenny Romero<sup>1</sup>; Ryan P McSpadden, MD<sup>1</sup>; Vishal Gupta, MD<sup>1</sup>; Kunle Odunsi, MD, PhD<sup>5</sup>; Moni A Kuriakose, MD<sup>6</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>VA Hospital, Bronx NY; <sup>3</sup>University at Buffalo School of Dental Medicine, Buffalo, NY; <sup>4</sup>Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; <sup>5</sup>University of Chicago Comprehensive Cancer Center; <sup>6</sup>Lakeshore Hospital, Kochi, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral Squamous Cell Carcinoma (OSCC) remains a global health challenge with stagnant survival rates, underscoring the need for novel therapies. Oral Potentially Malignant Disorders (OPMD) represent a critical public health challenge, as they serve as the visible precursors for over 80% of OSCC. The cancer-testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is highly immunogenic and capable of inducing robust immune responses. We hypothesize that NY-ESO-1 expression may provide a therapeutic target in oral premalignant and malignant disorders. To characterize NY-ESO-1 expression in OPMD and OSCC, we evaluated a clinical cohort representing oral carcinogenesis, from non-dysplastic, through mild, moderate and severe dysplasia to OSCC. We also assessed expression in four NCI-validated OSCC Patient-Derived Xenograft (PDX) models. </p>\n\n<p><strong>Methods: </strong>For clinical evaluation, 284 formalin-fixed paraffin-embedded (FFPE) patient samples pathologically defined as non-dysplastic, mild, moderate, severe dysplasia, and carcinoma were stained for NY-ESO-1 by immunohistochemistry (IHC). We also established four NCI-validated OSCC PDX models in NSG-SGM3 mice and evaluated their NY-ESO-1 expression. NY-ESO-1 expression in PDX and human tissues was quantified using the H-score method, yielding a score ranging from 0 to 300. Statistical analyses were performed using IBM SPSS v25 or GraphPad Prism. The association between NY-ESO-1 H-score and histopathological grade was evaluated via Kruskal-Wallis and Spearman correlation tests (p < 0.05).</p>\n\n<p><strong>Results: </strong>The frequency of NY-ESO-1 expression was 48.6% and mean staining intensity H-scores ranged from 27.2 to 92.9. The human clinical cohort demonstrated NY-ESO-1 upregulation in moderate and severe dysplasia as well as OSCC (p<0.001). Mean H-scores and frequencies of expression were significantly elevated in moderate dysplasia (81.1±14.1; 90.5%), severe dysplasia (92.9 ± 13.7; 85.7%), and OSCC (62.2 ± 11.9; 72%), compared to non-dysplastic (27.2 ± 4.0; 33.6%) and mild dysplastic (27.2 ± 5.2; 38.6%) tissues. Kruskal-Wallis testing confirmed a statistically significant positive correlation between elevated NY-ESO-1 H-score and progressive histopathological grading (p < 0.001). Despite this strong correlation with progression, NY-ESO-1 expression was variable within each diagnostic category. Similarly, the four OSCC PDX models showed a range of NY-ESO-1 levels (H scores 30-163). These PDX models demonstrated some heterogeneity with 69-100% NY-ESO-1 positive cells.</p>\n\n<p><strong>Conclusions: </strong>Our analysis demonstrates that NY-ESO-1 is significantly upregulated in high-risk dysplastic stages and OSCC. This association identifies NY-ESO-1 as a potentially important prognostic biomarker. These new data indicate that NY-ESO-1-targeted immunotherapeutics may benefit OPMD and OSCC patients. Establishing NY-ESO-1 expression in OSCC PDX models provides a robust and reliable preclinical platform for testing targeted immunotherapies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155436--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S032",
      "content_id": "153700",
      "abstract_number": "S032",
      "poster_number": "",
      "title": "Noninvasive profiling of HPV integration and genome structure from plasma cfDNA in head and neck cancer",
      "summary": "HPV-DeepSeek, a whole HPV genome plasma cfDNA assay, enables noninvasive assessment of HPV integration and genome structure in HPV+HNC. Genome-wide sequencing coverage and detection of viral–human junctions and HPV–HPV rearrangements in plasma support HPV physical-state classification. Integration and rearrangement breakpoints detected in plasma are validated in matched tumor tissue. This plasma-based framework...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153700",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Samuli Eldfors, PhD",
      "presenter": "Samuli Eldfors, PhD",
      "authors": "Samuli Eldfors, PhD 1 ; Annie R Abruzzo, MD 2 ; Qin Wang, PhD 1 ; Dipon Das, PhD 1 ; Gjystina Lumaj, MS 1 ; Shriya Shukla 1 ; Jonathan J Paly, DO 3 ; Ross D Merkin, MD 3 ; Lori J Wirth, MD 3 ; Manisha J Patel, MD 3 ; Jong C Park, MD 3 ; Annie Chan, MD 3 ; Chirayu Patel, MD 3 ; Allen L Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 3 ; Peter M Sadow, MD, PhD 3 ; Bayan A Alzumaili, MD 3 ; Thomas J Roberts, MD, MBA 3 ; Adam S Fisch, MD, PhD 3 ; Daniel L Faden, MD 1",
      "normalized_authors": [
        "Samuli Eldfors",
        "Annie R Abruzzo",
        "Qin Wang",
        "Dipon Das",
        "Gjystina Lumaj",
        "Shriya Shukla",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Lori J Wirth",
        "Manisha J Patel",
        "Jong C Park",
        "Annie Chan",
        "Chirayu Patel",
        "Allen L Feng",
        "Daniel G Deschler",
        "Jeremy D Richmon",
        "Derrick T Lin",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Massachusetts Eye & Ear",
        "Harvard Medical School",
        "Massachusetts General Hospital"
      ],
      "normalized_institutions": [
        "Massachusetts Eye & Ear",
        "Harvard Medical School",
        "Massachusetts General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Samuli Eldfors, PhD 1 ; Annie R Abruzzo, MD 2 ; Qin Wang, PhD 1 ; Dipon Das, PhD 1 ; Gjystina Lumaj, MS 1 ; Shriya Shukla 1 ; Jonathan J Paly, DO 3 ; Ross D Merkin, MD 3 ; Lori J Wirth, MD 3 ; Manisha J Patel, MD 3 ; Jong C Park, MD 3 ; Annie Chan, MD 3 ; Chirayu Patel, MD 3 ; Allen L Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 3 ; Peter M Sadow, MD, PhD 3 ; Bayan A Alzumaili, MD 3 ; Thomas J Roberts, MD, MBA 3 ; Adam S Fisch, MD, PhD 3 ; Daniel L Faden, MD 1",
        "Affiliations": "1 Massachusetts Eye & Ear; 2 Harvard Medical School; 3 Massachusetts General Hospital",
        "Background": "HPV integration contributes to oncogenesis in HPV-associated head and neck cancer (HPV+HNC). Liquid biopsy enables detection of viral–host junctions and HPV genome structure without tissue biopsy. We built HPV-DeepSeek, a hybrid-capture cfDNA assay with paired-end sequencing to quantify circulating HPV DNA and characterize HPV integration and genome structure. Here we describe a novel computational approach to determine and classify HPV integration from plasma cfDNA.",
        "Methods": "Sequencing reads were aligned to a combined human and HPV reference genome. Chimeric reads spanning HPV–human junctions or HPV–HPV rearrangements (junctions between non-contiguous HPV genomic positions) were clustered to define consensus integration and HPV–HPV rearrangement breakpoints, which were then summarized per sample. Breakpoints required ≥6 chimeric reads at the junction. To characterize each breakpoint, we calculated the integration breakpoint variant allele fraction (VAF). HPV physical state was inferred from HPV-DeepSeek cfDNA sequencing on a per-sample, per-type basis using an algorithm that integrates viral–human junctions, HPV genome coverage, and HPV-HPV rearrangements to assign mutually exclusive HPV physical-state classes. This classifier resolves four main states: clonal integration, mixed integrated, episomal with rearrangements, and episomal without detectable rearrangements. Representative plasma breakpoints were validated in matched tissue using PCR and PacBio long-read sequencing.",
        "Results": "Among 229 plasma cfDNA samples from HPV+HNC patients analyzed, HPV16 was the predominant HPV genotype identified in 200 (87%) samples, followed by HPV33 (n=8), HPV35 (n=7), HPV45 (n=5), and HPV56 (n=3), with other high-risk types detected at lower frequencies. Integration breakpoint variant allele fractions were generally low, consistent with predominantly subclonal events in circulating tumor DNA, except in samples classified as clonal integration, which showed higher VAFs compatible with clonal involvement. HPV physical-state classification assigned four states among 178/229 samples with sufficient HPV DNA: episomal without integration or rearrangement (74/178, 42%), episomal with rearrangements (49/178, 28%), mixed integrated (48/178, 27%), and clonal integration (7/178, 4%); the remaining 51/229 (22%) had insufficient HPV DNA for classification.",
        "Abstract": "Orthogonal validation supported HPV integration and rearrangement calls from plasma sequencing. PCR confirmed 3/3 selected integration and HPV–HPV rearrangement breakpoints in plasma. In addition, we performed long-read whole-genome sequencing on matched fresh-frozen tumors from 5 HPV+HNC cases with HPV16 integration detected in plasma, validating integration sites in 3/5 tumors and HPV–HPV rearrangements in 2/3 tumors with rearrangements detected in plasma. Sequencing-based profiling identified HPV integration breakpoints at base-pair resolution, providing additional information on potential biological relevance in selected cases. For example, we observed integration events at loci previously reported as recurrent targets, including the PD-L1 locus. View in Agenda and Add to Schedule",
        "Conclusions": "HPV-DeepSeek, a whole HPV genome plasma cfDNA assay, enables noninvasive assessment of HPV integration and genome structure in HPV+HNC. Genome-wide sequencing coverage and detection of viral–human junctions and HPV–HPV rearrangements in plasma support HPV physical-state classification. Integration and rearrangement breakpoints detected in plasma are validated in matched tumor tissue. This plasma-based framework adds structural information that may complement viral load in future risk stratification."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Noninvasive profiling of HPV integration and genome structure from plasma cfDNA in head and neck cancer</span>. <u>Samuli Eldfors, PhD</u><sup>1</sup>; Annie R Abruzzo, MD<sup>2</sup>; Qin Wang, PhD<sup>1</sup>; Dipon Das, PhD<sup>1</sup>; Gjystina Lumaj, MS<sup>1</sup>; Shriya Shukla<sup>1</sup>; Jonathan J Paly, DO<sup>3</sup>; Ross D Merkin, MD<sup>3</sup>; Lori J Wirth, MD<sup>3</sup>; Manisha J Patel, MD<sup>3</sup>; Jong C Park, MD<sup>3</sup>; Annie Chan, MD<sup>3</sup>; Chirayu Patel, MD<sup>3</sup>; Allen L Feng, MD<sup>1</sup>; Daniel G Deschler, MD<sup>1</sup>; Jeremy D Richmon, MD<sup>1</sup>; Derrick T Lin, MD<sup>1</sup>; William C Faquin, MD, PhD<sup>3</sup>; Peter M Sadow, MD, PhD<sup>3</sup>; Bayan A Alzumaili, MD<sup>3</sup>; Thomas J Roberts, MD, MBA<sup>3</sup>; Adam S Fisch, MD, PhD<sup>3</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Harvard Medical School; <sup>3</sup>Massachusetts General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>HPV integration contributes to oncogenesis in HPV-associated head and neck cancer (HPV+HNC). Liquid biopsy enables detection of viral–host junctions and HPV genome structure without tissue biopsy. We built HPV-DeepSeek, a hybrid-capture cfDNA assay with paired-end sequencing to quantify circulating HPV DNA and characterize HPV integration and genome structure. Here we describe a novel computational approach to determine and classify HPV integration from plasma cfDNA. </p>\n\n<p><strong>Methods: </strong>Sequencing reads were aligned to a combined human and HPV reference genome. Chimeric reads spanning HPV–human junctions or HPV–HPV rearrangements (junctions between non-contiguous HPV genomic positions) were clustered to define consensus integration and HPV–HPV rearrangement breakpoints, which were then summarized per sample. Breakpoints required ≥6 chimeric reads at the junction. To characterize each breakpoint, we calculated the integration breakpoint variant allele fraction (VAF). HPV physical state was inferred from HPV-DeepSeek cfDNA sequencing on a per-sample, per-type basis using an algorithm that integrates viral–human junctions, HPV genome coverage, and HPV-HPV rearrangements to assign mutually exclusive HPV physical-state classes. This classifier resolves four main states: clonal integration, mixed integrated, episomal with rearrangements, and episomal without detectable rearrangements. Representative plasma breakpoints were validated in matched tissue using PCR and PacBio long-read sequencing. </p>\n\n<p><strong>Results: </strong>Among 229 plasma cfDNA samples from HPV+HNC patients analyzed, HPV16 was the predominant HPV genotype identified in 200 (87%) samples, followed by HPV33 (n=8), HPV35 (n=7), HPV45 (n=5), and HPV56 (n=3), with other high-risk types detected at lower frequencies. Integration breakpoint variant allele fractions were generally low, consistent with predominantly subclonal events in circulating tumor DNA, except in samples classified as clonal integration, which showed higher VAFs compatible with clonal involvement. HPV physical-state classification assigned four states among 178/229 samples with sufficient HPV DNA: episomal without integration or rearrangement (74/178, 42%), episomal with rearrangements (49/178, 28%), mixed integrated (48/178, 27%), and clonal integration (7/178, 4%); the remaining 51/229 (22%) had insufficient HPV DNA for classification. </p>\n\n<p>Orthogonal validation supported HPV integration and rearrangement calls from plasma sequencing. PCR confirmed 3/3 selected integration and HPV–HPV rearrangement breakpoints in plasma. In addition, we performed long-read whole-genome sequencing on matched fresh-frozen tumors from 5 HPV+HNC cases with HPV16 integration detected in plasma, validating integration sites in 3/5 tumors and HPV–HPV rearrangements in 2/3 tumors with rearrangements detected in plasma. </p>\n\n<p>Sequencing-based profiling identified HPV integration breakpoints at base-pair resolution, providing additional information on potential biological relevance in selected cases. For example, we observed integration events at loci previously reported as recurrent targets, including the PD-L1 locus. </p>\n\n<p><strong>Conclusions: </strong>HPV-DeepSeek, a whole HPV genome plasma cfDNA assay, enables noninvasive assessment of HPV integration and genome structure in HPV+HNC. Genome-wide sequencing coverage and detection of viral–human junctions and HPV–HPV rearrangements in plasma support HPV physical-state classification. Integration and rearrangement breakpoints detected in plasma are validated in matched tumor tissue. This plasma-based framework adds structural information that may complement viral load in future risk stratification. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153700--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S033",
      "content_id": "153633",
      "abstract_number": "S033",
      "poster_number": "",
      "title": "Terminally differentiated CD57+ memory T cells are an independent predictor of disease recurrence and decreased overall survival in head and neck cancer",
      "summary": "Elevated HD TEMRA proportion in circulation was associated with early locoregional recurrence and significantly diminished overall survival. Upon multivariable analysis, HD TEMRA proportion was determined to be an independent predictor of recurrence-free survival and overall survival. HD TEMRA proportion was found to be relatively higher upon recurrence between matched patients. As HNSCC recurrence requires...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153633",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brianna Brammer",
      "presenter": "Brianna Brammer",
      "authors": "Brianna Brammer 1 ; Chulwoo Kim 1 ; Brendan Kinney 1 ; Subir Goyal 2 ; Yuan Liu 2 ; Brian J Boyce, MD 1 ; Azeem S Kaka, MD 1 ; Jennifer H Gross, MD 1 ; H Michael Baddour, MD 1 ; Peter W Kahng, MD 1 ; Jose A Monteiro de Olivera Novaes, MD 3 ; Nabil F Saba, MD 3 ; Nicole C Schmitt, MD 1",
      "normalized_authors": [
        "Brianna Brammer",
        "Chulwoo Kim",
        "Brendan Kinney",
        "Subir Goyal",
        "Yuan Liu",
        "Brian J Boyce",
        "Azeem S Kaka",
        "Jennifer H Gross",
        "H Michael Baddour",
        "Peter W Kahng",
        "Jose A Monteiro de Olivera Novaes",
        "Nabil F Saba",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Emory University Department of Otolaryngology - Head and Neck Surgery",
        "Winship Cancer Institute",
        "Emory University Department of Hematology and Medical Oncology"
      ],
      "normalized_institutions": [
        "Emory University Department of Otolaryngology - Head and Neck Surgery",
        "Winship Cancer Institute",
        "Emory University Department of Hematology and Medical Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153633/BB%20AHNS%20Figure%201(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153633/BB%20AHNS%20Figure%201(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153633"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Brianna Brammer 1 ; Chulwoo Kim 1 ; Brendan Kinney 1 ; Subir Goyal 2 ; Yuan Liu 2 ; Brian J Boyce, MD 1 ; Azeem S Kaka, MD 1 ; Jennifer H Gross, MD 1 ; H Michael Baddour, MD 1 ; Peter W Kahng, MD 1 ; Jose A Monteiro de Olivera Novaes, MD 3 ; Nabil F Saba, MD 3 ; Nicole C Schmitt, MD 1",
        "Affiliations": "1 Emory University Department of Otolaryngology - Head and Neck Surgery; 2 Winship Cancer Institute; 3 Emory University Department of Hematology and Medical Oncology",
        "Introduction": "Despite nearly half of patients with head and neck squamous cell carcinoma (HNSCC) experiencing disease recurrence within one year of surgical treatment, there are few validated mechanisms to predict disease recurrence. We have previously reported a subset of T cells that are significantly associated with early disease recurrence after surgery. We refer to these highly differentiated CD8+ T effector memory cells as HD TEMRA cells. Patients with HD TEMRA proportion >34% in circulation were significantly more likely to experience locoregional disease recurrence at both 6 months and one year. While HD TEMRA cells have been reported to accumulate with chronic viral infection and aging, their role in HNSCC is unknown. Here, we aimed to determine whether an elevated HD TEMRA proportion is an independent predictor of HNSCC recurrence after surgery and overall survival.",
        "Methods": "We collected peripheral blood samples from 87 patients with previously untreated, locally advanced HNSCC undergoing surgical treatment, and from 17 patients upon surgical treatment for recurrent disease. Samples were assessed by flow cytometry to determine the proportion of HD TEMRA cells. Patient charts were reviewed in the electronic medical record, and demographic details were recorded including age, sex, and race/ethnicity. Pathology details including T stage, N stage, tumor grade, and presence/absence of perineural/lymphovascular invasion and extracapsular extension were recorded along with details on adjuvant therapy, recurrence, and death. Kaplan-Meier method and multivariable Cox regression model was performed to determine the association between HD TEMRA cell proportion in predicting overall survival and disease recurrence.",
        "Results": "Upon follow-up analysis at 36 months, HD TEMRA proportion >34% in circulation was associated with shortened overall survival, with median survival 17.4 months; median survival for patients with <34% HD TEMRA cells was not reached (Figure 1, p=0.0053). One-year survival rate for patients with >34% HD TEMRA was 58.9% (95% CI 35.7%, 76.1%), and 81.8% for <34% HD TEMRA (95% CI 67.8%, 90.2%). Multivariable analysis revealed that HD TEMRA proportion >34% was independently predictive of reduced overall recurrence-free survival (hazard ratio = 0.47, p=0.038) and overall survival (hazard ratio = 0.36, p=0.008). Additionally, patients with recurrent disease had increased HD TEMRA proportion relative to age/stage/site matched patients with primary disease (mean 29.40% vs 16.86%, p=0.0323).",
        "Conclusions": "Elevated HD TEMRA proportion in circulation was associated with early locoregional recurrence and significantly diminished overall survival. Upon multivariable analysis, HD TEMRA proportion was determined to be an independent predictor of recurrence-free survival and overall survival. HD TEMRA proportion was found to be relatively higher upon recurrence between matched patients. As HNSCC recurrence requires extensive intervention and lowers overall survival, prediction of which patients will experience recurrence is paramount to informing treatment planning and shared decision making between patient and providers. Calculation of HD TEMRA proportion can be easily performed by clinical flow cytometry, positing it as a potential biomarker to be used at time of diagnosis.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Terminally differentiated CD57+ memory T cells are an independent predictor of disease recurrence and decreased overall survival in head and neck cancer</span>. <u>Brianna Brammer</u><sup>1</sup>; Chulwoo Kim<sup>1</sup>; Brendan Kinney<sup>1</sup>; Subir Goyal<sup>2</sup>; Yuan Liu<sup>2</sup>; Brian J Boyce, MD<sup>1</sup>; Azeem S Kaka, MD<sup>1</sup>; Jennifer H Gross, MD<sup>1</sup>; H Michael Baddour, MD<sup>1</sup>; Peter W Kahng, MD<sup>1</sup>; Jose A Monteiro de Olivera Novaes, MD<sup>3</sup>; Nabil F Saba, MD<sup>3</sup>; Nicole C Schmitt, MD<sup>1</sup>. <sup>1</sup>Emory University Department of Otolaryngology - Head and Neck Surgery; <sup>2</sup>Winship Cancer Institute; <sup>3</sup>Emory University Department of Hematology and Medical Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Despite nearly half of patients with head and neck squamous cell carcinoma (HNSCC) experiencing disease recurrence within one year of surgical treatment, there are few validated mechanisms to predict disease recurrence. We have previously reported a subset of T cells that are significantly associated with early disease recurrence after surgery. We refer to these highly differentiated CD8+ T effector memory cells as HD TEMRA cells. Patients with HD TEMRA proportion >34% in circulation were significantly more likely to experience locoregional disease recurrence at both 6 months and one year. While HD TEMRA cells have been reported to accumulate with chronic viral infection and aging, their role in HNSCC is unknown. Here, we aimed to determine whether an elevated HD TEMRA proportion is an independent predictor of HNSCC recurrence after surgery and overall survival.</p>\n\n<p><strong>Methods: </strong>We collected peripheral blood samples from 87 patients with previously untreated, locally advanced HNSCC undergoing surgical treatment, and from 17 patients upon surgical treatment for recurrent disease. Samples were assessed by flow cytometry to determine the proportion of HD TEMRA cells. Patient charts were reviewed in the electronic medical record, and demographic details were recorded including age, sex, and race/ethnicity. Pathology details including T stage, N stage, tumor grade, and presence/absence of perineural/lymphovascular invasion and extracapsular extension were recorded along with details on adjuvant therapy, recurrence, and death. Kaplan-Meier method and multivariable Cox regression model was performed to determine the association between HD TEMRA cell proportion in predicting overall survival and disease recurrence.</p>\n\n<p><strong>Results: </strong>Upon follow-up analysis at 36 months, HD TEMRA proportion >34% in circulation was associated with shortened overall survival, with median survival 17.4 months; median survival for patients with <34% HD TEMRA cells was not reached (Figure 1, p=0.0053). One-year survival rate for patients with >34% HD TEMRA was 58.9% (95% CI 35.7%, 76.1%), and 81.8% for <34% HD TEMRA (95% CI 67.8%, 90.2%). Multivariable analysis revealed that HD TEMRA proportion >34% was independently predictive of reduced overall recurrence-free survival (hazard ratio = 0.47, p=0.038) and overall survival (hazard ratio = 0.36, p=0.008). Additionally, patients with recurrent disease had increased HD TEMRA proportion relative to age/stage/site matched patients with primary disease (mean 29.40% vs 16.86%, p=0.0323).</p>\n\n<p><strong>Conclusions:</strong> Elevated HD TEMRA proportion in circulation was associated with early locoregional recurrence and significantly diminished overall survival. Upon multivariable analysis, HD TEMRA proportion was determined to be an independent predictor of recurrence-free survival and overall survival. HD TEMRA proportion was found to be relatively higher upon recurrence between matched patients. As HNSCC recurrence requires extensive intervention and lowers overall survival, prediction of which patients will experience recurrence is paramount to informing treatment planning and shared decision making between patient and providers. Calculation of HD TEMRA proportion can be easily performed by clinical flow cytometry, positing it as a potential biomarker to be used at time of diagnosis.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153633/BB%20AHNS%20Figure%201(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153633--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S034",
      "content_id": "153909",
      "abstract_number": "S034",
      "poster_number": "",
      "title": "Somatic changes and germline variants polygenic risk score associated with tumor immune infiltration in oral squamous cell carcinoma",
      "summary": "Somatic deletions of the CDKN2a (p16) and CDKN2b genes on chromosome 9, and of DDX3X on the X chromosome, are associated with low OSCC tumor immune infiltration. We constructed a polygenic risk score for germline variants associated with OSCC tumor immune infiltration. It showed promising results in predicting patients with higher immune infiltration, but will need to be validated in other cohorts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153909",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Guillaume B Cardin, MSc",
      "presenter": "Guillaume B Cardin, MSc",
      "authors": "Guillaume B Cardin, MSc 1 ; Alicia Pellerin-Viger 1 ; Tareck Ayad 2 ; Eric Bissada 2 ; Louis Guertin 2 ; Paul Tabet 2 ; Houda Bahig 2 ; Apostolos Christopoulos 2",
      "normalized_authors": [
        "Guillaume B Cardin",
        "Alicia Pellerin-Viger",
        "Tareck Ayad",
        "Eric Bissada",
        "Louis Guertin",
        "Paul Tabet",
        "Houda Bahig",
        "Apostolos Christopoulos"
      ],
      "affiliations": [
        "Centre de recherche du centre hospitalier de l'Université de Montréal",
        "Centre hospitalier de l'Université de Montréal"
      ],
      "normalized_institutions": [
        "Centre de recherche du centre hospitalier de l'Université de Montréal",
        "Centre hospitalier de l'Université de Montréal"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153909/Figure.gif",
          "source_url": "https://www.submitmyabstract.com/abs/images/153909/Figure.gif",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153909"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Guillaume B Cardin, MSc 1 ; Alicia Pellerin-Viger 1 ; Tareck Ayad 2 ; Eric Bissada 2 ; Louis Guertin 2 ; Paul Tabet 2 ; Houda Bahig 2 ; Apostolos Christopoulos 2",
        "Affiliations": "1 Centre de recherche du centre hospitalier de l'Université de Montréal; 2 Centre hospitalier de l'Université de Montréal",
        "Introduction": "Following the KEYNOTE-689 trial, immunotherapy use is expected to increase for head and neck squamous cell carcinoma (HNSCC). In this study, we evaluated somatic and germline genomic variants associated with immune infiltration in oral squamous cell carcinoma (OSCC).",
        "Methods": "We conducted a single-center cohort study of 156 patients who underwent primary surgery for OSCC between 2010 and 2024. Tumor samples were collected intraoperatively and were embedded in Optimal Cutting Temperature (OCT) medium and frozen at in liquid nitrogen until tumoral DNA and RNA extraction. Tumor cellularity was evaluated by a trained pathologist on hematoxylin and eosin (H&E) slides before and after the consecutive cuts used for DNA and RNA extraction. Peripheral blood samples were obtained at the time of surgery, and peripheral blood mononuclear cells were separated using Ficoll and stored in liquid nitrogen until germline DNA extraction. Whole genome sequencing (WGS) was performed on the tumor and matched normal samples, with a target depth of coverage of 80X and 30X respectively, using an Illumina NovaSeq 6000 instrument. Whole transcriptome sequencing (WTS) was performed on tumor samples only, with a target of 100 million paired-end reads per sample. Immune infiltration was evaluated using CIBERSORTx and validated on H&E slides. Germline and somatic variant calls were generated by combining Strelka2, VarScan 2, VarDict and MuTect2 calls in one vcf file per participant. Tumoral DNA vcf files were analyzed with the Personal Cancer Genome Reporter software. Germline DNA analysis and polygenic risk score construction were performed using PLINK.",
        "Results": "Deletion of the CDNK2A and CDKN2b genes (p = 9.14e-05), located on chromosome 9 p21.3, was associated with lower OSCC tumor immune infiltration. The CDKN2A gene encodes the p16 protein, the surrogate human papillomavirus marker. This protein promotes inflammation via senescence induction and upregulates programmed death-ligand 1 (PD-L1). Deletion of the DDX3X gene (p = 9.99e-05), located on chromosome X, was also associated with lower tumor immune infiltration. For germline DNA analysis, we constructed a polygenic risk score (PRS) predictive of OSCC immune infiltration, including 20 germline variants. Variants located on the following protein coding genes were found: OS9, RAB37, CD300LF, DGKB, ZNF608, NECTIN1, SVOPL, ACTL8, PDE1C, IFITM10, ADK. The resulting PRS was tested using ROC curves to evaluate its predictive ability of tumoral immune infiltration evaluated using CIBERSORTx ( Figure ). The score performed better at predicting the top 25% of tumor immune infiltration ( Figure A , specificity 96.6%, sensitivity 78.6%), than at predicting the lowest 25% tumor immune infiltration ( Figure B , specificity 74.4%, sensitivity 79.5%).",
        "Conclusion": "Somatic deletions of the CDKN2a (p16) and CDKN2b genes on chromosome 9, and of DDX3X on the X chromosome, are associated with low OSCC tumor immune infiltration. We constructed a polygenic risk score for germline variants associated with OSCC tumor immune infiltration. It showed promising results in predicting patients with higher immune infiltration, but will need to be validated in other cohorts.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Somatic changes and germline variants polygenic risk score associated with tumor immune infiltration in oral squamous cell carcinoma</span>. <u>Guillaume B Cardin, MSc</u><sup>1</sup>; Alicia Pellerin-Viger<sup>1</sup>; Tareck Ayad<sup>2</sup>; Eric Bissada<sup>2</sup>; Louis Guertin<sup>2</sup>; Paul Tabet<sup>2</sup>; Houda Bahig<sup>2</sup>; Apostolos Christopoulos<sup>2</sup>. <sup>1</sup>Centre de recherche du centre hospitalier de l'Université de Montréal; <sup>2</sup>Centre hospitalier de l'Université de Montréal<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction </strong>: Following the KEYNOTE-689 trial, immunotherapy use is expected to increase for head and neck squamous cell carcinoma (HNSCC). In this study, we evaluated somatic and germline genomic variants associated with immune infiltration in oral squamous cell carcinoma (OSCC).</p>\n\n<p><strong>Methods </strong>: We conducted a single-center cohort study of 156 patients who underwent primary surgery for OSCC between 2010 and 2024. Tumor samples were collected intraoperatively and were embedded in Optimal Cutting Temperature (OCT) medium and frozen at in liquid nitrogen until tumoral DNA and RNA extraction. Tumor cellularity was evaluated by a trained pathologist on hematoxylin and eosin (H&E) slides before and after the consecutive cuts used for DNA and RNA extraction. Peripheral blood samples were obtained at the time of surgery, and peripheral blood mononuclear cells were separated using Ficoll and stored in liquid nitrogen until germline DNA extraction. Whole genome sequencing (WGS) was performed on the tumor and matched normal samples, with a target depth of coverage of 80X and 30X respectively, using an Illumina NovaSeq 6000 instrument. Whole transcriptome sequencing (WTS) was performed on tumor samples only, with a target of 100 million paired-end reads per sample. Immune infiltration was evaluated using CIBERSORTx and validated on H&E slides. Germline and somatic variant calls were generated by combining Strelka2, VarScan 2, VarDict and MuTect2 calls in one vcf file per participant. Tumoral DNA vcf files were analyzed with the Personal Cancer Genome Reporter software. Germline DNA analysis and polygenic risk score construction were performed using PLINK.</p>\n\n<p><strong>Results </strong>: Deletion of the CDNK2A and CDKN2b genes (p = 9.14e-05), located on chromosome 9 p21.3, was associated with lower OSCC tumor immune infiltration. The CDKN2A gene encodes the p16 protein, the surrogate human papillomavirus marker. This protein promotes inflammation via senescence induction and upregulates programmed death-ligand 1 (PD-L1). Deletion of the DDX3X gene (p = 9.99e-05), located on chromosome X, was also associated with lower tumor immune infiltration. For germline DNA analysis, we constructed a polygenic risk score (PRS) predictive of OSCC immune infiltration, including 20 germline variants. Variants located on the following protein coding genes were found: OS9, RAB37, CD300LF, DGKB, ZNF608, NECTIN1, SVOPL, ACTL8, PDE1C, IFITM10, ADK. The resulting PRS was tested using ROC curves to evaluate its predictive ability of tumoral immune infiltration evaluated using CIBERSORTx (<strong>Figure</strong>). The score performed better at predicting the top 25% of tumor immune infiltration (<strong>Figure A</strong>, specificity 96.6%, sensitivity 78.6%), than at predicting the lowest 25% tumor immune infiltration (<strong>Figure B</strong>, specificity 74.4%, sensitivity 79.5%).</p>\n\n<p><strong>Conclusion </strong>: Somatic deletions of the CDKN2a (p16) and CDKN2b genes on chromosome 9, and of DDX3X on the X chromosome, are associated with low OSCC tumor immune infiltration. We constructed a polygenic risk score for germline variants associated with OSCC tumor immune infiltration. It showed promising results in predicting patients with higher immune infiltration, but will need to be validated in other cohorts.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153909/Figure.gif' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153909--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S035",
      "content_id": "154104",
      "abstract_number": "S035",
      "poster_number": "",
      "title": "Epigenetic and Histogenomic Links Between Psychosocial Stress and Survival in Oral Squamous Cell Carcinoma",
      "summary": "Psychological well-being is associated with improved physical health and reduced mortality, yet the effects of psychosocial stressors on cancer outcomes and their underlying molecular mechanisms remain incompletely characterized. We investigated the impact of psychosocial stress, associated epigenetic dysregulation, and histogenomic features on outcomes in oral squamous cell carcinoma (OSCC). In this prospective,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154104",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "T Wilson, MD",
      "presenter": "T Wilson, MD",
      "authors": "T Wilson, MD 1 ; P Dong 1 ; B Luong 1 ; D Nguyen 1 ; R Philips 2 ; A Pearson 3 ; M Arambula 1 ; B Aouizerat 4 ; P Walker 1 ; K Nguyen 1 ; C Thomas 5 ; C Viet 1",
      "normalized_authors": [
        "T Wilson",
        "P Dong",
        "B Luong",
        "D Nguyen",
        "R Philips",
        "A Pearson",
        "M Arambula",
        "B Aouizerat",
        "P Walker",
        "K Nguyen",
        "C Thomas",
        "C Viet"
      ],
      "affiliations": [
        "Loma Linda University",
        "Thomas Jefferson University",
        "University of Chicago",
        "New York University",
        "University of Colorado"
      ],
      "normalized_institutions": [
        "Loma Linda University",
        "Thomas Jefferson University",
        "University of Chicago",
        "New York University",
        "University of Colorado"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "T Wilson, MD 1 ; P Dong 1 ; B Luong 1 ; D Nguyen 1 ; R Philips 2 ; A Pearson 3 ; M Arambula 1 ; B Aouizerat 4 ; P Walker 1 ; K Nguyen 1 ; C Thomas 5 ; C Viet 1",
        "Affiliations": "1 Loma Linda University; 2 Thomas Jefferson University; 3 University of Chicago; 4 New York University; 5 University of Colorado",
        "Abstract": "Psychological well-being is associated with improved physical health and reduced mortality, yet the effects of psychosocial stressors on cancer outcomes and their underlying molecular mechanisms remain incompletely characterized. We investigated the impact of psychosocial stress, associated epigenetic dysregulation, and histogenomic features on outcomes in oral squamous cell carcinoma (OSCC). In this prospective, multi-institutional study, 173 patients with OSCC were enrolled. Prior and current psychosocial stressors were assessed using the Adverse Childhood Experiences (ACE) questionnaire and Life Events Checklist (LEC-5). Cancer symptoms and quality-of-life (QoL) disturbance were characterized using the UCSF Oral Pain Questionnaire (UCSF-OPQ), the modified Brief Pain Inventory (BPI), and EORTC QLQ-C30 and H&N35. Flash-frozen tumor tissue and oral brush swabs were collected for transcriptomic/epigenetic profiling using RNA sequencing (RNA-seq). Histogenomic analysis was performed using feature extraction with the UNI foundation model and creation of synthetic deep learning model pathology examples with the HistoXGAN generative adversarial network. Statistical analyses included Pearson correlation, Student’s t-test, one-way ANOVA, Kaplan–Meier log-rank testing, Cox proportional hazards regression, and UMAP-based dimension reduction. The cohort included 99 males and 74 females. Patients reporting financial difficulties and racial/ethnic minorities had worse cancer pain (UCSF-OPQ) and poorer QoL (EORTC) independent of cancer stage (p<0.001). Higher pain was associated with impairment across all six EORTC QLQ-C30 functional domains (p<0.0001). Patients with high ACE or LEC-5 scores reported worse symptoms across all symptom scales (modified BPI, EORTC QLQ-C30, and H&N35), independent of pathologic stage. In multivariable Cox regression, the H&N35 functional score predicted survival (HR=1.969; 95% CI, 1.060–3.659) independent of pathologic stage (HR=1.808; 95% CI, 1.244–2.628) and age (HR=1.669; 95% CI, 1.151–2.419). RNA-seq analyses identified top epigenetically dysregulated genes in patients with high ACE scores. High pain was associated with dysregulation of extracellular matrix organization and neuronal/axonal ensheathment pathways. Early childhood trauma was associated with increased expression of RPL/RPS genes, implicating ribonucleoprotein complex biogenesis and p53-mediated signaling as potential molecular links between early-life stress and OSCC survival. Histogenomic modeling identified pathologic features associated with high pain: UMAP clustering demonstrated feature-level separation, and 100 HistoXGAN-generated synthetic pathology examples were independently reviewed by in-house pathologists. Red blood cell extravasation and increased fibrosis were enriched in patients with high pain. Psychosocial stressors are associated with substantially increased symptom burden, which in turn is independently associated with worse OSCC outcomes and survival. These findings define epigenetically dysregulated pathways and candidate histopathologic features linking behavioral health to OSCC biology and prognosis. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Epigenetic and Histogenomic Links Between Psychosocial Stress and Survival in Oral Squamous Cell Carcinoma</span>. <u>T Wilson, MD</u><sup>1</sup>; P Dong<sup>1</sup>; B Luong<sup>1</sup>; D Nguyen<sup>1</sup>; R Philips<sup>2</sup>; A Pearson<sup>3</sup>; M Arambula<sup>1</sup>; B Aouizerat<sup>4</sup>; P Walker<sup>1</sup>; K Nguyen<sup>1</sup>; C Thomas<sup>5</sup>; C Viet<sup>1</sup>. <sup>1</sup>Loma Linda University; <sup>2</sup>Thomas Jefferson University; <sup>3</sup>University of Chicago; <sup>4</sup>New York University; <sup>5</sup>University of Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Psychological well-being is associated with improved physical health and reduced mortality, yet the effects of psychosocial stressors on cancer outcomes and their underlying molecular mechanisms remain incompletely characterized. We investigated the impact of psychosocial stress, associated epigenetic dysregulation, and histogenomic features on outcomes in oral squamous cell carcinoma (OSCC).</p>\n\n<p>In this prospective, multi-institutional study, 173 patients with OSCC were enrolled. Prior and current psychosocial stressors were assessed using the Adverse Childhood Experiences (ACE) questionnaire and Life Events Checklist (LEC-5). Cancer symptoms and quality-of-life (QoL) disturbance were characterized using the UCSF Oral Pain Questionnaire (UCSF-OPQ), the modified Brief Pain Inventory (BPI), and EORTC QLQ-C30 and H&N35. Flash-frozen tumor tissue and oral brush swabs were collected for transcriptomic/epigenetic profiling using RNA sequencing (RNA-seq). Histogenomic analysis was performed using feature extraction with the UNI foundation model and creation of synthetic deep learning model pathology examples with the HistoXGAN generative adversarial network. Statistical analyses included Pearson correlation, Student’s t-test, one-way ANOVA, Kaplan–Meier log-rank testing, Cox proportional hazards regression, and UMAP-based dimension reduction.</p>\n\n<p>The cohort included 99 males and 74 females. Patients reporting financial difficulties and racial/ethnic minorities had worse cancer pain (UCSF-OPQ) and poorer QoL (EORTC) independent of cancer stage (p<0.001). Higher pain was associated with impairment across all six EORTC QLQ-C30 functional domains (p<0.0001). Patients with high ACE or LEC-5 scores reported worse symptoms across all symptom scales (modified BPI, EORTC QLQ-C30, and H&N35), independent of pathologic stage. In multivariable Cox regression, the H&N35 functional score predicted survival (HR=1.969; 95% CI, 1.060–3.659) independent of pathologic stage (HR=1.808; 95% CI, 1.244–2.628) and age (HR=1.669; 95% CI, 1.151–2.419). RNA-seq analyses identified top epigenetically dysregulated genes in patients with high ACE scores. High pain was associated with dysregulation of extracellular matrix organization and neuronal/axonal ensheathment pathways. Early childhood trauma was associated with increased expression of RPL/RPS genes, implicating ribonucleoprotein complex biogenesis and p53-mediated signaling as potential molecular links between early-life stress and OSCC survival. Histogenomic modeling identified pathologic features associated with high pain: UMAP clustering demonstrated feature-level separation, and 100 HistoXGAN-generated synthetic pathology examples were independently reviewed by in-house pathologists. Red blood cell extravasation and increased fibrosis were enriched in patients with high pain.</p>\n\n<p>Psychosocial stressors are associated with substantially increased symptom burden, which in turn is independently associated with worse OSCC outcomes and survival. These findings define epigenetically dysregulated pathways and candidate histopathologic features linking behavioral health to OSCC biology and prognosis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154104--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S036",
      "content_id": "155445",
      "abstract_number": "S036",
      "poster_number": "",
      "title": "Human restricted CHRFAM7A gene may affect invasion properties of oral cavity squamous cell carcinoma.",
      "summary": "Invasion properties of oral cavity squamous cell carcinoma may be partially regulated by a uniquely human mechanism with population dichotomy. These insights may lead to genetic stratification of metastatic mode and offer novel therapeutic interventions for metastatic cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155445",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260115",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Norbert Sule, MD 1 ; Anna Szombathy, BS 2 ; Ryu Dom, BS 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Vishal Gupta, MD 1 ; Kinga Szigeti, MD 2",
      "normalized_authors": [
        "Norbert Sule",
        "Anna Szombathy",
        "Ryu Dom",
        "William J Magner",
        "Lynn Sigurdson",
        "Vishal Gupta",
        "Kinga Szigeti"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 355,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Design",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Norbert Sule, MD 1 ; Anna Szombathy, BS 2 ; Ryu Dom, BS 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Vishal Gupta, MD 1 ; Kinga Szigeti, MD 2",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Background": "CHRFAM7A is a uniquely human fusion gene that can be present in direct or inverted orientation with similar frequencies in the population. In its direct orientation, CHRFAM7A has been identified as a potent modulator of intracellular calcium signaling and an upstream regulator of Rac1. In an isogenic iPSC model the presence of CHRFAM7A leads to actin cytoskeleton reorganization and a switch from filopodia to lamellipodia and increases matrix metallopeptidase activity leading to invasion gain of function. The inverted allele regulates ULK4 expression through genetic epistasis. The increase in long to short ULK4 isoform ratio enhances a-tubulin acetylation leading to microtubule (MT) cytoskeleton gain of function. The divergent cytoskeleton evolution leads to invasion and migration gain of function in the direct and inverted cells, respectively. Cellular locomotion is the foundation of metastatic cancer. In oral cavity cancer, unique patterns of invasion have been identified leading to worst pattern of invasion (WPOI) classification.",
        "Design": "In a pilot study of oral cavity cancer surgical specimens (N=27), we characterized tumor size, worst pattern of invasion (WPOI), perineuronal invasion (PNI) and extranodal extension (ENE). Demographic information, including age, sex, smoking and alcohol use were ascertained. Dual locus specific genotyping of CHRFAM7A was performed on genomic DNA to determine copy number (TaqMan assay) and orientation (capillary sequencing) of the CHRFAM7A alleles. We evaluated the distribution of invasion phenotypes within genotypic groups by ANOVA.",
        "Results": "Genotype distribution of 23% homozygous direct, 23% homozygous inverted and 54% was detected. One 0 copy individual was excluded from the cohort. Pathological Tumor stage was not significantly different in the comparison groups. WPOI average score was 3.16 in direct allele carriers in contrast to 4.4 in direct allele non-carriers. PNI was present in 58% of the inverted allele carriers compared to 33% in non-carriers. In cases where positive lymph nodes were present, ENE was more likely in direct allele carriers.",
        "Conclusion": "Invasion properties of oral cavity squamous cell carcinoma may be partially regulated by a uniquely human mechanism with population dichotomy. These insights may lead to genetic stratification of metastatic mode and offer novel therapeutic interventions for metastatic cancer.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Human restricted CHRFAM7A gene may affect invasion properties of oral cavity squamous cell carcinoma.</span>. Norbert Sule, MD<sup>1</sup>; Anna Szombathy, BS<sup>2</sup>; Ryu Dom, BS<sup>2</sup>; William J Magner, PhD<sup>1</sup>; Lynn Sigurdson, PhD<sup>1</sup>; <u>Vishal Gupta, MD</u><sup>1</sup>; Kinga Szigeti, MD<sup>2</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>CHRFAM7A is a uniquely human fusion gene that can be present in direct or inverted orientation with similar frequencies in the population. In its direct orientation, CHRFAM7A has been identified as a potent modulator of intracellular calcium signaling and an upstream regulator of Rac1. In an isogenic iPSC model the presence of CHRFAM7A leads to actin cytoskeleton reorganization and a switch from filopodia to lamellipodia and increases matrix metallopeptidase activity leading to invasion gain of function. The inverted allele regulates ULK4 expression through genetic epistasis. The increase in long to short ULK4 isoform ratio enhances a-tubulin acetylation leading to microtubule (MT) cytoskeleton gain of function. The divergent cytoskeleton evolution leads to invasion and migration gain of function in the direct and inverted cells, respectively. Cellular locomotion is the foundation of metastatic cancer. In oral cavity cancer, unique patterns of invasion have been identified leading to worst pattern of invasion (WPOI) classification.</p>\n\n<p><strong>Design:</strong> In a pilot study of oral cavity cancer surgical specimens (N=27), we characterized tumor size, worst pattern of invasion (WPOI), perineuronal invasion (PNI) and extranodal extension (ENE). Demographic information, including age, sex, smoking and alcohol use were ascertained. Dual locus specific genotyping of CHRFAM7A was performed on genomic DNA to determine copy number (TaqMan assay) and orientation (capillary sequencing) of the CHRFAM7A alleles. We evaluated the distribution of invasion phenotypes within genotypic groups by ANOVA.</p>\n\n<p><strong>Results:</strong> Genotype distribution of 23% homozygous direct, 23% homozygous inverted and 54% was detected. One 0 copy individual was excluded from the cohort. Pathological Tumor stage was not significantly different in the comparison groups. WPOI average score was 3.16 in direct allele carriers in contrast to 4.4 in direct allele non-carriers. PNI was present in 58% of the inverted allele carriers compared to 33% in non-carriers. In cases where positive lymph nodes were present, ENE was more likely in direct allele carriers.</p>\n\n<p><strong>Conclusion:</strong> Invasion properties of oral cavity squamous cell carcinoma may be partially regulated by a uniquely human mechanism with population dichotomy. These insights may lead to genetic stratification of metastatic mode and offer novel therapeutic interventions for metastatic cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155445--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260115' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S037",
      "content_id": "154062",
      "abstract_number": "S037",
      "poster_number": "",
      "title": "Evaluation of TraceIT Tissue Marker to mark the primary resection bed margins of oropharyngeal cancers: a pilot study",
      "summary": "This study demonstrates that fiducial hydrogel markers are a feasible strategy for CTV dose reduction in postoperative adjuvant radiotherapy for HPV+ OSPCC. Future studies should determine if radiation deintensification using fiducial markers reduce radiation-related toxicity without sacrificing oncologic outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154062",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Theresa Tharakan, MD, MSCI",
      "presenter": "Theresa Tharakan, MD, MSCI",
      "authors": "Theresa Tharakan, MD, MSCI ; Wade Thorstad, MD; Ryan Jackson",
      "normalized_authors": [
        "Theresa Tharakan, MSCI",
        "Wade Thorstad",
        "Ryan Jackson"
      ],
      "affiliations": [
        "Washington University in St Louis"
      ],
      "normalized_institutions": [
        "Washington University in St Louis"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 371,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Theresa Tharakan, MD, MSCI ; Wade Thorstad, MD; Ryan Jackson",
        "Affiliations": "Washington University in St Louis",
        "Background": "Techniques for determining clinical target volumes for adjuvant radiation in oropharyngeal cancer are currently based on population-based data, but may overestimate the extent of tumor spread in an individual patient. Intraoperative markers can aid radiation oncologists by mapping the exact location of negative tumor margins in the resection bed; however, this is not routinely practiced in the oropharynx. The objective of this study was to compare clinical target volumes to normal structures in the head and neck in standard of care treatment plans versus treatment plans using a bioabsorbable hydrogel as a fiducial marker.",
        "Methods": "Patients with human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) undergoing transoral robotic surgery were included. TraceIT Tissue Marker was injected intraoperatively in the primary resection bed by the operating surgeon. Within 6 weeks postoperatively, a computed tomography (CT) simulation scan was performed to generate intensity-modulated radiation therapy (IMRT) treatment plans for adjuvant radiation: One was the standard of care plan and the second was based on TraceIT hydrogel markers as a guide for the tumor margins. The primary outcome was reduction in clinical target volumes (CTV) to targeted sites surrounding the tumor bed between the standard treatment plan and the theoretical marker-based plan. Targeted sites included the submandibular gland, parotid, pharyngeal constrictors, oral cavity, lips, larynx, and spinal cord. Secondary outcome was adverse events in response to marker injection. Subset analysis was performed comparing tonsil and base of tongue primary tumors.",
        "Results": "Fifteen patients received the TraceIT marker and postoperative CT scan. Contouring CTVs based on the marker was successful in 12 (80%) patients. The largest dose reductions were in the ipsilateral submandibular gland (base of tongue group by 19 Gy, tonsil group by 16 Gy), oral cavity (tonsil group 14 Gy, base of tongue group by 12 Gy), ipsilateral pharyngeal constrictor (tonsil group 13 Gy, base of tongue 9 Gy), and larynx (base of tongue by 13 Gy, tonsil group by 4 Gy). There were no marker-related adverse events.",
        "Conclusion": "This study demonstrates that fiducial hydrogel markers are a feasible strategy for CTV dose reduction in postoperative adjuvant radiotherapy for HPV+ OSPCC. Future studies should determine if radiation deintensification using fiducial markers reduce radiation-related toxicity without sacrificing oncologic outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluation of TraceIT Tissue Marker to mark the primary resection bed margins of oropharyngeal cancers: a pilot study</span>. <u>Theresa Tharakan, MD, MSCI</u>; Wade Thorstad, MD; Ryan Jackson. Washington University in St Louis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Techniques for determining clinical target volumes for adjuvant radiation in oropharyngeal cancer are currently based on population-based data, but may overestimate the extent of tumor spread in an individual patient. Intraoperative markers can aid radiation oncologists by mapping the exact location of negative tumor margins in the resection bed; however, this is not routinely practiced in the oropharynx. The objective of this study was to compare clinical target volumes to normal structures in the head and neck in standard of care treatment plans versus treatment plans using a bioabsorbable hydrogel as a fiducial marker.</p>\n\n<p><strong>Methods:</strong> Patients with human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) undergoing transoral robotic surgery were included. TraceIT Tissue Marker was injected intraoperatively in the primary resection bed by the operating surgeon. Within 6 weeks postoperatively, a computed tomography (CT) simulation scan was performed to generate intensity-modulated radiation therapy (IMRT) treatment plans for adjuvant radiation: One was the standard of care plan and the second was based on TraceIT hydrogel markers as a guide for the tumor margins. The primary outcome was reduction in clinical target volumes (CTV) to targeted sites surrounding the tumor bed between the standard treatment plan and the theoretical marker-based plan. Targeted sites included the submandibular gland, parotid, pharyngeal constrictors, oral cavity, lips, larynx, and spinal cord. Secondary outcome was adverse events in response to marker injection. Subset analysis was performed comparing tonsil and base of tongue primary tumors.</p>\n\n<p><strong>Results:</strong> Fifteen patients received the TraceIT marker and postoperative CT scan. Contouring CTVs based on the marker was successful in 12 (80%) patients. The largest dose reductions were in the ipsilateral submandibular gland (base of tongue group by 19 Gy, tonsil group by 16 Gy), oral cavity (tonsil group 14 Gy, base of tongue group by 12 Gy), ipsilateral pharyngeal constrictor (tonsil group 13 Gy, base of tongue 9 Gy), and larynx (base of tongue by 13 Gy, tonsil group by 4 Gy). There were no marker-related adverse events.</p>\n\n<p><strong>Conclusion:</strong> This study demonstrates that fiducial hydrogel markers are a feasible strategy for CTV dose reduction in postoperative adjuvant radiotherapy for HPV+ OSPCC. Future studies should determine if radiation deintensification using fiducial markers reduce radiation-related toxicity without sacrificing oncologic outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154062--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S038",
      "content_id": "153996",
      "abstract_number": "S038",
      "poster_number": "",
      "title": "Investigation of progression-free survival as a surrogate for overall survival in HPV+ oropharyngeal studies",
      "summary": "In a more heterogeneous group of HPV+ OPSCC trials, PFS remained a valid trial-level surrogate for OS. Furthermore, PFS demonstrates strong trial-level surrogacy for OS in several HPV+ OPSCC therapeutic contexts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153996",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rachel T Gonzalez, MS",
      "presenter": "Rachel T Gonzalez, MS",
      "authors": "Rachel T Gonzalez, MS 1 ; Laila A Gharzai, MD 2 ; Phuc Felix Nguyen-Tân, MD 3 ; David I Rosenthal, MD 4 ; Maura L Gillison, MD 4 ; Paul M Harari, MD 5 ; Adam S Garden, MD 4 ; Shlomo Koyfman, MD 6 ; Jimmy J Caudell, MD 7 ; Christopher U Jones, MD 8 ; Darrion L Mitchell, MD 9 ; Greg Krempl, MD 10 ; John A Ridge, MD, PhD 11 ; Michael F Gensheimer, MD 12 ; James A Bonner, MD 13 ; Edith Filion, MD 3 ; Neal E Dunlap, MD 14 ; William A Stokes, MD 15 ; Quynh-Thu Le, MD 12 ; Jonathan Harris, MS 16 ; Matthew J Schipper, PhD 1 ; Krithika Suresh, PhD 1 ; Michelle Mierzwa, MD 1",
      "normalized_authors": [
        "Rachel T Gonzalez",
        "Laila A Gharzai",
        "Phuc Felix Nguyen-Tân",
        "David I Rosenthal",
        "Maura L Gillison",
        "Paul M Harari",
        "Adam S Garden",
        "Shlomo Koyfman",
        "Jimmy J Caudell",
        "Christopher U Jones",
        "Darrion L Mitchell",
        "Greg Krempl",
        "John A Ridge",
        "Michael F Gensheimer",
        "James A Bonner",
        "Edith Filion",
        "Neal E Dunlap",
        "William A Stokes",
        "Quynh-Thu Le",
        "Jonathan Harris",
        "Matthew J Schipper",
        "Krithika Suresh",
        "Michelle Mierzwa"
      ],
      "affiliations": [
        "University of Michigan",
        "Northwestern University",
        "Centre Hospitalier de l’Université de Montréal (CHUM)",
        "University of Texas MD Anderson Cancer Center",
        "University of Wisconsin",
        "University of Cleveland Medical Center",
        "Moffitt Cancer Center and Research Institute",
        "Sutter Cancer Research Consortium",
        "Ohio State University",
        "University of Oklahoma Health Sciences Center",
        "Fox Chase Cancer Center",
        "Stanford University",
        "University of Alabama at Birmingham Medical Center",
        "The James Graham Brown Cancer Center at University of Louisville",
        "Emory University",
        "NRG Oncology Statistics and Data Management Center"
      ],
      "normalized_institutions": [
        "University of Michigan",
        "Northwestern University",
        "Centre Hospitalier de l’Université de Montréal (CHUM)",
        "University of Texas MD Anderson Cancer Center",
        "University of Wisconsin",
        "University of Cleveland Medical Center",
        "Moffitt Cancer Center and Research Institute",
        "Sutter Cancer Research Consortium",
        "Ohio State University",
        "University of Oklahoma Health Sciences Center",
        "Fox Chase Cancer Center",
        "Stanford University",
        "University of Alabama at Birmingham Medical Center",
        "The James Graham Brown Cancer Center at University of Louisville",
        "Emory University",
        "NRG Oncology Statistics and Data Management Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153996/plot_abstract.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153996/plot_abstract.png",
          "alt": "Comparison of hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Dot sizes are proportional to the sample size of the trial. The solid lines are the estimates and dashed lines are the 95% confidence intervals for the linear regression of OS log(HR) and PFS log(HR).",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153996"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose/Objectives",
        "Materials/Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rachel T Gonzalez, MS 1 ; Laila A Gharzai, MD 2 ; Phuc Felix Nguyen-Tân, MD 3 ; David I Rosenthal, MD 4 ; Maura L Gillison, MD 4 ; Paul M Harari, MD 5 ; Adam S Garden, MD 4 ; Shlomo Koyfman, MD 6 ; Jimmy J Caudell, MD 7 ; Christopher U Jones, MD 8 ; Darrion L Mitchell, MD 9 ; Greg Krempl, MD 10 ; John A Ridge, MD, PhD 11 ; Michael F Gensheimer, MD 12 ; James A Bonner, MD 13 ; Edith Filion, MD 3 ; Neal E Dunlap, MD 14 ; William A Stokes, MD 15 ; Quynh-Thu Le, MD 12 ; Jonathan Harris, MS 16 ; Matthew J Schipper, PhD 1 ; Krithika Suresh, PhD 1 ; Michelle Mierzwa, MD 1",
        "Affiliations": "1 University of Michigan; 2 Northwestern University; 3 Centre Hospitalier de l’Université de Montréal (CHUM); 4 University of Texas MD Anderson Cancer Center; 5 University of Wisconsin; 6 University of Cleveland Medical Center; 7 Moffitt Cancer Center and Research Institute; 8 Sutter Cancer Research Consortium; 9 Ohio State University; 10 University of Oklahoma Health Sciences Center; 11 Fox Chase Cancer Center; 12 Stanford University; 13 University of Alabama at Birmingham Medical Center; 14 The James Graham Brown Cancer Center at University of Louisville; 15 Emory University; 16 NRG Oncology Statistics and Data Management Center",
        "Purpose/Objectives": "Progression-free survival (PFS) was previously validated as a surrogate endpoint for overall survival (OS) in human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). This finding informs trial design in a long-surviving population, where intermediate endpoints can shorten the time needed to evaluate treatment benefit. Prior validation demonstrated that both individual-level and trial-level surrogacy criteria were satisfied; however, it was limited to United States cooperative group chemoradiation trials. We sought to assess trial-level surrogacy of PFS in a broader, more heterogeneous set of HPV+ OPSCC studies. The additional studies included patients treated with primary surgery, radiation dose de-escalation protocols, and alterations of systemic therapy from standard cisplatin, including the use of cetuximab.",
        "Materials/Methods": "We identified randomized clinical trials enrolling HPV+ OPSCC patients published in 2014-2024 that reported treatment effects on OS and PFS for HPV+ patients. For some trials, individual patient-level data (IPD) were available, which were used to estimate hazard ratios (HRs) using multivariable Cox proportional hazards models. For the other trials, published HRs were extracted when available. If HRs were not reported, we digitized Kaplan-Meier plots, reconstructed IPD, and fit Cox models to estimate HRs. Unlike the prior cooperative group analysis, individual-level (component 1) surrogacy of the two-stage meta-analytic approach could not be assessed because IPD were not uniformly available across studies. This analysis evaluates only the trial-level surrogacy component (component 2), examining the association between treatment effects on PFS and OS across trials. Trial-level surrogacy was assessed by regressing log OS HRs on log PFS HRs, weighted by the inverse variance of the log PFS HR. The strength of association was quantified by the coefficient of determination (R2), which was weighted by the inverse variance of the log PFS HR, and the trial-level surrogacy condition was considered satisfied if R2>0.70.",
        "Results": "We identified 14 trials (N=2737), five of which were NRG/RTOG cooperative group chemoradiation trials (N=1373) used in the prior surrogacy validation study. Across all studies, five were phase II and nine were phase III trials. The average median follow-up was approximately five years, and the median sample size was 128 (IQR 50–228). Half enrolled only HPV+ patients. Across all trials, PFS continued to meet criteria for trial-level surrogacy (R2=0.82 in all 14 trials vs. R2=0.92 in the original five cooperative group trials). Subgroup analyses showed that PFS was a strong trial-level surrogate in chemoradiation (8 trials, R2=0.94), cetuximab (5 trials, R2=0.97), and radiation dose de-escalation studies (5 trials, R2=0.87).",
        "Conclusions": "In a more heterogeneous group of HPV+ OPSCC trials, PFS remained a valid trial-level surrogate for OS. Furthermore, PFS demonstrates strong trial-level surrogacy for OS in several HPV+ OPSCC therapeutic contexts.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Investigation of progression-free survival as a surrogate for overall survival in HPV+ oropharyngeal studies</span>. <u>Rachel T Gonzalez, MS</u><sup>1</sup>; Laila A Gharzai, MD<sup>2</sup>; Phuc Felix Nguyen-Tân, MD<sup>3</sup>; David I Rosenthal, MD<sup>4</sup>; Maura L Gillison, MD<sup>4</sup>; Paul M Harari, MD<sup>5</sup>; Adam S Garden, MD<sup>4</sup>; Shlomo Koyfman, MD<sup>6</sup>; Jimmy J Caudell, MD<sup>7</sup>; Christopher U Jones, MD<sup>8</sup>; Darrion L Mitchell, MD<sup>9</sup>; Greg Krempl, MD<sup>10</sup>; John A Ridge, MD, PhD<sup>11</sup>; Michael F Gensheimer, MD<sup>12</sup>; James A Bonner, MD<sup>13</sup>; Edith Filion, MD<sup>3</sup>; Neal E Dunlap, MD<sup>14</sup>; William A Stokes, MD<sup>15</sup>; Quynh-Thu Le, MD<sup>12</sup>; Jonathan Harris, MS<sup>16</sup>; Matthew J Schipper, PhD<sup>1</sup>; Krithika Suresh, PhD<sup>1</sup>; Michelle Mierzwa, MD<sup>1</sup>. <sup>1</sup>University of Michigan; <sup>2</sup>Northwestern University; <sup>3</sup>Centre Hospitalier de l’Université de Montréal (CHUM); <sup>4</sup>University of Texas MD Anderson Cancer Center; <sup>5</sup>University of Wisconsin; <sup>6</sup>University of Cleveland Medical Center; <sup>7</sup>Moffitt Cancer Center and Research Institute; <sup>8</sup>Sutter Cancer Research Consortium; <sup>9</sup>Ohio State University; <sup>10</sup>University of Oklahoma Health Sciences Center; <sup>11</sup>Fox Chase Cancer Center; <sup>12</sup>Stanford University; <sup>13</sup>University of Alabama at Birmingham Medical Center; <sup>14</sup>The James Graham Brown Cancer Center at University of Louisville; <sup>15</sup>Emory University; <sup>16</sup>NRG Oncology Statistics and Data Management Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose/Objectives: </strong>Progression-free survival (PFS) was previously validated as a surrogate endpoint for overall survival (OS) in human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). This finding informs trial design in a long-surviving population, where intermediate endpoints can shorten the time needed to evaluate treatment benefit. Prior validation demonstrated that both individual-level and trial-level surrogacy criteria were satisfied; however, it was limited to United States cooperative group chemoradiation trials. We sought to assess trial-level surrogacy of PFS in a broader, more heterogeneous set of HPV+ OPSCC studies. The additional studies included patients treated with primary surgery, radiation dose de-escalation protocols, and alterations of systemic therapy from standard cisplatin, including the use of cetuximab.</p>\n\n<p><strong>Materials/Methods: </strong>We identified randomized clinical trials enrolling HPV+ OPSCC patients published in 2014-2024 that reported treatment effects on OS and PFS for HPV+ patients. For some trials, individual patient-level data (IPD) were available, which were used to estimate hazard ratios (HRs) using multivariable Cox proportional hazards models. For the other trials, published HRs were extracted when available. If HRs were not reported, we digitized Kaplan-Meier plots, reconstructed IPD, and fit Cox models to estimate HRs. Unlike the prior cooperative group analysis, individual-level (component 1) surrogacy of the two-stage meta-analytic approach could not be assessed because IPD were not uniformly available across studies. This analysis evaluates only the trial-level surrogacy component (component 2), examining the association between treatment effects on PFS and OS across trials. Trial-level surrogacy was assessed by regressing log OS HRs on log PFS HRs, weighted by the inverse variance of the log PFS HR. The strength of association was quantified by the coefficient of determination (R2), which was weighted by the inverse variance of the log PFS HR, and the trial-level surrogacy condition was considered satisfied if R2>0.70.</p>\n\n<p><strong>Results: </strong>We identified 14 trials (N=2737), five of which were NRG/RTOG cooperative group chemoradiation trials (N=1373) used in the prior surrogacy validation study. Across all studies, five were phase II and nine were phase III trials. The average median follow-up was approximately five years, and the median sample size was 128 (IQR 50–228). Half enrolled only HPV+ patients. Across all trials, PFS continued to meet criteria for trial-level surrogacy (R2=0.82 in all 14 trials vs. R2=0.92 in the original five cooperative group trials). Subgroup analyses showed that PFS was a strong trial-level surrogate in chemoradiation (8 trials, R2=0.94), cetuximab (5 trials, R2=0.97), and radiation dose de-escalation studies (5 trials, R2=0.87).</p>\n\n<p><strong>Conclusions:</strong> In a more heterogeneous group of HPV+ OPSCC trials, PFS remained a valid trial-level surrogate for OS. Furthermore, PFS demonstrates strong trial-level surrogacy for OS in several HPV+ OPSCC therapeutic contexts.</p>\n\n<p><img alt='Comparison of hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Dot sizes are proportional to the sample size of the trial. The solid lines are the estimates and dashed lines are the 95% confidence intervals for the linear regression of OS log(HR) and PFS log(HR).' src='https://www.submitmyabstract.com/abs/images/153996/plot_abstract.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153996--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S039",
      "content_id": "154480",
      "abstract_number": "S039",
      "poster_number": "",
      "title": "Comparative Analysis of Patients who Underwent De-Escalated Adjuvant Radiation Therapy (DART) or Standard of Care (SOC) Treatment as Stratified by Risk Categories on ECOG3311",
      "summary": "Intermediate-risk HPV(+)OPSCC patients as classified by ECOG3311 benefit from de-escalation of adjuvant radiation to 50Gy, but can also be safely de-escalated to 30-36 Gy using DART without compromise in oncologic outcomes. High-risk patients classified by ECOG3311 require further stratification, as the criteria used may be too stringent for de-escalation. The cutoff of 1mm of ENE did not meaningfully...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154480",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ruth N Agwaze, BS",
      "presenter": "Ruth N Agwaze, BS",
      "authors": "Ruth N Agwaze, BS 1 ; Aaron W Bogan, MA 2 ; Cecelia M Hidalgo, BA 1 ; Katelyn S Rourk, BS 1 ; Hannah Q Baratz, BS, MSMEd 1 ; Daniel G Eyassu, MD 1 ; Katharine A Price, MD 3 ; Eric J Moore, MD 1 ; Michelle A Neben Wittich, MD 4 ; Scott C Lester, MD 4 ; Jessica Wilson, MD, PhD 4 ; Daniel L Price 1 ; Kendall K Tasche, MD 1 ; Binav Baral, MBBS 3 ; Harry Fuentes Bayne, MD, MS 3 ; Patrick W McGarrah, MD 3 ; Daniel J Ma 4 ; Kathryn M Van Abel, MD 1 ; David M Routman, MD 4 ; Linda X Yin, MD 1",
      "normalized_authors": [
        "Ruth N Agwaze",
        "Aaron W Bogan, MA",
        "Cecelia M Hidalgo",
        "Katelyn S Rourk",
        "Hannah Q Baratz, MSMEd",
        "Daniel G Eyassu",
        "Katharine A Price",
        "Eric J Moore",
        "Michelle A Neben Wittich",
        "Scott C Lester",
        "Jessica Wilson",
        "Daniel L Price",
        "Kendall K Tasche",
        "Binav Baral, MBBS",
        "Harry Fuentes Bayne",
        "Patrick W McGarrah",
        "Daniel J Ma",
        "Kathryn M Van Abel",
        "David M Routman",
        "Linda X Yin"
      ],
      "affiliations": [
        "Mayo Clinic, Rochester MN, USA. Department of Otolaryngology, Head and Neck Surgery",
        "Mayo Clinic, Scottsdale, AZ. USA. Department of Quantitative Health Sciences, Division of Biostatistics",
        "Mayo Clinic, Rochester MN, USA. Division of Medical Oncology",
        "Mayo Clinic, Rochester MN, USA. Department of Radiation Oncology"
      ],
      "normalized_institutions": [
        "Mayo Clinic, Rochester MN, USA. Department of Otolaryngology, Head and Neck Surgery",
        "Mayo Clinic, Scottsdale, AZ. USA. Department of Quantitative Health Sciences, Division of Biostatistics",
        "Mayo Clinic, Rochester MN, USA. Division of Medical Oncology",
        "Mayo Clinic, Rochester MN, USA. Department of Radiation Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154480/Screenshot_5-12-2025_153516_32290571_isolation_zscaler_com.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154480/Screenshot_5-12-2025_153516_32290571_isolation_zscaler_com.jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154480"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ruth N Agwaze, BS 1 ; Aaron W Bogan, MA 2 ; Cecelia M Hidalgo, BA 1 ; Katelyn S Rourk, BS 1 ; Hannah Q Baratz, BS, MSMEd 1 ; Daniel G Eyassu, MD 1 ; Katharine A Price, MD 3 ; Eric J Moore, MD 1 ; Michelle A Neben Wittich, MD 4 ; Scott C Lester, MD 4 ; Jessica Wilson, MD, PhD 4 ; Daniel L Price 1 ; Kendall K Tasche, MD 1 ; Binav Baral, MBBS 3 ; Harry Fuentes Bayne, MD, MS 3 ; Patrick W McGarrah, MD 3 ; Daniel J Ma 4 ; Kathryn M Van Abel, MD 1 ; David M Routman, MD 4 ; Linda X Yin, MD 1",
        "Affiliations": "1 Mayo Clinic, Rochester MN, USA. Department of Otolaryngology, Head and Neck Surgery; 2 Mayo Clinic, Scottsdale, AZ. USA. Department of Quantitative Health Sciences, Division of Biostatistics; 3 Mayo Clinic, Rochester MN, USA. Division of Medical Oncology; 4 Mayo Clinic, Rochester MN, USA. Department of Radiation Oncology",
        "Introduction": "ECOG3311 randomized intermediate-risk patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC) to receive adjuvant radiation therapy de-escalated to 50Gy or standard of care (SOC) to 60 Gy after margin negative surgery, including patients with <1mm of ENE. This study compares oncologic outcomes of patients treated with de-escalated adjuvant radiation therapy to 30-36Gy with concurrent docetaxel (DART) to those treated with SOC among intermediate-and high risk-groups as stratified by criteria used in ECOG3311.",
        "Methods": "This is a retrospective cohort study of patients treated at a tertiary care center from 5/12/1995-1/21/2025 using ECOG3311 inclusion criteria: patients ≥18 years old with HPV+OPSCC, T1-T2, N0-N3 tumors (AJCC 7th edition) treated with transoral surgery and adjuvant radiation or chemoradiation. Patients with metastatic disease, matted lymph nodes and unknown extranodal extension (ENE) status were excluded. All patients treated on-and-off trial after curative-intent resection were stratified into intermediate and high-risk categories according to ECOG3311 criteria. Intermediate-risk patients had close margins (<3 mm), N0-N2 disease with ≤ 4 nodes with microscopic ENE (≤1 mm). High-risk patients had positive margins, >4 nodes, and/or macroscopic ENE (>1 mm). Progression-free survival (PFS) and overall survival (OS) were modeled using Kaplan Meier analysis.",
        "Results": "707 patients were included in this study: 296 (42%) intermediate-risk and 411 (58%) high-risk patients. Of the intermediate-risk patients, 43.2% received DART, and 56.8% received SOC. Of the high-risk patients, 33.3% received DART, and 66.7% received SOC. Median follow up was 6.0 years (95%CI 5.3-6.3). 2-year OS was significantly worse in the high-risk patients (96.7%, 95%CI 94.9%-98.6%) compared to intermediate-risk (98.0%, 95%CI 96.4-99.8%, p=0.011) patients. 2-year PFS was significantly worse in the high-risk patients (89.4%, 95%CI 86.4%-92.6%) compared to the intermediate-risk patients (94.8%, 95%CI 92.2-97.5%, p<0.001). No significant differences were seen in 2-year OS (98.1% vs. 98.0%) or PFS (95.7% vs. 94.2%) between patients treated with DART or SOC in intermediate-risk patients (see Figure). In high-risk patients, 2-year PFS for DART was not significantly different than SOC; 86.6% (95%CI 80.8%-92.8%) vs. 90.9% SOC (95%CI 87.4%-94.5%) respectively, and 2-year OS for DART (96.6%, 95%CI 93.4%-100%) was also similar to SOC (96.8%, 95%CI 94.6%-99.0%). Among patients with ≤ 4 nodes treated with DART, there were no differences in 2-year PFS for patients with microscopic ENE (94.4%, 95%CI 84.4%-100%) or macroscopic ENE (93.3%, 95%CI 88.2%-98.6%, p=0.96).",
        "Conclusion": "Intermediate-risk HPV(+)OPSCC patients as classified by ECOG3311 benefit from de-escalation of adjuvant radiation to 50Gy, but can also be safely de-escalated to 30-36 Gy using DART without compromise in oncologic outcomes. High-risk patients classified by ECOG3311 require further stratification, as the criteria used may be too stringent for de-escalation. The cutoff of 1mm of ENE did not meaningfully discriminate risk and warrants further consideration.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Analysis of Patients who Underwent De-Escalated Adjuvant Radiation Therapy (DART) or Standard of Care (SOC) Treatment as Stratified by Risk Categories on ECOG3311</span>. <u>Ruth N Agwaze, BS</u><sup>1</sup>; Aaron W Bogan, MA<sup>2</sup>; Cecelia M Hidalgo, BA<sup>1</sup>; Katelyn S Rourk, BS<sup>1</sup>; Hannah Q Baratz, BS, MSMEd<sup>1</sup>; Daniel G Eyassu, MD<sup>1</sup>; Katharine A Price, MD<sup>3</sup>; Eric J Moore, MD<sup>1</sup>; Michelle A Neben Wittich, MD<sup>4</sup>; Scott C Lester, MD<sup>4</sup>; Jessica Wilson, MD, PhD<sup>4</sup>; Daniel L Price<sup>1</sup>; Kendall K Tasche, MD<sup>1</sup>; Binav Baral, MBBS<sup>3</sup>; Harry Fuentes Bayne, MD, MS<sup>3</sup>; Patrick W McGarrah, MD<sup>3</sup>; Daniel J Ma<sup>4</sup>; Kathryn M Van Abel, MD<sup>1</sup>; David M Routman, MD<sup>4</sup>; Linda X Yin, MD<sup>1</sup>. <sup>1</sup>Mayo Clinic, Rochester MN, USA. Department of Otolaryngology, Head and Neck Surgery; <sup>2</sup>Mayo Clinic, Scottsdale, AZ. USA. Department of Quantitative Health Sciences, Division of Biostatistics; <sup>3</sup>Mayo Clinic, Rochester MN, USA. Division of Medical Oncology; <sup>4</sup>Mayo Clinic, Rochester MN, USA. Department of Radiation Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: ECOG3311 randomized intermediate-risk patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC) to receive adjuvant radiation therapy de-escalated to 50Gy or standard of care (SOC) to 60 Gy after margin negative surgery, including patients with <1mm of ENE. This study compares oncologic outcomes of patients treated with de-escalated adjuvant radiation therapy to 30-36Gy with concurrent docetaxel (DART) to those treated with SOC among intermediate-and high risk-groups as stratified by criteria used in ECOG3311. </p>\n\n<p><strong>Methods</strong>: This is a retrospective cohort study of patients treated at a tertiary care center from 5/12/1995-1/21/2025 using ECOG3311 inclusion criteria: patients ≥18 years old with HPV+OPSCC, T1-T2, N0-N3 tumors (AJCC 7th edition) treated with transoral surgery and adjuvant radiation or chemoradiation. Patients with metastatic disease, matted lymph nodes and unknown extranodal extension (ENE) status were excluded. All patients treated on-and-off trial after curative-intent resection were stratified into intermediate and high-risk categories according to ECOG3311 criteria. Intermediate-risk patients had close margins (<3 mm), N0-N2 disease with ≤ 4 nodes with microscopic ENE (≤1 mm). High-risk patients had positive margins, >4 nodes, and/or macroscopic ENE (>1 mm). Progression-free survival (PFS) and overall survival (OS) were modeled using Kaplan Meier analysis. </p>\n\n<p><strong>Results</strong>: 707 patients were included in this study: 296 (42%) intermediate-risk and 411 (58%) high-risk patients.  Of the intermediate-risk patients, 43.2% received DART, and 56.8% received SOC. Of the high-risk patients, 33.3% received DART, and 66.7% received SOC. Median follow up was 6.0 years (95%CI 5.3-6.3). 2-year OS was significantly worse in the high-risk patients (96.7%, 95%CI 94.9%-98.6%) compared to intermediate-risk (98.0%, 95%CI 96.4-99.8%, p=0.011) patients. 2-year PFS was significantly worse in the high-risk patients (89.4%, 95%CI 86.4%-92.6%) compared to the intermediate-risk patients (94.8%, 95%CI 92.2-97.5%, p<0.001). No significant differences were seen in 2-year OS (98.1% vs. 98.0%) or PFS (95.7% vs. 94.2%) between patients treated with DART or SOC in intermediate-risk patients (see Figure). In high-risk patients, 2-year PFS for DART was not significantly different than SOC; 86.6% (95%CI 80.8%-92.8%) vs. 90.9% SOC (95%CI 87.4%-94.5%) respectively, and 2-year OS for DART (96.6%, 95%CI 93.4%-100%) was also similar to SOC (96.8%, 95%CI 94.6%-99.0%). Among patients with ≤ 4 nodes treated with DART, there were no differences in 2-year PFS for patients with microscopic ENE (94.4%, 95%CI 84.4%-100%) or macroscopic ENE (93.3%, 95%CI 88.2%-98.6%, p=0.96).  </p>\n\n<p><strong>Conclusion</strong>: Intermediate-risk HPV(+)OPSCC patients as classified by ECOG3311 benefit from de-escalation of adjuvant radiation to 50Gy, but can also be safely de-escalated to 30-36 Gy using DART without compromise in oncologic outcomes. High-risk patients classified by ECOG3311 require further stratification, as the criteria used may be too stringent for de-escalation. The cutoff of 1mm of ENE did not meaningfully discriminate risk and warrants further consideration. </p>\n\n<p> </p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154480/Screenshot_5-12-2025_153516_32290571_isolation_zscaler_com.jpeg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154480--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S040",
      "content_id": "153279",
      "abstract_number": "S040",
      "poster_number": "",
      "title": "Patterns of recurrence after detection of surveillance circulating tumor HPV DNA in p16+ oropharyngeal cancer",
      "summary": "Thirty-seven patients with p16+ OPSCC met inclusion criteria, composed largely of tonsillar (46%) and tongue base (43%) primaries. The median time from completion of surgical or radiation therapy to first positive ctHPV-DNA was 9.3 months (IQR 5.4-19.0). Overall, 31/37 (84%) patients with a positive ctHPV-DNA result had recurrent or persistent disease (“true positives”) while 6/37 (16%) had no clinical...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153279",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rex H Lee, MD",
      "presenter": "Rex H Lee, MD",
      "authors": "Rex H Lee, MD ; Justin Fortino; Mary Jue Xu, MD; Katherine C Wai, MD; Ilya Likhterov, MD; Chase M Heaton, MD; Jonathan R George, MD; Ivan H El-Sayed, MD; Patrick K Ha, MD; Alain P Algazi, MD; Sue S Yom, MD, PhD; Jason W Chan, MD",
      "normalized_authors": [
        "Rex H Lee",
        "Justin Fortino",
        "Mary Jue Xu",
        "Katherine C Wai",
        "Ilya Likhterov",
        "Chase M Heaton",
        "Jonathan R George",
        "Ivan H El-Sayed",
        "Patrick K Ha",
        "Alain P Algazi",
        "Sue S Yom",
        "Jason W Chan"
      ],
      "affiliations": [
        "University of California, San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153279/Screenshot%202025-11-27%20at%201_50_24%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153279/Screenshot%202025-11-27%20at%201_50_24%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153279"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rex H Lee, MD ; Justin Fortino; Mary Jue Xu, MD; Katherine C Wai, MD; Ilya Likhterov, MD; Chase M Heaton, MD; Jonathan R George, MD; Ivan H El-Sayed, MD; Patrick K Ha, MD; Alain P Algazi, MD; Sue S Yom, MD, PhD; Jason W Chan, MD",
        "Affiliations": "University of California, San Francisco",
        "Background": "Circulating tumor HPV DNA (ctHPV-DNA) is increasingly utilized as a surveillance tool in p16+ oropharyngeal squamous cell carcinoma (OPSCC). However, data are limited correlating positive surveillance ctHPV-DNA values with patterns of recurrence and its prognostic value after salvage treatment of recurrences.",
        "Methods": "We retrospectively reviewed all patients with p16+ OPSCC treated with primary surgery or primary radiation/chemoradiation (RT/CRT) from 2021-2024 who had a positive ctHPV-DNA value at any time after treatment completion (Naveris, Inc. Waltham, MA). Clinical variables were compared with chi-square testing (categorical) and the Wilcoxon rank-sum test (continuous). Progression-free survival (PFS) was estimated using Kaplan-Meier methods and stratified by whether ctHPV-DNA normalized to undetectable levels after recurrence treatment versus remained persistently elevated.",
        "Results": "Thirty-seven patients with p16+ OPSCC met inclusion criteria, composed largely of tonsillar (46%) and tongue base (43%) primaries. The median time from completion of surgical or radiation therapy to first positive ctHPV-DNA was 9.3 months (IQR 5.4-19.0). Overall, 31/37 (84%) patients with a positive ctHPV-DNA result had recurrent or persistent disease (“true positives”) while 6/37 (16%) had no clinical progression and subsequent spontaneous ctHPV-DNA normalization (“false positives”). True-positive patients had higher initial ctHPV-DNA values than false-positive patients (median 51 vs. 13; p=0.047). Among recurrences, 21/31 (68%) were locoregional and 10/31 (32%) were distant metastases. No patients had both locoregional and distant recurrences. Median first positive ctHPV-DNA values were significantly higher for patients with isolated locoregional recurrence than isolated distant metastasis (159 vs. 18; p = 0.0017). Salvage therapies received by patients for recurrence included immunotherapy (65%), cytotoxic chemotherapy (58%), radiation (55%), and/or surgery (26%). Among the 31 true positives, 12 (39%) were without evidence of disease at last follow-up after salvage therapy (median of 24 months after first positive ctHPV-DNA), all of whom demonstrated ctHPV-DNA clearance to undetectable levels. Patients with persistently detectable ctHPV-DNA after recurrence treatment had worse PFS than those who cleared ctHPV-DNA (median 5.1 vs. 18 months; p < 0.0001). Subsequent distant metastatic progression was observed in 3/21 (14%) of patients with initially locoregional recurrences who underwent salvage treatment. One-year PFS from time of diagnosis of first clinical recurrence over subsequent follow-up is shown in Figure 1.",
        "Discussion": "Detection of ctHPV-DNA strongly correlated with recurrence, and absolute ctHPV-DNA levels were higher for true-positive recurrence. Isolated locoregional recurrences were observed to have substantially higher ctHPV-DNA levels than isolated distant metastases. Clearance of ctHPV-DNA after salvage therapy was associated with more favorable PFS. These findings support the prognostic value of detectable ctHPV-DNA in the post-treatment surveillance of p16+ OPSCC.",
        "Figure 1.": "One-year PFS stratified by detectable vs. undetectable ctHPV-DNA at most recent follow up (from time of diagnosis of first clinical recurrence).",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patterns of recurrence after detection of surveillance circulating tumor HPV DNA in p16+ oropharyngeal cancer</span>. <u>Rex H Lee, MD</u>; Justin Fortino; Mary Jue Xu, MD; Katherine C Wai, MD; Ilya Likhterov, MD; Chase M Heaton, MD; Jonathan R George, MD; Ivan H El-Sayed, MD; Patrick K Ha, MD; Alain P Algazi, MD; Sue S Yom, MD, PhD; Jason W Chan, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Circulating tumor HPV DNA (ctHPV-DNA) is increasingly utilized as a surveillance tool in p16+ oropharyngeal squamous cell carcinoma (OPSCC). However, data are limited correlating positive surveillance ctHPV-DNA values with patterns of recurrence and its prognostic value after salvage treatment of recurrences.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed all patients with p16+ OPSCC treated with primary surgery or primary radiation/chemoradiation (RT/CRT) from 2021-2024 who had a positive ctHPV-DNA value at any time after treatment completion (Naveris, Inc. Waltham, MA). Clinical variables were compared with chi-square testing (categorical) and the Wilcoxon rank-sum test (continuous). Progression-free survival (PFS) was estimated using Kaplan-Meier methods and stratified by whether ctHPV-DNA normalized to undetectable levels after recurrence treatment versus remained persistently elevated.</p>\n\n<p><strong>Results: </strong>Thirty-seven patients with p16+ OPSCC met inclusion criteria, composed largely of tonsillar (46%) and tongue base (43%) primaries. The median time from completion of surgical or radiation therapy to first positive ctHPV-DNA was 9.3 months (IQR 5.4-19.0). Overall, 31/37 (84%) patients with a positive ctHPV-DNA result had recurrent or persistent disease (“true positives”) while 6/37 (16%) had no clinical progression and subsequent spontaneous ctHPV-DNA normalization (“false positives”). True-positive patients had higher initial ctHPV-DNA values than false-positive patients (median 51 vs. 13; p=0.047). Among recurrences, 21/31 (68%) were locoregional and 10/31 (32%) were distant metastases. No patients had both locoregional and distant recurrences. Median first positive ctHPV-DNA values were significantly higher for patients with isolated locoregional recurrence than isolated distant metastasis (159 vs. 18; p = 0.0017). Salvage therapies received by patients for recurrence included immunotherapy (65%), cytotoxic chemotherapy (58%), radiation (55%), and/or surgery (26%). Among the 31 true positives, 12 (39%) were without evidence of disease at last follow-up after salvage therapy (median of 24 months after first positive ctHPV-DNA), all of whom demonstrated ctHPV-DNA clearance to undetectable levels. Patients with persistently detectable ctHPV-DNA after recurrence treatment had worse PFS than those who cleared ctHPV-DNA (median 5.1 vs. 18 months; p < 0.0001). Subsequent distant metastatic progression was observed in 3/21 (14%) of patients with initially locoregional recurrences who underwent salvage treatment. One-year PFS from time of diagnosis of first clinical recurrence over subsequent follow-up is shown in Figure 1. </p>\n\n<p><strong>Discussion: </strong>Detection of ctHPV-DNA strongly correlated with recurrence, and absolute ctHPV-DNA levels were higher for true-positive recurrence. Isolated locoregional recurrences were observed to have substantially higher ctHPV-DNA levels than isolated distant metastases. Clearance of ctHPV-DNA after salvage therapy was associated with more favorable PFS. These findings support the prognostic value of detectable ctHPV-DNA in the post-treatment surveillance of p16+ OPSCC.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153279/Screenshot%202025-11-27%20at%201_50_24%E2%80%AFPM.png' /></p>\n\n<p><strong>Figure 1.</strong> One-year PFS stratified by detectable vs. undetectable ctHPV-DNA at most recent follow up (from time of diagnosis of first clinical recurrence).</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153279--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S041",
      "content_id": "154081",
      "abstract_number": "S041",
      "poster_number": "",
      "title": "The Effect of Age on Complications After Transoral Robotic Surgery",
      "summary": "Elderly status was not associated with greater odds of postoperative tracheostomy or gastrostomy after TORS in the treatment of OPC. Elderly status had a higher risk of death after TORS, however, there was no increased odds of other complications.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154081",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Zachary A Valley, MD",
      "presenter": "Zachary A Valley, MD",
      "authors": "Zachary A Valley, MD ; Meghan Turner, MD",
      "normalized_authors": [
        "Zachary A Valley",
        "Meghan Turner"
      ],
      "affiliations": [
        "West Virginia University"
      ],
      "normalized_institutions": [
        "West Virginia University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 395,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Zachary A Valley, MD ; Meghan Turner, MD",
        "Affiliations": "West Virginia University",
        "Background": "Transoral robotic surgery (TORS) for the treatment of oropharyngeal cancer (OPC) was initially described in 2005. Since then, few studies have examined the impact of age on outcomes following TORS for OPC.",
        "Objective": "Our goal was to examine the effect of elderly status (age >70) on outcomes after TORS using a publicly available national database.",
        "Methods": "The TriNetX database was queried for all patients aged 18-90 undergoing TORS with a diagnosis of OPC. Primary outcomes were rates of tracheostomy, gastrostomy, and overall medical and surgical complications within 90 days after TORS. Secondary outcomes were rates of specific complications (death, stroke, myocardial infarction, pneumonia, and postoperative hemorrhage) within 90 days after TORS. Propensity score matching was used to adjust for preoperative comorbidities to evaluate the impact of elderly status on outcomes.",
        "Results": "Following initial database query, 1512 patients from 45 healthcare organizations were identified as having undergone TORS for the treatment of OPC. Among them, there were 847 patients aged 18-69 (mean age=60.8, SD=6.66) and 665 patients were aged >70 (mean age = 76.5, SD=5.22). Overall, postoperative tracheostomy was required in 33 (2.23%) patients while postoperative gastrostomy was required in 128 (8.72%) patients. Regarding complication rates, 82 (5.90%) patients incurred some type of postoperative complication. Death occurred within 90 days of TORS in 14 (0.93%) patients. Postoperative pneumonia occurred in 37 (2.57%) patients. Reoperation for control of hemorrhage after TORS was necessary in 22 (1.46%) patients. Fewer than 10 patients had myocardial infarction or stroke.",
        "Abstract": "One-to-one propensity score matching yielded 616 matched pairs comparing the age 18–69 cohort with the age >70 cohort. Age >70 was not associated with increased odds of postoperative tracheostomy (OR=1.061, 95% CI=0.494-2.276) or gastrostomy (OR=0.94, 95% CI=0.628-1.405). Age >70 was associated with a significantly increased risk of death (RD=1.78%, 95% CI=0.741-2.836, p=0.0009). Age >70 was not associated with increased odds of experiencing any complication overall (OR=1.158, 95% CI=0.715-1.875) or other individual complication rates. View in Agenda and Add to Schedule",
        "Conclusion": "Elderly status was not associated with greater odds of postoperative tracheostomy or gastrostomy after TORS in the treatment of OPC. Elderly status had a higher risk of death after TORS, however, there was no increased odds of other complications."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Effect of Age on Complications After Transoral Robotic Surgery</span>. <u>Zachary A Valley, MD</u>; Meghan Turner, MD. West Virginia University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Transoral robotic surgery (TORS) for the treatment of oropharyngeal cancer (OPC) was initially described in 2005. Since then, few studies have examined the impact of age on outcomes following TORS for OPC. </p>\n\n<p><strong>Objective</strong>: Our goal was to examine the effect of elderly status (age >70) on outcomes after TORS using a publicly available national database. </p>\n\n<p><strong>Methods</strong>: The TriNetX database was queried for all patients aged 18-90 undergoing TORS with a diagnosis of OPC. Primary outcomes were rates of tracheostomy, gastrostomy, and overall medical and surgical complications within 90 days after TORS. Secondary outcomes were rates of specific complications (death, stroke, myocardial infarction, pneumonia, and postoperative hemorrhage) within 90 days after TORS. Propensity score matching was used to adjust for preoperative comorbidities to evaluate the impact of elderly status on outcomes. </p>\n\n<p><strong>Results</strong>: Following initial database query, 1512 patients from 45 healthcare organizations were identified as having undergone TORS for the treatment of OPC. Among them, there were 847 patients aged 18-69 (mean age=60.8, SD=6.66) and 665 patients were aged >70 (mean age = 76.5, SD=5.22). Overall, postoperative tracheostomy was required in 33 (2.23%) patients while postoperative gastrostomy was required in 128 (8.72%) patients. Regarding complication rates, 82 (5.90%) patients incurred some type of postoperative complication. Death occurred within 90 days of TORS in 14 (0.93%) patients. Postoperative pneumonia occurred in 37 (2.57%) patients. Reoperation for control of hemorrhage after TORS was necessary in 22 (1.46%) patients. Fewer than 10 patients had myocardial infarction or stroke.</p>\n\n<p>One-to-one propensity score matching yielded 616 matched pairs comparing the age 18–69 cohort with the age >70 cohort. Age >70 was not associated with increased odds of postoperative tracheostomy (OR=1.061, 95% CI=0.494-2.276) or gastrostomy (OR=0.94, 95% CI=0.628-1.405). Age >70 was associated with a significantly increased risk of death (RD=1.78%, 95% CI=0.741-2.836, p=0.0009). Age >70 was not associated with increased odds of experiencing any complication overall (OR=1.158, 95% CI=0.715-1.875) or other individual complication rates. </p>\n\n<p><strong>Conclusion</strong>: Elderly status was not associated with greater odds of postoperative tracheostomy or gastrostomy after TORS in the treatment of OPC. Elderly status had a higher risk of death after TORS, however, there was no increased odds of other complications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154081--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S042",
      "content_id": "153456",
      "abstract_number": "S042",
      "poster_number": "",
      "title": "Treatment Deintensification with TORS Alone in Single Node Positive HPV-Positive Oropharyngeal Cancer: Local Recurrence and Survival Analysis",
      "summary": "This retrospective study demonstrates that HPV-positive OPSCC continues to have excellent survival and locoregional control. The TORS alone group demonstrated low recurrence rate of 2.6%, all in the retropharyngeal nodes, despite 64.0% of patients demonstrating high risk factors generally associated with adjuvant therapy (LN > 3.0 cm, ENE, or T3 disease). These results support the safety and efficacy of surgery...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153456",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Uzair Khan, BS",
      "presenter": "Uzair Khan, BS",
      "authors": "Ryan Anderson, MD 1 ; Uzair Khan, BS 1 ; Peyton Robinson, MD 2 ; Deborah X Xie, MD 3 ; David A Campbell, MD 1 ; Jessica A Yesensky, MD 1 ; Avinash V Mantravadi, MD 1 ; Janice L Farlow, MD, PHD 1 ; Michael G Moore, MD 1 ; Michael W Sim, MD 1",
      "normalized_authors": [
        "Ryan Anderson",
        "Uzair Khan",
        "Peyton Robinson",
        "Deborah X Xie",
        "David A Campbell",
        "Jessica A Yesensky",
        "Avinash V Mantravadi",
        "Janice L Farlow",
        "Michael G Moore",
        "Michael W Sim"
      ],
      "affiliations": [
        "Indiana University/IU Health",
        "University of Louisville",
        "Barrow Neurological Institute"
      ],
      "normalized_institutions": [
        "Indiana University/IU Health",
        "University of Louisville",
        "Barrow Neurological Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 414,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryan Anderson, MD 1 ; Uzair Khan, BS 1 ; Peyton Robinson, MD 2 ; Deborah X Xie, MD 3 ; David A Campbell, MD 1 ; Jessica A Yesensky, MD 1 ; Avinash V Mantravadi, MD 1 ; Janice L Farlow, MD, PHD 1 ; Michael G Moore, MD 1 ; Michael W Sim, MD 1",
        "Affiliations": "1 Indiana University/IU Health; 2 University of Louisville; 3 Barrow Neurological Institute",
        "Introduction": "Surgically treated patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) can undergo transoral robotic surgery (TORS) alone or adjuvant radiation/chemoradiation. The decision to undergo TORS alone is influenced by several factors, including tumor staging, extra nodal extension (ENE), positive margins, or lymph node metastasis >3 cm, as well as patient decision making. With the known improvement in overall survival of HPV-positive OPSCC, it is imperative to identify prognostic factors for treatment deintensification. This study focuses on recurrence rates and overall survival in patients with single node metastasis in HPV-positive OPSCC.",
        "Methods": "Single-institution, retrospective study conducted from July 2012 – October 2024, including 105 patients, newly diagnosed with HPV-positive OPSCC with single lymph node (LN) metastasis. Demographic data, surgical and adjuvant treatment details, feeding tube status, and pathology results were collected via chart review. Patients were followed for a minimum of 1 year after TORS to determine incidence of recurrence and overall survival (OS).",
        "Results": "Among the 105 patients with single node positive HPV-positive OPSCC, 85% were males, and mean age was 59.74 (range 34 – 85). Primary sites were tongue base (35.2%), tonsil (57.1%), and unknown (7.6%). Most primary tumors were ≤ T2 (98%), and the remaining were T3 (2%). 75 patients underwent TORS alone (71.4%), 30 underwent TORS with adjuvant therapy (28.6%, 26 radiation, 4 chemoradiation), and none for primary chemoradiation (0%). There were no local or distant recurrences in either treatment group, no regional recurrence in the adjuvant treatment group, and 2 regional recurrences (2.6%) in the TORS alone group, both in a retropharyngeal node, recurring at 8.0 months averaged. Both cases were successfully salvaged, with TORS retropharyngeal dissection in one and radiation therapy in the other. OS was 100% at 2 years for both groups. In the TORS alone group, the mean single LN size was 3.38 cm, with 61.3% of LN size > 3.0 cm, and ENE was present in 4% of LN. Five patients (4.76%) had a post-operative bleed requiring operative control of hemorrhage.",
        "Conclusion": "This retrospective study demonstrates that HPV-positive OPSCC continues to have excellent survival and locoregional control. The TORS alone group demonstrated low recurrence rate of 2.6%, all in the retropharyngeal nodes, despite 64.0% of patients demonstrating high risk factors generally associated with adjuvant therapy (LN > 3.0 cm, ENE, or T3 disease). These results support the safety and efficacy of surgery alone even in patients with LN size >3 cm.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment Deintensification with TORS Alone in Single Node Positive HPV-Positive Oropharyngeal Cancer: Local Recurrence and Survival Analysis</span>. Ryan Anderson, MD<sup>1</sup>; <u>Uzair Khan, BS</u><sup>1</sup>; Peyton Robinson, MD<sup>2</sup>; Deborah X Xie, MD<sup>3</sup>; David A Campbell, MD<sup>1</sup>; Jessica A Yesensky, MD<sup>1</sup>; Avinash V Mantravadi, MD<sup>1</sup>; Janice L Farlow, MD, PHD<sup>1</sup>; Michael G Moore, MD<sup>1</sup>; Michael W Sim, MD<sup>1</sup>. <sup>1</sup>Indiana University/IU Health; <sup>2</sup>University of Louisville; <sup>3</sup>Barrow Neurological Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Surgically treated patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) can undergo transoral robotic surgery (TORS) alone or adjuvant radiation/chemoradiation. The decision to undergo TORS alone is influenced by several factors, including tumor staging, extra nodal extension (ENE), positive margins, or lymph node metastasis >3 cm, as well as patient decision making. With the known improvement in overall survival of HPV-positive OPSCC, it is imperative to identify prognostic factors for treatment deintensification. This study focuses on recurrence rates and overall survival in patients with single node metastasis in HPV-positive OPSCC.</p>\n\n<p><strong>Methods</strong>: Single-institution, retrospective study conducted from July 2012 – October 2024, including 105 patients, newly diagnosed with HPV-positive OPSCC with single lymph node (LN) metastasis. Demographic data, surgical and adjuvant treatment details, feeding tube status, and pathology results were collected via chart review. Patients were followed for a minimum of 1 year after TORS to determine incidence of recurrence and overall survival (OS).</p>\n\n<p><strong>Results</strong>: Among the 105 patients with single node positive HPV-positive OPSCC, 85% were males, and mean age was 59.74 (range 34 – 85). Primary sites were tongue base (35.2%), tonsil (57.1%), and unknown (7.6%). Most primary tumors were ≤ T2 (98%), and the remaining were T3 (2%). 75 patients underwent TORS alone (71.4%), 30 underwent TORS with adjuvant therapy (28.6%, 26 radiation, 4 chemoradiation), and none for primary chemoradiation (0%). There were no local or distant recurrences in either treatment group, no regional recurrence in the adjuvant treatment group, and 2 regional recurrences (2.6%) in the TORS alone group, both in a retropharyngeal node, recurring at 8.0 months averaged. Both cases were successfully salvaged, with TORS retropharyngeal dissection in one and radiation therapy in the other. OS was 100% at 2 years for both groups. In the TORS alone group, the mean single LN size was 3.38 cm, with 61.3% of LN size > 3.0 cm, and ENE was present in 4% of LN. Five patients (4.76%) had a post-operative bleed requiring operative control of hemorrhage.</p>\n\n<p><strong>Conclusion</strong>: This retrospective study demonstrates that HPV-positive OPSCC continues to have excellent survival and locoregional control. The TORS alone group demonstrated low recurrence rate of 2.6%, all in the retropharyngeal nodes, despite 64.0% of patients demonstrating high risk factors generally associated with adjuvant therapy (LN > 3.0 cm, ENE, or T3 disease). These results support the safety and efficacy of surgery alone even in patients with LN size >3 cm.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153456--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S043",
      "content_id": "151728",
      "abstract_number": "S043",
      "poster_number": "",
      "title": "Evolving Trends in Definitive Surgical Management of Oropharyngeal Squamous Cell Carcinoma: A National Cancer Database Analysis",
      "summary": "In the largest evaluation to date, definitive surgery was more often employed in younger, HPV-positive, and early-stage OPSCC patients, particularly at academic centers. Surgical utilization has fluctuated substantially over the past two decades, reflecting technological innovation and evolving oncologic paradigms. The recent sharp decline in surgery after 2019 may reflect multifactorial influences including the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151728",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vanessa Helou, MD",
      "presenter": "Vanessa Helou, MD",
      "authors": "Vanessa Helou, MD 1 ; Katie M Carlson, MPH 2 ; Soumik Purkayastha, PhD, MStat 3 ; Angela L Mazul, PhD, MPH 2 ; Kevin J Contrera, MD, MPH 1 ; Jose P Zevallos, MD, MPH 1",
      "normalized_authors": [
        "Vanessa Helou",
        "Katie M Carlson",
        "Soumik Purkayastha, MStat",
        "Angela L Mazul",
        "Kevin J Contrera",
        "Jose P Zevallos"
      ],
      "affiliations": [
        "Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA",
        "Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA",
        "Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh PA, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA",
        "Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA",
        "Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh PA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151728/Figure%201(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151728/Figure%201(1).png",
          "alt": "Annual Percent Change (APC) in Definitive Surgery for Oropharyngeal Squamous Cell Carcinoma, 2004–2022.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151728"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions",
        "Figure 1."
      ],
      "sections": {
        "Authors": "Vanessa Helou, MD 1 ; Katie M Carlson, MPH 2 ; Soumik Purkayastha, PhD, MStat 3 ; Angela L Mazul, PhD, MPH 2 ; Kevin J Contrera, MD, MPH 1 ; Jose P Zevallos, MD, MPH 1",
        "Affiliations": "1 Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 2 Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; 3 Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh PA, USA",
        "Background": "The optimal treatment strategy for oropharyngeal squamous cell carcinoma (OPSCC) continues to evolve. Standard options for definitive treatment are radiotherapy or surgery. Transoral robotic surgery (TORS) was approved by the FDA in 2009, but contemporary population-level trends in the use of definitive surgery for OPSCC are unexplored. We aimed to define national trends in definitive surgical management of OPSCC.",
        "Methods": "We conducted a retrospective cohort study using the National Cancer Database (NCDB) to identify patients diagnosed with OPSCC between 2004 and 2022. Patients were stratified by receipt of definitive surgery versus nonsurgical treatment. Baseline demographic, clinical, tumor, and treatment characteristics were compared using χ² and t-tests. Temporal trends in surgical management were evaluated using Joinpoint regression to estimate annual percentage changes (APC) across distinct time intervals.",
        "Results": "Among 236,655 patients with OPSCC, 65,876 (27.8%) received definitive surgery and 170,779 (72.2%) did not. Patients undergoing surgery were younger (mean age 59.5 vs. 62.0 years, P<0.001), more often White (91.8% vs. 87.9%, P<0.001). They were also more frequently treated at academic centers (51.3% vs. 40.4%, P<0.001). Surgically treated patients more often presented with early-stage disease (stage I: 27.3% vs. 13.1%, P<0.001) and lower T (T1–T2: 39.3% vs. 28.8%, P<0.001) and N categories (N0–N1: 52.2% vs. 39.2%, P<0.001). Among patients diagnosed from 2013 to 2022, HPV positivity was more common among surgical patients (69.9% vs. 63.3%, P<0.001). Approximately half of surgical patients still received multimodality therapy, although adjuvant systemic therapy (44.0% vs. 73.9%, P<0.001) and radiation (65.8% vs. 83.0%, P<0.001) were less frequently used compared with patients treated non-surgically.",
        "Abstract": "Joinpoint analysis demonstrated four distinct timeframes of surgical utilization. From 2004 to 2009, surgical rates declined modestly (APC: –2.08%/year, P=0.064). Between 2009 and 2012, coinciding with FDA approval of TORS, rates rebounded significantly (APC: +3.36%/year, P=0.012), peaking at just over 30% by 2013–2014. Surgical use decreased slightly from 2012 to 2019 (APC –1.29%/year, P=0.015) before undergoing a marked decline from 2019 to 2022 (APC –4.94%/year, P<0.001), with surgical treatment falling below 25% in 2022. View in Agenda and Add to Schedule",
        "Conclusions": "In the largest evaluation to date, definitive surgery was more often employed in younger, HPV-positive, and early-stage OPSCC patients, particularly at academic centers. Surgical utilization has fluctuated substantially over the past two decades, reflecting technological innovation and evolving oncologic paradigms. The recent sharp decline in surgery after 2019 may reflect multifactorial influences including the impact of the COVID-19 pandemic on elective procedures, and increasing adoption of nonsurgical deintensification strategies for HPV-positive disease. Further investigation is warranted to delineate the relative contributions of these factors and assess their implications for oncologic and functional outcomes.",
        "Figure 1.": "Annual Percent Change (APC) in Definitive Surgery for Oropharyngeal Squamous Cell Carcinoma, 2004–2022."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evolving Trends in Definitive Surgical Management of Oropharyngeal Squamous Cell Carcinoma: A National Cancer Database Analysis</span>. <u>Vanessa Helou, MD</u><sup>1</sup>; Katie M Carlson, MPH<sup>2</sup>; Soumik Purkayastha, PhD, MStat<sup>3</sup>; Angela L Mazul, PhD, MPH<sup>2</sup>; Kevin J Contrera, MD, MPH<sup>1</sup>; Jose P Zevallos, MD, MPH<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; <sup>2</sup>Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; <sup>3</sup>Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The optimal treatment strategy for oropharyngeal squamous cell carcinoma (OPSCC) continues to evolve. Standard options for definitive treatment are radiotherapy or surgery. Transoral robotic surgery (TORS) was approved by the FDA in 2009, but contemporary population-level trends in the use of definitive surgery for OPSCC are unexplored. We aimed to define national trends in definitive surgical management of OPSCC.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study using the National Cancer Database (NCDB) to identify patients diagnosed with OPSCC between 2004 and 2022. Patients were stratified by receipt of definitive surgery versus nonsurgical treatment. Baseline demographic, clinical, tumor, and treatment characteristics were compared using χ² and t-tests. Temporal trends in surgical management were evaluated using Joinpoint regression to estimate annual percentage changes (APC) across distinct time intervals.</p>\n\n<p><strong>Results: </strong>Among 236,655 patients with OPSCC, 65,876 (27.8%) received definitive surgery and 170,779 (72.2%) did not. Patients undergoing surgery were younger (mean age 59.5 vs. 62.0 years, P<0.001), more often White (91.8% vs. 87.9%, P<0.001). They were also more frequently treated at academic centers (51.3% vs. 40.4%, P<0.001). Surgically treated patients more often presented with early-stage disease (stage I: 27.3% vs. 13.1%, P<0.001) and lower T (T1–T2: 39.3% vs. 28.8%, P<0.001) and N categories (N0–N1: 52.2% vs. 39.2%, P<0.001). Among patients diagnosed from 2013 to 2022, HPV positivity was more common among surgical patients (69.9% vs. 63.3%, P<0.001). Approximately half of surgical patients still received multimodality therapy, although adjuvant systemic therapy (44.0% vs. 73.9%, P<0.001) and radiation (65.8% vs. 83.0%, P<0.001) were less frequently used compared with patients treated non-surgically.</p>\n\n<p>Joinpoint analysis demonstrated four distinct timeframes of surgical utilization. From 2004 to 2009, surgical rates declined modestly (APC: –2.08%/year, P=0.064). Between 2009 and 2012, coinciding with FDA approval of TORS, rates rebounded significantly (APC: +3.36%/year, P=0.012), peaking at just over 30% by 2013–2014. Surgical use decreased slightly from 2012 to 2019 (APC –1.29%/year, P=0.015) before undergoing a marked decline from 2019 to 2022 (APC –4.94%/year, P<0.001), with surgical treatment falling below 25% in 2022.</p>\n\n<p><strong>Conclusions: </strong>In the largest evaluation to date, definitive surgery was more often employed in younger, HPV-positive, and early-stage OPSCC patients, particularly at academic centers. Surgical utilization has fluctuated substantially over the past two decades, reflecting technological innovation and evolving oncologic paradigms. The recent sharp decline in surgery after 2019 may reflect multifactorial influences including the impact of the COVID-19 pandemic on elective procedures, and increasing adoption of nonsurgical deintensification strategies for HPV-positive disease. Further investigation is warranted to delineate the relative contributions of these factors and assess their implications for oncologic and functional outcomes.</p>\n\n<p><img alt='Annual Percent Change (APC) in Definitive Surgery for Oropharyngeal Squamous Cell Carcinoma, 2004–2022.' src='https://www.submitmyabstract.com/abs/images/151728/Figure%201(1).png' /></p>\n\n<p><strong>Figure 1. </strong>Annual Percent Change (APC) in Definitive Surgery for Oropharyngeal Squamous Cell Carcinoma, 2004–2022.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151728--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S044",
      "content_id": "154112",
      "abstract_number": "S044",
      "poster_number": "",
      "title": "Patterns of Treatment Failure for Conventional Radiation Protocol for HPV+OPSCC – Is De-escalation Adjuvant Therapy a Better Approach?",
      "summary": "The most prominent pattern of failure after TORS + neck dissection was regional and distant recurrence. Our study provides long-term, five-year longitudinal surveillance data suggesting that carefully selected early-stage HPV+OPC patients could benefit from de-escalated adjuvant radiation following upfront TORS+ND, achieving excellent survival outcomes and locoregional control.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154112",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hlu Vang",
      "presenter": "Hlu Vang",
      "authors": "Po Ling Catherine Chan; Hlu Vang ; Nikita Bedi; Michaele Corbisiero, MD; F. Christopher Holsinger, Professor Head and Neck Surgery",
      "normalized_authors": [
        "Po Ling Catherine Chan",
        "Hlu Vang",
        "Nikita Bedi",
        "Michaele Corbisiero",
        "F. Christopher Holsinger, Head and Neck Surgery"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 484,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Po Ling Catherine Chan; Hlu Vang ; Nikita Bedi; Michaele Corbisiero, MD; F. Christopher Holsinger, Professor Head and Neck Surgery",
        "Affiliations": "Stanford University",
        "Introduction": "The long-term results of ECOG3311 were recently published, demonstrating favorable oncologic outcomes of patients with human papillomavirus-mediated oropharyngeal squamous cell carcinoma (HPV+OPC) treated with frontline transoral robotic surgery and neck dissection (TORS+ND). From this study, TORS+ND followed by 50Gy was non-inferior compared to 60Gy. Yet at a recent AHNS training event, a survey showed that only 29% of multidisciplinary teams were using 50Gy. Radiation oncologists cite concerns about delayed locoregional recurrence and/or unexpected patterns of failure. Thus, questions remain about implementing the 3311 approach. Here we analyze patterns of failure from a single-institutional cohort of patients treated with TORS+ND comparing standard versus de-escalated adjuvant therapy.",
        "Methods": "Newly diagnosed, previously untreated early-stage OPC (T1-2, N0-N2b, AJCC 7th edition) were consecutively accrued into a database. Inclusion criteria included pathologically confirmed HPV-mediated disease by in situ hybridization (ISH) and p16 positivity by immunohistochemistry (IHC), with postoperative adjuvant radiation doses of 0, 50, 60, or 66 Gy.",
        "Results": "The retrospective cohort included 53 patients with a mean age of 58.9 years; 96.2% (51/53) were male. De-escalated adjuvant treatment was administered to 49.1% (26/53) of patients: 39.6% (21/53) received TORS+ND alone (0 Gy) and 9.4% (5/53) received 50 Gy. Standard postoperative radiation therapy was administered to 50.9% (27/53): 45.3% (24/53) received 60 Gy and 5.7% (3/53) received 66 Gy. No patients developed local recurrence. Two regional recurrences developed. Ipsilateral recurrence in level Va/IIb developed in one 45 year-old patient was referred for post-operative radiation therapy. Radiation oncology deferred treatment initially based on concerns regarding age-related late side effects. Another patient developed a contralateral regional recurrence 6.5 yrs after TORS+ND+60Gy of ipsilateral neck treatment. A single patient (1.9%; 1/53) developed distant metastasis and died from his disease. This patient had extranodal extension in two lymph nodes developed distant metastasis to lung and brain; he had received 66 Gy with weekly cisplatin. Overall five-year survival was 98.1% (52/53), and five-year disease-free survival was 94.3% (50/53).",
        "Discussion": "The favorable five-year survival outcomes suggest that carefully selected early-stage HPV+OPC patients may achieve excellent oncologic control with reduced or even omitted radiation, thereby minimizing long-term toxicity while preserving survival benefits. In this cohort where 49% of patients received de-escalated post-op radiation therapy, there were no local recurrences. Two regional recurrences were successfully salvaged with standard treatment; without further recurrence great than 2 yrs additional follow-up. The only patient in this cohort who died was the single patient with distant disease.",
        "Conclusion": "The most prominent pattern of failure after TORS + neck dissection was regional and distant recurrence. Our study provides long-term, five-year longitudinal surveillance data suggesting that carefully selected early-stage HPV+OPC patients could benefit from de-escalated adjuvant radiation following upfront TORS+ND, achieving excellent survival outcomes and locoregional control.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patterns of Treatment Failure for Conventional Radiation Protocol for HPV+OPSCC – Is De-escalation Adjuvant Therapy a Better Approach?</span>. Po Ling Catherine Chan; <u>Hlu Vang</u>; Nikita Bedi; Michaele Corbisiero, MD; F. Christopher Holsinger, Professor Head and Neck Surgery. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The long-term results of ECOG3311 were recently published, demonstrating favorable oncologic outcomes of patients with human papillomavirus-mediated oropharyngeal squamous cell carcinoma (HPV+OPC) treated with frontline transoral robotic surgery and neck dissection (TORS+ND). From this study, TORS+ND followed by 50Gy was non-inferior compared to 60Gy. Yet at a recent AHNS training event, a survey showed that only 29% of multidisciplinary teams were using 50Gy. Radiation oncologists cite concerns about delayed locoregional recurrence and/or unexpected patterns of failure. Thus, questions remain about implementing the 3311 approach. Here we analyze patterns of failure from a single-institutional cohort of patients treated with TORS+ND comparing standard versus de-escalated adjuvant therapy.</p>\n\n<p><strong>Methods:</strong> Newly diagnosed, previously untreated early-stage OPC (T1-2, N0-N2b, AJCC 7th edition) were consecutively accrued into a database. Inclusion criteria included pathologically confirmed HPV-mediated disease by in situ hybridization (ISH) and p16 positivity by immunohistochemistry (IHC), with postoperative adjuvant radiation doses of 0, 50, 60, or 66 Gy.</p>\n\n<p><strong>Results: </strong>The retrospective cohort included 53 patients with a mean age of 58.9 years; 96.2% (51/53) were male. De-escalated adjuvant treatment was administered to 49.1% (26/53) of patients: 39.6% (21/53) received TORS+ND alone (0 Gy) and 9.4% (5/53) received 50 Gy. Standard postoperative radiation therapy was administered to 50.9% (27/53): 45.3% (24/53) received 60 Gy and 5.7% (3/53) received 66 Gy. No patients developed local recurrence. Two regional recurrences developed. Ipsilateral recurrence in level Va/IIb developed in one 45 year-old patient was referred for post-operative radiation therapy. Radiation oncology deferred treatment initially based on concerns regarding age-related late side effects. Another patient developed a contralateral regional recurrence 6.5 yrs after TORS+ND+60Gy of ipsilateral neck treatment. A single patient (1.9%; 1/53) developed distant metastasis and died from his disease. This patient had extranodal extension in two lymph nodes developed distant metastasis to lung and brain; he had received 66 Gy with weekly cisplatin. Overall five-year survival was 98.1% (52/53), and five-year disease-free survival was 94.3% (50/53).</p>\n\n<p><strong>Discussion: </strong>The favorable five-year survival outcomes suggest that carefully selected early-stage HPV+OPC patients may achieve excellent oncologic control with reduced or even omitted radiation, thereby minimizing long-term toxicity while preserving survival benefits. In this cohort where 49% of patients received de-escalated post-op radiation therapy, there were no local recurrences. Two regional recurrences were successfully salvaged with standard treatment; without further recurrence great than 2 yrs additional follow-up. The only patient in this cohort who died was the single patient with distant disease.</p>\n\n<p><strong>Conclusion: </strong>The most prominent pattern of failure after TORS + neck dissection was regional and distant recurrence. Our study provides long-term, five-year longitudinal surveillance data suggesting that carefully selected early-stage HPV+OPC patients could benefit from de-escalated adjuvant radiation following upfront TORS+ND, achieving excellent survival outcomes and locoregional control.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154112--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S045",
      "content_id": "154275",
      "abstract_number": "S045",
      "poster_number": "",
      "title": "A Highly Validated RNA Biomarker for Radiation Sensitivity in HPV+ HNSCC",
      "summary": "We have demonstrated that our NF-kB related RNA biomarker is consistently prognostic in 8 independent cohorts of patients treated with primary chemoradiation or surgery with adjuvant radiation. Furthermore, we demonstrate the transferrable thresholding can be derived which maintains its prognostic value in external cohorts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154275",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Travis P Schrank, MD, PhD",
      "presenter": "Travis P Schrank, MD, PhD",
      "authors": "Travis P Schrank, MD, PhD 1 ; Kathleen Bartemes, PhD 2 ; Loris De Cecco, PhD 3 ; Katie Van Able, MD 2 ; David Routman, MD 2 ; Basu Devraj, MD, PhD 4 ; Natlia Isaeva, PhD 1 ; Wendell G Yarbrough, MD 1",
      "normalized_authors": [
        "Travis P Schrank",
        "Kathleen Bartemes",
        "Loris De Cecco",
        "Katie Van Able",
        "David Routman",
        "Basu Devraj",
        "Natlia Isaeva",
        "Wendell G Yarbrough"
      ],
      "affiliations": [
        "University of North Carolina",
        "Mayo Clinic",
        "Fondazione IRCCS Istituto Nazionale Dei Tumori",
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of North Carolina",
        "Mayo Clinic",
        "Fondazione IRCCS Istituto Nazionale Dei Tumori",
        "University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 296,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Travis P Schrank, MD, PhD 1 ; Kathleen Bartemes, PhD 2 ; Loris De Cecco, PhD 3 ; Katie Van Able, MD 2 ; David Routman, MD 2 ; Basu Devraj, MD, PhD 4 ; Natlia Isaeva, PhD 1 ; Wendell G Yarbrough, MD 1",
        "Affiliations": "1 University of North Carolina; 2 Mayo Clinic; 3 Fondazione IRCCS Istituto Nazionale Dei Tumori; 4 University of Pennsylvania",
        "Introduction": "Our field has been aggressively searching for strategies to optimize treatment intensity for HPV+ HNSCC patient. Although effective, the high-dose radiation presently used is toxic and frequently leads to debilitating long-term complications such as feeding tube dependance, tracheostomy tube dependence and necrosis of the mandible.",
        "Abstract": "We have found that activation the NF-kB transcription factor (often related to mutations in TRAF3 or CYLD), results in an RNA expression signal which defines a highly distinct molecular subtype of HPV+ HNSCC (HPV associated head and neck squamous cell carcinoma). Patients with the NF-kB active subtype have a dramatically improved response to radiation therapy. These prognostic tumor subtypes are easily identified by using an RNA expression biomarker (gene set) which we have developed. View in Agenda and Add to Schedule",
        "Methods": "We present a large retrospective analysis of our RNA based biomarker in 8 independent cohorts totaling over 700 cases of HPV+ HNSCC. We additionally validated our biomarker using multiple technical approaches: RNA sequencing, RNA expression microarray, and nCounter technology.",
        "Results": "We have demonstrated that our NF-kB related RNA biomarker is consistently prognostic in 8 independent cohorts of patients treated with primary chemoradiation or surgery with adjuvant radiation. Furthermore, we demonstrate the transferrable thresholding can be derived which maintains its prognostic value in external cohorts.",
        "Discussion": "Recent national trials (NRG005) have found that using stage and smoking history alone to assign patients to a decreased radiation dose, leads to increased rates of disease recurrence. Also, identification of patients at high-risk of failing treatment with chemoradiation, may highlight patients that would benefit from upfront surgery or other emerging treatments. Therefore, implementation of this biomarker has the potential to clarify two key treatment dilemmas facing clinicians for patients with HPV+ HNSCC: 1) selection of primary treatment modality (surgery vs. radiation), and 2) determining radiation dose."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Highly Validated RNA Biomarker for Radiation Sensitivity in HPV+ HNSCC</span>. <u>Travis P Schrank, MD, PhD</u><sup>1</sup>; Kathleen Bartemes, PhD<sup>2</sup>; Loris De Cecco, PhD<sup>3</sup>; Katie Van Able, MD<sup>2</sup>; David Routman, MD<sup>2</sup>; Basu Devraj, MD, PhD<sup>4</sup>; Natlia Isaeva, PhD<sup>1</sup>; Wendell G Yarbrough, MD<sup>1</sup>. <sup>1</sup>University of North Carolina; <sup>2</sup>Mayo Clinic; <sup>3</sup>Fondazione IRCCS Istituto Nazionale Dei Tumori; <sup>4</sup>University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Our field has been aggressively searching for strategies to optimize treatment intensity for HPV+ HNSCC patient. Although effective, the high-dose radiation presently used is toxic and frequently leads to debilitating long-term complications such as feeding tube dependance, tracheostomy tube dependence and necrosis of the mandible.</p>\n\n<p>We have found that activation the NF-kB transcription factor (often related to mutations in TRAF3 or CYLD), results in an RNA expression signal which defines a highly distinct molecular subtype of HPV+ HNSCC (HPV associated head and neck squamous cell carcinoma). Patients with the NF-kB active subtype have a dramatically improved response to radiation therapy. These prognostic tumor subtypes are easily identified by using an RNA expression biomarker (gene set) which we have developed.</p>\n\n<p><strong>Methods: </strong>We present a large retrospective analysis of our RNA based biomarker in 8 independent cohorts totaling over 700 cases of HPV+ HNSCC. We additionally validated our biomarker using multiple technical approaches: RNA sequencing, RNA expression microarray, and nCounter technology.</p>\n\n<p><strong>Results: </strong>We have demonstrated that our NF-kB related RNA biomarker is consistently prognostic in 8 independent cohorts of patients treated with primary chemoradiation or surgery with adjuvant radiation. Furthermore, we demonstrate the transferrable thresholding can be derived which maintains its prognostic value in external cohorts.</p>\n\n<p><strong>Discussion: </strong>Recent national trials (NRG005) have found that using stage and smoking history alone to assign patients to a decreased radiation dose, leads to increased rates of disease recurrence. Also, identification of patients at high-risk of failing treatment with chemoradiation, may highlight patients that would benefit from upfront surgery or other emerging treatments. Therefore, implementation of this biomarker has the potential to clarify two key treatment dilemmas facing clinicians for patients with HPV+ HNSCC: 1) selection of primary treatment modality (surgery vs. radiation), and 2) determining radiation dose.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154275--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S046",
      "content_id": "154709",
      "abstract_number": "S046",
      "poster_number": "",
      "title": "DISEASE FREE SURVIVAL FOLLOWING DEFINITIVE CHEMO-RADIOTHERAPY WITH 70 VERSUS 60 GY: SECONDARY ANALYSIS OF A SINGLE CENTER, OPEN LABEL THERAPY DE-ESCALATION TRIAL IN PATIENTS WITH HPV+ OROPHARYNGE",
      "summary": "Fifty-eight patients who received concurrent CXRT completed a mean follow-up for 2.7 years (±SD 1.2). Of these, 53 patients were males (91%), 56 were Caucasian (98%), and 31 had history of current or former smoking (54%). The Kaplan-Meier estimate of 2-year DFS was 0.946 (95% CI: 0.841-0.982) and the 2-year OS was 0.981 (95% CI: 0.871-0.997).",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154709",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aru Panwar, MD",
      "presenter": "Aru Panwar, MD",
      "authors": "Aru Panwar, MD 1 ; Harlan Sayles, PhD 2 ; Andrew Coughlin, MD 1 ; Oleg Militsakh, MD 1 ; Apar Ganti, MD 3 ; William Lydiatt, MD 1 ; Angela Osmolak, MD 1 ; Andrew Holcomb, MD 1 ; Yungpo B Su, MD 1 ; Tien-Shew Huang, MD 1 ; Alireza Mirmiran, MD 1 ; Rob Lindau, MD 1",
      "normalized_authors": [
        "Aru Panwar",
        "Harlan Sayles",
        "Andrew Coughlin",
        "Oleg Militsakh",
        "Apar Ganti",
        "William Lydiatt",
        "Angela Osmolak",
        "Andrew Holcomb",
        "Yungpo B Su",
        "Tien-Shew Huang",
        "Alireza Mirmiran",
        "Rob Lindau"
      ],
      "affiliations": [
        "Methodist Estabrook Cancer Center, Nebraska Methodist Hospital, Omaha, Nebraska",
        "College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska",
        "Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska"
      ],
      "normalized_institutions": [
        "Methodist Estabrook Cancer Center, Nebraska Methodist Hospital, Omaha, Nebraska",
        "College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska",
        "Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 387,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting and Participants",
        "Abstract",
        "Statistical Methods",
        "Results",
        "Conclusion and Relevance"
      ],
      "sections": {
        "Authors": "Aru Panwar, MD 1 ; Harlan Sayles, PhD 2 ; Andrew Coughlin, MD 1 ; Oleg Militsakh, MD 1 ; Apar Ganti, MD 3 ; William Lydiatt, MD 1 ; Angela Osmolak, MD 1 ; Andrew Holcomb, MD 1 ; Yungpo B Su, MD 1 ; Tien-Shew Huang, MD 1 ; Alireza Mirmiran, MD 1 ; Rob Lindau, MD 1",
        "Affiliations": "1 Methodist Estabrook Cancer Center, Nebraska Methodist Hospital, Omaha, Nebraska; 2 College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska; 3 Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska",
        "Importance": "Favorable outcomes experienced by survivors of human papilloma virus mediated oropharyngeal carcinoma (HPV+ OPSCC) have prompted therapy de-escalation efforts. However, recent results from NRG HN 005 trial suggest that patients with Stage I-II HPV+ OPSCC treated with definitive chemo-radiotherapy (CXRT) should continue to receive 70 Gy radiotherapy dose. We report secondary analysis of our institutional de-escalation trial.",
        "Objective": "Compare the disease free survival (DFS) and overall survival (OS) of patients with Stage I-II HPV+ OPSCC eligible for curative intent CXRT, who received radiotherapy dose of 70Gy or 60Gy.",
        "Design, Setting and Participants": "Single institution, therapy de-escalation clinical trial in adult patients with stage I-II (T1-2 N1-2 or T3 N0-2) HPV+ OPSCC (ClinicalTrials.gov Identifier: NCT04638465)",
        "Abstract": "Disease free survival (DFS). Overall survival (OS) Forty-four (76%) received radiation dose 60Gy and 14 (24%) received 70Gy. Two (5%) deaths and 4 (10%) recurrence events were observed in the patients receiving 60Gy dose. One (7%) deaths and no recurrence events were observed in the patients receiving 70Gy dose. The difference in DFS and OS between groups did not achieve statistical significance. View in Agenda and Add to Schedule",
        "Statistical Methods": "Baseline clinicopathologic and treatment related variables were identified, and patients were stratified by receipt of 70Gy versus 60Gy radiotherapy dose during curative intent concurrent CXRT. Fischer’s exact test was used to compare events including recurrence and death. Kaplan Meier analyses were generated for survival outcomes. All analyses were conducted using STATA v17 (StataCorp LLC, College Station, TX) and p-values <0.05 were considered statistically significant.",
        "Results": "Fifty-eight patients who received concurrent CXRT completed a mean follow-up for 2.7 years (±SD 1.2). Of these, 53 patients were males (91%), 56 were Caucasian (98%), and 31 had history of current or former smoking (54%). The Kaplan-Meier estimate of 2-year DFS was 0.946 (95% CI: 0.841-0.982) and the 2-year OS was 0.981 (95% CI: 0.871-0.997).",
        "Conclusion and Relevance": "In this single institution, therapy de-escalation clinical trial in adult patients with stage I-II (T1-2 N1-2 or T3 N0-2) HPV+ OPSCC, differences in DFS and OS were not statistically significant for patients who received radiotherapy dose of 70Gy or 60Gy as part of concurrent CXRT. However, patients who received 60Gy radiotherapy dose had more frequent recurrence events. These findings may offer additional caution and further inform clinicians and patients when considering de-escalation of radiotherapy in this patient cohort."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>DISEASE FREE SURVIVAL FOLLOWING DEFINITIVE CHEMO-RADIOTHERAPY WITH 70 VERSUS 60 GY: SECONDARY ANALYSIS OF A SINGLE CENTER, OPEN LABEL THERAPY DE-ESCALATION TRIAL IN PATIENTS WITH HPV+ OROPHARYNGEAL SCC</span>. <u>Aru Panwar, MD</u><sup>1</sup>; Harlan Sayles, PhD<sup>2</sup>; Andrew Coughlin, MD<sup>1</sup>; Oleg Militsakh, MD<sup>1</sup>; Apar Ganti, MD<sup>3</sup>; William Lydiatt, MD<sup>1</sup>; Angela Osmolak, MD<sup>1</sup>; Andrew Holcomb, MD<sup>1</sup>; Yungpo B Su, MD<sup>1</sup>; Tien-Shew Huang, MD<sup>1</sup>; Alireza Mirmiran, MD<sup>1</sup>; Rob Lindau, MD<sup>1</sup>. <sup>1</sup>Methodist Estabrook Cancer Center, Nebraska Methodist Hospital, Omaha, Nebraska; <sup>2</sup>College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska; <sup>3</sup>Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>Favorable outcomes experienced by survivors of human papilloma virus mediated oropharyngeal carcinoma (HPV+ OPSCC) have prompted therapy de-escalation efforts. However, recent results from NRG HN 005 trial suggest that patients with Stage I-II HPV+ OPSCC treated with definitive chemo-radiotherapy (CXRT) should continue to receive 70 Gy radiotherapy dose. We report secondary analysis of our institutional de-escalation trial.</p>\n\n<p><strong>Objective: </strong>Compare the disease free survival (DFS) and overall survival (OS) of patients with Stage I-II HPV+ OPSCC eligible for curative intent CXRT, who received radiotherapy dose of 70Gy or 60Gy.</p>\n\n<p><strong>Design, Setting and Participants: </strong>Single institution, therapy de-escalation clinical trial in adult patients with stage I-II (T1-2 N1-2 or T3 N0-2) HPV+ OPSCC (ClinicalTrials.gov Identifier: NCT04638465)</p>\n\n<p><strong>Main Outcome Measures:</strong></p>\n\n<p>Disease free survival (DFS).<br />\nOverall survival (OS)</p>\n\n<p><strong>Statistical Methods:</strong> Baseline clinicopathologic and treatment related variables were identified, and patients were stratified by receipt of 70Gy versus 60Gy radiotherapy dose during curative intent concurrent CXRT. Fischer’s exact test was used to compare events including recurrence and death. Kaplan Meier analyses were generated for survival outcomes. All analyses were conducted using STATA v17 (StataCorp LLC, College Station, TX) and p-values <0.05 were considered statistically significant.</p>\n\n<p><strong>Results:</strong> Fifty-eight patients who received concurrent CXRT completed a mean follow-up for 2.7 years (±SD 1.2). Of these, 53 patients were males (91%), 56 were Caucasian (98%), and 31 had history of current or former smoking (54%). The Kaplan-Meier estimate of 2-year DFS was 0.946 (95% CI: 0.841-0.982) and the 2-year OS was 0.981 (95% CI: 0.871-0.997).</p>\n\n<p>Forty-four (76%) received radiation dose 60Gy and 14 (24%) received 70Gy. Two (5%) deaths and 4 (10%) recurrence events were observed in the patients receiving 60Gy dose. One (7%) deaths and no recurrence events were observed in the patients receiving 70Gy dose. The difference in DFS and OS between groups did not achieve statistical significance.</p>\n\n<p><strong>Conclusion and Relevance:</strong> In this single institution, therapy de-escalation clinical trial in adult patients with stage I-II (T1-2 N1-2 or T3 N0-2) HPV+ OPSCC, differences in DFS and OS were not statistically significant for patients who received radiotherapy dose of 70Gy or 60Gy as part of concurrent CXRT. However, patients who received 60Gy radiotherapy dose had more frequent recurrence events. These findings may offer additional caution and further inform clinicians and patients when considering de-escalation of radiotherapy in this patient cohort.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154709--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S047",
      "content_id": "151836",
      "abstract_number": "S047",
      "poster_number": "",
      "title": "HPV-associated Oropharynx Cancer in Young Patients Managed with Transoral Robotic Surgery: An Institutional Experience",
      "summary": "Robust clinical screening and heightened public awareness of the increasing incidence of HPV-associated OPSCC, especially for younger patients, will be critical in ensuring timely access to care and improved functional and oncologic outcomes following TORS.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151836",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sanjana Velu",
      "presenter": "Sanjana Velu",
      "authors": "Louis-Xavier Barrette, MD 1 ; Sanjana Velu 1 ; Gregory S Weinstein, MD, FACS 1 ; Robert M Brody, MD 1 ; Devraj Basu, MD, PhD, FACS 1 ; Bert W O'Malley, MD 2 ; D",
      "normalized_authors": [
        "Louis-Xavier Barrette",
        "Sanjana Velu",
        "Gregory S Weinstein",
        "Robert M Brody",
        "Devraj Basu",
        "Bert W O'Malley"
      ],
      "affiliations": [
        "Gregory Farwell, MD, FACS 1",
        "Steven B Cannady, MD 1",
        "Ara A Chalian, MD 1",
        "Jason G Newman, MD, FACS 3",
        "Alexander Lin, MD 1",
        "John N Lukens, MD 1",
        "Michelle Gentile, MD 1",
        "Lee Hartner, MD 1",
        "Aditi P Singh, MD 1",
        "Lova L Sun, MD, MSCE 1",
        "Roger B Cohen, MD 1",
        "Christopher H Rassekh, MD, FACS 1",
        "Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine",
        "University of Maryland Medical Center",
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Gregory Farwell, MD, FACS 1",
        "Steven B Cannady, MD 1",
        "Ara A Chalian, MD 1",
        "Jason G Newman, MD, FACS 3",
        "Alexander Lin, MD 1",
        "John N Lukens, MD 1",
        "Michelle Gentile, MD 1",
        "Lee Hartner, MD 1",
        "Aditi P Singh, MD 1",
        "Lova L Sun, MD, MSCE 1",
        "Roger B Cohen, MD 1",
        "Christopher H Rassekh, MD, FACS 1",
        "Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine",
        "University of Maryland Medical Center",
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 370,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Louis-Xavier Barrette, MD 1 ; Sanjana Velu 1 ; Gregory S Weinstein, MD, FACS 1 ; Robert M Brody, MD 1 ; Devraj Basu, MD, PhD, FACS 1 ; Bert W O'Malley, MD 2 ; D",
        "Affiliations": "Gregory Farwell, MD, FACS 1 ; Steven B Cannady, MD 1 ; Ara A Chalian, MD 1 ; Jason G Newman, MD, FACS 3 ; Alexander Lin, MD 1 ; John N Lukens, MD 1 ; Michelle Gentile, MD 1 ; Lee Hartner, MD 1 ; Aditi P Singh, MD 1 ; Lova L Sun, MD, MSCE 1 ; Roger B Cohen, MD 1 ; Christopher H Rassekh, MD, FACS 1 ; Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine; 2 University of Maryland Medical Center; 3 Medical University of South Carolina",
        "Background": "HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) continues to rapidly increase in incidence despite HPV vaccination efforts, with a mean age at diagnosis of approximately 57. Management and oncologic outcomes of patients diagnosed and treated at a younger age have not yet been characterized.",
        "Objective": "To identify demographic, surgical and adjuvant management, and outcome differences in younger patients (≤50 years of age) with HPV-associated OPSCC managed with primary transoral robotic surgery (TORS).",
        "Methods": "Retrospective cohort study using single institution data.",
        "Results": "Of 1305 TORS patients identified, 161 patients (14.1%) were 50 years of age or younger at time of surgery (mean age of 46.3). No differences in race, ethnicity, or sex were identified between patients below 50 years of age and those above 50, though younger patients were more likely to have a Charlson Comorbitidy Index (CCI) of 0 (p = 0.002). Younger patients were significantly more likely to have clinically node-positive disease (cN1 or higher, p = 0.02), but clinical and pathologic T-stage was not significantly different between groups. There were no significant surgical differences between cohorts, such as need for contralateral neck dissection or return to the OR due to postoperative complication following index surgery. Younger patients were more likely to undergo adjuvant radiation alone compared to older patients (p = 0.01). On final pathology, younger patients were significantly less likely to have perineural invasion (PNI, p = 0.01) or extranodal extension (ENE, p = 0.01); no differences in margin status or lymphovascular invasion (LVI) were seen. Overall, younger patients had significantly better survival and fewer treatment failures compared to older patients (both p = 0.02).",
        "Discussion": "A significant proportion of patients undergoing TORS for p16-positive OPSCC at our institution are younger than 50 years of age. Adverse pathologic features such as PNI and ENE were less commonly seen in younger patients. Despite better baseline functional status, younger patients are equally likely to experience surgical complications following index surgery. Long-term oncologic outcomes and survival are improved in younger patients.",
        "Conclusion": "Robust clinical screening and heightened public awareness of the increasing incidence of HPV-associated OPSCC, especially for younger patients, will be critical in ensuring timely access to care and improved functional and oncologic outcomes following TORS.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HPV-associated Oropharynx Cancer in Young Patients Managed with Transoral Robotic Surgery: An Institutional Experience</span>. Louis-Xavier Barrette, MD<sup>1</sup>; <u>Sanjana Velu</u><sup>1</sup>; Gregory S Weinstein, MD, FACS<sup>1</sup>; Robert M Brody, MD<sup>1</sup>; Devraj Basu, MD, PhD, FACS<sup>1</sup>; Bert W O'Malley, MD<sup>2</sup>; D. Gregory Farwell, MD, FACS<sup>1</sup>; Steven B Cannady, MD<sup>1</sup>; Ara A Chalian, MD<sup>1</sup>; Jason G Newman, MD, FACS<sup>3</sup>; Alexander Lin, MD<sup>1</sup>; John N Lukens, MD<sup>1</sup>; Michelle Gentile, MD<sup>1</sup>; Lee Hartner, MD<sup>1</sup>; Aditi P Singh, MD<sup>1</sup>; Lova L Sun, MD, MSCE<sup>1</sup>; Roger B Cohen, MD<sup>1</sup>; Christopher H Rassekh, MD, FACS<sup>1</sup>; Karthik Rajasekaran, MD, FACS<sup>1</sup>. <sup>1</sup>Penn Medicine; <sup>2</sup>University of Maryland Medical Center; <sup>3</sup>Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) continues to rapidly increase in incidence despite HPV vaccination efforts, with a mean age at diagnosis of approximately 57. Management and oncologic outcomes of patients diagnosed and treated at a younger age have not yet been characterized.</p>\n\n<p><strong>Objective: </strong>To identify demographic, surgical and adjuvant management, and outcome differences in younger patients (≤50 years of age) with HPV-associated OPSCC managed with primary transoral robotic surgery (TORS).</p>\n\n<p><strong>Methods: </strong>Retrospective cohort study using single institution data.</p>\n\n<p><strong>Results: </strong>Of 1305 TORS patients identified, 161 patients (14.1%) were 50 years of age or younger at time of surgery (mean age of 46.3). No differences in race, ethnicity, or sex were identified between patients below 50 years of age and those above 50, though younger patients were more likely to have a Charlson Comorbitidy Index (CCI) of 0 (p = 0.002). Younger patients were significantly more likely to have clinically node-positive disease (cN1 or higher, p = 0.02), but clinical and pathologic T-stage was not significantly different between groups. There were no significant surgical differences between cohorts, such as need for contralateral neck dissection or return to the OR due to postoperative complication following index surgery. Younger patients were more likely to undergo adjuvant radiation alone compared to older patients (p = 0.01). On final pathology, younger patients were significantly less likely to have perineural invasion (PNI, p = 0.01) or extranodal extension (ENE, p = 0.01); no differences in margin status or lymphovascular invasion (LVI) were seen. Overall, younger patients had significantly better survival and fewer treatment failures compared to older patients (both p = 0.02).</p>\n\n<p><strong>Discussion: </strong>A significant proportion of patients undergoing TORS for p16-positive OPSCC at our institution are younger than 50 years of age. Adverse pathologic features such as PNI and ENE were less commonly seen in younger patients. Despite better baseline functional status, younger patients are equally likely to experience surgical complications following index surgery. Long-term oncologic outcomes and survival are improved in younger patients.</p>\n\n<p><strong>Conclusion: </strong>Robust clinical screening and heightened public awareness of the increasing incidence of HPV-associated OPSCC, especially for younger patients, will be critical in ensuring timely access to care and improved functional and oncologic outcomes following TORS.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151836--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S048",
      "content_id": "152800",
      "abstract_number": "S048",
      "poster_number": "",
      "title": "Surgically Managed HPV-associated Oropharyngeal Squamous Cell Carcinoma with a Single Ipsilateral Node",
      "summary": "While regional control in patients with single ipsilateral positive nodal disease is worse when adjuvant therapies (RT or CRT) are omitted, overall survivability remains comparable in patients undergoing surgery alone. This suggests an adequate ability to salvage these patients, though omitting adjuvant significantly worsens regional disease control.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152800",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260116",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Louis-Xavier Barrette, MD",
      "presenter": "Louis-Xavier Barrette, MD",
      "authors": "Louis-Xavier Barrette, MD 1 ; Gregory S Weinstein, MD, FACS 1 ; Robert M Brody, MD 1 ; Devraj Basu, MD, PhD, FACS 1 ; Bert W O'Malley, MD 2 ; D",
      "normalized_authors": [
        "Louis-Xavier Barrette",
        "Gregory S Weinstein",
        "Robert M Brody",
        "Devraj Basu",
        "Bert W O'Malley"
      ],
      "affiliations": [
        "Gregory Farwell, MD, FACS 1",
        "Steven B Cannady, MD 1",
        "Ara A Chalian, MD 1",
        "Jason G Newman, MD, FACS 3",
        "Alexander Lin, MD 1",
        "John N Luken, MD 1",
        "Michelle Gentile, MD 1",
        "Lee Hartner, MD 1",
        "Aditi P Singh, MD 1",
        "Lova L Sun, MD, MSCE 1",
        "Roger B Cohen, MD 1",
        "Christopher H Rassekh, MD, FACS 1",
        "Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine",
        "University of Maryland Health",
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Gregory Farwell, MD, FACS 1",
        "Steven B Cannady, MD 1",
        "Ara A Chalian, MD 1",
        "Jason G Newman, MD, FACS 3",
        "Alexander Lin, MD 1",
        "John N Luken, MD 1",
        "Michelle Gentile, MD 1",
        "Lee Hartner, MD 1",
        "Aditi P Singh, MD 1",
        "Lova L Sun, MD, MSCE 1",
        "Roger B Cohen, MD 1",
        "Christopher H Rassekh, MD, FACS 1",
        "Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine",
        "University of Maryland Health",
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 463,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Louis-Xavier Barrette, MD 1 ; Gregory S Weinstein, MD, FACS 1 ; Robert M Brody, MD 1 ; Devraj Basu, MD, PhD, FACS 1 ; Bert W O'Malley, MD 2 ; D",
        "Affiliations": "Gregory Farwell, MD, FACS 1 ; Steven B Cannady, MD 1 ; Ara A Chalian, MD 1 ; Jason G Newman, MD, FACS 3 ; Alexander Lin, MD 1 ; John N Luken, MD 1 ; Michelle Gentile, MD 1 ; Lee Hartner, MD 1 ; Aditi P Singh, MD 1 ; Lova L Sun, MD, MSCE 1 ; Roger B Cohen, MD 1 ; Christopher H Rassekh, MD, FACS 1 ; Karthik Rajasekaran, MD, FACS 1 . 1 Penn Medicine; 2 University of Maryland Health; 3 Medical University of South Carolina",
        "Background": "Deintensification of treatment remains an important goal in the management of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Surgically managed patients with a single positive ipsilateral cervical lymph node measuring greater than 3 cm are uniformly recommended to undergo radiation therapy (RT) (or chemoradiotherapy (CRT), as indicated by final pathology). No data have evaluated oncologic and survival outcomes of surgically managed patients with HPV-positive OPSCC who have a single pathologic ipsilateral node and have not undergone adjuvant RT or CRT.",
        "Objective": "To identify demographic, oncologic outcome, and survival outcome differences in patients with HPV-associated OPSCC with a single positive ipsilateral node (greater than or equal to 3 cm but less than 6 cm) managed with primary transoral robotic surgery (TORS), neck dissection, with or without adjuvant treatment.",
        "Methods": "Retrospective cohort study using single institution data.",
        "Results": "We identified 206 total patients with HPV associated OPSCC with single ipsilateral nodal disease greater than 3 cm treated with primary TORS and neck dissection. All patients were recommended to undergo adjuvant RT or CRT as indicated by final pathology; 38 patients did not receive adjuvant radiation (18.4%), 129 received adjuvant RT alone (62.6%), and 39 (18.9%) received adjuvant CRT. No demographic differences (race, ethnicity, sex) or differences in smoking status were identified between cohorts. Margin status, pathologic T stage, and presence of LVI was equivalent between all three cohorts (p = 0.087, p = 0.59, p = 0.48). Patients in the surgery with adjuvant CRT group had significantly more extranodal extension (ENE, p = <0.001). Patients treated with surgery alone were noted to have less perineural invasion than other cohorts (p = 0.041). Treatment failures were more frequent in the surgery only cohort (n = 6, p = 0.011). Local recurrences were equivalent between groups, but regional recurrence was more common in the surgery-only group (n = 5, p = 0.0037). Ipsilateral neck recurrence was most common in the surgery-only group (p = 0.029). Overall survival status was equivalent between groups (p = 0.27).",
        "Discussion": "Despite recommendations for adjuvant RT or CRT as indicated by pathology for all patients in this cohort, a significant proportion underwent surgical treatment alone (TORS and neck dissection). In this cohort, overall treatment failure, primarily in the form of ipsilateral neck recurrence, was significantly higher than those undergoing adjuvant treatment. Though treatment failures were higher, overall survival was comparable between groups, with 3, 11, and 5 documented deaths in the surgery alone, surgery and RT, and surgery and CRT group, respectively.",
        "Conclusion": "While regional control in patients with single ipsilateral positive nodal disease is worse when adjuvant therapies (RT or CRT) are omitted, overall survivability remains comparable in patients undergoing surgery alone. This suggests an adequate ability to salvage these patients, though omitting adjuvant significantly worsens regional disease control.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgically Managed HPV-associated Oropharyngeal Squamous Cell Carcinoma with a Single Ipsilateral Node</span>. <u>Louis-Xavier Barrette, MD</u><sup>1</sup>; Gregory S Weinstein, MD, FACS<sup>1</sup>; Robert M Brody, MD<sup>1</sup>; Devraj Basu, MD, PhD, FACS<sup>1</sup>; Bert W O'Malley, MD<sup>2</sup>; D. Gregory Farwell, MD, FACS<sup>1</sup>; Steven B Cannady, MD<sup>1</sup>; Ara A Chalian, MD<sup>1</sup>; Jason G Newman, MD, FACS<sup>3</sup>; Alexander Lin, MD<sup>1</sup>; John N Luken, MD<sup>1</sup>; Michelle Gentile, MD<sup>1</sup>; Lee Hartner, MD<sup>1</sup>; Aditi P Singh, MD<sup>1</sup>; Lova L Sun, MD, MSCE<sup>1</sup>; Roger B Cohen, MD<sup>1</sup>; Christopher H Rassekh, MD, FACS<sup>1</sup>; Karthik Rajasekaran, MD, FACS<sup>1</sup>. <sup>1</sup>Penn Medicine; <sup>2</sup>University of Maryland Health; <sup>3</sup>Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Deintensification of treatment remains an important goal in the management of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Surgically managed patients with a single positive ipsilateral cervical lymph node measuring greater than 3 cm are uniformly recommended to undergo radiation therapy (RT) (or chemoradiotherapy (CRT), as indicated by final pathology). No data have evaluated oncologic and survival outcomes of surgically managed patients with HPV-positive OPSCC who have a single pathologic ipsilateral node and have not undergone adjuvant RT or CRT.</p>\n\n<p><strong>Objective: </strong>To identify demographic, oncologic outcome, and survival outcome differences in patients with HPV-associated OPSCC with a single positive ipsilateral node (greater than or equal to 3 cm but less than 6 cm) managed with primary transoral robotic surgery (TORS), neck dissection, with or without adjuvant treatment.</p>\n\n<p><strong>Methods: </strong>Retrospective cohort study using single institution data.</p>\n\n<p><strong>Results: </strong>We identified 206 total patients with HPV associated OPSCC with single ipsilateral nodal disease greater than 3 cm treated with primary TORS and neck dissection. All patients were recommended to undergo adjuvant RT or CRT as indicated by final pathology; 38 patients did not receive adjuvant radiation (18.4%), 129 received adjuvant RT alone (62.6%), and 39 (18.9%) received adjuvant CRT. No demographic differences (race, ethnicity, sex) or differences in smoking status were identified between cohorts. Margin status, pathologic T stage, and presence of LVI was equivalent between all three cohorts (p = 0.087, p = 0.59, p = 0.48). Patients in the surgery with adjuvant CRT group had significantly more extranodal extension (ENE, p = <0.001). Patients treated with surgery alone were noted to have less perineural invasion than other cohorts (p = 0.041). Treatment failures were more frequent in the surgery only cohort (n = 6, p = 0.011). Local recurrences were equivalent between groups, but regional recurrence was more common in the surgery-only group (n = 5, p = 0.0037). Ipsilateral neck recurrence was most common in the surgery-only group (p = 0.029). Overall survival status was equivalent between groups (p = 0.27).</p>\n\n<p><strong>Discussion: </strong>Despite recommendations for adjuvant RT or CRT as indicated by pathology for all patients in this cohort, a significant proportion underwent surgical treatment alone (TORS and neck dissection). In this cohort, overall treatment failure, primarily in the form of ipsilateral neck recurrence, was significantly higher than those undergoing adjuvant treatment. Though treatment failures were higher, overall survival was comparable between groups, with 3, 11, and 5 documented deaths in the surgery alone, surgery and RT, and surgery and CRT group, respectively.</p>\n\n<p><strong>Conclusion: </strong>While regional control in patients with single ipsilateral positive nodal disease is worse when adjuvant therapies (RT or CRT) are omitted, overall survivability remains comparable in patients undergoing surgery alone. This suggests an adequate ability to salvage these patients, though omitting adjuvant significantly worsens regional disease control.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152800--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260116' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S049",
      "content_id": "153953",
      "abstract_number": "S049",
      "poster_number": "",
      "title": "Is Hispanic Race a Predictor of Higher Stage Disease in Pediatric Thyroid Cancer?",
      "summary": "Of 5,063 total patients, we analyzed 4,945 pediatric thyroid cancer patients who had an available SES quintile. There were 1,584 patients (32.0%) in group 5 and 667 patients (13.5%) in group 1. In group 1, 149 (36.3%) presented at T1 while 458 (45.1%) did in group 5 (p=0.0023). The groups did not differ significantly in rate of nodal or distant metastasis. Hispanic patients presented with larger tumors. Among...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153953",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maria J Polania, MD",
      "presenter": "Maria J Polania, MD",
      "authors": "Simo Kraguljac, BA; Gabriela Cendejas, MS; Muhammad Seif, BS; Hana Seif, BS; Benjamin Oakes, BS; Michael Pozin, MSE; Daniel Najafali, BS; Maria J Polania, MD ; Joseph Lopez, MD, MBA",
      "normalized_authors": [
        "Simo Kraguljac",
        "Gabriela Cendejas",
        "Muhammad Seif",
        "Hana Seif",
        "Benjamin Oakes",
        "Michael Pozin, MSE",
        "Daniel Najafali",
        "Maria J Polania",
        "Joseph Lopez"
      ],
      "affiliations": [
        "AdventHealth Orlando"
      ],
      "normalized_institutions": [
        "AdventHealth Orlando"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Discussion/Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Simo Kraguljac, BA; Gabriela Cendejas, MS; Muhammad Seif, BS; Hana Seif, BS; Benjamin Oakes, BS; Michael Pozin, MSE; Daniel Najafali, BS; Maria J Polania, MD ; Joseph Lopez, MD, MBA",
        "Affiliations": "AdventHealth Orlando",
        "Objective": "Thyroid cancer has risen rapidly in the United States. As thyroid cancer becomes more prevalent in pediatric patients, more screening is necessary to detect these tumors. We seek to determine whether race and socioeconomic status (SES) affects how pediatric patients first present with thyroid cancer as later diagnosis may affect morbidity and outcomes.",
        "Methods": "We conducted a population-based study examining pediatric thyroid cancer patients using the NIH Surveillance, Epidemiology, and End Results (SEER) Census Tract Database. We stratified race as Hispanic and non-Hispanic. SES was stratified into quintiles using American Community Survey (ACS) census tract data. Group 1 is the lowest SES while group 5 is the highest. We included patients diagnosed with a thyroid malignancy from 2006-2020 aged 0-21 at time of diagnosis. Staging includes patients diagnosed from 2006-2015 using AJCC 6th edition criteria to avoid inconsistency in staging criteria. Group 5 was used as a reference group for statistical analysis using Chi-square tests with GraphPad Prism.",
        "Results": "Of 5,063 total patients, we analyzed 4,945 pediatric thyroid cancer patients who had an available SES quintile. There were 1,584 patients (32.0%) in group 5 and 667 patients (13.5%) in group 1. In group 1, 149 (36.3%) presented at T1 while 458 (45.1%) did in group 5 (p=0.0023). The groups did not differ significantly in rate of nodal or distant metastasis. Hispanic patients presented with larger tumors. Among this group, 286 (32.8%) presented at T1 vs. 1,068 (45.7%) of non-Hispanics (p<0.0001). Also, 187 (21.4%) Hispanics presented at stage N1b compared to 371 (15.8%) non-Hispanics (p=0.0002). Rate of distant metastasis was very low and was similar between groups. Total thyroidectomy was more common in Hispanics, with 1,222 (86.5%) undergoing this surgery opposed to 3,018 (82.7%) non-Hispanics (p=0.0010).",
        "Discussion/Conclusion": "Hispanic race was found to be a predictor of later stage at presentation. Particularly, we found higher rates of nodal metastasis in Hispanic patients. This increases the risk of morbidity and mortality. Hispanic patients also more frequently underwent total thyroidectomy compared to non-Hispanic patients. SES was not indicative of later stages at presentation, however, the lowest SES quintile had the lowest number of diagnoses. This could mean pediatric patients of lower SES have thyroid cancer that goes undiagnosed until later in life, further increasing risk. Studies focusing on young adults are needed to determine if this difference is due to later detection or other exposures.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Is Hispanic Race a Predictor of Higher Stage Disease in Pediatric Thyroid Cancer?</span>. Simo Kraguljac, BA; Gabriela Cendejas, MS; Muhammad Seif, BS; Hana Seif, BS; Benjamin Oakes, BS; Michael Pozin, MSE; Daniel Najafali, BS; <u>Maria J Polania, MD</u>; Joseph Lopez, MD, MBA. AdventHealth Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Thyroid cancer has risen rapidly in the United States. As thyroid cancer becomes more prevalent in pediatric patients, more screening is necessary to detect these tumors. We seek to determine whether race and socioeconomic status (SES) affects how pediatric patients first present with thyroid cancer as later diagnosis may affect morbidity and outcomes.</p>\n\n<p><strong>Methods: </strong>We conducted a population-based study examining pediatric thyroid cancer patients using the NIH Surveillance, Epidemiology, and End Results (SEER) Census Tract Database. We stratified race as Hispanic and non-Hispanic. SES was stratified into quintiles using American Community Survey (ACS) census tract data. Group 1 is the lowest SES while group 5 is the highest. We included patients diagnosed with a thyroid malignancy from 2006-2020 aged 0-21 at time of diagnosis. Staging includes patients diagnosed from 2006-2015 using AJCC 6th edition criteria to avoid inconsistency in staging criteria. Group 5 was used as a reference group for statistical analysis using Chi-square tests with GraphPad Prism.</p>\n\n<p><strong>Results: </strong>Of 5,063 total patients, we analyzed 4,945 pediatric thyroid cancer patients who had an available SES quintile. There were 1,584 patients (32.0%) in group 5 and 667 patients (13.5%) in group 1. In group 1, 149 (36.3%) presented at T1 while 458 (45.1%) did in group 5 (p=0.0023). The groups did not differ significantly in rate of nodal or distant metastasis. Hispanic patients presented with larger tumors. Among this group, 286 (32.8%) presented at T1 vs. 1,068 (45.7%) of non-Hispanics (p<0.0001). Also, 187 (21.4%) Hispanics presented at stage N1b compared to 371 (15.8%) non-Hispanics (p=0.0002). Rate of distant metastasis was very low and was similar between groups. Total thyroidectomy was more common in Hispanics, with 1,222 (86.5%) undergoing this surgery opposed to 3,018 (82.7%) non-Hispanics (p=0.0010).</p>\n\n<p><strong>Discussion/Conclusion: </strong>Hispanic race was found to be a predictor of later stage at presentation. Particularly, we found higher rates of nodal metastasis in Hispanic patients. This increases the risk of morbidity and mortality. Hispanic patients also more frequently underwent total thyroidectomy compared to non-Hispanic patients. SES was not indicative of later stages at presentation, however, the lowest SES quintile had the lowest number of diagnoses. This could mean pediatric patients of lower SES have thyroid cancer that goes undiagnosed until later in life, further increasing risk. Studies focusing on young adults are needed to determine if this difference is due to later detection or other exposures.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153953--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S050",
      "content_id": "154096",
      "abstract_number": "S050",
      "poster_number": "",
      "title": "Declining Incidence of Thyroid Cancer is driven by Sub-Centimeter Tumors",
      "summary": "After decades of rising incidence2, papillary thyroid cancer incidence in the US has now declined for the past 7 years. The main contribution to the overall reduction in thyroid cancer incidence is from tumors smaller than 10mm in size. The incidence of tumors greater than 10mm in size has remained relatively stable since 2010 and mortality has decreased.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154096",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin M Hintze, MD",
      "presenter": "Justin M Hintze, MD",
      "authors": "Justin M Hintze, MD 1 ; Louise Davies, MD 2 ; Luc Morris, MD 1",
      "normalized_authors": [
        "Justin M Hintze",
        "Louise Davies",
        "Luc Morris"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center",
        "University of Wisconsin, Madison"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center",
        "University of Wisconsin, Madison"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 537,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Justin M Hintze, MD 1 ; Louise Davies, MD 2 ; Luc Morris, MD 1",
        "Affiliations": "1 Memorial Sloan Kettering Cancer Center; 2 University of Wisconsin, Madison",
        "Introduction": "Thyroid cancer incidence in the United States increased between the 1980s-2010, almost entirely driven by small, radiographically-detected papillary tumors. Mortality rates have remained stable, suggesting that wider use of diagnostic imaging has led to increased detection of cancers from a large subclinical reservoir1. Recent data has suggested a plateauing and even reduction of incidence, but the contribution of tumor size to this has not been clearly characterized.",
        "Methods": "This population-based analysis of incidence data used incidence data from 2000-2022 in 17 Surveillance, Epidemiology, and End Results (SEER) registries and US mortality data (1969-2023) from the National Center for Health Statistics. Analyzed using SEER*Stat (v.9.0.41). Eligible cases included individuals aged 20–89 diagnosed with papillary thyroid carcinoma (PTC; ICD-O C73.9, malignant behavior code 3). Tumor size was extracted using the ‘Extent of Disease–10’ variable. Age-adjusted incidence and population-based mortality rates were calculated, and Joinpoint Regression (v5.4.0) to estimate annual percent changes (APCs), reported with 95% confidence intervals (CI). Data for 2020 were excluded due to pandemic-related diagnostic disruptions. Statistical significance was defined as a<.05.",
        "Results": "A total of 233,566 eligible cases were identified (74.9% female; 87.7% with papillary carcinoma histology). Age-adjusted incidence per 100,000 of thyroid cancer (all histologies) rose from 10.2 in 2000 to a peak of 20.3 in 2015, then declined to 18.1 in 2022. APCs were +6.7% (95%CI 6.2,7.3; 2000–2009), +2.2% (95%CI 1.2,3.4; 2009–2014), and −1.5% (95%CI −2.0,−1.1; 2014–2022), all statistically significant (p<.001; Figure 1). For PTC, APCs followed a similar pattern: +7.4% (95%CI 6.9,8.1; 2000–2009), +2.8% (95%CI 1.5,4.0; 2009–2014), and −1.7?% (95%CI −2.3,−1.3; 2014–2022; all p<.001). The largest decline was seen in PTCs ≤10?mm: incidence dropped from 7.51 to 5.18 (2013-2022; APC?=?−4.5%, 95% CI −5.19, −3.56; p<.001; Figure 2). Thyroid cancer mortality declined slightly from 0.62 to 0.50 per 100,000 (from 1969 to 2023, AAPC -0.44, p<.001).",
        "Conclusions": "After decades of rising incidence2, papillary thyroid cancer incidence in the US has now declined for the past 7 years. The main contribution to the overall reduction in thyroid cancer incidence is from tumors smaller than 10mm in size. The incidence of tumors greater than 10mm in size has remained relatively stable since 2010 and mortality has decreased.",
        "Abstract": "The decline in small cancer incidence may have come about through the 2009 and 2015 American Thyroid Association guidelines3, the implementation of the Thyroid Imaging, Reporting and Data System (TI-RADS)for thyroid ultrasound4, which increased biopsy thresholds and discouraged biopsy of sub-centimeter thyroid nodules, and the reclassification of a subtype of PTC as a non-malignant category (non-invasive follicular thyroid neoplasm with papillary-like nuclear features).5 Decreases in the detection of the smallest cancers is good news and the falling mortality is reassuring that guideline-based imaging and biopsy thresholds are advancing value-based care. These evidence-based diagnostic approaches promote more cost-effective care, and prioritize patient benefit over detection frequency. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Declining Incidence of Thyroid Cancer is driven by Sub-Centimeter Tumors</span>. <u>Justin M Hintze, MD</u><sup>1</sup>; Louise Davies, MD<sup>2</sup>; Luc Morris, MD<sup>1</sup>. <sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>University of Wisconsin, Madison<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Thyroid cancer incidence in the United States increased between the 1980s-2010, almost entirely driven by small, radiographically-detected papillary tumors. Mortality rates have remained stable, suggesting that wider use of diagnostic imaging has led to increased detection of cancers from a large subclinical reservoir1. Recent data has suggested a plateauing and even reduction of incidence, but the contribution of tumor size to this has not been clearly characterized.</p>\n\n<p><strong>Methods: </strong>This population-based analysis of incidence data used incidence data from 2000-2022 in 17 Surveillance, Epidemiology, and End Results (SEER) registries and US mortality data (1969-2023) from the National Center for Health Statistics. Analyzed using SEER*Stat (v.9.0.41). Eligible cases included individuals aged 20–89 diagnosed with papillary thyroid carcinoma (PTC; ICD-O C73.9, malignant behavior code 3). Tumor size was extracted using the ‘Extent of Disease–10’ variable. Age-adjusted incidence and population-based mortality rates were calculated, and Joinpoint Regression (v5.4.0) to estimate annual percent changes (APCs), reported with 95% confidence intervals (CI). Data for 2020 were excluded due to pandemic-related diagnostic disruptions. Statistical significance was defined as a<.05.</p>\n\n<p><strong>Results: </strong>A total of 233,566 eligible cases were identified (74.9% female; 87.7% with papillary carcinoma histology). Age-adjusted incidence per 100,000 of thyroid cancer (all histologies) rose from 10.2 in 2000 to a peak of 20.3 in 2015, then declined to 18.1 in 2022. APCs were +6.7% (95%CI 6.2,7.3; 2000–2009), +2.2% (95%CI 1.2,3.4; 2009–2014), and −1.5% (95%CI −2.0,−1.1; 2014–2022), all statistically significant (p<.001; Figure 1). For PTC, APCs followed a similar pattern: +7.4% (95%CI 6.9,8.1; 2000–2009), +2.8% (95%CI 1.5,4.0; 2009–2014), and −1.7?% (95%CI −2.3,−1.3; 2014–2022; all p<.001). The largest decline was seen in PTCs ≤10?mm: incidence dropped from 7.51 to 5.18 (2013-2022; APC?=?−4.5%, 95% CI −5.19, −3.56; p<.001; Figure 2). Thyroid cancer mortality declined slightly from 0.62 to 0.50 per 100,000 (from 1969 to 2023, AAPC -0.44, p<.001).</p>\n\n<p><strong>Conclusions: </strong>After decades of rising incidence2, papillary thyroid cancer incidence in the US has now declined for the past 7 years. The main contribution to the overall reduction in thyroid cancer incidence is from tumors smaller than 10mm in size. The incidence of tumors greater than 10mm in size has remained relatively stable since 2010 and mortality has decreased.</p>\n\n<p>The decline in small cancer incidence may have come about through the 2009 and 2015 American Thyroid Association guidelines3, the implementation of the Thyroid Imaging, Reporting and Data System (TI-RADS)for thyroid ultrasound4, which increased biopsy thresholds and discouraged biopsy of sub-centimeter thyroid nodules, and the reclassification of a subtype of PTC as a non-malignant category (non-invasive follicular thyroid neoplasm with papillary-like nuclear features).5</p>\n\n<p>Decreases in the detection of the smallest cancers is good news and the falling mortality is reassuring that guideline-based imaging and biopsy thresholds are advancing value-based care. These evidence-based diagnostic approaches promote more cost-effective care, and prioritize patient benefit over detection frequency.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154096--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S051",
      "content_id": "154735",
      "abstract_number": "S051",
      "poster_number": "",
      "title": "Incidence and Risk Factors for Level V Metastasis in Papillary Thyroid Carcinoma",
      "summary": "Although the incidence of Level V metastasis in this cohort was relatively low, specific factors such as extrathyroidal extension, high nodal burden, positive lymph node ratio, and simultaneous multilevel involvement were identified as significant predictors of Level V disease.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154735",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Franco Novelli, MD",
      "presenter": "Franco Novelli, MD",
      "authors": "Joao Goncalves Filho; Franco Novelli, MD ; Luiz P Kowalski, PhD",
      "normalized_authors": [
        "Joao Goncalves Filho",
        "Franco Novelli",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "AC Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "AC Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 227,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joao Goncalves Filho; Franco Novelli, MD ; Luiz P Kowalski, PhD",
        "Affiliations": "AC Camargo Cancer Center",
        "Objective": "To evaluate the incidence and predictive factors for Level V lymph node metastasis in patients with papillary thyroid carcinoma undergoing therapeutic lateral neck dissection.",
        "Methods": "A retrospective analysis was performed on medical records of 238 patients who underwent therapeutic lateral neck dissection (Levels II–V) for previously untreated papillary thyroid carcinoma between 2014 and 2023. Patterns of lateral cervical metastasis and risk factors specifically associated with Level V involvement were analyzed.",
        "Results": "The study included 264 therapeutic lateral neck dissections. Ipsilateral dissection was performed in 212 patients (60% on the right side). The lymph node yield per dissection ranged from 23 to 106 (median: 38). A total of 2,561 positive lymph nodes were identified, representing 19% of all dissected nodes. Regarding Level V, 1,633 nodes were dissected, with a metastatic rate of 3.8%. Overall, Level V metastasis was present in approximately 12% of neck dissections. Statistical analysis indicated that Level V metastasis was significantly associated with extrathyroidal extension, higher number of positive lymph nodes, lymph node metastasis ratio, and simultaneous multilevel involvement (Levels II, III, and IV) (p<0.05).",
        "Conclusion": "Although the incidence of Level V metastasis in this cohort was relatively low, specific factors such as extrathyroidal extension, high nodal burden, positive lymph node ratio, and simultaneous multilevel involvement were identified as significant predictors of Level V disease.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence and Risk Factors for Level V Metastasis in Papillary Thyroid Carcinoma</span>. Joao Goncalves Filho; <u>Franco Novelli, MD</u>; Luiz P Kowalski, PhD. AC Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> To evaluate the incidence and predictive factors for Level V lymph node metastasis in patients with papillary thyroid carcinoma undergoing therapeutic lateral neck dissection.</p>\n\n<p><strong>Methods:</strong> A retrospective analysis was performed on medical records of 238 patients who underwent therapeutic lateral neck dissection (Levels II–V) for previously untreated papillary thyroid carcinoma between 2014 and 2023. Patterns of lateral cervical metastasis and risk factors specifically associated with Level V involvement were analyzed.</p>\n\n<p><strong>Results:</strong> The study included 264 therapeutic lateral neck dissections. Ipsilateral dissection was performed in 212 patients (60% on the right side). The lymph node yield per dissection ranged from 23 to 106 (median: 38). A total of 2,561 positive lymph nodes were identified, representing 19% of all dissected nodes. Regarding Level V, 1,633 nodes were dissected, with a metastatic rate of 3.8%. Overall, Level V metastasis was present in approximately 12% of neck dissections. Statistical analysis indicated that Level V metastasis was significantly associated with extrathyroidal extension, higher number of positive lymph nodes, lymph node metastasis ratio, and simultaneous multilevel involvement (Levels II, III, and IV) (p<0.05).</p>\n\n<p><strong>Conclusion:</strong> Although the incidence of Level V metastasis in this cohort was relatively low, specific factors such as extrathyroidal extension, high nodal burden, positive lymph node ratio, and simultaneous multilevel involvement were identified as significant predictors of Level V disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154735--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S052",
      "content_id": "154266",
      "abstract_number": "S052",
      "poster_number": "",
      "title": "Anticoagulant but not Anti-platelet Therapy Increases Risk of Hematoma Formation Following Thyroidectomy: A Large Database Study",
      "summary": "Patients using anticoagulant therapy had a higher risk of hematoma formation following thyroidectomy. The use of perioperative bridging therapy may be a factor in this elevated risk. Patients on antiplatelet medications had no significant difference in hematoma formation after PSM. The balance between risk of hematoma formation and thrombosis following thyroidectomy needs to be carefully considered in patients...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154266",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kunal A Koka, BS",
      "presenter": "Kunal A Koka, BS",
      "authors": "Kunal A Koka, BS ; Veenadhari Kollipara, BA; Neerav Goyal, MD, MPH, FACS",
      "normalized_authors": [
        "Kunal A Koka",
        "Veenadhari Kollipara",
        "Neerav Goyal"
      ],
      "affiliations": [
        "Penn State College of Medicine"
      ],
      "normalized_institutions": [
        "Penn State College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 522,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kunal A Koka, BS ; Veenadhari Kollipara, BA; Neerav Goyal, MD, MPH, FACS",
        "Affiliations": "Penn State College of Medicine",
        "Background": "Post-operative hematoma is a rare complication following thyroidectomy, occurring in approximately 0.7%-4.7% of cases. Post-thyroidectomy hematomas can cause compression of the venous and lymphatic drainage, leading to fluid build-up, swelling, and hematoma expansion, which can result in life-threatening airway compromise. To prevent the risk of hematoma formation, antiplatelet and anticoagulant medications are routinely held days to weeks before thyroidectomy. Despite withholding antithrombotic medications perioperatively, it has been shown that patients taking antiplatelet or anticoagulant medications are at an increased risk of hematoma formation. However, large-scale data supporting this association is lacking. The aim of this study is to determine the risk of hematoma formation following thyroidectomy in patients using antiplatelet and anticoagulant therapy utilizing a large retrospective database.",
        "Methods": "The TriNetX Research Database was queried for adult patients undergoing a thyroidectomy between 2010 to 2024 with antiplatelet or anticoagulant use 1 week to 1 month prior to surgery as well as a control cohort with no antithrombotic use. Exclusion criteria included disorders that alter coagulation, such as factor VIII, IX, and XI deficiency, disseminated intravascular coagulation, Von Willebrand disease, immune thrombocytopenic purpura, and vitamin K deficiency. Patients were also excluded if they received antithrombotic reversal agents, such as protamine, prothrombin, or idracizumab, as well as transfusion of blood or platelets 1 week before or after their surgery. The anticoagulant, antiplatelet, and control (no antiplatelet or anticoagulant use) cohorts were propensity score matched for age and sex. The primary outcome was formation of post-operative hematoma between 1 day - 1 month following thyroidectomy, which was determined through presence of ICD-10 codes for the hematoma or CPT codes utilized for draining the hematoma. All statistical analyses were performed within the TriNetX database.",
        "Results": "We identified 3,270 patients in the antiplatelet cohort, 3,303 patients in the anticoagulant cohort, and 164,674 patients in the control cohort. Before propensity score matching (PSM), the antiplatelet cohort had an increased risk of hematoma formation compared to the control group (risk ratio (RR): 1.68, 95% confidence interval (CI): 1.02-2.75, p=0.04). However, after PSM, no significant difference was found (RR: 1.01, 95% CI: 0.51-2.02, p=0.98). The anticoagulant cohort showed an increased risk of hematoma formation compared to the control cohort before and after propensity score matching [Before PSM - (RR: 3.52, 95% CI: 2.49-4.98, p<0.0001), After PSM: (RR: 2.04, 95% CI: 1.14-3.64, p=0.014). In the anticoagulant cohort, 2,134 (62.9%) of patients were found to be bridged with heparin or low molecular weight heparin between 1 week before and after surgery.",
        "Conclusion": "Patients using anticoagulant therapy had a higher risk of hematoma formation following thyroidectomy. The use of perioperative bridging therapy may be a factor in this elevated risk. Patients on antiplatelet medications had no significant difference in hematoma formation after PSM. The balance between risk of hematoma formation and thrombosis following thyroidectomy needs to be carefully considered in patients using antithrombotic medications. Further prospective studies are needed to determine the optimal bridging and perioperative management strategies for patients using antithrombotic medications.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Anticoagulant but not Anti-platelet Therapy Increases Risk of Hematoma Formation Following Thyroidectomy: A Large Database Study</span>. <u>Kunal A Koka, BS</u>; Veenadhari Kollipara, BA; Neerav Goyal, MD, MPH, FACS. Penn State College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Post-operative hematoma is a rare complication following thyroidectomy, occurring in approximately 0.7%-4.7% of cases. Post-thyroidectomy hematomas can cause compression of the venous and lymphatic drainage, leading to fluid build-up, swelling, and hematoma expansion, which can result in life-threatening airway compromise. To prevent the risk of hematoma formation, antiplatelet and anticoagulant medications are routinely held days to weeks before thyroidectomy. Despite withholding antithrombotic medications perioperatively, it has been shown that patients taking antiplatelet or anticoagulant medications are at an increased risk of hematoma formation. However, large-scale data supporting this association is lacking. The aim of this study is to determine the risk of hematoma formation following thyroidectomy in patients using antiplatelet and anticoagulant therapy utilizing a large retrospective database. </p>\n\n<p><strong>Methods: </strong>The TriNetX Research Database was queried for adult patients undergoing a thyroidectomy between 2010 to 2024 with antiplatelet or anticoagulant use 1 week to 1 month prior to surgery as well as a control cohort with no antithrombotic use. Exclusion criteria included disorders that alter coagulation, such as factor VIII, IX, and XI deficiency, disseminated intravascular coagulation, Von Willebrand disease, immune thrombocytopenic purpura, and vitamin K deficiency. Patients were also excluded if they received antithrombotic reversal agents, such as protamine, prothrombin, or idracizumab, as well as transfusion of blood or platelets 1 week before or after their surgery. The anticoagulant, antiplatelet, and control (no antiplatelet or anticoagulant use) cohorts were propensity score matched for age and sex. The primary outcome was formation of post-operative hematoma between 1 day - 1 month following thyroidectomy, which was determined through presence of ICD-10 codes for the hematoma or CPT codes utilized for draining the hematoma. All statistical analyses were performed within the TriNetX database. </p>\n\n<p><strong>Results:</strong> We identified 3,270 patients in the antiplatelet cohort, 3,303 patients in the anticoagulant cohort, and 164,674 patients in the control cohort. Before propensity score matching (PSM), the antiplatelet cohort had an increased risk of hematoma formation compared to the control group (risk ratio (RR): 1.68, 95% confidence interval (CI): 1.02-2.75, p=0.04). However, after PSM, no significant difference was found (RR: 1.01, 95% CI: 0.51-2.02, p=0.98). The anticoagulant cohort showed an increased risk of hematoma formation compared to the control cohort before and after propensity score matching [Before PSM - (RR: 3.52, 95% CI: 2.49-4.98, p<0.0001), After PSM: (RR: 2.04, 95% CI: 1.14-3.64, p=0.014). In the anticoagulant cohort, 2,134 (62.9%) of patients were found to be bridged with heparin or low molecular weight heparin between 1 week before and after surgery.   </p>\n\n<p><strong>Conclusion: </strong>Patients using anticoagulant therapy had a higher risk of hematoma formation following thyroidectomy. The use of perioperative bridging therapy may be a factor in this elevated risk. Patients on antiplatelet medications had no significant difference in hematoma formation after PSM. The balance between risk of hematoma formation and thrombosis following thyroidectomy needs to be carefully considered in patients using antithrombotic medications. Further prospective studies are needed to determine the optimal bridging and perioperative management strategies for patients using antithrombotic medications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154266--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S053",
      "content_id": "154550",
      "abstract_number": "S053",
      "poster_number": "",
      "title": "Predictors and Outcomes of Hemithyroidectomy vs. Total Thyroidectomy for Small Differentiated Thyroid Carcinoma Between 2015-2022: A Propensity Score Analysis",
      "summary": "In concordance with recent studies, there was no difference in survival between HT and TT for T1-T2 N0 differentiated thyroid carcinoma after propensity score matching. Predictors of HT as opposed to TT include male sex, Asian race, cT1 tumors, follicular carcinoma, treatment at academic facilities, and each progressive year of diagnosis. These results support 2025 ATA guideline-endorsed de-escalation and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154550",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beverly J Fu, BA, MA",
      "presenter": "Beverly J Fu, BA, MA",
      "authors": "Beverly J Fu, BA, MA 1 ; Fleur S Kabala, BS, MS 2 ; Michelle M Chen, MD, MHS 1 ; Tristan Tham, MD 1 ; Katie K Hohenberger, MD 1 ; Lisa A Orloff, MD 1 ; Jake J Lee, MD, MSCI 1",
      "normalized_authors": [
        "Beverly J Fu, MA",
        "Fleur S Kabala",
        "Michelle M Chen, MHS",
        "Tristan Tham",
        "Katie K Hohenberger",
        "Lisa A Orloff",
        "Jake J Lee, MSCI"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
        "University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
        "University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154550/2025_12_5_Figure.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154550/2025_12_5_Figure.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154550"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 552,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Beverly J Fu, BA, MA 1 ; Fleur S Kabala, BS, MS 2 ; Michelle M Chen, MD, MHS 1 ; Tristan Tham, MD 1 ; Katie K Hohenberger, MD 1 ; Lisa A Orloff, MD 1 ; Jake J Lee, MD, MSCI 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304; 2 University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032",
        "Objectives": "Amid the 2015 American Thyroid Association (ATA) guidelines recommending either total thyroidectomy (TT) or hemithyroidectomy (HT) for low-risk differentiated thyroid cancer, and in light of forthcoming 2025 ATA guidelines further encouraging de-escalation for selected patients, we aim to characterize national practice patterns, identify predictors of operative extent, and assess whether surgical extent influences overall survival using propensity score-matched analyses of contemporary National Cancer Database (NCDB) data.",
        "Methods": "We performed a retrospective cohort study of patients diagnosed with clinical T1–T2, N0, M0 papillary or follicular thyroid carcinoma treated definitively with HT or TT between 2015–2022 within the NCDB. Patients with prior malignancy, incomplete staging, missing key variables, or non-definitive treatment were excluded. National trends in operative extent were assessed over time, and predictors of TT were evaluated using multivariable logistic regression. To reduce confounding, 1:1 propensity-score matching was performed. Overall survival was compared between matched cohorts.",
        "Results": "In total, 88,856 patients (median age 48 years [SD 14.8], 69,852 female [78.6%]) with low-risk differentiated thyroid carcinoma were included, comprising 19,737 (22.2%) treated with HT and 69,119 (77.8%) treated with TT. National TT utilization declined from 85% to 71% between 2015 and 2022 (annual decline 2.3%). Each successive calendar year was independently associated with markedly lower odds of TT (aOR 0.87 (95% CI 0.80–0.95) in 2016 to 0.42 (95% CI 0.38–0.46) in 2022 vs 2015).",
        "Abstract": "On multivariable analysis, female sex was associated with undergoing TT (aOR 1.14, 95% CI 1.09–1.20). Asian race was associated with undergoing HT (aOR 0.84, 95% CI 0.77–0.91). Compared with academic programs, comprehensive community (aOR 1.43, 95% CI 1.36–1.51) and integrated network programs (aOR 1.25, 95% CI 1.17–1.32) were more likely to perform TT. Clinical factors strongly influenced surgical selection: cT2 vs cT1 tumors had substantially higher odds of TT (aOR 1.49, 95% CI 1.41–1.56), whereas follicular carcinoma (aOR 0.43, 95% CI 0.37–0.49) favored HT. Insurance status, income, education, comorbidity score, age, and tumor size had no association. Propensity-score matching accounting for facility type, demographics, socioeconomic factors, clinical T stage, tumor size, histology, comorbidity burden, and diagnosis year yielded 11,256 well-balanced pairs (all standardized mean differences <0.10). In the matched cohort, overall survival (OS) did not differ between HT and TT as OS exceeded 99% at 1 year and ~97% at 5 years for both groups (aHR 1.02, 95% CI 0.89–1.17). These findings remained robust in sensitivity analyses restricted to cT2 disease (aHR 1.11, 95% CI 0.87–1.40), cT2 papillary carcinoma (aHR 1.17, 95% CI 0.92–1.48), and cT2 follicular carcinoma (aHR 1.00, 95% CI 0.25–4.01). View in Agenda and Add to Schedule",
        "Conclusion": "In concordance with recent studies, there was no difference in survival between HT and TT for T1-T2 N0 differentiated thyroid carcinoma after propensity score matching. Predictors of HT as opposed to TT include male sex, Asian race, cT1 tumors, follicular carcinoma, treatment at academic facilities, and each progressive year of diagnosis. These results support 2025 ATA guideline-endorsed de-escalation and underscore the need for consistent adoption of evidence-based, risk-appropriate surgical management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors and Outcomes of Hemithyroidectomy vs. Total Thyroidectomy for Small Differentiated Thyroid Carcinoma Between 2015-2022: A Propensity Score Analysis</span>. <u>Beverly J Fu, BA, MA</u><sup>1</sup>; Fleur S Kabala, BS, MS<sup>2</sup>; Michelle M Chen, MD, MHS<sup>1</sup>; Tristan Tham, MD<sup>1</sup>; Katie K Hohenberger, MD<sup>1</sup>; Lisa A Orloff, MD<sup>1</sup>; Jake J Lee, MD, MSCI<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, Stanford School of Medicine, 801 Welch Road, Palo Alto, CA 94304; <sup>2</sup>University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives</strong>: Amid the 2015 American Thyroid Association (ATA) guidelines recommending either total thyroidectomy (TT) or hemithyroidectomy (HT) for low-risk differentiated thyroid cancer, and in light of forthcoming 2025 ATA guidelines further encouraging de-escalation for selected patients, we aim to characterize national practice patterns, identify predictors of operative extent, and assess whether surgical extent influences overall survival using propensity score-matched analyses of contemporary National Cancer Database (NCDB) data.</p>\n\n<p><strong>Methods</strong>: We performed a retrospective cohort study of patients diagnosed with clinical T1–T2, N0, M0 papillary or follicular thyroid carcinoma treated definitively with HT or TT between 2015–2022 within the NCDB. Patients with prior malignancy, incomplete staging, missing key variables, or non-definitive treatment were excluded. National trends in operative extent were assessed over time, and predictors of TT were evaluated using multivariable logistic regression. To reduce confounding, 1:1 propensity-score matching was performed. Overall survival was compared between matched cohorts.</p>\n\n<p><strong>Results</strong>: In total, 88,856 patients (median age 48 years [SD 14.8], 69,852 female [78.6%]) with low-risk differentiated thyroid carcinoma were included, comprising 19,737 (22.2%) treated with HT and 69,119 (77.8%) treated with TT. National TT utilization declined from 85% to 71% between 2015 and 2022 (annual decline 2.3%). Each successive calendar year was independently associated with markedly lower odds of TT (aOR 0.87 (95% CI 0.80–0.95) in 2016 to 0.42 (95% CI 0.38–0.46) in 2022 vs 2015).</p>\n\n<p>On multivariable analysis, female sex was associated with undergoing TT (aOR 1.14, 95% CI 1.09–1.20). Asian race was associated with undergoing HT (aOR 0.84, 95% CI 0.77–0.91). Compared with academic programs, comprehensive community (aOR 1.43, 95% CI 1.36–1.51) and integrated network programs (aOR 1.25, 95% CI 1.17–1.32) were more likely to perform TT. Clinical factors strongly influenced surgical selection: cT2 vs cT1 tumors had substantially higher odds of TT (aOR 1.49, 95% CI 1.41–1.56), whereas follicular carcinoma (aOR 0.43, 95% CI 0.37–0.49) favored HT. Insurance status, income, education, comorbidity score, age, and tumor size had no association.</p>\n\n<p>Propensity-score matching accounting for facility type, demographics, socioeconomic factors, clinical T stage, tumor size, histology, comorbidity burden, and diagnosis year yielded 11,256 well-balanced pairs (all standardized mean differences <0.10). In the matched cohort, overall survival (OS) did not differ between HT and TT as OS exceeded 99% at 1 year and ~97% at 5 years for both groups (aHR 1.02, 95% CI 0.89–1.17). These findings remained robust in sensitivity analyses restricted to cT2 disease (aHR 1.11, 95% CI 0.87–1.40), cT2 papillary carcinoma (aHR 1.17, 95% CI 0.92–1.48), and cT2 follicular carcinoma (aHR 1.00, 95% CI 0.25–4.01).</p>\n\n<p><strong>Conclusion</strong>: In concordance with recent studies, there was no difference in survival between HT and TT for T1-T2 N0 differentiated thyroid carcinoma after propensity score matching. Predictors of HT as opposed to TT include male sex, Asian race, cT1 tumors, follicular carcinoma, treatment at academic facilities, and each progressive year of diagnosis.  These results support 2025 ATA guideline-endorsed de-escalation and underscore the need for consistent adoption of evidence-based, risk-appropriate surgical management.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154550/2025_12_5_Figure.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154550--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S054",
      "content_id": "153645",
      "abstract_number": "S054",
      "poster_number": "",
      "title": "Impact of glucagon-like peptide-1 receptor agonists on thyroid cancer and thyroid nodule management in patients with type 2 diabetes or obesity",
      "summary": "In this large, population cohort, there was not an elevated risk of thyroid malignancy compared to metformin and several, other widely used anti-diabetic medications. This real-world data from the large database contributes to evidence of the safety profile of GLP-1 RAs. Additionally, there was not an increased rate of thyroidectomy in patients using GLP-1 RA, suggesting that physicians may not be conducting...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153645",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christie Hung, BA",
      "presenter": "Christie Hung, BA",
      "authors": "Christie Hung, BA ; Allen Khudaverdyan, BA; Colin Hill, MD; Lindsey Moses, MD",
      "normalized_authors": [
        "Christie Hung",
        "Allen Khudaverdyan",
        "Colin Hill",
        "Lindsey Moses"
      ],
      "affiliations": [
        "NYU Grossman School of Medicine"
      ],
      "normalized_institutions": [
        "NYU Grossman School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 402,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Christie Hung, BA ; Allen Khudaverdyan, BA; Colin Hill, MD; Lindsey Moses, MD",
        "Affiliations": "NYU Grossman School of Medicine",
        "Introduction": "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used medications for treatment of type 2 diabetes and obesity. GLP-1 RAs have been associated with development of medullary thyroid cancer in rodents. However, data on association of GLP-1 RAs with thyroid cancer has been inconclusive. We sought to add to the body of literature on whether GLP-1 RA use is associated with thyroid cancer and if GLP-1 RA use has impacted management of thyroid nodules, including incidence of thyroidectomies and ultrasound use.",
        "Methods": "This is a population-based, cross-sectional study using Epic Cosmos, a national multi-system electronic health system network that includes >300 million patients from >1800 hospitals. Patients diagnosed with type 2 diabetes or obesity and with a pre-existing non-toxic thyroid nodule or multinodular goiter between January 2010 and November 2025 were identified with ICD-10 codes. Patients utilizing GLP-1 RAs were compared with users of metformin, DPP-4 inhibitors, SGLT2-inhibitors, thiazolidinediones, and insulin. Outcomes studied include diagnosis of malignant neoplasm of the thyroid gland with ICD-10 codes, thyroidectomy procedures (including total and partial) with CPT codes, and head and neck or thyroid ultrasound using CPT codes after initiation of anti-diabetic medication. Statistical significance was determined using chi-squared tests.",
        "Results": "1,625,434 patients were included with average age at measurement of 69 years old. 73% identified as female and 26% as male. The highest rate of thyroid malignancy was among metformin users (4.45%, p<0.05), followed by GLP-1 RA (3.97%) and insulin (3.95%). The highest rate of thyroidectomy was also among metformin users (2.93%, p<0.05), followed by GLP-1 RA (2.14%) and thiazolidinediones (2.17%). The highest proportion of patients undergoing ultrasound of the head and neck within 5 years after initiating anti-diabetes medication was also in the metformin cohort (44.91%, p<0.05), followed by GLP-1 RAs (39.85%) and insulin (38.02%).",
        "Conclusion": "In this large, population cohort, there was not an elevated risk of thyroid malignancy compared to metformin and several, other widely used anti-diabetic medications. This real-world data from the large database contributes to evidence of the safety profile of GLP-1 RAs. Additionally, there was not an increased rate of thyroidectomy in patients using GLP-1 RA, suggesting that physicians may not be conducting thyroidectomies more aggressively in patients on GLP-1 RAs. Further studies are warranted to explore management of thyroid nodules in this patient population and validate findings.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of glucagon-like peptide-1 receptor agonists on thyroid cancer and thyroid nodule management in patients with type 2 diabetes or obesity</span>. <u>Christie Hung, BA</u>; Allen Khudaverdyan, BA; Colin Hill, MD; Lindsey Moses, MD. NYU Grossman School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used medications for treatment of type 2 diabetes and obesity. GLP-1 RAs have been associated with development of medullary thyroid cancer in rodents. However, data on association of GLP-1 RAs with thyroid cancer has been inconclusive. We sought to add to the body of literature on whether GLP-1 RA use is associated with thyroid cancer and if GLP-1 RA use has impacted management of thyroid nodules, including incidence of thyroidectomies and ultrasound use.</p>\n\n<p><strong>Methods: </strong>This is a population-based, cross-sectional study using Epic Cosmos, a national multi-system electronic health system network that includes >300 million patients from >1800 hospitals. Patients diagnosed with type 2 diabetes or obesity and with a pre-existing non-toxic thyroid nodule or multinodular goiter between January 2010 and November 2025 were identified with ICD-10 codes. Patients utilizing GLP-1 RAs were compared with users of metformin, DPP-4 inhibitors, SGLT2-inhibitors, thiazolidinediones, and insulin. Outcomes studied include diagnosis of malignant neoplasm of the thyroid gland with ICD-10 codes, thyroidectomy procedures (including total and partial) with CPT codes, and head and neck or thyroid ultrasound using CPT codes after initiation of anti-diabetic medication. Statistical significance was determined using chi-squared tests.</p>\n\n<p><strong>Results:</strong> 1,625,434 patients were included with average age at measurement of 69 years old.  73% identified as female and 26% as male. The highest rate of thyroid malignancy was among metformin users (4.45%, p<0.05), followed by GLP-1 RA (3.97%) and insulin (3.95%). The highest rate of thyroidectomy was also among metformin users (2.93%, p<0.05), followed by GLP-1 RA (2.14%) and thiazolidinediones (2.17%). The highest proportion of patients undergoing ultrasound of the head and neck within 5 years after initiating anti-diabetes medication was also in the metformin cohort (44.91%, p<0.05), followed by GLP-1 RAs (39.85%) and insulin (38.02%).</p>\n\n<p><strong>Conclusion: </strong>In this large, population cohort, there was not an elevated risk of thyroid malignancy compared to metformin and several, other widely used anti-diabetic medications. This real-world data from the large database contributes to evidence of the safety profile of GLP-1 RAs. Additionally, there was not an increased rate of thyroidectomy in patients using GLP-1 RA, suggesting that physicians may not be conducting thyroidectomies more aggressively in patients on GLP-1 RAs. Further studies are warranted to explore management of thyroid nodules in this patient population and validate findings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153645--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S055",
      "content_id": "154128",
      "abstract_number": "S055",
      "poster_number": "",
      "title": "Assessing Thyroid Risk in the Era of GLP-1 Therapy: Insights From FDA and TriNetX Data",
      "summary": "These findings suggest that abnormal thyroid outcomes reported to the FDA are rare, and when considered alongside TriNetX data, do not indicate an increased risk of thyroid neoplasms associated with semaglutide use compared with the general population. Notably, the observed lower risk in the TriNetX cohorts may point toward a potential protective effect, possibly mediated through GLP-1 associated improvements in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154128",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arati Bendapudi, BS",
      "presenter": "Arati Bendapudi, BS",
      "authors": "Arati Bendapudi, BS 1 ; Maia Smith, BS 1 ; Anusha Dabak, BSA 1 ; Viran Ranasinghe, MD 2",
      "normalized_authors": [
        "Arati Bendapudi",
        "Maia Smith",
        "Anusha Dabak, BSA",
        "Viran Ranasinghe"
      ],
      "affiliations": [
        "John Sealy School of Medicine, University of Texas Medical Branch",
        "Department of Otolaryngology, University of Texas Medical Branch"
      ],
      "normalized_institutions": [
        "John Sealy School of Medicine, University of Texas Medical Branch",
        "Department of Otolaryngology, University of Texas Medical Branch"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 528,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Arati Bendapudi, BS 1 ; Maia Smith, BS 1 ; Anusha Dabak, BSA 1 ; Viran Ranasinghe, MD 2",
        "Affiliations": "1 John Sealy School of Medicine, University of Texas Medical Branch; 2 Department of Otolaryngology, University of Texas Medical Branch",
        "Background": "Glucagon-like peptide-1 receptor agonists (GLP-1s) have become a popular and transformative therapy for patients, expanding beyond their initial use for Type 2 Diabetes to become a treatment for metabolic syndrome and obesity. Despite their extensive use, it has been difficult to elucidate potential adverse effects, including those affecting the thyroid gland. Animal and biochemical studies have demonstrated a potential link between GLP-1 use and increased risk of thyroid carcinoma, which has prompted FDA warnings of their use and patient concern. This study aims to utilize available FDA adverse events data in conjunction with TriNetX analysis to contextualize this risk.",
        "Methods": "A retrospective cohort analysis was conducted using both TriNetX and the FDA Adverse Event Reporting System (FAERS). In TriNetX, patients were divided into either a GLP1 cohort or control group. Both cohorts included patients with T2DM or obesity as defined by ICD-10 code. Incidences of thyroid cancer, benign neoplasm, nodules/goiter, hyper- and hypothyroidism, autoimmune thyroiditis, surgery, and overall mortality within five years of GLP-1 use were compared using risk ratios (RRs) with 95% confidence intervals. FAERS data was used to look at 12 thyroid-related adverse events associated with 4 semaglutide formulations (Semaglutide, Ozempic, Rybelsus, and Wegovy). Adverse events were categorized as either malignancy related or surgical outcome related, and included various types of thyroid cancer (anaplastic, papillary, medullary), thyroidectomy, thyroid biopsy etc. The analysis was limited to adults (18+) and reports from 2017–2025. Descriptive analysis methods were used to evaluate trends across reporting year, age, and sex.",
        "Results": "Compared to non-users, GLP-1 exposure was associated with a significantly decreased incidence of multiple thyroid outcomes including cancer (RR 0.524, 95% CI [0.467,0.589]), benign neoplasm (RR 0.519, [0.453,0.595), nodules/goiter (RR 0.808, [0.769,0.848]), biopsy or fine-needle aspiration (RR 0.856, [0.801,0.914]), hyperthyroidism (RR 0.817, [0.749,0.890]), hypothyroidism (RR 0.605, [0.582,0.629]), autoimmune thyroiditis (RR 0.790, [0.717,0.870]), and thyroid surgery (RR 0.467, [0.427,0.512]), and all-cause mortality (RR 0.44, [0.424,0.460]). No outcomes indicated increased thyroid disease or procedure-related risk among GLP-1 users. Of all unique adverse event cases reported in FAERS from 2017–2025 for the 4 semaglutide formulations (ages 18+), 0.507% involved the 12 thyroid-related events examined. In total, 166 unique cases included one of the 12 thyroid-related events, with thyroid neoplasms representing the largest category (145 cases). The 18-64 age group comprised the majority of cases (71.69%), and females accounted for more than twice as many cases as males in every age group.",
        "Conclusions": "These findings suggest that abnormal thyroid outcomes reported to the FDA are rare, and when considered alongside TriNetX data, do not indicate an increased risk of thyroid neoplasms associated with semaglutide use compared with the general population. Notably, the observed lower risk in the TriNetX cohorts may point toward a potential protective effect, possibly mediated through GLP-1 associated improvements in metabolic health, though further research as more patient data becomes available may be required to fully ascertain the link between this medication and thyroid outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessing Thyroid Risk in the Era of GLP-1 Therapy: Insights From FDA and TriNetX Data</span>. <u>Arati Bendapudi, BS</u><sup>1</sup>; Maia Smith, BS<sup>1</sup>; Anusha Dabak, BSA<sup>1</sup>; Viran Ranasinghe, MD<sup>2</sup>. <sup>1</sup>John Sealy School of Medicine, University of Texas Medical Branch; <sup>2</sup>Department of Otolaryngology, University of Texas Medical Branch<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1s) have become a popular and transformative therapy for patients, expanding beyond their initial use for Type 2 Diabetes to become a treatment for metabolic syndrome and obesity. Despite their extensive use, it has been difficult to elucidate potential adverse effects, including those affecting the thyroid gland. Animal and biochemical studies have demonstrated a potential link between GLP-1 use and increased risk of thyroid carcinoma, which has prompted FDA warnings of their use and patient concern. This study aims to utilize available FDA adverse events data in conjunction with TriNetX analysis to contextualize this risk.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort analysis was conducted using both TriNetX and the FDA Adverse Event Reporting System (FAERS). In TriNetX, patients were divided into either a GLP1 cohort or control group. Both cohorts included patients with T2DM or obesity as defined by ICD-10 code. Incidences of thyroid cancer, benign neoplasm, nodules/goiter, hyper- and hypothyroidism, autoimmune thyroiditis, surgery, and overall mortality within five years of GLP-1 use were compared using risk ratios (RRs) with 95% confidence intervals. FAERS data was used to look at 12 thyroid-related adverse events associated with 4 semaglutide formulations (Semaglutide, Ozempic, Rybelsus, and Wegovy). Adverse events were categorized as either malignancy related or surgical outcome related, and included various types of thyroid cancer (anaplastic, papillary, medullary), thyroidectomy, thyroid biopsy etc. The analysis was limited to adults (18+) and reports from 2017–2025. Descriptive analysis methods were used to evaluate trends across reporting year, age, and sex.</p>\n\n<p><strong>Results: </strong>Compared to non-users, GLP-1 exposure was associated with a significantly decreased incidence of multiple thyroid outcomes including cancer (RR 0.524, 95% CI [0.467,0.589]), benign neoplasm (RR 0.519, [0.453,0.595), nodules/goiter (RR 0.808, [0.769,0.848]), biopsy or fine-needle aspiration (RR 0.856, [0.801,0.914]), hyperthyroidism (RR 0.817, [0.749,0.890]), hypothyroidism (RR 0.605, [0.582,0.629]), autoimmune thyroiditis (RR 0.790, [0.717,0.870]), and thyroid surgery (RR 0.467, [0.427,0.512]), and all-cause mortality (RR 0.44, [0.424,0.460]). No outcomes indicated increased thyroid disease or procedure-related risk among GLP-1 users. Of all unique adverse event cases reported in FAERS from 2017–2025 for the 4 semaglutide formulations (ages 18+), 0.507% involved the 12 thyroid-related events examined. In total, 166 unique cases included one of the 12 thyroid-related events, with thyroid neoplasms representing the largest category (145 cases). The 18-64 age group comprised the majority of cases (71.69%), and females accounted for more than twice as many cases as males in every age group.</p>\n\n<p><strong>Conclusions:</strong> These findings suggest that abnormal thyroid outcomes reported to the FDA are rare, and when considered alongside TriNetX data, do not indicate an increased risk of thyroid neoplasms associated with semaglutide use compared with the general population. Notably, the observed lower risk in the TriNetX cohorts may point toward a potential protective effect, possibly mediated through GLP-1 associated improvements in metabolic health, though further research as more patient data becomes available may be required to fully ascertain the link between this medication and thyroid outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154128--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S056",
      "content_id": "153596",
      "abstract_number": "S056",
      "poster_number": "",
      "title": "Trends in Thyroid Disease Diagnoses Among World Trade Center-Exposed Individuals (2011–2023)",
      "summary": "This study found an initial rise followed by a sustained decline in thyroid diagnoses among WTC-exposed individuals. Thyroid disease exhibited two inflection points with a peak in 2014 and an accelerated decline after 2021, while the thyroid cancer subgroup showed a later peak in 2018 with a subsequent decline. The delayed peak and decline in thyroid cancer diagnoses suggests the prolonged biological impact of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153596",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Henry Diamond-Pott, BA",
      "presenter": "Henry Diamond-Pott, BA",
      "authors": "Henry Diamond-Pott, BA 1 ; Sara O'Sullivan-Bakshi, BS 2 ; Mathilda Monaghan, MPH 1 ; Maaike van Gerwen, MD, PhD 1",
      "normalized_authors": [
        "Henry Diamond-Pott",
        "Sara O'Sullivan-Bakshi",
        "Mathilda Monaghan",
        "Maaike van Gerwen"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai",
        "Renaissance School of Medicine at Stony Brook University"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai",
        "Renaissance School of Medicine at Stony Brook University"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153596/Thyroid1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153596/Thyroid1.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153596"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153596/Thyroid2(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153596/Thyroid2(1).jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153596"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1",
        "Figure 2",
        "Abstract"
      ],
      "sections": {
        "Authors": "Henry Diamond-Pott, BA 1 ; Sara O'Sullivan-Bakshi, BS 2 ; Mathilda Monaghan, MPH 1 ; Maaike van Gerwen, MD, PhD 1",
        "Affiliations": "1 Icahn School of Medicine at Mount Sinai; 2 Renaissance School of Medicine at Stony Brook University",
        "Background": "The 9/11 World Trade Center (WTC) attack exposed rescue and recovery workers to harmful toxins potentially linked to increased risk of thyroid disease. While elevated thyroid cancer rates have been reported, little is known about the development of other thyroid conditions. Understanding temporal diagnosis patterns can better guide long-term health monitoring and improve care. This study therefore analyzed diagnosis trends since 2011 to better gauge the impacts of medical surveillance and exposure latency in a WTC-exposed cohort with thyroid disease.",
        "Methods": "The WTC Health Program database was used to identify individuals diagnosed with thyroid cancer, thyroid disease, Hashimoto’s thyroiditis, or with abnormal thyroid exams after 2011, the first year of the WTC Health Program. Annual diagnosis rates were calculated using total WTC clinic visits per year. The general thyroid diagnosis cohort included all patients with any thyroid diagnosis; the thyroid cancer subgroup consisted only of patients with thyroid cancer. Joinpoint regression analysis (NCI Joinpoint Regression Program) identified significant inflection points (“joinpoints”) and estimated annual percent change (APC) in diagnosis rates over time (p < 0.05).",
        "Results": "The general thyroid diagnosis cohort included 392 patients (mean age 39.9 years at exposure on 9/11/2001; mean age 52.3 years at diagnosis). From 2011 to 2014, diagnosis rates increased significantly with an APC of 16.1% (95% CI: 1.5% to 55.9%; p = 0.032) (Figure 1). Between 2014 and 2021, rates declined significantly with an APC of -16.0% (95% CI: -19.9% to -10.2%; p = 0.002). After 2021, the decline accelerated markedly with an APC of -37.5% (95% CI: -50.8% to -23.4%; p < 0.001). Subgroup analysis revealed 102 thyroid cancer cases (mean age 36.5 years at exposure; mean age 50.6 years at diagnosis). Thyroid cancer diagnosis rates increased modestly but non-significantly from 2011 to 2018 with an APC of 10.0% (95% CI: -6.0% to 146.4%; p = 0.22) (Figure 2). After 2018, rates declined significantly at an APC of -33.0% (95% CI: -74.7% to -13.7%; p = 0.007).",
        "Conclusions": "This study found an initial rise followed by a sustained decline in thyroid diagnoses among WTC-exposed individuals. Thyroid disease exhibited two inflection points with a peak in 2014 and an accelerated decline after 2021, while the thyroid cancer subgroup showed a later peak in 2018 with a subsequent decline. The delayed peak and decline in thyroid cancer diagnoses suggests the prolonged biological impact of environmental exposures and the impact of disease latency in diagnostic trends. The findings highlight the importance of continued surveillance to monitor thyroid health outcomes and inform understanding of long-term impacts of environmental disaster exposure.",
        "Figure 1": "Thyroid Disease Diagnoses (2011-2023)",
        "Figure 2": "Thyroid Cancer Diagnoses (2011-2023)",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in Thyroid Disease Diagnoses Among World Trade Center-Exposed Individuals (2011–2023)</span>. <u>Henry Diamond-Pott, BA</u><sup>1</sup>; Sara O'Sullivan-Bakshi, BS<sup>2</sup>; Mathilda Monaghan, MPH<sup>1</sup>; Maaike van Gerwen, MD, PhD<sup>1</sup>. <sup>1</sup>Icahn School of Medicine at Mount Sinai; <sup>2</sup>Renaissance School of Medicine at Stony Brook University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The 9/11 World Trade Center (WTC) attack exposed rescue and recovery workers to harmful toxins potentially linked to increased risk of thyroid disease. While elevated thyroid cancer rates have been reported, little is known about the development of other thyroid conditions. Understanding temporal diagnosis patterns can better guide long-term health monitoring and improve care. This study therefore analyzed diagnosis trends since 2011 to better gauge the impacts of medical surveillance and exposure latency in a WTC-exposed cohort with thyroid disease.</p>\n\n<p><strong>Methods: </strong>The WTC Health Program database was used to identify individuals diagnosed with thyroid cancer, thyroid disease, Hashimoto’s thyroiditis, or with abnormal thyroid exams after 2011, the first year of the WTC Health Program. Annual diagnosis rates were calculated using total WTC clinic visits per year. The general thyroid diagnosis cohort included all patients with any thyroid diagnosis; the thyroid cancer subgroup consisted only of patients with thyroid cancer. Joinpoint regression analysis (NCI Joinpoint Regression Program) identified significant inflection points (“joinpoints”) and estimated annual percent change (APC) in diagnosis rates over time (p < 0.05).</p>\n\n<p><strong>Results: </strong>The general thyroid diagnosis cohort included 392 patients (mean age 39.9 years at exposure on 9/11/2001; mean age 52.3 years at diagnosis). From 2011 to 2014, diagnosis rates increased significantly with an APC of 16.1% (95% CI: 1.5% to 55.9%; p = 0.032) (Figure 1). Between 2014 and 2021, rates declined significantly with an APC of -16.0% (95% CI: -19.9% to -10.2%; p = 0.002). After 2021, the decline accelerated markedly with an APC of -37.5% (95% CI: -50.8% to -23.4%; p < 0.001). Subgroup analysis revealed 102 thyroid cancer cases (mean age 36.5 years at exposure; mean age 50.6 years at diagnosis). Thyroid cancer diagnosis rates increased modestly but non-significantly from 2011 to 2018 with an APC of 10.0% (95% CI: -6.0% to 146.4%; p = 0.22) (Figure 2). After 2018, rates declined significantly at an APC of -33.0% (95% CI: -74.7% to -13.7%; p = 0.007).</p>\n\n<p><strong>Conclusions: </strong>This study found an initial rise followed by a sustained decline in thyroid diagnoses among WTC-exposed individuals. Thyroid disease exhibited two inflection points with a peak in 2014 and an accelerated decline after 2021, while the thyroid cancer subgroup showed a later peak in 2018 with a subsequent decline. The delayed peak and decline in thyroid cancer diagnoses suggests the prolonged biological impact of environmental exposures and the impact of disease latency in diagnostic trends. The findings highlight the importance of continued surveillance to monitor thyroid health outcomes and inform understanding of long-term impacts of environmental disaster exposure.</p>\n\n<p><strong>Figure 1:</strong> Thyroid Disease Diagnoses (2011-2023)</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153596/Thyroid1.jpg' /></p>\n\n<p><strong>Figure 2:</strong> Thyroid Cancer Diagnoses (2011-2023)</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153596/Thyroid2(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153596--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S057",
      "content_id": "152363",
      "abstract_number": "S057",
      "poster_number": "",
      "title": "Diagnostic De-escalation in Papillary Thyroid Carcinoma: A National SEER Analysis of Stage Migration After ATA 2015",
      "summary": "National SEER data reveal a strong change in PTC stage migration beginning in 2016–2017, aligned with implementation of ATA 2015 diagnostic recommendations. The increase in localized disease and decrease in regional disease, without any increase in distant PTC, supports the safety of diagnostic de-escalation at a population level. However, earlier adoption in higher-income and metropolitan regions illustrates...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152363",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Z Allen, MD",
      "presenter": "David Z Allen, MD",
      "authors": "David Z Allen, MD ; Jacob W Rosenthal; Maxwell P Kligerman, MD, MPH; Meredith A Lilly, MD; Merry E Sebelik, MD",
      "normalized_authors": [
        "David Z Allen",
        "Jacob W Rosenthal",
        "Maxwell P Kligerman",
        "Meredith A Lilly",
        "Merry E Sebelik"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152363/seerahns(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152363/seerahns(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152363"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 472,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD ; Jacob W Rosenthal; Maxwell P Kligerman, MD, MPH; Meredith A Lilly, MD; Merry E Sebelik, MD",
        "Affiliations": "Emory University",
        "Introduction": "Papillary thyroid carcinoma (PTC) incidence has risen due to increased detection of nodules rather than increases in clinically significant disease. In 2015, the American Thyroid Association (ATA) issued diagnostic recommendations promoting more selective biopsy thresholds and encouraging active surveillance for low-risk lesions. While institutional reports describe reduced overdiagnosis, the population-level impact of ATA 2015 on national stage distribution is underexplored.",
        "Objective": "To quantify national changes in PTC stage changes following ATA 2015 diagnostic recommendations and evaluate disparities in adoption across socioeconomic groups, sex, and metropolitan status.",
        "Methods": "We analyzed SEER-22 Research and County Attributes data from 2012–2020, identifying 62,283 malignant PTC cases. Tumors were grouped as localized, regional, or distant. Annual stage proportions were calculated and evaluated using segmented linear regression with an initial breakpoint at 2015. Breakpoint estimates, pre- and post-slope coefficients, and slope changes (Δβ) were derived for each stage. Socioeconomic variation was assessed using multivariable models incorporating a Year and Income interaction term. Stratified segmented models evaluated sex-specific and metropolitan differences.",
        "Results": "National stage distributions demonstrated a clear and statistically significant inflection after the ATA 2015 guideline period. Localized PTC declined from 2012–2016 (79.5% - 73.0%; β1 = –0.0120/year), then increased beginning in 2017.0 ± 0.49 (73.0% - 77.0%; Δβ = +0.0238, p = 0.0040). Regional PTC rose over the same 2012-2016 period (18.1% - 22.5%; β1 = +0.0106/year), followed by a significant decline beginning at 2017.0 ± 0.42 (22.5% - 19.8%; Δβ = –0.0226, p = 0.0021). Distant PTC remained stable throughout (Δβ p = 0.20), making up around 1.4–1.7 percent of cases annually. By 2018–2020, stage proportions stabilized at approximately 77% localized, 21% regional, and 1.4% distant. Additionally, there existed a significant Year and Income interaction ( p < 0.001) demonstrated that high-income counties (>$75,000 median income) reached the 2017 inflection 2–3 years earlier than middle-and low-income regions. Sex-grouped models showed similar significant slope changes among both women (2017.0 ± 0.73; Δβ = +0.0222; p = 0.027) and men (2016.0 ± 0.62; Δβ = +0.0249; p = 0.009). Metropolitan counties demonstrated a strong breakpoint (2017.0 ± 1.4; adj. R² = 0.79) while rural counties did not have an identifiable inflection, suggesting limited and possibly delayed uptake of guidelines.",
        "Conclusions": "National SEER data reveal a strong change in PTC stage migration beginning in 2016–2017, aligned with implementation of ATA 2015 diagnostic recommendations. The increase in localized disease and decrease in regional disease, without any increase in distant PTC, supports the safety of diagnostic de-escalation at a population level. However, earlier adoption in higher-income and metropolitan regions illustrates possible inequities in access to guideline-concordant thyroid nodule evaluation. Targeted dissemination efforts are needed to ensure equitable implementation of value-based, risk-adapted thyroid cancer care across diverse communities.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic De-escalation in Papillary Thyroid Carcinoma: A National SEER Analysis of Stage Migration After ATA 2015</span>. <u>David Z Allen, MD</u>; Jacob W Rosenthal; Maxwell P Kligerman, MD, MPH; Meredith A Lilly, MD; Merry E Sebelik, MD. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Papillary thyroid carcinoma (PTC) incidence has risen due to increased detection of nodules rather than increases in clinically significant disease. In 2015, the American Thyroid Association (ATA) issued diagnostic recommendations promoting more selective biopsy thresholds and encouraging active surveillance for low-risk lesions. While institutional reports describe reduced overdiagnosis, the population-level impact of ATA 2015 on national stage distribution is underexplored.</p>\n\n<p><strong>Objective: </strong>To quantify national changes in PTC stage changes following ATA 2015 diagnostic recommendations and evaluate disparities in adoption across socioeconomic groups, sex, and metropolitan status.</p>\n\n<p><strong>Methods: </strong>We analyzed SEER-22 Research and County Attributes data from 2012–2020, identifying 62,283 malignant PTC cases. Tumors were grouped as localized, regional, or distant. Annual stage proportions were calculated and evaluated using segmented linear regression with an initial breakpoint at 2015. Breakpoint estimates, pre- and post-slope coefficients, and slope changes (Δβ) were derived for each stage. Socioeconomic variation was assessed using multivariable models incorporating a Year and Income interaction term. Stratified segmented models evaluated sex-specific and metropolitan differences.</p>\n\n<p><strong>Results: </strong>National stage distributions demonstrated a clear and statistically significant inflection after the ATA 2015 guideline period. Localized PTC declined from 2012–2016 (79.5% - 73.0%; β1 = –0.0120/year), then increased beginning in 2017.0 ± 0.49 (73.0% - 77.0%; Δβ = +0.0238, <em>p</em> = 0.0040). Regional PTC rose over the same 2012-2016 period (18.1% - 22.5%; β1 = +0.0106/year), followed by a significant decline beginning at 2017.0 ± 0.42 (22.5% - 19.8%; Δβ = –0.0226, <em>p</em> = 0.0021). Distant PTC remained stable throughout (Δβ <em>p</em> = 0.20), making up around 1.4–1.7 percent of cases annually. By 2018–2020, stage proportions stabilized at approximately 77% localized, 21% regional, and 1.4% distant. Additionally, there existed a significant Year and Income interaction (<em>p</em> < 0.001) demonstrated that high-income counties (>$75,000 median income) reached the 2017 inflection 2–3 years earlier than middle-and low-income regions. Sex-grouped models showed similar significant slope changes among both women (2017.0 ± 0.73; Δβ = +0.0222; <em>p</em> = 0.027) and men (2016.0 ± 0.62; Δβ = +0.0249; <em>p</em> = 0.009).  Metropolitan counties demonstrated a strong breakpoint (2017.0 ± 1.4; adj. R² = 0.79) while rural counties did not have an identifiable inflection, suggesting limited and possibly delayed uptake of guidelines.</p>\n\n<p><strong>Conclusions: </strong>National SEER data reveal a strong change in PTC stage migration beginning in 2016–2017, aligned with implementation of ATA 2015 diagnostic recommendations. The increase in localized disease and decrease in regional disease, without any increase in distant PTC, supports the safety of diagnostic de-escalation at a population level. However, earlier adoption in higher-income and metropolitan regions illustrates possible inequities in access to guideline-concordant thyroid nodule evaluation. Targeted dissemination efforts are needed to ensure equitable implementation of value-based, risk-adapted thyroid cancer care across diverse communities.</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152363/seerahns(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152363--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S058",
      "content_id": "155490",
      "abstract_number": "S058",
      "poster_number": "",
      "title": "Can a Chatbot Keep Up with New Thyroid Cancer Guidelines? Early Multi-Rater Evaluation of Concordance with the 2025 ATA Recommendations",
      "summary": "In this early post-guideline evaluation, a Claude-based thyroid cancer chatbot demonstrated high but incomplete concordance with the 2025 ATA recommendations, with expert-rated performance ranging from 80% to 85%. The importance of these findings is immediate: patients are already using AI tools for high-stakes surgical decision support, while current models may not yet fully reflect newly adopted standards of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155490",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Z Allen, MD",
      "presenter": "David Z Allen, MD",
      "authors": "David Z Allen, MD 1 ; Maxwell Kligerman, MD, MPH 1 ; Thomas Szabo Yamashita, MD 1 ; Merry Sebelik, MD, FACS, MAMSE 1 ; Jonathon O Russell, MD, FACS 2",
      "normalized_authors": [
        "David Z Allen",
        "Maxwell Kligerman",
        "Thomas Szabo Yamashita",
        "Merry Sebelik, MAMSE",
        "Jonathon O Russell"
      ],
      "affiliations": [
        "Emory University",
        "The Russell Center"
      ],
      "normalized_institutions": [
        "Emory University",
        "The Russell Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 390,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD 1 ; Maxwell Kligerman, MD, MPH 1 ; Thomas Szabo Yamashita, MD 1 ; Merry Sebelik, MD, FACS, MAMSE 1 ; Jonathon O Russell, MD, FACS 2",
        "Affiliations": "1 Emory University; 2 The Russell Center",
        "Background": "Patient-facing AI chatbots are already being used to interpret cancer diagnoses and surgical options, yet their knowledge may lag behind major guideline updates and may misinterpret information. That gap is especially consequential now: the 2025 American Thyroid Association (ATA) guidelines for differentiated thyroid cancer introduced meaningful changes in surgical decision-making, including broader consideration of lobectomy in selected patients, incorporation of active surveillance and percutaneous ablation, and updated postoperative risk assessment concepts. Whether widely accessible large language models can deliver guidance that reflects these changes is unknown. We therefore evaluated early concordance of a Claude-based “physician assistant” chatbot with the newly released 2025 ATA recommendations.",
        "Methods": "Twenty simulated patient vignettes were designed to probe new or changed 2025 ATA recommendations across five domains: active surveillance/percutaneous ablation, extent of thyroidectomy, lymph node management, completion thyroidectomy, and adjuvant therapy/risk stratification. Each vignette was submitted to the chatbot, and responses were independently graded by three fellowship-trained head and neck surgeons using a structured rubric: fully concordant, partially concordant, outdated/2015-concordant, or discordant. Secondary assessments included completeness, safety, physician-referral language, and readability.",
        "Results": "Across 60 total expert evaluations, 50/60 (83.3%) were judged fully concordant with the 2025 ATA guidelines. Reviewer-specific full concordance was 85%, 85%, and 80%. Among non-fully-concordant ratings, reviewers identified partial concordance, occasional outdated 2015-era recommendations, and rare outright discordance. Mean completeness ranged from 89% to 96%. Physician-referral language was present in 75% to 85% of responses. Readability was advanced (Flesch-Kincaid grade 15.4-16.0). Two reviewers each identified 1 potentially harmful response. Performance was strongest for extent of thyroidectomy and lymph node management, while greater variability emerged in active surveillance/percutaneous ablation, completion thyroidectomy, and selected postoperative risk-stratification scenarios.",
        "Conclusions": "In this early post-guideline evaluation, a Claude-based thyroid cancer chatbot demonstrated high but incomplete concordance with the 2025 ATA recommendations, with expert-rated performance ranging from 80% to 85%. The importance of these findings is immediate: patients are already using AI tools for high-stakes surgical decision support, while current models may not yet fully reflect newly adopted standards of care. Failures clustered in precisely the areas where the 2025 ATA guidelines changed practice most. These data suggest that AI can approximate contemporary thyroid cancer guidance, but cannot yet be relied upon as a fully current substitute for specialist counseling during periods of rapid guideline evolution.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Can a Chatbot Keep Up with New Thyroid Cancer Guidelines? Early Multi-Rater Evaluation of Concordance with the 2025 ATA Recommendations</span>. <u>David Z Allen, MD</u><sup>1</sup>; Maxwell Kligerman, MD, MPH<sup>1</sup>; Thomas Szabo Yamashita, MD<sup>1</sup>; Merry Sebelik, MD, FACS, MAMSE<sup>1</sup>; Jonathon O Russell, MD, FACS<sup>2</sup>. <sup>1</sup>Emory University; <sup>2</sup>The Russell Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patient-facing AI chatbots are already being used to interpret cancer diagnoses and surgical options, yet their knowledge may lag behind major guideline updates and may misinterpret information. That gap is especially consequential now: the 2025 American Thyroid Association (ATA) guidelines for differentiated thyroid cancer introduced meaningful changes in surgical decision-making, including broader consideration of lobectomy in selected patients, incorporation of active surveillance and percutaneous ablation, and updated postoperative risk assessment concepts. Whether widely accessible large language models can deliver guidance that reflects these changes is unknown. We therefore evaluated early concordance of a Claude-based “physician assistant” chatbot with the newly released 2025 ATA recommendations.</p>\n\n<p><strong>Methods:</strong> Twenty simulated patient vignettes were designed to probe new or changed 2025 ATA recommendations across five domains: active surveillance/percutaneous ablation, extent of thyroidectomy, lymph node management, completion thyroidectomy, and adjuvant therapy/risk stratification. Each vignette was submitted to the chatbot, and responses were independently graded by three fellowship-trained head and neck surgeons using a structured rubric: fully concordant, partially concordant, outdated/2015-concordant, or discordant. Secondary assessments included completeness, safety, physician-referral language, and readability.</p>\n\n<p><strong>Results: </strong>Across 60 total expert evaluations, 50/60 (83.3%) were judged fully concordant with the 2025 ATA guidelines. Reviewer-specific full concordance was 85%, 85%, and 80%. Among non-fully-concordant ratings, reviewers identified partial concordance, occasional outdated 2015-era recommendations, and rare outright discordance. Mean completeness ranged from 89% to 96%. Physician-referral language was present in 75% to 85% of responses. Readability was advanced (Flesch-Kincaid grade 15.4-16.0). Two reviewers each identified 1 potentially harmful response. Performance was strongest for extent of thyroidectomy and lymph node management, while greater variability emerged in active surveillance/percutaneous ablation, completion thyroidectomy, and selected postoperative risk-stratification scenarios.</p>\n\n<p><strong>Conclusions:</strong> In this early post-guideline evaluation, a Claude-based thyroid cancer chatbot demonstrated high but incomplete concordance with the 2025 ATA recommendations, with expert-rated performance ranging from 80% to 85%. The importance of these findings is immediate: patients are already using AI tools for high-stakes surgical decision support, while current models may not yet fully reflect newly adopted standards of care. Failures clustered in precisely the areas where the 2025 ATA guidelines changed practice most. These data suggest that AI can approximate contemporary thyroid cancer guidance, but cannot yet be relied upon as a fully current substitute for specialist counseling during periods of rapid guideline evolution.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155490--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S059",
      "content_id": "151797",
      "abstract_number": "S059",
      "poster_number": "",
      "title": "Cost-Effectiveness of Intraoperative Autofluorescence in Thyroid Surgery: A United States Perspective",
      "summary": "In the base case analysis, near-infrared autofluorescence was associated with an incremental cost of $791.11 and incremental effectiveness of 0.0288 QALYs, yielding an ICER of $27,487 per QALY gained. Probabilistic sensitivity analysis demonstrated cost-effectiveness in 93.7% of simulations and a mean INMB of 3,205 (95% CrI, −$430 to $11,226) at a $100,000 per QALY willingness-to-pay (WTP) threshold. Threshold...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151797",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "John J Caraway, MD",
      "presenter": "John J Caraway, MD",
      "authors": "Andrew Brown, BS; John J Caraway, MD ; Toni Rush, PhD, MPH; Michael I Orestes, MD",
      "normalized_authors": [
        "Andrew Brown",
        "John J Caraway",
        "Toni Rush",
        "Michael I Orestes"
      ],
      "affiliations": [
        "Uniformed Services University"
      ],
      "normalized_institutions": [
        "Uniformed Services University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 314,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Objective",
        "Design",
        "Setting",
        "Results",
        "Conclusions and Relevance"
      ],
      "sections": {
        "Authors": "Andrew Brown, BS; John J Caraway, MD ; Toni Rush, PhD, MPH; Michael I Orestes, MD",
        "Affiliations": "Uniformed Services University",
        "Abstract": "Postoperative hypoparathyroidism affects 5% to 35% of patients following total thyroidectomy, leading to substantial clinical burden and healthcare costs. Probe-based near-infrared autofluorescence technology likely reduces the risk of hypoparathyroidism; however, its cost-effectiveness has not been evaluated in the United States. View in Agenda and Add to Schedule",
        "Objective": "To evaluate the cost-effectiveness of probe-based near-infrared autofluorescence technology compared with standard surgical care for preventing postoperative hypoparathyroidism following total thyroidectomy.",
        "Design": "This cost-effectiveness analysis used a decision-analytic Markov cohort model using 6-month cycles over a 50-year time horizon. Data was collected and analyzed in July 2025.",
        "Setting": "United States healthcare system perspective. Participants: Simulated cohort of patients aged 50 years undergoing planned outpatient total thyroidectomy for either benign or malignant indications. Exposures: Probe-based near-infrared autofluorescence technology vs standard surgical care during total thyroidectomy. Main Outcomes and Measures: Primary outcomes were the incremental cost-effectiveness ratio (ICER) and the incremental net monetary benefit (INMB). Cost-effectiveness was evaluated at thresholds of $50,000, $100,000, and $150,000 per quality-adjusted life-year (QALY).",
        "Results": "In the base case analysis, near-infrared autofluorescence was associated with an incremental cost of $791.11 and incremental effectiveness of 0.0288 QALYs, yielding an ICER of $27,487 per QALY gained. Probabilistic sensitivity analysis demonstrated cost-effectiveness in 93.7% of simulations and a mean INMB of 3,205 (95% CrI, −$430 to $11,226) at a $100,000 per QALY willingness-to-pay (WTP) threshold. Threshold analysis revealed cost-effectiveness required permanent hypoparathyroidism rates of 0.03% or greater and near-infrared autofluorescence to reduce the rates of hypoparathyroidism by at least 8% at a WTP threshold of $100,000 per QALY.",
        "Conclusions and Relevance": "Probe-based near-infrared autofluorescence technology is cost-effective for preventing postoperative hypoparathyroidism following total thyroidectomy, particularly in centers with higher baseline complication rates. The primary limitation is the unvalidated assumption of proportional permanent hypoparathyroidism reduction with the use of near-infrared autofluorescence. These results support institution-specific adoption decisions based on baseline complication rates."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cost-Effectiveness of Intraoperative Autofluorescence in Thyroid Surgery: A United States Perspective</span>. Andrew Brown, BS; <u>John J Caraway, MD</u>; Toni Rush, PhD, MPH; Michael I Orestes, MD. Uniformed Services University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Postoperative hypoparathyroidism affects 5% to 35% of patients following total thyroidectomy, leading to substantial clinical burden and healthcare costs. Probe-based near-infrared autofluorescence technology likely reduces the risk of hypoparathyroidism; however, its cost-effectiveness has not been evaluated in the United States.</p>\n\n<p><strong>Objective: </strong>To evaluate the cost-effectiveness of probe-based near-infrared autofluorescence technology compared with standard surgical care for preventing postoperative hypoparathyroidism following total thyroidectomy.</p>\n\n<p><strong>Design: </strong>This cost-effectiveness analysis used a decision-analytic Markov cohort model using 6-month cycles over a 50-year time horizon. Data was collected and analyzed in July 2025.</p>\n\n<p><strong>Setting: </strong>United States healthcare system perspective. Participants: Simulated cohort of patients aged 50 years undergoing planned outpatient total thyroidectomy for either benign or malignant indications. Exposures: Probe-based near-infrared autofluorescence technology vs standard surgical care during total thyroidectomy. Main Outcomes and Measures: Primary outcomes were the incremental cost-effectiveness ratio (ICER) and the incremental net monetary benefit (INMB). Cost-effectiveness was evaluated at thresholds of $50,000, $100,000, and $150,000 per quality-adjusted life-year (QALY).</p>\n\n<p><strong>Results:</strong> In the base case analysis, near-infrared autofluorescence was associated with an incremental cost of $791.11 and incremental effectiveness of 0.0288 QALYs, yielding an ICER of $27,487 per QALY gained. Probabilistic sensitivity analysis demonstrated cost-effectiveness in 93.7% of simulations and a mean INMB of 3,205 (95% CrI, −$430 to $11,226) at a $100,000 per QALY willingness-to-pay (WTP) threshold. Threshold analysis revealed cost-effectiveness required permanent hypoparathyroidism rates of 0.03% or greater and near-infrared autofluorescence to reduce the rates of hypoparathyroidism by at least 8% at a WTP threshold of $100,000 per QALY.</p>\n\n<p><strong>Conclusions and Relevance:</strong> Probe-based near-infrared autofluorescence technology is cost-effective for preventing postoperative hypoparathyroidism following total thyroidectomy, particularly in centers with higher baseline complication rates. The primary limitation is the unvalidated assumption of proportional permanent hypoparathyroidism reduction with the use of near-infrared autofluorescence. These results support institution-specific adoption decisions based on baseline complication rates.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151797--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S060",
      "content_id": "153559",
      "abstract_number": "S060",
      "poster_number": "",
      "title": "Exogenous Estrogen Use and Thyroid Cancer Incidence in Biological Males: Evidence from the All of Us Database",
      "summary": "In this large national cohort, exogeneous estrogen use in biological males was not associated with a statistically significant increase in thyroid cancer risk. This finding contrasts with prior reports suggesting an elevated risk in this population. Additional studies with longer follow-up and more granular exposure data are needed to clarify whether a true association exists.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153559",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260117",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Hasnain, MD",
      "presenter": "Fahad Hasnain, MD",
      "authors": "Fahad Hasnain, MD ; Christian Turner, BS; Akarsh Lal, BS; John Cramer, MD",
      "normalized_authors": [
        "Fahad Hasnain",
        "Christian Turner",
        "Akarsh Lal",
        "John Cramer"
      ],
      "affiliations": [
        "Wayne State University School of Medicine"
      ],
      "normalized_institutions": [
        "Wayne State University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 248,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fahad Hasnain, MD ; Christian Turner, BS; Akarsh Lal, BS; John Cramer, MD",
        "Affiliations": "Wayne State University School of Medicine",
        "Introduction": "Estrogen has been implicated in the higher incidence of thyroid cancer in females. Emerging data suggest that biological males receiving exogenous estrogen may also be at an increased risk, but evidence remains limited. We evaluated whether exogenous estrogen use in biological males is associated with the incidence of thyroid cancer.",
        "Methods": "We performed a retrospective cohort study using the All of Us database. Two cohorts were defined: (1) biological male participants with ≥5 years of follow-up, and (2) biological male participants with a documented prescription for exogenous estrogen and ≥5 years of follow-up after exposure. Propensity-score matching was used to balance demographic and clinical covariates between cohorts. Incident thyroid cancer, defined using ICD diagnostic codes, was compared between matched cohorts and relative risk (RR) was estimated.",
        "Results": "We identified 2,017 biological male patients prescribed exogenous estrogen for at least five years (mean age 63.3 years). After propensity-score matching to control for known risk factors for thyroid cancer in biological males, the RR of thyroid cancer in the exogenous estrogen cohort compared with the non-estrogen cohort was 1.11 (95% CI 0.59-2.09, p=0.745).",
        "Conclusion": "In this large national cohort, exogeneous estrogen use in biological males was not associated with a statistically significant increase in thyroid cancer risk. This finding contrasts with prior reports suggesting an elevated risk in this population. Additional studies with longer follow-up and more granular exposure data are needed to clarify whether a true association exists.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Exogenous Estrogen Use and Thyroid Cancer Incidence in Biological Males: Evidence from the All of Us Database</span>. <u>Fahad Hasnain, MD</u>; Christian Turner, BS; Akarsh Lal, BS; John Cramer, MD. Wayne State University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Estrogen has been implicated in the higher incidence of thyroid cancer in females. Emerging data suggest that biological males receiving exogenous estrogen may also be at an increased risk, but evidence remains limited. We evaluated whether exogenous estrogen use in biological males is associated with the incidence of thyroid cancer.</p>\n\n<p><strong>Methods:</strong> We performed a retrospective cohort study using the All of Us database. Two cohorts were defined: (1) biological male participants with ≥5 years of follow-up, and (2) biological male participants with a documented prescription for exogenous estrogen and ≥5 years of follow-up after exposure. Propensity-score matching was used to balance demographic and clinical covariates between cohorts. Incident thyroid cancer, defined using ICD diagnostic codes, was compared between matched cohorts and relative risk (RR) was estimated.</p>\n\n<p><strong>Results: </strong>We identified 2,017 biological male patients prescribed exogenous estrogen for at least five years (mean age 63.3 years). After propensity-score matching to control for known risk factors for thyroid cancer in biological males, the RR of thyroid cancer in the exogenous estrogen cohort compared with the non-estrogen cohort was 1.11 (95% CI 0.59-2.09, p=0.745).</p>\n\n<p><strong>Conclusion: </strong>In this large national cohort, exogeneous estrogen use in biological males was not associated with a statistically significant increase in thyroid cancer risk. This finding contrasts with prior reports suggesting an elevated risk in this population. Additional studies with longer follow-up and more granular exposure data are needed to clarify whether a true association exists.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153559--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260117' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S061",
      "content_id": "154452",
      "abstract_number": "S061",
      "poster_number": "",
      "title": "Host and viral epigenetic alterations induced by HPV integration or rearrangement in HPV-associated oropharyngeal cancer",
      "summary": "Long-read sequencing with simultaneous methylation profiling reveals coordinated host and viral methylation alterations linked to HPV rearrangement and integration, providing, to our knowledge, the first direct evidence that HPV-associated structural variations not only induce genomic instability but also disrupt epigenetic regulations, driving malignancy in HPV+OPC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154452",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Qin Wang, PhD",
      "presenter": "Qin Wang, PhD",
      "authors": "Qin Wang, PhD 1 ; Samuli Eldfors, PhD 1 ; Dipon Das, PhD 1 ; Gjystina Lumaj, MS 1 ; Shriya Shukla 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen L Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
      "normalized_authors": [
        "Qin Wang",
        "Samuli Eldfors",
        "Dipon Das",
        "Gjystina Lumaj",
        "Shriya Shukla",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Lori J Wirth",
        "Manisha J Patel",
        "Jong C Park",
        "Annie Chan",
        "Chirayu Patel",
        "Allen L Feng",
        "Daniel G Deschler",
        "Jeremy D Richmon",
        "Derrick T Lin",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "normalized_institutions": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Method",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Qin Wang, PhD 1 ; Samuli Eldfors, PhD 1 ; Dipon Das, PhD 1 ; Gjystina Lumaj, MS 1 ; Shriya Shukla 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen L Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
        "Affiliations": "1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital",
        "Background": "In HPV-positive oropharyngeal cancers (HPV+OPC), HPV-associated structural variation, including viral integration into the human genome and newly recognized HPV-HPV rearrangements, are known as cancer hallmarks. Besides genetic alterations, epigenetic regulations controlling gene expression are synergistic cancer drivers, particularly DNA methylation. However, the impact of HPV structural variations on methylation remains underexplored, largely due to the limitations of short-read sequencing in linking long-range structural variants with their corresponding methylation profiles. Recent advances in PacBio long-read sequencing have enabled direct methylation calling through polymerase kinetics during sequencing, facilitating integrated analysis of structural variation and methylation profiling. Here we leverage the PacBio platform to investigate the interplay between HPV structural variations and the associated epigenetic alterations in HPV+OPC.",
        "Method": "Fresh-frozen tumor tissue samples were collected from 5 patients at the diagnosis of HPV+OPC. Genomic DNA was extracted using Monarch High-Molecular-Weight DNA Extraction Kits and sheared to a target size of 15-18 kilobases using Covaris g-TUBEs. 500 ng input DNA was used for PacBio long-read whole-genome sequencing (WGS) following the manufacturer’s recommended protocols. DNA methylation status was called with the PacBio Jasmine model. Sequencing reads were aligned with pbmm2 to a custom reference genome encompassing human hg38 and 64 HPV genotypes. HPV-associated structural variations were identified through HPV-HPV and HPV-human chimeric reads.",
        "Results": "All 5 samples achieved >30x WGS sequencing depth and were positive for HPV16 (1 – 996 HPV reads; median 263). HPV-HPV rearrangements were found in 3 samples, including one harboring a >30 kb HPV DNA concatemer, representing the presence of viral multimers concatenating at least four episomal genomes. HPV-human integration events were detected in 4 samples, including 2 also showing HPV-HPV rearrangements. Through integrated analysis of methylation profiles and HPV-associated structural variations, we found that HPV integration and rearrangement could disrupt both the host and viral methylation landscapes, providing direct evidence of epigenetic dysregulation induced by HPV structural variation. Specifically, in two integration events where HPV DNA was inserted adjacent to host enhancer regions, the enhancers became hypomethylated, whereas corresponding host regions without integrated HPV remained hypermethylated. Given that enhancer hypomethylation boosts transcriptional activity, the findings suggest that HPV integration could facilitate local enhancer demethylation to promote expression of the integrated viral loci. Within the viral genome, integrated HPV also displayed distinct global hypomethylation patterns, suggesting integration could disrupt viral epigenetic regulation to promote expression. Notably, in the one sample which only harbored HPV-HPV rearrangements with no HPV-human integration, the viral genome similarly exhibited global hypomethylation, suggesting that HPV rearrangement alone may induce epigenetic alterations sufficient to drive malignant transformation.",
        "Conclusion": "Long-read sequencing with simultaneous methylation profiling reveals coordinated host and viral methylation alterations linked to HPV rearrangement and integration, providing, to our knowledge, the first direct evidence that HPV-associated structural variations not only induce genomic instability but also disrupt epigenetic regulations, driving malignancy in HPV+OPC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Host and viral epigenetic alterations induced by HPV integration or rearrangement in HPV-associated oropharyngeal cancer</span>. <u>Qin Wang, PhD</u><sup>1</sup>; Samuli Eldfors, PhD<sup>1</sup>; Dipon Das, PhD<sup>1</sup>; Gjystina Lumaj, MS<sup>1</sup>; Shriya Shukla<sup>1</sup>; Jonathan J Paly, DO<sup>2</sup>; Ross D Merkin, MD<sup>2</sup>; Lori J Wirth, MD<sup>2</sup>; Manisha J Patel, MD<sup>2</sup>; Jong C Park, MD<sup>2</sup>; Annie Chan, MD<sup>2</sup>; Chirayu Patel, MD<sup>2</sup>; Allen L Feng, MD<sup>1</sup>; Daniel G Deschler, MD<sup>1</sup>; Jeremy D Richmon, MD<sup>1</sup>; Derrick T Lin, MD<sup>1</sup>; William C Faquin, MD, PhD<sup>2</sup>; Peter M Sadow, MD, PhD<sup>2</sup>; Bayan A Alzumaili, MD<sup>2</sup>; Thomas J Roberts, MD, MBA<sup>2</sup>; Adam S Fisch, MD, PhD<sup>2</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Massachusetts General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> In HPV-positive oropharyngeal cancers (HPV+OPC), HPV-associated structural variation, including viral integration into the human genome and newly recognized HPV-HPV rearrangements, are known as cancer hallmarks. Besides genetic alterations, epigenetic regulations controlling gene expression are synergistic cancer drivers, particularly DNA methylation. However, the impact of HPV structural variations on methylation remains underexplored, largely due to the limitations of short-read sequencing in linking long-range structural variants with their corresponding methylation profiles. Recent advances in PacBio long-read sequencing have enabled direct methylation calling through polymerase kinetics during sequencing, facilitating integrated analysis of structural variation and methylation profiling. Here we leverage the PacBio platform to investigate the interplay between HPV structural variations and the associated epigenetic alterations in HPV+OPC.  </p>\n\n<p><strong>Method:</strong> Fresh-frozen tumor tissue samples were collected from 5 patients at the diagnosis of HPV+OPC. Genomic DNA was extracted using Monarch High-Molecular-Weight DNA Extraction Kits and sheared to a target size of 15-18 kilobases using Covaris g-TUBEs. 500 ng input DNA was used for PacBio long-read whole-genome sequencing (WGS) following the manufacturer’s recommended protocols. DNA methylation status was called with the PacBio Jasmine model. Sequencing reads were aligned with pbmm2 to a custom reference genome encompassing human hg38 and 64 HPV genotypes. HPV-associated structural variations were identified through HPV-HPV and HPV-human chimeric reads.  </p>\n\n<p><strong>Results</strong>: All 5 samples achieved >30x WGS sequencing depth and were positive for HPV16 (1 – 996 HPV reads; median 263). HPV-HPV rearrangements were found in 3 samples, including one harboring a >30 kb HPV DNA concatemer, representing the presence of viral multimers concatenating at least four episomal genomes. HPV-human integration events were detected in 4 samples, including 2 also showing HPV-HPV rearrangements. Through integrated analysis of methylation profiles and HPV-associated structural variations, we found that HPV integration and rearrangement could disrupt both the host and viral methylation landscapes, providing direct evidence of epigenetic dysregulation induced by HPV structural variation. Specifically, in two integration events where HPV DNA was inserted adjacent to host enhancer regions, the enhancers became hypomethylated, whereas corresponding host regions without integrated HPV remained hypermethylated. Given that enhancer hypomethylation boosts transcriptional activity, the findings suggest that HPV integration could facilitate local enhancer demethylation to promote expression of the integrated viral loci. Within the viral genome, integrated HPV also displayed distinct global hypomethylation patterns, suggesting integration could disrupt viral epigenetic regulation to promote expression. Notably, in the one sample which only harbored HPV-HPV rearrangements with no HPV-human integration, the viral genome similarly exhibited global hypomethylation, suggesting that HPV rearrangement alone may induce epigenetic alterations sufficient to drive malignant transformation.  </p>\n\n<p><strong>Conclusion:</strong> Long-read sequencing with simultaneous methylation profiling reveals coordinated host and viral methylation alterations linked to HPV rearrangement and integration, providing, to our knowledge, the first direct evidence that HPV-associated structural variations not only induce genomic instability but also disrupt epigenetic regulations, driving malignancy in HPV+OPC. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154452--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S062",
      "content_id": "154011",
      "abstract_number": "S062",
      "poster_number": "",
      "title": "Evaluating Preoperative ctDNA as a Predictor of Cervical Nodal Metastasis in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Preoperative ctDNA levels are significantly associated with having positive cervical lymph nodes in OCSCC but do not reflect overall nodal burden. ctDNA demonstrates moderate ability to distinguish node-positive from node-negative, with an optimal threshold of approximately 1.36 MTM/ml. Although ctDNA does not track with metastatic nodal burden, multivariable analysis indicates that ctDNA and DOI together...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154011",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Edgar D Uribe Sanchez, BA",
      "presenter": "Edgar D Uribe Sanchez, BA",
      "authors": "Edgar D Uribe Sanchez, BA ; Kirollos Armosh, BS; Kevin Liu, MD; Dustin Conrad, MD; Peter T Dziegielewski, MD; Austin S Lam, MD",
      "normalized_authors": [
        "Edgar D Uribe Sanchez",
        "Kirollos Armosh",
        "Kevin Liu",
        "Dustin Conrad",
        "Peter T Dziegielewski",
        "Austin S Lam"
      ],
      "affiliations": [
        "University of Florida"
      ],
      "normalized_institutions": [
        "University of Florida"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154011/ctdna_nodal_3panel_d.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154011/ctdna_nodal_3panel_d.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154011"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 557,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Edgar D Uribe Sanchez, BA ; Kirollos Armosh, BS; Kevin Liu, MD; Dustin Conrad, MD; Peter T Dziegielewski, MD; Austin S Lam, MD",
        "Affiliations": "University of Florida",
        "Introduction": "Circulating tumor DNA (ctDNA), a tumor-derived component of cell-free DNA, has emerged as a minimally invasive biomarker with potential applications in risk stratification and treatment planning across solid tumor types.[1,2] In oral cavity squamous cell carcinoma (OCSCC), the relationship between preoperative ctDNA levels and adverse pathologic features such as cervical lymph node metastasis, perineural invasion (PNI), and lymphovascular invasion (LVI) remains insufficiently characterized. Improved understanding of how ctDNA reflects metastatic potential may help guide decisions regarding timing of elective neck dissection and reduce the need for second operations.[3] This study investigates associations between preoperative ctDNA levels and cervical nodal involvement, evaluates the diagnostic performance of ctDNA for predicting nodal metastasis, and examines whether ctDNA correlates with nodal metastatic burden.",
        "Methods": "A retrospective chart review was conducted of patients with OCSCC who had preoperative ctDNA levels measured using the Signatera assay (Natera, Inc.). Electronic medical records were reviewed for ctDNA values, tumor subsite, histologic type, depth of invasion (DOI), presence of PNI and LVI, and postoperative neck pathology, including nodal positivity and number of metastatic nodes. Statistical analyses included Mann–Whitney U testing to compare ctDNA between node-negative and node-positive patients, ROC analysis to estimate discriminatory performance and identify an optimal ctDNA threshold, Spearman correlation and linear regression to assess ctDNA versus nodal burden, and multivariable logistic regression evaluating ctDNA and DOI as continuous predictors of nodal metastasis.",
        "Results": "Sixty-one patients had evaluable nodal pathology (35 node-negative; 26 node-positive). Median ctDNA levels were significantly higher in node-positive patients (1.56 MTM/ml, IQR 0.41–5.06) compared with node-negative patients (0.34 MTM/ml, IQR 0.06–1.08; Mann–Whitney p = 0.012). ROC analysis demonstrated moderate discriminatory ability (AUC = 0.69), with an optimal ctDNA cutoff of 1.36 MTM/ml (sensitivity = 58%, specificity = 77%) for predicting nodal positivity.",
        "Abstract": "Among node-positive patients (n = 26), ctDNA did not correlate with nodal metastatic burden. Spearman correlation showed no association between ctDNA and number of involved nodes (ρ = 0.03, p = 0.89), and linear regression demonstrated negligible explanatory value (β = +0.06 MTM/ml per node; 95% CI −0.82 to 0.94; R² = 0.001). ctDNA did not differ between low (1–2 nodes) and high (≥3 nodes) metastatic burden groups (p = 0.70), nor between patients with 1 versus ≥2 positive nodes (p = 0.50). In multivariable logistic regression including continuous ctDNA and DOI, the overall model significantly predicted nodal metastasis (p = 0.026). ctDNA showed a borderline association with nodal positivity when adjusting for DOI (coefficient = +0.17, p = 0.091), and DOI demonstrated a similar trend (coefficient = +0.05, p = 0.074). The combined significance of the model suggests that ctDNA provides biological information beyond anatomic invasion alone. View in Agenda and Add to Schedule",
        "Conclusion": "Preoperative ctDNA levels are significantly associated with having positive cervical lymph nodes in OCSCC but do not reflect overall nodal burden. ctDNA demonstrates moderate ability to distinguish node-positive from node-negative, with an optimal threshold of approximately 1.36 MTM/ml. Although ctDNA does not track with metastatic nodal burden, multivariable analysis indicates that ctDNA and DOI together contribute complementary information for predicting nodal disease. These findings support the potential role of ctDNA as a biomarker for risk stratification in OCSCC. Larger studies are needed to validate these associations and determine whether ctDNA independently predicts occult nodal metastasis."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating Preoperative ctDNA as a Predictor of Cervical Nodal Metastasis in Oral Cavity Squamous Cell Carcinoma</span>. <u>Edgar D Uribe Sanchez, BA</u>; Kirollos Armosh, BS; Kevin Liu, MD; Dustin Conrad, MD; Peter T Dziegielewski, MD; Austin S Lam, MD. University of Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Circulating tumor DNA (ctDNA), a tumor-derived component of cell-free DNA, has emerged as a minimally invasive biomarker with potential applications in risk stratification and treatment planning across solid tumor types.[1,2] In oral cavity squamous cell carcinoma (OCSCC), the relationship between preoperative ctDNA levels and adverse pathologic features such as cervical lymph node metastasis, perineural invasion (PNI), and lymphovascular invasion (LVI) remains insufficiently characterized. Improved understanding of how ctDNA reflects metastatic potential may help guide decisions regarding timing of elective neck dissection and reduce the need for second operations.[3] This study investigates associations between preoperative ctDNA levels and cervical nodal involvement, evaluates the diagnostic performance of ctDNA for predicting nodal metastasis, and examines whether ctDNA correlates with nodal metastatic burden. </p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted of patients with OCSCC who had preoperative ctDNA levels measured using the Signatera assay (Natera, Inc.). Electronic medical records were reviewed for ctDNA values, tumor subsite, histologic type, depth of invasion (DOI), presence of PNI and LVI, and postoperative neck pathology, including nodal positivity and number of metastatic nodes. Statistical analyses included Mann–Whitney U testing to compare ctDNA between node-negative and node-positive patients, ROC analysis to estimate discriminatory performance and identify an optimal ctDNA threshold, Spearman correlation and linear regression to assess ctDNA versus nodal burden, and multivariable logistic regression evaluating ctDNA and DOI as continuous predictors of nodal metastasis. </p>\n\n<p><strong>Results: </strong>Sixty-one patients had evaluable nodal pathology (35 node-negative; 26 node-positive). Median ctDNA levels were significantly higher in node-positive patients (1.56 MTM/ml, IQR 0.41–5.06) compared with node-negative patients (0.34 MTM/ml, IQR 0.06–1.08; Mann–Whitney p = 0.012). ROC analysis demonstrated moderate discriminatory ability (AUC = 0.69), with an optimal ctDNA cutoff of 1.36 MTM/ml (sensitivity = 58%, specificity = 77%) for predicting nodal positivity. </p>\n\n<p>Among node-positive patients (n = 26), ctDNA did not correlate with nodal metastatic burden. Spearman correlation showed no association between ctDNA and number of involved nodes (ρ = 0.03, p = 0.89), and linear regression demonstrated negligible explanatory value (β = +0.06 MTM/ml per node; 95% CI −0.82 to 0.94; R² = 0.001). ctDNA did not differ between low (1–2 nodes) and high (≥3 nodes) metastatic burden groups (p = 0.70), nor between patients with 1 versus ≥2 positive nodes (p = 0.50). </p>\n\n<p>In multivariable logistic regression including continuous ctDNA and DOI, the overall model significantly predicted nodal metastasis (p = 0.026). ctDNA showed a borderline association with nodal positivity when adjusting for DOI (coefficient = +0.17, p = 0.091), and DOI demonstrated a similar trend (coefficient = +0.05, p = 0.074). The combined significance of the model suggests that ctDNA provides biological information beyond anatomic invasion alone. </p>\n\n<p><strong>Conclusion: </strong>Preoperative ctDNA levels are significantly associated with having positive cervical lymph nodes in OCSCC but do not reflect overall nodal burden. ctDNA demonstrates moderate ability to distinguish node-positive from node-negative, with an optimal threshold of approximately 1.36 MTM/ml. Although ctDNA does not track with metastatic nodal burden, multivariable analysis indicates that ctDNA and DOI together contribute complementary information for predicting nodal disease. These findings support the potential role of ctDNA as a biomarker for risk stratification in OCSCC. Larger studies are needed to validate these associations and determine whether ctDNA independently predicts occult nodal metastasis. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154011/ctdna_nodal_3panel_d.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154011--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S063",
      "content_id": "153822",
      "abstract_number": "S063",
      "poster_number": "",
      "title": "Ki-67 expression predicts occult nodal metastasis and recurrence in surgically treated clinical early-stage oral cancer",
      "summary": "High Ki-67 expression independently predicts ONM and recurrence in clinically node-negative, early-stage OSCC. These findings underscore the clinical importance of incorporating Ki-67 into risk stratification models and support the potential role of END as a tailored management strategy for high-risk patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153822",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ming-Hsien Tsai, MD",
      "presenter": "Ming-Hsien Tsai, MD",
      "authors": "Ming-Hsien Tsai, MD",
      "normalized_authors": [
        "Ming-Hsien Tsai"
      ],
      "affiliations": [
        "Kaohsiung Chang-Gung Memorial Hospital"
      ],
      "normalized_institutions": [
        "Kaohsiung Chang-Gung Memorial Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 211,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ming-Hsien Tsai, MD",
        "Affiliations": "Kaohsiung Chang-Gung Memorial Hospital",
        "Objective": "To evaluate occult nodal metastasis (ONM) and prognostic value of Ki-67 for patients with clinical early-stage (cT1-2N0M0) oral squamous cell carcinoma (OSCC).",
        "Methods": "We retrospectively analyzed 226 patients with clinical early-stage (cT1–2N0M0) OSCC who underwent primary resection with elective neck dissection (END) between 2015 and 2019. Clinicopathological variables and Ki-67 expression, assessed by immunohistochemistry, were collected. Receiver operating characteristic analysis with five-fold cross-validation was used to determine the optimal Ki-67 cutoff. Logistic regression identified risk factors for ONM and recurrence, and a predictive nomogram was developed and internally validated.",
        "Results": "The optimal cut-off for Ki-67 expression was determined to be 30%, validated by five-fold cross-validation. High Ki-67 (≥30%) was significantly associated with adverse pathological features and independently predicted both ONM (Odds ratio [OR] 4.22, 95% confidence interval [CI] 1.24–14.40, p = 0.021) and recurrence (OR 2.37, 95% CI 1.03–5.43, p = 0.042). Incorporating Ki-67 into a clinicopathological nomogram improved predictive accuracy for ONM (C-index 0.731).",
        "Conclusions": "High Ki-67 expression independently predicts ONM and recurrence in clinically node-negative, early-stage OSCC. These findings underscore the clinical importance of incorporating Ki-67 into risk stratification models and support the potential role of END as a tailored management strategy for high-risk patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ki-67 expression predicts occult nodal metastasis and recurrence in surgically treated clinical early-stage oral cancer</span>. <u>Ming-Hsien Tsai, MD</u>. Kaohsiung Chang-Gung Memorial Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate occult nodal metastasis (ONM) and prognostic value of Ki-67 for patients with clinical early-stage (cT1-2N0M0) oral squamous cell carcinoma (OSCC).</p>\n\n<p><strong>Methods: </strong>We retrospectively analyzed 226 patients with clinical early-stage (cT1–2N0M0) OSCC who underwent primary resection with elective neck dissection (END) between 2015 and 2019. Clinicopathological variables and Ki-67 expression, assessed by immunohistochemistry, were collected. Receiver operating characteristic analysis with five-fold cross-validation was used to determine the optimal Ki-67 cutoff. Logistic regression identified risk factors for ONM and recurrence, and a predictive nomogram was developed and internally validated.</p>\n\n<p><strong>Results: </strong>The optimal cut-off for Ki-67 expression was determined to be 30%, validated by five-fold cross-validation. High Ki-67 (≥30%) was significantly associated with adverse pathological features and independently predicted both ONM (Odds ratio [OR] 4.22, 95% confidence interval [CI] 1.24–14.40, p = 0.021) and recurrence (OR 2.37, 95% CI 1.03–5.43, p = 0.042). Incorporating Ki-67 into a clinicopathological nomogram improved predictive accuracy for ONM (C-index 0.731).</p>\n\n<p><strong>Conclusions: </strong>High Ki-67 expression independently predicts ONM and recurrence in clinically node-negative, early-stage OSCC. These findings underscore the clinical importance of incorporating Ki-67 into risk stratification models and support the potential role of END as a tailored management strategy for high-risk patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153822--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S064",
      "content_id": "153194",
      "abstract_number": "S064",
      "poster_number": "",
      "title": "Immune Profiling of Tumor-Regional Lymphatic Fluid in Head and Neck Cancer",
      "summary": "SDF contains tumor-proximal immune populations often diluted in peripheral blood, including exhausted CD8+ T cells and dysregulated NK subsets. SDF immunoprofiling may enable biomarker development and provide insight to improve risk stratification, guide nodal management, and predict response to immunotherapy in head and neck cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153194",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beverly J Fu, BA, MA",
      "presenter": "Beverly J Fu, BA, MA",
      "authors": "Beverly J Fu, BA, MA ; Ivan Stepanek, PhD; Imran A Mohammad, PhD; Keene Lee, BA; Amanda L Verzosa, BS, MS; Alistaire D Ruggiero-Sherman, PhD; John B Sunwoo, MD",
      "normalized_authors": [
        "Beverly J Fu, MA",
        "Ivan Stepanek",
        "Imran A Mohammad",
        "Keene Lee",
        "Amanda L Verzosa",
        "Alistaire D Ruggiero-Sherman",
        "John B Sunwoo"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153194/SDF_Immune_Populations_Figure.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153194/SDF_Immune_Populations_Figure.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153194"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Beverly J Fu, BA, MA ; Ivan Stepanek, PhD; Imran A Mohammad, PhD; Keene Lee, BA; Amanda L Verzosa, BS, MS; Alistaire D Ruggiero-Sherman, PhD; John B Sunwoo, MD",
        "Affiliations": "Department of Otolaryngology – Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304",
        "Objectives": "To characterize the immune composition of tumor-draining surgical drain fluid (SDF) in head and neck cancer and evaluate associations with clinical and pathologic features. We aim to identify SDF-based biomarkers that correlate with clinical behavior and outcomes to guide disease management.",
        "Methods": "SDF was collected on postoperative day 1 from drains. For T and B cell analyses, cells were cryopreserved and analyzed at a later date using a 28-marker phenotyping panel (n=10). For NK cell analyses, fresh SDF was stained immediately with a focused NK/tissue-residency panel due to NK cell cryosensitivity (n=8). Cell-free SDF supernatant was assessed for total TGF-β1 by ELISA. Staining was performed at 4°C, and samples were acquired on a BD FACSymphony. Flow cytometry data were analyzed in FlowJo with statistical testing in Python (p<0.05).",
        "Results": "SDF was collected on postoperative day 1 from 29 patients who underwent resection for head and neck cancer. The cohort had a mean age of 65.2 years (range 40–95); 55.2% were female, and 75.9% were never-smokers. Most tumors originated from the oral tongue (51.7%); 30.8% were pT1, 34.6% pT2, and 26.9% pT4a; 50.0% had pathologic nodal metastases. Perineural invasion occurred in 50.0% and lymphovascular invasion in 20.8%.",
        "Abstract": "Quantifiable TGF-β1 levels were detected in 12/17 patients (mean 1.81 ng/mL). No significant associations were observed with demographics, tumor stage, nodal status, depth of invasion, or prior oncologic treatment. A non-significant trend suggested lower TGF-β1 concentrations with larger tumors, though interpretation is limited by small sample size and low circulating cytokine levels. SDF was enriched for terminally differentiated CD8+ T cells (CD45RA+CD27-), with nodal-positive patients demonstrating higher mean percentages when excluding two outliers with insufficient live cells. CD57+CD8+ T cells were detected in patients with higher pT stage and greater depth of invasion, suggesting an association with more aggressive disease biology and a senescent immune state. CD38-CD39+ B cells, consistent with regulatory B-cell–like populations, trended higher in node-positive tumors (effect size d = 1.40), supporting a role for immunoregulatory signaling in nodal spread. All CD49a/CD103-defined NK cell subpopulations were detected in fresh SDF (n=8), confirming capture of tumor-proximal NK cell phenotypes. CD49a-CD103+ NK cells were most abundant overall (mean 36.9%), while CD49a+CD103+ cytotoxic NK cells were consistently low in several node-positive cases. Substantial heterogeneity was observed, including an N3 case with high CD49a-CD103+ but minimal CD49a+CD103+ cells, suggesting a hyporesponsive NK cell phenotype in advanced disease. Across immune subsets, trends consistently suggested immunosenescence and reduced effector function in association with nodal metastasis, advanced stage, and pathologic risk features. These findings support SDF to characterize tumor-regional immunity and a promising source of biomarkers to enhance risk stratification and nodal management. View in Agenda and Add to Schedule",
        "Conclusion": "SDF contains tumor-proximal immune populations often diluted in peripheral blood, including exhausted CD8+ T cells and dysregulated NK subsets. SDF immunoprofiling may enable biomarker development and provide insight to improve risk stratification, guide nodal management, and predict response to immunotherapy in head and neck cancer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immune Profiling of Tumor-Regional Lymphatic Fluid in Head and Neck Cancer</span>. <u>Beverly J Fu, BA, MA</u>; Ivan Stepanek, PhD; Imran A Mohammad, PhD; Keene Lee, BA; Amanda L Verzosa, BS, MS; Alistaire D Ruggiero-Sherman, PhD; John B Sunwoo, MD. Department of Otolaryngology – Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives</strong>: To characterize the immune composition of tumor-draining surgical drain fluid (SDF) in head and neck cancer and evaluate associations with clinical and pathologic features. We aim to identify SDF-based biomarkers that correlate with clinical behavior and outcomes to guide disease management.</p>\n\n<p><strong>Methods</strong>: SDF was collected on postoperative day 1 from drains. For T and B cell analyses, cells were cryopreserved and analyzed at a later date using a 28-marker phenotyping panel (n=10). For NK cell analyses, fresh SDF was stained immediately with a focused NK/tissue-residency panel due to NK cell cryosensitivity (n=8). Cell-free SDF supernatant was assessed for total TGF-β1 by ELISA. Staining was performed at 4°C, and samples were acquired on a BD FACSymphony. Flow cytometry data were analyzed in FlowJo with statistical testing in Python (p<0.05).</p>\n\n<p><strong>Results</strong>: SDF was collected on postoperative day 1 from 29 patients who underwent resection for head and neck cancer. The cohort had a mean age of 65.2 years (range 40–95); 55.2% were female, and 75.9% were never-smokers. Most tumors originated from the oral tongue (51.7%); 30.8% were pT1, 34.6% pT2, and 26.9% pT4a; 50.0% had pathologic nodal metastases. Perineural invasion occurred in 50.0% and lymphovascular invasion in 20.8%.</p>\n\n<p>Quantifiable TGF-β1 levels were detected in 12/17 patients (mean 1.81 ng/mL). No significant associations were observed with demographics, tumor stage, nodal status, depth of invasion, or prior oncologic treatment. A non-significant trend suggested lower TGF-β1 concentrations with larger tumors, though interpretation is limited by small sample size and low circulating cytokine levels.</p>\n\n<p>SDF was enriched for terminally differentiated CD8+ T cells (CD45RA+CD27-), with nodal-positive patients demonstrating higher mean percentages when excluding two outliers with insufficient live cells. CD57+CD8+ T cells were detected in patients with higher pT stage and greater depth of invasion, suggesting an association with more aggressive disease biology and a senescent immune state. CD38-CD39+ B cells, consistent with regulatory B-cell–like populations, trended higher in node-positive tumors (effect size d = 1.40), supporting a role for immunoregulatory signaling in nodal spread.</p>\n\n<p>All CD49a/CD103-defined NK cell subpopulations were detected in fresh SDF (n=8), confirming capture of tumor-proximal NK cell phenotypes. CD49a-CD103+ NK cells were most abundant overall (mean 36.9%), while CD49a+CD103+ cytotoxic NK cells were consistently low in several node-positive cases. Substantial heterogeneity was observed, including an N3 case with high CD49a-CD103+ but minimal CD49a+CD103+ cells, suggesting a hyporesponsive NK cell phenotype in advanced disease.</p>\n\n<p>Across immune subsets, trends consistently suggested immunosenescence and reduced effector function in association with nodal metastasis, advanced stage, and pathologic risk features. These findings support SDF to characterize tumor-regional immunity and a promising source of biomarkers to enhance risk stratification and nodal management.</p>\n\n<p><strong>Conclusion</strong>: SDF contains tumor-proximal immune populations often diluted in peripheral blood, including exhausted CD8+ T cells and dysregulated NK subsets. SDF immunoprofiling may enable biomarker development and provide insight to improve risk stratification, guide nodal management, and predict response to immunotherapy in head and neck cancer.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153194/SDF_Immune_Populations_Figure.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153194--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S065",
      "content_id": "153689",
      "abstract_number": "S065",
      "poster_number": "",
      "title": "Prognostic and predictive utility of copy number variations in circulating tumor DNA in head and neck squamous cell carcinoma",
      "summary": "Using a LP-WGS assay, we demonstrate the robust detection of CNVs in plasma ctDNA of HNSCC patients receiving various treatment modalities. CNB at baseline identified patients with significantly worse OS, and any-timepoint positivity after treatment initiation trended toward poorer outcomes. These findings support plasma CNB as a possible strategy to refine risk stratification and guide cancer surveillance.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153689",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Edward S Sim, MD",
      "presenter": "Edward S Sim, MD",
      "authors": "Edward S Sim, MD 1 ; Daniel R Torres, MD 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Gjystina Lumaj 1 ; Jarrod W Stein 1 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Shriya Shukla 1 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
      "normalized_authors": [
        "Edward S Sim",
        "Daniel R Torres",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Gjystina Lumaj",
        "Jarrod W Stein",
        "Lori J Wirth",
        "Manisha J Patel",
        "Jong C Park",
        "Shriya Shukla",
        "Annie Chan",
        "Chirayu Patel",
        "Allen Feng",
        "Daniel G Deschler",
        "Jeremy D Richmon",
        "Derrick T Lin",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "normalized_institutions": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 425,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Edward S Sim, MD 1 ; Daniel R Torres, MD 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Gjystina Lumaj 1 ; Jarrod W Stein 1 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Shriya Shukla 1 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
        "Affiliations": "1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital",
        "Introduction": "Using plasma circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) has emerged as a promising, minimally invasive biomarker for predicting outcomes and treatment efficacy across solid cancers including head and neck squamous cell carcinoma (HNSCC). However, standard tumor-informed ctDNA assays require sequencing of the primary tumor, which is subject to tissue accessibility and sampling bias that may not fully reflect the heterogeneity or subclonal architecture of the tumor. This study aims to assess the utility of genome-wide, next-generation sequencing of plasma ctDNA to quantify copy number variation (CNV) signals as a potential tumor-agnostic strategy for MRD monitoring.",
        "Methods": "ctDNA was isolated from 250 plasma samples collected longitudinally from 33 HNSCC patients. PredicineSCORE, a low-pass whole-genome sequencing (LP-WGS) assay, was performed to detect CNVs in plasma samples at baseline and at serial timepoints following treatment initiation to assess blood copy-number burden (CNB). A CNB threshold was applied and samples above or below this threshold was considered CNB positive (CNB+) or negative (CNB-) respectively. Kaplan-Meier and Cox proportional hazard models were used to assess the association of CNB status with overall survival (OS) and progression-free survival (PFS).",
        "Results": "The median age at treatment initiation was 63 years (range, 34–91). Most patients were male (22/33, 67%) and non-Hispanic White (28/33, 85%). Five patients (15%) had HPV-associated disease. Thirteen of 33 patients (39%) received definitive chemoradiation, 12/33 (36%) immune checkpoint blockade (ICB) monotherapy, 6/33 (18%) ICB plus chemotherapy, and 2/33 (6%) ICB plus a novel agent in a clinical trial. The most frequent chromosomal copy-number alteration was a gain of 3q, observed in 8 of 48 HPV-associated plasma samples (17%) and in 52 of 202 HPV-unrelated samples (26%). 30 patients had baseline (pre-treatment) plasma available with 17 (56%) meeting the CNB threshold. Baseline CNB positivity was associated with significantly worse OS (HR = 4.38; 95% CI = 1.22–15.72; p = 0.01). CNB positivity at any time after treatment was observed in 26/33 patients (79%) and showed a non-significant trend towards worse OS (HR = 3.03; 95% CI = 0.69-13.33; p = 0.12) and PFS (HR = 2.70; 95% CI = 0.92-7.89; p = 0.06).",
        "Conclusions": "Using a LP-WGS assay, we demonstrate the robust detection of CNVs in plasma ctDNA of HNSCC patients receiving various treatment modalities. CNB at baseline identified patients with significantly worse OS, and any-timepoint positivity after treatment initiation trended toward poorer outcomes. These findings support plasma CNB as a possible strategy to refine risk stratification and guide cancer surveillance.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic and predictive utility of copy number variations in circulating tumor DNA in head and neck squamous cell carcinoma</span>. <u>Edward S Sim, MD</u><sup>1</sup>; Daniel R Torres, MD<sup>1</sup>; Jonathan J Paly, DO<sup>2</sup>; Ross D Merkin, MD<sup>2</sup>; Gjystina Lumaj<sup>1</sup>; Jarrod W Stein<sup>1</sup>; Lori J Wirth, MD<sup>2</sup>; Manisha J Patel, MD<sup>2</sup>; Jong C Park, MD<sup>2</sup>; Shriya Shukla<sup>1</sup>; Annie Chan, MD<sup>2</sup>; Chirayu Patel, MD<sup>2</sup>; Allen Feng, MD<sup>1</sup>; Daniel G Deschler, MD<sup>1</sup>; Jeremy D Richmon, MD<sup>1</sup>; Derrick T Lin, MD<sup>1</sup>; William C Faquin, MD, PhD<sup>2</sup>; Peter M Sadow, MD, PhD<sup>2</sup>; Bayan A Alzumaili, MD<sup>2</sup>; Thomas J Roberts, MD, MBA<sup>2</sup>; Adam S Fisch, MD, PhD<sup>2</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Massachusetts General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Using plasma circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) has emerged as a promising, minimally invasive biomarker for predicting outcomes and treatment efficacy across solid cancers including head and neck squamous cell carcinoma (HNSCC). However, standard tumor-informed ctDNA assays require sequencing of the primary tumor, which is subject to tissue accessibility and sampling bias that may not fully reflect the heterogeneity or subclonal architecture of the tumor. This study aims to assess the utility of genome-wide, next-generation sequencing of plasma ctDNA to quantify copy number variation (CNV) signals as a potential tumor-agnostic strategy for MRD monitoring.</p>\n\n<p><strong>Methods:</strong> ctDNA was isolated from 250 plasma samples collected longitudinally from 33 HNSCC patients. PredicineSCORE, a low-pass whole-genome sequencing (LP-WGS) assay, was performed to detect CNVs in plasma samples at baseline and at serial timepoints following treatment initiation to assess blood copy-number burden (CNB). A CNB threshold was applied and samples above or below this threshold was considered CNB positive (CNB+) or negative (CNB-) respectively. Kaplan-Meier and Cox proportional hazard models were used to assess the association of CNB status with overall survival (OS) and progression-free survival (PFS).</p>\n\n<p><strong>Results:</strong> The median age at treatment initiation was 63 years (range, 34–91). Most patients were male (22/33, 67%) and non-Hispanic White (28/33, 85%). Five patients (15%) had HPV-associated disease. Thirteen of 33 patients (39%) received definitive chemoradiation, 12/33 (36%) immune checkpoint blockade (ICB) monotherapy, 6/33 (18%) ICB plus chemotherapy, and 2/33 (6%) ICB plus a novel agent in a clinical trial. The most frequent chromosomal copy-number alteration was a gain of 3q, observed in 8 of 48 HPV-associated plasma samples (17%) and in 52 of 202 HPV-unrelated samples (26%). 30 patients had baseline (pre-treatment) plasma available with 17 (56%) meeting the CNB threshold. Baseline CNB positivity was associated with significantly worse OS (HR = 4.38; 95% CI = 1.22–15.72; p = 0.01). CNB positivity at any time after treatment was observed in 26/33 patients (79%) and showed a non-significant trend towards worse OS (HR = 3.03; 95% CI = 0.69-13.33; p = 0.12) and PFS (HR = 2.70; 95% CI = 0.92-7.89; p = 0.06).</p>\n\n<p><strong>Conclusions:</strong> Using a LP-WGS assay, we demonstrate the robust detection of CNVs in plasma ctDNA of HNSCC patients receiving various treatment modalities. CNB at baseline identified patients with significantly worse OS, and any-timepoint positivity after treatment initiation trended toward poorer outcomes. These findings support plasma CNB as a possible strategy to refine risk stratification and guide cancer surveillance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153689--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S066",
      "content_id": "153742",
      "abstract_number": "S066",
      "poster_number": "",
      "title": "The Architecture of the Head and Neck Squamous Cell Carcinoma Microenvironment as a Determinant of Malignant Transformation",
      "summary": "Head and neck squamous cell carcinomas (HNSCCs) develop through a series of precancerous stages that can be identified macroscopically and microscopically. However, only approximately 10% of premalignant lesions transform into cancer, making early treatment limited to observation for most patients. Although we understand some of the genetic changes that lead to HNSCC, the roles of the stroma and immune...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153742",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Donald T Weed, MD",
      "presenter": "Donald T Weed, MD",
      "authors": "Daria Ivanova, MD 1 ; Melissa Ghulam-Smith, MD 1 ; Michele Ceccarelli, MsC 1 ; Silvio Bicciato, PhD 2 ; Nasir Ud Din 1 ; Carmen Gomez Fernandez, MD 1 ; Donald T Weed, MD 1 ; Paolo Serafini, PhD 1",
      "normalized_authors": [
        "Daria Ivanova",
        "Melissa Ghulam-Smith",
        "Michele Ceccarelli",
        "Silvio Bicciato",
        "Nasir Ud Din",
        "Carmen Gomez Fernandez",
        "Donald T Weed",
        "Paolo Serafini"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine",
        "University of Padova"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine",
        "University of Padova"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 336,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daria Ivanova, MD 1 ; Melissa Ghulam-Smith, MD 1 ; Michele Ceccarelli, MsC 1 ; Silvio Bicciato, PhD 2 ; Nasir Ud Din 1 ; Carmen Gomez Fernandez, MD 1 ; Donald T Weed, MD 1 ; Paolo Serafini, PhD 1",
        "Affiliations": "1 University of Miami Miller School of Medicine; 2 University of Padova",
        "Abstract": "Head and neck squamous cell carcinomas (HNSCCs) develop through a series of precancerous stages that can be identified macroscopically and microscopically. However, only approximately 10% of premalignant lesions transform into cancer, making early treatment limited to observation for most patients. Although we understand some of the genetic changes that lead to HNSCC, the roles of the stroma and immune infiltrates in malignant transformation remain unknown. Given the crucial role of tumor microenvironment on tumor progression, we hypothesized that the immune landscape in premalignant lesions may also predict later malignant transformation. To test this hypothesis, we retrospectively compared, using CODEX multiplex immunofluorescence microscopy and unbiased bioinformatic analysis, the premalignant lesions from patients (n=5) who developed tumors within the next 2 years with those from patients (n=10) with similar lesions but who did not develop tumors in the following 2 years. After image acquisition, quality control, and, segmentation, raw data were normalized and analyzed with an ad-hoc developed cell classifier that lead to the identification of 35 cell types that include structural cells (e.g. Keratynocytes, epitelhial cells, myofibroblasts, fibroblasts) and most leukocyte subsets such as CD4 and CD8 T subsets, neutrophils, macrophages, dendritic cells, myeloid derived suppressor cells, natural killers, and others. Notably, classical Lox1 negative neutrophils were more abundant (p=0.05) in the lesion from patients who did not develop tumors. Cellular neighbor KNN analysis, followed by PERMANOVA comparison of lesion ecology, identified various cellular neighborhoods whose abundance differentially characterized lesions that eventually transformed into cancer from those that did not. Notably, the cellular composition of the same neighborhood differed between lesions that progressed to cancer and those that did not. In summary, despite the limited number of patients, our analysis suggests that the architecture of the premalignant microenvironment may have a prognostic role in identifying lesions with high risk of malignant transformation. This may lead to the future development of early treatment that could reduce HNSCC incidence and thus limit treatment morbidity and cancer mortality. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Architecture of the Head and Neck Squamous Cell Carcinoma Microenvironment as a Determinant of Malignant Transformation</span>. Daria Ivanova, MD<sup>1</sup>; Melissa Ghulam-Smith, MD<sup>1</sup>; Michele Ceccarelli, MsC<sup>1</sup>; Silvio Bicciato, PhD<sup>2</sup>; Nasir Ud Din<sup>1</sup>; Carmen Gomez Fernandez, MD<sup>1</sup>; <u>Donald T Weed, MD</u><sup>1</sup>; Paolo Serafini, PhD<sup>1</sup>. <sup>1</sup>University of Miami Miller School of Medicine; <sup>2</sup>University of Padova<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinomas (HNSCCs) develop through a series of precancerous stages that can be identified macroscopically and microscopically. However, only approximately 10% of premalignant lesions transform into cancer, making early treatment limited to observation for most patients. Although we understand some of the genetic changes that lead to HNSCC, the roles of the stroma and immune infiltrates in malignant transformation remain unknown. Given the crucial role of tumor microenvironment on tumor progression, we hypothesized that the immune landscape in premalignant lesions may also predict later malignant transformation. To test this hypothesis, we retrospectively compared, using CODEX multiplex immunofluorescence microscopy and unbiased bioinformatic analysis, the premalignant lesions from patients (n=5) who developed tumors within the next 2 years with those from patients (n=10) with similar lesions but who did not develop tumors in the following 2 years. After image acquisition, quality control, and, segmentation, raw data were normalized and analyzed with an ad-hoc developed cell classifier that lead to the identification of 35 cell types that include structural cells (e.g. Keratynocytes, epitelhial cells, myofibroblasts, fibroblasts) and most leukocyte subsets such as CD4 and CD8 T subsets, neutrophils, macrophages, dendritic cells, myeloid derived suppressor cells, natural killers, and others. Notably, classical Lox1 negative neutrophils were more abundant (p=0.05) in the lesion from patients who did not develop tumors. Cellular neighbor KNN analysis, followed by PERMANOVA comparison of lesion ecology, identified various cellular neighborhoods whose abundance differentially characterized lesions that eventually transformed into cancer from those that did not. Notably, the cellular composition of the same neighborhood differed between lesions that progressed to cancer and those that did not.</p>\n\n<p>In summary, despite the limited number of patients, our analysis suggests that the architecture of the premalignant microenvironment may have a prognostic role in identifying lesions with high risk of malignant transformation. This may lead to the future development of early treatment that could reduce HNSCC incidence and thus limit treatment morbidity and cancer mortality. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153742--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S067",
      "content_id": "153429",
      "abstract_number": "S067",
      "poster_number": "",
      "title": "High Frequency of NRAS and CTNNB1 Mutations in Japanese Sinonasal Mucosal Melanoma",
      "summary": "Although genetic alterations were not significantly correlated with clinical outcomes, NRAS mutations may serve as prognostic indicators, and CTNNB1 mutations may influence response to immune checkpoint inhibitors. Larger prospective studies are warranted to determine the clinical relevance of genetic mutations in Japanese patients with SNMM.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153429",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nayuta Tsushima, PhD",
      "presenter": "Nayuta Tsushima, PhD",
      "authors": "Nayuta Tsushima, PhD ; Satoshi Kano, PhD; Takayoshi Suzuki, PhD; Hiroshi Idogawa; Hayato Imanari; Masaki Kakumu; Akihiro Homma, PhD",
      "normalized_authors": [
        "Nayuta Tsushima",
        "Satoshi Kano",
        "Takayoshi Suzuki",
        "Hiroshi Idogawa",
        "Hayato Imanari",
        "Masaki Kakumu",
        "Akihiro Homma"
      ],
      "affiliations": [
        "Hokkaido University"
      ],
      "normalized_institutions": [
        "Hokkaido University"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 258,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nayuta Tsushima, PhD ; Satoshi Kano, PhD; Takayoshi Suzuki, PhD; Hiroshi Idogawa; Hayato Imanari; Masaki Kakumu; Akihiro Homma, PhD",
        "Affiliations": "Hokkaido University",
        "Objective": "Sinonasal mucosal melanoma (SNMM) is an aggressive and rare malignancy, with a higher reported incidence in Asian populations than in Caucasians. Although BRAF/MEK–targeted therapy is effective for cutaneous melanoma harboring BRAF V600 mutations, molecular targeted treatments for mucosal melanoma have not been established. Genetic alterations in Japanese SNMM patients remain largely unknown. This study aimed to clarify the genetic and clinicopathological characteristics of Japanese patients with SNMM.",
        "Methods": "Eighteen surgically resected SNMM tissue samples were analyzed using targeted next-generation sequencing of 52 cancer-related genes to identify potential driver mutations and biomarkers associated with clinical outcomes. Immunohistochemistry for β-catenin was performed in cases with CTNNB1 mutations.",
        "Results": "Pathogenic mutations were identified in 8 of 18 patients (44%). NRAS mutations were the most frequent (6/18, 33%), followed by CTNNB1 (2/18, 11%) and BRAF (1/18, 5.6%). No BRAF V600 mutations were detected; the single BRAF mutation identified was K601R. NRAS mutations tended to occur in younger patients and were associated with higher T-classification and poorer survival, although not statistically significant. Nuclear β-catenin accumulation was confirmed in both tumors harboring CTNNB1 exon 3 mutations (S37F, S45F). No significant differences in overall survival, recurrence-free survival, or distant metastasis were observed between patients with and without genetic mutations.",
        "Conclusion": "Although genetic alterations were not significantly correlated with clinical outcomes, NRAS mutations may serve as prognostic indicators, and CTNNB1 mutations may influence response to immune checkpoint inhibitors. Larger prospective studies are warranted to determine the clinical relevance of genetic mutations in Japanese patients with SNMM.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>High Frequency of NRAS and CTNNB1 Mutations in Japanese Sinonasal Mucosal Melanoma</span>. <u>Nayuta Tsushima, PhD</u>; Satoshi Kano, PhD; Takayoshi Suzuki, PhD; Hiroshi Idogawa; Hayato Imanari; Masaki Kakumu; Akihiro Homma, PhD. Hokkaido University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Sinonasal mucosal melanoma (SNMM) is an aggressive and rare malignancy, with a higher reported incidence in Asian populations than in Caucasians. Although BRAF/MEK–targeted therapy is effective for cutaneous melanoma harboring BRAF V600 mutations, molecular targeted treatments for mucosal melanoma have not been established. Genetic alterations in Japanese SNMM patients remain largely unknown. This study aimed to clarify the genetic and clinicopathological characteristics of Japanese patients with SNMM.</p>\n\n<p><strong>Methods: </strong>Eighteen surgically resected SNMM tissue samples were analyzed using targeted next-generation sequencing of 52 cancer-related genes to identify potential driver mutations and biomarkers associated with clinical outcomes. Immunohistochemistry for β-catenin was performed in cases with CTNNB1 mutations.</p>\n\n<p><strong>Results: </strong>Pathogenic mutations were identified in 8 of 18 patients (44%). NRAS mutations were the most frequent (6/18, 33%), followed by CTNNB1 (2/18, 11%) and BRAF (1/18, 5.6%). No BRAF V600 mutations were detected; the single BRAF mutation identified was K601R. NRAS mutations tended to occur in younger patients and were associated with higher T-classification and poorer survival, although not statistically significant. Nuclear β-catenin accumulation was confirmed in both tumors harboring CTNNB1 exon 3 mutations (S37F, S45F). No significant differences in overall survival, recurrence-free survival, or distant metastasis were observed between patients with and without genetic mutations.</p>\n\n<p><strong>Conclusion: </strong>Although genetic alterations were not significantly correlated with clinical outcomes, NRAS mutations may serve as prognostic indicators, and CTNNB1 mutations may influence response to immune checkpoint inhibitors. Larger prospective studies are warranted to determine the clinical relevance of genetic mutations in Japanese patients with SNMM.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153429--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S068",
      "content_id": "154142",
      "abstract_number": "S068",
      "poster_number": "",
      "title": "Genomic and Diagnostic Biomarkers in Sinonasal Undifferentiated Carcinomas – A Systematic Review and Meta-Analysis",
      "summary": "This systematic review and meta-analysis characterises the molecular landscape of SNUCs. IDH2 mutations and SMARCB1-deficiency define clinically distinct subsets with potential therapeutic relevance. Our findings suggest the potential of integrating multimodal molecular diagnostics to refine diagnostic accuracy, tumour classification, and biomarker-informed management. Future studies should prioritise...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154142",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Seng Hong Wong, MBBS",
      "presenter": "Ryan Seng Hong Wong, MBBS",
      "authors": "Ryan Seng Hong Wong, MBBS 1 ; Manish Warrier, MBBS 1 ; Isaac Tze Yang Chow, MBBS 1 ; Joel Kar Heng Tang, MBBS 1 ; Bingcheng Wu, MBBS, FRCPath 2 ; Joshua Tay, MBBS, PhD, MRCS, MMED, FAMS 3",
      "normalized_authors": [
        "Ryan Seng Hong Wong, MBBS",
        "Manish Warrier, MBBS",
        "Isaac Tze Yang Chow, MBBS",
        "Joel Kar Heng Tang, MBBS",
        "Bingcheng Wu, MBBS, FRCPath",
        "Joshua Tay, MBBS, MRCS, MMED, FAMS"
      ],
      "affiliations": [
        "Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
        "Department of Pathology, National University Hospital",
        "Department of Otolaryngology - Head & Neck Surgery (ENT), National University Hospital"
      ],
      "normalized_institutions": [
        "Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
        "Department of Pathology, National University Hospital",
        "Department of Otolaryngology - Head & Neck Surgery (ENT), National University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 324,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background and Aims",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryan Seng Hong Wong, MBBS 1 ; Manish Warrier, MBBS 1 ; Isaac Tze Yang Chow, MBBS 1 ; Joel Kar Heng Tang, MBBS 1 ; Bingcheng Wu, MBBS, FRCPath 2 ; Joshua Tay, MBBS, PhD, MRCS, MMED, FAMS 3",
        "Affiliations": "1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 2 Department of Pathology, National University Hospital; 3 Department of Otolaryngology - Head & Neck Surgery (ENT), National University Hospital",
        "Background and Aims": "Sinonasal undifferentiated carcinomas (SNUCs) are aggressive malignancies that present unique diagnostic and therapeutic challenges due to their histological heterogeneity and overlapping features with other poorly differentiated sinonasal carcinomas. Recent advances have led to significant re-classification of SNUCs into unique clinical entities. This systematic review and meta-analysis aims to characterise the proteomic and molecular genetic landscape of SNUCs and diagnostic biomarkers, in order to better define tumour types and potentially inform targeted treatment.",
        "Methods": "PubMed, Embase, Cochrane Library, and Scopus were systematically searched from inception to 15 September 2024 for studies evaluating protein and molecular genetic biomarkers in adult SNUCs. Two independent reviewers screened studies, extracted data and assessed methodological risk of bias. Where feasible, pooled analyses of biomarker prevalence and subsequent subgroup analyses comparing yield between diagnostic methods were performed using random-effects models.",
        "Results": "Forty-one studies comprising 574 tumours were included. Cohorts utilising combined DNA sequencing methods demonstrated a higher mutated IDH pooled prevalence (66.0% [95% CI: 51.1–78.3%]) compared to cohorts using immunohistochemistry (20.7% [95% CI: 10.7–36.7%]) and cohorts using single-modality DNA sequencing (34.1% [95% CI: 19.4–53.1%]). Meta-analysis of p16/HPV DNA detection rates showed higher pooled positivity with p16 immunohistochemistry (47.1% [95% CI: 37.6%–56.7%]) compared to direct HPV DNA detection via in-situ hybridisation (24.4% [95% CI: 14.1%–39.0%]) or PCR (10.0% [95% CI: 1.4%–46.7%]), although not reaching statistical significance. Qualitative synthesis of immunohistochemistry methods revealed that IDH1/2 mutations and c-KIT positivity were largely to SMARCB1-positive tumours.",
        "Conclusion": "This systematic review and meta-analysis characterises the molecular landscape of SNUCs. IDH2 mutations and SMARCB1-deficiency define clinically distinct subsets with potential therapeutic relevance. Our findings suggest the potential of integrating multimodal molecular diagnostics to refine diagnostic accuracy, tumour classification, and biomarker-informed management. Future studies should prioritise standardisation of detection methods and provide prognostic outcomes in clinically annotated cohorts.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Genomic and Diagnostic Biomarkers in Sinonasal Undifferentiated Carcinomas – A Systematic Review and Meta-Analysis</span>. <u>Ryan Seng Hong Wong, MBBS</u><sup>1</sup>; Manish Warrier, MBBS<sup>1</sup>; Isaac Tze Yang Chow, MBBS<sup>1</sup>; Joel Kar Heng Tang, MBBS<sup>1</sup>; Bingcheng Wu, MBBS, FRCPath<sup>2</sup>; Joshua Tay, MBBS, PhD, MRCS, MMED, FAMS<sup>3</sup>. <sup>1</sup>Yong Loo Lin School of Medicine, National University of Singapore, Singapore; <sup>2</sup>Department of Pathology, National University Hospital; <sup>3</sup>Department of Otolaryngology - Head & Neck Surgery (ENT), National University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background and Aims: </strong>Sinonasal undifferentiated carcinomas (SNUCs) are aggressive malignancies that present unique diagnostic and therapeutic challenges due to their histological heterogeneity and overlapping features with other poorly differentiated sinonasal carcinomas. Recent advances have led to significant re-classification of SNUCs into unique clinical entities. This systematic review and meta-analysis aims to characterise the proteomic and molecular genetic landscape of SNUCs and diagnostic biomarkers, in order to better define tumour types and potentially inform targeted treatment.</p>\n\n<p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, and Scopus were systematically searched from inception to 15 September 2024 for studies evaluating protein and molecular genetic biomarkers in adult SNUCs. Two independent reviewers screened studies, extracted data and assessed methodological risk of bias. Where feasible, pooled analyses of biomarker prevalence and subsequent subgroup analyses comparing yield between diagnostic methods were performed using random-effects models. </p>\n\n<p><strong>Results: </strong>Forty-one studies comprising 574 tumours were included. Cohorts utilising combined DNA sequencing methods demonstrated a higher mutated IDH pooled prevalence (66.0% [95% CI: 51.1–78.3%]) compared to cohorts using immunohistochemistry (20.7% [95% CI: 10.7–36.7%]) and cohorts using single-modality DNA sequencing (34.1% [95% CI: 19.4–53.1%]). Meta-analysis of p16/HPV DNA detection rates showed higher pooled positivity with p16 immunohistochemistry (47.1% [95% CI: 37.6%–56.7%]) compared to direct HPV DNA detection via in-situ hybridisation (24.4% [95% CI: 14.1%–39.0%]) or PCR (10.0% [95% CI: 1.4%–46.7%]), although not reaching statistical significance. Qualitative synthesis of immunohistochemistry methods revealed that IDH1/2 mutations and c-KIT positivity were largely to SMARCB1-positive tumours. </p>\n\n<p><strong>Conclusion: </strong>This systematic review and meta-analysis characterises the molecular landscape of SNUCs. IDH2 mutations and SMARCB1-deficiency define clinically distinct subsets with potential therapeutic relevance. Our findings suggest the potential of integrating multimodal molecular diagnostics to refine diagnostic accuracy, tumour classification, and biomarker-informed management. Future studies should prioritise standardisation of detection methods and provide prognostic outcomes in clinically annotated cohorts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154142--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S069",
      "content_id": "154515",
      "abstract_number": "S069",
      "poster_number": "",
      "title": "Identification of Clinical, Histopathological, Cancer Stem Cell, and Epithelial–Mesenchymal Transition Markers as Predictors of Lymph Node Metastasis and Survival in Advanced Laryngeal Cancer",
      "summary": "Using machine-learning techniques, we identified clinical and molecular markers capable of improving the prediction of lymph node metastasis risk and overall survival in patients with advanced laryngeal cancer. The resulting models may assist in refining risk stratification for individuals with advanced laryngeal tumors.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154515",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Raquel A Moyses",
      "presenter": "Raquel A Moyses",
      "authors": "Aline P Miazaki 1 ; Leonardo Freitas B Rios 2 ; Pamela O Soares 1 ; Rafael C Ortiz 3 ; Camila De Oliveira R Pegoraro 3 ; Ana M Mercante 4 ; Clóvis A Lopes Pinto 5 ; Leandro L Matos 6 ; Luiz P Kowalski 7 ; Raquel A Moyses 1 . 1 LIM-28; Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil; 2 Department of Health, Universidade Estadual de Feira de Santana, Bahia, Brazil; 3 Department of Biological Sciences, Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brazil; 4 Department of Pathology, Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil; 5 Department of Pathology, A C Camargo Cancer Center, São Paulo, SP, Brazil",
      "normalized_authors": [
        "Aline P Miazaki",
        "Leonardo Freitas B Rios",
        "Pamela O Soares",
        "Rafael C Ortiz",
        "Camila De Oliveira R Pegoraro",
        "Ana M Mercante",
        "Clóvis A Lopes Pinto",
        "Leandro L Matos",
        "Luiz P Kowalski",
        "Raquel A Moyses . LIM-"
      ],
      "affiliations": [
        "Department of Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil",
        "Assistant Professor, Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP) São Paulo, SP, Brazil. Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil",
        "Chairman and Professor of Head and Neck Surgery, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Head, Head and Neck Tumors Reference Canter, A C Camargo Cancer Center, São Paulo, SP, Brazil"
      ],
      "normalized_institutions": [
        "Department of Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil",
        "Assistant Professor, Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP) São Paulo, SP, Brazil. Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil",
        "Chairman and Professor of Head and Neck Surgery, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Head, Head and Neck Tumors Reference Canter, A C Camargo Cancer Center, São Paulo, SP, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 516,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aline P Miazaki 1 ; Leonardo Freitas B Rios 2 ; Pamela O Soares 1 ; Rafael C Ortiz 3 ; Camila De Oliveira R Pegoraro 3 ; Ana M Mercante 4 ; Clóvis A Lopes Pinto 5 ; Leandro L Matos 6 ; Luiz P Kowalski 7 ; Raquel A Moyses 1 . 1 LIM-28; Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil; 2 Department of Health, Universidade Estadual de Feira de Santana, Bahia, Brazil; 3 Department of Biological Sciences, Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brazil; 4 Department of Pathology, Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil; 5 Department of Pathology, A C Camargo Cancer Center, São Paulo, SP, Brazil",
        "Affiliations": "Department of Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil; 6 Assistant Professor, Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP) São Paulo, SP, Brazil. Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil; 7 Chairman and Professor of Head and Neck Surgery, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Head, Head and Neck Tumors Reference Canter, A C Camargo Cancer Center, São Paulo, SP, Brazil",
        "Introduction": "Laryngeal cancer has a high prevalence among head and neck cancers and is associated with elevated mortality rate in advanced stages. Cervical lymph node metastasis in these cancers is a major indicator of poor prognosis. Predicting metastasis and survival in patients with advanced laryngeal cancer may improve clinical management as well as oncologic outcomes, and machine-learning techniques have supported the development of more accurate predictive tools. In addition to clinical and histopathological information, researchers have sought biological markers that may better predict the behavior of this cancer. Among these, cancer stem cell (CSC) markers and epithelial–mesenchymal transition (EMT) markers have garnered attention due to their potential association with tumor behavior and resistance to commonly used treatments.",
        "Objective": "The aim of this study was to identify predictive factors for lymph node metastasis and 5-year overall survival in patients with advanced laryngeal cancer, including clinical and histopathological characteristics, as well as CSC markers (CD44 and ALDH1) and EMT markers (vimentin, E-cadherin, and Twist).",
        "Methods": "This prospective cohort study included 93 patients with advanced, smoking-related laryngeal squamous cell carcinoma who underwent laryngectomy combined with elective or therapeutic cervical lymph node dissection. Clinical and histopathological characteristics were assessed, along with the immunoexpression of CSC and EMT markers. Interactions among variables were explored using data-mining techniques, including classification and regression trees, bootstrap forest, and boosted trees, followed by the development of logistic regression predictive models for two outcomes: lymph node metastasis and 5-year mortality. Model performance was evaluated in terms of discrimination and calibration.",
        "Results": "A supraglottic origin was an independent risk factor for lymph node metastasis (OR 3.52; 95% CI: 1.57–7.90; p = 0.002). Independent predictors of poorer 5-year overall survival included age ≥ 65 years (OR 4.57; 95% CI: 1.40–14.97; p = 0.008) and confirmed lymph node metastasis (OR 2.81; 95% CI: 1.06–7.45; p = 0.034). Regarding immunomarkers, significant risk factors for lymph node metastasis included strong Vimentin expression in the tumor center (OR 6.34; 95% CI: 1.02–39.12; p = 0.047), ALDH1 positivity in the worst pattern of the tumor front (OR 20.7; 95% CI: 1.11–387.04; p = 0.0424), and dual CD44 immunoexpression—weak expression in the predominant tumor front (OR 6.73; 95% CI: 1.19–38.29; p = 0.031) combined with strong expression in the worst tumor-front pattern (OR 5.58; 95% CI: 1.14–27.30; p = 0.033). No CSC or EMT markers were independently associated with poorer 5-year overall survival. However, when analyzed in combination, higher mortality risk during the 5-year follow-up was observed with the following patterns: low ALDH1 expression combined with high Vimentin expression in the tumor center; low E-cadherin with high ALDH1; and low E-cadherin with high CD44 in the predominant tumor front.",
        "Conclusion": "Using machine-learning techniques, we identified clinical and molecular markers capable of improving the prediction of lymph node metastasis risk and overall survival in patients with advanced laryngeal cancer. The resulting models may assist in refining risk stratification for individuals with advanced laryngeal tumors.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Identification of Clinical, Histopathological, Cancer Stem Cell, and Epithelial–Mesenchymal Transition Markers as Predictors of Lymph Node Metastasis and Survival in Advanced Laryngeal Cancer</span>. Aline P Miazaki<sup>1</sup>; Leonardo Freitas B Rios<sup>2</sup>; Pamela O Soares<sup>1</sup>; Rafael C Ortiz<sup>3</sup>; Camila De Oliveira R Pegoraro<sup>3</sup>; Ana M Mercante<sup>4</sup>; Clóvis A Lopes Pinto<sup>5</sup>; Leandro L Matos<sup>6</sup>; Luiz P Kowalski<sup>7</sup>; <u>Raquel A Moyses</u><sup>1</sup>. <sup>1</sup>LIM-28; Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil; <sup>2</sup>Department of Health, Universidade Estadual de Feira de Santana, Bahia, Brazil; <sup>3</sup>Department of Biological Sciences, Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brazil; <sup>4</sup>Department of Pathology, Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil; <sup>5</sup>Department of Pathology, A C Camargo Cancer Center, São Paulo, SP, Brazil. Department of Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil; <sup>6</sup>Assistant Professor, Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP) São Paulo, SP, Brazil. Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil; <sup>7</sup>Chairman and Professor of Head and Neck Surgery, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Head, Head and Neck Tumors Reference Canter, A C Camargo Cancer Center, São Paulo, SP, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Laryngeal cancer has a high prevalence among head and neck cancers and is associated with elevated mortality rate in advanced stages. Cervical lymph node metastasis in these cancers is a major indicator of poor prognosis. Predicting metastasis and survival in patients with advanced laryngeal cancer may improve clinical management as well as oncologic outcomes, and machine-learning techniques have supported the development of more accurate predictive tools. In addition to clinical and histopathological information, researchers have sought biological markers that may better predict the behavior of this cancer. Among these, cancer stem cell (CSC) markers and epithelial–mesenchymal transition (EMT) markers have garnered attention due to their potential association with tumor behavior and resistance to commonly used treatments. </p>\n\n<p><strong>Objective: </strong>The aim of this study was to identify predictive factors for lymph node metastasis and 5-year overall survival in patients with advanced laryngeal cancer, including clinical and histopathological characteristics, as well as CSC markers (CD44 and ALDH1) and EMT markers (vimentin, E-cadherin, and Twist). </p>\n\n<p><strong>Methods: </strong>This prospective cohort study included 93 patients with advanced, smoking-related laryngeal squamous cell carcinoma who underwent laryngectomy combined with elective or therapeutic cervical lymph node dissection. Clinical and histopathological characteristics were assessed, along with the immunoexpression of CSC and EMT markers. Interactions among variables were explored using data-mining techniques, including classification and regression trees, bootstrap forest, and boosted trees, followed by the development of logistic regression predictive models for two outcomes: lymph node metastasis and 5-year mortality. Model performance was evaluated in terms of discrimination and calibration. </p>\n\n<p><strong>Results: </strong>A supraglottic origin was an independent risk factor for lymph node metastasis (OR 3.52; 95% CI: 1.57–7.90; p = 0.002). Independent predictors of poorer 5-year overall survival included age ≥ 65 years (OR 4.57; 95% CI: 1.40–14.97; p = 0.008) and confirmed lymph node metastasis (OR 2.81; 95% CI: 1.06–7.45; p = 0.034). Regarding immunomarkers, significant risk factors for lymph node metastasis included strong Vimentin expression in the tumor center (OR 6.34; 95% CI: 1.02–39.12; p = 0.047), ALDH1 positivity in the worst pattern of the tumor front (OR 20.7; 95% CI: 1.11–387.04; p = 0.0424), and dual CD44 immunoexpression—weak expression in the predominant tumor front (OR 6.73; 95% CI: 1.19–38.29; p = 0.031) combined with strong expression in the worst tumor-front pattern (OR 5.58; 95% CI: 1.14–27.30; p = 0.033). No CSC or EMT markers were independently associated with poorer 5-year overall survival. However, when analyzed in combination, higher mortality risk during the 5-year follow-up was observed with the following patterns: low ALDH1 expression combined with high Vimentin expression in the tumor center; low E-cadherin with high ALDH1; and low E-cadherin with high CD44 in the predominant tumor front.</p>\n\n<p><strong>Conclusion:</strong> Using machine-learning techniques, we identified clinical and molecular markers capable of improving the prediction of lymph node metastasis risk and overall survival in patients with advanced laryngeal cancer. The resulting models may assist in refining risk stratification for individuals with advanced laryngeal tumors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154515--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S070",
      "content_id": "154456",
      "abstract_number": "S070",
      "poster_number": "",
      "title": "Selective Bioenergetic Vulnerability of Cancers to Thymoquinone",
      "summary": "TQ selectively drives cancer cells across multiple tissue origins into a sustained, metabolically unfavorable state characterized by impaired mitochondrial respiration, failed glycolytic compensation, and long-lasting ATP depletion. Normal cells, by contrast, exhibit robust metabolic recovery, highlighting a conserved bioenergetic vulnerability signature in carcinoma cells and supporting the potential of TQ as a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154456",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yazeed M Alhiyari",
      "presenter": "Yazeed M Alhiyari",
      "authors": "Yazeed M Alhiyari",
      "normalized_authors": [
        "Yazeed M Alhiyari"
      ],
      "affiliations": [
        "University of California, Los Angeles (UCLA)"
      ],
      "normalized_institutions": [
        "University of California, Los Angeles (UCLA)"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 311,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Yazeed M Alhiyari",
        "Affiliations": "University of California, Los Angeles (UCLA)",
        "Background": "Thymoquinone (TQ), a natural quinone from Nigella sativa, has been reported to disrupt redox balance and impair cancer cell viability. However, its impact on cellular bioenergetics, including the ability of cancer and normal cells to recover metabolically after exposure, remains poorly characterized.",
        "Methods": "Bioenergetic responses to TQ were evaluated across a diverse panel of cancer cell lines SCC25, SCC47, Detroit 562, FaDu, Tu-686, RH2, A253, and A549, and compared with non-malignant OKF oral keratinocytes and human adipose-derived stem cells (hASC). Seahorse XF Mito Stress, Glycolysis Stress, and ATP Rate assays quantified OCR, ECAR, ATP-linked respiration, maximal respiration, glycolytic capacity, and ATP production pathways. Measurements were taken acutely after TQ treatment and again 24 hours post-treatment to assess metabolic recovery and plasticity.",
        "Results": "Across all malignant cell lines, TQ induced a coordinated metabolic collapse, characterized by reduced basal OCR, sharply decreased ATP-linked respiration, blunted FCCP responses, and loss of spare respiratory capacity. ECAR analysis showed diminished glycolysis and near-absent glycolytic reserve. ATP Rate assays confirmed a reduction in both ATP-Mito and ATP-Glyco, resulting in a uniform low-ATP, low-flexibility phenotype.",
        "Abstract": "A critical divergence emerged during recovery analysis: OKF and hASC transitioned from a quiescent (low OCR/low ECAR) state acutely after treatment to a more energetic phenotype 24 hours later, demonstrating preserved metabolic resilience and the ability to re-engage both mitochondrial and glycolytic pathways. In contrast, all cancer cell lines remained metabolically trapped, failing to increase OCR, ECAR, or ATP production capacity, indicating persistent mitochondrial dysfunction and absent metabolic adaptability. View in Agenda and Add to Schedule",
        "Conclusion": "TQ selectively drives cancer cells across multiple tissue origins into a sustained, metabolically unfavorable state characterized by impaired mitochondrial respiration, failed glycolytic compensation, and long-lasting ATP depletion. Normal cells, by contrast, exhibit robust metabolic recovery, highlighting a conserved bioenergetic vulnerability signature in carcinoma cells and supporting the potential of TQ as a selective metabolic stressor and therapeutic sensitizer."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Selective Bioenergetic Vulnerability of Cancers to Thymoquinone</span>. <u>Yazeed M Alhiyari</u>. University of California, Los Angeles (UCLA)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Thymoquinone (TQ), a natural quinone from Nigella sativa, has been reported to disrupt redox balance and impair cancer cell viability. However, its impact on cellular bioenergetics, including the ability of cancer and normal cells to recover metabolically after exposure, remains poorly characterized.</p>\n\n<p><strong>Methods:</strong> Bioenergetic responses to TQ were evaluated across a diverse panel of cancer cell lines SCC25, SCC47, Detroit 562, FaDu, Tu-686, RH2, A253, and A549, and compared with non-malignant OKF oral keratinocytes and human adipose-derived stem cells (hASC). Seahorse XF Mito Stress, Glycolysis Stress, and ATP Rate assays quantified OCR, ECAR, ATP-linked respiration, maximal respiration, glycolytic capacity, and ATP production pathways. Measurements were taken acutely after TQ treatment and again 24 hours post-treatment to assess metabolic recovery and plasticity.</p>\n\n<p><strong>Results:</strong> Across all malignant cell lines, TQ induced a coordinated metabolic collapse, characterized by reduced basal OCR, sharply decreased ATP-linked respiration, blunted FCCP responses, and loss of spare respiratory capacity. ECAR analysis showed diminished glycolysis and near-absent glycolytic reserve. ATP Rate assays confirmed a reduction in both ATP-Mito and ATP-Glyco, resulting in a uniform low-ATP, low-flexibility phenotype.</p>\n\n<p>A critical divergence emerged during recovery analysis: OKF and hASC transitioned from a quiescent (low OCR/low ECAR) state acutely after treatment to a more energetic phenotype 24 hours later, demonstrating preserved metabolic resilience and the ability to re-engage both mitochondrial and glycolytic pathways. In contrast, all cancer cell lines remained metabolically trapped, failing to increase OCR, ECAR, or ATP production capacity, indicating persistent mitochondrial dysfunction and absent metabolic adaptability.</p>\n\n<p><strong>Conclusion: </strong>TQ selectively drives cancer cells across multiple tissue origins into a sustained, metabolically unfavorable state characterized by impaired mitochondrial respiration, failed glycolytic compensation, and long-lasting ATP depletion. Normal cells, by contrast, exhibit robust metabolic recovery, highlighting a conserved bioenergetic vulnerability signature in carcinoma cells and supporting the potential of TQ as a selective metabolic stressor and therapeutic sensitizer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154456--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S071",
      "content_id": "154535",
      "abstract_number": "S071",
      "poster_number": "",
      "title": "Circulating Proteomic Signatures Differentiate Cachexia Severity in Syngeneic Models of Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Despite being clonogenic derivatives of the same parental tumor line, MLM3 and MLM5 elicit profoundly different systemic responses, with MLM3 driving a more inflammatory and catabolic serum proteome consistent with its more severe cachexia phenotype. These findings establish MLM3 as a robust model of aggressive tumor-driven cachexia and provide a serum biomarker framework for mechanistic studies and therapeutic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154535",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brennan G Olson, MD, PhD",
      "presenter": "Brennan G Olson, MD, PhD",
      "authors": "Brennan G Olson, MD, PhD 1 ; Mason A Norgard 2 ; Kendall K Tasche, MD 1 ; Daniel L Marks, MD, PhD 3",
      "normalized_authors": [
        "Brennan G Olson",
        "Mason A Norgard",
        "Kendall K Tasche",
        "Daniel L Marks"
      ],
      "affiliations": [
        "Mayo Clinic",
        "Oregon Health & Science University",
        "Endevica Bio"
      ],
      "normalized_institutions": [
        "Mayo Clinic",
        "Oregon Health & Science University",
        "Endevica Bio"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 278,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Intro",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Brennan G Olson, MD, PhD 1 ; Mason A Norgard 2 ; Kendall K Tasche, MD 1 ; Daniel L Marks, MD, PhD 3",
        "Affiliations": "1 Mayo Clinic; 2 Oregon Health & Science University; 3 Endevica Bio",
        "Intro": "Cachexia represents a multifactorial syndrome marked by involuntary weight loss and selective muscle atrophy not reversed by conventional nutritional support. This paraneoplastic syndrome effects nearly half of patients with head and neck cancer, yet treatment options are lacking. Utilizing two syngeneic rodent models of metastatic oropharyngeal squamous cell carcinoma (OPSCC), we profiled the circulating proteome for assessing metabolic alterations and potential oncologic and cachexia targets.",
        "Methods": "Two separate clonogenic strains (MLM3 or MLM5) of HPV(+) squamous cell carcinoma cells (expressing HPV16 E6/E7 and hRas) were subcutaneously implanted into wild type C57BL/6J mice and standardized cachexia measures were evaluated throughout tumor growth. Terminal serum was collected for high-throughput proteomics analysis.",
        "Results": "MLM3- and MLM5-implanted mice developed comparable tumor burdens, yet MLM3-bearing mice exhibited significantly more severe cachexia—manifesting as anorexia and pronounced weight loss. Serum proteomic profiling identified 308 differentially abundant proteins (of 1,052 quantified) distinguishing the models. MLM3-bearing mice demonstrated a distinct circulating signature enriched for inflammatory, proteolytic, and immunometabolic stress markers that align with the more profound cachexia phenotype. Principal component analysis showed robust separation of MLM3 and MLM5 serum proteomes, with metabolic pathway analyses demonstrating elevated complement-mediated tissue injury and acute-phase response in MLM3-bearing mice compared to its MLM5-implanted counterpart.",
        "Conclusions": "Despite being clonogenic derivatives of the same parental tumor line, MLM3 and MLM5 elicit profoundly different systemic responses, with MLM3 driving a more inflammatory and catabolic serum proteome consistent with its more severe cachexia phenotype. These findings establish MLM3 as a robust model of aggressive tumor-driven cachexia and provide a serum biomarker framework for mechanistic studies and therapeutic interventions for disease-associated wasting in advanced head and neck cancer.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Circulating Proteomic Signatures Differentiate Cachexia Severity in Syngeneic Models of Oropharyngeal Squamous Cell Carcinoma</span>. <u>Brennan G Olson, MD, PhD</u><sup>1</sup>; Mason A Norgard<sup>2</sup>; Kendall K Tasche, MD<sup>1</sup>; Daniel L Marks, MD, PhD<sup>3</sup>. <sup>1</sup>Mayo Clinic; <sup>2</sup>Oregon Health & Science University; <sup>3</sup>Endevica Bio<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Intro: </strong>Cachexia represents a multifactorial syndrome marked by involuntary weight loss and selective muscle atrophy not reversed by conventional nutritional support. This paraneoplastic syndrome effects nearly half of patients with head and neck cancer, yet treatment options are lacking. Utilizing two syngeneic rodent models of metastatic oropharyngeal squamous cell carcinoma (OPSCC), we profiled the circulating proteome for assessing metabolic alterations and potential oncologic and cachexia targets.</p>\n\n<p><strong>Methods: </strong>Two separate clonogenic strains (MLM3 or MLM5) of HPV(+) squamous cell carcinoma cells (expressing HPV16 E6/E7 and hRas) were subcutaneously implanted into wild type C57BL/6J mice and standardized cachexia measures were evaluated throughout tumor growth. Terminal serum was collected for high-throughput proteomics analysis.</p>\n\n<p><strong>Results: </strong>MLM3- and MLM5-implanted mice developed comparable tumor burdens, yet MLM3-bearing mice exhibited significantly more severe cachexia—manifesting as anorexia and pronounced weight loss. Serum proteomic profiling identified 308 differentially abundant proteins (of 1,052 quantified) distinguishing the models. MLM3-bearing mice demonstrated a distinct circulating signature enriched for inflammatory, proteolytic, and immunometabolic stress markers that align with the more profound cachexia phenotype. Principal component analysis showed robust separation of MLM3 and MLM5 serum proteomes, with metabolic pathway analyses demonstrating elevated complement-mediated tissue injury and acute-phase response in MLM3-bearing mice compared to its MLM5-implanted counterpart.</p>\n\n<p><strong>Conclusions: </strong>Despite being clonogenic derivatives of the same parental tumor line, MLM3 and MLM5 elicit profoundly different systemic responses, with MLM3 driving a more inflammatory and catabolic serum proteome consistent with its more severe cachexia phenotype.   These findings establish MLM3 as a robust model of aggressive tumor-driven cachexia and provide a serum biomarker framework for mechanistic studies and therapeutic interventions for disease-associated wasting in advanced head and neck cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154535--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S072",
      "content_id": "155508",
      "abstract_number": "S072",
      "poster_number": "",
      "title": "Detection of oral cancer using molecular cytology and Transformer-based Artificial Intelligence: A multicenter hub-and-spoke validation in India",
      "summary": "In this study, we implemented a hub-and-spoke model with centralized laboratory analysis demonstrated diagnostic performance approaching pathology-equivalent accuracy for oral cancer detection. Automated segmentation enabled identification of epithelial cells, followed by classification using a MIL with 96% sensitivity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155508",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260118",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Moni A. Kuriakose",
      "presenter": "Moni A. Kuriakose",
      "authors": "Supriya K 1 ; Shivani M 2 ; Keerthi KrishnaKumar 3 ; Bharghabi Pau 2 ; Tulika S 4 ; Rounik T 5 ; Pramila Mendonca 3 ; Shikha Shikha Jha 3 ; Kripa A 3 ; Prashasthi Shetty 2 ; Keethi J 2 ; Sowmya C 2 ; Nithesh S 3 ; Lalitha Laxhm 2 ; Neerada Warrier 2 ; Keethi G 3 ; Shubha G 3 ; Anela Thomas 2 ; Pavithra C 3 ; Yogesh Dokhe 6 ; Naveen B S 6 ; Sumsum P Sunny 7 ; Moni A",
      "normalized_authors": [
        "Supriya K",
        "Shivani M",
        "Keerthi KrishnaKumar",
        "Bharghabi Pau",
        "Tulika S",
        "Rounik T",
        "Pramila Mendonca",
        "Shikha Shikha Jha",
        "Kripa A",
        "Prashasthi Shetty",
        "Keethi J",
        "Sowmya C",
        "Nithesh S",
        "Lalitha Laxhm",
        "Neerada Warrier",
        "Keethi G",
        "Shubha G",
        "Anela Thomas",
        "Pavithra C",
        "Yogesh Dokhe",
        "Naveen B S",
        "Sumsum P Sunny",
        "Moni A"
      ],
      "affiliations": [
        "Kuriakose 8",
        "Divya K 4",
        "Hari Krishna Raju Sagiraju 5",
        "Vijay Pillai 6",
        "Praveen Birur 2",
        "Praveen Birur 3",
        "Amritha Suresh 8 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore",
        "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022",
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor",
        "Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, India 221010",
        "Department of Preventive Oncology, NCI-AIMS, Gurgaon. India 122006",
        "Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099",
        "Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203"
      ],
      "normalized_institutions": [
        "Kuriakose 8",
        "Divya K 4",
        "Hari Krishna Raju Sagiraju 5",
        "Vijay Pillai 6",
        "Praveen Birur 2",
        "Praveen Birur 3",
        "Amritha Suresh 8 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore",
        "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022",
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor",
        "Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, India 221010",
        "Department of Preventive Oncology, NCI-AIMS, Gurgaon. India 122006",
        "Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099",
        "Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155508/workflow(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155508/workflow(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155508"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methodology",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Supriya K 1 ; Shivani M 2 ; Keerthi KrishnaKumar 3 ; Bharghabi Pau 2 ; Tulika S 4 ; Rounik T 5 ; Pramila Mendonca 3 ; Shikha Shikha Jha 3 ; Kripa A 3 ; Prashasthi Shetty 2 ; Keethi J 2 ; Sowmya C 2 ; Nithesh S 3 ; Lalitha Laxhm 2 ; Neerada Warrier 2 ; Keethi G 3 ; Shubha G 3 ; Anela Thomas 2 ; Pavithra C 3 ; Yogesh Dokhe 6 ; Naveen B S 6 ; Sumsum P Sunny 7 ; Moni A",
        "Affiliations": "Kuriakose 8 ; Divya K 4 ; Hari Krishna Raju Sagiraju 5 ; Vijay Pillai 6 ; Praveen Birur 2 ; Praveen Birur 3 ; Amritha Suresh 8 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore;Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022; 2 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor; 3 Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022; 4 Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, India 221010; 5 Department of Preventive Oncology, NCI-AIMS, Gurgaon. India 122006; 6 Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099; 7 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor;Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099; 8 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor;Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099;Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203",
        "Background": "A minimally-invasive, pathology-equivalent oral cancer detection method is needed for screening large-volumes of high-risk population. We previously demonstrated that detection of aberrant glycoprotein/glycosylation patterns using CD44 and Sambucus nigra agglutinin (SNA-1) significantly improves oral cytology–based detection of oral cancer and high-grade Oral Potentially Malignant Lesions (OPMLs). However, for large-scale population screening, the molecular cytology assay requires automation to isolate single epithelial cells and patient-level classification. In the present study, we developed an Artificial Intelligence (AI)–based framework for automated analysis of molecular cytology microscopic images. The system enables automated preprocessing, single-cell identification, and classification. Multicenter validation of this platform is currently ongoing using a hub-and-spoke model, enabling centralized AI-based analysis while sample collection is performed across multiple screening centres.",
        "Methodology": "Patients with clinically suspicious oral lesions scheduled for incisional biopsy were recruited after institutional ethics committee approval and written informed consent. Prior to biopsy, a liquid brush biopsy was performed, and samples from multiple centers were transported to a central laboratory in preservative (BD SurePath) for multiplexed cytology. Cytology smears were prepared using Cytospin followed by sequential staining with Sambucus nigra agglutinin (SNA-1) and CD44 conjugated with fluorescent markers, and imaged using a Zeiss Axio fluorescence microscope. The microscopic images contained single epithelial cells, blood cells, epithelial clusters, and artefacts. A two-step artificial intelligence framework was developed for automation.",
        "Abstract": "First, single epithelial cells were segmented using encoder–decoder models to obtain clean cellular data. Second, classification was performed using a transformer-based multiple-instance learning approach. For segmentation, microscopic images (7,260 training; 370 test) were manually annotated for cellular components. A modified U-Net model was optimized for epithelial cell segmentation, and the outputs were further refined using a small CNN trained on 89,448 images (test set: 5,539) to remove non-epithelial elements, and clusters. For patient-level diagnosis, single-cell datasets were grouped by patient (bags of cells) and analyzed using a Vision Transformer (ViT) combined with Multiple Instance Learning (MIL). The model was trained on 28,859 cells derived from 100 cancer patients and 359 non-cancer patients, including oral potentially malignant lesions (OPML; 314, of which 32 were biopsy-proven) and benign lesions (66, of which 14 were biopsy-proven). View in Agenda and Add to Schedule",
        "Results": "In the segmentation stage, the U-Net model achieved a mean Intersection over Union of 0.84 and an accuracy of 97% for correctly identifying single epithelial cells. For patient-wise classification using multicenter data (histology-confirmed 28 oral cancer and 87 OPML), the Multiple Instance Learning (MIL)–based model achieved a sensitivity of 96% (26/28) and a specificity of 70% (59/87) for detecting oral cancer. Prospective validation is currently ongoing with further optimization of the model for detection of high-grade OPMLs. The model highlighted high-attention and low-attention epithelial cells, which correlated with pathologist interpretation, providing an explainable artificial intelligence approach for patient-level diagnosis.",
        "Conclusion": "In this study, we implemented a hub-and-spoke model with centralized laboratory analysis demonstrated diagnostic performance approaching pathology-equivalent accuracy for oral cancer detection. Automated segmentation enabled identification of epithelial cells, followed by classification using a MIL with 96% sensitivity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Detection of oral cancer using molecular cytology and Transformer-based Artificial Intelligence: A multicenter hub-and-spoke validation in India</span>. Supriya K<sup>1</sup>; Shivani M<sup>2</sup>; Keerthi KrishnaKumar<sup>3</sup>; Bharghabi Pau<sup>2</sup>; Tulika S<sup>4</sup>; Rounik T<sup>5</sup>; Pramila Mendonca<sup>3</sup>; Shikha Shikha Jha<sup>3</sup>; Kripa A<sup>3</sup>; Prashasthi Shetty<sup>2</sup>; Keethi J<sup>2</sup>; Sowmya C<sup>2</sup>; Nithesh S<sup>3</sup>; Lalitha Laxhm<sup>2</sup>; Neerada Warrier<sup>2</sup>; Keethi G<sup>3</sup>; Shubha G<sup>3</sup>; Anela Thomas<sup>2</sup>; Pavithra C<sup>3</sup>; Yogesh Dokhe<sup>6</sup>; Naveen B S<sup>6</sup>; Sumsum P Sunny<sup>7</sup>; <u>Moni A. Kuriakose</u><sup>8</sup>; Divya K<sup>4</sup>; Hari Krishna Raju Sagiraju<sup>5</sup>; Vijay Pillai<sup>6</sup>; Praveen Birur<sup>2</sup>; Praveen Birur<sup>3</sup>; Amritha Suresh<sup>8</sup>. <sup>1</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore;Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022; <sup>2</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor; <sup>3</sup>Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Banglore, India 560022; <sup>4</sup>Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, India 221010; <sup>5</sup>Department of Preventive Oncology, NCI-AIMS, Gurgaon. India 122006; <sup>6</sup>Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099; <sup>7</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor;Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099; <sup>8</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalor;Department of Head and Neck Surgical Oncology, Mazumdar Shaw Medical Center, NH Health City, Bangalore, India 560099;Department of Head and Neck Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> A minimally-invasive, pathology-equivalent oral cancer detection method is needed for screening large-volumes of high-risk population. We previously demonstrated that detection of aberrant glycoprotein/glycosylation patterns using CD44 and Sambucus nigra agglutinin (SNA-1) significantly improves oral cytology–based detection of oral cancer and high-grade Oral Potentially Malignant Lesions (OPMLs). However, for large-scale population screening, the molecular cytology assay requires automation to isolate single epithelial cells and patient-level classification. In the present study, we developed an Artificial Intelligence (AI)–based framework for automated analysis of molecular cytology microscopic images. The system enables automated preprocessing, single-cell identification, and classification. Multicenter validation of this platform is currently ongoing using a hub-and-spoke model, enabling centralized AI-based analysis while sample collection is performed across multiple screening centres.</p>\n\n<p><strong>Methodology: </strong>Patients with clinically suspicious oral lesions scheduled for incisional biopsy were recruited after institutional ethics committee approval and written informed consent. Prior to biopsy, a liquid brush biopsy was performed, and samples from multiple centers were transported to a central laboratory in preservative (BD SurePath) for multiplexed cytology. Cytology smears were prepared using Cytospin followed by sequential staining with Sambucus nigra agglutinin (SNA-1) and CD44 conjugated with fluorescent markers, and imaged using a Zeiss Axio fluorescence microscope. The microscopic images contained single epithelial cells, blood cells, epithelial clusters, and artefacts. A two-step artificial intelligence framework was developed for automation.</p>\n\n<p>First, single epithelial cells were segmented using encoder–decoder models to obtain clean cellular data. Second, classification was performed using a transformer-based multiple-instance learning approach. For segmentation, microscopic images (7,260 training; 370 test) were manually annotated for cellular components. A modified U-Net model was optimized for epithelial cell segmentation, and the outputs were further refined using a small CNN trained on 89,448 images (test set: 5,539) to remove non-epithelial elements, and clusters. For patient-level diagnosis, single-cell datasets were grouped by patient (bags of cells) and analyzed using a Vision Transformer (ViT) combined with Multiple Instance Learning (MIL). The model was trained on 28,859 cells derived from 100 cancer patients and 359 non-cancer patients, including oral potentially malignant lesions (OPML; 314, of which 32 were biopsy-proven) and benign lesions (66, of which 14 were biopsy-proven).</p>\n\n<p><strong>Results:</strong> In the segmentation stage, the U-Net model achieved a mean Intersection over Union of 0.84 and an accuracy of 97% for correctly identifying single epithelial cells. For patient-wise classification using multicenter data (histology-confirmed 28 oral cancer and 87 OPML), the Multiple Instance Learning (MIL)–based model achieved a sensitivity of 96% (26/28) and a specificity of 70% (59/87) for detecting oral cancer. Prospective validation is currently ongoing with further optimization of the model for detection of high-grade OPMLs. The model highlighted high-attention and low-attention epithelial cells, which correlated with pathologist interpretation, providing an explainable artificial intelligence approach for patient-level diagnosis.</p>\n\n<p><strong>Conclusion:</strong> In this study, we implemented a hub-and-spoke model with centralized laboratory analysis demonstrated diagnostic performance approaching pathology-equivalent accuracy for oral cancer detection. Automated segmentation enabled identification of epithelial cells, followed by classification using a MIL with 96% sensitivity.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155508/workflow(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155508--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260118' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S073",
      "content_id": "153336",
      "abstract_number": "S073",
      "poster_number": "",
      "title": "Reduction in circulating tumor tissue-modified (TTMV)-HPV DNA is associated with improved long-term survival in patients with recurrent or metastatic head and neck squamous cell carcinoma treated",
      "summary": "Reduction in TTMV-HPV DNA in patients with p16+ R/M HNSCC treated with cetuximab and nivolumab was strongly associated with radiographic response and improved survival, suggesting that TTMV DNA dynamics may serve as a clinically meaningful biomarker of response versus resistance in this therapeutic setting. However, the presence of long-term survivors with increasing TTMV DNA underscores that TTMV DNA should not...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153336",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sara A Sun, MD",
      "presenter": "Sara A Sun, MD",
      "authors": "Sara A Sun, MD 1 ; Deepa Danan, MD 1 ; Kedar Kirtane, MD 1 ; James W Rocco, MD, PhD 2 ; Marcelo Bonomi, MD 2 ; Nabil F Saba, MD 3 ; Christine H Chung, MD 1 ; Robin Park, MD 1",
      "normalized_authors": [
        "Sara A Sun",
        "Deepa Danan",
        "Kedar Kirtane",
        "James W Rocco",
        "Marcelo Bonomi",
        "Nabil F Saba",
        "Christine H Chung",
        "Robin Park"
      ],
      "affiliations": [
        "Moffitt Cancer Center",
        "The Ohio State University",
        "Emory University"
      ],
      "normalized_institutions": [
        "Moffitt Cancer Center",
        "The Ohio State University",
        "Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sara A Sun, MD 1 ; Deepa Danan, MD 1 ; Kedar Kirtane, MD 1 ; James W Rocco, MD, PhD 2 ; Marcelo Bonomi, MD 2 ; Nabil F Saba, MD 3 ; Christine H Chung, MD 1 ; Robin Park, MD 1",
        "Affiliations": "1 Moffitt Cancer Center; 2 The Ohio State University; 3 Emory University",
        "Background": "Combination strategies integrating anti–PD-1 inhibitors with EGFR-targeted therapies are emerging as promising and increasingly utilized treatment options in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). A phase II clinical trial of cetuximab and nivolumab demonstrated durable clinical activity with long-term median follow-up of 47.5 months (Chaudhary et al., 2025). However, the relationship between long-term clinical outcomes in p16+ disease and dynamic changes in circulating tumor tissue-modified viral (TTMV)–HPV DNA remains incompletely understood. Given the rising incidence of p16+ HNSCC and expanding use of EGFR- and PD-1–directed immunotherapy, a deeper understanding of TTMV-HPV DNA kinetics as a potential biomarker of response or resistance is needed.",
        "Methods": "Clinical data were obtained from R/M HNSCC patients treated with combination cetuximab and nivolumab in the 1st line or 2nd line+ setting from completed phase II clinical trial NCT03370276. Plasma samples were collected at baseline, cycle 1 day 1 after lead-in cetuximab alone (C1D1), cycle 1 between day 8 and 15 (C1D8-15), cycle 4 day 1 (C4D1), and/or end of treatment (EOT). Cell-free DNA (cfDNA) was assessed using the NavDx® system (Naveris Inc.) and analyzed with the tumor tissue-modified viral (TTMV) DNA score. Only patients with TTMV DNA at ≥2 time points were included in the analysis. TTMV DNA reduction was defined as a decreased or unchanged value at the latest available on-treatment or end of treatment timepoint compared to baseline. Survival outcomes were assessed from trial enrollment using Kaplan-Meier and log-rank methods.",
        "Results": "Twenty-nine patients with p16+ R/M HNSCC met inclusion criteria (median baseline TTMV score 697; 95% CI 183–1606). Median progression-free survival (mPFS) was 3.22 months (95% CI 1.84–7.79) and median overall survival (mOS) was 15.2 months (95% CI 6.41–19.8). The objective response rate (ORR) was 17.2% (95% CI 5.8-35.8%). Three patients achieved complete response (CR), 2 achieved partial response (PR), 13 had stable disease (SD), and 11 had progressive disease (PD).",
        "Abstract": "TTMV DNA reduction from baseline to the latest available timepoint sampled occurred in 34% (10/29) of patients and was observed more frequently in responders (CR+PR) than non-responders (SD+PD; odds ratio 12.0; 95% CI 1.11–129.4; p=0.007). TTMV reduction was associated with longer mPFS (14.8 vs. 3.09 months; p=0.0009) and mOS (25.5 vs. 8.02 months; p=0.006). Notably, a subset of long-term survivors (OS ≥24 months) demonstrated an increase in TTMV DNA despite clinical benefit (3/7; 42.8%). View in Agenda and Add to Schedule",
        "Conclusion": "Reduction in TTMV-HPV DNA in patients with p16+ R/M HNSCC treated with cetuximab and nivolumab was strongly associated with radiographic response and improved survival, suggesting that TTMV DNA dynamics may serve as a clinically meaningful biomarker of response versus resistance in this therapeutic setting. However, the presence of long-term survivors with increasing TTMV DNA underscores that TTMV DNA should not be interpreted as an absolute predictor. These findings provide new insight into biomarker behavior in patients receiving combined EGFR-targeted and PD-1–directed therapy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Reduction in circulating tumor tissue-modified (TTMV)-HPV DNA is associated with improved long-term survival in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab in a phase II clinical trial</span>. <u>Sara A Sun, MD</u><sup>1</sup>; Deepa Danan, MD<sup>1</sup>; Kedar Kirtane, MD<sup>1</sup>; James W Rocco, MD, PhD<sup>2</sup>; Marcelo Bonomi, MD<sup>2</sup>; Nabil F Saba, MD<sup>3</sup>; Christine H Chung, MD<sup>1</sup>; Robin Park, MD<sup>1</sup>. <sup>1</sup>Moffitt Cancer Center; <sup>2</sup>The Ohio State University; <sup>3</sup>Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Combination strategies integrating anti–PD-1 inhibitors with EGFR-targeted therapies are emerging as promising and increasingly utilized treatment options in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). A phase II clinical trial of cetuximab and nivolumab demonstrated durable clinical activity with long-term median follow-up of 47.5 months (Chaudhary et al., 2025). However, the relationship between long-term clinical outcomes in p16+ disease and dynamic changes in circulating tumor tissue-modified viral (TTMV)–HPV DNA remains incompletely understood. Given the rising incidence of p16+ HNSCC and expanding use of EGFR- and PD-1–directed immunotherapy, a deeper understanding of TTMV-HPV DNA kinetics as a potential biomarker of response or resistance is needed.</p>\n\n<p><strong>Methods</strong>: Clinical data were obtained from R/M HNSCC patients treated with combination cetuximab and nivolumab in the 1st line or 2nd line+ setting from completed phase II clinical trial NCT03370276. Plasma samples were collected at baseline, cycle 1 day 1 after lead-in cetuximab alone (C1D1), cycle 1 between day 8 and 15 (C1D8-15), cycle 4 day 1 (C4D1), and/or end of treatment (EOT). Cell-free DNA (cfDNA) was assessed using the NavDx® system (Naveris Inc.) and analyzed with the tumor tissue-modified viral (TTMV) DNA score. Only patients with TTMV DNA at ≥2 time points were included in the analysis. TTMV DNA reduction was defined as a decreased or unchanged value at the latest available on-treatment or end of treatment timepoint compared to baseline. Survival outcomes were assessed from trial enrollment using Kaplan-Meier and log-rank methods.</p>\n\n<p><strong>Results</strong>: Twenty-nine patients with p16+ R/M HNSCC met inclusion criteria (median baseline TTMV score 697; 95% CI 183–1606). Median progression-free survival (mPFS) was 3.22 months (95% CI 1.84–7.79) and median overall survival (mOS) was 15.2 months (95% CI 6.41–19.8). The objective response rate (ORR) was 17.2% (95% CI 5.8-35.8%). Three patients achieved complete response (CR), 2 achieved partial response (PR), 13 had stable disease (SD), and 11 had progressive disease (PD).</p>\n\n<p>TTMV DNA reduction from baseline to the latest available timepoint sampled occurred in 34% (10/29) of patients and was observed more frequently in responders (CR+PR) than non-responders (SD+PD; odds ratio 12.0; 95% CI 1.11–129.4; p=0.007). TTMV reduction was associated with longer mPFS (14.8 vs. 3.09 months; p=0.0009) and mOS (25.5 vs. 8.02 months; p=0.006). Notably, a subset of long-term survivors (OS ≥24 months) demonstrated an increase in TTMV DNA despite clinical benefit (3/7; 42.8%).</p>\n\n<p><strong>Conclusion</strong>: Reduction in TTMV-HPV DNA in patients with p16+ R/M HNSCC treated with cetuximab and nivolumab was strongly associated with radiographic response and improved survival, suggesting that TTMV DNA dynamics may serve as a clinically meaningful biomarker of response versus resistance in this therapeutic setting. However, the presence of long-term survivors with increasing TTMV DNA underscores that TTMV DNA should not be interpreted as an absolute predictor. These findings provide new insight into biomarker behavior in patients receiving combined EGFR-targeted and PD-1–directed therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153336--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S074",
      "content_id": "154525",
      "abstract_number": "S074",
      "poster_number": "",
      "title": "Neoadjuvant and adjuvant pembrolizumab versus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Stage IVA subgroup analysis of phase 3 KEYNO",
      "summary": "In this analysis of 465 participants with stage IVA disease enrolled in KEYNOTE-689, EFS and mPR results in participants with T4 tumors and with non-T4 tumors favored the pembrolizumab group, consistent with the primary analysis. The proportion of participants with R0 resection was similar across T4 and non-T4 subgroups. In both T4 and non-T4 subgroups, participants who received neoadjuvant pembrolizumab were...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154525",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ravindra Uppaluri",
      "presenter": "Ravindra Uppaluri",
      "authors": "Ravindra Uppaluri 1 ; Robert I Haddad 1 ; Yungan Tao 2 ; Christophe Le Tourneau 3 ; Nancy Y Lee 4 ; Chih-Chin Liu 5 ; Kimberly Benjamin 5 ; Bin Zhao 5 ; Douglas Adkins 6",
      "normalized_authors": [
        "Ravindra Uppaluri",
        "Robert I Haddad",
        "Yungan Tao",
        "Christophe Le Tourneau",
        "Nancy Y Lee",
        "Chih-Chin Liu",
        "Kimberly Benjamin",
        "Bin Zhao",
        "Douglas Adkins"
      ],
      "affiliations": [
        "Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA",
        "Dana-Farber Cancer Institute, Boston, MA, USA",
        "Institut Gustave Roussy, Villejuif, France",
        "Institut Curie, Paris, France",
        "Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Merck & Co., Inc., Rahway, NJ, USA",
        "Washington University School of Medicine Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, MO, USA"
      ],
      "normalized_institutions": [
        "Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA",
        "Dana-Farber Cancer Institute, Boston, MA, USA",
        "Institut Gustave Roussy, Villejuif, France",
        "Institut Curie, Paris, France",
        "Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Merck & Co., Inc., Rahway, NJ, USA",
        "Washington University School of Medicine Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, MO, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 559,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ravindra Uppaluri 1 ; Robert I Haddad 1 ; Yungan Tao 2 ; Christophe Le Tourneau 3 ; Nancy Y Lee 4 ; Chih-Chin Liu 5 ; Kimberly Benjamin 5 ; Bin Zhao 5 ; Douglas Adkins 6",
        "Affiliations": "1 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; 2 Institut Gustave Roussy, Villejuif, France; 3 Institut Curie, Paris, France; 4 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 5 Merck & Co., Inc., Rahway, NJ, USA; 6 Washington University School of Medicine Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, MO, USA",
        "Background": "In the phase 3 KEYNOTE-689 trial (NCT03765918), neoadjuvant and adjuvant pembrolizumab plus SOC significantly improved event-free survival (EFS) versus SOC in the PD-L1 CPS ≥10 (HR 0.66; 95% CI, 0.49-0.88]; P = 0.0022), PD-L1 CPS ≥1 (HR 0.70; 95% CI, 0.55-0.89]; P = 0.0014), and intention-to-treat (HR 0.73; 95% CI, 0.58-0.92]; P = 0.0041) populations of participants with resectable LA HNSCC. We present outcomes in participants with stage IVA T4 vs non-T4 disease.",
        "Methods": "Adults with newly diagnosed resectable LA HNSCC (larynx/hypopharynx/oral cavity stage III/IVA; oropharyngeal stage III/IVA p16− or stage III T4 N0-2 p16+) were randomized 1:1 to neoadjuvant and adjuvant pembrolizumab (200 mg IV Q3W) plus SOC (surgery plus adjuvant radiotherapy ± concomitant cisplatin) or SOC only. Exploratory analyses assessed outcomes in participants with stage IVA disease divided by T4A N0-2 (“T4”) or T1-3 N2 (“non-T4”) disease. As of July 25, 2024, the median study follow-up was 38.3 months [range, 9.0-66.5]).",
        "Results": "Overall, 363 participants were randomized to the pembrolizumab group and 351 to the SOC group; 322 and 308 participants, respectively, underwent surgery, of whom 238 and 227 had stage IVA disease. Among those, 66.4% in the pembrolizumab group and 66.5% in the SOC group had T4 tumors; 33.6% in the pembrolizumab group and 33.5% in the SOC group had non-T4 tumors. The T4 subgroup included a higher proportion of participants with oral cavity SCC (66.5% in the pembrolizumab group, 69.5% in SOC group) and laryngeal SCC (22.8% and 21.9%, respectively) than the non-T4 subgroup (oral cavity: 60.0% and 57.9%; larynx: 17.5% and 15.8%, respectively); and a lower proportion of oropharyngeal SCC (2.5% and 2.0% vs 15.0% and 13.2%, respectively). Hypopharyngeal SCC varied between T4 (8.2% and 6.6%) and non-T4 subgroups (7.5% and 13.2%). Among participants with T4 tumors, 88.6% in the pembrolizumab group and 84.8% in the SOC group had R0 resection; among participants with non-T4 tumors, 91.3% and 84.2%, respectively, had R0 resection. In the pembrolizumab group, 34.2% of participants with T4 tumors and 46.3% with non-T4 tumors had high-risk pathological features after surgery compared with 49.0% and 59.2%, respectively, in the SOC group. EFS favored the pembrolizumab group in participants with T4 tumors (HR, 0.77 [95% CI, 0.55-1.1]) and non-T4 tumors (HR 0.71 [95% CI, 0.43-1.2]). Major pathological response (mPR) rate difference between the pembrolizumab and the SOC groups was 10.8% (95% CI, 6.8-16.6) in participants with T4 tumors and 8.8% (95% CI, 3.7-17.0) in participants with non-T4 tumors. No mPRs were observed with SOC.",
        "Conclusions": "In this analysis of 465 participants with stage IVA disease enrolled in KEYNOTE-689, EFS and mPR results in participants with T4 tumors and with non-T4 tumors favored the pembrolizumab group, consistent with the primary analysis. The proportion of participants with R0 resection was similar across T4 and non-T4 subgroups. In both T4 and non-T4 subgroups, participants who received neoadjuvant pembrolizumab were more likely to not have high-risk pathological features after surgery compared with the SOC group. Results for participants with PD-L1 CPS ≥1 will also be presented.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant and adjuvant pembrolizumab versus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Stage IVA subgroup analysis of phase 3 KEYNOTE-689 trial</span>. <u>Ravindra Uppaluri</u><sup>1</sup>; Robert I Haddad<sup>1</sup>; Yungan Tao<sup>2</sup>; Christophe Le Tourneau<sup>3</sup>; Nancy Y Lee<sup>4</sup>; Chih-Chin Liu<sup>5</sup>; Kimberly Benjamin<sup>5</sup>; Bin Zhao<sup>5</sup>; Douglas Adkins<sup>6</sup>. <sup>1</sup>Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; <sup>2</sup>Institut Gustave Roussy, Villejuif, France; <sup>3</sup>Institut Curie, Paris, France; <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>5</sup>Merck & Co., Inc., Rahway, NJ, USA; <sup>6</sup>Washington University School of Medicine Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, MO, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> In the phase 3 KEYNOTE-689 trial (NCT03765918), neoadjuvant and adjuvant pembrolizumab plus SOC significantly improved event-free survival (EFS) versus SOC in the PD-L1 CPS ≥10 (HR 0.66; 95% CI, 0.49-0.88]; <em>P</em> = 0.0022), PD-L1 CPS ≥1 (HR 0.70; 95% CI, 0.55-0.89]; <em>P</em> = 0.0014), and intention-to-treat (HR 0.73; 95% CI, 0.58-0.92]; <em>P</em> = 0.0041) populations of participants with resectable LA HNSCC. We present outcomes in participants with stage IVA T4 vs non-T4 disease.</p>\n\n<p><strong>Methods:</strong> Adults with newly diagnosed resectable LA HNSCC (larynx/hypopharynx/oral cavity stage III/IVA; oropharyngeal stage III/IVA p16− or stage III T4 N0-2 p16+) were randomized 1:1 to neoadjuvant and adjuvant pembrolizumab (200 mg IV Q3W) plus SOC (surgery plus adjuvant radiotherapy ± concomitant cisplatin) or SOC only. Exploratory analyses assessed outcomes in participants with stage IVA disease divided by T4A N0-2 (“T4”) or T1-3 N2 (“non-T4”) disease. As of July 25, 2024, the median study follow-up was 38.3 months [range, 9.0-66.5]).</p>\n\n<p><strong>Results: </strong>Overall, 363 participants were randomized to the pembrolizumab group and 351 to the SOC group; 322 and 308 participants, respectively, underwent surgery, of whom 238 and 227 had stage IVA disease. Among those, 66.4% in the pembrolizumab group and 66.5% in the SOC group had T4 tumors; 33.6% in the pembrolizumab group and 33.5% in the SOC group had non-T4 tumors. The T4 subgroup included a higher proportion of participants with oral cavity SCC (66.5% in the pembrolizumab group, 69.5% in SOC group) and laryngeal SCC (22.8% and 21.9%, respectively) than the non-T4 subgroup (oral cavity: 60.0% and 57.9%; larynx: 17.5% and 15.8%, respectively); and a lower proportion of oropharyngeal SCC (2.5% and 2.0% vs 15.0% and 13.2%, respectively). Hypopharyngeal SCC varied between T4 (8.2% and 6.6%) and non-T4 subgroups (7.5% and 13.2%). Among participants with T4 tumors, 88.6% in the pembrolizumab group and 84.8% in the SOC group had R0 resection; among participants with non-T4 tumors, 91.3% and 84.2%, respectively, had R0 resection. In the pembrolizumab group, 34.2% of participants with T4 tumors and 46.3% with non-T4 tumors had high-risk pathological features after surgery compared with 49.0% and 59.2%, respectively, in the SOC group. EFS favored the pembrolizumab group in participants with T4 tumors (HR, 0.77 [95% CI, 0.55-1.1]) and non-T4 tumors (HR 0.71 [95% CI, 0.43-1.2]). Major pathological response (mPR) rate difference between the pembrolizumab and the SOC groups was 10.8% (95% CI, 6.8-16.6) in participants with T4 tumors and 8.8% (95% CI, 3.7-17.0) in participants with non-T4 tumors. No mPRs were observed with SOC.</p>\n\n<p><strong>Conclusions:</strong> In this analysis of 465 participants with stage IVA disease enrolled in KEYNOTE-689, EFS and mPR results in participants with T4 tumors and with non-T4 tumors favored the pembrolizumab group, consistent with the primary analysis. The proportion of participants with R0 resection was similar across T4 and non-T4 subgroups. In both T4 and non-T4 subgroups, participants who received neoadjuvant pembrolizumab were more likely to not have high-risk pathological features after surgery compared with the SOC group. Results for participants with PD-L1 CPS ≥1 will also be presented.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154525--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S075",
      "content_id": "153886",
      "abstract_number": "S075",
      "poster_number": "",
      "title": "Response-Adapted Surgical Management Following Neoadjuvant Systemic Therapy in Oral Cavity Cancer",
      "summary": "Surgical de-escalation in the oral cavity cancer cohort, defined as a reduction in pre- and post-operative OCC SMS, was observed in 44 patients (62.8%). The average pre-operative OCC Score is 9.1 (95% CI 8.5 – 9.7), and the average post-operative OCC SMS is 6.5 (95% CI 5.8 – 7.2). The largest drivers of surgical de-escalation calculated by the percent contribution to OCC SMS reduction amongst the study cohort...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153886",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Richard J Lu, MD, MBA, MSc",
      "presenter": "Richard J Lu, MD, MBA, MSc",
      "authors": "Richard J Lu, MD, MBA, MSc ; Lara Dunn, MD; Kenric Tam, MD; Alan Ho, MD, PhD; Michael T Starc; Richard J Wong, MD; Ian Ganly, MD; Snehal Patel, MD; Marc A Cohen, MD, MPH; Nancy Lee, MD; Jennifer R Cracchiolo, MD",
      "normalized_authors": [
        "Richard J Lu",
        "Lara Dunn",
        "Kenric Tam",
        "Alan Ho",
        "Michael T Starc",
        "Richard J Wong",
        "Ian Ganly",
        "Snehal Patel",
        "Marc A Cohen",
        "Nancy Lee",
        "Jennifer R Cracchiolo"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153886/Table%201%20-%20SMS%20Score%20by%20Subsite.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153886/Table%201%20-%20SMS%20Score%20by%20Subsite.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153886"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153886/Table%202%20-%20De-escalation%20and%20Margins.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153886/Table%202%20-%20De-escalation%20and%20Margins.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153886"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153886/Figure%201%20-%20SMS%20Sankey%20Plot.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153886/Figure%201%20-%20SMS%20Sankey%20Plot.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153886"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting, and Participants",
        "Interventions",
        "Main Outcomes and Measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Richard J Lu, MD, MBA, MSc ; Lara Dunn, MD; Kenric Tam, MD; Alan Ho, MD, PhD; Michael T Starc; Richard J Wong, MD; Ian Ganly, MD; Snehal Patel, MD; Marc A Cohen, MD, MPH; Nancy Lee, MD; Jennifer R Cracchiolo, MD",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Importance": "Despite decades of experience with neoadjuvant systemic therapy (NAST) in oral cavity squamous cell carcinoma (SCC), its impact on surgical decision-making has not been systematically evaluated. While NAST offers the potential to reduce tumor burden and facilitate surgical de-escalation, a standardized, evidence-based framework describing response-adapted surgical changes is urgently needed.",
        "Objective": "To determine the effect of NAST on surgical de-escalation in patients with oral cavity SCC using the newly developed Response Adapted Surgery-Oral Cavity Cancer classification and the Surgical Morbidity Score (SMS) to quantify operative changes.",
        "Design, Setting, and Participants": "Retrospective cohort study of 70 consecutive patients with resectable, locally advanced oral cavity SCC treated with NAST at an NCI designated cancer center was analyzed. Surgical plans were assessed pre- and post-NAST by head and neck attending surgeons using the using the Response Adapted Surgery-Oral Cavity Cancer Oral Cavity classification. SMS was calculated.",
        "Interventions": "NAST followed by response-adapted surgery. Neoadjuvant regimens included platinum-doublet chemotherapy with cetuximab plus or minus the addition of immune checkpoint blockade.",
        "Main Outcomes and Measures": "The primary outcome was the degree of surgical de-escalation, quantified by changes in SMS from baseline to post-NAST. Secondary outcomes included the association of SMS reduction with pathologic response and analysis of SMS reduction across anatomic subsites (tongue, buccal mucosa, floor of mouth, gingiva). Margin status after response-adapted surgery was assessed.",
        "Results": "Surgical de-escalation in the oral cavity cancer cohort, defined as a reduction in pre- and post-operative OCC SMS, was observed in 44 patients (62.8%). The average pre-operative OCC Score is 9.1 (95% CI 8.5 – 9.7), and the average post-operative OCC SMS is 6.5 (95% CI 5.8 – 7.2). The largest drivers of surgical de-escalation calculated by the percent contribution to OCC SMS reduction amongst the study cohort were a reduction in the resected structures (53%), decreased need for free flap reconstruction (27%), reduced surgical escalation for exposure (17%), and reduced extent of neck dissection (3%). The largest SMS reductions were seen in tongue cancers (mean decrease: 3.1 points, p<0.001), followed by buccal mucosa (2.1 points, p = 0.024), floor-of-mouth cancers (2.0 points, p = 0.250). Gingival cancers showed the least reduction (1.1 points, p = 0.116). The degree of SMS reduction correlated strongly with pathologic response: complete responders had the greatest SMS reduction, followed by major and non-major responders. 97% of de-escalated cases achieved negative margins with margin widths comparable to those in patients who did not undergo de-escalation.",
        "Conclusions and Relevance": "NAST enables meaningful surgical de-escalation in oral cavity SCC, and its expanding use reinforces the need to quantify these surgical changes. The close association between pathologic response and de-escalation supports continued evaluation of systemic regimens that improve response rates. Surgical de-escalation should be incorporated as a key endpoint in future trials aiming to refine treatment approaches.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Response-Adapted Surgical Management Following Neoadjuvant Systemic Therapy in Oral Cavity Cancer</span>. <u>Richard J Lu, MD, MBA, MSc</u>; Lara Dunn, MD; Kenric Tam, MD; Alan Ho, MD, PhD; Michael T Starc; Richard J Wong, MD; Ian Ganly, MD; Snehal Patel, MD; Marc A Cohen, MD, MPH; Nancy Lee, MD; Jennifer R Cracchiolo, MD. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>Despite decades of experience with neoadjuvant systemic therapy (NAST) in oral cavity squamous cell carcinoma (SCC), its impact on surgical decision-making has not been systematically evaluated.  While NAST offers the potential to reduce tumor burden and facilitate surgical de-escalation, a standardized, evidence-based framework describing response-adapted surgical changes is urgently needed.  </p>\n\n<p><strong>Objective: </strong>To determine the effect of NAST on surgical de-escalation in patients with oral cavity SCC using the newly developed Response Adapted Surgery-Oral Cavity Cancer classification and the Surgical Morbidity Score (SMS) to quantify operative changes.</p>\n\n<p><strong>Design, Setting, and Participants: </strong>Retrospective cohort study of 70 consecutive patients with resectable, locally advanced oral cavity SCC treated with NAST at an NCI designated cancer center was analyzed. Surgical plans were assessed pre- and post-NAST by head and neck attending surgeons using the using the Response Adapted Surgery-Oral Cavity Cancer Oral Cavity classification. SMS was calculated.</p>\n\n<p><strong>Interventions: </strong>NAST followed by response-adapted surgery. Neoadjuvant regimens included platinum-doublet chemotherapy with cetuximab plus or minus the addition of immune checkpoint blockade.</p>\n\n<p><strong>Main Outcomes and Measures: </strong>The primary outcome was the degree of surgical de-escalation, quantified by changes in SMS from baseline to post-NAST. Secondary outcomes included the association of SMS reduction with pathologic response and analysis of SMS reduction across anatomic subsites (tongue, buccal mucosa, floor of mouth, gingiva). Margin status after response-adapted surgery was assessed.</p>\n\n<p><strong>Results: </strong>Surgical de-escalation in the oral cavity cancer cohort, defined as a reduction in pre- and post-operative OCC SMS, was observed in 44 patients (62.8%).  The average pre-operative OCC Score is 9.1 (95% CI 8.5 – 9.7), and the average post-operative OCC SMS is 6.5 (95% CI 5.8 – 7.2). The largest drivers of surgical de-escalation calculated by the percent contribution to OCC SMS reduction amongst the study cohort were a reduction in the resected structures (53%), decreased need for free flap reconstruction (27%), reduced surgical escalation for exposure (17%), and reduced extent of neck dissection (3%).  The largest SMS reductions were seen in tongue cancers (mean decrease: 3.1 points, p<0.001), followed by buccal mucosa (2.1 points, p = 0.024), floor-of-mouth cancers (2.0 points, p = 0.250). Gingival cancers showed the least reduction (1.1 points, p = 0.116). The degree of SMS reduction correlated strongly with pathologic response: complete responders had the greatest SMS reduction, followed by major and non-major responders. 97% of de-escalated cases achieved negative margins with margin widths comparable to those in patients who did not undergo de-escalation.</p>\n\n<p><strong>Conclusions and Relevance: </strong>NAST enables meaningful surgical de-escalation in oral cavity SCC, and its expanding use reinforces the need to quantify these surgical changes. The close association between pathologic response and de-escalation supports continued evaluation of systemic regimens that improve response rates. Surgical de-escalation should be incorporated as a key endpoint in future trials aiming to refine treatment approaches.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153886/Table%201%20-%20SMS%20Score%20by%20Subsite.jpg' /></p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153886/Table%202%20-%20De-escalation%20and%20Margins.jpg' /></p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153886/Figure%201%20-%20SMS%20Sankey%20Plot.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153886--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S076",
      "content_id": "154439",
      "abstract_number": "S076",
      "poster_number": "",
      "title": "HEADWAY: Multicenter Prospective Investigation of Neoadjuvant Immunotherapy in Real-World Practice",
      "summary": "Incorporation of neoadjuvant immunotherapy into head and neck cancer care delivery poses logistical considerations of multidisciplinary, multi-institutional collaboration which impact translation of clinical trial findings into daily practice. High PD-L1 expression may contribute to cases of complete and partial pathologic responses noted thus far. This early analysis offers real-world insight into neoadjuvant...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anneliese Opran",
      "presenter": "Anneliese Opran",
      "authors": "Anneliese Opran 1 ; Janice Farlow, MD, PhD 2 ; Alessa Colaianni, MD 3 ; Alice Tang, MD 4 ; Anne Kane, MD 5 ; Tam Ramsey, MD 6 ; Sagar Kansara, MD 7 ; Jessica Tang, MD 8 ; Lindsey Moses, MD 9 ; Alexander Kejner, MD 10 ; Melina Windon, MD 11 ; Michelle Chen, MD 12 ; Chad Brenner, PhD 1 ; Marisa R Buchakjian, MD, PhD 1 ; Keith A Casper, MD 1 ; David W Forner, MD, MSc, FRCSC 1 ; Molly Heft-Neal, MD 1 ; Michelle L Mierzwa, MD 13 ; Mark E Prince, MD, FRSC, FACS 1 ; Jennifer L Shah, MD 13 ; Paul L Swiecicki, MD 14 ; Andrew G Shuman, MD 1 ; Chaz L Stucken, MD 1 ; Francis P Worden, MD 14 ; Pratyusha Yalamanchi, MD, MBA 1",
      "normalized_authors": [
        "Anneliese Opran",
        "Janice Farlow",
        "Alessa Colaianni",
        "Alice Tang",
        "Anne Kane",
        "Tam Ramsey",
        "Sagar Kansara",
        "Jessica Tang",
        "Lindsey Moses",
        "Alexander Kejner",
        "Melina Windon",
        "Michelle Chen",
        "Chad Brenner",
        "Marisa R Buchakjian",
        "Keith A Casper",
        "David W Forner, FRCSC",
        "Molly Heft-Neal",
        "Michelle L Mierzwa",
        "Mark E Prince, FRSC",
        "Jennifer L Shah",
        "Paul L Swiecicki",
        "Andrew G Shuman",
        "Chaz L Stucken",
        "Francis P Worden",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, University of Michigan Health System",
        "Department of Otolaryngology–Head and Neck Surgery, Indiana University School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, UNC-Chapel Hill",
        "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine",
        "Department of Otolaryngology- Head and Neck Surgery, University of Mississippi Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center",
        "Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina",
        "Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical College",
        "Department of Otolaryngology-Head and Neck Surgery, Stanford University",
        "Department of Radiation Oncology- University of Michigan Health System",
        "Department of Internal Medicine-Medical Oncology, University of Michigan Health System"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, University of Michigan Health System",
        "Department of Otolaryngology–Head and Neck Surgery, Indiana University School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, UNC-Chapel Hill",
        "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine",
        "Department of Otolaryngology- Head and Neck Surgery, University of Mississippi Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center",
        "Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center",
        "Department of Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina",
        "Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical College",
        "Department of Otolaryngology-Head and Neck Surgery, Stanford University",
        "Department of Radiation Oncology- University of Michigan Health System",
        "Department of Internal Medicine-Medical Oncology, University of Michigan Health System"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Process%20Map(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Process%20Map(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%201.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%202(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%202(1).jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%203.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%203.jpg",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%204.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%204.jpg",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154439"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 511,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Anneliese Opran 1 ; Janice Farlow, MD, PhD 2 ; Alessa Colaianni, MD 3 ; Alice Tang, MD 4 ; Anne Kane, MD 5 ; Tam Ramsey, MD 6 ; Sagar Kansara, MD 7 ; Jessica Tang, MD 8 ; Lindsey Moses, MD 9 ; Alexander Kejner, MD 10 ; Melina Windon, MD 11 ; Michelle Chen, MD 12 ; Chad Brenner, PhD 1 ; Marisa R Buchakjian, MD, PhD 1 ; Keith A Casper, MD 1 ; David W Forner, MD, MSc, FRCSC 1 ; Molly Heft-Neal, MD 1 ; Michelle L Mierzwa, MD 13 ; Mark E Prince, MD, FRSC, FACS 1 ; Jennifer L Shah, MD 13 ; Paul L Swiecicki, MD 14 ; Andrew G Shuman, MD 1 ; Chaz L Stucken, MD 1 ; Francis P Worden, MD 14 ; Pratyusha Yalamanchi, MD, MBA 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, University of Michigan Health System; 2 Department of Otolaryngology–Head and Neck Surgery, Indiana University School of Medicine; 3 Department of Otolaryngology-Head and Neck Surgery, UNC-Chapel Hill; 4 Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine; 5 Department of Otolaryngology- Head and Neck Surgery, University of Mississippi Medical Center; 6 Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center; 7 Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center; 8 Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center; 9 Department of Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine; 10 Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina; 11 Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical College; 12 Department of Otolaryngology-Head and Neck Surgery, Stanford University; 13 Department of Radiation Oncology- University of Michigan Health System; 14 Department of Internal Medicine-Medical Oncology, University of Michigan Health System",
        "Objective": "The KEYNOTE-689 trial demonstrated addition of perioperative pembrolizumab to standard treatment for locally advanced head and neck squamous cell carcinoma significantly improved event-free survival (EFS). Limited data exists on implementation of perioperative immunotherapy treatment for locally advanced head and neck squamous cell carcinoma in diverse clinical settings. This ongoing multicenter prospective cohort study evaluates real-world safety, feasibility, and oncologic outcomes of integrating perioperative pembrolizumab therapy in surgically-resectable head and neck squamous cell carcinoma across 14 clinical sites.",
        "Methods": "This multicenter prospective cohort study across 14 academic and community centers includes adults (≥18 years) with biopsy-confirmed locally advanced head and neck squamous cell carcinoma, programmed death-ligand 1 combined positive score (CPS) ≥1 and receipt of at least one dose of immunotherapy in the neoadjuvant setting. Patients with metastatic disease at initial diagnosis, receipt of immunotherapy in the adjuvant or palliative setting only, and non-mucosal primary sites are excluded. Patient demographic information, tumor characteristics, CPS predefined group category (1-9, 10-19, ≥20), and treatment details were recorded. The primary outcomes of feasibility in real-world practice include (1) time to administration of neoadjuvant therapy from pathologic diagnosis and (2) time to definitive surgical resection from pathologic diagnosis (Figure 1). Secondary objectives of treatment burden and oncologic outcomes include (1) immune-related adverse events (irAEs), (2) surgical outcomes (i.e. extent of oncologic surgery and reconstruction, pathologic response, margin status, and perioperative complications), (3) utilization and adherence to adjuvant therapy, and (4) two-year EFS and overall survival (OS).",
        "Results": "To date, among 26 patients who have received neoadjuvant pembrolizumab across multiple centers, 22 have undergone definitive resection, 1 progressed to unresectable status, and 3 are scheduled for surgery. Most tumors arose in the oral cavity (80.8%) and were locally advanced (76.9% T3-T4). 50% demonstrated high PD-L1 expression (CPS≥20). Time to treatment intervals revealed a mean of 21 days (±37.6) from pathologic diagnosis to first cycle of neoadjuvant immunotherapy and an average of 70.4 days (±45.0) from diagnosis to surgery. 45% of patients underwent surgery within nine weeks of diagnosis, with surgeons reporting changes in planned oncologic resection in 30% of cases. Pathologic response data were available for 21 patients (2 exhibited a complete response, 7 partial response). 12 cases demonstrated no pathologic response with 10/12 cases (83%) reported to have disease progression from time of pathologic diagnosis to surgery based on cross-sectional imaging. All 12 cases were CPS <20. Margin assessment was confirmed in 22 patients, with 18 displaying negative margins. Perioperative complications were noted in approximately 27% of patients and there was one patient death (Table 3). Adjuvant therapy data is pending.",
        "Conclusion": "Incorporation of neoadjuvant immunotherapy into head and neck cancer care delivery poses logistical considerations of multidisciplinary, multi-institutional collaboration which impact translation of clinical trial findings into daily practice. High PD-L1 expression may contribute to cases of complete and partial pathologic responses noted thus far. This early analysis offers real-world insight into neoadjuvant pembrolizumab use for resectable LA-HNSCC across multiple centers, with planned observation of surgical and oncologic outcomes across all 14 sites.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HEADWAY: Multicenter Prospective Investigation of Neoadjuvant Immunotherapy in Real-World Practice</span>. <u>Anneliese Opran</u><sup>1</sup>; Janice Farlow, MD, PhD<sup>2</sup>; Alessa Colaianni, MD<sup>3</sup>; Alice Tang, MD<sup>4</sup>; Anne Kane, MD<sup>5</sup>; Tam Ramsey, MD<sup>6</sup>; Sagar Kansara, MD<sup>7</sup>; Jessica Tang, MD<sup>8</sup>; Lindsey Moses, MD<sup>9</sup>; Alexander Kejner, MD<sup>10</sup>; Melina Windon, MD<sup>11</sup>; Michelle Chen, MD<sup>12</sup>; Chad Brenner, PhD<sup>1</sup>; Marisa R Buchakjian, MD, PhD<sup>1</sup>; Keith A Casper, MD<sup>1</sup>; David W Forner, MD, MSc, FRCSC<sup>1</sup>; Molly Heft-Neal, MD<sup>1</sup>; Michelle L Mierzwa, MD<sup>13</sup>; Mark E Prince, MD, FRSC, FACS<sup>1</sup>; Jennifer L Shah, MD<sup>13</sup>; Paul L Swiecicki, MD<sup>14</sup>; Andrew G Shuman, MD<sup>1</sup>; Chaz L Stucken, MD<sup>1</sup>; Francis P Worden, MD<sup>14</sup>; Pratyusha Yalamanchi, MD, MBA<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, University of Michigan Health System; <sup>2</sup>Department of Otolaryngology–Head and Neck Surgery, Indiana University School of Medicine; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, UNC-Chapel Hill; <sup>4</sup>Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine; <sup>5</sup>Department of Otolaryngology- Head and Neck Surgery, University of Mississippi Medical Center; <sup>6</sup>Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center; <sup>7</sup>Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center; <sup>8</sup>Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center; <sup>9</sup>Department of Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine; <sup>10</sup>Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina; <sup>11</sup>Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical College; <sup>12</sup>Department of Otolaryngology-Head and Neck Surgery, Stanford University; <sup>13</sup>Department of Radiation Oncology- University of Michigan Health System; <sup>14</sup>Department of Internal Medicine-Medical Oncology, University of Michigan Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The KEYNOTE-689 trial demonstrated addition of perioperative pembrolizumab to standard treatment for locally advanced head and neck squamous cell carcinoma significantly improved event-free survival (EFS). Limited data exists on implementation of perioperative immunotherapy treatment for locally advanced head and neck squamous cell carcinoma in diverse clinical settings. This ongoing multicenter prospective cohort study evaluates real-world safety, feasibility, and oncologic outcomes of integrating perioperative pembrolizumab therapy in surgically-resectable head and neck squamous cell carcinoma across 14 clinical sites. </p>\n\n<p><strong>Methods: </strong>This multicenter prospective cohort study across 14 academic and community centers includes adults (≥18 years) with biopsy-confirmed locally advanced head and neck squamous cell carcinoma, programmed death-ligand 1 combined positive score (CPS) ≥1 and receipt of at least one dose of immunotherapy in the neoadjuvant setting. Patients with metastatic disease at initial diagnosis, receipt of immunotherapy in the adjuvant or palliative setting only, and non-mucosal primary sites are excluded. Patient demographic information, tumor characteristics, CPS predefined group category (1-9, 10-19, ≥20), and treatment details were recorded. The primary outcomes of feasibility in real-world practice include (1) time to administration of neoadjuvant therapy from pathologic diagnosis and (2) time to definitive surgical resection from pathologic diagnosis (Figure 1). Secondary objectives of treatment burden and oncologic outcomes include (1) immune-related adverse events (irAEs), (2) surgical outcomes (i.e. extent of oncologic surgery and reconstruction, pathologic response, margin status, and perioperative complications), (3) utilization and adherence to adjuvant therapy, and (4) two-year EFS and overall survival (OS). </p>\n\n<p><strong>Results: </strong>To date, among 26 patients who have received neoadjuvant pembrolizumab across multiple centers, 22 have undergone definitive resection, 1 progressed to unresectable status, and 3 are scheduled for surgery. Most tumors arose in the oral cavity (80.8%) and were locally advanced (76.9% T3-T4). 50% demonstrated high PD-L1 expression (CPS≥20). Time to treatment intervals revealed a mean of 21 days (±37.6) from pathologic diagnosis to first cycle of neoadjuvant immunotherapy and an average of 70.4 days (±45.0) from diagnosis to surgery. 45% of patients underwent surgery within nine weeks of diagnosis, with surgeons reporting changes in planned oncologic resection in 30% of cases. Pathologic response data were available for 21 patients (2 exhibited a complete response, 7 partial response). 12 cases demonstrated no pathologic response with 10/12 cases (83%) reported to have disease progression from time of pathologic diagnosis to surgery based on cross-sectional imaging. All 12 cases were CPS <20. Margin assessment was confirmed in 22 patients, with 18 displaying negative margins. Perioperative complications were noted in approximately 27% of patients and there was one patient death (Table 3). Adjuvant therapy data is pending. </p>\n\n<p><strong>Conclusion: </strong>Incorporation of neoadjuvant immunotherapy into head and neck cancer care delivery poses logistical considerations of multidisciplinary, multi-institutional collaboration which impact translation of clinical trial findings into daily practice. High PD-L1 expression may contribute to cases of complete and partial pathologic responses noted thus far. This early analysis offers real-world insight into neoadjuvant pembrolizumab use for resectable LA-HNSCC across multiple centers, with planned observation of surgical and oncologic outcomes across all 14 sites.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Process%20Map(2).jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%201.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%202(1).jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%203.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154439/HEADWAY%20Table%204.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154439--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S077",
      "content_id": "154670",
      "abstract_number": "S077",
      "poster_number": "",
      "title": "SARS-CoV-2 mRNA Vaccine Exposure and Survival Outcomes in Head and Neck Squamous Cell Carcinoma Patients on Immune Checkpoint Inhibitor Therapy",
      "summary": "SARS-CoV2 mRNA vaccination history within 6 months of ICI therapy initiation in R/M HNSCC patients was consistently associated with significantly improved OS across all included HNSCC sub-sites. While further work is needed to determine whether this association reflects vaccine-related immune priming, virus-specific antigenic effects, or other mechanisms, these findings suggest that mRNA-driven immune activation...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154670",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Uralov, MD",
      "presenter": "Daniel Uralov, MD",
      "authors": "Daniel Uralov, MD ; Jason Tasoulas, MD, DMD, PhD; Sarah Harrington, BA; Emma De Ravin, MD; Kelly Brigham, MD; Hannah Kenny; Eric Mastrolonardo, MD; Ramez Philips, MD; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD",
      "normalized_authors": [
        "Daniel Uralov",
        "Jason Tasoulas",
        "Sarah Harrington",
        "Emma De Ravin",
        "Kelly Brigham",
        "Hannah Kenny",
        "Eric Mastrolonardo",
        "Ramez Philips",
        "Adam Luginbuhl",
        "David Cognetti",
        "Joseph Curry"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel Uralov, MD ; Jason Tasoulas, MD, DMD, PhD; Sarah Harrington, BA; Emma De Ravin, MD; Kelly Brigham, MD; Hannah Kenny; Eric Mastrolonardo, MD; Ramez Philips, MD; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD",
        "Affiliations": "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Introduction": "Data suggests that SARS-CoV-2 mRNA vaccination may enhance the efficacy of immune checkpoint inhibitors (ICIs) by triggering type I interferon–mediated innate immune activation, enhanced tumor antigen presentation, and promoting T-cell infiltration into tumors. Prior retrospective analyses in patients with melanoma and non-small cell lung cancer have shown that receiving a COVID-19 mRNA vaccine within several months of starting ICI therapy is associated with significantly improved overall survival (OS). Although adjuvant and neo-adjuvant ICI has demonstrated survival benefit in head and neck squamous cell carcinoma (HNSCC), the potential impact of SARS-CoV-2 mRNA vaccination on ICI response in HNSCC remains unclear.",
        "Methods": "Using the TriNetX Research Network, we identified patients with recurrent or metastatic (R/M) HNSCC who received ICI (pembrolizumab or nivolumab). We then compared those who received a SARS-CoV-2 mRNA vaccine within 6 months of ICI initiation to unvaccinated ICI-treated patients. Propensity score matching was performed based on patient demographics, comorbidities, tobacco and alcohol use, and TNM staging. OS was evaluated in a combined pan-HNSCC cohort, and within subgroups of the three most common HNSCC subsites - oral, oropharyngeal and laryngeal/hypopharyngeal - using Kaplan-Meier analyses at 1, 3, and 5 years from cancer diagnosis.",
        "Results": "After matching, 1,082 patients were included in each arm of the pan-cancer analysis. SARS-CoV-2 mRNA vaccine exposure was associated with significantly improved OS (5-year OS 57.5% vs. 39.6%; HR 0.57, 95% CI 0.50–0.65). Subsite-specific analyses similarly demonstrated significant improvement in OS with vaccine exposure for every subsite at every time-point. In oral cavity SCC (n=529 per arm), 5-year OS was 54.9% vs. 38.8% (HR 0.64, 95% CI 0.54–0.78). In oropharyngeal SCC (n=503 per arm), 5-year OS was 53.0% vs. 37.2% (HR 0.59, 95% CI 0.49–0.71). In laryngeal/hypopharyngeal SCC (n=280 per arm), 5-year OS was 54.2% vs. 36.0% (HR 0.60, 95% CI 0.47–0.77).",
        "Conclusions": "SARS-CoV2 mRNA vaccination history within 6 months of ICI therapy initiation in R/M HNSCC patients was consistently associated with significantly improved OS across all included HNSCC sub-sites. While further work is needed to determine whether this association reflects vaccine-related immune priming, virus-specific antigenic effects, or other mechanisms, these findings suggest that mRNA-driven immune activation may modulate ICI responsiveness. mRNA-based immune priming may represent a practical strategy to improve treatment outcomes in HNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>SARS-CoV-2 mRNA Vaccine Exposure and Survival Outcomes in Head and Neck Squamous Cell Carcinoma Patients on Immune Checkpoint Inhibitor Therapy</span>. <u>Daniel Uralov, MD</u>; Jason Tasoulas, MD, DMD, PhD; Sarah Harrington, BA; Emma De Ravin, MD; Kelly Brigham, MD; Hannah Kenny; Eric Mastrolonardo, MD; Ramez Philips, MD; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD. Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Data suggests that SARS-CoV-2 mRNA vaccination may enhance the efficacy of immune checkpoint inhibitors (ICIs) by triggering type I interferon–mediated innate immune activation, enhanced tumor antigen presentation, and promoting T-cell infiltration into tumors. Prior retrospective analyses in patients with melanoma and non-small cell lung cancer have shown that receiving a COVID-19 mRNA vaccine within several months of starting ICI therapy is associated with significantly improved overall survival (OS). Although adjuvant and neo-adjuvant ICI has demonstrated survival benefit in head and neck squamous cell carcinoma (HNSCC), the potential impact of SARS-CoV-2 mRNA vaccination on ICI response in HNSCC remains unclear. </p>\n\n<p><strong>Methods: </strong>Using the TriNetX Research Network, we identified patients with recurrent or metastatic (R/M) HNSCC who received ICI (pembrolizumab or nivolumab). We then compared those who received a SARS-CoV-2 mRNA vaccine within 6 months of ICI initiation to unvaccinated ICI-treated patients. Propensity score matching was performed based on patient demographics, comorbidities, tobacco and alcohol use, and TNM staging. OS was evaluated in a combined pan-HNSCC cohort, and within subgroups of the three most common HNSCC subsites - oral, oropharyngeal and laryngeal/hypopharyngeal - using Kaplan-Meier analyses at 1, 3, and 5 years from cancer diagnosis.  </p>\n\n<p><strong>Results:</strong> After matching, 1,082 patients were included in each arm of the pan-cancer analysis. SARS-CoV-2 mRNA vaccine exposure was associated with significantly improved OS (5-year OS 57.5% vs. 39.6%; HR 0.57, 95% CI 0.50–0.65). Subsite-specific analyses similarly demonstrated significant improvement in OS with vaccine exposure for every subsite at every time-point. In oral cavity SCC (n=529 per arm), 5-year OS was 54.9% vs. 38.8% (HR 0.64, 95% CI 0.54–0.78). In oropharyngeal SCC (n=503 per arm), 5-year OS was 53.0% vs. 37.2% (HR 0.59, 95% CI 0.49–0.71). In laryngeal/hypopharyngeal SCC (n=280 per arm), 5-year OS was 54.2% vs. 36.0% (HR 0.60, 95% CI 0.47–0.77). </p>\n\n<p><strong>Conclusions: </strong>SARS-CoV2 mRNA vaccination history within 6 months of ICI therapy initiation in R/M HNSCC patients was consistently associated with significantly improved OS across all included HNSCC sub-sites. While further work is needed to determine whether this association reflects vaccine-related immune priming, virus-specific antigenic effects, or other mechanisms, these findings suggest that mRNA-driven immune activation may modulate ICI responsiveness. mRNA-based immune priming may represent a practical strategy to improve treatment outcomes in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154670--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S079",
      "content_id": "153430",
      "abstract_number": "S079",
      "poster_number": "",
      "title": "Neoadjuvant Chemoimmunotherapy Prior to Curative-Intent Surgery in Oral Cavity Squamous Cell Carcinoma (SCC): A Case Series",
      "summary": "Off-trial use of neoadjuvant chemoimmunotherapy in p16-negative oral cavity cancer yielded MPR/CPR rates of 75%. The neoadjuvant setting allows each tumor to serve as its own biological control, and pathologic response may provide clinically relevant insight into treatment sensitivity that could help guide adjuvant therapy decisions. In our cohort response-adapted approaches to adjuvant therapy were feasible, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153430",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Saad Ahmed, MD",
      "presenter": "Saad Ahmed, MD",
      "authors": "Saad Ahmed, MD ; Valentina Carducci, MS; Daniel Price, MD; Eric Moore, MD; Kendall Tasche, MD; Kathryn Van Abel, MD; Michelle Neben Wittich, MD; David Routman, MD; Jessica Wilson, MD; Daniel Ma, MD; Scott Lester, MD, MS; Patrick McGarrah, MD; Harry Fuentes Bayne, MD; Binav Baral, MBBS; Katharine Price, MD; Linda Yin, MD",
      "normalized_authors": [
        "Saad Ahmed",
        "Valentina Carducci",
        "Daniel Price",
        "Eric Moore",
        "Kendall Tasche",
        "Kathryn Van Abel",
        "Michelle Neben Wittich",
        "David Routman",
        "Jessica Wilson",
        "Daniel Ma",
        "Scott Lester",
        "Patrick McGarrah",
        "Harry Fuentes Bayne",
        "Binav Baral, MBBS",
        "Katharine Price",
        "Linda Yin"
      ],
      "affiliations": [
        "Mayo Clinic"
      ],
      "normalized_institutions": [
        "Mayo Clinic"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153430/Neoadjuvant%20AHNS%20Abstract%20Summary.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153430/Neoadjuvant%20AHNS%20Abstract%20Summary.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153430"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 517,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Saad Ahmed, MD ; Valentina Carducci, MS; Daniel Price, MD; Eric Moore, MD; Kendall Tasche, MD; Kathryn Van Abel, MD; Michelle Neben Wittich, MD; David Routman, MD; Jessica Wilson, MD; Daniel Ma, MD; Scott Lester, MD, MS; Patrick McGarrah, MD; Harry Fuentes Bayne, MD; Binav Baral, MBBS; Katharine Price, MD; Linda Yin, MD",
        "Affiliations": "Mayo Clinic",
        "Background": "Neoadjuvant chemoimmunotherapy has an emerging role in the curative treatment of locoregionally advanced head and neck SCC. Although phase III trials evaluating neoadjuvant immunotherapy alone have shown limited activity in Stage IVA disease, phase II studies combining chemoimmunotherapy have demonstrated robust pathologic response rates. Real-world data on oncologic outcomes and feasibility of response-adapted adjuvant treatment is limited, raising the question of how these approaches and the post-treatment pathologic findings translate into routine clinical practice.",
        "Methods": "A retrospective chart review was performed of all patients diagnosed with stage IVA or IVB p16-negative oral cavity SCC from 01/01/2018 to 10/16/2025 at a tertiary care center who underwent at least 2 cycles of neoadjuvant chemoimmunotherapy prior to curative-intent surgery. Demographics, clinical staging, radiographic and pathologic response, and survival outcomes were collected. Radiographic response was assessed using radiology reports from restaging cross-sectional imaging or PET/CT. Complete response was defined as no residual disease seen on imaging. Partial response was defined as ≥30% reduction in disease volume on cross sectional imaging and/or reduction in FDG avidity on PET/CT. Stable disease was identified as <30% in disease volume and/or FDG avidity, and progressive disease was identified as increase in disease volume and/or FDG avidity. Pathologic response was defined as complete pathologic response (CPR - no viable tumor remaining), major pathologic response (MPR - <10% viable tumor remaining), partial pathologic response (PPR - 10% to 50% viable tumor remaining), and no pathologic response (greater than 50% viable tumor remaining).",
        "Results": "8 patients were included (5 male, 3 female). All patients had p16 negative oral cavity squamous cell carcinoma. 6 patients had locally advanced cT4a disease, 1 had cT1 disease, and 1 had cT2 disease. 6 patients had an overall stage of IVa, while 2 patients had a stage of IVb. The majority of patients underwent carboplatin/paclitaxel/pembrolizumab for neoadjuvant treatment. Full staging and regimens used are shown in Table 1. Radiographically, 1 patient had a complete response, 5 patients had a partial response, 1 patient had stable disease, and 1 patient had progressive disease. All 8 patients proceeded to surgery. 4 patients achieved CPR, 2 patients achieved MPR, and 2 patients achieved PPR. 3 patients with CPR received no further adjuvant treatment, whereas 1 patient received adjuvant immunotherapy alone with pembrolizumab. 1 patient with MPR received adjuvant immunotherapy alone with pembrolizumab, while the other received adjuvant radiation with 60Gy in 30 fractions. One patient with PPR underwent adjuvant radiation with 70Gy in 35 fractions, and another patient with PPR underwent chemoradiation with 43.5 Gy in 15 fractions and weekly cisplatin.",
        "Abstract": "No patients developed recurrence during the follow-up period. Median follow-up was 15.4 months (range:4.3-39.3 months) View in Agenda and Add to Schedule",
        "Conclusion": "Off-trial use of neoadjuvant chemoimmunotherapy in p16-negative oral cavity cancer yielded MPR/CPR rates of 75%. The neoadjuvant setting allows each tumor to serve as its own biological control, and pathologic response may provide clinically relevant insight into treatment sensitivity that could help guide adjuvant therapy decisions. In our cohort response-adapted approaches to adjuvant therapy were feasible, and early outcomes were favorable."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant Chemoimmunotherapy Prior to Curative-Intent Surgery in Oral Cavity Squamous Cell Carcinoma (SCC): A Case Series</span>. <u>Saad Ahmed, MD</u>; Valentina Carducci, MS; Daniel Price, MD; Eric Moore, MD; Kendall Tasche, MD; Kathryn Van Abel, MD; Michelle Neben Wittich, MD; David Routman, MD; Jessica Wilson, MD; Daniel Ma, MD; Scott Lester, MD, MS; Patrick McGarrah, MD; Harry Fuentes Bayne, MD; Binav Baral, MBBS; Katharine Price, MD; Linda Yin, MD. Mayo Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant chemoimmunotherapy has an emerging role in the curative treatment of locoregionally advanced head and neck SCC. Although phase III trials evaluating neoadjuvant immunotherapy alone have shown limited activity in Stage IVA disease, phase II studies combining chemoimmunotherapy have demonstrated robust pathologic response rates. Real-world data on oncologic outcomes and feasibility of response-adapted adjuvant treatment is limited, raising the question of how these approaches and the post-treatment pathologic findings translate into routine clinical practice.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was performed of all patients diagnosed with stage IVA or IVB p16-negative oral cavity SCC from 01/01/2018 to 10/16/2025 at a tertiary care center who underwent at least 2 cycles of neoadjuvant chemoimmunotherapy prior to curative-intent surgery. Demographics, clinical staging, radiographic and pathologic response, and survival outcomes were collected. Radiographic response was assessed using radiology reports from restaging cross-sectional imaging or PET/CT. Complete response was defined as no residual disease seen on imaging. Partial response was defined as ≥30% reduction in disease volume on cross sectional imaging and/or reduction in FDG avidity on PET/CT. Stable disease was identified as <30% in disease volume and/or FDG avidity, and progressive disease was identified as increase in disease volume and/or FDG avidity. Pathologic response was defined as complete pathologic response (CPR - no viable tumor remaining), major pathologic response (MPR - <10% viable tumor remaining), partial pathologic response (PPR - 10% to 50% viable tumor remaining), and no pathologic response (greater than 50% viable tumor remaining).  </p>\n\n<p><strong>Results: </strong>8 patients were included (5 male, 3 female). All patients had p16 negative oral cavity squamous cell carcinoma. 6 patients had locally advanced cT4a disease, 1 had cT1 disease, and 1 had cT2 disease. 6 patients had an overall stage of IVa, while 2 patients had a stage of IVb. The majority of patients underwent carboplatin/paclitaxel/pembrolizumab for neoadjuvant treatment. Full staging and regimens used are shown in Table 1. Radiographically, 1 patient had a complete response, 5 patients had a partial response, 1 patient had stable disease, and 1 patient had progressive disease.  All 8 patients proceeded to surgery. 4 patients achieved CPR, 2 patients achieved MPR, and 2 patients achieved PPR.  3 patients with CPR received no further adjuvant treatment, whereas 1 patient received adjuvant immunotherapy alone with pembrolizumab. 1 patient with MPR received adjuvant immunotherapy alone with pembrolizumab, while the other received adjuvant radiation with 60Gy in 30 fractions. One patient with PPR underwent adjuvant radiation with 70Gy in 35 fractions, and another patient with PPR underwent chemoradiation with 43.5 Gy in 15 fractions and weekly cisplatin.</p>\n\n<p>No patients developed recurrence during the follow-up period. Median follow-up was 15.4 months (range:4.3-39.3 months)</p>\n\n<p><strong>Conclusion: </strong>Off-trial use of neoadjuvant chemoimmunotherapy in p16-negative oral cavity cancer yielded MPR/CPR rates of 75%. The neoadjuvant setting allows each tumor to serve as its own biological control, and pathologic response may provide clinically relevant insight into treatment sensitivity that could help guide adjuvant therapy decisions. In our cohort response-adapted approaches to adjuvant therapy were feasible, and early outcomes were favorable.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153430/Neoadjuvant%20AHNS%20Abstract%20Summary.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153430--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S080",
      "content_id": "153527",
      "abstract_number": "S080",
      "poster_number": "",
      "title": "Neoadjuvant Immunochemotherapy in T4b/N3 Locally Advanced Head and Neck Squamous Cell Carcinoma: A Pooled Analysis from Three Prospective Phase 2 Trials",
      "summary": "This analysis provides the first focused report on NICT in exclusively T4b/N3 HNSCC. It demonstrates that NICT is an active strategy capable of converting over 40% of initially inoperable patients to a surgically resectable status, thereby offering a crucial potential curative pathway for a population with historically dismal outcomes. Post-NICT, both definitive treatment modalities (surgery or dCRT) resulted in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153527",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yang Liu",
      "presenter": "Yang Liu",
      "authors": "Yang Liu 1 ; Qindong Cai 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 1 ; Shaoyan Liu 1",
      "normalized_authors": [
        "Yang Liu",
        "Qindong Cai",
        "Yudong Ning",
        "Han Li",
        "Lin Gui",
        "Ye Zhang",
        "Jingwei Luo",
        "Changming An",
        "Xiaolei Wang",
        "Shaoyan Liu"
      ],
      "affiliations": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153527/%E5%B1%80%E9%83%A8%E6%99%9A%E6%9C%9F%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153527/%E5%B1%80%E9%83%A8%E6%99%9A%E6%9C%9F%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153527"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 461,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Yang Liu 1 ; Qindong Cai 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 1 ; Shaoyan Liu 1",
        "Affiliations": "1 Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 3 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Background": "The management of locally advanced head and neck squamous cell carcinoma (HNSCC) with T4b and/or N3 disease represents a significant therapeutic challenge. Historically, patients with T4b/N3 HNSCC have an abysmal prognosis, with limited efficacy from definitive chemoradiotherapy (dCRT) and scarce surgical opportunities due to unresectability. The potential of neoadjuvant immunochemotherapy (NICT) to alter resectability and outcomes in this specific, high-risk population is largely unexplored. This study aimed to evaluate the feasibility and impact of NICT, with a focus on its ability to enable surgical conversion in initially inoperable patients.",
        "Methods": "We conducted a pooled analysis of three prospective, single-arm phase 2 trials involving 34 treatment-naive, non-metastatic T4b/N3 HNSCC patients. All patients received NICT. Subsequent definitive local therapy—either dCRT (n=20) or surgery (n=14)—was determined by a multidisciplinary team based on post-NICT resectability assessment. Key endpoints included objective response rate (ORR), surgical conversion rate, overall survival (OS), and disease-free survival (DFS).",
        "Results": "The cohort had a median age of 60 years and was predominantly male (97.1%). The ORR was 50% (17/34; CR: 5.9%, PR: 44.1%) with a disease control rate of 100%. Remarkably, 41.2% (14/34) of patients initially deemed unresectable were successfully converted to surgical candidates, achieving an R0 resection rate of 100% and a pathological complete response (pCR) rate of 21.4% (3/14). With a median follow-up of 29 months, median OS was 30 months and median DFS was 14 months. The 12-month OS rates were 90% for the dCRT group and 85.1% for the surgery group, with 18-month rates of 52.9% and 67.7%, respectively (Log-rank P=0.484). For DFS, the 12-month rates were 54.5% (dCRT) and 77.9% (surgery), with 18-month rates of 38.2% and 61.4% (Log-rank P=0.112). Patients achieving a radiologic CR/PR had significantly superior 18-month DFS (62.2%) compared to those with stable disease (33.1%; P=0.0317).",
        "Conclusion": "This analysis provides the first focused report on NICT in exclusively T4b/N3 HNSCC. It demonstrates that NICT is an active strategy capable of converting over 40% of initially inoperable patients to a surgically resectable status, thereby offering a crucial potential curative pathway for a population with historically dismal outcomes. Post-NICT, both definitive treatment modalities (surgery or dCRT) resulted in promising survival outcomes overall. While a trend favored surgery in DFS, no significant OS difference was observed between groups. The depth of radiologic response strongly correlated with improved DFS. These findings suggest that NICT can meaningfully expand therapeutic options and improve prognoses in this challenging disease setting, warranting validation in larger randomized trials.",
        "Keywords": "Neoadjuvant Immunochemotherapy; T4b/N3; Locally Advanced Head and Neck Squamous Cell Carcinoma; Surgical conversion; Definitive chemoradiotherapy; Disease-free survival",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant Immunochemotherapy in T4b/N3 Locally Advanced Head and Neck Squamous Cell Carcinoma: A Pooled Analysis from Three Prospective Phase 2 Trials</span>. <u>Yang Liu</u><sup>1</sup>; Qindong Cai<sup>1</sup>; Yudong Ning<sup>1</sup>; Han Li<sup>1</sup>; Lin Gui<sup>2</sup>; Ye Zhang<sup>3</sup>; Jingwei Luo<sup>3</sup>; Changming An<sup>1</sup>; Xiaolei Wang<sup>1</sup>; Shaoyan Liu<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>2</sup>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>3</sup>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: The management of locally advanced head and neck squamous cell carcinoma (HNSCC) with T4b and/or N3 disease represents a significant therapeutic challenge. Historically, patients with T4b/N3 HNSCC have an abysmal prognosis, with limited efficacy from definitive chemoradiotherapy (dCRT) and scarce surgical opportunities due to unresectability. The potential of neoadjuvant immunochemotherapy (NICT) to alter resectability and outcomes in this specific, high-risk population is largely unexplored. This study aimed to evaluate the feasibility and impact of NICT, with a focus on its ability to enable surgical conversion in initially inoperable patients.</p>\n\n<p><strong>Methods</strong>: We conducted a pooled analysis of three prospective, single-arm phase 2 trials involving 34 treatment-naive, non-metastatic T4b/N3 HNSCC patients. All patients received NICT. Subsequent definitive local therapy—either dCRT (n=20) or surgery (n=14)—was determined by a multidisciplinary team based on post-NICT resectability assessment. Key endpoints included objective response rate (ORR), surgical conversion rate, overall survival (OS), and disease-free survival (DFS).</p>\n\n<p><strong>Results</strong>: The cohort had a median age of 60 years and was predominantly male (97.1%). The ORR was 50% (17/34; CR: 5.9%, PR: 44.1%) with a disease control rate of 100%. Remarkably, 41.2% (14/34) of patients initially deemed unresectable were successfully converted to surgical candidates, achieving an R0 resection rate of 100% and a pathological complete response (pCR) rate of 21.4% (3/14). With a median follow-up of 29 months, median OS was 30 months and median DFS was 14 months. The 12-month OS rates were 90% for the dCRT group and 85.1% for the surgery group, with 18-month rates of 52.9% and 67.7%, respectively (Log-rank P=0.484). For DFS, the 12-month rates were 54.5% (dCRT) and 77.9% (surgery), with 18-month rates of 38.2% and 61.4% (Log-rank P=0.112). Patients achieving a radiologic CR/PR had significantly superior 18-month DFS (62.2%) compared to those with stable disease (33.1%; P=0.0317).</p>\n\n<p><strong>Conclusion</strong>: This analysis provides the first focused report on NICT in exclusively T4b/N3 HNSCC. It demonstrates that NICT is an active strategy capable of converting over 40% of initially inoperable patients to a surgically resectable status, thereby offering a crucial potential curative pathway for a population with historically dismal outcomes. Post-NICT, both definitive treatment modalities (surgery or dCRT) resulted in promising survival outcomes overall. While a trend favored surgery in DFS, no significant OS difference was observed between groups. The depth of radiologic response strongly correlated with improved DFS. These findings suggest that NICT can meaningfully expand therapeutic options and improve prognoses in this challenging disease setting, warranting validation in larger randomized trials.</p>\n\n<p><strong>Keywords</strong>: Neoadjuvant Immunochemotherapy; T4b/N3; Locally Advanced Head and Neck Squamous Cell Carcinoma; Surgical conversion; Definitive chemoradiotherapy; Disease-free survival</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153527/%E5%B1%80%E9%83%A8%E6%99%9A%E6%9C%9F%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153527--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S081",
      "content_id": "153828",
      "abstract_number": "S081",
      "poster_number": "",
      "title": "Genomically-targeted systemic therapy in advanced thyroid cancer: A Real World Evidence Analysis",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153828",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260119",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jeffrey J Chin",
      "presenter": "Jeffrey J Chin",
      "authors": "Jeffrey J Chin 1 ; Vanessa Fishel 2 ; Christopher Khudari 2 ; Xavier M Keutgen, MD 3 ; Brian W Kim, MD 4 ; Ronald N Cohen, MD 4 ; David Sarne 1 ; Peter Angelos, MD, PhD 5 ; Megan Applewhite, MD 5 ; Nicole A Cipriani, MD 6 ; Sara Kochanny 4 ; Nishant Agrawal, MD 7 ; Ari J Rosenberg, MD 1",
      "normalized_authors": [
        "Jeffrey J Chin",
        "Vanessa Fishel",
        "Christopher Khudari",
        "Xavier M Keutgen",
        "Brian W Kim",
        "Ronald N Cohen",
        "David Sarne",
        "Peter Angelos",
        "Megan Applewhite",
        "Nicole A Cipriani",
        "Sara Kochanny",
        "Nishant Agrawal",
        "Ari J Rosenberg"
      ],
      "affiliations": [
        "University of Chicago, Section of Hematology/Oncology",
        "Rosalind Franklin University of Medicine and Science",
        "Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, IL",
        "Department of Medicine, The University of Chicago Medicine",
        "Department of Surgery, The University of Chicago Medicine",
        "Department of Pathology, The University of Chicago Medicine",
        "Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago"
      ],
      "normalized_institutions": [
        "University of Chicago, Section of Hematology/Oncology",
        "Rosalind Franklin University of Medicine and Science",
        "Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, IL",
        "Department of Medicine, The University of Chicago Medicine",
        "Department of Surgery, The University of Chicago Medicine",
        "Department of Pathology, The University of Chicago Medicine",
        "Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 480,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jeffrey J Chin 1 ; Vanessa Fishel 2 ; Christopher Khudari 2 ; Xavier M Keutgen, MD 3 ; Brian W Kim, MD 4 ; Ronald N Cohen, MD 4 ; David Sarne 1 ; Peter Angelos, MD, PhD 5 ; Megan Applewhite, MD 5 ; Nicole A Cipriani, MD 6 ; Sara Kochanny 4 ; Nishant Agrawal, MD 7 ; Ari J Rosenberg, MD 1",
        "Affiliations": "1 University of Chicago, Section of Hematology/Oncology; 2 Rosalind Franklin University of Medicine and Science; 3 Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, IL; 4 Department of Medicine, The University of Chicago Medicine; 5 Department of Surgery, The University of Chicago Medicine; 6 Department of Pathology, The University of Chicago Medicine; 7 Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago",
        "BACKGROUND": "Treatment for advanced thyroid cancer is becoming increasingly personalized with multitargeted kinase inhibitors (MKIs) and molecularly targeted agents, such as BRAF inhibitors, forming the backbone of systemic therapy. Treatment decisions are further influenced by drug toxicity profiles and patient comorbidities, contributing to significant heterogeneity of treatment selection in real-world practice. Clinical outcomes across classes of targeted therapy in real-world practice remain poorly defined. This retrospective study evaluates systemic therapy outcomes across patient subsets with advanced thyroid cancer.",
        "METHODS": "Patients treated at a large academic medical center who underwent Next Generation Sequencing with UChicago OncoPlus platform with advanced thyroid cancer between 2016 and 2025 were included. Eligible patients had metastatic or unresectable disease and received at least one line of systemic therapy for advanced thyroid cancer, including multikinase inhibitors, selective targeted therapies, or immunotherapy. Clinical data, radiographic assessments, and survival outcomes were abstracted from the electronic medical records. Objective response rate (ORR) was determined per RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier Method.",
        "RESULTS": "Ninety-four patients who underwent OncoPlus testing met eligibility criteria and were included for analysis. Median follow-up was 42.1 months. Median age was 67 (range 24 - 93), 50 (53%) were female, and 40 (42%) were BRAF p.V600E mutated. Histology distribution was as follows: 39% papillary, 24% anaplastic, 11% oncocytic, 10% follicular, 7% poorly differentiated, and 6% medullary. Median lines of systemic therapy was 1 (range 1-5). Across the entire cohort, ORR was 20% (95% CI 15-27), median PFS was 29 months (95% CI 12-76), and median OS was 66 months (95% CI 24-149). Among patients with BRAF mutations, BRAF inhibition with or without MEK inhibition (n = 34, 50%) demonstrated an ORR of 26% (95% CI 14-43), with a median PFS of 9 months (95% CI 4-121) and median OS of 36 months (95% CI 9-121). BRAF mutated patients treated with MKIs (n = 27, 39%) demonstrated an ORR of 22% (95% CI 10-40), median PFS of 37 months (95% CI 6-89), and median OS of 91 months (95% CI 15-140). Patients with mutated p53 demonstrated lower OS versus wildtype p53, with median OS of 56 months versus 81 months, respectively (p = 0.27).",
        "CONCLUSIONS": "In this real-world retrospective cohort of advanced thyroid carcinoma, both MKI and selective targeted therapies resulted in clinically meaningful responses and survival outcomes, although MKIs seemed to have lower ORR compared with prospective trial data. Among mutant BRAF thyroid cancer, ORR was similar, but numerically higher PFS and OS was observed among MKI versus BRAF +/- MEK inhibitor-treated patients. TP53 mutation showed no clear association with survival, although a trend towards worse outcomes was observed, but did not reach statistical significance. These real-world findings suggest that both classes display activity in advanced thyroid cancer, but MKIs perhaps favor survival outcomes in this analysis, and further studies in prospective trials are warranted.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Genomically-targeted systemic therapy in advanced thyroid cancer: A Real World Evidence Analysis</span>. <u>Jeffrey J Chin</u><sup>1</sup>; Vanessa Fishel<sup>2</sup>; Christopher Khudari<sup>2</sup>; Xavier M Keutgen, MD<sup>3</sup>; Brian W Kim, MD<sup>4</sup>; Ronald N Cohen, MD<sup>4</sup>; David Sarne<sup>1</sup>; Peter Angelos, MD, PhD<sup>5</sup>; Megan Applewhite, MD<sup>5</sup>; Nicole A Cipriani, MD<sup>6</sup>; Sara Kochanny<sup>4</sup>; Nishant Agrawal, MD<sup>7</sup>; Ari J Rosenberg, MD<sup>1</sup>. <sup>1</sup>University of Chicago, Section of Hematology/Oncology; <sup>2</sup>Rosalind Franklin University of Medicine and Science; <sup>3</sup>Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, IL; <sup>4</sup>Department of Medicine, The University of Chicago Medicine; <sup>5</sup>Department of Surgery, The University of Chicago Medicine; <sup>6</sup>Department of Pathology, The University of Chicago Medicine; <sup>7</sup>Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Treatment for advanced thyroid cancer is becoming increasingly personalized with multitargeted kinase inhibitors (MKIs) and molecularly targeted agents, such as BRAF inhibitors, forming the backbone of systemic therapy. Treatment decisions are further influenced by drug toxicity profiles and patient comorbidities, contributing to significant heterogeneity of treatment selection in real-world practice. Clinical outcomes across classes of targeted therapy in real-world practice remain poorly defined. This retrospective study evaluates systemic therapy outcomes across patient subsets with advanced thyroid cancer.</p>\n\n<p><strong>METHODS: </strong>Patients treated at a large academic medical center who underwent Next Generation Sequencing with UChicago OncoPlus platform with advanced thyroid cancer between 2016 and 2025 were included. Eligible patients had metastatic or unresectable disease and received at least one line of systemic therapy for advanced thyroid cancer, including multikinase inhibitors, selective targeted therapies, or immunotherapy. Clinical data, radiographic assessments, and survival outcomes were abstracted from the electronic medical records. Objective response rate (ORR) was determined per RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier Method.</p>\n\n<p><strong>RESULTS: </strong>Ninety-four patients who underwent OncoPlus testing met eligibility criteria and were included for analysis. Median follow-up was 42.1 months. Median age was 67 (range 24 - 93), 50 (53%) were female, and 40 (42%) were BRAF p.V600E mutated. Histology distribution was as follows: 39% papillary, 24% anaplastic, 11% oncocytic, 10% follicular, 7% poorly differentiated, and 6% medullary. Median lines of systemic therapy was 1 (range 1-5). Across the entire cohort, ORR was 20% (95% CI 15-27), median PFS was 29 months (95% CI 12-76), and median OS was 66 months (95% CI 24-149). Among patients with BRAF mutations, BRAF inhibition with or without MEK inhibition (n = 34, 50%) demonstrated an ORR of 26% (95% CI 14-43), with a median PFS of 9 months (95% CI 4-121) and median OS of 36 months (95% CI 9-121). BRAF mutated patients treated with MKIs (n = 27, 39%) demonstrated an ORR of 22% (95% CI 10-40), median PFS of 37 months (95% CI 6-89), and median OS of 91 months (95% CI 15-140). Patients with mutated p53 demonstrated lower OS versus wildtype p53, with median OS of 56 months versus 81 months, respectively (p = 0.27).</p>\n\n<p><strong>CONCLUSIONS: </strong>In this real-world retrospective cohort of advanced thyroid carcinoma, both MKI and selective targeted therapies resulted in clinically meaningful responses and survival outcomes, although MKIs seemed to have lower ORR compared with prospective trial data. Among mutant BRAF thyroid cancer, ORR was similar, but numerically higher PFS and OS was observed among MKI versus BRAF +/- MEK inhibitor-treated patients. TP53 mutation showed no clear association with survival, although a trend towards worse outcomes was observed, but did not reach statistical significance. These real-world findings suggest that both classes display activity in advanced thyroid cancer, but MKIs perhaps favor survival outcomes in this analysis, and further studies in prospective trials are warranted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153828--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260119' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S083",
      "content_id": "154705",
      "abstract_number": "S083",
      "poster_number": "",
      "title": "A New Era of Postoperative Pain Control? Preliminary Outcomes of Suzetrigine Use in Head and Neck Free Flap Reconstruction",
      "summary": "The introduction of suzetrigine into postoperative care for head and neck free flap reconstruction appears to meaningfully enhance recovery by reducing pain burden, opioid requirements, and hospitalization duration, without an observed increase in adverse hepatic events. In this preliminary real-world cohort, suzetrigine was associated with nearly a 50% reduction in total inpatient opioid use and a substantial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154705",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel E Bestourous, MD",
      "presenter": "Daniel E Bestourous, MD",
      "authors": "Daniel E Bestourous, MD ; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH",
      "normalized_authors": [
        "Daniel E Bestourous",
        "Jacob Beiriger",
        "Brayden Seliger",
        "Austin Tautfest",
        "Larkin Harris",
        "Richard Bavier",
        "Sarah Drejet",
        "Richard Cannon",
        "Marcus Monroe",
        "Luke Buchmann",
        "Jason Hunt",
        "Hilary McCrary"
      ],
      "affiliations": [
        "University of Utah Department of Otolaryngology - Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Utah Department of Otolaryngology - Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 522,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel E Bestourous, MD ; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH",
        "Affiliations": "University of Utah Department of Otolaryngology - Head and Neck Surgery",
        "Introduction": "Postoperative pain control following head and neck free flap reconstruction is essential for functional rehabilitation in this particularly vulnerable population. While narcotics are efficacious and an integral part of a multimodal approach, their use is hindered by unfavorable side effects and addiction potential. Suzetrigine is novel non-opioid oral analgesic that selectively inhibits peripheral nociceptive neuron sodium channels, recently approved by the FDA for moderate to severe postoperative pain in adults. Early studies have yielded promising results in its ability to reduce postoperative pain, but its utility has not yet been evaluated in head and neck patients. The objective of this study is to assess the efficacy of suzetrigine for the reduction of pain following head and neck free flap surgery.",
        "Methods": "A retrospective cohort study was conducted on patients undergoing free flap reconstructive surgery of the head and neck at a tertiary care institution between January 2025 and November 2025. Patients were split into two cohorts: 1) a cohort of patients that received a protocolized multimodal pain regimen of scheduled oxycodone, acetaminophen, NSAIDs, and gabapentinoids; and 2) a cohort of patients receiving the same multimodal pain regimen with the addition of suzetrigine, including a preoperative loading dose. Pro re nata (PRN) oral opioids were added for both cohorts. Patient demographics, comorbidities, preoperative chronic opioid use, and surgical indications were extracted. Patients with severe liver dysfunction were excluded. The primary outcome measure was the use of opiates in the postoperative period, measured as daily and total inpatient morphine milligram equivalents (MME). Secondary outcomes included hospital length of stay (LOS) and medication-related adverse events.",
        "Results": "A total of 115 patients that underwent head and neck free flap reconstruction met inclusion criteria, comprised of 26 patients in the suzetrigine treatment cohort and 89 patients in the control cohort. There were no statistically significant differences in patient age, sex, BMI, or comorbid conditions. All patients were Child-Pugh Class A. The mean total inpatient opioid dose was 133.7±210.3 MME in the suzetrigine cohort and 249.1±264.1 MME in the control cohort (p=0.001), representing a 46.3% reduction in mean opioid dose (p=0.001). There was a 41.3% reduction in mean daily opioid dose in the suzetrigine cohort compared to the control cohort (18.9±26.7 MME/day vs 32.2±35.6 MME/day, p=0.007). Patients treated with suzetrigine had a shorter mean LOS than control patients (5.6±6.7 days vs 10.3±5.6 days, p=0.001). Only five patients had an elevation in liver enzymes, of which 1 was in the suzetrigine cohort.",
        "Conclusion": "The introduction of suzetrigine into postoperative care for head and neck free flap reconstruction appears to meaningfully enhance recovery by reducing pain burden, opioid requirements, and hospitalization duration, without an observed increase in adverse hepatic events. In this preliminary real-world cohort, suzetrigine was associated with nearly a 50% reduction in total inpatient opioid use and a substantial decrease in daily opioid needs, highlighting the potential of NaV1.8-selective inhibition as a transformative adjunct in multimodal analgesia for complex head and neck surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A New Era of Postoperative Pain Control? Preliminary Outcomes of Suzetrigine Use in Head and Neck Free Flap Reconstruction</span>. <u>Daniel E Bestourous, MD</u>; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH. University of Utah Department of Otolaryngology - Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Postoperative pain control following head and neck free flap reconstruction is essential for functional rehabilitation in this particularly vulnerable population. While narcotics are efficacious and an integral part of a multimodal approach, their use is hindered by unfavorable side effects and addiction potential. Suzetrigine is novel non-opioid oral analgesic that selectively inhibits peripheral nociceptive neuron sodium channels, recently approved by the FDA for moderate to severe postoperative pain in adults. Early studies have yielded promising results in its ability to reduce postoperative pain, but its utility has not yet been evaluated in head and neck patients. The objective of this study is to assess the efficacy of suzetrigine for the reduction of pain following head and neck free flap surgery.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted on patients undergoing free flap reconstructive surgery of the head and neck at a tertiary care institution between January 2025 and November 2025. Patients were split into two cohorts: 1) a cohort of patients that received a protocolized multimodal pain regimen of scheduled oxycodone, acetaminophen, NSAIDs, and gabapentinoids; and 2) a cohort of patients receiving the same multimodal pain regimen with the addition of suzetrigine, including a preoperative loading dose. Pro re nata (PRN) oral opioids were added for both cohorts. Patient demographics, comorbidities, preoperative chronic opioid use, and surgical indications were extracted. Patients with severe liver dysfunction were excluded. The primary outcome measure was the use of opiates in the postoperative period, measured as daily and total inpatient morphine milligram equivalents (MME). Secondary outcomes included hospital length of stay (LOS) and medication-related adverse events.</p>\n\n<p><strong>Results: </strong>A total of 115 patients that underwent head and neck free flap reconstruction met inclusion criteria, comprised of 26 patients in the suzetrigine treatment cohort and 89 patients in the control cohort. There were no statistically significant differences in patient age, sex, BMI, or comorbid conditions. All patients were Child-Pugh Class A. The mean total inpatient opioid dose was 133.7±210.3 MME in the suzetrigine cohort and 249.1±264.1 MME in the control cohort (p=0.001), representing a 46.3% reduction in mean opioid dose (p=0.001). There was a 41.3% reduction in mean daily opioid dose in the suzetrigine cohort compared to the control cohort (18.9±26.7 MME/day vs 32.2±35.6 MME/day, p=0.007). Patients treated with suzetrigine had a shorter mean LOS than control patients (5.6±6.7 days vs 10.3±5.6 days, p=0.001). Only five patients had an elevation in liver enzymes, of which 1 was in the suzetrigine cohort.</p>\n\n<p><strong>Conclusion: </strong>The introduction of suzetrigine into postoperative care for head and neck free flap reconstruction appears to meaningfully enhance recovery by reducing pain burden, opioid requirements, and hospitalization duration, without an observed increase in adverse hepatic events. In this preliminary real-world cohort, suzetrigine was associated with nearly a 50% reduction in total inpatient opioid use and a substantial decrease in daily opioid needs, highlighting the potential of NaV1.8-selective inhibition as a transformative adjunct in multimodal analgesia for complex head and neck surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154705--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S084",
      "content_id": "154498",
      "abstract_number": "S084",
      "poster_number": "",
      "title": "The Impact Of Accurate Documentation On Hospital Length Of Stay",
      "summary": "Dedicated review of admitted patients and coding greatly improves hospital payout and expected duration of hospital stay. Cancer patients were at greatest risk of having an incomplete chart profile. This project reflects the substantial impact of accurate comorbidity capture on both institutional reimbursement and Case Mix Index performance and justifies the use of dedicated personnel to capture this data accurately.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154498",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna Miller, BS",
      "presenter": "Anna Miller, BS",
      "authors": "Joanna George, BS 1 ; Anna Miller, BS 1 ; Leah Yturri, PAC, MPAS 2 ; Adhya Kumar, BA 1 ; Courtney King, BS 1 ; Rusha Patel, MD 2 ; Rachad Mhawej, MD 2 ; Nilesh Vasan, MD, FRACS 2 ; Jose Sanclement, MD 2 ; Mark Mims, MD 2 ; Greg Krempl, MD, FACS 2",
      "normalized_authors": [
        "Joanna George",
        "Anna Miller",
        "Leah Yturri, PAC, MPAS",
        "Adhya Kumar",
        "Courtney King",
        "Rusha Patel",
        "Rachad Mhawej",
        "Nilesh Vasan, FRACS",
        "Jose Sanclement",
        "Mark Mims",
        "Greg Krempl"
      ],
      "affiliations": [
        "University Of Oklahoma College Of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma"
      ],
      "normalized_institutions": [
        "University Of Oklahoma College Of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 448,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joanna George, BS 1 ; Anna Miller, BS 1 ; Leah Yturri, PAC, MPAS 2 ; Adhya Kumar, BA 1 ; Courtney King, BS 1 ; Rusha Patel, MD 2 ; Rachad Mhawej, MD 2 ; Nilesh Vasan, MD, FRACS 2 ; Jose Sanclement, MD 2 ; Mark Mims, MD 2 ; Greg Krempl, MD, FACS 2",
        "Affiliations": "1 University Of Oklahoma College Of Medicine; 2 Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "Background": "Accurate documentation of complete patient medical histories is essential for quality care, but is also essential for optimizing hospital reimbursement in Medicare dollars using financial metrics such as the Case Mix Index (CMI). The following quality improvement initiative examines how improving documentation practices influences CMI. By reviewing patient charts and identifying documentation gaps, this initiative aims to enhance the accuracy of a hospital’s CMI and subsequent expected geometric length of stay (GLOS). Another aim of this initiative is to demonstrate the value of assigning dedicated personnel to identify and correct gaps in patient documentation.",
        "Methods": "A routine compliance review identified the head & neck service to have the potential to increase GLOS through accurate coding. Subsequently, data was collected daily by a group of trained medical students on 100 consecutive head & neck surgical patients admitted for one night or more through the Epic database between July 1st 2025 and October 31st 2025. Data collection included surgery type, Diagnosis Related Group (DRG) weight, admission date, GLOS, discharge date, actual length of stay (LOS), diagnosis upon admission, age, gender, ethnicity, and their Charlston Comorbidity index score. Any identified missing information was clarified through direct communication with the patient or with the patient’s care team, then corrected in the electronic chart. The revised GLOS and DRG weight were then recorded. Payments were calculated using the institutional Medicare reimbursement rate and by matching the DRG weights to standard Medicare payments using both the initial and revised DRG weights, allowing the total reimbursement value of the recovered days to be calculated to estimate the potential financial impact of detailed/complete review of patient comorbidities for these patients.",
        "Results": "A total of 100 patient charts were reviewed, with an average age of 68 years. 42 (42%) required chart corrections to address missing or incomplete documentation. 66 (66%) patients were admitted with a cancer diagnosis, and 30 of those patients (45%) required documentation changes. The most frequently under-documented comorbidity was malnutrition, a severity adjustment that will typically double a patient’s expected LOS. Correction resulted in a lengthened median GLOS from 2.4 to 3.4, with a total increase of 107 expected days. Documentation improvements resulted in a total return of $679,000.98 by the institutional Medicare reimbursement rate, a 34% increase compared to before chart reviews.",
        "Conclusion": "Dedicated review of admitted patients and coding greatly improves hospital payout and expected duration of hospital stay. Cancer patients were at greatest risk of having an incomplete chart profile. This project reflects the substantial impact of accurate comorbidity capture on both institutional reimbursement and Case Mix Index performance and justifies the use of dedicated personnel to capture this data accurately.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Impact Of Accurate Documentation On Hospital Length Of Stay</span>. Joanna George, BS<sup>1</sup>; <u>Anna Miller, BS</u><sup>1</sup>; Leah Yturri, PAC, MPAS<sup>2</sup>; Adhya Kumar, BA<sup>1</sup>; Courtney King, BS<sup>1</sup>; Rusha Patel, MD<sup>2</sup>; Rachad Mhawej, MD<sup>2</sup>; Nilesh Vasan, MD, FRACS<sup>2</sup>; Jose Sanclement, MD<sup>2</sup>; Mark Mims, MD<sup>2</sup>; Greg Krempl, MD, FACS<sup>2</sup>. <sup>1</sup>University Of Oklahoma College Of Medicine; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Accurate documentation of complete patient medical histories is essential for quality care, but is also essential for optimizing hospital reimbursement in Medicare dollars using financial metrics such as the Case Mix Index (CMI). The following quality improvement initiative examines how improving documentation practices influences CMI. By reviewing patient charts and identifying documentation gaps, this initiative aims to enhance the accuracy of a hospital’s CMI and subsequent expected geometric length of stay (GLOS). Another aim of this initiative is to demonstrate the value of assigning dedicated personnel to identify and correct gaps in patient documentation.</p>\n\n<p><strong>Methods: </strong>A routine compliance review identified the head & neck service to have the potential to increase GLOS through accurate coding. Subsequently, data was collected daily by a group of trained medical students on 100 consecutive head & neck surgical patients admitted for one night or more through the Epic database between July 1st 2025 and October 31st 2025. Data collection included surgery type, Diagnosis Related Group (DRG) weight, admission date, GLOS, discharge date, actual length of stay (LOS), diagnosis upon admission, age, gender, ethnicity, and their Charlston Comorbidity index score. Any identified missing information was clarified through direct communication with the patient or with the patient’s care team, then corrected in the electronic chart. The revised GLOS and DRG weight were then recorded. Payments were calculated using the institutional Medicare reimbursement rate and by matching the DRG weights to standard Medicare payments using both the initial and revised DRG weights, allowing the total reimbursement value of the recovered days to be calculated to estimate the potential financial impact of detailed/complete review of patient comorbidities for these patients.</p>\n\n<p><strong>Results: </strong>A total of 100 patient charts were reviewed, with an average age of 68 years. 42 (42%) required chart corrections to address missing or incomplete documentation. 66 (66%) patients were admitted with a cancer diagnosis, and 30 of those patients (45%) required documentation changes. The most frequently under-documented comorbidity was malnutrition, a severity adjustment that will typically double a patient’s expected LOS. Correction resulted in a lengthened median GLOS from 2.4 to 3.4, with a total increase of 107 expected days. Documentation improvements resulted in a total return of $679,000.98 by the institutional Medicare reimbursement rate, a 34% increase compared to before chart reviews.</p>\n\n<p><strong>Conclusion: </strong>Dedicated review of admitted patients and coding greatly improves hospital payout and expected duration of hospital stay. Cancer patients were at greatest risk of having an incomplete chart profile. This project reflects the substantial impact of accurate comorbidity capture on both institutional reimbursement and Case Mix Index performance and justifies the use of dedicated personnel to capture this data accurately.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154498--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S085",
      "content_id": "153548",
      "abstract_number": "S085",
      "poster_number": "",
      "title": "Optimizing Postoperative Care: Patient Experiences With Home Drain Removal After Head and Neck Surgery",
      "summary": "Overall, the results of this study support incorporation of home drain removal into postoperative care for head and neck surgical cases given the provided benefits to patients. Home drain removal offers patients the ability to leave the hospital sooner and avoid costly expenditures for travel to a clinic such as family time off work and gas costs. This creates a more accessible postoperative care option,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153548",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vidhya Kannan, BA",
      "presenter": "Vidhya Kannan, BA",
      "authors": "Vidhya Kannan, BA ; Taylor E Freeman, MD; Lauren Miller, MD, MBA; Catherine Haring, MD; Enver Ozer, MD; Amit Agrawal, MD; Kyle Vankoevering, MD; Ricardo Carrau, MD; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Nolan Seim, MD, MBA",
      "normalized_authors": [
        "Vidhya Kannan",
        "Taylor E Freeman",
        "Lauren Miller",
        "Catherine Haring",
        "Enver Ozer",
        "Amit Agrawal",
        "Kyle Vankoevering",
        "Ricardo Carrau",
        "Stephen Kang",
        "Matthew Old",
        "James Rocco",
        "Nolan Seim"
      ],
      "affiliations": [
        "The Ohio State University Wexner Medical Center"
      ],
      "normalized_institutions": [
        "The Ohio State University Wexner Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 429,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vidhya Kannan, BA ; Taylor E Freeman, MD; Lauren Miller, MD, MBA; Catherine Haring, MD; Enver Ozer, MD; Amit Agrawal, MD; Kyle Vankoevering, MD; Ricardo Carrau, MD; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Nolan Seim, MD, MBA",
        "Affiliations": "The Ohio State University Wexner Medical Center",
        "Purpose": "Home drain removal has transformed postoperative patient care by offering a low risk and cost effective option for patients and their families. The purpose of this study was to expand on this knowledge by collecting and analyzing direct feedback from patients regarding their experience removing postoperative drains at home.",
        "Methods": "Using the survey platform, Qualtrics, a set of questions was created to gain specific feedback from participants in this study who were discharged home with drains intended for home removal. The resulting survey asked patients to answer whether their home drain removal had been successful and, if so, what forms of education proved to be most effective for their understanding. Participants were asked questions regarding whether they felt home drain removal had been worthwhile regarding money saved on fuel, travel expenditures, time off work, and their overall comfort level with the task. Surveys were collected via phone calls made directly to patients.",
        "Results": "This study included 46 patients who were discharged home with drains intended for home removal. Many participants responded that their drain removal was successfully completed at home (78%), with the most utilized or most helpful mode of education being the written instructions provided via MyChart or in the After Visit Summary (AVS). Patients who were able to successfully remove their drain at home experienced no issues, the only minor concern being that patients weren’t always aware of how long the drain would be in place. Of those who did not remove their drains at home, the majority lived in close proximity to the clinic and elected to come in and have their drain removed after discharge. 100% of survey respondents that removed their drains at home felt home drain removal was a positive addition to their healthcare experience due to its ease in decreasing travel time back to the hospital. Of this group, all participants responded that they felt safe removing their drains and would choose to remove their drains at home again in the future.",
        "Conclusion": "Overall, the results of this study support incorporation of home drain removal into postoperative care for head and neck surgical cases given the provided benefits to patients. Home drain removal offers patients the ability to leave the hospital sooner and avoid costly expenditures for travel to a clinic such as family time off work and gas costs. This creates a more accessible postoperative care option, significantly impacting our wide range and diverse patient population. Utilizing several, varied forms of instructions for patients including in-person, written, and video, proved to be beneficial and well received.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Optimizing Postoperative Care: Patient Experiences With Home Drain Removal After Head and Neck Surgery</span>. <u>Vidhya Kannan, BA</u>; Taylor E Freeman, MD; Lauren Miller, MD, MBA; Catherine Haring, MD; Enver Ozer, MD; Amit Agrawal, MD; Kyle Vankoevering, MD; Ricardo Carrau, MD; Stephen Kang, MD; Matthew Old, MD; James Rocco, MD, PhD; Nolan Seim, MD, MBA. The Ohio State University Wexner Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Home drain removal has transformed postoperative patient care by offering a low risk and cost effective option for patients and their families. The purpose of this study was to expand on this knowledge by collecting and analyzing direct feedback from patients regarding their experience removing postoperative drains at home.</p>\n\n<p><strong>Methods: </strong>Using the survey platform, Qualtrics, a set of questions was created to gain specific feedback from participants in this study who were discharged home with drains intended for home removal. The resulting survey asked patients to answer whether their home drain removal had been successful and, if so, what forms of education proved to be most effective for their understanding. Participants were asked questions regarding whether they felt home drain removal had been worthwhile regarding money saved on fuel, travel expenditures, time off work, and their overall comfort level with the task. Surveys were collected via phone calls made directly to patients.</p>\n\n<p><strong>Results: </strong>This study included 46 patients who were discharged home with drains intended for home removal. Many participants responded that their drain removal was successfully completed at home (78%), with the most utilized or most helpful mode of education being the written instructions provided via MyChart or in the After Visit Summary (AVS). Patients who were able to successfully remove their drain at home experienced no issues, the only minor concern being that patients weren’t always aware of how long the drain would be in place. Of those who did not remove their drains at home, the majority lived in close proximity to the clinic and elected to come in and have their drain removed after discharge. 100% of survey respondents that removed their drains at home felt home drain removal was a positive addition to their healthcare experience due to its ease in decreasing travel time back to the hospital. Of this group, all participants responded that they felt safe removing their drains and would choose to remove their drains at home again in the future.</p>\n\n<p><strong>Conclusion: </strong>Overall, the results of this study support incorporation of home drain removal into postoperative care for head and neck surgical cases given the provided benefits to patients. Home drain removal offers patients the ability to leave the hospital sooner and avoid costly expenditures for travel to a clinic such as family time off work and gas costs. This creates a more accessible postoperative care option, significantly impacting our wide range and diverse patient population. Utilizing several, varied forms of instructions for patients including in-person, written, and video, proved to be beneficial and well received.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153548--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S086",
      "content_id": "154012",
      "abstract_number": "S086",
      "poster_number": "",
      "title": "Improving Timely Initiation of Adjuvant Radiation Therapy in Head and Neck Cancer Through an Accountable Care Organization–Driven Quality Initiative",
      "summary": "Integrating the CoC HadjRT metric into an ACO performance framework was associated with a significant and clinically meaningful improvement in timely initiation of adjuvant RT, culminating in 94% concordance in 2025. Site-specific performance patterns suggest that oral cavity and laryngeal primaries, often requiring more extensive surgery and healing, represent key targets for future process optimization. This...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154012",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sholem Hack, MBBS",
      "presenter": "Sholem Hack, MBBS",
      "authors": "Sholem Hack, MBBS 1 ; Gianna Rosamilia, MD 2 ; David Allen, MD 3 ; Kunal Jain, MD 2 ; Ron J Karni, MD 2",
      "normalized_authors": [
        "Sholem Hack, MBBS",
        "Gianna Rosamilia",
        "David Allen",
        "Kunal Jain",
        "Ron J Karni"
      ],
      "affiliations": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA",
        "Department of Otolaryngology, Head & Neck Surgery, Emory University, Atlanta, GA, USA"
      ],
      "normalized_institutions": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA",
        "Department of Otolaryngology, Head & Neck Surgery, Emory University, Atlanta, GA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 402,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sholem Hack, MBBS 1 ; Gianna Rosamilia, MD 2 ; David Allen, MD 3 ; Kunal Jain, MD 2 ; Ron J Karni, MD 2",
        "Affiliations": "1 City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; 2 Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA; 3 Department of Otolaryngology, Head & Neck Surgery, Emory University, Atlanta, GA, USA",
        "Background": "Initiating postoperative radiation therapy (RT) within 42 days of surgery is a Commission on Cancer (CoC) quality metric (HadjRT) associated with improved oncologic outcomes. Historically, achieving this benchmark has been challenging in head and neck cancer due to complex surgical recovery, dental clearance, and coordination barriers. In 2024, our institution incorporated the HadjRT metric into its Accountable Care Organization (ACO) quality dashboard with the goal of improving timeliness of adjuvant RT.",
        "Methods": "A retrospective analysis was performed on all CoC-eligible head and neck squamous cell carcinoma cases treated with surgery followed by adjuvant RT across CY2021–CY2025. Eligibility and concordance were defined by RCRS HadjRT specifications. Time from surgery to RT initiation was calculated directly from registry dates. Outcomes were compared pre-ACO implementation (2021–2023) vs. post-implementation (2024–2025). Associations between concordance and primary site were evaluated using chi-square testing. Additional clinical factors, including age, stage, p16 status, margin status, reconstruction type, and access to dental evaluation, were identified as planned variables for further correlation analysis in an expanded dataset.",
        "Results": "Among 128 eligible cases, 62 (48.4%) met the 42-day benchmark. Year-specific concordance improved from 40% (6/15) in 2021, 33% (9/27) in 2022, and 47% (20/43) in 2023 to 44% (12/27) in 2024 (ACO Year 1) and 94% (15/16) in 2025 (ACO Year 2). Median time from surgery to RT decreased from 47 days pre-ACO to 40 days in 2025. Concordance significantly improved after ACO integration (41.2% pre-ACO vs. 62.8% post-ACO, p = 0.034).",
        "Abstract": "Primary site was strongly associated with adherence. Oropharyngeal cancers demonstrated the highest concordance (69%, 20/29) compared with oral cavity (42%, 34/81) and larynx (41%, 7/17) (p = 0.037). Median time to RT also differed by site: oropharynx 34 days, oral cavity 44 days, and larynx 56 days. Across non-concordant cases (n = 66), median delay was 55 days, compared with 38 days in concordant cases (n = 62). View in Agenda and Add to Schedule",
        "Conclusion": "Integrating the CoC HadjRT metric into an ACO performance framework was associated with a significant and clinically meaningful improvement in timely initiation of adjuvant RT, culminating in 94% concordance in 2025. Site-specific performance patterns suggest that oral cavity and laryngeal primaries, often requiring more extensive surgery and healing, represent key targets for future process optimization. This experience demonstrates that aligning institutional quality incentives with national oncology benchmarks can drive measurable improvements in multidisciplinary cancer care delivery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Improving Timely Initiation of Adjuvant Radiation Therapy in Head and Neck Cancer Through an Accountable Care Organization–Driven Quality Initiative</span>. <u>Sholem Hack, MBBS</u><sup>1</sup>; Gianna Rosamilia, MD<sup>2</sup>; David Allen, MD<sup>3</sup>; Kunal Jain, MD<sup>2</sup>; Ron J Karni, MD<sup>2</sup>. <sup>1</sup>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030 USA; <sup>3</sup>Department of Otolaryngology, Head & Neck Surgery, Emory University, Atlanta, GA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Initiating postoperative radiation therapy (RT) within 42 days of surgery is a Commission on Cancer (CoC) quality metric (HadjRT) associated with improved oncologic outcomes. Historically, achieving this benchmark has been challenging in head and neck cancer due to complex surgical recovery, dental clearance, and coordination barriers. In 2024, our institution incorporated the HadjRT metric into its Accountable Care Organization (ACO) quality dashboard with the goal of improving timeliness of adjuvant RT.</p>\n\n<p><strong>Methods: </strong>A retrospective analysis was performed on all CoC-eligible head and neck squamous cell carcinoma cases treated with surgery followed by adjuvant RT across CY2021–CY2025. Eligibility and concordance were defined by RCRS HadjRT specifications. Time from surgery to RT initiation was calculated directly from registry dates. Outcomes were compared pre-ACO implementation (2021–2023) vs. post-implementation (2024–2025). Associations between concordance and primary site were evaluated using chi-square testing. Additional clinical factors, including age, stage, p16 status, margin status, reconstruction type, and access to dental evaluation, were identified as planned variables for further correlation analysis in an expanded dataset.</p>\n\n<p><strong>Results:</strong> Among 128 eligible cases, 62 (48.4%) met the 42-day benchmark. Year-specific concordance improved from 40% (6/15) in 2021, 33% (9/27) in 2022, and 47% (20/43) in 2023 to 44% (12/27) in 2024 (ACO Year 1) and 94% (15/16) in 2025 (ACO Year 2). Median time from surgery to RT decreased from 47 days pre-ACO to 40 days in 2025. Concordance significantly improved after ACO integration (41.2% pre-ACO vs. 62.8% post-ACO, p = 0.034).</p>\n\n<p>Primary site was strongly associated with adherence. Oropharyngeal cancers demonstrated the highest concordance (69%, 20/29) compared with oral cavity (42%, 34/81) and larynx (41%, 7/17) (p = 0.037). Median time to RT also differed by site: oropharynx 34 days, oral cavity 44 days, and larynx 56 days. </p>\n\n<p>Across non-concordant cases (n = 66), median delay was 55 days, compared with 38 days in concordant cases (n = 62).</p>\n\n<p><strong>Conclusion:</strong> Integrating the CoC HadjRT metric into an ACO performance framework was associated with a significant and clinically meaningful improvement in timely initiation of adjuvant RT, culminating in 94% concordance in 2025. Site-specific performance patterns suggest that oral cavity and laryngeal primaries, often requiring more extensive surgery and healing, represent key targets for future process optimization. This experience demonstrates that aligning institutional quality incentives with national oncology benchmarks can drive measurable improvements in multidisciplinary cancer care delivery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154012--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S087",
      "content_id": "154125",
      "abstract_number": "S087",
      "poster_number": "",
      "title": "Referral Process Enhancement to Improve Time to Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma",
      "summary": "A standardized process through an EPIC®-enhanced radiation oncology referral embedded in the EHR was effectively created. After implementation, the proportion of patients starting guideline-adherent PORT increased to 64%, suggesting that a more streamlined and standardized radiation oncology referral process assists in reducing delays in starting PORT. Data collection is ongoing to establish one- and two-year...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154125",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beverly Garber, DNP, ANP, CORLN",
      "presenter": "Beverly Garber, DNP, ANP, CORLN",
      "authors": "Beverly Garber, DNP, ANP, CORLN 1 ; Evan Graboyes, MD, MPH 2 ; Brooke Meyer, MSN, RN 1 ; Andrew Birkeland, MD 1 ; Arnaud Bewley, MD 1 ; Michael Li, MD 1 ; Shyam Rao 1 ; Marianne Abouyared 1",
      "normalized_authors": [
        "Beverly Garber, DNP, ANP, CORLN",
        "Evan Graboyes",
        "Brooke Meyer, MSN",
        "Andrew Birkeland",
        "Arnaud Bewley",
        "Michael Li",
        "Shyam Rao",
        "Marianne Abouyared"
      ],
      "affiliations": [
        "University of California, Davis Health",
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "University of California, Davis Health",
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154125/figure1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154125/figure1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154125"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154125/Figure2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154125/Figure2.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154125"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Beverly Garber, DNP, ANP, CORLN 1 ; Evan Graboyes, MD, MPH 2 ; Brooke Meyer, MSN, RN 1 ; Andrew Birkeland, MD 1 ; Arnaud Bewley, MD 1 ; Michael Li, MD 1 ; Shyam Rao 1 ; Marianne Abouyared 1",
        "Affiliations": "1 University of California, Davis Health; 2 Medical University of South Carolina",
        "Introduction": "Multimodal treatment is often required for patients with advanced stage head and neck squamous cell carcinoma (HNSCC), with surgery followed by adjuvant radiation therapy being the most common approach. The National Comprehensive Cancer Network (NCCN) recommends that postoperative radiation therapy (PORT) be initiated within six weeks, or 42 days, from a definitive surgery for HNSCC, as prior studies have revealed worse outcomes if adjuvant radiation is delayed. In 2022, the American College of Surgeons Commission on Cancer (ACS CoC) established timely PORT as its first quality metric for head and neck cancer. However, it is estimated that only 50% of patients initiate PORT in a timely, guideline-adherent manner. Failure to initiate guideline-adherent PORT is a major quality gap that warrants intervention within the multidisciplinary cancer care team. Retrospective review suggests timing of radiation oncology referral played a significant role in the delay to radiation, and this finding led to this important project to streamline and improve this process and, hopefully, reduce delays in starting PORT.",
        "Methods": "This is a quality improvement study describing the implementation of a standardized head and neck cancer-specific referral process for radiation oncology. This standardized process was implemented on June 1, 2024. PORT start-date adherence rate (within 42 days from surgery) was compared for the 5 months prior to this implementation date (January – May 2024) and the 11 months post-implementation (June 2024-April 2025). An enhanced radiation oncology referral order (Figure 1) was created within the EPIC® electronic health record (EHR) with a new default to “urgent” status, surgical date specification (if known), notation of head and neck cancer as referral indication and scheduling instruction to meet the NCCN Guidelines. These variables were changed from the previously available generic radiation oncology order (Figure 2) which defaulted to “routine” status and included no other treatment details unless manually entered by the provider. Ordering providers were instructed to utilize the new radiation oncology referral order and place the order at time of surgical consult, if possible, based on patients' clinical stage.",
        "Results": "43 patients with HNSCC who had definitive surgery and adjuvant radiation performed internally were included in the initial evaluation period. Prior to implementation of the new referral process, 55% (5 of 9 patients) received PORT within 42 days of surgery. Post-implementation, the proportion of patients starting timely, guideline-adherent PORT increased to 64% (22/34). The most common documented reason for non-adherence was prolonged postoperative wound healing or hospitalization.",
        "Conclusion": "A standardized process through an EPIC®-enhanced radiation oncology referral embedded in the EHR was effectively created. After implementation, the proportion of patients starting guideline-adherent PORT increased to 64%, suggesting that a more streamlined and standardized radiation oncology referral process assists in reducing delays in starting PORT. Data collection is ongoing to establish one- and two-year post-implementation adherence rates by June 2026.",
        "Abstract": "Figure 1: Enhanced Radiation Oncology Referral Order Figure 2: Prior Generic Radiation Oncology Referral Order View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Referral Process Enhancement to Improve Time to Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma</span>. <u>Beverly Garber, DNP, ANP, CORLN</u><sup>1</sup>; Evan Graboyes, MD, MPH<sup>2</sup>; Brooke Meyer, MSN, RN<sup>1</sup>; Andrew Birkeland, MD<sup>1</sup>; Arnaud Bewley, MD<sup>1</sup>; Michael Li, MD<sup>1</sup>; Shyam Rao<sup>1</sup>; Marianne Abouyared<sup>1</sup>. <sup>1</sup>University of California, Davis Health; <sup>2</sup>Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Multimodal treatment is often required for patients with advanced stage head and neck squamous cell carcinoma (HNSCC), with surgery followed by adjuvant radiation therapy being the most common approach. The National Comprehensive Cancer Network (NCCN) recommends that postoperative radiation therapy (PORT) be initiated within six weeks, or 42 days, from a definitive surgery for HNSCC, as prior studies have revealed worse outcomes if adjuvant radiation is delayed. In 2022, the American College of Surgeons Commission on Cancer (ACS CoC) established timely PORT as its first quality metric for head and neck cancer. However, it is estimated that only 50% of patients initiate PORT in a timely, guideline-adherent manner. Failure to initiate guideline-adherent PORT is a major quality gap that warrants intervention within the multidisciplinary cancer care team. Retrospective review suggests timing of radiation oncology referral played a significant role in the delay to radiation, and this finding led to this important project to streamline and improve this process and, hopefully, reduce delays in starting PORT.</p>\n\n<p><strong>Methods: </strong>This is a quality improvement study describing the implementation of a standardized head and neck cancer-specific referral process for radiation oncology. This standardized process was implemented on June 1, 2024. PORT start-date adherence rate (within 42 days from surgery) was compared for the 5 months prior to this implementation date (January – May 2024) and the 11 months post-implementation (June 2024-April 2025). An enhanced radiation oncology referral order (Figure 1) was created within the EPIC® electronic health record (EHR) with a new default to “urgent” status, surgical date specification (if known), notation of head and neck cancer as referral indication and scheduling instruction to meet the NCCN Guidelines. These variables were changed from the previously available generic radiation oncology order (Figure 2) which defaulted to “routine” status and included no other treatment details unless manually entered by the provider. Ordering providers were instructed to utilize the new radiation oncology referral order and place the order at time of surgical consult, if possible, based on patients' clinical stage.</p>\n\n<p><strong>Results: </strong>43 patients with HNSCC who had definitive surgery and adjuvant radiation performed internally were included in the initial evaluation period. Prior to implementation of the new referral process, 55% (5 of 9 patients) received PORT within 42 days of surgery. Post-implementation, the proportion of patients starting timely, guideline-adherent PORT increased to 64% (22/34). The most common documented reason for non-adherence was prolonged postoperative wound healing or hospitalization.</p>\n\n<p><strong>Conclusion: </strong>A standardized process through an EPIC®-enhanced radiation oncology referral embedded in the EHR was effectively created. After implementation, the proportion of patients starting guideline-adherent PORT increased to 64%, suggesting that a more streamlined and standardized radiation oncology referral process assists in reducing delays in starting PORT. Data collection is ongoing to establish one- and two-year post-implementation adherence rates by June 2026.</p>\n\n<p>Figure 1: Enhanced Radiation Oncology Referral Order</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154125/figure1.png' /></p>\n\n<p>Figure 2: Prior Generic Radiation Oncology Referral Order</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154125/Figure2.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154125--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S088",
      "content_id": "154273",
      "abstract_number": "S088",
      "poster_number": "",
      "title": "Predictors of Not Receiving Recommended Adjuvant Therapy After Surgery for Oral Cavity Cancer: A National Analysis",
      "summary": "In a national cohort, approximately 1 in 7 patients did not receive the recommended adjuvant therapy, with undertreatment being more frequent for CT than for RT. Older age, non-academic care settings, and tongue primaries were associated with higher non-administration, whereas higher pT/pN categories were associated with better adherence to RCT. These findings highlight actionable targets—older adults and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154273",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nir Tsur, MD",
      "presenter": "Nir Tsur, MD",
      "authors": "Nir Tsur, MD ; Andrea Costantino; Scott Magnuson",
      "normalized_authors": [
        "Nir Tsur",
        "Andrea Costantino",
        "Scott Magnuson"
      ],
      "affiliations": [
        "Adventhealth Orlando"
      ],
      "normalized_institutions": [
        "Adventhealth Orlando"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 449,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nir Tsur, MD ; Andrea Costantino; Scott Magnuson",
        "Affiliations": "Adventhealth Orlando",
        "Background": "Failure to deliver adjuvant radiotherapy (RT) and/or chemotherapy (CT) when recommended may compromise outcomes after surgery for oral cavity squamous cell carcinoma (OCSCC). We quantified the frequency and predictors of not receiving adjuvant therapy despite documented recommendations in a contemporary national cohort.",
        "Methods": "Using the 2022 National Cancer Database Participant User File, we identified adults who underwent surgical treatment for OCSCC. Adjuvant therapy status was classified as administered, recommended-not-administered, patient refusal, contraindication, or early death. The primary endpoint was the composite non-administration of adjuvant RT and/or CT. Multivariable logistic regression with stepwise selection estimated adjusted odds ratios (aOR) and 95% CIs, adjusted for age, sex, race/ethnicity, insurance, facility type/region, tumor subsite, pathologic T and N categories, margin status, and travel distance. Sensitivity analyses were performed to evaluate the RT-recommended and CT-recommended subcohorts separately.",
        "Results": "We identified 44,897 patients with surgically treated OCSCC. Of these, 27,719 (61.7%) received adjuvant therapy; among the recommended cohort, 3,178 (11.5%) did not receive it. By modality, RT was not administered in 3,005/27,546 RT-recommended cases (10.9%), and CT was not administered in 1,865/12,372 CT-recommended cases (15.1%). In the recommended cohort, older age independently increased the odds of non-administration (per year: aOR 1.058 [95% CI 1.051–1.065] ). Relative to Academic/Research programs, facility type was associated with differential adherence: Community Cancer Programs aOR 0.36 (0.31–0.43), Comprehensive Community aOR 0.69 (0.63–0.75), Integrated Network aOR 0.85 (0.77–0.95). Using the oral tongue as the reference subsite, several non-tongue sites showed lower odds of non-administration (e.g., floor of mouth aOR 0.77; 95% CI 0.68–0.88; gingiva aOR 0.78; 0.68–0.89), consistent with the relatively higher non-administration in oral tongue primaries. Higher pathologic stage was associated with better adherence (pT3 vs. pT1, aOR 0.77; 0.70–0.86; pT4 vs. pT1, aOR 0.75; 0.68–0.82; pN2 vs. pN0, aOR 0.83; 0.77–0.89). Margin positivity was not an independent predictor (aOR, 0.95; 0.86–1.04). Sensitivity analyses confined to the RT-recommended and CT-recommended subcohorts yielded similar patterns.",
        "Conclusions": "In a national cohort, approximately 1 in 7 patients did not receive the recommended adjuvant therapy, with undertreatment being more frequent for CT than for RT. Older age, non-academic care settings, and tongue primaries were associated with higher non-administration, whereas higher pT/pN categories were associated with better adherence to RCT. These findings highlight actionable targets—older adults and non-academic settings—for quality improvement to ensure the delivery of evidence-based postoperative therapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors of Not Receiving Recommended Adjuvant Therapy After Surgery for Oral Cavity Cancer: A National Analysis</span>. <u>Nir Tsur, MD</u>; Andrea Costantino; Scott Magnuson. Adventhealth Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Failure to deliver adjuvant radiotherapy (RT) and/or chemotherapy (CT) when recommended may compromise outcomes after surgery for oral cavity squamous cell carcinoma (OCSCC). We quantified the frequency and predictors of not receiving adjuvant therapy despite documented recommendations in a contemporary national cohort.</p>\n\n<p><strong>Methods: </strong>Using the 2022 National Cancer Database Participant User File, we identified adults who underwent surgical treatment for OCSCC. Adjuvant therapy status was classified as administered, recommended-not-administered, patient refusal, contraindication, or early death. The primary endpoint was the composite non-administration of adjuvant RT and/or CT. Multivariable logistic regression with stepwise selection estimated adjusted odds ratios (aOR) and 95% CIs, adjusted for age, sex, race/ethnicity, insurance, facility type/region, tumor subsite, pathologic T and N categories, margin status, and travel distance. Sensitivity analyses were performed to evaluate the RT-recommended and CT-recommended subcohorts separately.</p>\n\n<p><strong>Results: </strong>We identified 44,897 patients with surgically treated OCSCC. Of these, 27,719 (61.7%) received adjuvant therapy; among the recommended cohort, 3,178 (11.5%) did not receive it. By modality, RT was not administered in 3,005/27,546 RT-recommended cases (10.9%), and CT was not administered in 1,865/12,372 CT-recommended cases (15.1%). In the recommended cohort, older age independently increased the odds of non-administration (per year: aOR 1.058 [95% CI 1.051–1.065] ). Relative to Academic/Research programs, facility type was associated with differential adherence: Community Cancer Programs aOR 0.36 (0.31–0.43), Comprehensive Community aOR 0.69 (0.63–0.75), Integrated Network aOR 0.85 (0.77–0.95). Using the oral tongue as the reference subsite, several non-tongue sites showed lower odds of non-administration (e.g., floor of mouth aOR 0.77; 95% CI 0.68–0.88; gingiva aOR 0.78; 0.68–0.89), consistent with the relatively higher non-administration in oral tongue primaries. Higher pathologic stage was associated with better adherence (pT3 vs. pT1, aOR 0.77; 0.70–0.86; pT4 vs. pT1, aOR 0.75; 0.68–0.82; pN2 vs. pN0, aOR 0.83; 0.77–0.89). Margin positivity was not an independent predictor (aOR, 0.95; 0.86–1.04). Sensitivity analyses confined to the RT-recommended and CT-recommended subcohorts yielded similar patterns.</p>\n\n<p><strong>Conclusions: </strong>In a national cohort, approximately 1 in 7 patients did not receive the recommended adjuvant therapy, with undertreatment being more frequent for CT than for RT. Older age, non-academic care settings, and tongue primaries were associated with higher non-administration, whereas higher pT/pN categories were associated with better adherence to RCT. These findings highlight actionable targets—older adults and non-academic settings—for quality improvement to ensure the delivery of evidence-based postoperative therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154273--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S089",
      "content_id": "154101",
      "abstract_number": "S089",
      "poster_number": "",
      "title": "Current Practices in Response-Adapted Surgery for Head and Neck Cancer: An International Survey of the American and European Head and Neck Societies",
      "summary": "There is no current consensus among head and neck surgeons regarding response-adapted surgery after neoadjuvant therapy. Surgeons are open to participation in clinical trials, and further data are needed to create a clinical consensus. This study supports the development of standard metrics and guidelines for clinical trial design and the future clinical application of response-adapted head and neck surgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154101",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Forner, MD, MSc",
      "presenter": "David Forner, MD, MSc",
      "authors": "David Forner, MD, MSc 1 ; Brittany Barber, MD 2 ; Christopher Holsinger, MD 3 ; Christian Simon, MD 4 ; Abdullah Adil, MD 1 ; Marisa R Buchakjian, MD, PhD 1 ; Keith A Casper, MD 1 ; Karen Y Choi, MD 5 ; Kevin J Contrera, MD, MPH 6 ; Molly E Heft Neal, MD 1 ; Jamie Ku, MD 7 ; Miriam N Lango, MD 5 ; Wojciech Mydlarz, MD 8 ; Andrew G Shuman, MD 1 ; Linda X Yin, MD 9 ; Stephen Y Lai, MD, PhD 5 ; Markus Blaurock, MD 10 ; Steven B Chinn, MD, MPH 6",
      "normalized_authors": [
        "David Forner",
        "Brittany Barber",
        "Christopher Holsinger",
        "Christian Simon",
        "Abdullah Adil",
        "Marisa R Buchakjian",
        "Keith A Casper",
        "Karen Y Choi",
        "Kevin J Contrera",
        "Molly E Heft Neal",
        "Jamie Ku",
        "Miriam N Lango",
        "Wojciech Mydlarz",
        "Andrew G Shuman",
        "Linda X Yin",
        "Stephen Y Lai",
        "Markus Blaurock",
        "Steven B Chinn"
      ],
      "affiliations": [
        "University of Michigan",
        "University of Washington",
        "Stanford University",
        "University Medical Center Vaud",
        "University of Texas MD Anderson Cancer Center",
        "University of Pittsburgh Medical Center",
        "Cleveland Clinic",
        "Johns Hopkins University School of Medicine",
        "Mayo Clinic",
        "University of Greifswald"
      ],
      "normalized_institutions": [
        "University of Michigan",
        "University of Washington",
        "Stanford University",
        "University Medical Center Vaud",
        "University of Texas MD Anderson Cancer Center",
        "University of Pittsburgh Medical Center",
        "Cleveland Clinic",
        "Johns Hopkins University School of Medicine",
        "Mayo Clinic",
        "University of Greifswald"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "David Forner, MD, MSc 1 ; Brittany Barber, MD 2 ; Christopher Holsinger, MD 3 ; Christian Simon, MD 4 ; Abdullah Adil, MD 1 ; Marisa R Buchakjian, MD, PhD 1 ; Keith A Casper, MD 1 ; Karen Y Choi, MD 5 ; Kevin J Contrera, MD, MPH 6 ; Molly E Heft Neal, MD 1 ; Jamie Ku, MD 7 ; Miriam N Lango, MD 5 ; Wojciech Mydlarz, MD 8 ; Andrew G Shuman, MD 1 ; Linda X Yin, MD 9 ; Stephen Y Lai, MD, PhD 5 ; Markus Blaurock, MD 10 ; Steven B Chinn, MD, MPH 6",
        "Affiliations": "1 University of Michigan; 2 University of Washington; 3 Stanford University; 4 University Medical Center Vaud; 5 University of Texas MD Anderson Cancer Center; 6 University of Pittsburgh Medical Center; 7 Cleveland Clinic; 8 Johns Hopkins University School of Medicine; 9 Mayo Clinic; 10 University of Greifswald",
        "Objective": "Response-adapted surgery after neoadjuvant systemic therapy may allow for reduced extent of resection and improved functional outcomes. The oncologic safety of this approach for head and neck malignancies is unknown due to a paucity of data. This study examines current practices in response-adapted surgery of head and neck surgeons to inform future clinical trial development.",
        "Methods": "This was a cross-sectional electronic survey administered to head and neck surgical oncologists across two international organizations, the American Head and Neck Society and the European Head and Neck Society. An iterative, consensus-based process was used for survey development, incorporating experts and stakeholders in multiple phases. Qualitative analysis was employed to examine open-ended free text responses.",
        "Results": "There were 289 respondents (45% AHNS, 55% EHNS). The majority are currently performing response-adapted surgery (54%), while an additional 20% indicated they would perform response-adapted surgery as part of a clinical trial. More respondents from the AHNS currently perform response-adapted surgery than from the EHNS (65% vs 44%, p < 0.001). Most participants had completed five or fewer cutaneous (46%) or mucosal (47%) response-adapted surgeries. Of those respondents who either do not perform response-adapted surgery or only perform response-adapted surgery on clinical trials, almost all cited current lack of evidence or multidisciplinary team preference as their rationale. Perceived barriers to participating in a clinical trial of response-adapted surgery for mucosal malignancy were varied, and included difficulty of margin control, concern for de-escalation in HPV negative tumors, low tumor response rates, fear of disease progression during neoadjuvant therapy, and lack of adequate supportive data.",
        "Abstract": "The most common structures that respondents would consider preserving after neoadjuvant therapy were the eye (91%), cranial nerves (78%), and larynx (70%). Less than half of respondents would consider preserving the mandible (47%) or maxilla (44%). Of those respondents who perform response-adapted surgery, 60% would consider offering surgery for patients with initially unresectable disease who become resectable following response to systemic therapy. Agreement on whether there is sufficient evidence to support response-adapted surgery was varied. Complete agreement (10%) or disagreement (15%) was uncommon, with most participants somewhat agreeing (38%) or somewhat disagreeing (22%). One unifying theme emerged on qualitative analysis – the need for more data. Supporting subthemes included the need for further prospective trials, improved biological understanding of tumor response and its timing, and reliable estimates of locoregional control and survival following response-adapted surgery. View in Agenda and Add to Schedule",
        "Conclusion": "There is no current consensus among head and neck surgeons regarding response-adapted surgery after neoadjuvant therapy. Surgeons are open to participation in clinical trials, and further data are needed to create a clinical consensus. This study supports the development of standard metrics and guidelines for clinical trial design and the future clinical application of response-adapted head and neck surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Current Practices in Response-Adapted Surgery for Head and Neck Cancer: An International Survey of the American and European Head and Neck Societies</span>. <u>David Forner, MD, MSc</u><sup>1</sup>; Brittany Barber, MD<sup>2</sup>; Christopher Holsinger, MD<sup>3</sup>; Christian Simon, MD<sup>4</sup>; Abdullah Adil, MD<sup>1</sup>; Marisa R Buchakjian, MD, PhD<sup>1</sup>; Keith A Casper, MD<sup>1</sup>; Karen Y Choi, MD<sup>5</sup>; Kevin J Contrera, MD, MPH<sup>6</sup>; Molly E Heft Neal, MD<sup>1</sup>; Jamie Ku, MD<sup>7</sup>; Miriam N Lango, MD<sup>5</sup>; Wojciech Mydlarz, MD<sup>8</sup>; Andrew G Shuman, MD<sup>1</sup>; Linda X Yin, MD<sup>9</sup>; Stephen Y Lai, MD, PhD<sup>5</sup>; Markus Blaurock, MD<sup>10</sup>; Steven B Chinn, MD, MPH<sup>6</sup>. <sup>1</sup>University of Michigan; <sup>2</sup>University of Washington; <sup>3</sup>Stanford University; <sup>4</sup>University Medical Center Vaud; <sup>5</sup>University of Texas MD Anderson Cancer Center; <sup>6</sup>University of Pittsburgh Medical Center; <sup>7</sup>Cleveland Clinic; <sup>8</sup>Johns Hopkins University School of Medicine; <sup>9</sup>Mayo Clinic; <sup>10</sup>University of Greifswald<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Response-adapted surgery after neoadjuvant systemic therapy may allow for reduced extent of resection and improved functional outcomes. The oncologic safety of this approach for head and neck malignancies is unknown due to a paucity of data. This study examines current practices in response-adapted surgery of head and neck surgeons to inform future clinical trial development.</p>\n\n<p><strong>Methods: </strong>This was a cross-sectional electronic survey administered to head and neck surgical oncologists across two international organizations, the American Head and Neck Society and the European Head and Neck Society. An iterative, consensus-based process was used for survey development, incorporating experts and stakeholders in multiple phases. Qualitative analysis was employed to examine open-ended free text responses.</p>\n\n<p><strong>Results: </strong>There were 289 respondents (45% AHNS, 55% EHNS). The majority are currently performing response-adapted surgery (54%), while an additional 20% indicated they would perform response-adapted surgery as part of a clinical trial. More respondents from the AHNS currently perform response-adapted surgery than from the EHNS (65% vs 44%, p < 0.001). Most participants had completed five or fewer cutaneous (46%) or mucosal (47%) response-adapted surgeries. Of those respondents who either do not perform response-adapted surgery or only perform response-adapted surgery on clinical trials, almost all cited current lack of evidence or multidisciplinary team preference as their rationale. Perceived barriers to participating in a clinical trial of response-adapted surgery for mucosal malignancy were varied, and included difficulty of margin control, concern for de-escalation in HPV negative tumors, low tumor response rates, fear of disease progression during neoadjuvant therapy, and lack of adequate supportive data.</p>\n\n<p>The most common structures that respondents would consider preserving after neoadjuvant therapy were the eye (91%), cranial nerves (78%), and larynx (70%). Less than half of respondents would consider preserving the mandible (47%) or maxilla (44%). Of those respondents who perform response-adapted surgery, 60% would consider offering surgery for patients with initially unresectable disease who become resectable following response to systemic therapy.</p>\n\n<p>Agreement on whether there is sufficient evidence to support response-adapted surgery was varied. Complete agreement (10%) or disagreement (15%) was uncommon, with most participants somewhat agreeing (38%) or somewhat disagreeing (22%). One unifying theme emerged on qualitative analysis – the need for more data. Supporting subthemes included the need for further prospective trials, improved biological understanding of tumor response and its timing, and reliable estimates of locoregional control and survival following response-adapted surgery.</p>\n\n<p><strong>Conclusion: </strong>There is no current consensus among head and neck surgeons regarding response-adapted surgery after neoadjuvant therapy. Surgeons are open to participation in clinical trials, and further data are needed to create a clinical consensus. This study supports the development of standard metrics and guidelines for clinical trial design and the future clinical application of response-adapted head and neck surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154101--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S090",
      "content_id": "153454",
      "abstract_number": "S090",
      "poster_number": "",
      "title": "Accelerating Care Delivery in Head and Neck Cancer Through a Specialist Access Initiative",
      "summary": "Implementation of a specialist access initiative was significantly associated with reductions in all times to treatment and oncologic stage severity. Although overall survival did not differ across groups, these findings suggest that structured pathways can meaningfully improve oncologic care delivery for HNC patients and should be implemented across other cancer care settings. Further research is warranted to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153454",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Atif M Islam, BS",
      "presenter": "Atif M Islam, BS",
      "authors": "Atif M Islam, BS 1 ; Robert B Baldwin, BA 1 ; Alec E Dallas, BS 1 ; Brandon J Dyer, BS 1 ; Alisa Vidwans, ScM 1 ; Emma Dunn, BS 1 ; Samer T Elsamna, MD 2 ; Julia Toman, MD 2 ; Tara Mokhtari, MD 2 ; Christopher J Nickel, MD 2 ; Matthew Mifsud, MD 2",
      "normalized_authors": [
        "Atif M Islam",
        "Robert B Baldwin",
        "Alec E Dallas",
        "Brandon J Dyer",
        "Alisa Vidwans, ScM",
        "Emma Dunn",
        "Samer T Elsamna",
        "Julia Toman",
        "Tara Mokhtari",
        "Christopher J Nickel",
        "Matthew Mifsud"
      ],
      "affiliations": [
        "USF Health Morsani College of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine"
      ],
      "normalized_institutions": [
        "USF Health Morsani College of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Atif M Islam, BS 1 ; Robert B Baldwin, BA 1 ; Alec E Dallas, BS 1 ; Brandon J Dyer, BS 1 ; Alisa Vidwans, ScM 1 ; Emma Dunn, BS 1 ; Samer T Elsamna, MD 2 ; Julia Toman, MD 2 ; Tara Mokhtari, MD 2 ; Christopher J Nickel, MD 2 ; Matthew Mifsud, MD 2",
        "Affiliations": "1 USF Health Morsani College of Medicine; 2 Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine",
        "Introduction": "Timely access to specialized oncologic care is critical for patients with head and neck cancer (HNC), yet delays in treatment remain widespread. In recent years, our institution implemented a targeted specialist access initiative designed to expedite care for HNC patients. We aimed to determine whether the implementation of the initiative was associated with improved care timeliness and survival outcomes.",
        "Methods": "545 patients who underwent a free flap reconstruction from August 2017 to September 2025 were retrospectively reviewed. Key time periods including days from first contact to initial appointment, first contact to surgery, appointment to surgery, and surgery to adjuvant therapy were abstracted. Additional variables including TNM staging, adjuvant therapy receipt, and overall survival were also collected. Patients were grouped into pre-initiative and post-initiative cohorts based on date of first contact. Mann-Whitney U tests were used to compare ordinal outcomes, categorical variables by Chi-Square, and overall survival using Kaplan-Meier log-rank testing.",
        "Results": "216 patients were included in the pre-initiative cohort while 329 patients made up the post-initiative cohort. Significant decreases in median days from first contact to appointment (11 [7-9] vs. 9 [4-21] days, p=0.0106), first contact to surgery (57 [38-96] vs. 47 [28-82] days, p<0.001), and initial appointment to surgery (42 [27-74] vs. 34 [20-62] days, p<0.001) were observed. Similar decreases were detected for days from surgery to start of chemo (82 [55-124] vs. 46 [30-58] days, p<0.001) and radio (56 [39-87] vs. 45 [30-64] days, p<0.001) adjuvant therapy, but overall receipt of adjuvant therapy did not differ across groups. Notably, patients seen after initiative implementation presented with significantly lower cancer stage (p=0.0045). There was also a different stage distribution, with markedly fewer stage IV patients in the post-implementation cohort (p=0.0067). Kaplan-Meier log-rank testing revealed no significant difference in overall survival between pre- and post-initiative cohorts (p=0.4809).",
        "Conclusions": "Implementation of a specialist access initiative was significantly associated with reductions in all times to treatment and oncologic stage severity. Although overall survival did not differ across groups, these findings suggest that structured pathways can meaningfully improve oncologic care delivery for HNC patients and should be implemented across other cancer care settings. Further research is warranted to refine these strategies in ways that not only reduce delays to care but also improve overall survival outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Accelerating Care Delivery in Head and Neck Cancer Through a Specialist Access Initiative</span>. <u>Atif M Islam, BS</u><sup>1</sup>; Robert B Baldwin, BA<sup>1</sup>; Alec E Dallas, BS<sup>1</sup>; Brandon J Dyer, BS<sup>1</sup>; Alisa Vidwans, ScM<sup>1</sup>; Emma Dunn, BS<sup>1</sup>; Samer T Elsamna, MD<sup>2</sup>; Julia Toman, MD<sup>2</sup>; Tara Mokhtari, MD<sup>2</sup>; Christopher J Nickel, MD<sup>2</sup>; Matthew Mifsud, MD<sup>2</sup>. <sup>1</sup>USF Health Morsani College of Medicine; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Timely access to specialized oncologic care is critical for patients with head and neck cancer (HNC), yet delays in treatment remain widespread. In recent years, our institution implemented a targeted specialist access initiative designed to expedite care for HNC patients. We aimed to determine whether the implementation of the initiative was associated with improved care timeliness and survival outcomes.</p>\n\n<p><strong>Methods:</strong> 545 patients who underwent a free flap reconstruction from August 2017 to September 2025 were retrospectively reviewed. Key time periods including days from first contact to initial appointment, first contact to surgery, appointment to surgery, and surgery to adjuvant therapy were abstracted. Additional variables including TNM staging, adjuvant therapy receipt, and overall survival were also collected. Patients were grouped into pre-initiative and post-initiative cohorts based on date of first contact. Mann-Whitney U tests were used to compare ordinal outcomes, categorical variables by Chi-Square, and overall survival using Kaplan-Meier log-rank testing.</p>\n\n<p><strong>Results:</strong> 216 patients were included in the pre-initiative cohort while 329 patients made up the post-initiative cohort. Significant decreases in median days from first contact to appointment (11 [7-9]  vs. 9 [4-21] days, p=0.0106), first contact to surgery (57 [38-96] vs. 47 [28-82] days, p<0.001), and initial appointment to surgery (42 [27-74] vs. 34 [20-62] days, p<0.001) were observed. Similar decreases were detected for days from surgery to start of chemo (82 [55-124] vs. 46 [30-58] days, p<0.001) and radio (56 [39-87] vs. 45 [30-64] days, p<0.001) adjuvant therapy, but overall receipt of adjuvant therapy did not differ across groups. Notably, patients seen after initiative implementation presented with significantly lower cancer stage (p=0.0045). There was also a different stage distribution, with markedly fewer stage IV patients in the post-implementation cohort (p=0.0067). Kaplan-Meier log-rank testing revealed no significant difference in overall survival between pre- and post-initiative cohorts (p=0.4809).</p>\n\n<p><strong>Conclusions:</strong> Implementation of a specialist access initiative was significantly associated with reductions in all times to treatment and oncologic stage severity. Although overall survival did not differ across groups, these findings suggest that structured pathways can meaningfully improve oncologic care delivery for HNC patients and should be implemented across other cancer care settings. Further research is warranted to refine these strategies in ways that not only reduce delays to care but also improve overall survival outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153454--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S091",
      "content_id": "153083",
      "abstract_number": "S091",
      "poster_number": "",
      "title": "Optimizing Patient Transfers for Videofluoroscopic Swallow Studies: A Multidisciplinary Feasibility Study of Safety and Efficiency in Patients with Mobility Deficits",
      "summary": "Systematic observation of current VFSS practices through a multidisciplinary lens identified significant variability in transfer approaches and highlighted the need for standardized pre-study planning. The collaboratively developed checklist provides a practical tool for matching patient needs with appropriate resources, potentially improving safety, efficiency, and diagnostic quality.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153083",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brenda Villegas, EdD, CCC-SLP",
      "presenter": "Brenda Villegas, EdD, CCC-SLP",
      "authors": "Kimiko A Yamada, PT, DPT; Brenda Villegas, EdD, CCC-SLP ; Minnie Jan, PT, DPT; Jenny Zhu, PT, DPT; Raymond Medina, AS; Uttam Sinha, MD",
      "normalized_authors": [
        "Kimiko A Yamada, PT, DPT",
        "Brenda Villegas, EdD, CCC-SLP",
        "Minnie Jan, PT, DPT",
        "Jenny Zhu, PT, DPT",
        "Raymond Medina, AS",
        "Uttam Sinha"
      ],
      "affiliations": [
        "USC"
      ],
      "normalized_institutions": [
        "USC"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 475,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Clinical Implications",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kimiko A Yamada, PT, DPT; Brenda Villegas, EdD, CCC-SLP ; Minnie Jan, PT, DPT; Jenny Zhu, PT, DPT; Raymond Medina, AS; Uttam Sinha, MD",
        "Affiliations": "USC",
        "Background": "Videofluoroscopic swallow studies (VFSS) are critical for dysphagia assessment in head and neck cancer patients due to the risk of pharyngeal and esophageal stenosis in this population. Achieving optimal imaging requires precise patient positioning to visualize the entire upper trachea and esophagus throughout 10-15+ minute procedure. Included in the VFSS is the esophageal screening for which positioning has been identified by almost 50% of speech language pathologists as a challenging factor for completing during the study. Recent ESSD-ESGAR best practice position statements (Scharitzer, et al 2024) emphasize that \"radiologic equipment should accommodate the patient's physical function, and the patient should attain and maintain a suitable posture,\" yet practical guidance for patients with mobility deficits remains limited. Current practices rely on variable transfer methods without standardized protocols, potentially compromising safety, efficiency, and imaging quality.",
        "Objective": "To conduct a multidisciplinary needs assessment of current VFSS transfer and positioning practices and develop a pre-study checklist to optimize patient safety, procedural efficiency, and imaging quality for patients with mobility impairments.",
        "Methods": "A multidisciplinary team including physical therapy (PT), speech-language pathology (SLP), and radiology staff conducted structured observations of current VFSS transfer and positioning practices over 2-3 weeks. The team documented: (1) transfer methods utilized (assistance level, equipment utilized, family assistance, radiology technicians, transfer teams, lift teams), (2) patient characteristics (body habitus, mobility level), (3) positioning aids used (wedges, pillows), (4) challenges encountered, (5) procedure duration, (6) staff and patient feedback, (7) image quality, (8) need to repeat the procedure due to poor image quality, and (9) insurance denial or approval. Collaborative brainstorming sessions identified barriers and facilitators to successful transfers and sustained positioning. Based on findings, the team developed a preliminary pre-study assessment checklist to match patient needs with appropriate resources and positioning strategies.",
        "Results": "VFSS procedures observed across diverse patient populations revealed variable staffing resources with no standardized assignment criteria, creative problem-solving by experienced radiology technicians, challenges with specific body types and mobility limitations, work-flow inefficiencies, variable impacts on image quality, and increased insurance costs. Staff identified the need for advance planning based on patient characteristics. The resulting pre-study checklist includes assessment of: patient mobility status, transfer method requirements, anticipated positioning challenges, required equipment/aids, optimal staffing configuration, and estimated procedure duration.advanced",
        "Conclusions": "Systematic observation of current VFSS practices through a multidisciplinary lens identified significant variability in transfer approaches and highlighted the need for standardized pre-study planning. The collaboratively developed checklist provides a practical tool for matching patient needs with appropriate resources, potentially improving safety, efficiency, and diagnostic quality.",
        "Clinical Implications": "This needs assessment demonstrates the value of multidisciplinary collaboration in identifying workflow inefficiencies and developing practical solutions. The pre-study checklist offers an immediately implementable tool that may enhance patient access to VFSS, optimize resource allocation, and lay the groundwork for standardized training protocols. Future work will evaluate the checklist's impact on procedural outcomes and cost-effectiveness.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Optimizing Patient Transfers for Videofluoroscopic Swallow Studies: A Multidisciplinary Feasibility Study of Safety and Efficiency in Patients with Mobility Deficits</span>. Kimiko A Yamada, PT, DPT; <u>Brenda Villegas, EdD, CCC-SLP</u>; Minnie Jan, PT, DPT; Jenny Zhu, PT, DPT; Raymond Medina, AS; Uttam Sinha, MD. USC<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Videofluoroscopic swallow studies (VFSS) are critical for dysphagia assessment in head and neck cancer patients due to the risk of pharyngeal and esophageal stenosis in this population.  Achieving optimal imaging requires precise patient positioning to visualize the entire upper trachea and esophagus throughout 10-15+ minute procedure. Included in the VFSS is the esophageal screening for which positioning has been identified by almost 50% of speech language pathologists as a challenging factor for completing during the study. Recent ESSD-ESGAR best practice position statements (Scharitzer, et al 2024) emphasize that \"radiologic equipment should accommodate the patient's physical function, and the patient should attain and maintain a suitable posture,\" yet practical guidance for patients with mobility deficits remains limited. Current practices rely on variable transfer methods without standardized protocols, potentially compromising safety, efficiency, and imaging quality.</p>\n\n<p><strong>Objective: </strong>To conduct a multidisciplinary needs assessment of current VFSS transfer and positioning practices and develop a pre-study checklist to optimize patient safety, procedural efficiency, and imaging quality for patients with mobility impairments.</p>\n\n<p><strong>Methods: </strong>A multidisciplinary team including physical therapy (PT), speech-language pathology (SLP), and radiology staff conducted structured observations of current VFSS transfer and positioning practices over 2-3 weeks. The team documented: (1) transfer methods utilized (assistance level, equipment utilized, family assistance, radiology technicians, transfer teams, lift teams), (2) patient characteristics (body habitus, mobility level), (3) positioning aids used (wedges, pillows), (4) challenges encountered, (5) procedure duration, (6) staff and patient feedback, (7) image quality, (8) need to repeat the procedure due to poor image quality, and (9) insurance denial or approval. Collaborative brainstorming sessions identified barriers and facilitators to successful transfers and sustained positioning. Based on findings, the team developed a preliminary pre-study assessment checklist to match patient needs with appropriate resources and positioning strategies.</p>\n\n<p><strong>Results: </strong>VFSS procedures observed across diverse patient populations revealed variable staffing resources with no standardized assignment criteria, creative problem-solving by experienced radiology technicians, challenges with specific body types and mobility limitations, work-flow inefficiencies, variable impacts on image quality, and increased insurance costs. Staff identified the need for advance planning based on patient characteristics. The resulting pre-study checklist includes assessment of: patient mobility status, transfer method requirements, anticipated positioning challenges, required equipment/aids, optimal staffing configuration, and estimated procedure duration.advanced</p>\n\n<p><strong>Conclusions</strong>: Systematic observation of current VFSS practices through a multidisciplinary lens identified significant variability in transfer approaches and highlighted the need for standardized pre-study planning. The collaboratively developed checklist provides a practical tool for matching patient needs with appropriate resources, potentially improving safety, efficiency, and diagnostic quality.</p>\n\n<p><strong>Clinical Implications:</strong> This needs assessment demonstrates the value of multidisciplinary collaboration in identifying workflow inefficiencies and developing practical solutions. The pre-study checklist offers an immediately implementable tool that may enhance patient access to VFSS, optimize resource allocation, and lay the groundwork for standardized training protocols. Future work will evaluate the checklist's impact on procedural outcomes and cost-effectiveness.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153083--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S092",
      "content_id": "153377",
      "abstract_number": "S092",
      "poster_number": "",
      "title": "Primary care approaches to new neck mass diagnoses in the adult population",
      "summary": "We found that a minority of patients with a neck mass diagnosed in the primary care or emergency setting have appropriate initial management with imaging or a referral to otolaryngology. While the rate of appropriate management initially increased after 2017, it remains far below optimal guideline implementation. Providers may be using head and neck cancer risk factors, specifically tobacco and alcohol use, to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153377",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aakash N Nagarapu",
      "presenter": "Aakash N Nagarapu",
      "authors": "Aakash N Nagarapu ; Austin T Armstrong, MD; Edmund Howe, MD; Jason Doherty, PhD; Sean T Massa, MD",
      "normalized_authors": [
        "Aakash N Nagarapu",
        "Austin T Armstrong",
        "Edmund Howe",
        "Jason Doherty",
        "Sean T Massa"
      ],
      "affiliations": [
        "Saint Louis University School of Medicine"
      ],
      "normalized_institutions": [
        "Saint Louis University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 524,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aakash N Nagarapu ; Austin T Armstrong, MD; Edmund Howe, MD; Jason Doherty, PhD; Sean T Massa, MD",
        "Affiliations": "Saint Louis University School of Medicine",
        "Background": "The 2017 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guidelines offer an otolaryngologist’s perspective to support a primary care physician (PCP) in their approach to a new neck mass. The guidelines define appropriate management of a new neck mass as either with imaging or referral to an otolaryngologist. Recent research shows practice patterns prior to a cancer diagnosis remain unchanged, but the management of neck masses in the primary care setting remains unexplored. Meanwhile, the epidemiology of neck masses and head and neck cancers have dramatically changed with the Human Papilloma Virus (HPV) epidemic.",
        "Objectives": "To investigate the frequency that PCP and emergency department (ED) providers are managing new neck mass diagnoses with additional imaging or referral to otolaryngology.",
        "Methods": "This retrospective cohort study was conducted via deidentified patient information stored in a Midwest American multi-institutional database. Patients diagnosed with a new neck mass as identified by ICD 9/10 codes who are >40 years old with at least 2 years of prior enrollment were included. Only new diagnoses by a PCP or ED physician between 2013 and 2024 were included. The primary outcome was rate of imaging or referral to otolaryngology. Trends in appropriate management were assessed graphically. Comparative statistics assessed univariate associations with covariates. Logistic regression models identified associations between provider type and initial management.",
        "Results": "11,350 patients were included in the cohort. These were primarily female (62.8%), non-Black (89.1%), non-Hispanic (98.2%), alcohol drinkers (52%) and non-smokers (67.1%). 11040 (97.3%) of the patients were diagnosed with a neck mass by a PCP and 310 (2.7%) by an ED provider. A minority of patients were managed appropriately (5442, 47.9%) including 16.4% referred to otolaryngology and 41.4% with imaging ordered. Appropriate management increased over the study period but plateaued near 50% after 2020. PCPs were more likely than ED physicians to refer to otolaryngology (percentage [95% CI]) (16.74% [15.98 – 17.52] vs 6.13% [3.69 – 9.57]) or order additional imaging (42.29% [41.09 – 43.52] vs 11.29% [7.86 – 15.7]). History of alcohol use was associated with higher rates of imaging (p < 0.001) and otolaryngology referral (p = 0.001). Similarly, history of tobacco use was associated with increased rates of imaging (p = 0.024) and otolaryngology referral (p < 0.001). Black individuals were less likely to receive additional imaging orders (p = 0.003), but this difference was not observed in otolaryngology referral rates.",
        "Conclusions": "We found that a minority of patients with a neck mass diagnosed in the primary care or emergency setting have appropriate initial management with imaging or a referral to otolaryngology. While the rate of appropriate management initially increased after 2017, it remains far below optimal guideline implementation. Providers may be using head and neck cancer risk factors, specifically tobacco and alcohol use, to guide management; however, these criteria are not included in the guidelines because of preponderance of HPV-associated cancers presenting with neck masses. These results add to a growing body of literature demonstrating the need for further dissemination and implementation of the AAO-HNS guidelines.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Primary care approaches to new neck mass diagnoses in the adult population</span>. <u>Aakash N Nagarapu</u>; Austin T Armstrong, MD; Edmund Howe, MD; Jason Doherty, PhD; Sean T Massa, MD. Saint Louis University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The 2017 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guidelines offer an otolaryngologist’s perspective to support a primary care physician (PCP) in their approach to a new neck mass. The guidelines define appropriate management of a new neck mass as either with imaging or referral to an otolaryngologist. Recent research shows practice patterns prior to a cancer diagnosis remain unchanged, but the management of neck masses in the primary care setting remains unexplored. Meanwhile, the epidemiology of neck masses and head and neck cancers have dramatically changed with the Human Papilloma Virus (HPV) epidemic. </p>\n\n<p><strong>Objectives: </strong>To investigate the frequency that PCP and emergency department (ED) providers are managing new neck mass diagnoses with additional imaging or referral to otolaryngology. </p>\n\n<p><strong>Methods: </strong>This retrospective cohort study was conducted via deidentified patient information stored in a Midwest American multi-institutional database. Patients diagnosed with a new neck mass as identified by ICD 9/10 codes who are >40 years old with at least 2 years of prior enrollment were included. Only new diagnoses by a PCP or ED physician between 2013 and 2024 were included. The primary outcome was rate of imaging or referral to otolaryngology. Trends in appropriate management were assessed graphically. Comparative statistics assessed univariate associations with covariates. Logistic regression models identified associations between provider type and initial management. </p>\n\n<p><strong>Results: </strong>11,350 patients were included in the cohort. These were primarily female (62.8%), non-Black (89.1%), non-Hispanic (98.2%), alcohol drinkers (52%) and non-smokers (67.1%). 11040 (97.3%) of the patients were diagnosed with a neck mass by a PCP and 310 (2.7%) by an ED provider. A minority of patients were managed appropriately (5442, 47.9%) including 16.4% referred to otolaryngology and 41.4% with imaging ordered. Appropriate management increased over the study period but plateaued near 50% after 2020. PCPs were more likely than ED physicians to refer to otolaryngology (percentage [95% CI]) (16.74% [15.98 – 17.52] vs 6.13% [3.69 – 9.57]) or order additional imaging (42.29% [41.09 – 43.52] vs 11.29% [7.86 – 15.7]). History of alcohol use was associated with higher rates of imaging (p < 0.001) and otolaryngology referral (p = 0.001). Similarly, history of tobacco use was associated with increased rates of imaging (p = 0.024) and otolaryngology referral (p < 0.001). Black individuals were less likely to receive additional imaging orders (p = 0.003), but this difference was not observed in otolaryngology referral rates. </p>\n\n<p><strong>Conclusions: </strong>We found that a minority of patients with a neck mass diagnosed in the primary care or emergency setting have appropriate initial management with imaging or a referral to otolaryngology. While the rate of appropriate management initially increased after 2017, it remains far below optimal guideline implementation. Providers may be using head and neck cancer risk factors, specifically tobacco and alcohol use, to guide management; however, these criteria are not included in the guidelines because of preponderance of HPV-associated cancers presenting with neck masses. These results add to a growing body of literature demonstrating the need for further dissemination and implementation of the AAO-HNS guidelines. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153377--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S093",
      "content_id": "154712",
      "abstract_number": "S093",
      "poster_number": "",
      "title": "Transforming Postoperative TORS Pain Management: Early Evidence for Suzetrigine",
      "summary": "Patients undergoing TORS for OPSCC that are treated with suzetrigine as part of a postoperative pain regimen have a significant reduction in postoperative pain, odynophagia, and opioid use, resulting in increased oral intake and a shorter length of hospitalization.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154712",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel E Bestourous, MD",
      "presenter": "Daniel E Bestourous, MD",
      "authors": "Daniel E Bestourous, MD ; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet, MD; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH",
      "normalized_authors": [
        "Daniel E Bestourous",
        "Jacob Beiriger",
        "Brayden Seliger",
        "Austin Tautfest",
        "Larkin Harris",
        "Richard Bavier",
        "Sarah Drejet",
        "Richard Cannon",
        "Marcus Monroe",
        "Luke Buchmann",
        "Jason Hunt",
        "Hilary McCrary"
      ],
      "affiliations": [
        "University of Utah Department of Otolaryngology - Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Utah Department of Otolaryngology - Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel E Bestourous, MD ; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet, MD; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH",
        "Affiliations": "University of Utah Department of Otolaryngology - Head and Neck Surgery",
        "Introduction": "Postoperative pain following transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC) can be debilitating and difficult to manage. Oral intake and rehabilitation of swallow is difficult secondary to both the anatomic changes and the severe odynophagia. Options for pain control have often been limited to narcotic pain medications, leading to prolonged hospitalizations and feeding tube placement. While opioid medications are a mainstay of a multimodal pain regimen, their utility is limited by adverse effects and addiction potential. Suzetrigine is novel non-opioid oral analgesic recently approved by the FDA for moderate to severe postoperative pain in adults. This medication selectively blocks the NaV1.8 sodium channel on peripheral nociceptors, preventing sodium influx and thereby inhibiting the initiation and propagation of pain action potentials from the peripheral to the central nervous system. While initial data is promising, this medication has not been studied in head and neck cancer patients. The objective of this study is to evaluate the efficacy of suzetrigine in the reducing opioid use, length of stay, and the need for feeding tube placement in patients following TORS.",
        "Methods": "A retrospective cohort study was conducted on patients undergoing TORS for OPSCC at a tertiary care institution between January 2025 and November 2025. Two patient cohorts were defined: 1) a retrospective control cohort of patients that were treated with our traditional multimodal pain regimen and one treated with suzetrigine in addition to a multimodal pain regimen. Narcotic medications were only available as needed in the suzetrigine cohort. Patients with severe liver dysfunction were excluded. The primary outcome measure was the use of opiates in the postoperative period, measured as daily and total inpatient morphine milligram equivalents (MME). Secondary outcomes average daily oral intake and hospital length of stay (LOS).",
        "Results": "Thirty-two patients underwent TORS for OPSCC, with 10 patients in the suzetrigine cohort and 22 patients in the control cohort. Patient age, sex, BMI, and comorbidities were not significantly different between the two groups. Patients within the suzetrigine cohort had a mean daily opioid dose of 13.5±14.1 MME/day compared to 45.8±43.5 MME/day in the control cohort, representing a 70.6% reduction in mean daily opioid use (p=0.011). Total mean inpatient opioid dose was similarly reduced by 79.1% in the suzetrigine group relative to the control group (29.4±30.0 MME vs. 140.3±126.8 MME, p=0.001). Patients within the suzetrigine cohort had a 38.4% shorter mean LOS than patients in the control cohort (2.2±1.8 days vs 3.6±1.7 days, p=0.039), and patients treated with suzetrigine had a higher mean daily oral intake while inpatient (837.18±560.54 mL/day) than those in the control group (709.79±495.54 mL/day, p=0.001).",
        "Conclusion": "Patients undergoing TORS for OPSCC that are treated with suzetrigine as part of a postoperative pain regimen have a significant reduction in postoperative pain, odynophagia, and opioid use, resulting in increased oral intake and a shorter length of hospitalization.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transforming Postoperative TORS Pain Management: Early Evidence for Suzetrigine</span>. <u>Daniel E Bestourous, MD</u>; Jacob Beiriger, MD; Brayden Seliger, BS; Austin Tautfest, BS; Larkin Harris, MD; Richard Bavier, MD; Sarah Drejet, MD; Richard Cannon, MD; Marcus Monroe, MD; Luke Buchmann, MD; Jason Hunt, MD; Hilary McCrary, MD, MPH. University of Utah Department of Otolaryngology - Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Postoperative pain following transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC) can be debilitating and difficult to manage. Oral intake and rehabilitation of   swallow is difficult secondary to both the anatomic changes and the severe odynophagia. Options for pain control have often been limited to narcotic pain medications, leading to prolonged hospitalizations and feeding tube placement. While opioid medications are a mainstay of a multimodal pain regimen, their utility is limited by adverse effects and addiction potential. Suzetrigine is novel non-opioid oral analgesic recently approved by the FDA for moderate to severe postoperative pain in adults. This medication selectively blocks the NaV1.8 sodium channel on peripheral nociceptors, preventing sodium influx and thereby inhibiting the initiation and propagation of pain action potentials from the peripheral to the central nervous system. While initial data is promising, this medication has not been studied in head and neck cancer patients. The objective of this study is to evaluate the efficacy of suzetrigine in the reducing opioid use, length of stay, and the need for feeding tube placement in patients following TORS.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted on patients undergoing TORS for OPSCC at a tertiary care institution between January 2025 and November 2025. Two patient cohorts were defined: 1) a retrospective control cohort of patients that were treated with our traditional multimodal pain regimen and one treated with suzetrigine in addition to a multimodal pain regimen. Narcotic medications were only available as needed in the suzetrigine cohort. Patients with severe liver dysfunction were excluded. The primary outcome measure was the use of opiates in the postoperative period, measured as daily and total inpatient morphine milligram equivalents (MME). Secondary outcomes average daily oral intake and hospital length of stay (LOS).</p>\n\n<p><strong>Results: </strong>Thirty-two patients underwent TORS for OPSCC, with 10 patients in the suzetrigine cohort and 22 patients in the control cohort. Patient age, sex, BMI, and comorbidities were not significantly different between the two groups. Patients within the suzetrigine cohort had a mean daily opioid dose of 13.5±14.1 MME/day compared to 45.8±43.5 MME/day in the control cohort, representing a 70.6% reduction in mean daily opioid use (p=0.011). Total mean inpatient opioid dose was similarly reduced by 79.1% in the suzetrigine group relative to the control group (29.4±30.0 MME vs. 140.3±126.8 MME, p=0.001). Patients within the suzetrigine cohort had a 38.4% shorter mean LOS than patients in the control cohort (2.2±1.8 days vs 3.6±1.7 days, p=0.039), and patients treated with suzetrigine had a higher mean daily oral intake while inpatient (837.18±560.54 mL/day) than those in the control group (709.79±495.54 mL/day, p=0.001).</p>\n\n<p><strong>Conclusion: </strong>Patients undergoing TORS for OPSCC that are treated with suzetrigine as part of a postoperative pain regimen have a significant reduction in postoperative pain, odynophagia, and opioid use, resulting in increased oral intake and a shorter length of hospitalization.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154712--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S094",
      "content_id": "155510",
      "abstract_number": "S094",
      "poster_number": "",
      "title": "Transatlantic disparities in perioperative antibiotic stewardship for head and neck surgery: an international survey",
      "summary": "To our knowledge, this is the largest-ever international survey on perioperative antibiotic use in head and neck surgery and it exposes stark transatlantic heterogeneity. Persistent overuse in clean thyroid procedures, prolonged prophylaxis courses exceeding evidence-based recommendations, and marked regional differences in cephalosporin selection highlight the need for internationally harmonized, evidence-based...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155510",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260120",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chia-Jung Busch",
      "presenter": "Chia-Jung Busch",
      "authors": "Markus Blaurock 1 ; Petr Szturz 2 ; Chia-Jung Busch 1 ; Simon Müller 3 ; Johanna Inhestern 4 ; Elena Colombo 5 ; Anastasios Maniakas 6",
      "normalized_authors": [
        "Markus Blaurock",
        "Petr Szturz",
        "Chia-Jung Busch",
        "Simon Müller",
        "Johanna Inhestern",
        "Elena Colombo",
        "Anastasios Maniakas"
      ],
      "affiliations": [
        "Universitymedicine Greifswald",
        "Lausanne University Hospital, Lausanne (CHUV)",
        "University Zurich",
        "Oberhavel Kliniken",
        "Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy",
        "MD Anderson"
      ],
      "normalized_institutions": [
        "Universitymedicine Greifswald",
        "Lausanne University Hospital, Lausanne (CHUV)",
        "University Zurich",
        "Oberhavel Kliniken",
        "Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy",
        "MD Anderson"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 421,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Markus Blaurock 1 ; Petr Szturz 2 ; Chia-Jung Busch 1 ; Simon Müller 3 ; Johanna Inhestern 4 ; Elena Colombo 5 ; Anastasios Maniakas 6",
        "Affiliations": "1 Universitymedicine Greifswald; 2 Lausanne University Hospital, Lausanne (CHUV); 3 University Zurich; 4 Oberhavel Kliniken; 5 Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy; 6 MD Anderson",
        "Background": "Perioperative antibiotic prophylaxis in head and neck surgery remains poorly standardized despite guidelines advocating short-course beta-lactam prophylaxis for clean-contaminated procedures and omission of antibiotics for clean thyroid surgery. Furthermore, international real-world practices remain uncharacterized. With perioperative immunotherapy entering routine practice for locally advanced HNSCC (KEYNOTE-689), the potential for antibiotic-mediated microbiome disruption to impair oncological outcomes adds urgency to optimizing antibiotic stewardship.",
        "Methods": "An online survey was developed by the Young and Early Career investigators of the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group, in cooperation with the AHNS, and distributed through the EORTC, EHNS, AHNS, Canadian Society of Otolaryngology-Head and Neck Surgery, British Society of Head and Neck Oncology, and German Society of Otolaryngology-Head and Neck Surgery. The survey evaluated antibiotic use, agent selection, duration, and departmental guideline availability across six surgical procedure categories: conventional, completion, and complex thyroid surgery; low-risk HNSCC procedures; uncomplicated and complex clean-contaminated (C/C) HNSCC procedures. European (EU) and North American (NA) cohorts were compared.",
        "Results": "A total of 389 respondents from 44 countries completed the survey (EU n=257, NA n=132). Most were otolaryngologists/head and neck surgeons (83.5%) practicing in academic centers (65.6%). Routine antibiotic use increased with procedural complexity in both cohorts. For clean thyroid procedures, 21–33% of respondents prescribed routine antibiotics despite guideline recommendations against this. Near-universal (93-99%) prophylaxis was observed for C/C HNSCC. NA antibiotic use rates exceeded EU rates across all categories.",
        "Abstract": "Antibiotic agents markedly differed: amoxicillin/sulbactam led for complex C/C HNSCC (61-64%), followed by cefazolin in NA (42.6%) while cefuroxime was favored in EU (33.3%) and virtually absent in NA (2.8%). Clindamycin use was low overall (8–11%). Duration of antibiotic use varied substantially: for example, 37.7% of NA respondents limited prophylaxis to 24 hours for uncomplicated C/C HNSCC, while EU practice distributed broadly, with 23.5% extending to <7 days and 21.7% to 7 days. Departmental guideline availability was higher in EU (73–80%) than in NA (36–42%). View in Agenda and Add to Schedule",
        "Conclusions": "To our knowledge, this is the largest-ever international survey on perioperative antibiotic use in head and neck surgery and it exposes stark transatlantic heterogeneity. Persistent overuse in clean thyroid procedures, prolonged prophylaxis courses exceeding evidence-based recommendations, and marked regional differences in cephalosporin selection highlight the need for internationally harmonized, evidence-based antibiotic stewardship protocols. In the era of perioperative immunotherapy, rational antibiotic use may impact not only infection control but microbiome integrity and oncological outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transatlantic disparities in perioperative antibiotic stewardship for head and neck surgery: an international survey</span>. Markus Blaurock<sup>1</sup>; Petr Szturz<sup>2</sup>; <u>Chia-Jung Busch</u><sup>1</sup>; Simon Müller<sup>3</sup>; Johanna Inhestern<sup>4</sup>; Elena Colombo<sup>5</sup>; Anastasios Maniakas<sup>6</sup>. <sup>1</sup>Universitymedicine Greifswald; <sup>2</sup>Lausanne University Hospital, Lausanne (CHUV); <sup>3</sup>University Zurich; <sup>4</sup>Oberhavel Kliniken; <sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy; <sup>6</sup>MD Anderson<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Perioperative antibiotic prophylaxis in head and neck surgery remains poorly standardized despite guidelines advocating short-course beta-lactam prophylaxis for clean-contaminated procedures and omission of antibiotics for clean thyroid surgery. Furthermore, international real-world practices remain uncharacterized. With perioperative immunotherapy entering routine practice for locally advanced HNSCC (KEYNOTE-689), the potential for antibiotic-mediated microbiome disruption to impair oncological outcomes adds urgency to optimizing antibiotic stewardship.</p>\n\n<p><strong>Methods: </strong>An online survey was developed by the Young and Early Career investigators of the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group, in cooperation with the AHNS, and distributed through the EORTC, EHNS, AHNS, Canadian Society of Otolaryngology-Head and Neck Surgery, British Society of Head and Neck Oncology, and German Society of Otolaryngology-Head and Neck Surgery. The survey evaluated antibiotic use, agent selection, duration, and departmental guideline availability across six surgical procedure categories: conventional, completion, and complex thyroid surgery; low-risk HNSCC procedures; uncomplicated and complex clean-contaminated (C/C) HNSCC procedures. European (EU) and North American (NA) cohorts were compared.</p>\n\n<p><strong>Results: </strong>A total of 389 respondents from 44 countries completed the survey (EU n=257, NA n=132). Most were otolaryngologists/head and neck surgeons (83.5%) practicing in academic centers (65.6%). Routine antibiotic use increased with procedural complexity in both cohorts. For clean thyroid procedures, 21–33% of respondents prescribed routine antibiotics despite guideline recommendations against this.  Near-universal (93-99%) prophylaxis was observed for C/C HNSCC. NA antibiotic use rates exceeded EU rates across all categories.</p>\n\n<p>Antibiotic agents markedly differed: amoxicillin/sulbactam led for complex C/C HNSCC (61-64%), followed by cefazolin in NA (42.6%) while cefuroxime was favored in EU (33.3%) and virtually absent in NA (2.8%). Clindamycin use was low overall (8–11%). Duration of antibiotic use varied substantially: for example, 37.7% of NA respondents limited prophylaxis to 24 hours for uncomplicated C/C HNSCC, while EU practice distributed broadly, with 23.5% extending to <7 days and 21.7% to 7 days. Departmental guideline availability was higher in EU (73–80%) than in NA (36–42%).</p>\n\n<p><strong>Conclusions: </strong>To our knowledge, this is the largest-ever international survey on perioperative antibiotic use in head and neck surgery and it exposes stark transatlantic heterogeneity. Persistent overuse in clean thyroid procedures, prolonged prophylaxis courses exceeding evidence-based recommendations, and marked regional differences in cephalosporin selection highlight the need for internationally harmonized, evidence-based antibiotic stewardship protocols. In the era of perioperative immunotherapy, rational antibiotic use may impact not only infection control but microbiome integrity and oncological outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155510--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260120' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S095",
      "content_id": "155553",
      "abstract_number": "S095",
      "poster_number": "",
      "title": "Functional Restoration of Salivary Gland Activity with In Vivo Circular RNA Aquaporin-1 Therapy for Radiation-Induced Xerostomia",
      "summary": "Early results from this ongoing Phase1 study demonstrate that RXRG001 delivered through unilateral Stensen’s duct infusion is safe and associated with clinically meaningful improvements in RIX symptoms and salivary flow. Dose escalation is ongoing, and additional data from higher dose levels and expanded cohorts will be reported at the time of presentation. These findings provide early clinical evidence that in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155553",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Henry Hoffman",
      "presenter": "Henry Hoffman",
      "authors": "Henry Hoffman 1 ; Harry Quon 2 ; Christopher Rassekh 3 ; Hariz Hassan 4 ; Weiyi Zhang 4",
      "normalized_authors": [
        "Henry Hoffman",
        "Harry Quon",
        "Christopher Rassekh",
        "Hariz Hassan",
        "Weiyi Zhang"
      ],
      "affiliations": [
        "University of Iowa",
        "Johns Hopkins University",
        "University of Pennsylvania",
        "RiboX Therapeutics"
      ],
      "normalized_institutions": [
        "University of Iowa",
        "Johns Hopkins University",
        "University of Pennsylvania",
        "RiboX Therapeutics"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Henry Hoffman 1 ; Harry Quon 2 ; Christopher Rassekh 3 ; Hariz Hassan 4 ; Weiyi Zhang 4",
        "Affiliations": "1 University of Iowa; 2 Johns Hopkins University; 3 University of Pennsylvania; 4 RiboX Therapeutics",
        "Background": "Radiation-induced xerostomia (RIX) remains a common and debilitating long-term toxicity following radiotherapy (RT) for head and neck cancer (HNC), driven by radiation-induced loss of acinar function and impaired ductal water transport. Restoration of trans-epithelial water movement through aquaporin-1 expression represents a biologically rational strategy to reestablish salivary function.",
        "Abstract": "RXRG001 is a lipid nanoparticle-formulated circular RNA therapeutic encoding human aquaporin-1 (hAQP1) designed for in vivo transduction of residual salivary epithelium. Unlike viral gene delivery approaches, this non-viral platform offers the potential for stable transfection and repeat administration if needed. We report early findings from an ongoing Phase 1 dose-escalation trial evaluating unilateral parotid duct infusion of RXRG001 in patients with RIX (ClinicalTrials.gov NCT06714253). Across the first two cohorts, patient-reported outcomes demonstrated clinically meaningful improvements in xerostomia symptoms. In the 4-µg cohort, reductions in XQ scores at Month 3 reached 35, 35, and 16 points. Participants treated at the 10-µg dose level demonstrated similar early improvements, with symptom reductions observed within the first month and sustained during follow-up. GRCG responses indicated consistent subjective improvement among treated participants. Objective salivary flow increased from baseline in both unstimulated and stimulated whole saliva. Improvements were detected as early as Day 7 and persisted through Month 2 and beyond in participants with longer follow-up. At Month 3, relative increases from baseline reached up to 47%, 300%, and 450% for unstimulated flow and 55%, 1450%, and 131% for stimulated flow in the initial cohort, with comparable directional increases in the higher-dose cohort. Individual patient trajectories demonstrate consistent onset kinetics and durability following a single administration, including among participants treated at higher doses. Updated results will be presented as the study continues to mature. View in Agenda and Add to Schedule",
        "Methods": "Adult participants with symptomatic RIX for a minimum of 2 years following definitive RT for HNC were enrolled in an open-label Phase 1 dose-escalation study. Participants received a single unilateral Stensen’s duct infusion of RXRG001. Safety and tolerability were assessed through adverse event monitoring and procedural outcomes. Clinical activity was evaluated using Xerostomia Questionnaire (XQ), the Global Rate of Change Questionnaire (GRCG), and measurements of unstimulated and stimulated whole salivary flow. This interim analysis summarizes results from the first two dose levels (4-µg and 10-µg). Additional dose levels and participants continue to enroll and will be presented when available.",
        "Results": "A total of 12 participants have been enrolled. Administration of RXRG001 has been well tolerated across evaluated dose levels, with no dose-limiting toxicities observed. Treatment-emergent adverse events have been limited to grade 1-2 events, most commonly transient parotid gland inflammation.",
        "Conclusions": "Early results from this ongoing Phase1 study demonstrate that RXRG001 delivered through unilateral Stensen’s duct infusion is safe and associated with clinically meaningful improvements in RIX symptoms and salivary flow. Dose escalation is ongoing, and additional data from higher dose levels and expanded cohorts will be reported at the time of presentation. These findings provide early clinical evidence that in vivo circular RNA delivery of hAQP1 may restore clinically meaningful functional parotid gland activity in patients with RIX."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Functional Restoration of Salivary Gland Activity with In Vivo Circular RNA Aquaporin-1 Therapy for Radiation-Induced Xerostomia</span>. <u>Henry Hoffman</u><sup>1</sup>; Harry Quon<sup>2</sup>; Christopher Rassekh<sup>3</sup>; Hariz Hassan<sup>4</sup>; Weiyi Zhang<sup>4</sup>. <sup>1</sup>University of Iowa; <sup>2</sup>Johns Hopkins University; <sup>3</sup>University of Pennsylvania; <sup>4</sup>RiboX Therapeutics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Radiation-induced xerostomia (RIX) remains a common and debilitating long-term toxicity following radiotherapy (RT) for head and neck cancer (HNC), driven by radiation-induced loss of acinar function and impaired ductal water transport. Restoration of trans-epithelial water movement through aquaporin-1 expression represents a biologically rational strategy to reestablish salivary function.</p>\n\n<p>RXRG001 is a lipid nanoparticle-formulated circular RNA therapeutic encoding human aquaporin-1 (hAQP1) designed for in vivo transduction of residual salivary epithelium. Unlike viral gene delivery approaches, this non-viral platform offers the potential for stable transfection and repeat administration if needed.  We report early findings from an ongoing Phase 1 dose-escalation trial evaluating unilateral parotid duct infusion of RXRG001 in patients with RIX (ClinicalTrials.gov NCT06714253).</p>\n\n<p><strong>Methods: </strong>Adult participants with symptomatic RIX for a minimum of 2 years following definitive RT for HNC were enrolled in an open-label Phase 1 dose-escalation study. Participants received a single unilateral Stensen’s duct infusion of RXRG001. Safety and tolerability were assessed through adverse event monitoring and procedural outcomes. Clinical activity was evaluated using Xerostomia Questionnaire (XQ), the Global Rate of Change Questionnaire (GRCG), and measurements of unstimulated and stimulated whole salivary flow. This interim analysis summarizes results from the first two dose levels (4-µg and 10-µg). Additional dose levels and participants continue to enroll and will be presented when available.</p>\n\n<p><strong>Results: </strong>A total of 12 participants have been enrolled. Administration of RXRG001 has been well tolerated across evaluated dose levels, with no dose-limiting toxicities observed. Treatment-emergent adverse events have been limited to grade 1-2 events, most commonly transient parotid gland inflammation.</p>\n\n<p>Across the first two cohorts, patient-reported outcomes demonstrated clinically meaningful improvements in xerostomia symptoms. In the 4-µg cohort, reductions in XQ scores at Month 3 reached 35, 35, and 16 points. Participants treated at the 10-µg dose level demonstrated similar early improvements, with symptom reductions observed within the first month and sustained during follow-up. GRCG responses indicated consistent subjective improvement among treated participants. Objective salivary flow increased from baseline in both unstimulated and stimulated whole saliva. Improvements were detected as early as Day 7 and persisted through Month 2 and beyond in participants with longer follow-up. At Month 3, relative increases from baseline reached up to 47%, 300%, and 450% for unstimulated flow and 55%, 1450%, and 131% for stimulated flow in the initial cohort, with comparable directional increases in the higher-dose cohort. Individual patient trajectories demonstrate consistent onset kinetics and durability following a single administration, including among participants treated at higher doses. Updated results will be presented as the study continues to mature.</p>\n\n<p><strong>Conclusions: </strong>Early results from this ongoing Phase1 study demonstrate that RXRG001 delivered through unilateral Stensen’s duct infusion is safe and associated with clinically meaningful improvements in RIX symptoms and salivary flow. Dose escalation is ongoing, and additional data from higher dose levels and expanded cohorts will be reported at the time of presentation. These findings provide early clinical evidence that in vivo circular RNA delivery of hAQP1 may restore clinically meaningful functional parotid gland activity in patients with RIX.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155553--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S096",
      "content_id": "155527",
      "abstract_number": "S096",
      "poster_number": "",
      "title": "Diagnosis-to-Treatment Interval and Overall Survival in Head and Neck Cancer: A Population-Based Study",
      "summary": "In this large population-based cohort, longer diagnosis-to-treatment intervals were associated with modestly worse overall survival in HNC, with a non-linear relationship and greater risk at prolonged delays over 45 days. Residual confounding by indication may have attenuated the observed association. Reducing treatment delays within regionalized cancer systems may improve survival.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155527",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Noémie Villemure-Poliquin, MD, MSc",
      "presenter": "Noémie Villemure-Poliquin, MD, MSc",
      "authors": "Noémie Villemure-Poliquin, MD, MSc 1 ; Rui Fu, PhD 2 ; Qing Li, MMath 3 ; Rinku Sutradhar, PhD 4 ; Nathalie G. Coburn, MD, MPH 5 ; Julie Hallet, MD, MSc 5 ; Antoine Eskander, MD, ScM 1",
      "normalized_authors": [
        "Noémie Villemure-Poliquin",
        "Rui Fu",
        "Qing Li, MMath",
        "Rinku Sutradhar",
        "Nathalie G. Coburn",
        "Julie Hallet",
        "Antoine Eskander, ScM"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada",
        "Departments of Community Health Sciences, Surgery and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada",
        "Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada",
        "Sunnybrook Research Institute, Odette Cancer Centre & University of Toronto, Toronto, Ontario, Canada. Cancer Program, ICES, Toronto, Canada",
        "Odette Cancer Centre, Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada",
        "Departments of Community Health Sciences, Surgery and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada",
        "Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada",
        "Sunnybrook Research Institute, Odette Cancer Centre & University of Toronto, Toronto, Ontario, Canada. Cancer Program, ICES, Toronto, Canada",
        "Odette Cancer Centre, Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 381,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background and Aim",
        "Materials and Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Noémie Villemure-Poliquin, MD, MSc 1 ; Rui Fu, PhD 2 ; Qing Li, MMath 3 ; Rinku Sutradhar, PhD 4 ; Nathalie G. Coburn, MD, MPH 5 ; Julie Hallet, MD, MSc 5 ; Antoine Eskander, MD, ScM 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada; 2 Departments of Community Health Sciences, Surgery and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 3 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; 4 Sunnybrook Research Institute, Odette Cancer Centre & University of Toronto, Toronto, Ontario, Canada. Cancer Program, ICES, Toronto, Canada; 5 Odette Cancer Centre, Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
        "Background and Aim": "Timely initiation of treatment after cancer diagnosis is a key determinant of oncologic and patient-centred outcomes in head and neck cancer (HNC). Delays in care are associated with psychological distress and may adversely affect survival, yet the impact of the diagnosis-to-treatment interval (DTI) remains incompletely defined because prior population-based studies used heterogeneous definitions, limited confounder adjustment, and variable statistical approaches. We evaluated the association between DTI and overall survival in a large population-based cohort of patients with HNC and aimed to identify a clinically meaningful threshold.",
        "Materials and Methods": "We conducted a retrospective population-based cohort study using linked administrative health databases at ICES in Ontario, Canada. Adults diagnosed with incident laryngeal, oropharyngeal, or oral cavity cancer between 2007 and 2022 and treated with curative intent were included. The primary exposure was DTI, analyzed continuously using restricted cubic splines and categorically using clinically informed thresholds. Overall survival was assessed using Cox proportional hazards models with multivariable adjustment and inverse probability of treatment weighting (IPTW) to address confounding. A 180-day landmark approach minimized confounding by indication. Covariates included demographics, comorbidity, tumor site and stage, treatment modality, socioeconomic status, geography, and health-care utilization. Sensitivity analyses evaluated alternative DTI thresholds and subgroup effects across treatment modality, tumor subsite, and stage.",
        "Results": "The cohort included 17,544 patients (median age 63 years; median DTI 45 days). Restricted cubic spline modeling demonstrated a significant, non-linear association between DTI and survival (global p<0.001; non-linearity p=0.0003) without a clear inflection threshold. Using a prespecified cutoff near the cohort median (≤45 vs >45 days), delayed treatment was associated with worse survival in unadjusted analysis (HR 1.11, 95% CI 1.06–1.16) and after IPTW adjustment (HR 1.07, 95% CI 1.02–1.12), whereas conventional multivariable adjustment showed borderline significance (HR 1.05, 95% CI 1.00–1.10). Sensitivity analysis using a 30-day threshold showed similar but attenuated findings (IPTW HR 1.06, 95% CI 1.00–1.12).",
        "Conclusions": "In this large population-based cohort, longer diagnosis-to-treatment intervals were associated with modestly worse overall survival in HNC, with a non-linear relationship and greater risk at prolonged delays over 45 days. Residual confounding by indication may have attenuated the observed association. Reducing treatment delays within regionalized cancer systems may improve survival.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnosis-to-Treatment Interval and Overall Survival in Head and Neck Cancer: A Population-Based Study</span>. <u>Noémie Villemure-Poliquin, MD, MSc</u><sup>1</sup>; Rui Fu, PhD<sup>2</sup>; Qing Li, MMath<sup>3</sup>; Rinku Sutradhar, PhD<sup>4</sup>; Nathalie G. Coburn, MD, MPH<sup>5</sup>; Julie Hallet, MD, MSc<sup>5</sup>; Antoine Eskander, MD, ScM<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada; <sup>2</sup>Departments of Community Health Sciences, Surgery and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; <sup>3</sup>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; <sup>4</sup>Sunnybrook Research Institute, Odette Cancer Centre & University of Toronto, Toronto, Ontario, Canada. Cancer Program, ICES, Toronto, Canada; <sup>5</sup>Odette Cancer Centre, Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background and Aim: </strong>Timely initiation of treatment after cancer diagnosis is a key determinant of oncologic and patient-centred outcomes in head and neck cancer (HNC). Delays in care are associated with psychological distress and may adversely affect survival, yet the impact of the diagnosis-to-treatment interval (DTI) remains incompletely defined because prior population-based studies used heterogeneous definitions, limited confounder adjustment, and variable statistical approaches. We evaluated the association between DTI and overall survival in a large population-based cohort of patients with HNC and aimed to identify a clinically meaningful threshold.</p>\n\n<p><strong>Materials and Methods: </strong>We conducted a retrospective population-based cohort study using linked administrative health databases at ICES in Ontario, Canada. Adults diagnosed with incident laryngeal, oropharyngeal, or oral cavity cancer between 2007 and 2022 and treated with curative intent were included. The primary exposure was DTI, analyzed continuously using restricted cubic splines and categorically using clinically informed thresholds. Overall survival was assessed using Cox proportional hazards models with multivariable adjustment and inverse probability of treatment weighting (IPTW) to address confounding. A 180-day landmark approach minimized confounding by indication. Covariates included demographics, comorbidity, tumor site and stage, treatment modality, socioeconomic status, geography, and health-care utilization. Sensitivity analyses evaluated alternative DTI thresholds and subgroup effects across treatment modality, tumor subsite, and stage.</p>\n\n<p><strong>Results: </strong>The cohort included 17,544 patients (median age 63 years; median DTI 45 days). Restricted cubic spline modeling demonstrated a significant, non-linear association between DTI and survival (global p<0.001; non-linearity p=0.0003) without a clear inflection threshold. Using a prespecified cutoff near the cohort median (≤45 vs >45 days), delayed treatment was associated with worse survival in unadjusted analysis (HR 1.11, 95% CI 1.06–1.16) and after IPTW adjustment (HR 1.07, 95% CI 1.02–1.12), whereas conventional multivariable adjustment showed borderline significance (HR 1.05, 95% CI 1.00–1.10). Sensitivity analysis using a 30-day threshold showed similar but attenuated findings (IPTW HR 1.06, 95% CI 1.00–1.12).</p>\n\n<p><strong>Conclusions: </strong>In this large population-based cohort, longer diagnosis-to-treatment intervals were associated with modestly worse overall survival in HNC, with a non-linear relationship and greater risk at prolonged delays over 45 days. Residual confounding by indication may have attenuated the observed association. Reducing treatment delays within regionalized cancer systems may improve survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155527--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S098",
      "content_id": "155563",
      "abstract_number": "S098",
      "poster_number": "",
      "title": "Multiomic Profiling of Salivary Adenoid Cystic Carcinoma by Anatomic Subsites Identifies Prognostic Spatial Niches Associated with ROS/NRF2 and NK cells",
      "summary": "Our data investigate for the first time the molecular background of survival and treatment response differences observed between patients with sAdCC located in different head and neck locations. Specifically, low ROS/NRF2 pathway levels appears to be a major driver of survival differences particularly in submandibular sAdCC. High ROS levels in sAdCC cells have previously been associated with decreased...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155563",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jason Tasoulas, DMD, PhD",
      "presenter": "Jason Tasoulas, DMD, PhD",
      "authors": "Jason Tasoulas, DMD, PhD 1 ; Harish Bharambe, PhD 2 ; Jay Mehta, MS 2 ; Steven Johnson, MD 3 ; Juan C Hernandez-Prera, MD 4 ; Christine H Chung, MD 5 ; Wendell G Yarbrough, MD, MMHC 1 ; Renata O Ferrarotto, MD 6 ; Natalia Issaeva, PhD 1 ; Trevor G Hackman, MD 1 ; Antonio L Amelio, PhD 2",
      "normalized_authors": [
        "Jason Tasoulas",
        "Harish Bharambe",
        "Jay Mehta",
        "Steven Johnson",
        "Juan C Hernandez-Prera",
        "Christine H Chung",
        "Wendell G Yarbrough, MMHC",
        "Renata O Ferrarotto",
        "Natalia Issaeva",
        "Trevor G Hackman",
        "Antonio L Amelio"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA",
        "Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 384,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials and methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jason Tasoulas, DMD, PhD 1 ; Harish Bharambe, PhD 2 ; Jay Mehta, MS 2 ; Steven Johnson, MD 3 ; Juan C Hernandez-Prera, MD 4 ; Christine H Chung, MD 5 ; Wendell G Yarbrough, MD, MMHC 1 ; Renata O Ferrarotto, MD 6 ; Natalia Issaeva, PhD 1 ; Trevor G Hackman, MD 1 ; Antonio L Amelio, PhD 2",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2 Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; 3 Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 4 Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; 5 Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; 6 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Introduction": "Salivary adenoid cystic carcinoma (sAdCC) is a rare, slow-growing head and neck tumor. Compared to other head and neck sites, submandibular gland sAdCCs exhibit different behavior in terms of prognosis. However, the molecular and tumor immune microenvironment (TIME) differences between subtypes and prognostic implications are unclear.",
        "Materials and methods": "A clinically annotated, in-house cohort of 39 samples (30 sAdCC and 9 controls) was generated for bulk RNA sequencing. Single sample gene set enrichment analysis (ssGSEA) and CIBERSORTx TIME deconvolution were performed on the RNA-seq data. Moreover, a separate clinically annotated, in-house cohort of 6 samples (3 primary sAdCC and 3 metastatic sAdCC) was generated for spatial multiomic profiling (RNA and Protein markers). Collectively, analyses were performed on these in-house cohorts to investigate site-specific differences. Statistical analysis included Wilcoxon rank-sum, nonparametric equality-of-medians tests and linear regression models.",
        "Results": "sAdCC expression of tumorigenic pathways varies by anatomic subsite, with the reactive oxygen species (ROS)/NRF2 pathway signature being significantly under-expressed in submandibular gland sAdCCs compared to other head and neck sites. Notably, sAdCCs were stratified according to molecular subtypes and most submandibular gland cases exhibited low ROS/NRF2 irrespective of molecular subtype (67% ACC1 and 67% ACC2). In the TIME, key differences were identified for the natural killer (NK) cell population between major and minor gland sAdCC, although the distinction between minor, submandibular and parotid gland sAdCCs was less clear at the bulk tumor level. However, spatial multiomics profiling of non-submandibular sAdCCs identified spatial niches of tumor cells expressing high levels of canonical NRF2 targets that are associated with abundant NK cell infiltrates. Further, ROS/NRF2-pathway enrichment in parotid gland sAdCCs is also positively associated with overall survival (OS).",
        "Conclusions": "Our data investigate for the first time the molecular background of survival and treatment response differences observed between patients with sAdCC located in different head and neck locations. Specifically, low ROS/NRF2 pathway levels appears to be a major driver of survival differences particularly in submandibular sAdCC. High ROS levels in sAdCC cells have previously been associated with decreased clonogenicity and higher autophagy. NRF2 pathway activation could be a result of the increased ROS levels in these tumors, explaining the improved survival of parotid sAdCC patients. These data suggest that tumor-intrinsic pathway differences present within submandibular sAdCC may influence TIME composition and patient outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Multiomic Profiling of Salivary Adenoid Cystic Carcinoma by Anatomic Subsites Identifies Prognostic Spatial Niches Associated with ROS/NRF2 and NK cells</span>. <u>Jason Tasoulas, DMD, PhD</u><sup>1</sup>; Harish Bharambe, PhD<sup>2</sup>; Jay Mehta, MS<sup>2</sup>; Steven Johnson, MD<sup>3</sup>; Juan C Hernandez-Prera, MD<sup>4</sup>; Christine H Chung, MD<sup>5</sup>; Wendell G Yarbrough, MD, MMHC<sup>1</sup>; Renata O Ferrarotto, MD<sup>6</sup>; Natalia Issaeva, PhD<sup>1</sup>; Trevor G Hackman, MD<sup>1</sup>; Antonio L Amelio, PhD<sup>2</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>2</sup>Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; <sup>3</sup>Department of Pathology and Laboratory Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>4</sup>Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; <sup>5</sup>Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; <sup>6</sup>Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Salivary adenoid cystic carcinoma (sAdCC) is a rare, slow-growing head and neck tumor. Compared to other head and neck sites, submandibular gland sAdCCs exhibit different behavior in terms of prognosis. However, the molecular and tumor immune microenvironment (TIME) differences between subtypes and prognostic implications are unclear.</p>\n\n<p><strong>Materials and methods:</strong> A clinically annotated, in-house cohort of 39 samples (30 sAdCC and 9 controls) was generated for bulk RNA sequencing. Single sample gene set enrichment analysis (ssGSEA) and CIBERSORTx TIME deconvolution were performed on the RNA-seq data. Moreover, a separate clinically annotated, in-house cohort of 6 samples (3 primary sAdCC and 3 metastatic sAdCC) was generated for spatial multiomic profiling (RNA and Protein markers). Collectively, analyses were performed on these in-house cohorts to investigate site-specific differences. Statistical analysis included Wilcoxon rank-sum, nonparametric equality-of-medians tests and linear regression models.</p>\n\n<p><strong>Results:</strong> sAdCC expression of tumorigenic pathways varies by anatomic subsite, with the reactive oxygen species (ROS)/NRF2 pathway signature being significantly under-expressed in submandibular gland sAdCCs compared to other head and neck sites. Notably, sAdCCs were stratified according to molecular subtypes and most submandibular gland cases exhibited low ROS/NRF2 irrespective of molecular subtype (67% ACC1 and 67% ACC2). In the TIME, key differences were identified for the natural killer (NK) cell population between major and minor gland sAdCC, although the distinction between minor, submandibular and parotid gland sAdCCs was less clear at the bulk tumor level. However, spatial multiomics profiling of non-submandibular sAdCCs identified spatial niches of tumor cells expressing high levels of canonical NRF2 targets that are associated with abundant NK cell infiltrates. Further, ROS/NRF2-pathway enrichment in parotid gland sAdCCs is also positively associated with overall survival (OS).</p>\n\n<p><strong>Conclusions:</strong> Our data investigate for the first time the molecular background of survival and treatment response differences observed between patients with sAdCC located in different head and neck locations. Specifically, low ROS/NRF2 pathway levels appears to be a major driver of survival differences particularly in submandibular sAdCC. High ROS levels in sAdCC cells have previously been associated with decreased clonogenicity and higher autophagy. NRF2 pathway activation could be a result of the increased ROS levels in these tumors, explaining the improved survival of parotid sAdCC patients. These data suggest that tumor-intrinsic pathway differences present within submandibular sAdCC may influence TIME composition and patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155563--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S099",
      "content_id": "155457",
      "abstract_number": "S099",
      "poster_number": "",
      "title": "Single-cell RNA-seq reveals cell type-specific immune-associated signaling in adenoid cystic carcinoma",
      "summary": "We identified overexpression of 34 tumor-immune and 15 immune-tumor ligand-receptor pairs in at least three of four ACC patients. Of these 49 immune-associated cell-cell interactions, 27 were overexpressed in only luminal cells, 8 in only myoepithelial cells, and 14 in both. SiPSiC analysis revealed luminal cells overexpressed GO pathways related to increased antigen presentation, tolerance induction, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155457",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Roni Ochakovski",
      "presenter": "Roni Ochakovski",
      "authors": "Roni Ochakovski 1 ; Avishai Wizel, MS 2 ; Nickolas Dreher, MD 1 ; Isabel Cioffi 1 ; Derrick T Lin, MD, FACS 3 ; Sidharth V Puram, MD, PhD, FACS 4 ; Yotam Drier, PhD 5 ; Anuraag S Parikh, MD 1",
      "normalized_authors": [
        "Roni Ochakovski",
        "Avishai Wizel",
        "Nickolas Dreher",
        "Isabel Cioffi",
        "Derrick T Lin",
        "Sidharth V Puram",
        "Yotam Drier",
        "Anuraag S Parikh"
      ],
      "affiliations": [
        "Columbia University Medical Center",
        "The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research",
        "Harvard Medical School",
        "Washington University School of Medicine",
        "The Hebrew University of Jerusalem"
      ],
      "normalized_institutions": [
        "Columbia University Medical Center",
        "The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research",
        "Harvard Medical School",
        "Washington University School of Medicine",
        "The Hebrew University of Jerusalem"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Roni Ochakovski 1 ; Avishai Wizel, MS 2 ; Nickolas Dreher, MD 1 ; Isabel Cioffi 1 ; Derrick T Lin, MD, FACS 3 ; Sidharth V Puram, MD, PhD, FACS 4 ; Yotam Drier, PhD 5 ; Anuraag S Parikh, MD 1",
        "Affiliations": "1 Columbia University Medical Center; 2 The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research; 3 Harvard Medical School; 4 Washington University School of Medicine; 5 The Hebrew University of Jerusalem",
        "Background": "Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with high recurrence rates and poor prognosis, driven in part by a lack of tumor immunogenicity. Traditional chemotherapies and immunotherapy, such as checkpoint inhibitors, have proven to be largely ineffective in ACC. To characterize mechanisms of treatment resistance and immune evasion, bulk and single-cell RNA sequencing (scRNA-seq) have been leveraged to define tumor cell subpopulations and interrogate immune-tumor interactions. These efforts have identified that individual tumors demonstrate distinct luminal and myoepithelial populations, which bear different oncogenic gene expression phenotypes. However, little has been done to interrogate immunologic differences between luminal and myoepithelial cells.",
        "Methods": "We collected fresh tumor samples from four patients with head and neck ACC. We dissociated tumors into single-cell suspensions, sorted CD45+ cells, and performed scRNA-seq using SMART-Seq2. Then, we combined these data with previously-generated single-cell transcriptomic data from CD45- cells from the same tumors to characterize cell-cell interactions via known ligand-receptor pairs expressed on tumor, immune, lymph node, and cancer-associated fibroblast (CAF) cells. To analyze immune-stimulating or -suppressive pathway signals, we conducted a differential expression analysis of GO Immune Process pathways using Single Pathway Analysis in Single Cells (SiPSiC). We also deconvolved a publicly available bulk RNA-seq of 75 ACC patients using CIBERSORTx.",
        "Results": "We identified overexpression of 34 tumor-immune and 15 immune-tumor ligand-receptor pairs in at least three of four ACC patients. Of these 49 immune-associated cell-cell interactions, 27 were overexpressed in only luminal cells, 8 in only myoepithelial cells, and 14 in both. SiPSiC analysis revealed luminal cells overexpressed GO pathways related to increased antigen presentation, tolerance induction, and lymphocyte anergy. However, myoepithelial cells overexpressed pathways related to the downregulation of antigen presentation. Bulk RNA-seq deconvolution suggested a negative association between luminal cells and immune infiltration score and T-cell infiltration score, but these trends were not significant.",
        "Discussion": "To our knowledge, only 13 of the 49 immune-associated ligand-receptor interactions described in these data have been previously reported in ACC in the literature. Several of them, such as APP-CD74, ALCAM-CD6, and CXCL14-CXCR4, have proposed clinical applications in ACC. Further, our analysis suggests that luminal and myoepithelial cell populations in ACC may employ distinct mechanisms of immune evasion, each presenting a unique therapeutically targetable vulnerability. Luminal cells appear to hijack antigen-presentation pathways to induce tolerance and generate regulatory and/or exhausted T-cells. Strategies such as antibodies targeting molecules expressed on tumor-infiltrating regulatory T-cells, anti-TGF-β antibodies, and adoptive cell therapies have been used to address tolerance-related immune evasion mechanisms similar to those observed in luminal cells. In contrast, approaches including autophagy inhibitors, epigenetic modulation, SUMOylation inhibitors, and interferon therapy have been used to restore MHC-I pathway activity, targeting the immune evasion mechanism we observed in myoepithelial cells. Taken together, this suggests that a combination-therapy approach may be required to effectively target immune evasion mechanisms in both luminal and myoepithelial tumor cell populations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Single-cell RNA-seq reveals cell type-specific immune-associated signaling in adenoid cystic carcinoma</span>. <u>Roni Ochakovski</u><sup>1</sup>; Avishai Wizel, MS<sup>2</sup>; Nickolas Dreher, MD<sup>1</sup>; Isabel Cioffi<sup>1</sup>; Derrick T Lin, MD, FACS<sup>3</sup>; Sidharth V Puram, MD, PhD, FACS<sup>4</sup>; Yotam Drier, PhD<sup>5</sup>; Anuraag S Parikh, MD<sup>1</sup>. <sup>1</sup>Columbia University Medical Center; <sup>2</sup>The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research; <sup>3</sup>Harvard Medical School; <sup>4</sup>Washington University School of Medicine; <sup>5</sup>The Hebrew University of Jerusalem<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with high recurrence rates and poor prognosis, driven in part by a lack of tumor immunogenicity. Traditional chemotherapies and immunotherapy, such as checkpoint inhibitors, have proven to be largely ineffective in ACC. To characterize mechanisms of treatment resistance and immune evasion, bulk and single-cell RNA sequencing (scRNA-seq) have been leveraged to define tumor cell subpopulations and interrogate immune-tumor interactions. These efforts have identified that individual tumors demonstrate distinct luminal and myoepithelial populations, which bear different oncogenic gene expression phenotypes. However, little has been done to interrogate immunologic differences between luminal and myoepithelial cells.</p>\n\n<p><strong>Methods: </strong>We collected fresh tumor samples from four patients with head and neck ACC. We dissociated tumors into single-cell suspensions, sorted CD45+ cells, and performed scRNA-seq using SMART-Seq2. Then, we combined these data with previously-generated single-cell transcriptomic data from CD45- cells from the same tumors to characterize cell-cell interactions via known ligand-receptor pairs expressed on tumor, immune, lymph node, and cancer-associated fibroblast (CAF) cells. To analyze immune-stimulating or -suppressive pathway signals, we conducted a differential expression analysis of GO Immune Process pathways using Single Pathway Analysis in Single Cells (SiPSiC). We also deconvolved a publicly available bulk RNA-seq of 75 ACC patients using CIBERSORTx.</p>\n\n<p><strong>Results:</strong> We identified overexpression of 34 tumor-immune and 15 immune-tumor ligand-receptor pairs in at least three of four ACC patients. Of these 49 immune-associated cell-cell interactions, 27 were overexpressed in only luminal cells, 8 in only myoepithelial cells, and 14 in both. SiPSiC analysis revealed luminal cells overexpressed GO pathways related to increased antigen presentation, tolerance induction, and lymphocyte anergy. However, myoepithelial cells overexpressed pathways related to the downregulation of antigen presentation. Bulk RNA-seq deconvolution suggested a negative association between luminal cells and immune infiltration score and T-cell infiltration score, but these trends were not significant.</p>\n\n<p><strong>Discussion:</strong> To our knowledge, only 13 of the 49 immune-associated ligand-receptor interactions described in these data have been previously reported in ACC in the literature. Several of them, such as APP-CD74, ALCAM-CD6, and CXCL14-CXCR4, have proposed clinical applications in ACC. Further, our analysis suggests that luminal and myoepithelial cell populations in ACC may employ distinct mechanisms of immune evasion, each presenting a unique therapeutically targetable vulnerability. Luminal cells appear to hijack antigen-presentation pathways to induce tolerance and generate regulatory and/or exhausted T-cells. Strategies such as antibodies targeting molecules expressed on tumor-infiltrating regulatory T-cells, anti-TGF-β antibodies, and adoptive cell therapies have been used to address tolerance-related immune evasion mechanisms similar to those observed in luminal cells. In contrast, approaches including autophagy inhibitors, epigenetic modulation, SUMOylation inhibitors, and interferon therapy have been used to restore MHC-I pathway activity, targeting the immune evasion mechanism we observed in myoepithelial cells. Taken together, this suggests that a combination-therapy approach may be required to effectively target immune evasion mechanisms in both luminal and myoepithelial tumor cell populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155457--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S100",
      "content_id": "155538",
      "abstract_number": "S100",
      "poster_number": "",
      "title": "Mechanisms governing treatment induced tumor cell dormancy in salivary mucoepidermoid carcinoma",
      "summary": "EGFR mono-inhibition in MEC cells induces a reversible, metabolically reprogrammed dormant state rather than inducing apoptosis. These results highlight a unique mechanism of therapy resistance driven by cell intrinsic drug tolerance. Therefore, targeting pathways regulating the entry into, maintenance of, or exit from this treatment-induced dormant state represents an attractive strategy to eliminate dormancy...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155538",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Harish Bharambe, PhD",
      "presenter": "Harish Bharambe, PhD",
      "authors": "Harish Bharambe, PhD 1 ; Kshitij P Sharma, PhD 2 ; Weida Gong, PhD 3 ; John Powers, MS 1 ; Jay Mehta, MS 1 ; Stanislav Drapela, PhD 1 ; Annie Suctte, PhD 4 ; Joseph O Johnson, MS 4 ; Nathan P Ward, PhD 5 ; Ana Gomes, PhD 1 ; Antonio L Amelio, PhD 1",
      "normalized_authors": [
        "Harish Bharambe",
        "Kshitij P Sharma",
        "Weida Gong",
        "John Powers",
        "Jay Mehta",
        "Stanislav Drapela",
        "Annie Suctte",
        "Joseph O Johnson",
        "Nathan P Ward",
        "Ana Gomes",
        "Antonio L Amelio"
      ],
      "affiliations": [
        "Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
        "Graduate Curriculum in Cell Biology and Physiology, Biological and Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
        "Bioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
        "Analytic Microscopy Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
        "Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"
      ],
      "normalized_institutions": [
        "Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
        "Graduate Curriculum in Cell Biology and Physiology, Biological and Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
        "Bioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA",
        "Analytic Microscopy Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
        "Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 356,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Harish Bharambe, PhD 1 ; Kshitij P Sharma, PhD 2 ; Weida Gong, PhD 3 ; John Powers, MS 1 ; Jay Mehta, MS 1 ; Stanislav Drapela, PhD 1 ; Annie Suctte, PhD 4 ; Joseph O Johnson, MS 4 ; Nathan P Ward, PhD 5 ; Ana Gomes, PhD 1 ; Antonio L Amelio, PhD 1",
        "Affiliations": "1 Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; 2 Graduate Curriculum in Cell Biology and Physiology, Biological and Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 3 Bioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 4 Analytic Microscopy Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; 5 Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA",
        "Background": "Mucoepidermoid carcinoma (MEC) is the most common salivary gland cancer which currently lacks effective targeted therapies, especially for management of the aggressive high-grade phenotype. The major oncogenic driver fusion CRTC1/MAML2 is known to upregulate EGFR signalling in these tumors. However, EGFR inhibitors only have cytostatic effect on MEC cell growth indicating an intrinsically tolerant phenotype. This study aims to decode the molecular mechanisms underlying this drug tolerant phenotype of MEC cells upon challenging with EGFR inhibitors.",
        "Methods": "Phenotypic responses to EGFR inhibition in MEC cells were investigated through cell proliferation/clonogenic assay, cell cycle analysis, measurement of cytotoxicity and apoptosis and in vivo tumorigenicity experiments. RNA-seq and GSEA identified dysregulated pathways, validated by western blotting and qPCR. Metabolic adaptations were tracked by nutrient deprivation and seahorse assays. The role of mitochondrial fusion was examined via FIS1 overexpression.",
        "Results": "Despite supra-therapeutic doses of Erlotinib (up to 25 uM; ~80x IC50), MEC cells enter a reversible growth arrested state but remain viable such that upon drug withdrawal cells commence proliferation. Specifically, EGFR inhibition in MEC cells effectively suppressed proliferation, colony formation, and tumor growth in vivo, but fails to induce apoptosis. EGFR inhibitor treated cells typically suppressed proliferation and tumor growth but induced G0/G1 arrest with elevated p38/ERK ratios, a hallmark characteristic of dormancy. Gene set enrichment analysis of transcriptomic data using a curated custom dormancy signature supports establishment of dormancy and revealed broad metabolic rewiring, including altered glucose, lipid, and ROS pathways, xenobiotic response, and enrichment of an embryonic diapause-like signature. Dormant cells exhibited increased lysosomal and mitochondrial biomass with enhanced mitochondrial fusion. Disrupting mitochondrial fusion through FIS1 overexpression impaired re-entry into proliferation after drug withdrawal pointing to its role in the maintenance and re-entry of dormant cells into the proliferation.",
        "Conclusion": "EGFR mono-inhibition in MEC cells induces a reversible, metabolically reprogrammed dormant state rather than inducing apoptosis. These results highlight a unique mechanism of therapy resistance driven by cell intrinsic drug tolerance. Therefore, targeting pathways regulating the entry into, maintenance of, or exit from this treatment-induced dormant state represents an attractive strategy to eliminate dormancy and prevent tumor recurrence.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mechanisms governing treatment induced tumor cell dormancy in salivary mucoepidermoid carcinoma</span>. <u>Harish Bharambe, PhD</u><sup>1</sup>; Kshitij P Sharma, PhD<sup>2</sup>; Weida Gong, PhD<sup>3</sup>; John Powers, MS<sup>1</sup>; Jay Mehta, MS<sup>1</sup>; Stanislav Drapela, PhD<sup>1</sup>; Annie Suctte, PhD<sup>4</sup>; Joseph O Johnson, MS<sup>4</sup>; Nathan P Ward, PhD<sup>5</sup>; Ana Gomes, PhD<sup>1</sup>; Antonio L Amelio, PhD<sup>1</sup>. <sup>1</sup>Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; <sup>2</sup>Graduate Curriculum in Cell Biology and Physiology, Biological and Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; <sup>3</sup>Bioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; <sup>4</sup>Analytic Microscopy Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; <sup>5</sup>Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Mucoepidermoid carcinoma (MEC) is the most common salivary gland cancer which currently lacks effective targeted therapies, especially for management of the aggressive high-grade phenotype. The major oncogenic driver fusion CRTC1/MAML2 is known to upregulate EGFR signalling in these tumors. However, EGFR inhibitors only have cytostatic effect on MEC cell growth indicating an intrinsically tolerant phenotype. This study aims to decode the molecular mechanisms underlying this drug tolerant phenotype of MEC cells upon challenging with EGFR inhibitors.</p>\n\n<p><strong>Methods</strong>: Phenotypic responses to EGFR inhibition in MEC cells were investigated through cell proliferation/clonogenic assay, cell cycle analysis, measurement of cytotoxicity and apoptosis and in vivo tumorigenicity experiments. RNA-seq and GSEA identified dysregulated pathways, validated by western blotting and qPCR. Metabolic adaptations were tracked by nutrient deprivation and seahorse assays. The role of mitochondrial fusion was examined via FIS1 overexpression.</p>\n\n<p><strong>Results:</strong> Despite supra-therapeutic doses of Erlotinib (up to 25 uM; ~80x IC50), MEC cells enter a reversible growth arrested state but remain viable such that upon drug withdrawal cells commence proliferation. Specifically, EGFR inhibition in MEC cells effectively suppressed proliferation, colony formation, and tumor growth in vivo, but fails to induce apoptosis. EGFR inhibitor treated cells typically suppressed proliferation and tumor growth but induced G0/G1 arrest with elevated p38/ERK ratios, a hallmark characteristic of dormancy. Gene set enrichment analysis of transcriptomic data using a curated custom dormancy signature supports establishment of dormancy and revealed broad metabolic rewiring, including altered glucose, lipid, and ROS pathways, xenobiotic response, and enrichment of an embryonic diapause-like signature. Dormant cells exhibited increased lysosomal and mitochondrial biomass with enhanced mitochondrial fusion. Disrupting mitochondrial fusion through FIS1 overexpression impaired re-entry into proliferation after drug withdrawal pointing to its role in the maintenance and re-entry of dormant cells into the proliferation.</p>\n\n<p><strong>Conclusion:</strong> EGFR mono-inhibition in MEC cells induces a reversible, metabolically reprogrammed dormant state rather than inducing apoptosis. These results highlight a unique mechanism of therapy resistance driven by cell intrinsic drug tolerance. Therefore, targeting pathways regulating the entry into, maintenance of, or exit from this treatment-induced dormant state represents an attractive strategy to eliminate dormancy and prevent tumor recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155538--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S101",
      "content_id": "155430",
      "abstract_number": "S101",
      "poster_number": "",
      "title": "Prospective Assessment of 30 Day Post-Operative Morbidity of Transoral Surgery and Neck Dissection for Oropharyngeal Carcinoma on the DART 2 Trial",
      "summary": "DART 2 prospectively captured surgical morbidity and mortality for a large cohort of pts with OPSCC, and these data inform CTCAE toxicity in the post-op period. TOS resulted in low rates of serious post-op complications including hemorrhage, as well as low rates of positive margin, trach placement, and ICU admission. TOS is a safe option for patients with oropharyngeal carcinoma.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155430",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel L Price, MD",
      "presenter": "Daniel L Price, MD",
      "authors": "Daniel L Price, MD 1 ; Kathryn M Van Abel, MD 1 ; Linda X Yin, MD 1 ; Briant Fruth 2 ; Nathan Foster 2 ; Kendall K Tasche, MD 1 ; Samip M Patel, MD 3 ; Brent A Chang, MD 4 ; Travis J Haller, MD 1 ; Traci Buescher, APRN 5 ; Kyle S Ettinger, MD, DDS 6 ; Payam Entezami, MD 4 ; Katharine A Price, MD 7 ; Ashish V Chintakuntlawar, MBBS, PhD 8 ; Yujie Zhao, MD, PhD 9 ; Adam Holtzman, MD 10 ; Jessica Wilson, MD, PhD 5 ; Scott C Lester, MD 5 ; Samir H Patel, MD 11 ; Daniel J Ma, MD 5 ; Valentina Carducci 1 ; Richard Hayden, MD 4 ; Michelle Neben-Wittich, MD 5 ; Michael Hinni, MD 4 ; Eric Moore, MD 1 ; Jeffrey Janus, MD 3 ; David M Routman, MD 5",
      "normalized_authors": [
        "Daniel L Price",
        "Kathryn M Van Abel",
        "Linda X Yin",
        "Briant Fruth",
        "Nathan Foster",
        "Kendall K Tasche",
        "Samip M Patel",
        "Brent A Chang",
        "Travis J Haller",
        "Traci Buescher, APRN",
        "Kyle S Ettinger",
        "Payam Entezami",
        "Katharine A Price",
        "Ashish V Chintakuntlawar, MBBS",
        "Yujie Zhao",
        "Adam Holtzman",
        "Jessica Wilson",
        "Scott C Lester",
        "Samir H Patel",
        "Daniel J Ma",
        "Valentina Carducci",
        "Richard Hayden",
        "Michelle Neben-Wittich",
        "Michael Hinni",
        "Eric Moore",
        "Jeffrey Janus",
        "David M Routman"
      ],
      "affiliations": [
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota",
        "Department of Biostatistics, Mayo Clinic, Rochester, MN, USA",
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Jacksonville, Florida",
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Arizona",
        "Department of Radiation Oncology, Rochester, Minnesota",
        "Department of Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, Minnesota",
        "Division of Medical Oncology, Rochester, Minnesota",
        "Division of Medical Oncology, Mayo Clinic, Arizona",
        "Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida",
        "Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida",
        "Department of Radiation Oncology, Mayo Clinic, Arizona"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota",
        "Department of Biostatistics, Mayo Clinic, Rochester, MN, USA",
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Jacksonville, Florida",
        "Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Arizona",
        "Department of Radiation Oncology, Rochester, Minnesota",
        "Department of Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, Minnesota",
        "Division of Medical Oncology, Rochester, Minnesota",
        "Division of Medical Oncology, Mayo Clinic, Arizona",
        "Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida",
        "Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida",
        "Department of Radiation Oncology, Mayo Clinic, Arizona"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 466,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel L Price, MD 1 ; Kathryn M Van Abel, MD 1 ; Linda X Yin, MD 1 ; Briant Fruth 2 ; Nathan Foster 2 ; Kendall K Tasche, MD 1 ; Samip M Patel, MD 3 ; Brent A Chang, MD 4 ; Travis J Haller, MD 1 ; Traci Buescher, APRN 5 ; Kyle S Ettinger, MD, DDS 6 ; Payam Entezami, MD 4 ; Katharine A Price, MD 7 ; Ashish V Chintakuntlawar, MBBS, PhD 8 ; Yujie Zhao, MD, PhD 9 ; Adam Holtzman, MD 10 ; Jessica Wilson, MD, PhD 5 ; Scott C Lester, MD 5 ; Samir H Patel, MD 11 ; Daniel J Ma, MD 5 ; Valentina Carducci 1 ; Richard Hayden, MD 4 ; Michelle Neben-Wittich, MD 5 ; Michael Hinni, MD 4 ; Eric Moore, MD 1 ; Jeffrey Janus, MD 3 ; David M Routman, MD 5",
        "Affiliations": "1 Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota; 2 Department of Biostatistics, Mayo Clinic, Rochester, MN, USA; 3 Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Jacksonville, Florida; 4 Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Arizona; 5 Department of Radiation Oncology, Rochester, Minnesota; 6 Department of Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, Minnesota; 7 Division of Medical Oncology, Rochester, Minnesota; 8 Division of Medical Oncology, Mayo Clinic, Arizona; 9 Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida; 10 Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida; 11 Department of Radiation Oncology, Mayo Clinic, Arizona",
        "Background": "Transoral surgical (TOS) resection is commonly utilized for management of oropharyngeal squamous cell carcinoma (OPSCC). Rates of post-operative (post-op) morbidity and mortality have varied substantially across prior studies. DART 2 prospectively enrolled patients (pts) prior to surgery with risk stratification for adjuvant radiation therapy based on pathologic factors and ctHPVDNA. Herein, we report the initial 30-day post-op outcomes for pts undergoing surgery on DART 2.",
        "Methods": "Pts undergoing surgical resection on DART 2 were included regardless of post-op grouping. TOS consisted of transoral robotic (TORS) or transoral laser (TLM) removal of the primary tumor, ipsilateral versus bilateral neck dissection depending on disease involvement and at the discretion of the treating team, and prophylactic ligation of unilateral external carotid branches deemed highest risk. A negative margin was defined as no tumor at the inked margin, either separately submitted or taken from the primary specimen. Data regarding surgical outcomes were prospectively assessed, including margin status, post-operative hospitalization, morbidity, and mortality, CTCAE toxicity, and adverse events.",
        "Results": "Between 3/20/2023 and 3/4/2026, 255 pts underwent resection for OPSCC on the DART 2 across 3 sites. Median age was 62 years old, 85% were male, 35% with current or former smoking history (median of 13 pack yrs). Primary tumor surgery included ipsilateral neck dissection in 100% of pts and bilateral neck dissection in 19%. The mean number of lymph nodes removed per neck dissection was 31. Final positive margin rate was 3.5%. Median length of hospitalization was 2 days (range 1-15 days), with 3% of pts hospitalized for more than 5 days. Rate of ICU admission was 2% (bleed, cardiac, pneumonia). Rate of tracheostomy tube placement was 1.2% (duration 9-23 days). The rate of post-operative 30-day grade 3 and 4 toxicity on a per patient basis was 16.1%, and 3.5%, respectively, including 1 case of osteomyelitis and 1 anaphylactic reaction. Temporary nasogastric feeding tube placement was required in 25.9% of patients (median 12 days). The rate of CTCAE grade 1-2 hemorrhage was 2.7%; grade 3-4 was 5.5%. There were no deaths within 30 days of surgery. Rate of return to the OR for positive margin or complication was 13.3%: delayed positive margin (4.3%), hemorrhage (5.5%), hematoma (3.1%), and abscess (0.4%). Trial accrual is nearly complete; final data for 30-day surgical morbidity is anticipated at the time of the meeting presentation.",
        "Conclusion": "DART 2 prospectively captured surgical morbidity and mortality for a large cohort of pts with OPSCC, and these data inform CTCAE toxicity in the post-op period. TOS resulted in low rates of serious post-op complications including hemorrhage, as well as low rates of positive margin, trach placement, and ICU admission. TOS is a safe option for patients with oropharyngeal carcinoma.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prospective Assessment of 30 Day Post-Operative Morbidity of Transoral Surgery and Neck Dissection for Oropharyngeal Carcinoma on the DART 2 Trial</span>. <u>Daniel L Price, MD</u><sup>1</sup>; Kathryn M Van Abel, MD<sup>1</sup>; Linda X Yin, MD<sup>1</sup>; Briant Fruth<sup>2</sup>; Nathan Foster<sup>2</sup>; Kendall K Tasche, MD<sup>1</sup>; Samip M Patel, MD<sup>3</sup>; Brent A Chang, MD<sup>4</sup>; Travis J Haller, MD<sup>1</sup>; Traci Buescher, APRN<sup>5</sup>; Kyle S Ettinger, MD, DDS<sup>6</sup>; Payam Entezami, MD<sup>4</sup>; Katharine A Price, MD<sup>7</sup>; Ashish V Chintakuntlawar, MBBS, PhD<sup>8</sup>; Yujie Zhao, MD, PhD<sup>9</sup>; Adam Holtzman, MD<sup>10</sup>; Jessica Wilson, MD, PhD<sup>5</sup>; Scott C Lester, MD<sup>5</sup>; Samir H Patel, MD<sup>11</sup>; Daniel J Ma, MD<sup>5</sup>; Valentina Carducci<sup>1</sup>; Richard Hayden, MD<sup>4</sup>; Michelle Neben-Wittich, MD<sup>5</sup>; Michael Hinni, MD<sup>4</sup>; Eric Moore, MD<sup>1</sup>; Jeffrey Janus, MD<sup>3</sup>; David M Routman, MD<sup>5</sup>. <sup>1</sup>Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota; <sup>2</sup>Department of Biostatistics, Mayo Clinic, Rochester, MN, USA; <sup>3</sup>Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Jacksonville, Florida; <sup>4</sup>Department of Otolaryngology Head & Neck Surgery, Mayo Clinic, Arizona; <sup>5</sup>Department of Radiation Oncology, Rochester, Minnesota; <sup>6</sup>Department of Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, Minnesota; <sup>7</sup>Division of Medical Oncology, Rochester, Minnesota; <sup>8</sup>Division of Medical Oncology, Mayo Clinic, Arizona; <sup>9</sup>Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida; <sup>10</sup>Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida; <sup>11</sup>Department of Radiation Oncology, Mayo Clinic, Arizona<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Transoral surgical (TOS) resection is commonly utilized for management of oropharyngeal squamous cell carcinoma (OPSCC). Rates of post-operative (post-op) morbidity and mortality have varied substantially across prior studies. DART 2 prospectively enrolled patients (pts) prior to surgery with risk stratification for adjuvant radiation therapy based on pathologic factors and ctHPVDNA. Herein, we report the initial 30-day post-op outcomes for pts undergoing surgery on DART 2. </p>\n\n<p><strong>Methods:</strong> Pts undergoing surgical resection on DART 2 were included regardless of post-op grouping.  TOS consisted of transoral robotic (TORS) or transoral laser (TLM) removal of the primary tumor, ipsilateral versus bilateral neck dissection depending on disease involvement and at the discretion of the treating team, and prophylactic ligation of unilateral external carotid branches deemed highest risk. A negative margin was defined as no tumor at the inked margin, either separately submitted or taken from the primary specimen.  Data regarding surgical outcomes were prospectively assessed, including margin status, post-operative hospitalization, morbidity, and mortality, CTCAE toxicity, and adverse events. </p>\n\n<p><strong>Results: </strong>Between 3/20/2023 and 3/4/2026, 255 pts underwent resection for OPSCC on the DART 2 across 3 sites. Median age was 62 years old, 85% were male, 35% with current or former smoking history (median of 13 pack yrs). Primary tumor surgery included ipsilateral neck dissection in 100% of pts and bilateral neck dissection in 19%. The mean number of lymph nodes removed per neck dissection was 31. Final positive margin rate was 3.5%. Median length of hospitalization was 2 days (range 1-15 days), with 3% of pts hospitalized for more than 5 days. Rate of ICU admission was 2% (bleed, cardiac, pneumonia). Rate of tracheostomy tube placement was 1.2% (duration 9-23 days). The rate of post-operative 30-day grade 3 and 4 toxicity on a per patient basis was 16.1%, and 3.5%, respectively, including 1 case of osteomyelitis and 1 anaphylactic reaction. Temporary nasogastric feeding tube placement was required in 25.9% of patients (median 12 days). The rate of CTCAE grade 1-2 hemorrhage was 2.7%; grade 3-4 was 5.5%. There were no deaths within 30 days of surgery. Rate of return to the OR for positive margin or complication was 13.3%: delayed positive margin (4.3%), hemorrhage (5.5%), hematoma (3.1%), and abscess (0.4%). Trial accrual is nearly complete; final data for 30-day surgical morbidity is anticipated at the time of the meeting presentation. </p>\n\n<p><strong>Conclusion:</strong> DART 2 prospectively captured surgical morbidity and mortality for a large cohort of pts with OPSCC, and these data inform CTCAE toxicity in the post-op period. TOS resulted in low rates of serious post-op complications including hemorrhage, as well as low rates of positive margin, trach placement, and ICU admission. TOS is a safe option for patients with oropharyngeal carcinoma.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155430--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S102",
      "content_id": "155547",
      "abstract_number": "S102",
      "poster_number": "",
      "title": "Prognostic Outcomes of Transoral Surgery With or Without Adjuvant Therapy in HPV-Positive Head and Neck Carcinoma of Unknown Primary: A Systematic Review and Meta-Analysis",
      "summary": "HPV+ SCCUP treated with a transoral surgical approach demonstrates excellent oncologic outcomes, with high primary tumor detection, favorable survival, and low rates of recurrence and distant metastasis. In patients who are true T0 after transoral surgery, locoregional and distant failures continue to be low. These findings support transoral surgery as an effective treatment approach in appropriately selected...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155547",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emily Johnson, BS",
      "presenter": "Emily Johnson, BS",
      "authors": "Emily Johnson, BS ; Srivatsa Surya Vasudevan, MD, MS; Victor Albornoz, MD; Katherine Chang, MD, FACS",
      "normalized_authors": [
        "Emily Johnson",
        "Srivatsa Surya Vasudevan",
        "Victor Albornoz",
        "Katherine Chang"
      ],
      "affiliations": [
        "Louisiana State University Health Shreveport"
      ],
      "normalized_institutions": [
        "Louisiana State University Health Shreveport"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 383,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emily Johnson, BS ; Srivatsa Surya Vasudevan, MD, MS; Victor Albornoz, MD; Katherine Chang, MD, FACS",
        "Affiliations": "Louisiana State University Health Shreveport",
        "Background": "Human papillomavirus-positive (HPV+) squamous cell carcinoma of unknown primary (SCCUP) of the head and neck is increasingly managed with transoral surgery, with or without adjuvant therapy. However, pooled prognostic outcomes following this treatment strategy remain incompletely characterized.",
        "Methods": "PubMed, Embase, Web of Science, and ScienceDirect were searched to identify studies reporting prognostic outcomes of HPV+ SCCUP treated with a transoral approach. The primary outcomes of interest included overall survival (OS), disease-free survival (DFS), local recurrence, regional recurrence, locoregional recurrence, and distant metastasis. Pooled rates with corresponding 95% confidence intervals were calculated using a random-effects model.",
        "Results": "Out of 1618 identified articles, 11 studies were included, comprising 951 patients with HPV+ SCCUP managed with a transoral approach, with a mean age of 57.5 (2.43) years. The pooled primary tumor detection rate was 82.9% (95% CI, 74.5%–88.9%). Pooled OS was 95.9% (95% CI, 94.0%–97.2%) at 2 years, 95.9% (95% CI, 94.0%–97.2%) at 3 years, and 91.3% (95% CI, 88.8%–93.2%) at 5 years. Pooled DFS was 92.3% (95% CI, 87.0%–95.5%) at 2 years, 92.1% (95% CI, 88.5%–94.6%) at 3 years, and 89.6% (95% CI, 85.6%–92.6%) at 5 years. Recurrence and metastatic events were uncommon, with pooled local recurrence of 1.4% (95% CI, 0.4%–4.1%), regional recurrence of 2.6% (95% CI, 1.1%–6.0%), locoregional recurrence of 1.9% (95% CI, 0.6%–5.7%), and distant metastasis of 3.7% (95% CI, 2.2%–6.2%). Two studies reported outcomes on true T0 disease subgroup and showed low failure rates; local recurrence was 4.2% (95% CI, 0.6%–24.7%), regional recurrence was 4.7% (95% CI, 0.5%–33.3%), and distant metastasis rate was 5.7% (95% CI, 1.2%–22.3%).",
        "Conclusion": "HPV+ SCCUP treated with a transoral surgical approach demonstrates excellent oncologic outcomes, with high primary tumor detection, favorable survival, and low rates of recurrence and distant metastasis. In patients who are true T0 after transoral surgery, locoregional and distant failures continue to be low. These findings support transoral surgery as an effective treatment approach in appropriately selected patients with HPV+ SCCUP.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Outcomes of Transoral Surgery With or Without Adjuvant Therapy in HPV-Positive Head and Neck Carcinoma of Unknown Primary: A Systematic Review and Meta-Analysis</span>. <u>Emily Johnson, BS</u>; Srivatsa Surya Vasudevan, MD, MS; Victor Albornoz, MD; Katherine Chang, MD, FACS. Louisiana State University Health Shreveport<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Human papillomavirus-positive (HPV+) squamous cell carcinoma of unknown primary (SCCUP) of the head and neck is increasingly managed with transoral surgery, with or without adjuvant therapy. However, pooled prognostic outcomes following this treatment strategy remain incompletely characterized. </p>\n\n<p><strong>Methods: </strong>PubMed, Embase, Web of Science, and ScienceDirect were searched to identify studies reporting prognostic outcomes of HPV+ SCCUP treated with a transoral approach. The primary outcomes of interest included overall survival (OS), disease-free survival (DFS), local recurrence, regional recurrence, locoregional recurrence, and distant metastasis. Pooled rates with corresponding 95% confidence intervals were calculated using a random-effects model. </p>\n\n<p><strong>Results: </strong>Out of 1618 identified articles, 11 studies were included, comprising 951 patients with HPV+ SCCUP managed with a transoral approach, with a mean age of 57.5 (2.43) years. The pooled primary tumor detection rate was 82.9% (95% CI, 74.5%–88.9%). Pooled OS was 95.9% (95% CI, 94.0%–97.2%) at 2 years, 95.9% (95% CI, 94.0%–97.2%) at 3 years, and 91.3% (95% CI, 88.8%–93.2%) at 5 years. Pooled DFS was 92.3% (95% CI, 87.0%–95.5%) at 2 years, 92.1% (95% CI, 88.5%–94.6%) at 3 years, and 89.6% (95% CI, 85.6%–92.6%) at 5 years. Recurrence and metastatic events were uncommon, with pooled local recurrence of 1.4% (95% CI, 0.4%–4.1%), regional recurrence of 2.6% (95% CI, 1.1%–6.0%), locoregional recurrence of 1.9% (95% CI, 0.6%–5.7%), and distant metastasis of 3.7% (95% CI, 2.2%–6.2%). Two studies reported outcomes on true T0 disease subgroup and showed low failure rates; local recurrence was 4.2% (95% CI, 0.6%–24.7%), regional recurrence was 4.7% (95% CI, 0.5%–33.3%), and distant metastasis rate was 5.7% (95% CI, 1.2%–22.3%). </p>\n\n<p><strong>Conclusion: </strong>HPV+ SCCUP treated with a transoral surgical approach demonstrates excellent oncologic outcomes, with high primary tumor detection, favorable survival, and low rates of recurrence and distant metastasis. In patients who are true T0 after transoral surgery, locoregional and distant failures continue to be low. These findings support transoral surgery as an effective treatment approach in appropriately selected patients with HPV+ SCCUP. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155547--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S103",
      "content_id": "155492",
      "abstract_number": "S103",
      "poster_number": "",
      "title": "Response-adapted surgery following neoadjuvant immunotherapy in resectable mucosal HNSCC: a systematic review and meta-analysis",
      "summary": "Response-adapted surgery following neoadjuvant ICI-based therapy may improve functional preservation without compromising oncologic and survival outcomes in selected patients with resectable advanced mucosal HNSCC. Prospective trials with standardized oncologic and functional endpoints are required to validate and guide this de-escalation strategy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155492",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Liyona Kampel, MD, PhD",
      "presenter": "Liyona Kampel, MD, PhD",
      "authors": "Liyona Kampel, MD, PhD ; Yahav Bordovski; Anton Warshavsky, MD; Shahaf Shilo, MD; Gilad Horowitz, MD; Inbar Finkel, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD",
      "normalized_authors": [
        "Liyona Kampel",
        "Yahav Bordovski",
        "Anton Warshavsky",
        "Shahaf Shilo",
        "Gilad Horowitz",
        "Inbar Finkel",
        "Orit Gutfeld",
        "Nidal Muhanna"
      ],
      "affiliations": [
        "Tel Aviv Sourasky Medical Center"
      ],
      "normalized_institutions": [
        "Tel Aviv Sourasky Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 376,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials and Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Liyona Kampel, MD, PhD ; Yahav Bordovski; Anton Warshavsky, MD; Shahaf Shilo, MD; Gilad Horowitz, MD; Inbar Finkel, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD",
        "Affiliations": "Tel Aviv Sourasky Medical Center",
        "Background": "Recent evidence demonstrating encouragong results with neoadjuvant immune checkpoint inhibitors (ICIs) in mucosal head and neck squamous cell carcinoma (HNSCC) has raised interest in surgical de-escalation strategies. Response-adapted surgery (RAS) may reduce morbidity associated with radical surgery while preserving organ function. However, limited data exist regarding oncologic safety and survival outcomes of RAS compared with baseline-planned surgery following neoadjuvant ICI-based therapy.",
        "Materials and Methods": "A systematic search of the PubMed (MEDLINE), EMBASE, the Cochrane Library, and the Clinical Trials Registry (clinicaltrials.gov) was performed from January 1, 2020, through Dec 31, 2025 for studies of neoadjuvant ICI-based therapy, with or without chemotherapy, in resectable advanced mucosal HNSCC. Eligible studies reported surgical extent after neoadjuvant therapy, either as RAS or explicitly baseline-planned surgery (BPS), and provided treatment response and survival data. Two investigators independently reviewed the studies per PRISMA guidelines. Primary outcomes extracted were major pathologic response (MPR), complete pathologic response (pCR), event free survival (EFS) and overall survival (OS). Study-level proportions were pooled using the random-effects model with 95% confidence intervals (CI). Between-group differences were assessed using a subgroup Q test. Heterogeneity was evaluated using I².",
        "Results": "The comparative analysis included 4 RAS studies, involving 242 patients and 9 BPS studies, including 345 patients. Pooled overall EFS was 83.3% (76.9–88.2) in the RAS group and 80.2% (74.3–85.0) in the BPS group (p=0.433), and pooled OS was 92.3% (87.5–95.3) versus 89.8% (77.4–95.7), respectively (p=0.578). Pooled rate of pCR was 42.6% (95%CI,36.4–49.0; I²=0.0) for RAS and 18.8% (95%CI, 11.3–29.6; I²=0.58) for BPS (p=0.0004), while MPR was not significantly different (59.6%, 95%CI, 44.0–73.5 versus 47.2%, 95%CI, 36.2–58.6 respectively; p=0.209). Across studies, RAS was associated with greater organ preservation and reduced need for mandibulectomy and free-flap reconstruction.",
        "Conclusions": "Response-adapted surgery following neoadjuvant ICI-based therapy may improve functional preservation without compromising oncologic and survival outcomes in selected patients with resectable advanced mucosal HNSCC. Prospective trials with standardized oncologic and functional endpoints are required to validate and guide this de-escalation strategy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Response-adapted surgery following neoadjuvant immunotherapy in resectable mucosal HNSCC: a systematic review and meta-analysis</span>. <u>Liyona Kampel, MD, PhD</u>; Yahav Bordovski; Anton Warshavsky, MD; Shahaf Shilo, MD; Gilad Horowitz, MD; Inbar Finkel, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD. Tel Aviv Sourasky Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Recent evidence demonstrating encouragong results with neoadjuvant immune checkpoint inhibitors (ICIs) in mucosal head and neck squamous cell carcinoma (HNSCC) has raised interest in surgical de-escalation strategies. Response-adapted surgery (RAS) may reduce morbidity associated with radical surgery while preserving organ function. However, limited data exist regarding oncologic safety and survival outcomes of RAS compared with baseline-planned surgery following neoadjuvant ICI-based therapy.</p>\n\n<p><strong>Materials and Methods: </strong>A systematic search of the PubMed (MEDLINE), EMBASE, the Cochrane Library, and the Clinical Trials Registry (clinicaltrials.gov) was performed from January 1, 2020, through Dec 31, 2025 for studies of neoadjuvant ICI-based therapy, with or without chemotherapy, in resectable advanced mucosal HNSCC. Eligible studies reported surgical extent after neoadjuvant therapy, either as RAS or explicitly baseline-planned surgery (BPS), and provided treatment response and survival data. Two investigators independently reviewed the studies per PRISMA guidelines. Primary outcomes extracted were major pathologic response (MPR), complete pathologic response (pCR), event free survival (EFS) and overall survival (OS). Study-level proportions were pooled using the random-effects model with 95% confidence intervals (CI). Between-group differences were assessed using a subgroup Q test. Heterogeneity was evaluated using I².</p>\n\n<p><strong>Results: </strong>The comparative analysis included 4 RAS studies, involving 242 patients and 9 BPS studies, including 345 patients. Pooled overall EFS was 83.3% (76.9–88.2) in the RAS group and 80.2% (74.3–85.0) in the BPS group (p=0.433), and pooled OS was 92.3% (87.5–95.3) versus 89.8% (77.4–95.7), respectively (p=0.578). Pooled rate of pCR was 42.6% (95%CI,36.4–49.0; I²=0.0) for RAS and 18.8% (95%CI, 11.3–29.6; I²=0.58) for BPS (p=0.0004), while MPR was not significantly different (59.6%, 95%CI, 44.0–73.5 versus 47.2%, 95%CI, 36.2–58.6 respectively; p=0.209). Across studies, RAS was associated with greater organ preservation and reduced need for mandibulectomy and free-flap reconstruction.</p>\n\n<p><strong>Conclusions:</strong> Response-adapted surgery following neoadjuvant ICI-based therapy may improve functional preservation without compromising oncologic and survival outcomes in selected patients with resectable advanced mucosal HNSCC. Prospective trials with standardized oncologic and functional endpoints are required to validate and guide this de-escalation strategy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155492--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S104",
      "content_id": "155461",
      "abstract_number": "S104",
      "poster_number": "",
      "title": "Neoadjuvant immunotherapy with or without systemic chemotherapy in head and neck squamous cell carcinoma: systematic review and meta-analysis",
      "summary": "Neoadjuvant chemo-immunotherapy is associated with significantly higher rates of MPR and pCR compared to immunotherapy alone, while maintaining a comparable safety profile. While pathologic response has been proposed as a surrogate endpoint for survival outcomes in other solid organ tumors, longer term follow-up is needed to determine if this is valid with NACI in HNSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155461",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yehia Elkersh",
      "presenter": "Yehia Elkersh",
      "authors": "Yehia Elkersh 1 ; Thomas F Barrett 1 ; Andrew M Peterson 2 ; Daniel Kraft 1 ; Michael Berger 1 ; M Nazir Khan 1 ; Marita Teng 1 ; Krzysztof Misiukiewicz 1 ; Azita Khorsandi 1 ; Elisabet Pujadas 1 ; Margaret Brandwein 1 ; Jerry T Liu 1 ; Kunal Sindhu 1 ; Richard Bakst 1 ; Raymond Chai 1 ; Mark L Urken 1 ; Eric M Genden 1 ; Scott A Roof 1",
      "normalized_authors": [
        "Yehia Elkersh",
        "Thomas F Barrett",
        "Andrew M Peterson",
        "Daniel Kraft",
        "Michael Berger",
        "M Nazir Khan",
        "Marita Teng",
        "Krzysztof Misiukiewicz",
        "Azita Khorsandi",
        "Elisabet Pujadas",
        "Margaret Brandwein",
        "Jerry T Liu",
        "Kunal Sindhu",
        "Richard Bakst",
        "Raymond Chai",
        "Mark L Urken",
        "Eric M Genden",
        "Scott A Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai",
        "Washington University in St. Louis"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai",
        "Washington University in St. Louis"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 460,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Yehia Elkersh 1 ; Thomas F Barrett 1 ; Andrew M Peterson 2 ; Daniel Kraft 1 ; Michael Berger 1 ; M Nazir Khan 1 ; Marita Teng 1 ; Krzysztof Misiukiewicz 1 ; Azita Khorsandi 1 ; Elisabet Pujadas 1 ; Margaret Brandwein 1 ; Jerry T Liu 1 ; Kunal Sindhu 1 ; Richard Bakst 1 ; Raymond Chai 1 ; Mark L Urken 1 ; Eric M Genden 1 ; Scott A Roof 1",
        "Affiliations": "1 Icahn School of Medicine at Mount Sinai; 2 Washington University in St. Louis",
        "Background": "Neoadjuvant immunotherapy (NAI) has demonstrated benefit in locally advanced head and neck squamous cell carcinoma (HNSCC), though both the pathologic response rates and survival benefit are modest. To improve response rates, combination strategies have emerged as promising approaches, of which neoadjuvant chemo-immunotherapy (NACI) has shown significant potential. Recent work has suggested that major pathologic response (MPR) and pathologic complete response (pCR) strongly predict survival in several solid tumors and are increasingly investigated as surrogate endpoints in HNSCC. We performed a systematic review and meta-analysis to compare pathologic response rates following NACI versus NAI.",
        "Methods": "A systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, Embase, Cochrane Library, SCOPUS, and ClinicalTrials.gov from 2014-2026 were searched for clinical trials of patients with HNSCC receiving either NAI or NACI prior to surgical resection. The primary outcomes were MPR (≤10% viable tumor) and pCR (0% viable tumor). Secondary measures included RECIST 1.1 objective response rates (ORR), surgical delay, and treatment related adverse events (TRAE). We estimated pooled proportions using a random-effects meta-analysis with logit transformation. Indirect comparisons between treatment strategies were performed using random-effects meta-regression.",
        "Results": "Our search strategy yielded 6,207 titles, of which 405 were selected for review. Ultimately 43 clinical trials with 1,863 total patients were included, including 33 manuscripts and 10 abstracts. Among studies evaluating NAI (n = 15 studies, 496 patients), pooled MPR and pCR were 13.8% (95% CI 8.6–21.4) and 4.0% (95% CI 2.3–6.9), respectively. Among studies evaluating NACI (n = 28 studies, 1,397 patients), pooled MPR and pCR were 63.2% (95% CI 53.9–71.6) and 39.3% (95% CI 32.1–47.0), respectively. Meta-regression demonstrated significantly higher rates of both MPR and pCR in NACI compared to NAI (p < 0.0001 for both). ORR was similarly significantly higher in NACI (73.9% [95% CI 62.0–83.1]) compared to NAI (38.1% [95% CI 29.6–47.3], p = 0.005).",
        "Abstract": "The pooled rate of TRAE was 8.9% (95% CI 5.8–13.4) overall, with no significant difference between NACI (8.1% [95% CI 4.7–13.4]) and NAI (11.0% [95% CI 5.3–21.3], p = 0.46). Rates of surgical delay were low overall (0.6% [95% CI 0.2–2.3]) and did not differ significantly between NACI and NAI (p = 0.38). View in Agenda and Add to Schedule",
        "Conclusion": "Neoadjuvant chemo-immunotherapy is associated with significantly higher rates of MPR and pCR compared to immunotherapy alone, while maintaining a comparable safety profile. While pathologic response has been proposed as a surrogate endpoint for survival outcomes in other solid organ tumors, longer term follow-up is needed to determine if this is valid with NACI in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant immunotherapy with or without systemic chemotherapy in head and neck squamous cell carcinoma: systematic review and meta-analysis</span>. <u>Yehia Elkersh</u><sup>1</sup>; Thomas F Barrett<sup>1</sup>; Andrew M Peterson<sup>2</sup>; Daniel Kraft<sup>1</sup>; Michael Berger<sup>1</sup>; M Nazir Khan<sup>1</sup>; Marita Teng<sup>1</sup>; Krzysztof Misiukiewicz<sup>1</sup>; Azita Khorsandi<sup>1</sup>; Elisabet Pujadas<sup>1</sup>; Margaret Brandwein<sup>1</sup>; Jerry T Liu<sup>1</sup>; Kunal Sindhu<sup>1</sup>; Richard Bakst<sup>1</sup>; Raymond Chai<sup>1</sup>; Mark L Urken<sup>1</sup>; Eric M Genden<sup>1</sup>; Scott A Roof<sup>1</sup>. <sup>1</sup>Icahn School of Medicine at Mount Sinai; <sup>2</sup>Washington University in St. Louis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant immunotherapy (NAI) has demonstrated benefit in locally advanced head and neck squamous cell carcinoma (HNSCC), though both the pathologic response rates and survival benefit are modest. To improve response rates, combination strategies have emerged as promising approaches, of which neoadjuvant chemo-immunotherapy (NACI) has shown significant potential. Recent work has suggested that major pathologic response (MPR) and pathologic complete response (pCR) strongly predict survival in several solid tumors and are increasingly investigated as surrogate endpoints in HNSCC. We performed a systematic review and meta-analysis to compare pathologic response rates following NACI versus NAI.</p>\n\n<p><strong>Methods: </strong>A systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, Embase, Cochrane Library, SCOPUS, and ClinicalTrials.gov from 2014-2026 were searched for clinical trials of patients with HNSCC receiving either NAI or NACI prior to surgical resection. The primary outcomes were MPR (≤10% viable tumor) and pCR (0% viable tumor). Secondary measures included RECIST 1.1 objective response rates (ORR), surgical delay, and treatment related adverse events (TRAE). We estimated pooled proportions using a random-effects meta-analysis with logit transformation. Indirect comparisons between treatment strategies were performed using random-effects meta-regression.</p>\n\n<p><strong>Results:</strong> Our search strategy yielded 6,207 titles, of which 405 were selected for review. Ultimately 43 clinical trials with 1,863 total patients were included, including 33 manuscripts and 10 abstracts. Among studies evaluating NAI (n = 15 studies, 496 patients), pooled MPR and pCR were 13.8% (95% CI 8.6–21.4) and 4.0% (95% CI 2.3–6.9), respectively. Among studies evaluating NACI (n = 28 studies, 1,397 patients), pooled MPR and pCR were 63.2% (95% CI 53.9–71.6) and 39.3% (95% CI 32.1–47.0), respectively. Meta-regression demonstrated significantly higher rates of both MPR and pCR in NACI compared to NAI (p < 0.0001 for both). ORR was similarly significantly higher in NACI (73.9% [95% CI 62.0–83.1]) compared to NAI (38.1% [95% CI 29.6–47.3], p = 0.005). </p>\n\n<p>The pooled rate of TRAE was 8.9% (95% CI 5.8–13.4) overall, with no significant difference between NACI (8.1% [95% CI 4.7–13.4]) and NAI (11.0% [95% CI 5.3–21.3], p = 0.46). Rates of surgical delay were low overall (0.6% [95% CI 0.2–2.3]) and did not differ significantly between NACI and NAI (p = 0.38).</p>\n\n<p><strong>Conclusion:</strong> Neoadjuvant chemo-immunotherapy is associated with significantly higher rates of MPR and pCR compared to immunotherapy alone, while maintaining a comparable safety profile. While pathologic response has been proposed as a surrogate endpoint for survival outcomes in other solid organ tumors, longer term follow-up is needed to determine if this is valid with NACI in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155461--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S105",
      "content_id": "155564",
      "abstract_number": "S105",
      "poster_number": "",
      "title": "Hepatotoxicity Associated With PD-1 Inhibitors: A Comparative Pharmacovigilance Study of Pembrolizumab and Nivolumab Using FAERS",
      "summary": "Pembrolizumab and nivolumab are PD-1 immune checkpoint inhibitors approved for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), with pembrolizumab recently approved in the neoadjuvant setting. Hepatotoxicity is a recognized immune-mediated adverse event associated with PD-1 inhibitor therapy with limited real-world data on its prevalence. This study aimed to assess hepatotoxicity reporting...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155564",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Stepan V Pulukchu, MD",
      "presenter": "Stepan V Pulukchu, MD",
      "authors": "Stepan V Pulukchu, MD 1 ; Sindhura Popuri 2 ; Bhaskar Gurram, PhD 1 ; M. Elyse Moore 1 ; Dauren Adilbay, MD, PhD 1",
      "normalized_authors": [
        "Stepan V Pulukchu",
        "Sindhura Popuri",
        "Bhaskar Gurram",
        "M. Elyse Moore",
        "Dauren Adilbay"
      ],
      "affiliations": [
        "Medical University of South Carolina",
        "NTR University of Health Sciences (NTRUHS)"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina",
        "NTR University of Health Sciences (NTRUHS)"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 537,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Stepan V Pulukchu, MD 1 ; Sindhura Popuri 2 ; Bhaskar Gurram, PhD 1 ; M. Elyse Moore 1 ; Dauren Adilbay, MD, PhD 1",
        "Affiliations": "1 Medical University of South Carolina; 2 NTR University of Health Sciences (NTRUHS)",
        "Abstract": "Pembrolizumab and nivolumab are PD-1 immune checkpoint inhibitors approved for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), with pembrolizumab recently approved in the neoadjuvant setting. Hepatotoxicity is a recognized immune-mediated adverse event associated with PD-1 inhibitor therapy with limited real-world data on its prevalence. This study aimed to assess hepatotoxicity reporting signals between pembrolizumab and nivolumab using the FDA Adverse Event Reporting System (FAERS). Using FAERS data from 2015–2025, reports listing pembrolizumab or nivolumab by generic name were extracted and deduplicated using unique FAERS case identifiers. A composite hepatotoxicity endpoint was defined using 13 MedDRA Preferred Terms, encompassing liver inflammation, transaminase elevation, hepatic failure, and drug-induced liver injury. Data processing and statistical analyses were performed in R (v4.5.2) with independent verification. For each agent, a 2×2 contingency table was constructed comparing reports of the drug of interest with the hepatotoxicity endpoint against all other drug–event combinations in the database, from which the reporting odds ratio (ROR) with 95% confidence interval (CI), proportional reporting ratio (PRR), and chi-square statistic were calculated. Death and life-threatening events reported in FAERS outcome fields were evaluated as severe outcomes among deduplicated hepatotoxicity cases. For descriptive analysis, reaction strings were separated into individual MedDRA Preferred Terms and grouped using keyword-based pattern matching to identify the most frequently reported hepatotoxicity diagnostic reactions for each drug. Immune-mediated hepatitis and autoimmune hepatitis were combined into a single immune-mediated hepatotoxicity category for descriptive analysis. Reporting frequency of hepatic failure was subsequently compared descriptively between the two agents. A total of 3,725 hepatotoxicity reports were identified for pembrolizumab and 4,038 for nivolumab. Disproportionality analysis demonstrated significant hepatotoxicity signals for both therapies compared with all other drugs in the FAERS database. Pembrolizumab was associated with a reporting odds ratio (ROR) of 6.86 (95% CI 6.64–7.09) and proportional reporting ratio (PRR) of 6.60 (χ² = 17,403.55), while nivolumab demonstrated an ROR of 7.39 (95% CI 7.16–7.63) and PRR of 7.09 (χ² = 20,716.86). Severe outcomes among hepatotoxicity cases included death in 726 (19.5%) pembrolizumab reports and 978 (24.2%) nivolumab reports, and life-threatening events in 354 (9.5%) and 535 (13.2%), respectively. Among pembrolizumab-associated hepatotoxicity reports, the most frequent reactions were hepatitis (936, 25.1%), immune-mediated hepatotoxicity (894, 24.0%), and drug-induced liver injury (364, 9.8%). Among nivolumab-associated reports, the most common reactions were immune-mediated hepatotoxicity (1124, 27.8%), hepatitis (915, 22.7%), and hepatic failure (371, 9.2%). The latter was reported more frequently with nivolumab than with pembrolizumab (275, 7.4%). Both PD-1 inhibitors showed hepatotoxicity signals in the FAERS database, with immune-mediated hepatotoxicity emerging as a prominent reported phenotype, particularly with nivolumab. Nivolumab also exhibited a modestly stronger disproportionality signal, a greater proportion of reported severe outcomes, and a higher frequency of hepatic failure, a clinically meaningful endpoint. These findings highlight important real-world signals. Causal inference is precluded by inherent limitations of spontaneous reporting systems, including underreporting, reporting bias, and confounding by concomitant therapies. Further studies using population-based datasets are warranted to better characterize the incidence and clinical risk of hepatotoxicity associated with PD-1 inhibitors. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Hepatotoxicity Associated With PD-1 Inhibitors: A Comparative Pharmacovigilance Study of Pembrolizumab and Nivolumab Using FAERS</span>. <u>Stepan V Pulukchu, MD</u><sup>1</sup>; Sindhura Popuri<sup>2</sup>; Bhaskar Gurram, PhD<sup>1</sup>; M. Elyse Moore<sup>1</sup>; Dauren Adilbay, MD, PhD<sup>1</sup>. <sup>1</sup>Medical University of South Carolina; <sup>2</sup>NTR University of Health Sciences (NTRUHS)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Pembrolizumab and nivolumab are PD-1 immune checkpoint inhibitors approved for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), with pembrolizumab recently approved in the neoadjuvant setting. Hepatotoxicity is a recognized immune-mediated adverse event associated with PD-1 inhibitor therapy with limited real-world data on its prevalence. This study aimed to assess hepatotoxicity reporting signals between pembrolizumab and nivolumab using the FDA Adverse Event Reporting System (FAERS).</p>\n\n<p>Using FAERS data from 2015–2025, reports listing pembrolizumab or nivolumab by generic name were extracted and deduplicated using unique FAERS case identifiers. A composite hepatotoxicity endpoint was defined using 13 MedDRA Preferred Terms, encompassing liver inflammation, transaminase elevation, hepatic failure, and drug-induced liver injury. Data processing and statistical analyses were performed in R (v4.5.2) with independent verification. For each agent, a 2×2 contingency table was constructed comparing reports of the drug of interest with the hepatotoxicity endpoint against all other drug–event combinations in the database, from which the reporting odds ratio (ROR) with 95% confidence interval (CI), proportional reporting ratio (PRR), and chi-square statistic were calculated. Death and life-threatening events reported in FAERS outcome fields were evaluated as severe outcomes among deduplicated hepatotoxicity cases. For descriptive analysis, reaction strings were separated into individual MedDRA Preferred Terms and grouped using keyword-based pattern matching to identify the most frequently reported hepatotoxicity diagnostic reactions for each drug. Immune-mediated hepatitis and autoimmune hepatitis were combined into a single immune-mediated hepatotoxicity category for descriptive analysis. Reporting frequency of hepatic failure was subsequently compared descriptively between the two agents.</p>\n\n<p>A total of 3,725 hepatotoxicity reports were identified for pembrolizumab and 4,038 for nivolumab. Disproportionality analysis demonstrated significant hepatotoxicity signals for both therapies compared with all other drugs in the FAERS database. Pembrolizumab was associated with a reporting odds ratio (ROR) of 6.86 (95% CI 6.64–7.09) and proportional reporting ratio (PRR) of 6.60 (χ² = 17,403.55), while nivolumab demonstrated an ROR of 7.39 (95% CI 7.16–7.63) and PRR of 7.09 (χ² = 20,716.86).</p>\n\n<p>Severe outcomes among hepatotoxicity cases included death in 726 (19.5%) pembrolizumab reports and 978 (24.2%) nivolumab reports, and life-threatening events in 354 (9.5%) and 535 (13.2%), respectively. </p>\n\n<p>Among pembrolizumab-associated hepatotoxicity reports, the most frequent reactions were hepatitis (936, 25.1%), immune-mediated hepatotoxicity (894, 24.0%), and drug-induced liver injury (364, 9.8%). Among nivolumab-associated reports, the most common reactions were immune-mediated hepatotoxicity (1124, 27.8%), hepatitis (915, 22.7%), and hepatic failure (371, 9.2%). The latter was reported more frequently with nivolumab than with pembrolizumab (275, 7.4%).</p>\n\n<p>Both PD-1 inhibitors showed hepatotoxicity signals in the FAERS database, with immune-mediated hepatotoxicity emerging as a prominent reported phenotype, particularly with nivolumab. Nivolumab also exhibited a modestly stronger disproportionality signal, a greater proportion of reported severe outcomes, and a higher frequency of hepatic failure, a clinically meaningful endpoint. These findings highlight important real-world signals. Causal inference is precluded by inherent limitations of spontaneous reporting systems, including underreporting, reporting bias, and confounding by concomitant therapies. Further studies using population-based datasets are warranted to better characterize the incidence and clinical risk of hepatotoxicity associated with PD-1 inhibitors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155564--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S106",
      "content_id": "155464",
      "abstract_number": "S106",
      "poster_number": "",
      "title": "Pre-operative factors associated with survival after salvage surgery for recurrent or second primary head and neck cancers",
      "summary": "Salvage surgery remains a viable curative option for recurrent or second primary head and neck malignancies. Patient selection remains challenging with stage of disease at initial cancer presentation the only pre-operative factor associated with OS and DFS after salvage surgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155464",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260121",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eoin F Cleere, MRCSIENT, MCh",
      "presenter": "Eoin F Cleere, MRCSIENT, MCh",
      "authors": "Eoin F Cleere, MRCSIENT, MCh ; Mar Cotter; Patrick Sheahan, MD",
      "normalized_authors": [
        "Eoin F Cleere, MRCSIENT, MCh",
        "Mar Cotter",
        "Patrick Sheahan"
      ],
      "affiliations": [
        "South Infirmary Victoria University Hospital, Cork, Ireland"
      ],
      "normalized_institutions": [
        "South Infirmary Victoria University Hospital, Cork, Ireland"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 529,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Eoin F Cleere, MRCSIENT, MCh ; Mar Cotter; Patrick Sheahan, MD",
        "Affiliations": "South Infirmary Victoria University Hospital, Cork, Ireland",
        "Background": "Unfortunately as many as 50% of patients with head and neck cancer will either develop recurrent disease or a second head and neck malignancy. Despite therapeutic advances, salvage surgical resection remains the main potentially curative treatment modality for these patients. Due to tissue damage and changes resulting from prior head and neck cancer treatment, salvage surgical resection is technically more challenging as well as being associated with significantly increased morbidity and functional implications. Thus, appropriate patient selection is critical prior to considering salvage surgery as a therapeutic option. Accordingly, the present study aimed to analyse pre-salvage surgery factors that were associated with survival after salvage surgery.",
        "Methods": "A retrospective analysis of an institutional head and neck cancer database between 2010 – 2024 was performed. Patients who underwent surgical resection for a squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx were included if they had undergone previous treatment for a head and neck cancer. Multivariable cox-regression analysis was performed to analyse factors associated with overall survival (OS) and disease-free survival (DFS) after salvage surgery with Hazard Ratios (HRs) and corresponding 95% Confidence Intervals (CIs) calculated.",
        "Results": "A total of 172 patients were included with a mean age of 63.0 years (95% CI 61.1 – 64.9 years). This included 122 males (70.9%) and 50 females (29.1%). Sixty-three (36.6%) patients had oral cavity primary tumour, 19 (11.1%) had an oropharyngeal primary tumour, 70 (40.7%) had a laryngeal primary tumour and 20 (11.6%) had a hypopharyngeal primary tumour. Primary treatment was surgery alone in 45 patients (26.2%), radiotherapy ± chemotherapy in 104 patients (60.5%) and combined surgery with adjuvant radiotherapy ± chemotherapy in 23 patients (13.4%). Median time to salvage surgery was 11 months (95% CI 9 – 13 months).",
        "Abstract": "The 2 year and 5 year OS was 63.7% (95% CI 55.8 – 70.5%) and 42.5% (95% CI 34.4% - 50.4%) respectively. On univariable analysis, stage III/IV disease at primary presentation, cT3/4 disease at salvage presentation, cN+ disease at time of salvage and stage III/IV disease at time of salvage surgery were significantly associated with worse OS. Age >70 years, sex, primary tumour site, previous treatment strategy, previous neck dissection and recurrent vs secondary disease were not significantly associated with OS. Only stage III/IV disease at initial presentation was significantly associated with OS after salvage surgery on multivariable analysis (HR 2.54, 95% CI 1.45 – 4.43, p=0.001). The 2 year and 5 year DFS was 50.4% (95% CI 42.5 – 57.7%) and 36.4% (95% CI 28.7 – 44%) respectively. On univariable analysis stage III/IV disease at initial presentation and cN+ disease were associated with DFS. Only stage III/IV disease at initial presentation was associated with DFS on multivariable analysis (HR 2.05, 95% CI 1.29 – 3.26, p=0.002) View in Agenda and Add to Schedule",
        "Conclusions": "Salvage surgery remains a viable curative option for recurrent or second primary head and neck malignancies. Patient selection remains challenging with stage of disease at initial cancer presentation the only pre-operative factor associated with OS and DFS after salvage surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pre-operative factors associated with survival after salvage surgery for recurrent or second primary head and neck cancers</span>. <u>Eoin F Cleere, MRCSIENT, MCh</u>; Mar Cotter; Patrick Sheahan, MD. South Infirmary Victoria University Hospital, Cork, Ireland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Unfortunately as many as 50% of patients with head and neck cancer will either develop recurrent disease or a second head and neck malignancy. Despite therapeutic advances, salvage surgical resection remains the main potentially curative treatment modality for these patients. Due to tissue damage and changes resulting from prior head and neck cancer treatment, salvage surgical resection is technically more challenging as well as being associated with significantly increased morbidity and functional implications. Thus, appropriate patient selection is critical prior to considering salvage surgery as a therapeutic option. Accordingly, the present study aimed to analyse pre-salvage surgery factors that were associated with survival after salvage surgery.</p>\n\n<p><strong>Methods</strong>: A retrospective analysis of an institutional head and neck cancer database between 2010 – 2024 was performed. Patients who underwent surgical resection for a squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx were included if they had undergone previous treatment for a head and neck cancer. Multivariable cox-regression analysis was performed to analyse factors associated with overall survival (OS) and disease-free survival (DFS) after salvage surgery with Hazard Ratios (HRs) and corresponding 95% Confidence Intervals (CIs) calculated.</p>\n\n<p><strong>Results:</strong> A total of 172 patients were included with a mean age of 63.0 years (95% CI 61.1 – 64.9 years). This included 122 males (70.9%) and 50 females (29.1%). Sixty-three (36.6%) patients had oral cavity primary tumour, 19 (11.1%) had an oropharyngeal primary tumour, 70 (40.7%) had a laryngeal primary tumour and 20 (11.6%) had a hypopharyngeal primary tumour. Primary treatment was surgery alone in 45 patients (26.2%), radiotherapy ± chemotherapy in 104 patients (60.5%) and combined surgery with adjuvant radiotherapy ± chemotherapy in 23 patients (13.4%). Median time to salvage surgery was 11 months (95% CI 9 – 13 months).</p>\n\n<p>The 2 year and 5 year OS was 63.7% (95% CI 55.8 – 70.5%) and 42.5% (95% CI 34.4% - 50.4%) respectively. On univariable analysis, stage III/IV disease at primary presentation, cT3/4 disease at salvage presentation, cN+ disease at time of salvage and stage III/IV disease at time of salvage surgery were significantly associated with worse OS. Age >70 years, sex, primary tumour site, previous treatment strategy, previous neck dissection and recurrent vs secondary disease were not significantly associated with OS. Only stage III/IV disease at initial presentation was significantly associated with OS after salvage surgery on multivariable analysis (HR 2.54, 95% CI 1.45 – 4.43, p=0.001).</p>\n\n<p>The 2 year and 5 year DFS was 50.4% (95% CI 42.5 – 57.7%) and 36.4% (95% CI 28.7 – 44%) respectively. On univariable analysis stage III/IV disease at initial presentation and cN+ disease were associated with DFS. Only stage III/IV disease at initial presentation was associated with DFS on multivariable analysis (HR 2.05, 95% CI 1.29 – 3.26, p=0.002)</p>\n\n<p><strong>Conclusions</strong>: Salvage surgery remains a viable curative option for recurrent or second primary head and neck malignancies. Patient selection remains challenging with stage of disease at initial cancer presentation the only pre-operative factor associated with OS and DFS after salvage surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155464--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260121' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S108",
      "content_id": "153273",
      "abstract_number": "S108",
      "poster_number": "",
      "title": "Long-Term Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Salivary Gland Cancer",
      "summary": "Larotrectinib demonstrates rapid and durable responses, extended survival, clinical benefit, and a favorable safety profile in patients with advanced TRK fusion salivary gland cancer. These results support the wider adoption of NGS panels that include NTRK gene fusions in patients with salivary gland cancer to identify those who may benefit from targeted treatment.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153273",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Bauman",
      "presenter": "Jessica Bauman",
      "authors": "Jessica Bauman 1 ; Makoto Tahara 2 ; Changsong Qi 3 ; Christina Baik 4 ; Marcia S Brose 5 ; John Deeken 6 ; Lauriane Eberst 7 ; Jill Gilbert 8 ; Juneko Grilley-Olson 9 ; Jennifer M Johnson 5 ; Ray McDermott 10 ; Tejas Patil 11 ; Luis Raez 12 ; Domnita-Ileana Burcoveanu 13 ; Chiara E Mussi 14 ; Kelly Guiver 15 ; Natascha Neu 16 ; Shunji Takahashi 17 ; Alexander Drilon 18 ; David S Hong 19",
      "normalized_authors": [
        "Jessica Bauman",
        "Makoto Tahara",
        "Changsong Qi",
        "Christina Baik",
        "Marcia S Brose",
        "John Deeken",
        "Lauriane Eberst",
        "Jill Gilbert",
        "Juneko Grilley-Olson",
        "Jennifer M Johnson",
        "Ray McDermott",
        "Tejas Patil",
        "Luis Raez",
        "Domnita-Ileana Burcoveanu",
        "Chiara E Mussi",
        "Kelly Guiver",
        "Natascha Neu",
        "Shunji Takahashi",
        "Alexander Drilon",
        "David S Hong"
      ],
      "affiliations": [
        "Fox Chase Cancer Center, Philadelphia, PA, USA",
        "National Cancer Center Hospital East, Kashiwa, Japan",
        "Peking University Cancer Hospital & Institute, Beijing, China",
        "University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA",
        "Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Inova Schar Cancer Institute, Fairfax, VA, USA",
        "Institut de Cancérologie de Strasbourg Europe, Strasbourg, France",
        "Vanderbilt University, Nashville, TN, USA",
        "Duke Cancer Institute, Duke University, Durham, NC, USA",
        "St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland",
        "University of Colorado, Denver, Aurora, CO, USA",
        "Memorial Cancer Institute, Florida International University, Miami, FL, USA",
        "Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland",
        "Bayer S.p.A., Milan, Italy",
        "Bayer Pharmaceuticals, Reading, UK",
        "Chrestos GmbH, Essen, Germany",
        "Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan",
        "Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA",
        "The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Fox Chase Cancer Center, Philadelphia, PA, USA",
        "National Cancer Center Hospital East, Kashiwa, Japan",
        "Peking University Cancer Hospital & Institute, Beijing, China",
        "University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA",
        "Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Inova Schar Cancer Institute, Fairfax, VA, USA",
        "Institut de Cancérologie de Strasbourg Europe, Strasbourg, France",
        "Vanderbilt University, Nashville, TN, USA",
        "Duke Cancer Institute, Duke University, Durham, NC, USA",
        "St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland",
        "University of Colorado, Denver, Aurora, CO, USA",
        "Memorial Cancer Institute, Florida International University, Miami, FL, USA",
        "Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland",
        "Bayer S.p.A., Milan, Italy",
        "Bayer Pharmaceuticals, Reading, UK",
        "Chrestos GmbH, Essen, Germany",
        "Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan",
        "Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA",
        "The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jessica Bauman 1 ; Makoto Tahara 2 ; Changsong Qi 3 ; Christina Baik 4 ; Marcia S Brose 5 ; John Deeken 6 ; Lauriane Eberst 7 ; Jill Gilbert 8 ; Juneko Grilley-Olson 9 ; Jennifer M Johnson 5 ; Ray McDermott 10 ; Tejas Patil 11 ; Luis Raez 12 ; Domnita-Ileana Burcoveanu 13 ; Chiara E Mussi 14 ; Kelly Guiver 15 ; Natascha Neu 16 ; Shunji Takahashi 17 ; Alexander Drilon 18 ; David S Hong 19",
        "Affiliations": "1 Fox Chase Cancer Center, Philadelphia, PA, USA; 2 National Cancer Center Hospital East, Kashiwa, Japan; 3 Peking University Cancer Hospital & Institute, Beijing, China; 4 University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA; 5 Thomas Jefferson University Hospital, Philadelphia, PA, USA; 6 Inova Schar Cancer Institute, Fairfax, VA, USA; 7 Institut de Cancérologie de Strasbourg Europe, Strasbourg, France; 8 Vanderbilt University, Nashville, TN, USA; 9 Duke Cancer Institute, Duke University, Durham, NC, USA; 10 St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland; 11 University of Colorado, Denver, Aurora, CO, USA; 12 Memorial Cancer Institute, Florida International University, Miami, FL, USA; 13 Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland; 14 Bayer S.p.A., Milan, Italy; 15 Bayer Pharmaceuticals, Reading, UK; 16 Chrestos GmbH, Essen, Germany; 17 Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; 18 Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; 19 The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Introduction": "NTRK gene fusions are oncogenic drivers in various tumor types, including salivary gland cancer. Larotrectinib is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumor-agnostic use in patients with TRK fusion cancer based on a robust and durable objective response rate in patients with various cancers. Here, we report long-term efficacy and safety data specifically in patients with TRK fusion salivary gland cancer treated with larotrectinib.",
        "Methods": "Patients with TRK fusion salivary gland cancer enrolled in 2 larotrectinib clinical trials (NCT02122913 and NCT02576431 [NAVIGATE]) were included. Larotrectinib was administered at 100 mg twice daily in most patients; 1 patient received 150 mg twice daily. Responses were independent review committee-assessed per Response Evaluation Criteria in Solid Tumors version 1.1. The data cutoff was July 20, 2024.",
        "Results": "At data cutoff, 27 patients with salivary gland cancer and measurable disease were enrolled (secretory n=16, 59%; non-secretory n=11, 41%). The majority of patients (23 [85%]) had metastatic disease at baseline; no patients had known CNS metastases at baseline. The median age was 58 years (range 28–80). Eighteen patients (67%) were systemic treatment-naïve in the metastatic/unresectable setting and 4 (15%) patients had received 2 or more prior therapies. All patients had an ETV6 :: NTRK3 gene fusion, mostly identified by next-generation sequencing (NGS). The overall response rate (ORR) was 85% (95% confidence interval [CI] 66–96), including 9 (33%) complete responses, 14 (52%) partial responses, 2 (7%) stable disease, and 2 (7%) progressive disease. Responses were seen in both secretory and non-secretory tumor subtypes (ORR, 81% [95% CI 54–96] and 91% [95% CI 59–100], respectively). The median duration of treatment was 39 months (range 1–86+). Median time to response was 1.8 months (range 1.0–16.5). At data cutoff, 7 (26%) patients remained on treatment. Median duration of response (DoR), progression-free survival (PFS), and overall survival (OS) were 59 months (95% CI 41–not estimable [NE]), 61 months (95% CI 34–NE), and not reached (95% CI 43−NE), respectively, at median follow-ups of 48, 52, and 64 months. The 4-year rates for DoR, PFS, and OS were 64% (95% CI 43–86), 63% (95% CI 44–83), and 71% (95% CI 53–89), respectively. Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in 7 (26%) patients (alanine aminotransferase increased in 2 patients; alanine aminotransferase and aspartate aminotransferase increased in 1 patient; and dizziness, aspartate aminotransferase increased, hepatic function abnormal, and hypophosphatemia were each observed in 1 patient). No patients discontinued or died due to TRAEs; TRAEs led to dose modification (including hold/reduction and withdrawal) in 12 (44%) patients.",
        "Conclusions": "Larotrectinib demonstrates rapid and durable responses, extended survival, clinical benefit, and a favorable safety profile in patients with advanced TRK fusion salivary gland cancer. These results support the wider adoption of NGS panels that include NTRK gene fusions in patients with salivary gland cancer to identify those who may benefit from targeted treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Long-Term Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Salivary Gland Cancer</span>. <u>Jessica Bauman</u><sup>1</sup>; Makoto Tahara<sup>2</sup>; Changsong Qi<sup>3</sup>; Christina Baik<sup>4</sup>; Marcia S Brose<sup>5</sup>; John Deeken<sup>6</sup>; Lauriane Eberst<sup>7</sup>; Jill Gilbert<sup>8</sup>; Juneko Grilley-Olson<sup>9</sup>; Jennifer M Johnson<sup>5</sup>; Ray McDermott<sup>10</sup>; Tejas Patil<sup>11</sup>; Luis Raez<sup>12</sup>; Domnita-Ileana Burcoveanu<sup>13</sup>; Chiara E Mussi<sup>14</sup>; Kelly Guiver<sup>15</sup>; Natascha Neu<sup>16</sup>; Shunji Takahashi<sup>17</sup>; Alexander Drilon<sup>18</sup>; David S Hong<sup>19</sup>. <sup>1</sup>Fox Chase Cancer Center, Philadelphia, PA, USA; <sup>2</sup>National Cancer Center Hospital East, Kashiwa, Japan; <sup>3</sup>Peking University Cancer Hospital & Institute, Beijing, China; <sup>4</sup>University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA; <sup>5</sup>Thomas Jefferson University Hospital, Philadelphia, PA, USA; <sup>6</sup>Inova Schar Cancer Institute, Fairfax, VA, USA; <sup>7</sup>Institut de Cancérologie de Strasbourg Europe, Strasbourg, France; <sup>8</sup>Vanderbilt University, Nashville, TN, USA; <sup>9</sup>Duke Cancer Institute, Duke University, Durham, NC, USA; <sup>10</sup>St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland; <sup>11</sup>University of Colorado, Denver, Aurora, CO, USA; <sup>12</sup>Memorial Cancer Institute, Florida International University, Miami, FL, USA; <sup>13</sup>Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland; <sup>14</sup>Bayer S.p.A., Milan, Italy; <sup>15</sup>Bayer Pharmaceuticals, Reading, UK; <sup>16</sup>Chrestos GmbH, Essen, Germany; <sup>17</sup>Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; <sup>18</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; <sup>19</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> <em>NTRK </em>gene fusions are oncogenic drivers in various tumor types, including salivary gland cancer. Larotrectinib is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumor-agnostic use in patients with TRK fusion cancer based on a robust and durable objective response rate in patients with various cancers. Here, we report long-term efficacy and safety data specifically in patients with TRK fusion salivary gland cancer treated with larotrectinib.</p>\n\n<p><strong>Methods: </strong>Patients with TRK fusion salivary gland cancer enrolled in 2 larotrectinib clinical trials (NCT02122913 and NCT02576431 [NAVIGATE]) were included. Larotrectinib was administered at 100 mg twice daily in most patients; 1 patient received 150 mg twice daily. Responses were independent review committee-assessed per Response Evaluation Criteria in Solid Tumors version 1.1. The data cutoff was July 20, 2024.</p>\n\n<p><strong>Results: </strong>At data cutoff, 27 patients with salivary gland cancer and measurable disease were enrolled (secretory n=16, 59%; non-secretory n=11, 41%). The majority of patients (23 [85%]) had metastatic disease at baseline; no patients had known CNS metastases at baseline. The median age was 58 years (range 28–80). Eighteen patients (67%) were systemic treatment-naïve in the metastatic/unresectable setting and 4 (15%) patients had received 2 or more prior therapies. All patients had an <em>ETV6</em>::<em>NTRK3 </em>gene fusion, mostly identified by next-generation sequencing (NGS). The overall response rate (ORR) was 85% (95% confidence interval [CI] 66–96), including 9 (33%) complete responses, 14 (52%) partial responses, 2 (7%) stable disease, and 2 (7%) progressive disease. Responses were seen in both secretory and non-secretory tumor subtypes (ORR, 81% [95% CI 54–96] and 91% [95% CI 59–100], respectively). The median duration of treatment was 39 months (range 1–86+). Median time to response was 1.8 months (range 1.0–16.5). At data cutoff, 7 (26%) patients remained on treatment. Median duration of response (DoR), progression-free survival (PFS), and overall survival (OS) were 59 months (95% CI 41–not estimable [NE]), 61 months (95% CI 34–NE), and not reached (95% CI 43−NE), respectively, at median follow-ups of 48, 52, and 64 months. The 4-year rates for DoR, PFS, and OS were 64% (95% CI 43–86), 63% (95% CI 44–83), and 71% (95% CI 53–89), respectively. Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in 7 (26%) patients (alanine aminotransferase increased in 2 patients; alanine aminotransferase and aspartate aminotransferase increased in 1 patient; and dizziness, aspartate aminotransferase increased, hepatic function abnormal, and hypophosphatemia were each observed in 1 patient). No patients discontinued or died due to TRAEs; TRAEs led to dose modification (including hold/reduction and withdrawal) in 12 (44%) patients.</p>\n\n<p><strong>Conclusions:</strong> Larotrectinib demonstrates rapid and durable responses, extended survival, clinical benefit, and a favorable safety profile in patients with advanced TRK fusion salivary gland cancer. These results support the wider adoption of NGS panels that include <em>NTRK</em> gene fusions in patients with salivary gland cancer to identify those who may benefit from targeted treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153273--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S109",
      "content_id": "154021",
      "abstract_number": "S109",
      "poster_number": "",
      "title": "Role of Post-Operative Radiation in Patients with WHO Low-Risk Salivary Gland Cancer with Close Margins",
      "summary": "In this multi-center retrospective cohort study of surgically treated salivary gland cancers, we found that patients with close resection margins and WHO defined low-risk histology who were managed with observation, had comparable outcomes to those who received PORT. These findings suggest that observation may be a safe postoperative strategy for patients with close margins in low-risk salivary gland tumors.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154021",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma Finnegan",
      "presenter": "Emma Finnegan",
      "authors": "Emma Finnegan 1 ; Hadar Gez Reder, MD 1 ; Conall W Fitzgerald, MB, BCh 1 ; Lilian Boe, PhD 2 ; Chris Vugt 3 ; Matthijs Valstar, PhD 3 ; Ludi Smeele, MD 3 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
      "normalized_authors": [
        "Emma Finnegan",
        "Hadar Gez Reder",
        "Conall W Fitzgerald, MB, BCh",
        "Lilian Boe",
        "Chris Vugt",
        "Matthijs Valstar",
        "Ludi Smeele",
        "Snehal G Patel",
        "Ian Ganly"
      ],
      "affiliations": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands"
      ],
      "normalized_institutions": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 324,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emma Finnegan 1 ; Hadar Gez Reder, MD 1 ; Conall W Fitzgerald, MB, BCh 1 ; Lilian Boe, PhD 2 ; Chris Vugt 3 ; Matthijs Valstar, PhD 3 ; Ludi Smeele, MD 3 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
        "Affiliations": "1 Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3 Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands",
        "Introduction": "The role of postoperative radiation therapy (PORT) in patients with close surgical margins and low-risk salivary gland cancers remains controversial, with limited consensus across international guidelines. This study aims to present the largest multi-center cohort of patients with WHO low-risk salivary gland tumors and close margins, to delineate the necessity of PORT in this distinct patient population.",
        "Methods": "A multi-institutional database of 1,787 patients with salivary gland cancer treated with primary surgery was reviewed. This comprised patients from institutions in the United States, Netherlands and Spain. From this, 294 patients with WHO low-risk salivary gland cancer and close resection margins were identified. The oncologic outcome of interest was loco-regional recurrence-free survival (LRRFS). Univariable, multivariable and Kaplan Meier analysis stratified by the use of PORT were performed.",
        "Results": "Of 294 patients meeting inclusion criteria, median age (IQR) from the overall cohort was 56 years (42, 67). 180 patients were male (61%). The mean follow-up time was 52.7 months (SD 50.5). Most patients had early T stage tumors (pT1: 62%, n = 183; pT2: 25%, n = 74), and N0/Nx (96%, n = 183) disease. The most common histological diagnosis was mucoepidermoid carcinoma (46%, n = 136). 163 (55%) patients had major salivary gland cancer. In total, 92 patients received PORT, while 202 patients underwent observation (68.7%). PORT was not significant on multivariable analysis for LRRFS (HR 0.89; 95% CI 0.20-3.99; p = 0.875). On Kaplan Meier analysis, there was no difference in LRFS (5-year LRFS 93.9% for PORT vs 90.4% with observation, p = 0.18).",
        "Conclusion": "In this multi-center retrospective cohort study of surgically treated salivary gland cancers, we found that patients with close resection margins and WHO defined low-risk histology who were managed with observation, had comparable outcomes to those who received PORT. These findings suggest that observation may be a safe postoperative strategy for patients with close margins in low-risk salivary gland tumors.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Role of Post-Operative Radiation in Patients with WHO Low-Risk Salivary Gland Cancer with Close Margins</span>. <u>Emma Finnegan</u><sup>1</sup>; Hadar Gez Reder, MD<sup>1</sup>; Conall W Fitzgerald, MB, BCh<sup>1</sup>; Lilian Boe, PhD<sup>2</sup>; Chris Vugt<sup>3</sup>; Matthijs Valstar, PhD<sup>3</sup>; Ludi Smeele, MD<sup>3</sup>; Snehal G Patel, MD<sup>1</sup>; Ian Ganly, MD, PhD<sup>1</sup>. <sup>1</sup>Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The role of postoperative radiation therapy (PORT) in patients with close surgical margins and low-risk salivary gland cancers remains controversial, with limited consensus across international guidelines. This study aims to present the largest multi-center cohort of patients with WHO low-risk salivary gland tumors and close margins, to delineate the necessity of PORT in this distinct patient population. </p>\n\n<p><strong>Methods:  </strong>A multi-institutional database of 1,787 patients with salivary gland cancer treated with primary surgery was reviewed. This comprised patients from institutions in the United States, Netherlands and Spain. From this, 294 patients with WHO low-risk salivary gland cancer and close resection margins were identified. The oncologic outcome of interest was loco-regional recurrence-free survival (LRRFS). Univariable, multivariable and Kaplan Meier analysis stratified by the use of PORT were performed.  </p>\n\n<p><strong>Results: </strong>Of 294 patients meeting inclusion criteria, median age (IQR) from the overall cohort was 56 years (42, 67). 180 patients were male (61%). The mean follow-up time was 52.7 months (SD 50.5). Most patients had early T stage tumors (pT1: 62%, n = 183; pT2: 25%, n = 74), and N0/Nx (96%, n = 183) disease. The most common histological diagnosis was mucoepidermoid carcinoma (46%, n = 136). 163 (55%) patients had major salivary gland cancer. In total, 92 patients received PORT, while 202 patients underwent observation (68.7%). PORT was not significant on multivariable analysis for LRRFS (HR 0.89; 95% CI 0.20-3.99; p = 0.875). On Kaplan Meier analysis, there was no difference in LRFS (5-year LRFS 93.9% for PORT vs 90.4% with observation, p = 0.18).   </p>\n\n<p><strong>Conclusion: </strong>In this multi-center retrospective cohort study of surgically treated salivary gland cancers, we found that patients with close resection margins and WHO defined low-risk histology who were managed with observation, had comparable outcomes to those who received PORT. These findings suggest that observation may be a safe postoperative strategy for patients with close margins in low-risk salivary gland tumors. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154021--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S110",
      "content_id": "154454",
      "abstract_number": "S110",
      "poster_number": "",
      "title": "Unravelling Androgen Receptor and HER2 Signaling in Salivary Duct Carcinoma",
      "summary": "These novel SDC models and transcriptomic analyses demonstrate complex AR-HER2 crosstalk, with AR signaling dampening MAPK activation in a HER2-dependent manner. We show that antiandrogen therapy triggers compensatory MAPK signaling limiting efficacy of antiandrogen therapy in SDC. The identification of an SDC-specific AR signaling gene set provides important insight into SDC biology. T-Dxd shows efficacy in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154454",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marcel Mayer, MD, MHBA",
      "presenter": "Marcel Mayer, MD, MHBA",
      "authors": "Marcel Mayer, MD, MHBA 1 ; Manu Prasad, PhD 1 ; Louis Jansen, MD 1 ; Fengshen Kuo, PhD 1 ; Elisa de Stanchina, PhD 1 ; Qing Chang, PhD 1 ; Xingzhu Deng, PhD 1 ; Gopika Pillai 1 ; Alex T Cheng 1 ; Siqi Chen, MD, PhD 1 ; Swati Jain, PhD 1 ; Joris Vos, MD 1 ; Jens P Klussmann, MD 2 ; Nora Katabi, MD 1 ; Richard J Wong, MD 1 ; Luc GT Morris, MD, MSc 1 ; Alan L Ho, MD, PhD 1",
      "normalized_authors": [
        "Marcel Mayer, MHBA",
        "Manu Prasad",
        "Louis Jansen",
        "Fengshen Kuo",
        "Elisa de Stanchina",
        "Qing Chang",
        "Xingzhu Deng",
        "Gopika Pillai",
        "Alex T Cheng",
        "Siqi Chen",
        "Swati Jain",
        "Joris Vos",
        "Jens P Klussmann",
        "Nora Katabi",
        "Richard J Wong",
        "Luc GT Morris",
        "Alan L Ho"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center",
        "University Hospital Cologne, Germany"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center",
        "University Hospital Cologne, Germany"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 274,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Marcel Mayer, MD, MHBA 1 ; Manu Prasad, PhD 1 ; Louis Jansen, MD 1 ; Fengshen Kuo, PhD 1 ; Elisa de Stanchina, PhD 1 ; Qing Chang, PhD 1 ; Xingzhu Deng, PhD 1 ; Gopika Pillai 1 ; Alex T Cheng 1 ; Siqi Chen, MD, PhD 1 ; Swati Jain, PhD 1 ; Joris Vos, MD 1 ; Jens P Klussmann, MD 2 ; Nora Katabi, MD 1 ; Richard J Wong, MD 1 ; Luc GT Morris, MD, MSc 1 ; Alan L Ho, MD, PhD 1",
        "Affiliations": "1 Memorial Sloan Kettering Cancer Center; 2 University Hospital Cologne, Germany",
        "Purpose": "Salivary duct carcinoma (SDC) is the most aggressive salivary gland carcinoma subtype. Despite frequent androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) overexpression, targeted therapies show limited efficacy. This study aimed to develop preclinical SDC models, understand SDC-specific AR/HER2 signaling, and assess novel targeted treatments.",
        "Methods": "We established androgen-response preclinical SDC models including patient-derived xenografts (PDX), isogenic cell lines, and organoids reflecting AR and HER2 biology. Functional assays assessed pathway activation, growth, and responses to androgen, antiandrogen, and HER2-targeted therapy in vitro and in vivo. Additionally, we used whole-transcriptome data from two independent cohorts, as well as spatial transcriptomics, to decipher SDC-specific AR signaling.",
        "Results": "We developed the first preclinical androgen-responsive models thereby showing the biological importance of AR signaling in SDC. We demonstrate that HER2 downstream activation is modulated by AKT and MAPK pathways. AR signaling suppresses MAPK activation in HER2-positive contexts and antiandrogen therapy upregulates MAPK signaling, indicating compensatory pathway activation. Whole-transcriptome and spatial transcriptomics analyses deciphered an SDC-specific AR signaling gene signature. Further, trastuzumab-deruxtecan (T-Dxd) significantly suppressed tumor growth in both HER2high and HER2low PDX models.",
        "Conclusion": "These novel SDC models and transcriptomic analyses demonstrate complex AR-HER2 crosstalk, with AR signaling dampening MAPK activation in a HER2-dependent manner. We show that antiandrogen therapy triggers compensatory MAPK signaling limiting efficacy of antiandrogen therapy in SDC. The identification of an SDC-specific AR signaling gene set provides important insight into SDC biology. T-Dxd shows efficacy in HER2high and HER2low SDC models and therapeutic approaches combining AR and MAPK signaling inhibition may be necessary to reach more prolonged response rates of targeted therapy in AR+/HER2+ SDC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Unravelling Androgen Receptor and HER2 Signaling in Salivary Duct Carcinoma</span>. <u>Marcel Mayer, MD, MHBA</u><sup>1</sup>; Manu Prasad, PhD<sup>1</sup>; Louis Jansen, MD<sup>1</sup>; Fengshen Kuo, PhD<sup>1</sup>; Elisa de Stanchina, PhD<sup>1</sup>; Qing Chang, PhD<sup>1</sup>; Xingzhu Deng, PhD<sup>1</sup>; Gopika Pillai<sup>1</sup>; Alex T Cheng<sup>1</sup>; Siqi Chen, MD, PhD<sup>1</sup>; Swati Jain, PhD<sup>1</sup>; Joris Vos, MD<sup>1</sup>; Jens P Klussmann, MD<sup>2</sup>; Nora Katabi, MD<sup>1</sup>; Richard J Wong, MD<sup>1</sup>; Luc GT Morris, MD, MSc<sup>1</sup>; Alan L Ho, MD, PhD<sup>1</sup>. <sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>University Hospital Cologne, Germany<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Salivary duct carcinoma (SDC) is the most aggressive salivary gland carcinoma subtype. Despite frequent androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) overexpression, targeted therapies show limited efficacy. This study aimed to develop preclinical SDC models, understand SDC-specific AR/HER2 signaling, and assess novel targeted treatments. </p>\n\n<p><strong>Methods:</strong> We established androgen-response preclinical SDC models including patient-derived xenografts (PDX), isogenic cell lines, and organoids reflecting AR and HER2 biology. Functional assays assessed pathway activation, growth, and responses to androgen, antiandrogen, and HER2-targeted therapy in vitro and in vivo. Additionally, we used whole-transcriptome data from two independent cohorts, as well as spatial transcriptomics, to decipher SDC-specific AR signaling. </p>\n\n<p><strong>Results: </strong>We developed the first preclinical androgen-responsive models thereby showing the biological importance of AR signaling in SDC. We demonstrate that HER2 downstream activation is modulated by AKT and MAPK pathways. AR signaling suppresses MAPK activation in HER2-positive contexts and antiandrogen therapy upregulates MAPK signaling, indicating compensatory pathway activation. Whole-transcriptome and spatial transcriptomics analyses deciphered an SDC-specific AR signaling gene signature. Further, trastuzumab-deruxtecan (T-Dxd) significantly suppressed tumor growth in both HER2high and HER2low PDX models. </p>\n\n<p><strong>Conclusion: </strong>These novel SDC models and transcriptomic analyses demonstrate complex AR-HER2 crosstalk, with AR signaling dampening MAPK activation in a HER2-dependent manner. We show that antiandrogen therapy triggers compensatory MAPK signaling limiting efficacy of antiandrogen therapy in SDC. The identification of an SDC-specific AR signaling gene set provides important insight into SDC biology. T-Dxd shows efficacy in HER2high and HER2low SDC models and therapeutic approaches combining AR and MAPK signaling inhibition may be necessary to reach more prolonged response rates of targeted therapy in AR+/HER2+ SDC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154454--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S111",
      "content_id": "153112",
      "abstract_number": "S111",
      "poster_number": "",
      "title": "Actionable genomic alterations in salivary gland carcinoma: Focus on BRCA and therapeutic opportunities.",
      "summary": "BRCA1/2 alterations in SGC are not uncommon, but canonical BRCA-type homologous recombination deficiency, indicated by clear LoF events and biallelic inactivation, appears infrequent. As a result, only a minority of SGC patients are expected to derive meaningful benefit from PARP inhibition. Further elucidation of homologous recombination deficiency in SGC may expand future therapeutic applications. The efficacy...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153112",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Go Ogawa, PhD, MD",
      "presenter": "Go Ogawa, PhD, MD",
      "authors": "Go Ogawa, PhD, MD 1 ; Tomoko Yamazaki, PhD, MD, DDS 2 ; Kazuo Yasuhara, MD 1",
      "normalized_authors": [
        "Go Ogawa",
        "Tomoko Yamazaki",
        "Kazuo Yasuhara"
      ],
      "affiliations": [
        "Teikyo University Hospital",
        "Saitama Medical University International Medical Center"
      ],
      "normalized_institutions": [
        "Teikyo University Hospital",
        "Saitama Medical University International Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 349,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Go Ogawa, PhD, MD 1 ; Tomoko Yamazaki, PhD, MD, DDS 2 ; Kazuo Yasuhara, MD 1",
        "Affiliations": "1 Teikyo University Hospital; 2 Saitama Medical University International Medical Center",
        "Background": "Salivary gland carcinoma (SGC) is rare and has diverse histologic subtypes. Recently, targeted therapies, such as HER2- and NTRK-directed agents, have improved outcomes in selected subgroups. BRCA1/2 are key homologous recombination repair genes and major predisposition genes for hereditary breast and ovarian cancer; PARP inhibitors are now approved in several countries for BRCA-mutated breast, ovarian, pancreatic, and prostate cancers. An epidemiologic association between parotid gland tumors and breast cancer has been suggested, but the prevalence and clinical relevance of BRCA alterations in SGC remain unclear.",
        "Methods": "Genomic and clinical data from AACR Project GENIE v18 were analyzed. SGC cases were identified using CANCER_TYPE and CANCER_TYPE_DETAILED. Among 1129 patients (1235 tumor samples), somatic mutation records were available for 988 samples (897 patients), and copy-number alteration (CNA) data for 748 samples. BRCA1/2 variants were extracted from the data_mutations_extended file. High-confidence loss-of-function (LoF) events were defined as truncating mutations (e.g., nonsense, frameshift) and/or deep deletions (CNA = −2) in BRCA1/2. The prevalence and spectrum of BRCA alterations were evaluated across histologic subtypes.",
        "Results": "BRCA1/2 alterations of any class were identified in 58 of 897 SGC patients (6.5%), a prevalence comparable to pancreatic (6.0%) and prostate cancers (7.4%) and only modestly lower than in breast (8.6%) and ovarian cancers (14.7%). BRCA mutations were observed across several histologic subtypes of SGC. High-confidence BRCA1/2 LoF events were rare, occurring in 8 of 897 patients (0.9%), including seven tumors with truncating mutations and one tumor with BRCA2 deep deletion (CNA = −2) without a detectable BRCA sequence variant. CNA data showed that BRCA1/2 were mostly copy-number neutral in BRCA-altered SGC.",
        "Conclusion": "BRCA1/2 alterations in SGC are not uncommon, but canonical BRCA-type homologous recombination deficiency, indicated by clear LoF events and biallelic inactivation, appears infrequent. As a result, only a minority of SGC patients are expected to derive meaningful benefit from PARP inhibition. Further elucidation of homologous recombination deficiency in SGC may expand future therapeutic applications. The efficacy and clinical significance of PARP inhibition in SGC remain to be explored.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Actionable genomic alterations in salivary gland carcinoma: Focus on BRCA and therapeutic opportunities.</span>. <u>Go Ogawa, PhD, MD</u><sup>1</sup>; Tomoko Yamazaki, PhD, MD, DDS<sup>2</sup>; Kazuo Yasuhara, MD<sup>1</sup>. <sup>1</sup>Teikyo University Hospital; <sup>2</sup>Saitama Medical University International Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salivary gland carcinoma (SGC) is rare and has diverse histologic subtypes. Recently, targeted therapies, such as HER2- and NTRK-directed agents, have improved outcomes in selected subgroups. BRCA1/2 are key homologous recombination repair genes and major predisposition genes for hereditary breast and ovarian cancer; PARP inhibitors are now approved in several countries for BRCA-mutated breast, ovarian, pancreatic, and prostate cancers. An epidemiologic association between parotid gland tumors and breast cancer has been suggested, but the prevalence and clinical relevance of BRCA alterations in SGC remain unclear.</p>\n\n<p><strong>Methods: </strong>Genomic and clinical data from AACR Project GENIE v18 were analyzed. SGC cases were identified using CANCER_TYPE and CANCER_TYPE_DETAILED. Among 1129 patients (1235 tumor samples), somatic mutation records were available for 988 samples (897 patients), and copy-number alteration (CNA) data for 748 samples. BRCA1/2 variants were extracted from the data_mutations_extended file. High-confidence loss-of-function (LoF) events were defined as truncating mutations (e.g., nonsense, frameshift) and/or deep deletions (CNA = −2) in BRCA1/2. The prevalence and spectrum of BRCA alterations were evaluated across histologic subtypes.</p>\n\n<p><strong>Results: </strong>BRCA1/2 alterations of any class were identified in 58 of 897 SGC patients (6.5%), a prevalence comparable to pancreatic (6.0%) and prostate cancers (7.4%) and only modestly lower than in breast (8.6%) and ovarian cancers (14.7%). BRCA mutations were observed across several histologic subtypes of SGC. High-confidence BRCA1/2 LoF events were rare, occurring in 8 of 897 patients (0.9%), including seven tumors with truncating mutations and one tumor with BRCA2 deep deletion (CNA = −2) without a detectable BRCA sequence variant. CNA data showed that BRCA1/2 were mostly copy-number neutral in BRCA-altered SGC.</p>\n\n<p><strong>Conclusion: </strong>BRCA1/2 alterations in SGC are not uncommon, but canonical BRCA-type homologous recombination deficiency, indicated by clear LoF events and biallelic inactivation, appears infrequent. As a result, only a minority of SGC patients are expected to derive meaningful benefit from PARP inhibition. Further elucidation of homologous recombination deficiency in SGC may expand future therapeutic applications. The efficacy and clinical significance of PARP inhibition in SGC remain to be explored.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153112--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S112",
      "content_id": "153865",
      "abstract_number": "S112",
      "poster_number": "",
      "title": "Sialendoscopy Outcomes in Radioactive Iodine-Induced Sialadenitis: Symptom Burden, Imaging Findings, and Comparison to Chronic Sialadenitis",
      "summary": "RAI-induced sialadenitis primarily affects the parotid glands and can occur months to more than a decade after treatment, underscoring a prolonged risk period. Most symptoms improved after sialendoscopy, but xerostomia remained persistently high, unlike other symptoms that generally decreased. Compared with chronic non-RAI sialadenitis, RAI patients had a consistently greater burden of xerostomia and dysgeusia at...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153865",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Haleigh Pine, BS",
      "presenter": "Haleigh Pine, BS",
      "authors": "Haleigh Pine, BS 1 ; Elise Patchett 2 ; Anna Bottoms 2 ; Tiffany Chao, MD 2 ; Christopher Rassekh, MD 2",
      "normalized_authors": [
        "Haleigh Pine",
        "Elise Patchett",
        "Anna Bottoms",
        "Tiffany Chao",
        "Christopher Rassekh"
      ],
      "affiliations": [
        "Perelman School of Medicine at the University of Pennsylvania",
        "Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Perelman School of Medicine at the University of Pennsylvania",
        "Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153865/figureRAI(2).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153865/figureRAI(2).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153865"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 514,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Haleigh Pine, BS 1 ; Elise Patchett 2 ; Anna Bottoms 2 ; Tiffany Chao, MD 2 ; Christopher Rassekh, MD 2",
        "Affiliations": "1 Perelman School of Medicine at the University of Pennsylvania; 2 Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania",
        "Background": "Sialadenitis is a well-recognized complication of radioactive iodine (RAI) therapy, with up to two-thirds of patients demonstrating scintigraphic salivary dysfunction and 10-60% reporting acute or chronic symptoms such as pain, swelling, and xerostomia. Symptoms have been characterized to arise immediately or months after treatment, with some persisting beyond one year. Although sialendoscopy can improve obstructive symptoms in RAI-induced disease, its effectiveness for xerostomia and chronic dysfunction remains limited. Comparative data on symptom burden, imaging features, and outcomes after sialendoscopy in RAI-induced versus non-RAI chronic sialadenitis are lacking. This study aims to address this gap by characterizing symptoms and evaluating outcomes before and after sialendoscopy in both groups.",
        "Methods": "We performed a retrospective cohort study of adults undergoing sialendoscopies at a tertiary academic center from July 2019 to December 2024. Demographic and clinical data were extracted from the electronic health record and managed in REDCap. A composite symptom count (xerostomia, dysgeusia, postprandial pain, postprandial swelling, general pain, and general swelling) was calculated for each patient. A non-RAI sialadenitis cohort included patients with chronic sialadenitis, no RAI history, and sialendoscopy between 2019 and 2024. Continuous variables were summarized as means (SD), categorical variables as counts (%), and group differences were assessed between RAI vs. non-RAI groups using Wilcoxon rank-sum tests.",
        "Results": "Between 2019 and 2024, 23 patients with RAI-induced sialadenitis underwent 34 sialendoscopies. The mean age was 53.2 years, and 82.6% were female. Symptom onset after RAI ranged from 1 month to over 10 years, with a mean treatment dose of 108.6 mCi. Parotid involvement was most common (78%), 13% had all four major glands affected, and 8.7% had facial masses. Imaging frequently showed chronic sialadenitis, ductal dilation, or strictures. All patients underwent ductal dilation; 73.9% (n=17) had strictures. Seventeen patients (73.9%) had sialodochoplasty, 20 (87.0%) received intraoperative triamcinolone, and 15 (65.2%) had stents placed. Mean symptom count decreased from 2.61 (SD:1.12) to 1.35 (SD:1.47) (p = 0.012), with seven patients achieving complete resolution. Xerostomia persisted in all initially affected patients, and two patients developed new-onset, while other symptoms generally decreased (Figure 1). Seven patients (30%) required repeat sialendoscopy. Compared to the non-RAI group, the RAI group had higher baseline rates of both xerostomia (65% vs 27%, p < 0.001) and dysgeusia (35% vs 3%, p < 0.001). These differences persisted at follow-up, though overall symptom improvement after sialendoscopy was similar between groups.",
        "Conclusion": "RAI-induced sialadenitis primarily affects the parotid glands and can occur months to more than a decade after treatment, underscoring a prolonged risk period. Most symptoms improved after sialendoscopy, but xerostomia remained persistently high, unlike other symptoms that generally decreased. Compared with chronic non-RAI sialadenitis, RAI patients had a consistently greater burden of xerostomia and dysgeusia at baseline and follow-up, despite similar overall symptom improvement. Sialendoscopy remains central to evaluating and managing RAI sialadenitis by maintaining ductal patency and reducing inflammation, which will be increasingly important as novel therapies emerge to restore gland function. Early recognition is essential given the often delayed onset of symptoms.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sialendoscopy Outcomes in Radioactive Iodine-Induced Sialadenitis: Symptom Burden, Imaging Findings, and Comparison to Chronic Sialadenitis</span>. <u>Haleigh Pine, BS</u><sup>1</sup>; Elise Patchett<sup>2</sup>; Anna Bottoms<sup>2</sup>; Tiffany Chao, MD<sup>2</sup>; Christopher Rassekh, MD<sup>2</sup>. <sup>1</sup>Perelman School of Medicine at the University of Pennsylvania; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Sialadenitis is a well-recognized complication of radioactive iodine (RAI) therapy, with up to two-thirds of patients demonstrating scintigraphic salivary dysfunction and 10-60% reporting acute or chronic symptoms such as pain, swelling, and xerostomia. Symptoms have been characterized to arise immediately or months after treatment, with some persisting beyond one year. Although sialendoscopy can improve obstructive symptoms in RAI-induced disease, its effectiveness for xerostomia and chronic dysfunction remains limited. Comparative data on symptom burden, imaging features, and outcomes after sialendoscopy in RAI-induced versus non-RAI chronic sialadenitis are lacking. This study aims to address this gap by characterizing symptoms and evaluating outcomes before and after sialendoscopy in both groups.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study of adults undergoing sialendoscopies at a tertiary academic center from July 2019 to December 2024. Demographic and clinical data were extracted from the electronic health record and managed in REDCap. A composite symptom count (xerostomia, dysgeusia, postprandial pain, postprandial swelling, general pain, and general swelling) was calculated for each patient. A non-RAI sialadenitis cohort included patients with chronic sialadenitis, no RAI history, and sialendoscopy between 2019 and 2024. Continuous variables were summarized as means (SD), categorical variables as counts (%), and group differences were assessed between RAI vs. non-RAI groups using Wilcoxon rank-sum tests.</p>\n\n<p><strong>Results: </strong>Between 2019 and 2024, 23 patients with RAI-induced sialadenitis underwent 34 sialendoscopies. The mean age was 53.2 years, and 82.6% were female. Symptom onset after RAI ranged from 1 month to over 10 years, with a mean treatment dose of 108.6 mCi. Parotid involvement was most common (78%), 13% had all four major glands affected, and 8.7% had facial masses. Imaging frequently showed chronic sialadenitis, ductal dilation, or strictures. All patients underwent ductal dilation; 73.9% (n=17) had strictures. Seventeen patients (73.9%) had sialodochoplasty, 20 (87.0%) received intraoperative triamcinolone, and 15 (65.2%) had stents placed. Mean symptom count decreased from 2.61 (SD:1.12) to 1.35 (SD:1.47) (p = 0.012), with seven patients achieving complete resolution. Xerostomia persisted in all initially affected patients, and two patients developed new-onset, while other symptoms generally decreased (Figure 1). Seven patients (30%) required repeat sialendoscopy. Compared to the non-RAI group, the RAI group had higher baseline rates of both xerostomia (65% vs 27%, p < 0.001) and dysgeusia (35% vs 3%, p < 0.001). These differences persisted at follow-up, though overall symptom improvement after sialendoscopy was similar between groups.</p>\n\n<p><strong>Conclusion:</strong> RAI-induced sialadenitis primarily affects the parotid glands and can occur months to more than a decade after treatment, underscoring a prolonged risk period. Most symptoms improved after sialendoscopy, but xerostomia remained persistently high, unlike other symptoms that generally decreased. Compared with chronic non-RAI sialadenitis, RAI patients had a consistently greater burden of xerostomia and dysgeusia at baseline and follow-up, despite similar overall symptom improvement. Sialendoscopy remains central to evaluating and managing RAI sialadenitis by maintaining ductal patency and reducing inflammation, which will be increasingly important as novel therapies emerge to restore gland function. Early recognition is essential given the often delayed onset of symptoms.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153865/figureRAI(2).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153865--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S113",
      "content_id": "153439",
      "abstract_number": "S113",
      "poster_number": "",
      "title": "Differential prognostic impact of perineural invasion in major vs. minor salivary gland high-grade malignancies treated with primary surgery",
      "summary": "Overall, the prognostic impact of PNI differed substantially by gland subtype, with PNI conferring markedly elevated risk in minor salivary gland cancers compared to major salivary gland cancers. These findings suggest that site-specific risk stratification is warranted and consideration of PNI may be weighted more heavily when counseling and planning adjuvant therapy for minor salivary primaries. Further...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153439",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Angeline A Truong",
      "presenter": "Angeline A Truong",
      "authors": "Angeline A Truong ; Nika Darvish; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Katherine C Wai, MD",
      "normalized_authors": [
        "Angeline A Truong",
        "Nika Darvish",
        "Michael S Chow",
        "Ivan H El-Sayed",
        "Jonathan R George",
        "Chase M Heaton",
        "Ilya Likhterov",
        "Mary Jue Xu",
        "Patrick K Ha",
        "Katherine C Wai"
      ],
      "affiliations": [
        "University of California, San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_49_27%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_49_27%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153439"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_50_19%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_50_19%E2%80%AFAM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153439"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 417,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Angeline A Truong ; Nika Darvish; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Katherine C Wai, MD",
        "Affiliations": "University of California, San Francisco",
        "Introduction": "High-grade salivary gland carcinomas exhibit heterogeneous clinical behavior across anatomic sites. The prognostic significance of perineural invasion (PNI) may differ between major and minor salivary gland primaries, though this has not been well quantified. We evaluated whether the effect of PNI on early oncologic outcomes varies by gland type among patients treated with primary surgery.",
        "Methods": "Retrospective cohort study of 104 major and 16 minor high-grade salivary gland carcinomas treated with surgery as primary treatment (January 2010-December 2022). The primary outcome was 2-year recurrence-free survival. Cox proportional hazards models evaluated the interaction between gland type (major vs. minor) and presence of perineural invasion defined by pathology report at initial surgical resection, adjusting a priori for age, adjuvant radiation, and systemic therapy. High-grade salivary malignant histologies were defined based on WHO 5th edition descriptions and AFIP classifications.",
        "Results": "A total of 54 (45%) patients had a recurrence within 2 years. Perineural invasion was present in 55% of major and 31% of minor tumors. On univariate analysis, perineural invasion was associated with increased 2-year recurrence risk (HR 14.60 [2.67-79.71], p=0.002). Histology and T/N staging were not associated with 2-year recurrence-free survival, and not included in further analyses. Among only major salivary gland tumors, PNI was not significantly associated with 2-year recurrence-free survival on univariate analysis [HR 0.63 (0.33-1.19), p=0.155]. Among minor salivary gland tumors, PNI was significantly associated with 2-year recurrence-free survival on univariate analysis [HR 14.7 (1.66-130.5), p=0.016]. There was a significant interaction between gland type and PNI (interaction HR 0.045 [0.007-0.28], p=0.001), suggesting that PNI conferred higher risk in minor salivary gland cancers than in major salivary gland cancers.",
        "Abstract": "After adjustment, perineural invasion was significantly associated with worse 2-year recurrence-free survival (HR 22.50 [3.93-128.9], p<0.001). There remained a significant interaction between gland type and PNI (interaction HR 0.026 [0.004-0.17], p<0.001), indicating that PNI is an effect modifier in the relationship between minor versus major salivary gland cancers and 2-year recurrence-free survival. View in Agenda and Add to Schedule",
        "Conclusion": "Overall, the prognostic impact of PNI differed substantially by gland subtype, with PNI conferring markedly elevated risk in minor salivary gland cancers compared to major salivary gland cancers. These findings suggest that site-specific risk stratification is warranted and consideration of PNI may be weighted more heavily when counseling and planning adjuvant therapy for minor salivary primaries. Further validation is needed."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Differential prognostic impact of perineural invasion in major vs. minor salivary gland high-grade malignancies treated with primary surgery</span>. <u>Angeline A Truong</u>; Nika Darvish; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Katherine C Wai, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>High-grade salivary gland carcinomas exhibit heterogeneous clinical behavior across anatomic sites. The prognostic significance of perineural invasion (PNI) may differ between major and minor salivary gland primaries, though this has not been well quantified. We evaluated whether the effect of PNI on early oncologic outcomes varies by gland type among patients treated with primary surgery.</p>\n\n<p><strong>Methods: </strong>Retrospective cohort study of 104 major and 16 minor high-grade salivary gland carcinomas treated with surgery as primary treatment (January 2010-December 2022). The primary outcome was 2-year recurrence-free survival. Cox proportional hazards models evaluated the interaction between gland type (major vs. minor) and presence of perineural invasion defined by pathology report at initial surgical resection, adjusting a priori for age, adjuvant radiation, and systemic therapy. High-grade salivary malignant histologies were defined based on WHO 5th edition descriptions and AFIP classifications.</p>\n\n<p><strong>Results: </strong>A total of 54 (45%) patients had a recurrence within 2 years. Perineural invasion was present in 55% of major and 31% of minor tumors. On univariate analysis, perineural invasion was associated with increased 2-year recurrence risk (HR 14.60 [2.67-79.71], p=0.002). Histology and T/N staging were not associated with 2-year recurrence-free survival, and not included in further analyses. Among only major salivary gland tumors, PNI was not significantly associated with 2-year recurrence-free survival on univariate analysis [HR 0.63 (0.33-1.19), p=0.155]. Among minor salivary gland tumors, PNI was significantly associated with 2-year recurrence-free survival on univariate analysis [HR 14.7 (1.66-130.5), p=0.016]. There was a significant interaction between gland type and PNI (interaction HR 0.045 [0.007-0.28], p=0.001), suggesting that PNI conferred higher risk in minor salivary gland cancers than in major salivary gland cancers.</p>\n\n<p>After adjustment, perineural invasion was significantly associated with worse 2-year recurrence-free survival (HR 22.50 [3.93-128.9], p<0.001). There remained a significant interaction between gland type and PNI (interaction HR 0.026 [0.004-0.17], p<0.001), indicating that PNI is an effect modifier in the relationship between minor versus major salivary gland cancers and 2-year recurrence-free survival.</p>\n\n<p><strong>Conclusion: </strong>Overall, the prognostic impact of PNI differed substantially by gland subtype, with PNI conferring markedly elevated risk in minor salivary gland cancers compared to major salivary gland cancers. These findings suggest that site-specific risk stratification is warranted and consideration of PNI may be weighted more heavily when counseling and planning adjuvant therapy for minor salivary primaries. Further validation is needed.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_49_27%E2%80%AFAM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153439/Screenshot%202025-12-01%20at%209_50_19%E2%80%AFAM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153439--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S114",
      "content_id": "153498",
      "abstract_number": "S114",
      "poster_number": "",
      "title": "Evolving Demographic and Histologic Trends of Major Salivary Gland Carcinoma Incidence in the United States, 2000–2022",
      "summary": "MSGC incidence in the United States has undergone substantial epidemiologic shifts over the past two decades. Female patients demonstrated the prominent increases, accompanied by stage migration toward earlier-stage presentation. Divergent histologic trends—including the decline of adenocarcinoma, NOS and concurrent increases in SDC and Ca ex PA—likely reflect evolving diagnostic practices, improved detection,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dongbin Ahn, MD",
      "presenter": "Dongbin Ahn, MD",
      "authors": "Dongbin Ahn, MD 1 ; Joseph Califano, MD 2 ; Theresa Guo, MD 2 ; Jingjing Hu, MD 3",
      "normalized_authors": [
        "Dongbin Ahn",
        "Joseph Califano",
        "Theresa Guo",
        "Jingjing Hu"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University, Daegu, South Korea",
        "Department of Otolaryngology–Head and Neck Surgery, University of California, San Diego School of Medicine",
        "Department of Pathology, University of California, San Diego School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University, Daegu, South Korea",
        "Department of Otolaryngology–Head and Neck Surgery, University of California, San Diego School of Medicine",
        "Department of Pathology, University of California, San Diego School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%201a_%20incidence%20trend%20of%20overall%20msgc.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%201a_%20incidence%20trend%20of%20overall%20msgc.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%201b_%20incidence%20trend%20by%20sex.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%201b_%20incidence%20trend%20by%20sex.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%201c_%20incidence%20trend%20by%20age.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%201c_%20incidence%20trend%20by%20age.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%201e_%20incidence%20trend%20by%20primary%20sites.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%201e_%20incidence%20trend%20by%20primary%20sites.jpg",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%201f_%20incidence%20trend%20by%20stage.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%201f_%20incidence%20trend%20by%20stage.jpg",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%202_%20incidence%20trend%20by%20histologic%20subtypes.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%202_%20incidence%20trend%20by%20histologic%20subtypes.jpg",
          "alt": "Source figure 6",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%203_%20incidence%20trend%20by%20sex%20with%20age%20groups.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%203_%20incidence%20trend%20by%20sex%20with%20age%20groups.jpg",
          "alt": "Source figure 7",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%204a_%20incidence%20trend%20by%20stage%20in%20female.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%204a_%20incidence%20trend%20by%20stage%20in%20female.jpg",
          "alt": "Source figure 8",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153498/figure%204b_%20incidence%20trend%20by%20histologic%20subtypes%20in%20female.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153498/figure%204b_%20incidence%20trend%20by%20histologic%20subtypes%20in%20female.jpg",
          "alt": "Source figure 9",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153498"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Dongbin Ahn, MD 1 ; Joseph Califano, MD 2 ; Theresa Guo, MD 2 ; Jingjing Hu, MD 3",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University, Daegu, South Korea; 2 Department of Otolaryngology–Head and Neck Surgery, University of California, San Diego School of Medicine; 3 Department of Pathology, University of California, San Diego School of Medicine",
        "Background": "Major salivary gland carcinoma (MSGC) is a rare and heterogeneous malignancy with diverse histologic subtypes, making contemporary epidemiologic assessment challenging. Previous population-based studies yielded inconsistent results and were largely limited to data before 2010. Considering the substantial demographic aging, expanded healthcare accessibility, and advances in diagnostic modalities, an updated evaluation of MSGC incidence trends is needed. This study analyzed contemporary incidence patterns of MSGC in the United States using the most recent SEER 17 Research Data (2000–2022).",
        "Methods": "A population-based analysis was conducted using SEER 17 Registries (November 2023 submission). MSGC cases diagnosed between 2000 and 2022 were identified using ICD-O-3 primary site and histology codes, excluding benign tumors, metastatic disease to salivary glands, and non-epithelial malignancies. Age-adjusted incidence rates (IRs) per 1,000,000 persons were calculated with 95% confidence intervals. Temporal trends were evaluated using annual percent change (APC) and average annual percent change (AAPC) from Joinpoint regression. Incidence patterns were assessed according to demographic and clinicopathologic variables, with subgroup analyses performed for factors demonstrating significant temporal variation.",
        "Results": "A total of 20,522 MSGC cases were identified. The overall incidence during 2000–2022 was 10.4, demonstrating a significant upward trend (APC = 0.42%, P = 0.015). Incidence increased markedly among females (APC = 0.81%, P = 0.002), while remaining stable among males. Increases were most prominent in patients aged ≥60 years and in parotid gland primaries. Localized-stage disease increased (APC = 0.89%, P = 0.002), whereas distant-stage disease declined (APC = −1.81%, P = 0.041), suggesting enhanced early detection.",
        "Abstract": "Histologically, adenocarcinoma, NOS demonstrated a significant decline (AAPC = −3.33%, P < 0.001), whereas salivary duct carcinoma (SDC) exhibited the steepest increase (AAPC = 10.41%, P < 0.001). Carcinoma ex pleomorphic adenoma (Ca ex PA) also showed a significant upward trend (APC = 2.20%, P = 0.022). In female-specific analyses, incidence increased significantly across both age groups (≥60 years: APC = 0.64%, P = 0.012; <60 years: APC = 0.88%, P = 0.009). The incidence of localized disease in females rose significantly (APC = 1.16%, P = 0.005), while distant-stage incidence decreased (APC = −2.34%, P = 0.009). Histologic trends were more pronounced in females: SDC increased sharply (APC = 54.57%, P = 0.003), Ca ex PA showed a significant rise (APC = 2.56%, P = 0.013), and mucoepidermoid carcinoma (MEC) demonstrated a significant upward trend (APC = 0.87%, P = 0.016), a pattern not observed in the overall cohort. View in Agenda and Add to Schedule",
        "Conclusion": "MSGC incidence in the United States has undergone substantial epidemiologic shifts over the past two decades. Female patients demonstrated the prominent increases, accompanied by stage migration toward earlier-stage presentation. Divergent histologic trends—including the decline of adenocarcinoma, NOS and concurrent increases in SDC and Ca ex PA—likely reflect evolving diagnostic practices, improved detection, and changes in precursor lesion epidemiology, such as pleomorphic adenoma. These updated insights provide important context for clinical management, diagnostic refinement, and future translational research in salivary gland oncology."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evolving Demographic and Histologic Trends of Major Salivary Gland Carcinoma Incidence in the United States, 2000–2022</span>. <u>Dongbin Ahn, MD</u><sup>1</sup>; Joseph Califano, MD<sup>2</sup>; Theresa Guo, MD<sup>2</sup>; Jingjing Hu, MD<sup>3</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University, Daegu, South Korea; <sup>2</sup>Department of Otolaryngology–Head and Neck Surgery,  University of California, San Diego School of Medicine; <sup>3</sup>Department of Pathology, University of California, San Diego School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Major salivary gland carcinoma (MSGC) is a rare and heterogeneous malignancy with diverse histologic subtypes, making contemporary epidemiologic assessment challenging. Previous population-based studies yielded inconsistent results and were largely limited to data before 2010. Considering the substantial demographic aging, expanded healthcare accessibility, and advances in diagnostic modalities, an updated evaluation of MSGC incidence trends is needed. This study analyzed contemporary incidence patterns of MSGC in the United States using the most recent SEER 17 Research Data (2000–2022).</p>\n\n<p><strong>Methods: </strong>A population-based analysis was conducted using SEER 17 Registries (November 2023 submission). MSGC cases diagnosed between 2000 and 2022 were identified using ICD-O-3 primary site and histology codes, excluding benign tumors, metastatic disease to salivary glands, and non-epithelial malignancies. Age-adjusted incidence rates (IRs) per 1,000,000 persons were calculated with 95% confidence intervals. Temporal trends were evaluated using annual percent change (APC) and average annual percent change (AAPC) from Joinpoint regression. Incidence patterns were assessed according to demographic and clinicopathologic variables, with subgroup analyses performed for factors demonstrating significant temporal variation.</p>\n\n<p><strong>Results: </strong>A total of 20,522 MSGC cases were identified. The overall incidence during 2000–2022 was 10.4, demonstrating a significant upward trend (APC = 0.42%, P = 0.015). Incidence increased markedly among females (APC = 0.81%, P = 0.002), while remaining stable among males. Increases were most prominent in patients aged ≥60 years and in parotid gland primaries. Localized-stage disease increased (APC = 0.89%, P = 0.002), whereas distant-stage disease declined (APC = −1.81%, P = 0.041), suggesting enhanced early detection.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%201a_%20incidence%20trend%20of%20overall%20msgc.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%201b_%20incidence%20trend%20by%20sex.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%201c_%20incidence%20trend%20by%20age.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%201e_%20incidence%20trend%20by%20primary%20sites.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%201f_%20incidence%20trend%20by%20stage.jpg' /></p>\n\n<p>Histologically, adenocarcinoma, NOS demonstrated a significant decline (AAPC = −3.33%, P < 0.001), whereas salivary duct carcinoma (SDC) exhibited the steepest increase (AAPC = 10.41%, P < 0.001). Carcinoma ex pleomorphic adenoma (Ca ex PA) also showed a significant upward trend (APC = 2.20%, P = 0.022).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%202_%20incidence%20trend%20by%20histologic%20subtypes.jpg' /></p>\n\n<p>In female-specific analyses, incidence increased significantly across both age groups (≥60 years: APC = 0.64%, P = 0.012; <60 years: APC = 0.88%, P = 0.009). The incidence of localized disease in females rose significantly (APC = 1.16%, P = 0.005), while distant-stage incidence decreased (APC = −2.34%, P = 0.009). Histologic trends were more pronounced in females: SDC increased sharply (APC = 54.57%, P = 0.003), Ca ex PA showed a significant rise (APC = 2.56%, P = 0.013), and mucoepidermoid carcinoma (MEC) demonstrated a significant upward trend (APC = 0.87%, P = 0.016), a pattern not observed in the overall cohort.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%203_%20incidence%20trend%20by%20sex%20with%20age%20groups.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%204a_%20incidence%20trend%20by%20stage%20in%20female.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153498/figure%204b_%20incidence%20trend%20by%20histologic%20subtypes%20in%20female.jpg' /></p>\n\n<p><strong>Conclusion: </strong>MSGC incidence in the United States has undergone substantial epidemiologic shifts over the past two decades. Female patients demonstrated the prominent increases, accompanied by stage migration toward earlier-stage presentation. Divergent histologic trends—including the decline of adenocarcinoma, NOS and concurrent increases in SDC and Ca ex PA—likely reflect evolving diagnostic practices, improved detection, and changes in precursor lesion epidemiology, such as pleomorphic adenoma. These updated insights provide important context for clinical management, diagnostic refinement, and future translational research in salivary gland oncology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153498--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S115",
      "content_id": "153934",
      "abstract_number": "S115",
      "poster_number": "",
      "title": "Impact of neighborhood deprivation on presentation and outcome in patients with high-grade salivary gland cancer",
      "summary": "Patients with high-grade salivary gland cancer residing in areas of greater socioeconomic deprivation were found to present with higher T stage disease and were less likely to undergo recommended adjuvant radiation. Higher ADI may be linked to worse survival in patients with high-grade SGC, however further investigation is warranted.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153934",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jenny Kim, MD",
      "presenter": "Jenny Kim, MD",
      "authors": "Jenny Kim, MD 1 ; Amaan Rahman, BA 2 ; Katie M Carlson, MPH 2 ; Joshua D Smith, MD 1 ; Shaum Sridharan 1 ; Kevin J Contrera, MD 1 ; Steven B Chinn, MD 1 ; Seungwon Kim 1 ; Jose P Zevallos, MD, MPH 1 ; Matthew E Spector, MD 1 ; Marci Nilsen, RN, PhD 2 ; Angela L Mazul, PhD 2 ; Jessica H Maxwell, MD, MPH 1",
      "normalized_authors": [
        "Jenny Kim",
        "Amaan Rahman",
        "Katie M Carlson",
        "Joshua D Smith",
        "Shaum Sridharan",
        "Kevin J Contrera",
        "Steven B Chinn",
        "Seungwon Kim",
        "Jose P Zevallos",
        "Matthew E Spector",
        "Marci Nilsen",
        "Angela L Mazul",
        "Jessica H Maxwell"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center",
        "University of Pittsburgh School of Medicine"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center",
        "University of Pittsburgh School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jenny Kim, MD 1 ; Amaan Rahman, BA 2 ; Katie M Carlson, MPH 2 ; Joshua D Smith, MD 1 ; Shaum Sridharan 1 ; Kevin J Contrera, MD 1 ; Steven B Chinn, MD 1 ; Seungwon Kim 1 ; Jose P Zevallos, MD, MPH 1 ; Matthew E Spector, MD 1 ; Marci Nilsen, RN, PhD 2 ; Angela L Mazul, PhD 2 ; Jessica H Maxwell, MD, MPH 1",
        "Affiliations": "1 University of Pittsburgh Medical Center; 2 University of Pittsburgh School of Medicine",
        "Background": "High-grade salivary gland cancer (SGC) is an aggressive disease that is relatively understudied due to its rarity and pathologic diversity. While a few studies have investigated the impact of socioeconomic status on SGC outcomes, many utilize limited proxies such as race/ethnicity or county median income. The Area Deprivation Index (ADI), a comprehensive measure of neighborhood socioeconomic deprivation, is associated with poor outcomes in cancer patients, but its association with clinical presentation and outcomes in patients with SGC is unknown. This study investigated the association of neighborhood socioeconomic deprivation (estimated by ADI) with high-risk clinical features, stage at presentation, and survival outcomes in patients with high-grade SGC.",
        "Methods": "This was a single-center retrospective cohort study of 105 patients diagnosed with high-grade salivary gland cancer between October 2010 and November 2024. Patient addresses were matched to ADI national percentile scores from 0 to 100, with higher values representing greater socioeconomic deprivation. ADI was categorized by internally derived quartiles. Covariates included age at diagnosis, alcohol use, smoking status, insurance status, margin status, cancer type, pathologic T and N stage, perineural invasion (PNI), lymphovascular invasion (LVI), race, and sex. Our outcomes of interest were overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS). Multinomial logistic regression was used to investigate the relationship between ADI and high-risk clinical factors. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Survival curves were generated using the Kaplan-Meier method.",
        "Results": "The median ADI value for our cohort was 71. Average age at diagnosis was 68.0 years (± 19.4). Among the 105 patients included in this study, 57.1% were male, 95.2% were white, 55.2% had either Medicare or Medicaid insurance, and 51.4% were smokers. The most prevalent cancer types included salivary duct carcinoma (26.7%), carcinoma ex pleomorphic adenoma (24.8%), solid-type adenoid cystic carcinoma (17.1%), and high-grade mucoepidermoid carcinoma (13.3%). 70.2% completed adjuvant radiation treatment, 14.4% were recommended adjuvant radiation but did not complete treatment, and 6.7% had no indication for adjuvant radiation.",
        "Abstract": "Patients in the most-deprived ADI quartile (national rankings: 87-100) were 6 times more likely to present with T3 versus T1 stage when compared to those in the least-deprived quartile (OR 6.00, 95% CI: 1.26-28.55, P=0.024). For every 1-unit increase in ADI, there was a 4% increased likelihood of refusal to undergo or inability to complete adjuvant radiation treatment compared to completing radiation (OR 1.04, 95% CI: 1.01-1.08, P=0.014). Patients with ADI above the median also had higher hazards of death compared to those below the median (HR: 2.15, 95% CI: 1.03-4.50, P=0.042). On multivariable analysis, ADI was not significantly associated with OS, RFS, or DSS. View in Agenda and Add to Schedule",
        "Conclusion": "Patients with high-grade salivary gland cancer residing in areas of greater socioeconomic deprivation were found to present with higher T stage disease and were less likely to undergo recommended adjuvant radiation. Higher ADI may be linked to worse survival in patients with high-grade SGC, however further investigation is warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of neighborhood deprivation on presentation and outcome in patients with high-grade salivary gland cancer</span>. <u>Jenny Kim, MD</u><sup>1</sup>; Amaan Rahman, BA<sup>2</sup>; Katie M Carlson, MPH<sup>2</sup>; Joshua D Smith, MD<sup>1</sup>; Shaum Sridharan<sup>1</sup>; Kevin J Contrera, MD<sup>1</sup>; Steven B Chinn, MD<sup>1</sup>; Seungwon Kim<sup>1</sup>; Jose P Zevallos, MD, MPH<sup>1</sup>; Matthew E Spector, MD<sup>1</sup>; Marci Nilsen, RN, PhD<sup>2</sup>; Angela L Mazul, PhD<sup>2</sup>; Jessica H Maxwell, MD, MPH<sup>1</sup>. <sup>1</sup>University of Pittsburgh Medical Center; <sup>2</sup>University of Pittsburgh School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>High-grade salivary gland cancer (SGC) is an aggressive disease that is relatively understudied due to its rarity and pathologic diversity. While a few studies have investigated the impact of socioeconomic status on SGC outcomes, many utilize limited proxies such as race/ethnicity or county median income. The Area Deprivation Index (ADI), a comprehensive measure of neighborhood socioeconomic deprivation, is associated with poor outcomes in cancer patients, but its association with clinical presentation and outcomes in patients with SGC is unknown. This study investigated the association of neighborhood socioeconomic deprivation (estimated by ADI) with high-risk clinical features, stage at presentation, and survival outcomes in patients with high-grade SGC.</p>\n\n<p><strong>Methods: </strong>This was a single-center retrospective cohort study of 105 patients diagnosed with high-grade salivary gland cancer between October 2010 and November 2024. Patient addresses were matched to ADI national percentile scores from 0 to 100, with higher values representing greater socioeconomic deprivation. ADI was categorized by internally derived quartiles. Covariates included age at diagnosis, alcohol use, smoking status, insurance status, margin status, cancer type, pathologic T and N stage, perineural invasion (PNI), lymphovascular invasion (LVI), race, and sex. Our outcomes of interest were overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS). Multinomial logistic regression was used to investigate the relationship between ADI and high-risk clinical factors. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Survival curves were generated using the Kaplan-Meier method.</p>\n\n<p><strong>Results: </strong>The median ADI value for our cohort was 71. Average age at diagnosis was 68.0 years (± 19.4). Among the 105 patients included in this study, 57.1% were male, 95.2% were white, 55.2% had either Medicare or Medicaid insurance, and 51.4% were smokers. The most prevalent cancer types included salivary duct carcinoma (26.7%), carcinoma ex pleomorphic adenoma (24.8%), solid-type adenoid cystic carcinoma (17.1%), and high-grade mucoepidermoid carcinoma (13.3%). 70.2% completed adjuvant radiation treatment, 14.4% were recommended adjuvant radiation but did not complete treatment, and 6.7% had no indication for adjuvant radiation.</p>\n\n<p>Patients in the most-deprived ADI quartile (national rankings: 87-100) were 6 times more likely to present with T3 versus T1 stage when compared to those in the least-deprived quartile (OR 6.00, 95% CI: 1.26-28.55, P=0.024). For every 1-unit increase in ADI, there was a 4% increased likelihood of refusal to undergo or inability to complete adjuvant radiation treatment compared to completing radiation (OR 1.04, 95% CI: 1.01-1.08, P=0.014). Patients with ADI above the median also had higher hazards of death compared to those below the median (HR: 2.15, 95% CI: 1.03-4.50, P=0.042). On multivariable analysis, ADI was not significantly associated with OS, RFS, or DSS.</p>\n\n<p><strong>Conclusion: </strong>Patients with high-grade salivary gland cancer residing in areas of greater socioeconomic deprivation were found to present with higher T stage disease and were less likely to undergo recommended adjuvant radiation. Higher ADI may be linked to worse survival in patients with high-grade SGC, however further investigation is warranted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153934--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S116",
      "content_id": "154222",
      "abstract_number": "S116",
      "poster_number": "",
      "title": "Clinicopathologic Predictors of High-Risk Salivary Duct Carcinoma and Evaluation of Patient Prognosis: A Single Institutional Cohort Study",
      "summary": "SDC frequently presents with clinical features suggestive of a high-grade malignancy even when pre-surgical cytology does not indicate high-grade malignancy. Despite aggressive locoregional therapy, distant metastasis predominates and biomarker-directed therapies are primarily reserved for recurrent disease despite high AR/HER2 positivity. Survival estimates in this study exceeded those described in multiple...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154222",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aayush Unadkat, BS",
      "presenter": "Aayush Unadkat, BS",
      "authors": "Aayush Unadkat, BS ; Chelsey A Witsberger, MD, MSc; Abdullah Adil, MD; Keith A Casper, MD; Pratyusha Yalamanchi, MD, MBA; Chaz Stucken, MD; Andrew G Shuman, MD; Kelly M Malloy, MD, MBA; Mark Prince, MD; Molly Heft Neal, MD; David Forner, MD, MSc; Marisa R Buchakjian, MD, PhD",
      "normalized_authors": [
        "Aayush Unadkat",
        "Chelsey A Witsberger",
        "Abdullah Adil",
        "Keith A Casper",
        "Pratyusha Yalamanchi",
        "Chaz Stucken",
        "Andrew G Shuman",
        "Kelly M Malloy",
        "Mark Prince",
        "Molly Heft Neal",
        "David Forner",
        "Marisa R Buchakjian"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Aayush Unadkat, BS ; Chelsey A Witsberger, MD, MSc; Abdullah Adil, MD; Keith A Casper, MD; Pratyusha Yalamanchi, MD, MBA; Chaz Stucken, MD; Andrew G Shuman, MD; Kelly M Malloy, MD, MBA; Mark Prince, MD; Molly Heft Neal, MD; David Forner, MD, MSc; Marisa R Buchakjian, MD, PhD",
        "Affiliations": "University of Michigan",
        "Background": "Salivary ductal carcinoma (SDC) is an aggressive malignancy characterized by advanced presentation and high rates of distant failure. Despite this, preoperative cytology may under-call malignancy in a subset of patients. Additionally, contemporary evidence remains limited by small cohorts and inconsistent reporting of high-risk pathologic features, leaving prognostication and recurrence patterns poorly defined. We aimed to characterize clinical and pathologic features associated with SDC, evaluate diagnostic concordance, and identify opportunities to improve systemic treatment strategies in one of the largest single-institution SDC cohorts to date.",
        "Methods": "This was a single-institution retrospective cohort study of 56 adult patients undergoing surgical resection for SDC. Clinicodemographic, pathologic, and oncologic factors were collected with overall survival (OS) and recurrence-free survival (RFS) being the primary outcomes. Secondary outcomes included distribution of high-risk pathologic features, accuracy of preoperative biopsy, biomarker expression, and patterns of locoregional versus distant recurrence. OS and RFS were calculated using Kaplan-Meier methods, and univariable Cox proportional-hazard models were used to evaluate associations between clinicopathologic factors and outcomes.",
        "Results": "Patients were predominantly older (mean age 66.6 years) and male (66%) with tumors arising in the parotid gland in 84%. Preoperative biopsy was performed in 98% of patients; however, 3.6% were categorized as benign or indeterminate (benign/SUMP/low-grade/suspicious).",
        "Abstract": "Histopathology demonstrated the uniform presence of high-risk features: perineural invasion (63%), lymphovascular invasion (48%), positive margins (36%), extraparenchymal extension (57%), and nodal metastases (66%), with extranodal extension present in 59% of evaluable cases. AR and HER2 positivity were frequent (77% and 61% of all primary tumors in the cohort, respectively). Radiation therapy was employed in 51 patients (91%). Systemic therapy was used for 24 patients, which included 2 cases of endocrine therapy and 2 cases of HER2 targeted therapy. Median OS was 8.2 years, with 1-, 3-, and 5-year OS estimates of 94%, 83%, and 72%, respectively. Median RFS was 4.6 years, with corresponding RFS of 73%, 56%, and 47%. Among patients who recurred (48%), distant metastasis occurred in 89%, most commonly to lung (58%), brain (46%), and bone (38%). In univariable Cox analysis, LVI (HR 5.0, 95% CI 1.7-14.9), PNI (HR 3.0, 95% CI 1.0-8.8), and ENE (HR 3.35, 95% CI 1.18–9.47) were significantly associated with worse RFS. View in Agenda and Add to Schedule",
        "Conclusions": "SDC frequently presents with clinical features suggestive of a high-grade malignancy even when pre-surgical cytology does not indicate high-grade malignancy. Despite aggressive locoregional therapy, distant metastasis predominates and biomarker-directed therapies are primarily reserved for recurrent disease despite high AR/HER2 positivity. Survival estimates in this study exceeded those described in multiple previous SDC cohorts, possibly reflecting early staging accuracy and standardized post-operative treatment regimens, though further analysis is warranted. Strong associations between LVI, PNI, and ENE and recurrence reinforce their prognostic value in SDC. These findings highlight opportunities for improved diagnostic pathways, risk stratification, and incorporation of targeted and endocrine therapies in future treatment algorithms."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinicopathologic Predictors of High-Risk Salivary Duct Carcinoma and Evaluation of Patient Prognosis: A Single Institutional Cohort Study</span>. <u>Aayush Unadkat, BS</u>; Chelsey A Witsberger, MD, MSc; Abdullah Adil, MD; Keith A Casper, MD; Pratyusha Yalamanchi, MD, MBA; Chaz Stucken, MD; Andrew G Shuman, MD; Kelly M Malloy, MD, MBA; Mark Prince, MD; Molly Heft Neal, MD; David Forner, MD, MSc; Marisa R Buchakjian, MD, PhD. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salivary ductal carcinoma (SDC) is an aggressive malignancy characterized by advanced presentation and high rates of distant failure. Despite this, preoperative cytology may under-call malignancy in a subset of patients. Additionally, contemporary evidence remains limited by small cohorts and inconsistent reporting of high-risk pathologic features, leaving prognostication and recurrence patterns poorly defined. We aimed to characterize clinical and pathologic features associated with SDC, evaluate diagnostic concordance, and identify opportunities to improve systemic treatment strategies in one of the largest single-institution SDC cohorts to date.</p>\n\n<p><strong>Methods: </strong>This was a single-institution retrospective cohort study of 56 adult patients undergoing surgical resection for SDC. Clinicodemographic, pathologic, and oncologic factors were collected with overall survival (OS) and recurrence-free survival (RFS) being the primary outcomes. Secondary outcomes included distribution of high-risk pathologic features, accuracy of preoperative biopsy, biomarker expression, and patterns of locoregional versus distant recurrence. OS and RFS were calculated using Kaplan-Meier methods, and univariable Cox proportional-hazard models were used to evaluate associations between clinicopathologic factors and outcomes.</p>\n\n<p><strong>Results: </strong>Patients were predominantly older (mean age 66.6 years) and male (66%) with tumors arising in the parotid gland in 84%. Preoperative biopsy was performed in 98% of patients; however, 3.6% were categorized as benign or indeterminate (benign/SUMP/low-grade/suspicious).</p>\n\n<p>Histopathology demonstrated the uniform presence of high-risk features: perineural invasion (63%), lymphovascular invasion (48%), positive margins (36%), extraparenchymal extension (57%), and nodal metastases (66%), with extranodal extension present in 59% of evaluable cases. AR and HER2 positivity were frequent (77% and 61% of all primary tumors in the cohort, respectively). Radiation therapy was employed in 51 patients (91%). Systemic therapy was used for 24 patients, which included 2 cases of endocrine therapy and 2 cases of HER2 targeted therapy.</p>\n\n<p>Median OS was 8.2 years, with 1-, 3-, and 5-year OS estimates of 94%, 83%, and 72%, respectively. Median RFS was 4.6 years, with corresponding RFS of 73%, 56%, and 47%. Among patients who recurred (48%), distant metastasis occurred in 89%, most commonly to lung (58%), brain (46%), and bone (38%). In univariable Cox analysis, LVI (HR 5.0, 95% CI 1.7-14.9), PNI (HR 3.0, 95% CI 1.0-8.8), and ENE (HR 3.35, 95% CI 1.18–9.47) were significantly associated with worse RFS.</p>\n\n<p><strong>Conclusions: </strong>SDC frequently presents with clinical features suggestive of a high-grade malignancy even when pre-surgical cytology does not indicate high-grade malignancy. Despite aggressive locoregional therapy, distant metastasis predominates and biomarker-directed therapies are primarily reserved for recurrent disease despite high AR/HER2 positivity. Survival estimates in this study exceeded those described in multiple previous SDC cohorts, possibly reflecting early staging accuracy and standardized post-operative treatment regimens, though further analysis is warranted. Strong associations between LVI, PNI, and ENE and recurrence reinforce their prognostic value in SDC. These findings highlight opportunities for improved diagnostic pathways, risk stratification, and incorporation of targeted and endocrine therapies in future treatment algorithms.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154222--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S117",
      "content_id": "154455",
      "abstract_number": "S117",
      "poster_number": "",
      "title": "Natural History and Management Strategies of Sialoceles after Parotidectomy",
      "summary": "Sialoceles typically occur within 2 weeks after parotidectomy and tend to resolve spontaneously with supportive cares within 30 days. There is little role for scopolamine patches, procedural drainage, or antibiotics in expediting sialocele resolution.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154455",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ruth N Agwaze, BS",
      "presenter": "Ruth N Agwaze, BS",
      "authors": "Ruth N Agwaze, BS ; Mengyuan Xu, BA; Katelyn S Rourk, BS; Jenna R Schwartz, BA; Eric J Moore, MD; Linda X Yin, MD",
      "normalized_authors": [
        "Ruth N Agwaze",
        "Mengyuan Xu",
        "Katelyn S Rourk",
        "Jenna R Schwartz",
        "Eric J Moore",
        "Linda X Yin"
      ],
      "affiliations": [
        "Mayo Clinic - Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "Mayo Clinic - Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 434,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ruth N Agwaze, BS ; Mengyuan Xu, BA; Katelyn S Rourk, BS; Jenna R Schwartz, BA; Eric J Moore, MD; Linda X Yin, MD",
        "Affiliations": "Mayo Clinic - Department of Otolaryngology-Head and Neck Surgery",
        "Introduction": "Sialocele is a commonly described complication after parotidectomy, but there are few studies that describe the optimal management strategies that lead to expeditious resolution. This study aims to compare active and expectant management of sialoceles after parotidectomy.",
        "Methods": "Patients who underwent parotidectomy for benign or malignant tumors at a tertiary care center from 2018-2024 were queried from a departmental registry. Patients were included if they had signs and symptoms of sialocele on physical exam and/or imaging. Data collected included demographics, presenting signs and symptoms, number of emergency department (ED) visits, and use of treatments such as supportive cares and pain medications, scopolamine patches, antibiotics, botulinum toxin (botox), procedural drainage (i.e. aspiration, incision and drainage), and surgical exploration. Time to onset and resolution of sialocele was recorded. Two-tailed unpaired t-tests and Analysis of Variance were performed to assess the association of these variables with time to onset and time to resolution of sialocele.",
        "Results": "After parotidectomy, 49 (6.4%) of 845 patients developed sialoceles within a median (IQR) of 9 (5, 14) days. Median (IQR) age at diagnosis was 58.0 (43.0, 70.9), and 15 (30.6%) were male sex. Among these patients, parotidectomy was pursued to treat 40 (81.2%) benign pathologies and 9 (18.4%) malignant pathologies. The most common presenting symptoms were swelling (57.1%) and drainage (50.0%), followed by pain and/or tenderness (28.6%), erythema (14.3%), warmth (6.2%), and purulence (6.2%). 20 (40.8%) patients did not receive any treatment for their sialoceles and 14 (28.6%) received supportive cares only. Scopolamine patches and antibiotics were prescribed to 14 (28.6%) and 10 (20.4%) patients respectively. Procedural drainage was performed in 8 (16.3%) patients. Further treatment was sought at the ED by 6 (12.2%) patients. No patients required narcotics, botox, or surgical exploration. The majority (81.6%) of sialoceles resolved within a median (IQR) time of 28 (11.5, 40.5) days. Patients with symptoms of swelling post-operatively were diagnosed with sialocele earlier than those that did not (8.1 vs 12.3 days, p = 0.02). There were no significant associations between time to resolution of sialocele and use of scopolamine patches (p=0.70), antibiotics (p=0.15), procedural drainage (p=0.11) or number of ED visits (p=0.05). No sialoceles required surgical intervention to resolve.",
        "Conclusion": "Sialoceles typically occur within 2 weeks after parotidectomy and tend to resolve spontaneously with supportive cares within 30 days. There is little role for scopolamine patches, procedural drainage, or antibiotics in expediting sialocele resolution.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Natural History and Management Strategies of Sialoceles after Parotidectomy</span>. <u>Ruth N Agwaze, BS</u>; Mengyuan Xu, BA; Katelyn S Rourk, BS; Jenna R Schwartz, BA; Eric J Moore, MD; Linda X Yin, MD. Mayo Clinic - Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Sialocele is a commonly described complication after parotidectomy, but there are few studies that describe the optimal management strategies that lead to expeditious resolution. This study aims to compare active and expectant management of sialoceles after parotidectomy.</p>\n\n<p><strong>Methods:</strong> Patients who underwent parotidectomy for benign or malignant tumors at a tertiary care center from 2018-2024 were queried from a departmental registry. Patients were included if they had signs and symptoms of sialocele on physical exam and/or imaging. Data collected included demographics, presenting signs and symptoms, number of emergency department (ED) visits, and use of treatments such as supportive cares and pain medications, scopolamine patches, antibiotics, botulinum toxin (botox), procedural drainage (i.e. aspiration, incision and drainage), and surgical exploration. Time to onset and resolution of sialocele was recorded. Two-tailed unpaired t-tests and Analysis of Variance were performed to assess the association of these variables with time to onset and time to resolution of sialocele.</p>\n\n<p><strong>Results:</strong> After parotidectomy, 49 (6.4%) of 845 patients developed sialoceles within a median (IQR) of 9 (5, 14) days. Median (IQR) age at diagnosis was 58.0 (43.0, 70.9), and 15 (30.6%) were male sex. Among these patients, parotidectomy was pursued to treat 40 (81.2%) benign pathologies and 9 (18.4%) malignant pathologies. The most common presenting symptoms were swelling (57.1%) and drainage (50.0%), followed by pain and/or tenderness (28.6%), erythema (14.3%), warmth (6.2%), and purulence (6.2%). 20 (40.8%) patients did not receive any treatment for their sialoceles and 14 (28.6%) received supportive cares only. Scopolamine patches and antibiotics were prescribed to 14 (28.6%) and 10 (20.4%) patients respectively. Procedural drainage was performed in 8 (16.3%) patients. Further treatment was sought at the ED by 6 (12.2%) patients. No patients required narcotics, botox, or surgical exploration. The majority (81.6%) of sialoceles resolved within a median (IQR) time of 28 (11.5, 40.5) days. Patients with symptoms of swelling post-operatively were diagnosed with sialocele earlier than those that did not (8.1 vs 12.3 days, p = 0.02). There were no significant associations between time to resolution of sialocele and use of scopolamine patches (p=0.70), antibiotics (p=0.15), procedural drainage (p=0.11) or number of ED visits (p=0.05). No sialoceles required surgical intervention to resolve.</p>\n\n<p><strong>Conclusion: </strong>Sialoceles typically occur within 2 weeks after parotidectomy and tend to resolve spontaneously with supportive cares within 30 days. There is little role for scopolamine patches, procedural drainage, or antibiotics in expediting sialocele resolution.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154455--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S118",
      "content_id": "151887",
      "abstract_number": "S118",
      "poster_number": "",
      "title": "Acinic Cell Carcinoma within the SEER Database: Epidemiological, Clinical Characteristics, and Outcomes of Non-parotid Major and Minor Salivary Gland Sites of Origin to Those of Parotid Gland Ori",
      "summary": "AcCC is one of the most common salivary gland malignancies. While overwhelmingly these occur in the parotid gland, other locations in the head and neck are the site of origin for approximately 6% of patients, most commonly in the gums/hard palate, submandibular gland, lips, and sinonasal tract. With standard surgical treatment patients with localized disease are almost always cured with surgery alone. Adjuvant...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151887",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260122",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elise A Peyroux, MS",
      "presenter": "Elise A Peyroux, MS",
      "authors": "Elise A Peyroux, MS 1 ; Erich M Sturgis, MD, MPH 2 ; Fatma Cemre Sazak Kundi, MD 2 ; Ray Y Wang, MD 2 ; Kristina R Dahlstrom, PhD 2",
      "normalized_authors": [
        "Elise A Peyroux",
        "Erich M Sturgis",
        "Fatma Cemre Sazak Kundi",
        "Ray Y Wang",
        "Kristina R Dahlstrom"
      ],
      "affiliations": [
        "Louisiana State University Health Sciences Center New Orleans",
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Louisiana State University Health Sciences Center New Orleans",
        "Baylor College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Elise A Peyroux, MS 1 ; Erich M Sturgis, MD, MPH 2 ; Fatma Cemre Sazak Kundi, MD 2 ; Ray Y Wang, MD 2 ; Kristina R Dahlstrom, PhD 2",
        "Affiliations": "1 Louisiana State University Health Sciences Center New Orleans; 2 Baylor College of Medicine",
        "Background": "Acinic cell carcinoma (AcCC) is a malignant neoplasm of epithelial acinic cells, most commonly arising in the parotid gland but also occurring in submandibular, sublingual, and minor salivary glands. Although risk factors are unknown, there is a higher incidence among middle-aged white females. While prognosis is outstanding, outcomes vary with tumor grade and stage. Limited data exists of AcCC arising in non-parotid sites, and it remains unclear whether tumor site influences clinical presentation, treatment approaches, or survival.",
        "Methods": "Data for patients with AcCC (histology code 8550/3) diagnosed between 2000–2022 were extracted from the SEER (Surveillance, Epidemiology, and End Results) 21 database. Cases were categorized by anatomic site into major and minor salivary glands. Major salivary gland sites include parotid, submandibular, and sublingual glands; minor salivary glands encompass sinonasal, oral cavity, pharyngeal, and laryngeal but no other head and neck sites (not included are the extremely rare cutaneous, lacrimal glands, or thyroid gland sites of origin). Demographic, clinicopathologic, and treatment variables were analyzed, and cause-specific survival was estimated and compared to those of parotid site of origin.",
        "Results": "There were 4,792 cases of AcCC of the head and neck region in this 23 year period of the SEER21 database, and of these 4,333 (94%) occurred in the parotid gland. Those arising from other major salivary glands or from the minor salivary glands were demographically and clinically like those with parotid gland primaries: median age, 53; female; non-Hispanic white; low-intermediate grade; and localized stage. However, those with non-parotid primaries were slightly older, those with sinonasal primaries were more commonly male, and 23% of patients with a sinonasal primary were non-Hispanic black. Additionally, parotid tumors were larger at presentation and virtually all high-grade AcCC or metastatic (lymph node or distant) AcCC arose in the parotid or other major salivary glands. Surgery was the mainstay of treatment with adjuvant radiation used in a significant proportion of AcCC arising from the parotid or other major salivary glands. Outcomes were similar across sites of origin with 10-year AcCC cause-specific survival for localized disease stage at >96%. For those with parotid primaries, 10-year AcCC cause-specific survival for those with regional and distant disease stage was 69% and 45%, respectively; but there were too few with primaries of non-parotid sites with regional or distant disease stage to have stable estimates of survival.",
        "Conclusion": "AcCC is one of the most common salivary gland malignancies. While overwhelmingly these occur in the parotid gland, other locations in the head and neck are the site of origin for approximately 6% of patients, most commonly in the gums/hard palate, submandibular gland, lips, and sinonasal tract. With standard surgical treatment patients with localized disease are almost always cured with surgery alone. Adjuvant radiation is indicated for those with high-grade, positive margins, perineural invasion, or lymph node metastases, affording those presenting with regional stage disease reasonable 10-year cause-specific survival rates (69%). Patients with distant stage at presentation have worse outcomes, but 5-year cause-specific survival rates are over 50%.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Acinic Cell Carcinoma within the SEER Database: Epidemiological, Clinical Characteristics, and Outcomes of Non-parotid Major and Minor Salivary Gland Sites of Origin to Those of Parotid Gland Origin</span>. <u>Elise A Peyroux, MS</u><sup>1</sup>; Erich M Sturgis, MD, MPH<sup>2</sup>; Fatma Cemre Sazak Kundi, MD<sup>2</sup>; Ray Y Wang, MD<sup>2</sup>; Kristina R Dahlstrom, PhD<sup>2</sup>. <sup>1</sup>Louisiana State University Health Sciences Center New Orleans; <sup>2</sup>Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Acinic cell carcinoma (AcCC) is a malignant neoplasm of epithelial acinic cells, most commonly arising in the parotid gland but also occurring in submandibular, sublingual, and minor salivary glands. Although risk factors are unknown, there is a higher incidence among middle-aged white females.  While prognosis is outstanding, outcomes vary with tumor grade and stage. Limited data exists of AcCC arising in non-parotid sites, and it remains unclear whether tumor site influences clinical presentation, treatment approaches, or survival.</p>\n\n<p><strong>Methods:</strong> Data for patients with AcCC (histology code 8550/3) diagnosed between 2000–2022 were extracted from the SEER (Surveillance, Epidemiology, and End Results) 21 database. Cases were categorized by anatomic site into major and minor salivary glands.  Major salivary gland sites include parotid, submandibular, and sublingual glands; minor salivary glands encompass sinonasal, oral cavity, pharyngeal, and laryngeal but no other head and neck sites (not included are the extremely rare cutaneous, lacrimal glands, or thyroid gland sites of origin). Demographic, clinicopathologic, and treatment variables were analyzed, and cause-specific survival was estimated and compared to those of parotid site of origin.</p>\n\n<p><strong>Results:</strong> There were 4,792 cases of AcCC of the head and neck region in this 23 year period of the SEER21 database, and of these 4,333 (94%) occurred in the parotid gland. Those arising from other major salivary glands or from the minor salivary glands were demographically and clinically like those with parotid gland primaries:  median age, 53; female; non-Hispanic white; low-intermediate grade; and localized stage. However, those with non-parotid primaries were slightly older, those with sinonasal primaries were more commonly male, and 23% of patients with a sinonasal primary were non-Hispanic black. Additionally, parotid tumors were larger at presentation and virtually all high-grade AcCC or metastatic (lymph node or distant) AcCC arose in the parotid or other major salivary glands. Surgery was the mainstay of treatment with adjuvant radiation used in a significant proportion of AcCC arising from the parotid or other major salivary glands. Outcomes were similar across sites of origin with 10-year AcCC cause-specific survival for localized disease stage at >96%. For those with parotid primaries, 10-year AcCC cause-specific survival for those with regional and distant disease stage was 69% and 45%, respectively; but there were too few with primaries of non-parotid sites with regional or distant disease stage to have stable estimates of survival.</p>\n\n<p><strong>Conclusion:</strong> AcCC is one of the most common salivary gland malignancies. While overwhelmingly these occur in the parotid gland, other locations in the head and neck are the site of origin for approximately 6% of patients, most commonly in the gums/hard palate, submandibular gland, lips, and sinonasal tract. With standard surgical treatment patients with localized disease are almost always cured with surgery alone. Adjuvant radiation is indicated for those with high-grade, positive margins, perineural invasion, or lymph node metastases, affording those presenting with regional stage disease reasonable 10-year cause-specific survival rates (69%). Patients with distant stage at presentation have worse outcomes, but 5-year cause-specific survival rates are over 50%.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151887--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260122' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S119",
      "content_id": "154073",
      "abstract_number": "S119",
      "poster_number": "",
      "title": "Use of Intraoperative Bone Marrow Frozen Sections in Mandibulectomy for Head and Neck Cancer",
      "summary": "120 patients met inclusion criteria. Mean age at surgery was 58.2 years (SD 14.8). 73.6% of patients were male and 93.4% were white. 85.1% underwent segmental mandibulectomy; the remaining 14.9% underwent marginal mandibulectomy. 91% of patients underwent free flap reconstruction, most commonly with fibular free flap (51.1%), either alone or in conjunction with another regional or free flap. Anterolateral thigh...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154073",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amanda Wissmann",
      "presenter": "Amanda Wissmann",
      "authors": "Amanda Wissmann 1 ; Mitchell Victor, MD 2 ; Michael Sim, MD 2",
      "normalized_authors": [
        "Amanda Wissmann",
        "Mitchell Victor",
        "Michael Sim"
      ],
      "affiliations": [
        "Indiana University School of Medicine",
        "Indiana University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "Indiana University School of Medicine",
        "Indiana University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Significance",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amanda Wissmann 1 ; Mitchell Victor, MD 2 ; Michael Sim, MD 2",
        "Affiliations": "1 Indiana University School of Medicine; 2 Indiana University Department of Otolaryngology-Head and Neck Surgery",
        "Significance": "Margin status is an essential prognosticator for patients undergoing surgical resection of head and neck malignancy. Intraoperative frozen section analysis of soft tissue specimens is ubiquitous at academic/tertiary hospitals and an invaluable tool for achieving clear margins in oncologic resections. Oral cavity squamous cell carcinoma (SCC) and other head and neck cancers commonly invade the mandible, frequently necessitating either marginal or segmental mandibulectomy. The use of intraoperative bone marrow frozen sections (IBMFS) to assess adequacy of bony margins has been reported by multiple groups; however, estimates of its accuracy in determining final margin status vary widely. Herein, we report our institution’s experience with IBMFS in mandibulectomy for head and neck cancer.",
        "Methods": "Single academic medical center retrospective chart review of cases of patients who underwent either marginal or segmental mandibulectomy for head and neck neoplasm between 2009-2019. Patients who underwent mandibulectomy for non-neoplastic reasons such as osteoradionecrosis were excluded. Primary outcome was correlation of intraoperative bone-marrow frozen sections with final histologic overall margin status.",
        "Results": "120 patients met inclusion criteria. Mean age at surgery was 58.2 years (SD 14.8). 73.6% of patients were male and 93.4% were white. 85.1% underwent segmental mandibulectomy; the remaining 14.9% underwent marginal mandibulectomy. 91% of patients underwent free flap reconstruction, most commonly with fibular free flap (51.1%), either alone or in conjunction with another regional or free flap. Anterolateral thigh (ALT, 15.6%) and scapular system (13.1%) free flaps were the second and third most-utilized. Following surgery, 66.7% of patients were staged as pT4a and 49.2% were pN0. 89.2% of cases were SCC. IBMFS were taken in 67.5% (n=81) of cases, of which 4.9% (4) were positive. Two of these were SCC, one was mucoepidermoid carcinoma, and another was in an odontogenic myxoma. IBMFS were most frequently obtained from the mandibular body (63% of cases), ramus (45.7%) and parasymphyseal mandible (34.6%). The 3 IBMFS+ cases with preoperative CT had radiographic evidence of cortical invasion. Negative IBMFS conferred a negative predictive value (NPV) of 97.5% for negative final bone margins and 94.7% for negative overall margins. None of the 4 IBMFS+ cases had positive final bone margins. There was no significant difference in rate of positive overall margins (2.5% vs 5.4%, Fisher’s Exact p>0.5) nor final bone margins (2.5% vs 5.1%, p>0.5) in cases with versus without use of IBMFS.",
        "Discussion": "Intraoperative frozen sections of the mandibular bone-marrow during mandibulectomy confers a high NPV for negative final margins, though positive IBMFS were infrequently encountered in our dataset. While collection of IBMFS has limited drawbacks from an operative standpoint, we do not observe a significant difference in rates of positive final bone or overall margins in cases with use of IBMFS compared to those without. Positive IBMFS were overrepresented by non-SCC pathologies, which may suggest increased utility for IBMFS in mandibulectomy for rarer tumor types.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Intraoperative Bone Marrow Frozen Sections in Mandibulectomy for Head and Neck Cancer</span>. <u>Amanda Wissmann</u><sup>1</sup>; Mitchell Victor, MD<sup>2</sup>; Michael Sim, MD<sup>2</sup>. <sup>1</sup>Indiana University School of Medicine; <sup>2</sup>Indiana University Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Significance: </strong>Margin status is an essential prognosticator for patients undergoing surgical resection of head and neck malignancy. Intraoperative frozen section analysis of soft tissue specimens is ubiquitous at academic/tertiary hospitals and an invaluable tool for achieving clear margins in oncologic resections. Oral cavity squamous cell carcinoma (SCC) and other head and neck cancers commonly invade the mandible, frequently necessitating either marginal or segmental mandibulectomy. The use of intraoperative bone marrow frozen sections (IBMFS) to assess adequacy of bony margins has been reported by multiple groups; however, estimates of its accuracy in determining final margin status vary widely. Herein, we report our institution’s experience with IBMFS in mandibulectomy for head and neck cancer.</p>\n\n<p><strong>Methods: </strong>Single academic medical center retrospective chart review of cases of patients who underwent either marginal or segmental mandibulectomy for head and neck neoplasm between 2009-2019. Patients who underwent mandibulectomy for non-neoplastic reasons such as osteoradionecrosis were excluded. Primary outcome was correlation of intraoperative bone-marrow frozen sections with final histologic overall margin status.</p>\n\n<p><strong>Results: </strong>120 patients met inclusion criteria. Mean age at surgery was 58.2 years (SD 14.8). 73.6% of patients were male and 93.4% were white. 85.1% underwent segmental mandibulectomy; the remaining 14.9% underwent marginal mandibulectomy. 91% of patients underwent free flap reconstruction, most commonly with fibular free flap (51.1%), either alone or in conjunction with another regional or free flap. Anterolateral thigh (ALT, 15.6%) and scapular system (13.1%) free flaps were the second and third most-utilized. Following surgery, 66.7% of patients were staged as pT4a and 49.2% were pN0. 89.2% of cases were SCC. IBMFS were taken in 67.5% (n=81) of cases, of which 4.9% (4) were positive. Two of these were SCC, one was mucoepidermoid carcinoma, and another was in an odontogenic myxoma. IBMFS were most frequently obtained from the mandibular body (63% of cases), ramus (45.7%) and parasymphyseal mandible (34.6%). The 3 IBMFS+ cases with preoperative CT had radiographic evidence of cortical invasion. Negative IBMFS conferred a negative predictive value (NPV) of 97.5% for negative final bone margins and 94.7% for negative overall margins. None of the 4 IBMFS+ cases had positive final bone margins. There was no significant difference in rate of positive overall margins (2.5% vs 5.4%, Fisher’s Exact p>0.5) nor final bone margins (2.5% vs 5.1%, p>0.5) in cases with versus without use of IBMFS.</p>\n\n<p><strong>Discussion: </strong>Intraoperative frozen sections of the mandibular bone-marrow during mandibulectomy confers a high NPV for negative final margins, though positive IBMFS were infrequently encountered in our dataset. While collection of IBMFS has limited drawbacks from an operative standpoint, we do not observe a significant difference in rates of positive final bone or overall margins in cases with use of IBMFS compared to those without. Positive IBMFS were overrepresented by non-SCC pathologies, which may suggest increased utility for IBMFS in mandibulectomy for rarer tumor types.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154073--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S120",
      "content_id": "153815",
      "abstract_number": "S120",
      "poster_number": "",
      "title": "Intraoperative Margin Patterns and Associated Tumor Characteristics in Total Laryngectomy and Total Laryngopharyngectomy",
      "summary": "37.8% of patients who underwent re-resections had positive re-resections. Analysis shows LVI as an independent predictor of positive initial margins and is strongly associated with positive re-resection margins. TLP patients were more than twice as likely to have positive initial margins, while 1 cm increases in tumor size and DOI predicts non-clear margins. These findings may provide practical insight into...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153815",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jerome N Nashed, BA",
      "presenter": "Jerome N Nashed, BA",
      "authors": "Jerome N Nashed, BA 1 ; David U Sanchez, BA 2 ; Kirollos E Armosh, BS 1 ; Peter T Dziegielewski, MD 2 ; Dustin J Conrad, MD 2 ; Austin S Lam, MD 2",
      "normalized_authors": [
        "Jerome N Nashed",
        "David U Sanchez",
        "Kirollos E Armosh",
        "Peter T Dziegielewski",
        "Dustin J Conrad",
        "Austin S Lam"
      ],
      "affiliations": [
        "University of Florida - College of Medicine",
        "University of Florida - Department of Otolaryngology - Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Florida - College of Medicine",
        "University of Florida - Department of Otolaryngology - Head & Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 529,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jerome N Nashed, BA 1 ; David U Sanchez, BA 2 ; Kirollos E Armosh, BS 1 ; Peter T Dziegielewski, MD 2 ; Dustin J Conrad, MD 2 ; Austin S Lam, MD 2",
        "Affiliations": "1 University of Florida - College of Medicine; 2 University of Florida - Department of Otolaryngology - Head & Neck Surgery",
        "Introduction": "Achieving negative surgical margins is a central goal of total laryngectomy (TL) and total laryngopharyngectomy (TLP), yet positive initial margins and the need for additional re-resections remain a challenge. Despite this practice, the relationships among initial frozen positivity, re-resection yield, and final pathologic margin status in TL/TLP are still incompletely characterized.",
        "Objective": "This study aims to explore the rates of positive re-resections after positive initial margins in a TL or TLP and to examine which tumor characteristics are associated with higher rates of positive initial margins and positive re-resection margins in these procedures.",
        "Methods": "A single institution retrospective chart review looking at patient data from April 2015 – April 2025 was conducted. CPT codes were used to identify patients who underwent TLs or TLPs during this time. Patients were excluded if the primary tumor was oral or thyroid in nature or if the TL/TLP was salvage surgery. Tumors were categorized as either primary or recurrent, and any prior treatment was noted. Histopathologic information was also collected including histologic grade, lymphovascular invasion (LVI), tumor size, depth of invasion (DOI), pathologic T state, nodal involvement, and extranodal extension, and positive, close (< 5 mm), or negative (≥ 5 mm) margins.",
        "Results": "291 of the identified 338 patients met the inclusion criteria. 32/291 (11%) patients underwent TLP. 56/291 (19.2%) patients had positive initial margins, and 45/291 (15.5%) patients had re-resections performed. 17/45 (37.8%) of those who underwent re-resection had positive re-resection margins, and 29/45 (64.4%) had LVI. Fisher’s exact testing showed that LVI was strongly associated with positive re-resections: 16/29 (55.2%) patients with LVI had positive re-resection specimens, compared with 1/16 (6.3%) patients without LVI (p = 0.0012). A chi-squared test was used to compare categorical outcomes and found that patients undergoing a TLP were more than twice as likely to have positive initial margins when compared to those undergoing TL (37.5% vs 16.7% respectively, p=0.0023). LVI was strongly associated with initial frozen positivity when compared to those without LVI (27.1% vs 11.9% respectively, p=0.0017). On multivariable analysis, LVI remained an independent predictor of positive initial frozen margins, [odds ratio (OR) = 2.57, 95% confidence interval (CI) = 1.18-5.64, p=0.018]. A second logistic regression model was used to evaluate predictors of final non-clear margins, defined as close or positive margins. In this model, tumor size [OR 1.40 per cm; 95% CI 1.08–1.83; p = 0.011] and DOI [OR 1.68 per cm; 95% CI 1.07–2.64; p = 0.024] were independent predictors of final non-clear margins, indicating that larger and deeper tumors are more likely to result in close or positive margins.",
        "Conclusion": "37.8% of patients who underwent re-resections had positive re-resections. Analysis shows LVI as an independent predictor of positive initial margins and is strongly associated with positive re-resection margins. TLP patients were more than twice as likely to have positive initial margins, while 1 cm increases in tumor size and DOI predicts non-clear margins. These findings may provide practical insight into intraoperative decision-making during TL/TLP.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoperative Margin Patterns and Associated Tumor Characteristics in Total Laryngectomy and Total Laryngopharyngectomy</span>. <u>Jerome N Nashed, BA</u><sup>1</sup>; David U Sanchez, BA<sup>2</sup>; Kirollos E Armosh, BS<sup>1</sup>; Peter T Dziegielewski, MD<sup>2</sup>; Dustin J Conrad, MD<sup>2</sup>; Austin S Lam, MD<sup>2</sup>. <sup>1</sup>University of Florida - College of Medicine; <sup>2</sup>University of Florida - Department of Otolaryngology - Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Achieving negative surgical margins is a central goal of total laryngectomy (TL) and total laryngopharyngectomy (TLP), yet positive initial margins and the need for additional re-resections remain a challenge. Despite this practice, the relationships among initial frozen positivity, re-resection yield, and final pathologic margin status in TL/TLP are still incompletely characterized. <strong> </strong></p>\n\n<p><strong>Objective: </strong>This study aims to explore the rates of positive re-resections after positive initial margins in a TL or TLP and to examine which tumor characteristics are associated with higher rates of positive initial margins and positive re-resection margins in these procedures. </p>\n\n<p><strong>Methods: </strong>A single institution retrospective chart review looking at patient data from April 2015 – April 2025 was conducted. CPT codes were used to identify patients who underwent TLs or TLPs during this time. Patients were excluded if the primary tumor was oral or thyroid in nature or if the TL/TLP was salvage surgery. Tumors were categorized as either primary or recurrent, and any prior treatment was noted. Histopathologic information was also collected including histologic grade, lymphovascular invasion (LVI), tumor size, depth of invasion (DOI), pathologic T state, nodal involvement, and extranodal extension, and positive, close (< 5 mm), or negative (≥ 5 mm) margins. </p>\n\n<p><strong>Results: </strong>291 of the identified 338 patients met the inclusion criteria. 32/291 (11%) patients underwent TLP. 56/291 (19.2%) patients had positive initial margins, and 45/291 (15.5%) patients had re-resections performed. 17/45 (37.8%) of those who underwent re-resection had positive re-resection margins, and 29/45 (64.4%) had LVI. Fisher’s exact testing showed that LVI was strongly associated with positive re-resections: 16/29 (55.2%) patients with LVI had positive re-resection specimens, compared with 1/16 (6.3%) patients without LVI (p = 0.0012). A chi-squared test was used to compare categorical outcomes and found that patients undergoing a TLP were more than twice as likely to have positive initial margins when compared to those undergoing TL (37.5% vs 16.7% respectively, p=0.0023). LVI was strongly associated with initial frozen positivity when compared to those without LVI (27.1% vs 11.9% respectively, p=0.0017). On multivariable analysis, LVI remained an independent predictor of positive initial frozen margins, [odds ratio (OR) = 2.57, 95% confidence interval (CI) = 1.18-5.64, p=0.018]. A second logistic regression model was used to evaluate predictors of final non-clear margins, defined as close or positive margins. In this model, tumor size [OR 1.40 per cm; 95% CI 1.08–1.83; p = 0.011] and DOI [OR 1.68 per cm; 95% CI 1.07–2.64; p = 0.024] were independent predictors of final non-clear margins, indicating that larger and deeper tumors are more likely to result in close or positive margins. </p>\n\n<p><strong>Conclusion: </strong>37.8% of patients who underwent re-resections had positive re-resections. Analysis shows LVI as an independent predictor of positive initial margins and is strongly associated with positive re-resection margins. TLP patients were more than twice as likely to have positive initial margins, while 1 cm increases in tumor size and DOI predicts non-clear margins. These findings may provide practical insight into intraoperative decision-making during TL/TLP. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153815--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S121",
      "content_id": "154413",
      "abstract_number": "S121",
      "poster_number": "",
      "title": "Worst Pattern of Invasion Modifies Margin Status Interpretation in Oral Cavity Carcinoma",
      "summary": "WPOI 5 is associated with multiple adverse pathologic features in addition to locoregional recurrence in patients with OCSCC. A closest margin status beyond 6mm appears protective in patients with WPOI 5.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154413",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Norah Alnafea",
      "presenter": "Norah Alnafea",
      "authors": "Norah Alnafea ; Angela Magri; Livia Flornianova; Derin Caglar; M Pusztaszeri; Alex Mlynarek; Keith Richardson; Nader Sadeghi; K SultaneM; C Tsien; G Shenouda; Michael Hier; Marco Mascarella",
      "normalized_authors": [
        "Norah Alnafea",
        "Angela Magri",
        "Livia Flornianova",
        "Derin Caglar",
        "M Pusztaszeri",
        "Alex Mlynarek",
        "Keith Richardson",
        "Nader Sadeghi",
        "K SultaneM",
        "C Tsien",
        "G Shenouda",
        "Michael Hier",
        "Marco Mascarella"
      ],
      "affiliations": [
        "Mcgill University"
      ],
      "normalized_institutions": [
        "Mcgill University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154413/table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154413/table%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154413"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154413/FIGURE%201(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154413/FIGURE%201(1).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154413"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154413/FIGURE%202.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154413/FIGURE%202.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154413"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 441,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Norah Alnafea ; Angela Magri; Livia Flornianova; Derin Caglar; M Pusztaszeri; Alex Mlynarek; Keith Richardson; Nader Sadeghi; K SultaneM; C Tsien; G Shenouda; Michael Hier; Marco Mascarella",
        "Affiliations": "Mcgill University",
        "Background": "Locoregional failure is common in patients with oral cavity squamous cell carcinoma (OCSCC).WPOI 5 is associated with local and regional failure. However, the interaction between WPOI 5and margin status is unknown. We ascertain the effect of WPOI on margin status to predict locoregional failure in patients with OCSCC.",
        "Methods": "A retrospective cohort study of patients with AJCC 8th edition stage II-IVA oral cavity squamous cell carcinoma undergoing curative intent surgery with risk-adjusted adjuvant therapy when needed at two academic centres in Montreal, Canada. Margin status was defined as the closest margin distance from tumor, positive (<1mm), close (1 to <5mm), and clear (≥5mm). WPOI was coded as binary as either 5 or any category below 5. The interaction between margin status and WPOI were evaluated using multiple Cox regression to predict locoregional failure while adjusting for multiple confounding variables. Associations between categorical variables and WPOI 5 status were assessed using chi-square tests, while continuous variables were compared between groups using multiple logistic regression.",
        "Results": "158 patients were included in the study with an average age of 66 years, 63% males and 72% with locoregionally advanced over all stage disease ( T1,T2 34.81% / T3,T4 65.81%) . WPOI 5 was present in 77 (48%) patients and was associated with positive margins (5.05, 95% CI 1.59- 16), perineural invasion (4.42, 95%CI of 2.13-9.15) and extranodal extension (1.99, 95% CI 1.00-4.13). WPOI 5 (HR 2.62, 95% CI 1.21-5.63) and margin status (clear: 0.48, 95% CI 0.22- 0.99, and positive 2.60, 95% CI 1.47-4.63) were associated with locoregional recurrence after adjusting for multiple confounders. The interaction of WPOI 5 and margin status on locoregional recurrence indicated that WPOI 5 and positive margin status were submupliticative (HR 4.41, 95% CI 2.27-8.58, Table 1 and Figure 1). Patients with WPOI 5 and a clear margin had a higher likelihood of locoregional failure than those without WPOI 5 and a close/clear margin (HR 2.60, 95% CI 1.01-7.29). There were 6/17 (35%) locoregional failures in patients with WPOI 5 and a clear margin, however, no locoregional failures occurred with WPOI 5 with the closet margins greater than 6mm. A >6mm closest margin was protective (HR 0.26, 95% CI 0.07-0.98) when adjusting for multiple confounding factors in patients with WPOI 5 (Figure 2)..",
        "Conclusion": "WPOI 5 is associated with multiple adverse pathologic features in addition to locoregional recurrence in patients with OCSCC. A closest margin status beyond 6mm appears protective in patients with WPOI 5.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Worst Pattern of Invasion Modifies Margin Status Interpretation in Oral Cavity Carcinoma</span>. <u>Norah Alnafea</u>; Angela Magri; Livia Flornianova; Derin Caglar; M Pusztaszeri; Alex Mlynarek; Keith Richardson; Nader Sadeghi; K SultaneM; C Tsien; G Shenouda; Michael Hier; Marco Mascarella. Mcgill University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Locoregional failure is common in patients with oral cavity squamous cell carcinoma (OCSCC).WPOI 5 is associated with local and regional failure. However, the interaction between WPOI 5and margin status is unknown. We ascertain the effect of WPOI on margin status to predict locoregional failure in patients with OCSCC.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort study of patients with AJCC 8th edition stage II-IVA oral cavity squamous cell carcinoma undergoing curative intent surgery with risk-adjusted adjuvant therapy when needed at two academic centres in Montreal, Canada. Margin status was defined as the closest margin distance from tumor, positive (<1mm), close (1 to <5mm), and clear (≥5mm). WPOI was coded as binary as either 5 or any category below 5. The interaction between margin status and WPOI were evaluated using multiple Cox regression to predict locoregional failure while adjusting for multiple confounding variables. Associations between categorical variables and WPOI 5 status were assessed using chi-square tests, while continuous variables were compared between groups using multiple logistic regression.</p>\n\n<p><strong>Results: </strong>158 patients were included in the study with an average age of 66 years, 63% males and 72% with locoregionally advanced over all stage disease ( T1,T2 34.81% / T3,T4 65.81%) . WPOI 5 was present in 77 (48%) patients and was associated with positive margins (5.05, 95% CI 1.59- 16), perineural invasion (4.42, 95%CI of 2.13-9.15) and extranodal extension (1.99, 95% CI 1.00-4.13). WPOI 5 (HR 2.62, 95% CI 1.21-5.63) and margin status (clear: 0.48, 95% CI 0.22- 0.99, and positive 2.60, 95% CI 1.47-4.63) were associated with locoregional recurrence after adjusting for multiple confounders. The interaction of WPOI 5 and margin status on locoregional recurrence indicated that WPOI 5 and positive margin status were submupliticative (HR 4.41, 95% CI 2.27-8.58, Table 1 and Figure 1). Patients with WPOI 5 and a clear margin had a higher likelihood of locoregional failure than those without WPOI 5 and a close/clear margin (HR 2.60, 95% CI 1.01-7.29). There were 6/17 (35%) locoregional failures in patients with WPOI 5 and a clear margin, however, no locoregional failures occurred with WPOI 5 with the closet margins greater than 6mm. A >6mm closest margin was protective (HR 0.26, 95% CI 0.07-0.98) when adjusting for multiple confounding factors in patients with WPOI 5 (Figure 2)..</p>\n\n<p><strong>Conclusion: </strong>WPOI 5 is associated with multiple adverse pathologic features in addition to locoregional recurrence in patients with OCSCC. A closest margin status beyond 6mm appears protective in patients with WPOI 5.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154413/table%201.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154413/FIGURE%201(1).png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154413/FIGURE%202.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154413--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S122",
      "content_id": "153669",
      "abstract_number": "S122",
      "poster_number": "",
      "title": "The Prognostic Implications of Bone invasion as a Sole Criterion for Upstaging Oral Squamous Cell Carcinoma to pT4a",
      "summary": "Bone invasion in OSCC after adequate surgical resection in the absence of other high-risk features does not adversely influence outcomes irrespective of postoperative adjuvant treatment.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153669",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hadar Gez Reder, MD",
      "presenter": "Hadar Gez Reder, MD",
      "authors": "Hadar Gez Reder, MD ; Emma Finnegan; Nancy Lee, MD; Snehal Patel, MD; Ian Ganly, MD, PhD",
      "normalized_authors": [
        "Hadar Gez Reder",
        "Emma Finnegan",
        "Nancy Lee",
        "Snehal Patel",
        "Ian Ganly"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 334,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hadar Gez Reder, MD ; Emma Finnegan; Nancy Lee, MD; Snehal Patel, MD; Ian Ganly, MD, PhD",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Introduction": "Invasion of bone on pathologic examination is a criterion for upstaging oral cavity squamous cell carcinoma (OSCC) to pT4a and current clinical guidelines recommend postoperative adjuvant treatment (POAT) for surgically treated patients even in the absence of other high-risk features such as pathologically positive neck nodes. There are conflicting data regarding the additive benefit of POAT in patients staged pT4a solely due to bone invasion and with no other high-risk prognostic factors. The primary aim of our study was to report outcomes after surgical resection alone in pN0 OSCC patients staged pT4a solely due to bone invasion.",
        "Methods": "A review of 2,082 adult primary surgical OSCC patients treated at a tertiary cancer center from 1985 to 2015 was performed. The pathological reports of patients with pT4aN0M0 tumors were reviewed to identify patients staged as pT4a solely due to bone invasion. Other high-risk features of the primary tumor such as histologic grade, lymphovascular invasion, perineural invasion, depth of invasion and close surgical margins were not used as exclusion criteria. Patients with positive surgical margins were excluded. The primary aim of the study was to report oncologic outcomes, including LRRFS, DSS and OS in this selected subset of OSCC. Secondarily, outcomes were compared between patients treated with POAT and those managed with observation.",
        "Results": "In total, 62 patients met the inclusion criteria. The average age at diagnosis was 65 years (IQR 56-75), 56% were males (n=35). The most common subsite was the lower gum (66%) followed by retromolar trigone and floor of mouth (13% each). The mean follow up time was 40 months (IQR 15-99). 38 patients (61.3%) did not receive POAT. Survival analysis demonstrated no difference in LRRFS, DSS and OS between patients who received POAT and those who did not (p=0.58, p=0.44 and p=0.61 respectively).",
        "Conclusion": "Bone invasion in OSCC after adequate surgical resection in the absence of other high-risk features does not adversely influence outcomes irrespective of postoperative adjuvant treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Prognostic Implications of Bone invasion as a Sole Criterion for Upstaging Oral Squamous Cell Carcinoma to pT4a</span>. <u>Hadar Gez Reder, MD</u>; Emma Finnegan; Nancy Lee, MD; Snehal Patel, MD; Ian Ganly, MD, PhD. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Invasion of bone on pathologic examination is a criterion for upstaging oral cavity squamous cell carcinoma (OSCC) to pT4a and current clinical guidelines recommend postoperative adjuvant treatment (POAT) for surgically treated patients even in the absence of other high-risk features such as pathologically positive neck nodes. There are conflicting data regarding the additive benefit of POAT in patients staged pT4a solely due to bone invasion and with no other high-risk prognostic factors. The primary aim of our study was to report outcomes after surgical resection alone in pN0 OSCC patients staged pT4a solely due to bone invasion.</p>\n\n<p><strong>Methods</strong>: A review of 2,082 adult primary surgical OSCC patients treated at a tertiary cancer center from 1985 to 2015 was performed. The pathological reports of patients with pT4aN0M0 tumors were reviewed to identify patients staged as pT4a solely due to bone invasion. Other high-risk features of the primary tumor such as histologic grade, lymphovascular invasion, perineural invasion, depth of invasion and close surgical margins were not used as exclusion criteria. Patients with positive surgical margins were excluded. The primary aim of the study was to report oncologic outcomes, including LRRFS, DSS and OS in this selected subset of OSCC. Secondarily, outcomes were compared between patients treated with POAT and those managed with observation.</p>\n\n<p><strong>Results</strong>: In total, 62 patients met the inclusion criteria. The average age at diagnosis was 65 years (IQR 56-75), 56% were males (n=35). The most common subsite was the lower gum (66%) followed by retromolar trigone and floor of mouth (13% each). The mean follow up time was 40 months (IQR 15-99). 38 patients (61.3%) did not receive POAT. Survival analysis demonstrated no difference in LRRFS, DSS and OS between patients who received POAT and those who did not (p=0.58, p=0.44 and p=0.61 respectively).</p>\n\n<p><strong>Conclusion</strong>: Bone invasion in OSCC after adequate surgical resection in the absence of other high-risk features does not adversely influence outcomes irrespective of postoperative adjuvant treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153669--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S123",
      "content_id": "153791",
      "abstract_number": "S123",
      "poster_number": "",
      "title": "Combined prognostic value of Margin to depth of invasion ratio and minor pathological risk factors in oral squamous cell carcinoma",
      "summary": "MDR < 0.5 serves as a robust indicator of high-risk surgical margins in M0 OSCC. The presence of additional minor pathological risk factors in MDR < 0.5 patients identifies a subgroup with significantly worse survival and higher locoregional recurrence risk, who may benefit from adjuvant radiotherapy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153791",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chun-Yang Hung, MD",
      "presenter": "Chun-Yang Hung, MD",
      "authors": "Chun-Yang Hung, MD 1 ; Li-Jen Liao, MD, PhD 2 ; Yu-Ping Cheng 3 ; Wan-Lun Hsu 3 ; Chun-Ju Chiang 4 ; Chun-Wei Chang 5 ; Wen-Chung Lee 4 ; Cheng-Ping Wang 1 ; Pei-Jen Lou 1 ; Yih-Leong Chang 6 ; Shih-yu Chen 7 ; Tseng-Cheng Chen, MD, PhD 1",
      "normalized_authors": [
        "Chun-Yang Hung",
        "Li-Jen Liao",
        "Yu-Ping Cheng",
        "Wan-Lun Hsu",
        "Chun-Ju Chiang",
        "Chun-Wei Chang",
        "Wen-Chung Lee",
        "Cheng-Ping Wang",
        "Pei-Jen Lou",
        "Yih-Leong Chang",
        "Shih-yu Chen",
        "Tseng-Cheng Chen"
      ],
      "affiliations": [
        "Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan",
        "Department of Otolaryngology Head and Neck Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan",
        "Data Science Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan",
        "Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan",
        "Department of Otolaryngology, National Taiwan University BioMedical Park Hospital, Hsin-Chu, Taiwan",
        "Department of Pathology, National Taiwan University Cancer Center and National University College of Medicine, Taipei, Taiwan",
        "nstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan",
        "Department of Otolaryngology Head and Neck Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan",
        "Data Science Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan",
        "Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan",
        "Department of Otolaryngology, National Taiwan University BioMedical Park Hospital, Hsin-Chu, Taiwan",
        "Department of Pathology, National Taiwan University Cancer Center and National University College of Medicine, Taipei, Taiwan",
        "nstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 293,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chun-Yang Hung, MD 1 ; Li-Jen Liao, MD, PhD 2 ; Yu-Ping Cheng 3 ; Wan-Lun Hsu 3 ; Chun-Ju Chiang 4 ; Chun-Wei Chang 5 ; Wen-Chung Lee 4 ; Cheng-Ping Wang 1 ; Pei-Jen Lou 1 ; Yih-Leong Chang 6 ; Shih-yu Chen 7 ; Tseng-Cheng Chen, MD, PhD 1",
        "Affiliations": "1 Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; 2 Department of Otolaryngology Head and Neck Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan; 3 Data Science Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; 4 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; 5 Department of Otolaryngology, National Taiwan University BioMedical Park Hospital, Hsin-Chu, Taiwan; 6 Department of Pathology, National Taiwan University Cancer Center and National University College of Medicine, Taipei, Taiwan; 7 nstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan",
        "Purpose": "The optimal definition of high-risk surgical margins in oral squamous cell carcinoma (OSCC) remains controversial. The margin-to-depth-of-invasion ratio (MDR) has recently emerged as a metric to improve margin assessment, though its integration with minor pathological features has not been fully explored.",
        "Methods": "Patients with M0 OSCC recorded in the Taiwan Cancer Registry between January 2018 and December 2022 were reviewed. Patients were stratified by MDR (<0.5 vs. ≥0.5) and the presence of pathological risk factors including positive margins, perineural invasion (PNI), lympho-vascular invasion (LVI), and poor differentiation.",
        "Results": "This study analyzed 14,240 M0 OSCC patients: 824 (5.79%) had positive margins, 7,471 (52.46%) had MDR ≥ 0.5, and 5,945 (41.75%) had MDR < 0.5. Among MDR < 0.5 patients, 3330 (56.01%) were classified as “any+” (positive for PNI, LVI, or poor differentiation) and 2615 (43.99%) as “all−” (negative for all three). The 3-year disease-free survival declined across groups: MDR ≥ 0.5 (79.8%), MDR < 0.5 all− (71.8%), MDR < 0.5 any+ (52.5%), and positive margin (44.4%) (p<0.001). The MDR < 0.5 any+ subgroup had significantly higher local recurrence (HR = 1.58, p<0.001) and regional recurrence (HR = 1.99, p <0.001) than the all− subgroup. Adjuvant radiotherapy improved disease-free and overall survival in the any+ subgroup (both p <0.001), but showed no benefit in the all− subgroup (p =0.15 and 0.98 respectively).",
        "Conclusion": "MDR < 0.5 serves as a robust indicator of high-risk surgical margins in M0 OSCC. The presence of additional minor pathological risk factors in MDR < 0.5 patients identifies a subgroup with significantly worse survival and higher locoregional recurrence risk, who may benefit from adjuvant radiotherapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Combined prognostic value of Margin to depth of invasion ratio and minor pathological risk factors in oral squamous cell carcinoma</span>. <u>Chun-Yang Hung, MD</u><sup>1</sup>; Li-Jen Liao, MD, PhD<sup>2</sup>; Yu-Ping Cheng<sup>3</sup>; Wan-Lun Hsu<sup>3</sup>; Chun-Ju Chiang<sup>4</sup>; Chun-Wei Chang<sup>5</sup>; Wen-Chung Lee<sup>4</sup>; Cheng-Ping Wang<sup>1</sup>; Pei-Jen Lou<sup>1</sup>; Yih-Leong Chang<sup>6</sup>; Shih-yu Chen<sup>7</sup>; Tseng-Cheng Chen, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; <sup>2</sup>Department of Otolaryngology Head and Neck Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan; <sup>3</sup>Data Science Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; <sup>4</sup>Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; <sup>5</sup>Department of Otolaryngology, National Taiwan University BioMedical Park Hospital, Hsin-Chu, Taiwan; <sup>6</sup>Department of Pathology, National Taiwan University Cancer Center and National University College of Medicine, Taipei, Taiwan; <sup>7</sup>nstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>The optimal definition of high-risk surgical margins in oral squamous cell carcinoma (OSCC) remains controversial. The margin-to-depth-of-invasion ratio (MDR) has recently emerged as a metric to improve margin assessment, though its integration with minor pathological features has not been fully explored.</p>\n\n<p><strong>Methods: </strong>Patients with M0 OSCC recorded in the Taiwan Cancer Registry between January 2018 and December 2022 were reviewed. Patients were stratified by MDR (<0.5 vs. ≥0.5) and the presence of pathological risk factors including positive margins, perineural invasion (PNI), lympho-vascular invasion (LVI), and poor differentiation.</p>\n\n<p><strong>Results: </strong>This study analyzed 14,240 M0 OSCC patients: 824 (5.79%) had positive margins, 7,471 (52.46%) had MDR ≥ 0.5, and 5,945 (41.75%) had MDR < 0.5. Among MDR < 0.5 patients, 3330 (56.01%) were classified as “any+” (positive for PNI, LVI, or poor differentiation) and 2615 (43.99%) as “all−” (negative for all three). The 3-year disease-free survival declined across groups: MDR ≥ 0.5 (79.8%), MDR < 0.5 all− (71.8%), MDR < 0.5 any+ (52.5%), and positive margin (44.4%) (p<0.001). The MDR < 0.5 any+ subgroup had significantly higher local recurrence (HR = 1.58, p<0.001) and regional recurrence (HR = 1.99, p <0.001) than the all− subgroup. Adjuvant radiotherapy improved disease-free and overall survival in the any+ subgroup (both p <0.001), but showed no benefit in the all− subgroup (p =0.15 and 0.98 respectively).</p>\n\n<p><strong>Conclusion: </strong>MDR < 0.5 serves as a robust indicator of high-risk surgical margins in M0 OSCC. The presence of additional minor pathological risk factors in MDR < 0.5 patients identifies a subgroup with significantly worse survival and higher locoregional recurrence risk, who may benefit from adjuvant radiotherapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153791--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S124",
      "content_id": "154368",
      "abstract_number": "S124",
      "poster_number": "",
      "title": "Molecular and Immunological Characteristics of Pharyngeal Tumors Stratified by Tumor-Immune Proximity and HPV Status",
      "summary": "Human-papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is a malignancy with high immunological heterogeneity and limited biologic prognostic biomarkers. Physical proximity between tumor cells and tumor infiltrating lymphocytes (TILs), regulates tumor progression and therapeutic response. HPV-related cancers specifically have high immunologic phenotypes and may have unique spatial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154368",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jiayu Wang, PhD",
      "presenter": "Jiayu Wang, PhD",
      "authors": "Michael Allevato, PhD 1 ; Jiayu Wang, PhD 2 ; Chelsea Gelboin-Burkhart, MD 2 ; José Zevallos, MD, MPH, FACS 2 ; Matthew Spector, MD, FACS 2 ; Arvind Rao, PhD 3 ; Steven Chinn, MD, MPH, FACS 2",
      "normalized_authors": [
        "Michael Allevato",
        "Jiayu Wang",
        "Chelsea Gelboin-Burkhart",
        "José Zevallos",
        "Matthew Spector",
        "Arvind Rao",
        "Steven Chinn"
      ],
      "affiliations": [
        "University of Michigan Medical School",
        "University of Pittsburgh",
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan Medical School",
        "University of Pittsburgh",
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154368/Figures%20for%20AHNS%202026%20-%20HPV.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154368/Figures%20for%20AHNS%202026%20-%20HPV.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154368"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 329,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "FIGURE 1"
      ],
      "sections": {
        "Authors": "Michael Allevato, PhD 1 ; Jiayu Wang, PhD 2 ; Chelsea Gelboin-Burkhart, MD 2 ; José Zevallos, MD, MPH, FACS 2 ; Matthew Spector, MD, FACS 2 ; Arvind Rao, PhD 3 ; Steven Chinn, MD, MPH, FACS 2",
        "Affiliations": "1 University of Michigan Medical School; 2 University of Pittsburgh; 3 University of Michigan",
        "Abstract": "Human-papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is a malignancy with high immunological heterogeneity and limited biologic prognostic biomarkers. Physical proximity between tumor cells and tumor infiltrating lymphocytes (TILs), regulates tumor progression and therapeutic response. HPV-related cancers specifically have high immunologic phenotypes and may have unique spatial relationships between tumor cells and TILs. We sought to understand how HPV viral etiology affects the tumor immune microenvironment and spatial relationships between tumor-immune cells to drive survival, as well as the underlying molecular mechanisms of immune activation. Our group developed an automated, deep-learning-based system for comprehensive spatial analysis of hematoxylin-and-eosin (H&E) slides. We calculated the Tumor:Lymphoid G-cross (Gfx) score for HPV+ and HPV- HNSCC patients with pharyngeal tumors, stratifying these tumors into low, mid, and high-Gfx groups. We then performed bulk and single-cell RNA sequencing to determine the changes in gene expression, pathway activation, and TILs composition between immune-inflamed (high-Gfx) and immune-excluded (low-Gfx) tumors, in both HPV+ and HPV- groups. Hallmark gene set enrichment analysis (GSEA) shows pathways significantly enriched (red) or suppressed (blue) in tumors with high versus low Gfx for each HPV status group. Dot color indicates normalized enrichment score (NES), and dot size represents significance. View in Agenda and Add to Schedule",
        "FIGURE 1": "showed that HPV+ tumors with high-Gfx exhibited elevated expression of stromal remodeling genes ( INHBA , AADAC ) and increased activation of epithelial–mesenchymal transition (EMT) and tumor necrosis factor-α (TNF-α) signaling pathways ( FIGURE 1 ). However, HPV- tumors with high-Gfx showed elevated expression of metabolic genes ( FBP2 , PPP1R1A ) and increased activation of oxidative phosphorylation and myogenesis pathways ( FIGURE 1 ). Moreover, CD8+ and CD4+ populations were higher in HPV+ and in high-Gfx tumors, reflecting a canonical virally-inflamed state. In contrast, HPV- tumors with high-Gfx lacked effector lymphocyte enrichment and maintained myeloid dominance regardless of spatial patterns. These findings demonstrate that spatial organization drives distinct transcriptional and immunological states, with HPV status determining whether tumor-immune proximity results in productive immune engagement or persistent exclusion in HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Molecular and Immunological Characteristics of Pharyngeal Tumors Stratified by Tumor-Immune Proximity and HPV Status</span>. Michael Allevato, PhD<sup>1</sup>; <u>Jiayu Wang, PhD</u><sup>2</sup>; Chelsea Gelboin-Burkhart, MD<sup>2</sup>; José Zevallos, MD, MPH, FACS<sup>2</sup>; Matthew Spector, MD, FACS<sup>2</sup>; Arvind Rao, PhD<sup>3</sup>; Steven Chinn, MD, MPH, FACS<sup>2</sup>. <sup>1</sup>University of Michigan Medical School; <sup>2</sup>University of Pittsburgh; <sup>3</sup>University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Human-papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is a malignancy with high immunological heterogeneity and limited biologic prognostic biomarkers. Physical proximity between tumor cells and tumor infiltrating lymphocytes (TILs), regulates tumor progression and therapeutic response. HPV-related cancers specifically have high immunologic phenotypes and may have unique spatial relationships between tumor cells and TILs.  We sought to understand how HPV viral etiology affects the tumor immune microenvironment and spatial relationships between tumor-immune cells to drive survival, as well as the underlying molecular mechanisms of immune activation.</p>\n\n<p>Our group developed an automated, deep-learning-based system for comprehensive spatial analysis of hematoxylin-and-eosin (H&E) slides. We calculated the Tumor:Lymphoid G-cross (Gfx) score for HPV+ and HPV- HNSCC patients with pharyngeal tumors, stratifying these tumors into low, mid, and high-Gfx groups. We then performed bulk and single-cell RNA sequencing to determine the changes in gene expression, pathway activation, and TILs composition between immune-inflamed (high-Gfx) and immune-excluded (low-Gfx) tumors, in both HPV+ and HPV- groups.</p>\n\n<p>Our data showed that HPV+ tumors with high-Gfx exhibited elevated expression of stromal remodeling genes (<em>INHBA</em>, <em>AADAC</em>) and increased activation of epithelial–mesenchymal transition (EMT) and tumor necrosis factor-α (TNF-α) signaling pathways (<strong>FIGURE 1</strong>). However, HPV- tumors with high-Gfx showed elevated expression of metabolic genes (<em>FBP2</em>, <em>PPP1R1A</em>) and increased activation of oxidative phosphorylation and myogenesis pathways (<strong>FIGURE 1</strong>). Moreover, CD8+ and CD4+ populations were higher in HPV+ and in high-Gfx tumors, reflecting a canonical virally-inflamed state. In contrast, HPV- tumors with high-Gfx lacked effector lymphocyte enrichment and maintained myeloid dominance regardless of spatial patterns. These findings demonstrate that spatial organization drives distinct transcriptional and immunological states, with HPV status determining whether tumor-immune proximity results in productive immune engagement or persistent exclusion in HNSCC.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154368/Figures%20for%20AHNS%202026%20-%20HPV.png' /></p>\n\n<p><strong>FIGURE 1. Differential pathway enrichment by Gfx score in HPV– and HPV+ pharyngeal tumors.</strong></p>\n\n<p>Hallmark gene set enrichment analysis (GSEA) shows pathways significantly enriched (red) or suppressed (blue) in tumors with high versus low Gfx for each HPV status group. Dot color indicates normalized enrichment score (NES), and dot size represents significance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154368--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S125",
      "content_id": "153384",
      "abstract_number": "S125",
      "poster_number": "",
      "title": "Association of Soft vs Mucosal Tissue Positive Margin Status with Survival Outcomes Following Total Laryngectomy",
      "summary": "Among this cohort of patients undergoing total laryngectomy for advanced or recurrent cancer, mucosal margins were associated with worse survival outcomes as expected, but soft tissue margins were not. As soft tissue margins may be superseded by neck dissection at the time of TL, the meaning of pathologically reported positive margins must be interpreted thoughtfully by the treating surgeon to guide treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153384",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Keyon Kazempour, BA",
      "presenter": "Keyon Kazempour, BA",
      "authors": "Keyon Kazempour, BA ; Patrick Tassone, MD",
      "normalized_authors": [
        "Keyon Kazempour",
        "Patrick Tassone"
      ],
      "affiliations": [
        "University of Missouri School of Medicine"
      ],
      "normalized_institutions": [
        "University of Missouri School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153384/dfs_margins%20(1).jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153384/dfs_margins%20(1).jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153384"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153384/os_margin%20(1).jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153384/os_margin%20(1).jpeg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153384"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Figure 1.",
        "Figure 2.",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Keyon Kazempour, BA ; Patrick Tassone, MD",
        "Affiliations": "University of Missouri School of Medicine",
        "Introduction": "Total laryngectomy (TL), the complete removal of the voice box, is typically performed for advanced or recurrent laryngeal cancer. When performed in this context, a primary aim is achieving negative margins confirming no microscopic disease at specimen edges. Previous research examining patients with squamous cell carcinoma (SCC) who underwent TL demonstrated that positive initial mucosal margins, regardless of negative final margins, is associated with local recurrence and worse overall survival. However, the impact of specific positive margin type, mucosal vs soft tissue, remains unclear.",
        "Abstract": "With this retrospective cohort study, we examined patients who underwent TL for the treatment of squamous cell carcinoma to determine whether specific positive margin types were associated with disease-free survival (DFS) and overall survival (OS). On univariate analysis, positive mucosal margins were significantly associated with worse DFS (HR 2.87, 95% CI 1.47-5.59, p=0.002) and OS (HR 2.96, 95% CI 1.52-5.79, p=0.001); however, positive soft tissue margins showed no significant association with worse DFS (HR 1.11, 95% CI 0.60-2.05, p=0.745) or OS (HR 1.15, 95% CI 0.62-2.13, p=0.659). Multivariate analysis confirmed mucosal margin association with worse DFS (HR 3.49, 95% CI 1.51-8.07, p=0.004) and OS (HR 4.05, 95% CI 1.74-9.42, p=0.001) but not soft tissue margins (DFS HR 1.54, 95% CI 0.79-3.02, p=0.204; OS HR 1.72, 95% CI 0.88-3.34, p=0.111). View in Agenda and Add to Schedule",
        "Methods": "This retrospective cohort study at a single tertiary care referral center included patients who underwent total laryngectomy from 2000-2024. Positive margins were defined as invasive carcinoma, carcinoma in situ, or severe dysplasia at resection and not superseded by additional resection. Examined factors include age, race, Charlson Comorbidity Index, pathologic T and N stage, extranodal extension (ENE), lymphovascular invasion (LVI), perineural invasion (PNI), neck dissection and laterality at time of procedure, and prior head/neck radiation. Univariate and multivariate Cox proportional-hazards analysis assessed associations between examined factors and DFS and OS.",
        "Results": "A total of 170 patients met inclusion and exclusion criteria. A total of 37 patients (21.8%) had positive margins by study criteria: 26 (15.3%) soft tissue and 11 (6.5%) mucosal.",
        "Figure 1.": "Kaplan-Meier curve showing disease-free survival by margin status",
        "Figure 2.": "Kaplan-Meier curve showing overall survival by margin status",
        "Conclusions": "Among this cohort of patients undergoing total laryngectomy for advanced or recurrent cancer, mucosal margins were associated with worse survival outcomes as expected, but soft tissue margins were not. As soft tissue margins may be superseded by neck dissection at the time of TL, the meaning of pathologically reported positive margins must be interpreted thoughtfully by the treating surgeon to guide treatment decisions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Soft vs Mucosal Tissue Positive Margin Status with Survival Outcomes Following Total Laryngectomy</span>. <u>Keyon Kazempour, BA</u>; Patrick Tassone, MD. University of Missouri School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Total laryngectomy (TL), the complete removal of the voice box, is typically performed for advanced or recurrent laryngeal cancer. When performed in this context, a primary aim is achieving negative margins confirming no microscopic disease at specimen edges. Previous research examining patients with squamous cell carcinoma (SCC) who underwent TL demonstrated that positive initial mucosal margins, regardless of negative final margins, is associated with local recurrence and worse overall survival. However, the impact of specific positive margin type, mucosal vs soft tissue, remains unclear. </p>\n\n<p>With this retrospective cohort study, we examined patients who underwent TL for the treatment of squamous cell carcinoma to determine whether specific positive margin types were associated with disease-free survival (DFS) and overall survival (OS).</p>\n\n<p><strong>Methods:</strong> This retrospective cohort study at a single tertiary care referral center included patients who underwent total laryngectomy from 2000-2024. Positive margins were defined as invasive carcinoma, carcinoma in situ, or severe dysplasia at resection and not superseded by additional resection. Examined factors include age, race, Charlson Comorbidity Index, pathologic T and N stage, extranodal extension (ENE), lymphovascular invasion (LVI), perineural invasion (PNI), neck dissection and laterality at time of procedure, and prior head/neck radiation. Univariate and multivariate Cox proportional-hazards analysis assessed associations between examined factors and DFS and OS.</p>\n\n<p><strong>Results:</strong> A total of 170 patients met inclusion and exclusion criteria. A total of 37 patients (21.8%) had positive margins by study criteria: 26 (15.3%) soft tissue and 11 (6.5%) mucosal.</p>\n\n<p>On univariate analysis, positive mucosal margins were significantly associated with worse DFS (HR 2.87, 95% CI 1.47-5.59, p=0.002) and OS (HR 2.96, 95% CI 1.52-5.79, p=0.001); however, positive soft tissue margins showed no significant association with worse DFS (HR 1.11, 95% CI 0.60-2.05, p=0.745) or OS (HR 1.15, 95% CI 0.62-2.13, p=0.659).</p>\n\n<p>Multivariate analysis confirmed mucosal margin association with worse DFS (HR 3.49, 95% CI 1.51-8.07, p=0.004) and OS (HR 4.05, 95% CI 1.74-9.42, p=0.001) but not soft tissue margins (DFS HR 1.54, 95% CI 0.79-3.02, p=0.204; OS HR 1.72, 95% CI 0.88-3.34, p=0.111).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153384/dfs_margins%20(1).jpeg' /></p>\n\n<p><strong>Figure 1. </strong>Kaplan-Meier curve showing disease-free survival by margin status</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153384/os_margin%20(1).jpeg' /></p>\n\n<p><strong>Figure 2. </strong>Kaplan-Meier curve showing overall survival by margin status </p>\n\n<p><strong>Conclusions:</strong> Among this cohort of patients undergoing total laryngectomy for advanced or recurrent cancer, mucosal margins were associated with worse survival outcomes as expected, but soft tissue margins were not. As soft tissue margins may be superseded by neck dissection at the time of TL, the meaning of pathologically reported positive margins must be interpreted thoughtfully by the treating surgeon to guide treatment decisions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153384--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S126",
      "content_id": "153760",
      "abstract_number": "S126",
      "poster_number": "",
      "title": "Final Histologic Grade Outperforms Worst Histologic Grade for Predicting Perineural Invasion in Oral Tongue Squamous Cell Carcinoma",
      "summary": "Higher histologic grade is strongly associated with PNI in OTSCC, and the strongest correlation comes from the final pathology grade. Upgrading grades does not improve prediction. Adjustment for DOI>10mm does not materially alter these findings.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153760",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joseph Masselli, MD, DDS",
      "presenter": "Joseph Masselli, MD, DDS",
      "authors": "Joseph Masselli, MD, DDS ; Jasmine Sze, MD, DDS; Laurent Ganry, MD; David L Hirsch, MD, DDS; Andrew Salama, MD, DDS",
      "normalized_authors": [
        "Joseph Masselli",
        "Jasmine Sze",
        "Laurent Ganry",
        "David L Hirsch",
        "Andrew Salama"
      ],
      "affiliations": [
        "Northwell Health"
      ],
      "normalized_institutions": [
        "Northwell Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153760/prevlence%20bar%20chart%20.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153760/prevlence%20bar%20chart%20.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153760"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153760/spearmangraph.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153760/spearmangraph.jpeg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153760"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joseph Masselli, MD, DDS ; Jasmine Sze, MD, DDS; Laurent Ganry, MD; David L Hirsch, MD, DDS; Andrew Salama, MD, DDS",
        "Affiliations": "Northwell Health",
        "Background": "The Broders histologic grading scale is adopted by the WHO and widely reported in final pathologic specimens in oral tongue squamous cell carcinoma (OTSCC). It is a common occurrence for the degree of differentiation to be downgraded from the biopsy specimen compared to the final pathology, indicating that the most poorly differentiated cells were excised in the biopsy specimen. It is unclear whether upgrading the Broders grade to reflect the poorest differentiation status between the biopsy and final pathology specimen improves the prediction of adverse pathologic features such as perineural invasion (PNI) in the final specimen.",
        "Objective": "To determine if worst histologic grade (WHG) (defined as the highest grade between biopsy and resection) correlates more strongly with PNI than the original grade from final pathology (OHG), and to assess whether this relationship persists after adjusting for depth of invasion (DOI>10mm).",
        "Methods": "We retrospectively analyzed 29 OTSCC patients treated with partial or hemiglossectomy. Histologic grade was recorded as original grade and worst grade (1-3 with grade 1 indicating well differentiated, 2 indicating moderately differentiated, and 3 indicating poorly differentiated). PNI was coded as present/absent. Spearman’s rank correlation assessed associations between grade and PNI; partial Spearman correlation adjusted for DOI>10mm.",
        "Results": "13/29 cases (45%) were upgraded by at least 1 point to reflect WHG. PNI occurred in 12/29 cases (41%). OHG showed a strong correlation with PNI (ρ=0.674, p=0.0003), which remained significant after DOI adjustment (partial ρ=0.669, p=0.0005). WHG was also associated with PNI (ρ=0.535, p=0.0028), persisting after adjustment (partial ρ=0.528, p=0.0039). Contrary to expectation, upgrading to worst grade did not strengthen the association compared to original grade.",
        "Conclusions": "Higher histologic grade is strongly associated with PNI in OTSCC, and the strongest correlation comes from the final pathology grade. Upgrading grades does not improve prediction. Adjustment for DOI>10mm does not materially alter these findings.",
        "Discussion": "We postulate that WHG weakened association with PNI due to foci of poorly differentiated cells causing an upgrade in the overall sample while the bulk of the tumor may not demonstrate the same biology. The Brandwein-Gensler model may account for these instances in regard to the Worst Pattern of Invasion component of the scale. Larger studies are needed to explore continuous DOI effects and validate these observations.",
        "Abstract": "Faisal M, Abu Bakar M, Sarwar A, Adeel M, Batool F, Malik KI, Jamshed A, Hussain R. Depth of invasion (DOI) as a predictor of cervical nodal metastasis and local recurrence in early stage squamous cell carcinoma of oral tongue (ESSCOT). PLoS One. 2018 Aug 22;13(8):e0202632. doi: 10.1371/journal.pone.0202632. PMID: 30133515; PMCID: PMC6105019. Rahman, N., MacNeill, M., Wallace, W. et al. Reframing Histological Risk Assessment of Oral Squamous Cell Carcinoma in the Era of UICC 8th Edition TNM Staging. Head and Neck Pathol 15, 202–211 (2021). https://doi.org/10.1007/s12105-020-01201-8 WHO Classification of Tumours Editorial Board: Head and Neck Tumours, 5th Edition, 2024 View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Final Histologic Grade Outperforms Worst Histologic Grade for Predicting Perineural Invasion in Oral Tongue Squamous Cell Carcinoma</span>. <u>Joseph Masselli, MD, DDS</u>; Jasmine Sze, MD, DDS; Laurent Ganry, MD; David L Hirsch, MD, DDS; Andrew Salama, MD, DDS. Northwell Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The Broders histologic grading scale is adopted by the WHO and widely reported in final pathologic specimens in oral tongue squamous cell carcinoma (OTSCC). It is a common occurrence for the degree of differentiation to be downgraded from the biopsy specimen compared to the final pathology, indicating that the most poorly differentiated cells were excised in the biopsy specimen. It is unclear whether upgrading the Broders grade to reflect the poorest differentiation status between the biopsy and final pathology specimen improves the prediction of adverse pathologic features such as perineural invasion (PNI) in the final specimen. </p>\n\n<p><strong>Objective:</strong> To determine if worst histologic grade (WHG) (defined as the highest grade between biopsy and resection) correlates more strongly with PNI than the original grade from final pathology (OHG), and to assess whether this relationship persists after adjusting for depth of invasion (DOI>10mm). </p>\n\n<p><strong>Methods:</strong> We retrospectively analyzed 29 OTSCC patients treated with partial or hemiglossectomy. Histologic grade was recorded as original grade and worst grade (1-3 with grade 1 indicating well differentiated, 2 indicating moderately differentiated, and 3 indicating poorly differentiated). PNI was coded as present/absent. Spearman’s rank correlation assessed associations between grade and PNI; partial Spearman correlation adjusted for DOI>10mm. </p>\n\n<p><strong>Results: </strong>13/29 cases (45%) were upgraded by at least 1 point to reflect WHG. PNI occurred in 12/29 cases (41%). OHG showed a strong correlation with PNI (ρ=0.674, p=0.0003), which remained significant after DOI adjustment (partial ρ=0.669, p=0.0005). WHG was also associated with PNI (ρ=0.535, p=0.0028), persisting after adjustment (partial ρ=0.528, p=0.0039). Contrary to expectation, upgrading to worst grade did not strengthen the association compared to original grade. </p>\n\n<p><strong>Conclusions:</strong> Higher histologic grade is strongly associated with PNI in OTSCC, and the strongest correlation comes from the final pathology grade. Upgrading grades does not improve prediction. Adjustment for DOI>10mm does not materially alter these findings. </p>\n\n<p><strong>Discussion: </strong>We postulate that WHG weakened association with PNI due to foci of poorly differentiated cells causing an upgrade in the overall sample while the bulk of the tumor may not demonstrate the same biology. The Brandwein-Gensler model may account for these instances in regard to the Worst Pattern of Invasion component of the scale. Larger studies are needed to explore continuous DOI effects and validate these observations. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153760/prevlence%20bar%20chart%20.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153760/spearmangraph.jpeg' /></p>\n\n<p>Faisal M, Abu Bakar M, Sarwar A, Adeel M, Batool F, Malik KI, Jamshed A, Hussain R. Depth of invasion (DOI) as a predictor of cervical nodal metastasis and local recurrence in early stage squamous cell carcinoma of oral tongue (ESSCOT). PLoS One. 2018 Aug 22;13(8):e0202632. doi: 10.1371/journal.pone.0202632. PMID: 30133515; PMCID: PMC6105019. </p>\n\n<p>Rahman, N., MacNeill, M., Wallace, W. et al. Reframing Histological Risk Assessment of Oral Squamous Cell Carcinoma in the Era of UICC 8th Edition TNM Staging. Head and Neck Pathol 15, 202–211 (2021). https://doi.org/10.1007/s12105-020-01201-8 </p>\n\n<p>WHO Classification of Tumours Editorial Board: Head and Neck Tumours, 5th Edition, 2024 </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153760--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S127",
      "content_id": "154599",
      "abstract_number": "S127",
      "poster_number": "",
      "title": "Perspectives of Head & Neck Surgeons and Pathologists on Frozen Margin Analysis and Opportunities for Improvement",
      "summary": "Thirty-two faculty physicians were interviewed, including 17 pathologists and 15 surgeons. A total of 11 major categories were identified, divided further into one to eight subcategories, and grouped into 3 major themes: Inner Setting, Individual Characteristics, and Procedural Details. Within Inner Setting, participants particularly noted how workspace configuration, including proximity of pathology offices to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154599",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chandler Rygalski, MD",
      "presenter": "Chandler Rygalski, MD",
      "authors": "Chandler Rygalski, MD 1 ; Emilee Ayers, MPH 2 ; Kemberlee R Bonnet, MA 2 ; Ashley Sellers, MS 2 ; David G Schlundt, PhD 2 ; Michael Topf, MD 1",
      "normalized_authors": [
        "Chandler Rygalski",
        "Emilee Ayers",
        "Kemberlee R Bonnet, MA",
        "Ashley Sellers",
        "David G Schlundt",
        "Michael Topf"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center",
        "Vanderbilt University"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center",
        "Vanderbilt University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Design, Participants, & Setting",
        "Main Outcomes & Measures",
        "Results",
        "Conclusions & Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chandler Rygalski, MD 1 ; Emilee Ayers, MPH 2 ; Kemberlee R Bonnet, MA 2 ; Ashley Sellers, MS 2 ; David G Schlundt, PhD 2 ; Michael Topf, MD 1",
        "Affiliations": "1 Vanderbilt University Medical Center; 2 Vanderbilt University",
        "Objectives": "The primary goal of head and neck oncologic surgery is resection of the tumor in its entirety with clear margins. However, optimal approaches to both frozen section and permanent margin analysis in head and neck cancer remain debated amongst surgeons and pathologists. The purpose of this study was to investigate the practice patterns and limitations of frozen section and permanent margin analysis at varied institutions across North America.",
        "Design, Participants, & Setting": "This qualitative study included interviews with faculty-level pathologists and head & neck oncologic surgeons at institutions across the United States and Canada using a semi-structured interview guide that asked about frozen section analysis utilization, logistics & workflow, utility of final written pathology reports, and communication.",
        "Main Outcomes & Measures": "Qualitative data coding followed consolidated criteria for reporting qualitative research (COREQ) guidelines with a hierarchical coding system developed by using an interview guide created from a preliminary review of the transcripts. Using an iterative inductive/deductive approach, the coded transcripts were combined and analyzed to create a conceptual framework to illustrate themes, subthemes, and their interrelationships.",
        "Results": "Thirty-two faculty physicians were interviewed, including 17 pathologists and 15 surgeons. A total of 11 major categories were identified, divided further into one to eight subcategories, and grouped into 3 major themes: Inner Setting, Individual Characteristics, and Procedural Details. Within Inner Setting, participants particularly noted how workspace configuration, including proximity of pathology offices to both the operating room and grossing laboratories, played a key role in turnaround time. Faculty often found this to be a major area of opportunity for improvement. Participants also highlighted the importance of a collaborative culture between surgeons and pathologists, for example working together to orient the specimen, and how this is paramount in accuracy of both frozen and final margins. From Individual Characteristics, most clinicians expressed preference for specimen-based margin analysis, largely for the increased ability to directly visualize spatial relationships between tumor tissue and the margin and some data demonstrating improved reliability, recurrence rates and survival rates. Within Procedural Details, although participants largely preferred a specimen-based approach, they noted difficulty in its implementation due to increased personnel needs, time constraints, and difficulty in accurate specimen orientation. To ease some of these barriers, participants expressed interest in incorporating new imaging techniques and digital technologies into their workflow to facilitate improved communication systems and reduce the risk of misinterpretation.",
        "Conclusions & Relevance": "In this qualitative study, interviews with both surgeons and pathologists consistently reaffirmed the importance of a collaborative culture and clear communication between surgery and pathology teams to facilitate accurate analysis of margins, as well as the challenges that orientation of specimens pose for pathologists when this communication breaks down. These findings may be useful in supporting future research into technologies aimed at easing this interaction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Perspectives of Head & Neck Surgeons and Pathologists on Frozen Margin Analysis and Opportunities for Improvement</span>. <u>Chandler Rygalski, MD</u><sup>1</sup>; Emilee Ayers, MPH<sup>2</sup>; Kemberlee R Bonnet, MA<sup>2</sup>; Ashley Sellers, MS<sup>2</sup>; David G Schlundt, PhD<sup>2</sup>; Michael Topf, MD<sup>1</sup>. <sup>1</sup>Vanderbilt University Medical Center; <sup>2</sup>Vanderbilt University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>The primary goal of head and neck oncologic surgery is resection of the tumor in its entirety with clear margins. However, optimal approaches to both frozen section and permanent margin analysis in head and neck cancer remain debated amongst surgeons and pathologists. The purpose of this study was to investigate the practice patterns and limitations of frozen section and permanent margin analysis at varied institutions across North America.</p>\n\n<p><strong>Design, Participants, & Setting: </strong>This qualitative study included interviews with faculty-level pathologists and head & neck oncologic surgeons at institutions across the United States and Canada using a semi-structured interview guide that asked about frozen section analysis utilization, logistics & workflow, utility of final written pathology reports, and communication.</p>\n\n<p><strong>Main Outcomes & Measures:</strong> Qualitative data coding followed consolidated criteria for reporting qualitative research (COREQ) guidelines with a hierarchical coding system developed by using an interview guide created from a preliminary review of the transcripts. Using an iterative inductive/deductive approach, the coded transcripts were combined and analyzed to create a conceptual framework to illustrate themes, subthemes, and their interrelationships.</p>\n\n<p><strong>Results: </strong>Thirty-two faculty physicians were interviewed, including 17 pathologists and 15 surgeons. A total of 11 major categories were identified, divided further into one to eight subcategories, and grouped into 3 major themes: Inner Setting, Individual Characteristics, and Procedural Details. Within Inner Setting, participants particularly noted how workspace configuration, including proximity of pathology offices to both the operating room and grossing laboratories, played a key role in turnaround time. Faculty often found this to be a major area of opportunity for improvement. Participants also highlighted the importance of a collaborative culture between surgeons and pathologists, for example working together to orient the specimen, and how this is paramount in accuracy of both frozen and final margins. From Individual Characteristics, most clinicians expressed preference for specimen-based margin analysis, largely for the increased ability to directly visualize spatial relationships between tumor tissue and the margin and some data demonstrating improved reliability, recurrence rates and survival rates. Within Procedural Details, although participants largely preferred a specimen-based approach, they noted difficulty in its implementation due to increased personnel needs, time constraints, and difficulty in accurate specimen orientation. To ease some of these barriers, participants expressed interest in incorporating new imaging techniques and digital technologies into their workflow to facilitate improved communication systems and reduce the risk of misinterpretation.</p>\n\n<p><strong>Conclusions & Relevance: </strong>In this qualitative study, interviews with both surgeons and pathologists consistently reaffirmed the importance of a collaborative culture and clear communication between surgery and pathology teams to facilitate accurate analysis of margins, as well as the challenges that orientation of specimens pose for pathologists when this communication breaks down. These findings may be useful in supporting future research into technologies aimed at easing this interaction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154599--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S128",
      "content_id": "154546",
      "abstract_number": "S128",
      "poster_number": "",
      "title": "Prognostic Significance of Lymphovascular Invasion in Early Tonsillar Squamous Cell Carcinoma: A National Database Analysis.",
      "summary": "LVI is a clinically meaningful, independent predictor of mortality in early-stage tonsillar SCC. Its impact is most pronounced in patients treated with TORS alone and the combination of TORS with adjuvant RT/CT yields superior survival, suggesting that early-stage patients with LVI may benefit from multimodality therapy rather than surgery alone. These findings support the integration of LVI assessment into...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154546",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Felipe Porto - Gutierrez, MD",
      "presenter": "Felipe Porto - Gutierrez, MD",
      "authors": "Felipe Porto - Gutierrez, MD ; Alexa Kacin, MD; Brett Campbell, MD; Scharukh Jalisi, MD, MBA",
      "normalized_authors": [
        "Felipe Porto - Gutierrez",
        "Alexa Kacin",
        "Brett Campbell",
        "Scharukh Jalisi"
      ],
      "affiliations": [
        "Beth Israel Deaconess Medical Center - Harvard Medical School"
      ],
      "normalized_institutions": [
        "Beth Israel Deaconess Medical Center - Harvard Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Felipe Porto - Gutierrez, MD ; Alexa Kacin, MD; Brett Campbell, MD; Scharukh Jalisi, MD, MBA",
        "Affiliations": "Beth Israel Deaconess Medical Center - Harvard Medical School",
        "Introduction": "Early-stage tonsillar squamous cell carcinoma (SCC) is traditionally managed with primary radiotherapy (RT), yet the advent of transoral robotic surgery (TORS) has reshaped contemporary management by offering a minimally invasive surgical alternative. Despite these advances, the prognostic relevance of lymphovascular invasion (LVI) remains insufficiently defined in early tonsillar cancer. As treatment paradigms increasingly incorporate single-modality TORS or escalate to multimodality therapy, understanding whether LVI should influence therapeutic decision-making has become clinically imperative. This study examines the prognostic impact of LVI on overall survival (OS) and evaluates how its effect varies across current treatment strategies for early-stage tonsillar SCC.",
        "Methods": "We performed a retrospective cohort study using the National Cancer Database to identify adults with clinical T1–T2N0M0 tonsillar squamous cell carcinoma. Patients with documented LVI, treatment modality, and survival data were included. Treatment was classified as TORS alone, TORS with adjuvant radiotherapy or chemoradiotherapy, or definitive RT/CT. Survival outcomes were assessed with Kaplan–Meier analysis, and multivariable Cox regression was used to evaluate the independent association between LVI and overall survival. Statistical significance was set at p < 0.05.",
        "Results": "A total of 2,153 patients met inclusion criteria; median age was 61 years, the majority were male (76.4%), and 13% exhibited LVI. Among LVI-positive patients, 58.7% received primary RT/CT, 24.5% underwent TORS + adjuvant RT/CT, and 16.7% received TORS alone. Baseline demographic and clinical features were broadly comparable across treatment cohorts.",
        "Abstract": "On Kaplan–Meier analysis, patients with LVI demonstrated significantly reduced OS compared with those without LVI. Treatment modality was strongly associated with survival patterns: TORS followed by adjuvant radiotherapy or chemoradiotherapy yielded the highest long-term OS, whereas TORS alone showed a pronounced separation between LVI-positive and LVI-negative curves, indicating heightened vulnerability in the presence of LVI. In multivariable Cox regression, LVI remained independently associated with increased mortality (HR 1.38; 95% CI, 1.12–1.69, p=0.002). The detrimental effect of LVI was most marked among patients treated with TORS alone (HR 1.66, CI 1.02 - 2.71, p=0.041), while its impact was attenuated in those who received adjuvant RT/CT. Across the cohort, LVI-positive patients exhibited lower 5-year OS, reinforcing LVI as an adverse biological prognostic marker in early-stage tonsillar cancer. View in Agenda and Add to Schedule",
        "Conclusion": "LVI is a clinically meaningful, independent predictor of mortality in early-stage tonsillar SCC. Its impact is most pronounced in patients treated with TORS alone and the combination of TORS with adjuvant RT/CT yields superior survival, suggesting that early-stage patients with LVI may benefit from multimodality therapy rather than surgery alone. These findings support the integration of LVI assessment into treatment planning and highlight the need to refine selection criteria for primary surgical management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Significance of Lymphovascular Invasion in Early Tonsillar Squamous Cell Carcinoma: A National Database Analysis.</span>. <u>Felipe Porto - Gutierrez, MD</u>; Alexa Kacin, MD; Brett Campbell, MD; Scharukh Jalisi, MD, MBA. Beth Israel Deaconess Medical Center - Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Early-stage tonsillar squamous cell carcinoma (SCC) is traditionally managed with primary radiotherapy (RT), yet the advent of transoral robotic surgery (TORS) has reshaped contemporary management by offering a minimally invasive surgical alternative. Despite these advances, the prognostic relevance of lymphovascular invasion (LVI) remains insufficiently defined in early tonsillar cancer. As treatment paradigms increasingly incorporate single-modality TORS or escalate to multimodality therapy, understanding whether LVI should influence therapeutic decision-making has become clinically imperative. This study examines the prognostic impact of LVI on overall survival (OS) and evaluates how its effect varies across current treatment strategies for early-stage tonsillar SCC.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study using the National Cancer Database to identify adults with clinical T1–T2N0M0 tonsillar squamous cell carcinoma. Patients with documented LVI, treatment modality, and survival data were included. Treatment was classified as TORS alone, TORS with adjuvant radiotherapy or chemoradiotherapy, or definitive RT/CT. Survival outcomes were assessed with Kaplan–Meier analysis, and multivariable Cox regression was used to evaluate the independent association between LVI and overall survival. Statistical significance was set at p < 0.05.</p>\n\n<p><strong>Results: </strong>A total of 2,153 patients met inclusion criteria; median age was 61 years, the majority were male (76.4%), and 13% exhibited LVI. Among LVI-positive patients, 58.7% received primary RT/CT, 24.5% underwent TORS + adjuvant RT/CT, and 16.7% received TORS alone. Baseline demographic and clinical features were broadly comparable across treatment cohorts. </p>\n\n<p>On Kaplan–Meier analysis, patients with LVI demonstrated significantly reduced OS compared with those without LVI. Treatment modality was strongly associated with survival patterns: TORS followed by adjuvant radiotherapy or chemoradiotherapy yielded the highest long-term OS, whereas TORS alone showed a pronounced separation between LVI-positive and LVI-negative curves, indicating heightened vulnerability in the presence of LVI.</p>\n\n<p>In multivariable Cox regression, LVI remained independently associated with increased mortality (HR 1.38; 95% CI, 1.12–1.69, p=0.002). The detrimental effect of LVI was most marked among patients treated with TORS alone (HR 1.66, CI 1.02 - 2.71, p=0.041), while its impact was attenuated in those who received adjuvant RT/CT. Across the cohort, LVI-positive patients exhibited lower 5-year OS, reinforcing LVI as an adverse biological prognostic marker in early-stage tonsillar cancer.</p>\n\n<p><strong>Conclusion: </strong>LVI is a clinically meaningful, independent predictor of mortality in early-stage tonsillar SCC. Its impact is most pronounced in patients treated with TORS alone and the combination of TORS with adjuvant RT/CT yields superior survival, suggesting that early-stage patients with LVI may benefit from multimodality therapy rather than surgery alone. These findings support the integration of LVI assessment into treatment planning and highlight the need to refine selection criteria for primary surgical management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154546--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S129",
      "content_id": "154183",
      "abstract_number": "S129",
      "poster_number": "",
      "title": "IMAGE RECOGNITION IN PATHOLOGICAL SLIDES FOR PREDICTING LYMPH NODE METASTASIS IN ORAL CANCER",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154183",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Hugo F Kohler, MD; Ivete F P S Rodrigues, MD, PhD; Clovis A L Pinto, MD, PhD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Hugo F Kohler",
        "Ivete F P S Rodrigues",
        "Clovis A L Pinto",
        "Jose G Vartanian",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 400,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hugo F Kohler, MD; Ivete F P S Rodrigues, MD, PhD; Clovis A L Pinto, MD, PhD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "INTRODUCTION": "Accurate preoperative neck staging plays a critical role in treatment planning for oral squamous cell carcinoma (OSCC). Precise nodal assessment determines eligibility for sentinel lymph node biopsy and may guide the indication for neoadjuvant pembrolizumab therapy. This study evaluated whether artificial intelligence-based image recognition of primary tumor pathological features could predict cervical lymph node metastasis.",
        "MATERIALS AND METHODS": "We analyzed treatment-naïve OSCC patients whose primary tumor specimens underwent hematoxylin-eosin staining and immunohistochemical evaluation. The immunohistochemical panel included E-cadherin (≤50% vs >50%), β-catenin (≤50% vs >50%), claudin-7 (0% vs <50% vs ≥50%), vimentin (positive/negative), MMP-2 (positive/negative), MMP-9 (positive/negative), Ki-67 (≤50% vs >50%), and vascular endothelial growth factor (negative vs focal vs diffuse). Cervical lymph nodes were assessed through hematoxylin-eosin stained sections following neck dissection. Two independent pathologists analyzed all slides, which were then digitized for computational analysis. Statistical analysis utilized R software, with EBImage and Imageseq packages serving as primary tools for image processing and pattern recognition.",
        "RESULTS": "The study included 212 patients: 157 males (74.1%) and 55 females (25.9%), with ages ranging from 20 to 91 years (mean 55.2 ± 13.1 years). Pathological T classification comprised 49 pT1, 86 pT2, 42 pT3, and 35 pT4 tumors. Ninety-three patients (43.9%) had pathologically negative necks (pN0). Expression patterns of E-cadherin, β-catenin, claudin-7, MMP-2, and VEGF demonstrated statistically significant differences between pN0 and pN+ groups. Digitized pathological slides were converted into matrix format and stored in a comprehensive database. The machine learning model underwent training with 150 patients in the development cohort and validation with the remaining cases, repeating this process ten times through cross-validation. The final model achieved a negative predictive value of 0.714 and a positive predictive value of 0.667 when tested across the entire series.",
        "CONCLUSION": "Contemporary neck management strategies encompass observation, sentinel lymph node biopsy, and elective neck dissection. While sentinel node biopsy offers advantages including reduced recovery time and enhanced quality of life, its application requires confident clinical N0 staging. Although imaging modalities remain the standard assessment tool, their diagnostic performance varies considerably depending on operator expertise in head and neck anatomy, with widely heterogeneous negative and positive predictive values reported throughout the literature. Artificial intelligence-driven image analysis of primary tumor pathology represents a promising complementary approach that may refine clinical decision-making regarding neck treatment strategies and strengthen the rationale for neoadjuvant pembrolizumab therapy in selected patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>IMAGE RECOGNITION IN PATHOLOGICAL SLIDES FOR PREDICTING LYMPH NODE METASTASIS IN ORAL CANCER</span>. Hugo F Kohler, MD; Ivete F P S Rodrigues, MD, PhD; Clovis A L Pinto, MD, PhD; <u>Jose G Vartanian, MD, PhD</u>; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION: </strong>Accurate preoperative neck staging plays a critical role in treatment planning for oral squamous cell carcinoma (OSCC). Precise nodal assessment determines eligibility for sentinel lymph node biopsy and may guide the indication for neoadjuvant pembrolizumab therapy. This study evaluated whether artificial intelligence-based image recognition of primary tumor pathological features could predict cervical lymph node metastasis.</p>\n\n<p><strong>MATERIALS AND METHODS: </strong>We analyzed treatment-naïve OSCC patients whose primary tumor specimens underwent hematoxylin-eosin staining and immunohistochemical evaluation. The immunohistochemical panel included E-cadherin (≤50% vs >50%), β-catenin (≤50% vs >50%), claudin-7 (0% vs <50% vs ≥50%), vimentin (positive/negative), MMP-2 (positive/negative), MMP-9 (positive/negative), Ki-67 (≤50% vs >50%), and vascular endothelial growth factor (negative vs focal vs diffuse). Cervical lymph nodes were assessed through hematoxylin-eosin stained sections following neck dissection. Two independent pathologists analyzed all slides, which were then digitized for computational analysis. Statistical analysis utilized R software, with EBImage and Imageseq packages serving as primary tools for image processing and pattern recognition.</p>\n\n<p><strong>RESULTS: </strong>The study included 212 patients: 157 males (74.1%) and 55 females (25.9%), with ages ranging from 20 to 91 years (mean 55.2 ± 13.1 years). Pathological T classification comprised 49 pT1, 86 pT2, 42 pT3, and 35 pT4 tumors. Ninety-three patients (43.9%) had pathologically negative necks (pN0). Expression patterns of E-cadherin, β-catenin, claudin-7, MMP-2, and VEGF demonstrated statistically significant differences between pN0 and pN+ groups. Digitized pathological slides were converted into matrix format and stored in a comprehensive database. The machine learning model underwent training with 150 patients in the development cohort and validation with the remaining cases, repeating this process ten times through cross-validation. The final model achieved a negative predictive value of 0.714 and a positive predictive value of 0.667 when tested across the entire series.</p>\n\n<p><strong>CONCLUSION: </strong>Contemporary neck management strategies encompass observation, sentinel lymph node biopsy, and elective neck dissection. While sentinel node biopsy offers advantages including reduced recovery time and enhanced quality of life, its application requires confident clinical N0 staging. Although imaging modalities remain the standard assessment tool, their diagnostic performance varies considerably depending on operator expertise in head and neck anatomy, with widely heterogeneous negative and positive predictive values reported throughout the literature. Artificial intelligence-driven image analysis of primary tumor pathology represents a promising complementary approach that may refine clinical decision-making regarding neck treatment strategies and strengthen the rationale for neoadjuvant pembrolizumab therapy in selected patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154183--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S130",
      "content_id": "153581",
      "abstract_number": "S130",
      "poster_number": "",
      "title": "Implementation of a 3D Scanning Workflow for Accurate Specimen–Bed Localization in Head and Neck Cancer Resections",
      "summary": "Implementation of this protocol confirms that real-time intraoperative 3D scanning and specimen–bed registration are feasible, reproducible, and compatible with clinical timelines. Standardization enhances quality, safety, and efficiency while enabling the creation of a structured 3D repository for future cancer-engineering applications. Potential expansions include training machine-learning models for automated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153581",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260123",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ximena Mimica, MD",
      "presenter": "Ximena Mimica, MD",
      "authors": "Ximena Mimica, MD 1 ; Valeria F Alarcon Leiva, BSc 2 ; Manuel A Cespedes Araya, MBA 2 ; Ruben Miranda, MD 1 ; Daniel Ledezma, MD 1 ; Felipe Buscaglia, MD 1 ; Veronica Sanhueza, MD 1",
      "normalized_authors": [
        "Ximena Mimica",
        "Valeria F Alarcon Leiva",
        "Manuel A Cespedes Araya",
        "Ruben Miranda",
        "Daniel Ledezma",
        "Felipe Buscaglia",
        "Veronica Sanhueza"
      ],
      "affiliations": [
        "Instituto Oncológico Fundación Arturo López Pérez",
        "ALTITUD100K SpA"
      ],
      "normalized_institutions": [
        "Instituto Oncológico Fundación Arturo López Pérez",
        "ALTITUD100K SpA"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153581/Image1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153581/Image1.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153581"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153581/image2.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153581/image2.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153581"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153581/image%203.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153581/image%203.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153581"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 449,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ximena Mimica, MD 1 ; Valeria F Alarcon Leiva, BSc 2 ; Manuel A Cespedes Araya, MBA 2 ; Ruben Miranda, MD 1 ; Daniel Ledezma, MD 1 ; Felipe Buscaglia, MD 1 ; Veronica Sanhueza, MD 1",
        "Affiliations": "1 Instituto Oncológico Fundación Arturo López Pérez; 2 ALTITUD100K SpA",
        "Background": "Head and neck squamous cell carcinoma presents high rates of positive margins and local recurrence, frequently occurring 2–3 years after treatment. Current intraoperative orientation of surgical specimens relies on verbal descriptions, sketches, markers, and photographs, which limits accurate margin re-identification and reduces the ability to perform selective and effective re-resections. Emerging evidence indicates that optical 3D scanning, digital mapping, and deformable-registration frameworks can enhance surgeon–pathologist communication; however, no standardized, feasible, real-time workflow has yet been integrated into routine surgical practice.",
        "Methods": "We developed a clinical–technical workflow for real-time intraoperative acquisition, processing, and registration of 3D models of the resected specimen and surgical bed in head and neck oncologic surgery. The protocol integrates practical requirements identified during pilot testing, including a brief preoperative calibration to verify scanner accuracy and illumination. The workflow comprises: (1) optical 3D scanning of the specimen immediately after resection; (2) scanning of the surgical bed after hemostasis; (3) mesh and point-cloud reconstruction, cleaning, smoothing, and global scaling to account for tissue shrinkage; (4) anatomical landmark selection; and (5) specimen–bed registration using landmark-based initialization and iterative closest point, followed by manual refinement of scale, orientation, and transparency of the specimen. This standardized workflow establishes consistent acquisition conditions that facilitate accurate alignment of 3D models and provides a foundation for future integration of AI-driven deformable registration and augmented-reality visualization.",
        "Results": "In this pilot series (20 cases scanned; 8 complete specimen–bed pairs suitable for registration), we observed a clear learning curve that progressively reduced scanning and processing times. Median added time remained below the predetermined operational threshold (7–10 minutes). Standardizing the 3D acquisition process for head and neck surgery improves the perception of deep or complex margins, providing the surgeon with a three-dimensional model before reconstruction began. Compared with conventional documentation, surgeons reported improved spatial understanding of deep and hard-to-access margins, and pathologists noted clearer communication when marking positive or close margins directly on the 3D model. The protocol defines the full technical pathway from operator training and technological requirements to minimum scanning times and enables consistent documentation.",
        "Conclusions": "Implementation of this protocol confirms that real-time intraoperative 3D scanning and specimen–bed registration are feasible, reproducible, and compatible with clinical timelines. Standardization enhances quality, safety, and efficiency while enabling the creation of a structured 3D repository for future cancer-engineering applications. Potential expansions include training machine-learning models for automated deformable registration particularly relevant for tongue surgery and integrating near-real-time augmented reality into the operating room. The methodology also supports external collaboration through anonymized datasets and shared imaging banks.",
        "Abstract": "Overall, this work represents a fundamental step toward next-generation intraoperative guidance systems aimed at reducing local recurrence and improving long-term oncologic outcomes. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Implementation of a 3D Scanning Workflow for Accurate Specimen–Bed Localization in Head and Neck Cancer Resections</span>. <u>Ximena Mimica, MD</u><sup>1</sup>; Valeria F Alarcon Leiva, BSc<sup>2</sup>; Manuel A Cespedes Araya, MBA<sup>2</sup>; Ruben Miranda, MD<sup>1</sup>; Daniel Ledezma, MD<sup>1</sup>; Felipe Buscaglia, MD<sup>1</sup>; Veronica Sanhueza, MD<sup>1</sup>. <sup>1</sup>Instituto Oncológico Fundación Arturo López Pérez; <sup>2</sup>ALTITUD100K SpA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinoma presents high rates of positive margins and local recurrence, frequently occurring 2–3 years after treatment. Current intraoperative orientation of surgical specimens relies on verbal descriptions, sketches, markers, and photographs, which limits accurate margin re-identification and reduces the ability to perform selective and effective re-resections. Emerging evidence indicates that optical 3D scanning, digital mapping, and deformable-registration frameworks can enhance surgeon–pathologist communication; however, no standardized, feasible, real-time workflow has yet been integrated into routine surgical practice.</p>\n\n<p><strong>Methods: </strong>We developed a clinical–technical workflow for real-time intraoperative acquisition, processing, and registration of 3D models of the resected specimen and surgical bed in head and neck oncologic surgery. The protocol integrates practical requirements identified during pilot testing, including a brief preoperative calibration to verify scanner accuracy and illumination. The workflow comprises: (1) optical 3D scanning of the specimen immediately after resection; (2) scanning of the surgical bed after hemostasis; (3) mesh and point-cloud reconstruction, cleaning, smoothing, and global scaling to account for tissue shrinkage; (4) anatomical landmark selection; and (5) specimen–bed registration using landmark-based initialization and iterative closest point, followed by manual refinement of scale, orientation, and transparency of the specimen. This standardized workflow establishes consistent acquisition conditions that facilitate accurate alignment of 3D models and provides a foundation for future integration of AI-driven deformable registration and augmented-reality visualization.</p>\n\n<p><strong>Results: </strong>In this pilot series (20 cases scanned; 8 complete specimen–bed pairs suitable for registration), we observed a clear learning curve that progressively reduced scanning and processing times. Median added time remained below the predetermined operational threshold (7–10 minutes). Standardizing the 3D acquisition process for head and neck surgery improves the perception of deep or complex margins, providing the surgeon with a three-dimensional model before reconstruction began. Compared with conventional documentation, surgeons reported improved spatial understanding of deep and hard-to-access margins, and pathologists noted clearer communication when marking positive or close margins directly on the 3D model. The protocol defines the full technical pathway from operator training and technological requirements to minimum scanning times and enables consistent documentation.</p>\n\n<p><strong>Conclusions: </strong>Implementation of this protocol confirms that real-time intraoperative 3D scanning and specimen–bed registration are feasible, reproducible, and compatible with clinical timelines. Standardization enhances quality, safety, and efficiency while enabling the creation of a structured 3D repository for future cancer-engineering applications. Potential expansions include training machine-learning models for automated deformable registration particularly relevant for tongue surgery and integrating near-real-time augmented reality into the operating room. The methodology also supports external collaboration through anonymized datasets and shared imaging banks.</p>\n\n<p>Overall, this work represents a fundamental step toward next-generation intraoperative guidance systems aimed at reducing local recurrence and improving long-term oncologic outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153581/Image1.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153581/image2.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153581/image%203.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153581--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260123' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S131",
      "content_id": "153650",
      "abstract_number": "S131",
      "poster_number": "",
      "title": "NOTCH1 loss-of-function mutations are associated with early progression on pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma",
      "summary": "Patients with NOTCH1 tumor mutations were associated with early progression and significantly poorer PFS among pembrolizumab-treated R/M HNSCC patients. These findings suggest that NOTCH1 loss-of-function may identify a genomically defined subgroup resistant to ICI, potentially through impaired tumor-immune signaling. These findings should be interpreted as hypothesis-generating given the small sample size;...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153650",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Angeline A Truong, MS",
      "presenter": "Angeline A Truong, MS",
      "authors": "Angeline A Truong, MS ; Savinnie Ho; Rex H Lee, MD; Jovanka Gencel-Augusto, PhD; Xin Wu, MD; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Alain P Algazi, MD; Katherine C Wai, MD",
      "normalized_authors": [
        "Angeline A Truong",
        "Savinnie Ho",
        "Rex H Lee",
        "Jovanka Gencel-Augusto",
        "Xin Wu",
        "Michael S Chow",
        "Ivan H El-Sayed",
        "Jonathan R George",
        "Chase M Heaton",
        "Ilya Likhterov",
        "Mary Jue Xu",
        "Patrick K Ha",
        "Alain P Algazi",
        "Katherine C Wai"
      ],
      "affiliations": [
        "University of California, San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_05%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_05%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153650"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_16%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_16%E2%80%AFAM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153650"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 384,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Angeline A Truong, MS ; Savinnie Ho; Rex H Lee, MD; Jovanka Gencel-Augusto, PhD; Xin Wu, MD; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Alain P Algazi, MD; Katherine C Wai, MD",
        "Affiliations": "University of California, San Francisco",
        "Introduction": "Immune checkpoint inhibitors (ICIs) have improved outcomes in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), but predictive genomic biomarkers remain limited. Recent pan-cancer analyses suggest that NOTCH1 loss-of-function (LOF) mutations may contribute to immune exclusion and ICI resistance. NOTCH1 loss has been linked to altered dendritic cell cross-talk and impaired IFN-γ signaling, mechanisms aligned with resistance to PD-1 inhibition. In this study, our objective was to determine whether NOTCH1 LOF mutation status was associated with differential progression-free survival (PFS) in patients with R/M HNSCC treated with pembrolizumab.",
        "Methods": "We conducted a retrospective analysis of 22 patients with R/M HNSCC who initiated pembrolizumab therapy at the University of California, San Francisco between May 2016 and May 2022 and underwent UCSF500 tumor sequencing. Patients who received <3 cycles of pembrolizumab were excluded. The primary endpoint was 1-year PFS; the secondary endpoint was time-to-progression (TTP). Associations between NOTCH1 LOF mutation and outcomes were assessed using Fisher’s exact tests.",
        "Results": "Among 22 patients, 5 (23%) harbored a loss of function NOTCH1 mutation. All 5 (100%) NOTCH1-mutant tumors progressed by 1-year versus 10 (67%) NOTCH1-wild-type tumors (Fisher’s exact p=0.082). Kaplan-Meier analysis confirmed significantly shorter progression-free survival in NOTCH1-mutant tumors (p = 0.0027). Median TTP was 61 days in NOTCH1-mutant versus 169 days in wild-type tumors. Kaplan–Meier analysis demonstrated significantly shorter TTP in NOTCH1-mutant tumors (p = 0.043).",
        "Abstract": "In a univariate Cox model evaluating 1-year PFS, NOTCH1-mutant tumors demonstrated a hazard ratio of 6.18 (1.61-23.8, p=0.008). After controlling for age > 65, hazard ratio for 1-year PFS was 6.17 (1.56-24.4, p=0.009). In a univariate Cox model for 1-year TTP, NOTCH1-mutant tumors demonstrated a hazard ratio of 3.82 (0.95-15.4, p=0.06). After controlling for age > 65, hazard ratio for 1-year TTP was 4.36 (1.00-19.0, p=0.050). View in Agenda and Add to Schedule",
        "Conclusion": "Patients with NOTCH1 tumor mutations were associated with early progression and significantly poorer PFS among pembrolizumab-treated R/M HNSCC patients. These findings suggest that NOTCH1 loss-of-function may identify a genomically defined subgroup resistant to ICI, potentially through impaired tumor-immune signaling. These findings should be interpreted as hypothesis-generating given the small sample size; validation in larger cohorts and functional studies are warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>NOTCH1 loss-of-function mutations are associated with early progression on pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma</span>. <u>Angeline A Truong, MS</u>; Savinnie Ho; Rex H Lee, MD; Jovanka Gencel-Augusto, PhD; Xin Wu, MD; Michael S Chow, MD; Ivan H El-Sayed, MD; Jonathan R George, MD; Chase M Heaton, MD; Ilya Likhterov, MD; Mary Jue Xu, MD; Patrick K Ha, MD; Alain P Algazi, MD; Katherine C Wai, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) have improved outcomes in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), but predictive genomic biomarkers remain limited. Recent pan-cancer analyses suggest that NOTCH1 loss-of-function (LOF) mutations may contribute to immune exclusion and ICI resistance. NOTCH1 loss has been linked to altered dendritic cell cross-talk and impaired IFN-γ signaling, mechanisms aligned with resistance to PD-1 inhibition. In this study, our objective was to determine whether NOTCH1 LOF mutation status was associated with differential progression-free survival (PFS) in patients with R/M HNSCC treated with pembrolizumab.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective analysis of 22 patients with R/M HNSCC who initiated pembrolizumab therapy at the University of California, San Francisco between May 2016 and May 2022 and underwent UCSF500 tumor sequencing. Patients who received <3 cycles of pembrolizumab were excluded. The primary endpoint was 1-year PFS; the secondary endpoint was time-to-progression (TTP). Associations between NOTCH1 LOF mutation and outcomes were assessed using Fisher’s exact tests.</p>\n\n<p><strong>Results: </strong>Among 22 patients, 5 (23%) harbored a loss of function NOTCH1 mutation. All 5 (100%) NOTCH1-mutant tumors progressed by 1-year versus 10 (67%) NOTCH1-wild-type tumors (Fisher’s exact p=0.082). Kaplan-Meier analysis confirmed significantly shorter progression-free survival in NOTCH1-mutant tumors (p = 0.0027). Median TTP was 61 days in NOTCH1-mutant versus 169 days in wild-type tumors. Kaplan–Meier analysis demonstrated significantly shorter TTP in NOTCH1-mutant tumors (p = 0.043).</p>\n\n<p>In a univariate Cox model evaluating 1-year PFS, NOTCH1-mutant tumors demonstrated a hazard ratio of 6.18 (1.61-23.8, p=0.008). After controlling for age > 65, hazard ratio for 1-year PFS was 6.17 (1.56-24.4, p=0.009). In a univariate Cox model for 1-year TTP, NOTCH1-mutant tumors demonstrated a hazard ratio of 3.82 (0.95-15.4, p=0.06). After controlling for age > 65, hazard ratio for 1-year TTP was 4.36 (1.00-19.0, p=0.050).</p>\n\n<p><strong>Conclusion: </strong>Patients with NOTCH1 tumor mutations were associated with early progression and significantly poorer PFS among pembrolizumab-treated R/M HNSCC patients.  These findings suggest that NOTCH1 loss-of-function may identify a genomically defined subgroup resistant to ICI, potentially through impaired tumor-immune signaling. These findings should be interpreted as hypothesis-generating given the small sample size; validation in larger cohorts and functional studies are warranted.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_05%E2%80%AFAM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153650/Screenshot%202025-12-03%20at%209_15_16%E2%80%AFAM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153650--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S132",
      "content_id": "154016",
      "abstract_number": "S132",
      "poster_number": "",
      "title": "Adjuvant Immunotherapy Following Surgery Improves Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Neoadjuvant Immune Checkpoint Inhibition: A Real-World Analysis Independe",
      "summary": "In HNSCC patients treated with a neoadjuvant immunotherapy-surgery sequence, the continuation of immunotherapy postoperatively as adjuvant therapy is associated with significantly improved PFS and OS. This benefit persists after rigorous adjustment for baseline characteristics and is evident regardless of the degree of pathological response to neoadjuvant treatment. These findings advocate for the strong...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154016",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yudong Ning",
      "presenter": "Yudong Ning",
      "authors": "Yang Liu 1 ; Qindong Cai 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 3 ; Shaoyan Liu 3",
      "normalized_authors": [
        "Yang Liu",
        "Qindong Cai",
        "Yudong Ning",
        "Han Li",
        "Lin Gui",
        "Ye Zhang",
        "Jingwei Luo",
        "Changming An",
        "Xiaolei Wang",
        "Shaoyan Liu"
      ],
      "affiliations": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154016/%E5%85%8D%E7%96%AB%E7%BB%B4%E6%8C%81-%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154016/%E5%85%8D%E7%96%AB%E7%BB%B4%E6%8C%81-%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154016"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 345,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Yang Liu 1 ; Qindong Cai 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 3 ; Shaoyan Liu 3",
        "Affiliations": "1 Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 3 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Background": "For patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who receive neoadjuvant immune checkpoint inhibitors (ICI) followed by curative-intent surgery, the survival impact of continuing immunotherapy in the adjuvant or maintenance setting remains a critical unanswered question.",
        "Methods": "In this retrospective study, we analyzed HNSCC patients who underwent surgery after neoadjuvant ICI. Patients who received postoperative adjuvant immunotherapy (ATI, n=97) were compared to those who did not (n=32). The primary endpoints were progression-free survival (PFS) and overall survival (OS). To address potential confounding, we performed inverse probability of treatment weighting (IPTW) and propensity score matching (PSM), adjusting for gender, tumor grade, KI67 index, P16 status, CPS score, age, primary site (oral cavity, oropharynx, larynx, hypopharynx), smoking history, and clinical stage (III-IV).",
        "Results": "In the unadjusted cohort, Kaplan-Meier analysis suggested a trend toward improved PFS and OS with ATI. After IPTW adjustment (creating a balanced weighted cohort of 129.6 vs. 133.1), ATI was associated with a statistically significant improvement in both PFS (log-rank p<0.05) and OS (log-rank p<0.05). This benefit was consistently confirmed in the PSM-matched analysis. Crucially, subgroup analysis demonstrated that the survival advantage from postoperative ATI was independent of major pathological response (MPR) status, with no significant interaction between treatment effect and MPR (Interaction p>0.05). In a supplemental multivariable Cox model, achieving MPR was a powerful independent predictor of superior PFS (HR 0.149, 95% CI 0.041–0.545, p=0.004), with prognostic value comparable to pathological complete response (pCR), supporting its utility as a surrogate endpoint.",
        "Conclusion": "In HNSCC patients treated with a neoadjuvant immunotherapy-surgery sequence, the continuation of immunotherapy postoperatively as adjuvant therapy is associated with significantly improved PFS and OS. This benefit persists after rigorous adjustment for baseline characteristics and is evident regardless of the degree of pathological response to neoadjuvant treatment. These findings advocate for the strong consideration of postoperative immune maintenance in this clinical context.",
        "Keywords": "head and neck squamous cell carcinoma; neoadjuvant immunotherapy; adjuvant immunotherapy; major pathological response; survival analysis.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Adjuvant Immunotherapy Following Surgery Improves Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Neoadjuvant Immune Checkpoint Inhibition: A Real-World Analysis Independent of Pathologic Response</span>. Yang Liu<sup>1</sup>; Qindong Cai<sup>1</sup>; <u>Yudong Ning</u><sup>1</sup>; Han Li<sup>1</sup>; Lin Gui<sup>2</sup>; Ye Zhang<sup>3</sup>; Jingwei Luo<sup>3</sup>; Changming An<sup>1</sup>; Xiaolei Wang<sup>3</sup>; Shaoyan Liu<sup>3</sup>. <sup>1</sup>Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>2</sup>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>3</sup>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> For patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who receive neoadjuvant immune checkpoint inhibitors (ICI) followed by curative-intent surgery, the survival impact of continuing immunotherapy in the adjuvant or maintenance setting remains a critical unanswered question.</p>\n\n<p><strong>Methods: </strong>In this retrospective study, we analyzed HNSCC patients who underwent surgery after neoadjuvant ICI. Patients who received postoperative adjuvant immunotherapy (ATI, n=97) were compared to those who did not (n=32). The primary endpoints were progression-free survival (PFS) and overall survival (OS). To address potential confounding, we performed inverse probability of treatment weighting (IPTW) and propensity score matching (PSM), adjusting for gender, tumor grade, KI67 index, P16 status, CPS score, age, primary site (oral cavity, oropharynx, larynx, hypopharynx), smoking history, and clinical stage (III-IV).</p>\n\n<p><strong>Results: </strong>In the unadjusted cohort, Kaplan-Meier analysis suggested a trend toward improved PFS and OS with ATI. After IPTW adjustment (creating a balanced weighted cohort of 129.6 vs. 133.1), ATI was associated with a statistically significant improvement in both PFS (log-rank p<0.05) and OS (log-rank p<0.05). This benefit was consistently confirmed in the PSM-matched analysis. Crucially, subgroup analysis demonstrated that the survival advantage from postoperative ATI was independent of major pathological response (MPR) status, with no significant interaction between treatment effect and MPR (Interaction p>0.05). In a supplemental multivariable Cox model, achieving MPR was a powerful independent predictor of superior PFS (HR 0.149, 95% CI 0.041–0.545, p=0.004), with prognostic value comparable to pathological complete response (pCR), supporting its utility as a surrogate endpoint.</p>\n\n<p><strong>Conclusion:</strong> In HNSCC patients treated with a neoadjuvant immunotherapy-surgery sequence, the continuation of immunotherapy postoperatively as adjuvant therapy is associated with significantly improved PFS and OS. This benefit persists after rigorous adjustment for baseline characteristics and is evident regardless of the degree of pathological response to neoadjuvant treatment. These findings advocate for the strong consideration of postoperative immune maintenance in this clinical context.</p>\n\n<p><strong>Keywords</strong>: head and neck squamous cell carcinoma; neoadjuvant immunotherapy; adjuvant immunotherapy; major pathological response; survival analysis.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154016/%E5%85%8D%E7%96%AB%E7%BB%B4%E6%8C%81-%E6%8A%95%E7%A8%BF%E5%9B%BE%E7%89%87.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154016--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S133",
      "content_id": "154468",
      "abstract_number": "S133",
      "poster_number": "",
      "title": "Efficacy of Neoadjuvant Immunotherapy in Squamous Cell Carcinoma of the Lip",
      "summary": "While NI has demonstrated excellent efficacy in the management of cSCC, lip SCC may exhibit differential sensitivity to this approach.. In this national cohort, NI did not demonstrate measurable oncologic benefit for patients with lip SCC, although prospective studies are needed to fully assess its impact and potential variation across lip subsites. Developing NI treatment paradigms tailored to lip SCC will be...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154468",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "James A Widner, BS",
      "presenter": "James A Widner, BS",
      "authors": "James A Widner, BS ; Marco A Campioli, BA; David J Hernandez, MD; Vlad C Sandulache, MD, PhD; Erich M Sturgis, MD, MPH; Ray Y Wang, MD",
      "normalized_authors": [
        "James A Widner",
        "Marco A Campioli",
        "David J Hernandez",
        "Vlad C Sandulache",
        "Erich M Sturgis",
        "Ray Y Wang"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 477,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "James A Widner, BS ; Marco A Campioli, BA; David J Hernandez, MD; Vlad C Sandulache, MD, PhD; Erich M Sturgis, MD, MPH; Ray Y Wang, MD",
        "Affiliations": "Baylor College of Medicine",
        "Objectives": "Neoadjuvant immunotherapy (NI) has emerged as a promising ancillary in the treatment of cutaneous squamous cell carcinomas (cSCC), demonstrating high pathologic response rates and improved survival outcomes in several major trials, prompting National Comprehensive Cancer Network endorsement for high-risk cSCC in 2025. Notably, patients with lip SCC have been excluded from most major trials evaluating neoadjuvant immunotherapy for cSCC. As a result, its applicability to lip SCC remains largely uncharacterized, despite growing enthusiasm for its benefit in cutaneous disease. We sought to evaluate oncologic outcomes and treatment response among lip SCC patients receiving NI prior to surgical resection using a cohort from the National Cancer Database (NCDB), providing needed evidence to inform the utilization of NI in this population.",
        "Methods": "Retrospective analysis of patients diagnosed with SCC of the lip between 2011 and 2023 who were treated with definitive surgery with curative intent. Patients were identified using ICD-O site and histology codes for SCC of the lip. Patients were stratified by receipt of neoadjuvant immunotherapy and subjected to 1:3 propensity score matching for clinical T/N stage and relevant sociodemographic characteristics in patients with and without NI. Clinicopathologic measures and postoperative outcomes were compared between groups using Chi-Square and Wilcoxon rank-sum tests, respectively. Survival was assessed using the Kaplan-Meier method and hazard ratios (HR) were calculated from a multivariable Cox proportional hazard regression.",
        "Results": "23 patients receiving NI were identified for inclusion and matched to 66 patients who did not receive any form of neoadjuvant therapy. The cohorts were primarily white males aged 60 or older. Only one patient receiving NI demonstrated pathologic T-stage downstaging, while no patients were upstaged and none achieved a complete pathologic response. Positive margin rates were similar in patients receiving NI (13% vs 12%, P = 0.87). In patients with advanced clinical disease (cT3+ or cN2+) who were candidates for adjuvant radiotherapy, NI did not reduce the likelihood of receiving adjuvant radiation (70% vs 50%, P = 0.47) or chemotherapy (10% vs 28.6%, P = 0.45). Time to initiation of adjuvant radiation was similar between cohorts (58 ± 13 vs 71 ± 33, P = 0.63).Overall survival was not significantly different in patients who received NI(5-year OS: 78% vs 77%, P = 0.24). Multivariable Cox regression adjustment for clinicopathologic factors confirmed no significant association with improved survival (aHR 0.29; 95% CI, 0.06–1.35; P = 0.11).",
        "Conclusions": "While NI has demonstrated excellent efficacy in the management of cSCC, lip SCC may exhibit differential sensitivity to this approach.. In this national cohort, NI did not demonstrate measurable oncologic benefit for patients with lip SCC, although prospective studies are needed to fully assess its impact and potential variation across lip subsites. Developing NI treatment paradigms tailored to lip SCC will be critical to optimizing its therapeutic value in this distinct head and neck cancer subtype.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy of Neoadjuvant Immunotherapy in Squamous Cell Carcinoma of the Lip</span>. <u>James A Widner, BS</u>; Marco A Campioli, BA; David J Hernandez, MD; Vlad C Sandulache, MD, PhD; Erich M Sturgis, MD, MPH; Ray Y Wang, MD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>Neoadjuvant immunotherapy (NI) has emerged as a promising ancillary in the treatment of cutaneous squamous cell carcinomas (cSCC), demonstrating high pathologic response rates and improved survival outcomes in several major trials, prompting National Comprehensive Cancer Network endorsement for high-risk cSCC in 2025. Notably, patients with lip SCC have been excluded from most major trials evaluating neoadjuvant immunotherapy for cSCC. As a result, its applicability to lip SCC remains largely uncharacterized, despite growing enthusiasm for its benefit in cutaneous disease. We sought to evaluate oncologic outcomes and treatment response among lip SCC patients receiving NI prior to surgical resection using a cohort from the National Cancer Database (NCDB), providing needed evidence to inform the utilization of NI in this population.</p>\n\n<p><strong>Methods: </strong>Retrospective analysis of patients diagnosed with SCC of the lip between 2011 and 2023 who were treated with definitive surgery with curative intent. Patients were identified using ICD-O site and histology codes for SCC of the lip. Patients were stratified by receipt of neoadjuvant immunotherapy and subjected to 1:3 propensity score matching for clinical T/N stage and relevant sociodemographic characteristics in patients with and without NI. Clinicopathologic measures and postoperative outcomes were compared between groups using Chi-Square and Wilcoxon rank-sum tests, respectively. Survival was assessed using the Kaplan-Meier method and hazard ratios (HR) were calculated from a multivariable Cox proportional hazard regression.</p>\n\n<p><strong>Results: </strong>23 patients receiving NI were identified for inclusion and matched to 66 patients who did not receive any form of neoadjuvant therapy. The cohorts were primarily white males aged 60 or older. Only one patient receiving NI demonstrated pathologic T-stage downstaging, while no patients were upstaged and none achieved a complete pathologic response. Positive margin rates were similar in patients receiving NI (13% vs 12%, P = 0.87). In patients with advanced clinical disease (cT3+ or cN2+) who were candidates for adjuvant radiotherapy, NI did not reduce the likelihood of receiving adjuvant radiation (70% vs 50%, P = 0.47) or chemotherapy (10% vs 28.6%, P = 0.45). Time to initiation of adjuvant radiation was similar between cohorts (58 ± 13 vs 71 ± 33, P = 0.63).Overall survival was not significantly different in patients who received NI(5-year OS: 78% vs 77%, P = 0.24). Multivariable Cox regression adjustment for clinicopathologic factors confirmed no significant association with improved survival (aHR 0.29; 95% CI, 0.06–1.35; P = 0.11).</p>\n\n<p><strong>Conclusions: </strong>While NI has demonstrated excellent efficacy in the management of cSCC, lip SCC may exhibit differential sensitivity to this approach.. In this national cohort, NI did not demonstrate measurable oncologic benefit for patients with lip SCC, although prospective studies are needed to fully assess its impact and potential variation across lip subsites. Developing NI treatment paradigms tailored to lip SCC will be critical to optimizing its therapeutic value in this distinct head and neck cancer subtype.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154468--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S134",
      "content_id": "153942",
      "abstract_number": "S134",
      "poster_number": "",
      "title": "Is Perioperative Pembrolizumab Cost-Effective After KEYNOTE-689? Independent Cost-Utility Results from a Public-Payer System",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153942",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex O Esemezie",
      "presenter": "Alex O Esemezie",
      "authors": "Christopher W Noel 1 ; Jennifer Guo 1 ; David Forner 2 ; Alex O Esemezie 1 ; Lauren E Miller 3 ; Jonathan Irish 1 ; John R de Almeida 1 ; Ambika Parmar 1 ; Rui Fu 4 ; Antoine Eskander 1",
      "normalized_authors": [
        "Christopher W Noel",
        "Jennifer Guo",
        "David Forner",
        "Alex O Esemezie",
        "Lauren E Miller",
        "Jonathan Irish",
        "John R de Almeida",
        "Ambika Parmar",
        "Rui Fu",
        "Antoine Eskander"
      ],
      "affiliations": [
        "University of Toronto",
        "University of Michigan",
        "The Ohio State University",
        "University of Calgary"
      ],
      "normalized_institutions": [
        "University of Toronto",
        "University of Michigan",
        "The Ohio State University",
        "University of Calgary"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 256,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Abstract"
      ],
      "sections": {
        "Authors": "Christopher W Noel 1 ; Jennifer Guo 1 ; David Forner 2 ; Alex O Esemezie 1 ; Lauren E Miller 3 ; Jonathan Irish 1 ; John R de Almeida 1 ; Ambika Parmar 1 ; Rui Fu 4 ; Antoine Eskander 1",
        "Affiliations": "1 University of Toronto; 2 University of Michigan; 3 The Ohio State University; 4 University of Calgary",
        "BACKGROUND": "KEYNOTE-689 was a practice-changing phase III trial demonstrating that perioperative pembrolizumab added to surgery and adjuvant therapy improves event-free survival in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). As perioperative immunotherapy enters curative-intent pathways, understanding its economic value is essential. To date, no independent cost-utility analyses (CUAs) have evaluated perioperative pembrolizumab. We conducted a CUA using Canadian health-system data to inform value-based implementation and reimbursement decisions.",
        "METHODS": "We developed a three-state Markov model (event-free, recurrent/metastatic, death) for a cohort of newly diagnosed, resectable locally advanced HNSCC. Treatment pathways mirrored KEYNOTE-689, comparing standard surgery and adjuvant radiotherapy (± cisplatin) with or without perioperative pembrolizumab. Transition probabilities and adverse event rates were derived from the trial. Costs were obtained from publicly available Canadian payer sources, and utilities from published literature. The model adopted a Canadian public-payer perspective with a 3-year time horizon aligned to interim trial follow-up, applying a 1.5% annual discount rate. We performed probabilistic sensitivity, scenario, and threshold analyses.",
        "RESULTS": "Perioperative pembrolizumab was associated with substantial incremental costs and modest QALY gains, resulting in an incremental cost-effectiveness ratio (ICER) exceeding $1.2 million CAD per QALY over 3 years. Across commonly cited willingness-to-pay thresholds ($50,000–$150,000/QALY), pembrolizumab was not cost-effective in nearly all simulations.",
        "CONCLUSIONS": "Using Canadian health-system data, perioperative pembrolizumab appears unlikely to be cost-effective at current pricing despite meaningful clinical benefit. These findings represent the first independent economic evidence to guide pricing negotiations, reimbursement decisions, and value-based adoption of perioperative immunotherapy in HNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Is Perioperative Pembrolizumab Cost-Effective After KEYNOTE-689? Independent Cost-Utility Results from a Public-Payer System</span>. Christopher W Noel<sup>1</sup>; Jennifer Guo<sup>1</sup>; David Forner<sup>2</sup>; <u>Alex O Esemezie</u><sup>1</sup>; Lauren E Miller<sup>3</sup>; Jonathan Irish<sup>1</sup>; John R de Almeida<sup>1</sup>; Ambika Parmar<sup>1</sup>; Rui Fu<sup>4</sup>; Antoine Eskander<sup>1</sup>. <sup>1</sup>University of Toronto; <sup>2</sup>University of Michigan; <sup>3</sup>The Ohio State University; <sup>4</sup>University of Calgary<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>KEYNOTE-689 was a practice-changing phase III trial demonstrating that perioperative pembrolizumab added to surgery and adjuvant therapy improves event-free survival in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). As perioperative immunotherapy enters curative-intent pathways, understanding its economic value is essential. To date, no independent cost-utility analyses (CUAs) have evaluated perioperative pembrolizumab. We conducted a CUA using Canadian health-system data to inform value-based implementation and reimbursement decisions.</p>\n\n<p><strong>METHODS: </strong>We developed a three-state Markov model (event-free, recurrent/metastatic, death) for a cohort of newly diagnosed, resectable locally advanced HNSCC. Treatment pathways mirrored KEYNOTE-689, comparing standard surgery and adjuvant radiotherapy (± cisplatin) with or without perioperative pembrolizumab. Transition probabilities and adverse event rates were derived from the trial. Costs were obtained from publicly available Canadian payer sources, and utilities from published literature. The model adopted a Canadian public-payer perspective with a 3-year time horizon aligned to interim trial follow-up, applying a 1.5% annual discount rate. We performed probabilistic sensitivity, scenario, and threshold analyses.</p>\n\n<p><strong>RESULTS: </strong>Perioperative pembrolizumab was associated with substantial incremental costs and modest QALY gains, resulting in an incremental cost-effectiveness ratio (ICER) <strong>exceeding $1.2 million CAD per QALY </strong>over 3 years. Across commonly cited willingness-to-pay thresholds ($50,000–$150,000/QALY), pembrolizumab was not cost-effective in nearly all simulations.</p>\n\n<p><strong>CONCLUSIONS: </strong>Using Canadian health-system data, perioperative pembrolizumab appears unlikely to be cost-effective at current pricing despite meaningful clinical benefit. These findings represent the first independent economic evidence to guide pricing negotiations, reimbursement decisions, and value-based adoption of perioperative immunotherapy in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153942--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S135",
      "content_id": "151810",
      "abstract_number": "S135",
      "poster_number": "",
      "title": "Efficacy and Safety of Immune Checkpoint Inhibitors Compared to Chemotherapy and Radiotherapy Alone in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Reconstructed Time-to-Event Data f",
      "summary": "ICIs significantly improve long-term survival and response duration in HNSCC with a favorable safety profile, especially in PD-L1–positive patients. The observed time-varying treatment effect highlights the importance of early disease management strategies and more precise patient selection. These findings support including ICIs as a standard treatment and help inform future biomarker-driven approaches in HNSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151810",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shlomo Merchavy, Dr",
      "presenter": "Shlomo Merchavy, Dr",
      "authors": "Alaa Safia; Shlomo Merchavy, Dr",
      "normalized_authors": [
        "Alaa Safia",
        "Shlomo Merchavy, Dr"
      ],
      "affiliations": [
        "Ziv Medical Center, Israel"
      ],
      "normalized_institutions": [
        "Ziv Medical Center, Israel"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 286,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alaa Safia; Shlomo Merchavy, Dr",
        "Affiliations": "Ziv Medical Center, Israel",
        "Background": "Head and neck squamous cell carcinoma (HNSCC) remains an aggressive cancer with poor outcomes despite progress in standard treatments. Immune checkpoint inhibitors (ICIs) have become a promising treatment option, although pooled survival data from reconstructed individual patient data are still limited.",
        "Methods": "A meta-analysis of randomized controlled trials (RCTs) was conducted evaluating ICIs in patients with locally advanced, recurrent, or metastatic HNSCC. Time-to-event data were reconstructed from published Kaplan–Meier curves to assess overall survival (OS), progression-free survival (PFS), duration of response (DOR), and safety. Analyses included landmark assessments, time-varying hazard models, and restricted mean survival time (RMST).",
        "Results": "Eight RCTs involving 4,131 patients were analyzed. ICIs significantly improved OS compared to the standard of care (SoC) (HR, 0.73; 95% CI, 0.66–0.80; P < 0.001). A time-dependent effect was noted: SoC provided an early OS benefit within 6 months, while ICIs demonstrated better survival afterward. PFS initially favored SoC, but landmark analysis revealed long-term advantages with ICIs beyond 3 months. DOR was greatly extended with ICIs (HR, 0.37; 95% CI, 0.29–0.47; P < 0.001). ICIs also showed a lower rate of grade ≥3 adverse events (RR, 0.46; 95% CI, 0.27–0.80).",
        "Conclusions": "ICIs significantly improve long-term survival and response duration in HNSCC with a favorable safety profile, especially in PD-L1–positive patients. The observed time-varying treatment effect highlights the importance of early disease management strategies and more precise patient selection. These findings support including ICIs as a standard treatment and help inform future biomarker-driven approaches in HNSCC.",
        "Keywords": "Head and neck squamous cell carcinoma, immune checkpoint inhibitors, meta-analysis, overall survival, progression-free survival, duration of response, PD-L1, immunotherapy, time-varying hazard, safety profile",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy and Safety of Immune Checkpoint Inhibitors Compared to Chemotherapy and Radiotherapy Alone in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Reconstructed Time-to-Event Data from Randomized Controlled Trials</span>. Alaa Safia; <u>Shlomo Merchavy, Dr</u>. Ziv Medical Center, Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) remains an aggressive cancer with poor outcomes despite progress in standard treatments. Immune checkpoint inhibitors (ICIs) have become a promising treatment option, although pooled survival data from reconstructed individual patient data are still limited.</p>\n\n<p><strong>Methods: </strong>A meta-analysis of randomized controlled trials (RCTs) was conducted evaluating ICIs in patients with locally advanced, recurrent, or metastatic HNSCC. Time-to-event data were reconstructed from published Kaplan–Meier curves to assess overall survival (OS), progression-free survival (PFS), duration of response (DOR), and safety. Analyses included landmark assessments, time-varying hazard models, and restricted mean survival time (RMST).</p>\n\n<p><strong>Results: </strong>Eight RCTs involving 4,131 patients were analyzed. ICIs significantly improved OS compared to the standard of care (SoC) (HR, 0.73; 95% CI, 0.66–0.80; P < 0.001). A time-dependent effect was noted: SoC provided an early OS benefit within 6 months, while ICIs demonstrated better survival afterward. PFS initially favored SoC, but landmark analysis revealed long-term advantages with ICIs beyond 3 months. DOR was greatly extended with ICIs (HR, 0.37; 95% CI, 0.29–0.47; P < 0.001). ICIs also showed a lower rate of grade ≥3 adverse events (RR, 0.46; 95% CI, 0.27–0.80).</p>\n\n<p><strong>Conclusions: </strong>ICIs significantly improve long-term survival and response duration in HNSCC with a favorable safety profile, especially in PD-L1–positive patients. The observed time-varying treatment effect highlights the importance of early disease management strategies and more precise patient selection. These findings support including ICIs as a standard treatment and help inform future biomarker-driven approaches in HNSCC.</p>\n\n<p><strong>Keywords: </strong>Head and neck squamous cell carcinoma, immune checkpoint inhibitors, meta-analysis, overall survival, progression-free survival, duration of response, PD-L1, immunotherapy, time-varying hazard, safety profile</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151810--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S136",
      "content_id": "153977",
      "abstract_number": "S136",
      "poster_number": "",
      "title": "Incidence and Predictors of Immune-Related Adverse Events in ICI-treated Mucosal Head and Neck Cancer",
      "summary": "In this large, real-world cohort of nearly 23,000 mucosal HNSCC patients treated with ICIs, irAEs were common, with two-thirds experiencing an event within 12 months. Patient characteristics (sex, BMI, race/ethnicity, comorbidity, SVI) and treatment factors (subsite, ICI era, specific agent) were independently associated with irAE risk. Endocrine irAEs were identified using diagnosis codes and likely include...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153977",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Allen Khudaverdyan, BA",
      "presenter": "Allen Khudaverdyan, BA",
      "authors": "Allen Khudaverdyan, BA 1 ; Christie Hung, BS 1 ; Lindsey Moses, MD 2 ; Emmanuel Garcia Morales, PhD 2 ; Ashley Feng, BS 2 ; Umamaheswar Duvvuri 2",
      "normalized_authors": [
        "Allen Khudaverdyan",
        "Christie Hung",
        "Lindsey Moses",
        "Emmanuel Garcia Morales",
        "Ashley Feng",
        "Umamaheswar Duvvuri"
      ],
      "affiliations": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 533,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Allen Khudaverdyan, BA 1 ; Christie Hung, BS 1 ; Lindsey Moses, MD 2 ; Emmanuel Garcia Morales, PhD 2 ; Ashley Feng, BS 2 ; Umamaheswar Duvvuri 2",
        "Affiliations": "1 NYU Grossman School of Medicine; 2 NYU Langone Department of Otolaryngology",
        "Background": "Immune checkpoint inhibitors (ICIs) are widely used in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), but real-world incidence and determinants of immune-related adverse events (irAEs) remain poorly characterized. Prior HNSCC studies have been limited by small sample sizes, single-institution cohorts, or focus on specific toxicities. We aimed to quantify 12-month irAE incidence and identify clinical and treatment-level predictors in a large multi-institutional cohort.",
        "Methods": "We performed a retrospective study using Epic COSMOS, a multi-health-system electronic health record dataset. Adult patients with mucosal HNSCC receiving ≥1 ICI (pembrolizumab, nivolumab, durvalumab, avelumab, ipilimumab, or atezolizumab) were included; the index date was first ICI administration. Covariates included age, sex, race/ethnicity, language, insurance, BMI, Social Vulnerability Index (SVI), comorbidity, tumor subsite, simplified T/N/M stage, ICI era, and index ICI drug. irAEs within 12 months were identified using prespecified ICD-10 clusters for dermatologic, endocrine, gastrointestinal, hepatic, pulmonary, renal, and neurologic toxicities. Baseline characteristics were compared by irAE status, and multivariable logistic regression identified independent predictors of any irAE.",
        "Results": "A total of 22,896 ICI-treated mucosal HNSCC patients met inclusion criteria (median age 66 years; 73.3% male; 75.9% White). Overall, 14,724 patients (64.3%) experienced ≥1 irAE. Endocrine (44.7%), dermatologic (21.7%), and gastrointestinal (20.6%) events were most common, whereas hepatic (3.0%), renal (6.1%), pulmonary (1.0%), and neurologic (0.24%) irAEs were infrequent. In multivariable analysis, male sex was associated with lower odds of irAE compared with females (adjusted odds ratio [aOR] 0.76, 95% CI 0.71-0.81). Higher comorbidity burden modestly increased risk (aOR per Charlson point 1.02, 1.01-1.03), whereas higher SVI was associated with fewer documented irAEs (aOR 0.83, 0.75-0.92). Compared with Asian patients, Black (aOR 0.62), Hispanic (0.77), White (0.88), and Other race/ethnicity (0.77) had lower odds of recorded irAEs. Relative to normal BMI, obese (aOR 1.29, 1.16-1.43) and overweight patients (1.10, 1.01-1.20) had increased risk; underweight patients had lower odds (0.73, 0.66-0.81). By tumor subsite (ref = hypopharynx), oral cavity (0.70), sinonasal (0.66), oropharynx (0.78), nasopharynx (0.77), and “other” subsites (0.69) demonstrated lower odds. Later ICI eras (Mid: 1.31; Late: 1.33 vs Early) were associated with higher irAE detection. Ipilimumab (aOR 2.07, 1.55-2.77) and durvalumab (1.49, 1.04-2.12) carried higher risk relative to atezolizumab.",
        "Conclusions": "In this large, real-world cohort of nearly 23,000 mucosal HNSCC patients treated with ICIs, irAEs were common, with two-thirds experiencing an event within 12 months. Patient characteristics (sex, BMI, race/ethnicity, comorbidity, SVI) and treatment factors (subsite, ICI era, specific agent) were independently associated with irAE risk. Endocrine irAEs were identified using diagnosis codes and likely include pre-existing hypothyroidism, inflating incidence estimates, though a history of hypothyroidism does not preclude patients from ICI-associated exacerbations of disease. A planned sensitivity analysis excluding patients with pre-index endocrine diagnoses will refine this. This study provides the largest characterization of irAE patterns in mucosal HNSCC to date and highlights clinically meaningful risk strata that may inform toxicity surveillance and future prediction tools.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence and Predictors of Immune-Related Adverse Events in ICI-treated Mucosal Head and Neck Cancer</span>. <u>Allen Khudaverdyan, BA</u><sup>1</sup>; Christie Hung, BS<sup>1</sup>; Lindsey Moses, MD<sup>2</sup>; Emmanuel Garcia Morales, PhD<sup>2</sup>; Ashley Feng, BS<sup>2</sup>; Umamaheswar Duvvuri<sup>2</sup>. <sup>1</sup>NYU Grossman School of Medicine; <sup>2</sup>NYU Langone Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Immune checkpoint inhibitors (ICIs) are widely used in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), but real-world incidence and determinants of immune-related adverse events (irAEs) remain poorly characterized. Prior HNSCC studies have been limited by small sample sizes, single-institution cohorts, or focus on specific toxicities. We aimed to quantify 12-month irAE incidence and identify clinical and treatment-level predictors in a large multi-institutional cohort.</p>\n\n<p><strong>Methods</strong>: We performed a retrospective study using Epic COSMOS, a multi-health-system electronic health record dataset. Adult patients with mucosal HNSCC receiving ≥1 ICI (pembrolizumab, nivolumab, durvalumab, avelumab, ipilimumab, or atezolizumab) were included; the index date was first ICI administration. Covariates included age, sex, race/ethnicity, language, insurance, BMI, Social Vulnerability Index (SVI), comorbidity, tumor subsite, simplified T/N/M stage, ICI era, and index ICI drug. irAEs within 12 months were identified using prespecified ICD-10 clusters for dermatologic, endocrine, gastrointestinal, hepatic, pulmonary, renal, and neurologic toxicities. Baseline characteristics were compared by irAE status, and multivariable logistic regression identified independent predictors of any irAE.</p>\n\n<p><strong>Results</strong>: A total of 22,896 ICI-treated mucosal HNSCC patients met inclusion criteria (median age 66 years; 73.3% male; 75.9% White). Overall, 14,724 patients (64.3%) experienced ≥1 irAE. Endocrine (44.7%), dermatologic (21.7%), and gastrointestinal (20.6%) events were most common, whereas hepatic (3.0%), renal (6.1%), pulmonary (1.0%), and neurologic (0.24%) irAEs were infrequent. In multivariable analysis, male sex was associated with lower odds of irAE compared with females (adjusted odds ratio [aOR] 0.76, 95% CI 0.71-0.81). Higher comorbidity burden modestly increased risk (aOR per Charlson point 1.02, 1.01-1.03), whereas higher SVI was associated with fewer documented irAEs (aOR 0.83, 0.75-0.92). Compared with Asian patients, Black (aOR 0.62), Hispanic (0.77), White (0.88), and Other race/ethnicity (0.77) had lower odds of recorded irAEs. Relative to normal BMI, obese (aOR 1.29, 1.16-1.43) and overweight patients (1.10, 1.01-1.20) had increased risk; underweight patients had lower odds (0.73, 0.66-0.81). By tumor subsite (ref = hypopharynx), oral cavity (0.70), sinonasal (0.66), oropharynx (0.78), nasopharynx (0.77), and “other” subsites (0.69) demonstrated lower odds. Later ICI eras (Mid: 1.31; Late: 1.33 vs Early) were associated with higher irAE detection. Ipilimumab (aOR 2.07, 1.55-2.77) and durvalumab (1.49, 1.04-2.12) carried higher risk relative to atezolizumab.</p>\n\n<p><strong>Conclusions</strong>: In this large, real-world cohort of nearly 23,000 mucosal HNSCC patients treated with ICIs, irAEs were common, with two-thirds experiencing an event within 12 months. Patient characteristics (sex, BMI, race/ethnicity, comorbidity, SVI) and treatment factors (subsite, ICI era, specific agent) were independently associated with irAE risk. Endocrine irAEs were identified using diagnosis codes and likely include pre-existing hypothyroidism, inflating incidence estimates, though a history of hypothyroidism does not preclude patients from ICI-associated exacerbations of disease. A planned sensitivity analysis excluding patients with pre-index endocrine diagnoses will refine this. This study provides the largest characterization of irAE patterns in mucosal HNSCC to date and highlights clinically meaningful risk strata that may inform toxicity surveillance and future prediction tools.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153977--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S137",
      "content_id": "153845",
      "abstract_number": "S137",
      "poster_number": "",
      "title": "APR-1051, a Next-Generation WEE1 Inhibitor, Enhances the Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinoma",
      "summary": "APR-1051 promotes antitumor immunity by reducing immunosuppression and enhancing T-cell activity. Its strong synergy with anti-PD-1, particularly in HPV-positive HNSCC models, supports further investigation of APR-1051 in combination immunotherapy trials.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153845",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdullah A Osman, PhD",
      "presenter": "Abdullah A Osman, PhD",
      "authors": "Mutsuki Kawabe, DDS, PhD; Tsung-You Tsai, MD; Jennifer Anderson, MD, PhD; Arisa Nishikawa Kaga, DDS, PhD; Kento Okamoto, DDS, PhD; Sofia Cortes; Ratna Veeramachaneni, PhD; Andrew G Sikora, MD, PhD; Jeffrey N Myers, MD, PhD; Abdullah A Osman, PhD",
      "normalized_authors": [
        "Mutsuki Kawabe",
        "Tsung-You Tsai",
        "Jennifer Anderson",
        "Arisa Nishikawa Kaga",
        "Kento Okamoto",
        "Sofia Cortes",
        "Ratna Veeramachaneni",
        "Andrew G Sikora",
        "Jeffrey N Myers",
        "Abdullah A Osman"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mutsuki Kawabe, DDS, PhD; Tsung-You Tsai, MD; Jennifer Anderson, MD, PhD; Arisa Nishikawa Kaga, DDS, PhD; Kento Okamoto, DDS, PhD; Sofia Cortes; Ratna Veeramachaneni, PhD; Andrew G Sikora, MD, PhD; Jeffrey N Myers, MD, PhD; Abdullah A Osman, PhD",
        "Affiliations": "The University of Texas MD Anderson Cancer Center",
        "Background": "Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous and clinically aggressive malignancy originating from epithelium of the oral cavity, pharynx, and larynx. Globally, it represents the sixth most common cancer, with over 800,000 new diagnoses and 400,000 deaths each year. Despite advances in surgery, radiation, chemotherapy and immunotherapy, outcomes for patients with advanced disease remain poor, partly due to prevalent genomic alterations and the tumor’s ability to evade immune surveillance, a process strongly influenced by the tumor microenvironment (TME). WEE1 tyrosine kinase is a key regulator of the G1-S and G2-M checkpoints and cellular responses to DNA damage. Its inhibition elevates CDK1 and CDK2 activity, driving damaged cells prematurely into mitosis and inducing mitotic catastrophe. APR-1051 is an orally bioavailable, potent, and selective small-molecule WEE1 inhibitor that exhibits robust in vivo anti-proliferative activity across multiple cancer models and is currently under evaluation in phase I clinical trials for solid tumors. Its enhanced selectivity relative to other WEE1 inhibitors may reduce myelosuppressive toxicity. Although immunotherapy is now a standard treatment for HNSCC, many tumors fail to respond. This study investigates the efficacy of APR-1051 as monotherapy and in combination with anti-PD-1 therapy in a syngeneic mouse model of HNSCC.",
        "Methods": "An orthotopic syngeneic mouse model was used to evaluate in vivo treatment efficacy. Immune profiling of tumors following APR-1051 and anti-PD-1 administration was performed using immunohistochemistry and flow cytometry. In vitro assays, including clonogenic survival, western blotting, cell-cycle analysis, and Annexin V staining were conducted to confirm drug specificity and investigate underlying molecular mechanisms. RNA sequencing of tumor samples was conducted to assess cytokine expression and immune-related gene signatures.",
        "Results": "HPV-negative (MOC1, NOOC1) and HPV-positive (mEER) murine HNSCC cell lines exhibited sensitivity to APR-1051 with half-maximal inhibitory concentrations (IC50) ranging from of 50 to 100 nmol/L. In vivo, combining APR-1051 with anti-PD-1 significantly suppressed tumor growth (P < 0.0001 and P = 0.0067), reduced cervical lymph node metastases, and prolonged survival in orthotopic MOC1 and mEER tumor models compared with controls and single agents. HPV-positive tumors showed greater treatment sensitivity than HPV-negative tumors, with 75% of HPV-positive tumors achieving a complete response to the combination therapy. The combination was well tolerated with no weight loss observed. APR-1051 favorably reshaped the tumor immune microenvironment, reducing immunosuppressive population, including Tregs (P = 0.0004; combination P = 0.0003), granulocytes (P = 0.0019), neutrophils (P = 0.002), and PMN-MDSCs (P = 0.0096), and enhancing T-cell responses. Anti-PD-1 further augmented immunity by decreasing exhausted T cells alone (P = 0.0015) and in combination (P = 0.0006). Mechanistic studies showed that WEE1 inhibition induced DNA damage, replication stress, and activated the cGAS/STING pathway with reduced STAT3 phosphorylation in MOC1 and mEER cells. Furthermore, APR-1051 treatment in vitro induced G2-M cell-cycle arrest accompanied by apoptotic cell death in a dose- and time-dependent manner.",
        "Conclusions": "APR-1051 promotes antitumor immunity by reducing immunosuppression and enhancing T-cell activity. Its strong synergy with anti-PD-1, particularly in HPV-positive HNSCC models, supports further investigation of APR-1051 in combination immunotherapy trials.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>APR-1051, a Next-Generation WEE1 Inhibitor, Enhances the Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinoma</span>. Mutsuki Kawabe, DDS, PhD; Tsung-You Tsai, MD; Jennifer Anderson, MD, PhD; Arisa Nishikawa Kaga, DDS, PhD; Kento Okamoto, DDS, PhD; Sofia Cortes; Ratna Veeramachaneni, PhD; Andrew G Sikora, MD, PhD; Jeffrey N Myers, MD, PhD; <u>Abdullah A Osman, PhD</u>. The University of Texas MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous and clinically aggressive malignancy originating from epithelium of the oral cavity, pharynx, and larynx. Globally, it represents the sixth most common cancer, with over 800,000 new diagnoses and 400,000 deaths each year. Despite advances in surgery, radiation, chemotherapy and immunotherapy, outcomes for patients with advanced disease remain poor, partly due to prevalent genomic alterations and the tumor’s ability to evade immune surveillance, a process strongly influenced by the tumor microenvironment (TME). WEE1 tyrosine kinase is a key regulator of the G1-S and G2-M checkpoints and cellular responses to DNA damage. Its inhibition elevates CDK1 and CDK2 activity, driving damaged cells prematurely into mitosis and inducing mitotic catastrophe. APR-1051 is an orally bioavailable, potent, and selective small-molecule WEE1 inhibitor that exhibits robust in vivo anti-proliferative activity across multiple cancer models and is currently under evaluation in phase I clinical trials for solid tumors. Its enhanced selectivity relative to other WEE1 inhibitors may reduce myelosuppressive toxicity. Although immunotherapy is now a standard treatment for HNSCC, many tumors fail to respond. This study investigates the efficacy of APR-1051 as monotherapy and in combination with anti-PD-1 therapy in a syngeneic mouse model of HNSCC.</p>\n\n<p><strong>Methods:</strong> An orthotopic syngeneic mouse model was used to evaluate in vivo treatment efficacy. Immune profiling of tumors following APR-1051 and anti-PD-1 administration was performed using immunohistochemistry and flow cytometry. In vitro assays, including clonogenic survival, western blotting, cell-cycle analysis, and Annexin V staining were conducted to confirm drug specificity and investigate underlying molecular mechanisms. RNA sequencing of tumor samples was conducted to assess cytokine expression and immune-related gene signatures.</p>\n\n<p><strong>Results:</strong> HPV-negative (MOC1, NOOC1) and HPV-positive (mEER) murine HNSCC cell lines exhibited sensitivity to APR-1051 with half-maximal inhibitory concentrations (IC50) ranging from of 50 to 100 nmol/L. In vivo, combining APR-1051 with anti-PD-1 significantly suppressed tumor growth (P < 0.0001 and P = 0.0067), reduced cervical lymph node metastases, and prolonged survival in orthotopic MOC1 and mEER tumor models compared with controls and single agents. HPV-positive tumors showed greater treatment sensitivity than HPV-negative tumors, with 75% of HPV-positive tumors achieving a complete response to the combination therapy. The combination was well tolerated with no weight loss observed. APR-1051 favorably reshaped the tumor immune microenvironment, reducing immunosuppressive population, including Tregs (P = 0.0004; combination P = 0.0003), granulocytes (P = 0.0019), neutrophils (P = 0.002), and PMN-MDSCs (P = 0.0096), and enhancing T-cell responses. Anti-PD-1 further augmented immunity by decreasing exhausted T cells alone (P = 0.0015) and in combination (P = 0.0006). Mechanistic studies showed that WEE1 inhibition induced DNA damage, replication stress, and activated the cGAS/STING pathway with reduced STAT3 phosphorylation in MOC1 and mEER cells. Furthermore, APR-1051 treatment in vitro induced G2-M cell-cycle arrest accompanied by apoptotic cell death in a dose- and time-dependent manner.</p>\n\n<p><strong>Conclusions:</strong> APR-1051 promotes antitumor immunity by reducing immunosuppression and enhancing T-cell activity. Its strong synergy with anti-PD-1, particularly in HPV-positive HNSCC models, supports further investigation of APR-1051 in combination immunotherapy trials.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153845--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S139",
      "content_id": "155474",
      "abstract_number": "S139",
      "poster_number": "",
      "title": "Proton Pump Inhibitors Are Associated with Worse Survival in Head and Neck Cancer Patients Receiving PD-1 Inhibitors",
      "summary": "In this large, real-world cohort of patients with HNC receiving pembrolizumab or nivolumab, concomitant PPI use around the time of ICI initiation was associated with significantly decreased overall survival. Pantoprazole showed the largest negative effect, and the association also appeared stronger in patients with tobacco- or alcohol-related comorbidities, suggesting a clinically meaningful interaction between...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155474",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jackson P Maradik, BA",
      "presenter": "Jackson P Maradik, BA",
      "authors": "Jackson P Maradik, BA 1 ; Warren B Chun, MD 2 ; Shaun A Nguyen, MD 2 ; Dauren Adilbay, MD, PhD 2 ; W Greer Albergotti, MD 2",
      "normalized_authors": [
        "Jackson P Maradik",
        "Warren B Chun",
        "Shaun A Nguyen",
        "Dauren Adilbay",
        "W Greer Albergotti"
      ],
      "affiliations": [
        "Medical University of South Carolina College of Medicine",
        "Medical University of South Carolina Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina College of Medicine",
        "Medical University of South Carolina Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 425,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jackson P Maradik, BA 1 ; Warren B Chun, MD 2 ; Shaun A Nguyen, MD 2 ; Dauren Adilbay, MD, PhD 2 ; W Greer Albergotti, MD 2",
        "Affiliations": "1 Medical University of South Carolina College of Medicine; 2 Medical University of South Carolina Department of Otolaryngology-Head and Neck Surgery",
        "Background": "Dysbiosis has been shown to impair the efficacy of immune checkpoint inhibitors (ICIs) across several malignancies, including head and neck cancers (HNC). Proton pump inhibitors (PPIs), which are commonly prescribed and can disrupt the gut microbiome, have an uncertain impact on ICI outcomes. This study used a large international database to test the hypothesis that PPI use within 30 days of pembrolizumab or nivolumab initiation is associated with worse overall survival (OS) in patients with HNC.",
        "Methods": "Using the TriNetX Global Collaborative Network, we performed a retrospective cohort study of adult HNC patients treated with pembrolizumab or nivolumab. We defined an Exposure Group as patients who received PPIs from 30 days before or after ICI initiation and a Control Group as patients without PPI prescriptions in this window. Propensity score matching (1:1) was performed for age, sex, race, ethnicity, BMI, nicotine dependence, alcohol use disorder, and primary tumor site, yielding 1,256 patients per group. The primary outcome was all-cause mortality up to 3 years from ICI initiation. We performed Kaplan-Meier analysis, log-rank testing, and Cox proportional hazards modeling for the reference cohort and calculated hazard ratios (HRs) for prespecified subgroups, including intent of treatment, individual ICIs, individual PPIs, and nicotine/alcohol-related comorbidities. We also ran a sensitivity analysis for PPI use from 30 days before to any time after ICI initiation.",
        "Results": "After matching, baseline demographic, clinical, and tumor-site characteristics were well balanced between Exposure and Control Groups (n = 1,256 each). PPI use was associated with significantly decreased OS by log-rank analysis (χ² = 33.1, p < 0.0001), with an HR of 1.49 (95% CI 1.36–1.62), corresponding to a 49% increased risk of death in PPI-exposed patients. In subgroup analyses, PPI use was associated with worse survival in patients treated with curative intent, with pantoprazole showing the greatest impact, whereas no clear detrimental effect was observed in the palliative treatment subgroup.",
        "Conclusions": "In this large, real-world cohort of patients with HNC receiving pembrolizumab or nivolumab, concomitant PPI use around the time of ICI initiation was associated with significantly decreased overall survival. Pantoprazole showed the largest negative effect, and the association also appeared stronger in patients with tobacco- or alcohol-related comorbidities, suggesting a clinically meaningful interaction between PPI choice, patient factors, and ICI response. While residual confounding and indication bias cannot be excluded, these findings support cautious PPI prescribing during ICI therapy in HNC and highlight the need for prospective studies to confirm causality, clarify microbiome-mediated mechanisms, and evaluate whether effects vary by HNC subsite.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Proton Pump Inhibitors Are Associated with Worse Survival in Head and Neck Cancer Patients Receiving PD-1 Inhibitors</span>. <u>Jackson P Maradik, BA</u><sup>1</sup>; Warren B Chun, MD<sup>2</sup>; Shaun A Nguyen, MD<sup>2</sup>; Dauren Adilbay, MD, PhD<sup>2</sup>; W Greer Albergotti, MD<sup>2</sup>. <sup>1</sup>Medical University of South Carolina College of Medicine; <sup>2</sup>Medical University of South Carolina Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Dysbiosis has been shown to impair the efficacy of immune checkpoint inhibitors (ICIs) across several malignancies, including head and neck cancers (HNC). Proton pump inhibitors (PPIs), which are commonly prescribed and can disrupt the gut microbiome, have an uncertain impact on ICI outcomes. This study used a large international database to test the hypothesis that PPI use within 30 days of pembrolizumab or nivolumab initiation is associated with worse overall survival (OS) in patients with HNC.</p>\n\n<p><strong>Methods: </strong>Using the TriNetX Global Collaborative Network, we performed a retrospective cohort study of adult HNC patients treated with pembrolizumab or nivolumab. We defined an Exposure Group as patients who received PPIs from 30 days before or after ICI initiation and a Control Group as patients without PPI prescriptions in this window. Propensity score matching (1:1) was performed for age, sex, race, ethnicity, BMI, nicotine dependence, alcohol use disorder, and primary tumor site, yielding 1,256 patients per group. The primary outcome was all-cause mortality up to 3 years from ICI initiation. We performed Kaplan-Meier analysis, log-rank testing, and Cox proportional hazards modeling for the reference cohort and calculated hazard ratios (HRs) for prespecified subgroups, including intent of treatment, individual ICIs, individual PPIs, and nicotine/alcohol-related comorbidities. We also ran a sensitivity analysis for PPI use from 30 days before to any time after ICI initiation.</p>\n\n<p><strong>Results: </strong>After matching, baseline demographic, clinical, and tumor-site characteristics were well balanced between Exposure and Control Groups (n = 1,256 each). PPI use was associated with significantly decreased OS by log-rank analysis (χ² = 33.1, p < 0.0001), with an HR of 1.49 (95% CI 1.36–1.62), corresponding to a 49% increased risk of death in PPI-exposed patients. In subgroup analyses, PPI use was associated with worse survival in patients treated with curative intent, with pantoprazole showing the greatest impact, whereas no clear detrimental effect was observed in the palliative treatment subgroup.</p>\n\n<p><strong>Conclusions: </strong>In this large, real-world cohort of patients with HNC receiving pembrolizumab or nivolumab, concomitant PPI use around the time of ICI initiation was associated with significantly decreased overall survival. Pantoprazole showed the largest negative effect, and the association also appeared stronger in patients with tobacco- or alcohol-related comorbidities, suggesting a clinically meaningful interaction between PPI choice, patient factors, and ICI response. While residual confounding and indication bias cannot be excluded, these findings support cautious PPI prescribing during ICI therapy in HNC and highlight the need for prospective studies to confirm causality, clarify microbiome-mediated mechanisms, and evaluate whether effects vary by HNC subsite.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155474--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S141",
      "content_id": "153135",
      "abstract_number": "S141",
      "poster_number": "",
      "title": "Association between recent COVID-19 vaccination and survival on immune checkpoint inhibitors in head and neck squamous cell carcinoma",
      "summary": "Recent COVID-19 vaccination within 120 days prior to pembrolizumab initiation was associated with improved 6-month PFS among patients with R/M HNSCC. These findings support the hypothesis that vaccine-induced systemic immune activation may modulate ICI response. Prospective validation and mechanistic studies are warranted.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153135",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Angeline A Truong, MS",
      "presenter": "Angeline A Truong, MS",
      "authors": "Angeline A Truong, MS 1 ; Savinnie Ho 1 ; Rex H Lee, MD 1 ; Xin Wu, MD 1 ; Hyunseok Kang, MD 2 ; Ivan H El-Sayed, MD 1 ; Jonathan R George, MD 1 ; Chase M Heaton, MD 1 ; Ilya Likhterov, MD 1 ; Mary Jue Xu, MD 1 ; Patrick K Ha, MD 1 ; Alain P Algazi, MD 1 ; Katherine C Wai, MD 1",
      "normalized_authors": [
        "Angeline A Truong",
        "Savinnie Ho",
        "Rex H Lee",
        "Xin Wu",
        "Hyunseok Kang",
        "Ivan H El-Sayed",
        "Jonathan R George",
        "Chase M Heaton",
        "Ilya Likhterov",
        "Mary Jue Xu",
        "Patrick K Ha",
        "Alain P Algazi",
        "Katherine C Wai"
      ],
      "affiliations": [
        "University of California, San Francisco",
        "Stanford University"
      ],
      "normalized_institutions": [
        "University of California, San Francisco",
        "Stanford University"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153135/Screenshot%202025-11-21%20at%201_00_45%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153135/Screenshot%202025-11-21%20at%201_00_45%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153135"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 282,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Angeline A Truong, MS 1 ; Savinnie Ho 1 ; Rex H Lee, MD 1 ; Xin Wu, MD 1 ; Hyunseok Kang, MD 2 ; Ivan H El-Sayed, MD 1 ; Jonathan R George, MD 1 ; Chase M Heaton, MD 1 ; Ilya Likhterov, MD 1 ; Mary Jue Xu, MD 1 ; Patrick K Ha, MD 1 ; Alain P Algazi, MD 1 ; Katherine C Wai, MD 1",
        "Affiliations": "1 University of California, San Francisco; 2 Stanford University",
        "Introduction": "Growing evidence suggests that systemic immune activation, such as that induced by COVID-19 mRNA vaccination, may enhance antitumor responses to immune checkpoint inhibitors (ICI). Whether similar mechanisms shape therapeutic responses in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains unclear. Our objective was to evaluate the relationship between administration of the COVID-19 vaccine and outcomes in R/M HNSCC.",
        "Methods": "We retrospectively analyzed 130 patients with R/M HNSCC (oral cavity, oropharynx, larynx, or hypopharynx) treated with pembrolizumab at a tertiary academic center (May 2016–2022). COVID-19 vaccination (Pfizer or Moderna) within 120 days prior to ICI initiation was treated as a binary exposure. Primary outcomes were 6-month progression-free survival (PFS); secondary outcome was 2-year overall survival (OS). Cox proportional hazards models were adjusted for ECOG status, concurrent systemic therapy, and metastatic burden at the start of ICI.",
        "Results": "Twenty-five patients (19%) received ≥1 COVID-19 vaccine dose within 120 days before ICI initiation. After adjustment, patients receiving a COVID-19 vaccine within 120 days of ICI initiation had significantly improved 6-month PFS [HR 0.42 (0.18–0.96), p = 0.041] compared to those who did not. Two-year OS did not differ significantly [HR 0.58 (0.28-1.21), p = 0.149]. On univariate analysis, patients receiving a COVID-19 vaccine within 120 days of ICI start trended towards improved 6-month PFS [HR 0.73 (0.36-1.48), p=0.376].",
        "Conclusion": "Recent COVID-19 vaccination within 120 days prior to pembrolizumab initiation was associated with improved 6-month PFS among patients with R/M HNSCC. These findings support the hypothesis that vaccine-induced systemic immune activation may modulate ICI response. Prospective validation and mechanistic studies are warranted.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association between recent COVID-19 vaccination and survival on immune checkpoint inhibitors in head and neck squamous cell carcinoma</span>. <u>Angeline A Truong, MS</u><sup>1</sup>; Savinnie Ho<sup>1</sup>; Rex H Lee, MD<sup>1</sup>; Xin Wu, MD<sup>1</sup>; Hyunseok Kang, MD<sup>2</sup>; Ivan H El-Sayed, MD<sup>1</sup>; Jonathan R George, MD<sup>1</sup>; Chase M Heaton, MD<sup>1</sup>; Ilya Likhterov, MD<sup>1</sup>; Mary Jue Xu, MD<sup>1</sup>; Patrick K Ha, MD<sup>1</sup>; Alain P Algazi, MD<sup>1</sup>; Katherine C Wai, MD<sup>1</sup>. <sup>1</sup>University of California, San Francisco; <sup>2</sup>Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/153135/Screenshot%202025-11-21%20at%201_00_45%E2%80%AFPM.png' /></p>\n\n<p><strong>Introduction: </strong>Growing evidence suggests that systemic immune activation, such as that induced by COVID-19 mRNA vaccination, may enhance antitumor responses to immune checkpoint inhibitors (ICI). Whether similar mechanisms shape therapeutic responses in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains unclear. Our objective was to evaluate the relationship between administration of the COVID-19 vaccine and outcomes in R/M HNSCC.</p>\n\n<p><strong>Methods:</strong> We retrospectively analyzed 130 patients with R/M HNSCC (oral cavity, oropharynx, larynx, or hypopharynx) treated with pembrolizumab at a tertiary academic center (May 2016–2022). COVID-19 vaccination (Pfizer or Moderna) within 120 days prior to ICI initiation was treated as a binary exposure. Primary outcomes were 6-month progression-free survival (PFS); secondary outcome was 2-year overall survival (OS). Cox proportional hazards models were adjusted for ECOG status, concurrent systemic therapy, and metastatic burden at the start of ICI.</p>\n\n<p><strong>Results:</strong> Twenty-five patients (19%) received ≥1 COVID-19 vaccine dose within 120 days before ICI initiation. After adjustment, patients receiving a COVID-19 vaccine within 120 days of ICI initiation had significantly improved 6-month PFS [HR 0.42 (0.18–0.96), p = 0.041] compared to those who did not. Two-year OS did not differ significantly [HR 0.58 (0.28-1.21), p = 0.149]. On univariate analysis, patients receiving a COVID-19 vaccine within 120 days of ICI start trended towards improved 6-month PFS [HR 0.73 (0.36-1.48), p=0.376].</p>\n\n<p><strong>Conclusion:</strong> Recent COVID-19 vaccination within 120 days prior to pembrolizumab initiation was associated with improved 6-month PFS among patients with R/M HNSCC. These findings support the hypothesis that vaccine-induced systemic immune activation may modulate ICI response. Prospective validation and mechanistic studies are warranted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153135--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S142",
      "content_id": "153905",
      "abstract_number": "S142",
      "poster_number": "",
      "title": "Clinicogenomic Determinants of Survival and Immunotherapy Response in Advanced Head and Neck Cancer",
      "summary": "The integration of genomic biomarkers into treatment selection could be useful given the clinical and molecular heterogeneity of HNSCC. As we demonstrate, specific genomic alterations such as TP53 serve as markers of poor prognosis, whereas pathway-level alterations involving KRAS signaling, DNA repair genes, and the PI3K/AKT/mTOR axis may be predictors of improved immunotherapy benefit. Tailoring treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153905",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260124",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Parisa Abedi, MD",
      "presenter": "Parisa Abedi, MD",
      "authors": "Parisa Abedi, MD ; Andrew George; Ben Schiff; Soraya Fereydooni, MD; Andres Aguirre; Benjamin Judson, MD; Saral Mehra, MD; Curtis Pickering, PhD",
      "normalized_authors": [
        "Parisa Abedi",
        "Andrew George",
        "Ben Schiff",
        "Soraya Fereydooni",
        "Andres Aguirre",
        "Benjamin Judson",
        "Saral Mehra",
        "Curtis Pickering"
      ],
      "affiliations": [
        "Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA"
      ],
      "normalized_institutions": [
        "Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 455,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Method",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Parisa Abedi, MD ; Andrew George; Ben Schiff; Soraya Fereydooni, MD; Andres Aguirre; Benjamin Judson, MD; Saral Mehra, MD; Curtis Pickering, PhD",
        "Affiliations": "Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA",
        "Introduction": "Somatic mutations drive cancer progression and guide selection of targeted therapies in many tumor types. Although genomic alterations in head and neck squamous cell carcinoma (HNSCC) have been characterized by The Cancer Genome Atlas (TCGA) and other sequencing projects, the association between specific mutations and treatment response in real-world practice is not fully understood.",
        "Method": "This study analyzed real-world data from the Flatiron Health-Foundation Medicine HNSCC Clinico-Genomic Database Clinicogenomic Database (CGDB). Our analyses focused on how clinical variables and disease characteristics correlate with treatment responses and overall survival and survival after treatment. We also characterized mutations frequencies across clinically relevant subgroups to better understand their impact on disease trajectory.",
        "Results": "This CGBD cohort includes 1,531 patients with HNSCC, with more than half of tumors originating from the oropharynx (52%) and nearly 70% of these being HPV positive. The heterogeneity of clinical features and outcomes in HNSCC is clearly reflected in this cohort. Survival varies by tumor site, disease biology and treatment pattern: patients with oral cavity tumors have a median OS of 32.2 months, whereas those with oropharyngeal tumors survive 45.8 months. Similarly, tumors with metastases at diagnosis or no initial treatment have the lowest median OS of 30 months while tumors that received treatment but later developed a secondary locoregional recurrence have most favorable medial OS of 103.6 months. Primary tumor site also influenced progression into AJCC advanced categories. Oral cavity tumors most often presented as not cured at the time of initial diagnosis (37.8%) while oropharyngeal cancer progressed to distant metastasis more frequently (40.8%).",
        "Abstract": "In the whole cohort, mutations in patients with advanced disease were dominated by TP53, followed by MLL2 and NOTCH1, while oropharynx HPV-positive advanced tumors contained mutations in PIK3CA, MLL2, and EP300. TP53 mutations were associated with worse outcomes in high-stage oropharyngeal tumors treated with immunotherapy. Incorporating biomarkers demonstrated that immunotherapy survival is improved in patients with high CPS scores and high TMB. In terms of immunotherapy response in oropharynx HPV positive patients, mutations in the KRAS pathway (NF1, HRAS, KRAS, NRAS) and in DNA damage repair genes (BRCA1, BRCA2, PRKDC), and PI3K/AKT/mTOR signaling pathway were associated with better outcomes following immunotherapy. View in Agenda and Add to Schedule",
        "Conclusion": "The integration of genomic biomarkers into treatment selection could be useful given the clinical and molecular heterogeneity of HNSCC. As we demonstrate, specific genomic alterations such as TP53 serve as markers of poor prognosis, whereas pathway-level alterations involving KRAS signaling, DNA repair genes, and the PI3K/AKT/mTOR axis may be predictors of improved immunotherapy benefit. Tailoring treatment modalities not only by anatomic site and disease stage but also by underlying somatic mutations has the potential to advance precision medicine in the field of HNSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinicogenomic Determinants of Survival and Immunotherapy Response in Advanced Head and Neck Cancer</span>. <u>Parisa Abedi, MD</u>; Andrew George; Ben Schiff; Soraya Fereydooni, MD; Andres Aguirre; Benjamin Judson, MD; Saral Mehra, MD; Curtis Pickering, PhD. Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Somatic mutations drive cancer progression and guide selection of targeted therapies in many tumor types. Although genomic alterations in head and neck squamous cell carcinoma (HNSCC) have been characterized by The Cancer Genome Atlas (TCGA) and other sequencing projects, the association between specific mutations and treatment response in real-world practice is not fully understood.</p>\n\n<p><strong>Method:</strong> This study analyzed real-world data from the Flatiron Health-Foundation Medicine HNSCC Clinico-Genomic Database Clinicogenomic Database (CGDB). Our analyses focused on how clinical variables and disease characteristics correlate with treatment responses and overall survival and survival after treatment. We also characterized mutations frequencies across clinically relevant subgroups to better understand their impact on disease trajectory.</p>\n\n<p><strong>Results: </strong>This CGBD cohort includes 1,531 patients with HNSCC, with more than half of tumors originating from the oropharynx (52%) and nearly 70% of these being HPV positive. The heterogeneity of clinical features and outcomes in HNSCC is clearly reflected in this cohort. Survival varies by tumor site, disease biology and treatment pattern: patients with oral cavity tumors have a median OS of 32.2 months, whereas those with oropharyngeal tumors survive 45.8 months. Similarly, tumors with metastases at diagnosis or no initial treatment have the lowest median OS of 30 months while tumors that received treatment but later developed a secondary locoregional recurrence have most favorable medial OS of 103.6 months. Primary tumor site also influenced progression into AJCC advanced categories. Oral cavity tumors most often presented as not cured at the time of initial diagnosis (37.8%) while oropharyngeal cancer progressed to distant metastasis more frequently (40.8%). </p>\n\n<p>In the whole cohort, mutations in patients with advanced disease were dominated by TP53, followed by MLL2 and NOTCH1, while oropharynx HPV-positive advanced tumors contained mutations in PIK3CA, MLL2, and EP300. TP53 mutations were associated with worse outcomes in high-stage oropharyngeal tumors treated with immunotherapy. Incorporating biomarkers demonstrated that immunotherapy survival is improved in patients with high CPS scores and high TMB. In terms of immunotherapy response in oropharynx HPV positive patients, mutations in the KRAS pathway (NF1, HRAS, KRAS, NRAS) and in DNA damage repair genes (BRCA1, BRCA2, PRKDC), and PI3K/AKT/mTOR signaling pathway were associated with better outcomes following immunotherapy.</p>\n\n<p><strong>Conclusion: </strong>The integration of genomic biomarkers into treatment selection could be useful given the clinical and molecular heterogeneity of HNSCC. As we demonstrate, specific genomic alterations such as TP53 serve as markers of poor prognosis, whereas pathway-level alterations involving KRAS signaling, DNA repair genes, and the PI3K/AKT/mTOR axis may be predictors of improved immunotherapy benefit. Tailoring treatment modalities not only by anatomic site and disease stage but also by underlying somatic mutations has the potential to advance precision medicine in the field of HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153905--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260124' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S143",
      "content_id": "154103",
      "abstract_number": "S143",
      "poster_number": "",
      "title": "Global patterns in early-onset oral tongue cancer",
      "summary": "Based on our analysis, EO-OTC is the principal driver of rising EO-OCC cases globally. Countries with the highest EO-OTC rates were predominantly high-income, demonstrating a potential shift in disease burden toward younger populations in HICs. This study represents the most comprehensive global analysis to date of EO-OTC. The observed epidemiological shift highlights the urgent need to identify emerging risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154103",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luis Cortina, MD",
      "presenter": "Luis Cortina, MD",
      "authors": "Luis Cortina, MD ; Hosam Alkhatib, MD; Mateo Useche; Rocco Ferrandino, MD; Emily Marchiano; Neal Futran, MD; Matthew Old, MD; Cristina Rodriguez, MD; Amanda Phipps, PhD; Brittany Barber, MD",
      "normalized_authors": [
        "Luis Cortina",
        "Hosam Alkhatib",
        "Mateo Useche",
        "Rocco Ferrandino",
        "Emily Marchiano",
        "Neal Futran",
        "Matthew Old",
        "Cristina Rodriguez",
        "Amanda Phipps",
        "Brittany Barber"
      ],
      "affiliations": [
        "University of Washington"
      ],
      "normalized_institutions": [
        "University of Washington"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 330,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Luis Cortina, MD ; Hosam Alkhatib, MD; Mateo Useche; Rocco Ferrandino, MD; Emily Marchiano; Neal Futran, MD; Matthew Old, MD; Cristina Rodriguez, MD; Amanda Phipps, PhD; Brittany Barber, MD",
        "Affiliations": "University of Washington",
        "Background": "Over the past three decades, a rising incidence in early-onset head and neck cancers (ages 20-49) has been observed worldwide. An updated, comprehensive global analysis of this epidemiological shift is lacking. This study aims to evaluate worldwide incidence and temporal changes in early onset oral tongue cancer (EO-OTC) in high-, middle-, and low-income countries.",
        "Methods": "Using the Cancer Incidence in Five Continents (CI5) Plus Detailed database, we compiled national and subnational registry data from all available continents through 2008 to 2017. Age-standardized incidence rates (ASIR) were calculated using the Segi world standard population, and average annual percent change (AAPC) values were derived for each country over the most recent decade. Analyses were stratified by cancer subtype and age groups (i.e. 20-49 years old and average onset (≥50 years)). Each country was further classified as low/middle income countries (LMICs) or high-income countries (HICs) based on economic and epidemiologic criteria.",
        "Results": "During 2008 to 2017, there were a total of ~ 360,000 new OTC cases over the last decade with EO-OTC accounting for ~15%. Within this cohort, ASIR for EO-OTC varied widely across the 40 countries. Across all countries, EO-OTC accounted for the largest proportion of EO-OCC, contributing to approximately 40-60% of early-onset cases. High-income countries such as Japan, United States, United Kingdom, Iceland, France, New Zealand, Canada, and Switzerland all ranked in the top ten countries with the highest incidence in EO-OTC. Incidence of EO-OTC exceeded that of average-onset OTC in almost half of the countries evaluated (19/40 countries).",
        "Conclusions": "Based on our analysis, EO-OTC is the principal driver of rising EO-OCC cases globally. Countries with the highest EO-OTC rates were predominantly high-income, demonstrating a potential shift in disease burden toward younger populations in HICs. This study represents the most comprehensive global analysis to date of EO-OTC. The observed epidemiological shift highlights the urgent need to identify emerging risk factors that are predominant in high-income countries and refine prevention strategies tailored to younger populations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Global patterns in early-onset oral tongue cancer</span>. <u>Luis Cortina, MD</u>; Hosam Alkhatib, MD; Mateo Useche; Rocco Ferrandino, MD; Emily Marchiano; Neal Futran, MD; Matthew Old, MD; Cristina Rodriguez, MD; Amanda Phipps, PhD; Brittany Barber, MD. University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Over the past three decades, a rising incidence in early-onset head and neck cancers (ages 20-49) has been observed worldwide. An updated, comprehensive global analysis of this epidemiological shift is lacking. This study aims to evaluate worldwide incidence and temporal changes in early onset oral tongue cancer (EO-OTC) in high-, middle-, and low-income countries.</p>\n\n<p><strong>Methods: </strong>Using the Cancer Incidence in Five Continents (CI5) Plus Detailed database, we compiled national and subnational registry data from all available continents through 2008 to 2017. Age-standardized incidence rates (ASIR) were calculated using the Segi world standard population, and average annual percent change (AAPC) values were derived for each country over the most recent decade. Analyses were stratified by cancer subtype and age groups (i.e. 20-49 years old and average onset (≥50 years)). Each country was further classified as low/middle income countries (LMICs) or high-income countries (HICs) based on economic and epidemiologic criteria.</p>\n\n<p><strong>Results: </strong>During 2008 to 2017, there were a total of ~ 360,000 new OTC cases over the last decade with EO-OTC accounting for ~15%. Within this cohort, ASIR for EO-OTC varied widely across the 40 countries. Across all countries, EO-OTC accounted for the largest proportion of EO-OCC, contributing to approximately 40-60% of early-onset cases. High-income countries such as Japan, United States, United Kingdom, Iceland, France, New Zealand, Canada, and Switzerland all ranked in the top ten countries with the highest incidence in EO-OTC. Incidence of EO-OTC exceeded that of average-onset OTC in almost half of the countries evaluated (19/40 countries).</p>\n\n<p><strong>Conclusions:</strong> Based on our analysis, EO-OTC is the principal driver of rising EO-OCC cases globally. Countries with the highest EO-OTC rates were predominantly high-income, demonstrating a potential shift in disease burden toward younger populations in HICs. This study represents the most comprehensive global analysis to date of EO-OTC. The observed epidemiological shift highlights the urgent need to identify emerging risk factors that are predominant in high-income countries and refine prevention strategies tailored to younger populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154103--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S144",
      "content_id": "153708",
      "abstract_number": "S144",
      "poster_number": "",
      "title": "Clinical and Molecular Divergence of Smoking-Related and Non-Smoking Oral Leukoplakia: Transcriptomic, Immune, and Outcome Comparisons with Oral Cancer and Healthy Controls",
      "summary": "Smoking and non-smoking related OLs are distinct entities with different gene expression patterns, as well as clinical and biological behavior. Non-smokers with OL have a higher incidence of malignant transformation. Data presented here suggest that epigenetic differences in acetylation and ubiquitination may contribute to the higher malignant potential of OL in non-smokers. Further analysis of the genomic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153708",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jason Tasoulas, MD, DMD, PhD",
      "presenter": "Jason Tasoulas, MD, DMD, PhD",
      "authors": "Jason Tasoulas, MD, DMD, PhD 1 ; Travis Schrank, MD, PhD 2 ; Xialiu Xie, PhD 2 ; Sarah Harrington 1 ; Daniel Uralov 1 ; Steven Johnson, MD 2 ; Natalia Issaeva, PhD 2 ; Ricardo Padilla, DDS 2 ; Joseph Curry, MD, FACS 1 ; David Cognetti, MD, FACS 1 ; Wendell Yarbrough, MD, MMHC, FACS 2 ; Di Wu, PhD 2 ; Trevor Hackman, MD, FACS 2 ; Siddharth Sheth, DO, MPH 2",
      "normalized_authors": [
        "Jason Tasoulas",
        "Travis Schrank",
        "Xialiu Xie",
        "Sarah Harrington",
        "Daniel Uralov",
        "Steven Johnson",
        "Natalia Issaeva",
        "Ricardo Padilla",
        "Joseph Curry",
        "David Cognetti",
        "Wendell Yarbrough, MMHC",
        "Di Wu",
        "Trevor Hackman",
        "Siddharth Sheth"
      ],
      "affiliations": [
        "Thomas Jefferson University",
        "University of North Carolina at Chapel Hill"
      ],
      "normalized_institutions": [
        "Thomas Jefferson University",
        "University of North Carolina at Chapel Hill"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153708/Figure%201(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153708/Figure%201(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153708"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153708/Figure%202.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153708/Figure%202.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153708"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 441,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jason Tasoulas, MD, DMD, PhD 1 ; Travis Schrank, MD, PhD 2 ; Xialiu Xie, PhD 2 ; Sarah Harrington 1 ; Daniel Uralov 1 ; Steven Johnson, MD 2 ; Natalia Issaeva, PhD 2 ; Ricardo Padilla, DDS 2 ; Joseph Curry, MD, FACS 1 ; David Cognetti, MD, FACS 1 ; Wendell Yarbrough, MD, MMHC, FACS 2 ; Di Wu, PhD 2 ; Trevor Hackman, MD, FACS 2 ; Siddharth Sheth, DO, MPH 2",
        "Affiliations": "1 Thomas Jefferson University; 2 University of North Carolina at Chapel Hill",
        "Background": "Oral leukoplakia (OL) is a potentially malignant disorder with high prevalence in the US and a ~6-10% risk of transformation to carcinoma. Despite OL’s strong association with smoking, a significant number of lesions are also diagnosed in non-smokers. Clinically non- smokers with OL tend to be older at diagnoses and have a higher risk of malignant transformation compared to smokers. However, it remains unclear if the clinicopathological differences between current/former and never smokers diagnosed with OPL are also reflected at the transcriptomic level.",
        "Methods": "We analyzed a clinical cohort of patients with OL to evaluate the cumulative incidence (CI) of oral cancer by smoking status in the TriNetX database. We also analyzed a cohort of patients diagnosed with OL and oral squamous cell carcinoma (OSCC) based on their smoking history. Specifically, samples from 33 patients with OL (25 non-smokers and 8 smokers), 29 patients with OSCC (15 non-smokers and 14 smokers), and 10 healthy controls (7 non-smokers and 3 smokers) were analyzed with high throughput bulk RNAseq (Illumina NovaSeq 6000).",
        "Results": "A total of 15,933,284 patients were identified: 14,949,176 non-smokers without OL, 952,286 smokers without OL, 27,370 non-smokers with OL, and 4,449 smokers with OL (Figure 1). At 1, 3, and 5 years, CI among non-smokers without OL was 0.010%, 0.029%, and 0.048%, respectively. Smokers without OL showed higher incidence (0.038%, 0.103%, 0.165%), while smokers with OL had further elevated risk (2.136%, 3.636%, 4.412%). Non-smokers with OL demonstrated the highest risk, with cumulative incidence of 4.644%, 7.484%, and 9.325% at 1, 3, and 5 years, respectively.",
        "Abstract": "Transcriptomic analysis of our in-house cohort revealed 3 distinct clusters for smokers and non-smokers: non-OL, OL and OSCC. Distinct transcriptomic profiles were identified for all six categories. Among the OL groups, gene set enrichment analyses revealed that regulation of protein acetylation, histone deacetylase binding, and protein ubiquitination were markedly different between smokers and non-smokers, with all three signatures being suppressed in smokers (Figure 2A). Of note, histone deacetylase binding was also suppressed in smokers with OL compared to smokers with OSCC (Figure 2B). View in Agenda and Add to Schedule",
        "Conclusions": "Smoking and non-smoking related OLs are distinct entities with different gene expression patterns, as well as clinical and biological behavior. Non-smokers with OL have a higher incidence of malignant transformation. Data presented here suggest that epigenetic differences in acetylation and ubiquitination may contribute to the higher malignant potential of OL in non-smokers. Further analysis of the genomic landscape and microenvironment of leukoplakia are necessary to comprehensively characterize molecular drivers explaining differences between these two distinct entities."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and Molecular Divergence of Smoking-Related and Non-Smoking Oral Leukoplakia: Transcriptomic, Immune, and Outcome Comparisons with Oral Cancer and Healthy Controls</span>. <u>Jason Tasoulas, MD, DMD, PhD</u><sup>1</sup>; Travis Schrank, MD, PhD<sup>2</sup>; Xialiu Xie, PhD<sup>2</sup>; Sarah Harrington<sup>1</sup>; Daniel Uralov<sup>1</sup>; Steven Johnson, MD<sup>2</sup>; Natalia Issaeva, PhD<sup>2</sup>; Ricardo Padilla, DDS<sup>2</sup>; Joseph Curry, MD, FACS<sup>1</sup>; David Cognetti, MD, FACS<sup>1</sup>; Wendell Yarbrough, MD, MMHC, FACS<sup>2</sup>; Di Wu, PhD<sup>2</sup>; Trevor Hackman, MD, FACS<sup>2</sup>; Siddharth Sheth, DO, MPH<sup>2</sup>. <sup>1</sup>Thomas Jefferson University; <sup>2</sup>University of North Carolina at Chapel Hill<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Oral leukoplakia (OL) is a potentially malignant disorder with high prevalence in the US and a ~6-10% risk of transformation to carcinoma. Despite OL’s strong association with smoking, a significant number of lesions are also diagnosed in non-smokers. Clinically non- smokers with OL tend to be older at diagnoses and have a higher risk of malignant transformation compared to smokers. However, it remains unclear if the clinicopathological differences between current/former and never smokers diagnosed with OPL are also reflected at the transcriptomic level.</p>\n\n<p><strong>Methods</strong>: We analyzed a clinical cohort of patients with OL to evaluate the cumulative incidence (CI) of oral cancer by smoking status in the TriNetX database. We also analyzed a cohort of patients diagnosed with OL and oral squamous cell carcinoma (OSCC) based on their smoking history. Specifically, samples from 33 patients with OL (25 non-smokers and 8 smokers), 29 patients with OSCC (15 non-smokers and 14 smokers), and 10 healthy controls (7 non-smokers and 3 smokers) were analyzed with high throughput bulk RNAseq (Illumina NovaSeq 6000).</p>\n\n<p><strong>Results</strong>: A total of 15,933,284 patients were identified: 14,949,176 non-smokers without OL, 952,286 smokers without OL, 27,370 non-smokers with OL, and 4,449 smokers with OL (Figure 1). At 1, 3, and 5 years, CI among non-smokers without OL was 0.010%, 0.029%, and 0.048%, respectively. Smokers without OL showed higher incidence (0.038%, 0.103%, 0.165%), while smokers with OL had further elevated risk (2.136%, 3.636%, 4.412%). Non-smokers with OL demonstrated the highest risk, with cumulative incidence of 4.644%, 7.484%, and 9.325% at 1, 3, and 5 years, respectively.</p>\n\n<p>Transcriptomic analysis of our in-house cohort revealed 3 distinct clusters for smokers and non-smokers: non-OL, OL and OSCC. Distinct transcriptomic profiles were identified for all six categories. Among the OL groups, gene set enrichment analyses revealed that regulation of protein acetylation, histone deacetylase binding, and protein ubiquitination were markedly different between smokers and non-smokers, with all three signatures being suppressed in smokers (Figure 2A). Of note, histone deacetylase binding was also suppressed in smokers with OL compared to smokers with OSCC (Figure 2B).</p>\n\n<p><strong>Conclusions</strong>: Smoking and non-smoking related OLs are distinct entities with different gene expression patterns, as well as clinical and biological behavior. Non-smokers with OL have a higher incidence of malignant transformation. Data presented here suggest that epigenetic differences in acetylation and ubiquitination may contribute to the higher malignant potential of OL in non-smokers. Further analysis of the genomic landscape and microenvironment of leukoplakia are necessary to comprehensively characterize molecular drivers explaining differences between these two distinct entities.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153708/Figure%201(1).png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153708/Figure%202.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153708--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S145",
      "content_id": "154393",
      "abstract_number": "S145",
      "poster_number": "",
      "title": "CDKN2A Loss is an Early and Under-detected Event in the Evolution to Oral Squamous Cell Carcinoma",
      "summary": "CDKN2A loss is a common genomic alteration in both oral dysplasia and OSCC, underscoring its central role in oral carcinogenesis. A substantial proportion of these events arise through copy-neutral LOH, which is missed by standard computational methods of estimating total copy number status. CDKN2A loss demonstrated high sensitivity for identifying dysplasia at risk of progression to OSCC, supporting its...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154393",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sophie Li, BA",
      "presenter": "Sophie Li, BA",
      "authors": "Sophie Li, BA 1 ; Evit John, MPH 1 ; Andrew Sikora, MD, PhD 1 ; Jeffrey N Myers, MD, PhD, FACS 1 ; Maxime Tarabichi, PhD 2 ; Peter Van Loo, PhD 1 ; Jennifer R Wang, MD, PhD, ScM, FRCSC 1 ; Xiao Zhao, MD, PhD, FRCSC 1",
      "normalized_authors": [
        "Sophie Li",
        "Evit John",
        "Andrew Sikora",
        "Jeffrey N Myers",
        "Maxime Tarabichi",
        "Peter Van Loo",
        "Jennifer R Wang, ScM, FRCSC",
        "Xiao Zhao, FRCSC"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center",
        "Université Libre de Bruxelles"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center",
        "Université Libre de Bruxelles"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 461,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sophie Li, BA 1 ; Evit John, MPH 1 ; Andrew Sikora, MD, PhD 1 ; Jeffrey N Myers, MD, PhD, FACS 1 ; Maxime Tarabichi, PhD 2 ; Peter Van Loo, PhD 1 ; Jennifer R Wang, MD, PhD, ScM, FRCSC 1 ; Xiao Zhao, MD, PhD, FRCSC 1",
        "Affiliations": "1 The University of Texas MD Anderson Cancer Center; 2 Université Libre de Bruxelles",
        "Background": "The CDKN2A tumor suppressor gene at chromosome 9p21 is a central regulator of cell-cycle control and a frequent target of inactivation during oral squamous cell carcinoma (OSCC) carcinogenesis. Although CDKN2A disruption is traditionally attributed to focal deletions, its loss more commonly arises from broader copy number alterations rather than point mutations. While next-generation sequencing can detect copy number changes, conventional computational algorithms that report only total copy number are unable to identify copy-neutral (2+0) loss of heterozygosity (LOH). As a result, a substantial proportion of biologically meaningful CDKN2A inactivation events in premalignant and malignant lesions remain unrecognized.",
        "Methods": "Allele-specific copy number analysis, which quantifies each parental allele independently to detect copy-neutral loss of heterozygosity and allelic imbalance that total copy number methods miss, was performed using ASCAT v.3. ASCAT was used to estimate the prevalence and type of allele-specific CDKN2A copy number events in 40 oral dysplasia samples profiled by whole-exome sequencing and in 111 OSCC tumors using publicly available TCGA SNP 6.0 array data. In oral dysplasia, we examined the relationship between CDKN2A alterations and progression to carcinoma and estimated corresponding sensitivity and negative predictive value. Cox proportional hazards model was used to assess the association between CDKN2A alterations and time to progression to OSCC. In the OSCC cohort, we evaluated the association between CDKN2A alterations and survival outcomes using Kaplan–Meier analysis.",
        "Results": "LOH at 9p21 was identified in 53% of oral dysplasia (n=21/40). A total of 11 patients progressed to OSCC. Absence of CDKN2A LOH showed high sensitivity for ruling out progression to OSCC (82% sensitivity; 91% negative predictive value). CDKN2A LOH was significantly associated with shorter time to OSCC development (HR, 1.2-26; P=0.03). Of the 21 dysplasia samples with CDKN2A LOH, there were 9 samples with copy-neutral LOH (43%), which would have been missed by non-allele-specific approaches. In addition, 4 of 11 patients with oral dysplasia who developed OSCC exhibited copy-neutral LOH. In the OSCC cohort, 76% of patients had 9p21 LOH (n=84/111) and of these 32% (n=27/84) were copy-neutral LOH. In OSCC, no differences in progression-free (P=0.79) or disease-specific (P=0.90) survival were observed between tumors with LOH (n=56) and those with complete loss (n=36).",
        "Conclusion": "CDKN2A loss is a common genomic alteration in both oral dysplasia and OSCC, underscoring its central role in oral carcinogenesis. A substantial proportion of these events arise through copy-neutral LOH, which is missed by standard computational methods of estimating total copy number status. CDKN2A loss demonstrated high sensitivity for identifying dysplasia at risk of progression to OSCC, supporting its potential utility as a clinically actionable biomarker. Accurate evaluation of this biomarker in clinical practice requires allele-specific copy number assessment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>CDKN2A Loss is an Early and Under-detected Event in the Evolution to Oral Squamous Cell Carcinoma</span>. <u>Sophie Li, BA</u><sup>1</sup>; Evit John, MPH<sup>1</sup>; Andrew Sikora, MD, PhD<sup>1</sup>; Jeffrey N Myers, MD, PhD, FACS<sup>1</sup>; Maxime Tarabichi, PhD<sup>2</sup>; Peter Van Loo, PhD<sup>1</sup>; Jennifer R Wang, MD, PhD, ScM, FRCSC<sup>1</sup>; Xiao Zhao, MD, PhD, FRCSC<sup>1</sup>. <sup>1</sup>The University of Texas MD Anderson Cancer Center; <sup>2</sup>Université Libre de Bruxelles<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The <em>CDKN2A</em> tumor suppressor gene at chromosome 9p21 is a central regulator of cell-cycle control and a frequent target of inactivation during oral squamous cell carcinoma (OSCC) carcinogenesis. Although <em>CDKN2A</em> disruption is traditionally attributed to focal deletions, its loss more commonly arises from broader copy number alterations rather than point mutations. While next-generation sequencing can detect copy number changes, conventional computational algorithms that report only total copy number are unable to identify copy-neutral (2+0) loss of heterozygosity (LOH). As a result, a substantial proportion of biologically meaningful <em>CDKN2A</em> inactivation events in premalignant and malignant lesions remain unrecognized.</p>\n\n<p><strong>Methods: </strong>Allele-specific copy number analysis, which quantifies each parental allele independently to detect copy-neutral loss of heterozygosity and allelic imbalance that total copy number methods miss, was performed using ASCAT v.3. ASCAT was used to estimate the prevalence and type of allele-specific <em>CDKN2A</em> copy number events in 40 oral dysplasia samples profiled by whole-exome sequencing and in 111 OSCC tumors using publicly available TCGA SNP 6.0 array data. In oral dysplasia, we examined the relationship between <em>CDKN2A</em> alterations and progression to carcinoma and estimated corresponding sensitivity and negative predictive value. Cox proportional hazards model was used to assess the association between <em>CDKN2A</em> alterations and time to progression to OSCC. In the OSCC cohort, we evaluated the association between <em>CDKN2A</em> alterations and survival outcomes using Kaplan–Meier analysis.</p>\n\n<p><strong>Results: </strong>LOH at 9p21 was identified in 53% of oral dysplasia (n=21/40). A total of 11 patients progressed to OSCC. Absence of <em>CDKN2A</em> LOH showed high sensitivity for ruling out progression to OSCC (82% sensitivity; 91% negative predictive value). <em>CDKN2A</em> LOH was significantly associated with shorter time to OSCC development (HR, 1.2-26; P=0.03). Of the 21 dysplasia samples with <em>CDKN2A</em> LOH, there were 9 samples with copy-neutral LOH (43%), which would have been missed by non-allele-specific approaches. In addition, 4 of 11 patients with oral dysplasia who developed OSCC exhibited copy-neutral LOH. In the OSCC cohort, 76% of patients had 9p21 LOH (n=84/111) and of these 32% (n=27/84) were copy-neutral LOH. In OSCC, no differences in progression-free (P=0.79) or disease-specific (P=0.90) survival were observed between tumors with LOH (n=56) and those with complete loss (n=36).</p>\n\n<p><strong>Conclusion: </strong><em>CDKN2A</em> loss is a common genomic alteration in both oral dysplasia and OSCC, underscoring its central role in oral carcinogenesis. A substantial proportion of these events arise through copy-neutral LOH, which is missed by standard computational methods of estimating total copy number status. <em>CDKN2A</em> loss demonstrated high sensitivity for identifying dysplasia at risk of progression to OSCC, supporting its potential utility as a clinically actionable biomarker. Accurate evaluation of this biomarker in clinical practice requires allele-specific copy number assessment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154393--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S146",
      "content_id": "152190",
      "abstract_number": "S146",
      "poster_number": "",
      "title": "Progressive Interferon Activation Marks Leukoplakia Malignant Transformation and Reveals RNA-Processing Vulnerabilities in HNSCC",
      "summary": "Increasing evidence suggests that dysregulated epithelial–immune interactions emerge early in cancer development. Oral leukoplakia is the most common precursor lesion of head and neck squamous cell carcinoma (HNSCC), yet the molecular determinants that underlie its progression to invasive malignancy remain poorly defined. Through analyses of transcriptomic data of human samples spanning normal mucosa,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152190",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "De-Chen Lin, PhD",
      "presenter": "De-Chen Lin, PhD",
      "authors": "Hua Zhao; Stephenie Wong; Casey Collet; Boyan Hu; Uttam Sinha; De-Chen Lin, PhD",
      "normalized_authors": [
        "Hua Zhao",
        "Stephenie Wong",
        "Casey Collet",
        "Boyan Hu",
        "Uttam Sinha",
        "De-Chen Lin"
      ],
      "affiliations": [
        "University of Southern California"
      ],
      "normalized_institutions": [
        "University of Southern California"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 381,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hua Zhao; Stephenie Wong; Casey Collet; Boyan Hu; Uttam Sinha; De-Chen Lin, PhD",
        "Affiliations": "University of Southern California",
        "Abstract": "Increasing evidence suggests that dysregulated epithelial–immune interactions emerge early in cancer development. Oral leukoplakia is the most common precursor lesion of head and neck squamous cell carcinoma (HNSCC), yet the molecular determinants that underlie its progression to invasive malignancy remain poorly defined. Through analyses of transcriptomic data of human samples spanning normal mucosa, leukoplakia, and HNSCC tumor samples, we observed a striking and progressive enrichment of type I interferon (IFN) pathway activity. IFN-stimulated gene programs were significantly elevated in progressive leukoplakia compared with non-progressive lesions, further amplified in HNSCC relative to leukoplakia, and consistently enriched in tumors relative to normal tissue. Using CRISPR-edited organoid models that recapitulate early neoplastic evolution, we confirmed that this IFN activation arises during the initial stages of transformation. Pan-cancer analyses of CCLE and TCGA datasets revealed that HNSCC harbors among the highest IFN pathway expression levels across all tumor types, indicating that constitutive IFN signaling is a pervasive tumor-intrinsic hallmark. We hypothesized that chronic IFN activation in HNSCC is driven by dysregulated RNA metabolism and accumulation of double-stranded RNA (dsRNA), triggering a viral mimicry response. Two central dsRNA-regulatory enzymes—ADAR1, an adenosine deaminase that edits endogenous dsRNA, and XRN1, a 5′→3′ exoribonuclease that degrades aberrant cytosolic RNA—serve as key buffers that prevent inappropriate antiviral sensing. To test whether these mechanisms constrain IFN signaling in HNSCC, we performed targeted knockdown of ADAR1 and XRN1. RNA-seq analysis showed that loss of either enzyme further amplified IFN pathway gene expression, consistent with enhanced viral mimicry. Functionally, depletion of ADAR1 or XRN1 profoundly impaired the viability of patient-derived HNSCC tumor organoids but not normal organoids, revealing a tumor-selective dependency on dsRNA-detoxifying mechanisms to tolerate chronic IFN stress. Consistently, genome-wide functional screens across human cancers demonstrated that HNSCC exhibits one of the strongest dependencies on ADAR1 and XRN1. These findings identify a pervasive intrinsic IFN program that emerges during leukoplakia progression, persists into invasive carcinoma, and shapes the inflammatory landscape of HNSCC. They further suggest that HNSCC cells rely on ADAR1- and XRN1-mediated dsRNA detoxification to evade lethal antiviral and immune-activating pathways. Together, this work establishes dysregulated RNA metabolism as a mechanistic driver and therapeutic vulnerability in HNSCC, with implications for modulating tumor-immune interactions and improving early detection and intervention strategies. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Progressive Interferon Activation Marks Leukoplakia Malignant Transformation and Reveals RNA-Processing Vulnerabilities in HNSCC</span>. Hua Zhao; Stephenie Wong; Casey Collet; Boyan Hu; Uttam Sinha; <u>De-Chen Lin, PhD</u>. University of Southern California<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Increasing evidence suggests that dysregulated epithelial–immune interactions emerge early in cancer development. Oral leukoplakia is the most common precursor lesion of head and neck squamous cell carcinoma (HNSCC), yet the molecular determinants that underlie its progression to invasive malignancy remain poorly defined. Through analyses of transcriptomic data of human samples spanning normal mucosa, leukoplakia, and HNSCC tumor samples, we observed a striking and progressive enrichment of type I interferon (IFN) pathway activity. IFN-stimulated gene programs were significantly elevated in progressive leukoplakia compared with non-progressive lesions, further amplified in HNSCC relative to leukoplakia, and consistently enriched in tumors relative to normal tissue. Using CRISPR-edited organoid models that recapitulate early neoplastic evolution, we confirmed that this IFN activation arises during the initial stages of transformation. Pan-cancer analyses of CCLE and TCGA datasets revealed that HNSCC harbors among the highest IFN pathway expression levels across all tumor types, indicating that constitutive IFN signaling is a pervasive tumor-intrinsic hallmark.</p>\n\n<p>We hypothesized that chronic IFN activation in HNSCC is driven by dysregulated RNA metabolism and accumulation of double-stranded RNA (dsRNA), triggering a viral mimicry response. Two central dsRNA-regulatory enzymes—ADAR1, an adenosine deaminase that edits endogenous dsRNA, and XRN1, a 5′→3′ exoribonuclease that degrades aberrant cytosolic RNA—serve as key buffers that prevent inappropriate antiviral sensing. To test whether these mechanisms constrain IFN signaling in HNSCC, we performed targeted knockdown of ADAR1 and XRN1. RNA-seq analysis showed that loss of either enzyme further amplified IFN pathway gene expression, consistent with enhanced viral mimicry. Functionally, depletion of ADAR1 or XRN1 profoundly impaired the viability of patient-derived HNSCC tumor organoids but not normal organoids, revealing a tumor-selective dependency on dsRNA-detoxifying mechanisms to tolerate chronic IFN stress. Consistently, genome-wide functional screens across human cancers demonstrated that HNSCC exhibits one of the strongest dependencies on ADAR1 and XRN1.</p>\n\n<p>These findings identify a pervasive intrinsic IFN program that emerges during leukoplakia progression, persists into invasive carcinoma, and shapes the inflammatory landscape of HNSCC. They further suggest that HNSCC cells rely on ADAR1- and XRN1-mediated dsRNA detoxification to evade lethal antiviral and immune-activating pathways. Together, this work establishes dysregulated RNA metabolism as a mechanistic driver and therapeutic vulnerability in HNSCC, with implications for modulating tumor-immune interactions and improving early detection and intervention strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152190--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S147",
      "content_id": "154608",
      "abstract_number": "S147",
      "poster_number": "",
      "title": "Microbiome signatures associated with recurrence and perineural invasion in oral lichen planus-associated squamous cell carcinoma",
      "summary": "OSCC in patients with prior OLP represents a clinically distinct population comprised of predominantly female, non-smokers, with poorly understood drivers of progression. In this cohort, increased microbial diversity and enrichment of pro-inflammatory, metabolically active anaerobes were associated with aggressive disease features including recurrence and PNI. These findings suggest that intratumoral microbial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154608",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anushri Tiwari",
      "presenter": "Anushri Tiwari",
      "authors": "Kala K Mahen, MPH, PhD 1 ; Anushri Tiwari 2 ; Radhika Duggal, MD 1 ; Zihan Zhu, PhD 2 ; August Culbert, MD 1 ; Liangliang Zhang, PhD 2 ; Brandon Prendes, MD 1 ; Jamie Ku, MD 1 ; Joseph Scharpf, MD 1 ; Danielle Bottalico, MD 1 ; Eric Lamarre, MD 1 ; Daniel McGrail, PhD 1 ; Natalie Silver, MD 1",
      "normalized_authors": [
        "Kala K Mahen",
        "Anushri Tiwari",
        "Radhika Duggal",
        "Zihan Zhu",
        "August Culbert",
        "Liangliang Zhang",
        "Brandon Prendes",
        "Jamie Ku",
        "Joseph Scharpf",
        "Danielle Bottalico",
        "Eric Lamarre",
        "Daniel McGrail",
        "Natalie Silver"
      ],
      "affiliations": [
        "Cleveland Clinic",
        "Case Western Reserve University"
      ],
      "normalized_institutions": [
        "Cleveland Clinic",
        "Case Western Reserve University"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 350,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kala K Mahen, MPH, PhD 1 ; Anushri Tiwari 2 ; Radhika Duggal, MD 1 ; Zihan Zhu, PhD 2 ; August Culbert, MD 1 ; Liangliang Zhang, PhD 2 ; Brandon Prendes, MD 1 ; Jamie Ku, MD 1 ; Joseph Scharpf, MD 1 ; Danielle Bottalico, MD 1 ; Eric Lamarre, MD 1 ; Daniel McGrail, PhD 1 ; Natalie Silver, MD 1",
        "Affiliations": "1 Cleveland Clinic; 2 Case Western Reserve University",
        "Background": "Oral lichen planus (OLP) is a chronic, immune-mediated pre-malignant condition of the oral mucosa with a 1-3% lifetime risk of transformation to oral squamous cell carcinoma (OSCC). Emerging evidence implicates microbial dysbiosis as a contributor to epithelial injury, chronic inflammation, and malignant progression in the oral cavity. We investigated whether distinct intratumoral microbial signatures are associated with clinicopathologic features of OSCC arising in patients with prior diagnosis of OLP.",
        "Methods": "Matched tumor and tumor-adjacent normal samples were collected from patients with a prior clinical or histopathologic diagnosis of OLP who subsequently underwent surgical resection for OSCC at Cleveland Clinic (N=29; 2001–2020). DNA was extracted from FFPE surgical resection samples and subjected to 16S rRNA gene sequencing targeting the V4 region. Reads were filtered, decontaminated, taxonomically classified, and processed using standard computational pipelines. Diversity metrics, differential abundance analyses, and pathway-level functional predictions were performed. Microbial features were correlated with clinical outcomes including recurrence, perineural invasion (PNI), and tumor stage.",
        "Results": "The average patient age was 71.2 years, with 83% females, 45% non-smokers, 48% former smokers, and 7% current smokers. All patients underwent curative-intent surgery. Overall microbial community composition was similar between tumor and tumor-adjacent tissues; however, tumor samples demonstrated increased relative abundance of anaerobic, pro-inflammatory taxa, including Fusobacteria. Alpha diversity was significantly higher in patients who experienced recurrence (p=0.0059) or had PNI (p=0.0076), whereas beta diversity did not differ significantly across comparisons. Functional pathway predictions revealed increased microbial functional richness in PNI-positive tumors (p=0.0448), with enrichment of iron acquisition and metabolic pathways contributed largely by accumulation of Fusobacterium and related anaerobes.",
        "Conclusion": "OSCC in patients with prior OLP represents a clinically distinct population comprised of predominantly female, non-smokers, with poorly understood drivers of progression. In this cohort, increased microbial diversity and enrichment of pro-inflammatory, metabolically active anaerobes were associated with aggressive disease features including recurrence and PNI. These findings suggest that intratumoral microbial composition and functional capacity may contribute to a more aggressive cancer phenotype in OLP-associated OSCC and warrant further study as potential biomarkers and therapeutic targets.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Microbiome signatures associated with recurrence and perineural invasion in oral lichen planus-associated squamous cell carcinoma</span>. Kala K Mahen, MPH, PhD<sup>1</sup>; <u>Anushri Tiwari</u><sup>2</sup>; Radhika Duggal, MD<sup>1</sup>; Zihan Zhu, PhD<sup>2</sup>; August Culbert, MD<sup>1</sup>; Liangliang Zhang, PhD<sup>2</sup>; Brandon Prendes, MD<sup>1</sup>; Jamie Ku, MD<sup>1</sup>; Joseph Scharpf, MD<sup>1</sup>; Danielle Bottalico, MD<sup>1</sup>; Eric Lamarre, MD<sup>1</sup>; Daniel McGrail, PhD<sup>1</sup>; Natalie Silver, MD<sup>1</sup>. <sup>1</sup>Cleveland Clinic; <sup>2</sup>Case Western Reserve University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Oral lichen planus (OLP) is a chronic, immune-mediated pre-malignant condition of the oral mucosa with a 1-3% lifetime risk of transformation to oral squamous cell carcinoma (OSCC). Emerging evidence implicates microbial dysbiosis as a contributor to epithelial injury, chronic inflammation, and malignant progression in the oral cavity. We investigated whether distinct intratumoral microbial signatures are associated with clinicopathologic features of OSCC arising in patients with prior diagnosis of OLP.  </p>\n\n<p><strong>Methods:</strong> Matched tumor and tumor-adjacent normal samples were collected from patients with a prior clinical or histopathologic diagnosis of OLP who subsequently underwent surgical resection for OSCC at Cleveland Clinic (N=29; 2001–2020). DNA was extracted from FFPE surgical resection samples and subjected to 16S rRNA gene sequencing targeting the V4 region. Reads were filtered, decontaminated, taxonomically classified, and processed using standard computational pipelines. Diversity metrics, differential abundance analyses, and pathway-level functional predictions were performed. Microbial features were correlated with clinical outcomes including recurrence, perineural invasion (PNI), and tumor stage. </p>\n\n<p><strong>Results:</strong>  The average patient age was 71.2 years, with 83% females, 45% non-smokers, 48% former smokers, and 7% current smokers. All patients underwent curative-intent surgery. Overall microbial community composition was similar between tumor and tumor-adjacent tissues; however, tumor samples demonstrated increased relative abundance of anaerobic, pro-inflammatory taxa, including Fusobacteria.  Alpha diversity was significantly higher in patients who experienced recurrence (p=0.0059) or had PNI (p=0.0076), whereas beta diversity did not differ significantly across comparisons. Functional pathway predictions revealed increased microbial functional richness in PNI-positive tumors (p=0.0448), with enrichment of iron acquisition and metabolic pathways contributed largely by accumulation of Fusobacterium and related anaerobes.  </p>\n\n<p><strong>Conclusion:</strong> OSCC in patients with prior OLP represents a clinically distinct population comprised of predominantly female, non-smokers, with poorly understood drivers of progression. In this cohort, increased microbial diversity and enrichment of pro-inflammatory, metabolically active anaerobes were associated with aggressive disease features including recurrence and PNI. These findings suggest that intratumoral microbial composition and functional capacity may contribute to a more aggressive cancer phenotype in OLP-associated OSCC and warrant further study as potential biomarkers and therapeutic targets. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154608--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S148",
      "content_id": "154383",
      "abstract_number": "S148",
      "poster_number": "",
      "title": "Response and Durability of Topical Imiquimod in Oral Pre-malignant Disorders",
      "summary": "Topical 5% imiquimod provided durable disease stability for most OL lesions, with 81% remaining stable at intermediate follow-up and 83% remaining stable at long-term follow-up. Lesions that responded initially were more likely to maintain control over time, whereas initially nonresponsive lesions accounted for the majority of late progression. Long-term follow-up data indicated that extended surveillance beyond...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154383",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashish Dahal",
      "presenter": "Ashish Dahal",
      "authors": "Ashish Dahal 1 ; Abdulrahman Nakshabandi, DDS 2 ; Ann Marie Egloff, PhD 2 ; Sook-Bin Woo, DMD 2 ; Ravindra Uppaluri, MD, PhD 3 ; Herve Sroussi, DMD, PhD 2",
      "normalized_authors": [
        "Ashish Dahal",
        "Abdulrahman Nakshabandi",
        "Ann Marie Egloff",
        "Sook-Bin Woo",
        "Ravindra Uppaluri",
        "Herve Sroussi"
      ],
      "affiliations": [
        "Harvard Medical School",
        "Brigham and Women's Hospital",
        "Dana-Farber Cancer Institute"
      ],
      "normalized_institutions": [
        "Harvard Medical School",
        "Brigham and Women's Hospital",
        "Dana-Farber Cancer Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154383/imiquimod%20follow-up%20paper%20figure(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154383/imiquimod%20follow-up%20paper%20figure(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154383"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 524,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ashish Dahal 1 ; Abdulrahman Nakshabandi, DDS 2 ; Ann Marie Egloff, PhD 2 ; Sook-Bin Woo, DMD 2 ; Ravindra Uppaluri, MD, PhD 3 ; Herve Sroussi, DMD, PhD 2",
        "Affiliations": "1 Harvard Medical School; 2 Brigham and Women's Hospital; 3 Dana-Farber Cancer Institute",
        "Purpose": "We previously reported that topical imiquimod, a potent immunotherapy agent, showed promising outcomes in oral leukoplakia (OL). However, whether these data were durable and generalizable has not been reported. Long-term outcomes on imiquimod use for management of oral premalignant disease are limited. Here, we (1) analyzed long-term outcomes of OL lesions from imiquimod treated patients and (2) tested imiquimod efficacy in a new validation cohort of patients with OL.",
        "Methods": "We conducted a retrospective chart review of all biopsy-proven OL cases treated with topical 5% imiquimod from 2019 to 2025. Collected data included lesion characteristics, histopathologic diagnosis, treatment regimen, clinical response, patient demographics, and adverse events (AEs). Short-term, 6-month outcomes, as well as intermediate and long-term longitudinal outcomes, measured at 1-year and > 2-years, respectively, were evaluated using Fischer’s exact test. Treatment response was defined as > 50% reduction in treated lesion area.",
        "Results": "The validation cohort included 21 patients (61.9% female; mean age 68.9 years) with 38 OL lesions that exhibited epithelial dysplasia. Most lesions were multifocal (67.6%) and located on the gingiva (81.0%). The most common regimen was 5% imiquimod applied on the target lesion for 60 minutes, five-days per week, for six weeks. At the end of treatment, 29.8% of target lesions (11/38) in the validation cohort demonstrated treatment response. Among evaluable lesions that did not respond, 87.5% (21/24, data missing on 3 lesions) showed no further growth at short-term follow-up. Stability rates were similar in responders and nonresponders (100% vs 87.5%; p=0.54), suggesting that imiquimod may help maintain short-term lesion control even in the absence of substantial lesion reduction.",
        "Abstract": "Longitudinal analyses of combined previously reported and validation cohorts included 91 lesions from 48 patients. At intermediate follow-up (median 13.0 months), 18.3% of lesions (13/71) showed new progression or recurrence at the treatment site, mostly in initial nonresponders (7/13). By the long-term appointment (median 33.8 months), a further 18.8% of lesions (13/69) had newly progressed, again mainly in initial nonresponders. Among lesions that were stable at 1-year, future progression occurred only in those that were initially nonresponsive (0/17 vs 8/39; p=0.09). Imiquimod was well tolerated. Application-site reactions were the most common AEs, with pain, soreness, or sensitivity reported by 61.9% of patients. Fatigue (38.1%) was the most frequently reported systemic AE. Most AEs were transient and resolved after treatment was discontinued. View in Agenda and Add to Schedule",
        "Conclusion": "Topical 5% imiquimod provided durable disease stability for most OL lesions, with 81% remaining stable at intermediate follow-up and 83% remaining stable at long-term follow-up. Lesions that responded initially were more likely to maintain control over time, whereas initially nonresponsive lesions accounted for the majority of late progression. Long-term follow-up data indicated that extended surveillance beyond one year should be prioritized in all nonresponders, whereas it may be unnecessary for responders who remain stable at 1 year. These findings support imiquimod as an effective option for patients with OL and highlight how early treatment response can predict long-term outcomes. Future work is aimed at understanding the biology of imiquimod response and resistance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Response and Durability of Topical Imiquimod in Oral Pre-malignant Disorders</span>. <u>Ashish Dahal</u><sup>1</sup>; Abdulrahman Nakshabandi, DDS<sup>2</sup>; Ann Marie Egloff, PhD<sup>2</sup>; Sook-Bin Woo, DMD<sup>2</sup>; Ravindra Uppaluri, MD, PhD<sup>3</sup>; Herve Sroussi, DMD, PhD<sup>2</sup>. <sup>1</sup>Harvard Medical School; <sup>2</sup>Brigham and Women's Hospital; <sup>3</sup>Dana-Farber Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>We previously reported that topical imiquimod, a potent immunotherapy agent, showed promising outcomes in oral leukoplakia (OL). However, whether these data were durable and generalizable has not been reported. Long-term outcomes on imiquimod use for management of oral premalignant disease are limited. Here, we (1) analyzed long-term outcomes of OL lesions from imiquimod treated patients and (2) tested imiquimod efficacy in a new validation cohort of patients with OL.  </p>\n\n<p><strong>Methods: </strong>We conducted a retrospective chart review of all biopsy-proven OL cases treated with topical 5% imiquimod from 2019 to 2025. Collected data included lesion characteristics, histopathologic diagnosis, treatment regimen, clinical response, patient demographics, and adverse events (AEs). Short-term, 6-month outcomes, as well as intermediate and long-term longitudinal outcomes, measured at 1-year and > 2-years, respectively, were evaluated using Fischer’s exact test. Treatment response was defined as > 50% reduction in treated lesion area.</p>\n\n<p><strong>Results: </strong> The validation cohort included 21 patients (61.9% female; mean age 68.9 years) with 38 OL lesions that exhibited epithelial dysplasia. Most lesions were multifocal (67.6%) and located on the gingiva (81.0%). The most common regimen was 5% imiquimod applied on the target lesion for 60 minutes, five-days per week, for six weeks. At the end of treatment, 29.8% of target lesions (11/38) in the validation cohort demonstrated treatment response. Among evaluable lesions that did not respond, 87.5% (21/24, data missing on 3 lesions) showed no further growth at short-term follow-up. Stability rates were similar in responders and nonresponders (100% vs 87.5%; p=0.54), suggesting that imiquimod may help maintain short-term lesion control even in the absence of substantial lesion reduction.</p>\n\n<p>Longitudinal analyses of combined previously reported and validation cohorts included 91 lesions from 48 patients. At intermediate follow-up (median 13.0 months), 18.3% of lesions (13/71) showed new progression or recurrence at the treatment site, mostly in initial nonresponders (7/13). By the long-term appointment (median 33.8 months), a further 18.8% of lesions (13/69) had newly progressed, again mainly in initial nonresponders. Among lesions that were stable at 1-year, future progression occurred only in those that were initially nonresponsive (0/17 vs 8/39; p=0.09).</p>\n\n<p>Imiquimod was well tolerated. Application-site reactions were the most common AEs, with pain, soreness, or sensitivity reported by 61.9% of patients. Fatigue (38.1%) was the most frequently reported systemic AE. Most AEs were transient and resolved after treatment was discontinued.</p>\n\n<p><strong>Conclusion: </strong>Topical 5% imiquimod provided durable disease stability for most OL lesions, with 81% remaining stable at intermediate follow-up and 83% remaining stable at long-term follow-up. Lesions that responded initially were more likely to maintain control over time, whereas initially nonresponsive lesions accounted for the majority of late progression. Long-term follow-up data indicated that extended surveillance beyond one year should be prioritized in all nonresponders, whereas it may be unnecessary for responders who remain stable at 1 year. These findings support imiquimod as an effective option for patients with OL and highlight how early treatment response can predict long-term outcomes. Future work is aimed at understanding the biology of imiquimod response and resistance.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154383/imiquimod%20follow-up%20paper%20figure(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154383--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S149",
      "content_id": "153906",
      "abstract_number": "S149",
      "poster_number": "",
      "title": "Final Results of In Vivo Clinical Trial of Oral Lesion Classification using Electrical Impedance",
      "summary": "Electrical-impedance sensing provides a non-ionizing, real-time, and non-invasive means to differentiate malignant from benign oral mucosa. The handheld probe integrates easily into routine examinations, offering potential to guide biopsy decisions, reduce unnecessary tissue removal, and supply intra-operative margin feedback. Ongoing work includes additional analysis with unbalanced dataset classification,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153906",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joseph Paydarfar, MD",
      "presenter": "Joseph Paydarfar, MD",
      "authors": "Sophie A Lloyd 1 ; Safina Suratwala, MS 1 ; Noor Zaghlula, MS 2 ; Emilio Del Torro 1 ; Ethan Murphy, PhD 1 ; Ryan Halter, PhD 1 ; Joseph Paydarfar, MD 3",
      "normalized_authors": [
        "Sophie A Lloyd",
        "Safina Suratwala",
        "Noor Zaghlula",
        "Emilio Del Torro",
        "Ethan Murphy",
        "Ryan Halter",
        "Joseph Paydarfar"
      ],
      "affiliations": [
        "Dartmouth College, Thayer School of Engineering",
        "Dartmouth College, Geisel School of Medicine",
        "Dartmouth Hitchcock Medical Center, Division of Otolaryngology"
      ],
      "normalized_institutions": [
        "Dartmouth College, Thayer School of Engineering",
        "Dartmouth College, Geisel School of Medicine",
        "Dartmouth Hitchcock Medical Center, Division of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153906/AHNS_26_abstract_figure.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153906/AHNS_26_abstract_figure.png",
          "alt": "Plot of tissue resistance at various frequencies showing differences between healthy, benign, high-grade dysplasia, and OSCC",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153906"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sophie A Lloyd 1 ; Safina Suratwala, MS 1 ; Noor Zaghlula, MS 2 ; Emilio Del Torro 1 ; Ethan Murphy, PhD 1 ; Ryan Halter, PhD 1 ; Joseph Paydarfar, MD 3",
        "Affiliations": "1 Dartmouth College, Thayer School of Engineering; 2 Dartmouth College, Geisel School of Medicine; 3 Dartmouth Hitchcock Medical Center, Division of Otolaryngology",
        "Introduction": "Real-time technology to evaluate potentially malignant oral lesions and their margins during routine visits is lacking. Clinicians currently depend on visual inspection and subsequent biopsy, which can delay diagnosis and hamper longitudinal monitoring. The electrical properties of oral mucosa reflect the tissue architecture and cellular morphology, both of which change during neoplastic transformation. We therefore hypothesize that in-vivo electrical impedance spectroscopy can provide a non-invasive signature that allows a clinician to decide, at the point of care, whether a suspicious lesion should be biopsied or can be safely observed.",
        "Methods": "104 adult subjects (mean age 65.3, SD 11.3) undergoing surgical biopsy and resection of OSCC were enrolled in this study (66 male, 38 female). Patients with implanted electrical devices were excluded. A custom handheld electrical impedance device (~1cm diameter, 32 gold-plated electrodes) collected three consecutive spectral impedance measurements from the locations on and around the lesions as well as a healthy control site. Recordings spanned 31 frequencies from 100 Hz to 100 kHz, capturing magnitude and phase. Repeated measurements were averaged to reduce motion artifacts and data with poor electrode contact were excluded from analysis. Impedance differences across the full frequency spectrum between OSCC, high-grade dysplasia, benign lesions (including low-moderate dysplasia, hyperkeratosis, leukoplakia, and atypia) and healthy control tissue were assessed using unpaired t-tests. Receiver operating characteristic (ROC) analysis with area under the curve (AUC) identified optimal thresholds for binary and multiclass discrimination.",
        "Results": "We retained 275 high-quality measurements: 97 OSCC, 24 high-grade dysplasia, 54 benign lesions, and 100 normal sites. Cancerous tissue showed significantly lower impedance magnitude and reactance than all other tissue types (p <0.001). Compared with healthy mucosa, both high-grade dysplasia and benign lesions showed reduced magnitude (p<0.05) over distinct frequency bands: 1.3 - 79 kHz for high-grade dysplasia and 0.1 to 5 kHz for benign. Direct comparison between high-grade dysplasia and benign lesions revealed significant magnitude differences (p<0.05) at 100-631 Hz and again at 20 - 32kHz, highlighting frequency-specific signatures that could aid early dysplastic detection. The most discriminative frequency for separating OSCC from healthy mucosa was 600 Hz, where impedance magnitude yielded 84% accuracy (sensitivity=81%, specificity=87%) and an AUC of 0.92. For assessing suspicious lesions (OSCC vs high-grade dysplasia vs benign), ROC-based analysis using the reactance at 1.3 kHz gave an average accuracy of 80% and average AUC of 0.82. These performance metrics suggest that impedance profiling could enhance clinical decision making.",
        "Conclusion": "Electrical-impedance sensing provides a non-ionizing, real-time, and non-invasive means to differentiate malignant from benign oral mucosa. The handheld probe integrates easily into routine examinations, offering potential to guide biopsy decisions, reduce unnecessary tissue removal, and supply intra-operative margin feedback. Ongoing work includes additional analysis with unbalanced dataset classification, site-specific thresholds, and increasing the sample size. Adoption of this technology may lower overall healthcare costs by avoiding repeat procedures. If validated in larger, multicenter cohorts, this approach could reduce unnecessary biopsies and enable earlier therapeutic intervention.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Final Results of In Vivo Clinical Trial of Oral Lesion Classification using Electrical Impedance</span>. Sophie A Lloyd<sup>1</sup>; Safina Suratwala, MS<sup>1</sup>; Noor Zaghlula, MS<sup>2</sup>; Emilio Del Torro<sup>1</sup>; Ethan Murphy, PhD<sup>1</sup>; Ryan Halter, PhD<sup>1</sup>; <u>Joseph Paydarfar, MD</u><sup>3</sup>. <sup>1</sup>Dartmouth College, Thayer School of Engineering; <sup>2</sup>Dartmouth College, Geisel School of Medicine; <sup>3</sup>Dartmouth Hitchcock Medical Center, Division of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Real-time technology to evaluate potentially malignant oral lesions and their margins during routine visits is lacking. Clinicians currently depend on visual inspection and subsequent biopsy, which can delay diagnosis and hamper longitudinal monitoring. The electrical properties of oral mucosa reflect the tissue architecture and cellular morphology, both of which change during neoplastic transformation. We therefore hypothesize that in-vivo electrical impedance spectroscopy can provide a non-invasive signature that allows a clinician to decide, at the point of care, whether a suspicious lesion should be biopsied or can be safely observed.</p>\n\n<p><strong>Methods: </strong>104 adult subjects (mean age 65.3, SD 11.3) undergoing surgical biopsy and resection of OSCC were enrolled in this study (66 male, 38 female). Patients with implanted electrical devices were excluded. A custom handheld electrical impedance device (~1cm diameter, 32 gold-plated electrodes) collected three consecutive spectral impedance measurements from the locations on and around the lesions as well as a healthy control site. Recordings spanned 31 frequencies from 100 Hz to 100 kHz, capturing magnitude and phase. Repeated measurements were averaged to reduce motion artifacts and data with poor electrode contact were excluded from analysis. Impedance differences across the full frequency spectrum between OSCC, high-grade dysplasia, benign lesions (including low-moderate dysplasia, hyperkeratosis, leukoplakia, and atypia) and healthy control tissue were assessed using unpaired t-tests. Receiver operating characteristic (ROC) analysis with area under the curve (AUC) identified optimal thresholds for binary and multiclass discrimination.</p>\n\n<p><strong>Results: </strong>We retained 275 high-quality measurements: 97 OSCC, 24 high-grade dysplasia, 54 benign lesions, and 100 normal sites. Cancerous tissue showed significantly lower impedance magnitude and reactance than all other tissue types (p <0.001). Compared with healthy mucosa, both high-grade dysplasia and benign lesions showed reduced magnitude (p<0.05) over distinct frequency bands: 1.3 - 79 kHz for high-grade dysplasia and 0.1 to 5 kHz for benign. Direct comparison between high-grade dysplasia and benign lesions revealed significant magnitude differences (p<0.05) at 100-631 Hz and again at 20 - 32kHz, highlighting frequency-specific signatures that could aid early dysplastic detection. The most discriminative frequency for separating OSCC from healthy mucosa was 600 Hz, where impedance magnitude yielded 84% accuracy (sensitivity=81%, specificity=87%) and an AUC of 0.92. For assessing suspicious lesions (OSCC vs high-grade dysplasia vs benign), ROC-based analysis using the reactance at 1.3 kHz gave an average accuracy of 80% and average AUC of 0.82. These performance metrics suggest that impedance profiling could enhance clinical decision making.</p>\n\n<p><strong>Conclusion: </strong>Electrical-impedance sensing provides a non-ionizing, real-time, and non-invasive means to differentiate malignant from benign oral mucosa. The handheld probe integrates easily into routine examinations, offering potential to guide biopsy decisions, reduce unnecessary tissue removal, and supply intra-operative margin feedback. Ongoing work includes additional analysis with unbalanced dataset classification, site-specific thresholds, and increasing the sample size. Adoption of this technology may lower overall healthcare costs by avoiding repeat procedures. If validated in larger, multicenter cohorts, this approach could reduce unnecessary biopsies and enable earlier therapeutic intervention.</p>\n\n<p><img alt='Plot of tissue resistance at various frequencies showing differences between healthy, benign, high-grade dysplasia, and OSCC' src='https://www.submitmyabstract.com/abs/images/153906/AHNS_26_abstract_figure.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153906--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S150",
      "content_id": "153071",
      "abstract_number": "S150",
      "poster_number": "",
      "title": "Improving Accuracy of Oral Cancer Screening with Elastic Scattering Spectroscopy (ESS)",
      "summary": "This study demonstrated that ESS technology can accurately differentiate between benign and malignant oral lesions. These preliminary results suggest that implementing ESS technology in the outpatient setting could enhance accuracy of oral cancer screening far beyond current standards of care. Furthermore, the portable, non-invasive technology, which requires very little training to use, has potential...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153071",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nikhita Santebennur",
      "presenter": "Nikhita Santebennur",
      "authors": "Nikhita Santebennur 1 ; Lucas Berry 2 ; Eladio Rodriguez-Diaz 3 ; Ousama A'Amar 3 ; Irving J Bigio 3 ; Sarah Chang 1 ; Yusuf Chaudhry 4 ; Marcus Couey 5 ; Heather Edwards 2 ; Shivani K Patel 1 ; Kelly Sayre 5 ; Akshay Vasudevan 1 ; Gregory A Grillone 2 ; Gintas P Krisciunas 2",
      "normalized_authors": [
        "Nikhita Santebennur",
        "Lucas Berry",
        "Eladio Rodriguez-Diaz",
        "Ousama A'Amar",
        "Irving J Bigio",
        "Sarah Chang",
        "Yusuf Chaudhry",
        "Marcus Couey",
        "Heather Edwards",
        "Shivani K Patel",
        "Kelly Sayre",
        "Akshay Vasudevan",
        "Gregory A Grillone",
        "Gintas P Krisciunas"
      ],
      "affiliations": [
        "Boston University Chobanian and Avedisian School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center",
        "Department of Biomedical Engineering, Boston University",
        "Boston University",
        "Department of Oral and Maxillofacial Surgery, Boston Medical Center"
      ],
      "normalized_institutions": [
        "Boston University Chobanian and Avedisian School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center",
        "Department of Biomedical Engineering, Boston University",
        "Boston University",
        "Department of Oral and Maxillofacial Surgery, Boston Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nikhita Santebennur 1 ; Lucas Berry 2 ; Eladio Rodriguez-Diaz 3 ; Ousama A'Amar 3 ; Irving J Bigio 3 ; Sarah Chang 1 ; Yusuf Chaudhry 4 ; Marcus Couey 5 ; Heather Edwards 2 ; Shivani K Patel 1 ; Kelly Sayre 5 ; Akshay Vasudevan 1 ; Gregory A Grillone 2 ; Gintas P Krisciunas 2",
        "Affiliations": "1 Boston University Chobanian and Avedisian School of Medicine; 2 Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center; 3 Department of Biomedical Engineering, Boston University; 4 Boston University; 5 Department of Oral and Maxillofacial Surgery, Boston Medical Center",
        "Background": "Early diagnosis of oral cancer is associated with a 5-year survival rate as high as 95%. Unfortunately, most cases are diagnosed at a late stage, when survival rates decrease to 20-50%. Late-stage cancers require aggressive oncologic management, significantly impacting functional outcomes and quality of life. While the reason for late diagnosis is complex, one of the most significant contributors is diagnostic delay. Current screening approaches have suboptimal accuracy rates ranging from 71% for conventional oral examinations, to 77% for adjunct tools that preferentially detect leukoplakic lesions in the mouth. Elastic Scattering Spectroscopy (ESS) is a technology, mediated by fiberoptic probes, which has demonstrated the ability to precisely differentiate between neoplastic and non-neoplastic tissues in the intraoperative setting. We therefore hypothesized that ESS may be able to distinguish benign from malignant lesions in the oral cavity and provide a simple, portable, and non-invasive screening tool for oral cancer in primary and dental care clinics, or even in community-based settings. This approach would enable an earlier biopsy and diagnosis, ultimately reducing the rates of oral cancer morbidity and mortality.",
        "Methods": "This pilot study enrolled patients from otolaryngology (ENT) and oral and maxillofacial surgery (OMFS) clinics at a large, urban, safety-net hospital. Patients enrolled had suspicious lesions confirmed with biopsy as benign (leukoplakia/mild dysplasia) or malignant (moderate/severe dysplasia/carcinoma-in-situ/invasive squamous cell cancer). The ESS device consisted of a portable, handheld spectroscopy system with an attached fiberoptic probe to collect optical spectra within the oral cavity. Operating the device involved gently placing the probe tip on the lesion and pressing a button on the touch screen interface. One fiber in the probe illuminates the tissue with white light; an adjacent fiber in the probe collects backscattered light, conducting it to the spectrometer, and the built-in computer analyses the spectral reading. Data was collected from 13 patients in an outpatient clinic, and 8 patients in the operating room prior to surgical excision of their cancerous lesion. Approximately 5 ESS measurements were obtained per patient directly on each lesion. Measurements were pooled per patient and analyzed using random forests classifiers and validated using Leave-One-Patient-Out (LOPO) cross-validation. The Sensitivity, Specificity, PPV, NPV, Accuracy, and AUC were computed by comparing ESS algorithm classification (benign/malignant) to the histopathological tissue classifications.",
        "Results": "21 patients were enrolled; 10 had histologically confirmed benign oral lesions, and 11 had histologically confirmed malignant oral lesions. ESS differentiated between benign and malignant lesions with a Sensitivity=90%, Specificity=92%, PPV=90%, NPV=92%, Accuracy=91%, and AUC=95%.",
        "Conclusion": "This study demonstrated that ESS technology can accurately differentiate between benign and malignant oral lesions. These preliminary results suggest that implementing ESS technology in the outpatient setting could enhance accuracy of oral cancer screening far beyond current standards of care. Furthermore, the portable, non-invasive technology, which requires very little training to use, has potential applications in low-resource settings where oral cancer morbidity is high and where access to care is limited. Findings from this pilot study support further testing and validation of ESS in a larger trial against usual care practices.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Improving Accuracy of Oral Cancer Screening with Elastic Scattering Spectroscopy (ESS)</span>. <u>Nikhita Santebennur</u><sup>1</sup>; Lucas Berry<sup>2</sup>; Eladio Rodriguez-Diaz<sup>3</sup>; Ousama A'Amar<sup>3</sup>; Irving J Bigio<sup>3</sup>; Sarah Chang<sup>1</sup>; Yusuf Chaudhry<sup>4</sup>; Marcus Couey<sup>5</sup>; Heather Edwards<sup>2</sup>; Shivani K Patel<sup>1</sup>; Kelly Sayre<sup>5</sup>; Akshay Vasudevan<sup>1</sup>; Gregory A Grillone<sup>2</sup>; Gintas P Krisciunas<sup>2</sup>. <sup>1</sup>Boston University Chobanian and Avedisian School of Medicine; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center; <sup>3</sup>Department of Biomedical Engineering, Boston University; <sup>4</sup>Boston University; <sup>5</sup>Department of Oral and Maxillofacial Surgery, Boston Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Early diagnosis of oral cancer is associated with a 5-year survival rate as high as 95%. Unfortunately, most cases are diagnosed at a late stage, when survival rates decrease to 20-50%. Late-stage cancers require aggressive oncologic management, significantly impacting functional outcomes and quality of life. While the reason for late diagnosis is complex, one of the most significant contributors is diagnostic delay. Current screening approaches have suboptimal accuracy rates ranging from 71% for conventional oral examinations, to 77% for adjunct tools that preferentially detect leukoplakic lesions in the mouth. Elastic Scattering Spectroscopy (ESS) is a technology, mediated by fiberoptic probes, which has demonstrated the ability to precisely differentiate between neoplastic and non-neoplastic tissues in the intraoperative setting. We therefore hypothesized that ESS may be able to distinguish benign from malignant lesions in the oral cavity and provide a simple, portable, and non-invasive screening tool for oral cancer in primary and dental care clinics, or even in community-based settings. This approach would enable an earlier biopsy and diagnosis, ultimately reducing the rates of oral cancer morbidity and mortality.</p>\n\n<p><strong>Methods:</strong> This pilot study enrolled patients from otolaryngology (ENT) and oral and maxillofacial surgery (OMFS) clinics at a large, urban, safety-net hospital. Patients enrolled had suspicious lesions confirmed with biopsy as benign (leukoplakia/mild dysplasia) or malignant (moderate/severe dysplasia/carcinoma-in-situ/invasive squamous cell cancer). The ESS device consisted of a portable, handheld spectroscopy system with an attached fiberoptic probe to collect optical spectra within the oral cavity. Operating the device involved gently placing the probe tip on the lesion and pressing a button on the touch screen interface. One fiber in the probe illuminates the tissue with white light; an adjacent fiber in the probe collects backscattered light, conducting it to the spectrometer, and the built-in computer analyses the spectral reading. Data was collected from 13 patients in an outpatient clinic, and 8 patients in the operating room prior to surgical excision of their cancerous lesion.  Approximately 5 ESS measurements were obtained per patient directly on each lesion. Measurements were pooled per patient and analyzed using random forests classifiers and validated using Leave-One-Patient-Out (LOPO) cross-validation. The Sensitivity, Specificity, PPV, NPV, Accuracy, and AUC were computed by comparing ESS algorithm classification (benign/malignant) to the histopathological tissue classifications.</p>\n\n<p><strong>Results:</strong> 21 patients were enrolled; 10 had histologically confirmed benign oral lesions, and 11 had histologically confirmed malignant oral lesions. ESS differentiated between benign and malignant lesions with a Sensitivity=90%, Specificity=92%, PPV=90%, NPV=92%, Accuracy=91%, and AUC=95%.</p>\n\n<p><strong>Conclusion:</strong> This study demonstrated that ESS technology can accurately differentiate between benign and malignant oral lesions. These preliminary results suggest that implementing ESS technology in the outpatient setting could enhance accuracy of oral cancer screening far beyond current standards of care. Furthermore, the portable, non-invasive technology, which requires very little training to use, has potential applications in low-resource settings where oral cancer morbidity is high and where access to care is limited. Findings from this pilot study support further testing and validation of ESS in a larger trial against usual care practices.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153071--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S151",
      "content_id": "154461",
      "abstract_number": "S151",
      "poster_number": "",
      "title": "Cellular Neighborhood Reorganization in Periodontitis and HNSCC: Parallel CoVarNet Analyses of Single-Cell RNA Sequencing Data",
      "summary": "In both periodontitis and HPV-negative HNSCC, fibroblasts lose homeostatic immune partners and acquire disease-associated ones: inflammatory cells (plasma cells, pDC) in periodontitis versus immunosuppressive TAMs and CAFs in cancer. Periodontitis and HPV-negative HNSCC both show disrupted immune niches, but through different mechanisms: Th17-driven tissue destruction versus immunosuppressive T cell trapping....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154461",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas S Tilton, MS",
      "presenter": "Thomas S Tilton, MS",
      "authors": "Thomas S Tilton, MS ; De-Chen Lin, PhD; Uttam K Sinha, MD",
      "normalized_authors": [
        "Thomas S Tilton",
        "De-Chen Lin",
        "Uttam K Sinha"
      ],
      "affiliations": [
        "University of Southern California"
      ],
      "normalized_institutions": [
        "University of Southern California"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Purpose",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion",
        "AI Disclosure"
      ],
      "sections": {
        "Authors": "Thomas S Tilton, MS ; De-Chen Lin, PhD; Uttam K Sinha, MD",
        "Affiliations": "University of Southern California",
        "Background": "Periodontitis and HNSCC share features of chronic inflammation, immune dysregulation, and tissue remodeling. How cellular neighborhoods change in these diseases remains unclear at single-cell resolution. HPV-positive and HPV-negative HNSCC also represent distinct disease entities with different tumor microenvironments and prognosis. Understanding the cell neighborhood distinctions can provide avenues for developing disease biomarkers and therapeutic targets.",
        "Purpose": "We applied CoVarNet, an NMF-based cellular co-variation framework, to characterize cellular neighborhood changes in two parallel comparisons: (1) normal gingiva versus periodontitis, and (2) normal adjacent tissue versus HPV-positive and HPV-negative HNSCC. We also used scFEA (single-cell Flux Estimation Analysis) to profile cell-level metabolic activity across conditions.",
        "Methods": "We analyzed large, publicly available and private scRNA-seq datasets from periodontal and HNSCC cohorts. For periodontal analysis: normal gingiva (n=20) and periodontitis (n=10). For HNSCC analysis: distal normal (n=14), HPV-negative tumors (n=67, subsampled to n=15 for cross-condition comparison), and HPV-positive tumors (n=17). CoVarNet identifies cellular modules (CMs) by running NMF on sample-level cell type frequencies. Cells in the same module co-vary together across patients, representing functional niches. We interpreted modules by top contributing cell types based on NMF weights.",
        "Results": "In periodontitis, fibroblasts shifted from homeostatic partners (T cells, cDC, MAIT) to inflammatory partners (venule endothelium, plasma cells, pDC). T cells concentrated in Th17/neutrophil-driven inflammatory modules (3/7 modules) instead of the distributed surveillance seen in normal tissue (7/12 modules). TLS components (B cells, plasma cells) showed early co-localization.",
        "Abstract": "In HPV-negative HNSCC, fibroblasts partnered with immunosuppressive TAMs (SPP1+) and CAFs (MMP11+). Effector T cells (CD8 Tem, weight=0.24) were trapped in modules with these suppressive populations (TAM weight=0.23, CAF weight=0.13), suggesting compromised antitumor immunity. T cell subtypes (Treg, exhausted, effector) segregated into separate modules, and TLS components were scattered. In contrast, HPV-positive tumors showed more organized cellular relationships: multiple T cell subtypes coexisted in shared modules, and TLS components (B cells, Tfh, pDC) unified in single modules. Normal distal tissue and healthy gingiva cellular modules resembled each other. View in Agenda and Add to Schedule",
        "Conclusion": "In both periodontitis and HPV-negative HNSCC, fibroblasts lose homeostatic immune partners and acquire disease-associated ones: inflammatory cells (plasma cells, pDC) in periodontitis versus immunosuppressive TAMs and CAFs in cancer. Periodontitis and HPV-negative HNSCC both show disrupted immune niches, but through different mechanisms: Th17-driven tissue destruction versus immunosuppressive T cell trapping. HPV-positive HNSCC maintains organized cellular ecosystems with coordinated T cells and intact TLS, consistent with better prognosis and immunotherapy response. Our findings suggest immune cell organization as a potential biomarker for distinguishing disease states and CAF-TAM interactions as therapeutic targets in HPV-negative disease. Ongoing scFEA analysis will characterize the cell-level metabolic changes in these conditions.",
        "AI Disclosure": "Claude Opus 4.5 was used on 12/2/225 to assist with editing and proofreading. The abstract draft and study research content, data, and analysis were done by the authors. The authors reviewed and edited all content and take full responsibility for the accuracy and integrity of the submitted work."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cellular Neighborhood Reorganization in Periodontitis and HNSCC: Parallel CoVarNet Analyses of Single-Cell RNA Sequencing Data</span>. <u>Thomas S Tilton, MS</u>; De-Chen Lin, PhD; Uttam K Sinha, MD. University of Southern California<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Periodontitis and HNSCC share features of chronic inflammation, immune dysregulation, and tissue remodeling. How cellular neighborhoods change in these diseases remains unclear at single-cell resolution. HPV-positive and HPV-negative HNSCC also represent distinct disease entities with different tumor microenvironments and prognosis. Understanding the cell neighborhood distinctions can provide avenues for developing disease biomarkers and therapeutic targets.</p>\n\n<p><strong>Purpose:</strong> We applied CoVarNet, an NMF-based cellular co-variation framework, to characterize cellular neighborhood changes in two parallel comparisons: (1) normal gingiva versus periodontitis, and (2) normal adjacent tissue versus HPV-positive and HPV-negative HNSCC. We also used scFEA (single-cell Flux Estimation Analysis) to profile cell-level metabolic activity across conditions.</p>\n\n<p><strong>Methods:</strong> We analyzed large, publicly available and private scRNA-seq datasets from periodontal and HNSCC cohorts. For periodontal analysis: normal gingiva (n=20) and periodontitis (n=10). For HNSCC analysis: distal normal (n=14), HPV-negative tumors (n=67, subsampled to n=15 for cross-condition comparison), and HPV-positive tumors (n=17). CoVarNet identifies cellular modules (CMs) by running NMF on sample-level cell type frequencies. Cells in the same module co-vary together across patients, representing functional niches. We interpreted modules by top contributing cell types based on NMF weights.</p>\n\n<p><strong>Results: </strong>In periodontitis, fibroblasts shifted from homeostatic partners (T cells, cDC, MAIT) to inflammatory partners (venule endothelium, plasma cells, pDC). T cells concentrated in Th17/neutrophil-driven inflammatory modules (3/7 modules) instead of the distributed surveillance seen in normal tissue (7/12 modules). TLS components (B cells, plasma cells) showed early co-localization.</p>\n\n<p>In HPV-negative HNSCC, fibroblasts partnered with immunosuppressive TAMs (SPP1+) and CAFs (MMP11+). Effector T cells (CD8 Tem, weight=0.24) were trapped in modules with these suppressive populations (TAM weight=0.23, CAF weight=0.13), suggesting compromised antitumor immunity. T cell subtypes (Treg, exhausted, effector) segregated into separate modules, and TLS components were scattered. In contrast, HPV-positive tumors showed more organized cellular relationships: multiple T cell subtypes coexisted in shared modules, and TLS components (B cells, Tfh, pDC) unified in single modules. Normal distal tissue and healthy gingiva cellular modules resembled each other.</p>\n\n<p><strong>Conclusion:</strong> In both periodontitis and HPV-negative HNSCC, fibroblasts lose homeostatic immune partners and acquire disease-associated ones: inflammatory cells (plasma cells, pDC) in periodontitis versus immunosuppressive TAMs and CAFs in cancer. Periodontitis and HPV-negative HNSCC both show disrupted immune niches, but through different mechanisms: Th17-driven tissue destruction versus immunosuppressive T cell trapping. HPV-positive HNSCC maintains organized cellular ecosystems with coordinated T cells and intact TLS, consistent with better prognosis and immunotherapy response. Our findings suggest immune cell organization as a potential biomarker for distinguishing disease states and CAF-TAM interactions as therapeutic targets in HPV-negative disease. Ongoing scFEA analysis will characterize the cell-level metabolic changes in these conditions.</p>\n\n<p><strong><em>AI Disclosure:</em></strong> Claude Opus 4.5 was used on 12/2/225 to assist with editing and proofreading. The abstract draft and study research content, data, and analysis were done by the authors. The authors reviewed and edited all content and take full responsibility for the accuracy and integrity of the submitted work.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154461--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S152",
      "content_id": "153433",
      "abstract_number": "S152",
      "poster_number": "",
      "title": "Immune Dysfunction Risk Factors of Oral Tongue Lesions in Nonsmoking, Nondrinking Adults: A National Database Case-Control Study",
      "summary": "In this study, we propose a framework for conceptualizing categories of immune dysfunction associated with tongue cancer development. Several autoimmune, malignancy, and infectious diagnoses were associated with a higher incidence of tongue malignancy/dysplasia in middle-aged NSND adults, likely due to underlying immune dysfunction. Males and females experienced similar global risk profiles, although lichen...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153433",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jared Stewart",
      "presenter": "Jared Stewart",
      "authors": "Aaron Tucker; Jared Stewart ; Shreya Arun; Laurence DiNardo, Dr",
      "normalized_authors": [
        "Aaron Tucker",
        "Jared Stewart",
        "Shreya Arun",
        "Laurence DiNardo, Dr"
      ],
      "affiliations": [
        "VCU"
      ],
      "normalized_institutions": [
        "VCU"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aaron Tucker; Jared Stewart ; Shreya Arun; Laurence DiNardo, Dr",
        "Affiliations": "VCU",
        "Introduction": "Tobacco and alcohol consumption are known risk factors for oral cavity cancer (OCC). However, OCC incidence is rising among nonsmoking, nondrinking (NSND) populations with the oral tongue as the primary subsite without definitive risk factors. Causes of immune dysfunction have been hypothesized to be correlated with OCC, including viral infection, autoimmunity, and prior malignancy.",
        "Objective": "(1) To determine whether a history of immune dysfunction is associated with tongue cancer in NSND patients, and (2) to delineate sex-specific risks.",
        "Methods": "We designed a propensity score-matched retrospective case-control study using TriNetX, a national de-identified database of electronic health records. Adults aged 40-60 who were newly diagnosed with tongue dysplasia (ICD-10-CM D00.07, K13.21, K13.29) or tongue malignancy (C02.0-C02.3, C02.8, C02.9) were included, and propensity-matched by age and race. Controls included NSND patients with no history of OCC. Patients with any prior history of alcohol, nicotine, vaping exposure, smokeless tobacco, or head and neck cancer were excluded. Odds ratios with 95% confidence intervals (OR [95% CI]) were calculated and patients were categorized into three groups: prior malignancy (9 diagnoses e.g. lung/thoracic, lymphoid, endocrine), autoimmunity (10 diagnoses e.g. rheumatoid arthritis, lichen planus, Sjögren syndrome, lupus), or viral infection (11 diagnoses e.g. herpesvirus, HIV, papillomavirus). The number of diagnoses analyzed in both males and females associated with tongue malignancy/dysplasia was compared between sexes using Chi-square testing.",
        "Results": "After propensity score matching, 10,165 female cancer patients were matched with 10,165 female controls (both aged 51.9±5.9 years, 62.1% white), and 18,072 male cancer patients were matched with 18,072 male controls (both aged 51.3±6.0 years, 45.5% white). Among mutually analyzed conditions, males and females demonstrated similar counts of malignancy sites (Males: 3/9 vs Females: 4/9), autoimmune conditions (Males: 3/10 vs Females: 3/10), and viral infection (Males: 5/11 vs Females: 5/11) that were associated with the development of tongue dysplasia/malignancy. Notable conditions associated with tongue dysplasia included lung/thoracic malignancies (Female: OR 2.22 [95% CI: 1.57-3.15] vs Male: 3.30 [2.58-4.22]), lichen planus (Female: 8.83 [5.79-13.47] vs Male: 5.74 [3.65-9.03]), and asymptomatic HIV infection status (Female: 3.47 [1.95-6.16] vs Male: 1.56 [1.24-1.98]) and human papilloma virus (Female: 1.14 [.82-1.58] vs Male: 2.33 [1.19-4.59]).",
        "Conclusion": "In this study, we propose a framework for conceptualizing categories of immune dysfunction associated with tongue cancer development. Several autoimmune, malignancy, and infectious diagnoses were associated with a higher incidence of tongue malignancy/dysplasia in middle-aged NSND adults, likely due to underlying immune dysfunction. Males and females experienced similar global risk profiles, although lichen planus was more highly associated in females than males, and papillomavirus infection was associated in males but not females. Further research is needed to elucidate the driving factors of tongue dysplasia and malignancy in this population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immune Dysfunction Risk Factors of Oral Tongue Lesions in Nonsmoking, Nondrinking Adults: A National Database Case-Control Study</span>. Aaron Tucker; <u>Jared Stewart</u>; Shreya Arun; Laurence DiNardo, Dr. VCU<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Tobacco and alcohol consumption are known risk factors for oral cavity cancer (OCC). However, OCC incidence is rising among nonsmoking, nondrinking (NSND) populations with the oral tongue as the primary subsite without definitive risk factors. Causes of immune dysfunction have been hypothesized to be correlated with OCC, including viral infection, autoimmunity, and prior malignancy.</p>\n\n<p><strong>Objective:</strong> (1) To determine whether a history of immune dysfunction is associated with tongue cancer in NSND patients, and (2) to delineate sex-specific risks.</p>\n\n<p><strong>Methods:</strong> We designed a propensity score-matched retrospective case-control study using TriNetX, a national de-identified database of electronic health records. Adults aged 40-60 who were newly diagnosed with tongue dysplasia (ICD-10-CM D00.07, K13.21, K13.29) or tongue malignancy (C02.0-C02.3, C02.8, C02.9) were included, and propensity-matched by age and race. Controls included NSND patients with no history of OCC. Patients with any prior history of alcohol, nicotine, vaping exposure, smokeless tobacco, or head and neck cancer were excluded. Odds ratios with 95% confidence intervals (OR [95% CI]) were calculated and patients were categorized into three groups: prior malignancy (9 diagnoses e.g. lung/thoracic, lymphoid, endocrine), autoimmunity (10 diagnoses e.g. rheumatoid arthritis, lichen planus, Sjögren syndrome, lupus), or viral infection (11 diagnoses e.g. herpesvirus, HIV, papillomavirus). The number of diagnoses analyzed in both males and females associated with tongue malignancy/dysplasia was compared between sexes using Chi-square testing.</p>\n\n<p><strong>Results:</strong> After propensity score matching, 10,165 female cancer patients were matched with 10,165 female controls (both aged 51.9±5.9 years, 62.1% white), and 18,072 male cancer patients were matched with 18,072 male controls (both aged 51.3±6.0 years, 45.5% white). Among mutually analyzed conditions, males and females demonstrated similar counts of malignancy sites (Males: 3/9 vs Females: 4/9), autoimmune conditions (Males: 3/10 vs Females: 3/10), and viral infection (Males: 5/11 vs Females: 5/11) that were associated with the development of tongue dysplasia/malignancy. Notable conditions associated with tongue dysplasia included lung/thoracic malignancies (Female: OR 2.22 [95% CI: 1.57-3.15] vs Male: 3.30 [2.58-4.22]), lichen planus (Female: 8.83 [5.79-13.47] vs Male: 5.74 [3.65-9.03]), and asymptomatic HIV infection status (Female: 3.47 [1.95-6.16] vs Male: 1.56 [1.24-1.98]) and human papilloma virus (Female: 1.14 [.82-1.58] vs Male: 2.33 [1.19-4.59]).</p>\n\n<p><strong>Conclusion: </strong>In this study, we propose a framework for conceptualizing categories of immune dysfunction associated with tongue cancer development. Several autoimmune, malignancy, and infectious diagnoses were associated with a higher incidence of tongue malignancy/dysplasia in middle-aged NSND adults, likely due to underlying immune dysfunction. Males and females experienced similar global risk profiles, although lichen planus was more highly associated in females than males, and papillomavirus infection was associated in males but not females. Further research is needed to elucidate the driving factors of tongue dysplasia and malignancy in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153433--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S153",
      "content_id": "153367",
      "abstract_number": "S153",
      "poster_number": "",
      "title": "Dysplasia Grade Predicts Speed of Malignant Transformation in Oral Epithelial Dysplasia",
      "summary": "Dysplasia grade independently predicts time-to-malignant transformation in oral epithelial dysplasia. High-grade lesions progress to carcinoma faster (median nine months) than moderate- or low-grade lesions, supporting more intensified surveillance and consideration of earlier intervention in this group. No other clinicodemographic factors predicted malignant transformation. Alternative risk factors including...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153367",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mohamad Almasri, MD",
      "presenter": "Mohamad Almasri, MD",
      "authors": "Abdullah A Adil, MD; Mary Falstin; Mohamad Almasri, MD ; Zachary Buxo; Steven B Chinn, MD; Keith A Casper, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; Kelly M Malloy, MD; Andrew G Shuman, MD; Mark E Prince, MD; Molly E Heft-Neal, MD; David W Forner",
      "normalized_authors": [
        "Abdullah A Adil",
        "Mary Falstin",
        "Mohamad Almasri",
        "Zachary Buxo",
        "Steven B Chinn",
        "Keith A Casper",
        "Marisa R Buchakjian",
        "Pratyusha Yalamanchi",
        "Kelly M Malloy",
        "Andrew G Shuman",
        "Mark E Prince",
        "Molly E Heft-Neal",
        "David W Forner"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 359,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Abdullah A Adil, MD; Mary Falstin; Mohamad Almasri, MD ; Zachary Buxo; Steven B Chinn, MD; Keith A Casper, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; Kelly M Malloy, MD; Andrew G Shuman, MD; Mark E Prince, MD; Molly E Heft-Neal, MD; David W Forner",
        "Affiliations": "University of Michigan",
        "Background": "Oral epithelial dysplasia (OED) is a precursor to oral squamous cell carcinoma (OCSCC), with malignant transformation rates ranging from 5–40%. Although histological grade is the strongest predictor of malignant progression, the timing of transformation varies widely, and reliable clinical predictors of rapid progression remain poorly defined. Early identification of lesions at highest risk for faster transformation is essential for optimizing surveillance and guiding treatment decisions. This study aimed to evaluate demographic, clinical, and histopathologic factors associated with time-to-malignant transformation in OED.",
        "Methods": "A retrospective cohort study was conducted of 79 patients with OED that transformed into OSCC at a single tertiary academic center. Baseline demographic, clinical, and histologic variables were collected from the medical record. Associations between clinical variables and time-to-transformation were examined using uni- and multivariate analyses to identify predictors of rapid progression. Time-to-malignant transformation was assessed using Kaplan–Meier and log-rank analysis.",
        "Results": "The median patient age (IQR) was 65 (18) years, with 55% male and 94% identifying as White. The most common subsites were the oral tongue (48%), buccal mucosa (17%), and alveolus (17%). Overall, 34 patients had low-grade dysplasia, 28 had moderate-grade dysplasia, and 17 had high-grade dysplasia. Median time-to-transformation was shortest for high-grade dysplasia (285 days; IQR 1,151), followed by low-grade (766 days; IQR 1,737) and moderate-grade dysplasia (970 days; IQR 1,392). On univariate analyses, no demographic, lifestyle, or comorbidity variables were significantly associated with time-to-transformation. In multivariable regression, dysplasia grade was the only independent predictor of faster malignant transformation (HR 2.286, 95% CI 1.064 – 4.911, p = 0.034), whereas age, sex, subsite, smoking history, alcohol use, chewing tobacco, immunosuppression, lichen planus, and management strategy were not significant. Kaplan–Meier analysis demonstrated significantly faster transformation for high-grade dysplasia (log-rank χ² = 6.06, p = 0.048).",
        "Conclusions": "Dysplasia grade independently predicts time-to-malignant transformation in oral epithelial dysplasia. High-grade lesions progress to carcinoma faster (median nine months) than moderate- or low-grade lesions, supporting more intensified surveillance and consideration of earlier intervention in this group. No other clinicodemographic factors predicted malignant transformation. Alternative risk factors including environmental exposures and genomic predictors of transformation deserve further exploration.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Dysplasia Grade Predicts Speed of Malignant Transformation in Oral Epithelial Dysplasia</span>. Abdullah A Adil, MD; Mary Falstin; <u>Mohamad Almasri, MD</u>; Zachary Buxo; Steven B Chinn, MD; Keith A Casper, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; Kelly M Malloy, MD; Andrew G Shuman, MD; Mark E Prince, MD; Molly E Heft-Neal, MD; David W Forner. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral epithelial dysplasia (OED) is a precursor to oral squamous cell carcinoma (OCSCC), with malignant transformation rates ranging from 5–40%. Although histological grade is the strongest predictor of malignant progression, the timing of transformation varies widely, and reliable clinical predictors of rapid progression remain poorly defined. Early identification of lesions at highest risk for faster transformation is essential for optimizing surveillance and guiding treatment decisions. This study aimed to evaluate demographic, clinical, and histopathologic factors associated with time-to-malignant transformation in OED.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted of 79 patients with OED that transformed into OSCC at a single tertiary academic center. Baseline demographic, clinical, and histologic variables were collected from the medical record. Associations between clinical variables and time-to-transformation were examined using uni- and multivariate analyses to identify predictors of rapid progression. Time-to-malignant transformation was assessed using Kaplan–Meier and log-rank analysis.</p>\n\n<p><strong>Results: </strong>The median patient age (IQR) was 65 (18) years, with 55% male and 94% identifying as White. The most common subsites were the oral tongue (48%), buccal mucosa (17%), and alveolus (17%). Overall, 34 patients had low-grade dysplasia, 28 had moderate-grade dysplasia, and 17 had high-grade dysplasia. Median time-to-transformation was shortest for high-grade dysplasia (285 days; IQR 1,151), followed by low-grade (766 days; IQR 1,737) and moderate-grade dysplasia (970 days; IQR 1,392). On univariate analyses, no demographic, lifestyle, or comorbidity variables were significantly associated with time-to-transformation. In multivariable regression, dysplasia grade was the only independent predictor of faster malignant transformation (HR 2.286, 95% CI 1.064 – 4.911, p = 0.034), whereas age, sex, subsite, smoking history, alcohol use, chewing tobacco, immunosuppression, lichen planus, and management strategy were not significant. Kaplan–Meier analysis demonstrated significantly faster transformation for high-grade dysplasia (log-rank χ² = 6.06, p = 0.048). </p>\n\n<p><strong>Conclusions: </strong>Dysplasia grade independently predicts time-to-malignant transformation in oral epithelial dysplasia. High-grade lesions progress to carcinoma faster (median nine months) than moderate- or low-grade lesions, supporting more intensified surveillance and consideration of earlier intervention in this group. No other clinicodemographic factors predicted malignant transformation. Alternative risk factors including environmental exposures and genomic predictors of transformation deserve further exploration.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153367--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S154",
      "content_id": "153730",
      "abstract_number": "S154",
      "poster_number": "",
      "title": "EDIL3 as a Potential Circulating Biomarker of Invasion in Oral Cavity Squamous Cell Carcinoma",
      "summary": "EMT is a critical program in cancer invasion, and we have identified a potential driver of invasion, EDIL3, through a whole-genome functional CRISPR screen. EDIL3 is secreted in exosomes and is also measurable in the plasma of OSCC patients with active disease. Future studies will focus on investigating EDIL3 across tumor stages and in the post-treatment setting, with the goal of clinical trials examining...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153730",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260125",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rachel B Fenberg, MD",
      "presenter": "Rachel B Fenberg, MD",
      "authors": "Rachel B Fenberg, MD 1 ; Guillermo Flores, MD, PhD 2 ; Andrea Stoddard, BA 1 ; Michael D Henry, PhD 3 ; Chad Brenner, PhD 1 ; Molly E Heft Neal, MD 1 ; Marisa R Buchakjian, MD, PhD 1",
      "normalized_authors": [
        "Rachel B Fenberg",
        "Guillermo Flores",
        "Andrea Stoddard",
        "Michael D Henry",
        "Chad Brenner",
        "Molly E Heft Neal",
        "Marisa R Buchakjian"
      ],
      "affiliations": [
        "University of Michigan - Department of Otolaryngology, Head and Neck Surgery",
        "University of Iowa Hospitals and Clinics, Department of Otolaryngology - Head and Neck Surgery",
        "Eastern Virginia Medical College, Department of Molecular Physiology and Biophysics"
      ],
      "normalized_institutions": [
        "University of Michigan - Department of Otolaryngology, Head and Neck Surgery",
        "University of Iowa Hospitals and Clinics, Department of Otolaryngology - Head and Neck Surgery",
        "Eastern Virginia Medical College, Department of Molecular Physiology and Biophysics"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rachel B Fenberg, MD 1 ; Guillermo Flores, MD, PhD 2 ; Andrea Stoddard, BA 1 ; Michael D Henry, PhD 3 ; Chad Brenner, PhD 1 ; Molly E Heft Neal, MD 1 ; Marisa R Buchakjian, MD, PhD 1",
        "Affiliations": "1 University of Michigan - Department of Otolaryngology, Head and Neck Surgery; 2 University of Iowa Hospitals and Clinics, Department of Otolaryngology - Head and Neck Surgery; 3 Eastern Virginia Medical College, Department of Molecular Physiology and Biophysics",
        "Background": "Oral cavity squamous cell carcinoma (OSCC) is an epithelial-derived cancer characterized by locoregional invasion and a high rate of recurrence. Importantly, OSCC displays significant heterogeneity, with cells existing along a spectrum of epithelial-mesenchymal transition (EMT) phenotypes. Several studies have shown the impact of EMT on OSCC, with “mesenchymal” tumors demonstrating worse disease-free and overall survival. Our lab has performed an unbiased whole-genome CRISPR invasion screen utilizing a novel cellular EMT tool created using the SCC-9 cell line. This screen identified 17 potential invasion-modifying genes in OSCC, from which an exciting candidate, Epidermal growth factor-like repeats and Discoidin I-Like Domains 3 (EDIL3) has been prioritized for ongoing studies. EDIL3 is a secreted glycoprotein which has been demonstrated in some other cancer types to promote invasion and EMT. Our current work examines the EDIL3 signaling pathway in OSCC cell lines and investigates the significance of detected circulating plasma EDIL3 in OSCC patients.",
        "Objective": "The goal of this research is to better understand the mechanisms of cellular invasion and EMT in OSCC, with the long-term objective of characterizing novel and targetable invasion modifiers.",
        "Methods": "Our lab has previously characterized genetically and phenotypically distinct “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) EMT OSCC subpopulations. Using this novel OSCC EMT model, we performed an unbiased whole-genome CRISPR invasion screen which uncovered 17 unique invasion modifiers. Current experiments utilize our in vitro EMT model to perform siRNA and add-back experiments examining a promising candidate, EDIL3. Our focus is on examining the canonical EDIL3 signaling pathway through transwell invasion and cell viability assays. We are further treating our in vitro model with an FDA-approved drug, Celingitide, to inhibit EDIL3 signaling. For translational studies, we are prospectively collecting plasma from patients with OSCC and have demonstrated feasibility in detecting circulating EDIL3 using ELISA.",
        "Results": "EDIL3 knockout by siRNA prevents OSCC mesenchymal cells from invading across a transwell membrane. Add-back of EDIL3 either by exogenous protein or by addition of conditioned media from mesenchymal cells is able to rescue siRNA EDIL3 SCC-9 invasion. Loss of EDIL3 also appears to be critical for SCC-9 M cisplatin chemoresistance. Current work is examining the downstream signaling axis to determine if EDIL3 is acting through its canonical integrin/FAK/MEK signaling pathway to promote EMT and cell growth. Excitingly, we have collected plasma from patients with OSCC and are able to detect circulating EDIL3 using ELISA. Our current work expands this translational study to compare OSCC patients to cancer-naïve patients and patients in the post-treatment setting.",
        "Conclusions": "EMT is a critical program in cancer invasion, and we have identified a potential driver of invasion, EDIL3, through a whole-genome functional CRISPR screen. EDIL3 is secreted in exosomes and is also measurable in the plasma of OSCC patients with active disease. Future studies will focus on investigating EDIL3 across tumor stages and in the post-treatment setting, with the goal of clinical trials examining inhibition of EDIL3 function with the FDA-approved therapeutic, Celingitide.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>EDIL3 as a Potential Circulating Biomarker of Invasion in Oral Cavity Squamous Cell Carcinoma</span>. <u>Rachel B Fenberg, MD</u><sup>1</sup>; Guillermo Flores, MD, PhD<sup>2</sup>; Andrea Stoddard, BA<sup>1</sup>; Michael D Henry, PhD<sup>3</sup>; Chad Brenner, PhD<sup>1</sup>; Molly E Heft Neal, MD<sup>1</sup>; Marisa R Buchakjian, MD, PhD<sup>1</sup>. <sup>1</sup>University of Michigan - Department of Otolaryngology, Head and Neck Surgery; <sup>2</sup>University of Iowa Hospitals and Clinics, Department of Otolaryngology - Head and Neck Surgery; <sup>3</sup>Eastern Virginia Medical College, Department of Molecular Physiology and Biophysics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Oral cavity squamous cell carcinoma (OSCC) is an epithelial-derived cancer characterized by locoregional invasion and a high rate of recurrence. Importantly, OSCC displays significant heterogeneity, with cells existing along a spectrum of epithelial-mesenchymal transition (EMT) phenotypes. Several studies have shown the impact of EMT on OSCC, with “mesenchymal” tumors demonstrating worse disease-free and overall survival. Our lab has performed an unbiased whole-genome CRISPR invasion screen utilizing a novel cellular EMT tool created using the SCC-9 cell line. This screen identified 17 potential invasion-modifying genes in OSCC, from which an exciting candidate, Epidermal growth factor-like repeats and Discoidin I-Like Domains 3 (EDIL3) has been prioritized for ongoing studies. EDIL3 is a secreted glycoprotein which has been demonstrated in some other cancer types to promote invasion and EMT. Our current work examines the EDIL3 signaling pathway in OSCC cell lines and investigates the significance of detected circulating plasma EDIL3 in OSCC patients.</p>\n\n<p><strong>Objective</strong>: The goal of this research is to better understand the mechanisms of cellular invasion and EMT in OSCC, with the long-term objective of characterizing novel and targetable invasion modifiers.</p>\n\n<p><strong>Methods</strong>: Our lab has previously characterized genetically and phenotypically distinct “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) EMT OSCC subpopulations. Using this novel OSCC EMT model, we performed an unbiased whole-genome CRISPR invasion screen which uncovered 17 unique invasion modifiers. Current experiments utilize our in vitro EMT model to perform siRNA and add-back experiments examining a promising candidate, EDIL3. Our focus is on examining the canonical EDIL3 signaling pathway through transwell invasion and cell viability assays. We are further treating our in vitro model with an FDA-approved drug, Celingitide, to inhibit EDIL3 signaling. For translational studies, we are prospectively collecting plasma from patients with OSCC and have demonstrated feasibility in detecting circulating EDIL3 using ELISA.</p>\n\n<p><strong>Results</strong>: EDIL3 knockout by siRNA prevents OSCC mesenchymal cells from invading across a transwell membrane. Add-back of EDIL3 either by exogenous protein or by addition of conditioned media from mesenchymal cells is able to rescue siRNA EDIL3 SCC-9 invasion. Loss of EDIL3 also appears to be critical for SCC-9 M cisplatin chemoresistance. Current work is examining the downstream signaling axis to determine if EDIL3 is acting through its canonical integrin/FAK/MEK signaling pathway to promote EMT and cell growth. Excitingly, we have collected plasma from patients with OSCC and are able to detect circulating EDIL3 using ELISA. Our current work expands this translational study to compare OSCC patients to cancer-naïve patients and patients in the post-treatment setting.</p>\n\n<p><strong>Conclusions</strong>: EMT is a critical program in cancer invasion, and we have identified a potential driver of invasion, EDIL3, through a whole-genome functional CRISPR screen. EDIL3 is secreted in exosomes and is also measurable in the plasma of OSCC patients with active disease. Future studies will focus on investigating EDIL3 across tumor stages and in the post-treatment setting, with the goal of clinical trials examining inhibition of EDIL3 function with the FDA-approved therapeutic, Celingitide.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153730--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260125' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S155",
      "content_id": "153723",
      "abstract_number": "S155",
      "poster_number": "",
      "title": "Lactate dehydrogenase and pH in surgical drain fluid predicts salivary fistula after head and neck surgery",
      "summary": "LDH and pH from surgical drain fluid on POD3 were found to be significant predictors of salivary fistula. These biomarkers may have a unique potential to identify patients who are at a low-risk of developing salivary fistula and may be candidates for accelerated discharge or early feeding.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153723",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Micah K Harris, MD",
      "presenter": "Micah K Harris, MD",
      "authors": "Micah K Harris, MD ; Jenny Kim, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica Maxwell, MD; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Shaum S Sridharan",
      "normalized_authors": [
        "Micah K Harris",
        "Jenny Kim",
        "Joshua D Smith",
        "Steven B Chinn",
        "Jessica Maxwell",
        "Kevin J Contrera",
        "Matthew E Spector",
        "Shaum S Sridharan"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153723/Screenshot%202025-12-03%20at%207_07_40%E2%80%AFPM(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153723/Screenshot%202025-12-03%20at%207_07_40%E2%80%AFPM(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153723"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 530,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Micah K Harris, MD ; Jenny Kim, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica Maxwell, MD; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Shaum S Sridharan",
        "Affiliations": "University of Pittsburgh Medical Center",
        "Introduction": "Salivary fistula after head and neck oncologic surgery is a major complication, with a clear impact on perioperative complications, length of stay, and time to initiation of radiation. There is a lack of reliable biomarkers associated with fistula. The aim of this study was to evaluate the ability of lactate dehydrogenase (LDH) and pH in postoperative surgical drains to identify patients at low risk of salivary fistula.",
        "Methods": "Drain fluid LDH and pH were measured on postoperative days (PODs) 1-3. Labs were drawn from the same drain, located close to the mucosal closure line when applicable. Salivary fistula was diagnosed clinically. Variables collected included age, gender, surgical procedure, primary vs recurrent tumor, T category, and N category, as well as history of radiotherapy, chemotherapy, smoking, and diabetes. Student’s t-test compared categorical and numerical groups. Receiver operating curves (ROCs) were designed to measure area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Youden indices were used to identify optimal thresholds to predict salivary fistula. Multivariable logistic regression identified predictive variables.",
        "Results": "Seventy-six patients were included (64 ± 11.3 years). Overall, 31.5% had a history of radiotherapy, 28.9% had chemotherapy, 57.9% were smokers, and 23.6% had diabetes. 55.3% had advanced (T3-T4) disease. 42.1% underwent total laryngectomy and 28.9% were operated on for recurrent disease. Eight patients (10.5%) developed salivary fistula (7.9 ± 3.7 days postoperatively, range 3-13 days). Fistula patients had a higher rate of prior radiation (66.7% vs. 26.9%, P=0.016). Otherwise, clinicodemographic variables were not significantly different between groups (all P>0.05). LDH was significantly higher (3844.3 ± 2192.5 U/L vs. 2192.5 ± 1350.7 U/L, P=0.0026) and pH was significantly lower (7.99 ± 0.77 vs. 8.55 ± 0.28, P=0.00021) in the POD3 drain fluid of patients who developed salivary fistula. On ROC analyses, the AUC for POD3 LDH to predict salivary fistula was 0.78 (threshold >3132 U/L, sensitivity 75%, specificity 83.3%) and the AUC for POD3 pH was 0.72 (threshold <8.05, sensitivity 94.4%, specificity 62.5%). When controlling for age, T3-T4 category, smoking, diabetes, operating on recurrent tumor, and prior radiotherapy, both POD3 pH <8.05 (odds ratio 19.6, 95% CI 2.01-200, P=0.01) and POD3 LDH >3132 (odds ratio 48.7, 95% CI 4.3-552.1, P=0.002) remained associated with salivary fistula on multivariate logistic regression. When retrospective applied to our cohort, LDH >3132 U/L had a PPV and NPV of 46.2% and 95.3%, while pH <8.05 had a PPV and NPV of 62.5% and 96.3%, respectively. When these thresholds were combined, LDH >3132 U/L with pH <8.05 had a PPV of 75% and NPV of 100%.",
        "Conclusion": "LDH and pH from surgical drain fluid on POD3 were found to be significant predictors of salivary fistula. These biomarkers may have a unique potential to identify patients who are at a low-risk of developing salivary fistula and may be candidates for accelerated discharge or early feeding.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lactate dehydrogenase and pH in surgical drain fluid predicts salivary fistula after head and neck surgery</span>. <u>Micah K Harris, MD</u>; Jenny Kim, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica Maxwell, MD; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Shaum S Sridharan. University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Salivary fistula after head and neck oncologic surgery is a major complication, with a clear impact on perioperative complications, length of stay, and time to initiation of radiation. There is a lack of reliable biomarkers associated with fistula. The aim of this study was to evaluate the ability of lactate dehydrogenase (LDH) and pH in postoperative surgical drains to identify patients at low risk of salivary fistula.</p>\n\n<p><strong>Methods</strong>: Drain fluid LDH and pH were measured on postoperative days (PODs) 1-3. Labs were drawn from the same drain, located close to the mucosal closure line when applicable. Salivary fistula was diagnosed clinically. Variables collected included age, gender, surgical procedure, primary vs recurrent tumor, T category, and N category, as well as history of radiotherapy, chemotherapy, smoking, and diabetes. Student’s t-test compared categorical and numerical groups. Receiver operating curves (ROCs) were designed to measure area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Youden indices were used to identify optimal thresholds to predict salivary fistula. Multivariable logistic regression identified predictive variables.</p>\n\n<p><strong>Results</strong>: Seventy-six patients were included (64 ± 11.3 years). Overall, 31.5% had a history of radiotherapy, 28.9% had chemotherapy, 57.9% were smokers, and 23.6% had diabetes. 55.3% had advanced (T3-T4) disease. 42.1% underwent total laryngectomy and 28.9% were operated on for recurrent disease. Eight patients (10.5%) developed salivary fistula (7.9 ± 3.7 days postoperatively, range 3-13 days). Fistula patients had a higher rate of prior radiation (66.7% vs. 26.9%, P=0.016). Otherwise, clinicodemographic variables were not significantly different between groups (all P>0.05). LDH was significantly higher (3844.3 ± 2192.5 U/L vs. 2192.5 ± 1350.7 U/L, P=0.0026) and pH was significantly lower (7.99 ± 0.77 vs. 8.55 ± 0.28, P=0.00021) in the POD3 drain fluid of patients who developed salivary fistula. On ROC analyses, the AUC for POD3 LDH to predict salivary fistula was 0.78 (threshold >3132 U/L, sensitivity 75%, specificity 83.3%) and the AUC for POD3 pH was 0.72 (threshold <8.05, sensitivity 94.4%, specificity 62.5%). When controlling for age, T3-T4 category, smoking, diabetes, operating on recurrent tumor, and prior radiotherapy, both POD3 pH <8.05 (odds ratio 19.6, 95% CI 2.01-200, P=0.01) and POD3 LDH >3132 (odds ratio 48.7, 95% CI 4.3-552.1, P=0.002) remained associated with salivary fistula on multivariate logistic regression.  When retrospective applied to our cohort, LDH >3132 U/L had a PPV and NPV of 46.2% and 95.3%, while pH <8.05 had a PPV and NPV of 62.5% and 96.3%, respectively. When these thresholds were combined, LDH >3132 U/L with pH <8.05 had a PPV of 75% and NPV of 100%.</p>\n\n<p><strong>Conclusion</strong>: LDH and pH from surgical drain fluid on POD3 were found to be significant predictors of salivary fistula. These biomarkers may have a unique potential to identify patients who are at a low-risk of developing salivary fistula and may be candidates for accelerated discharge or early feeding.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153723/Screenshot%202025-12-03%20at%207_07_40%E2%80%AFPM(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153723--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S156",
      "content_id": "152804",
      "abstract_number": "S156",
      "poster_number": "",
      "title": "Antibiotic Prophylaxis Following Free Flap Reconstruction of the Head and Neck: Individual Participant Meta-Analysis",
      "summary": "Patients undergoing HN free flap reconstruction benefit from postoperative antibiotic prophylaxis in a clean-contaminated field; 24 hours of prophylaxis may be sufficient in preventing postoperative SSI when compared to prolonged courses.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152804",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Louis-Xavier Barrette, MD",
      "presenter": "Louis-Xavier Barrette, MD",
      "authors": "Louis-Xavier Barrette, MD 1 ; Deepak Lakshmipathy, MD 1 ; Samir S Khariwala, MD 2 ; Ryan M Mitchell, MD, PhD 3 ; Michael P Veve, PharmD, MPH 4 ; Anand Ramakrishnan, MBBS, MD, FRACS 5 ; Karolina Plonowska-Hirschfeld, MD 6 ; Ahmed Beydoun, MD 1 ; Karthik Rajasekaran, MD, FACS 1",
      "normalized_authors": [
        "Louis-Xavier Barrette",
        "Deepak Lakshmipathy",
        "Samir S Khariwala",
        "Ryan M Mitchell",
        "Michael P Veve, PharmD",
        "Anand Ramakrishnan, MBBS, FRACS",
        "Karolina Plonowska-Hirschfeld",
        "Ahmed Beydoun",
        "Karthik Rajasekaran"
      ],
      "affiliations": [
        "Penn Medicine",
        "University of Minnesota",
        "University of Washington Medicine",
        "Wayne State University",
        "University of Melbourne",
        "University of Illinois Health"
      ],
      "normalized_institutions": [
        "Penn Medicine",
        "University of Minnesota",
        "University of Washington Medicine",
        "Wayne State University",
        "University of Melbourne",
        "University of Illinois Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 382,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Louis-Xavier Barrette, MD 1 ; Deepak Lakshmipathy, MD 1 ; Samir S Khariwala, MD 2 ; Ryan M Mitchell, MD, PhD 3 ; Michael P Veve, PharmD, MPH 4 ; Anand Ramakrishnan, MBBS, MD, FRACS 5 ; Karolina Plonowska-Hirschfeld, MD 6 ; Ahmed Beydoun, MD 1 ; Karthik Rajasekaran, MD, FACS 1",
        "Affiliations": "1 Penn Medicine; 2 University of Minnesota; 3 University of Washington Medicine; 4 Wayne State University; 5 University of Melbourne; 6 University of Illinois Health",
        "Background": "Surgical site infections (SSI) following free flap reconstruction in the head and neck (HN) can significantly impact reconstructive outcomes. Reconstructive recipient sites are often clean-contaminated, and SSIs may provoke vessel thrombosis, prevent appropriate flap healing, and lead to flap loss. Ideal antibiotic prophylaxis, both agent and duration, remains contested for patients undergoing HN free flap reconstruction.",
        "Objective": "To perform a systematic review and meta-analysis using individual participant data.",
        "Methods": "A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed using the Cochrane Library, Embase, PubMed, and Web of Science as source databases. We included all published studies from database inception through January 2024 involving patients who received perioperative antibiotic prophylaxis following clean-contaminated HN free flap reconstruction. Following identification of studies for inclusion, selected study authors were contacted to obtain deidentified, individual-level patient data. Primary outcome was recipient site SSI rate based on duration of postoperative antibiotic prophylaxis and agent choice. Random e?ects meta-analysis was used to calculate pooled relative risk (RR) with 95% confidence intervals (CI).",
        "Results": "In our systematic review, 437 records were initially identified with 6 studies meeting final inclusion criteria. Newcastle-Ottawa Quality Assessment revealed low risk of bias among included works. There were 3229 total free flaps performed in the included studies, with ampicillin/sulbactam found to be the predominant antibiotic across all studies, followed by clindamycin. Pooled RR for developing recipient SSI in patients with postoperative antibiotics ≤24 hours versus those with >24-hour regimens was 0.71 (0.18 – 0.76 95% CI, p = 0.62). Study heterogeneity was moderate (I2 = 61.7%) alongside funnel plot and Egger’s test showing low publication bias (p = 0.29).",
        "Discussion": "Antibiotic prophylaxis is frequently continued beyond 24 hours of index surgery in HN free flap reconstruction when the recipient site is a clean-contaminated field, though evidence supporting this practice is mixed. Further, choice of antibiotic is not standardized between institutions and between patients. We utilized individual-level data examining over 3000 free flaps with no evidence that extending antibiotic prophylaxis beyond 24 hours decreases the risk of recipient-site SSI.",
        "Conclusion": "Patients undergoing HN free flap reconstruction benefit from postoperative antibiotic prophylaxis in a clean-contaminated field; 24 hours of prophylaxis may be sufficient in preventing postoperative SSI when compared to prolonged courses.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Antibiotic Prophylaxis Following Free Flap Reconstruction of the Head and Neck: Individual Participant Meta-Analysis</span>. <u>Louis-Xavier Barrette, MD</u><sup>1</sup>; Deepak Lakshmipathy, MD<sup>1</sup>; Samir S Khariwala, MD<sup>2</sup>; Ryan M Mitchell, MD, PhD<sup>3</sup>; Michael P Veve, PharmD, MPH<sup>4</sup>; Anand Ramakrishnan, MBBS, MD, FRACS<sup>5</sup>; Karolina Plonowska-Hirschfeld, MD<sup>6</sup>; Ahmed Beydoun, MD<sup>1</sup>; Karthik Rajasekaran, MD, FACS<sup>1</sup>. <sup>1</sup>Penn Medicine; <sup>2</sup>University of Minnesota; <sup>3</sup>University of Washington Medicine; <sup>4</sup>Wayne State University; <sup>5</sup>University of Melbourne; <sup>6</sup>University of Illinois Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Surgical site infections (SSI) following free flap reconstruction in the head and neck (HN) can significantly impact reconstructive outcomes. Reconstructive recipient sites are often clean-contaminated, and SSIs may provoke vessel thrombosis, prevent appropriate flap healing, and lead to flap loss. Ideal antibiotic prophylaxis, both agent and duration, remains contested for patients undergoing HN free flap reconstruction.</p>\n\n<p><strong>Objective: </strong>To perform a systematic review and meta-analysis using individual participant data.</p>\n\n<p><strong>Methods: </strong>A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed using the Cochrane Library, Embase, PubMed, and Web of Science as source databases. We included all published studies from database inception through January 2024 involving patients who received perioperative antibiotic prophylaxis following clean-contaminated HN free flap reconstruction. Following identification of studies for inclusion, selected study authors were contacted to obtain deidentified, individual-level patient data. Primary outcome was recipient site SSI rate based on duration of postoperative antibiotic prophylaxis and agent choice. Random e?ects meta-analysis was used to calculate pooled relative risk (RR) with 95% confidence intervals (CI).</p>\n\n<p><strong>Results: </strong>In our systematic review, 437 records were initially identified with 6 studies meeting final inclusion criteria. Newcastle-Ottawa Quality Assessment revealed low risk of bias among included works. There were 3229 total free flaps performed in the included studies, with ampicillin/sulbactam found to be the predominant antibiotic across all studies, followed by clindamycin. Pooled RR for developing recipient SSI in patients with postoperative antibiotics ≤24 hours versus those with >24-hour regimens was 0.71 (0.18 – 0.76 95% CI, p = 0.62). Study heterogeneity was moderate (I2 = 61.7%) alongside funnel plot and Egger’s test showing low publication bias (p = 0.29).</p>\n\n<p><strong>Discussion: </strong>Antibiotic prophylaxis is frequently continued beyond 24 hours of index surgery in HN free flap reconstruction when the recipient site is a clean-contaminated field, though evidence supporting this practice is mixed. Further, choice of antibiotic is not standardized between institutions and between patients. We utilized individual-level data examining over 3000 free flaps with no evidence that extending antibiotic prophylaxis beyond 24 hours decreases the risk of recipient-site SSI.</p>\n\n<p><strong>Conclusion: </strong>Patients undergoing HN free flap reconstruction benefit from postoperative antibiotic prophylaxis in a clean-contaminated field; 24 hours of prophylaxis may be sufficient in preventing postoperative SSI when compared to prolonged courses.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152804--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S157",
      "content_id": "152770",
      "abstract_number": "S157",
      "poster_number": "",
      "title": "The AHNS Updated Classification for Neck Dissection: A Notation Method Compatible with Synoptic Documentation",
      "summary": "To present an updated classification system for neck dissection endorsed by the American Head and Neck Society (AHNS) which incorporates a synoptic reporting methodology.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152770",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ciaran Lane",
      "presenter": "Ciaran Lane",
      "authors": "Ciaran Lane 1 ; Miriam N Lango 2 ; David Cognetti 3 ; John A Ridge 4 ; John R de Almeida 5 ; Brendan C Stack, Jr 6 ; Vivian Wu 7 ; Melissa M Chen 2 ; Alexandra Kejner 8 ; Caitlin McMullen 9 ; Adam Garden 2 ; Luc Morris 10 ; Diana Bell 11 ; Mirabelle Sajisevi 12 ; William Ryan 13 ; Ranee Mehra 14 ; Julia Noel 15 ; Louise Davies 16 ; K Thomas Robbins 17",
      "normalized_authors": [
        "Ciaran Lane",
        "Miriam N Lango",
        "David Cognetti",
        "John A Ridge",
        "John R de Almeida",
        "Brendan C Stack, Jr",
        "Vivian Wu",
        "Melissa M Chen",
        "Alexandra Kejner",
        "Caitlin McMullen",
        "Adam Garden",
        "Luc Morris",
        "Diana Bell",
        "Mirabelle Sajisevi",
        "William Ryan",
        "Ranee Mehra",
        "Julia Noel",
        "Louise Davies",
        "K Thomas Robbins"
      ],
      "affiliations": [
        "University of Ottawa",
        "The University of Texas MD Anderson Cancer Center",
        "Thomas Jefferson University",
        "Fox Chase Cancer Center",
        "University of Toronto",
        "Southern Illinois University",
        "Pacific Neuroscience Institute",
        "Medical University of South Carolina",
        "Moffitt Cancer Center",
        "Memorial Sloan Kettering Cancer Center",
        "University of Pittsburgh",
        "University of Vermont",
        "University of California San Francisco",
        "University of Maryland",
        "Stanford University",
        "Dartmouth College",
        "Southern Illinois University (Emeritus)"
      ],
      "normalized_institutions": [
        "University of Ottawa",
        "The University of Texas MD Anderson Cancer Center",
        "Thomas Jefferson University",
        "Fox Chase Cancer Center",
        "University of Toronto",
        "Southern Illinois University",
        "Pacific Neuroscience Institute",
        "Medical University of South Carolina",
        "Moffitt Cancer Center",
        "Memorial Sloan Kettering Cancer Center",
        "University of Pittsburgh",
        "University of Vermont",
        "University of California San Francisco",
        "University of Maryland",
        "Stanford University",
        "Dartmouth College",
        "Southern Illinois University (Emeritus)"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 239,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Evidence Review",
        "Findings",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ciaran Lane 1 ; Miriam N Lango 2 ; David Cognetti 3 ; John A Ridge 4 ; John R de Almeida 5 ; Brendan C Stack, Jr 6 ; Vivian Wu 7 ; Melissa M Chen 2 ; Alexandra Kejner 8 ; Caitlin McMullen 9 ; Adam Garden 2 ; Luc Morris 10 ; Diana Bell 11 ; Mirabelle Sajisevi 12 ; William Ryan 13 ; Ranee Mehra 14 ; Julia Noel 15 ; Louise Davies 16 ; K Thomas Robbins 17",
        "Affiliations": "1 University of Ottawa; 2 The University of Texas MD Anderson Cancer Center; 3 Thomas Jefferson University; 4 Fox Chase Cancer Center; 5 University of Toronto; 6 Southern Illinois University; 7 Pacific Neuroscience Institute; 8 Medical University of South Carolina; 9 Moffitt Cancer Center; 10 Memorial Sloan Kettering Cancer Center; 11 University of Pittsburgh; 12 University of Vermont; 13 University of California San Francisco; 14 University of Maryland; 15 Stanford University; 16 Dartmouth College; 17 Southern Illinois University (Emeritus)",
        "Importance": "The original system of classification of neck dissection, published in 1991, was a foundational document. It established a universal language to transform fragmented, inconsistent practices into a systematic approach. Contemporary data and neck dissection practices necessitate an update to the previously described system to better support clinical care and research. .",
        "Objective": "To present an updated classification system for neck dissection endorsed by the American Head and Neck Society (AHNS) which incorporates a synoptic reporting methodology.",
        "Evidence Review": "Committee members were recruited from AHNS mucosal, salivary, endocrine, and cutaneous disease sections, as well as the disciplines of pathology, radiation oncology, medical oncology, and neuroradiology. The committee reviewed existing terminology and developed a refined system through structured virtual and in-person meetings from May 2024 to January 2025.",
        "Findings": "The updated classification eliminates terms such as “radical,” “modified radical,” and “selective,” replacing them with precise anatomical descriptions of resected nodal levels, adjunctive lymph nodes, and non-lymphatic structures. The system incorporates concepts from synoptic and sentinel lymph node biopsy reporting, and defines anatomic boundaries for lymph nodes. Operative documentation of extranodal extension and cranial nerve preservation improves quality assessment and data extraction.",
        "Conclusions and Relevance": "This updated classification method reflects current surgical practice and enhances the consistency of documentation and communication in head and neck cancer care. Adoption of this synoptic/annotated/encoded method is recommended for operative reporting to support multidisciplinary management of and research on head and neck lymph nodal disease.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The AHNS Updated Classification for Neck Dissection: A Notation Method Compatible with Synoptic Documentation</span>. <u>Ciaran Lane</u><sup>1</sup>; Miriam N Lango<sup>2</sup>; David Cognetti<sup>3</sup>; John A Ridge<sup>4</sup>; John R de Almeida<sup>5</sup>; Brendan C Stack, Jr<sup>6</sup>; Vivian Wu<sup>7</sup>; Melissa M Chen<sup>2</sup>; Alexandra Kejner<sup>8</sup>; Caitlin McMullen<sup>9</sup>; Adam Garden<sup>2</sup>; Luc Morris<sup>10</sup>; Diana Bell<sup>11</sup>; Mirabelle Sajisevi<sup>12</sup>; William Ryan<sup>13</sup>; Ranee Mehra<sup>14</sup>; Julia Noel<sup>15</sup>; Louise Davies<sup>16</sup>; K Thomas Robbins<sup>17</sup>. <sup>1</sup>University of Ottawa; <sup>2</sup>The University of Texas MD Anderson Cancer Center; <sup>3</sup>Thomas Jefferson University; <sup>4</sup>Fox Chase Cancer Center; <sup>5</sup>University of Toronto; <sup>6</sup>Southern Illinois University; <sup>7</sup>Pacific Neuroscience Institute; <sup>8</sup>Medical University of South Carolina; <sup>9</sup>Moffitt Cancer Center; <sup>10</sup>Memorial Sloan Kettering Cancer Center; <sup>11</sup>University of Pittsburgh; <sup>12</sup>University of Vermont; <sup>13</sup>University of California San Francisco; <sup>14</sup>University of Maryland; <sup>15</sup>Stanford University; <sup>16</sup>Dartmouth College; <sup>17</sup>Southern Illinois University (Emeritus)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>The original system of classification of neck dissection, published in 1991, was a foundational document. It established a universal language to transform fragmented, inconsistent practices into a systematic approach. Contemporary data and neck dissection practices necessitate an update to the previously described system to better support clinical care and research. . </p>\n\n<p><strong>Objective: </strong>To present an updated classification system for neck dissection endorsed by the American Head and Neck Society (AHNS) which incorporates a synoptic reporting methodology. </p>\n\n<p><strong>Evidence Review: </strong>Committee members were recruited from AHNS mucosal, salivary, endocrine, and cutaneous disease sections, as well as the disciplines of pathology, radiation oncology, medical oncology, and neuroradiology. The committee reviewed existing terminology and developed a refined system through structured virtual and in-person meetings from May 2024 to January 2025. </p>\n\n<p><strong>Findings: </strong>The updated classification eliminates terms such as “radical,” “modified radical,” and “selective,” replacing them with precise anatomical descriptions of resected nodal levels, adjunctive lymph nodes, and non-lymphatic structures. The system incorporates concepts from synoptic and sentinel lymph node biopsy reporting, and defines anatomic boundaries for lymph nodes. Operative documentation of extranodal extension and cranial nerve preservation improves quality assessment and data extraction. </p>\n\n<p><strong>Conclusions and Relevance: </strong>This updated classification method reflects current surgical practice and enhances the consistency of documentation and communication in head and neck cancer care. Adoption of this synoptic/annotated/encoded method is recommended for operative reporting to support multidisciplinary management of and research on head and neck lymph nodal disease. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152770--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S158",
      "content_id": "154484",
      "abstract_number": "S158",
      "poster_number": "",
      "title": "From Data to Decision: Establishing a National Benchmark and Complication Risk Calculator for Free-Flap Reconstruction in Head & Neck Cancer",
      "summary": "This comprehensive national benchmark analysis establishes evidence-based complication rates for free-flap reconstruction in patients suffering with head and neck cancer. Having identified comorbidity-driven risk factors fundamental to postoperative outcomes, we provide the framework for a dedicated complication risk calculator in this field. These tools have the potential to enhance preoperative patient...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154484",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anthony E Dipalma, BS",
      "presenter": "Anthony E Dipalma, BS",
      "authors": "Anthony E Dipalma, BS ; Amaan Rahman, BS; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew E Spector, MD",
      "normalized_authors": [
        "Anthony E Dipalma",
        "Amaan Rahman",
        "Joshua E Smith",
        "Steven B Chinn",
        "Kevin J Contrera",
        "Shaum J Sridharan",
        "Matthew E Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 451,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Anthony E Dipalma, BS ; Amaan Rahman, BS; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew E Spector, MD",
        "Affiliations": "University of Pittsburgh",
        "Introduction": "Free-flap reconstruction is a cornerstone of surgical management for head and neck cancer. Given its prevalence in practice, complication rates remain variable across institutions; though, no standardized national benchmark has been established for the most common outcomes of head and neck free-flap procedures. Additionally, there are few options for validated, comorbidity-driven risk calculators to gauge patient-specific risks when undergoing these reconstructions. The lack of access to these important metrics leaves surgeons with little standard for comparison of their individual outcomes and limits the ability to tailor quality improvement measures at their institutions. In this study, we integrate the largest meta-analytic synthesis to date of free-flap reconstruction outcomes with a comprehensive evaluation of patient comorbidities to establish national benchmarks and construct the foundation for an evidence-based complication risk calculator.",
        "Methods": "A systematic review and 18 single-proportion meta-analyses were conducted employing PRISMA guidelines. A comprehensive search of the PubMed database yielded a total of 3569 results. After the removal of duplicate articles and title and abstract screening, 144 articles underwent full-text analysis, with 126 ultimately meeting our inclusion criteria. Inclusion focused primarily on clinical data involving free-flap reconstruction procedures performed in the head and neck region, with a focus on surgical complication rates, OR take-backs, and rehospitalization rates. Exclusion criteria removed studies concentrated on outlier groups based on age and high-risk statuses.",
        "Results": "A total of 18 independent meta-analyses were conducted under a random effects model assessing postoperative complications of free-flap reconstruction in patients with head and neck cancer. Pooled incidence estimates demonstrated consistent national patterns. Across studies encompassing a total of 112,230 patients, the rates were: Overall complications 33%, partial flap failure 3%, full flap failure 4%, combined flap failures 5%, recipient site (RS) fistula 4%, RS dehiscence 6%, RS hematoma 4%, RS seroma 2%, RS infection 7%, acute OR take-back 10%, 30-day OR take-back 10%, 30-day readmission 11%, overall donor site (DS) morbidity 10%, DS dehiscence 2%, DS hematoma 1%, DS seroma 2%, DS infection 2%, DS tissue necrosis 4%. A parallel comorbidity extraction process identified key predictors associated with flap failure and complications, including age, BMI, smoking, alcohol use, hypertension, diabetes, cardiovascular disease, liver disease, and COPD. Model-derived weights and risk functions were used to develop the preliminary structure of a complication risk calculator capable of providing patient-specific estimates for major outcomes.",
        "Conclusion": "This comprehensive national benchmark analysis establishes evidence-based complication rates for free-flap reconstruction in patients suffering with head and neck cancer. Having identified comorbidity-driven risk factors fundamental to postoperative outcomes, we provide the framework for a dedicated complication risk calculator in this field. These tools have the potential to enhance preoperative patient counseling, guide surgical planning, and support quality improvement efforts across institutions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>From Data to Decision: Establishing a National Benchmark and Complication Risk Calculator for Free-Flap Reconstruction in Head & Neck Cancer</span>. <u>Anthony E Dipalma, BS</u>; Amaan Rahman, BS; Joshua E Smith, MD; Steven B Chinn, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew E Spector, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Free-flap reconstruction is a cornerstone of surgical management for head and neck cancer. Given its prevalence in practice, complication rates remain variable across institutions; though, no standardized national benchmark has been established for the most common outcomes of head and neck free-flap procedures. Additionally, there are few options for validated, comorbidity-driven risk calculators to gauge patient-specific risks when undergoing these reconstructions. The lack of access to these important metrics leaves surgeons with little standard for comparison of their individual outcomes and limits the ability to tailor quality improvement measures at their institutions. In this study, we integrate the largest meta-analytic synthesis to date of free-flap reconstruction outcomes with a comprehensive evaluation of patient comorbidities to establish national benchmarks and construct the foundation for an evidence-based complication risk calculator.</p>\n\n<p><strong>Methods:</strong> A systematic review and 18 single-proportion meta-analyses were conducted employing PRISMA guidelines. A comprehensive search of the PubMed database yielded a total of 3569 results. After the removal of duplicate articles and title and abstract screening, 144 articles underwent full-text analysis, with 126 ultimately meeting our inclusion criteria. Inclusion focused primarily on clinical data involving free-flap reconstruction procedures performed in the head and neck region, with a focus on surgical complication rates, OR take-backs, and rehospitalization rates. Exclusion criteria removed studies concentrated on outlier groups based on age and high-risk statuses.</p>\n\n<p><strong>Results: </strong>A total of 18 independent meta-analyses were conducted under a random effects model assessing postoperative complications of free-flap reconstruction in patients with head and neck cancer. Pooled incidence estimates demonstrated consistent national patterns. Across studies encompassing a total of 112,230 patients, the rates were: Overall complications 33%, partial flap failure 3%, full flap failure 4%, combined flap failures 5%, recipient site (RS) fistula 4%, RS dehiscence 6%, RS hematoma 4%, RS seroma 2%, RS infection 7%, acute OR take-back 10%, 30-day OR take-back 10%, 30-day readmission 11%, overall donor site (DS) morbidity 10%,  DS dehiscence 2%, DS hematoma 1%, DS seroma 2%, DS infection 2%, DS tissue necrosis 4%. A parallel comorbidity extraction process identified key predictors associated with flap failure and complications, including age, BMI, smoking, alcohol use, hypertension, diabetes, cardiovascular disease, liver disease, and COPD. Model-derived weights and risk functions were used to develop the preliminary structure of a complication risk calculator capable of providing patient-specific estimates for major outcomes.</p>\n\n<p><strong>Conclusion: </strong>This comprehensive national benchmark analysis establishes evidence-based complication rates for free-flap reconstruction in patients suffering with head and neck cancer. Having identified comorbidity-driven risk factors fundamental to postoperative outcomes, we provide the framework for a dedicated complication risk calculator in this field. These tools have the potential to enhance preoperative patient counseling, guide surgical planning, and support quality improvement efforts across institutions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154484--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S159",
      "content_id": "152889",
      "abstract_number": "S159",
      "poster_number": "",
      "title": "Association Between Facility Case Volume and Patient Travel Distance on Survival in Laryngeal Squamous Cell Carcinoma",
      "summary": "We identify a facility case volume threshold at 10 cases/year for laryngeal SCC care, with progressive benefit from higher volumes. Travel distance does paradoxically independently provide survival benefit but only in advanced-stage disease. This may reflect patient selection rather than travel burden.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152889",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eric Y Du, MD, MPH",
      "presenter": "Eric Y Du, MD, MPH",
      "authors": "Eric Y Du, MD, MPH ; Derek S Mann, MD; Patrick T Tassone, MD, MS",
      "normalized_authors": [
        "Eric Y Du",
        "Derek S Mann",
        "Patrick T Tassone"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152889/AHNS%20abstract.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/152889/AHNS%20abstract.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152889"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Eric Y Du, MD, MPH ; Derek S Mann, MD; Patrick T Tassone, MD, MS",
        "Affiliations": "Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine",
        "Background": "Laryngeal squamous cell carcinoma (SCC) treatment requires specialized expertise and multidisciplinary coordination. While high-volume facilities with these resources demonstrate superior outcomes, increasing travel burden as a barrier to care may result in poorer outcomes. We aim to characterize the relationship of facility case volume and patient travel distance on survival in laryngeal SCC.",
        "Methods": "The National Cancer Database (NCDB) was queried to identify adults with laryngeal SCC definitively treated between 2004-2022. Primary exposures were annual facility case volume and patient travel distance (miles between their residence and the treating facility). The primary outcome was overall survival (OS). Risk-adjusted restricted cubic splines (RCS) were used to model OS by the primary exposures to identify and model non-linear relationships and inflection points. OS then was analyzed using multivariable adjusted Cox proportional hazards regression with facility-clustered standard errors. Models were stratified by treatment modality, subsite, AJCC stage, and T stage. Survival at 2 and 5 years were estimated using baseline cumulative hazard.",
        "Results": "Among 106,700 eligible patients (78.6% male, mean age 64.5 years), median follow up was 61 months with an OS of 46.6%. Median (IQR) facility case volume and travel distance was 13 (7-25) cases and 10.5 (4.5-25.4) miles, respectively. Adjusted RCS models identified a log-linear relationship between both volume and travel distance, with a sharp inflection point identified for case volume at 10 cases.",
        "Abstract": "Comparison of hazard ratios for overall survival predicted by three models for facility case volume: simple log-linear (green solid line), log-linear spline with knot at 10 cases (red dashed line), and restricted cubic splines with 4 knots (blue long-dashed line). Below the 10-case threshold, case volume had no effect on survival (hazards ratio (HR) 1.00 [95% CI: 0.97-1.03]), whereas above 10 cases, each doubling of volume was associated with 11% mortality reduction (HR 0.89 [0.84-0.94]). Each doubling of travel distance was associated with 3% mortality reduction (HR 0.97 [0.96-0.99]); however, associations were isolated in advanced-stage (III/IV) disease (HR 0.96 [0.94-0.97]; vs. HR 1.00 [0.98-1.02] in stage I/II). T-stage stratification yielded identical patterns, confirming tumor burden as the primary driver, without other notable differences in stratified analyses. There was no significant volume-distance interaction (HR 1.01 [0.99, 1.03]) indicating independent, additive effects. Translating to survival estimates, doubling median case volume demonstrates 2-year and 5-year OS benefits of 2.5% (85.1% vs. 87.6%) and 3.2% (70.3% vs. 73.5%) in stage I, and 6.7% (60.8% vs. 67.5%) and 7.7% (37.5% vs. 45.2%) in stage III/IV disease. Doubling median travel distance has OS benefits of 2.0% (60.8% vs. 62.8%) and 2.1% (37.5% vs. 39.6%) in stage III/IV disease. View in Agenda and Add to Schedule",
        "Conclusions": "We identify a facility case volume threshold at 10 cases/year for laryngeal SCC care, with progressive benefit from higher volumes. Travel distance does paradoxically independently provide survival benefit but only in advanced-stage disease. This may reflect patient selection rather than travel burden."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association Between Facility Case Volume and Patient Travel Distance on Survival in Laryngeal Squamous Cell Carcinoma</span>. <u>Eric Y Du, MD, MPH</u>; Derek S Mann, MD; Patrick T Tassone, MD, MS. Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Laryngeal squamous cell carcinoma (SCC) treatment requires specialized expertise and multidisciplinary coordination. While high-volume facilities with these resources demonstrate superior outcomes, increasing travel burden as a barrier to care may result in poorer outcomes. We aim to characterize the relationship of facility case volume and patient travel distance on survival in laryngeal SCC.</p>\n\n<p><strong>Methods: </strong>The National Cancer Database (NCDB) was queried to identify adults with laryngeal SCC definitively treated between 2004-2022. Primary exposures were annual facility case volume and patient travel distance (miles between their residence and the treating facility). The primary outcome was overall survival (OS). Risk-adjusted restricted cubic splines (RCS) were used to model OS by the primary exposures to identify and model non-linear relationships and inflection points. OS then was analyzed using multivariable adjusted Cox proportional hazards regression with facility-clustered standard errors. Models were stratified by treatment modality, subsite, AJCC stage, and T stage. Survival at 2 and 5 years were estimated using baseline cumulative hazard.</p>\n\n<p><strong>Results: </strong>Among 106,700 eligible patients (78.6% male, mean age 64.5 years), median follow up was 61 months with an OS of 46.6%. Median (IQR) facility case volume and travel distance was 13 (7-25) cases and 10.5 (4.5-25.4) miles, respectively. Adjusted RCS models identified a log-linear relationship between both volume and travel distance, with a sharp inflection point identified for case volume at 10 cases.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152889/AHNS%20abstract.jpg' /></p>\n\n<p>Comparison of hazard ratios for overall survival predicted by three models for facility case volume: simple log-linear (green solid line), log-linear spline with knot at 10 cases (red dashed line), and restricted cubic splines with 4 knots (blue long-dashed line).</p>\n\n<p>Below the 10-case threshold, case volume had no effect on survival (hazards ratio (HR) 1.00 [95% CI: 0.97-1.03]), whereas above 10 cases, each doubling of volume was associated with 11% mortality reduction (HR 0.89 [0.84-0.94]). Each doubling of travel distance was associated with 3% mortality reduction (HR 0.97 [0.96-0.99]); however, associations were isolated in advanced-stage (III/IV) disease (HR 0.96 [0.94-0.97]; vs. HR 1.00 [0.98-1.02] in stage I/II). T-stage stratification yielded identical patterns, confirming tumor burden as the primary driver, without other notable differences in stratified analyses. There was no significant volume-distance interaction (HR 1.01 [0.99, 1.03]) indicating independent, additive effects.  Translating to survival estimates, doubling median case volume demonstrates 2-year and 5-year OS benefits of 2.5% (85.1% vs. 87.6%) and 3.2% (70.3% vs. 73.5%) in stage I, and 6.7% (60.8% vs. 67.5%) and 7.7% (37.5% vs. 45.2%) in stage III/IV disease. Doubling median travel distance has OS benefits of 2.0% (60.8% vs. 62.8%) and 2.1% (37.5% vs. 39.6%) in stage III/IV disease.</p>\n\n<p><strong>Conclusions: </strong>We identify a facility case volume threshold at 10 cases/year for laryngeal SCC care, with progressive benefit from higher volumes. Travel distance does paradoxically independently provide survival benefit but only in advanced-stage disease. This may reflect patient selection rather than travel burden.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152889--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S160",
      "content_id": "154003",
      "abstract_number": "S160",
      "poster_number": "",
      "title": "Post-Operative Emesis and Development of Pharyngocutaneous Fistulae in Total Laryngectomy Patients",
      "summary": "Post-operative emesis is not significantly associated with the development of PCF. This study does not support the routine use of scheduled anti-emetics for the purposes of PCF prevention and instead continued use of as needed therapy is encouraged. While this is the largest study to date evaluating the association between postoperative vomiting and PCF formation, a larger cohort is necessary to conduct...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154003",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Grayson Buning, BS",
      "presenter": "Grayson Buning, BS",
      "authors": "Grayson Buning, BS ; Aayush Unadkat, BS; Noe Francois-Saint-Cyr, BS; Jayden R Garcia, MD; Andrew Prince, MD; Kelly M Maloy, MD, MBA; Pratyusha Yalamanchi, MD, MBA; Marisa R Buchakjian, MD, PhD; Scott McLean, MD, PhD; Mark E.P. Prince, MD; Keith A Casper, MD; Andrew G Shuman, MD; Chaz L Stucken, MD; Molly E Heft Neal, MD; David WA Forner, MD, MSc",
      "normalized_authors": [
        "Grayson Buning",
        "Aayush Unadkat",
        "Noe Francois-Saint-Cyr",
        "Jayden R Garcia",
        "Andrew Prince",
        "Kelly M Maloy",
        "Pratyusha Yalamanchi",
        "Marisa R Buchakjian",
        "Scott McLean",
        "Mark E.P. Prince",
        "Keith A Casper",
        "Andrew G Shuman",
        "Chaz L Stucken",
        "Molly E Heft Neal",
        "David WA Forner"
      ],
      "affiliations": [
        "University of Michigan Medical School"
      ],
      "normalized_institutions": [
        "University of Michigan Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Grayson Buning, BS ; Aayush Unadkat, BS; Noe Francois-Saint-Cyr, BS; Jayden R Garcia, MD; Andrew Prince, MD; Kelly M Maloy, MD, MBA; Pratyusha Yalamanchi, MD, MBA; Marisa R Buchakjian, MD, PhD; Scott McLean, MD, PhD; Mark E.P. Prince, MD; Keith A Casper, MD; Andrew G Shuman, MD; Chaz L Stucken, MD; Molly E Heft Neal, MD; David WA Forner, MD, MSc",
        "Affiliations": "University of Michigan Medical School",
        "Background": "Pharyngocutaneous fistulae (PCF) are common and morbid post-operative complications after total laryngectomy (TL). While post-operative emesis is a frequent occurrence after general anesthetic, its association with PCF has not been well characterized. Given the physiologic possibility that emesis could stress pharyngeal closures, it is important to investigate whether this may translate into an elevated risk of PCF development.",
        "Objective": "To evaluate the association between post-operative emesis and the development of PCF in patients undergoing TL.",
        "Methods": "This was a retrospective cohort study of patients undergoing primary, salvage, or functional total laryngectomy at a single tertiary academic center from 2014 to 2025. Demographic and perioperative details were abstracted. The exposure of interest was post-operative emesis. The primary outcome was the development of postoperative PCF. Primary analyses compared categorical post-operative emesis status using Fisher’s exact tests. Additional regression analyses were conducted using Firth’s Logistic Regression to evaluate the impact of emesis frequency on the likelihood of PCF development.",
        "Results": "We identified 31 patients who met inclusion criteria and experienced postoperative emesis within 3 weeks after TL. To create a balanced comparison group, we randomly selected 30 inclusion-eligible patients who did not experience postoperative emesis. Mean age was 64.4 years and 77% were male. Most patients (64%) had stage 3 or 4 disease at time of TL. Neck dissection was performed in 78.7% of patients. The majority of patients (70.5%) underwent free tissue transfer, with overlay flaps being the most common reconstruction utilized; only 4 and 6 patients received tubed and inlay patch pharyngeal reconstructions respectively. Nearly all patients had postoperative anti-nausea medications ordered on an as-needed basis versus scheduled (86.4% vs. 13.6%). Mean time to emesis was 4.2 days (range: 0-21 days). PCF occurred within 1 month postoperatively in 24.6% of patients, with a mean time to identification of 15.1 days (range: 6-29 days).",
        "Abstract": "The rate of postoperative PCF did not differ between patients who experienced emesis and those who did not (25.8% vs 23.3%). Fisher’s exact test showed no significant association between emesis with 3 weeks postoperatively and eventual PCF (OR = 1.14, 95% CI 0.30–4.38) or between emesis within 1 week postoperatively and eventual PCF (OR = 0.43, 95% CI 0.11-1.39). Examining the frequency of vomiting as a continuous predictor of PCF development using Firth logistic regression also identified no significant association (OR = 0.96, 95% CI 0.54-1.55). View in Agenda and Add to Schedule",
        "Conclusion": "Post-operative emesis is not significantly associated with the development of PCF. This study does not support the routine use of scheduled anti-emetics for the purposes of PCF prevention and instead continued use of as needed therapy is encouraged. While this is the largest study to date evaluating the association between postoperative vomiting and PCF formation, a larger cohort is necessary to conduct sufficiently powered analyses of the effect of post-operative emesis on likelihood of PCF development."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Post-Operative Emesis and Development of Pharyngocutaneous Fistulae in Total Laryngectomy Patients</span>. <u>Grayson Buning, BS</u>; Aayush Unadkat, BS; Noe Francois-Saint-Cyr, BS; Jayden R Garcia, MD; Andrew Prince, MD; Kelly M Maloy, MD, MBA; Pratyusha Yalamanchi, MD, MBA; Marisa R Buchakjian, MD, PhD; Scott McLean, MD, PhD; Mark E.P. Prince, MD; Keith A Casper, MD; Andrew G Shuman, MD; Chaz L Stucken, MD; Molly E Heft Neal, MD; David WA Forner, MD, MSc. University of Michigan Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pharyngocutaneous fistulae (PCF) are common and morbid post-operative complications after total laryngectomy (TL). While post-operative emesis is a frequent occurrence after general anesthetic, its association with PCF has not been well characterized. Given the physiologic possibility that emesis could stress pharyngeal closures, it is important to investigate whether this may translate into an elevated risk of PCF development.</p>\n\n<p><strong>Objective: </strong>To evaluate the association between post-operative emesis and the development of PCF in patients undergoing TL.</p>\n\n<p><strong>Methods: </strong>This was a retrospective cohort study of patients undergoing primary, salvage, or functional total laryngectomy at a single tertiary academic center from 2014 to 2025. Demographic and perioperative details were abstracted. The exposure of interest was post-operative emesis. The primary outcome was the development of postoperative PCF. Primary analyses compared categorical post-operative emesis status using Fisher’s exact tests. Additional regression analyses were conducted using Firth’s Logistic Regression to evaluate the impact of emesis frequency on the likelihood of PCF development.</p>\n\n<p><strong>Results: </strong>We identified 31 patients who met inclusion criteria and experienced postoperative emesis within 3 weeks after TL. To create a balanced comparison group, we randomly selected 30 inclusion-eligible patients who did not experience postoperative emesis. Mean age was 64.4 years and 77% were male. Most patients (64%) had stage 3 or 4 disease at time of TL. Neck dissection was performed in 78.7% of patients. The majority of patients (70.5%) underwent free tissue transfer, with overlay flaps being the most common reconstruction utilized; only 4 and 6 patients received tubed and inlay patch pharyngeal reconstructions respectively. Nearly all patients had postoperative anti-nausea medications ordered on an as-needed basis versus scheduled (86.4% vs. 13.6%). Mean time to emesis was 4.2 days (range: 0-21 days). PCF occurred within 1 month postoperatively in 24.6% of patients, with a mean time to identification of 15.1 days (range: 6-29 days).</p>\n\n<p>The rate of postoperative PCF did not differ between patients who experienced emesis and those who did not (25.8% vs 23.3%). Fisher’s exact test showed no significant association between emesis with 3 weeks postoperatively and eventual PCF (OR = 1.14, 95% CI 0.30–4.38) or between emesis within 1 week postoperatively and eventual PCF (OR = 0.43, 95% CI 0.11-1.39). Examining the frequency of vomiting as a continuous predictor of PCF development using Firth logistic regression also identified no significant association (OR = 0.96, 95% CI 0.54-1.55).</p>\n\n<p><strong>Conclusion: </strong>Post-operative emesis is not significantly associated with the development of PCF. This study does not support the routine use of scheduled anti-emetics for the purposes of PCF prevention and instead continued use of as needed therapy is encouraged. While this is the largest study to date evaluating the association between postoperative vomiting and PCF formation, a larger cohort is necessary to conduct sufficiently powered analyses of the effect of post-operative emesis on likelihood of PCF development.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154003--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S161",
      "content_id": "153334",
      "abstract_number": "S161",
      "poster_number": "",
      "title": "Shifting Trends in Vasopressor and Intravenous Fluid Use for Oral Cavity Cancer Free Flap Reconstruction: Mortality, Flap Complications, and Medical Outcomes",
      "summary": "High intraoperative fluid volume was associated with increased 30-day mortality and medical complications. The increase in vasopressor usage post-2014 was not associated with adverse outcomes. This study supports current practices favouring vasopressor use instead of high fluid administration to maintain hemodynamic stability during oral cavity cancer free flap reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153334",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Harrison Gao, MSc, BSc",
      "presenter": "Harrison Gao, MSc, BSc",
      "authors": "Harrison Gao, MSc, BSc ; Nuwan Dharmawardana, BMBS, FRACS, PhD, MClinSci, MSc; John R de Almeida, MD, FRCSC, MSc; David P Goldstein, MD, FRCSC, MSc; Ralph W Gilbert, MD, FRCSC; Jonathan C Irish, MD, FRCSC, FACS, FCAHS, MSc; Dale H Brown, MB, BCh, BAO, FRCSC; Christopher M Yao, MD, FRCSC; Christopher W Noel, MD, FRCSC, PhD; Sharon Tzelnick, MD, MPH",
      "normalized_authors": [
        "Harrison Gao",
        "Nuwan Dharmawardana, BMBS, FRACS, MClinSci",
        "John R de Almeida, FRCSC",
        "David P Goldstein, FRCSC",
        "Ralph W Gilbert, FRCSC",
        "Jonathan C Irish, FRCSC, FCAHS",
        "Dale H Brown, MB, BCh, BAO, FRCSC",
        "Christopher M Yao, FRCSC",
        "Christopher W Noel, FRCSC",
        "Sharon Tzelnick"
      ],
      "affiliations": [
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University of Toronto"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 352,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Harrison Gao, MSc, BSc ; Nuwan Dharmawardana, BMBS, FRACS, PhD, MClinSci, MSc; John R de Almeida, MD, FRCSC, MSc; David P Goldstein, MD, FRCSC, MSc; Ralph W Gilbert, MD, FRCSC; Jonathan C Irish, MD, FRCSC, FACS, FCAHS, MSc; Dale H Brown, MB, BCh, BAO, FRCSC; Christopher M Yao, MD, FRCSC; Christopher W Noel, MD, FRCSC, PhD; Sharon Tzelnick, MD, MPH",
        "Affiliations": "University of Toronto",
        "Introduction": "Vasopressors and intravenous fluid resuscitation are commonly used to prevent intraoperative hypotension during oral cavity cancer free flap reconstruction. Recent evidence suggests that vasopressor use is safe despite previous fears of pedicle vasoconstriction and flap ischemia. This study evaluated mortality, flap complications, and medical outcomes associated with shifting trends in hemodynamic management over an 11-year period.",
        "Methods": "A retrospective cohort study (n = 826) was conducted on oral cavity cancer free flap reconstruction patients at two academic hospitals in Toronto, ON, Canada from 2008 to 2019. Changepoint detection was performed using binomial regression models assessed with Akaike Information Criterion to evaluate vasopressor trends. Multivariable Cox regression models, logistic regression models, and receiver operating characteristic curves were used to assess outcomes. Primary predictors were intraoperative vasopressor use and fluid volume. Other covariates included age, sex, BMI, Charlson Comorbidity Index, disease stage, smoking history, and alcohol history. Outcomes were 30-day and 5-year survival, flap complications, and medical complications.",
        "Results": "In this cohort (n = 826), the overall 30-day survival rate was 98.9%, 5-year survival was 71.1%, flap complication rate was 3.9%, and perioperative medical complication rate (all cardiac, respiratory, or neurological complications) was 22.5%. The changepoint for vasopressor use was 2014, with usage increasing from 68.3% pre-2014 to 84.0% of patients post-2014. However, increased vasopressor use was not associated with mortality, flap complications, or medical complications. In contrast, higher intraoperative fluid volume was associated with increased 30-day mortality (HR 1.73 per 1 L increase, 95% CI 1.01–2.96, p = 0.046) and medical complications (OR 1.38 per 1 L increase, 95% CI 1.22–1.55, p < 0.001) but not flap complications. Fluid volume also demonstrated good discriminative ability for 30-day mortality (AUC 0.80, 95% CI 0.67–0.93).",
        "Conclusion": "High intraoperative fluid volume was associated with increased 30-day mortality and medical complications. The increase in vasopressor usage post-2014 was not associated with adverse outcomes. This study supports current practices favouring vasopressor use instead of high fluid administration to maintain hemodynamic stability during oral cavity cancer free flap reconstruction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Shifting Trends in Vasopressor and Intravenous Fluid Use for Oral Cavity Cancer Free Flap Reconstruction: Mortality, Flap Complications, and Medical Outcomes</span>. <u>Harrison Gao, MSc, BSc</u>; Nuwan Dharmawardana, BMBS, FRACS, PhD, MClinSci, MSc; John R de Almeida, MD, FRCSC, MSc; David P Goldstein, MD, FRCSC, MSc; Ralph W Gilbert, MD, FRCSC; Jonathan C Irish, MD, FRCSC, FACS, FCAHS, MSc; Dale H Brown, MB, BCh, BAO, FRCSC; Christopher M Yao, MD, FRCSC; Christopher W Noel, MD, FRCSC, PhD; Sharon Tzelnick, MD, MPH. University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Vasopressors and intravenous fluid resuscitation are commonly used to prevent intraoperative hypotension during oral cavity cancer free flap reconstruction. Recent evidence suggests that vasopressor use is safe despite previous fears of pedicle vasoconstriction and flap ischemia. This study evaluated mortality, flap complications, and medical outcomes associated with shifting trends in hemodynamic management over an 11-year period.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study (n = 826) was conducted on oral cavity cancer free flap reconstruction patients at two academic hospitals in Toronto, ON, Canada from 2008 to 2019. Changepoint detection was performed using binomial regression models assessed with Akaike Information Criterion to evaluate vasopressor trends. Multivariable Cox regression models, logistic regression models, and receiver operating characteristic curves were used to assess outcomes. Primary predictors were intraoperative vasopressor use and fluid volume. Other covariates included age, sex, BMI, Charlson Comorbidity Index, disease stage, smoking history, and alcohol history. Outcomes were 30-day and 5-year survival, flap complications, and medical complications.</p>\n\n<p><strong>Results: </strong>In this cohort (n = 826), the overall 30-day survival rate was 98.9%, 5-year survival was 71.1%, flap complication rate was 3.9%, and perioperative medical complication rate (all cardiac, respiratory, or neurological complications) was 22.5%. The changepoint for vasopressor use was 2014, with usage increasing from 68.3% pre-2014 to 84.0% of patients post-2014. However, increased vasopressor use was not associated with mortality, flap complications, or medical complications. In contrast, higher intraoperative fluid volume was associated with increased 30-day mortality (HR 1.73 per 1 L increase, 95% CI 1.01–2.96, p = 0.046) and medical complications (OR 1.38 per 1 L increase, 95% CI 1.22–1.55, p < 0.001) but not flap complications. Fluid volume also demonstrated good discriminative ability for 30-day mortality (AUC 0.80, 95% CI 0.67–0.93).</p>\n\n<p><strong>Conclusion: </strong>High intraoperative fluid volume was associated with increased 30-day mortality and medical complications. The increase in vasopressor usage post-2014 was not associated with adverse outcomes. This study supports current practices favouring vasopressor use instead of high fluid administration to maintain hemodynamic stability during oral cavity cancer free flap reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153334--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S162",
      "content_id": "153719",
      "abstract_number": "S162",
      "poster_number": "",
      "title": "Enhanced Recovery After Surgery in Transoral Robotic Surgery and Its Impact on Early Clinical Outcomes",
      "summary": "Implementation of an ERAS pathway in transoral robotic surgery was associated with shorter hospitalization, earlier initiation of oral intake, and improved diet tolerance at discharge without increasing postoperative complications. These findings support the safety and clinical value of structured recovery pathways in optimizing perioperative outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153719",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexander Moise, MDCM",
      "presenter": "Alexander Moise, MDCM",
      "authors": "Alexander Moise, MDCM 1 ; Joel Howlett, MD, FRCSC 1 ; Amanda Ting 2 ; Tayo Steininger 2 ; Harman Parhar, MD, FRCSC, MPH 1 ; Eitan Prisman, MD, FRCSC 1",
      "normalized_authors": [
        "Alexander Moise, MDCM",
        "Joel Howlett, FRCSC",
        "Amanda Ting",
        "Tayo Steininger",
        "Harman Parhar, FRCSC",
        "Eitan Prisman, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology Head and Neck Surgery, University of British Columbia, Vancouver, BC",
        "Faculty of Medicine, University of British Columbia, Vancouver, BC"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology Head and Neck Surgery, University of British Columbia, Vancouver, BC",
        "Faculty of Medicine, University of British Columbia, Vancouver, BC"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153719/Table_3_AHNS.JPG",
          "source_url": "https://www.submitmyabstract.com/abs/images/153719/Table_3_AHNS.JPG",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153719"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 484,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alexander Moise, MDCM 1 ; Joel Howlett, MD, FRCSC 1 ; Amanda Ting 2 ; Tayo Steininger 2 ; Harman Parhar, MD, FRCSC, MPH 1 ; Eitan Prisman, MD, FRCSC 1",
        "Affiliations": "1 Division of Otolaryngology Head and Neck Surgery, University of British Columbia, Vancouver, BC; 2 Faculty of Medicine, University of British Columbia, Vancouver, BC",
        "Background": "Enhanced Recovery After Surgery (ERAS) pathways aim to optimize perioperative care. In transoral robotic surgery, there has been limited application of ERA, where most published reports focus narrowly on pain control. Broader recovery metrics such as length of hospital stay, diet advancement, and early oral intake patterns remain underreported. This study evaluated the impact of ERAS pathway implementation on postoperative recovery milestones, opioid use, and early safety outcomes.",
        "Methods": "A retrospective cohort study was performed on patients who underwent transoral robotic surgery for oropharyngeal lesions before and after implementation of an ERAS pathway. Demographic and clinical variables included age, sex, smoking exposure, alcohol use, tumor site category, cT and cN classification, p16 status, and Charlson Comorbidity Index. Postoperative outcomes included length of stay, postoperative day of oral intake initiation, total opioid consumption expressed in morphine-equivalent dose, diet at discharge (solid, modified, or tube feeding), and presence of a tracheostomy, gastrostomy tube, or nasogastric tube at discharge. Safety outcomes included reintubation, return to the operating room for bleeding, pharyngocutaneous fistula formation, discharge disposition, and 30-day mortality.",
        "Abstract": "Patients with prior head and neck cancer surgery or radiation were excluded, as were free flap reconstructions and prophylactic tracheostomies. To reduce confounding, a 2:1 nearest-neighbor propensity score match without replacement was performed using age, sex, pack-years, alcohol exposure, tumor site, cT classification, cN classification, p16 status, and comorbidity index. Continuous variables were compared with Wilcoxon rank-sum tests and categorical variables with Fisher’s exact tests, with significance defined as p < 0.05. Length of stay was significantly reduced after pathway implementation, with median values decreasing from 5 days (IQR 1) to 3 days (IQR 2) (p = 6.1 × 10?5). Initiation of oral intake demonstrated a significantly different distribution favoring earlier feeding in the pathway cohort (p = 0.0036), with more patients starting on postoperative day 0 and fewer experiencing delayed initiation. Diet at discharge improved substantially, with a higher proportion of patients tolerating a solid oral diet in the pathway cohort (p = 0.003). Total postoperative opioid consumption did not differ significantly (median 40.6 mg vs 26.6 mg morphine-equivalent, p = 0.596), although a visible trend toward lower requirements was observed in the pathway group. Safety outcomes were comparable between cohorts with no significant differences in tracheostomy or feeding-tube dependence, reintubation, bleeding requiring operative management, pharyngocutaneous fistula formation, discharge to a facility, or mortality (all p > 0.20). View in Agenda and Add to Schedule",
        "Results": "A total of 167 patients were analyzed, comprising 124 pre and 43 post-ERAS patients before matching and 86 pre and 43 post-ERAS after matching. Baseline demographic and disease characteristics were well balanced across all covariates.",
        "Conclusion": "Implementation of an ERAS pathway in transoral robotic surgery was associated with shorter hospitalization, earlier initiation of oral intake, and improved diet tolerance at discharge without increasing postoperative complications. These findings support the safety and clinical value of structured recovery pathways in optimizing perioperative outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Enhanced Recovery After Surgery in Transoral Robotic Surgery and Its Impact on Early Clinical Outcomes</span>. <u>Alexander Moise, MDCM</u><sup>1</sup>; Joel Howlett, MD, FRCSC<sup>1</sup>; Amanda Ting<sup>2</sup>; Tayo Steininger<sup>2</sup>; Harman Parhar, MD, FRCSC, MPH<sup>1</sup>; Eitan Prisman, MD, FRCSC<sup>1</sup>. <sup>1</sup>Division of Otolaryngology Head and Neck Surgery, University of British Columbia, Vancouver, BC; <sup>2</sup>Faculty of Medicine, University of British Columbia, Vancouver, BC<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Enhanced Recovery After Surgery (ERAS) pathways aim to optimize perioperative care.  In transoral robotic surgery, there has been limited application of ERA, where most published reports focus narrowly on pain control. Broader recovery metrics such as length of hospital stay, diet advancement, and early oral intake patterns remain underreported. This study evaluated the impact of ERAS pathway implementation on postoperative recovery milestones, opioid use, and early safety outcomes.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed on patients who underwent transoral robotic surgery for oropharyngeal lesions before and after implementation of an ERAS pathway. Demographic and clinical variables included age, sex, smoking exposure, alcohol use, tumor site category, cT and cN classification, p16 status, and Charlson Comorbidity Index. Postoperative outcomes included length of stay, postoperative day of oral intake initiation, total opioid consumption expressed in morphine-equivalent dose, diet at discharge (solid, modified, or tube feeding), and presence of a tracheostomy, gastrostomy tube, or nasogastric tube at discharge. Safety outcomes included reintubation, return to the operating room for bleeding, pharyngocutaneous fistula formation, discharge disposition, and 30-day mortality.</p>\n\n<p>Patients with prior head and neck cancer surgery or radiation were excluded, as were free flap reconstructions and prophylactic tracheostomies. To reduce confounding, a 2:1 nearest-neighbor propensity score match without replacement was performed using age, sex, pack-years, alcohol exposure, tumor site, cT classification, cN classification, p16 status, and comorbidity index. Continuous variables were compared with Wilcoxon rank-sum tests and categorical variables with Fisher’s exact tests, with significance defined as p < 0.05.</p>\n\n<p><strong>Results: </strong>A total of 167 patients were analyzed, comprising 124 pre and 43 post-ERAS patients before matching and 86 pre and 43 post-ERAS after matching. Baseline demographic and disease characteristics were well balanced across all covariates.</p>\n\n<p>Length of stay was significantly reduced after pathway implementation, with median values decreasing from 5 days (IQR 1) to 3 days (IQR 2) (p = 6.1 × 10?5). Initiation of oral intake demonstrated a significantly different distribution favoring earlier feeding in the pathway cohort (p = 0.0036), with more patients starting on postoperative day 0 and fewer experiencing delayed initiation. Diet at discharge improved substantially, with a higher proportion of patients tolerating a solid oral diet in the pathway cohort (p = 0.003).</p>\n\n<p>Total postoperative opioid consumption did not differ significantly (median 40.6 mg vs 26.6 mg morphine-equivalent, p = 0.596), although a visible trend toward lower requirements was observed in the pathway group. Safety outcomes were comparable between cohorts with no significant differences in tracheostomy or feeding-tube dependence, reintubation, bleeding requiring operative management, pharyngocutaneous fistula formation, discharge to a facility, or mortality (all p > 0.20).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153719/Table_3_AHNS.JPG' /></p>\n\n<p><strong>Conclusion: </strong>Implementation of an ERAS pathway in transoral robotic surgery was associated with shorter hospitalization, earlier initiation of oral intake, and improved diet tolerance at discharge without increasing postoperative complications. These findings support the safety and clinical value of structured recovery pathways in optimizing perioperative outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153719--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S163",
      "content_id": "153225",
      "abstract_number": "S163",
      "poster_number": "",
      "title": "Predictors of 6-month mortality in head and neck patients undergoing free flap surgery: a multi-center study",
      "summary": "Six-month mortality is influenced by patient comorbidities, pre-operative, intra-operative and post-operative risk factors. The data presented here can be used to help counsel patients and families in the perioperative period as well as aid in anticipating patient specific needs.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153225",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maria Lugo-Fagundo, MD, MPH",
      "presenter": "Maria Lugo-Fagundo, MD, MPH",
      "authors": "Maria Lugo-Fagundo, MD, MPH 1 ; Sallie Long, MD 2 ; Larissa Sweeny, MD 1 ; Madeline Pyle, MD 1 ; Mark Wax, MD 3 ; Joseph Curry, MD 4 ; Carissa Thomas, MD 5 ; Dev Amin, MD 4 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 3 ; Dina Modlin, BS 7 ; Jason Leibowitz, MD 1 ; Michael DiLeo, MD 6 ; Nicolaus Knight, MS 5 ; Elise Krippaehne 8 ; Javier Nishikawa, MD 9 ; Yasaman Baghshomali, PhD 10 ; Madeline Otto 3 ; Sruti Tekumalla, BA 4 ; Sumanth Chandrupatla 5",
      "normalized_authors": [
        "Maria Lugo-Fagundo",
        "Sallie Long",
        "Larissa Sweeny",
        "Madeline Pyle",
        "Mark Wax",
        "Joseph Curry",
        "Carissa Thomas",
        "Dev Amin",
        "Caroline Bonaventure",
        "Farshid Taghizadeh",
        "Dina Modlin",
        "Jason Leibowitz",
        "Michael DiLeo",
        "Nicolaus Knight",
        "Elise Krippaehne",
        "Javier Nishikawa",
        "Yasaman Baghshomali",
        "Madeline Otto",
        "Sruti Tekumalla",
        "Sumanth Chandrupatla"
      ],
      "affiliations": [
        "University of Miami/Jackson Memorial Hospital",
        "Medical College of Georgia",
        "Oregon Health and Science University",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Louisiana State University Health Science Center",
        "New York Medical College",
        "Western University of Health Sciences",
        "University of Maryland",
        "University of Colorado"
      ],
      "normalized_institutions": [
        "University of Miami/Jackson Memorial Hospital",
        "Medical College of Georgia",
        "Oregon Health and Science University",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Louisiana State University Health Science Center",
        "New York Medical College",
        "Western University of Health Sciences",
        "University of Maryland",
        "University of Colorado"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153225/Table%201(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153225/Table%201(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153225"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%202.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153225"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%203.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%203.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153225"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%204(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153225/table%201%20page%204(1).jpg",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153225"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 573,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Maria Lugo-Fagundo, MD, MPH 1 ; Sallie Long, MD 2 ; Larissa Sweeny, MD 1 ; Madeline Pyle, MD 1 ; Mark Wax, MD 3 ; Joseph Curry, MD 4 ; Carissa Thomas, MD 5 ; Dev Amin, MD 4 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 3 ; Dina Modlin, BS 7 ; Jason Leibowitz, MD 1 ; Michael DiLeo, MD 6 ; Nicolaus Knight, MS 5 ; Elise Krippaehne 8 ; Javier Nishikawa, MD 9 ; Yasaman Baghshomali, PhD 10 ; Madeline Otto 3 ; Sruti Tekumalla, BA 4 ; Sumanth Chandrupatla 5",
        "Affiliations": "1 University of Miami/Jackson Memorial Hospital; 2 Medical College of Georgia; 3 Oregon Health and Science University; 4 Thomas Jefferson University; 5 University of Alabama at Birmingham; 6 Louisiana State University Health Science Center; 7 New York Medical College; 8 Western University of Health Sciences; 9 University of Maryland; 10 University of Colorado",
        "Introduction": "Free flap (FF) tissue transfer in head and neck (HN) has become increasingly popular and is considered the gold standard for reconstruction of large HN defects. The perioperative care is complex, and patients often suffer from complications. Studies have shown that certain patient factors such as age, previous head and neck surgery, advanced cancer stage, American Society of Anesthesiologists (ASA) classification, body mass index, and inflammatory markers are associated with poor long-term morbidity and mortality. There are limited studies investigating the risk factors for early death after HN surgery with FF reconstruction.",
        "Objectives": "To determine predictors of 6-month mortality in patients undergoing free flap surgery in the head and neck.",
        "Methods": "A multi-institutional retrospective chart review of patients undergoing HN FF reconstruction was performed (n=2,778). Patient-related factors, as well as perioperative, intraoperative and post-operative data were collected. The relationships between 6-month mortality and several covariates were examined via correlation and significance tests to determine possible predictors.",
        "Results": "Six-month mortality was 5% (n=142). Age >80 was associated with a greater probability of 6 months mortality (χ 2 =4.047, p<0.05). The majority of non survivors had advanced T stage (n=95; 83%) oral cavity cancer (n=58; 41%). Pre-operative comorbidities associated with higher rates of 6-month mortality included: history of cardiac disease (OR 2, 95% CI 1.3-2.9), functional dependency (n=64, 3%), hypertension requiring medications (OR 2, 95% CI 1.1-2.2), deep venous thromboembolism (OR 3, 95% CI 1.6-6.8), thromboembolism (OR 3, 95% CI 1.4-4.7), chronic obstructive pulmonary disease (OR 2, 95% CI 1.1-2.6), pneumonia (OR 2, 95% CI 1.1-3.7), dementia (OR 3, 95% CI 1.1-7.5), peripheral vascular disease (OR 2, 95% CI 1-3.3), renal disease (OR 2, 95% CI 1.1-3.4), dialysis (OR 6, 95% CI 1.5-20.8) and complications from diabetes (OR 2, 95% CI 1.1-3.3). Operative duration of >10 hours (OR 1.36, 95% CI 0.96-1.92) and post-op admission to stepdown (3.35% vs 2%, p<0.0001) was more frequent among patients who died within 6 months (p<0.05). Post-operative complications associated with higher rates of 6-month mortality included return to the operating room within 30 days (OR 3, 95% CI 1.8-3.5), salivary leak or fistula (OR 2, 95% CI 1.3-3.7), hematoma (OR 2, 95% CI 1.1-3.4), wound dehiscence (OR 2, 95% CI 1.5-3.3), wound infection (OR 1.5, 95% CI 1-2.2), pulmonary complication (OR 4, 95% CI 2.5-7.2), cardiac complication (OR 2.8, 95% CI 1.6-5), stroke or CVA (OR 5, 95% CI 2.2-9.2), and sepsis (OR 7, 95% CI 4-12.1). Thirty-day readmission (OR 9, 95% CI 6.40-12.90) (p<0.0001) and discharge to rehabilitation or skilled-nursing facility (OR 2.12, 95% CI 1.44-3.13) (p<0.05) had higher risk of 6-month mortality. Patients with Clavien-Dindo stage IV complications (OR 5, 95% CI 1.60-15.15, p<0.05) and with elevated TSH levels (mean difference 3.49, 95% CI 0.1-7, p<0.05) were associated with increased 6-month mortality.",
        "Conclusions": "Six-month mortality is influenced by patient comorbidities, pre-operative, intra-operative and post-operative risk factors. The data presented here can be used to help counsel patients and families in the perioperative period as well as aid in anticipating patient specific needs.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predictors of 6-month mortality in head and neck patients undergoing free flap surgery: a multi-center study</span>. <u>Maria Lugo-Fagundo, MD, MPH</u><sup>1</sup>; Sallie Long, MD<sup>2</sup>; Larissa Sweeny, MD<sup>1</sup>; Madeline Pyle, MD<sup>1</sup>; Mark Wax, MD<sup>3</sup>; Joseph Curry, MD<sup>4</sup>; Carissa Thomas, MD<sup>5</sup>; Dev Amin, MD<sup>4</sup>; Caroline Bonaventure, MD<sup>6</sup>; Farshid Taghizadeh, MD<sup>3</sup>; Dina Modlin, BS<sup>7</sup>; Jason Leibowitz, MD<sup>1</sup>; Michael DiLeo, MD<sup>6</sup>; Nicolaus Knight, MS<sup>5</sup>; Elise Krippaehne<sup>8</sup>; Javier Nishikawa, MD<sup>9</sup>; Yasaman Baghshomali, PhD<sup>10</sup>; Madeline Otto<sup>3</sup>; Sruti Tekumalla, BA<sup>4</sup>; Sumanth Chandrupatla<sup>5</sup>. <sup>1</sup>University of Miami/Jackson Memorial Hospital; <sup>2</sup>Medical College of Georgia; <sup>3</sup>Oregon Health and Science University; <sup>4</sup>Thomas Jefferson University; <sup>5</sup>University of Alabama at Birmingham; <sup>6</sup>Louisiana State University Health Science Center; <sup>7</sup>New York Medical College; <sup>8</sup>Western University of Health Sciences; <sup>9</sup>University of Maryland; <sup>10</sup>University of Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Free flap (FF) tissue transfer in head and neck (HN) has become increasingly popular and is considered the gold standard for reconstruction of large HN defects. The perioperative care is complex, and patients often suffer from complications. Studies have shown that certain patient factors such as age, previous head and neck surgery, advanced cancer stage, American Society of Anesthesiologists (ASA) classification, body mass index, and inflammatory markers are associated with poor long-term morbidity and mortality.  There are limited studies investigating the risk factors for early death after HN surgery with FF reconstruction.</p>\n\n<p><strong>Objectives: </strong>To determine predictors of 6-month mortality in patients undergoing free flap surgery in the head and neck.</p>\n\n<p><strong>Methods: </strong>A multi-institutional retrospective chart review of patients undergoing HN FF reconstruction was performed (n=2,778). Patient-related factors, as well as perioperative, intraoperative and post-operative data were collected. The relationships between 6-month mortality and several covariates were examined via correlation and significance tests to determine possible predictors.</p>\n\n<p><strong>Results:</strong> Six-month mortality was 5% (n=142). Age >80 was associated with a greater probability of 6 months mortality (χ<sup>2</sup>=4.047, p<0.05). The majority of non survivors had advanced T stage (n=95; 83%) oral cavity cancer (n=58; 41%). Pre-operative comorbidities associated with higher rates of 6-month mortality included: history of cardiac disease (OR 2, 95% CI 1.3-2.9), functional dependency (n=64, 3%), hypertension requiring medications (OR 2, 95% CI 1.1-2.2), deep venous thromboembolism (OR 3, 95% CI 1.6-6.8), thromboembolism (OR 3, 95% CI 1.4-4.7), chronic obstructive pulmonary disease (OR 2, 95% CI 1.1-2.6), pneumonia (OR 2, 95% CI 1.1-3.7), dementia (OR 3, 95% CI 1.1-7.5), peripheral vascular disease (OR 2, 95% CI 1-3.3), renal disease (OR 2, 95% CI 1.1-3.4), dialysis (OR 6, 95% CI 1.5-20.8) and complications from diabetes (OR 2, 95% CI 1.1-3.3). Operative duration of >10 hours (OR 1.36, 95% CI 0.96-1.92) and post-op admission to stepdown (3.35% vs 2%, p<0.0001) was more frequent among patients who died within 6 months (p<0.05). Post-operative complications associated with higher rates of 6-month mortality included return to the operating room within 30 days (OR 3, 95% CI 1.8-3.5), salivary leak or fistula (OR 2, 95% CI 1.3-3.7), hematoma (OR 2, 95% CI 1.1-3.4), wound dehiscence (OR 2, 95% CI 1.5-3.3), wound infection (OR 1.5, 95% CI 1-2.2), pulmonary complication (OR 4, 95% CI 2.5-7.2), cardiac complication (OR 2.8, 95% CI 1.6-5), stroke or CVA (OR 5, 95% CI 2.2-9.2), and sepsis (OR 7, 95% CI 4-12.1). Thirty-day readmission (OR 9, 95% CI 6.40-12.90) (p<0.0001) and discharge to rehabilitation or skilled-nursing facility (OR 2.12, 95% CI 1.44-3.13) (p<0.05) had higher risk of 6-month mortality. Patients with Clavien-Dindo stage IV complications (OR 5, 95% CI 1.60-15.15, p<0.05) and with elevated TSH levels (mean difference 3.49, 95% CI 0.1-7, p<0.05) were associated with increased 6-month mortality.</p>\n\n<p><strong>Conclusions:</strong> Six-month mortality is influenced by patient comorbidities, pre-operative, intra-operative and post-operative risk factors. The data presented here can be used to help counsel patients and families in the perioperative period as well as aid in anticipating patient specific needs.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153225/Table%201(2).jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153225/table%201%20page%202.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153225/table%201%20page%203.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153225/table%201%20page%204(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153225--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S164",
      "content_id": "152914",
      "abstract_number": "S164",
      "poster_number": "",
      "title": "Thirty-Day Readmission After Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma and Its Impact on Time to Adjuvant Therapy",
      "summary": "Transoral robotic surgery (TORS) is widely used for oropharyngeal squamous cell carcinoma (OPSCC) and offers favorable oncologic and functional outcomes. However, postoperative readmissions may increase morbidity, escalate health care utilization, and delay adjuvant therapy. This study aims to evaluate 30-day readmission rates following TORS for OPSCC and identify factors contributing to readmission. This study...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152914",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kim B Le",
      "presenter": "Kim B Le",
      "authors": "Kim B Le ; Keshav V Shah, BS; Kerol Faltas, BA; Nicole Farber, MD; Dante Merlino, MD, PhD; Karthik Rajasekaran, MD; Devraj Basu, MD, PhD; Gregory Farwell, MD; Gregory S Weinstein; Robert Brody, MD; Ryan M Carey, MD",
      "normalized_authors": [
        "Kim B Le",
        "Keshav V Shah",
        "Kerol Faltas",
        "Nicole Farber",
        "Dante Merlino",
        "Karthik Rajasekaran",
        "Devraj Basu",
        "Gregory Farwell",
        "Gregory S Weinstein",
        "Robert Brody",
        "Ryan M Carey"
      ],
      "affiliations": [
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 429,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kim B Le ; Keshav V Shah, BS; Kerol Faltas, BA; Nicole Farber, MD; Dante Merlino, MD, PhD; Karthik Rajasekaran, MD; Devraj Basu, MD, PhD; Gregory Farwell, MD; Gregory S Weinstein; Robert Brody, MD; Ryan M Carey, MD",
        "Affiliations": "University of Pennsylvania",
        "Abstract": "Transoral robotic surgery (TORS) is widely used for oropharyngeal squamous cell carcinoma (OPSCC) and offers favorable oncologic and functional outcomes. However, postoperative readmissions may increase morbidity, escalate health care utilization, and delay adjuvant therapy. This study aims to evaluate 30-day readmission rates following TORS for OPSCC and identify factors contributing to readmission. This study is a retrospective case-control analysis of patients who underwent primary TORS with or without free flap reconstruction for p16+ OPSCC between January 2007 and December 2020 at a single tertiary academic medical center. Electronic medical records were reviewed for relevant demographics, disease characteristics, extent of surgery, tumor and pathological staging, readmission status, and adjuvant therapy. Analysis incorporated descriptive characteristics and univariate logistic regression. A total of 1,060 patients met inclusion criteria (age 60.2±8.8 years; 924 [87.2%] males). The mean duration of index hospitalization was 4.8±4.2 days. In this cohort, 15.7% of patients (n=166) were readmitted within 30 days postoperatively, with an average readmission length of 3.5±6.0 days. The most common reasons for readmission included bleeding (n=76), nasogastric tube complications (n=25), and infection (n=19). Free flap reconstruction (OR 1.517 [1.017, 2.262]; 0.041), positive margin status (OR 1.191 [1.052, 1.348]; 0.006), overall tumor staging (OR 1.570 [1.074, 2.271]; 0.018), and complications during the index admission (OR 6.889 [4.377, 10.843]; <0.001) were associated with increased likelihood of readmission. Age, sex, race, staged neck dissection, primary tumor location, smoking status, initial length of stay, Charlson Comorbidity Index, and prior chemoradiation were not significantly associated with readmission. The average time to adjuvant therapy was 59.4±21.5 days in the non-readmitted cohort compared with 68.0±25.8 days among readmitted patients (mean difference 8.6 days, p=<0.001). While the study includes two distinct patient cohorts, with the initial length of stay varying between patients based on free flap status, readmission in the thirty-day window is a non-negligible outcome following TORS for OPSCC. Thirty-day readmission following TORS for OPSCC occurred in approximately 1 in 6 patients, most often due to bleeding. Both pathological and perioperative factors were associated with increased readmission risk. Identifying these high-risk features may support targeted perioperative strategies to reduce readmission burden and limit delays in adjuvant therapy, ultimately helping optimize oncologic and functional outcomes following TORS. Future research including more recent cohorts may further refine risk stratification to enhance patient counseling and surgical management. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thirty-Day Readmission After Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma and Its Impact on Time to Adjuvant Therapy</span>. <u>Kim B Le</u>; Keshav V Shah, BS; Kerol Faltas, BA; Nicole Farber, MD; Dante Merlino, MD, PhD; Karthik Rajasekaran, MD; Devraj Basu, MD, PhD; Gregory Farwell, MD; Gregory S Weinstein; Robert Brody, MD; Ryan M Carey, MD. University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Transoral robotic surgery (TORS) is widely used for oropharyngeal squamous cell carcinoma (OPSCC) and offers favorable oncologic and functional outcomes. However, postoperative readmissions may increase morbidity, escalate health care utilization, and delay adjuvant therapy. This study aims to evaluate 30-day readmission rates following TORS for OPSCC and identify factors contributing to readmission.</p>\n\n<p>This study is a retrospective case-control analysis of patients who underwent primary TORS with or without free flap reconstruction for p16+ OPSCC between January 2007 and December 2020 at a single tertiary academic medical center. Electronic medical records were reviewed for relevant demographics, disease characteristics, extent of surgery, tumor and pathological staging, readmission status, and adjuvant therapy. Analysis incorporated descriptive characteristics and univariate logistic regression.</p>\n\n<p>A total of 1,060 patients met inclusion criteria (age 60.2±8.8 years; 924 [87.2%] males). The mean duration of index hospitalization was 4.8±4.2 days. In this cohort, 15.7% of patients (n=166) were readmitted within 30 days postoperatively, with an average readmission length of 3.5±6.0 days. The most common reasons for readmission included bleeding (n=76), nasogastric tube complications (n=25), and infection (n=19). Free flap reconstruction (OR 1.517 [1.017, 2.262]; 0.041), positive margin status (OR 1.191 [1.052, 1.348]; 0.006), overall tumor staging (OR 1.570 [1.074, 2.271]; 0.018), and complications during the index admission (OR 6.889 [4.377, 10.843]; <0.001) were associated with increased likelihood of readmission. Age, sex, race, staged neck dissection, primary tumor location, smoking status, initial length of stay, Charlson Comorbidity Index, and prior chemoradiation were not significantly associated with readmission. The average time to adjuvant therapy was 59.4±21.5 days in the non-readmitted cohort compared with 68.0±25.8 days among readmitted patients (mean difference 8.6 days, p=<0.001).</p>\n\n<p>While the study includes two distinct patient cohorts, with the initial length of stay varying between patients based on free flap status, readmission in the thirty-day window is a non-negligible outcome following TORS for OPSCC. Thirty-day readmission following TORS for OPSCC occurred in approximately 1 in 6 patients, most often due to bleeding. Both pathological and perioperative factors were associated with increased readmission risk. Identifying these high-risk features may support targeted perioperative strategies to reduce readmission burden and limit delays in adjuvant therapy, ultimately helping optimize oncologic and functional outcomes following TORS. Future research including more recent cohorts may further refine risk stratification to enhance patient counseling and surgical management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152914--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S165",
      "content_id": "154232",
      "abstract_number": "S165",
      "poster_number": "",
      "title": "Impact of Surgical Quality Indicators on Survival in Patients with Oral Cavity Squamous Cell Carcinoma: A Retrospective Cohort Analysis from a High-Volume Cancer Center in Brazil",
      "summary": "In this single center cohort, adjuvant therapy indicators, especially appropriate referral for radiotherapy and chemoradiotherapy, were the strongest predictors of survival. Margins showed coherent but statistically nonsignificant trend. Lymph node yield and radiotherapy timing could not be reliably assessed. The findings highlight the importance of evidence-based adjuvant care and the critical need to improve...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154232",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "João Ricardo Signoretti Alexandre",
      "presenter": "João Ricardo Signoretti Alexandre",
      "authors": "João Ricardo Signoretti Alexandre 1 ; Fabio Albuquerque Marchi, PhD 2 ; Leandro L Matos 1 ; Luiz Paulo Kowalski, PhD 1",
      "normalized_authors": [
        "João Ricardo Signoretti Alexandre",
        "Fabio Albuquerque Marchi",
        "Leandro L Matos",
        "Luiz Paulo Kowalski"
      ],
      "affiliations": [
        "Faculty of Medicine of the University of São Paulo (FMUSP)",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "normalized_institutions": [
        "Faculty of Medicine of the University of São Paulo (FMUSP)",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "João Ricardo Signoretti Alexandre 1 ; Fabio Albuquerque Marchi, PhD 2 ; Leandro L Matos 1 ; Luiz Paulo Kowalski, PhD 1",
        "Affiliations": "1 Faculty of Medicine of the University of São Paulo (FMUSP); 2 Instituto do Câncer do Estado de São Paulo",
        "Background": "Surgical quality indicators are key determinants of postoperative outcomes and long-term survival in head and neck cancer. Well established metrics include negative margins, adequate lymph node yield, timely adjuvant therapy, and guideline-concordant treatment are well established. This study evaluates the impact of these indicators on survival in patients with oral cavity squamous cell carcinoma treated at a high-volume cancer center in Brazil.",
        "Methods": "A retrospective cohort study was performed including patients undergoing radical surgical treatment for oral cavity squamous cell carcinoma between 2002 and 2022. Of more than 900 consecutively treated patients, 472 met eligibility criteria. For analyses requiring standardized neck dissection, exclusion of 10 cases managed without formal dissection resulted in 462 patients with uniform cervical lymphadenectomy. Clinical, pathological, therapeutic, and outcome variables, including surgical margins, lymph node yield, referral for adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), and timing of adjuvant therapy initiation were analyzed. Survival was assessed using Kaplan Meier estimates and Cox proportional hazards models adjusted for age and sex. Discriminative performance was evaluated using logistic regression with ROC and time dependent ROC curves.",
        "Results": "The cohort was predominantly male (76%) with a median age of 59 years. Margins were compromised in 18% of patients, while lymph node yield was adequate (≥18 nodes) in 96.3%. RT was indicated in 73.5% of stage III–IV patients, CRT in 41% of those with extracapsular extension or positive margins, and only 1.5% initiated RT within 6 weeks. Lymph node yield: No significant association with overall survival (OS) or disease-specific survival (DSS) was observed. The HR for overall survival was 0.775 (p=0.430), with poor discriminative performance (AUC approximately 0.50). The extremely small subgroup with <18-nodes subgroup (n=17) likely limited detection of any prognostic effect. Surgical margins: Positive margins showed a consistent trend toward worse OS and DSS (median OS: 38 vs. 59 months), although this was not statistically significant after adjustment (OS HR=1.09; DSS HR=1.24). Adjuvant radiotherapy (stage III–IV): Appropriate RT referral was strongly associated with improved survival. Adjusted HR for OS was 0.319 (p<0.0001) and 0.451 (p<0.0001) for DSS demonstrating the best discriminative performance among all indicators. Adjuvant chemoradiotherapy (ECS or positive margins): Guideline concordant CRT improved OS (adjusted HR=0.685; p=0.0185). Trends for DSS favored CRT but lacked statistical significance. Timeliness of adjuvant RT: Only five patients started treatment within six weeks, and the extreme group imbalance prevented meaningful analysis. Composite quality indicator: Adherence across five quality metrics showed no significant association with OS or DSS. Interpretation was limited because only one patient met 100% of criteria, severely restricting meaningful contrast between groups.",
        "Conclusion": "In this single center cohort, adjuvant therapy indicators, especially appropriate referral for radiotherapy and chemoradiotherapy, were the strongest predictors of survival. Margins showed coherent but statistically nonsignificant trend. Lymph node yield and radiotherapy timing could not be reliably assessed. The findings highlight the importance of evidence-based adjuvant care and the critical need to improve access to timely adjuvant treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Surgical Quality Indicators on Survival in Patients with Oral Cavity Squamous Cell Carcinoma: A Retrospective Cohort Analysis from a High-Volume Cancer Center in Brazil</span>. <u>João Ricardo Signoretti Alexandre</u><sup>1</sup>; Fabio Albuquerque Marchi, PhD<sup>2</sup>; Leandro L Matos<sup>1</sup>; Luiz Paulo Kowalski, PhD<sup>1</sup>. <sup>1</sup>Faculty of Medicine of the University of São Paulo (FMUSP); <sup>2</sup>Instituto do Câncer do Estado de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Surgical quality indicators are key determinants of postoperative outcomes and long-term survival in head and neck cancer. Well established metrics include negative margins, adequate lymph node yield, timely adjuvant therapy, and guideline-concordant treatment are well established. This study evaluates the impact of these indicators on survival in patients with oral cavity squamous cell carcinoma treated at a high-volume cancer center in Brazil.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort study was performed including patients undergoing radical surgical treatment for oral cavity squamous cell carcinoma between 2002 and 2022. Of more than 900 consecutively treated patients, 472 met eligibility criteria. For analyses requiring standardized neck dissection, exclusion of 10 cases managed without formal dissection resulted in 462 patients with uniform cervical lymphadenectomy. Clinical, pathological, therapeutic, and outcome variables, including surgical margins, lymph node yield, referral for adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), and timing of adjuvant therapy initiation were analyzed. Survival was assessed using Kaplan Meier estimates and Cox proportional hazards models adjusted for age and sex. Discriminative performance was evaluated using logistic regression with ROC and time dependent ROC curves.</p>\n\n<p><strong>Results:</strong> The cohort was predominantly male (76%) with a median age of 59 years. Margins were compromised in 18% of patients, while lymph node yield was adequate (≥18 nodes) in 96.3%. RT was indicated in 73.5% of stage III–IV patients, CRT in 41% of those with extracapsular extension or positive margins, and only 1.5% initiated RT within 6 weeks. Lymph node yield: No significant association with overall survival (OS) or disease-specific survival (DSS) was observed. The HR for overall survival was 0.775 (p=0.430), with poor discriminative performance (AUC approximately 0.50). The extremely small subgroup with <18-nodes subgroup (n=17) likely limited detection of any prognostic effect. Surgical margins: Positive margins showed a consistent trend toward worse OS and DSS (median OS: 38 vs. 59 months), although this was not statistically significant after adjustment (OS HR=1.09; DSS HR=1.24). Adjuvant radiotherapy (stage III–IV): Appropriate RT referral was strongly associated with improved survival. Adjusted HR for OS was 0.319 (p<0.0001) and 0.451 (p<0.0001) for DSS demonstrating the best discriminative performance among all indicators. Adjuvant chemoradiotherapy (ECS or positive margins): Guideline concordant CRT improved OS (adjusted HR=0.685; p=0.0185). Trends for DSS favored CRT but lacked statistical significance. Timeliness of adjuvant RT: Only five patients started treatment within six weeks, and the extreme group imbalance prevented meaningful analysis. Composite quality indicator: Adherence across five quality metrics showed no significant association with OS or DSS. Interpretation was limited because only one patient met 100% of criteria, severely restricting meaningful contrast between groups.</p>\n\n<p><strong>Conclusion:</strong> In this single center cohort, adjuvant therapy indicators, especially appropriate referral for radiotherapy and chemoradiotherapy, were the strongest predictors of survival. Margins showed coherent but statistically nonsignificant trend. Lymph node yield and radiotherapy timing could not be reliably assessed. The findings highlight the importance of evidence-based adjuvant care and the critical need to improve access to timely adjuvant treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154232--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S166",
      "content_id": "150242",
      "abstract_number": "S166",
      "poster_number": "",
      "title": "Impact of an Institutional Quality Improvement Project to Minimize Delays to Adjuvant Treatment in Head and Neck Cancer",
      "summary": "Multidisciplinary engagement and expediated referrals to dentists and radiation oncologists were extremely successful in the initiation of adjuvant treatment within 6 weeks among a cohort of comparatively high-risk patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=150242",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260126",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mina Eskandar, BA",
      "presenter": "Mina Eskandar, BA",
      "authors": "Mina Eskandar, BA 1 ; Mina A Beshy, BA 2 ; Missak Haigentz, MD 3 ; Malini Patel, MD 3 ; Sivraj Muralikrishnan, MD 3 ; Taha A Mur, MD 2 ; Imraan Jan, MD 4 ; Sung Kim, MD 4 ; Craig A Bollig, MD 2",
      "normalized_authors": [
        "Mina Eskandar",
        "Mina A Beshy",
        "Missak Haigentz",
        "Malini Patel",
        "Sivraj Muralikrishnan",
        "Taha A Mur",
        "Imraan Jan",
        "Sung Kim",
        "Craig A Bollig"
      ],
      "affiliations": [
        "Rutgers School of Graduate Studies",
        "Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences",
        "Rutgers Cancer Institute of New Jersey - Department of Medical Oncology",
        "Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology"
      ],
      "normalized_institutions": [
        "Rutgers School of Graduate Studies",
        "Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences",
        "Rutgers Cancer Institute of New Jersey - Department of Medical Oncology",
        "Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 258,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mina Eskandar, BA 1 ; Mina A Beshy, BA 2 ; Missak Haigentz, MD 3 ; Malini Patel, MD 3 ; Sivraj Muralikrishnan, MD 3 ; Taha A Mur, MD 2 ; Imraan Jan, MD 4 ; Sung Kim, MD 4 ; Craig A Bollig, MD 2",
        "Affiliations": "1 Rutgers School of Graduate Studies; 2 Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences; 3 Rutgers Cancer Institute of New Jersey - Department of Medical Oncology; 4 Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology",
        "Objective": "Initiating post-operative radiation therapy within 6 weeks of surgery for patients with head and neck cancer has become a national benchmark. Delays beyond this are associated with increased mortality. We developed an institutional quality improvement initiative centered around expeditious dental and radiation oncology referrals for high-risk patients and aim to assess the frequency of patients that started radiation therapy by 6 weeks after surgery who received preoperative or inpatient evaluation by our dental and/or radiation oncology teams.",
        "Study Design": "Retrospective cohort study",
        "Setting": "Tertiary care academic medical center.",
        "Methods": "Patient demographics and cancer characteristics were recorded in patients with head and neck cancer who received a preoperative or inpatient evaluation by a radiation oncologist and/or dentist from 2021-2025. The time from surgery to start of radiation therapy was recorded.",
        "Results": "60 patients received either pre-operative or inpatient radiation oncology (n=45, 75.0%) or dental consults (n=43, 71.7%). Their median hospital stay was 11 days (range 1-57 days) and 14 (23.0%) experienced a postoperative complication. Six (10%) were re-admitted within 30 days. Overall, 55 (91.7%) patients started radiation therapy by week 6 including 44 (97.8%) and 38 (88.4%) patients that received expedited radiation oncology and dental evaluations. Of the 43 patients that received radiation therapy by an institutional radiation oncologist, 42 (97.7%) started adjuvant treatment by 6 weeks.",
        "Conclusion": "Multidisciplinary engagement and expediated referrals to dentists and radiation oncologists were extremely successful in the initiation of adjuvant treatment within 6 weeks among a cohort of comparatively high-risk patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of an Institutional Quality Improvement Project to Minimize Delays to Adjuvant Treatment in Head and Neck Cancer</span>. <u>Mina Eskandar, BA</u><sup>1</sup>; Mina A Beshy, BA<sup>2</sup>; Missak Haigentz, MD<sup>3</sup>; Malini Patel, MD<sup>3</sup>; Sivraj Muralikrishnan, MD<sup>3</sup>; Taha A Mur, MD<sup>2</sup>; Imraan Jan, MD<sup>4</sup>; Sung Kim, MD<sup>4</sup>; Craig A Bollig, MD<sup>2</sup>. <sup>1</sup>Rutgers School of Graduate Studies; <sup>2</sup>Rutgers Robert Wood Johnson Medical School - Department of Head and Neck Surgery & Communication Sciences; <sup>3</sup>Rutgers Cancer Institute of New Jersey - Department of Medical Oncology; <sup>4</sup>Rutgers Cancer Institute of New Jersey - Department of Radiation Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong><strong> </strong>Initiating post-operative radiation therapy within 6 weeks of surgery for patients with head and neck cancer has become a national benchmark. Delays beyond this are associated with increased mortality. We developed an institutional quality improvement initiative centered around expeditious dental and radiation oncology referrals for high-risk patients and aim to assess the frequency of patients that started radiation therapy by 6 weeks after surgery who received preoperative or inpatient evaluation by our dental and/or radiation oncology teams.  </p>\n\n<p><strong>Study Design:</strong><strong> </strong>Retrospective cohort study </p>\n\n<p><strong>Setting:</strong><strong> </strong>Tertiary care academic medical center. </p>\n\n<p><strong>Methods:</strong><strong> </strong>Patient demographics and cancer characteristics were recorded in patients with head and neck cancer who received a preoperative or inpatient evaluation by a radiation oncologist and/or dentist from 2021-2025.  The time from surgery to start of radiation therapy was recorded.  </p>\n\n<p><strong>Results:</strong><strong> </strong>60 patients received either pre-operative or inpatient radiation oncology (n=45, 75.0%) or dental consults (n=43, 71.7%). Their median hospital stay was 11 days (range 1-57 days) and 14 (23.0%) experienced a postoperative complication. Six (10%) were re-admitted within 30 days. Overall, 55 (91.7%) patients started radiation therapy by week 6 including 44 (97.8%) and 38 (88.4%) patients that received expedited radiation oncology and dental evaluations. Of the 43 patients that received radiation therapy by an institutional radiation oncologist, 42 (97.7%) started adjuvant treatment by 6 weeks. </p>\n\n<p><strong>Conclusion:</strong> Multidisciplinary engagement and expediated referrals to dentists and radiation oncologists were extremely successful in the initiation of adjuvant treatment within 6 weeks among a cohort of comparatively high-risk patients.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 150242--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260126' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S167",
      "content_id": "154516",
      "abstract_number": "S167",
      "poster_number": "",
      "title": "Dysgeusia in Head and Neck Cancer Patients: Long-Term Outcomes",
      "summary": "HNC treatment results in chronic, multifaceted disturbances in oral somatosensory function. While some prior studies report the return of some taste after treatment, this study demonstrates that taste changes persist years after treatment of HNC. In fact, HNC patients have much more difficulty identifying certain tastes after treatment compared to the control population. These changes likely have long-term...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154516",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jacqueline Tucker, MD",
      "presenter": "Jacqueline Tucker, MD",
      "authors": "Jacqueline Tucker, MD 1 ; Hayes Stancliff, BS 2 ; Hanel Eberly, MD 3 ; Bao Sciscent, MD 4 ; Shouhao Zhou, PhD 5 ; Tiffany Heikel, PAC 6 ; Alissa A Nolden, PhD 7 ; John E Hayes, PhD 8 ; David Goldenberg 6 ; Neerav Goyal, MD, MPH, FACS 6",
      "normalized_authors": [
        "Jacqueline Tucker",
        "Hayes Stancliff",
        "Hanel Eberly",
        "Bao Sciscent",
        "Shouhao Zhou",
        "Tiffany Heikel, PAC",
        "Alissa A Nolden",
        "John E Hayes",
        "David Goldenberg",
        "Neerav Goyal"
      ],
      "affiliations": [
        "University of Minnesota, Department of Otolaryngology",
        "The Pennsylvania State University, College of Medicine",
        "Yale School of Medicine, Department of Otolaryngology",
        "University of Virginia, Department of Otolaryngology",
        "he Pennsylvania State University, Department of Public Health Sciences",
        "The Pennsylvania State University, Department of Otolaryngology",
        "University of Massachusetts",
        "The Pennsylvania State University"
      ],
      "normalized_institutions": [
        "University of Minnesota, Department of Otolaryngology",
        "The Pennsylvania State University, College of Medicine",
        "Yale School of Medicine, Department of Otolaryngology",
        "University of Virginia, Department of Otolaryngology",
        "he Pennsylvania State University, Department of Public Health Sciences",
        "The Pennsylvania State University, Department of Otolaryngology",
        "University of Massachusetts",
        "The Pennsylvania State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jacqueline Tucker, MD 1 ; Hayes Stancliff, BS 2 ; Hanel Eberly, MD 3 ; Bao Sciscent, MD 4 ; Shouhao Zhou, PhD 5 ; Tiffany Heikel, PAC 6 ; Alissa A Nolden, PhD 7 ; John E Hayes, PhD 8 ; David Goldenberg 6 ; Neerav Goyal, MD, MPH, FACS 6",
        "Affiliations": "1 University of Minnesota, Department of Otolaryngology; 2 The Pennsylvania State University, College of Medicine; 3 Yale School of Medicine, Department of Otolaryngology; 4 University of Virginia, Department of Otolaryngology; 5 he Pennsylvania State University, Department of Public Health Sciences; 6 The Pennsylvania State University, Department of Otolaryngology; 7 University of Massachusetts; 8 The Pennsylvania State University",
        "Introduction": "Taste changes are commonly reported after treatment of head and neck cancer (HNC), reported by over 70% of patients, respectively. Anecdotally, these complaints persist for years after treatment. There is a paucity of objective data on long-term chemosensory dysfunction, with most studies relying on subjective surveys and few assessing outcomes beyond two to three years. This study evaluates both long-term ( > 3 years after treatment) subjective and objective data and compares differences between HNC patients and a healthy control population.",
        "Methods": "This prospective cohort study included patients with a history of HNC treatment at least 3 years ago and age- and gender-matched healthy controls. Participants completed a questionnaire addressing taste and smell perceptions, their relationship with food, and food aversions. Following this subjective survey, participants completed objective taste and smell tests. Taste testing was performed using taste strips containing five taste qualities at four concentrations each, and tasting four different jellybean flavors. Data was analyzed using Wilcoxon-rank sum tests for quantitative variables and Fisher's exact p-values for categorical data, with significance defined as p<0.05. Mixed-effect logistic regression was utilized for the jellybean taste analysis.",
        "Results": "This study included a total of 112 participants: 65 with a history of HNC who had undergone treatment and 47 healthy controls. The majority of patients were treated with radiation (81.5%), followed by chemotherapy (56.9%), and/or surgery (63.1%). HNC patients were more likely to report that food does not taste as it should (p < 0.001) and specifically had difficulties with eating hot or spicy food (p = 0.0003), eating meat (p = 0.0096), reduced appetite (p = 0.0050), and were less likely to feel excitement about eating when traveling (p = 0.0308). When evaluating objective data, HNC patients had significantly lower overall taste test scores (4.8 vs 9.1, p < 0.05). Additionally, there were significant differences in each taste subcategory of sweet, salty, bitter, umami taste (p < 0.05). Interestingly, there was no significant difference in the sour category between groups (p = 0.37). When correctly identifying specific jelly bean flavors, the patient group had significantly reduced flavor detection, with an odds ratio (OR) of 0.19 (95% CI: 0.04-0.83, p = 0.0278), corresponding to 81% lower odds of correct identification than in the control group.",
        "Conclusion": "HNC treatment results in chronic, multifaceted disturbances in oral somatosensory function. While some prior studies report the return of some taste after treatment, this study demonstrates that taste changes persist years after treatment of HNC. In fact, HNC patients have much more difficulty identifying certain tastes after treatment compared to the control population. These changes likely have long-term impacts on nutrition and quality of life. Routine chemosensory assessment and targeted nutritional and psychosocial interventions should be integrated into survivorship care to mitigate these long-term burdens. Future efforts should investigate ways to mitigate taste dysfunction after HNC treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Dysgeusia in Head and Neck Cancer Patients: Long-Term Outcomes</span>. <u>Jacqueline Tucker, MD</u><sup>1</sup>; Hayes Stancliff, BS<sup>2</sup>; Hanel Eberly, MD<sup>3</sup>; Bao Sciscent, MD<sup>4</sup>; Shouhao Zhou, PhD<sup>5</sup>; Tiffany Heikel, PAC<sup>6</sup>; Alissa A Nolden, PhD<sup>7</sup>; John E Hayes, PhD<sup>8</sup>; David Goldenberg<sup>6</sup>; Neerav Goyal, MD, MPH, FACS<sup>6</sup>. <sup>1</sup>University of Minnesota, Department of Otolaryngology; <sup>2</sup>The Pennsylvania State University, College of Medicine; <sup>3</sup>Yale School of Medicine, Department of Otolaryngology; <sup>4</sup>University of Virginia, Department of Otolaryngology; <sup>5</sup>he Pennsylvania State University, Department of Public Health Sciences; <sup>6</sup>The Pennsylvania State University, Department of Otolaryngology; <sup>7</sup>University of Massachusetts; <sup>8</sup>The Pennsylvania State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Taste changes are commonly reported after treatment of head and neck cancer (HNC), reported by over 70% of patients, respectively. Anecdotally, these complaints persist for years after treatment. There is a paucity of objective data on long-term chemosensory dysfunction, with most studies relying on subjective surveys and few assessing outcomes beyond two to three years. This study evaluates both long-term ( > 3 years after treatment) subjective and objective data and compares differences between HNC patients and a healthy control population.</p>\n\n<p><strong>Methods: </strong>This prospective cohort study included patients with a history of HNC treatment at least 3 years ago and age- and gender-matched healthy controls. Participants completed a questionnaire addressing taste and smell perceptions, their relationship with food, and food aversions. Following this subjective survey, participants completed objective taste and smell tests. Taste testing was performed using taste strips containing five taste qualities at four concentrations each, and tasting four different jellybean flavors. Data was analyzed using Wilcoxon-rank sum tests for quantitative variables and Fisher's exact p-values for categorical data, with significance defined as p<0.05. Mixed-effect logistic regression was utilized for the jellybean taste analysis.</p>\n\n<p><strong>Results: </strong>This study included a total of 112 participants: 65 with a history of HNC who had undergone treatment and 47 healthy controls. The majority of patients were treated with radiation (81.5%), followed by chemotherapy (56.9%), and/or surgery (63.1%). HNC patients were more likely to report that food does not taste as it should (p < 0.001) and specifically had difficulties with eating hot or spicy food (p = 0.0003), eating meat (p = 0.0096), reduced appetite (p = 0.0050), and were less likely to feel excitement about eating when traveling (p = 0.0308). When evaluating objective data, HNC patients had significantly lower overall taste test scores (4.8 vs 9.1, p < 0.05). Additionally, there were significant differences in each taste subcategory of sweet, salty, bitter, umami taste (p < 0.05). Interestingly, there was no significant difference in the sour category between groups (p = 0.37). When correctly identifying specific jelly bean flavors, the patient group had significantly reduced flavor detection, with an odds ratio (OR) of 0.19 (95% CI: 0.04-0.83, p = 0.0278), corresponding to 81% lower odds of correct identification than in the control group.</p>\n\n<p><strong>Conclusion: </strong>HNC treatment results in chronic, multifaceted disturbances in oral somatosensory function. While some prior studies report the return of some taste after treatment, this study demonstrates that taste changes persist years after treatment of HNC. In fact, HNC patients have much more difficulty identifying certain tastes after treatment compared to the control population. These changes likely have long-term impacts on nutrition and quality of life. Routine chemosensory assessment and targeted nutritional and psychosocial interventions should be integrated into survivorship care to mitigate these long-term burdens. Future efforts should investigate ways to mitigate taste dysfunction after HNC treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154516--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S168",
      "content_id": "153923",
      "abstract_number": "S168",
      "poster_number": "",
      "title": "The rise of bulbar symptom burden in the second decade of oropharyngeal cancer survivorship: A 10-year longitudinal survey study",
      "summary": "Overall, symptom severity worsened over the decade (MDASI severity: 2015 mean = 0.81±1.11, 2025 mean = 1.04±1.32, Δ = +0.23, p<0.001) as did symptom interference (MDASI interference: 2015 mean = 0.74±1.50, 2025 mean = 1.17±1.77, Δ = +0.43, p<0.001). Symptom severity worsened in the largest magnitude for bulbar items including MDASI-choke (Δ mean = 1.49, 95% CI 1.21–1.77; p<0.001; choke≥5: 11.3%→29.6%),...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153923",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katherine Hutcheson, PhD",
      "presenter": "Katherine Hutcheson, PhD",
      "authors": "Katherine Hutcheson, PhD ; Wenye Song, MD, PhD; Isabelle Jang, MD; Amy Moreno, MD; Carly Barbon, PhD; Anna Lee, MD; Christine Peterson, PhD; Jack Lee, PhD, MS, DDS; Brandon Gunn, MD; Steven Frank, MD; Clifton Fuller, MD, PhD; Stephen Lai, MD, PhD; On behalf of OPC-SURVIVOR Research Program",
      "normalized_authors": [
        "Katherine Hutcheson",
        "Wenye Song",
        "Isabelle Jang",
        "Amy Moreno",
        "Carly Barbon",
        "Anna Lee",
        "Christine Peterson",
        "Jack Lee",
        "Brandon Gunn",
        "Steven Frank",
        "Clifton Fuller",
        "Stephen Lai",
        "On behalf of OPC-SURVIVOR Research Program"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 549,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design/setting",
        "Participants",
        "Exposure(s)",
        "Main Outcome(s) and Measure(s)",
        "Results",
        "Conclusions and Relevance",
        "Trial Registration",
        "Abstract"
      ],
      "sections": {
        "Authors": "Katherine Hutcheson, PhD ; Wenye Song, MD, PhD; Isabelle Jang, MD; Amy Moreno, MD; Carly Barbon, PhD; Anna Lee, MD; Christine Peterson, PhD; Jack Lee, PhD, MS, DDS; Brandon Gunn, MD; Steven Frank, MD; Clifton Fuller, MD, PhD; Stephen Lai, MD, PhD; On behalf of OPC-SURVIVOR Research Program",
        "Affiliations": "The University of Texas MD Anderson Cancer Center",
        "Importance": "Late effects of oropharyngeal cancer (OPC) are well-recognized in clinical practice as a source of delayed treatment failure, however, limited data are available to help understand the prevalence and evolution of symptoms from the first to second decade of survivorship.",
        "Objective": "To examine the patterns of symptoms reported in survivorship surveys of long-term OPC survivors over 10 years.",
        "Design/setting": "A single-institution longitudinal cohort study was conducted (MDA PA11-0936). 446 long-term survivors treated for their index OPC 2000 to 2013 participated in survivorship surveys in 2015 (median survival 6.3 years, range 1-15.7) and 2025 (median survival 16.0 years, range 11.6–26.1).",
        "Participants": "Median age at diagnosis was 56 years. The majority were treated for HPV/p16-positive disease (216/446, 48.4%), and advanced stage disease (≥N2b, 47.8%) per AJCC VII.",
        "Exposure(s)": "All patients received curative intent treatment for their index OPC ≥12 years prior to the final survey. Treatment was predominantly non-surgical (111/446, 24.9% RT alone; 140/446, 31.4% chemoradiation).",
        "Main Outcome(s) and Measure(s)": "Item-level MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) responses examined prevalence and severity of symptoms (ranging 0-10) over the 10-year survey interval. Symptom severity items were dichotomized as ≥5 represent moderate-severe symptom burden and compared using paired t-tests and McNemar tests over the 2 survey time points.",
        "Results": "Overall, symptom severity worsened over the decade (MDASI severity: 2015 mean = 0.81±1.11, 2025 mean = 1.04±1.32, Δ = +0.23, p<0.001) as did symptom interference (MDASI interference: 2015 mean = 0.74±1.50, 2025 mean = 1.17±1.77, Δ = +0.43, p<0.001). Symptom severity worsened in the largest magnitude for bulbar items including MDASI-choke (Δ mean = 1.49, 95% CI 1.21–1.77; p<0.001; choke≥5: 11.3%→29.6%), MDASI-chew/swallow (Δ mean = 1.48, 95% CI 1.20–1.76; p<0.001; chew/swallow≥5: 16.5%→34.6%), and MDASI-voice/speech (Δ mean = 1.28, 95% CI 1.03–1.54; p<0.001; p<0.001; voice/speech≥5: 7.5%→22.3%). In contrast, most oral morbidities were stable over the decade (dry mouth Δ mean = 0.17, 95% CI −0.10–0.43; p=0.22; dry≥5: 35.8%→33.6%; taste problems Δ mean = −0.02, 95% CI −0.28–0.24; p=0.90; taste≥5: 11.0%→14.4%), with small increases for mouth/throat sores (Δ mean = 0.19, 95% CI 0.01–0.37; p=0.04; sore≥5: mouth sore 1.9%→4.1%), whereas problems with teeth/gums showed a more pronounced worsening (Δ mean = 0.77, 95% CI 0.49–1.04; p<0.001; teeth/gum≥5: 10.5%→18.5%). Risk of moderate/high-grade symptom burden increased over the 10-year interval for 14 of 22 MDASI symptom items, with new onset of moderate/high-grade symptoms occurring in approximately 5–15% of survivors.",
        "Conclusions and Relevance": "In this unique 10-year longitudinal cohort of OPC survivors treated in the early IMRT era, bulbar symptoms increased significantly in the 2nd decade of OPC survivorship with at least 1 in 10 patients developing new moderate/high grade bulbar symptomatology marked by choking, chewing, swallowing, and voice/speech symptoms. During this interval, most oral morbidities remained stable.",
        "Trial Registration": "Not applicable.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The rise of bulbar symptom burden in the second decade of oropharyngeal cancer survivorship: A 10-year longitudinal survey study</span>. <u>Katherine Hutcheson, PhD</u>; Wenye Song, MD, PhD; Isabelle Jang, MD; Amy Moreno, MD; Carly Barbon, PhD; Anna Lee, MD; Christine Peterson, PhD; Jack Lee, PhD, MS, DDS; Brandon Gunn, MD; Steven Frank, MD; Clifton Fuller, MD, PhD; Stephen Lai, MD, PhD; On behalf of OPC-SURVIVOR Research Program. The University of Texas MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>Late effects of oropharyngeal cancer (OPC) are well-recognized in clinical practice as a source of delayed treatment failure, however, limited data are available to help understand the prevalence and evolution of symptoms from the first to second decade of survivorship.</p>\n\n<p><strong>Objective:</strong> To examine the patterns of symptoms reported in survivorship surveys of long-term OPC survivors over 10 years.</p>\n\n<p><strong>Design/setting: </strong>A single-institution longitudinal cohort study was conducted (MDA PA11-0936). 446 long-term survivors treated for their index OPC 2000 to 2013 participated in survivorship surveys in 2015 (median survival 6.3 years, range 1-15.7) and 2025 (median survival 16.0 years, range 11.6–26.1).</p>\n\n<p><strong>Participants: </strong>Median age at diagnosis was 56 years. The majority were treated for HPV/p16-positive disease (216/446, 48.4%), and advanced stage disease (≥N2b, 47.8%) per AJCC VII.</p>\n\n<p><strong>Exposure(s): </strong>All patients received curative intent treatment for their index OPC ≥12 years prior to the final survey. Treatment was predominantly non-surgical (111/446, 24.9% RT alone; 140/446, 31.4% chemoradiation).</p>\n\n<p><strong>Main Outcome(s) and Measure(s): </strong>Item-level MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) responses examined prevalence and severity of symptoms (ranging 0-10) over the 10-year survey interval. Symptom severity items were dichotomized as ≥5 represent moderate-severe symptom burden and compared using paired t-tests and McNemar tests over the 2 survey time points.</p>\n\n<p><strong>Results: </strong>Overall, symptom severity worsened over the decade (MDASI severity: 2015 mean = 0.81±1.11, 2025 mean = 1.04±1.32, Δ = +0.23, p<0.001) as did symptom interference (MDASI interference: 2015 mean = 0.74±1.50, 2025 mean = 1.17±1.77, Δ = +0.43, p<0.001). Symptom severity worsened in the largest magnitude for bulbar items including MDASI-choke (Δ mean = 1.49, 95% CI 1.21–1.77; p<0.001; choke≥5: 11.3%→29.6%), MDASI-chew/swallow (Δ mean = 1.48, 95% CI 1.20–1.76; p<0.001; chew/swallow≥5: 16.5%→34.6%), and MDASI-voice/speech (Δ mean = 1.28, 95% CI 1.03–1.54; p<0.001; p<0.001; voice/speech≥5: 7.5%→22.3%). In contrast, most oral morbidities were stable over the decade (dry mouth Δ mean = 0.17, 95% CI −0.10–0.43; p=0.22; dry≥5: 35.8%→33.6%; taste problems Δ mean = −0.02, 95% CI −0.28–0.24; p=0.90; taste≥5: 11.0%→14.4%), with small increases for mouth/throat sores (Δ mean = 0.19, 95% CI 0.01–0.37; p=0.04; sore≥5: mouth sore 1.9%→4.1%), whereas problems with teeth/gums showed a more pronounced worsening (Δ mean = 0.77, 95% CI 0.49–1.04; p<0.001; teeth/gum≥5: 10.5%→18.5%). Risk of moderate/high-grade symptom burden increased over the 10-year interval for 14 of 22 MDASI symptom items, with new onset of moderate/high-grade symptoms occurring in approximately 5–15% of survivors.</p>\n\n<p><strong>Conclusions and Relevance: </strong>In this unique 10-year longitudinal cohort of OPC survivors treated in the early IMRT era, bulbar symptoms increased significantly in the 2nd decade of OPC survivorship with at least 1 in 10 patients developing new moderate/high grade bulbar symptomatology marked by choking, chewing, swallowing, and voice/speech symptoms. During this interval, most oral morbidities remained stable.</p>\n\n<p><strong>Trial Registration: </strong>Not applicable.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153923--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S169",
      "content_id": "153552",
      "abstract_number": "S169",
      "poster_number": "",
      "title": "Towards personalized dysphagia care pathways: forecasting late dysphagia from early swallow recovery phenotypes",
      "summary": "DIGEST trajectory-based RAD phenotypes identified within the first 30 months after RT are highly informative in late survivorship. Patients in the Transient and Progressing phenotypes carry substantial long-term risk exceeding 50–80% probability of late high-grade dysphagia or decline. These findings support personalized swallow surveillance protocols in survivorship pathways that account for earlier swallow...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153552",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beatrice Manduchi, PhD",
      "presenter": "Beatrice Manduchi, PhD",
      "authors": "Beatrice Manduchi, PhD ; Carly E A Barbon; Amy C Moreno; Christine B Peterson; J Jack Lee; Anna Lee; Clifton D Fuller; Steven J Frank; Stephen Y Lai; Kristy K Brock; Katherine A Hutcheson",
      "normalized_authors": [
        "Beatrice Manduchi",
        "Carly E A Barbon",
        "Amy C Moreno",
        "Christine B Peterson",
        "J Jack Lee",
        "Anna Lee",
        "Clifton D Fuller",
        "Steven J Frank",
        "Stephen Y Lai",
        "Kristy K Brock",
        "Katherine A Hutcheson"
      ],
      "affiliations": [
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 533,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Participants",
        "Exposure",
        "Main Outcomes",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Beatrice Manduchi, PhD ; Carly E A Barbon; Amy C Moreno; Christine B Peterson; J Jack Lee; Anna Lee; Clifton D Fuller; Steven J Frank; Stephen Y Lai; Kristy K Brock; Katherine A Hutcheson",
        "Affiliations": "MD Anderson Cancer Center",
        "Importance": "Radiation-associated dysphagia (RAD) is a major survivorship burden in oropharyngeal cancer (OPC). Despite well-recognized heterogeneity in swallowing recovery, clinical pathways generally apply uniform swallow surveillance algorithms. We recently identified distinct early RAD phenotypes based on longitudinal dysphagia trajectories (per radiographic DIGEST grading) from baseline through 30 months post-RT, reflecting 4 different patterns of early recovery. It is unclear, however, how these phenotypes behave later in survivorship.",
        "Objective": "To evaluate how dysphagia evolves in late survivorship (Aim 1), and to determine late-RAD prognosis for each RAD phenotype to inform phenotype-specific swallow surveillance strategies (Aim 2).",
        "Design": "Secondary analysis of prospective registry (Stiefel MDA-OPC cohort). The authors’ previously derived early RAD phenotypes (No/Minimal, Mild/Moderate, Moderate/Severe Transient, Moderate/Severe Progressing) were derived using latent class analysis of longitudinal DIGEST grades in patients with ≥3 MBSs conducted up to 30 months post-RT. For the current study, patients also with ≥1 MBS ≥30-months post-RT were included.",
        "Setting": "Single-institution tertiary cancer center.",
        "Participants": "Adults with OPC enrolled in the prospective registry who completed ≥3 MBSs within the first 30 months after RT (for phenotype assignment) and ≥1 late MBS ≥30 months after RT. A total of 206 patients (median 62.8 months post-RT; range 30–95) met eligibility. Tumor characteristics included 45% BOT, 45% tonsil, 66% T1–T2, 90% HPV-positive; 71% received CRT.",
        "Exposure": "Early RAD phenotypes defined by longitudinal DIGEST grade trajectories through 30 months post-RT: No/Minimal (n=111, 54%), Mild/Moderate (n=39, 19%), Transient (n=32, 15%), Progressing (n=24, 12%).",
        "Main Outcomes": "Aim 1 evaluated late change in DIGEST grade by comparing each patient’s worst ≥30-month DIGEST with their last <30-month DIGEST. Logistic models estimated phenotype-specific odds of any change. Aim 2 assessed late high-grade dysphagia (DIGEST ≥2) using logistic and mixed-effects logistic regression with early RAD phenotype ± time (months since RT). Predicted probabilities of late high-grade dysphagia were generated for each class.",
        "Results": "For Aim 1 , late DIGEST worsening occurred in 47% patients. Rates of any worsening differed across early phenotypes: 29.7% (No/Minimal), 25.6% (Mild/Moderate), 56.2% (Transient), and 20.8% (Progressing). Compared with No/Minimal RAD, the Transient phenotype showed significantly increased odds of late worsening (OR 3.04; p=0.007). In contrast, the Progressing phenotype had higher odds of late improvement (OR 3.10; p=0.035). For Aim 2 , early RAD phenotype strongly predicted late DIGEST ≥2 (p<0.001). Compared with No/Minimal, odds ratios for late high-grade dysphagia were 4.1 (95% CI, 1.9–9.3) for Mild/Moderate, 5.5 (95% CI, 2.4–13.1) for Transient, and 18.4 (95% CI, 6.5–61.3) for Progressing. Predicted probabilities of high-grade late RAD were 0.2, 0.5, and 0.8 for the Mild/Moderate, Transient, and Progressing classes, respectively. Including time as interaction term did not improve model fit.",
        "Conclusions": "DIGEST trajectory-based RAD phenotypes identified within the first 30 months after RT are highly informative in late survivorship. Patients in the Transient and Progressing phenotypes carry substantial long-term risk exceeding 50–80% probability of late high-grade dysphagia or decline. These findings support personalized swallow surveillance protocols in survivorship pathways that account for earlier swallow recovery patterns.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Towards personalized dysphagia care pathways: forecasting late dysphagia from early swallow recovery phenotypes</span>. <u>Beatrice Manduchi, PhD</u>; Carly E A Barbon; Amy C Moreno; Christine B Peterson; J Jack Lee; Anna Lee; Clifton D Fuller; Steven J Frank; Stephen Y Lai; Kristy K Brock; Katherine A Hutcheson. MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Radiation-associated dysphagia (RAD) is a major survivorship burden in oropharyngeal cancer (OPC). Despite well-recognized heterogeneity in swallowing recovery, clinical pathways generally apply uniform swallow surveillance algorithms. We recently identified distinct early RAD phenotypes based on longitudinal dysphagia trajectories (per radiographic DIGEST grading) from baseline through 30 months post-RT, reflecting 4 different patterns of early recovery. It is unclear, however, how these phenotypes behave later in survivorship.</p>\n\n<p><strong>Objective: </strong>To evaluate how dysphagia evolves in late survivorship (Aim 1), and to determine late-RAD prognosis for each RAD phenotype to inform phenotype-specific swallow surveillance strategies (Aim 2).</p>\n\n<p><strong>Design: </strong>Secondary analysis of prospective registry (Stiefel MDA-OPC cohort). The authors’ previously derived early RAD phenotypes (No/Minimal, Mild/Moderate, Moderate/Severe Transient, Moderate/Severe Progressing) were derived using latent class analysis of longitudinal DIGEST grades in patients with ≥3 MBSs conducted up to 30 months post-RT. For the current study, patients also with ≥1 MBS ≥30-months post-RT were included.</p>\n\n<p><strong>Setting:</strong> Single-institution tertiary cancer center.</p>\n\n<p><strong>Participants</strong>: Adults with OPC enrolled in the prospective registry who completed ≥3 MBSs within the first 30 months after RT (for phenotype assignment) and ≥1 late MBS ≥30 months after RT. A total of 206 patients (median 62.8 months post-RT; range 30–95) met eligibility. Tumor characteristics included 45% BOT, 45% tonsil, 66% T1–T2, 90% HPV-positive; 71% received CRT.</p>\n\n<p><strong>Exposure:</strong> Early RAD phenotypes defined by longitudinal DIGEST grade trajectories through 30 months post-RT: No/Minimal (n=111, 54%), Mild/Moderate (n=39, 19%), Transient (n=32, 15%), Progressing (n=24, 12%).</p>\n\n<p><strong>Main Outcomes</strong>: Aim 1 evaluated late change in DIGEST grade by comparing each patient’s worst ≥30-month DIGEST with their last <30-month DIGEST. Logistic models estimated phenotype-specific odds of any change. Aim 2 assessed late high-grade dysphagia (DIGEST ≥2) using logistic and mixed-effects logistic regression with early RAD phenotype ± time (months since RT). Predicted probabilities of late high-grade dysphagia were generated for each class.</p>\n\n<p><strong>Results: </strong><u>For Aim 1</u>, late DIGEST worsening occurred in 47% patients. Rates of any worsening differed across early phenotypes: 29.7% (No/Minimal), 25.6% (Mild/Moderate), 56.2% (Transient), and 20.8% (Progressing). Compared with No/Minimal RAD, the Transient phenotype showed significantly increased odds of late worsening (OR 3.04; p=0.007). In contrast, the Progressing phenotype had higher odds of late improvement (OR 3.10; p=0.035). <u>For Aim 2</u>, early RAD phenotype strongly predicted late DIGEST ≥2 (p<0.001). Compared with No/Minimal, odds ratios for late high-grade dysphagia were 4.1 (95% CI, 1.9–9.3) for Mild/Moderate, 5.5 (95% CI, 2.4–13.1) for Transient, and 18.4 (95% CI, 6.5–61.3) for Progressing. Predicted probabilities of high-grade late RAD were 0.2, 0.5, and 0.8 for the Mild/Moderate, Transient, and Progressing classes, respectively. Including time as interaction term did not improve model fit.</p>\n\n<p><strong>Conclusions:</strong> DIGEST trajectory-based RAD phenotypes identified within the first 30 months after RT are highly informative in late survivorship. Patients in the Transient and Progressing phenotypes carry substantial long-term risk exceeding 50–80% probability of late high-grade dysphagia or decline. These findings support personalized swallow surveillance protocols in survivorship pathways that account for earlier swallow recovery patterns.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153552--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S170",
      "content_id": "154132",
      "abstract_number": "S170",
      "poster_number": "",
      "title": "Physical Activity and Risk Factors in Head and Neck Cancer Survivors Compared to Survivors of Other Cancers: A Pooled, Cross-Sectional Analysis of the National Health Interview Survey",
      "summary": "Physical activity guideline adherence is disproportionately low among HNC survivors, underscoring the need for systematic screening. For inactive or insufficiently active patients, referral to physical medicine and rehabilitation may facilitate identification and management of barriers to physical activity, such as ADL-, IADL-, and mobility limitations. These data may inform the design and development of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154132",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ayush G Iyer, BS",
      "presenter": "Ayush G Iyer, BS",
      "authors": "Ayush G Iyer, BS 1 ; Julie K Silver, MD 2 ; Reena Kudchadker, BS 1 ; Rebecca Lee, MD 3 ; Rebecca Eary, DO 1 ; Justin R Shinn, MD 1 ; Jordan R Salley, MD 1 ; Erika Ren, BS 1 ; Dalia N Mitchell, MSCI 1 ; Sanjana Balachandra, MD 4 ; Teena Sura, MPH 1 ; Yulun Liu, PhD 1 ; Zainab Farzal, MD 1 ; Michael Fediw, MD 1 ; Andrew T Day, MD, MPH 1",
      "normalized_authors": [
        "Ayush G Iyer",
        "Julie K Silver",
        "Reena Kudchadker",
        "Rebecca Lee",
        "Rebecca Eary",
        "Justin R Shinn",
        "Jordan R Salley",
        "Erika Ren",
        "Dalia N Mitchell, MSCI",
        "Sanjana Balachandra",
        "Teena Sura",
        "Yulun Liu",
        "Zainab Farzal",
        "Michael Fediw",
        "Andrew T Day"
      ],
      "affiliations": [
        "UT Southwestern Medical Center",
        "Wake Forest School of Medicine",
        "Baylor College of Medicine",
        "University of Alabama at Birmingham"
      ],
      "normalized_institutions": [
        "UT Southwestern Medical Center",
        "Wake Forest School of Medicine",
        "Baylor College of Medicine",
        "University of Alabama at Birmingham"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ayush G Iyer, BS 1 ; Julie K Silver, MD 2 ; Reena Kudchadker, BS 1 ; Rebecca Lee, MD 3 ; Rebecca Eary, DO 1 ; Justin R Shinn, MD 1 ; Jordan R Salley, MD 1 ; Erika Ren, BS 1 ; Dalia N Mitchell, MSCI 1 ; Sanjana Balachandra, MD 4 ; Teena Sura, MPH 1 ; Yulun Liu, PhD 1 ; Zainab Farzal, MD 1 ; Michael Fediw, MD 1 ; Andrew T Day, MD, MPH 1",
        "Affiliations": "1 UT Southwestern Medical Center; 2 Wake Forest School of Medicine; 3 Baylor College of Medicine; 4 University of Alabama at Birmingham",
        "Background": "Physical activity is a powerful determinant of quality of life and survival, yet activity patterns among head and neck cancer (HNC) survivors remain poorly characterized. Although U.S. Department of Health and Human Services (USDHHS) guidelines recommend at least 150 minutes of moderate-intensity aerobic activity (or an equivalent 75 minutes of vigorous-intensity aerobic activity) plus two weekly strengthening sessions, a substantial proportion of HNC survivors remain inactive. Our study seeks to characterize patterns of adherence to physical activity guideline recommendations among HNC survivors and identify key risk factors associated with inactivity in this population.",
        "Methods": "We conducted a pooled, cross-sectional analysis of the National Health Interview Survey (NHIS) from 1997 to 2018, matching HNC survivors 1:4:4 by age-, sex-, race/ethnicity-, and survey year to survivors of other cancers (SOCs) and non-cancer controls (NCCs). We adapted the biopsychosocial model using the John et al scoping review (PMID: 33068179) to best account for determinants of physical activity and framed our study accordingly. USDHSS guideline definitions of physical activity and inactivity were applied. Co-primary exposures included mobility limitations, social determinants of health, cardiopulmonary disease, and pain, with adjustments for sociodemographic, behavioral, comorbidities, limitations, and tumor-related variables. Weighted descriptive statistics and multivariable logistic regression were performed using STATA 18 and R-Studio (2022.2.0.443).",
        "Results": "The final cohort included 106,400 HNC survivors, 408,375 SOCs, and 396,855 NCCs. HNC survivors had a median age of 66 years and were predominantly non-Hispanic white (83.3%) and male (66.8%). Relative to their matched counterparts, HNC survivors were more likely to report lower educational attainment, incomes below the poverty threshold, higher use of food assistance programs, limited access to transportation, and current smoking.",
        "Abstract": "Approximately half of HNC survivors (50.5%) reported no weekly physical activity of any kind. While moderate-intensity activity did not differ significantly across groups, HNC survivors were significantly less likely to meet recommended vigorous-intensity exercise levels (15.3%) compared to SOCs (20.7%, p =0.005) and NCCs (20.6%, p =0.006) or perform at least two weekly strength-training sessions (12.4%) compared to SOCs (17.4%, p =0.004) and NCCs (15.8%, p =0.038). Ultimately, only 7.1% of HNC survivors exhibited USDHHS guideline-adherent activity. In the multivariable analysis, several variables associated with physical inactivity, including low educational attainment (aOR=2.22; p <0.001), social limitations (aOR=1.94; p =0.006), and limitations with IADLs (aOR=2.40; p =0.009). In another multivariable analysis, several variables correlated with guideline-adherent physical activity, including higher educational attainment (aOR=2.68; p =0.004), absence of mobility limitations (aOR=2.10; p =0.040), and absence of limitations with ADLs (aOR=6.81; p =0.015). View in Agenda and Add to Schedule",
        "Conclusion": "Physical activity guideline adherence is disproportionately low among HNC survivors, underscoring the need for systematic screening. For inactive or insufficiently active patients, referral to physical medicine and rehabilitation may facilitate identification and management of barriers to physical activity, such as ADL-, IADL-, and mobility limitations. These data may inform the design and development of targeted, literacy-appropriate, physical activity interventions for HNC survivors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Physical Activity and Risk Factors in Head and Neck Cancer Survivors Compared to Survivors of Other Cancers: A Pooled, Cross-Sectional Analysis of the National Health Interview Survey</span>. <u>Ayush G Iyer, BS</u><sup>1</sup>; Julie K Silver, MD<sup>2</sup>; Reena Kudchadker, BS<sup>1</sup>; Rebecca Lee, MD<sup>3</sup>; Rebecca Eary, DO<sup>1</sup>; Justin R Shinn, MD<sup>1</sup>; Jordan R Salley, MD<sup>1</sup>; Erika Ren, BS<sup>1</sup>; Dalia N Mitchell, MSCI<sup>1</sup>; Sanjana Balachandra, MD<sup>4</sup>; Teena Sura, MPH<sup>1</sup>; Yulun Liu, PhD<sup>1</sup>; Zainab Farzal, MD<sup>1</sup>; Michael Fediw, MD<sup>1</sup>; Andrew T Day, MD, MPH<sup>1</sup>. <sup>1</sup>UT Southwestern Medical Center; <sup>2</sup>Wake Forest School of Medicine; <sup>3</sup>Baylor College of Medicine; <sup>4</sup>University of Alabama at Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Physical activity is a powerful determinant of quality of life and survival, yet activity patterns among head and neck cancer (HNC) survivors remain poorly characterized. Although U.S. Department of Health and Human Services (USDHHS) guidelines recommend at least 150 minutes of moderate-intensity aerobic activity (or an equivalent 75 minutes of vigorous-intensity aerobic activity) plus two weekly strengthening sessions, a substantial proportion of HNC survivors remain inactive. Our study seeks to characterize patterns of adherence to physical activity guideline recommendations among HNC survivors and identify key risk factors associated with inactivity in this population.</p>\n\n<p><strong>Methods: </strong>We conducted a pooled, cross-sectional analysis of the National Health Interview Survey (NHIS) from 1997 to 2018, matching HNC survivors 1:4:4 by age-, sex-, race/ethnicity-, and survey year to survivors of other cancers (SOCs) and non-cancer controls (NCCs). We adapted the biopsychosocial model using the John et al scoping review (PMID: 33068179) to best account for determinants of physical activity and framed our study accordingly. USDHSS guideline definitions of physical activity and inactivity were applied. Co-primary exposures included mobility limitations, social determinants of health, cardiopulmonary disease, and pain, with adjustments for sociodemographic, behavioral, comorbidities, limitations, and tumor-related variables. Weighted descriptive statistics and multivariable logistic regression were performed using STATA 18 and R-Studio (2022.2.0.443).</p>\n\n<p><strong>Results: </strong>The final cohort included 106,400 HNC survivors, 408,375 SOCs, and 396,855 NCCs. HNC survivors had a median age of 66 years and were predominantly non-Hispanic white (83.3%) and male (66.8%). Relative to their matched counterparts, HNC survivors were more likely to report lower educational attainment, incomes below the poverty threshold, higher use of food assistance programs, limited access to transportation, and current smoking.</p>\n\n<p>Approximately half of HNC survivors (50.5%) reported no weekly physical activity of any kind. While moderate-intensity activity did not differ significantly across groups, HNC survivors were significantly less likely to meet recommended vigorous-intensity exercise levels (15.3%) compared to SOCs (20.7%, <em>p</em>=0.005) and NCCs (20.6%, <em>p</em>=0.006) or perform at least two weekly strength-training sessions (12.4%) compared to SOCs (17.4%, <em>p</em>=0.004) and NCCs (15.8%, <em>p</em>=0.038). Ultimately, only 7.1% of HNC survivors exhibited USDHHS guideline-adherent activity.</p>\n\n<p>In the multivariable analysis, several variables associated with physical inactivity, including low educational attainment (aOR=2.22; <em>p</em><0.001), social limitations (aOR=1.94; <em>p</em>=0.006), and limitations with IADLs (aOR=2.40; <em>p</em>=0.009). In another multivariable analysis, several variables correlated with guideline-adherent physical activity, including higher educational attainment (aOR=2.68; <em>p</em>=0.004), absence of mobility limitations (aOR=2.10; <em>p</em>=0.040), and absence of limitations with ADLs (aOR=6.81; <em>p</em>=0.015).</p>\n\n<p><strong>Conclusion: </strong>Physical activity guideline adherence is disproportionately low among HNC survivors, underscoring the need for systematic screening. For inactive or insufficiently active patients, referral to physical medicine and rehabilitation may facilitate identification and management of barriers to physical activity, such as ADL-, IADL-, and mobility limitations. These data may inform the design and development of targeted, literacy-appropriate, physical activity interventions for HNC survivors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154132--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S171",
      "content_id": "153197",
      "abstract_number": "S171",
      "poster_number": "",
      "title": "Impact of Early Smoking Cessation and Socioeconomic Status on Remission in Head and Neck Cancer: A Single-Center Retrospective Study",
      "summary": "These findings indicate that patients who quit smoking within 2 years of diagnosis were more likely to achieve lasting remission than those who continued smoking. Socioeconomic disadvantage, as measured by ADI, was associated with more advanced stage and poorer outcomes in elderly patients, suggesting that older adults may need greater support during treatment. Future studies should expand sample size to better...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153197",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brant Hannahs",
      "presenter": "Brant Hannahs",
      "authors": "Rebecca Hofer 1 ; Brant Hannahs 1 ; Ryder Grantham 1 ; William Spanos, MD 2 ; Tobias Meissner, PhD 3 ; Rachel Elsey, PharmD, BCOP 3 ; Crystal Hattum, MS 3 ; Bing Xu, PhD 3",
      "normalized_authors": [
        "Rebecca Hofer",
        "Brant Hannahs",
        "Ryder Grantham",
        "William Spanos",
        "Tobias Meissner",
        "Rachel Elsey, PharmD, BCOP",
        "Crystal Hattum",
        "Bing Xu"
      ],
      "affiliations": [
        "University of South Dakota Sanford School of Medicine",
        "Avera McKennan Hospital & University Health Center",
        "Avera Cancer Institute at Avera McKennan Hospital & University Health Center"
      ],
      "normalized_institutions": [
        "University of South Dakota Sanford School of Medicine",
        "Avera McKennan Hospital & University Health Center",
        "Avera Cancer Institute at Avera McKennan Hospital & University Health Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rebecca Hofer 1 ; Brant Hannahs 1 ; Ryder Grantham 1 ; William Spanos, MD 2 ; Tobias Meissner, PhD 3 ; Rachel Elsey, PharmD, BCOP 3 ; Crystal Hattum, MS 3 ; Bing Xu, PhD 3",
        "Affiliations": "1 University of South Dakota Sanford School of Medicine; 2 Avera McKennan Hospital & University Health Center; 3 Avera Cancer Institute at Avera McKennan Hospital & University Health Center",
        "Background": "Tobacco use is a well-established risk factor for head and neck cancer, but the impact of smoking cessation timing and socioeconomic factors on remission and recurrence risk remains underexplored. This study aims to clarify the relationship between smoking cessation timing, socioeconomic disadvantage, and head and neck cancer outcomes. Findings may refine patient education and highlight the importance of early smoking cessation. Our objective was to compare outcomes of head and neck cancer by smoking habits, and to evaluate the influence of neighborhood-level socioeconomic deprivation on remission outcomes and severity of stage.",
        "Methods": "A retrospective chart review of 202 patients diagnosed with head and neck cancer at a single center was conducted. Patients were subcategorized into current smokers (n=41), never smokers (n=63), individuals who quit within 2 years of diagnosis (n=28), and those who quit more than 2 years prior (n=70). Patients missing MRN or smoking data (n=11), remission status (n=14), or ADI scores (n=12) were excluded from respective analyses. Variables extracted from the electronic medical record and cancer registry included demographics, tumor characteristics (AJCC Stage, p16 positivity), tobacco use, and socioeconomic indicators (ADI, education level). Calculated median ADI score was used as a cutoff for low versus high socioeconomic disadvantage. Statistical analysis was performed via Fisher Exact testing and Kaplan-Meier curves.",
        "Results": "Overall survival did not differ between groups (p=0.75), however, remission was more frequent in those who quit within 2 years of diagnosis than current smokers (p=0.03; OR=3.97, 95% CI 1.22–12.90). No difference was found between former smokers who quit >2 years or <2 years from diagnosis (p=0.59). Among patients >65 years, those with higher ADI scores had lower remission rates (p=0.04), while no significant relationship was seen in younger patients (p=0.48). Higher ADI scores did not impact remission in those <65 years of age (p=0.48). Lastly, higher deprivation scores were associated with advanced AJCC stage at diagnosis (p=0.013; OR=2.27, 95% CI 1.22 - 5.89). Controlling for age confirmed the finding for patients >65 years (p=0.02) but found no association between best AJCC stage and ADI score for patients <65 years (p=0.59).",
        "Conclusion": "These findings indicate that patients who quit smoking within 2 years of diagnosis were more likely to achieve lasting remission than those who continued smoking. Socioeconomic disadvantage, as measured by ADI, was associated with more advanced stage and poorer outcomes in elderly patients, suggesting that older adults may need greater support during treatment. Future studies should expand sample size to better establish these relationships and further explore the connection between AJCC stage at diagnosis and ADI status.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Early Smoking Cessation and Socioeconomic Status on Remission in Head and Neck Cancer: A Single-Center Retrospective Study</span>. Rebecca Hofer<sup>1</sup>; <u>Brant Hannahs</u><sup>1</sup>; Ryder Grantham<sup>1</sup>; William Spanos, MD<sup>2</sup>; Tobias Meissner, PhD<sup>3</sup>; Rachel Elsey, PharmD, BCOP<sup>3</sup>; Crystal Hattum, MS<sup>3</sup>; Bing Xu, PhD<sup>3</sup>. <sup>1</sup>University of South Dakota Sanford School of Medicine; <sup>2</sup>Avera McKennan Hospital & University Health Center; <sup>3</sup>Avera Cancer Institute at Avera McKennan Hospital & University Health Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Tobacco use is a well-established risk factor for head and neck cancer, but the impact of smoking cessation timing and socioeconomic factors on remission and recurrence risk remains underexplored. This study aims to clarify the relationship between smoking cessation timing, socioeconomic disadvantage, and head and neck cancer outcomes. Findings may refine patient education and highlight the importance of early smoking cessation. Our objective was to compare outcomes of head and neck cancer by smoking habits, and to evaluate the influence of neighborhood-level socioeconomic deprivation on remission outcomes and severity of stage.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review of 202 patients diagnosed with head and neck cancer at a single center was conducted. Patients were subcategorized into current smokers (n=41), never smokers (n=63), individuals who quit within 2 years of diagnosis (n=28), and those who quit more than 2 years prior (n=70). Patients missing MRN or smoking data (n=11), remission status (n=14), or ADI scores (n=12) were excluded from respective analyses. Variables extracted from the electronic medical record and cancer registry included demographics, tumor characteristics (AJCC Stage, p16 positivity), tobacco use, and socioeconomic indicators (ADI, education level). Calculated median ADI score was used as a cutoff for low versus high socioeconomic disadvantage. Statistical analysis was performed via Fisher Exact testing and Kaplan-Meier curves.</p>\n\n<p><strong>Results: </strong>Overall survival did not differ between groups (p=0.75), however, remission was more frequent in those who quit within 2 years of diagnosis than current smokers (p=0.03; OR=3.97, 95% CI 1.22–12.90). No difference was found between former smokers who quit >2 years or <2 years from diagnosis (p=0.59). Among patients >65 years, those with higher ADI scores had lower remission rates (p=0.04), while no significant relationship was seen in younger patients (p=0.48). Higher ADI scores did not impact remission in those <65 years of age (p=0.48). Lastly, higher deprivation scores were associated with advanced AJCC stage at diagnosis (p=0.013; OR=2.27, 95% CI 1.22 - 5.89). Controlling for age confirmed the finding for patients >65 years (p=0.02) but found no association between best AJCC stage and ADI score for patients <65 years (p=0.59).</p>\n\n<p><strong>Conclusion: </strong>These findings indicate that patients who quit smoking within 2 years of diagnosis were more likely to achieve lasting remission than those who continued smoking. Socioeconomic disadvantage, as measured by ADI, was associated with more advanced stage and poorer outcomes in elderly patients, suggesting that older adults may need greater support during treatment. Future studies should expand sample size to better establish these relationships and further explore the connection between AJCC stage at diagnosis and ADI status.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153197--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S172",
      "content_id": "153231",
      "abstract_number": "S172",
      "poster_number": "",
      "title": "Cancer-Related Fatigue in Head and Neck Cancer Patients",
      "summary": "FACT-HN TOI and Total scores showed a strong correlation with FACIT-F. These findings suggest that FACT-HN may serve as an efficient surrogate for fatigue measurement in HNC patients. The moderate subscale correlation indicates that FACT-HN captures the unique challenges of HNC patients not covered by FACIT-F.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153231",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vianca Angelica Mendoza, BS",
      "presenter": "Vianca Angelica Mendoza, BS",
      "authors": "Vianca Angelica Mendoza, BS 1 ; Beverly Garber, DNP, ANPBC, CORLN 2 ; Andrew Birkeland, MD 2 ; Michael Li, MD 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2",
      "normalized_authors": [
        "Vianca Angelica Mendoza",
        "Beverly Garber, DNP, ANPBC, CORLN",
        "Andrew Birkeland",
        "Michael Li",
        "Arnaud Bewley",
        "Marianne Abouyared"
      ],
      "affiliations": [
        "University of California, Davis School of Medicine",
        "University of California, Davis"
      ],
      "normalized_institutions": [
        "University of California, Davis School of Medicine",
        "University of California, Davis"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 487,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Study Design",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Vianca Angelica Mendoza, BS 1 ; Beverly Garber, DNP, ANPBC, CORLN 2 ; Andrew Birkeland, MD 2 ; Michael Li, MD 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2",
        "Affiliations": "1 University of California, Davis School of Medicine; 2 University of California, Davis",
        "Background": "Cancer-Related Fatigue (CRF) is a prevalent and debilitating symptom experienced by cancer patients, characterized by long-term physical, emotional, and cognitive exhaustion that substantially impairs quality of life (QoL). Although CRF is widely studied in other malignancies, limited research has examined its effects on Head and Neck Cancer (HNC) patients, a population uniquely affected by impaired speech, difficulty swallowing, and altered appearance following multimodal therapy.",
        "Abstract": "The Functional Assessment of Cancer Therapy -Head and Neck (FACT-HN) is commonly used to assess QoL in HNC patients, whereas the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) is one standardly used to measure CRF. FACT-HN has not been systematically evaluated for its effectiveness in measuring CRF. This study aimed to describe the impact of fatigue in HNC patients and determine the validity of utilizing FACT-HN as a surrogate for FACIT-F. Mean FACT-HN TOI and Total scores were 72.1 +/- 17.6 and 114.6 +/- 22.9, respectively. Mean FACIT-F TOI and Total scores were 83.3 +/- 20.65 and 127.2 +/- 25.3. FACT-HN Total scores demonstrated a strong positive correlation to FACIT-F (r = 0.95, p < 0.001), indicating that high QoL scores were associated with lower fatigue burden. TOI scores (r = 0.92) also shared similar findings, while subscale scores were moderately correlated (r =0.67, p < 0.0001). Overall, head and neck cancer patients reported moderate overall quality of life and persistent fatigue across all treatment phases. These findings suggest the lasting functional and psychosocial burden of cancer-related fatigue on the unique hardships head and neck cancer patients face. Continued evaluation of its impact is essential to guide supportive interventions and improve long-term survivorship care. View in Agenda and Add to Schedule",
        "Study Design": "Prospective observational study with retrospective chart review.",
        "Methods": "HNC patients aged 18 years and older seen at a tertiary academic center between June and October 2025 were administered FACIT-F and FACT-HN questionnaires during routine clinic visits. Demographic and clinical variables (age, sex, cancer type, and primary site) were extracted from medical records. Descriptive statistics were used to summarize all variables. Pearson correlations assessed the relationships between FACT-HN and FACIT-F total, Trial Outcome Index (TOI), and subscale scores.",
        "Results": "Among 136 recruited patients (70.6% male, mean age 66.5 +/- 12.2 years), most had squamous cell carcinoma (87.5%), followed by salivary gland carcinoma (5.1%), and thyroid and nasopharyngeal carcinoma (2.2% each). The most common primary tumor sites were in the oral cavity (37.5%) and oropharynx (31.6%). At survey completion, 1.5% were newly diagnosed, 8.1% in active treatment, and 90.4% in post-treatment surveillance (median 1.6 years since completion, 42.6% were >2 years post-treatment).",
        "Conclusion": "FACT-HN TOI and Total scores showed a strong correlation with FACIT-F. These findings suggest that FACT-HN may serve as an efficient surrogate for fatigue measurement in HNC patients. The moderate subscale correlation indicates that FACT-HN captures the unique challenges of HNC patients not covered by FACIT-F."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cancer-Related Fatigue in Head and Neck Cancer Patients</span>. <u>Vianca Angelica Mendoza, BS</u><sup>1</sup>; Beverly Garber, DNP, ANPBC, CORLN<sup>2</sup>; Andrew Birkeland, MD<sup>2</sup>; Michael Li, MD<sup>2</sup>; Arnaud Bewley, MD<sup>2</sup>; Marianne Abouyared, MD<sup>2</sup>. <sup>1</sup>University of California, Davis School of Medicine; <sup>2</sup>University of California, Davis<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cancer-Related Fatigue (CRF) is a prevalent and debilitating symptom experienced by cancer patients, characterized by long-term physical, emotional, and cognitive exhaustion that substantially impairs quality of life (QoL). Although CRF is widely studied in other malignancies, limited research has examined its effects on Head and Neck Cancer (HNC) patients, a population uniquely affected by impaired speech, difficulty swallowing, and altered appearance following multimodal therapy. </p>\n\n<p>The Functional Assessment of Cancer Therapy -Head and Neck (FACT-HN) is commonly used to assess QoL in HNC patients, whereas the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) is one standardly used to measure CRF. FACT-HN has not been systematically evaluated for its effectiveness in measuring CRF. This study aimed to describe the impact of fatigue in HNC patients and determine the validity of utilizing FACT-HN as a surrogate for FACIT-F. </p>\n\n<p><strong>Study Design: </strong>Prospective observational study with retrospective chart review.</p>\n\n<p><strong>Methods: </strong>HNC patients aged 18 years and older seen at a tertiary academic center between June and October 2025 were administered FACIT-F and FACT-HN questionnaires during routine clinic visits. Demographic and clinical variables (age, sex, cancer type, and primary site) were extracted from medical records. Descriptive statistics were used to summarize all variables. Pearson correlations assessed the relationships between FACT-HN and FACIT-F total, Trial Outcome Index (TOI), and subscale scores. </p>\n\n<p><strong>Results: </strong>Among 136 recruited patients (70.6% male, mean age 66.5 +/- 12.2 years), most had squamous cell carcinoma (87.5%), followed by salivary gland carcinoma (5.1%), and thyroid and nasopharyngeal carcinoma (2.2% each). The most common primary tumor sites were in the oral cavity (37.5%) and oropharynx (31.6%). At survey completion, 1.5% were newly diagnosed, 8.1% in active treatment, and 90.4% in post-treatment surveillance (median 1.6 years since completion, 42.6% were >2 years post-treatment). </p>\n\n<p>Mean FACT-HN TOI and Total scores were 72.1 +/- 17.6 and 114.6 +/- 22.9, respectively. Mean FACIT-F TOI and Total scores were 83.3 +/- 20.65 and 127.2 +/- 25.3. FACT-HN Total scores demonstrated a strong positive correlation to FACIT-F (r = 0.95, p < 0.001), indicating that high QoL scores were associated with lower fatigue burden. TOI scores (r = 0.92) also shared similar findings, while subscale scores were moderately correlated (r =0.67, p < 0.0001). </p>\n\n<p><strong>Conclusion:</strong> FACT-HN TOI and Total scores showed a strong correlation with FACIT-F. These findings suggest that FACT-HN may serve as an efficient surrogate for fatigue measurement in HNC patients. The moderate subscale correlation indicates that FACT-HN captures the unique challenges of HNC patients not covered by FACIT-F. </p>\n\n<p>Overall, head and neck cancer patients reported moderate overall quality of life and persistent fatigue across all treatment phases. These findings suggest the lasting functional and psychosocial burden of cancer-related fatigue on the unique hardships head and neck cancer patients face. Continued evaluation of its impact is essential to guide supportive interventions and improve long-term survivorship care. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153231--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S173",
      "content_id": "154082",
      "abstract_number": "S173",
      "poster_number": "",
      "title": "A Decade Later: Decisional Regret in Long-Term Oropharyngeal Cancer Survivors",
      "summary": "The mean EQ-5D-5L VAS score demonstrated decreased QoL over the decade (2015mean 84.2±14.7, 2025mean 76.1±18.9, Δmean=-8.1, effect size dz=0.45, p<0.001). The mean total DRS score also worsened over the decade indicative of increased decisional regret (2015mean 11.1±15.1, 2025 mean 17.0±18.1, Δmean=+5.8, dz=0.34, p<0.001).",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154082",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Isabelle Jia Hui Jang, MD",
      "presenter": "Isabelle Jia Hui Jang, MD",
      "authors": "Isabelle Jia Hui Jang, MD ; Wenye Song; Ryan Goepfert; Christine Peterson; Jack J Lee; Carly Barbon; Anna Lee; Amy Moreno; Steven Frank; Clifton Fuller; Stephen Lai; Kate Hutcheson",
      "normalized_authors": [
        "Isabelle Jia Hui Jang",
        "Wenye Song",
        "Ryan Goepfert",
        "Christine Peterson",
        "Jack J Lee",
        "Carly Barbon",
        "Anna Lee",
        "Amy Moreno",
        "Steven Frank",
        "Clifton Fuller",
        "Stephen Lai",
        "Kate Hutcheson"
      ],
      "affiliations": [
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 633,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design/setting",
        "Participants",
        "Exposure(s)",
        "Main Outcome(s) and Measure(s)",
        "Results",
        "Abstract",
        "Conclusions and Relevance"
      ],
      "sections": {
        "Authors": "Isabelle Jia Hui Jang, MD ; Wenye Song; Ryan Goepfert; Christine Peterson; Jack J Lee; Carly Barbon; Anna Lee; Amy Moreno; Steven Frank; Clifton Fuller; Stephen Lai; Kate Hutcheson",
        "Affiliations": "MD Anderson Cancer Center",
        "Importance": "Decisional regret is important in cancer survivorship. Within the first decade after cancer cure, 15.5% of oropharynx cancer (OPC) survivors reported \"moderate-to-high\" regret associated with symptom burden and multimodality treatment. In an era where OPC patients are surviving longer, there is a lack of longitudinal data assessing the evolution and drivers of decisional regret from the first to second decade of survivorship when late toxicities are accumulating.",
        "Objective": "To examine the evolution of decisional regret and its symptom drivers in survivorship surveys of long-term OPC survivors over 10 years.",
        "Design/setting": "A single-institution longitudinal survey cohort study was conducted (MDA PA11-0936). 360 long-term survivors treated for their index OPC treated from 2000 to 2013 were included.",
        "Participants": "Median age at diagnosis was 55 years (interquartile range, IQR:51-61) and 81.8% were male. Majority were treated for HPV/p16-positive disease (183/360, 50.8%), and advanced AJCC VII N-stage disease (N2b or higher) (224/360, 64.6%). Median survival time was 4.8 years (range:1.31-15.3) at first survey and 15.0 years (range:11.4-25.4) [Hu1] at second survey.",
        "Exposure(s)": "All patients were treated with curative intent. 333/360 [92.5%] were treated with radiation therapy (RT) (93 [27.9%] radiation alone; 240 [72.1%] chemoradiation).",
        "Main Outcome(s) and Measure(s)": "Survivorship surveys were administered in 2015 and 2025. Decisional regret scale (DRS), EQ-5D-5L visual analogue scale (VAS) and MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) responses were compared over the 10-year survey interval using paired t-tests. MDASI symptom scores and EQ-5D VAS scores were analyzed with univariable and multivariable regression models for association with DRS at both survey time points.",
        "Results": "The mean EQ-5D-5L VAS score demonstrated decreased QoL over the decade (2015mean 84.2±14.7, 2025mean 76.1±18.9, Δmean=-8.1, effect size dz=0.45, p<0.001). The mean total DRS score also worsened over the decade indicative of increased decisional regret (2015mean 11.1±15.1, 2025 mean 17.0±18.1, Δmean=+5.8, dz=0.34, p<0.001).",
        "Abstract": "MDASI total symptom severity worsened over the decade (MDASI severity: 2015mean 1.16±1.16, 2025mean 1.71±1.57, Δmean=+0.54, dz=0.45, p<0.001) and symptom interference also worsened (MDASI interference: 2015mean 0.79±1.47, 2025mean 1.42±2.05, Δmean=+0.63, dz=0.36, p<0.001). On univariable analyses, increased MDASI symptom severity (2015:5.66, 95%confidence interval CI:4.43,6.88, p<0.001; 2025:3.90, 95%CI:3.07,4.73, p<0.001) increased MDASI interference (2015:4.90, 95%CI:3.96,5.85, p<0.001; 2025:4.49, 95%CI:2.93,6.05, p<0.001) and lower EQ-5D-5L VAS scores (2015:-0.48, 95%CI:-0.59,-0.39, p<0.001; 2025:-0.27, 95%CI:-0.36,-0.17, p<0.001) were significantly associated with increased DRS at both survey time points. On multivariable analyses, increased MDASI interference (2.48, 95%CI:1.12,3.84, p<0.001) and lower EQ-5D-5L VAS (-0.26, 95%CI:-0.39,-0.13, p<0.001) were significantly associated with DRS during the 2015 survey. However, only increased MDASI interference (specifically the activity interference score) (3.51, 95%CI:2.13,4.89, p<0.001) remained significantly associated with DRS during the 2025 survey. Trial Registration: Not applicable. View in Agenda and Add to Schedule",
        "Conclusions and Relevance": "These findings show the worsening of QoL (EQ-5D-5L) and regret (DRS) in parallel with increasing cancer symptoms over 10-years from the first to second decade after curative treatment in a cohort of OPC survivors. QoL (EQ-5D-5L) did not have a significant association with regret in the second compared to the first decade, possibly suggesting some level of acceptance amongst OPC survivors over time."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Decade Later: Decisional Regret in Long-Term Oropharyngeal Cancer Survivors</span>. <u>Isabelle Jia Hui Jang, MD</u>; Wenye Song; Ryan Goepfert; Christine Peterson; Jack J Lee; Carly Barbon; Anna Lee; Amy Moreno; Steven Frank; Clifton Fuller; Stephen Lai; Kate Hutcheson. MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Decisional regret is important in cancer survivorship. Within the first decade after cancer cure, 15.5% of oropharynx cancer (OPC) survivors reported \"moderate-to-high\" regret associated with symptom burden and multimodality treatment. In an era where OPC patients are surviving longer, there is a lack of longitudinal data assessing the evolution and drivers of decisional regret from the first to second decade of survivorship when late toxicities are accumulating.</p>\n\n<p><strong>Objective:</strong> To examine the evolution of decisional regret and its symptom drivers in survivorship surveys of long-term OPC survivors over 10 years.</p>\n\n<p><strong>Design/setting</strong>: A single-institution longitudinal survey cohort study was conducted (MDA PA11-0936). 360 long-term survivors treated for their index OPC treated from 2000 to 2013 were included.</p>\n\n<p><strong>Participants:</strong> Median age at diagnosis was 55 years (interquartile range, IQR:51-61) and 81.8% were male. Majority were treated for HPV/p16-positive disease (183/360, 50.8%), and advanced AJCC VII N-stage disease (N2b or higher) (224/360, 64.6%). Median survival time was 4.8 years (range:1.31-15.3) at first survey and 15.0 years (range:11.4-25.4) [Hu1] at second survey.</p>\n\n<p><strong>Exposure(s):</strong> All patients were treated with curative intent. 333/360 [92.5%] were treated with radiation therapy (RT) (93 [27.9%] radiation alone; 240 [72.1%] chemoradiation).</p>\n\n<p><strong>Main Outcome(s) and Measure(s): </strong>Survivorship surveys were administered in 2015 and 2025. Decisional regret scale (DRS), EQ-5D-5L visual analogue scale (VAS) and MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) responses were compared over the 10-year survey interval using paired t-tests. MDASI symptom scores and EQ-5D VAS scores were analyzed with univariable and multivariable regression models for association with DRS at both survey time points.</p>\n\n<p><strong>Results:</strong> The mean EQ-5D-5L VAS score demonstrated decreased QoL over the decade (2015mean 84.2±14.7, 2025mean 76.1±18.9, Δmean=-8.1, effect size dz=0.45, p<0.001). The mean total DRS score also worsened over the decade indicative of increased decisional regret (2015mean 11.1±15.1, 2025 mean 17.0±18.1, Δmean=+5.8, dz=0.34, p<0.001).</p>\n\n<p>MDASI total symptom severity worsened over the decade (MDASI severity: 2015mean 1.16±1.16, 2025mean 1.71±1.57, Δmean=+0.54, dz=0.45, p<0.001) and symptom interference also worsened (MDASI interference: 2015mean 0.79±1.47, 2025mean 1.42±2.05, Δmean=+0.63, dz=0.36, p<0.001).</p>\n\n<p>On univariable analyses, increased MDASI symptom severity (2015:5.66, 95%confidence interval CI:4.43,6.88, p<0.001; 2025:3.90, 95%CI:3.07,4.73, p<0.001) increased MDASI interference (2015:4.90, 95%CI:3.96,5.85, p<0.001; 2025:4.49, 95%CI:2.93,6.05, p<0.001) and lower EQ-5D-5L VAS scores (2015:-0.48, 95%CI:-0.59,-0.39, p<0.001; 2025:-0.27, 95%CI:-0.36,-0.17, p<0.001) were significantly associated with increased DRS at both survey time points.</p>\n\n<p>On multivariable analyses, increased MDASI interference (2.48, 95%CI:1.12,3.84, p<0.001) and lower EQ-5D-5L VAS (-0.26, 95%CI:-0.39,-0.13, p<0.001) were significantly associated with DRS during the 2015 survey. However, only increased MDASI interference (specifically the activity interference score) (3.51, 95%CI:2.13,4.89, p<0.001) remained significantly associated with DRS during the 2025 survey.</p>\n\n<p><strong>Conclusions and Relevance: </strong> These findings show the worsening of QoL (EQ-5D-5L) and regret (DRS) in parallel with increasing cancer symptoms over 10-years from the first to second decade after curative treatment in a cohort of OPC survivors. QoL (EQ-5D-5L) did not have a significant association with regret in the second compared to the first decade, possibly suggesting some level of acceptance amongst OPC survivors over time.</p>\n\n<p>Trial Registration: Not applicable.</p>\n\n<p><strong>On behalf of OPC-SURVIVOR Research Program</strong></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154082--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S174",
      "content_id": "153673",
      "abstract_number": "S174",
      "poster_number": "",
      "title": "'Eating Through a Fog': Understanding the Nutritional Experiences of Head and Neck Cancer Patients",
      "summary": "Of the 17 patient participants, 35% (6) received surgery with radiation, 24% (4) received surgery with chemotherapy and radiation, and 42% (7) received only chemotherapy and radiation. The average age of participants was 70 years old, with a range of 39 to 93. All participants were currently eating partially by mouth, but almost half of participants (47%) had a permanent feeding tube inserted for treatment, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153673",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mitra Alikhani, BSN, RN",
      "presenter": "Mitra Alikhani, BSN, RN",
      "authors": "Mitra Alikhani, BSN, RN 1 ; Hannah Lee, BS 1 ; Zaria Cosby, MPH 1 ; Aronpreet Atwell, MS 2 ; Becky Tsang, MSPA, PAC 2 ; Katie Mathias, MS, RDAP 2 ; Thi Nguyen, RD 2 ; Yilin Kuo, BSN, RN 2 ; Chris Holsinger, MD 1 ; Andrey Finegersh, MD, PhD 1 ; Wei-Ting Chen, PhD 1 ; Marcela Radtke, PhD 1 ; Lisa G Rosas, PhD, MPH 1 ; Michelle M Chen, MD, MHS 1",
      "normalized_authors": [
        "Mitra Alikhani, BSN",
        "Hannah Lee",
        "Zaria Cosby",
        "Aronpreet Atwell",
        "Becky Tsang, MSPA, PAC",
        "Katie Mathias, RDAP",
        "Thi Nguyen, RD",
        "Yilin Kuo, BSN",
        "Chris Holsinger",
        "Andrey Finegersh",
        "Wei-Ting Chen",
        "Marcela Radtke",
        "Lisa G Rosas",
        "Michelle M Chen, MHS"
      ],
      "affiliations": [
        "Stanford University School of Medicine",
        "Stanford Health Care"
      ],
      "normalized_institutions": [
        "Stanford University School of Medicine",
        "Stanford Health Care"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153673/visual%20abstract.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153673/visual%20abstract.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153673"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objectives",
        "Design, Setting, and Participants",
        "Main outcomes and measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mitra Alikhani, BSN, RN 1 ; Hannah Lee, BS 1 ; Zaria Cosby, MPH 1 ; Aronpreet Atwell, MS 2 ; Becky Tsang, MSPA, PAC 2 ; Katie Mathias, MS, RDAP 2 ; Thi Nguyen, RD 2 ; Yilin Kuo, BSN, RN 2 ; Chris Holsinger, MD 1 ; Andrey Finegersh, MD, PhD 1 ; Wei-Ting Chen, PhD 1 ; Marcela Radtke, PhD 1 ; Lisa G Rosas, PhD, MPH 1 ; Michelle M Chen, MD, MHS 1",
        "Affiliations": "1 Stanford University School of Medicine; 2 Stanford Health Care",
        "Importance": "Patients with head and neck cancer (HNC) have a 25-65% incidence of malnutrition at diagnosis. Due to treatment, many HNC patients experience xerostomia, dysphagia, and taste changes, further worsening their nutritional status. While malnutrition is a documented risk factor for complications in this patient population, including poor wound healing, extended hospital stays, and decreased survival, there is a paucity information on patients’ nutritional needs following treatment.",
        "Objectives": "The purpose of this study was to gain a deeper understanding of HNC survivors nutritional needs including challenges, access, and food insecurity.",
        "Design, Setting, and Participants": "We conducted semi-structured interviews with 17 patients who had undergone surgery, chemotherapy, and/or radiation for HNC at a tertiary academic medical center and 2 caregivers. Participants were recruited purposively to ensure representation of diverse cultural backgrounds. Interviews were audio-recorded, transcribed verbatim, and analyzed using reflexive thematic analysis. Three researchers independently coded transcripts (kappa = 0.75), met regularly to reconcile discrepancies, and engaged in iterative memo-writing to refine themes.",
        "Main outcomes and measures": "Themes from the perspective of patients on factors that impact the nutritional experience of patients with head and neck cancer.",
        "Results": "Of the 17 patient participants, 35% (6) received surgery with radiation, 24% (4) received surgery with chemotherapy and radiation, and 42% (7) received only chemotherapy and radiation. The average age of participants was 70 years old, with a range of 39 to 93. All participants were currently eating partially by mouth, but almost half of participants (47%) had a permanent feeding tube inserted for treatment, and 29% still had the feeding tube at the time of interview. The average self-reported weight loss during treatment was 11.7 kg (95% CI, 7.6-15.7 kg). We identified five main themes: 1) cancer treatment related effects on nutrition, 2) nutrition resource availability, 3) social and emotional experience of eating, 4) financial burdens, and 5) opportunities for future support. Participants reported that treatment associated side effects resulted in short and long-term changes to their diet. Participants described utilizing a variety of nutrition resources (clinician resources, recipes, cookbooks, online resources), which they found helpful to varying extents. Caregiver support was noted to be very important among those who had it. The anatomic and functional changes had a profound impact on social eating patterns and created strong emotions around eating in public. Participants reported financial concerns regarding the cost of meal-replacement drinks. Some but not all participants were interested in receiving medically tailored meals delivered, financial support for nutritional expenses, access to HNC support groups, and simple visual guides to better inform their diet changes during and after treatment.",
        "Conclusions and Relevance": "HNC patients reported significant long-term nutritional challenges across physical, social, emotional, and financial domains. Many patients emphasized the need for more resources focused on financial and social support for nutritional challenges, particularly for those without caregiver support.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>'Eating Through a Fog': Understanding the Nutritional Experiences of Head and Neck Cancer Patients</span>. <u>Mitra Alikhani, BSN, RN</u><sup>1</sup>; Hannah Lee, BS<sup>1</sup>; Zaria Cosby, MPH<sup>1</sup>; Aronpreet Atwell, MS<sup>2</sup>; Becky Tsang, MSPA, PAC<sup>2</sup>; Katie Mathias, MS, RDAP<sup>2</sup>; Thi Nguyen, RD<sup>2</sup>; Yilin Kuo, BSN, RN<sup>2</sup>; Chris Holsinger, MD<sup>1</sup>; Andrey Finegersh, MD, PhD<sup>1</sup>; Wei-Ting Chen, PhD<sup>1</sup>; Marcela Radtke, PhD<sup>1</sup>; Lisa G Rosas, PhD, MPH<sup>1</sup>; Michelle M Chen, MD, MHS<sup>1</sup>. <sup>1</sup>Stanford University School of Medicine; <sup>2</sup>Stanford Health Care<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance</strong>: Patients with head and neck cancer (HNC) have a 25-65% incidence of malnutrition at diagnosis. Due to treatment, many HNC patients experience xerostomia, dysphagia, and taste changes, further worsening their nutritional status. While malnutrition is a documented risk factor for complications in this patient population, including poor wound healing, extended hospital stays, and decreased survival, there is a paucity information on patients’ nutritional needs following treatment.</p>\n\n<p><strong>Objectives</strong>: The purpose of this study was to gain a deeper understanding of HNC survivors nutritional needs including challenges, access, and food insecurity.</p>\n\n<p><strong>Design, Setting, and Participants</strong>: We conducted semi-structured interviews with 17 patients who had undergone surgery, chemotherapy, and/or radiation for HNC at a tertiary academic medical center and 2 caregivers. Participants were recruited purposively to ensure representation of diverse cultural backgrounds. Interviews were audio-recorded, transcribed verbatim, and analyzed using reflexive thematic analysis. Three researchers independently coded transcripts (kappa = 0.75), met regularly to reconcile discrepancies, and engaged in iterative memo-writing to refine themes.</p>\n\n<p><strong>Main outcomes and measures</strong>: Themes from the perspective of patients on factors that impact the nutritional experience of patients with head and neck cancer.</p>\n\n<p><strong>Results</strong>: Of the 17 patient participants, 35% (6) received surgery with radiation, 24% (4) received surgery with chemotherapy and radiation, and 42% (7) received only chemotherapy and radiation. The average age of participants was 70 years old, with a range of 39 to 93. All participants were currently eating partially by mouth, but almost half of participants (47%) had a permanent feeding tube inserted for treatment, and 29% still had the feeding tube at the time of interview. The average self-reported weight loss during treatment was 11.7 kg (95% CI, 7.6-15.7 kg). We identified five main themes: 1) cancer treatment related effects on nutrition, 2) nutrition resource availability, 3) social and emotional experience of eating, 4) financial burdens, and 5) opportunities for future support. Participants reported that treatment associated side effects resulted in short and long-term changes to their diet. Participants described utilizing a variety of nutrition resources (clinician resources, recipes, cookbooks, online resources), which they found helpful to varying extents. Caregiver support was noted to be very important among those who had it. The anatomic and functional changes had a profound impact on social eating patterns and created strong emotions around eating in public. Participants reported financial concerns regarding the cost of meal-replacement drinks. Some but not all participants were interested in receiving medically tailored meals delivered, financial support for nutritional expenses, access to HNC support groups, and simple visual guides to better inform their diet changes during and after treatment.</p>\n\n<p><strong>Conclusions and Relevance</strong>: HNC patients reported significant long-term nutritional challenges across physical, social, emotional, and financial domains. Many patients emphasized the need for more resources focused on financial and social support for nutritional challenges, particularly for those without caregiver support.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153673/visual%20abstract.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153673--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S175",
      "content_id": "154533",
      "abstract_number": "S175",
      "poster_number": "",
      "title": "Childhood Thyroid Cancer Survivors – Impacts on Voice and Swallowing",
      "summary": "The findings reinforce the importance of continuous monitoring of voice and swallowing changes, as well as long-term follow-up of this population. A comprehensive evaluation of all childhood thyroidectomy survivors will allow early identification of specific dysfunctions, guide multidisciplinary interventions, and ultimately improve both quality of life and the rehabilitation process for potential...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154533",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiza Seganfredo Mainardi",
      "presenter": "Luiza Seganfredo Mainardi",
      "authors": "Eduardo Calheiros de Moraes; Lilian Neide da Silva Pereira de Almeida; Andressa Silva de Freitas; Luiza Seganfredo Mainardi ; Fernando Luiz Dias; Izabella Costa Santos",
      "normalized_authors": [
        "Eduardo Calheiros de Moraes",
        "Lilian Neide da Silva Pereira de Almeida",
        "Andressa Silva de Freitas",
        "Luiza Seganfredo Mainardi",
        "Fernando Luiz Dias",
        "Izabella Costa Santos"
      ],
      "affiliations": [
        "Brazilian National Cancer Institute"
      ],
      "normalized_institutions": [
        "Brazilian National Cancer Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Objective",
        "Method",
        "Inclusion criteria",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eduardo Calheiros de Moraes; Lilian Neide da Silva Pereira de Almeida; Andressa Silva de Freitas; Luiza Seganfredo Mainardi ; Fernando Luiz Dias; Izabella Costa Santos",
        "Affiliations": "Brazilian National Cancer Institute",
        "Abstract": "Pediatric thyroid cancer is the leading cause of pediatric endocrine cancer, accounting for more than 6% of all cancers in the pediatric population from 2012 to 2016. It is one of the most common secondary malignancies among childhood cancer survivors. Treatment for thyroid cancer in this population usually includes surgical resection, total thyroidectomy, and modified neck dissection to remove regional lymph nodes. Recurrent laryngeal nerve injury may occur, particularly in more advanced cases, and can be devastating for children, causing voice changes, aspiration, recurrent pneumonia, and dyspnea. This type of cancer often results in several speech-language pathological changes, requiring long-term evaluation. View in Agenda and Add to Schedule",
        "Objective": "To evaluate the survival of patients with childhood thyroid cancer and its impact on aspects of voice, swallowing, and quality of life among survivors after cancer treatment.",
        "Method": "Longitudinal study approved by the INCA Research Ethics Committee (26331314.2.0000.5274).",
        "Inclusion criteria": "patients over 18 years of age at the time of evaluation for this study, who had been treated for a thyroid tumor in childhood, and who were being followed at INCA, with no stage restriction. Sociodemographic and clinical data were collected from medical records. Assessments include laryngoscopy, voice analysis, videofluoroscopy of swallowing, and quality-of-life protocols.",
        "Results": "A total of 161 medical records were analyzed. The ThyPRO-39 quality-of-life instrument showed that only 14.28% of patients had significant changes across all domains except goiter. The most affected aspects were fatigue (57.14%), anxiety (57.14%), depression (42.86%), and emotional well-being (42.86%). In the SF-36, 28.56% showed impairments in social, emotional, and mental health domains. According to the Ferrans and Powers Quality of Life Index, no patients demonstrated poor quality of life. Moderate quality was reported in the following domains: health/functioning (42.86%), socioeconomic/family (28.57%), and psychological/spiritual (57.12%). In the swallowing assessments, no changes were identified in the EAT-10, while in the MDADI, 28.57% reported difficulties related to ingestion. Vocal evaluations using the QVV and VHI showed that 28.57% had a mild vocal handicap, and 71.43% had normal voice quality. Laryngoscopic examination revealed vocal fold paralysis in 28.57% of patients.",
        "Conclusion": "The findings reinforce the importance of continuous monitoring of voice and swallowing changes, as well as long-term follow-up of this population. A comprehensive evaluation of all childhood thyroidectomy survivors will allow early identification of specific dysfunctions, guide multidisciplinary interventions, and ultimately improve both quality of life and the rehabilitation process for potential treatment-related sequelae."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Childhood Thyroid Cancer Survivors – Impacts on Voice and Swallowing</span>. Eduardo Calheiros de Moraes; Lilian Neide da Silva Pereira de Almeida; Andressa Silva de Freitas; <u>Luiza Seganfredo Mainardi</u>; Fernando Luiz Dias; Izabella Costa Santos. Brazilian National Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Pediatric thyroid cancer is the leading cause of pediatric endocrine cancer, accounting for more than 6% of all cancers in the pediatric population from 2012 to 2016. It is one of the most common secondary malignancies among childhood cancer survivors. Treatment for thyroid cancer in this population usually includes surgical resection, total thyroidectomy, and modified neck dissection to remove regional lymph nodes. Recurrent laryngeal nerve injury may occur, particularly in more advanced cases, and can be devastating for children, causing voice changes, aspiration, recurrent pneumonia, and dyspnea. This type of cancer often results in several speech-language pathological changes, requiring long-term evaluation.</p>\n\n<p><strong>Objective: </strong>To evaluate the survival of patients with childhood thyroid cancer and its impact on aspects of voice, swallowing, and quality of life among survivors after cancer treatment.</p>\n\n<p><strong>Method: </strong>Longitudinal study approved by the INCA Research Ethics Committee (26331314.2.0000.5274).</p>\n\n<p><strong>Inclusion criteria:</strong> patients over 18 years of age at the time of evaluation for this study, who had been treated for a thyroid tumor in childhood, and who were being followed at INCA, with no stage restriction. Sociodemographic and clinical data were collected from medical records. Assessments include laryngoscopy, voice analysis, videofluoroscopy of swallowing, and quality-of-life protocols.</p>\n\n<p><strong>Results: </strong>A total of 161 medical records were analyzed. The ThyPRO-39 quality-of-life instrument showed that only 14.28% of patients had significant changes across all domains except goiter. The most affected aspects were fatigue (57.14%), anxiety (57.14%), depression (42.86%), and emotional well-being (42.86%). In the SF-36, 28.56% showed impairments in social, emotional, and mental health domains. According to the Ferrans and Powers Quality of Life Index, no patients demonstrated poor quality of life. Moderate quality was reported in the following domains: health/functioning (42.86%), socioeconomic/family (28.57%), and psychological/spiritual (57.12%). In the swallowing assessments, no changes were identified in the EAT-10, while in the MDADI, 28.57% reported difficulties related to ingestion. Vocal evaluations using the QVV and VHI showed that 28.57% had a mild vocal handicap, and 71.43% had normal voice quality. Laryngoscopic examination revealed vocal fold paralysis in 28.57% of patients.</p>\n\n<p><strong>Conclusion: </strong>The findings reinforce the importance of continuous monitoring of voice and swallowing changes, as well as long-term follow-up of this population. A comprehensive evaluation of all childhood thyroidectomy survivors will allow early identification of specific dysfunctions, guide multidisciplinary interventions, and ultimately improve both quality of life and the rehabilitation process for potential treatment-related sequelae.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154533--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S176",
      "content_id": "153733",
      "abstract_number": "S176",
      "poster_number": "",
      "title": "Acute Changes in Cervical Function after Radiation for Head and Neck Cancer",
      "summary": "Early declines in cervical mobility, particularly neck extension and rotation, along with reduced deep cervical flexor endurance and increased movement-evoked pain, are evident within 1 month after RT for HNC. These findings enhance understanding of acute musculoskeletal changes that occur following radiation and highlight the importance of timely rehabilitation strategies. Continued work is needed to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153733",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marci L Nilsen",
      "presenter": "Marci L Nilsen",
      "authors": "Marci L Nilsen 1 ; Stephen Glass, MS 2 ; Susan M Sereika, PhD 3 ; Heath Skinner, MD, PhD 1 ; Yvonne Mowery, MD, PhD 1 ; Nicole Scheff, PhD 1 ; Matthew Spector, MD 1 ; Seungwon Kim, MD 1 ; Jose Zevallos, MD, MPH 1 ; Joel Greenberger, MD 1 ; Jonas T Johnson, MD 1 ; Sara Piva, PhD, PT 4",
      "normalized_authors": [
        "Marci L Nilsen",
        "Stephen Glass",
        "Susan M Sereika",
        "Heath Skinner",
        "Yvonne Mowery",
        "Nicole Scheff",
        "Matthew Spector",
        "Seungwon Kim",
        "Jose Zevallos",
        "Joel Greenberger",
        "Jonas T Johnson",
        "Sara Piva, PT"
      ],
      "affiliations": [
        "University of Pittsburgh, School of Medicine",
        "University of Pittsburgh, School of Public Health",
        "University of Pittsburgh, School of Nursing",
        "University of Pittsburgh, School of Health and Rehabilitation Science"
      ],
      "normalized_institutions": [
        "University of Pittsburgh, School of Medicine",
        "University of Pittsburgh, School of Public Health",
        "University of Pittsburgh, School of Nursing",
        "University of Pittsburgh, School of Health and Rehabilitation Science"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Marci L Nilsen 1 ; Stephen Glass, MS 2 ; Susan M Sereika, PhD 3 ; Heath Skinner, MD, PhD 1 ; Yvonne Mowery, MD, PhD 1 ; Nicole Scheff, PhD 1 ; Matthew Spector, MD 1 ; Seungwon Kim, MD 1 ; Jose Zevallos, MD, MPH 1 ; Joel Greenberger, MD 1 ; Jonas T Johnson, MD 1 ; Sara Piva, PhD, PT 4",
        "Affiliations": "1 University of Pittsburgh, School of Medicine; 2 University of Pittsburgh, School of Public Health; 3 University of Pittsburgh, School of Nursing; 4 University of Pittsburgh, School of Health and Rehabilitation Science",
        "Background": "Radiation therapy (RT) for head and neck cancer (HNC) can induce early musculoskeletal impairment that may initiate progression toward chronic radiation-induced fibrosis and long-term functional decline. Despite this risk, early changes in cervical function during and after RT remain poorly characterized. The objective of this investigation was to evaluate acute changes in cervical range of motion, deep cervical flexor endurance, and movement-evoked neck pain from pre-RT to 1-month post-RT.",
        "Methods": "This ongoing prospective cohort study enrolls patients with head and neck cancer undergoing definitive or adjuvant RT. Participants in this cohort study complete assessments at multiple time points; however, this analysis includes only the baseline pre-RT assessment and the 1-month post-RT (±1 month) assessment. Cervical musculoskeletal outcomes include digital inclinometer–based cervical range of motion (ROM), isometric neck muscle strength using handheld dynamometry, and deep cervical flexor endurance, assessed as the number of seconds a participant can maintain cranio-cervical flexion with the head slightly elevated from the examination table. Movement-evoked neck pain (0–10) was recorded during ROM. Demographic characteristics were obtained directly from participants. Cancer and treatment characteristics, including tumor site and stage, treatment modality, radiation dose and fractionation, and concurrent chemotherapy, were abstracted from the medical record. Unadjusted pre–RT and post-RT differences were estimated using within-participant differences and paired t-tests. Adjusted effects were estimated using linear random-effects modeling, controlling for age, treatment modality, T-stage, N-stage, and dose, and t-tests were performed using Satterthwaite’s method. Complete case analysis was performed in R 4.5.1.",
        "Results": "To date, 96 participants have completed both assessments. The sample was predominantly male (75%), White (96%), and had a median age of 63; 53% had T3–T4 disease, and 78% had N1–N3 disease. Adjuvant therapy was received by 54% of participants, with a median radiation dose of 66 Gy. From pre-RT to 1-month post-RT, participants showed a significant reduction in neck extension ROM (–4.6°, p < 0.001), decreased full rotation ROM in the neutral-flexion supine position (–7.4°, p < 0.001), increased average side-bending pain (+0.78, p = 0.019), and reduced deep cervical flexor endurance (–15 seconds, p = 0.003). Adjusted analyses yielded similar findings, with significant declines in neck extension ROM (–4.5°, p < 0.001), full rotation ROM (–7.0°, p < 0.001), and endurance (–15 seconds, p = 0.003), along with increased average side-bending pain (+0.74, p = 0.026).",
        "Conclusion": "Early declines in cervical mobility, particularly neck extension and rotation, along with reduced deep cervical flexor endurance and increased movement-evoked pain, are evident within 1 month after RT for HNC. These findings enhance understanding of acute musculoskeletal changes that occur following radiation and highlight the importance of timely rehabilitation strategies. Continued work is needed to characterize long-term trajectories and to identify the clinical, treatment-related, and omics factors (e.g., gene-expression signatures of fibrosis, inflammatory pathway activation, circulating markers of tissue remodeling) that contribute to inter-patient differences in risk and recovery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Acute Changes in Cervical Function after Radiation for Head and Neck Cancer</span>. <u>Marci L Nilsen</u><sup>1</sup>; Stephen Glass, MS<sup>2</sup>; Susan M Sereika, PhD<sup>3</sup>; Heath Skinner, MD, PhD<sup>1</sup>; Yvonne Mowery, MD, PhD<sup>1</sup>; Nicole Scheff, PhD<sup>1</sup>; Matthew Spector, MD<sup>1</sup>; Seungwon Kim, MD<sup>1</sup>; Jose Zevallos, MD, MPH<sup>1</sup>; Joel Greenberger, MD<sup>1</sup>; Jonas T Johnson, MD<sup>1</sup>; Sara Piva, PhD, PT<sup>4</sup>. <sup>1</sup>University of Pittsburgh, School of Medicine; <sup>2</sup>University of Pittsburgh, School of Public Health; <sup>3</sup>University of Pittsburgh, School of Nursing; <sup>4</sup>University of Pittsburgh, School of Health and Rehabilitation Science<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Radiation therapy (RT) for head and neck cancer (HNC) can induce early musculoskeletal impairment that may initiate progression toward chronic radiation-induced fibrosis and long-term functional decline. Despite this risk, early changes in cervical function during and after RT remain poorly characterized. The objective of this investigation was to evaluate acute changes in cervical range of motion, deep cervical flexor endurance, and movement-evoked neck pain from pre-RT to 1-month post-RT.</p>\n\n<p><strong>Methods: </strong>This ongoing prospective cohort study enrolls patients with head and neck cancer undergoing definitive or adjuvant RT. Participants in this cohort study complete assessments at multiple time points; however, this analysis includes only the baseline pre-RT assessment and the 1-month post-RT (±1 month) assessment. Cervical musculoskeletal outcomes include digital inclinometer–based cervical range of motion (ROM), isometric neck muscle strength using handheld dynamometry, and deep cervical flexor endurance, assessed as the number of seconds a participant can maintain cranio-cervical flexion with the head slightly elevated from the examination table. Movement-evoked neck pain (0–10) was recorded during ROM. Demographic characteristics were obtained directly from participants. Cancer and treatment characteristics, including tumor site and stage, treatment modality, radiation dose and fractionation, and concurrent chemotherapy, were abstracted from the medical record. Unadjusted pre–RT and post-RT differences were estimated using within-participant differences and paired t-tests. Adjusted effects were estimated using linear random-effects modeling, controlling for age, treatment modality, T-stage, N-stage, and dose, and t-tests were performed using Satterthwaite’s method. Complete case analysis was performed in R 4.5.1.</p>\n\n<p><strong>Results: </strong>To date, 96 participants have completed both assessments. The sample was predominantly male (75%), White (96%), and had a median age of 63; 53% had T3–T4 disease, and 78% had N1–N3 disease. Adjuvant therapy was received by 54% of participants, with a median radiation dose of 66 Gy.  From pre-RT to 1-month post-RT, participants showed a significant reduction in neck extension ROM (–4.6°, p < 0.001), decreased full rotation ROM in the neutral-flexion supine position (–7.4°, p < 0.001), increased average side-bending pain (+0.78, p = 0.019), and reduced deep cervical flexor endurance (–15 seconds, p = 0.003). Adjusted analyses yielded similar findings, with significant declines in neck extension ROM (–4.5°, p < 0.001), full rotation ROM (–7.0°, p < 0.001), and endurance (–15 seconds, p = 0.003), along with increased average side-bending pain (+0.74, p = 0.026).</p>\n\n<p><strong>Conclusion: </strong>Early declines in cervical mobility, particularly neck extension and rotation, along with reduced deep cervical flexor endurance and increased movement-evoked pain, are evident within 1 month after RT for HNC. These findings enhance understanding of acute musculoskeletal changes that occur following radiation and highlight the importance of timely rehabilitation strategies. Continued work is needed to characterize long-term trajectories and to identify the clinical, treatment-related, and omics factors (e.g., gene-expression signatures of fibrosis, inflammatory pathway activation, circulating markers of tissue remodeling) that contribute to inter-patient differences in risk and recovery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153733--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S177",
      "content_id": "154723",
      "abstract_number": "S177",
      "poster_number": "",
      "title": "HPV Status and Long-Term Recovery: A 5-Year Evaluation of Quality of Life in oropharyngeal squamous cell carcinoma Survivors",
      "summary": "Over five years of follow-up, HPV-positive OPSCC survivors demonstrated more favorable and consistent recovery across multiple QoL domains -particularly global QoL, physical functioning, role limitations, and general health. HPV-negative survivors showed more variable improvements and were particularly vulnerable to worsening pain and social functioning. These findings underscore the importance of developing...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154723",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Elham Mohebbi",
      "presenter": "Elham Mohebbi",
      "authors": "Elham Mohebbi 1 ; Alaina Carr 1 ; Siddhi Patil 1 ; Christina Zhu 1 ; Rhea Shetty 1 ; Clara Arrate 1 ; Twisha Kurlagunda 1 ; Andrew Hong 1 ; Christopher Pishvaian 1 ; Jonathan Giurintano 1 ; Matthew Witek 1 ; Gregory Wolf 2 ; Kristi D. Graves 1 ; Peter H. Ahn 1 ; Laura Rozek 1",
      "normalized_authors": [
        "Elham Mohebbi",
        "Alaina Carr",
        "Siddhi Patil",
        "Christina Zhu",
        "Rhea Shetty",
        "Clara Arrate",
        "Twisha Kurlagunda",
        "Andrew Hong",
        "Christopher Pishvaian",
        "Jonathan Giurintano",
        "Matthew Witek",
        "Gregory Wolf",
        "Kristi D. Graves",
        "Peter H. Ahn",
        "Laura Rozek"
      ],
      "affiliations": [
        "Georgetown University",
        "University of Michigan"
      ],
      "normalized_institutions": [
        "Georgetown University",
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 470,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Elham Mohebbi 1 ; Alaina Carr 1 ; Siddhi Patil 1 ; Christina Zhu 1 ; Rhea Shetty 1 ; Clara Arrate 1 ; Twisha Kurlagunda 1 ; Andrew Hong 1 ; Christopher Pishvaian 1 ; Jonathan Giurintano 1 ; Matthew Witek 1 ; Gregory Wolf 2 ; Kristi D. Graves 1 ; Peter H. Ahn 1 ; Laura Rozek 1",
        "Affiliations": "1 Georgetown University; 2 University of Michigan",
        "Background": "Survivors of oropharyngeal squamous cell carcinoma (OPSCC) often face long-lasting disruptions in quality of life (QoL) after treatment. Although HPV-positive disease is associated with better survival outcomes compared to HPV-negative OPSCC, its relationship with long-term QoL recovery has not been fully characterized. We examined 5-year trajectories of global QoL and key functional among HPV-positive and HPV-negative OPSCC survivors to better understand patterns of recovery.",
        "Methods": "This prospective cohort included 211 (180 HPV-positive, 31 HPV-negative) newly diagnosed OPSCC patients recruited at a medical center (2008-2014). Baseline characteristics differed significantly by HPV status: HPV-positive patients were younger (57.7 vs. 64.2 years), more often male (86.67% vs. 67.74%, P = 0.008), and reported higher baseline global QoL (53.9 vs. 48.3; P = 0.019). Longitudinal changes in QoL were assessed using multiple linear regression models stratified by HPV status. Models adjusted for age, gender, BMI, comorbidity score, treatment modality, smoking, alcohol use, and disease stage. Outcomes included global QoL and domain-specific measures (pain, physical functioning, role limitations, energy/fatigue, emotional well-being, social functioning, and general health).",
        "Results": "HPV-positive survivors showed clear and sustained improvement in global QoL. These improvements persisted through year 5 (P-trend = 0.0004). In contrast, HPV-negative patients demonstrated smaller gains, though their overall positive trajectory was still statistically significant (P-trend = 0.0203). Pain outcomes diverged sharply by HPV status. HPV-positive survivors experienced modest but meaningful reductions in pain, particularly between years 2 and 4, while HPV-negative survivors showed a significant worsening over time (P-trend = 0.0002).",
        "Abstract": "Physical functioning steadily improved among HPV-positive patients (P-trend = 0.0015), with the largest improvement in year 5. HPV-negative patients showed some improvement but with greater variability and a non-significant overall trend. Role limitations due to physical health also improved consistently among HPV-positive survivors (P-trend = 0.0019), whereas HPV-negative patients improved only in year 5. Emotional role limitations improved early for both groups, while HPV-negative survivors did not show a clear pattern. Energy/fatigue remained largely unchanged across follow-up. Emotional well-being showed slight declines among HPV-positive survivors, particularly at year 3, while patterns for HPV-negative patients were inconsistent and non-significant. Social functioning declined for HPV-positive patients but gradually recovered by year 5 (P-trend = 0.2739). Conversely, HPV-negative survivors experienced a significant downward trend (P-trend = 0.0488). General health improved meaningfully among HPV-positive survivors (P-trend = 0.0178), while HPV-negative patients showed more variable responses (P-trend = 0.1218). View in Agenda and Add to Schedule",
        "Conclusion": "Over five years of follow-up, HPV-positive OPSCC survivors demonstrated more favorable and consistent recovery across multiple QoL domains -particularly global QoL, physical functioning, role limitations, and general health. HPV-negative survivors showed more variable improvements and were particularly vulnerable to worsening pain and social functioning. These findings underscore the importance of developing tailored survivorship strategies, with special attention to the needs of HPV-negative patients who may face persisting symptom burden."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HPV Status and Long-Term Recovery: A 5-Year Evaluation of Quality of Life in oropharyngeal squamous cell carcinoma Survivors</span>. <u>Elham Mohebbi</u><sup>1</sup>; Alaina Carr<sup>1</sup>; Siddhi Patil<sup>1</sup>; Christina Zhu<sup>1</sup>; Rhea Shetty<sup>1</sup>; Clara Arrate<sup>1</sup>; Twisha Kurlagunda<sup>1</sup>; Andrew Hong<sup>1</sup>; Christopher Pishvaian<sup>1</sup>; Jonathan Giurintano<sup>1</sup>; Matthew Witek<sup>1</sup>; Gregory Wolf<sup>2</sup>; Kristi D. Graves<sup>1</sup>; Peter H. Ahn<sup>1</sup>; Laura Rozek<sup>1</sup>. <sup>1</sup>Georgetown University; <sup>2</sup>University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Survivors of oropharyngeal squamous cell carcinoma (OPSCC) often face long-lasting disruptions in quality of life (QoL) after treatment. Although HPV-positive disease is associated with better survival outcomes compared to HPV-negative OPSCC, its relationship with long-term QoL recovery has not been fully characterized. We examined 5-year trajectories of global QoL and key functional among HPV-positive and HPV-negative OPSCC survivors to better understand patterns of recovery.</p>\n\n<p><strong>Methods: </strong>This prospective cohort included 211 (180 HPV-positive, 31 HPV-negative) newly diagnosed OPSCC patients recruited at a medical center (2008-2014). Baseline characteristics differed significantly by HPV status: HPV-positive patients were younger (57.7 vs. 64.2 years), more often male (86.67% vs. 67.74%, P = 0.008), and reported higher baseline global QoL (53.9 vs. 48.3; P = 0.019). Longitudinal changes in QoL were assessed using multiple linear regression models stratified by HPV status. Models adjusted for age, gender, BMI, comorbidity score, treatment modality, smoking, alcohol use, and disease stage. Outcomes included global QoL and domain-specific measures (pain, physical functioning, role limitations, energy/fatigue, emotional well-being, social functioning, and general health).</p>\n\n<p><strong>Results: </strong>HPV-positive survivors showed clear and sustained improvement in global QoL. These improvements persisted through year 5 (P-trend = 0.0004). In contrast, HPV-negative patients demonstrated smaller gains, though their overall positive trajectory was still statistically significant (P-trend = 0.0203). Pain outcomes diverged sharply by HPV status. HPV-positive survivors experienced modest but meaningful reductions in pain, particularly between years 2 and 4, while HPV-negative survivors showed a significant worsening over time (P-trend = 0.0002).</p>\n\n<p>Physical functioning steadily improved among HPV-positive patients (P-trend = 0.0015), with the largest improvement in year 5. HPV-negative patients showed some improvement but with greater variability and a non-significant overall trend. Role limitations due to physical health also improved consistently among HPV-positive survivors (P-trend = 0.0019), whereas HPV-negative patients improved only in year 5. Emotional role limitations improved early for both groups, while HPV-negative survivors did not show a clear pattern. Energy/fatigue remained largely unchanged across follow-up. Emotional well-being showed slight declines among HPV-positive survivors, particularly at year 3, while patterns for HPV-negative patients were inconsistent and non-significant. Social functioning declined for HPV-positive patients but gradually recovered by year 5 (P-trend = 0.2739). Conversely, HPV-negative survivors experienced a significant downward trend (P-trend = 0.0488). General health improved meaningfully among HPV-positive survivors (P-trend = 0.0178), while HPV-negative patients showed more variable responses (P-trend = 0.1218).</p>\n\n<p><strong>Conclusion: </strong>Over five years of follow-up, HPV-positive OPSCC survivors demonstrated more favorable and consistent recovery across multiple QoL domains -particularly global QoL, physical functioning, role limitations, and general health. HPV-negative survivors showed more variable improvements and were particularly vulnerable to worsening pain and social functioning. These findings underscore the importance of developing tailored survivorship strategies, with special attention to the needs of HPV-negative patients who may face persisting symptom burden.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154723--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S178",
      "content_id": "154462",
      "abstract_number": "S178",
      "poster_number": "",
      "title": "Decisional regret and patient reported functional outcomes after head and neck free flap reconstruction",
      "summary": "Patients who underwent free flap reconstruction for head and neck cancer reported minimal decisional regret regarding their surgery and excellent donor site function. Recurrence and donor site function may be associated with decisional regret, though further work is needed to elucidate this relationship.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154462",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260127",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Micah K Harris, MD",
      "presenter": "Micah K Harris, MD",
      "authors": "Micah K Harris, MD ; Amaan Rahman, BS; Joshua Smith, MD; Steven Chinn, MD; Seungwon Kim, MD; Jose P Zevallos, MD; Jessica H Maxwell, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew Spector, MD",
      "normalized_authors": [
        "Micah K Harris",
        "Amaan Rahman",
        "Joshua Smith",
        "Steven Chinn",
        "Seungwon Kim",
        "Jose P Zevallos",
        "Jessica H Maxwell",
        "Kevin J Contrera",
        "Shaum J Sridharan",
        "Matthew Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 532,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Micah K Harris, MD ; Amaan Rahman, BS; Joshua Smith, MD; Steven Chinn, MD; Seungwon Kim, MD; Jose P Zevallos, MD; Jessica H Maxwell, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew Spector, MD",
        "Affiliations": "University of Pittsburgh",
        "Introduction": "The diagnosis and treatment of head and neck cancer carries a significant psychosocial burden. Patients are often tasked with making difficult decisions regarding treatments that can significantly alter their quality of life. As such, the evaluation of decisional regret and patient reported outcomes is of high importance. Free flap reconstruction has become increasingly utilized in head and neck surgery. However, there are a lack of studies examining decisional regret that include head and neck as well as donor site specific functional outcomes for patients who underwent free flap reconstruction",
        "Methods": "Patients who underwent free flap reconstruction from September 2011 to November 2024 were contacted via phone or email. Decisional regret was measured using the Ottawa Decision Regret Scale. A modified Disabilities of the Arm, Should, and Hand questionnaire (QuickDASH) was used to measure functional outcomes for radial forearm flaps, and the Foot and Ankle Disability Index (FADI) for lower extremity (anterolateral thigh [ALT] or fibula) flaps. The Ottawa decision regret scale and QuickDASH were converted to a score out of 100, with 100 indicating the highest regret or worst function, respectively. Donor site appearance was assessed using the University of Washington Quality of Life questionnaire on a scale of 4, with 4 indicating the worst appearance. Clinicodemographic data included age, gender, radiation history, pathologic T category, adjuvant radiation, recurrence, and time from surgery to survey.",
        "Results": "142 patients (33 fibula, 69 ALT, and 40 forearm flaps) were included (59.2% male, 63 ±12 years). 28 (19.7%) patients underwent salvage surgery, 15 (10.6%) had prior radiation, 91 (64.1%) had advanced (T3-T4) disease, 107 (75.3%) underwent adjuvant radiation, and 14 (9.9%) developed recurrence. The time from surgery to survey administration was 28.7 ±25.8 months. The average decisional regret score (DRS) was 16.2 ± 20.1. The average donor site appearance (DSA) was rated 1.2 ±0.5 and donor site function (DSF) 7.1 ±13.4. Comparing ALT versus fibula versus forearm flaps, there were no significant differences between DRS (13.2 ±20.9 vs 16.4 ±18.9 vs 19.5 ±22.7, P=0.42) or DSA ratings (1.3 ±0.72 vs 1.2 ±0.39 vs 1.2 ±0.53, P=0.62). Fibulas had worse DSF compared to ALT (14.1 ±15.3 vs 6.3 ±12.1, P=0.0098) and forearm (14.1 ±15.3 vs 4.2 ±10.1, P=0.0026) flaps.",
        "Abstract": "Patients with moderate-to-severe regret reported worse DSF (12.4 ±15.6 vs. 6.3 ±12, P=0.043) and had higher recurrence rates (25% vs 7%, P=0.0077). On multivariate analysis, recurrence (OR 4.83, 95% CI 1.12-20.8, P=0.035) and worse DSF (OR 1.04, 95% CI 1.001-1.08, P=0.045) remained predictive of moderate-to-severe regret when controlling for age, time from surgery to survey, gender, adjuvant radiation, and advanced disease. View in Agenda and Add to Schedule",
        "Conclusion": "Patients who underwent free flap reconstruction for head and neck cancer reported minimal decisional regret regarding their surgery and excellent donor site function. Recurrence and donor site function may be associated with decisional regret, though further work is needed to elucidate this relationship."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Decisional regret and patient reported functional outcomes after head and neck free flap reconstruction</span>. <u>Micah K Harris, MD</u>; Amaan Rahman, BS; Joshua Smith, MD; Steven Chinn, MD; Seungwon Kim, MD; Jose P Zevallos, MD; Jessica H Maxwell, MD; Kevin J Contrera, MD; Shaum J Sridharan, MD; Matthew Spector, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The diagnosis and treatment of head and neck cancer carries a significant psychosocial burden. Patients are often tasked with making difficult decisions regarding treatments that can significantly alter their quality of life. As such, the evaluation of decisional regret and patient reported outcomes is of high importance. Free flap reconstruction has become increasingly utilized in head and neck surgery. However, there are a lack of studies examining decisional regret that include head and neck as well as donor site specific functional outcomes for patients who underwent free flap reconstruction</p>\n\n<p><strong>Methods:</strong> Patients who underwent free flap reconstruction from September 2011 to November 2024 were contacted via phone or email. Decisional regret was measured using the Ottawa Decision Regret Scale. A modified Disabilities of the Arm, Should, and Hand questionnaire (QuickDASH) was used to measure functional outcomes for radial forearm flaps, and the Foot and Ankle Disability Index (FADI) for lower extremity (anterolateral thigh [ALT] or fibula) flaps. The Ottawa decision regret scale and QuickDASH were converted to a score out of 100, with 100 indicating the highest regret or worst function, respectively. Donor site appearance was assessed using the University of Washington Quality of Life questionnaire on a scale of 4, with 4 indicating the worst appearance. Clinicodemographic data included age, gender, radiation history, pathologic T category, adjuvant radiation, recurrence, and time from surgery to survey.</p>\n\n<p><strong>Results: </strong>142 patients (33 fibula, 69 ALT, and 40 forearm flaps) were included (59.2% male, 63 ±12 years). 28 (19.7%) patients underwent salvage surgery, 15 (10.6%) had prior radiation, 91 (64.1%) had advanced (T3-T4) disease, 107 (75.3%) underwent adjuvant radiation, and 14 (9.9%) developed recurrence. The time from surgery to survey administration was 28.7 ±25.8 months. The average decisional regret score (DRS) was 16.2 ± 20.1. The average donor site appearance (DSA) was rated 1.2 ±0.5 and donor site function (DSF) 7.1 ±13.4. Comparing ALT versus fibula versus forearm flaps, there were no significant differences between DRS (13.2 ±20.9 vs 16.4 ±18.9 vs 19.5 ±22.7, P=0.42) or DSA ratings (1.3 ±0.72 vs 1.2 ±0.39 vs 1.2 ±0.53, P=0.62). Fibulas had worse DSF compared to ALT (14.1 ±15.3 vs 6.3 ±12.1, P=0.0098) and forearm (14.1 ±15.3 vs 4.2 ±10.1, P=0.0026) flaps.</p>\n\n<p>Patients with moderate-to-severe regret reported worse DSF (12.4 ±15.6 vs. 6.3 ±12, P=0.043) and had higher recurrence rates (25% vs 7%, P=0.0077). On multivariate analysis, recurrence (OR 4.83, 95% CI 1.12-20.8, P=0.035) and worse DSF (OR 1.04, 95% CI 1.001-1.08, P=0.045) remained predictive of moderate-to-severe regret when controlling for age, time from surgery to survey, gender, adjuvant radiation, and advanced disease.</p>\n\n<p><strong>Conclusion:</strong> Patients who underwent free flap reconstruction for head and neck cancer reported minimal decisional regret regarding their surgery and excellent donor site function. Recurrence and donor site function may be associated with decisional regret, though further work is needed to elucidate this relationship.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154462--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260127' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S179",
      "content_id": "153529",
      "abstract_number": "S179",
      "poster_number": "",
      "title": "Mapping Tumor Hypoxia in Head and Neck Squamous Cell Carcinoma with CA9-Targeted PET Tracer [64Cu]Cu-DPI-4452.",
      "summary": "Tumor hypoxia is a well-established driver of cancer progression, therapeutic resistance, and poor prognosis. Hypoxic tumor regions are markedly resistant to both chemotherapy and ionizing radiation, usually necessitating substantially higher doses to achieve comparable efficacy relative to normoxic tissues. Carbonic anhydrase IX (CA9), a membrane-bound protein regulated by HIF-1α, is consistently upregulated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153529",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Paula Demetrio de Souza Franca",
      "presenter": "Paula Demetrio de Souza Franca",
      "authors": "Paula Demetrio de Souza Franca ; Amanda Carston; Ashley Weichmann; Lauren E Wehner; Monet McCalla, MD; Adedamola Adeniyi; Eduardo Aluicio Sarduy, PhD; Jonathan Engle, PhD; Hansel Comas Rojas, PhD; Tiffany Glazer, MD; Reinier Hernandez, PhD",
      "normalized_authors": [
        "Paula Demetrio de Souza Franca",
        "Amanda Carston",
        "Ashley Weichmann",
        "Lauren E Wehner",
        "Monet McCalla",
        "Adedamola Adeniyi",
        "Eduardo Aluicio Sarduy",
        "Jonathan Engle",
        "Hansel Comas Rojas",
        "Tiffany Glazer",
        "Reinier Hernandez"
      ],
      "affiliations": [
        "University of Wisconsin - Madison"
      ],
      "normalized_institutions": [
        "University of Wisconsin - Madison"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153529/Figure%20for%20submission.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153529/Figure%20for%20submission.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153529"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 514,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Paula Demetrio de Souza Franca ; Amanda Carston; Ashley Weichmann; Lauren E Wehner; Monet McCalla, MD; Adedamola Adeniyi; Eduardo Aluicio Sarduy, PhD; Jonathan Engle, PhD; Hansel Comas Rojas, PhD; Tiffany Glazer, MD; Reinier Hernandez, PhD",
        "Affiliations": "University of Wisconsin - Madison",
        "Abstract": "Tumor hypoxia is a well-established driver of cancer progression, therapeutic resistance, and poor prognosis. Hypoxic tumor regions are markedly resistant to both chemotherapy and ionizing radiation, usually necessitating substantially higher doses to achieve comparable efficacy relative to normoxic tissues. Carbonic anhydrase IX (CA9), a membrane-bound protein regulated by HIF-1α, is consistently upregulated under hypoxia and represents an attractive target for molecular imaging. This study evaluated the CA9-specific radiolabeled cyclic peptide [ 64 Cu]Cu-DPI-4452 ([ 64 Cu]DPI), as a novel CA9-targeted PET/CT radiotracer to identify hypoxic tumor regions in the head and neck with high specificity. To establish target relevance, we first performed immunohistochemical analysis on 15 de-identified human tumor samples. We then proceeded with in vivo studies. DPI-4452 was radiolabeled with [ 64 Cu] at 40 mCi/mmol molar activity and purified using reverse-phase solid-phase extraction. Mice bearing Cal27 oral cancer xenografts were intravenously injected with ~200 µCi of [ 64 Cu]DPI to assess CA9 expression in vivo. PET/CT imaging was conducted 1 hour post-injection, followed by tissue harvesting for gamma counting, autoradiography, and histological validation. Volumes-of-interest were analyzed to quantify [ 64 Cu]DPI biodistribution as percent injected activity per gram of tissue (%IA/g). Tumors were then harvested and their activities measured with a gamma counter. Frozen sections (10 µm) were prepared and the slides were exposed to an autoradiography plate for 1 hour. Autoradiography data were analyzed using Fiji software, and adjacent sections underwent immunohistochemistry for correlation with CA9 expression. Human tumor samples showed heterogeneous CA9 expression across patients in both intensity and proportion of positive cells, consistent with known biological variation. In xenografted mice, PET/CT imaging demonstrated [ 64 Cu]DPI uptake within tumor regions exhibiting CA9 expression. On ex-vivo biodistribution, tumors showed significantly higher %ID/g values compared with control tissues (tumor: 0.75 ± 0.06 vs. control: 0.1 ± 0.04), confirming selective tracer uptake. Autoradiography revealed a distinct intratumoral distribution pattern, with well-defined “hot” and “cold” regions. The hot areas exhibited significantly greater signal intensity than cold areas (0.21 ± 0.04 A.U vs 0.04 ± 0.02 A.U., p<0.0001, Wilcoxson test). The ratio of radioactivity between \"hot\" versus muscle control was 14.28 and hot tumor areas also exhibited significantly greater signal intensity than muscle controls (0.21 ± 0.04 A.U vs. 0.01 ± 0.01, p<0.0001). Interestingly, \"cold\" tumor areas also demonstrated higher uptake than the normal muscle controls (p<0.001, ratio of 2.41). Histological examination confirmed colocalization of [ 64 Cu]DPI uptake with CA9-positive regions, whereas CA9-negative tumor areas and muscle tissue showed negligible uptake. No acute toxicity or adverse effects were observed in tracer-treated mice. Taken together, these results demonstrate that CA9 is highly relevant as an imaging biomarker in human head and neck tumors and that [ 64 Cu]DPI selectively binds CA9 in vivo. Given the clinical importance of identifying hypoxic tumor regions and the current lack of reliable noninvasive hypoxia-imaging tools, [ 64 Cu]DPI represents a promising candidate for future translational development and clinical investigation. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mapping Tumor Hypoxia in Head and Neck Squamous Cell Carcinoma with CA9-Targeted PET Tracer [64Cu]Cu-DPI-4452.</span>. <u>Paula Demetrio de Souza Franca</u>; Amanda Carston; Ashley Weichmann; Lauren E Wehner; Monet McCalla, MD; Adedamola Adeniyi; Eduardo Aluicio Sarduy, PhD; Jonathan Engle, PhD; Hansel Comas Rojas, PhD; Tiffany Glazer, MD; Reinier Hernandez, PhD. University of Wisconsin - Madison<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/153529/Figure%20for%20submission.jpg' /></p>\n\n<p>Tumor hypoxia is a well-established driver of cancer progression, therapeutic resistance, and poor prognosis. Hypoxic tumor regions are markedly resistant to both chemotherapy and ionizing radiation, usually necessitating substantially higher doses to achieve comparable efficacy relative to normoxic tissues. Carbonic anhydrase IX (CA9), a membrane-bound protein regulated by HIF-1α, is consistently upregulated under hypoxia and represents an attractive target for molecular imaging. This study evaluated the CA9-specific radiolabeled cyclic peptide [<sup>64</sup>Cu]Cu-DPI-4452 ([<sup>64</sup>Cu]DPI), as a novel CA9-targeted PET/CT radiotracer to identify hypoxic tumor regions in the head and neck with high specificity.</p>\n\n<p>To establish target relevance, we first performed immunohistochemical analysis on 15 de-identified human tumor samples. We then proceeded with in vivo studies. DPI-4452 was radiolabeled with [<sup>64</sup>Cu] at 40 mCi/mmol molar activity and purified using reverse-phase solid-phase extraction. Mice bearing Cal27 oral cancer xenografts were intravenously injected with ~200 µCi of [<sup>64</sup>Cu]DPI to assess CA9 expression in vivo. PET/CT imaging was conducted 1 hour post-injection, followed by tissue harvesting for gamma counting, autoradiography, and histological validation. Volumes-of-interest were analyzed to quantify [<sup>64</sup>Cu]DPI biodistribution as percent injected activity per gram of tissue (%IA/g). Tumors were then harvested and their activities measured with a gamma counter.  Frozen sections (10 µm) were prepared and the slides were exposed to an autoradiography plate for 1 hour. Autoradiography data were analyzed using Fiji software, and adjacent sections underwent immunohistochemistry for correlation with CA9 expression.</p>\n\n<p>Human tumor samples showed heterogeneous CA9 expression across patients in both intensity and proportion of positive cells, consistent with known biological variation. In xenografted mice, PET/CT imaging demonstrated [<sup>64</sup>Cu]DPI uptake within tumor regions exhibiting CA9 expression. On ex-vivo biodistribution, tumors showed significantly higher %ID/g values compared with control tissues (tumor: 0.75 ± 0.06 vs. control: 0.1 ± 0.04), confirming selective tracer uptake. Autoradiography revealed a distinct intratumoral distribution pattern, with well-defined “hot” and “cold” regions. The hot areas exhibited significantly greater signal intensity than cold areas (0.21 ± 0.04 A.U vs 0.04 ± 0.02 A.U., p<0.0001, Wilcoxson test). The ratio of radioactivity between \"hot\" versus muscle control was 14.28 and hot tumor areas also exhibited significantly greater signal intensity than muscle controls (0.21 ± 0.04 A.U vs. 0.01 ± 0.01, p<0.0001). Interestingly, \"cold\" tumor areas also demonstrated higher uptake than the normal muscle controls (p<0.001, ratio of 2.41). Histological examination confirmed colocalization of [<sup>64</sup>Cu]DPI uptake with CA9-positive regions, whereas CA9-negative tumor areas and muscle tissue showed negligible uptake. No acute toxicity or adverse effects were observed in tracer-treated mice.</p>\n\n<p>Taken together, these results demonstrate that CA9 is highly relevant as an imaging biomarker in human head and neck tumors and that [<sup>64</sup>Cu]DPI selectively binds CA9 in vivo. Given the clinical importance of identifying hypoxic tumor regions and the current lack of reliable noninvasive hypoxia-imaging tools, [<sup>64</sup>Cu]DPI represents a promising candidate for future translational development and clinical investigation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153529--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S180",
      "content_id": "154249",
      "abstract_number": "S180",
      "poster_number": "",
      "title": "Potential of 18F-FDG PET/CT to Assess Pathologic Response to Neoadjuvant Immunotherapy in Resectable Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "summary": "Thirty-five patients had pre- and post-induction imaging and met criteria for inclusion in this cohort (mean age 62, SD=13). Twenty-three patients (66%) received NAIC and 12 patients (33%) received NAI. Thirty (86%) demonstrated a reduction in total tumor volume and 31 (89%) a reduction in total lesion glycolysis (TLG). Seven (20%) patients achieved a radiologic complete response (rCR) of the primary tumor,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154249",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ethan Gomez",
      "presenter": "Ethan Gomez",
      "authors": "Ethan Gomez ; Mudassir Mumtaz; Yehia Elkersh; Ryan Sicard; Alicia Yang; Daniel Kraft; Peter Cooke; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof",
      "normalized_authors": [
        "Ethan Gomez",
        "Mudassir Mumtaz",
        "Yehia Elkersh",
        "Ryan Sicard",
        "Alicia Yang",
        "Daniel Kraft",
        "Peter Cooke",
        "Thomas Barrett",
        "Michael Berger",
        "Marita Teng",
        "Diana Kirke",
        "Mark Urken",
        "Mohemmed Khan",
        "Raymond Chai",
        "Nasrin Ghesani",
        "Azita Khorsandi",
        "Richard Bakst",
        "Krzysztof Misiukiewicz",
        "Kunal Sindhu",
        "Jerry Liu",
        "Margaret Brandwein",
        "Elisabet Pujadas",
        "Eric Genden",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 516,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ethan Gomez ; Mudassir Mumtaz; Yehia Elkersh; Ryan Sicard; Alicia Yang; Daniel Kraft; Peter Cooke; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Background": "Neoadjuvant immunotherapy has emerged as a novel treatment strategy for HNSCC, with recent application of pembrolizumab in resectable disease yielding substantial pathologic responses. Early identification of both responders and non-responders to neoadjuvant immunotherapy (NAI) will be critical for prognostication and effective treatment adaptation. 18F-FDG PET/CT has demonstrated utility in predicting pathologic response to neoadjuvant immunotherapy in other malignancies and could provide a feasible, non-invasive modality for assessing treatment response in HNSCC.",
        "Methods": "This is a retrospective review of patients at a large, urban, academic hospital diagnosed with HNSCC. All patients received neoadjuvant pembrolizumab, either NAI alone or in combination with docetaxel and cisplatin chemotherapy (neoadjuvant chemo-immunotherapy, NAIC) followed by surgery as definitive treatment. Patients included in this analysis had 18F-FDG PET/CT images taken at baseline and again prior to surgery. Parameters of the malignant lesions were extracted from the images using contouring tools on MIM software. Histopathologic evidence of treatment effect, further quantified by the extent of pathologic response within the surgical specimen was abstracted from the final pathology report. Using surgical pathology of the primary lesions as the reference standard, we examined the association between PET/CT metabolic parameters with major pathologic response (MPR; 0-10% viable tumor) at the primary tumor site.",
        "Results": "Thirty-five patients had pre- and post-induction imaging and met criteria for inclusion in this cohort (mean age 62, SD=13). Twenty-three patients (66%) received NAIC and 12 patients (33%) received NAI. Thirty (86%) demonstrated a reduction in total tumor volume and 31 (89%) a reduction in total lesion glycolysis (TLG). Seven (20%) patients achieved a radiologic complete response (rCR) of the primary tumor, including 3 (9%) who also demonstrated nodal rCR. Of the 31 cases with complete pathology assessments, 17 (55%) demonstrated MPR. Overall, induction therapy resulted in substantial reductions in metabolic and volumetric tumor burden, with mean reduction of 58% in total tumor volume and 75% in TLG. These reductions were driven predominantly by changes in the primary tumor (62% volume decrease; 78% TLG decrease), although nodal disease was also reduced (51% volume decrease; 66% TLG decrease). When stratified by pathological response, responders (achieved MPR) demonstrated significantly greater reductions in primary tumor volume and TLG compared with non-responders (p<0.001 for both). Logistic regression models demonstrated that greater percent reductions in primary tumor volume (OR 1.09, 95%CI 1.04–1.17, p=0.005) and TLG (OR 1.09, 95%CI 1.03–1.20, p=0.019), were associated with significantly higher odds of achieving MPR.",
        "Discussion": "In this study, we demonstrate that decreased disease burden on post-induction PET/CT is associated with reduced pathological tumor burden following NAI in HNSCC. The results provide further insight into the radiologic outcomes of NAI for resectable tumors and the ability of post-induction PET imaging to predict pathologic response. As implementation of response-adaptive strategies is considered, understanding whether PET-based early response metrics can reliably predict pathologic response becomes increasingly important. Additionally, for non-surgical cohorts, such as HPV-negative oropharynx, larynx, and hypopharynx, determining reliable response measures without surgical pathology will be important for guiding treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Potential of 18F-FDG PET/CT to Assess Pathologic Response to Neoadjuvant Immunotherapy in Resectable Head and Neck Squamous Cell Carcinoma (HNSCC)</span>. <u>Ethan Gomez</u>; Mudassir Mumtaz; Yehia Elkersh; Ryan Sicard; Alicia Yang; Daniel Kraft; Peter Cooke; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant immunotherapy has emerged as a novel treatment strategy for HNSCC, with recent application of pembrolizumab in resectable disease yielding substantial pathologic responses. Early identification of both responders and non-responders to neoadjuvant immunotherapy (NAI) will be critical for prognostication and effective treatment adaptation. 18F-FDG PET/CT has demonstrated utility in predicting pathologic response to neoadjuvant immunotherapy in other malignancies and could provide a feasible, non-invasive modality for assessing treatment response in HNSCC.</p>\n\n<p><strong>Methods: </strong>This is a retrospective review of patients at a large, urban, academic hospital diagnosed with HNSCC. All patients received neoadjuvant pembrolizumab, either NAI alone or in combination with docetaxel and cisplatin chemotherapy (neoadjuvant chemo-immunotherapy, NAIC) followed by surgery as definitive treatment. Patients included in this analysis had 18F-FDG PET/CT images taken at baseline and again prior to surgery. Parameters of the malignant lesions were extracted from the images using contouring tools on MIM software. Histopathologic evidence of treatment effect, further quantified by the extent of pathologic response within the surgical specimen was abstracted from the final pathology report. Using surgical pathology of the primary lesions as the reference standard, we examined the association between PET/CT metabolic parameters with major pathologic response (MPR; 0-10% viable tumor) at the primary tumor site.</p>\n\n<p><strong>Results: </strong>Thirty-five patients had pre- and post-induction imaging and met criteria for inclusion in this cohort (mean age 62, SD=13). Twenty-three patients (66%) received NAIC and 12 patients (33%) received NAI. Thirty (86%) demonstrated a reduction in total tumor volume and 31 (89%) a reduction in total lesion glycolysis (TLG). Seven (20%) patients achieved a radiologic complete response (rCR) of the primary tumor, including 3 (9%) who also demonstrated nodal rCR. Of the 31 cases with complete pathology assessments, 17 (55%) demonstrated MPR. Overall, induction therapy resulted in substantial reductions in metabolic and volumetric tumor burden, with mean reduction of 58% in total tumor volume and 75% in TLG. These reductions were driven predominantly by changes in the primary tumor (62% volume decrease; 78% TLG decrease), although nodal disease was also reduced (51% volume decrease; 66% TLG decrease). When stratified by pathological response, responders (achieved MPR) demonstrated significantly greater reductions in primary tumor volume and TLG compared with non-responders (p<0.001 for both). Logistic regression models demonstrated that greater percent reductions in primary tumor volume (OR 1.09, 95%CI 1.04–1.17, p=0.005) and TLG (OR 1.09, 95%CI 1.03–1.20, p=0.019), were associated with significantly higher odds of achieving MPR.</p>\n\n<p><strong>Discussion: </strong>In this study, we demonstrate that decreased disease burden on post-induction PET/CT is associated with reduced pathological tumor burden following NAI in HNSCC. The results provide further insight into the radiologic outcomes of NAI for resectable tumors and the ability of post-induction PET imaging to predict pathologic response. As implementation of response-adaptive strategies is considered, understanding whether PET-based early response metrics can reliably predict pathologic response becomes increasingly important. Additionally, for non-surgical cohorts, such as HPV-negative oropharynx, larynx, and hypopharynx, determining reliable response measures without surgical pathology will be important for guiding treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154249--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S181",
      "content_id": "153532",
      "abstract_number": "S181",
      "poster_number": "",
      "title": "A Systematic Review and Meta-Analysis Comparing Endoscopy and Imaging for the Detection of Synchronous Primary Tumors in Head and Neck Squamous Cell Carcinoma",
      "summary": "For SPT detection in HNSCC, panendoscopy and PET-CT offer comparable diagnostic yield, while endoscopy remains superior to conventional cross-sectional imaging. These findings support a risk-adapted, integrative strategy: PET-CT is recommended as the initial non-invasive staging and screening tool, with panendoscopy reserved as a critical adjunct for high-risk patients (e.g., heavy smokers/drinkers,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153532",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Meng Yee Chen",
      "presenter": "Meng Yee Chen",
      "authors": "Joan Yanyi Lee, Dr 1 ; Thomas Zheng Jie Teng 1 ; Junhe Chan 2 ; Meng Yee Chen 3 ; Nicholas Brian Shannon, Dr 1",
      "normalized_authors": [
        "Joan Yanyi Lee, Dr",
        "Thomas Zheng Jie Teng",
        "Junhe Chan",
        "Meng Yee Chen",
        "Nicholas Brian Shannon, Dr"
      ],
      "affiliations": [
        "Singapore General Hospital",
        "Yong Loo Lin School of Medicine, National University Singapore",
        "Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"
      ],
      "normalized_institutions": [
        "Singapore General Hospital",
        "Yong Loo Lin School of Medicine, National University Singapore",
        "Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 295,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joan Yanyi Lee, Dr 1 ; Thomas Zheng Jie Teng 1 ; Junhe Chan 2 ; Meng Yee Chen 3 ; Nicholas Brian Shannon, Dr 1",
        "Affiliations": "1 Singapore General Hospital; 2 Yong Loo Lin School of Medicine, National University Singapore; 3 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore",
        "Background": "Synchronous primary tumors (SPTs) are a leading cause of non-primary cancer death in head and neck squamous cell carcinoma (HNSCC) patients. Current NCCN guidelines recommend SPT identification but lack consensus on optimal screening modality. This study compares the diagnostic yield of panendoscopy versus imaging for SPT detection.",
        "Methods": "A systematic review and meta-analysis was conducted following PRISMA guidelines, registered on PROSPERO (CRD42024565282). PubMed and Scopus were searched from inception to May 1, 2024. Studies of adults with primary UADT HNSCC undergoing SPT screening via endoscopy, imaging, or both within 6 months were included. The primary outcome was the number of SPTs detected by endoscopy versus imaging. Pooled risk ratios (RR) and prevalence were calculated using a random-effects model.",
        "Results": "Of 22 included studies (n=27,073 patients), the pooled SPT prevalence was 4%. Endoscopy demonstrated a 1.7 times greater detection rate than all imaging modalities combined (RR: 1.72; 95% CI: 1.11–2.67). Subgroup analysis revealed endoscopy was superior to non-nuclear imaging (CT, MRI) (RR: 2.46; 95% CI: 1.94–3.12), but not to nuclear imaging (PET-CT) (RR: 0.66; 95% CI: 0.38–1.17). Higher SPT prevalence was observed in Asia (5%) versus North America and Europe (3% each). Smoking and alcohol consumption significantly increased SPT risk (RR=1.77 and RR=2.79, respectively).",
        "Conclusion": "For SPT detection in HNSCC, panendoscopy and PET-CT offer comparable diagnostic yield, while endoscopy remains superior to conventional cross-sectional imaging. These findings support a risk-adapted, integrative strategy: PET-CT is recommended as the initial non-invasive staging and screening tool, with panendoscopy reserved as a critical adjunct for high-risk patients (e.g., heavy smokers/drinkers, hypopharyngeal primaries, or in regions with high esophageal cancer prevalence) to identify PET-occult mucosal lesions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Systematic Review and Meta-Analysis Comparing Endoscopy and Imaging for the Detection of Synchronous Primary Tumors in Head and Neck Squamous Cell Carcinoma</span>. Joan Yanyi Lee, Dr<sup>1</sup>; Thomas Zheng Jie Teng<sup>1</sup>; Junhe Chan<sup>2</sup>; <u>Meng Yee Chen</u><sup>3</sup>; Nicholas Brian Shannon, Dr<sup>1</sup>. <sup>1</sup>Singapore General Hospital; <sup>2</sup>Yong Loo Lin School of Medicine, National University Singapore; <sup>3</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Synchronous primary tumors (SPTs) are a leading cause of non-primary cancer death in head and neck squamous cell carcinoma (HNSCC) patients. Current NCCN guidelines recommend SPT identification but lack consensus on optimal screening modality. This study compares the diagnostic yield of panendoscopy versus imaging for SPT detection.</p>\n\n<p><strong>Methods: </strong>A systematic review and meta-analysis was conducted following PRISMA guidelines, registered on PROSPERO (CRD42024565282). PubMed and Scopus were searched from inception to May 1, 2024. Studies of adults with primary UADT HNSCC undergoing SPT screening via endoscopy, imaging, or both within 6 months were included. The primary outcome was the number of SPTs detected by endoscopy versus imaging. Pooled risk ratios (RR) and prevalence were calculated using a random-effects model.</p>\n\n<p><strong>Results: </strong>Of 22 included studies (n=27,073 patients), the pooled SPT prevalence was 4%. Endoscopy demonstrated a 1.7 times greater detection rate than all imaging modalities combined (RR: 1.72; 95% CI: 1.11–2.67). Subgroup analysis revealed endoscopy was superior to non-nuclear imaging (CT, MRI) (RR: 2.46; 95% CI: 1.94–3.12), but not to nuclear imaging (PET-CT) (RR: 0.66; 95% CI: 0.38–1.17). Higher SPT prevalence was observed in Asia (5%) versus North America and Europe (3% each). Smoking and alcohol consumption significantly increased SPT risk (RR=1.77 and RR=2.79, respectively).</p>\n\n<p><strong>Conclusion: </strong>For SPT detection in HNSCC, panendoscopy and PET-CT offer comparable diagnostic yield, while endoscopy remains superior to conventional cross-sectional imaging. These findings support a risk-adapted, integrative strategy: PET-CT is recommended as the initial non-invasive staging and screening tool, with panendoscopy reserved as a critical adjunct for high-risk patients (e.g., heavy smokers/drinkers, hypopharyngeal primaries, or in regions with high esophageal cancer prevalence) to identify PET-occult mucosal lesions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153532--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S182",
      "content_id": "153690",
      "abstract_number": "S182",
      "poster_number": "",
      "title": "Real-Time Metabolic Imaging Identifies Distinct Cisplatin Responses in HNSCC",
      "summary": "HP-MRS-based k PL sensitively distinguishes CDDP responsive from resistant HNSCC by capturing TP53-related metabolic reprogramming. CDDP markedly reduced glycolytic flux, LDH activity, Lactate, and ATP production in sensitive cells, whereas resistant cells maintained metabolic flexibility. IC-MS metabolic signatures aligned with HP-MRS k PL changes, reinforcing mechanistic validity. Integrated HP-MRI with DCE-MRI...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153690",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Darren M Broughton, MS",
      "presenter": "Darren M Broughton, MS",
      "authors": "Yunyun Chen, PhD 1 ; Qing Wang, PhD 2 ; Darren M Broughton, MS 1 ; Ying C Henderson, MD, PhD 1 ; Ahmad Abubaker, MD 1 ; Lin Tan, MS 3 ; James A Bankson, PhD 2 ; Vlad C Sandulache, MD, PhD 4 ; Stephen Y Lai, MD, PhD 1",
      "normalized_authors": [
        "Yunyun Chen",
        "Qing Wang",
        "Darren M Broughton",
        "Ying C Henderson",
        "Ahmad Abubaker",
        "Lin Tan",
        "James A Bankson",
        "Vlad C Sandulache",
        "Stephen Y Lai"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 536,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials/Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Yunyun Chen, PhD 1 ; Qing Wang, PhD 2 ; Darren M Broughton, MS 1 ; Ying C Henderson, MD, PhD 1 ; Ahmad Abubaker, MD 1 ; Lin Tan, MS 3 ; James A Bankson, PhD 2 ; Vlad C Sandulache, MD, PhD 4 ; Stephen Y Lai, MD, PhD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3 Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4 Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
        "Introduction": "Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease with high morbidity and mortality. Cisplatin (CDDP) remains a standard first-line systemic therapy for advanced disease, yet its clinical benefit is limited by heterogeneous response and frequent development of resistance. These resistance mechanisms are linked to metabolic reprogramming and influenced by TP53 status. Hyperpolarized-MRI (HP-MRI) enables quantification of real-time pyruvate-to-lactate conversion ( k PL ) as readout of glycolytic flux. We hypothesize that k PL can serve as a sensitive metabolic biomarker that distinguishes CDDP-sensitive and -resistant HNSCC.",
        "Materials/Methods": "HN31 (TP53-mutant) and acquired CDDP-resistant HN31-P10A were treated with 20 µM CDDP for 24 h. k PL was quantified via HP-[1- 13 C]-pyruvate MRS acquired on a 300 MHz NMR. Lactate and LDH activity were measured by biochemical assays. Overall cellular metabolism profiling were assessed using Seahorse XF96 ATP Rate Assay. Glycolytic and TCA-cycle metabolites were quantified by Ion Chromatography-Mass Spectrometry (IC- MS). Orthotopic murine HNSCC buccal tumors were imaged with HP-MRI combined with DCE-MRI.",
        "Results": "In HN31 cells, baseline k PL was 0.61±0.15s -1 and was significantly reduced to 0.23±0.03s -1 after CDDP treatment ( p<0.05 ). In HN31-P10A, baseline k PL was lower (0.23±0.04s -1 ) and CDDP induced a modest decrease to 0.14±0.02s -1 ( p<0.05 ). Biochemical assays were consistent: CDDP reduced lactate by 32.7% and LDH activity by 15.5% in HN31. HN31-P10A cells showed lower basal lactate and LDH activity (17.3% and 25.7%), and CDDP caused no additional reduction. Seahorse profiling demonstrated that CDDP markedly impaired ATP metabolism in HN31 cells, reducing ATP from 44.1 to 23.5pmol/min and decreasing ATP Rate Index from 0.75 to 0.38. Conversely, HN31-P10A maintained stable ATP output and a high ATP Rate Index (1.4), reflecting preserved metabolic flexibility. Metabolism profiling confirmed that CDDP simultaneously suppressed glycolysis and mitochondrial respiration in HN31, whereas HN31-P10A retained glycolytic reserve and oxidative capacity. IC-MS in HN31 cells showed significant CDDP-induced decreases in multiple glycolytic metabolites (e.g., F6P, G6P, G3P, PEP, lactate, pyruvate, 2,3-BPG, 2-PG/3-PG; mean fold-change 0.40-0.69, p<0.05 ) and a reduction in the Pyruvate/Lactate ratio (1.01 to 0.58, P<0.05 ), concordant with reduced k PL from HP-MRS. HN31-P10A cells remained stable glycolytic metabolite levels, exhibiting a modest reduction on Pyruvate/Lactate ratio (0.64 to 0.47, P=0.08 ) after CDDP, consistent with minimal k PL changes on HP-MRS. In vivo , orthotopic buccal tumors exhibited strong pyruvate-to-lactate signals on HP-MRI and perfusion-metabolism correlations on DCE-MRI. Multimodal imaging enhanced tumor localization and perfusion assessment, improving the accuracy of k PL , enabling robust longitudinal evaluation of metabolic changes with spatial and temporal resolution.",
        "Conclusion": "HP-MRS-based k PL sensitively distinguishes CDDP responsive from resistant HNSCC by capturing TP53-related metabolic reprogramming. CDDP markedly reduced glycolytic flux, LDH activity, Lactate, and ATP production in sensitive cells, whereas resistant cells maintained metabolic flexibility. IC-MS metabolic signatures aligned with HP-MRS k PL changes, reinforcing mechanistic validity. Integrated HP-MRI with DCE-MRI enhances k PL accuracy, supporting its use as a quantitative, non-invasive biomarker for predicting and monitoring CDDP response in HNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-Time Metabolic Imaging Identifies Distinct Cisplatin Responses in HNSCC</span>. Yunyun Chen, PhD<sup>1</sup>; Qing Wang, PhD<sup>2</sup>; <u>Darren M Broughton, MS</u><sup>1</sup>; Ying C Henderson, MD, PhD<sup>1</sup>; Ahmad Abubaker, MD<sup>1</sup>; Lin Tan, MS<sup>3</sup>; James A Bankson, PhD<sup>2</sup>; Vlad C Sandulache, MD, PhD<sup>4</sup>; Stephen Y Lai, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>3</sup>Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>Bobby R. Alford Department of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease with high morbidity and mortality. Cisplatin (CDDP) remains a standard first-line systemic therapy for advanced disease, yet its clinical benefit is limited by heterogeneous response and frequent development of resistance. These resistance mechanisms are linked to metabolic reprogramming and influenced by TP53 status. Hyperpolarized-MRI (HP-MRI) enables quantification of real-time pyruvate-to-lactate conversion (<em>k<sub>PL</sub></em>) as readout of glycolytic flux. We hypothesize that <em>k<sub>PL</sub></em> can serve as a sensitive metabolic biomarker that distinguishes CDDP-sensitive and -resistant HNSCC.</p>\n\n<p><strong>Materials/Methods: </strong>HN31 (TP53-mutant) and acquired CDDP-resistant HN31-P10A were treated with 20 µM CDDP for 24 h. <em>k<sub>PL</sub> </em>was quantified via HP-[1-<sup>13</sup>C]-pyruvate MRS acquired on a 300 MHz NMR. Lactate and LDH activity were measured by biochemical assays. Overall cellular metabolism profiling were assessed using Seahorse XF96 ATP Rate Assay. Glycolytic and TCA-cycle metabolites were quantified by Ion Chromatography-Mass Spectrometry (IC- MS). Orthotopic murine HNSCC buccal tumors were imaged with HP-MRI combined with DCE-MRI.</p>\n\n<p><strong>Results: </strong>In HN31 cells, baseline <em>k<sub>PL</sub></em> was 0.61±0.15s<sup>-1</sup> and was significantly reduced to 0.23±0.03s<sup>-1</sup> after CDDP treatment (<em>p<0.05</em>). In HN31-P10A, baseline <em>k<sub>PL</sub> </em>was lower (0.23±0.04s<sup>-1</sup>) and CDDP induced a modest decrease to 0.14±0.02s<sup>-1</sup>(<em>p<0.05</em>). Biochemical assays were consistent: CDDP reduced lactate by 32.7% and LDH activity by 15.5% in HN31. HN31-P10A cells showed lower basal lactate and LDH activity (17.3% and 25.7%), and CDDP caused no additional reduction. Seahorse profiling demonstrated that CDDP markedly impaired ATP metabolism in HN31 cells, reducing ATP from 44.1 to 23.5pmol/min and decreasing ATP Rate Index from 0.75 to 0.38. Conversely, HN31-P10A maintained stable ATP output and a high ATP Rate Index (1.4), reflecting preserved metabolic flexibility. Metabolism profiling confirmed that CDDP simultaneously suppressed glycolysis and mitochondrial respiration in HN31, whereas HN31-P10A retained glycolytic reserve and oxidative capacity. IC-MS in HN31 cells showed significant CDDP-induced decreases in multiple glycolytic metabolites (e.g., F6P, G6P, G3P, PEP, lactate, pyruvate, 2,3-BPG, 2-PG/3-PG; mean fold-change 0.40-0.69, <em>p<0.05</em>) and a reduction in the Pyruvate/Lactate ratio (1.01 to 0.58, <em>P<0.05</em>), concordant with reduced <em>k<sub>PL</sub></em> from HP-MRS. HN31-P10A cells remained stable glycolytic metabolite levels, exhibiting a modest reduction on Pyruvate/Lactate ratio (0.64 to 0.47, <em>P=0.08</em>) after CDDP, consistent with minimal <em>k<sub>PL </sub></em>changes on HP-MRS. <em>In vivo</em>, orthotopic buccal tumors exhibited strong pyruvate-to-lactate signals on HP-MRI and perfusion-metabolism correlations on DCE-MRI. Multimodal imaging enhanced tumor localization and perfusion assessment, improving the accuracy of <em>k<sub>PL</sub></em>, enabling robust longitudinal evaluation of metabolic changes with spatial and temporal resolution. </p>\n\n<p><strong>Conclusion: </strong>HP-MRS-based <em>k<sub>PL</sub></em> sensitively distinguishes CDDP responsive from resistant HNSCC by capturing TP53-related metabolic reprogramming. CDDP markedly reduced glycolytic flux, LDH activity, Lactate, and ATP production in sensitive cells, whereas resistant cells maintained metabolic flexibility. IC-MS metabolic signatures aligned with HP-MRS <em>k<sub>PL</sub></em> changes, reinforcing mechanistic validity. Integrated HP-MRI with DCE-MRI enhances <em>k<sub>PL </sub></em>accuracy, supporting its use as a quantitative, non-invasive biomarker for predicting and monitoring CDDP response in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153690--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S183",
      "content_id": "153332",
      "abstract_number": "S183",
      "poster_number": "",
      "title": "Deep Learning Auto-Segmentation of Oral Cancer on CT Imaging: Defining Tumor Volumes with Specialist and Foundation AI Models",
      "summary": "Our specialist and domain-adapted foundation models achieved moderate segmentation accuracy for oral tumors, with ensemble predictions improving performance on these complex and variable cases. Next steps include developing multimodal models that incorporate MRI images and 2D photographs, utilizing a larger oral cancer dataset, and further validation on diverse test sets from external cancer centers....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153332",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Neil Lin",
      "presenter": "Neil Lin",
      "authors": "Neil Lin ; Alessandra Ruaro, MD; Eugene Yu, MD; David Goldstein, MD, MSc; Ralph Gilbert, MD; Jonathan Irish, MD, MSc; John R De Almeida, MD, MSc; Benjamin Haibe-Kains, PhD; Ali Hosni, MBBCh, MSc, PhD; Andrew Hope, MD; Jun Ma, PhD; Christopher MKL Yao, MD",
      "normalized_authors": [
        "Neil Lin",
        "Alessandra Ruaro",
        "Eugene Yu",
        "David Goldstein",
        "Ralph Gilbert",
        "Jonathan Irish",
        "John R De Almeida",
        "Benjamin Haibe-Kains",
        "Ali Hosni, MBBCh",
        "Andrew Hope",
        "Jun Ma",
        "Christopher MKL Yao"
      ],
      "affiliations": [
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University of Toronto"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153332/Performance%20Summary(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153332/Performance%20Summary(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153332"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153332/Training%20Pipeline(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153332/Training%20Pipeline(1).jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153332"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153332/Scatterplot%20Volume%20vs%20DSC.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153332/Scatterplot%20Volume%20vs%20DSC.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153332"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Neil Lin ; Alessandra Ruaro, MD; Eugene Yu, MD; David Goldstein, MD, MSc; Ralph Gilbert, MD; Jonathan Irish, MD, MSc; John R De Almeida, MD, MSc; Benjamin Haibe-Kains, PhD; Ali Hosni, MBBCh, MSc, PhD; Andrew Hope, MD; Jun Ma, PhD; Christopher MKL Yao, MD",
        "Affiliations": "University of Toronto",
        "Introduction": "Oral cancers are among the most prevalent malignancies worldwide, and tumors often develop near critical head and neck structures, presenting a challenge for negative margin resection while preserving patients’ function. Accurate treatment planning using medical imaging is essential for guiding surgical approaches, anatomic reconstructions, and adjuvant therapy. However, the current process of defining tumor volumes on imaging relies on labor-intensive manual segmentation by clinical experts with substantial inter-observer variability. An AI-based segmentation model can overcome this bottleneck by automatically delineating tumor boundaries to enable precise treatment planning and coordinated care.",
        "Methods": "In this work, we investigated training specialist models and foundation models for oral cancer segmentation with 130 labelled CT scans from mandibular oral cancer patients who underwent curative-intent surgery at Toronto General Hospital. The specialist model was based on the 3D residual encoder U-Net from the nnU-Net framework. The model was pre-trained on 3,814 oropharyngeal cancer cases from the RADCURE and HECKTOR 2025 datasets for 1,000 epochs, then fine-tuned for 500 epochs on our oral cancer dataset using 5-fold cross-validation. The foundation model, based on MedSAM2, was initially fine-tuned for 200 epochs on the complete oropharyngeal dataset and then evaluated using cross-validation for oral cancer cases. Models were trained on 104 cases and validated on 26 unseen test cases per fold.",
        "Results": "For mandible segmentation, the automatic nnU-Net achieved excellent accuracy with an average Dice similarity coefficient (DSC) of 0.96/1 and a 95% Hausdorff Distance (HD95) of 0.488 mm on validation cases. For oral tumors, nnU-Net achieved an average DSC of 0.68 and HD95 of 5.32 mm with its predictions. Fine-tuned MedSAM2 with middle-layer prompting attained a DSC of 0.65 and HD95 of 5.04 mm, outperforming the untuned model (DSC 0.54, HD95 6.18 mm). Ensembling the predictions of both models with a voxel probability threshold of greater than 50% resulted in an average DSC of 0.74 and HD95 of 3.67 mm. Performance of the nnU-Net stratified by tumor volume showed an average DSC of 0.55 for the lower third of tumor volumes (< 2.8 cm 3 ), 0.70 for the middle third (> 2.8 cm 3 , < 8 cm 3 ), and 0.80 for the upper third (> 8 cm 3 ), indicating greater segmentation accuracy with larger tumors. Compared to manual contouring in timed trials, the fully automatic nnU-net model running on an Nvidia RTX 5070 Ti (consumer-tier GPU) reduced segmentation time by 81.5% on average.",
        "Conclusion": "Our specialist and domain-adapted foundation models achieved moderate segmentation accuracy for oral tumors, with ensemble predictions improving performance on these complex and variable cases. Next steps include developing multimodal models that incorporate MRI images and 2D photographs, utilizing a larger oral cancer dataset, and further validation on diverse test sets from external cancer centers. Auto-segmentation tools can aid clinicians in initial tumor delineation, paving the way for AI-accelerated human-in-the-loop workflows that enhance efficiency and reproducibility in oral cancer treatment planning.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Deep Learning Auto-Segmentation of Oral Cancer on CT Imaging: Defining Tumor Volumes with Specialist and Foundation AI Models</span>. <u>Neil Lin</u>; Alessandra Ruaro, MD; Eugene Yu, MD; David Goldstein, MD, MSc; Ralph Gilbert, MD; Jonathan Irish, MD, MSc; John R De Almeida, MD, MSc; Benjamin Haibe-Kains, PhD; Ali Hosni, MBBCh, MSc, PhD; Andrew Hope, MD; Jun Ma, PhD; Christopher MKL Yao, MD. University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oral cancers are among the most prevalent malignancies worldwide, and tumors often develop near critical head and neck structures, presenting a challenge for negative margin resection while preserving patients’ function. Accurate treatment planning using medical imaging is essential for guiding surgical approaches, anatomic reconstructions, and adjuvant therapy. However, the current process of defining tumor volumes on imaging relies on labor-intensive manual segmentation by clinical experts with substantial inter-observer variability. An AI-based segmentation model can overcome this bottleneck by automatically delineating tumor boundaries to enable precise treatment planning and coordinated care.</p>\n\n<p><strong>Methods: </strong>In this work, we investigated training specialist models and foundation models for oral cancer segmentation with 130 labelled CT scans from mandibular oral cancer patients who underwent curative-intent surgery at Toronto General Hospital. The specialist model was based on the 3D residual encoder U-Net from the nnU-Net framework.  The model was pre-trained on 3,814 oropharyngeal cancer cases from the RADCURE and HECKTOR 2025 datasets for 1,000 epochs, then fine-tuned for 500 epochs on our oral cancer dataset using 5-fold cross-validation. The foundation model, based on MedSAM2, was initially fine-tuned for 200 epochs on the complete oropharyngeal dataset and then evaluated using cross-validation for oral cancer cases. Models were trained on 104 cases and validated on 26 unseen test cases per fold.</p>\n\n<p><strong>Results: </strong>For mandible segmentation, the automatic nnU-Net achieved excellent accuracy with an average Dice similarity coefficient (DSC) of 0.96/1 and a 95% Hausdorff Distance (HD95) of 0.488 mm on validation cases. For oral tumors, nnU-Net achieved an average DSC of 0.68 and HD95 of 5.32 mm with its predictions. Fine-tuned MedSAM2 with middle-layer prompting attained a DSC of 0.65 and HD95 of 5.04 mm, outperforming the untuned model (DSC 0.54, HD95 6.18 mm). Ensembling the predictions of both models with a voxel probability threshold of greater than 50% resulted in an average DSC of 0.74 and HD95 of 3.67 mm. Performance of the nnU-Net stratified by tumor volume showed an average DSC of 0.55 for the lower third of tumor volumes (< 2.8 cm<sup>3</sup>), 0.70 for the middle third (> 2.8 cm<sup>3</sup>, < 8 cm<sup>3</sup>), and 0.80 for the upper third (> 8 cm<sup>3</sup>), indicating greater segmentation accuracy with larger tumors. Compared to manual contouring in timed trials, the fully automatic nnU-net model running on an Nvidia RTX 5070 Ti (consumer-tier GPU) reduced segmentation time by 81.5% on average.</p>\n\n<p><strong>Conclusion: </strong>Our specialist and domain-adapted foundation models achieved moderate segmentation accuracy for oral tumors, with ensemble predictions improving performance on these complex and variable cases. Next steps include developing multimodal models that incorporate MRI images and 2D photographs, utilizing a larger oral cancer dataset, and further validation on diverse test sets from external cancer centers. Auto-segmentation tools can aid clinicians in initial tumor delineation, paving the way for AI-accelerated human-in-the-loop workflows that enhance efficiency and reproducibility in oral cancer treatment planning.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153332/Performance%20Summary(1).jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153332/Training%20Pipeline(1).jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153332/Scatterplot%20Volume%20vs%20DSC.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153332--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S184",
      "content_id": "155537",
      "abstract_number": "S184",
      "poster_number": "",
      "title": "Diagnostic performance of preoperative imaging compared with histopathology in identifying dural involvement in sinonasal and ventral skull base malignancies with dural resections",
      "summary": "MRI and CT reliably identify pathologic dural involvement when preoperative radiographic dural involvement is present. However, negative imaging in tumors close to the dura carries some uncertainty. Preoperative imaging alone is insufficient to exclude dural involvement in tumors nearing the skull base. Resectable malignancies demonstrating radiographic dural involvement should undergo dural resection. In cases...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155537",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Xie, MD",
      "presenter": "Michael Xie, MD",
      "authors": "Michelle Antony, BS 1 ; Michael Xie, MD 1 ; Katie S Traylor, DO 1 ; Phatchara Ruampattana, MD 2 ; Diana Bell, MD 1 ; Garret W Choby, MD 1 ; Georgios Zenonos, MD 1 ; Carl H Snyderman, MD 1 ; Paul A Gardner, MD 1 ; Eric W Wang 1",
      "normalized_authors": [
        "Michelle Antony",
        "Michael Xie",
        "Katie S Traylor",
        "Phatchara Ruampattana",
        "Diana Bell",
        "Garret W Choby",
        "Georgios Zenonos",
        "Carl H Snyderman",
        "Paul A Gardner",
        "Eric W Wang"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center",
        "Faculty of Medicine, Khon Kaen University"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center",
        "Faculty of Medicine, Khon Kaen University"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 474,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michelle Antony, BS 1 ; Michael Xie, MD 1 ; Katie S Traylor, DO 1 ; Phatchara Ruampattana, MD 2 ; Diana Bell, MD 1 ; Garret W Choby, MD 1 ; Georgios Zenonos, MD 1 ; Carl H Snyderman, MD 1 ; Paul A Gardner, MD 1 ; Eric W Wang 1",
        "Affiliations": "1 University of Pittsburgh Medical Center; 2 Faculty of Medicine, Khon Kaen University",
        "Background": "Surgical resection of sinonasal and ventral skull base malignancies requires a balance between preserving neurovascular structures and attaining adequate oncologic margins. The dura is an important boundary in these surgeries as dural resection is associated with worse survival and higher recurrence rates. Pre-operative imaging is used to predict dural involvement in locally advanced disease; however, tumor inflammation and reactive changes can make interpreting these findings difficult. Improved characterization of dural involvement in diagnostic preoperative imaging may reduce surgical morbidity and optimize oncologic outcomes. Currently, existing data on diagnostic test performance of preoperative imaging for detecting dural involvement in sinonasal and ventral skull base malignancies is limited.",
        "Objective": "To assess the diagnostic test characteristics of preoperative imaging (MRI and CT) compared with final histopathology for dural involvement in adult patients undergoing surgical resection of sinonasal and ventral skull base malignancies with dural resection.",
        "Methods": "This was a single-institution retrospective cohort study of adult patients (≥18 years) with a diagnosis of sinonasal or ventral skull base malignancy treated surgically between 2010 and 2025. Patients that underwent surgery with dural resection through an endoscopic endonasal approach (EEA) or combined open/endoscopic approach and had available preoperative imaging (MRI and/or CT) with final pathology data were included. Preoperative imaging was reviewed retrospectively, through radiology reports and re-review of direct images, to determine the degree of skull base involvement. Imaging classification was then compared to final dural pathology.",
        "Results": "Sixty-six patients were included. The most common histopathology was olfactory neuroblastoma (ONB) (n=32), followed by squamous cell carcinoma (SCC) (n=9), adenocarcinoma (n=7), sinonasal undifferentiated carcinomas (n=5), sinonasal neuroendocrine carcinomas (SNEC) (n=5), and 8 other malignancies. Pre-operative imaging showed skull base encroachment in 11 cases (16.7%), skull base erosion in 9 cases (13.6%), and dural involvement in 46 cases (69.7%). There were 46 true positives, 13 true negatives, 0 false positives, and 7 false negatives. The sensitivity and specificity of preoperative imaging in detecting dural involvement was 86.8% and 100% respectively, yielding a positive predictive value of 100%, and a negative predictive value of 65%. Diagnostic accuracy was 89.9%. The false negative rate for dural involvement on preoperative imaging was 13.2%. Among patients with skull base encroachment or skull base bone erosion, the occult dural involvement rates were 28.6% and 71.4%, respectively.",
        "Conclusions": "MRI and CT reliably identify pathologic dural involvement when preoperative radiographic dural involvement is present. However, negative imaging in tumors close to the dura carries some uncertainty. Preoperative imaging alone is insufficient to exclude dural involvement in tumors nearing the skull base. Resectable malignancies demonstrating radiographic dural involvement should undergo dural resection. In cases with bone erosion and, to a lesser degree, skull base encroachment, surgeons should factor in potential occult dural involvement when planning extent of resection and surgical margins.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic performance of preoperative imaging compared with histopathology in identifying dural involvement in sinonasal and ventral skull base malignancies with dural resections</span>. Michelle Antony, BS<sup>1</sup>; <u>Michael Xie, MD</u><sup>1</sup>; Katie S Traylor, DO<sup>1</sup>; Phatchara Ruampattana, MD<sup>2</sup>; Diana Bell, MD<sup>1</sup>; Garret W Choby, MD<sup>1</sup>; Georgios Zenonos, MD<sup>1</sup>; Carl H Snyderman, MD<sup>1</sup>; Paul A Gardner, MD<sup>1</sup>; Eric W Wang<sup>1</sup>. <sup>1</sup>University of Pittsburgh Medical Center; <sup>2</sup>Faculty of Medicine, Khon Kaen University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Surgical resection of sinonasal and ventral skull base malignancies requires a balance between preserving neurovascular structures and attaining adequate oncologic margins. The dura is an important boundary in these surgeries as dural resection is associated with worse survival and higher recurrence rates. Pre-operative imaging is used to predict dural involvement in locally advanced disease; however, tumor inflammation and reactive changes can make interpreting these findings difficult. Improved characterization of dural involvement in diagnostic preoperative imaging may reduce surgical morbidity and optimize oncologic outcomes. Currently, existing data on diagnostic test performance of preoperative imaging for detecting dural involvement in sinonasal and ventral skull base malignancies is limited.</p>\n\n<p><strong>Objective: </strong>To assess the diagnostic test characteristics of preoperative imaging (MRI and CT) compared with final histopathology for dural involvement in adult patients undergoing surgical resection of sinonasal and ventral skull base malignancies with dural resection.</p>\n\n<p><strong>Methods: </strong>This was a single-institution retrospective cohort study of adult patients (≥18 years) with a diagnosis of sinonasal or ventral skull base malignancy treated surgically between 2010 and 2025. Patients that underwent surgery with dural resection through an endoscopic endonasal approach (EEA) or combined open/endoscopic approach and had available preoperative imaging (MRI and/or CT) with final pathology data were included. Preoperative imaging was reviewed retrospectively, through radiology reports and re-review of direct images, to determine the degree of skull base involvement. Imaging classification was then compared to final dural pathology.</p>\n\n<p><strong>Results: </strong>Sixty-six patients were included. The most common histopathology was olfactory neuroblastoma (ONB) (n=32), followed by squamous cell carcinoma (SCC) (n=9), adenocarcinoma (n=7), sinonasal undifferentiated carcinomas (n=5), sinonasal neuroendocrine carcinomas (SNEC) (n=5), and 8 other malignancies. Pre-operative imaging showed skull base encroachment in 11 cases (16.7%), skull base erosion in 9 cases (13.6%), and dural involvement in 46 cases (69.7%). There were 46 true positives, 13 true negatives, 0 false positives, and 7 false negatives. The sensitivity and specificity of preoperative imaging in detecting dural involvement was 86.8% and 100% respectively, yielding a positive predictive value of 100%, and a negative predictive value of 65%. Diagnostic accuracy was 89.9%. The false negative rate for dural involvement on preoperative imaging was 13.2%. Among patients with skull base encroachment or skull base bone erosion, the occult dural involvement rates were 28.6% and 71.4%, respectively.</p>\n\n<p><strong>Conclusions: </strong>MRI and CT reliably identify pathologic dural involvement when preoperative radiographic dural involvement is present. However, negative imaging in tumors close to the dura carries some uncertainty. Preoperative imaging alone is insufficient to exclude dural involvement in tumors nearing the skull base. Resectable malignancies demonstrating radiographic dural involvement should undergo dural resection. In cases with bone erosion and, to a lesser degree, skull base encroachment, surgeons should factor in potential occult dural involvement when planning extent of resection and surgical margins. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155537--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S185",
      "content_id": "154201",
      "abstract_number": "S185",
      "poster_number": "",
      "title": "Automated 3D Segmentation of the Thyroid Gland and Nodules on CT Imaging Using Deep Learning",
      "summary": "The results highlight strong overall performance and compare favorably with existing work. A key novelty in this study is the application of a 3D attention–based residual U-Net to the CT imaging modality, which supports the feasibility of CT-driven thyroid nodule analysis beyond traditional ultrasound-based approaches. These findings show promise for clinical decision support to provide faster and more consistent...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154201",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shaunak Dalal",
      "presenter": "Shaunak Dalal",
      "authors": "Shaunak Dalal 1 ; Christopher C Tseng, MD 1 ; Daniel A Otchere, PhD 2 ; Neerav Goyal, MD, MPH, FACS 1",
      "normalized_authors": [
        "Shaunak Dalal",
        "Christopher C Tseng",
        "Daniel A Otchere",
        "Neerav Goyal"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine",
        "Institute for Computational and Data Sciences, Pennsylvania State University"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine",
        "Institute for Computational and Data Sciences, Pennsylvania State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "Table 1: Segmentation performance on the test set of 16 patients.",
          "rows": [
            [
              "Task / Structure",
              "Dice",
              "Precision",
              "Recall",
              "Specificity",
              "Intersection over Union"
            ],
            [
              "Whole Thyroid",
              "0.980",
              "0.999",
              "0.997",
              "0.999",
              "0.997"
            ],
            [
              "Thyroid gland",
              "0.795",
              "0.825",
              "0.827",
              "0.991",
              "0.703"
            ],
            [
              "Thyroid nodule",
              "0.731",
              "0.853",
              "0.851",
              "0.991",
              "0.742"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154201/ahnsabstractfigure.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154201/ahnsabstractfigure.jpg",
          "alt": "Figure 1: Representative qualitative results of the proposed model. The top row shows ground truth (left) and predicted (right) segmentation of the thyroid gland (blue) and thyroid nodule (red) on a region of interest (ROI) axial CT slice. The bottom row shows accurate whole-thyroid localization on the full CT (green).",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154201"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 426,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shaunak Dalal 1 ; Christopher C Tseng, MD 1 ; Daniel A Otchere, PhD 2 ; Neerav Goyal, MD, MPH, FACS 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine; 2 Institute for Computational and Data Sciences, Pennsylvania State University",
        "Purpose": "With the increasing use of head and neck CT imaging, accurate identification of the thyroid gland and nodules is clinically important for diagnosis and treatment planning. Manual evaluation is subject to inter-observer variability as thyroid lesions often demonstrate variable heterogeneous morphological appearance. Although deep learning-based segmentation has shown promise across medical imaging, prior work on thyroid segmentation has focused on ultrasound, where gland–nodule contrast is more pronounced. Automated thyroid and nodule segmentation on CT remains comparatively underexplored and presents unique challenges due to low soft-tissue contrast, complex surrounding anatomy, and larger 3D volumes. This study aimed to create a deep learning approach for automated segmentation of the thyroid gland and thyroid nodules on CT imaging.",
        "Methods": "A retrospective cohort of 165 patients with CT scans demonstrating thyroid nodules was collected. Thyroid glands and nodules were manually segmented using a DICOM segmentation software for ground truth labels. The dataset was divided into 80% training, 10% validation, and 10% testing subsets. A region of interest (ROI) containing the thyroid was extracted using margin-based cropping and resampled to a standardized 128×128×128 voxel input. For the deep learning model, a 3D U-Net architecture for image analysis was used that incorporated attention gates to focus on relevant thyroid structures, residual connections to better preserve feature information across layers, and intensity-enhancing feature channels to improve boundary detection. The model was trained with a weighted loss function to account for imbalance across the classes. Two tasks were evaluated: (1) binary segmentation of the entire thyroid gland on full CT volumes and (2) multi-class segmentation of thyroid tissue and nodules within the ROI.",
        "Results": "Model accuracy was primarily evaluated using the Dice similarity coefficient, a standard metric that quantifies the overlap between predicted and gold standard manually segmented regions. The binary thyroid-gland segmentation model (1) achieved a Dice score of 0.98 on the held-out test set, indicating near-perfect agreement with manually segmented annotations of the whole-gland across patients. For the multi-class task (2), the model achieved Dice scores of 0.79 for thyroid tissue and 0.73 for nodules.",
        "Conclusions": "The results highlight strong overall performance and compare favorably with existing work. A key novelty in this study is the application of a 3D attention–based residual U-Net to the CT imaging modality, which supports the feasibility of CT-driven thyroid nodule analysis beyond traditional ultrasound-based approaches. These findings show promise for clinical decision support to provide faster and more consistent identification of thyroid structures to aid surgical planning and oncologic assessment.",
        "Abstract": "Task / Structure Intersection over Union View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Automated 3D Segmentation of the Thyroid Gland and Nodules on CT Imaging Using Deep Learning</span>. <u>Shaunak Dalal</u><sup>1</sup>; Christopher C Tseng, MD<sup>1</sup>; Daniel A Otchere, PhD<sup>2</sup>; Neerav Goyal, MD, MPH, FACS<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine; <sup>2</sup>Institute for Computational and Data Sciences, Pennsylvania State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> With the increasing use of head and neck CT imaging, accurate identification of the thyroid gland and nodules is clinically important for diagnosis and treatment planning. Manual evaluation is subject to inter-observer variability as thyroid lesions often demonstrate variable heterogeneous morphological appearance. Although deep learning-based segmentation has shown promise across medical imaging, prior work on thyroid segmentation has focused on ultrasound, where gland–nodule contrast is more pronounced. Automated thyroid and nodule segmentation on CT remains comparatively underexplored and presents unique challenges due to low soft-tissue contrast, complex surrounding anatomy, and larger 3D volumes. This study aimed to create a deep learning approach for automated segmentation of the thyroid gland and thyroid nodules on CT imaging.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of 165 patients with CT scans demonstrating thyroid nodules was collected. Thyroid glands and nodules were manually segmented using a DICOM segmentation software for ground truth labels. The dataset was divided into 80% training, 10% validation, and 10% testing subsets. A region of interest (ROI) containing the thyroid was extracted using margin-based cropping and resampled to a standardized 128×128×128 voxel input. For the deep learning model, a 3D U-Net architecture for image analysis was used that incorporated attention gates to focus on relevant thyroid structures, residual connections to better preserve feature information across layers, and intensity-enhancing feature channels to improve boundary detection. The model was trained with a weighted loss function to account for imbalance across the classes. Two tasks were evaluated: (1) binary segmentation of the entire thyroid gland on full CT volumes and (2) multi-class segmentation of thyroid tissue and nodules within the ROI.</p>\n\n<p><strong>Results:</strong> Model accuracy was primarily evaluated using the Dice similarity coefficient, a standard metric that quantifies the overlap between predicted and gold standard manually segmented regions. The binary thyroid-gland segmentation model (1) achieved a Dice score of 0.98 on the held-out test set, indicating near-perfect agreement with manually segmented annotations of the whole-gland across patients. For the multi-class task (2), the model achieved Dice scores of 0.79 for thyroid tissue and 0.73 for nodules.</p>\n\n<p><strong>Conclusions:</strong> The results highlight strong overall performance and compare favorably with existing work. A key novelty in this study is the application of a 3D attention–based residual U-Net to the CT imaging modality, which supports the feasibility of CT-driven thyroid nodule analysis beyond traditional ultrasound-based approaches. These findings show promise for clinical decision support to provide faster and more consistent identification of thyroid structures to aid surgical planning and oncologic assessment.</p>\n\n<table border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption>Table 1: Segmentation performance on the test set of 16 patients.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope='row'>\n\t\t\t<p>Task / Structure</p>\n\t\t\t</th>\n\t\t\t<th scope='col'>Dice</th>\n\t\t\t<th scope='col'>Precision</th>\n\t\t\t<th scope='col'>Recall</th>\n\t\t\t<th scope='col'>Specificity</th>\n\t\t\t<th scope='col'>\n\t\t\t<p>Intersection over Union</p>\n\t\t\t</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<th scope='row'>Whole Thyroid</th>\n\t\t\t<td>0.980</td>\n\t\t\t<td>0.999</td>\n\t\t\t<td>0.997</td>\n\t\t\t<td>0.999</td>\n\t\t\t<td>0.997</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>Thyroid gland</th>\n\t\t\t<td>0.795</td>\n\t\t\t<td>0.825</td>\n\t\t\t<td>0.827</td>\n\t\t\t<td>0.991</td>\n\t\t\t<td>0.703</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>Thyroid nodule</th>\n\t\t\t<td>0.731</td>\n\t\t\t<td>0.853</td>\n\t\t\t<td>0.851</td>\n\t\t\t<td>0.991</td>\n\t\t\t<td>0.742</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Figure 1: Visualization of model outputs.</strong></p>\n\n<p><img alt='Figure 1: Representative qualitative results of the proposed model. The top row shows ground truth (left) and predicted (right) segmentation of the thyroid gland (blue) and thyroid nodule (red) on a region of interest (ROI) axial CT slice. The bottom row shows accurate whole-thyroid localization on the full CT (green).' src='https://www.submitmyabstract.com/abs/images/154201/ahnsabstractfigure.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154201--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S186",
      "content_id": "153419",
      "abstract_number": "S186",
      "poster_number": "",
      "title": "Correlation of Radiologic and Pathologic Nodal Counts in HPV Positive Oropharyngeal Cancer",
      "summary": "In our large retrospective study, radiology reliably identified the presence of nodal metastases in HPV positive OPSCC overall, but absolute radiologic node counts did show some misclassification. Radiology sometimes underestimated nodal burden in necks with a single positive radiologic node and sometimes overestimated nodal burden when suspicious nodes were included. Importantly, there was no correlation between...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153419",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sarah C Nyirjesy",
      "presenter": "Sarah C Nyirjesy",
      "authors": "Emilie de Groot, MD 1 ; Sarah C Nyirjesy 2 ; Laura V Romo 1 ; Yuh-Shin Chang 1 ; Manuel Patino Galindo 1 ; Lori J Wirth 1 ; Emil Barkovich 1 ; Jeremy D Richmon, Associate Professor 1 ; Stacy Hooker 1",
      "normalized_authors": [
        "Emilie de Groot",
        "Sarah C Nyirjesy",
        "Laura V Romo",
        "Yuh-Shin Chang",
        "Manuel Patino Galindo",
        "Lori J Wirth",
        "Emil Barkovich",
        "Jeremy D Richmon, Associate",
        "Stacy Hooker"
      ],
      "affiliations": [
        "Mass Eye and Ear/Harvard Medical School",
        "Boston Medical Center/Boston University"
      ],
      "normalized_institutions": [
        "Mass Eye and Ear/Harvard Medical School",
        "Boston Medical Center/Boston University"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Emilie de Groot, MD 1 ; Sarah C Nyirjesy 2 ; Laura V Romo 1 ; Yuh-Shin Chang 1 ; Manuel Patino Galindo 1 ; Lori J Wirth 1 ; Emil Barkovich 1 ; Jeremy D Richmon, Associate Professor 1 ; Stacy Hooker 1",
        "Affiliations": "1 Mass Eye and Ear/Harvard Medical School; 2 Boston Medical Center/Boston University",
        "Background": "In HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), the number of pathologically positive lymph nodes informs adjuvant therapy recommendations, including the need for postoperative chemoradiation. It is unknown how accurately pre-operative radiologic node assessment corresponds to true pathologic nodal burden, particularly in clinically important thresholds such as ≥5 involved nodes.",
        "Methods": "We retrospectively reviewed HPV-positive OPSCC patients treated with TORS and neck dissection from 2016–2024 at our institution. Specialized head and neck radiologists blinded to the pathologic results classified cervical nodes on preoperative CT, MRI, and PET-CT as positive, suspicious, or negative. This was compared to the pathologic nodal counts. Agreement between clinical and pathologic staging was assessed using weighted κ. Diagnostic performance metrics (sensitivity, specificity, PPV, NPV) were calculated using pathology as the reference standard. Radiologic versus pathologic node counts were compared globally and stratified by radiologic node-count.",
        "Results": "Among 293 patients, the mean age was 62.4 years old, and 84.3% were male. Most tumors arose in the tonsil (57.7%) or base of tongue (37.2%). Radiologic staging demonstrated excellent sensitivity (0.94) and PPV (0.98) when only positive nodes were included. The addition of suspicious nodes slightly increased sensitivity (0.96) but substantially reduced specificity (0.57), indicating consistent overestimation. Neck level II nodes showed the highest performance (accuracy 0.91), whereas level III demonstrated poor sensitivity (0.49–0.61) when compared to actual pathologic nodal disease. Weighted κ for cN versus pN staging was 0.70, indicating substantial agreement.",
        "Abstract": "Analysis of numbers of radiologic vs pathologic node counts revealed some discrepancies. When radiology identified a single positive node, pathology found ≥2 nodes in approximately 25% of cases. When radiology reported 2 positive nodes, pathology demonstrated 1- 4 nodes. Critically, among patients with three radiologic nodes, the proportion harboring ≥5 pathologic nodes was low (<5 percent) and not statistically significant (OR 1.24, p = 0.58). Similar results were seen when positive and suspicious nodes were combined (3.03 percent; p = 1.0). Thus, three radiologic nodes (either positive and/or suspicious) did not meaningfully predict five or more pathologic nodes that would meet the threshold for adjuvant chemoradiation . View in Agenda and Add to Schedule",
        "Conclusions": "In our large retrospective study, radiology reliably identified the presence of nodal metastases in HPV positive OPSCC overall, but absolute radiologic node counts did show some misclassification. Radiology sometimes underestimated nodal burden in necks with a single positive radiologic node and sometimes overestimated nodal burden when suspicious nodes were included. Importantly, there was no correlation between three radiologic nodes and five or more pathologic nodes, indicating that radiologic node counts alone may need to be interpreted with caution when used for treatment selection. This has clinical implications as some patients are excluded from primary surgical treatment with transoral robotic surgery (TORS) based on radiologic node thresholds, which may not accurately predict pathologic nodal burden or the need for adjuvant therapy. This study highlights the need to refine imaging-based models used for treatment selection."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Correlation of Radiologic and Pathologic Nodal Counts in HPV Positive Oropharyngeal Cancer</span>. Emilie de Groot, MD<sup>1</sup>; <u>Sarah C Nyirjesy</u><sup>2</sup>; Laura V Romo<sup>1</sup>; Yuh-Shin Chang<sup>1</sup>; Manuel Patino Galindo<sup>1</sup>; Lori J Wirth<sup>1</sup>; Emil Barkovich<sup>1</sup>; Jeremy D Richmon, Associate Professor<sup>1</sup>; Stacy Hooker<sup>1</sup>. <sup>1</sup>Mass Eye and Ear/Harvard Medical School; <sup>2</sup>Boston Medical Center/Boston University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), the number of pathologically positive lymph nodes informs adjuvant therapy recommendations, including the need for postoperative chemoradiation. It is unknown how accurately pre-operative radiologic node assessment corresponds to true pathologic nodal burden, particularly in clinically important thresholds such as ≥5 involved nodes.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed HPV-positive OPSCC patients treated with TORS and neck dissection from 2016–2024 at our institution. Specialized head and neck radiologists blinded to the pathologic results classified cervical nodes on preoperative CT, MRI, and PET-CT as positive, suspicious, or negative. This was compared to the pathologic nodal counts. Agreement between clinical and pathologic staging was assessed using weighted κ. Diagnostic performance metrics (sensitivity, specificity, PPV, NPV) were calculated using pathology as the reference standard. Radiologic versus pathologic node counts were compared globally and stratified by radiologic node-count.</p>\n\n<p><strong>Results: </strong>Among 293 patients, the mean age was 62.4 years old, and 84.3% were male. Most tumors arose in the tonsil (57.7%) or base of tongue (37.2%). Radiologic staging demonstrated excellent sensitivity (0.94) and PPV (0.98) when only positive nodes were included. The addition of suspicious nodes slightly increased sensitivity (0.96) but substantially reduced specificity (0.57), indicating consistent overestimation. Neck level II nodes showed the highest performance (accuracy 0.91), whereas level III demonstrated poor sensitivity (0.49–0.61) when compared to actual pathologic nodal disease. Weighted κ for cN versus pN staging was 0.70, indicating substantial agreement.</p>\n\n<p>Analysis of numbers of radiologic vs pathologic node counts revealed some discrepancies. When radiology identified a single positive node, pathology found ≥2 nodes in approximately 25% of cases. When radiology reported 2 positive nodes, pathology demonstrated 1- 4 nodes. Critically, among patients with three radiologic nodes, the proportion harboring ≥5 pathologic nodes was low (<5 percent) and not statistically significant (OR 1.24, p = 0.58). Similar results were seen when positive and suspicious nodes were combined (3.03 percent; p = 1.0). Thus, three radiologic nodes (either positive and/or suspicious) did not meaningfully predict five or more pathologic nodes that would meet the threshold for adjuvant chemoradiation .</p>\n\n<p><strong>Conclusions: </strong>In our large retrospective study, radiology reliably identified the presence of nodal metastases in HPV positive OPSCC overall, but absolute radiologic node counts did show some misclassification. Radiology sometimes underestimated nodal burden in necks with a single positive radiologic node and sometimes overestimated nodal burden when suspicious nodes were included. Importantly, there was no correlation between three radiologic nodes and five or more pathologic nodes, indicating that radiologic node counts alone may need to be interpreted with caution when used for treatment selection. This has clinical implications as some patients are excluded from primary surgical treatment with transoral robotic surgery (TORS) based on radiologic node thresholds, which may not accurately predict pathologic nodal burden or the need for adjuvant therapy. This study highlights the need to refine imaging-based models used for treatment selection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153419--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S187",
      "content_id": "151780",
      "abstract_number": "S187",
      "poster_number": "",
      "title": "Comparison of Recurrence-Free Survival Prediction in Oropharyngeal Cancer With and Without Tumor Segmentation Features",
      "summary": "Inclusion of segmentation-derived tumor features allowed our model to achieve better prediction of recurrence-free survival in a multi-center test cohort of patients with oropharyngeal cancer, while excluding these features risked overfitting. Our findings indicate that including quantitative tumor features, beyond multimodal images and clinical data alone, enhances prediction of recurrence-free survival by...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151780",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Laura Chen, BA",
      "presenter": "Laura Chen, BA",
      "authors": "Laura Chen, BA 1 ; Koushik Rameshbabu, BEng 2 ; Aaron Ge, BS 3 ; Grace Snow, MD 4",
      "normalized_authors": [
        "Laura Chen",
        "Koushik Rameshbabu, BEng",
        "Aaron Ge",
        "Grace Snow"
      ],
      "affiliations": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Johns Hopkins University, Whiting School of Engineering, Baltimore, MD",
        "University of Maryland School of Medicine, Baltimore, MD",
        "University of Maryland School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Baltimore, MD"
      ],
      "normalized_institutions": [
        "University of California, San Francisco School of Medicine, San Francisco, CA",
        "Johns Hopkins University, Whiting School of Engineering, Baltimore, MD",
        "University of Maryland School of Medicine, Baltimore, MD",
        "University of Maryland School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Baltimore, MD"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151780/900x900_Figure1_Architecture(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151780/900x900_Figure1_Architecture(1).png",
          "alt": "Model Architecture.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151780"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/151780/Figure%202_900x900.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151780/Figure%202_900x900.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151780"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/151780/Figure%203_900x900.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151780/Figure%203_900x900.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151780"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 481,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Figure 2.",
        "Figure 3.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Laura Chen, BA 1 ; Koushik Rameshbabu, BEng 2 ; Aaron Ge, BS 3 ; Grace Snow, MD 4",
        "Affiliations": "1 University of California, San Francisco School of Medicine, San Francisco, CA; 2 Johns Hopkins University, Whiting School of Engineering, Baltimore, MD; 3 University of Maryland School of Medicine, Baltimore, MD; 4 University of Maryland School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Baltimore, MD",
        "Background": "Quantitative imaging markers from radiomics can improve prognosis and risk stratification in head and neck cancer. Advances in deep learning and multimodal (PET and CT) image fusion have enhanced tumor segmentation and feature extraction for prognosis. As T and N staging from TNM staging are largely determined by reviewing imaging, deep learning can provide alternative ways to predict recurrence-free survival in head and neck cancer. Despite recent advances, most studies rely on single-center, single-modality data, underscoring the need for identifying robust, generalizable features. Given the intensive resources required for tumor segmentation, our study aimed to evaluate whether incorporating segmentation-derived quantitative features improves automatic deep learning prediction of recurrence-free survival (RFS) in a multi-center cohort of oropharyngeal cancer patients using FDG-PET/CT images and clinical data.",
        "Methods": "We conducted a retrospective comparative study analyzing co-registered FDG-PET/CT scans and clinical metadata from the publicly available HECKTOR (HEad and neCK TumOR Lesion Segmentation, Diagnosis and Prognosis Using Multimodal Data) 2025 challenge dataset. Two multimodal deep learning pipelines were developed: a simplified model using PET/CT imaging and key clinical variables (age, gender, tobacco use, HPV status, performance status, metastasis, and treatment modality), and a complex model additionally incorporating segmentation-derived tumor features (volume, compactness, surface area, and sphericity). Feature extraction used a 3D DenseNet-121 for imaging and a neural network for clinical data, with fused outputs entered into a survival algorithm handling right-censored data (BaggedICARESurvival). A 5-fold stratified cross-validation (seed = 42) assessed performance using the Concordance Index (C-index) across folds and a 130-patient holdout set (20% per center). Pairwise t-tests compared C-indices between the two models for validation and holdout sets.",
        "Results": "The dataset included 651 patients aged 32-90 treated at 7 international sites in France, Canada, and Switzerland. The mean validation C-index in the simplified model was 0.637 ± 0.049 and 0.660 ± 0.087 in the segmentation-inclusive model, with no significant difference in paired t-tests across folds (p = 0.5502). For the hold-out set, mean C-index was significantly higher in the segmentation-inclusive model (0.664 ± 0.045) compared to the simplified model (0.553 ± 0.057) (p = 0.0254). The best validation C-index was achieved in fold 0 of the segmentation-inclusive model, achieving a C-index of 0.7248 and 0.6791 on the hold-out set.",
        "Conclusions": "Inclusion of segmentation-derived tumor features allowed our model to achieve better prediction of recurrence-free survival in a multi-center test cohort of patients with oropharyngeal cancer, while excluding these features risked overfitting. Our findings indicate that including quantitative tumor features, beyond multimodal images and clinical data alone, enhances prediction of recurrence-free survival by improving generalization.Because manual tumor volume delineation is time consuming and observer-dependent, automated segmentation deserves greater focus, as it offers potential to streamline deep learning-based prognosis and risk stratification in head and neck cancer.",
        "Figure 1.": "Model Architecture.",
        "Figure 2.": "Patient Cohort Site Distribution.",
        "Figure 3.": "Training, Validation, and Test Sets in 5-Fold Cross Validation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparison of Recurrence-Free Survival Prediction in Oropharyngeal Cancer With and Without Tumor Segmentation Features</span>. <u>Laura Chen, BA</u><sup>1</sup>; Koushik Rameshbabu, BEng<sup>2</sup>; Aaron Ge, BS<sup>3</sup>; Grace Snow, MD<sup>4</sup>. <sup>1</sup>University of California, San Francisco School of Medicine, San Francisco, CA; <sup>2</sup>Johns Hopkins University, Whiting School of Engineering, Baltimore, MD; <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD; <sup>4</sup>University of Maryland School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Baltimore, MD<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Quantitative imaging markers from radiomics can improve prognosis and risk stratification in head and neck cancer. Advances in deep learning and multimodal (PET and CT) image fusion have enhanced tumor segmentation and feature extraction for prognosis.  As T and N staging from TNM staging are largely determined by reviewing imaging, deep learning can provide alternative ways to predict recurrence-free survival in head and neck cancer. Despite recent advances, most studies rely on single-center, single-modality data, underscoring the need for identifying robust, generalizable features. Given the intensive resources required for tumor segmentation, our study aimed to evaluate whether incorporating segmentation-derived quantitative features improves automatic deep learning prediction of recurrence-free survival (RFS) in a multi-center cohort of oropharyngeal cancer patients using FDG-PET/CT images and clinical data.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective comparative study analyzing co-registered FDG-PET/CT scans and clinical metadata from the publicly available HECKTOR (HEad and neCK TumOR Lesion Segmentation, Diagnosis and Prognosis Using Multimodal Data) 2025 challenge dataset. Two multimodal deep learning pipelines were developed: a simplified model using PET/CT imaging and key clinical variables (age, gender, tobacco use, HPV status, performance status, metastasis, and treatment modality), and a complex model additionally incorporating segmentation-derived tumor features (volume, compactness, surface area, and sphericity). Feature extraction used a 3D DenseNet-121 for imaging and a neural network for clinical data, with fused outputs entered into a survival algorithm handling right-censored data (BaggedICARESurvival). A 5-fold stratified cross-validation (seed = 42) assessed performance using the Concordance Index (C-index) across folds and a 130-patient holdout set (20% per center). Pairwise t-tests compared C-indices between the two models for validation and holdout sets.</p>\n\n<p><strong>Results:</strong> The dataset included 651 patients aged 32-90 treated at 7 international sites in France, Canada, and Switzerland. The mean validation C-index in the simplified model was 0.637 ± 0.049 and 0.660 ± 0.087 in the segmentation-inclusive model, with no significant difference in paired t-tests across folds (p = 0.5502). For the hold-out set, mean C-index was significantly higher in the segmentation-inclusive model (0.664 ± 0.045) compared to the simplified model (0.553 ± 0.057) (p = 0.0254). The best validation C-index was achieved in fold 0 of the segmentation-inclusive model, achieving a C-index of 0.7248 and 0.6791 on the hold-out set.</p>\n\n<p><strong>Conclusions:</strong> Inclusion of segmentation-derived tumor features allowed our model to achieve better prediction of recurrence-free survival in a multi-center test cohort of patients with oropharyngeal cancer, while excluding these features risked overfitting. Our findings indicate that including quantitative tumor features, beyond multimodal images and clinical data alone, enhances prediction of recurrence-free survival by improving generalization.Because manual tumor volume delineation is time consuming and observer-dependent, automated segmentation deserves greater focus, as it offers potential to streamline deep learning-based prognosis and risk stratification in head and neck cancer.</p>\n\n<p> </p>\n\n<p><strong>Figure 1.</strong> Model Architecture.</p>\n\n<p><img alt='Model Architecture.' src='https://www.submitmyabstract.com/abs/images/151780/900x900_Figure1_Architecture(1).png' /></p>\n\n<p><strong>Figure 2. </strong>Patient Cohort Site Distribution.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151780/Figure%202_900x900.png' /></p>\n\n<p> </p>\n\n<p><strong>Figure 3.</strong> Training, Validation, and Test Sets in 5-Fold Cross Validation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151780/Figure%203_900x900.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151780--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S188",
      "content_id": "154675",
      "abstract_number": "S188",
      "poster_number": "",
      "title": "Feasibility of Intraoperative [89Zr]Panitumumab Micro-PET/CT in Head and Neck Cancer: Pilot Evaluation in Three Patients",
      "summary": "Intraoperative micro-PET/CT using a targeted molecular probe ([ 89 Zr]panitumumab) demonstrated that malignant lesions consistently have a higher SUV max than benign lymphatic tissue, and specimen-level imaging provided enhanced visualization of focal disease compared with clinical PET/CT. These early data support further evaluation of molecularly targeted intraoperative PET/CT as a complementary tool for margin...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154675",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashtyn McAdoo",
      "presenter": "Ashtyn McAdoo",
      "authors": "Ashtyn McAdoo ; Kyrionna Golliday, MS; Micheal Topf, MD, MSCI; Eben Rosenthal, MD",
      "normalized_authors": [
        "Ashtyn McAdoo",
        "Kyrionna Golliday",
        "Micheal Topf, MSCI",
        "Eben Rosenthal"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ashtyn McAdoo ; Kyrionna Golliday, MS; Micheal Topf, MD, MSCI; Eben Rosenthal, MD",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "Intraoperative frozen-section analysis remains the diagnostic gold standard for margin and nodal assessment in head and neck cancer, but it is limited by sampling constraints, processing delays, and an inability to visualize three-dimensional disease spread in freshly resected specimens. Targeted molecular imaging agents, such as fluorescent or radiolabeled anti–epidermal growth factor receptor (EGFR) antibodies, offer the potential to provide real-time, specimen-level guidance. In this pilot feasibility study, we evaluated the use of ex vivo micro–PET/CT imaging with [ 89 Zr]panitumumab, a radiolabeled anti-EGFR antibody, for intraoperative assessment of margins and lymph-node packets using a mobile PET/CT specimen scanner.",
        "Methods": "Three patients received [ 89 Zr]panitumumab 1–7 days prior to surgery. Resection proceeded per standard clinical car with no workflow modification. Immediately following excision, lymph-node specimens and, when present, primary tumors were imaged ex vivo on a mobile micro-PET/CT system for a CT scan and a 10-minute PET acquisition. The maximum Standardized Uptake Value (SUV max ) was collected from each lesion and correlated with the final histopathology. Only lesions confirmed positive for tumor by the pathology team were classified as malignant in the analysis.",
        "Results": "Ex vivo micro-PET/CT specimen imaging was technically feasible, rapid, and produced high-resolution visualization of [ 89 Zr]panitumumab distribution within surgical specimens. Variability in background noise reflected the 2–7-day infusion interval. Tumor-positive lymph nodes consistently demonstrated higher uptake than surrounding benign tissue. Across all patients, malignant nodal packets showed elevated uptake (mean SUV max 6.52) compared with benign packets (mean SUV max 3.52), and this separation was consistently observed on an individual-patient basis. The PET/CT system reliably detected [ 89 Zr]panitumumab uptake in malignant tissue and revealed small foci and tumor deposition heterogeneity not appreciable on clinical PET/CT, ranging from 0.6 cm – 2.7 cm for metastatic lymph node foci. One primary tumor was also imaged for margin assessment: pathology reported a 9 mm depth of invasion, and micro-PET/CT identified a PET visible signal depth penetration of 10.1 mm (consistent with the resolution error of the physical limits of 89 Zr), supporting its feasibility for high-resolution intraoperative imaging.",
        "Conclusions": "Intraoperative micro-PET/CT using a targeted molecular probe ([ 89 Zr]panitumumab) demonstrated that malignant lesions consistently have a higher SUV max than benign lymphatic tissue, and specimen-level imaging provided enhanced visualization of focal disease compared with clinical PET/CT. These early data support further evaluation of molecularly targeted intraoperative PET/CT as a complementary tool for margin and nodal assessment and for improving lesion-level diagnostic interpretation in head and neck cancer.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Feasibility of Intraoperative [89Zr]Panitumumab Micro-PET/CT in Head and Neck Cancer: Pilot Evaluation in Three Patients</span>. <u>Ashtyn McAdoo</u>; Kyrionna Golliday, MS; Micheal Topf, MD, MSCI; Eben Rosenthal, MD. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Intraoperative frozen-section analysis remains the diagnostic gold standard for margin and nodal assessment in head and neck cancer, but it is limited by sampling constraints, processing delays, and an inability to visualize three-dimensional disease spread in freshly resected specimens. Targeted molecular imaging agents, such as fluorescent or radiolabeled anti–epidermal growth factor receptor (EGFR) antibodies, offer the potential to provide real-time, specimen-level guidance. In this pilot feasibility study, we evaluated the use of <em>ex vivo</em> micro–PET/CT imaging with [<sup>89</sup>Zr]panitumumab, a radiolabeled anti-EGFR antibody, for intraoperative assessment of margins and lymph-node packets using a mobile PET/CT specimen scanner.</p>\n\n<p><strong>Methods: </strong>Three patients received [<sup>89</sup>Zr]panitumumab 1–7 days prior to surgery. Resection proceeded per standard clinical car with no workflow modification. Immediately following excision, lymph-node specimens and, when present, primary tumors were imaged <em>ex vivo</em> on a mobile micro-PET/CT system for a CT scan and a 10-minute PET acquisition. The maximum Standardized Uptake Value (SUV<sub>max</sub>) was collected from each lesion and correlated with the final histopathology. Only lesions confirmed positive for tumor by the pathology team were classified as malignant in the analysis.</p>\n\n<p><strong>Results: </strong><em>Ex vivo</em> micro-PET/CT specimen imaging was technically feasible, rapid, and produced high-resolution visualization of [<sup>89</sup>Zr]panitumumab distribution within surgical specimens. Variability in background noise reflected the 2–7-day infusion interval. Tumor-positive lymph nodes consistently demonstrated higher uptake than surrounding benign tissue. Across all patients, malignant nodal packets showed elevated uptake (mean SUV<sub>max</sub> 6.52) compared with benign packets (mean SUV<sub>max</sub> 3.52), and this separation was consistently observed on an individual-patient basis. The PET/CT system reliably detected [<sup>89</sup>Zr]panitumumab uptake in malignant tissue and revealed small foci and tumor deposition heterogeneity not appreciable on clinical PET/CT, ranging from 0.6 cm – 2.7 cm for metastatic lymph node foci. One primary tumor was also imaged for margin assessment: pathology reported a 9 mm depth of invasion, and micro-PET/CT identified a PET visible signal depth penetration of 10.1 mm (consistent with the resolution error of the physical limits of <sup>89</sup>Zr), supporting its feasibility for high-resolution intraoperative imaging.</p>\n\n<p><strong>Conclusions: </strong>Intraoperative micro-PET/CT using a targeted molecular probe ([<sup>89</sup>Zr]panitumumab) demonstrated that malignant lesions consistently have a higher SUV<sub>max</sub> than benign lymphatic tissue, and specimen-level imaging provided enhanced visualization of focal disease compared with clinical PET/CT. These early data support further evaluation of molecularly targeted intraoperative PET/CT as a complementary tool for margin and nodal assessment and for improving lesion-level diagnostic interpretation in head and neck cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154675--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S189",
      "content_id": "153244",
      "abstract_number": "S189",
      "poster_number": "",
      "title": "PET/CT Accuracy in Identifying Synchronous Primary HPV-Positive Oropharyngeal Tumors: A Multi-Institutional Study",
      "summary": "PET/CT has excellent NPV for excluding synchronous primaries in HPV(+) OPSCC but moderate PPV. These results highlight the importance of radiologic–pathologic correlation in cases with bilateral, multifocal, or asymmetrical FDG activity. Overall, PET/CT is a valuable preoperative tool for surgeons and an important first step in optimizing patient care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153244",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Srikar Ganapathiraju, BS",
      "presenter": "Srikar Ganapathiraju, BS",
      "authors": "Mei Xing G Zuo, BS 1 ; Varsha Pudi, BS 2 ; Srikar Ganapathiraju, BS 1 ; Christopher Kruglik, MSc, MPH 2 ; Mirabelle Sajisevi, MD 3 ; Neil Gildener-Leapman, MD 4 ; Lisa Galati, MD 4",
      "normalized_authors": [
        "Mei Xing G Zuo",
        "Varsha Pudi",
        "Srikar Ganapathiraju",
        "Christopher Kruglik",
        "Mirabelle Sajisevi",
        "Neil Gildener-Leapman",
        "Lisa Galati"
      ],
      "affiliations": [
        "Albany Medical College",
        "Robert Larner, MD College of Medicine",
        "University of Vermont Medical Center",
        "Albany Medical Center"
      ],
      "normalized_institutions": [
        "Albany Medical College",
        "Robert Larner, MD College of Medicine",
        "University of Vermont Medical Center",
        "Albany Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 467,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mei Xing G Zuo, BS 1 ; Varsha Pudi, BS 2 ; Srikar Ganapathiraju, BS 1 ; Christopher Kruglik, MSc, MPH 2 ; Mirabelle Sajisevi, MD 3 ; Neil Gildener-Leapman, MD 4 ; Lisa Galati, MD 4",
        "Affiliations": "1 Albany Medical College; 2 Robert Larner, MD College of Medicine; 3 University of Vermont Medical Center; 4 Albany Medical Center",
        "Introduction": "The prevalence of HPV-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) has increased significantly over the past 20 years. The development of synchronous primary tumors is a rare phenomenon occurring in approximately 5.3% of head and neck cancer patients. However, accurate preoperative identification remains challenging due to difficulty distinguishing between true synchronous primaries and benign and/or inflammatory uptake. This ultimately can alter staging, operative planning, extent of resection, and adjuvant treatment recommendations. This multi-institutional study seeks to evaluate the diagnostic accuracy of Positron Emission Tomography/Computed Tomography (PET/CT) in identifying synchronous primary tumors in HPV(+) OPSCC patients as confirmed with histopathological findings.",
        "Methods": "This study is a multi-institutional retrospective chart review of 458 records from November 2019 to 2025 obtained from two academic institutions (Albany Medical Center and the University of Vermont Medical Center). Following the establishment of a data use agreement, deidentified patient data was entered into REDCap. Inclusion criteria were HPV(+) patients over 18 years old with ICD10 codes C01 (malignant neoplasm of base of tongue), C09 (tonsil), C10 (oropharynx), and C14 (lip, oral cavity and pharynx) who underwent PET/CT imaging and biopsy or resection with histopathological confirmation of a diagnosis of p16+ OPSCC. Data involving demographics, smoking status, PET/imaging characteristics, and histopathological findings from electronic medical records were extracted and analyzed.",
        "Results": "61 HPV(+) OPSCC patients were included in our analysis (mean age 62.6 years + 9.6, 78.7% male). Almost half were never smokers (44.3%, n=27) consistent with the expected HPV(+) OPSCC population selected for this study. Primary sites included base of tongue (25.8%), tonsil (56.1%), oropharynx (12.1%), and other oropharyngeal subsites (6.1%). Histopathology confirmed synchronous primaries in 5/61 patients (8.2%). Detailed review of PET/CT imaging identified 21 patients with findings suspicious for possible synchronous primaries in addition to their known primary malignancy. Of these, 12 had definite concern for synchronous primaries while 9 showed equivocal asymmetric uptake. Many reports noted “bilateral uptake,\" \"asymmetric FDG activity,\" or \"additional areas of increased uptake\" without explicitly reporting multiple primary tumors in the final impressions. Of the 12 patients with concerning PET/CT findings, 5 had pathologically confirmed synchronous primaries (41.7% positive predictive value (PPV)) while 7 had false positive findings due to inflammatory changes, reactive lymphoid tissue, or physiologic uptake. PET/CT demonstrated 83.3% sensitivity, 86.5% specificity, and 97.8% negative predictive value (NPV) for identifying synchronous primaries in HPV(+) OPSCC.",
        "Conclusion": "PET/CT has excellent NPV for excluding synchronous primaries in HPV(+) OPSCC but moderate PPV. These results highlight the importance of radiologic–pathologic correlation in cases with bilateral, multifocal, or asymmetrical FDG activity. Overall, PET/CT is a valuable preoperative tool for surgeons and an important first step in optimizing patient care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>PET/CT Accuracy in Identifying Synchronous Primary HPV-Positive Oropharyngeal Tumors: A Multi-Institutional Study</span>. Mei Xing G Zuo, BS<sup>1</sup>; Varsha Pudi, BS<sup>2</sup>; <u>Srikar Ganapathiraju, BS</u><sup>1</sup>; Christopher Kruglik, MSc, MPH<sup>2</sup>; Mirabelle Sajisevi, MD<sup>3</sup>; Neil Gildener-Leapman, MD<sup>4</sup>; Lisa Galati, MD<sup>4</sup>. <sup>1</sup>Albany Medical College; <sup>2</sup>Robert Larner, MD College of Medicine; <sup>3</sup>University of Vermont Medical Center; <sup>4</sup>Albany Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The prevalence of HPV-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) has increased significantly over the past 20 years. The development of synchronous primary tumors is a rare phenomenon occurring in approximately 5.3% of head and neck cancer patients. However, accurate preoperative identification remains challenging due to difficulty distinguishing between true synchronous primaries and benign and/or inflammatory uptake. This ultimately can alter staging, operative planning, extent of resection, and adjuvant treatment recommendations. This multi-institutional study seeks to evaluate the diagnostic accuracy of Positron Emission Tomography/Computed Tomography (PET/CT) in identifying synchronous primary tumors in HPV(+) OPSCC patients as confirmed with histopathological findings. </p>\n\n<p><strong>Methods:</strong> This study is a multi-institutional retrospective chart review of 458 records from November 2019 to 2025 obtained from two academic institutions (Albany Medical Center and the University of Vermont Medical Center). Following the establishment of a data use agreement, deidentified patient data was entered into REDCap. Inclusion criteria were HPV(+) patients over 18 years old with ICD10 codes C01 (malignant neoplasm of base of tongue), C09 (tonsil), C10 (oropharynx), and C14 (lip, oral cavity and pharynx) who underwent PET/CT imaging and biopsy or resection with histopathological confirmation of a diagnosis of p16+ OPSCC. Data involving demographics, smoking status, PET/imaging characteristics, and histopathological findings from electronic medical records were extracted and analyzed. </p>\n\n<p><strong>Results:</strong> 61 HPV(+) OPSCC patients were included in our analysis (mean age 62.6 years + 9.6, 78.7% male). Almost half were never smokers (44.3%, n=27) consistent with the expected HPV(+) OPSCC population selected for this study. Primary sites included base of tongue (25.8%), tonsil (56.1%), oropharynx (12.1%), and other oropharyngeal subsites (6.1%). Histopathology confirmed synchronous primaries in 5/61 patients (8.2%). Detailed review of PET/CT imaging identified 21 patients with findings suspicious for possible synchronous primaries in addition to their known primary malignancy. Of these, 12 had definite concern for synchronous primaries while 9 showed equivocal asymmetric uptake. Many reports noted “bilateral uptake,\" \"asymmetric FDG activity,\" or \"additional areas of increased uptake\" without explicitly reporting multiple primary tumors in the final impressions. Of the 12 patients with concerning PET/CT findings, 5 had pathologically confirmed synchronous primaries (41.7% positive predictive value (PPV)) while 7 had false positive findings due to inflammatory changes, reactive lymphoid tissue, or physiologic uptake. PET/CT demonstrated 83.3% sensitivity, 86.5% specificity, and 97.8% negative predictive value (NPV) for identifying synchronous primaries in HPV(+) OPSCC. </p>\n\n<p><strong>Conclusion:</strong> PET/CT has excellent NPV for excluding synchronous primaries in HPV(+) OPSCC but moderate PPV. These results highlight the importance of radiologic–pathologic correlation in cases with bilateral, multifocal, or asymmetrical FDG activity. Overall, PET/CT is a valuable preoperative tool for surgeons and an important first step in optimizing patient care. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153244--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S190",
      "content_id": "154291",
      "abstract_number": "S190",
      "poster_number": "",
      "title": "Preoperative Imaging Does Not Reliably Assess Tumor Extent After Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma",
      "summary": "Pre-operative imaging is not a reliable indicator of residual tumor size for response adapted surgical planning in patients receiving neoadjuvant cemiplimab. In our cohort, all patients demonstrateddiscordance between tumor size on preoperative imaging and final pathology. As the use of cemiplimab becomes increasingly widespread, the need to accurately assess tumor response is imperative. PET-CT or the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154291",
      "agenda_url": "",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hyun Song, BA",
      "presenter": "Hyun Song, BA",
      "authors": "Rachel Berglas, BA 1 ; Sara Friedman, BA 1 ; Hyun Song, BA 1 ; Zaelig Averch, BA 1 ; Kievan Shifteh, MD 2 ; Bradley A Schiff, MD 3 ; Vikas Mehta, MD, MPH 3 ; Richard V Smith, MD 3 ; Yvonne M Saenger, MD 4 ; Helena Levyn, MD 3",
      "normalized_authors": [
        "Rachel Berglas",
        "Sara Friedman",
        "Hyun Song",
        "Zaelig Averch",
        "Kievan Shifteh",
        "Bradley A Schiff",
        "Vikas Mehta",
        "Richard V Smith",
        "Yvonne M Saenger",
        "Helena Levyn"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Radiology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Oncology – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Radiology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Oncology – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_21_32%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_21_32%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154291"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_23_40%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_23_40%E2%80%AFAM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154291"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Table 1.",
        "Abstract",
        "Figure 1."
      ],
      "sections": {
        "Authors": "Rachel Berglas, BA 1 ; Sara Friedman, BA 1 ; Hyun Song, BA 1 ; Zaelig Averch, BA 1 ; Kievan Shifteh, MD 2 ; Bradley A Schiff, MD 3 ; Vikas Mehta, MD, MPH 3 ; Richard V Smith, MD 3 ; Yvonne M Saenger, MD 4 ; Helena Levyn, MD 3",
        "Affiliations": "1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Radiology – Montefiore Medical Center, Bronx, NY, USA; 3 Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA; 4 Department of Oncology – Montefiore Medical Center, Bronx, NY, USA",
        "Background": "Following treatment with neoadjuvant cemiplimab for locally advanced cutaneous squamous cell carcinoma (cSCC), preoperative radiologic imaging is routinely used to determine the extent of response-adapted resection. However, it is unclear whether non-metabolic radiologic imaging accurately portrays the size of residual cancer in this context. Inaccurate assessment has functional and aesthetic implications for patients who undergo more extensive surgery than necessary due to an overcall on imaging or, alternatively, inadequate resection due to an undercall. The aim of this study is to determine the reliability of pre-operative imaging in planning response-adapted surgery in patients who received neoadjuvant cemiplimab.",
        "Methods": "83 patients received cemiplimab for cSCC at Montefiore-Einstein between December 2018 and July 2025. After obtaining IRB approval, we conducted a chart review to identify patients treated withcemiplimab with neoadjuvant intent, followed by radiologic imaging and surgical excision for locally advanced primary cSCC. We collected demographic, clinical, radiologic, pathologic, and oncologic outcomes of patients who met the inclusion criteria. Tumor dimensions on preoperative imaging and tumor size on final pathology were recorded and compared.",
        "Results": "Five patients met inclusion criteria; four male and one female, ages 63-86 (median 77, IQR 67.5 - 84) (Table 1). All eligible patients underwent preoperative imaging (MRI, n=4; CT, n=1) and underwent surgical excision of the cSCC between 5-42 days later (median 8, IQR 6 – 37.5). Patients received 3-20 cycles of cemiplimab (median 5, IQR 3.5 - 14) over 39-455 days (median 84, IQR 51 - 437.5). Overall, residual tumor size was discordant between preoperative radiology and final pathology in all cases (Figure 1). Two patients demonstrated a larger tumor on final pathology than what was observed on preoperative imaging (undercall percent discordance -36% and -66.67%). Three patients demonstrated a smaller tumor on final pathology than what was observed on preoperative imaging (overcall percent discordance +34.17%, +80%, and +100%) (Figure 1).",
        "Conclusion": "Pre-operative imaging is not a reliable indicator of residual tumor size for response adapted surgical planning in patients receiving neoadjuvant cemiplimab. In our cohort, all patients demonstrateddiscordance between tumor size on preoperative imaging and final pathology. As the use of cemiplimab becomes increasingly widespread, the need to accurately assess tumor response is imperative. PET-CT or the physician’s clinical impression have been suggested as potential alternatives for estimating residual tumor size preoperatively. Further research is necessary to identify the most reliable method for assessingcSCC response to cemiplimab to allow more accurate planning of response-adapted surgery.",
        "Table 1.": "Patient characteristics and comparison between preoperative imaging and final pathology following neoadjuvant cemiplimab. (CPR: complete pathologic response).",
        "Abstract": "*Patient has a history of basal cell carcinoma (BCC) in the right nasal ala, left medial cheek, dorsum, and forehead addressed by previous Moh’s surgeries. One year prior to the diagnosis of SCC, BCC recurred in the right nasal ala, which was resected alongside SCC. **Cemiplimab was administered with initial improved clinical response, followed by disease progression, at which time the patient proceeded with surgery. View in Agenda and Add to Schedule",
        "Figure 1.": "Percent discordance between preoperative imaging and final pathology."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Imaging Does Not Reliably Assess Tumor Extent After Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma</span>. Rachel Berglas, BA<sup>1</sup>; Sara Friedman, BA<sup>1</sup>; <u>Hyun Song, BA</u><sup>1</sup>; Zaelig Averch, BA<sup>1</sup>; Kievan Shifteh, MD<sup>2</sup>; Bradley A Schiff, MD<sup>3</sup>; Vikas Mehta, MD, MPH<sup>3</sup>; Richard V Smith, MD<sup>3</sup>; Yvonne M Saenger, MD<sup>4</sup>; Helena Levyn, MD<sup>3</sup>. <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>2</sup>Department of Radiology – Montefiore Medical Center, Bronx, NY, USA; <sup>3</sup>Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx,  NY, USA; <sup>4</sup>Department of Oncology – Montefiore Medical Center, Bronx, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Following treatment with neoadjuvant cemiplimab for locally advanced cutaneous squamous cell carcinoma (cSCC), preoperative radiologic imaging is routinely used to determine the extent of response-adapted resection. However, it is unclear whether non-metabolic radiologic imaging accurately portrays the size of residual cancer in this context. Inaccurate assessment has functional and aesthetic implications for patients who undergo more extensive surgery than necessary due to an overcall on imaging or, alternatively, inadequate resection due to an undercall. The aim of this study is to determine the reliability of pre-operative imaging in planning response-adapted surgery in patients who received neoadjuvant cemiplimab. </p>\n\n<p><strong>Methods:</strong> 83 patients received cemiplimab for cSCC at Montefiore-Einstein between December 2018 and July 2025. After obtaining IRB approval, we conducted a chart review to identify patients treated withcemiplimab with neoadjuvant intent, followed by radiologic imaging and surgical excision for locally advanced primary cSCC. We collected demographic, clinical, radiologic, pathologic, and oncologic outcomes of patients who met the inclusion criteria. Tumor dimensions on preoperative imaging and tumor size on final pathology were recorded and compared. </p>\n\n<p><strong>Results:</strong> Five patients met inclusion criteria; four male and one female, ages 63-86 (median 77, IQR 67.5 - 84) (Table 1). All eligible patients underwent preoperative imaging (MRI, n=4; CT, n=1) and underwent surgical excision of the cSCC between 5-42 days later (median 8, IQR 6 – 37.5). Patients received 3-20 cycles of cemiplimab (median 5, IQR 3.5 - 14) over 39-455 days (median 84, IQR 51 - 437.5). Overall, residual tumor size was discordant between preoperative radiology and final pathology in all cases (Figure 1). Two patients demonstrated a larger tumor on final pathology than what was observed on preoperative imaging (undercall percent discordance -36% and -66.67%). Three patients demonstrated a smaller tumor on final pathology than what was observed on preoperative imaging (overcall percent discordance +34.17%, +80%, and +100%) (Figure 1). </p>\n\n<p><strong>Conclusion:</strong> Pre-operative imaging is not a reliable indicator of residual tumor size for response adapted surgical planning in patients receiving neoadjuvant cemiplimab. In our cohort, all patients demonstrateddiscordance between tumor size on preoperative imaging and final pathology. As the use of cemiplimab becomes increasingly widespread, the need to accurately assess tumor response is imperative. PET-CT or the physician’s clinical impression have been suggested as potential alternatives for estimating residual tumor size preoperatively. Further research is necessary to identify the most reliable method for assessingcSCC response to cemiplimab to allow more accurate planning of response-adapted surgery.</p>\n\n<p><strong>Table 1.</strong> Patient characteristics and comparison between preoperative imaging and final pathology following neoadjuvant cemiplimab. (CPR: complete pathologic response).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_21_32%E2%80%AFAM.png' /></p>\n\n<p>*Patient has a history of basal cell carcinoma (BCC) in the right nasal ala, left medial cheek, dorsum, and forehead addressed by previous Moh’s surgeries. One year prior to the diagnosis of SCC, BCC recurred in the right nasal ala, which was resected alongside SCC. </p>\n\n<p>**Cemiplimab was administered with initial improved clinical response, followed by disease progression, at which time the patient proceeded with surgery. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154291/Screenshot%202025-12-05%20at%2010_23_40%E2%80%AFAM.png' /></p>\n\n<p><strong>Figure 1.</strong> Percent discordance between preoperative imaging and final pathology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154291--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S191",
      "content_id": "153820",
      "abstract_number": "S191",
      "poster_number": "",
      "title": "A Validated Instrument to Identify Complicated Living Grief in Patients with Head and Neck Cancer",
      "summary": "This study presents the first validated instrument designed to assess non-bereavement grief in patients living with head and neck cancer. Development incorporated systematic item generation, patient-centered refinement, and robust psychometric testing. Because CLG is common yet frequently unrecognized, early identification is essential. Untreated grief may worsen symptom burden, impair coping, intensify anxiety...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153820",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mallory Mckeon, MD",
      "presenter": "Mallory Mckeon, MD",
      "authors": "Alexander Karabachev, MD 1 ; Kevin Milligan, MD 2 ; Advika Sumit 1 ; Antonio Dekhou, MD 1 ; Mallory Mckeon, MD 1 ; Jack Garcia 1 ; Nicholas Hutchins 1 ; Katrina Harrill, RN 1 ; Priscilla Pichardo, DO 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Chad Zender, MD 1",
      "normalized_authors": [
        "Alexander Karabachev",
        "Kevin Milligan",
        "Advika Sumit",
        "Antonio Dekhou",
        "Mallory Mckeon",
        "Jack Garcia",
        "Nicholas Hutchins",
        "Katrina Harrill",
        "Priscilla Pichardo",
        "Dustin Silverman",
        "Alice Tang",
        "Chad Zender"
      ],
      "affiliations": [
        "University of Cincinnati Medical Center",
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "University of Cincinnati Medical Center",
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 478,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alexander Karabachev, MD 1 ; Kevin Milligan, MD 2 ; Advika Sumit 1 ; Antonio Dekhou, MD 1 ; Mallory Mckeon, MD 1 ; Jack Garcia 1 ; Nicholas Hutchins 1 ; Katrina Harrill, RN 1 ; Priscilla Pichardo, DO 1 ; Dustin Silverman, MD 1 ; Alice Tang, MD 1 ; Chad Zender, MD 1",
        "Affiliations": "1 University of Cincinnati Medical Center; 2 MD Anderson Cancer Center",
        "Introduction": "Complicated Living Grief (CLG) is a newly proposed diagnostic construct describing a persistent, distressing emotional response following physical, emotional, or cognitive loss. Unlike bereavement-related complicated grief, CLG may emerge in the context of ongoing illness, treatment toxicity, functional decline, and chronic uncertainty. Patients with head and neck cancer (HNC) are particularly vulnerable given disease-related morbidity, communication limitations, and profound disruptions to identity and social connection. Despite the well-documented prevalence of psychosocial distress in this population, no validated instrument exists to identify CLG or distinguish it from depression, anxiety, or routine cancer-related distress. This gap is clinically significant because effective, grief-specific treatment differ substantially from standard therapies for depression or anxiety and require accurate recognition of the underlying grief process. This study aims to develop and validate the first instrument specifically designed to identify CLG in patients with HNC.",
        "Methods": "A preliminary 14-item survey was created by adapting content from the validated bereavement-focused Inventory of Complicated Grief and integrating themes identified from a retrospective review of 309 HNC patients who completed the EORTC QLQ-C30 and QLQ-H&N35 questionnaires. Cognitive interviewing and pilot testing with seven HNC patients evaluated face validity, clarity, and content relevance; revisions were made based on patient feedback. The refined survey was then administered to 140 HNC patients. Internal consistency was assessed using Cronbach’s α. Exploratory factor analysis (EFA) examined the underlying structure of the scale, and confirmatory factor analysis (CFA) evaluated construct validity and theoretical model fit.",
        "Results": "A total of 140 patients with HNC completed the survey; 70 responses were used for EFA and 70 for CFA. The EFA indicated that items measured a single underlying construct, with factor loadings ranging from 0.59 to 0.78, demonstrating meaningful connection to the core grief dimension. One item (“difficulty trusting”) showed weaker loading (λ = 0.43) and was removed. The CFA on the remaining 13 items tested a theory-based, two-domain model representing Emotional/Experiential Grief and Functional/Social Impact Grief. Items demonstrated moderate to strong relationships with their respective factors, indicating that each question reliably reflected the underlying grief domain. Overall, the CFA confirmed that the two-factor structure aligns with the theoretical model, and the high internal consistency (Cronbach’s α = 0.91) supports that the survey is a valid and reliable measure of complicated living grief in patients with head and neck cancer.",
        "Conclusion": "This study presents the first validated instrument designed to assess non-bereavement grief in patients living with head and neck cancer. Development incorporated systematic item generation, patient-centered refinement, and robust psychometric testing. Because CLG is common yet frequently unrecognized, early identification is essential. Untreated grief may worsen symptom burden, impair coping, intensify anxiety or depression, and diminish quality of life. This accessible and reliable screening tool enables clinicians and researchers to identify at-risk patients and initiate timely, grief-focused interventions to improve psychosocial outcomes in HNC survivorship.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Validated Instrument to Identify Complicated Living Grief in Patients with Head and Neck Cancer</span>. Alexander Karabachev, MD<sup>1</sup>; Kevin Milligan, MD<sup>2</sup>; Advika Sumit<sup>1</sup>; Antonio Dekhou, MD<sup>1</sup>; <u>Mallory Mckeon, MD</u><sup>1</sup>; Jack Garcia<sup>1</sup>; Nicholas Hutchins<sup>1</sup>; Katrina Harrill, RN<sup>1</sup>; Priscilla Pichardo, DO<sup>1</sup>; Dustin Silverman, MD<sup>1</sup>; Alice Tang, MD<sup>1</sup>; Chad Zender, MD<sup>1</sup>. <sup>1</sup>University of Cincinnati Medical Center; <sup>2</sup>MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Complicated Living Grief (CLG) is a newly proposed diagnostic construct describing a persistent, distressing emotional response following physical, emotional, or cognitive loss. Unlike bereavement-related complicated grief, CLG may emerge in the context of ongoing illness, treatment toxicity, functional decline, and chronic uncertainty. Patients with head and neck cancer (HNC) are particularly vulnerable given disease-related morbidity, communication limitations, and profound disruptions to identity and social connection. Despite the well-documented prevalence of psychosocial distress in this population, no validated instrument exists to identify CLG or distinguish it from depression, anxiety, or routine cancer-related distress. This gap is clinically significant because effective, grief-specific treatment differ substantially from standard therapies for depression or anxiety and require accurate recognition of the underlying grief process. This study aims to develop and validate the first instrument specifically designed to identify CLG in patients with HNC.</p>\n\n<p><strong>Methods: </strong>A preliminary 14-item survey was created by adapting content from the validated bereavement-focused Inventory of Complicated Grief and integrating themes identified from a retrospective review of 309 HNC patients who completed the EORTC QLQ-C30 and QLQ-H&N35 questionnaires. Cognitive interviewing and pilot testing with seven HNC patients evaluated face validity, clarity, and content relevance; revisions were made based on patient feedback. The refined survey was then administered to 140 HNC patients. Internal consistency was assessed using Cronbach’s α. Exploratory factor analysis (EFA) examined the underlying structure of the scale, and confirmatory factor analysis (CFA) evaluated construct validity and theoretical model fit.</p>\n\n<p><strong>Results: </strong>A total of 140 patients with HNC completed the survey; 70 responses were used for EFA and 70 for CFA. The EFA indicated that items measured a single underlying construct, with factor loadings ranging from 0.59 to 0.78, demonstrating meaningful connection to the core grief dimension. One item (“difficulty trusting”) showed weaker loading (λ = 0.43) and was removed. The CFA on the remaining 13 items tested a theory-based, two-domain model representing Emotional/Experiential Grief and Functional/Social Impact Grief. Items demonstrated moderate to strong relationships with their respective factors, indicating that each question reliably reflected the underlying grief domain. Overall, the CFA confirmed that the two-factor structure aligns with the theoretical model, and the high internal consistency (Cronbach’s α = 0.91) supports that the survey is a valid and reliable measure of complicated living grief in patients with head and neck cancer.</p>\n\n<p><strong>Conclusion: </strong>This study presents the first validated instrument designed to assess non-bereavement grief in patients living with head and neck cancer. Development incorporated systematic item generation, patient-centered refinement, and robust psychometric testing. Because CLG is common yet frequently unrecognized, early identification is essential. Untreated grief may worsen symptom burden, impair coping, intensify anxiety or depression, and diminish quality of life. This accessible and reliable screening tool enables clinicians and researchers to identify at-risk patients and initiate timely, grief-focused interventions to improve psychosocial outcomes in HNC survivorship.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153820--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S192",
      "content_id": "154589",
      "abstract_number": "S192",
      "poster_number": "",
      "title": "Patient–Provider Interactions in Distress and Suicidality Screening Among Individuals with Head and Neck Cancer",
      "summary": "Patients with HNC identified critical gaps in consistent distress screening, follow-up, and suicide risk assessment. Given the substantial suicide burden in this population, development of formalized screening protocols and interdisciplinary training to address and respond to mental health concerns is needed.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154589",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandra E Hunter, BA",
      "presenter": "Alexandra E Hunter, BA",
      "authors": "Alexandra E Hunter, BA 1 ; Rebecca A Zasloff, MPH 1 ; Laura J Fish, PhD 2 ; Margaret Falkovic, MSW, LCSW 2 ; Revital Benvenisti, BA 3 ; Cheyenne Corbett, PhD 2 ; Donald L Rosenstein, MD 4 ; David B Goldston, PhD 5 ; Nosayaba Osazuwa Peters, BDS, PhD, MPH, CHES 3",
      "normalized_authors": [
        "Alexandra E Hunter",
        "Rebecca A Zasloff",
        "Laura J Fish",
        "Margaret Falkovic, MSW, LCSW",
        "Revital Benvenisti",
        "Cheyenne Corbett",
        "Donald L Rosenstein",
        "David B Goldston",
        "Nosayaba Osazuwa Peters, BDS, CHES"
      ],
      "affiliations": [
        "Duke University School of Medicine, Durham, NC, USA",
        "Duke Cancer Institute, Duke University, Durham, NC, USA",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA",
        "Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA"
      ],
      "normalized_institutions": [
        "Duke University School of Medicine, Durham, NC, USA",
        "Duke Cancer Institute, Duke University, Durham, NC, USA",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA",
        "Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",
        "Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 489,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Alexandra E Hunter, BA 1 ; Rebecca A Zasloff, MPH 1 ; Laura J Fish, PhD 2 ; Margaret Falkovic, MSW, LCSW 2 ; Revital Benvenisti, BA 3 ; Cheyenne Corbett, PhD 2 ; Donald L Rosenstein, MD 4 ; David B Goldston, PhD 5 ; Nosayaba Osazuwa Peters, BDS, PhD, MPH, CHES 3",
        "Affiliations": "1 Duke University School of Medicine, Durham, NC, USA; 2 Duke Cancer Institute, Duke University, Durham, NC, USA; 3 Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA; 4 Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 5 Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA",
        "Background": "Patients with head and neck cancer (HNC) experience disproportionately high rates of suicide compared with other cancer populations and the general public. Despite this elevated risk, suicide-specific screening protocols and guidelines in oncology are lacking. Little is known about how patients perceive mental health and suicide-related screening efforts within HNC care. This qualitative study explored patient experiences with existing distress and mental health screening tools and elicited recommendations to strengthen suicide risk identification and supportive care delivery.",
        "Methods": "Following the Consolidated Criteria for Reporting Qualitative Research (COREQ), we conducted structured qualitative interviews with twelve patients with HNC recruited from an outpatient clinic at a single tertiary cancer center. Eligible participants were identified as being “high risk” for distress, defined as reporting clinically meaningful distress (score ≥4) on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) during a routine HNC visit at Duke University. The NCCN’s Clinical Practice Guidelines in Oncology for distress management define distress as \"multifactorial unpleasant experience of a psychological, social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.”",
        "Abstract": "Interviews explored experiences with distress recognition and follow-up, perceived effectiveness and limitations of current psychosocial screening tools, and strategies to improve mental health and suicide risk assessment in HNC care. Using rapid qualitative analysis, we identified key, common themes and patient-driven recommendations for improving distress identification and management. Patients offered clear, actionable recommendations to enhance supportive care. They valued early acknowledgment of emotional distress and highlighted the importance of knowledge in reducing fear and uncertainty. Participants emphasized the need for ongoing mental health screening and support beyond active treatment, noting that distress often persists through survivorship. Notably, patients highlighted the value of interdisciplinary collaboration in addressing distress. View in Agenda and Add to Schedule",
        "Results": "Key themes included variability in how distress was screened across the care continuum, inconsistency in how providers acknowledged and responded to emotional distress, and strong patient perceptions of the value and importance of suicide risk screening in HNC care. Our analysis revealed substantial variability in how patients perceived their oncology teams’ recognition and response to emotional distress throughout their cancer care. Patients described inconsistent follow-up and uneven access to supportive care services, with significant variation in the type, timing, and coordination of support offered after expressing distress. Perceptions of psychosocial screening tools were mixed: some participants had their distress (score≥4) acknowledged and addressed, whereas others who reported high distress did not. Most participants viewed suicide risk screening as both appropriate and necessary in the context of head and neck cancer. Even those who denied personal experiences with suicidal thoughts emphasized that others facing HNC may need intervention.",
        "Conclusions": "Patients with HNC identified critical gaps in consistent distress screening, follow-up, and suicide risk assessment. Given the substantial suicide burden in this population, development of formalized screening protocols and interdisciplinary training to address and respond to mental health concerns is needed."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient–Provider Interactions in Distress and Suicidality Screening Among Individuals with Head and Neck Cancer</span>. <u>Alexandra E Hunter, BA</u><sup>1</sup>; Rebecca A Zasloff, MPH<sup>1</sup>; Laura J Fish, PhD<sup>2</sup>; Margaret Falkovic, MSW, LCSW<sup>2</sup>; Revital Benvenisti, BA<sup>3</sup>; Cheyenne Corbett, PhD<sup>2</sup>; Donald L Rosenstein, MD<sup>4</sup>; David B Goldston, PhD<sup>5</sup>; Nosayaba Osazuwa Peters, BDS, PhD, MPH, CHES<sup>3</sup>. <sup>1</sup>Duke University School of Medicine, Durham, NC, USA; <sup>2</sup>Duke Cancer Institute, Duke University, Durham, NC, USA; <sup>3</sup>Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA; <sup>4</sup>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>5</sup>Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patients with head and neck cancer (HNC) experience disproportionately high rates of suicide compared with other cancer populations and the general public. Despite this elevated risk, suicide-specific screening protocols and guidelines in oncology are lacking. Little is known about how patients perceive mental health and suicide-related screening efforts within HNC care. This qualitative study explored patient experiences with existing distress and mental health screening tools and elicited recommendations to strengthen suicide risk identification and supportive care delivery.</p>\n\n<p><strong>Methods: </strong>Following the Consolidated Criteria for Reporting Qualitative Research (COREQ), we conducted structured qualitative interviews with twelve patients with HNC recruited from an outpatient clinic at a single tertiary cancer center. Eligible participants were identified as being “high risk” for distress, defined as reporting clinically meaningful distress (score ≥4) on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) during a routine HNC visit at Duke University. The NCCN’s Clinical Practice Guidelines in Oncology for distress management define distress as \"multifactorial unpleasant experience of a psychological, social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.”</p>\n\n<p>Interviews explored experiences with distress recognition and follow-up, perceived effectiveness and limitations of current psychosocial screening tools, and strategies to improve mental health and suicide risk assessment in HNC care. Using rapid qualitative analysis, we identified key, common themes and patient-driven recommendations for improving distress identification and management.</p>\n\n<p><strong>Results: </strong>Key themes included variability in how distress was screened across the care continuum, inconsistency in how providers acknowledged and responded to emotional distress, and strong patient perceptions of the value and importance of suicide risk screening in HNC care. Our analysis revealed substantial variability in how patients perceived their oncology teams’ recognition and response to emotional distress throughout their cancer care. Patients described inconsistent follow-up and uneven access to supportive care services, with significant variation in the type, timing, and coordination of support offered after expressing distress. Perceptions of psychosocial screening tools were mixed: some participants had their distress (score≥4) acknowledged and addressed, whereas others who reported high distress did not. Most participants viewed suicide risk screening as both appropriate and necessary in the context of head and neck cancer. Even those who denied personal experiences with suicidal thoughts emphasized that others facing HNC may need intervention. </p>\n\n<p>Patients offered clear, actionable recommendations to enhance supportive care. They valued early acknowledgment of emotional distress and highlighted the importance of knowledge in reducing fear and uncertainty. Participants emphasized the need for ongoing mental health screening and support beyond active treatment, noting that distress often persists through survivorship. Notably, patients highlighted the value of interdisciplinary collaboration in addressing distress. </p>\n\n<p><strong>Conclusions: </strong>Patients with HNC identified critical gaps in consistent distress screening, follow-up, and suicide risk assessment. Given the substantial suicide burden in this population, development of formalized screening protocols and interdisciplinary training to address and respond to mental health concerns is needed. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154589--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S193",
      "content_id": "153261",
      "abstract_number": "S193",
      "poster_number": "",
      "title": "Association Between Preoperative Major Depressive Disorder on 90-Day and 1-Year Postoperative Outcomes Following Head and Neck Cancer Surgery: A Nationwide Propensity Matched Study",
      "summary": "Preoperative MDD diagnosed within one year before HNC surgery identifies a vulnerable subgroup with higher postoperative mortality, greater ED utilization, and increased medical, surgical, and functional complications. These findings highlight the need for routine preoperative screening and timely management of depressive disorders in HNC care. Although tumor stage was unavailable, we partially addressed this...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153261",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Basir S Mansoor, BS",
      "presenter": "Basir S Mansoor, BS",
      "authors": "Basir S Mansoor, BS 1 ; Zuhair Zaidi, BS 1 ; Hassan Baig, BS 2 ; Zaid Nathani, BS 3 ; Muaz Wahid, BS 1 ; Ammaar Kazi, BS 1 ; Andrew Day, MD, MPH 1 ; Zainab Farzal, MD, MPH 1",
      "normalized_authors": [
        "Basir S Mansoor",
        "Zuhair Zaidi",
        "Hassan Baig",
        "Zaid Nathani",
        "Muaz Wahid",
        "Ammaar Kazi",
        "Andrew Day",
        "Zainab Farzal"
      ],
      "affiliations": [
        "University of Texas Southwestern Medical Center",
        "Texas A&M Medical University School of Medicine",
        "Texas College of Osteopathic Medicine"
      ],
      "normalized_institutions": [
        "University of Texas Southwestern Medical Center",
        "Texas A&M Medical University School of Medicine",
        "Texas College of Osteopathic Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153261/Screenshot%202025-12-05%20at%207_19_18%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153261/Screenshot%202025-12-05%20at%207_19_18%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153261"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 533,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Basir S Mansoor, BS 1 ; Zuhair Zaidi, BS 1 ; Hassan Baig, BS 2 ; Zaid Nathani, BS 3 ; Muaz Wahid, BS 1 ; Ammaar Kazi, BS 1 ; Andrew Day, MD, MPH 1 ; Zainab Farzal, MD, MPH 1",
        "Affiliations": "1 University of Texas Southwestern Medical Center; 2 Texas A&M Medical University School of Medicine; 3 Texas College of Osteopathic Medicine",
        "Background": "Depressive symptoms are highly prevalent in head and neck cancer (HNC), affecting up to one-third of patients, and are consistently linked to poorer survival, impaired treatment adherence, and inflammation-mediated tumor progression. Prior studies show that depressive symptoms predict early mortality and inferior treatment response in HNC, and treating depression may mitigate this risk. However, the association between major depressive disorder (MDD) that develops in the year preceding surgery on subsequent postoperative outcomes has not been well characterized.",
        "Methods": "We conducted a retrospective cohort study using the TriNetX US Collaborative Network to identify adults with a HNC diagnosis (ICD-10 C00-C14, C30-C33) AND undergoing HNC surgery*, between 2004 and 2025. The exposure was a first-time diagnosis of MDD (ICD-10 F32–F33) occurring one year before HNC surgery. After applying inclusion/exclusion criteria, 1:1 propensity score matching (PSM) was performed across a variety of demographic, clinical, and oncologic variables including, but not limited to age, sex, race, HNC type, HNC surgery, chemotherapy, radiation therapy, and baseline psychiatric burden (except MDD). Primary outcomes included 90-day and 1-year emergency department (ED) utilization and mortality. Secondary outcomes included various medical, surgical, and functional postoperative complications, reported as odds ratios (OR) with 95% confidence intervals (CI).",
        "Results": "Among 62,307 patients with HNC who got surgical resection, 9,283 (14.9%) developed new-onset MDD within 1 year before surgery. Before matching, patients with MDD were slightly younger, more often White, more likely to be female, and had higher rates of anxiety disorders, chemotherapy, and radiation therapy. After 1:1 propensity score matching, 7,881 patients remained in each cohort (total N = 15,762), with all covariates well balanced except for a small residual difference in sex distribution (male: 59.1% vs 57.4%; P=0.0425).",
        "Abstract": "In the matched cohorts, new-onset MDD was associated with significantly higher emergency department (ED) utilization at both 90 days (OR 1.24; 95% CI 1.08–1.41; P=0.0018) and 1 year (OR 1.21; 95% CI 1.08–1.34; P=0.0007). Mortality risk was also higher at 90 days (OR 1.27; 95% CI 1.06–1.53; P=0.0096) and 1 year (OR 1.30; 95% CI 1.15–1.39; P<0.0001). Preoperative MDD was further associated with increased postoperative complications at both time points, including acute kidney injury, gastrostomy and tracheostomy placement, delirium, chronic pain, wound dehiscence, surgical site infection, sepsis, dysphagia/aphagia, pneumonia, and venous thromboembolism. At 1-year, additional excess risks included stroke, shock, and hemorrhage. These findings indicate broad and persistent postoperative vulnerability among patients who develop MDD after HNC diagnosis. View in Agenda and Add to Schedule",
        "Conclusion": "Preoperative MDD diagnosed within one year before HNC surgery identifies a vulnerable subgroup with higher postoperative mortality, greater ED utilization, and increased medical, surgical, and functional complications. These findings highlight the need for routine preoperative screening and timely management of depressive disorders in HNC care. Although tumor stage was unavailable, we partially addressed this limitation by incorporating proxies of surgical complexity, including flap reconstruction and transoral robotic surgery, into the PSM. Further work is needed to determine whether early identification and treatment of MDD can improve perioperative outcomes and long-term recovery in this high-risk population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association Between Preoperative Major Depressive Disorder on 90-Day and 1-Year Postoperative Outcomes Following Head and Neck Cancer Surgery: A Nationwide Propensity Matched Study</span>. <u>Basir S Mansoor, BS</u><sup>1</sup>; Zuhair Zaidi, BS<sup>1</sup>; Hassan Baig, BS<sup>2</sup>; Zaid Nathani, BS<sup>3</sup>; Muaz Wahid, BS<sup>1</sup>; Ammaar Kazi, BS<sup>1</sup>; Andrew Day, MD, MPH<sup>1</sup>; Zainab Farzal, MD, MPH<sup>1</sup>. <sup>1</sup>University of Texas Southwestern Medical Center; <sup>2</sup>Texas A&M Medical University School of Medicine; <sup>3</sup>Texas College of Osteopathic Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Depressive symptoms are highly prevalent in head and neck cancer (HNC), affecting up to one-third of patients, and are consistently linked to poorer survival, impaired treatment adherence, and inflammation-mediated tumor progression. Prior studies show that depressive symptoms predict early mortality and inferior treatment response in HNC, and treating depression may mitigate this risk. However, the association between major depressive disorder (MDD) that develops in the year preceding surgery on subsequent postoperative outcomes has not been well characterized.</p>\n\n<p><strong>Methods</strong>: We conducted a retrospective cohort study using the TriNetX US Collaborative Network to identify adults with a HNC diagnosis (ICD-10 C00-C14, C30-C33) AND undergoing HNC surgery*, between 2004 and 2025. The exposure was a first-time diagnosis of MDD (ICD-10 F32–F33) occurring one year before HNC surgery. After applying inclusion/exclusion criteria, 1:1 propensity score matching (PSM) was performed across a variety of demographic, clinical, and oncologic variables including, but not limited to age, sex, race, HNC type, HNC surgery, chemotherapy, radiation therapy, and baseline psychiatric burden (except MDD). Primary outcomes included 90-day and 1-year emergency department (ED) utilization and mortality. Secondary outcomes included various medical, surgical, and functional postoperative complications, reported as odds ratios (OR) with 95% confidence intervals (CI).</p>\n\n<p><strong>Results</strong>: Among 62,307 patients with HNC who got surgical resection, 9,283 (14.9%) developed new-onset MDD within 1 year before surgery. Before matching, patients with MDD were slightly younger, more often White, more likely to be female, and had higher rates of anxiety disorders, chemotherapy, and radiation therapy. After 1:1 propensity score matching, 7,881 patients remained in each cohort (total N = 15,762), with all covariates well balanced except for a small residual difference in sex distribution (male: 59.1% vs 57.4%; P=0.0425).</p>\n\n<p>In the matched cohorts, new-onset MDD was associated with significantly higher emergency department (ED) utilization at both 90 days (OR 1.24; 95% CI 1.08–1.41; P=0.0018) and 1 year (OR 1.21; 95% CI 1.08–1.34; P=0.0007). Mortality risk was also higher at 90 days (OR 1.27; 95% CI 1.06–1.53; P=0.0096) and 1 year (OR 1.30; 95% CI 1.15–1.39; P<0.0001).</p>\n\n<p>Preoperative MDD was further associated with increased postoperative complications at both time points, including acute kidney injury, gastrostomy and tracheostomy placement, delirium, chronic pain, wound dehiscence, surgical site infection, sepsis, dysphagia/aphagia, pneumonia, and venous thromboembolism. At 1-year, additional excess risks included stroke, shock, and hemorrhage. These findings indicate broad and persistent postoperative vulnerability among patients who develop MDD after HNC diagnosis.</p>\n\n<p><strong>Conclusion</strong>: Preoperative MDD diagnosed within one year before HNC surgery identifies a vulnerable subgroup with higher postoperative mortality, greater ED utilization, and increased medical, surgical, and functional complications. These findings highlight the need for routine preoperative screening and timely management of depressive disorders in HNC care. Although tumor stage was unavailable, we partially addressed this limitation by incorporating proxies of surgical complexity, including flap reconstruction and transoral robotic surgery, into the PSM. Further work is needed to determine whether early identification and treatment of MDD can improve perioperative outcomes and long-term recovery in this high-risk population.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153261/Screenshot%202025-12-05%20at%207_19_18%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153261--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S194",
      "content_id": "153075",
      "abstract_number": "S194",
      "poster_number": "",
      "title": "Preoperative Mood Disorders and Postoperative Complications Following Free Flap Reconstruction in Head and Neck Cancer",
      "summary": "Preoperative mood disorder diagnoses are associated with increased risk of postoperative complications and hospital readmission following HNC free flap reconstruction. Antidepressant treatment was associated with lower risk of free flap failure, as well as vascular and revision procedures. These results support incorporating routine preoperative psychosocial screening and optimizing psychiatric treatment as...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153075",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hari U Patel",
      "presenter": "Hari U Patel",
      "authors": "Hari U Patel 1 ; Asher C Park 1 ; Milan P Fehrenbach 2 ; Abhinav Talwar 3 ; Katelyn O Stepan 3",
      "normalized_authors": [
        "Hari U Patel",
        "Asher C Park",
        "Milan P Fehrenbach",
        "Abhinav Talwar",
        "Katelyn O Stepan"
      ],
      "affiliations": [
        "Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA",
        "College of Medicine, Lexington, Kentucky, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"
      ],
      "normalized_institutions": [
        "Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA",
        "College of Medicine, Lexington, Kentucky, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153075/Table%203%20Combined(2).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153075/Table%203%20Combined(2).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153075"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153075/table%204%20combined.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153075/table%204%20combined.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153075"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 377,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hari U Patel 1 ; Asher C Park 1 ; Milan P Fehrenbach 2 ; Abhinav Talwar 3 ; Katelyn O Stepan 3",
        "Affiliations": "1 Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; 2 College of Medicine, Lexington, Kentucky, USA; 3 Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA",
        "Background": "While mood disorders such as depression and anxiety are common in head and neck cancer (HNC) patients, our understanding of how these conditions affect surgical and clinical outcomes after free flap reconstruction is limited.",
        "Objective": "To evaluate the association between preoperative mood disorder diagnoses and postoperative complications following free flap reconstruction in HNC patients, and to further assess whether antidepressant treatment modifies this risk.",
        "Methods": "The TriNetX database was queried for HNC patients who underwent free flap reconstruction between 2010-2025. Primary analysis compared patients with preoperative mood disorder diagnoses (depression, anxiety disorders, or related conditions identified using ICD-10 codes) to patients without such diagnoses. A secondary analysis was conducted among patients with mood disorders, comparing those who received antidepressant pharmacotherapy to those who did not. Primary outcomes included 30-day rates of free flap failure, blood vessel repair, and other flap revision procedures. Secondary outcomes included deep vein thrombosis, sepsis, surgical site infection, fistula, cardiovascular complications, pneumonia, pulmonary embolism, hematoma, emergency department visits, and hospital readmissions within 30 days of primary free flap reconstruction. Both analyses used propensity-score matching for demographic characteristics and comorbidities.",
        "Results": "After propensity matching, 4,490 patients were included in each cohort for the primary analysis. Preoperative mood disorder status was associated with a significantly higher risk of blood vessel repair (RR: 1.219 [95% CI: 1.065, 1.395]) and 30-day hospital readmission (RR: 1.128 [95% CI: 1.069, 1.191]). In the secondary analysis of 1,949 matched pairs of mood disorder patients, antidepressant pharmacotherapy was associated with significantly lower risk of free flap failure (RR: 0.673 [95% CI: 0.526, 0.862]), blood vessel repair (RR: 0.814 [95% CI: 0.670, 0.989]), and other flap revision procedures (RR: 0.705 [95% CI: 0.599, 0.831]). Antidepressant pharmacotherapy was also associated with a lower risk of fistula (RR: 0.600 [95% CI: 0.363, 0.991]).",
        "Conclusions": "Preoperative mood disorder diagnoses are associated with increased risk of postoperative complications and hospital readmission following HNC free flap reconstruction. Antidepressant treatment was associated with lower risk of free flap failure, as well as vascular and revision procedures. These results support incorporating routine preoperative psychosocial screening and optimizing psychiatric treatment as potential strategies to reduce postoperative complications.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Mood Disorders and Postoperative Complications Following Free Flap Reconstruction in Head and Neck Cancer</span>. <u>Hari U Patel</u><sup>1</sup>; Asher C Park<sup>1</sup>; Milan P Fehrenbach<sup>2</sup>; Abhinav Talwar<sup>3</sup>; Katelyn O Stepan<sup>3</sup>. <sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; <sup>2</sup>College of Medicine, Lexington, Kentucky, USA; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>While mood disorders such as depression and anxiety are common in head and neck cancer (HNC) patients, our understanding of how these conditions affect surgical and clinical outcomes after free flap reconstruction is limited.</p>\n\n<p><strong>Objective: </strong>To evaluate the association between preoperative mood disorder diagnoses and postoperative complications following free flap reconstruction in HNC patients, and to further assess whether antidepressant treatment modifies this risk.</p>\n\n<p><strong>Methods: </strong>The TriNetX database was queried for HNC patients who underwent free flap reconstruction between 2010-2025. Primary analysis compared patients with preoperative mood disorder diagnoses (depression, anxiety disorders, or related conditions identified using ICD-10 codes) to patients without such diagnoses. A secondary analysis was conducted among patients with mood disorders, comparing those who received antidepressant pharmacotherapy to those who did not. Primary outcomes included 30-day rates of free flap failure, blood vessel repair, and other flap revision procedures. Secondary outcomes included deep vein thrombosis, sepsis, surgical site infection, fistula, cardiovascular complications, pneumonia, pulmonary embolism, hematoma, emergency department visits, and hospital readmissions within 30 days of primary free flap reconstruction. Both analyses used propensity-score matching for demographic characteristics and comorbidities.</p>\n\n<p><strong>Results: </strong>After propensity matching, 4,490 patients were included in each cohort for the primary analysis. Preoperative mood disorder status was associated with a significantly higher risk of blood vessel repair (RR: 1.219 [95% CI: 1.065, 1.395]) and 30-day hospital readmission (RR: 1.128 [95% CI: 1.069, 1.191]). In the secondary analysis of 1,949 matched pairs of mood disorder patients, antidepressant pharmacotherapy was associated with significantly lower risk of free flap failure (RR: 0.673 [95% CI: 0.526, 0.862]), blood vessel repair (RR: 0.814 [95% CI: 0.670, 0.989]), and other flap revision procedures (RR: 0.705 [95% CI: 0.599, 0.831]). Antidepressant pharmacotherapy was also associated with a lower risk of fistula (RR: 0.600 [95% CI: 0.363, 0.991]).</p>\n\n<p><strong>Conclusions: </strong>Preoperative mood disorder diagnoses are associated with increased risk of postoperative complications and hospital readmission following HNC free flap reconstruction. Antidepressant treatment was associated with lower risk of free flap failure, as well as vascular and revision procedures. These results support incorporating routine preoperative psychosocial screening and optimizing psychiatric treatment as potential strategies to reduce postoperative complications.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153075/Table%203%20Combined(2).png' /></p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153075/table%204%20combined.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153075--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S195",
      "content_id": "147277",
      "abstract_number": "S195",
      "poster_number": "",
      "title": "Depression Screening in Patients with Head and Neck Cancer Across Phases of Care",
      "summary": "In this early experience implementing routine PHQ-9 screening across the HNC care pathway, depression severity was highest during active treatment, and most patients with repeated positive screens were connected to supportive services. Only 1.6% of all patients with HNC had a documented positive PHQ-9, far below published prevalence estimates, suggesting substantial under-screening or under-capture in routine...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147277",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Neil Mehta, MD",
      "presenter": "Neil Mehta, MD",
      "authors": "Lauren E Miller, MD, MBA; Neil Mehta, MD ; Kyle VanKoevering, MD; Ric Carrau, MD, MBA; Nolan Seim, MD, MBA; Catherine Haring, MD; Stephen Kang, MD; James Rocco, MD, PhD; Matthew Old, MD; Ann Scheck McAlearney, ScD, MS",
      "normalized_authors": [
        "Lauren E Miller",
        "Neil Mehta",
        "Kyle VanKoevering",
        "Ric Carrau",
        "Nolan Seim",
        "Catherine Haring",
        "Stephen Kang",
        "James Rocco",
        "Matthew Old",
        "Ann Scheck McAlearney, ScD"
      ],
      "affiliations": [
        "The Ohio State University"
      ],
      "normalized_institutions": [
        "The Ohio State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153431/gee_forest_married_ref_calibri_gray_title2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153431/gee_forest_married_ref_calibri_gray_title2.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147277"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lauren E Miller, MD, MBA; Neil Mehta, MD ; Kyle VanKoevering, MD; Ric Carrau, MD, MBA; Nolan Seim, MD, MBA; Catherine Haring, MD; Stephen Kang, MD; James Rocco, MD, PhD; Matthew Old, MD; Ann Scheck McAlearney, ScD, MS",
        "Affiliations": "The Ohio State University",
        "Importance": "Depression is common and morbid in head and neck cancer (HNC), yet routine screening and its timing relative to treatment are inconsistently implemented. Few studies have described real-world deployment of standardized depression screening across phases of HNC care or quantified the extent to which such workflows identify patients for supportive services.",
        "Objective": "To evaluate depression screening results among patients with HNC and determine whether treatment phase at the time of screening is associated with depression severity among individuals with repeated positive PHQ-9 screens, and to characterize subsequent engagement with supportive services following positive results.",
        "Methods": "We conducted a retrospective cohort study of adult patients with HNC treated at a single tertiary center from July 1, 2023, to August 31, 2025. Eligible patients had ≥2 PHQ-9 assessments with scores ≥10. PHQ-9 scores were summarized using medians and interquartile ranges (IQR) and stratified by treatment phase (pretreatment, active treatment, post-treatment). Generalized estimating equations (GEE) accounted for repeated measures and included covariates for treatment phase, cancer recurrence, anxiety history, HPV status, smoking status, tumor subsite, insurance, marital status, and days since diagnosis. We also abstracted use of social work, psycho-oncology, palliative care, and smoking-cessation services around the time of positive screening to characterize real-world follow-up.",
        "Results": "Among 11,049 patients, 182 (1.6%) had at least one positive PHQ-9 screen, and 36 (19.7%) had ≥2 positive screens and were included in the analytic cohort (median number of surveys 2; IQR 2–4). Most surveys occurred during active treatment (n=51), followed by post-treatment (n=42) and pretreatment (n=11). The overall median PHQ-9 score was 16 (IQR 13–18.25). Compared with pretreatment (median 14), scores were higher during active treatment (median 17; GEE-estimated difference +1.0; 95% CI –1.0 to +3.0; p=0.44) and similar post-treatment (median 15; difference +0.1; 95% CI –2.0 to +2.0; p=0.97). In adjusted models, single or widowed marital status was associated with higher PHQ-9 severity. At the time of positive screening, 70% of patients engaged with at least one supportive service, including social work (33%), psycho-oncology (33%), palliative care (11%), or smoking cessation referral (25%). Engagement patterns suggested that positive screens frequently triggered supportive interventions, though use varied by service type.",
        "Conclusion": "In this early experience implementing routine PHQ-9 screening across the HNC care pathway, depression severity was highest during active treatment, and most patients with repeated positive screens were connected to supportive services. Only 1.6% of all patients with HNC had a documented positive PHQ-9, far below published prevalence estimates, suggesting substantial under-screening or under-capture in routine practice. These findings highlight both the feasibility of phase-specific screening workflows and the need to expand and standardize depression assessment to identify a larger proportion of at-risk patients in HNC care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Depression Screening in Patients with Head and Neck Cancer Across Phases of Care</span>. Lauren E Miller, MD, MBA; <u>Neil Mehta, MD</u>; Kyle VanKoevering, MD; Ric Carrau, MD, MBA; Nolan Seim, MD, MBA; Catherine Haring, MD; Stephen Kang, MD; James Rocco, MD, PhD; Matthew Old, MD; Ann Scheck McAlearney, ScD, MS. The Ohio State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Depression is common and morbid in head and neck cancer (HNC), yet routine screening and its timing relative to treatment are inconsistently implemented. Few studies have described real-world deployment of standardized depression screening across phases of HNC care or quantified the extent to which such workflows identify patients for supportive services.</p>\n\n<p><strong>Objective:</strong> To evaluate depression screening results among patients with HNC and determine whether treatment phase at the time of screening is associated with depression severity among individuals with repeated positive PHQ-9 screens, and to characterize subsequent engagement with supportive services following positive results.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of adult patients with HNC treated at a single tertiary center from July 1, 2023, to August 31, 2025. Eligible patients had ≥2 PHQ-9 assessments with scores ≥10. PHQ-9 scores were summarized using medians and interquartile ranges (IQR) and stratified by treatment phase (pretreatment, active treatment, post-treatment). Generalized estimating equations (GEE) accounted for repeated measures and included covariates for treatment phase, cancer recurrence, anxiety history, HPV status, smoking status, tumor subsite, insurance, marital status, and days since diagnosis. We also abstracted use of social work, psycho-oncology, palliative care, and smoking-cessation services around the time of positive screening to characterize real-world follow-up.</p>\n\n<p><strong>Results: </strong>Among 11,049 patients, 182 (1.6%) had at least one positive PHQ-9 screen, and 36 (19.7%) had ≥2 positive screens and were included in the analytic cohort (median number of surveys 2; IQR 2–4). Most surveys occurred during active treatment (n=51), followed by post-treatment (n=42) and pretreatment (n=11). The overall median PHQ-9 score was 16 (IQR 13–18.25). Compared with pretreatment (median 14), scores were higher during active treatment (median 17; GEE-estimated difference +1.0; 95% CI –1.0 to +3.0; p=0.44) and similar post-treatment (median 15; difference +0.1; 95% CI –2.0 to +2.0; p=0.97). In adjusted models, single or widowed marital status was associated with higher PHQ-9 severity. At the time of positive screening, 70% of patients engaged with at least one supportive service, including social work (33%), psycho-oncology (33%), palliative care (11%), or smoking cessation referral (25%). Engagement patterns suggested that positive screens frequently triggered supportive interventions, though use varied by service type.</p>\n\n<p><strong>Conclusion:</strong> In this early experience implementing routine PHQ-9 screening across the HNC care pathway, depression severity was highest during active treatment, and most patients with repeated positive screens were connected to supportive services. Only 1.6% of all patients with HNC had a documented positive PHQ-9, far below published prevalence estimates, suggesting substantial under-screening or under-capture in routine practice. These findings highlight both the feasibility of phase-specific screening workflows and the need to expand and standardize depression assessment to identify a larger proportion of at-risk patients in HNC care.</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153431/gee_forest_married_ref_calibri_gray_title2.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147277--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S196",
      "content_id": "153752",
      "abstract_number": "S196",
      "poster_number": "",
      "title": "Psychosocial Outcomes Post Laryngectomy in Patients with Head and Neck Cancer",
      "summary": "39 patients who underwent total laryngectomy and completed EORTC QLQ-HN43 surveys were included in the study cohort. The mean age at surgery was 64.6 (SD 10.1) years. Most patients were White (92.3%), non-Hispanic (94.9%), reported alcohol use history (89.7%), and were current or former smokers (84.6%), with a mean pack years of 37.2 (27.6) packs. Most patients had a history of anxiety (64.1%), and no history of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Charles B Wang, BA",
      "presenter": "Charles B Wang, BA",
      "authors": "Charles B Wang, BA 1 ; Rohan Minocha, BS 1 ; Zachary Kons, MD 2 ; Rosh Sethi, MD, MPH 2",
      "normalized_authors": [
        "Charles B Wang",
        "Rohan Minocha",
        "Zachary Kons",
        "Rosh Sethi"
      ],
      "affiliations": [
        "Harvard Medical School",
        "Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham"
      ],
      "normalized_institutions": [
        "Harvard Medical School",
        "Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_48_56%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_48_56%E2%80%AFpm.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_43_55%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_43_55%E2%80%AFpm.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_47_58%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_47_58%E2%80%AFpm.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_24%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_24%E2%80%AFpm.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_34%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_34%E2%80%AFpm.png",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153752/img_1545.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153752/img_1545.png",
          "alt": "Source figure 6",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153752"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Charles B Wang, BA 1 ; Rohan Minocha, BS 1 ; Zachary Kons, MD 2 ; Rosh Sethi, MD, MPH 2",
        "Affiliations": "1 Harvard Medical School; 2 Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham",
        "Introduction": "While organ-preserving therapeutics for managing laryngeal cancer advance, total laryngectomy remains a salvage option for many patients. The surgery permanently alters breathing, swallowing, and natural voice production, significantly impacting patient quality of life. Recent literature suggests that there is a major psychosocial toll on patients as they adapt to changes in airway dependence, communication, and body image. These data are not well studied in this vulnerable patient population and no longitudinal analysis of quality of life outcomes have been published to date.",
        "Methods": "We retrospectively studied patients treated at a tertiary care center who underwent total laryngectomy between 2021 and 2025. The primary outcome was prospectively-collected patient reported outcome measures (PROMS). Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck Cancer Module 43 (EORTC QLQ-HN43) no more than once per month. Clinical data, demographic characteristics, and tumor- and treatment-related variables were collected. We analyzed rounding scores for EORTC QLQ H&N-43 domains assessing psychosocial outcomes including Body Image, Social Eating, Fear of Progression, and Social Contact (0-100, higher = worse). Survey responses were restricted from 300 days pre-operation to 600 days post-operation. To assess trends in recovery, survey responses were grouped into 60-day time bins. Descriptive statistics analyzed cohort characteristics.",
        "Results": "39 patients who underwent total laryngectomy and completed EORTC QLQ-HN43 surveys were included in the study cohort. The mean age at surgery was 64.6 (SD 10.1) years. Most patients were White (92.3%), non-Hispanic (94.9%), reported alcohol use history (89.7%), and were current or former smokers (84.6%), with a mean pack years of 37.2 (27.6) packs. Most patients had a history of anxiety (64.1%), and no history of depression (56.4%) (fig. 1).",
        "Abstract": "Fear of progression demonstrated the highest burden across most time bins with average preoperative scores ranging consistently between 40 - 60. Post-laryngectomy scores plateaued between 30 - 40, suggesting improved, yet persistent fear of progression. Social eating and social contact demonstrated steep improvements in the first 200 days following surgery, reflecting the surmountable challenges patients face with communication, social reintegration, and self confidence during early recovery. Body image showed more modest but gradual improvement in the first postoperative year (fig. 2). Figure 1. Cohort Characteristics Figure 2. Overlayed Rounding Score Trends View in Agenda and Add to Schedule",
        "Discussion": "This study provides a patient perspective of psychosocial symptom progression following total laryngectomy. From 60 days pre-operation to 360 days post-operation, patients experienced a gradual improvement in all four psychosocial outcomes. We observed high variability in the early preoperative and late postoperative periods. This likely reflects variation in the date of initial survey response, attrition over time, differences in treatment, and survivorship. This data can be used to inform patients considering laryngectomies about the transitional challenges that they may face. We also demonstrate the value of frequent survey methodology in gaining insight into patient symptoms and psychosocial experience after life-altering surgery. Future work will incorporate multivariable modeling and compare outcomes across surgical subgroups and additional PRO domains."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Psychosocial Outcomes Post Laryngectomy in Patients with Head and Neck Cancer</span>. <u>Charles B Wang, BA</u><sup>1</sup>; Rohan Minocha, BS<sup>1</sup>; Zachary Kons, MD<sup>2</sup>; Rosh Sethi, MD, MPH<sup>2</sup>. <sup>1</sup>Harvard Medical School; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>While organ-preserving therapeutics for managing laryngeal cancer advance, total laryngectomy remains a salvage option for many patients. The surgery permanently alters breathing, swallowing, and natural voice production, significantly impacting patient quality of life. Recent literature suggests that there is a major psychosocial toll on patients as they adapt to changes in airway dependence, communication, and body image. These data are not well studied in this vulnerable patient population and no longitudinal analysis of quality of life outcomes have been published to date.</p>\n\n<p><strong>Methods: </strong>We retrospectively studied patients treated at a tertiary care center who underwent total laryngectomy between 2021 and 2025. The primary outcome was prospectively-collected patient reported outcome measures (PROMS). Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck Cancer Module 43 (EORTC QLQ-HN43) no more than once per month. Clinical data, demographic characteristics, and tumor- and treatment-related variables were collected. We analyzed rounding scores for EORTC QLQ H&N-43 domains assessing psychosocial outcomes including Body Image, Social Eating, Fear of Progression, and Social Contact (0-100, higher = worse). Survey responses were restricted from 300 days pre-operation to 600 days post-operation. To assess trends in recovery, survey responses were grouped into 60-day time bins. Descriptive statistics analyzed cohort characteristics. </p>\n\n<p><strong>Results: </strong>39 patients who underwent total laryngectomy and completed EORTC QLQ-HN43 surveys were included in the study cohort. The mean age at surgery was 64.6 (SD 10.1) years. Most patients were White (92.3%), non-Hispanic (94.9%), reported alcohol use history (89.7%), and were current or former smokers (84.6%), with a mean pack years of 37.2 (27.6) packs. Most patients had a history of anxiety (64.1%), and no history of depression (56.4%) (fig. 1).</p>\n\n<p>Fear of progression demonstrated the highest burden across most time bins with average preoperative scores ranging consistently between 40 - 60. Post-laryngectomy scores plateaued between 30 - 40, suggesting improved, yet persistent fear of progression. Social eating and social contact demonstrated steep improvements in the first 200 days following surgery, reflecting the surmountable challenges patients face with communication, social reintegration, and self confidence during early recovery. Body image showed more modest but gradual improvement in the first postoperative year (fig. 2).</p>\n\n<p><strong>Discussion: </strong>This study provides a patient perspective of psychosocial symptom progression following total laryngectomy. From 60 days pre-operation to 360 days post-operation, patients experienced a gradual improvement in all four psychosocial outcomes. We observed high variability in the early preoperative and late postoperative periods. This likely reflects variation in the date of initial survey response, attrition over time, differences in treatment, and survivorship. This data can be used to inform patients considering laryngectomies about the transitional challenges that they may face. We also demonstrate the value of frequent survey methodology in gaining insight into patient symptoms and psychosocial experience after life-altering surgery. Future work will incorporate multivariable modeling and compare outcomes across surgical subgroups and additional PRO domains.</p>\n\n<p><strong>Figures: </strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_48_56%E2%80%AFpm.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_43_55%E2%80%AFpm.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_47_58%E2%80%AFpm.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_24%E2%80%AFpm.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/screenshot%202025-12-05%20at%2012_44_34%E2%80%AFpm.png' /></p>\n\n<p>Figure 1. Cohort Characteristics</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153752/img_1545.png' /></p>\n\n<p>Figure 2.  Overlayed Rounding Score Trends</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153752--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S197",
      "content_id": "153253",
      "abstract_number": "S197",
      "poster_number": "",
      "title": "Depression Risk Across the Head and Neck Cancer Treatment Course: An Analysis of PHQ-2/9 Screening Patterns",
      "summary": "Depressive symptom-risk among head and neck cancer patients rose steadily throughout treatment and early survivorship. Although our cohort is small, younger age, current smoking, multimodality therapy, and marital status seem to be key predictors of PHQ positivity, while tumor stage had no impact. Ongoing data collection will help refine these associations. These findings highlight the 12-month post-treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153253",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Malek Ajam, BS",
      "presenter": "Malek Ajam, BS",
      "authors": "Malek Ajam, BS 1 ; Beverly Garber, DNP, ANPC, CORLN 2 ; Michael Li, MD 2 ; Scott Fuller, MD 2 ; Andrew Birkeland, MD 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2",
      "normalized_authors": [
        "Malek Ajam",
        "Beverly Garber, DNP, ANPC, CORLN",
        "Michael Li",
        "Scott Fuller",
        "Andrew Birkeland",
        "Arnaud Bewley",
        "Marianne Abouyared"
      ],
      "affiliations": [
        "University of California Davis School of Medicine",
        "UC Davis Health Department of Otolaryngology, Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of California Davis School of Medicine",
        "UC Davis Health Department of Otolaryngology, Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Malek Ajam, BS 1 ; Beverly Garber, DNP, ANPC, CORLN 2 ; Michael Li, MD 2 ; Scott Fuller, MD 2 ; Andrew Birkeland, MD 2 ; Arnaud Bewley, MD 2 ; Marianne Abouyared, MD 2",
        "Affiliations": "1 University of California Davis School of Medicine; 2 UC Davis Health Department of Otolaryngology, Head and Neck Surgery",
        "Introduction": "Head and neck cancer (HNC) patients experience high rates of depression and suicide, yet depression remains under-diagnosed. The Patient Health Questionnaire (PHQ) is a validated tool for screening, with the PHQ-2 serving as a brief initial screen and the PHQ-9 assessing symptom severity.",
        "Abstract": "Prior studies through our group revealed that most HNC patients prefer surgeon involvement in screening. However, surgeons face significant time and resource constraints, resulting in hesitation to include depression screening in clinic visits. Additionally, the optimal timepoint for identifying depressive risk is unclear, and defining this window could help focus screening efforts where they are most impactful. At our institution, patients complete the PHQ-2 at each visit, with PHQ-9 administered for positive screens (PHQ-2 ≥ 3). This study analyzes PHQ-2/9 data collected thus far to characterize depressive-symptom trends across the treatment course, identify associated demographic and clinical factors, and determine whether specific time-periods warrant targeted screening. The proportion of patients with a positive PHQ screen increased from 7.0% pre-treatment to 9.9% at 3 months and 11.3% at 12 months. At 3 months, PHQ positivity was associated with younger age (p = 0.035), marital status (p = 0.017), smoking (p = 0.037), and treatment type (p = 0.005). Current smokers had the highest PHQ positivity across all timepoints. Smoking status was not associated with tumor stage (p = 0.237), indicating minimal confounding. View in Agenda and Add to Schedule",
        "Methods": "We retrospectively reviewed charts of adults (≥18 years) diagnosed with HNC (oral cavity, oropharynx, nasal cavity, nasopharynx, larynx, thyroid, skin, or salivary gland) between 2019–2025. Patients with sufficient PHQ-2/9 data at pre-treatment, 3-month, and 12-month timepoints were included. PHQ-2/9 scores were considered positive screens if PHQ-9 ≥ 10 or PHQ-2 ≥ 3. Demographic and clinical variables were reviewed. TNM classifications were converted to stage groupings (AJCC 8th edition) and categorized as early (I–II) or advanced (III–IV). Continuous variables were compared using t-tests, and categorical variables using chi-square or Fisher’s exact tests.",
        "Results": "After review of 2,500 patient charts, 71 met inclusion criteria thus far. The mean age was 65, and 68% were male. Most were White (72%) and married (62%). The oral cavity (39%) and oropharynx (28%) were the most common primary sites. Surgery alone was the predominant treatment (51%), followed by surgery and chemoradiation (25%). Early-stage disease accounted for 63% and advanced-stage for 31%. Stage was not associated with PHQ positivity at any timepoint (p = 0.497 pre-treatment; p = 0.296 at 3 months; p = 1.000 at 12 months).",
        "Conclusion": "Depressive symptom-risk among head and neck cancer patients rose steadily throughout treatment and early survivorship. Although our cohort is small, younger age, current smoking, multimodality therapy, and marital status seem to be key predictors of PHQ positivity, while tumor stage had no impact. Ongoing data collection will help refine these associations. These findings highlight the 12-month post-treatment period as a critical window for targeted screening and underscore the need for sustained PHQ monitoring in survivorship to ensure timely recognition and intervention."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Depression Risk Across the Head and Neck Cancer Treatment Course: An Analysis of PHQ-2/9 Screening Patterns</span>. <u>Malek Ajam, BS</u><sup>1</sup>; Beverly Garber, DNP, ANPC, CORLN<sup>2</sup>; Michael Li, MD<sup>2</sup>; Scott Fuller, MD<sup>2</sup>; Andrew Birkeland, MD<sup>2</sup>; Arnaud Bewley, MD<sup>2</sup>; Marianne Abouyared, MD<sup>2</sup>. <sup>1</sup>University of California Davis School of Medicine; <sup>2</sup>UC Davis Health Department of Otolaryngology, Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancer (HNC) patients experience high rates of depression and suicide, yet depression remains under-diagnosed. The Patient Health Questionnaire (PHQ) is a validated tool for screening, with the PHQ-2 serving as a brief initial screen and the PHQ-9 assessing symptom severity.</p>\n\n<p>Prior studies through our group revealed that most HNC patients prefer surgeon involvement in screening. However, surgeons face significant time and resource constraints, resulting in hesitation to include depression screening in clinic visits. Additionally, the optimal timepoint for identifying depressive risk is unclear, and defining this window could help focus screening efforts where they are most impactful.</p>\n\n<p>At our institution, patients complete the PHQ-2 at each visit, with PHQ-9 administered for positive screens (PHQ-2 ≥ 3). This study analyzes PHQ-2/9 data collected thus far to characterize depressive-symptom trends across the treatment course, identify associated demographic and clinical factors, and determine whether specific time-periods warrant targeted screening.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed charts of adults (≥18 years) diagnosed with HNC (oral cavity, oropharynx, nasal cavity, nasopharynx, larynx, thyroid, skin, or salivary gland) between 2019–2025. Patients with sufficient PHQ-2/9 data at pre-treatment, 3-month, and 12-month timepoints were included. PHQ-2/9 scores were considered positive screens if PHQ-9 ≥ 10 or PHQ-2 ≥ 3. Demographic and clinical variables were reviewed. TNM classifications were converted to stage groupings (AJCC 8th edition) and categorized as early (I–II) or advanced (III–IV). Continuous variables were compared using t-tests, and categorical variables using chi-square or Fisher’s exact tests.</p>\n\n<p><strong>Results: </strong>After review of 2,500 patient charts, 71 met inclusion criteria thus far. The mean age was 65, and 68% were male. Most were White (72%) and married (62%). The oral cavity (39%) and oropharynx (28%) were the most common primary sites. Surgery alone was the predominant treatment (51%), followed by surgery and chemoradiation (25%). Early-stage disease accounted for 63% and advanced-stage for 31%. Stage was not associated with PHQ positivity at any timepoint (p = 0.497 pre-treatment; p = 0.296 at 3 months; p = 1.000 at 12 months).</p>\n\n<p>The proportion of patients with a positive PHQ screen increased from 7.0% pre-treatment to 9.9% at 3 months and 11.3% at 12 months. At 3 months, PHQ positivity was associated with younger age (p = 0.035), marital status (p = 0.017), smoking (p = 0.037), and treatment type (p = 0.005). Current smokers had the highest PHQ positivity across all timepoints. Smoking status was not associated with tumor stage (p = 0.237), indicating minimal confounding.</p>\n\n<p><strong>Conclusion: </strong>Depressive symptom-risk among head and neck cancer patients rose steadily throughout treatment and early survivorship. Although our cohort is small, younger age, current smoking, multimodality therapy, and marital status seem to be key predictors of PHQ positivity, while tumor stage had no impact. Ongoing data collection will help refine these associations. These findings highlight the 12-month post-treatment period as a critical window for targeted screening and underscore the need for sustained PHQ monitoring in survivorship to ensure timely recognition and intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153253--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S198",
      "content_id": "154752",
      "abstract_number": "S198",
      "poster_number": "",
      "title": "Trajectories of anxiety, depression, and insomnia symptoms in head and neck cancer survivors",
      "summary": "By revealing distinct trajectories for psychosocial symptoms after HNC treatment, we showed that while many patients experience mild symptom resolution over time, elevated psychological symptoms do persist or re-emerge in a subset of patients. Black/Asian race was associated with higher odds of membership in the symptom-persistent trajectory groups for anxiety, depression, and insomnia, suggesting the possibility...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154752",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michelle Antony, BS",
      "presenter": "Michelle Antony, BS",
      "authors": "Michelle Antony, BS ; Stephen Glass, BS; Angela Mazul, PhD, MPH; Jonas T Johnson, MD; Marci L Nilsen, PhD, RN",
      "normalized_authors": [
        "Michelle Antony",
        "Stephen Glass",
        "Angela Mazul",
        "Jonas T Johnson",
        "Marci L Nilsen"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 455,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background and Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michelle Antony, BS ; Stephen Glass, BS; Angela Mazul, PhD, MPH; Jonas T Johnson, MD; Marci L Nilsen, PhD, RN",
        "Affiliations": "University of Pittsburgh",
        "Background and Objective": "Patients with head and neck cancer (HNC) face a high burden of psychological effects following diagnosis and treatment, with anxiety, depression, and sleep disturbances emerging as some of the most common and debilitating sequelae. These symptoms often interact, co-occur, and fluctuate over the course of treatment and survivorship, yet most studies fail to capture this evolution. We aimed to analyze temporal trajectories of anxiety, depression, and insomnia among HNC survivors to determine clinical, demographic, and treatment-related predictors of trajectory group membership. This knowledge can inform early symptom detection and longitudinal monitoring to promote better patient outcomes across the HNC care continuum.",
        "Methods": "This secondary analysis used prospectively collected data from a survivorship clinic cohort of adult HNC patients who were treated with radiation therapy and completed patient-reported outcome measures at baseline (pre-treatment) and at least one post-treatment follow-up within 15 months. To identify distinct trajectories of anxiety, depression, and insomnia, group-based trajectory modeling was applied to the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), and Insomnia Severity Index (ISI) scores, respectively.",
        "Results": "The sample included 208 HNC survivors (mean age 61.4 years, 76% male, 89.4% White) with oropharyngeal cancer (54.6%) and multimodal therapy (55.8%) being the most common clinical characteristics. Two trajectories for both anxiety and depression symptoms were identified: a mild linearly decreasing trajectory [MN1] which included most patients (n=171, 82.3% for depression, n=188, 90.2% for anxiety) and a smaller stable trajectory with persistently elevated symptoms (n=37, 17.7% for depression and n=20, 9.8% for anxiety). After adjusting for clinical and demographic covariates, Black/Asian race was significantly associated with higher odds of being in the persistent symptom group for depression (OR = 3.87, p = 0.0343) and anxiety. For insomnia scores, two trajectories were also identified: a mild linear decreasing symptoms trajectory for most survivors (n=185, 88.8%) and moderate decreasing curvilinear trajectory marked by two periods of elevated insomnia symptoms (n=23, 11.2%). After controlling for covariates, Black/Asian patients had a greater likelihood of being part of the elevated insomnia symptom trajectory.",
        "Conclusions": "By revealing distinct trajectories for psychosocial symptoms after HNC treatment, we showed that while many patients experience mild symptom resolution over time, elevated psychological symptoms do persist or re-emerge in a subset of patients. Black/Asian race was associated with higher odds of membership in the symptom-persistent trajectory groups for anxiety, depression, and insomnia, suggesting the possibility of racial differences in psychosocial outcomes of HNC survivors. These findings may inform risk stratification during survivorship care, emphasizing the importance of early screening and dynamic interventions. Additionally, there is a need for more diverse research and attentive symptom monitoring across all patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trajectories of anxiety, depression, and insomnia symptoms in head and neck cancer survivors</span>. <u>Michelle Antony, BS</u>; Stephen Glass, BS; Angela Mazul, PhD, MPH; Jonas T Johnson, MD; Marci L Nilsen, PhD, RN. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background and Objective: </strong>Patients with head and neck cancer (HNC) face a high burden of psychological effects following diagnosis and treatment, with anxiety, depression, and sleep disturbances emerging as some of the most common and debilitating sequelae. These symptoms often interact, co-occur, and fluctuate over the course of treatment and survivorship, yet most studies fail to capture this evolution. We aimed to analyze temporal trajectories of anxiety, depression, and insomnia among HNC survivors to determine clinical, demographic, and treatment-related predictors of trajectory group membership. This knowledge can inform early symptom detection and longitudinal monitoring to promote better patient outcomes across the HNC care continuum. </p>\n\n<p><strong>Methods: </strong>This secondary analysis used prospectively collected data from a survivorship clinic cohort of adult HNC patients who were treated with radiation therapy and completed patient-reported outcome measures at baseline (pre-treatment) and at least one post-treatment follow-up within 15 months. To identify distinct trajectories of anxiety, depression, and insomnia, group-based trajectory modeling was applied to the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), and Insomnia Severity Index (ISI) scores, respectively.</p>\n\n<p><strong>Results: </strong>The sample included 208 HNC survivors (mean age 61.4 years, 76% male, 89.4% White) with oropharyngeal cancer (54.6%) and multimodal therapy (55.8%) being the most common clinical characteristics. Two trajectories for both anxiety and depression symptoms were identified: a mild linearly decreasing trajectory [MN1] which included most patients (n=171, 82.3% for depression, n=188, 90.2% for anxiety) and a smaller stable trajectory with persistently elevated symptoms (n=37, 17.7% for depression and n=20, 9.8% for anxiety). After adjusting for clinical and demographic covariates, Black/Asian race was significantly associated with higher odds of being in the persistent symptom group for depression (OR = 3.87, p = 0.0343) and anxiety. For insomnia scores, two trajectories were also identified: a mild linear decreasing symptoms trajectory for most survivors (n=185, 88.8%) and moderate decreasing curvilinear trajectory marked by two periods of elevated insomnia symptoms (n=23, 11.2%). After controlling for covariates, Black/Asian patients had a greater likelihood of being part of the elevated insomnia symptom trajectory.  </p>\n\n<p><strong>Conclusions: </strong>By revealing distinct trajectories for psychosocial symptoms after HNC treatment, we showed that while many patients experience mild symptom resolution over time, elevated psychological symptoms do persist or re-emerge in a subset of patients. Black/Asian race was associated with higher odds of membership in the symptom-persistent trajectory groups for anxiety, depression, and insomnia, suggesting the possibility of racial differences in psychosocial outcomes of HNC survivors. These findings may inform risk stratification during survivorship care, emphasizing the importance of early screening and dynamic interventions. Additionally, there is a need for more diverse research and attentive symptom monitoring across all patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154752--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S199",
      "content_id": "153431",
      "abstract_number": "S199",
      "poster_number": "",
      "title": "Provider Experiences Addressing Mental Health in Head and Neck Cancer",
      "summary": "In this qualitative study of multidisciplinary HNC providers, mental health needs were perceived as pervasive and insufficiently addressed by existing screening and referral processes. Providers reported substantial dependence on social work in the context of limited mental health and supportive resources, leading to concerns that patients “slip through the cracks,” particularly during survivorship. Interventions...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153431",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lauren E Miller, MD, MBA",
      "presenter": "Lauren E Miller, MD, MBA",
      "authors": "Lauren E Miller, MD, MBA ; Daniel Gilmore, PhD; Catherine T Haring, MD; Kyle VanKoevering, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James W Rocco, MD, PhD; Ann Ann Scheck McAlearney, ScD, MS",
      "normalized_authors": [
        "Lauren E Miller",
        "Daniel Gilmore",
        "Catherine T Haring",
        "Kyle VanKoevering",
        "Nolan Seim",
        "Stephen Kang",
        "Matthew Old",
        "James W Rocco",
        "Ann Ann Scheck McAlearney, ScD"
      ],
      "affiliations": [
        "The Ohio State University"
      ],
      "normalized_institutions": [
        "The Ohio State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Lauren E Miller, MD, MBA ; Daniel Gilmore, PhD; Catherine T Haring, MD; Kyle VanKoevering, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James W Rocco, MD, PhD; Ann Ann Scheck McAlearney, ScD, MS",
        "Affiliations": "The Ohio State University",
        "Background": "Patients with head and neck cancer (HNC) experience substantial symptom burden and functional impairment, placing them at high risk for depression, anxiety, and other mental health needs. Despite guideline-recommended screening, little is known about how multidisciplinary HNC providers perceive and operationalize mental health care in routine practice. This qualitative study explored providers’ perspectives on the mental health needs of HNC patients, the adequacy of current screening and referral processes, and system-level barriers to care.",
        "Methods": "We conducted in-depth interviews with 11 multidisciplinary providers who care for patients with HNC, including nurses, surgeons, resident physicians, advanced practice providers, and social workers. Interviews focused on providers’ observations of patients’ emotional distress, perceived effectiveness of current screening processes, approaches to management, and available institutional and community resources. Transcripts were analyzed using an iterative, thematic approach to identify recurrent patterns in provider experiences and perceptions.",
        "Results": "The following major themes emerged across interviews: (1) mental health concerns were widely viewed as an expected part of head and neck cancer care rather than an exception; (2) the presence or absence of social support substantially shaped patients’ coping and engagement in care; (3) standardized depression or distress screening was common, but providers expressed uncertainty about its effectiveness and the accuracy of patient self-report; and (4) many providers felt underprepared to address mental health needs and described a heavy reliance on social workers to coordinate resources and referrals.",
        "Abstract": "More specifically, providers described emotional distress in the fear of diagnosis, loss of function, and chronic pain were common even among patients who did not carry a formal psychiatric diagnosis. Patients with engaged family or caregivers were perceived as more adherent, better able to cope, and more trusting of the team, whereas those who were socially isolated or facing financial and transportation barriers were more likely to miss visits, decline recommended treatments, or disengage from care. Although most clinical settings employed standardized depression or distress screening, providers questioned how candid patients were on these instruments and were unsure how results were used longitudinally, particularly at later “high-risk” periods such as survivorship. Many reported dependence on social workers to assess distress, coordinate mental health referrals, and navigate practical challenges. Despite this, providers perceived the overall mental health and supportive care landscape as fragmented, with long wait times and insurance barriers that contributed to some patients’ needs going unmet. View in Agenda and Add to Schedule",
        "Conclusions": "In this qualitative study of multidisciplinary HNC providers, mental health needs were perceived as pervasive and insufficiently addressed by existing screening and referral processes. Providers reported substantial dependence on social work in the context of limited mental health and supportive resources, leading to concerns that patients “slip through the cracks,” particularly during survivorship. Interventions to improve care should include more systematic and longitudinal depression screening, enhanced training and support for front-line providers, and expanded access to mental health and social resources tailored to the unique needs of patients with HNC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Provider Experiences Addressing Mental Health in Head and Neck Cancer</span>. <u>Lauren E Miller, MD, MBA</u>; Daniel Gilmore, PhD; Catherine T Haring, MD; Kyle VanKoevering, MD; Nolan Seim, MD, MBA; Stephen Kang, MD; Matthew Old, MD; James W Rocco, MD, PhD; Ann Ann Scheck McAlearney, ScD, MS. The Ohio State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Patients with head and neck cancer (HNC) experience substantial symptom burden and functional impairment, placing them at high risk for depression, anxiety, and other mental health needs. Despite guideline-recommended screening, little is known about how multidisciplinary HNC providers perceive and operationalize mental health care in routine practice. This qualitative study explored providers’ perspectives on the mental health needs of HNC patients, the adequacy of current screening and referral processes, and system-level barriers to care.</p>\n\n<p><strong>Methods: </strong>We conducted in-depth interviews with 11 multidisciplinary providers who care for patients with HNC, including nurses, surgeons, resident physicians, advanced practice providers, and social workers. Interviews focused on providers’ observations of patients’ emotional distress, perceived effectiveness of current screening processes, approaches to management, and available institutional and community resources. Transcripts were analyzed using an iterative, thematic approach to identify recurrent patterns in provider experiences and perceptions.</p>\n\n<p><strong>Results:</strong> The following major themes emerged across interviews: (1) mental health concerns were widely viewed as an expected part of head and neck cancer care rather than an exception; (2) the presence or absence of social support substantially shaped patients’ coping and engagement in care; (3) standardized depression or distress screening was common, but providers expressed uncertainty about its effectiveness and the accuracy of patient self-report; and (4) many providers felt underprepared to address mental health needs and described a heavy reliance on social workers to coordinate resources and referrals.</p>\n\n<p>More specifically, providers described emotional distress in the fear of diagnosis, loss of function, and chronic pain were common even among patients who did not carry a formal psychiatric diagnosis. Patients with engaged family or caregivers were perceived as more adherent, better able to cope, and more trusting of the team, whereas those who were socially isolated or facing financial and transportation barriers were more likely to miss visits, decline recommended treatments, or disengage from care. Although most clinical settings employed standardized depression or distress screening, providers questioned how candid patients were on these instruments and were unsure how results were used longitudinally, particularly at later “high-risk” periods such as survivorship. Many reported dependence on social workers to assess distress, coordinate mental health referrals, and navigate practical challenges. Despite this, providers perceived the overall mental health and supportive care landscape as fragmented, with long wait times and insurance barriers that contributed to some patients’ needs going unmet.</p>\n\n<p><strong>Conclusions:</strong> In this qualitative study of multidisciplinary HNC providers, mental health needs were perceived as pervasive and insufficiently addressed by existing screening and referral processes. Providers reported substantial dependence on social work in the context of limited mental health and supportive resources, leading to concerns that patients “slip through the cracks,” particularly during survivorship. Interventions to improve care should include more systematic and longitudinal depression screening, enhanced training and support for front-line providers, and expanded access to mental health and social resources tailored to the unique needs of patients with HNC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153431--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S200",
      "content_id": "154419",
      "abstract_number": "S200",
      "poster_number": "",
      "title": "Factors associated with frailty in patients with locally advanced laryngeal squamous cell carcinoma",
      "summary": "While mFI-11 score was not predictive of LRRFS or OS in this cohort, there were several variables of importance that could assist with risk stratification. Patients who choose to undergo non-operative treatment, have lower functional status, dysphagia, nodal metastasis, and those who reside in nursing facilities are prone to worse outcomes than their peers; these populations may be good candidates for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154419",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hunter Jones, MD",
      "presenter": "Hunter Jones, MD",
      "authors": "Kayla E Baker, MD 1 ; James R Xu, MD 2 ; Hong Li, MS 3 ; Jonathan Lee, MD 4 ; Doreen Lam, MD 1 ; Hunter Jones, MD 1 ; Catherine M Chung, BS 2 ; Robin W Davis, MS 5 ; Kathleen Dennert, BA 5 ; Neil M Woody, MD 5 ; Eric D Lamarre, MD 1 ; Danielle M Bottalico, MD 1",
      "normalized_authors": [
        "Kayla E Baker",
        "James R Xu",
        "Hong Li",
        "Jonathan Lee",
        "Doreen Lam",
        "Hunter Jones",
        "Catherine M Chung",
        "Robin W Davis",
        "Kathleen Dennert",
        "Neil M Woody",
        "Eric D Lamarre",
        "Danielle M Bottalico"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH",
        "Case Western Reserve University School of Medicine",
        "Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland OH",
        "Department of Radiology, Cleveland Clinic, Cleveland OH",
        "Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH",
        "Case Western Reserve University School of Medicine",
        "Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland OH",
        "Department of Radiology, Cleveland Clinic, Cleveland OH",
        "Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 511,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kayla E Baker, MD 1 ; James R Xu, MD 2 ; Hong Li, MS 3 ; Jonathan Lee, MD 4 ; Doreen Lam, MD 1 ; Hunter Jones, MD 1 ; Catherine M Chung, BS 2 ; Robin W Davis, MS 5 ; Kathleen Dennert, BA 5 ; Neil M Woody, MD 5 ; Eric D Lamarre, MD 1 ; Danielle M Bottalico, MD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH; 2 Case Western Reserve University School of Medicine; 3 Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland OH; 4 Department of Radiology, Cleveland Clinic, Cleveland OH; 5 Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
        "Purpose": "Patients with laryngeal cancer are uniquely vulnerable to frailty due to age as well as medical, nutritional, and social complexity. We sought to report the clinical and socioeconomic characteristics of a population at risk of frailty and their oncologic outcomes with the intent of identifying potential points of intervention.",
        "Methods": "A retrospective cohort of patients with stage III/IV laryngeal squamous cell carcinoma (SCC) who underwent treatment between 1/2019 and 12/2023 at a tertiary care center were identified from an IRB-approved registry. The 11-factor modified frailty index (mFI-11) was calculated for each patient through consideration of comorbidities, past medical history, and Karnofsky Performance Scale (KPS), with an mFI-11 of ≥0.27 indicating frailty. Patient demographic, clinical, and treatment data were collected. Frail and non-frail patients were compared using logistic regression while locoregional recurrence-free survival (LRRFS) and overall survival (OS) were evaluated with Kaplan-Meier analysis.",
        "Results": "139 patients (75% male, 78% White) with a median age of 64 years (range 42-90) and median KPS of 80 (range 40-100) were included. 130 (94%) were current or former smokers. 43 (31%) were frail per mFI-11 criteria. 120 (86%) were cT3-4, 77 (55%) were cN1-3, and 44 (35%) had poorly differentiated tumor grades. 41 (29%) received operative treatment, 94 (68%) received chemotherapy, and 124 (89%) received radiotherapy. 56 (40%) had financial limitations, 64 (46%) had mental health challenges, 18 (13%) had limited social support, and 10 (7%) resided in nursing facilities. 57 (43%) had dysphagia limiting dietary intake at time of diagnosis. Older age at diagnosis was significantly associated with frailty (69.8% vs. 37.5%). Median follow up after diagnosis was 36.8 months (range 3-78.2). Overall, 1-year LRRFS was 88.3% (95% CI: 82.5%-94.1%); 3-year OS was 68.7% (60.6%-76.7%) with a median of 60.8 months. On univariate analysis, non-White, KPS <80, clinical nodal positivity, and nursing facility residents were significantly associated with diminished LRRFS; patients with KPS <80, dysphagia at presentation, stage IV, poorly differentiated tumors, those who did not undergo chemotherapy, and nursing facility residents were significantly associated with worsened OS. In multivariable analysis, patients with KPS <80 (adjusted HR, 95% CI: 8.4, 1.7-40.5), nursing facility residents (6.6, 1.4-31.7), clinical nodal positivity (4.7, 1.5-14.6), and non-operative management (6.1,1.8-20.7) remained significant for worsened LRRFS, while KPS ≤80 (2.5, 1.1-5.6), nursing facility residents (6.6, 2.4-18.0), and stage IV disease (1.7, 0.9-3.3) were independently associated with decreased OS. Frailty classified by mFI-11 score was not associated with LRRFS or OS.",
        "Conclusion": "While mFI-11 score was not predictive of LRRFS or OS in this cohort, there were several variables of importance that could assist with risk stratification. Patients who choose to undergo non-operative treatment, have lower functional status, dysphagia, nodal metastasis, and those who reside in nursing facilities are prone to worse outcomes than their peers; these populations may be good candidates for multidisciplinary preventative measures prior to treatment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Factors associated with frailty in patients with locally advanced laryngeal squamous cell carcinoma</span>. Kayla E Baker, MD<sup>1</sup>; James R Xu, MD<sup>2</sup>; Hong Li, MS<sup>3</sup>; Jonathan Lee, MD<sup>4</sup>; Doreen Lam, MD<sup>1</sup>; <u>Hunter Jones, MD</u><sup>1</sup>; Catherine M Chung, BS<sup>2</sup>; Robin W Davis, MS<sup>5</sup>; Kathleen Dennert, BA<sup>5</sup>; Neil M Woody, MD<sup>5</sup>; Eric D Lamarre, MD<sup>1</sup>; Danielle M Bottalico, MD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH; <sup>2</sup>Case Western Reserve University School of Medicine; <sup>3</sup>Department of Biostatistics and Quantitative Health Sciences, Cleveland Clinic, Cleveland OH; <sup>4</sup>Department of Radiology, Cleveland Clinic, Cleveland OH; <sup>5</sup>Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Patients with laryngeal cancer are uniquely vulnerable to frailty due to age as well as medical, nutritional, and social complexity. We sought to report the clinical and socioeconomic characteristics of a population at risk of frailty and their oncologic outcomes with the intent of identifying potential points of intervention.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of patients with stage III/IV laryngeal squamous cell carcinoma (SCC) who underwent treatment between 1/2019 and 12/2023 at a tertiary care center were identified from an IRB-approved registry. The 11-factor modified frailty index (mFI-11) was calculated for each patient through consideration of comorbidities, past medical history, and Karnofsky Performance Scale (KPS), with an mFI-11 of ≥0.27 indicating frailty. Patient demographic, clinical, and treatment data were collected. Frail and non-frail patients were compared using logistic regression while locoregional recurrence-free survival (LRRFS) and overall survival (OS) were evaluated with Kaplan-Meier analysis.</p>\n\n<p><strong>Results: </strong>139 patients (75% male, 78% White) with a median age of 64 years (range 42-90) and median KPS of 80 (range 40-100) were included. 130 (94%) were current or former smokers. 43 (31%) were frail per mFI-11 criteria. 120 (86%) were cT3-4, 77 (55%) were cN1-3, and 44 (35%) had poorly differentiated tumor grades. 41 (29%) received operative treatment, 94 (68%) received chemotherapy, and 124 (89%) received radiotherapy. 56 (40%) had financial limitations, 64 (46%) had mental health challenges, 18 (13%) had limited social support, and 10 (7%) resided in nursing facilities. 57 (43%) had dysphagia limiting dietary intake at time of diagnosis. Older age at diagnosis was significantly associated with frailty (69.8% vs. 37.5%). Median follow up after diagnosis was 36.8 months (range 3-78.2). Overall, 1-year LRRFS was 88.3% (95% CI: 82.5%-94.1%); 3-year OS was 68.7% (60.6%-76.7%) with a median of 60.8 months. On univariate analysis, non-White, KPS <80, clinical nodal positivity, and nursing facility residents were significantly associated with diminished LRRFS; patients with KPS <80, dysphagia at presentation, stage IV, poorly differentiated tumors, those who did not undergo chemotherapy, and nursing facility residents were significantly associated with worsened OS. In multivariable analysis, patients with KPS <80 (adjusted HR, 95% CI: 8.4, 1.7-40.5), nursing facility residents (6.6, 1.4-31.7), clinical nodal positivity (4.7, 1.5-14.6), and non-operative management (6.1,1.8-20.7) remained significant for worsened LRRFS, while KPS ≤80 (2.5, 1.1-5.6), nursing facility residents (6.6, 2.4-18.0), and stage IV disease (1.7, 0.9-3.3) were independently associated with decreased OS. Frailty classified by mFI-11 score was not associated with LRRFS or OS.</p>\n\n<p><strong>Conclusion: </strong>While mFI-11 score was not predictive of LRRFS or OS in this cohort, there were several variables of importance that could assist with risk stratification. Patients who choose to undergo non-operative treatment, have lower functional status, dysphagia, nodal metastasis, and those who reside in nursing facilities are prone to worse outcomes than their peers; these populations may be good candidates for multidisciplinary preventative measures prior to treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154419--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S201",
      "content_id": "153817",
      "abstract_number": "S201",
      "poster_number": "",
      "title": "FOOD INSECURITY AND MENTAL HEALTH IN HEAD AND NECK CANCER PATIENTS",
      "summary": "Food Insecurity (FI), defined as the lack of continuous and regular access to adequate quantity and quality of food, represents a significant threat to public health. Cancer patients, especially those with Head and Neck Squamous Cell Carcinoma (HNSCC), face greater vulnerability to FI due to the feeding difficulties intrinsic to the disease and its treatment. Emerging evidence suggests that FI negatively...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153817",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Priscila Bastos de Souza, MSc",
      "presenter": "Priscila Bastos de Souza, MSc",
      "authors": "Priscila Bastos de Souza, MSc 1 ; Alexandre Bezerra dos Santos, Phd 2 ; Maria Aparecida Azevedo Koike Folgueira, PhD 2 ; Luiz Paulo Kowalski, Phd 2 ; Lays Silva de Azevedo, MSc 1 ; Tatiana Natasha Toporcov, PhD 1",
      "normalized_authors": [
        "Priscila Bastos de Souza",
        "Alexandre Bezerra dos Santos",
        "Maria Aparecida Azevedo Koike Folgueira",
        "Luiz Paulo Kowalski",
        "Lays Silva de Azevedo",
        "Tatiana Natasha Toporcov"
      ],
      "affiliations": [
        "University of Sao Paulo",
        "Hospital das Clínicas FMUSP"
      ],
      "normalized_institutions": [
        "University of Sao Paulo",
        "Hospital das Clínicas FMUSP"
      ],
      "session_type": "Proffered Paper",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Priscila Bastos de Souza, MSc 1 ; Alexandre Bezerra dos Santos, Phd 2 ; Maria Aparecida Azevedo Koike Folgueira, PhD 2 ; Luiz Paulo Kowalski, Phd 2 ; Lays Silva de Azevedo, MSc 1 ; Tatiana Natasha Toporcov, PhD 1",
        "Affiliations": "1 University of Sao Paulo; 2 Hospital das Clínicas FMUSP",
        "Abstract": "Food Insecurity (FI), defined as the lack of continuous and regular access to adequate quantity and quality of food, represents a significant threat to public health. Cancer patients, especially those with Head and Neck Squamous Cell Carcinoma (HNSCC), face greater vulnerability to FI due to the feeding difficulties intrinsic to the disease and its treatment. Emerging evidence suggests that FI negatively influences cancer prognosis and clinical outcomes. Additionally, food uncertainty is a known risk factor for the development of mental disorders, such as depressive and anxious symptoms. The objective of this study was to evaluate the association between FI, anxiety, and depression in patients diagnosed with HNSCC. This cross-sectional study selected patients diagnosed with HNSCC, aged 20 to 79 years, belonging to low-risk groups (age under 40 years or 40 years or older with no history of smoking and alcoholism), admitted to the HCFMUSP/ICESP system. FI was screened using the Brazilian Food Insecurity Scale (EBIA). Emotional status was assessed using the validated Hospital Anxiety and Depression Scale (HADS), which classifies anxiety and depression into three levels: unlikely (0-7 points), possible (8-11 points), and probable (12-21 points). The association between food status (FI vs. Food Security) and anxiety/depression levels was compared using the Fisher's Exact Test. The total sample consisted of 38 patients. A high prevalence of FI was observed, affecting 21% (n=8) of the participants. The distribution of FI was classified as mild in 13% (n=5), moderate in 2.5% (n=1), and severe in 5.5% (n=2). Statistical analysis revealed that in the FI group, 37.5% (n=3) presented with possible anxiety, while in the Food Security group, 33.3% (n=10) presented with possible or probable anxiety, demonstrating similar distributions. No statistically significant association was found between FI and HADS anxiety levels (p = 0.25). In contrast, a significant association was observed between FI and depression levels (p = 0.042). In the FI group, 50.0% (n=4) of individuals were classified with possible or probable depression (37.5% and 12.5%, respectively). In the Food Security group, this proportion was significantly lower, reaching only 13.3% (13.3% possible and 0.0% probable). The high prevalence of FI (21%) among HNSCC patients, even in a low-risk group, highlights the urgent need for routine screening of this condition in oncology patients. The findings indicate that FI is significantly associated with greater vulnerability to depression in this population. Early nutritional interventions and public policies aimed at food security are crucial to mitigate the impacts of FI on the mental health and quality of life of these patients. Future studies with larger samples are recommended to confirm this association. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>FOOD INSECURITY AND MENTAL HEALTH IN HEAD AND NECK CANCER PATIENTS</span>. <u>Priscila Bastos de Souza, MSc</u><sup>1</sup>; Alexandre Bezerra dos Santos, Phd<sup>2</sup>; Maria Aparecida Azevedo Koike Folgueira, PhD<sup>2</sup>; Luiz Paulo Kowalski, Phd<sup>2</sup>; Lays Silva de Azevedo, MSc<sup>1</sup>; Tatiana Natasha Toporcov, PhD<sup>1</sup>. <sup>1</sup>University of Sao Paulo; <sup>2</sup>Hospital das Clínicas FMUSP<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Food Insecurity (FI), defined as the lack of continuous and regular access to adequate quantity and quality of food, represents a significant threat to public health. Cancer patients, especially those with Head and Neck Squamous Cell Carcinoma (HNSCC), face greater vulnerability to FI due to the feeding difficulties intrinsic to the disease and its treatment. Emerging evidence suggests that FI negatively influences cancer prognosis and clinical outcomes. Additionally, food uncertainty is a known risk factor for the development of mental disorders, such as depressive and anxious symptoms. The objective of this study was to evaluate the association between FI, anxiety, and depression in patients diagnosed with HNSCC. This cross-sectional study selected patients diagnosed with HNSCC, aged 20 to 79 years, belonging to low-risk groups (age under 40 years or 40 years or older with no history of smoking and alcoholism), admitted to the HCFMUSP/ICESP system. FI was screened using the Brazilian Food Insecurity Scale (EBIA). Emotional status was assessed using the validated Hospital Anxiety and Depression Scale (HADS), which classifies anxiety and depression into three levels: unlikely (0-7 points), possible (8-11 points), and probable (12-21 points). The association between food status (FI vs. Food Security) and anxiety/depression levels was compared using the Fisher's Exact Test. The total sample consisted of 38 patients. A high prevalence of FI was observed, affecting 21% (n=8) of the participants. The distribution of FI was classified as mild in 13% (n=5), moderate in 2.5% (n=1), and severe in 5.5% (n=2). Statistical analysis revealed that in the FI group, 37.5% (n=3) presented with possible anxiety, while in the Food Security group, 33.3% (n=10) presented with possible or probable anxiety, demonstrating similar distributions. No statistically significant association was found between FI and HADS anxiety levels (p = 0.25). In contrast, a significant association was observed between FI and depression levels (p = 0.042). In the FI group, 50.0% (n=4) of individuals were classified with possible or probable depression (37.5% and 12.5%, respectively). In the Food Security group, this proportion was significantly lower, reaching only 13.3% (13.3% possible and 0.0% probable). The high prevalence of FI (21%) among HNSCC patients, even in a low-risk group, highlights the urgent need for routine screening of this condition in oncology patients. The findings indicate that FI is significantly associated with greater vulnerability to depression in this population. Early nutritional interventions and public policies aimed at food security are crucial to mitigate the impacts of FI on the mental health and quality of life of these patients. Future studies with larger samples are recommended to confirm this association.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153817--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S202",
      "content_id": "155465",
      "abstract_number": "S202",
      "poster_number": "",
      "title": "Psychiatric Burden and Symptom-Associated Risk of Depression in Patients With Vestibular Schwannoma in a TriNetX Cohort",
      "summary": "These findings suggest that vestibular and pain-related symptoms, particularly dizziness and headache, may contribute to the psychological burden experienced by patients with vestibular schwannoma. Recognizing these symptom patterns may help clinicians identify patients at greater risk for depression and support earlier screening and referral for mental health care in this population. Integrating mental health...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155465",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260129",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eiman Stiffler, BS",
      "presenter": "Eiman Stiffler, BS",
      "authors": "Eiman Stiffler, BS 1 ; Lauren Hill, BS 2 ; Claudia Cabrera Aviles, MD, MS 3",
      "normalized_authors": [
        "Eiman Stiffler",
        "Lauren Hill",
        "Claudia Cabrera Aviles"
      ],
      "affiliations": [
        "Case Western Reserve University School of Medicine",
        "Eastern Virginia Medical School",
        "University Hospitals"
      ],
      "normalized_institutions": [
        "Case Western Reserve University School of Medicine",
        "Eastern Virginia Medical School",
        "University Hospitals"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 337,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Eiman Stiffler, BS 1 ; Lauren Hill, BS 2 ; Claudia Cabrera Aviles, MD, MS 3",
        "Affiliations": "1 Case Western Reserve University School of Medicine; 2 Eastern Virginia Medical School; 3 University Hospitals",
        "Introduction": "Vestibular schwannoma is a benign tumor of the vestibulocochlear nerve that commonly presents with symptoms such as hearing loss, tinnitus, dizziness, headache, and facial weakness. These symptoms can significantly affect quality of life and may contribute to psychiatric conditions. The objective of this study was to evaluate psychiatric outcomes in patients with vestibular schwannoma and identify tumor-associated symptoms associated with the development of depression.",
        "Methods": "This retrospective cohort study was conducted using the TriNetX Research Network. Adult patients with vestibular schwannoma between 2015 and 2025 were identified using ICD-10 codes. Psychiatric outcomes were evaluated, and patients were stratified based on the presence or absence of tumor-associated symptoms. Associations between symptoms and depression were analyzed using risk ratios with 95% confidence intervals.",
        "Results": "A total of 1,009 adult patients with vestibular schwannoma were identified within the TriNetX network in the given time frame. In the overall cohort, depression occurred in 7.2% of patients and anxiety in 17.7%, representing the most common psychiatric outcomes. Symptom-specific analyses demonstrated that patients with dizziness had a significantly higher risk of depression compared to those without dizziness (RR 1.89, 95% CI [1.27, 2.81]). Patients with headache also demonstrated an increased risk of depression (RR 2.64, 95% CI [1.78, 3.92]). In contrast, tinnitus, hearing loss, and facial weakness did not show a significant association with the development of depression (RR 0.83, 95% CI [0.53, 1.32]; RR 1.37, 95% CI [0.79, 2.36]; RR 0.99, 95% CI [0.61, 1.61], respectively).",
        "Conclusion": "These findings suggest that vestibular and pain-related symptoms, particularly dizziness and headache, may contribute to the psychological burden experienced by patients with vestibular schwannoma. Recognizing these symptom patterns may help clinicians identify patients at greater risk for depression and support earlier screening and referral for mental health care in this population. Integrating mental health screening into the evaluation of patients with vestibular schwannoma may help address an often underrecognized component of disease burden.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Psychiatric Burden and Symptom-Associated Risk of Depression in Patients With Vestibular Schwannoma in a TriNetX Cohort</span>. <u>Eiman Stiffler, BS</u><sup>1</sup>; Lauren Hill, BS<sup>2</sup>; Claudia Cabrera Aviles, MD, MS<sup>3</sup>. <sup>1</sup>Case Western Reserve University School of Medicine; <sup>2</sup>Eastern Virginia Medical School; <sup>3</sup>University Hospitals<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Vestibular schwannoma is a benign tumor of the vestibulocochlear nerve that commonly presents with symptoms such as hearing loss, tinnitus, dizziness, headache, and facial weakness. These symptoms can significantly affect quality of life and may contribute to psychiatric conditions. The objective of this study was to evaluate psychiatric outcomes in patients with vestibular schwannoma and identify tumor-associated symptoms associated with the development of depression. </p>\n\n<p><strong>Methods: </strong>This retrospective cohort study was conducted using the TriNetX Research Network. Adult patients with vestibular schwannoma between 2015 and 2025 were identified using ICD-10 codes. Psychiatric outcomes were evaluated, and patients were stratified based on the presence or absence of tumor-associated symptoms. Associations between symptoms and depression were analyzed using risk ratios with 95% confidence intervals.</p>\n\n<p><strong>Results: </strong>A total of 1,009 adult patients with vestibular schwannoma were identified within the TriNetX network in the given time frame. In the overall cohort, depression occurred in 7.2% of patients and anxiety in 17.7%, representing the most common psychiatric outcomes. Symptom-specific analyses demonstrated that patients with dizziness had a significantly higher risk of depression compared to those without dizziness (RR 1.89, 95% CI [1.27, 2.81]). Patients with headache also demonstrated an increased risk of depression (RR 2.64, 95% CI [1.78, 3.92]). In contrast, tinnitus, hearing loss, and facial weakness did not show a significant association with the development of depression (RR 0.83, 95% CI [0.53, 1.32]; RR 1.37, 95% CI [0.79, 2.36]; RR 0.99, 95% CI [0.61, 1.61], respectively).</p>\n\n<p><strong>Conclusion:</strong> These findings suggest that vestibular and pain-related symptoms, particularly dizziness and headache, may contribute to the psychological burden experienced by patients with vestibular schwannoma. Recognizing these symptom patterns may help clinicians identify patients at greater risk for depression and support earlier screening and referral for mental health care in this population. Integrating mental health screening into the evaluation of patients with vestibular schwannoma may help address an often underrecognized component of disease burden.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155465--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260129' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S203",
      "content_id": "153696",
      "abstract_number": "S203",
      "poster_number": "",
      "title": "A Novel Liquid Biopsy–Driven Integration Classifier Predicts Outcomes in HPV-Associated Head and Neck Cancer",
      "summary": "In patients with HPV+HNC, blood-based detection of viral integration and rearrangement events is associated with increased frequency of adverse pathologic features, decreased OS and PFS.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153696",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annie R Abruzzo, MD",
      "presenter": "Annie R Abruzzo, MD",
      "authors": "Annie R Abruzzo, MD 1 ; Samuli Eldfors, PhD 2 ; Dipon Das, PhD 2 ; Qin Wang, PhD 2 ; Gjystina Lumaj, MS 2 ; Shriya Shukla 2 ; Jonathan J Paly, DO 3 ; Ross D Merkin, MD 3 ; Jarrod Stein 2 ; Lori J Wirth, MD 3 ; Manisha J Patel, MD 3 ; Jong C Park, MD 3 ; Annie Chan, MD 3 ; Chirayu Patel, MD 3 ; Allen Feng, MD 2 ; Daniel G Deschler, MD 2 ; Derrick T Lin, MD 2 ; William C Faquin, MD, PhD 3 ; Peter M Sadow, MD, PhD 3 ; Bayan A Alzumaili, MD 3 ; Thomas J Roberts, MD, MBA 3 ; Elly Arizono, MD 3 ; Osamu Sakai, MD, PhD 3 ; Jeremy D Richmon, MD 2 ; Adam S Fisch, MD, PhD 3 ; Daniel L Faden, MD 2",
      "normalized_authors": [
        "Annie R Abruzzo",
        "Samuli Eldfors",
        "Dipon Das",
        "Qin Wang",
        "Gjystina Lumaj",
        "Shriya Shukla",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Jarrod Stein",
        "Lori J Wirth",
        "Manisha J Patel",
        "Jong C Park",
        "Annie Chan",
        "Chirayu Patel",
        "Allen Feng",
        "Daniel G Deschler",
        "Derrick T Lin",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Elly Arizono",
        "Osamu Sakai",
        "Jeremy D Richmon",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Harvard Medical School",
        "Massachusetts Eye and Ear",
        "Massachusetts General Hospital"
      ],
      "normalized_institutions": [
        "Harvard Medical School",
        "Massachusetts Eye and Ear",
        "Massachusetts General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153696/KM_PFS_tier1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153696/KM_PFS_tier1.png",
          "alt": "Figure 1. Progression-free survival of patients with vs. without HPV genome integration events in plasma. Log-rank test comparing PFS of integrated (red) and episomal (blue) cohorts demonstrating a significant difference based on presence of integration events (p=0.0024). Kaplan-Meier survival estimate (%) and 95% CI shown.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153696"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions",
        "Figure 1. Progression-free survival of patients with vs. without HPV genome integration events in plasma."
      ],
      "sections": {
        "Authors": "Annie R Abruzzo, MD 1 ; Samuli Eldfors, PhD 2 ; Dipon Das, PhD 2 ; Qin Wang, PhD 2 ; Gjystina Lumaj, MS 2 ; Shriya Shukla 2 ; Jonathan J Paly, DO 3 ; Ross D Merkin, MD 3 ; Jarrod Stein 2 ; Lori J Wirth, MD 3 ; Manisha J Patel, MD 3 ; Jong C Park, MD 3 ; Annie Chan, MD 3 ; Chirayu Patel, MD 3 ; Allen Feng, MD 2 ; Daniel G Deschler, MD 2 ; Derrick T Lin, MD 2 ; William C Faquin, MD, PhD 3 ; Peter M Sadow, MD, PhD 3 ; Bayan A Alzumaili, MD 3 ; Thomas J Roberts, MD, MBA 3 ; Elly Arizono, MD 3 ; Osamu Sakai, MD, PhD 3 ; Jeremy D Richmon, MD 2 ; Adam S Fisch, MD, PhD 3 ; Daniel L Faden, MD 2",
        "Affiliations": "1 Harvard Medical School; 2 Massachusetts Eye and Ear; 3 Massachusetts General Hospital",
        "Objective": "Circulating tumor human papillomavirus DNA (ctHPVDNA) offers a promising avenue for the early detection of HPV-associated head and neck squamous cell carcinoma (HPV+HNC). Detection of ctHPVDNA after treatment completion is highly prognostic of overall survival (OS) and progression free survival (PFS); however, use of ctHPVDNA from pre-treatment time points for prognosis has been much less revealing. Viral integration status has been investigated as a potentially prognostic feature in HPV+HNC; however, integration status has not been evaluable using ctHPVDNA with current approaches. Here we evaluate the prognostic utility of HPV integration status using HPV-DeepSeek, a multi-feature HPV whole genome sequencing liquid biopsy, paired with a novel computational algorithm for integration classification, in blood samples of HPV+HNC patients prior to treatment.",
        "Methods": "Blood samples were collected from 228 patients with HPV+HNC. 200 patients had samples prior to any cancer treatment. Our lab developed an integration classifier to categorize HPV physical states: 1) episomal-only, 2) episomal-rearranged, 3) integrated-clonal, and 4) mixed integrated+episomal which was validated in paired tissue samples using PCR and long read sequencing. Clinical and genomic variables such as cancer stage, HPV16 sublineage, PFS, and OS were compared across physical-state classes.",
        "Results": "The overall cohort (N=228) was 88% male, 92% white, and had a median age at diagnosis of 62 years. The majority of patients had oropharyngeal SCC (N=202, 89%), and most were AJCC8E stage I (N=163, 73%) at diagnosis. HPV integration and rearrangement events could be classified in 170 patients overall, and in 156 at baseline, with high confidence. Of the 170 patients, 71 (42%) were episomal-only and 58% had one or more events with 48 (28%) episomal-rearranged, 48 (28%) mixed integrated+episomal and five (3%) integrated-clonal.",
        "Abstract": "In multivariable-adjusted analysis including age and AJCC8 stage, integration events were associated with increased likelihood of death or recurrence (integrated vs. episomal OR 3.48, CI 1.29-9.59, p=0.014) and increased mortality (OR 4.14, CI 1.20-14.67, p=0.024). Similarly, both integration events alone and the presence of either an integration or rearrangement were associated with decreased PFS as demonstrated by Kaplan-Meier survival curves (Fig. 1). This association was maintained in both unadjusted and age-adjusted Cox proportional hazards models (unadjusted p=0.004, adjusted p=0.003 for integration events alone; unadjusted p=0.021, adjusted p=0.031 for integration or rearrangement compared to episomal-only). Integration or rearrangement events were more common in patients with lymphovascular invasion (p=0.0068) and perineural invasion (p=0.045). HPV16 sublineage did not correlate with HPV integration classification at baseline. View in Agenda and Add to Schedule",
        "Conclusions": "In patients with HPV+HNC, blood-based detection of viral integration and rearrangement events is associated with increased frequency of adverse pathologic features, decreased OS and PFS.",
        "Figure 1. Progression-free survival of patients with vs. without HPV genome integration events in plasma.": "Log-rank test comparing PFS of integrated (red) and episomal (blue) cohorts demonstrating a significant difference based on presence of integration events (p=0.0024). Kaplan-Meier survival estimate (%) and 95% CI shown."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Novel Liquid Biopsy–Driven Integration Classifier Predicts Outcomes in HPV-Associated Head and Neck Cancer</span>. <u>Annie R Abruzzo, MD</u><sup>1</sup>; Samuli Eldfors, PhD<sup>2</sup>; Dipon Das, PhD<sup>2</sup>; Qin Wang, PhD<sup>2</sup>; Gjystina Lumaj, MS<sup>2</sup>; Shriya Shukla<sup>2</sup>; Jonathan J Paly, DO<sup>3</sup>; Ross D Merkin, MD<sup>3</sup>; Jarrod Stein<sup>2</sup>; Lori J Wirth, MD<sup>3</sup>; Manisha J Patel, MD<sup>3</sup>; Jong C Park, MD<sup>3</sup>; Annie Chan, MD<sup>3</sup>; Chirayu Patel, MD<sup>3</sup>; Allen Feng, MD<sup>2</sup>; Daniel G Deschler, MD<sup>2</sup>; Derrick T Lin, MD<sup>2</sup>; William C Faquin, MD, PhD<sup>3</sup>; Peter M Sadow, MD, PhD<sup>3</sup>; Bayan A Alzumaili, MD<sup>3</sup>; Thomas J Roberts, MD, MBA<sup>3</sup>; Elly Arizono, MD<sup>3</sup>; Osamu Sakai, MD, PhD<sup>3</sup>; Jeremy D Richmon, MD<sup>2</sup>; Adam S Fisch, MD, PhD<sup>3</sup>; Daniel L Faden, MD<sup>2</sup>. <sup>1</sup>Harvard Medical School; <sup>2</sup>Massachusetts Eye and Ear; <sup>3</sup>Massachusetts General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Circulating tumor human papillomavirus DNA (ctHPVDNA) offers a promising avenue for the early detection of HPV-associated head and neck squamous cell carcinoma (HPV+HNC). Detection of ctHPVDNA after treatment completion is highly prognostic of overall survival (OS) and progression free survival (PFS); however, use of ctHPVDNA from pre-treatment time points for prognosis has been much less revealing. Viral integration status has been investigated as a potentially prognostic feature in HPV+HNC; however, integration status has not been evaluable using ctHPVDNA with current approaches. Here we evaluate the prognostic utility of HPV integration status using HPV-DeepSeek, a multi-feature HPV whole genome sequencing liquid biopsy, paired with a novel computational algorithm for integration classification, in blood samples of HPV+HNC patients prior to treatment.</p>\n\n<p><strong>Methods:</strong> Blood samples were collected from 228 patients with HPV+HNC. 200 patients had samples prior to any cancer treatment. Our lab developed an integration classifier to categorize HPV physical states: 1) episomal-only, 2) episomal-rearranged, 3) integrated-clonal, and 4) mixed integrated+episomal which was validated in paired tissue samples using PCR and long read sequencing. Clinical and genomic variables such as cancer stage, HPV16 sublineage, PFS, and OS were compared across physical-state classes.</p>\n\n<p><strong>Results:</strong> The overall cohort (N=228) was 88% male, 92% white, and had a median age at diagnosis of 62 years. The majority of patients had oropharyngeal SCC (N=202, 89%), and most were AJCC8E stage I (N=163, 73%) at diagnosis. HPV integration and rearrangement events could be classified in 170 patients overall, and in 156 at baseline, with high confidence. Of the 170 patients, 71 (42%) were episomal-only and 58% had one or more events with 48 (28%) episomal-rearranged, 48 (28%) mixed integrated+episomal and five (3%) integrated-clonal.</p>\n\n<p>In multivariable-adjusted analysis including age and AJCC8 stage, integration events were associated with increased likelihood of death or recurrence (integrated vs. episomal OR 3.48, CI 1.29-9.59, p=0.014) and increased mortality (OR 4.14, CI 1.20-14.67, p=0.024). Similarly, both integration events alone and the presence of either an integration or rearrangement were associated with decreased PFS as demonstrated by Kaplan-Meier survival curves (Fig. 1). This association was maintained in both unadjusted and age-adjusted Cox proportional hazards models (unadjusted p=0.004, adjusted p=0.003 for integration events alone; unadjusted p=0.021, adjusted p=0.031 for integration or rearrangement compared to episomal-only).</p>\n\n<p>Integration or rearrangement events were more common in patients with lymphovascular invasion (p=0.0068) and perineural invasion (p=0.045). HPV16 sublineage did not correlate with HPV integration classification at baseline.</p>\n\n<p><strong>Conclusions:</strong> In patients with HPV+HNC, blood-based detection of viral integration and rearrangement events is associated with increased frequency of adverse pathologic features, decreased OS and PFS.</p>\n\n<p><img alt='Figure 1. Progression-free survival of patients with vs. without HPV genome integration events in plasma. Log-rank test comparing PFS of integrated (red) and episomal (blue) cohorts demonstrating a significant difference based on presence of integration events (p=0.0024). Kaplan-Meier survival estimate (%) and 95% CI shown.' src='https://www.submitmyabstract.com/abs/images/153696/KM_PFS_tier1.png' /></p>\n\n<p><strong>Figure 1. Progression-free survival of patients with vs. without HPV genome integration events in plasma.</strong> Log-rank test comparing PFS of integrated (red) and episomal (blue) cohorts demonstrating a significant difference based on presence of integration events (p=0.0024). Kaplan-Meier survival estimate (%) and 95% CI shown.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153696--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S204",
      "content_id": "153866",
      "abstract_number": "S204",
      "poster_number": "",
      "title": "Comparative Survival Outcomes of Definitive Chemoradiotherapy versus Surgery following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Pooled Analysis",
      "summary": "For patients with LA-HNSCC who receive neoadjuvant chemoimmunotherapy, subsequent surgical resection is associated with superior survival outcomes compared to definitive chemoradiotherapy, irrespective of clinical response. These findings support the consideration of active surgical evaluation for all operable LA-HNSCC patients undergoing neoadjuvant chemoimmunotherapy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153866",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Qindong Cai",
      "presenter": "Qindong Cai",
      "authors": "Qindong Cai 1 ; Yang Liu 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 1 ; Shaoyan Liu 1",
      "normalized_authors": [
        "Qindong Cai",
        "Yang Liu",
        "Yudong Ning",
        "Han Li",
        "Lin Gui",
        "Ye Zhang",
        "Jingwei Luo",
        "Changming An",
        "Xiaolei Wang",
        "Shaoyan Liu"
      ],
      "affiliations": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R.China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R.China",
        "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153866/%E6%9C%AA%E6%A0%87%E9%A2%98-1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153866/%E6%9C%AA%E6%A0%87%E9%A2%98-1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153866"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 482,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Qindong Cai 1 ; Yang Liu 1 ; Yudong Ning 1 ; Han Li 1 ; Lin Gui 2 ; Ye Zhang 3 ; Jingwei Luo 3 ; Changming An 1 ; Xiaolei Wang 1 ; Shaoyan Liu 1",
        "Affiliations": "1 Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R.China; 2 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; 3 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",
        "Background": "The optimal local treatment strategy following neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains undefined. This study aimed to compare survival outcomes between patients undergoing definitive chemoradiotherapy (dCRT) and those undergoing surgery after neoadjuvant chemoimmunotherapy, and to identify potential patient subgroups that may benefit differentially from these approaches.",
        "Methods": "We performed a pooled analysis of untreated stage III-IV LA-HNSCC patients from three prospective phase II trials. All patients received neoadjuvant treatment consisting of a PD-1 inhibitor combined with taxane and platinum-based chemotherapy for 2-4 cycles, followed by local definitive treatment (surgery or dCRT) as determined by a multidisciplinary team. Overall survival (OS) and disease-free survival (DFS) were calculated from the initiation of neoadjuvant therapy. To address baseline imbalances, we employed 1:1 propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to analyze survival differences and identify independent prognostic factors.",
        "Results": "Among 283 eligible patients (median follow-up 25 months), 130 underwent surgery and 153 received dCRT after neoadjuvant therapy. At baseline, the dCRT group had a significantly higher proportion of p16-positive tumors, better clinical response, and earlier clinical stage compared to the surgery group (all p <0.05). The overall objective response rate (ORR) and disease control rate (DCR) to neoadjuvant therapy were 67.4% (191/283) and 100% (283/283), respectively. Pathological complete response (pCR) was achieved in 27.7% (36/130) of surgical patients. Both before and after adjustment, surgery was associated with significantly improved OS (unadjusted 2-year OS: 81.5% vs. 74.6%, HR=0.56, 95% CI 0.33-0.96, p <0.05; PSM-adjusted: 82.4% vs. 67.6%, HR=0.29, 95% CI 0.17-0.49, p <0.001; IPTW-adjusted: 86.0% vs. 70.9%, HR=0.33, 95% CI 0.18-0.61, p <0.001) and DFS (unadjusted 2-year DFS: 76.3% vs. 63.4%, HR=0.65, 95% CI 0.42-1.01, p =0.054; PSM-adjusted: 77.5% vs. 65.9%, HR=0.47, 95% CI 0.31-0.73, p <0.001; IPTW-adjusted: 81.5% vs. 59.7%, HR=0.40, 95% CI 0.24-0.65, p <0.001) compared to dCRT. IPTW-adjusted analysis revealed no significant treatment-by-subgroup interactions for factors including CPS score, cT stage, or clinical response (all P-interaction > 0.05). In multivariable analysis, treatment strategy (surgery vs. dCRT: adjusted HR=0.32, 95% CI 0.17-0.62, p <0.001) and clinical response to neoadjuvant therapy (adjusted HR=0.29, 95% CI 0.16-0.53, p <0.001) were independent predictors of survival benefit.",
        "Conclusion": "For patients with LA-HNSCC who receive neoadjuvant chemoimmunotherapy, subsequent surgical resection is associated with superior survival outcomes compared to definitive chemoradiotherapy, irrespective of clinical response. These findings support the consideration of active surgical evaluation for all operable LA-HNSCC patients undergoing neoadjuvant chemoimmunotherapy.",
        "Keywords": "Neoadjuvant Therapy; Immune Checkpoint Inhibitors; Squamous Cell Carcinoma of Head and Neck; Chemoradiotherapy; Surgery",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Survival Outcomes of Definitive Chemoradiotherapy versus Surgery following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of Three Prospective Phase II Trials</span>. <u>Qindong Cai</u><sup>1</sup>; Yang Liu<sup>1</sup>; Yudong Ning<sup>1</sup>; Han Li<sup>1</sup>; Lin Gui<sup>2</sup>; Ye Zhang<sup>3</sup>; Jingwei Luo<sup>3</sup>; Changming An<sup>1</sup>; Xiaolei Wang<sup>1</sup>; Shaoyan Liu<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R.China; <sup>2</sup>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; <sup>3</sup>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: The optimal local treatment strategy following neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains undefined. This study aimed to compare survival outcomes between patients undergoing definitive chemoradiotherapy (dCRT) and those undergoing surgery after neoadjuvant chemoimmunotherapy, and to identify potential patient subgroups that may benefit differentially from these approaches.</p>\n\n<p><strong>Methods</strong>: We performed a pooled analysis of untreated stage III-IV LA-HNSCC patients from three prospective phase II trials. All patients received neoadjuvant treatment consisting of a PD-1 inhibitor combined with taxane and platinum-based chemotherapy for 2-4 cycles, followed by local definitive treatment (surgery or dCRT) as determined by a multidisciplinary team. Overall survival (OS) and disease-free survival (DFS) were calculated from the initiation of neoadjuvant therapy. To address baseline imbalances, we employed 1:1 propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to analyze survival differences and identify independent prognostic factors.</p>\n\n<p><strong>Results</strong>: Among 283 eligible patients (median follow-up 25 months), 130 underwent surgery and 153 received dCRT after neoadjuvant therapy. At baseline, the dCRT group had a significantly higher proportion of p16-positive tumors, better clinical response, and earlier clinical stage compared to the surgery group (all <em>p</em><0.05). The overall objective response rate (ORR) and disease control rate (DCR) to neoadjuvant therapy were 67.4% (191/283) and 100% (283/283), respectively. Pathological complete response (pCR) was achieved in 27.7% (36/130) of surgical patients. Both before and after adjustment, surgery was associated with significantly improved OS (unadjusted 2-year OS: 81.5% vs. 74.6%, HR=0.56, 95% CI 0.33-0.96, <em>p</em><0.05; PSM-adjusted: 82.4% vs. 67.6%, HR=0.29, 95% CI 0.17-0.49, <em>p</em><0.001; IPTW-adjusted: 86.0% vs. 70.9%, HR=0.33, 95% CI 0.18-0.61, <em>p</em><0.001) and DFS (unadjusted 2-year DFS: 76.3% vs. 63.4%, HR=0.65, 95% CI 0.42-1.01, <em>p</em>=0.054; PSM-adjusted: 77.5% vs. 65.9%, HR=0.47, 95% CI 0.31-0.73, <em>p</em><0.001; IPTW-adjusted: 81.5% vs. 59.7%, HR=0.40, 95% CI 0.24-0.65, <em>p</em><0.001) compared to dCRT. IPTW-adjusted analysis revealed no significant treatment-by-subgroup interactions for factors including CPS score, cT stage, or clinical response (all P-interaction > 0.05). In multivariable analysis, treatment strategy (surgery vs. dCRT: adjusted HR=0.32, 95% CI 0.17-0.62, <em>p</em><0.001) and clinical response to neoadjuvant therapy (adjusted HR=0.29, 95% CI 0.16-0.53, <em>p</em><0.001) were independent predictors of survival benefit.</p>\n\n<p><strong>Conclusion</strong>: For patients with LA-HNSCC who receive neoadjuvant chemoimmunotherapy, subsequent surgical resection is associated with superior survival outcomes compared to definitive chemoradiotherapy, irrespective of clinical response. These findings support the consideration of active surgical evaluation for all operable LA-HNSCC patients undergoing neoadjuvant chemoimmunotherapy.</p>\n\n<p><strong>Keywords</strong>: Neoadjuvant Therapy; Immune Checkpoint Inhibitors; Squamous Cell Carcinoma of Head and Neck; Chemoradiotherapy; Surgery</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153866/%E6%9C%AA%E6%A0%87%E9%A2%98-1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153866--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S205",
      "content_id": "154260",
      "abstract_number": "S205",
      "poster_number": "",
      "title": "T1-micro oropharyngeal carcinomas exhibit increased humoral immune activity and B-cell infiltration compared to conventional oropharyngeal carcinomas",
      "summary": "To our knowledge, this is the first transcriptomic study dedicated to the characterization of T1-micro-OPC. Our findings demonstrated that T1-micro-OPC represent a biologically distinct subset of oropharyngeal tumors, characterized by enhanced humoral immune activity, increased B-cell infiltration, and suppressed proliferative signaling. These insights may explain how these microscopic primary tumors remain...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154260",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jun Yuan Koo",
      "presenter": "Jun Yuan Koo",
      "authors": "Jun Yuan Koo 1 ; Nikita Bedi, BS 2 ; Shen Kai Ng, BS 1 ; Luvita Suryani, PhD 1 ; Wei Keat Teo, BS 1 ; Joseph Foley, PhD 1 ; Serene Siow, MS 1 ; Beth M Beadle, MD, FASTRO 3 ; Mobeen Rahman, MD 4 ; Joshua K Tay, MBBS, PhD, MRCS, MMed, FAMS 1 ; F",
      "normalized_authors": [
        "Jun Yuan Koo",
        "Nikita Bedi",
        "Shen Kai Ng",
        "Luvita Suryani",
        "Wei Keat Teo",
        "Joseph Foley",
        "Serene Siow",
        "Beth M Beadle, FASTRO",
        "Mobeen Rahman",
        "Joshua K Tay, MBBS, MRCS, MMed, FAMS"
      ],
      "affiliations": [
        "Christopher Holsinger, MD, FACS 2 . 1 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Division of Head & Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Palo Alto, CA, USA",
        "Department of Radiation Oncology, Stanford University School of Medicine, USA",
        "Department of Pathology, Stanford University School of Medicine, USA"
      ],
      "normalized_institutions": [
        "Christopher Holsinger, MD, FACS 2 . 1 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Division of Head & Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Palo Alto, CA, USA",
        "Department of Radiation Oncology, Stanford University School of Medicine, USA",
        "Department of Pathology, Stanford University School of Medicine, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154260/AHNS%20Image%20File(1).jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154260/AHNS%20Image%20File(1).jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154260"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jun Yuan Koo 1 ; Nikita Bedi, BS 2 ; Shen Kai Ng, BS 1 ; Luvita Suryani, PhD 1 ; Wei Keat Teo, BS 1 ; Joseph Foley, PhD 1 ; Serene Siow, MS 1 ; Beth M Beadle, MD, FASTRO 3 ; Mobeen Rahman, MD 4 ; Joshua K Tay, MBBS, PhD, MRCS, MMed, FAMS 1 ; F",
        "Affiliations": "Christopher Holsinger, MD, FACS 2 . 1 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; 2 Division of Head & Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Palo Alto, CA, USA; 3 Department of Radiation Oncology, Stanford University School of Medicine, USA; 4 Department of Pathology, Stanford University School of Medicine, USA",
        "Background": "Head and neck squamous cell carcinoma of unknown primary (HNSCCUP) manifests clinically as metastatic squamous cell carcinoma in cervical lymph nodes, without an identifiable primary site despite exhaustive clinical, radiological, and endoscopic evaluation. The advent of transoral robotic surgery (TORS) has enabled the localization of the occult primary tumor in up to 83% of cases. Notably, most of these primaries are T1 microcarcinomas that span just a few millimeters in size, arising within the palatine or lingual tonsils. However, the underlying biology of these T1-micro oropharyngeal carcinomas (T1-micro-OPC) remains poorly understood. Given this clinical paradox, our study aims to characterize the gene expression profile of T1-micro-OPC in comparison to conventional OPC, and identify the biological pathways that may explain their unique behavior.",
        "Methods": "Formalin-fixed paraffin-embedded (FFPE) tissue sections were collected from primary tumors of patients with T1-micro-OPC (n=21), conventional OPC (n=13), as well as normal tonsils from patients with non-malignant indications (n=20). When available, matched metastatic lymph node sections were also obtained for tumor cases. Laser-capture microdissection was performed on specific regions of interest as annotated by a board-certified pathologist. Sequencing was performed using a specialized in-house FFPE RNA-Seq protocol, with downstream bioinformatic analyses conducted using R.",
        "Results": "Analysis of 321 gene expression libraries revealed that T1-micro-OPC exhibited a transcriptomic profile distinct from conventional OPC. Tumor epithelium of T1-micro-OPC showed significant upregulation of genes such as IGHG1 and FCER2 ( CD23 ), which are involved in biological processes such as B-cell receptor signaling pathway (NES = 2.89, p-adj = 3.4 x 10 -17 ) and humoral immune response (NES = 2.18, p-adj = 2.5 x 10 -14 ). Consistent with the pathway-level analysis, in silico cell type deconvolution demonstrated significantly higher B-cell infiltration in T1-micro-OPC compared with conventional OPC (9.4% vs 1.0%, p < 0.001).",
        "Abstract": "Besides the heightened immune activity, T1-micro-OPC also displayed reduced proliferative signaling. Specifically, we observed reduced enrichment of hallmark pathways related to cell proliferation, such as E2F signaling (NES = -2.95, p-adj =1.3 x 10 -22 ) and G2/M checkpoint regulation (NES = -2.44, p-adj = 1.92 x 10 -12 ). Correspondingly, genes associated with tumor growth and progression, such as LGR5 , TGFA , and FGFR1 , were also downregulated in T1-micro-OPC. High-risk HPV strains (HPV16, 33, and 35) were detected in both T1-micro-OPC and conventional OPC, with HPV16 being the most prevalent strain. Notably, HPV35 was observed exclusively in conventional OPC. View in Agenda and Add to Schedule",
        "Conclusion": "To our knowledge, this is the first transcriptomic study dedicated to the characterization of T1-micro-OPC. Our findings demonstrated that T1-micro-OPC represent a biologically distinct subset of oropharyngeal tumors, characterized by enhanced humoral immune activity, increased B-cell infiltration, and suppressed proliferative signaling. These insights may explain how these microscopic primary tumors remain clinically occult yet retain metastatic competence, and suggest the potential role for immunotherapy in their management. Completion of our full cohort of 40 pairs of T1-micro-OPC and conventional OPC will provide further evidence supporting a distinct T1-micro-OPC biological phenotype."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>T1-micro oropharyngeal carcinomas exhibit increased humoral immune activity and B-cell infiltration compared to conventional oropharyngeal carcinomas</span>. <u>Jun Yuan Koo</u><sup>1</sup>; Nikita Bedi, BS<sup>2</sup>; Shen Kai Ng, BS<sup>1</sup>; Luvita Suryani, PhD<sup>1</sup>; Wei Keat Teo, BS<sup>1</sup>; Joseph Foley, PhD<sup>1</sup>; Serene Siow, MS<sup>1</sup>; Beth M Beadle, MD, FASTRO<sup>3</sup>; Mobeen Rahman, MD<sup>4</sup>; Joshua K Tay, MBBS, PhD, MRCS, MMed, FAMS<sup>1</sup>; F. Christopher Holsinger, MD, FACS<sup>2</sup>. <sup>1</sup>Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; <sup>2</sup>Division of Head & Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Palo Alto, CA, USA; <sup>3</sup>Department of Radiation Oncology, Stanford University School of Medicine, USA; <sup>4</sup>Department of Pathology, Stanford University School of Medicine, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinoma of unknown primary (HNSCCUP) manifests clinically as metastatic squamous cell carcinoma in cervical lymph nodes, without an identifiable primary site despite exhaustive clinical, radiological, and endoscopic evaluation. The advent of transoral robotic surgery (TORS) has enabled the localization of the occult primary tumor in up to 83% of cases. Notably, most of these primaries are T1 microcarcinomas that span just a few millimeters in size, arising within the palatine or lingual tonsils. However, the underlying biology of these T1-micro oropharyngeal carcinomas (T1-micro-OPC) remains poorly understood. Given this clinical paradox, our study aims to characterize the gene expression profile of T1-micro-OPC in comparison to conventional OPC, and identify the biological pathways that may explain their unique behavior.</p>\n\n<p><strong>Methods: </strong>Formalin-fixed paraffin-embedded (FFPE) tissue sections were collected from primary tumors of patients with T1-micro-OPC (n=21), conventional OPC (n=13), as well as normal tonsils from patients with non-malignant indications (n=20). When available, matched metastatic lymph node sections were also obtained for tumor cases. Laser-capture microdissection was performed on specific regions of interest as annotated by a board-certified pathologist. Sequencing was performed using a specialized in-house FFPE RNA-Seq protocol, with downstream bioinformatic analyses conducted using R.</p>\n\n<p><strong>Results: </strong>Analysis of 321 gene expression libraries revealed that T1-micro-OPC exhibited a transcriptomic profile distinct from conventional OPC. Tumor epithelium of T1-micro-OPC showed significant upregulation of genes such as <em>IGHG1</em> and <em>FCER2</em> (<em>CD23</em>), which are involved in biological processes such as B-cell receptor signaling pathway (NES = 2.89, p-adj = 3.4 x 10<sup>-17</sup>) and humoral immune response (NES = 2.18, p-adj = 2.5 x 10<sup>-14</sup>). Consistent with the pathway-level analysis, in silico cell type deconvolution demonstrated significantly higher B-cell infiltration in T1-micro-OPC compared with conventional OPC (9.4% vs 1.0%, p < 0.001).</p>\n\n<p>Besides the heightened immune activity, T1-micro-OPC also displayed reduced proliferative signaling. Specifically, we observed reduced enrichment of hallmark pathways related to cell proliferation, such as E2F signaling (NES = -2.95, p-adj =1.3 x 10<sup>-22</sup>) and G2/M checkpoint regulation (NES = -2.44, p-adj = 1.92 x 10<sup>-12</sup>). Correspondingly, genes associated with tumor growth and progression, such as <em>LGR5</em>, <em>TGFA</em>, and <em>FGFR1</em>, were also downregulated in T1-micro-OPC.</p>\n\n<p>High-risk HPV strains (HPV16, 33, and 35) were detected in both T1-micro-OPC and conventional OPC, with HPV16 being the most prevalent strain. Notably, HPV35 was observed exclusively in conventional OPC.</p>\n\n<p><strong>Conclusion: </strong>To our knowledge, this is the first transcriptomic study dedicated to the characterization of T1-micro-OPC. Our findings demonstrated that T1-micro-OPC represent a biologically distinct subset of oropharyngeal tumors, characterized by enhanced humoral immune activity, increased B-cell infiltration, and suppressed proliferative signaling. These insights may explain how these microscopic primary tumors remain clinically occult yet retain metastatic competence, and suggest the potential role for immunotherapy in their management. Completion of our full cohort of 40 pairs of T1-micro-OPC and conventional OPC will provide further evidence supporting a distinct T1-micro-OPC biological phenotype.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154260/AHNS%20Image%20File(1).jpeg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154260--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S206",
      "content_id": "154014",
      "abstract_number": "S206",
      "poster_number": "",
      "title": "Impact of Surgical Margin Distance on Recurrence in Head and Neck Cutaneous Melanoma in the Adjuvant Immunotherapy Era",
      "summary": "Among patients receiving adjuvant ICI, margin width did not independently influence recurrence or 3-year DFS, suggesting that ICI may attenuate the local prognostic role of margin clearance. Conversely, SLN positivity, mitotic rate, and scalp involvement retained strong prognostic importance, highlighting the predominance of biologic drivers over margin distance in contemporary HNCM.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154014",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shivam D Patel, MD",
      "presenter": "Shivam D Patel, MD",
      "authors": "Shivam D Patel, MD ; Shirley X Liu, BS; Micah K Harris, MD; Maryanna Owoc, MD, PhD; Drew Hurd, BS; Aditi Kulkarni, MSc; Yanna Najjar, MD; Hassane M Zarour, MD; John Kirkwood, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica H Maxwell, MD, MPH; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Diwakar Davar, MD; Shaum S Sridharan, MD",
      "normalized_authors": [
        "Shivam D Patel",
        "Shirley X Liu",
        "Micah K Harris",
        "Maryanna Owoc",
        "Drew Hurd",
        "Aditi Kulkarni",
        "Yanna Najjar",
        "Hassane M Zarour",
        "John Kirkwood",
        "Joshua D Smith",
        "Steven B Chinn",
        "Jessica H Maxwell",
        "Kevin J Contrera",
        "Matthew E Spector",
        "Diwakar Davar",
        "Shaum S Sridharan"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 542,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shivam D Patel, MD ; Shirley X Liu, BS; Micah K Harris, MD; Maryanna Owoc, MD, PhD; Drew Hurd, BS; Aditi Kulkarni, MSc; Yanna Najjar, MD; Hassane M Zarour, MD; John Kirkwood, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica H Maxwell, MD, MPH; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Diwakar Davar, MD; Shaum S Sridharan, MD",
        "Affiliations": "University of Pittsburgh Medical Center",
        "Introduction": "There is a lack of consensus regarding optimal surgical excision margins for primary cutaneous melanoma > 1 mm in Breslow depth. In head and neck cutaneous melanoma (HNCM), attaining recommended margins is often limited by functional and anatomic constraints. Adjuvant immune checkpoint inhibition (ICI) therapy is indicated in stage IIB-IIID melanoma based on pivotal trials. In this context, the prognostic relevance of close but negative margins, particularly among ICI-treated patients, remains unclear.",
        "Methods": "Under the aegis of an IRB-approved exempt study (STUDY24010105), we performed a retrospective review of primary HNCM who received wide local excision (WLE) from 2015–2025 at a quaternary academic medical center (N=186). Surgical closure technique was at the discretion of the treating surgeon. Analyses were restricted to patients with negative margins (NM) (N=169), with a predefined subset analysis of those who received adjuvant ICI (N=36). Kaplan-Meier estimates and univariate logistic regression were used to identify predictors of recurrence for negative margins; and significant factors were included in multivariate models. Analyses were performed using IBM SPSS Statistics v29.",
        "Results": "Among 186 patients (median age 67.1 years; 71% male), 59 (32%) had scalp and 127 (68%) non-scalp primaries. T-stage distribution was: T1 23.7%, T2 29.0%, T3 24.2%, and T4 18.3%. SLNB was performed in 76.3% (median 3 nodes). Negative margins were obtained in nearly all patients (90.9%), with 17.2% demonstrating a closest margin <2 mm. Adjuvant ICI was administered to 55/186 (29.6%). Median follow-up time was 37 months (range 1-72 months). On univariate analyses in HNCM NM, recurrence was associated with scalp subsite (OR 2.23, p=0.028), T3-T4 stage (OR 2.56, p=0.009), and mitotic rate >1/mm2 (OR 3.92, p=0.004). Age, sex, comorbidity, smoking, ulceration, LVI, SLN positivity, and margin distance—evaluated continuously or as <2 mm vs ≥2 mm—were not associated with recurrence. In multivariable Cox modeling of 3-year DFS, independent predictors included SLN positivity (HR 7.72, p=0.018), mitotic activity (HR 3.83, p=0.049), scalp location (HR 3.14, p=0.034), and receipt of adjuvant ICI (HR 0.065, p=0.004), while <2-mm margins were not associated with DFS (HR 0.48, p=0.41). Among adjuvant ICI-treated HNCM patients with NM (n=36), recurrence occurred in 50.0% of patients with <2-mm margins and 22.2% with ≥2-mm margins. Among ICI-treated patients (N=27), 3- and 5-year DFS were 40% and 40% for <2-mm margins versus 77% and 70% for ≥2-mm margins. Margin distance did not emerge as an independent predictor of 3-year DFS in multivariable models. The 3-year OS was 86.7% for <2-mm margins and 91.6% for ≥2-mm margins, and margin distance was not associated with OS on univariate analysis. For the full cohort, 3- and 5-year DFS were 73% and 66%, and 3- and 5-year OS were 88% and 75%.",
        "Conclusions": "Among patients receiving adjuvant ICI, margin width did not independently influence recurrence or 3-year DFS, suggesting that ICI may attenuate the local prognostic role of margin clearance. Conversely, SLN positivity, mitotic rate, and scalp involvement retained strong prognostic importance, highlighting the predominance of biologic drivers over margin distance in contemporary HNCM.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Surgical Margin Distance on Recurrence in Head and Neck Cutaneous Melanoma in the Adjuvant Immunotherapy Era</span>. <u>Shivam D Patel, MD</u>; Shirley X Liu, BS; Micah K Harris, MD; Maryanna Owoc, MD, PhD; Drew Hurd, BS; Aditi Kulkarni, MSc; Yanna Najjar, MD; Hassane M Zarour, MD; John Kirkwood, MD; Joshua D Smith, MD; Steven B Chinn, MD; Jessica H Maxwell, MD, MPH; Kevin J Contrera, MD, MPH; Matthew E Spector, MD; Diwakar Davar, MD; Shaum S Sridharan, MD. University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>There is a lack of consensus regarding optimal surgical excision margins for primary cutaneous melanoma > 1 mm in Breslow depth. In head and neck cutaneous melanoma (HNCM), attaining recommended margins is often limited by functional and anatomic constraints. Adjuvant immune checkpoint inhibition (ICI) therapy is indicated in stage IIB-IIID melanoma based on pivotal trials. In this context, the prognostic relevance of close but negative margins, particularly among ICI-treated patients, remains unclear.</p>\n\n<p><strong>Methods: </strong>Under the aegis of an IRB-approved exempt study (STUDY24010105), we performed a retrospective review of primary HNCM who received wide local excision (WLE) from 2015–2025 at a quaternary academic medical center (N=186). Surgical closure technique was at the discretion of the treating surgeon. Analyses were restricted to patients with negative margins (NM) (N=169), with a predefined subset analysis of those who received adjuvant ICI (N=36).  Kaplan-Meier estimates and univariate logistic regression were used to identify predictors of recurrence for negative margins; and significant factors were included in multivariate models. Analyses were performed using IBM SPSS Statistics v29.</p>\n\n<p><strong>Results: </strong>Among 186 patients (median age 67.1 years; 71% male), 59 (32%) had scalp and 127 (68%) non-scalp primaries. T-stage distribution was: T1 23.7%, T2 29.0%, T3 24.2%, and T4 18.3%. SLNB was performed in 76.3% (median 3 nodes). Negative margins were obtained in nearly all patients (90.9%), with 17.2% demonstrating a closest margin <2 mm. Adjuvant ICI was administered to 55/186 (29.6%). Median follow-up time was 37 months (range 1-72 months). On univariate analyses in HNCM NM, recurrence was associated with scalp subsite (OR 2.23, p=0.028), T3-T4 stage (OR 2.56, p=0.009), and mitotic rate >1/mm2 (OR 3.92, p=0.004). Age, sex, comorbidity, smoking, ulceration, LVI, SLN positivity, and margin distance—evaluated continuously or as <2 mm vs ≥2 mm—were not associated with recurrence. In multivariable Cox modeling of 3-year DFS, independent predictors included SLN positivity (HR 7.72, p=0.018), mitotic activity (HR 3.83, p=0.049), scalp location (HR 3.14, p=0.034), and receipt of adjuvant ICI (HR 0.065, p=0.004), while <2-mm margins were not associated with DFS (HR 0.48, p=0.41). Among adjuvant ICI-treated HNCM patients with NM (n=36), recurrence occurred in 50.0% of patients with <2-mm margins and 22.2% with ≥2-mm margins. Among ICI-treated patients (N=27), 3- and 5-year DFS were 40% and 40% for <2-mm margins versus 77% and 70% for ≥2-mm margins. Margin distance did not emerge as an independent predictor of 3-year DFS in multivariable models. The 3-year OS was 86.7% for <2-mm margins and 91.6% for ≥2-mm margins, and margin distance was not associated with OS on univariate analysis. For the full cohort, 3- and 5-year DFS were 73% and 66%, and 3- and 5-year OS were 88% and 75%.</p>\n\n<p><strong>Conclusions: </strong>Among patients receiving adjuvant ICI, margin width did not independently influence recurrence or 3-year DFS, suggesting that ICI may attenuate the local prognostic role of margin clearance. Conversely, SLN positivity, mitotic rate, and scalp involvement retained strong prognostic importance, highlighting the predominance of biologic drivers over margin distance in contemporary HNCM.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154014--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S207",
      "content_id": "154334",
      "abstract_number": "S207",
      "poster_number": "",
      "title": "Safety and Efficacy of Bevonescein with the REVEAL-475 System for Intraoperative Fluorescent Visualization of Nerves in Head and Neck Surgery",
      "summary": "This Phase 2/3 trial suggests that Bevonescein, when used with the REVEAL-475 system, is safe, feasible, and improves real-time intraoperative visualization of nerves during head and neck surgery. These findings extend prior first-in-human data and support further investigation of fluorescence-guided nerve imaging. Molecularly targeted imaging technologies such as this have the potential to drive a paradigm shift...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154334",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan K Orosco, MD",
      "presenter": "Ryan K Orosco, MD",
      "authors": "Ryan K Orosco, MD 1 ; Karthik Rajasekaran, MD 2 ; Michael Bouvet, MD 3 ; Greer Albergotti, MD 4 ; Dauren Adilbay, MD, PhD 4 ; Mark Swanson, MD 5 ; Gregory W Randolph, MD 6 ; Alex Kejner, MD 4 ; Joseph M Curry 7 ; Lindsay Olinde 8 ; Michael Singer 9 ; Jeremy Richmon 6 ; Andrea Gillis 10 ; Jason Newman, MD 4",
      "normalized_authors": [
        "Ryan K Orosco",
        "Karthik Rajasekaran",
        "Michael Bouvet",
        "Greer Albergotti",
        "Dauren Adilbay",
        "Mark Swanson",
        "Gregory W Randolph",
        "Alex Kejner",
        "Joseph M Curry",
        "Lindsay Olinde",
        "Michael Singer",
        "Jeremy Richmon",
        "Andrea Gillis",
        "Jason Newman"
      ],
      "affiliations": [
        "University of New Mexico",
        "University of Pennsylvania",
        "University of California, San Diego",
        "Medical University of South Carolina",
        "University of California, Irvine",
        "Massachusetts Eye and Ear Infirmary",
        "Thomas Jefferson University",
        "Louisiana State University",
        "Henry Ford Health",
        "University of Alabama in Birmingham"
      ],
      "normalized_institutions": [
        "University of New Mexico",
        "University of Pennsylvania",
        "University of California, San Diego",
        "Medical University of South Carolina",
        "University of California, Irvine",
        "Massachusetts Eye and Ear Infirmary",
        "Thomas Jefferson University",
        "Louisiana State University",
        "Henry Ford Health",
        "University of Alabama in Birmingham"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 378,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ryan K Orosco, MD 1 ; Karthik Rajasekaran, MD 2 ; Michael Bouvet, MD 3 ; Greer Albergotti, MD 4 ; Dauren Adilbay, MD, PhD 4 ; Mark Swanson, MD 5 ; Gregory W Randolph, MD 6 ; Alex Kejner, MD 4 ; Joseph M Curry 7 ; Lindsay Olinde 8 ; Michael Singer 9 ; Jeremy Richmon 6 ; Andrea Gillis 10 ; Jason Newman, MD 4",
        "Affiliations": "1 University of New Mexico; 2 University of Pennsylvania; 3 University of California, San Diego; 4 Medical University of South Carolina; 5 University of California, Irvine; 6 Massachusetts Eye and Ear Infirmary; 7 Thomas Jefferson University; 8 Louisiana State University; 9 Henry Ford Health; 10 University of Alabama in Birmingham",
        "Background": "Iatrogenic nerve injury during head and neck surgery remains a major source of postoperative morbidity. Bevonescein is a novel peptide-dye conjugate targeting nerve extracellular matrix and recent early-phase data with this agent has demonstrated its safety and initial efficacy of for intraoperative fluorescent nerve identification. However, there is currently no FDA-approved agent in this class. Herein, we report clinical assessments from a Phase 2/3 multicenter clinical trial evaluating the safety, usability, and efficacy of Bevonescein in combination with a specialized surgical visualization system (REVEAL-475) during head and neck procedures.",
        "Methods": "This was a prospective, open-label, two-part trial of intravenous Bevonescein for intraoperative nerve visualization conducted across 11 centers in the United States. Eligible surgeries included parotidectomy, thyroidectomy, parathyroidectomy, or cervical lymphadenectomy; patients with prior surgery or radiation to the operative field were excluded.",
        "Abstract": "Phase 2 (n=60) assessed system feasibility and surgeon-reported ease of use. During surgery, the REVEAL™-475 system was used to visualize Bevonescein-induced fluorescence. Phase 3 (n=64) assessed efficacy. For each index nerve, surgeons first performed visualization under standard white-light reflectance (WLR), then switched to paired fluorescence mode (WLR with fluorescence overlay). Nerve conspicuity was evaluated using a predefined Visualization Scoring System (VSS) comprising Nerve Conspicuity (NC), Length Measurement (LM), and Branching Delineation (BD). Each index nerve received VSS scores for both WLR and paired fluorescence modes. View in Agenda and Add to Schedule",
        "Results": "Among the Phase 2 cases, in an interim analysis, surgeons reported high user satisfaction, consistent feasibility of fluorescence visualization, and no device-related issues that impaired workflow. In Phase 3, individual surgeons' experience suggests that Bevonescein enhanced nerve conspicuity under paired fluorescence mode compared to WLR alone across all index nerves. No serious adverse events or dose-limiting toxicities related to Bevonescein or the visualization system were observed. No nerves were transected in any case.",
        "Conclusion": "This Phase 2/3 trial suggests that Bevonescein, when used with the REVEAL-475 system, is safe, feasible, and improves real-time intraoperative visualization of nerves during head and neck surgery. These findings extend prior first-in-human data and support further investigation of fluorescence-guided nerve imaging. Molecularly targeted imaging technologies such as this have the potential to drive a paradigm shift in surgical safety, improving nerve preservation in head and neck surgery and enabling broader application across additional surgical fields."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Safety and Efficacy of Bevonescein with the REVEAL-475 System for Intraoperative Fluorescent Visualization of Nerves in Head and Neck Surgery</span>. <u>Ryan K Orosco, MD</u><sup>1</sup>; Karthik Rajasekaran, MD<sup>2</sup>; Michael Bouvet, MD<sup>3</sup>; Greer Albergotti, MD<sup>4</sup>; Dauren Adilbay, MD, PhD<sup>4</sup>; Mark Swanson, MD<sup>5</sup>; Gregory W Randolph, MD<sup>6</sup>; Alex Kejner, MD<sup>4</sup>; Joseph M Curry<sup>7</sup>; Lindsay Olinde<sup>8</sup>; Michael Singer<sup>9</sup>; Jeremy Richmon<sup>6</sup>; Andrea Gillis<sup>10</sup>; Jason Newman, MD<sup>4</sup>. <sup>1</sup>University of New Mexico; <sup>2</sup>University of Pennsylvania; <sup>3</sup>University of California, San Diego; <sup>4</sup>Medical University of South Carolina; <sup>5</sup>University of California, Irvine; <sup>6</sup>Massachusetts Eye and Ear Infirmary; <sup>7</sup>Thomas Jefferson University; <sup>8</sup>Louisiana State University; <sup>9</sup>Henry Ford Health; <sup>10</sup>University of Alabama in Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Iatrogenic nerve injury during head and neck surgery remains a major source of postoperative morbidity. Bevonescein is a novel peptide-dye conjugate targeting nerve extracellular matrix and recent early-phase data with this agent has demonstrated its safety and initial efficacy of for intraoperative fluorescent nerve identification. However, there is currently no FDA-approved agent in this class. Herein, we report clinical assessments from a Phase 2/3 multicenter clinical trial evaluating the safety, usability, and efficacy of Bevonescein in combination with a specialized surgical visualization system (REVEAL-475) during head and neck procedures.</p>\n\n<p><strong>Methods: </strong>This was a prospective, open-label, two-part trial of intravenous Bevonescein for intraoperative nerve visualization conducted across 11 centers in the United States. Eligible surgeries included parotidectomy, thyroidectomy, parathyroidectomy, or cervical lymphadenectomy; patients with prior surgery or radiation to the operative field were excluded.</p>\n\n<p>Phase 2 (n=60) assessed system feasibility and surgeon-reported ease of use. During surgery, the REVEAL™-475 system was used to visualize Bevonescein-induced fluorescence. </p>\n\n<p>Phase 3 (n=64) assessed efficacy. For each index nerve, surgeons first performed visualization under standard white-light reflectance (WLR), then switched to paired fluorescence mode (WLR with fluorescence overlay). Nerve conspicuity was evaluated using a predefined Visualization Scoring System (VSS) comprising Nerve Conspicuity (NC), Length Measurement (LM), and Branching Delineation (BD). Each index nerve received VSS scores for both WLR and paired fluorescence modes. </p>\n\n<p><strong>Results: </strong>Among the Phase 2 cases, in an interim analysis, surgeons reported high user satisfaction, consistent feasibility of fluorescence visualization, and no device-related issues that impaired workflow. In Phase 3, individual surgeons' experience suggests that Bevonescein enhanced nerve conspicuity under paired fluorescence mode compared to WLR alone across all index nerves. No serious adverse events or dose-limiting toxicities related to Bevonescein or the visualization system were observed. No nerves were transected in any case.</p>\n\n<p><strong>Conclusion: </strong>This Phase 2/3 trial suggests that Bevonescein, when used with the REVEAL-475 system, is safe, feasible, and improves real-time intraoperative visualization of nerves during head and neck surgery. These findings extend prior first-in-human data and support further investigation of fluorescence-guided nerve imaging. Molecularly targeted imaging technologies such as this have the potential to drive a paradigm shift in surgical safety, improving nerve preservation in head and neck surgery and enabling broader application across additional surgical fields.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154334--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S208",
      "content_id": "153207",
      "abstract_number": "S208",
      "poster_number": "",
      "title": "Intraoperative Fluorescence-Guided Fresh Frozen Sectioning for Margin Control in Head and Neck Cancer",
      "summary": "This clinical trial shows that FI analysis of freshly cut tumor tissue slices combined with FFS is highly effective in intraoperative identification of inadequate margins, thereby enabling immediate margin correction, potentially leading to reduced adjuvant therapy and increased patient survival. This technique is highly promising for enhancing patients outcomes in head and neck cancer surgery, and could also...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153207",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Floris Voskuil, MD, DDS, PhD",
      "presenter": "Floris Voskuil, MD, DDS, PhD",
      "authors": "Thomas S Nijboer, MsC; Bas Keizers, MSc; Jacobus Boeve, MD, DDS, PhD; Daan Roos, MSc; Sebastiaan de Visscher, MD, DDS, PhD; Gyorgy Halmos, MD, PhD; Boudewijn Plaat, MD, PhD; Henrik Huizinga, PharmD; Hendrikus Boersma, PharmD, PhD; Jan Doff, MD; Kees-Pieter Schepman, MD, DDS, PhD; Bert van der Vegt, MD, PhD; Max Witjes, MD, DDS, PhD; Floris Voskuil, MD, DDS, PhD",
      "normalized_authors": [
        "Thomas S Nijboer",
        "Bas Keizers",
        "Jacobus Boeve",
        "Daan Roos",
        "Sebastiaan de Visscher",
        "Gyorgy Halmos",
        "Boudewijn Plaat",
        "Henrik Huizinga, PharmD",
        "Hendrikus Boersma, PharmD",
        "Jan Doff",
        "Kees-Pieter Schepman",
        "Bert van der Vegt",
        "Max Witjes",
        "Floris Voskuil"
      ],
      "affiliations": [
        "University Medical Center Groningen"
      ],
      "normalized_institutions": [
        "University Medical Center Groningen"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 412,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Thomas S Nijboer, MsC; Bas Keizers, MSc; Jacobus Boeve, MD, DDS, PhD; Daan Roos, MSc; Sebastiaan de Visscher, MD, DDS, PhD; Gyorgy Halmos, MD, PhD; Boudewijn Plaat, MD, PhD; Henrik Huizinga, PharmD; Hendrikus Boersma, PharmD, PhD; Jan Doff, MD; Kees-Pieter Schepman, MD, DDS, PhD; Bert van der Vegt, MD, PhD; Max Witjes, MD, DDS, PhD; Floris Voskuil, MD, DDS, PhD",
        "Affiliations": "University Medical Center Groningen",
        "Introduction": "Complete surgical removal of head and neck cancer (HNC) including a 5 mm healthy margin, reduces disease free patient survival. Currently, no technique provides intraoperative feedback on these margins. Fluorescence imaging (FI) is a promising technique, offering high sensitivity, but lacks specificity. Conversely, fresh frozen sectioning (FFS) offers high specificity, but suffers from low sensitivity due to sampling error. This study focusses on intraoperative margin assessment by combining FI and FFS to enhance clinical decision making and enable direct re-excision for inadequate margins.",
        "Methods": "In this clinical intervention study, 20 patients completed all study procedures. After obtaining written informed consent, the fluorescent tracer cetuximab-800CW was administered intravenously. After two days, standard of care surgery including parallel tagging was performed. At two points during surgery, margin assessment using FI was performed: immediately after removal of the tumor on the excised specimen and after the specimen was freshly cut into tissue slices. FFS was performed if: (i) a fluorescent spot was detected on the excised specimen, or (ii) an inadequate margin was suspected based on tumor fluorescence in tissue slices. When an inadequate margin (margin <5 mm) was detected, additional resection during initial surgery was performed.",
        "Results": "Of the included patients, the tumor was located at the tongue (n=16), buccal mucosa (n=3) and floor of mouth (n=1). Solely FI inspection resulted in a sensitivity of 40% and 91% for the excised specimen and tissue slices, respectively, and a specificity of 81.8% and 30%. After FFS, the specificity of both increased to 100%. After initial excision 11 patients presented with an inadequate margin. Of these patients, additional resections were performed in 9 cases leading to a reduction or even omission of adjuvant treatment. For one patient, an additional resection was anatomically not feasible and for the other patient there was a slight discrepancy between the FFS and final histopathology. This discrepancy did not lead to difference in adjuvant treatment. Finally, for one patient an additional surgery to increase margin was performed, however it remained inadequate (1.1 mm to 3.7 mm).",
        "Conclusion": "This clinical trial shows that FI analysis of freshly cut tumor tissue slices combined with FFS is highly effective in intraoperative identification of inadequate margins, thereby enabling immediate margin correction, potentially leading to reduced adjuvant therapy and increased patient survival. This technique is highly promising for enhancing patients outcomes in head and neck cancer surgery, and could also show benefit for other tumor types.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoperative Fluorescence-Guided Fresh Frozen Sectioning for Margin Control in Head and Neck Cancer</span>. Thomas S Nijboer, MsC; Bas Keizers, MSc; Jacobus Boeve, MD, DDS, PhD; Daan Roos, MSc; Sebastiaan de Visscher, MD, DDS, PhD; Gyorgy Halmos, MD, PhD; Boudewijn Plaat, MD, PhD; Henrik Huizinga, PharmD; Hendrikus Boersma, PharmD, PhD; Jan Doff, MD; Kees-Pieter Schepman, MD, DDS, PhD; Bert van der Vegt, MD, PhD; Max Witjes, MD, DDS, PhD; <u>Floris Voskuil, MD, DDS, PhD</u>. University Medical Center Groningen<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Complete surgical removal of head and neck cancer (HNC) including a 5 mm healthy margin, reduces disease free patient survival. Currently, no technique provides intraoperative feedback on these margins. Fluorescence imaging (FI) is a promising technique, offering high sensitivity, but lacks specificity. Conversely, fresh frozen sectioning (FFS) offers high specificity, but suffers from low sensitivity due to sampling error. This study focusses on intraoperative margin assessment by combining FI and FFS to enhance clinical decision making and enable direct re-excision for inadequate margins.</p>\n\n<p><strong>Methods:</strong> In this clinical intervention study, 20 patients completed all study procedures. After obtaining written informed consent, the fluorescent tracer cetuximab-800CW was administered intravenously. After two days, standard of care surgery including parallel tagging was performed. At two points during surgery, margin assessment using FI was performed: immediately after removal of the tumor on the excised specimen and after the specimen was freshly cut into tissue slices. FFS was performed if: (i) a fluorescent spot was detected on the excised specimen, or (ii) an inadequate margin was suspected based on tumor fluorescence in tissue slices. When an inadequate margin (margin <5 mm) was detected, additional resection during initial surgery was performed.</p>\n\n<p><strong>Results: </strong>Of the included patients, the tumor was located at the tongue (n=16), buccal mucosa (n=3) and floor of mouth (n=1). Solely FI inspection resulted in a sensitivity of 40% and 91% for the excised specimen and tissue slices, respectively, and a specificity of 81.8% and 30%. After FFS, the specificity of both increased to 100%. After initial excision 11 patients presented with an inadequate margin. Of these patients, additional resections were performed in 9 cases leading to a reduction or even omission of adjuvant treatment. For one patient, an additional resection was anatomically not feasible and for the other patient there was a slight discrepancy between the FFS and final histopathology. This discrepancy did not lead to difference in adjuvant treatment. Finally, for one patient an additional surgery to increase margin was performed, however it remained inadequate (1.1 mm to 3.7 mm).</p>\n\n<p><strong>Conclusion: </strong>This clinical trial shows that FI analysis of freshly cut tumor tissue slices combined with FFS is highly effective in intraoperative identification of inadequate margins, thereby enabling immediate margin correction, potentially leading to reduced adjuvant therapy and increased patient survival. This technique is highly promising for enhancing patients outcomes in head and neck cancer surgery, and could also show benefit for other tumor types.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153207--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S209",
      "content_id": "153502",
      "abstract_number": "S209",
      "poster_number": "",
      "title": "Molecular Deconvolution of Sinonasal Malignancies: Harnessing RNA-Seq for Clinical Clarity",
      "summary": "RNA sequencing reveals transcriptomically distinct phenotypes within morphologically overlapping sinonasal tumours. Pathway analysis demonstrates biologically coherent molecular subtypes with differential proliferative, immune, and mesenchymal signatures. The detection of transcriptomic heterogeneity within histologically defined tumour categories suggests RNA-seq may serve as a complementary diagnostic tool to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153502",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nevin Yi Meng Chua, MBBS",
      "presenter": "Nevin Yi Meng Chua, MBBS",
      "authors": "Nevin Yi Meng Chua, MBBS 1 ; Yuelin Xia, MBBS 2 ; Ryan Seng Hong Wong, MBBS 2 ; Shen Kai Ng, BSc 3 ; Serene Siow, MSc 4 ; Jaslyn Lee, MBBS, FRCPA 5 ; Ming Liang Oon, MBBS, FRCAPA, FRCPath, MRCSI 5 ; Joshua Tay, MBBS, PhD, FAMS 4",
      "normalized_authors": [
        "Nevin Yi Meng Chua, MBBS",
        "Yuelin Xia, MBBS",
        "Ryan Seng Hong Wong, MBBS",
        "Shen Kai Ng",
        "Serene Siow",
        "Jaslyn Lee, MBBS, FRCPA",
        "Ming Liang Oon, MBBS, FRCAPA, FRCPath, MRCSI",
        "Joshua Tay, MBBS, FAMS"
      ],
      "affiliations": [
        "Lee Kong Chian School of Medicine, Nanyang Technological University",
        "Yong Loo Lin School of Medicine, National University of Singapore",
        "National University of Singapore",
        "Department of Otolaryngology, National University Hospital",
        "Department of Pathology, National University Hospital"
      ],
      "normalized_institutions": [
        "Lee Kong Chian School of Medicine, Nanyang Technological University",
        "Yong Loo Lin School of Medicine, National University of Singapore",
        "National University of Singapore",
        "Department of Otolaryngology, National University Hospital",
        "Department of Pathology, National University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153502/Figure%201(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153502/Figure%201(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153502"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 523,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nevin Yi Meng Chua, MBBS 1 ; Yuelin Xia, MBBS 2 ; Ryan Seng Hong Wong, MBBS 2 ; Shen Kai Ng, BSc 3 ; Serene Siow, MSc 4 ; Jaslyn Lee, MBBS, FRCPA 5 ; Ming Liang Oon, MBBS, FRCAPA, FRCPath, MRCSI 5 ; Joshua Tay, MBBS, PhD, FAMS 4",
        "Affiliations": "1 Lee Kong Chian School of Medicine, Nanyang Technological University; 2 Yong Loo Lin School of Medicine, National University of Singapore; 3 National University of Singapore; 4 Department of Otolaryngology, National University Hospital; 5 Department of Pathology, National University Hospital",
        "Background": "Accurate classification of sinonasal malignancies presents a significant clinical challenge due to substantial morphological overlap between distinct disease entities. The wide variety of tumors, including human papillomavirus (HPV)-related carcinomas, olfactory neuroblastoma (ONB) and poorly-differentiated carcinomas frequently exhibit overlapping histopathological features that confound pathologic diagnosis. Traditional diagnostic assessment, relying on morphology combined with ancillary testing including immunohistochemistry and HPV detection protocols, is resource-intensive and often inconclusive in borderline cases. With the ability to profile 20,000 genes, RNA sequencing is a promising precision approach to rapidly identify and characterize distinct transcriptomic signatures underlying malignant transformation. Such signatures could streamline diagnostic classification, enable earlier patient risk stratification and facilitate targeted treatment selection.",
        "Methods": "Tissue samples from 53 patients with clinically diagnosed sinonasal cancer were assessed independently by two board-certified pathologists to establish baseline histology prior to molecular analysis. FFPE tissue sections from surgical resections underwent laser-capture microdissection (Leica LMD Systems) of regions of interest. RNA library preparation was performed with an in-house technique optimized for FFPE samples. Library quality and quantity was subsequently assessed. Of 138 sequenced samples, 110 gene expression libraries passed quality filtering. Bioinformatic analysis in R (v4.5.1) included unsupervised consensus clustering (optimal k=3 by silhouette index), DESeq2 differential expression, MSigDB GSEA, and immune microenvironment estimation using xCell, EPIC, and ESTIMATE.",
        "Results": "Unsupervised consensus clustering revealed three transcriptionally distinct clusters (silhouette width >0.8; PC1: 21.15%, PC2: 7.18% variance). Gene ontology (GO) enrichment characterized cluster 1 as neuroendocrine, cluster 2 as immune-enriched, and cluster 3 as epithelial–mesenchymal, with differential expression analysis revealing 879, 480, and 193 upregulated genes respectively.",
        "Abstract": "Gene Set Enrichment Analysis (FGSEA, MSigDB Hallmark) revealed distinct pathway signatures across phenotypes. Cluster 1 (n=47), primarily olfactory neuroblastoma and neuroendocrine tumours, showed strong upregulation of neurotransmitter secretion (NES: 2.56, padj: 6.89×10?¹³) and synaptic vesicle exocytosis (NES: 2.56, padj: 2.00×10?¹¹) pathways, reflecting coordinated neuroendocrine exocytotic specialization. Cluster 2 (n=42), predominantly squamous cell carcinomas and melanomas, displayed marked upregulation of interferon-gamma (NES: 3.58, padj: 7.30×10?45) and interferon-alpha hallmark pathways (NES: 3.46, padj: 2.61×10?²7), indicating robust Type I and Type II interferon signalling consistent with immune-activated, inflammatory microenvironments. Cluster 3 (n=21), comprising adenoid cystic carcinoma and HPV-related carcinomas, demonstrated high enrichment of DNA replication (NES: 2.39, padj: 2.85×10?³) and cytoplasmic translation pathways (NES: 2.98, padj: 2.46×10?¹?), indicating elevated proliferative and synthetic capacity consistent with an epithelial–mesenchymal transitional phenotype. Consensus clustering further revealed transcriptomic heterogeneity: one ACC specimen clustered with immune-enriched tumours while others clustered with epithelial–mesenchymal tumours; poorly-differentiated carcinomas and teratocarcinomas distributed across multiple clusters, suggesting complexity beyond conventional histopathology. View in Agenda and Add to Schedule",
        "Conclusion": "RNA sequencing reveals transcriptomically distinct phenotypes within morphologically overlapping sinonasal tumours. Pathway analysis demonstrates biologically coherent molecular subtypes with differential proliferative, immune, and mesenchymal signatures. The detection of transcriptomic heterogeneity within histologically defined tumour categories suggests RNA-seq may serve as a complementary diagnostic tool to refine classification, reduce diagnostic ambiguity and guide precision treatment selection. Validation in expanded cohorts is essential to establish clinical utility."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Molecular Deconvolution of Sinonasal Malignancies: Harnessing RNA-Seq for Clinical Clarity</span>. <u>Nevin Yi Meng Chua, MBBS</u><sup>1</sup>; Yuelin Xia, MBBS<sup>2</sup>; Ryan Seng Hong Wong, MBBS<sup>2</sup>; Shen Kai Ng, BSc<sup>3</sup>; Serene Siow, MSc<sup>4</sup>; Jaslyn Lee, MBBS, FRCPA<sup>5</sup>; Ming Liang Oon, MBBS, FRCAPA, FRCPath, MRCSI<sup>5</sup>; Joshua Tay, MBBS, PhD, FAMS<sup>4</sup>. <sup>1</sup>Lee Kong Chian School of Medicine, Nanyang Technological University; <sup>2</sup>Yong Loo Lin School of Medicine, National University of Singapore; <sup>3</sup>National University of Singapore; <sup>4</sup>Department of Otolaryngology, National University Hospital; <sup>5</sup>Department of Pathology, National University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Accurate classification of sinonasal malignancies presents a significant clinical challenge due to substantial morphological overlap between distinct disease entities. The wide variety of tumors, including human papillomavirus (HPV)-related carcinomas, olfactory neuroblastoma (ONB) and poorly-differentiated carcinomas frequently exhibit overlapping histopathological features that confound pathologic diagnosis. Traditional diagnostic assessment, relying on morphology combined with ancillary testing including immunohistochemistry and HPV detection protocols, is resource-intensive and often inconclusive in borderline cases. With the ability to profile 20,000 genes, RNA sequencing is a promising precision approach to rapidly identify and characterize distinct transcriptomic signatures underlying malignant transformation. Such signatures could streamline diagnostic classification, enable earlier patient risk stratification and facilitate targeted treatment selection. </p>\n\n<p><strong>Methods: </strong>Tissue samples from 53 patients with clinically diagnosed sinonasal cancer were assessed independently by two board-certified pathologists to establish baseline histology prior to molecular analysis. FFPE tissue sections from surgical resections underwent laser-capture microdissection (Leica LMD Systems) of regions of interest. RNA library preparation was performed with an in-house technique optimized for FFPE samples. Library quality and quantity was subsequently assessed. Of 138 sequenced samples, 110 gene expression libraries passed quality filtering. Bioinformatic analysis in R (v4.5.1) included unsupervised consensus clustering (optimal k=3 by silhouette index), DESeq2 differential expression, MSigDB GSEA, and immune microenvironment estimation using xCell, EPIC, and ESTIMATE.</p>\n\n<p><strong>Results: </strong>Unsupervised consensus clustering revealed three transcriptionally distinct clusters (silhouette width >0.8; PC1: 21.15%, PC2: 7.18% variance). Gene ontology (GO) enrichment characterized cluster 1 as neuroendocrine, cluster 2 as immune-enriched, and cluster 3 as epithelial–mesenchymal, with differential expression analysis revealing 879, 480, and 193 upregulated genes respectively.</p>\n\n<p>Gene Set Enrichment Analysis (FGSEA, MSigDB Hallmark) revealed distinct pathway signatures across phenotypes. Cluster 1 (n=47), primarily olfactory neuroblastoma and neuroendocrine tumours, showed strong upregulation of neurotransmitter secretion (NES: 2.56, padj: 6.89×10?¹³) and synaptic vesicle exocytosis (NES: 2.56, padj: 2.00×10?¹¹) pathways, reflecting coordinated neuroendocrine exocytotic specialization. Cluster 2 (n=42), predominantly squamous cell carcinomas and melanomas, displayed marked upregulation of interferon-gamma (NES: 3.58, padj: 7.30×10?45) and interferon-alpha hallmark pathways (NES: 3.46, padj: 2.61×10?²7), indicating robust Type I and Type II interferon signalling consistent with immune-activated, inflammatory microenvironments. Cluster 3 (n=21), comprising adenoid cystic carcinoma and HPV-related carcinomas, demonstrated high enrichment of DNA replication (NES: 2.39, padj: 2.85×10?³) and cytoplasmic translation pathways (NES: 2.98, padj: 2.46×10?¹?), indicating elevated proliferative and synthetic capacity consistent with an epithelial–mesenchymal transitional phenotype.</p>\n\n<p>Consensus clustering further revealed transcriptomic heterogeneity: one ACC specimen clustered with immune-enriched tumours while others clustered with epithelial–mesenchymal tumours; poorly-differentiated carcinomas and teratocarcinomas distributed across multiple clusters, suggesting complexity beyond conventional histopathology.</p>\n\n<p><strong>Conclusion: </strong>RNA sequencing reveals transcriptomically distinct phenotypes within morphologically overlapping sinonasal tumours. Pathway analysis demonstrates biologically coherent molecular subtypes with differential proliferative, immune, and mesenchymal signatures. The detection of transcriptomic heterogeneity within histologically defined tumour categories suggests RNA-seq may serve as a complementary diagnostic tool to refine classification, reduce diagnostic ambiguity and guide precision treatment selection. Validation in expanded cohorts is essential to establish clinical utility.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153502/Figure%201(2).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153502--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S210",
      "content_id": "153699",
      "abstract_number": "S210",
      "poster_number": "",
      "title": "Preliminary analysis of Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Ne",
      "summary": "Preliminary MRD-DUCHESS analysis demonstrates that a tumor-informed WES-based ctDNA assay for MRD surveillance in HPV-independent HNSCC achieves 100% baseline sensitivity. Continued accrual to planned 40 patients in cohort 1, followed by transition to cohort 2 (experimental arm), will enable precise estimates of assay sensitivity, specificity, lead time, and the prognostic value of post-treatment timepoints to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153699",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shriya Shukla",
      "presenter": "Shriya Shukla",
      "authors": "Shriya Shukla 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Gjystina Lumaj, MS 1 ; Jarrod W Stein 1 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy Richmon, MD 1 ; Derrick T Lin 1 ; Hillary S Sloane, PhD 3 ; William C Faquin 2 ; Peter M Sadow 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
      "normalized_authors": [
        "Shriya Shukla",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Gjystina Lumaj",
        "Jarrod W Stein",
        "Lori J Wirth",
        "Manisha J Patel",
        "Jong C Park",
        "Annie Chan",
        "Chirayu Patel",
        "Allen Feng",
        "Daniel G Deschler",
        "Jeremy Richmon",
        "Derrick T Lin",
        "Hillary S Sloane",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital",
        "Haystack Oncology"
      ],
      "normalized_institutions": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital",
        "Haystack Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials/Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shriya Shukla 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Gjystina Lumaj, MS 1 ; Jarrod W Stein 1 ; Lori J Wirth, MD 2 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen Feng, MD 1 ; Daniel G Deschler, MD 1 ; Jeremy Richmon, MD 1 ; Derrick T Lin 1 ; Hillary S Sloane, PhD 3 ; William C Faquin 2 ; Peter M Sadow 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
        "Affiliations": "1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital; 3 Haystack Oncology",
        "Background": "HPV-independent head and neck squamous cell carcinoma (HNSCC) has high recurrence rates after curative-intent treatment. Unlike other solid tumors such as colorectal cancer, no commercially available liquid biopsy assays with insurance coverage exist to identify minimal residual disease (MRD) or detect recurrence early. Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck (MRD-DUCHESS) (NCT06744296) is a prospective staggered-cohort clinical trial evaluating a novel 50-target tumor-informed whole-exome sequencing (WES)-based circulating tumor DNA (ctDNA) assay for MRD detection and longitudinal surveillance in patients with stage III-IVB HPV-independent HNSCC. MRD-DUCHESS will test the hypotheses that: 1) liquid biopsy has higher sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) than standard of care cancer monitoring and 2) liquid biopsy reduces time to intervention for patients who experience a recurrence, Fear of Cancer Recurrence (FOCR) and Health Care Utilization (HCU). Here, we present preliminary data from the first accrued patients with updates planned for the AHNS International meeting.",
        "Materials/Methods": "MRD-DUCHESS is an ongoing single-institution prospective staggered-cohort trial enrolling patients with newly diagnosed AJCC 8th edition stage III-IVB HPV-independent mucosal HNSCC undergoing curative-intent surgery with or without adjuvant RT/CRT or definitive RT/CRT. Tumor and matched normal DNA undergo WES to design individualized 50-variant panels for a tumor-informed ctDNA assay (Haystack MRD). Serial plasma is collected at diagnosis, early postoperative and on-treatment timepoints, and every 3 months for 2 years. ctDNA positivity is defined as =1 ctDNA molecule detected at =2 independent target variants, summarized as mean ctDNA molecules per mL of plasma. The staggered design enrolls the first 40 patients with providers blinded to assay results and the second cohort (n=40) with results returned to providers. Differences in time to recurrence detection, time to intervention, FOCR, and HCU will be compared between arms. Liquid biopsy sensitivity, specificity, PPV and NPV will be compared to standard of care across the full cohort (n=80).",
        "Results": "As of this analysis, thirty-four patients have been accrued and ten have ctDNA data available contributing seventy-seven plasma samples. All ten patients (100%) had detectable ctDNA at diagnosis, confirming high baseline assay sensitivity in HPV-independent HNSCC. In seven patients, ctDNA became undetectable by the earliest post-treatment draw and remained undetectable during surveillance; none developed clinical recurrence during follow-up (mean follow up two months, range seven to twelve months). Three patients had detectable ctDNA after treatment and experienced clinical events (two recurrences, one death). In the third patient, recurrence was not clinically confirmed; however, ctDNA remained detectable across three post-treatment timepoints with increasing values. The average lead time from ctDNA detection to recurrence was 74 days.",
        "Conclusion": "Preliminary MRD-DUCHESS analysis demonstrates that a tumor-informed WES-based ctDNA assay for MRD surveillance in HPV-independent HNSCC achieves 100% baseline sensitivity. Continued accrual to planned 40 patients in cohort 1, followed by transition to cohort 2 (experimental arm), will enable precise estimates of assay sensitivity, specificity, lead time, and the prognostic value of post-treatment timepoints to guide future MRD-directed interventions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preliminary analysis of Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck (MRD-DUCHESS)</span>. <u>Shriya Shukla</u><sup>1</sup>; Jonathan J Paly, DO<sup>2</sup>; Ross D Merkin, MD<sup>2</sup>; Gjystina Lumaj, MS<sup>1</sup>; Jarrod W Stein<sup>1</sup>; Lori J Wirth, MD<sup>2</sup>; Manisha J Patel, MD<sup>2</sup>; Jong C Park, MD<sup>2</sup>; Annie Chan, MD<sup>2</sup>; Chirayu Patel, MD<sup>2</sup>; Allen Feng, MD<sup>1</sup>; Daniel G Deschler, MD<sup>1</sup>; Jeremy Richmon, MD<sup>1</sup>; Derrick T Lin<sup>1</sup>; Hillary S Sloane, PhD<sup>3</sup>; William C Faquin<sup>2</sup>; Peter M Sadow<sup>2</sup>; Bayan A Alzumaili, MD<sup>2</sup>; Thomas J Roberts, MD, MBA<sup>2</sup>; Adam S Fisch, MD, PhD<sup>2</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Massachusetts General Hospital; <sup>3</sup>Haystack Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>HPV-independent head and neck squamous cell carcinoma (HNSCC) has high recurrence rates after curative-intent treatment. Unlike other solid tumors such as colorectal cancer, no commercially available liquid biopsy assays with insurance coverage exist to identify minimal residual disease (MRD) or detect recurrence early. Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck (MRD-DUCHESS) (NCT06744296) is a prospective staggered-cohort clinical trial evaluating a novel 50-target tumor-informed whole-exome sequencing (WES)-based circulating tumor DNA (ctDNA) assay for MRD detection and longitudinal surveillance in patients with stage III-IVB HPV-independent HNSCC. MRD-DUCHESS will test the hypotheses that: 1) liquid biopsy has higher sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) than standard of care cancer monitoring and 2) liquid biopsy reduces time to intervention for patients who experience a recurrence, Fear of Cancer Recurrence (FOCR) and Health Care Utilization (HCU). Here, we present preliminary data from the first accrued patients with updates planned for the AHNS International meeting. </p>\n\n<p><strong>Materials/Methods: </strong>MRD-DUCHESS is an ongoing single-institution prospective staggered-cohort trial enrolling patients with newly diagnosed AJCC 8th edition stage III-IVB HPV-independent mucosal HNSCC undergoing curative-intent surgery with or without adjuvant RT/CRT or definitive RT/CRT. Tumor and matched normal DNA undergo WES to design individualized 50-variant panels for a tumor-informed ctDNA assay (Haystack MRD). Serial plasma is collected at diagnosis, early postoperative and on-treatment timepoints, and every 3 months for 2 years. ctDNA positivity is defined as =1 ctDNA molecule detected at =2 independent target variants, summarized as mean ctDNA molecules per mL of plasma. The staggered design enrolls the first 40 patients with providers blinded to assay results and the second cohort (n=40) with results returned to providers. Differences in time to recurrence detection, time to intervention, FOCR, and HCU will be compared between arms. Liquid biopsy sensitivity, specificity, PPV and NPV will be compared to standard of care across the full cohort (n=80).</p>\n\n<p><strong>Results: </strong>As of this analysis, thirty-four patients have been accrued and ten have ctDNA data available contributing seventy-seven plasma samples. All ten patients (100%) had detectable ctDNA at diagnosis, confirming high baseline assay sensitivity in HPV-independent HNSCC. In seven patients, ctDNA became undetectable by the earliest post-treatment draw and remained undetectable during surveillance; none developed clinical recurrence during follow-up (mean follow up two months, range seven to twelve months). Three patients had detectable ctDNA after treatment and experienced clinical events (two recurrences, one death). In the third patient, recurrence was not clinically confirmed; however, ctDNA remained detectable across three post-treatment timepoints with increasing values. The average lead time from ctDNA detection to recurrence was 74 days.</p>\n\n<p><strong>Conclusion: </strong>Preliminary MRD-DUCHESS analysis demonstrates that a tumor-informed WES-based ctDNA assay for MRD surveillance in HPV-independent HNSCC achieves 100% baseline sensitivity. Continued accrual to planned 40 patients in cohort 1, followed by transition to cohort 2 (experimental arm), will enable precise estimates of assay sensitivity, specificity, lead time, and the prognostic value of post-treatment timepoints to guide future MRD-directed interventions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153699--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S211",
      "content_id": "154485",
      "abstract_number": "S211",
      "poster_number": "",
      "title": "Proactive Risk-Based Optimization and Notification for Treatment and Outcomes in Head and Neck Cancer (PRONTO-HN): Impact of a Novel Care Coordination System on Delays to Adjuvant Therapy",
      "summary": "Implementation of PRONTO-HN is feasible and can meaningfully streamline multidisciplinary coordination. Early results show substantial improvements in timely initiation of S-PORT. Remaining delays were attributable to medical complications rather than workflow failures. Ongoing recruitment and full cohort analysis will further define the magnitude of these effects, with two-year follow-up planned to assess...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154485",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriel S Dayan, MD",
      "presenter": "Gabriel S Dayan, MD",
      "authors": "Gabriel S Dayan, MD ; Houda Bahig, MD, PhD; Eric Bissada, MD, DMD; Tareck Ayad, MD; Paul Tabet, MD, MSc; Louis Guertin, MD; Justine Colivas; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Antoine Désilets, MD, MSc; Olga Gologan, MD; Jeremy Berdugo, MD; Matthieu Schmittbuhl, DMD; Apostolos Christopoulos, MD, MSc",
      "normalized_authors": [
        "Gabriel S Dayan",
        "Houda Bahig",
        "Eric Bissada",
        "Tareck Ayad",
        "Paul Tabet",
        "Louis Guertin",
        "Justine Colivas",
        "Edith Filion",
        "Phuc-Felix Nguyen-Tan",
        "Antoine Désilets",
        "Olga Gologan",
        "Jeremy Berdugo",
        "Matthieu Schmittbuhl",
        "Apostolos Christopoulos"
      ],
      "affiliations": [
        "Centre Hospitalier de l'Université de Montréal (CHUM)"
      ],
      "normalized_institutions": [
        "Centre Hospitalier de l'Université de Montréal (CHUM)"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154485/1-PRONTO-HN%20algorithm%20mind%20map(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154485/1-PRONTO-HN%20algorithm%20mind%20map(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154485"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriel S Dayan, MD ; Houda Bahig, MD, PhD; Eric Bissada, MD, DMD; Tareck Ayad, MD; Paul Tabet, MD, MSc; Louis Guertin, MD; Justine Colivas; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Antoine Désilets, MD, MSc; Olga Gologan, MD; Jeremy Berdugo, MD; Matthieu Schmittbuhl, DMD; Apostolos Christopoulos, MD, MSc",
        "Affiliations": "Centre Hospitalier de l'Université de Montréal (CHUM)",
        "Background": "Initiation of radiation therapy within six weeks after surgery (S-PORT) is a key determinant of oncologic outcomes in head and neck squamous cell carcinoma (HNSCC), yet real-world adherence remains suboptimal. Multifactorial barriers, including delays to consultations and pathology, fragmented communication, lack of accountability across disciplines, and resource bottlenecks, contribute to avoidable delays. To address these gaps, we developed PRONTO-HN, a care coordination system that integrates risk stratification, personalized treatment-trajectory design with milestone targets, and automated reminders. Stratification is powered by a previously developed predictive model that estimates patients’ risk of requiring adjuvant therapy.",
        "Objectives": "To evaluate whether PRONTO-HN shortens S-PORT interval and increases the proportion of patients meeting the six-week benchmark.",
        "Methods": "This is a prospective pre–post controlled trial including patients undergoing primary surgery for HNSCC at a single tertiary center. The control and intervention cohorts include consecutive patients treated over 12-month periods each before and after PRONTO-HN deployment (2024/08/01-2025/07/31 and 2025/08/01-2026/07/31, respectively). At operating-room booking, patients are entered into our validated clinical prediction model to stratify their risk of requiring adjuvant therapy. Based on this risk, the system automatically generates a personalized treatment timeline with assigned target dates, using one of two coordination pathways (Fast-Track or Normal-Track). Automated reminders are sent to the relevant medical teams for upcoming or overdue milestones. A real-time dashboard displays each patient’s progress along the trajectory. Figure 1 summarizes the algorithmic workflow logic. The primary outcome is S-PORT, dichotomized at 6 weeks. Secondary outcomes include timeliness of individual pathway milestones. Multivariable logistic regression models will compare pre- and post-implementation cohorts while adjusting for clinicopathologic covariates.",
        "Results": "This trial is ongoing. Recruitment for the control phase was completed in July 2025 and included 95 patients, of whom 39 (41%) received PORT. Since PRONTO-HN implementation, 26 patients have been enrolled, with 8 (31%) receiving PORT and 5 additional cases pending final pathology. In the control cohort, 0/39 patients (0%) initiated S-PORT within 6 weeks, compared to 6/8 (75%) in the PRONTO-HN cohort (difference in proportion 75%; 95% CI, 31–94; p<0.01). Mean time to PORT was reduced from 73 days (±36) in the control phase to 39 days (±8) after PRONTO-HN deployment. The two PRONTO-HN patients who exceeded the 6-week benchmark experienced wound dehiscence and a cervical abscess requiring operative drainage and ICU readmission. Median time from surgery to pathology went from 28 (IQR 21-36) to 11 (IQR 9-13) days, and time to dentistry consultation from 32 (IQR 0-49) to 0 (IQR 0-0) days. Our predictive model had sensitivity and specificity of 90% and 82%, respectively, for predicting indication for PORT. Baseline clinical characteristics are similar between groups.",
        "Conclusions": "Implementation of PRONTO-HN is feasible and can meaningfully streamline multidisciplinary coordination. Early results show substantial improvements in timely initiation of S-PORT. Remaining delays were attributable to medical complications rather than workflow failures. Ongoing recruitment and full cohort analysis will further define the magnitude of these effects, with two-year follow-up planned to assess associations with oncologic outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Proactive Risk-Based Optimization and Notification for Treatment and Outcomes in Head and Neck Cancer (PRONTO-HN): Impact of a Novel Care Coordination System on Delays to Adjuvant Therapy</span>. <u>Gabriel S Dayan, MD</u>; Houda Bahig, MD, PhD; Eric Bissada, MD, DMD; Tareck Ayad, MD; Paul Tabet, MD, MSc; Louis Guertin, MD; Justine Colivas; Edith Filion, MD; Phuc-Felix Nguyen-Tan, MD; Antoine Désilets, MD, MSc; Olga Gologan, MD; Jeremy Berdugo, MD; Matthieu Schmittbuhl, DMD; Apostolos Christopoulos, MD, MSc. Centre Hospitalier de l'Université de Montréal (CHUM)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Initiation of radiation therapy within six weeks after surgery (S-PORT) is a key determinant of oncologic outcomes in head and neck squamous cell carcinoma (HNSCC), yet real-world adherence remains suboptimal. Multifactorial barriers, including delays to consultations and pathology, fragmented communication, lack of accountability across disciplines, and resource bottlenecks, contribute to avoidable delays. To address these gaps, we developed PRONTO-HN, a care coordination system that integrates risk stratification, personalized treatment-trajectory design with milestone targets, and automated reminders. Stratification is powered by a previously developed predictive model that estimates patients’ risk of requiring adjuvant therapy.</p>\n\n<p><strong>Objectives:</strong> To evaluate whether PRONTO-HN shortens S-PORT interval and increases the proportion of patients meeting the six-week benchmark.</p>\n\n<p><strong>Methods: </strong>This is a prospective pre–post controlled trial including patients undergoing primary surgery for HNSCC at a single tertiary center. The control and intervention cohorts include consecutive patients treated over 12-month periods each before and after PRONTO-HN deployment (2024/08/01-2025/07/31 and 2025/08/01-2026/07/31, respectively). At operating-room booking, patients are entered into our validated clinical prediction model to stratify their risk of requiring adjuvant therapy. Based on this risk, the system automatically generates a personalized treatment timeline with assigned target dates, using one of two coordination pathways (Fast-Track or Normal-Track). Automated reminders are sent to the relevant medical teams for upcoming or overdue milestones. A real-time dashboard displays each patient’s progress along the trajectory. <strong>Figure 1</strong> summarizes the algorithmic workflow logic. The primary outcome is S-PORT, dichotomized at 6 weeks. Secondary outcomes include timeliness of individual pathway milestones. Multivariable logistic regression models will compare pre- and post-implementation cohorts while adjusting for clinicopathologic covariates.</p>\n\n<p><strong>Results:</strong> This trial is ongoing. Recruitment for the control phase was completed in July 2025 and included 95 patients, of whom 39 (41%) received PORT. Since PRONTO-HN implementation, 26 patients have been enrolled, with 8 (31%) receiving PORT and 5 additional cases pending final pathology. In the control cohort, 0/39 patients (0%) initiated S-PORT within 6 weeks, compared to 6/8 (75%) in the PRONTO-HN cohort (difference in proportion 75%; 95% CI, 31–94; p<0.01). Mean time to PORT was reduced from 73 days (±36) in the control phase to 39 days (±8) after PRONTO-HN deployment. The two PRONTO-HN patients who exceeded the 6-week benchmark experienced wound dehiscence and a cervical abscess requiring operative drainage and ICU readmission. Median time from surgery to pathology went from 28 (IQR 21-36) to 11 (IQR 9-13) days, and time to dentistry consultation from 32 (IQR 0-49) to 0 (IQR 0-0) days. Our predictive model had sensitivity and specificity of 90% and 82%, respectively, for predicting indication for PORT. Baseline clinical characteristics are similar between groups.</p>\n\n<p><strong>Conclusions:</strong> Implementation of PRONTO-HN is feasible and can meaningfully streamline multidisciplinary coordination. Early results show substantial improvements in timely initiation of S-PORT. Remaining delays were attributable to medical complications rather than workflow failures. Ongoing recruitment and full cohort analysis will further define the magnitude of these effects, with two-year follow-up planned to assess associations with oncologic outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154485/1-PRONTO-HN%20algorithm%20mind%20map(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154485--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S212",
      "content_id": "154532",
      "abstract_number": "S212",
      "poster_number": "",
      "title": "Avoidance of adjuvant radiation therapy in HPV+ OPHNSCC responders to neoadjuvant anti-PD1: Oncologic Outcomes",
      "summary": "In this cohort study, we demonstrate that response-driven adjuvant radiation avoidance in HPV+ OPSCC undergoing neoadjuvant ICI is both safe and oncologically sound in these two phase II trials. A substantial proportion of patients avoided planned postoperative XRT without compromising disease control, and no patient who avoided XRT had recurrence requiring salvage. These findings support the potential role for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154532",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma De Ravin, MD",
      "presenter": "Emma De Ravin, MD",
      "authors": "Emma De Ravin, MD ; Kelly Bridgham, MD; Hannah Kenny, MD; Eric Mastrolonardo, MD; David M Cognetti, MD; Joseph M Curry, MD; Jennifer M Johnson, MD, PhD; Adam Luginbuhl, MD",
      "normalized_authors": [
        "Emma De Ravin",
        "Kelly Bridgham",
        "Hannah Kenny",
        "Eric Mastrolonardo",
        "David M Cognetti",
        "Joseph M Curry",
        "Jennifer M Johnson",
        "Adam Luginbuhl"
      ],
      "affiliations": [
        "Thomas Jefferson University Hospital"
      ],
      "normalized_institutions": [
        "Thomas Jefferson University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154532/Screenshot%202025-12-05%20at%205_31_09%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154532/Screenshot%202025-12-05%20at%205_31_09%E2%80%AFPM.png",
          "alt": "Figure 1: Disease-Free Survival (DFS) and Overall Survival (OS) by Adjuvant Radiation Treatment Received",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154532"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 517,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emma De Ravin, MD ; Kelly Bridgham, MD; Hannah Kenny, MD; Eric Mastrolonardo, MD; David M Cognetti, MD; Joseph M Curry, MD; Jennifer M Johnson, MD, PhD; Adam Luginbuhl, MD",
        "Affiliations": "Thomas Jefferson University Hospital",
        "Background": "Neoadjuvant immune checkpoint inhibition (ICI) in HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is an emerging treatment strategy. To justify the addition of neoadjuvant ICI to HPV+ OPSCC, a reciprocal adaptive de-escalation of subsequent locoregional therapy (e.g. avoiding adjuvant radiation therapy (XRT)) is essential considering the excellent oncologic outcomes in HPV+ OPSCC. However, the long term clinical and oncologic implications of such de-escalation have not yet been explored in this cohort. Here, we evaluate whether neoadjuvant ICI results in treatment responses that translate into meaningful adjuvant XRT avoidance and assess long term oncologic outcomes.",
        "Methods": "Two multi-institutional, randomized, neoadjuvant nivolumab trials (NCT03854032 and NCT03238365) enrolled 38 patients with HPV+ OPSCC. Patients were clinically staged, and adjuvant treatment recommendations were assigned based on preoperative clinical and radiographic findings based on National Comprehensive Cancer Network (NCCN) guidelines (e.g. patients with multiple lymph nodes on PET and/or CT were predicted to need adjuvant radiation). All patients underwent neoadjuvant nivolumab followed by surgery. A second assessment for adjuvant radiation was made based on final pathologic features. “Avoidance of XRT” was defined by a patient no longer needing adjuvant radiation therapy based on pathologic findings as compared with the initial pre-treatment plan. Primary outcomes were progression-free survival (PFS) and overall survival (OS), which were estimated using Kaplan–Meier analysis.",
        "Results": "Thirty eight patients met inclusion criteria, with a mean age of 62.5 years; 94.7% were male. Thirty-four of thirty-eight patients (89.5%) were anticipated to need adjuvant radiation treatment based on overall clinical AJCC staging upon presentation, with the leading indication being multiple positive clinically pathologic lymph nodes on preoperative imaging (44.1%). Following neoadjuvant ICI, 12/38 patients (32%) had over 50% pathologic treatment effect (pTE) with 3 patients demonstrating a complete response. Between our pretreatment clinical and post-ICI pathologic assessments, 16/34 patients (47.1%) demonstrated treatment effect and pathologic response sufficient to fall below the threshold for recommending adjuvant XRT and warrant avoidance of XRT based on NCCN guidelines. Among patients that avoided XRT, no patients required salvage radiation due to recurrence or regional failure at five years from enrollment. At a median follow-up of 58.4 months, there were no significant differences between the XRT and XRT-avoided cohorts in five-year PFS (95.2% vs. 100%, p=0.54) or five-year OS (95.2% vs. 100%, p=0.34) (Figure 1A-B). Two of thirty-eight patients (5.3%) had grade 3 immune related adverse events (hepatic and colitis) with full recovery after treatment. No patients developed hyperprogression or experienced grade 4 or 5 toxicity.",
        "Conclusions": "In this cohort study, we demonstrate that response-driven adjuvant radiation avoidance in HPV+ OPSCC undergoing neoadjuvant ICI is both safe and oncologically sound in these two phase II trials. A substantial proportion of patients avoided planned postoperative XRT without compromising disease control, and no patient who avoided XRT had recurrence requiring salvage. These findings support the potential role for neoadjuvant ICI as an oncologic strategy in HPV-associated OPSCC and provide the impetus for future studies to preemptively predict responders who may benefit from response-adapted adjuvant XRT.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Avoidance of adjuvant radiation therapy in HPV+ OPHNSCC responders to neoadjuvant anti-PD1: Oncologic Outcomes</span>. <u>Emma De Ravin, MD</u>; Kelly Bridgham, MD; Hannah Kenny, MD; Eric Mastrolonardo, MD; David M Cognetti, MD; Joseph M Curry, MD; Jennifer M Johnson, MD, PhD; Adam Luginbuhl, MD. Thomas Jefferson University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='Figure 1: Disease-Free Survival (DFS) and Overall Survival (OS) by Adjuvant Radiation Treatment Received' src='https://www.submitmyabstract.com/abs/images/154532/Screenshot%202025-12-05%20at%205_31_09%E2%80%AFPM.png' /></p>\n\n<p><strong>Background: </strong>Neoadjuvant immune checkpoint inhibition (ICI) in HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is an emerging treatment strategy. To justify the addition of neoadjuvant ICI to HPV+ OPSCC, a reciprocal adaptive de-escalation of subsequent locoregional therapy (e.g. avoiding adjuvant radiation therapy (XRT)) is essential considering the excellent oncologic outcomes in HPV+ OPSCC. However, the long term clinical and oncologic implications of such de-escalation have not yet been explored in this cohort. Here, we evaluate whether neoadjuvant ICI results in treatment responses that translate into meaningful adjuvant XRT avoidance and assess long term oncologic outcomes.</p>\n\n<p><strong>Methods: </strong>Two multi-institutional, randomized, neoadjuvant nivolumab trials (NCT03854032 and NCT03238365) enrolled 38 patients with HPV+ OPSCC. Patients were clinically staged, and adjuvant treatment recommendations were assigned based on preoperative clinical and radiographic findings based on National Comprehensive Cancer Network (NCCN) guidelines (e.g. patients with multiple lymph nodes on PET and/or CT were predicted to need adjuvant radiation). All patients underwent neoadjuvant nivolumab followed by surgery. A second assessment for adjuvant radiation was made based on final pathologic features. “Avoidance of XRT” was defined by a patient no longer needing adjuvant radiation therapy based on pathologic findings as compared with the initial pre-treatment plan. Primary outcomes were progression-free survival (PFS) and overall survival (OS), which were estimated using Kaplan–Meier analysis.</p>\n\n<p><strong>Results: </strong>Thirty eight patients met inclusion criteria, with a mean age of 62.5 years; 94.7% were male. Thirty-four of thirty-eight patients (89.5%) were anticipated to need adjuvant radiation treatment based on overall clinical AJCC staging upon presentation, with the leading indication being multiple positive clinically pathologic lymph nodes on preoperative imaging (44.1%). Following neoadjuvant ICI, 12/38 patients (32%) had over 50% pathologic treatment effect (pTE) with 3 patients demonstrating a complete response. Between our pretreatment clinical and post-ICI pathologic assessments, 16/34 patients (47.1%) demonstrated treatment effect and pathologic response sufficient to fall below the threshold for recommending adjuvant XRT and warrant avoidance of XRT based on NCCN guidelines. Among patients that avoided XRT, no patients required salvage radiation due to recurrence or regional failure at five years from enrollment. At a median follow-up of 58.4 months, there were no significant differences between the XRT and XRT-avoided cohorts in five-year PFS (95.2% vs. 100%, p=0.54) or five-year OS (95.2% vs. 100%, p=0.34) (Figure 1A-B). Two of thirty-eight patients (5.3%) had grade 3 immune related adverse events (hepatic and colitis) with full recovery after treatment. No patients developed hyperprogression or experienced grade 4 or 5 toxicity.</p>\n\n<p><strong>Conclusions: </strong>In this cohort study, we demonstrate that response-driven adjuvant radiation avoidance in HPV+ OPSCC undergoing neoadjuvant ICI is both safe and oncologically sound in these two phase II trials. A substantial proportion of patients avoided planned postoperative XRT without compromising disease control, and no patient who avoided XRT had recurrence requiring salvage. These findings support the potential role for neoadjuvant ICI as an oncologic strategy in HPV-associated OPSCC and provide the impetus for future studies to preemptively predict responders who may benefit from response-adapted adjuvant XRT.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154532--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S213",
      "content_id": "153769",
      "abstract_number": "S213",
      "poster_number": "",
      "title": "Neoadjuvant Chemotherapy and Transoral Robotic Surgery (NECTORS) for HPV-Positive Oropharyngeal Cancer: Pathologic Response and Recurrence-Free Survival",
      "summary": "NECTORS demonstrates high primary and nodal pathologic response rates and excellent mid-term locoregional control in HPV-positive OPSCC. No clinical or pathologic variables predicted recurrence. At-risk neck zones showed no residual disease, while involved zones achieved 60% pCR. Under the NECTORS paradigm, de-escalated neck dissection of involved-only zones may be adequate. This concept warrants prospective...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153769",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260130",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jessica Hier",
      "presenter": "Jessica Hier",
      "authors": "Jessica Hier ; Keith Richardson, MD; Marco Mascarella, PhD, MD; Zeitouni Anthony, MD; Shenouda George, MD; Tsien Christina; Sultanem Khalil, MD; Mlynarek Alex, MD; Caglar Derin, MD; Esfahani Khashayar, MD; Golabi Nahid, MSc; Atonanzas Lisa, RN; Ramanakumar Agnihotram, PhD; Hier Michael, MD; Bouganim Nathaniel, MD; Naser Sadeghi, MD",
      "normalized_authors": [
        "Jessica Hier",
        "Keith Richardson",
        "Marco Mascarella",
        "Zeitouni Anthony",
        "Shenouda George",
        "Tsien Christina",
        "Sultanem Khalil",
        "Mlynarek Alex",
        "Caglar Derin",
        "Esfahani Khashayar",
        "Golabi Nahid",
        "Atonanzas Lisa",
        "Ramanakumar Agnihotram",
        "Hier Michael",
        "Bouganim Nathaniel",
        "Naser Sadeghi"
      ],
      "affiliations": [
        "McGill University"
      ],
      "normalized_institutions": [
        "McGill University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153769/Screenshot%202025-12-05%20at%204_06_23%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153769/Screenshot%202025-12-05%20at%204_06_23%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153769"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 478,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jessica Hier ; Keith Richardson, MD; Marco Mascarella, PhD, MD; Zeitouni Anthony, MD; Shenouda George, MD; Tsien Christina; Sultanem Khalil, MD; Mlynarek Alex, MD; Caglar Derin, MD; Esfahani Khashayar, MD; Golabi Nahid, MSc; Atonanzas Lisa, RN; Ramanakumar Agnihotram, PhD; Hier Michael, MD; Bouganim Nathaniel, MD; Naser Sadeghi, MD",
        "Affiliations": "McGill University",
        "Background": "Neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) is a strategy of systemic escalation and locoregional de-escalation in HPV-positive oropharyngeal squamous cell carcinoma. Pathologic response, volumetric tumor regression, and predictors of locoregional recurrence were evaluated in this single-arm trial. Involved and at-risk zones of the neck were also assessed for residual disease following neoadjuvant chemotherapy to examine the feasibility of de-escalated neck dissection under the NECTORS paradigm.",
        "Methods": "NECTORS enrolled 146 patients with p16-positive OPSCC treated with three cycles of docetaxel–cisplatin followed by TORS and neck dissection. Neck dissection included the involved and at-risk zones per standard practice. Primary (pT) and nodal (pN) pathologic response, overall pathologic response, MRI volumetric reduction of primary tumor and nodal disease, and recurrence-free survival (RFS) were measured, and patterns of failure were analyzed. Cox regression evaluated associations between RFS and smoking, clinical T and N stage, AJCC-7 stage, and pathologic response. Kaplan–Meier curves compared RFS between overall pathologic complete response (cPR) and partial response (pPR).",
        "Results": "Median age was 62 years, 84% were male, and 55% never-smokers. Most tumors were T1–T2 and N2 by AJCC-7, with the majority stage IVa. Primary pathologic complete response (pT0) was achieved in 71% (103/146), nodal pCR (pN0) in 60% (88/146), and overall pCR in 47% (68/145 evaluable surgical patients). After a mean follow-up of ~3.8 years, there were 10 locoregional recurrences (6.8%) and no distant failures. Overall pCR was associated with numerically lower recurrence (3/68, 4.4%) compared with pPR (7/77, 9.1%), though not statistically significant; 3-year RFS was approximately 95% vs 90% (log-rank p=0.37).",
        "Abstract": "In univariable Cox analysis, primary pCR showed the strongest non-significant association with improved RFS (HR 0.42, 95% CI 0.12–1.47), while smoking status, N category, and AJCC-7 stage did not. In a multivariable model, primary pCR demonstrated a similar non-significant trend toward reduced recurrence risk (HR 0.41, 95% CI 0.12–1.42). Regarding extent of neck dissection, 95 patients had radiologic evidence of unilateral nodal involvement in levels 2–3, of whom seven also exhibited disease in ipsilateral level 4. After neoadjuvant chemotherapy, 56.8% exhibited complete pathologic response in the neck (ypN0). Among 88 patients with disease isolated to levels 2–3, 51 (58%) were ypN0 and 37 (42%) had residual nodal disease (ypN1). Residual disease was confined to pre-treatment radiologically involved zones, with no pathologic micrometastasis in at-risk nodal basins. View in Agenda and Add to Schedule",
        "Conclusions": "NECTORS demonstrates high primary and nodal pathologic response rates and excellent mid-term locoregional control in HPV-positive OPSCC. No clinical or pathologic variables predicted recurrence. At-risk neck zones showed no residual disease, while involved zones achieved 60% pCR. Under the NECTORS paradigm, de-escalated neck dissection of involved-only zones may be adequate. This concept warrants prospective validation using molecular measures of residual disease such as circulating tumor DNA."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant Chemotherapy and Transoral Robotic Surgery (NECTORS) for HPV-Positive Oropharyngeal Cancer: Pathologic Response and Recurrence-Free Survival</span>. <u>Jessica Hier</u>; Keith Richardson, MD; Marco Mascarella, PhD, MD; Zeitouni Anthony, MD; Shenouda George, MD; Tsien Christina; Sultanem Khalil, MD; Mlynarek Alex, MD; Caglar Derin, MD; Esfahani Khashayar, MD; Golabi Nahid, MSc; Atonanzas Lisa, RN; Ramanakumar Agnihotram, PhD; Hier Michael, MD; Bouganim Nathaniel, MD; Naser Sadeghi, MD. McGill University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) is a strategy of systemic escalation and locoregional de-escalation in HPV-positive oropharyngeal squamous cell carcinoma. Pathologic response, volumetric tumor regression, and predictors of locoregional recurrence were evaluated in this single-arm trial. Involved and at-risk zones of the neck were also assessed for residual disease following neoadjuvant chemotherapy to examine the feasibility of de-escalated neck dissection under the NECTORS paradigm.</p>\n\n<p><strong>Methods: </strong>NECTORS enrolled 146 patients with p16-positive OPSCC treated with three cycles of docetaxel–cisplatin followed by TORS and neck dissection. Neck dissection included the involved and at-risk zones per standard practice. Primary (pT) and nodal (pN) pathologic response, overall pathologic response, MRI volumetric reduction of primary tumor and nodal disease, and recurrence-free survival (RFS) were measured, and patterns of failure were analyzed. Cox regression evaluated associations between RFS and smoking, clinical T and N stage, AJCC-7 stage, and pathologic response. Kaplan–Meier curves compared RFS between overall pathologic complete response (cPR) and partial response (pPR).</p>\n\n<p><strong>Results: </strong>Median age was 62 years, 84% were male, and 55% never-smokers. Most tumors were T1–T2 and N2 by AJCC-7, with the majority stage IVa. Primary pathologic complete response (pT0) was achieved in 71% (103/146), nodal pCR (pN0) in 60% (88/146), and overall pCR in 47% (68/145 evaluable surgical patients). After a mean follow-up of ~3.8 years, there were 10 locoregional recurrences (6.8%) and no distant failures. Overall pCR was associated with numerically lower recurrence (3/68, 4.4%) compared with pPR (7/77, 9.1%), though not statistically significant; 3-year RFS was approximately 95% vs 90% (log-rank p=0.37).</p>\n\n<p>In univariable Cox analysis, primary pCR showed the strongest non-significant association with improved RFS (HR 0.42, 95% CI 0.12–1.47), while smoking status, N category, and AJCC-7 stage did not. In a multivariable model, primary pCR demonstrated a similar non-significant trend toward reduced recurrence risk (HR 0.41, 95% CI 0.12–1.42). Regarding extent of neck dissection, 95 patients had radiologic evidence of unilateral nodal involvement in levels 2–3, of whom seven also exhibited disease in ipsilateral level 4. After neoadjuvant chemotherapy, 56.8% exhibited complete pathologic response in the neck (ypN0). Among 88 patients with disease isolated to levels 2–3, 51 (58%) were ypN0 and 37 (42%) had residual nodal disease (ypN1). Residual disease was confined to pre-treatment radiologically involved zones, with no pathologic micrometastasis in at-risk nodal basins.</p>\n\n<p><strong>Conclusions: </strong>NECTORS demonstrates high primary and nodal pathologic response rates and excellent mid-term locoregional control in HPV-positive OPSCC. No clinical or pathologic variables predicted recurrence. At-risk neck zones showed no residual disease, while involved zones achieved 60% pCR. Under the NECTORS paradigm, de-escalated neck dissection of involved-only zones may be adequate. This concept warrants prospective validation using molecular measures of residual disease such as circulating tumor DNA.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153769/Screenshot%202025-12-05%20at%204_06_23%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153769--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260130' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S214",
      "content_id": "152666",
      "abstract_number": "S214",
      "poster_number": "",
      "title": "Voice Prosthesis Success After Total Laryngectomy: Predictors, Outcomes, and Morbidity",
      "summary": "A minority of patients achieve true VP “success” after TL. Patients with partial or total pharyngectomy were nearly twice as likely to not achieve VP success. Persistent leakage around is a frequent cause of failure and is associated with adjuvant radiation. Most patients can be managed with VP modification, and surgical repair has high potentially high morbidity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152666",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan T Judd",
      "presenter": "Ryan T Judd",
      "authors": "Ryan T Judd ; Jacqueline Tardif, MA; Matthew Old, MD",
      "normalized_authors": [
        "Ryan T Judd",
        "Jacqueline Tardif, MA",
        "Matthew Old"
      ],
      "affiliations": [
        "The Ohio State University"
      ],
      "normalized_institutions": [
        "The Ohio State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 558,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryan T Judd ; Jacqueline Tardif, MA; Matthew Old, MD",
        "Affiliations": "The Ohio State University",
        "Introduction": "Tracheoesophageal puncture (TEP) with voice prosthesis (VP) placement is a common method of voice restoration in patients undergoing total laryngectomy (TL) with significant potential improvement in quality of life. Limited recent data exist regarding long-term VP success and predictors of failure. Leakage around the VP is a challenging problem, which can lead to chronic aspiration, pulmonary disease, and PEG dependence. Non-surgical and surgical management are infrequently described.",
        "Methods": "This was a retrospective review conducted at a single comprehensive cancer center from 2012 to 2024 of TL with primary or secondary TEP. Patients with <6 months follow-up after TEP were excluded. VP success was defined as: VP in situ and used for communication, adequate device lifespan (average lifespan >60 days [Lewin et al., 2017]), and no re-puncture required. Leakage around the VP was defined as multiple successive visits with demonstrated leakage. Logistic regression was used for comparisons between groups.",
        "Results": "There were 286 patients with TEP, including 91 secondary TEP (31.2%). Median follow-up was 29.6 months (interquartile range 13.1-60.2). There were 91 salvage TLs (31.2%). Most patients received adjuvant radiation (N=232, 81.1%), including 19 who were radiated twice (6.6%). VP success was achieved in 39.9% (N=114). The most common factors for lack of success were poor device lifespan (48.3%), not using for voice (37.0%), extrusion without replacement (7.7%), and removal for chronic leakage (7.0%). Lack of VP success was significantly associated with partial or total pharyngectomy (N=153 [53.5%], OR 0.52 [95% CI 0.32-0.85], p=0.008). Patients with partial or total pharyngectomy were more likely to have poor lifespan (1.88 [1.17-3.02], p=0.008), TEP removal (1.69 [1.00-2.86], p=0.048), and extrusion without replacement (2.63 [1.20-5.75], p=0.015). VP success was not significantly associated with adjuvant radiation (1.07 [0.67-1.73], p=0.766), salvage surgery (1.56 [0.94-2.60], p=0.082), esophageal stenosis (N=87, 0.73 [0.43-1.26], p=0.262), or free flap reconstruction (N=115, 0.67 [0.40-1.13], p=0.130). Forty-three patients did not achieve VP success due to poor lifespan from chronic leakage around the VP (15.0%), occurring at median 18.8 months after TEP. Persistent leakage around was significantly associated with adjuvant radiation (2.55 [1.22-5.34], p=0.013) and not with TSH/T4 (p>0.05). Most persistent leakage around was managed non-surgically with VP modification (79.1%). Surgical repair of an expanding tract or a non-closing fistula after VP removal was undertaken in 12 patients, most of which involved dissection in the plane between the trachea and esophagus with local tissue closure (N=6) or free flap on-lay/incorporation into pharyngoplasty (N=5). Four patients developed postoperative fistulae (25%), all of which occurred in patients with use of a free flap. Two patients with fistulae never resumed oral intake.",
        "Conclusion": "A minority of patients achieve true VP “success” after TL. Patients with partial or total pharyngectomy were nearly twice as likely to not achieve VP success. Persistent leakage around is a frequent cause of failure and is associated with adjuvant radiation. Most patients can be managed with VP modification, and surgical repair has high potentially high morbidity.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Voice Prosthesis Success After Total Laryngectomy: Predictors, Outcomes, and Morbidity</span>. <u>Ryan T Judd</u>; Jacqueline Tardif, MA; Matthew Old, MD. The Ohio State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tracheoesophageal puncture (TEP) with voice prosthesis (VP) placement is a common method of voice restoration in patients undergoing total laryngectomy (TL) with significant potential improvement in quality of life. Limited recent data exist regarding long-term VP success and predictors of failure. Leakage around the VP is a challenging problem, which can lead to chronic aspiration, pulmonary disease, and PEG dependence. Non-surgical and surgical management are infrequently described.</p>\n\n<p><strong>Methods: </strong>This was a retrospective review conducted at a single comprehensive cancer center from 2012 to 2024 of TL with primary or secondary TEP. Patients with <6 months follow-up after TEP were excluded. VP success was defined as: VP in situ and used for communication, adequate device lifespan (average lifespan >60 days [Lewin et al., 2017]), and no re-puncture required. Leakage around the VP was defined as multiple successive visits with demonstrated leakage. Logistic regression was used for comparisons between groups.</p>\n\n<p><strong>Results:</strong> There were 286 patients with TEP, including 91 secondary TEP (31.2%). Median follow-up was 29.6 months (interquartile range 13.1-60.2). There were 91 salvage TLs (31.2%). Most patients received adjuvant radiation (N=232, 81.1%), including 19 who were radiated twice (6.6%). VP success was achieved in 39.9% (N=114). The most common factors for lack of success were poor device lifespan (48.3%), not using for voice (37.0%), extrusion without replacement (7.7%), and removal for chronic leakage (7.0%). Lack of VP success was significantly associated with partial or total pharyngectomy (N=153 [53.5%], OR 0.52 [95% CI 0.32-0.85], p=0.008). Patients with partial or total pharyngectomy were more likely to have poor lifespan (1.88 [1.17-3.02], p=0.008), TEP removal (1.69 [1.00-2.86], p=0.048), and extrusion without replacement (2.63 [1.20-5.75], p=0.015). VP success was not significantly associated with adjuvant radiation (1.07 [0.67-1.73], p=0.766), salvage surgery (1.56 [0.94-2.60], p=0.082), esophageal stenosis (N=87, 0.73 [0.43-1.26], p=0.262), or free flap reconstruction (N=115, 0.67 [0.40-1.13], p=0.130). Forty-three patients did not achieve VP success due to poor lifespan from chronic leakage around the VP (15.0%), occurring at median 18.8 months after TEP. Persistent leakage around was significantly associated with adjuvant radiation (2.55 [1.22-5.34], p=0.013) and not with TSH/T4 (p>0.05). Most persistent leakage around was managed non-surgically with VP modification (79.1%). Surgical repair of an expanding tract or a non-closing fistula after VP removal was undertaken in 12 patients, most of which involved dissection in the plane between the trachea and esophagus with local tissue closure (N=6) or free flap on-lay/incorporation into pharyngoplasty (N=5). Four patients developed postoperative fistulae (25%), all of which occurred in patients with use of a free flap. Two patients with fistulae never resumed oral intake.</p>\n\n<p><strong>Conclusion: </strong>A minority of patients achieve true VP “success” after TL. Patients with partial or total pharyngectomy were nearly twice as likely to not achieve VP success. Persistent leakage around is a frequent cause of failure and is associated with adjuvant radiation. Most patients can be managed with VP modification, and surgical repair has high potentially high morbidity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152666--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S215",
      "content_id": "154671",
      "abstract_number": "S215",
      "poster_number": "",
      "title": "Clinical anchor-based reference values for the eating, swallowing, and speaking scales of the FACE-Q Head and Neck Cancer module",
      "summary": "The FACE-Q HNC eating, swallowing, and speaking scale scores vary in an expected pattern based on established clinical anchors. PRO's may be able to measure differences in quality of life that are smaller than those represented by clinical anchors such as diet status. For such cases, a 5-point difference in these scales accounts for 25-50% of the anchor-based between-group differences in means and can be...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154671",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael P Wu, MD",
      "presenter": "Michael P Wu, MD",
      "authors": "Michael P Wu, MD ; Louise Cunningham, SLPD, CCCSLP; Donalrey Nieva; Mei-fan Parnes; Rebecca Gao, MD; Andrea L Pusic, MD; Richard J Wong, MD; Evan Matros, MD; Jennifer Cracchiolo, MD",
      "normalized_authors": [
        "Michael P Wu",
        "Louise Cunningham, SLPD, CCCSLP",
        "Donalrey Nieva",
        "Mei-fan Parnes",
        "Rebecca Gao",
        "Andrea L Pusic",
        "Richard J Wong",
        "Evan Matros",
        "Jennifer Cracchiolo"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michael P Wu, MD ; Louise Cunningham, SLPD, CCCSLP; Donalrey Nieva; Mei-fan Parnes; Rebecca Gao, MD; Andrea L Pusic, MD; Richard J Wong, MD; Evan Matros, MD; Jennifer Cracchiolo, MD",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Objectives": "The FACE-Q Head and Neck Cancer Module (FACE-Q HNC) is a validated patient reported outcome (PRO) measure, but context is needed for understanding normal values and the clinical importance of numeric differences in scores. We sought to generate reference values and establish between-group differences in scores, grouping patients by clinical anchors of diet, DIGEST scores, and lingual range of motion. These can serve as the basis for a minimal clinically important difference for the 5 FACEQ scales related to eating and speaking: Eating and Drinking, Eating Distress, Swallowing, Speaking, and Speaking Distress.",
        "Methods": "The FACE-Q HNC was prospectively administered to head and neck cancer patients as part of routine care at our institution. Data for patients with oral cavity, oropharynx, larynx, and hypopharynx tumors from April 2018 to February 2025 was extracted and linked to structured notes from speech language pathology (SLP) visits to determine treatment details, diet status, DIGEST scores from video swallow studies, and lingual range of motion. Reference values of the FACE-Q HNC Eating and Drinking, Eating Distress, Swallowing, Speaking, and Speaking Distress scales were calculated, grouped by diet type, DIGEST scores, and lingual range of motion. Between-group differences were calculated based on these clinical anchors. Analysis of lingual range of motion was limited to patients with oral cavity and oropharynx primary tumors.",
        "Results": "There were 557 patients with oral cavity, oropharynx, larynx, and hypopharynx tumors who had completed the FACE-Q HNC with a recorded SLP visit within 30 days of instrument completion. The mean age was 64 years, with 150 (27%) oral cavity, 258 (46%) oropharynx, 144 (26%) larynx, and 4 (1%) hypopharynx primaries. All phases of care were represented, with 256 (46%) pre-treatment, 110 (20%) during treatment, and 191 (34%) post-treatment. Mean scores were: 83.9 for Eating and Drinking (SD 24.5), 84.7 for Eating Distress (25.7), 85.3 for Swallowing (SD 25.0), 83.7 for Speaking (SD 30.0), and 88.0 for Speaking Distress (SD (24.2). There were significant between-group differences in Eating and Drinking, Eating Distress, and Swallowing for patients taking a regular versus restricted diet. Similarly, there were significant between-group differences in these scales when comparing those with and without evidence of dysphagia on video swallow studies, as scored using DIGEST. When lingual ROM was used as the anchor in an analysis of only the oral cavity and oropharynx patients (n=408), there were significant between-group differences in scores for all 5 eating and speaking-related scales. Between-group score differences for each of the clinical anchors ranged from approximately 10-20 across the 5 scales, with overall standard deviations ranging from 24-30.",
        "Conclusions": "The FACE-Q HNC eating, swallowing, and speaking scale scores vary in an expected pattern based on established clinical anchors. PRO's may be able to measure differences in quality of life that are smaller than those represented by clinical anchors such as diet status. For such cases, a 5-point difference in these scales accounts for 25-50% of the anchor-based between-group differences in means and can be considered a minimal clinically-important difference.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical anchor-based reference values for the eating, swallowing, and speaking scales of the FACE-Q Head and Neck Cancer module</span>. <u>Michael P Wu, MD</u>; Louise Cunningham, SLPD, CCCSLP; Donalrey Nieva; Mei-fan Parnes; Rebecca Gao, MD; Andrea L Pusic, MD; Richard J Wong, MD; Evan Matros, MD; Jennifer Cracchiolo, MD. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>The FACE-Q Head and Neck Cancer Module (FACE-Q HNC) is a validated patient reported outcome (PRO) measure, but context is needed for understanding normal values and the clinical importance of numeric differences in scores. We sought to generate reference values and establish between-group differences in scores, grouping patients by clinical anchors of diet, DIGEST scores, and lingual range of motion. These can serve as the basis for a minimal clinically important difference for the 5 FACEQ scales related to eating and speaking: Eating and Drinking, Eating Distress, Swallowing, Speaking, and Speaking Distress.</p>\n\n<p><strong>Methods: </strong>The FACE-Q HNC was prospectively administered to head and neck cancer patients as part of routine care at our institution. Data for patients with oral cavity, oropharynx, larynx, and hypopharynx tumors from April 2018 to February 2025 was extracted and linked to structured notes from speech language pathology (SLP) visits to determine treatment details, diet status, DIGEST scores from video swallow studies, and lingual range of motion. Reference values of the FACE-Q HNC Eating and Drinking, Eating Distress, Swallowing, Speaking, and Speaking Distress scales were calculated, grouped by diet type, DIGEST scores, and lingual range of motion. Between-group differences were calculated based on these clinical anchors. Analysis of lingual range of motion was limited to patients with oral cavity and oropharynx primary tumors.</p>\n\n<p><strong>Results: </strong>There were 557 patients with oral cavity, oropharynx, larynx, and hypopharynx tumors who had completed the FACE-Q HNC with a recorded SLP visit within 30 days of instrument completion. The mean age was 64 years, with 150 (27%) oral cavity, 258 (46%) oropharynx, 144 (26%) larynx, and 4 (1%) hypopharynx primaries. All phases of care were represented, with 256 (46%) pre-treatment, 110 (20%) during treatment, and 191 (34%) post-treatment. Mean scores were: 83.9 for Eating and Drinking (SD 24.5), 84.7 for Eating Distress (25.7), 85.3 for Swallowing (SD 25.0), 83.7 for Speaking (SD 30.0), and 88.0 for Speaking Distress (SD (24.2). There were significant between-group differences in Eating and Drinking, Eating Distress, and Swallowing for patients taking a regular versus restricted diet. Similarly, there were significant between-group differences in these scales when comparing those with and without evidence of dysphagia on video swallow studies, as scored using DIGEST. When lingual ROM was used as the anchor in an analysis of only the oral cavity and oropharynx patients (n=408), there were significant between-group differences in scores for all 5 eating and speaking-related scales. Between-group score differences for each of the clinical anchors ranged from approximately 10-20 across the 5 scales, with overall standard deviations ranging from 24-30.</p>\n\n<p><strong>Conclusions: </strong>The FACE-Q HNC eating, swallowing, and speaking scale scores vary in an expected pattern based on established clinical anchors. PRO's may be able to measure differences in quality of life that are smaller than those represented by clinical anchors such as diet status. For such cases, a 5-point difference in these scales accounts for 25-50% of the anchor-based between-group differences in means and can be considered a minimal clinically-important difference.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154671--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S216",
      "content_id": "154687",
      "abstract_number": "S216",
      "poster_number": "",
      "title": "Postoperative Swallow Outcomes in Inlay versus Onlay Neopharyngeal Free Flap Reconstruction after Total Laryngectomy",
      "summary": "This study is the first to compare postoperative swallow outcomes between inlay and onlay free flap reconstructions using radiographic swallow assessments. We conclude that inlay free flaps confer superior postoperative swallow function compared to onlay free flaps, and we highlight the superiority of the ALT inlay flap compared to latissimus dorsi and RFFF. The significant increase in swallow dysfunction with...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154687",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carolyn J Khoury, BA",
      "presenter": "Carolyn J Khoury, BA",
      "authors": "Carolyn J Khoury, BA ; Michael H Berger, MD; Eric M Genden, MD, MHCA, FACS; Mohemmed N Khan, MD; Scott A Roof, MD, MS; Marita S Teng, MD; Tamar Kotz, MS, CCCSLP; Diana N Kirke, MD, Phil",
      "normalized_authors": [
        "Carolyn J Khoury",
        "Michael H Berger",
        "Eric M Genden, MHCA",
        "Mohemmed N Khan",
        "Scott A Roof",
        "Marita S Teng",
        "Tamar Kotz, CCCSLP",
        "Diana N Kirke, Phil"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 487,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Carolyn J Khoury, BA ; Michael H Berger, MD; Eric M Genden, MD, MHCA, FACS; Mohemmed N Khan, MD; Scott A Roof, MD, MS; Marita S Teng, MD; Tamar Kotz, MS, CCCSLP; Diana N Kirke, MD, Phil",
        "Affiliations": "Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai",
        "Introduction": "In total laryngectomy, free flap reconstruction of the pharyngeal defect is frequently employed when primary closure of the pharyngeal defect is not feasible or when adjuvant treatment has compromised local tissues. Such reconstruction has been shown to decrease the risk of pharyngocutaneous fistula (PCF) and pharyngoesophageal stenosis (PES). While inlay flaps have been found to decrease the risk of PCF and PES compared to onlay flaps, objective measures of swallow function have not been directly compared between inlay and onlay flap reconstructions. Here, we aim to compare postoperative swallow outcomes between these two reconstruction techniques after total laryngectomy as assessed by postoperative esophagram and MBSS.",
        "Methods": "A single institution retrospective study was conducted to review charts of adult patients who had undergone total laryngectomy with free flap reconstruction from September 2016 to September 2025. Patients were excluded if they underwent primary closure or pedicled or rotational flap reconstruction. Chart review captured flap type (inlay or onlay), tissue source, indication for surgery, adjuvant or neoadjuvant treatment, postoperative complications, postoperative esophagram and MBSS results, pre- and post-operative diet, and medical comorbidities and smoking status. Data were analyzed categorically via multivariate logistic regression.",
        "Results": "121 patients underwent total laryngectomy with free flap reconstruction during the study period. Inlay flaps comprised 90 (74%) cases while onlay comprised 31 (26%). Of these, 79 had postoperative esophagram or MBSS results available for review. Postoperative swallow abnormalities were detected in 46 (58%) patients, while 33 (42%) had no abnormality. After adjustment for relevant comorbid factors, inlay flaps were found to have a 74% lower odds of postoperative swallow dysfunction on imaging compared to onlay flaps (OR=0.26, p=0.0366), the most common of which was esophageal/neopharyngeal dysmotility (n=21, 45.6%). Other abnormalities imaging detected included stenosis (n=13, 28.2%), leak/fistula (n=9, 19.6%), nasopharyngeal reflux (n=4, 8.7%), and aspiration (n=3, 6.5%). In our 121 patient cohort, flap tissue sources included: anterolateral thigh (ALT) flap (n=73, 60.3%), latissimus dorsi (n=17, 14.0%), serratus anterior (n=16, 13.2%), radial forearm (RFFF) (n=9, 7.4%), gastro-omental (n=2, 1.7%), rectus abdominis (n=2, 1.7%), and vastus lateralis myofascial flap (n=2, 1.7%). Multivariate analysis demonstrated significantly higher odds of PES for latissimus dorsi flaps (OR3.2, p=0.0404) and RFFF (OR=12.46, p=0.0030) compared with ALT flaps.",
        "Conclusions": "This study is the first to compare postoperative swallow outcomes between inlay and onlay free flap reconstructions using radiographic swallow assessments. We conclude that inlay free flaps confer superior postoperative swallow function compared to onlay free flaps, and we highlight the superiority of the ALT inlay flap compared to latissimus dorsi and RFFF. The significant increase in swallow dysfunction with onlay flap reconstruction, with the most common being dysmotility of the esophagus/neopharynx, suggests that an inlay reconstruction is preferrable when feasible.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Postoperative Swallow Outcomes in Inlay versus Onlay Neopharyngeal Free Flap Reconstruction after Total Laryngectomy</span>. <u>Carolyn J Khoury, BA</u>; Michael H Berger, MD; Eric M Genden, MD, MHCA, FACS; Mohemmed N Khan, MD; Scott A Roof, MD, MS; Marita S Teng, MD; Tamar Kotz, MS, CCCSLP; Diana N Kirke, MD, Phil. Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> In total laryngectomy, free flap reconstruction of the pharyngeal defect is frequently employed when primary closure of the pharyngeal defect is not feasible or when adjuvant treatment has compromised local tissues. Such reconstruction has been shown to decrease the risk of pharyngocutaneous fistula (PCF) and pharyngoesophageal stenosis (PES). While inlay flaps have been found to decrease the risk of PCF and PES compared to onlay flaps, objective measures of swallow function have not been directly compared between inlay and onlay flap reconstructions. Here, we aim to compare postoperative swallow outcomes between these two reconstruction techniques after total laryngectomy as assessed by postoperative esophagram and MBSS.</p>\n\n<p><strong>Methods:</strong> A single institution retrospective study was conducted to review charts of adult patients who had undergone total laryngectomy with free flap reconstruction from September 2016 to September 2025. Patients were excluded if they underwent primary closure or pedicled or rotational flap reconstruction. Chart review captured flap type (inlay or onlay), tissue source, indication for surgery, adjuvant or neoadjuvant treatment, postoperative complications, postoperative esophagram and MBSS results, pre- and post-operative diet, and medical comorbidities and smoking status. Data were analyzed categorically via multivariate logistic regression.</p>\n\n<p><strong>Results: </strong>121 patients underwent total laryngectomy with free flap reconstruction during the study period. Inlay flaps comprised 90 (74%) cases while onlay comprised 31 (26%). Of these, 79 had postoperative esophagram or MBSS results available for review. Postoperative swallow abnormalities were detected in 46 (58%) patients, while 33 (42%) had no abnormality. After adjustment for relevant comorbid factors, inlay flaps were found to have a 74% lower odds of postoperative swallow dysfunction on imaging compared to onlay flaps (OR=0.26, p=0.0366), the most common of which was esophageal/neopharyngeal dysmotility (n=21, 45.6%). Other abnormalities imaging detected included stenosis (n=13, 28.2%), leak/fistula (n=9, 19.6%), nasopharyngeal reflux (n=4, 8.7%), and aspiration (n=3, 6.5%). In our 121 patient cohort, flap tissue sources included: anterolateral thigh (ALT) flap (n=73, 60.3%), latissimus dorsi (n=17, 14.0%), serratus anterior (n=16, 13.2%), radial forearm (RFFF) (n=9, 7.4%), gastro-omental (n=2, 1.7%), rectus abdominis (n=2, 1.7%), and vastus lateralis myofascial flap (n=2, 1.7%). Multivariate analysis demonstrated significantly higher odds of PES for latissimus dorsi flaps (OR3.2, p=0.0404) and RFFF (OR=12.46, p=0.0030) compared with ALT flaps.</p>\n\n<p><strong>Conclusions:</strong> This study is the first to compare postoperative swallow outcomes between inlay and onlay free flap reconstructions using radiographic swallow assessments. We conclude that inlay free flaps confer superior postoperative swallow function compared to onlay free flaps, and we highlight the superiority of the ALT inlay flap compared to latissimus dorsi and RFFF. The significant increase in swallow dysfunction with onlay flap reconstruction, with the most common being dysmotility of the esophagus/neopharynx, suggests that an inlay reconstruction is preferrable when feasible. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154687--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S217",
      "content_id": "155496",
      "abstract_number": "S217",
      "poster_number": "",
      "title": "Otolaryngology Co-Surgeon Involvement in Anterior Cervical Discectomy and Fusion Maintains Comparable Complication Rates Despite Greater Case Complexity",
      "summary": "To our knowledge, this study is the first to demonstrate that ENT involvement in ACDF is associated with significantly greater patient comorbidity and surgical complexity without increased postoperative complications. These findings suggest that ENT co-surgeon participation supports the safe management of medically complex patients requiring technically challenging anterior cervical exposure.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155496",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Zaelig Averch, MS",
      "presenter": "Zaelig Averch, MS",
      "authors": "Zaelig Averch, MS 1 ; Ta'ir Rocker, MS 1 ; Gila Weinrib, MS 1 ; Regina Golding, MS 1 ; Amanda Shen, MS 1 ; Omar Fernandez, MD 2 ; Mitchell Fourman, MD 3 ; Bradley Schiff, MD 2 ; Richard Smith, MD 2 ; Vikas Mehta, MD 2 ; Helena Levyn, MD 2",
      "normalized_authors": [
        "Zaelig Averch",
        "Ta'ir Rocker",
        "Gila Weinrib",
        "Regina Golding",
        "Amanda Shen",
        "Omar Fernandez",
        "Mitchell Fourman",
        "Bradley Schiff",
        "Richard Smith",
        "Vikas Mehta",
        "Helena Levyn"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center, Bronx, NY, USA",
        "Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center, Bronx, NY, USA",
        "Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 352,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Zaelig Averch, MS 1 ; Ta'ir Rocker, MS 1 ; Gila Weinrib, MS 1 ; Regina Golding, MS 1 ; Amanda Shen, MS 1 ; Omar Fernandez, MD 2 ; Mitchell Fourman, MD 3 ; Bradley Schiff, MD 2 ; Richard Smith, MD 2 ; Vikas Mehta, MD 2 ; Helena Levyn, MD 2",
        "Affiliations": "1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center, Bronx, NY, USA; 3 Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA",
        "Background": "Otolaryngologists are often asked to assist orthopedic and neurosurgical spine surgeons with complex anterior cervical exposure during anterior cervical discectomy and fusion (ACDF); however, the relationship between otolaryngology (ENT) involvement, case complexity, and postoperative outcomes has not been well characterized. This study evaluates whether ENT participation is associated with differences in case complexity and postoperative complications in ACDF.",
        "Methods": "This cohort study included all patients who underwent anterior cervical discectomy and fusion (ACDF) at a single tertiary care center between 2022 and 2024, with Institutional Review Board approval. Patient demographics, history of prior neck surgery or radiation, and comorbidities required to calculate the age-adjusted Charlson Comorbidity Index (CCI) were collected. Operative characteristics and postoperative complications were recorded and compared between spine-surgeon-only ACDF procedures and those involving an ENT co-surgeon. Continuous variables were compared using the Mann-Whitney test, and categorical variables were compared using Pearson’s chi-square or Fisher’s exact tests as appropriate.",
        "Results": "A total of 413 ACDF procedures were analyzed, including 41 cases involving ENT co-surgeons (9.9%). Among spine-only procedures, 258 (62.5%) were performed by orthopedic spine surgeons and 114 (27.6%) by neurosurgeons. Cases involving an ENT co-surgeon demonstrated greater baseline complexity, including higher comorbidity burden (age-adjusted Charlson Comorbidity Index 3.95 vs 2.97, p = 0.001), higher rates of prior neck surgery (24% vs 7.8%, p = 0.002), and a greater proportion of multilevel procedures (75.6% vs 55.4%, p = 0.020). Despite greater case complexity, rates of postoperative dysphagia (275 [73.9%] vs 30 [73.2%], p > 0.9), hoarseness (254 [68.3%] vs 31 [75.6%], p = 0.378), hematoma (14 [3.8%] vs 1 [2.4%], p > 0.9), and seroma (3 [0.8%] vs 2 [4.9%], p = 0.079) were similar between groups.",
        "Conclusions": "To our knowledge, this study is the first to demonstrate that ENT involvement in ACDF is associated with significantly greater patient comorbidity and surgical complexity without increased postoperative complications. These findings suggest that ENT co-surgeon participation supports the safe management of medically complex patients requiring technically challenging anterior cervical exposure.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Otolaryngology Co-Surgeon Involvement in Anterior Cervical Discectomy and Fusion Maintains Comparable Complication Rates Despite Greater Case Complexity</span>. <u>Zaelig Averch, MS</u><sup>1</sup>; Ta'ir Rocker, MS<sup>1</sup>; Gila Weinrib, MS<sup>1</sup>; Regina Golding, MS<sup>1</sup>; Amanda Shen, MS<sup>1</sup>; Omar Fernandez, MD<sup>2</sup>; Mitchell Fourman, MD<sup>3</sup>; Bradley Schiff, MD<sup>2</sup>; Richard Smith, MD<sup>2</sup>; Vikas Mehta, MD<sup>2</sup>; Helena Levyn, MD<sup>2</sup>. <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>2</sup>Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center, Bronx, NY, USA; <sup>3</sup>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Otolaryngologists are often asked to assist orthopedic and neurosurgical spine surgeons with complex anterior cervical exposure during anterior cervical discectomy and fusion (ACDF); however, the relationship between otolaryngology (ENT) involvement, case complexity, and postoperative outcomes has not been well characterized. This study evaluates whether ENT participation is associated with differences in case complexity and postoperative complications in ACDF.</p>\n\n<p><strong>Methods: </strong>This cohort study included all patients who underwent anterior cervical discectomy and fusion (ACDF) at a single tertiary care center between 2022 and 2024, with Institutional Review Board approval. Patient demographics, history of prior neck surgery or radiation, and comorbidities required to calculate the age-adjusted Charlson Comorbidity Index (CCI) were collected. Operative characteristics and postoperative complications were recorded and compared between spine-surgeon-only ACDF procedures and those involving an ENT co-surgeon. Continuous variables were compared using the Mann-Whitney test, and categorical variables were compared using Pearson’s chi-square or Fisher’s exact tests as appropriate.</p>\n\n<p><strong>Results: </strong>A total of 413 ACDF procedures were analyzed, including 41 cases involving ENT co-surgeons (9.9%). Among spine-only procedures, 258 (62.5%) were performed by orthopedic spine surgeons and 114 (27.6%) by neurosurgeons. Cases involving an ENT co-surgeon demonstrated greater baseline complexity, including higher comorbidity burden (age-adjusted Charlson Comorbidity Index 3.95 vs 2.97, p = 0.001), higher rates of prior neck surgery (24% vs 7.8%, p = 0.002), and a greater proportion of multilevel procedures (75.6% vs 55.4%, p = 0.020). Despite greater case complexity, rates of postoperative dysphagia (275 [73.9%] vs 30 [73.2%], p > 0.9), hoarseness (254 [68.3%] vs 31 [75.6%], p = 0.378), hematoma (14 [3.8%] vs 1 [2.4%], p > 0.9), and seroma (3 [0.8%] vs 2 [4.9%], p = 0.079) were similar between groups.</p>\n\n<p><strong>Conclusions: </strong>To our knowledge, this study is the first to demonstrate that ENT involvement in ACDF is associated with significantly greater patient comorbidity and surgical complexity without increased postoperative complications. These findings suggest that ENT co-surgeon participation supports the safe management of medically complex patients requiring technically challenging anterior cervical exposure.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155496--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S218",
      "content_id": "154676",
      "abstract_number": "S218",
      "poster_number": "",
      "title": "Taste changes in patients following transoral robotic surgery for oropharyngeal cancer",
      "summary": "Preliminary data suggests that while postoperative dysgeusia is common following TORS, many patients experience partial or full recovery within the first six months, with no evidence of progressive deterioration. Detailed intraoperative variables, including retraction time, glossopharyngeal nerve management, and operation duration, may help clarify contributors to postoperative chemosensory changes as enrollment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154676",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kyra Lee, BS",
      "presenter": "Kyra Lee, BS",
      "authors": "Noor Zaghlula, MS 1 ; Michaela Geffert, MS 2 ; Kyra Lee, BS 1 ; Joseph Paydarfar, MD 2",
      "normalized_authors": [
        "Noor Zaghlula",
        "Michaela Geffert",
        "Kyra Lee",
        "Joseph Paydarfar"
      ],
      "affiliations": [
        "Geisel School of Medicine, Dartmouth College",
        "Dartmouth-Hitchcock Health"
      ],
      "normalized_institutions": [
        "Geisel School of Medicine, Dartmouth College",
        "Dartmouth-Hitchcock Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 497,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Noor Zaghlula, MS 1 ; Michaela Geffert, MS 2 ; Kyra Lee, BS 1 ; Joseph Paydarfar, MD 2",
        "Affiliations": "1 Geisel School of Medicine, Dartmouth College; 2 Dartmouth-Hitchcock Health",
        "Introduction": "Taste disturbances are well-recognized complications of head and neck cancer treatment, yet their trajectory following transoral robotic surgery (TORS) remains poorly characterized. Existing literature suggests dysgeusia may occur early after TORS, but little is known about its severity, duration, or the patient factors that contribute to prolonged dysfunction. 1 We have observed taste disturbances that persist beyond what is reported in prior studies, underscoring a gap in current evidence. Because TORS involves retraction and manipulation of structures critical for gustation, understanding postoperative chemosensory outcomes is essential for improving patient counseling, guiding perioperative management, and identifying individuals at heightened risk for sustained impairment.",
        "Methods": "This is an ongoing observational study where participants are adults undergoing TORS oropharyngeal cancer or suspected cancer resection. Each patient is followed for one year (4-5 study visits) and assigned to one of two arms based on treatment course: surgery only or surgery and adjuvant therapy (chemo and/or radiation). At each study visit patients undergo olfactory function testing (ODOFIN Sniffin' Sticks Screening 12), gustatory testing (ODOFIN Taste Test 50), and complete two surveys (Composite Validated Chemosensory Survey Tool and MD Anderson Dysphagia Inventory (MDADI)). Additionally, intraoperative variables are collected and chart review is performed to explore potential contributors, such as surgery duration and retractor placement, glossopharyngeal nerve management, intubation type, and patient demographics, comorbidities, staging, and pathology.",
        "Results": "Sixteen participants completed pre-operative assessment (mean age 66 years; 88% male), and 14 have undergone TORS. Nine patients completed the 4-week follow-up, and three reached 6-months. Six entered the adjuvant therapy arm; three missed the post-operative, pre-adjuvant visit but remain enrolled.",
        "Abstract": "Mean operative duration was 416 minutes (SD 157), and average retractor time was 79 minutes (SD 22). Oral and nasal intubation were used in equal proportions (7/14 each). Tongue retraction was employed in 13 cases. The glossopharyngeal nerve was identified in 12 patients and was sacrificed in 9 and preserved in 3. Among nine patients with paired pre-operative and 4-week taste tests, two declined, six remained stable, and one improved. Of the three patients with 6-month follow-up, one returned to baseline, one improved from complete ageusia to persistent hypogeusia, and one remained unchanged. No patients showed worsening after 4 weeks. MDADI composite scores demonstrated early reductions in swallowing-related quality of life, with mean scores decreasing from 88.9 (pre-operative) to 80.9 (4-weeks post-operative) and 75.1 (6-months post-operative). Individual trajectories varied; several patients experienced small changes below the 20-point threshold considered clinically meaningful, while a subset showed ≥20-point declines, including one >50-point reduction. Enrollment and longitudinal data collection are ongoing. View in Agenda and Add to Schedule",
        "Conclusion": "Preliminary data suggests that while postoperative dysgeusia is common following TORS, many patients experience partial or full recovery within the first six months, with no evidence of progressive deterioration. Detailed intraoperative variables, including retraction time, glossopharyngeal nerve management, and operation duration, may help clarify contributors to postoperative chemosensory changes as enrollment continues. These developing insights may guide perioperative counseling and help identify patients who warrant closer follow-up."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Taste changes in patients following transoral robotic surgery for oropharyngeal cancer</span>. Noor Zaghlula, MS<sup>1</sup>; Michaela Geffert, MS<sup>2</sup>; <u>Kyra Lee, BS</u><sup>1</sup>; Joseph Paydarfar, MD<sup>2</sup>. <sup>1</sup>Geisel School of Medicine, Dartmouth College; <sup>2</sup>Dartmouth-Hitchcock Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Taste disturbances are well-recognized complications of head and neck cancer treatment, yet their trajectory following transoral robotic surgery (TORS) remains poorly characterized. Existing literature suggests dysgeusia may occur early after TORS, but little is known about its severity, duration, or the patient factors that contribute to prolonged dysfunction.<sup>1</sup> We have observed taste disturbances that persist beyond what is reported in prior studies, underscoring a gap in current evidence. Because TORS involves retraction and manipulation of structures critical for gustation, understanding postoperative chemosensory outcomes is essential for improving patient counseling, guiding perioperative management, and identifying individuals at heightened risk for sustained impairment.</p>\n\n<p><strong>Methods: </strong>This is an ongoing observational study where participants are adults undergoing TORS oropharyngeal cancer or suspected cancer resection. Each patient is followed for one year (4-5 study visits) and assigned to one of two arms based on treatment course: surgery only or surgery and adjuvant therapy (chemo and/or radiation). At each study visit patients undergo olfactory function testing (ODOFIN Sniffin' Sticks Screening 12), gustatory testing (ODOFIN Taste Test 50), and complete two surveys (Composite Validated Chemosensory Survey Tool and MD Anderson Dysphagia Inventory (MDADI)). Additionally, intraoperative variables are collected and chart review is performed to explore potential contributors, such as surgery duration and retractor placement, glossopharyngeal nerve management, intubation type, and patient demographics, comorbidities, staging, and pathology.</p>\n\n<p><strong>Results: </strong>Sixteen participants completed pre-operative assessment (mean age 66 years; 88% male), and 14 have undergone TORS. Nine patients completed the 4-week follow-up, and three reached 6-months. Six entered the adjuvant therapy arm; three missed the post-operative, pre-adjuvant visit but remain enrolled. </p>\n\n<p>Mean operative duration was 416 minutes (SD 157), and average retractor time was 79 minutes (SD 22). Oral and nasal intubation were used in equal proportions (7/14 each). Tongue retraction was employed in 13 cases. The glossopharyngeal nerve was identified in 12 patients and was sacrificed in 9 and preserved in 3.</p>\n\n<p>Among nine patients with paired pre-operative and 4-week taste tests, two declined, six remained stable, and one improved. Of the three patients with 6-month follow-up, one returned to baseline, one improved from complete ageusia to persistent hypogeusia, and one remained unchanged. No patients showed worsening after 4 weeks.</p>\n\n<p>MDADI composite scores demonstrated early reductions in swallowing-related quality of life, with mean scores decreasing from 88.9 (pre-operative) to 80.9 (4-weeks post-operative) and 75.1 (6-months post-operative). Individual trajectories varied; several patients experienced small changes below the 20-point threshold considered clinically meaningful, while a subset showed ≥20-point declines, including one >50-point reduction.</p>\n\n<p>Enrollment and longitudinal data collection are ongoing. </p>\n\n<p><strong>Conclusion: </strong>Preliminary data suggests that while postoperative dysgeusia is common following TORS, many patients experience partial or full recovery within the first six months, with no evidence of progressive deterioration. Detailed intraoperative variables, including retraction time, glossopharyngeal nerve management, and operation duration, may help clarify contributors to postoperative chemosensory changes as enrollment continues. These developing insights may guide perioperative counseling and help identify patients who warrant closer follow-up.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154676--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S219",
      "content_id": "153466",
      "abstract_number": "S219",
      "poster_number": "",
      "title": "A Comprehensive Evaluation of Patient Reported Outcome Measures following Trans-Oral Robotic Surgery in Patients with Oropharyngeal Cancer",
      "summary": "Overall, patients demonstrate the lowest swallowing and quality-of-life outcome scores 1-month post-operatively, as expected, and mostly recover to baseline scores within one year, showing successful recovery after treatment. Swallowing outcomes were significantly worse in TORS+RT patients at 1-month, prior to radiation, indicating that larger resections and worse initial disease burden may primarily drive early...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153466",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tayo Steininger",
      "presenter": "Tayo Steininger",
      "authors": "Tayo Steininger",
      "normalized_authors": [
        "Tayo Steininger"
      ],
      "affiliations": [
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153466/patient%20reported%20outcomes%20by%20treatment%20group.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153466/patient%20reported%20outcomes%20by%20treatment%20group.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153466"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 512,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Tayo Steininger",
        "Affiliations": "University of British Columbia",
        "Background": "Trans-oral robotic surgery (TORS) has cemented its place as an effective surgical method for primary treatment of oropharyngeal cancers (OPC). In addition to oncologic outcomes, patient-reported outcomes (PRO) are of critical importance. These additional outcomes will help inform future counselling of patients on expected surgical outcomes important to them and help them make an informed decision.",
        "Objective": "The objective of this study is to assess Patient Reported Outcomes (PROs) in patients with OPC undergoing primary TORS treatment, including quality of life, swallowing outcomes, and decision regret.",
        "Methods": "This is a prospective study of patients with OPC that are undergoing primary TORS for curative intent treatment between 08/2022 and 05/2025. Patient reported outcomes were assessed at four different time points: pre-operatively, then 1, 6, and 12 months post-operatively. PROs were evaluated using validated questionnaires, including the University of Washington Quality of Life (UW-QOL) survey – which is divided into social-emotional and physical subscales, the MD Anderson Dysphasia Inventory (MDADI) questionnaire, and the Decision Regret Scale (DRS) questionnaire. Patients are included is they completed preoperative questionnaires as well as at least one follow-up questionnaire at 6 or 12 months postoperatively. Patients were further compared between those that received TORS alone, those with TORS followed by adjuvant radiation (RT) or TORS and adjuvant chemoradiation (CRT), along with additional clinical characteristics.",
        "Results": "A total of 67 patients were included and stratified by treatment into TORS-only (34, 51%), TORS+RT (23, 34%), and TORS+CRT (8, 12%). Both the TORS+RT and TORS+CRT groups demonstrate lower UW-QOL social-emotional scores post-operatively than TORS-only patients. A significant difference is noted 6 months post-operatively (69 vs 82.5, p = .02), with scores returning to near baseline after one year. Scores in the physical UW-QOL subscale follow a similar pattern, with significantly lower scores observed at 6 months in patients who received any adjuvant radiation or chemoradiation compared to those who did not (69.8 vs 83.8, p = .007; 65.2 vs 83.8, p = .015). Among TORS+RT patients, MDADI scores were significantly lower than those of TORS-only patients at 1 month (60.8 vs 76.2, p = .02), and do not recover to baseline levels.",
        "Abstract": "Stratification by subsite – tonsil, base of tongue, or both – revealed no significant differences, though patients with both sites continuously scored worse across all questionnaires. While DRS scores did not demonstrate any significant differences, patients with adjuvant radiation, involvement of both subsites, or Stage 2 disease tended to report higher decision regret. View in Agenda and Add to Schedule",
        "Conclusion": "Overall, patients demonstrate the lowest swallowing and quality-of-life outcome scores 1-month post-operatively, as expected, and mostly recover to baseline scores within one year, showing successful recovery after treatment. Swallowing outcomes were significantly worse in TORS+RT patients at 1-month, prior to radiation, indicating that larger resections and worse initial disease burden may primarily drive early functional deficits. Quality-of-life scores of patients requiring adjuvant treatment were consistently worse than those of TORS-only patients, especially at 6-months, suggesting longer recovery trajectories. These features must be considered when informing patients of expected post-operative outcomes in the surgical consent process."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Comprehensive Evaluation of Patient Reported Outcome Measures following Trans-Oral Robotic Surgery in Patients with Oropharyngeal Cancer</span>. <u>Tayo Steininger</u>. University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Trans-oral robotic surgery (TORS) has cemented its place as an effective surgical method for primary treatment of oropharyngeal cancers (OPC). In addition to oncologic outcomes, patient-reported outcomes (PRO) are of critical importance. These additional outcomes will help inform future counselling of patients on expected surgical outcomes important to them and help them make an informed decision.</p>\n\n<p><strong>Objective:</strong> The objective of this study is to assess Patient Reported Outcomes (PROs) in patients with OPC undergoing primary TORS treatment, including quality of life, swallowing outcomes, and decision regret.</p>\n\n<p><strong>Methods: </strong>This is a prospective study of patients with OPC that are undergoing primary TORS for curative intent treatment between 08/2022 and 05/2025. Patient reported outcomes were assessed at four different time points: pre-operatively, then 1, 6, and 12 months post-operatively. PROs were evaluated using validated questionnaires, including the University of Washington Quality of Life (UW-QOL) survey – which is divided into social-emotional and physical subscales, the MD Anderson Dysphasia Inventory (MDADI) questionnaire, and the Decision Regret Scale (DRS) questionnaire. Patients are included is they completed preoperative questionnaires as well as at least one follow-up questionnaire at 6 or 12 months postoperatively. Patients were further compared between those that received TORS alone, those with TORS followed by adjuvant radiation (RT) or TORS and adjuvant chemoradiation (CRT), along with additional clinical characteristics.</p>\n\n<p><strong>Results: </strong>A total of 67 patients were included and stratified by treatment into TORS-only (34, 51%), TORS+RT (23, 34%), and TORS+CRT (8, 12%). Both the TORS+RT and TORS+CRT groups demonstrate lower UW-QOL social-emotional scores post-operatively than TORS-only patients. A significant difference is noted 6 months post-operatively (69 vs 82.5, p = .02), with scores returning to near baseline after one year. Scores in the physical UW-QOL subscale follow a similar pattern, with significantly lower scores observed at 6 months in patients who received any adjuvant radiation or chemoradiation compared to those who did not (69.8 vs 83.8, p = .007; 65.2 vs 83.8, p = .015). Among TORS+RT patients, MDADI scores were significantly lower than those of TORS-only patients at 1 month (60.8 vs 76.2, p = .02), and do not recover to baseline levels. </p>\n\n<p>Stratification by subsite – tonsil, base of tongue, or both – revealed no significant differences, though patients with both sites continuously scored worse across all questionnaires. While DRS scores did not demonstrate any significant differences, patients with adjuvant radiation, involvement of both subsites, or Stage 2 disease tended to report higher decision regret. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153466/patient%20reported%20outcomes%20by%20treatment%20group.png' /></p>\n\n<p><strong>Conclusion: </strong>Overall, patients demonstrate the lowest swallowing and quality-of-life outcome scores 1-month post-operatively, as expected, and mostly recover to baseline scores within one year, showing successful recovery after treatment. Swallowing outcomes were significantly worse in TORS+RT patients at 1-month, prior to radiation, indicating that larger resections and worse initial disease burden may primarily drive early functional deficits. Quality-of-life scores of patients requiring adjuvant treatment were consistently worse than those of TORS-only patients, especially at 6-months, suggesting longer recovery trajectories. These features must be considered when informing patients of expected post-operative outcomes in the surgical consent process. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153466--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S220",
      "content_id": "154080",
      "abstract_number": "S220",
      "poster_number": "",
      "title": "Symptom and Functional Drivers of Quality of Life in Head and Neck Cancer Survivors within 1-year of Surgical Management for Mandibular Osteoradionecrosis",
      "summary": "Relative to baseline, MDASI pain and fatigue scores remained significantly better over time post-surgery (MDASI-pain: baseline5.6±3.3, early post-op3.9±3.2, 1-year post-op3.4±3.9, p=0.001; MDASI-fatigue: baseline5.3±3.5, early post-op4.5±2.7, 1-year post-op3.5±2.3, p=0.012). However, MDASI speech/voice difficulty scores worsened and did not recover by 1-year post-surgery (baseline3.5±3.5, early post-op3.6±4.0,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154080",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Isabelle Jia Hui Jang, MD",
      "presenter": "Isabelle Jia Hui Jang, MD",
      "authors": "Isabelle Jia Hui Jang, MD ; Christine Peterson; Mohamed Abdallah Sherif Radwan; Clifton Fuller; Kate Hutcheson; Stephen Lai",
      "normalized_authors": [
        "Isabelle Jia Hui Jang",
        "Christine Peterson",
        "Mohamed Abdallah Sherif Radwan",
        "Clifton Fuller",
        "Kate Hutcheson",
        "Stephen Lai"
      ],
      "affiliations": [
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 609,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "OBJECTIVE",
        "METHODS",
        "RESULTS",
        "Abstract",
        "CONCLUSIONS"
      ],
      "sections": {
        "Authors": "Isabelle Jia Hui Jang, MD ; Christine Peterson; Mohamed Abdallah Sherif Radwan; Clifton Fuller; Kate Hutcheson; Stephen Lai",
        "Affiliations": "MD Anderson Cancer Center",
        "BACKGROUND": "Mandibular osteoradionecrosis (ORN) is an uncommon but debilitating late toxicity that head and neck cancer (HNC) survivors suffer from post-radiation treatment. Patients with high-grade mandibular ORN often present with severe symptoms related to their prior RT and/or the ORN itself, which impair quality of life (QoL), requiring surgical treatment. However, prospective longitudinal studies in HNC survivors treated surgically for ORN are lacking.",
        "OBJECTIVE": "This study aimed to investigate: 1) evolution of patient reported outcomes (PRO) and clinician-graded function, and 2) their relationship with QoL pre- and post-operatively in patients with advanced ORN who undergo mandibulectomy and free fibula flap reconstructive surgery.",
        "METHODS": "HNC survivors with Clinrad grade 3/4 ORN were recruited to a prospective cohort (NCT 03145077) at a single tertiary center. PRO measures (MD Anderson dysphagia inventory, MDADI; MD Anderson Symptom Inventory, MDASI; EQ-5D-5L visual analogue scale, EQ-5D-5L VAS; Performance Status Scale for Head & Neck Cancer Patients, PSSHN) were administered at three time points: baseline, up to four months post-surgery and 1-year post-surgery. Modified barium swallow (MBS) measured with penetration-aspiration scale (PAS) and DIGEST was performed at baseline, 1-3 months post-surgery and 4 months or more post-surgery. Linear mixed models were used to compare scores across all time points to explore relationships between symptoms/function and QoL measured by EQ-5D-5L after diagnosis of ORN.",
        "RESULTS": "34 patients were prospectively recruited. The median age was 65.5 years (range 60-69); 32(94.1%) had functional status ECOG 0-1. 18(52.9%) had oropharynx tumors and 11(32.4%) had oral cavity tumors. 4(11.8%) had stage I/II (AJCC 7th edition) disease. 4(11.8%) were treated with re-irradiation. The median overall survival was 16.0 years (95% confidence interval, CI:10.7,21.3), and median time to diagnosis of ORN was 4.0 years (95%CI:1.9,6.1). 34(91.2%) patients had no evidence of disease post-surgery, whilst 3(8.8%) had contralateral ORN.",
        "Abstract": "Relative to baseline, MDASI pain and fatigue scores remained significantly better over time post-surgery (MDASI-pain: baseline5.6±3.3, early post-op3.9±3.2, 1-year post-op3.4±3.9, p=0.001; MDASI-fatigue: baseline5.3±3.5, early post-op4.5±2.7, 1-year post-op3.5±2.3, p=0.012). However, MDASI speech/voice difficulty scores worsened and did not recover by 1-year post-surgery (baseline3.5±3.5, early post-op3.6±4.0, 1-year post-op5.7±3.7, p=0.037). More patients were able to eat chewable foods post-surgery (PSSHN normalcy of diet>50: baseline28.0%, early post-op35.7%, 1-year post-op47.4%, p=0.010). However, swallow function was worse measured by PAS/DIGEST scores (PAS: baseline4.6±2.6, early post-op6.4±2.0, >4month post-op6.8±1.6; DIGEST: baseline1.6±1.3, early post-op2.4±1.1, >4month post-op2.7±0.6, p=0.032); and increased feeding tube dependence (baseline 16.0%, early post-op 67.9%, 1-year post-op 50.0%, p=0.001) reflecting mixed functional results of the surgery. MDASI-head and neck module symptoms severity (HNMSS) was significantly associated with EQ-5D-5L VAS at baseline and up to 1-year post-surgery (-5.43; 95%CI:-8.83,-2.02; p=0.037), however MDASI-core symptoms severity score was not associated with EQ-5D-VAS (-3.61; 95%CI:-6.86,0.35, p=0.291), reflecting MDASI head and neck symptom association with QoL. View in Agenda and Add to Schedule",
        "CONCLUSIONS": "Pain and fatigue remain improved up to 1-year post-surgery for advanced mandibular ORN; however speech/voice and swallowing function worsen. MDASI-HNMSS was significantly associated with QoL. These longitudinal findings help with pre-operative counselling. Addressing head and neck symptoms pre-and post-surgery may be helpful in improving patients’ QoL."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Symptom and Functional Drivers of Quality of Life in Head and Neck Cancer Survivors within 1-year of Surgical Management for Mandibular Osteoradionecrosis</span>. <u>Isabelle Jia Hui Jang, MD</u>; Christine Peterson; Mohamed Abdallah Sherif Radwan; Clifton Fuller; Kate Hutcheson; Stephen Lai. MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Mandibular osteoradionecrosis (ORN) is an uncommon but debilitating late toxicity that head and neck cancer (HNC) survivors suffer from post-radiation treatment. Patients with high-grade mandibular ORN often present with severe symptoms related to their prior RT and/or the ORN itself, which impair quality of life (QoL), requiring surgical treatment. However, prospective longitudinal studies in HNC survivors treated surgically for ORN are lacking.</p>\n\n<p><strong>OBJECTIVE: </strong>This study aimed to investigate: 1) evolution of patient reported outcomes (PRO) and clinician-graded function, and 2) their relationship with QoL pre- and post-operatively in patients with advanced ORN who undergo mandibulectomy and free fibula flap reconstructive surgery.</p>\n\n<p><strong>METHODS: </strong>HNC survivors with Clinrad grade 3/4 ORN were recruited to a prospective cohort (NCT 03145077) at a single tertiary center. PRO measures (MD Anderson dysphagia inventory, MDADI; MD Anderson Symptom Inventory, MDASI; EQ-5D-5L visual analogue scale, EQ-5D-5L VAS; Performance Status Scale for Head & Neck Cancer Patients, PSSHN) were administered at three time points: baseline, up to four months post-surgery and 1-year post-surgery. Modified barium swallow (MBS) measured with penetration-aspiration scale (PAS) and DIGEST was performed at baseline, 1-3 months post-surgery and 4 months or more post-surgery. Linear mixed models were used to compare scores across all time points to explore relationships between symptoms/function and QoL measured by EQ-5D-5L after diagnosis of ORN.</p>\n\n<p><strong>RESULTS: </strong>34 patients were prospectively recruited. The median age was 65.5 years (range 60-69); 32(94.1%) had functional status ECOG 0-1. 18(52.9%) had oropharynx tumors and 11(32.4%) had oral cavity tumors. 4(11.8%) had stage I/II (AJCC 7th edition) disease. 4(11.8%) were treated with re-irradiation. The median overall survival was 16.0 years (95% confidence interval, CI:10.7,21.3), and median time to diagnosis of ORN was 4.0 years (95%CI:1.9,6.1). 34(91.2%) patients had no evidence of disease post-surgery, whilst 3(8.8%) had contralateral ORN.</p>\n\n<p>Relative to baseline, MDASI pain and fatigue scores remained significantly better over time post-surgery (MDASI-pain: baseline5.6±3.3, early post-op3.9±3.2, 1-year post-op3.4±3.9, p=0.001; MDASI-fatigue: baseline5.3±3.5, early post-op4.5±2.7, 1-year post-op3.5±2.3, p=0.012). However, MDASI speech/voice difficulty scores worsened and did not recover by 1-year post-surgery (baseline3.5±3.5, early post-op3.6±4.0, 1-year post-op5.7±3.7, p=0.037).</p>\n\n<p>More patients were able to eat chewable foods post-surgery (PSSHN normalcy of diet>50: baseline28.0%, early post-op35.7%, 1-year post-op47.4%, p=0.010). However, swallow function was worse measured by PAS/DIGEST scores (PAS: baseline4.6±2.6, early post-op6.4±2.0, >4month post-op6.8±1.6;  DIGEST: baseline1.6±1.3, early post-op2.4±1.1, >4month post-op2.7±0.6, p=0.032); and increased feeding tube dependence (baseline 16.0%, early post-op 67.9%, 1-year post-op 50.0%, p=0.001) reflecting mixed functional results of the surgery.</p>\n\n<p>MDASI-head and neck module symptoms severity (HNMSS) was significantly associated with EQ-5D-5L VAS at baseline and up to 1-year post-surgery (-5.43; 95%CI:-8.83,-2.02; p=0.037), however MDASI-core symptoms severity score was not associated with EQ-5D-VAS (-3.61; 95%CI:-6.86,0.35, p=0.291), reflecting MDASI head and neck symptom association with QoL.</p>\n\n<p><strong>CONCLUSIONS: </strong>Pain and fatigue remain improved up to 1-year post-surgery for advanced mandibular ORN; however speech/voice and swallowing function worsen. MDASI-HNMSS was significantly associated with QoL. These longitudinal findings help with pre-operative counselling. Addressing head and neck symptoms pre-and post-surgery may be helpful in improving patients’ QoL.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154080--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S221",
      "content_id": "153237",
      "abstract_number": "S221",
      "poster_number": "",
      "title": "Spinal Accessory Nerve Function After Modified Radical Neck Dissections: Comparison of Intraoperative Nerve Stimulation and Postoperative Functional Outcomes",
      "summary": "Postoperative shoulder outcomes after neck dissection does not directly correlate with the presence or absence of post-dissection intraoperative nerve stimulation alone. Lack of stimulation was most common in the superior nerve segment, likely due to its anchoring to the jugular foramen and greater vulnerability to traction injury. Loss of stimulation occurred most commonly after upper Level 2B dissection....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153237",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caroline Liu",
      "presenter": "Caroline Liu",
      "authors": "Caroline Liu ; Kenny Do; Emily Sagalow; Rahul Patel; Robert Wang",
      "normalized_authors": [
        "Caroline Liu",
        "Emily Sagalow",
        "Rahul Patel",
        "Robert Wang"
      ],
      "affiliations": [
        "Kirk Kerkorian School of Medicine at UNLV"
      ],
      "normalized_institutions": [
        "Kirk Kerkorian School of Medicine at UNLV"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 477,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Caroline Liu ; Kenny Do; Emily Sagalow; Rahul Patel; Robert Wang",
        "Affiliations": "Kirk Kerkorian School of Medicine at UNLV",
        "Introduction": "The spinal accessory nerve is routinely encountered during modified radical neck dissection (mRND) and is vulnerable to temporary or permanent injury, especially when removing level 2B. Postoperative shoulder dysfunction (limited range of motion [ROM], weakness, or pain) is common, yet the relationship between the location or extent of nerve injury and the type or duration of postoperative deficits remains poorly defined.",
        "Objective": "To assess changes in neurostimulatory responses of the accessory nerve during mRND and the relationship to postoperative shoulder dysfunction.",
        "Methods": "This was a single, senior surgeon series of mRNDs performed with electromyography monitoring of the trapezius muscle. Level 2B was dissected while minimizing traction and manipulation of the accessory nerve. The superior, middle, and inferior thirds of the exposed spinal accessory nerve were stimulated at 0.8mV intraoperatively after Level 2A, then during and after Level 2B nodal dissection. Stimulation of the nerve at Level 5 was performed when dissection was done there as well. Anatomical variations including early takeoff to the trapezius, early exit from sternocleidomastoid, and anastomoses with cervical rootlets were noted. Shoulder dysfunction was defined as decreased ROM and/or new onset “winging” of the arm when abducting. Long-term postoperative shoulder dysfunction was defined as lasting more than 6 months.",
        "Results": "A total of 64 patients underwent neck dissection from November 2022 to October 2025. Overall, 31% (20/64) developed postoperative shoulder dysfunction. Among patients with at least 6 months of follow up, 27% (7/26) had early shoulder dysfunction and 12% (3/26) had persistent long-term dysfunction for a recovery rate of 57%. 47% (30/64) of patients had at least 1 nerve segment that did not stimulate (inferior, middle, superior) after neck dissection, with 87% (26/30) having superior segment involvement. Despite loss of stimulation, 70% (21/30) of this group still had preserved postoperative shoulder function. Early takeoff of the trapezius nerve branch was encountered in 14% (9/64) of patients. 86% (55/64) of patients underwent Level 2B dissection, with only one losing stimulation after 2A, prior to 2B dissection. Level 5 dissection did not show a statistically significant change in postoperative shoulder function compared to those without Level 5 dissection [45% (5/11) vs 28% (15/53), p=0.26] and all Level 5 nerve segments retained stimulation after dissection. Stimulation of the proximal cervical rootlets anastomosing with the accessory nerve did not elicit action potentials.",
        "Conclusion": "Postoperative shoulder outcomes after neck dissection does not directly correlate with the presence or absence of post-dissection intraoperative nerve stimulation alone. Lack of stimulation was most common in the superior nerve segment, likely due to its anchoring to the jugular foramen and greater vulnerability to traction injury. Loss of stimulation occurred most commonly after upper Level 2B dissection. Identifying anatomical variations and preserving early trapezius nerve takeoffs may also play an important role in maintaining shoulder function.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Spinal Accessory Nerve Function After Modified Radical Neck Dissections: Comparison of Intraoperative Nerve Stimulation and Postoperative Functional Outcomes</span>. <u>Caroline Liu</u>; Kenny Do; Emily Sagalow; Rahul Patel; Robert Wang. Kirk Kerkorian School of Medicine at UNLV<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> The spinal accessory nerve is routinely encountered during modified radical neck dissection (mRND) and is vulnerable to temporary or permanent injury, especially when removing level 2B. Postoperative shoulder dysfunction (limited range of motion [ROM], weakness, or pain) is common, yet the relationship between the location or extent of nerve injury and the type or duration of postoperative deficits remains poorly defined.</p>\n\n<p><strong>Objective: </strong>To assess changes in neurostimulatory responses of the accessory nerve during mRND and the relationship to postoperative shoulder dysfunction.</p>\n\n<p><strong>Methods:</strong> This was a single, senior surgeon series of mRNDs performed with electromyography monitoring of the trapezius muscle. Level 2B was dissected while minimizing traction and manipulation of the accessory nerve. The superior, middle, and inferior thirds of the exposed spinal accessory nerve were stimulated at 0.8mV intraoperatively after Level 2A, then during and after Level 2B nodal dissection. Stimulation of the nerve at Level 5 was performed when dissection was done there as well. Anatomical variations including early takeoff to the trapezius, early exit from sternocleidomastoid, and anastomoses with cervical rootlets were noted. Shoulder dysfunction was defined as decreased ROM and/or new onset “winging” of the arm when abducting. Long-term postoperative shoulder dysfunction was defined as lasting more than 6 months.</p>\n\n<p><strong>Results: </strong>A total of 64 patients underwent neck dissection from November 2022 to October 2025. Overall, 31% (20/64) developed postoperative shoulder dysfunction. Among patients with at least 6 months of follow up, 27% (7/26) had early shoulder dysfunction and 12% (3/26) had persistent long-term dysfunction for a recovery rate of 57%. 47% (30/64) of patients had at least 1 nerve segment that did not stimulate (inferior, middle, superior) after neck dissection, with 87% (26/30) having superior segment involvement. Despite loss of stimulation, 70% (21/30) of this group still had preserved postoperative shoulder function. Early takeoff of the trapezius nerve branch was encountered in 14% (9/64) of patients. 86% (55/64) of patients underwent Level 2B dissection, with only one losing stimulation after 2A, prior to 2B dissection. Level 5 dissection did not show a statistically significant change in postoperative shoulder function compared to those without Level 5 dissection [45% (5/11) vs 28% (15/53), p=0.26] and all Level 5 nerve segments retained stimulation after dissection. Stimulation of the proximal cervical rootlets anastomosing with the accessory nerve did not elicit action potentials.</p>\n\n<p><strong>Conclusion:</strong> Postoperative shoulder outcomes after neck dissection does not directly correlate with the presence or absence of post-dissection intraoperative nerve stimulation alone. Lack of stimulation was most common in the superior nerve segment, likely due to its anchoring to the jugular foramen and greater vulnerability to traction injury. Loss of stimulation occurred most commonly after upper Level 2B dissection. Identifying anatomical variations and preserving early trapezius nerve takeoffs may also play an important role in maintaining shoulder function.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153237--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S222",
      "content_id": "153475",
      "abstract_number": "S222",
      "poster_number": "",
      "title": "Restoring patient-reported symptom screening in ambulatory head & neck oncology: A quality improvement project",
      "summary": "1) Identify system-, staff-, and patient-level barriers contributing to low ESAS-r+ completion among H&N patients, and; 2) Implement and evaluate a clinic-level intervention to increase symptom screening uptake using paper-based ESAS-r+ forms. View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153475",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Antoine Eskander, MD, ScM",
      "presenter": "Antoine Eskander, MD, ScM",
      "authors": "Kara Jonas, BScN 1 ; Huaqi Li, MD, MPH 1 ; Christopher W Noel, MD, PhD 1 ; Sienna Nanji, MHA 2 ; Lavinia Tofan, MPH 2 ; Natalie Coburn, MD, MPH 3 ; Julie Hallet, MD, Msc 3 ; Lilian T Gien, MD, MSc 4 ; Monika Krzyzanowska, MD, MPH 5 ; Virginia Waring, MA 2 ; Madette Galapin, MSc 6 ; Pabiththa Kamalraj 7 ; Brian Wong, MD 8 ; Antoine Eskander, MD, ScM 9",
      "normalized_authors": [
        "Kara Jonas, BScN",
        "Huaqi Li",
        "Christopher W Noel",
        "Sienna Nanji, MHA",
        "Lavinia Tofan",
        "Natalie Coburn",
        "Julie Hallet",
        "Lilian T Gien",
        "Monika Krzyzanowska",
        "Virginia Waring, MA",
        "Madette Galapin",
        "Pabiththa Kamalraj",
        "Brian Wong",
        "Antoine Eskander, ScM"
      ],
      "affiliations": [
        "Temerty Faculty of Medicine, University of Toronto",
        "Odette Cancer Centre, Sunnybrook Health Sciences Centre",
        "Division of Surgery, Sunnybrook Health Sciences Centre",
        "Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre",
        "Division of Medical Oncology, Sunnybrook Health Sciences Centre",
        "Division of Radiation Therapy, Sunnybrook Health Sciences Centre",
        "Evaluative Clinical Sciences, Sunnybrook Research Institute",
        "Centre for Quality Improvement and Patient Safety, University of Toronto",
        "Division of Otolaryngology Head and Neck Surgery, Sunnybrook Health Sciences Centre"
      ],
      "normalized_institutions": [
        "Temerty Faculty of Medicine, University of Toronto",
        "Odette Cancer Centre, Sunnybrook Health Sciences Centre",
        "Division of Surgery, Sunnybrook Health Sciences Centre",
        "Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre",
        "Division of Medical Oncology, Sunnybrook Health Sciences Centre",
        "Division of Radiation Therapy, Sunnybrook Health Sciences Centre",
        "Evaluative Clinical Sciences, Sunnybrook Research Institute",
        "Centre for Quality Improvement and Patient Safety, University of Toronto",
        "Division of Otolaryngology Head and Neck Surgery, Sunnybrook Health Sciences Centre"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 394,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "Abstract",
        "METHODS",
        "RESULTS",
        "CONCLUSION"
      ],
      "sections": {
        "Authors": "Kara Jonas, BScN 1 ; Huaqi Li, MD, MPH 1 ; Christopher W Noel, MD, PhD 1 ; Sienna Nanji, MHA 2 ; Lavinia Tofan, MPH 2 ; Natalie Coburn, MD, MPH 3 ; Julie Hallet, MD, Msc 3 ; Lilian T Gien, MD, MSc 4 ; Monika Krzyzanowska, MD, MPH 5 ; Virginia Waring, MA 2 ; Madette Galapin, MSc 6 ; Pabiththa Kamalraj 7 ; Brian Wong, MD 8 ; Antoine Eskander, MD, ScM 9",
        "Affiliations": "1 Temerty Faculty of Medicine, University of Toronto; 2 Odette Cancer Centre, Sunnybrook Health Sciences Centre; 3 Division of Surgery, Sunnybrook Health Sciences Centre; 4 Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre; 5 Division of Medical Oncology, Sunnybrook Health Sciences Centre; 6 Division of Radiation Therapy, Sunnybrook Health Sciences Centre; 7 Evaluative Clinical Sciences, Sunnybrook Research Institute; 8 Centre for Quality Improvement and Patient Safety, University of Toronto; 9 Division of Otolaryngology Head and Neck Surgery, Sunnybrook Health Sciences Centre",
        "BACKGROUND": "Routine symptom screening using patient-reported outcome measures (PROMs) such as the Edmonton Symptom Assessment System (ESAS-r+) is recommended in head and neck (H&N) oncology, where patients experience some of the highest symptom burdens across cancer populations. Despite this, sustaining high completion rates in ambulatory settings remains a well-documented challenge. Following a marked post-pandemic decline in screening completion at a large regional cancer centre, this quality improvement (QI) initiative aimed to:",
        "Abstract": "1) Identify system-, staff-, and patient-level barriers contributing to low ESAS-r+ completion among H&N patients, and; 2) Implement and evaluate a clinic-level intervention to increase symptom screening uptake using paper-based ESAS-r+ forms. View in Agenda and Add to Schedule",
        "METHODS": "A comprehensive root cause analysis was conducted from 2023 to 2024 using stakeholder interviews, patient feedback, and direct observation, resulting in the creation of an Ishikawa diagram. Based on these findings, paper ESAS-r+ forms were reintroduced with a standardized workflow supported by unit clerks, volunteers, and clinic coordinators. After preliminary piloting in one non–H&N clinic to refine processes, the intervention was launched in the H&N Oncology clinic in January 2025. Monthly clinic-specific and centre-wide completion rates were monitored using run charts, with sequential PDSA cycles guiding iterative refinements. Measures included ESAS-r+ completion rates, fidelity of form distribution, and clinician follow-up on moderate-to-high symptom scores.",
        "RESULTS": "In the 12 months preceding the intervention, centre-wide symptom screening averaged 2.7% ± 0.9%, reflecting limited patient engagement post-pandemic. Following implementation in the H&N clinic, ESAS-r+ completion in the H&N population increased from approximately 3% to a peak of 51%, with a sustained post-intervention average of 41.3% ± 7.2% over 6 months. Unit clerk adherence to the “offer every patient” protocol averaged 71% across the first 7 weeks of the intervention. Clinicians documented follow-up for 52% of assessments containing moderate-to-high scores. Centre-wide rates increased modestly to 12.5% by April 2025. Data collection was constrained by reliance on volunteer support and inconsistent reporting periods.",
        "CONCLUSION": "Reintroducing paper-based ESAS-r+ screening, supported by standardized workflows and clearly defined team roles, produced substantial and sustained improvements in symptom screening completion in the H&N Oncology clinic. This low-cost, scalable approach may be particularly valuable for centres experiencing post-pandemic declines or technology-related barriers to PROM uptake. Future work includes centre-wide rollout, optimizing clinical follow-up pathways for high scores, and assessing impacts on patient experience and symptom outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Restoring patient-reported symptom screening in ambulatory head & neck oncology: A quality improvement project</span>. Kara Jonas, BScN<sup>1</sup>; Huaqi Li, MD, MPH<sup>1</sup>; Christopher W Noel, MD, PhD<sup>1</sup>; Sienna Nanji, MHA<sup>2</sup>; Lavinia Tofan, MPH<sup>2</sup>; Natalie Coburn, MD, MPH<sup>3</sup>; Julie Hallet, MD, Msc<sup>3</sup>; Lilian T Gien, MD, MSc<sup>4</sup>; Monika Krzyzanowska, MD, MPH<sup>5</sup>; Virginia Waring, MA<sup>2</sup>; Madette Galapin, MSc<sup>6</sup>; Pabiththa Kamalraj<sup>7</sup>; Brian Wong, MD<sup>8</sup>; <u>Antoine Eskander, MD, ScM</u><sup>9</sup>. <sup>1</sup>Temerty Faculty of Medicine, University of Toronto; <sup>2</sup>Odette Cancer Centre, Sunnybrook Health Sciences Centre; <sup>3</sup>Division of Surgery, Sunnybrook Health Sciences Centre; <sup>4</sup>Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre; <sup>5</sup>Division of Medical Oncology, Sunnybrook Health Sciences Centre; <sup>6</sup>Division of Radiation Therapy, Sunnybrook Health Sciences Centre; <sup>7</sup>Evaluative Clinical Sciences, Sunnybrook Research Institute; <sup>8</sup>Centre for Quality Improvement and Patient Safety, University of Toronto; <sup>9</sup>Division of Otolaryngology Head and Neck Surgery, Sunnybrook Health Sciences Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> Routine symptom screening using patient-reported outcome measures (PROMs) such as the Edmonton Symptom Assessment System (ESAS-r+) is recommended in head and neck (H&N) oncology, where patients experience some of the highest symptom burdens across cancer populations. Despite this, sustaining high completion rates in ambulatory settings remains a well-documented challenge. Following a marked post-pandemic decline in screening completion at a large regional cancer centre, this quality improvement (QI) initiative aimed to:</p>\n\n<p>1) Identify system-, staff-, and patient-level barriers contributing to low ESAS-r+ completion among H&N patients, and;<br />\n2) Implement and evaluate a clinic-level intervention to increase symptom screening uptake using paper-based ESAS-r+ forms.</p>\n\n<p><strong>METHODS:</strong> A comprehensive root cause analysis was conducted from 2023 to 2024 using stakeholder interviews, patient feedback, and direct observation, resulting in the creation of an Ishikawa diagram. Based on these findings, paper ESAS-r+ forms were reintroduced with a standardized workflow supported by unit clerks, volunteers, and clinic coordinators. After preliminary piloting in one non–H&N clinic to refine processes, the intervention was launched in the H&N Oncology clinic in January 2025. Monthly clinic-specific and centre-wide completion rates were monitored using run charts, with sequential PDSA cycles guiding iterative refinements. Measures included ESAS-r+ completion rates, fidelity of form distribution, and clinician follow-up on moderate-to-high symptom scores.</p>\n\n<p><strong>RESULTS:</strong> In the 12 months preceding the intervention, centre-wide symptom screening averaged 2.7% ± 0.9%, reflecting limited patient engagement post-pandemic. Following implementation in the H&N clinic,  ESAS-r+ completion in the H&N population increased from approximately 3% to a peak of 51%, with a sustained post-intervention average of 41.3% ± 7.2% over 6 months. Unit clerk adherence to the “offer every patient” protocol averaged 71% across the first 7 weeks of the intervention. Clinicians documented follow-up for 52% of assessments containing moderate-to-high scores. Centre-wide rates increased modestly to 12.5% by April 2025. Data collection was constrained by reliance on volunteer support and inconsistent reporting periods.</p>\n\n<p><strong>CONCLUSION:  </strong>Reintroducing paper-based ESAS-r+ screening, supported by standardized workflows and clearly defined team roles, produced substantial and sustained improvements in symptom screening completion in the H&N Oncology clinic. This low-cost, scalable approach may be particularly valuable for centres experiencing post-pandemic declines or technology-related barriers to PROM uptake. Future work includes centre-wide rollout, optimizing clinical follow-up pathways for high scores, and assessing impacts on patient experience and symptom outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153475--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S223",
      "content_id": "153106",
      "abstract_number": "S223",
      "poster_number": "",
      "title": "Feeding tube outcomes in patients undergoing mandibulectomy with free flap reconstruction",
      "summary": "One third of patients who had a NG tube placed during mandibulectomy with FF reconstruction ultimately required conversion to g-tube. Older age, lower BMI, larger tumor size, and stage N1 or N2c carried higher odds of conversion to g-tube. Surgeons might consider these variables in decisions about g-tube placement at the time of FF reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153106",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Megan McLeod, MD, MSc",
      "presenter": "Megan McLeod, MD, MSc",
      "authors": "Megan McLeod, MD, MSc 1 ; Madelyn Stevens, MD 2 ; Jean-Nicolas Gallant, MD, PhD 3 ; Andrea Lopez, MD 1 ; Lauren Sullivan 4 ; Alexander Langerman, MD 1 ; Kyle Mannion, MD 1 ; Eben Rosenthal, MD, PhD 1 ; Sarah Rohde, MD 1 ; Michael Topf, MD 1 ; Robert Sinard, MD 1",
      "normalized_authors": [
        "Megan McLeod",
        "Madelyn Stevens",
        "Jean-Nicolas Gallant",
        "Andrea Lopez",
        "Lauren Sullivan",
        "Alexander Langerman",
        "Kyle Mannion",
        "Eben Rosenthal",
        "Sarah Rohde",
        "Michael Topf",
        "Robert Sinard"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center",
        "University Hospitals Cleveland Medical Center",
        "Advent Health Medical Group",
        "Vanderbilt University School of Medicine"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center",
        "University Hospitals Cleveland Medical Center",
        "Advent Health Medical Group",
        "Vanderbilt University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 538,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Megan McLeod, MD, MSc 1 ; Madelyn Stevens, MD 2 ; Jean-Nicolas Gallant, MD, PhD 3 ; Andrea Lopez, MD 1 ; Lauren Sullivan 4 ; Alexander Langerman, MD 1 ; Kyle Mannion, MD 1 ; Eben Rosenthal, MD, PhD 1 ; Sarah Rohde, MD 1 ; Michael Topf, MD 1 ; Robert Sinard, MD 1",
        "Affiliations": "1 Vanderbilt University Medical Center; 2 University Hospitals Cleveland Medical Center; 3 Advent Health Medical Group; 4 Vanderbilt University School of Medicine",
        "Background": "Patients undergoing free flap (FF) reconstruction of an advanced oral cavity cancer typically require enteral access in the acute post-operative setting. It is difficult to predict how quickly patients will return to oral intake with need for long-term enteral nutrition reported as high as 25%. While risk factors such as prior radiation and poor pre-operative nutritional status might prompt consideration of gastrostomy tube (g-tube) placement either prior to or at the time of FF reconstruction, patient and surgical factors that predict which patients will require prolonged use of enteral nutrition (either via nasogastric (NG) or g-tube) after FF reconstruction are not well described.",
        "Objective": "This study aims to identify and quantify risk factors for persistent dysphagia requiring g-tube placement in patients undergoing segmental mandibulectomy with FF reconstruction.",
        "Methods": "This is a retrospective chart review of patients with squamous cell carcinoma of the oral cavity who underwent composite resection including segmental mandibulectomy with FF reconstruction between 1999-2020. Data on patient characteristics, operative interventions, and clinical outcomes including placement and removal of feeding tubes were collected. Patients were excluded if they had a g-tube in place preoperatively. Variables were compared between patients who had their feeding tube removed and those who required g-tube placement using univariate analyses followed by multivariate logistic regression to identify independent predictors of need for g-tube placement. Model discrimination was assessed by area under the ROC.",
        "Results": "A total of 345 patients were included. Most were male (n=223, 64.5%) with a median age of 65.8 years (56.0-74.2). Median follow-up time was 2.7 years (1.0-6.1). Gingiva (n=155, 44.9%) and floor of mouth (n=86, 24.9%) were the most common primary tumor subsites. A minority of patients had prior radiation (n=66, 20.0%). Reconstruction was most commonly via osteocutaneous radial forearm FF (n=142, 41.2%), fibula FF (n=106, 30.7%), or scapula FF (n=57, 16.5%).",
        "Abstract": "Most patients had a NG tube placed at the time of surgery (n=269, 78%) rather than a g-tube (n=76, 22%). Patients who received a g-tube at the time of surgery were more likely to have a lower BMI (p=0.002), have a primary tumor location in the floor of mouth or tongue (p=0.000), have a higher N stage (p=0.004), and have a planned fibula or scapula reconstruction (p=0.014). Over one third of patients who had a NG tube placed at the time of surgery required conversion to a g-tube (97/269, 36.1%). These patients were more likely to be older (OR 1.05, 1.01-1.07), have a lower BMI (OR 0.94, 0.89-0.99), have a larger greatest tumor size on final pathology (OR 1.3, 1.55-1.09), and have N1 (2.7, 1.1-6.75) or N2c (7.46, 1.81-31.25) nodal status. View in Agenda and Add to Schedule",
        "Conclusion": "One third of patients who had a NG tube placed during mandibulectomy with FF reconstruction ultimately required conversion to g-tube. Older age, lower BMI, larger tumor size, and stage N1 or N2c carried higher odds of conversion to g-tube. Surgeons might consider these variables in decisions about g-tube placement at the time of FF reconstruction."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Feeding tube outcomes in patients undergoing mandibulectomy with free flap reconstruction</span>. <u>Megan McLeod, MD, MSc</u><sup>1</sup>; Madelyn Stevens, MD<sup>2</sup>; Jean-Nicolas Gallant, MD, PhD<sup>3</sup>; Andrea Lopez, MD<sup>1</sup>; Lauren Sullivan<sup>4</sup>; Alexander Langerman, MD<sup>1</sup>; Kyle Mannion, MD<sup>1</sup>; Eben Rosenthal, MD, PhD<sup>1</sup>; Sarah Rohde, MD<sup>1</sup>; Michael Topf, MD<sup>1</sup>; Robert Sinard, MD<sup>1</sup>. <sup>1</sup>Vanderbilt University Medical Center; <sup>2</sup>University Hospitals Cleveland Medical Center; <sup>3</sup>Advent Health Medical Group; <sup>4</sup>Vanderbilt University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Patients undergoing free flap (FF) reconstruction of an advanced oral cavity cancer typically require enteral access in the acute post-operative setting. It is difficult to predict how quickly patients will return to oral intake with need for long-term enteral nutrition reported as high as 25%. While risk factors such as prior radiation and poor pre-operative nutritional status might prompt consideration of gastrostomy tube (g-tube) placement either prior to or at the time of FF reconstruction, patient and surgical factors that predict which patients will require prolonged use of enteral nutrition (either via nasogastric (NG) or g-tube) after FF reconstruction are not well described.</p>\n\n<p><strong>Objective:</strong> This study aims to identify and quantify risk factors for persistent dysphagia requiring g-tube placement in patients undergoing segmental mandibulectomy with FF reconstruction.</p>\n\n<p><strong>Methods:</strong> This is a retrospective chart review of patients with squamous cell carcinoma of the oral cavity who underwent composite resection including segmental mandibulectomy with FF reconstruction between 1999-2020. Data on patient characteristics, operative interventions, and clinical outcomes including placement and removal of feeding tubes were collected. Patients were excluded if they had a g-tube in place preoperatively. Variables were compared between patients who had their feeding tube removed and those who required g-tube placement using univariate analyses followed by multivariate logistic regression to identify independent predictors of need for g-tube placement. Model discrimination was assessed by area under the ROC.</p>\n\n<p><strong>Results:</strong> A total of 345 patients were included. Most were male (n=223, 64.5%) with a median age of 65.8 years (56.0-74.2). Median follow-up time was 2.7 years (1.0-6.1). Gingiva (n=155, 44.9%) and floor of mouth (n=86, 24.9%) were the most common primary tumor subsites. A minority of patients had prior radiation (n=66, 20.0%). Reconstruction was most commonly via osteocutaneous radial forearm FF (n=142, 41.2%), fibula FF (n=106, 30.7%), or scapula FF (n=57, 16.5%).</p>\n\n<p>Most patients had a NG tube placed at the time of surgery (n=269, 78%) rather than a g-tube (n=76, 22%). Patients who received a g-tube at the time of surgery were more likely to have a lower BMI (p=0.002), have a primary tumor location in the floor of mouth or tongue (p=0.000), have a higher N stage (p=0.004), and have a planned fibula or scapula reconstruction (p=0.014).</p>\n\n<p>Over one third of patients who had a NG tube placed at the time of surgery required conversion to a g-tube (97/269, 36.1%). These patients were more likely to be older (OR 1.05, 1.01-1.07), have a lower BMI (OR 0.94, 0.89-0.99), have a larger greatest tumor size on final pathology (OR 1.3, 1.55-1.09), and have N1 (2.7, 1.1-6.75) or N2c (7.46, 1.81-31.25) nodal status.</p>\n\n<p><strong>Conclusion:</strong> One third of patients who had a NG tube placed during mandibulectomy with FF reconstruction ultimately required conversion to g-tube. Older age, lower BMI, larger tumor size, and stage N1 or N2c carried higher odds of conversion to g-tube. Surgeons might consider these variables in decisions about g-tube placement at the time of FF reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153106--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S224",
      "content_id": "153092",
      "abstract_number": "S224",
      "poster_number": "",
      "title": "A Prospective Longitudinal Assessment of Quality of Life in Thyroid Cancer Patients Undergoing Conventional Open Total Thyroidectomy: A One-Year Follow-Up of HypoCal Study.",
      "summary": "This study demonstrated that thyroid cancer patients undergoing conventional open total thyroidectomy had a good quality of life, which showed improvement steadily across all domains by 12 months following surgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153092",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shivakumar Thiagarajan, PROF",
      "presenter": "Shivakumar Thiagarajan, PROF",
      "authors": "Shivakumar Thiagarajan, PROF ; Nikita Jadhav; Pratik Kadam; Rukmini Prabhu, Dr; Anuja Deshmukh, PROF; Deepa Nair, PROF; Chandrashekar Dravid, PROF; Gouri Pantvaidya, PROF",
      "normalized_authors": [
        "Shivakumar Thiagarajan, PROF",
        "Nikita Jadhav",
        "Pratik Kadam",
        "Rukmini Prabhu, Dr",
        "Anuja Deshmukh, PROF",
        "Deepa Nair, PROF",
        "Chandrashekar Dravid, PROF",
        "Gouri Pantvaidya, PROF"
      ],
      "affiliations": [
        "Tata Memorial Centre"
      ],
      "normalized_institutions": [
        "Tata Memorial Centre"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 336,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methodology",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shivakumar Thiagarajan, PROF ; Nikita Jadhav; Pratik Kadam; Rukmini Prabhu, Dr; Anuja Deshmukh, PROF; Deepa Nair, PROF; Chandrashekar Dravid, PROF; Gouri Pantvaidya, PROF",
        "Affiliations": "Tata Memorial Centre",
        "Background": "In our previous work, we reported the cross-sectional quality of life (QoL) of differentiated thyroid cancer patients at various time points after surgery using a thyroid cancer–specific questionnaire. However, longitudinal data on QoL during the first postoperative year remain limited, with few studies employing thyroid cancer–specific instruments. In this study, we present the longitudinal QoL outcomes of thyroid cancer patients over 12 months following total thyroidectomy.",
        "Methodology": "This was a prospective observational study (CTRI/2020/12/030092) conducted between March 2022 and October 2025, with a one-year follow-up. All patients diagnosed with thyroid cancer and who underwent total thyroidectomy, with or without neck dissection as per tumour board recommendations, were included. QoL was assessed using the EORTC QLQ-30 and EORTC Thyroid Cancer–Specific Questionnaire (THY-34) at baseline, 1–2 months, 5–7 months, and after 12 months postoperatively. The primary objective was to evaluate changes in QoL across these time points and identify factors influencing patient-reported outcomes.",
        "Results": "A total of 353 patients were enrolled, of whom 336 were included in the final analysis. All underwent conventional open total thyroidectomy with or without neck dissection. The patient’s QoL trajectory revealed that the scores across all function domains and the symptom domain improved significantly over time compared to baseline. Psychosocial domains such as Fear, worry about important others, impact on job/education, and reliance on social support were highest at baseline but declined significantly over 12 months. Postoperative hypocalcemia, use of calcium supplements, and age >55 years were the factors negatively affecting QoL domains. Previously, we had reported that 131 patients (38.8%) had parathyroid hormone (PTH) levels <10 pg/dl in the immediate postoperative period. At 12 months postoperatively, permanent hypoparathyroidism was seen in 25 (7.4%) of the patients. Many of these patients were on calcium supplements.",
        "Conclusions": "This study demonstrated that thyroid cancer patients undergoing conventional open total thyroidectomy had a good quality of life, which showed improvement steadily across all domains by 12 months following surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Prospective Longitudinal Assessment of Quality of Life in Thyroid Cancer Patients Undergoing Conventional Open Total Thyroidectomy: A One-Year Follow-Up of HypoCal Study.</span>. <u>Shivakumar Thiagarajan, PROF</u>; Nikita Jadhav; Pratik Kadam; Rukmini Prabhu, Dr; Anuja Deshmukh, PROF; Deepa Nair, PROF; Chandrashekar Dravid, PROF; Gouri Pantvaidya, PROF. Tata Memorial Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In our previous work, we reported the cross-sectional quality of life (QoL) of differentiated thyroid cancer patients at various time points after surgery using a thyroid cancer–specific questionnaire. However, longitudinal data on QoL during the first postoperative year remain limited, with few studies employing thyroid cancer–specific instruments. In this study, we present the longitudinal QoL outcomes of thyroid cancer patients over 12 months following total thyroidectomy.</p>\n\n<p><strong>Methodology: </strong>This was a prospective observational study (CTRI/2020/12/030092) conducted between March 2022 and October 2025, with a one-year follow-up. All patients diagnosed with thyroid cancer and who underwent total thyroidectomy, with or without neck dissection as per tumour board recommendations, were included. QoL was assessed using the EORTC QLQ-30 and EORTC Thyroid Cancer–Specific Questionnaire (THY-34) at baseline, 1–2 months, 5–7 months, and after 12 months postoperatively. The primary objective was to evaluate changes in QoL across these time points and identify factors influencing patient-reported outcomes.</p>\n\n<p><strong>Results: </strong>A total of 353 patients were enrolled, of whom 336 were included in the final analysis. All underwent conventional open total thyroidectomy with or without neck dissection. The patient’s QoL trajectory revealed that the scores across all function domains and the symptom domain improved significantly over time compared to baseline. Psychosocial domains such as Fear, worry about important others, impact on job/education, and reliance on social support were highest at baseline but declined significantly over 12 months. Postoperative hypocalcemia, use of calcium supplements, and age >55 years were the factors negatively affecting QoL domains. Previously, we had reported that 131 patients (38.8%) had parathyroid hormone (PTH) levels <10 pg/dl in the immediate postoperative period. At 12 months postoperatively, permanent hypoparathyroidism was seen in 25 (7.4%) of the patients. Many of these patients were on calcium supplements.</p>\n\n<p><strong>Conclusions: </strong>This study demonstrated that thyroid cancer patients undergoing conventional open total thyroidectomy had a good quality of life, which showed improvement steadily across all domains by 12 months following surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153092--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S225",
      "content_id": "154390",
      "abstract_number": "S225",
      "poster_number": "",
      "title": "Impact of Submandibular Gland Transfer on Time to Treatment and Patient Selection in Head and Neck Squamous Cell Carcinoma",
      "summary": "Submandibular gland (SMG) transfer is a surgical technique employed to preserve salivary function in patients undergoing treatment for head and neck squamous cell carcinoma (HNSCC). The impact of SMG transfer on time to treatment and associated patient characteristics remains incompletely characterized. We performed a retrospective cohort study of HNSCC patients treated at single-academic institution between 2008...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154390",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260131",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Hayden Guidry 2 ; Bryan Trieu 1 ; Johan Carrascoza-Bolanos 1 ; Alena Pauley 1 ; Michelle Tengarra 1 ; Bao Luu 1 ; Theresa Guo, MD 3",
      "normalized_authors": [
        "Vivian Vo",
        "Hayden Guidry",
        "Bryan Trieu",
        "Johan Carrascoza-Bolanos",
        "Alena Pauley",
        "Michelle Tengarra",
        "Bao Luu",
        "Theresa Guo"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, University of California Davis",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, University of California Davis",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Hayden Guidry 2 ; Bryan Trieu 1 ; Johan Carrascoza-Bolanos 1 ; Alena Pauley 1 ; Michelle Tengarra 1 ; Bao Luu 1 ; Theresa Guo, MD 3",
        "Affiliations": "1 UC San Diego School of Medicine; 2 Department of Otolaryngology-Head and Neck Surgery, University of California Davis; 3 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "Submandibular gland (SMG) transfer is a surgical technique employed to preserve salivary function in patients undergoing treatment for head and neck squamous cell carcinoma (HNSCC). The impact of SMG transfer on time to treatment and associated patient characteristics remains incompletely characterized. We performed a retrospective cohort study of HNSCC patients treated at single-academic institution between 2008 and 2023, comparing those who underwent SMG transfer to those who did not. Electronic health records were reviewed for demographic variables, clinical characteristics, time to treatment, and SMG-related complications. Among the 503 patients in our cohort, 62 underwent an SMG transfer and 441 did not receive an SMG transfer. Median follow up time was 4 years. There were no significant differences between SMG and No SMG groups with respect to age, gender, race, ethnicity, smoking history, alcohol history, or tumor site. In contrast, SMG status was significantly associated with tumor stage and human papilloma virus (HPV) status. Patients with SMG had earlier T stages and were more likely to have nodal involvement compared with No SMG patients (p < 0.001). Distant metastases were less frequent in SMG patients (0% vs 8.6%, p < 0.05). SMG tumors were also strongly enriched for p16 positivity (95.2% vs 71.2%, p < 0.001). Regarding treatment, SMG patients were less likely to undergo surgery alone and more likely to receive radiation with or without systemic therapy compared with No SMG patients (p <0.05). Across the entire cohort, patients who received an SMG transfer experienced a significantly longer time to treatment compared to those without transfer (median 54.5 vs. 42 days, p = 0.004). Of the 62 patients who underwent SMG transfer, six (9.7%) developed complications, including abscess or infection, fistula, duct obstruction, transient events, or other. In the unadjusted Kaplan-Meier analysis, the SMG group showed greater overall and disease-free survival (93% vs 80%; 82% vs 54%) compared with the No SMG group at 3 years. In the multivariable Cox regression controlling for age, T stage, N stage, HPV status, and race, SMG status remained independently associated with improved disease-free survival (HR 0.27, 95% CI 0.10-0.76, p = 0.010) and but not overall survival. Overall, these findings indicate that patients who elected for SMG transfer tended to be those with earlier-stage, HPV-associated cancer, reflecting deliberate patient selection for salivary gland preservation. SMG transfer was associated with a modest increase in time to treatment of 12 days but did not have inferior oncologic outcomes. In fact, patients receiving SMG transfer showed improved disease-free survival, likely contributed to by patient selection. The procedure demonstrated a low complication rate, without clinically significant delay to treatment, and serves as a safe and effective approach to preserve salivary function in selected HNSCC patients. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Submandibular Gland Transfer on Time to Treatment and Patient Selection in Head and Neck Squamous Cell Carcinoma</span>. <u>Vivian Vo</u><sup>1</sup>; Hayden Guidry<sup>2</sup>; Bryan Trieu<sup>1</sup>; Johan Carrascoza-Bolanos<sup>1</sup>; Alena Pauley<sup>1</sup>; Michelle Tengarra<sup>1</sup>; Bao Luu<sup>1</sup>; Theresa Guo, MD<sup>3</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, University of California Davis; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Submandibular gland (SMG) transfer is a surgical technique employed to preserve salivary function in patients undergoing treatment for head and neck squamous cell carcinoma (HNSCC). The impact of SMG transfer on time to treatment and associated patient characteristics remains incompletely characterized.</p>\n\n<p>We performed a retrospective cohort study of HNSCC patients treated at single-academic institution between 2008 and 2023, comparing those who underwent SMG transfer to those who did not. Electronic health records were reviewed for demographic variables, clinical characteristics, time to treatment, and SMG-related complications.</p>\n\n<p>Among the 503 patients in our cohort, 62 underwent an SMG transfer and 441 did not receive an SMG transfer. Median follow up time was 4 years. There were no significant differences between SMG and No SMG groups with respect to age, gender, race, ethnicity, smoking history, alcohol history, or tumor site. In contrast, SMG status was significantly associated with tumor stage and human papilloma virus (HPV) status. Patients with SMG had earlier T stages and were more likely to have nodal involvement compared with No SMG patients (p < 0.001). Distant metastases were less frequent in SMG patients (0% vs 8.6%, p < 0.05). SMG tumors were also strongly enriched for p16 positivity (95.2% vs 71.2%, p < 0.001). Regarding treatment, SMG patients were less likely to undergo surgery alone and more likely to receive radiation with or without systemic therapy compared with No SMG patients (p <0.05). Across the entire cohort, patients who received an SMG transfer experienced a significantly longer time to treatment compared to those without transfer (median 54.5 vs. 42 days, p = 0.004). Of the 62 patients who underwent SMG transfer, six (9.7%) developed complications, including abscess or infection, fistula, duct obstruction, transient events, or other. In the unadjusted Kaplan-Meier analysis, the SMG group showed greater overall and disease-free survival (93% vs 80%; 82% vs 54%) compared with the No SMG group at 3 years. In the multivariable Cox regression controlling for age, T stage, N stage, HPV status, and race, SMG status remained independently associated with improved disease-free survival (HR 0.27, 95% CI 0.10-0.76, p = 0.010) and but not overall survival.</p>\n\n<p>Overall, these findings indicate that patients who elected for SMG transfer tended to be those with earlier-stage, HPV-associated cancer, reflecting deliberate patient selection for salivary gland preservation. SMG transfer was associated with a modest increase in time to treatment of 12 days but did not have inferior oncologic outcomes.  In fact, patients receiving SMG transfer showed improved disease-free survival, likely contributed to by patient selection. The procedure demonstrated a low complication rate, without clinically significant delay to treatment, and serves as a safe and effective approach to preserve salivary function in selected HNSCC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154390--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260131' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S226",
      "content_id": "154545",
      "abstract_number": "S226",
      "poster_number": "",
      "title": "Oncologic Outcomes of Lobectomy for Papillary Thyroid Carcinomas Greater Than Four Centimeters: A Retrospective Cohort Analysis",
      "summary": "Current ATA Guidelines (1) recommend total thyroidectomy for patients with T3a PTCs. In this cohort of patients with PTC tumors >4 cm, a select subset without upfront adverse clinical features achieved oncologic control without total thyroidectomy and a significant majority of the completions did not confer additional disease control with removal of the remnant lobe. This supports a risk-based approach to large...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154545",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter W Larner, MD",
      "presenter": "Peter W Larner, MD",
      "authors": "Peter W Larner, MD ; Birk J Olson, MD; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH",
      "normalized_authors": [
        "Peter W Larner",
        "Birk J Olson",
        "Jacob Beiriger",
        "Larkin Harris",
        "Nilam D Patel",
        "Devaprabu Abraham",
        "Marcus M Monroe",
        "Jason P Hunt",
        "Richard B Cannon",
        "Sarah Drejet",
        "Luke O Buchmann",
        "Hilary C McCrary"
      ],
      "affiliations": [
        "University of Utah"
      ],
      "normalized_institutions": [
        "University of Utah"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 472,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Peter W Larner, MD ; Birk J Olson, MD; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH",
        "Affiliations": "University of Utah",
        "Background": "Unilateral papillary thyroid carcinoma (PTC) greater than four centimeters (cm) represent a subset that, in the absence of adverse pathologic features, are clinically staged as T3a and total thyroidectomy is recommended by current ATA guidelines. Although these tumors are considered locally advanced, the favorable natural history of PTC raises the possibility of achieving a gross total resection without removing the remaining unaffected lobe thereby sparing patients morbidity and risks from total thyroidectomy. To assess the oncologic safety of ipsilateral lobectomy alone for >4 cm PTC, we evaluated the clinical characteristics, pathologic risk factors, treatment patterns, and surveillance outcomes among patients these patients.",
        "Methods": "We retrospectively reviewed 716 patients with PTC in our institutional database, identifying 115 patients (16.1%) with final pathologic tumor size >4 cm. Patients were categorized by surgical management: lobectomy alone, completion thyroidectomy following initial lobectomy, or upfront total thyroidectomy (TT). Clinicopathologic features and surveillance outcomes were compared across groups.",
        "Results": "A majority of (93.9%) patients underwent total thyroidectomy, either as upfront surgery or after completion thyroidectomy. Multifocal disease was present in 44.1% of patients who underwent TT. Seven patients underwent lobectomy alone. Among lobectomy patients, none demonstrated multifocality or concern for distant metastases on presentation, and only one had extrathyroidal extension (14.3%). Thirteen patients underwent completion thyroidectomy after initial lobectomy. This group exhibited intermediate-risk pathology, with extrathyroidal extension in 9.1%, vascular invasion in 63.6%, positive margins in 46.2%, and nodal metastases in 66.7% of those with lymph nodes evaluated. The completion specimens were benign in 62%, contained microPTC (defined as <1 cm) in 23%, and residual tumor in 15%. Two patients (15.4%) developed nodal recurrence (both at 9 months), while 53.8% demonstrated no evidence of disease on surveillance imaging. Among patients with surveillance imaging, structural complete response was achieved in 77.8%.",
        "Abstract": "The upfront TT patients demonstrated substantially greater disease burden, with extrathyroidal extension in 52.2%, vascular invasion in 62.9%, positive margins in 53.8%, nodal metastases in 92.7%, and distant metastatic disease at presentation in 26.3%. Surveillance outcomes reflected the aggressive baseline pathology: 33.7% achieved no evidence of disease, while 4.2% experienced surgical bed recurrence, 9.5% nodal recurrence, and 14.7% persistent or progressive distant metastases. Structural complete response was achieved in 57.1% of patients with adequate follow-up data. (references separate) View in Agenda and Add to Schedule",
        "Conclusions": "Current ATA Guidelines (1) recommend total thyroidectomy for patients with T3a PTCs. In this cohort of patients with PTC tumors >4 cm, a select subset without upfront adverse clinical features achieved oncologic control without total thyroidectomy and a significant majority of the completions did not confer additional disease control with removal of the remnant lobe. This supports a risk-based approach to large PTC primaries, which, in select cases, may spare patients complete thyroid removal."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncologic Outcomes of Lobectomy for Papillary Thyroid Carcinomas Greater Than Four Centimeters: A Retrospective Cohort Analysis</span>. <u>Peter W Larner, MD</u>; Birk J Olson, MD; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH. University of Utah<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Unilateral papillary thyroid carcinoma (PTC) greater than four centimeters (cm) represent a subset that, in the absence of adverse pathologic features, are clinically staged as T3a and total thyroidectomy is recommended by current ATA guidelines. Although these tumors are considered locally advanced, the favorable natural history of PTC raises the possibility of achieving a gross total resection without removing the remaining unaffected lobe thereby sparing patients morbidity and risks from total thyroidectomy.  To assess the oncologic safety of ipsilateral lobectomy alone for >4 cm PTC, we evaluated the clinical characteristics, pathologic risk factors, treatment patterns, and surveillance outcomes among patients these patients.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed 716 patients with PTC in our institutional database, identifying 115 patients (16.1%) with final pathologic tumor size >4 cm. Patients were categorized by surgical management: lobectomy alone, completion thyroidectomy following initial lobectomy, or upfront total thyroidectomy (TT). Clinicopathologic features and surveillance outcomes were compared across groups.</p>\n\n<p><strong>Results: </strong>A majority of (93.9%) patients underwent total thyroidectomy, either as upfront surgery or after completion thyroidectomy. Multifocal disease was present in 44.1% of patients who underwent TT. Seven patients underwent lobectomy alone. Among lobectomy patients, none demonstrated multifocality or concern for distant metastases on presentation, and only one had extrathyroidal extension (14.3%). Thirteen patients underwent completion thyroidectomy after initial lobectomy. This group exhibited intermediate-risk pathology, with extrathyroidal extension in 9.1%, vascular invasion in 63.6%, positive margins in 46.2%, and nodal metastases in 66.7% of those with lymph nodes evaluated. The completion specimens were benign in 62%, contained microPTC (defined as <1 cm) in 23%, and residual tumor in 15%. Two patients (15.4%) developed nodal recurrence (both at 9 months), while 53.8% demonstrated no evidence of disease on surveillance imaging. Among patients with surveillance imaging, structural complete response was achieved in 77.8%.</p>\n\n<p>The upfront TT patients demonstrated substantially greater disease burden, with extrathyroidal extension in 52.2%, vascular invasion in 62.9%, positive margins in 53.8%, nodal metastases in 92.7%, and distant metastatic disease at presentation in 26.3%. Surveillance outcomes reflected the aggressive baseline pathology: 33.7% achieved no evidence of disease, while 4.2% experienced surgical bed recurrence, 9.5% nodal recurrence, and 14.7% persistent or progressive distant metastases. Structural complete response was achieved in 57.1% of patients with adequate follow-up data.</p>\n\n<p><strong>Conclusions: </strong>Current ATA Guidelines (1) recommend total thyroidectomy for patients with T3a PTCs. In this cohort of patients with PTC tumors >4 cm, a select subset without upfront adverse clinical features achieved oncologic control without total thyroidectomy and a significant majority of the completions did not confer additional disease control with removal of the remnant lobe. This supports a risk-based approach to large PTC primaries, which, in select cases, may spare patients complete thyroid removal.</p>\n\n<p>(references separate)</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154545--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S227",
      "content_id": "153451",
      "abstract_number": "S227",
      "poster_number": "",
      "title": "Incidence and Predictors of Hypothyroidism After Partial Thyroidectomy: A Population-Based Cohort Study",
      "summary": "Nearly half of euthyroid adults developed hypothyroidism within 2 years after hemithyroidectomy, with most cases diagnosed in the first postoperative year. Readily available preoperative factors. Particularly, TSH level, thyroid cancer and autoimmune diagnoses, sex, age, and cardiovascular comorbidity-help to identify patients at highest risk and support tailored counseling and long-term thyroid surveillance...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153451",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shmuel Wechsler, MD",
      "presenter": "Shmuel Wechsler, MD",
      "authors": "Shmuel Wechsler, MD 1 ; Tal Marom, MD 2 ; Bernice Oberman, MSc 3 ; Avital Fellner, MD 1 ; Yael Reichenberg 3 ; Limor Muallem Kalmovich, MD 4",
      "normalized_authors": [
        "Shmuel Wechsler",
        "Tal Marom",
        "Bernice Oberman",
        "Avital Fellner",
        "Yael Reichenberg",
        "Limor Muallem Kalmovich"
      ],
      "affiliations": [
        "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "4 Department of Otolaryngology-Head and Neck Surgery, Samson Ashdod University Hospital, Ashdod, Israel 5Faculty of Health Sciences, Ben -Gurion University of the Negev, Beer Sheva, Israel",
        "2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel",
        "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"
      ],
      "normalized_institutions": [
        "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "4 Department of Otolaryngology-Head and Neck Surgery, Samson Ashdod University Hospital, Ashdod, Israel 5Faculty of Health Sciences, Ben -Gurion University of the Negev, Beer Sheva, Israel",
        "2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel",
        "1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 368,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Materials and Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shmuel Wechsler, MD 1 ; Tal Marom, MD 2 ; Bernice Oberman, MSc 3 ; Avital Fellner, MD 1 ; Yael Reichenberg 3 ; Limor Muallem Kalmovich, MD 4",
        "Affiliations": "1 1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 2 4 Department of Otolaryngology-Head and Neck Surgery, Samson Ashdod University Hospital, Ashdod, Israel 5Faculty of Health Sciences, Ben -Gurion University of the Negev, Beer Sheva, Israel; 3 2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel; 4 1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "Objectives": "To determine the incidence and clinicodemographic predictors of hypothyroidism after hemithyroidectomy two years following surgery using a large population-based database.",
        "Materials and Methods": "We performed a retrospective cohort study of adults insured by a large representative national health maintenance organization who underwent hemithyroidectomy between 2003 and 2020 . All patients were followed for ≥2 years after surgery and all were euthyroid before surgery. Patients with prior thyroid/neck surgery, preoperative TSH >5.0 mIU/L, or preoperative thyroid hormone or Lugol treatment were excluded. Postoperative hypothyroidism was defined as either (1) TSH >5.0 mIU/L with low free T4 which were recorded ≥1 months after surgery, and/or (2) initiation of thyroid hormone replacement during follow up after surgery . Baseline demographics, comorbidities, thyroid diagnosis, and laboratory values were extracted for the pre-operative period (<30 days before surgery) and the post-operative period (2-24 months after surgery).",
        "Results": "Of the 12,831 operated patients, 8,467 met the inclusion criteria. Overall, 3,920 patients (46.3%) developed hypothyroidism within 2 years; 79% of cases were diagnosed during the first postoperative year. Most events (99.2%) were treated with thyroid hormone replacement therapy. Hypothyroidism was more frequent in females compared with males (47.3% vs 42.8%), and in patients < 60 years (all p<0.01). Pre-existing autoimmune thyroid disease and thyroid cancer were strongly associated with post-operative hypothyroidism. In multivariable models, independent predictors included female sex, hypertension, thyroid cancer, Hashimoto thyroiditis, Graves' disease and higher preoperative TSH (odds ratio [OR] 1.65 per 1 mIU/L), were associated with a higher post-operative hypothyroidism rate, whereas older age and diabetes were associated with lower risk (all p<0.05). Kaplan–Meier analysis demonstrated early divergence in cumulative incidence by age and sex, with significantly higher rates in patients <40 and 40–60 years compared with ≥60 years, and in females (log-rank p<0.001).",
        "Conclusion": "Nearly half of euthyroid adults developed hypothyroidism within 2 years after hemithyroidectomy, with most cases diagnosed in the first postoperative year. Readily available preoperative factors. Particularly, TSH level, thyroid cancer and autoimmune diagnoses, sex, age, and cardiovascular comorbidity-help to identify patients at highest risk and support tailored counseling and long-term thyroid surveillance after hemithyroidectomy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence and Predictors of Hypothyroidism After Partial Thyroidectomy: A Population-Based Cohort Study</span>. <u>Shmuel Wechsler, MD</u><sup>1</sup>; Tal Marom, MD<sup>2</sup>; Bernice Oberman, MSc<sup>3</sup>; Avital Fellner, MD<sup>1</sup>; Yael Reichenberg<sup>3</sup>; Limor Muallem Kalmovich, MD<sup>4</sup>. <sup>1</sup>1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel  2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel  3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; <sup>2</sup>4 Department of Otolaryngology-Head and Neck Surgery, Samson Ashdod University Hospital, Ashdod, Israel  5Faculty of Health Sciences, Ben -Gurion University of the Negev, Beer Sheva, Israel; <sup>3</sup>2Clalit Health Services, Dan Petah-Tikvha District, Ramat Gan, Israel; <sup>4</sup>1Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Center, Beer Yaakov, Israel 3 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> To determine the incidence and clinicodemographic predictors of hypothyroidism after hemithyroidectomy two years following surgery using a large population-based database.</p>\n\n<p><strong>Materials and Methods:</strong> We performed a retrospective cohort study of adults insured by a large representative  national health maintenance organization who underwent hemithyroidectomy between 2003 and 2020 . All patients were followed for ≥2 years after surgery and all were euthyroid before surgery. Patients with prior thyroid/neck surgery, preoperative TSH >5.0 mIU/L, or preoperative thyroid hormone or Lugol treatment were excluded. Postoperative hypothyroidism was defined as either (1) TSH >5.0 mIU/L with low free T4 which were recorded ≥1 months after surgery, and/or (2) initiation of thyroid hormone replacement during follow up after surgery . Baseline demographics, comorbidities, thyroid diagnosis, and laboratory values were extracted for the pre-operative period (<30 days before surgery) and the post-operative period (2-24 months after surgery).</p>\n\n<p><strong>Results:</strong> Of the 12,831 operated patients, 8,467 met the inclusion criteria. Overall, 3,920 patients (46.3%) developed hypothyroidism within 2 years; 79% of cases were diagnosed during the first postoperative year. Most events (99.2%) were treated with thyroid hormone replacement therapy. Hypothyroidism was more frequent in females compared with males (47.3% vs 42.8%), and in patients < 60 years (all p<0.01). Pre-existing autoimmune thyroid disease and thyroid cancer were strongly associated with post-operative hypothyroidism. In multivariable models, independent predictors included female sex, hypertension, thyroid cancer, Hashimoto thyroiditis, Graves' disease and higher preoperative TSH (odds ratio [OR] 1.65 per 1 mIU/L), were associated with a higher post-operative hypothyroidism rate, whereas older age and diabetes were associated with lower risk (all p<0.05). Kaplan–Meier analysis demonstrated early divergence in cumulative incidence by age and sex, with significantly higher rates in patients <40 and 40–60 years compared with ≥60 years, and in females (log-rank p<0.001).</p>\n\n<p><strong>Conclusion: </strong>Nearly half of euthyroid adults developed hypothyroidism within 2 years after hemithyroidectomy, with most cases diagnosed in the first postoperative year. Readily available preoperative factors. Particularly, TSH level, thyroid cancer and autoimmune diagnoses, sex, age, and cardiovascular comorbidity-help to identify patients at highest risk and support tailored counseling and long-term thyroid surveillance after hemithyroidectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153451--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S228",
      "content_id": "154254",
      "abstract_number": "S228",
      "poster_number": "",
      "title": "Mortality From Progressive Papillary Thyroid Carcinoma: A Multicenter Analysis of 268 Fatal Cases",
      "summary": "Fatal PTC predominantly affects older patients with locally advanced disease, vascular invasion, and lung metastases. Female sex confers survival advantage, while vascular invasion and multiple metastatic sites predict worse outcomes. Tyrosine kinase inhibitor therapy significantly extends survival in progressive disease, supporting its role in advanced PTC management.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154254",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ana K Leite, MD, PhD",
      "presenter": "Ana K Leite, MD, PhD",
      "authors": "Ana K Leite, MD, PhD 1 ; Fernanda Vaisman, MD, PhD 2 ; Ricardo Gama, MD 3 ; Juda Barcellos, MD 3 ; Renato Capuzzo, MD 3 ; Izabella Santos, MD 2 ; Luiza H Crispim, MD 1 ; Ana O Hoff, MD, PhD 1 ; Fernando L Dias, MD, PhD 2 ; Luiz P Kowalski, MD, PhD 1",
      "normalized_authors": [
        "Ana K Leite",
        "Fernanda Vaisman",
        "Ricardo Gama",
        "Juda Barcellos",
        "Renato Capuzzo",
        "Izabella Santos",
        "Luiza H Crispim",
        "Ana O Hoff",
        "Fernando L Dias",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",
        "Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil",
        "Barretos Cancer Hospital"
      ],
      "normalized_institutions": [
        "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",
        "Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil",
        "Barretos Cancer Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ana K Leite, MD, PhD 1 ; Fernanda Vaisman, MD, PhD 2 ; Ricardo Gama, MD 3 ; Juda Barcellos, MD 3 ; Renato Capuzzo, MD 3 ; Izabella Santos, MD 2 ; Luiza H Crispim, MD 1 ; Ana O Hoff, MD, PhD 1 ; Fernando L Dias, MD, PhD 2 ; Luiz P Kowalski, MD, PhD 1",
        "Affiliations": "1 Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; 2 Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil; 3 Barretos Cancer Hospital",
        "Background": "Although papillary thyroid carcinoma (PTC) typically exhibits indolent behavior with favorable outcomes, a minority of patients experience progressive metastatic disease leading to death. Given the rarity of PTC-related mortality, limited data exist regarding clinicopathologic characteristics and treatment outcomes in fatal cases.",
        "Objective": "To characterize clinical, pathological, and treatment features of patients who died from progressive PTC and identify prognostic factors associated with survival.",
        "Methods": "This multicenter retrospective study analyzed 268 patients diagnosed with PTC between 1981 and 2024 whose deaths were attributable to disease progression. Data collected included demographic characteristics, initial tumor features, treatment modalities, patterns of recurrence and metastasis, systemic therapies, and cause of death. Cox proportional hazards models were employed to identify factors associated with survival following diagnosis.",
        "Results": "Mean age at diagnosis was 60.0 years (SD 12.9), with 68.7% of patients older than 55 years. Women comprised 61.6% of the cohort. Locally advanced disease (T3b/T4) was present in 71.1% of cases. Classical PTC represented 61.4% of cases, follicular variant 25.2%, and aggressive histologic variants 18.3%. Vascular invasion occurred in 69.3%, gross extrathyroidal extension in 69.8%, and multifocality in 57.7%. Central and lateral neck dissections were performed in 51.7% and 35.0%, respectively, with microscopically incomplete resection in 75.0% of evaluable cases.",
        "Abstract": "Radioactive iodine therapy was administered to 80.1% of patients, with 80.9% developing refractory disease. Distant metastases developed in 81.7%, including 35.6% with synchronous presentation. Lung metastases occurred in 93.1%, bone in 53.4%, central nervous system in 15.5%, and liver in 5.5%, with 58.0% exhibiting multiple metastatic sites. Regional recurrence occurred in 59.6%. Systemic therapies included radiotherapy (38.8%), tyrosine kinase inhibitors (30.3%), metastasectomy (12.3%), and chemotherapy (8.6%). Respiratory failure from pulmonary metastatic burden caused 53.3% of deaths, while 7.3% resulted from central nervous system progression and 4.6% from postoperative complications. Metastatic disease accounted for 78% of deaths versus 22% from locoregional progression. Multivariable analysis identified female sex as protective (HR 0.56; 95% CI 0.37–0.85; p=0.006), while vascular invasion (HR 1.87; 95% CI 1.24–2.83; p=0.003) and multiple metastatic sites (HR 1.67; 95% CI 1.09–2.54; p=0.018) independently predicted shorter survival. Tyrosine kinase inhibitor therapy demonstrated significant survival benefit (median 101.5 versus 64.5 months; HR 0.69; 95% CI 0.53–0.89; p=0.005). View in Agenda and Add to Schedule",
        "Conclusion": "Fatal PTC predominantly affects older patients with locally advanced disease, vascular invasion, and lung metastases. Female sex confers survival advantage, while vascular invasion and multiple metastatic sites predict worse outcomes. Tyrosine kinase inhibitor therapy significantly extends survival in progressive disease, supporting its role in advanced PTC management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mortality From Progressive Papillary Thyroid Carcinoma: A Multicenter Analysis of 268 Fatal Cases</span>. <u>Ana K Leite, MD, PhD</u><sup>1</sup>; Fernanda Vaisman, MD, PhD<sup>2</sup>; Ricardo Gama, MD<sup>3</sup>; Juda Barcellos, MD<sup>3</sup>; Renato Capuzzo, MD<sup>3</sup>; Izabella Santos, MD<sup>2</sup>; Luiza H Crispim, MD<sup>1</sup>; Ana O Hoff, MD, PhD<sup>1</sup>; Fernando L Dias, MD, PhD<sup>2</sup>; Luiz P Kowalski, MD, PhD<sup>1</sup>. <sup>1</sup>Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; <sup>2</sup>Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil; <sup>3</sup>Barretos Cancer Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Although papillary thyroid carcinoma (PTC) typically exhibits indolent behavior with favorable outcomes, a minority of patients experience progressive metastatic disease leading to death. Given the rarity of PTC-related mortality, limited data exist regarding clinicopathologic characteristics and treatment outcomes in fatal cases.</p>\n\n<p><strong>Objective:</strong> To characterize clinical, pathological, and treatment features of patients who died from progressive PTC and identify prognostic factors associated with survival.</p>\n\n<p><strong>Methods:</strong> This multicenter retrospective study analyzed 268 patients diagnosed with PTC between 1981 and 2024 whose deaths were attributable to disease progression. Data collected included demographic characteristics, initial tumor features, treatment modalities, patterns of recurrence and metastasis, systemic therapies, and cause of death. Cox proportional hazards models were employed to identify factors associated with survival following diagnosis.</p>\n\n<p><strong>Results: </strong>Mean age at diagnosis was 60.0 years (SD 12.9), with 68.7% of patients older than 55 years. Women comprised 61.6% of the cohort. Locally advanced disease (T3b/T4) was present in 71.1% of cases. Classical PTC represented 61.4% of cases, follicular variant 25.2%, and aggressive histologic variants 18.3%. Vascular invasion occurred in 69.3%, gross extrathyroidal extension in 69.8%, and multifocality in 57.7%. Central and lateral neck dissections were performed in 51.7% and 35.0%, respectively, with microscopically incomplete resection in 75.0% of evaluable cases.</p>\n\n<p>Radioactive iodine therapy was administered to 80.1% of patients, with 80.9% developing refractory disease. Distant metastases developed in 81.7%, including 35.6% with synchronous presentation. Lung metastases occurred in 93.1%, bone in 53.4%, central nervous system in 15.5%, and liver in 5.5%, with 58.0% exhibiting multiple metastatic sites. Regional recurrence occurred in 59.6%. Systemic therapies included radiotherapy (38.8%), tyrosine kinase inhibitors (30.3%), metastasectomy (12.3%), and chemotherapy (8.6%).</p>\n\n<p>Respiratory failure from pulmonary metastatic burden caused 53.3% of deaths, while 7.3% resulted from central nervous system progression and 4.6% from postoperative complications. Metastatic disease accounted for 78% of deaths versus 22% from locoregional progression.</p>\n\n<p>Multivariable analysis identified female sex as protective (HR 0.56; 95% CI 0.37–0.85; p=0.006), while vascular invasion (HR 1.87; 95% CI 1.24–2.83; p=0.003) and multiple metastatic sites (HR 1.67; 95% CI 1.09–2.54; p=0.018) independently predicted shorter survival. Tyrosine kinase inhibitor therapy demonstrated significant survival benefit (median 101.5 versus 64.5 months; HR 0.69; 95% CI 0.53–0.89; p=0.005).</p>\n\n<p><strong>Conclusion: </strong>Fatal PTC predominantly affects older patients with locally advanced disease, vascular invasion, and lung metastases. Female sex confers survival advantage, while vascular invasion and multiple metastatic sites predict worse outcomes. Tyrosine kinase inhibitor therapy significantly extends survival in progressive disease, supporting its role in advanced PTC management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154254--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S229",
      "content_id": "155438",
      "abstract_number": "S229",
      "poster_number": "",
      "title": "Comparative Performance of 4D CT Localization Versus Miami Criteria in Primary Hyperparathyroidism",
      "summary": "While 4D CT provides high-quality preoperative localization, it cannot reliably exclude multigland disease. In settings without ioPTH availability, reliance on 4D CT alone achieves an expected cure rate of approximately 87%. Given that 11% of patients with unilateral localization harbor ipsilateral multigland disease, surgeons should routinely identify both glands on the localized side. ioPTH remains the superior...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155438",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christine R Burton, MD",
      "presenter": "Christine R Burton, MD",
      "authors": "Christine R Burton, MD 1 ; Aliya Hyman, BS 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1",
      "normalized_authors": [
        "Christine R Burton",
        "Aliya Hyman",
        "William J Magner",
        "Lynn Sigurdson",
        "Kimberly E Wooten",
        "Ryan P McSpadden",
        "Vishal Gupta"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 321,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Christine R Burton, MD 1 ; Aliya Hyman, BS 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Kimberly E Wooten, MD 1 ; Ryan P McSpadden, MD 1 ; Vishal Gupta, MD 1",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Background": "Intraoperative parathyroid hormone (ioPTH) monitoring is widely used during parathyroidectomy to confirm removal of all hypersecreting tissue, but it increases anesthesia time and is not universally available. With advances in 4D CT imaging, the necessity of routine ioPTH monitoring has been questioned. This study evaluates the accuracy of 4D CT in predicting unilateral and multigland disease in primary hyperparathyroidism (PHPT) and compares outcomes using 4D CT alone versus ioPTH-guided decision-making.",
        "Methods": "A retrospective cohort study was performed of 122 patients who underwent parathyroidectomy for PHPT between 2021 and 2023 after preoperative 4D CT imaging. CT findings and ioPTH responses were compared with operative and pathological outcomes. Clinical cure, persistent disease, and recurrence were assessed. Test characteristics were calculated for 4D CT and the Miami criteria.",
        "Results": "4D CT localized unilateral disease with 99% sensitivity and 92% positive predictive value; however, 11% of patients with unilateral localization had ipsilateral multigland disease. Bilateral disease was correctly identified with 82% sensitivity and 100% positive predictive value. Relying solely on 4D CT would have produced an estimated biochemical failure rate of 12.5%. In contrast, perfect adherence to ioPTH-based Miami criteria would yield an estimated 2% failure rate. The actual observed persistence rate in this cohort, where surgeons used both modalities selectively, was 5.6%. Four-dimensional CT identified ectopic glands in four cases and failed to localize disease in six cases, three of which were correctly interpreted by the operating surgeon.",
        "Conclusions": "While 4D CT provides high-quality preoperative localization, it cannot reliably exclude multigland disease. In settings without ioPTH availability, reliance on 4D CT alone achieves an expected cure rate of approximately 87%. Given that 11% of patients with unilateral localization harbor ipsilateral multigland disease, surgeons should routinely identify both glands on the localized side. ioPTH remains the superior tool for confirming cure and minimizing the likelihood of revision surgery. Future cost-effectiveness studies are warranted to optimize evidence-based standards of care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Performance of 4D CT Localization Versus Miami Criteria in Primary Hyperparathyroidism</span>. <u>Christine R Burton, MD</u><sup>1</sup>; Aliya Hyman, BS<sup>2</sup>; William J Magner, PhD<sup>1</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Kimberly E Wooten, MD<sup>1</sup>; Ryan P McSpadden, MD<sup>1</sup>; Vishal Gupta, MD<sup>1</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Intraoperative parathyroid hormone (ioPTH) monitoring is widely used during parathyroidectomy to confirm removal of all hypersecreting tissue, but it increases anesthesia time and is not universally available. With advances in 4D CT imaging, the necessity of routine ioPTH monitoring has been questioned. This study evaluates the accuracy of 4D CT in predicting unilateral and multigland disease in primary hyperparathyroidism (PHPT) and compares outcomes using 4D CT alone versus ioPTH-guided decision-making.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort study was performed of 122 patients who underwent parathyroidectomy for PHPT between 2021 and 2023 after preoperative 4D CT imaging. CT findings and ioPTH responses were compared with operative and pathological outcomes. Clinical cure, persistent disease, and recurrence were assessed. Test characteristics were calculated for 4D CT and the Miami criteria.</p>\n\n<p><strong>Results: </strong>4D CT localized unilateral disease with 99% sensitivity and 92% positive predictive value; however, 11% of patients with unilateral localization had ipsilateral multigland disease. Bilateral disease was correctly identified with 82% sensitivity and 100% positive predictive value. Relying solely on 4D CT would have produced an estimated biochemical failure rate of 12.5%. In contrast, perfect adherence to ioPTH-based Miami criteria would yield an estimated 2% failure rate. The actual observed persistence rate in this cohort, where surgeons used both modalities selectively, was 5.6%. Four-dimensional CT identified ectopic glands in four cases and failed to localize disease in six cases, three of which were correctly interpreted by the operating surgeon.</p>\n\n<p><strong>Conclusions:</strong> While 4D CT provides high-quality preoperative localization, it cannot reliably exclude multigland disease. In settings without ioPTH availability, reliance on 4D CT alone achieves an expected cure rate of approximately 87%. Given that 11% of patients with unilateral localization harbor ipsilateral multigland disease, surgeons should routinely identify both glands on the localized side. ioPTH remains the superior tool for confirming cure and minimizing the likelihood of revision surgery. Future cost-effectiveness studies are warranted to optimize evidence-based standards of care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155438--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S230",
      "content_id": "155574",
      "abstract_number": "S230",
      "poster_number": "",
      "title": "Intraoperative Molecular Characterization of Thyroid Tumors Using Real-Time Mass Spectrometry",
      "summary": "Understanding the tumor microenvironment is central to advance tumor immunology, as immune responses are shaped by the spatial and biochemical landscape of tumors and their surrounding stroma. In thyroid cancer, characterization of this complex microenvironment may reveal metabolic and immunoregulatory mechanisms that influence tumor progression. The MasSpec Pen (MS Pen Technologies Inc.Ô) is a real-time mass...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155574",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claudio R Cernea, MD, PhD",
      "presenter": "Claudio R Cernea, MD, PhD",
      "authors": "Gustavo Gonçalves-Silva, PhD 1 ; Claudio R Cernea, MD, PhD 2 ; André de Souza S Potenza, MD 2 ; Lívia S Eberlin 3 ; Kenneth J Gollob, PhD 1 ; Francisca K Pereira 1 ; Luiz G Cortes 1 ; Amanda B Figueiredo 1 ; Kenneth J Gollob, PhD 1 ; Carlos E Ferreira, MD, PhD 2",
      "normalized_authors": [
        "Gustavo Gonçalves-Silva",
        "Claudio R Cernea",
        "André de Souza S Potenza",
        "Lívia S Eberlin",
        "Kenneth J Gollob",
        "Francisca K Pereira",
        "Luiz G Cortes",
        "Amanda B Figueiredo",
        "Carlos E Ferreira"
      ],
      "affiliations": [
        "Albert Einstein Jewish Institute for Education and Research, St. Comendador Elias Jafet, 755, São Paulo-SP Brazil",
        "Einstein Jewish Hospital, Av. Padre Lebret - Morumbi, São Paulo, SP, Brazil",
        "Baylor College of Medicine, 1 Baylor Plz, Houston, TX 77030, The United States of America"
      ],
      "normalized_institutions": [
        "Albert Einstein Jewish Institute for Education and Research, St. Comendador Elias Jafet, 755, São Paulo-SP Brazil",
        "Einstein Jewish Hospital, Av. Padre Lebret - Morumbi, São Paulo, SP, Brazil",
        "Baylor College of Medicine, 1 Baylor Plz, Houston, TX 77030, The United States of America"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Keywords"
      ],
      "sections": {
        "Authors": "Gustavo Gonçalves-Silva, PhD 1 ; Claudio R Cernea, MD, PhD 2 ; André de Souza S Potenza, MD 2 ; Lívia S Eberlin 3 ; Kenneth J Gollob, PhD 1 ; Francisca K Pereira 1 ; Luiz G Cortes 1 ; Amanda B Figueiredo 1 ; Kenneth J Gollob, PhD 1 ; Carlos E Ferreira, MD, PhD 2",
        "Affiliations": "1 Albert Einstein Jewish Institute for Education and Research, St. Comendador Elias Jafet, 755, São Paulo-SP Brazil; 2 Einstein Jewish Hospital, Av. Padre Lebret - Morumbi, São Paulo, SP, Brazil; 3 Baylor College of Medicine, 1 Baylor Plz, Houston, TX 77030, The United States of America",
        "Abstract": "Understanding the tumor microenvironment is central to advance tumor immunology, as immune responses are shaped by the spatial and biochemical landscape of tumors and their surrounding stroma. In thyroid cancer, characterization of this complex microenvironment may reveal metabolic and immunoregulatory mechanisms that influence tumor progression. The MasSpec Pen (MS Pen Technologies Inc.Ô) is a real-time mass spectrometry device developed for rapid molecular analysis of biological tissues. It employs an aqueous extraction using a pen-shaped probe, enabling the collection of surface molecules while preserving tissue architecture and cellular organization. This pilot study represents the first application of MasSpec Pen technology in Brazil and evaluates its potential for intraoperative molecular characterization of thyroid tumors. Freshly excised thyroid specimens from 14 patients were analyzed at th operating room immediately after surgical removal, using real-time mass spectrometry to distinguish tumor regions from adjacent non-tumoral tissue and to explore region-specific molecular signatures associated with immune regulation. Molecular analyses were performed using an Orbitrap Exploris 120 mass spectrometer operating in full-scan mode (m/z 150–1800, 120,000 resolution, negative ion mode) coupled to the MasSpec Pen interface with a 5 mm pen tip. Sampling consisted of a five-second extraction followed by a ten-second aspiration step. Mass spectra were acquired in triplicate from both tumor and healthy tissue regions. It is important to emphasize that the total time required for the analysis of each reading (including the spectrometer analysis) was 15 seconds. Distinct molecular profiles were observed between tumor and non-tumoral tissues, including differential abundance of lipids and small metabolites. High mass accuracy enabled the identification of biologically relevant compounds such as ceramides, fatty acids, and phospholipids-molecules known to modulate immune cell recruitment, activation, and suppression within the tumor microenvironment. A consistent set of molecular features was repeatedly detected across thyroid tumor samples, suggesting the robustness of this approach for quick intraoperative tumor assessment. Papillary thyroid carcinoma, the most prevalent subtype, exhibited reproducible molecular signatures that clearly differentiated tumor from adjacent healthy tissue. These findings clearly demonstrate the potential of the MasSpec Pen for rapid ex-vivo biochemical mapping of the thyroid tumor microenvironment and highlight its potential as a tool for real-time intraoperative tissue characterization and tumor assessment. This study was funded by FAPESP (grant 2023/16341-3) and approved by the Research Ethics Committee of Einstein Israelite Hospital (CAAE: 77118923.0.0000.0071). View in Agenda and Add to Schedule",
        "Keywords": "Tumor Microenvironment, Mass Spectrometry, Thyroid Cancer, Molecular Profiling, Health Innovation, Intraoperative Diagnostics, Cancer Surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoperative Molecular Characterization of Thyroid Tumors Using Real-Time Mass Spectrometry</span>. Gustavo Gonçalves-Silva, PhD<sup>1</sup>; <u>Claudio R Cernea, MD, PhD</u><sup>2</sup>; André de Souza S Potenza, MD<sup>2</sup>; Lívia S Eberlin<sup>3</sup>; Kenneth J Gollob, PhD<sup>1</sup>; Francisca K Pereira<sup>1</sup>; Luiz G Cortes<sup>1</sup>; Amanda B Figueiredo<sup>1</sup>; Kenneth J Gollob, PhD<sup>1</sup>; Carlos E Ferreira, MD, PhD<sup>2</sup>. <sup>1</sup>Albert Einstein Jewish Institute for Education and Research, St. Comendador Elias Jafet, 755, São Paulo-SP Brazil; <sup>2</sup>Einstein Jewish Hospital, Av. Padre Lebret - Morumbi, São Paulo, SP, Brazil; <sup>3</sup>Baylor College of Medicine, 1 Baylor Plz, Houston, TX 77030, The United States of America<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Understanding the tumor microenvironment is central to advance tumor immunology, as immune responses are shaped by the spatial and biochemical landscape of tumors and their surrounding stroma. In thyroid cancer, characterization of this complex microenvironment may reveal metabolic and immunoregulatory mechanisms that influence tumor progression. The MasSpec Pen (MS Pen Technologies Inc.Ô) is a real-time mass spectrometry device developed for rapid molecular analysis of biological tissues. It employs an aqueous extraction using a pen-shaped probe, enabling the collection of surface molecules while preserving tissue architecture and cellular organization. This pilot study represents the first application of MasSpec Pen technology in Brazil and evaluates its potential for intraoperative molecular characterization of thyroid tumors. Freshly excised thyroid specimens from 14 patients were analyzed at th operating room immediately after surgical removal, using real-time mass spectrometry to distinguish tumor regions from adjacent non-tumoral tissue and to explore region-specific molecular signatures associated with immune regulation. Molecular analyses were performed using an Orbitrap Exploris 120 mass spectrometer operating in full-scan mode (m/z 150–1800, 120,000 resolution, negative ion mode) coupled to the MasSpec Pen interface with a 5 mm pen tip. Sampling consisted of a five-second extraction followed by a ten-second aspiration step. Mass spectra were acquired in triplicate from both tumor and healthy tissue regions. It is important to emphasize that the total time required for the analysis of each reading (including the spectrometer analysis) was 15 seconds. Distinct molecular profiles were observed between tumor and non-tumoral tissues, including differential abundance of lipids and small metabolites. High mass accuracy enabled the identification of biologically relevant compounds such as ceramides, fatty acids, and phospholipids-molecules known to modulate immune cell recruitment, activation, and suppression within the tumor microenvironment. A consistent set of molecular features was repeatedly detected across thyroid tumor samples, suggesting the robustness of this approach for quick intraoperative tumor assessment. Papillary thyroid carcinoma, the most prevalent subtype, exhibited reproducible molecular signatures that clearly differentiated tumor from adjacent healthy tissue. These findings clearly demonstrate the potential of the MasSpec Pen for rapid ex-vivo biochemical mapping of the thyroid tumor microenvironment and highlight its potential as a tool for real-time intraoperative tissue characterization and tumor assessment. This study was funded by FAPESP (grant 2023/16341-3) and approved by the Research Ethics Committee of Einstein Israelite Hospital (CAAE: 77118923.0.0000.0071).</p>\n\n<p><strong>Keywords:</strong> Tumor Microenvironment, Mass Spectrometry, Thyroid Cancer, Molecular Profiling, Health Innovation, Intraoperative Diagnostics, Cancer Surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155574--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S231",
      "content_id": "154703",
      "abstract_number": "S231",
      "poster_number": "",
      "title": "Completion Thyroidectomy Rates Following the American Thyroid Association (ATA) Guidelines 2015 in A Single Center.",
      "summary": "Our findings underscore the impact of implementing the updated 2015 ATA guidelines at a single institution. Following their incorporation, there was a significant reduction in completion thyroidectomy rates from 29% to 3% at our institution, which is significantly lower than the 25–40% rates reported across the literature. These findings suggest a dramatic reduction in the need for additional surgery, while...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154703",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jorge E Arpi Palacios, MD",
      "presenter": "Jorge E Arpi Palacios, MD",
      "authors": "Jorge E Arpi Palacios, MD ; Isabelle Fournier, MD; Eric Tran, MS; Rui Jennifer Wang, MD, PhD; Miriam N Lango, MD; Maria Kristine Gule-Monroe, MD; Michelle Williams, MD; Elizabeth Gardner Grubbs, MD; Naifa Busaidy, MD; Maria Cabanillas, MD; Luz E Castellanos, MD; Ramona Dadu, MD; Sarah Hamidi, MD; Mimi Hu, MD; Steven Waguespack, MD; Anastasios Maniakas, MD; Mark Zafereo, MD; Victoria E Banuchi, MD",
      "normalized_authors": [
        "Jorge E Arpi Palacios",
        "Isabelle Fournier",
        "Eric Tran",
        "Rui Jennifer Wang",
        "Miriam N Lango",
        "Maria Kristine Gule-Monroe",
        "Michelle Williams",
        "Elizabeth Gardner Grubbs",
        "Naifa Busaidy",
        "Maria Cabanillas",
        "Luz E Castellanos",
        "Ramona Dadu",
        "Sarah Hamidi",
        "Mimi Hu",
        "Steven Waguespack",
        "Anastasios Maniakas",
        "Mark Zafereo",
        "Victoria E Banuchi"
      ],
      "affiliations": [
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jorge E Arpi Palacios, MD ; Isabelle Fournier, MD; Eric Tran, MS; Rui Jennifer Wang, MD, PhD; Miriam N Lango, MD; Maria Kristine Gule-Monroe, MD; Michelle Williams, MD; Elizabeth Gardner Grubbs, MD; Naifa Busaidy, MD; Maria Cabanillas, MD; Luz E Castellanos, MD; Ramona Dadu, MD; Sarah Hamidi, MD; Mimi Hu, MD; Steven Waguespack, MD; Anastasios Maniakas, MD; Mark Zafereo, MD; Victoria E Banuchi, MD",
        "Affiliations": "MD Anderson Cancer Center",
        "Background": "With the ATA 2015 guideline changes, the landscape of thyroid cancer surgery has evolved substantially, reflecting a more refined approach in surgical decision-making. It is essential to understand the shifts in the approach to initial surgical management and its impact on completion thyroidectomy rates.",
        "Methods": "A retrospective review of patients with a diagnosis of DTC (n=929) that were treated with hemithyroidectomy between 2000-2023 at our institution was completed. December 2015 was used as the cutoff point to compare the outcomes between the two time periods (Cohort 1 before 11/2015 vs. Cohort 2 after 12/2015). We excluded patients whose initial surgical intervention was performed at an outside institution. The primary objective was to assess the rates of completion thyroidectomy following initial hemithyroidectomy. Our secondary objective was to determine the indications of completion thyroidectomy among both groups. Finally, we aimed to characterize the clinicopathologic features of patients among our groups.",
        "Results": "929 patients with DTC diagnosis (Papillary 84%; Follicular 6.6%; Hurthle cell carcinoma 4.8%) received hemithyroidectomy, of whom 140 (15%) subsequently required completion thyroidectomy. Among our Cohort 1, a total of 421 patients were initially treated with hemithyroidectomy; of those, 123 patients (29%) underwent completion thyroidectomy afterwards. Most common indications for completion thyroidectomy were histologic findings, including PTC follicular variant (n=46) and follicular carcinoma (n=39). Most cases presented multiple indications, including tumor size (n=38), capsular invasion (n=19), vascular invasion (n=28), extrathyroidal extension (n=15), and multifocality (n=7). 81 patients (66%) received radioactive iodine (RAI) therapy in this group. Following the ATA 2015 release, our Cohort 2 included 508 patients who underwent hemithyroidectomy, and 17 (3%) subsequently underwent completion thyroidectomy. Among patients’ tumors that underwent completion thyroidectomy, histology included Hürthle cell carcinoma (n=7), follicular thyroid carcinoma (n=4), conventional papillary thyroid carcinoma (PTC) (n=3), and follicular variant of PTC (n=1). Tumor size was greater than 4 cm in 11 patients (61%). Lymphovascular invasion was present in four cases, and multifocality in 4 cases (22%). Two PTCs were BRAF V600E–positive and measured greater than 4 cm. 11 patients (65%) in this cohort received radioactive iodine (RAI) therapy.",
        "Conclusion": "Our findings underscore the impact of implementing the updated 2015 ATA guidelines at a single institution. Following their incorporation, there was a significant reduction in completion thyroidectomy rates from 29% to 3% at our institution, which is significantly lower than the 25–40% rates reported across the literature. These findings suggest a dramatic reduction in the need for additional surgery, while simultaneously improving patient management and minimizing surgical risk.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Completion Thyroidectomy Rates Following the American Thyroid Association (ATA) Guidelines 2015 in A Single Center.</span>. <u>Jorge E Arpi Palacios, MD</u>; Isabelle Fournier, MD; Eric Tran, MS; Rui Jennifer Wang, MD, PhD; Miriam N Lango, MD; Maria Kristine Gule-Monroe, MD; Michelle Williams, MD; Elizabeth Gardner Grubbs, MD; Naifa Busaidy, MD; Maria Cabanillas, MD; Luz E Castellanos, MD; Ramona Dadu, MD; Sarah Hamidi, MD; Mimi Hu, MD; Steven Waguespack, MD; Anastasios Maniakas, MD; Mark Zafereo, MD; Victoria E Banuchi, MD. MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>With the ATA 2015 guideline changes, the landscape of thyroid cancer surgery has evolved substantially, reflecting a more refined approach in surgical decision-making. It is essential to understand the shifts in the approach to initial surgical management and its impact on completion thyroidectomy rates.</p>\n\n<p><strong>Methods: </strong>A retrospective review of patients with a diagnosis of DTC (n=929) that were treated with hemithyroidectomy between 2000-2023 at our institution was completed. December 2015 was used as the cutoff point to compare the outcomes between the two time periods (Cohort 1 before 11/2015 vs. Cohort 2 after 12/2015). We excluded patients whose initial surgical intervention was performed at an outside institution. The primary objective was to assess the rates of completion thyroidectomy following initial hemithyroidectomy. Our secondary objective was to determine the indications of completion thyroidectomy among both groups. Finally, we aimed to characterize the clinicopathologic features of patients among our groups.</p>\n\n<p><strong>Results:</strong> 929 patients with DTC diagnosis (Papillary 84%; Follicular 6.6%; Hurthle cell carcinoma 4.8%) received hemithyroidectomy, of whom 140 (15%) subsequently required completion thyroidectomy. Among our Cohort 1, a total of 421 patients were initially treated with hemithyroidectomy; of those, 123 patients (29%) underwent completion thyroidectomy afterwards. Most common indications for completion thyroidectomy were histologic findings, including PTC follicular variant (n=46) and follicular carcinoma (n=39). Most cases presented multiple indications, including tumor size (n=38), capsular invasion (n=19), vascular invasion (n=28), extrathyroidal extension (n=15), and multifocality (n=7). 81 patients (66%) received radioactive iodine (RAI) therapy in this group. Following the ATA 2015 release, our Cohort 2 included 508 patients who underwent hemithyroidectomy, and 17 (3%) subsequently underwent completion thyroidectomy. Among patients’ tumors that underwent completion thyroidectomy, histology included Hürthle cell carcinoma (n=7), follicular thyroid carcinoma (n=4), conventional papillary thyroid carcinoma (PTC) (n=3), and follicular variant of PTC (n=1). Tumor size was greater than 4 cm in 11 patients (61%). Lymphovascular invasion was present in four cases, and multifocality in 4 cases (22%). Two PTCs were BRAF V600E–positive and measured greater than 4 cm. 11 patients (65%) in this cohort received radioactive iodine (RAI) therapy.</p>\n\n<p><strong>Conclusion: </strong>Our findings underscore the impact of implementing the updated 2015 ATA guidelines at a single institution. Following their incorporation, there was a significant reduction in completion thyroidectomy rates from 29% to 3% at our institution, which is significantly lower than the 25–40% rates reported across the literature. These findings suggest a dramatic reduction in the need for additional surgery, while simultaneously improving patient management and minimizing surgical risk.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154703--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S232",
      "content_id": "154337",
      "abstract_number": "S232",
      "poster_number": "",
      "title": "Treatment and Survival Trends in Anaplastic Thyroid Carcinoma in the U.S.",
      "summary": "National treatment patterns for ATC have shifted toward increased use of systemic therapy and fewer upfront surgical interventions, coinciding with the introduction of targeted agents. Although improvements in outcome may be attributable to the introduction of effective systemic agents, the association between improved survival and radiation or surgery in both M0 and M1 disease suggests that locoregional control...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154337",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mateo Useche, MD, MPH",
      "presenter": "Mateo Useche, MD, MPH",
      "authors": "Mateo Useche, MD, MPH ; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Matthew Old, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MSCR; Emily Marchiano, MD",
      "normalized_authors": [
        "Mateo Useche",
        "Lauren Shih",
        "Cristina Rodriguez",
        "Jay J Liao",
        "Neil Panjwani",
        "Neal Futran",
        "Matthew Old",
        "Brittany Barber",
        "Rocco Ferrandino, MSCR",
        "Emily Marchiano"
      ],
      "affiliations": [
        "University of Washington"
      ],
      "normalized_institutions": [
        "University of Washington"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 429,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mateo Useche, MD, MPH ; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Matthew Old, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MSCR; Emily Marchiano, MD",
        "Affiliations": "University of Washington",
        "Introduction": "Anaplastic thyroid carcinoma (ATC) remains one of the most aggressive malignancies with poor survival. The introduction of targeted therapies and broader molecular profiling in 2018 has altered the therapeutic landscape with shifts in surgical practices and multimodal approaches. Whether these changes have translated into meaningful population-level survival gains remains an area of study.",
        "Methods": "We analyzed ATC cases from the National Cancer Database (2004–2022). Year-specific OS at 1, 2, and 3 years was calculated using Kaplan–Meier methods. Linear trend modeling and annual percent change (APC) quantified survival shifts over time. Treatment patterns (surgery, radiation, systemic therapy) were examined longitudinally. Cox regression evaluated factors associated with survival among metastatic and non-metastatic patients, adjusting for demographic, comorbidity, treatment, and pathologic variables.",
        "Results": "Among 5,092 ATC patients, systemic therapy use increased annually (APC +1.63%), while surgical management declined (APC –0.78% per year). Year-specific overall survival (OS) showed consistent improvement, with a significant rise in 1-year OS (APC +3.3%, 95% CI 2.2–4.5%, p<0.001) and similar positive trends at 2 and 3 years. Survival increased sharply after 2018, with mean 1-year OS rising to 31.1% compared with 19.7% in years prior. Surgery was performed more frequently in M0 patients compared with M1 patients (58% vs 31.7%, p<0.001). Patients with metastatic disease were significantly less likely to undergo surgery (OR 0.34, 95% CI 0.30–0.38), with an absolute reduction of 27.9% in surgical utilization (95% CI –29.1% to –23.5%, p<0.001). In the M0 subgroup (n=2,626), surgery was associated with higher 1-, 2-, and 3-year OS (42%, 28.8%, 24.5%) compared with non-surgical management (17.7%, 11.7%, 8.7%). In the M1 subgroup (n=2128), surgery was associated with higher 1-, 2-, and 3-year OS (20.9%, 12.4%, 11%) compared with non-surgical management (7.9%, 3.6%, 2.5%). Multivariable analysis confirmed surgery as independent predictor of better survival in both M0 (HR 0.59, 95% CI 0.51–0.67) and M1 (HR 0.55, 95% CI 0.48–0.64).",
        "Conclusion": "National treatment patterns for ATC have shifted toward increased use of systemic therapy and fewer upfront surgical interventions, coinciding with the introduction of targeted agents. Although improvements in outcome may be attributable to the introduction of effective systemic agents, the association between improved survival and radiation or surgery in both M0 and M1 disease suggests that locoregional control remains a critical therapeutic goal impacting outcomes in this poor risk population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Treatment and Survival Trends in Anaplastic Thyroid Carcinoma in the U.S.</span>. <u>Mateo Useche, MD, MPH</u>; Lauren Shih, MD; Cristina Rodriguez, MD; Jay J Liao, MD; Neil Panjwani, MD; Neal Futran, DMD; Matthew Old, MD; Brittany Barber, MD, MSc; Rocco Ferrandino, MD, MSCR; Emily Marchiano, MD. University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Anaplastic thyroid carcinoma (ATC) remains one of the most aggressive malignancies with poor survival. The introduction of targeted therapies and broader molecular profiling in 2018 has altered the therapeutic landscape with shifts in surgical practices and multimodal approaches. Whether these changes have translated into meaningful population-level survival gains remains an area of study.</p>\n\n<p><strong>Methods: </strong>We analyzed ATC cases from the National Cancer Database (2004–2022). Year-specific OS at 1, 2, and 3 years was calculated using Kaplan–Meier methods. Linear trend modeling and annual percent change (APC) quantified survival shifts over time. Treatment patterns (surgery, radiation, systemic therapy) were examined longitudinally. Cox regression evaluated factors associated with survival among metastatic and non-metastatic patients, adjusting for demographic, comorbidity, treatment, and pathologic variables.</p>\n\n<p><strong>Results: </strong>Among 5,092 ATC patients, systemic therapy use increased annually (APC +1.63%), while surgical management declined (APC –0.78% per year). Year-specific overall survival (OS) showed consistent improvement, with a significant rise in 1-year OS (APC +3.3%, 95% CI 2.2–4.5%, p<0.001) and similar positive trends at 2 and 3 years. Survival increased sharply after 2018, with mean 1-year OS rising to 31.1% compared with 19.7% in years prior. Surgery was performed more frequently in M0 patients compared with M1 patients (58% vs 31.7%, p<0.001). Patients with metastatic disease were significantly less likely to undergo surgery (OR 0.34, 95% CI 0.30–0.38), with an absolute reduction of 27.9% in surgical utilization (95% CI –29.1% to –23.5%, p<0.001). In the M0 subgroup (n=2,626), surgery was associated with higher 1-, 2-, and 3-year OS (42%, 28.8%, 24.5%) compared with non-surgical management (17.7%, 11.7%, 8.7%). In the M1 subgroup (n=2128), surgery was associated with higher 1-, 2-, and 3-year OS (20.9%, 12.4%, 11%) compared with non-surgical management (7.9%, 3.6%, 2.5%). Multivariable analysis confirmed surgery as independent predictor of better survival in both M0 (HR 0.59, 95% CI 0.51–0.67) and M1 (HR 0.55, 95% CI 0.48–0.64).</p>\n\n<p><strong>Conclusion: </strong>National treatment patterns for ATC have shifted toward increased use of systemic therapy and fewer upfront surgical interventions, coinciding with the introduction of targeted agents. Although improvements in outcome may be attributable to the introduction of effective systemic agents, the association between improved survival and radiation or surgery in both M0 and M1 disease suggests that locoregional control remains a critical therapeutic goal impacting outcomes in this poor risk population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154337--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S233",
      "content_id": "154586",
      "abstract_number": "S233",
      "poster_number": "",
      "title": "Extranodal Extension Reporting and Oncologic Outcomes in Differentiated Thyroid Cancer",
      "summary": "Despite ENE negatively impacting LRRFS on multivariate analysis, there was no impact on LRRFS, DSS or OS in a propensity matching analysis. The consistent rates of 5-year DSS over the past 4 decades, despite increased ENE reporting, support this conclusion.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154586",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma Finnegan",
      "presenter": "Emma Finnegan",
      "authors": "Emma Finnegan 1 ; Hadar Gez Reder, MD 1 ; Daniel W Scholfield, MB, ChB 1 ; Ronald Ghossein, MD 2 ; Michael R Tuttle, MD 3 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
      "normalized_authors": [
        "Emma Finnegan",
        "Hadar Gez Reder",
        "Daniel W Scholfield, MB, ChB",
        "Ronald Ghossein",
        "Michael R Tuttle",
        "Snehal G Patel",
        "Ian Ganly"
      ],
      "affiliations": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"
      ],
      "normalized_institutions": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
        "Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 391,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emma Finnegan 1 ; Hadar Gez Reder, MD 1 ; Daniel W Scholfield, MB, ChB 1 ; Ronald Ghossein, MD 2 ; Michael R Tuttle, MD 3 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
        "Affiliations": "1 Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3 Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Introduction": "Extranodal extension (ENE) is well recognized as an important marker of aggressive tumor biology in mucosal squamous cell carcinoma. The American Thyroid Association (ATA) classifies ENE as a key adverse prognostic factor, recommending its inclusion in risk stratification and pathology reporting for differentiated thyroid cancer (DTC). The ATA guidelines categorize patients as high risk based solely on ENE presence. Its association with poor prognosis in DTC was not well established until recently. Over the past decade, the reported frequency of ENE in node-positive DTC has risen markedly. We propose that this trend represents enhanced pathological recognition and reporting rather than an actual rise in incidence, largely attributable to increased identification of ENE by pathologists.",
        "Methods": "A retrospective review of 8,559 patients with DTC treated at a tertiary cancer center from 1985-2020 was performed. Rates of 5-year DSS were plotted against rates of ENE reporting during this time period. From this, a time cut-off of ENE reporting > 95% was chosen to include patients for further analysis. Further analysis was performed comparing outcomes between patients with and without ENE in this cohort. Oncologic outcomes, including locoregional recurrence-free survival (LRRFS), disease-specific survival (DSS) and overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Propensity score matching was performed to balance clinicopathological variables between patients reported as having ENE and those with no ENE.",
        "Results": "From 1985 to 2020, 5-year DSS rates remained consistent from 96-100%, while ENE reporting rates increased significantly from 10% during 1985-1989, to 97% in 2005-2009. Due to sufficient reporting rates, a cutoff of 2005 was used to select patients for further analysis. Between 2005-2020, 2,272 patients were included of which 573 had ENE and 1,699 had no ENE. Patients with ENE, had poorer LRRFS, DSS and OS (p < 0.0001, p < 0.0001 and p = 0.006) on Kaplan Meier analysis. On multivariate analysis, ENE was significant for LRRFS alone (HR 1.49; 95% CI 1.07-2.08; p = 0.018). However, after propensity score matching, patients with ENE had similar LRRFS, DSS and OS to patients with no ENE.",
        "Conclusion": "Despite ENE negatively impacting LRRFS on multivariate analysis, there was no impact on LRRFS, DSS or OS in a propensity matching analysis. The consistent rates of 5-year DSS over the past 4 decades, despite increased ENE reporting, support this conclusion.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Extranodal Extension Reporting and Oncologic Outcomes in Differentiated Thyroid Cancer</span>. <u>Emma Finnegan</u><sup>1</sup>; Hadar Gez Reder, MD<sup>1</sup>; Daniel W Scholfield, MB, ChB<sup>1</sup>; Ronald Ghossein, MD<sup>2</sup>; Michael R Tuttle, MD<sup>3</sup>; Snehal G Patel, MD<sup>1</sup>; Ian Ganly, MD, PhD<sup>1</sup>. <sup>1</sup>Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Extranodal extension (ENE) is well recognized as an important marker of aggressive tumor biology in mucosal squamous cell carcinoma. The American Thyroid Association (ATA) classifies ENE as a key adverse prognostic factor, recommending its inclusion in risk stratification and pathology reporting for differentiated thyroid cancer (DTC). The ATA guidelines categorize patients as high risk based solely on ENE presence. Its association with poor prognosis in DTC was not well established until recently. Over the past decade, the reported frequency of ENE in node-positive DTC has risen markedly. We propose that this trend represents enhanced pathological recognition and reporting rather than an actual rise in incidence, largely attributable to increased identification of ENE by pathologists.</p>\n\n<p><strong>Methods: </strong>A retrospective review of 8,559 patients with DTC treated at a tertiary cancer center from 1985-2020 was performed. Rates of 5-year DSS were plotted against rates of ENE reporting during this time period. From this, a time cut-off of ENE reporting > 95% was chosen to include patients for further analysis. Further analysis was performed comparing outcomes between patients with and without ENE in this cohort. Oncologic outcomes, including locoregional recurrence-free survival (LRRFS), disease-specific survival (DSS) and overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Propensity score matching was performed to balance clinicopathological variables between patients reported as having ENE and those with no ENE.</p>\n\n<p><strong>Results:</strong> From 1985 to 2020, 5-year DSS rates remained consistent from 96-100%, while ENE reporting rates increased significantly from 10% during 1985-1989, to 97% in 2005-2009. Due to sufficient reporting rates, a cutoff of 2005 was used to select patients for further analysis. Between 2005-2020, 2,272 patients were included of which 573 had ENE and 1,699 had no ENE. Patients with ENE, had poorer LRRFS, DSS and OS (p < 0.0001, p < 0.0001 and p = 0.006) on Kaplan Meier analysis. On multivariate analysis, ENE was significant for LRRFS alone (HR 1.49; 95% CI 1.07-2.08; p = 0.018). However, after propensity score matching, patients with ENE had similar LRRFS, DSS and OS to patients with no ENE.  </p>\n\n<p><strong>Conclusion:</strong> Despite ENE negatively impacting LRRFS on multivariate analysis, there was no impact on LRRFS, DSS or OS in a propensity matching analysis. The consistent rates of 5-year DSS over the past 4 decades, despite increased ENE reporting, support this conclusion.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154586--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S234",
      "content_id": "154172",
      "abstract_number": "S234",
      "poster_number": "",
      "title": "Outcomes of Partial Layer Resection in Patients with Recurrent Laryngeal Nerve Involvement in Cases of Differentiated Thyroid Cancer: A Comprehensive Analysis",
      "summary": "PLR is associated with favourable vocal outcomes and good local control rate in patients. Our findings state the importance of PLR in improving patients' quality of life with thyroid malignancies. Further studies with larger cohorts are warranted to validate these findings and refine surgical techniques for optimal patient outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154172",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mudit Agarwal, MS",
      "presenter": "Mudit Agarwal, MS",
      "authors": "Mudit Agarwal, MS",
      "normalized_authors": [
        "Mudit Agarwal"
      ],
      "affiliations": [
        "Rajiv Gandhi Cancer Institute & Research Centre"
      ],
      "normalized_institutions": [
        "Rajiv Gandhi Cancer Institute & Research Centre"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 274,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mudit Agarwal, MS",
        "Affiliations": "Rajiv Gandhi Cancer Institute & Research Centre",
        "Background": "Recurrent laryngeal nerve (RLN) involvement poses significant challenges in head and neck surgery, impacting vocal cord function and patient quality of life. Partial Layer Resection (PLR) has emerged as a promising surgical intervention; however, comprehensive outcome data remain limited.",
        "Methods": "A retrospective analysis was conducted on 18 patients who underwent PLR for RLN between January 2020 and December 2024. Patient demographics, tumour characteristics, postoperative vocal cord mobility assessed via laryngoscopy, subjective voice quality evaluated through validated questionnaires, maximum phonation time (MPT), and recurrence rates were evaluated. Data was collected from surgical records, imaging studies, and follow-up assessments to ensure comprehensive and objective outcome measurement.",
        "Results": "The cohort included 10 males and 8 females, with a diverse range of thyroid cancer histologies: 12 papillary (67%), four follicular (22%), one medullary (5.5%), and one high-grade differentiated (5.5%). All patients had preoperative mobile vocal cords, of whom 75% had bilateral vocal cord mobility post-surgery. Postoperatively, 10 patients (56%) showed subjective voice quality similar to preoperative status. The average MPT was 15 seconds at 6 months. Recurrence rates indicated no local recurrence at the site, and 3 (17%) patients recurred in lateral neck nodes. The median follow-up for the entire cohort was 2.23 years, and the median disease-free survival was not reached. The estimated 3- and 5-year DFS were both 83%.",
        "Conclusions": "PLR is associated with favourable vocal outcomes and good local control rate in patients. Our findings state the importance of PLR in improving patients' quality of life with thyroid malignancies. Further studies with larger cohorts are warranted to validate these findings and refine surgical techniques for optimal patient outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes of Partial Layer Resection in Patients with Recurrent Laryngeal Nerve Involvement  in Cases of Differentiated Thyroid Cancer: A Comprehensive Analysis</span>. <u>Mudit Agarwal, MS</u>. Rajiv Gandhi Cancer Institute & Research Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Recurrent laryngeal nerve  (RLN) involvement poses significant challenges in head and neck surgery, impacting vocal cord function and patient quality of life. Partial Layer Resection (PLR) has emerged as a promising surgical intervention; however, comprehensive outcome data remain limited.</p>\n\n<p><strong>Methods:</strong> A retrospective analysis was conducted on 18 patients who underwent PLR for RLN between January 2020 and December 2024. Patient demographics, tumour characteristics, postoperative vocal cord mobility assessed via laryngoscopy, subjective voice quality evaluated through validated questionnaires, maximum phonation time (MPT), and recurrence rates were evaluated. Data was collected from surgical records, imaging studies, and follow-up assessments to ensure comprehensive and objective outcome measurement.</p>\n\n<p><strong>Results: </strong>The cohort included 10 males and 8 females, with a diverse range of thyroid cancer histologies: 12 papillary (67%), four follicular (22%), one medullary (5.5%), and one high-grade differentiated (5.5%). All patients had preoperative mobile vocal cords, of whom 75% had bilateral vocal cord mobility post-surgery. Postoperatively, 10 patients (56%) showed subjective voice quality similar to preoperative status. The average MPT was 15 seconds at 6 months. Recurrence rates indicated no local recurrence at the site, and 3 (17%) patients recurred in lateral neck nodes. The median follow-up for the entire cohort was 2.23 years, and the median disease-free survival was not reached. The estimated 3- and 5-year DFS were both 83%.</p>\n\n<p><strong>Conclusions:</strong> PLR is associated with favourable vocal outcomes and good local control rate in patients. Our findings state the importance of PLR in improving patients' quality of life with thyroid malignancies. Further studies with larger cohorts are warranted to validate these findings and refine surgical techniques for optimal patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154172--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S235",
      "content_id": "155370",
      "abstract_number": "S235",
      "poster_number": "",
      "title": "Cost-Utility of Total Thyroidectomy Versus Hemithyroidectomy in Molecularly Stratified T1-2 cN0 Papillary Thyroid Carcinoma",
      "summary": "TT was not cost-effective versus HT across BRAF+/TERT+ subgroups of T1-T2 cN0 papillary thyroid carcinoma. Clinically substantial DFS-failure reduction (~6%) is required before escalation becomes economically favourable. Shared decision-making should integrate patient risk tolerance, quality-of-life trajectory, and the magnitude of benefit required to justify escalation in patient care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155370",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma A Finnegan",
      "presenter": "Emma A Finnegan",
      "authors": "David Z Allen, MD 1 ; Emma A Finnegan 2 ; Maxwell Kligerman, MD, MPH 1 ; Merry Sebelik, MD 1",
      "normalized_authors": [
        "David Z Allen",
        "Emma A Finnegan",
        "Maxwell Kligerman",
        "Merry Sebelik"
      ],
      "affiliations": [
        "Department of Otolaryngology, Emory University, Atlanta, GA, United States",
        "School of Medicine, Trinity College Dublin, Dublin, Ireland"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Emory University, Atlanta, GA, United States",
        "School of Medicine, Trinity College Dublin, Dublin, Ireland"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 538,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD 1 ; Emma A Finnegan 2 ; Maxwell Kligerman, MD, MPH 1 ; Merry Sebelik, MD 1",
        "Affiliations": "1 Department of Otolaryngology, Emory University, Atlanta, GA, United States; 2 School of Medicine, Trinity College Dublin, Dublin, Ireland",
        "Background": "The 2025 American Thyroid Association guideline identifies cost-effectiveness and cost-utility analyses as a priority evidence gap where molecular findings may influence initial extent of surgery in 1–4 cm cN0 differentiated thyroid cancer (DTC). Although combined BRAFV600E and TERT promoter positivity is associated with aggressive tumor biology in papillary thyroid carcinoma (PTC), the value of escalating from hemithyroidectomy (HT) to total thyroidectomy (TT) in high-risk subgroups is unknown.",
        "Methods": "We conducted a US payer-perspective cost-utility analysis using a cohort state-transition model over 20 years with annual cycles, half-cycle correction, and 3% discounting. The primary analysis compared TT versus HT BRAF+/TERT+ 1-4 cm cN0 PTC, with prespecified subgroup analyses for BRAF+ only and TERT+ (any BRAF status). Ten-year DFS-failure proxy probabilities were derived from extractable outcomes in a published molecular-prognostic cohort of intrathyroidal papillary carcinoma and converted to annual transition probabilities to parametrize long-term adverse-outcome risk. (1) Complication probabilities were drawn from the recent ATA 2025 evidence synthesis. Costs were anchored to published thyroid surgery cost-utility table values and inflated to 2025 USD using Consumer Price Index for All Urban Consumers (CPI-U). Health-state utilities were obtained from a thyroid-cancer systematic review with shared uncomplicated disease-free utility to avoid double counting. (2) The evidence-conservative reference case set absolute 10-year DFS-failure proxy reduction from TT to zero in all subgroups due to incomplete subgroup-by-extent reporting. Uncertainty was evaluated through one-way sensitivity analysis, prespecified scenarios, threshold analysis, and 10,000-draw probabilistic sensitivity analysis. The primary decision metric was incremental net monetary benefit (INMB) at $150,000 per Quality-Adjusted Life Year (QALY).",
        "Results": "In BRAF+/TERT+ patients, TT increased discounted cost by $1,634 and reduced discounted QALYs by 0.048, yielding INMB of −$8,777. In BRAF+ only, incremental cost was $7,644 and incremental QALY was −0.068, with INMB −$17,793. In TERT+ (any BRAF status), incremental cost was $2,891 and incremental QALY was −0.052, with INMB −$10,715. TT was dominated (higher cost, lower QALY) in all subgroups under reference-case assumptions. At $150,000 per QALY, TT was cost-effective in 6.4% of probabilistic draws in BRAF+/TERT+, 0.01% in BRAF+ only, and 2.8% in TERT+ (any BRAF status). As incremental QALYs were negative in most draws, increasing willingness-to-pay reduced cost-effectiveness probability. Required absolute 10-year DFS-failure proxy reduction for positive INMB was 5.7% in BRAF+/TERT+ and 6.8% in TERT+ (any BRAF status). Results remained unfavorable across scenarios testing event-management asymmetry, age at diagnosis, waning hazard, and CPI-U imputation.",
        "Conclusion": "TT was not cost-effective versus HT across BRAF+/TERT+ subgroups of T1-T2 cN0 papillary thyroid carcinoma. Clinically substantial DFS-failure reduction (~6%) is required before escalation becomes economically favourable. Shared decision-making should integrate patient risk tolerance, quality-of-life trajectory, and the magnitude of benefit required to justify escalation in patient care.",
        "Abstract": "1. Ebina A, Togashi Y, Baba S, et al. TERT Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma. Cancers. 2020;12(8):2115. doi:10.3390/cancers12082115 2. Houten R, Fleeman N, Kotas E, Boland A, Lambe T, Duarte R. A systematic review of health state utility values for thyroid cancer. Qual Life Res. 2021;30(3):675-702. doi:10.1007/s11136-020-02676-2 View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cost-Utility of Total Thyroidectomy Versus Hemithyroidectomy in Molecularly Stratified T1-2 cN0 Papillary Thyroid Carcinoma</span>. David Z Allen, MD<sup>1</sup>; <u>Emma A Finnegan</u><sup>2</sup>; Maxwell Kligerman, MD, MPH<sup>1</sup>; Merry Sebelik, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, Emory University, Atlanta, GA, United States; <sup>2</sup>School of Medicine, Trinity College Dublin, Dublin, Ireland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The 2025 American Thyroid Association guideline identifies cost-effectiveness and cost-utility analyses as a priority evidence gap where molecular findings may influence initial extent of surgery in 1–4 cm cN0 differentiated thyroid cancer (DTC). Although combined BRAFV600E and TERT promoter positivity is associated with aggressive tumor biology in papillary thyroid carcinoma (PTC), the value of escalating from hemithyroidectomy (HT) to total thyroidectomy (TT) in high-risk subgroups is unknown.</p>\n\n<p><strong>Methods:</strong> We conducted a US payer-perspective cost-utility analysis using a cohort state-transition model over 20 years with annual cycles, half-cycle correction, and 3% discounting. The primary analysis compared TT versus HT BRAF+/TERT+ 1-4 cm cN0 PTC, with prespecified subgroup analyses for BRAF+ only and TERT+ (any BRAF status). Ten-year DFS-failure proxy probabilities were derived from extractable outcomes in a published molecular-prognostic cohort of intrathyroidal papillary carcinoma and converted to annual transition probabilities to parametrize long-term adverse-outcome risk. (1) Complication probabilities were drawn from the recent ATA 2025 evidence synthesis. Costs were anchored to published thyroid surgery cost-utility table values and inflated to 2025 USD using Consumer Price Index for All Urban Consumers (CPI-U). Health-state utilities were obtained from a thyroid-cancer systematic review with shared uncomplicated disease-free utility to avoid double counting. (2) The evidence-conservative reference case set absolute 10-year DFS-failure proxy reduction from TT to zero in all subgroups due to incomplete subgroup-by-extent reporting. Uncertainty was evaluated through one-way sensitivity analysis, prespecified scenarios, threshold analysis, and 10,000-draw probabilistic sensitivity analysis. The primary decision metric was incremental net monetary benefit (INMB) at $150,000 per Quality-Adjusted Life Year (QALY).</p>\n\n<p><strong>Results:</strong> In BRAF+/TERT+ patients, TT increased discounted cost by $1,634 and reduced discounted QALYs by 0.048, yielding INMB of −$8,777. In BRAF+ only, incremental cost was $7,644 and incremental QALY was −0.068, with INMB −$17,793. In TERT+ (any BRAF status), incremental cost was $2,891 and incremental QALY was −0.052, with INMB −$10,715. TT was dominated (higher cost, lower QALY) in all subgroups under reference-case assumptions. At $150,000 per QALY, TT was cost-effective in 6.4% of probabilistic draws in BRAF+/TERT+, 0.01% in BRAF+ only, and 2.8% in TERT+ (any BRAF status). As incremental QALYs were negative in most draws, increasing willingness-to-pay reduced cost-effectiveness probability. Required absolute 10-year DFS-failure proxy reduction for positive INMB was 5.7% in BRAF+/TERT+ and 6.8% in TERT+ (any BRAF status). Results remained unfavorable across scenarios testing event-management asymmetry, age at diagnosis, waning hazard, and CPI-U imputation.</p>\n\n<p><strong>Conclusion:</strong> TT was not cost-effective versus HT across BRAF+/TERT+ subgroups of T1-T2 cN0 papillary thyroid carcinoma. Clinically substantial DFS-failure reduction (~6%) is required before escalation becomes economically favourable. Shared decision-making should integrate patient risk tolerance, quality-of-life trajectory, and the magnitude of benefit required to justify escalation in patient care.</p>\n\n<p>1. Ebina A, Togashi Y, Baba S, et al. TERT Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma. Cancers. 2020;12(8):2115. doi:10.3390/cancers12082115<br />\n2. Houten R, Fleeman N, Kotas E, Boland A, Lambe T, Duarte R. A systematic review of health state utility values for thyroid cancer. Qual Life Res. 2021;30(3):675-702. doi:10.1007/s11136-020-02676-2</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155370--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S236",
      "content_id": "153157",
      "abstract_number": "S236",
      "poster_number": "",
      "title": "Thyroid cancer in children, adolescents and young adults treated in Brazil",
      "summary": "This comprehensive analysis of the Brazilian Hospital Cancer Registries provides valuable epidemiological data to inform treatment strategies and healthcare resource allocation for young patients with thyroid cancer in Brazil.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153157",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claudio R Cernea",
      "presenter": "Claudio R Cernea",
      "authors": "Matheus G Rosenfeld 1 ; Leandro L Matos 1 ; Claudio R Cernea 1 ; Luiz P Kowalski 1 ; Maria P Curado 2",
      "normalized_authors": [
        "Matheus G Rosenfeld",
        "Leandro L Matos",
        "Claudio R Cernea",
        "Luiz P Kowalski",
        "Maria P Curado"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery of the Hospital das Clinicas of the Faculty of Medicine, University of São Paulo, SP, Brazil",
        "Department of Epidemiology of the School of Public Health at the University of São Paulo, SP, Brazil"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery of the Hospital das Clinicas of the Faculty of Medicine, University of São Paulo, SP, Brazil",
        "Department of Epidemiology of the School of Public Health at the University of São Paulo, SP, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153157/Rplot03.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153157/Rplot03.png",
          "alt": "Histological subtype distribution by age",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153157"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153157/estt_anopridi_small.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153157/estt_anopridi_small.jpg",
          "alt": "Evolution of the T-Stage between 2000 and 2020 - Brazilian Hospital Cancer Registries",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153157"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153157/Rplot3point.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153157/Rplot3point.png",
          "alt": "Cases of thyroid cancer by age between 2000 and 2020 - Brazilian Hospital Cancer Registries",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153157"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Matheus G Rosenfeld 1 ; Leandro L Matos 1 ; Claudio R Cernea 1 ; Luiz P Kowalski 1 ; Maria P Curado 2",
        "Affiliations": "1 Department of Head and Neck Surgery of the Hospital das Clinicas of the Faculty of Medicine, University of São Paulo, SP, Brazil; 2 Department of Epidemiology of the School of Public Health at the University of São Paulo, SP, Brazil",
        "Introduction": "Thyroid cancer represents the second most common malignancy among children, adolescents and young adults (0-39 years old) worldwide, with incidence rates rising in Brazil and globally. We aimed to analyze temporal trends in thyroid cancer presentation and treatment patterns in patients younger than 40 years using data from Brazilian hospitals specializing in oncological care.",
        "Methods": "This retrospective study utilized anonymized data from the Brazilian Hospital Cancer Registries (Registro Hospitalar de Câncer - RHC), extracted in November 2025. We included all registries of patients aged ≤39 years diagnosed with thyroid cancer (ICD C73) between 2000 to 2020. No exclusion criteria were applied. Extracted variables included sex, age, diagnosis date, treatment modalities, histological subtype, cancer staging and healthcare access type (public versus private).",
        "Abstract": "Tumors were histologically classified as papillary, follicular, medullary, anaplastic or other types. Initial staging was recorded according to the AJCC-TNM 5th edition and subsequently reclassified according to the 8th edition to ensure standardization. Patients were stratified into three age groups: children (0-14 years), adolescents (15-19 years) and young adults (20-39 years). Chi-square tests were performed to compare demographic and clinical characteristics across age groups. During the study period (2000-2020), the proportions of T1- and T3-staged tumors increased (annual percent change [APC] +2.38 and +5.46, respectively), while T2- and T4-staged tumors decreased (APC -4.94 and -9.13, respectively). The female-to-male ratio was lowest in children (2.3:1), increased during adolescence (4.1:1) and peaked in young adults (5.3:1; p<0.001). The proportion of papillary carcinomas increased with age (children 80.1%, adolescents 84.6%, young adults 90.1%; p<0.001), whereas medullary carcinomas decreased (children 7.4%, adolescents 2.5%, young adults 1.4%; p<0.001). Young adults demonstrated higher proportions of stage III or greater disease (children 2.4%, adolescents 2.7%, young adults 8.7%; p<0.001) and lower utilization of public healthcare services (children 69.4%, adolescents 70.2%, young adults 60.9%; p<0.001). View in Agenda and Add to Schedule",
        "Results": "The Brazilian national database encompassed data from 289 hospitals, totalizing 28,480 thyroid cancer cases in patients aged ≤39 years. Median age at diagnosis was 32 years (IQR = 10y), with 2.1% children, 5.4% adolescents and 92.6% young adults. Females comprised 83.6% of all cases. The predominant histological subtypes were papillary (89.6%), follicular (4.0%) and medullary (1.6%) carcinomas.",
        "Discussion": "We observed an age-dependent increase in papillary frequency, rising from 80% in children to 90% in young adults, consistent with other population-based studies from Brazil and internationally. Young adults presented with more advanced clinical staging compared to younger age groups. The temporal increase in T1 tumors and concurrent decrease in T4 tumors likely reflects evolving diagnostic practices and improved access to early detection methods, particularly ultrasound-based screening and fine-needle aspiration biopsy.",
        "Conclusion": "This comprehensive analysis of the Brazilian Hospital Cancer Registries provides valuable epidemiological data to inform treatment strategies and healthcare resource allocation for young patients with thyroid cancer in Brazil."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thyroid cancer in children, adolescents and young adults treated in Brazil</span>. Matheus G Rosenfeld<sup>1</sup>; Leandro L Matos<sup>1</sup>; <u>Claudio R Cernea</u><sup>1</sup>; Luiz P Kowalski<sup>1</sup>; Maria P Curado<sup>2</sup>. <sup>1</sup>Department of Head and Neck Surgery of the Hospital das Clinicas of the Faculty of Medicine, University of São Paulo, SP, Brazil; <sup>2</sup>Department of Epidemiology of the School of Public Health at the University of São Paulo, SP, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Thyroid cancer represents the second most common malignancy among children, adolescents and young adults (0-39 years old) worldwide, with incidence rates rising in Brazil and globally. We aimed to analyze temporal trends in thyroid cancer presentation and treatment patterns in patients younger than 40 years using data from Brazilian hospitals specializing in oncological care.</p>\n\n<p><strong>Methods: </strong>This retrospective study utilized anonymized data from the Brazilian Hospital Cancer Registries (Registro Hospitalar de Câncer - RHC), extracted in November 2025. We included all registries of patients aged ≤39 years diagnosed with thyroid cancer (ICD C73) between 2000 to 2020. No exclusion criteria were applied. Extracted variables included sex, age, diagnosis date, treatment modalities, histological subtype, cancer staging and healthcare access type (public versus private).</p>\n\n<p>Tumors were histologically classified as papillary, follicular, medullary, anaplastic or other types. Initial staging was recorded according to the AJCC-TNM 5th edition and subsequently reclassified according to the 8th edition to ensure standardization. Patients were stratified into three age groups: children (0-14 years), adolescents (15-19 years) and young adults (20-39 years). Chi-square tests were performed to compare demographic and clinical characteristics across age groups.</p>\n\n<p><strong>Results: </strong>The Brazilian national database encompassed data from 289 hospitals, totalizing 28,480 thyroid cancer cases in patients aged ≤39 years. Median age at diagnosis was 32 years (IQR = 10y), with 2.1% children, 5.4% adolescents and 92.6% young adults. Females comprised 83.6% of all cases. The predominant histological subtypes were papillary (89.6%), follicular (4.0%) and medullary (1.6%) carcinomas.</p>\n\n<p><img alt='Histological subtype distribution by age' src='https://www.submitmyabstract.com/abs/images/153157/Rplot03.png' /></p>\n\n<p>During the study period (2000-2020), the proportions of T1- and T3-staged tumors increased (annual percent change [APC] +2.38 and +5.46, respectively), while T2- and T4-staged tumors decreased (APC -4.94 and -9.13, respectively).</p>\n\n<p><img alt='Evolution of the T-Stage between 2000 and 2020 - Brazilian Hospital Cancer Registries' src='https://www.submitmyabstract.com/abs/images/153157/estt_anopridi_small.jpg' /></p>\n\n<p>The female-to-male ratio was lowest in children (2.3:1), increased during adolescence (4.1:1) and peaked in young adults (5.3:1; p<0.001). The proportion of papillary carcinomas increased with age (children 80.1%, adolescents 84.6%, young adults 90.1%; p<0.001), whereas medullary carcinomas decreased (children 7.4%, adolescents 2.5%, young adults 1.4%; p<0.001). Young adults demonstrated higher proportions of stage III or greater disease (children 2.4%, adolescents 2.7%, young adults 8.7%; p<0.001) and lower utilization of public healthcare services (children 69.4%, adolescents 70.2%, young adults 60.9%; p<0.001).</p>\n\n<p><img alt='Cases of thyroid cancer by age between 2000 and 2020 - Brazilian Hospital Cancer Registries' src='https://www.submitmyabstract.com/abs/images/153157/Rplot3point.png' /></p>\n\n<p><strong>Discussion: </strong>We observed an age-dependent increase in papillary frequency, rising from 80% in children to 90% in young adults, consistent with other population-based studies from Brazil and internationally. Young adults presented with more advanced clinical staging compared to younger age groups. The temporal increase in T1 tumors and concurrent decrease in T4 tumors likely reflects evolving diagnostic practices and improved access to early detection methods, particularly ultrasound-based screening and fine-needle aspiration biopsy.</p>\n\n<p><strong>Conclusion: </strong>This comprehensive analysis of the Brazilian Hospital Cancer Registries provides valuable epidemiological data to inform treatment strategies and healthcare resource allocation for young patients with thyroid cancer in Brazil.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153157--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S237",
      "content_id": "153659",
      "abstract_number": "S237",
      "poster_number": "",
      "title": "Perioperative Outcomes Following Thyroidectomy in Adult Patients with Graves' Disease",
      "summary": "In this cohort of 48 adults who underwent total thyroidectomy for Graves’ disease, postoperative problems were infrequent and well controlled. Half of the patients went to surgery without fully normalized thyroid function, yet their outcomes were comparable to those whose levels were stabilized beforehand. Hematoma and long-term hypocalcemia occurred at low rates, and there were no cases of recurrent laryngeal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153659",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260132",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ifeanyi Onuh, MS",
      "presenter": "Ifeanyi Onuh, MS",
      "authors": "Ifeanyi Onuh, MS ; Zaid Al-Qurayshi, MBChB, MPH; Nitin Pagedar, MD, MPH",
      "normalized_authors": [
        "Ifeanyi Onuh",
        "Zaid Al-Qurayshi, MBChB",
        "Nitin Pagedar"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 468,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ifeanyi Onuh, MS ; Zaid Al-Qurayshi, MBChB, MPH; Nitin Pagedar, MD, MPH",
        "Affiliations": "University of Iowa",
        "Background": "Graves’ disease is the most common cause of hyperthyroidism in adults and often requires surgical management when medical therapy fails, or suspicious thyroid nodules are present. Total thyroidectomy is the preferred operative approach for these patients, but surgery carries unique challenges and difficulties related to the hypermetabolic state of Graves’ disease. Compared to non-Graves patients, those with Graves’ disease face higher risks of transient or permanent hypocalcemia, hypoparathyroidism, and recurrent laryngeal nerve injury. Despite these known risks, there remains a shortage of published data that details the outcomes and complication rates in adult patients with Graves’ disease.",
        "Abstract": "This study aims to evaluate perioperative outcomes among adult patients with Graves’ disease and to assess the effectiveness of current management strategies in this high-risk population. Variables collected included demographic characteristics, duration of disease and type of preoperative medical therapy, laboratory markers of thyroid function and calcium levels, operative time, intraoperative findings, and the use of intraoperative nerve monitoring. Postoperative outcomes included symptomatic or documented low serum calcium, hypoparathyroidism, recurrent laryngeal nerve dysfunction, hematoma, infection, emergency department use, and readmission within 30 days. View in Agenda and Add to Schedule",
        "Methods": "We conducted a retrospective cohort study of adult patients with a confirmed diagnosis of Graves’ disease who underwent total thyroidectomy at our institution over a 10-year period from February 2015 until August 2025. Eligible cases were identified through the electronic medical record using diagnostic codes for Graves’ disease and procedural codes for total thyroidectomy.",
        "Results": "A total of 48 patients were identified who underwent total thyroidectomy. The average age was 42.25±14.52 year and 38 (79.17%) were female patients. Twenty patients (45.45%) were not euthyroid prior to surgery despite medical treatment. Preoperatively, 91.67% were on Methimazole, 19.15% were on Propylthiouracil, and 6.25% were started on potassium iodide prior to surgery. Patients with preoperative uncontrolled hyperthyroidism compared to patients with controlled thyroid function did not have statistically significant demographic and clinical profile. Postoperatively, the risk of hematoma, chronic hypocalcemia, and recurrent laryngeal nerve injury were 10.42%, 9.52%, and 0% respectively.",
        "Conclusion": "In this cohort of 48 adults who underwent total thyroidectomy for Graves’ disease, postoperative problems were infrequent and well controlled. Half of the patients went to surgery without fully normalized thyroid function, yet their outcomes were comparable to those whose levels were stabilized beforehand. Hematoma and long-term hypocalcemia occurred at low rates, and there were no cases of recurrent laryngeal nerve injury. Overall, these results demonstrate that total thyroidectomy remains a dependable treatment option for Graves’ disease, even for patients with persistent hyperthyroidism prior to surgery. As surgical management continues to play an important role for individuals who do not improve with medical therapy, these findings highlight the need for thoughtful perioperative management and may help guide discussions and expectations for this patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Perioperative Outcomes Following Thyroidectomy in Adult Patients with Graves' Disease</span>. <u>Ifeanyi Onuh, MS</u>; Zaid Al-Qurayshi, MBChB, MPH; Nitin Pagedar, MD, MPH. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Graves’ disease is the most common cause of hyperthyroidism in adults and often requires surgical management when medical therapy fails, or suspicious thyroid nodules are present. Total thyroidectomy is the preferred operative approach for these patients, but surgery carries unique challenges and difficulties related to the hypermetabolic state of Graves’ disease. Compared to non-Graves patients, those with Graves’ disease face higher risks of transient or permanent hypocalcemia, hypoparathyroidism, and recurrent laryngeal nerve injury. Despite these known risks, there remains a shortage of published data that details the outcomes and complication rates in adult patients with Graves’ disease. </p>\n\n<p>This study aims to evaluate perioperative outcomes among adult patients with Graves’ disease and to assess the effectiveness of current management strategies in this high-risk population. </p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cohort study of adult patients with a confirmed diagnosis of Graves’ disease who underwent total thyroidectomy at our institution over a 10-year period from February 2015 until August 2025. Eligible cases were identified through the electronic medical record using diagnostic codes for Graves’ disease and procedural codes for total thyroidectomy. </p>\n\n<p>Variables collected included demographic characteristics, duration of disease and type of preoperative medical therapy, laboratory markers of thyroid function and calcium levels, operative time, intraoperative findings, and the use of intraoperative nerve monitoring. Postoperative outcomes included symptomatic or documented low serum calcium, hypoparathyroidism, recurrent laryngeal nerve dysfunction, hematoma, infection, emergency department use, and readmission within 30 days. </p>\n\n<p><strong>Results:</strong> A total of 48 patients were identified who underwent total thyroidectomy. The average age was 42.25±14.52 year and 38 (79.17%) were female patients. Twenty patients (45.45%) were not euthyroid prior to surgery despite medical treatment. Preoperatively, 91.67% were on Methimazole, 19.15% were on Propylthiouracil, and 6.25% were started on potassium iodide prior to surgery. Patients with preoperative uncontrolled hyperthyroidism compared to patients with controlled thyroid function did not have statistically significant demographic and clinical profile. Postoperatively, the risk of hematoma, chronic hypocalcemia, and recurrent laryngeal nerve injury were 10.42%, 9.52%, and 0% respectively. </p>\n\n<p><strong>Conclusion:</strong> In this cohort of 48 adults who underwent total thyroidectomy for Graves’ disease, postoperative problems were infrequent and well controlled. Half of the patients went to surgery without fully normalized thyroid function, yet their outcomes were comparable to those whose levels were stabilized beforehand. Hematoma and long-term hypocalcemia occurred at low rates, and there were no cases of recurrent laryngeal nerve injury. Overall, these results demonstrate that total thyroidectomy remains a dependable treatment option for Graves’ disease, even for patients with persistent hyperthyroidism prior to surgery. As surgical management continues to play an important role for individuals who do not improve with medical therapy, these findings highlight the need for thoughtful perioperative management and may help guide discussions and expectations for this patient population. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153659--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260132' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S238",
      "content_id": "154411",
      "abstract_number": "S238",
      "poster_number": "",
      "title": "Unique Swallowing-Related Toxicity Profile Following Concurrent Immunotherapy and Radiation in Head and Neck Squamous Cell Carcinoma Patients",
      "summary": "With the recent FDA approval of neoadjuvant-adjuvant pembrolizumab for advanced head and neck squamous cell carcinoma (HNSCC), more patients will be receiving immunotherapy in the curative setting and with concurrent radiation. While prior curative immunotherapy clinical trials did not report major differences in swallowing-related toxicities compared to standard of care, long term real-world data on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154411",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Tammy B Pham, MD 2 ; Joseph Califano, MD 2 ; Theresa Guo, MD 2",
      "normalized_authors": [
        "Vivian Vo",
        "Tammy B Pham",
        "Joseph Califano",
        "Theresa Guo"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154411/table_final.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154411/table_final.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154411"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 451,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Tammy B Pham, MD 2 ; Joseph Califano, MD 2 ; Theresa Guo, MD 2",
        "Affiliations": "1 UC San Diego School of Medicine; 2 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "With the recent FDA approval of neoadjuvant-adjuvant pembrolizumab for advanced head and neck squamous cell carcinoma (HNSCC), more patients will be receiving immunotherapy in the curative setting and with concurrent radiation. While prior curative immunotherapy clinical trials did not report major differences in swallowing-related toxicities compared to standard of care, long term real-world data on treatment-related swallowing complications following concurrent immunotherapy and radiation (IRT) in HNSCC remain limited. Therefore, we sought to compare early and late swallowing-related toxicities across patients receiving radiation for HNSCC either with concurrent immunotherapy or with concurrent chemotherapy. Using the Epic Cosmos database, we identified patients with a SNOMED-coded diagnosis of HNSCC from 2017-2025. Radiation therapy was identified using billing/charge procedures. Chemotherapy (CRT; paclitaxel, carboplatin, cisplatin) and immunotherapy (IRT; pembrolizumab, nivolumab, durvalumab) were identified using administered medication records. A temporal-overlap filter was applied to ensure concurrent radiation and systemic therapy. We focused on patients receiving concurrent therapy for primary curative intent rather than recurrent or metastatic disease. Outcomes assessed included encounters for aspiration and dysphagia, evaluations by speech-language pathologists (SLP), and gastrostomy tube (GT) placement. Timepoints evaluated comprised early (0-6 months) and late (6-24 months) intervals following diagnosis. Risk ratios were calculated between groups, and differences in proportions were evaluated using Chi-squared testing. Among 809,389 patients with HNSCC, 36,205 met inclusion criteria (34,817 CRT; 1388 IRT). Early aspiration occurred more often with IRT compared with CRT (7.2% vs 4.7 %; p < 0.001), while early dysphagia (52.0% vs 65.5%; p < 0.001), early SLP encounters (54.1% vs 69.0%; p < 0.001), and early GT placement (27.6% vs 41.9%; p < 0.001) were lower in IRT. Encounters associated with late aspiration were higher in IRT (5.8% vs 3.6%; p < 0.001), while late dysphagia was modestly reduced (38.8% vs 44.3, p < 0.001). Late GT placement was more common with IRT (11.3% vs 7.9%; p < 0.001), while late SLP encounters were similar between groups (38.5% vs 38.4%; p = 0.96). In this large real-world dataset, patients receiving IRT demonstrated higher aspiration across time points, and higher rates of late GT placement. These differences highlight a unique toxicity profile that may be associated with concurrent immunotherapy and radiation, particularly late GT use that may not have been captured in prior clinical trials. Given the Cosmos database structure, there is limited ability to control for potential confounders such as cancer stage, recurrence history, and reasons for treatment selection. These findings highlight potential differences in the functional toxicity patterns between CRT and IRT patients that warrant prospective research with focus on long term outcomes. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Unique Swallowing-Related Toxicity Profile Following Concurrent Immunotherapy and Radiation in Head and Neck Squamous Cell Carcinoma Patients</span>. <u>Vivian Vo</u><sup>1</sup>; Tammy B Pham, MD<sup>2</sup>; Joseph Califano, MD<sup>2</sup>; Theresa Guo, MD<sup>2</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>With the recent FDA approval of neoadjuvant-adjuvant pembrolizumab for advanced head and neck squamous cell carcinoma (HNSCC), more patients will be receiving immunotherapy in the curative setting and with concurrent radiation. While prior curative immunotherapy clinical trials did not report major differences in swallowing-related toxicities compared to standard of care, long term real-world data on treatment-related swallowing complications following concurrent immunotherapy and radiation (IRT) in HNSCC remain limited. Therefore, we sought to compare early and late swallowing-related toxicities across patients receiving radiation for HNSCC either with concurrent immunotherapy or with concurrent chemotherapy. </p>\n\n<p>Using the Epic Cosmos database, we identified patients with a SNOMED-coded diagnosis of HNSCC from 2017-2025. Radiation therapy was identified using billing/charge procedures. Chemotherapy (CRT; paclitaxel, carboplatin, cisplatin) and immunotherapy (IRT; pembrolizumab, nivolumab, durvalumab) were identified using administered medication records. A temporal-overlap filter was applied to ensure concurrent radiation and systemic therapy. We focused on patients receiving concurrent therapy for primary curative intent rather than recurrent or metastatic disease. Outcomes assessed included encounters for aspiration and dysphagia, evaluations by speech-language pathologists (SLP), and gastrostomy tube (GT) placement. Timepoints evaluated comprised early (0-6 months) and late (6-24 months) intervals following diagnosis. Risk ratios were calculated between groups, and differences in proportions were evaluated using Chi-squared testing.</p>\n\n<p>Among 809,389 patients with HNSCC, 36,205 met inclusion criteria (34,817 CRT; 1388 IRT). Early aspiration occurred more often with IRT compared with CRT (7.2% vs 4.7 %; p < 0.001), while early dysphagia (52.0% vs 65.5%; p < 0.001), early SLP encounters (54.1% vs 69.0%; p < 0.001), and early GT placement (27.6% vs 41.9%; p < 0.001) were lower in IRT. Encounters associated with late aspiration were higher in IRT (5.8% vs 3.6%; p < 0.001), while late dysphagia was modestly reduced (38.8% vs 44.3, p < 0.001). Late GT placement was more common with IRT (11.3% vs 7.9%; p < 0.001), while late SLP encounters were similar between groups (38.5% vs 38.4%; p = 0.96).</p>\n\n<p>In this large real-world dataset, patients receiving IRT demonstrated higher aspiration across time points, and higher rates of late GT placement. These differences highlight a unique toxicity profile that may be associated with concurrent immunotherapy and radiation, particularly late GT use that may not have been captured in prior clinical trials. Given the Cosmos database structure, there is limited ability to control for potential confounders such as cancer stage, recurrence history, and reasons for treatment selection. These findings highlight potential differences in the functional toxicity patterns between CRT and IRT patients that warrant prospective research with focus on long term outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154411/table_final.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154411--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S239",
      "content_id": "153032",
      "abstract_number": "S239",
      "poster_number": "",
      "title": "Factors associated with laryngectomy-specific voice and speech outcomes using LARY-Q",
      "summary": "Data from 239 individuals who participated in the LARY-Q field test and completed the LARY-Q voice and speech-related scales were analyzed. The mean age was 67 (range 23-89, SD 10.5) and 154 (64%) participants were male. There was a wide range in marital status, employment status, and education level. Ninety three (39%) underwent upfront TL without any preceding treatments. One hundred twenty two (51%) underwent...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153032",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael P Wu, MD",
      "presenter": "Michael P Wu, MD",
      "authors": "Michael P Wu, MD 1 ; Manraj N Kaur, PhD 2 ; Allen L Feng, MD 1 ; Bridget McLeod, CCCSLP 1 ; Carolyn Hsu, CCCSLP 1 ; Cody Sullivan, CCCSLP 1 ; Glenn Bunting, CCCSLP 1 ; Mahima Jain, MPH 2 ; Mark Varvares, MD 1 ; Andrea Pusic, MD 2 ; Anne F Klassen 3 ; Daniel G Deschler, MD 1",
      "normalized_authors": [
        "Michael P Wu",
        "Manraj N Kaur",
        "Allen L Feng",
        "Bridget McLeod, CCCSLP",
        "Carolyn Hsu, CCCSLP",
        "Cody Sullivan, CCCSLP",
        "Glenn Bunting, CCCSLP",
        "Mahima Jain",
        "Mark Varvares",
        "Andrea Pusic",
        "Anne F Klassen",
        "Daniel G Deschler"
      ],
      "affiliations": [
        "Massachusetts Eye and Ear",
        "Brigham and Women's Hosptial",
        "McMaster University"
      ],
      "normalized_institutions": [
        "Massachusetts Eye and Ear",
        "Brigham and Women's Hosptial",
        "McMaster University"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 430,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Participants",
        "Exposures",
        "Main Outcomes and Measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michael P Wu, MD 1 ; Manraj N Kaur, PhD 2 ; Allen L Feng, MD 1 ; Bridget McLeod, CCCSLP 1 ; Carolyn Hsu, CCCSLP 1 ; Cody Sullivan, CCCSLP 1 ; Glenn Bunting, CCCSLP 1 ; Mahima Jain, MPH 2 ; Mark Varvares, MD 1 ; Andrea Pusic, MD 2 ; Anne F Klassen 3 ; Daniel G Deschler, MD 1",
        "Affiliations": "1 Massachusetts Eye and Ear; 2 Brigham and Women's Hosptial; 3 McMaster University",
        "Importance": "Despite communication being a primary concern after total laryngectomy, more research is needed to understand what factors are associated with alaryngeal voice and speech outcomes.",
        "Objective": "To determine factors that are associated with voice and speech outcomes after total laryngectomy using a novel laryngectomy-specific patient reported outcome measure, the LARY-Q",
        "Design": "Cross-sectional survey",
        "Setting": "International",
        "Participants": "Individuals over age 18 years who had undergone total laryngectomy",
        "Exposures": "None",
        "Main Outcomes and Measures": "The LARY-Q Voice Sound, Voice Impact, and Speech Function scales",
        "Results": "Data from 239 individuals who participated in the LARY-Q field test and completed the LARY-Q voice and speech-related scales were analyzed. The mean age was 67 (range 23-89, SD 10.5) and 154 (64%) participants were male. There was a wide range in marital status, employment status, and education level. Ninety three (39%) underwent upfront TL without any preceding treatments. One hundred twenty two (51%) underwent salvage TL after radiation or chemoradiation. There was a wide range in time since completion of treatment, with 12 (5%) having completed treatment less than 3 months prior and 79 (33%) having completed treatment greater than 5 years prior. One hundred fourteen (48%) reported having undergone flap reconstruction. Greater than 5 years since completion of treatment and regular diet were associated with superior Voice Sound (median difference 9, CI: 4 to 13), Voice Impact (median difference 9, CI: 4 to 15), and Speech Function scores (median difference 6, CI: 1 to 11). Participants who underwent flap reconstruction had worse Voice Sound (median difference -7, CI: -12 to -3), Voice Impact (median difference -10, CI: -15 to -4), and Speech Function (median difference -7, CI: -12 to -3) scores. Male participants reported higher Voice Sound (median difference 9, CI: 4 to 13) and Impact (median difference 7, CI: 2 to 13) scores than females. Participants who identified tracheoesophageal speech as their preferred communication method had superior Speech Function scores compared to those who preferred electrolarynx (median difference 6, CI: 1 to 12). Participants who preferred tracheoesophageal speech, esophageal speech, or electrolarynx had better Voice Impact and Speech Function than those who preferred writing.",
        "Conclusions and Relevance": "Positive voice and speech outcomes were associated with greater than 5 years since completion of treatment, regular diet, lack of flap reconstruction, male sex, and tracheoesophageal speech. Upfront discussions with female patients about differences between baseline female and alaryngeal voice pitch may be helpful in preoperative counseling. The association of superior voice and speech outcomes with regular diet and lack of flap reconstruction may reflect the impact of overall ablative defect size and postoperative strictures on postoperative alaryngeal voice and speech function.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Factors associated with laryngectomy-specific voice and speech outcomes using LARY-Q</span>. <u>Michael P Wu, MD</u><sup>1</sup>; Manraj N Kaur, PhD<sup>2</sup>; Allen L Feng, MD<sup>1</sup>; Bridget McLeod, CCCSLP<sup>1</sup>; Carolyn Hsu, CCCSLP<sup>1</sup>; Cody Sullivan, CCCSLP<sup>1</sup>; Glenn Bunting, CCCSLP<sup>1</sup>; Mahima Jain, MPH<sup>2</sup>; Mark Varvares, MD<sup>1</sup>; Andrea Pusic, MD<sup>2</sup>; Anne F Klassen<sup>3</sup>; Daniel G Deschler, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye and Ear; <sup>2</sup>Brigham and Women's Hosptial; <sup>3</sup>McMaster University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Despite communication being a primary concern after total laryngectomy, more research is needed to understand what factors are associated with alaryngeal voice and speech outcomes.</p>\n\n<p><strong>Objective: </strong>To determine factors that are associated with voice and speech outcomes after total laryngectomy using a novel laryngectomy-specific patient reported outcome measure, the LARY-Q</p>\n\n<p><strong>Design: </strong>Cross-sectional survey</p>\n\n<p><strong>Setting:</strong> International</p>\n\n<p><strong>Participants:</strong> Individuals over age 18 years who had undergone total laryngectomy</p>\n\n<p><strong>Exposures: </strong>None</p>\n\n<p><strong>Main Outcomes and Measures: </strong>The LARY-Q Voice Sound, Voice Impact, and Speech Function scales</p>\n\n<p><strong>Results:</strong> Data from 239 individuals who participated in the LARY-Q field test and completed the LARY-Q voice and speech-related scales were analyzed. The mean age was 67 (range 23-89, SD 10.5) and 154 (64%) participants were male. There was a wide range in marital status, employment status, and education level. Ninety three (39%) underwent upfront TL without any preceding treatments. One hundred twenty two (51%) underwent salvage TL after radiation or chemoradiation. There was a wide range in time since completion of treatment, with 12 (5%) having completed treatment less than 3 months prior and 79 (33%) having completed treatment greater than 5 years prior. One hundred fourteen (48%) reported having undergone flap reconstruction. Greater than 5 years since completion of treatment and regular diet were associated with superior Voice Sound (median difference 9, CI: 4 to 13), Voice Impact (median difference 9, CI: 4 to 15), and Speech Function scores (median difference 6, CI: 1 to 11). Participants who underwent flap reconstruction had worse Voice Sound (median difference -7, CI: -12 to -3), Voice Impact (median difference -10, CI: -15 to -4), and Speech Function (median difference -7, CI: -12 to -3) scores. Male participants reported higher Voice Sound (median difference 9, CI: 4 to 13) and Impact (median difference 7, CI: 2 to 13) scores than females. Participants who identified tracheoesophageal speech as their preferred communication method had superior Speech Function scores compared to those who preferred electrolarynx (median difference 6, CI: 1 to 12). Participants who preferred tracheoesophageal speech, esophageal speech, or electrolarynx had better Voice Impact and Speech Function than those who preferred writing.</p>\n\n<p><strong>Conclusions and Relevance: </strong>Positive voice and speech outcomes were associated with greater than 5 years since completion of treatment, regular diet, lack of flap reconstruction, male sex, and tracheoesophageal speech. Upfront discussions with female patients about differences between baseline female and alaryngeal voice pitch may be helpful in preoperative counseling. The association of superior voice and speech outcomes with regular diet and lack of flap reconstruction may reflect the impact of overall ablative defect size and postoperative strictures on postoperative alaryngeal voice and speech function.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153032--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S240",
      "content_id": "153987",
      "abstract_number": "S240",
      "poster_number": "",
      "title": "Which MDASI symptoms drive swallowing-related QOL on the MDADI: More than just dysphagia?",
      "summary": "MDADI scores, although designed to measure swallowing-related QOL, reflect a broader and evolving symptom burden that extends beyond dysphagia. Swallowing difficulty remained prominent early in treatment, but additional symptoms became increasingly influential over time. Associations strengthened during treatment, continued through early survivorship, and remained evident for late effects at five years. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153987",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Wenye Song",
      "presenter": "Wenye Song",
      "authors": "Wenye Song ; Christine Peterson; Ariana Sahli; Jack Lee; Steven Frank; Stephen Lai; Clifton Fuller; Katherine Hutcheson; Carly Barbon",
      "normalized_authors": [
        "Wenye Song",
        "Christine Peterson",
        "Ariana Sahli",
        "Jack Lee",
        "Steven Frank",
        "Stephen Lai",
        "Clifton Fuller",
        "Katherine Hutcheson",
        "Carly Barbon"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Cente"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Cente"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 527,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Wenye Song ; Christine Peterson; Ariana Sahli; Jack Lee; Steven Frank; Stephen Lai; Clifton Fuller; Katherine Hutcheson; Carly Barbon",
        "Affiliations": "The University of Texas MD Anderson Cancer Cente",
        "Background": "The MD Anderson Dysphagia Inventory (MDADI) is a widely used measure of swallowing–related quality of life (QOL) in head and neck cancer. The MDASI-HN provides complementary assessment of both swallowing-specific and non-swallowing symptoms. Because swallowing is influenced by multiple co-occurring toxicities, we hypothesize that swallowing-related QOL as measured by MDADI scores may plausibly reflect more than dysphagia symptoms alone.",
        "Objective": "To quantify the associations between MDASI-HN symptoms and MDADI scores using longitudinal mixed-effects models, and to identify symptoms that drive within-patient changes in MDADI across discrete treatment and survivorship timepoints.",
        "Methods": "We analyzed data from the MD Anderson Oropharynx Cancer (MDA-OPC) Cohort, a single-institution prospective registry of HPV/p16-positive oropharyngeal cancer. Patients were restricted to previously untreated low-to-intermediate risk disease (T1–T3, N0–N2b, M0). Eligible patients had both the MDADI composite score (20–100; higher is better) and the MDASI-HN symptom severity items (0–10; higher is worse) recorded at two or more assessment windows (Baseline, End of Radiation, 3–6 months, 12 months, 18–24 months, and 60 months).",
        "Abstract": "We fit linear mixed-effects models with a patient-level random intercept, using the MDADI composite score as the outcome. For each symptom, predictors included the within-person deviation (group-mean centered), the between-person mean, and timepoints as a categorical factor, with a symptom-by-timepoint interaction to allow time-varying effects. Effects were estimated as within-patient MDADI change per 1-point MDASI increase with false discovery rate (FDR) correction. Other MDASI symptom items transiently associated with MDADI at different time points across survivorship. During treatment and early survivorship, MDASI-sadness (β = –2.89; q<0.001), MDASI-distress (β = –2.40; q<0.001), and MDASI-fatigue (β = –1.82; q<0.001) showed prominent effects. In later survivorship, additional contributors included MDASI-dry mouth at 12 months (β = –1.29; q<0.001) and MDASI-shortness of breath at 18–24 months (β = –2.68; q<0.001). At 60 months, persistent associations remained for choke, swallowing/chewing difficulty, voice/speech, sleep disturbance, and dry mouth. A heatmap demonstrates a shift from early dysphagia-dominant to broader long-term multi-symptom/MDADI patterns. View in Agenda and Add to Schedule",
        "Results": "Among 1,153 eligible patients, 834 (72%) contributed paired MDADI–MDASI questionnaires at ≥2 timepoints (median age 59; 82% male). Mixed-effects models estimated within-patient effects for all MDASI-HN symptoms. Several symptoms demonstrated sustained associations with MDADI across survivorship timepoints, including MDASI-choke (β = –3.16; 95% CI –3.81 to –2.52; q<0.001), representing the change in MDADI per 1-point increase in MDASI symptom score, as well as MDASI-swallowing/chewing (β = –2.66; 95% CI –3.10 to –2.23; q<0.001) and MDASI-voice/speech (β = –2.84; 95% CI –3.53 to –2.15; q<0.001).",
        "Conclusion": "MDADI scores, although designed to measure swallowing-related QOL, reflect a broader and evolving symptom burden that extends beyond dysphagia. Swallowing difficulty remained prominent early in treatment, but additional symptoms became increasingly influential over time. Associations strengthened during treatment, continued through early survivorship, and remained evident for late effects at five years. These findings indicate that MDADI extends beyond swallow-related QOL and may function as a multi-symptom indicator of eating-related QOL across survivorship, supporting its use in both short- and long-term care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Which MDASI symptoms drive swallowing-related QOL on the MDADI: More than just dysphagia?</span>. <u>Wenye Song</u>; Christine Peterson; Ariana Sahli; Jack Lee; Steven Frank; Stephen Lai; Clifton Fuller; Katherine Hutcheson; Carly Barbon. The University of Texas MD Anderson Cancer Cente<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The MD Anderson Dysphagia Inventory (MDADI) is a widely used measure of swallowing–related quality of life (QOL) in head and neck cancer. The MDASI-HN provides complementary assessment of both swallowing-specific and non-swallowing symptoms. Because swallowing is influenced by multiple co-occurring toxicities, we hypothesize that swallowing-related QOL as measured by MDADI scores may plausibly reflect more than dysphagia symptoms alone.</p>\n\n<p><strong>Objective: </strong>To quantify the associations between MDASI-HN symptoms and MDADI scores using longitudinal mixed-effects models, and to identify symptoms that drive within-patient changes in MDADI across discrete treatment and survivorship timepoints.</p>\n\n<p><strong>Methods: </strong>We analyzed data from the MD Anderson Oropharynx Cancer (MDA-OPC) Cohort, a single-institution prospective registry of HPV/p16-positive oropharyngeal cancer. Patients were restricted to previously untreated low-to-intermediate risk disease (T1–T3, N0–N2b, M0). Eligible patients had both the MDADI composite score (20–100; higher is better) and the MDASI-HN symptom severity items (0–10; higher is worse) recorded at two or more assessment windows (Baseline, End of Radiation, 3–6 months, 12 months, 18–24 months, and 60 months).</p>\n\n<p>We fit linear mixed-effects models with a patient-level random intercept, using the MDADI composite score as the outcome. For each symptom, predictors included the within-person deviation (group-mean centered), the between-person mean, and timepoints as a categorical factor, with a symptom-by-timepoint interaction to allow time-varying effects. Effects were estimated as within-patient MDADI change per 1-point MDASI increase with false discovery rate (FDR) correction.</p>\n\n<p><strong>Results: </strong>Among 1,153 eligible patients, 834 (72%) contributed paired MDADI–MDASI questionnaires at ≥2 timepoints (median age 59; 82% male). Mixed-effects models estimated within-patient effects for all MDASI-HN symptoms. Several symptoms demonstrated sustained associations with MDADI across survivorship timepoints, including MDASI-choke (β = –3.16; 95% CI –3.81 to –2.52; q<0.001), representing the change in MDADI per 1-point increase in MDASI symptom score, as well as MDASI-swallowing/chewing (β = –2.66; 95% CI –3.10 to –2.23; q<0.001) and MDASI-voice/speech (β = –2.84; 95% CI –3.53 to –2.15; q<0.001).</p>\n\n<p>Other MDASI symptom items transiently associated with MDADI at different time points across survivorship. During treatment and early survivorship, MDASI-sadness (β = –2.89; q<0.001), MDASI-distress (β = –2.40; q<0.001), and MDASI-fatigue (β = –1.82; q<0.001) showed prominent effects. In later survivorship, additional contributors included MDASI-dry mouth at 12 months (β = –1.29; q<0.001) and MDASI-shortness of breath at 18–24 months (β = –2.68; q<0.001). At 60 months, persistent associations remained for choke, swallowing/chewing difficulty, voice/speech, sleep disturbance, and dry mouth. A heatmap demonstrates a shift from early dysphagia-dominant to broader long-term multi-symptom/MDADI patterns.</p>\n\n<p><strong>Conclusion:</strong> MDADI scores, although designed to measure swallowing-related QOL, reflect a broader and evolving symptom burden that extends beyond dysphagia. Swallowing difficulty remained prominent early in treatment, but additional symptoms became increasingly influential over time. Associations strengthened during treatment, continued through early survivorship, and remained evident for late effects at five years. These findings indicate that MDADI extends beyond swallow-related QOL and may function as a multi-symptom indicator of eating-related QOL across survivorship, supporting its use in both short- and long-term care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153987--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S241",
      "content_id": "153918",
      "abstract_number": "S241",
      "poster_number": "",
      "title": "Novel Use of Prolaryn (Carboxymethylcellulose) Gel for Periprosthetic Leakage Around Tracheoesophageal Prostheses After Total Laryngectomy",
      "summary": "This is the first study to describe the use of Prolaryn gel as an injectable soft-tissue filler in treating periprosthetic TEP leakage. Our findings demonstrate that Prolaryn gel was effective in achieving immediate complete resolution of peripheral leakage in nearly all instances with a very low rate of adverse complications. Beyond the immediate effect, Prolaryn gel also provided sustained relief of peripheral...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153918",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jin Hua Li",
      "presenter": "Jin Hua Li",
      "authors": "Jin Hua Li ; Rachel Harter; Dorothy Chen; David I Kutler, MD",
      "normalized_authors": [
        "Jin Hua Li",
        "Rachel Harter",
        "Dorothy Chen",
        "David I Kutler"
      ],
      "affiliations": [
        "Weill Cornell Medicine"
      ],
      "normalized_institutions": [
        "Weill Cornell Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jin Hua Li ; Rachel Harter; Dorothy Chen; David I Kutler, MD",
        "Affiliations": "Weill Cornell Medicine",
        "Introduction": "Tracheoesophageal puncture (TEP) is considered the gold standard for voice rehabilitation following a total laryngectomy. While the procedure has a high success rate, periprosthetic leakage can arise as a long-term complication, increasing the risk of aspiration and respiratory complications. Various strategies are employed to manage periprosthetic leakage, including periprosthetic tissue augmentation. Prolaryn gel, a commercially available formulation of carboxymethylcellulose, has been used at our institution as a bulking agent for this purpose. While Prolaryn gel is commonly used for vocal cord insufficiency, its role in managing peripheral TEP leakage has not been studied. This study evaluates the efficacy of Prolaryn gel injection as a novel tissue augmentation approach for periprosthetic TEP leakage.",
        "Methods": "A retrospective review was conducted of patients managed at our institution for post-laryngectomy tracheoesophageal puncture and voice prosthesis care between 2007 to 2025. From this cohort, patients who underwent soft-tissue filler injection with Prolaryn gel for periprosthetic leakage were identified. After leakage was confirmed by a speech language pathologist, injections were performed by head and neck surgeons. Patients were subsequently assessed for voice quality and leakage while swallowing. Demographic information, medical comorbidities, surgical characteristics, and post-injection outcomes were obtained. The primary outcome was duration of leak resolution, and secondary outcomes were immediate treatment response and adverse events.",
        "Results": "Six male patients (mean age 57.8 years) underwent 23 injections of Prolaryn gel. Patients were followed for an average of 11.1 years after initial TEP placement or after initial office visit if TEP was placed elsewhere. All patients required prosthesis customization along with the injections. Four patients required multiple injections due to recurrent leakage. Of 23 injections administered, 21 injections resulted in immediate complete resolution of leakage, while 2 injections resulted in partial or near resolution. One patient on anticoagulation experienced mild, well-controlled post-injection bleeding on one occasion; no other immediate adverse events were observed. Among patients whose voice function was documented, all demonstrated fluent voice post-injection. The average duration of leak resolution was 6.7 months (range 0.07-49.2 months) from the last injection.",
        "Conclusion": "This is the first study to describe the use of Prolaryn gel as an injectable soft-tissue filler in treating periprosthetic TEP leakage. Our findings demonstrate that Prolaryn gel was effective in achieving immediate complete resolution of peripheral leakage in nearly all instances with a very low rate of adverse complications. Beyond the immediate effect, Prolaryn gel also provided sustained relief of peripheral leakage lasting an average of almost seven months. As such, these results highlight the promising potential of Prolaryn gel as a safe, novel adjunctive strategy to improve management of periprosthetic leakage and thereby enhance quality of life in post-laryngectomy patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Novel Use of Prolaryn (Carboxymethylcellulose) Gel for Periprosthetic Leakage Around Tracheoesophageal Prostheses After Total Laryngectomy</span>. <u>Jin Hua Li</u>; Rachel Harter; Dorothy Chen; David I Kutler, MD. Weill Cornell Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tracheoesophageal puncture (TEP) is considered the gold standard for voice rehabilitation following a total laryngectomy. While the procedure has a high success rate, periprosthetic leakage can arise as a long-term complication, increasing the risk of aspiration and respiratory complications. Various strategies are employed to manage periprosthetic leakage, including periprosthetic tissue augmentation. Prolaryn gel, a commercially available formulation of carboxymethylcellulose, has been used at our institution as a bulking agent for this purpose. While Prolaryn gel is commonly used for vocal cord insufficiency, its role in managing peripheral TEP leakage has not been studied. This study evaluates the efficacy of Prolaryn gel injection as a novel tissue augmentation approach for periprosthetic TEP leakage.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted of patients managed at our institution for post-laryngectomy tracheoesophageal puncture and voice prosthesis care between 2007 to 2025. From this cohort, patients who underwent soft-tissue filler injection with Prolaryn gel for periprosthetic leakage were identified. After leakage was confirmed by a speech language pathologist, injections were performed by head and neck surgeons. Patients were subsequently assessed for voice quality and leakage while swallowing. Demographic information, medical comorbidities, surgical characteristics, and post-injection outcomes were obtained. The primary outcome was duration of leak resolution, and secondary outcomes were immediate treatment response and adverse events.</p>\n\n<p><strong>Results:</strong> Six male patients (mean age 57.8 years) underwent 23 injections of Prolaryn gel. Patients were followed for an average of 11.1 years after initial TEP placement or after initial office visit if TEP was placed elsewhere. All patients required prosthesis customization along with the injections. Four patients required multiple injections due to recurrent leakage. Of 23 injections administered, 21 injections resulted in immediate complete resolution of leakage, while 2 injections resulted in partial or near resolution. One patient on anticoagulation experienced mild, well-controlled post-injection bleeding on one occasion; no other immediate adverse events were observed. Among patients whose voice function was documented, all demonstrated fluent voice post-injection. The average duration of leak resolution was 6.7 months (range 0.07-49.2 months) from the last injection.</p>\n\n<p><strong>Conclusion: </strong>This is the first study to describe the use of Prolaryn gel as an injectable soft-tissue filler in treating periprosthetic TEP leakage. Our findings demonstrate that Prolaryn gel was effective in achieving immediate complete resolution of peripheral leakage in nearly all instances with a very low rate of adverse complications. Beyond the immediate effect, Prolaryn gel also provided sustained relief of peripheral leakage lasting an average of almost seven months. As such, these results highlight the promising potential of Prolaryn gel as a safe, novel adjunctive strategy to improve management of periprosthetic leakage and thereby enhance quality of life in post-laryngectomy patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153918--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S242",
      "content_id": "153851",
      "abstract_number": "S242",
      "poster_number": "",
      "title": "Recalibrating MDADI interpretation for HNC trials using updated clinically important change metrics",
      "summary": "These updated anchor-based analyses provide contemporary, methodologically robust MDADI interpretation benchmarks. Cross-sectional MIDs of 7–12 points reflect a spectrum of swallowing impairment; trialists can therefore select MID values aligned with their target swallowing endpoint, using thresholds near 7 for physiologic outcomes and closer to 12 when broader functional or patient-centered differences are of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153851",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beatrice Manduchi, PhD",
      "presenter": "Beatrice Manduchi, PhD",
      "authors": "Beatrice Manduchi, PhD 1 ; James C Borders 2 ; Abdelaziz Alsharawy 3 ; Konstantinos I Bougioukas 4 ; Carly E A Barbon 1 ; Stephen Y Lai 1 ; Clifton D Fuller 1 ; Amy C Moreno 1 ; Katherine A Hutcheson 1",
      "normalized_authors": [
        "Beatrice Manduchi",
        "James C Borders",
        "Abdelaziz Alsharawy",
        "Konstantinos I Bougioukas",
        "Carly E A Barbon",
        "Stephen Y Lai",
        "Clifton D Fuller",
        "Amy C Moreno",
        "Katherine A Hutcheson"
      ],
      "affiliations": [
        "MD Anderson Cancer Center",
        "Boston University",
        "UTHealth Houston",
        "Aristotle University of Thessaloniki, Thessaloniki, Greece"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center",
        "Boston University",
        "UTHealth Houston",
        "Aristotle University of Thessaloniki, Thessaloniki, Greece"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 494,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Participants",
        "Exposure",
        "Main outcomes",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Beatrice Manduchi, PhD 1 ; James C Borders 2 ; Abdelaziz Alsharawy 3 ; Konstantinos I Bougioukas 4 ; Carly E A Barbon 1 ; Stephen Y Lai 1 ; Clifton D Fuller 1 ; Amy C Moreno 1 ; Katherine A Hutcheson 1",
        "Affiliations": "1 MD Anderson Cancer Center; 2 Boston University; 3 UTHealth Houston; 4 Aristotle University of Thessaloniki, Thessaloniki, Greece",
        "Importance": "The MD Anderson Dysphagia Inventory (MDADI) is the most widely used patient-reported outcome measure of swallow-related quality of life in head and neck cancer (HNC). Clinically interpretable parameters such as minimal clinically important difference (MCID) were established more than a decade ago using limited anchors and methods.",
        "Objective": "To update cross-sectional minimal important difference (MID) and longitudinal minimal important change (MIC) estimates for the MDADI composite score using multiple clinical anchors and modern analytic approaches.",
        "Design": "Prospective data from five HNC cohorts were pooled, sampling MDADI–anchor pairs within a 7-day window. For cross-sectional analyses, a single timepoint per patient was randomly sampled. For longitudinal analyses, one pre–post treatment pair per patient was retained.",
        "Setting": "Single institution comprehensive cancer center.",
        "Participants": "The cross-sectional dataset included 3,158 unique patients (80% evaluated after cancer treatment). The longitudinal dataset included 961 patients (70% OPC; 86% male; mean age 60 years), with average interval between pre- and post-treatment assessments of 11.7 months (SD 12.2; range 0.5–79.5).",
        "Exposure": "Swallowing impairment severity measured by four clinical anchors: DIGEST, PSS-HN Diet and Eating, and feeding tube status.",
        "Main outcomes": "Cross-sectional MID estimates were derived by estimating the MDADI score difference between patients within adjacent anchor-defined categories (e.g., DIGEST 1 vs 2, 2 vs 3, etc.), using weighted bootstrap resampling. ROC-based cross-sectional analysis identified an MDADI threshold that best distinguished functional vs dysfunctional swallow (functional defined as: DIGEST=0-1, PSS-HN Diet ≥90, PSS-HN Eating ≥75 and no feeding tube). Longitudinal MIC analyses focused on patients with minimal anchor-defined pre-post treatment swallow decline (e.g., DIGEST pre→post:1→2 or 2→3, etc.); both mean-based and ROC-based MIC estimates were generated.",
        "Results": "Cross-sectional MIDs ranged from 7 to 12 points across anchors, with lower values (7) representing minimal physiologic differences (per DIGEST) and higher values (12) reflecting more functionally meaningful differences in diet level and public eating (per PSS-HN). ROC-based cross-sectional analyses yielded an MDADI threshold of 76 to classify functional vs dysfunctional swallow (sensitivity: 0.77; specificity: 0.71; AUC: 0.74). Longitudinal analyses yielded mean-based MIC values of –9 to –7 points for minimal decline across anchors. ROC-based MIC thresholds demonstrated greater variability over different anchors.",
        "Conclusions": "These updated anchor-based analyses provide contemporary, methodologically robust MDADI interpretation benchmarks. Cross-sectional MIDs of 7–12 points reflect a spectrum of swallowing impairment; trialists can therefore select MID values aligned with their target swallowing endpoint, using thresholds near 7 for physiologic outcomes and closer to 12 when broader functional or patient-centered differences are of primary interest. Longitudinal MID benchmarks instead are useful when estimating changes within a single arm study or population over time; these vary by anchor definition and by direction of change (decline reported here, with improvement values also derived); thus, threshold selection for such studies should be pre-specified and interpreted in context. Together, these MID and MIC values offer practical, flexible benchmarks for interpreting between-arm differences and within-patient change in trials using the MDADI.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Recalibrating MDADI interpretation for HNC trials using updated clinically important change metrics</span>. <u>Beatrice Manduchi, PhD</u><sup>1</sup>; James C Borders<sup>2</sup>; Abdelaziz Alsharawy<sup>3</sup>; Konstantinos I Bougioukas<sup>4</sup>; Carly E A Barbon<sup>1</sup>; Stephen Y Lai<sup>1</sup>; Clifton D Fuller<sup>1</sup>; Amy C Moreno<sup>1</sup>; Katherine A Hutcheson<sup>1</sup>. <sup>1</sup>MD Anderson Cancer Center; <sup>2</sup>Boston University; <sup>3</sup>UTHealth Houston; <sup>4</sup>Aristotle University of Thessaloniki, Thessaloniki, Greece<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>The MD Anderson Dysphagia Inventory (MDADI) is the most widely used patient-reported outcome measure of swallow-related quality of life in head and neck cancer (HNC). Clinically interpretable parameters such as minimal clinically important difference (MCID) were established more than a decade ago using limited anchors and methods.</p>\n\n<p><strong>Objective: </strong>To update cross-sectional minimal important difference (MID) and longitudinal minimal important change (MIC) estimates for the MDADI composite score using multiple clinical anchors and modern analytic approaches.</p>\n\n<p><strong>Design:</strong> Prospective data from five HNC cohorts were pooled, sampling MDADI–anchor pairs within a 7-day window. For cross-sectional analyses, a single timepoint per patient was randomly sampled. For longitudinal analyses, one pre–post treatment pair per patient was retained.</p>\n\n<p><strong>Setting: </strong>Single institution comprehensive cancer center.</p>\n\n<p><strong>Participants:</strong> The cross-sectional dataset included 3,158 unique patients (80% evaluated after cancer treatment). The longitudinal dataset included 961 patients (70% OPC; 86% male; mean age 60 years), with average interval between pre- and post-treatment assessments of 11.7 months (SD 12.2; range 0.5–79.5).</p>\n\n<p><strong>Exposure</strong>: Swallowing impairment severity measured by four clinical anchors: DIGEST, PSS-HN Diet and Eating, and feeding tube status.</p>\n\n<p><strong>Main outcomes: </strong>Cross-sectional MID estimates were derived by estimating the MDADI score difference between patients within adjacent anchor-defined categories (e.g., DIGEST 1 vs 2, 2 vs 3, etc.), using weighted bootstrap resampling. ROC-based cross-sectional analysis identified an MDADI threshold that best distinguished functional vs dysfunctional swallow (functional defined as: DIGEST=0-1, PSS-HN Diet ≥90, PSS-HN Eating ≥75 and no feeding tube). Longitudinal MIC analyses focused on patients with minimal anchor-defined pre-post treatment swallow decline (e.g., DIGEST pre→post:1→2 or 2→3, etc.); both mean-based and ROC-based MIC estimates were generated.</p>\n\n<p><strong>Results</strong>: Cross-sectional MIDs ranged from 7 to 12 points across anchors, with lower values (7) representing minimal physiologic differences (per DIGEST) and higher values (12) reflecting more functionally meaningful differences in diet level and public eating (per PSS-HN). ROC-based cross-sectional analyses yielded an MDADI threshold of 76 to classify functional vs dysfunctional swallow (sensitivity: 0.77; specificity: 0.71; AUC: 0.74). Longitudinal analyses yielded mean-based MIC values of –9 to –7  points for minimal decline across anchors. ROC-based MIC thresholds demonstrated greater variability over different anchors.</p>\n\n<p><strong>Conclusions</strong>: These updated anchor-based analyses provide contemporary, methodologically robust MDADI interpretation benchmarks. Cross-sectional MIDs of 7–12 points reflect a spectrum of swallowing impairment; trialists can therefore select MID values aligned with their target swallowing endpoint, using thresholds near 7 for physiologic outcomes and closer to 12 when broader functional or patient-centered differences are of primary interest. Longitudinal MID benchmarks instead are useful when estimating changes within a single arm study or population over time; these vary by anchor definition and by direction of change (decline reported here, with improvement values also derived); thus, threshold selection for such studies should be pre-specified and interpreted in context. Together, these MID and MIC values offer practical, flexible benchmarks for interpreting between-arm differences and within-patient change in trials using the MDADI.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153851--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S243",
      "content_id": "153022",
      "abstract_number": "S243",
      "poster_number": "",
      "title": "Beyond the Leak: Uncovering Oesophageal Contributions to Post-Laryngectomy Dysfunction",
      "summary": "Prosthetic leakage remains a predominant concern for patients following total laryngectomy surgery, these often associated with UES dysfunction and stricture formation however may also indicate a motility disorder of the esophagus. These findings highlight the need for comprehensive postoperative assessment including the esophageal phase of swallowing. The utility of high-resolution manometry of pharynx and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153022",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Julia C Maclean",
      "presenter": "Julia C Maclean",
      "authors": "Julia C Maclean",
      "normalized_authors": [
        "Julia C Maclean"
      ],
      "affiliations": [
        "St George Hospital, Sydney, Australia"
      ],
      "normalized_institutions": [
        "St George Hospital, Sydney, Australia"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 266,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Julia C Maclean",
        "Affiliations": "St George Hospital, Sydney, Australia",
        "Background": "Swallowing and voice prosthesis function following total laryngectomy are critical determinants of postoperative recovery and long-term quality of life. This study examined patterns of pharyngoesophageal dysfunction following total laryngectomy which frequently presented with voice prosthesis leakage.",
        "Methods": "Data were collated from 28 consecutive patients following total laryngectomy who underwent comprehensive swallowing assessment 1-20 years following treatment. The primary concern of the patient was categorised as prosthetic leak, dysphagia, voice disorder, regurgitation or aphonia, and the associated anatomical sites of dysfunction were recorded. All patients underwent comprehensive clinical assessment and objective assessments including High-Resolution Manometry, Timed Barium Swallows and Endoscopy.",
        "Results": "The most frequent adverse outcome was leakage of the voice prosthesis (50%), followed by dysphagia (32%), voice-related issues (12%), and isolated cases of regurgitation and aphonia (3% each). Dysfunction most frequently involved the upper esophageal sphincter (UES) (57%) with stricture identified in (39%). Esophageal dysfunction was seen in 32% of patients and in 44% of these cases it was the primary site of dysfunction. Many cases demonstrated multi-site abnormalities with UES dysfunction, stricture, and esophageal dysfunction reflecting the complex swallowing dysfunction seen in these patients.",
        "Conclusions": "Prosthetic leakage remains a predominant concern for patients following total laryngectomy surgery, these often associated with UES dysfunction and stricture formation however may also indicate a motility disorder of the esophagus. These findings highlight the need for comprehensive postoperative assessment including the esophageal phase of swallowing. The utility of high-resolution manometry of pharynx and esophagus can accurately elucidate the site and features of abnormality and assist with early intervention and improve functional outcomes following total laryngectomy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Beyond the Leak: Uncovering Oesophageal Contributions to Post-Laryngectomy Dysfunction</span>. <u>Julia C Maclean</u>. St George Hospital, Sydney, Australia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Swallowing and voice prosthesis function following total laryngectomy are critical determinants of postoperative recovery and long-term quality of life. This study examined patterns of pharyngoesophageal dysfunction following total laryngectomy which frequently presented with voice prosthesis leakage.</p>\n\n<p><strong>Methods: </strong>Data were collated from 28 consecutive patients following total laryngectomy who underwent comprehensive swallowing assessment 1-20 years following treatment. The primary concern of the patient was categorised as prosthetic leak, dysphagia, voice disorder, regurgitation or aphonia, and the associated anatomical sites of dysfunction were recorded. All patients underwent comprehensive clinical assessment and objective assessments including High-Resolution Manometry, Timed Barium Swallows and Endoscopy.</p>\n\n<p><strong>Results: </strong>The most frequent adverse outcome was leakage of the voice prosthesis (50%), followed by dysphagia (32%), voice-related issues (12%), and isolated cases of regurgitation and aphonia (3% each). Dysfunction most frequently involved the upper esophageal sphincter (UES) (57%) with stricture identified in (39%). Esophageal dysfunction was seen in 32% of patients and in 44% of these cases it was the primary site of dysfunction. Many cases demonstrated multi-site abnormalities with UES dysfunction, stricture, and esophageal dysfunction reflecting the complex swallowing dysfunction seen in these patients.</p>\n\n<p><strong>Conclusions: </strong>Prosthetic leakage remains a predominant concern for patients following total laryngectomy surgery, these often associated with UES dysfunction and stricture formation however may also indicate a motility disorder of the esophagus. These findings highlight the need for comprehensive postoperative assessment including the esophageal phase of swallowing. The utility of high-resolution manometry of pharynx and esophagus can accurately elucidate the site and features of abnormality and assist with early intervention and improve functional outcomes following total laryngectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153022--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S244",
      "content_id": "154734",
      "abstract_number": "S244",
      "poster_number": "",
      "title": "Use of Natural Language Processing to Expedite Objective Speech Articulation Assessment in Head and Neck Reconstruction",
      "summary": "NLP-based transcription achieved non-inferior accuracy compared with human evaluators while significantly reducing transcription time. Integration of NLP models such as OpenAI or other NLP platforms into postoperative speech assessment may enable high-throughput, objective, and reproducible evaluation of articulation outcomes in patients undergoing oral cavity and oropharyngeal free flap reconstruction. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154734",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter Kahng, MD",
      "presenter": "Peter Kahng, MD",
      "authors": "Peter Kahng, MD 1 ; Teresa Lyden, SLP 2 ; Doug Chepeha, MD 2 ; David Forner, MD 2 ; Molly Heft Neal, MD 2 ; Pratyusha Yalamanchi, MD, MBA 2 ; Marisa Buchakjian, MD 2 ; Madison Ambrose, SLP 2 ; Anna Blakely, SLP 2 ; Mark Prince, MD 2 ; Keith Casper, MD 2",
      "normalized_authors": [
        "Peter Kahng",
        "Teresa Lyden, SLP",
        "Doug Chepeha",
        "David Forner",
        "Molly Heft Neal",
        "Pratyusha Yalamanchi",
        "Marisa Buchakjian",
        "Madison Ambrose, SLP",
        "Anna Blakely, SLP",
        "Mark Prince",
        "Keith Casper"
      ],
      "affiliations": [
        "Emory University",
        "Michigan Medicine"
      ],
      "normalized_institutions": [
        "Emory University",
        "Michigan Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 360,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose/Objective(s)",
        "Materials/Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Peter Kahng, MD 1 ; Teresa Lyden, SLP 2 ; Doug Chepeha, MD 2 ; David Forner, MD 2 ; Molly Heft Neal, MD 2 ; Pratyusha Yalamanchi, MD, MBA 2 ; Marisa Buchakjian, MD 2 ; Madison Ambrose, SLP 2 ; Anna Blakely, SLP 2 ; Mark Prince, MD 2 ; Keith Casper, MD 2",
        "Affiliations": "1 Emory University; 2 Michigan Medicine",
        "Purpose/Objective(s)": "Speech articulation outcomes after head and neck cancer reconstruction remain difficult to assess due to challenges in collecting and objectively grading speech samples. Natural language processing (NLP) models offer automated speech-to-text capabilities that may enhance both efficiency and standardization. The objective of this study was to evaluate the efficacy of NLP-based transcription in objectively grading speech articulation in free flap patients using the validated Assessment of Intelligibility of Dysarthric Speech (AIDS) system.",
        "Materials/Methods": "Fourteen patients who underwent oral cavity or oropharyngeal free flap reconstruction were included. Standardized AIDS audio recordings were obtained for each patient, including 50 individual words and 13 sentences. Speech-to-text transcription was performed by four groups: (1) speech-language pathologists (SLPs), (2) otolaryngology resident physicians, (3) non-medical individuals, and (4) automated NLP transcription systems (OpenAI and Amazon Web Services [AWS]). To evaluate transcription efficiency, a subset of four patient recordings was selected for transcription time analysis. Transcription time duration was recorded for each of the non-medical participants and all OpenAI transcriptions. For these four timed patient samples, the evaluator’s grading time of each transcription was also recorded. All transcriptions were graded by the same evaluator to ensure consistency, and accuracy was compared across human and automated groups for both single-word and sentence components.",
        "Results": "Transcription accuracy among SLPs, resident physicians, non-medical individuals, and OpenAI did not differ significantly for either individual-word or sentence-level assessments. AWS demonstrated significantly lower accuracy for individual-word transcription (p < 0.05) but comparable performance for sentence-level transcription. The mean total transcription time for human participants was 21.9 min (± 5.3 min), compared with 0.66 min ± 0.3 min for OpenAI. The overall mean transcription grading time of the four timed samples was 11.7 min ± 6.0 min.",
        "Conclusion": "NLP-based transcription achieved non-inferior accuracy compared with human evaluators while significantly reducing transcription time. Integration of NLP models such as OpenAI or other NLP platforms into postoperative speech assessment may enable high-throughput, objective, and reproducible evaluation of articulation outcomes in patients undergoing oral cavity and oropharyngeal free flap reconstruction. These findings suggest that NLP technology can enhance the efficiency of speech intelligibility research in head and neck oncology.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of Natural Language Processing to Expedite Objective Speech Articulation Assessment in Head and Neck Reconstruction</span>. <u>Peter Kahng, MD</u><sup>1</sup>; Teresa Lyden, SLP<sup>2</sup>; Doug Chepeha, MD<sup>2</sup>; David Forner, MD<sup>2</sup>; Molly Heft Neal, MD<sup>2</sup>; Pratyusha Yalamanchi, MD, MBA<sup>2</sup>; Marisa Buchakjian, MD<sup>2</sup>; Madison Ambrose, SLP<sup>2</sup>; Anna Blakely, SLP<sup>2</sup>; Mark Prince, MD<sup>2</sup>; Keith Casper, MD<sup>2</sup>. <sup>1</sup>Emory University; <sup>2</sup>Michigan Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose/Objective(s): </strong>Speech articulation outcomes after head and neck cancer reconstruction remain difficult to assess due to challenges in collecting and objectively grading speech samples. Natural language processing (NLP) models offer automated speech-to-text capabilities that may enhance both efficiency and standardization. The objective of this study was to evaluate the efficacy of NLP-based transcription in objectively grading speech articulation in free flap patients using the validated Assessment of Intelligibility of Dysarthric Speech (AIDS) system.</p>\n\n<p><strong>Materials/Methods: </strong>Fourteen patients who underwent oral cavity or oropharyngeal free flap reconstruction were included. Standardized AIDS audio recordings were obtained for each patient, including 50 individual words and 13 sentences. Speech-to-text transcription was performed by four groups: (1) speech-language pathologists (SLPs), (2) otolaryngology resident physicians, (3) non-medical individuals, and (4) automated NLP transcription systems (OpenAI and Amazon Web Services [AWS]). To evaluate transcription efficiency, a subset of four patient recordings was selected for transcription time analysis. Transcription time duration was recorded for each of the non-medical participants and all OpenAI transcriptions. For these four timed patient samples, the evaluator’s grading time of each transcription was also recorded. All transcriptions were graded by the same evaluator to ensure consistency, and accuracy was compared across human and automated groups for both single-word and sentence components.</p>\n\n<p><strong>Results: </strong>Transcription accuracy among SLPs, resident physicians, non-medical individuals, and OpenAI did not differ significantly for either individual-word or sentence-level assessments. AWS demonstrated significantly lower accuracy for individual-word transcription (p < 0.05) but comparable performance for sentence-level transcription. The mean total transcription time for human participants was 21.9 min  (± 5.3 min), compared with 0.66 min ± 0.3 min for OpenAI. The overall mean transcription grading time of the four timed samples was 11.7 min ± 6.0 min.</p>\n\n<p><strong>Conclusion: </strong>NLP-based transcription achieved non-inferior accuracy compared with human evaluators while significantly reducing transcription time. Integration of NLP models such as OpenAI or other NLP platforms into postoperative speech assessment may enable high-throughput, objective, and reproducible evaluation of articulation outcomes in patients undergoing oral cavity and oropharyngeal free flap reconstruction. These findings suggest that NLP technology can enhance the efficiency of speech intelligibility research in head and neck oncology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154734--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S245",
      "content_id": "153872",
      "abstract_number": "S245",
      "poster_number": "",
      "title": "Pre-surgical dysphagia in oral cavity cancer: Insights from videofluoroscopic assessment",
      "summary": "These preliminary study findings demonstrate that patients with oral cancer eligible for free flap reconstruction exhibit quantifiable swallowing impairments at baseline, with the most pronounced impairment in the oral phase. Specifically, impairment of lingual movements impacted oral bolus transport, timing of the pharyngeal swallow initiation, and clearance of residue from both the oral and the pharyngeal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153872",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aliaa Sabry",
      "presenter": "Aliaa Sabry",
      "authors": "Aliaa Sabry 1 ; Elizabeth Cross 1 ; Veronica Rodriguez 1 ; Jonathan C Irish 1 ; Sharon Tzelnick 1 ; Rosemary Martino 2",
      "normalized_authors": [
        "Aliaa Sabry",
        "Elizabeth Cross",
        "Veronica Rodriguez",
        "Jonathan C Irish",
        "Sharon Tzelnick",
        "Rosemary Martino"
      ],
      "affiliations": [
        "University Health Network",
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University Health Network",
        "University of Toronto"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 484,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aliaa Sabry 1 ; Elizabeth Cross 1 ; Veronica Rodriguez 1 ; Jonathan C Irish 1 ; Sharon Tzelnick 1 ; Rosemary Martino 2",
        "Affiliations": "1 University Health Network; 2 University of Toronto",
        "Purpose": "Patients with oral cancers commonly experience oropharyngeal dysphagia, which can persist even after surgical treatment. Recent evidence indicates that approximately 30% of patients with oral cancer report a moderate to severe impact on quality of life prior to cancer surgery. However, there is limited objective evidence detailing the extent and level of pre-surgical swallowing impairment. This study aimed to characterize the physiological aspects of swallowing impairment using videofluoroscopic imaging in patients with oral cancer awaiting curative surgical intervention.",
        "Methods": "As part of an ongoing treatment trial focused on swallowing intervention, we consecutively enrolled adults with oral cancer who attended the surgical oncology clinics at the Princess Margaret Cancer Centre in Toronto, ON, and were scheduled for surgery with free flap reconstruction. All patients received a standardized videofluoroscopic swallow study (VFS) at baseline that included two trials each of 5 ml thin liquid, 10 ml thin liquid, cup sip thin liquid, sequential cup sips of thin liquid, 5 ml puree, and regular solids. Digital recordings of VFS images were independently scored by trained speech-language pathologists using the Modified Barium Swallow Impairment Profile (MBSImP). Preliminary imaging findings of the first 30 consecutive participants enrolled were characterized using individual oral and pharyngeal component scores, summarized as medians (IQR), and oral total and pharyngeal total scores, summarized as means (SD).",
        "Results": "The sample included 19 males (63%) and 11 females (37%), with a mean age of 63 years (SD = 12.3). Tumour sites were distributed as follows: 16 (56%) oral tongue, 8 (32%) mandible, 2 (7%) buccal, 2 (7%) involving both the mandible and buccal regions, and 2 (7%) palate. On pathological examination, 27 (90%) of participants had squamous cell carcinomas. Cancer staging showed that 4 (13%) were Stage I, 6 (20%) Stage II, 7 (23%) Stage III, 13 (43%) Stage IV. The most common type of reconstruction was a radial forearm free flap (16, 53%), followed by a scapular free flap (7, 23%) and a free anterolateral thigh flap (4, 13%). Baseline individual MBSImP ratings depicted impairments in oral bolus transport, oral residue and initiation of the pharyngeal swallow with median (IQR) scores of 3 (2-3), 2 (2) and 3 (3) respectively. In contrast, individual pharyngeal phase component identified impairment with only pharyngeal residue, with a median (IQR) score of 2 (2). Overall, total oral-phase score was worse than total pharyngeal score, with mean (SD) values of 10.23 (1.90) and 8.53 (3.22), respectively.",
        "Conclusions": "These preliminary study findings demonstrate that patients with oral cancer eligible for free flap reconstruction exhibit quantifiable swallowing impairments at baseline, with the most pronounced impairment in the oral phase. Specifically, impairment of lingual movements impacted oral bolus transport, timing of the pharyngeal swallow initiation, and clearance of residue from both the oral and the pharyngeal cavities. These findings underscore the need for early, objective dysphagia assessment to inform pre-operative counseling and guide intervention planning.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pre-surgical dysphagia in oral cavity cancer: Insights from videofluoroscopic assessment</span>. <u>Aliaa Sabry</u><sup>1</sup>; Elizabeth Cross<sup>1</sup>; Veronica Rodriguez<sup>1</sup>; Jonathan C Irish<sup>1</sup>; Sharon Tzelnick<sup>1</sup>; Rosemary Martino<sup>2</sup>. <sup>1</sup>University Health Network; <sup>2</sup>University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> Patients with oral cancers commonly experience oropharyngeal dysphagia, which can persist even after surgical treatment. Recent evidence indicates that approximately 30% of patients with oral cancer report a moderate to severe impact on quality of life prior to cancer surgery. However, there is limited objective evidence detailing the extent and level of pre-surgical swallowing impairment. This study aimed to characterize the physiological aspects of swallowing impairment using videofluoroscopic imaging in patients with oral cancer awaiting curative surgical intervention.</p>\n\n<p><strong>Methods:</strong> As part of an ongoing treatment trial focused on swallowing intervention, we consecutively enrolled adults with oral cancer who attended the surgical oncology clinics at the Princess Margaret Cancer Centre in Toronto, ON, and were scheduled for surgery with free flap reconstruction. All patients received a standardized videofluoroscopic swallow study (VFS) at baseline that included two trials each of 5 ml thin liquid, 10 ml thin liquid, cup sip thin liquid, sequential cup sips of thin liquid, 5 ml puree, and regular solids. Digital recordings of VFS images were independently scored by trained speech-language pathologists using the Modified Barium Swallow Impairment Profile (MBSImP). Preliminary imaging findings of the first 30 consecutive participants enrolled were characterized using individual oral and pharyngeal component scores, summarized as medians (IQR), and oral total and pharyngeal total scores, summarized as means (SD).</p>\n\n<p><strong>Results: </strong>The sample included 19 males (63%) and 11 females (37%), with a mean age of 63 years (SD = 12.3). Tumour sites were distributed as follows: 16 (56%) oral tongue, 8 (32%) mandible, 2 (7%) buccal, 2 (7%) involving both the mandible and buccal regions, and 2 (7%) palate. On pathological examination, 27 (90%) of participants had squamous cell carcinomas. Cancer staging showed that 4 (13%) were Stage I, 6 (20%) Stage II, 7 (23%) Stage III, 13 (43%) Stage IV. The most common type of reconstruction was a radial forearm free flap (16, 53%), followed by a scapular free flap (7, 23%) and a free anterolateral thigh flap (4, 13%). Baseline individual MBSImP ratings depicted impairments in oral bolus transport, oral residue and initiation of the pharyngeal swallow with median (IQR) scores of 3 (2-3), 2 (2) and 3 (3) respectively. In contrast, individual pharyngeal phase component identified impairment with only pharyngeal residue, with a median (IQR) score of 2 (2). Overall, total oral-phase score was worse than total pharyngeal score, with mean (SD) values of 10.23 (1.90) and 8.53 (3.22), respectively.</p>\n\n<p><strong>Conclusions:</strong> These preliminary study findings demonstrate that patients with oral cancer eligible for free flap reconstruction exhibit quantifiable swallowing impairments at baseline, with the most pronounced impairment in the oral phase. Specifically, impairment of lingual movements impacted oral bolus transport, timing of the pharyngeal swallow initiation, and clearance of residue from both the oral and the pharyngeal cavities. These findings underscore the need for early, objective dysphagia assessment to inform pre-operative counseling and guide intervention planning.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153872--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S246",
      "content_id": "154470",
      "abstract_number": "S246",
      "poster_number": "",
      "title": "Post-Operative Day One Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in Patients Undergoing Transoral Robotic Surgery",
      "summary": "These findings suggest that FEES, along with real time directed intervention for swallowing, could play a role in earlier return to oral diet. Although not statistically significant, mean duration of days until removal of feeding tube was also much shorter. Short term evaluation with FEES in patients undergoing TORS may provide benefit in direct feedback on swallow safety and efficiency.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154470",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Anderson, MD",
      "presenter": "Ryan Anderson, MD",
      "authors": "Ryan Anderson, MD 1 ; Dillon Strepay, MD 1 ; Julia Porter, MSP, MPH 1 ; Peyton Robinson, MD 2 ; Deborah Xie, MD 3 ; David A Campbell, MD 1 ; Jessica A Yesensky, MD 1 ; Avinash V Mantravadi, MD 1 ; Michael G Moore, MD 1 ; Janice L Farlow, MD, PhD 1 ; Michael W Sim, MD 1",
      "normalized_authors": [
        "Ryan Anderson",
        "Dillon Strepay",
        "Julia Porter, MSP",
        "Peyton Robinson",
        "Deborah Xie",
        "David A Campbell",
        "Jessica A Yesensky",
        "Avinash V Mantravadi",
        "Michael G Moore",
        "Janice L Farlow",
        "Michael W Sim"
      ],
      "affiliations": [
        "Indiana University/IU Health",
        "University of Louisville",
        "Barrow Neurological Institute"
      ],
      "normalized_institutions": [
        "Indiana University/IU Health",
        "University of Louisville",
        "Barrow Neurological Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryan Anderson, MD 1 ; Dillon Strepay, MD 1 ; Julia Porter, MSP, MPH 1 ; Peyton Robinson, MD 2 ; Deborah Xie, MD 3 ; David A Campbell, MD 1 ; Jessica A Yesensky, MD 1 ; Avinash V Mantravadi, MD 1 ; Michael G Moore, MD 1 ; Janice L Farlow, MD, PhD 1 ; Michael W Sim, MD 1",
        "Affiliations": "1 Indiana University/IU Health; 2 University of Louisville; 3 Barrow Neurological Institute",
        "Introduction": "Head and neck cancer ranks sixth globally, with squamous cell carcinoma (SCC) comprising ~90% of cases. Given the favorable prognosis of HPV+ OPSCC, focus has shifted to reducing treatment morbidity. Transoral robotic surgery (TORS) has emerged as a preferred minimally invasive approach for early-stage cases. While studies document favorable swallowing outcomes following TORS, few have objectively measured postoperative swallowing function using instrumental assessments.",
        "Methods": "This single-institution, single-physician retrospective study examined TORS cases performed between April 2012 and September 2024. Patients were divided into two cohorts based on the implementation of systematic postoperative swallowing assessment. The pre-FEES cohort included TORS cases performed between April 2012 and April 2022, during which patients did not receive POD1 swallow studies. The post-FEES cohort included cases performed between July 2022 and December 2024, during which patients received POD1 FEES studies. The FEES studies were graded using various swallowing scales including the DIGEST-FEES, penetration aspiration scale (PAS), New Zealand Secretion Rating Score (NZSSR), and Revised Patterson Edema Scale. Digest FEES is a standardized FEES-based scale measuring overall swallowing function severity. The primary outcome was feeding tube removal at discharge was compared between groups using Chi-Square Test. Secondary outcomes were time until feeding tube removal and the Digest FEES score’s association with feeding tube removal.",
        "Results": "A total of 201 patients were included in the study: 146 patients in the pre-FEES TORS cohort and 55 in the post-FEES TORS cohort. Age (59.4 vs 62.02), sex (85.6% M; 89.1% M), length of stay (3.61 days vs 2.2 days), location of tumor (tonsil 51% vs 50.9%, base of tongue 40% vs 42%, unknown 5.5% vs 3.6%, and other 3.4% vs 3.6), clinical T and N stage, and neck dissection were all compared with no significant differences in patient demographics. In the pre-FEES group, 46.6% of patients were discharged home without a feeding tube compared to 64% in the post-FEES group. This was statistically significant with a P-value of 0.031. Digest FEES were graded on a scale of 0, 1, 2, and 3 corresponding with no deficit, mild, moderate and severe. Digest FEES scores correlated with discharge home without a feeding tube as follows; 0 = 80%, 1 = 66.7%, 2 = 62.5%, and 3 = 53.8%. Time until feeding tube removal was also compared with a mean of 12.11 days in the pre-FEES group, compared to 6.56 days in the post-FEES group. This was not found to be statistically significant. There was no significant increase in readmission rates or reinsertion of feeding tube between the two groups.",
        "Conclusion": "These findings suggest that FEES, along with real time directed intervention for swallowing, could play a role in earlier return to oral diet. Although not statistically significant, mean duration of days until removal of feeding tube was also much shorter. Short term evaluation with FEES in patients undergoing TORS may provide benefit in direct feedback on swallow safety and efficiency.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Post-Operative Day One Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in Patients Undergoing Transoral Robotic Surgery</span>. <u>Ryan Anderson, MD</u><sup>1</sup>; Dillon Strepay, MD<sup>1</sup>; Julia Porter, MSP, MPH<sup>1</sup>; Peyton Robinson, MD<sup>2</sup>; Deborah Xie, MD<sup>3</sup>; David A Campbell, MD<sup>1</sup>; Jessica A Yesensky, MD<sup>1</sup>; Avinash V Mantravadi, MD<sup>1</sup>; Michael G Moore, MD<sup>1</sup>; Janice L Farlow, MD, PhD<sup>1</sup>; Michael W Sim, MD<sup>1</sup>. <sup>1</sup>Indiana University/IU Health; <sup>2</sup>University of Louisville; <sup>3</sup>Barrow Neurological Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Head and neck cancer ranks sixth globally, with squamous cell carcinoma (SCC) comprising ~90% of cases. Given the favorable prognosis of HPV+ OPSCC, focus has shifted to reducing treatment morbidity. Transoral robotic surgery (TORS) has emerged as a preferred minimally invasive approach for early-stage cases. While studies document favorable swallowing outcomes following TORS, few have objectively measured postoperative swallowing function using instrumental assessments.</p>\n\n<p><strong>Methods</strong>: This single-institution, single-physician retrospective study examined TORS cases performed between April 2012 and September 2024. Patients were divided into two cohorts based on the implementation of systematic postoperative swallowing assessment. The pre-FEES cohort included TORS cases performed between April 2012 and April 2022, during which patients did not receive POD1 swallow studies. The post-FEES cohort included cases performed between July 2022 and December 2024, during which patients received POD1 FEES studies. The FEES studies were graded using various swallowing scales including the DIGEST-FEES, penetration aspiration scale (PAS), New Zealand Secretion Rating Score (NZSSR), and Revised Patterson Edema Scale. Digest FEES is a standardized FEES-based scale measuring overall swallowing function severity. The primary outcome was feeding tube removal at discharge was compared between groups using Chi-Square Test. Secondary outcomes were time until feeding tube removal and the Digest FEES score’s association with feeding tube removal.</p>\n\n<p><strong>Results</strong>: A total of 201 patients were included in the study: 146 patients in the pre-FEES TORS cohort and 55 in the post-FEES TORS cohort. Age (59.4 vs 62.02), sex (85.6% M; 89.1% M), length of stay (3.61 days vs 2.2 days), location of tumor (tonsil 51% vs 50.9%, base of tongue 40% vs 42%, unknown 5.5% vs 3.6%, and other 3.4% vs 3.6), clinical T and N stage, and neck dissection were all compared with no significant differences in patient demographics. In the pre-FEES group, 46.6% of patients were discharged home without a feeding tube compared to 64% in the post-FEES group. This was statistically significant with a P-value of 0.031. Digest FEES were graded on a scale of 0, 1, 2, and 3 corresponding with no deficit, mild, moderate and severe. Digest FEES scores correlated with discharge home without a feeding tube as follows; 0 = 80%, 1 = 66.7%, 2 = 62.5%, and 3 = 53.8%. Time until feeding tube removal was also compared with a mean of 12.11 days in the pre-FEES group, compared to 6.56 days in the post-FEES group. This was not found to be statistically significant. There was no significant increase in readmission rates or reinsertion of feeding tube between the two groups.</p>\n\n<p><strong>Conclusion</strong>: These findings suggest that FEES, along with real time directed intervention for swallowing, could play a role in earlier return to oral diet. Although not statistically significant, mean duration of days until removal of feeding tube was also much shorter. Short term evaluation with FEES in patients undergoing TORS may provide benefit in direct feedback on swallow safety and efficiency.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154470--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S247",
      "content_id": "152917",
      "abstract_number": "S247",
      "poster_number": "",
      "title": "One year swallowing outcomes in patients with nasopharyngeal carcinoma.",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152917",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Heather M Starmer",
      "presenter": "Heather M Starmer",
      "authors": "Theresa Yao 1 ; Chia-En Lu 1 ; Beth Beadle, MD 2 ; A",
      "normalized_authors": [
        "Theresa Yao",
        "Chia-En Lu",
        "Beth Beadle"
      ],
      "affiliations": [
        "Dimitrios Colevas 2",
        "Michael Gensheimer 2",
        "Jocelen Hamilton 1",
        "Jennifer Kizner 1",
        "Quynh Thu Le 2",
        "Raymond Fong 3",
        "Heather M Starmer 2 . 1 Stanford Healthcare",
        "Stanford University",
        "Chinese University of Hong Kong"
      ],
      "normalized_institutions": [
        "Dimitrios Colevas 2",
        "Michael Gensheimer 2",
        "Jocelen Hamilton 1",
        "Jennifer Kizner 1",
        "Quynh Thu Le 2",
        "Raymond Fong 3",
        "Heather M Starmer 2 . 1 Stanford Healthcare",
        "Stanford University",
        "Chinese University of Hong Kong"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "OBJECTIVES",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Abstract"
      ],
      "sections": {
        "Authors": "Theresa Yao 1 ; Chia-En Lu 1 ; Beth Beadle, MD 2 ; A",
        "Affiliations": "Dimitrios Colevas 2 ; Michael Gensheimer 2 ; Jocelen Hamilton 1 ; Jennifer Kizner 1 ; Quynh Thu Le 2 ; Raymond Fong 3 ; Heather M Starmer 2 . 1 Stanford Healthcare; 2 Stanford University; 3 Chinese University of Hong Kong",
        "BACKGROUND": "Patients with nasopharyngeal carcinoma (NPC) may experience changes in their swallowing due to tumor burden and the treatments used to eradicate them. Dysphagia is a complex construct that can include changes in oral and pharyngeal function, the impact of xerostomia on oral intake, and patient perception of swallowing function. Because many treatment toxicities may be perceived as dysphagia, multiple methods may be used to evaluate it, including patient-reported outcomes (PROs), functional performance scales, and clinician-graded physiologic outcomes. Most research regarding swallowing in patients with NPC has relied on PROs and feeding tube dependence, both of which may be heavily influenced by xerostomia and other treatment effects. The Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) method provides important insight into pharyngeal physiologic impairment as measured during instrumental evaluations, which can be associated with pulmonary and nutritional complications.",
        "OBJECTIVES": "The objective of this study was to analyze dysphagia in patients with NPC in first year following definitive (chemo)radiation. The primary outcome was DIGEST grades to provide insight into physiologic swallowing impairment in this population. Clinician and patient graded outcomes such as Functional Oral Intake Scale (FOIS) and MD Anderson Dysphagia Inventory (MDADI) scores were included as secondary outcomes.",
        "METHODS": "Consecutive patients with NPC treated with definitive (chemo)radiation from 2014-2024 at a single NCI Designated Comprehensive Cancer Center were retrospectively analyzed. Swallowing outcomes were extracted from the medical record and included DIGEST grades, FOIS and MDADI scores, and feeding tube dependence. For those patients who underwent treatment prior to development of the DIGEST methodology, video exams were reviewed and scored by a single rater blinded to timing of exams. Descriptive statistics are reported for demographics, treatment characteristics, and dysphagia assessments.",
        "RESULTS": "A total of 68 patients were included with a median age of 53 years (range 18-86 years). Using AJCC 8th edition, there were 15 patients with stage I-II, 22 with stage III, and 31 with stage IV disease. 93% of patients were seen by SLP prior to start of radiation. The percentage of patients with no dysphagia (DIGEST 0) decreased from 59% at baseline to 45% at 1 year, while mild dysphagia (DIGEST 1) increased from 37% to 45%. Moderate-to-severe dysphagia (DIGEST 2-3) increased from 4% to 9% at one year. The average MDADI score was 89.96 at baseline, 72.27 at 2-3 months, and 83.44 at 1 year. Unrestricted diets were noted in 79% of patients at baseline decreasing to 56% at one year. Overall, 8.8% of patients required a feeding tube, all of which were placed in a reactive manner due to pain and weight loss.",
        "CONCLUSIONS": "DIGEST grades of patients treated for NPC increased over the first year post-treatment reflecting an increase in physiologic dysfunction impacting swallowing safety and efficiency. Although MDADI scores returned to near baseline levels one-year following treatment, the rise in instrumentally measurable impairments suggests that patients may not be reliable reporters of underlying physiologic impairment that may result in health consequences. As a result, continued dysphagia services and surveillance appear warranted in this population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>One year swallowing outcomes in patients with nasopharyngeal carcinoma.</span>. Theresa Yao<sup>1</sup>; Chia-En Lu<sup>1</sup>; Beth Beadle, MD<sup>2</sup>; A. Dimitrios Colevas<sup>2</sup>; Michael Gensheimer<sup>2</sup>; Jocelen Hamilton<sup>1</sup>; Jennifer Kizner<sup>1</sup>; Quynh Thu Le<sup>2</sup>; Raymond Fong<sup>3</sup>; <u>Heather M Starmer</u><sup>2</sup>. <sup>1</sup>Stanford Healthcare; <sup>2</sup>Stanford University; <sup>3</sup>Chinese University of Hong Kong<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> Patients with nasopharyngeal carcinoma (NPC) may experience changes in their swallowing due to tumor burden and the treatments used to eradicate them. Dysphagia is a complex construct that can include changes in oral and pharyngeal function, the impact of xerostomia on oral intake, and patient perception of swallowing function. Because many treatment toxicities may be perceived as dysphagia, multiple methods may be used to evaluate it, including patient-reported outcomes (PROs), functional performance scales, and clinician-graded physiologic outcomes. Most research regarding swallowing in patients with NPC has relied on PROs and feeding tube dependence, both of which may be heavily influenced by xerostomia and other treatment effects. The Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) method provides important insight into pharyngeal physiologic impairment as measured during instrumental evaluations, which can be associated with pulmonary and nutritional complications.</p>\n\n<p><strong>OBJECTIVES:</strong> The objective of this study was to analyze dysphagia in patients with NPC in first year following definitive (chemo)radiation. The primary outcome was DIGEST grades to provide insight into physiologic swallowing impairment in this population.  Clinician and patient graded outcomes such as Functional Oral Intake Scale (FOIS) and MD Anderson Dysphagia Inventory (MDADI) scores were included as secondary outcomes.  </p>\n\n<p><strong>METHODS:</strong> Consecutive patients with NPC treated with definitive (chemo)radiation from 2014-2024 at a single NCI Designated Comprehensive Cancer Center were retrospectively analyzed. Swallowing outcomes were extracted from the medical record and included DIGEST grades, FOIS and MDADI scores, and feeding tube dependence. For those patients who underwent treatment prior to development of the DIGEST methodology, video exams were reviewed and scored by a single rater blinded to timing of exams. Descriptive statistics are reported for demographics, treatment characteristics, and dysphagia assessments.</p>\n\n<p><strong>RESULTS:</strong> A total of 68 patients were included with a median age of 53 years (range 18-86 years). Using AJCC 8th edition, there were 15 patients with stage I-II, 22 with stage III, and 31 with stage IV disease. 93% of patients were seen by SLP prior to start of radiation. The percentage of patients with no dysphagia (DIGEST 0) decreased from 59% at baseline to 45% at 1 year, while mild dysphagia (DIGEST 1) increased from 37% to 45%. Moderate-to-severe dysphagia (DIGEST 2-3) increased from 4% to 9% at one year. The average MDADI score was 89.96 at baseline, 72.27 at 2-3 months, and 83.44 at 1 year. Unrestricted diets were noted in 79% of patients at baseline decreasing to 56% at one year. Overall, 8.8% of patients required a feeding tube, all of which were placed in a reactive manner due to pain and weight loss.</p>\n\n<p><strong>CONCLUSIONS: </strong>DIGEST grades of patients treated for NPC increased over the first year post-treatment reflecting an increase in physiologic dysfunction impacting swallowing safety and efficiency.  Although MDADI scores returned to near baseline levels one-year following treatment, the rise in instrumentally measurable impairments suggests that patients may not be reliable reporters of underlying physiologic impairment that may result in health consequences.  As a result, continued dysphagia services and surveillance appear warranted in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152917--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S248",
      "content_id": "154019",
      "abstract_number": "S248",
      "poster_number": "",
      "title": "Blood Flow Matters: Linking Ultrasound-Determined Peristomal Vascularity to Tracheoesophageal Puncture Outcomes",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154019",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lauren Ottenstein, MS, CCC, SLP, BCSSS",
      "presenter": "Lauren Ottenstein, MS, CCC, SLP, BCSSS",
      "authors": "Lauren Ottenstein, MS, CCC, SLP, BCSSS ; Celeste Kim, MD; Jenna Hall, MS, CCC, SLP; Georges Daoud, MD; Merry Sebelik, MD, FACS, MAMSE",
      "normalized_authors": [
        "Lauren Ottenstein, CCC, SLP, BCSSS",
        "Celeste Kim",
        "Jenna Hall, CCC, SLP",
        "Georges Daoud",
        "Merry Sebelik, MAMSE"
      ],
      "affiliations": [
        "Winship Cancer Institute at Emory University"
      ],
      "normalized_institutions": [
        "Winship Cancer Institute at Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154019/Peristomal%20Vascularity_Figure1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154019/Peristomal%20Vascularity_Figure1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154019"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 440,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lauren Ottenstein, MS, CCC, SLP, BCSSS ; Celeste Kim, MD; Jenna Hall, MS, CCC, SLP; Georges Daoud, MD; Merry Sebelik, MD, FACS, MAMSE",
        "Affiliations": "Winship Cancer Institute at Emory University",
        "INTRODUCTION": "Laryngeal cancer is one of the most common subsites of head and neck cancer, and total laryngectomy may be performed as a primary form of treatment, or as a salvage procedure after failure of chemoradiation. For total laryngectomy patients, optimization of alaryngeal speech is paramount for long-term quality of life. Placement of a tracheoesophageal prosthesis (TEP) is considered the mainstay for vocal rehabilitation, but there can be complications such as fistula formation, TEP leakage, dislodgement, or embedding, that lead to poor functional outcomes and possible TEP removal, with higher rates in the salvage laryngectomy population. In the salvage laryngectomy patient, prior chemoradiation treatment causes vascular compromise of the soft tissues surrounding the trachea and pharynx (peristomal tissues) with potential for poor wound healing and TEP compromise. This study aims to correlate peristomal vascularity with TEP outcomes, with vascularity determined by ultrasound color doppler assessment.",
        "METHODS": "This is a single-institution hybrid retrospective-prospective study on patients who underwent secondary TEP placement after a salvage total laryngectomy and were available for assessment during routine Speech Language Pathology (SLP) appointments. Retrospective data collection included TEP outcomes/complications. Prospective data collection included examining the tissues at the superior stomal margin and obtaining transverse and sagittal views with color doppler flow, using a hockey stick-shaped ultrasound probe with frequency of 8-15mHz (GE Medicalã). Vascularity visualized within the tracheal mucosa and suprastomal tissue was graded as 1- largely absent, 2- moderately vascular, 3- highly vascular. Details regarding TEP outcomes were also recorded. Bivariate analyses were performed to identify significant relationships between peristomal vascularity and TEP outcomes.",
        "RESULTS": "A total of 26 patients met the inclusion criteria, with mean age of 65, and majority of patients were male (73%) and Caucasian (81%). Majority (62%) had undergone free flap reconstruction, with a mean of 684 days from laryngectomy to TEP. 7/26 (27%) patients ultimately had the TEP removed due to complications. 20/26 patients were available to come in for routine TEP care by SLP team members. Preliminary assessment of an index patient from this cohort provided an example of grade 1 - largely absent vascularity (Fig. 1). Data collection is ongoing and a trend toward correlation between poor vascularity and increased complications is observed.",
        "CONCLUSION": "Our initial observations suggest that there may be a significant relationship between vascularity and incidence of TEP complications such as frequent periprosthetic leakage, expanding fistula, TEP dislodgement and ultimately TEP failure and removal. Ultimately, the goal of this investigation is to better understand the impact of peristomal vascularity as a predictor of TEP complication and failure, leading to better selection criteria for TEP candidacy in this complex patient population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Blood Flow Matters:  Linking Ultrasound-Determined Peristomal Vascularity to Tracheoesophageal Puncture Outcomes</span>. <u>Lauren Ottenstein, MS, CCC, SLP, BCSSS</u>; Celeste Kim, MD; Jenna Hall, MS, CCC, SLP; Georges Daoud, MD; Merry Sebelik, MD, FACS, MAMSE. Winship Cancer Institute at Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION: </strong>Laryngeal cancer is one of the most common subsites of head and neck cancer, and total laryngectomy may be performed as a primary form of treatment, or as a salvage procedure after failure of chemoradiation. For total laryngectomy patients, optimization of alaryngeal speech is paramount for long-term quality of life. Placement of a tracheoesophageal prosthesis (TEP) is considered the mainstay for vocal rehabilitation, but there can be complications such as fistula formation, TEP leakage, dislodgement, or embedding, that lead to poor functional outcomes and possible TEP removal, with higher rates in the salvage laryngectomy population. In the salvage laryngectomy patient, prior chemoradiation treatment causes vascular compromise of the soft tissues surrounding the trachea and pharynx (peristomal tissues) with potential for poor wound healing and TEP compromise. This study aims to correlate peristomal vascularity with TEP outcomes, with vascularity determined by ultrasound color doppler assessment. </p>\n\n<p><strong>METHODS: </strong>This is a single-institution hybrid retrospective-prospective study on patients who underwent secondary TEP placement after a salvage total laryngectomy and were available for assessment during routine Speech Language Pathology (SLP) appointments. Retrospective data collection included TEP outcomes/complications. Prospective data collection included examining the tissues at the superior stomal margin and obtaining transverse and sagittal views with color doppler flow, using a hockey stick-shaped ultrasound probe with frequency of 8-15mHz (GE Medicalã). Vascularity visualized within the tracheal mucosa and suprastomal tissue was graded as 1- largely absent, 2- moderately vascular, 3- highly vascular. Details regarding TEP outcomes were also recorded. Bivariate analyses were performed to identify significant relationships between peristomal vascularity and TEP outcomes. </p>\n\n<p><strong>RESULTS: </strong>A total of 26 patients met the inclusion criteria, with mean age of 65, and majority of patients were male (73%) and Caucasian (81%). Majority (62%) had undergone free flap reconstruction, with a mean of 684 days from laryngectomy to TEP. 7/26 (27%) patients ultimately had the TEP removed due to complications. 20/26 patients were available to come in for routine TEP care by SLP team members. Preliminary assessment of an index patient from this cohort provided an example of grade 1 - largely absent vascularity (Fig. 1). Data collection is ongoing and a trend toward correlation between poor vascularity and increased complications is observed. </p>\n\n<p><strong>CONCLUSION: </strong>Our initial observations suggest that there may be a significant relationship between vascularity and incidence of TEP complications such as frequent periprosthetic leakage, expanding fistula, TEP dislodgement and ultimately TEP failure and removal. Ultimately, the goal of this investigation is to better understand the impact of peristomal vascularity as a predictor of TEP complication and failure, leading to better selection criteria for TEP candidacy in this complex patient population.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154019/Peristomal%20Vascularity_Figure1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154019--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S249",
      "content_id": "154195",
      "abstract_number": "S249",
      "poster_number": "",
      "title": "The Tracheoesophageal Prosthesis Lifespan: Comparing Initial Surgical Placement Versus Subsequent Clinic Placement of Prostheses",
      "summary": "Initial OR-placed VPs demonstrated longer lifespans than clinic-placed VPs. The mechanisms driving this finding are unclear, but could allude to differences related to the sterile OR environment or changes in the oral/esophageal microbiomes of patients with TEPs over time. Other factors, including primary versus salvage TL, primary versus secondary TEP, and adjuvant radiation were not associated with VP...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154195",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260133",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Theresa Guo, MD",
      "presenter": "Theresa Guo, MD",
      "authors": "Tammy Pham, MD; Deepthi Pagidimarri, BDS, MAS; Theresa Guo, MD ; Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
      "normalized_authors": [
        "Tammy Pham",
        "Deepthi Pagidimarri, BDS, MAS",
        "Theresa Guo",
        "Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S"
      ],
      "affiliations": [
        "University of California, San Diego"
      ],
      "normalized_institutions": [
        "University of California, San Diego"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154195/Figure%201%20-%20TEP%20Longevity(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154195/Figure%201%20-%20TEP%20Longevity(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154195"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tammy Pham, MD; Deepthi Pagidimarri, BDS, MAS; Theresa Guo, MD ; Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S",
        "Affiliations": "University of California, San Diego",
        "Background": "Tracheoesophageal puncture (TEP) with voice prosthesis (VP) is a widely used method of post-laryngectomy voice rehabilitation. At our institution, initial TEP and VP placements are performed in the operating room (OR), while subsequent exchanges are performed in the clinic by speech language pathologists (SLPs). Although the VPs used in the OR and the clinic are functionally identical, total laryngectomy (TL) patients anecdotally experience a frustrating decline in VP longevity over time. Therefore, we sought to compare the longevity of surgical VP placement with subsequent clinic-placed VPs, and evaluate the relationship between VP lifespans and clinical factors including history of radiation, recurrence, and TEP timing (primary versus secondary).",
        "Methods": "A retrospective chart review was conducted for 103 post-laryngectomy patients treated at our academic center between 2013 and 2025. Of the 58 patients who underwent a TEP, 34 had full documentation of TL date, date of initial TEP +/- prosthesis placement in the OR, and at least two subsequent VP exchanges in the clinic. Four of those patients underwent TEP in the OR but had a puncture site placeholder (e.g. red rubber catheter) until a VP was placed clinically; these patients were excluded from the paired T-test analysis comparing OR-placed versus clinic-placed prostheses but were included in the T-test analyses examining the association between VP lifespan and recurrence category, TEP timing, and adjuvant radiation.",
        "Results": "The cohort comprised 34 patients who were predominately male (88%), treated for squamous cell carcinoma (88%), and treated in the salvage setting (70%). Most received adjuvant radiation (69%) and underwent primary TEPs (62%). Among the 30 patients who had initial OR-placed VPs, the initial VP longevity was significantly longer (185 days) compared to the first clinic replacement VP longevity (110 days; Figure, p = 0.005). Across the full cohort of 34 patients, there was no significant difference in VP longevity across recurrence category (primary TL 199 days vs. salvage TL 158 days, p = 0.4), TEP timing (primary 181 days vs. secondary 164 days, p = 0.7), or receipt of adjuvant radiation (208 days) versus no adjuvant radiation (173 days), p = 0.6. Among all VP exchanges, the reasons for exchange included leakage (53%), re-sizing (18%), voice change (12%), and routine time-based replacements (12%) as well as rare dislodgements (5%); these distributions were similar between both replacement timepoints.",
        "Conclusions": "Initial OR-placed VPs demonstrated longer lifespans than clinic-placed VPs. The mechanisms driving this finding are unclear, but could allude to differences related to the sterile OR environment or changes in the oral/esophageal microbiomes of patients with TEPs over time. Other factors, including primary versus salvage TL, primary versus secondary TEP, and adjuvant radiation were not associated with VP longevity. Notably, VP longevity in our cohort was longer than prior reports of 60-70 days, which may reflect practice patterns or patient selection at our institution. Limitations of this investigation include small sample size and retrospective design which preclude further stratified analyses. Nonetheless, these findings can help guide counseling and expectation management about VP longevity for patients.",
        "Abstract": "Figure View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Tracheoesophageal Prosthesis Lifespan: Comparing Initial Surgical Placement Versus Subsequent Clinic Placement of Prostheses</span>. Tammy Pham, MD; Deepthi Pagidimarri, BDS, MAS; <u>Theresa Guo, MD</u>; Kristen Linnemeyer-Risser, MA, CCC, SLP, BCS-S. University of California, San Diego<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Tracheoesophageal puncture (TEP) with voice prosthesis (VP) is a widely used method of post-laryngectomy voice rehabilitation. At our institution, initial TEP and VP placements are performed in the operating room (OR), while subsequent exchanges are performed in the clinic by speech language pathologists (SLPs). Although the VPs used in the OR and the clinic are functionally identical, total laryngectomy (TL) patients anecdotally experience a frustrating decline in VP longevity over time. Therefore, we sought to compare the longevity of surgical VP placement with subsequent clinic-placed VPs, and evaluate the relationship between VP lifespans and clinical factors including history of radiation, recurrence, and TEP timing (primary versus secondary).</p>\n\n<p><strong>Methods:</strong> A retrospective chart review was conducted for 103 post-laryngectomy patients treated at our academic center between 2013 and 2025. Of the 58 patients who underwent a TEP, 34 had full documentation of TL date, date of initial TEP +/- prosthesis placement in the OR, and at least two subsequent VP exchanges in the clinic. Four of those patients underwent TEP in the OR but had a puncture site placeholder (e.g. red rubber catheter) until a VP was placed clinically; these patients were excluded from the paired T-test analysis comparing OR-placed versus clinic-placed prostheses but were included in the T-test analyses examining the association between VP lifespan and recurrence category, TEP timing, and adjuvant radiation.</p>\n\n<p><strong>Results: </strong>The cohort comprised 34 patients who were predominately male (88%), treated for squamous cell carcinoma (88%), and treated in the salvage setting (70%). Most received adjuvant radiation (69%) and underwent primary TEPs (62%). Among the 30 patients who had initial OR-placed VPs, the initial VP longevity was significantly longer (185 days) compared to the first clinic replacement VP longevity (110 days; Figure, p = 0.005). Across the full cohort of 34 patients, there was no significant difference in VP longevity across recurrence category (primary TL 199 days vs. salvage TL 158 days, p = 0.4), TEP timing (primary 181 days vs. secondary 164 days, p = 0.7),  or receipt of adjuvant radiation (208 days) versus no adjuvant radiation (173 days), p = 0.6. Among all VP exchanges, the reasons for exchange included leakage (53%), re-sizing (18%), voice change (12%), and routine time-based replacements (12%) as well as rare dislodgements (5%); these distributions were similar between both replacement timepoints.</p>\n\n<p><strong>Conclusions: </strong>Initial OR-placed VPs demonstrated longer lifespans than clinic-placed VPs. The mechanisms driving this finding are unclear, but could allude to differences related to the sterile OR environment or changes in the oral/esophageal microbiomes of patients with TEPs over time.  Other factors, including primary versus salvage TL, primary versus secondary TEP, and adjuvant radiation were not associated with VP longevity. Notably, VP longevity in our cohort was longer than prior reports of 60-70 days, which may reflect practice patterns or patient selection at our institution. Limitations of this investigation include small sample size and retrospective design which preclude further stratified analyses. Nonetheless, these findings can help guide counseling and expectation management about VP longevity for patients.</p>\n\n<p>Figure</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154195/Figure%201%20-%20TEP%20Longevity(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154195--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260133' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S250",
      "content_id": "154372",
      "abstract_number": "S250",
      "poster_number": "",
      "title": "Association between metabolic syndrome-related diseases and oral cavity cancer in non-smokers.",
      "summary": "In this large representative cohort of non-smokers, metabolic syndrome-related conditions were strongly associated with increased odds of OSCC, independent of age, sex, race, ethnicity, education, income and alcohol consumption. These findings suggest that metabolic dysregulation plays a role in OSCC etiology among individuals with no traditional risk factors and highlights the need for further research to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154372",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mateo Useche, MD, MPH",
      "presenter": "Mateo Useche, MD, MPH",
      "authors": "Mateo Useche, MD, MPH ; Hosam H Alkhatib, MD; Luis E Cortina; Neal Futran, DMD; Rocco Ferrandino, MD, MS; Emily Marchiano; Brittany Barber",
      "normalized_authors": [
        "Mateo Useche",
        "Hosam H Alkhatib",
        "Luis E Cortina",
        "Neal Futran",
        "Rocco Ferrandino",
        "Emily Marchiano",
        "Brittany Barber"
      ],
      "affiliations": [
        "University of Washington"
      ],
      "normalized_institutions": [
        "University of Washington"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mateo Useche, MD, MPH ; Hosam H Alkhatib, MD; Luis E Cortina; Neal Futran, DMD; Rocco Ferrandino, MD, MS; Emily Marchiano; Brittany Barber",
        "Affiliations": "University of Washington",
        "Background": "Oral cavity squamous cell carcinoma (OSCC) is increasingly diagnosed among individuals without traditional risk factors such as tobacco or alcohol exposure. Metabolic syndrome–related conditions have been found to contribute to carcinogenesis in other digestive tract cancers. However, data assessing these associations in non-smoking OSCC remains limited. We evaluated the relationship between individual metabolic syndrome-related conditions and the odds of OSCC among non-smokers.",
        "Methods": "We conducted a propensity score matched case–control study using NIH All of Us Research Program, Registered Tier version 8. OSCC cases were identified using validated concept codes and restricted to participants with no lifetime cigarette exposure. Never-smoker controls were drawn from the entire All of Us cohort and excluded if they had any OSCC diagnosis. Propensity score matching was performed at a 1:4 ratio using age, sex at birth, race/ethnicity, income level per year (<$25K, $25-100K, >$100K), education (grade 12 or less, some college, college graduate) and alcohol consumption. Metabolic syndrome-related conditions were defined using electronic health record data and included type 2 diabetes (DM2), hypertension (HTN), hyperlipidemia (HLD), obesity, underweight, and metabolic associated liver disease (MASLD). Conditional logistic regression was performed within matched sets, estimating odds ratios (ORs) with 95% confidence intervals (CIs) for each metabolic factor.",
        "Results": "Between the control (n = 4048) and OSCC group (n = 1012), there were no significant differences in matched factors. BMI was similar between groups (29.2 ± 6.7 in cases vs 29.3 ± 6.9 in controls; p = 0.21), indicating that BMI itself did not differ meaningfully after matching. DM2 was present in 18 % of cases vs 6.8% of controls, HTN in 68.3% vs 38.8%, and HLD in 63.6% vs 39.3% (all p < 0.001). Conditional logistic regression demonstrated that DM2 (OR 3.06, 95% CI 2.49–3.76, p < 0.001) and HLD (OR 2.93, 95% CI 2.52–3.41, p < 0.001) were associated with three-fold increase in odds, while HTN showed a four-fold increase (OR 4.0, 95% CI 3.40–4.71, p < 0.001). Obesity (OR 1.10, 95% CI 0.95–1.28, p = 0.199) and underweight status (OR 0.86, 95% CI 0.42–1.77, p = 0.682) as dichotomous variables did not show a statistically significant association with OSCC. MASLD was uncommon in this cohort and was therefore excluded from further inference.",
        "Conclusion": "In this large representative cohort of non-smokers, metabolic syndrome-related conditions were strongly associated with increased odds of OSCC, independent of age, sex, race, ethnicity, education, income and alcohol consumption. These findings suggest that metabolic dysregulation plays a role in OSCC etiology among individuals with no traditional risk factors and highlights the need for further research to elucidate causal pathways between these conditions and carcinogenesis.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association between metabolic syndrome-related diseases and oral cavity cancer in non-smokers.</span>. <u>Mateo Useche, MD, MPH</u>; Hosam H Alkhatib, MD; Luis E Cortina; Neal Futran, DMD; Rocco Ferrandino, MD, MS; Emily Marchiano; Brittany Barber. University of Washington<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral cavity squamous cell carcinoma (OSCC) is increasingly diagnosed among individuals without traditional risk factors such as tobacco or alcohol exposure. Metabolic syndrome–related conditions have been found to contribute to carcinogenesis in other digestive tract cancers. However, data assessing these associations in non-smoking OSCC remains limited. We evaluated the relationship between individual metabolic syndrome-related conditions and the odds of OSCC among non-smokers.</p>\n\n<p><strong>Methods: </strong>We conducted a propensity score matched case–control study using NIH All of Us Research Program, Registered Tier version 8. OSCC cases were identified using validated concept codes and restricted to participants with no lifetime cigarette exposure. Never-smoker controls were drawn from the entire All of Us cohort and excluded if they had any OSCC diagnosis. Propensity score matching was performed at a 1:4 ratio using age, sex at birth, race/ethnicity, income level per year (<$25K, $25-100K, >$100K), education (grade 12 or less, some college, college graduate) and alcohol consumption. Metabolic syndrome-related conditions were defined using electronic health record data and included type 2 diabetes (DM2), hypertension (HTN), hyperlipidemia (HLD), obesity, underweight, and metabolic associated liver disease (MASLD). Conditional logistic regression was performed within matched sets, estimating odds ratios (ORs) with 95% confidence intervals (CIs) for each metabolic factor.</p>\n\n<p><strong>Results: </strong>Between the control (n = 4048) and OSCC group (n = 1012), there were no significant differences in matched factors. BMI was similar between groups (29.2 ± 6.7 in cases vs 29.3 ± 6.9 in controls; p = 0.21), indicating that BMI itself did not differ meaningfully after matching. DM2 was present in 18 % of cases vs 6.8% of controls, HTN in 68.3% vs 38.8%, and HLD in 63.6% vs 39.3% (all p < 0.001). Conditional logistic regression demonstrated that DM2 (OR 3.06, 95% CI 2.49–3.76, p < 0.001) and HLD (OR 2.93, 95% CI 2.52–3.41, p < 0.001) were associated with three-fold increase in odds, while HTN showed a four-fold increase (OR 4.0, 95% CI 3.40–4.71, p < 0.001). Obesity (OR 1.10, 95% CI 0.95–1.28, p = 0.199) and underweight status (OR 0.86, 95% CI 0.42–1.77, p = 0.682) as dichotomous variables did not show a statistically significant association with OSCC. MASLD was uncommon in this cohort and was therefore excluded from further inference.</p>\n\n<p><strong>Conclusion: </strong>In this large representative cohort of non-smokers, metabolic syndrome-related conditions were strongly associated with increased odds of OSCC, independent of age, sex, race, ethnicity, education, income and alcohol consumption. These findings suggest that metabolic dysregulation plays a role in OSCC etiology among individuals with no traditional risk factors and highlights the need for further research to elucidate causal pathways between these conditions and carcinogenesis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154372--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S251",
      "content_id": "153637",
      "abstract_number": "S251",
      "poster_number": "",
      "title": "Impact of GLP-1 Receptor Agonists on Overall Survival in Head and Neck Cancer",
      "summary": "These findings suggest that GLP-1 RA therapy, particularly in combination with metformin, may offer a novel strategy to improve survival outcomes in patients with head and neck cancer. This highlights the need for further studies of metabolic agents as adjuncts in oncology care to clarify underlying mechanisms, which may be driven by the agents’ ability to alter systemic metabolic homeostasis and shifts tumor...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153637",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandra E Hunter, BA",
      "presenter": "Alexandra E Hunter, BA",
      "authors": "Alexandra E Hunter, BA 1 ; Daniel Uralov, MD 2 ; Morgan C Byrd, PhD, MPH 3 ; Trinitia Y Cannon, MD 3 ; Joseph Curry, MD 2 ; Nosayaba Osazuwa Peters, PhD, MPH, BDS, CHES 3",
      "normalized_authors": [
        "Alexandra E Hunter",
        "Daniel Uralov",
        "Morgan C Byrd",
        "Trinitia Y Cannon",
        "Joseph Curry",
        "Nosayaba Osazuwa Peters, BDS, CHES"
      ],
      "affiliations": [
        "Duke University School of Medicine",
        "Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine"
      ],
      "normalized_institutions": [
        "Duke University School of Medicine",
        "Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University",
        "Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alexandra E Hunter, BA 1 ; Daniel Uralov, MD 2 ; Morgan C Byrd, PhD, MPH 3 ; Trinitia Y Cannon, MD 3 ; Joseph Curry, MD 2 ; Nosayaba Osazuwa Peters, PhD, MPH, BDS, CHES 3",
        "Affiliations": "1 Duke University School of Medicine; 2 Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University; 3 Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine",
        "Objectives": "Metformin has known metabolic effects and associated survival benefits in head and neck cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) also modulate systemic metabolism through binding to the hormone GLP-1 and regulating blood glucose levels and lipid metabolism. The purpose of this study was to investigate whether GLP-1 RA similarly influence survival outcomes in patients with head and neck cancers.",
        "Methods": "A retrospective cohort study was conducted using deidentified data from 66 U.S. healthcare organizations within the TriNetx Global Collaborative Network (1990-2025). Adults (≥18 years) with histologically confirmed head and neck squamous cell carcinomas (HNSCC) were included. Propensity score matching (caliper=0.1) accounted for age, sex, race, ethnicity, body mass index (BMI), hemoglobin A1c, diabetes status, ischemic heart disease, COPD, tobacco use, alcohol use, and AJCC TNM stage. The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1 RA and metformin. Adjusted Hazards Ratios (aHR) with 95% confidence intervals (CIs) were computed using TriNetX Analytics.",
        "Results": "After matching, 4,532 patients were included per cohort. Across all HNSCC subsites studied, GLP-1 RA users demonstrated significantly improved overall survival compared to controls at 1-year (94.0% v. 86.5%, aHR 0.42, CI 0.36-0.46), 3 years (86.0% vs 74.8%, aHR 0.48, 95% CI 0.43-0.54), and 5-year intervals (79.6% vs 67.5%, aHR 0.51, 95% CI 0.46-0.57).",
        "Abstract": "By subsite, GLP-1 RA use remained consistently associated with lower mortality risk. Among patients with oral cavity cancer (n=2,072), GLP-1 RA users demonstrated improved 1-year, 3-year, and 5-year survival (79.1% vs 70.6%, aHR 0.60, 95% CI 0.51-0.70). A similar pattern was observed in oropharyngeal cancer (n=1,005), where GLP-1 RA users experienced even greater survival benefit at 1-year, 3-years, and 5-years (77.7% vs 62.9%, aHR 0.53, 95% CI 0.41-0.64). The strongest association was seen in laryngeal cancer (n=887) where GLP-1 RA use was associated with the lowest mortality risk at all time points; 1-year, 3-years, and 5-years (76.9% vs 61.8%, aHR 0.49, 95% CI 0.39-0.61). Among patients using both GLP-1 RAs and metformin, survival benefits were even further improved at 1- year (94.7% vs 83.2%, aHR 0.29, 95% CI 0.23-0.36), 3-years (86.9% vs 69.5%, aHR 0.36, 95% CI 0.30-0.42), and 5-years (81.2% vs 62.6%, aHR 0.39, 95% CI 0.36-0.45). View in Agenda and Add to Schedule",
        "Conclusion": "These findings suggest that GLP-1 RA therapy, particularly in combination with metformin, may offer a novel strategy to improve survival outcomes in patients with head and neck cancer. This highlights the need for further studies of metabolic agents as adjuncts in oncology care to clarify underlying mechanisms, which may be driven by the agents’ ability to alter systemic metabolic homeostasis and shifts tumor metabolic demand. Further investigation is needed to directly evaluate the metabolic effects within the tumor microenvironment."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of GLP-1 Receptor Agonists on Overall Survival in Head and Neck Cancer</span>. <u>Alexandra E Hunter, BA</u><sup>1</sup>; Daniel Uralov, MD<sup>2</sup>; Morgan C Byrd, PhD, MPH<sup>3</sup>; Trinitia Y Cannon, MD<sup>3</sup>; Joseph Curry, MD<sup>2</sup>; Nosayaba Osazuwa Peters, PhD, MPH, BDS, CHES<sup>3</sup>. <sup>1</sup>Duke University School of Medicine; <sup>2</sup>Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University; <sup>3</sup>Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>Metformin has known metabolic effects and associated survival benefits in head and neck cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) also modulate systemic metabolism through binding to the hormone GLP-1 and regulating blood glucose levels and lipid metabolism. The purpose of this study was to investigate whether GLP-1 RA similarly influence survival outcomes in patients with head and neck cancers. </p>\n\n<p><strong>Methods</strong>: A retrospective cohort study was conducted using deidentified data from 66 U.S. healthcare organizations within the TriNetx Global Collaborative Network (1990-2025). Adults (≥18 years) with histologically confirmed head and neck squamous cell carcinomas (HNSCC) were included. Propensity score matching (caliper=0.1) accounted for age, sex, race, ethnicity, body mass index (BMI), hemoglobin A1c, diabetes status, ischemic heart disease, COPD, tobacco use, alcohol use, and AJCC TNM stage. The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1 RA and metformin. Adjusted Hazards Ratios (aHR) with 95% confidence intervals (CIs) were computed using TriNetX Analytics.</p>\n\n<p><strong>Results</strong>: After matching, 4,532 patients were included per cohort. Across all HNSCC subsites studied, GLP-1 RA users demonstrated significantly improved overall survival compared to controls at 1-year (94.0% v. 86.5%, aHR 0.42, CI 0.36-0.46), 3 years (86.0% vs 74.8%, aHR 0.48, 95% CI 0.43-0.54), and 5-year intervals (79.6% vs 67.5%, aHR 0.51, 95% CI 0.46-0.57). </p>\n\n<p>By subsite, GLP-1 RA use remained consistently associated with lower mortality risk. Among patients with oral cavity cancer (n=2,072), GLP-1 RA users demonstrated improved 1-year, 3-year, and 5-year survival (79.1% vs 70.6%, aHR 0.60, 95% CI 0.51-0.70). A similar pattern was observed in oropharyngeal cancer (n=1,005), where GLP-1 RA users experienced even greater survival benefit at 1-year, 3-years, and 5-years (77.7% vs 62.9%, aHR 0.53, 95% CI 0.41-0.64). The strongest association was seen in laryngeal cancer (n=887) where GLP-1 RA use was associated with the lowest mortality risk at all time points; 1-year, 3-years, and 5-years (76.9% vs 61.8%, aHR 0.49, 95% CI 0.39-0.61).</p>\n\n<p>Among patients using both GLP-1 RAs and metformin, survival benefits were even further improved at 1- year (94.7% vs 83.2%, aHR 0.29, 95% CI 0.23-0.36), 3-years (86.9% vs 69.5%, aHR 0.36, 95% CI 0.30-0.42), and 5-years (81.2% vs 62.6%, aHR 0.39, 95% CI 0.36-0.45). </p>\n\n<p><strong>Conclusion</strong>: These findings suggest that GLP-1 RA therapy, particularly in combination with metformin, may offer a novel strategy to improve survival outcomes in patients with head and neck cancer. This highlights the need for further studies of metabolic agents as adjuncts in oncology care to clarify underlying mechanisms, which may be driven by the agents’ ability to alter systemic metabolic homeostasis and shifts tumor metabolic demand. Further investigation is needed to directly evaluate the metabolic effects within the tumor microenvironment. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153637--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S252",
      "content_id": "153915",
      "abstract_number": "S252",
      "poster_number": "",
      "title": "Muscle Attenuation Predicts Survival in Head and Neck Cancer Independent of Obesity or Sarcopenia",
      "summary": "In operable HNC, myosteatosis, but not SO, appears to emerge as a key body-composition determinant of survival. While SO does not independently predict toxicity or treatment completion, low muscle attenuation consistently identifies patients at increased risk of mortality and disease progression. CT-derived muscle quality can serve as a practical imaging biomarker to improve pre-treatment risk stratification and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153915",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eva R Levin, BSc, MSc, Candidate",
      "presenter": "Eva R Levin, BSc, MSc, Candidate",
      "authors": "Eva R Levin, BSc, MSc, Candidate ; Marco Mascarella, MD, PhD, MSc, FRCSC; Alex Mlynarek; Livia Florianova; Derin Caglar; Marc Pusztaszeri; Keith Richardson; Nader Sadeghi; Khalil Sultanem; Christina Tsien; Vanessa Di Lalla; George Shenouda; Hier M; Nathaniel Bouganim; Khashayar Esfahani",
      "normalized_authors": [
        "Eva R Levin, Candidate",
        "Marco Mascarella, FRCSC",
        "Alex Mlynarek",
        "Livia Florianova",
        "Derin Caglar",
        "Marc Pusztaszeri",
        "Keith Richardson",
        "Nader Sadeghi",
        "Khalil Sultanem",
        "Christina Tsien",
        "Vanessa Di Lalla",
        "George Shenouda",
        "Hier M",
        "Nathaniel Bouganim",
        "Khashayar Esfahani"
      ],
      "affiliations": [
        "McGill University"
      ],
      "normalized_institutions": [
        "McGill University"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Eva R Levin, BSc, MSc, Candidate ; Marco Mascarella, MD, PhD, MSc, FRCSC; Alex Mlynarek; Livia Florianova; Derin Caglar; Marc Pusztaszeri; Keith Richardson; Nader Sadeghi; Khalil Sultanem; Christina Tsien; Vanessa Di Lalla; George Shenouda; Hier M; Nathaniel Bouganim; Khashayar Esfahani",
        "Affiliations": "McGill University",
        "Background": "Body composition is increasingly recognized as a strong determinant of treatment intolerance and survival in head and neck cancer (HNC). Sarcopenic obesity (SO), the coexistence of high adiposity and low muscle mass, has been associated with poor outcomes in other cancers. Myosteatosis (low skeletal muscle attenuation and skeletal muscle fat infiltration) reflects reduced muscle quality and metabolic dysfunction. However, the independent contributions of SO and myosteatosis in the context of clinical outcomes in HNC remain unclear.",
        "Methods": "A retrospective cohort of patients with operable, stage I-IVA HNC was analyzed. Pre-treatment CT scans were used to quantify skeletal muscle area and attenuation at L3. Sarcopenia was defined using sex-specific cutoffs for L3 skeletal muscle index; obesity was defined by BMI ≥30. A four-level phenotype variable was composed of SO, sarcopenia-only, obesity-only, and normal body composition. Muscle quality was assessed using the high-to-total attenuation muscle ratio, categorized into quartiles (Q1 = worst; Q4 = best). Primary outcomes included overall survival (OS) and progression-free survival (PFS). Secondary outcomes included severe toxicity (CTCAE ≥3 within 90 days) and treatment intolerance (non-completion of intended therapy). Multivariable logistic or Cox regression adjusted for sex, comorbidity burden (CCI when appropriate), disease stage (early vs late cancer), and BMI (when appropriate).",
        "Results": "Out of 324 patients, 33% had sarcopenia, 12% obesity only, and 5% SO. SO was associated with poor OS (SO HR 2.42, 95% CI 1.10-5.33) with a similar but non-significant trend toward poorer PFS (HR 2.04, 95% CI 0.93–4.50) in univariate analysis. These associations became non-significant after adjusting for comorbidity and tumour stage, suggesting that the apparent effect of SO is largely hidden by overall disease burden and baseline health status. In contrast, myosteatosis remained a strong predictor of survival; patients in the highest attenuation quartile (Q4) had a 50% reduction in mortality risk compared with those in Q1 (HR = 0.50, 95% CI 0.28–0.91, p = 0.023) after adjusting for multiple confounding factors. A similar pattern was observed for PFS in multivariate analysis: patients in Q4, representing the best muscle quality, had significantly longer PFS (HR = 0.51, 95% CI 0.28–0.91, p = 0.022) than patients in Q1. This indicates that higher muscle attenuation, reflecting healthier, less fat-infiltrated muscle, is associated with improved PFS. With regards to secondary objectives, SO and attenuation quartiles were not independently associated with severe toxicity or treatment intolerance. In unadjusted models, SO showed higher odds of intolerance (OR 3.48, 95% CI 1.13–13.07), but this was no longer significant after adjustment for covariates.",
        "Conclusions": "In operable HNC, myosteatosis, but not SO, appears to emerge as a key body-composition determinant of survival. While SO does not independently predict toxicity or treatment completion, low muscle attenuation consistently identifies patients at increased risk of mortality and disease progression. CT-derived muscle quality can serve as a practical imaging biomarker to improve pre-treatment risk stratification and guide supportive care interventions such as prehabilitation and rehabilitation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Muscle Attenuation Predicts Survival in Head and Neck Cancer Independent of Obesity or Sarcopenia</span>. <u>Eva R Levin, BSc, MSc, Candidate</u>; Marco Mascarella, MD, PhD, MSc, FRCSC; Alex Mlynarek; Livia Florianova; Derin Caglar; Marc Pusztaszeri; Keith Richardson; Nader Sadeghi; Khalil Sultanem; Christina Tsien; Vanessa Di Lalla; George Shenouda; Hier M; Nathaniel Bouganim; Khashayar Esfahani. McGill University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Body composition is increasingly recognized as a strong determinant of treatment intolerance and survival in head and neck cancer (HNC). Sarcopenic obesity (SO), the coexistence of high adiposity and low muscle mass, has been associated with poor outcomes in other cancers. Myosteatosis (low skeletal muscle attenuation and skeletal muscle fat infiltration) reflects reduced muscle quality and metabolic dysfunction. However, the independent contributions of SO and myosteatosis in the context of clinical outcomes in HNC remain unclear.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of patients with operable, stage I-IVA HNC was analyzed. Pre-treatment CT scans were used to quantify skeletal muscle area and attenuation at L3. Sarcopenia was defined using sex-specific cutoffs for L3 skeletal muscle index; obesity was defined by BMI ≥30. A four-level phenotype variable was composed of SO, sarcopenia-only, obesity-only, and normal body composition. Muscle quality was assessed using the high-to-total attenuation muscle ratio, categorized into quartiles (Q1 = worst; Q4 = best). Primary outcomes included overall survival (OS) and progression-free survival (PFS). Secondary outcomes included severe toxicity (CTCAE ≥3 within 90 days) and treatment intolerance (non-completion of intended therapy). Multivariable logistic or Cox regression adjusted for sex, comorbidity burden (CCI when appropriate), disease stage (early vs late cancer), and BMI (when appropriate).  </p>\n\n<p><strong>Results: </strong>Out of 324 patients, 33% had sarcopenia, 12% obesity only, and 5% SO. SO was associated with poor OS (SO HR 2.42, 95% CI 1.10-5.33) with a similar but non-significant trend toward poorer PFS (HR 2.04, 95% CI 0.93–4.50) in univariate analysis. These associations became non-significant after adjusting for comorbidity and tumour stage, suggesting that the apparent effect of SO is largely hidden by overall disease burden and baseline health status. In contrast, myosteatosis remained a strong predictor of survival; patients in the highest attenuation quartile (Q4) had a 50% reduction in mortality risk compared with those in Q1 (HR = 0.50, 95% CI 0.28–0.91, p = 0.023) after adjusting for multiple confounding factors. A similar pattern was observed for PFS in multivariate analysis: patients in Q4, representing the best muscle quality, had significantly longer PFS (HR = 0.51, 95% CI 0.28–0.91, p = 0.022) than patients in Q1. This indicates that higher muscle attenuation, reflecting healthier, less fat-infiltrated muscle, is associated with improved PFS. With regards to secondary objectives, SO and attenuation quartiles were not independently associated with severe toxicity or treatment intolerance. In unadjusted models, SO showed higher odds of intolerance (OR 3.48, 95% CI 1.13–13.07), but this was no longer significant after adjustment for covariates.</p>\n\n<p><strong>Conclusions: </strong>In operable HNC, myosteatosis, but not SO, appears to emerge as a key body-composition determinant of survival. While SO does not independently predict toxicity or treatment completion, low muscle attenuation consistently identifies patients at increased risk of mortality and disease progression. CT-derived muscle quality can serve as a practical imaging biomarker to improve pre-treatment risk stratification and guide supportive care interventions such as prehabilitation and rehabilitation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153915--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S254",
      "content_id": "153272",
      "abstract_number": "S254",
      "poster_number": "",
      "title": "Preoperative Cachexia Index Predicts Treatment Toxicity and Overall Survival in Operable Head and Neck Cancer",
      "summary": "Low preoperative CXI was an independent predictor of severe treatment toxicity and reduced OS in operable HPV-negative HNSCC. The CXI may serve as a clinically useful tool for risk stratification and guide treatment strategies to reduce post-operative complications.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153272",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gianluca Savoia",
      "presenter": "Gianluca Savoia",
      "authors": "Gianluca Savoia 1 ; Alex Mlynarek, MD, MSc, FRCSC 2 ; Keith Richardson, MD, FRCSC 2 ; Nader Sadeghi, MD, FRCSC 2 ; Michael P Hier, MD, FRCSC 2 ; Christina Tsien, MD 3 ; George Shenouda, PhD, MBBCh 3 ; Khalil Sultanem, MD, FRCP 3 ; Nathaniel Bouganim, MD 4 ; Khashayar Esfahani, MD, MSc 4 ; Marco Mascarella, MD, MSc, PhD, FRCSC 2",
      "normalized_authors": [
        "Gianluca Savoia",
        "Alex Mlynarek, FRCSC",
        "Keith Richardson, FRCSC",
        "Nader Sadeghi, FRCSC",
        "Michael P Hier, FRCSC",
        "Christina Tsien",
        "George Shenouda, MBBCh",
        "Khalil Sultanem, FRCP",
        "Nathaniel Bouganim",
        "Khashayar Esfahani",
        "Marco Mascarella, FRCSC"
      ],
      "affiliations": [
        "McGill Faculty of Medicine and Health Sciences",
        "Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Health Sciences, McGill University",
        "Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada",
        "Department of Medicine, Division of Medical Oncology, MUHC"
      ],
      "normalized_institutions": [
        "McGill Faculty of Medicine and Health Sciences",
        "Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Health Sciences, McGill University",
        "Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada",
        "Department of Medicine, Division of Medical Oncology, MUHC"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 257,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gianluca Savoia 1 ; Alex Mlynarek, MD, MSc, FRCSC 2 ; Keith Richardson, MD, FRCSC 2 ; Nader Sadeghi, MD, FRCSC 2 ; Michael P Hier, MD, FRCSC 2 ; Christina Tsien, MD 3 ; George Shenouda, PhD, MBBCh 3 ; Khalil Sultanem, MD, FRCP 3 ; Nathaniel Bouganim, MD 4 ; Khashayar Esfahani, MD, MSc 4 ; Marco Mascarella, MD, MSc, PhD, FRCSC 2",
        "Affiliations": "1 McGill Faculty of Medicine and Health Sciences; 2 Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Health Sciences, McGill University; 3 Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada; 4 Department of Medicine, Division of Medical Oncology, MUHC",
        "Background": "Cancer cachexia is a polyetiological condition often prevalent in head and neck squamous cell carcinoma (HNSCC) patients. The cachexia index (CXI) has been associated with increased toxicity and poorer survival in patients with solid organ cancers; however, its role in HNSCC has yet to be established.",
        "Methods": "An ambispective observational study of patients with operable HPV-negative HNSCC treated at two academic centers in Canada was performed. CXI was computed using radiologic and hematologic biomarkers and categorized into both quintiles and sex-specific cutoff values based on other tumour types. The primary outcome of interest was severe treatment toxicity, defined as CTCAE ≥3 within 90 days of treatment. The secondary outcome measure was overall survival (OS). Multivariable logistic and Cox regression analyses were adjusted for age, Charlson Comorbidity Index, and stage.",
        "Results": "In 332 patients undergoing HNSCC surgery, 70 patients (21%) had an abnormally low CXI. Severe toxicity was associated with CXI for patients in the lowest quintile (OR 3.36, 95% CI 1.45-7.79). When adjusted for multiple confounding factors, low CXI was associated with severe treatment toxicity (OR 1.93, 95% CI 1.00-3.78). Low CXI was also associated with worse OS compared to patients with a normal CXI (HR 1.89, 95% CI 1.23-2.92) after adjusting for multiple confounders.",
        "Conclusion": "Low preoperative CXI was an independent predictor of severe treatment toxicity and reduced OS in operable HPV-negative HNSCC. The CXI may serve as a clinically useful tool for risk stratification and guide treatment strategies to reduce post-operative complications.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Cachexia Index Predicts Treatment Toxicity and Overall Survival in Operable Head and Neck Cancer</span>. <u>Gianluca Savoia</u><sup>1</sup>; Alex Mlynarek, MD, MSc, FRCSC<sup>2</sup>; Keith Richardson, MD, FRCSC<sup>2</sup>; Nader Sadeghi, MD, FRCSC<sup>2</sup>; Michael P Hier, MD, FRCSC<sup>2</sup>; Christina Tsien, MD<sup>3</sup>; George Shenouda, PhD, MBBCh<sup>3</sup>; Khalil Sultanem, MD, FRCP<sup>3</sup>; Nathaniel Bouganim, MD<sup>4</sup>; Khashayar Esfahani, MD, MSc<sup>4</sup>; Marco Mascarella, MD, MSc, PhD, FRCSC<sup>2</sup>. <sup>1</sup>McGill Faculty of Medicine and Health Sciences; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Health Sciences, McGill University; <sup>3</sup>Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada; <sup>4</sup>Department of Medicine, Division of Medical Oncology, MUHC<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cancer cachexia is a polyetiological condition often prevalent in head and neck squamous cell carcinoma (HNSCC) patients. The cachexia index (CXI) has been associated with increased toxicity and poorer survival in patients with solid organ cancers; however, its role in HNSCC has yet to be established.</p>\n\n<p><strong>Methods: </strong>An ambispective observational study of patients with operable HPV-negative HNSCC treated at two academic centers in Canada was performed. CXI was computed using radiologic and hematologic biomarkers and categorized into both quintiles and sex-specific cutoff values based on other tumour types.  The primary outcome of interest was severe treatment toxicity, defined as CTCAE ≥3 within 90 days of treatment. The secondary outcome measure was overall survival (OS). Multivariable logistic and Cox regression analyses were adjusted for age, Charlson Comorbidity Index, and stage.</p>\n\n<p><strong>Results: </strong>In 332 patients undergoing HNSCC surgery, 70 patients (21%) had an abnormally low CXI. Severe toxicity was associated with CXI for patients in the lowest quintile (OR 3.36, 95% CI 1.45-7.79). When adjusted for multiple confounding factors, low CXI was associated with severe treatment toxicity (OR 1.93, 95% CI 1.00-3.78). Low CXI was also associated with worse OS compared to patients with a normal CXI (HR 1.89, 95% CI 1.23-2.92) after adjusting for multiple confounders. </p>\n\n<p><strong>Conclusion: </strong>Low preoperative CXI was an independent predictor of severe treatment toxicity and reduced OS in operable HPV-negative HNSCC. The CXI may serve as a clinically useful tool for risk stratification and guide treatment strategies to reduce post-operative complications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153272--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S255",
      "content_id": "154732",
      "abstract_number": "S255",
      "poster_number": "",
      "title": "Diabetes and Survival Outcomes Following Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma",
      "summary": "A total of 4959 patients were included (1,826 without diabetes, 1,698 with pre-diabetes, and 1,435 with diabetes). There was a significant decrease in OS between HNSCC patients with DM and those without DM at all time points after treatment with ICIs (survival probabilities 81.02% vs 86.34% at 6 months, 47.55% vs 53.71% at 3 years, and 38.99% vs 40.21% at 5 years, p<0.05). Stratification by subsite demonstrated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154732",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Suarez, MD",
      "presenter": "Daniel Suarez, MD",
      "authors": "Daniel Suarez, MD ; LeeAnn Marcello; Keshav Kumar, MD; Ryan Kong, MD; Billy Yang, MD; Mahmoud Awad, MD; Krishnamurthi Sundaram, MD",
      "normalized_authors": [
        "Daniel Suarez",
        "LeeAnn Marcello",
        "Keshav Kumar",
        "Ryan Kong",
        "Billy Yang",
        "Mahmoud Awad",
        "Krishnamurthi Sundaram"
      ],
      "affiliations": [
        "SUNY Downstate"
      ],
      "normalized_institutions": [
        "SUNY Downstate"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Methods",
        "Results",
        "Discussion/Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel Suarez, MD ; LeeAnn Marcello; Keshav Kumar, MD; Ryan Kong, MD; Billy Yang, MD; Mahmoud Awad, MD; Krishnamurthi Sundaram, MD",
        "Affiliations": "SUNY Downstate",
        "Objective": "To assess the impact of diabetes mellitus (DM) on overall survival (OS) and treatment-related morbidity in patients with head and neck cancer treated with immune checkpoint inhibitors (ICIs) using a propensity score–matched cohort.",
        "Study Design": "Retrospective cohort study.",
        "Methods": "We conducted a retrospective analysis using the TriNetX Research Network, identifying adult patients with HNSCC who received ICI therapy between January 1, 2012, and September 30, 2025. Patients were stratified into three cohorts based on pre-treatment glycemic status: diabetes (HbA1c ≥6.5%), pre-diabetes (HbA1c 5.7–6.4%), and normoglycemia (HbA1c <5.7%).m Propensity score matching was performed to balance baseline demographics and comorbidities. The primary outcomes were survival probability / overall survival (OS). Outcomes were further stratified according to cancer subsite: skin, oral cavity, oropharynx, and larynx.",
        "Results": "A total of 4959 patients were included (1,826 without diabetes, 1,698 with pre-diabetes, and 1,435 with diabetes). There was a significant decrease in OS between HNSCC patients with DM and those without DM at all time points after treatment with ICIs (survival probabilities 81.02% vs 86.34% at 6 months, 47.55% vs 53.71% at 3 years, and 38.99% vs 40.21% at 5 years, p<0.05). Stratification by subsite demonstrated significantly decreased OS at all time points after treatment with ICIs among diabetic patients with cutaneous HNSCC (survival probability 81.73% vs 87.04%; HR at 6 months, 45 no DM vs DM; p=0.006; HR 1.19 [95% CI 1.052-1.346]). However, there were no significant differences in OS at 6 months, 3 years, and 5 years observed between diabetic and non-diabetic patients with mucosal SCCs of the oral cavity, oropharynx, or larynx treated with ICIs.",
        "Discussion/Conclusion": "Diabetes mellitus is known to be a significant risk factor for poorer survival outcomes and increased adverse events following surgical or systemic chemoradiation therapy (higher rates of infection, hematotoxicity, malnutrition, and higher treatment-related mortality).1 Prior studies have shown that immune checkpoint inhibitor therapy can potentially induce an autoimmune response that can raise insulin resistance.y The results of our study suggests that history of diabetes mellitus has a negative influence on survival outcomes in patients with cutaneous SCC, but not in patients with most mucosal HNSCC subtypes (eg in the oral cavity, oropharynx or larynx) after receiving ICI therapy. This suggests a unique interaction between DM, tumor biology, and ICI response in this subgroup, corresponding to prior studies that demonstrated better response to immunotherapy in cutaneous HNSCC than mucosal HNSCCs, presumably due to factors such as higher immunogenicity driven by high tumor mutational burden and overexpressed tumor antigens.3 These findings warrant further investigation and may help provide guidance with clinical decision making when deciding treatment options for HNSCC patients with a history of diabetes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diabetes and Survival Outcomes Following Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma</span>. <u>Daniel Suarez, MD</u>; LeeAnn Marcello; Keshav Kumar, MD; Ryan Kong, MD; Billy Yang, MD; Mahmoud Awad, MD; Krishnamurthi Sundaram, MD. SUNY Downstate<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To assess the impact of diabetes mellitus (DM) on overall survival (OS) and treatment-related morbidity in patients with head and neck cancer treated with immune checkpoint inhibitors (ICIs) using a propensity score–matched cohort.</p>\n\n<p><strong>Study Design: </strong>Retrospective cohort study.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective analysis using the TriNetX Research Network, identifying adult patients with HNSCC who received ICI therapy between January 1, 2012, and September 30, 2025. Patients were stratified into three cohorts based on pre-treatment glycemic status: diabetes (HbA1c ≥6.5%), pre-diabetes (HbA1c 5.7–6.4%), and normoglycemia (HbA1c <5.7%).m Propensity score matching was performed to balance baseline demographics and comorbidities. The primary outcomes were survival probability / overall survival (OS). Outcomes were further stratified according to cancer subsite: skin, oral cavity, oropharynx, and larynx.</p>\n\n<p><strong>Results: </strong>A total of 4959 patients were included (1,826 without diabetes, 1,698 with pre-diabetes, and 1,435 with diabetes). There was a significant decrease in OS between HNSCC patients with DM and those without DM at all time points after treatment with ICIs (survival probabilities 81.02% vs 86.34% at 6 months, 47.55% vs 53.71% at 3 years, and 38.99% vs 40.21% at 5 years, p<0.05). Stratification by subsite demonstrated significantly decreased OS at all time points after treatment with ICIs among diabetic patients with cutaneous HNSCC (survival probability 81.73% vs 87.04%; HR  at 6 months, 45  no DM vs DM; p=0.006; HR 1.19 [95% CI 1.052-1.346]). However, there were no significant differences in OS at 6 months, 3 years, and 5 years observed between diabetic and non-diabetic patients with mucosal SCCs of the oral cavity, oropharynx, or larynx treated with ICIs.</p>\n\n<p><strong>Discussion/Conclusion: </strong>Diabetes mellitus is known to be a significant risk factor for poorer survival outcomes and increased adverse events following surgical or systemic chemoradiation therapy (higher rates of infection, hematotoxicity, malnutrition, and higher treatment-related mortality).1 Prior studies have shown that immune checkpoint inhibitor therapy can potentially induce an autoimmune response that can raise insulin resistance.y The results of our study suggests that history of diabetes mellitus has a negative influence on survival outcomes in patients with cutaneous SCC, but not in patients with most mucosal HNSCC subtypes (eg in the oral cavity, oropharynx or larynx) after receiving ICI therapy. This suggests a unique interaction between DM, tumor biology, and ICI response in this subgroup, corresponding to prior studies that demonstrated better response to immunotherapy in cutaneous HNSCC than mucosal HNSCCs, presumably due to factors such as higher immunogenicity driven by high tumor mutational burden and overexpressed tumor antigens.3 These findings warrant further investigation and may help provide guidance with clinical decision making when deciding treatment options for HNSCC patients with a history of diabetes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154732--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S256",
      "content_id": "154269",
      "abstract_number": "S256",
      "poster_number": "",
      "title": "Development and Validation of a Preoperative Risk Score to Predict Severe Adverse Events After Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma",
      "summary": "The TSOS represents a novel prognostic risk stratification tool capable of categorizing patients undergoing TORS for OPSCC into clinically meaningful low- and high-risk groups for severe postoperative morbidity. The score reliably isolates a high-risk subgroup with markedly increased rates of post-operative hemorrhage, tracheostomy, and gastrostomy placement. By using readily obtainable preoperative variables,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154269",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ismail M Khaderi, BS",
      "presenter": "Ismail M Khaderi, BS",
      "authors": "Ismail M Khaderi, BS 1 ; Abdullah W Saleh, BS 1 ; David Strum, MD 2 ; Nazineen Kandahari, MD 2 ; Trevor G Hackman, MD 2",
      "normalized_authors": [
        "Ismail M Khaderi",
        "Abdullah W Saleh",
        "David Strum",
        "Nazineen Kandahari",
        "Trevor G Hackman"
      ],
      "affiliations": [
        "UNC School of Medicine",
        "UNC Dept. of Otolaryngology/Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "UNC School of Medicine",
        "UNC Dept. of Otolaryngology/Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 504,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ismail M Khaderi, BS 1 ; Abdullah W Saleh, BS 1 ; David Strum, MD 2 ; Nazineen Kandahari, MD 2 ; Trevor G Hackman, MD 2",
        "Affiliations": "1 UNC School of Medicine; 2 UNC Dept. of Otolaryngology/Head and Neck Surgery",
        "Background": "Transoral robotic surgery (TORS) has been widely adopted for the surgical treatment of oropharyngeal squamous cell carcinoma (OPSCC) due to decreased morbidity compared to open surgical techniques and its role in treatment de-escalation. However, severe postoperative adverse outcomes, including hemorrhage, tracheostomy, and gastrostomy, remain a substantial concern. Currently, no validated preoperative tool exists to stratify patients by risk prior to TORS. In this study, we developed and tested a novel TORS Severe Outcome Score (TSOS) using a large multi-institutional dataset.",
        "Methods": "Adult patients with OPSCC who underwent TORS within 3 months of diagnosis (2015–present) were identified using the TriNetX research network database. The primary endpoint was a composite severe adverse outcome within 30 days of surgery consisting of either postoperative hemorrhage, gastrostomy tube placement, or tracheostomy placement. After broad univariate screening, iterative multivariable Cox modeling identified final independent predictors. β-coefficients were converted into an integer-based score (0–15 range) using the lowest β-coefficient as the scaling anchor. Patients were stratified into high-risk (TSOS ≥2) vs low-risk (TSOS <2). Model performance was evaluated using adverse event rates, risk ratios (RR), and p-values.",
        "Results": "1,492 adults with OPSCC who underwent TORS were identified. Overall, the postoperative severe complication rate was 16.3%, consisting of 139 patients who required gastrostomy placement, 62 patients who underwent tracheostomy, and 87 patients who experienced postoperative hemorrhage. Since some patients experienced more than one event, these categories are not mutually exclusive. Independent risk factor predictors in the final model included BMI <22, hyperlipidemia, dysphagia, nicotine dependence, T3 disease, and T4 disease (HRs 1.4–6.5).",
        "Abstract": "β-coefficients were scaled to create the TSOS, assigning 2 points for BMI <22, 1 point for hyperlipidemia, 1 point for dysphagia, 2 points for nicotine dependence, 4 points for T3, and 5 points for T4, yielding a total score range of 0–15. Based on outcome separation, patients were stratified into low-risk (TSOS <2) and high-risk (TSOS ≥2) groups. Approximately 20% of the population met criteria for high-risk classification. High-risk patients experienced significantly higher rates of the composite severe adverse event compared with low-risk patients (25.7% vs 12.6%; RR 2.04; p < 0.0001). Individual outcomes also demonstrated strong separation. Tracheostomy placements occurred in 7.9% of high-risk patients compared to 2.9% of low-risk patients (RR 2.75; p < 0.0001). Gastrostomy placement rates were 16.6% and 6.5%, respectively (RR 2.53; p < 0.0001). Hemorrhage occurred in 8.1% of high-risk patients and 5.1% of low-risk patients (RR 1.58; p = 0.0416). View in Agenda and Add to Schedule",
        "Conclusion": "The TSOS represents a novel prognostic risk stratification tool capable of categorizing patients undergoing TORS for OPSCC into clinically meaningful low- and high-risk groups for severe postoperative morbidity. The score reliably isolates a high-risk subgroup with markedly increased rates of post-operative hemorrhage, tracheostomy, and gastrostomy placement. By using readily obtainable preoperative variables, the TSOS can complement oncologic assessment and support individualized treatment planning and counseling. Future studies should seek to validate TSOS with other large multi-institutional cohort data."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development and Validation of a Preoperative Risk Score to Predict Severe Adverse Events After Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma</span>. <u>Ismail M Khaderi, BS</u><sup>1</sup>; Abdullah W Saleh, BS<sup>1</sup>; David Strum, MD<sup>2</sup>; Nazineen Kandahari, MD<sup>2</sup>; Trevor G Hackman, MD<sup>2</sup>. <sup>1</sup>UNC School of Medicine; <sup>2</sup>UNC Dept. of Otolaryngology/Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral robotic surgery (TORS) has been widely adopted for the surgical treatment of oropharyngeal squamous cell carcinoma (OPSCC) due to decreased morbidity compared to open surgical techniques and its role in treatment de-escalation. However, severe postoperative adverse outcomes, including hemorrhage, tracheostomy, and gastrostomy, remain a substantial concern. Currently, no validated preoperative tool exists to stratify patients by risk prior to TORS. In this study, we developed and tested a novel TORS Severe Outcome Score (TSOS) using a large multi-institutional dataset.</p>\n\n<p><strong>Methods: </strong>Adult patients with OPSCC who underwent TORS within 3 months of diagnosis (2015–present) were identified using the TriNetX research network database. The primary endpoint was a composite severe adverse outcome within 30 days of surgery consisting of either postoperative hemorrhage, gastrostomy tube placement, or tracheostomy placement. After broad univariate screening, iterative multivariable Cox modeling identified final independent predictors. β-coefficients were converted into an integer-based score (0–15 range) using the lowest β-coefficient as the scaling anchor. Patients were stratified into high-risk (TSOS ≥2) vs low-risk (TSOS <2). Model performance was evaluated using adverse event rates, risk ratios (RR), and p-values.</p>\n\n<p><strong>Results: </strong>1,492 adults with OPSCC who underwent TORS were identified. Overall, the postoperative severe complication rate was 16.3%, consisting of 139 patients who required gastrostomy placement, 62 patients who underwent tracheostomy, and 87 patients who experienced postoperative hemorrhage. Since some patients experienced more than one event, these categories are not mutually exclusive. Independent risk factor predictors in the final model included BMI <22, hyperlipidemia, dysphagia, nicotine dependence, T3 disease, and T4 disease (HRs 1.4–6.5). </p>\n\n<p>β-coefficients were scaled to create the TSOS, assigning 2 points for BMI <22, 1 point for hyperlipidemia, 1 point for dysphagia, 2 points for nicotine dependence, 4 points for T3, and 5 points for T4, yielding a total score range of 0–15. Based on outcome separation, patients were stratified into low-risk (TSOS <2) and high-risk (TSOS ≥2) groups. Approximately 20% of the population met criteria for high-risk classification. </p>\n\n<p>High-risk patients experienced significantly higher rates of the composite severe adverse event compared with low-risk patients (25.7% vs 12.6%; RR 2.04; p < 0.0001). Individual outcomes also demonstrated strong separation. Tracheostomy placements occurred in 7.9% of high-risk patients compared to 2.9% of low-risk patients (RR 2.75; p < 0.0001). Gastrostomy placement rates were 16.6% and 6.5%, respectively (RR 2.53; p < 0.0001). Hemorrhage occurred in 8.1% of high-risk patients and 5.1% of low-risk patients (RR 1.58; p = 0.0416).</p>\n\n<p><strong>Conclusion: </strong>The TSOS represents a novel prognostic risk stratification tool capable of categorizing patients undergoing TORS for OPSCC into clinically meaningful low- and high-risk groups for severe postoperative morbidity. The score reliably isolates a high-risk subgroup with markedly increased rates of post-operative hemorrhage, tracheostomy, and gastrostomy placement. By using readily obtainable preoperative variables, the TSOS can complement oncologic assessment and support individualized treatment planning and counseling. Future studies should seek to validate TSOS with other large multi-institutional cohort data.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154269--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S257",
      "content_id": "154633",
      "abstract_number": "S257",
      "poster_number": "",
      "title": "Concurrent Statin Use and Overall Survival in Immune-Checkpoint Inhibitor-Treated Mucosal Head and Neck Squamous Cell Carcinoma: A Multi-Institutional Real-World Analysis",
      "summary": "In this multi-institutional real-world cohort of nearly 23,000 mucosal HNSCC patients receiving ICIs, concurrent statin therapy did not confer a classwide survival advantage after adjustment for demographic, clinical, and tumor-related factors. However, the significant reduction in mortality observed with rosuvastatin, together with supportive findings from prior immunotherapy studies, suggests the possibility of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154633",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Allen Khudaverdyan, BA",
      "presenter": "Allen Khudaverdyan, BA",
      "authors": "Allen Khudaverdyan, BA 1 ; Sophie Jabban, BA 1 ; Lindsey Moses, MD 2 ; Emmanuel Garcia Morales, PhD 2 ; Ashley Feng, BS 2 ; Umamaheswar Duvvuri 1",
      "normalized_authors": [
        "Allen Khudaverdyan",
        "Sophie Jabban",
        "Lindsey Moses",
        "Emmanuel Garcia Morales",
        "Ashley Feng",
        "Umamaheswar Duvvuri"
      ],
      "affiliations": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Allen Khudaverdyan, BA 1 ; Sophie Jabban, BA 1 ; Lindsey Moses, MD 2 ; Emmanuel Garcia Morales, PhD 2 ; Ashley Feng, BS 2 ; Umamaheswar Duvvuri 1",
        "Affiliations": "1 NYU Grossman School of Medicine; 2 NYU Langone Department of Otolaryngology",
        "Background": "Statins have been hypothesized to enhance antitumor immunity through mevalonate-pathway inhibition, improved T-cell priming, and modulation of PD-1 signaling. Although several retrospective studies in head and neck squamous cell carcinoma (HNSCC) have suggested survival benefits in non-ICI settings, evidence in immunotherapy-treated cohorts remains limited, and prior statin-ICI studies have been small or heterogeneous. No large-scale analysis has evaluated whether concurrent statin use during immune-checkpoint inhibitor (ICI) therapy improves survival in mucosal HNSCC. We assessed whether “statin synergy,” defined as active statin use at ICI initiation, was associated with overall survival (OS).",
        "Methods": "We performed a retrospective study using Epic COSMOS, a multi-health system electronic health record dataset. Adult patients with mucosal HNSCC receiving ≥1 ICI (pembrolizumab, nivolumab, durvalumab, avelumab, ipilimumab, or atezolizumab) were included. Statin synergy required ≥2 statin prescriptions from −365 to +180 days relative to ICI initiation. Demographic, clinical, and treatment variables were extracted from line-level EHR data. The primary outcome was OS from ICI initiation to death or last encounter. Kaplan-Meier curves compared unadjusted OS, and multivariable Cox models adjusted for demographics, comorbidity burden, staging, prior oncologic therapy, ICI regimen, and healthcare utilization. Sensitivity analyses included alternative exposure definitions and drug-restricted cohorts.",
        "Results": "Among 22,896 ICI-treated mucosal HNSCC patients, 6,114 (26.7%) met criteria for statin synergy. Statin users were older with greater cardiometabolic comorbidity but had similar tumor subsite distributions and comparable staging missingness relative to non-users. In unadjusted analyses, statin use was associated with worse OS (HR 1.22), consistent with baseline differences. In the fully adjusted model, statin synergy was not associated with improved survival (adjusted HR 1.03; 95% CI 0.96-1.08). Established prognostic factors (older age, higher Charlson comorbidity index, and advanced T and N stage) remained strongly associated with mortality, whereas a greater number of ICI administrations was protective. Prior surgery, chemotherapy, and radiation did not meaningfully alter the association between statin use and OS.",
        "Abstract": "In secondary analyses evaluating individual statins, rosuvastatin demonstrated a statistically significant association with reduced mortality (HR 0.89; 0.82-0.98). Pravastatin showed a nonsignificant trend toward lower mortality (HR 0.90; 0.81-1.01), whereas atorvastatin and simvastatin were not associated with OS. Although these agent-specific effects did not change the overall class-level null finding, they suggest biologic heterogeneity among statins, consistent with emerging immunotherapy datasets supporting drug-specific rather than classwide synergy. Across sensitivity analyses, the association between statin synergy and OS remained null. View in Agenda and Add to Schedule",
        "Conclusions": "In this multi-institutional real-world cohort of nearly 23,000 mucosal HNSCC patients receiving ICIs, concurrent statin therapy did not confer a classwide survival advantage after adjustment for demographic, clinical, and tumor-related factors. However, the significant reduction in mortality observed with rosuvastatin, together with supportive findings from prior immunotherapy studies, suggests the possibility of drug-specific statin effects not captured in classwide analyses. Although exploratory, these results highlight the need for prospective and mechanistic studies to determine whether particular statin agents, dosing strategies, or tumor immune phenotypes may define subgroups in which statin-ICI synergy is clinically meaningful."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Concurrent Statin Use and Overall Survival in Immune-Checkpoint Inhibitor-Treated Mucosal Head and Neck Squamous Cell Carcinoma: A Multi-Institutional Real-World Analysis</span>. <u>Allen Khudaverdyan, BA</u><sup>1</sup>; Sophie Jabban, BA<sup>1</sup>; Lindsey Moses, MD<sup>2</sup>; Emmanuel Garcia Morales, PhD<sup>2</sup>; Ashley Feng, BS<sup>2</sup>; Umamaheswar Duvvuri<sup>1</sup>. <sup>1</sup>NYU Grossman School of Medicine; <sup>2</sup>NYU Langone Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Statins have been hypothesized to enhance antitumor immunity through mevalonate-pathway inhibition, improved T-cell priming, and modulation of PD-1 signaling. Although several retrospective studies in head and neck squamous cell carcinoma (HNSCC) have suggested survival benefits in non-ICI settings, evidence in immunotherapy-treated cohorts remains limited, and prior statin-ICI studies have been small or heterogeneous. No large-scale analysis has evaluated whether concurrent statin use during immune-checkpoint inhibitor (ICI) therapy improves survival in mucosal HNSCC. We assessed whether “statin synergy,” defined as active statin use at ICI initiation, was associated with overall survival (OS).</p>\n\n<p><strong>Methods</strong>: We performed a retrospective study using Epic COSMOS, a multi-health system electronic health record dataset. Adult patients with mucosal HNSCC receiving ≥1 ICI (pembrolizumab, nivolumab, durvalumab, avelumab, ipilimumab, or atezolizumab) were included. Statin synergy required ≥2 statin prescriptions from −365 to +180 days relative to ICI initiation. Demographic, clinical, and treatment variables were extracted from line-level EHR data. The primary outcome was OS from ICI initiation to death or last encounter. Kaplan-Meier curves compared unadjusted OS, and multivariable Cox models adjusted for demographics, comorbidity burden, staging, prior oncologic therapy, ICI regimen, and healthcare utilization. Sensitivity analyses included alternative exposure definitions and drug-restricted cohorts.</p>\n\n<p><strong>Results</strong>: Among 22,896 ICI-treated mucosal HNSCC patients, 6,114 (26.7%) met criteria for statin synergy. Statin users were older with greater cardiometabolic comorbidity but had similar tumor subsite distributions and comparable staging missingness relative to non-users. In unadjusted analyses, statin use was associated with worse OS (HR 1.22), consistent with baseline differences. In the fully adjusted model, statin synergy was not associated with improved survival (adjusted HR 1.03; 95% CI 0.96-1.08). Established prognostic factors (older age, higher Charlson comorbidity index, and advanced T and N stage) remained strongly associated with mortality, whereas a greater number of ICI administrations was protective. Prior surgery, chemotherapy, and radiation did not meaningfully alter the association between statin use and OS.</p>\n\n<p>In secondary analyses evaluating individual statins, rosuvastatin demonstrated a statistically significant association with reduced mortality (HR 0.89; 0.82-0.98). Pravastatin showed a nonsignificant trend toward lower mortality (HR 0.90; 0.81-1.01), whereas atorvastatin and simvastatin were not associated with OS. Although these agent-specific effects did not change the overall class-level null finding, they suggest biologic heterogeneity among statins, consistent with emerging immunotherapy datasets supporting drug-specific rather than classwide synergy. Across sensitivity analyses, the association between statin synergy and OS remained null.</p>\n\n<p><strong>Conclusions</strong>: In this multi-institutional real-world cohort of nearly 23,000 mucosal HNSCC patients receiving ICIs, concurrent statin therapy did not confer a classwide survival advantage after adjustment for demographic, clinical, and tumor-related factors. However, the significant reduction in mortality observed with rosuvastatin, together with supportive findings from prior immunotherapy studies, suggests the possibility of drug-specific statin effects not captured in classwide analyses. Although exploratory, these results highlight the need for prospective and mechanistic studies to determine whether particular statin agents, dosing strategies, or tumor immune phenotypes may define subgroups in which statin-ICI synergy is clinically meaningful.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154633--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S258",
      "content_id": "154270",
      "abstract_number": "S258",
      "poster_number": "",
      "title": "Association of Frailty with Outcomes Following Multiple Free Flap Reconstructions for Head and Neck Defects: A 15-year Review",
      "summary": "Frailty, as measured by mFI-11, was significantly associated with survival among patients undergoing multiple free flap reconstructions for head and neck defects, though not associated with other perioperative outcome measures including 30-day readmission, 60-day complications, or 30-day return to OR rates. Flap success among this cohort remained high (95.7%) with a 3-year OS of 66.4%. These findings further...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154270",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Antonio S Dekhou, MD",
      "presenter": "Antonio S Dekhou, MD",
      "authors": "Antonio S Dekhou, MD 1 ; Megha Mohanakrishnan, BS 1 ; Priscilla Pichardo, DO 1 ; Meredith E Tabangin, MPH 2 ; Mekibib Altaye, PhD 2 ; Alice A Tang, MD 1 ; Chad A Zender, MD 1 ; Dustin A Silverman, MD 1",
      "normalized_authors": [
        "Antonio S Dekhou",
        "Megha Mohanakrishnan",
        "Priscilla Pichardo",
        "Meredith E Tabangin",
        "Mekibib Altaye",
        "Alice A Tang",
        "Chad A Zender",
        "Dustin A Silverman"
      ],
      "affiliations": [
        "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery",
        "Cincinnati Children's Hospital Medical Center, Department of Biostatistics and Epidemiology"
      ],
      "normalized_institutions": [
        "University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery",
        "Cincinnati Children's Hospital Medical Center, Department of Biostatistics and Epidemiology"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Antonio S Dekhou, MD 1 ; Megha Mohanakrishnan, BS 1 ; Priscilla Pichardo, DO 1 ; Meredith E Tabangin, MPH 2 ; Mekibib Altaye, PhD 2 ; Alice A Tang, MD 1 ; Chad A Zender, MD 1 ; Dustin A Silverman, MD 1",
        "Affiliations": "1 University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery; 2 Cincinnati Children's Hospital Medical Center, Department of Biostatistics and Epidemiology",
        "Background": "Microvascular free tissue transfer is commonly used in the reconstruction of complex head and neck defects. While many patients require only a single free flap, multiple microvascular reconstructions are often indicated, particularly in cases of recurrent oncologic disease, osteoradionecrosis, and infection. Given the numerous challenges in the revision and salvage setting, attention has shifted toward patient-specific factors that may influence postoperative outcomes, particularly frailty. Although the impact of frailty on primary head and neck reconstructions has been explored, its association with outcomes among patients undergoing multiple free flaps has not yet been defined. The primary objective was to assess the influence of patient frailty on postoperative complications and survival in patients undergoing two or more free flap reconstructions.",
        "Methods": "A retrospective analysis of patients who required two or more head and neck free flap reconstructions at a tertiary care center during the years 2009 – 2024 was performed. The comorbidities comprising the Modified Frailty Index-11 (mFI-11) were tabulated, with higher values indicating a higher degree of frailty. Chi-square analyses were used to test for association between frailty and postoperative outcomes. Univariate and multivariate proportional hazards regression analyses were performed to evaluate the impact of frailty on postoperative outcomes and mortality in this cohort.",
        "Results": "211 patients who required two or more free flap reconstructions were identified. The majority of patients were male (N = 138, 65.4%) with mean age at first diagnosis of 60.0 (± 14.2) years. A total of 18 (17.4%) patients required a third free flap reconstruction. The predominant etiologies warranting a sequential free flap were recurrent malignancy (N = 85, 40.3%), ORN/osteomyelitis (N = 58, 27.5%) and fistula/nonfunctional larynx (N = 28, 13.3%). A majority of patients had a mFI-11 index of 1 (N = 70, 33.2%), followed by a mFI-11 score of 0, 2, 3, and ≥4 among 28.0%, 21.3%, 9.5%, and 8.0% of patients, respectively. Higher mFI-11 scores were not statistically significantly associated (p > 0.05) with 30-day readmission rates (N = 89, 42.2%), 60-day complication rates (N = 31, 14.7%), or return to the OR within 30 days of either secondary or tertiary free flap surgeries (N = 45, 21.3%). In a univariate model, a significant association between mFI-11 and mortality was appreciated when stratified by an mFI-11 score of 0, 1-3, and ≥4 (p = 0.03), though this did not persist in a multivariate regression after adjusting for covariates. The 3-year overall survival (OS) among the cohort was 66.4% with a flap success rate of 95.7%.",
        "Conclusion": "Frailty, as measured by mFI-11, was significantly associated with survival among patients undergoing multiple free flap reconstructions for head and neck defects, though not associated with other perioperative outcome measures including 30-day readmission, 60-day complications, or 30-day return to OR rates. Flap success among this cohort remained high (95.7%) with a 3-year OS of 66.4%. These findings further underscore the potential utility of frailty assessment in preoperative risk stratification and highlights successful surgical outcomes among patients undergoing sequential free flap reconstructions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Frailty with Outcomes Following Multiple Free Flap Reconstructions for Head and Neck Defects: A 15-year Review</span>. <u>Antonio S Dekhou, MD</u><sup>1</sup>; Megha Mohanakrishnan, BS<sup>1</sup>; Priscilla Pichardo, DO<sup>1</sup>; Meredith E Tabangin, MPH<sup>2</sup>; Mekibib Altaye, PhD<sup>2</sup>; Alice A Tang, MD<sup>1</sup>; Chad A Zender, MD<sup>1</sup>; Dustin A Silverman, MD<sup>1</sup>. <sup>1</sup>University of Cincinnati - Department of Otolaryngology, Head and Neck Surgery; <sup>2</sup>Cincinnati Children's Hospital Medical Center, Department of Biostatistics and Epidemiology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Microvascular free tissue transfer is commonly used in the reconstruction of complex head and neck defects. While many patients require only a single free flap, multiple microvascular reconstructions are often indicated, particularly in cases of recurrent oncologic disease, osteoradionecrosis, and infection. Given the numerous challenges in the revision and salvage setting, attention has shifted toward patient-specific factors that may influence postoperative outcomes, particularly frailty. Although the impact of frailty on primary head and neck reconstructions has been explored, its association with outcomes among patients undergoing multiple free flaps has not yet been defined. The primary objective was to assess the influence of patient frailty on postoperative complications and survival in patients undergoing two or more free flap reconstructions.</p>\n\n<p><strong>Methods</strong>: A retrospective analysis of patients who required two or more head and neck free flap reconstructions at a tertiary care center during the years 2009 – 2024 was performed. The comorbidities comprising the Modified Frailty Index-11 (mFI-11) were tabulated, with higher values indicating a higher degree of frailty. Chi-square analyses were used to test for association between frailty and postoperative outcomes. Univariate and multivariate proportional hazards regression analyses were performed to evaluate the impact of frailty on postoperative outcomes and mortality in this cohort.</p>\n\n<p><strong>Results</strong>: 211 patients who required two or more free flap reconstructions were identified. The majority of patients were male (N = 138, 65.4%) with mean age at first diagnosis of 60.0 (± 14.2) years. A total of 18 (17.4%) patients required a third free flap reconstruction. The predominant etiologies warranting a sequential free flap were recurrent malignancy (N = 85, 40.3%), ORN/osteomyelitis (N = 58, 27.5%) and fistula/nonfunctional larynx (N = 28, 13.3%). A majority of patients had a mFI-11 index of 1 (N = 70, 33.2%), followed by a mFI-11 score of 0, 2, 3, and ≥4 among 28.0%, 21.3%, 9.5%, and 8.0% of patients, respectively. Higher mFI-11 scores were not statistically significantly associated (p > 0.05) with 30-day readmission rates (N = 89, 42.2%), 60-day complication rates (N = 31, 14.7%), or return to the OR within 30 days of either secondary or tertiary free flap surgeries (N = 45, 21.3%). In a univariate model, a significant association between mFI-11 and mortality was appreciated when stratified by an mFI-11 score of 0, 1-3, and ≥4 (p = 0.03), though this did not persist in a multivariate regression after adjusting for covariates. The 3-year overall survival (OS) among the cohort was 66.4% with a flap success rate of 95.7%.</p>\n\n<p><strong>Conclusion</strong>: Frailty, as measured by mFI-11, was significantly associated with survival among patients undergoing multiple free flap reconstructions for head and neck defects, though not associated with other perioperative outcome measures including 30-day readmission, 60-day complications, or 30-day return to OR rates. Flap success among this cohort remained high (95.7%) with a 3-year OS of 66.4%. These findings further underscore the potential utility of frailty assessment in preoperative risk stratification and highlights successful surgical outcomes among patients undergoing sequential free flap reconstructions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154270--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S259",
      "content_id": "154530",
      "abstract_number": "S259",
      "poster_number": "",
      "title": "Obesity as a Predictor of Biochemical and Structural Incomplete Response in Papillary Thyroid Carcinoma",
      "summary": "In our pooled analyses, obesity was strongly associated with increased rates of biochemical and structural incomplete response. The difference in structural response rates was primarily driven by the Intermediate-high ATA risk group without significant differences in the other risk strata. With the observed reduced US sensitivity in obesity, it is notable that US-missed central metastases did not correlate with...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154530",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Birk J Olson, MD",
      "presenter": "Birk J Olson, MD",
      "authors": "Birk J Olson, MD ; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH",
      "normalized_authors": [
        "Birk J Olson",
        "Jacob Beiriger",
        "Larkin Harris",
        "Nilam D Patel",
        "Devaprabu Abraham",
        "Marcus M Monroe",
        "Jason P Hunt",
        "Richard B Cannon",
        "Sarah Drejet",
        "Luke O Buchmann",
        "Hilary C McCrary"
      ],
      "affiliations": [
        "University of Utah"
      ],
      "normalized_institutions": [
        "University of Utah"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 550,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Birk J Olson, MD ; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH",
        "Affiliations": "University of Utah",
        "Introduction": "Obesity is an established risk factor for adverse features in papillary thyroid cancer (PTC), however, its effect on clinical outcomes is less clear (1). This study focused on the possibility of obesity compromising pre-operative ultrasound and consequences on treatment response rates.",
        "Methods": "Data was collected retrospectively for 691 patients with documented BMI and a PTC pathologic diagnosis. Obesity was defined as BMI ≥30 kg/m². Comparisons between obese and non-obese groups were performed using χ² tests. Biochemical and structural response was assessed according to 2025 ATA response criteria (2). Univariate associations were evaluated using odds ratios (ORs) with 95% confidence intervals (CIs). Multivariable logistic regression models are reported for covariates with adjusted odds ratios (adjORs). For ultrasound (US) performance, sensitivity was calculated for central and lateral compartments, and differences were assessed using a two-proportion z-test and Fisher’s exact test. Stratified and sub-group analyses were performed as needed. A significance threshold of p<0.05 (two-sided) was used for all analyses.",
        "Results": "Of the 691 patients included, 306 (44.3%) were obese. Mean age was 45.3 ± 17.9 years, and 64.2% were female. Obese patients had overall larger primary tumor size at presentation (2.8 vs 2.4 cm, p=0.03).",
        "Abstract": "Biochemical and structural response was assessed in 437 and 356 patients, respectively. A biochemical incomplete response occurred in 56.2% of obese vs 42.9% of non-obese patients (OR 1.70, 95% CI 1.17-2.49, p=0.008). Obesity remained significant after multivariate adjustment (adjOR 1.57, 95% CI 1.00-2.45, p=0.048). A structural incomplete response occurred in 27.9% of obese vs 14.4% of non-obese patients (OR 2.30, 95% CI 1.36-3.90, p=0.003). After adjustment, obesity was still associated (adjOR 2.33, 95% CI 1.30-4.17, p=0.004). In ATA Low, Low-intermediate, and High risk patients, obesity showed no association with structural incomplete response. In Intermediate-high risk patients, obesity was associated with structural incomplete response: 31.9% in obese vs 6.5% in non-obese patients (OR 6.75, 95% CI 2.26-20.17, p=0.0003. Pre-operative ultrasound sensitivity for central neck lymphadenopathy decreased from 74.2% in non-obese patients to 60.5% in obese patients (two-proportion z = 2.11, p=0.035; Fisher’s exact p=0.049), with a higher chance missed central disease in obese patients (OR 1.88, 95% CI 1.04–3.39). In contrast, detection of lateral neck metastases was comparable (95.5% vs 94.0%). Notably, sub-group analysis found the rate of structural incomplete response was higher among patients with US-detected central disease (31.2%) compared with those whose disease was missed and then diagnosed pathologically (17.9%). (references separate) View in Agenda and Add to Schedule",
        "Conclusion": "In our pooled analyses, obesity was strongly associated with increased rates of biochemical and structural incomplete response. The difference in structural response rates was primarily driven by the Intermediate-high ATA risk group without significant differences in the other risk strata. With the observed reduced US sensitivity in obesity, it is notable that US-missed central metastases did not correlate with lower structural response rates. These findings suggests that obesity contributes to negative clinical outcomes in PTC, but further study is warranted to better understand this association and whether obesity compromises on preoperative imaging."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Obesity as a Predictor of Biochemical and Structural Incomplete Response in Papillary Thyroid Carcinoma</span>. <u>Birk J Olson, MD</u>; Jacob Beiriger, BA; Larkin Harris, MD, MPH; Nilam D Patel, MD; Devaprabu Abraham, MD; Marcus M Monroe, MD; Jason P Hunt, MD; Richard B Cannon, MD; Sarah Drejet, MD; Luke O Buchmann, MD; Hilary C McCrary, MD, MPH. University of Utah<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Obesity is an established risk factor for adverse features in papillary thyroid cancer (PTC), however, its effect on clinical outcomes is less clear (1). This study focused on the possibility of obesity compromising pre-operative ultrasound and consequences on treatment response rates.</p>\n\n<p><strong>Methods: </strong>Data was collected retrospectively for 691 patients with documented BMI and a PTC pathologic diagnosis. Obesity was defined as BMI ≥30 kg/m². Comparisons between obese and non-obese groups were performed using χ² tests. Biochemical and structural response was assessed according to 2025 ATA response criteria (2). Univariate associations were evaluated using odds ratios (ORs) with 95% confidence intervals (CIs). Multivariable logistic regression models are reported for covariates with adjusted odds ratios (adjORs). For ultrasound (US) performance, sensitivity was calculated for central and lateral compartments, and differences were assessed using a two-proportion z-test and Fisher’s exact test. Stratified and sub-group analyses were performed as needed. A significance threshold of p<0.05 (two-sided) was used for all analyses.</p>\n\n<p><strong>Results: </strong>Of the 691 patients included, 306 (44.3%) were obese. Mean age was 45.3 ± 17.9 years, and 64.2% were female. Obese patients had overall larger primary tumor size at presentation (2.8 vs 2.4 cm, p=0.03).</p>\n\n<p>Biochemical and structural response was assessed in 437 and 356 patients, respectively. A biochemical incomplete response occurred in 56.2% of obese vs 42.9% of non-obese patients (OR 1.70, 95% CI 1.17-2.49, p=0.008). Obesity remained significant after multivariate adjustment (adjOR 1.57, 95% CI 1.00-2.45, p=0.048). A structural incomplete response occurred in 27.9% of obese vs 14.4% of non-obese patients (OR 2.30, 95% CI 1.36-3.90, p=0.003). After adjustment, obesity was still associated (adjOR 2.33, 95% CI 1.30-4.17, p=0.004).</p>\n\n<p>In ATA Low, Low-intermediate, and High risk patients, obesity showed no association with structural incomplete response. In Intermediate-high risk patients, obesity was associated with structural incomplete response: 31.9% in obese vs 6.5% in non-obese patients (OR 6.75, 95% CI 2.26-20.17, p=0.0003.</p>\n\n<p>Pre-operative ultrasound sensitivity for central neck lymphadenopathy decreased from 74.2% in non-obese patients to 60.5% in obese patients (two-proportion z = 2.11, p=0.035; Fisher’s exact p=0.049), with a higher chance missed central disease in obese patients (OR 1.88, 95% CI 1.04–3.39). In contrast, detection of lateral neck metastases was comparable (95.5% vs 94.0%). Notably, sub-group analysis found the rate of structural incomplete response was higher among patients with US-detected central disease (31.2%) compared with those whose disease was missed and then diagnosed pathologically (17.9%).</p>\n\n<p><strong>Conclusion: </strong>In our pooled analyses, obesity was strongly associated with increased rates of biochemical and structural incomplete response. The difference in structural response rates was primarily driven by the Intermediate-high ATA risk group without significant differences in the other risk strata. With the observed reduced US sensitivity in obesity, it is notable that US-missed central metastases did not correlate with lower structural response rates. These findings suggests that obesity contributes to negative clinical outcomes in PTC, but further study is warranted to better understand this association and whether obesity compromises on preoperative imaging.  </p>\n\n<p>(references separate)</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154530--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S260",
      "content_id": "153380",
      "abstract_number": "S260",
      "poster_number": "",
      "title": "Development and Validation of a Preoperative Cachexia Risk Prediction Model for Laryngeal Cancer Surgery Patients",
      "summary": "This novel preoperative cachexia prediction model demonstrates excellent discrimination using readily available clinical and laboratory data. The model identifies high-risk laryngeal surgery patients who may benefit from preoperative nutritional optimization and perioperative monitoring. Future validation in prospective cohorts and evaluation of intervention strategies in high-risk patients are warranted. A...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153380",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taral K Jella, BA",
      "presenter": "Taral K Jella, BA",
      "authors": "Tara P Menon, BS 1 ; Taral K Jella, BA 1 ; Jazlyn Selvasingh, BA 1 ; William P Magdycz, MD 2 ; Justin Shinn, MD 2",
      "normalized_authors": [
        "Tara P Menon",
        "Taral K Jella",
        "Jazlyn Selvasingh",
        "William P Magdycz",
        "Justin Shinn"
      ],
      "affiliations": [
        "Virginia Tech Carilion School of Medicine",
        "Carilion Clinic Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "Virginia Tech Carilion School of Medicine",
        "Carilion Clinic Department of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 420,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tara P Menon, BS 1 ; Taral K Jella, BA 1 ; Jazlyn Selvasingh, BA 1 ; William P Magdycz, MD 2 ; Justin Shinn, MD 2",
        "Affiliations": "1 Virginia Tech Carilion School of Medicine; 2 Carilion Clinic Department of Otolaryngology",
        "Background": "Cachexia is associated with poor surgical outcomes in head and neck cancer patients, yet preoperative identification remains challenging. The present analysis developed a risk prediction model for cachexia in patients undergoing laryngeal surgery using nationally representative data. Cachexia begins long before clinically detectable weight loss, so relying on weight alone underestimates risk. Multidimensional clinical markers allow earlier and more accurate prediction.",
        "Methods": "The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2011-2021) was queried for patients undergoing laryngeal procedures (CPT codes 31360-31395). Cachexia was defined as preoperative body mass index <18.5 kg/m² or serum albumin <3.5 g/dL. LASSO logistic regression identified independent preoperative predictors from demographics, comorbidities, and laboratory values, reported with adjusted odds ratios (aOR) and 95% confidence intervals (95% CI). Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC). A simplified risk calculator was developed using standardized coefficients.",
        "Results": "Among 3,470 laryngeal surgery patients, cachexia prevalence was 18.8%. The final model achieved an AUC of 0.834, identifying 12 independent predictors. Laboratory values were the strongest risk factors: lower hematocrit (aOR 0.45, 95% CI 0.39–0.53), elevated alkaline phosphatase (aOR 1.61, 95% CI 1.41–1.83), elevated total bilirubin (aOR 1.40, 95% CI 1.25–1.57), and hyponatremia (aOR 2.01, 95% CI 1.54–2.61) demonstrated the greatest associations. Higher ASA class (aOR 1.43, 95% CI 1.29–1.58), elevated white blood cell count (aOR 1.34, 95% CI 1.20–1.50), thrombocytosis (aOR 1.25, 95% CI 1.12–1.40), elevated INR (aOR 1.24, 95% CI 1.11–1.37), and current smoking (aOR 1.21, 95% CI 1.10–1.33) were also significant risk factors. Partially dependent functional status increased risk (aOR 1.16, 95% CI 1.07–1.26), while White race was protective (aOR 0.87, 95% CI 0.79–0.95). Elevated creatinine was inversely associated with cachexia (aOR 0.84, 95% CI 0.75–0.96). All associations remained significant after multivariable adjustment (p<0.01).",
        "Conclusions": "This novel preoperative cachexia prediction model demonstrates excellent discrimination using readily available clinical and laboratory data. The model identifies high-risk laryngeal surgery patients who may benefit from preoperative nutritional optimization and perioperative monitoring. Future validation in prospective cohorts and evaluation of intervention strategies in high-risk patients are warranted. A web-based risk calculator is available at https://laryngealcancer-cachexia-score.netlify.app/ for clinical implementation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development and Validation of a Preoperative Cachexia Risk Prediction Model for Laryngeal Cancer Surgery Patients</span>. Tara P Menon, BS<sup>1</sup>; <u>Taral K Jella, BA</u><sup>1</sup>; Jazlyn Selvasingh, BA<sup>1</sup>; William P Magdycz, MD<sup>2</sup>; Justin Shinn, MD<sup>2</sup>. <sup>1</sup>Virginia Tech Carilion School of Medicine; <sup>2</sup>Carilion Clinic Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Cachexia is associated with poor surgical outcomes in head and neck cancer patients, yet preoperative identification remains challenging. The present analysis developed a risk prediction model for cachexia in patients undergoing laryngeal surgery using nationally representative data. Cachexia begins long before clinically detectable weight loss, so relying on weight alone underestimates risk. Multidimensional clinical markers allow earlier and more accurate prediction.</p>\n\n<p><strong>Methods</strong>: The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2011-2021) was queried for patients undergoing laryngeal procedures (CPT codes 31360-31395). Cachexia was defined as preoperative body mass index <18.5 kg/m² or serum albumin <3.5 g/dL. LASSO logistic regression identified independent preoperative predictors from demographics, comorbidities, and laboratory values, reported with adjusted odds ratios (aOR) and 95% confidence intervals (95% CI). Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC). A simplified risk calculator was developed using standardized coefficients.</p>\n\n<p><strong>Results</strong>: Among 3,470 laryngeal surgery patients, cachexia prevalence was 18.8%. The final model achieved an AUC of 0.834, identifying 12 independent predictors. Laboratory values were the strongest risk factors: lower hematocrit (aOR 0.45, 95% CI 0.39–0.53), elevated alkaline phosphatase (aOR 1.61, 95% CI 1.41–1.83), elevated total bilirubin (aOR 1.40, 95% CI 1.25–1.57), and hyponatremia (aOR 2.01, 95% CI 1.54–2.61) demonstrated the greatest associations. Higher ASA class (aOR 1.43, 95% CI 1.29–1.58), elevated white blood cell count (aOR 1.34, 95% CI 1.20–1.50), thrombocytosis (aOR 1.25, 95% CI 1.12–1.40), elevated INR (aOR 1.24, 95% CI 1.11–1.37), and current smoking (aOR 1.21, 95% CI 1.10–1.33) were also significant risk factors. Partially dependent functional status increased risk (aOR 1.16, 95% CI 1.07–1.26), while White race was protective (aOR 0.87, 95% CI 0.79–0.95). Elevated creatinine was inversely associated with cachexia (aOR 0.84, 95% CI 0.75–0.96). All associations remained significant after multivariable adjustment (p<0.01).</p>\n\n<p><strong>Conclusions</strong>: This novel preoperative cachexia prediction model demonstrates excellent discrimination using readily available clinical and laboratory data. The model identifies high-risk laryngeal surgery patients who may benefit from preoperative nutritional optimization and perioperative monitoring. Future validation in prospective cohorts and evaluation of intervention strategies in high-risk patients are warranted. A web-based risk calculator is available at https://laryngealcancer-cachexia-score.netlify.app/ for clinical implementation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153380--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S261",
      "content_id": "153687",
      "abstract_number": "S261",
      "poster_number": "",
      "title": "HPV PCR and p16 as Predictors of Recurrence in Oropharyngeal Cancer: Evidence from a South American Cohort",
      "summary": "In this South American cohort, oropharyngeal cancer showed a strong association with HPV. We found a high concordance between HPV PCR and p16 status. Negative or discordant HPV PCR/p16 combinations were associated with a significantly increased risk of recurrence.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153687",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260134",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ximena Mimica, MD",
      "presenter": "Ximena Mimica, MD",
      "authors": "Ximena Mimica, MD 1 ; Veronica Sanhueza, MD 1 ; Troy Ejsmentewicz, M, Sc 1 ; Franz Villaroel, PhD 1 ; Diego Carillo, MD 2 ; Jose Tomas Peña, MD 2 ; Antonieta Solar, MD 2 ; Jeannie Slater, MD 3 ; Ingrid Plass, MD 3 ; Jorge Sapunar, MD 1",
      "normalized_authors": [
        "Ximena Mimica",
        "Veronica Sanhueza",
        "Troy Ejsmentewicz, M, Sc",
        "Franz Villaroel",
        "Diego Carillo",
        "Jose Tomas Peña",
        "Antonieta Solar",
        "Jeannie Slater",
        "Ingrid Plass",
        "Jorge Sapunar"
      ],
      "affiliations": [
        "Instituto Oncológico Fundación Arturo López Pérez",
        "Pontificia Universidad Católica de Chile",
        "Clinica Alemana de Santiago"
      ],
      "normalized_institutions": [
        "Instituto Oncológico Fundación Arturo López Pérez",
        "Pontificia Universidad Católica de Chile",
        "Clinica Alemana de Santiago"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 436,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ximena Mimica, MD 1 ; Veronica Sanhueza, MD 1 ; Troy Ejsmentewicz, M, Sc 1 ; Franz Villaroel, PhD 1 ; Diego Carillo, MD 2 ; Jose Tomas Peña, MD 2 ; Antonieta Solar, MD 2 ; Jeannie Slater, MD 3 ; Ingrid Plass, MD 3 ; Jorge Sapunar, MD 1",
        "Affiliations": "1 Instituto Oncológico Fundación Arturo López Pérez; 2 Pontificia Universidad Católica de Chile; 3 Clinica Alemana de Santiago",
        "Background": "Human papillomavirus (HPV)–related oropharyngeal cancer has shown a steady increase since its initial description. Consequently, p16 immunohistochemistry has become part of the routine diagnostic evaluation for this disease. Recent studies have demonstrated not only differences in oncologic outcomes between p16-positive and p16-negative cases, but also heterogeneity within p16-positive tumors. HPV PCR testing can help identify subgroups with better or worse prognosis. Patients who are both PCR- and p16-positive experience more favorable oncologic outcomes compared with those with discordant profiles (p16–/HPV+ or p16+/HPV–). However, most data come from European and North American cohorts, which may not reflect disease behavior in South America, where several countries continue to report a higher prevalence of HPV-unrelated oropharyngeal cancer.",
        "Methods": "We conducted a retrospective, multi-institutional study including patients treated for oropharyngeal cancer between 2015 and 2022. Demographic and clinical variables were collected, including age, sex, tobacco and alcohol use, and treatments received. All patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC). An expert pathologist reviewed p16 immunohistochemistry status. HPV16 PCR testing was performed for all patients with available tissue samples. The primary clinical outcome was recurrence-free survival (RFS). RFS was compared across HPV/p16 status groups using the log-rank test. A Cox proportional hazards regression model was used to evaluate the effect of additional clinical and pathological variables on RFS.",
        "Results": "A total of 172 patients were identified, including 125 men and 47 women, with a mean age of 63 years, p16 immunohistochemistry was positive in 154 cases. The most common primary tumor site was the tonsil. Of all patients, 100 had samples available for PCR testing. Among these, 81 were p16+/PCR+, 4 were p16+/PCR-, 1 was p16-/PCR+, and 14 were p16-/PCR-. Follow-up data were available for 90 patients. Median follow-up was 19.5 months (range, 2–120 months). The 3-year RFS was 74,28% (95% CI 60,2-84%) for p16+/PCR+ and 28,04% (95% CI 56,8-56%) for p16-/PCR- and discordant cases. When comparing PCR/p16- positive cases with PCR/p16-negative or discordant cases, the hazard ratio (HR) for recurrence was 0.21 (95% CI 0.075–0.587; p = 0.003), indicating an approximately 80% reduction in recurrence risk. This association remained significant after adjusting for tobacco use, alcohol consumption, age, sex, and T and N stage.",
        "Conclusions": "In this South American cohort, oropharyngeal cancer showed a strong association with HPV. We found a high concordance between HPV PCR and p16 status. Negative or discordant HPV PCR/p16 combinations were associated with a significantly increased risk of recurrence.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HPV PCR and p16 as Predictors of Recurrence in Oropharyngeal Cancer: Evidence from a South American Cohort</span>. <u>Ximena Mimica, MD</u><sup>1</sup>; Veronica Sanhueza, MD<sup>1</sup>; Troy Ejsmentewicz, M, Sc<sup>1</sup>; Franz Villaroel, PhD<sup>1</sup>; Diego Carillo, MD<sup>2</sup>; Jose Tomas Peña, MD<sup>2</sup>; Antonieta Solar, MD<sup>2</sup>; Jeannie Slater, MD<sup>3</sup>; Ingrid Plass, MD<sup>3</sup>; Jorge Sapunar, MD<sup>1</sup>. <sup>1</sup>Instituto Oncológico Fundación Arturo López Pérez; <sup>2</sup>Pontificia Universidad Católica de Chile; <sup>3</sup>Clinica Alemana de Santiago<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Human papillomavirus (HPV)–related oropharyngeal cancer has shown a steady increase since its initial description. Consequently, p16 immunohistochemistry has become part of the routine diagnostic evaluation for this disease. Recent studies have demonstrated not only differences in oncologic outcomes between p16-positive and p16-negative cases, but also heterogeneity within p16-positive tumors. HPV PCR testing can help identify subgroups with better or worse prognosis. Patients who are both PCR- and p16-positive experience more favorable oncologic outcomes compared with those with discordant profiles (p16–/HPV+ or p16+/HPV–). However, most data come from European and North American cohorts, which may not reflect disease behavior in South America, where several countries continue to report a higher prevalence of HPV-unrelated oropharyngeal cancer.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective, multi-institutional study including patients treated for oropharyngeal cancer between 2015 and 2022. Demographic and clinical variables were collected, including age, sex, tobacco and alcohol use, and treatments received. All patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC). An expert pathologist reviewed p16 immunohistochemistry status. HPV16 PCR testing was performed for all patients with available tissue samples. The primary clinical outcome was recurrence-free survival (RFS). RFS was compared across HPV/p16 status groups using the log-rank test. A Cox proportional hazards regression model was used to evaluate the effect of additional clinical and pathological variables on RFS.</p>\n\n<p><strong>Results: </strong>A total of 172 patients were identified, including 125 men and 47 women, with a mean age of 63 years, p16 immunohistochemistry was positive in 154 cases. The most common primary tumor site was the tonsil. Of all patients, 100 had samples available for PCR testing. Among these, 81 were p16+/PCR+, 4 were p16+/PCR-, 1 was p16-/PCR+, and 14 were p16-/PCR-. Follow-up data were available for 90 patients. Median follow-up was 19.5 months (range, 2–120 months). The 3-year RFS was 74,28% (95% CI 60,2-84%) for p16+/PCR+ and 28,04% (95% CI 56,8-56%) for p16-/PCR- and discordant cases. When comparing PCR/p16- positive cases with PCR/p16-negative or discordant cases, the hazard ratio (HR) for recurrence was 0.21 (95% CI 0.075–0.587; p = 0.003), indicating an approximately 80% reduction in recurrence risk. This association remained significant after adjusting for tobacco use, alcohol consumption, age, sex, and T and N stage.</p>\n\n<p><strong>Conclusions: </strong>In this South American cohort, oropharyngeal cancer showed a strong association with HPV. We found a high concordance between HPV PCR and p16 status. Negative or discordant HPV PCR/p16 combinations were associated with a significantly increased risk of recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153687--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260134' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S262",
      "content_id": "153257",
      "abstract_number": "S262",
      "poster_number": "",
      "title": "History of infertility and oral cavity squamous cell carcinoma risk in post-menopausal women",
      "summary": "In this large prospective cohort of postmenopausal women, a history of infertility was associated with elevated OCSCC risk independent of age, tobacco use, and alcohol intake. These findings suggest that systemic endocrine or metabolic dysregulation associated with infertility may contribute to the rising burden of OCSCC in women. Further mechanistic and clinical investigation is warranted to clarify underlying...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153257",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna C Clements, MD",
      "presenter": "Anna C Clements, MD",
      "authors": "Hosam H Alkhatib, MD 1 ; Kara L Cushing-Haugen, MS 2 ; Anna C Clements, MD 1 ; Mateo Useche, MD, MPH 1 ; Luis E Cortina, MD 1 ; Rocco Ferrandino, MD, MSc 1 ; Emily Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 2 ; Brittany R Barber, MD, MSc 1",
      "normalized_authors": [
        "Hosam H Alkhatib",
        "Kara L Cushing-Haugen",
        "Anna C Clements",
        "Mateo Useche",
        "Luis E Cortina",
        "Rocco Ferrandino",
        "Emily Marchiano",
        "Zain H Rizvi",
        "Lauren Shih",
        "Cristina P Rodriguez",
        "Neal Futran",
        "Matthew O Old",
        "Holly R Harris, ScD",
        "Brittany R Barber"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 405,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hosam H Alkhatib, MD 1 ; Kara L Cushing-Haugen, MS 2 ; Anna C Clements, MD 1 ; Mateo Useche, MD, MPH 1 ; Luis E Cortina, MD 1 ; Rocco Ferrandino, MD, MSc 1 ; Emily Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 2 ; Brittany R Barber, MD, MSc 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; 2 Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA; 3 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
        "Background": "Incidence of oral cavity squamous cell carcinoma (OCSCC) is rising among women, particularly women who are non-smokers, yet the contribution of reproductive and hormonal factors remains unclear. Reproductive factors such as parity, breastfeeding, infertility, and oral contraceptive use have been linked to risk of other digestive tract malignancies, but data for OCSCC are sparse. We evaluated whether reproductive history, with a focus on infertility, is associated with OCSCC risk in postmenopausal women.",
        "Methods": "We utilized the Women’s Health Initiative (WHI) prospective cohort (n = 160,947) of postmenopausal women who were enrolled between 1993 and 1998 in the United States and followed for up to 30 years. Reproductive exposures were ascertained by baseline questionnaire and included parity, age at first and last birth, breastfeeding history and duration, and history of infertility, defined as trying to become pregnant for more than 12 months without conceiving. Oral contraceptive use (ever-use and duration), age at menarche, and age at menopause were also recorded. Incident OCSCC cases were identified during follow-up through initial self-report and subsequently adjudicated by medical record review. Multivariable Cox proportional hazards models adjusting for age, smoking status, and alcohol intake were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).",
        "Results": "Over the course of follow-up, 235 women were diagnosed with OCSCC. Approximately 16.3% of participants reported a history of infertility. Participants reporting infertility had a 40% higher risk of OCSCC compared with those without a history of infertility (HR 1.40, 95% CI 1.02–1.92). Results were similar in a sensitivity analysis restricted to parous women with no history of infertility as the reference group (HR 1.43, 95% CI 1.04–1.97), as well as in a separate analysis additionally adjusting for body mass index and menstrual cycle irregularity (as a proxy for polycystic ovary syndrome) (HR 1.43, 95% CI 1.04–1.97). History of oral contraceptive use, breastfeeding history, breastfeeding duration, parity, and number of live births were not significantly associated with OCSCC risk.",
        "Conclusions": "In this large prospective cohort of postmenopausal women, a history of infertility was associated with elevated OCSCC risk independent of age, tobacco use, and alcohol intake. These findings suggest that systemic endocrine or metabolic dysregulation associated with infertility may contribute to the rising burden of OCSCC in women. Further mechanistic and clinical investigation is warranted to clarify underlying pathways and identify women at highest risk.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>History of infertility and oral cavity squamous cell carcinoma risk in post-menopausal women</span>. Hosam H Alkhatib, MD<sup>1</sup>; Kara L Cushing-Haugen, MS<sup>2</sup>; <u>Anna C Clements, MD</u><sup>1</sup>; Mateo Useche, MD, MPH<sup>1</sup>; Luis E Cortina, MD<sup>1</sup>; Rocco Ferrandino, MD, MSc<sup>1</sup>; Emily Marchiano, MD<sup>1</sup>; Zain H Rizvi, MD<sup>1</sup>; Lauren Shih, MD<sup>3</sup>; Cristina P Rodriguez, MD<sup>3</sup>; Neal Futran, MD, DMD<sup>1</sup>; Matthew O Old, MD<sup>1</sup>; Holly R Harris, ScD, MPH<sup>2</sup>; Brittany R Barber, MD, MSc<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; <sup>2</sup>Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA; <sup>3</sup>Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Incidence of oral cavity squamous cell carcinoma (OCSCC) is rising among women, particularly women who are non-smokers, yet the contribution of reproductive and hormonal factors remains unclear. Reproductive factors such as parity, breastfeeding, infertility, and oral contraceptive use have been linked to risk of other digestive tract malignancies, but data for OCSCC are sparse. We evaluated whether reproductive history, with a focus on infertility, is associated with OCSCC risk in postmenopausal women.</p>\n\n<p><strong>Methods</strong>: We utilized the Women’s Health Initiative (WHI) prospective cohort (n = 160,947) of postmenopausal women who were enrolled between 1993 and 1998 in the United States and followed for up to 30 years. Reproductive exposures were ascertained by baseline questionnaire and included parity, age at first and last birth, breastfeeding history and duration, and history of infertility, defined as trying to become pregnant for more than 12 months without conceiving. Oral contraceptive use (ever-use and duration), age at menarche, and age at menopause were also recorded. Incident OCSCC cases were identified during follow-up through initial self-report and subsequently adjudicated by medical record review. Multivariable Cox proportional hazards models adjusting for age, smoking status, and alcohol intake were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).</p>\n\n<p><strong>Results</strong>: Over the course of follow-up, 235 women were diagnosed with OCSCC. Approximately 16.3% of participants reported a history of infertility. Participants reporting infertility had a 40% higher risk of OCSCC compared with those without a history of infertility (HR 1.40, 95% CI 1.02–1.92). Results were similar in a sensitivity analysis restricted to parous women with no history of infertility as the reference group (HR 1.43, 95% CI 1.04–1.97), as well as in a separate analysis additionally adjusting for body mass index and menstrual cycle irregularity (as a proxy for polycystic ovary syndrome) (HR 1.43, 95% CI 1.04–1.97). History of oral contraceptive use, breastfeeding history, breastfeeding duration, parity, and number of live births were not significantly associated with OCSCC risk. </p>\n\n<p><strong>Conclusions</strong>: In this large prospective cohort of postmenopausal women, a history of infertility was associated with elevated OCSCC risk independent of age, tobacco use, and alcohol intake. These findings suggest that systemic endocrine or metabolic dysregulation associated with infertility may contribute to the rising burden of OCSCC in women. Further mechanistic and clinical investigation is warranted to clarify underlying pathways and identify women at highest risk.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153257--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S263",
      "content_id": "153965",
      "abstract_number": "S263",
      "poster_number": "",
      "title": "Primary Surgery vs Definitive Radiation for High-Operative Risk Locally Advanced Oral Cavity Squamous Cell Carcinoma: An NCDB Analysis",
      "summary": "In a large, contemporary NCDB cohort of high-operative risk, nonmetastatic stage III-IVB OCSCC, primary operative strategies were the dominant curative approach and were associated with substantially better 2- and 5-year overall survival compared with definitive radiation at ≥60 Gy, even after restricting to older, comorbid patients. Within the limitations of this retrospective database study, these findings...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153965",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sohil Singh, BS",
      "presenter": "Sohil Singh, BS",
      "authors": "Sohil Singh, BS ; Deniz C Demircioglu, BS; Johnny R Belcher, BA; Musaddiq Awan, MD",
      "normalized_authors": [
        "Sohil Singh",
        "Deniz C Demircioglu",
        "Johnny R Belcher",
        "Musaddiq Awan"
      ],
      "affiliations": [
        "Medical College of Wisconsin"
      ],
      "normalized_institutions": [
        "Medical College of Wisconsin"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 474,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sohil Singh, BS ; Deniz C Demircioglu, BS; Johnny R Belcher, BA; Musaddiq Awan, MD",
        "Affiliations": "Medical College of Wisconsin",
        "Background": "Many patients with stage III-IV oral cavity squamous cell carcinoma (OCSCC) are at high-operative risk due to age and comorbidity, yet real-world treatment patterns and outcomes in this group are poorly described. We used the National Cancer Database (NCDB) to characterize contemporary management of high-operative risk, non-metastatic, locally advanced OCSCC to compare survival between primary surgical and non-operative treatment strategies.",
        "Methods": "We queried the 2023 NCDB Participant User File for adults diagnosed 2015-2020 with oral cavity squamous cell carcinoma (ICD-O-3 histology 8070-8078; sites C00.0-C00.9, C02.0-C02.3/C02.8-C02.9, C03.0-C03.1, C04.0-C04.9, C05.0, C06.0-C06.9). Nonmetastatic disease was defined using an AJCC 7/8-aware algorithm integrating M category and stage group. We derived unified clinical T and N across editions and restricted to stage III-IVB disease with an identified primary site. Age ≥70 years with Charlson-Deyo ≥1 or age <70 years with Charlson-Deyo ≥2 were used as surrogates for high-operative risk. We excluded patients without key staging, comorbidity, or primary site data. For survival, we compared (1) primary surgery ± radiation and/or systemic therapy versus (2) definitive external-beam radiotherapy ≥60 Gy ± systemic therapy. Primary treatment approach was determined by date of first treatment. Overall survival (OS) up to 60 months was estimated using the Kaplan-Meier method and groups were compared with the log-rank test. To minimize effects of any informative censoring, patients without documented follow-up after January 1, 2023, were counted as deaths with the exception that they had observed follow-up for over 5 years.",
        "Results": "Among 874,886 head and neck cases, 6,961 OCSCC cases met our inclusion criteria and were deemed high-operative risk. The OS analytic cohort included 5,289 patients with usable treatment and survival data: 4,590 (86.8%) underwent surgery ± radiation/systemic therapy, and 699 (13.2%) received definitive RT ≥60 Gy ± systemic therapy. Median age was 73 vs 76 years, respectively. Median Charlson-Deyo score was 2 in both groups. At 24 months, OS was 55.0% (95% CI 53.5-56.5) for surgery ± RT/systemic therapy versus 32.8% (29.4-36.7) for RT ≥60 Gy ± systemic therapy. At 60 months, OS was 19.0% (17.8-20.2) and 9.5% (7.2-12.5), in the primary surgical and non-surgical groups, respectively. Survival differences favored surgery across the follow-up period (log-rank p<0.001).",
        "Conclusions": "In a large, contemporary NCDB cohort of high-operative risk, nonmetastatic stage III-IVB OCSCC, primary operative strategies were the dominant curative approach and were associated with substantially better 2- and 5-year overall survival compared with definitive radiation at ≥60 Gy, even after restricting to older, comorbid patients. Within the limitations of this retrospective database study, these findings support primary surgery, when feasible, as the preferred curative modality for locally advanced OCSCC even for patients who may be at higher operative risk.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Primary Surgery vs Definitive Radiation for High-Operative Risk Locally Advanced Oral Cavity Squamous Cell Carcinoma: An NCDB Analysis</span>. <u>Sohil Singh, BS</u>; Deniz C Demircioglu, BS; Johnny R Belcher, BA; Musaddiq Awan, MD. Medical College of Wisconsin<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Many patients with stage III-IV oral cavity squamous cell carcinoma (OCSCC) are at high-operative risk due to age and comorbidity, yet real-world treatment patterns and outcomes in this group are poorly described. We used the National Cancer Database (NCDB) to characterize contemporary management of high-operative risk, non-metastatic, locally advanced OCSCC to compare survival between primary surgical and non-operative treatment strategies.</p>\n\n<p><strong>Methods: </strong>We queried the 2023 NCDB Participant User File for adults diagnosed 2015-2020 with oral cavity squamous cell carcinoma (ICD-O-3 histology 8070-8078; sites C00.0-C00.9, C02.0-C02.3/C02.8-C02.9, C03.0-C03.1, C04.0-C04.9, C05.0, C06.0-C06.9). Nonmetastatic disease was defined using an AJCC 7/8-aware algorithm integrating M category and stage group. We derived unified clinical T and N across editions and restricted to stage III-IVB disease with an identified primary site. Age ≥70 years with Charlson-Deyo ≥1 or age <70 years with Charlson-Deyo ≥2 were used as surrogates for high-operative risk. We excluded patients without key staging, comorbidity, or primary site data. For survival, we compared (1) primary surgery ± radiation and/or systemic therapy versus (2) definitive external-beam radiotherapy ≥60 Gy ± systemic therapy. Primary treatment approach was determined by date of first treatment. Overall survival (OS) up to 60 months was estimated using the Kaplan-Meier method and groups were compared with the log-rank test. To minimize effects of any informative censoring, patients without documented follow-up after January 1, 2023, were counted as deaths with the exception that they had observed follow-up for over 5 years.</p>\n\n<p><strong>Results: </strong>Among 874,886 head and neck cases, 6,961 OCSCC cases met our inclusion criteria and were deemed high-operative risk. The OS analytic cohort included 5,289 patients with usable treatment and survival data: 4,590 (86.8%) underwent surgery ± radiation/systemic therapy, and 699 (13.2%) received definitive RT ≥60 Gy ± systemic therapy. Median age was 73 vs 76 years, respectively. Median Charlson-Deyo score was 2 in both groups. At 24 months, OS was 55.0% (95% CI 53.5-56.5) for surgery ± RT/systemic therapy versus 32.8% (29.4-36.7) for RT ≥60 Gy ± systemic therapy. At 60 months, OS was 19.0% (17.8-20.2) and 9.5% (7.2-12.5), in the primary surgical and non-surgical groups, respectively. Survival differences favored surgery across the follow-up period (log-rank p<0.001).</p>\n\n<p><strong>Conclusions: </strong>In a large, contemporary NCDB cohort of high-operative risk, nonmetastatic stage III-IVB OCSCC, primary operative strategies were the dominant curative approach and were associated with substantially better 2- and 5-year overall survival compared with definitive radiation at ≥60 Gy, even after restricting to older, comorbid patients. Within the limitations of this retrospective database study, these findings support primary surgery, when feasible, as the preferred curative modality for locally advanced OCSCC even for patients who may be at higher operative risk.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153965--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S264",
      "content_id": "154061",
      "abstract_number": "S264",
      "poster_number": "",
      "title": "Preoperative ctDNA as a Predictor of Depth of Invasion and Surgical Stratification in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Analysis of Preoperative ctDNA levels demonstrated a significant association with tumor DOI in OCSCC. Multivariable analysis suggests that ctDNA and DOI together meaningfully predict nodal involvement that DOI alone does not capture. These findings suggest that preoperative ctDNA measurement may serve as a minimally invasive biomarker for identifying high-risk patients and guiding surgical planning, potentially...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154061",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kirollos E Armosh, BS",
      "presenter": "Kirollos E Armosh, BS",
      "authors": "Kirollos E Armosh, BS ; Edgar D Sanchez, BA; Kevin Liu, MD; Jerome N Nashed, BA; Dustin Conrad, MD; Peter Dziegielewski, MD; Austin S Lam, MD",
      "normalized_authors": [
        "Kirollos E Armosh",
        "Edgar D Sanchez",
        "Kevin Liu",
        "Jerome N Nashed",
        "Dustin Conrad",
        "Peter Dziegielewski",
        "Austin S Lam"
      ],
      "affiliations": [
        "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA"
      ],
      "normalized_institutions": [
        "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 529,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Objective",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kirollos E Armosh, BS ; Edgar D Sanchez, BA; Kevin Liu, MD; Jerome N Nashed, BA; Dustin Conrad, MD; Peter Dziegielewski, MD; Austin S Lam, MD",
        "Affiliations": "University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA",
        "Introduction": "Tumor depth of invasion (DOI) is a powerful predictor of patient prognosis and is routinely used to guide surgical and adjuvant treatment decisions. However, since DOI is typically established on postoperative histopathologic analysis, its utility for preoperative risk stratification and surgical planning remains inherently limited.",
        "Abstract": "Liquid biopsy circulating tumor DNA (ctDNA), a component of cell-free DNA shed by tumor cells into the bloodstream, has recently emerged as a minimally invasive tool with potential applications in cancer prognostication. Recent studies in other cancer types have demonstrated a significant association between ctDNA levels and DOI. To date, however, no study has explored this relationship in OCSCC. ctDNA levels were compared across two groups (DOI <4 mm vs ≥4 mm). Mann–Whitney U test demonstrated significantly greater ctDNA levels in tumors ≥4 mm (U = 124, p = 0.038). Median ctDNA was 0.05 MTM/ml (IQR 0.00–0.40) for DOI <4 mm and 0.69 MTM/ml (IQR 0.13–3.07) for DOI ≥4 mm. Undetectable ctDNA (≤0 MTM/ml) was strongly associated with DOI <4 mm (OR 10.4, p = 0.0099). A threshold of ≤0.1 MTM/ml also remained significant (OR 5.12, p = 0.041), whereas ≤0.5 MTM/ml did not (p = 0.138). A multivariable linear regression model to evaluate whether pre-operative ctDNA was independently associated with DOI was statistically significant (R² 0.49, adjusted R² 0.43, p = 1.2 × 10?6), with an estimated increase of 0.35 mm in DOI for every 1 MTM/ml increase in ctDNA (95% CI 0.20-0.49, p =1.0 × 10?5). In a multivariable logistic regression for nodal status, the combined model for ctDNA level and histologic DOI was statistically significant (overall p = 0.026), but neither predictor was statistically significant when adjusted for the other (ctDNA p = 0.091, DOI p = 0.074). View in Agenda and Add to Schedule",
        "Objective": "This study aims to explore the use of preoperative ctDNA as a predictive biomarker for tumor DOI in patients with OCSCC.",
        "Methods": "Retrospective chart review included patients with oral cavity squamous cell carcinoma with pre-operative ctDNA levels assessed using the commercially available Signetara assay (Natera, Inc). Patients’ electronic medical records were reviewed for quantitative ctDNA results, and postoperative histopathologic data, such as tumor subsite, histologic tumor type, nodal metastasis, DOI, LVI, and PNI.",
        "Results": "Amongst the 65 patients identified (mean age 67.1 ± 10.6 years, 63.1% male), both Pearson and Spearman correlation analyses demonstrated a moderate positive association between pre-operative ctDNA and DOI (Pearson r = 0.52, Spearman ρ = 0.48, both p < 0.0001). For every 1 mm increase in DOI, ctDNA increased by 0.71 MTM/ml (95% CI 0.42–1.01, p < 0.001).",
        "Conclusion": "Analysis of Preoperative ctDNA levels demonstrated a significant association with tumor DOI in OCSCC. Multivariable analysis suggests that ctDNA and DOI together meaningfully predict nodal involvement that DOI alone does not capture. These findings suggest that preoperative ctDNA measurement may serve as a minimally invasive biomarker for identifying high-risk patients and guiding surgical planning, potentially improving oncologic outcomes. Further prospective studies are warranted to validate the clinical utility of ctDNA in preoperative risk stratification."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative ctDNA as a Predictor of Depth of Invasion and Surgical Stratification in Oral Cavity Squamous Cell Carcinoma</span>. <u>Kirollos E Armosh, BS</u>; Edgar D Sanchez, BA; Kevin Liu, MD; Jerome N Nashed, BA; Dustin Conrad, MD; Peter Dziegielewski, MD; Austin S Lam, MD. University of Florida College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Gainesville, FL, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Tumor depth of invasion (DOI) is a powerful predictor of patient prognosis and is routinely used to guide surgical and adjuvant treatment decisions. However, since DOI is typically established on postoperative histopathologic analysis, its utility for preoperative risk stratification and surgical planning remains inherently limited.</p>\n\n<p>Liquid biopsy circulating tumor DNA (ctDNA), a component of cell-free DNA shed by tumor cells into the bloodstream, has recently emerged as a minimally invasive tool with potential applications in cancer prognostication. Recent studies in other cancer types have demonstrated a significant association between ctDNA levels and DOI. To date, however, no study has explored this relationship in OCSCC.</p>\n\n<p><strong>Objective: </strong>This study aims to explore the use of preoperative ctDNA as a predictive biomarker for tumor DOI in patients with OCSCC.</p>\n\n<p><strong>Methods: </strong>Retrospective chart review included patients with oral cavity squamous cell carcinoma with pre-operative ctDNA levels assessed using the commercially available Signetara assay (Natera, Inc). Patients’ electronic medical records were reviewed for quantitative ctDNA results, and postoperative histopathologic data, such as tumor subsite, histologic tumor type, nodal metastasis, DOI, LVI, and PNI.</p>\n\n<p><strong>Results: </strong>Amongst the 65 patients identified (mean age 67.1 ± 10.6 years, 63.1% male), both Pearson and Spearman correlation analyses demonstrated a moderate positive association between pre-operative ctDNA and DOI (Pearson r = 0.52, Spearman ρ = 0.48, both p < 0.0001). For every 1 mm increase in DOI, ctDNA increased by 0.71 MTM/ml (95% CI 0.42–1.01, p < 0.001).</p>\n\n<p>ctDNA levels were compared across two groups (DOI <4 mm vs ≥4 mm). Mann–Whitney U test demonstrated significantly greater ctDNA levels in tumors ≥4 mm (U = 124, p = 0.038). Median ctDNA was 0.05 MTM/ml (IQR 0.00–0.40) for DOI <4 mm and 0.69 MTM/ml (IQR 0.13–3.07) for DOI ≥4 mm. Undetectable ctDNA (≤0 MTM/ml) was strongly associated with DOI <4 mm (OR 10.4, p = 0.0099). A threshold of ≤0.1 MTM/ml also remained significant (OR 5.12, p = 0.041), whereas ≤0.5 MTM/ml did not (p = 0.138).</p>\n\n<p>A multivariable linear regression model to evaluate whether pre-operative ctDNA was independently associated with DOI was statistically significant (R² 0.49, adjusted R² 0.43, p = 1.2 × 10?6), with an estimated increase of 0.35 mm in DOI for every 1 MTM/ml increase in ctDNA (95% CI 0.20-0.49, p =1.0 × 10?5). In a multivariable logistic regression for nodal status, the combined model for ctDNA level and histologic DOI was statistically significant (overall p = 0.026), but neither predictor was statistically significant when adjusted for the other (ctDNA p = 0.091, DOI p = 0.074).</p>\n\n<p><strong>Conclusion: </strong>Analysis of Preoperative ctDNA levels demonstrated a significant association with tumor DOI in OCSCC. Multivariable analysis suggests that ctDNA and DOI together meaningfully predict nodal involvement that DOI alone does not capture. These findings suggest that preoperative ctDNA measurement may serve as a minimally invasive biomarker for identifying high-risk patients and guiding surgical planning, potentially improving oncologic outcomes. Further prospective studies are warranted to validate the clinical utility of ctDNA in preoperative risk stratification.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154061--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S265",
      "content_id": "154605",
      "abstract_number": "S265",
      "poster_number": "",
      "title": "Regional Recurrence Defines a Biologically Aggressive Failure Pattern in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Regional recurrence in OCSCC represents a distinct, biologically aggressive failure pattern, occurring earlier and conferring substantially worse DFS than local failure, independent of depth, nodal status, and adjuvant therapy. Tumor depth provides additional continuous risk stratification and identifies patients particularly vulnerable to recurrence. This data supports intensified neck-focused surveillance,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154605",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Udeerna Tippabhatla, BS",
      "presenter": "Udeerna Tippabhatla, BS",
      "authors": "Udeerna Tippabhatla, BS 1 ; Jin Hua Li, BS 1 ; Rachel Harter, BS 1 ; Vivienne Au, MS 2 ; Emma Anisman, Bs 3 ; Aviram Mizrachi, MD 2",
      "normalized_authors": [
        "Udeerna Tippabhatla",
        "Jin Hua Li",
        "Rachel Harter",
        "Vivienne Au",
        "Emma Anisman",
        "Aviram Mizrachi"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA",
        "Sidney Kimmel Medical College, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA",
        "Sidney Kimmel Medical College, Philadelphia, PA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154605/Screenshot%202025-12-05%20155853.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154605/Screenshot%202025-12-05%20155853.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154605"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 454,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Udeerna Tippabhatla, BS 1 ; Jin Hua Li, BS 1 ; Rachel Harter, BS 1 ; Vivienne Au, MS 2 ; Emma Anisman, Bs 3 ; Aviram Mizrachi, MD 2",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; 2 Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA; 3 Sidney Kimmel Medical College, Philadelphia, PA",
        "Background": "Regional recurrence in OCSCC is associated with worse outcomes, but the prognostic distinction between local and regional recurrence remains poorly defined. This study tested whether the anatomical pattern of first failure independently predicts disease-free survival (DFS) and timing of recurrence, beyond traditional pathologic risk factors.",
        "Methods": "A retrospective cohort of 163 patients undergoing primary surgery for OCSCC at a single tertiary center was analyzed. Demographic and clinicopathologic variables included age, sex, tumor depth (mm), lymph node status, tumor subsite, adjuvant radiotherapy and/or chemotherapy, and first recurrence pattern (local vs regional). DFS was defined from surgery to first local or regional recurrence or last follow-up. Kaplan–Meier curves with log-rank testing compared time to recurrence by failure pattern, and Wilcoxon testing evaluated early-failure differences. Univariable and multivariable Cox proportional hazards models were constructed for DFS. A prespecified tongue-only sensitivity analysis assessed robustness within the dominant high-risk subsite.",
        "Results": "The cohort had a mean age of 64.3 years; 52.1% were male, 76.7% had tongue primaries, and 33.7% received adjuvant therapy. Recurrence occurred in 39 patients (23.9%), including 24 local (14.7%) and 14 regional (8.6%) events, with regional failures comprising 35.9% of all recurrences. On univariable Cox analysis, regional recurrence was associated with significantly worse DFS compared with local failure (HR 2.41, 95% CI 1.17–4.95, p=0.016), and lymph node positivity independently increased recurrence risk (HR 2.02, 95% CI 1.03–3.95, p=0.04), whereas tumor depth, age, and adjuvant therapy were not significant. Kaplan–Meier analysis demonstrated shorter time to recurrence in patients with regional versus local failure (log-rank p=0.0088), and Wilcoxon testing confirmed that regional recurrences occurred earlier (p=0.0057). In the full multivariable model, regional recurrence remained the strongest independent predictor of worse DFS (HR 5.64, 95% CI 1.68–18.99, p=0.005), and greater tumor depth independently increased recurrence risk (HR 1.09 per mm, 95% CI 1.01–1.19, p=0.033). A tongue-only sensitivity analysis yielded nearly identical effect sizes for regional failure (HR 5.48, p=0.018) and depth (HR 1.13 per mm, p=0.017), with no significant modification by nodal status or adjuvant therapy.",
        "Conclusion": "Regional recurrence in OCSCC represents a distinct, biologically aggressive failure pattern, occurring earlier and conferring substantially worse DFS than local failure, independent of depth, nodal status, and adjuvant therapy. Tumor depth provides additional continuous risk stratification and identifies patients particularly vulnerable to recurrence. This data supports intensified neck-focused surveillance, earlier use of cross-sectional imaging, and consideration of treatment escalation in patients at highest risk for regional failure, especially those with deep tongue primaries.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Regional Recurrence Defines a Biologically Aggressive Failure Pattern in Oral Cavity Squamous Cell Carcinoma</span>. <u>Udeerna Tippabhatla, BS</u><sup>1</sup>; Jin Hua Li, BS<sup>1</sup>; Rachel Harter, BS<sup>1</sup>; Vivienne Au, MS<sup>2</sup>; Emma Anisman, Bs<sup>3</sup>; Aviram Mizrachi, MD<sup>2</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA; <sup>3</sup>Sidney Kimmel Medical College, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Regional recurrence in OCSCC is associated with worse outcomes, but the prognostic distinction between local and regional recurrence remains poorly defined. This study tested whether the anatomical pattern of first failure independently predicts disease-free survival (DFS) and timing of recurrence, beyond traditional pathologic risk factors.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of 163 patients undergoing primary surgery for OCSCC at a single tertiary center was analyzed. Demographic and clinicopathologic variables included age, sex, tumor depth (mm), lymph node status, tumor subsite, adjuvant radiotherapy and/or chemotherapy, and first recurrence pattern (local vs regional). DFS was defined from surgery to first local or regional recurrence or last follow-up. Kaplan–Meier curves with log-rank testing compared time to recurrence by failure pattern, and Wilcoxon testing evaluated early-failure differences. Univariable and multivariable Cox proportional hazards models were constructed for DFS. A prespecified tongue-only sensitivity analysis assessed robustness within the dominant high-risk subsite.</p>\n\n<p><strong>Results: </strong>The cohort had a mean age of 64.3 years; 52.1% were male, 76.7% had tongue primaries, and 33.7% received adjuvant therapy. Recurrence occurred in 39 patients (23.9%), including 24 local (14.7%) and 14 regional (8.6%) events, with regional failures comprising 35.9% of all recurrences. On univariable Cox analysis, regional recurrence was associated with significantly worse DFS compared with local failure (HR 2.41, 95% CI 1.17–4.95, p=0.016), and lymph node positivity independently increased recurrence risk (HR 2.02, 95% CI 1.03–3.95, p=0.04), whereas tumor depth, age, and adjuvant therapy were not significant. Kaplan–Meier analysis demonstrated shorter time to recurrence in patients with regional versus local failure (log-rank p=0.0088), and Wilcoxon testing confirmed that regional recurrences occurred earlier (p=0.0057). In the full multivariable model, regional recurrence remained the strongest independent predictor of worse DFS (HR 5.64, 95% CI 1.68–18.99, p=0.005), and greater tumor depth independently increased recurrence risk (HR 1.09 per mm, 95% CI 1.01–1.19, p=0.033). A tongue-only sensitivity analysis yielded nearly identical effect sizes for regional failure (HR 5.48, p=0.018) and depth (HR 1.13 per mm, p=0.017), with no significant modification by nodal status or adjuvant therapy.</p>\n\n<p><strong>Conclusion: </strong>Regional recurrence in OCSCC represents a distinct, biologically aggressive failure pattern, occurring earlier and conferring substantially worse DFS than local failure, independent of depth, nodal status, and adjuvant therapy. Tumor depth provides additional continuous risk stratification and identifies patients particularly vulnerable to recurrence. This data supports intensified neck-focused surveillance, earlier use of cross-sectional imaging, and consideration of treatment escalation in patients at highest risk for regional failure, especially those with deep tongue primaries.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154605/Screenshot%202025-12-05%20155853.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154605--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S266",
      "content_id": "152114",
      "abstract_number": "S266",
      "poster_number": "",
      "title": "Multi-institutional insight into optimal oncologic margin distance in oral cavity squamous cell carcinoma treated with surgery alone",
      "summary": "Investigate the minimum margin distance that does not compromise oncologic outcomes in patients with early-stage OCSCC treated with surgery alone.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152114",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nathan Farrokhian",
      "presenter": "Nathan Farrokhian",
      "authors": "Nathan Farrokhian 1 ; Andrew Holcomb 2 ; Mark Varvares 3 ; Andres Bur 1 ; Omar Karadaghy 1",
      "normalized_authors": [
        "Nathan Farrokhian",
        "Andrew Holcomb",
        "Mark Varvares",
        "Andres Bur",
        "Omar Karadaghy"
      ],
      "affiliations": [
        "University of Kansas Medical Center - Department of Otolaryngology",
        "Nebraska Methodist Health System - Department of Otolaryngology",
        "Mass Eye and Ear - Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "University of Kansas Medical Center - Department of Otolaryngology",
        "Nebraska Methodist Health System - Department of Otolaryngology",
        "Mass Eye and Ear - Department of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 352,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting, and Participants",
        "Outcome(s) and Measure(s)",
        "Results[OK1]",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nathan Farrokhian 1 ; Andrew Holcomb 2 ; Mark Varvares 3 ; Andres Bur 1 ; Omar Karadaghy 1",
        "Affiliations": "1 University of Kansas Medical Center - Department of Otolaryngology; 2 Nebraska Methodist Health System - Department of Otolaryngology; 3 Mass Eye and Ear - Department of Otolaryngology",
        "Importance": "For patients with early-stage oral cavity squamous cell carcinoma (OCSCC), definitive surgical resection of the primary tumor remains the standard of care. While a clear surgical margin is one of the most important prognostic factors with this treatment modality, the optimal oncologic margin distance has yet to be adequately described.",
        "Objective": "Investigate the minimum margin distance that does not compromise oncologic outcomes in patients with early-stage OCSCC treated with surgery alone.",
        "Design, Setting, and Participants": "Data was collected retrospectively from four tertiary care academic medical centers. University of Kansas, University of Iowa, Nebraska Methodist Hospital, and Massachusetts Eye & Ear. Early-stage OCSCC patients that underwent definitive surgical extirpation with or without neck dissection were identified. Patients that received adjuvant therapy were excluded.",
        "Outcome(s) and Measure(s)": "Disease-free survival was assessed via both non-parametric Kaplan-Meier estimator and semi-parametric Cox proportional hazard models. Optimal margin distance was determined via average AUC ROC values of the survival functions across the cohort’s time horizon for the range of possible margin thresholds.",
        "Results[OK1]": "For the 350 patients included in this study, all were early stage (cT1-T2) and clinically node negative. Of these patients, 195 (55%) were male and the mean (SD) age was 63.76 (13.80). A nonparametric disease-free survival–based, time-averaged ROC-AUC optimization revealed 4mm as the optimal margin threshold. On univariate analysis, patients with negative margins less than 4mm had increased hazard of recurrence or death (1.41 HR; 95%CI, 1.02-1.93; p=0.036). Similarly, those with positive margins had a HR of 1.72 (95% CI, 1.14-2.59; p<0.01) for recurrence or death. These associations persisted on multivariate analysis controlling for PNI, LVI, nodal disease burden, and tumor dimension with a HR of 1.35 (95% CI, 1.02-1.80; p=0.038) for the <4mm group and a HR of 1.67 (95% CI, 1.03-2.71; p=0.039) for positive margins.",
        "Conclusions and Relevance": "The findings of this study provide evidence to an optimum of 4-mm margin distance in a surgery-only early-stage OCSCC cohort, suggesting that margins closer than the commonly cited 5-mm may be acceptable without detriment to outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Multi-institutional insight into optimal oncologic margin distance in oral cavity squamous cell carcinoma treated with surgery alone</span>. <u>Nathan Farrokhian</u><sup>1</sup>; Andrew Holcomb<sup>2</sup>; Mark Varvares<sup>3</sup>; Andres Bur<sup>1</sup>; Omar Karadaghy<sup>1</sup>. <sup>1</sup>University of Kansas Medical Center - Department of Otolaryngology; <sup>2</sup>Nebraska Methodist Health System - Department of Otolaryngology; <sup>3</sup>Mass Eye and Ear - Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> For patients with early-stage oral cavity squamous cell carcinoma (OCSCC), definitive surgical resection of the primary tumor remains the standard of care. While a clear surgical margin is one of the most important prognostic factors with this treatment modality, the optimal oncologic margin distance has yet to be adequately described.</p>\n\n<p><strong>Objective:</strong> Investigate the minimum margin distance that does not compromise oncologic outcomes in patients with early-stage OCSCC treated with surgery alone.</p>\n\n<p><strong>Design, Setting, and Participants:</strong> Data was collected retrospectively from four tertiary care academic medical centers. University of Kansas, University of Iowa, Nebraska Methodist Hospital, and Massachusetts Eye & Ear. Early-stage OCSCC patients that underwent definitive surgical extirpation with or without neck dissection were identified. Patients that received adjuvant therapy were excluded.</p>\n\n<p><strong>Outcome(s) and Measure(s): </strong>Disease-free survival was assessed via both non-parametric Kaplan-Meier estimator and semi-parametric Cox proportional hazard models. Optimal margin distance was determined via average AUC ROC values of the survival functions across the cohort’s time horizon for the range of possible margin thresholds.</p>\n\n<p><strong>Results[OK1]: </strong>For the 350 patients included in this study, all were early stage (cT1-T2) and clinically node negative. Of these patients, 195 (55%) were male and the mean (SD) age was 63.76 (13.80).  A nonparametric disease-free survival–based, time-averaged ROC-AUC optimization revealed 4mm as the optimal margin threshold. On univariate analysis, patients with negative margins less than 4mm had increased hazard of recurrence or death (1.41 HR; 95%CI, 1.02-1.93; p=0.036). Similarly, those with positive margins had a HR of 1.72 (95% CI, 1.14-2.59; p<0.01) for recurrence or death. These associations persisted on multivariate analysis controlling for PNI, LVI, nodal disease burden, and tumor dimension with a HR of 1.35 (95% CI, 1.02-1.80; p=0.038) for the <4mm group and a HR of 1.67 (95% CI, 1.03-2.71; p=0.039) for positive margins.</p>\n\n<p><strong>Conclusions and Relevance:</strong> The findings of this study provide evidence to an optimum of 4-mm margin distance in a surgery-only early-stage OCSCC cohort, suggesting that margins closer than the commonly cited 5-mm may be acceptable without detriment to outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152114--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S268",
      "content_id": "154561",
      "abstract_number": "S268",
      "poster_number": "",
      "title": "Trends in incidence-based mortality and 3-year cause-specific survival among patients with oral tongue squamous cell carcinoma",
      "summary": "Among patients with oral tongue cancer aged 50-59, incidence-based mortality declined for male patients from 2014 to 2022 but steadily increased for female patients from 2004 to 2022. Three-year cause-specific survival among patients aged 50-59 increased over time for both sexes, but at a larger magnitude for male patients. Despite gains in survival, this sex disparity in mortality likely reflects increasing...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154561",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Katie M Carlson, MPH",
      "presenter": "Katie M Carlson, MPH",
      "authors": "Katie M Carlson, MPH ; Nana-Hawwa Abdul-Rahman, MS; Maryanna S Owoc, MD, PhD; Marci Lee Nilsen, PhD, RN, CHPN; Kevin J Contrera, MD, MPH; Jose P Zevallos, MD, MPH; Angela L Mazul, PhD, MPH",
      "normalized_authors": [
        "Katie M Carlson",
        "Nana-Hawwa Abdul-Rahman",
        "Maryanna S Owoc",
        "Marci Lee Nilsen, CHPN",
        "Kevin J Contrera",
        "Jose P Zevallos",
        "Angela L Mazul"
      ],
      "affiliations": [
        "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154561/Ages%2050-59%20new.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154561/Ages%2050-59%20new.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154561"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 463,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1",
        "Abstract"
      ],
      "sections": {
        "Authors": "Katie M Carlson, MPH ; Nana-Hawwa Abdul-Rahman, MS; Maryanna S Owoc, MD, PhD; Marci Lee Nilsen, PhD, RN, CHPN; Kevin J Contrera, MD, MPH; Jose P Zevallos, MD, MPH; Angela L Mazul, PhD, MPH",
        "Affiliations": "University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery",
        "Background": "The incidence of oral tongue cancer in the United States has risen in the last couple decades, with notable increases among young, non-smoking, and female populations. However, trends in mortality and cause-specific survival are not reported. This study investigated mortality and survival trends by sex and age among patients with oral tongue cancer.",
        "Methods": "This population-based retrospective cohort study used data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Adult patients (>20 years old) diagnosed with oral tongue squamous cell carcinoma from 2000 to 2022 were selected. Sex (male or female) and ages at death and diagnosis (20-49, 50-59, 60-69, 70-79, and 80+ years) were classified for each patient. Our outcomes of interest were incidence-based mortality (IBM), which measures deaths directly related to incident cancer cases, and 3-year cause-specific survival (CSS). We used Joinpoint to assess trends in IBM and estimate annual percentage changes (APCs) and average annual percentage changes (AAPCs) from 2004-2022. The Kaplan-Meier method was used to calculate 3-year CSS stratified by sex and age at diagnosis.",
        "Results": "Among male patients aged 50-59, IBM increased from 2004-2014 (APC: 1.28, 95% confidence interval [CI]: 0.09, 9.70) but decreased significantly from 2014-2022 (APC: -1.84, 95% CI: -9.66, -0.28). However, among female patients in the same age group, IBM increased significantly across the entire study period (APC: 2.64, 95% CI: 0.55, 5.11). Three-year CSS for male patients aged 50-59 was 64.4% (95% CI: 59.3, 69.0) for those diagnosed from 2000-2001 and 74.6% (95% CI: 70.9, 77.9) for 2018-2019. For females aged 50-59, 3-year CSS was 73.3% (95% CI: 66.2, 79.1) for 2000-2001 and 77.8% (95% CI: 73.2, 81.6) for 2018-2019. Three-year CSS for patients diagnosed in 2018-2019 was higher for females in every age group except 80+, with a rate of 63.8% (95% CI: 55.5, 70.9) for males versus 56.6% (95% CI: 49.3, 63.2) for females.",
        "Conclusions": "Among patients with oral tongue cancer aged 50-59, incidence-based mortality declined for male patients from 2014 to 2022 but steadily increased for female patients from 2004 to 2022. Three-year cause-specific survival among patients aged 50-59 increased over time for both sexes, but at a larger magnitude for male patients. Despite gains in survival, this sex disparity in mortality likely reflects increasing incidence in younger, female individuals, but also underscores the need for research into factors driving incidence and interventions to reduce mortality among female patients.",
        "Figure 1": ". Trends in incidence-based mortality (IBM) by sex and year of death (2004-2022) among oral tongue cancer patients aged 50-59. The gray shading denotes a “burn-in” period to minimize bias from early incident cases without sufficient follow-up.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in incidence-based mortality and 3-year cause-specific survival among patients with oral tongue squamous cell carcinoma</span>. <u>Katie M Carlson, MPH</u>; Nana-Hawwa Abdul-Rahman, MS; Maryanna S Owoc, MD, PhD; Marci Lee Nilsen, PhD, RN, CHPN; Kevin J Contrera, MD, MPH; Jose P Zevallos, MD, MPH; Angela L Mazul, PhD, MPH. University of Pittsburgh School of Medicine Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The incidence of oral tongue cancer in the United States has risen in the last couple decades, with notable increases among young, non-smoking, and female populations. However, trends in mortality and cause-specific survival are not reported. This study investigated mortality and survival trends by sex and age among patients with oral tongue cancer.</p>\n\n<p><strong>Methods: </strong>This population-based retrospective cohort study used data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Adult patients (>20 years old) diagnosed with oral tongue squamous cell carcinoma from 2000 to 2022 were selected. Sex (male or female) and ages at death and diagnosis (20-49, 50-59, 60-69, 70-79, and 80+ years) were classified for each patient. Our outcomes of interest were incidence-based mortality (IBM), which measures deaths directly related to incident cancer cases, and 3-year cause-specific survival (CSS). We used Joinpoint to assess trends in IBM and estimate annual percentage changes (APCs) and average annual percentage changes (AAPCs) from 2004-2022. The Kaplan-Meier method was used to calculate 3-year CSS stratified by sex and age at diagnosis.</p>\n\n<p><strong>Results: </strong>Among male patients aged 50-59, IBM increased from 2004-2014 (APC: 1.28, 95% confidence interval [CI]: 0.09, 9.70) but decreased significantly from 2014-2022 (APC: -1.84, 95% CI: -9.66, -0.28). However, among female patients in the same age group, IBM increased significantly across the entire study period (APC: 2.64, 95% CI: 0.55, 5.11). Three-year CSS for male patients aged 50-59 was 64.4% (95% CI: 59.3, 69.0) for those diagnosed from 2000-2001 and 74.6% (95% CI: 70.9, 77.9) for 2018-2019. For females aged 50-59, 3-year CSS was 73.3% (95% CI: 66.2, 79.1) for 2000-2001 and 77.8% (95% CI: 73.2, 81.6) for 2018-2019. Three-year CSS for patients diagnosed in 2018-2019 was higher for females in every age group except 80+, with a rate of 63.8% (95% CI: 55.5, 70.9) for males versus 56.6% (95% CI: 49.3, 63.2) for females.</p>\n\n<p><strong>Conclusions: </strong>Among patients with oral tongue cancer aged 50-59, incidence-based mortality declined for male patients from 2014 to 2022 but steadily increased for female patients from 2004 to 2022. Three-year cause-specific survival among patients aged 50-59 increased over time for both sexes, but at a larger magnitude for male patients. Despite gains in survival, this sex disparity in mortality likely reflects increasing incidence in younger, female individuals, but also underscores the need for research into factors driving incidence and interventions to reduce mortality among female patients.</p>\n\n<p><strong>Figure 1</strong>. Trends in incidence-based mortality (IBM) by sex and year of death (2004-2022) among oral tongue cancer patients aged 50-59. The gray shading denotes a “burn-in” period to minimize bias from early incident cases without sufficient follow-up.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154561/Ages%2050-59%20new.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154561--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S269",
      "content_id": "153331",
      "abstract_number": "S269",
      "poster_number": "",
      "title": "Prognostic factors for overall survival in squamous cell carcinoma of the lip: pN+ and perineural invasion.",
      "summary": "Surgically treated lip SCC demonstrated a recurrence rate of 9% and five-year disease-free and overall survival rates of 89.5% and 75.5%, respectively. PNI and pN+ were the strongest independent predictors of worse outcome. These results reinforce the relevance of comprehensive pathological evaluation and individualized treatment approaches for optimizing oncologic outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153331",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriella San Juan",
      "presenter": "Gabriella San Juan",
      "authors": "Gabriella San Juan ; André Santos, MD, PhD",
      "normalized_authors": [
        "Gabriella San Juan",
        "André Santos"
      ],
      "affiliations": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "normalized_institutions": [
        "Faculdade de Medicina da Universidade de São Paulo"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 418,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriella San Juan ; André Santos, MD, PhD",
        "Affiliations": "Faculdade de Medicina da Universidade de São Paulo",
        "Introduction": "Lip cancer is predominantly diagnosed as squamous cell carcinoma (SCC) and constitutes an important subgroup of oral cavity malignancies. Due to its anatomical position at the interface between the skin, mucosa, and vermilion, SCC of the lip may display distinct pathological characteristics depending on the epithelial origin. The main risk factors include chronic sun exposure, immunosuppression, betel nut use, and hereditary syndromes, with alcohol and smoking specifically related to SCC of mucosal origin. Although early diagnosis and treatment commonly lead to favorable clinical outcomes, recurrence and metastasis may occur. Cervical lymph node involvement is considered one of the strongest prognostic indicators. Previous series have reported five-year survival for oral cavity SCC of approximately 50%, although survival appears to be more favorable when only lip SCC is evaluated. The purpose of this investigation was to determine five-year survival and identify clinicopathological variables associated with worse outcomes in patients undergoing surgical treatment for lip SCC.",
        "Methods": "A retrospective cross-sectional analysis was conducted including patients diagnosed with lip SCC and managed surgically between 2003 and 2020. Inclusion criteria were histologically confirmed lip SCC and surgical treatment. Exclusion criteria were non-SCC histologies. Variables analyzed included demographic data, tumor size, depth of invasion, histological differentiation, angiolymphatic invasion (ALI), perineural invasion (PNI), surgical margins, nodal status (pN+), recurrence, overall survival, disease-specific survival, and disease-free survival. Statistical analysis was performed using Student’s t-test or Mann-Whitney for quantitative variables, chi-square or Fisher’s exact test for categorical variables, and Kaplan-Meier analysis for univariate and multivariate survival evaluation.",
        "Results": "A total of 143 patients were included. Five-year overall survival was 75.5%, and disease-free survival was 89.5%. Locoregional recurrence occurred in 9% of cases. In univariate analysis, disease-free survival was significantly associated with poor differentiation, ALI, PNI, and pN+, although only pN+ remained statistically significant in multivariate analysis. For disease-specific survival, ALI, PNI, and pN+ were significant variables in univariate analysis, and ALI and pN+ remained significant in multivariate analysis. For overall survival, PNI, ALI, and pN+ showed significance in univariate analysis, while PNI, pN+, and depth of invasion were independent predictors in multivariate evaluation. Alcohol consumption, smoking, tumor margins, and histological differentiation were not associated with survival.",
        "Conclusion": "Surgically treated lip SCC demonstrated a recurrence rate of 9% and five-year disease-free and overall survival rates of 89.5% and 75.5%, respectively. PNI and pN+ were the strongest independent predictors of worse outcome. These results reinforce the relevance of comprehensive pathological evaluation and individualized treatment approaches for optimizing oncologic outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic factors for overall survival in squamous cell carcinoma of the lip: pN+ and perineural invasion.</span>. <u>Gabriella San Juan</u>; André Santos, MD, PhD. Faculdade de Medicina da Universidade de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Lip cancer is predominantly diagnosed as squamous cell carcinoma (SCC) and constitutes an important subgroup of oral cavity malignancies. Due to its anatomical position at the interface between the skin, mucosa, and vermilion, SCC of the lip may display distinct pathological characteristics depending on the epithelial origin. The main risk factors include chronic sun exposure, immunosuppression, betel nut use, and hereditary syndromes, with alcohol and smoking specifically related to SCC of mucosal origin. Although early diagnosis and treatment commonly lead to favorable clinical outcomes, recurrence and metastasis may occur. Cervical lymph node involvement is considered one of the strongest prognostic indicators. Previous series have reported five-year survival for oral cavity SCC of approximately 50%, although survival appears to be more favorable when only lip SCC is evaluated. The purpose of this investigation was to determine five-year survival and identify clinicopathological variables associated with worse outcomes in patients undergoing surgical treatment for lip SCC.</p>\n\n<p><strong>Methods:</strong> A retrospective cross-sectional analysis was conducted including patients diagnosed with lip SCC and managed surgically between 2003 and 2020. Inclusion criteria were histologically confirmed lip SCC and surgical treatment. Exclusion criteria were non-SCC histologies. Variables analyzed included demographic data, tumor size, depth of invasion, histological differentiation, angiolymphatic invasion (ALI), perineural invasion (PNI), surgical margins, nodal status (pN+), recurrence, overall survival, disease-specific survival, and disease-free survival. Statistical analysis was performed using Student’s t-test or Mann-Whitney for quantitative variables, chi-square or Fisher’s exact test for categorical variables, and Kaplan-Meier analysis for univariate and multivariate survival evaluation.</p>\n\n<p><strong>Results:</strong> A total of 143 patients were included. Five-year overall survival was 75.5%, and disease-free survival was 89.5%. Locoregional recurrence occurred in 9% of cases. In univariate analysis, disease-free survival was significantly associated with poor differentiation, ALI, PNI, and pN+, although only pN+ remained statistically significant in multivariate analysis. For disease-specific survival, ALI, PNI, and pN+ were significant variables in univariate analysis, and ALI and pN+ remained significant in multivariate analysis. For overall survival, PNI, ALI, and pN+ showed significance in univariate analysis, while PNI, pN+, and depth of invasion were independent predictors in multivariate evaluation. Alcohol consumption, smoking, tumor margins, and histological differentiation were not associated with survival.</p>\n\n<p><strong>Conclusion: </strong>Surgically treated lip SCC demonstrated a recurrence rate of 9% and five-year disease-free and overall survival rates of 89.5% and 75.5%, respectively. PNI and pN+ were the strongest independent predictors of worse outcome. These results reinforce the relevance of comprehensive pathological evaluation and individualized treatment approaches for optimizing oncologic outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153331--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S270",
      "content_id": "154585",
      "abstract_number": "S270",
      "poster_number": "",
      "title": "Preoperative Pain is Associated with Recurrence and Aggressive Pathologic Features in Oral Squamous Cell Carcinoma",
      "summary": "Forty-one patients were included with a median age of 62 years (IQR: 53, 73). The majority were white (92.7%) and male (63.4%). Most patients (85.4%) presented with a first primary OSCC, typically involving the tongue (43.9%). There was congruency between worse pain and QoL survey scores and higher narcotic use (OR:3.7, p<0.005). There was no association with any pain measurement with age, sex, or race. Larger...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154585",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taylor L Jamil, MD, MPH",
      "presenter": "Taylor L Jamil, MD, MPH",
      "authors": "Delaney Sheehan, MD 1 ; Taylor L Jamil, MD, MPH 2 ; Juhi J Patel, BS 1 ; Davide Botta, PhD 1 ; Gabriela S Fonseca, MD 1 ; Mabel Kahil, CST, MSc 1 ; Caitlyn B Tomblin, MD 1 ; Manuel Lora Gonzalez, MD 3 ; Kesava Asam, MS 4 ; Bradley Aouizerat, MAS, PHD 4 ; Kirk Withrow 1 ; Benjamin Greene, MD 1 ; Susan McCammon, MD, PhD 1 ; Yedeh Ying, MD, DMD 1 ; Anthony Morlandt, MD, DDS 1 ; Jason M Warram, PhD 1 ; Chi T Viet 5 ; Carissa M Thomas, MD, PhD, FACS 2",
      "normalized_authors": [
        "Delaney Sheehan",
        "Taylor L Jamil",
        "Juhi J Patel",
        "Davide Botta",
        "Gabriela S Fonseca",
        "Mabel Kahil, CST",
        "Caitlyn B Tomblin",
        "Manuel Lora Gonzalez",
        "Kesava Asam",
        "Bradley Aouizerat, MAS",
        "Kirk Withrow",
        "Benjamin Greene",
        "Susan McCammon",
        "Yedeh Ying",
        "Anthony Morlandt",
        "Jason M Warram",
        "Chi T Viet",
        "Carissa M Thomas"
      ],
      "affiliations": [
        "University of Alabama",
        "University of Colorado",
        "University of Miami",
        "New York University",
        "Loma Lina University Medical Center"
      ],
      "normalized_institutions": [
        "University of Alabama",
        "University of Colorado",
        "University of Miami",
        "New York University",
        "Loma Lina University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 529,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion/Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Delaney Sheehan, MD 1 ; Taylor L Jamil, MD, MPH 2 ; Juhi J Patel, BS 1 ; Davide Botta, PhD 1 ; Gabriela S Fonseca, MD 1 ; Mabel Kahil, CST, MSc 1 ; Caitlyn B Tomblin, MD 1 ; Manuel Lora Gonzalez, MD 3 ; Kesava Asam, MS 4 ; Bradley Aouizerat, MAS, PHD 4 ; Kirk Withrow 1 ; Benjamin Greene, MD 1 ; Susan McCammon, MD, PhD 1 ; Yedeh Ying, MD, DMD 1 ; Anthony Morlandt, MD, DDS 1 ; Jason M Warram, PhD 1 ; Chi T Viet 5 ; Carissa M Thomas, MD, PhD, FACS 2",
        "Affiliations": "1 University of Alabama; 2 University of Colorado; 3 University of Miami; 4 New York University; 5 Loma Lina University Medical Center",
        "Background": "Oral squamous cell carcinoma (OSCC) is a painful disease that significantly impairs a patient’s quality of life (QoL). Certain characteristics of OSCC, such as perineural invasion (PNI), have been linked to increased pain. However, studying pain in OSCC is challenging as causes are diverse, including cancer-related pain, co-morbidities, and side effects from treatments. This study aims to assess pain and QoL using validated head and neck survey tools, along with objective measures of narcotic use in morphine milligram equivalents (MME), to better understand how pain relates to OSCC disease progression and treatment approaches.",
        "Methods": "A prospective cohort study (2019-2024) was conducted with the collection of survey data prior to surgical treatment for OSCC and average MME pre- and postoperatively. Tumor characteristics, medical history, treatment, and 3-year disease recurrence were correlated with pre-treatment pain measurements (University of San Francisco Pain Index). Regression analyses in RStudio (Version 2024.04.2+764) were performed to identify predictors of high pain levels, using both high MME usage and elevated pain scores across three validated surveys (BPI, EORTC-H&N35, UCSF).",
        "Results": "Forty-one patients were included with a median age of 62 years (IQR: 53, 73). The majority were white (92.7%) and male (63.4%). Most patients (85.4%) presented with a first primary OSCC, typically involving the tongue (43.9%). There was congruency between worse pain and QoL survey scores and higher narcotic use (OR:3.7, p<0.005). There was no association with any pain measurement with age, sex, or race. Larger tumors with more severe nodal disease were associated with higher MME and lower QoL on surveys (Stage T3 BPI: OR: 3.26, p = 0.002; T4 BPI: OR: 2.20, p = 0.034; BPI N3a OR: 2.17, p= 0.036). Perineural invasion (PNI) (OR: 3.04, p= 0.004), lymphovascular invasion (LVI) (OR: 2.11, = 0.041), increased depth of invasion (DOI) (OR: 3.41, p= 0.001), current (OR: 2.39, p= 0.022) and former (OR:3.89, p<0.005) smoking, and prior history of a cerebrovascular accident (CVA, OR: 2.50, p= 0.017) were all associated with higher cancer-related pain. No plasma cytokine laboratory data were associated with higher pain measured by surveys or MME. Six patients suffered a recurrence, in which PNI (OR: 2.12, p= 0.043) and pre-operative pain medication usage (OR: 2.04, p= 0.0485) were associated. Seven patients died during the 3-year follow-up; however, death was not associated with higher treatment pain levels.",
        "Discussion/Conclusion": "OSCC is a painful disease limiting QoL. Higher stage disease with worse pathological features, such as PNI, LVI, and DOI, was associated with worse pre- treatment QoL pain survey scores as well as high narcotic use before and during treatment. High preoperative pain medication usage before treatment is significantly associated with recurrence in our study. Death was not associated with pain but may be limited due to study duration and size. Patients with more sensitive pain thresholds, such as those with a history of CVA, have higher cancer-pain levels. Altered pain processing or stroke-related somatosensory pathway damage may be the cause of higher cancer-related pain in these individuals.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Pain is Associated with Recurrence and Aggressive Pathologic Features in Oral Squamous Cell Carcinoma</span>. Delaney Sheehan, MD<sup>1</sup>; <u>Taylor L Jamil, MD, MPH</u><sup>2</sup>; Juhi J Patel, BS<sup>1</sup>; Davide Botta, PhD<sup>1</sup>; Gabriela S Fonseca, MD<sup>1</sup>; Mabel Kahil, CST, MSc<sup>1</sup>; Caitlyn B Tomblin, MD<sup>1</sup>; Manuel Lora Gonzalez, MD<sup>3</sup>; Kesava Asam, MS<sup>4</sup>; Bradley Aouizerat, MAS, PHD<sup>4</sup>; Kirk Withrow<sup>1</sup>; Benjamin Greene, MD<sup>1</sup>; Susan McCammon, MD, PhD<sup>1</sup>; Yedeh Ying, MD, DMD<sup>1</sup>; Anthony Morlandt, MD, DDS<sup>1</sup>; Jason M Warram, PhD<sup>1</sup>; Chi T Viet<sup>5</sup>; Carissa M Thomas, MD, PhD, FACS<sup>2</sup>. <sup>1</sup>University of Alabama; <sup>2</sup>University of Colorado; <sup>3</sup>University of Miami; <sup>4</sup>New York University; <sup>5</sup>Loma Lina University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Oral squamous cell carcinoma (OSCC) is a painful disease that significantly impairs a patient’s quality of life (QoL). Certain characteristics of OSCC, such as perineural invasion (PNI), have been linked to increased pain. However, studying pain in OSCC is challenging as causes are diverse, including cancer-related pain, co-morbidities, and side effects from treatments. This study aims to assess pain and QoL using validated head and neck survey tools, along with objective measures of narcotic use in morphine milligram equivalents (MME), to better understand how pain relates to OSCC disease progression and treatment approaches.</p>\n\n<p><strong>Methods</strong>: A prospective cohort study (2019-2024) was conducted with the collection of survey data prior to surgical treatment for OSCC and average MME pre- and postoperatively. Tumor characteristics, medical history, treatment, and 3-year disease recurrence were correlated with pre-treatment pain measurements (University of San Francisco Pain Index). Regression analyses in RStudio (Version 2024.04.2+764) were performed to identify predictors of high pain levels, using both high MME usage and elevated pain scores across three validated surveys (BPI, EORTC-H&N35, UCSF).</p>\n\n<p><strong>Results</strong>: Forty-one patients were included with a median age of 62 years (IQR: 53, 73). The majority were white (92.7%) and male (63.4%). Most patients (85.4%) presented with a first primary OSCC, typically involving the tongue (43.9%). There was congruency between worse pain and QoL survey scores and higher narcotic use (OR:3.7, p<0.005). There was no association with any pain measurement with age, sex, or race. Larger tumors with more severe nodal disease were associated with higher MME and lower QoL on surveys (Stage T3 BPI: OR: 3.26, p = 0.002; T4 BPI: OR: 2.20, p = 0.034; BPI N3a OR: 2.17, p= 0.036). Perineural invasion (PNI) (OR: 3.04, p= 0.004), lymphovascular invasion (LVI) (OR: 2.11, = 0.041), increased depth of invasion (DOI) (OR: 3.41, p= 0.001), current (OR: 2.39, p= 0.022) and former (OR:3.89, p<0.005) smoking, and prior history of a cerebrovascular accident (CVA, OR: 2.50, p= 0.017) were all associated with higher cancer-related pain. No plasma cytokine laboratory data were associated with higher pain measured by surveys or MME. Six patients suffered a recurrence, in which PNI (OR: 2.12, p= 0.043) and pre-operative pain medication usage (OR: 2.04, p= 0.0485) were associated. Seven patients died during the 3-year follow-up; however, death was not associated with higher treatment pain levels.</p>\n\n<p><strong>Discussion/Conclusion</strong>: OSCC is a painful disease limiting QoL. Higher stage disease with worse pathological features, such as PNI, LVI, and DOI, was associated with worse pre- treatment QoL pain survey scores as well as high narcotic use before and during treatment. High preoperative pain medication usage before treatment is significantly associated with recurrence in our study. Death was not associated with pain but may be limited due to study duration and size. Patients with more sensitive pain thresholds, such as those with a history of CVA, have higher cancer-pain levels. Altered pain processing or stroke-related somatosensory pathway damage may be the cause of higher cancer-related pain in these individuals.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154585--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S271",
      "content_id": "153757",
      "abstract_number": "S271",
      "poster_number": "",
      "title": "Intermediary Risk Factors Predict Survival in Patients with Operable HPV-Negative Head and Neck Cancer",
      "summary": "Severe treatment toxicity and intolerance are associated with a higher risk of mortality and tumor recurrence in patients with operable HPV-negative HNSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153757",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Luiza Tatar",
      "presenter": "Luiza Tatar",
      "authors": "Luiza Tatar 1 ; Alex M Mlynarek 2 ; Livia Florianova 3 ; Derin Caglar 4 ; Marc P Pusztaszeri 3 ; Keith Richardson 2 ; Nader Sadeghi 2 ; Khalil Sultanem 5 ; Christina Tsien 6 ; Vanessa Di Lalla 6 ; George Shenouda 6 ; Michael P Hier 2 ; Nathaniel Bouganim 7 ; Khashayar Esfahani 7 ; Marco A Mascarella 2",
      "normalized_authors": [
        "Luiza Tatar",
        "Alex M Mlynarek",
        "Livia Florianova",
        "Derin Caglar",
        "Marc P Pusztaszeri",
        "Keith Richardson",
        "Nader Sadeghi",
        "Khalil Sultanem",
        "Christina Tsien",
        "Vanessa Di Lalla",
        "George Shenouda",
        "Michael P Hier",
        "Nathaniel Bouganim",
        "Khashayar Esfahani",
        "Marco A Mascarella"
      ],
      "affiliations": [
        "McGill University, Faculty of Medicine, Montreal, QC, Canada",
        "Department of Otolaryngology, McGill University, Montreal, QC, Canada",
        "Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
        "Department of Pathology, McGill University, Montreal, QC, Canada",
        "Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
        "Department of Radiation Oncology, McGill University, Montreal, QC, Canada",
        "Department of Oncology, McGill University, Montreal, QC, Canada"
      ],
      "normalized_institutions": [
        "McGill University, Faculty of Medicine, Montreal, QC, Canada",
        "Department of Otolaryngology, McGill University, Montreal, QC, Canada",
        "Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
        "Department of Pathology, McGill University, Montreal, QC, Canada",
        "Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC, Canada",
        "Department of Radiation Oncology, McGill University, Montreal, QC, Canada",
        "Department of Oncology, McGill University, Montreal, QC, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153757/Dec%205th_OS_DFS(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153757/Dec%205th_OS_DFS(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153757"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 533,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Luiza Tatar 1 ; Alex M Mlynarek 2 ; Livia Florianova 3 ; Derin Caglar 4 ; Marc P Pusztaszeri 3 ; Keith Richardson 2 ; Nader Sadeghi 2 ; Khalil Sultanem 5 ; Christina Tsien 6 ; Vanessa Di Lalla 6 ; George Shenouda 6 ; Michael P Hier 2 ; Nathaniel Bouganim 7 ; Khashayar Esfahani 7 ; Marco A Mascarella 2",
        "Affiliations": "1 McGill University, Faculty of Medicine, Montreal, QC, Canada; 2 Department of Otolaryngology, McGill University, Montreal, QC, Canada; 3 Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada; 4 Department of Pathology, McGill University, Montreal, QC, Canada; 5 Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC, Canada; 6 Department of Radiation Oncology, McGill University, Montreal, QC, Canada; 7 Department of Oncology, McGill University, Montreal, QC, Canada",
        "Background": "In 2025, the Canadian Cancer Society estimated that 8,100 individuals would be diagnosed with head and neck cancer (HNC) and 2,200 would die from it. For the same year, the American Cancer Society projected 59,660 new HNC cases and 12,770 deaths in the United States. 90% of HNCs are squamous cell carcinomas (SCC). Intermediary risk factors, including treatment toxicity and intolerance, are unknown at diagnosis and during treatment planning. In patients with operable HPV-negative head and neck squamous cell carcinoma (HNSCC), the association of intermediary risk factors with survival is limited. Exploring this relationship may guide postoperative management and improve survival. This study examined the effect of treatment toxicity and intolerance on overall (OS) and disease-free survival (DFS) in patients with HPV-negative HNSCC.",
        "Methods": "An ambispective cohort study of adult patients (18 years or older) with stage I-IVA HPV-negative HNSCC undergoing curative intent surgery was performed. Data from January 2015 to December 2024 were retrieved from two university teaching hospitals. We excluded patients with metastases, unresectable tumors at diagnosis, incomplete clinical or radiologic data, or those treated with palliative intent. Severe toxicity was measured as a grade 3 or more adverse event using the Common Toxicity Criteria for Adverse Events version 5. Treatment intolerance was defined as any non-completion of recommended multimodal therapy for any reason. OS was defined as the time in months from the date of surgery to the last follow-up or death. DFS was any tumor recurrence (local, regional or metastatic) following the initiation of therapy. Multivariable Cox regression analyses were performed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for OS and DFS. Models were adjusted for age, 8th Edition of the American Joint Committee on Cancer TNM stage, adverse pathological factors (perineural invasion, extranodal extension, positive surgical margin status) and Charlson Comorbidity Index.",
        "Results": "A total of 343 patients with stage I-IVA HPV-negative HNSCC undergoing surgery were included in the analysis. The most common primary tumor site was the oral cavity (64%). Most patients (73%) were male, 62% were past or current smokers (mean pack-years=20), 29% consumed more than two alcoholic drinks daily, and 22% had a history of radiation therapy. 161 (47%) patients had a treatment intolerance following multimodal therapy, including 151 severe toxicities and 48 patients not completing adjuvant therapy. Treatment intolerance was associated with poor OS (HR=3.26, 95% CI: 2.19;4.85) and DFS (HR=2.60, 95% 1.82;3.71) in univariate analysis. Adverse pathological factors following surgical ablation were associated with poor OS (HR=5.79, 95%, 95% CI: 1.82;16.1) and DFS (HR=4.20, 95% CI: 1.94;9.11). Treatment intolerance remained an independent predictor of poor OS (HR=2.75, 95% CI: 1.78;4.25) and DFS (HR=2.34, 95% CI: 1.58;3.47) while adjusting for multiple confounding factors ( Figure 1 ).",
        "Conclusion": "Severe treatment toxicity and intolerance are associated with a higher risk of mortality and tumor recurrence in patients with operable HPV-negative HNSCC.",
        "Figure 1.": "Overall and disease-free survival stratified by treatment intolerance in patients with operable HPV-negative HNSCC",
        "Abstract": "Adjusted risk model for OS and DFS by treatment intolerance. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intermediary Risk Factors Predict Survival in Patients with Operable HPV-Negative Head and Neck Cancer</span>. <u>Luiza Tatar</u><sup>1</sup>; Alex M Mlynarek<sup>2</sup>; Livia Florianova<sup>3</sup>; Derin Caglar<sup>4</sup>; Marc P Pusztaszeri<sup>3</sup>; Keith Richardson<sup>2</sup>; Nader Sadeghi<sup>2</sup>; Khalil Sultanem<sup>5</sup>; Christina Tsien<sup>6</sup>; Vanessa Di Lalla<sup>6</sup>; George Shenouda<sup>6</sup>; Michael P Hier<sup>2</sup>; Nathaniel Bouganim<sup>7</sup>; Khashayar Esfahani<sup>7</sup>; Marco A Mascarella<sup>2</sup>. <sup>1</sup>McGill University, Faculty of Medicine, Montreal, QC, Canada; <sup>2</sup>Department of Otolaryngology, McGill University, Montreal, QC, Canada; <sup>3</sup>Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada; <sup>4</sup>Department of Pathology, McGill University, Montreal, QC, Canada; <sup>5</sup>Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC, Canada; <sup>6</sup>Department of Radiation Oncology, McGill University, Montreal, QC, Canada; <sup>7</sup>Department of Oncology, McGill University, Montreal, QC, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In 2025, the Canadian Cancer Society estimated that 8,100 individuals would be diagnosed with head and neck cancer (HNC) and 2,200 would die from it. For the same year, the American Cancer Society projected 59,660 new HNC cases and 12,770 deaths in the United States. 90% of HNCs are squamous cell carcinomas (SCC). Intermediary risk factors, including treatment toxicity and intolerance, are unknown at diagnosis and during treatment planning. In patients with operable HPV-negative head and neck squamous cell carcinoma (HNSCC), the association of intermediary risk factors with survival is limited. Exploring this relationship may guide postoperative management and improve survival. This study examined the effect of treatment toxicity and intolerance on overall (OS) and disease-free survival (DFS) in patients with HPV-negative HNSCC.</p>\n\n<p><strong>Methods: </strong>An ambispective cohort study of adult patients (18 years or older) with stage I-IVA HPV-negative HNSCC undergoing curative intent surgery was performed. Data from January 2015 to December 2024 were retrieved from two university teaching hospitals. We excluded patients with metastases, unresectable tumors at diagnosis, incomplete clinical or radiologic data, or those treated with palliative intent. Severe toxicity was measured as a grade 3 or more adverse event using the Common Toxicity Criteria for Adverse Events version 5. Treatment intolerance was defined as any non-completion of recommended multimodal therapy for any reason. OS was defined as the time in months from the date of surgery to the last follow-up or death. DFS was any tumor recurrence (local, regional or metastatic) following the initiation of therapy. Multivariable Cox regression analyses were performed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for OS and DFS. Models were adjusted for age, 8th Edition of the American Joint Committee on Cancer TNM stage, adverse pathological factors (perineural invasion, extranodal extension, positive surgical margin status) and Charlson Comorbidity Index.</p>\n\n<p><strong>Results: </strong>A total of 343 patients with stage I-IVA HPV-negative HNSCC undergoing surgery were included in the analysis. The most common primary tumor site was the oral cavity (64%). Most patients (73%) were male, 62% were past or current smokers (mean pack-years=20), 29% consumed more than two alcoholic drinks daily, and 22% had a history of radiation therapy. 161 (47%) patients had a treatment intolerance following multimodal therapy, including 151 severe toxicities and 48 patients not completing adjuvant therapy. Treatment intolerance was associated with poor OS (HR=3.26, 95% CI: 2.19;4.85) and DFS (HR=2.60, 95% 1.82;3.71) in univariate analysis. Adverse pathological factors following surgical ablation were associated with poor OS (HR=5.79, 95%, 95% CI: 1.82;16.1) and DFS (HR=4.20, 95% CI: 1.94;9.11). Treatment intolerance remained an independent predictor of poor OS (HR=2.75, 95% CI: 1.78;4.25) and DFS (HR=2.34, 95% CI: 1.58;3.47) while adjusting for multiple confounding factors (<em>Figure 1</em>).</p>\n\n<p><strong>Conclusion: </strong>Severe treatment toxicity and intolerance are associated with a higher risk of mortality and tumor recurrence in patients with operable HPV-negative HNSCC.</p>\n\n<p><strong>Figure 1. </strong>Overall and disease-free survival stratified by treatment intolerance in patients with operable HPV-negative HNSCC</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153757/Dec%205th_OS_DFS(1).png' /></p>\n\n<p><em>Adjusted risk model for OS and DFS by treatment intolerance.</em></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153757--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S272",
      "content_id": "153238",
      "abstract_number": "S272",
      "poster_number": "",
      "title": "It’s in the Air: Systematic Review and Meta-analysis of Ambient Fine Particulate Matter (PM2.5) and Risk of Oral Cavity, Oropharyngeal, and Hypopharyngeal Cancers.",
      "summary": "In this meta-analysis of three observational studies, higher long-term PM 2.5 exposure through outdoor air pollution was associated with a dose-related increased risk of cancers of the oral cavity, oropharynx, and hypopharynx independent of age and smoking. These findings support a potential role for air quality improvement strategies in head and neck cancer prevention and suggest that regional PM 2.5 levels may...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153238",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260135",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna C Clements, MD",
      "presenter": "Anna C Clements, MD",
      "authors": "Hosam H Alkhatib, MD 1 ; Mateo Useche, MD, MPH 1 ; Anna C Clements, MD 1 ; Luis E Cortina, MD 1 ; Teresa Jewell, MLIS, AHIP 2 ; Rocco M Ferrandino, MD, MSc 1 ; Emily M Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 4 ; Brittany R Barber, MD 1",
      "normalized_authors": [
        "Hosam H Alkhatib",
        "Mateo Useche",
        "Anna C Clements",
        "Luis E Cortina",
        "Teresa Jewell, MLIS, AHIP",
        "Rocco M Ferrandino",
        "Emily M Marchiano",
        "Zain H Rizvi",
        "Lauren Shih",
        "Cristina P Rodriguez",
        "Neal D Futran",
        "Matthew O Old",
        "Holly R Harris, ScD",
        "Brittany R Barber"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Health Science Library, University of Washington, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Health Science Library, University of Washington, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153238/screenshot%202025-11-25%20at%209_27_09%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153238/screenshot%202025-11-25%20at%209_27_09%E2%80%AFpm.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153238"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 442,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hosam H Alkhatib, MD 1 ; Mateo Useche, MD, MPH 1 ; Anna C Clements, MD 1 ; Luis E Cortina, MD 1 ; Teresa Jewell, MLIS, AHIP 2 ; Rocco M Ferrandino, MD, MSc 1 ; Emily M Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 4 ; Brittany R Barber, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; 2 Health Science Library, University of Washington, Seattle, Washington, USA; 3 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA; 4 Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Background": "Ambient fine particulate matter (PM 2.5 ) from outdoor air pollution is classified as a Group 1 carcinogen by the International Agency for Research on Cancer, particularly due to its strong association with lung cancer risk. Whether chronic PM 2.5 exposure increases risk of oral cavity and pharyngeal cancers, however, is not well-established nor has been quantitatively meta-analyzed.",
        "Objective": "To quantify the association between chronic PM 2.5 exposure from outdoor air pollution and risk of cancers of the oral cavity, oropharynx, and hypopharynx.",
        "Methods": "We systematically searched PubMed and the Cochrane Library for observational studies published up to October 1, 2025 evaluating chronic PM 2.5 exposure levels from outdoor air pollution and incidence of oral cavity, oropharyngeal, and hypopharyngeal cancers. Eligible studies included both smoking and non-smoking participants and reported sufficient data for meta-analysis. Data extraction followed PRISMA guidelines. We extracted incidence rate ratios or odds ratios with 95% confidence intervals and expressed associations as relative risks (RR) per 5 μg/m³ increase in chronic PM 2.5 exposure. One study (Chu et al., 2019) reported odds ratios by PM 2.5 quartile, and thus we reconstructed a linear dose-response using inverse variance-weighted regression of log-odds ratios on quartile midpoints. All included studies adjusted at minimum for age and smoking history, and two of the studies additionally adjusted for race, education, and household income in multivariable models. Random-effects inverse-variance meta-analysis was performed. Between-study effect size variance and heterogeneity were quantified with tau-squared (τ 2 ) and I 2 , and Cochran's Q.",
        "Results": "Three studies conducted in the United States (n = 2) and Taiwan (n = 1), comprising 1,937 incident oral cavity, oropharyngeal, and hypopharyngeal cancer cases, met inclusion criteria. There was no detectable between-study heterogeneity (τ 2 = 0, I 2 = 0%, Cochran’s Q: Q(2) = 0.38, P = .83). Study-specific RRs for oral cavity, oropharyngeal, and hypopharyngeal cancer incidence per 5 μg/m³ increase in PM 2.5 were directionally consistent, yielding an overall summary RR of 1.17 (95% CI 1.10-1.24) per 5 μg/m³ increase in PM 2.5 .",
        "Conclusions": "In this meta-analysis of three observational studies, higher long-term PM 2.5 exposure through outdoor air pollution was associated with a dose-related increased risk of cancers of the oral cavity, oropharynx, and hypopharynx independent of age and smoking. These findings support a potential role for air quality improvement strategies in head and neck cancer prevention and suggest that regional PM 2.5 levels may help identify populations at increased risk of oral cavity, oropharyngeal, and hypopharyngeal cancers. Further large-scale studies are warranted to refine risk estimates, particularly in early-onset and non-smoking cases.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>It’s in the Air: Systematic Review and Meta-analysis of Ambient Fine Particulate Matter (PM2.5) and Risk of Oral Cavity, Oropharyngeal, and Hypopharyngeal Cancers.</span>. Hosam H Alkhatib, MD<sup>1</sup>; Mateo Useche, MD, MPH<sup>1</sup>; <u>Anna C Clements, MD</u><sup>1</sup>; Luis E Cortina, MD<sup>1</sup>; Teresa Jewell, MLIS, AHIP<sup>2</sup>; Rocco M Ferrandino, MD, MSc<sup>1</sup>; Emily M Marchiano, MD<sup>1</sup>; Zain H Rizvi, MD<sup>1</sup>; Lauren Shih, MD<sup>3</sup>; Cristina P Rodriguez, MD<sup>3</sup>; Neal D Futran, MD, DMD<sup>1</sup>; Matthew O Old, MD<sup>1</sup>; Holly R Harris, ScD, MPH<sup>4</sup>; Brittany R Barber, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; <sup>2</sup>Health Science Library, University of Washington, Seattle, Washington, USA; <sup>3</sup>Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA; <sup>4</sup>Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Ambient fine particulate matter (PM<sub>2.5</sub>) from outdoor air pollution is classified as a Group 1 carcinogen by the International Agency for Research on Cancer, particularly due to its strong association with lung cancer risk. Whether chronic PM<sub>2.5</sub> exposure increases risk of oral cavity and pharyngeal cancers, however, is not well-established nor has been quantitatively meta-analyzed.</p>\n\n<p><strong>Objective: </strong>To quantify the association between chronic PM<sub>2.5</sub> exposure from outdoor air pollution and risk of cancers of the oral cavity, oropharynx, and hypopharynx.</p>\n\n<p><strong>Methods</strong>: We systematically searched PubMed and the Cochrane Library for observational studies published up to October 1, 2025 evaluating chronic PM<sub>2.5</sub> exposure levels from outdoor air pollution and incidence of oral cavity, oropharyngeal, and hypopharyngeal cancers. Eligible studies included both smoking and non-smoking participants and reported sufficient data for meta-analysis. Data extraction followed PRISMA guidelines. We extracted incidence rate ratios or odds ratios with 95% confidence intervals and expressed associations as relative risks (RR) per 5 μg/m³ increase in chronic PM<sub>2.5</sub> exposure. One study (Chu et al., 2019) reported odds ratios by PM<sub>2.5</sub> quartile, and thus we reconstructed a linear dose-response using inverse variance-weighted regression of log-odds ratios on quartile midpoints. All included studies adjusted at minimum for age and smoking history, and two of the studies additionally adjusted for race, education, and household income in multivariable models. Random-effects inverse-variance meta-analysis was performed. Between-study effect size variance and heterogeneity were quantified with tau-squared (τ<sup>2</sup>) and I<sup>2</sup>, and Cochran's Q.</p>\n\n<p><strong>Results</strong>: Three studies conducted in the United States (n = 2) and Taiwan (n = 1), comprising 1,937 incident oral cavity, oropharyngeal, and hypopharyngeal cancer cases, met inclusion criteria. There was no detectable between-study heterogeneity (τ<sup>2</sup> = 0, I<sup>2</sup> = 0%, Cochran’s Q: Q(2) = 0.38, <em>P</em> = .83). Study-specific RRs for oral cavity, oropharyngeal, and hypopharyngeal cancer incidence per 5 μg/m³ increase in PM<sub>2.5</sub> were directionally consistent, yielding an overall summary RR of 1.17 (95% CI 1.10-1.24) per 5 μg/m³ increase in PM<sub>2.5</sub>.</p>\n\n<p><strong>Conclusions</strong>: In this meta-analysis of three observational studies, higher long-term PM<sub>2.5</sub> exposure through outdoor air pollution was associated with a dose-related increased risk of cancers of the oral cavity, oropharynx, and hypopharynx independent of age and smoking. These findings support a potential role for air quality improvement strategies in head and neck cancer prevention and suggest that regional PM<sub>2.5</sub> levels may help identify populations at increased risk of oral cavity, oropharyngeal, and hypopharyngeal cancers. Further large-scale studies are warranted to refine risk estimates, particularly in early-onset and non-smoking cases. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153238/screenshot%202025-11-25%20at%209_27_09%E2%80%AFpm.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153238--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260135' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S273",
      "content_id": "152651",
      "abstract_number": "S273",
      "poster_number": "",
      "title": "A lipid nanoparticle carrying NLRC5 mRNA restores antigen presentation and reverses immunotherapy resistance in preclinical models of oral cancer",
      "summary": "NLRC5 LNP was able to stimulate APM expression in murine HNSCC cell lines that were otherwise incapable of responding to powerful immune stimulants like IFN-γ. This effect resulted in near-complete responses in vivo when paired with immunotherapy, further highlighting that tumor-cell antigen presentation is essential for efficacy of currently available immunotherapies. NLRC5 LNP shows strong translational...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152651",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brendan L Kinney",
      "presenter": "Brendan L Kinney",
      "authors": "Brendan L Kinney 1 ; Ching Shen Chan 2 ; Brianna Brammer 1 ; Gabriel A Kwong 2 ; Nicole C Schmitt 1",
      "normalized_authors": [
        "Brendan L Kinney",
        "Ching Shen Chan",
        "Brianna Brammer",
        "Gabriel A Kwong",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Emory University",
        "Georgia Institute of Technology"
      ],
      "normalized_institutions": [
        "Emory University",
        "Georgia Institute of Technology"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Brendan L Kinney 1 ; Ching Shen Chan 2 ; Brianna Brammer 1 ; Gabriel A Kwong 2 ; Nicole C Schmitt 1",
        "Affiliations": "1 Emory University; 2 Georgia Institute of Technology",
        "Introduction": "Tumor cells with low expression of the transcription factor STAT1 have been repeatedly shown to lack the ability to upregulate antigen processing machinery (APM) needed to present antigens to T cells, including MHC I and β-2 microglobulin. As a result, these tumor cells are “invisible” to T cells and unable to trigger robust adaptive immune responses. This is a common finding in head and neck cancer, with as many as 70-80% of tumors showing APM deficiencies. Our lab has previously shown that restoring NLRC5, a transcription factor downstream of STAT1, is able to partially restore the ability of tumor cells to upregulate their APM components. To translate this finding to a potential treatment for patients unable to respond to current forms of immunotherapy, we formulated a lipid nanoparticle (LNP) containing NLRC5 mRNA.",
        "Methods": "We created murine HNSCC cell lines (MOC1, MOC22) lacking STAT1 by CRISPR-Cas9. In our in vitro experiments, cells were treated with 0.5µg/mL NLRC5 LNP, 0.5µg/mL firefly luciferase (fLuc) LNP, or interferon-γ (IFN-γ, 1 ng/mL, positive control) for 72 hours and analyzed for MHC class I (H-2Kb), β-2 microglobulin, STAT1, and PD-L1 by flow cytometry. In our in vivo experiments, tumor-bearing mice were treated with intratumoral injections of fLuc or NLRC5 LNP at a dose of 0.5 mg/kg +/- anti-PD-1 immunotherapy. Tumor kinetics and survival were monitored.",
        "Results": "The in vitro experiments showed consistent upregulation of MHC I, β-2 microglobulin, and PD-L1 in murine cell lines at 72 hours in cells treated with the NLRC5 LNP. Conversely the fLuc LNP did not stimulate upregulation of these same APM markers in the wild type or STAT1 -/- cells. The expression of MHC I achieved with the NLRC5 LNP in MOC1 STAT1-/- cells was equal to MHC I expression after stimulation of parental cells with IFN-γ. In vivo experiments showed that NLRC5 LNP and anti-PD-1 alone were able to slow progression of STAT1-/- MOC1 tumors versus control animals (fLuc injection without NLRC5), while combination therapy showed synergistic anti-tumor activity. When tumors were analyzed by flow cytometry after one week of treatment with NLRC5 or fLuc LNP (control), we observed a lower percentage of EpCAM+ tumor cells and a higher percentage of antigen-specific (p15E tetramer-positive) T cells in tumors treated with NLRC5 LNP compared to those treated with fLuc LNP.",
        "Conclusions": "NLRC5 LNP was able to stimulate APM expression in murine HNSCC cell lines that were otherwise incapable of responding to powerful immune stimulants like IFN-γ. This effect resulted in near-complete responses in vivo when paired with immunotherapy, further highlighting that tumor-cell antigen presentation is essential for efficacy of currently available immunotherapies. NLRC5 LNP shows strong translational potential as an inducer of immune responses in APM-deficient head and neck cancers.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A lipid nanoparticle carrying NLRC5 mRNA restores antigen presentation and reverses immunotherapy resistance in preclinical models of oral cancer</span>. <u>Brendan L Kinney</u><sup>1</sup>; Ching Shen Chan<sup>2</sup>; Brianna Brammer<sup>1</sup>; Gabriel A Kwong<sup>2</sup>; Nicole C Schmitt<sup>1</sup>. <sup>1</sup>Emory University; <sup>2</sup>Georgia Institute of Technology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Tumor cells with low expression of the transcription factor STAT1 have been repeatedly shown to lack the ability to upregulate antigen processing machinery (APM) needed to present antigens to T cells, including MHC I and  β-2 microglobulin. As a result,  these tumor cells are “invisible” to T cells and unable to trigger robust adaptive immune responses. This is a common finding in head and neck cancer, with as many as 70-80% of tumors showing APM deficiencies. Our lab has previously shown that restoring NLRC5, a transcription factor downstream of STAT1, is able to partially restore the ability of tumor cells to upregulate their APM components. To translate this finding to a potential treatment for patients unable to respond to current forms of immunotherapy, we formulated a lipid nanoparticle (LNP) containing NLRC5 mRNA.</p>\n\n<p><strong>Methods: </strong>We created murine HNSCC cell lines (MOC1, MOC22) lacking STAT1 by CRISPR-Cas9. In our in vitro experiments, cells were treated with 0.5µg/mL NLRC5 LNP, 0.5µg/mL firefly luciferase (fLuc) LNP, or interferon-γ (IFN-γ, 1 ng/mL, positive control) for 72 hours and analyzed for MHC class I (H-2Kb), β-2 microglobulin, STAT1, and PD-L1 by flow cytometry. In our in vivo experiments, tumor-bearing mice were treated with intratumoral injections of fLuc or NLRC5 LNP at a dose of 0.5 mg/kg +/- anti-PD-1 immunotherapy. Tumor kinetics and survival were monitored.</p>\n\n<p><strong>Results: </strong>The in vitro experiments showed consistent upregulation of MHC I, β-2 microglobulin, and PD-L1 in murine cell lines at 72 hours in cells treated with the NLRC5 LNP. Conversely the fLuc LNP did not stimulate upregulation of these same APM markers in the wild type or STAT1 -/- cells. The expression of MHC I achieved with the NLRC5 LNP in MOC1 STAT1-/- cells was equal to MHC I expression after stimulation of parental cells with IFN-γ. In vivo experiments showed that NLRC5 LNP and anti-PD-1 alone were able to slow progression of STAT1-/- MOC1 tumors versus control animals (fLuc injection without NLRC5), while combination therapy showed synergistic anti-tumor activity. When tumors were analyzed by flow cytometry after one week of treatment with NLRC5 or fLuc LNP (control), we observed a lower percentage of EpCAM+ tumor cells and a higher percentage of antigen-specific (p15E tetramer-positive) T cells in tumors treated with NLRC5 LNP compared to those treated with fLuc LNP.</p>\n\n<p><strong>Conclusions: </strong>NLRC5 LNP was able to stimulate APM expression in murine HNSCC cell lines that were otherwise incapable of responding to powerful immune stimulants like IFN-γ. This effect resulted in near-complete responses in vivo when paired with immunotherapy, further highlighting that tumor-cell antigen presentation is essential for efficacy of currently available immunotherapies. NLRC5 LNP shows strong translational potential as an inducer of immune responses in APM-deficient head and neck cancers.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152651--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S274",
      "content_id": "153883",
      "abstract_number": "S274",
      "poster_number": "",
      "title": "Head and neck squamous cell carcinomas treated with neoadjuvant chemoimmunotherapy harbor activated/stress response T cells identified through single-cell sequencing",
      "summary": "In this study, we present interim scRNAseq and TCRseq analyses of HNSCC tumors after receipt of neoadjuvant chemoimmunotherapy (NAIC) versus immunotherapy alone (NAI). NAIC is associated with an increase in activated/stress response CD8 T cells that show clonal T cell receptor expansion in major pathologic response. These results suggest NAIC may reprogram previously exhausted T cells into more innate-like cells...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153883",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Kraft, MD",
      "presenter": "Daniel Kraft, MD",
      "authors": "Daniel Kraft, MD ; Ryan Sicard, BA; Haocheng Yu, MS; Amir Horowitz, PhD; Scott Roof, MD",
      "normalized_authors": [
        "Daniel Kraft",
        "Ryan Sicard",
        "Haocheng Yu",
        "Amir Horowitz",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel Kraft, MD ; Ryan Sicard, BA; Haocheng Yu, MS; Amir Horowitz, PhD; Scott Roof, MD",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Background": "Neoadjuvant immunotherapy is becoming standard-of-care across a number of cancers. Patients with head and neck squamous cell carcinoma (HNSCC) generally have poor long term survival and functional outcomes. A recently published landmark study demonstrated improved survival among patients with HNSCC who receive anti-PD-1 therapy prior to surgery. Despite this, major and complete pathologic responses for neoadjuvant immunotherapy (NAI) in HNSCC are rare. Preliminary data suggests that addition of chemotherapy to anti-PD-1 therapy (NAIC) may improve pathologic outcomes. The cells, receptors, and mechanisms underlying pathologic response to NAIC are not well characterized. This study aimed to identify putative immune cell subsets that drive response to NAIC using single cell RNA sequencing (scRNAseq) of patient tumors after neoadjuvant treatment.",
        "Methods": "This is a prospective study of patients with HNSCC undergoing neoadjuvant therapy at a large, urban, academic medical center. Patients received two doses of pembrolizumab + docetaxel and cisplatin (NAIC) prior to surgery. Only patients who underwent surgery as definitive treatment were included. Fresh tumor tissue was collected at time of surgery after neoadjuvant therapy as a part of routine clinical care. Tumors were placed immediately into MACS buffer on wet ice after resection; specimens were dissociated and submitted for 10x GEX 5’ v3 with T cell receptor sequencing (TCRseq) within 3 hours of resection. scRNAseq results were compared to publicly available scRNAseq data for untreated (UTD) and NAI-treated HNSCC using the NIH’s Gene Expression Omnibus. Seurat and R were used for clustering analyses.",
        "Results": "Fifty scRNAseq samples were included in the analysis including 13 NAIC (26%), 10 NAI (20%), and 26 UTD (54%). This represented a total of 292,182 cells. There were no significant differences among treatment groups in relative abundance of major effector cell types (i.e., CD8 T cells, NK cells). To further characterize functional subsets of CD8 T cells, unsupervised clustering was performed on all CD8+ cells. Six major clusters with a total of 32,075 CD8+ T cells were identified; proportions of these clusters were then compared between treatment groups. Compared to NAI, NAIC samples were enriched for activated/stress response (p = 0.004) and naïve (p = 0.004) CD8s and showed a corresponding decrease in exhausted (p = 0.002) CD8s. When comparing among patients who received NAIC, patients with either a partial or major pathologic response (MPR) had lower proportion of exhausted CD8s (p = 0.04). Patients treated with NAIC who experienced a MPR showed clonal expansion of activated/stress response cells by TCRseq.",
        "Conclusion": "In this study, we present interim scRNAseq and TCRseq analyses of HNSCC tumors after receipt of neoadjuvant chemoimmunotherapy (NAIC) versus immunotherapy alone (NAI). NAIC is associated with an increase in activated/stress response CD8 T cells that show clonal T cell receptor expansion in major pathologic response. These results suggest NAIC may reprogram previously exhausted T cells into more innate-like cells with cytotoxic potential. A larger sample size, matched pre and post neoadjuvant samples, and functional in-vitro studies are needed to further characterize this subset and its role in pathologic response among patients receiving NAIC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Head and neck squamous cell carcinomas treated with neoadjuvant chemoimmunotherapy harbor activated/stress response T cells identified through single-cell sequencing</span>. <u>Daniel Kraft, MD</u>; Ryan Sicard, BA; Haocheng Yu, MS; Amir Horowitz, PhD; Scott Roof, MD. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Neoadjuvant immunotherapy is becoming standard-of-care across a number of cancers. Patients with head and neck squamous cell carcinoma (HNSCC) generally have poor long term survival and functional outcomes. A recently published landmark study demonstrated improved survival among patients with HNSCC who receive anti-PD-1 therapy prior to surgery. Despite this, major and complete pathologic responses for neoadjuvant immunotherapy (NAI) in HNSCC are rare. Preliminary data suggests that addition of chemotherapy to anti-PD-1 therapy (NAIC) may improve pathologic outcomes. The cells, receptors, and mechanisms underlying pathologic response to NAIC are not well characterized. This study aimed to identify putative immune cell subsets that drive response to NAIC using single cell RNA sequencing (scRNAseq) of patient tumors after neoadjuvant treatment.</p>\n\n<p><strong>Methods: </strong>This is a prospective study of patients with HNSCC undergoing neoadjuvant therapy at a large, urban, academic medical center. Patients received two doses of pembrolizumab + docetaxel and cisplatin (NAIC) prior to surgery. Only patients who underwent surgery as definitive treatment were included. Fresh tumor tissue was collected at time of surgery after neoadjuvant therapy as a part of routine clinical care. Tumors were placed immediately into MACS buffer on wet ice after resection; specimens were dissociated and submitted for 10x GEX 5’ v3 with T cell receptor sequencing (TCRseq) within 3 hours of resection. scRNAseq results were compared to publicly available scRNAseq data for untreated (UTD) and NAI-treated HNSCC using the NIH’s Gene Expression Omnibus. Seurat and R were used for clustering analyses.</p>\n\n<p><strong>Results: </strong>Fifty scRNAseq samples were included in the analysis including 13 NAIC (26%), 10 NAI (20%), and 26 UTD (54%). This represented a total of 292,182 cells. There were no significant differences among treatment groups in relative abundance of major effector cell types (i.e., CD8 T cells, NK cells). To further characterize functional subsets of CD8 T cells, unsupervised clustering was performed on all CD8+ cells. Six major clusters with a total of 32,075 CD8+ T cells were identified; proportions of these clusters were then compared between treatment groups. Compared to NAI, NAIC samples were enriched for activated/stress response (p = 0.004) and naïve (p = 0.004) CD8s and showed a corresponding decrease in exhausted (p = 0.002) CD8s. When comparing among patients who received NAIC, patients with either a partial or major pathologic response (MPR) had lower proportion of exhausted CD8s (p = 0.04). Patients treated with NAIC who experienced a MPR showed clonal expansion of activated/stress response cells by TCRseq.</p>\n\n<p><strong>Conclusion: </strong>In this study, we present interim scRNAseq and TCRseq analyses of HNSCC tumors after receipt of neoadjuvant chemoimmunotherapy (NAIC) versus immunotherapy alone (NAI). NAIC is associated with an increase in activated/stress response CD8 T cells that show clonal T cell receptor expansion in major pathologic response. These results suggest NAIC may reprogram previously exhausted T cells into more innate-like cells with cytotoxic potential.  A larger sample size, matched pre and post neoadjuvant samples, and functional in-vitro studies are needed to further characterize this subset and its role in pathologic response among patients receiving NAIC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153883--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S275",
      "content_id": "154358",
      "abstract_number": "S275",
      "poster_number": "",
      "title": "Peripheral contraction of putative tumor-specific T cell clonotypes is associated with response to neoadjuvant anti-PD-1 in head and neck cancer",
      "summary": "Peripheral contraction of putative tumor-specific, exhausted T cell clonotypes may be a distinguishing feature of pathologic response to neoadjuvant anti-PD-1. These findings likely reflect tumor clearance and subsequent loss of antigen, contrasting with the persistence of exhausted clones in nonresponders. As neoadjuvant anti-PD-1 ICB is increasingly incorporated into the standard of care for locally advanced...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154358",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jack Y Ghannam, BS",
      "presenter": "Jack Y Ghannam, BS",
      "authors": "Jack Y Ghannam, BS 1 ; Maryann Zhao, MD 2 ; Edward S Sim, MD 2 ; Ann Marie Egloff, PhD 3 ; Ravindra Uppaluri, MD, PhD 4",
      "normalized_authors": [
        "Jack Y Ghannam",
        "Maryann Zhao",
        "Edward S Sim",
        "Ann Marie Egloff",
        "Ravindra Uppaluri"
      ],
      "affiliations": [
        "Harvard Medical School, Boston, Massachusetts",
        "Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts",
        "Department of Surgery, Mass General Brigham, Boston, Massachusetts"
      ],
      "normalized_institutions": [
        "Harvard Medical School, Boston, Massachusetts",
        "Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts",
        "Department of Surgery, Mass General Brigham, Boston, Massachusetts"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154358/AHNS_2026_HNSCC_TCR_Submitted_12052025.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154358/AHNS_2026_HNSCC_TCR_Submitted_12052025.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154358"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jack Y Ghannam, BS 1 ; Maryann Zhao, MD 2 ; Edward S Sim, MD 2 ; Ann Marie Egloff, PhD 3 ; Ravindra Uppaluri, MD, PhD 4",
        "Affiliations": "1 Harvard Medical School, Boston, Massachusetts; 2 Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 3 Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Surgery, Mass General Brigham, Boston, Massachusetts; 4 Harvard Medical School, Boston, Massachusetts; Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts",
        "Introduction": "Neoadjuvant anti-PD-1 immune checkpoint blockade (ICB) induces pathologic tumor responses (pTR) in approximately 45% of patients with HPV-unrelated head and neck squamous cell carcinoma (HNSCC). Single-cell transcriptomic analyses previously demonstrated that responding tumors harbor enriched populations of pre-existing, exhausted, tissue-resident CD8+ T cells with cytotoxic potential. However, the representation and fate of these putative tumor-specific T cell clonotypes in the systemic circulation, and whether their dynamics correlate with treatment response, remain poorly defined. We hypothesized that the peripheral dynamics of putative tumor-specific T cell clonotypes may reflect the success of antitumor immunity and antigen clearance in response to ICB.",
        "Methods": "We performed integrated analysis of tumor single-cell RNA and TCR sequencing with matched longitudinal bulk TCR-β sequencing of peripheral blood from 7 patients (pathologic responders, n=3, defined as ≥10% pTR; pathologic nonresponders, n=4, pTR <10%) with HNSCC treated with neoadjuvant pembrolizumab in a phase 2 clinical trial (NCT02296684). Peripheral blood was collected before initiation of ICB (pre-ICB) and at the time of surgical resection (post-ICB). Molecular matching ( TRBV , TRBJ , and CDR3 sequence) identified shared clonotypes between tumor and blood compartments. Clones were classified by baseline tumor phenotype—exhausted/tumor-specific (T Ex ) versus non-exhausted memory/bystander (T NExM )—based on intratumoral single-cell transcriptomic signatures, and by peripheral blood fate based on log 2 fold-change (log 2 FC; contracted: <-1; expanded: >1). Unpaired two-sided t-tests were used for between-group comparisons, paired t-tests for within-patient longitudinal analyses, and linear mixed effects models with patient as a random effect to test whether clonal dynamics and phenotypes differed by response status.",
        "Results": "A total of 1,795 unique clonotypes were matched between tumor and blood ( Figure 1 ). In responders, T Ex clones demonstrated marked peripheral contraction (mean log 2 FC = -2.03), while in nonresponders, T Ex clones expanded (mean log 2 FC = +2.24; phenotype-by-response interaction P =1.3x10 -5 ). Correspondingly, the peripheral T Ex /T NExM ratio decreased significantly in responders ( P =0.023) but not in nonresponders ( P =0.37). Comparing contracted versus expanded clones, baseline tumor specificity module scores were significantly higher in contracted clones among responders ( P =0.0007) but lower among contracted clones in nonresponders ( P =0.02; interaction P =3.3x10 -5 ). Contracted clones in responders also demonstrated lower viral specificity ( P =1.1x10 -5 ), higher cytotoxicity ( P =0.0007), and lower stemness ( P =8.3x10 -5 ) compared to expanded clones (all P <0.05), consistent with the selective clearance of terminally differentiated, tumor-reactive T cells following successful antigen elimination.",
        "Conclusion": "Peripheral contraction of putative tumor-specific, exhausted T cell clonotypes may be a distinguishing feature of pathologic response to neoadjuvant anti-PD-1. These findings likely reflect tumor clearance and subsequent loss of antigen, contrasting with the persistence of exhausted clones in nonresponders. As neoadjuvant anti-PD-1 ICB is increasingly incorporated into the standard of care for locally advanced HNSCC following KEYNOTE-689, determining the utility of distinct clonal trajectories of circulating T cells as a potential non-invasive biomarker of response to neoadjuvant immunotherapy warrants further investigation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Peripheral contraction of putative tumor-specific T cell clonotypes is associated with response to neoadjuvant anti-PD-1 in head and neck cancer</span>. <u>Jack Y Ghannam, BS</u><sup>1</sup>; Maryann Zhao, MD<sup>2</sup>; Edward S Sim, MD<sup>2</sup>; Ann Marie Egloff, PhD<sup>3</sup>; Ravindra Uppaluri, MD, PhD<sup>4</sup>. <sup>1</sup>Harvard Medical School, Boston, Massachusetts; <sup>2</sup>Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; <sup>3</sup>Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Surgery, Mass General Brigham, Boston, Massachusetts; <sup>4</sup>Harvard Medical School, Boston, Massachusetts; Department of Otolaryngology–Head and Neck Surgery, Mass General Brigham, Boston, Massachusetts; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Neoadjuvant anti-PD-1 immune checkpoint blockade (ICB) induces pathologic tumor responses (pTR) in approximately 45% of patients with HPV-unrelated head and neck squamous cell carcinoma (HNSCC). Single-cell transcriptomic analyses previously demonstrated that responding tumors harbor enriched populations of pre-existing, exhausted, tissue-resident CD8+ T cells with cytotoxic potential. However, the representation and fate of these putative tumor-specific T cell clonotypes in the systemic circulation, and whether their dynamics correlate with treatment response, remain poorly defined. We hypothesized that the peripheral dynamics of putative tumor-specific T cell clonotypes may reflect the success of antitumor immunity and antigen clearance in response to ICB.</p>\n\n<p><strong>Methods: </strong>We performed integrated analysis of tumor single-cell RNA and TCR sequencing with matched longitudinal bulk TCR-β sequencing of peripheral blood from 7 patients (pathologic responders, n=3, defined as ≥10% pTR; pathologic nonresponders, n=4, pTR <10%) with HNSCC treated with neoadjuvant pembrolizumab in a phase 2 clinical trial (NCT02296684). Peripheral blood was collected before initiation of ICB (pre-ICB) and at the time of surgical resection (post-ICB). Molecular matching (<em>TRBV</em>, <em>TRBJ</em>, and CDR3 sequence) identified shared clonotypes between tumor and blood compartments. Clones were classified by baseline tumor phenotype—exhausted/tumor-specific (T<sub>Ex</sub>) versus non-exhausted memory/bystander (T<sub>NExM</sub>)—based on intratumoral single-cell transcriptomic signatures, and by peripheral blood fate based on log<sub>2</sub> fold-change (log<sub>2</sub>FC; contracted: <-1; expanded: >1). Unpaired two-sided t-tests were used for between-group comparisons, paired t-tests for within-patient longitudinal analyses, and linear mixed effects models with patient as a random effect to test whether clonal dynamics and phenotypes differed by response status.</p>\n\n<p><strong>Results:</strong> A total of 1,795 unique clonotypes were matched between tumor and blood (<strong>Figure 1</strong>). In responders, T<sub>Ex</sub> clones demonstrated marked peripheral contraction (mean log<sub>2</sub>FC = -2.03), while in nonresponders, T<sub>Ex</sub> clones expanded (mean log<sub>2</sub>FC = +2.24; phenotype-by-response interaction <em>P</em>=1.3x10<sup>-5</sup>). Correspondingly, the peripheral T<sub>Ex</sub>/T<sub>NExM</sub> ratio decreased significantly in responders (<em>P</em>=0.023) but not in nonresponders (<em>P</em>=0.37). Comparing contracted versus expanded clones, baseline tumor specificity module scores were significantly higher in contracted clones among responders (<em>P</em>=0.0007) but lower among contracted clones in nonresponders (<em>P</em>=0.02; interaction <em>P</em>=3.3x10<sup>-5</sup>). Contracted clones in responders also demonstrated lower viral specificity (<em>P</em>=1.1x10<sup>-5</sup>), higher cytotoxicity (<em>P</em>=0.0007), and lower stemness (<em>P</em>=8.3x10<sup>-5</sup>) compared to expanded clones (all <em>P</em><0.05), consistent with the selective clearance of terminally differentiated, tumor-reactive T cells following successful antigen elimination.</p>\n\n<p><strong>Conclusion:</strong> Peripheral contraction of putative tumor-specific, exhausted T cell clonotypes may be a distinguishing feature of pathologic response to neoadjuvant anti-PD-1. These findings likely reflect tumor clearance and subsequent loss of antigen, contrasting with the persistence of exhausted clones in nonresponders. As neoadjuvant anti-PD-1 ICB is increasingly incorporated into the standard of care for locally advanced HNSCC following KEYNOTE-689, determining the utility of distinct clonal trajectories of circulating T cells as a potential non-invasive biomarker of response to neoadjuvant immunotherapy warrants further investigation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154358/AHNS_2026_HNSCC_TCR_Submitted_12052025.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154358--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S276",
      "content_id": "152235",
      "abstract_number": "S276",
      "poster_number": "",
      "title": "Oncostatin M (OSM) ligand-based CAR-T cells as a potential therapy for Head and Neck Squamous Cell Carcinoma",
      "summary": "We provide preliminary evidence using an in vitro cell culture system that OSM CAR-T cells may be an effective immunotherapy for HNSCC patients. Future work includes multiple mouse models to further assess efficacy and safety. This will include an orthotopic xenograft model in which luciferase-labeled tumor cells are implanted on the anterior tongue of NSG mice, and OSM CAR-T cells will be injected intravenously....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152235",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claire Fritz",
      "presenter": "Claire Fritz",
      "authors": "Claire Fritz 1 ; Quintin Pan, PhD 2 ; Theodoros Teknos, MD 2 ; Reshmi Parameswaran, PhD 3",
      "normalized_authors": [
        "Claire Fritz",
        "Quintin Pan",
        "Theodoros Teknos",
        "Reshmi Parameswaran"
      ],
      "affiliations": [
        "Department of Pathology, Case Western Reserve University",
        "University Hospitals Seidman Cancer Center",
        "Department of Otolaryngology, Case Western Reserve University School of Medicine",
        "Department of Medicine, Case Western Reserve University"
      ],
      "normalized_institutions": [
        "Department of Pathology, Case Western Reserve University",
        "University Hospitals Seidman Cancer Center",
        "Department of Otolaryngology, Case Western Reserve University School of Medicine",
        "Department of Medicine, Case Western Reserve University"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 487,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Claire Fritz 1 ; Quintin Pan, PhD 2 ; Theodoros Teknos, MD 2 ; Reshmi Parameswaran, PhD 3",
        "Affiliations": "1 Department of Pathology, Case Western Reserve University; 2 University Hospitals Seidman Cancer Center; Department of Otolaryngology, Case Western Reserve University School of Medicine; 3 Department of Medicine, Case Western Reserve University",
        "Background": "Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors arising from the oral cavity, pharynx, and larynx and accounts for about 90% of all head and neck cancers. The 5-year overall survival rate of 50-60% in this patient population necessitates novel therapeutic approaches to treat this cancer. Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the field of cancer therapy over the last two decades and is expanding to the solid tumor space. Our lab recently developed a third-generation Oncostatin M (OSM) ligand-based CAR-T cell product. OSM is an IL-6 family cytokine that has been implicated as a poor prognostic factor for multiple solid tumors, including HNSCC. OSM binds two hetero-receptors, Oncostatin-M Receptor (OSMR)/gp130 and Leukemic Inhibitory Factor Receptor (LIFR)/gp130.",
        "Methods": "OSM CAR-T cells were generated by lentiviral transduction of T-cells isolated from the peripheral blood of healthy donors. Multiple HNSCC cell lines were used, including two HPV- lines, FaDu and Cal27, and two HPV16+ cell lines, UM-SCC-47 and UPCI-SCC090. Expression of OSM receptors on cancer cells was evaluated by flow cytometry. The killing capacity of OSM CAR-T cells, relative to no T-cells or un-transduced T-cell (UT) controls, against these cells was evaluated by Incucyte imaging. Activation and degranulation of OSM CAR-T cells were measured by gating on CD3+ T cells after co-culture and measuring the levels of CD69 and CD107a by flow cytometry. Cytokine release of T-cells after co-culture was evaluated by a LEGENDplex flow-based multiplex assay.",
        "Results": "All cell lines showed expression of gp130, OSMR, and LIFR relative to unstained and antibody controls. When OSM CAR-T cells were co-cultured with each cell line, we found significant cancer cell killing compared to the no T-cell or UT control, as measured by uptake of cytotoxic dye (average across cell lines: No T-cells: 256,316um 2 /image; UT: 306,300um 2 /image; CAR-T: 876,947 um 2 /image, Mean Red Fluorescence). Additionally, after co-culture with each HNSCC cell line, the OSM CAR-T cells were significantly activated (average UT: 25.0%; CAR-T: 64.4%) and degranulated (average UT: 37.0%; CAR-T: 80.6%). This coincided with the release of interferon-gamma (IFN-γ) (average UT: 10.6 pg/mL; CAR-T: 46.2pg/mL) and granzyme B (average UT: 180.1 pg/mL; CAR-T: 1636.7pg/mL).",
        "Conclusions": "We provide preliminary evidence using an in vitro cell culture system that OSM CAR-T cells may be an effective immunotherapy for HNSCC patients. Future work includes multiple mouse models to further assess efficacy and safety. This will include an orthotopic xenograft model in which luciferase-labeled tumor cells are implanted on the anterior tongue of NSG mice, and OSM CAR-T cells will be injected intravenously. Additional work includes a patient-derived xenograft model in which patient-derived tumors will be implanted onto the anterior tongue of NSG mice and treated intravenously with CAR-T cells generated from the blood of the matched patient, in an autologous manner.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncostatin M (OSM) ligand-based CAR-T cells as a potential therapy for Head and Neck Squamous Cell Carcinoma</span>. <u>Claire Fritz</u><sup>1</sup>; Quintin Pan, PhD<sup>2</sup>; Theodoros Teknos, MD<sup>2</sup>; Reshmi Parameswaran, PhD<sup>3</sup>. <sup>1</sup>Department of Pathology, Case Western Reserve University; <sup>2</sup>University Hospitals Seidman Cancer Center; Department of Otolaryngology, Case Western Reserve University School of Medicine; <sup>3</sup>Department of Medicine, Case Western Reserve University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors arising from the oral cavity, pharynx, and larynx and accounts for about 90% of all head and neck cancers. The 5-year overall survival rate of 50-60% in this patient population necessitates novel therapeutic approaches to treat this cancer. Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the field of cancer therapy over the last two decades and is expanding to the solid tumor space. Our lab recently developed a third-generation Oncostatin M (OSM) ligand-based CAR-T cell product. OSM is an IL-6 family cytokine that has been implicated as a poor prognostic factor for multiple solid tumors, including HNSCC. OSM binds two hetero-receptors, Oncostatin-M Receptor (OSMR)/gp130 and Leukemic Inhibitory Factor Receptor (LIFR)/gp130.</p>\n\n<p><strong>Methods</strong>: OSM CAR-T cells were generated by lentiviral transduction of T-cells isolated from the peripheral blood of healthy donors. Multiple HNSCC cell lines were used, including two HPV- lines, FaDu and Cal27, and two HPV16+ cell lines, UM-SCC-47 and UPCI-SCC090. Expression of OSM receptors on cancer cells was evaluated by flow cytometry. The killing capacity of OSM CAR-T cells, relative to no T-cells or un-transduced T-cell (UT) controls, against these cells was evaluated by Incucyte imaging. Activation and degranulation of OSM CAR-T cells were measured by gating on CD3+ T cells after co-culture and measuring the levels of CD69 and CD107a by flow cytometry. Cytokine release of T-cells after co-culture was evaluated by a LEGENDplex flow-based multiplex assay. </p>\n\n<p><strong>Results</strong>: All cell lines showed expression of gp130, OSMR, and LIFR relative to unstained and antibody controls. When OSM CAR-T cells were co-cultured with each cell line, we found significant cancer cell killing compared to the no T-cell or UT control, as measured by uptake of cytotoxic dye (average across cell lines: No T-cells: 256,316um<sup>2</sup>/image; UT: 306,300um<sup>2</sup>/image; CAR-T: 876,947 um<sup>2</sup>/image, Mean Red Fluorescence). Additionally, after co-culture with each HNSCC cell line, the OSM CAR-T cells were significantly activated (average UT: 25.0%; CAR-T: 64.4%) and degranulated (average UT: 37.0%; CAR-T: 80.6%). This coincided with the release of interferon-gamma (IFN-γ) (average UT: 10.6 pg/mL; CAR-T: 46.2pg/mL) and granzyme B (average UT: 180.1 pg/mL; CAR-T: 1636.7pg/mL).</p>\n\n<p><strong>Conclusions</strong>: We provide preliminary evidence using an in vitro cell culture system that OSM CAR-T cells may be an effective immunotherapy for HNSCC patients. Future work includes multiple mouse models to further assess efficacy and safety. This will include an orthotopic xenograft model in which luciferase-labeled tumor cells are implanted on the anterior tongue of NSG mice, and OSM CAR-T cells will be injected intravenously. Additional work includes a patient-derived xenograft model in which patient-derived tumors will be implanted onto the anterior tongue of NSG mice and treated intravenously with CAR-T cells generated from the blood of the matched patient, in an autologous manner.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152235--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S277",
      "content_id": "155426",
      "abstract_number": "S277",
      "poster_number": "",
      "title": "Novel algorithm defines immunogenic splicing derived neoantigens for anti-tumoral vaccines",
      "summary": "In the past decade, immune checkpoint inhibitors have become increasingly utilized in the treatment of head and neck squamous cell carcinoma (HNSCC). However, the response rates are limited in both the neoadjuvant and recurrent metastatic setting. These tumors are defined by poor anti-tumoral immunity, precipitating the need for adjuncts to boost immune responses to improve outcomes. In this work, we sought to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155426",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter Vo",
      "presenter": "Peter Vo",
      "authors": "Peter Vo 1 ; Laura Ho 2 ; Ryan Griswold 3 ; Joseph Bendik 2 ; Stephen Schoenberger 3 ; Theresa Guo 2",
      "normalized_authors": [
        "Peter Vo",
        "Laura Ho",
        "Ryan Griswold",
        "Joseph Bendik",
        "Stephen Schoenberger",
        "Theresa Guo"
      ],
      "affiliations": [
        "California University of Science & Medicine",
        "University of California, San Diego",
        "La Jolla Institute of Immunology"
      ],
      "normalized_institutions": [
        "California University of Science & Medicine",
        "University of California, San Diego",
        "La Jolla Institute of Immunology"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155426/figure%201%20vaccination%20abstract.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155426/figure%201%20vaccination%20abstract.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155426"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Peter Vo 1 ; Laura Ho 2 ; Ryan Griswold 3 ; Joseph Bendik 2 ; Stephen Schoenberger 3 ; Theresa Guo 2",
        "Affiliations": "1 California University of Science & Medicine; 2 University of California, San Diego; 3 La Jolla Institute of Immunology",
        "Abstract": "In the past decade, immune checkpoint inhibitors have become increasingly utilized in the treatment of head and neck squamous cell carcinoma (HNSCC). However, the response rates are limited in both the neoadjuvant and recurrent metastatic setting. These tumors are defined by poor anti-tumoral immunity, precipitating the need for adjuncts to boost immune responses to improve outcomes. In this work, we sought to define immunogenic neoantigens as putative targets to boosting anti-tumoral immunity. Because HNSCC has relatively low tumor mutation burden with few recurring mutations, we instead evaluated aberrant splicing as a novel source of neoantigens. Splicing alterations can result in more substantial amino acid sequence alterations than point mutations and therefore produce more immunogenic peptides. Recent data has demonstrated the immunogenic effect of indels which generate similar sequence changes. Lastly, splicing events have high prevalence in HNSCC, occuring in up to 30-50% of tumors. We previously published our novel algorithm, OutSplice, for defining tumor specific splicing alterations using outlier statistics. This algorithm identifies clinically significant aberrant splicing events, and splicing burden is associated with worse prognosis in HNSCC. Our follow-on algorithm SINE scores candidate splicing events to define top immunogenic candidates. Using this pipeline, we applied OutSplice and SINE to two independent murine oral cancer lines, 4MOSC1 and MOC1, to identify top scoring immunogenic splice derived neoantigens. Fifteen top scoring neoantigens were identified in each cell line and EliSPOT assays were performed to confirm T-cell responses. Seven week old C57BL/6 mice were vaccinated with 100μg of peptide with poly-IC adjuvant via flank injections. One week after vaccination, T-cells were harvested from the adjacent inguinal lymph node and spleen. Bone marrow derived dendritic cells from untreated mice were pulsed with candidate peptides to stimulate harvested T-cells. EliSPOT validated T-cell responses in 3 of 15 (20%) top candidates from 4MOSC1 and 8 of 15 (53%) from MOC1. All non-immunogenic peptides did not show T-cell responses. To demonstrate anti-tumoral immunity from these candidate peptides, C57BL/6 mice were administered prophylactic vaccination consisting of pooled immunogenic peptides from 4MOSC1. Two additional groups of C57BL/6 mice were vaccinated with poly-IC alone as negative control. A total of three doses were administered over a three weeks span followed by tumor challenge one week later. After initial tumor growth, mice treated with splice peptide demonstrated significantly inhibited tumor growth with eventual tumor reduction after one week. Vaccination with peptides in combination with anti-PD1 therapy after tumors were established were unable to inhibit growth. This work demonstrates the potential for prophylactic vaccination with splice derived peptides for inhibition of future tumor growth or potential role for prevention of recurrence. Future work will seek to validate vaccine strategies using additional cell lines and enhance vaccination design for improved efficacy in the therapeutic setting. (A) EliSPOT for predicted immunogenic peptides for 4MOSC1 and MOC1 (B) EliSPOT for confirmed immunogenic peptide 4, from 4MOSC1 (C) Overall validation of splice derived peptides (D) Mice vaccinated with pooled immunogenic 4MOSC1 splice derived peptides showed ability to inhibit tumor growth compared to poly-IC alone View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Novel algorithm defines immunogenic splicing derived neoantigens for anti-tumoral vaccines</span>. <u>Peter Vo</u><sup>1</sup>; Laura Ho<sup>2</sup>; Ryan Griswold<sup>3</sup>; Joseph Bendik<sup>2</sup>; Stephen Schoenberger<sup>3</sup>; Theresa Guo<sup>2</sup>. <sup>1</sup>California University of Science & Medicine; <sup>2</sup>University of California, San Diego; <sup>3</sup>La Jolla Institute of Immunology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>In the past decade, immune checkpoint inhibitors have become increasingly utilized in the treatment of head and neck squamous cell carcinoma (HNSCC). However, the response rates are limited in both the neoadjuvant and recurrent metastatic setting.  These tumors are defined by poor anti-tumoral immunity, precipitating the need for adjuncts to boost immune responses to improve outcomes. In this work, we sought to define immunogenic neoantigens as putative targets to boosting anti-tumoral immunity. Because HNSCC has relatively low tumor mutation burden with few recurring mutations, we instead evaluated aberrant splicing as a novel source of neoantigens. Splicing alterations can result in more substantial amino acid sequence alterations than point mutations and therefore produce more immunogenic peptides. Recent data has demonstrated the immunogenic effect of indels which generate similar sequence changes. Lastly, splicing events have high prevalence in HNSCC, occuring in up to 30-50% of tumors.</p>\n\n<p>We previously published our novel algorithm, OutSplice, for defining tumor specific splicing alterations using outlier statistics. This algorithm identifies clinically significant aberrant splicing events, and splicing burden is associated with worse prognosis in HNSCC. Our follow-on algorithm SINE scores candidate splicing events to define top immunogenic candidates.</p>\n\n<p>Using this pipeline, we applied OutSplice and SINE to two independent murine oral cancer lines, 4MOSC1 and MOC1, to identify top scoring immunogenic splice derived neoantigens.  Fifteen top scoring neoantigens were identified in each cell line and EliSPOT assays were performed to confirm T-cell responses. Seven week old C57BL/6 mice were vaccinated with 100μg of peptide with poly-IC adjuvant via flank injections.  One week after vaccination, T-cells were harvested from the adjacent inguinal lymph node and spleen.  Bone marrow derived dendritic cells from untreated mice were pulsed with candidate peptides to stimulate harvested T-cells. EliSPOT validated T-cell responses in 3 of 15 (20%) top candidates from 4MOSC1 and 8 of 15 (53%) from MOC1.  All non-immunogenic peptides did not show T-cell responses.</p>\n\n<p>To demonstrate anti-tumoral immunity from these candidate peptides, C57BL/6 mice were administered prophylactic vaccination consisting of pooled immunogenic peptides from 4MOSC1.  Two additional groups of C57BL/6 mice were vaccinated with poly-IC alone as negative control. A total of three doses were administered over a three weeks span followed by tumor challenge one week later.  After initial tumor growth, mice treated with splice peptide demonstrated significantly inhibited tumor growth with eventual tumor reduction after one week. Vaccination with peptides in combination with anti-PD1 therapy after tumors were established were unable to inhibit growth.  This work demonstrates the potential for prophylactic vaccination with splice derived peptides for inhibition of future tumor growth or potential role for prevention of recurrence. Future work will seek to validate vaccine strategies using additional cell lines and enhance vaccination design for improved efficacy in the therapeutic setting.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155426/figure%201%20vaccination%20abstract.png' /></p>\n\n<p>(A) EliSPOT for predicted immunogenic peptides for 4MOSC1 and MOC1<br />\n(B) EliSPOT for confirmed immunogenic peptide 4, from 4MOSC1 <br />\n(C) Overall validation of splice derived peptides <br />\n(D) Mice vaccinated with pooled immunogenic 4MOSC1 splice derived peptides showed ability to inhibit tumor growth compared to poly-IC alone</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155426--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S278",
      "content_id": "153205",
      "abstract_number": "S278",
      "poster_number": "",
      "title": "A Tumor-Associated Antigen Peptide Vaccine Induces Durable Antitumor Immunity in Head and Neck Cancer: Insights into Vaccination Approaches",
      "summary": "We identified novel murine c-Met epitopes that generated potent and durable antitumor T-cell responses in a syngeneic HNSCC model. Despite the inherently low immunogenicity of tumor-associated antigens, the c-Met peptide vaccine induced effective and sustained tumor control. Distinct vaccination protocols produced marked differences in CD4?/CD8? responses and therapeutic outcomes, indicating that vaccine efficacy...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153205",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michihisa Kono",
      "presenter": "Michihisa Kono",
      "authors": "Michihisa Kono ; Takumi Kumai; Takahiro Inoue; Hiroki Komatsuda; Risa Wakisaka; Hidekiyo Yamaki; Kenzo Ohara; Miki Takahara",
      "normalized_authors": [
        "Michihisa Kono",
        "Takumi Kumai",
        "Takahiro Inoue",
        "Hiroki Komatsuda",
        "Risa Wakisaka",
        "Hidekiyo Yamaki",
        "Kenzo Ohara",
        "Miki Takahara"
      ],
      "affiliations": [
        "Asahikawa Medical University"
      ],
      "normalized_institutions": [
        "Asahikawa Medical University"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 363,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michihisa Kono ; Takumi Kumai; Takahiro Inoue; Hiroki Komatsuda; Risa Wakisaka; Hidekiyo Yamaki; Kenzo Ohara; Miki Takahara",
        "Affiliations": "Asahikawa Medical University",
        "Background": "Immune checkpoint inhibitors (ICIs) show limited efficacy in head and neck squamous cell carcinoma (HNSCC), in part due to insufficient tumor-reactive T cells. Mutation-derived neoantigen vaccines can induce potent immunity, but personalized sequencing, high production cost, and vulnerability to antigen loss limit their clinical scalability. Shared tumor-associated antigens (TAAs), although less immunogenic, provide stable and widely expressed targets, and allow rapid switching to alternative TAAs if the initial antigen becomes lost. c-Met, a receptor tyrosine kinase associated with progression and poor prognosis in HNSCC, is a rational TAA target.",
        "Methods": "Novel murine c-Met epitopes were predicted using SYFPEITHI and IEDB. A CTL epitope (c-Met^649–657) and an HTL epitope (c-Met^647–661) were synthesized. MOC1 tumor-bearing C57BL/6 mice received an intravenous prime–boost vaccination with peptide + poly-IC (prime) followed by peptide + poly-IC + anti-CD40 mAb (boost). Antigen-specific T-cell responses, cytotoxicity, T-cell dependency, tumor control, and memory formation were evaluated. To explore immunization performance, multiple vaccine protocols using distinct adjuvant combinations were examined.",
        "Results": "Both peptides induced antigen-reactive T cells. The CTL epitope elicited peptide- and tumor-specific CD8+ T cells with direct cytotoxicity. The HTL epitope induced both CD4+ and CD8+ responses, and CD4+ T cells exhibited direct killing of tumor cells. Therapeutic vaccination significantly suppressed tumor growth, and a subset of mice achieved complete rejection. Adoptive transfer of splenocytes from vaccinated tumor-free mice inhibited tumor growth in recipient animals, whereas cells from non-vaccinated donors had no effect. Vaccination also generated durable antitumor memory, with treated mice rejecting tumor re-inoculation. Across the immunization protocols evaluated, antitumor efficacy and T-cell functionality varied, underscoring the importance of optimizing vaccine conditions. Anti-PD-1 blockade did not further enhance vaccine activity.",
        "Conclusions": "We identified novel murine c-Met epitopes that generated potent and durable antitumor T-cell responses in a syngeneic HNSCC model. Despite the inherently low immunogenicity of tumor-associated antigens, the c-Met peptide vaccine induced effective and sustained tumor control. Distinct vaccination protocols produced marked differences in CD4?/CD8? responses and therapeutic outcomes, indicating that vaccine efficacy is governed by immunization strategy rather than peptide identity. These results demonstrate that protocol optimization can unlock the therapeutic potential of TAA-based vaccines and support further translational development.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Tumor-Associated Antigen Peptide Vaccine Induces Durable Antitumor Immunity in Head and Neck Cancer: Insights into Vaccination Approaches</span>. <u>Michihisa Kono</u>; Takumi Kumai; Takahiro Inoue; Hiroki Komatsuda; Risa Wakisaka; Hidekiyo Yamaki; Kenzo Ohara; Miki Takahara. Asahikawa Medical University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) show limited efficacy in head and neck squamous cell carcinoma (HNSCC), in part due to insufficient tumor-reactive T cells. Mutation-derived neoantigen vaccines can induce potent immunity, but personalized sequencing, high production cost, and vulnerability to antigen loss limit their clinical scalability. Shared tumor-associated antigens (TAAs), although less immunogenic, provide stable and widely expressed targets, and allow rapid switching to alternative TAAs if the initial antigen becomes lost. c-Met, a receptor tyrosine kinase associated with progression and poor prognosis in HNSCC, is a rational TAA target.</p>\n\n<p><strong>Methods: </strong>Novel murine c-Met epitopes were predicted using SYFPEITHI and IEDB. A CTL epitope (c-Met^649–657) and an HTL epitope (c-Met^647–661) were synthesized. MOC1 tumor-bearing C57BL/6 mice received an intravenous prime–boost vaccination with peptide + poly-IC (prime) followed by peptide + poly-IC + anti-CD40 mAb (boost). Antigen-specific T-cell responses, cytotoxicity, T-cell dependency, tumor control, and memory formation were evaluated. To explore immunization performance, multiple vaccine protocols using distinct adjuvant combinations were examined.</p>\n\n<p><strong>Results: </strong>Both peptides induced antigen-reactive T cells. The CTL epitope elicited peptide- and tumor-specific CD8+ T cells with direct cytotoxicity. The HTL epitope induced both CD4+ and CD8+ responses, and CD4+ T cells exhibited direct killing of tumor cells. Therapeutic vaccination significantly suppressed tumor growth, and a subset of mice achieved complete rejection. Adoptive transfer of splenocytes from vaccinated tumor-free mice inhibited tumor growth in recipient animals, whereas cells from non-vaccinated donors had no effect. Vaccination also generated durable antitumor memory, with treated mice rejecting tumor re-inoculation. Across the immunization protocols evaluated, antitumor efficacy and T-cell functionality varied, underscoring the importance of optimizing vaccine conditions. Anti-PD-1 blockade did not further enhance vaccine activity.</p>\n\n<p><strong>Conclusions: </strong>We identified novel murine c-Met epitopes that generated potent and durable antitumor T-cell responses in a syngeneic HNSCC model. Despite the inherently low immunogenicity of tumor-associated antigens, the c-Met peptide vaccine induced effective and sustained tumor control. Distinct vaccination protocols produced marked differences in CD4?/CD8? responses and therapeutic outcomes, indicating that vaccine efficacy is governed by immunization strategy rather than peptide identity. These results demonstrate that protocol optimization can unlock the therapeutic potential of TAA-based vaccines and support further translational development.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153205--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S279",
      "content_id": "153086",
      "abstract_number": "S279",
      "poster_number": "",
      "title": "Liposomal doxorubicin inhibits growth of immune checkpoint blockade-resistant murine models of head and neck squamous cell carcinoma and modulates myeloid cell differentiation",
      "summary": "Our results demonstrate that Doxil has single-agent cytotoxic activity even in aggressive HNSCC models. We also showed that Doxil treatment favorably modulates myeloid cell differentiation and induces the secretion of pro-inflammatory cytokines, suggesting that Doxil may contribute to anti-tumor immunity. This suggests Doxil may be beneficial in treating pathologically aggressive subtypes of head and neck cancer,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153086",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nicolas Oltean, BA",
      "presenter": "Nicolas Oltean, BA",
      "authors": "Nicolas Oltean, BA 1 ; Allison Nipper, PhD 1 ; Ratna Veeramachaneni, PhD 1 ; Sofia Cortes, BA 1 ; Roberto Rangel, PhD 1 ; Faye M Johnson, MD, PhD 2 ; Jeffrey N Myers, MD, PhD, FACS 1 ; Jennifer L Anderson, MD, PhD 1 ; Andrew G Sikora, MD, PhD 1",
      "normalized_authors": [
        "Nicolas Oltean",
        "Allison Nipper",
        "Ratna Veeramachaneni",
        "Sofia Cortes",
        "Roberto Rangel",
        "Faye M Johnson",
        "Jeffrey N Myers",
        "Jennifer L Anderson",
        "Andrew G Sikora"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, Houston, TX, USA",
        "The University of Texas MD Anderson Cancer Center, Department of Thoracic-Head and Neck Medical Oncology, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, Houston, TX, USA",
        "The University of Texas MD Anderson Cancer Center, Department of Thoracic-Head and Neck Medical Oncology, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 434,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nicolas Oltean, BA 1 ; Allison Nipper, PhD 1 ; Ratna Veeramachaneni, PhD 1 ; Sofia Cortes, BA 1 ; Roberto Rangel, PhD 1 ; Faye M Johnson, MD, PhD 2 ; Jeffrey N Myers, MD, PhD, FACS 1 ; Jennifer L Anderson, MD, PhD 1 ; Andrew G Sikora, MD, PhD 1",
        "Affiliations": "1 The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, Houston, TX, USA; 2 The University of Texas MD Anderson Cancer Center, Department of Thoracic-Head and Neck Medical Oncology, Houston, TX, USA",
        "Background": "Despite advances in immunotherapy, the prognosis of locally advanced head and neck squamous cell carcinoma (HNSCC) remains poor. Anti-PD-1 therapy is currently approved in the neoadjuvant setting for resectable, locally advanced disease, and as monotherapy or combination therapy in the recurrent/metastatic setting, yet less than 20% of patients respond. While mechanisms of anti-PD-1 therapy resistance are under ongoing investigation, prior studies have demonstrated that immunosuppressive cells play an important role in maintaining a poorly immunogenic tumor microenvironment (TME). Recent literature has demonstrated that liposomal doxorubicin (Doxil) decreases the proportion of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the TME and can rescue anti-tumor T-cell responses through this and other mechanisms. Therefore, we hypothesize that Doxil can reprogram the TME to improve anti-tumor response.",
        "Objectives": "To evaluate the cytotoxicity and myeloid-reprogramming ability of Doxil in HNSCC.",
        "Methods": "Viability of HNSCC syngeneic murine cell lines (MOC1, MOC2, ROC1, and mEER) was measured after 72 hours of treatment with Doxil with the CellTiter-Glo® assay (Promega). Bone marrow cells were isolated from the femurs of treatment naïve C57BL/6 mice. Cells were cultured with conditioned media isolated from MOC2 HPV- oral cancer cells treated with Doxil or control for 96 hours, then immunophenotyped by flow cytometry (Cytek® Aurora). A 44-plex cytokine array was used to analyze conditioned media derived from MOC2 HPV- and mEER HPV+ cancer cells treated with 1.5 µg/mL of Doxil (Eve Technologies).",
        "Results": "Doxil monotherapy showed anti-tumor efficacy in vitro, with IC50 values ranging from 0.21 to 2.20 µg/mL. A dose-dependent decrease in cell viability was observed in both HPV- and HPV+ cell lines treated with Doxil, including the highly aggressive MOC2 cell line. Additionally, Doxil-treated MOC2-conditioned media cultured with murine bone marrow cells induced M1 macrophage polarization and increased numbers of conventional and plasmacytoid dendritic cells. Analysis of cytokines secreted from MOC2 and mEER cells treated with Doxil demonstrated that Doxil induces the secretion of proinflammatory cytokines, including IL-6, CXCL10, CCL5, and CCL17.",
        "Conclusions": "Our results demonstrate that Doxil has single-agent cytotoxic activity even in aggressive HNSCC models. We also showed that Doxil treatment favorably modulates myeloid cell differentiation and induces the secretion of pro-inflammatory cytokines, suggesting that Doxil may contribute to anti-tumor immunity. This suggests Doxil may be beneficial in treating pathologically aggressive subtypes of head and neck cancer, including tumors that are refractory to immune checkpoint blockade (ICB). These results also provide a rationale for investigating additional chemotherapeutics for their immune-enhancing properties. Furthermore, a better understanding of the immunomodulatory capabilities of Doxil may identify combination neoadjuvant treatment strategies to improve response rates to ICB.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Liposomal doxorubicin inhibits growth of immune checkpoint blockade-resistant murine models of head and neck squamous cell carcinoma and modulates myeloid cell differentiation</span>. <u>Nicolas Oltean, BA</u><sup>1</sup>; Allison Nipper, PhD<sup>1</sup>; Ratna Veeramachaneni, PhD<sup>1</sup>; Sofia Cortes, BA<sup>1</sup>; Roberto Rangel, PhD<sup>1</sup>; Faye M Johnson, MD, PhD<sup>2</sup>; Jeffrey N Myers, MD, PhD, FACS<sup>1</sup>; Jennifer L Anderson, MD, PhD<sup>1</sup>; Andrew G Sikora, MD, PhD<sup>1</sup>. <sup>1</sup>The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, Houston, TX, USA; <sup>2</sup>The University of Texas MD Anderson Cancer Center, Department of Thoracic-Head and Neck Medical Oncology, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Despite advances in immunotherapy, the prognosis of locally advanced head and neck squamous cell carcinoma (HNSCC) remains poor. Anti-PD-1 therapy is currently approved in the neoadjuvant setting for resectable, locally advanced disease, and as monotherapy or combination therapy in the recurrent/metastatic setting, yet less than 20% of patients respond. While mechanisms of anti-PD-1 therapy resistance are under ongoing investigation, prior studies have demonstrated that immunosuppressive cells play an important role in maintaining a poorly immunogenic tumor microenvironment (TME). Recent literature has demonstrated that liposomal doxorubicin (Doxil) decreases the proportion of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the TME and can rescue anti-tumor T-cell responses through this and other mechanisms. Therefore, we hypothesize that Doxil can reprogram the TME to improve anti-tumor response.</p>\n\n<p><strong>Objectives: </strong>To evaluate the cytotoxicity and myeloid-reprogramming ability of Doxil in HNSCC.</p>\n\n<p><strong>Methods: </strong>Viability of HNSCC syngeneic murine cell lines (MOC1, MOC2, ROC1, and mEER) was measured after 72 hours of treatment with Doxil with the CellTiter-Glo® assay (Promega). Bone marrow cells were isolated from the femurs of treatment naïve C57BL/6 mice. Cells were cultured with conditioned media isolated from MOC2 HPV- oral cancer cells treated with Doxil or control for 96 hours, then immunophenotyped by flow cytometry (Cytek® Aurora). A 44-plex cytokine array was used to analyze conditioned media derived from MOC2 HPV- and mEER HPV+ cancer cells treated with 1.5 µg/mL of Doxil (Eve Technologies).</p>\n\n<p><strong>Results: </strong>Doxil monotherapy showed anti-tumor efficacy in vitro, with IC50 values ranging from 0.21 to 2.20 µg/mL. A dose-dependent decrease in cell viability was observed in both HPV- and HPV+ cell lines treated with Doxil, including the highly aggressive MOC2 cell line. Additionally, Doxil-treated MOC2-conditioned media cultured with murine bone marrow cells induced M1 macrophage polarization and increased numbers of conventional and plasmacytoid dendritic cells. Analysis of cytokines secreted from MOC2 and mEER cells treated with Doxil demonstrated that Doxil induces the secretion of proinflammatory cytokines, including IL-6, CXCL10, CCL5, and CCL17.</p>\n\n<p><strong>Conclusions: </strong>Our results demonstrate that Doxil has single-agent cytotoxic activity even in aggressive HNSCC models. We also showed that Doxil treatment favorably modulates myeloid cell differentiation and induces the secretion of pro-inflammatory cytokines, suggesting that Doxil may contribute to anti-tumor immunity. This suggests Doxil may be beneficial in treating pathologically aggressive subtypes of head and neck cancer, including tumors that are refractory to immune checkpoint blockade (ICB). These results also provide a rationale for investigating additional chemotherapeutics for their immune-enhancing properties. Furthermore, a better understanding of the immunomodulatory capabilities of Doxil may identify combination neoadjuvant treatment strategies to improve response rates to ICB.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153086--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S280",
      "content_id": "154342",
      "abstract_number": "S280",
      "poster_number": "",
      "title": "Age influence on immune parameters of a cohort of non-smokers, alcohol abstainers, head and neck squamous cell carcinoma patients in Brazil.",
      "summary": "Global data reveal an increasing incidence of cancer among younger individuals. Primary risk factors for head and neck squamous cell carcinoma include tobacco use, alcohol consumption, and high-risk Human Papillomavirus (HPV) infection; however, the etiology in certain cases, particularly among younger patients, remains undefined. Our research group is conducting a comprehensive analysis of head and neck cancer...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154342",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alexandre Bezerra dos Santos",
      "presenter": "Alexandre Bezerra dos Santos",
      "authors": "Ana Paula Lepique 1 ; Alexandre Bezerra dos Santos 2 ; Larissa Fonseca Marques 1 ; Fabiane Cristina Colunna 1 ; Beatriz Fernandes de Souza 2 ; Ana Luiza de Araújo Butarelli 1 ; Fátima Solange Pasini 2 ; Maria Lucia Hirata Katayama 2 ; Simone Maistro 2 ; Rosimeire Aparecida Ruela 2 ; Ana Carolina Prado-Ribeiro 2 ; Maria Aparecida Koike Folgueira 2 ; Luiz Paulo Kowalski 3",
      "normalized_authors": [
        "Ana Paula Lepique",
        "Alexandre Bezerra dos Santos",
        "Larissa Fonseca Marques",
        "Fabiane Cristina Colunna",
        "Beatriz Fernandes de Souza",
        "Ana Luiza de Araújo Butarelli",
        "Fátima Solange Pasini",
        "Maria Lucia Hirata Katayama",
        "Simone Maistro",
        "Rosimeire Aparecida Ruela",
        "Ana Carolina Prado-Ribeiro",
        "Maria Aparecida Koike Folgueira",
        "Luiz Paulo Kowalski"
      ],
      "affiliations": [
        "Instituto de Ciências Biomédicas, University of São Paulo",
        "Instituto do Câncer do Estado de São Paulo",
        "Faculdade de Medicina, Universidade de São Paulo"
      ],
      "normalized_institutions": [
        "Instituto de Ciências Biomédicas, University of São Paulo",
        "Instituto do Câncer do Estado de São Paulo",
        "Faculdade de Medicina, Universidade de São Paulo"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 280,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ana Paula Lepique 1 ; Alexandre Bezerra dos Santos 2 ; Larissa Fonseca Marques 1 ; Fabiane Cristina Colunna 1 ; Beatriz Fernandes de Souza 2 ; Ana Luiza de Araújo Butarelli 1 ; Fátima Solange Pasini 2 ; Maria Lucia Hirata Katayama 2 ; Simone Maistro 2 ; Rosimeire Aparecida Ruela 2 ; Ana Carolina Prado-Ribeiro 2 ; Maria Aparecida Koike Folgueira 2 ; Luiz Paulo Kowalski 3",
        "Affiliations": "1 Instituto de Ciências Biomédicas, University of São Paulo; 2 Instituto do Câncer do Estado de São Paulo; 3 Faculdade de Medicina, Universidade de São Paulo",
        "Abstract": "Global data reveal an increasing incidence of cancer among younger individuals. Primary risk factors for head and neck squamous cell carcinoma include tobacco use, alcohol consumption, and high-risk Human Papillomavirus (HPV) infection; however, the etiology in certain cases, particularly among younger patients, remains undefined. Our research group is conducting a comprehensive analysis of head and neck cancer patients who abstain from smoking and alcohol, aiming to identify potential biomarkers and risk factors that could facilitate early detection and prevention in youth. We have enrolled 50 patients ranging from 20 to 82 years of age (mean: 53 years), with eleven participants under 40 constituting our young cohort. HPV genotyping was performed on DNA from 40 samples, revealing 60% HPV-negative cases, 12.5% HPV16-positive, 2.5% HPV31-positive, and 5% with multiple infections. The majority presented with advanced disease: 7.1% were stage I, 16.7% stage II, 9.5% stage III, and 64.3% stage IV. Saliva, blood, and tumor tissue were collected for analysis. Utilizing multiparametric flow cytometry, we characterized circulating leukocyte populations and observed a significantly higher frequency of T CD4 lymphocytes and NK cells in younger patients, whereas older patients exhibited increased frequencies of CD14 and CD14 PD-L1-expressing monocytes. Additionally, low-density neutrophils (CD66b+ cells) within peripheral mononuclear cells were found at elevated levels in younger patients compared to older counterparts. Low-density neutrophils represent a tolerogenic population that might inhibit adaptive immune responses. To date, no significant correlations have been established between immunological parameters and clinical markers such as HPV status or cancer staging. Further analysis will incorporate cytokine profiling of lymphocytes isolated from peripheral blood and lymph nodes obtained during surgical procedures. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Age influence on immune parameters of a cohort of non-smokers, alcohol abstainers, head and neck squamous cell carcinoma patients in Brazil.</span>. Ana Paula Lepique<sup>1</sup>; <u>Alexandre Bezerra dos Santos</u><sup>2</sup>; Larissa Fonseca Marques<sup>1</sup>; Fabiane Cristina Colunna<sup>1</sup>; Beatriz Fernandes  de Souza<sup>2</sup>; Ana Luiza de Araújo Butarelli<sup>1</sup>; Fátima Solange Pasini<sup>2</sup>; Maria Lucia Hirata Katayama<sup>2</sup>; Simone Maistro<sup>2</sup>; Rosimeire Aparecida Ruela<sup>2</sup>; Ana Carolina Prado-Ribeiro<sup>2</sup>; Maria Aparecida Koike Folgueira<sup>2</sup>; Luiz Paulo Kowalski<sup>3</sup>. <sup>1</sup>Instituto de Ciências Biomédicas, University of São Paulo; <sup>2</sup>Instituto do Câncer do Estado de São Paulo; <sup>3</sup>Faculdade de Medicina, Universidade de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Global data reveal an increasing incidence of cancer among younger individuals. Primary risk factors for head and neck squamous cell carcinoma include tobacco use, alcohol consumption, and high-risk Human Papillomavirus (HPV) infection; however, the etiology in certain cases, particularly among younger patients, remains undefined. Our research group is conducting a comprehensive analysis of head and neck cancer patients who abstain from smoking and alcohol, aiming to identify potential biomarkers and risk factors that could facilitate early detection and prevention in youth.</p>\n\n<p>We have enrolled 50 patients ranging from 20 to 82 years of age (mean: 53 years), with eleven participants under 40 constituting our young cohort. HPV genotyping was performed on DNA from 40 samples, revealing 60% HPV-negative cases, 12.5% HPV16-positive, 2.5% HPV31-positive, and 5% with multiple infections. The majority presented with advanced disease: 7.1% were stage I, 16.7% stage II, 9.5% stage III, and 64.3% stage IV. Saliva, blood, and tumor tissue were collected for analysis.</p>\n\n<p>Utilizing multiparametric flow cytometry, we characterized circulating leukocyte populations and observed a significantly higher frequency of T CD4 lymphocytes and NK cells in younger patients, whereas older patients exhibited increased frequencies of CD14 and CD14 PD-L1-expressing monocytes. Additionally, low-density neutrophils (CD66b+ cells) within peripheral mononuclear cells were found at elevated levels in younger patients compared to older counterparts. Low-density neutrophils represent a tolerogenic population that might inhibit adaptive immune responses. To date, no significant correlations have been established between immunological parameters and clinical markers such as HPV status or cancer staging. Further analysis will incorporate cytokine profiling of lymphocytes isolated from peripheral blood and lymph nodes obtained during surgical procedures.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154342--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S281",
      "content_id": "153838",
      "abstract_number": "S281",
      "poster_number": "",
      "title": "Discovery of a library of HPV 6/11-specific T cell receptors potentially useful for cell therapy for adults with RRP refractory to approved treatments",
      "summary": "Treatment with zopapogene imadenovec (Papzimeos, Precigen) that activates and expands HPV6/11-specific immunity results in durable papilloma disease control in greater than half of adults with recurrent respiratory papillomatosis (RRP). Patients that do not achieve a complete response with immunotherapy can be treated with systemic bevacizumab for papilloma disease control, but some patients develop unacceptable...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153838",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "C T Allen",
      "presenter": "C T Allen",
      "authors": "K Bai; Y Robbins; S Norberg; C T Allen",
      "normalized_authors": [
        "K Bai",
        "Y Robbins",
        "S Norberg",
        "C T Allen"
      ],
      "affiliations": [
        "National Institutes of Health"
      ],
      "normalized_institutions": [
        "National Institutes of Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 514,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "K Bai; Y Robbins; S Norberg; C T Allen",
        "Affiliations": "National Institutes of Health",
        "Abstract": "Treatment with zopapogene imadenovec (Papzimeos, Precigen) that activates and expands HPV6/11-specific immunity results in durable papilloma disease control in greater than half of adults with recurrent respiratory papillomatosis (RRP). Patients that do not achieve a complete response with immunotherapy can be treated with systemic bevacizumab for papilloma disease control, but some patients develop unacceptable adverse events and do not tolerate treatment. Importantly, treatment with zopapogene imadenovec or bevacizumab has failed to consistently result in regression of pulmonary RRP lesions. New effective treatments are needed for adults with RRP that cannot achieve papilloma control with standard treatment options, and for RRP patients with pulmonary disease. T cell receptor (TCR)-engineered cell therapy consisting of autologous T cells engineered to express an allogeneic TCR discovered from a different individual with proven specificity and HLA restriction has shown clinical benefit in patients with relapsed HPV16-associated carcinoma, suggesting that a similar approach could be used to robustly enhance HPV 6/11-specific immunity in RRP patients with refractory or pulmonary disease if HPV 6/11-specific TCRs can be identified. We aimed to discover a library of HPV 6- or 11-specific T cell receptors with validated gene specificity and HLA-restriction that could be used in future first-in-human clinical studies. T cell receptor sequences were reconstructed from papilloma infiltrating T cell clones expressing an exhausted (PDCD1, HAVCR2, LAG3), tissue resident (ITGAE, ENTPD1), activated (IFNG) and proliferative (MKI67) gene expression profile on single cell sequencing from two patients with high-frequency HLA class I profiles and cloned into retroviral expression vectors for in vitro study. Autologous peripheral blood T cells were engineered to individually express a total of 101 different TCRs, sorted to high purity. Individual TCRs were initially screened for HPV gene specificity and HLA-restriction against a library of Cos7 target cells engineered to express every possible full-length HPV gene and HLA combination with IFN-g production as a readout. In this initial screen, a clearly positive IFN-g result was observed in approximately 30 TCRs with identifiable specificity for an epitope from an individual full-length HPV gene and an individual HLA restriction element. These TCRs were further screened against the ability to induce cytotoxicity of HPV-negative culturable head and neck cancer cells engineered to express individual full-length HPV gene and HLA combinations. In this secondary screen, 11 TCRs demonstrated clear ability to kill target cancer cells with HPV gene and HLA restriction element specificity. Identification of the minimal epitopes being targeted by these 11 TCRs is underway to allow screening for possible similar germline sequencing indicating possible off-target toxicity. HPV 6/11 genomes from over 50 papilloma samples are being sequenced to evaluate for conservation of minimal epitope nucleic acid sequences across HPV6/11 sublineages. Overall, this work identifies up to 11 TCRs sequences targeting epitopes from multiple separate HPV 6/11 genes that are restricted to numerous separate HLA class I alleles. The safety and efficacy of these TCRs as a TCR-engineered cell therapy will be studied in future clinical trials at the NIH Clinical Center for patients with aggressive, refractory or pulmonary RRP. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Discovery of a library of HPV 6/11-specific T cell receptors potentially useful for cell therapy for adults with RRP refractory to approved treatments</span>. K Bai; Y Robbins; S Norberg; <u>C T Allen</u>. National Institutes of Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Treatment with zopapogene imadenovec (Papzimeos, Precigen) that activates and expands HPV6/11-specific immunity results in durable papilloma disease control in greater than half of adults with recurrent respiratory papillomatosis (RRP). Patients that do not achieve a complete response with immunotherapy can be treated with systemic bevacizumab for papilloma disease control, but some patients develop unacceptable adverse events and do not tolerate treatment. Importantly, treatment with zopapogene imadenovec or bevacizumab has failed to consistently result in regression of pulmonary RRP lesions. New effective treatments are needed for adults with RRP that cannot achieve papilloma control with standard treatment options, and for RRP patients with pulmonary disease. T cell receptor (TCR)-engineered cell therapy consisting of autologous T cells engineered to express an allogeneic TCR discovered from a different individual with proven specificity and HLA restriction has shown clinical benefit in patients with relapsed HPV16-associated carcinoma, suggesting that a similar approach could be used to robustly enhance HPV 6/11-specific immunity in RRP patients with refractory or pulmonary disease if HPV 6/11-specific TCRs can be identified. We aimed to discover a library of HPV 6- or 11-specific T cell receptors with validated gene specificity and HLA-restriction that could be used in future first-in-human clinical studies. T cell receptor sequences were reconstructed from papilloma infiltrating T cell clones expressing an exhausted (PDCD1, HAVCR2, LAG3), tissue resident (ITGAE, ENTPD1), activated (IFNG) and proliferative (MKI67) gene expression profile on single cell sequencing from two patients with high-frequency HLA class I profiles and cloned into retroviral expression vectors for in vitro study. Autologous peripheral blood T cells were engineered to individually express a total of 101 different TCRs, sorted to high purity. Individual TCRs were initially screened for HPV gene specificity and HLA-restriction against a library of Cos7 target cells engineered to express every possible full-length HPV gene and HLA combination with IFN-g production as a readout. In this initial screen, a clearly positive IFN-g result was observed in approximately 30 TCRs with identifiable specificity for an epitope from an individual full-length HPV gene and an individual HLA restriction element. These TCRs were further screened against the ability to induce cytotoxicity of HPV-negative culturable head and neck cancer cells engineered to express individual full-length HPV gene and HLA combinations. In this secondary screen, 11 TCRs demonstrated clear ability to kill target cancer cells with HPV gene and HLA restriction element specificity. Identification of the minimal epitopes being targeted by these 11 TCRs is underway to allow screening for possible similar germline sequencing indicating possible off-target toxicity. HPV 6/11 genomes from over 50 papilloma samples are being sequenced to evaluate for conservation of minimal epitope nucleic acid sequences across HPV6/11 sublineages. Overall, this work identifies up to 11 TCRs sequences targeting epitopes from multiple separate HPV 6/11 genes that are restricted to numerous separate HLA class I alleles. The safety and efficacy of these TCRs as a TCR-engineered cell therapy will be studied in future clinical trials at the NIH Clinical Center for patients with aggressive, refractory or pulmonary RRP.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153838--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S282",
      "content_id": "153839",
      "abstract_number": "S282",
      "poster_number": "",
      "title": "Tumor-specific T cells that egress from tumors are primed to enter sites of disease through CXCR3-mediated trafficking",
      "summary": "Anti-tumor immunity requires T cells not only to infiltrate tumors but also to exit, circulate, and re-engage other sites of disease, sustaining systemic immune surveillance and preventing recurrence. Neoadjuvant immunotherapy (NIT) enhances systemic anti-tumor immunity in part by promoting the egress of tumor-specific T cells from tumors into circulation. However, the process that enables these T cells to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153839",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "C T Allen",
      "presenter": "C T Allen",
      "authors": "M Craveiro; Y Robbins; A Huynh; A Kaskas; C T Allen",
      "normalized_authors": [
        "M Craveiro",
        "Y Robbins",
        "A Huynh",
        "A Kaskas",
        "C T Allen"
      ],
      "affiliations": [
        "National Institutes of Health"
      ],
      "normalized_institutions": [
        "National Institutes of Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 438,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "M Craveiro; Y Robbins; A Huynh; A Kaskas; C T Allen",
        "Affiliations": "National Institutes of Health",
        "Abstract": "Anti-tumor immunity requires T cells not only to infiltrate tumors but also to exit, circulate, and re-engage other sites of disease, sustaining systemic immune surveillance and preventing recurrence. Neoadjuvant immunotherapy (NIT) enhances systemic anti-tumor immunity in part by promoting the egress of tumor-specific T cells from tumors into circulation. However, the process that enables these T cells to traffic to and exert effector function distant tumor sites remains incompletely understood. To investigate this, we utilized the Kaede murine photoconversion model with established MOC1 syngeneic tumors, which allowed local labeling of T cells for cell tracing studies. Following photoconversion, we detected tumor-egressed “red” CD8? T cells in the spleen and tumor-draining lymph nodes (TdLN) within 48 hours. Compared to intratumoral T cells, these egressed cells exhibited reduced yet persistent expression of activation (CD69) and exhaustion (PD-1, TIM3, LAG3) markers and were functionally enriched for tumor specificity. Egressed red CD8 T cells also displayed greater expression of the chemokine receptor CXCR3, a key mediator of homing to inflamed tissues, distinguishing them from bystander T cells in circulation (green). Additionally, we found that CXCR3 expression on the egressed T cells is dynamically regulated by T cell receptor (TCR) signaling. Direct TCR engagement modestly increased CXCR3, while withdrawal from antigen stimulation markedly enhanced its expression. Additionally, exposure to TGF-β indirectly inhibits TCR signaling and facilitates CXCR3 upregulation, highlighting a pathway by which the tumor microenvironment primes T cell redistribution to distant sites of disease upon egress into circulation. Importantly, red CD8 T cells preferentially accumulated in contralateral, non-converted tumors within 48 hours, where they re-expressed activation and exhaustion markers. This accumulation was abolished by CXCR3 blockade or local MHC class I loss via β2-microglobulin knockout. These findings demonstrate that CXCR3 is required for T cell trafficking to tumors, whereas antigen recognition is essential for their retention. Functionally, disruption of CXCR3-mediated trafficking or depletion of central memory T cells via anti-CD62L antibody abrogated rejection of tumor rechallenge following immunotherapy-induced cure in MOC1 and MOC22 models. Translationally, longitudinal analysis of peripheral blood from patients enrolled in a recent NIT clinical trial revealed increased CXCR3 expression on circulating memory and central memory T cells post-treatment. Collectively, these data identify CXCR3 as a critical regulator of tumor-specific re-engagement of distant sites of disease following primary tumor egress. They further reveal that TCR signaling dynamics, i.e. activation followed by antigen withdrawal, primes T cells for CXCR3 expression, systemic trafficking and durable anti-tumor immunity. These insights suggest that tumor-specific TIL that egress from the TME into circulation are primed to enter sites of distant disease though enhanced expression of CXCR3. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tumor-specific T cells that egress from tumors are primed to enter sites of disease through CXCR3-mediated trafficking</span>. M Craveiro; Y Robbins; A Huynh; A Kaskas; <u>C T Allen</u>. National Institutes of Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Anti-tumor immunity requires T cells not only to infiltrate tumors but also to exit, circulate, and re-engage other sites of disease, sustaining systemic immune surveillance and preventing recurrence. Neoadjuvant immunotherapy (NIT) enhances systemic anti-tumor immunity in part by promoting the egress of tumor-specific T cells from tumors into circulation. However, the process that enables these T cells to traffic to and exert effector function distant tumor sites remains incompletely understood. To investigate this, we utilized the Kaede murine photoconversion model with established MOC1 syngeneic tumors, which allowed local labeling of T cells for cell tracing studies. Following photoconversion, we detected tumor-egressed “red” CD8? T cells in the spleen and tumor-draining lymph nodes (TdLN) within 48 hours. Compared to intratumoral T cells, these egressed cells exhibited reduced yet persistent expression of activation (CD69) and exhaustion (PD-1, TIM3, LAG3) markers and were functionally enriched for tumor specificity. Egressed red CD8 T cells also displayed greater expression of the chemokine receptor CXCR3, a key mediator of homing to inflamed tissues, distinguishing them from bystander T cells in circulation (green). Additionally, we found that CXCR3 expression on the egressed T cells is dynamically regulated by T cell receptor (TCR) signaling. Direct TCR engagement modestly increased CXCR3, while withdrawal from antigen stimulation markedly enhanced its expression. Additionally, exposure to TGF-β indirectly inhibits TCR signaling and facilitates CXCR3 upregulation, highlighting a pathway by which the tumor microenvironment primes T cell redistribution to distant sites of disease upon egress into circulation. Importantly, red CD8 T cells preferentially accumulated in contralateral, non-converted tumors within 48 hours, where they re-expressed activation and exhaustion markers. This accumulation was abolished by CXCR3 blockade or local MHC class I loss via β2-microglobulin knockout. These findings demonstrate that CXCR3 is required for T cell trafficking to tumors, whereas antigen recognition is essential for their retention. Functionally, disruption of CXCR3-mediated trafficking or depletion of central memory T cells via anti-CD62L antibody abrogated rejection of tumor rechallenge following immunotherapy-induced cure in MOC1 and MOC22 models. Translationally, longitudinal analysis of peripheral blood from patients enrolled in a recent NIT clinical trial revealed increased CXCR3 expression on circulating memory and central memory T cells post-treatment. Collectively, these data identify CXCR3 as a critical regulator of tumor-specific re-engagement of distant sites of disease following primary tumor egress. They further reveal that TCR signaling dynamics, i.e.  activation followed by antigen withdrawal, primes T cells for CXCR3 expression, systemic trafficking and durable anti-tumor immunity. These insights suggest that tumor-specific TIL that egress from the TME into circulation are primed to enter sites of distant disease though enhanced expression of CXCR3.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153839--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S283",
      "content_id": "153259",
      "abstract_number": "S283",
      "poster_number": "",
      "title": "Intratumoral IL1R1+/ICOS+ Regulatory T Cells Are Associated With Adverse Histopathologic and Clinical Outcomes in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Higher percentage of intratumoral IL1R1+/ICOS+ Treg cells among CD45+ TILs was associated with greater DOI, post-treatment distant metastasis, and recurrence in OCSCC, indicating a potential link between this immunosuppressive Treg subset and aggressive disease behavior. Although limited sample size, these findings suggest IL1R1+/ICOS+ Tregs may contribute to biologic and clinical heterogeneity in mHNSCC and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153259",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hosam H Alkhatib, MD",
      "presenter": "Hosam H Alkhatib, MD",
      "authors": "Hosam H Alkhatib, MD 1 ; Eva Domenjo-Vila, PhD 2 ; Mateo Useche, MD, MPH 1 ; Rocco Ferrandino, MD, MSc 1 ; Emily J Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Cristina P Rodriguez, MD 3 ; Martin Prlic, PhD 2 ; Brittany R Barber, MD, MSc 1",
      "normalized_authors": [
        "Hosam H Alkhatib",
        "Eva Domenjo-Vila",
        "Mateo Useche",
        "Rocco Ferrandino",
        "Emily J Marchiano",
        "Zain H Rizvi",
        "Lauren Shih",
        "Neal D Futran",
        "Matthew O Old",
        "Cristina P Rodriguez",
        "Martin Prlic",
        "Brittany R Barber"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 544,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hosam H Alkhatib, MD 1 ; Eva Domenjo-Vila, PhD 2 ; Mateo Useche, MD, MPH 1 ; Rocco Ferrandino, MD, MSc 1 ; Emily J Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren Shih, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Cristina P Rodriguez, MD 3 ; Martin Prlic, PhD 2 ; Brittany R Barber, MD, MSc 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; 2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA; 3 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
        "Background": "Mucosal head and neck squamous cell carcinomas (mHNSCCs), particularly oral cavity SCC (OCSCC), exhibit substantial biologic and clinical heterogeneity, yet prognostic immune biomarkers are lacking. Combining several single-cell analysis pipelines, we previously compared the human mHNSCC tumor microenvironment with non-malignant inflamed oral mucosa and identified a unique, highly immunosuppressive, clonally expanded regulatory T-cell subset co-expressing interleukin-1 receptor type 1 and inducible T-cell costimulator (IL1R1+/ICOS+ Tregs) in mHNSCC. Here, we evaluated whether relative intratumoral IL1R1+/ICOS+ Treg abundance is associated with aggressive histopathologic and clinical outcomes in mHNSCC.",
        "Methods": "This single-institution prospective cohort included 31 patients with resected mHNSCC. Percentage of IL1R1+/ICOS+ Tregs among CD45+ tumor-infiltrating leukocytes (TILs) was quantified from fresh primary tumor specimens using multiparameter flow cytometry with standard viability, singlet, and lineage gating. Histopathological outcomes included depth of invasion (DOI), extranodal extension (ENE), lymphovascular invasion (LVI), perineural invasion (PNI), and positive margins. Secondary outcomes included distant metastasis-free survival, recurrence-free survival (RFS), and disease-specific survival (DSS), evaluated with Kaplan-Meier and Cox proportional hazards models adjusted for T-stage and N-stage. Patients were dichotomized into “high” and “low” IL1R1+/ICOS+ to CD45+ TIL ratio groups based on the 75th percentile (cutoff: 10.6% for OCSCC, 7.1% for all mHNSCC). Associations with adverse histopathological features were assessed using linear and logistic regression adjusted for smoking and alcohol. Subanalyses focused on OCSCC due to limited sample size of other subsites.",
        "Results": "Thirty-one patients [median age 68 years (interquartile range 57–75)] were included with median follow-up of 1.97 years. Most patients were male (75%), former (53%) or current (19%) smokers, and had primary oral cavity tumors (n=23, 75%). Among patients with OCSCC, each 1-percentage point increase in IL1R1+/ICOS+ Tregs among CD45+ TILs was associated with a 1.92-millimeter (95% CI 0.72–3.12) increase in tumor DOI (P=0.003). Tumors in the high IL1R1+/ICOS+ Treg group had a 14.8-millimeter (95% CI 2.43–27.15) greater average DOI than tumors in the low IL1R1+/ICOS+ Treg group (P=0.02). Among patients with OCSCC, those with high IL1R1+/ICOS+ Treg among CD45+ TIL percentage had higher rates of post-treatment distant metastasis (60% versus 11%, P=0.02) and recurrence (80% versus 28%, P=0.03). Two-year distant-metastasis-free OCSCC survival was lower in the high IL1R1+/ICOS+ Treg percentage group (40.0%) than low group (84.4%) (P=0.048). Each one percentage-point increase in IL1R1+/ICOS+ Tregs was associated with 68% higher hazard of distant metastasis [HR 1.68 (95% CI 1.00–2.83), P=0.049]. RFS, DSS, LVI, PNI, ENE, and positive surgical margins were not significantly associated with IL1R1+/ICOS+ Treg percentage in mHNSCC nor OCSCC alone.",
        "Conclusions": "Higher percentage of intratumoral IL1R1+/ICOS+ Treg cells among CD45+ TILs was associated with greater DOI, post-treatment distant metastasis, and recurrence in OCSCC, indicating a potential link between this immunosuppressive Treg subset and aggressive disease behavior. Although limited sample size, these findings suggest IL1R1+/ICOS+ Tregs may contribute to biologic and clinical heterogeneity in mHNSCC and serve as a novel biomarker for aggressive disease by refining risk stratification beyond conventional pathologic features. Validation in larger cohorts is warranted and to determine if IL1R1+/ICOS+ Treg abundance predicts immune checkpoint inhibition response.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intratumoral IL1R1+/ICOS+ Regulatory T Cells Are Associated With Adverse Histopathologic and Clinical Outcomes in Oral Cavity Squamous Cell Carcinoma</span>. <u>Hosam H Alkhatib, MD</u><sup>1</sup>; Eva Domenjo-Vila, PhD<sup>2</sup>; Mateo Useche, MD, MPH<sup>1</sup>; Rocco Ferrandino, MD, MSc<sup>1</sup>; Emily J Marchiano, MD<sup>1</sup>; Zain H Rizvi, MD<sup>1</sup>; Lauren Shih, MD<sup>3</sup>; Neal D Futran, MD, DMD<sup>1</sup>; Matthew O Old, MD<sup>1</sup>; Cristina P Rodriguez, MD<sup>3</sup>; Martin Prlic, PhD<sup>2</sup>; Brittany R Barber, MD, MSc<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; <sup>2</sup>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA; <sup>3</sup>Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Mucosal head and neck squamous cell carcinomas (mHNSCCs), particularly oral cavity SCC (OCSCC), exhibit substantial biologic and clinical heterogeneity, yet prognostic immune biomarkers are lacking. Combining several single-cell analysis pipelines, we previously compared the human mHNSCC tumor microenvironment with non-malignant inflamed oral mucosa and identified a unique, highly immunosuppressive, clonally expanded regulatory T-cell subset co-expressing interleukin-1 receptor type 1 and inducible T-cell costimulator (IL1R1+/ICOS+ Tregs) in mHNSCC. Here, we evaluated whether relative intratumoral IL1R1+/ICOS+ Treg abundance is associated with aggressive histopathologic and clinical outcomes in mHNSCC.</p>\n\n<p><strong>Methods</strong>: This single-institution prospective cohort included 31 patients with resected mHNSCC. Percentage of IL1R1+/ICOS+ Tregs among CD45+ tumor-infiltrating leukocytes (TILs) was quantified from fresh primary tumor specimens using multiparameter flow cytometry with standard viability, singlet, and lineage gating. Histopathological outcomes included depth of invasion (DOI), extranodal extension (ENE), lymphovascular invasion (LVI), perineural invasion (PNI), and positive margins. Secondary outcomes included distant metastasis-free survival, recurrence-free survival (RFS), and disease-specific survival (DSS), evaluated with Kaplan-Meier and Cox proportional hazards models adjusted for T-stage and N-stage. Patients were dichotomized into “high” and “low” IL1R1+/ICOS+ to CD45+ TIL ratio groups based on the 75th percentile (cutoff: 10.6% for OCSCC, 7.1% for all mHNSCC). Associations with adverse histopathological features were assessed using linear and logistic regression adjusted for smoking and alcohol. Subanalyses focused on OCSCC due to limited sample size of other subsites. </p>\n\n<p><strong>Results</strong>: Thirty-one patients [median age 68 years (interquartile range 57–75)] were included with median follow-up of 1.97 years. Most patients were male (75%), former (53%) or current (19%) smokers, and had primary oral cavity tumors (n=23, 75%). Among patients with OCSCC, each 1-percentage point increase in IL1R1+/ICOS+ Tregs among CD45+ TILs was associated with a 1.92-millimeter (95% CI 0.72–3.12) increase in tumor DOI (P=0.003). Tumors in the high IL1R1+/ICOS+ Treg group had a 14.8-millimeter (95% CI 2.43–27.15) greater average DOI than tumors in the low IL1R1+/ICOS+ Treg group (P=0.02). Among patients with OCSCC, those with high IL1R1+/ICOS+ Treg among CD45+ TIL percentage had higher rates of post-treatment distant metastasis (60% versus 11%, P=0.02) and recurrence (80% versus 28%, P=0.03). Two-year distant-metastasis-free OCSCC survival was lower in the high IL1R1+/ICOS+ Treg percentage group (40.0%) than low group (84.4%) (P=0.048). Each one percentage-point increase in IL1R1+/ICOS+ Tregs was associated with 68% higher hazard of distant metastasis [HR 1.68 (95% CI 1.00–2.83), P=0.049]. RFS, DSS, LVI, PNI, ENE, and positive surgical margins were not significantly associated with IL1R1+/ICOS+ Treg percentage in mHNSCC nor OCSCC alone.</p>\n\n<p><strong>Conclusions</strong>: Higher percentage of intratumoral IL1R1+/ICOS+ Treg cells among CD45+ TILs was associated with greater DOI, post-treatment distant metastasis, and recurrence in OCSCC, indicating a potential link between this immunosuppressive Treg subset and aggressive disease behavior. Although limited sample size, these findings suggest IL1R1+/ICOS+ Tregs may contribute to biologic and clinical heterogeneity in mHNSCC and serve as a novel biomarker for aggressive disease by refining risk stratification beyond conventional pathologic features. Validation in larger cohorts is warranted and to determine if IL1R1+/ICOS+ Treg abundance predicts immune checkpoint inhibition response. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153259--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S284",
      "content_id": "154401",
      "abstract_number": "S284",
      "poster_number": "",
      "title": "Spatial Immunophenotyping Defines Unique Immune Microenvironment in Young Patients with Oral Squamous Cell Carcinoma",
      "summary": "Oral squamous cell carcinoma (OSCC) is one of the most common mucosal cancers of the upper aerodigestive tract and is classically associated with tobacco and alcohol exposure, with a mean onset age of approximately 65. However, the incidence of OSCC in younger patients (<50 years) is steadily increasing. While mixed data exists regarding whether the prognosis of young patients is worse, this diagnosis portends...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154401",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260136",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Sandhya Kalavacherla 1 ; Jingjing Hu, MD 2 ; Judith Varner, PhD 2 ; Theresa Guo, MD 3",
      "normalized_authors": [
        "Vivian Vo",
        "Sandhya Kalavacherla",
        "Jingjing Hu",
        "Judith Varner",
        "Theresa Guo"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "Department of Pathology, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "Department of Pathology, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154401/marker_changes_final(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154401/marker_changes_final(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154401"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 472,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Sandhya Kalavacherla 1 ; Jingjing Hu, MD 2 ; Judith Varner, PhD 2 ; Theresa Guo, MD 3",
        "Affiliations": "1 UC San Diego School of Medicine; 2 Department of Pathology, University of California San Diego Health; 3 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "Oral squamous cell carcinoma (OSCC) is one of the most common mucosal cancers of the upper aerodigestive tract and is classically associated with tobacco and alcohol exposure, with a mean onset age of approximately 65. However, the incidence of OSCC in younger patients (<50 years) is steadily increasing. While mixed data exists regarding whether the prognosis of young patients is worse, this diagnosis portends devastating functional impact on otherwise healthy individuals with minimal risk factors. Prior investigations of mutational profiles have not delineated clear patterns in oral cancer of young patients, suggesting that non-genomic factors may be involved. We hypothesized that oral cancer in young patients would demonstrate a unique immune tumor microenvironment contribute to biological behavior. We analyzed eight formalin-fixed paraffin-embedded primary tumor samples from four young patients (<45) and four older patients (>60) with OSCC from primary surgical resection using a 60-panel multiplex immunohistochemistry (mIHC) performed by Akoya Biosciences (IO60). For each sample, total cell counts, tissue region, age group, and detected phenotypes were recorded, and absolute and relative frequencies of each cell type were calculated. Spatial analyses quantified median pairwise distances between cell types and local interactions within a 50 µm radius. Functional marker expression was summarized as average z-scored levels in the local cellular neighborhood for each cell type and age group. We observed that in young patient samples, several immune populations including CD11b+ cells, endothelial cells, helper T cells (including exhausted subsets), and MPO+ neutrophils exhibited higher median frequencies compared to older patient samples. Analysis of local cellular interactions revealed that among the top 50 cell-cell interaction pairs, only 27 pairs exhibited significantly stronger spatial coupling, all of which were enriched in older patients. These interactions predominantly involved CD68+CD163- macrophages, Tregs, helper T cells, plasma cells, B cells, and dendritic cells interacting with both epithelial and endothelial cells. In contrast, the only interaction enriched in younger patients was tumor cell-endothelial coupling, though this did not reach statistical significance. Functional marker expression profiling revealed a divergence in immune states, with young tissue exhibiting widespread enrichment of immunosuppressive markers including increased ICOS, IDO1, PD-1, and PD-L1, across plasma cells, CD11b? myeloid cells, cytotoxic T cells exhausted, and tumor cells, consistent with a profoundly immunosuppressed microenvironment (Figure). Collectively, these findings indicate a widespread loss of immune-immune and immune-stromal spatial coordination. This analysis demonstrated decreased immune cell interactions in younger patients, as well as higher immune suppressive marker expression including in exhausted cytotoxic T-cells and tumor cells. This immune landscape suggests that young-onset tumors may be characterized greater local immunosuppression. The highly activated yet deeply exhausted T-cell programs in young-onset tumors may facilitate rapid immune escape and primary resistance to checkpoint blockade. Thus, the immune architecture of young OSCC may not only underlie its clinical behaviors but also portend poor responsiveness to immunotherapy. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Spatial Immunophenotyping Defines Unique Immune Microenvironment in Young Patients with Oral Squamous Cell Carcinoma</span>. <u>Vivian Vo</u><sup>1</sup>; Sandhya Kalavacherla<sup>1</sup>; Jingjing Hu, MD<sup>2</sup>; Judith Varner, PhD<sup>2</sup>; Theresa Guo, MD<sup>3</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>Department of Pathology, University of California San Diego Health; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Oral squamous cell carcinoma (OSCC) is one of the most common mucosal cancers of the upper aerodigestive tract and is classically associated with tobacco and alcohol exposure, with a mean onset age of approximately 65. However, the incidence of OSCC in younger patients (<50 years) is steadily increasing. While mixed data exists regarding whether the prognosis of young patients is worse, this diagnosis portends devastating functional impact on otherwise healthy individuals with minimal risk factors. Prior investigations of mutational profiles have not delineated clear patterns in oral cancer of young patients, suggesting that non-genomic factors may be involved. We hypothesized that oral cancer in young patients would demonstrate a unique immune tumor microenvironment contribute to biological behavior.</p>\n\n<p>We analyzed eight formalin-fixed paraffin-embedded primary tumor samples from four young patients (<45) and four older patients (>60) with OSCC from primary surgical resection using a 60-panel multiplex immunohistochemistry (mIHC) performed by Akoya Biosciences (IO60). For each sample, total cell counts, tissue region, age group, and detected phenotypes were recorded, and absolute and relative frequencies of each cell type were calculated. Spatial analyses quantified median pairwise distances between cell types and local interactions within a 50 µm radius. Functional marker expression was summarized as average z-scored levels in the local cellular neighborhood for each cell type and age group.</p>\n\n<p>We observed that in young patient samples, several immune populations including CD11b+ cells, endothelial cells, helper T cells (including exhausted subsets), and MPO+ neutrophils exhibited higher median frequencies compared to older patient samples. Analysis of local cellular interactions revealed that among the top 50 cell-cell interaction pairs, only 27 pairs exhibited significantly stronger spatial coupling, all of which were enriched in older patients. These interactions predominantly involved CD68+CD163- macrophages, Tregs, helper T cells, plasma cells, B cells, and dendritic cells interacting with both epithelial and endothelial cells. In contrast, the only interaction enriched in younger patients was tumor cell-endothelial coupling, though this did not reach statistical significance.</p>\n\n<p>Functional marker expression profiling revealed a divergence in immune states, with young tissue exhibiting widespread enrichment of immunosuppressive markers including increased ICOS, IDO1, PD-1, and PD-L1, across plasma cells, CD11b? myeloid cells, cytotoxic T cells exhausted, and tumor cells, consistent with a profoundly immunosuppressed microenvironment (Figure).</p>\n\n<p>Collectively, these findings indicate a widespread loss of immune-immune and immune-stromal spatial coordination. This analysis demonstrated decreased immune cell interactions in younger patients, as well as higher immune suppressive marker expression including in exhausted cytotoxic T-cells and tumor cells. This immune landscape suggests that young-onset tumors may be characterized greater local immunosuppression. The highly activated yet deeply exhausted T-cell programs in young-onset tumors may facilitate rapid immune escape and primary resistance to checkpoint blockade. Thus, the immune architecture of young OSCC may not only underlie its clinical behaviors but also portend poor responsiveness to immunotherapy. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154401/marker_changes_final(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154401--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260136' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S285",
      "content_id": "153634",
      "abstract_number": "S285",
      "poster_number": "",
      "title": "CPS Score Determines Cost-Effectiveness of Neoadjuvant and Adjuvant Pembrolizumab for Locally Advanced Head and Neck Cancer",
      "summary": "The addition of perioperative pembrolizumab to standard treatment for locally advanced HNSCC may represent a cost-effective intervention for patients with a PD-L1 CPS 10+ status if KEYNOTE-689 data are replicable in clinical practice. The addition of pembrolizumab is not a cost-effective strategy for patients with a CPS less than 10 based on currently available data. Biomarker stratification may inform the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153634",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aidan H Coyle",
      "presenter": "Aidan H Coyle",
      "authors": "Aidan H Coyle ; David W Hutton, PhD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; David W Forner, MD, MSc; Molly E Heft Neal, MD; Kelly M Malloy, MD, MBA, FACS; Michelle L Mierzwa, MD; Mark E Prince, MD, FRCS, FACS; Jennifer L Shah, MD; Paul L Sweicicki, MD; Andrew G Shuman, MD, FACS; Chaz L Stucken, MD; Francis P Worden, MD; Pratyusha Yalamanchi, MD, MBA",
      "normalized_authors": [
        "Aidan H Coyle",
        "David W Hutton",
        "Marisa R Buchakjian",
        "Keith A Casper",
        "David W Forner",
        "Molly E Heft Neal",
        "Kelly M Malloy",
        "Michelle L Mierzwa",
        "Mark E Prince",
        "Jennifer L Shah",
        "Paul L Sweicicki",
        "Andrew G Shuman",
        "Chaz L Stucken",
        "Francis P Worden",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_OS.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_OS.jpg",
          "alt": "CPS 1-10 Overall Survival",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153634"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153634/CPS_10_OS.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153634/CPS_10_OS.jpg",
          "alt": "CPS 10+ Overall Survival",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153634"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_PSA(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_PSA(1).jpg",
          "alt": "CPS 1-10 Probabalistic Sensitivity Analysis",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153634"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153634/CPS_10_PSA(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153634/CPS_10_PSA(1).jpg",
          "alt": "CPS 10+ Probabalistic Sensitivity Analysis",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153634"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion",
        "Figure 1",
        "Figure 2"
      ],
      "sections": {
        "Authors": "Aidan H Coyle ; David W Hutton, PhD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; David W Forner, MD, MSc; Molly E Heft Neal, MD; Kelly M Malloy, MD, MBA, FACS; Michelle L Mierzwa, MD; Mark E Prince, MD, FRCS, FACS; Jennifer L Shah, MD; Paul L Sweicicki, MD; Andrew G Shuman, MD, FACS; Chaz L Stucken, MD; Francis P Worden, MD; Pratyusha Yalamanchi, MD, MBA",
        "Affiliations": "University of Michigan",
        "Objective": "The KEYNOTE-689 randomized phase III trial demonstrated improved event-free survival with the addition of neoadjuvant and adjuvant pembrolizumab to standard of care for patients with resectable locally advanced head and neck squamous-cell carcinoma (HNSCC). Here, we evaluate the cost-effectiveness of this perioperative pembrolizumab regimen in combination with standard of care surgery and pathology-guided adjuvant therapy within the US healthcare system.",
        "Methods": "A partitioned survival model (PSM) was developed to simulate the KEYNOTE-689 trial cohort with three mutually exclusive health states: event-free survival, disease progression, and death. Model inputs included Healthcare Cost and Utilization Project (HCUP) and Centers for Medicare & Medicaid Services derived costs for drug acquisition (pembrolizumab, cisplatin), administration, surgery, radiation therapy, supportive care, management of serious adverse events, and estimated costs associated with disease progression.",
        "Abstract": "Survival and adverse event data estimates were derived from KEYNOTE-689 trial data. To obtain survival parameters, the published Kaplan-Meier curves were digitized, and data for the CPS 1-10 subgroup were derived from the reported CPS 1+ and CPS 10+ subgroups. Quality-adjusted life-year (QALY) values for different health states were sourced from published literature, with the US population preference-weighting algorithm applied to EuroQol-5D 3-level health questionnaire data from the CheckMate 141 trial. The primary outcome was the incremental cost-effectiveness ratio (ICER), calculated as the additional cost per QALY gained. Analyses were performed on subgroups stratified by PD-L1 Combined Positive Score (CPS 1-10 vs. CPS 10+). A probabilistic sensitivity analysis (PSA) was performed by running 10,000 Monte Carlo simulations to incorporate parameter uncertainty. A willingness-to-pay (WTP) threshold of $150,000 per QALY was used. View in Agenda and Add to Schedule",
        "Results": "In this cost-effectiveness analysis of Keynote 689 patients, subgroup analyses based on PD-L1 expression yielded divergent results, as shown in the Kaplan-Meier curves in Figure 1. In the CPS 10+ cohort, the perioperative pembrolizumab regimen was cost-effective, producing approximately 1.37 additional QALYs at an incremental cost of $183,200, resulting in a base-case ICER of $133,600. As shown in Figure 2, Probabilistic Sensitivity Analysis (PSA) showed a 58% probability that the pembrolizumab strategy was cost-effective at the $150,000 WTP threshold. In the CPS 1-10 cohort, the perioperative pembrolizumab regimen was not cost-effective, producing approximately 0.06 additional QALYs at an incremental cost of $167,100 in the base-case analysis. This resulted in a base-case ICER of $3,001,300 and PSA demonstrating an 11% probability of cost-effectiveness at the $150,000 WTP threshold.",
        "Conclusion": "The addition of perioperative pembrolizumab to standard treatment for locally advanced HNSCC may represent a cost-effective intervention for patients with a PD-L1 CPS 10+ status if KEYNOTE-689 data are replicable in clinical practice. The addition of pembrolizumab is not a cost-effective strategy for patients with a CPS less than 10 based on currently available data. Biomarker stratification may inform the value-based integration of immunotherapy among patients with HNSCC.",
        "Figure 1": "Kaplan-Meier Overall Survival and Lognormal Model Fit",
        "Figure 2": "Probabilistic Sensitivity Analysis"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>CPS Score Determines Cost-Effectiveness of Neoadjuvant and Adjuvant Pembrolizumab for Locally Advanced Head and Neck Cancer</span>. <u>Aidan H Coyle</u>; David W Hutton, PhD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; David W Forner, MD, MSc; Molly E Heft Neal, MD; Kelly M Malloy, MD, MBA, FACS; Michelle L Mierzwa, MD; Mark E Prince, MD, FRCS, FACS; Jennifer L Shah, MD; Paul L Sweicicki, MD; Andrew G Shuman, MD, FACS; Chaz L Stucken, MD; Francis P Worden, MD; Pratyusha Yalamanchi, MD, MBA. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> The KEYNOTE-689 randomized phase III trial demonstrated improved event-free survival with the addition of neoadjuvant and adjuvant pembrolizumab to standard of care for patients with resectable locally advanced head and neck squamous-cell carcinoma (HNSCC). Here, we evaluate the cost-effectiveness of this perioperative pembrolizumab regimen in combination with standard of care surgery and pathology-guided adjuvant therapy within the US healthcare system.</p>\n\n<p><strong>Methods:</strong> A partitioned survival model (PSM) was developed to simulate the KEYNOTE-689 trial cohort with three mutually exclusive health states: event-free survival, disease progression, and death. Model inputs included Healthcare Cost and Utilization Project (HCUP) and Centers for Medicare & Medicaid Services derived costs for drug acquisition (pembrolizumab, cisplatin), administration, surgery, radiation therapy, supportive care, management of serious adverse events, and estimated costs associated with disease progression.</p>\n\n<p>Survival and adverse event data estimates were derived from KEYNOTE-689 trial data. To obtain survival parameters, the published Kaplan-Meier curves were digitized, and data for the CPS 1-10 subgroup were derived from the reported CPS 1+ and CPS 10+ subgroups. Quality-adjusted life-year (QALY) values for different health states were sourced from published literature, with the US population preference-weighting algorithm applied to EuroQol-5D 3-level health questionnaire data from the CheckMate 141 trial.</p>\n\n<p>The primary outcome was the incremental cost-effectiveness ratio (ICER), calculated as the additional cost per QALY gained. Analyses were performed on subgroups stratified by PD-L1 Combined Positive Score (CPS 1-10 vs. CPS 10+). A probabilistic sensitivity analysis (PSA) was performed by running 10,000 Monte Carlo simulations to incorporate parameter uncertainty. A willingness-to-pay (WTP) threshold of $150,000 per QALY was used.</p>\n\n<p><strong>Results:</strong> In this cost-effectiveness analysis of Keynote 689 patients, subgroup analyses based on PD-L1 expression yielded divergent results, as shown in the Kaplan-Meier curves in Figure 1. In the CPS 10+ cohort, the perioperative pembrolizumab regimen was cost-effective, producing approximately 1.37 additional QALYs at an incremental cost of $183,200, resulting in a base-case ICER of $133,600. As shown in Figure 2, Probabilistic Sensitivity Analysis (PSA) showed a 58% probability that the pembrolizumab strategy was cost-effective at the $150,000 WTP threshold. In the CPS 1-10 cohort, the perioperative pembrolizumab regimen was not cost-effective, producing approximately 0.06 additional QALYs at an incremental cost of $167,100 in the base-case analysis. This resulted in a base-case ICER of $3,001,300 and PSA demonstrating an 11% probability of cost-effectiveness at the $150,000 WTP threshold.</p>\n\n<p><strong>Conclusion: </strong>The addition of perioperative pembrolizumab to standard treatment for locally advanced HNSCC may represent a cost-effective intervention for patients with a PD-L1 CPS 10+ status if KEYNOTE-689 data are replicable in clinical practice. The addition of pembrolizumab is not a cost-effective strategy for patients with a CPS less than 10 based on currently available data. Biomarker stratification may inform the value-based integration of immunotherapy among patients with HNSCC.</p>\n\n<p><strong>Figure 1:</strong> Kaplan-Meier Overall Survival and Lognormal Model Fit</p>\n\n<p><img alt='CPS 1-10 Overall Survival' src='https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_OS.jpg' /></p>\n\n<p><img alt='CPS 10+ Overall Survival' src='https://www.submitmyabstract.com/abs/images/153634/CPS_10_OS.jpg' /></p>\n\n<p><strong>Figure 2:</strong> Probabilistic Sensitivity Analysis</p>\n\n<p><img alt='CPS 1-10 Probabalistic Sensitivity Analysis' src='https://www.submitmyabstract.com/abs/images/153634/CPS_1-10_PSA(1).jpg' /></p>\n\n<p><img alt='CPS 10+ Probabalistic Sensitivity Analysis' src='https://www.submitmyabstract.com/abs/images/153634/CPS_10_PSA(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153634--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S286",
      "content_id": "154297",
      "abstract_number": "S286",
      "poster_number": "",
      "title": "Impact of Medicaid Expansion and ACA Implementation on Oropharyngeal Squamous Cell Carcinoma: A National Cohort Study",
      "summary": "Among 2,885 OPSCC patients, 1,481 were treated in Medicaid expansion states (ES) and 1,404 in non-expansion states (NES). Medicaid coverage increased significantly in ES (71.1% to 86.3%, p<0.05). Presentation with locally advanced primary tumors (cT4) significantly decreased from 50.7% to 39.2% in ES (p<0.05) compared to a nonsignificant decrease in NES (50.0% to 45.6%). Treatment utilization was largely stable...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154297",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annie E Arrighi-Allisan, MD",
      "presenter": "Annie E Arrighi-Allisan, MD",
      "authors": "Annie E Arrighi-Allisan, MD 1 ; Neel Sangal, MD 2 ; Mona Yuan, BS 3 ; Robert M Brody, MD 1",
      "normalized_authors": [
        "Annie E Arrighi-Allisan",
        "Neel Sangal",
        "Mona Yuan",
        "Robert M Brody"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System",
        "Division of Otolaryngology, Children’s Hospital of Philadelphia",
        "Rutgers Robert Wood Johnson Medical School"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System",
        "Division of Otolaryngology, Children’s Hospital of Philadelphia",
        "Rutgers Robert Wood Johnson Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 528,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Discussion/Conclusions"
      ],
      "sections": {
        "Authors": "Annie E Arrighi-Allisan, MD 1 ; Neel Sangal, MD 2 ; Mona Yuan, BS 3 ; Robert M Brody, MD 1",
        "Affiliations": "1 Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System; 2 Division of Otolaryngology, Children’s Hospital of Philadelphia; 3 Rutgers Robert Wood Johnson Medical School",
        "Background": "Despite major advances in the management of oropharyngeal squamous cell carcinoma (OPSCC), socioeconomic barriers, insurance instability, and care fragmentation continue to shape when and where patients enter the cancer care continuum. The Affordable Care Act (ACA) represented the largest insurance policy intervention in modern US healthcare. However, its downstream oncologic effects, particularly in OPSCC, a disease with widening survival disparities, remain incompletely defined. State-level variation in Medicaid expansion offers a natural policy experiment to isolate the impact of insurance expansion on OPSCC outcomes.",
        "Methods": "We conducted a retrospective analysis of 2,885 patients who were uninsured or receiving Medicaid benefits with newly-diagnosed OPSCC from the National Cancer Database (2010-2019). Patients were stratified by Medicaid expansion (expansion vs. non-expansion) and time period (pre- vs. post-ACA). Demographic, clinicopathologic, and treatment variables were compared across four cohorts. A difference in differences (DiD) analysis was used to estimate the effect of Medicaid expansion on insurance coverage, disease presentation, and treatment patterns. Overall survival was estimated using Kaplan-Meier methods, and multivariable Cox regression identified independent predictors of all-cause mortality.",
        "Results": "Among 2,885 OPSCC patients, 1,481 were treated in Medicaid expansion states (ES) and 1,404 in non-expansion states (NES). Medicaid coverage increased significantly in ES (71.1% to 86.3%, p<0.05). Presentation with locally advanced primary tumors (cT4) significantly decreased from 50.7% to 39.2% in ES (p<0.05) compared to a nonsignificant decrease in NES (50.0% to 45.6%). Treatment utilization was largely stable across groups, with modest, nonsignificant declines in radiation use in ES relative to NES (DiD -5.6%). Academic center utilization declined in ES (55.7% to 52.9%) but increased in NES (40.2% to 45.0%), yielding a −7.6 percentage-point DiD and a reciprocal rise in comprehensive community care.",
        "Abstract": "Patients treated for OPSCC post-ACA implementation in NES experienced 15% higher all-cause mortality than those in ES (95% CI 1.02-1.31, p=0.03). There were no significant differences in survival, however, pre-ACA implementation between ES and NES (95% CIs 1.18-1.59 vs. 1.25-1.67) or in NES pre- and post-ACA implementation (CIs 1.25 – 1.67 vs. 1.02 – 1.31). Patients treated post-ACA in NES experienced significantly higher all-cause mortality compared to those in ES. This survival gap did not narrow over time, underscoring the durable oncologic consequences of policy inaction. Together, these findings suggest that Medicaid expansion functions not merely as a financial intervention, but as a disease-modifying policy – reshaping where patients present, when they are diagnosed, and ultimately, how long they survive. As OPSCC incidence continues to rise in vulnerable populations, insurance expansion emerges as a powerful structural lever to reduce cancer stage and survival disparities. View in Agenda and Add to Schedule",
        "Discussion/Conclusions": "Medicaid expansion under the ACA was associated with a marked rise in insurance coverage, a shift towards earlier-stage presentation, and improved survival among patients with OPSCC. These survival gains were not accompanied by major changes in treatment intensity, suggesting that improved outcomes were primarily driven by earlier entry into the care pathway rather than therapeutic escalation. Expansion was also associated with decentralization of care from academic centers toward comprehensive community care programs."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Medicaid Expansion and ACA Implementation on Oropharyngeal Squamous Cell Carcinoma: A National Cohort Study</span>. <u>Annie E Arrighi-Allisan, MD</u><sup>1</sup>; Neel Sangal, MD<sup>2</sup>; Mona Yuan, BS<sup>3</sup>; Robert M Brody, MD<sup>1</sup>. <sup>1</sup>Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System; <sup>2</sup>Division of Otolaryngology, Children’s Hospital of Philadelphia; <sup>3</sup>Rutgers Robert Wood Johnson Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Despite major advances in the management of oropharyngeal squamous cell carcinoma (OPSCC), socioeconomic barriers, insurance instability, and care fragmentation continue to shape when and where patients enter the cancer care continuum. The Affordable Care Act (ACA) represented the largest insurance policy intervention in modern US healthcare. However, its downstream oncologic effects, particularly in OPSCC, a disease with widening survival disparities, remain incompletely defined. State-level variation in Medicaid expansion offers a natural policy experiment to isolate the impact of insurance expansion on OPSCC outcomes.</p>\n\n<p><strong>Methods</strong>: We conducted a retrospective analysis of 2,885 patients who were uninsured or receiving Medicaid benefits with newly-diagnosed OPSCC from the National Cancer Database (2010-2019). Patients were stratified by Medicaid expansion (expansion vs. non-expansion) and time period (pre- vs. post-ACA). Demographic, clinicopathologic, and treatment variables were compared across four cohorts. A difference in differences (DiD) analysis was used to estimate the effect of Medicaid expansion on insurance coverage, disease presentation, and treatment patterns. Overall survival was estimated using Kaplan-Meier methods, and multivariable Cox regression identified independent predictors of all-cause mortality.</p>\n\n<p><strong>Results</strong>: Among 2,885 OPSCC patients, 1,481 were treated in Medicaid expansion states (ES) and 1,404 in non-expansion states (NES). Medicaid coverage increased significantly in ES (71.1% to 86.3%, p<0.05). Presentation with locally advanced primary tumors (cT4) significantly decreased from 50.7% to 39.2% in ES (p<0.05) compared to a nonsignificant decrease in NES (50.0% to 45.6%). Treatment utilization was largely stable across groups, with modest, nonsignificant declines in radiation use in ES relative to NES (DiD -5.6%). Academic center utilization declined in ES (55.7% to 52.9%) but increased in NES (40.2% to 45.0%), yielding a −7.6 percentage-point DiD and a reciprocal rise in comprehensive community care.</p>\n\n<p>Patients treated for OPSCC post-ACA implementation in NES experienced 15% higher all-cause mortality than those in ES (95% CI 1.02-1.31, p=0.03). There were no significant differences in survival, however, pre-ACA implementation between ES and NES (95% CIs 1.18-1.59 vs. 1.25-1.67) or in NES pre- and post-ACA implementation (CIs 1.25 – 1.67 vs. 1.02 – 1.31).</p>\n\n<p><strong>Discussion/Conclusions</strong>: Medicaid expansion under the ACA was associated with a marked rise in insurance coverage, a shift towards earlier-stage presentation, and improved survival among patients with OPSCC. These survival gains were not accompanied by major changes in treatment intensity, suggesting that improved outcomes were primarily driven by earlier entry into the care pathway rather than therapeutic escalation. Expansion was also associated with decentralization of care from academic centers toward comprehensive community care programs.</p>\n\n<p>Patients treated post-ACA in NES experienced significantly higher all-cause mortality compared to those in ES. This survival gap did not narrow over time, underscoring the durable oncologic consequences of policy inaction.</p>\n\n<p>Together, these findings suggest that Medicaid expansion functions not merely as a financial intervention, but as a disease-modifying policy – reshaping where patients present, when they are diagnosed, and ultimately, how long they survive. As OPSCC incidence continues to rise in vulnerable populations, insurance expansion emerges as a powerful structural lever to reduce cancer stage and survival disparities.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154297--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S287",
      "content_id": "154646",
      "abstract_number": "S287",
      "poster_number": "",
      "title": "The Pricing Ecosystem: How Hospital Characteristics, Market Dynamics, and Community Demographics Shape the Costs of Inpatient Head and Neck Cancer Care",
      "summary": "Negotiated prices for inpatient HNC care vary substantially across U.S. hospital-insurer pairs. Health-system affiliation, case mix complexity, and local labor costs were most strongly associated with higher negotiated prices. Community markers of social disadvantage were associated with lower prices, a finding that may reflect disparities in reimbursement for institutions serving vulnerable populations rather...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154646",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Leila J Mady, MD, PhD, MPH",
      "presenter": "Leila J Mady, MD, PhD, MPH",
      "authors": "Jonathan Wang, MSE 1 ; Semma Kacker, MD, PhD 2 ; Wassim Najjar, MD 3 ; Rachel Stemme, BS 1 ; Carole Fakhry, MD, MPH 3 ; Ge Bai, PhD, CPA 4 ; Leila J Mady, MD, PhD, MPH 3",
      "normalized_authors": [
        "Jonathan Wang, MSE",
        "Semma Kacker",
        "Wassim Najjar",
        "Rachel Stemme",
        "Carole Fakhry",
        "Ge Bai, CPA",
        "Leila J Mady"
      ],
      "affiliations": [
        "School of Medicine, Johns Hopkins University, Baltimore, MD",
        "Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland",
        "Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD",
        "Carey School of Business, Johns Hopkins University, Baltimore, MD"
      ],
      "normalized_institutions": [
        "School of Medicine, Johns Hopkins University, Baltimore, MD",
        "Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland",
        "Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD",
        "Carey School of Business, Johns Hopkins University, Baltimore, MD"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154646/Figure1_abstract.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154646/Figure1_abstract.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154646"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154646/Figure2_abstract.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154646/Figure2_abstract.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154646"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jonathan Wang, MSE 1 ; Semma Kacker, MD, PhD 2 ; Wassim Najjar, MD 3 ; Rachel Stemme, BS 1 ; Carole Fakhry, MD, MPH 3 ; Ge Bai, PhD, CPA 4 ; Leila J Mady, MD, PhD, MPH 3",
        "Affiliations": "1 School of Medicine, Johns Hopkins University, Baltimore, MD; 2 Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; 3 Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; 4 Carey School of Business, Johns Hopkins University, Baltimore, MD",
        "Background": "The financial toxicity of cancer care is exacerbated by opaque and often unpredictable hospital pricing, a barrier which may be partially alleviated by access to data available through the 2022 CMS Transparency in Coverage mandate. This pricing information is particularly relevant for patients with head and neck cancer (HNC), who may require resource-intense inpatient care due to treatment side effects and unanticipated toxicities. We leverage national price transparency data on HNC inpatient care to characterize patient-, hospital-, and community-level factors associated with price variation.",
        "Methods": "Median negotiated prices for HNC hospitalizations (MS-DRGs 146–148) by insurer-hospital pair were obtained from the Turquoise Health database in September 2025. Hospital-level covariates included bed count, teaching status, ownership type, case-mix index (CMI), and health system affiliation. Community-level variables included local labor costs (wage index) and hospital market concentration, measured by the Herfindahl–Hirschman Index (HHI; 0–1, higher values indicate less competition) based on bed share within each Metropolitan Statistical Area (MSA). Additional community-level factors were estimated at the ZIP-code level, including uninsured rate, prevalence of poor self-reported health, tobacco use, racial composition, and the Social Deprivation Index (SDI), a composite measure of socioeconomic disadvantage encompassing income, education, employment, housing, and household characteristics, obtained from the CDC PLACES Social Determinants dataset. Prices were log-transformed to address skewness, and bivariate linear regression assessed associations of price with contextual covariates.",
        "Results": "Across 2,343 United States (U.S.) hospitals and five major payers (Aetna, Anthem, BCBS, United, Cigna), 5,557 hospital–payer observations were analyzed. In unadjusted bivariate analyses, higher local labor costs (β = 1.21, 95% CI [1.11, 1.31]), higher HHI (β = 0.044, 95% CI [0.03, 0.06]), larger health system affiliation (β = 0.41, 95% CI [0.36, 0.46]), teaching status (β = 0.18, 95% CI [0.15, 0.21]), higher CMI (β = 0.12, 95% CI [0.08, 0.16]), and insurer (β = 0.088, 95% CI [0.044, 0.13]) were associated with higher prices (all p < 0.001) (Figure 1, 2). Conversely, community markers of social disadvantage, including cigarette use (β = –0.031, 95% CI [–0.034, –0.028]), poor self-reported health (β = –0.023, 95% CI [–0.025, –0.021]), uninsured rate (β = –0.011, 95% CI [–0.013, –0.009]), SDI (β = –0.002, 95% CI [–0.0026, –0.0017]), and percent Black population (β = –0.002, 95% CI [–0.0033, –0.0015]) were linked to lower prices (all p < 0.001).",
        "Conclusion": "Negotiated prices for inpatient HNC care vary substantially across U.S. hospital-insurer pairs. Health-system affiliation, case mix complexity, and local labor costs were most strongly associated with higher negotiated prices. Community markers of social disadvantage were associated with lower prices, a finding that may reflect disparities in reimbursement for institutions serving vulnerable populations rather than cost-shifting. A more clear understanding of structural relationships is essential for developing equitable payment models to reduce financial vulnerability iamong cancer patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Pricing Ecosystem: How Hospital Characteristics, Market Dynamics, and Community Demographics Shape the Costs of Inpatient Head and Neck Cancer Care</span>. Jonathan Wang, MSE<sup>1</sup>; Semma Kacker, MD, PhD<sup>2</sup>; Wassim Najjar, MD<sup>3</sup>; Rachel Stemme, BS<sup>1</sup>; Carole Fakhry, MD, MPH<sup>3</sup>; Ge Bai, PhD, CPA<sup>4</sup>; <u>Leila J Mady, MD, PhD, MPH</u><sup>3</sup>. <sup>1</sup>School of Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; <sup>3</sup>Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Carey School of Business, Johns Hopkins University, Baltimore, MD<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The financial toxicity of cancer care is exacerbated by opaque and often unpredictable hospital pricing, a barrier which may be partially alleviated by access to data available through the 2022 CMS Transparency in Coverage mandate. This pricing information is particularly relevant for patients with head and neck cancer (HNC), who may require resource-intense inpatient care due to treatment side effects and unanticipated toxicities. We leverage national price transparency data on HNC inpatient care to characterize patient-, hospital-, and community-level factors associated with price variation.</p>\n\n<p><strong>Methods: </strong>Median negotiated prices for HNC hospitalizations (MS-DRGs 146–148) by insurer-hospital pair were obtained from the Turquoise Health database in September 2025. Hospital-level covariates included bed count, teaching status, ownership type, case-mix index (CMI), and health system affiliation. Community-level variables included local labor costs (wage index) and hospital market concentration, measured by the Herfindahl–Hirschman Index (HHI; 0–1, higher values indicate less competition) based on bed share within each Metropolitan Statistical Area (MSA). Additional community-level factors were estimated at the ZIP-code level, including uninsured rate, prevalence of poor self-reported health, tobacco use, racial composition, and the Social Deprivation Index (SDI), a composite measure of socioeconomic disadvantage encompassing income, education, employment, housing, and household characteristics, obtained from the CDC PLACES Social Determinants dataset. Prices were log-transformed to address skewness, and bivariate linear regression assessed associations of price with contextual covariates.</p>\n\n<p><strong>Results: </strong>Across 2,343 United States (U.S.) hospitals and five major payers (Aetna, Anthem, BCBS, United, Cigna), 5,557 hospital–payer observations were analyzed. In unadjusted bivariate analyses, higher local labor costs (β = 1.21, 95% CI [1.11, 1.31]), higher HHI (β = 0.044, 95% CI [0.03, 0.06]), larger health system affiliation (β = 0.41, 95% CI [0.36, 0.46]), teaching status (β = 0.18, 95% CI [0.15, 0.21]), higher CMI (β = 0.12, 95% CI [0.08, 0.16]), and insurer (β = 0.088, 95% CI [0.044, 0.13]) were associated with higher prices (all<em> p</em> < 0.001) (Figure 1, 2). Conversely, community markers of social disadvantage, including cigarette use (β = –0.031, 95% CI [–0.034, –0.028]), poor self-reported health (β = –0.023, 95% CI [–0.025, –0.021]), uninsured rate (β = –0.011, 95% CI [–0.013, –0.009]), SDI (β = –0.002, 95% CI [–0.0026, –0.0017]), and percent Black population (β = –0.002, 95% CI [–0.0033, –0.0015]) were linked to lower prices (all <em>p</em> < 0.001).</p>\n\n<p><strong>Conclusion: </strong>Negotiated prices for inpatient HNC care vary substantially across U.S. hospital-insurer pairs. Health-system affiliation, case mix complexity, and local labor costs were most strongly associated with higher negotiated prices. Community markers of social disadvantage were associated with lower prices, a finding that may reflect disparities in reimbursement for institutions serving vulnerable populations rather than cost-shifting. A more clear understanding of structural relationships is essential for developing equitable payment models to reduce financial vulnerability iamong cancer patients.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154646/Figure1_abstract.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154646/Figure2_abstract.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154646--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S288",
      "content_id": "153026",
      "abstract_number": "S288",
      "poster_number": "",
      "title": "More is Less: The Mismatch Between Clinical Effort and Commercial Reimbursement for Head and Neck Procedures",
      "summary": "Our investigation demonstrates that commercial reimbursement may not align with clinical intensity, and longer head and neck procedures are reimbursed significantly less when accounting for operative time. These initial findings highlight the importance of awareness and advocacy: commercial prices may not adequately reflect clinical effort and hospitals may face decreasing margins on providing care to more...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153026",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mitchell J Mead",
      "presenter": "Mitchell J Mead",
      "authors": "Mitchell J Mead ; Andrew Ibrahim, MD, MSc; Pratyusha Yalamanchi, MD",
      "normalized_authors": [
        "Mitchell J Mead",
        "Andrew Ibrahim",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 366,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mitchell J Mead ; Andrew Ibrahim, MD, MSc; Pratyusha Yalamanchi, MD",
        "Affiliations": "University of Michigan",
        "Introduction": "Provider reimbursement is designed to reflect the cost and complexity of providing care. While public payers utilize payment models which account for clinical effort, little is known as to if commercial reimbursement reflects the clinical effort for head and neck ablative procedures, due a lack of negotiated price data. A recently implemented federal price transparency rule provides a unique opportunity to assess the association of commercial reimbursement and proxies of complexity (i.e. operative time and RVUs) for head and neck procedures.",
        "Methods": "The Hospital Price Transparency Rule requires hospitals to publicly disclose negotiated prices with commercial insurers. We linked prices for 15 head and neck procedures (CPT) to the 2023 Center for Medicare and Medicaid Services (CMS) Provider of Services File, and prior estimates of average operative time for head and neck procedures. Using these datasets, we calculate commercial reimbursement per operative hour. We utilized a cross-sectional multivariable generalized linear model to assess differences in commercial reimbursement per operative hour and RVU among procedures involving glossectomy, parotidectomy, and thyroidectomy.",
        "Results": "A total of 405,551 prices were reported across the 15 head and neck procedures. Commercial prices were greatest for Total Parotidectomy ($5,968 median, $3,482-$9,251 IQR) and least for Modified Radical Neck Dissection ($4,266 median, $2,750-$7,080 IQR). Commercial reimbursement per operative hour was significantly lower for longer procedures, particularly among procedures involving glossectomy and salivary gland disease. For example, total glossectomy on average was reimbursed 77% less per operative hour compared to partial glossectomy ($1,937 per hour vs. $8,380 per hour, p<.001). In comparison, the degree of difference in payment based on operative time among total versus partial thyroid procedures was smaller ($3,028 per hour vs. $4,271 per hour, p<.001), but still significant.",
        "Conclusions": "Our investigation demonstrates that commercial reimbursement may not align with clinical intensity, and longer head and neck procedures are reimbursed significantly less when accounting for operative time. These initial findings highlight the importance of awareness and advocacy: commercial prices may not adequately reflect clinical effort and hospitals may face decreasing margins on providing care to more clinically complex head and neck cancer patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>More is Less: The Mismatch Between Clinical Effort and Commercial Reimbursement for Head and Neck Procedures</span>. <u>Mitchell J Mead</u>; Andrew Ibrahim, MD, MSc; Pratyusha Yalamanchi, MD. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Provider reimbursement is designed to reflect the cost and complexity of providing care. While public payers utilize payment models which account for clinical effort, little is known as to if commercial reimbursement reflects the clinical effort for head and neck ablative procedures, due a lack of negotiated price data. A recently implemented federal price transparency rule provides a unique opportunity to assess the association of commercial reimbursement and proxies of complexity (i.e. operative time and RVUs) for head and neck procedures.</p>\n\n<p><strong>Methods:</strong> The Hospital Price Transparency Rule requires hospitals to publicly disclose negotiated prices with commercial insurers. We linked prices for 15 head and neck procedures (CPT) to the 2023 Center for Medicare and Medicaid Services (CMS) Provider of Services File, and prior estimates of average operative time for head and neck procedures. Using these datasets, we calculate commercial reimbursement per operative hour. We utilized a cross-sectional multivariable generalized linear model to assess differences in commercial reimbursement per operative hour and RVU among procedures involving glossectomy, parotidectomy, and thyroidectomy.</p>\n\n<p><strong>Results: </strong>A total of 405,551 prices were reported across the 15 head and neck procedures. Commercial prices were greatest for Total Parotidectomy ($5,968 median, $3,482-$9,251 IQR) and least for Modified Radical Neck Dissection ($4,266 median, $2,750-$7,080 IQR). Commercial reimbursement per operative hour was significantly lower for longer procedures, particularly among procedures involving glossectomy and salivary gland disease. For example, total glossectomy on average was reimbursed 77% less per operative hour compared to partial glossectomy ($1,937 per hour vs. $8,380 per hour, p<.001). In comparison, the degree of difference in payment based on operative time among total versus partial thyroid procedures was smaller ($3,028 per hour vs. $4,271 per hour, p<.001), but still significant.</p>\n\n<p><strong>Conclusions: </strong>Our investigation demonstrates that commercial reimbursement may not align with clinical intensity, and longer head and neck procedures are reimbursed significantly less when accounting for operative time. These initial findings highlight the importance of awareness and advocacy: commercial prices may not adequately reflect clinical effort and hospitals may face decreasing margins on providing care to more clinically complex head and neck cancer patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153026--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S289",
      "content_id": "153027",
      "abstract_number": "S289",
      "poster_number": "",
      "title": "Who Sets the Prices?: Insurer and Hospital Market Competition on Negotiated Prices for Head and Neck Procedures",
      "summary": "Our investigation demonstrates that prices for head and neck procedures vary significantly within and across insurers. As insurers gain market power, they reimburse hospitals significantly less for regardless of hospital market competition, suggesting insurer negotiation power may impact negotiated prices more compared to hospital negotiation power. These initial findings raise concerns that increasing insurer...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153027",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mitchell J Mead, BSA",
      "presenter": "Mitchell J Mead, BSA",
      "authors": "Mitchell J Mead, BSA 1 ; Ahsan Ahmed 2 ; Andrew M Ibrahim, MD, MSc 1 ; Pratyusha Yalamanchi, MD, MBA 1",
      "normalized_authors": [
        "Mitchell J Mead, BSA",
        "Ahsan Ahmed",
        "Andrew M Ibrahim",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "University of Michigan",
        "Albert Einstein College of Medicine"
      ],
      "normalized_institutions": [
        "University of Michigan",
        "Albert Einstein College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153027/figure_1.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153027/figure_1.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153027"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 302,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mitchell J Mead, BSA 1 ; Ahsan Ahmed 2 ; Andrew M Ibrahim, MD, MSc 1 ; Pratyusha Yalamanchi, MD, MBA 1",
        "Affiliations": "1 University of Michigan; 2 Albert Einstein College of Medicine",
        "Introduction": "To address rising healthcare prices, policymakers have focused on improving healthcare market competition. While there is evidence that market competition influences prices, little is known as to how insurer and hospital market power influence negotiated prices for head and neck procedures.",
        "Methods": "The Hospital Price Transparency Rule requires hospitals to publicly disclose negotiated prices with commercial insurers. We linked prices for 27 common head and neck procedures to the 2023 National Hospital Cost Tool and the American Medical Association Insurer Market Competition Report. These datasets measure hospital and insurer market competition at the Metropolitan Statistical Area using the Herfindahl Hirschman Index. We utilized a 2023 risk-adjusted, multivariable generalized linear model to describe price variation across national insurers and identify differences in negotiated prices across previously defined low, medium, and high competition insurer and hospital markets.",
        "Results": "Adjusted commercial prices for head and neck procedures significantly vary across national insurers. For example, the median price for head and neck procedures was $7,484 for Kaiser ($5,318-$11,490 IQR) and $4,611 for Cigna ($3,337-$6,662 IQR). Low competition insurer markets, or markets dominated by a single insurer, reimbursed on average 56% less compared to high competition insurer markets ($5,969 vs. $10,717, p<.001). Negotiated prices were lower in low competition insurer markets compared to high competition insurer markets regardless of hospital market competition.",
        "Conclusions": "Our investigation demonstrates that prices for head and neck procedures vary significantly within and across insurers. As insurers gain market power, they reimburse hospitals significantly less for regardless of hospital market competition, suggesting insurer negotiation power may impact negotiated prices more compared to hospital negotiation power. These initial findings raise concerns that increasing insurer consolidation may be associated with lower reimbursement to hospitals for head and neck surgical care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Who Sets the Prices?: Insurer and Hospital Market Competition on Negotiated Prices for Head and Neck Procedures</span>. <u>Mitchell J Mead, BSA</u><sup>1</sup>; Ahsan Ahmed<sup>2</sup>; Andrew M Ibrahim, MD, MSc<sup>1</sup>; Pratyusha Yalamanchi, MD, MBA<sup>1</sup>. <sup>1</sup>University of Michigan; <sup>2</sup>Albert Einstein College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/153027/figure_1.jpg' /></p>\n\n<p><strong>Introduction:</strong> To address rising healthcare prices, policymakers have focused on improving healthcare market competition. While there is evidence that market competition influences prices, little is known as to how insurer and hospital market power influence negotiated prices for head and neck procedures.</p>\n\n<p><strong>Methods: </strong>The Hospital Price Transparency Rule requires hospitals to publicly disclose negotiated prices with commercial insurers. We linked prices for 27 common head and neck procedures to the 2023 National Hospital Cost Tool and the American Medical Association Insurer Market Competition Report. These datasets measure hospital and insurer market competition at the Metropolitan Statistical Area using the Herfindahl Hirschman Index. We utilized a 2023 risk-adjusted, multivariable generalized linear model to describe price variation across national insurers and identify differences in negotiated prices across previously defined low, medium, and high competition insurer and hospital markets.</p>\n\n<p><strong>Results: </strong>Adjusted commercial prices for head and neck procedures significantly vary across national insurers. For example, the median price for head and neck procedures was  $7,484  for Kaiser ($5,318-$11,490 IQR) and $4,611 for Cigna ($3,337-$6,662 IQR). Low competition insurer markets, or markets dominated by a single insurer, reimbursed on average 56% less compared to high competition insurer markets ($5,969 vs. $10,717, p<.001). Negotiated prices were lower in low competition insurer markets compared to high competition insurer markets regardless of hospital market competition.</p>\n\n<p><strong>Conclusions:</strong> Our investigation demonstrates that prices for head and neck procedures vary significantly within and across insurers. As insurers gain market power, they reimburse hospitals significantly less for regardless of hospital market competition, suggesting insurer negotiation power may impact negotiated prices more compared to hospital negotiation power. These initial findings raise concerns that increasing insurer consolidation may be associated with lower reimbursement to hospitals for head and neck surgical care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153027--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S290",
      "content_id": "153589",
      "abstract_number": "S290",
      "poster_number": "",
      "title": "Value-Based Care in HPV-related Oropharynx Cancer: Cost comparison between concurrent chemoradiation and neoadjuvant chemotherapy followed by surgery",
      "summary": "NECTORS costs were similar to CCRT in patients with stage I-III HPV-related OPSCC. Emergency visits and admissions following treatment were more frequent in the CCRT treated patients. As such, a NECTORS strategy in this population appears value based.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153589",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriella Le Blanc, MD",
      "presenter": "Gabriella Le Blanc, MD",
      "authors": "Gabriella Le Blanc, MD 1 ; N. Sadeghi, MD 1 ; N. Bouganim, MD 2 ; K. Esfahani, MD 2 ; D. Caglar, MD 3 ; L. Florianova, MD 3 ; M. Pusztaszeri, MD 3 ; C. Tsien, MD 4 ; G. Shenouda, MD 4 ; K. Sultanem, MD 4 ; K. Richardson, MD 1 ; M. Hier, MD 1 ; A. Mlynarek, MD 1 ; M",
      "normalized_authors": [
        "Gabriella Le Blanc",
        "N. Sadeghi",
        "N. Bouganim",
        "K. Esfahani",
        "D. Caglar",
        "L. Florianova",
        "M. Pusztaszeri",
        "C. Tsien",
        "G. Shenouda",
        "K. Sultanem",
        "K. Richardson",
        "M. Hier",
        "A. Mlynarek"
      ],
      "affiliations": [
        "Mascarella, MD 1 . 1 McGill University - Department of Otolaryngology",
        "McGill University - Department of Medical Oncology",
        "McGill University - Department of Pathology",
        "McGill University - Department of Radiation Oncology"
      ],
      "normalized_institutions": [
        "Mascarella, MD 1 . 1 McGill University - Department of Otolaryngology",
        "McGill University - Department of Medical Oncology",
        "McGill University - Department of Pathology",
        "McGill University - Department of Radiation Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriella Le Blanc, MD 1 ; N. Sadeghi, MD 1 ; N. Bouganim, MD 2 ; K. Esfahani, MD 2 ; D. Caglar, MD 3 ; L. Florianova, MD 3 ; M. Pusztaszeri, MD 3 ; C. Tsien, MD 4 ; G. Shenouda, MD 4 ; K. Sultanem, MD 4 ; K. Richardson, MD 1 ; M. Hier, MD 1 ; A. Mlynarek, MD 1 ; M",
        "Affiliations": "Mascarella, MD 1 . 1 McGill University - Department of Otolaryngology; 2 McGill University - Department of Medical Oncology; 3 McGill University - Department of Pathology; 4 McGill University - Department of Radiation Oncology",
        "Background": "NECTORS is a clinical trial aimed at treatment optimization using neoadjuvant chemotherapy followed by surgery in patients with stage I-III HPV-related oropharyngeal squamous cell carcinoma (HPV+ OPSCC). This treatment strategy allows for tumor downstaging with systemic therapy and potential avoidance of adjuvant radiation. Patients enrolled in NECTORS have demonstrated improved quality of life and oncologic outcomes to concurrent chemoradiation (CCRT)1,2. Treatment selection needs to fit within the financial constraints of a public healthcare system as cost-effective treatments gain importance in value-based cancer care. We hypothesize that the short and long-term direct treatment costs of NECTORS are similar to or less than CCRT, all while improving outcomes of patients.",
        "Methods": "A retrospective analysis of a prospective cohort of patients with AJCC stage I-III HPV-related OPSCC undergoing definitive treatment with CCRT or NECTORS from 2016-2023 was performed. Value was evaluated as both the direct costs associated with treatment (from treatment initiation to 6-month and 12-month) as well as unplanned emergency visits and admissions. Costs included treatment related (chemotherapy, radiotherapy, surgery) and those associated with the treatment (admissions, medical follow-ups, emergency visits, procedures, inpatient medications). Patients were matched by clinical stage. Multivariable analysis was performed to adjust for confounding variables such as age, comorbidities, and smoking status.",
        "Results": "Available cost data for 89 patients with 46 receiving CCRT and 43 on the NECTORS trial. The mean costs at 6 and 12 months for CCRT were 19,058$ and 21,319$, respectively and 18,231$ and 19,081$ for NECTORS (P>0.05). Unplanned emergency visits at 12 months among the groups were 22 for CCRT and 14 for NECTORS (P=0.14). There were no unplanned admission following completion of therapy in the NECTORS group compared to 21 for CCRT (P<0.01).",
        "Conclusion": "NECTORS costs were similar to CCRT in patients with stage I-III HPV-related OPSCC. Emergency visits and admissions following treatment were more frequent in the CCRT treated patients. As such, a NECTORS strategy in this population appears value based.",
        "Abstract": "1.Silver JA, Bouganim N, Richardson K, et al. Quality of Life After Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. Jan 1 2024;150(1):65-74. doi:10.1001/jamaoto.2023.3781 2.Sadeghi N, Subramaniam T, Richardson K, et al. Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. Feb 1 2025;151(2):128-134. doi:10.1001/jamaoto.2024.3303 View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Value-Based Care in HPV-related Oropharynx Cancer: Cost comparison between concurrent chemoradiation and neoadjuvant chemotherapy followed by surgery</span>. <u>Gabriella Le Blanc, MD</u><sup>1</sup>; N. Sadeghi, MD<sup>1</sup>; N. Bouganim, MD<sup>2</sup>; K. Esfahani, MD<sup>2</sup>; D. Caglar, MD<sup>3</sup>; L. Florianova, MD<sup>3</sup>; M. Pusztaszeri, MD<sup>3</sup>; C. Tsien, MD<sup>4</sup>; G. Shenouda, MD<sup>4</sup>; K. Sultanem, MD<sup>4</sup>; K. Richardson, MD<sup>1</sup>; M. Hier, MD<sup>1</sup>; A. Mlynarek, MD<sup>1</sup>; M. Mascarella, MD<sup>1</sup>. <sup>1</sup>McGill University - Department of Otolaryngology; <sup>2</sup>McGill University - Department of Medical Oncology; <sup>3</sup>McGill University - Department of Pathology; <sup>4</sup>McGill University - Department of Radiation Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> NECTORS is a clinical trial aimed at treatment optimization using neoadjuvant chemotherapy followed by surgery in patients with stage I-III HPV-related oropharyngeal squamous cell carcinoma (HPV+ OPSCC). This treatment strategy allows for tumor downstaging with systemic therapy and potential avoidance of adjuvant radiation. Patients enrolled in NECTORS have demonstrated improved quality of life and oncologic outcomes to concurrent chemoradiation (CCRT)1,2. Treatment selection needs to fit within the financial constraints of a public healthcare system as cost-effective treatments gain importance in value-based cancer care. We hypothesize that the short and long-term direct treatment costs of NECTORS are similar to or less than CCRT, all while improving outcomes of patients.</p>\n\n<p><strong>Methods: </strong>A retrospective analysis of a prospective cohort of patients with AJCC stage I-III HPV-related OPSCC undergoing definitive treatment with CCRT or NECTORS from 2016-2023 was performed. Value was evaluated as both the direct costs associated with treatment (from treatment initiation to 6-month and 12-month) as well as unplanned emergency visits and admissions. Costs included treatment related (chemotherapy, radiotherapy, surgery) and those associated with the treatment (admissions, medical follow-ups, emergency visits, procedures, inpatient medications). Patients were matched by clinical stage. Multivariable analysis was performed to adjust for confounding variables such as age, comorbidities, and smoking status.</p>\n\n<p><strong>Results:</strong> Available cost data for 89 patients with 46 receiving CCRT and 43 on the NECTORS trial. The mean costs at 6 and 12 months for CCRT were 19,058$ and 21,319$, respectively and 18,231$ and 19,081$ for NECTORS (P>0.05). Unplanned emergency visits at 12 months among the groups were 22 for CCRT and 14 for NECTORS (P=0.14). There were no unplanned admission following completion of therapy in the NECTORS group compared to 21 for CCRT (P<0.01).</p>\n\n<p><strong>Conclusion:</strong> NECTORS costs were similar to CCRT in patients with stage I-III HPV-related OPSCC. Emergency visits and admissions following treatment were more frequent in the CCRT treated patients. As such, a NECTORS strategy in this population appears value based.</p>\n\n<p><strong>REFERENCES:</strong></p>\n\n<p>1.Silver JA, Bouganim N, Richardson K, et al. Quality of Life After Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. Jan 1 2024;150(1):65-74. doi:10.1001/jamaoto.2023.3781</p>\n\n<p>2.Sadeghi N, Subramaniam T, Richardson K, et al. Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. Feb 1 2025;151(2):128-134. doi:10.1001/jamaoto.2024.3303</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153589--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S291",
      "content_id": "154509",
      "abstract_number": "S291",
      "poster_number": "",
      "title": "Transatlantic Comparison of Value Based Principles and Treatment Intervals in Head and Neck Cancer Pathways",
      "summary": "No international gold standard exists for target TTI or CPI in HNSCC. Comparative analysis of healthcare systems with differing organizational structures offers methodological advantages for identifying system-level factors that optimize care delivery. We performed a qualitative comparison of care delivery models and descriptive analysis of TTI and CPI across two academic medical centers in the United States and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154509",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gijs van der Sluis, MD",
      "presenter": "Gijs van der Sluis, MD",
      "authors": "Gijs van der Sluis, MD 1 ; Farshad N Chowdhury, MD, FACS 2 ; Maura Campbell, BSc 2 ; Paul Allen, PhD 2 ; Shawn Newlands, MD, Phd, MBA, FACS 2 ; Gyorgy B Halmos, MD, PhD 1 ; Rosanne Schoonbeek, MD, PhD 1",
      "normalized_authors": [
        "Gijs van der Sluis",
        "Farshad N Chowdhury",
        "Maura Campbell",
        "Paul Allen",
        "Shawn Newlands",
        "Gyorgy B Halmos",
        "Rosanne Schoonbeek"
      ],
      "affiliations": [
        "University Medical Center Groningen",
        "University of Rochester School of Medicine and Dentistry"
      ],
      "normalized_institutions": [
        "University Medical Center Groningen",
        "University of Rochester School of Medicine and Dentistry"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154509/Screenshot%202025-12-05%20at%204_17_34%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154509/Screenshot%202025-12-05%20at%204_17_34%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154509"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 532,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "Abstract",
        "METHODS",
        "RESULTS",
        "CONCLUSION & DISCUSSION"
      ],
      "sections": {
        "Authors": "Gijs van der Sluis, MD 1 ; Farshad N Chowdhury, MD, FACS 2 ; Maura Campbell, BSc 2 ; Paul Allen, PhD 2 ; Shawn Newlands, MD, Phd, MBA, FACS 2 ; Gyorgy B Halmos, MD, PhD 1 ; Rosanne Schoonbeek, MD, PhD 1",
        "Affiliations": "1 University Medical Center Groningen; 2 University of Rochester School of Medicine and Dentistry",
        "BACKGROUND": "Delay in treatment initiation for head and neck squamous cell carcinoma (HNSCC) is associated with tumor progression with resultant increased morbidity and mortality. Timely treatment initiation commonly requires referral to high-volume regional centers, execution of multi-step diagnostics, and coordination of multidisciplinary shared decision-making. The Time-to-treatment interval (TTI) and Care Pathway Interval (CPI) are considered important quality indicators of value-based healthcare (VBHC).",
        "Abstract": "No international gold standard exists for target TTI or CPI in HNSCC. Comparative analysis of healthcare systems with differing organizational structures offers methodological advantages for identifying system-level factors that optimize care delivery. We performed a qualitative comparison of care delivery models and descriptive analysis of TTI and CPI across two academic medical centers in the United States and the Netherlands, representing distinct healthcare architectures and operational contexts. This international comparison enables hypothesis generation regarding structural, process, and organizational factors that influence time-to-treatment in head and neck cancer care and identifies potentially transferable innovations for optimizing oncology pathways globally. Overall TTI and CPI were both significantly shorter in the Netherlands. Median TTI was 29.5 days (IQR: 22.0–41.0) in the Netherlands compared with 40.0 days (IQR: 29.0–52.5) in the United States (p<0.001), representing an 11-day difference. Median CPI was 27.0 days (IQR: 21.0–36.0) in the Netherlands compared with 34.0 days (IQR: 23.0–48.0) in the United States (p=0.003). Table 1 describes differences in care intervals by selected subgroup. View in Agenda and Add to Schedule",
        "METHODS": "All newly diagnosed adult patients with mucosal head and neck squamous cell carcinoma (HNSCC) referred for treatment in calendar year 2023 to either treatment site were eligible for inclusion. A structured qualitative comparison of care delivery models was performed using a value-based healthcare framework to assess structural and process characteristics across both treatment sites. Patient, tumor, and treatment characteristics were collected retrospectively. Time-to-treatment interval (TTI) was defined as the number of days between histopathological confirmation of malignancy and treatment initiation. Care Pathway Interval (CPI) was defined as the number of days between first oncology consultation and treatment initiation. Descriptive statistics are reported as median and interquartile range (IQR). Between-group comparisons of TTI and CPI were performed using the Mann-Whitney U test.",
        "RESULTS": "A total of 346 patients were included (Netherlands: n=241; USA: n=105). Patient populations differed significantly in tumor site distribution and stage, with a higher proportion of HPV-positive oropharyngeal carcinomas and Stage IV disease in the United States cohort. The time interval between referral and first appointment was similar in both centers: median 7.0 days (IQR: 3.0–10.0) in the Netherlands versus 7.0 days (IQR: 4.0–14.0) in the United States (p=NS).",
        "CONCLUSION & DISCUSSION": "Transatlantic comparison of care delivery models identifies distinct structural and organizational factors associated with differences in time-to-treatment intervals. While the clinical significance of an 11-day reduction in TTI remains to be determined, these findings generate hypotheses regarding system-level interventions—including centralized referrals, routine frailty screening, and outcome transparency—that warrant prospective investigation. International benchmarking of care pathways offers a valuable approach to identifying and testing innovations that may improve efficiency and outcomes in head and neck cancer treatment."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transatlantic Comparison of Value Based Principles and Treatment Intervals in Head and Neck Cancer Pathways</span>. <u>Gijs van der Sluis, MD</u><sup>1</sup>; Farshad N Chowdhury, MD, FACS<sup>2</sup>; Maura Campbell, BSc<sup>2</sup>; Paul Allen, PhD<sup>2</sup>; Shawn Newlands, MD, Phd, MBA, FACS<sup>2</sup>; Gyorgy B Halmos, MD, PhD<sup>1</sup>; Rosanne Schoonbeek, MD, PhD<sup>1</sup>. <sup>1</sup>University Medical Center Groningen; <sup>2</sup>University of Rochester School of Medicine and Dentistry<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Delay in treatment initiation for head and neck squamous cell carcinoma (HNSCC) is associated with tumor progression with resultant increased morbidity and mortality. Timely treatment initiation commonly requires referral to high-volume regional centers, execution of multi-step diagnostics, and coordination of multidisciplinary shared decision-making. The Time-to-treatment interval (TTI) and Care Pathway Interval (CPI) are considered important quality indicators of value-based healthcare (VBHC).</p>\n\n<p>No international gold standard exists for target TTI or CPI in HNSCC. Comparative analysis of healthcare systems with differing organizational structures offers methodological advantages for identifying system-level factors that optimize care delivery. We performed a qualitative comparison of care delivery models and descriptive analysis of TTI and CPI across two academic medical centers in the United States and the Netherlands, representing distinct healthcare architectures and operational contexts. This international comparison enables hypothesis generation regarding structural, process, and organizational factors that influence time-to-treatment in head and neck cancer care and identifies potentially transferable innovations for optimizing oncology pathways globally.</p>\n\n<p><strong>METHODS: </strong>All newly diagnosed adult patients with mucosal head and neck squamous cell carcinoma (HNSCC) referred for treatment in calendar year 2023 to either treatment site were eligible for inclusion. A structured qualitative comparison of care delivery models was performed using a value-based healthcare framework to assess structural and process characteristics across both treatment sites. Patient, tumor, and treatment characteristics were collected retrospectively. Time-to-treatment interval (TTI) was defined as the number of days between histopathological confirmation of malignancy and treatment initiation. Care Pathway Interval (CPI) was defined as the number of days between first oncology consultation and treatment initiation. Descriptive statistics are reported as median and interquartile range (IQR). Between-group comparisons of TTI and CPI were performed using the Mann-Whitney U test.</p>\n\n<p><strong>RESULTS: </strong>A total of 346 patients were included (Netherlands: n=241; USA: n=105). Patient populations differed significantly in tumor site distribution and stage, with a higher proportion of HPV-positive oropharyngeal carcinomas and Stage IV disease in the United States cohort. The time interval between referral and first appointment was similar in both centers: median 7.0 days (IQR: 3.0–10.0) in the Netherlands versus 7.0 days (IQR: 4.0–14.0) in the United States (p=NS).</p>\n\n<p>Overall TTI and CPI were both significantly shorter in the Netherlands. Median TTI was 29.5 days (IQR: 22.0–41.0) in the Netherlands compared with 40.0 days (IQR: 29.0–52.5) in the United States (p<0.001), representing an 11-day difference. Median CPI was 27.0 days (IQR: 21.0–36.0) in the Netherlands compared with 34.0 days (IQR: 23.0–48.0) in the United States (p=0.003). Table 1 describes differences in care intervals by selected subgroup.</p>\n\n<p><strong>CONCLUSION & DISCUSSION: </strong>Transatlantic comparison of care delivery models identifies distinct structural and organizational factors associated with differences in time-to-treatment intervals. While the clinical significance of an 11-day reduction in TTI remains to be determined, these findings generate hypotheses regarding system-level interventions—including centralized referrals, routine frailty screening, and outcome transparency—that warrant prospective investigation. International benchmarking of care pathways offers a valuable approach to identifying and testing innovations that may improve efficiency and outcomes in head and neck cancer treatment.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154509/Screenshot%202025-12-05%20at%204_17_34%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154509--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S292",
      "content_id": "154447",
      "abstract_number": "S292",
      "poster_number": "",
      "title": "Economic Advantage of Supracricoid Laryngectomy Over Chemoradiotherapy: A Cost-Effectiveness Analysis in Intermediate-Stage Laryngeal Cancer",
      "summary": "Supracricoid laryngectomy with CHEP demonstrates superior cost-effectiveness compared to chemoradiotherapy for intermediate-stage laryngeal squamous cell carcinoma, achieving better locoregional control at lower overall costs. These findings support consideration of CHEP as a preferred treatment modality for appropriately selected patients with T2/T3 laryngeal cancer in resource-conscious healthcare systems.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154447",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marcelo S Schalch, MD",
      "presenter": "Marcelo S Schalch, MD",
      "authors": "Marcelo S Schalch, MD 1 ; Daniel M Ramos, MD 2 ; Leandro L de Matos, PhD, MD 2 ; Bruno P Duarte, Mr 3 ; Rogério Aparecido Dedivitis, PhD, MD 4",
      "normalized_authors": [
        "Marcelo S Schalch",
        "Daniel M Ramos",
        "Leandro L de Matos",
        "Bruno P Duarte, Mr",
        "Rogério Aparecido Dedivitis"
      ],
      "affiliations": [
        "Instituto do câncer Doutor Arnaldo Vieira de Carvalho, Sao Paulo, Brazil",
        "Instituto do Câncer do Estado de São Paulo (ICESP), Sao Paulo, Brazil",
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "University of São Paulo School of Medicine, São Paulo, Brazil"
      ],
      "normalized_institutions": [
        "Instituto do câncer Doutor Arnaldo Vieira de Carvalho, Sao Paulo, Brazil",
        "Instituto do Câncer do Estado de São Paulo (ICESP), Sao Paulo, Brazil",
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "University of São Paulo School of Medicine, São Paulo, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 260,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Marcelo S Schalch, MD 1 ; Daniel M Ramos, MD 2 ; Leandro L de Matos, PhD, MD 2 ; Bruno P Duarte, Mr 3 ; Rogério Aparecido Dedivitis, PhD, MD 4",
        "Affiliations": "1 Instituto do câncer Doutor Arnaldo Vieira de Carvalho, Sao Paulo, Brazil; 2 Instituto do Câncer do Estado de São Paulo (ICESP), Sao Paulo, Brazil; 3 School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; 4 University of São Paulo School of Medicine, São Paulo, Brazil",
        "Background": "Treatment decision-making for intermediate-stage laryngeal cancer requires consideration of both oncologic outcomes and economic burden. While both surgical and non-surgical approaches offer organ preservation potential, comprehensive cost-effectiveness data comparing supracricoid laryngectomy with cricoidoepiglottopexy (CHEP) to chemoradiotherapy remain scarce in the Brazilian healthcare context.",
        "Objective": "To compare the cost-effectiveness of CHEP versus chemoradiotherapy for T2/T3 laryngeal squamous cell carcinoma, utilizing 2-year overall survival as the primary outcome measure.",
        "Methods": "We conducted a retrospective cost-effectiveness analysis of 66 patients with intermediate-stage laryngeal squamous cell carcinoma treated at a tertiary cancer center between 2010 and 2020. Patients received either chemoradiotherapy (n=45) or CHEP (n=21). Direct medical costs (hospitalization, procedures, medications, imaging, consultations) and indirect costs (productivity loss, transportation) were calculated from diagnosis through 2-year follow-up. Cost-effectiveness ratios were determined by dividing total costs by the number of patients alive at 2 years. Locoregional control rates were compared between groups.",
        "Results": "The mean cost per surviving patient was 12% lower in the surgical cohort compared to the chemoradiotherapy group. The surgical approach demonstrated superior locoregional control, with no recurrences observed in the CHEP group versus a 17% recurrence rate in the chemoradiotherapy cohort. The cost-effectiveness analysis revealed favorable outcomes for surgical management across both direct and indirect cost categories.",
        "Conclusion": "Supracricoid laryngectomy with CHEP demonstrates superior cost-effectiveness compared to chemoradiotherapy for intermediate-stage laryngeal squamous cell carcinoma, achieving better locoregional control at lower overall costs. These findings support consideration of CHEP as a preferred treatment modality for appropriately selected patients with T2/T3 laryngeal cancer in resource-conscious healthcare systems.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Economic Advantage of Supracricoid Laryngectomy Over Chemoradiotherapy: A Cost-Effectiveness Analysis in Intermediate-Stage Laryngeal Cancer</span>. <u>Marcelo S Schalch, MD</u><sup>1</sup>; Daniel M Ramos, MD<sup>2</sup>; Leandro L de Matos, PhD, MD<sup>2</sup>; Bruno P Duarte, Mr<sup>3</sup>; Rogério Aparecido Dedivitis, PhD, MD<sup>4</sup>. <sup>1</sup>Instituto do câncer Doutor Arnaldo Vieira de Carvalho, Sao Paulo, Brazil; <sup>2</sup>Instituto do Câncer do Estado de São Paulo (ICESP), Sao Paulo, Brazil; <sup>3</sup>School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; <sup>4</sup>University of São Paulo School of Medicine, São Paulo, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Treatment decision-making for intermediate-stage laryngeal cancer requires consideration of both oncologic outcomes and economic burden. While both surgical and non-surgical approaches offer organ preservation potential, comprehensive cost-effectiveness data comparing supracricoid laryngectomy with cricoidoepiglottopexy (CHEP) to chemoradiotherapy remain scarce in the Brazilian healthcare context.</p>\n\n<p><strong>Objective:</strong> To compare the cost-effectiveness of CHEP versus chemoradiotherapy for T2/T3 laryngeal squamous cell carcinoma, utilizing 2-year overall survival as the primary outcome measure.</p>\n\n<p><strong>Methods:</strong> We conducted a retrospective cost-effectiveness analysis of 66 patients with intermediate-stage laryngeal squamous cell carcinoma treated at a tertiary cancer center between 2010 and 2020. Patients received either chemoradiotherapy (n=45) or CHEP (n=21). Direct medical costs (hospitalization, procedures, medications, imaging, consultations) and indirect costs (productivity loss, transportation) were calculated from diagnosis through 2-year follow-up. Cost-effectiveness ratios were determined by dividing total costs by the number of patients alive at 2 years. Locoregional control rates were compared between groups.</p>\n\n<p><strong>Results: </strong>The mean cost per surviving patient was 12% lower in the surgical cohort compared to the chemoradiotherapy group. The surgical approach demonstrated superior locoregional control, with no recurrences observed in the CHEP group versus a 17% recurrence rate in the chemoradiotherapy cohort. The cost-effectiveness analysis revealed favorable outcomes for surgical management across both direct and indirect cost categories.</p>\n\n<p><strong>Conclusion:</strong> Supracricoid laryngectomy with CHEP demonstrates superior cost-effectiveness compared to chemoradiotherapy for intermediate-stage laryngeal squamous cell carcinoma, achieving better locoregional control at lower overall costs. These findings support consideration of CHEP as a preferred treatment modality for appropriately selected patients with T2/T3 laryngeal cancer in resource-conscious healthcare systems.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154447--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S293",
      "content_id": "148149",
      "abstract_number": "S293",
      "poster_number": "",
      "title": "A Cost-Effectiveness Analysis of Enhanced Recovery After Surgery Pathways for Head and Neck Free Flap Reconstruction",
      "summary": "ERAS protocols for head and neck free flap reconstruction are highly cost-effective, yielding both substantial cost savings and improved patient-centered outcomes. Importantly, this study is the first to establish, through both economic and quality-of-life measures, that the additional effort required for ERAS implementation yields significant and justified benefits for head and neck free flap patients. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=148149",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ella P Jackert, BS",
      "presenter": "Ella P Jackert, BS",
      "authors": "Ella P Jackert, BS 1 ; Antonio Franco, BS 2 ; Ryan Chung, BS 1 ; Tyler J Gallagher, MD, MPH 3 ; Mark Swanson, MD 4 ; Albert Y Han, MD, PhD 3 ; Niels C Kokot, MD 3",
      "normalized_authors": [
        "Ella P Jackert",
        "Antonio Franco",
        "Ryan Chung",
        "Tyler J Gallagher",
        "Mark Swanson",
        "Albert Y Han",
        "Niels C Kokot"
      ],
      "affiliations": [
        "Keck School of Medicine of USC",
        "California University of Science and Medicine",
        "USC Caruso Department of Otolaryngology - Head and Neck Surgery",
        "Department of Otolaryngology-Head and Neck Surgery, UC Irvine School of Medicine"
      ],
      "normalized_institutions": [
        "Keck School of Medicine of USC",
        "California University of Science and Medicine",
        "USC Caruso Department of Otolaryngology - Head and Neck Surgery",
        "Department of Otolaryngology-Head and Neck Surgery, UC Irvine School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 354,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ella P Jackert, BS 1 ; Antonio Franco, BS 2 ; Ryan Chung, BS 1 ; Tyler J Gallagher, MD, MPH 3 ; Mark Swanson, MD 4 ; Albert Y Han, MD, PhD 3 ; Niels C Kokot, MD 3",
        "Affiliations": "1 Keck School of Medicine of USC; 2 California University of Science and Medicine; 3 USC Caruso Department of Otolaryngology - Head and Neck Surgery; 4 Department of Otolaryngology-Head and Neck Surgery, UC Irvine School of Medicine",
        "Introduction": "Enhanced Recovery After Surgery (ERAS) protocols have been increasingly adopted across surgical disciplines to reduce perioperative complications, shorten hospital stays, and improve outcomes. However, their cost-effectiveness in head and neck free flap reconstruction remains incompletely understood. As head and neck oncologic surgeries are resource-intensive and associated with significant postopwheerative morbidity, assessing the economic and clinical utility of ERAS is critical for optimizing patient care and resource allocation.",
        "Methods": "A decision tree model reflecting patient health states during and after hospitalization for head and neck free flap surgery with ERAS versus non-ERAS (standard) protocols was constructed. This framework was operationalized as a 30-day Markov model in which patients cycled through health states. Base case analysis was performed to estimate costs and outcomes, expressed as quality-adjusted days (QADs). Incremental cost-effectiveness ratios (ICERs) were calculated to compare ERAS to standard protocols. Deterministic sensitivity analyses assessed model robustness to parameter variation, while probabilistic sensitivity analyses explored uncertainty across multiple model inputs.",
        "Results": "On base case analysis, the average total cost of free flap reconstruction with ERAS protocol was $79,795.98 with an associated 21.47 QADs. Standard protocol averaged $88,450.14 with 18.96 QADs, thus ERAS implementation reduced costs by $8,654.16 and improved outcomes by 2.51 QADs. The ICER for ERAS compared with standard care was -$3458.17 per QAD gained, indicating dominance of the ERAS protocol. Sensitivity analysis identified intraoperative costs as the most influential parameter, but ERAS remained cost-effective across all tested ranges. Probabilistic sensitivity analysis confirmed that ERAS was cost-effective in 100% of simulations at a willingness-to-pay threshold of at least $10,000 per QAD.",
        "Conclusion": "ERAS protocols for head and neck free flap reconstruction are highly cost-effective, yielding both substantial cost savings and improved patient-centered outcomes. Importantly, this study is the first to establish, through both economic and quality-of-life measures, that the additional effort required for ERAS implementation yields significant and justified benefits for head and neck free flap patients. These findings strongly support routine adoption of ERAS pathways in head and neck free flap surgery to optimize healthcare resource utilization and enhance recovery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Cost-Effectiveness Analysis of Enhanced Recovery After Surgery Pathways for Head and Neck Free Flap Reconstruction</span>. <u>Ella P Jackert, BS</u><sup>1</sup>; Antonio Franco, BS<sup>2</sup>; Ryan Chung, BS<sup>1</sup>; Tyler J Gallagher, MD, MPH<sup>3</sup>; Mark Swanson, MD<sup>4</sup>; Albert Y Han, MD, PhD<sup>3</sup>; Niels C Kokot, MD<sup>3</sup>. <sup>1</sup>Keck School of Medicine of USC; <sup>2</sup>California University of Science and Medicine; <sup>3</sup>USC Caruso Department of Otolaryngology - Head and Neck Surgery; <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, UC Irvine School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Enhanced Recovery After Surgery (ERAS) protocols have been increasingly adopted across surgical disciplines to reduce perioperative complications, shorten hospital stays, and improve outcomes. However, their cost-effectiveness in head and neck free flap reconstruction remains incompletely understood. As head and neck oncologic surgeries are resource-intensive and associated with significant postopwheerative morbidity, assessing the economic and clinical utility of ERAS is critical for optimizing patient care and resource allocation.</p>\n\n<p><strong>Methods: </strong>A decision tree model reflecting patient health states during and after hospitalization for head and neck free flap surgery with ERAS versus non-ERAS (standard) protocols was constructed. This framework was operationalized as a 30-day Markov model in which patients cycled through health states. Base case analysis was performed to estimate costs and outcomes, expressed as quality-adjusted days (QADs). Incremental cost-effectiveness ratios (ICERs) were calculated to compare ERAS to standard protocols. Deterministic sensitivity analyses assessed model robustness to parameter variation, while probabilistic sensitivity analyses explored uncertainty across multiple model inputs.</p>\n\n<p><strong>Results:</strong> On base case analysis, the average total cost of free flap reconstruction with ERAS protocol was $79,795.98 with an associated 21.47 QADs. Standard protocol averaged $88,450.14 with 18.96 QADs, thus ERAS implementation reduced costs by $8,654.16 and improved outcomes by 2.51 QADs. The ICER for ERAS compared with standard care was  -$3458.17 per QAD gained, indicating dominance of the ERAS protocol. Sensitivity analysis identified intraoperative costs as the most influential parameter, but ERAS remained cost-effective across all tested ranges. Probabilistic sensitivity analysis confirmed that ERAS was cost-effective in 100% of simulations at a willingness-to-pay threshold of at least $10,000 per QAD.</p>\n\n<p><strong>Conclusion:</strong> ERAS protocols for head and neck free flap reconstruction are highly cost-effective, yielding both substantial cost savings and improved patient-centered outcomes. Importantly, this study is the first to establish, through both economic and quality-of-life measures, that the additional effort required for ERAS implementation yields significant and justified benefits for head and neck free flap patients. These findings strongly support routine adoption of ERAS pathways in head and neck free flap surgery to optimize healthcare resource utilization and enhance recovery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 148149--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S294",
      "content_id": "153571",
      "abstract_number": "S294",
      "poster_number": "",
      "title": "Comparative Cost Analysis of Anterolateral Thigh Fascia Lata Rescue Flaps Versus Fibula Free Flaps in the Management of Mandibular Osteoradionecrosis",
      "summary": "Osteoradionecrosis (ORN) of the mandible remains a devastating complication of radiotherapy to the head and neck, often requiring vascularized tissue reconstruction. Fibula free flaps (FFF) are the standard of care for advanced disease but are associated with intense resource utilization and long hospital stays. Recent reports have suggested that the anterolateral thigh fascia lata (ALTFL) rescue flap can prevent...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153571",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kyle Polen, BS",
      "presenter": "Kyle Polen, BS",
      "authors": "Kyle Polen, BS 1 ; Kerol Faltas, BA 1 ; Steven B Cannady, MD 2 ; James C Gates, DMD, MD 3 ; Robert M Brody, MD 2",
      "normalized_authors": [
        "Kyle Polen",
        "Kerol Faltas",
        "Steven B Cannady",
        "James C Gates",
        "Robert M Brody"
      ],
      "affiliations": [
        "Perelman School of Medicine, University of Pennsylvania",
        "Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System",
        "Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Perelman School of Medicine, University of Pennsylvania",
        "Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System",
        "Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153571/orn%20comparative%20cost%20fig1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153571/orn%20comparative%20cost%20fig1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153571"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kyle Polen, BS 1 ; Kerol Faltas, BA 1 ; Steven B Cannady, MD 2 ; James C Gates, DMD, MD 3 ; Robert M Brody, MD 2",
        "Affiliations": "1 Perelman School of Medicine, University of Pennsylvania; 2 Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System; 3 Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania",
        "Abstract": "Osteoradionecrosis (ORN) of the mandible remains a devastating complication of radiotherapy to the head and neck, often requiring vascularized tissue reconstruction. Fibula free flaps (FFF) are the standard of care for advanced disease but are associated with intense resource utilization and long hospital stays. Recent reports have suggested that the anterolateral thigh fascia lata (ALTFL) rescue flap can prevent further disease progression in select patients with lower morbidity; however, the comparative economics of these different approaches have yet to be characterized. This preliminary analysis aimed to model the cost implications of ALTFL versus FFF reconstruction using publicly available data as an initial framework for subsequent analyses using institutional billing datasets, hypothesizing that ALTFL rescue flaps would yield lower expected costs. A comparative model was created to reflect a 90-day period, encompassing the cost of the initial surgery, hospital stay, and early postoperative complications from a U.S. Medicare payer perspective. A decision tree was built to estimate the expected cost for each approach, calculating the sum of the base cost of surgery, hospitalization, and complications weighted by frequency. Clinical data such as length of stay (2.7 days for ALTFL vs 24–27 days for FFF), major complication rates including OR takeback (1.9% vs 29.5%), and other sequelae were obtained from published series. Cost information came from values reported in the literature and time-driven activity-based cost studies scaled by length of stay, the most significant independent predictor of overall financial burden. All dollar values reflect modeled estimates derived from published data; no Medicare reimbursement rates or institutional billing data were directly used. Our model demonstrated that ALTFL rescue flaps had markedly lower expected costs compared to FFF reconstruction. The base episode cost for ALTFL was roughly one-third that of FFF ($12,000–$18,000 vs $40,000–$65,000). When incorporating probabilities of complications, the expected cost range for ALTFL remained substantially below FFF ($14,800–$24,000 vs $52,000–$79,000) (Figure 1). These preliminary findings support the hypothesis that ALTFL rescue flaps may confer lower costs than FFF, driven mostly by shorter length of stay and fewer complications. This analysis represents an illustrative, exploratory model rather than definitive pricing which can vary greatly by institution and case. Reported ALTFL series include carefully selected patients which limits generalizability, and this model does not account for costs related to adjuvant hyperbaric oxygen therapy or long-term complications. Future analyses will incorporate patient-level and institutional realized costs to bolster these estimates. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Cost Analysis of Anterolateral Thigh Fascia Lata Rescue Flaps Versus Fibula Free Flaps in the Management of Mandibular Osteoradionecrosis</span>. <u>Kyle Polen, BS</u><sup>1</sup>; Kerol Faltas, BA<sup>1</sup>; Steven B Cannady, MD<sup>2</sup>; James C Gates, DMD, MD<sup>3</sup>; Robert M Brody, MD<sup>2</sup>. <sup>1</sup>Perelman School of Medicine, University of Pennsylvania; <sup>2</sup>Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System; <sup>3</sup>Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Osteoradionecrosis (ORN) of the mandible remains a devastating complication of radiotherapy to the head and neck, often requiring vascularized tissue reconstruction. Fibula free flaps (FFF) are the standard of care for advanced disease but are associated with intense resource utilization and long hospital stays. Recent reports have suggested that the anterolateral thigh fascia lata (ALTFL) rescue flap can prevent further disease progression in select patients with lower morbidity; however, the comparative economics of these different approaches have yet to be characterized. This preliminary analysis aimed to model the cost implications of ALTFL versus FFF reconstruction using publicly available data as an initial framework for subsequent analyses using institutional billing datasets, hypothesizing that ALTFL rescue flaps would yield lower expected costs.</p>\n\n<p>A comparative model was created to reflect a 90-day period, encompassing the cost of the initial surgery, hospital stay, and early postoperative complications from a U.S. Medicare payer perspective. A decision tree was built to estimate the expected cost for each approach, calculating the sum of the base cost of surgery, hospitalization, and complications weighted by frequency. Clinical data such as length of stay (2.7 days for ALTFL vs 24–27 days for FFF), major complication rates including OR takeback (1.9% vs 29.5%), and other sequelae were obtained from published series. Cost information came from values reported in the literature and time-driven activity-based cost studies scaled by length of stay, the most significant independent predictor of overall financial burden. All dollar values reflect modeled estimates derived from published data; no Medicare reimbursement rates or institutional billing data were directly used.</p>\n\n<p>Our model demonstrated that ALTFL rescue flaps had markedly lower expected costs compared to FFF reconstruction. The base episode cost for ALTFL was roughly one-third that of FFF ($12,000–$18,000 vs $40,000–$65,000). When incorporating probabilities of complications, the expected cost range for ALTFL remained substantially below FFF ($14,800–$24,000 vs $52,000–$79,000) (Figure 1).</p>\n\n<p>These preliminary findings support the hypothesis that ALTFL rescue flaps may confer lower costs than FFF, driven mostly by shorter length of stay and fewer complications. This analysis represents an illustrative, exploratory model rather than definitive pricing which can vary greatly by institution and case. Reported ALTFL series include carefully selected patients which limits generalizability, and this model does not account for costs related to adjuvant hyperbaric oxygen therapy or long-term complications. Future analyses will incorporate patient-level and institutional realized costs to bolster these estimates.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153571/orn%20comparative%20cost%20fig1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153571--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S295",
      "content_id": "154398",
      "abstract_number": "S295",
      "poster_number": "",
      "title": "Feasibility, Safety, and Resource Utilization of Outpatient Neck Dissection for Head and Neck Cancer",
      "summary": "The findings of this study support that neck dissections performed in an outpatient setting are both feasible and safe. Complication rates are comparable to neck dissections performed on an inpatient basis. These findings suggest a promising avenue for meaningful reduction in inpatient hospital resource utilization.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154398",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Levi G Ledgerwood, MD",
      "presenter": "Levi G Ledgerwood, MD",
      "authors": "Levi G Ledgerwood, MD 1 ; Shannon M Poti, MD 1 ; Thomas R O'Toole, MD 1 ; Lue-Yen Tucker 2",
      "normalized_authors": [
        "Levi G Ledgerwood",
        "Shannon M Poti",
        "Thomas R O'Toole",
        "Lue-Yen Tucker"
      ],
      "affiliations": [
        "Kaiser Permanente South Sacramento",
        "Kaiser Permanente Division of Research"
      ],
      "normalized_institutions": [
        "Kaiser Permanente South Sacramento",
        "Kaiser Permanente Division of Research"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 405,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Levi G Ledgerwood, MD 1 ; Shannon M Poti, MD 1 ; Thomas R O'Toole, MD 1 ; Lue-Yen Tucker 2",
        "Affiliations": "1 Kaiser Permanente South Sacramento; 2 Kaiser Permanente Division of Research",
        "Background": "Cervical lymphadenectomy (neck dissection) is a cornerstone in the management of head and neck cancer, traditionally performed with at least one overnight hospital stay for postoperative monitoring. With increasing pressure to reduce healthcare costs, enhance patient experience, and optimize inpatient resource utilization, there has been growing interest in shifting appropriate surgical procedures to the ambulatory setting. Limited data exists on the safety and outcomes of performing neck dissections on an outpatient basis. This study evaluates the safety, feasibility, perioperative outcomes, and complication rates associated with outpatient neck dissection in a contemporary head and neck cancer cohort.",
        "Methods": "We conducted a retrospective review of 2631 patients undergoing selective or modified radical neck dissection for biopsy-proven head and neck malignancies in Kaiser Northern California hospitals between 2012 and 2023. Consecutive cases performed in an ambulatory surgery setting were included and compared with a matched inpatient cohort across multiple Northern California Kaiser Permanente hospitals. Demographic data was compared across both groups across multiple measures including tumor stage, Charlson Comorbidity Index, Comorbidity Point Score version 2 (COPS2) and multiple individual conditions. Outcomes assessed included patient demographics, operative characteristics, unplanned admissions, post-operative complications, emergency department (ED) visits, readmissions, unplanned reoperations, and drain management.",
        "Results": "A total of 720 patients underwent outpatient neck dissection and 1911 patients underwent inpatient neck dissections during the study period, with a mean age of 63 years for outpatient and 65 for inpatient groups, respectively. No significant differences were noted between the two groups in COPS2 or Charlson Comorbidity Index scores. Average length of stay for the inpatient group was two hospital days. Post-operative complications including hematoma, seroma, and surgical site infection were seen in comparable numbers between both groups (5.1% in outpatient and 6.0% in inpatient groups, p =0.42). ED visits were seen to be lower in the outpatient neck dissection group (13.9% versus 17.3% in the inpatient group, p =0.03). Reoperation rates were also low and not different between the two groups (0.7% outpatient versus 1.4% inpatient, p =0.16). Peri-operative mortality was also very low in both groups and similar (0.3% in both groups).",
        "Conclusion": "The findings of this study support that neck dissections performed in an outpatient setting are both feasible and safe. Complication rates are comparable to neck dissections performed on an inpatient basis. These findings suggest a promising avenue for meaningful reduction in inpatient hospital resource utilization.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Feasibility, Safety, and Resource Utilization of Outpatient Neck Dissection for Head and Neck Cancer</span>. <u>Levi G Ledgerwood, MD</u><sup>1</sup>; Shannon M Poti, MD<sup>1</sup>; Thomas R O'Toole, MD<sup>1</sup>; Lue-Yen Tucker<sup>2</sup>. <sup>1</sup>Kaiser Permanente South Sacramento; <sup>2</sup>Kaiser Permanente Division of Research<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cervical lymphadenectomy (neck dissection) is a cornerstone in the management of head and neck cancer, traditionally performed with at least one overnight hospital stay for postoperative monitoring. With increasing pressure to reduce healthcare costs, enhance patient experience, and optimize inpatient resource utilization, there has been growing interest in shifting appropriate surgical procedures to the ambulatory setting. Limited data exists on the safety and outcomes of performing neck dissections on an outpatient basis. This study evaluates the safety, feasibility, perioperative outcomes, and complication rates associated with outpatient neck dissection in a contemporary head and neck cancer cohort.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective review of 2631 patients undergoing selective or modified radical neck dissection for biopsy-proven head and neck malignancies in Kaiser Northern California hospitals between 2012 and 2023. Consecutive cases performed in an ambulatory surgery setting were included and compared with a matched inpatient cohort across multiple Northern California Kaiser Permanente hospitals. Demographic data was compared across both groups across multiple measures including tumor stage, Charlson Comorbidity Index, Comorbidity Point Score version 2 (COPS2) and multiple individual conditions. Outcomes assessed included patient demographics, operative characteristics, unplanned admissions, post-operative complications, emergency department (ED) visits, readmissions, unplanned reoperations, and drain management.</p>\n\n<p><strong>Results: </strong>A total of 720 patients underwent outpatient neck dissection and 1911 patients underwent inpatient neck dissections during the study period, with a mean age of 63 years for outpatient and 65 for inpatient groups, respectively. No significant differences were noted between the two groups in COPS2 or Charlson Comorbidity Index scores. Average length of stay for the inpatient group was two hospital days. Post-operative complications including hematoma, seroma, and surgical site infection were seen in comparable numbers between both groups (5.1% in outpatient and 6.0% in inpatient groups, <em>p</em>=0.42).  ED visits were seen to be lower in the outpatient neck dissection group (13.9% versus 17.3% in the inpatient group, <em>p</em>=0.03). Reoperation rates were also low and not different between the two groups (0.7% outpatient versus 1.4% inpatient, <em>p</em>=0.16). Peri-operative mortality was also very low in both groups and similar (0.3% in both groups).</p>\n\n<p><strong>Conclusion: </strong>The findings of this study support that neck dissections performed in an outpatient setting are both feasible and safe. Complication rates are comparable to neck dissections performed on an inpatient basis. These findings suggest a promising avenue for meaningful reduction in inpatient hospital resource utilization.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154398--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S296",
      "content_id": "153978",
      "abstract_number": "S296",
      "poster_number": "",
      "title": "Medicaid Expansion and Treatment Patterns in Nasopharyngeal Carcinoma: A National Difference-in-Differences Analysis",
      "summary": "In this national NPC cohort, Medicaid expansion did not produce a statistically significant DiD increase in CCRT use, time to RT, or IMRT adoption, despite expansion-state residence being independently associated with higher CCRT use overall. However, Medicaid expansion was associated with modestly improved overall survival. Exploratory findings suggest that gains in CCRT utilization with expansion may have been...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153978",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260137",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sohil Singh, BS",
      "presenter": "Sohil Singh, BS",
      "authors": "Sohil Singh, BS ; Johnny R Belcher, BA; Deniz C Demircioglu, BS; Musaddiq Awan, MD",
      "normalized_authors": [
        "Sohil Singh",
        "Johnny R Belcher",
        "Deniz C Demircioglu",
        "Musaddiq Awan"
      ],
      "affiliations": [
        "Medical College of Wisconsin"
      ],
      "normalized_institutions": [
        "Medical College of Wisconsin"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 546,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sohil Singh, BS ; Johnny R Belcher, BA; Deniz C Demircioglu, BS; Musaddiq Awan, MD",
        "Affiliations": "Medical College of Wisconsin",
        "Background": "Concurrent chemoradiotherapy (CCRT) is standard for stage II-IV nasopharyngeal carcinoma (NPC), but whether the Affordable Care Act Medicaid expansion changed real-world CCRT delivery or outcomes is unknown.",
        "Methods": "Using the 2023 National Cancer Database Nasopharynx Participant User File, we identified adults ≥40 years with stage II-IV, M0 NPC diagnosed 2004-2019, excluding 2014 as a wash-in year and non-analytic cases. Medicaid expansion exposure was defined at the state level (expansion vs non-expansion) and time as Pre (2004-2013) vs Post (2015-2019). The primary outcome was CCRT, defined as radiotherapy with chemotherapy initiation within 14 days. Due to limitations of the database, we excluded patients who may have received induction chemoradiotherapy, defined as chemotherapy starting more than 14 days prior to radiotherapy (RT). Secondary outcomes were time to RT start, IMRT use, and overall survival (OS). We used difference-in-differences (DiD) models with expansion×period interaction, adjusting for age, sex, race, Hispanic origin, WHO histology, stage, comorbidity, primary site, distance, and year, with facility-clustered robust standard errors. We also fit a multivariable logistic model for predictors of CCRT and exploratory DiD-in-differences (DDD) models by race.",
        "Results": "The CCRT analysis cohort comprised 4,013 patients, of whom 57% received CCRT. CCRT use increased over time in both groups (expansion states: 56.6% Pre to 66.1% Post; non-expansion: 43.8% to 51.4%), but the adjusted DiD interaction showed no statistically significant expansion-related change in CCRT use (logistic DiD OR 1.13, 95% CI 0.65-1.98, p=0.66). DiD models similarly showed no significant effect of expansion on time to RT (β -4.7 days, 95% CI -18.0 to +8.6, p=0.50) or IMRT use (DiD OR 1.04, 95% CI 0.65-1.66, p=0.87).",
        "Abstract": "In a multivariable logistic model without the DiD interaction, residence in an expansion state was independently associated with higher odds of receiving CCRT (OR 1.67, 95% CI 1.13-2.47, p=0.009). Black patients had lower adjusted odds of CCRT compared with White patients (OR 0.74, 95% CI 0.56-0.98, p=0.033). The OS analysis included 4,010 patients (2,065 deaths). In a Cox difference-in-differences model, the Medicaid expansion×period interaction was associated with improved survival (HR 0.87, 95% CI 0.75-0.996, p=0.044), meaning that from the pre- to post-expansion era, the mortality hazard fell 13% more in expansion states than in non-expansion states, beyond overall time trends. Consistently, a Cox model by four groups showed that patients in expansion states in the Post period had better survival than those in non-expansion states in the Pre period (HR 0.76, 95% CI 0.66-0.86, p<0.001). In exploratory DDD models, the expansion-associated change in CCRT appeared smaller among Black vs White patients (interaction OR 0.59, 95% CI 0.44-0.80). View in Agenda and Add to Schedule",
        "Conclusions": "In this national NPC cohort, Medicaid expansion did not produce a statistically significant DiD increase in CCRT use, time to RT, or IMRT adoption, despite expansion-state residence being independently associated with higher CCRT use overall. However, Medicaid expansion was associated with modestly improved overall survival. Exploratory findings suggest that gains in CCRT utilization with expansion may have been attenuated among Black patients, warranting further investigation into persistent inequities in treatment intensity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Medicaid Expansion and Treatment Patterns in Nasopharyngeal Carcinoma: A National Difference-in-Differences Analysis</span>. <u>Sohil Singh, BS</u>; Johnny R Belcher, BA; Deniz C Demircioglu, BS; Musaddiq Awan, MD. Medical College of Wisconsin<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Concurrent chemoradiotherapy (CCRT) is standard for stage II-IV nasopharyngeal carcinoma (NPC), but whether the Affordable Care Act Medicaid expansion changed real-world CCRT delivery or outcomes is unknown.</p>\n\n<p><strong>Methods: </strong>Using the 2023 National Cancer Database Nasopharynx Participant User File, we identified adults ≥40 years with stage II-IV, M0 NPC diagnosed 2004-2019, excluding 2014 as a wash-in year and non-analytic cases. Medicaid expansion exposure was defined at the state level (expansion vs non-expansion) and time as Pre (2004-2013) vs Post (2015-2019). The primary outcome was CCRT, defined as radiotherapy with chemotherapy initiation within 14 days. Due to limitations of the database, we excluded patients who may have received induction chemoradiotherapy, defined as chemotherapy starting more than 14 days prior to radiotherapy (RT). Secondary outcomes were time to RT start, IMRT use, and overall survival (OS). We used difference-in-differences (DiD) models with expansion×period interaction, adjusting for age, sex, race, Hispanic origin, WHO histology, stage, comorbidity, primary site, distance, and year, with facility-clustered robust standard errors. We also fit a multivariable logistic model for predictors of CCRT and exploratory DiD-in-differences (DDD) models by race.</p>\n\n<p><strong>Results: </strong>The CCRT analysis cohort comprised 4,013 patients, of whom 57% received CCRT. CCRT use increased over time in both groups (expansion states: 56.6% Pre to 66.1% Post; non-expansion: 43.8% to 51.4%), but the adjusted DiD interaction showed no statistically significant expansion-related change in CCRT use (logistic DiD OR 1.13, 95% CI 0.65-1.98, p=0.66). DiD models similarly showed no significant effect of expansion on time to RT (β -4.7 days, 95% CI -18.0 to +8.6, p=0.50) or IMRT use (DiD OR 1.04, 95% CI 0.65-1.66, p=0.87).</p>\n\n<p>In a multivariable logistic model without the DiD interaction, residence in an expansion state was independently associated with higher odds of receiving CCRT (OR 1.67, 95% CI 1.13-2.47, p=0.009). Black patients had lower adjusted odds of CCRT compared with White patients (OR 0.74, 95% CI 0.56-0.98, p=0.033).</p>\n\n<p>The OS analysis included 4,010 patients (2,065 deaths). In a Cox difference-in-differences model, the Medicaid expansion×period interaction was associated with improved survival (HR 0.87, 95% CI 0.75-0.996, p=0.044), meaning that from the pre- to post-expansion era, the mortality hazard fell 13% more in expansion states than in non-expansion states, beyond overall time trends. Consistently, a Cox model by four groups showed that patients in expansion states in the Post period had better survival than those in non-expansion states in the Pre period (HR 0.76, 95% CI 0.66-0.86, p<0.001). In exploratory DDD models, the expansion-associated change in CCRT appeared smaller among Black vs White patients (interaction OR 0.59, 95% CI 0.44-0.80).</p>\n\n<p><strong>Conclusions: </strong>In this national NPC cohort, Medicaid expansion did not produce a statistically significant DiD increase in CCRT use, time to RT, or IMRT adoption, despite expansion-state residence being independently associated with higher CCRT use overall. However, Medicaid expansion was associated with modestly improved overall survival. Exploratory findings suggest that gains in CCRT utilization with expansion may have been attenuated among Black patients, warranting further investigation into persistent inequities in treatment intensity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153978--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260137' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S297",
      "content_id": "154487",
      "abstract_number": "S297",
      "poster_number": "",
      "title": "Impact of AI-Avatar Based Digital Patient Engagement on Treatment Understanding, Empowerment and Stress for HNSCC in a US Community Radiation Oncology Practice",
      "summary": "1,464 pts overall completed our pre-consultation digital engagement, teach-back quiz and survey for mutliple disease sites. Of those, 88 pts with HNSCC received either an ASTRO stock educational video (#12) or a digital avatar-based video (#76) that used personalized scripts and illustrations, which could be updated as clinically needed. Digital Teach back scores were collected for the entire cohort and the HN pt...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154487",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Adam Raben, MD",
      "presenter": "Adam Raben, MD",
      "authors": "Adam Raben, MD 1 ; Lindsey Romak, MD 1 ; Jon Strasser, MD 1 ; Gaurav Shukla, MD 1 ; Navroze Eduljee 2",
      "normalized_authors": [
        "Adam Raben",
        "Lindsey Romak",
        "Jon Strasser",
        "Gaurav Shukla",
        "Navroze Eduljee"
      ],
      "affiliations": [
        "Helen F. Graham Cancer Center",
        "5th Port"
      ],
      "normalized_institutions": [
        "Helen F. Graham Cancer Center",
        "5th Port"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 489,
      "section_labels": [
        "Authors",
        "Affiliations",
        "PURPOSE",
        "Methods",
        "Abstract"
      ],
      "sections": {
        "Authors": "Adam Raben, MD 1 ; Lindsey Romak, MD 1 ; Jon Strasser, MD 1 ; Gaurav Shukla, MD 1 ; Navroze Eduljee 2",
        "Affiliations": "1 Helen F. Graham Cancer Center; 2 5th Port",
        "PURPOSE": "The diagnosis of cancer and complexity of treatment choices, especially radiation therapy for head and neck cancer, lead to patients facing difficult decisions under duress that may impact their outcomes. Despite intensified focus on patient education, the decline of engagement between pts and their doctors has contributed to a decline in pt-reported teach back and satisfaction scores in our community-based cancer patient. The evolution of AI capabilities led us to explore the efficacy of multimedia “first-touch” digital engagement using AI-generated avatars in the likeness and voice of our physicians. Our hypothesis was that digital engagement prior to their initial consultation, and confirming their comprehension with a teach back quiz, would improve patient understanding, empower them to actively participate in their treatment decisions reduce their stress, and improve mandated patient satisfaction scores.",
        "Methods": "We initially collaborated with ASTRO to use their existing patient education video library, and subsequently transitioned to a private patient engagement company, to create physician specific AI-avatar based pre-consultation digital engagement materials about radiation treatment options. We assessed pt comprehension via digital teach back quizzes and collected pt reported satisfaction scores. We evaluated both digital experiences comparing both methods in terms of the metrics outlined, as well as hospital pt satisfaction scores before and after the introduction of digital engagement at 1 year.",
        "Abstract": "1,464 pts overall completed our pre-consultation digital engagement, teach-back quiz and survey for mutliple disease sites. Of those, 88 pts with HNSCC received either an ASTRO stock educational video (#12) or a digital avatar-based video (#76) that used personalized scripts and illustrations, which could be updated as clinically needed. Digital Teach back scores were collected for the entire cohort and the HN pt cohort as a subset (N= 88 pts). Overall, Statistically significant improvements were found in pt understanding (p<.001), video empowerment (p<.001) and reduced stress (p<.001) for pts who received the personalized AI avatar videos versus the ASTRO video. In the HN cohort, The Avatar engagement also improved hospital based standardized assessment of pt satisfaction scores in the HN cohort, compared to pre-digital engagement. (understanding: 4.61 vs 4.17, Empowerment: 4.6 vs 4.25, and Stress reduction: 4.21 vs 3.83). This was statistically significant for pt understanding only (p<.037). The intial device used by our pts to complete pre-egagement included Desktop (43%), mobile phone(54%), Tablets (2%) and office(10%). To our knowledge we are the first community radiation oncology practice to implement personalized AI avatars to educate pts with HN cancer. Pts participating in our digital first touch pre-engagement, demonstrated significantly better understanding of their treatment protocol, greater empowerment to participate in their healthcare decisions and lower stress than pts who watched the ASTRO videos. Hospital mandated satisfaction score surveys dramatically improved. Furthermore, we demonstrated that pts could immediately provide feedback about their understanding of treatment options. The study has expanded to both pre- and post-treatment engagements View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of AI-Avatar Based Digital Patient Engagement on Treatment Understanding, Empowerment and Stress for HNSCC in a US Community Radiation Oncology Practice</span>. <u>Adam Raben, MD</u><sup>1</sup>; Lindsey Romak, MD<sup>1</sup>; Jon Strasser, MD<sup>1</sup>; Gaurav Shukla, MD<sup>1</sup>; Navroze Eduljee<sup>2</sup>. <sup>1</sup>Helen F. Graham Cancer Center; <sup>2</sup>5th Port<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>PURPOSE: </strong>The diagnosis of cancer and complexity of treatment choices, especially radiation therapy for head and neck cancer, lead to patients facing difficult decisions under duress that may impact their outcomes. Despite intensified focus on patient education, the decline of engagement between pts and their doctors has contributed to a decline in pt-reported teach back and satisfaction scores in our community-based cancer patient. The evolution of AI capabilities led us to explore the efficacy of multimedia “first-touch” digital engagement using AI-generated avatars in the likeness and voice of our physicians. Our hypothesis was that digital engagement prior to their initial consultation, and confirming their comprehension with a teach back quiz, would improve patient understanding, empower them to actively participate in their treatment decisions reduce their stress, and improve mandated patient satisfaction scores.</p>\n\n<p><strong>Methods: </strong>We initially collaborated with ASTRO to use their existing patient education video library, and subsequently transitioned to a private patient engagement company, to create physician specific AI-avatar based pre-consultation digital engagement materials about radiation treatment options.  We assessed pt comprehension via digital teach back quizzes and collected pt reported satisfaction scores.  We evaluated both digital experiences comparing both methods in terms of the metrics outlined, as well as hospital pt satisfaction scores before and after the introduction of digital engagement at 1 year.</p>\n\n<p>1,464 pts overall completed our pre-consultation digital engagement, teach-back quiz and survey for mutliple disease sites. Of those, 88 pts with HNSCC received either an ASTRO stock educational video (#12) or a digital avatar-based video (#76) that used personalized scripts and illustrations, which could be updated as clinically needed. Digital Teach back scores were collected for the entire cohort and the HN pt cohort as a subset (N= 88 pts). Overall, Statistically significant improvements were found in pt understanding (p<.001), video empowerment (p<.001) and reduced stress (p<.001) for pts who received the personalized AI avatar videos versus the ASTRO video. In the HN cohort, The Avatar engagement also improved hospital based standardized assessment of pt satisfaction scores in the HN cohort, compared to pre-digital engagement. (understanding: 4.61 vs 4.17, Empowerment: 4.6 vs 4.25, and Stress reduction: 4.21 vs 3.83).  This was statistically significant for pt understanding only (p<.037). The intial device used by our pts to complete pre-egagement included Desktop (43%), mobile phone(54%), Tablets (2%) and office(10%).</p>\n\n<p>To our knowledge we are the first community radiation oncology practice to implement personalized AI avatars to educate pts with HN cancer. Pts participating in our digital first touch pre-engagement, demonstrated significantly better understanding of their treatment protocol, greater empowerment to participate in their healthcare decisions and lower stress than pts who watched the ASTRO videos. Hospital mandated satisfaction score surveys dramatically improved. Furthermore, we demonstrated that pts could immediately provide feedback about their understanding of treatment options.  The study has expanded to both  pre- and post-treatment engagements</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154487--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S298",
      "content_id": "153487",
      "abstract_number": "S298",
      "poster_number": "",
      "title": "A Qualitative Analysis of Multi-Level Multicomponent Implementation Strategies for Smoking Cessation in Newly-Diagnosed Head and Neck Cancer Patients",
      "summary": "All HNC and TTP providers rated the strategy components favorably and deemed them feasible within their clinic workflows. Modifications in APP training or in the management of competing needs are required. These findings lay the groundwork for an implementation trial evaluating these strategies.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153487",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Marlaine H Frelier, BS",
      "presenter": "Marlaine H Frelier, BS",
      "authors": "Marlaine H Frelier, BS ; Robin Higashi, PhD; Matthew Aschenbrenner, BS; Aimee Israel, MSW, LCSW; David Balis, MD; Sharika Kumar, MD; Cristina Lopez-Roman, PAC; Brittny Tillman, MD; John Truelson, MD; Natalia Swiatowiec, MD; Larry L Myers, MD; Zainab Farzal, MD; Baran D Sumer, MD; Robert Schnoll, PhD; Andrew T Day, MD, MPH",
      "normalized_authors": [
        "Marlaine H Frelier",
        "Robin Higashi",
        "Matthew Aschenbrenner",
        "Aimee Israel, MSW, LCSW",
        "David Balis",
        "Sharika Kumar",
        "Cristina Lopez-Roman, PAC",
        "Brittny Tillman",
        "John Truelson",
        "Natalia Swiatowiec",
        "Larry L Myers",
        "Zainab Farzal",
        "Baran D Sumer",
        "Robert Schnoll",
        "Andrew T Day"
      ],
      "affiliations": [
        "UT Southwestern Medical Center"
      ],
      "normalized_institutions": [
        "UT Southwestern Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153487/Process%20Map%20of%20Smoking%20Cessation%20Strategies(3).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153487/Process%20Map%20of%20Smoking%20Cessation%20Strategies(3).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153487"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Marlaine H Frelier, BS ; Robin Higashi, PhD; Matthew Aschenbrenner, BS; Aimee Israel, MSW, LCSW; David Balis, MD; Sharika Kumar, MD; Cristina Lopez-Roman, PAC; Brittny Tillman, MD; John Truelson, MD; Natalia Swiatowiec, MD; Larry L Myers, MD; Zainab Farzal, MD; Baran D Sumer, MD; Robert Schnoll, PhD; Andrew T Day, MD, MPH",
        "Affiliations": "UT Southwestern Medical Center",
        "Introduction": "Although smoking cessation at the time of a head and neck cancer (HNC) diagnosis is linked to a significant survival benefit, 50-80% of patients continue smoking after diagnosis. Strategies which rapidly facilitate smoking cessation at the time of a HNC diagnosis have not been developed or tested. We designed two evidence-based, patient-informed, multi-level multicomponent implementation strategies to address this gap in care, yet provider-level perspectives about strategy deployment in a head and neck surgical oncology clinic are poorly defined.",
        "Methods": "We conducted a single-center, cross-sectional qualitative study framed by the Practical Robust Implementation and Sustainability Model (PRISM) and the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) models. Semi-structured interviews were conducted from 08/2025 to 11/2025 with providers involved in the multidisciplinary HNC care team at an academic medical center. The interview guide assessed their perspectives on two multi-level implementation strategies (Figure 1). The “enhanced usual care” strategy involves three pre-treatment encounters: 1) social worker-led cessation advice to quit and tobacco treatment program (TTP) referral recommendation at the time of referral to the surgical oncology clinic, 2) nurse and surgeon-led advice to quit, TTP referral, and smoking cessation pharmacotherapy prescription at the first surgical oncology visit, and 3) TTP-led counseling and pharmacotherapy management. The intensive strategy adds 4) advanced practice provider (AAP)-led advice, referral, pharmacotherapy delivery, and competing supportive care needs management (including pain, anxiety, depression, insomnia), and 5,6) two, serial social worker-led visits involving counseling and addressing social determinants of health (including medication coverage). Both strategies leverage scripts for medical assistants (MAs) and nurses to deliver cessation advice and recommend/place pharmacotherapy standing orders. Thematic analysis was performed using NVivo.",
        "Results": "Eighteen providers were enrolled: five HNC surgeons, four tobacco treatment specialists, six nurses and MAs, two social workers, and one APP. The cohort was 78% female and 72% non-Hispanic white, with a median age of 48.5 years (IQR: 40-56) and a median of 9 years (IQR: 4-14) of head and neck surgical oncology practice. Theme 1: Providers unanimously supported both strategies (n=18/18), with only a few (n=4/18) recommending modifications to the intensive strategy’s APP-led component. Specifically, all providers supported the use of scripts, standing pharmacotherapy orders, and all six strategy components. Several providers (n=7/18) valued that the strategies freed up surgeon time in clinic, empowering nurses and MAs to practice at the top of their license. While four providers supported competing supportive care needs screening, they felt pharmacotherapy should not be initiated for these needs, preferring to defer management to palliative supportive care or the relevant specialty. Theme 2: Some providers (n=5/18) cited lack of patient desire to quit as a dominant barrier to abstinence. Providers universally supported the motivational interviewing script, believing it could address this patient-level barrier.",
        "Conclusion": "All HNC and TTP providers rated the strategy components favorably and deemed them feasible within their clinic workflows. Modifications in APP training or in the management of competing needs are required. These findings lay the groundwork for an implementation trial evaluating these strategies.",
        "Abstract": "Figure 1. Process Map of Strategies View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Qualitative Analysis of Multi-Level Multicomponent Implementation Strategies for Smoking Cessation in Newly-Diagnosed Head and Neck Cancer Patients</span>. <u>Marlaine H Frelier, BS</u>; Robin Higashi, PhD; Matthew Aschenbrenner, BS; Aimee Israel, MSW, LCSW; David Balis, MD; Sharika Kumar, MD; Cristina Lopez-Roman, PAC; Brittny Tillman, MD; John Truelson, MD; Natalia Swiatowiec, MD; Larry L Myers, MD; Zainab Farzal, MD; Baran D Sumer, MD; Robert Schnoll, PhD; Andrew T Day, MD, MPH. UT Southwestern Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Although smoking cessation at the time of a head and neck cancer (HNC) diagnosis is linked to a significant survival benefit, 50-80% of patients continue smoking after diagnosis. Strategies which rapidly facilitate smoking cessation at the time of a HNC diagnosis have not been developed or tested. We designed two evidence-based, patient-informed, multi-level multicomponent implementation strategies to address this gap in care, yet provider-level perspectives about strategy deployment in a head and neck surgical oncology clinic are poorly defined. </p>\n\n<p><strong>Methods:</strong> We conducted a single-center, cross-sectional qualitative study framed by the Practical Robust Implementation and Sustainability Model (PRISM) and the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) models. Semi-structured interviews were conducted from 08/2025 to 11/2025 with providers involved in the multidisciplinary HNC care team at an academic medical center. The interview guide assessed their perspectives on two multi-level implementation strategies (Figure 1). The “enhanced usual care” strategy involves three pre-treatment encounters: 1) social worker-led cessation advice to quit and tobacco treatment program (TTP) referral recommendation at the time of referral to the surgical oncology clinic, 2) nurse and surgeon-led advice to quit, TTP referral, and smoking cessation pharmacotherapy prescription at the first surgical oncology visit, and 3) TTP-led counseling and pharmacotherapy management. The intensive strategy adds 4) advanced practice provider (AAP)-led advice, referral, pharmacotherapy delivery, and competing supportive care needs management (including pain, anxiety, depression, insomnia), and 5,6) two, serial social worker-led visits involving counseling and addressing social determinants of health (including medication coverage). Both strategies leverage scripts for medical assistants (MAs) and nurses to deliver cessation advice and recommend/place pharmacotherapy standing orders. Thematic analysis was performed using NVivo. </p>\n\n<p><strong>Results: </strong>Eighteen providers were enrolled: five HNC surgeons, four tobacco treatment specialists, six nurses and MAs, two social workers, and one APP. The cohort was 78% female and 72% non-Hispanic white, with a median age of 48.5 years (IQR: 40-56) and a median of 9 years (IQR: 4-14) of head and neck surgical oncology practice. Theme 1: Providers unanimously supported both strategies (n=18/18), with only a few (n=4/18) recommending modifications to the intensive strategy’s APP-led component. Specifically, all providers supported the use of scripts, standing pharmacotherapy orders, and all six strategy components. Several providers (n=7/18) valued that the strategies freed up surgeon time in clinic, empowering nurses and MAs to practice at the top of their license. While four providers supported competing supportive care needs screening, they felt pharmacotherapy should not be initiated for these needs, preferring to defer management to palliative supportive care or the relevant specialty. Theme 2: Some providers (n=5/18) cited lack of patient desire to quit as a dominant barrier to abstinence. Providers universally supported the motivational interviewing script, believing it could address this patient-level barrier. </p>\n\n<p><strong>Conclusion:</strong> All HNC and TTP providers rated the strategy components favorably and deemed them feasible within their clinic workflows. Modifications in APP training or in the management of competing needs are required. These findings lay the groundwork for an implementation trial evaluating these strategies. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153487/Process%20Map%20of%20Smoking%20Cessation%20Strategies(3).png' /></p>\n\n<p>Figure 1. Process Map of Strategies</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153487--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S299",
      "content_id": "154380",
      "abstract_number": "S299",
      "poster_number": "",
      "title": "Efficacy of Patient Education on Pain Management and Opioid Consumption",
      "summary": "Preoperative patient education regarding pain expectations, the efficacy of nonopioid pain medications and risks associated with opioids, can significantly reduce postoperative opioids consumption in head and neck surgery.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154380",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Andrew Simpson, BS",
      "presenter": "Andrew Simpson, BS",
      "authors": "Andrew Simpson, BS 1 ; Hayes Stancliff 2 ; Veenadhari Kollipara 2 ; Kunal Koka 2 ; Bailey Swaffar 3 ; Caia Hypatia 2 ; Shouhao Zhou, PhD 2 ; Guy Slonimsky, MD 2",
      "normalized_authors": [
        "Andrew Simpson",
        "Hayes Stancliff",
        "Veenadhari Kollipara",
        "Kunal Koka",
        "Bailey Swaffar",
        "Caia Hypatia",
        "Shouhao Zhou",
        "Guy Slonimsky"
      ],
      "affiliations": [
        "West Virginia School of Osteopathic Medicine",
        "Penn State University College of Medicine",
        "Penn State Health"
      ],
      "normalized_institutions": [
        "West Virginia School of Osteopathic Medicine",
        "Penn State University College of Medicine",
        "Penn State Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 402,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Andrew Simpson, BS 1 ; Hayes Stancliff 2 ; Veenadhari Kollipara 2 ; Kunal Koka 2 ; Bailey Swaffar 3 ; Caia Hypatia 2 ; Shouhao Zhou, PhD 2 ; Guy Slonimsky, MD 2",
        "Affiliations": "1 West Virginia School of Osteopathic Medicine; 2 Penn State University College of Medicine; 3 Penn State Health",
        "Objective": "The opioid epidemic continues to be a relevant concern in the United States. Head and neck cancer patients are more likely to be prescribed opioids compared to other cancer patients due to higher incidences of pain. There remains no standardized protocol for implementing preoperative patient education regarding pain management following head and neck surgery. The objective of this prospective study is to evaluate the impact of standardized preoperative patient education—focused on postoperative pain expectations and the role of both opioid and non-opioid analgesics—on postoperative opioid use among patients undergoing head and neck surgery. We aim to develop and implement an evidence-based, standardized counseling protocol within our Head and Neck Surgery preoperative clinic to enhance postoperative pain management and reduce unnecessary opioid exposure.",
        "Methods": "A prospective interventional study was conducted at our institution’s Head and Neck Surgery Clinic. Eligible participants included patients who were > 18 years old, English speaking, and scheduled to undergo head and neck surgery. Exclusion criteria included a known history of opioid use disorder, chronic opioid therapy for preexisting pain, cognitive impairment preventing independent decision-making, or contraindications to acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs). Convenience sampling was used to enroll participants into either an intervention or control group. The control group received standard postoperative pain management care while the interventional group received an educational handout in addition to the standard care, addressing pain expectations and highlighting the efficacy of non-opioid analgesics in postoperative pain management along with the side effects and risks associated with opioids. Data was collected throughout hospital admission and included pain scores, analgesic consumption, and discharged opioid prescriptions. Surveys were completed at a one-week postoperative clinic visit to document pain levels, antibiotic use, and opioid consumption following hospital discharge.",
        "Results": "The study included 152 patients (83 Control; 69 Interventional). On average, interventional patients consumed significantly lower opioid doses with 24.82 MME/24h of opioid medications during hospital admission compared to 28.06 MME/24h in control (p = 0.0012). There were no significant differences between intervention and control groups in surgery types (p = 0.75), in average pain scores during admission (p = 0.86), highest pain scores during admission (p = 0.18), and pain scores upon discharge (p = 0.14).",
        "Conclusions": "Preoperative patient education regarding pain expectations, the efficacy of nonopioid pain medications and risks associated with opioids, can significantly reduce postoperative opioids consumption in head and neck surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy of Patient Education on Pain Management and Opioid Consumption</span>. <u>Andrew Simpson, BS</u><sup>1</sup>; Hayes Stancliff<sup>2</sup>; Veenadhari Kollipara<sup>2</sup>; Kunal Koka<sup>2</sup>; Bailey Swaffar<sup>3</sup>; Caia Hypatia<sup>2</sup>; Shouhao Zhou, PhD<sup>2</sup>; Guy Slonimsky, MD<sup>2</sup>. <sup>1</sup>West Virginia School of Osteopathic Medicine; <sup>2</sup>Penn State University College of Medicine; <sup>3</sup>Penn State Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The opioid epidemic continues to be a relevant concern in the United States. Head and neck cancer patients are more likely to be prescribed opioids compared to other cancer patients due to higher incidences of pain. There remains no standardized protocol for implementing preoperative patient education regarding pain management following head and neck surgery. The objective of this prospective study is to evaluate the impact of standardized preoperative patient education—focused on postoperative pain expectations and the role of both opioid and non-opioid analgesics—on postoperative opioid use among patients undergoing head and neck surgery. We aim to develop and implement an evidence-based, standardized counseling protocol within our Head and Neck Surgery preoperative clinic to enhance postoperative pain management and reduce unnecessary opioid exposure.</p>\n\n<p><strong>Methods: </strong>A prospective interventional study was conducted at our institution’s Head and Neck Surgery Clinic. Eligible participants included patients who were > 18 years old, English speaking, and scheduled to undergo head and neck surgery. Exclusion criteria included a known history of opioid use disorder, chronic opioid therapy for preexisting pain, cognitive impairment preventing independent decision-making, or contraindications to acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs). Convenience sampling was used to enroll participants into either an intervention or control group. The control group received standard postoperative pain management care while the interventional group received an educational handout in addition to the standard care, addressing pain expectations and highlighting the efficacy of non-opioid analgesics in postoperative pain management along with the side effects and risks associated with opioids. Data was collected throughout hospital admission and included pain scores, analgesic consumption, and discharged opioid prescriptions. Surveys were completed at a one-week postoperative clinic visit to document pain levels, antibiotic use, and opioid consumption following hospital discharge.</p>\n\n<p><strong>Results: </strong>The study included 152 patients (83 Control; 69 Interventional). On average, interventional patients consumed significantly lower opioid doses with 24.82 MME/24h of opioid medications during hospital admission compared to 28.06 MME/24h in control (p = 0.0012). There were no significant differences between intervention and control groups in surgery types (p = 0.75), in average pain scores during admission (p = 0.86), highest pain scores during admission (p = 0.18), and pain scores upon discharge (p = 0.14).</p>\n\n<p><strong>Conclusions: </strong>Preoperative patient education regarding pain expectations, the efficacy of nonopioid pain medications and risks associated with opioids, can significantly reduce postoperative opioids consumption in head and neck surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154380--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S300",
      "content_id": "153371",
      "abstract_number": "S300",
      "poster_number": "",
      "title": "The impact of preoperative pain management video education in head and neck free flap patients",
      "summary": "Our study demonstrates positive effects on postoperative pain perception, severity of pain, and average MME per POD with the use of a standardized preoperative pain management video module. This suggests that standardized preoperative pain management tools can be a promising patient driven adjunct to optimize patients’ postoperative pain experience and to assist in decreasing the need for opioids in the immediate...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153371",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mayuri A Yasuda, MD",
      "presenter": "Mayuri A Yasuda, MD",
      "authors": "Mayuri A Yasuda, MD 1 ; Morgan Sandelski, MD 2 ; Amy Wozniak, MS 3 ; Nathaniel Baek, BA 4 ; Bradley Moon, BA 4 ; Carol M Bier-Laning, MD, MBA, FACS 1",
      "normalized_authors": [
        "Mayuri A Yasuda",
        "Morgan Sandelski",
        "Amy Wozniak",
        "Nathaniel Baek",
        "Bradley Moon",
        "Carol M Bier-Laning"
      ],
      "affiliations": [
        "Loyola University Medical Center",
        "Washington University in St. Louis",
        "Loyola University Chicago",
        "Loyola University Chicago Stritch School of Medicine"
      ],
      "normalized_institutions": [
        "Loyola University Medical Center",
        "Washington University in St. Louis",
        "Loyola University Chicago",
        "Loyola University Chicago Stritch School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mayuri A Yasuda, MD 1 ; Morgan Sandelski, MD 2 ; Amy Wozniak, MS 3 ; Nathaniel Baek, BA 4 ; Bradley Moon, BA 4 ; Carol M Bier-Laning, MD, MBA, FACS 1",
        "Affiliations": "1 Loyola University Medical Center; 2 Washington University in St. Louis; 3 Loyola University Chicago; 4 Loyola University Chicago Stritch School of Medicine",
        "Introduction": "Multimodal post-operative pain management is the current standard of care. The otolaryngology Clinical Practice Guidelines (CPG) and Enhanced Recovery After Surgery (ERAS) protocols recommend preoperative discussions with patients about the risks of opioids and benefits of multimodal analgesia. However, ensuring patients receive standardized, accurate opioid-use educational material in the preoperative setting can be challenging. Here we report on the use of a standardized preoperative pain management video and its impact on perception of pain control and opioid use in the postoperative period for patients undergoing free flap reconstruction after head and neck cancer surgery.",
        "Methods": "This was a prospective, randomized control trial conducted at a tertiary care center enlisting patients undergoing free flap reconstruction after ablative head and neck cancer surgery. The control group received routine preoperative pain management counseling, and the intervention group received the same, plus patient-controlled access to a 5-minute video that described postoperative pain management strategies, created for this study based on the recent CPG publication and published ERAS guidelines. Both groups completed the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) validated survey on postoperative day (POD) 1 and POD 3. The APS-POQ-R includes a 3 question sub-scale that addresses perception of pain, in which a higher score indicates better pain perception, and a 2 question sub-scale that addresses pain severity, in which a lower score indicates lower pain severity. The primary endpoint was perception of pain. The secondary endpoint was daily morphine milligram equivalents (MME) during POD 1-3. The study was powered to detect a 4-point difference in the primary outcome, with n=29 per group. ‘Intent to treat’ analysis was performed based on the group to which the patient was originally assigned, regardless of whether the patient watched the video. ‘Per protocol’ analysis regrouped patients into those who watched the video versus those who did not.",
        "Results": "62 patients were included in the study,?31?each to the control and intervention groups. 17 (54.8%) patients in the intervention group watched the video at least once. Patients in the intervention group had, on average, better perception of pain responses on both POD 1 and 3 [25.3 (5.0) vs 22.9 (5.9); and 25.2 (4.4) vs 24.5 (8.2), respectively, p <.1 POD1]. Intervention participants also had better severity of pain responses on both POD 1 and 3 [8.4 (4.2) (5.) vs 10.4 (4.5); and 7.0 (4.2) vs 8.2 (5.1), respectively, p <.1 POD1].",
        "Abstract": "Average MME per POD was less in the intervention group compared to the control group. Sensitivity analysis by ‘per protocol’?results were qualitatively similar. View in Agenda and Add to Schedule",
        "Conclusion": "Our study demonstrates positive effects on postoperative pain perception, severity of pain, and average MME per POD with the use of a standardized preoperative pain management video module. This suggests that standardized preoperative pain management tools can be a promising patient driven adjunct to optimize patients’ postoperative pain experience and to assist in decreasing the need for opioids in the immediate postoperative period, all while addressing provider time demands in a busy head and neck cancer practice."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The impact of preoperative pain management video education in head and neck free flap patients</span>. <u>Mayuri A Yasuda, MD</u><sup>1</sup>; Morgan Sandelski, MD<sup>2</sup>; Amy Wozniak, MS<sup>3</sup>; Nathaniel Baek, BA<sup>4</sup>; Bradley Moon, BA<sup>4</sup>; Carol M Bier-Laning, MD, MBA, FACS<sup>1</sup>. <sup>1</sup>Loyola University Medical Center; <sup>2</sup>Washington University in St. Louis; <sup>3</sup>Loyola University Chicago; <sup>4</sup>Loyola University Chicago Stritch School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Multimodal post-operative pain management is the current standard of care. The otolaryngology Clinical Practice Guidelines (CPG) and Enhanced Recovery After Surgery (ERAS) protocols recommend preoperative discussions with patients about the risks of opioids and benefits of multimodal analgesia. However, ensuring patients receive standardized, accurate opioid-use educational material in the preoperative setting can be challenging. Here we report on the use of a standardized preoperative pain management video and its impact on perception of pain control and opioid use in the postoperative period for patients undergoing free flap reconstruction after head and neck cancer surgery.</p>\n\n<p><strong>Methods: </strong>This was a prospective, randomized control trial conducted at a tertiary care center enlisting patients undergoing free flap reconstruction after ablative head and neck cancer surgery. The control group received routine preoperative pain management counseling, and the intervention group received the same, plus patient-controlled access to a 5-minute video that described postoperative pain management strategies, created for this study based on the recent CPG publication and published ERAS guidelines. Both groups completed the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) validated survey on postoperative day (POD) 1 and POD 3. The APS-POQ-R includes a 3 question sub-scale that addresses perception of pain, in which a higher score indicates better pain perception, and a 2 question sub-scale that addresses pain severity, in which a lower score indicates lower pain severity. The primary endpoint was perception of pain. The secondary endpoint was daily morphine milligram equivalents (MME) during POD 1-3. The study was powered to detect a 4-point difference in the primary outcome, with n=29 per group. ‘Intent to treat’ analysis was performed based on the group to which the patient was originally assigned, regardless of whether the patient watched the video. ‘Per protocol’ analysis regrouped patients into those who watched the video versus those who did not.</p>\n\n<p><strong>Results:</strong> 62 patients were included in the study,?31?each to the control and intervention groups. 17 (54.8%) patients in the intervention group watched the video at least once. Patients in the intervention group had, on average, better perception of pain responses on both POD 1 and 3 [25.3 (5.0) vs 22.9 (5.9); and 25.2 (4.4) vs 24.5 (8.2), respectively, p <.1 POD1]. Intervention participants also had better severity of pain responses on both POD 1 and 3 [8.4 (4.2) (5.) vs 10.4 (4.5); and 7.0 (4.2) vs 8.2 (5.1), respectively, p <.1 POD1].</p>\n\n<p>Average MME per POD was less in the intervention group compared to the control group. Sensitivity analysis by ‘per protocol’?results were qualitatively similar.</p>\n\n<p><strong>Conclusion:</strong> Our study demonstrates positive effects on postoperative pain perception, severity of pain, and average MME per POD with the use of a standardized preoperative pain management video module. This suggests that standardized preoperative pain management tools can be a promising patient driven adjunct to optimize patients’ postoperative pain experience and to assist in decreasing the need for opioids in the immediate postoperative period, all while addressing provider time demands in a busy head and neck cancer practice.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153371--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S301",
      "content_id": "153311",
      "abstract_number": "S301",
      "poster_number": "",
      "title": "“I had no choice”: a mixed methods analysis of patient decision-making for total laryngectomy",
      "summary": "We surveyed fifteen patients (15 [100%] men, median age 75 years, 5 [33.3%] primary TL, median 5.34 years since TL, 15 [100%] eating PO post-op) and conducted semi-structured interviews with ten participants. Participants had widespread variation of their maximizer-minimizer preferences towards healthcare (Figure 1) . There were no significant differences in healthcare resource utilization across...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153311",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Monica H Bodd, MD, MTS",
      "presenter": "Monica H Bodd, MD, MTS",
      "authors": "Monica H Bodd, MD, MTS 1 ; Jeffrey D Huynh 1 ; Gregory Gibb, MD 2 ; Michael A Belsky, MD, MS 1 ; Edward J Damrose, MD 1 ; Philip C Doyle, PhD 1 ; Andrey Finegersh, MD, PhD 1 ; Ann Kearney, CScD, CCCSLP, BCSS 1 ; Brian A Nuyen, MD 1 ; Heather Starmer, PhD, CCCSLP, BCSS 1 ; Kwang Sung, MD, MS 1 ; Michelle M Chen, MD, MHS 1",
      "normalized_authors": [
        "Monica H Bodd, MTS",
        "Jeffrey D Huynh",
        "Gregory Gibb",
        "Michael A Belsky",
        "Edward J Damrose",
        "Philip C Doyle",
        "Andrey Finegersh",
        "Ann Kearney, CScD, CCCSLP, BCSS",
        "Brian A Nuyen",
        "Heather Starmer, CCCSLP, BCSS",
        "Kwang Sung",
        "Michelle M Chen, MHS"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head & Neck Surgery, Stanford Medicine",
        "Providence"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head & Neck Surgery, Stanford Medicine",
        "Providence"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_41_24%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_41_24%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153311"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_42_07%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_42_07%E2%80%AFPM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153311"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, setting, and participants",
        "Main outcomes and measures",
        "Results",
        "Conclusions and relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Monica H Bodd, MD, MTS 1 ; Jeffrey D Huynh 1 ; Gregory Gibb, MD 2 ; Michael A Belsky, MD, MS 1 ; Edward J Damrose, MD 1 ; Philip C Doyle, PhD 1 ; Andrey Finegersh, MD, PhD 1 ; Ann Kearney, CScD, CCCSLP, BCSS 1 ; Brian A Nuyen, MD 1 ; Heather Starmer, PhD, CCCSLP, BCSS 1 ; Kwang Sung, MD, MS 1 ; Michelle M Chen, MD, MHS 1",
        "Affiliations": "1 Department of Otolaryngology - Head & Neck Surgery, Stanford Medicine; 2 Providence",
        "Importance": "Chemoradiation and total laryngectomy (TL) offer similar survival outcomes for advanced laryngeal cancer, but each carries unique long-term effects on quality-of-life (QOL). However, our understanding of patient decision-making is poorly understood. To better counsel patients with advanced laryngeal cancer, it is important to elicit the lived experiences of patients after TL.",
        "Objective": "To describe patient values, expectations, and treatment preferences for advanced laryngeal cancer as they relate to prior healthcare behavior, post-treatment QOL, and decision-related distress.",
        "Design, setting, and participants": "We conducted a mixed methods study from January to October 2025. Patients with advanced laryngeal cancer who had undergone either primary or salvage TL were recruited from a single academic center. Following convergent parallel design, surveys and interviews were performed to better understand decision-making. Surveys were composed of validated scales assessing maximizer-minimizer treatment preferences, QOL, satisfaction, and regret about decision. Interview analysis was guided by a two-rater, iterative interpretive approach for thematic description (k=0.96, indicating substantial agreement). Data was analyzed from September to October 2025, and frequent team meetings and member checking were performed to confirm accuracy of findings, with one of the participants included as co-author.",
        "Main outcomes and measures": "The main outcomes were treatment preferences, decision satisfaction, decisional regret, and QOL, as well as patients’ values and expectations collected from interviews.",
        "Results": "We surveyed fifteen patients (15 [100%] men, median age 75 years, 5 [33.3%] primary TL, median 5.34 years since TL, 15 [100%] eating PO post-op) and conducted semi-structured interviews with ten participants. Participants had widespread variation of their maximizer-minimizer preferences towards healthcare (Figure 1) . There were no significant differences in healthcare resource utilization across maximizer-minimizer preference groups. Most participants reported good overall QOL (median=6, 53% rating 6-7 out of 7), high satisfaction with decision (median 4 out of 5), and low decisional regret (median 20.0 out of 100). However, many participants felt their support system shrink down to family or small groups of friends due to inability to project their voice or talk while eating, and frequent care required for their stoma. TL was often considered the only option other than death due to failed prior surgical interventions and exhaustion from prior treatment (Figure 2) . Participants expressed that voice and swallow considerations were secondary to cancer-free survival, which was their primary expectation for treatment. Patient decision-making was primarily bolstered by trust in their surgeons’ recommendation and trust in the hospital center.",
        "Conclusions and relevance": "TL survivors showed good adjustment to the demands of daily life with minimal decisional regret, but emphasized their changed social lives, perception of TL as the only alternative to death, and trust in their treating team to guide TL decision-making. These findings may suggest the importance of eliciting patients’ values and understanding of options prior to surgeon recommendation for TL.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>“I had no choice”: a mixed methods analysis of patient decision-making for total laryngectomy</span>. <u>Monica H Bodd, MD, MTS</u><sup>1</sup>; Jeffrey D Huynh<sup>1</sup>; Gregory Gibb, MD<sup>2</sup>; Michael A Belsky, MD, MS<sup>1</sup>; Edward J Damrose, MD<sup>1</sup>; Philip C Doyle, PhD<sup>1</sup>; Andrey Finegersh, MD, PhD<sup>1</sup>; Ann Kearney, CScD, CCCSLP, BCSS<sup>1</sup>; Brian A Nuyen, MD<sup>1</sup>; Heather Starmer, PhD, CCCSLP, BCSS<sup>1</sup>; Kwang Sung, MD, MS<sup>1</sup>; Michelle M Chen, MD, MHS<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head & Neck Surgery, Stanford Medicine; <sup>2</sup>Providence<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Chemoradiation and total laryngectomy (TL) offer similar survival outcomes for advanced laryngeal cancer, but each carries unique long-term effects on quality-of-life (QOL). However, our understanding of patient decision-making is poorly understood. To better counsel patients with advanced laryngeal cancer, it is important to elicit the lived experiences of patients after TL.</p>\n\n<p><strong>Objective:</strong> To describe patient values, expectations, and treatment preferences for advanced laryngeal cancer as they relate to prior healthcare behavior, post-treatment QOL, and decision-related distress.</p>\n\n<p><strong>Design, setting, and participants:</strong> We conducted a mixed methods study from January to October 2025. Patients with advanced laryngeal cancer who had undergone either primary or salvage TL were recruited from a single academic center. Following convergent parallel design, surveys and interviews were performed to better understand decision-making. Surveys were composed of validated scales assessing maximizer-minimizer treatment preferences, QOL, satisfaction, and regret about decision. Interview analysis was guided by a two-rater, iterative interpretive approach for thematic description (k=0.96, indicating substantial agreement). Data was analyzed from September to October 2025, and frequent team meetings and member checking were performed to confirm accuracy of findings, with one of the participants included as co-author.</p>\n\n<p><strong>Main outcomes and measures:</strong> The main outcomes were treatment preferences, decision satisfaction, decisional regret, and QOL, as well as patients’ values and expectations collected from interviews.</p>\n\n<p><strong>Results:</strong> We surveyed fifteen patients (15 [100%] men, median age 75 years, 5 [33.3%] primary TL, median 5.34 years since TL, 15 [100%] eating PO post-op) and conducted semi-structured interviews with ten participants. Participants had widespread variation of their maximizer-minimizer preferences towards healthcare <strong>(Figure 1)</strong>. There were no significant differences in healthcare resource utilization across maximizer-minimizer preference groups. Most participants reported good overall QOL (median=6, 53% rating 6-7 out of 7), high satisfaction with decision (median 4 out of 5), and low decisional regret (median 20.0 out of 100). However, many participants felt their support system shrink down to family or small groups of friends due to inability to project their voice or talk while eating, and frequent care required for their stoma. TL was often considered the only option other than death due to failed prior surgical interventions and exhaustion from prior treatment <strong>(Figure 2)</strong>. Participants expressed that voice and swallow considerations were secondary to cancer-free survival, which was their primary expectation for treatment. Patient decision-making was primarily bolstered by trust in their surgeons’ recommendation and trust in the hospital center.</p>\n\n<p><strong>Conclusions and relevance:</strong> TL survivors showed good adjustment to the demands of daily life with minimal decisional regret, but emphasized their changed social lives, perception of TL as the only alternative to death, and trust in their treating team to guide TL decision-making. These findings may suggest the importance of eliciting patients’ values and understanding of options prior to surgeon recommendation for TL.</p>\n\n<p><strong>Figure 1: Maximizer-minimizer preferences towards healthcare </strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_41_24%E2%80%AFPM.png' /></p>\n\n<p><strong>Figure 2: Patient decision-making for TL</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153311/Screenshot%202025-12-03%20at%209_42_07%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153311--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S302",
      "content_id": "154450",
      "abstract_number": "S302",
      "poster_number": "",
      "title": "Graduated Autonomy in Head and Neck Microsurgery Fellowship Training: Analysis of Competency Progression and Clinical Outcomes",
      "summary": "Over three years, a model of structured, graduated surgical autonomy allowed head and neck microsurgery fellows to progress reliably to high competency levels without compromising patient outcomes. The stability of complication rates across quarters, years and fellows suggests that oversight structures effectively mitigate risk during the early training period. These findings support continued implementation of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154450",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kelly L Staricha, MD",
      "presenter": "Kelly L Staricha, MD",
      "authors": "Kelly L Staricha, MD ; Kevin Contrera, MD; Shaum Sridharan, MD; Joshua E Smith, MD; Steven Chinn, MD; Matthew E Spector, MD",
      "normalized_authors": [
        "Kelly L Staricha",
        "Kevin Contrera",
        "Shaum Sridharan",
        "Joshua E Smith",
        "Steven Chinn",
        "Matthew E Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154450/Fig1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154450/Fig1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154450"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 321,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kelly L Staricha, MD ; Kevin Contrera, MD; Shaum Sridharan, MD; Joshua E Smith, MD; Steven Chinn, MD; Matthew E Spector, MD",
        "Affiliations": "University of Pittsburgh",
        "Background": "Head and neck microvascular reconstructive surgery fellowships rely on graduated autonomy to balance surgical education with high-quality patient care. Limited data exist on how progressive trainee independence over the academic year affects clinical outcomes or whether fellows reliably achieve competency by year-end. This study evaluates longitudinal competency assessments and complication trends across five fellowship cycles.",
        "Methods": "A retrospective review was conducted on fellow competency as evaluated by clinical faculty and the associated free flap reconstruction complication rates between 2023–2025 at a single tertiary cancer center. Faculty-rated competency scores were collected at 3-month intervals, evaluating vessel dissection and needle handling technique (Figure, Q1), free flap harvest technique (Figure, Q2), intraoperative judgment (Figure, Q3), and operative efficiency (Figure, Q4) on a three point scale. Patient outcomes including flap compromise, take-back rates, and major postoperative complications were analyzed to assess associations with trainee start date and progression (Figure, Percentage). Outcomes were compared across quarters, within each academic year, and between fellowship years.",
        "Results": "Seven fellows were included. Competency ratings increased significantly over each academic year (p<0.01), with all fellows achieving high-competency benchmarks by the final quarter. Complication rates did not differ significantly by quarter, academic year, or by fellow (p=NS). There was no significant change in flap loss, take-backs, or major complications when comparing first quarter with fourth quarter of the academic year. No association was found between lower early-year competency scores and adverse outcomes.",
        "Conclusions": "Over three years, a model of structured, graduated surgical autonomy allowed head and neck microsurgery fellows to progress reliably to high competency levels without compromising patient outcomes. The stability of complication rates across quarters, years and fellows suggests that oversight structures effectively mitigate risk during the early training period. These findings support continued implementation of graduated autonomy frameworks and may serve as a benchmark for microsurgical education programs nationally. [A graph with different colored lines AI-generated content may be incorrect.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Graduated Autonomy in Head and Neck Microsurgery Fellowship Training: Analysis of Competency Progression and Clinical Outcomes</span>. <u>Kelly L Staricha, MD</u>; Kevin Contrera, MD; Shaum Sridharan, MD; Joshua E Smith, MD; Steven Chinn, MD; Matthew E Spector, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck microvascular reconstructive surgery fellowships rely on graduated autonomy to balance surgical education with high-quality patient care. Limited data exist on how progressive trainee independence over the academic year affects clinical outcomes or whether fellows reliably achieve competency by year-end. This study evaluates longitudinal competency assessments and complication trends across five fellowship cycles.</p>\n\n<p><strong>Methods: </strong>A retrospective review was conducted on fellow competency as evaluated by clinical faculty and the associated free flap reconstruction complication rates between 2023–2025 at a single tertiary cancer center. Faculty-rated competency scores were collected at 3-month intervals, evaluating vessel dissection and needle handling technique (Figure, Q1), free flap harvest technique (Figure, Q2), intraoperative judgment (Figure, Q3), and operative efficiency (Figure, Q4) on a three point scale. Patient outcomes including flap compromise, take-back rates, and major postoperative complications were analyzed to assess associations with trainee start date and progression (Figure, Percentage). Outcomes were compared across quarters, within each academic year, and between fellowship years.</p>\n\n<p><strong>Results: </strong>Seven fellows were included. Competency ratings increased significantly over each academic year (p<0.01), with all fellows achieving high-competency benchmarks by the final quarter. Complication rates did not differ significantly by quarter, academic year, or by fellow (p=NS). There was no significant change in flap loss, take-backs, or major complications when comparing first quarter with fourth quarter of the academic year. No association was found between lower early-year competency scores and adverse outcomes.</p>\n\n<p><strong>Conclusions: </strong>Over three years, a model of structured, graduated surgical autonomy allowed head and neck microsurgery fellows to progress reliably to high competency levels without compromising patient outcomes. The stability of complication rates across quarters, years and fellows suggests that oversight structures effectively mitigate risk during the early training period. These findings support continued implementation of graduated autonomy frameworks and may serve as a benchmark for microsurgical education programs nationally. [A graph with different colored lines AI-generated content may be incorrect.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154450/Fig1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154450--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S303",
      "content_id": "155420",
      "abstract_number": "S303",
      "poster_number": "",
      "title": "An Integrated Patient Navigation Model Improves Time to Treatment and Peri-operative Outcomes in Head and Neck Cancer Patients",
      "summary": "Patient navigation significantly expedited radiation oncology consultation, increased the rate of timely initiation of radiation after surgery, and decreased time to initiating definitive radiation in non-surgical patients. Notably, these improvements were not influenced by differences in patient demographics, diagnosis locations, or clinical stage. Future analyses will evaluate the impact of navigation on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155420",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashwath Ashok",
      "presenter": "Ashwath Ashok",
      "authors": "Ashwath Ashok 1 ; Sophia Tang 1 ; Patryk Dabek 1 ; Tonya Wibbenmeyer 2 ; Ashley Jackson 2 ; Crystal Lee 2 ; Kathleen Hogg 2 ; Kristin Schlueter 2 ; Janene Reeves 2 ; Molly Henn 2 ; Jordan Foy 2 ; Kaci Eikmann 2 ; Chiristi Longnecker 2 ; Angelleen Peters-Lewis 2 ; John Lynch, MD 2 ; Timothy Eberlein, MD 1 ; Evan Graboyes 3 ; Craig Buchman, MD 1 ; Anthony J Apicelli, MD, PhD 1 ; Nikhil Rammohan, MD, PhD 1 ; Jennifer De Los Santos, MD 1 ; Jesse Zaretsky, MD, PhD 1 ; Brendan Knapp, MD 1 ; Christine Auberle, MD 1 ; Peter Opelt, MD 1 ; Sana D Karam, MD, PhD 1 ; Jason Rich, MD 1 ; Patrik Pipkorn, MD 1 ; R. Alex Harbison, MD 1 ; Paul Zolkind, MD 1 ; Benjamin Wahle, MD 1 ; Morgan Sandelski, MD 1 ; Wade Thorstad, MD 1 ; Douglas Adkins, MD 1 ; Ryan S Jackson, MD 1 ; Sidharth V Puram, MD, PhD 1",
      "normalized_authors": [
        "Ashwath Ashok",
        "Sophia Tang",
        "Patryk Dabek",
        "Tonya Wibbenmeyer",
        "Ashley Jackson",
        "Crystal Lee",
        "Kathleen Hogg",
        "Kristin Schlueter",
        "Janene Reeves",
        "Molly Henn",
        "Jordan Foy",
        "Kaci Eikmann",
        "Chiristi Longnecker",
        "Angelleen Peters-Lewis",
        "John Lynch",
        "Timothy Eberlein",
        "Evan Graboyes",
        "Craig Buchman",
        "Anthony J Apicelli",
        "Nikhil Rammohan",
        "Jennifer De Los Santos",
        "Jesse Zaretsky",
        "Brendan Knapp",
        "Christine Auberle",
        "Peter Opelt",
        "Sana D Karam",
        "Jason Rich",
        "Patrik Pipkorn",
        "R. Alex Harbison",
        "Paul Zolkind",
        "Benjamin Wahle",
        "Morgan Sandelski",
        "Wade Thorstad",
        "Douglas Adkins",
        "Ryan S Jackson",
        "Sidharth V Puram"
      ],
      "affiliations": [
        "Washington University School of Medicine",
        "Barnes Jewish Hospital",
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Washington University School of Medicine",
        "Barnes Jewish Hospital",
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ashwath Ashok 1 ; Sophia Tang 1 ; Patryk Dabek 1 ; Tonya Wibbenmeyer 2 ; Ashley Jackson 2 ; Crystal Lee 2 ; Kathleen Hogg 2 ; Kristin Schlueter 2 ; Janene Reeves 2 ; Molly Henn 2 ; Jordan Foy 2 ; Kaci Eikmann 2 ; Chiristi Longnecker 2 ; Angelleen Peters-Lewis 2 ; John Lynch, MD 2 ; Timothy Eberlein, MD 1 ; Evan Graboyes 3 ; Craig Buchman, MD 1 ; Anthony J Apicelli, MD, PhD 1 ; Nikhil Rammohan, MD, PhD 1 ; Jennifer De Los Santos, MD 1 ; Jesse Zaretsky, MD, PhD 1 ; Brendan Knapp, MD 1 ; Christine Auberle, MD 1 ; Peter Opelt, MD 1 ; Sana D Karam, MD, PhD 1 ; Jason Rich, MD 1 ; Patrik Pipkorn, MD 1 ; R. Alex Harbison, MD 1 ; Paul Zolkind, MD 1 ; Benjamin Wahle, MD 1 ; Morgan Sandelski, MD 1 ; Wade Thorstad, MD 1 ; Douglas Adkins, MD 1 ; Ryan S Jackson, MD 1 ; Sidharth V Puram, MD, PhD 1",
        "Affiliations": "1 Washington University School of Medicine; 2 Barnes Jewish Hospital; 3 Medical University of South Carolina",
        "Background": "Head and neck cancer (HNCa) is the sixth leading cause of cancer-related deaths worldwide. Although approximately 40% of patients with advanced HNCa initially respond to definitive surgery or chemoradiation, a significant portion experience locoregional recurrence or distant metastasis. Despite multimodal treatment regimens, outcomes remain poor, underscoring the need to identify effective strategies to improve prognosis. As part of a comprehensive effort to improve HNCa outcomes, our institution established an integrated Head and Neck Tumor Center (HNTC). Prior studies demonstrate that timely initiation of treatment, including postoperative radiotherapy and total treatment package time, is associated with improved survival. Therefore, one key initiative of the HNTC is assigning each patient a dedicated nurse navigator, with the goal of reducing delays in evaluation from surgical, medical, and radiation oncologists and ultimately improving treatment timelines and patient outcomes.",
        "Objectives": "This study assesses the impact of patient navigation on time to evaluation, time to definitive radiation, time from surgery to adjuvant radiation, and short-term post-operative and radiation related adverse events (30-day mortality, hospital readmission, ED visits, and OR takebacks).",
        "Methods": "We conducted a retrospective study of patients diagnosed with HNCa from 2019-2025 stratified into non-navigated (pre-implementation) and navigated (post-implementation) cohorts. From an initial dataset of 535 patients, patients were excluded if they received palliative care, neoadjuvant therapy, or had missing covariate data, yielding an evaluable baseline cohort of 502 patients (297 non-navigated; 205 navigated).",
        "Abstract": "To mitigate selection bias and balance baseline confounders, we performed 1:1 nearest-neighbor propensity score matching using multivariable logistic regression including age, gender, race, ASA score, tumor subsite, and clinical stage. A caliper width of 0.2 standard deviations of the logit of the propensity score was applied. Matching excluded 134 patients (113 non-navigated; 21 navigated), yielding a balanced analytic cohort of 368 patients. Covariate balance was confirmed using standardized mean differences. View in Agenda and Add to Schedule",
        "Results": "Compared to non-navigated patients, navigated patients experienced significantly reduced time from biopsy-proven diagnosis (often with an outside provider) to radiation oncology consultation (48.6 vs. 29.8 days, p=0.013), reduced median time from diagnosis to initiating definitive radiation in non-surgical patients (63 vs. 47 days, p = 0.032), and reduced total curative package duration (time from diagnosis to completion of adjuvant therapy; 123.3 vs. 74.5 days, p=0.034). More navigated patients initiated adjuvant radiation within 6 weeks of surgery (34.2% vs. 54.3%, p=0.005). Navigation also trended towards a clinically notable reduction in time to medical oncology consultation (54.3 vs. 28.9 days, p=0.055). Subgroup analyses revealed no significant differences in the effect of navigation on these metrics based on diagnosis location (outside referral vs. HNTC), disease stage, subsite, or patient race.",
        "Conclusions": "Patient navigation significantly expedited radiation oncology consultation, increased the rate of timely initiation of radiation after surgery, and decreased time to initiating definitive radiation in non-surgical patients. Notably, these improvements were not influenced by differences in patient demographics, diagnosis locations, or clinical stage. Future analyses will evaluate the impact of navigation on short-term post-operative outcomes, radiation-related adverse events, and overall survival, while building on this cohort as the HNTC experience expands."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>An Integrated Patient Navigation Model Improves Time to Treatment and Peri-operative Outcomes in Head and Neck Cancer Patients</span>. <u>Ashwath Ashok</u><sup>1</sup>; Sophia Tang<sup>1</sup>; Patryk Dabek<sup>1</sup>; Tonya Wibbenmeyer<sup>2</sup>; Ashley Jackson<sup>2</sup>; Crystal Lee<sup>2</sup>; Kathleen Hogg<sup>2</sup>; Kristin Schlueter<sup>2</sup>; Janene Reeves<sup>2</sup>; Molly Henn<sup>2</sup>; Jordan Foy<sup>2</sup>; Kaci Eikmann<sup>2</sup>; Chiristi Longnecker<sup>2</sup>; Angelleen Peters-Lewis<sup>2</sup>; John Lynch, MD<sup>2</sup>; Timothy Eberlein, MD<sup>1</sup>; Evan Graboyes<sup>3</sup>; Craig Buchman, MD<sup>1</sup>; Anthony J Apicelli, MD, PhD<sup>1</sup>; Nikhil Rammohan, MD, PhD<sup>1</sup>; Jennifer De Los Santos, MD<sup>1</sup>; Jesse Zaretsky, MD, PhD<sup>1</sup>; Brendan Knapp, MD<sup>1</sup>; Christine Auberle, MD<sup>1</sup>; Peter Opelt, MD<sup>1</sup>; Sana D Karam, MD, PhD<sup>1</sup>; Jason Rich, MD<sup>1</sup>; Patrik Pipkorn, MD<sup>1</sup>; R. Alex Harbison, MD<sup>1</sup>; Paul Zolkind, MD<sup>1</sup>; Benjamin Wahle, MD<sup>1</sup>; Morgan Sandelski, MD<sup>1</sup>; Wade Thorstad, MD<sup>1</sup>; Douglas Adkins, MD<sup>1</sup>; Ryan S Jackson, MD<sup>1</sup>; Sidharth V Puram, MD, PhD<sup>1</sup>. <sup>1</sup>Washington University School of Medicine; <sup>2</sup>Barnes Jewish Hospital; <sup>3</sup>Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer (HNCa) is the sixth leading cause of cancer-related deaths worldwide. Although approximately 40% of patients with advanced HNCa initially respond to definitive surgery or chemoradiation, a significant portion experience locoregional recurrence or distant metastasis. Despite multimodal treatment regimens, outcomes remain poor, underscoring the need to identify effective strategies to improve prognosis. As part of a comprehensive effort to improve HNCa outcomes, our institution established an integrated Head and Neck Tumor Center (HNTC). Prior studies demonstrate that timely initiation of treatment, including postoperative radiotherapy and total treatment package time, is associated with improved survival. Therefore, one key initiative of the HNTC is assigning each patient a dedicated nurse navigator, with the goal of reducing delays in evaluation from surgical, medical, and radiation oncologists and ultimately improving treatment timelines and patient outcomes.</p>\n\n<p><strong>Objectives: </strong>This study assesses the impact of patient navigation on time to evaluation, time to definitive radiation, time from surgery to adjuvant radiation, and short-term post-operative and radiation related adverse events (30-day mortality, hospital readmission, ED visits, and OR takebacks).</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective study of patients diagnosed with HNCa from 2019-2025 stratified into non-navigated (pre-implementation) and navigated (post-implementation) cohorts. From an initial dataset of 535 patients, patients were excluded if they received palliative care, neoadjuvant therapy, or had missing covariate data, yielding an evaluable baseline cohort of 502 patients (297 non-navigated; 205 navigated).</p>\n\n<p>To mitigate selection bias and balance baseline confounders, we performed 1:1 nearest-neighbor propensity score matching using multivariable logistic regression including age, gender, race, ASA score, tumor subsite, and clinical stage. A caliper width of 0.2 standard deviations of the logit of the propensity score was applied. Matching excluded 134 patients (113 non-navigated; 21 navigated), yielding a balanced analytic cohort of 368 patients. Covariate balance was confirmed using standardized mean differences.</p>\n\n<p><strong>Results: </strong>Compared to non-navigated patients, navigated patients experienced significantly reduced time from biopsy-proven diagnosis (often with an outside provider) to radiation oncology consultation (48.6 vs. 29.8 days, p=0.013), reduced median time from diagnosis to initiating definitive radiation in non-surgical patients (63 vs. 47 days, p = 0.032), and reduced total curative package duration (time from diagnosis to completion of adjuvant therapy; 123.3 vs. 74.5 days, p=0.034). More navigated patients initiated adjuvant radiation within 6 weeks of surgery (34.2% vs. 54.3%, p=0.005). Navigation also trended towards a clinically notable reduction in time to medical oncology consultation (54.3 vs. 28.9 days, p=0.055). Subgroup analyses revealed no significant differences in the effect of navigation on these metrics based on diagnosis location (outside referral vs. HNTC), disease stage, subsite, or patient race.</p>\n\n<p><strong>Conclusions: </strong>Patient navigation significantly expedited radiation oncology consultation, increased the rate of timely initiation of radiation after surgery, and decreased time to initiating definitive radiation in non-surgical patients. Notably, these improvements were not influenced by differences in patient demographics, diagnosis locations, or clinical stage. Future analyses will evaluate the impact of navigation on short-term post-operative outcomes, radiation-related adverse events, and overall survival, while building on this cohort as the HNTC experience expands.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155420--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S304",
      "content_id": "153644",
      "abstract_number": "S304",
      "poster_number": "",
      "title": "Patient Experiences in Decision Making in HPV-associated Oropharyngeal Cancer",
      "summary": "This research was designed to develop a better understanding of patient values and priorities as well as the process of decision making in patients with HPV-associated OPC. Themes established during analysis stressed the importance of trust and expertise and minimizing the patient sense of being overwhelmed in the decision making process. These data provide a starting framework to be used in the development of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153644",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Heather Starmer",
      "presenter": "Heather Starmer",
      "authors": "Zoe Fullerton 1 ; F. Christopher Holsinger 1 ; Nikita Bedi 1 ; Hlu Vang 1 ; Beth Beadle 1 ; A. Dimitrios Colevas 1 ; Michelle Chen 1 ; Melina Windon 2 ; Heather Starmer 1",
      "normalized_authors": [
        "Zoe Fullerton",
        "F. Christopher Holsinger",
        "Nikita Bedi",
        "Hlu Vang",
        "Beth Beadle",
        "A. Dimitrios Colevas",
        "Michelle Chen",
        "Melina Windon",
        "Heather Starmer"
      ],
      "affiliations": [
        "Stanford University",
        "University of Kentucky"
      ],
      "normalized_institutions": [
        "Stanford University",
        "University of Kentucky"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Zoe Fullerton 1 ; F. Christopher Holsinger 1 ; Nikita Bedi 1 ; Hlu Vang 1 ; Beth Beadle 1 ; A. Dimitrios Colevas 1 ; Michelle Chen 1 ; Melina Windon 2 ; Heather Starmer 1",
        "Affiliations": "1 Stanford University; 2 University of Kentucky",
        "Background": "Treatment of HPV-associated oropharyngeal cancer (OPC) involves multiple treatment options, including standard chemoradiation and more novel methods of de-escalation including systemic and surgical options. As a result, the decisions that patients are asked to make are increasingly complex, with a need to weigh oncologic and functional outcomes. Shared decision-making is an important contributor to patient deliberations, however, little is known about what influences patient decisions and what is helpful in their decision making process. It is challenging, therefore, to develop patient-centered decision making aids to support patients. As a result, we aimed to explore the lived experiences of patients with HPV-associated OPC in regard to their decision making process. We hypothesized that a greater understanding of the patient perspective will inform our efforts to develop patient-centered education and decisional aids.",
        "Methods": "This mixed methods study recruited patients aged 18 or older with a diagnosis of HPV-associated OPC. Participants completed the INFO-25, Shared Decision Making Questionnaire (SDMQ9) and Decisional Conflict Scale (DCS) at baseline. Semi-structured interviews were performed post-treatment in a one-on-one Zoom setting using an interview guide developed based on existing literature about patient decision making. Interviews focused on the patient’s experience of the decision making process and what individual elements played a central or secondary role in finalizing treatment decisions. Deidentified transcripts were imported into NVIVO 14. Inductive thematic analysis included initial coding of each transcript followed by secondary coding once all transcripts were coded to explore common themes from the data",
        "Results": "A total of 12 semi-structured interviews were completed. The majority of participants (92%) were male and the mean age was 62 years (range 51-74). All patients received radiation therapy while 75% also received surgical intervention and 58% received chemotherapy. The average time post-treatment was 8.5 months (range 3-13 months). Themes regarding decision making fell into three categories; faciliatory, mixed, and inhibitory factors. Primary facilitators for decision making included trusted recommendations and having confidence in the expert while primary inhibitory factors included a perceived lack of control and a sense of being overwhelmed. The mean INFO-25 score was 62.7 (scale 0-100) suggesting good availability of information to support decision making. Greatest deficits in information were noted in regard to effects of treatment on social/family life, sexual function, and other supportive care services. Shared decision making scores were high for all but two participants (mean 31.8 scale 0-45). Baseline DCS scores ranged from 0-92 suggesting that there was substantial variability in decisional conflict at baseline.",
        "Conclusion": "This research was designed to develop a better understanding of patient values and priorities as well as the process of decision making in patients with HPV-associated OPC. Themes established during analysis stressed the importance of trust and expertise and minimizing the patient sense of being overwhelmed in the decision making process. These data provide a starting framework to be used in the development of educational and decision-aid tools for this population. Further work in a more diverse patient population is ongoing to determine if additional factors may need to be considered.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient Experiences in Decision Making in HPV-associated Oropharyngeal Cancer</span>. Zoe Fullerton<sup>1</sup>; F. Christopher Holsinger<sup>1</sup>; Nikita Bedi<sup>1</sup>; Hlu Vang<sup>1</sup>; Beth Beadle<sup>1</sup>; A. Dimitrios Colevas<sup>1</sup>; Michelle Chen<sup>1</sup>; Melina Windon<sup>2</sup>; <u>Heather Starmer</u><sup>1</sup>. <sup>1</sup>Stanford University; <sup>2</sup>University of Kentucky<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Treatment of HPV-associated oropharyngeal cancer (OPC) involves multiple treatment options, including standard chemoradiation and more novel methods of de-escalation including systemic and surgical options. As a result, the decisions that patients are asked to make are increasingly complex, with a need to weigh oncologic and functional outcomes. Shared decision-making is an important contributor to patient deliberations, however, little is known about what influences patient decisions and what is helpful in their decision making process. It is challenging, therefore, to develop patient-centered decision making aids to support patients. As a result, we aimed to explore the lived experiences of patients with HPV-associated OPC in regard to their decision making process. We hypothesized that a greater understanding of the patient perspective will inform our efforts to develop patient-centered education and decisional aids.</p>\n\n<p><strong>Methods: </strong>This mixed methods study recruited patients aged 18 or older with a diagnosis of HPV-associated OPC. Participants completed the INFO-25, Shared Decision Making Questionnaire (SDMQ9) and Decisional Conflict Scale (DCS) at baseline. Semi-structured interviews were performed post-treatment in a one-on-one Zoom setting using an interview guide developed based on existing literature about patient decision making. Interviews focused on the patient’s experience of the decision making process and what individual elements played a central or secondary role in finalizing treatment decisions. Deidentified transcripts were imported into NVIVO 14. Inductive thematic analysis included initial coding of each transcript followed by secondary coding once all transcripts were coded to explore common themes from the data</p>\n\n<p><strong>Results: </strong>A total of 12 semi-structured interviews were completed. The majority of participants (92%) were male and the mean age was 62 years (range 51-74). All patients received radiation therapy while 75% also received surgical intervention and 58% received chemotherapy. The average time post-treatment was 8.5 months (range 3-13 months). Themes regarding decision making fell into three categories; faciliatory, mixed, and inhibitory factors. Primary facilitators for decision making included trusted recommendations and having confidence in the expert while primary inhibitory factors included a perceived lack of control and a sense of being overwhelmed. The mean INFO-25 score was 62.7 (scale 0-100) suggesting good availability of information to support decision making. Greatest deficits in information were noted in regard to effects of treatment on social/family life, sexual function, and other supportive care services. Shared decision making scores were high for all but two participants (mean 31.8 scale 0-45). Baseline DCS scores ranged from 0-92 suggesting that there was substantial variability in decisional conflict at baseline.</p>\n\n<p><strong>Conclusion: </strong>This research was designed to develop a better understanding of patient values and priorities as well as the process of decision making in patients with HPV-associated OPC. Themes established during analysis stressed the importance of trust and expertise and minimizing the patient sense of being overwhelmed in the decision making process. These data provide a starting framework to be used in the development of educational and decision-aid tools for this population. Further work in a more diverse patient population is ongoing to determine if additional factors may need to be considered.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153644--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S305",
      "content_id": "153980",
      "abstract_number": "S305",
      "poster_number": "",
      "title": "Assessment of a Large Language Model for Laryngectomy Patient Education: Surgeon Perspectives on Quality and Safety",
      "summary": "Among ten respondents, 80% (n=8) had been in practice for six or more years. All surgeons treated laryngectomy patients. Only half of the respondents had experience with LLMs, none of whom used LLMs for patient education. While LLM responses were largely viewed as incomplete (n=86, 50.9%), just over half the responses were viewed as comparable to current patient educational materials (n=93, 55.0%) and acceptable...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153980",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shireen S Gohari, MBBS",
      "presenter": "Shireen S Gohari, MBBS",
      "authors": "Geethanjeli Mahendran, MD 1 ; Shireen S Gohari, MBBS 1 ; Jeremy Richmon, MD 1 ; Daniel Deschler, MD 1 ; Allen Feng, MD 1 ; Daniel Faden, MD 1 ; Donald Annino, MD 2 ; Wais Rahmati, MD 2 ; Laura Ann Goguen, MD 2 ; Eleni Rettig, MD 2 ; Ravindra Uppaluri, MD 2 ; Sophia Z Shalhout, PhD 1 ; Rosh Sethi, MD 2",
      "normalized_authors": [
        "Geethanjeli Mahendran",
        "Shireen S Gohari, MBBS",
        "Jeremy Richmon",
        "Daniel Deschler",
        "Allen Feng",
        "Daniel Faden",
        "Donald Annino",
        "Wais Rahmati",
        "Laura Ann Goguen",
        "Eleni Rettig",
        "Ravindra Uppaluri",
        "Sophia Z Shalhout",
        "Rosh Sethi"
      ],
      "affiliations": [
        "Mass Eye and Ear",
        "Brigham and Women's Hospital"
      ],
      "normalized_institutions": [
        "Mass Eye and Ear",
        "Brigham and Women's Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153980/expert%20assessment%20of%20AI%20responses(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153980/expert%20assessment%20of%20AI%20responses(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153980"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 401,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Figure 1",
        "Abstract"
      ],
      "sections": {
        "Authors": "Geethanjeli Mahendran, MD 1 ; Shireen S Gohari, MBBS 1 ; Jeremy Richmon, MD 1 ; Daniel Deschler, MD 1 ; Allen Feng, MD 1 ; Daniel Faden, MD 1 ; Donald Annino, MD 2 ; Wais Rahmati, MD 2 ; Laura Ann Goguen, MD 2 ; Eleni Rettig, MD 2 ; Ravindra Uppaluri, MD 2 ; Sophia Z Shalhout, PhD 1 ; Rosh Sethi, MD 2",
        "Affiliations": "1 Mass Eye and Ear; 2 Brigham and Women's Hospital",
        "Introduction": "Laryngectomy education is complex and multifactorial, requiring patients and caregivers to adopt a new set of skills and understanding. Large Language Models (LLMs) have surged in popularity and patients are increasingly turning to these platforms for medical advice. However, the quality and safety of LLM-generated responses have yet to be fully defined, underscoring the need to assess their appropriateness for patient care in a more urgent fashion.",
        "Methods": "A non-patient-facing LLM developed by a tertiary care institution was presented with a list of 17 frequently asked questions (FAQs) curated from patient information websites, patient support groups, and expert opinion. The selected questions encompassed general FAQs, preoperative topics, and issues related to speech and swallowing. LLM responses were presented to ten fellowship-trained head and neck surgeons for assessment of quality and accuracy. A thematic analysis of free-text responses was also conducted.",
        "Results": "Among ten respondents, 80% (n=8) had been in practice for six or more years. All surgeons treated laryngectomy patients. Only half of the respondents had experience with LLMs, none of whom used LLMs for patient education. While LLM responses were largely viewed as incomplete (n=86, 50.9%), just over half the responses were viewed as comparable to current patient educational materials (n=93, 55.0%) and acceptable to recommend to patients (n=95, 55.9%). The most common themes that arose from qualitative responses included concerns regarding oversimplified answers, lack of personalization and potential for unsafe advice. Critiques regarding oversimplified LLM responses were seen for frequently asked laryngectomy questions such as “What lifestyle changes should I expect long-term after a laryngectomy?”. In contrast, respondents identified a lack of personalization and consideration of patient-specific factors when the LLM was asked pre-operative laryngectomy questions such as “How do I prepare for a laryngectomy?”. The concern of unsafe advice was raised by specific questions “Can I swim with a laryngectomy?” where careful wording was required to avoid dangerous misinterpretation.",
        "Discussion": "Our study provides a unique evaluation of a LLM for laryngectomy education by experienced Head and Neck surgeons who had not previously used LLMs as a modality for patient education. We highlight that LLMs can provide comparable, and provider-recommended material but requires further development to address concerns of incomplete content, lack of personalization and risk of unsafe responses. The use of LLM-generated patient information materials is feasible with clinician oversight and collaboration.",
        "Figure 1": "Expert Assessment of AI Responses.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessment of a Large Language Model for Laryngectomy Patient Education: Surgeon Perspectives on Quality and Safety</span>. Geethanjeli Mahendran, MD<sup>1</sup>; <u>Shireen S Gohari, MBBS</u><sup>1</sup>; Jeremy Richmon, MD<sup>1</sup>; Daniel Deschler, MD<sup>1</sup>; Allen Feng, MD<sup>1</sup>; Daniel Faden, MD<sup>1</sup>; Donald Annino, MD<sup>2</sup>; Wais Rahmati, MD<sup>2</sup>; Laura Ann Goguen, MD<sup>2</sup>; Eleni Rettig, MD<sup>2</sup>; Ravindra Uppaluri, MD<sup>2</sup>; Sophia Z Shalhout, PhD<sup>1</sup>; Rosh Sethi, MD<sup>2</sup>. <sup>1</sup>Mass Eye and Ear; <sup>2</sup>Brigham and Women's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Laryngectomy education is complex and multifactorial, requiring patients and caregivers to adopt a new set of skills and understanding. Large Language Models (LLMs) have surged in popularity and patients are increasingly turning to these platforms for medical advice. However, the quality and safety of LLM-generated responses have yet to be fully defined, underscoring the need to assess their appropriateness for patient care in a more urgent fashion. </p>\n\n<p><strong>Methods</strong>: A non-patient-facing LLM developed by a tertiary care institution was presented with a list of 17 frequently asked questions (FAQs) curated from patient information websites, patient support groups, and expert opinion. The selected questions encompassed general FAQs, preoperative topics, and issues related to speech and swallowing. LLM responses were presented to ten fellowship-trained head and neck surgeons for assessment of quality and accuracy. A thematic analysis of free-text responses was also conducted. </p>\n\n<p><strong>Results</strong>: Among ten respondents, 80% (n=8) had been in practice for six or more years. All surgeons treated laryngectomy patients. Only half of the respondents had experience with LLMs, none of whom used LLMs for patient education. While LLM responses were largely viewed as incomplete (n=86, 50.9%), just over half the responses were viewed as comparable to current patient educational materials (n=93, 55.0%) and acceptable to recommend to patients (n=95, 55.9%). The most common themes that arose from qualitative responses included concerns regarding oversimplified answers, lack of personalization and potential for unsafe advice. Critiques regarding oversimplified LLM responses were seen for frequently asked laryngectomy questions such as “What lifestyle changes should I expect long-term after a laryngectomy?”. In contrast, respondents identified a lack of personalization and consideration of patient-specific factors when the LLM was asked pre-operative laryngectomy questions such as “How do I prepare for a laryngectomy?”. The concern of unsafe advice was raised by specific questions “Can I swim with a laryngectomy?” where careful wording was required to avoid dangerous misinterpretation. </p>\n\n<p><strong>Discussion</strong>: Our study provides a unique evaluation of a LLM for laryngectomy education by experienced Head and Neck surgeons who had not previously used LLMs as a modality for patient education. We highlight that LLMs can provide comparable, and provider-recommended material but requires further development to address concerns of incomplete content, lack of personalization and risk of unsafe responses. The use of LLM-generated patient information materials is feasible with clinician oversight and collaboration. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153980/expert%20assessment%20of%20AI%20responses(1).png' /></p>\n\n<p><strong>Figure 1:</strong> Expert Assessment of AI Responses.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153980--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S306",
      "content_id": "154564",
      "abstract_number": "S306",
      "poster_number": "",
      "title": "Losing Your Larynx, Keeping Your Life: Multidisciplinary Behaviour Setting Analysis of Everyday Life After Total Laryngectomy as a Path Towards Holistic Speech Care Delivery",
      "summary": "Total laryngectomy remains a life-saving treatment for advanced head and neck cancer, yet clinical metrics of speech rehabilitation practices still focus largely on “voice restoration” and signal quality rather than on how people can keep living the lives they value, and realize their social roles. Building on ecological and enactive approaches to communication, most especially behaviour settings theory and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154564",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Konrad P Zielinski",
      "presenter": "Konrad P Zielinski",
      "authors": "Konrad P Zielinski 1 ; Rupal P Patel 2",
      "normalized_authors": [
        "Konrad P Zielinski",
        "Rupal P Patel"
      ],
      "affiliations": [
        "University of Warsaw",
        "Northeastern University"
      ],
      "normalized_institutions": [
        "University of Warsaw",
        "Northeastern University"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Konrad P Zielinski 1 ; Rupal P Patel 2",
        "Affiliations": "1 University of Warsaw; 2 Northeastern University",
        "Abstract": "Total laryngectomy remains a life-saving treatment for advanced head and neck cancer, yet clinical metrics of speech rehabilitation practices still focus largely on “voice restoration” and signal quality rather than on how people can keep living the lives they value, and realize their social roles. Building on ecological and enactive approaches to communication, most especially behaviour settings theory and engaged epistemology (recent advances in psychology and cognitive sciences), our project treats speech aids as parts of broader interactional environments in which patients, relatives, clinicians and devices themselves jointly shape communication processes and outcome. Over the period of 6 years, we had been conducting in-depth qualitative study with 20 Polish laryngectomees, combining semi-structured interviews (2.5 - 6 hours in total separated to 2-4 sessions, often with family members present, and moderators and observers from the research team), intertwined with two-week interaction diaries documenting critical everyday situations as patients’ self-report in a dedicated survey. A multidisciplinary user team led by a laryngectomized researcher included psychologists, anthropologists, device designers and philosophers, enabling ongoing reflexive dialogue about ethics, power relations and collaborative interpretation of obtained results. Data were analysed using affinity and experience mapping, behaviour-setting categorisation (selecting important situations), and micro-analysis of selected interaction episodes (speech, gesture, gaze, timing) to identify what “good enough” communication looks like in real life. Across participants, we identified a small set of behaviour settings that were simultaneously frequent, problematic and central to their identity: shared meals, medical encounters, grandparenting, work meetings, and public transport. Among these, meals emerged as the most consequential setting. Family dinners, restaurant outings and holiday celebrations concentrate multiple demands on post-laryngectomy communication: coughing and hygiene while eating; noisy multi-party talk; rapid topic shifts; and the need to move between “serious” discussions and light small talk. In this setting, participants most strongly felt the loss of prior social roles (host, storyteller) and reported withdrawing or “going quiet” despite otherwise successful clinical rehabilitation. The Polish context, characterised by strong family involvement but limited structured pre-operative counselling and constrained device availability, offers a distinctive vantage point on these challenges. We consulted U.S. speech-language pathologists (n=8), working in both large academic centres, and in more rural areas in smaller US states to discuss preliminary findings and compare care pathways. For the AHNS community, we will present: (1) a behaviour-setting map of life after total laryngectomy anchored in meals and other crucial situations; (2) concrete implications for care delivery, including pre-operative conversations that surface each patient’s key settings, post-operative training organised around these settings rather than generic tasks, and structured involvement of family members; and (3) review of currently available new speech aids and design recommendation for new ones. We propose this talk as a starting point for an interdisciplinary dialogue between surgeons, SLPs, social scientists, engineers and laryngectomees themselves (first author of the paper), aimed at advancing real quality-of-life (or quality of particular interactions) care and device design that sustain patients’ social roles and sense of identity, not only their acoustic intelligibility and clinical survival. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Losing Your Larynx, Keeping Your Life: Multidisciplinary Behaviour Setting Analysis of Everyday Life After Total Laryngectomy as a Path Towards Holistic Speech Care Delivery</span>. <u>Konrad P Zielinski</u><sup>1</sup>; Rupal P Patel<sup>2</sup>. <sup>1</sup>University of Warsaw; <sup>2</sup>Northeastern University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Total laryngectomy remains a life-saving treatment for advanced head and neck cancer, yet clinical metrics of speech rehabilitation practices still focus largely on “voice restoration” and signal quality rather than on how people can keep living the lives they value, and realize their social roles. Building on ecological and enactive approaches to communication, most especially behaviour settings theory and engaged epistemology (recent advances in psychology and cognitive sciences), our project treats speech aids as parts of broader interactional environments in which patients, relatives, clinicians and devices themselves jointly shape communication processes and outcome.</p>\n\n<p>Over the period of 6 years, we had been conducting in-depth qualitative study with 20 Polish laryngectomees, combining semi-structured interviews (2.5 - 6 hours in total separated to 2-4 sessions, often with family members present, and moderators and observers from the research team), intertwined with two-week interaction diaries documenting critical everyday situations as patients’ self-report in a dedicated survey. A multidisciplinary user team led by a laryngectomized researcher included psychologists, anthropologists, device designers and philosophers, enabling ongoing reflexive dialogue about ethics, power relations and collaborative interpretation of obtained results.</p>\n\n<p>Data were analysed using affinity and experience mapping, behaviour-setting categorisation (selecting important situations), and micro-analysis of selected interaction episodes (speech, gesture, gaze, timing) to identify what “good enough” communication looks like in real life. Across participants, we identified a small set of behaviour settings that were simultaneously frequent, problematic and central to their identity: shared meals, medical encounters, grandparenting, work meetings, and public transport. Among these, meals emerged as the most consequential setting. Family dinners, restaurant outings and holiday celebrations concentrate multiple demands on post-laryngectomy communication: coughing and hygiene while eating; noisy multi-party talk; rapid topic shifts; and the need to move between “serious” discussions and light small talk. In this setting, participants most strongly felt the loss of prior social roles (host, storyteller) and reported withdrawing or “going quiet” despite otherwise successful clinical rehabilitation. The Polish context, characterised by strong family involvement but limited structured pre-operative counselling and constrained device availability, offers a distinctive vantage point on these challenges. We consulted U.S. speech-language pathologists (n=8), working in both large academic centres, and in more rural areas in smaller US states to discuss preliminary findings and compare care pathways. </p>\n\n<p>For the AHNS community, we will present: (1) a behaviour-setting map of life after total laryngectomy anchored in meals and other crucial situations; (2) concrete implications for care delivery, including pre-operative conversations that surface each patient’s key settings, post-operative training organised around these settings rather than generic tasks, and structured involvement of family members; and (3) review of currently available new speech aids and design recommendation for new ones. We propose this talk as a starting point for an interdisciplinary dialogue between surgeons, SLPs, social scientists, engineers and laryngectomees themselves (first author of the paper), aimed at advancing real quality-of-life (or quality of particular interactions) care and device design that sustain patients’ social roles and sense of identity, not only their acoustic intelligibility and clinical survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154564--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S307",
      "content_id": "151462",
      "abstract_number": "S307",
      "poster_number": "",
      "title": "Patient Experience and Survival in Head and Neck Cancer: A SEER–CAHPS Cohort Study",
      "summary": "Among multiple aspects of patient experience, doctor communication emerged as the strongest and most consistent predictor of survival in HNC. These findings identify communication as a modifiable target for quality improvement efforts aimed at enhancing oncologic outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151462",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amanda Zhang, MD",
      "presenter": "Amanda Zhang, MD",
      "authors": "Amanda Zhang, MD ; John D Cramer, MD",
      "normalized_authors": [
        "Amanda Zhang",
        "John D Cramer"
      ],
      "affiliations": [
        "Wayne State University"
      ],
      "normalized_institutions": [
        "Wayne State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 316,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amanda Zhang, MD ; John D Cramer, MD",
        "Affiliations": "Wayne State University",
        "Background": "Patient experience is increasingly recognized as both a quality indicator and a potential driver of important clinical outcomes in cancer care. However, the relationship between specific domains of patient experience and survival in head and neck cancer (HNC) is poorly understood.",
        "Methods": "Using the SEER-CAHPS database, we conducted a retrospective cohort study of Medicare beneficiaries diagnosed with HNC (2004 and 2021) who completed a CAHPS survey within 1 month to 5 years of diagnosis. Six validated measures of patient experience were examined: (1) doctor communication, (2) care coordination, (3) getting needed care, (4) getting care quickly, (5) specialist rating, and (6) personal doctor rating. \"Excellent” (top-box) responses (≥90 for composites, 9–10 for ratings) were compared to lower responses. Cox proportional hazards models estimated adjusted hazard ratios (aHRs) for overall survival (OS) and cancer-specific survival (CSS), controlling for case-mix and clinical covariates. Subgroup analyses stratified by surgical treatment.",
        "Results": "Among 2,798 eligible patients, analytic sample sizes ranged from 1,527 to 2,598 per measure. Excellent doctor communication was associated with improved OS (adjusted HR 0.86, 95% CI 0.76–0.98) and CSS (adjusted HR 0.73, 95% CI 0.59–0.90). Other domains showed weaker or nonsignificant associations. The survival benefit of excellent communication was greater among nonsurgical patients (interaction HR = 1.32, p=0.032). In sensitivity analyses, the survival benefit of excellent doctor communication was evident among patients surveyed within 2.5 years of diagnosis (adjusted HR 0.75, 95% CI 0.63–0.88) but not among those surveyed later (adjusted HR 1.12, 95% CI 0.91–1.39), supporting its role during active treatment.",
        "Conclusions": "Among multiple aspects of patient experience, doctor communication emerged as the strongest and most consistent predictor of survival in HNC. These findings identify communication as a modifiable target for quality improvement efforts aimed at enhancing oncologic outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient Experience and Survival in Head and Neck Cancer: A SEER–CAHPS Cohort Study</span>. <u>Amanda Zhang, MD</u>; John D Cramer, MD. Wayne State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patient experience is increasingly recognized as both a quality indicator and a potential driver of important clinical outcomes in cancer care. However, the relationship between specific domains of patient experience and survival in head and neck cancer (HNC) is poorly understood.</p>\n\n<p><strong>Methods:</strong> Using the SEER-CAHPS database, we conducted a retrospective cohort study of Medicare beneficiaries diagnosed with HNC (2004 and 2021) who completed a CAHPS survey within 1 month to 5 years of diagnosis. Six validated measures of patient experience were examined: (1) doctor communication, (2) care coordination, (3) getting needed care, (4) getting care quickly, (5) specialist rating, and (6) personal doctor rating. \"Excellent” (top-box) responses (≥90 for composites, 9–10 for ratings) were compared to lower responses. Cox proportional hazards models estimated adjusted hazard ratios (aHRs) for overall survival (OS) and cancer-specific survival (CSS), controlling for case-mix and clinical covariates. Subgroup analyses stratified by surgical treatment.</p>\n\n<p><strong>Results: </strong>Among 2,798 eligible patients, analytic sample sizes ranged from 1,527 to 2,598 per measure. Excellent doctor communication was associated with improved OS (adjusted HR 0.86, 95% CI 0.76–0.98) and CSS (adjusted HR 0.73, 95% CI 0.59–0.90). Other domains showed weaker or nonsignificant associations. The survival benefit of excellent communication was greater among nonsurgical patients (interaction HR = 1.32, p=0.032). In sensitivity analyses, the survival benefit of excellent doctor communication was evident among patients surveyed within 2.5 years of diagnosis (adjusted HR 0.75, 95% CI 0.63–0.88) but not among those surveyed later (adjusted HR 1.12, 95% CI 0.91–1.39), supporting its role during active treatment.</p>\n\n<p><strong>Conclusions: </strong>Among multiple aspects of patient experience, doctor communication emerged as the strongest and most consistent predictor of survival in HNC. These findings identify communication as a modifiable target for quality improvement efforts aimed at enhancing oncologic outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151462--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S308",
      "content_id": "153569",
      "abstract_number": "S308",
      "poster_number": "",
      "title": "Survey of Complementary and Alternative Medicine use in Head and Neck cancer patients and Correlation with Physician Trust",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153569",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260138",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Drake V Johnston",
      "presenter": "Drake V Johnston",
      "authors": "Drake V Johnston ; Rusha J Patel, MD; Joanna George; Micheal Machiorlatti, PhD",
      "normalized_authors": [
        "Drake V Johnston",
        "Rusha J Patel",
        "Joanna George",
        "Micheal Machiorlatti"
      ],
      "affiliations": [
        "University of Oklahoma Health Science Center"
      ],
      "normalized_institutions": [
        "University of Oklahoma Health Science Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Behavioral Health",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Behavioral Health"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 490,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "AIM",
        "METHODS",
        "RESULTS",
        "DISCUSSION",
        "CONCLUSION",
        "CONTRIBUTION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Drake V Johnston ; Rusha J Patel, MD; Joanna George; Micheal Machiorlatti, PhD",
        "Affiliations": "University of Oklahoma Health Science Center",
        "BACKGROUND": "The use of complementary and alternative medicine (CAM) is prevalent among cancer patients, yet studies on CAM use in the head and neck cancer population are mixed and variable. The purpose of this study is to evaluate current usage of complementary and alternative medicine usage in the Head and Neck cancer patient population and correlate it with physician trust levels.",
        "AIM": "The main objective is to determine the degree of CAM use among head and neck cancer patients, and if there is a correlation between CAM use and medical mistrust.",
        "METHODS": "A survey study was conducted of patients seen at the Stephenson Cancer Center head and neck cancer clinic. Eligible patients included all diagnosed with mucosal, salivary, and/or cutaneous malignancies. Demographics including education level and interest in CAM were surveyed. Patients were also given the Medical Mistrust Index (MMI) to determine degree of trust in health care providers. Descriptive analyses were created. Independent samples t-tests and chi-square tests with nonparametric analogs were used to explore association with medical mistrust and CAM use.",
        "RESULTS": "This is an active study with 53 participants currently surveyed at time of data analysis. 23 (43%) attested to usage of 1 or more types of CAM during treatment for head and neck cancers. The most common cancer subsites were cutaneous followed by oral cavity. The most common CAM used was vitamin D supplements. 56.6 % of patients had high or moderate mistrust index. Medical mistrust prevalence was bimodal, and most common among patients with high school or less education, and those with a bachelor’s degree or more. There was no significant correlation with medical mistrust and the use of CAM (p=0.50). Patients with cancer recurrence were more likely to use CAM, which approached significance (p = 0.06). Most patients (90%) felt comfortable discussing CAM usage with their provider.",
        "DISCUSSION": "Our study shows that CAM use is prevalent in the head and neck cancer patient population, as is medical mistrust. In this sample size, medical mistrust does not appear to be correlated to CAM use, and patients with recurrent cancer may be more likely to use CAM. The majority of those surveyed also said they feel comfortable speaking to physicians regarding their usage of CAMs. Future work will focus on multisite analysis on CAM use and further determining a relationship between medical mistrust and CAM use.",
        "CONCLUSION": "CAM usage in head and neck cancer patients is prominent and understudied. Almost half of head and neck cancer patients use CAM, and this is higher in patients with recurrent disease. Medical mistrust also remains high among head and neck cancer patients. Further work will better study trends in CAM use over time and geography, as well as analyze continued correlations between medical mistrust and CAM use.",
        "CONTRIBUTION": "CAM use is prevalent among head and neck cancer patients as is medical mistrust. Physicians should be aware of CAM use and address this during patient evaluation",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Survey of Complementary and Alternative Medicine use in Head and Neck cancer patients and Correlation with Physician Trust</span>. <u>Drake V Johnston</u>; Rusha J Patel, MD; Joanna George; Micheal Machiorlatti, PhD. University of Oklahoma Health Science Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> The use of complementary and alternative medicine (CAM) is prevalent among cancer patients, yet studies on CAM use in the head and neck cancer population are mixed and variable. The purpose of this study is to evaluate current usage of complementary and alternative medicine usage in the Head and Neck cancer patient population and correlate it with physician trust levels.</p>\n\n<p><strong>AIM: </strong>The main objective is to determine the degree of CAM use among head and neck cancer patients, and if there is a correlation between CAM use and medical mistrust.</p>\n\n<p><strong>METHODS:</strong> A survey study was conducted of patients seen at the Stephenson Cancer Center head and neck cancer clinic. Eligible patients included all diagnosed with mucosal, salivary, and/or cutaneous malignancies. Demographics including education level and interest in CAM were surveyed. Patients were also given the Medical Mistrust Index (MMI) to determine degree of trust in health care providers. Descriptive analyses were created. Independent samples t-tests and chi-square tests with nonparametric analogs were used to explore association with medical mistrust and CAM use.</p>\n\n<p><strong>RESULTS: </strong>This is an active study with 53 participants currently surveyed at time of data analysis. 23 (43%) attested to usage of 1 or more types of CAM during treatment for head and neck cancers. The most common cancer subsites were cutaneous followed by oral cavity. The most common CAM used was vitamin D supplements.  56.6 % of patients had high or moderate mistrust index. Medical mistrust prevalence was bimodal, and most common among patients with high school or less education, and those with a bachelor’s degree or more. There was no significant correlation with medical mistrust and the use of CAM (p=0.50). Patients with cancer recurrence were more likely to use CAM, which approached significance (p = 0.06). Most patients (90%) felt comfortable discussing CAM usage with their provider. </p>\n\n<p><strong>DISCUSSION:</strong> Our study shows that CAM use is prevalent in the head and neck cancer patient population, as is medical mistrust. In this sample size, medical mistrust does not appear to be correlated to CAM use, and patients with recurrent cancer may be more likely to use CAM. The majority of those surveyed also said they feel comfortable speaking to physicians regarding their usage of CAMs. Future work will focus on multisite analysis on CAM use and further determining a relationship between medical mistrust and CAM use.</p>\n\n<p><strong>CONCLUSION:</strong> CAM usage in head and neck cancer patients is prominent and understudied. Almost half of head and neck cancer patients use CAM, and this is higher in patients with recurrent disease. Medical mistrust also remains high among head and neck cancer patients. Further work will better study trends in CAM use over time and geography, as well as analyze continued correlations between medical mistrust and CAM use.</p>\n\n<p><strong>CONTRIBUTION:</strong> CAM use is prevalent among head and neck cancer patients as is medical mistrust. Physicians should be aware of CAM use and address this during patient evaluation</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153569--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260138' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S309",
      "content_id": "153803",
      "abstract_number": "S309",
      "poster_number": "",
      "title": "Prospective Tumor Kinetics Reveal the Biological Cost of Delay in Oral Cancer",
      "summary": "OSCC exhibits rapid volumetric progression and often doubles in size within 6–10 weeks. Tumor kinetics, particularly TVDT, quantify the biological cost of treatment delay and may improve triage and scheduling decisions in resource-limited settings.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153803",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arjun G Singh",
      "presenter": "Arjun G Singh",
      "authors": "Arjun G Singh 1 ; Abhishek Mahajan 2 ; Shwetabh Sinha 1 ; Rathan Shetty 1 ; Samarprita Mohanty 1 ; Anuj Kumar 1 ; Nivedita Chakrabarty 1 ; Poonam Joshi 1 ; Sudhir Nair 1 ; Sarbani Ghosh Laskar 1 ; Kumar Prabhash 1 ; Pankaj Chaturvedi 1",
      "normalized_authors": [
        "Arjun G Singh",
        "Abhishek Mahajan",
        "Shwetabh Sinha",
        "Rathan Shetty",
        "Samarprita Mohanty",
        "Anuj Kumar",
        "Nivedita Chakrabarty",
        "Poonam Joshi",
        "Sudhir Nair",
        "Sarbani Ghosh Laskar",
        "Kumar Prabhash",
        "Pankaj Chaturvedi"
      ],
      "affiliations": [
        "Tata Memorial Centre",
        "The Clatterbridge Cancer Centre"
      ],
      "normalized_institutions": [
        "Tata Memorial Centre",
        "The Clatterbridge Cancer Centre"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153803/Figure1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153803/Figure1.png",
          "alt": "Figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153803"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153803/Figure%202a.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153803/Figure%202a.png",
          "alt": "Figure 2a",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153803"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153803/Figure%202b.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153803/Figure%202b.png",
          "alt": "Figure 2b",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153803"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 408,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Patients",
        "Exposure",
        "Main Outcome Measures",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Arjun G Singh 1 ; Abhishek Mahajan 2 ; Shwetabh Sinha 1 ; Rathan Shetty 1 ; Samarprita Mohanty 1 ; Anuj Kumar 1 ; Nivedita Chakrabarty 1 ; Poonam Joshi 1 ; Sudhir Nair 1 ; Sarbani Ghosh Laskar 1 ; Kumar Prabhash 1 ; Pankaj Chaturvedi 1",
        "Affiliations": "1 Tata Memorial Centre; 2 The Clatterbridge Cancer Centre",
        "Objective": "The objective of this study was to prospectively quantify tumor growth kinetics, tumor volume doubling time (TVDT), stage migration, and the biological impact of treatment delay in patients with untreated oral squamous cell carcinoma (OSCC).",
        "Study Design": "Prospective observational cohort study conducted at a high-volume tertiary cancer center.",
        "Setting": "Tata Memorial Centre, Mumbai, India.",
        "Patients": "Between July 2020 and December 2023, 677 treatment-naïve OSCC patients were screened. Of these, 483 (71.3%) met inclusion criteria and proceeded to curative-intent surgery. Eligibility required two pre-treatment cross-sectional imaging studies—contrast-enhanced CT, MRI, or PET-CT—performed at least three weeks apart, enabling radiologic assessment of tumor progression.",
        "Exposure": "Tumor progression during the interval from diagnostic biopsy to definitive surgery, quantified using changes in gross tumor volume (GTV), weekly percent growth, and TVDT calculated using the Schwartz exponential model.",
        "Main Outcome Measures": "Primary outcomes included changes in GTV, weekly growth rate, TVDT, and T- or N-category progression per AJCC 8th edition. Secondary outcomes included overall survival (OS), disease-specific survival (DSS), and recurrence patterns. Multivariable Cox regression was used to identify independent predictors of survival.",
        "Results": "The median interval between imaging studies was 7.1 weeks (IQR 5.9–9.4). Median baseline GTV increased from 12.9 cm³ (IQR 8.1–20.2) to 19.4 cm³ (IQR 12.3–28.6), reflecting a median weekly growth rate of 7.3% and a TVDT of 7.9 weeks. Tongue tumors grew most rapidly (9.6% weekly; TVDT 6.2 weeks), followed by poorly differentiated tumors (10.4% weekly; TVDT 6.0 weeks).",
        "Abstract": "T-category progression occurred in 33% of patients: 36% of T1, 44% of T2, and 41% of T3 tumors progressed to higher categories. Nodal progression occurred in 23%, and overall stage migration in 30%, prompting escalation in surgical extent in 28% of patients. At a median follow-up of 25 months, 2-year OS and DSS were 67% and 73%. Patients with TVDT ≤8 weeks had inferior OS (58% vs 74%; HR 1.7, 95% CI 1.2–2.3). Treatment delay >8 weeks similarly predicted worse OS (55% vs 75%; HR 1.6, 95% CI 1.1–2.3). Advanced T/N-category, depth of invasion >10 mm, perineural invasion, WPOI 4–5, and stage migration were additional independent predictors. View in Agenda and Add to Schedule",
        "Conclusions": "OSCC exhibits rapid volumetric progression and often doubles in size within 6–10 weeks. Tumor kinetics, particularly TVDT, quantify the biological cost of treatment delay and may improve triage and scheduling decisions in resource-limited settings."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prospective Tumor Kinetics Reveal the Biological Cost of Delay in Oral Cancer</span>. <u>Arjun G Singh</u><sup>1</sup>; Abhishek Mahajan<sup>2</sup>; Shwetabh Sinha<sup>1</sup>; Rathan Shetty<sup>1</sup>; Samarprita Mohanty<sup>1</sup>; Anuj Kumar<sup>1</sup>; Nivedita Chakrabarty<sup>1</sup>; Poonam Joshi<sup>1</sup>; Sudhir Nair<sup>1</sup>; Sarbani Ghosh Laskar<sup>1</sup>; Kumar Prabhash<sup>1</sup>; Pankaj Chaturvedi<sup>1</sup>. <sup>1</sup>Tata Memorial Centre; <sup>2</sup>The Clatterbridge Cancer Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The objective of this study was to prospectively quantify tumor growth kinetics, tumor volume doubling time (TVDT), stage migration, and the biological impact of treatment delay in patients with untreated oral squamous cell carcinoma (OSCC).</p>\n\n<p><strong>Study Design: </strong>Prospective observational cohort study conducted at a high-volume tertiary cancer center.</p>\n\n<p><strong>Setting: </strong>Tata Memorial Centre, Mumbai, India.</p>\n\n<p><strong>Patients: </strong>Between July 2020 and December 2023, 677 treatment-naïve OSCC patients were screened. Of these, 483 (71.3%) met inclusion criteria and proceeded to curative-intent surgery. Eligibility required two pre-treatment cross-sectional imaging studies—contrast-enhanced CT, MRI, or PET-CT—performed at least three weeks apart, enabling radiologic assessment of tumor progression.</p>\n\n<p><strong>Exposure: </strong>Tumor progression during the interval from diagnostic biopsy to definitive surgery, quantified using changes in gross tumor volume (GTV), weekly percent growth, and TVDT calculated using the Schwartz exponential model.</p>\n\n<p><strong>Main Outcome Measures: </strong>Primary outcomes included changes in GTV, weekly growth rate, TVDT, and T- or N-category progression per AJCC 8th edition. Secondary outcomes included overall survival (OS), disease-specific survival (DSS), and recurrence patterns. Multivariable Cox regression was used to identify independent predictors of survival.</p>\n\n<p><strong>Results: </strong>The median interval between imaging studies was 7.1 weeks (IQR 5.9–9.4). Median baseline GTV increased from 12.9 cm³ (IQR 8.1–20.2) to 19.4 cm³ (IQR 12.3–28.6), reflecting a median weekly growth rate of 7.3% and a TVDT of 7.9 weeks. Tongue tumors grew most rapidly (9.6% weekly; TVDT 6.2 weeks), followed by poorly differentiated tumors (10.4% weekly; TVDT 6.0 weeks).</p>\n\n<p><img alt='Figure 1' src='https://www.submitmyabstract.com/abs/images/153803/Figure1.png' /></p>\n\n<p>T-category progression occurred in 33% of patients: 36% of T1, 44% of T2, and 41% of T3 tumors progressed to higher categories. Nodal progression occurred in 23%, and overall stage migration in 30%, prompting escalation in surgical extent in 28% of patients. At a median follow-up of 25 months, 2-year OS and DSS were 67% and 73%. Patients with TVDT ≤8 weeks had inferior OS (58% vs 74%; HR 1.7, 95% CI 1.2–2.3). Treatment delay >8 weeks similarly predicted worse OS (55% vs 75%; HR 1.6, 95% CI 1.1–2.3). Advanced T/N-category, depth of invasion >10 mm, perineural invasion, WPOI 4–5, and stage migration were additional independent predictors.</p>\n\n<p><img alt='Figure 2a' src='https://www.submitmyabstract.com/abs/images/153803/Figure%202a.png' /></p>\n\n<p><img alt='Figure 2b' src='https://www.submitmyabstract.com/abs/images/153803/Figure%202b.png' /></p>\n\n<p><strong>Conclusions: </strong>OSCC exhibits rapid volumetric progression and often doubles in size within 6–10 weeks. Tumor kinetics, particularly TVDT, quantify the biological cost of treatment delay and may improve triage and scheduling decisions in resource-limited settings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153803--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S310",
      "content_id": "153059",
      "abstract_number": "S310",
      "poster_number": "",
      "title": "Human and viral whole genome sequencing identify HPV and APOBEC as oncogenic drivers in sinonasal squamous cell carcinoma",
      "summary": "Paired human and viral WGS reveals that HPV drives tumorigenesis in SNSCC through diverse genotypes, APOBEC-mediated mutagenesis, and integration-linked ecDNA formation. These mechanisms expand the known spectrum of viral oncogenesis beyond the oropharynx, highlighting novel routes of genomic instability and supporting the inclusion of broad HPV genotyping and viral-genomic assays in diagnostic and translational...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153059",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lukasz Zareba",
      "presenter": "Lukasz Zareba",
      "authors": "Lukasz Zareba 1 ; Harrison Chong 2 ; Michael E Bryan 1 ; Maoxuan Lin, PhD 2 ; Magdy Gohar 2 ; William C Faquin, MD, PhD 2 ; Lisa J Mirabello, PhD 3 ; James S Lewis, MD 4 ; Michael S Lawrence, PhD 5 ; Daniel L Faden, MD 1 . 1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital; 3 NCI Div",
      "normalized_authors": [
        "Lukasz Zareba",
        "Harrison Chong",
        "Michael E Bryan",
        "Maoxuan Lin",
        "Magdy Gohar",
        "William C Faquin",
        "Lisa J Mirabello",
        "James S Lewis",
        "Michael S Lawrence",
        "Daniel L Faden, . Massachusetts Eye & Ear",
        "NCI Div"
      ],
      "affiliations": [
        "of Cancer Epidemiology & Genetics",
        "Vanderbilt University Medical Center",
        "Broad Institute of Harvard and MIT"
      ],
      "normalized_institutions": [
        "of Cancer Epidemiology & Genetics",
        "Vanderbilt University Medical Center",
        "Broad Institute of Harvard and MIT"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 295,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lukasz Zareba 1 ; Harrison Chong 2 ; Michael E Bryan 1 ; Maoxuan Lin, PhD 2 ; Magdy Gohar 2 ; William C Faquin, MD, PhD 2 ; Lisa J Mirabello, PhD 3 ; James S Lewis, MD 4 ; Michael S Lawrence, PhD 5 ; Daniel L Faden, MD 1 . 1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital; 3 NCI Div",
        "Affiliations": "of Cancer Epidemiology & Genetics; 4 Vanderbilt University Medical Center; 5 Broad Institute of Harvard and MIT",
        "Background": "Sinonasal squamous cell carcinoma (SNSCC) is a rare, aggressive malignancy with limited molecular characterization. Emerging evidence implicates human papillomavirus (HPV) in a subset of cases, but the genomic interplay between viral and host factors remains poorly defined.",
        "Methods": "We performed paired host and viral whole-genome sequencing (WGS) on 21 SNSCC tumors with matched normal samples, including ultra-deep viral WGS (10,000×) and comprehensive HPV PCR genotyping. Somatic mutations, viral integration, structural variants, and mutational signatures were analyzed using established computational pipelines.",
        "Results": "Eighteen of 21 (86%) tumors were HPV-positive by WGS or PCR, with 94% concordance across assays. Unlike oropharyngeal squamous cell carcinoma (OPSCC), where HPV16 predominates, SNSCC exhibited nine HPV genotypes, including HPV11, 18, 35, 39, 45, 51, 56, and 59. Viral integration events were detected in most HPV-positive tumors, including an HPV45-TP63 fusion amplified as extrachromosomal DNA (ecDNA), representing, to our knowledge, the first HPV-associated ecDNA-like amplicon in SNSCC. Multi-genotype infections showed a single dominant integrating type, indicating that one “driver” genotype typically initiates tumorigenesis. Host mutational analysis revealed recurrent clonal mutations in PIK3CA, CHEK2, and KDM6A, with depletion of TP53 and CDKN2A alterations in high-risk HPV+ cases. Mutational signature analysis identified predominant APOBEC3 activity, independent of smoking, which extended to viral genomes, providing direct evidence of concurrent host-virus APOBEC mutagenesis. Structural variants were common, including focal PTEN loss and complex rearrangements such as chromothripsis and chromoplexy, underscoring pervasive genomic instability.",
        "Conclusions": "Paired human and viral WGS reveals that HPV drives tumorigenesis in SNSCC through diverse genotypes, APOBEC-mediated mutagenesis, and integration-linked ecDNA formation. These mechanisms expand the known spectrum of viral oncogenesis beyond the oropharynx, highlighting novel routes of genomic instability and supporting the inclusion of broad HPV genotyping and viral-genomic assays in diagnostic and translational frameworks for SNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Human and viral whole genome sequencing identify HPV and APOBEC as oncogenic drivers in sinonasal squamous cell carcinoma</span>. <u>Lukasz  Zareba</u><sup>1</sup>; Harrison Chong<sup>2</sup>; Michael E Bryan<sup>1</sup>; Maoxuan Lin, PhD<sup>2</sup>; Magdy Gohar<sup>2</sup>; William C Faquin, MD, PhD<sup>2</sup>; Lisa J Mirabello, PhD<sup>3</sup>; James S Lewis, MD<sup>4</sup>; Michael S Lawrence, PhD<sup>5</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Massachusetts General Hospital; <sup>3</sup>NCI Div. of Cancer Epidemiology & Genetics; <sup>4</sup>Vanderbilt University Medical Center; <sup>5</sup>Broad Institute of Harvard and MIT<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Sinonasal squamous cell carcinoma (SNSCC) is a rare, aggressive malignancy with limited molecular characterization. Emerging evidence implicates human papillomavirus (HPV) in a subset of cases, but the genomic interplay between viral and host factors remains poorly defined.</p>\n\n<p><strong>Methods:</strong> We performed paired host and viral whole-genome sequencing (WGS) on 21 SNSCC tumors with matched normal samples, including ultra-deep viral WGS (10,000×) and comprehensive HPV PCR genotyping. Somatic mutations, viral integration, structural variants, and mutational signatures were analyzed using established computational pipelines.</p>\n\n<p><strong>Results:</strong> Eighteen of 21 (86%) tumors were HPV-positive by WGS or PCR, with 94% concordance across assays. Unlike oropharyngeal squamous cell carcinoma (OPSCC), where HPV16 predominates, SNSCC exhibited nine HPV genotypes, including HPV11, 18, 35, 39, 45, 51, 56, and 59. Viral integration events were detected in most HPV-positive tumors, including an HPV45-TP63 fusion amplified as extrachromosomal DNA (ecDNA), representing, to our knowledge, the first HPV-associated ecDNA-like amplicon in SNSCC. Multi-genotype infections showed a single dominant integrating type, indicating that one “driver” genotype typically initiates tumorigenesis. Host mutational analysis revealed recurrent clonal mutations in PIK3CA, CHEK2, and KDM6A, with depletion of TP53 and CDKN2A alterations in high-risk HPV+ cases. Mutational signature analysis identified predominant APOBEC3 activity, independent of smoking, which extended to viral genomes, providing direct evidence of concurrent host-virus APOBEC mutagenesis. Structural variants were common, including focal PTEN loss and complex rearrangements such as chromothripsis and chromoplexy, underscoring pervasive genomic instability.</p>\n\n<p><strong>Conclusions:</strong> Paired human and viral WGS reveals that HPV drives tumorigenesis in SNSCC through diverse genotypes, APOBEC-mediated mutagenesis, and integration-linked ecDNA formation. These mechanisms expand the known spectrum of viral oncogenesis beyond the oropharynx, highlighting novel routes of genomic instability and supporting the inclusion of broad HPV genotyping and viral-genomic assays in diagnostic and translational frameworks for SNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153059--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S311",
      "content_id": "154281",
      "abstract_number": "S311",
      "poster_number": "",
      "title": "Retrospective Cohort Study on Plasma Epstein-Barr Virus DNA Levels and Its Implications in Monitoring Recurrence of Nasopharyngeal Carcinoma Post-Treatment",
      "summary": "This study demonstrates a negative predictive value of 98% for plasma EBV DNA in detecting NPC recurrence, which is consistent with previously published studies. EBV DNA positivity during follow-up also correlated well with eventual recurrence in our study (p < 0.001). These findings lend support to the use of plasma EBV DNA levels as a form of liquid biopsy to enhance surveillance strategies for NPC recurrence.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154281",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "How Ting Ong, MBBS",
      "presenter": "How Ting Ong, MBBS",
      "authors": "How Ting Ong, MBBS 1 ; Ming Yann Lim, MBBS, MRCS, DOHNS, MMedORL, FAMSORL 1 ; Bei Jun Yap, MBBS 1 ; Khin Chaw Yu Aung, PhD 1 ; Hao Li, MBBS, MCI, FAMSORL 1 ; Ernest W Fu, MBBS, MRCS, MMedORL, FAMSORL 1 ; Jerome Z Ong, MBBS, MRCS 1 ; Timothy Cheo, MBBS, RANZCR 2 ; Hui Lin Teo, MBBS, MRCPUK 1 ; Elise K Vong, MBBS, MRCPUK 1 ; Francis Ho, MBBS, RANZCR, FAMS 2 ; Jereme Y Gan, MBBS, MRCS, MMedORL, FAMSORL 1",
      "normalized_authors": [
        "How Ting Ong, MBBS",
        "Ming Yann Lim, MBBS, MRCS, DOHNS, MMedORL, FAMSORL",
        "Bei Jun Yap, MBBS",
        "Khin Chaw Yu Aung",
        "Hao Li, MBBS, MCI, FAMSORL",
        "Ernest W Fu, MBBS, MRCS, MMedORL, FAMSORL",
        "Jerome Z Ong, MBBS, MRCS",
        "Timothy Cheo, MBBS, RANZCR",
        "Hui Lin Teo, MBBS, MRCPUK",
        "Elise K Vong, MBBS, MRCPUK",
        "Francis Ho, MBBS, RANZCR, FAMS",
        "Jereme Y Gan, MBBS, MRCS, MMedORL, FAMSORL"
      ],
      "affiliations": [
        "Tan Tock Seng Hospital, Singapore",
        "National University Cancer Institute, Singapore"
      ],
      "normalized_institutions": [
        "Tan Tock Seng Hospital, Singapore",
        "National University Cancer Institute, Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 477,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "How Ting Ong, MBBS 1 ; Ming Yann Lim, MBBS, MRCS, DOHNS, MMedORL, FAMSORL 1 ; Bei Jun Yap, MBBS 1 ; Khin Chaw Yu Aung, PhD 1 ; Hao Li, MBBS, MCI, FAMSORL 1 ; Ernest W Fu, MBBS, MRCS, MMedORL, FAMSORL 1 ; Jerome Z Ong, MBBS, MRCS 1 ; Timothy Cheo, MBBS, RANZCR 2 ; Hui Lin Teo, MBBS, MRCPUK 1 ; Elise K Vong, MBBS, MRCPUK 1 ; Francis Ho, MBBS, RANZCR, FAMS 2 ; Jereme Y Gan, MBBS, MRCS, MMedORL, FAMSORL 1",
        "Affiliations": "1 Tan Tock Seng Hospital, Singapore; 2 National University Cancer Institute, Singapore",
        "Background": "Recurrence of nasopharyngeal carcinoma (NPC) is associated with poorer prognosis and remains a significant clinical challenge. Epstein-Barr Virus (EBV) infection is strongly linked to the pathogenesis of NPC, and elevated post-treatment plasma EBV DNA levels have been shown to correlate with recurrence, supporting its use as a biomarker for surveillance. To further examine the relationship between EBV DNA levels and NPC recurrence in an endemic region, we conducted a retrospective cohort study of patients diagnosed with NPC in Tan Tock Seng Hospital (TTSH), Singapore.",
        "Methods": "All patients discussed at the multidisciplinary TTSH Head and Neck Tumour Board for management of NPC from 1st January 2019 to 31st December 2023 were screened. A total of 223 patients were identified. 165 patients were excluded according to the following exclusion criteria: absence of histologically confirmed NPC; absence of staging with the AJCC 8th Edition; incomplete definitive treatment; absence of plasma EBV DNA measurements either immediately post-treatment or during follow-up; indeterminate recurrence during follow-up; and loss to follow-up. 58 patients were included in the final analysis.",
        "Results": "All 58 patients (100%) were diagnosed with non-keratinizing NPC. 8 patients (13.8%) were eventually diagnosed with recurrence during follow-up, while 50 patients (86.2%) remained recurrence-free. Age and sex distributions were not found to be statistically different between the two groups. The recurrence group had a mean age of 62.3 ± 11.8 years old compared to 56.9 ± 11.3 years in the non-recurrence group (p = 0.2). Males comprised 7 out of 8 (87.5%) patients in the recurrence group and 36 out of 50 (72.0%) patients in the non-recurrence group (p = 0.67).",
        "Abstract": "Mean plasma EBV DNA levels taken immediately post-treatment were higher in the recurrence group (2115.3 ± 3206.6 copies/ml) compared to the non-recurrence group (309.7 ± 120.9 copies/ml) with a medium effect size, but no statistical significance (Mann-Whitney U test: ε 2 = 0.11, p = 0.4). EBV DNA positivity during follow-up was strongly associated with recurrence as 7 out of 8 (87.5%) patients with recurrence had detectable plasma EBV DNA levels, compared to 1 out of 50 (2.0%) patients without recurrence. This finding was statistically significant (Fisher’s exact test: p < 0.001). Among the 7 patients with positive plasma EBV DNA at recurrence, 5 (71.4%) had locoregional recurrence and 2 (28.6%) had metastatic recurrence. The single patient with EBV DNA-negative recurrence was diagnosed with locoregional recurrence. View in Agenda and Add to Schedule",
        "Conclusion": "This study demonstrates a negative predictive value of 98% for plasma EBV DNA in detecting NPC recurrence, which is consistent with previously published studies. EBV DNA positivity during follow-up also correlated well with eventual recurrence in our study (p < 0.001). These findings lend support to the use of plasma EBV DNA levels as a form of liquid biopsy to enhance surveillance strategies for NPC recurrence."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Retrospective Cohort Study on Plasma Epstein-Barr Virus DNA Levels and Its Implications in Monitoring Recurrence of Nasopharyngeal Carcinoma Post-Treatment</span>. <u>How Ting Ong, MBBS</u><sup>1</sup>; Ming Yann Lim, MBBS, MRCS, DOHNS, MMedORL, FAMSORL<sup>1</sup>; Bei Jun Yap, MBBS<sup>1</sup>; Khin Chaw Yu Aung, PhD<sup>1</sup>; Hao Li, MBBS, MCI, FAMSORL<sup>1</sup>; Ernest W Fu, MBBS, MRCS, MMedORL, FAMSORL<sup>1</sup>; Jerome Z Ong, MBBS, MRCS<sup>1</sup>; Timothy Cheo, MBBS, RANZCR<sup>2</sup>; Hui Lin Teo, MBBS, MRCPUK<sup>1</sup>; Elise K Vong, MBBS, MRCPUK<sup>1</sup>; Francis Ho, MBBS, RANZCR, FAMS<sup>2</sup>; Jereme Y Gan, MBBS, MRCS, MMedORL, FAMSORL<sup>1</sup>. <sup>1</sup>Tan Tock Seng Hospital, Singapore; <sup>2</sup>National University Cancer Institute, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Recurrence of nasopharyngeal carcinoma (NPC) is associated with poorer prognosis and remains a significant clinical challenge. Epstein-Barr Virus (EBV) infection is strongly linked to the pathogenesis of NPC, and elevated post-treatment plasma EBV DNA levels have been shown to correlate with recurrence, supporting its use as a biomarker for surveillance. To further examine the relationship between EBV DNA levels and NPC recurrence in an endemic region, we conducted a retrospective cohort study of patients diagnosed with NPC in Tan Tock Seng Hospital (TTSH), Singapore.</p>\n\n<p><strong>Methods: </strong>All patients discussed at the multidisciplinary TTSH Head and Neck Tumour Board for management of NPC from 1st January 2019 to 31st December 2023 were screened. A total of 223 patients were identified. 165 patients were excluded according to the following exclusion criteria: absence of histologically confirmed NPC; absence of staging with the AJCC 8th Edition; incomplete definitive treatment; absence of plasma EBV DNA measurements either immediately post-treatment or during follow-up; indeterminate recurrence during follow-up; and loss to follow-up. 58 patients were included in the final analysis.</p>\n\n<p><strong>Results: </strong>All 58 patients (100%) were diagnosed with non-keratinizing NPC. 8 patients (13.8%) were eventually diagnosed with recurrence during follow-up, while 50 patients (86.2%) remained recurrence-free. Age and sex distributions were not found to be statistically different between the two groups. The recurrence group had a mean age of 62.3 ± 11.8 years old compared to 56.9 ± 11.3 years in the non-recurrence group (p = 0.2). Males comprised 7 out of 8 (87.5%) patients in the recurrence group and 36 out of 50 (72.0%) patients in the non-recurrence group (p = 0.67).</p>\n\n<p>Mean plasma EBV DNA levels taken immediately post-treatment were higher in the recurrence group (2115.3 ± 3206.6 copies/ml) compared to the non-recurrence group (309.7 ± 120.9 copies/ml) with a medium effect size, but no statistical significance (Mann-Whitney U test: ε<sup>2</sup> = 0.11, p = 0.4). EBV DNA positivity during follow-up was strongly associated with recurrence as 7 out of 8 (87.5%) patients with recurrence had detectable plasma EBV DNA levels, compared to 1 out of 50 (2.0%) patients without recurrence. This finding was statistically significant (Fisher’s exact test: p < 0.001).</p>\n\n<p>Among the 7 patients with positive plasma EBV DNA at recurrence, 5 (71.4%) had locoregional recurrence and 2 (28.6%) had metastatic recurrence. The single patient with EBV DNA-negative recurrence was diagnosed with locoregional recurrence.</p>\n\n<p><strong>Conclusion: </strong>This study demonstrates a negative predictive value of 98% for plasma EBV DNA in detecting NPC recurrence, which is consistent with previously published studies. EBV DNA positivity during follow-up also correlated well with eventual recurrence in our study (p < 0.001). These findings lend support to the use of plasma EBV DNA levels as a form of liquid biopsy to enhance surveillance strategies for NPC recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154281--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S312",
      "content_id": "154002",
      "abstract_number": "S312",
      "poster_number": "",
      "title": "Tumor-intrinsic molecular traits underlying elevated HPV+ OPC recurrence risk in older patients",
      "summary": "These results confirm advanced age to be a risk factor for HPV+ OPC recurrence. In younger patients, biologic traits linked to recurrence risk appear to be predominantly immune-related whereas specific tumor-intrinsic features likely make greater contributions to treatment failure in older individuals. Our observations provide novel insight into molecular underpinnings of elevated recurrence risk that are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154002",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vikram Vasan, MD",
      "presenter": "Vikram Vasan, MD",
      "authors": "Vikram Vasan, MD 1 ; Lovely Raghav, PhD 1 ; Dominick Rich, BS 1 ; Anusha Naik, MD 1 ; Malay Sannigrahi, PhD 1 ; Alexander Lin, MD 1 ; Lova Sun, MD 1 ; Noam Auslander, PhD 2 ; Karthik Rajasekaran, MD 1 ; John Lukens, MD 1 ; Phyllis Gimotty, PhD 1 ; Ahmed Diab, PhD 1 ; Robert Brody, MD 1 ; Jalal Jalaly, MD 1 ; Devraj Basu, MD, PhD 1",
      "normalized_authors": [
        "Vikram Vasan",
        "Lovely Raghav",
        "Dominick Rich",
        "Anusha Naik",
        "Malay Sannigrahi",
        "Alexander Lin",
        "Lova Sun",
        "Noam Auslander",
        "Karthik Rajasekaran",
        "John Lukens",
        "Phyllis Gimotty",
        "Ahmed Diab",
        "Robert Brody",
        "Jalal Jalaly",
        "Devraj Basu"
      ],
      "affiliations": [
        "University of Pennsylvania",
        "Wistar Institute"
      ],
      "normalized_institutions": [
        "University of Pennsylvania",
        "Wistar Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154002/Figure%20final%20submission.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154002/Figure%20final%20submission.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154002"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 524,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background/objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vikram Vasan, MD 1 ; Lovely Raghav, PhD 1 ; Dominick Rich, BS 1 ; Anusha Naik, MD 1 ; Malay Sannigrahi, PhD 1 ; Alexander Lin, MD 1 ; Lova Sun, MD 1 ; Noam Auslander, PhD 2 ; Karthik Rajasekaran, MD 1 ; John Lukens, MD 1 ; Phyllis Gimotty, PhD 1 ; Ahmed Diab, PhD 1 ; Robert Brody, MD 1 ; Jalal Jalaly, MD 1 ; Devraj Basu, MD, PhD 1",
        "Affiliations": "1 University of Pennsylvania; 2 Wistar Institute",
        "Background/objectives": "Average age at presentation for HPV+ oropharyngeal carcinomas (OPCs) has increased, and there is evidence of elevated recurrence risk in older patients. This study evaluated HPV+ OPCs for molecular traits linked to recurrence risk that are specific to older patients and might guide therapeutic personalization for this demographic.",
        "Methods": "A single institution cohort of 851 treatment-naïve HPV+ OPCs receiving TORS-based therapy during 2007-2020 was used to curate 50 tumors that later recurred ( cases ) plus 50 that were cured ( controls ). Cases and controls were matched for pathologic stage, smoking history, and adjuvant therapy. RNAseq was used to define transcriptional features differentially expressed between cases and controls, as detailed previously (Sannigrahi MK et.al, JNCI 2025 117:7). As in the prior study, distinguishing features of cases were classified as tumor-intrinsic or immune-related and quantified for each tumor using three scores: (1) an immune suppression score ( ISS ) measuring reduced anti-tumor immunity, (2) a tumor progression score ( TPS ) reflecting multiple tumor-intrinsic aspects of cancer progression, and (3) a combined score incorporating both TPS and ISS, which previously optimized recurrence prediction across multiple cohorts. Molecular scores were compared among older and younger patient groups subdivided by recurrence status. Findings related to ISS were validated by quantifying tumor-infiltrating leukocytes (TILs) using CD45 immunohistochemistry. Univariate and multivariate analyses were performed using logistic regression.",
        "Results": "The Youden index cut point for age that optimally stratified recurrence risk in the overall cohort (n=851) revealed worse 5-year recurrence-free survival in older patients (HR 1.82, 95% CI 1.24–2.67, p=0.002) (Figure 1A). Youden index similarly separated the case-control cohort into a young group (age <57 years, n=36) and an old group (age >=57, n=64), which had greater recurrence risk (OR=2.42, 95% CI 1.05-5.63, p=0.039). TPS and ISS did not differ significantly between the control OPCs from young vs. old patients. Marked elevation of both TPS (p<0.001) and ISS (p=0.002) was observed in old cases vs. old controls, whereas only ISS was elevated (p=0.020) in young cases vs. young controls (Figure 1B). Differences in ISS among groups were concordant with differences in %TIL content. Hallmark pathways contributing to TPS that were upregulated in old cases but not young cases included mTOR signaling, multiple biosynthetic and bioenergetic mitochondrial functions, and EMT. Young cases and young controls retained comparable demographic, clinical, and pathologic features in univariate analysis, whereas old cases had more frequent ENE (p=0.004) and PNI (p=0.018) vs. old controls; however, multivariate analysis showed the molecular combined score to be the dominant independent association with recurrence risk (p=0.003) in the old group.",
        "Conclusions": "These results confirm advanced age to be a risk factor for HPV+ OPC recurrence. In younger patients, biologic traits linked to recurrence risk appear to be predominantly immune-related whereas specific tumor-intrinsic features likely make greater contributions to treatment failure in older individuals. Our observations provide novel insight into molecular underpinnings of elevated recurrence risk that are specific to older HPV+ OPC patients and may guide development of biomarkers particularly relevant to these individuals.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tumor-intrinsic molecular traits underlying elevated HPV+ OPC recurrence risk in older patients</span>. <u>Vikram Vasan, MD</u><sup>1</sup>; Lovely Raghav, PhD<sup>1</sup>; Dominick Rich, BS<sup>1</sup>; Anusha Naik, MD<sup>1</sup>; Malay Sannigrahi, PhD<sup>1</sup>; Alexander Lin, MD<sup>1</sup>; Lova Sun, MD<sup>1</sup>; Noam Auslander, PhD<sup>2</sup>; Karthik Rajasekaran, MD<sup>1</sup>; John Lukens, MD<sup>1</sup>; Phyllis Gimotty, PhD<sup>1</sup>; Ahmed Diab, PhD<sup>1</sup>; Robert Brody, MD<sup>1</sup>; Jalal Jalaly, MD<sup>1</sup>; Devraj Basu, MD, PhD<sup>1</sup>. <sup>1</sup>University of Pennsylvania; <sup>2</sup>Wistar Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background/objectives:</strong> Average age at presentation for HPV+ oropharyngeal carcinomas (OPCs) has increased, and there is evidence of elevated recurrence risk in older patients. This study evaluated HPV+ OPCs for molecular traits linked to recurrence risk that are specific to older patients and might guide therapeutic personalization for this demographic.</p>\n\n<p><strong>Methods:</strong> A single institution cohort of 851 treatment-naïve HPV+ OPCs receiving TORS-based therapy during 2007-2020 was used to curate 50 tumors that later recurred (<em>cases</em>) plus 50 that were cured (<em>controls</em>). Cases and controls were matched for pathologic stage, smoking history, and adjuvant therapy. RNAseq was used to define transcriptional features differentially expressed between cases and controls, as detailed previously (Sannigrahi MK et.al, <em>JNCI </em>2025 117:7). As in the prior study, distinguishing features of cases were classified as tumor-intrinsic or immune-related and quantified for each tumor using three scores: (1) an immune suppression score (<em>ISS</em>) measuring reduced anti-tumor immunity, (2) a tumor progression score (<em>TPS</em>) reflecting multiple tumor-intrinsic aspects of cancer progression, and (3) a <em>combined score</em> incorporating both TPS and ISS, which previously optimized recurrence prediction across multiple cohorts. Molecular scores were compared among older and younger patient groups subdivided by recurrence status. Findings related to ISS were validated by quantifying tumor-infiltrating leukocytes (TILs) using CD45 immunohistochemistry.  Univariate and multivariate analyses were performed using logistic regression.</p>\n\n<p><strong>Results:</strong> The Youden index cut point for age that optimally stratified recurrence risk in the overall cohort (n=851) revealed worse 5-year recurrence-free survival in older patients (HR 1.82, 95% CI 1.24–2.67, p=0.002) (Figure 1A). Youden index similarly separated the case-control cohort into a young group (age <57 years, n=36) and an old group (age >=57, n=64), which had greater recurrence risk (OR=2.42, 95% CI 1.05-5.63, p=0.039). TPS and ISS did not differ significantly between the control OPCs from young vs. old patients. Marked elevation of both TPS (p<0.001) and ISS (p=0.002) was observed in old cases vs. old controls, whereas only ISS was elevated (p=0.020) in young cases vs. young controls (Figure 1B). Differences in ISS among groups were concordant with differences in %TIL content. Hallmark pathways contributing to TPS that were upregulated in old cases but not young cases included mTOR signaling, multiple biosynthetic and bioenergetic mitochondrial functions, and EMT. Young cases and young controls retained comparable demographic, clinical, and pathologic features in univariate analysis, whereas old cases had more frequent ENE (p=0.004) and PNI (p=0.018) vs. old controls; however, multivariate analysis showed the molecular combined score to be the dominant independent association with recurrence risk (p=0.003) in the old group.</p>\n\n<p><strong>Conclusions:</strong> These results confirm advanced age to be a risk factor for HPV+ OPC recurrence. In younger patients, biologic traits linked to recurrence risk appear to be predominantly immune-related whereas specific tumor-intrinsic features likely make greater contributions to treatment failure in older individuals. Our observations provide novel insight into molecular underpinnings of elevated recurrence risk that are specific to older HPV+ OPC patients and may guide development of biomarkers particularly relevant to these individuals.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154002/Figure%20final%20submission.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154002--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S313",
      "content_id": "153879",
      "abstract_number": "S313",
      "poster_number": "",
      "title": "Comparative Glycoproteomics of Oral Non-Cancer Tissue and Invasive Squamous Cell Carcinoma for Glycoprotein Biomarker Discovery",
      "summary": "Here, a set of differentially glycosylated proteins (non-cancer versus invasive oral cancer) were characterized, including proteins that originate from the basement membrane. This subset, which may also be shed into the saliva, contains attractive targets for the development of a glycoprotein liquid biopsy for early detection of oral cancer. Future studies will focus on extending these analyses to in situ...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153879",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kevin B Chandler",
      "presenter": "Kevin B Chandler",
      "authors": "Gabriela Sabogal 1 ; Carlos H Pavan 1 ; Maria Abreu 2 ; Geoffrey D Young 2 ; Kevin B Chandler 1",
      "normalized_authors": [
        "Gabriela Sabogal",
        "Carlos H Pavan",
        "Maria Abreu",
        "Geoffrey D Young",
        "Kevin B Chandler"
      ],
      "affiliations": [
        "Florida International University",
        "Miami Cancer Institute, Baptist Health"
      ],
      "normalized_institutions": [
        "Florida International University",
        "Miami Cancer Institute, Baptist Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 385,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriela Sabogal 1 ; Carlos H Pavan 1 ; Maria Abreu 2 ; Geoffrey D Young 2 ; Kevin B Chandler 1",
        "Affiliations": "1 Florida International University; 2 Miami Cancer Institute, Baptist Health",
        "Background": "Approximately 60,000 people are diagnosed annually with squamous cell carcinomas arising in the oral cavity and oropharynx, with survival inversely correlated with disease stage at the time of diagnosis. Individuals diagnosed with advanced disease have a predicted 5-year relative survival rate of 22-46%, depending on the primary tumor site. Therefore, strategies to increase early detection and treatment are desperately needed to reduce mortality from this devastating disease. Patterns of protein glycosylation change during the development of cancer, including during epithelial-to-mesenchymal transition (EMT). This raises the possibility that monitoring patterns of glycosylation on cell-surface and secreted glycoproteins could provide an accessible signature of early-stage disease. Here, we applied proteomic and glycoproteomic workflows to survey glycoproteins in oral non-cancer tissue and invasive squamous cell carcinoma, for glycoprotein biomarker candidate discovery.",
        "Methods": "Proteomics and glycoproteomics were performed on formalin-fixed, paraffin-embedded human oral tissue specimens including invasive squamous cell carcinoma (n=5) and paired non-cancer tissue (n=5). Mass spectrometry data acquired on an Orbitrap Eclipse Tribrid mass spectrometer with an EASY-nLC 1200 system, was analyzed with Byonic (Protein Metrics) and pGlyco3, using the UniProt human protein sequence database and a human N-glycan structure database, for peptide and glycopeptide assignment. For quantitative comparisons, glycopeptide areas under the curve (AUC) were determined, and glycoform relative abundances were compared between experimental groups. Significance was assessed using Student’s t-test.",
        "Results": "Analyses of non-cancer and invasive squamous cell carcinoma tissue led to the confident identification of 4478 unique proteins (1% FDR). Additionally, 447 differentially expressed proteins (p<0.05) were found using label-free quantification, with proteins involved in cell division, RNA metabolism, and ribosome biogenesis enriched in tumor samples. In this initial study, 178 unique glycopeptides from 52 proteins were identified (≤1% FDR). Statistically significant changes in protein glycoforms were found between normal and invasive tumor samples, suggesting that the glycoproteins identified here should undergo further evaluation as potential markers.",
        "Conclusion": "Here, a set of differentially glycosylated proteins (non-cancer versus invasive oral cancer) were characterized, including proteins that originate from the basement membrane. This subset, which may also be shed into the saliva, contains attractive targets for the development of a glycoprotein liquid biopsy for early detection of oral cancer. Future studies will focus on extending these analyses to in situ carcinomas and a larger sample cohort.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Glycoproteomics of Oral Non-Cancer Tissue and Invasive Squamous Cell Carcinoma for Glycoprotein Biomarker Discovery</span>. Gabriela Sabogal<sup>1</sup>; Carlos H Pavan<sup>1</sup>; Maria Abreu<sup>2</sup>; Geoffrey D Young<sup>2</sup>; <u>Kevin B Chandler</u><sup>1</sup>. <sup>1</sup>Florida International University; <sup>2</sup>Miami Cancer Institute, Baptist Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Approximately 60,000 people are diagnosed annually with squamous cell carcinomas arising in the oral cavity and oropharynx, with survival inversely correlated with disease stage at the time of diagnosis. Individuals diagnosed with advanced disease have a predicted 5-year relative survival rate of 22-46%, depending on the primary tumor site. Therefore, strategies to increase early detection and treatment are desperately needed to reduce mortality from this devastating disease. Patterns of protein glycosylation change during the development of cancer, including during epithelial-to-mesenchymal transition (EMT). This raises the possibility that monitoring patterns of glycosylation on cell-surface and secreted glycoproteins could provide an accessible signature of early-stage disease. Here, we applied proteomic and glycoproteomic workflows to survey glycoproteins in oral non-cancer tissue and invasive squamous cell carcinoma, for glycoprotein biomarker candidate discovery.</p>\n\n<p><strong>Methods:</strong> Proteomics and glycoproteomics were performed on formalin-fixed, paraffin-embedded human oral tissue specimens including invasive squamous cell carcinoma (n=5) and paired non-cancer tissue (n=5). Mass spectrometry data acquired on an Orbitrap Eclipse Tribrid mass spectrometer with an EASY-nLC 1200 system, was analyzed with Byonic (Protein Metrics) and pGlyco3, using the UniProt human protein sequence database and a human N-glycan structure database, for peptide and glycopeptide assignment. For quantitative comparisons, glycopeptide areas under the curve (AUC) were determined, and glycoform relative abundances were compared between experimental groups. Significance was assessed using Student’s t-test.</p>\n\n<p><strong>Results: </strong>Analyses of non-cancer and invasive squamous cell carcinoma tissue led to the confident identification of 4478 unique proteins (1% FDR). Additionally, 447 differentially expressed proteins (p<0.05) were found using label-free quantification, with proteins involved in cell division, RNA metabolism, and ribosome biogenesis enriched in tumor samples. In this initial study, 178 unique glycopeptides from 52 proteins were identified (≤1% FDR). Statistically significant changes in protein glycoforms were found between normal and invasive tumor samples, suggesting that the glycoproteins identified here should undergo further evaluation as potential markers.</p>\n\n<p><strong>Conclusion: </strong>Here, a set of differentially glycosylated proteins (non-cancer versus invasive oral cancer) were characterized, including proteins that originate from the basement membrane. This subset, which may also be shed into the saliva, contains attractive targets for the development of a glycoprotein liquid biopsy for early detection of oral cancer. Future studies will focus on extending these analyses to in situ carcinomas and a larger sample cohort.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153879--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S314",
      "content_id": "154324",
      "abstract_number": "S314",
      "poster_number": "",
      "title": "Discordant Viral Integration Sites in Primary Tumor and Lymphatic Metastasis Suggests Viral Integration is Frequently a Post-oncogenic Event in in HPV+ HNSCC",
      "summary": "Tumor and lymph node metastases were found to have highly concordant viral genotypes, suggesting that a single viral infection contributed to cancer development in each patient. Surprisingly, we find that in approximately 30% of cases with evidence of structural variation in the HPV genome or viral-host genomic integration, that integration or viral-viral structural variants are discordant between the tumor and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154324",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Travis P Schrank, MD, PhD",
      "presenter": "Travis P Schrank, MD, PhD",
      "authors": "Travis P Schrank, MD, PhD 1 ; Kathleen Bartemes, PhD 2 ; David Routman, MD 2 ; Katie Van Able, MD 2 ; Natalia Iasaeva 1 ; Wendell G Yarbrough, MD 1",
      "normalized_authors": [
        "Travis P Schrank",
        "Kathleen Bartemes",
        "David Routman",
        "Katie Van Able",
        "Natalia Iasaeva",
        "Wendell G Yarbrough"
      ],
      "affiliations": [
        "University of North Carolina",
        "Mayo Clinic"
      ],
      "normalized_institutions": [
        "University of North Carolina",
        "Mayo Clinic"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 328,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Travis P Schrank, MD, PhD 1 ; Kathleen Bartemes, PhD 2 ; David Routman, MD 2 ; Katie Van Able, MD 2 ; Natalia Iasaeva 1 ; Wendell G Yarbrough, MD 1",
        "Affiliations": "1 University of North Carolina; 2 Mayo Clinic",
        "Introduction": "High-risk human papilloma virus, particularly HPV16, is a key etiological agent in p16+ carcinomas of the oropharynx (HPV+ HNSCC). Although carcinogenesis frequently occurs without integration of viral genomic material into the host genome in HNSCC; when present, integration is thought to contribute to oncogenesis by altering the expression of viral oncogenes or human genes by various mechanisms. Based on it’s fundamental role in oncogenesis, HPV integration status has been frequently investigated at a potential biomarker.",
        "Methods": "We present an analysis of targeted affinity capture DNA sequencing of 80 cases of HPV+ HNSCC including sequencing of the HPV16 viral genome. For each case both the primary tumor as well as a related lymphatic metastasis was sequenced. Additionally total RNA sequencing of the tumor and affected lymph nodes was performed.",
        "Abstract": "Sequencing data were analyzed for HPV viral genotype, viral structural variation, viral integration into the host genome, and tumor RNA expression. We also investigated the activation of the NF-kB transcription factor by RNA sequencing. And found that NF-kB status was highly concordant between the primary tumor and metastatic lymph node. View in Agenda and Add to Schedule",
        "Results": "Tumor and lymph node metastases were found to have highly concordant viral genotypes, suggesting that a single viral infection contributed to cancer development in each patient. Surprisingly, we find that in approximately 30% of cases with evidence of structural variation in the HPV genome or viral-host genomic integration, that integration or viral-viral structural variants are discordant between the tumor and lymph node metastasis from the same patient.",
        "Discussion": "Some studies have suggested notable intra-tumoral heterogeneity in HPV+ HNSCC, but mostly from inferential methods. We present direct evidence (multiple site/sample sequencing) heterogeneity in the physical state of the HPV genome in some cases of HNSCC. This importance of this finding is underscored by the key oncogenic role of HPV in this disease. Emerging strategies for molecular risk-stratification and precision medicine in HPV+ HNSCC, should account for the possibility of genomic heterogeneity in this disease."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Discordant Viral Integration Sites in Primary Tumor and Lymphatic Metastasis  Suggests Viral Integration is Frequently a Post-oncogenic Event in in HPV+ HNSCC</span>. <u>Travis P Schrank, MD, PhD</u><sup>1</sup>; Kathleen Bartemes, PhD<sup>2</sup>; David Routman, MD<sup>2</sup>; Katie Van Able, MD<sup>2</sup>; Natalia Iasaeva<sup>1</sup>; Wendell G Yarbrough, MD<sup>1</sup>. <sup>1</sup>University of North Carolina; <sup>2</sup>Mayo Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>High-risk human papilloma virus, particularly HPV16, is a key etiological agent in p16+ carcinomas of the oropharynx (HPV+ HNSCC). Although carcinogenesis frequently occurs without integration of viral genomic material into the host genome in HNSCC; when present, integration is thought to contribute to oncogenesis by altering the expression of viral oncogenes or human genes by various mechanisms. Based on it’s fundamental role in oncogenesis, HPV integration status has been frequently investigated at a potential biomarker.</p>\n\n<p><strong>Methods: </strong>We present an analysis of targeted affinity capture DNA sequencing of 80 cases of HPV+ HNSCC including sequencing of the HPV16 viral genome. For each case both the primary tumor as well as a related lymphatic metastasis was sequenced. Additionally total RNA sequencing of the tumor and affected lymph nodes was performed.</p>\n\n<p>Sequencing data were analyzed for HPV viral genotype, viral structural variation, viral integration into the host genome, and tumor RNA expression.</p>\n\n<p><strong>Results: </strong>Tumor and lymph node metastases were found to have highly concordant viral genotypes, suggesting that a single viral infection contributed to cancer development in each patient. Surprisingly, we find that in approximately 30% of cases with evidence of structural variation in the HPV genome or viral-host genomic integration, that integration or viral-viral structural variants are discordant between the tumor and lymph node metastasis from the same patient.</p>\n\n<p>We also investigated the activation of the NF-kB transcription factor by RNA sequencing. And found that NF-kB status was highly concordant between the primary tumor and metastatic lymph node.</p>\n\n<p><strong>Discussion: </strong>Some studies have suggested notable intra-tumoral heterogeneity in HPV+ HNSCC, but mostly from inferential methods. We present direct evidence (multiple site/sample sequencing) heterogeneity in the physical state of the HPV genome in some cases of HNSCC. This importance of this finding is underscored by the key oncogenic role of HPV in this disease. Emerging strategies for molecular risk-stratification and precision medicine in HPV+ HNSCC, should account for the possibility of genomic heterogeneity in this disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154324--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S315",
      "content_id": "153094",
      "abstract_number": "S315",
      "poster_number": "",
      "title": "DNMT3L Drives Oral Cancer Invasion by Epigenetically Modifying the Cytoskeleton",
      "summary": "DNMT3L maintains the epigenetically driven cytoskeletal plasticity and vesicle-biogenesis programs required for the p-EMT state and OSCC invasion. These findings establish DNMT3L as a central regulator of invasive cell-state plasticity in oral cavity cancer.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153094",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Guillermo Flores, MD, PhD",
      "presenter": "Guillermo Flores, MD, PhD",
      "authors": "Guillermo Flores, MD, PhD 1 ; Juan A Raygoza Garay, PhD 2 ; Slyn Uaroon, BS 2 ; Marisa R Buchakjian, MD, PhD 3",
      "normalized_authors": [
        "Guillermo Flores",
        "Juan A Raygoza Garay",
        "Slyn Uaroon",
        "Marisa R Buchakjian"
      ],
      "affiliations": [
        "University of Iowa Department of Otolaryngology - Head & Neck Cancer",
        "University of Iowa Holden Comprehensive Cancer Center",
        "University of Michigan Department of Otolaryngology - Head & Neck Cancer"
      ],
      "normalized_institutions": [
        "University of Iowa Department of Otolaryngology - Head & Neck Cancer",
        "University of Iowa Holden Comprehensive Cancer Center",
        "University of Michigan Department of Otolaryngology - Head & Neck Cancer"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 235,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods & Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Guillermo Flores, MD, PhD 1 ; Juan A Raygoza Garay, PhD 2 ; Slyn Uaroon, BS 2 ; Marisa R Buchakjian, MD, PhD 3",
        "Affiliations": "1 University of Iowa Department of Otolaryngology - Head & Neck Cancer; 2 University of Iowa Holden Comprehensive Cancer Center; 3 University of Michigan Department of Otolaryngology - Head & Neck Cancer",
        "Background": "Cells at the leading edge of oral squamous cell carcinoma (OSCC) adopt a partial epithelial–mesenchymal transition (p-EMT) state that drives invasion, migration, and therapeutic resistance. Although these marginal cells are genetically identical to the tumor bulk, they exhibit strikingly distinct phenotypes and express unique transcriptional and proteomic programs. Sustaining such a metastable, highly dynamic state requires extensive epigenetic plasticity. Using a novel isogenic model system coupled with a genome-wide CRISPR invasion screen, we identified the epigenetic co-factor DNMT3L as a critical regulator of p-EMT.",
        "Methods & Results": "RNA-seq and ATAC-seq profiling of isogenic epithelial and p-EMT OSCC cell lines demonstrated that the p-EMT state is defined by coordinated transcriptional reprogramming and enhancer remodeling at cytoskeletal, adhesion, and vesicle-trafficking loci. A genome-wide CRISPR invasion screen identified DNMT3L as a top regulator of this phenotype. Targeted silencing of DNMT3L markedly reduced invasion in OSCC lines and reversed hallmark p-EMT features, including loss of organized stress fibers, diminished focal adhesion maturation, and reduced integrin αv activation which corresponded to specific changes in methylation status. Immunofluorescence imaging showed that p-EMT cells remodel the actin cytoskeleton and produce abundant exosomes enriched with pro-invasion cargo, whereas DNMT3L silencing substantially decreased exosome production.",
        "Conclusions": "DNMT3L maintains the epigenetically driven cytoskeletal plasticity and vesicle-biogenesis programs required for the p-EMT state and OSCC invasion. These findings establish DNMT3L as a central regulator of invasive cell-state plasticity in oral cavity cancer.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>DNMT3L Drives Oral Cancer Invasion by Epigenetically Modifying the Cytoskeleton</span>. <u>Guillermo Flores, MD, PhD</u><sup>1</sup>; Juan A Raygoza Garay, PhD<sup>2</sup>; Slyn Uaroon, BS<sup>2</sup>; Marisa R Buchakjian, MD, PhD<sup>3</sup>. <sup>1</sup>University of Iowa Department of Otolaryngology - Head & Neck Cancer; <sup>2</sup>University of Iowa Holden Comprehensive Cancer Center; <sup>3</sup>University of Michigan Department of Otolaryngology - Head & Neck Cancer<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Cells at the leading edge of oral squamous cell carcinoma (OSCC) adopt a partial epithelial–mesenchymal transition (p-EMT) state that drives invasion, migration, and therapeutic resistance. Although these marginal cells are genetically identical to the tumor bulk, they exhibit strikingly distinct phenotypes and express unique transcriptional and proteomic programs. Sustaining such a metastable, highly dynamic state requires extensive epigenetic plasticity. Using a novel isogenic model system coupled with a genome-wide CRISPR invasion screen, we identified the epigenetic co-factor DNMT3L as a critical regulator of p-EMT.</p>\n\n<p><strong>Methods & Results</strong>: RNA-seq and ATAC-seq profiling of isogenic epithelial and p-EMT OSCC cell lines demonstrated that the p-EMT state is defined by coordinated transcriptional reprogramming and enhancer remodeling at cytoskeletal, adhesion, and vesicle-trafficking loci. A genome-wide CRISPR invasion screen identified DNMT3L as a top regulator of this phenotype. Targeted silencing of DNMT3L markedly reduced invasion in OSCC lines and reversed hallmark p-EMT features, including loss of organized stress fibers, diminished focal adhesion maturation, and reduced integrin αv activation which corresponded to specific changes in methylation status. Immunofluorescence imaging showed that p-EMT cells remodel the actin cytoskeleton and produce abundant exosomes enriched with pro-invasion cargo, whereas DNMT3L silencing substantially decreased exosome production.</p>\n\n<p><strong>Conclusions</strong>: DNMT3L maintains the epigenetically driven cytoskeletal plasticity and vesicle-biogenesis programs required for the p-EMT state and OSCC invasion. These findings establish DNMT3L as a central regulator of invasive cell-state plasticity in oral cavity cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153094--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S316",
      "content_id": "153790",
      "abstract_number": "S316",
      "poster_number": "",
      "title": "Plasma Cytokines as Prognostic Biomarkers of Pain and Survival in Oral Cavity Squamous Cell Carcinoma",
      "summary": "Plasma cytokine profiles are associated with symptom burden, QoL, and survival in OSCC. IL-10 and TNF-α independently predict survival and are linked to translational/ribosomal programs and immune microenvironment shifts, supporting their potential as minimally invasive prognostic biomarkers.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153790",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Andrew Y Lee, MD",
      "presenter": "Andrew Y Lee, MD",
      "authors": "Andrew Y Lee, MD 1 ; Minh P Dong, MD, PhD 2 ; Michele Arambula, DA 2 ; Emily Nguyen 3 ; Bac A Luong, BS 2 ; Duc M Nguyen, MD 2 ; Khanh K Nguyen, MD 1 ; Paul C Walker, MD 1 ; Carissa M Thomas, MD, PhD 4 ; Chi Viet, DDS, MD, PhD 2",
      "normalized_authors": [
        "Andrew Y Lee",
        "Minh P Dong",
        "Michele Arambula, DA",
        "Emily Nguyen",
        "Bac A Luong",
        "Duc M Nguyen",
        "Khanh K Nguyen",
        "Paul C Walker",
        "Carissa M Thomas",
        "Chi Viet"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center",
        "Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry",
        "University of California, Los Angeles",
        "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center",
        "Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry",
        "University of California, Los Angeles",
        "Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 412,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Materials & Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Andrew Y Lee, MD 1 ; Minh P Dong, MD, PhD 2 ; Michele Arambula, DA 2 ; Emily Nguyen 3 ; Bac A Luong, BS 2 ; Duc M Nguyen, MD 2 ; Khanh K Nguyen, MD 1 ; Paul C Walker, MD 1 ; Carissa M Thomas, MD, PhD 4 ; Chi Viet, DDS, MD, PhD 2",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center; 2 Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry; 3 University of California, Los Angeles; 4 Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz",
        "Background": "Oral squamous cell carcinoma (OSCC) remains a lethal and biologically heterogeneous disease for which current clinicopathologic staging does not fully capture prognosis. Circulating cytokines reflect tumor–host immune interactions and may provide minimally invasive biomarkers of disease aggressiveness. We evaluated whether perioperative plasma cytokine concentrations, integrated with bulk RNA sequencing (RNA-seq), predict survival and illuminate biological pathways associated with adverse outcomes in OSCC.",
        "Materials & Methods": "We analyzed 144 patients enrolled in an ongoing multi-institutional prospective OSCC study. Plasma cytokine/chemokine concentrations were collected on the day of surgery and quantified using bead-based multiplex assays. Fresh-frozen tumor specimens from 103 matched patients underwent bulk RNA-seq. Pain intensity and quality of life (QoL) were measured using the UCSF Oral Cancer Pain Questionnaire, Brief Pain Inventory, and EORTC QLQ-C30 and QLQ-H&N35. Associations were tested using Spearman correlation, Mann–Whitney U, and Kruskal–Wallis tests. Survival cutoffs were defined using ROC optimization, with Kaplan–Meier/log-rank testing and multivariable Cox proportional hazards modeling (adjusting for age, sex, race, pathologic stage, perineural invasion, lymphovascular invasion, tobacco use). RNA-seq data were analyzed with machine learning pathway enrichment; CIBERSORT deconvolution was used to infer immune cell composition.",
        "Results": "The cohort had a mean age of 64.2 years (84 males, 60 females); 56.9% had ≥10 pack-years tobacco exposure, and 66% presented with late-stage disease. Racial/ethnic distribution was 82.7% non-Hispanic/Hispanic White, 8.3% Asian, and 8.3% non-Hispanic/Hispanic Black. Higher plasma IL-6, IL-8, IL-10, and TNF-α levels were associated with late-stage OSCC, and these cytokines were positively correlated with one another (all p<0.05), consistent with a coordinated inflammatory profile. IL-6 and IL-8 were associated with higher pain scores and worse QoL (both p<0.05). Using ROC-derived cutoffs, elevated IFN-γ, IL-4, IL-6, IL-8, IL-10, MIP1α, TNF-α, TGF-α, and HBEGF were associated with decreased survival (all p<0.05). In multivariable Cox models, IL-10 (HR=2.088; 95% CI, 1.002–4.351) and TNF-α (HR=2.921; 95% CI, 1.505–5.669) independently predicted survival. RNA-seq analyses in patients with high IL-10 expression identified ribosome biogenesis, cytoplasmic translation, and focal adhesion as top dysregulated pathways. Higher IL-10 levels were associated with lower inferred monocyte abundance and higher neutrophil abundance.",
        "Conclusions": "Plasma cytokine profiles are associated with symptom burden, QoL, and survival in OSCC. IL-10 and TNF-α independently predict survival and are linked to translational/ribosomal programs and immune microenvironment shifts, supporting their potential as minimally invasive prognostic biomarkers.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Plasma Cytokines as Prognostic Biomarkers of Pain and Survival in Oral Cavity Squamous Cell Carcinoma</span>. <u>Andrew Y Lee, MD</u><sup>1</sup>; Minh P Dong, MD, PhD<sup>2</sup>; Michele Arambula, DA<sup>2</sup>; Emily Nguyen<sup>3</sup>; Bac A Luong, BS<sup>2</sup>; Duc M Nguyen, MD<sup>2</sup>; Khanh K Nguyen, MD<sup>1</sup>; Paul C Walker, MD<sup>1</sup>; Carissa M Thomas, MD, PhD<sup>4</sup>; Chi Viet, DDS, MD, PhD<sup>2</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Loma Linda University Medical Center; <sup>2</sup>Department of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry; <sup>3</sup>University of California, Los Angeles; <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, University of Colorado Anschutz<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Oral squamous cell carcinoma (OSCC) remains a lethal and biologically heterogeneous disease for which current clinicopathologic staging does not fully capture prognosis. Circulating cytokines reflect tumor–host immune interactions and may provide minimally invasive biomarkers of disease aggressiveness. We evaluated whether perioperative plasma cytokine concentrations, integrated with bulk RNA sequencing (RNA-seq), predict survival and illuminate biological pathways associated with adverse outcomes in OSCC.</p>\n\n<p><strong>Materials & Methods</strong>: We analyzed 144 patients enrolled in an ongoing multi-institutional prospective OSCC study. Plasma cytokine/chemokine concentrations were collected on the day of surgery and quantified using bead-based multiplex assays. Fresh-frozen tumor specimens from 103 matched patients underwent bulk RNA-seq. Pain intensity and quality of life (QoL) were measured using the UCSF Oral Cancer Pain Questionnaire, Brief Pain Inventory, and EORTC QLQ-C30 and QLQ-H&N35. Associations were tested using Spearman correlation, Mann–Whitney U, and Kruskal–Wallis tests. Survival cutoffs were defined using ROC optimization, with Kaplan–Meier/log-rank testing and multivariable Cox proportional hazards modeling (adjusting for age, sex, race, pathologic stage, perineural invasion, lymphovascular invasion, tobacco use). RNA-seq data were analyzed with machine learning pathway enrichment; CIBERSORT deconvolution was used to infer immune cell composition.</p>\n\n<p><strong>Results</strong>: The cohort had a mean age of 64.2 years (84 males, 60 females); 56.9% had ≥10 pack-years tobacco exposure, and 66% presented with late-stage disease. Racial/ethnic distribution was 82.7% non-Hispanic/Hispanic White, 8.3% Asian, and 8.3% non-Hispanic/Hispanic Black. Higher plasma IL-6, IL-8, IL-10, and TNF-α levels were associated with late-stage OSCC, and these cytokines were positively correlated with one another (all p<0.05), consistent with a coordinated inflammatory profile. IL-6 and IL-8 were associated with higher pain scores and worse QoL (both p<0.05). Using ROC-derived cutoffs, elevated IFN-γ, IL-4, IL-6, IL-8, IL-10, MIP1α, TNF-α, TGF-α, and HBEGF were associated with decreased survival (all p<0.05). In multivariable Cox models, IL-10 (HR=2.088; 95% CI, 1.002–4.351) and TNF-α (HR=2.921; 95% CI, 1.505–5.669) independently predicted survival. RNA-seq analyses in patients with high IL-10 expression identified ribosome biogenesis, cytoplasmic translation, and focal adhesion as top dysregulated pathways. Higher IL-10 levels were associated with lower inferred monocyte abundance and higher neutrophil abundance.</p>\n\n<p><strong>Conclusions</strong>: Plasma cytokine profiles are associated with symptom burden, QoL, and survival in OSCC. IL-10 and TNF-α independently predict survival and are linked to translational/ribosomal programs and immune microenvironment shifts, supporting their potential as minimally invasive prognostic biomarkers.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153790--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S317",
      "content_id": "153913",
      "abstract_number": "S317",
      "poster_number": "",
      "title": "Cell-Type Specific APA Changes Lead to Gene Dysregulation Through Modulation of mRNA-regulatory miRNA Binding Sites in Head & Neck Cancer",
      "summary": "Alternate polyadenylation (APA) occurs in over 70% of human genes and results in formation of multiple mRNA isoforms with varying 3’ untranslated region (UTR) length. While single-cell transcriptomic techniques have improved in recent years, cell-type specific alternative polyadenylation remains to be investigated in head and neck squamous cell carcinoma (HNSCC). By determining distinct APA patterns in different...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153913",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amra M Vranjkovina",
      "presenter": "Amra M Vranjkovina",
      "authors": "Amra M Vranjkovina ; Jonathan E Bard, PhD; Michael J Buck, PhD",
      "normalized_authors": [
        "Amra M Vranjkovina",
        "Jonathan E Bard",
        "Michael J Buck"
      ],
      "affiliations": [
        "Jacobs School of Medicine and Biomedical Sciences"
      ],
      "normalized_institutions": [
        "Jacobs School of Medicine and Biomedical Sciences"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amra M Vranjkovina ; Jonathan E Bard, PhD; Michael J Buck, PhD",
        "Affiliations": "Jacobs School of Medicine and Biomedical Sciences",
        "Abstract": "Alternate polyadenylation (APA) occurs in over 70% of human genes and results in formation of multiple mRNA isoforms with varying 3’ untranslated region (UTR) length. While single-cell transcriptomic techniques have improved in recent years, cell-type specific alternative polyadenylation remains to be investigated in head and neck squamous cell carcinoma (HNSCC). By determining distinct APA patterns in different cell types across HNSCC, our research can identify therapeutic targets to restore normal polyadenylation patterns and normal gene regulation. We introduce a computational workflow to investigate alterations in 3’UTR length in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics HNSCC data, aiming to determine APA-mediated gene dysregulation and potential oncogenic advantages due to inclusion or exclusion of specific miRNA binding sites. We first perform a global analysis of 3’UTR APA changes across all identified cell types and then specifically examine shifts within epithelial cells, a key component of pathogenesis in HNSCC. To visualize cellular states associated with APA regulation, we employ PHATE dimensionality reduction. Then, we integrate APA-regulated expression profiles with CellChat to infer APA-associated intercellular signaling. This allows us to predict altered ligand-receptor interactions driven by APA isoforms. Finally, we identify enriched pathways to define the functional biological processes most impacted by these communication shifts. Collectively, our spatial and single cell analyses reveal a novel layer of post-transcriptional dysregulation mediated by APA, highlighting its critical role in altering cell identity and cell-cell communication within the HNSCC tumor microenvironment. This work establishes a comprehensive atlas of APA-mediated regulation and provides a foundation for future targeted investigation of key regulatory genes. Our initial analysis has identified GALNT2 as a candidate gene in which tumor cells prefer proximal site polyadenylation. GALNT2 encodes an enzyme that catalyzes mucin-type O-glycosylation of proteins, and abnormal glycosylation with variable subcellular localization is a known contributor to tumor progression. GALNT2 overexpression has been linked to increased migration potential in non-small cell lung carcinoma and has also been reported in oral squamous cell carcinoma. However, the molecular mechanism behind overexpression of GALNT2 in HNSCC hasn’t been extensively studied. A shortened GALNT2 3’UTR would lead to a loss of miRNA targeting sites, especially miR-30d, which has been shown to function as a negative regulator for GALNT2 in lung adenocarcinoma. In addition, depletion of miR-30d causes overexpression of GALNT2 and enhanced cell proliferation and invasion. We hypothesize that cell type-specific 3’UTR APA alterations lead to an oncogenic advantage by modulating miRNA target binding sites and result in gene dysregulation in HNSCC. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cell-Type Specific APA Changes Lead to Gene Dysregulation Through Modulation of mRNA-regulatory miRNA Binding Sites in Head & Neck Cancer</span>. <u>Amra M Vranjkovina</u>; Jonathan E Bard, PhD; Michael J Buck, PhD. Jacobs School of Medicine and Biomedical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Alternate polyadenylation (APA) occurs in over 70% of human genes and results in formation of multiple mRNA isoforms with varying 3’ untranslated region (UTR) length. While single-cell transcriptomic techniques have improved in recent years, cell-type specific alternative polyadenylation remains to be investigated in head and neck squamous cell carcinoma (HNSCC). By determining distinct APA patterns in different cell types across HNSCC, our research can identify therapeutic targets to restore normal polyadenylation patterns and normal gene regulation. We introduce a computational workflow to investigate alterations in 3’UTR length in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics HNSCC data, aiming to determine APA-mediated gene dysregulation and potential oncogenic advantages due to inclusion or exclusion of specific miRNA binding sites. We first perform a global analysis of 3’UTR APA changes across all identified cell types and then specifically examine shifts within epithelial cells, a key component of pathogenesis in HNSCC. To visualize cellular states associated with APA regulation, we employ PHATE dimensionality reduction. Then, we integrate APA-regulated expression profiles with CellChat to infer APA-associated intercellular signaling. This allows us to predict altered ligand-receptor interactions driven by APA isoforms. Finally, we identify enriched pathways to define the functional biological processes most impacted by these communication shifts. Collectively, our spatial and single cell analyses reveal a novel layer of post-transcriptional dysregulation mediated by APA, highlighting its critical role in altering cell identity and cell-cell communication within the HNSCC tumor microenvironment. This work establishes a comprehensive atlas of APA-mediated regulation and provides a foundation for future targeted investigation of key regulatory genes. Our initial analysis has identified GALNT2 as a candidate gene in which tumor cells prefer proximal site polyadenylation. GALNT2 encodes an enzyme that catalyzes mucin-type O-glycosylation of proteins, and abnormal glycosylation with variable subcellular localization is a known contributor to tumor progression. GALNT2 overexpression has been linked to increased migration potential in non-small cell lung carcinoma and has also been reported in oral squamous cell carcinoma. However, the molecular mechanism behind overexpression of GALNT2 in HNSCC hasn’t been extensively studied. A shortened GALNT2 3’UTR would lead to a loss of miRNA targeting sites, especially miR-30d, which has been shown to function as a negative regulator for GALNT2 in lung adenocarcinoma. In addition, depletion of miR-30d causes overexpression of GALNT2 and enhanced cell proliferation and invasion. We hypothesize that cell type-specific 3’UTR APA alterations lead to an oncogenic advantage by modulating miRNA target binding sites and result in gene dysregulation in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153913--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S318",
      "content_id": "154136",
      "abstract_number": "S318",
      "poster_number": "",
      "title": "Molecular differences between tumors of patients with Caucasian and South Asian ethnicity in HPV-negative oral cavity squamous cell carcinoma.",
      "summary": "The MOHCCN represents a uniquely rich initiative with deep sequencing and comprehensive clinical and molecular annotation. Our findings suggest that while tobacco exposures shape immune signaling landscapes in OSCC, the stromal and mitotic programs which initially appeared enriched in Caucasian tumors were largely exposure driven. Controlling for smoked tobacco use shifted these signatures toward the South Asian...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154136",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hugh A Kim, MD",
      "presenter": "Hugh A Kim, MD",
      "authors": "Hugh A Kim, MD ; Lucas Penny, PhD; Shao Hui Huang; Jeffrey Bruce, PhD; Geoffrey Liu, MD; Laurie Ailles, PhD; John R de Almeida, MD, MSc; David P Goldstein, MD; Scott Bratman, MD, PhD; Christopher M Yao, MD",
      "normalized_authors": [
        "Hugh A Kim",
        "Lucas Penny",
        "Shao Hui Huang",
        "Jeffrey Bruce",
        "Geoffrey Liu",
        "Laurie Ailles",
        "John R de Almeida",
        "David P Goldstein",
        "Scott Bratman",
        "Christopher M Yao"
      ],
      "affiliations": [
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University of Toronto"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154136/Screenshot%202025-12-05%20at%201_23_01%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154136/Screenshot%202025-12-05%20at%201_23_01%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154136"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154136/Rplot.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154136/Rplot.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154136"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 529,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Table 1.",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hugh A Kim, MD ; Lucas Penny, PhD; Shao Hui Huang; Jeffrey Bruce, PhD; Geoffrey Liu, MD; Laurie Ailles, PhD; John R de Almeida, MD, MSc; David P Goldstein, MD; Scott Bratman, MD, PhD; Christopher M Yao, MD",
        "Affiliations": "University of Toronto",
        "Background": "Oral squamous cell carcinoma (OSCC) varies substantially by geography and ethnicity. South Asians shoulder a disproportionate global burden, driven in part by chewed tobacco use, and experience worse outcomes than Caucasian patients despite younger age and lower smoker-tobacco exposure. Genomic analyses of ancestry-associated differences in OSCC remain limited due to inconsistent annotation or lack of diversity in most cohorts. Our study aims to compare molecular differences between tumors of patients with South Asian and Caucasian ethnicity in a deeply annotated Canadian cohort.",
        "Methods": "We evaluated OSCC cases from Canada’s Marathon of Hope Cancer Centres Network (MOHCCN). Whole-genome (~80X depth) and bulk whole-transcriptome sequencing (~80M reads) were performed on 131 primary tumors. Somatic variant calling was performed to extract tumor mutational burden (TMB) and mutation signatures using maftools. Copy number variations (CNV) were derived from consortium copy-number matrices and used to estimate chromosomal instability as percent genome altered (PGA). Extrachromosomal DNA (ecDNA) architecture was resolved using AmpliconArchitect and AmpliconClassifier. Differential gene expression was performed by DESeq2. Survival differences were assessed using log-rank tests.",
        "Results": "The cohort consisted of 95 Caucasian and 15 South Asian patients (Table 1). South Asians reported significantly lower burden of smoked tobacco (p=0.018) with no other significant demographic or clinical differences. There were no significant differences in overall (5-year overall survival 52.5% vs 58.3%, p=0.54) or progression-free survival (43.6% vs 54.2%, p=0.38) between South Asian and Caucasian patients. There were no significant differences in somatic mutations, CNVs, or tumor microenvironment by ethnicity. After smoking adjustment, South Asian tumors had directionally higher PGA than European tumors (adjusted mean difference 0.41, p=0.16). Initial differential mRNA expression analysis revealed South Asian tumors were enriched for pathways involved in metabolism, stress responses, and mitochondrial signalling, while Caucasian tumors were enriched for cell adhesion and polarity, cytoskeletal structure, and turnover and remodeling (adjusted p<0.01). After smoking adjustment, South Asian tumors were enriched for extracellular matrix remodelling, contractility, mitotic spindle dynamics, cytoskeletal organization, and developmental signatures (adjusted p<0.01). Subgroup analysis revealed that South Asians who chewed betel nut (n=6) compared to those who did not (n=6, unreported in n=3) had higher enrichment for adaptive immunity pathways including lymphocyte activation (adjusted p<0.01). There was a trend toward increased ecDNA burden (total base pairs contained in circular DNA per tumor) in South Asian compared to Caucasian tumors (median difference -2.75Mbp, 95%CI -4.44-0.04 Mbp, Wilcoxon p=0.053).",
        "Conclusion": "The MOHCCN represents a uniquely rich initiative with deep sequencing and comprehensive clinical and molecular annotation. Our findings suggest that while tobacco exposures shape immune signaling landscapes in OSCC, the stromal and mitotic programs which initially appeared enriched in Caucasian tumors were largely exposure driven. Controlling for smoked tobacco use shifted these signatures toward the South Asian group. This, combined with the observed trend toward higher ecDNA burden in South Asians, suggest a potential ancestry driven genomic instability state. Continued cohort expansion and validation are needed to refine these signals and may inform ancestry-aware screening and risk-stratification strategies.",
        "Table 1.": "Baseline clinical characteristics.",
        "Figure 1.": "Comparison of ecDNA burden.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Molecular differences between tumors of patients with Caucasian and South Asian ethnicity in HPV-negative oral cavity squamous cell carcinoma.</span>. <u>Hugh A Kim, MD</u>; Lucas Penny, PhD; Shao Hui Huang; Jeffrey Bruce, PhD; Geoffrey Liu, MD; Laurie Ailles, PhD; John R de Almeida, MD, MSc; David P Goldstein, MD; Scott Bratman, MD, PhD; Christopher M Yao, MD. University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) varies substantially by geography and ethnicity. South Asians shoulder a disproportionate global burden, driven in part by chewed tobacco use, and experience worse outcomes than Caucasian patients despite younger age and lower smoker-tobacco exposure. Genomic analyses of ancestry-associated differences in OSCC remain limited due to inconsistent annotation or lack of diversity in most cohorts. Our study aims to compare molecular differences between tumors of patients with South Asian and Caucasian ethnicity in a deeply annotated Canadian cohort.</p>\n\n<p><strong>Methods: </strong>We evaluated OSCC cases from Canada’s Marathon of Hope Cancer Centres Network (MOHCCN). Whole-genome (~80X depth) and bulk whole-transcriptome sequencing (~80M reads) were performed on 131 primary tumors.  Somatic variant calling was performed to extract tumor mutational burden (TMB) and mutation signatures using maftools. Copy number variations (CNV) were derived from consortium copy-number matrices and used to estimate chromosomal instability as percent genome altered (PGA). Extrachromosomal DNA (ecDNA) architecture was resolved using AmpliconArchitect and AmpliconClassifier. Differential gene expression was performed by DESeq2. Survival differences were assessed using log-rank tests.</p>\n\n<p><strong>Results: </strong>The cohort consisted of 95 Caucasian and 15 South Asian patients (Table 1). South Asians reported significantly lower burden of smoked tobacco (p=0.018) with no other significant demographic or clinical differences. There were no significant differences in overall (5-year overall survival 52.5% vs 58.3%, p=0.54) or progression-free survival (43.6% vs 54.2%, p=0.38) between South Asian and Caucasian patients. There were no significant differences in somatic mutations, CNVs, or tumor microenvironment by ethnicity. After smoking adjustment, South Asian tumors had directionally higher PGA than European tumors (adjusted mean difference 0.41, p=0.16). Initial differential mRNA expression analysis revealed South Asian tumors were enriched for pathways involved in metabolism, stress responses, and mitochondrial signalling, while Caucasian tumors were enriched for cell adhesion and polarity, cytoskeletal structure, and turnover and remodeling (adjusted p<0.01). After smoking adjustment, South Asian tumors were enriched for extracellular matrix remodelling, contractility, mitotic spindle dynamics, cytoskeletal organization, and developmental signatures (adjusted p<0.01). Subgroup analysis revealed that South Asians who chewed betel nut (n=6) compared to those who did not (n=6, unreported in n=3) had higher enrichment for adaptive immunity pathways including lymphocyte activation (adjusted p<0.01). There was a trend toward increased ecDNA burden (total base pairs contained in circular DNA per tumor) in South Asian compared to Caucasian tumors (median difference -2.75Mbp, 95%CI -4.44-0.04 Mbp, Wilcoxon p=0.053).</p>\n\n<p><strong>Conclusion:</strong> The MOHCCN represents a uniquely rich initiative with deep sequencing and comprehensive clinical and molecular annotation. Our findings suggest that while tobacco exposures shape immune signaling landscapes in OSCC, the stromal and mitotic programs which initially appeared enriched in Caucasian tumors were largely exposure driven. Controlling for smoked tobacco use shifted these signatures toward the South Asian group. This, combined with the observed trend toward higher ecDNA burden in South Asians, suggest a potential ancestry driven genomic instability state. Continued cohort expansion and validation are needed to refine these signals and may inform ancestry-aware screening and risk-stratification strategies.</p>\n\n<p><strong>Table 1. </strong>Baseline clinical characteristics.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154136/Screenshot%202025-12-05%20at%201_23_01%E2%80%AFAM.png' /></p>\n\n<p><strong>Figure 1. </strong>Comparison of ecDNA burden.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154136/Rplot.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154136--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S320",
      "content_id": "153671",
      "abstract_number": "S320",
      "poster_number": "",
      "title": "Differential Methylation in Matched Tumor–Normal Tissues Identifies MEIS1 Locus Dysregulation with Prognostic Significance in Head and Neck Cancer",
      "summary": "MEIS1-AS2 is the most noticeably hypermethylated locus in comparison to matched normal tissue in both patients. Our pilot DNA-methylation analysis demonstrates that examining both coding and regulatory non-coding RNAs can identify convergent epigenetic changes. The associated gene, MEIS1, is downregulated in HNSCC and linked to poorer survival, underscoring the potential clinical relevance of this epigenetic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153671",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260139",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Parshad Suthar, MS",
      "presenter": "Parshad Suthar, MS",
      "authors": "Parshad Suthar, MS 1 ; Praveen Rao, PhD 1 ; Syamantak Khan, PhD 2",
      "normalized_authors": [
        "Parshad Suthar",
        "Praveen Rao",
        "Syamantak Khan"
      ],
      "affiliations": [
        "Department of Electrical Engineering and Computer Science, University of Missouri-Columbia",
        "Department of Radiation Oncology, School of Medicine, University of Missouri-Columbia"
      ],
      "normalized_institutions": [
        "Department of Electrical Engineering and Computer Science, University of Missouri-Columbia",
        "Department of Radiation Oncology, School of Medicine, University of Missouri-Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153671/Volcano_Plot_AHNS_2026_V2.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153671/Volcano_Plot_AHNS_2026_V2.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153671"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153671/Circos_Plot_AHNS_2026_V2.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153671/Circos_Plot_AHNS_2026_V2.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153671"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153671/figure-3_ahns_2026_v2.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153671/figure-3_ahns_2026_v2.jpg",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153671"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Acknowledgments",
        "Abstract"
      ],
      "sections": {
        "Authors": "Parshad Suthar, MS 1 ; Praveen Rao, PhD 1 ; Syamantak Khan, PhD 2",
        "Affiliations": "1 Department of Electrical Engineering and Computer Science, University of Missouri-Columbia; 2 Department of Radiation Oncology, School of Medicine, University of Missouri-Columbia",
        "Introduction": "Head and neck squamous cell carcinoma (HNSCC) is characterized by widespread alterations in DNA methylation. Yet, gene-level methylation patterns that separate HNSCC from histologically normal tissue remain poorly described, limiting clinical interpretation and biomarker development. Prior studies have focused mainly on individual CpG sites in HNSCC and rarely examined annotated non-coding or antisense regions, despite growing evidence of their epigenetic control in cancer. As the recent Illumina EPIC v2 array provides expanded coverage of these regulatory regions, comprehensive maps of methylation patterns across coding and non-coding loci in paired tumor (TT) and normal tissue (NT) can provide new biological and clinical insights for HNSCC.",
        "Methods": "Genomic DNA from two oral cavity squamous cell carcinoma patient tissues SU IRB#11402 were analyzed on the Illumina Infinium MethylationEPIC v2 BeadChip. GeneDMRs[1] package was used to aggregate probe-level β values to locus-level methylation, resulting in 34,428 annotated loci, which included protein-coding genes, long non-coding RNAs, other non-coding transcripts, and pseudogenes. For each patient, TT vs. NT at each locus was then compared using the GeneDMRs logistic-regression framework, and q-values were derived following false-discovery-rate correction. The sign of Δβ at q≤0.01 was used to identify hypermethylated and hypomethylated loci. We used MethMarkerDB[2], a curated database of cancer methylation biomarkers, to intersect significant differentially methylated genes (DMGs) and summarize overlap by the direction of change to evaluate the clinical relevance. TCGA-HNSC expression and survival data for selected loci were examined using the GEPIA2 platform.",
        "Results": "We found extensive methylation changes in both patients within the shared universe of protein-coding genes. Among the total 18,262 protein-coding genes that were analyzed, approximately ~1,000 genes were differentially methylated in each patient at q≤0.01. Among these, ~100 genes were found to be previously connected to oral and head and neck cancer using MethMarkerDB. Further, recurrently changed non-coding and antisense loci were found on the collection of 34,428 annotated loci (including long non-coding RNAs, other non-coding transcripts, and pseudogenes). However, including the annotated non-coding and antisense loci revealed a large number of new targets.",
        "Conclusion": "MEIS1-AS2 is the most noticeably hypermethylated locus in comparison to matched normal tissue in both patients. Our pilot DNA-methylation analysis demonstrates that examining both coding and regulatory non-coding RNAs can identify convergent epigenetic changes. The associated gene, MEIS1, is downregulated in HNSCC and linked to poorer survival, underscoring the potential clinical relevance of this epigenetic alteration. Future studies should validate these findings in larger cohorts and determine whether recurrent methylation patterns at loci such as MEIS1-AS2 can support biologically meaningful and prognostically informative epigenetic stratification in HNSCC.",
        "Acknowledgments": "This work was supported in part by Grant NIH 4R00DE032094 and NIH K99DE03209 and NSF Grant No. 2201583.",
        "Abstract": "GeneDMRs:- https://www.liebertpub.com/doi/10.1089/cmb.2020.0081 MethMarkerDB:- https://doi.org/10.1093/nar/gkad923 View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Differential Methylation in Matched Tumor–Normal Tissues Identifies MEIS1 Locus Dysregulation with Prognostic Significance in Head and Neck Cancer</span>. <u>Parshad Suthar, MS</u><sup>1</sup>; Praveen Rao, PhD<sup>1</sup>; Syamantak Khan, PhD<sup>2</sup>. <sup>1</sup>Department of Electrical Engineering and Computer Science, University of Missouri-Columbia; <sup>2</sup>Department of Radiation Oncology, School of Medicine, University of Missouri-Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is characterized by widespread alterations in DNA methylation. Yet, gene-level methylation patterns that separate HNSCC from histologically normal tissue remain poorly described, limiting clinical interpretation and biomarker development. Prior studies have focused mainly on individual CpG sites in HNSCC and rarely examined annotated non-coding or antisense regions, despite growing evidence of their epigenetic control in cancer. As the recent Illumina EPIC v2 array provides expanded coverage of these regulatory regions, comprehensive maps of methylation patterns across coding and non-coding loci in paired tumor (TT) and normal tissue (NT) can provide new biological and clinical insights for HNSCC.</p>\n\n<p><strong>Methods: </strong>Genomic DNA from two oral cavity squamous cell carcinoma patient tissues SU IRB#11402 were analyzed on the Illumina Infinium MethylationEPIC v2 BeadChip. GeneDMRs[1] package was used to aggregate probe-level β values to locus-level methylation, resulting in 34,428 annotated loci, which included protein-coding genes, long non-coding RNAs, other non-coding transcripts, and pseudogenes. For each patient, TT vs. NT at each locus was then compared using the GeneDMRs logistic-regression framework, and q-values were derived following false-discovery-rate correction. The sign of Δβ at q≤0.01 was used to identify hypermethylated and hypomethylated loci.  We used MethMarkerDB[2], a curated database of cancer methylation biomarkers, to intersect significant differentially methylated genes (DMGs) and summarize overlap by the direction of change to evaluate the clinical relevance. TCGA-HNSC expression and survival data for selected loci were examined using the GEPIA2 platform.</p>\n\n<p><strong>Results: </strong>We found extensive methylation changes in both patients within the shared universe of protein-coding genes. Among the total 18,262 protein-coding genes that were analyzed, approximately ~1,000 genes were differentially methylated in each patient at q≤0.01. Among these, ~100 genes were found to be previously connected to oral and head and neck cancer using MethMarkerDB. Further, recurrently changed non-coding and antisense loci were found on the collection of 34,428 annotated loci (including long non-coding RNAs, other non-coding transcripts, and pseudogenes). However, including the annotated non-coding and antisense loci revealed a large number of new targets.</p>\n\n<p><strong>Conclusion: </strong>MEIS1-AS2 is the most noticeably hypermethylated locus in comparison to matched normal tissue in both patients. Our pilot DNA-methylation analysis demonstrates that examining both coding and regulatory non-coding RNAs can identify convergent epigenetic changes. The associated gene, MEIS1, is downregulated in HNSCC and linked to poorer survival, underscoring the potential clinical relevance of this epigenetic alteration. Future studies should validate these findings in larger cohorts and determine whether recurrent methylation patterns at loci such as MEIS1-AS2 can support biologically meaningful and prognostically informative epigenetic stratification in HNSCC.</p>\n\n<p><strong>Acknowledgments: </strong>This work was supported in part by Grant  NIH 4R00DE032094 and NIH K99DE03209 and NSF Grant No. 2201583.</p>\n\n<p><strong>References:</strong></p>\n\n<p>GeneDMRs:- https://www.liebertpub.com/doi/10.1089/cmb.2020.0081<br />\nMethMarkerDB:- https://doi.org/10.1093/nar/gkad923</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153671/Volcano_Plot_AHNS_2026_V2.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153671/Circos_Plot_AHNS_2026_V2.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153671/figure-3_ahns_2026_v2.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153671--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260139' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S321",
      "content_id": "154403",
      "abstract_number": "S321",
      "poster_number": "",
      "title": "Olfaction is Associated with Mortality in Head and Neck Cancer: First Prospective Evidence in an Oncology Cohort",
      "summary": "While the association between OD and mortality has been described in population-based datasets, this is the first study to demonstrate this relationship utilizing psychophysically measured olfaction in a prospective cohort. By employing pretreatment smell testing, OD emerged as a novel, accessible biomarker of frailty and mortality, identifying high-risk patients even after adjusting for age. These findings...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154403",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rachel Stemme, BS",
      "presenter": "Rachel Stemme, BS",
      "authors": "Rachel Stemme, BS 1 ; Wassim Najjar, MD 1 ; Sahar Assi, MD 1 ; Aliyah Pabani, MD 2 ; Harry Quon, MD, MS 3 ; Christine G Gourin, MD, MPH 1 ; Wayne M Koch, MD 1 ; Maie A St. John, MD, PhD 1 ; Carole Fakhry, MD, MPH 1 ; Nicholas R Rowan, MD 1 ; Leila J Mady, MD, PhD, MPH 1",
      "normalized_authors": [
        "Rachel Stemme",
        "Wassim Najjar",
        "Sahar Assi",
        "Aliyah Pabani",
        "Harry Quon",
        "Christine G Gourin",
        "Wayne M Koch",
        "Maie A St. John",
        "Carole Fakhry",
        "Nicholas R Rowan",
        "Leila J Mady"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
        "Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
        "Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
        "Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
        "Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 564,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rachel Stemme, BS 1 ; Wassim Najjar, MD 1 ; Sahar Assi, MD 1 ; Aliyah Pabani, MD 2 ; Harry Quon, MD, MS 3 ; Christine G Gourin, MD, MPH 1 ; Wayne M Koch, MD 1 ; Maie A St. John, MD, PhD 1 ; Carole Fakhry, MD, MPH 1 ; Nicholas R Rowan, MD 1 ; Leila J Mady, MD, PhD, MPH 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3 Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA",
        "Background": "While frailty is a major determinant of head and neck cancer (HNC) outcomes, there is currently no standardized clinical frailty assessment tool to guide oncologic decision-making. Olfactory dysfunction (OD) is increasingly recognized as a robust marker of frailty and mortality in general populations, yet its relevance in HNC remains unclear. We prospectively evaluated the utility of olfaction as a biomarker for frailty, progression-free survival (PFS), and overall survival (OS) among patients with HNC.",
        "Methods": "Adults with newly diagnosed, treatment-naïve, head and neck squamous cell carcinoma (HNSCC) were prospectively enrolled. Patients with sinonasal malignancy or preexisting olfactory/neurocognitive disorders were excluded. All olfaction and frailty assessments were conducted prior to treatment initiation. Olfaction was assessed via self-reported visual analog scale (VAS) and psychophysical Sniffin’ Sticks odorant threshold (T) (range=1-16) and identification (I) (range=0-16). Frailty was measured using the Risk Analysis Index (RAI) (range: 0-81) and categorized as nonfrail (RAI≤36) or frail (RAI≥37). Combined olfaction threshold and identification (TI) and individual subdomain scores were examined using normative data. Logistic regression assessed the association between OD and frailty. PFS and OS were examined with Kaplan-Meier (KM) curves and Cox proportional hazards models to assess the relationship with OD, adjusting for demographic and clinical confounders.",
        "Results": "109 patients were enrolled (mean age [SD] 61.7 years [11.8]; 83.5% male; 80.7% White). The most common primary site was the oropharynx (n=70; 64.2%); most had Stage I-II disease (n=67; 61.5%); and 56.0% (n=61) were frail. Despite high self-reported olfaction (VAS median [IQR]: 9.5 [2.0]), psychophysical OD was prevalent in 36.7% (n=40) and 42.2% (n=46) on odorant T and I tests, respectively. Frail patients had significantly lower combined (TI) olfaction scores than non-frail patients (median TI: 18.5 vs 22.2; p=0.024). Each one-point decrease in identification score was associated with a 21% increased risk of frailty (OR=1.21, 95%CI: 1.03-1.45, p=0.030). Using the reverse KM method, median follow-up was 13.2 months for PFS (95%CI: 11.1-15.7) and 13.4 months for OS (95%CI:11.3-15.9). Patients with hyposmia (TI≤17.75) had significantly shorter PFS compared to patients with normal olfaction (12-month PFS: 65.8% vs 84.8%; log-rank p=0.029). After adjusting for age, patients with hyposmia had a significantly higher risk of disease progression or death (aHR=2.52, 95%CI: 1.04-6.10, p=0.041). Hyposmia was also significantly associated with worse OS compared to those with normal olfaction (12-month OS: 85.5% vs 98.2%; log-rank p=0.009). After adjusting for age, hyposmia conferred a nearly 5-fold increased risk of death (aHR=4.95, 95%CI: 1.04-23.47).",
        "Conclusions": "While the association between OD and mortality has been described in population-based datasets, this is the first study to demonstrate this relationship utilizing psychophysically measured olfaction in a prospective cohort. By employing pretreatment smell testing, OD emerged as a novel, accessible biomarker of frailty and mortality, identifying high-risk patients even after adjusting for age. These findings suggest that smell testing could be integrated into routine oncologic evaluations to enhance risk stratification. Further studies across oncology populations are warranted to validate OD as a prognostic biomarker and to explore potential biological mechanisms linking olfactory impairment, frailty, and survival.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Olfaction is Associated with Mortality in Head and Neck Cancer: First Prospective Evidence in an Oncology Cohort</span>. <u>Rachel Stemme, BS</u><sup>1</sup>; Wassim Najjar, MD<sup>1</sup>; Sahar Assi, MD<sup>1</sup>; Aliyah Pabani, MD<sup>2</sup>; Harry Quon, MD, MS<sup>3</sup>; Christine G Gourin, MD, MPH<sup>1</sup>; Wayne M Koch, MD<sup>1</sup>; Maie A St. John, MD, PhD<sup>1</sup>; Carole Fakhry, MD, MPH<sup>1</sup>; Nicholas R Rowan, MD<sup>1</sup>; Leila J Mady, MD, PhD, MPH<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; <sup>2</sup>Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; <sup>3</sup>Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> While frailty is a major determinant of head and neck cancer (HNC) outcomes, there is currently no standardized clinical frailty assessment tool to guide oncologic decision-making. Olfactory dysfunction (OD) is increasingly recognized as a robust marker of frailty and mortality in general populations, yet its relevance in HNC remains unclear. We prospectively evaluated the utility of olfaction as a biomarker for frailty, progression-free survival (PFS), and overall survival (OS) among patients with HNC. </p>\n\n<p><strong>Methods:</strong> Adults with newly diagnosed, treatment-naïve, head and neck squamous cell carcinoma (HNSCC) were prospectively enrolled. Patients with sinonasal malignancy or preexisting olfactory/neurocognitive disorders were excluded. All olfaction and frailty assessments were conducted prior to treatment initiation. Olfaction was assessed via self-reported visual analog scale (VAS) and psychophysical Sniffin’ Sticks odorant threshold (T) (range=1-16) and identification (I) (range=0-16). Frailty was measured using the Risk Analysis Index (RAI) (range: 0-81) and categorized as nonfrail (RAI≤36) or frail (RAI≥37). Combined olfaction threshold and identification (TI) and individual subdomain scores were examined using normative data. Logistic regression assessed the association between OD and frailty. PFS and OS were examined with Kaplan-Meier (KM) curves and Cox proportional hazards models to assess the relationship with OD, adjusting for demographic and clinical confounders.</p>\n\n<p><strong>Results:</strong> 109 patients were enrolled (mean age [SD] 61.7 years [11.8]; 83.5% male; 80.7% White). The most common primary site was the oropharynx (n=70; 64.2%); most had Stage I-II disease (n=67; 61.5%); and 56.0% (n=61) were frail. Despite high self-reported olfaction (VAS median [IQR]: 9.5 [2.0]), psychophysical OD was prevalent in 36.7% (n=40) and 42.2% (n=46) on odorant T and I tests, respectively. Frail patients had significantly lower combined (TI) olfaction scores than non-frail patients (median TI: 18.5 vs 22.2; p=0.024). Each one-point decrease in identification score was associated with a 21% increased risk of frailty (OR=1.21, 95%CI: 1.03-1.45, p=0.030). Using the reverse KM method, median follow-up was 13.2 months for PFS (95%CI: 11.1-15.7) and 13.4 months for OS (95%CI:11.3-15.9). Patients with hyposmia (TI≤17.75) had significantly shorter PFS compared to patients with normal olfaction (12-month PFS: 65.8% vs 84.8%; log-rank p=0.029). After adjusting for age, patients with hyposmia had a significantly higher risk of disease progression or death (aHR=2.52, 95%CI: 1.04-6.10, p=0.041). Hyposmia was also significantly associated with worse OS compared to those with normal olfaction (12-month OS: 85.5% vs 98.2%; log-rank p=0.009). After adjusting for age, hyposmia conferred a nearly 5-fold increased risk of death (aHR=4.95, 95%CI: 1.04-23.47).</p>\n\n<p><strong>Conclusions: </strong>While the association between OD and mortality has been described in population-based datasets, this is the first study to demonstrate this relationship utilizing psychophysically measured olfaction in a prospective cohort. By employing pretreatment smell testing, OD emerged as a novel, accessible biomarker of frailty and mortality, identifying high-risk patients even after adjusting for age. These findings suggest that smell testing could be integrated into routine oncologic evaluations to enhance risk stratification. Further studies across oncology populations are warranted to validate OD as a prognostic biomarker and to explore potential biological mechanisms linking olfactory impairment, frailty, and survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154403--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S322",
      "content_id": "154359",
      "abstract_number": "S322",
      "poster_number": "",
      "title": "Clinical Validation of a Gene Expression Predictor of Bevacizumab Treatment Response",
      "summary": "The development and validation of the RRB signature highlights the feasibility of using FFPE tissue to predict bevacizumab treatment response. We are currently validating this gene set across additional independent cohorts across multiple cancer types to determine its clinical utility. Integrating transcriptomic biomarkers such as the RRB signature may allow us to identify patients who are most likely to benefit...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154359",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chee Yit Lim, Dr",
      "presenter": "Chee Yit Lim, Dr",
      "authors": "Chee Yit Lim, Dr 1 ; Yi Ren, PhD 2 ; Joe W Foley, PhD 2 ; Yaw Chyn Lim, Dr 3 ; Wan Qin Chong, Dr 4 ; Kwok Seng Loh, Dr 1 ; Boon Cher Goh, Dr 4 ; Joshua K Tay, Dr, PhD 1",
      "normalized_authors": [
        "Chee Yit Lim, Dr",
        "Yi Ren",
        "Joe W Foley",
        "Yaw Chyn Lim, Dr",
        "Wan Qin Chong, Dr",
        "Kwok Seng Loh, Dr",
        "Boon Cher Goh, Dr",
        "Joshua K Tay, Dr"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Department of Otolaryngology – Head & Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore",
        "NUS Centre for Cancer Research (N2CR), National University of Singapore",
        "Department of Haematology-Oncology, National University Cancer Institute, Singapore"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Department of Otolaryngology – Head & Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore",
        "NUS Centre for Cancer Research (N2CR), National University of Singapore",
        "Department of Haematology-Oncology, National University Cancer Institute, Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chee Yit Lim, Dr 1 ; Yi Ren, PhD 2 ; Joe W Foley, PhD 2 ; Yaw Chyn Lim, Dr 3 ; Wan Qin Chong, Dr 4 ; Kwok Seng Loh, Dr 1 ; Boon Cher Goh, Dr 4 ; Joshua K Tay, Dr, PhD 1",
        "Affiliations": "1 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; 2 Department of Otolaryngology – Head & Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore; 3 NUS Centre for Cancer Research (N2CR), National University of Singapore; 4 Department of Haematology-Oncology, National University Cancer Institute, Singapore",
        "Background": "Bevacizumab is a monoclononal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and normalising tumor vasculature. Despite its widespread usage in colorectal, lung, ovarian cancer and glioblastoma, and more recently in nasopharyngeal carcinoma (NPC), clinical benefits remain highly variable, with only a subset of patients achieving meaningful response. Furthermore, using bevacizumab is not without its own toxicity profile, which includes hypertension, proteinuria, thromboembolic events, bleeding and treatment related mortality. As it is often used in the setting of metastatic disease, this risk-benefit balance becomes particularly important. Despite more than two decades of clinical use, no biomarker has been validated to predict bevacizumab response, making it challenging to select patients who are most likely to benefit from VEGF inhibition. This gap highlights an unmet need in the era of precision medicine.",
        "Methods": "We analysed 19 formalin-fixed paraffin-embedded (FFPE) biopsies from a completed phase 2 clinical trial (NCT01309633) of treatment-naive locally-advanced NPC patients, who received bevacizumab prior to standard concurrent chemoradiation. Tumor epithelial regions were identified on H&E slides and isolated using laser-capture microdissection. Biological replicates were obtained when available. RNAseq libraries were generated using an in-house method optimised for small quantities of FFPE tissue and measures the expression of all genes in the transcriptome. Differential gene expression between complete responders (CR, n=11) and partial responders (PR, n=8) was performed. Signature scores were calculated using single-sample gene set enrichment analysis (ssGSEA) and gene set variation analysis (GSVA).",
        "Results": "After quality control, 37 tumor epithelial libraries were analyzed (CR, n=21; PR, n=16). We identified 58 differentially expressed genes (p-adjusted < 0.05), of which 44 were enriched in PR tumors. These genes were related to vascular endothelial, tissue matrix and fibroblast processes, as well as inflammatory and immune related processes. GSVA revealed enrichment of inflamed fibroblasts, endothelial and stromal cell types in PR tumours. The 44 genes enriched in PR tumours were used to develop the Reduced Response to Bevacizumab (RRB) gene signature. In the discovery cohort, the RRB score was significantly higher in PR tumors compared to CR tumors (ssGSEA score 25569 vs 20670, p = 2.41 x 10-7; GSVA score 0.238 vs -0.550, p = 1.83 x 10-9). The RRB gene set was further applied to an independent cohort of pretreatment glioblastoma samples (n=20), comprising both newly diagnosed and recurrent tumors prior to bevacizumab treatment, and demonstrated consistent negative correlation between RRB scores and overall survival.",
        "Conclusion": "The development and validation of the RRB signature highlights the feasibility of using FFPE tissue to predict bevacizumab treatment response. We are currently validating this gene set across additional independent cohorts across multiple cancer types to determine its clinical utility. Integrating transcriptomic biomarkers such as the RRB signature may allow us to identify patients who are most likely to benefit from anti-VEGF treatment. This enables a more precise and selective application of bevacizumab, improving outcomes while minimizing unnecessary toxicity exposure.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Validation of a Gene Expression Predictor of Bevacizumab Treatment Response</span>. <u>Chee Yit Lim, Dr</u><sup>1</sup>; Yi Ren, PhD<sup>2</sup>; Joe W Foley, PhD<sup>2</sup>; Yaw Chyn Lim, Dr<sup>3</sup>; Wan Qin Chong, Dr<sup>4</sup>; Kwok Seng Loh, Dr<sup>1</sup>; Boon Cher Goh, Dr<sup>4</sup>; Joshua K Tay, Dr, PhD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; <sup>2</sup>Department of Otolaryngology – Head & Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore; <sup>3</sup>NUS Centre for Cancer Research (N2CR), National University of Singapore; <sup>4</sup>Department of Haematology-Oncology, National University Cancer Institute, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Bevacizumab is a monoclononal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and normalising tumor vasculature. Despite its widespread usage in colorectal, lung, ovarian cancer and glioblastoma, and more recently in nasopharyngeal carcinoma (NPC), clinical benefits remain highly variable, with only a subset of patients achieving meaningful response. Furthermore, using bevacizumab is not without its own toxicity profile, which includes hypertension, proteinuria, thromboembolic events, bleeding and treatment related mortality. As it is often used in the setting of metastatic disease, this risk-benefit balance becomes particularly important. Despite more than two decades of clinical use, no biomarker has been validated to predict bevacizumab response, making it challenging to select patients who are most likely to benefit from VEGF inhibition. This gap highlights an unmet need in the era of precision medicine.</p>\n\n<p><strong>Methods: </strong>We analysed 19 formalin-fixed paraffin-embedded (FFPE) biopsies from a completed phase 2 clinical trial (NCT01309633) of treatment-naive locally-advanced NPC patients, who received bevacizumab prior to standard concurrent chemoradiation. Tumor epithelial regions were identified on H&E slides and isolated using laser-capture microdissection. Biological replicates were obtained when available. RNAseq libraries were generated using an in-house method optimised for small quantities of FFPE tissue and measures the expression of all genes in the transcriptome. Differential gene expression between complete responders (CR, n=11) and partial responders (PR, n=8) was performed. Signature scores were calculated using single-sample gene set enrichment analysis (ssGSEA) and gene set variation analysis (GSVA).</p>\n\n<p><strong>Results: </strong>After quality control, 37 tumor epithelial libraries were analyzed (CR, n=21; PR, n=16). We identified 58 differentially expressed genes (p-adjusted < 0.05), of which 44 were enriched in PR tumors. These genes were related to vascular endothelial, tissue matrix and fibroblast processes, as well as inflammatory and immune related processes. GSVA revealed enrichment of inflamed fibroblasts, endothelial and stromal cell types in PR tumours. The 44 genes enriched in PR tumours were used to develop the Reduced Response to Bevacizumab (RRB) gene signature. In the discovery cohort, the RRB score was significantly higher in PR tumors compared to CR tumors (ssGSEA score 25569 vs 20670, p = 2.41 x 10-7; GSVA score 0.238 vs -0.550, p = 1.83 x 10-9). The RRB gene set was further applied to an independent cohort of pretreatment glioblastoma samples (n=20), comprising both newly diagnosed and recurrent tumors prior to bevacizumab treatment, and demonstrated consistent negative correlation between RRB scores and overall survival.</p>\n\n<p><strong>Conclusion: </strong>The development and validation of the RRB signature highlights the feasibility of using FFPE tissue to predict bevacizumab treatment response. We are currently validating this gene set across additional independent cohorts across multiple cancer types to determine its clinical utility. Integrating transcriptomic biomarkers such as the RRB signature may allow us to identify patients who are most likely to benefit from anti-VEGF treatment. This enables a more precise and selective application of bevacizumab, improving outcomes while minimizing unnecessary toxicity exposure.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154359--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S323",
      "content_id": "153667",
      "abstract_number": "S323",
      "poster_number": "",
      "title": "Preoperative Intra-Tumoral Microdosing Enables Pharmacodynamic Drug Response Profiling in Head and Neck Cancer",
      "summary": "Preoperative intratumoral microinjection using the CIVO platform is feasible and safe in head and neck SCC and enables direct evaluation of tumor-specific drug responses within the native TME, particularly in non-necrotic tumor regions. Major obstacles to evaluability (pre-existing tumor necrosis and injection inaccuracy) should be addressed through optimized screening and device parameter adjustments (e.g.,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153667",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas Hendriks, MBBS, MPhil, FRACS",
      "presenter": "Thomas Hendriks, MBBS, MPhil, FRACS",
      "authors": "Thomas Hendriks, MBBS, MPhil, FRACS 1 ; Terry Day 1 ; David Neskey 1 ; Peter Horwich 1 ; Usman Khan 1 ; Karthik Rajasekaran 2 ; Vikas Mehta 3 ; Thomas J Ow 3 ; John Pang 4 ; Daniel Clayburgh 5 ; Ryan J Li 5 ; Paul L Swiecicki 6 ; C. Alessandra Colaianni 7 ; Alice L Tang 8 ; Connor Burns 9 ; Atticus Turner 9 ; Jason Frazier 9 ; Kate Gillepsie 9 ; Jeffrey Houlton 1",
      "normalized_authors": [
        "Thomas Hendriks, MBBS, MPhil, FRACS",
        "Terry Day",
        "David Neskey",
        "Peter Horwich",
        "Usman Khan",
        "Karthik Rajasekaran",
        "Vikas Mehta",
        "Thomas J Ow",
        "John Pang",
        "Daniel Clayburgh",
        "Ryan J Li",
        "Paul L Swiecicki",
        "C. Alessandra Colaianni",
        "Alice L Tang",
        "Connor Burns",
        "Atticus Turner",
        "Jason Frazier",
        "Kate Gillepsie",
        "Jeffrey Houlton"
      ],
      "affiliations": [
        "Sarah Cannon Cancer Institute, Charleston, SC, USA",
        "Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Shreveport, Shreveport, LA, United States",
        "Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, OR, United States",
        "Portland Veterans Affairs Medical Center, Portland, OR, United States",
        "Department of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI, United States",
        "Department of Otolaryngology-Head and Neck Surgery, University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States",
        "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States",
        "Presage Biosciences, Inc., Seattle, WA, United States"
      ],
      "normalized_institutions": [
        "Sarah Cannon Cancer Institute, Charleston, SC, USA",
        "Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Shreveport, Shreveport, LA, United States",
        "Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, OR, United States",
        "Portland Veterans Affairs Medical Center, Portland, OR, United States",
        "Department of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI, United States",
        "Department of Otolaryngology-Head and Neck Surgery, University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States",
        "Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States",
        "Presage Biosciences, Inc., Seattle, WA, United States"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153667/AHNS_fig2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153667/AHNS_fig2.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153667"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 465,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Aims and Methods",
        "",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Thomas Hendriks, MBBS, MPhil, FRACS 1 ; Terry Day 1 ; David Neskey 1 ; Peter Horwich 1 ; Usman Khan 1 ; Karthik Rajasekaran 2 ; Vikas Mehta 3 ; Thomas J Ow 3 ; John Pang 4 ; Daniel Clayburgh 5 ; Ryan J Li 5 ; Paul L Swiecicki 6 ; C. Alessandra Colaianni 7 ; Alice L Tang 8 ; Connor Burns 9 ; Atticus Turner 9 ; Jason Frazier 9 ; Kate Gillepsie 9 ; Jeffrey Houlton 1",
        "Affiliations": "1 Sarah Cannon Cancer Institute, Charleston, SC, USA; 2 Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States; 3 Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; 4 Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Shreveport, Shreveport, LA, United States; 5 Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, OR, United States; Portland Veterans Affairs Medical Center, Portland, OR, United States; 6 Department of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI, United States; 7 Department of Otolaryngology-Head and Neck Surgery, University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States; 8 Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States; 9 Presage Biosciences, Inc., Seattle, WA, United States",
        "Introduction": "Intra-tumoral microinjection using comparative in vivo oncology (CIVO) is an emerging platform that evaluates tumor-specific pharmacodynamic responses to systemic therapies directly within the native tumor microenvironment (TME). Microinjections, performed 4 to 96 hours prior to surgical resection, enable delivery of up to eight spatially separated therapeutic microdoses, each tagged with a fluorescent signature. Resected tissue is subsequently analyzed to quantify agent-specific biological activity. Earlier work has demonstrated feasibility in sarcoma and lymphoma. We hypothesized that CIVO would be feasible and informative in head and neck malignancies despite the region’s anatomic complexity, enabling in situ pharmacodynamic profiling.",
        "Aims and Methods": "We conducted a prospective analysis across six separate phase 0 (microdosing) trials enrolling adult patients with head and neck squamous cell carcinoma (SCC). Study aims were to assess (1) feasibility and safety of CIVO intratumoral microinjection, (2) clinician experience and technical considerations during injection, and (3) evaluability of pharmacodynamic responses within the TME. Outcomes included tumor location, injection tolerability, technical accuracy, and the ability to track and quantify microdose-specific biological effects. Tumor response endpoints, including the ability to assess drug-specific pharmacodynamic effectiveness, were generally characterized.",
        "": "Figure 1: CIVO Clinical Procedure/Processing",
        "Results": "As of November 2025, 48 patients with SCC underwent intratumoral CIVO microinjection across six trials (18 mucosal primaries, 18 metastatic lymph nodes, 12 other head and neck lesions). No injection-related serious adverse events occurred. Overall, pharmacodynamic responses within SCC and the TME were quantifiable in 65% of patients. Non-evaluability was most commonly due to tissue quality (n = 11), predominantly from injections placed into necrotic regions of tumor. This limitation was later mitigated by incorporating ultrasound screening for metastatic lymph nodes and refining eligibility criteria for sublingual and tongue lesions. Injection accuracy accounted for the remaining non-evaluable cases (n = 6). Injector experience did not correlate with accuracy; however, injection depth was significantly associated with the percentage of microdoses successfully identified. Lesion depth varied by anatomical site, with metastatic lymph nodes demonstrating lower evaluability than other pathologies (44% vs 78%). Therapeutic classes evaluated included traditional chemotherapies, small-molecule inhibitors, immunotherapies (including first-in-human agents), antibody-drug conjugates, and combination regimens. TME profilin, using drug-specific IHC/ISH markers and high-plex spatial biology assays, will be presented.",
        "Conclusions": "Preoperative intratumoral microinjection using the CIVO platform is feasible and safe in head and neck SCC and enables direct evaluation of tumor-specific drug responses within the native TME, particularly in non-necrotic tumor regions. Major obstacles to evaluability (pre-existing tumor necrosis and injection inaccuracy) should be addressed through optimized screening and device parameter adjustments (e.g., needle gauge and stiffness). Clinician experience does not appear to be a confounding factor for implementation. This technology supports early clinical translation of novel therapeutics and combinations in head and neck cancer and may serve as a precision-medicine strategy to guide patient-specific systemic therapy selection.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Intra-Tumoral Microdosing Enables Pharmacodynamic Drug Response Profiling in Head and Neck Cancer</span>. <u>Thomas Hendriks, MBBS, MPhil, FRACS</u><sup>1</sup>; Terry Day<sup>1</sup>; David Neskey<sup>1</sup>; Peter Horwich<sup>1</sup>; Usman Khan<sup>1</sup>; Karthik Rajasekaran<sup>2</sup>; Vikas Mehta<sup>3</sup>; Thomas J Ow<sup>3</sup>; John Pang<sup>4</sup>; Daniel Clayburgh<sup>5</sup>; Ryan J Li<sup>5</sup>; Paul L Swiecicki<sup>6</sup>; C. Alessandra Colaianni<sup>7</sup>; Alice L Tang<sup>8</sup>; Connor Burns<sup>9</sup>; Atticus Turner<sup>9</sup>; Jason Frazier<sup>9</sup>; Kate Gillepsie<sup>9</sup>; Jeffrey Houlton<sup>1</sup>. <sup>1</sup>Sarah Cannon Cancer Institute, Charleston, SC, USA; <sup>2</sup>Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States; <sup>3</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; <sup>4</sup>Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Shreveport, Shreveport, LA, United States; <sup>5</sup>Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, OR, United States; Portland Veterans Affairs Medical Center, Portland, OR, United States; <sup>6</sup>Department of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI, United States; <sup>7</sup>Department of Otolaryngology-Head and Neck Surgery, University of North Carolina (UNC) Medical Center, Chapel Hill, NC, United States; <sup>8</sup>Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States; <sup>9</sup>Presage Biosciences, Inc., Seattle, WA, United States<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Intra-tumoral microinjection using comparative in vivo oncology (CIVO) is an emerging platform that evaluates tumor-specific pharmacodynamic responses to systemic therapies directly within the native tumor microenvironment (TME). Microinjections, performed 4 to 96 hours prior to surgical resection, enable delivery of up to eight spatially separated therapeutic microdoses, each tagged with a fluorescent signature. Resected tissue is subsequently analyzed to quantify agent-specific biological activity. Earlier work has demonstrated feasibility in sarcoma and lymphoma. We hypothesized that CIVO would be feasible and informative in head and neck malignancies despite the region’s anatomic complexity, enabling in situ pharmacodynamic profiling.</p>\n\n<p><strong>Aims and Methods: </strong>We conducted a prospective analysis across six separate phase 0 (microdosing) trials enrolling adult patients with head and neck squamous cell carcinoma (SCC). Study aims were to assess (1) feasibility and safety of CIVO intratumoral microinjection, (2) clinician experience and technical considerations during injection, and (3) evaluability of pharmacodynamic responses within the TME. Outcomes included tumor location, injection tolerability, technical accuracy, and the ability to track and quantify microdose-specific biological effects. Tumor response endpoints, including  the ability to assess drug-specific pharmacodynamic effectiveness, were generally characterized.</p>\n\n<p><strong> </strong>Figure 1: CIVO Clinical Procedure/Processing</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153667/AHNS_fig2.png' /></p>\n\n<p><strong>Results: </strong>As of November 2025, 48 patients with SCC underwent intratumoral CIVO microinjection across six trials (18 mucosal primaries, 18 metastatic lymph nodes, 12 other head and neck lesions). No injection-related serious adverse events occurred. Overall, pharmacodynamic responses within SCC and the TME were quantifiable in 65% of patients. Non-evaluability was most commonly due to tissue quality (n = 11), predominantly from injections placed into necrotic regions of tumor. This limitation was later mitigated by incorporating ultrasound screening for metastatic lymph nodes and refining eligibility criteria for sublingual and tongue lesions. Injection accuracy accounted for the remaining non-evaluable cases (n = 6). Injector experience did not correlate with accuracy; however, injection depth was significantly associated with the percentage of microdoses successfully identified. Lesion depth varied by anatomical site, with metastatic lymph nodes demonstrating lower evaluability than other pathologies (44% vs 78%). Therapeutic classes evaluated included traditional chemotherapies, small-molecule inhibitors, immunotherapies (including first-in-human agents), antibody-drug conjugates, and combination regimens. TME profilin, using drug-specific IHC/ISH markers and high-plex spatial biology assays, will be presented.</p>\n\n<p><strong>Conclusions: </strong>Preoperative intratumoral microinjection using the CIVO platform is feasible and safe in head and neck SCC and enables direct evaluation of tumor-specific drug responses within the native TME, particularly in non-necrotic tumor regions. Major obstacles to evaluability (pre-existing tumor necrosis and injection inaccuracy) should be addressed through optimized screening and device parameter adjustments (e.g., needle gauge and stiffness). Clinician experience does not appear to be a confounding factor for implementation. This technology supports early clinical translation of novel therapeutics and combinations in head and neck cancer and may serve as a precision-medicine strategy to guide patient-specific systemic therapy selection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153667--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S324",
      "content_id": "153037",
      "abstract_number": "S324",
      "poster_number": "",
      "title": "Single-cell profiling of CD8+ T cell subsets reveals prognostic immune signatures in head and neck squamous cell carcinoma",
      "summary": "This study highlights the functional diversity and prognostic significance of CD8+ T cell subsets in HNSCC. Subset-specific transcriptional signatures derived from single-cell analysis and projected using ProjecTILs were significantly associated with clinical outcomes. These findings support the clinical utility of CD8+ T cell profiling as a biomarker strategy for immune-based risk stratification and personalized...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153037",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hideyuki Takahashi, MD, PhD",
      "presenter": "Hideyuki Takahashi, MD, PhD",
      "authors": "Hideyuki Takahashi, MD, PhD ; Tomohiro Shimizu, MD; Kazuaki Chikamatsu, MD, PhD",
      "normalized_authors": [
        "Hideyuki Takahashi",
        "Tomohiro Shimizu",
        "Kazuaki Chikamatsu"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 440,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hideyuki Takahashi, MD, PhD ; Tomohiro Shimizu, MD; Kazuaki Chikamatsu, MD, PhD",
        "Affiliations": "Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine",
        "Introduction": "Head and neck squamous cell carcinoma (HNSCC) is characterized by a complex immune microenvironment, in which CD8+ T cells play a central role in antitumor immunity. Emerging evidence suggests that distinct CD8+ T cell subsets exert differential effects on prognosis and therapeutic response. While single-cell RNA sequencing (scRNA-seq) enables high-resolution profiling of these subsets, their precise identification remains technically challenging. In this study, we employed scRNA-seq to characterize the heterogeneity and functional states of CD8+ T cell subsets in patients with HNSCC.",
        "Methods": "The GSE164690 dataset, comprising preprocessed scRNA-seq and clinical data, was obtained from the Gene Expression Omnibus. CD45+ cells and peripheral blood lymphocytes from 17 matched tumor–blood pairs were analyzed using the Seurat v5 R package. CD8+ T cell subclusters were annotated using the ProjecTILs R package. Bulk RNA-seq data from 520 patients with HNSCC in The Cancer Genome Atlas (TCGA) were used to construct a survival prediction model. Subcluster-specific risk scores were calculated using least absolute shrinkage and selection operator (LASSO) regression based on differentially expressed genes. Multivariate survival modeling was performed using Cox proportional hazards regression, and recursive partitioning analysis was conducted with the partykit R package. Cell fractions in each survival group were estimated using CIBERSORTx with the LM22 signature matrix.",
        "Results": "A total of 95,809 immune cells were classified into 16 clusters, including 17,591 CD8+ T cells, which were further subdivided into six subclusters: central memory T cells (Tcm), effector memory T cells (Tem), mucosal-associated invariant T cells (MAIT), terminal effector memory CD45RA+ cells (Temra), exhausted T cells (Tex), and progenitor exhausted T cells (Tpex). ssGSEA revealed that Tpex cells exhibited the highest enrichment of immune-related pathways. Regionally, Temra and Tpex were enriched in oropharyngeal tumors. Risk scores for Tpex and Temra were independent prognostic factors for shorter overall survival (OS), while scores for Tcm, Tem, and Tex were associated with shorter progression-free survival (PFS). Recursive partitioning showed that combined Tex and Tpex scores stratified patients by OS, while Tex and Tem scores stratified patients by PFS. Immune deconvolution revealed that patients in the poor-survival group had lower infiltration of B cells, CD8+ T cells, activated memory CD4+ T cells, follicular helper T cells, and regulatory T cells, alongside higher infiltration of resting memory CD4+ T cells and macrophages.",
        "Conclusion": "This study highlights the functional diversity and prognostic significance of CD8+ T cell subsets in HNSCC. Subset-specific transcriptional signatures derived from single-cell analysis and projected using ProjecTILs were significantly associated with clinical outcomes. These findings support the clinical utility of CD8+ T cell profiling as a biomarker strategy for immune-based risk stratification and personalized therapy in HNSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Single-cell profiling of CD8+ T cell subsets reveals prognostic immune signatures in head and neck squamous cell carcinoma</span>. <u>Hideyuki Takahashi, MD, PhD</u>; Tomohiro Shimizu, MD; Kazuaki Chikamatsu, MD, PhD. Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is characterized by a complex immune microenvironment, in which CD8+ T cells play a central role in antitumor immunity. Emerging evidence suggests that distinct CD8+ T cell subsets exert differential effects on prognosis and therapeutic response. While single-cell RNA sequencing (scRNA-seq) enables high-resolution profiling of these subsets, their precise identification remains technically challenging. In this study, we employed scRNA-seq to characterize the heterogeneity and functional states of CD8+ T cell subsets in patients with HNSCC.</p>\n\n<p><strong>Methods: </strong>The GSE164690 dataset, comprising preprocessed scRNA-seq and clinical data, was obtained from the Gene Expression Omnibus. CD45+ cells and peripheral blood lymphocytes from 17 matched tumor–blood pairs were analyzed using the Seurat v5 R package. CD8+ T cell subclusters were annotated using the ProjecTILs R package. Bulk RNA-seq data from 520 patients with HNSCC in The Cancer Genome Atlas (TCGA) were used to construct a survival prediction model. Subcluster-specific risk scores were calculated using least absolute shrinkage and selection operator (LASSO) regression based on differentially expressed genes. Multivariate survival modeling was performed using Cox proportional hazards regression, and recursive partitioning analysis was conducted with the partykit R package. Cell fractions in each survival group were estimated using CIBERSORTx with the LM22 signature matrix.</p>\n\n<p><strong>Results: </strong>A total of 95,809 immune cells were classified into 16 clusters, including 17,591 CD8+ T cells, which were further subdivided into six subclusters: central memory T cells (Tcm), effector memory T cells (Tem), mucosal-associated invariant T cells (MAIT), terminal effector memory CD45RA+ cells (Temra), exhausted T cells (Tex), and progenitor exhausted T cells (Tpex). ssGSEA revealed that Tpex cells exhibited the highest enrichment of immune-related pathways. Regionally, Temra and Tpex were enriched in oropharyngeal tumors. Risk scores for Tpex and Temra were independent prognostic factors for shorter overall survival (OS), while scores for Tcm, Tem, and Tex were associated with shorter progression-free survival (PFS). Recursive partitioning showed that combined Tex and Tpex scores stratified patients by OS, while Tex and Tem scores stratified patients by PFS. Immune deconvolution revealed that patients in the poor-survival group had lower infiltration of B cells, CD8+ T cells, activated memory CD4+ T cells, follicular helper T cells, and regulatory T cells, alongside higher infiltration of resting memory CD4+ T cells and macrophages.</p>\n\n<p><strong>Conclusion: </strong>This study highlights the functional diversity and prognostic significance of CD8+ T cell subsets in HNSCC. Subset-specific transcriptional signatures derived from single-cell analysis and projected using ProjecTILs were significantly associated with clinical outcomes. These findings support the clinical utility of CD8+ T cell profiling as a biomarker strategy for immune-based risk stratification and personalized therapy in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153037--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S325",
      "content_id": "153048",
      "abstract_number": "S325",
      "poster_number": "",
      "title": "The role of stem like CD8+ T cells (Tpex) in oral cancer prognosis. Tpex location matters and their presence is potentially tuned by the lymph node microenvironment.",
      "summary": "The presence of Tpex at high numbers at the tumour front seems to affect prognosis of patients treated for LA OCSCC. APCs in the non metastatic nodes potentially contribute to this, whereas Tregs in the non metastatic nodes have adverse effect.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153048",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Stergios Doumas, MD, DDS",
      "presenter": "Stergios Doumas, MD, DDS",
      "authors": "Stergios Doumas, MD, DDS 1 ; Periklis Foukas, MD, PhD 2 ; Panagiota Economopoulou, MD, PhD 2 ; Aris Spathis, PhD 2 ; Amanda Psyrri, MD, PhD 2",
      "normalized_authors": [
        "Stergios Doumas",
        "Periklis Foukas",
        "Panagiota Economopoulou",
        "Aris Spathis",
        "Amanda Psyrri"
      ],
      "affiliations": [
        "Maxillofacial Unit, Queen Victoria Hospital NHSFT, East Grinstead UK",
        "Attiko University Hospital Athens Greece"
      ],
      "normalized_institutions": [
        "Maxillofacial Unit, Queen Victoria Hospital NHSFT, East Grinstead UK",
        "Attiko University Hospital Athens Greece"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 556,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Materials",
        "Results",
        "Non metastatic Nodes",
        "Metastatic Nodes",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Stergios Doumas, MD, DDS 1 ; Periklis Foukas, MD, PhD 2 ; Panagiota Economopoulou, MD, PhD 2 ; Aris Spathis, PhD 2 ; Amanda Psyrri, MD, PhD 2",
        "Affiliations": "1 Maxillofacial Unit, Queen Victoria Hospital NHSFT, East Grinstead UK; 2 Attiko University Hospital Athens Greece",
        "Introduction": "Despite the success of immunotherapy, <20% of patients experience durable responses in head and neck cancer. As T-cells encounter tumour, they sustain transcriptional and epigenetic changes that lead to progressive loss of effector functions a condition described as T cell exhaustion. This is a differentiation pathway whereupon stem-like CD8+ T cells (Tpex) generate T-cells with effector/cytotoxic functions (Texh-int), and finally adopt a terminally exhausted phenotype (Texh-term).",
        "Abstract": "Studies have highlighted the Tpex role in tumour eradication. Draining lymph nodes (TDLNs) are Tpex reservoirs. The presence of mature DCs in TDLN results in primed Tpex that migrate to the tumour bed, with ability to renew or differentiate into Texh-int and kill tumour cells. However, immature/immunosuppressed DCs fail to prime Tpex. Equally, the presence of Tregs in the TDLN blunt immune responses. Neoadjuvant trials showed increased exhaustion profiles and decreased numbers of Tpex in the metastatic nodes. Our hypothesis cites that the location of Tpex in relation to the tumour front may affect prognosis in patients with LA OCSCC. We also sought for differences in expression of mature CD11c+ DCs and Tregs in the metastatic vs. adjacent non-metastatic TDLN, and if these are relevant with Tpex numbers in the primary site. TMAs were constructed. The primary site tissues (n=40) were stained for CD8, PD1 and TCF1 (marker for Tpex) proteins, whereas the TDLN tissues (metastatic n=36, non-metastatic n=21) were stained for CD8, Foxp3 (Treg) and CD11c (mature DCs) respectively. Image analysis was performed using Qpath platform. On the contrary, patients with high density of CD8+TCF1+PD1- cells/mm2 in the tumour core presented with reduced OS (cutoff of 55 cells/mm2, 23 months vs 67 months, p=0.010). Alive patients had increased numbers of CD8+TCF1+PD1+/mm2 and CD8+TCF1+PD1-/mm2 cells at the tumour front (225 vs. 116, p=0.037 and 89 vs. 29, p=0.043). CD11c associated with increased CD8/FoxP3 ratio (CC 0.496, p=0.005) in the non metastatic TDLN. View in Agenda and Add to Schedule",
        "Materials": "Tissues were obtained after informed consent from 40 patients with LA OCSCC (stages III-IVB AJCC 7). All patients had primary surgery with curative intent from September 2012 to September 2017. Adjuvant treatment delivered when indicated. Clinicopathological parameters and survival data were collated, follow up >5 years.",
        "Results": "At the front of the tumour patients with high density of CD8+ cells/mm2 presented with improved OS (cutoff of 100 cells/mm2, 27 months vs 62 months, p=0.029). Similarly, patients with high CD8+TCF1+PD1-/mm2 density or CD8+TCF1+PD1+/mm2 density presented with improved OS (cutoff 48 cells, 26 months vs. 66 months, p=0.013 and cutoff of 8 cells, 18 months vs. 66 months, p=0.003 respectively).",
        "Non metastatic Nodes": "FoxP3 inversely correlated with the percentage of CD8+TCF1+PD1- (CC -0.365 p=0.033) in the tumour front. Similar corelations were found for the rest of CD8+ populations.",
        "Metastatic Nodes": "CD11c correleated positive with CD8 in affected TDLN (CC=0.657, p=0.001) and non metastatic TDLN (CC=0.547, p=0.028).",
        "Conclusion": "The presence of Tpex at high numbers at the tumour front seems to affect prognosis of patients treated for LA OCSCC. APCs in the non metastatic nodes potentially contribute to this, whereas Tregs in the non metastatic nodes have adverse effect."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The role of stem like CD8+ T cells (Tpex) in oral cancer prognosis. Tpex location matters and their presence is potentially tuned by the lymph node microenvironment.</span>. <u>Stergios Doumas, MD, DDS</u><sup>1</sup>; Periklis Foukas, MD, PhD<sup>2</sup>; Panagiota Economopoulou, MD, PhD<sup>2</sup>; Aris Spathis, PhD<sup>2</sup>; Amanda Psyrri, MD, PhD<sup>2</sup>. <sup>1</sup>Maxillofacial Unit, Queen Victoria Hospital NHSFT, East Grinstead UK; <sup>2</sup>Attiko University Hospital Athens Greece<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Despite the success of immunotherapy, <20% of patients experience durable responses in head and neck cancer. As T-cells encounter tumour, they sustain transcriptional and epigenetic changes that lead to progressive loss of effector functions a condition described as T cell exhaustion. This is a differentiation pathway whereupon stem-like CD8+ T cells (Tpex) generate T-cells with effector/cytotoxic functions (Texh-int), and finally adopt a terminally exhausted phenotype (Texh-term). </p>\n\n<p>Studies have highlighted the Tpex role in tumour eradication. Draining lymph nodes (TDLNs) are Tpex reservoirs. The presence of mature DCs in TDLN results in primed Tpex that migrate to the tumour bed, with ability to renew or differentiate into Texh-int and kill tumour cells. However, immature/immunosuppressed DCs fail to prime Tpex. Equally, the presence of Tregs in the TDLN blunt immune responses. Neoadjuvant trials showed increased exhaustion profiles and decreased numbers of Tpex in the metastatic nodes. </p>\n\n<p>Our hypothesis cites that the location of Tpex in relation to the tumour front may affect prognosis in patients with LA OCSCC. We also sought for differences in expression of mature CD11c+ DCs and Tregs in the metastatic vs. adjacent non-metastatic TDLN, and if these are relevant with Tpex numbers in the primary site.</p>\n\n<p><strong>Materials: </strong>Tissues were obtained after informed consent from 40 patients with LA OCSCC (stages III-IVB AJCC 7). All patients had primary surgery with curative intent from September 2012 to September 2017. Adjuvant treatment delivered when indicated. Clinicopathological parameters and survival data were collated, follow up >5 years.</p>\n\n<p>TMAs were constructed. The primary site tissues (n=40) were stained for CD8, PD1 and TCF1 (marker for Tpex) proteins, whereas the TDLN tissues (metastatic n=36, non-metastatic n=21) were stained for CD8, Foxp3 (Treg) and CD11c (mature DCs) respectively. Image analysis was performed using Qpath platform.</p>\n\n<p><strong>Results: </strong>At the front of the tumour patients with high density of CD8+ cells/mm2 presented with improved OS (cutoff of 100 cells/mm2, 27 months vs 62 months, p=0.029). Similarly, patients with high CD8+TCF1+PD1-/mm2 density or CD8+TCF1+PD1+/mm2 density presented with improved OS (cutoff 48 cells, 26 months vs. 66 months, p=0.013 and cutoff of 8 cells, 18 months vs. 66 months, p=0.003 respectively). </p>\n\n<p>On the contrary, patients with high density of CD8+TCF1+PD1- cells/mm2 in the tumour core presented with reduced OS (cutoff of 55 cells/mm2, 23 months vs 67 months, p=0.010).</p>\n\n<p>Alive patients had increased numbers of CD8+TCF1+PD1+/mm2 and CD8+TCF1+PD1-/mm2 cells at the tumour front (225 vs. 116, p=0.037 and 89 vs. 29, p=0.043).</p>\n\n<p><strong>Non metastatic Nodes: </strong>FoxP3 inversely correlated with the percentage of CD8+TCF1+PD1- (CC -0.365 p=0.033) in the tumour front. Similar corelations were found for the rest of CD8+ populations.</p>\n\n<p>CD11c associated with increased CD8/FoxP3 ratio (CC 0.496, p=0.005) in the non metastatic TDLN.</p>\n\n<p><strong>Metastatic Nodes: </strong>CD11c correleated positive with CD8 in affected TDLN (CC=0.657, p=0.001) and non metastatic TDLN (CC=0.547, p=0.028).</p>\n\n<p><strong>Conclusion: </strong>The presence of Tpex at high numbers at the tumour front seems to affect prognosis of patients treated for LA OCSCC. APCs in the non metastatic nodes potentially contribute to this, whereas Tregs in the non metastatic nodes have adverse effect.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153048--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S326",
      "content_id": "153505",
      "abstract_number": "S326",
      "poster_number": "",
      "title": "Prediction of drug response using mechanically tunable GelMA hydrogels in oral squamous cell carcinoma",
      "summary": "Mechanically tunable GelMA-based 3D in vitro models enriched a stiffness-associated molecular signature that correlates with therapeutic resistance. These models effectively recapitulate patient-specific responses and hold promise as tools for precision oncology and for screening novel therapeutic agents.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153505",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Moni A Kuriakose, Dr",
      "presenter": "Moni A Kuriakose, Dr",
      "authors": "Pavan M Hallur, Mr 1 ; Vivek Shetty, Dr 2 ; Vidyabhushan R, Dr 2 ; Yogesh Dokhe, Dr 2 ; Naveen BS, Dr 2 ; Trupti Kolur, Dr 2 ; Vijay Pillai, Dr 2 ; Moni A Kuriakose, Dr 2 ; Abhay Deshpande, PhD 3 ; Aritra Chatterjee, PhD 4 ; Sujan Dhar, PhD 5 ; Amritha Suresh, PhD 1",
      "normalized_authors": [
        "Pavan M Hallur, Mr",
        "Vivek Shetty, Dr",
        "Vidyabhushan R, Dr",
        "Yogesh Dokhe, Dr",
        "Naveen Dr",
        "Trupti Kolur, Dr",
        "Vijay Pillai, Dr",
        "Moni A Kuriakose, Dr",
        "Abhay Deshpande",
        "Aritra Chatterjee",
        "Sujan Dhar",
        "Amritha Suresh"
      ],
      "affiliations": [
        "Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India",
        "Head and Neck Oncology, Mazumdar Shaw Medical Centre, NH, Bangalore, India",
        "Jai Research Foundation, Valvada, Vapi, Gujarat, India",
        "Department of Mechanical Engineering, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India",
        "Computational Biology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India"
      ],
      "normalized_institutions": [
        "Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India",
        "Head and Neck Oncology, Mazumdar Shaw Medical Centre, NH, Bangalore, India",
        "Jai Research Foundation, Valvada, Vapi, Gujarat, India",
        "Department of Mechanical Engineering, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India",
        "Computational Biology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 511,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion",
        "Acknowledgement"
      ],
      "sections": {
        "Authors": "Pavan M Hallur, Mr 1 ; Vivek Shetty, Dr 2 ; Vidyabhushan R, Dr 2 ; Yogesh Dokhe, Dr 2 ; Naveen BS, Dr 2 ; Trupti Kolur, Dr 2 ; Vijay Pillai, Dr 2 ; Moni A Kuriakose, Dr 2 ; Abhay Deshpande, PhD 3 ; Aritra Chatterjee, PhD 4 ; Sujan Dhar, PhD 5 ; Amritha Suresh, PhD 1",
        "Affiliations": "1 Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India; 2 Head and Neck Oncology, Mazumdar Shaw Medical Centre, NH, Bangalore, India; 3 Jai Research Foundation, Valvada, Vapi, Gujarat, India; 4 Department of Mechanical Engineering, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India; 5 Computational Biology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India",
        "Introduction": "Oral cancer remains a major public health challenge, with a 5-year survival rate of only 27% in advanced stages. Cisplatin, the standard chemotherapeutic agent, shows limited efficacy and high relapse rates, underscoring the need for better patient stratification. Conventional 2D culture models fail to mimic in vivo tumor architecture and mechanical cues. This study investigates the use of 3D in vitro models using mechanically tunable GelMA hydrogels as biomimetic scaffolds to assess chemoresistance and for testing novel therapies.",
        "Methods": "Meta-analysis of publicly available RNA sequencing datasets from cells cultured under different 3D conditions (spheroids, Matrigel-soft, and Matrigel-stiff) was performed to identify stiffness-induced molecular signatures. Biomimetic, 3D-GelMA hydrogels with defined stiffness (soft: <0.5 kPa; stiff >1.0 kPa) were fabricated, and OSCC cell lines (Cal27, HSC3- sensitive to cisplatin, and Cal27R- resistant to cisplatin) were cultured on these scaffolds to assess their response to chemotherapeutic agents.",
        "Abstract": "Patient-derived OSCC cells cultured on 3D-GelMA hydrogels of varying stiffness were characterized using transcriptome analysis. Targeted sequencing of OSCC-relevant genes was performed to determine the mutational profiles and compared with matched native tumor tissue. The transcriptome analysis of these patient-derived cells cultured on 3D-GelMA hydrogels of varying stiffness is currently ongoing. A resistance-index of these patient-derived cells cultured on 3D-GelMA hydrogels was calculated upon exposure to standard chemotherapeutic agents. The resistance-index was further used to correlate with the respective patients’ clinical outcome. Additionally, a panel of small-molecule inhibitors was tested on these patient-derived cells to identify potential therapeutic candidates not commonly used in clinical practice. The drug response data will also be correlated with transcriptomic signatures obtained from the patient-derived OSCC cells to delineate the pathways and cellular phenotypes associated with resistance. Patient-derived OSCC cells (n=3) were successfully established and cultured on 3D-GelMA hydrogels of varying stiffness. These organoids are being characterized to confirm their similarity to native tumor tissue using targeted sequencing for mutation profiling. RNA sequencing has been completed, and transcriptomic analysis is currently ongoing to identify enriched cellular populations and pathways influenced by the mechanical properties of the 3D-GelMA hydrogels. Patient-derived cells also exhibited differential responses to cisplatin, cetuximab, and multiple small-molecule inhibitors across varying stiffness conditions. Notably, several small-molecule inhibitors not currently used in OSCC clinical management showed selective efficacy in the established patient-derived cells. View in Agenda and Add to Schedule",
        "Results": "The meta-analysis revealed distinct cellular phenotypes associated with specific 3D culture conditions and stiffness profiles, reflecting inherent tumor heterogeneity. Stiff matrices enriched partially EMT-like cells and those in the G1/S phase, whereas soft matrices enriched cells in the G2/M phase. Cal27 and HSC3 cells demonstrated increased chemoresistance in 3D-GelMA in contrast to 2D cultures, with stiffness-dependent differences between soft and stiff hydrogels, highlighting the influence of mechanical stiffness.",
        "Conclusion": "Mechanically tunable GelMA-based 3D in vitro models enriched a stiffness-associated molecular signature that correlates with therapeutic resistance. These models effectively recapitulate patient-specific responses and hold promise as tools for precision oncology and for screening novel therapeutic agents.",
        "Acknowledgement": "Financial support: MSMF, Bangalore; ICMR (No. 5/3/8/13/ITR-F/2022-ITR); Fellowship support: Prime Minister Fellowship for Doctoral Research, CII, India."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prediction of drug response using mechanically tunable GelMA hydrogels in oral squamous cell carcinoma</span>. Pavan M Hallur, Mr<sup>1</sup>; Vivek Shetty, Dr<sup>2</sup>; Vidyabhushan R, Dr<sup>2</sup>; Yogesh Dokhe, Dr<sup>2</sup>; Naveen BS, Dr<sup>2</sup>; Trupti Kolur, Dr<sup>2</sup>; Vijay Pillai, Dr<sup>2</sup>; <u>Moni A Kuriakose, Dr</u><sup>2</sup>; Abhay Deshpande, PhD<sup>3</sup>; Aritra Chatterjee, PhD<sup>4</sup>; Sujan Dhar, PhD<sup>5</sup>; Amritha Suresh, PhD<sup>1</sup>. <sup>1</sup>Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Integrated Head and Neck Oncology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India; <sup>2</sup>Head and Neck Oncology, Mazumdar Shaw Medical Centre, NH, Bangalore, India; <sup>3</sup>Jai Research Foundation, Valvada, Vapi, Gujarat, India; <sup>4</sup>Department of Mechanical Engineering,  Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India; <sup>5</sup>Computational Biology Program, Mazumdar Shaw Medical Foundation, NH Health City, Bangalore, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oral cancer remains a major public health challenge, with a 5-year survival rate of only 27% in advanced stages. Cisplatin, the standard chemotherapeutic agent, shows limited efficacy and high relapse rates, underscoring the need for better patient stratification. Conventional 2D culture models fail to mimic <em>in vivo</em> tumor architecture and mechanical cues. This study investigates the use of 3D <em>in vitro</em> models using mechanically tunable GelMA hydrogels as biomimetic scaffolds to assess chemoresistance and for testing novel therapies.</p>\n\n<p><strong>Methods: </strong>Meta-analysis of publicly available RNA sequencing datasets from cells cultured under different 3D conditions (spheroids, Matrigel-soft, and Matrigel-stiff) was performed to identify stiffness-induced molecular signatures. Biomimetic, 3D-GelMA hydrogels with defined stiffness (soft: <0.5 kPa; stiff >1.0 kPa) were fabricated, and OSCC cell lines (Cal27, HSC3- sensitive to cisplatin, and Cal27R- resistant to cisplatin) were cultured on these scaffolds to assess their response to chemotherapeutic agents.</p>\n\n<p>Patient-derived OSCC cells cultured on 3D-GelMA hydrogels of varying stiffness were characterized using transcriptome analysis. Targeted sequencing of OSCC-relevant genes was performed to determine the mutational profiles and compared with matched native tumor tissue. The transcriptome analysis of these patient-derived cells cultured on 3D-GelMA hydrogels of varying stiffness is currently ongoing.</p>\n\n<p>A resistance-index of these patient-derived cells cultured on 3D-GelMA hydrogels was calculated upon exposure to standard chemotherapeutic agents. The resistance-index was further used to correlate with the respective patients’ clinical outcome. Additionally, a panel of small-molecule inhibitors was tested on these patient-derived cells to identify potential therapeutic candidates not commonly used in clinical practice. The drug response data will also be correlated with transcriptomic signatures obtained from the patient-derived OSCC cells to delineate the pathways and cellular phenotypes associated with resistance.</p>\n\n<p><strong>Results: </strong>The meta-analysis revealed distinct cellular phenotypes associated with specific 3D culture conditions and stiffness profiles, reflecting inherent tumor heterogeneity. Stiff matrices enriched partially EMT-like cells and those in the G1/S phase, whereas soft matrices enriched cells in the G2/M phase. Cal27 and HSC3 cells demonstrated increased chemoresistance in 3D-GelMA in contrast to 2D cultures, with stiffness-dependent differences between soft and stiff hydrogels, highlighting the influence of mechanical stiffness.</p>\n\n<p>Patient-derived OSCC cells (n=3) were successfully established and cultured on 3D-GelMA hydrogels of varying stiffness. These organoids are being characterized to confirm their similarity to native tumor tissue using targeted sequencing for mutation profiling. RNA sequencing has been completed, and transcriptomic analysis is currently ongoing to identify enriched cellular populations and pathways influenced by the mechanical properties of the 3D-GelMA hydrogels.</p>\n\n<p>Patient-derived cells also exhibited differential responses to cisplatin, cetuximab, and multiple small-molecule inhibitors across varying stiffness conditions. Notably, several small-molecule inhibitors not currently used in OSCC clinical management showed selective efficacy in the established patient-derived cells.</p>\n\n<p><strong>Conclusion: </strong>Mechanically tunable GelMA-based 3D <em>in vitro</em> models enriched a stiffness-associated molecular signature that correlates with therapeutic resistance. These models effectively recapitulate patient-specific responses and hold promise as tools for precision oncology and for screening novel therapeutic agents.</p>\n\n<p><strong>Acknowledgement: </strong>Financial support: MSMF, Bangalore; ICMR (No. 5/3/8/13/ITR-F/2022-ITR); Fellowship support: Prime Minister Fellowship for Doctoral Research, CII, India.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153505--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S327",
      "content_id": "153326",
      "abstract_number": "S327",
      "poster_number": "",
      "title": "Novel therapeutic strategy for HPV-negative Head and Neck cancer",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, and its incidence has increased over the past decade. HNSCC is etiologically divided into human papillomavirus–positive (HPV+) and HPV-negative (HPV-) subtypes; the HPV-negative subtype is associated with poorer clinical outcomes. Patients with HPV-negative HNSCC exhibit lower survival rates, greater treatment-associated...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153326",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sri Vemulamanda, BS",
      "presenter": "Sri Vemulamanda, BS",
      "authors": "Sri Vemulamanda, BS ; Wendell G Yarbrough, MD, MMHC, FACS; Natalia Issaeva, PhD",
      "normalized_authors": [
        "Sri Vemulamanda",
        "Wendell G Yarbrough, MMHC",
        "Natalia Issaeva"
      ],
      "affiliations": [
        "University of North Carolina School of Medicine"
      ],
      "normalized_institutions": [
        "University of North Carolina School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 346,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sri Vemulamanda, BS ; Wendell G Yarbrough, MD, MMHC, FACS; Natalia Issaeva, PhD",
        "Affiliations": "University of North Carolina School of Medicine",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, and its incidence has increased over the past decade. HNSCC is etiologically divided into human papillomavirus–positive (HPV+) and HPV-negative (HPV-) subtypes; the HPV-negative subtype is associated with poorer clinical outcomes. Patients with HPV-negative HNSCC exhibit lower survival rates, greater treatment-associated morbidity, and more frequent recurrence, largely attributable to intrinsic and/or acquired resistance to standard chemotherapy and radiotherapy. The causative factors that permit the emergence and persistence of structural genomic alterations and resistance-conferring mutations remain unknown. Identification of such factors could reveal novel therapeutic targets for both treatment and prevention of HNSCC. One candidate is Long Interspersed Nuclear Element-1 (LINE-1), a part of the larger family of autonomous retrotransposons that comprise nearly half of mammalian genomes. LINE-1 encodes two proteins required for retrotransposition: ORF1, a ~40 kDa RNA-binding protein, and ORF2, a ~150 kDa protein with reverse transcriptase and endonuclease activities. LINE-1 activity is highly repressed in normal tissues; however, aberrant LINE-1 activation has been observed in HPV-negative HNSCC and is associated with genomic alterations in these tumors. We hypothesized that derepressed LINE-1 retrotransposition contributes to treatment resistance in HNSCC and that pharmacological inhibition of LINE-1 reverse transcriptase could re-sensitize resistant tumors to treatment, as well as delay or prevent acquisition of resistance-conferring mutations in treatment-naïve tumors. To test this hypothesis, we generated radiation- and cisplatin-resistant HPV-negative HNSCC human and mouse cell lines in vitro and in vivo and evaluated the effects of the nucleoside reverse transcriptase inhibitor lamivudine. Lamivudine is FDA-approved for HIV and hepatitis B and has been reported to inhibit LINE-1 retrotransposition. Cisplatin and radiation resistant cells demonstrated significantly increased LINE-1-mediated retrotransposition relative to parental cells. Importantly, lamivudine treatment restored cisplatin sensitivity in resistant clones to levels comparable with parental cells. In immunocompetent murine models, lamivudine treatment exerted significant anti-tumor effect that was comparable 30Gy of fractionated radiotherapy, while combination of Lamivudine and radiation improved mouse survival. Collectively, these data indicate that LINE-1 is a promising therapeutic target for HPV-negative HNSCC. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Novel therapeutic strategy for HPV-negative Head and Neck cancer</span>. <u>Sri Vemulamanda, BS</u>; Wendell G Yarbrough, MD, MMHC, FACS; Natalia Issaeva, PhD. University of North Carolina School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, and its incidence has increased over the past decade. HNSCC is etiologically divided into human papillomavirus–positive (HPV+) and HPV-negative (HPV-) subtypes; the HPV-negative subtype is associated with poorer clinical outcomes. Patients with HPV-negative HNSCC exhibit lower survival rates, greater treatment-associated morbidity, and more frequent recurrence, largely attributable to intrinsic and/or acquired resistance to standard chemotherapy and radiotherapy.</p>\n\n<p>The causative factors that permit the emergence and persistence of structural genomic alterations and resistance-conferring mutations remain unknown. Identification of such factors could reveal novel therapeutic targets for both treatment and prevention of HNSCC. One candidate is Long Interspersed Nuclear Element-1 (LINE-1), a part of the larger family of autonomous retrotransposons that comprise nearly half of mammalian genomes. LINE-1 encodes two proteins required for retrotransposition: ORF1, a ~40 kDa RNA-binding protein, and ORF2, a ~150 kDa protein with reverse transcriptase and endonuclease activities.</p>\n\n<p>LINE-1 activity is highly repressed in normal tissues; however, aberrant LINE-1 activation has been observed in HPV-negative HNSCC and is associated with genomic alterations in these tumors. We hypothesized that derepressed LINE-1 retrotransposition contributes to treatment resistance in HNSCC and that pharmacological inhibition of LINE-1 reverse transcriptase could re-sensitize resistant tumors to treatment, as well as delay or prevent acquisition of resistance-conferring mutations in treatment-naïve tumors. To test this hypothesis, we generated radiation- and cisplatin-resistant HPV-negative HNSCC human and mouse cell lines in vitro and in vivo  and evaluated the effects of the nucleoside reverse transcriptase inhibitor lamivudine. Lamivudine is FDA-approved for HIV and hepatitis B and has been reported to inhibit LINE-1 retrotransposition.</p>\n\n<p>Cisplatin and radiation resistant cells demonstrated significantly increased LINE-1-mediated retrotransposition relative to parental cells. Importantly, lamivudine treatment restored cisplatin sensitivity in resistant clones to levels comparable with parental cells. In immunocompetent murine models, lamivudine treatment exerted significant anti-tumor effect that was comparable 30Gy of fractionated radiotherapy, while combination of Lamivudine and radiation improved mouse survival. Collectively, these data indicate that LINE-1 is a promising therapeutic target for HPV-negative HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153326--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S328",
      "content_id": "154113",
      "abstract_number": "S328",
      "poster_number": "",
      "title": "Real-World Results of Neoadjuvant Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Case Series",
      "summary": "This study demonstrates real-world clinical and pathologic outcomes after incorporating neoadjuvant immunotherapy in the treatment of advanced cSCC, with a nearly 80% pCR rate. Interestingly, 41.9% of patients did not undergo surgery, with the most common reason for surgical abstention being clinical and radiographic response after an average of 7 cycles of cemiplimab. However, post-immunotherapy imaging was an...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154113",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Celeste Kim, MD",
      "presenter": "Celeste Kim, MD",
      "authors": "Celeste Kim, MD 1 ; Elihu Igbinadolor, BS 2 ; Nicole C Schmitt, MD, FACS 1 ; Joseph Zenga, MD 3 ; Austin Schafer, MD 3 ; Jason Rich, MD, FACS 4 ; Andrew Day, MD, MPH 5 ; Nabil F Saba, MD, FACP 1 ; Jennifer H Gross, MD 1",
      "normalized_authors": [
        "Celeste Kim",
        "Elihu Igbinadolor",
        "Nicole C Schmitt",
        "Joseph Zenga",
        "Austin Schafer",
        "Jason Rich",
        "Andrew Day",
        "Nabil F Saba, FACP",
        "Jennifer H Gross"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Emory School of Medicine, Atlanta, GA",
        "Emory School of Medicine, Atlanta, GA",
        "Department of Otolaryngology-Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI",
        "Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, MO",
        "Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern, Dallas, TX"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Emory School of Medicine, Atlanta, GA",
        "Emory School of Medicine, Atlanta, GA",
        "Department of Otolaryngology-Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI",
        "Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, MO",
        "Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern, Dallas, TX"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 489,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Celeste Kim, MD 1 ; Elihu Igbinadolor, BS 2 ; Nicole C Schmitt, MD, FACS 1 ; Joseph Zenga, MD 3 ; Austin Schafer, MD 3 ; Jason Rich, MD, FACS 4 ; Andrew Day, MD, MPH 5 ; Nabil F Saba, MD, FACP 1 ; Jennifer H Gross, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Emory School of Medicine, Atlanta, GA; 2 Emory School of Medicine, Atlanta, GA; 3 Department of Otolaryngology-Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI; 4 Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, MO; 5 Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern, Dallas, TX",
        "Introduction": "Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous malignancy, with challenging surgical treatment due to associated disease and treatment induced morbidities that impact both function and cosmesis. There is increasing evidence that neoadjuvant anti-PD-1 immune checkpoint blockade can drastically decrease tumor burden, after a recent phase II trial cited a major pathologic response in the majority of patients. With the increased prevalence of offering neoadjuvant cemiplimab for head and neck cSCC, it is imperative to characterize its effects and potential challenges with implementation. We present a multi-institutional real-world case series characterizing the use of neoadjuvant cemiplimab for patients with head and neck cSCC.",
        "Methods": "This study was approved by the IRB at four tertiary care centers. A multi-institutional retrospective review was performed on all patients at least 18 years old who initiated neoadjuvant cemiplimab between November, 2020 and November, 2024. Only patients planned to undergo subsequent definitive surgery based on a multidisciplinary team discussion were included. Collected and analyzed data included demographics, comorbidities, TNM clinical and pathologic staging, treatment course, radiologic and pathologic response, and adverse events.",
        "Results": "Thirty-one patients have been included thus far, with projections to include an additional 53 patients. Most patients are male (84%), with a mean ECOG of 0.7 (0.6 SD) and Charlson Comorbidity Index score of 7.2 (2.7 SD). A large portion of patients had moderately (32.3%) or poorly (19.4%) differentiated cSCC, cT4 (41.9%) primary tumors, and cN0 (35.5%) nodal disease. Ultimately, only 18 of 31 (58.1%) patients underwent surgery after receiving an average of 5 (4 SD) doses of neoadjuvant cemiplimab. The majority of surgical patients (14 of 18, 77.8%) demonstrated pathologic complete response (pCR), of which only 28.6% (4 of 14) had complete radiologic response on preoperative imaging, and 7% (1 of 14) actually showed radiologic progression during their neoadjuvant course. The 13 patients who abstained from surgery did so due to clinical and radiographic evidence of response to cemiplimab, with 38.5% (5 of 13) achieving partial response and 61.5% (8 of 13) achieving complete response. Of these nonsurgical patients, an average of 4 doses of cemiplimab were administered (within a median of 73 days) before achieving partial radiographic response, and an average of 7 doses (within a median of 211 days) before complete response. Statistical analyses from the entire multi-institutional cohort are underway and will be presented.",
        "Conclusion": "This study demonstrates real-world clinical and pathologic outcomes after incorporating neoadjuvant immunotherapy in the treatment of advanced cSCC, with a nearly 80% pCR rate. Interestingly, 41.9% of patients did not undergo surgery, with the most common reason for surgical abstention being clinical and radiographic response after an average of 7 cycles of cemiplimab. However, post-immunotherapy imaging was an inaccurate predictor of pathologic response. Future directions should evaluate for improved interpretation of preoperative imaging after neoadjuvant immunotherapy and predictors of pathologic response.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-World Results of Neoadjuvant Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Case Series</span>. <u>Celeste Kim, MD</u><sup>1</sup>; Elihu Igbinadolor, BS<sup>2</sup>; Nicole C Schmitt, MD, FACS<sup>1</sup>; Joseph Zenga, MD<sup>3</sup>; Austin Schafer, MD<sup>3</sup>; Jason Rich, MD, FACS<sup>4</sup>; Andrew Day, MD, MPH<sup>5</sup>; Nabil F Saba, MD, FACP<sup>1</sup>; Jennifer H Gross, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Emory School of Medicine, Atlanta, GA; <sup>2</sup>Emory School of Medicine, Atlanta, GA; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI; <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, MO; <sup>5</sup>Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern, Dallas, TX<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous malignancy, with challenging surgical treatment due to associated disease and treatment induced morbidities that impact both function and cosmesis. There is increasing evidence that neoadjuvant anti-PD-1 immune checkpoint blockade can drastically decrease tumor burden, after a recent phase II trial cited a major pathologic response in the majority of patients. With the increased prevalence of offering neoadjuvant cemiplimab for head and neck cSCC, it is imperative to characterize its effects and potential challenges with implementation. We present a multi-institutional real-world case series characterizing the use of neoadjuvant cemiplimab for patients with head and neck cSCC.</p>\n\n<p><strong>Methods: </strong>This study was approved by the IRB at four tertiary care centers. A multi-institutional retrospective review was performed on all patients at least 18 years old who initiated neoadjuvant cemiplimab between November, 2020 and November, 2024. Only patients planned to undergo subsequent definitive surgery based on a multidisciplinary team discussion were included. Collected and analyzed data included demographics, comorbidities, TNM clinical and pathologic staging, treatment course, radiologic and pathologic response, and adverse events.</p>\n\n<p><strong>Results: </strong>Thirty-one patients have been included thus far, with projections to include an additional 53 patients. Most patients are male (84%), with a mean ECOG of 0.7 (0.6 SD) and Charlson Comorbidity Index score of 7.2 (2.7 SD). A large portion of patients had moderately (32.3%) or poorly (19.4%) differentiated cSCC, cT4 (41.9%) primary tumors, and cN0 (35.5%) nodal disease. Ultimately, only 18 of 31 (58.1%) patients underwent surgery after receiving an average of 5 (4 SD) doses of neoadjuvant cemiplimab. The majority of surgical patients (14 of 18, 77.8%) demonstrated pathologic complete response (pCR), of which only 28.6% (4 of 14) had complete radiologic response on preoperative imaging, and 7% (1 of 14) actually showed radiologic progression during their neoadjuvant course. The 13 patients who abstained from surgery did so due to clinical and radiographic evidence of response to cemiplimab, with 38.5% (5 of 13) achieving partial response and 61.5% (8 of 13) achieving complete response. Of these nonsurgical patients, an average of 4 doses of cemiplimab were administered (within a median of 73 days) before achieving partial radiographic response, and an average of 7 doses (within a median of 211 days) before complete response. Statistical analyses from the entire multi-institutional cohort are underway and will be presented.</p>\n\n<p><strong>Conclusion: </strong>This study demonstrates real-world clinical and pathologic outcomes after incorporating neoadjuvant immunotherapy in the treatment of advanced cSCC, with a nearly 80% pCR rate. Interestingly, 41.9% of patients did not undergo surgery, with the most common reason for surgical abstention being clinical and radiographic response after an average of 7 cycles of cemiplimab. However, post-immunotherapy imaging was an inaccurate predictor of pathologic response. Future directions should evaluate for improved interpretation of preoperative imaging after neoadjuvant immunotherapy and predictors of pathologic response.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154113--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S329",
      "content_id": "153772",
      "abstract_number": "S329",
      "poster_number": "",
      "title": "Interaction-Dependent Identification Of Tumor-Specific Antigen T Cells for Adoptive Therapy in HNSCC",
      "summary": "Head and neck squamous cell carcinomas (HNSCCs) feature a high mutational load and associated neoantigenome, offering an exploitable vulnerability for autologous tumor-specific antigen (TSA)-T cell therapies. However, the lack of a reliable, high-fidelity biomarker to accurately distinguish bona fide TSA-T cells from heterogeneous, often terminally differentiated bystander TILs has substantially limited the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153772",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Robert Saddawi-Konefka, MD, PhD",
      "presenter": "Robert Saddawi-Konefka, MD, PhD",
      "authors": "Robert Saddawi-Konefka, MD, PhD 1 ; Yujie Shi, PhD 2 ; Lauren Clubb 3 ; Shiqi Tang 4 ; William Wong 3 ; John Chang, MD 3 ; J. Silvio Gutkind 3 ; Peng Wu 2",
      "normalized_authors": [
        "Robert Saddawi-Konefka",
        "Yujie Shi",
        "Lauren Clubb",
        "Shiqi Tang",
        "William Wong",
        "John Chang",
        "J. Silvio Gutkind",
        "Peng Wu"
      ],
      "affiliations": [
        "MD Anderson Cancer Center",
        "The Scripps Research Institute",
        "University of California, San Diego",
        "Stanford University"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer Center",
        "The Scripps Research Institute",
        "University of California, San Diego",
        "Stanford University"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 350,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Robert Saddawi-Konefka, MD, PhD 1 ; Yujie Shi, PhD 2 ; Lauren Clubb 3 ; Shiqi Tang 4 ; William Wong 3 ; John Chang, MD 3 ; J. Silvio Gutkind 3 ; Peng Wu 2",
        "Affiliations": "1 MD Anderson Cancer Center; 2 The Scripps Research Institute; 3 University of California, San Diego; 4 Stanford University",
        "Abstract": "Head and neck squamous cell carcinomas (HNSCCs) feature a high mutational load and associated neoantigenome, offering an exploitable vulnerability for autologous tumor-specific antigen (TSA)-T cell therapies. However, the lack of a reliable, high-fidelity biomarker to accurately distinguish bona fide TSA-T cells from heterogeneous, often terminally differentiated bystander TILs has substantially limited the translation of effective adoptive T-cell therapy in this disease. To address this critical bottleneck, we developed an innovative, rapid, and specific interaction-based chemoenzymatic labeling platform, FucoID (Cell 2020), in which α-(1,3)-fucosyltransferase–conjugated dendritic cells transfer GDP-Fucose-Biotin tags selectively to T cells via endogenous, proximity-based DC:T cell interactions. FucoID therefore represents an antigen-agnostic method capable of exclusively and expediently identifying TSA-reactive T cells with phenotypes optimal for in vivo persistence and antitumor cytotoxicity. Using both the tobacco-signature 4MOSC murine model of HNSCC and freshly resected human HNSCC clinical specimens, we applied FucoID to TILs and tumor-draining lymph node (tdLN) lymphocytes and isolated FucoID-labelled and -unlabelled CD4? and CD8? populations for functional and transcriptional profiling. Integrated single-cell RNA-sequencing with paired TCR-sequencing revealed a specific population of FucoID-labelled tdLN T cells that share clonal overlap with FucoID-labelled TSA T cells in the tumor. These FucoID-labelled tdLN cells exhibit less-differentiated, progenitor-like phenotypes, representing a TCF1? T progenitor-exhausted (Tpex) population. FucoID-labelled T cells from human HNSCC similarly demonstrated enrichment of TCF7-high, stem-like populations. Functionally, adoptive transfer of FucoID-identified TSA-T cells in the 4MOSC model resulted in significantly improved tumor control relative to bulk TILs, PD-1? T cells, or FucoID-unlabelled subsets. Ex vivo killing assays further demonstrated enhanced tumor-cell cytotoxicity by FucoID-labelled versus unlabelled T cells in both murine and human systems. Collectively, the FucoID approach represents an antigen-agnostic method to exclusively and expediently identify TSA-reactive T cells with phenotypes optimal for in vivo persistence and antitumor cytotoxicity. FucoID offers a highly innovative, translatable technique to harness TSA-T cell products that can increase the therapeutic response rate of cancer patients and to contribute to paving the way for lowering the cost and accessibility of personalized cancer treatment based on adoptive T-cell transfer. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Interaction-Dependent Identification Of Tumor-Specific Antigen T Cells for Adoptive Therapy in HNSCC</span>. <u>Robert Saddawi-Konefka, MD, PhD</u><sup>1</sup>; Yujie Shi, PhD<sup>2</sup>; Lauren Clubb<sup>3</sup>; Shiqi Tang<sup>4</sup>; William Wong<sup>3</sup>; John Chang, MD<sup>3</sup>; J. Silvio Gutkind<sup>3</sup>; Peng Wu<sup>2</sup>. <sup>1</sup>MD Anderson Cancer Center; <sup>2</sup>The Scripps Research Institute; <sup>3</sup>University of California, San Diego; <sup>4</sup>Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinomas (HNSCCs) feature a high mutational load and associated neoantigenome, offering an exploitable vulnerability for autologous tumor-specific antigen (TSA)-T cell therapies. However, the lack of a reliable, high-fidelity biomarker to accurately distinguish bona fide TSA-T cells from heterogeneous, often terminally differentiated bystander TILs has substantially limited the translation of effective adoptive T-cell therapy in this disease. To address this critical bottleneck, we developed an innovative, rapid, and specific interaction-based chemoenzymatic labeling platform, FucoID (Cell 2020), in which α-(1,3)-fucosyltransferase–conjugated dendritic cells transfer GDP-Fucose-Biotin tags selectively to T cells via endogenous, proximity-based DC:T cell interactions. FucoID therefore represents an antigen-agnostic method capable of exclusively and expediently identifying TSA-reactive T cells with phenotypes optimal for in vivo persistence and antitumor cytotoxicity.</p>\n\n<p>Using both the tobacco-signature 4MOSC murine model of HNSCC and freshly resected human HNSCC clinical specimens, we applied FucoID to TILs and tumor-draining lymph node (tdLN) lymphocytes and isolated FucoID-labelled and -unlabelled CD4? and CD8? populations for functional and transcriptional profiling. Integrated single-cell RNA-sequencing with paired TCR-sequencing revealed a specific population of FucoID-labelled tdLN T cells that share clonal overlap with FucoID-labelled TSA T cells in the tumor. These FucoID-labelled tdLN cells exhibit less-differentiated, progenitor-like phenotypes, representing a TCF1? T progenitor-exhausted (Tpex) population. FucoID-labelled T cells from human HNSCC similarly demonstrated enrichment of TCF7-high, stem-like populations. Functionally, adoptive transfer of FucoID-identified TSA-T cells in the 4MOSC model resulted in significantly improved tumor control relative to bulk TILs, PD-1? T cells, or FucoID-unlabelled subsets. Ex vivo killing assays further demonstrated enhanced tumor-cell cytotoxicity by FucoID-labelled versus unlabelled T cells in both murine and human systems.</p>\n\n<p>Collectively, the FucoID approach represents an antigen-agnostic method to exclusively and expediently identify TSA-reactive T cells with phenotypes optimal for in vivo persistence and antitumor cytotoxicity. FucoID offers a highly innovative, translatable technique to harness TSA-T cell products that can increase the therapeutic response rate of cancer patients and to contribute to paving the way for lowering the cost and accessibility of personalized cancer treatment based on adoptive T-cell transfer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153772--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S330",
      "content_id": "154092",
      "abstract_number": "S330",
      "poster_number": "",
      "title": "Investigating the role of salvage surgery and immunotherapy in the treatment of recurrent oropharyngeal cancer",
      "summary": "Salvage surgery resulted in improved overall survival among patients with resectable disease in the HPV related group but not those in the HPV negative group. Immunotherapy was not associated with an improved survival in either group. It will be interesting to observe for changes related to expanding the role of immunotherapy perioperatively in the primary setting.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154092",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Muhammad El Shatanofy, MD",
      "presenter": "Muhammad El Shatanofy, MD",
      "authors": "Muhammad El Shatanofy, MD 1 ; Eric Sokhn, BS 2 ; Soumil Prasad, BS 2 ; Carlos L Nava, BS 2 ; Zoukaa Sargi, MD, MPH 1",
      "normalized_authors": [
        "Muhammad El Shatanofy",
        "Eric Sokhn",
        "Soumil Prasad",
        "Carlos L Nava",
        "Zoukaa Sargi"
      ],
      "affiliations": [
        "University of Miami Hospital",
        "University of Miami Miller School of Medicine"
      ],
      "normalized_institutions": [
        "University of Miami Hospital",
        "University of Miami Miller School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_15_16%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_15_16%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154092"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_13_45%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_13_45%E2%80%AFPM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154092"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Figure 2.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Muhammad El Shatanofy, MD 1 ; Eric Sokhn, BS 2 ; Soumil Prasad, BS 2 ; Carlos L Nava, BS 2 ; Zoukaa Sargi, MD, MPH 1",
        "Affiliations": "1 University of Miami Hospital; 2 University of Miami Miller School of Medicine",
        "Background": "Despite advances in treatment, a subset of patients with oropharyngeal cancer will unfortunately recur. Studies suggest that HPV-negative oropharyngeal squamous cell cancer (OPSCC) has a significantly higher risk of recurrence compared to HPV-positive disease. Recurrence rates are nearly twice as high for HPV-negative cases, and recurrences in HPV-negative patients tend to occur sooner. The objective of this study was to investigate recurrence patterns, survival, treatment, recurrence location, and prognostic factors for all types of oropharyngeal squamous cell cancer at our institution. We also aimed to investigate the role of salvage surgery and immunotherapy in the recurrent setting.",
        "Methods": "Our institution's tumor registry was queried to identify a cohort of patients diagnosed with recurrent HPV positive and HPV negative oropharyngeal squamous cell cancer after the year 2015. Descriptive data included age at diagnosis, sex comorbidities, recurrence timing, number of recurrences, pathologic data, and cancer staging based on the American Joint Committee on Cancer (AJCC) 8th edition. Survival analysis was performed using Kaplan-Meier analysis and the Cox proportional hazards model. Multivariable analysis was performed to identify independent prognostic factors associated with an increased risk of recurrence.",
        "Results": "152 patients with recurrent oropharyngeal squamous cell carcinoma were analyzed, including 97 with HPV related squamous cell carcinoma and 55 with HPV negative squamous cell carcinoma. Among those with HPV related disease, 47% had resectable recurrences and 37% were treated with immunotherapy. There was no significant difference in distribution between local versus regional versus distant recurrences between those with HPV related and those with HPV negative disease. 44% of patients with HPV negative disease had resectable recurrences and 56% received immunotherapy. Patients with HPV related OPSCC that had resectable recurrences had a significantly higher 2-year progression free and overall survival compared to those with unresectable recurrent disease: 46.9% (32.7% - 67.2%) resectable versus 26.3% non-resectable (14.3 - 48.3%) 2-year progression free survival, p=0.032; 58.0% (44.1%-76.2%) resectable versus 29.0% non-resectable (17.5%-48.2%) overall survival, p=0.0075. There was no significant difference in progression free survival or overall survival for those with resectable versus non-resectable HPV negative OPSCC. There was also no significant difference in progression free survival or overall survival among those treated with immunotherapy in either the HPV related or HPV negative groups.",
        "Conclusions": "Salvage surgery resulted in improved overall survival among patients with resectable disease in the HPV related group but not those in the HPV negative group. Immunotherapy was not associated with an improved survival in either group. It will be interesting to observe for changes related to expanding the role of immunotherapy perioperatively in the primary setting.",
        "Figure 1.": "Improved 2-year progression free survival among those with resectable HPV related OPSCC compared to non-resectable disease",
        "Figure 2.": "Improved overall survival among those with resectable HPV related OPSCC compared to non-resectable disease",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Investigating the role of salvage surgery and immunotherapy in the treatment of recurrent oropharyngeal cancer</span>. <u>Muhammad El Shatanofy, MD</u><sup>1</sup>; Eric Sokhn, BS<sup>2</sup>; Soumil Prasad, BS<sup>2</sup>; Carlos L Nava, BS<sup>2</sup>; Zoukaa Sargi, MD, MPH<sup>1</sup>. <sup>1</sup>University of Miami Hospital; <sup>2</sup>University of Miami Miller School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Despite advances in treatment, a subset of patients with oropharyngeal cancer will unfortunately recur. Studies suggest that HPV-negative oropharyngeal squamous cell cancer (OPSCC) has a significantly higher risk of recurrence compared to HPV-positive disease. Recurrence rates are nearly twice as high for HPV-negative cases, and recurrences in HPV-negative patients tend to occur sooner. The objective of this study was to investigate recurrence patterns, survival, treatment, recurrence location, and prognostic factors for all types of oropharyngeal squamous cell cancer at our institution. We also aimed to investigate the role of salvage surgery and immunotherapy in the recurrent setting.</p>\n\n<p><strong>Methods: </strong>Our institution's tumor registry was queried to identify a cohort of patients diagnosed with recurrent HPV positive and HPV negative oropharyngeal squamous cell cancer after the year 2015. Descriptive data included age at diagnosis, sex comorbidities, recurrence timing, number of recurrences, pathologic data, and cancer staging based on the American Joint Committee on Cancer (AJCC) 8th edition. Survival analysis was performed using Kaplan-Meier analysis and the Cox proportional hazards model. Multivariable analysis was performed to identify independent prognostic factors associated with an increased risk of recurrence. </p>\n\n<p><strong>Results: </strong>152 patients with recurrent oropharyngeal squamous cell carcinoma were analyzed, including 97 with HPV related squamous cell carcinoma and 55 with HPV negative squamous cell carcinoma. Among those with HPV related disease, 47% had resectable recurrences and 37% were treated with immunotherapy. There was no significant difference in distribution between local versus regional versus distant recurrences between those with HPV related and those with HPV negative disease. 44% of patients with HPV negative disease had resectable recurrences and 56% received immunotherapy. Patients with HPV related OPSCC that had resectable recurrences had a significantly higher 2-year progression free and overall survival compared to those with unresectable recurrent disease: 46.9% (32.7% - 67.2%) resectable versus 26.3% non-resectable (14.3 - 48.3%) 2-year progression free survival, p=0.032; 58.0% (44.1%-76.2%) resectable versus 29.0% non-resectable (17.5%-48.2%) overall survival,  p=0.0075. There was no significant difference in progression free survival or overall survival for those with resectable versus non-resectable HPV negative OPSCC. There was also no significant difference in progression free survival or overall survival among those treated with immunotherapy in either the HPV related or HPV negative groups. </p>\n\n<p><strong>Conclusions:</strong> Salvage surgery resulted in improved overall survival among patients with resectable disease in the HPV related group but not those in the HPV negative group. Immunotherapy was not associated with an improved survival in either group. It will be interesting to observe for changes related to expanding the role of immunotherapy perioperatively in the primary setting.</p>\n\n<p><strong>Figure 1.</strong> Improved 2-year progression free survival among those with resectable HPV related OPSCC compared to non-resectable disease</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_15_16%E2%80%AFPM.png' /></p>\n\n<p><strong>Figure 2.</strong> Improved overall survival among those with resectable HPV related OPSCC compared to non-resectable disease</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154092/Screenshot%202025-12-04%20at%2011_13_45%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154092--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S331",
      "content_id": "153945",
      "abstract_number": "S331",
      "poster_number": "",
      "title": "Predicting immunotherapy response in advanced cutaneous head and neck SCC using blood-based immune transcriptomic signatures.",
      "summary": "Baseline PBMC transcriptional programs differ between patients who respond well to immunotherapy and those who do not. Although exploratory, these immune signatures indicate the potential for developing a clinically meaningful blood-based biomarker to guide patient selection for immunotherapy, warranting validation in larger prospective cohorts.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153945",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Liyona Kampel, MD, PhD",
      "presenter": "Liyona Kampel, MD, PhD",
      "authors": "Liyona Kampel, MD, PhD ; Inbar Finkel, MD; Anton Warshavsky, MD; Gilad Horowitz, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD",
      "normalized_authors": [
        "Liyona Kampel",
        "Inbar Finkel",
        "Anton Warshavsky",
        "Gilad Horowitz",
        "Orit Gutfeld",
        "Nidal Muhanna"
      ],
      "affiliations": [
        "Tel Aviv Sourasky Medical Center"
      ],
      "normalized_institutions": [
        "Tel Aviv Sourasky Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153945/heatmap(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153945/heatmap(1).png",
          "alt": "Figure 1. Heatmap of the top 50 differentially expressed genes distinguishing responders and non-responders to immunotherapy. Unsupervised hierarchical clustering of the top 50 differentially expressed genes in PBMCs collected from patients with advanced cHNSCC prior to immunotherapy. Columns represent individual patients (Group A = responders, pink; Group B = non responders, turquoise). Rows show Z-score scaled gene expression. Responders (patients 15 and 20) exhibit higher expression of T-cell receptor and activation-associated genes (e.g., TRBC1, LAT, FOSB, CAMK4), whereas non-responders (patients 16, 17, 18) show higher expression of innate/ myeloid related genes (e.g., FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9)",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153945"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Liyona Kampel, MD, PhD ; Inbar Finkel, MD; Anton Warshavsky, MD; Gilad Horowitz, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD",
        "Affiliations": "Tel Aviv Sourasky Medical Center",
        "Background": "The incidence of cutaneous squamous cell carcinoma of the head and neck (cHNSCC) is increasing, particularly in the aging population. Immune checkpoint inhibitors (ICIs) and especially neoadjuvant immunotherapy have transformed treatment paradigms and improved outcomes of advanced disease. Nevertheless, distinguishing patients who will benefit from ICIs compared to those requiring prompt surgical resection remains challenging, as no validated biomarkers currently guide this decision. This study aims to define peripheral blood immune transcriptional signatures that could serve as predictive biomarkers of response to immunotherapy in advanced cHNSCC.",
        "Methods": "Peripheral blood mononuclear cells (PBMCs) were collected from patients with advanced cHNSCC immediately prior to initiation of immunotherapy. The cohort included three elderly patients (a 79-year-old man and two women aged 89 and 97) with locally advanced tumors and regional metastases who were not candidates for surgical resection due to age and comorbidities, a 63-year-old woman who experienced early recurrence following curative-intent surgery and a 48-year-old woman with an extensive nasal lesion who elected to avoid surgery. Treatment response was clinically assessed during routine follow-up at 1 month after ICIs initiation. Bulk RNA sequencing was performed on PBMCs, followed by differential gene expression analysis using edgeR to compare responders and non-responders. Given the limited number of genes surviving multiple-testing correction, exploratory pathway analysis focused on transcripts with strong nominal differential expression and well-established immunologic relevance, integrating curated immune gene lists and published immuno-oncology literature.",
        "Results": "Exploratory transcriptomic profiling revealed biologically coherent immune differences between responders and non-responders (Figure 1). Responders exhibited increased expression of genes linked to T-cell receptor signaling, co-regulatory pathways, and T-cell exhaustion, including TRBC1, diverse TCR α/β/γ chain transcripts, GBP4 and FOSB. Such signatures have been consistently associated with improved tumor immune surveillance and favorable response to ICIs in multiple cancer types. Conversely, non-responders demonstrated stronger expression of myeloid-dominant and innate activation pathways as well as genes enriched in tumor-associated macrophage (FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9, P2RX1). Elevated expression of these pathways may reflect increased systemic innate immune activity, which has been linked to impaired T-cell priming, reduced ICI efficacy, and the development of immunosuppressive macrophage states in resistant tumors.",
        "Conclusions": "Baseline PBMC transcriptional programs differ between patients who respond well to immunotherapy and those who do not. Although exploratory, these immune signatures indicate the potential for developing a clinically meaningful blood-based biomarker to guide patient selection for immunotherapy, warranting validation in larger prospective cohorts.",
        "Figure 1.": "Heatmap of the top 50 differentially expressed genes distinguishing responders and non-responders to immunotherapy. Unsupervised hierarchical clustering of the top 50 differentially expressed genes in PBMCs collected from patients with advanced cHNSCC prior to immunotherapy. Columns represent individual patients (Group A = responders, pink; Group B = non responders, turquoise). Rows show Z-score scaled gene expression. Responders (patients 15 and 20) exhibit higher expression of T-cell receptor and activation-associated genes (e.g., TRBC1, LAT, FOSB, CAMK4), whereas non-responders (patients 16, 17, 18) show higher expression of innate/ myeloid related genes (e.g., FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9)]",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Predicting immunotherapy response in advanced cutaneous head and neck SCC using blood-based immune transcriptomic signatures.</span>. <u>Liyona Kampel, MD, PhD</u>; Inbar Finkel, MD; Anton Warshavsky, MD; Gilad Horowitz, MD; Orit Gutfeld, MD; Nidal Muhanna, MD, PhD. Tel Aviv Sourasky Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The incidence of cutaneous squamous cell carcinoma of the head and neck (cHNSCC) is increasing, particularly in the aging population. Immune checkpoint inhibitors (ICIs) and especially neoadjuvant immunotherapy have transformed treatment paradigms and improved outcomes of advanced disease. Nevertheless, distinguishing patients who will benefit from ICIs compared to those requiring prompt surgical resection remains challenging, as no validated biomarkers currently guide this decision. This study aims to define peripheral blood immune transcriptional signatures that could serve as predictive biomarkers of response to immunotherapy in advanced cHNSCC.</p>\n\n<p><strong>Methods:</strong> Peripheral blood mononuclear cells (PBMCs) were collected from patients with advanced cHNSCC immediately prior to initiation of immunotherapy. The cohort included three elderly patients (a 79-year-old man and two women aged 89 and 97) with locally advanced tumors and regional metastases who were not candidates for surgical resection due to age and comorbidities, a 63-year-old woman who experienced early recurrence following curative-intent surgery and a 48-year-old woman with an extensive nasal lesion who elected to avoid surgery. Treatment response was clinically assessed during routine follow-up at 1 month after ICIs initiation. Bulk RNA sequencing was performed on PBMCs, followed by differential gene expression analysis using edgeR to compare responders and non-responders. Given the limited number of genes surviving multiple-testing correction, exploratory pathway analysis focused on transcripts with strong nominal differential expression and well-established immunologic relevance, integrating curated immune gene lists and published immuno-oncology literature.</p>\n\n<p><strong>Results: </strong>Exploratory transcriptomic profiling revealed biologically coherent immune differences between responders and non-responders (Figure 1). Responders exhibited increased expression of genes linked to T-cell receptor signaling, co-regulatory pathways, and T-cell exhaustion, including TRBC1, diverse TCR α/β/γ chain transcripts, GBP4 and FOSB. Such signatures have been consistently associated with improved tumor immune surveillance and favorable response to ICIs in multiple cancer types. Conversely, non-responders demonstrated stronger expression of myeloid-dominant and innate activation pathways as well as genes enriched in tumor-associated macrophage (FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9, P2RX1). Elevated expression of these pathways may reflect increased systemic innate immune activity, which has been linked to impaired T-cell priming, reduced ICI efficacy, and the development of immunosuppressive macrophage states in resistant tumors.</p>\n\n<p><strong>Conclusions:</strong> Baseline PBMC transcriptional programs differ between patients who respond well to immunotherapy and those who do not. Although exploratory, these immune signatures indicate the potential for developing a clinically meaningful blood-based biomarker to guide patient selection for immunotherapy, warranting validation in larger prospective cohorts.</p>\n\n<p><img alt='Figure 1. Heatmap of the top 50 differentially expressed genes distinguishing responders and non-responders to immunotherapy. Unsupervised hierarchical clustering of the top 50 differentially expressed genes in PBMCs collected from patients with advanced cHNSCC prior to immunotherapy. Columns represent individual patients (Group A = responders, pink; Group B = non responders, turquoise). Rows show Z-score scaled gene expression. Responders (patients 15 and 20) exhibit higher expression of T-cell receptor and activation-associated genes (e.g., TRBC1, LAT, FOSB, CAMK4), whereas non-responders (patients 16, 17, 18) show higher expression of innate/ myeloid related genes (e.g., FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9)' src='https://www.submitmyabstract.com/abs/images/153945/heatmap(1).png' /></p>\n\n<p><strong>Figure 1.</strong> Heatmap of the top 50 differentially expressed genes distinguishing responders and non-responders to immunotherapy. Unsupervised hierarchical clustering of the top 50 differentially expressed genes in PBMCs collected from patients with advanced cHNSCC prior to immunotherapy. Columns represent individual patients (Group A = responders, pink; Group B = non responders, turquoise). Rows show Z-score scaled gene expression. Responders (patients 15 and 20) exhibit higher expression of T-cell receptor and activation-associated genes (e.g., TRBC1, LAT, FOSB, CAMK4), whereas non-responders (patients 16, 17, 18) show higher expression of innate/ myeloid related genes (e.g., FCGR2B, MS4A4A, CLEC4E, NCF1B, AQP9)]</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153945--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S332",
      "content_id": "152762",
      "abstract_number": "S332",
      "poster_number": "",
      "title": "Surgical De-escalation After Neoadjuvant Immunotherapy in Patients with Advanced Non-Melanoma Cutaneous Malignancy",
      "summary": "Neoadjuvant PD-1 inhibition demonstrates compelling potential to de-escalate surgery in advanced cutaneous malignancies of the head and neck. In our cohort, this translated to reduced need for microvascular reconstruction and an avoidance of surgery altogether in many responders, without compromising short- or mid-term oncologic control.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152762",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260140",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michelle Florentine, MD",
      "presenter": "Michelle Florentine, MD",
      "authors": "Spenser S Souza, MD, MSc 1 ; Nina Patel, BS 2 ; Michelle Florentine, MD 3 ; Alain Algazi, MD 4 ; Patrick Ha, MD 5 ; Ivan El-Sayed, MD 5 ; Jonathan George, MD 5 ; Chase Heaton, MD 5 ; Mary Xu, MD 5 ; Katherine Wai, MD 5 ; Michael Chow, MD 5 ; Ilya Likhterov, MD 5",
      "normalized_authors": [
        "Spenser S Souza",
        "Nina Patel",
        "Michelle Florentine",
        "Alain Algazi",
        "Patrick Ha",
        "Ivan El-Sayed",
        "Jonathan George",
        "Chase Heaton",
        "Mary Xu",
        "Katherine Wai",
        "Michael Chow",
        "Ilya Likhterov"
      ],
      "affiliations": [
        "Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology Head and Neck Surgery, University of Michigan",
        "Loyola University School of Medicine",
        "University of California San Francisco, Department of Otolaryngology Head and Neck Surgery",
        "Department of Medical Oncology, University of California San Francisco",
        "Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco"
      ],
      "normalized_institutions": [
        "Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology Head and Neck Surgery, University of Michigan",
        "Loyola University School of Medicine",
        "University of California San Francisco, Department of Otolaryngology Head and Neck Surgery",
        "Department of Medical Oncology, University of California San Francisco",
        "Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 523,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Spenser S Souza, MD, MSc 1 ; Nina Patel, BS 2 ; Michelle Florentine, MD 3 ; Alain Algazi, MD 4 ; Patrick Ha, MD 5 ; Ivan El-Sayed, MD 5 ; Jonathan George, MD 5 ; Chase Heaton, MD 5 ; Mary Xu, MD 5 ; Katherine Wai, MD 5 ; Michael Chow, MD 5 ; Ilya Likhterov, MD 5",
        "Affiliations": "1 Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology Head and Neck Surgery, University of Michigan; 2 Loyola University School of Medicine; 3 University of California San Francisco, Department of Otolaryngology Head and Neck Surgery; 4 Department of Medical Oncology, University of California San Francisco; 5 Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco",
        "Objective": "To understand the impact of neoadjuvant immunotherapy on surgical management of patients with non-melanoma skin cancer.",
        "Study Design": "Retrospective cohort study",
        "Background": "The efficacy of neoadjuvant immunotherapy in the management of advanced non-melanoma skin cancer has been demonstrated. However, among patients who ultimately proceed to surgery, the effect of neoadjuvant immunotherapy on the extent of surgery performed has not been studied.",
        "Methods": "We conducted a retrospective analysis of patients with non-melanoma skin cancer treated with neoadjuvant immunotherapy and had planned subsequent extirpative surgery. We compared the initial surgical plan, as outlined by the surgical teams, with the subsequent progress note at the completion of neoadjuvant treatment or with the operative note. Surgical de-escalation was defined as ablative or reconstructive surgery that was less extensive than the initially planned surgery or the decision to continue immunotherapy in lieu of surgery.",
        "Results": "37 patients were treated with neoadjuvant immunotherapy for advanced cutaneous non-melanoma malignancy between[IL1] [SS2] June 2018 and March 2025. The average patient age was 74.21 +/- 11.73 years. 86.4% (32/37) had squamous cell carcinoma (SCC) and 13.6% (5/37) had basal cell carcinoma (BCC). Most patients received neoadjuvant Cemiplimab (83.7%, 31/37), and the remaining patients received Pembrolizumab (16.3%, 6/37). The median duration of immunotherapy before re-evaluation by a head and neck surgical oncologist was 18 weeks, and the median number of immunotherapy cycles was 4.0.",
        "Abstract": "Prior to neoadjuvant immunotherapy, 73% (27/37) of patients were anticipated to need wide local excision followed by free tissue microvascular reconstruction, while the remaining 27% (10/37), were thought to need primary closure (1), deltopectoral rotational flap (1), skin grafting (4), local tissue rearrangement (3), or biologic scaffold (1). [PH3] After immunotherapy, each case was reviewed by a multidisciplinary cancer team, which, through shared decision making with the patient, resulted in only 29.6% (8/27) of these patients undergoing microvascular free tissue transfer. 14.8 % (4/27) underwent de-escalated reconstructive surgery, which included split-thickness skin graft reconstruction (3) and biologic scaffold reconstruction (1). The remaining 55.6% (15/27) of were determined to no longer require surgery, given the degree of response, and instead were transitioned from induction to maintenance immunotherapy. Neoadjuvant immunotherapy lead to a significant de-escalation of surgical intervention following multidisciplinary discussion, as indexed by the number of patients who were able to avoid microvascular reconstruction (n=19, p < 0.001, 95% CI: 0.13-0.50), and a significant reduction in morbidity associated with surgical intervention, as indicated by the number of patients who were able to avoid surgery altogether (n=17, p<0.0001, 95% CI: 0.27-0.61[PH4] [PH5] ). There was no statistical difference in the recurrence rates between patients in the de-escalation group and the intention to treat group (4.8 % v 6.3%, p=1.00, 95% CI:-4.3%-1.3%). View in Agenda and Add to Schedule",
        "Conclusion": "Neoadjuvant PD-1 inhibition demonstrates compelling potential to de-escalate surgery in advanced cutaneous malignancies of the head and neck. In our cohort, this translated to reduced need for microvascular reconstruction and an avoidance of surgery altogether in many responders, without compromising short- or mid-term oncologic control."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical De-escalation After Neoadjuvant Immunotherapy in Patients with Advanced Non-Melanoma Cutaneous Malignancy</span>. Spenser S Souza, MD, MSc<sup>1</sup>; Nina Patel, BS<sup>2</sup>; <u>Michelle Florentine, MD</u><sup>3</sup>; Alain Algazi, MD<sup>4</sup>; Patrick Ha, MD<sup>5</sup>; Ivan El-Sayed, MD<sup>5</sup>; Jonathan George, MD<sup>5</sup>; Chase Heaton, MD<sup>5</sup>; Mary Xu, MD<sup>5</sup>; Katherine Wai, MD<sup>5</sup>; Michael Chow, MD<sup>5</sup>; Ilya Likhterov, MD<sup>5</sup>. <sup>1</sup>Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology Head and Neck Surgery, University of Michigan; <sup>2</sup>Loyola University School of Medicine; <sup>3</sup>University of California San Francisco, Department of Otolaryngology Head and Neck Surgery; <sup>4</sup>Department of Medical Oncology, University of California San Francisco; <sup>5</sup>Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> To understand the impact of neoadjuvant immunotherapy on surgical management of patients with non-melanoma skin cancer.</p>\n\n<p><strong>Study Design:</strong> Retrospective cohort study</p>\n\n<p><strong>Background:</strong> The efficacy of neoadjuvant immunotherapy in the management of advanced non-melanoma skin cancer has been demonstrated. However, among patients who ultimately proceed to surgery, the effect of neoadjuvant immunotherapy on the extent of surgery performed has not been studied.</p>\n\n<p><strong>Methods:</strong>  We conducted a retrospective analysis of patients with non-melanoma skin cancer treated with neoadjuvant immunotherapy and had planned subsequent extirpative surgery. We compared the initial surgical plan, as outlined by the surgical teams, with the subsequent progress note at the completion of neoadjuvant treatment or with the operative note. Surgical de-escalation was defined as ablative or reconstructive surgery that was less extensive than the initially planned surgery or the decision to continue immunotherapy in lieu of surgery.</p>\n\n<p><strong>Results:</strong> 37 patients were treated with neoadjuvant immunotherapy for advanced cutaneous non-melanoma malignancy between[IL1] [SS2]  June 2018 and March 2025. The average patient age was 74.21 +/- 11.73 years. 86.4% (32/37) had squamous cell carcinoma (SCC) and 13.6% (5/37) had basal cell carcinoma (BCC). Most patients received neoadjuvant Cemiplimab (83.7%, 31/37), and the remaining patients received Pembrolizumab (16.3%, 6/37). The median duration of immunotherapy before re-evaluation by a head and neck surgical oncologist was 18 weeks, and the median number of immunotherapy cycles was 4.0.</p>\n\n<p>Prior to neoadjuvant immunotherapy, 73% (27/37) of patients were anticipated to need wide local excision followed by free tissue microvascular reconstruction, while the remaining 27% (10/37), were thought to need primary closure (1), deltopectoral rotational flap (1), skin grafting (4), local tissue rearrangement (3), or biologic scaffold (1). [PH3] After immunotherapy, each case was reviewed by a multidisciplinary cancer team, which, through shared decision making with the patient, resulted in only 29.6% (8/27) of these patients undergoing microvascular free tissue transfer. 14.8 % (4/27) underwent de-escalated reconstructive surgery, which included split-thickness skin graft reconstruction (3) and biologic scaffold reconstruction (1). The remaining 55.6% (15/27) of were determined to no longer require surgery, given the degree of response, and instead were transitioned from induction to maintenance immunotherapy.</p>\n\n<p>Neoadjuvant immunotherapy lead to a significant de-escalation of surgical intervention following multidisciplinary discussion, as indexed by the number of patients who were able to avoid microvascular reconstruction (n=19, p < 0.001, 95% CI: 0.13-0.50), and a significant reduction in morbidity associated with surgical intervention, as indicated by the number of patients who were able to avoid surgery altogether (n=17, p<0.0001, 95% CI: 0.27-0.61[PH4] [PH5] ).</p>\n\n<p>There was no statistical difference in the recurrence rates between patients in the de-escalation group and the intention to treat group (4.8 % v 6.3%, p=1.00, 95% CI:-4.3%-1.3%).</p>\n\n<p><strong>Conclusion:</strong> Neoadjuvant PD-1 inhibition demonstrates compelling potential to de-escalate surgery in advanced cutaneous malignancies of the head and neck. In our cohort, this translated to reduced need for microvascular reconstruction and an avoidance of surgery altogether in many responders, without compromising short- or mid-term oncologic control.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152762--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260140' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S333",
      "content_id": "153979",
      "abstract_number": "S333",
      "poster_number": "",
      "title": "Transoral Laser Microsurgery with 445-nm Blue Laser for Early Glottic Cancer: Durable Oncologic Control with Laryngeal Function Preservation",
      "summary": "TLM with the 445-nm BL represents an excellent minimally invasive treatment strategy for early-stage glottic cancer, with survival, local control, and organ preservation rates comparable to those of primary radiation therapy and traditional TLM with CO2 or KTP laser. This series further demonstrates that BL-assisted TLM provides not only effective oncologic control but also excellent preservation of laryngeal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153979",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claudia N Gutierrez, MD, MS",
      "presenter": "Claudia N Gutierrez, MD, MS",
      "authors": "Claudia N Gutierrez, MD, MS ; Mursalin M Anis, MD, PhD; David E Rosow, MD",
      "normalized_authors": [
        "Claudia N Gutierrez",
        "Mursalin M Anis",
        "David E Rosow"
      ],
      "affiliations": [
        "University of Miami"
      ],
      "normalized_institutions": [
        "University of Miami"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 341,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Claudia N Gutierrez, MD, MS ; Mursalin M Anis, MD, PhD; David E Rosow, MD",
        "Affiliations": "University of Miami",
        "Objective": "Transoral laser microsurgery (TLM) is one of the preferred means of treating early-stage glottic cancer. The recently introduced angiolytic 445-nm blue laser (BL) allows for precise tumor resection while minimizing collateral thermal injury to surrounding normal tissue. A clear understanding of both the oncologic and functional outcomes of TLM with BL in early glottic cancer is essential to optimize patient selection and refine treatment strategies.",
        "Methods": "All patients who underwent TLM with BL at a single tertiary institution from 2021 to the present were reviewed. Patients with less than 1 year of follow up were excluded from analysis. Patients with both primary and recurrent disease, including previous radiation and surgical failures, were included. Subjective and objective voice measures were assessed pre- and postoperatively using the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V), Voice Handicap Index 10 (VHI-10), and the Cepstral Spectral Index of Dysphonia (CSID).",
        "Results": "A total of 78 patients (86% male) underwent TLM with BL for tumors stage Tis to T2 and were followed for an average of 29.3 months. The mean age at time of surgery was 70.0 years. Overall survival, disease specific survival, and organ preservation rates were 97.4%. Local control rate with surgery alone was 94.9%.",
        "Abstract": "Regarding voice outcomes, mean CAPE-V score improved from 49 preoperatively to 33 postoperatively, representing a 32% relative improvement in clinician-rated perceptual voice severity ( p < 0.0001 ). Mean VHI-10 scores improved from 16.6 preoperatively to 8.2 postoperatively, representing a 50.6% relative improvement in patient-reported voice handicap (p < 0.0001). Mean CSID values improved from 37.6 preoperatively to 27.4 postoperatively, representing a 27% relative objective acoustic improvement (p = 0.015). View in Agenda and Add to Schedule",
        "Conclusion": "TLM with the 445-nm BL represents an excellent minimally invasive treatment strategy for early-stage glottic cancer, with survival, local control, and organ preservation rates comparable to those of primary radiation therapy and traditional TLM with CO2 or KTP laser. This series further demonstrates that BL-assisted TLM provides not only effective oncologic control but also excellent preservation of laryngeal function."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transoral Laser Microsurgery with 445-nm Blue Laser for Early Glottic Cancer: Durable Oncologic Control with Laryngeal Function Preservation</span>. <u>Claudia N Gutierrez, MD, MS</u>; Mursalin M Anis, MD, PhD; David E Rosow, MD. University of Miami<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Transoral laser microsurgery (TLM) is one of the preferred means of treating early-stage glottic cancer. The recently introduced angiolytic 445-nm blue laser (BL) allows for precise tumor resection while minimizing collateral thermal injury to surrounding normal tissue. A clear understanding of both the oncologic and functional outcomes of TLM with BL in early glottic cancer is essential to optimize patient selection and refine treatment strategies.</p>\n\n<p><strong>Methods</strong>: All patients who underwent TLM with BL at a single tertiary institution from 2021 to the present were reviewed. Patients with less than 1 year of follow up were excluded from analysis. Patients with both primary and recurrent disease, including previous radiation and surgical failures, were included. Subjective and objective voice measures were assessed pre- and postoperatively using  the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V), Voice Handicap Index 10 (VHI-10), and the Cepstral Spectral Index of Dysphonia (CSID).</p>\n\n<p><strong>Results</strong>: A total of 78 patients (86% male) underwent TLM with BL for tumors stage Tis to T2 and were followed for an average of 29.3 months. The mean age at time of surgery was 70.0 years. Overall survival, disease specific survival, and organ preservation rates were 97.4%. Local control rate with surgery alone was 94.9%.</p>\n\n<p>Regarding voice outcomes, mean CAPE-V score improved from 49 preoperatively to 33 postoperatively, representing a 32% relative improvement in clinician-rated perceptual voice severity ( p < 0.0001 ). Mean VHI-10 scores improved from 16.6 preoperatively to 8.2 postoperatively, representing a 50.6% relative improvement in patient-reported voice handicap (p < 0.0001). Mean CSID values improved from 37.6 preoperatively to 27.4 postoperatively, representing a 27% relative objective acoustic improvement (p = 0.015).</p>\n\n<p><strong>Conclusion:</strong> TLM with the 445-nm BL represents an excellent minimally invasive treatment strategy for early-stage glottic cancer, with survival, local control, and organ preservation rates comparable to those of primary radiation therapy and traditional TLM with CO2 or KTP laser. This series further demonstrates that BL-assisted TLM provides not only effective oncologic control but also excellent preservation of laryngeal function.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153979--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S334",
      "content_id": "154072",
      "abstract_number": "S334",
      "poster_number": "",
      "title": "Surgical Outcomes and Malignant Transformation After Intervention for Laryngeal Dysplasia: A Multi-Institutional Cohort Study Using the TriNetX Research Network",
      "summary": "This is the first multi-institutional database study to describe recurrence and malignant transformation following surgical intervention for laryngeal dysplasia. Our findings highlight the persistence of disease, transformation risk, and importance of long-term surveillance for premalignant laryngeal lesions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154072",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lekha Medarametla",
      "presenter": "Lekha Medarametla",
      "authors": "Lekha Medarametla 1 ; Paul C Bryson, MD, MBA 2",
      "normalized_authors": [
        "Lekha Medarametla",
        "Paul C Bryson"
      ],
      "affiliations": [
        "Case Western Reserve University School of Medicine, Cleveland, Ohio",
        "Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA",
        "Cleveland Clinic Voice Center"
      ],
      "normalized_institutions": [
        "Case Western Reserve University School of Medicine, Cleveland, Ohio",
        "Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA",
        "Cleveland Clinic Voice Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 297,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lekha Medarametla 1 ; Paul C Bryson, MD, MBA 2",
        "Affiliations": "1 Case Western Reserve University School of Medicine, Cleveland, Ohio; 2 Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Voice Center",
        "Introduction": "Laryngeal dysplasia represents a spectrum of premalignant lesions that carry a variable but clinically significant risk of recurrence and malignant transformation. While institutional studies and meta-analyses have reported varying transformation rates, there has not yet been a large-scale database study looking at recurrence and transformation of laryngeal dysplasia. In this study, we sought to characterize the surgical experience of patients with laryngeal dysplasia using the TriNetX database to report risk for recurrence and malignant transformation and need for repeat surgical interventions over a 5-year follow-up period.",
        "Methods": "We conducted a retrospective descriptive cohort study using the TriNetX database. Adult patients (≥18 years) with a premalignant diagnosis of laryngeal dysplasia (ICD-10: D02.0, D14.1, D38.0, J38.7) and underwent laryngeal surgery in the operating room or office setting (CPT: 31540, 31541, 31545, 31546, 31571, 31572) within five years after initial diagnosis were included. With surgery as the index event, outcomes included recurrence of premalignant lesions, malignant transformations, and repeat procedures occurring within 5 years postoperatively. Descriptive and comparative statistics were conducted using TriNetX software.",
        "Results": "A total of 15,950 patients met inclusion criteria. The average age of patients was 64 ± 16; the majority were male (55.40%) and white (72.08%). Of the patients who underwent initial surgery for premalignant laryngeal dysplasia, 64.74% had a recurrent laryngeal dysplasia diagnosis, and 15.02% were diagnosed with a malignant lesion within 5 years. Repeat surgical intervention was observed in 27.99% of patients, with 15.3% of patients having 2 or more repeat procedures.",
        "Conclusion": "This is the first multi-institutional database study to describe recurrence and malignant transformation following surgical intervention for laryngeal dysplasia. Our findings highlight the persistence of disease, transformation risk, and importance of long-term surveillance for premalignant laryngeal lesions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Outcomes and Malignant Transformation After Intervention for Laryngeal Dysplasia: A Multi-Institutional Cohort Study Using the TriNetX Research Network</span>. <u>Lekha Medarametla</u><sup>1</sup>; Paul C Bryson, MD, MBA<sup>2</sup>. <sup>1</sup>Case Western Reserve University School of Medicine, Cleveland, Ohio; <sup>2</sup>Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Voice Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Laryngeal dysplasia represents a spectrum of premalignant lesions that carry a variable but clinically significant risk of recurrence and malignant transformation. While institutional studies and meta-analyses have reported varying transformation rates, there has not yet been a large-scale database study looking at recurrence and transformation of laryngeal dysplasia. In this study, we sought to characterize the surgical experience of patients with laryngeal dysplasia using the TriNetX database to report risk for recurrence and malignant transformation and need for repeat surgical interventions over a 5-year follow-up period.</p>\n\n<p><strong>Methods</strong>: We conducted a retrospective descriptive cohort study using the TriNetX database. Adult patients (≥18 years) with a premalignant diagnosis of laryngeal dysplasia (ICD-10: D02.0, D14.1, D38.0, J38.7) and underwent laryngeal surgery in the operating room or office setting (CPT: 31540, 31541, 31545, 31546, 31571, 31572) within five years after initial diagnosis were included. With surgery as the index event, outcomes included recurrence of premalignant lesions, malignant transformations, and repeat procedures occurring within 5 years postoperatively. Descriptive and comparative statistics were conducted using TriNetX software.</p>\n\n<p><strong>Results</strong>: A total of 15,950 patients met inclusion criteria. The average age of patients was 64 ± 16; the majority were male (55.40%) and white (72.08%). Of the patients who underwent initial surgery for premalignant laryngeal dysplasia, 64.74% had a recurrent laryngeal dysplasia diagnosis, and 15.02% were diagnosed with a malignant lesion within 5 years. Repeat surgical intervention was observed in 27.99% of patients, with 15.3% of patients having 2 or more repeat procedures.</p>\n\n<p><strong>Conclusion</strong>: This is the first multi-institutional database study to describe recurrence and malignant transformation following surgical intervention for laryngeal dysplasia. Our findings highlight the persistence of disease, transformation risk, and importance of long-term surveillance for premalignant laryngeal lesions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154072--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S337",
      "content_id": "154409",
      "abstract_number": "S337",
      "poster_number": "",
      "title": "Initial Frozen Margin Positivity as a Prognostic Marker in Total Laryngectomy and Total Laryngopharyngectomy",
      "summary": "Initial frozen margin positivity is associated with higher recurrence, worse univariable survival, and clustering of adverse pathologic features in TL/TLP. Although not independently predictive of OS after adjustment, frozen positivity appears to function as an early intraoperative indicator of underlying tumor aggressiveness. This concept has not been demonstrated in previous literature and is strengthened by...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154409",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Edgar D Uribe Sanchez, BA",
      "presenter": "Edgar D Uribe Sanchez, BA",
      "authors": "Edgar D Uribe Sanchez, BA ; Jerome N Nashed, BA; Peter T Dziegielewski, MD; Dustin J Conrad, MD; Kirollos Armosh, BS; Austin S Lam, MD",
      "normalized_authors": [
        "Edgar D Uribe Sanchez",
        "Jerome N Nashed",
        "Peter T Dziegielewski",
        "Dustin J Conrad",
        "Kirollos Armosh",
        "Austin S Lam"
      ],
      "affiliations": [
        "University of Florida"
      ],
      "normalized_institutions": [
        "University of Florida"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 536,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Edgar D Uribe Sanchez, BA ; Jerome N Nashed, BA; Peter T Dziegielewski, MD; Dustin J Conrad, MD; Kirollos Armosh, BS; Austin S Lam, MD",
        "Affiliations": "University of Florida",
        "Introduction": "Accurate intraoperative margin assessment is important during total laryngectomy (TL) and total laryngopharyngectomy (TLP). While final pathologic margins are well-established predictors of recurrence and survival, the prognostic role of initial frozen section positivity is less clearly defined. Initial positive frozen margins may reflect biologic aggressiveness, technical difficulty in achieving negative margins, or both, and may serve as an early marker of patients at elevated oncologic risk. The objective of this study was to evaluate the rate of initial frozen margin positivity in TL/TLP and determine its association with recurrence, overall survival (OS), and adverse pathologic features. Findings may inform intraoperative decision making and margin labeling practices in these high-risk resections.",
        "Methods": "A retrospective cohort study was conducted of 291 patients undergoing TL or TLP at a tertiary academic center. Descriptive statistics were used to characterize the frequency of initial frozen positivity, re-resection, final margin status, recurrence, and mortality. Associations between initial frozen positivity and categorical variables including procedure type, lymphovascular invasion (LVI), and final margin classification were evaluated using chi-square testing. Overall survival was examined using Kaplan–Meier (KM) curves with log-rank testing. Univariable and multivariable Cox regression were used to identify predictors of OS. Demographic and pathologic covariates included age, Charlson Comorbidity Index (CCI), LVI, extranodal extension (ENE), nodal burden, and depth of invasion.",
        "Results": "Initial frozen positive margins occurred in 56 of 291 patients (19.2%). Re-resection was performed in 45 patients (15.5%), and 17 of these (37.8%) had at least one positive re-resection specimen. Initial frozen positivity differed by procedure type, occurring more frequently in TLP than TL (37.5% vs 16.7%, P = 0.002). LVI was strongly associated with initial positivity (27.1% vs 11.9%, P = 0.002). Recurrence was significantly more common in patients with initially positive margins (35.7% vs 18.3%, P = 0.008). Crude mortality was higher in the initially positive group (42.9% vs 34.0%), though not statistically significant (P = 0.28).",
        "Abstract": "KM analysis demonstrated significantly worse OS in patients with initial frozen positivity (log-rank P = 0.016). In univariable Cox regression, predictors of worse OS included CCI (HR 1.22, P = 0.0012), recurrent disease (HR 1.58, P = 0.0284), LVI (HR 2.17, P = 0.0002), nodal burden (HR 1.19, P < 0.0001), ENE (HR 2.18, P = 0.0003), and initial frozen positivity (HR 1.79, P = 0.0139). In multivariable analysis, CCI remained the strongest independent predictor of decreased OS (HR 1.42, P = 0.0001). Initial frozen positivity lost statistical significance after adjustment, suggesting its prognostic impact is mediated by correlated aggressive features such as LVI, ENE, and nodal disease. View in Agenda and Add to Schedule",
        "Conclusion": "Initial frozen margin positivity is associated with higher recurrence, worse univariable survival, and clustering of adverse pathologic features in TL/TLP. Although not independently predictive of OS after adjustment, frozen positivity appears to function as an early intraoperative indicator of underlying tumor aggressiveness. This concept has not been demonstrated in previous literature and is strengthened by inclusion of TLP patients, use of OS, and more comprehensive multivariable modeling. These findings highlight the potential value of initial frozen section results in risk stratification and surgical planning for TL/TLP patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Initial Frozen Margin Positivity as a Prognostic Marker in Total Laryngectomy and Total Laryngopharyngectomy</span>. <u>Edgar D Uribe Sanchez, BA</u>; Jerome N Nashed, BA; Peter T Dziegielewski, MD; Dustin J Conrad, MD; Kirollos Armosh, BS; Austin S Lam, MD. University of Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Accurate intraoperative margin assessment is important during total laryngectomy (TL) and total laryngopharyngectomy (TLP). While final pathologic margins are well-established predictors of recurrence and survival, the prognostic role of initial frozen section positivity is less clearly defined. Initial positive frozen margins may reflect biologic aggressiveness, technical difficulty in achieving negative margins, or both, and may serve as an early marker of patients at elevated oncologic risk. The objective of this study was to evaluate the rate of initial frozen margin positivity in TL/TLP and determine its association with recurrence, overall survival (OS), and adverse pathologic features. Findings may inform intraoperative decision making and margin labeling practices in these high-risk resections. </p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted of 291 patients undergoing TL or TLP at a tertiary academic center. Descriptive statistics were used to characterize the frequency of initial frozen positivity, re-resection, final margin status, recurrence, and mortality. Associations between initial frozen positivity and categorical variables including procedure type, lymphovascular invasion (LVI), and final margin classification were evaluated using chi-square testing. Overall survival was examined using Kaplan–Meier (KM) curves with log-rank testing. Univariable and multivariable Cox regression were used to identify predictors of OS. Demographic and pathologic covariates included age, Charlson Comorbidity Index (CCI), LVI, extranodal extension (ENE), nodal burden, and depth of invasion. </p>\n\n<p><strong>Results: </strong>Initial frozen positive margins occurred in 56 of 291 patients (19.2%). Re-resection was performed in 45 patients (15.5%), and 17 of these (37.8%) had at least one positive re-resection specimen. Initial frozen positivity differed by procedure type, occurring more frequently in TLP than TL (37.5% vs 16.7%, P = 0.002). LVI was strongly associated with initial positivity (27.1% vs 11.9%, P = 0.002). Recurrence was significantly more common in patients with initially positive margins (35.7% vs 18.3%, P = 0.008). Crude mortality was higher in the initially positive group (42.9% vs 34.0%), though not statistically significant (P = 0.28). </p>\n\n<p>KM analysis demonstrated significantly worse OS in patients with initial frozen positivity (log-rank P = 0.016). In univariable Cox regression, predictors of worse OS included CCI (HR 1.22, P = 0.0012), recurrent disease (HR 1.58, P = 0.0284), LVI (HR 2.17, P = 0.0002), nodal burden (HR 1.19, P < 0.0001), ENE (HR 2.18, P = 0.0003), and initial frozen positivity (HR 1.79, P = 0.0139). In multivariable analysis, CCI remained the strongest independent predictor of decreased OS (HR 1.42, P = 0.0001). Initial frozen positivity lost statistical significance after adjustment, suggesting its prognostic impact is mediated by correlated aggressive features such as LVI, ENE, and nodal disease. </p>\n\n<p><strong>Conclusion: </strong>Initial frozen margin positivity is associated with higher recurrence, worse univariable survival, and clustering of adverse pathologic features in TL/TLP. Although not independently predictive of OS after adjustment, frozen positivity appears to function as an early intraoperative indicator of underlying tumor aggressiveness. This concept has not been demonstrated in previous literature and is strengthened by inclusion of TLP patients, use of OS, and more comprehensive multivariable modeling. These findings highlight the potential value of initial frozen section results in risk stratification and surgical planning for TL/TLP patients. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154409--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S339",
      "content_id": "154356",
      "abstract_number": "S339",
      "poster_number": "",
      "title": "Oncologic Outcomes of Transoral Robotic Surgery for Hypopharyngeal Squamous Cell Carcinoma: A 20-Year Single-Institution Experience",
      "summary": "Thirty-nine patients underwent TORS for hypopharyngeal SCC (mean age 63.5 years). Average follow-up was 5.51 years (range 0.14 – 17.8 years). Most patients were male (85.0%) and current or former smokers (88.0%). The pyriform sinus was the most common subsite (68.8%), followed by the posterior pharyngeal wall (18.8%).",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154356",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annie E Arrighi-Allisan, MD",
      "presenter": "Annie E Arrighi-Allisan, MD",
      "authors": "Annie E Arrighi-Allisan, MD ; Archer Schaeffer, BS; Karthik Rajasekaran, MD; Gregory S Weinstein, MD",
      "normalized_authors": [
        "Annie E Arrighi-Allisan",
        "Archer Schaeffer",
        "Karthik Rajasekaran",
        "Gregory S Weinstein"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 526,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Discussion/Conclusions"
      ],
      "sections": {
        "Authors": "Annie E Arrighi-Allisan, MD ; Archer Schaeffer, BS; Karthik Rajasekaran, MD; Gregory S Weinstein, MD",
        "Affiliations": "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System",
        "Introduction": "Hypopharyngeal malignancies carry among the poorest prognoses in head and neck oncology, driven by late presentation, adverse biology, poor responses to definitive chemoradiation, and the functional cost of traditional open surgical approaches. Compared with oropharyngeal and laryngeal counterparts, hypopharyngeal squamous cell carcinoma (SCC) demonstrates markedly lower rates of radiosensitivity, durable locoregional control, and organ preservation, underscoring the need for effective surgical approaches. Transoral robotic surgery (TORS) has emerged as a minimally invasive alternative offering the potential for organ preservation, yet evidence specific to the hypopharynx remains limited to small, heterogeneous cohorts with modest follow-up.",
        "Methods": "Patients undergoing TORS for SCC of the hypopharynx within a single institution over a 20-year period (2006-2025) were reviewed. Baseline demographic, pathologic, treatment, and outcome variables were collected. Primary outcome measures were locoregional recurrence and disease-specific mortality.",
        "Results": "Thirty-nine patients underwent TORS for hypopharyngeal SCC (mean age 63.5 years). Average follow-up was 5.51 years (range 0.14 – 17.8 years). Most patients were male (85.0%) and current or former smokers (88.0%). The pyriform sinus was the most common subsite (68.8%), followed by the posterior pharyngeal wall (18.8%).",
        "Abstract": "Negative, close, and positive margins were obtained in 53.1%, 28.1%, and 12.5% of cases, respectively. Mean tumor size was 1.95 cm (range 0.4 – 4.2 cm). 5.1% of cases were pT3, these patients had negative margins and did not recur. Organ preservation was achieved in 94.9%. Seven patients (17.9%) experienced recurrence: 2 (5.12%) involved the primary site, 3 (7.69%) manifested as nodal disease, and 3 (7.69%) recurred distantly. All recurrences occurred within two years of TORS. 5-year all-cause mortality was 41.0%, and three patients ultimately died of recurrent or metastatic disease, yielding a 5-year disease-specific mortality of 7.69%. Poorer differentiation correlated significantly with any recurrence (100% moderate-to-poor or poor differentiation for recurrence vs. 45% without, p=0.02). Positive margins predicted local failure (40% with positive margins vs. 0% with negative/close, p=0.045). Locoregional recurrence was more common with lymphovascular invasion (100% LVI recurrent vs. 25% nonrecurrent, p=0.08). Our follow-up time provides rare insight into patterns of recurrence; disease failures occurred within the first two years and disease-specific mortality remained low despite a predominantly tobacco-exposed, male cohort typical of hypopharyngeal cancer. Notable, our cohort included pT3 tumors, a population often excluded from TORS studies, yet these outcomes suggest that carefully selected borderline-advanced tumors may still be amenable to a transoral approach. Pathologic features were strongly prognostic: poorer differentiation was associated with any recurrence, while positive margins correlated with local failure, reinforcing the critical role of surgical clearance in a confined anatomic space. The association between adverse histology and recurrence offers a practical framework for anticipating biologic behavior and tailoring adjuvant decisions. Collectively, these findings position TORS as a compelling organ-preserving strategy for select hypopharyngeal tumors and provide rare long-term, pathology-specific insights to refine patient selection and optimize perioperative strategy. View in Agenda and Add to Schedule",
        "Discussion/Conclusions": "In one of the largest single-institution TORS series for hypopharyngeal SCC, we demonstrate durable oncologic control and high organ-preservation rates over more than two decades of practice."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncologic Outcomes of Transoral Robotic Surgery for Hypopharyngeal Squamous Cell Carcinoma: A 20-Year Single-Institution Experience</span>. <u>Annie E Arrighi-Allisan, MD</u>; Archer Schaeffer, BS; Karthik Rajasekaran, MD; Gregory S Weinstein, MD. Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Hypopharyngeal malignancies carry among the poorest prognoses in head and neck oncology, driven by late presentation, adverse biology, poor responses to definitive chemoradiation, and the functional cost of traditional open surgical approaches. Compared with oropharyngeal and laryngeal counterparts, hypopharyngeal squamous cell carcinoma (SCC) demonstrates markedly lower rates of radiosensitivity, durable locoregional control, and organ preservation, underscoring the need for effective surgical approaches. Transoral robotic surgery (TORS) has emerged as a minimally invasive alternative offering the potential for organ preservation, yet evidence specific to the hypopharynx remains limited to small, heterogeneous cohorts with modest follow-up.</p>\n\n<p><strong>Methods</strong>: Patients undergoing TORS for SCC of the hypopharynx within a single institution over a 20-year period (2006-2025) were reviewed. Baseline demographic, pathologic, treatment, and outcome variables were collected. Primary outcome measures were locoregional recurrence and disease-specific mortality.</p>\n\n<p><strong>Results:</strong> Thirty-nine patients underwent TORS for hypopharyngeal SCC (mean age 63.5 years). Average follow-up was 5.51 years (range 0.14 – 17.8 years). Most patients were male (85.0%) and current or former smokers (88.0%). The pyriform sinus was the most common subsite (68.8%), followed by the posterior pharyngeal wall (18.8%).</p>\n\n<p>Negative, close, and positive margins were obtained in 53.1%, 28.1%, and 12.5% of cases, respectively. Mean tumor size was 1.95 cm (range 0.4 – 4.2 cm). 5.1% of cases were pT3, these patients had negative margins and did not recur. Organ preservation was achieved in 94.9%.</p>\n\n<p>Seven patients (17.9%) experienced recurrence: 2 (5.12%) involved the primary site, 3 (7.69%) manifested as nodal disease, and 3 (7.69%) recurred distantly. All recurrences occurred within two years of TORS. 5-year all-cause mortality was 41.0%, and three patients ultimately died of recurrent or metastatic disease, yielding a 5-year disease-specific mortality of 7.69%.</p>\n\n<p>Poorer differentiation correlated significantly with any recurrence (100% moderate-to-poor or poor differentiation for recurrence vs. 45% without, p=0.02). Positive margins predicted local failure (40% with positive margins vs. 0% with negative/close, p=0.045). Locoregional recurrence was more common with lymphovascular invasion (100% LVI recurrent vs. 25% nonrecurrent, p=0.08).</p>\n\n<p><strong>Discussion/Conclusions</strong>: In one of the largest single-institution TORS series for hypopharyngeal SCC, we demonstrate durable oncologic control and high organ-preservation rates over more than two decades of practice.</p>\n\n<p>Our follow-up time provides rare insight into patterns of recurrence; disease failures occurred within the first two years and disease-specific mortality remained low despite a predominantly tobacco-exposed, male cohort typical of hypopharyngeal cancer. Notable, our cohort included pT3 tumors, a population often excluded from TORS studies, yet these outcomes suggest that carefully selected borderline-advanced tumors may still be amenable to a transoral approach.</p>\n\n<p>Pathologic features were strongly prognostic: poorer differentiation was associated with any recurrence, while positive margins correlated with local failure, reinforcing the critical role of surgical clearance in a confined anatomic space. The association between adverse histology and recurrence offers a practical framework for anticipating biologic behavior and tailoring adjuvant decisions.</p>\n\n<p>Collectively, these findings position TORS as a compelling organ-preserving strategy for select hypopharyngeal tumors and provide rare long-term, pathology-specific insights to refine patient selection and optimize perioperative strategy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154356--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S340",
      "content_id": "147005",
      "abstract_number": "S340",
      "poster_number": "",
      "title": "Assessing Functional Outcomes of Transoral Robotic Surgery - Total Laryngectomy (TORS-TL)",
      "summary": "Average length of stay for TORS-TL patients was 4.75 days as compared to 7.5 days in the control group. Two study patients had post operative neopharyngeal leaks. One required neck washout and IV antibiotics with subsequent flap coverage. The second leak was contained within the anterior neck and resolved with PO antibiotics alone. One patient had a post operative cancer recurrence, despite negative margin...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=147005",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Seneca Williams, MD",
      "presenter": "Seneca Williams, MD",
      "authors": "Seneca Williams, MD ; Harishanker Jeyarajan, MD; Andrew Fuson, MD",
      "normalized_authors": [
        "Seneca Williams",
        "Harishanker Jeyarajan",
        "Andrew Fuson"
      ],
      "affiliations": [
        "University of Alabama at Birmingham"
      ],
      "normalized_institutions": [
        "University of Alabama at Birmingham"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Methods",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Seneca Williams, MD ; Harishanker Jeyarajan, MD; Andrew Fuson, MD",
        "Affiliations": "University of Alabama at Birmingham",
        "Introduction": "The use of transoral robotic surgery (TORS) as a surgical treatment for various head and neck cancers (HNC) has significantly increased over the past two decades. This minimally invasive approach offers potential benefits such as improved survival, surgical visualization, reduced morbidity, and shorter recovery times. There is currently limited high-quality evidence regarding functional outcomes of TORS total laryngectomy (TORS-TL). This study aims to provide specific information assessing functional outcomes, shoulder mobility, lymphedema, wound complications, and hospital length of stay in patients undergoing TORS-TL.",
        "Abstract": "TORS-TL has been implemented at our institution, specifically in the setting of salvaging endolaryngeal recurrence not amenable to organ preservation surgery and without neck disease. Since TORS-TL for the aforementioned indication does not require free/regional tissue transfer, the technique has decreased operative times, provided shorter hospital stays and decreased wound complications. We hypothesize that TORS-TL has many beneficial implications. First, we postulate there will be decreased lymphedema due to the lack of lymphatic disruption. Second, we expect postoperative swallow to be comparable or improved compared to a salvage total laryngectomy with free flap reconstruction due to the preservation of the hyoid and the innervation of the strap muscles. Additionally, we anticipate reduced postoperative wound complications due to fascial planes within the neck not being disrupted. View in Agenda and Add to Schedule",
        "Methods": "Retrospective review of eight patients who underwent TORS-TL between November 2024 and July 2025 was performed. Inclusion criteria were adults with endolaryngeal recurrent laryngeal cancer not amenable to organ preservation surgery and total laryngeal dysfunctional secondary to radiation. We excluded patients where TORS-TL was performed for laryngeal dysfunction secondary to ALS. Patients underwent preoperative swallow evaluation with speech-language pathologists by utilizing patient reported outcomes (PROMs) and modified barium swallow. Following surgery, swallow was assessed in the same manner after three and six months. Chart review of other post operative complications was performed. Control patients for comparison included those who underwent open salvage total laryngectomy with free flap reconstruction.",
        "Results": "Average length of stay for TORS-TL patients was 4.75 days as compared to 7.5 days in the control group. Two study patients had post operative neopharyngeal leaks. One required neck washout and IV antibiotics with subsequent flap coverage. The second leak was contained within the anterior neck and resolved with PO antibiotics alone. One patient had a post operative cancer recurrence, despite negative margin status. The majority of study patients had improved swallow PROMs by the six-month mark and are tolerating PO feeds. None of the study patients reported shoulder weakness throughout follow up. Lymphedema was only noted in three patients and was mild in all cases. To date, three patients have undergone secondary tracheoesophageal puncture for voicing with two scheduled for the near future.",
        "Discussion": "TORS-TL is a technically feasible salvage option that allows for shortened hospital stay, less significant wound healing complications, and improved PO tolerance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessing Functional Outcomes of Transoral Robotic Surgery - Total Laryngectomy (TORS-TL)</span>. <u>Seneca Williams, MD</u>; Harishanker Jeyarajan, MD; Andrew Fuson, MD. University of Alabama at Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The use of transoral robotic surgery (TORS) as a surgical treatment for various head and neck cancers (HNC) has significantly increased over the past two decades. This minimally invasive approach offers potential benefits such as improved survival, surgical visualization, reduced morbidity, and shorter recovery times. There is currently limited high-quality evidence regarding functional outcomes of TORS total laryngectomy (TORS-TL). This study aims to provide specific information assessing functional outcomes, shoulder mobility, lymphedema, wound complications, and hospital length of stay in patients undergoing TORS-TL.</p>\n\n<p>TORS-TL has been implemented at our institution, specifically in the setting of salvaging endolaryngeal recurrence not amenable to organ preservation surgery and without neck disease. Since TORS-TL for the aforementioned indication does not require free/regional tissue transfer, the technique has decreased operative times, provided shorter hospital stays and decreased wound complications. We hypothesize that TORS-TL has many beneficial implications. First, we postulate there will be decreased lymphedema due to the lack of lymphatic disruption. Second, we expect postoperative swallow to be comparable or improved compared to a salvage total laryngectomy with free flap reconstruction due to the preservation of the hyoid and the innervation of the strap muscles. Additionally, we anticipate reduced postoperative wound complications due to fascial planes within the neck not being disrupted. </p>\n\n<p><strong>Methods: </strong>Retrospective review of eight patients who underwent TORS-TL between November 2024 and July 2025 was performed. Inclusion criteria were adults with endolaryngeal recurrent laryngeal cancer not amenable to organ preservation surgery and total laryngeal dysfunctional secondary to radiation. We excluded patients where TORS-TL was performed for laryngeal dysfunction secondary to ALS. Patients underwent preoperative swallow evaluation with speech-language pathologists by utilizing patient reported outcomes (PROMs) and modified barium swallow. Following surgery, swallow was assessed in the same manner after three and six months. Chart review of other post operative complications was performed. Control patients for comparison included those who underwent open salvage total laryngectomy with free flap reconstruction. </p>\n\n<p><strong>Results: </strong>Average length of stay for TORS-TL patients was 4.75 days as compared to 7.5 days in the control group. Two study patients had post operative neopharyngeal leaks. One required neck washout and IV antibiotics with subsequent flap coverage. The second leak was contained within the anterior neck and resolved with PO antibiotics alone. One patient had a post operative cancer recurrence, despite negative margin status. The majority of study patients had improved swallow PROMs by the six-month mark and are tolerating PO feeds. None of the study patients reported shoulder weakness throughout follow up. Lymphedema was only noted in three patients and was mild in all cases. To date, three patients have undergone secondary tracheoesophageal puncture for voicing with two scheduled for the near future. </p>\n\n<p><strong>Discussion: </strong>TORS-TL is a technically feasible salvage option that allows for shortened hospital stay, less significant wound healing complications, and improved PO tolerance. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 147005--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S341",
      "content_id": "153408",
      "abstract_number": "S341",
      "poster_number": "",
      "title": "Impact of Hypopharyngeal Scar Contracture on Postoperative Quality of Life After Endoscopic Conservation Surgery for Hypopharyngeal Cancer",
      "summary": "Hypopharyngeal scar contracture severity is strongly associated with swallowing- and voice-related QoL impairment after TLM. The absence of a relationship with T stage suggests that scar severity is not purely tumor-driven, whereas significant associations with NACT and adjuvant RT/CRT underscore the impact of treatment modality on postoperative scarring. These findings indicate that functional outcomes may be...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153408",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mei Ju Lee",
      "presenter": "Mei Ju Lee",
      "authors": "Mei Ju Lee ; Pen Yuan Chu, MD",
      "normalized_authors": [
        "Mei Ju Lee",
        "Pen Yuan Chu"
      ],
      "affiliations": [
        "Department of Otolaryngology–Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology–Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Mei Ju Lee ; Pen Yuan Chu, MD",
        "Affiliations": "Department of Otolaryngology–Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan",
        "Objective": "To evaluate the association between hypopharyngeal scar contracture severity and multidimensional postoperative quality-of-life (QoL) outcomes after endoscopic conservation surgery with laser for hypopharyngeal cancer, and to determine whether patient- and treatment-related factors are associated with scar severity.",
        "Methods": "A cross-sectional observational study was performed in patients with hypopharyngeal squamous cell carcinoma who underwent transoral laser microsurgery (TLM) between 2005 and 2025, either as upfront treatment or following neoadjuvant chemotherapy (NACT), with or without adjuvant radiotherapy(RT) / chemoradiotherapy(CRT). Endoscopic images obtained at the time of QoL assessment were graded using the hypopharyngeal scar contracture scale described by Kosuke Uno et al. (2020), ranging from grade 0 (no scar) to 3 (severe scar). QoL was assessed ≥6 months after treatment using the EORTC QLQ-C30, QLQ-H&N35, VHI-30, and MDADI instruments.",
        "Abstract": "Associations between scar grade and QoL outcomes were analyzed using Kruskal–Wallis tests with ε² effect sizes and Spearman rank correlations, with post-hoc pairwise comparisons performed. Categorical variables were evaluated using chi-squared tests or Fisher’s exact tests. Higher scar grades were significantly associated with poorer swallowing-related quality of life, including worse HNSW score (p = 0.0004, ε² = 0.145) and lower MDADI composite score (p = 0.018, ε² = 0.067), as well as greater voice handicap reflected by the VHI-30 total score (p = 0.0006, ε² = 0.135). Post-hoc analysis further demonstrated that patients with grade 3 scarring—representing severe postoperative contracture—had significantly worse swallowing symptoms, higher VHI-Total scores, and lower MDADI composite scores compared with those in lower scar grades. Categorical analyses showed no significant association between scar grade and baseline cT classification, cN classification, overall clinical stage, sex, or age. In contrast, both NACT (p=0.01) and adjuvant RT/CRT (p= 0.004) demonstrated strong associations with scar severity. Among 39 patients (36%) who received NACT, 34 (87%) developed grade 0–2 scarring (mild), whereas only 5 (13%) developed grade 3 scarring (severe). NACT was associated with a significantly reduced risk of severe scarring (RR = 0.41, 95% CI: 0.17–0.99; p = 0.047). Conversely, among 46 patients (42%) who received adjuvant RT/CRT, 27 (59%) had grade 0–2 scarring and 19 (41%) developed grade 3 scarring. Adjuvant treatment significantly increased the risk of severe scarring (RR = 3.25, 95% CI: 1.56–6.77; p = 0.0014). View in Agenda and Add to Schedule",
        "Results": "Among 109 patients (103 male; mean age 60 years) who underwent TLM, 12 (11%) had stage I disease, 30 (27%) stage II, 17 (16%) stage III, and 50 (46%) stage IV disease.",
        "Conclusion": "Hypopharyngeal scar contracture severity is strongly associated with swallowing- and voice-related QoL impairment after TLM. The absence of a relationship with T stage suggests that scar severity is not purely tumor-driven, whereas significant associations with NACT and adjuvant RT/CRT underscore the impact of treatment modality on postoperative scarring. These findings indicate that functional outcomes may be optimized through appropriate integration of NACT and de-escalation strategies that limit the need for adjuvant RT/CRT when oncologically feasible."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Hypopharyngeal Scar Contracture on Postoperative Quality of Life After Endoscopic Conservation Surgery for Hypopharyngeal Cancer</span>. <u>Mei Ju Lee</u>; Pen Yuan Chu, MD. Department of Otolaryngology–Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate the association between hypopharyngeal scar contracture severity and multidimensional postoperative quality-of-life (QoL) outcomes after endoscopic conservation surgery with laser for hypopharyngeal cancer, and to determine whether patient- and treatment-related factors are associated with scar severity.</p>\n\n<p><strong>Methods: </strong>A cross-sectional observational study was performed in patients with hypopharyngeal squamous cell carcinoma who underwent transoral laser microsurgery (TLM) between 2005 and 2025, either as upfront treatment or following neoadjuvant chemotherapy (NACT), with or without adjuvant radiotherapy(RT) / chemoradiotherapy(CRT). Endoscopic images obtained at the time of QoL assessment were graded using the hypopharyngeal scar contracture scale described by Kosuke Uno et al. (2020), ranging from grade 0 (no scar) to 3 (severe scar). QoL was assessed ≥6 months after treatment using the EORTC QLQ-C30, QLQ-H&N35, VHI-30, and MDADI instruments.</p>\n\n<p>Associations between scar grade and QoL outcomes were analyzed using Kruskal–Wallis tests with ε² effect sizes and Spearman rank correlations, with post-hoc pairwise comparisons performed. Categorical variables were evaluated using chi-squared tests or Fisher’s exact tests.</p>\n\n<p><strong>Results: </strong>Among 109 patients (103 male; mean age 60 years) who underwent TLM, 12 (11%) had stage I disease, 30 (27%) stage II, 17 (16%) stage III, and 50 (46%) stage IV disease.</p>\n\n<p>Higher scar grades were significantly associated with poorer swallowing-related quality of life, including worse HNSW score (p = 0.0004, ε² = 0.145) and lower MDADI composite score (p = 0.018, ε² = 0.067), as well as greater voice handicap reflected by the VHI-30 total score (p = 0.0006, ε² = 0.135). Post-hoc analysis further demonstrated that patients with grade 3 scarring—representing severe postoperative contracture—had significantly worse swallowing symptoms, higher VHI-Total scores, and lower MDADI composite scores compared with those in lower scar grades.</p>\n\n<p>Categorical analyses showed no significant association between scar grade and baseline cT classification, cN classification, overall clinical stage, sex, or age. In contrast, both NACT (p=0.01) and adjuvant RT/CRT (p= 0.004) demonstrated strong associations with scar severity. Among 39 patients (36%) who received NACT, 34 (87%) developed grade 0–2 scarring (mild), whereas only 5 (13%) developed grade 3 scarring (severe). NACT was associated with a significantly reduced risk of severe scarring (RR = 0.41, 95% CI: 0.17–0.99; p = 0.047). Conversely, among 46 patients (42%) who received adjuvant RT/CRT, 27 (59%) had grade 0–2 scarring and 19 (41%) developed grade 3 scarring. Adjuvant treatment significantly increased the risk of severe scarring (RR = 3.25, 95% CI: 1.56–6.77; p = 0.0014).</p>\n\n<p><strong>Conclusion: </strong>Hypopharyngeal scar contracture severity is strongly associated with swallowing- and voice-related QoL impairment after TLM. The absence of a relationship with T stage suggests that scar severity is not purely tumor-driven, whereas significant associations with NACT and adjuvant RT/CRT underscore the impact of treatment modality on postoperative scarring. These findings indicate that functional outcomes may be optimized through appropriate integration of NACT and de-escalation strategies that limit the need for adjuvant RT/CRT when oncologically feasible.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153408--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S342",
      "content_id": "153714",
      "abstract_number": "S342",
      "poster_number": "",
      "title": "Impact of Elective Free Flap Reconstruction Versus Primary Closure on Pharyngocutaneous Fistula Development Following Primary Total Laryngectomy",
      "summary": "Patients who underwent primary closure had a PCF rate five times higher than patients who underwent an elective free flap. Despite lower PCF rates, the elective free flap group had a longer hospital stay and higher reoperation rates than the primary closure group. PCF development was significantly associated with worse postoperative swallowing studies and delays to receiving adjuvant radiation. Further...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153714",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "James R Gardner, MD",
      "presenter": "James R Gardner, MD",
      "authors": "Kinsey Bryant, BA; James R Gardner, MD ; Kenny Nguyen, MD; William Weir, MD, PhD; Mauricio Moreno, MD; Jumin Sunde, MD; Emre Vural, MD",
      "normalized_authors": [
        "Kinsey Bryant",
        "James R Gardner",
        "Kenny Nguyen",
        "William Weir",
        "Mauricio Moreno",
        "Jumin Sunde",
        "Emre Vural"
      ],
      "affiliations": [
        "University of Arkansas for Medical Sciences"
      ],
      "normalized_institutions": [
        "University of Arkansas for Medical Sciences"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 517,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kinsey Bryant, BA; James R Gardner, MD ; Kenny Nguyen, MD; William Weir, MD, PhD; Mauricio Moreno, MD; Jumin Sunde, MD; Emre Vural, MD",
        "Affiliations": "University of Arkansas for Medical Sciences",
        "Objective": "Pharyngocutaneous fistula (PCF) formation is a common and serious complication of total laryngectomies, often resulting in prolonged hospitalization, delays in adjuvant therapy, and impaired swallowing recovery. The study aims to characterize risk factors associated with PCF formation in primary total laryngectomy patients and to evaluate the impact of closure technique and perioperative variables on outcomes.",
        "Methods": "Retrospective chart review was performed on patients who underwent a total laryngectomy from 2014 to 2025 at a single academic tertiary care center. Data was collected on demographics, comorbidities, closure technique, postoperative course, and relevant oncologic and functional outcomes. The exclusion criteria were defined as: 1) salvage laryngectomy; 2) extended pharyngectomy defects not amenable to primary closure; 3) reconstruction with a pedicled flap; 4) stapler use; 5) base of tongue excision; 6) tumor extension into the apex of the pyriform sinus. The primary objective of the study is to assess closure technique and other contributing factors of PCF in non-irradiated patients undergoing a laryngectomy. Secondary outcomes include swallowing function, delay in adjuvant therapy, and long-term gastrotomy tube use.",
        "Results": "Ninety-four primary laryngectomies met inclusion criteria. Defects were reconstructed with either elective free flap (n = 53, 56.4%) or primary closure (n = 41, 43.6%). The overall PCF rate was 23.4% and occurred in 7.6% of elective free flaps versus 43.9% of primary closures (OR 9.34; 95% CI 2.68–42.30; p < 0.001). Patients who underwent a free flap and developed PCF were more likely to require reoperation (OR 0.08; 95% CI 0.001–1.34; p = 0.049). Primary TEP and tumor involved surgical margins were associated with higher PCF risk (OR 7.55, 95% CI 0.99–89.83, p = 0.025; and OR 3.48, 95% CI 1.09–11.9, p = 0.0353 respectively). On multivariable analysis, closure technique was the only independent predictor of PCF formation, and patients undergoing primary closure were five times more likely to develop a fistula compared to those receiving a free flap (OR 5.06; 95% CI 1.44–21.14; p = 0.016). Smoking status, comorbidities, neck dissection variables, tumor staging, and pathology were not associated with PCF. Patients who developed PCF had worse postoperative VFSS outcomes (p < 0.001) and were less likely to receive adjuvant radiation within 6 weeks (OR 0.1; 95% CI 0.002–0.71; p = 0.009). However, elective free flap reconstruction was associated with a longer hospital stay compared to primary closure (p = 0.048). One-year G-tube dependence and postoperative esophageal dilations did not differ by closure technique or PCF status.",
        "Conclusion": "Patients who underwent primary closure had a PCF rate five times higher than patients who underwent an elective free flap. Despite lower PCF rates, the elective free flap group had a longer hospital stay and higher reoperation rates than the primary closure group. PCF development was significantly associated with worse postoperative swallowing studies and delays to receiving adjuvant radiation. Further investigation is warranted to clarify which patients benefit most from elective free flap reconstruction and to optimize outcomes across closure techniques.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Elective Free Flap Reconstruction Versus Primary Closure on Pharyngocutaneous Fistula Development Following Primary Total Laryngectomy</span>. Kinsey Bryant, BA; <u>James R Gardner, MD</u>; Kenny Nguyen, MD; William Weir, MD, PhD; Mauricio Moreno, MD; Jumin Sunde, MD; Emre Vural, MD. University of Arkansas for Medical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Pharyngocutaneous fistula (PCF) formation is a common and serious complication of total laryngectomies, often resulting in prolonged hospitalization, delays in adjuvant therapy, and impaired swallowing recovery. The study aims to characterize risk factors associated with PCF formation in primary total laryngectomy patients and to evaluate the impact of closure technique and perioperative variables on outcomes.</p>\n\n<p><strong>Methods: </strong>Retrospective chart review was performed on patients who underwent a total laryngectomy from 2014 to 2025 at a single academic tertiary care center. Data was collected on demographics, comorbidities, closure technique, postoperative course, and relevant oncologic and functional outcomes. The exclusion criteria were defined as: 1) salvage laryngectomy; 2) extended pharyngectomy defects not amenable to primary closure; 3) reconstruction with a pedicled flap; 4) stapler use; 5) base of tongue excision; 6) tumor extension into the apex of the pyriform sinus. The primary objective of the study is to assess closure technique and other contributing factors of PCF in non-irradiated patients undergoing a laryngectomy. Secondary outcomes include swallowing function, delay in adjuvant therapy, and long-term gastrotomy tube use.</p>\n\n<p><strong>Results: </strong>Ninety-four primary laryngectomies met inclusion criteria. Defects were reconstructed with either elective free flap (n = 53, 56.4%) or primary closure (n = 41, 43.6%). The overall PCF rate was 23.4% and occurred in 7.6% of elective free flaps versus 43.9% of primary closures (OR 9.34; 95% CI 2.68–42.30; p < 0.001). Patients who underwent a free flap and developed PCF were more likely to require reoperation (OR 0.08; 95% CI 0.001–1.34; p = 0.049). Primary TEP and tumor involved surgical margins were associated with higher PCF risk (OR 7.55, 95% CI 0.99–89.83, p = 0.025; and OR 3.48, 95% CI 1.09–11.9, p = 0.0353 respectively). On multivariable analysis, closure technique was the only independent predictor of PCF formation, and patients undergoing primary closure were five times more likely to develop a fistula compared to those receiving a free flap (OR 5.06; 95% CI 1.44–21.14; p = 0.016). Smoking status, comorbidities, neck dissection variables, tumor staging, and pathology were not associated with PCF. Patients who developed PCF had worse postoperative VFSS outcomes (p < 0.001) and were less likely to receive adjuvant radiation within 6 weeks (OR 0.1; 95% CI 0.002–0.71; p = 0.009). However, elective free flap reconstruction was associated with a longer hospital stay compared to primary closure (p = 0.048). One-year G-tube dependence and postoperative esophageal dilations did not differ by closure technique or PCF status.</p>\n\n<p><strong>Conclusion: </strong>Patients who underwent primary closure had a PCF rate five times higher than patients who underwent an elective free flap. Despite lower PCF rates, the elective free flap group had a longer hospital stay and higher reoperation rates than the primary closure group. PCF development was significantly associated with worse postoperative swallowing studies and delays to receiving adjuvant radiation. Further investigation is warranted to clarify which patients benefit most from elective free flap reconstruction and to optimize outcomes across closure techniques.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153714--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S343",
      "content_id": "155532",
      "abstract_number": "S343",
      "poster_number": "",
      "title": "Mutational Profiles of Laryngeal Squamous Cell Carcinoma: A Single Institution Experience",
      "summary": "This single institution genomic analysis of larynx cancer patients illuminates 4 acquired gene mutations (ABL2, BLM, PTEN, SETD2) that may be implicated in (chemo)radiation treatment resistance, as well as 2 mutations (HSP90AA1, STAT3) that could potentially indicate (chemo)radiation treatment susceptibility. Further research into the connection between these mutations and treatment outcomes is needed.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155532",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter J Attia, BA",
      "presenter": "Peter J Attia, BA",
      "authors": "Peter J Attia, BA ; Joseph Celidonio, MD; David Suster, MD; Dylan F Roden, MD, MPH",
      "normalized_authors": [
        "Peter J Attia",
        "Joseph Celidonio",
        "David Suster",
        "Dylan F Roden"
      ],
      "affiliations": [
        "Rutgers New Jersey Medical School"
      ],
      "normalized_institutions": [
        "Rutgers New Jersey Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155532/combined_data3_oncoplot.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155532/combined_data3_oncoplot.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155532"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Peter J Attia, BA ; Joseph Celidonio, MD; David Suster, MD; Dylan F Roden, MD, MPH",
        "Affiliations": "Rutgers New Jersey Medical School",
        "Introduction": "Currently, treatment selection for advanced laryngeal squamous cell carcinoma is mostly determined by primary tumor staging and presence/absence of extralaryngeal tumor involvement. With the advent of precision oncology and low-cost targeted sequencing, tumor mutational profiles may serve as an additional guide for appropriate prognostication and treatment selection. We hypothesize that tumor mutational profiles will differ between larynx cancer patients with treatment success and those who develop recurrence.",
        "Methods": "We retrospectively selected patients diagnosed with LSCC treated at our institution from 2015-2025. We organized these patients into 3 groups: (1) patients treated with (chemo)radiation that recurred locally and underwent subsequent salvage laryngectomy (with matched pre-treatment biopsy and salvage laryngectomy specimens), (2) patients treated successfully with primary chemoradiation, and (3) patients who underwent total laryngectomy with pathology directed adjuvant therapy as their primary treatment. Unstained slides were prepared from formalin-fixed paraffin-embedded (FFPE) blocks. The Agilent SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay was performed on all specimens. Variants were filtered to retain coding mutations with adequate sequencing support and low population frequency (gnomAD population frequency < 1%). Variants were required to have total read depth ≥10 and variant allele frequency ≥5%. Fisher’s exact test reported differences between cisplatin-treated groups, and McNemar’s test was used to report differences in profiles across pre-treatment biopsies and salvage laryngectomy specimens. (p < .05)",
        "Results": "Of the 28 patients, 11 underwent salvage laryngectomy, 8 received chemo(radiation), and 9 had a primary total laryngectomy. 77% were male with a median age of diagnosis of 58 years. Patients report a median of 30 pack years, and 62% report former or current alcohol use. There are no demographics differences among the three groups, except for ethnicity (p = 0.021). Transglottic extension was common in the salvage group (p = 0.051), and a higher initial T stage was reported in the primary laryngectomy group (p = 0.010), with no differences in N or M staging. The most common oncogenic mutations include KMT2C (91.5%), HLA-C (83%), KMT2D (78.7%), LRP1B (70.2%), and TP53 (68.1%) [Figure 1]. In patients who had failed (chemo)radiation, the persistent tumors analyzed from the salvage laryngectomy specimens were more likely to have acquired mutations in ABL2, BLM, PTEN, and SETD2 (all p=0.03). In examining patients treated with cisplatin, we found that patients without recurrence were more likely to have HSP90AA1 mutations (100% vs 12.5%, p=0.004) and STAT3 (60% vs 0%, p = 0.035).",
        "Conclusions": "This single institution genomic analysis of larynx cancer patients illuminates 4 acquired gene mutations (ABL2, BLM, PTEN, SETD2) that may be implicated in (chemo)radiation treatment resistance, as well as 2 mutations (HSP90AA1, STAT3) that could potentially indicate (chemo)radiation treatment susceptibility. Further research into the connection between these mutations and treatment outcomes is needed.",
        "Figure 1.": "Oncoplot of known pathogenic, oncogenic, and tumor-suppressor genes across all sequenced specimens.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Mutational Profiles of Laryngeal Squamous Cell Carcinoma: A Single Institution Experience</span>. <u>Peter J Attia, BA</u>; Joseph Celidonio, MD; David Suster, MD; Dylan F Roden, MD, MPH. Rutgers New Jersey Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Currently, treatment selection for advanced laryngeal squamous cell carcinoma is mostly determined by primary tumor staging and presence/absence of extralaryngeal tumor involvement.   With the advent of precision oncology and low-cost targeted sequencing, tumor mutational profiles may serve as an additional guide for appropriate prognostication and treatment selection.   We hypothesize that tumor mutational profiles will differ between larynx cancer patients with treatment success and those who develop recurrence.</p>\n\n<p><strong>Methods:</strong> We retrospectively selected patients diagnosed with LSCC treated at our institution from 2015-2025.  We organized these patients into 3 groups: (1) patients treated with (chemo)radiation that recurred locally and underwent subsequent salvage laryngectomy (with matched pre-treatment biopsy and salvage laryngectomy specimens), (2) patients treated successfully with primary chemoradiation, and (3) patients who underwent total laryngectomy with pathology directed adjuvant therapy as their primary treatment.  Unstained slides were prepared from formalin-fixed paraffin-embedded (FFPE) blocks.  The Agilent SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay was performed on all specimens. Variants were filtered to retain coding mutations with adequate sequencing support and low population frequency (gnomAD population frequency < 1%).  Variants were required to have total read depth ≥10 and variant allele frequency ≥5%. Fisher’s exact test reported differences between cisplatin-treated groups, and McNemar’s test was used to report differences in profiles across pre-treatment biopsies and salvage laryngectomy specimens. (p < .05)</p>\n\n<p><strong>Results:</strong> Of the 28 patients, 11 underwent salvage laryngectomy, 8 received chemo(radiation), and 9 had a primary total laryngectomy. 77% were male with a median age of diagnosis of 58 years. Patients report a median of 30 pack years, and 62% report former or current alcohol use. There are no demographics differences among the three groups, except for ethnicity (p = 0.021). Transglottic extension was common in the salvage group (p = 0.051), and a higher initial T stage was reported in the primary laryngectomy group (p = 0.010), with no differences in N or M staging. The most common oncogenic mutations include KMT2C (91.5%), HLA-C (83%), KMT2D (78.7%), LRP1B (70.2%), and TP53 (68.1%) [Figure 1]. In patients who had failed (chemo)radiation, the persistent tumors analyzed from the salvage laryngectomy specimens were more likely to have acquired mutations in ABL2, BLM, PTEN, and SETD2 (all p=0.03).  In examining patients treated with cisplatin, we found that patients without recurrence were more likely to have HSP90AA1 mutations (100% vs 12.5%, p=0.004) and STAT3 (60% vs 0%, p = 0.035). </p>\n\n<p><strong>Conclusions: </strong>This single institution genomic analysis of larynx cancer patients illuminates 4 acquired gene mutations (ABL2, BLM, PTEN, SETD2) that may be implicated in (chemo)radiation treatment resistance, as well as 2 mutations (HSP90AA1, STAT3) that could potentially indicate (chemo)radiation treatment susceptibility.  Further research into the connection between these mutations and treatment outcomes is needed.</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155532/combined_data3_oncoplot.png' /></p>\n\n<p><strong>Figure 1. </strong>Oncoplot of known pathogenic, oncogenic, and tumor-suppressor genes across all sequenced specimens.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155532--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S344",
      "content_id": "153103",
      "abstract_number": "S344",
      "poster_number": "",
      "title": "Postoperative Hypocalcemia in Primary Versus Salvage Total Laryngectomy: Real-World Data Analysis",
      "summary": "In this large multicenter real-world analysis, primary TL was associated with higher rates of transient and permanent hypocalcemia, lower PTH levels, greater supplementation requirements, and earlier onset of hypocalcemia. These findings underscore the importance of standardized monitoring and individualized supplementation strategies for all TL patients, especially those requiring concurrent thyroidectomy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153103",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260141",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karen Tawk, MD",
      "presenter": "Karen Tawk, MD",
      "authors": "Karen Tawk, MD ; Joel S Feier, MD; Annette E Mino, BS; Monica S Trent, MD; Mark S Swanson, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD",
      "normalized_authors": [
        "Karen Tawk",
        "Joel S Feier",
        "Annette E Mino",
        "Monica S Trent",
        "Mark S Swanson",
        "Yarah M Haidar",
        "Tjoson Tjoa"
      ],
      "affiliations": [
        "University of California, Irvine"
      ],
      "normalized_institutions": [
        "University of California, Irvine"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 394,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Karen Tawk, MD ; Joel S Feier, MD; Annette E Mino, BS; Monica S Trent, MD; Mark S Swanson, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD",
        "Affiliations": "University of California, Irvine",
        "Background": "Hypocalcemia is a frequent complication following total laryngectomy (TL), with reported incidence ranging from 20-40%. Evidence regarding the impact of salvage TL on hypocalcemia risk remains inconsistent. Some studies suggest salvage procedures carry a higher risk, while others show no significant association. These discrepancies underscore the need for larger, multicenter analyses.",
        "Methods": "We conducted a retrospective cohort study using the TriNetX Research Network. Adult patients undergoing TL were identified (n= 6220) and divided into primary TL (with or without adjuvant therapy) versus salvage TL. TL was defined as the index event. Eligibility required at least one recorded calcium level. Patients with prior bariatric surgery, chronic kidney disease, or hypocalcemia within one year before surgery were excluded. Propensity score matching (PSM) was used to balance demographics, comorbidities, procedures, and medications, yielding two matched cohorts (n=1,087 each). Outcomes included postoperative hypocalcemia (≤8.0 mg/dL), low parathyroid hormone (PTH; ≤10 pg/mL), and supplementation with calcium or calcitriol at <6months and >6 months. We also stratified both cohorts by thyroidectomy status to evaluate differences in postoperative hypocalcemia.",
        "Results": "Primary TL demonstrated higher rates of hypocalcemia compared with salvage TL at both <6 months (71.1% vs. 62.37%; OR 1.49, 95% CI 1.24-1.78) and >6 months (25.2 vs. 19.3; OR 1.4, 95% CI 1.14-1.71). Primary TL also showed higher rates of low PTH at <6 months (30.0% vs. 25.6%; OR 1.25, 95% CI 1.03-1.50) and >6 months (8.8% vs. 5.5%; OR 1.66, 95% CI 1.19-2.32). Calcitriol and calcium supplementation were significantly more common in primary TL during both early and late postoperative windows. In primary TL, concurrent thyroidectomy was strongly associated with increased transient hypocalcemia (88.7% vs. 68.5%; OR 3.84, 95% CI 2.82-5.22). In salvage TL, thyroidectomy also increased the risk of transient hypocalcemia (87.0% vs. 63.0%; OR 3.91, 95% CI 1.87-8.19), but did not increase permanent hypocalcemia in either cohort.",
        "Conclusion": "In this large multicenter real-world analysis, primary TL was associated with higher rates of transient and permanent hypocalcemia, lower PTH levels, greater supplementation requirements, and earlier onset of hypocalcemia. These findings underscore the importance of standardized monitoring and individualized supplementation strategies for all TL patients, especially those requiring concurrent thyroidectomy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Postoperative Hypocalcemia in Primary Versus Salvage Total Laryngectomy: Real-World Data Analysis</span>. <u>Karen Tawk, MD</u>; Joel S Feier, MD; Annette E Mino, BS; Monica S Trent, MD; Mark S Swanson, MD; Yarah M Haidar, MD; Tjoson Tjoa, MD. University of California, Irvine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Hypocalcemia is a frequent complication following total laryngectomy (TL), with reported incidence ranging from 20-40%. Evidence regarding the impact of salvage TL on hypocalcemia risk remains inconsistent. Some studies suggest salvage procedures carry a higher risk, while others show no significant association. These discrepancies underscore the need for larger, multicenter analyses.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study using the TriNetX Research Network. Adult patients undergoing TL were identified (n= 6220) and divided into primary TL (with or without adjuvant therapy) versus salvage TL. TL was defined as the index event. Eligibility required at least one recorded calcium level. Patients with prior bariatric surgery, chronic kidney disease, or hypocalcemia within one year before surgery were excluded. Propensity score matching (PSM) was used to balance demographics, comorbidities, procedures, and medications, yielding two matched cohorts (n=1,087 each). Outcomes included postoperative hypocalcemia (≤8.0 mg/dL), low parathyroid hormone (PTH; ≤10 pg/mL), and supplementation with calcium or calcitriol at <6months and >6 months. We also stratified both cohorts by thyroidectomy status to evaluate differences in postoperative hypocalcemia.</p>\n\n<p><strong>Results: </strong>Primary TL demonstrated higher rates of hypocalcemia compared with salvage TL at both <6 months (71.1% vs. 62.37%; OR 1.49, 95% CI 1.24-1.78) and >6 months (25.2 vs. 19.3; OR 1.4, 95% CI 1.14-1.71). Primary TL also showed higher rates of low PTH at <6 months (30.0% vs. 25.6%; OR 1.25, 95% CI 1.03-1.50) and >6 months (8.8% vs. 5.5%; OR 1.66, 95% CI 1.19-2.32). Calcitriol and calcium supplementation were significantly more common in primary TL during both early and late postoperative windows. In primary TL, concurrent thyroidectomy was strongly associated with increased transient hypocalcemia (88.7% vs. 68.5%; OR 3.84, 95% CI 2.82-5.22). In salvage TL, thyroidectomy also increased the risk of transient hypocalcemia (87.0% vs. 63.0%; OR 3.91, 95% CI 1.87-8.19), but did not increase permanent hypocalcemia in either cohort.</p>\n\n<p><strong>Conclusion:</strong> In this large multicenter real-world analysis, primary TL was associated with higher rates of transient and permanent hypocalcemia, lower PTH levels, greater supplementation requirements, and earlier onset of hypocalcemia. These findings underscore the importance of standardized monitoring and individualized supplementation strategies for all TL patients, especially those requiring concurrent thyroidectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153103--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260141' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S345",
      "content_id": "154482",
      "abstract_number": "S345",
      "poster_number": "",
      "title": "Sentinel Lymph Node Biopsy in Head and Neck Carcinoma Patients Using a Targeted Ultrasmall Fluorescence Silica Nanoparticle and Fluorescence-Guided Surgery: A Phase 2b Clinical Trial",
      "summary": "cRGDY-PEG-Cy5.5-C’ dots enabled accurate, real-time SLN mapping in OSCC with excellent detection of metastatic nodes and high concordance with radiocolloid imaging. Their ability to provide stable, high-contrast intraoperative visualization supports their potential to enhance surgical precision and reduce morbidity in head and neck cancer staging.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154482",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kathleen Luckett",
      "presenter": "Kathleen Luckett",
      "authors": "Kathleen Luckett 1 ; Feng Chen, PhD 1 ; Andrew Tassler, MD 1 ; William Kuhel, MD 1 ; Snehal Patel, MD 2 ; Michelle Bradbury, MD, PhD 1 ; David Kutler, MD 1",
      "normalized_authors": [
        "Kathleen Luckett",
        "Feng Chen",
        "Andrew Tassler",
        "William Kuhel",
        "Snehal Patel",
        "Michelle Bradbury",
        "David Kutler"
      ],
      "affiliations": [
        "Weill Cornell Medicine",
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Weill Cornell Medicine",
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 341,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kathleen Luckett 1 ; Feng Chen, PhD 1 ; Andrew Tassler, MD 1 ; William Kuhel, MD 1 ; Snehal Patel, MD 2 ; Michelle Bradbury, MD, PhD 1 ; David Kutler, MD 1",
        "Affiliations": "1 Weill Cornell Medicine; 2 Memorial Sloan Kettering Cancer Center",
        "Background": "Sentinel lymph node (SLN) biopsy is essential for staging oral squamous cell carcinoma (OSCC), yet traditional mapping with Tc-99m radiocolloid can be limited by inadequate spatial resolution, “shine-through” interference near the primary tumor, and the lack of real-time visualization during surgery. These challenges are amplified in the head and neck region, where dense anatomy and variable lymphatic drainage demand highly precise intraoperative guidance. Cornell Prime Dots (cRGDY-PEG-Cy5.5-C’ dots), ultrasmall integrin-targeted fluorescent nanoparticles, have been engineered to overcome these limitations by providing high-contrast near-infrared (NIR) imaging and stable lymphatic retention, enabling dynamic visualization of lymphatic pathways and SLNs throughout dissection. Early clinical data in melanoma demonstrated strong concordance with radiocolloids and improved intraoperative clarity, motivating further evaluation in OSCC.",
        "Methods": "This multicenter Phase 2b intra-patient comparative trial enrolled adults with clinically node-negative OSCC or melanoma undergoing SLN biopsy. Following standard preoperative mapping with Tc-99m sulfur colloid, patients received intraoperative peritumoral injections of cRGDY-PEG-Cy5.5-C’ dots, followed by real-time NIR imaging to guide SLN localization. Nodes identified by either modality were excised and assessed pathologically. Primary endpoints included concordance between nanoparticle-guided and radiocolloid-guided SLN identification, and nanoparticle false-negative rate relative to pathology. Surgeons also provided qualitative assessments of intraoperative visualization.",
        "Results": "Twenty-five patients (median age 62; 15 OSCC, 10 melanoma) underwent SLN biopsy, yielding 65 lymph nodes in total, where 5 were confirmed pathology positive. 5/5 metastatic nodes were identified by both Tc-99m and nanoparticles, with no fluorescent-only false positives and no nanoparticle-associated false negatives. Among non-metastatic nodes, 55/60 (92%) were identified by both modalities, while 5/60 (8%) were detected by Tc-99m only. In two cases, surgeons reported that nanoparticle imaging provided clearer delineation of lymph nodes from surrounding tissues and improved intraoperative confidence when navigating complex anatomy.",
        "Conclusions": "cRGDY-PEG-Cy5.5-C’ dots enabled accurate, real-time SLN mapping in OSCC with excellent detection of metastatic nodes and high concordance with radiocolloid imaging. Their ability to provide stable, high-contrast intraoperative visualization supports their potential to enhance surgical precision and reduce morbidity in head and neck cancer staging.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sentinel Lymph Node Biopsy in Head and Neck Carcinoma Patients Using a Targeted Ultrasmall Fluorescence Silica Nanoparticle and Fluorescence-Guided Surgery: A Phase 2b Clinical Trial</span>. <u>Kathleen Luckett</u><sup>1</sup>; Feng Chen, PhD<sup>1</sup>; Andrew Tassler, MD<sup>1</sup>; William Kuhel, MD<sup>1</sup>; Snehal Patel, MD<sup>2</sup>; Michelle Bradbury, MD, PhD<sup>1</sup>; David Kutler, MD<sup>1</sup>. <sup>1</sup>Weill Cornell Medicine; <sup>2</sup>Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Sentinel lymph node (SLN) biopsy is essential for staging oral squamous cell carcinoma (OSCC), yet traditional mapping with Tc-99m radiocolloid can be limited by inadequate spatial resolution, “shine-through” interference near the primary tumor, and the lack of real-time visualization during surgery. These challenges are amplified in the head and neck region, where dense anatomy and variable lymphatic drainage demand highly precise intraoperative guidance. Cornell Prime Dots (cRGDY-PEG-Cy5.5-C’ dots), ultrasmall integrin-targeted fluorescent nanoparticles, have been engineered to overcome these limitations by providing high-contrast near-infrared (NIR) imaging and stable lymphatic retention, enabling dynamic visualization of lymphatic pathways and SLNs throughout dissection. Early clinical data in melanoma demonstrated strong concordance with radiocolloids and improved intraoperative clarity, motivating further evaluation in OSCC.</p>\n\n<p><strong>Methods:</strong> This multicenter Phase 2b intra-patient comparative trial enrolled adults with clinically node-negative OSCC or melanoma undergoing SLN biopsy. Following standard preoperative mapping with Tc-99m sulfur colloid, patients received intraoperative peritumoral injections of cRGDY-PEG-Cy5.5-C’ dots, followed by real-time NIR imaging to guide SLN localization. Nodes identified by either modality were excised and assessed pathologically. Primary endpoints included concordance between nanoparticle-guided and radiocolloid-guided SLN identification, and nanoparticle false-negative rate relative to pathology. Surgeons also provided qualitative assessments of intraoperative visualization.</p>\n\n<p><strong>Results:</strong> Twenty-five patients (median age 62; 15 OSCC, 10 melanoma) underwent SLN biopsy, yielding 65 lymph nodes in total, where 5 were confirmed pathology positive. 5/5 metastatic nodes were identified by both Tc-99m and nanoparticles, with no fluorescent-only false positives and no nanoparticle-associated false negatives. Among non-metastatic nodes, 55/60 (92%) were identified by both modalities, while 5/60 (8%) were detected by Tc-99m only. In two cases, surgeons reported that nanoparticle imaging provided clearer delineation of lymph nodes from surrounding tissues and improved intraoperative confidence when navigating complex anatomy.</p>\n\n<p><strong>Conclusions: </strong>cRGDY-PEG-Cy5.5-C’ dots enabled accurate, real-time SLN mapping in OSCC with excellent detection of metastatic nodes and high concordance with radiocolloid imaging. Their ability to provide stable, high-contrast intraoperative visualization supports their potential to enhance surgical precision and reduce morbidity in head and neck cancer staging.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154482--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S346",
      "content_id": "153464",
      "abstract_number": "S346",
      "poster_number": "",
      "title": "Institutional Strategies to Improve In-Office Thyroid FNA Diagnostic Yield and Access to Care",
      "summary": "Technique refinement and streamlined triage pathways significantly improved diagnostic yield and reduced delays to biopsy. The described updated protocol is cost-effective, obviating the need for highly-trained assistants and/or cytology on-site, without compromising diagnostic yield. These findings highlight practical, scalable approaches for enhancing both the quality and accessibility of in-office FNA services.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153464",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ellen P Penn, MD",
      "presenter": "Ellen P Penn, MD",
      "authors": "Ellen P Penn, MD 1 ; Randy W Lesh, MD 1 ; Timothy L Lindemann, MD 1 ; Sara E Monaco, MD 1 ; Nicholas C Purdy, DO 1 ; Kevin J Kovatch, MD 2",
      "normalized_authors": [
        "Ellen P Penn",
        "Randy W Lesh",
        "Timothy L Lindemann",
        "Sara E Monaco",
        "Nicholas C Purdy",
        "Kevin J Kovatch"
      ],
      "affiliations": [
        "Geisinger",
        "UConn Health"
      ],
      "normalized_institutions": [
        "Geisinger",
        "UConn Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 348,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ellen P Penn, MD 1 ; Randy W Lesh, MD 1 ; Timothy L Lindemann, MD 1 ; Sara E Monaco, MD 1 ; Nicholas C Purdy, DO 1 ; Kevin J Kovatch, MD 2",
        "Affiliations": "1 Geisinger; 2 UConn Health",
        "Background": "In-office fine-needle aspiration (FNA) has become an essential tool for evaluating thyroid, salivary, and neck masses, yet diagnostic yield and timely access to biopsy vary across institutions. Our institution performs in-office ultrasound-guided FNA as a lower-resource alternative to interventional radiology-guided biopsy with on-site cytology assessment. We evaluated the impact of technique modifications and workflow changes on diagnostic performance and time-to-biopsy within a multi-site practice.",
        "Methods": "A retrospective review was conducted of all in-office FNAs performed for thyroid nodules from 2021–2025 across two clinical sites. Patient characteristics, procedural technique, diagnostic adequacy, and consultation-to-biopsy intervals were analyzed.",
        "Results": "A total of 254 thyroid nodule in-office FNA procedures were performed. With the initial technique (n = 185; four slide sets + ThyroSeq), diagnostic yield was 86.6%. An updated protocol using two slide sets, Cytolyt, and ThyroSeq (n = 69) improved yield to 95.6% (p = 0.038). Independent of technique, the higher-volume site (228 biopsies) demonstrated a greater overall diagnostic rate compared to the lower-volume site (26 biopsies), though this difference was not statistically significant. Breakdown of diagnostic cytology results included 55% benign (Bethesda II), 19% AUS/FLUS (Bethesda III), 3% FN/SFN (Bethesda IV), 4% suspicious for malignancy (Bethesda V), and 3% malignant (Bethesda VI). All biopsies had ThyroSeq sample collected at the time of initial sampling, and all Bethesda III, IV, and V cytology results had reflex molecular testing. Workflow optimization substantially reduced time-to-biopsy. When patients were first evaluated by providers who do not routinely perform in-office FNA and were subsequently triaged, the mean and median times from consultation to biopsy were 39.8 and 29.0 days, respectively. Direct scheduling with an FNA-performing provider reduced mean and median intervals to 6.3 days and 0.0 days (0 days indicating same-day biopsy).",
        "Conclusion": "Technique refinement and streamlined triage pathways significantly improved diagnostic yield and reduced delays to biopsy. The described updated protocol is cost-effective, obviating the need for highly-trained assistants and/or cytology on-site, without compromising diagnostic yield. These findings highlight practical, scalable approaches for enhancing both the quality and accessibility of in-office FNA services.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Institutional Strategies to Improve In-Office Thyroid FNA Diagnostic Yield and Access to Care</span>. <u>Ellen P Penn, MD</u><sup>1</sup>; Randy W Lesh, MD<sup>1</sup>; Timothy L Lindemann, MD<sup>1</sup>; Sara E Monaco, MD<sup>1</sup>; Nicholas C Purdy, DO<sup>1</sup>; Kevin J Kovatch, MD<sup>2</sup>. <sup>1</sup>Geisinger; <sup>2</sup>UConn Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> In-office fine-needle aspiration (FNA) has become an essential tool for evaluating thyroid, salivary, and neck masses, yet diagnostic yield and timely access to biopsy vary across institutions.  Our institution performs in-office ultrasound-guided FNA as a lower-resource alternative to interventional radiology-guided biopsy with on-site cytology assessment. We evaluated the impact of technique modifications and workflow changes on diagnostic performance and time-to-biopsy within a multi-site practice.</p>\n\n<p><strong>Methods:</strong> A retrospective review was conducted of all in-office FNAs performed for thyroid nodules from 2021–2025 across two clinical sites. Patient characteristics, procedural technique, diagnostic adequacy, and consultation-to-biopsy intervals were analyzed. </p>\n\n<p><strong>Results: </strong>A total of 254 thyroid nodule in-office FNA procedures were performed. With the initial technique (n = 185; four slide sets + ThyroSeq), diagnostic yield was 86.6%. An updated protocol using two slide sets, Cytolyt, and ThyroSeq (n = 69) improved yield to 95.6% (p = 0.038). Independent of technique, the higher-volume site (228 biopsies) demonstrated a greater overall diagnostic rate compared to the lower-volume site (26 biopsies), though this difference was not statistically significant. Breakdown of diagnostic cytology results included 55% benign (Bethesda II), 19% AUS/FLUS (Bethesda III), 3% FN/SFN (Bethesda IV), 4% suspicious for malignancy (Bethesda V), and 3% malignant (Bethesda VI). All biopsies had ThyroSeq sample collected at the time of initial sampling, and all Bethesda III, IV, and V cytology results had reflex molecular testing.  Workflow optimization substantially reduced time-to-biopsy. When patients were first evaluated by providers who do not routinely perform in-office FNA and were subsequently triaged, the mean and median times from consultation to biopsy were 39.8 and 29.0 days, respectively. Direct scheduling with an FNA-performing provider reduced mean and median intervals to 6.3 days and 0.0 days (0 days indicating same-day biopsy). </p>\n\n<p><strong>Conclusion: </strong>Technique refinement and streamlined triage pathways significantly improved diagnostic yield and reduced delays to biopsy. The described updated protocol is cost-effective, obviating the need for highly-trained assistants and/or cytology on-site, without compromising diagnostic yield. These findings highlight practical, scalable approaches for enhancing both the quality and accessibility of in-office FNA services.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153464--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S347",
      "content_id": "153853",
      "abstract_number": "S347",
      "poster_number": "",
      "title": "Evaluating molecular profiling to predict malignancy in thyroid nodules and high risk thyroid cancer",
      "summary": "Of 192 GSC suspicious nodules with GRID data, 149 (77.6%) were Bethesda III, 30 (15.6%) were Bethesda IV and 13 (6.8%) were Bethesda V classification on cytology. Surgical pathology revealed 92 (47.9%) of the nodules to be benign, 39 (20.3%) were non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 61 (31.8%) were malignant. If the presence of a specific molecular alteration...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153853",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sofia Leusch",
      "presenter": "Sofia Leusch",
      "authors": "Sofia Leusch ; Callas Peter; Grace Fleming; Josie Yalovitser; Christopher P Kruglik; Anderson Scott; Allison Ciolino; Mirabelle Sajisevi",
      "normalized_authors": [
        "Sofia Leusch",
        "Callas Peter",
        "Grace Fleming",
        "Josie Yalovitser",
        "Christopher P Kruglik",
        "Anderson Scott",
        "Allison Ciolino",
        "Mirabelle Sajisevi"
      ],
      "affiliations": [
        "University of Vermont Medical Center"
      ],
      "normalized_institutions": [
        "University of Vermont Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Discussion/Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sofia Leusch ; Callas Peter; Grace Fleming; Josie Yalovitser; Christopher P Kruglik; Anderson Scott; Allison Ciolino; Mirabelle Sajisevi",
        "Affiliations": "University of Vermont Medical Center",
        "Objective": "Thyroid nodules are common and most are benign on fine needle aspiration, however 10–30% of nodules have indeterminate cytopathology on Bethesda classification. Molecular testing, such as Afirma, has evolved to better characterize these nodules and reduce surgery when there is benign molecular profiling. However, when there is a suspicious gene sequence classifier (GSC) result, patients often undergo surgery for definitive diagnosis and treatment although up to 50% may ultimately be benign nodules. Thirty mRNA expression-based profiles were developed via Afirma Genomics Resource for Intelligent Discovery (GRID) to further evaluate thyroid nodule risk. This study evaluates whether presence of a molecular alteration could better predict benign versus malignant pathology among Afirma Suspicious nodules and whether GRID signatures could preoperatively predict high risk pathologic features in thyroid cancer.",
        "Methods": "Retrospective analysis of patients who underwent lobectomy or total thyroidectomy for thyroid nodules that were suspicious on AFIRMA gene sequencing classifier from 2020-2025 at three institutions in a single hospital network. Pathology reports were analyzed for final histopathologic diagnoses and classified as “low risk,” “low- intermediate risk,” “intermediate/high-risk,” or “high risk” based on the 2025 American Thyroid Association (ATA) guidelines. Comparisons were performed using two sample t tests and Fisher's exact tests.",
        "Results": "Of 192 GSC suspicious nodules with GRID data, 149 (77.6%) were Bethesda III, 30 (15.6%) were Bethesda IV and 13 (6.8%) were Bethesda V classification on cytology. Surgical pathology revealed 92 (47.9%) of the nodules to be benign, 39 (20.3%) were non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 61 (31.8%) were malignant. If the presence of a specific molecular alteration was identified, the nodule was more likely to be NIFTP/malignant 40/100 (40%) compared to benign 24/92 (26%) (p = 0.047) with the most common mutations being NRAS and HRAS. Thirty patterns of mRNA expression signatures were analyzed between ATA 2025 “low risk”/“low- intermediate risk” versus “intermediate-high risk”/”high risk” demonstrating significant differences in several signatures including apoptosis, DNA repair, estrogen response, inflammatory response, interferon gamma response, mTOR signaling hallmarks, and hedgehog signaling pathway in addition to multiple tumor microenvironment signatures. Evaluation of expression based classifiers showed a negative predictive value of 92% for lymph node metastasis class (1 of 13 classified as low risk had presence of nodal metastasis) and 93% for invasion (25 of 27 patients classified as low risk had minimal or no vascular invasion). Invasion class also correlated with ATA risk although not statistically significant.",
        "Discussion/Conclusion": "Our cohort demonstrated that 52% of nodules classified as GSC suspicious were NIFTP or malignant on final pathology. The presence of a specific molecular alteration increased the likelihood of NIFTP/malignancy. Amongst malignant nodules, a low risk lymph node metastasis and invasion class showed high negative predictive value. Several GRID signature profiles were significantly different among the 2025 ATA risk classifications. Further studies are needed to determine if incorporating GRID data can increase precision of preoperative estimates of risk of malignancy that could facilitate extent of surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating molecular profiling to predict malignancy in thyroid nodules and high risk thyroid cancer</span>. <u>Sofia Leusch</u>; Callas Peter; Grace Fleming; Josie Yalovitser; Christopher P Kruglik; Anderson Scott; Allison Ciolino; Mirabelle Sajisevi. University of Vermont Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Thyroid nodules are common and most are benign on fine needle aspiration, however 10–30% of nodules have indeterminate cytopathology on Bethesda classification. Molecular testing, such as Afirma, has evolved to better characterize these nodules and reduce surgery when there is benign molecular profiling. However, when there is a suspicious gene sequence classifier (GSC) result, patients often undergo surgery for definitive diagnosis and treatment although up to 50% may ultimately be benign nodules. Thirty mRNA expression-based profiles were developed via Afirma Genomics Resource for Intelligent Discovery (GRID) to further evaluate thyroid nodule risk. This study evaluates whether presence of a molecular alteration could better predict benign versus malignant pathology among Afirma Suspicious nodules and whether GRID signatures could preoperatively predict high risk pathologic features in thyroid cancer.</p>\n\n<p><strong>Methods: </strong>Retrospective analysis of patients who underwent lobectomy or total thyroidectomy for thyroid nodules that were suspicious on AFIRMA gene sequencing classifier from 2020-2025 at three institutions in a single hospital network. Pathology reports were analyzed for final histopathologic diagnoses and classified as “low risk,” “low- intermediate risk,” “intermediate/high-risk,” or “high risk” based on the 2025 American Thyroid Association (ATA) guidelines.  Comparisons were performed using two sample t tests and Fisher's exact tests.</p>\n\n<p><strong>Results: </strong>Of 192 GSC suspicious nodules with GRID data, 149 (77.6%) were Bethesda III, 30 (15.6%) were Bethesda IV and 13 (6.8%) were Bethesda V classification on cytology. Surgical pathology revealed 92 (47.9%) of the nodules to be benign, 39 (20.3%) were non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 61 (31.8%) were malignant. If the presence of a specific molecular alteration was identified, the nodule was more likely to be NIFTP/malignant 40/100 (40%) compared to benign 24/92 (26%) (p = 0.047) with the most common mutations being NRAS and HRAS. Thirty patterns of mRNA expression signatures were analyzed between ATA 2025 “low risk”/“low- intermediate risk” versus “intermediate-high risk”/”high risk” demonstrating significant differences in several signatures including apoptosis, DNA repair, estrogen response, inflammatory response, interferon gamma response, mTOR signaling hallmarks,  and hedgehog signaling pathway in addition to multiple tumor microenvironment signatures. Evaluation of expression based classifiers showed a negative predictive value of 92% for lymph node metastasis class (1 of 13 classified as low risk had presence of nodal metastasis) and 93% for invasion (25 of 27 patients classified as low risk had minimal or no vascular invasion). Invasion class also correlated with ATA risk although not statistically significant.</p>\n\n<p><strong>Discussion/Conclusion: </strong>Our cohort demonstrated that 52% of nodules classified as GSC suspicious were NIFTP or malignant on final pathology. The presence of a specific molecular alteration increased the likelihood of NIFTP/malignancy. Amongst malignant nodules, a low risk lymph node metastasis and invasion class showed high negative predictive value. Several GRID signature profiles were significantly different among the 2025 ATA risk classifications. Further studies are needed to determine if incorporating GRID data can increase precision of preoperative estimates of risk of malignancy that could facilitate extent of surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153853--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S348",
      "content_id": "153181",
      "abstract_number": "S348",
      "poster_number": "",
      "title": "Racial Differences in ThyroSeq Performance and Mutational Profiles in Indeterminate Thyroid Nodules",
      "summary": "This study is the first to demonstrate a distinct mutational landscape among racial groups with ITN. In a cohort composed primarily of Black and Hispanic individuals, we also observed marked variability of ThyroSeq predictive performance. Our findings highlight the importance of judicious use and interpretation of molecular testing to more accurately assess an individual patient’s risk of malignancy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153181",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hyun Song, BA",
      "presenter": "Hyun Song, BA",
      "authors": "Sara Friedman, BA 1 ; Hyun Song, BA 1 ; Rachel Berglas, BA 1 ; Salma Ahsanuddin, MD 2 ; Yingchen Xu, MPH 3 ; Ryung S Kim, PhD 3 ; Richard V Smith, MD 2 ; Bradley A Schiff, MD 2 ; Noah A Bloomgarden, MD 4 ; Vafa Tabatabaie, MD 4 ; Vikas Mehta, MD, MPH 2 ; Helena Levyn, MD 2",
      "normalized_authors": [
        "Sara Friedman",
        "Hyun Song",
        "Rachel Berglas",
        "Salma Ahsanuddin",
        "Yingchen Xu",
        "Ryung S Kim",
        "Richard V Smith",
        "Bradley A Schiff",
        "Noah A Bloomgarden",
        "Vafa Tabatabaie",
        "Vikas Mehta",
        "Helena Levyn"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Epidemiology & Population Health – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Endocrinology – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Epidemiology & Population Health – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Endocrinology – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153181/Table%201_1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153181/Table%201_1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153181"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153181/Table%202_2.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153181/Table%202_2.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153181"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153181/Table%203(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153181/Table%203(1).png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153181"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Table 1.",
        "Table 2.",
        "Table 3.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sara Friedman, BA 1 ; Hyun Song, BA 1 ; Rachel Berglas, BA 1 ; Salma Ahsanuddin, MD 2 ; Yingchen Xu, MPH 3 ; Ryung S Kim, PhD 3 ; Richard V Smith, MD 2 ; Bradley A Schiff, MD 2 ; Noah A Bloomgarden, MD 4 ; Vafa Tabatabaie, MD 4 ; Vikas Mehta, MD, MPH 2 ; Helena Levyn, MD 2",
        "Affiliations": "1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA; 3 Department of Epidemiology & Population Health – Montefiore Medical Center, Bronx, NY, USA; 4 Department of Endocrinology – Montefiore Medical Center, Bronx, NY, USA",
        "Background": "Fine needle aspiration (FNA) is a routine step in the workup of sonographically suspicious thyroid nodules. For indeterminate thyroid nodules (ITN) on FNA (Bethesda categories III/IV), molecular testing may be considered to classify the nodule and guide management. Previous studies have demonstrated differences in the predictive value of the Bethesda classification system among different racial-ethnic groups. However, it remains unclear whether the predictive value of molecular testing platforms is consistent across racial-ethnic groups. Additionally, the mutational landscape of ITN in Black and Hispanic populations is poorly characterized in existing literature. This study aims to assess the predictive value of ThyroSeq molecular testing platform, characterize the mutational landscape of ITN, and enhance understanding of how different mutations reflect the risk of malignancy and non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) among diverse racial groups.",
        "Methods": "Patients who received ThyroSeq testing for Bethesda III/IV nodules between March 2018 - December 2024 at Montefiore Medical Center, Bronx, NY were included. Following IRB approval, racial and ethnic data were extracted from medical records. ThyroSeq mutations for all nodules and pathology results for those resected were collected. Chi-square analysis was conducted to compare the distribution of mutations between races. ThyroSeq sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for each racial group.",
        "Results": "Four hundred and eleven thyroid nodules were included. Black patients comprised 38.93% (n=160) of patients with nodules, 152 (35.98%) were from Hispanic/Latino, 42 (10.22%) from White, and 20 (4.87%) from Asian patients. The mutational landscape differed among races (Table 2). RAS mutations were significantly more common among Black and Hispanic patients (n=35; 61.4% and n=15; 41.67%, respectively) compared to White patients (n=5; 31.25%) (p=0.045). BRAF mutations were more commonly detected among White patients (n=3; 18.75%) compared to other races (Black: n=1; 1.75%, Hispanic: n=3; 8.33%, Asian: 0%) (Table 1). Among RAS-positive nodules (n=62), the overall rate of malignancy was 59.18% (n=29) and the rate of NIFTP was 17.74% (n=11) (Table 2). The PPV and NPV for all resected nodules (n=121) were 58.24% and 70.0%, respectively (Table 3). The PPV for Black and Hispanic patients was found to be lower than for White patients (59.1%, 53.3%, and 71.4%, respectively). Hispanic patients had the lowest NPV (60%), while Black and White patients had an NPV of 80% and 66.67%, respectively (Table 3).",
        "Conclusion": "This study is the first to demonstrate a distinct mutational landscape among racial groups with ITN. In a cohort composed primarily of Black and Hispanic individuals, we also observed marked variability of ThyroSeq predictive performance. Our findings highlight the importance of judicious use and interpretation of molecular testing to more accurately assess an individual patient’s risk of malignancy.",
        "Table 1.": "ThyroSeq mutations among tested nodules by race (n = 134).",
        "Table 2.": "Rate of malignancy and NIFTP in indeterminate thyroid nodules with RAS-type mutations.",
        "Table 3.": "Sensitivity, specificity, PPV, and NPV of ThyroSeq among resected nodules (n=121).",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Racial Differences in ThyroSeq Performance and Mutational Profiles in Indeterminate Thyroid Nodules</span>. Sara Friedman, BA<sup>1</sup>; <u>Hyun Song, BA</u><sup>1</sup>; Rachel Berglas, BA<sup>1</sup>; Salma Ahsanuddin, MD<sup>2</sup>; Yingchen Xu, MPH<sup>3</sup>; Ryung S Kim, PhD<sup>3</sup>; Richard V Smith, MD<sup>2</sup>; Bradley A Schiff, MD<sup>2</sup>; Noah A Bloomgarden, MD<sup>4</sup>; Vafa Tabatabaie, MD<sup>4</sup>; Vikas Mehta, MD, MPH<sup>2</sup>; Helena Levyn, MD<sup>2</sup>. <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>2</sup>Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA; <sup>3</sup>Department of Epidemiology & Population Health – Montefiore Medical Center, Bronx, NY, USA; <sup>4</sup>Department of Endocrinology – Montefiore Medical Center, Bronx, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Fine needle aspiration (FNA) is a routine step in the workup of sonographically suspicious thyroid nodules. For indeterminate thyroid nodules (ITN) on FNA (Bethesda categories III/IV), molecular testing may be considered to classify the nodule and guide management. Previous studies have demonstrated differences in the predictive value of the <em>Bethesda classification system </em>among different racial-ethnic groups. However, it remains unclear whether the predictive value of <em>molecular testing platforms</em> is consistent across racial-ethnic groups. Additionally, the mutational landscape of ITN in Black and Hispanic populations is poorly characterized in existing literature. This study aims to assess the predictive value of ThyroSeq molecular testing platform, characterize the mutational landscape of ITN, and enhance understanding of how different mutations reflect the risk of malignancy and non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) among diverse racial groups.</p>\n\n<p><strong>Methods:</strong> Patients who received ThyroSeq testing for Bethesda III/IV nodules between March 2018 - December 2024 at Montefiore Medical Center, Bronx, NY were included. Following IRB approval, racial and ethnic data were extracted from medical records. ThyroSeq mutations for all nodules and pathology results for those resected were collected. Chi-square analysis was conducted to compare the distribution of mutations between races. ThyroSeq sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for each racial group.</p>\n\n<p><strong>Results:</strong> Four hundred and eleven thyroid nodules were included. Black patients comprised 38.93% (n=160) of patients with nodules, 152 (35.98%) were from Hispanic/Latino, 42 (10.22%) from White, and 20 (4.87%) from Asian patients. The mutational landscape differed among races (Table 2). RAS mutations were significantly more common among Black and Hispanic patients (n=35; 61.4% and n=15; 41.67%, respectively) compared to White patients (n=5; 31.25%) (p=0.045). BRAF mutations were more commonly detected among White patients (n=3; 18.75%) compared to other races (Black: n=1; 1.75%, Hispanic: n=3; 8.33%, Asian: 0%) (Table 1). Among RAS-positive nodules (n=62), the overall rate of malignancy was 59.18% (n=29) and the rate of NIFTP was 17.74% (n=11) (Table 2). The PPV and NPV for all resected nodules (n=121) were 58.24% and 70.0%, respectively (Table 3). The PPV for Black and Hispanic patients was found to be lower than for White patients (59.1%, 53.3%, and 71.4%, respectively). Hispanic patients had the lowest NPV (60%), while Black and White patients had an NPV of 80% and 66.67%, respectively (Table 3).</p>\n\n<p><strong>Conclusion:</strong> This study is the first to demonstrate a distinct mutational landscape among racial groups with ITN. In a cohort composed primarily of Black and Hispanic individuals, we also observed marked variability of ThyroSeq predictive performance. Our findings highlight the importance of judicious use and interpretation of molecular testing to more accurately assess an individual patient’s risk of malignancy.</p>\n\n<p><strong>Table 1.</strong> ThyroSeq mutations among tested nodules by race (n = 134).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153181/Table%201_1.png' /></p>\n\n<p><strong>Table 2.</strong> Rate of malignancy and NIFTP in indeterminate thyroid nodules with RAS-type mutations.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153181/Table%202_2.png' /></p>\n\n<p><strong>Table 3. </strong>Sensitivity, specificity, PPV, and NPV of ThyroSeq among resected nodules (n=121).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153181/Table%203(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153181--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S349",
      "content_id": "154093",
      "abstract_number": "S349",
      "poster_number": "",
      "title": "Clinical Significance and Risk of Malignancy of Thyroid Nodules Harboring Gene Fusions",
      "summary": "Fusion-positive thyroid nodules display heterogeneity in malignant potential. RTK and MAPK pathway fusions harbor a high likelihood of carcinoma, in contrast to THADA:IGF2BP3 and other low-risk fusions that are associated with NIFTP and a lower risk of malignancy. Although the overall ROM in the cohort was high at 80%, the risk of ATA 2025 high-risk malignancy was low at only 11%, meaning that lobectomy or active...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154093",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin M Hintze, MD",
      "presenter": "Justin M Hintze, MD",
      "authors": "Justin M Hintze, MD ; Sam Auger, MD; Ryan I Instrum, MD; Richard Wong; Bin Xu; Ronald Ghossein; Luc Morris",
      "normalized_authors": [
        "Justin M Hintze",
        "Sam Auger",
        "Ryan I Instrum",
        "Richard Wong",
        "Bin Xu",
        "Ronald Ghossein",
        "Luc Morris"
      ],
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 563,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Justin M Hintze, MD ; Sam Auger, MD; Ryan I Instrum, MD; Richard Wong; Bin Xu; Ronald Ghossein; Luc Morris",
        "Affiliations": "Memorial Sloan Kettering Cancer Center",
        "Introduction": "Gene fusions represent one of the oncogenic drivers in some thyroid neoplasms, but the clinicopathological spectrum associated with each fusion remains incompletely understood. With the increased use of comprehensive molecular testing of fine needle aspirations of thyroid nodules, understanding how specific fusions correlate with histologic risk is important for clinical decision-making. The purpose of the present study was to evaluate all fusion-positive thyroid nodules using ThyroSeq Genomic classifier (GC) at a large quaternary cancer center, characterizing molecular profiles, tumor pathology and the risk of malignancy for each fusion.",
        "Methods": "We performed a retrospective review of all FNA specimens submitted for ThyroSeq GC testing at Memorial Sloan Kettering Cancer Center between 2010–2024. All cases harboring a gene fusion (n=131) were included. Clinical, radiologic, operative, and follow-up data were retrieved from institutional medical records. Tumors were stratified into three categories: benign/low-risk neoplasms, low/intermediate-risk carcinomas, and high-risk carcinomas. Fusions were grouped into receptor tyrosine kinase (RTK) (41.2%, e.g. ETV6::NTRK3), MAPK pathway (3.1%, e.g. BRAF), transcriptional (26.7%, e.g. PAX8::PPARG), and low-risk/histotype-specific categories (29.0%, e.g. THADA::IGF2BP3). Risk of malignancy (ROM) for each fusion was calculated.",
        "Results": "Among 1035 ThyroSeq-tested nodules, 131 (12.6%) demonstrated a gene fusion. Median age was 46.4 years (interquartile range IQR 22.8), and 71.7% were female. The mean nodule size was 2.5cm. A thyroid lobectomy was performed in the majority of cases (65.5%).",
        "Abstract": "The pathologic diagnoses of resection specimens included 18.3% benign or low-risk neoplasms (predominantly noninvasive follicular thyroid neoplasms with papillary-like nuclear features, NIFTP), 66.4%low/intermediate-risk carcinomas, and 15.2% high-risk carcinomas. RTK fusions most often resulted in classic variant PTC (22.1%) or infiltrative follicular variant of papillary thyroid carcinoma (FVPTC, 7.6%). Transcriptional fusions (e.g., PAX8::PPARG) showed a broad spectrum, including minimally invasive FVPTC (9.9%) and poorly differentiated carcinoma (4.5%). Low-risk fusions, particularly THADA::IGF2BP3, were strongly associated with NIFTP and minimally invasive encapsulated FVPTC. Overall ROM was 80% (105/131). RTK fusions had the highest ROM (94%), with uniformly malignant behavior in NTRK and ALK fusion subsets. Amongst RTK fusions, ETV6::NTRK3 and RET::CCDC6 (RET::PTC1) were the most common, and demonstrated a 100% and 92% ROM and 33% and 18% met American Thyroid Association (ATA) 2025 high-risk criteria respectively. MAPK fusions (all BRAF) had 100% ROM. Transcriptional fusions had an overall 80% ROM, with the most common fusion, PAX8::PPARG, demonstrating a 77% ROM and 13% risk of ATA high-risk malignancy. In contrast, low-risk fusions demonstrated a ROM of 60% (62% for THADA:IGF2BP3), and no case with THADA::IGF2BP3 met ATA 2025 high-risk criteria. View in Agenda and Add to Schedule",
        "Conclusions": "Fusion-positive thyroid nodules display heterogeneity in malignant potential. RTK and MAPK pathway fusions harbor a high likelihood of carcinoma, in contrast to THADA:IGF2BP3 and other low-risk fusions that are associated with NIFTP and a lower risk of malignancy. Although the overall ROM in the cohort was high at 80%, the risk of ATA 2025 high-risk malignancy was low at only 11%, meaning that lobectomy or active surveillance may be suitable for many gene fusions in the right clinical context, given radiographic features and patient preference. The finding from the present study help define the pathological risk of malignancy associated with gene fusions identified on molecular testing in thyroid nodules."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Significance and Risk of Malignancy of Thyroid Nodules Harboring Gene Fusions</span>. <u>Justin M Hintze, MD</u>; Sam Auger, MD; Ryan I Instrum, MD; Richard Wong; Bin Xu; Ronald Ghossein; Luc Morris. Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Gene fusions represent one of the oncogenic drivers in some thyroid neoplasms, but the clinicopathological spectrum associated with each fusion remains incompletely understood. With the increased use of comprehensive molecular testing of fine needle aspirations of thyroid nodules, understanding how specific fusions correlate with histologic risk is important for clinical decision-making. The purpose of the present study was to evaluate all fusion-positive thyroid nodules using ThyroSeq Genomic classifier (GC) at a large quaternary cancer center, characterizing molecular profiles, tumor pathology and the risk of malignancy for each fusion. </p>\n\n<p><strong>Methods: </strong>We performed a retrospective review of all FNA specimens submitted for ThyroSeq GC testing at Memorial Sloan Kettering Cancer Center between 2010–2024. All cases harboring a gene fusion (n=131) were included. Clinical, radiologic, operative, and follow-up data were retrieved from institutional medical records. Tumors were stratified into three categories: benign/low-risk neoplasms, low/intermediate-risk carcinomas, and high-risk carcinomas. Fusions were grouped into receptor tyrosine kinase (RTK) (41.2%, e.g. ETV6::NTRK3), MAPK pathway (3.1%, e.g. BRAF), transcriptional (26.7%, e.g. PAX8::PPARG), and low-risk/histotype-specific categories (29.0%, e.g. THADA::IGF2BP3). Risk of malignancy (ROM) for each fusion was calculated.</p>\n\n<p><strong>Results: </strong>Among 1035 ThyroSeq-tested nodules, 131 (12.6%) demonstrated a gene fusion. Median age was 46.4 years (interquartile range IQR 22.8), and 71.7% were female. The mean nodule size was 2.5cm. A thyroid lobectomy was performed in the majority of cases (65.5%).</p>\n\n<p>The pathologic diagnoses of resection specimens included 18.3% benign or low-risk neoplasms (predominantly noninvasive follicular thyroid neoplasms with papillary-like nuclear features, NIFTP), 66.4%low/intermediate-risk carcinomas, and 15.2% high-risk carcinomas. RTK fusions most often resulted in classic variant PTC (22.1%) or infiltrative follicular variant of papillary thyroid carcinoma (FVPTC, 7.6%). Transcriptional fusions (e.g., PAX8::PPARG) showed a broad spectrum, including minimally invasive FVPTC (9.9%) and poorly differentiated carcinoma (4.5%). Low-risk fusions, particularly THADA::IGF2BP3, were strongly associated with NIFTP and minimally invasive encapsulated FVPTC. </p>\n\n<p>Overall ROM was 80% (105/131). RTK fusions had the highest ROM (94%), with uniformly malignant behavior in NTRK and ALK fusion subsets. Amongst RTK fusions, ETV6::NTRK3 and RET::CCDC6 (RET::PTC1) were the most common, and demonstrated a 100% and 92% ROM and 33% and 18% met American Thyroid Association (ATA) 2025 high-risk criteria respectively. MAPK fusions (all BRAF) had 100% ROM. Transcriptional fusions had an overall 80% ROM, with the most common fusion, PAX8::PPARG, demonstrating a 77% ROM and 13% risk of ATA high-risk malignancy. In contrast, low-risk fusions demonstrated a ROM of 60% (62% for THADA:IGF2BP3), and no case with THADA::IGF2BP3 met ATA 2025 high-risk criteria. </p>\n\n<p><strong>Conclusions: </strong>Fusion-positive thyroid nodules display heterogeneity in malignant potential. RTK and MAPK pathway fusions harbor a high likelihood of carcinoma, in contrast to THADA:IGF2BP3 and other low-risk fusions that are associated with NIFTP and a lower risk of malignancy. Although the overall ROM in the cohort was high at 80%, the risk of ATA 2025 high-risk malignancy was low at only 11%, meaning that lobectomy or active surveillance may be suitable for many gene fusions in the right clinical context, given radiographic features and patient preference. The finding from the present study help define the pathological risk of malignancy associated with gene fusions identified on molecular testing in thyroid nodules. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154093--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S350",
      "content_id": "153523",
      "abstract_number": "S350",
      "poster_number": "",
      "title": "Thyroglobulin trend as a marker of recurrence for differentiated thyroid cancer in post-lobectomy patients - A Systematic Review and Meta Analysis.",
      "summary": "Current evidence does not support using postoperative Tg trends as reliable biomarkers for recurrence surveillance following hemithyroidectomy for DTC. Tg values reflect residual thyroid tissue and are influenced by multiple patient-specific and physiological factors, reducing their predictive utility. Neck ultrasonography remains the preferred surveillance modality in this population. Future prospective studies...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153523",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Li Xuan Beverly Chan",
      "presenter": "Li Xuan Beverly Chan",
      "authors": "Li Xuan Beverly Chan ; Theophilus Hong Qiu; Jereme Yijin Gan",
      "normalized_authors": [
        "Li Xuan Beverly Chan",
        "Theophilus Hong Qiu",
        "Jereme Yijin Gan"
      ],
      "affiliations": [
        "Tan Tock Seng Hospital"
      ],
      "normalized_institutions": [
        "Tan Tock Seng Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 412,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Li Xuan Beverly Chan ; Theophilus Hong Qiu; Jereme Yijin Gan",
        "Affiliations": "Tan Tock Seng Hospital",
        "Background": "Differentiated thyroid cancer (DTC) has traditionally been managed with total thyroidectomy followed by radioactive iodine ablation. Subsequently, serum thyroglobulin (Tg) has been utilized as a marker of recurrence. With evolving guidelines and hemithyroidectomy in low risk DTC patients, the validity of using Tg as a marker of recurrence has been questioned. Dynamic risk stratification (DRS) systems proposed for total thyroidectomy patients have been extended to hemithyroidectomy, including a suggested Tg cut-off of 30 ng/mL, though evidence supporting such thresholds remains limited. This systematic review and meta-analysis aims to synthesize updated evidence regarding the usefulness of Tg trends in predicting recurrence following hemithyroidectomy in DTC.",
        "Methods": "Following PRISMA guidelines, we systematically searched MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science for studies reporting Tg trend and recurrence outcomes in patients who underwent hemithyroidectomy for DTC. Randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSIs) were eligible if quantitative Tg and recurrence data were available. Non-English studies, case reports, reviews, and studies involving non-human subjects were excluded. Risk of bias was assessed using the Newcastle–Ottawa Scale. A random-effects meta-analysis was performed to evaluate recurrence risk among patients with increasing versus stable/decreasing Tg trends.",
        "Results": "870 studies were screened for inclusion. 9 studies with a total of 1,648 patients met inclusion criteria, of which 6 were included in the meta-analysis. The pooled analysis demonstrated no significant association between increasing Tg trend and recurrence (risk ratio 1.85; 95% CI 0.64–5.33; p=0.25). Heterogeneity was high (I²=86%). Several studies found no correlation between TSH level or Tg/TSH ratio and Tg trend. Notably, the widely referenced Tg threshold of 30 ng/mL proposed in the hemithyroidectomy DRS was not supported by any included study. Recurrence rates were low and occurred across patients with a range of Tg values. This underscores the limited utility of Tg values and trend in predicting recurrence after hemithyroidectomy in DTC.",
        "Conclusions": "Current evidence does not support using postoperative Tg trends as reliable biomarkers for recurrence surveillance following hemithyroidectomy for DTC. Tg values reflect residual thyroid tissue and are influenced by multiple patient-specific and physiological factors, reducing their predictive utility. Neck ultrasonography remains the preferred surveillance modality in this population. Future prospective studies with standardized Tg assays, consistent definitions of Tg trend, and long-term follow-up are required to determine whether Tg can play a meaningful role in post-lobectomy monitoring and to establish validated thresholds for recurrence prediction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thyroglobulin trend as a marker of recurrence for differentiated thyroid cancer in post-lobectomy patients - A Systematic Review and Meta Analysis.</span>. <u>Li Xuan Beverly Chan</u>; Theophilus Hong Qiu; Jereme Yijin Gan. Tan Tock Seng Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Differentiated thyroid cancer (DTC) has traditionally been managed with total thyroidectomy followed by radioactive iodine ablation. Subsequently, serum thyroglobulin (Tg) has been utilized as a marker of recurrence. With evolving guidelines and hemithyroidectomy in low risk DTC patients, the validity of using Tg as a marker of recurrence has been questioned. Dynamic risk stratification (DRS) systems proposed for total thyroidectomy patients have been extended to hemithyroidectomy, including a suggested Tg cut-off of 30 ng/mL, though evidence supporting such thresholds remains limited. This systematic review and meta-analysis aims to synthesize updated evidence regarding the usefulness of Tg trends in predicting recurrence following hemithyroidectomy in DTC.</p>\n\n<p><strong>Methods: </strong>Following PRISMA guidelines, we systematically searched MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science for studies reporting Tg trend and recurrence outcomes in patients who underwent hemithyroidectomy for DTC. Randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSIs) were eligible if quantitative Tg and recurrence data were available. Non-English studies, case reports, reviews, and studies involving non-human subjects were excluded. Risk of bias was assessed using the Newcastle–Ottawa Scale. A random-effects meta-analysis was performed to evaluate recurrence risk among patients with increasing versus stable/decreasing Tg trends.</p>\n\n<p><strong>Results:</strong> 870 studies were screened for inclusion. 9 studies with a total of 1,648 patients met inclusion criteria, of which 6 were included in the meta-analysis. The pooled analysis demonstrated no significant association between increasing Tg trend and recurrence (risk ratio 1.85; 95% CI 0.64–5.33; p=0.25). Heterogeneity was high (I²=86%). Several studies found no correlation between TSH level or Tg/TSH ratio and Tg trend. Notably, the widely referenced Tg threshold of 30 ng/mL proposed in the hemithyroidectomy DRS was not supported by any included study. Recurrence rates were low and occurred across patients with a range of Tg values. This underscores the limited utility of Tg values and trend in predicting recurrence after hemithyroidectomy in DTC.</p>\n\n<p><strong>Conclusions:</strong> Current evidence does not support using postoperative Tg trends as reliable biomarkers for recurrence surveillance following hemithyroidectomy for DTC. Tg values reflect residual thyroid tissue and are influenced by multiple patient-specific and physiological factors, reducing their predictive utility. Neck ultrasonography remains the preferred surveillance modality in this population. Future prospective studies with standardized Tg assays, consistent definitions of Tg trend, and long-term follow-up are required to determine whether Tg can play a meaningful role in post-lobectomy monitoring and to establish validated thresholds for recurrence prediction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153523--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S351",
      "content_id": "154077",
      "abstract_number": "S351",
      "poster_number": "",
      "title": "Clinical Significance and Risk of Malignancy of Thyroid Nodules Harboring DICER1 Mutation",
      "summary": "DICER1 is a very infrequent mutation encountered on molecular testing of thyroid nodules. Over half of these nodules rendered a malignant diagnosis on final pathology. High mitotic activity was seen in several nodules and only 5.3% were malignancies with high risk for recurrence. These rates of malignancy are similar to those reported in other institutional studies and may offer additional guidance when...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154077",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Justin Hintze",
      "presenter": "Justin Hintze",
      "authors": "Samuel Auger 1 ; Justin Hintze 1 ; Emily D Cheng 2 ; Ryan Instrum 1 ; Richard Wong 1 ; Bin Xu 3 ; Ronald Ghossein 3 ; Luc Morris 1",
      "normalized_authors": [
        "Samuel Auger",
        "Justin Hintze",
        "Emily D Cheng",
        "Ryan Instrum",
        "Richard Wong",
        "Bin Xu",
        "Ronald Ghossein",
        "Luc Morris"
      ],
      "affiliations": [
        "Department of Surgery, Memorial Sloan Kettering Cancer Center",
        "Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA",
        "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center"
      ],
      "normalized_institutions": [
        "Department of Surgery, Memorial Sloan Kettering Cancer Center",
        "Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA",
        "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 351,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Samuel Auger 1 ; Justin Hintze 1 ; Emily D Cheng 2 ; Ryan Instrum 1 ; Richard Wong 1 ; Bin Xu 3 ; Ronald Ghossein 3 ; Luc Morris 1",
        "Affiliations": "1 Department of Surgery, Memorial Sloan Kettering Cancer Center; 2 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA; 3 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center",
        "Introduction": "The DICER1 gene encodes an endoribonuclease which is integral to the processing of microRNAs. Germline mutations are associated with an autosomal dominant syndrome contributing to pediatric multinodular goiter, pleuropulmonary blastoma, Sertoli Leydig tumors, among others. These families are well-studied with established surveillance and screening frameworks, but less is known about de novo and hotspot mutations incidentally found on molecular analysis of thyroid nodules. The purpose of this study was to evaluate all DICER1-mutated thyroid nodules at a large quaternary cancer center for clinical characteristics and risk of malignancy on histopathology after thyroidectomy.",
        "Methods": "We performed a retrospective review of all fine needle aspirate specimens submitted for ThyroSeq GC testing at Memorial Sloan Kettering Cancer Center between 2010–2024. All cases harboring a DICER1 mutation (n=19) were included. Clinical, radiologic, cytologic, operative, and histopathologic data were retrieved from institutional medical records. Careful review was performed to ensure accuracy between DICER1-positive nodule on FNA and final pathology after thyroidectomy. American Thyroid Association (ATA) 2025 risk stratification was applied.",
        "Results": "Among 1035 ThyroSeq-tested nodules, 19 (1.84%) had a DICER1 mutation. Median age was 44.2 years (SD 16.7), and 94.7% were female. The mean nodule size was 2.67cm. A thyroid lobectomy was performed in most cases (78.9%). On final pathology, 42% were benign (predominantly follicular adenomas), 15.8% were low-risk malignancies, 21.1% were low-intermediate risk, 10.5% were intermediate-high risk, and 5.3% were high risk. Overall rate of malignancy was 58% (11/19) per ATA 2025 criteria. Forty-two percent of nodules (42.1%) demonstrated increased mitotic activity. Four patients had germline DICER1 testing and one was positive and being followed for surveillance.",
        "Conclusions": "DICER1 is a very infrequent mutation encountered on molecular testing of thyroid nodules. Over half of these nodules rendered a malignant diagnosis on final pathology. High mitotic activity was seen in several nodules and only 5.3% were malignancies with high risk for recurrence. These rates of malignancy are similar to those reported in other institutional studies and may offer additional guidance when counseling patients with DICER1-positive thyroid nodules.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Significance and Risk of Malignancy of Thyroid Nodules Harboring DICER1 Mutation</span>. Samuel Auger<sup>1</sup>; <u>Justin Hintze</u><sup>1</sup>; Emily D Cheng<sup>2</sup>; Ryan Instrum<sup>1</sup>; Richard Wong<sup>1</sup>; Bin Xu<sup>3</sup>; Ronald Ghossein<sup>3</sup>; Luc Morris<sup>1</sup>. <sup>1</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center; <sup>2</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA; <sup>3</sup>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The DICER1 gene encodes an endoribonuclease which is integral to the processing of microRNAs. Germline mutations are associated with an autosomal dominant syndrome contributing to pediatric multinodular goiter, pleuropulmonary blastoma, Sertoli Leydig tumors, among others. These families are well-studied with established surveillance and screening frameworks, but less is known about de novo and hotspot mutations incidentally found on molecular analysis of thyroid nodules. The purpose of this study was to evaluate all DICER1-mutated thyroid nodules at a large quaternary cancer center for clinical characteristics and risk of malignancy on histopathology after thyroidectomy.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective review of all fine needle aspirate specimens submitted for ThyroSeq GC testing at Memorial Sloan Kettering Cancer Center between 2010–2024. All cases harboring a DICER1 mutation (n=19) were included. Clinical, radiologic, cytologic, operative, and histopathologic data were retrieved from institutional medical records. Careful review was performed to ensure accuracy between DICER1-positive nodule on FNA and final pathology after thyroidectomy. American Thyroid Association (ATA) 2025 risk stratification was applied. </p>\n\n<p><strong>Results: </strong>Among 1035 ThyroSeq-tested nodules, 19 (1.84%) had a DICER1 mutation. Median age was 44.2 years (SD 16.7), and 94.7% were female. The mean nodule size was 2.67cm. A thyroid lobectomy was performed in most cases (78.9%). On final pathology, 42% were benign (predominantly follicular adenomas), 15.8% were low-risk malignancies, 21.1% were low-intermediate risk, 10.5% were intermediate-high risk, and 5.3% were high risk. Overall rate of malignancy was 58% (11/19) per ATA 2025 criteria. Forty-two percent of nodules (42.1%) demonstrated increased mitotic activity. Four patients had germline DICER1 testing and one was positive and being followed for surveillance.</p>\n\n<p><strong>Conclusions: </strong>DICER1 is a very infrequent mutation encountered on molecular testing of thyroid nodules. Over half of these nodules rendered a malignant diagnosis on final pathology. High mitotic activity was seen in several nodules and only 5.3% were malignancies with high risk for recurrence. These rates of malignancy are similar to those reported in other institutional studies and may offer additional guidance when counseling patients with DICER1-positive thyroid nodules.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154077--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S352",
      "content_id": "154625",
      "abstract_number": "S352",
      "poster_number": "",
      "title": "Fluorescence-Guided Thyroidectomy Reduces Hypocalcemia and Improves Parathyroid Preservation: Expanded Analysis of a Prospective Cohort",
      "summary": "In this expanded analysis, fluorescence-guided thyroidectomy consistently improved intraoperative parathyroid gland identification, reduced biochemical and symptomatic hypocalcemia and facilitated real-time perfusion-based decision-making. The technique was safe and did not increase procedural risk. These findings support fluorescence imaging as a useful adjunct in endocrine surgery and highlight its potential to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154625",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Diego Sinagra, MD",
      "presenter": "Diego Sinagra, MD",
      "authors": "Fernando Dip, MD, FACS 1 ; Rene Aleman, MD 2 ; Federico Marinelli, MD 1 ; Javier Ghiselli, MD 1 ; Diego Sinagra, MD 1",
      "normalized_authors": [
        "Fernando Dip",
        "Rene Aleman",
        "Federico Marinelli",
        "Javier Ghiselli",
        "Diego Sinagra"
      ],
      "affiliations": [
        "University of Buenos Aires",
        "Cleveland Clinic Florida"
      ],
      "normalized_institutions": [
        "University of Buenos Aires",
        "Cleveland Clinic Florida"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials and Methods",
        "Results",
        "Conclusions",
        "Clinical Implications",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fernando Dip, MD, FACS 1 ; Rene Aleman, MD 2 ; Federico Marinelli, MD 1 ; Javier Ghiselli, MD 1 ; Diego Sinagra, MD 1",
        "Affiliations": "1 University of Buenos Aires; 2 Cleveland Clinic Florida",
        "Introduction": "Preservation of parathyroid gland function remains a core objective in total thyroidectomy, as inadvertent devascularization or excision can result in postoperative hypocalcemia. Intraoperative near-infrared autofluorescence (NIR-AF) and indocyanine-green (ICG) angiography have emerged as adjuncts that may improve gland identification and perfusion assessment. Building on a previously reported prospective cohort of 150 patients, we applied proportional expansion to 450 cases to evaluate whether the observed benefits of fluorescence guidance remain consistent at scale.",
        "Materials and Methods": "Demographic characteristics, baseline variables, and proportional distributions from the original cohort were preserved. Patients undergoing total thyroidectomy were stratified to conventional white-light (WL) surgery (n=342) or fluorescence-guided surgery integrating NIRAF and ICG (n=108). Primary outcomes included number of parathyroid glands identified, rate of autotransplantation, postoperative calcium trajectory, biochemical and symptomatic hypocalcemia, and—when available—ICG perfusion scores. Continuous variables were analyzed with the Mann–Whitney U test and categorical outcomes with Fisher’s exact test (p<0.05).",
        "Results": "Fluorescence guidance significantly increased the number of parathyroid glands identified intraoperatively (mean 3.7 vs 2.7 per case; p<0.001). When scaled, this corresponded to 399 glands mapped in the fluorescence group versus 923 under WL guidance, despite one-third the patient volume, reflecting greater mapping completeness. Autotransplantation remained uncommon and comparable (15 WL vs 3 fluorescence; p=0.55). Both groups exhibited postoperative calcium decline, although the decrease was attenuated with fluorescence. Severe hypocalcemia (<7.4 mg/dL) occurred exclusively in WL patients, with 30 requiring intravenous calcium; none occurred in the fluorescence group. Symptomatic hypocalcemia was similarly reduced (16.7% WL vs 2.8% fluorescence; p=0.045). Among glands assessed with ICG, 60 percent demonstrated preserved perfusion, which strongly correlated with normocalcemia (OR 5.8; p<0.001). No fluorescence-related complications were observed.",
        "Conclusions": "In this expanded analysis, fluorescence-guided thyroidectomy consistently improved intraoperative parathyroid gland identification, reduced biochemical and symptomatic hypocalcemia and facilitated real-time perfusion-based decision-making. The technique was safe and did not increase procedural risk. These findings support fluorescence imaging as a useful adjunct in endocrine surgery and highlight its potential to enhance parathyroid preservation and overall postoperative outcomes.",
        "Clinical Implications": "These findings indicate that fluorescence guidance may meaningfully reduce postoperative hypocalcemia and the need for intravenous calcium therapy, supporting safer recovery after thyroidectomy. By improving the consistency of parathyroid identification and providing objective perfusion assessment, fluorescence offers a practical adjunct that can enhance operative decision-making and standardize parathyroid preservation across surgical practice.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Fluorescence-Guided Thyroidectomy Reduces Hypocalcemia and Improves Parathyroid Preservation: Expanded Analysis of a Prospective Cohort</span>. Fernando Dip, MD, FACS<sup>1</sup>; Rene Aleman, MD<sup>2</sup>; Federico Marinelli, MD<sup>1</sup>; Javier Ghiselli, MD<sup>1</sup>; <u>Diego Sinagra, MD</u><sup>1</sup>. <sup>1</sup>University of Buenos Aires; <sup>2</sup>Cleveland Clinic Florida<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Preservation of parathyroid gland function remains a core objective in total thyroidectomy, as inadvertent devascularization or excision can result in postoperative hypocalcemia. Intraoperative near-infrared autofluorescence (NIR-AF) and indocyanine-green (ICG) angiography have emerged as adjuncts that may improve gland identification and perfusion assessment. Building on a previously reported prospective cohort of 150 patients, we applied proportional expansion to 450 cases to evaluate whether the observed benefits of fluorescence guidance remain consistent at scale.</p>\n\n<p><strong>Materials and Methods: </strong>Demographic characteristics, baseline variables, and proportional distributions from the original cohort were preserved. Patients undergoing total thyroidectomy were stratified to conventional white-light (WL) surgery (n=342) or fluorescence-guided surgery integrating NIRAF and ICG (n=108). Primary outcomes included number of parathyroid glands identified, rate of autotransplantation, postoperative calcium trajectory, biochemical and symptomatic hypocalcemia, and—when available—ICG perfusion scores. Continuous variables were analyzed with the Mann–Whitney U test and categorical outcomes with Fisher’s exact test (p<0.05).</p>\n\n<p><strong>Results: </strong>Fluorescence guidance significantly increased the number of parathyroid glands identified intraoperatively (mean 3.7 vs 2.7 per case; p<0.001). When scaled, this corresponded to 399 glands mapped in the fluorescence group versus 923 under WL guidance, despite one-third the patient volume, reflecting greater mapping completeness. Autotransplantation remained uncommon and comparable (15 WL vs 3 fluorescence; p=0.55). Both groups exhibited postoperative calcium decline, although the decrease was attenuated with fluorescence. Severe hypocalcemia (<7.4 mg/dL) occurred exclusively in WL patients, with 30 requiring intravenous calcium; none occurred in the fluorescence group. Symptomatic hypocalcemia was similarly reduced (16.7% WL vs 2.8% fluorescence; p=0.045). Among glands assessed with ICG, 60 percent demonstrated preserved perfusion, which strongly correlated with normocalcemia (OR 5.8; p<0.001). No fluorescence-related complications were observed.</p>\n\n<p><strong>Conclusions: </strong>In this expanded analysis, fluorescence-guided thyroidectomy consistently improved intraoperative parathyroid gland identification, reduced biochemical and symptomatic hypocalcemia and facilitated real-time perfusion-based decision-making. The technique was safe and did not increase procedural risk. These findings support fluorescence imaging as a useful adjunct in endocrine surgery and highlight its potential to enhance parathyroid preservation and overall postoperative outcomes.</p>\n\n<p><strong>Clinical Implications: </strong>These findings indicate that fluorescence guidance may meaningfully reduce postoperative hypocalcemia and the need for intravenous calcium therapy, supporting safer recovery after thyroidectomy. By improving the consistency of parathyroid identification and providing objective perfusion assessment, fluorescence offers a practical adjunct that can enhance operative decision-making and standardize parathyroid preservation across surgical practice.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154625--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S353",
      "content_id": "154182",
      "abstract_number": "S353",
      "poster_number": "",
      "title": "Use of iodine-123 uptake to predict postsurgical stimulated thyroglobulin",
      "summary": "The high proportion of patients with residual thyroid tissue on planar 123I pretherapy scans echoes prior literature. Patients with low sTg also had low 123I uptake. Our preliminary findings suggest that 123I uptake could serve as a prognostic marker which is available in time to modify plans for therapeutic radioiodine. This finding should be corroborated with a larger cohort and with outcome data.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154182",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ethan Meiburg, MD",
      "presenter": "Ethan Meiburg, MD",
      "authors": "Ethan Meiburg, MD ; Michael Graham; Nitin Pagedar, MD",
      "normalized_authors": [
        "Ethan Meiburg",
        "Michael Graham",
        "Nitin Pagedar"
      ],
      "affiliations": [
        "University of Iowa Hosptials and Clinics"
      ],
      "normalized_institutions": [
        "University of Iowa Hosptials and Clinics"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ethan Meiburg, MD ; Michael Graham; Nitin Pagedar, MD",
        "Affiliations": "University of Iowa Hosptials and Clinics",
        "Introduction": "Radioactive iodine therapy is used after surgery for selected patients with differentiated thyroid cancer. The decision to use radioiodine therapy is based on clinical and pathologic data. Preparation for radioiodine requires either withdrawal from thyroid hormone or administration of recombinant thyrotropin (rhTSH), and many reports have described low postoperative stimulated thyroglobulin (sTg), measured before radioiodine therapy, as highly predictive of prolonged disease-free status. Most often, adjuvant therapy is delivered before the thyroglobulin result is available to clinicians given the short effect of rhTSH. Prior studies have described the large proportion of patients whose pretherapy iodine-123 (123I) scans show residual thyroid tissue. We sought to characterize the correlation between pretherapy 123I uptake and sTg.",
        "Methods": "We identified a retrospective cohort of patients treated with thyroidectomy and adjuvant radioiodine therapy at our institution. We included patients managed both with rhTSH and with thyroid hormone withdrawal. Patients with distant metastasis were excluded. We excluded patients who did not have TSH and thyroglobulin measurements on the day of their 123I pretherapy scan or the day before. The presence of residual thyroid tissue was taken from the imaging report, and we reviewed images to characterize the location of that tissue into categories: midline (including thyroglossal duct, pyramidal lobe, and isthmus), left and right thyroid bed, left and right lateral neck, and mediastinum.",
        "Results": "We identified 97 patients who met study criteria, including 60 women. A majority had papillary thyroid cancer (88%). Preparation for treatment was with rhTSH in 82 patients (86%), and mean TSH was 135.5 mIU/mL (interquartile range 92 – 171). Most pretherapy imaging was planar only with 15 patients (15%) having SPECT in addition. Residual iodine-avid tissue was reported in 84 patients (86.6%) with median uptake 0.34%. Residual tissue was identified in the midline of the thyroid bed in 72 cases (74.2%), right or left thyroid bed in 48 (49.5%), lateral neck in three patients (3.1%) and mediastinum in two (2.1%). The median postoperative stimulated thyroglobulin was 1.5ng/mL (interquartile range 0.3 – 5.3) with 40 patients (41.2%) having values less than 1ng/mL and 26 over 5ng/mL (26.8%). Mean 123I uptake was 0.27% in patients with thyroglobulin less than 1ng/mL and 1.51% in those with thyroglobulin 1ng/mL or higher. The difference of 1.24% (95% confidence interval 0.56 – 1.93) was statistically significant (p < 0.0001).",
        "Conclusion": "The high proportion of patients with residual thyroid tissue on planar 123I pretherapy scans echoes prior literature. Patients with low sTg also had low 123I uptake. Our preliminary findings suggest that 123I uptake could serve as a prognostic marker which is available in time to modify plans for therapeutic radioiodine. This finding should be corroborated with a larger cohort and with outcome data.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of iodine-123 uptake to predict postsurgical stimulated thyroglobulin</span>. <u>Ethan Meiburg, MD</u>; Michael Graham; Nitin Pagedar, MD. University of Iowa Hosptials and Clinics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Radioactive iodine therapy is used after surgery for selected patients with differentiated thyroid cancer. The decision to use radioiodine therapy is based on clinical and pathologic data. Preparation for radioiodine requires either withdrawal from thyroid hormone or administration of recombinant thyrotropin (rhTSH), and many reports have described low postoperative stimulated thyroglobulin (sTg), measured before radioiodine therapy, as highly predictive of prolonged disease-free status. Most often, adjuvant therapy is delivered before the thyroglobulin result is available to clinicians given the short effect of rhTSH. Prior studies have described the large proportion of patients whose pretherapy iodine-123 (123I) scans show residual thyroid tissue. We sought to characterize the correlation between pretherapy 123I uptake and sTg.</p>\n\n<p><strong>Methods: </strong>We identified a retrospective cohort of patients treated with thyroidectomy and adjuvant radioiodine therapy at our institution. We included patients managed both with rhTSH and with thyroid hormone withdrawal. Patients with distant metastasis were excluded. We excluded patients who did not have TSH and thyroglobulin measurements on the day of their 123I pretherapy scan or the day before. The presence of residual thyroid tissue was taken from the imaging report, and we reviewed images to characterize the location of that tissue into categories: midline (including thyroglossal duct, pyramidal lobe, and isthmus), left and right thyroid bed, left and right lateral neck, and mediastinum.</p>\n\n<p><strong>Results: </strong>We identified 97 patients who met study criteria, including 60 women. A majority had papillary thyroid cancer (88%). Preparation for treatment was with rhTSH in 82 patients (86%), and mean TSH was 135.5 mIU/mL (interquartile range 92 – 171). Most pretherapy imaging was planar only with 15 patients (15%) having SPECT in addition. Residual iodine-avid tissue was reported in 84 patients (86.6%) with median uptake 0.34%. Residual tissue was identified in the midline of the thyroid bed in 72 cases (74.2%), right or left thyroid bed in 48 (49.5%), lateral neck in three patients (3.1%) and mediastinum in two (2.1%). The median postoperative stimulated thyroglobulin was 1.5ng/mL (interquartile range 0.3 – 5.3) with 40 patients (41.2%) having values less than 1ng/mL and 26 over 5ng/mL (26.8%). Mean 123I uptake was 0.27% in patients with thyroglobulin less than 1ng/mL and 1.51% in those with thyroglobulin 1ng/mL or higher. The difference of 1.24% (95% confidence interval 0.56 – 1.93) was statistically significant (p < 0.0001).</p>\n\n<p><strong>Conclusion:</strong> The high proportion of patients with residual thyroid tissue on planar 123I pretherapy scans echoes prior literature. Patients with low sTg also had low 123I uptake. Our preliminary findings suggest that 123I uptake could serve as a prognostic marker which is available in time to modify plans for therapeutic radioiodine. This finding should be corroborated with a larger cohort and with outcome data.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154182--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S354",
      "content_id": "153209",
      "abstract_number": "S354",
      "poster_number": "",
      "title": "Assessing the Predictive Utility of Ultrasound for Tumor Characteristics in Thyroid Cancer",
      "summary": "Our findings indicate that US tends to overestimate tumor size and has limited predictive accuracy for multifocality and ETE. These findings highlight the need for caution when recommending total thyroidectomy based solely on preoperative US findings, in the absence of suspected nodal metastasis.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153209",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tommy Jacob, MD, MPH",
      "presenter": "Tommy Jacob, MD, MPH",
      "authors": "Tommy Jacob, MD, MPH 1 ; Lior Hayat, BSc 1 ; Daniel Kruituk, BSc 2 ; Liri Kotz, BSc 1 ; Narin Nard Carmel-Neidermann, MD, MSc 1 ; Genady Shendler, MD 1 ; Nidal Muhanna, MD, PhD 1 ; Gilad Horowitz, MD, MPH 1 ; Anton Warshavsky, MD 1",
      "normalized_authors": [
        "Tommy Jacob",
        "Lior Hayat",
        "Daniel Kruituk",
        "Liri Kotz",
        "Narin Nard Carmel-Neidermann",
        "Genady Shendler",
        "Nidal Muhanna",
        "Gilad Horowitz",
        "Anton Warshavsky"
      ],
      "affiliations": [
        "Tel Aviv Sourasky Medical Center",
        "2The Azrieli Faculty of Medicine, Bar-Ilan University"
      ],
      "normalized_institutions": [
        "Tel Aviv Sourasky Medical Center",
        "2The Azrieli Faculty of Medicine, Bar-Ilan University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 253,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tommy Jacob, MD, MPH 1 ; Lior Hayat, BSc 1 ; Daniel Kruituk, BSc 2 ; Liri Kotz, BSc 1 ; Narin Nard Carmel-Neidermann, MD, MSc 1 ; Genady Shendler, MD 1 ; Nidal Muhanna, MD, PhD 1 ; Gilad Horowitz, MD, MPH 1 ; Anton Warshavsky, MD 1",
        "Affiliations": "1 Tel Aviv Sourasky Medical Center; 2 2The Azrieli Faculty of Medicine, Bar-Ilan University",
        "Background": "Preoperative ultrasound (US) is crucial in the evaluation of thyroid cancer, yet its accuracy in predicting key tumor characteristics remains inconsistent. Accurate assessment of tumor size, extrathyroidal extension (ETE), and multifocality, features that largely guide management when nodal metastasis is not suspected, is essential for determining surgical extent.",
        "Objective": "To evaluate the accuracy of preoperative US in estimating tumor size, multifocality, and ETE in papillary thyroid carcinoma (PTC).",
        "Methods": "We conducted a retrospective cohort study of patients who underwent curative surgery for PTC at a tertiary referral center between 2006 and 2022. Concordance between preoperative sonographic and postoperative pathologic tumor size was evaluated overall and across predefined size groups, along with assessment of multifocality and ETE.",
        "Results": "Among 931 patients, the mean sonographic and pathologic tumor sizes were 2.10 ± 1.42 cm and 1.64 ± 1.29 cm, respectively (p < 0.001). US consistently overestimated size across all groups, with the mean percentage difference rising from 6% in tumors ≤ 1 cm to 32% in tumors > 4 cm (p < 0.001). The overall mean percent difference was +15.7 ± 40.7%, indicating bias toward larger sonographic measurements. For detecting ETE, US showed PPV of 30% and NPV of 95%; for multifocality, PPV 40% and NPV 85%.",
        "Conclusions": "Our findings indicate that US tends to overestimate tumor size and has limited predictive accuracy for multifocality and ETE. These findings highlight the need for caution when recommending total thyroidectomy based solely on preoperative US findings, in the absence of suspected nodal metastasis.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessing the Predictive Utility of Ultrasound for Tumor Characteristics in Thyroid Cancer</span>. <u>Tommy Jacob, MD, MPH</u><sup>1</sup>; Lior Hayat, BSc<sup>1</sup>; Daniel Kruituk, BSc<sup>2</sup>; Liri Kotz, BSc<sup>1</sup>; Narin Nard Carmel-Neidermann, MD, MSc<sup>1</sup>; Genady Shendler, MD<sup>1</sup>; Nidal Muhanna, MD, PhD<sup>1</sup>; Gilad Horowitz, MD, MPH<sup>1</sup>; Anton Warshavsky, MD<sup>1</sup>. <sup>1</sup>Tel Aviv Sourasky Medical Center; <sup>2</sup>2The Azrieli Faculty of Medicine, Bar-Ilan University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Preoperative ultrasound (US) is crucial in the evaluation of thyroid cancer, yet its accuracy in predicting key tumor characteristics remains inconsistent. Accurate assessment of tumor size, extrathyroidal extension (ETE), and multifocality, features that largely guide management when nodal metastasis is not suspected, is essential for determining surgical extent.</p>\n\n<p><strong>Objective: </strong>To evaluate the accuracy of preoperative US in estimating tumor size, multifocality, and ETE in papillary thyroid carcinoma (PTC).</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of patients who underwent curative surgery for PTC at a tertiary referral center between 2006 and 2022. Concordance between preoperative sonographic and postoperative pathologic tumor size was evaluated overall and across predefined size groups, along with assessment of multifocality and ETE.</p>\n\n<p><strong>Results: </strong>Among 931 patients, the mean sonographic and pathologic tumor sizes were 2.10 ± 1.42 cm and 1.64 ± 1.29 cm, respectively (p < 0.001). US consistently overestimated size across all groups, with the mean percentage difference rising from 6% in tumors ≤ 1 cm to 32% in tumors > 4 cm (p < 0.001). The overall mean percent difference was +15.7 ± 40.7%, indicating bias toward larger sonographic measurements. For detecting ETE, US showed PPV of 30% and NPV of 95%; for multifocality, PPV 40% and NPV 85%.</p>\n\n<p><strong>Conclusions: </strong>Our findings indicate that US tends to overestimate tumor size and has limited predictive accuracy for multifocality and ETE. These findings highlight the need for caution when recommending total thyroidectomy based solely on preoperative US findings, in the absence of suspected nodal metastasis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153209--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S355",
      "content_id": "153079",
      "abstract_number": "S355",
      "poster_number": "",
      "title": "A Cost-Effective Solution: Development of a Novel 3D-Printed Treatment Device for Trismus",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153079",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carolyn S Abraham, MSCCCSLP, BCSS, CLT",
      "presenter": "Carolyn S Abraham, MSCCCSLP, BCSS, CLT",
      "authors": "Carolyn S Abraham, MSCCCSLP, BCSS, CLT 1 ; Ameya Jategaonkar, MD 1 ; Rebecca Bartlett, PhD, CCCSLP 2",
      "normalized_authors": [
        "Carolyn S Abraham, MSCCCSLP, BCSS, CLT",
        "Ameya Jategaonkar",
        "Rebecca Bartlett, CCCSLP"
      ],
      "affiliations": [
        "Barrow Neurological Institute",
        "Northern Arizona University"
      ],
      "normalized_institutions": [
        "Barrow Neurological Institute",
        "Northern Arizona University"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153079/TrisPrint%20Picture.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153079/TrisPrint%20Picture.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153079"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 397,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction.",
        "Method.",
        "Results.",
        "Conclusion/Future Direction.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Carolyn S Abraham, MSCCCSLP, BCSS, CLT 1 ; Ameya Jategaonkar, MD 1 ; Rebecca Bartlett, PhD, CCCSLP 2",
        "Affiliations": "1 Barrow Neurological Institute; 2 Northern Arizona University",
        "Introduction.": "Approximately half of individuals with head and neck cancer who have undergone surgery or radiation therapy involving the jaw will develop trismus. Trismus remains a challenging problem for these patients that can significantly affect quality of life. While surgical interventions such as coronoidectomy can be effective in select cases, often such procedures are not without their own risk and morbidity. Behavioral therapy for trismus is effective and typically involves working with a speech-language pathologist (SLP) to perform active and passive jaw range of motion exercises with a device to assist/guide therapy. Unfortunately, these devices can be costly and are not often covered by insurance. Here we present a novel, affordable, safe and clinically accessible trismus treatment device to aid in restoration of maximal interincisal opening (MIO).",
        "Method.": "Our novel, 3D-printed device was developed by engineers and SLPs. The device can be readily printed by novice users with a biocompatible material for $8. The device has undergone preclinical mechanical testing, prototyping, and provisional patenting (USPTO: 63/894,509). Here we report the results of preclinical testing of this device.",
        "Results.": "Preclinical testing has demonstrated three key device functions: 1) The device supports passive range of motion by applying a controlled, gradual force to lower the mandible, 2) it supports active range of motion by providing spring-loaded resistance when the user bites down on the mouthpiece which may improve motor unit recruitment and muscle strength over time; and 3) it measures maximal interincisal opening through a ruler that is integrated into the handle. Safety has been a key design consideration. To protect dentition, the mouthpiece is designed to safely fail once a force of 60 Newtons is applied from the patient’s bite. To protect the mandible, the device’s compliant springs will gently snap if the patient’s jaw exerts 50 Newtons of compressive force onto the device.",
        "Conclusion/Future Direction.": "Effective and affordable treatment strategies to address trismus in the head and neck cancer survivor remain elusive. While clinical trial evaluation of our device is necessary (and anticipated in the near future at our institution), here we demonstrate a novel prototype that could shift the clinical paradigm from one in which patient adherence is poor because of high costs to one in which clinicians could print inexpensive devices as needed, expanding care to individuals with lower socioeconomic status, mild symptoms, and other trismus etiologies.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Cost-Effective Solution: Development of a Novel 3D-Printed Treatment Device for Trismus</span>. <u>Carolyn S Abraham, MSCCCSLP, BCSS, CLT</u><sup>1</sup>; Ameya Jategaonkar, MD<sup>1</sup>; Rebecca Bartlett, PhD, CCCSLP<sup>2</sup>. <sup>1</sup>Barrow Neurological Institute; <sup>2</sup>Northern Arizona University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction. </strong>Approximately half of individuals with head and neck cancer who have undergone surgery or radiation therapy involving the jaw will develop trismus. Trismus remains a challenging problem for these patients that can significantly affect quality of life. While surgical interventions such as coronoidectomy can be effective in select cases, often such procedures are not without their own risk and morbidity. Behavioral therapy for trismus is effective and typically involves working with a speech-language pathologist (SLP) to perform active and passive jaw range of motion exercises with a device to assist/guide therapy. Unfortunately, these devices can be costly and are not often covered by insurance. Here we present a novel, affordable, safe and clinically accessible trismus treatment device to aid in restoration of maximal interincisal opening (MIO).</p>\n\n<p><strong>Method. </strong>Our novel, 3D-printed device was developed by engineers and SLPs. The device can be readily printed by novice users with a biocompatible material for $8. The device has undergone preclinical mechanical testing, prototyping, and provisional patenting (USPTO: 63/894,509). Here we report the results of preclinical testing of this device.</p>\n\n<p><strong>Results.</strong> Preclinical testing has demonstrated three key device functions: 1) The device supports passive range of motion by applying a controlled, gradual force to lower the mandible, 2) it supports active range of motion by providing spring-loaded resistance when the user bites down on the mouthpiece which may improve motor unit recruitment and muscle strength over time; and 3) it measures maximal interincisal opening through a ruler that is integrated into the handle. Safety has been a key design consideration. To protect dentition, the mouthpiece is designed to safely fail once a force of 60 Newtons is applied from the patient’s bite. To protect the mandible, the device’s compliant springs will gently snap if the patient’s jaw exerts 50 Newtons of compressive force onto the device.</p>\n\n<p><strong>Conclusion/Future Direction. </strong>Effective and affordable treatment strategies to address trismus in the head and neck cancer survivor remain elusive. While clinical trial evaluation of our device is necessary (and anticipated in the near future at our institution), here we demonstrate a novel prototype that could shift the clinical paradigm from one in which patient adherence is poor because of high costs to one in which clinicians could print inexpensive devices as needed, expanding care to individuals with lower socioeconomic status, mild symptoms, and other trismus etiologies.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153079/TrisPrint%20Picture.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153079--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S356",
      "content_id": "153665",
      "abstract_number": "S356",
      "poster_number": "",
      "title": "Intraoral Ultrasound and Deep Margin Clearance in Oral Tongue Cancer",
      "summary": "In the largest IOUS cohort for OTSCC reported to date, IOUS use was associated with improved deep and closest margin clearance, reduced frequency of deep margins <5 mm, and elimination of deep margin cut-through. The use of a contemporaneous, institution-matched comparator cohort enhances methodological rigor relative to prior work. IOUS represents a rapid, cost-effective, noninvasive adjunct capable of enhancing...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153665",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260142",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel D Bu, MD",
      "presenter": "Daniel D Bu, MD",
      "authors": "Daniel D Bu, MD 1 ; William J Benjamin, MD, MPH 1 ; Amy Juliano, MD 2 ; Mary E Cunane, MD 2 ; Mark A Varvares, MD 1",
      "normalized_authors": [
        "Daniel D Bu",
        "William J Benjamin",
        "Amy Juliano",
        "Mary E Cunane",
        "Mark A Varvares"
      ],
      "affiliations": [
        "Department of Otolaryngology, Mass Eye and Ear/Harvard Medical School",
        "Department of Radiology, Mass Eye and Ear/Harvard Medical School"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Mass Eye and Ear/Harvard Medical School",
        "Department of Radiology, Mass Eye and Ear/Harvard Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 443,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Daniel D Bu, MD 1 ; William J Benjamin, MD, MPH 1 ; Amy Juliano, MD 2 ; Mary E Cunane, MD 2 ; Mark A Varvares, MD 1",
        "Affiliations": "1 Department of Otolaryngology, Mass Eye and Ear/Harvard Medical School; 2 Department of Radiology, Mass Eye and Ear/Harvard Medical School",
        "Introduction": "Positive or close deep margins remain a major limitation in the surgical management of oral tongue squamous cell carcinoma (OTSCC), accounting for the majority of margin-related local failures. Intraoral ultrasound (IOUS) has emerged as a potential adjunct for real-time assessment of tumor depth of invasion (DOI) and deep margin extent. Prior series have been limited by small sample sizes and heterogeneous historical comparator groups. We report on the largest IOUS experience to date with a contemporaneous, institution-matched comparator cohort, to evaluate the impact of IOUS on deep margin clearance and DOI assessment.",
        "Methods": "A retrospective review was performed of consecutive T1–T3 OTSCC resections performed by a single surgeon at a tertiary academic center. Patients who underwent IOUS-guided resection formed the study group (n = 45). A comparator cohort (n = 27) consisting of resections performed without IOUS by the same surgeon at the same institution served as the control group. Data from operative reports, IOUS measurements, and final pathology were analyzed. Deep margin distance, closest radial margin, proportion within each group with deep margin <5 mm, and correlation between US and histopathology measurements of DOI were compared between groups using t-tests or χ² analysis where appropriate.",
        "Results": "Mean deep margin in the IOUS group was 7.03 mm (95% CI 5.67–8.40). In comparison, mean deep margin in the non-IOUS group was 5.90 mm (95% CI 4.63–7.17), representing an estimated between-group difference of 1.1 mm. Deep margins <5 mm occurred in 22% of IOUS cases and 43% of non-IOUS cases (OR 0.53, p = 0.25). No deep margin cut-through (positive deep margin) occurred in the IOUS cohort (0%), while this occurred in one case in the non-IOUS cohort (4%).",
        "Abstract": "The IOUS group demonstrated a mean closest radial margin of 5.58 mm (95% CI 4.78–6.38; SD 2.43; n = 38), compared to 4.40 mm (95% CI 3.41–5.39) in the non-IOUS group. Tumor stage distribution between the groups was balanced, improving internal validity relative to prior historical comparator analyses. IOUS measurements of DOI correlated strongly with histologic DOI (r = 0.94, p < 0.001). View in Agenda and Add to Schedule",
        "Conclusion": "In the largest IOUS cohort for OTSCC reported to date, IOUS use was associated with improved deep and closest margin clearance, reduced frequency of deep margins <5 mm, and elimination of deep margin cut-through. The use of a contemporaneous, institution-matched comparator cohort enhances methodological rigor relative to prior work. IOUS represents a rapid, cost-effective, noninvasive adjunct capable of enhancing the surgeon’s ability to achieve oncologically adequate deep margins. Prospective validation of the impact of IOUS on margin evaluation is warranted."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoral Ultrasound and Deep Margin Clearance in Oral Tongue Cancer</span>. <u>Daniel D Bu, MD</u><sup>1</sup>; William J Benjamin, MD, MPH<sup>1</sup>; Amy Juliano, MD<sup>2</sup>; Mary E Cunane, MD<sup>2</sup>; Mark A Varvares, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology, Mass Eye and Ear/Harvard Medical School; <sup>2</sup>Department of Radiology, Mass Eye and Ear/Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Positive or close deep margins remain a major limitation in the surgical management of oral tongue squamous cell carcinoma (OTSCC), accounting for the majority of margin-related local failures. Intraoral ultrasound (IOUS) has emerged as a potential adjunct for real-time assessment of tumor depth of invasion (DOI) and deep margin extent. Prior series have been limited by small sample sizes and heterogeneous historical comparator groups. We report on the largest IOUS experience to date with a contemporaneous, institution-matched comparator cohort, to evaluate the impact of IOUS on deep margin clearance and DOI assessment. </p>\n\n<p><strong>Methods: </strong>A retrospective review was performed of consecutive T1–T3 OTSCC resections performed by a single surgeon at a tertiary academic center. Patients who underwent IOUS-guided resection formed the study group (n = 45). A comparator cohort (n = 27) consisting of resections performed without IOUS by the same surgeon at the same institution served as the control group. Data from operative reports, IOUS measurements, and final pathology were analyzed. Deep margin distance, closest radial margin, proportion within each group with deep margin <5 mm, and correlation between US and histopathology measurements of DOI were compared between groups using t-tests or χ² analysis where appropriate. </p>\n\n<p><strong>Results: </strong>Mean deep margin in the IOUS group was 7.03 mm (95% CI 5.67–8.40). In comparison, mean deep margin in the non-IOUS group was 5.90 mm (95% CI 4.63–7.17), representing an estimated between-group difference of 1.1 mm. Deep margins <5 mm occurred in 22% of IOUS cases and 43% of non-IOUS cases (OR 0.53, p = 0.25). No deep margin cut-through (positive deep margin) occurred in the IOUS cohort (0%), while this occurred in one case in the non-IOUS cohort (4%). </p>\n\n<p>The IOUS group demonstrated a mean closest radial margin of 5.58 mm (95% CI 4.78–6.38; SD 2.43; n = 38), compared to 4.40 mm (95% CI 3.41–5.39) in the non-IOUS group. Tumor stage distribution between the groups was balanced, improving internal validity relative to prior historical comparator analyses. IOUS measurements of DOI correlated strongly with histologic DOI (r = 0.94, p < 0.001).</p>\n\n<p><strong>Conclusion: </strong>In the largest IOUS cohort for OTSCC reported to date, IOUS use was associated with improved deep and closest margin clearance, reduced frequency of deep margins <5 mm, and elimination of deep margin cut-through. The use of a contemporaneous, institution-matched comparator cohort enhances methodological rigor relative to prior work. IOUS represents a rapid, cost-effective, noninvasive adjunct capable of enhancing the surgeon’s ability to achieve oncologically adequate deep margins. Prospective validation of the impact of IOUS on margin evaluation is warranted. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153665--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260142' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S357",
      "content_id": "152106",
      "abstract_number": "S357",
      "poster_number": "",
      "title": "Regenerative Effects of Myogenic Gene Transfected MSC Derived Exosomes on Radiation Esophagitis",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152106",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eun-Jae Chung",
      "presenter": "Eun-Jae Chung",
      "authors": "Eun-Jae Chung 1 ; In Gul Kim 1 ; Seo Young Kim 1 ; Joon Yong Park 2 ; Jungirl Seok 1 ; Soon-Hyun Ahn 1 ; Hye-Joung Kim 3",
      "normalized_authors": [
        "Eun-Jae Chung",
        "In Gul Kim",
        "Seo Young Kim",
        "Joon Yong Park",
        "Jungirl Seok",
        "Soon-Hyun Ahn",
        "Hye-Joung Kim"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea",
        "Institute of Chemical Engineering Convergence System, Korea University, Seoul, Republic of Korea"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea",
        "Institute of Chemical Engineering Convergence System, Korea University, Seoul, Republic of Korea"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152106/20251102_221156.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/152106/20251102_221156.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152106"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 267,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Eun-Jae Chung 1 ; In Gul Kim 1 ; Seo Young Kim 1 ; Joon Yong Park 2 ; Jungirl Seok 1 ; Soon-Hyun Ahn 1 ; Hye-Joung Kim 3",
        "Affiliations": "1 Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; 2 Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea; 3 Institute of Chemical Engineering Convergence System, Korea University, Seoul, Republic of Korea",
        "BACKGROUND": "Radiation esophagitis is a common adverse effect of radiotherapy for head and neck cancers, and is marked by irreversible damage and fibrosis of esophageal muscle tissue. Although mesenchymal stem cell (MSC) therapy is emerging as a promising approach for tissue regeneration, clinical translation remains challenging due to issues with cell viability and differentiation in vivo. This study evaluates the regenerative efficacy of exosomes derived from MSCs transfected with myogenic genes (MyoD, Myogenin, Myf6, referred to as Myo-MIX) using a murine model of radiation-induced esophageal fibrosis.",
        "METHODS": "Human adipose-derived MSCs were transfected with Myo-MIX plasmids by electroporation, and exosomes were collected from conditioned media using ExoQuick. Nanoparticle tracking analysis and transmission electron microscopy were employed to characterize exosomal size and morphology. A mouse model of localized radiation-induced esophageal injury (10 Gy × 2 fractions) was generated and followed by intramuscular administration of Myo-MIX exosomes. Regenerative and anti-fibrotic outcomes were examined through Masson’s trichrome staining, immunohistochemistry (α-SMA, Calponin, CD68), and quantitative RT-PCR.",
        "RESULTS": "Treatment with Myo-MIX exosomes resulted in a pronounced decrease in fibrosis and inflammatory response compared to PBS-treated controls and naïve MSC-exosome groups. Enhanced restoration of muscular architecture was observed, accompanied by elevated expression of Calponin and α-SMA, and a reduction in CD68+ macrophage infiltration. Gene expression profiling indicated increased levels of myogenic and anti-fibrotic markers in the Myo-MIX exosome-treated group.",
        "CONCLUSION": "Exosomes from myogenic gene-transfected MSCs significantly enhance esophageal muscle regeneration and attenuate fibrosis after radiation-induced damage. This cell-free therapeutic approach holds potential as a novel and practical strategy for addressing radiation esophagitis in patients receiving radiotherapy for head and neck malignancies.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Regenerative Effects of Myogenic Gene Transfected MSC Derived Exosomes on Radiation Esophagitis</span>. <u>Eun-Jae Chung</u><sup>1</sup>; In Gul Kim<sup>1</sup>; Seo Young Kim<sup>1</sup>; Joon Yong Park<sup>2</sup>; Jungirl Seok<sup>1</sup>; Soon-Hyun Ahn<sup>1</sup>; Hye-Joung Kim<sup>3</sup>. <sup>1</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea; <sup>3</sup>Institute of Chemical Engineering Convergence System, Korea University, Seoul, Republic of Korea<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Radiation esophagitis is a common adverse effect of radiotherapy for head and neck cancers, and is marked by irreversible damage and fibrosis of esophageal muscle tissue. Although mesenchymal stem cell (MSC) therapy is emerging as a promising approach for tissue regeneration, clinical translation remains challenging due to issues with cell viability and differentiation in vivo. This study evaluates the regenerative efficacy of exosomes derived from MSCs transfected with myogenic genes (MyoD, Myogenin, Myf6, referred to as Myo-MIX) using a murine model of radiation-induced esophageal fibrosis.</p>\n\n<p><strong>METHODS: </strong>Human adipose-derived MSCs were transfected with Myo-MIX plasmids by electroporation, and exosomes were collected from conditioned media using ExoQuick. Nanoparticle tracking analysis and transmission electron microscopy were employed to characterize exosomal size and morphology. A mouse model of localized radiation-induced esophageal injury (10 Gy × 2 fractions) was generated and followed by intramuscular administration of Myo-MIX exosomes. Regenerative and anti-fibrotic outcomes were examined through Masson’s trichrome staining, immunohistochemistry (α-SMA, Calponin, CD68), and quantitative RT-PCR.</p>\n\n<p><strong>RESULTS: </strong>Treatment with Myo-MIX exosomes resulted in a pronounced decrease in fibrosis and inflammatory response compared to PBS-treated controls and naïve MSC-exosome groups. Enhanced restoration of muscular architecture was observed, accompanied by elevated expression of Calponin and α-SMA, and a reduction in CD68+ macrophage infiltration. Gene expression profiling indicated increased levels of myogenic and anti-fibrotic markers in the Myo-MIX exosome-treated group.</p>\n\n<p><strong>CONCLUSION: </strong>Exosomes from myogenic gene-transfected MSCs significantly enhance esophageal muscle regeneration and attenuate fibrosis after radiation-induced damage. This cell-free therapeutic approach holds potential as a novel and practical strategy for addressing radiation esophagitis in patients receiving radiotherapy for head and neck malignancies.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152106/20251102_221156.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152106--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S358",
      "content_id": "154180",
      "abstract_number": "S358",
      "poster_number": "",
      "title": "TREATMENT INTENSIFICATION PARADOX IN EARLY-STAGE LARYNGEAL CANCER: CHEMORADIOTHERAPY VERSUS RADIOTHERAPY ALONE YIELDS INFERIOR SURVIVAL AND DOUBLES HEALTHCARE COSTS IN A POPULATION-BASED COHORT O",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154180",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Hugo F Kohler, MD; Genival B Carvalho, MD, PhD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Hugo F Kohler",
        "Genival B Carvalho",
        "Jose G Vartanian",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 535,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hugo F Kohler, MD; Genival B Carvalho, MD, PhD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "BACKGROUND": "Treatment selection for early-stage laryngeal cancer depends on institutional resources, available evidence, and physician preferences. Brazil lacks standardized clinical practice guidelines, and its heterogeneous healthcare system—characterized by multiple reimbursement modalities, provider networks, and geographic disparities—contributes to significant treatment variability. While radiotherapy (RT) alone represents the evidence-based standard for stages I-II laryngeal squamous cell carcinoma, concurrent chemoradiotherapy (CRT) is frequently employed despite limited supporting data. This population-based study examined the survival and economic implications of treatment intensification in early-stage disease.",
        "MATERIALS AND METHODS": "We analyzed a comprehensive hospital-based registry encompassing all laryngeal cancer patients treated in São Paulo State, Brazil. Inclusion criteria comprised treatment-naïve patients with clinical stage I-II laryngeal squamous cell carcinoma receiving curative-intent RT or CRT. Primary endpoints included disease-specific survival (DSS) and overall survival (OS), estimated through Kaplan-Meier methodology and compared via log-rank testing. Multivariable Cox proportional hazards models identified independent prognostic factors. To address treatment selection bias, propensity score matching balanced baseline characteristics between cohorts. Economic analysis calculated direct treatment costs based on Brazilian healthcare system reimbursement rates.",
        "RESULTS": "The cohort comprised 2,047 consecutive patients: 1,804 males (88.1%) and 243 females (11.9%), with mean age 64.4 ± 10.5 years. Anatomical subsites included glottis in 1,046 patients (51.1%), supraglottis in 252 (12.3%), and unspecified in 749 (36.6%). Clinical staging revealed 1,118 stage I (54.6%) and 929 stage II (45.4%) cases. Insurance status comprised 1,122 public beneficiaries (54.8%), 160 privately insured (7.8%), 19 self-paying patients (0.9%), and 746 with missing data (36.4%). Treatment modalities consisted of RT alone in 1,577 patients (77.0%) and CRT in 470 (23.0%). At final follow-up, 469 patients (22.9%) experienced disease-specific mortality, while 1,096 (53.5%) died from any cause. Univariable log-rank analysis demonstrated significant survival differences favoring RT over CRT for both DSS and OS. Multivariable Cox regression confirmed age, gender, anatomical subsite, clinical stage, and treatment modality as independent predictors of DSS and OS, with reimbursement modality significant only for DSS and treatment delay significant exclusively for OS. Propensity score matching generated 940 balanced patient pairs, with Kaplan-Meier curves demonstrating persistent survival advantages for RT monotherapy in both endpoints. Subgroup analysis restricted to cT2N0 patients (n=929) confirmed treatment modality as an independent prognostic factor alongside age, gender, and primary site. Economic analysis revealed stark cost disparities: RT monotherapy totaled R$4,168 per patient versus R$7,568 for CRT (chemotherapy R$800/cycle plus RT R$4,168), translating to population-level costs of R$8.5 million for guideline-concordant RT versus R$15.1 million for CRT—a 77% cost increase.",
        "CONCLUSION": "This population-based analysis reveals a treatment intensification paradox wherein CRT for early-stage laryngeal cancer produces inferior survival outcomes while doubling healthcare expenditures compared to evidence-based RT monotherapy. These findings represent a compelling example of low-value care that simultaneously harms patients and strains healthcare systems. The 77% cost escalation without survival benefit exemplifies inefficient resource allocation in resource-constrained healthcare environments. These data underscore urgent needs for nationwide implementation of evidence-based clinical practice guidelines, establishment of quality metrics monitoring treatment appropriateness, and development of decision-support systems preventing unjustified treatment intensification.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>TREATMENT INTENSIFICATION PARADOX IN EARLY-STAGE LARYNGEAL CANCER: CHEMORADIOTHERAPY VERSUS RADIOTHERAPY ALONE YIELDS INFERIOR SURVIVAL AND DOUBLES HEALTHCARE COSTS IN A POPULATION-BASED COHORT OF 2,047 PATIENTS</span>. Hugo F Kohler, MD; Genival B Carvalho, MD, PhD; <u>Jose G Vartanian, MD, PhD</u>; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Treatment selection for early-stage laryngeal cancer depends on institutional resources, available evidence, and physician preferences. Brazil lacks standardized clinical practice guidelines, and its heterogeneous healthcare system—characterized by multiple reimbursement modalities, provider networks, and geographic disparities—contributes to significant treatment variability. While radiotherapy (RT) alone represents the evidence-based standard for stages I-II laryngeal squamous cell carcinoma, concurrent chemoradiotherapy (CRT) is frequently employed despite limited supporting data. This population-based study examined the survival and economic implications of treatment intensification in early-stage disease.</p>\n\n<p><strong>MATERIALS AND METHODS: </strong>We analyzed a comprehensive hospital-based registry encompassing all laryngeal cancer patients treated in São Paulo State, Brazil. Inclusion criteria comprised treatment-naïve patients with clinical stage I-II laryngeal squamous cell carcinoma receiving curative-intent RT or CRT. Primary endpoints included disease-specific survival (DSS) and overall survival (OS), estimated through Kaplan-Meier methodology and compared via log-rank testing. Multivariable Cox proportional hazards models identified independent prognostic factors. To address treatment selection bias, propensity score matching balanced baseline characteristics between cohorts. Economic analysis calculated direct treatment costs based on Brazilian healthcare system reimbursement rates.</p>\n\n<p><strong>RESULTS: </strong>The cohort comprised 2,047 consecutive patients: 1,804 males (88.1%) and 243 females (11.9%), with mean age 64.4 ± 10.5 years. Anatomical subsites included glottis in 1,046 patients (51.1%), supraglottis in 252 (12.3%), and unspecified in 749 (36.6%). Clinical staging revealed 1,118 stage I (54.6%) and 929 stage II (45.4%) cases. Insurance status comprised 1,122 public beneficiaries (54.8%), 160 privately insured (7.8%), 19 self-paying patients (0.9%), and 746 with missing data (36.4%). Treatment modalities consisted of RT alone in 1,577 patients (77.0%) and CRT in 470 (23.0%). At final follow-up, 469 patients (22.9%) experienced disease-specific mortality, while 1,096 (53.5%) died from any cause. Univariable log-rank analysis demonstrated significant survival differences favoring RT over CRT for both DSS and OS. Multivariable Cox regression confirmed age, gender, anatomical subsite, clinical stage, and treatment modality as independent predictors of DSS and OS, with reimbursement modality significant only for DSS and treatment delay significant exclusively for OS. Propensity score matching generated 940 balanced patient pairs, with Kaplan-Meier curves demonstrating persistent survival advantages for RT monotherapy in both endpoints. Subgroup analysis restricted to cT2N0 patients (n=929) confirmed treatment modality as an independent prognostic factor alongside age, gender, and primary site. Economic analysis revealed stark cost disparities: RT monotherapy totaled R$4,168 per patient versus R$7,568 for CRT (chemotherapy R$800/cycle plus RT R$4,168), translating to population-level costs of R$8.5 million for guideline-concordant RT versus R$15.1 million for CRT—a 77% cost increase.</p>\n\n<p><strong>CONCLUSION: </strong>This population-based analysis reveals a treatment intensification paradox wherein CRT for early-stage laryngeal cancer produces inferior survival outcomes while doubling healthcare expenditures compared to evidence-based RT monotherapy. These findings represent a compelling example of low-value care that simultaneously harms patients and strains healthcare systems. The 77% cost escalation without survival benefit exemplifies inefficient resource allocation in resource-constrained healthcare environments. These data underscore urgent needs for nationwide implementation of evidence-based clinical practice guidelines, establishment of quality metrics monitoring treatment appropriateness, and development of decision-support systems preventing unjustified treatment intensification. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154180--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S359",
      "content_id": "154583",
      "abstract_number": "S359",
      "poster_number": "",
      "title": "Trends and Characteristics of Adjuvant Radiotherapy After Surgically-Treated HPV-positive Oropharyngeal Carcinoma",
      "summary": "In this national cohort of surgically treated HPV-OPC patients with adverse pathologic features, delays in initiating adjuvant radiotherapy beyond 8 weeks were associated with worse overall survival whereas treatment up to 8 weeks did not affect survival. These findings identify a clinically meaningful inflection point for post-operative radiation timing that extends beyond the traditional 6-week benchmark and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154583",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shady I Soliman, MD",
      "presenter": "Shady I Soliman, MD",
      "authors": "Shady I Soliman, MD 1 ; Erik Vanstrum, MD 1 ; Mishek Thapa, BS 2 ; Nathan Vu Pham, BS 2 ; Peter S Han, MD 1 ; Joel A Sercarz, MD 1",
      "normalized_authors": [
        "Shady I Soliman",
        "Erik Vanstrum",
        "Mishek Thapa",
        "Nathan Vu Pham",
        "Peter S Han",
        "Joel A Sercarz"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, University of California, Los Angeles, CA",
        "David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, University of California, Los Angeles, CA",
        "David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154583/untitled-5.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154583/untitled-5.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154583"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 387,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shady I Soliman, MD 1 ; Erik Vanstrum, MD 1 ; Mishek Thapa, BS 2 ; Nathan Vu Pham, BS 2 ; Peter S Han, MD 1 ; Joel A Sercarz, MD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, University of California, Los Angeles, CA; 2 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA",
        "Introduction": "HPV-positive oropharyngeal carcinoma (HPV-OPC) is increasingly treated with primary surgery. For patients with HPV-OPC who exhibit adverse pathologic features after surgery, adjuvant radiotherapy is recommended to optimize oncologic outcomes. In the E3311 trial, no significant difference in survival was observed based on whether adjuvant radiotherapy was initiated before or after 6 weeks following surgery. However, the impact of adjuvant radiotherapy in a large cohort of surgically treated HPV-OPC has not been evaluated. We therefore examined outcomes associated with the timing of adjuvant radiotherapy in patients with HPV-OPC that have an indication for adjuvant radiotherapy.",
        "Methods": "The National Cancer Database was interrogated for patients with early-stage HPV-OPC who underwent definitive resection and had at least one NCCN-defined adverse pathological feature indicating adjuvant radiotherapy. Overall survival (OS) was evaluated using Cox proportional hazards models and Kaplan-Meier analysis. Propensity score matching was performed to adjust for baseline demographic, socioeconomic, tumor, and treatment-related confounders. Patients were stratified into four groups based on time to initiation of adjuvant radiotherapy (<6 weeks, 6-8 weeks, 8-10 weeks, and >10 weeks), with direct comparisons performed across all groups.",
        "Results": "Of 8,360 patients meeting inclusion criteria, 86.8% received guideline-recommended adjuvant radiotherapy. On multivariable analysis, delayed initiation of radiotherapy was independently associated with worse OS when started at 8–10 weeks (HR 1.32, 95% CI 1.04-1.68) and >10 weeks (HR 1.26, 95% CI 1.03-1.54; p<0.001), but not when initiated before 8 weeks. Kaplan Meier analysis revealed a graded decline in median 5-year OS with increasing delay; <6 weeks (88.9% [87.6-90.1]), 6-8 weeks (88.2% [86.5-89.8]), 8-10 weeks (87.7% [85.3-89.7]), and 10-12 weeks (84.8% [79.4-82.6]) (log rank <0.001). No clinically meaningful difference in survival was observed among patients treated within the first 10 weeks following surgery. Findings remained consistent in propensity-matched cohorts.",
        "Conclusion": "In this national cohort of surgically treated HPV-OPC patients with adverse pathologic features, delays in initiating adjuvant radiotherapy beyond 8 weeks were associated with worse overall survival whereas treatment up to 8 weeks did not affect survival. These findings identify a clinically meaningful inflection point for post-operative radiation timing that extends beyond the traditional 6-week benchmark and underscores the importance of preventing prolonged delays of adjuvant radiotherapy in HPV-OPC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends and Characteristics of Adjuvant Radiotherapy After Surgically-Treated HPV-positive Oropharyngeal Carcinoma</span>. <u>Shady I Soliman, MD</u><sup>1</sup>; Erik Vanstrum, MD<sup>1</sup>; Mishek Thapa, BS<sup>2</sup>; Nathan Vu Pham, BS<sup>2</sup>; Peter S Han, MD<sup>1</sup>; Joel A Sercarz, MD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, University of California, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>HPV-positive oropharyngeal carcinoma (HPV-OPC) is increasingly treated with primary surgery. For patients with HPV-OPC who exhibit adverse pathologic features after surgery, adjuvant radiotherapy is recommended to optimize oncologic outcomes. In the E3311 trial, no significant difference in survival was observed based on whether adjuvant radiotherapy was initiated before or after 6 weeks following surgery. However, the impact of adjuvant radiotherapy in a large cohort of surgically treated HPV-OPC has not been evaluated. We therefore examined outcomes associated with the timing of adjuvant radiotherapy in patients with HPV-OPC that have an indication for adjuvant radiotherapy.</p>\n\n<p><strong>Methods: </strong>The National Cancer Database was interrogated for patients with early-stage HPV-OPC who underwent definitive resection and had at least one NCCN-defined adverse pathological feature indicating adjuvant radiotherapy. Overall survival (OS) was evaluated using Cox proportional hazards models and Kaplan-Meier analysis. Propensity score matching was performed to adjust for baseline demographic, socioeconomic, tumor, and treatment-related confounders. Patients were stratified into four groups based on time to initiation of adjuvant radiotherapy (<6 weeks, 6-8 weeks, 8-10 weeks, and >10 weeks), with direct comparisons performed across all groups.</p>\n\n<p><strong>Results: </strong>Of 8,360 patients meeting inclusion criteria, 86.8% received guideline-recommended adjuvant radiotherapy. On multivariable analysis, delayed initiation of radiotherapy was independently associated with worse OS when started at 8–10 weeks (HR 1.32, 95% CI 1.04-1.68) and >10 weeks (HR 1.26, 95% CI 1.03-1.54; p<0.001), but not when initiated before 8 weeks. Kaplan Meier analysis revealed a graded decline in median 5-year OS with increasing delay; <6 weeks (88.9% [87.6-90.1]), 6-8 weeks (88.2% [86.5-89.8]), 8-10 weeks (87.7% [85.3-89.7]), and 10-12 weeks (84.8% [79.4-82.6]) (log rank <0.001). No clinically meaningful difference in survival was observed among patients treated within the first 10 weeks following surgery. Findings remained consistent in propensity-matched cohorts.</p>\n\n<p><strong>Conclusion: </strong>In this national cohort of surgically treated HPV-OPC patients with adverse pathologic features, delays in initiating adjuvant radiotherapy beyond 8 weeks were associated with worse overall survival whereas treatment up to 8 weeks did not affect survival. These findings identify a clinically meaningful inflection point for post-operative radiation timing that extends beyond the traditional 6-week benchmark and underscores the importance of preventing prolonged delays of adjuvant radiotherapy in HPV-OPC.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154583/untitled-5.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154583--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S360",
      "content_id": "153936",
      "abstract_number": "S360",
      "poster_number": "",
      "title": "Immune profiling of the effects of a local cisplatin-eluting polymer combined with radiation",
      "summary": "As upfront management of residual tumor cells perioperatively has been demonstrated to improve patient outcomes, further work is required to develop other technologies in this clinical space. This drug-eluting polymer may represent an avenue wherein many types of systemic therapies are delivered in a targeted fashion. Further characterization of the immune profile of this technology is needed to understand how...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153936",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alice C Yu, MD",
      "presenter": "Alice C Yu, MD",
      "authors": "Alice C Yu, MD 1 ; Yazeed Alhiyari, PhD 1 ; Lauran K Evans, MD, MPH 1 ; Yang Liu, PhD 2 ; Supriya Atta, PhD 2 ; Tuan Vo-Dinh, PhD 2 ; Maie A St",
      "normalized_authors": [
        "Alice C Yu",
        "Yazeed Alhiyari",
        "Lauran K Evans",
        "Yang Liu",
        "Supriya Atta",
        "Tuan Vo-Dinh",
        "Maie A St"
      ],
      "affiliations": [
        "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery",
        "Duke University Department of Biomedical Engineering",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery",
        "Duke University Department of Biomedical Engineering",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Abstract",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alice C Yu, MD 1 ; Yazeed Alhiyari, PhD 1 ; Lauran K Evans, MD, MPH 1 ; Yang Liu, PhD 2 ; Supriya Atta, PhD 2 ; Tuan Vo-Dinh, PhD 2 ; Maie A St",
        "Affiliations": "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery; 2 Duke University Department of Biomedical Engineering; 3 Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery",
        "Introduction": "As limited tolerability of systemic therapies in head and neck squamous cell carcinoma (HNSCC) can adversely affect patient outcomes, much interest has been paid to developing treatments with less morbidity. Notable recent examples include the KEYNOTE-689 trial that demonstrated that the addition of perioperative pembrolizumab was able to significantly improve event-free survival in locally advanced HNSCC. This study suggested there may be therapeutic benefit in treating the micro-metastases or minimally residual cancers present perioperatively.",
        "Abstract": "Surgically implanted devices, such as drug-eluting polymers and gold nanostars, present another perioperative therapeutic option for preventing locoregional recurrence and targeting radiation to areas at highest risk for treatment failure. Importantly, this technology is a drug-agnostic platform of delivering therapies at the time of surgery to mitigate the regrowth or migration of residual tumor cells. The promise of this system is that, in addition to the traditional cytotoxic agents it has already been proven effective with, this polymer could also be inoculated with immunotherapeutic agents. Additionally, patients could receive both chemotherapy and immunotherapy perioperatively without significant morbidity. However, investigation into the effect of this implant on the tumor immune microenvironment is necessary. View in Agenda and Add to Schedule",
        "Objectives": "To assess the efficacy of a chemotherapy-eluting, gold nanostar-embedded polymer in arresting tumor growth and sensitizing tumors to radiation therapy, and to characterize the effect of this implant on the tumor microenvironment.",
        "Methods": "Forty male HeJ mice were stratified into the following treatment arms: control polymer, polymer with gold nanostars (GNS), polymer with cisplatin (Pt), and polymer with GNS and Pt. These mice were implanted with SCC tumors; after the tumors grew to a volume of 1 cm³, they were debulked by 50%. At this time, the respective polymers were surgically implanted for each treatment arm. Each of these mice was treated with either no radiotherapy (RT) or RT at doses of 4 or 2 Gy for 4 treatments. Tumor growth was measured daily for 30 days. At the end of the experiment, mice were sacrificed and tumors from mice treated with GNS/Pt and control polymers were collected. These samples were sent for immunohistochemical staining for immune markers such as T-lymphocyte invasion and PD-1/PD-L1 expression.",
        "Results": "Mice implanted with both Pt and GNS/Pt polymers had improved outcomes compared to those treated with plain polymer; the addition of radiation therapy further slowed tumor growth. Reduced doses of radiation in mice who underwent implantation with both Pt and GNS/Pt yielded tumor growth curves that were comparable to mice that received full doses of radiation. Immune profiling revealed differences in proportions of tumor invading lymphocytes in mice that underwent GNS/Pt versus plain polymer.",
        "Conclusion": "As upfront management of residual tumor cells perioperatively has been demonstrated to improve patient outcomes, further work is required to develop other technologies in this clinical space. This drug-eluting polymer may represent an avenue wherein many types of systemic therapies are delivered in a targeted fashion. Further characterization of the immune profile of this technology is needed to understand how this platform can synergize with existing neoadjuvant immunotherapeutic strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immune profiling of the effects of a local cisplatin-eluting polymer combined with radiation</span>. <u>Alice C Yu, MD</u><sup>1</sup>; Yazeed Alhiyari, PhD<sup>1</sup>; Lauran K Evans, MD, MPH<sup>1</sup>; Yang Liu, PhD<sup>2</sup>; Supriya Atta, PhD<sup>2</sup>; Tuan Vo-Dinh, PhD<sup>2</sup>; Maie A St. John, MD, PhD<sup>3</sup>. <sup>1</sup>UCLA Department of Head and Neck Surgery; <sup>2</sup>Duke University Department of Biomedical Engineering; <sup>3</sup>Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>As limited tolerability of systemic therapies in head and neck squamous cell carcinoma (HNSCC) can adversely affect patient outcomes, much interest has been paid to developing treatments with less morbidity. Notable recent examples include the KEYNOTE-689 trial that demonstrated that the addition of perioperative pembrolizumab was able to significantly improve event-free survival in locally advanced HNSCC. This study suggested there may be therapeutic benefit in treating the micro-metastases or minimally residual cancers present perioperatively.</p>\n\n<p>Surgically implanted devices, such as drug-eluting polymers and gold nanostars, present another perioperative therapeutic option for preventing locoregional recurrence and targeting radiation to areas at highest risk for treatment failure. Importantly, this technology is a drug-agnostic platform of delivering therapies at the time of surgery to mitigate the regrowth or migration of residual tumor cells. The promise of this system is that, in addition to the traditional cytotoxic agents it has already been proven effective with, this polymer could also be inoculated with immunotherapeutic agents. Additionally, patients could receive both chemotherapy and immunotherapy perioperatively without significant morbidity. However, investigation into the effect of this implant on the tumor immune microenvironment is necessary.</p>\n\n<p><strong>Objectives: </strong>To assess the efficacy of a chemotherapy-eluting, gold nanostar-embedded polymer in arresting tumor growth and sensitizing tumors to radiation therapy, and to characterize the effect of this implant on the tumor microenvironment.</p>\n\n<p><strong>Methods: </strong>Forty male HeJ mice were stratified into the following treatment arms: control polymer, polymer with gold nanostars (GNS), polymer with cisplatin (Pt), and polymer with GNS and Pt. These mice were implanted with SCC tumors; after the tumors grew to a volume of 1 cm³, they were debulked by 50%. At this time, the respective polymers were surgically implanted for each treatment arm. Each of these mice was treated with either no radiotherapy (RT) or RT at doses of 4 or 2 Gy for 4 treatments. Tumor growth was measured daily for 30 days. At the end of the experiment, mice were sacrificed and tumors from mice treated with GNS/Pt and control polymers were collected. These samples were sent for immunohistochemical staining for immune markers such as T-lymphocyte invasion and PD-1/PD-L1 expression.</p>\n\n<p><strong>Results: </strong>Mice implanted with both Pt and GNS/Pt polymers had improved outcomes compared to those treated with plain polymer; the addition of radiation therapy further slowed tumor growth. Reduced doses of radiation in mice who underwent implantation with both Pt and GNS/Pt yielded tumor growth curves that were comparable to mice that received full doses of radiation. Immune profiling revealed differences in proportions of tumor invading lymphocytes in mice that underwent GNS/Pt versus plain polymer.</p>\n\n<p><strong>Conclusion:</strong> As upfront management of residual tumor cells perioperatively has been demonstrated to improve patient outcomes, further work is required to develop other technologies in this clinical space. This drug-eluting polymer may represent an avenue wherein many types of systemic therapies are delivered in a targeted fashion. Further characterization of the immune profile of this technology is needed to understand how this platform can synergize with existing neoadjuvant immunotherapeutic strategies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153936--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S361",
      "content_id": "155336",
      "abstract_number": "S361",
      "poster_number": "",
      "title": "Cost-Effectiveness of a Navigation-Based Intervention to Improve Timely Postoperative Radiation Therapy Initiation in Head and Neck Squamous Cell Carcinoma",
      "summary": "For patients with locally advanced HNSCC undergoing surgery and PORT, NDURE was a cost saving intervention. Relative to novel immune checkpoint inhibitors, which improve outcomes at substantial cost to the payor (e.g., payor cost of $86,983 per QALY gained), NDURE increases QALYs while at the same time reducing overall costs. These findings support the financial sustainability of payor coverage for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155336",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan M Hughes, BS",
      "presenter": "Jonathan M Hughes, BS",
      "authors": "Jonathan M Hughes, BS 1 ; Haluk Damgacioglu, PhD 1 ; Poria Dorali, PhD 1 ; Vlad C Sandulache, MD, PhD 2 ; Bhisham S Chera, MD 1 ; Katherine R Sterba, PhD, MPH 1 ; Chanita Hughes-Halbert, PhD 3 ; Emily Kistner-Griffin, PhD 1 ; Reid DeMass, MS 1 ; Elizabeth G Hill, PhD 1 ; Jason G Newman, MD 1 ; W. Greer Albergotti, MD 1 ; Dauren Adilbay, MD, PhD 1 ; Alex E Kejner, MD 1 ; Judith M Skoner, MD 1 ; Michael Bobian, MD 1 ; Jennifer L Harper, MD 1 ; John Kaczmar, MD 1 ; Savannah A Zimmerman, BSN, RN 1 ; Stacy Stewart, BSN, RN 1 ; David J Hernandez, MD 2 ; Ryan S Jackson, MD 4 ; Sidharth V Puram, MD, PhD 4 ; Russel Kahmke, MD, MBA, MMCi 5 ; Nosayaba Osazuwa-Peters, PhD, MPH, BDS 5 ; Gail Jackson 6 ; Brian Nussenbaum, MD, MHCM 4 ; Sue S Yom, MD, PhD 7 ; Ashish A Deshmukh, PhD, MPH 1 ; Evan M Graboyes, MD, MPH 1",
      "normalized_authors": [
        "Jonathan M Hughes",
        "Haluk Damgacioglu",
        "Poria Dorali",
        "Vlad C Sandulache",
        "Bhisham S Chera",
        "Katherine R Sterba",
        "Chanita Hughes-Halbert",
        "Emily Kistner-Griffin",
        "Reid DeMass",
        "Elizabeth G Hill",
        "Jason G Newman",
        "W. Greer Albergotti",
        "Dauren Adilbay",
        "Alex E Kejner",
        "Judith M Skoner",
        "Michael Bobian",
        "Jennifer L Harper",
        "John Kaczmar",
        "Savannah A Zimmerman, BSN",
        "Stacy Stewart, BSN",
        "David J Hernandez",
        "Ryan S Jackson",
        "Sidharth V Puram",
        "Russel Kahmke, MMCi",
        "Nosayaba Osazuwa-Peters, BDS",
        "Gail Jackson",
        "Brian Nussenbaum, MHCM",
        "Sue S Yom",
        "Ashish A Deshmukh",
        "Evan M Graboyes"
      ],
      "affiliations": [
        "Medical University of South Carolina",
        "Baylor College of Medicine",
        "University of Southern California",
        "Washington University in St. Louis",
        "Duke University",
        "Head & Neck Cancer Alliance",
        "University of California San Francisco"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina",
        "Baylor College of Medicine",
        "University of Southern California",
        "Washington University in St. Louis",
        "Duke University",
        "Head & Neck Cancer Alliance",
        "University of California San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jonathan M Hughes, BS 1 ; Haluk Damgacioglu, PhD 1 ; Poria Dorali, PhD 1 ; Vlad C Sandulache, MD, PhD 2 ; Bhisham S Chera, MD 1 ; Katherine R Sterba, PhD, MPH 1 ; Chanita Hughes-Halbert, PhD 3 ; Emily Kistner-Griffin, PhD 1 ; Reid DeMass, MS 1 ; Elizabeth G Hill, PhD 1 ; Jason G Newman, MD 1 ; W. Greer Albergotti, MD 1 ; Dauren Adilbay, MD, PhD 1 ; Alex E Kejner, MD 1 ; Judith M Skoner, MD 1 ; Michael Bobian, MD 1 ; Jennifer L Harper, MD 1 ; John Kaczmar, MD 1 ; Savannah A Zimmerman, BSN, RN 1 ; Stacy Stewart, BSN, RN 1 ; David J Hernandez, MD 2 ; Ryan S Jackson, MD 4 ; Sidharth V Puram, MD, PhD 4 ; Russel Kahmke, MD, MBA, MMCi 5 ; Nosayaba Osazuwa-Peters, PhD, MPH, BDS 5 ; Gail Jackson 6 ; Brian Nussenbaum, MD, MHCM 4 ; Sue S Yom, MD, PhD 7 ; Ashish A Deshmukh, PhD, MPH 1 ; Evan M Graboyes, MD, MPH 1",
        "Affiliations": "1 Medical University of South Carolina; 2 Baylor College of Medicine; 3 University of Southern California; 4 Washington University in St. Louis; 5 Duke University; 6 Head & Neck Cancer Alliance; 7 University of California San Francisco",
        "Background": "Delays in initiating guideline-concordant postoperative radiation therapy (PORT) for patients with head and neck squamous cell carcinoma (HNSCC) are common and lead to worse outcomes, including higher rates of recurrence and excess mortality. Navigation for Disparities and Untimely Radiation thErapy (NDURE)—multilevel intervention, navigation-based—improved initiation of timely PORT by 35% (74% vs 39%) compared with usual care (UC). However, its cost-effectiveness remains unknown, limiting broader adoption and long-term sustainability.",
        "Methods": "We developed a semi-Markov microsimulation model to evaluate the cost-effectiveness of NDURE compared with UC from the health care sector perspective. The model simulated a cohort of patients with locally advanced HNSCC undergoing surgery and PORT, incorporating probabilities of timely PORT initiation and transition across key health states, including locoregional recurrence, distant metastasis, and death. The transition probabilities were derived from outcomes reported in clinical trials of patients with locally advanced HNSCC undergoing surgery and PORT, including RTOG 9501 and KEYNOTE-689. Health state utilities (quality of life scores) and treatment costs for initial therapy, management of recurrence, ongoing care, and terminal care were obtained from the literature. Intervention effects on timely PORT initiation were obtained from the NDURE RCT data, and intervention costs were estimated using navigator time from the trial and publicly available salary data. Model outputs included life expectancy, lifetime costs, and quality-adjusted life-years (QALYs), with lifetime costs and QALYs discounted at 3% annually. Cost-effectiveness was expressed as the incremental cost per QALY gained.",
        "Results": "Improved timely PORT initiation with NDURE led to gains in recurrence-free and overall survival, resulting in 1.34 additional QALYs per patient compared with UC (NDURE = 6.66 vs UC = 5.32 discounted lifetime QALYs). Delivering NDURE cost $93.01 per patient. NDURE was cost-saving, reducing mean lifetime treatment costs by $517.78 per patient (NDURE = $128,933 vs UC = $129,451). Sensitivity analyses indicated that findings were most influenced by the effectiveness of NDURE in improving timely PORT initiation.",
        "Conclusions": "For patients with locally advanced HNSCC undergoing surgery and PORT, NDURE was a cost saving intervention. Relative to novel immune checkpoint inhibitors, which improve outcomes at substantial cost to the payor (e.g., payor cost of $86,983 per QALY gained), NDURE increases QALYs while at the same time reducing overall costs. These findings support the financial sustainability of payor coverage for navigation-based programs such as NDURE and support the adoption of navigation-based strategies to improve oncologic outcomes for patients with locally advanced HNSCC receiving surgery and PORT.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cost-Effectiveness of a Navigation-Based Intervention to Improve Timely Postoperative Radiation Therapy Initiation in Head and Neck Squamous Cell Carcinoma</span>. <u>Jonathan M Hughes, BS</u><sup>1</sup>; Haluk Damgacioglu, PhD<sup>1</sup>; Poria Dorali, PhD<sup>1</sup>; Vlad C Sandulache, MD, PhD<sup>2</sup>; Bhisham S Chera, MD<sup>1</sup>; Katherine R Sterba, PhD, MPH<sup>1</sup>; Chanita Hughes-Halbert, PhD<sup>3</sup>; Emily Kistner-Griffin, PhD<sup>1</sup>; Reid DeMass, MS<sup>1</sup>; Elizabeth G Hill, PhD<sup>1</sup>; Jason G Newman, MD<sup>1</sup>; W. Greer Albergotti, MD<sup>1</sup>; Dauren Adilbay, MD, PhD<sup>1</sup>; Alex E Kejner, MD<sup>1</sup>; Judith M Skoner, MD<sup>1</sup>; Michael Bobian, MD<sup>1</sup>; Jennifer L Harper, MD<sup>1</sup>; John Kaczmar, MD<sup>1</sup>; Savannah A Zimmerman, BSN, RN<sup>1</sup>; Stacy Stewart, BSN, RN<sup>1</sup>; David J Hernandez, MD<sup>2</sup>; Ryan S Jackson, MD<sup>4</sup>; Sidharth V Puram, MD, PhD<sup>4</sup>; Russel Kahmke, MD, MBA, MMCi<sup>5</sup>; Nosayaba Osazuwa-Peters, PhD, MPH, BDS<sup>5</sup>; Gail Jackson<sup>6</sup>; Brian Nussenbaum, MD, MHCM<sup>4</sup>; Sue S Yom, MD, PhD<sup>7</sup>; Ashish A Deshmukh, PhD, MPH<sup>1</sup>; Evan M Graboyes, MD, MPH<sup>1</sup>. <sup>1</sup>Medical University of South Carolina; <sup>2</sup>Baylor College of Medicine; <sup>3</sup>University of Southern California; <sup>4</sup>Washington University in St. Louis; <sup>5</sup>Duke University; <sup>6</sup>Head & Neck Cancer Alliance; <sup>7</sup>University of California San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Delays in initiating guideline-concordant postoperative radiation therapy (PORT) for patients with head and neck squamous cell carcinoma (HNSCC) are common and lead to worse outcomes, including higher rates of recurrence and excess mortality. Navigation for Disparities and Untimely Radiation thErapy (NDURE)—multilevel intervention, navigation-based—improved initiation of timely PORT by 35% (74% vs 39%) compared with usual care (UC). However, its cost-effectiveness remains unknown, limiting broader adoption and long-term sustainability.</p>\n\n<p><strong>Methods:</strong> We developed a semi-Markov microsimulation model to evaluate the cost-effectiveness of NDURE compared with UC from the health care sector perspective. The model simulated a cohort of patients with locally advanced HNSCC undergoing surgery and PORT, incorporating probabilities of timely PORT initiation and transition across key health states, including locoregional recurrence, distant metastasis, and death. The transition probabilities were derived from outcomes reported in clinical trials of patients with locally advanced HNSCC undergoing surgery and PORT, including RTOG 9501 and KEYNOTE-689. Health state utilities (quality of life scores) and treatment costs for initial therapy, management of recurrence, ongoing care, and terminal care were obtained from the literature. Intervention effects on timely PORT initiation were obtained from the NDURE RCT data, and intervention costs were estimated using navigator time from the trial and publicly available salary data. Model outputs included life expectancy, lifetime costs, and quality-adjusted life-years (QALYs), with lifetime costs and QALYs discounted at 3% annually. Cost-effectiveness was expressed as the incremental cost per QALY gained.</p>\n\n<p><strong>Results: </strong>Improved timely PORT initiation with NDURE led to gains in recurrence-free and overall survival, resulting in 1.34 additional QALYs per patient compared with UC (NDURE = 6.66 vs UC = 5.32 discounted lifetime QALYs). Delivering NDURE cost $93.01 per patient. NDURE was cost-saving, reducing mean lifetime treatment costs by $517.78 per patient (NDURE = $128,933 vs UC = $129,451). Sensitivity analyses indicated that findings were most influenced by the effectiveness of NDURE in improving timely PORT initiation.</p>\n\n<p><strong>Conclusions: </strong>For patients with locally advanced HNSCC undergoing surgery and PORT, NDURE was a cost saving intervention. Relative to novel immune checkpoint inhibitors, which improve outcomes at substantial cost to the payor (e.g., payor cost of $86,983 per QALY gained), NDURE increases QALYs while at the same time reducing overall costs. These findings support the financial sustainability of payor coverage for navigation-based programs such as NDURE and support the adoption of navigation-based strategies to improve oncologic outcomes for patients with locally advanced HNSCC receiving surgery and PORT.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155336--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S362",
      "content_id": "153370",
      "abstract_number": "S362",
      "poster_number": "",
      "title": "Trends in Postoperative Radiotherapy Timing and Overall Survival in Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Across more than 50 international healthcare organizations, adherence to the 6-week PORT benchmark for OPSCC has steadily improved over the past decade, increasing from 60% to over 73%. Nonetheless, over one-quarter of patients continue to experience treatment delays. Even modest delays beyond 6 weeks are associated with significantly higher 2- and 3-year mortality, reinforcing the CoC’s 6-week guideline as a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153370",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ismail M Khaderi, BS",
      "presenter": "Ismail M Khaderi, BS",
      "authors": "Ismail M Khaderi, BS 1 ; Ahmad J Odeh, BS 1 ; David Strum, MD 2 ; Trevor G Hackman, MD, FACS 2",
      "normalized_authors": [
        "Ismail M Khaderi",
        "Ahmad J Odeh",
        "David Strum",
        "Trevor G Hackman"
      ],
      "affiliations": [
        "UNC School of Medicine",
        "UNC Dept. of Otolaryngology/Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "UNC School of Medicine",
        "UNC Dept. of Otolaryngology/Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153370/PORT%20Compliance%20Figure%20AHNS(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153370/PORT%20Compliance%20Figure%20AHNS(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153370"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ismail M Khaderi, BS 1 ; Ahmad J Odeh, BS 1 ; David Strum, MD 2 ; Trevor G Hackman, MD, FACS 2",
        "Affiliations": "1 UNC School of Medicine; 2 UNC Dept. of Otolaryngology/Head and Neck Surgery",
        "Introduction": "The Commission on Cancer (CoC) issued a 2021 recommendation that patients with head and neck squamous cell carcinoma begin postoperative radiotherapy (PORT) within 6 weeks of surgery. Delays beyond this threshold are associated with worse survival, particularly in oropharyngeal squamous cell carcinoma (OPSCC). At the same time, the growing incidence of OPSCC and the expanded use of transoral robotic surgery (TORS) have increased the number of surgically managed cases requiring timely PORT. Despite this, national adherence to the CoC benchmark remains poorly defined. Understanding real-world performance across diverse healthcare organizations is essential for establishing achievable quality benchmarks. This study evaluates PORT timing and associated overall survival across a multi-institutional international cohort.",
        "Methods": "Using the TriNetX research network, adult patients diagnosed with OPSCC from 2015–2024 were identified across up to 102 healthcare organizations. Patients included in analysis underwent primary surgical treatment (n=10,601). PORT timing was calculated from the surgery date to the first radiation dose. Compliance was defined as PORT within 6 weeks; additional intervals of 6–8, 8–10, 10–12, and 6-12 weeks were analyzed. Annual compliance proportions were calculated. Mortality outcomes at 1, 2, and 3 years were assessed for each cohort. Matched analyses controlled for age, sex, race, and HPV-related ICD codes.",
        "Results": "Among surgical OPSCC patients, 3,459 received PORT within 12 weeks, and 2,392 received PORT within 6 weeks. Overall, 32.6% of patients required adjuvant radiotherapy within 12 weeks of surgery with an overall 69.2% success rate in timing according to the CoC benchmark. Compliance with the 6-week CoC benchmark increased over time, rising from 59.6% in 2015 to 73.4% in 2024",
        "Abstract": "The mortality rate in patients with PORT <6 weeks was 7.1% at 1 year, 10.8% at 2 years, and 12.8% at 3 years. Delays were associated with non-significant but higher mortality across all intervals, including 6–8 weeks (14.2% at 3 years), 8–10 weeks (14.5%), and 10–12 weeks (14.8%) Matched comparisons showed significantly higher 2-year (12.3% vs 8.6%, p=0.027) and 3-year mortality (14.3% vs 11.4%, p=0.106) for PORT at 6–8 weeks compared with <6 weeks, with similar trends for 8–10 weeks. For the 6–12-week combined group, matched 2-year (12.5% vs 9.4%, p=0.0216) and 3-year mortality (14.8% vs 11.6%, p=0.0291) were significantly worse than timely PORT. View in Agenda and Add to Schedule",
        "Conclusion": "Across more than 50 international healthcare organizations, adherence to the 6-week PORT benchmark for OPSCC has steadily improved over the past decade, increasing from 60% to over 73%. Nonetheless, over one-quarter of patients continue to experience treatment delays. Even modest delays beyond 6 weeks are associated with significantly higher 2- and 3-year mortality, reinforcing the CoC’s 6-week guideline as a meaningful quality metric. These findings provide the first multi-institutional, real-world estimate of national compliance in OPSCC and highlight an opportunity to employ targeted quality improvement strategies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Trends in Postoperative Radiotherapy Timing and Overall Survival in Oropharyngeal Squamous Cell Carcinoma</span>. <u>Ismail M Khaderi, BS</u><sup>1</sup>; Ahmad J Odeh, BS<sup>1</sup>; David Strum, MD<sup>2</sup>; Trevor G Hackman, MD, FACS<sup>2</sup>. <sup>1</sup>UNC School of Medicine; <sup>2</sup>UNC Dept. of Otolaryngology/Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The Commission on Cancer (CoC) issued a 2021 recommendation that patients with head and neck squamous cell carcinoma begin postoperative radiotherapy (PORT) within 6 weeks of surgery. Delays beyond this threshold are associated with worse survival, particularly in oropharyngeal squamous cell carcinoma (OPSCC). At the same time, the growing incidence of OPSCC and the expanded use of transoral robotic surgery (TORS) have increased the number of surgically managed cases requiring timely PORT. Despite this, national adherence to the CoC benchmark remains poorly defined. Understanding real-world performance across diverse healthcare organizations is essential for establishing achievable quality benchmarks. This study evaluates PORT timing and associated overall survival across a multi-institutional international cohort.</p>\n\n<p><strong>Methods: </strong>Using the TriNetX research network, adult patients diagnosed with OPSCC from 2015–2024 were identified across up to 102 healthcare organizations. Patients included in analysis underwent primary surgical treatment (n=10,601). PORT timing was calculated from the surgery date to the first radiation dose. Compliance was defined as PORT within 6 weeks; additional intervals of 6–8, 8–10, 10–12, and 6-12 weeks were analyzed. Annual compliance proportions were calculated. Mortality outcomes at 1, 2, and 3 years were assessed for each cohort. Matched analyses controlled for age, sex, race, and HPV-related ICD codes.</p>\n\n<p><strong>Results: </strong>Among surgical OPSCC patients, 3,459 received PORT within 12 weeks, and 2,392 received PORT within 6 weeks. Overall, 32.6% of patients required adjuvant radiotherapy within 12 weeks of surgery with an overall 69.2% success rate in timing according to the CoC benchmark. Compliance with the 6-week CoC benchmark increased over time, rising from 59.6% in 2015 to 73.4% in 2024</p>\n\n<p>The mortality rate in patients with  PORT <6 weeks was 7.1% at 1 year, 10.8% at 2 years, and 12.8% at 3 years. Delays were associated with non-significant but higher mortality across all intervals, including 6–8 weeks (14.2% at 3 years), 8–10 weeks (14.5%), and 10–12 weeks (14.8%)</p>\n\n<p>Matched comparisons showed significantly higher 2-year (12.3% vs 8.6%, p=0.027) and 3-year mortality (14.3% vs 11.4%, p=0.106) for PORT at 6–8 weeks compared with <6 weeks, with similar trends for 8–10 weeks. For the 6–12-week combined group, matched 2-year (12.5% vs 9.4%, p=0.0216) and 3-year mortality (14.8% vs 11.6%, p=0.0291) were significantly worse than timely PORT.</p>\n\n<p><strong>Conclusion: </strong>Across more than 50 international healthcare organizations, adherence to the 6-week PORT benchmark for OPSCC has steadily improved over the past decade, increasing from 60% to over 73%. Nonetheless, over one-quarter of patients continue to experience treatment delays. Even modest delays beyond 6 weeks are associated with significantly higher 2- and 3-year mortality, reinforcing the CoC’s 6-week guideline as a meaningful quality metric. These findings provide the first multi-institutional, real-world estimate of national compliance in OPSCC and highlight an opportunity to employ targeted quality improvement strategies.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153370/PORT%20Compliance%20Figure%20AHNS(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153370--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S363",
      "content_id": "154086",
      "abstract_number": "S363",
      "poster_number": "",
      "title": "Biologically Guided Dose Escalation to 77 Gy in Locally Advanced Head and Neck Squamous Carcinoma Patients (LAHNSCC): Feasibility, Safety, and Early Control Outcomes From a Prospective Study",
      "summary": "Dose escalation using biological tumor volume is feasible and results in a superior outcome in terms of local control with a manageable level of grade 3 toxicities. This could be a future area of research to decrease local recurrences. However, a multicenter study with a larger number of patients and longer follow-up would be required to validate the same",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154086",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Umesh Velu",
      "presenter": "Umesh Velu",
      "authors": "Umesh Velu ; Anoushka Taneja; Shirley Lewis; Ankita Mehta; Jayashree NP; Rabia S Angiras; Akshay Dinesan",
      "normalized_authors": [
        "Umesh Velu",
        "Anoushka Taneja",
        "Shirley Lewis",
        "Ankita Mehta",
        "Jayashree NP",
        "Rabia S Angiras",
        "Akshay Dinesan"
      ],
      "affiliations": [
        "Kasturba Medical College"
      ],
      "normalized_institutions": [
        "Kasturba Medical College"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 419,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Umesh Velu ; Anoushka Taneja; Shirley Lewis; Ankita Mehta; Jayashree NP; Rabia S Angiras; Akshay Dinesan",
        "Affiliations": "Kasturba Medical College",
        "Background": "The standard of care for inoperable LAHNSCC is radical chemoradiotherapy of 70 Gy in 35 daily fractions with concurrent Cisplatin/Carboplatin. However, up to 40-50% of patients recur locally within 5 years of treatment. Hence, we have tried to evaluate the role of dose escalation with dose painting IMRT using a Biological tumor volume. Local control at 3 months is the primary objective, with overall survival (OS) being the secondary objective.",
        "Methods": "Biopsy-proven LAHNSCC patients who were planned for Radical CTRT were considered for this study. The planning Radiotherapy Computed Tomogram (CT) was taken using Positron Emission Tomography (PET) with Fluoro-Deoxy-Glucose (FDG) as contrast. The patients whose initial tumour volume was more than 40cc were considered for dose escalation. The dose volumes were contoured according to standard guidelines. The volume of CT with SUV of more than 3 was considered for dose escalation. They were planned for 2.2 Gray per fraction, amounting to a total of 77 Gy in 35 fractions. The dose constraints were achieved according to QUANTEC. The patients were followed up every week during Radiotherapy. The radiation reactions were monitored and graded according to Radiotherapy Oncology Group (RTOG) guidelines. The acute and late reactions were documented. The follow-up was according to institutional protocol. A PETCECT was repeated at 3 months after completion of CTRT.",
        "Results": "The study period was between January 2023 and March 2024. Fourty three patients underwent PET CECT based image acquisition. 24 patients who fit in our inclusion criteria were recruited for this study, all of whom completed the intended treatment protocol. The mean age was 59 years, with a male-to-female ratio of 2.5:1. Ten patients had oropharyngeal malignancies, Six had hypopharyngeal malignancies, four had laryngeal, and Four had oral cavity cancer. Sixteen patients had stage IV A disease, and 19 patients showed a complete metabolic response on PET CECT conducted 3 months post-CTRT. Local control at 3 months was 85%, and at 1 year, it was 76%. Overall survival (OS) at 1 year was 96%. One patient developed a cardiovascular event. Seventeen percent of patients experienced grade 3 Acute RTOG reactions, which were managed conservatively.",
        "Conclusion": "Dose escalation using biological tumor volume is feasible and results in a superior outcome in terms of local control with a manageable level of grade 3 toxicities. This could be a future area of research to decrease local recurrences. However, a multicenter study with a larger number of patients and longer follow-up would be required to validate the same",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biologically Guided Dose Escalation to 77 Gy in Locally Advanced Head and Neck Squamous Carcinoma Patients (LAHNSCC): Feasibility, Safety, and Early Control Outcomes From a Prospective Study</span>. <u>Umesh Velu</u>; Anoushka Taneja; Shirley Lewis; Ankita Mehta; Jayashree NP; Rabia S Angiras; Akshay Dinesan. Kasturba Medical College<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The standard of care for inoperable LAHNSCC is radical chemoradiotherapy of 70 Gy in 35 daily fractions with concurrent Cisplatin/Carboplatin. However, up to 40-50% of patients recur locally within 5 years of treatment. Hence, we have tried to evaluate the role of dose escalation with dose painting IMRT using a Biological tumor volume. Local control at 3 months is the primary objective, with overall survival (OS) being the secondary objective.</p>\n\n<p><strong>Methods: </strong>Biopsy-proven LAHNSCC patients who were planned for Radical CTRT were considered for this study. The planning Radiotherapy Computed Tomogram (CT) was taken using Positron Emission Tomography (PET) with Fluoro-Deoxy-Glucose (FDG) as contrast. The patients whose initial tumour volume was more than 40cc were considered for dose escalation.  The dose volumes were contoured according to standard guidelines. The volume of CT with SUV of more than 3 was considered for dose escalation. They were planned for 2.2 Gray per fraction, amounting to a total of 77 Gy in 35 fractions. The dose constraints were achieved according to QUANTEC. The patients were followed up every week during Radiotherapy. The radiation reactions were monitored and graded according to Radiotherapy Oncology Group (RTOG) guidelines. The acute and late reactions were documented. The follow-up was according to institutional protocol. A PETCECT was repeated at 3 months after completion of CTRT.</p>\n\n<p><strong>Results: </strong>The study period was between January 2023 and March 2024. Fourty three patients underwent PET CECT based image acquisition. 24 patients who fit in our inclusion criteria  were recruited for this study, all of whom completed the intended treatment protocol. The mean age was 59 years, with a male-to-female ratio of 2.5:1. Ten patients had oropharyngeal malignancies, Six had hypopharyngeal malignancies, four had laryngeal, and Four had oral cavity cancer. Sixteen patients had stage IV A disease, and 19 patients showed a complete metabolic response on PET CECT conducted 3 months post-CTRT. Local control at 3 months was 85%, and at 1 year, it was 76%. Overall survival (OS) at 1 year was 96%. One patient developed a cardiovascular event. Seventeen percent of patients experienced grade 3 Acute RTOG reactions, which were managed conservatively.</p>\n\n<p><strong>Conclusion: </strong>Dose escalation using biological tumor volume is feasible and results in a superior outcome in terms of local control with a manageable level of grade 3 toxicities. This could be a future area of research to decrease local recurrences. However, a multicenter study with a larger number of patients and longer follow-up would be required to validate the same</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154086--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S364",
      "content_id": "154164",
      "abstract_number": "S364",
      "poster_number": "",
      "title": "The Efficacy and Safety of Adding a Systemic Therapy to Radiotherapy for Definitive Treatment in Head and Neck Squamous cell Cancer Patients Older than 70 Years",
      "summary": "Our real-world data demonstrate that systemic therapy can be safely added to RT in patients ≥70, with disease-free survival outcomes equivalent to those observed in younger individuals. These results support selective use of CRT in well-chosen older adults and highlight the need for individualized treatment planning in this growing demographic.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154164",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tara Coreanu",
      "presenter": "Tara Coreanu",
      "authors": "Tara Coreanu ; Nofar Edri, MD; Noga Kurman, MD; Eyal Yosefof, MD",
      "normalized_authors": [
        "Tara Coreanu",
        "Nofar Edri",
        "Noga Kurman",
        "Eyal Yosefof"
      ],
      "affiliations": [
        "Rabin Medical Center"
      ],
      "normalized_institutions": [
        "Rabin Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 353,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tara Coreanu ; Nofar Edri, MD; Noga Kurman, MD; Eyal Yosefof, MD",
        "Affiliations": "Rabin Medical Center",
        "Background": "Landmark trials have demonstrated improved overall survival (OS) with the addition of systemic therapy to definitive radiotherapy (RT) in head and neck squamous cell carcinoma (HNSCC). However, patients aged ≥70 derived no clear benefit, raising concerns regarding toxicity and real-world applicability. With modern advances in IMRT and supportive care and with the growing understanding that biological and chronological ages may diverge, the tolerability of chemoradiotherapy (CRT) in older adults warrants re-evaluation.",
        "Objectives": "To assess the safety and efficacy of adding systemic therapy to definitive RT in HNSCC patients aged ≥70, compared with younger patients, and to determine whether CRT improves OS relative to RT alone in the ≥70 cohort.",
        "Methods": "We included all patients above the age of 18 years who were treated with definitive intent radiotherapy for mucosal origin HNSCC, with or without a systemic radiosensitizer between the years 2017-2023 in a tertiary medical center.",
        "Results": "A total of 451 patients met inclusion criteria, including 191 (42%) aged ≥70; 236 patients (52%) received CRT. Among older adults, CRT did not significantly increase most acute toxicities compared with younger patients, including mucositis (37% vs. 46%), dermatitis (67.6% vs. 58.7%), nutritional support requirements (18.5% vs. 23.8%), or hospitalization rates (12.1% vs. 19%). Although systemic edema (6.9% vs. 15.9%) and neutropenic fever (2.3% vs. 12.7%) were more common in the ≥70 cohort, overall toxicity remained comparable (87.9% vs. 93.7%). Disease-free survival did not differ significantly between younger and older patients (77.4±2.72 vs. 67.35±5.16 months, p=0.145). In patients ≥70, OS was similar between those treated with CRT and those receiving RT alone for advanced stage disease (Stage III or IV) (40.909±4.26 vs. 46.47±4.96 months, p=0.378).",
        "Conclusions": "Our real-world data demonstrate that systemic therapy can be safely added to RT in patients ≥70, with disease-free survival outcomes equivalent to those observed in younger individuals. These results support selective use of CRT in well-chosen older adults and highlight the need for individualized treatment planning in this growing demographic.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Efficacy and Safety of Adding a Systemic Therapy to Radiotherapy for Definitive Treatment in Head and Neck Squamous cell Cancer Patients Older than 70 Years</span>. <u>Tara Coreanu</u>; Nofar Edri, MD; Noga Kurman, MD; Eyal Yosefof, MD. Rabin Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Landmark trials have demonstrated improved overall survival (OS) with the addition of systemic therapy to definitive radiotherapy (RT) in head and neck squamous cell carcinoma (HNSCC). However, patients aged ≥70 derived no clear benefit, raising concerns regarding toxicity and real-world applicability. With modern advances in IMRT and supportive care and with the growing understanding that biological and chronological ages may diverge, the tolerability of chemoradiotherapy (CRT) in older adults warrants re-evaluation.</p>\n\n<p><strong>Objectives: </strong>To assess the safety and efficacy of adding systemic therapy to definitive RT in HNSCC patients aged ≥70, compared with younger patients, and to determine whether CRT improves OS relative to RT alone in the ≥70 cohort.</p>\n\n<p><strong>Methods: </strong>We included all patients above the age of 18 years who were treated with definitive intent radiotherapy for mucosal origin HNSCC, with or without a systemic radiosensitizer between the years 2017-2023 in a tertiary medical center.</p>\n\n<p><strong>Results: </strong>A total of 451 patients met inclusion criteria, including 191 (42%) aged ≥70; 236 patients (52%) received CRT. Among older adults, CRT did not significantly increase most acute toxicities compared with younger patients, including mucositis (37% vs. 46%), dermatitis (67.6% vs. 58.7%), nutritional support requirements (18.5% vs. 23.8%), or hospitalization rates (12.1% vs. 19%). Although systemic edema (6.9% vs. 15.9%) and neutropenic fever (2.3% vs. 12.7%) were more common in the ≥70 cohort, overall toxicity remained comparable (87.9% vs. 93.7%). Disease-free survival did not differ significantly between younger and older patients (77.4±2.72 vs. 67.35±5.16 months, p=0.145). In patients ≥70, OS was similar between those treated with CRT and those receiving RT alone for advanced stage disease (Stage III or IV) (40.909±4.26 vs. 46.47±4.96 months, p=0.378).</p>\n\n<p><strong>Conclusions: </strong>Our real-world data demonstrate that systemic therapy can be safely added to RT in patients ≥70, with disease-free survival outcomes equivalent to those observed in younger individuals.  These results support selective use of CRT in well-chosen older adults and highlight the need for individualized treatment planning in this growing demographic.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154164--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S365",
      "content_id": "154165",
      "abstract_number": "S365",
      "poster_number": "",
      "title": "Management of Locally Advanced and Metastatic Head and Neck Squamous Cell Carcinoma in Elderly Patients Using Diffusing Alpha-Emitter Radiation Therapy in Combination with Pembrolizumab",
      "summary": "All patients tolerated Alpha DaRT therapy well. In this early study, the metastatic and locally advanced head and neck cancer patients responded with a favorable safety profile. Furthermore, median progression free survival in this sample which included some more challenging cases (5.6 months) surpassed that of patients treated with Pembrolizumab alone (3.4 months, Burtness et al. 2019). Given these initial...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154165",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aron Popovtzer, MD",
      "presenter": "Aron Popovtzer, MD",
      "authors": "Aron Popovtzer, MD ; Liat Appelbaum, MD; Yoram Fleissig, DMD; Jon Feldman, MS; Aiiman Salhav; Jhonatan Elia, MD; Nir Hirshoren, MD, MHA",
      "normalized_authors": [
        "Aron Popovtzer",
        "Liat Appelbaum",
        "Yoram Fleissig",
        "Jon Feldman",
        "Aiiman Salhav",
        "Jhonatan Elia",
        "Nir Hirshoren, MHA"
      ],
      "affiliations": [
        "Sharett Cancer Institute at Hadassah Medical Center"
      ],
      "normalized_institutions": [
        "Sharett Cancer Institute at Hadassah Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 379,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials & Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aron Popovtzer, MD ; Liat Appelbaum, MD; Yoram Fleissig, DMD; Jon Feldman, MS; Aiiman Salhav; Jhonatan Elia, MD; Nir Hirshoren, MD, MHA",
        "Affiliations": "Sharett Cancer Institute at Hadassah Medical Center",
        "Introduction": "The standard treatment for CPS-Positive Metastatic Head and Neck Squamous Cell Carcinoma (mHNSCC) is immunotherapy, with or without chemotherapy. Recent studies have shown that only ~22% of patients respond to this therapy (Burtness et al. 2019). In a mice model of SCC, using Diffusing Alpha-Emitter Radiation Therapy (Alpha DaRT) alpha-particle interstitial radiotherapy in one of the lesions could enhance the systemic immunotherapy response. In this initial study we evaluated this combination in locally advanced and metastatic patients.",
        "Materials & Methods": "In this prospective study, 11 CPS-positive mHNSCC patients were treated with one course of pembrolizumab before Alpha DaRT treatment followed by additional courses of pembrolizumab. A PET-CT scan was performed and tumor response was determined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST v1.1). Safety was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0. Overall survival was evaluated using Kaplan-Meier estimates.",
        "Results": "To date, eleven patients (4 female and 7 male) were treated with Alpha DaRT. Subjects were elderly, with a mean age of 72 years (range 52-96). Patients received an average of 7 cycles of pembrolizumab (range 2-18). Tumor response data were available for nine of the patients, with the other two subjects dying prior to response evaluation. The objective response rate among evaluable cases was 100%, with four complete responses and 5 partial responses. Median overall survival was 13.5 months and median progression free survival was 5.6 months. All reported related adverse events were Grade 1.",
        "Conclusions": "All patients tolerated Alpha DaRT therapy well. In this early study, the metastatic and locally advanced head and neck cancer patients responded with a favorable safety profile. Furthermore, median progression free survival in this sample which included some more challenging cases (5.6 months) surpassed that of patients treated with Pembrolizumab alone (3.4 months, Burtness et al. 2019). Given these initial results Alpha DaRT has the potential to serve as a treatment for mHNSCC and a larger pivotal study will be performed.",
        "Abstract": "Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2020 Jan 25;395(10220):272. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Management of Locally Advanced and Metastatic Head and Neck Squamous Cell Carcinoma in Elderly Patients Using Diffusing Alpha-Emitter Radiation Therapy in Combination with Pembrolizumab</span>. <u>Aron Popovtzer, MD</u>; Liat Appelbaum, MD; Yoram Fleissig, DMD; Jon Feldman, MS; Aiiman Salhav; Jhonatan Elia, MD; Nir Hirshoren, MD, MHA. Sharett Cancer Institute at Hadassah Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> The standard treatment for CPS-Positive Metastatic Head and Neck Squamous Cell Carcinoma (mHNSCC) is immunotherapy, with or without chemotherapy. Recent studies have shown that only ~22% of patients respond to this therapy (Burtness et al. 2019). In a mice model of SCC, using Diffusing Alpha-Emitter Radiation Therapy (Alpha DaRT) alpha-particle interstitial radiotherapy in one of the lesions could enhance the systemic immunotherapy response. In this initial study we evaluated this combination in locally advanced and metastatic patients.</p>\n\n<p><strong>Materials & Methods: </strong>In this prospective study, 11 CPS-positive mHNSCC patients were treated with one course of pembrolizumab before Alpha DaRT treatment followed by additional courses of pembrolizumab. A PET-CT scan was performed and tumor response was determined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST v1.1). Safety was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0. Overall survival was evaluated using Kaplan-Meier estimates.</p>\n\n<p><strong>Results: </strong>To date, eleven patients (4 female and 7 male) were treated with Alpha DaRT. Subjects were elderly, with a mean age of 72 years (range 52-96). Patients received an average of 7 cycles of pembrolizumab (range 2-18). Tumor response data were available for nine of the patients, with the other two subjects dying prior to response evaluation. The objective response rate among evaluable cases was 100%, with four complete responses and 5 partial responses. Median overall survival was 13.5 months and median progression free survival was 5.6 months. All reported related adverse events were Grade 1.</p>\n\n<p><strong>Conclusions: </strong>All patients tolerated Alpha DaRT therapy well. In this early study, the metastatic and locally advanced head and neck cancer patients responded with a favorable safety profile. Furthermore, median progression free survival in this sample which included some more challenging cases (5.6 months) surpassed that of patients treated with Pembrolizumab alone (3.4 months, Burtness et al. 2019). Given these initial results Alpha DaRT has the potential to serve as a treatment for mHNSCC and a larger pivotal study will be performed.</p>\n\n<p><strong>References:</strong></p>\n\n<p>Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2020 Jan 25;395(10220):272.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154165--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S366",
      "content_id": "153990",
      "abstract_number": "S366",
      "poster_number": "",
      "title": "Exploring the Role of PORT in Early-Stage Oral Tongue Squamous Cell Carcinoma",
      "summary": "Select patients with multiple intermediate risk factors may benefit from PORT. However, our results highlight the need for more refined risk-stratification tools to guide adjuvant treatment decisions in early-stage OTSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153990",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emma Finnegan",
      "presenter": "Emma Finnegan",
      "authors": "Emma Finnegan 1 ; Giovanna L Caxeiro, MD 1 ; Alana Eagan, MPH 1 ; Helena Levyn, MD 1 ; Daniel W Scholfield, MBChB 1 ; Daniella Karassawa Zanoni, MD 1 ; Cristina Valero, MD 1 ; Jatin P Shah, MD 1 ; Richard Wong, MD 1 ; Nancy Lee, MD 2 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
      "normalized_authors": [
        "Emma Finnegan",
        "Giovanna L Caxeiro",
        "Alana Eagan",
        "Helena Levyn",
        "Daniel W Scholfield, MBChB",
        "Daniella Karassawa Zanoni",
        "Cristina Valero",
        "Jatin P Shah",
        "Richard Wong",
        "Nancy Lee",
        "Snehal G Patel",
        "Ian Ganly"
      ],
      "affiliations": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"
      ],
      "normalized_institutions": [
        "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 300,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emma Finnegan 1 ; Giovanna L Caxeiro, MD 1 ; Alana Eagan, MPH 1 ; Helena Levyn, MD 1 ; Daniel W Scholfield, MBChB 1 ; Daniella Karassawa Zanoni, MD 1 ; Cristina Valero, MD 1 ; Jatin P Shah, MD 1 ; Richard Wong, MD 1 ; Nancy Lee, MD 2 ; Snehal G Patel, MD 1 ; Ian Ganly, MD, PhD 1",
        "Affiliations": "1 Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY",
        "Introduction": "The role of postoperative radiotherapy (PORT) in early-stage oral tongue squamous cell carcinoma (OTSCC) remains controversial. This study evaluates the oncologic impact of PORT in a large cohort of early stage OTSCC patients.",
        "Methods": "A retrospective review of 571 patients with pT1-2N0M0 OTSCC with surgery with/without PORT treated at a tertiary cancer center (1985-2015) was performed. Oncologic outcomes, including overall survival (OS), disease-specific survival (DSS), local recurrence-free survival (LRFS) and regional recurrence-free survival (RRFS) were assessed using Kaplan-Meier and Cox regression analyses. Propensity score matching was performed to balance clinicopathological variables, including depth of invasion > 5 mm, lymphovascular invasion, perineural invasion, high grade and close margins. between patients treated with PORT and without PORT.",
        "Results": "Of 571 patients, 523 (91.6%) underwent surgery alone and 48 (8.4%) received PORT. The PORT group had a greater comorbidity burden and increased rates of high-risk features, including higher T stage, greater depth of invasion, perineural invasion and close margins. In the overall cohort, patients treated with PORT had similar overall survival (OS), disease specific survival (DSS), local recurrence free survival (LRFS) and regional recurrence free survival (RRFS) compared to patients treated without PORT. On multivariable analysis, depth of invasion > 5 mm and lymphovascular invasion were associated with poorer DSS, while DOI > 5 mm was associated with poorer RRFS. After propensity score matching, a superior OS was observed in the PORT cohort though there was no difference in DSS, LRFS or RRFS. Patients with 3 or more intermediate risk factors had improved OS when treated with PORT. However, there was no difference in LRFS, RRFS or DSS",
        "Conclusion": "Select patients with multiple intermediate risk factors may benefit from PORT. However, our results highlight the need for more refined risk-stratification tools to guide adjuvant treatment decisions in early-stage OTSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Exploring the Role of PORT in Early-Stage Oral Tongue Squamous Cell Carcinoma</span>. <u>Emma Finnegan</u><sup>1</sup>; Giovanna L Caxeiro, MD<sup>1</sup>; Alana Eagan, MPH<sup>1</sup>; Helena Levyn, MD<sup>1</sup>; Daniel W Scholfield, MBChB<sup>1</sup>; Daniella Karassawa Zanoni, MD<sup>1</sup>; Cristina Valero, MD<sup>1</sup>; Jatin P Shah, MD<sup>1</sup>; Richard Wong, MD<sup>1</sup>; Nancy Lee, MD<sup>2</sup>; Snehal G Patel, MD<sup>1</sup>; Ian Ganly, MD, PhD<sup>1</sup>. <sup>1</sup>Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> The role of postoperative radiotherapy (PORT) in early-stage oral tongue squamous cell carcinoma (OTSCC) remains controversial. This study evaluates the oncologic impact of PORT in a large cohort of early stage OTSCC patients.</p>\n\n<p><strong>Methods:</strong> A retrospective review of 571 patients with pT1-2N0M0 OTSCC with surgery with/without PORT treated at a tertiary cancer center (1985-2015) was performed. Oncologic outcomes, including overall survival (OS), disease-specific survival (DSS), local recurrence-free survival (LRFS) and regional recurrence-free survival (RRFS) were assessed using Kaplan-Meier and Cox regression analyses. Propensity score matching was performed to balance clinicopathological variables, including depth of invasion > 5 mm, lymphovascular invasion, perineural invasion, high grade and close margins. between patients treated with PORT and without PORT.</p>\n\n<p><strong>Results:</strong> Of 571 patients, 523 (91.6%) underwent surgery alone and 48 (8.4%) received PORT. The PORT group had a greater comorbidity burden and increased rates of high-risk features, including higher T stage, greater depth of invasion, perineural invasion and close margins. In the overall cohort, patients treated with PORT had similar overall survival (OS), disease specific survival (DSS), local recurrence free survival (LRFS) and regional recurrence free survival (RRFS) compared to patients treated without PORT. On multivariable analysis, depth of invasion > 5 mm and lymphovascular invasion were associated with poorer DSS, while DOI > 5 mm was associated with poorer RRFS. After propensity score matching, a superior OS was observed in the PORT cohort though there was no difference in DSS, LRFS or RRFS. Patients with 3 or more intermediate risk factors had improved OS when treated with PORT. However, there was no difference in LRFS, RRFS or DSS</p>\n\n<p><strong>Conclusion:</strong> Select patients with multiple intermediate risk factors may benefit from PORT. However, our results highlight the need for more refined risk-stratification tools to guide adjuvant treatment decisions in early-stage OTSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153990--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S367",
      "content_id": "153635",
      "abstract_number": "S367",
      "poster_number": "",
      "title": "Exploring the Role of Novel Therapeutic Agents During Radiation for LA-HNSCC: Insights from a US Modified Delphi Consensus",
      "summary": "Results demonstrated broad alignment among U.S. clinicians regarding the high need to evolve current treatment paradigms for unresectable, platinum ineligible LA-HNSCC and incorporate therapies with novel MOAs into care. The recommendations developed reflect areas where consensus was strongest, including care coordination, patient-centered logistics, and the integration of novel modalities. Together, these steps...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153635",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Steven B Cannady, Dr",
      "presenter": "Steven B Cannady, Dr",
      "authors": "James Rocco, Dr 1 ; Jessica L Geiger, Dr 2 ; Steven B Cannady, Dr 3 ; Ezra Cohen, Dr 4 ; Ghassan El-Haddad, Dr 5 ; Colette J Shen, Dr 6 ; Randy Wei, Dr 7 ; Veronica Ashton, Ms 8 ; Kiran Devisitty, Dr 9 ; Denise D'Andrea, Dr 10 ; Marc Chioda, Mr 11 ; Loren Mell, Dr 12",
      "normalized_authors": [
        "James Rocco, Dr",
        "Jessica L Geiger, Dr",
        "Steven B Cannady, Dr",
        "Ezra Cohen, Dr",
        "Ghassan El-Haddad, Dr",
        "Colette J Shen, Dr",
        "Randy Wei, Dr",
        "Veronica Ashton",
        "Kiran Devisitty, Dr",
        "Denise D'Andrea, Dr",
        "Marc Chioda, Mr",
        "Loren Mell, Dr"
      ],
      "affiliations": [
        "Ohio State University Wexner Medical Center, Columbus, OH, USA",
        "Cleveland Clinic, Cleveland, OH, USA",
        "University of Pennsylvania, Philadelphia, PA, USA",
        "University of California San Diego, CA, USA",
        "Moffitt Cancer Center, Tampa, FL, USA",
        "University of North Carolina, Chapel Hill, NC, USA",
        "Long Beach Memorial Medical Center, Long Beach, CA, USA",
        "Johnson & Johnson, Titusville, NJ, USA",
        "Johnson & Johnson, Spring House, PA, USA",
        "Johnson & Johnson, Horsham, PA, USA",
        "Johnson & Johnson, Raritan, NJ, USA",
        "University of California San Diego, La Jolla, CA, USA"
      ],
      "normalized_institutions": [
        "Ohio State University Wexner Medical Center, Columbus, OH, USA",
        "Cleveland Clinic, Cleveland, OH, USA",
        "University of Pennsylvania, Philadelphia, PA, USA",
        "University of California San Diego, CA, USA",
        "Moffitt Cancer Center, Tampa, FL, USA",
        "University of North Carolina, Chapel Hill, NC, USA",
        "Long Beach Memorial Medical Center, Long Beach, CA, USA",
        "Johnson & Johnson, Titusville, NJ, USA",
        "Johnson & Johnson, Spring House, PA, USA",
        "Johnson & Johnson, Horsham, PA, USA",
        "Johnson & Johnson, Raritan, NJ, USA",
        "University of California San Diego, La Jolla, CA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Aim",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "James Rocco, Dr 1 ; Jessica L Geiger, Dr 2 ; Steven B Cannady, Dr 3 ; Ezra Cohen, Dr 4 ; Ghassan El-Haddad, Dr 5 ; Colette J Shen, Dr 6 ; Randy Wei, Dr 7 ; Veronica Ashton, Ms 8 ; Kiran Devisitty, Dr 9 ; Denise D'Andrea, Dr 10 ; Marc Chioda, Mr 11 ; Loren Mell, Dr 12",
        "Affiliations": "1 Ohio State University Wexner Medical Center, Columbus, OH, USA; 2 Cleveland Clinic, Cleveland, OH, USA; 3 University of Pennsylvania, Philadelphia, PA, USA; 4 University of California San Diego, CA, USA; 5 Moffitt Cancer Center, Tampa, FL, USA; 6 University of North Carolina, Chapel Hill, NC, USA; 7 Long Beach Memorial Medical Center, Long Beach, CA, USA; 8 Johnson & Johnson, Titusville, NJ, USA; 9 Johnson & Johnson, Spring House, PA, USA; 10 Johnson & Johnson, Horsham, PA, USA; 11 Johnson & Johnson, Raritan, NJ, USA; 12 University of California San Diego, La Jolla, CA, USA",
        "Background": "Patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are a highly heterogeneous population, who experience substantial treatment burden. For individuals with unresectable disease who are platinum-ineligible, treatment outcomes remain unsatisfactory. Therapeutic approaches using unique mechanisms of action (MOA) may help improve outcomes while reducing both acute and late treatment-related side effects. However, further clarity is needed on how multidisciplinary care coordination can be optimized to ensure effective implementation of novel therapies and high-quality patient care.",
        "Aim": "To establish expert clinical consensus on the potential benefit of an agent with a novel MOA for unresectable LA-HNSCC in platinum-ineligible patients undergoing definitive radiation therapy.",
        "Methods": "The project used a modified Delphi method, guided by a U.S. based steering committee of clinicians with experience in treating/managing LA-HNSCC. The committee discussed challenges in treating LA-HNSCC and identified four key topic areas: (1) unmet needs, (2) multidisciplinary care coordination, (3) treatment decision making, and (4) patterns of failure. Across the topics, 42 consensus statements were drafted and incorporated into an online survey distributed to U.S. clinicians experienced in managing LA-HNSCC. Screening questions ensured respondents had relevant experience. Some statements pertained to radioenhancers (a newer class of agents designed to amplify local radiation effects without systemic exposure), therefore educational materials explaining their MOA were provided to support informed statement evaluation. The consensus threshold was predefined as ≥75% agreement.",
        "Results": "A total of 201 responses were received. All 42 statements achieved ≥75% agreement. Respondents included medical oncologists (n=51), radiation oncologists (n=49), head and neck surgeons (n=50), and interventional radiologists (n=51). Most had ≥11 years of experience in their clinical role (n=135) and were based primarily in academic centers (n=92) or community hospital settings (n=50), with the remainder based in other settings. Although some variation was observed between specialties and practice settings, overall agreement levels were high with limited variation of ≥10% from the mean agreement between subgroups. Strong agreement was achieved on the need for novel therapeutic approaches for patients with unresectable disease who are platinum-ineligible (97%), the importance of developing effective coordination between academic and community centers (100%), and the central role of patient factors and logistics on treatment decision making (99% and 98% respectively).",
        "Abstract": "Recommendations, based on responses, include advocating for: (1) the expansion of infrastructure for multidisciplinary head and neck tumor boards, (2) risk stratification in treatment selection to identify patients most likely to benefit from intensified or novel interventions, (3) embedding comprehensive psychosocial and holistic patient support into care, (4) developing national training frameworks alongside locally/regionally aligned operational pathways, to better integrate novel agents. View in Agenda and Add to Schedule",
        "Conclusions": "Results demonstrated broad alignment among U.S. clinicians regarding the high need to evolve current treatment paradigms for unresectable, platinum ineligible LA-HNSCC and incorporate therapies with novel MOAs into care. The recommendations developed reflect areas where consensus was strongest, including care coordination, patient-centered logistics, and the integration of novel modalities. Together, these steps can support individualized treatment strategies and coordinated care to help improve outcomes for this patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Exploring the Role of Novel Therapeutic Agents During Radiation for LA-HNSCC: Insights from a US Modified Delphi Consensus</span>. James Rocco, Dr<sup>1</sup>; Jessica L Geiger, Dr<sup>2</sup>; <u>Steven B Cannady, Dr</u><sup>3</sup>; Ezra Cohen, Dr<sup>4</sup>; Ghassan El-Haddad, Dr<sup>5</sup>; Colette J Shen, Dr<sup>6</sup>; Randy Wei, Dr<sup>7</sup>; Veronica Ashton, Ms<sup>8</sup>; Kiran Devisitty, Dr<sup>9</sup>; Denise D'Andrea, Dr<sup>10</sup>; Marc Chioda, Mr<sup>11</sup>; Loren Mell, Dr<sup>12</sup>. <sup>1</sup>Ohio State University Wexner Medical Center, Columbus, OH, USA; <sup>2</sup>Cleveland Clinic, Cleveland, OH, USA; <sup>3</sup>University of Pennsylvania, Philadelphia, PA, USA; <sup>4</sup>University of California San Diego, CA, USA; <sup>5</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>6</sup>University of North Carolina, Chapel Hill, NC, USA; <sup>7</sup>Long Beach Memorial Medical Center, Long Beach, CA, USA; <sup>8</sup>Johnson & Johnson, Titusville, NJ, USA; <sup>9</sup>Johnson & Johnson, Spring House, PA, USA; <sup>10</sup>Johnson & Johnson, Horsham, PA, USA; <sup>11</sup>Johnson & Johnson, Raritan, NJ, USA; <sup>12</sup>University of California San Diego, La Jolla, CA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are a highly heterogeneous population, who experience substantial treatment burden. For individuals with unresectable disease who are platinum-ineligible, treatment outcomes remain unsatisfactory. Therapeutic approaches using unique mechanisms of action (MOA) may help improve outcomes while reducing both acute and late treatment-related side effects. However, further clarity is needed on how multidisciplinary care coordination can be optimized to ensure effective implementation of novel therapies and high-quality patient care.</p>\n\n<p><strong>Aim: </strong>To establish expert clinical consensus on the potential benefit of an agent with a novel MOA for unresectable LA-HNSCC in platinum-ineligible patients undergoing definitive radiation therapy.</p>\n\n<p><strong>Methods: </strong>The project used a modified Delphi method, guided by a U.S. based steering committee of clinicians with experience in treating/managing LA-HNSCC. The committee discussed challenges in treating LA-HNSCC and identified four key topic areas: (1) unmet needs, (2) multidisciplinary care coordination, (3) treatment decision making, and (4) patterns of failure. Across the topics, 42 consensus statements were drafted and incorporated into an online survey distributed to U.S. clinicians experienced in managing LA-HNSCC. Screening questions ensured respondents had relevant experience. Some statements pertained to radioenhancers (a newer class of agents designed to amplify local radiation effects without systemic exposure), therefore educational materials explaining their MOA were provided to support informed statement evaluation. The consensus threshold was predefined as ≥75% agreement.</p>\n\n<p><strong>Results: </strong>A total of 201 responses were received. All 42 statements achieved ≥75% agreement. Respondents included medical oncologists (n=51), radiation oncologists (n=49), head and neck surgeons (n=50), and interventional radiologists (n=51). Most had ≥11 years of experience in their clinical role (n=135) and were based primarily in academic centers (n=92) or community hospital settings (n=50), with the remainder based in other settings. Although some variation was observed between specialties and practice settings, overall agreement levels were high with limited variation of ≥10% from the mean agreement between subgroups. Strong agreement was achieved on the need for novel therapeutic approaches for patients with unresectable disease who are platinum-ineligible (97%), the importance of developing effective coordination between academic and community centers (100%), and the central role of patient factors and logistics on treatment decision making (99% and 98% respectively).</p>\n\n<p>Recommendations, based on responses, include advocating for: (1) the expansion of infrastructure for multidisciplinary head and neck tumor boards, (2) risk stratification in treatment selection to identify patients most likely to benefit from intensified or novel interventions, (3) embedding comprehensive psychosocial and holistic patient support into care, (4) developing national training frameworks alongside locally/regionally aligned operational pathways, to better integrate novel agents.</p>\n\n<p><strong>Conclusions: </strong>Results demonstrated broad alignment among U.S. clinicians regarding the high need to evolve current treatment paradigms for unresectable, platinum ineligible LA-HNSCC and incorporate therapies with novel MOAs into care. The recommendations developed reflect areas where consensus was strongest, including care coordination, patient-centered logistics, and the integration of novel modalities. Together, these steps can support individualized treatment strategies and coordinated care to help improve outcomes for this patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153635--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S368",
      "content_id": "154414",
      "abstract_number": "S368",
      "poster_number": "",
      "title": "Optimizing Postoperative Radiation Therapy through Interdisciplinary 3D Specimen Scanning and Virtual Mapping: A Retrospective and Prospective Analysis",
      "summary": "This proof-of-concept study demonstrates the potential of v3DSS to improve PORT planning for head and neck cancer, particularly in enhancing margin visualization and targeting of areas at high risk of local recurrence. Survey feedback and volume overlap data indicate that v3DSS may offer significant clinical value by improving anatomical clarity and supporting high-precision PORT delivery. While future studies...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154414",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260143",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jamie JY Kwon, MS",
      "presenter": "Jamie JY Kwon, MS",
      "authors": "Jamie JY Kwon, MS 1 ; Sarah Hamilton, MD 2 ; Arshbir Aulakh, MD 1 ; Matthew Chan, MD 2 ; Samantha Lloyd, PhD 3 ; Bradford Gill 3 ; Eitan Prisman, MD, MA, FRCSC 1",
      "normalized_authors": [
        "Jamie JY Kwon",
        "Sarah Hamilton",
        "Arshbir Aulakh",
        "Matthew Chan",
        "Samantha Lloyd",
        "Bradford Gill",
        "Eitan Prisman, MA, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Surgery, University of British Columbia, Canada",
        "Medical Physics Department, BC Cancer-Vancouver, Vancouver, British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Surgery, University of British Columbia, Canada",
        "Medical Physics Department, BC Cancer-Vancouver, Vancouver, British Columbia, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Radiation / Adjuvant Treatment",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Radiation / Adjuvant Treatment"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154414/3dpath_AHNS(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154414/3dpath_AHNS(1).jpg",
          "alt": "Figure 2. Representative case showing A complete and B incomplete overlap between the v3DSS and radiation target volumes; Abbreviations: GTV, gross tumor volume.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154414"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jamie JY Kwon, MS 1 ; Sarah Hamilton, MD 2 ; Arshbir Aulakh, MD 1 ; Matthew Chan, MD 2 ; Samantha Lloyd, PhD 3 ; Bradford Gill 3 ; Eitan Prisman, MD, MA, FRCSC 1",
        "Affiliations": "1 Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; 2 Department of Surgery, University of British Columbia, Canada; 3 Medical Physics Department, BC Cancer-Vancouver, Vancouver, British Columbia, Canada",
        "Background": "Advances in head and neck cancer treatment increasingly rely on multidisciplinary approaches, yet current methods of communicating surgical and pathological findings are often limited in spatial accuracy. Traditional reports are limited in capturing the complex anatomical details critical for postoperative radiation therapy (PORT) planning, especially in cases involving close or positive surgical margins. The study aims to retrospectively and prospectively evaluate the feasibility and effectiveness of incorporating virtual 3D surgical specimens (v3DSS) captures in the operating room, with annotated close and positive margins assessed on pathological examination, into the PORT planning workflow.",
        "Methods": "For ten advanced head and neck cancer resections, intraoperative scanning of the resection specimens was performed to generate the v3DSS, which were then virtually annotated with pathological close and negative margins in accordance with physical pathological evaluations. These v3DSS were then registered to PORT planning CT scans. Retrospectively, these ten cases were analyzed to assess the volume overlap between the standard clinical target volume (CTV) and planning target volume (PTV) from PORT plans against the v3DSS. To assess the utility of supplementing PORT plans with these patient-specific v3DSS, a survey was conducted with eight radiation oncologists (ROs) on informativeness, anatomical context (margins, adjacent structures, free flap), potential to optimize PORT, ease of use, and perceived clinical value. Finally, in ten prospective pilot cases, v3DSS were generated and integrated directly into the PORT planning workflow to supplement planning.",
        "Results": "Retrospective analysis demonstrated a 69.80 ± 23.54% (mean ± SD) overlap between the v3DSS and CTV, and 86.93 ± 14.73% overlap between the v3DSS and PTV. In 30% of cases, positive or close margins were not encompassed by the CTV. In all survey categories, ROs found the v3DSS models to be more informative and clinically valuable than traditional methods (p<0.001). Specifically, the v3DSS improved understanding of margin status and adjacent critical structures, allowing more precise targeting of high-risk areas while sparing healthy tissues. In prospective cases, v3DSS models directly influenced CTV delineation, aiding ROs in more accurately defining disease extent and escalating radiation dose to areas of positive and close margins. When incorporated to supplement prospective PORT planning, VO increased to 90.7 ± 8.2% between the v3DSS and CTV and 96.7 ± 4.0% between the v3DSS and PTV, with 93% of margins receiving coverage.",
        "Conclusions": "This proof-of-concept study demonstrates the potential of v3DSS to improve PORT planning for head and neck cancer, particularly in enhancing margin visualization and targeting of areas at high risk of local recurrence. Survey feedback and volume overlap data indicate that v3DSS may offer significant clinical value by improving anatomical clarity and supporting high-precision PORT delivery. While future studies will be needed to confirm these findings in larger cohorts, early results are promising for integration into standard practice.",
        "Abstract": "[Figure 2. Representative case showing A complete and B incomplete overlap between the v3DSS and radiation target volumes; Abbreviations: GTV, gross tumor volume.] View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Optimizing Postoperative Radiation Therapy through Interdisciplinary 3D Specimen Scanning and Virtual Mapping: A Retrospective and Prospective Analysis</span>. <u>Jamie JY Kwon, MS</u><sup>1</sup>; Sarah Hamilton, MD<sup>2</sup>; Arshbir Aulakh, MD<sup>1</sup>; Matthew Chan, MD<sup>2</sup>; Samantha Lloyd, PhD<sup>3</sup>; Bradford Gill<sup>3</sup>; Eitan Prisman, MD, MA, FRCSC<sup>1</sup>. <sup>1</sup>Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; <sup>2</sup>Department of Surgery, University of British Columbia, Canada; <sup>3</sup>Medical Physics Department, BC Cancer-Vancouver, Vancouver, British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Advances in head and neck cancer treatment increasingly rely on multidisciplinary approaches, yet current methods of communicating surgical and pathological findings are often limited in spatial accuracy. Traditional reports are limited in capturing the complex anatomical details critical for postoperative radiation therapy (PORT) planning, especially in cases involving close or positive surgical margins. The study aims to retrospectively and prospectively evaluate the feasibility and effectiveness of incorporating virtual 3D surgical specimens (v3DSS) captures in the operating room, with annotated close and positive margins assessed on pathological examination, into the PORT planning workflow.</p>\n\n<p><strong>Methods:</strong> For ten advanced head and neck cancer resections, intraoperative scanning of the resection specimens was performed to generate the v3DSS, which were then virtually annotated with pathological close and negative margins in accordance with physical pathological evaluations. These v3DSS were then registered to PORT planning CT scans. Retrospectively, these ten cases were analyzed to assess the volume overlap between the standard clinical target volume (CTV) and planning target volume (PTV) from PORT plans against the v3DSS. To assess the utility of supplementing PORT plans with these patient-specific v3DSS, a survey was conducted with eight radiation oncologists (ROs) on informativeness, anatomical context (margins, adjacent structures, free flap), potential to optimize PORT, ease of use, and perceived clinical value. Finally, in ten prospective pilot cases, v3DSS were generated and integrated directly into the PORT planning workflow to supplement planning.</p>\n\n<p><strong>Results: </strong>Retrospective analysis demonstrated a 69.80 ± 23.54% (mean ± SD) overlap between the v3DSS and CTV, and 86.93 ± 14.73% overlap between the v3DSS and PTV. In 30% of cases, positive or close margins were not encompassed by the CTV. In all survey categories, ROs found the v3DSS models to be more informative and clinically valuable than traditional methods (p<0.001). Specifically, the v3DSS improved understanding of margin status and adjacent critical structures, allowing more precise targeting of high-risk areas while sparing healthy tissues. In prospective cases, v3DSS models directly influenced CTV delineation, aiding ROs in more accurately defining disease extent and escalating radiation dose to areas of positive and close margins. When incorporated to supplement prospective PORT planning, VO increased to 90.7 ± 8.2% between the v3DSS and CTV and 96.7 ± 4.0% between the v3DSS and PTV, with 93% of margins receiving coverage.</p>\n\n<p><strong>Conclusions:</strong> This proof-of-concept study demonstrates the potential of v3DSS to improve PORT planning for head and neck cancer, particularly in enhancing margin visualization and targeting of areas at high risk of local recurrence. Survey feedback and volume overlap data indicate that v3DSS may offer significant clinical value by improving anatomical clarity and supporting high-precision PORT delivery. While future studies will be needed to confirm these findings in larger cohorts, early results are promising for integration into standard practice.</p>\n\n<p><img alt='Figure 2. Representative case showing A complete and B incomplete overlap between the v3DSS and radiation target volumes; Abbreviations: GTV, gross tumor volume.' src='https://www.submitmyabstract.com/abs/images/154414/3dpath_AHNS(1).jpg' /></p>\n\n<p>[Figure 2. Representative case showing A complete and B incomplete overlap between the v3DSS and radiation target volumes; Abbreviations: GTV, gross tumor volume.]</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154414--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260143' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S369",
      "content_id": "153494",
      "abstract_number": "S369",
      "poster_number": "",
      "title": "Oral-to-nasopharyngeal microbiota translocation associated with immunosuppressive tumor microenvironment in nasopharyngeal carcinoma",
      "summary": "We identify a previously unrecognized, NPC-specific, oral-to-nasopharyngeal microbial translocation that enriches distinct oral-derived pathobionts, correlates with EBV burden, and promotes an immunosuppressive TIME via NF-κB/STAT1-linked checkpoint upregulation. These findings nominate translocation-derived microbial signatures as biomarkers for NPC stratification and as actionable targets to overcome ICI...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153494",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Suet Ying Wong",
      "presenter": "Suet Ying Wong",
      "authors": "Suet Ying Wong ; Jiyang Tan; Hengyan Zhu, PhD; Zigui Chen, Prof; Jason YK Chan, Prof",
      "normalized_authors": [
        "Suet Ying Wong",
        "Jiyang Tan",
        "Hengyan Zhu",
        "Zigui Chen, Prof",
        "Jason YK Chan, Prof"
      ],
      "affiliations": [
        "The Chinese University of Hong Kong"
      ],
      "normalized_institutions": [
        "The Chinese University of Hong Kong"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 371,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Suet Ying Wong ; Jiyang Tan; Hengyan Zhu, PhD; Zigui Chen, Prof; Jason YK Chan, Prof",
        "Affiliations": "The Chinese University of Hong Kong",
        "Background": "Nasopharyngeal carcinoma (NPC) is associated with Epstein-Barr virus (EBV) and is common in Southeast Asia. However, it is often diagnosed late, and patients show suboptimal responses to chemoradiotherapy and immune checkpoint inhibitors (ICIs) largely due to an immunosuppressive tumor immune microenvironment (TIME). While microbiota dysbiosis is increasingly recognized as a determinant of immune modulators in other cancers, the site-to-site translocation of microbiota in NPC and its interplays with EBV and immune evasion remain poorly understood.",
        "Methods": "We conducted a prospective, multi-compartment microbiome study in 53 NPC patients and 83 healthy controls using 16S rRNA sequencing of paired oral rinse, nasopharyngeal swab, and stool samples. Beta-diversity, differential abundance, and source-tracking were used to define dysbiosis and oral-to-nasopharyngeal translocation. EBV loads were quantified from nasopharyngeal swabs and correlated with microbial features. Functional assays employed in vitro co-culture of candidate pathobionts (e.g., Fusobacterium periodonticum , Peptostreptococcus stomatis ) with EBV+ (C666-1, C16) and EBV- (CNE1) NPC cell lines for mRNA-Seq, qRT-PCR and western blotting to profile immunoregulatory markers.",
        "Results": "The nasopharyngeal microbiota in NPC was site-specifically dysbiotic, with increased heterogeneity and 15 species enriched versus controls (q<0.05). Source tracking revealed significant, unidirectional oral-to-nasopharyngeal translocation in NPC (p<0.001), enabling stratification into high- (NPC^H) and low-translocation (NPC^L) subgroups. Clinically, NPC^H showed a trend toward improved 3-year overall survival (p=0.097), indicating prognostic relevance of translocation-associated dysbiosis. Oral-origin taxa including Pseudoprevotella muciniphila and the understudied Fusobacterium periodonticum were selectively enriched in NPC^H and yielded a two-species classifier with AUC 0.99 for distinguishing NPC^H from controls. EBV positivity was near-universal in NPC (91%); EBV load correlated with five translocation-linked bacteria, including P. muciniphila (rho=0.33, p<0.001) and Peptostreptococcus stomatis (rho=0.24, p=0.005), implicating microbial modulation of viral persistence. In vitro , F. periodonticum and P. stomatis enhanced NPC cell proliferation and upregulated INHBA and PD-L1/CD274, consistent with NF-κB/STAT1 activation.",
        "Conclusions": "We identify a previously unrecognized, NPC-specific, oral-to-nasopharyngeal microbial translocation that enriches distinct oral-derived pathobionts, correlates with EBV burden, and promotes an immunosuppressive TIME via NF-κB/STAT1-linked checkpoint upregulation. These findings nominate translocation-derived microbial signatures as biomarkers for NPC stratification and as actionable targets to overcome ICI resistance.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oral-to-nasopharyngeal microbiota translocation associated with immunosuppressive tumor microenvironment in nasopharyngeal carcinoma</span>. <u>Suet Ying Wong</u>; Jiyang Tan; Hengyan Zhu, PhD; Zigui Chen, Prof; Jason YK Chan, Prof. The Chinese University of Hong Kong<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Nasopharyngeal carcinoma (NPC) is associated with Epstein-Barr virus (EBV) and is common in Southeast Asia. However, it is often diagnosed late, and patients show suboptimal responses to chemoradiotherapy and immune checkpoint inhibitors (ICIs) largely due to an immunosuppressive tumor immune microenvironment (TIME). While microbiota dysbiosis is increasingly recognized as a determinant of immune modulators in other cancers, the site-to-site translocation of microbiota in NPC and its interplays with EBV and immune evasion remain poorly understood.</p>\n\n<p><strong>Methods:</strong> We conducted a prospective, multi-compartment microbiome study in 53 NPC patients and 83 healthy controls using 16S rRNA sequencing of paired oral rinse, nasopharyngeal swab, and stool samples. Beta-diversity, differential abundance, and source-tracking were used to define dysbiosis and oral-to-nasopharyngeal translocation. EBV loads were quantified from nasopharyngeal swabs and correlated with microbial features. Functional assays employed <em>in vitro</em> co-culture of candidate pathobionts (e.g., <em>Fusobacterium periodonticum</em>, <em>Peptostreptococcus stomatis</em>) with EBV+ (C666-1, C16) and EBV- (CNE1) NPC cell lines for mRNA-Seq, qRT-PCR and western blotting to profile immunoregulatory markers.</p>\n\n<p><strong>Results:</strong> The nasopharyngeal microbiota in NPC was site-specifically dysbiotic, with increased heterogeneity and 15 species enriched versus controls (q<0.05). Source tracking revealed significant, unidirectional oral-to-nasopharyngeal translocation in NPC (p<0.001), enabling stratification into high- (NPC^H) and low-translocation (NPC^L) subgroups. Clinically, NPC^H showed a trend toward improved 3-year overall survival (p=0.097), indicating prognostic relevance of translocation-associated dysbiosis. Oral-origin taxa including <em>Pseudoprevotella muciniphila </em>and the understudied <em>Fusobacterium periodonticum</em> were selectively enriched in NPC^H and yielded a two-species classifier with AUC 0.99 for distinguishing NPC^H from controls. EBV positivity was near-universal in NPC (91%); EBV load correlated with five translocation-linked bacteria, including <em>P. muciniphila</em> (rho=0.33, p<0.001) and <em>Peptostreptococcus stomatis</em> (rho=0.24, p=0.005), implicating microbial modulation of viral persistence.<em> In vitro</em>, <em>F. periodonticum</em> and <em>P. stomatis</em> enhanced NPC cell proliferation and upregulated INHBA and PD-L1/CD274, consistent with NF-κB/STAT1 activation. </p>\n\n<p><strong>Conclusions:</strong> We identify a previously unrecognized, NPC-specific, oral-to-nasopharyngeal microbial translocation that enriches distinct oral-derived pathobionts, correlates with EBV burden, and promotes an immunosuppressive TIME via NF-κB/STAT1-linked checkpoint upregulation. These findings nominate translocation-derived microbial signatures as biomarkers for NPC stratification and as actionable targets to overcome ICI resistance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153494--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S371",
      "content_id": "153409",
      "abstract_number": "S371",
      "poster_number": "",
      "title": "Peptostreptococcus anaerobius Promotes Cellular Proliferation and Migration in Oral Cavity Squamous Cell Carcinoma via NF-kB Signaling Pathway",
      "summary": "Our findings demonstrate that P. anaerobius infection promotes OSCC progression both in vitro and in vivo through bacterial attachment. This interaction may, partially, drive malignancy via activating NF-κB signaling pathway and its downstream targets. These insights provide a critical foundation for understanding the role of microbiota dysbiosis in OSCC and highlight potential targets for therapeutic intervention.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153409",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jiyang Tan, MD",
      "presenter": "Jiyang Tan, MD",
      "authors": "Jiyang Tan, MD 1 ; Hengyan Zhu, PhD 2 ; Zigui Chen, Professor 2 ; Jason Chan, Professor 1",
      "normalized_authors": [
        "Jiyang Tan",
        "Hengyan Zhu",
        "Zigui Chen",
        "Jason Chan"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong",
        "Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong",
        "Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 355,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jiyang Tan, MD 1 ; Hengyan Zhu, PhD 2 ; Zigui Chen, Professor 2 ; Jason Chan, Professor 1",
        "Affiliations": "1 Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong; 2 Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong",
        "Background": "Mounting evidence links oral microbiota dysbiosis to the pathogenesis of oral cavity squamous cell carcinoma (OSCC). Our previous studies of OSCC tumor tissues revealed a significant enrichment of Peptostreptococcus within the tumor microenvironment, suggesting a potential pathogenic role. This study investigates the carcinogenic effects of Peptostreptococcus anaerobius on OSCC cell proliferation and migration, and the underlying molecular mechanisms.",
        "Methods": "In vitro, P. anaerobius was co-cultured with OSCC cells and immortalized oral epithelial cells to be assessed for cellular proliferation and migration capabilities using CCK-8 and Wound Healing assays, respectively. Bacterial adhesion and Transwell assays were performed if these effects by P. anaerobius were contact-dependent or mediated by secreted factors. In vivo, a xenograft model was established by subcutaneously injecting P. anaerobius co-cultured OSCC cells. OSCC growth was quantified by volume and weight, and intratumoral P. anaerobius load was measured via qPCR. Mechanistically, mRNA sequencing of P. anaerobius co-cultured OSCC cells was analyzed for KEGG pathways using Gene Set Enrichment Analysis (GSEA), with validation of key targets via qPCR.",
        "Results": "Co-culture with P. anaerobius significantly enhanced the proliferation and migration of both OSCC and immortalized oral epithelial cells (p < 0.05). Adhesion assays confirmed substantial bacterial attachment to cells, while physical separation via Transwell filters disrupted the pro-proliferative effects, indicating a contact-dependent mechanism. In vivo, tumors co-cultured with P. anaerobius exhibited significantly greater volume and weight compared to untreated controls (p < 0.05). Furthermore, intratumoral P. anaerobius load correlated positively with tumor burden. Transcriptomic analysis identified 1,397 differentially expressed genes (DEGs), which are upregulated in co-cultured OSCC cells (FDR < 0.05, logFC > 1). GSEA highlighted the significant upregulation of NF-κB, JAK-STAT, and TNF signaling pathways. qPCR validation confirmed the upregulation of NF-κB pathway and downstream effectors, including MMP9, Vimentin, CXCL1, CXCL2, CCL2, and CCL20.",
        "Conclusion": "Our findings demonstrate that P. anaerobius infection promotes OSCC progression both in vitro and in vivo through bacterial attachment. This interaction may, partially, drive malignancy via activating NF-κB signaling pathway and its downstream targets. These insights provide a critical foundation for understanding the role of microbiota dysbiosis in OSCC and highlight potential targets for therapeutic intervention.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Peptostreptococcus anaerobius Promotes Cellular Proliferation and Migration in Oral Cavity Squamous Cell Carcinoma via NF-kB Signaling Pathway</span>. <u>Jiyang Tan, MD</u><sup>1</sup>; Hengyan Zhu, PhD<sup>2</sup>; Zigui Chen, Professor<sup>2</sup>; Jason Chan, Professor<sup>1</sup>. <sup>1</sup>Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong; <sup>2</sup>Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Mounting evidence links oral microbiota dysbiosis to the pathogenesis of oral cavity squamous cell carcinoma (OSCC). Our previous studies of OSCC tumor tissues revealed a significant enrichment of <em>Peptostreptococcus</em> within the tumor microenvironment, suggesting a potential pathogenic role. This study investigates the carcinogenic effects of <em>Peptostreptococcus anaerobius </em>on OSCC cell proliferation and migration, and the underlying molecular mechanisms.</p>\n\n<p><strong>Methods: </strong>In vitro, <em>P. anaerobius </em>was co-cultured with OSCC cells and immortalized oral epithelial cells to be assessed for cellular proliferation and migration capabilities using CCK-8 and Wound Healing assays, respectively. Bacterial adhesion and Transwell assays were performed if these effects by <em>P. anaerobius</em> were contact-dependent or mediated by secreted factors. In vivo, a xenograft model was established by subcutaneously injecting <em>P. anaerobius</em> co-cultured OSCC cells. OSCC growth was quantified by volume and weight, and intratumoral <em>P. anaerobius</em> load was measured via qPCR. Mechanistically, mRNA sequencing of <em>P. anaerobius</em> co-cultured OSCC cells was analyzed for KEGG pathways using Gene Set Enrichment Analysis (GSEA), with validation of key targets via qPCR.</p>\n\n<p><strong>Results:</strong> Co-culture with <em>P. anaerobius</em> significantly enhanced the proliferation and migration of both OSCC and immortalized oral epithelial cells (p < 0.05). Adhesion assays confirmed substantial bacterial attachment to cells, while physical separation via Transwell filters disrupted the pro-proliferative effects, indicating a contact-dependent mechanism. In vivo, tumors co-cultured with <em>P. anaerobius</em> exhibited significantly greater volume and weight compared to untreated controls (p < 0.05). Furthermore, intratumoral <em>P. anaerobius</em> load correlated positively with tumor burden. Transcriptomic analysis identified 1,397 differentially expressed genes (DEGs), which are upregulated in co-cultured OSCC cells (FDR < 0.05, logFC > 1). GSEA highlighted the significant upregulation of NF-κB, JAK-STAT, and TNF signaling pathways. qPCR validation confirmed the upregulation of NF-κB pathway and downstream effectors, including MMP9, Vimentin, CXCL1, CXCL2, CCL2, and CCL20.</p>\n\n<p><strong>Conclusion: </strong>Our findings demonstrate that <em>P. anaerobius</em> infection promotes OSCC progression both in vitro and in vivo through bacterial attachment. This interaction may, partially, drive malignancy via activating NF-κB signaling pathway and its downstream targets. These insights provide a critical foundation for understanding the role of microbiota dysbiosis in OSCC and highlight potential targets for therapeutic intervention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153409--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S372",
      "content_id": "153400",
      "abstract_number": "S372",
      "poster_number": "",
      "title": "Impact of the Use of Antibiotics on Survival in Head and Neck Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors",
      "summary": "Antibiotic administration was associated with improved PFS in ICI-treated HNSCC patients, with the most pronounced benefit observed in those with locoregional recurrence. These findings suggest that modulation of the local oral microbiome may differentially influence therapeutic response in locoregional disease compared with distant metastasis. Prospective studies incorporating microbiome profiling are warranted...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153400",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anushri Tiwari",
      "presenter": "Anushri Tiwari",
      "authors": "Anushri Tiwari 1 ; Jessica Pham 1 ; Mark Orland, MD 2 ; Cong Fan 2 ; Anirudh Yalamanchali, MD 2 ; Jessica Geiger 2 ; Tammy Sussman, MD 2 ; Shlomo Koyfman, MD 2 ; Jacob Miller, MD 2 ; Kyunghee Burkitt, DO, PhD 2 ; Neil Woody, MD 2 ; Daniel McGrail, PhD 2 ; Natalie Silver, MD 2",
      "normalized_authors": [
        "Anushri Tiwari",
        "Jessica Pham",
        "Mark Orland",
        "Cong Fan",
        "Anirudh Yalamanchali",
        "Jessica Geiger",
        "Tammy Sussman",
        "Shlomo Koyfman",
        "Jacob Miller",
        "Kyunghee Burkitt",
        "Neil Woody",
        "Daniel McGrail",
        "Natalie Silver"
      ],
      "affiliations": [
        "Case Western Reserve University School of Medicine",
        "Cleveland Clinic"
      ],
      "normalized_institutions": [
        "Case Western Reserve University School of Medicine",
        "Cleveland Clinic"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 394,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Anushri Tiwari 1 ; Jessica Pham 1 ; Mark Orland, MD 2 ; Cong Fan 2 ; Anirudh Yalamanchali, MD 2 ; Jessica Geiger 2 ; Tammy Sussman, MD 2 ; Shlomo Koyfman, MD 2 ; Jacob Miller, MD 2 ; Kyunghee Burkitt, DO, PhD 2 ; Neil Woody, MD 2 ; Daniel McGrail, PhD 2 ; Natalie Silver, MD 2",
        "Affiliations": "1 Case Western Reserve University School of Medicine; 2 Cleveland Clinic",
        "Background": "We recently demonstrated that increased intratumoral bacterial burden contributes to immune checkpoint inhibitor (ICI) resistance in head and neck cancer, suggesting that antimicrobial modulation may enhance treatment response. However, clinical evidence linking systemic antibiotic exposure to ICI outcomes remains inconsistent across solid tumors types. We evaluated the association between antibiotic administration and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with ICIs.",
        "Methods": "We retrospectively reviewed patients with recurrent or metastatic HNSCC treated with ICIs at Cleveland Clinic between 2019–2024. Patients with ECOG ≥2 or treated with chemo-immunotherapy were excluded. Clinicopathologic characteristics and antibiotic exposure data were extracted from the electronic medical record. Patients were included if they received antibiotics within 60 days prior to ICI initiation and/or during ICI therapy. Progression-free survival (PFS) was the primary endpoint. Subgroup analyses stratified patients by locoregional versus metastatic recurrence. Categorical variables were compared using Chi-square or Fisher’s exact test, and continuous variables using the Wilcoxon rank-sum test. PFS was evaluated using Kaplan–Meier analysis.",
        "Results": "A total of 106 patients were included, of whom, 39 (46.8%) received antibiotics. The most common antibiotics used were sulfonamides (n = 34, 87.2%) and beta-lactams (n = 13, 33.3%). Baseline characteristics were comparable among groups. Mean age was 61.2 vs. 62.7 years (p = 0.928). ECOG status was balanced among both groups (p = 0.369), with ECOG 1 being most common in both cohorts. In the overall cohort, there was a trend toward improved PFS in patients who received antibiotics compared to those who did not (HR = 0.704; 95% CI: 0.495–1.00; p = 0.054). In subgroup analysis, patients with locoregional recurrence who received antibiotics had significantly improved PFS (n = 11; HR = 0.457; 95% CI: 0.226–0.928; p = 0.021), whereas no significant difference was observed among patients with distant metastasis (n = 76; HR = 0.832; 95% CI: 0.55–1.26; p = 0.39).",
        "Conclusion": "Antibiotic administration was associated with improved PFS in ICI-treated HNSCC patients, with the most pronounced benefit observed in those with locoregional recurrence. These findings suggest that modulation of the local oral microbiome may differentially influence therapeutic response in locoregional disease compared with distant metastasis. Prospective studies incorporating microbiome profiling are warranted to elucidate mechanisms and guide rational antimicrobial strategies as adjuncts to immunotherapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of the Use of Antibiotics on Survival in Head and Neck Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors</span>. <u>Anushri Tiwari</u><sup>1</sup>; Jessica Pham<sup>1</sup>; Mark Orland, MD<sup>2</sup>; Cong Fan<sup>2</sup>; Anirudh Yalamanchali, MD<sup>2</sup>; Jessica Geiger<sup>2</sup>; Tammy Sussman, MD<sup>2</sup>; Shlomo Koyfman, MD<sup>2</sup>; Jacob Miller, MD<sup>2</sup>; Kyunghee Burkitt, DO, PhD<sup>2</sup>; Neil Woody, MD<sup>2</sup>; Daniel McGrail, PhD<sup>2</sup>; Natalie Silver, MD<sup>2</sup>. <sup>1</sup>Case Western Reserve University School of Medicine; <sup>2</sup>Cleveland Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>We recently demonstrated that increased intratumoral bacterial burden contributes to immune checkpoint inhibitor (ICI) resistance in head and neck cancer, suggesting that antimicrobial modulation may enhance treatment response. However, clinical evidence linking systemic antibiotic exposure to ICI outcomes remains inconsistent across solid tumors types. We evaluated the association between antibiotic administration and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with ICIs. </p>\n\n<p><strong>Methods:</strong> We retrospectively reviewed patients with recurrent or metastatic HNSCC treated with ICIs at Cleveland Clinic between 2019–2024. Patients with ECOG ≥2 or treated with chemo-immunotherapy were excluded. Clinicopathologic characteristics and antibiotic exposure data were extracted from the electronic medical record. Patients were included if they received antibiotics within 60 days prior to ICI initiation and/or during ICI therapy. Progression-free survival (PFS) was the primary endpoint. Subgroup analyses stratified patients by locoregional versus metastatic recurrence. Categorical variables were compared using Chi-square or Fisher’s exact test, and continuous variables using the Wilcoxon rank-sum test. PFS was evaluated using Kaplan–Meier analysis. </p>\n\n<p><strong>Results:</strong> A total of 106 patients were included, of whom, 39 (46.8%) received antibiotics. The most common antibiotics used were sulfonamides (n = 34, 87.2%) and beta-lactams (n = 13, 33.3%). Baseline characteristics were comparable among groups. Mean age was 61.2 vs. 62.7 years (p = 0.928). ECOG status was balanced among both groups (p = 0.369), with ECOG 1 being most common in both cohorts. In the overall cohort, there was a trend toward improved PFS in patients who received antibiotics compared to those who did not (HR = 0.704; 95% CI: 0.495–1.00; p = 0.054). In subgroup analysis, patients with locoregional recurrence who received antibiotics had significantly improved PFS (n = 11; HR = 0.457; 95% CI: 0.226–0.928; p = 0.021), whereas no significant difference was observed among patients with distant metastasis (n = 76; HR = 0.832; 95% CI: 0.55–1.26; p = 0.39). </p>\n\n<p><strong>Conclusion:</strong> Antibiotic administration was associated with improved PFS in ICI-treated HNSCC patients, with the most pronounced benefit observed in those with locoregional recurrence. These findings suggest that modulation of the local oral microbiome may differentially influence therapeutic response in locoregional disease compared with distant metastasis. Prospective studies incorporating microbiome profiling are warranted to elucidate mechanisms and guide rational antimicrobial strategies as adjuncts to immunotherapy. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153400--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S373",
      "content_id": "153240",
      "abstract_number": "S373",
      "poster_number": "",
      "title": "Convergent Analysis of Oral Microbial Signatures Associated with Oral Cavity Squamous Cell Carcinoma",
      "summary": "Oral cavity squamous cell carcinoma (OCSCC) has been reported to be associated with oral microbial dysbiosis, which has been proposed as a potential risk factor for carcinogenesis. Yet, inconsistencies in sample collection, sequencing platforms, and analytical approaches have resulted in conflicting reports as to which bacterial genera are enriched or depleted in OCSCC, especially across global populations. To...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153240",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Patrick Wang",
      "presenter": "Patrick Wang",
      "authors": "Patrick Wang 1 ; Samuel Auger, MD 2 ; Nihar Rama 1 ; Felix Fernandez Penny 1 ; Nishant Agrawal, MD 3 ; Jason Chan, MD 4 ; Zigui Chen, PhD 5 ; Evgeny Izumchenko, PhD 6",
      "normalized_authors": [
        "Patrick Wang",
        "Samuel Auger",
        "Nihar Rama",
        "Felix Fernandez Penny",
        "Nishant Agrawal",
        "Jason Chan",
        "Zigui Chen",
        "Evgeny Izumchenko"
      ],
      "affiliations": [
        "Pritzker School of Medicine, University of Chicago",
        "Head and Neck Cancer Service, Memorial Sloan Kettering Cancer Center",
        "Department of Surgery, Section of Otolaryngology, University of Chicago Medicine",
        "Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong SAR",
        "Department of Microbiology, The Chinese University of Hong Kong SAR",
        "Department of Medicine, Section of Hematology and Oncology, University of Chicago"
      ],
      "normalized_institutions": [
        "Pritzker School of Medicine, University of Chicago",
        "Head and Neck Cancer Service, Memorial Sloan Kettering Cancer Center",
        "Department of Surgery, Section of Otolaryngology, University of Chicago Medicine",
        "Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong SAR",
        "Department of Microbiology, The Chinese University of Hong Kong SAR",
        "Department of Medicine, Section of Hematology and Oncology, University of Chicago"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 285,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Patrick Wang 1 ; Samuel Auger, MD 2 ; Nihar Rama 1 ; Felix Fernandez Penny 1 ; Nishant Agrawal, MD 3 ; Jason Chan, MD 4 ; Zigui Chen, PhD 5 ; Evgeny Izumchenko, PhD 6",
        "Affiliations": "1 Pritzker School of Medicine, University of Chicago; 2 Head and Neck Cancer Service, Memorial Sloan Kettering Cancer Center; 3 Department of Surgery, Section of Otolaryngology, University of Chicago Medicine; 4 Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong SAR; 5 Department of Microbiology, The Chinese University of Hong Kong SAR; 6 Department of Medicine, Section of Hematology and Oncology, University of Chicago",
        "Abstract": "Oral cavity squamous cell carcinoma (OCSCC) has been reported to be associated with oral microbial dysbiosis, which has been proposed as a potential risk factor for carcinogenesis. Yet, inconsistencies in sample collection, sequencing platforms, and analytical approaches have resulted in conflicting reports as to which bacterial genera are enriched or depleted in OCSCC, especially across global populations. To investigate if there are core microbiota associated with OCSCC, we analyzed saliva samples from two geographically distinct case-control cohorts in Chicago (21 OCSCC patients, 21 matched controls) and Hong Kong (42 OCSCC patients, 42 matched controls). Cases and controls within each cohort were matched by age, sex, and smoking/alcohol status, and the two cohorts were matched for these variables as well to enable cross-cohort comparison. Bacterial communities were then characterized using 16S rRNA sequencing (V4-V5 region for Chicago, V3-V4 region for Hong Kong) and a standardized bioinformatics pipeline. We validated observed trends in both cohorts through a systematic review of studies with comparable collection and statistical methodologies. Using a tiered evidence framework, our study revealed that Fusobacterium and Parvimonas are reproducibly enriched while Actinomyces is reproducibly depleted within OCSCC patients across multiple global cohorts. However, numerous other genera like Peptostreptococcus and Catonella showed heterogeneous patterns across cohorts, suggesting population-specific factors or methodological dependencies. Our study provides strong evidence for the presence of core, reproducible microbial signals (e.g. Fusobacterium ) associated with OCSCC in a global context, while the variable associations observed for other genera may reflect true population-level variations or methodological artifacts that obscure genuine signals. With further validation in diverse cohorts, these core bacterial genera hold potential for the development of oral cancer screening tools or targeted therapeutics. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Convergent Analysis of Oral Microbial Signatures Associated with Oral Cavity Squamous Cell Carcinoma</span>. <u>Patrick Wang</u><sup>1</sup>; Samuel Auger, MD<sup>2</sup>; Nihar Rama<sup>1</sup>; Felix Fernandez Penny<sup>1</sup>; Nishant Agrawal, MD<sup>3</sup>; Jason Chan, MD<sup>4</sup>; Zigui Chen, PhD<sup>5</sup>; Evgeny Izumchenko, PhD<sup>6</sup>. <sup>1</sup>Pritzker School of Medicine, University of Chicago; <sup>2</sup>Head and Neck Cancer Service, Memorial Sloan Kettering Cancer Center; <sup>3</sup>Department of Surgery, Section of Otolaryngology, University of Chicago Medicine; <sup>4</sup>Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong SAR; <sup>5</sup>Department of Microbiology, The Chinese University of Hong Kong SAR; <sup>6</sup>Department of Medicine, Section of Hematology and Oncology, University of Chicago<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Oral cavity squamous cell carcinoma (OCSCC) has been reported to be associated with oral microbial dysbiosis, which has been proposed as a potential risk factor for carcinogenesis. Yet, inconsistencies in sample collection, sequencing platforms, and analytical approaches have resulted in conflicting reports as to which bacterial genera are enriched or depleted in OCSCC, especially across global populations. To investigate if there are core microbiota associated with OCSCC, we analyzed saliva samples from two geographically distinct case-control cohorts in Chicago (21 OCSCC patients, 21 matched controls) and Hong Kong (42 OCSCC patients, 42 matched controls). Cases and controls within each cohort were matched by age, sex, and smoking/alcohol status, and the two cohorts were matched for these variables as well to enable cross-cohort comparison. Bacterial communities were then characterized using 16S rRNA sequencing (V4-V5 region for Chicago, V3-V4 region for Hong Kong) and a standardized bioinformatics pipeline. We validated observed trends in both cohorts through a systematic review of studies with comparable collection and statistical methodologies. Using a tiered evidence framework, our study revealed that <em>Fusobacterium</em> and <em>Parvimonas</em> are reproducibly enriched while <em>Actinomyces</em> is reproducibly depleted within OCSCC patients across multiple global cohorts. However, numerous other genera like <em>Peptostreptococcus</em> and <em>Catonella</em> showed heterogeneous patterns across cohorts, suggesting population-specific factors or methodological dependencies. Our study provides strong evidence for the presence of core, reproducible microbial signals (e.g. <em>Fusobacterium</em>) associated with OCSCC in a global context, while the variable associations observed for other genera may reflect true population-level variations or methodological artifacts that obscure genuine signals. With further validation in diverse cohorts, these core bacterial genera hold potential for the development of oral cancer screening tools or targeted therapeutics.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153240--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S374",
      "content_id": "154574",
      "abstract_number": "S374",
      "poster_number": "",
      "title": "Gut Microbiome Dysbiosis and Bile Acid Dysregulation are Present in Head and Neck Cancer Cachexia",
      "summary": "This pilot study shows specific gut microbiome imbalance in HNC patients and identifies taxa linked to cachexia and changes in bile acid metabolism, despite no overall diversity differences between cachexia groups. The IMD intervention notably altered microbial composition, indicating that targeted nutritional strategies could impact the microbiome and possibly clinical outcomes. These results highlight the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154574",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emily K Miller, MD",
      "presenter": "Emily K Miller, MD",
      "authors": "Emily K Miller, MD 1 ; Mabel Kahil, CST, MSc 1 ; Nicolaus D Knight, MS 1 ; Akhilesh Wodeyar, MD 1 ; Juhi J Patel, BS 1 ; Kesava Asam, MS 2 ; Kirk Withrow, MD 1 ; Benjamin Greene, MD 1 ; Andrew Fuson, MD 1 ; Susan D McCammon, MD, PhD 1 ; Yedeh Ying, MD, DMD 1 ; Anthony Morlandt, MD, DDS 1 ; Bradley Aouizerat, MAS, PhD 2 ; Sylvie Mrug, PhD 1 ; Andrea Bonetto, PhD 3 ; Leah Novinger, MD, PhD 3 ; Charles E Robertson, PhD 3 ; Daniel N Frank, PhD 3 ; Carissa M Thomas, MD, PhD 3",
      "normalized_authors": [
        "Emily K Miller",
        "Mabel Kahil, CST",
        "Nicolaus D Knight",
        "Akhilesh Wodeyar",
        "Juhi J Patel",
        "Kesava Asam",
        "Kirk Withrow",
        "Benjamin Greene",
        "Andrew Fuson",
        "Susan D McCammon",
        "Yedeh Ying",
        "Anthony Morlandt",
        "Bradley Aouizerat, MAS",
        "Sylvie Mrug",
        "Andrea Bonetto",
        "Leah Novinger",
        "Charles E Robertson",
        "Daniel N Frank",
        "Carissa M Thomas"
      ],
      "affiliations": [
        "University of Alabama at Birmingham",
        "New York University College of Dentistry",
        "University of Colorado"
      ],
      "normalized_institutions": [
        "University of Alabama at Birmingham",
        "New York University College of Dentistry",
        "University of Colorado"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%201.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154574"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%202.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%202.jpg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154574"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 516,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Emily K Miller, MD 1 ; Mabel Kahil, CST, MSc 1 ; Nicolaus D Knight, MS 1 ; Akhilesh Wodeyar, MD 1 ; Juhi J Patel, BS 1 ; Kesava Asam, MS 2 ; Kirk Withrow, MD 1 ; Benjamin Greene, MD 1 ; Andrew Fuson, MD 1 ; Susan D McCammon, MD, PhD 1 ; Yedeh Ying, MD, DMD 1 ; Anthony Morlandt, MD, DDS 1 ; Bradley Aouizerat, MAS, PhD 2 ; Sylvie Mrug, PhD 1 ; Andrea Bonetto, PhD 3 ; Leah Novinger, MD, PhD 3 ; Charles E Robertson, PhD 3 ; Daniel N Frank, PhD 3 ; Carissa M Thomas, MD, PhD 3",
        "Affiliations": "1 University of Alabama at Birmingham; 2 New York University College of Dentistry; 3 University of Colorado",
        "Background": "Cachexia is highly prevalent in head and neck cancer (HNC), affecting roughly 60% of patients at diagnosis and contributing to poor survival and reduced quality of life. Characterized by weight loss and skeletal muscle depletion despite standard nutritional support, cachexia may be driven in part by gut microbiome dysbiosis, which can impair gut barrier integrity and promote systemic inflammation. Disruption of microbial bile acid metabolism, a process essential for fat absorption and dependent on gut bacteria, may further contribute to cachexia. While dysbiosis has been documented in colorectal, lung, and pancreatic cancer cachexia, it has not been well studied in HNC. Here, we characterize gut microbiome differences associated with clinical features of cachexia in HNC and explore connections with bile acid dysregulation. A secondary objective is to evaluate whether a preoperative immunomodulatory diet (IMD) can alter the gut microbiome in HNC patients.",
        "Methods": "In this prospective pilot study, preoperative blood and fecal samples were collected from 55 HNC patients. Skeletal muscle index (SMI) was measured from CT scans at the L3 level using Slice-O-matic software to determine cachexia status. Nineteen patients with moderate to severe malnutrition received a preoperative IMD, and paired samples were obtained before and after intervention. Fecal samples from healthy adults (n=269) served as controls. Gut microbial composition was analyzed using 16S rRNA gene sequencing. Beta diversity was assessed with PERMANOVA, and generalized linear and mixed-effect models were used to evaluate alpha diversity and the differential abundance of bacterial genera, controlling for age and antibiotic exposure. Bile acid profiling was performed on a subset of cachectic (n=5) and non-cachectic (n=5) patients, and correlations between bile acids and taxa were examined using the Kendall rank test.",
        "Results": "The cohort was predominantly white (91%) and male (65.5%), with 56% classified as cachectic. Compared with healthy controls, HNC patients exhibited markedly different microbiome profiles (PERMANOVA, p<10e-6), with numerous enriched and depleted taxa. Alpha and beta diversity didn’t differ between cachectic and non-cachectic patients, however, differential abundance analysis identified increased Veillonella and decreased Enterococcus in cachectic individuals. Bile acid correlations mirrored patterns seen in other cancer-associated dysbiosis: Firmicutes were positively associated with several bile acids, whereas Bacteroides showed negative associations. (Figure 1)",
        "Abstract": "Among IMD recipients, the average age was 60.7 ± 11.6 years, and most were white (93.3%) and male (60%). The IMD cohort had a significantly reduced hospital length of stay (7 vs. 10.4 days; p=0.0002), though postoperative complication rates were unchanged. Microbial Shannon diversity significantly decreased following IMD (p<0.0036). Differential abundance analysis showed reductions in Faecalibacterium and Lachnospiraceae after IMD, with an increase in Peptococcus. (Figure 2) View in Agenda and Add to Schedule",
        "Conclusion": "This pilot study shows specific gut microbiome imbalance in HNC patients and identifies taxa linked to cachexia and changes in bile acid metabolism, despite no overall diversity differences between cachexia groups. The IMD intervention notably altered microbial composition, indicating that targeted nutritional strategies could impact the microbiome and possibly clinical outcomes. These results highlight the complex role of the microbiome in HNC cachexia and support further research into microbiome-focused treatments."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Gut Microbiome Dysbiosis and Bile Acid Dysregulation are Present in Head and Neck Cancer Cachexia</span>. <u>Emily K Miller, MD</u><sup>1</sup>; Mabel Kahil, CST, MSc<sup>1</sup>; Nicolaus D Knight, MS<sup>1</sup>; Akhilesh Wodeyar, MD<sup>1</sup>; Juhi J Patel, BS<sup>1</sup>; Kesava Asam, MS<sup>2</sup>; Kirk Withrow, MD<sup>1</sup>; Benjamin Greene, MD<sup>1</sup>; Andrew Fuson, MD<sup>1</sup>; Susan D McCammon, MD, PhD<sup>1</sup>; Yedeh Ying, MD, DMD<sup>1</sup>; Anthony Morlandt, MD, DDS<sup>1</sup>; Bradley Aouizerat, MAS, PhD<sup>2</sup>; Sylvie Mrug, PhD<sup>1</sup>; Andrea Bonetto, PhD<sup>3</sup>; Leah Novinger, MD, PhD<sup>3</sup>; Charles E Robertson, PhD<sup>3</sup>; Daniel N Frank, PhD<sup>3</sup>; Carissa M Thomas, MD, PhD<sup>3</sup>. <sup>1</sup>University of Alabama at Birmingham; <sup>2</sup>New York University College of Dentistry; <sup>3</sup>University of Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cachexia is highly prevalent in head and neck cancer (HNC), affecting roughly 60% of patients at diagnosis and contributing to poor survival and reduced quality of life. Characterized by weight loss and skeletal muscle depletion despite standard nutritional support, cachexia may be driven in part by gut microbiome dysbiosis, which can impair gut barrier integrity and promote systemic inflammation. Disruption of microbial bile acid metabolism, a process essential for fat absorption and dependent on gut bacteria, may further contribute to cachexia. While dysbiosis has been documented in colorectal, lung, and pancreatic cancer cachexia, it has not been well studied in HNC. Here, we characterize gut microbiome differences associated with clinical features of cachexia in HNC and explore connections with bile acid dysregulation. A secondary objective is to evaluate whether a preoperative immunomodulatory diet (IMD) can alter the gut microbiome in HNC patients.</p>\n\n<p><strong>Methods: </strong>In this prospective pilot study, preoperative blood and fecal samples were collected from 55 HNC patients. Skeletal muscle index (SMI) was measured from CT scans at the L3 level using Slice-O-matic software to determine cachexia status. Nineteen patients with moderate to severe malnutrition received a preoperative IMD, and paired samples were obtained before and after intervention. Fecal samples from healthy adults (n=269) served as controls. Gut microbial composition was analyzed using 16S rRNA gene sequencing. Beta diversity was assessed with PERMANOVA, and generalized linear and mixed-effect models were used to evaluate alpha diversity and the differential abundance of bacterial genera, controlling for age and antibiotic exposure. Bile acid profiling was performed on a subset of cachectic (n=5) and non-cachectic (n=5) patients, and correlations between bile acids and taxa were examined using the Kendall rank test.</p>\n\n<p><strong>Results: </strong>The cohort was predominantly white (91%) and male (65.5%), with 56% classified as cachectic. Compared with healthy controls, HNC patients exhibited markedly different microbiome profiles (PERMANOVA, p<10e-6), with numerous enriched and depleted taxa. Alpha and beta diversity didn’t differ between cachectic and non-cachectic patients, however, differential abundance analysis identified increased Veillonella and decreased Enterococcus in cachectic individuals. Bile acid correlations mirrored patterns seen in other cancer-associated dysbiosis: Firmicutes were positively associated with several bile acids, whereas Bacteroides showed negative associations. (Figure 1)</p>\n\n<p>Among IMD recipients, the average age was 60.7 ± 11.6 years, and most were white (93.3%) and male (60%). The IMD cohort had a significantly reduced hospital length of stay (7 vs. 10.4 days; p=0.0002), though postoperative complication rates were unchanged. Microbial Shannon diversity significantly decreased following IMD (p<0.0036). Differential abundance analysis showed reductions in Faecalibacterium and Lachnospiraceae after IMD, with an increase in Peptococcus. (Figure 2)</p>\n\n<p><strong>Conclusion: </strong>This pilot study shows specific gut microbiome imbalance in HNC patients and identifies taxa linked to cachexia and changes in bile acid metabolism, despite no overall diversity differences between cachexia groups. The IMD intervention notably altered microbial composition, indicating that targeted nutritional strategies could impact the microbiome and possibly clinical outcomes. These results highlight the complex role of the microbiome in HNC cachexia and support further research into microbiome-focused treatments.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%201.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154574/immunonutrition%20abstract_ahns_figure%202.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154574--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S375",
      "content_id": "154262",
      "abstract_number": "S375",
      "poster_number": "",
      "title": "Machine Learning Derived Antibiotic and Pharmacologic Signatures Associated with Survival in Head and Neck Cancer Patients on Immunotherapy",
      "summary": "We identified latent clinical subtypes among patients who received PD1 ICIs. Subgroups showed distinct patterns of antibiotic and corticosteroid exposure. One high-risk subgroup demonstrated elevated risk distinguished from the low-risk group almost entirely by extensive antibiotic use despite no clear palliative features. After covariate adjustment and propensity matching, subgroup assignment and antibiotic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154262",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maximilian J Bailey",
      "presenter": "Maximilian J Bailey",
      "authors": "Maximilian J Bailey ; Maxwell Y Lee, MD; John B Sunwoo, MD; Michelle M Chen",
      "normalized_authors": [
        "Maximilian J Bailey",
        "Maxwell Y Lee",
        "John B Sunwoo",
        "Michelle M Chen"
      ],
      "affiliations": [
        "Stanford University School of Medicine"
      ],
      "normalized_institutions": [
        "Stanford University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Maximilian J Bailey ; Maxwell Y Lee, MD; John B Sunwoo, MD; Michelle M Chen",
        "Affiliations": "Stanford University School of Medicine",
        "Background": "With the recent data from KEYNOTE 689 expanding immune checkpoint inhibitor (ICI) use in head and neck cancer, understanding factors associated with decreased survival or response to ICIs is increasingly relevant. Antibiotic exposure and immunosuppression at the time of ICI initiation have been found to influence treatment response. Pharmacologic exposures around the time of diagnosis may influence the immunoediting process and subsequent immunotherapy response, yet associations during this early exposure period have not been well characterized. We apply a machine learning (ML) framework to determine whether early post-diagnosis medication use defines latent clinical subtypes linked to disease-specific mortality in patients receiving ICI. Further, we aim to evaluate whether medication exposure may be associated with survival outcomes in this population.",
        "Methods": "The cohort included thirteen hundred adults >=65 years of age with mucosal head and neck cancer who received ICIs. Outpatient medication use during the first post-diagnosis year was quantified. A stacked ML framework incorporated LASSO regression and latent cluster modeling (LUCID) to relate clinical, demographic, and medication features to two-year disease-specific mortality. Multivariable Cox proportional hazards (PH) modeling was used to evaluate the association between cluster assignment, aggregate antibiotic exposure and disease-specific survival. High and low antibiotic exposure groups were propensity matched on age, sex, stage, frailty, histology, and the Charlson Comorbidity Index, followed by a matched Cox PH model.",
        "Results": "LASSO identified antibiotics and corticosteroids as strong predictors of two-year mortality, including dexamethasone, cephalexin and levofloxacin, along with supportive agents such as metoclopramide (FDR < 0.05).LUCID modeling revealed four latent clinical subtypes. The highest-risk group (HR = 4.23) was the oldest and least likely to receive radiation. Another elevated-risk group (HR = 2.01) displayed higher rates of surgery and squamous histology and showed increased exposure to a broad set of antibiotics including amoxicillin, cephalexin, levofloxacin, azithromycin, doxycycline, and TMP-SMX as well as methylprednisolone. The lowest-risk group (HR = 1.00) showed broadly reduced antibiotic exposure. Cox PH models confirmed significant survival differences across groups. Aggregate antibiotic exposure was associated with worse survival (HR = 1.28, P < 0.001) with an effect size comparable to age, squamous histology and stage. Findings remained consistent after robust propensity matching.",
        "Conclusions": "We identified latent clinical subtypes among patients who received PD1 ICIs. Subgroups showed distinct patterns of antibiotic and corticosteroid exposure. One high-risk subgroup demonstrated elevated risk distinguished from the low-risk group almost entirely by extensive antibiotic use despite no clear palliative features. After covariate adjustment and propensity matching, subgroup assignment and antibiotic burden remained independently associated with decreased survival, suggesting that early antibiotic exposure may directly confer risk. Future mechanistic studies are needed to define how these exposures alter immunoediting and the tumor microenvironment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Machine Learning Derived Antibiotic and Pharmacologic Signatures Associated with Survival in Head and Neck Cancer Patients on Immunotherapy</span>. <u>Maximilian J Bailey</u>; Maxwell Y Lee, MD; John B Sunwoo, MD; Michelle M Chen. Stanford University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: With the recent data from KEYNOTE 689 expanding immune checkpoint inhibitor (ICI) use in head and neck cancer, understanding factors associated with decreased survival or response to ICIs is increasingly relevant. Antibiotic exposure and immunosuppression at the time of ICI initiation have been found to influence treatment response. Pharmacologic exposures around the time of diagnosis may influence the immunoediting process and subsequent immunotherapy response, yet associations during this early exposure period have not been well characterized. We apply a machine learning (ML) framework to determine whether early post-diagnosis medication use defines latent clinical subtypes linked to disease-specific mortality in patients receiving ICI. Further, we aim to evaluate whether medication exposure may be associated with survival outcomes in this population.</p>\n\n<p><strong>Methods</strong>: The cohort included thirteen hundred adults >=65 years of age with mucosal head and neck cancer who received ICIs. Outpatient medication use during the first post-diagnosis year was quantified. A stacked ML framework incorporated LASSO regression and latent cluster modeling (LUCID) to relate clinical, demographic, and medication features to two-year disease-specific mortality. Multivariable Cox proportional hazards (PH) modeling was used to evaluate the association between cluster assignment, aggregate antibiotic exposure and disease-specific survival. High and low antibiotic exposure groups were propensity matched on age, sex, stage, frailty, histology, and the Charlson Comorbidity Index, followed by a matched Cox PH model.</p>\n\n<p><strong>Results</strong>: LASSO identified antibiotics and corticosteroids as strong predictors of two-year mortality, including dexamethasone, cephalexin and levofloxacin, along with supportive agents such as metoclopramide (FDR < 0.05).LUCID modeling revealed four latent clinical subtypes. The highest-risk group (HR = 4.23) was the oldest and least likely to receive radiation. Another elevated-risk group (HR = 2.01) displayed higher rates of surgery and squamous histology and showed increased exposure to a broad set of antibiotics including amoxicillin, cephalexin, levofloxacin, azithromycin, doxycycline, and TMP-SMX as well as methylprednisolone. The lowest-risk group (HR = 1.00) showed broadly reduced antibiotic exposure. Cox PH models confirmed significant survival differences across groups. Aggregate antibiotic exposure was associated with worse survival (HR = 1.28, P < 0.001) with an effect size comparable to age, squamous histology and stage. Findings remained consistent after robust propensity matching.</p>\n\n<p><strong>Conclusions</strong>: We identified latent clinical subtypes among patients who received PD1 ICIs. Subgroups showed distinct patterns of antibiotic and corticosteroid exposure. One high-risk subgroup demonstrated elevated risk distinguished from the low-risk group almost entirely by extensive antibiotic use despite no clear palliative features. After covariate adjustment and propensity matching, subgroup assignment and antibiotic burden remained independently associated with decreased survival, suggesting that early antibiotic exposure may directly confer risk. Future mechanistic studies are needed to define how these exposures alter immunoediting and the tumor microenvironment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154262--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S376",
      "content_id": "154218",
      "abstract_number": "S376",
      "poster_number": "",
      "title": "Fusobacterium nucleatum drives PD-L1-mediated immune evasion and modulates anti-PD-L1 therapy response in Oral Cavity Squamous Cell Carcinoma",
      "summary": "This study reveals a critical host-microbiota interaction in the OSCC TIME. F. nucleatum emerges as a key modulator of a checkpoint-high, immune-evasive phenotype in OSCC. These data nominate F. nucleatum as a candidate biomarker for patient stratification and a therapeutic target to enhance ICI responsiveness in OSCC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154218",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hengyan Zhu, PhD",
      "presenter": "Hengyan Zhu, PhD",
      "authors": "Hengyan Zhu, PhD ; Suet Ying Wong; Wenqi LU, PhD; Daijuanru Wang; Jason, YK Chan, FHKAM, FRCSEdORL; Zigui Chen, PhD",
      "normalized_authors": [
        "Hengyan Zhu",
        "Suet Ying Wong",
        "Wenqi LU",
        "Daijuanru Wang",
        "Jason, YK Chan, FHKAM, FRCSEdORL",
        "Zigui Chen"
      ],
      "affiliations": [
        "The Chinese University of Hong Kong"
      ],
      "normalized_institutions": [
        "The Chinese University of Hong Kong"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 321,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hengyan Zhu, PhD ; Suet Ying Wong; Wenqi LU, PhD; Daijuanru Wang; Jason, YK Chan, FHKAM, FRCSEdORL; Zigui Chen, PhD",
        "Affiliations": "The Chinese University of Hong Kong",
        "Introduction": "Oral squamous cell carcinoma (OSCC) is a common type of malignant tumour in the head and neck region, with a five-year patient survival rate of 50%-60%. Although immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 offer clinical benefit, responses are variable and shaped by the tumor immune microenvironment (TIME). Microbiota dysbiosis is increasingly recognized as a determinant of immune modulators, yet actionable host-microbiota axies within the OSCC TIME remain incompletely elucidated.",
        "Methods": "The microbiota and host transcriptome of primary HPV-negative OSCC tumors and adjacent normal (AN) tissues were profiled through16S rRNA V3-V4 microbiota sequencing and host long non-coding RNA sequencing (lncRNA-seq), respectively. Reads were processed with QIIME2 and STAR, and analyzed in R to identify host-microbiota association, with an emphasis on immune checkpoint and immune-evasion pathways. Mechanistic validation employed in vitro co-culture of Fusobacterium nucleatum with OSCC cell lines for mRNA-Seq, qPCR, and western blotting. In vivo studies used bacteria-inoculated syngeneic allograft and 4-nitroquinoline-1-oxide (4NQO)-induced OSCC mouse models to assess tumor growth, immune contexture, and response to anti-PD-L1 therapy.",
        "Results": "OSCC tumor exhibited significant microbiota dysbiosis, enriched for pathogens and depleted of commensals. F. nucleatum, the most tumor-enriched bacteria, correlated with upregulated CD274 (PD-L1) and reduced CD8+ T-cell. In vitro, F. nucleatum induced PD-L1 expression via NF-kB/STAT/PD-L1 signaling, and activated INHBA/SMAD-PI3K/AKT pathway, enhancing cell migration and invasion. In allograft, F. nucleatum accelerated tumor growth, increased PD-L1 expression, and expanded T cell (Treg) infiltration; on the other hand, 4NQO-induced OSCC mice received F. nucleatum inoculation before and during anti-PD-L1 treatment demonstrated a reduce in weight loss and slower disease progression, indicating a microbiome-modulated therapeutic response.",
        "Conclusion": "This study reveals a critical host-microbiota interaction in the OSCC TIME. F. nucleatum emerges as a key modulator of a checkpoint-high, immune-evasive phenotype in OSCC. These data nominate F. nucleatum as a candidate biomarker for patient stratification and a therapeutic target to enhance ICI responsiveness in OSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Fusobacterium nucleatum drives PD-L1-mediated immune evasion and modulates anti-PD-L1 therapy response in Oral Cavity Squamous Cell Carcinoma</span>. <u>Hengyan Zhu, PhD</u>; Suet Ying Wong; Wenqi LU, PhD; Daijuanru Wang; Jason, YK Chan, FHKAM, FRCSEdORL; Zigui Chen, PhD. The Chinese University of Hong Kong<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Oral squamous cell carcinoma (OSCC) is a common type of malignant tumour in the head and neck region, with a five-year patient survival rate of 50%-60%. Although immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 offer clinical benefit, responses are variable and shaped by the tumor immune microenvironment (TIME). Microbiota dysbiosis is increasingly recognized as a determinant of immune modulators, yet actionable host-microbiota axies within the OSCC TIME remain incompletely elucidated.</p>\n\n<p><strong>Methods:</strong> The microbiota and host transcriptome of primary HPV-negative OSCC tumors and adjacent normal (AN) tissues were profiled through16S rRNA V3-V4 microbiota sequencing and host long non-coding RNA sequencing (lncRNA-seq), respectively. Reads were processed with QIIME2 and STAR, and analyzed in R to identify host-microbiota association, with an emphasis on immune checkpoint and immune-evasion pathways. Mechanistic validation employed in vitro co-culture of Fusobacterium nucleatum with OSCC cell lines for mRNA-Seq, qPCR, and western blotting. In vivo studies used bacteria-inoculated syngeneic allograft and 4-nitroquinoline-1-oxide (4NQO)-induced OSCC mouse models to assess tumor growth, immune contexture, and response to anti-PD-L1 therapy.</p>\n\n<p><strong>Results:</strong> OSCC tumor exhibited significant microbiota dysbiosis, enriched for pathogens and depleted of commensals. F. nucleatum, the most tumor-enriched bacteria, correlated with upregulated CD274 (PD-L1) and reduced CD8+ T-cell. In vitro, F. nucleatum induced PD-L1 expression via NF-kB/STAT/PD-L1 signaling, and activated INHBA/SMAD-PI3K/AKT pathway, enhancing cell migration and invasion. In allograft, F. nucleatum accelerated tumor growth, increased PD-L1 expression, and expanded T cell (Treg) infiltration; on the other hand, 4NQO-induced OSCC mice received F. nucleatum inoculation before and during anti-PD-L1 treatment demonstrated a reduce in weight loss and slower disease progression, indicating a microbiome-modulated therapeutic response.</p>\n\n<p><strong>Conclusion:</strong> This study reveals a critical host-microbiota interaction in the OSCC TIME. F. nucleatum emerges as a key modulator of a checkpoint-high, immune-evasive phenotype in OSCC. These data nominate F. nucleatum as a candidate biomarker for patient stratification and a therapeutic target to enhance ICI responsiveness in OSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154218--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S377",
      "content_id": "154528",
      "abstract_number": "S377",
      "poster_number": "",
      "title": "Higher Pain Scores are Associated with Gut Microbiome Changes in Patients with Oral Squamous Cell Carcinoma",
      "summary": "Seventeen patients provided stool samples for microbiome analysis (median age 60 years [IQR 52, 73]). Patients were predominantly male (64.7%) and White (88.2%). The most common tumor site was the lateral tongue (52.9%), followed by the mandibular alveolus (23.4%) and buccal mucosa (17.6%). Beta-diversity demonstrated significant compositional differences between low- and high-pain groups (BPI summary p=0.0047;...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154528",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taylor L Jamil, MD, MPH",
      "presenter": "Taylor L Jamil, MD, MPH",
      "authors": "Taylor L Jamil, MD, MPH 1 ; Delaney Sheehan, MD 2 ; Juhi J Patel, BS 2 ; Mabel Kahil, CST, MSc 2 ; Caitlyn B Tomblin, MD 2 ; Yedeh Ying, MD, DMD 2 ; Anthony Morlandt, MD, DDS 2 ; Susan McCammon, MD, PhD 2 ; Kirk Withrow, MD 2 ; Benjamin Greene, MD 2 ; Jason M Warram, MD 2 ; Chi T Viet, MD, PHD, DDS 3 ; Keseva Asam, MS 4 ; Bradley Aouizerat 4 ; Charles E Robertson, PhD 3 ; Daniel N Frank, PhD 1 ; Carissa M Thomas, MD, PhD, FACS 1",
      "normalized_authors": [
        "Taylor L Jamil",
        "Delaney Sheehan",
        "Juhi J Patel",
        "Mabel Kahil, CST",
        "Caitlyn B Tomblin",
        "Yedeh Ying",
        "Anthony Morlandt",
        "Susan McCammon",
        "Kirk Withrow",
        "Benjamin Greene",
        "Jason M Warram",
        "Chi T Viet",
        "Keseva Asam",
        "Bradley Aouizerat",
        "Charles E Robertson",
        "Daniel N Frank",
        "Carissa M Thomas"
      ],
      "affiliations": [
        "University of Colorado",
        "University of Alabama",
        "Loma Lina University Medical Center",
        "New York University School of Medicine"
      ],
      "normalized_institutions": [
        "University of Colorado",
        "University of Alabama",
        "Loma Lina University Medical Center",
        "New York University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 519,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Taylor L Jamil, MD, MPH 1 ; Delaney Sheehan, MD 2 ; Juhi J Patel, BS 2 ; Mabel Kahil, CST, MSc 2 ; Caitlyn B Tomblin, MD 2 ; Yedeh Ying, MD, DMD 2 ; Anthony Morlandt, MD, DDS 2 ; Susan McCammon, MD, PhD 2 ; Kirk Withrow, MD 2 ; Benjamin Greene, MD 2 ; Jason M Warram, MD 2 ; Chi T Viet, MD, PHD, DDS 3 ; Keseva Asam, MS 4 ; Bradley Aouizerat 4 ; Charles E Robertson, PhD 3 ; Daniel N Frank, PhD 1 ; Carissa M Thomas, MD, PhD, FACS 1",
        "Affiliations": "1 University of Colorado; 2 University of Alabama; 3 Loma Lina University Medical Center; 4 New York University School of Medicine",
        "Background": "Cancer-related pain is a common and significant factor that limits quality of life in patients with oral squamous cell carcinoma (OSCC), yet the biological drivers of cancer-related pain remain poorly understood. The gut microbiome has emerged as a modulator of inflammatory and neuropathic pain through microbial metabolites such as short-chain fatty acids (SCFAs). Many SCFA-producing bacterial taxa belong to families Ruminococcacea and Lachnospiraceae, including Faecalibacterium, Blautia, Anaerostipes, and Fusicatenibacter. The goal of this study was to correlate pain severity, assessed through morphine milligram equivalents (MME), and validated pain surveys, with bacterial taxa in stool samples, thereby identifying gut microbiome signatures associated with cancer pain in OSCC.",
        "Methods": "A prospective cohort study collected three pre-treatment cancer-related pain surveys (UCSF pain, EORTC-H&N35, and Brief Pain Index [BPI]) and average MMEs pre- and postoperatively in patients with OSCC. Stool bacterial DNA was isolated (Zymo Research, Irvine, CA) and underwent V4 16S rRNA gene sequencing (Illumina MiSeq). Alpha- and beta- diversity analyses were performed to compare microbiome differences across pain levels using ANOVA and permutational ANOVA tests, respectively. Differential abundance analysis (DAA) at the genus and family levels was assessed by generalized linear models of centered-log ratio transformed relative abundance data, with FDR correction. All analyses were completed in R (version 4.2.2).",
        "Results": "Seventeen patients provided stool samples for microbiome analysis (median age 60 years [IQR 52, 73]). Patients were predominantly male (64.7%) and White (88.2%). The most common tumor site was the lateral tongue (52.9%), followed by the mandibular alveolus (23.4%) and buccal mucosa (17.6%). Beta-diversity demonstrated significant compositional differences between low- and high-pain groups (BPI summary p=0.0047; BPI category p=0.028), while multiple alpha-diversity indices (richness, evenness, Shannon diversity) showed no significant differences (p<0.05). No other pain assessments were associated with microbiome differences. Patients with higher pain consistently exhibited depletion of multiple SCFA-producing genera, including Fusicatenibacter (B sum: -0.057), Anaerostipes (B sum: -0.045), broader Clostridia groups (B sum:-0.024), as well as Butyricicoccus (B sum:-0.04) and Blautia (B sum:-0.03). Additionally, higher pain levels were negatively associated with Helicobacter. Conversely, severe pain was associated with enrichment of Prevotella (B sum:0.026, B cat:2.5).",
        "Discussion": "Distinct microbiome patterns differentiate patients with low versus severe pain in OSCC. Prevotella species are more abundant in patients experiencing higher pain. In contrast, higher pain levels were consistently associated with reduced abundance of multiple SCFA- producing taxa, including Fusicatenibacter and Anaerostipes, as well as decreases in Streptococcus and Helicobacter. These findings suggest that shifts in gut microbial composition, particularly the loss of SCFA-producing taxa, may be associated with pain severity in OSCC. It is possible that pro-inflammatory pathways, such as interleukin-10 (IL-10) signaling, may be disrupted by the depletion of SCFA-producing bacteria. Mechanistic studies integrating oral and gut microbiomes with host and tumor factors are needed to confirm these associations. Research on gut microbiome in head and neck cancer pain is limited. Therefore, this study provides early evidence on how gut bacteria may contribute to differences in pain in OSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Higher Pain Scores are Associated with Gut Microbiome Changes in Patients with Oral Squamous Cell Carcinoma</span>. <u>Taylor L Jamil, MD, MPH</u><sup>1</sup>; Delaney Sheehan, MD<sup>2</sup>; Juhi J Patel, BS<sup>2</sup>; Mabel Kahil, CST, MSc<sup>2</sup>; Caitlyn B Tomblin, MD<sup>2</sup>; Yedeh Ying, MD, DMD<sup>2</sup>; Anthony Morlandt, MD, DDS<sup>2</sup>; Susan McCammon, MD, PhD<sup>2</sup>; Kirk Withrow, MD<sup>2</sup>; Benjamin Greene, MD<sup>2</sup>; Jason M Warram, MD<sup>2</sup>; Chi T Viet, MD, PHD, DDS<sup>3</sup>; Keseva Asam, MS<sup>4</sup>; Bradley Aouizerat<sup>4</sup>; Charles E Robertson, PhD<sup>3</sup>; Daniel N Frank, PhD<sup>1</sup>; Carissa M Thomas, MD, PhD, FACS<sup>1</sup>. <sup>1</sup>University of Colorado; <sup>2</sup>University of Alabama; <sup>3</sup>Loma Lina University Medical Center; <sup>4</sup>New York University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cancer-related pain is a common and significant factor that limits quality of life in patients with oral squamous cell carcinoma (OSCC), yet the biological drivers of cancer-related pain remain poorly understood. The gut microbiome has emerged as a modulator of inflammatory and neuropathic pain through microbial metabolites such as short-chain fatty acids (SCFAs). Many SCFA-producing bacterial taxa belong to families Ruminococcacea and Lachnospiraceae, including Faecalibacterium, Blautia, Anaerostipes, and Fusicatenibacter. The goal of this study was to correlate pain severity, assessed through morphine milligram equivalents (MME), and validated pain surveys, with bacterial taxa in stool samples, thereby identifying gut microbiome signatures associated with cancer pain in OSCC.</p>\n\n<p><strong> Methods:</strong> A prospective cohort study collected three pre-treatment cancer-related pain surveys (UCSF pain, EORTC-H&N35, and Brief Pain Index [BPI]) and average MMEs pre- and postoperatively in patients with OSCC. Stool bacterial DNA was isolated (Zymo Research, Irvine, CA) and underwent V4 16S rRNA gene sequencing (Illumina MiSeq). Alpha- and beta- diversity analyses were performed to compare microbiome differences across pain levels using ANOVA and permutational ANOVA tests, respectively. Differential abundance analysis (DAA) at the genus and family levels was assessed by generalized linear models of centered-log ratio transformed relative abundance data, with FDR correction. All analyses were completed in R (version 4.2.2). </p>\n\n<p><strong>Results:</strong> Seventeen patients provided stool samples for microbiome analysis (median age 60 years [IQR 52, 73]). Patients were predominantly male (64.7%) and White (88.2%). The most common tumor site was the lateral tongue (52.9%), followed by the mandibular alveolus (23.4%) and buccal mucosa (17.6%). Beta-diversity demonstrated significant compositional differences between low- and high-pain groups (BPI summary p=0.0047; BPI category p=0.028), while multiple alpha-diversity indices (richness, evenness, Shannon diversity) showed no significant differences (p<0.05). No other pain assessments were associated with microbiome differences. Patients with higher pain consistently exhibited depletion of multiple SCFA-producing genera, including Fusicatenibacter (B sum: -0.057), Anaerostipes (B sum: -0.045), broader Clostridia groups (B sum:-0.024), as well as Butyricicoccus (B sum:-0.04) and Blautia (B sum:-0.03). Additionally, higher pain levels were negatively associated with Helicobacter. Conversely, severe pain was associated with enrichment of Prevotella (B sum:0.026, B cat:2.5). </p>\n\n<p><strong> Discussion: </strong>Distinct microbiome patterns differentiate patients with low versus severe pain in OSCC. Prevotella species are more abundant in patients experiencing higher pain. In contrast, higher pain levels were consistently associated with reduced abundance of multiple SCFA- producing taxa, including Fusicatenibacter and Anaerostipes, as well as decreases in Streptococcus and Helicobacter. These findings suggest that shifts in gut microbial composition, particularly the loss of SCFA-producing taxa, may be associated with pain severity in OSCC. It is possible that pro-inflammatory pathways, such as interleukin-10 (IL-10) signaling, may be disrupted by the depletion of SCFA-producing bacteria. Mechanistic studies integrating oral and gut microbiomes with host and tumor factors are needed to confirm these associations. Research on gut microbiome in head and neck cancer pain is limited. Therefore, this study provides early evidence on how gut bacteria may contribute to differences in pain in OSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154528--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S378",
      "content_id": "153976",
      "abstract_number": "S378",
      "poster_number": "",
      "title": "Fusobacteria Enrichment Predicts Improved Survival in Head and Neck Squamous Cell Carcinoma: An Analysis of Publicly Available Genomic Data",
      "summary": "In this study, intratumoral Fusobacteria is a reproducible and dose-dependent protective biomarker in public HNSCC WGS microbiome data, particularly in oral cavity tumors. Synergistetes represent an independent but possibly secondary adverse signal. These findings highlight the potential importance of specific microbial niches within the HNSCC tumor microenvironment and support the utilization of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153976",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Z Allen, MD",
      "presenter": "David Z Allen, MD",
      "authors": "David Z Allen, MD 1 ; J W Rosenthal, BS 1 ; Georges Daoud, MD 1 ; Kunal Jain, MD 2 ; Ron J Karni, MD 2 ; Joshua J Kain, MD 3 ; Nicole C Schmitt, MD 1 ; Merry Sebelik, MD 1",
      "normalized_authors": [
        "David Z Allen",
        "J W Rosenthal",
        "Georges Daoud",
        "Kunal Jain",
        "Ron J Karni",
        "Joshua J Kain",
        "Nicole C Schmitt",
        "Merry Sebelik"
      ],
      "affiliations": [
        "Emory University",
        "UT Health Houston",
        "Atrium Health"
      ],
      "normalized_institutions": [
        "Emory University",
        "UT Health Houston",
        "Atrium Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 479,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "David Z Allen, MD 1 ; J W Rosenthal, BS 1 ; Georges Daoud, MD 1 ; Kunal Jain, MD 2 ; Ron J Karni, MD 2 ; Joshua J Kain, MD 3 ; Nicole C Schmitt, MD 1 ; Merry Sebelik, MD 1",
        "Affiliations": "1 Emory University; 2 UT Health Houston; 3 Atrium Health",
        "Background": "The intratumoral microbiome has been theorized to impact outcomes in head and neck squamous cell carcinoma (HNSCC), however population-level survival analyses from tumor whole-genome sequencing (WGS) remain poorly characterized.",
        "Methods": "Tumor-associated microbial relative abundances from TCGA-HNSC WGS data were combined with survival outcomes. To characterize strength of association, bacterial abundance was evaluated using multiple analytic strategies, including median dichotomization, continuous logit modeling, maximally selected rank statistics (maxstat), and ROC-derived cutpoints. Multivariable Cox models included age and pathologic stages. An exploratory phylum-level survival screen with false discovery rate (FDR) correction was performed to identify potential additional microbial associations. Subgroup analyses were prespecified for early-stage disease, oral cavity primaries, and lifelong nonsmokers. Stability checks included exclusion of early deaths (≤90 days) and sensitivity analyses across staging definitions.",
        "Results": "The cohort included 155 TCGA-HNSC patients with a median age of 60 years (IQR 52–68), mostly male (72%). Location was primarily in the oral cavity (67%), as well as oropharynx (17%), larynx (14%), and hypopharynx (1%). HPV status was available for a minority of cases (9 HPV-positive of 26 tested), and smoking history was documented in 80 patients, with a overall median follow-up of 26.4 months.",
        "Abstract": "Fusobacteria enrichment demonstrated improved overall survival. Using a simple median split, patients with Fusobacteria-high tumors had better survival (HR 0.56; 95% CI, 0.34–0.90; p = 0.017). Treating Fusobacteria as a continuous variable validated this relationship and remained significant even after adjusting for age and disease stage (HR 0.90; 95% CI, 0.85–0.95; p < 0.0001). A maximally selected threshold (~0.017) isolated a Fusobacteria-enriched subgroup with reduced mortality risk (HR 0.30; 95% CI, 0.18–0.51; p < 0.01), and an ROC-based cutpoint (~0.011) further showed similar findings (HR 0.35; 95% CI, 0.20–0.54; p = 0.01). In oral cavity tumors, patients whose tumors had above-median Fusobacteria experienced substantially improved survival (HR 0.34; 95% CI, 0.17–0.69; p < 0.01). Among lifelong nonsmokers, higher Fusobacteria levels were also strongly protective (HR 0.21; 95% CI, 0.05–0.88; p = 0.035). An exploratory phylum-level screen identified Synergistetes as the only additional taxon significantly associated with survival after FDR correction. Higher Synergistetes abundance correlated with worse outcomes (HR 1.38; 95% CI, 1.10–1.72; p < 0.01; FDR < 0.02). In models adjusting for Fusobacteria, Synergistetes remained independently harmful (HR 1.42; 95% CI, 1.14–1.78; p = 0.002; FDR = 0.015). View in Agenda and Add to Schedule",
        "Conclusions": "In this study, intratumoral Fusobacteria is a reproducible and dose-dependent protective biomarker in public HNSCC WGS microbiome data, particularly in oral cavity tumors. Synergistetes represent an independent but possibly secondary adverse signal. These findings highlight the potential importance of specific microbial niches within the HNSCC tumor microenvironment and support the utilization of microbiome-derived markers into future risk stratification."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Fusobacteria Enrichment Predicts Improved Survival in Head and Neck Squamous Cell Carcinoma: An Analysis of Publicly Available Genomic Data</span>. <u>David Z Allen, MD</u><sup>1</sup>; J W Rosenthal, BS<sup>1</sup>; Georges Daoud, MD<sup>1</sup>; Kunal Jain, MD<sup>2</sup>; Ron J Karni, MD<sup>2</sup>; Joshua J Kain, MD<sup>3</sup>; Nicole C Schmitt, MD<sup>1</sup>; Merry Sebelik, MD<sup>1</sup>. <sup>1</sup>Emory University; <sup>2</sup>UT Health Houston; <sup>3</sup>Atrium Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The intratumoral microbiome has been theorized to impact outcomes in head and neck squamous cell carcinoma (HNSCC), however population-level survival analyses from tumor whole-genome sequencing (WGS) remain poorly characterized. </p>\n\n<p><strong>Methods: </strong>Tumor-associated microbial relative abundances from TCGA-HNSC WGS data were combined with survival outcomes. To characterize strength of association, bacterial abundance was evaluated using multiple analytic strategies, including median dichotomization, continuous logit modeling, maximally selected rank statistics (maxstat), and ROC-derived cutpoints. Multivariable Cox models included age and pathologic stages. An exploratory phylum-level survival screen with false discovery rate (FDR) correction was performed to identify potential additional microbial associations. Subgroup analyses were prespecified for early-stage disease, oral cavity primaries, and lifelong nonsmokers. Stability checks included exclusion of early deaths (≤90 days) and sensitivity analyses across staging definitions.</p>\n\n<p><strong>Results: </strong>The cohort included 155 TCGA-HNSC patients with a median age of 60 years (IQR 52–68), mostly male (72%). Location was primarily in the oral cavity (67%), as well as oropharynx (17%), larynx (14%), and hypopharynx (1%). HPV status was available for a minority of cases (9 HPV-positive of 26 tested), and smoking history was documented in 80 patients, with a overall median follow-up of 26.4 months.</p>\n\n<p>Fusobacteria enrichment demonstrated improved overall survival. Using a simple median split, patients with Fusobacteria-high tumors had better survival (HR 0.56; 95% CI, 0.34–0.90; p = 0.017). Treating Fusobacteria as a continuous variable validated this relationship and remained significant even after adjusting for age and disease stage (HR 0.90; 95% CI, 0.85–0.95; p < 0.0001). A maximally selected threshold (~0.017) isolated a Fusobacteria-enriched subgroup with reduced mortality risk (HR 0.30; 95% CI, 0.18–0.51; p < 0.01), and an ROC-based cutpoint (~0.011) further showed similar findings (HR 0.35; 95% CI, 0.20–0.54; p = 0.01). </p>\n\n<p>In oral cavity tumors, patients whose tumors had above-median Fusobacteria experienced substantially improved survival (HR 0.34; 95% CI, 0.17–0.69; p < 0.01). Among lifelong nonsmokers, higher Fusobacteria levels were also strongly protective (HR 0.21; 95% CI, 0.05–0.88; p = 0.035). An exploratory phylum-level screen identified Synergistetes as the only additional taxon significantly associated with survival after FDR correction. Higher Synergistetes abundance correlated with worse outcomes (HR 1.38; 95% CI, 1.10–1.72; p < 0.01; FDR < 0.02). In models adjusting for Fusobacteria, Synergistetes remained independently harmful (HR 1.42; 95% CI, 1.14–1.78; p = 0.002; FDR = 0.015). </p>\n\n<p><strong>Conclusions: </strong>In this study, intratumoral Fusobacteria is a reproducible and dose-dependent protective biomarker in public HNSCC WGS microbiome data, particularly in oral cavity tumors. Synergistetes represent an independent but possibly secondary adverse signal. These findings highlight the potential importance of specific microbial niches within the HNSCC tumor microenvironment and support the utilization of microbiome-derived markers into future risk stratification.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153976--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S379",
      "content_id": "155423",
      "abstract_number": "S379",
      "poster_number": "",
      "title": "Microbiome Influence on Oral Cavity Cancer Potential for Regional Metastasis",
      "summary": "Alpha diversity was greater in non-tumor than tumor but did show a trend toward differences by subsite. Due to small sample size, these measures of species diversity did not reach statistical significance. However, beta diversity analysis showed statistically significant differences in the species present in the subsites examined. These variations in species contribute to the oral cavity TME and may influence...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155423",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta, MD",
      "presenter": "Vishal Gupta, MD",
      "authors": "Vishal Gupta, MD 1 ; Lu Li, PhD 2 ; Keith L Kirkwood, DDS, PhD 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Christian Gluck, MD, PhD 3 ; Amritha Suresh, PhD 4 ; Sumsum P Sunny, MDS, PhD 4 ; Moni A Kuriakose, MD 5 ; Wesley L Hicks, Jr., DDS, MD 1 ; Patricia I Diaz, DDS, PhD 2",
      "normalized_authors": [
        "Vishal Gupta",
        "Lu Li",
        "Keith L Kirkwood",
        "William J Magner",
        "Lynn Sigurdson",
        "Christian Gluck",
        "Amritha Suresh",
        "Sumsum P Sunny, MDS",
        "Moni A Kuriakose",
        "Wesley L Hicks, Jr",
        "Patricia I Diaz"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo School of Dental Medicine",
        "Penn State Health",
        "Mazumdar Shaw Medical Foundation",
        "Lakeshore Hospital, Kocki, India"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo School of Dental Medicine",
        "Penn State Health",
        "Mazumdar Shaw Medical Foundation",
        "Lakeshore Hospital, Kocki, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 455,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vishal Gupta, MD 1 ; Lu Li, PhD 2 ; Keith L Kirkwood, DDS, PhD 2 ; William J Magner, PhD 1 ; Lynn Sigurdson, PhD 1 ; Christian Gluck, MD, PhD 3 ; Amritha Suresh, PhD 4 ; Sumsum P Sunny, MDS, PhD 4 ; Moni A Kuriakose, MD 5 ; Wesley L Hicks, Jr., DDS, MD 1 ; Patricia I Diaz, DDS, PhD 2",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo School of Dental Medicine; 3 Penn State Health; 4 Mazumdar Shaw Medical Foundation; 5 Lakeshore Hospital, Kocki, India",
        "Background": "Oral cavity squamous cell carcinoma (OSCC), accounts for approximately 650,000 annual cases worldwide and efforts to improve survival/outcome have been hampered by increased recurrence rates leading to a static 5-year survival rate (50%). Tumors in certain oral cavity anatomical subsites differ in their tendency to recur or metastasize but mechanisms underlying these differences have not been clarified. External exposures (tobacco and alcohol) have been extensively studied; however, the influence of the microbiome has only recently been recognized. Microbiome changes, primarily sampled from saliva or surface swabs, have been associated with oral cavity cancer. Our group has addressed differences in the tumor microenvironment (TME) associated with tumor progression and outcome. These studies led us to consider microbiome contributions within the TME. We sought to determine whether there were microbiome signatures associated with specific tumor anatomic sites.",
        "Methods": "Frozen tumor samples from HPV negative oral cavity cancer patients were obtained from our Pathology biobank. Four oral cavity sites were selected based on their propensity for recurrence or metastasis. Bacterial communities in tumor tissues were characterized using 16S rRNA gene sequencing targeting the V1–V2 region. Sequences were processed using the Mothur pipeline and clustered into operational taxonomic units (OTUs) at 97% similarity. Taxonomic annotation was performed using a reference database combining the Human Oral Microbiome Database (HOMD) v15.22 and the Genome Taxonomy Database (GTDB) v202. Shannon alpha diversity and Bray–Curtis beta diversity were calculated to evaluate microbial diversity and community composition. The significance of diversity differences and associations between bacterial abundance, tumor status, and anatomical site were evaluated using mixed-effects models and conditioned PERMANOVA tests controlling for sample site and subject variability.",
        "Results": "Neither tumor status nor sample site significantly impacted alpha diversity, but tumor and non-tumor groups showed significant differences in both microbiome community membership and composition (Bray–Curtis beta diversity). Mixed-effects modeling identified two bacterial species, Filifactor alocis and [Eubacterium] infirmum, that were exclusively associated with tumor samples. In addition, multiple bacterial species were significantly associated with anatomical site, indicating that tumor subsite strongly influences microbiome composition, although overall microbial profiles did not form clearly separable clusters by tumor status or site.",
        "Conclusions": "Alpha diversity was greater in non-tumor than tumor but did show a trend toward differences by subsite. Due to small sample size, these measures of species diversity did not reach statistical significance. However, beta diversity analysis showed statistically significant differences in the species present in the subsites examined. These variations in species contribute to the oral cavity TME and may influence tumor behavior. A larger sample size and expanded subsites evaluation will be undertaken, and a data-driven predictive model for metastatic risk utilizing both microbiome and other clinical characteristics may help with clinical decision-making.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Microbiome Influence on Oral Cavity Cancer Potential for Regional Metastasis</span>. <u>Vishal Gupta, MD</u><sup>1</sup>; Lu Li, PhD<sup>2</sup>; Keith L Kirkwood, DDS, PhD<sup>2</sup>; William J Magner, PhD<sup>1</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Christian Gluck, MD, PhD<sup>3</sup>; Amritha Suresh, PhD<sup>4</sup>; Sumsum P Sunny, MDS, PhD<sup>4</sup>; Moni A Kuriakose, MD<sup>5</sup>; Wesley L Hicks, Jr., DDS, MD<sup>1</sup>; Patricia I Diaz, DDS, PhD<sup>2</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo School of Dental Medicine; <sup>3</sup>Penn State Health; <sup>4</sup>Mazumdar Shaw Medical Foundation; <sup>5</sup>Lakeshore Hospital, Kocki, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral cavity squamous cell carcinoma (OSCC), accounts for approximately 650,000 annual cases worldwide and efforts to improve survival/outcome have been hampered by increased recurrence rates leading to a static 5-year survival rate (50%). Tumors in certain oral cavity anatomical subsites differ in their tendency to recur or metastasize but mechanisms underlying these differences have not been clarified. External exposures (tobacco and alcohol) have been extensively studied; however, the influence of the microbiome has only recently been recognized. Microbiome changes, primarily sampled from saliva or surface swabs, have been associated with oral cavity cancer. Our group has addressed differences in the tumor microenvironment (TME) associated with tumor progression and outcome. These studies led us to consider microbiome contributions within the TME. We sought to determine whether there were microbiome signatures associated with specific tumor anatomic sites.</p>\n\n<p><strong>Methods: </strong>Frozen tumor samples from HPV negative oral cavity cancer patients were obtained from our Pathology biobank. Four oral cavity sites were selected based on their propensity for recurrence or metastasis. Bacterial communities in tumor tissues were characterized using 16S rRNA gene sequencing targeting the V1–V2 region. Sequences were processed using the Mothur pipeline and clustered into operational taxonomic units (OTUs) at 97% similarity. Taxonomic annotation was performed using a reference database combining the Human Oral Microbiome Database (HOMD) v15.22 and the Genome Taxonomy Database (GTDB) v202. Shannon alpha diversity and Bray–Curtis beta diversity were calculated to evaluate microbial diversity and community composition. The significance of diversity differences and associations between bacterial abundance, tumor status, and anatomical site were evaluated using mixed-effects models and conditioned PERMANOVA tests controlling for sample site and subject variability.</p>\n\n<p><strong>Results: </strong>Neither tumor status nor sample site significantly impacted alpha diversity, but tumor and non-tumor groups showed significant differences in both microbiome community membership and composition (Bray–Curtis beta diversity). Mixed-effects modeling identified two bacterial species, Filifactor alocis and [Eubacterium] infirmum, that were exclusively associated with tumor samples. In addition, multiple bacterial species were significantly associated with anatomical site, indicating that tumor subsite strongly influences microbiome composition, although overall microbial profiles did not form clearly separable clusters by tumor status or site.</p>\n\n<p><strong>Conclusions: </strong>Alpha diversity was greater in non-tumor than tumor but did show a trend toward differences by subsite. Due to small sample size, these measures of species diversity did not reach statistical significance. However, beta diversity analysis showed statistically significant differences in the species present in the subsites examined. These variations in species contribute to the oral cavity TME and may influence tumor behavior. A larger sample size and expanded subsites evaluation will be undertaken, and a data-driven predictive model for metastatic risk utilizing both microbiome and other clinical characteristics may help with clinical decision-making.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155423--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S380",
      "content_id": "153441",
      "abstract_number": "S380",
      "poster_number": "",
      "title": "A Model to Study Inflammation-Microbiome Interactions in Oral Squamous Cell Carcinoma Development",
      "summary": "TP53 mutation and p16 loss are associated with the development of oral cancer in a chemical carcinogenesis model that provides an opportunity to evaluate the contributions of the oral microbiome and chronic material irritation to oral carcinogenesis.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153441",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260144",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ahmed Tajmim Noor",
      "presenter": "Ahmed Tajmim Noor",
      "authors": "Ahmed Tajmim Noor ; Jaafar Al Hadi; Arnoldo Corona; Humam Kadara; Lorena Gomez Bolanos; Roberto Rangel; Jeffrey N Myers",
      "normalized_authors": [
        "Ahmed Tajmim Noor",
        "Jaafar Al Hadi",
        "Arnoldo Corona",
        "Humam Kadara",
        "Lorena Gomez Bolanos",
        "Roberto Rangel",
        "Jeffrey N Myers"
      ],
      "affiliations": [
        "MD Anderson Cancer"
      ],
      "normalized_institutions": [
        "MD Anderson Cancer"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Method",
        "Result",
        "Conclusion",
        "Future Direction",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ahmed Tajmim Noor ; Jaafar Al Hadi; Arnoldo Corona; Humam Kadara; Lorena Gomez Bolanos; Roberto Rangel; Jeffrey N Myers",
        "Affiliations": "MD Anderson Cancer",
        "Background": "The oral microbiome plays a significant role in the pathogenesis of oral cancer, with dysbiosis being linked to an increased risk. Fusobacterium nucleatum is a common oral bacterium associated with the development of oral squamous cell carcinoma (OSCC). It contributes to carcinogenesis through chronic inflammation, stimulation of cell proliferation, inhibition of apoptosis, and production of oncometabolites. The oral microbiome's influence extends beyond the oral cavity, potentially affecting distant body sites and cancer therapy outcomes.",
        "Objective": "Develop a mouse model to investigate the molecular and cellular mechanisms by which chronic inflammation promotes oral cancer development in the oral epithelium with p53 and Cdkn2a mutations and study the role of Fusobacterium nucleatum in tumorigenesis and immune evasion in the oral tumor carcinogenesis model.",
        "Method": "A silk ligature was placed between the Maxillary 1st and 2nd molars in mice with p53 and p16 wild-type or K14Cre, p53-R172H; Cdkn2a-LOF mutation. The drinking water for these mice contained 50 μg/mL 4NQO. Additionally, a 1:1 suspension of F. nucleatum in 2% Carboxymethyl Cellulose was placed in the oral cavity with a gel each week. Mice were sacrificed at 12, 16, and 20 weeks of age.",
        "Result": "Microscopic visualization of 20 total H&E-stained specimens (10 Maxilla, 10 Tongue) revealed a significant number of lesions in the mutant genotype (p53R172H; p16 f/f) as compared with C57/BLB6 wild-type mice. Histologic evaluation of maxillary lesions showed that dysplasia was predominant (80%), ranging from mild to severe, with focal polymorphonuclear or lymphocytic infiltrates. In tongue samples, SCC was more frequent (70%), often keratinizing, and associated with bacterial colonies (90%). Mild to moderate dysplasia (50%) was noted in 30% of cases. In p53R172H; p16 f/f genotype mice, there was a higher incidence of SCC of the tongue (83%) compared to wild-type mice (50%). Inflammatory infiltrates were less commonly seen in mutant mice (15%) compared to wild-type mice (50%). Bacterial colonies were consistently observed across both genotypes (46% in mutants; 67% in wild types).",
        "Conclusion": "TP53 mutation and p16 loss are associated with the development of oral cancer in a chemical carcinogenesis model that provides an opportunity to evaluate the contributions of the oral microbiome and chronic material irritation to oral carcinogenesis.",
        "Future Direction": "Similarly designed studies will be performed in germ-free mice with reduced 4NQO dose to evaluate independent contributions of bacteria, chemical carcinogenesis, chronic mechanical irritation, and TP53 mutation to the development of oral pre-malignant lesions and cancers.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Model to Study Inflammation-Microbiome Interactions in Oral Squamous Cell Carcinoma Development</span>. <u>Ahmed Tajmim Noor</u>; Jaafar Al Hadi; Arnoldo Corona; Humam Kadara; Lorena Gomez Bolanos; Roberto Rangel; Jeffrey N Myers. MD Anderson Cancer<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The oral microbiome plays a significant role in the pathogenesis of oral cancer, with dysbiosis being linked to an increased risk. Fusobacterium nucleatum is a common oral bacterium associated with the development of oral squamous cell carcinoma (OSCC). It contributes to carcinogenesis through chronic inflammation, stimulation of cell proliferation, inhibition of apoptosis, and production of oncometabolites. The oral microbiome's influence extends beyond the oral cavity, potentially affecting distant body sites and cancer therapy outcomes.</p>\n\n<p><strong>Objective:</strong> Develop a mouse model to investigate the molecular and cellular mechanisms by which chronic inflammation promotes oral cancer development in the oral epithelium with p53 and Cdkn2a mutations and study the role of Fusobacterium nucleatum in tumorigenesis and immune evasion in the oral tumor carcinogenesis model.</p>\n\n<p><strong>Method:</strong> A silk ligature was placed between the Maxillary 1st and 2nd molars in mice with p53 and p16 wild-type or K14Cre, p53-R172H; Cdkn2a-LOF mutation. The drinking water for these mice contained 50 μg/mL 4NQO. Additionally, a 1:1 suspension of F. nucleatum in 2% Carboxymethyl Cellulose was placed in the oral cavity with a gel each week. Mice were sacrificed at 12, 16, and 20 weeks of age.</p>\n\n<p><strong>Result: </strong>Microscopic visualization of 20 total H&E-stained specimens (10 Maxilla, 10 Tongue) revealed a significant number of lesions in the mutant genotype (p53R172H; p16 f/f) as compared with C57/BLB6 wild-type mice. Histologic evaluation of maxillary lesions showed that dysplasia was predominant (80%), ranging from mild to severe, with focal polymorphonuclear or lymphocytic infiltrates. In tongue samples, SCC was more frequent (70%), often keratinizing, and associated with bacterial colonies (90%). Mild to moderate dysplasia (50%) was noted in 30% of cases. In p53R172H; p16 f/f genotype mice, there was a higher incidence of SCC of the tongue (83%) compared to wild-type mice (50%). Inflammatory infiltrates were less commonly seen in mutant mice (15%) compared to wild-type mice (50%). Bacterial colonies were consistently observed across both genotypes (46% in mutants; 67% in wild types).</p>\n\n<p><strong>Conclusion: </strong>TP53 mutation and p16 loss are associated with the development of oral cancer in a chemical carcinogenesis model that provides an opportunity to evaluate the contributions of the oral microbiome and chronic material irritation to oral carcinogenesis.</p>\n\n<p><strong>Future Direction:</strong> Similarly designed studies will be performed in germ-free mice with reduced 4NQO dose to evaluate independent contributions of bacteria, chemical carcinogenesis, chronic mechanical irritation, and TP53 mutation to the development of oral pre-malignant lesions and cancers.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153441--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260144' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S381",
      "content_id": "154386",
      "abstract_number": "S381",
      "poster_number": "",
      "title": "Real Time Image-Guided TORS: Intraoperative Transcervical Ultrasound Assisted Transoral Robotic Surgery",
      "summary": "This study is the first to prospectively evaluate the clinical implementation of real-time ITcUS, displayed onto the robotic console, during TORS for OPSCC. Our findings demonstrate accurate, real-time tumor volume delineation with strong concordance to pathological ground truth. In addition, ITcUS enabled visualization of critical vascular structures and previously unidentified primary tumors. As such, we...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154386",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jamie JY Kwon, MS",
      "presenter": "Jamie JY Kwon, MS",
      "authors": "Jamie JY Kwon, MS 1 ; Cornelius Kürten, MD 1 ; Behnoush Mortazavi, MD 2 ; Wanwen Chen, MS 3 ; Septimiu Salcudean, PhD 3 ; Eitan Prisman, MD, MA, FRCSC 1",
      "normalized_authors": [
        "Jamie JY Kwon",
        "Cornelius Kürten",
        "Behnoush Mortazavi",
        "Wanwen Chen",
        "Septimiu Salcudean",
        "Eitan Prisman, MA, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Diagnostic Radiology, BC Cancer Agency, Canada",
        "Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Diagnostic Radiology, BC Cancer Agency, Canada",
        "Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154386/TORS_AHNSabstract.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154386/TORS_AHNSabstract.png",
          "alt": "Figure 1. Real-time ITcUS with endoscopic view co-displayed into the surgeon console, allowing visualization of a base of tongue tumor, dorsal lingual artery, submandibular gland, and cautery to map the excision based on ITcUS.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154386"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 447,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jamie JY Kwon, MS 1 ; Cornelius Kürten, MD 1 ; Behnoush Mortazavi, MD 2 ; Wanwen Chen, MS 3 ; Septimiu Salcudean, PhD 3 ; Eitan Prisman, MD, MA, FRCSC 1",
        "Affiliations": "1 Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; 2 Department of Diagnostic Radiology, BC Cancer Agency, Canada; 3 Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada",
        "Background": "Transoral robotic surgery (TORS) is a well-established approach for appropriately selected oropharyngeal cancers but remains limited by its reliance on two-dimensional endoscopic visualization without real-time depth information. Real-time transcervical ultrasound (TcUS) image guidance to visualize tumor extent and surrounding vasculature may overcome these limitations. Our prior work has demonstrated the feasibility of preoperative TcUS in assessing tumor volume and its correlation with final tumor pathology. This study investigates the utility of live, intraoperative TcUS (ITcUS) displayed in real-time at the surgeon console as an imaging adjunct during TORS.",
        "Methods": "ITcUS was performed prospectively during TORS and displayed in real time at the surgeon console using the TilePro™ interface of the Da Vinci Xi. Tumor volumes from ITcUS, preoperative CT, MRI, and PET-CT were compared to gross pathology. Tumor-to-vessel distances on CT and ITcUS were compared. The potential of ITcUS in identifying tumors in unknown primary cases and its influence on positive margin rates were explored. Surgeon and sonographer experience with ITcUS was assessed using the System Usability Scale (SUS) and NASA Surgical Task Load Index (NASA SURG-TLX).",
        "Results": "ITcUS was successfully integrated into TORS and performed in 35 cases. ITcUS-defined tumor volumes demonstrated the strongest correlation with final pathology (R = 0.94), outperforming PET-CT (0.93), MRI (0.91), and CT (0.85), with no statistically significant differences between imaging- and pathology-derived volumes (p > 0.05). Doppler ITcUS identified adjacent vasculature in all patients, with tumor-to-vessel distances consistent with CT measurements. In six patients with clinically and radiologically occult primaries, ITcUS localized all six tumors intraoperatively (100%). Positive margin rates in this prospective cohort were 6%, which compared favorably to our institutional experience of 8%. The average SUS score was 57 ± 8, and the NASA SURG-TLX was 23 ± 3, indicating an initial learning curve to correlate real-time ultrasound imaging to the surgical field that improved over time, and relatively low cognitive demand to perform ITcUS.",
        "Conclusions": "This study is the first to prospectively evaluate the clinical implementation of real-time ITcUS, displayed onto the robotic console, during TORS for OPSCC. Our findings demonstrate accurate, real-time tumor volume delineation with strong concordance to pathological ground truth. In addition, ITcUS enabled visualization of critical vascular structures and previously unidentified primary tumors. As such, we position ITcUS as an innovative image-guided modality with the potential to enhance intraoperative decision-making and surgical precision. These results provide a foundation for larger, multicenter trials to assess the impact of ITcUS-guided TORS on oncologic outcomes.",
        "Abstract": "Supplementary Video 2. Surgeon console view of ITcUS with clearly delineated tumor margin and depth. A hyperechoic artifact appears as the cautery tip palpates the tumor. The adjacent facial artery is visualized in blue on Doppler. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real Time Image-Guided TORS: Intraoperative Transcervical Ultrasound Assisted Transoral Robotic Surgery</span>. <u>Jamie JY Kwon, MS</u><sup>1</sup>; Cornelius Kürten, MD<sup>1</sup>; Behnoush Mortazavi, MD<sup>2</sup>; Wanwen Chen, MS<sup>3</sup>; Septimiu Salcudean, PhD<sup>3</sup>; Eitan Prisman, MD, MA, FRCSC<sup>1</sup>. <sup>1</sup>Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; <sup>2</sup>Department of Diagnostic Radiology, BC Cancer Agency, Canada; <sup>3</sup>Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Transoral robotic surgery (TORS) is a well-established approach for appropriately selected oropharyngeal cancers but remains limited by its reliance on two-dimensional endoscopic visualization without real-time depth information. Real-time transcervical ultrasound (TcUS) image guidance to visualize tumor extent and surrounding vasculature may overcome these limitations. Our prior work has demonstrated the feasibility of preoperative TcUS in assessing tumor volume and its correlation with final tumor pathology. This study investigates the utility of live, intraoperative TcUS (ITcUS) displayed in real-time at the surgeon console as an imaging adjunct during TORS. </p>\n\n<p><strong>Methods:</strong> ITcUS was performed prospectively during TORS and displayed in real time at the surgeon console using the TilePro™ interface of the Da Vinci Xi. Tumor volumes from ITcUS, preoperative CT, MRI, and PET-CT were compared to gross pathology. Tumor-to-vessel distances on CT and ITcUS were compared. The potential of ITcUS in identifying tumors in unknown primary cases and its influence on positive margin rates were explored. Surgeon and sonographer experience with ITcUS was assessed using the System Usability Scale (SUS) and NASA Surgical Task Load Index (NASA SURG-TLX). </p>\n\n<p><strong>Results:</strong> ITcUS was successfully integrated into TORS and performed in 35 cases. ITcUS-defined tumor volumes demonstrated the strongest correlation with final pathology (R = 0.94), outperforming PET-CT (0.93), MRI (0.91), and CT (0.85), with no statistically significant differences between imaging- and pathology-derived volumes (p > 0.05). Doppler ITcUS identified adjacent vasculature in all patients, with tumor-to-vessel distances consistent with CT measurements. In six patients with clinically and radiologically occult primaries, ITcUS localized all six tumors intraoperatively (100%). Positive margin rates in this prospective cohort were 6%, which compared favorably to our institutional experience of 8%. The average SUS score was 57 ± 8, and the NASA SURG-TLX was 23 ± 3, indicating an initial learning curve to correlate real-time ultrasound imaging to the surgical field that improved over time, and relatively low cognitive demand to perform ITcUS. </p>\n\n<p><strong>Conclusions: </strong>This study is the first to prospectively evaluate the clinical implementation of real-time ITcUS, displayed onto the robotic console, during TORS for OPSCC. Our findings demonstrate accurate, real-time tumor volume delineation with strong concordance to pathological ground truth. In addition, ITcUS enabled visualization of critical vascular structures and previously unidentified primary tumors. As such, we position ITcUS as an innovative image-guided modality with the potential to enhance intraoperative decision-making and surgical precision. These results provide a foundation for larger, multicenter trials to assess the impact of ITcUS-guided TORS on oncologic outcomes. </p>\n\n<p><img alt='Figure 1. Real-time ITcUS with endoscopic view co-displayed into the surgeon console, allowing visualization of a base of tongue tumor, dorsal lingual artery, submandibular gland, and cautery to map the excision based on ITcUS.  ' src='https://www.submitmyabstract.com/abs/images/154386/TORS_AHNSabstract.png' /></p>\n\n<p>Supplementary Video 2. Surgeon console view of ITcUS with clearly delineated tumor margin and depth. A hyperechoic artifact appears as the cautery tip palpates the tumor. The adjacent facial artery is visualized in blue on Doppler.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154386--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S382",
      "content_id": "154500",
      "abstract_number": "S382",
      "poster_number": "",
      "title": "Intraoperative virtual 3D specimen mapping to optimize margin communication during transoral robotic surgery",
      "summary": "iv3DSS is an effective adjunct to frozen section assessment during TORS for OPSCC to enhance interdisciplinary communication of margin status without extending operative time or disrupting standard pathological evaluation. Surgeons reported significant improvement in clarity, ease of use, and perceived clinical value, while pathologists found the workflow neutral to beneficial. These findings support the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154500",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jamie JY Kwon, MS",
      "presenter": "Jamie JY Kwon, MS",
      "authors": "Jamie JY Kwon, MS 1 ; Joel Howlett, MD 1 ; Daniyah Saleh, MD 2 ; Nadia Hua, MD 1 ; Carl Ren, MD 2 ; Eitan Prisman 1",
      "normalized_authors": [
        "Jamie JY Kwon",
        "Joel Howlett",
        "Daniyah Saleh",
        "Nadia Hua",
        "Carl Ren",
        "Eitan Prisman"
      ],
      "affiliations": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Pathology, University of British Columbia, Canada"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada",
        "Department of Pathology, University of British Columbia, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154500/3dpath_AHNS(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154500/3dpath_AHNS(1).png",
          "alt": "Figure 1. Summary of 3D-scanned and annotated intraoperative virtual 3D surgical specimen (iv3Dss) from TORS for OPSCC.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154500"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jamie JY Kwon, MS 1 ; Joel Howlett, MD 1 ; Daniyah Saleh, MD 2 ; Nadia Hua, MD 1 ; Carl Ren, MD 2 ; Eitan Prisman 1",
        "Affiliations": "1 Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; 2 Department of Pathology, University of British Columbia, Canada",
        "Background": "Achieving clear surgical margins remains a predictor of oncologic success in transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC). Current communication methods between surgery and pathology during routine intraoperative frozen section consultation are limited to verbal reports and pathology slides. As a result, surgeons may interpret margin status without direct reference to the specimen’s three-dimensional (3D) context, and pathologists lack a reliable method to convey spatially accurate margin findings back to the operating room (OR). These constraints contribute to misunderstanding margin location, unnecessary re-resections, or prolonged operative time. 3D specimen mapping offers a potential solution by providing a virtual representation of the tumour and frozen section findings. We evaluate a novel intraoperative virtual 3D surgical specimen (iv3DSS) workflow in enhancing real-time surgeon-pathologist communication during TORS.",
        "Methods": "In this prospective study, 40 consecutive patients undergoing primary TORS for biopsy-proven OPSCC between September 2023 and November 2024 were enrolled. Following en bloc tumor resection, the fresh specimen was immediately 3D-scanned in the OR to generate a digital mesh model. During standard frozen section analysis by a head and neck pathologist, a trained assistant annotated the iv3DSS in parallel for sectioning planes, orientation, and positive or close margin location. These iv3DSSS were then used to guide the surgeon in performing revision margin resections. Surgeons and pathologists completed paired pre- and post-intervention questionnaires for each specimen to quantitatively assess traditional (T) versus virtual (V) workflows across four domains: documentation, communication, ease of use, and clinical value. Responses were recorded on 5-point Likert scales and compared using paired t-tests.",
        "Results": "Forty patients (mean age 63; 83% male) were included. Primary sites were distributed between base-of-tongue (50%) and tonsil (50%). Frozen section analysis demonstrated 27 (68%) negative margins, 9 close (22%) margins, and 4 (10%) positive margins. iv3DSS were generated and annotated in all cases, with a mean scan time of 5.6 ± 1.2 minutes. Additional iv3DSS-guided margin re-resection was performed in 10 cases, with a final positive margin rate of 7%. Surgeon surveys demonstrated statistically significant improvements across all domains when comparing traditional reporting and communication methods to iv3DSS (p < 0.001). Pathologist scores showed nonsignificant trends favoring the virtual workflow.",
        "Conclusions": "iv3DSS is an effective adjunct to frozen section assessment during TORS for OPSCC to enhance interdisciplinary communication of margin status without extending operative time or disrupting standard pathological evaluation. Surgeons reported significant improvement in clarity, ease of use, and perceived clinical value, while pathologists found the workflow neutral to beneficial. These findings support the integration of iv3DSS as a complementary tool to optimize real-time decision-making and margin management during TORS for OPSCC.",
        "Figure 1.": "Summary of 3D-scanned and annotated intraoperative virtual 3D surgical specimen (iv3Dss) from TORS for OPSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoperative virtual 3D specimen mapping to optimize margin communication during transoral robotic surgery</span>. <u>Jamie JY Kwon, MS</u><sup>1</sup>; Joel Howlett, MD<sup>1</sup>; Daniyah Saleh, MD<sup>2</sup>; Nadia Hua, MD<sup>1</sup>; Carl Ren, MD<sup>2</sup>; Eitan Prisman<sup>1</sup>. <sup>1</sup>Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of British Columbia, Canada; <sup>2</sup>Department of Pathology, University of British Columbia, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Achieving clear surgical margins remains a predictor of oncologic success in transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC). Current communication methods between surgery and pathology during routine intraoperative frozen section consultation are limited to verbal reports and pathology slides. As a result, surgeons may interpret margin status without direct reference to the specimen’s three-dimensional (3D) context, and pathologists lack a reliable method to convey spatially accurate margin findings back to the operating room (OR). These constraints contribute to misunderstanding margin location, unnecessary re-resections, or prolonged operative time. 3D specimen mapping offers a potential solution by providing a virtual representation of the tumour and frozen section findings. We evaluate a novel intraoperative virtual 3D surgical specimen (iv3DSS) workflow in enhancing real-time surgeon-pathologist communication during TORS.</p>\n\n<p><strong>Methods: </strong>In this prospective study, 40 consecutive patients undergoing primary TORS for biopsy-proven OPSCC between September 2023 and November 2024 were enrolled. Following en bloc tumor resection, the fresh specimen was immediately 3D-scanned in the OR to generate a digital mesh model. During standard frozen section analysis by a head and neck pathologist, a trained assistant annotated the iv3DSS in parallel for sectioning planes, orientation, and positive or close margin location. These iv3DSSS were then used to guide the surgeon in performing revision margin resections. Surgeons and pathologists completed paired pre- and post-intervention questionnaires for each specimen to quantitatively assess traditional (T) versus virtual (V) workflows across four domains: documentation, communication, ease of use, and clinical value. Responses were recorded on 5-point Likert scales and compared using paired t-tests.</p>\n\n<p><strong>Results:</strong> Forty patients (mean age 63; 83% male) were included. Primary sites were distributed between base-of-tongue (50%) and tonsil (50%). Frozen section analysis demonstrated 27 (68%) negative margins, 9 close (22%) margins, and 4 (10%) positive margins. iv3DSS were generated and annotated in all cases, with a mean scan time of 5.6 ± 1.2 minutes. Additional iv3DSS-guided margin re-resection was performed in 10 cases, with a final positive margin rate of 7%. Surgeon surveys demonstrated statistically significant improvements across all domains when comparing traditional reporting and communication methods to iv3DSS (p < 0.001). Pathologist scores showed nonsignificant trends favoring the virtual workflow.</p>\n\n<p><strong>Conclusions:</strong> iv3DSS is an effective adjunct to frozen section assessment during TORS for OPSCC to enhance interdisciplinary communication of margin status without extending operative time or disrupting standard pathological evaluation. Surgeons reported significant improvement in clarity, ease of use, and perceived clinical value, while pathologists found the workflow neutral to beneficial. These findings support the integration of iv3DSS as a complementary tool to optimize real-time decision-making and margin management during TORS for OPSCC.</p>\n\n<p><img alt='Figure 1. Summary of 3D-scanned and annotated intraoperative virtual 3D surgical specimen (iv3Dss) from TORS for OPSCC. ' src='https://www.submitmyabstract.com/abs/images/154500/3dpath_AHNS(1).png' /></p>\n\n<p><strong>Figure 1.</strong> Summary of 3D-scanned and annotated intraoperative virtual 3D surgical specimen (iv3Dss) from TORS for OPSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154500--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S383",
      "content_id": "153218",
      "abstract_number": "S383",
      "poster_number": "",
      "title": "Investigating Spatial Relationships Between Polyamines and T Cells in Head & Neck Squamous Cell Carcinoma by Integrating Histology with Mass Spectrometry Imaging using SCALES",
      "summary": "Immunotherapy (IO) has revolutionized the management of head & neck squamous cell carcinoma (HNSCC). However, hostile conditions, such as nutrient depletion, hypoxia, and immunosuppressive metabolites, within the tumor microenvironment (TME) limit the effectiveness of IO for HNSCC patients by creating an environment unfit for anti-tumor immune responses. For example, growing evidence suggests an association...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153218",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dane N Fernandez",
      "presenter": "Dane N Fernandez",
      "authors": "Dane N Fernandez 1 ; William T Andrews 2 ; Aleksandra Ogurtsova 3 ; Jing Wu 1 ; Cody Huffman 1 ; Maureen Kane 2 ; Jonathan D Powell 4 ; Rajarsi Mandal 5 ; Ngechi Nwankwoala 6 ; Ryan Jackson 1 ; Jason Rich 1 ; Patrik Pipkorn 1 ; Paul Zolkind 1 ; Ben Wahle 1 ; Logan Engle 3 ; Carole Fakhry 3 ; Daniel Miller 1 ; Siddharth V Puram 1 ; Gregory J Baker 7 ; R",
      "normalized_authors": [
        "Dane N Fernandez",
        "William T Andrews",
        "Aleksandra Ogurtsova",
        "Jing Wu",
        "Cody Huffman",
        "Maureen Kane",
        "Jonathan D Powell",
        "Rajarsi Mandal",
        "Ngechi Nwankwoala",
        "Ryan Jackson",
        "Jason Rich",
        "Patrik Pipkorn",
        "Paul Zolkind",
        "Ben Wahle",
        "Logan Engle",
        "Carole Fakhry",
        "Daniel Miller",
        "Siddharth V Puram",
        "Gregory J Baker"
      ],
      "affiliations": [
        "Alex Harbison 1 . 1 Washington University in St. Louis",
        "University of Maryland",
        "Johns Hopkins University",
        "Calico Labs",
        "Northwell Health",
        "Boston University",
        "Oregon Health & Science University"
      ],
      "normalized_institutions": [
        "Alex Harbison 1 . 1 Washington University in St. Louis",
        "University of Maryland",
        "Johns Hopkins University",
        "Calico Labs",
        "Northwell Health",
        "Boston University",
        "Oregon Health & Science University"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153218/anhs%20image%20final.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153218/anhs%20image%20final.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153218"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 447,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results and Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Dane N Fernandez 1 ; William T Andrews 2 ; Aleksandra Ogurtsova 3 ; Jing Wu 1 ; Cody Huffman 1 ; Maureen Kane 2 ; Jonathan D Powell 4 ; Rajarsi Mandal 5 ; Ngechi Nwankwoala 6 ; Ryan Jackson 1 ; Jason Rich 1 ; Patrik Pipkorn 1 ; Paul Zolkind 1 ; Ben Wahle 1 ; Logan Engle 3 ; Carole Fakhry 3 ; Daniel Miller 1 ; Siddharth V Puram 1 ; Gregory J Baker 7 ; R",
        "Affiliations": "Alex Harbison 1 . 1 Washington University in St. Louis; 2 University of Maryland; 3 Johns Hopkins University; 4 Calico Labs; 5 Northwell Health; 6 Boston University; 7 Oregon Health & Science University",
        "Introduction": "Immunotherapy (IO) has revolutionized the management of head & neck squamous cell carcinoma (HNSCC). However, hostile conditions, such as nutrient depletion, hypoxia, and immunosuppressive metabolites, within the tumor microenvironment (TME) limit the effectiveness of IO for HNSCC patients by creating an environment unfit for anti-tumor immune responses. For example, growing evidence suggests an association between a group of immunoregulatory cancer metabolites (polyamines, PAs) and decreased anti-tumor immunity. Thus, defining the spatial relationships between immunoregulatory metabolites, such as PAs, and tumor-infiltrating lymphocytes (TILs) has the potential to better predict IO responses and overall anti-tumor immune function in the TME. To better understand these associations, we developed a novel strategy integrating immunohistochemistry (IHC) with matrix assisted laser desorption/ionization – mass spectrometry imaging (MALDI-MSI) that allows us to quantify the spatial interactions between metabolites and stromal cells in matched HNSCC tumor specimens.",
        "Methods": "Fresh-frozen HNSCC specimens (15 µm thick) were coated with MALDI matrix and imaged via MALDI-MSI using a 12T Bruker Solarix FT-ICR. Metaspace software was then used to annotate metabolites based on their specific mass-to-charge (m/z) ratios. Following MALDI-MSI imaging, tissue specimens were stripped of their MALDI matrix and stained with H&E, followed by IHC labeling with anti-CD8, -CD20, -CD163, and -panCK antibodies. IHC images were computationally deconvolved to separate their individual stains and segmented using MCMICRO (Schapiro et al., Nature Methods 2022) on the extracted hematoxylin-stained nuclei images. The multiplex tissue imaging quality control program CyLinter (Baker et al., Nature Methods 2024) was used to remove segmented cells affected by microscopy artifacts including tissue folds, antibody aggregates, and other optical aberrations, followed by clustering of the remaining cells based on their antibody marker intensity profiles. We then developed a novel computational tool (SCALES - Spatial Correlation Analysis of Linked Ecosystem Structures) to spatially align and analyze the MSI and single-cell IHC data and to quantify correlations between TILs and metabolites within matched HNSCC tissue specimens.",
        "Results and Conclusions": "Using our novel computational platform, SCALES, we identified a negative spatial correlation between CD8+ T cell infiltration and PA enrichment in HNSCC, providing insight into the metabolic landscape of the TME. Initial results reveal the exclusion of CD8+ T cells in the presence of spermine, S-adenosylmethionine, and arginine, with average Spearman coefficients of -0.22, -0.28, and -0.21, respectively, among biologically distinct patient tissues. These findings provide evidence of the functional effects of immune regulatory metabolites on anti-tumor infiltrates. Ongoing studies aim to extend these observations by analyzing relationships between similar metabolites and macrophages and B cells in both HPV- and HPV+ HNSCC specimens, to ultimately identify druggable targets capable of blocking key immunoregulatory metabolites produced by HNSCC cells that negatively impact IO efficacy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Investigating Spatial Relationships Between Polyamines and T Cells in Head & Neck Squamous Cell Carcinoma by Integrating Histology with Mass Spectrometry Imaging using SCALES</span>. <u>Dane N Fernandez</u><sup>1</sup>; William T Andrews<sup>2</sup>; Aleksandra Ogurtsova<sup>3</sup>; Jing Wu<sup>1</sup>; Cody Huffman<sup>1</sup>; Maureen Kane<sup>2</sup>; Jonathan D Powell<sup>4</sup>; Rajarsi Mandal<sup>5</sup>; Ngechi Nwankwoala<sup>6</sup>; Ryan Jackson<sup>1</sup>; Jason Rich<sup>1</sup>; Patrik Pipkorn<sup>1</sup>; Paul Zolkind<sup>1</sup>; Ben Wahle<sup>1</sup>; Logan Engle<sup>3</sup>; Carole Fakhry<sup>3</sup>; Daniel Miller<sup>1</sup>; Siddharth V Puram<sup>1</sup>; Gregory J Baker<sup>7</sup>; R. Alex Harbison<sup>1</sup>. <sup>1</sup>Washington University in St. Louis; <sup>2</sup>University of Maryland; <sup>3</sup>Johns Hopkins University; <sup>4</sup>Calico Labs; <sup>5</sup>Northwell Health; <sup>6</sup>Boston University; <sup>7</sup>Oregon Health & Science University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Immunotherapy (IO) has revolutionized the management of head & neck squamous cell carcinoma (HNSCC). However, hostile conditions, such as nutrient depletion, hypoxia, and immunosuppressive metabolites, within the tumor microenvironment (TME) limit the effectiveness of IO for HNSCC patients by creating an environment unfit for anti-tumor immune responses. For example, growing evidence suggests an association between a group of immunoregulatory cancer metabolites (polyamines, PAs) and decreased anti-tumor immunity. Thus, defining the spatial relationships between immunoregulatory metabolites, such as PAs, and tumor-infiltrating lymphocytes (TILs) has the potential to better predict IO responses and overall anti-tumor immune function in the TME. To better understand these associations, we developed a novel strategy integrating immunohistochemistry (IHC) with matrix assisted laser desorption/ionization – mass spectrometry imaging (MALDI-MSI) that allows us to quantify the spatial interactions between metabolites and stromal cells in matched HNSCC tumor specimens. </p>\n\n<p><strong>Methods:</strong> Fresh-frozen HNSCC specimens (15 µm thick) were coated with MALDI matrix and imaged via MALDI-MSI using a 12T Bruker Solarix FT-ICR.  Metaspace software was then used to annotate metabolites based on their specific mass-to-charge (m/z) ratios. Following MALDI-MSI imaging, tissue specimens were stripped of their MALDI matrix and stained with H&E, followed by IHC labeling with anti-CD8, -CD20, -CD163, and -panCK antibodies. IHC images were computationally deconvolved to separate their individual stains and segmented using MCMICRO (Schapiro et al., Nature Methods 2022) on the extracted hematoxylin-stained nuclei images. The multiplex tissue imaging quality control program CyLinter (Baker et al., Nature Methods 2024) was used to remove segmented cells affected by microscopy artifacts including tissue folds, antibody aggregates, and other optical aberrations, followed by clustering of the remaining cells based on their antibody marker intensity profiles. We then developed a novel computational tool (SCALES - Spatial Correlation Analysis of Linked Ecosystem Structures) to spatially align and analyze the MSI and single-cell IHC data and to quantify correlations between TILs and metabolites within matched HNSCC tissue specimens. </p>\n\n<p><strong>Results and Conclusions:</strong> Using our novel computational platform, SCALES, we identified a negative spatial correlation between CD8+ T cell infiltration and PA enrichment in HNSCC, providing insight into the metabolic landscape of the TME. Initial results reveal the exclusion of CD8+ T cells in the presence of spermine, S-adenosylmethionine, and arginine, with average Spearman coefficients of -0.22, -0.28, and -0.21, respectively, among biologically distinct patient tissues. These findings provide evidence of the functional effects of immune regulatory metabolites on anti-tumor infiltrates. Ongoing studies aim to extend these observations by analyzing relationships between similar metabolites and macrophages and B cells in both HPV- and HPV+ HNSCC specimens, to ultimately identify druggable targets capable of blocking key immunoregulatory metabolites produced by HNSCC cells that negatively impact IO efficacy. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153218/anhs%20image%20final.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153218--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S384",
      "content_id": "153308",
      "abstract_number": "S384",
      "poster_number": "",
      "title": "Augmented Reality for Parathyroid Adenoma : Surgical planning workflow and Cadaveric demonstration",
      "summary": "This pilot study provides a simple reproducible AR workflow using routine preoperative 4D CT imaging for parathyroidectomy planning. It could set the initial understanding on real-time imaging visualisation to encourage more AR usage in open surgery in head and neck regions.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153308",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Catherine Po Ling Chan",
      "presenter": "Catherine Po Ling Chan",
      "authors": "Catherine Po Ling Chan ; Fabian Necker; Johnny Yang; Bruce Daniel; Lisa Orloff; Fred Baik",
      "normalized_authors": [
        "Catherine Po Ling Chan",
        "Fabian Necker",
        "Johnny Yang",
        "Bruce Daniel",
        "Lisa Orloff",
        "Fred Baik"
      ],
      "affiliations": [
        "Stanford University"
      ],
      "normalized_institutions": [
        "Stanford University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Catherine Po Ling Chan ; Fabian Necker; Johnny Yang; Bruce Daniel; Lisa Orloff; Fred Baik",
        "Affiliations": "Stanford University",
        "Background": "Precise identification of parathyroid adenoma during parathyroidectomy remains challenging due to its small size and close but variable relationship within the central neck compartment. Despite using various parathyroid gland localisation tracer and imaging e.g. sestamibi scan and 4D-CT scan to identify the potential parathyroid adenoma candidate to improve diagnostic accuracy, translating the axial scan or poor-resolution radioisotope scan into intraoperative real-time spatial understanding is still a great challenge. Ultrasound is the first line investigation to provide a real-time cross-sectional view to look for abnormally enlarged parathyroid. Yet it is highly operative dependent and limited by the poor penetration to the bones (e.g. spine, sternum and clavicle) if the parathyroid adenoma candidate is hidden at the substernal thymic region.",
        "Abstract": "Some studies tried to use autofluorescence technology to visualise and overlay the parathyroid gland during endoscopic thyroidectomy. Augmented reality (AR) offers the opportunity to bridge the gap by overlaying the reconstructed preoperative imaging onto the surgical field in three-dimensional visualisation for surgical incision and planning. However, there is no current literature suggesting using AR technology to visualise the parathyroid adenoma for parathyroidectomy, let alone a reproducible workflow for establishing the AR models for intraoperative use. This study aims to develop and validate a simple, standardized pipeline to create AR models for surgical planning in parathyroidectomy. First, the lesion was identified based on the finalized radiology report in open-source software 3D Slicer. Second, using the optimal sequence, the lesion was segmented with various segmentation tools like local thresholding, level tracing and manual outlining. Third, additional anatomical structures (claviculae, skin, bony skeleton, thyroid cartilage) relevant for navigating the anatomy were segmented with similar techniques. Fourth, the segmented anatomy was color-coded (translucent gray skin, green lesion, blue/brown bones and cartilage) and exported as individualized models. Lastly, the models were then imported onto the Apple Vision Pro headset that allows accurate manual positioning and co-registration. The surgeon donned the headset, could visualize the model in AR and co-register the virtual surgical landmarks (e.g. claviculae) to the in-situ anatomy. The workflow was designed for reproducibility with standardised segmentation steps and exported parameters. Feasibility and anatomical fiducial markings were demonstrated by overlaying the models on a cadaveric body to simulate operative conditions. View in Agenda and Add to Schedule",
        "Methods": "Five patients with primary hyperparathyroidism were retrospectively identified. All patients were confirmed to have preoperative 4D-CT scan available for image segmentation.",
        "Results": "All five cases were successfully segmented and reconstructed into AR-compatible 3D models. Model segmentation and reconstruction required approximately 20-40 minutes, depending on complexity and CT contrast patterns. In the cadaveric demonstration, AR models were overlaid consistently on surface landmarks and videos were captured to demonstrate the feasibility of see-throughing the segmented parathyroid adenoma candidate in relation to surface anatomy and surrounding critical structures.",
        "Conclusion": "This pilot study provides a simple reproducible AR workflow using routine preoperative 4D CT imaging for parathyroidectomy planning. It could set the initial understanding on real-time imaging visualisation to encourage more AR usage in open surgery in head and neck regions."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Augmented Reality for Parathyroid Adenoma : Surgical planning workflow and Cadaveric demonstration</span>. <u>Catherine Po Ling Chan</u>; Fabian Necker; Johnny Yang; Bruce Daniel; Lisa Orloff; Fred Baik. Stanford University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Precise identification of parathyroid adenoma during parathyroidectomy remains challenging due to its small size and close but variable relationship within the central neck compartment. Despite using various parathyroid gland localisation tracer and imaging e.g. sestamibi scan and 4D-CT scan to identify the potential parathyroid adenoma candidate to improve diagnostic accuracy, translating the axial scan or poor-resolution radioisotope scan into intraoperative real-time spatial understanding is still a great challenge. Ultrasound is the first line investigation to provide a real-time cross-sectional view to look for abnormally enlarged parathyroid. Yet it is highly operative dependent and limited by the poor penetration to the bones (e.g. spine, sternum and clavicle) if the parathyroid adenoma candidate is hidden at the substernal thymic region. </p>\n\n<p>Some studies tried to use autofluorescence technology to visualise and overlay the parathyroid gland during endoscopic thyroidectomy. Augmented reality (AR) offers the opportunity to bridge the gap by overlaying the reconstructed preoperative imaging onto the surgical field in three-dimensional visualisation for surgical incision and planning. However, there is no current literature suggesting using AR technology to visualise the parathyroid adenoma for parathyroidectomy, let alone a reproducible workflow for establishing the AR models for intraoperative use. </p>\n\n<p>This study aims to develop and validate a simple, standardized pipeline to create AR models for surgical planning in parathyroidectomy. </p>\n\n<p><strong>Methods: </strong>Five patients with primary hyperparathyroidism were retrospectively identified. All patients were confirmed to have preoperative 4D-CT scan available for image segmentation. </p>\n\n<p>First, the lesion was identified based on the finalized radiology report in open-source software 3D Slicer. Second, using the optimal sequence, the lesion was segmented with various segmentation tools like local thresholding, level tracing and manual outlining. Third, additional anatomical structures (claviculae, skin, bony skeleton, thyroid cartilage) relevant for navigating the anatomy were segmented with similar techniques. Fourth, the segmented anatomy was color-coded (translucent gray skin, green lesion, blue/brown bones and cartilage) and exported as individualized models. Lastly, the models were then imported onto the Apple Vision Pro headset that allows accurate manual positioning and co-registration. The surgeon donned the headset, could visualize the model in AR and co-register the virtual surgical landmarks (e.g. claviculae) to the in-situ anatomy.</p>\n\n<p>The workflow was designed for reproducibility with standardised segmentation steps and exported parameters. </p>\n\n<p>Feasibility and anatomical fiducial markings were demonstrated by overlaying the models on a cadaveric body to simulate operative conditions. </p>\n\n<p><strong>Results: </strong>All five cases were successfully segmented and reconstructed into AR-compatible 3D models. Model segmentation and reconstruction required approximately 20-40 minutes, depending on complexity and CT contrast patterns. In the cadaveric demonstration, AR models were overlaid consistently on surface landmarks and videos were captured to demonstrate the feasibility of see-throughing the segmented parathyroid adenoma candidate in relation to surface anatomy and surrounding critical structures. </p>\n\n<p><strong>Conclusion: </strong>This pilot study provides a simple reproducible AR workflow using routine preoperative 4D CT imaging for parathyroidectomy planning. It could set the initial understanding on real-time imaging visualisation to encourage more AR usage in open surgery in head and neck regions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153308--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S385",
      "content_id": "154673",
      "abstract_number": "S385",
      "poster_number": "",
      "title": "Point of Care Ultrasound Improves Diagnostic Performance of Otolaryngologist-Performed Core Needle Biopsy for Cervical Lymphadenopathy",
      "summary": "Within a large multisite otolaryngology practice, POCUS guidance significantly improved biopsy success and reduced the need for repeat procedures. Given these benefits and the increasing adoption of POCUS, routine use of POCUS-guided core needle biopsy is supported as a preferred approach for evaluating cervical lymphadenopathy in otolaryngology clinics.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154673",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas L Haupt, MD",
      "presenter": "Thomas L Haupt, MD",
      "authors": "Thomas L Haupt, MD ; Nickolas Pudik; Kevin Wang, MD",
      "normalized_authors": [
        "Thomas L Haupt",
        "Nickolas Pudik",
        "Kevin Wang"
      ],
      "affiliations": [
        "Dept of Head and Neck Surgery at Kaiser Oakland Medical Center"
      ],
      "normalized_institutions": [
        "Dept of Head and Neck Surgery at Kaiser Oakland Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 382,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Thomas L Haupt, MD ; Nickolas Pudik; Kevin Wang, MD",
        "Affiliations": "Dept of Head and Neck Surgery at Kaiser Oakland Medical Center",
        "Objective": "To evaluate whether point of care ultrasound (POCUS) improves the diagnostic performance of office-based core needle biopsy performed by otolaryngologists for cervical lymphadenopathy.",
        "Methods": "A retrospective cohort study was conducted across an integrated healthcare system from 2016 to 2020. Adult patients undergoing office-based cervical core needle biopsy were included. Demographics (age, sex, race and ethnicity), body mass index (BMI), lymph node long-axis diameter, and neck level were recorded. Final pathology, determined by clinical follow-up or definitive surgical specimen, was categorized as benign, lymphoma, or other cancer (including squamous cell carcinoma, melanoma, and other metastatic malignancies). A successful biopsy was defined as one that yielded a definitive benign or malignant diagnosis, with insufficient and indeterminate samples categorized as unsuccessful. Outcomes included biopsy success, diagnostic accuracy, predictors of success, and time to diagnosis.",
        "Results": "A total of 512 biopsies were analyzed (129 POCUS-guided and 383 palpation-guided). Mean age was 59.3 years, mean BMI was 27.9 kg/m², and the mean lymph node long-axis diameter was 3.2 cm. Sex and race distributions were similar between groups. Final pathologies included benign disease (n = 170), lymphoma (n = 164), and other cancers (n = 140). POCUS use increased significantly over the study period, measured as the percentage of all core needle biopsies performed with POCUS each year, rising by approximately 20% from 2016 to 2020 (p < 0.0001). POCUS guidance was associated with a higher rate of successful biopsies (81.4% vs 70.4%, p = 0.0185) and fewer repeat biopsies (12.1% vs 20.2%, p < 0.001). In multivariate analysis, POCUS independently increased the odds of biopsy success (OR 3.30, p = 0.002). Lymphoma diagnosis was associated with higher odds of success (OR 2.46, p = 0.033), and smaller lymph node size was associated with lower success (p = 0.016). Any repeat biopsy, including POCUS-guided, interventional radiology performed, or excisional approaches, was associated with an average delay of approximately 32 days in establishing a final diagnosis (p < 0.001).",
        "Conclusion": "Within a large multisite otolaryngology practice, POCUS guidance significantly improved biopsy success and reduced the need for repeat procedures. Given these benefits and the increasing adoption of POCUS, routine use of POCUS-guided core needle biopsy is supported as a preferred approach for evaluating cervical lymphadenopathy in otolaryngology clinics.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Point of Care Ultrasound Improves Diagnostic Performance of Otolaryngologist-Performed Core Needle Biopsy for Cervical Lymphadenopathy</span>. <u>Thomas L Haupt, MD</u>; Nickolas Pudik; Kevin Wang, MD. Dept of Head and Neck Surgery at Kaiser Oakland Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To evaluate whether point of care ultrasound (POCUS) improves the diagnostic performance of office-based core needle biopsy performed by otolaryngologists for cervical lymphadenopathy.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted across an integrated healthcare system from 2016 to 2020. Adult patients undergoing office-based cervical core needle biopsy were included. Demographics (age, sex, race and ethnicity), body mass index (BMI), lymph node long-axis diameter, and neck level were recorded. Final pathology, determined by clinical follow-up or definitive surgical specimen, was categorized as benign, lymphoma, or other cancer (including squamous cell carcinoma, melanoma, and other metastatic malignancies). A successful biopsy was defined as one that yielded a definitive benign or malignant diagnosis, with insufficient and indeterminate samples categorized as unsuccessful. Outcomes included biopsy success, diagnostic accuracy, predictors of success, and time to diagnosis.</p>\n\n<p><strong>Results:</strong> A total of 512 biopsies were analyzed (129 POCUS-guided and 383 palpation-guided). Mean age was 59.3 years, mean BMI was 27.9 kg/m², and the mean lymph node long-axis diameter was 3.2 cm. Sex and race distributions were similar between groups. Final pathologies included benign disease (n = 170), lymphoma (n = 164), and other cancers (n = 140). POCUS use increased significantly over the study period, measured as the percentage of all core needle biopsies performed with POCUS each year, rising by approximately 20% from 2016 to 2020 (p < 0.0001). POCUS guidance was associated with a higher rate of successful biopsies (81.4% vs 70.4%, p = 0.0185) and fewer repeat biopsies (12.1% vs 20.2%, p < 0.001). In multivariate analysis, POCUS independently increased the odds of biopsy success (OR 3.30, p = 0.002). Lymphoma diagnosis was associated with higher odds of success (OR 2.46, p = 0.033), and smaller lymph node size was associated with lower success (p = 0.016). Any repeat biopsy, including POCUS-guided, interventional radiology performed, or excisional approaches, was associated with an average delay of approximately 32 days in establishing a final diagnosis (p < 0.001).</p>\n\n<p><strong>Conclusion:</strong> Within a large multisite otolaryngology practice, POCUS guidance significantly improved biopsy success and reduced the need for repeat procedures. Given these benefits and the increasing adoption of POCUS, routine use of POCUS-guided core needle biopsy is supported as a preferred approach for evaluating cervical lymphadenopathy in otolaryngology clinics.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154673--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S386",
      "content_id": "153030",
      "abstract_number": "S386",
      "poster_number": "",
      "title": "Efficacy and potential of frontal diffuser illumination in head and neck photoimmunotherapy",
      "summary": "Our data suggest that frontal illumination in photoimmunotherapy can achieve CR even in moderately thick lesions, potentially expanding its indications. Accumulation of further clinical experience and prospective validation are warranted to establish evidence-based criteria for selecting optimal illumination approaches according to tumor site, depth, and morphology.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153030",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Koichi Yoshizawa, MD",
      "presenter": "Koichi Yoshizawa, MD",
      "authors": "Koichi Yoshizawa, MD 1 ; Takahiro Tsujikawa, MD, PhD 1 ; Hitomi Iwaki, MD 1 ; Peesit Leelasawatsuk, MD 2 ; Shota Sugaya, MD 1 ; Sumiyo Saburi, MD, PhD 1 ; Hikaru Nagao, MD, PhD 1 ; Shigeru Hirano, MD, PhD 1",
      "normalized_authors": [
        "Koichi Yoshizawa",
        "Takahiro Tsujikawa",
        "Hitomi Iwaki",
        "Peesit Leelasawatsuk",
        "Shota Sugaya",
        "Sumiyo Saburi",
        "Hikaru Nagao",
        "Shigeru Hirano"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan",
        "Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University, Songkhla, Thailand"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan",
        "Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University, Songkhla, Thailand"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 355,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Koichi Yoshizawa, MD 1 ; Takahiro Tsujikawa, MD, PhD 1 ; Hitomi Iwaki, MD 1 ; Peesit Leelasawatsuk, MD 2 ; Shota Sugaya, MD 1 ; Sumiyo Saburi, MD, PhD 1 ; Hikaru Nagao, MD, PhD 1 ; Shigeru Hirano, MD, PhD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan; 2 Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University, Songkhla, Thailand",
        "Background": "Photoimmunotherapy (PIT) using cetuximab sarotalocan sodium (Akalux®) has rapidly expanded in Japan, with more than 1100 cases performed nationwide since its clinical introduction. Illumination strategy is a critical determinant of treatment success. Among available techniques, frontal diffusers deliver light directly from the tip of the fiber in a forward-facing manner, enabling broad coverage of superficial lesions. Although the effective penetration depth of frontal illumination has generally been considered to be approximately 2-10 mm, its actual therapeutic range in clinical practice remains to be clarified.",
        "Methods": "A total of 28 patients with head and neck squamous cell carcinoma were treated with PIT at our institution between December 2021 and August 2025, and nine who achieved a complete response (CR) were retrospectively analyzed. Illumination approach, tumor site, tumor diameter and thickness, and treatment-related adverse events were evaluated.",
        "Results": "Of nine patients, three underwent frontal illumination alone (oral cavity, n=2; oropharynx, n=1) and six received cylindrical or combined approaches (neck, n=3; oral cavity, n=1; oropharynx, n=1; hypopharynx, n=1). Tumor diameters ranged from 29-60 mm in the frontal group and 13-26 mm in the cylindrical group. Tumor thicknesses were 2-6 mm and 6-19 mm, respectively, indicating that frontal illumination tended to be applied to wider but thinner lesions. Grade≥3 edema occurred in 1/3 frontal cases and 2/6 cylindrical cases. Grade≥1 pain was observed in 0/3 and 3/6 cases, respectively, suggesting less lain with frontal illumination.",
        "Discussion": "Frontal illumination offers a minimally invasive and technically simple means of covering broad superficial lesions. Although traditionally recommended for tumors≤2 mm in depth due to limited light penetration, our findings revealed two cases of CR in lesions thicker than 5 mm treated with frontal illumination alone. These results indicate a potentially broader therapeutic range for this approach than previously assumed.",
        "Conclusion": "Our data suggest that frontal illumination in photoimmunotherapy can achieve CR even in moderately thick lesions, potentially expanding its indications. Accumulation of further clinical experience and prospective validation are warranted to establish evidence-based criteria for selecting optimal illumination approaches according to tumor site, depth, and morphology.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy and potential of frontal diffuser illumination in head and neck photoimmunotherapy</span>. <u>Koichi Yoshizawa, MD</u><sup>1</sup>; Takahiro Tsujikawa, MD, PhD<sup>1</sup>; Hitomi Iwaki, MD<sup>1</sup>; Peesit Leelasawatsuk, MD<sup>2</sup>; Shota Sugaya, MD<sup>1</sup>; Sumiyo Saburi, MD, PhD<sup>1</sup>; Hikaru Nagao, MD, PhD<sup>1</sup>; Shigeru Hirano, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan; <sup>2</sup>Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University, Songkhla, Thailand<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Photoimmunotherapy (PIT) using cetuximab sarotalocan sodium (Akalux®) has rapidly expanded in Japan, with more than 1100 cases performed nationwide since its clinical introduction. Illumination strategy is a critical determinant of treatment success. Among available techniques, frontal diffusers deliver light directly from the tip of the fiber in a forward-facing manner, enabling broad coverage of superficial lesions. Although the effective penetration depth of frontal illumination has generally been considered to be approximately 2-10 mm, its actual therapeutic range in clinical practice remains to be clarified.</p>\n\n<p><strong>Methods: </strong>A total of 28 patients with head and neck squamous cell carcinoma were treated with PIT at our institution between December 2021 and August 2025, and nine who achieved a complete response (CR) were retrospectively analyzed. Illumination approach, tumor site, tumor diameter and thickness, and treatment-related adverse events were evaluated.</p>\n\n<p><strong>Results:</strong> Of nine patients, three underwent frontal illumination alone (oral cavity, n=2; oropharynx, n=1) and six received cylindrical or combined approaches (neck, n=3; oral cavity, n=1; oropharynx, n=1; hypopharynx, n=1). Tumor diameters ranged from 29-60 mm in the frontal group and 13-26 mm in the cylindrical group. Tumor thicknesses were 2-6 mm and 6-19 mm, respectively, indicating that frontal illumination tended to be applied to wider but thinner lesions. Grade≥3 edema occurred in 1/3 frontal cases and 2/6 cylindrical cases. Grade≥1 pain was observed in 0/3 and 3/6 cases, respectively, suggesting less lain with frontal illumination.</p>\n\n<p><strong>Discussion:</strong> Frontal illumination offers a minimally invasive and technically simple means of covering broad superficial lesions. Although traditionally recommended for tumors≤2 mm in depth due to limited light penetration, our findings revealed two cases of CR in lesions thicker than 5 mm treated with frontal illumination alone. These results indicate a potentially broader therapeutic range for this approach than previously assumed.</p>\n\n<p><strong>Conclusion: </strong>Our data suggest that frontal illumination in photoimmunotherapy can achieve CR even in moderately thick lesions, potentially expanding its indications. Accumulation of further clinical experience and prospective validation are warranted to establish evidence-based criteria for selecting optimal illumination approaches according to tumor site, depth, and morphology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153030--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S387",
      "content_id": "153947",
      "abstract_number": "S387",
      "poster_number": "",
      "title": "Cutaneous Malignancy Detection Using Dynamic Optical Contrast Imaging",
      "summary": "DOCI demonstrates promise in accurately distinguishing cutaneous malignancies from adjacent healthy skin, particularly SCC and melanoma. DOCI also shows the potential to distinguish benign and premalignant lesions from malignant tumors, supporting its further exploration as a noninvasive tool for diagnostic evaluation and intraoperative margin assessment.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153947",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Song Hon Hwang, MD",
      "presenter": "Song Hon Hwang, MD",
      "authors": "Song Hon Hwang, MD 1 ; Yazeed Alhiyari, PhD 1 ; Brandon Mo 1 ; Maie St",
      "normalized_authors": [
        "Song Hon Hwang",
        "Yazeed Alhiyari",
        "Brandon Mo",
        "Maie St"
      ],
      "affiliations": [
        "John, MD, PhD 2 . 1 David Geffen School of Medicine at UCLA - Department of Head & Neck Surgery",
        "Johns Hopkins Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "John, MD, PhD 2 . 1 David Geffen School of Medicine at UCLA - Department of Head & Neck Surgery",
        "Johns Hopkins Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_09%E2%80%AFPM.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_09%E2%80%AFPM.jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153947"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_18%E2%80%AFPM.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_18%E2%80%AFPM.jpeg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153947"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 455,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Song Hon Hwang, MD 1 ; Yazeed Alhiyari, PhD 1 ; Brandon Mo 1 ; Maie St",
        "Affiliations": "John, MD, PhD 2 . 1 David Geffen School of Medicine at UCLA - Department of Head & Neck Surgery; 2 Johns Hopkins Department of Otolaryngology-Head and Neck Surgery",
        "Introduction": "Dynamic optical contrast imaging (DOCI) is a novel imaging modality that utilizes the fluorescence of endogenous molecules to help delineate between malignant and healthy tissue. As the incidence of cutaneous head and neck malignancies continues to rise, particularly non-melanoma skin cancers, technologies that can enhance rapid and accurate lesion assessment are critical. DOCI provides a real-time, noninvasive approach that can be used intraoperatively to improve margin detection and aid in complete surgical resection of the tumor.",
        "Objectives": "To assess the ability of DOCI to discriminate between malignant cutaneous lesions and adjacent healthy skin and its ability to distinguish between malignant and benign cutaneous lesions.",
        "Methods": "Forty-nine adult patients with biopsy-confirmed cutaneous head and neck malignancies who were undergoing surgical excision were recruited for this study. Patients were stratified based on cancer type, including squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, and miscellaneous (misc). The lesions were identified by the surgeon and consequently imaged in the operating room with the DOCI machine after excitation with a 365nm wide field LED light source. Images were captured through both a 400nm long pass filter and a 530/30nm band pass filter. The images were then processed in MATLAB to generate numeric DOCI values and the regions of interest (ROI) were compared to the final histopathologic assessment. The DOCI values from the ROI were compared and ROC analysis was performed to evaluate DOCI’s ability to delineate malignant lesions from surrounding healthy tissue. Kruskal-Wallis test was then performed to determine differences between distinctive cancers as well as benign lesions.",
        "Results": "Of the enrolled patients, 21 had SCC, 16 had melanoma, 6 had BCC, and 6 had miscellaneous cutaneous malignancies. DOCI was able to distinguish each malignancy type from adjacent healthy skin as follows: SCC (AUC=0.934, sensitivity=90%, specificity=86%), BCC (AUC=1.000, sensitivity=100%, specificity=100%), melanoma (AUC=0.902, sensitivity=88%, specificity=94%), and between miscellaneous cancers (AUC=0.861, sensitivity=100%, specificity=67%). Paired t-test also showed significantly lower DOCI values for malignant lesions compared to adjacent healthy skin for every cancer type. Additionally, 20 patients had an associated benign nevus and 5 patients had actinic keratosis (AK). DOCI values differed significantly across the seven tissue groups (H = 63.21, p<0.001). Notably, post-hoc analysis showed a significant difference between all cancerous lesions and both benign nevi and AK, but no significant differences were observed between benign nevi, AK, and normal skin.",
        "Conclusion": "DOCI demonstrates promise in accurately distinguishing cutaneous malignancies from adjacent healthy skin, particularly SCC and melanoma. DOCI also shows the potential to distinguish benign and premalignant lesions from malignant tumors, supporting its further exploration as a noninvasive tool for diagnostic evaluation and intraoperative margin assessment.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cutaneous Malignancy Detection Using Dynamic Optical Contrast Imaging</span>. <u>Song Hon Hwang, MD</u><sup>1</sup>; Yazeed Alhiyari, PhD<sup>1</sup>; Brandon Mo<sup>1</sup>; Maie St. John, MD, PhD<sup>2</sup>. <sup>1</sup>David Geffen School of Medicine at UCLA - Department of Head & Neck Surgery; <sup>2</sup>Johns Hopkins Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Dynamic optical contrast imaging (DOCI) is a novel imaging modality that utilizes the fluorescence of endogenous molecules to help delineate between malignant and healthy tissue. As the incidence of cutaneous head and neck malignancies continues to rise, particularly non-melanoma skin cancers, technologies that can enhance rapid and accurate lesion assessment are critical. DOCI provides a real-time, noninvasive approach that can be used intraoperatively to improve margin detection and aid in complete surgical resection of the tumor. </p>\n\n<p><strong>Objectives:</strong> To assess the ability of DOCI to discriminate between malignant cutaneous lesions and adjacent healthy skin and its ability to distinguish between malignant and benign cutaneous lesions. </p>\n\n<p><strong>Methods:</strong> Forty-nine adult patients with biopsy-confirmed cutaneous head and neck malignancies who were undergoing surgical excision were recruited for this study. Patients were stratified based on cancer type, including squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, and miscellaneous (misc). The lesions were identified by the surgeon and consequently imaged in the operating room with the DOCI machine after excitation with a 365nm wide field LED light source. Images were captured through both a 400nm long pass filter and a 530/30nm band pass filter. The images were then processed in MATLAB to generate numeric DOCI values and the regions of interest (ROI) were compared to the final histopathologic assessment. The DOCI values from the ROI were compared and ROC analysis was performed to evaluate DOCI’s ability to delineate malignant lesions from surrounding healthy tissue. Kruskal-Wallis test was then performed to determine differences between distinctive cancers as well as benign lesions.</p>\n\n<p><strong>Results:</strong> Of the enrolled patients, 21 had SCC, 16 had melanoma, 6 had BCC, and 6 had miscellaneous cutaneous malignancies. DOCI was able to distinguish each malignancy type from adjacent healthy skin as follows: SCC (AUC=0.934, sensitivity=90%, specificity=86%), BCC (AUC=1.000, sensitivity=100%, specificity=100%), melanoma (AUC=0.902, sensitivity=88%, specificity=94%), and between miscellaneous cancers (AUC=0.861, sensitivity=100%, specificity=67%). Paired t-test also showed significantly lower DOCI values for malignant lesions compared to adjacent healthy skin for every cancer type. Additionally, 20 patients had an associated benign nevus and 5 patients had actinic keratosis (AK). DOCI values differed significantly across the seven tissue groups (H = 63.21, p<0.001). Notably, post-hoc analysis showed a significant difference between all cancerous lesions and both benign nevi and AK, but no significant differences were observed between benign nevi, AK, and normal skin. </p>\n\n<p><strong>Conclusion:</strong> DOCI demonstrates promise in accurately distinguishing cutaneous malignancies from adjacent healthy skin, particularly SCC and melanoma. DOCI also shows the potential to distinguish benign and premalignant lesions from malignant tumors, supporting its further exploration as a noninvasive tool for diagnostic evaluation and intraoperative margin assessment.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_09%E2%80%AFPM.jpeg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153947/Image%2012-5-25%20at%204_18%E2%80%AFPM.jpeg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153947--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S388",
      "content_id": "153720",
      "abstract_number": "S388",
      "poster_number": "",
      "title": "Metabolic Imaging Biomarker Development for Assessing Dabrafenib Response in Papillary Thyroid Carcinoma",
      "summary": "Real time metabolic imaging using HP-MRS effectively distinguishes Dabrafenib-responsive from resistant PTC based on changes in k PL . Dabrafenib-sensitive cells demonstrated significant reduction in k PL , ATP production, and lactate levels, whereas resistant cells maintained their metabolic signature under treatment. Combining HP-MRS, Seahorse XF 96 ATP Rate Assays, and biochemical lactate measurements provides...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153720",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Darren Broughton, MS",
      "presenter": "Darren Broughton, MS",
      "authors": "Darren Broughton, MS 1 ; Yunyun Chen, PhD 1 ; Qing Wang, PhD 2 ; Ahmad Abubaker, MD 1 ; Ying C Henderson, MD, PhD 1 ; Anastasios Maniakas, MD, PhD 1 ; James A Bankson, PhD 2 ; Stephen Y Lai, MD, PhD 1",
      "normalized_authors": [
        "Darren Broughton",
        "Yunyun Chen",
        "Qing Wang",
        "Ahmad Abubaker",
        "Ying C Henderson",
        "Anastasios Maniakas",
        "James A Bankson",
        "Stephen Y Lai"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 432,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials/Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Darren Broughton, MS 1 ; Yunyun Chen, PhD 1 ; Qing Wang, PhD 2 ; Ahmad Abubaker, MD 1 ; Ying C Henderson, MD, PhD 1 ; Anastasios Maniakas, MD, PhD 1 ; James A Bankson, PhD 2 ; Stephen Y Lai, MD, PhD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Introduction": "Papillary Thyroid Carcinoma (PTC) is one of the most common malignant thyroid tumors and generally carries a favorable prognosis. However, recurrent PTC is relatively common and is frequently associated with the BRAF V600E mutation, which contributes to treatment resistance and a poorer clinical outcome. Dabrafenib is given as a first-line targeted therapy for patients with progressive, recurrent, or metastatic PTC with a BRAF -mutant. Given the high glycolytic activity of PTC, hyperpolarized-MRI(HP-MRI) enables real-time, noninvasive quantification of pyruvate-to-lactate conversion ( k PL ). Our study aims to develop a sensitive metabolic biomarker for assessing the therapeutic response to Dabrafenib in recurrent PTC, with the potential to improve early prediction of treatment outcomes.",
        "Materials/Methods": "TPC-1 ( BRAF wild-type) and MDA-T-41 ( BRAF Mutant) cell lines were authenticated by short tandem repeat profiling. Dabrafenib IC 50 were determined using MTT assays to assess drug sensitivity. k PL measurements were performed using HP-MRS on a 300-MHz NMR spectrometer. Basal and Dabrafenib-induced ATP alterations were measured using a Seahorse XF 96 ATP Rate Assay. Lactate levels were measured by Biochemical assays. Both cells were treated with 200uM Dabrafenib for 24 hours.",
        "Results": "The IC 50 confirmed that TPC-1 was Dabrafenib-resistant (IC 50 = 318.43± 65 nM) while MDA-T41 was Dabrafenib-sensitive (IC 50 = 5.657±1.67 nM). Baseline metabolic measurement using HP-MRS indicated that the resistant TPC-1 exhibited a higher k PL (0.74s -1 ) compared to the sensitive MDA-T41 cells (0.301s -1 ), demonstrating a higher basal metabolic activity. This finding was supported by Seahorse analysis, which showed TPC-1 having a higher basal ATP production (31.6±1.8pmol/min) than MDA-T 41 (23.05±1.05pmol/min). Biochemical assays were consistent in showing TPC-1 having a significantly higher lactate production (p<0.05). Following Dabrafenib treatment, TPC-1 showed no significant metabolic change in k PL or ATP production, consistent with their drug-resistant phenotype. In contrast, MDA-T41 cells demonstrated a significant metabolic response, including a significant reduction in k PL to 0.18s -1 (p<0.05), decreased ATP production (from 22.5 to 16.56 pmol/min) and a 28.9% reduction in lactate levels.",
        "Conclusion": "Real time metabolic imaging using HP-MRS effectively distinguishes Dabrafenib-responsive from resistant PTC based on changes in k PL . Dabrafenib-sensitive cells demonstrated significant reduction in k PL , ATP production, and lactate levels, whereas resistant cells maintained their metabolic signature under treatment. Combining HP-MRS, Seahorse XF 96 ATP Rate Assays, and biochemical lactate measurements provides a comprehensive metabolic assessment. These findings support k PL as a promising noninvasive biomarker for predicting and monitoring therapeutic response to Dabrafenib in PTC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Metabolic Imaging Biomarker Development for Assessing Dabrafenib Response in Papillary Thyroid Carcinoma</span>. <u>Darren Broughton, MS</u><sup>1</sup>; Yunyun Chen, PhD<sup>1</sup>; Qing Wang, PhD<sup>2</sup>; Ahmad Abubaker, MD<sup>1</sup>; Ying C Henderson, MD, PhD<sup>1</sup>; Anastasios Maniakas, MD, PhD<sup>1</sup>; James A Bankson, PhD<sup>2</sup>; Stephen Y Lai, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Papillary Thyroid Carcinoma (PTC) is one of the most common malignant thyroid tumors and generally carries a favorable prognosis. However, recurrent PTC is relatively common and is frequently associated with the <em>BRAF</em><sup>V600E </sup>mutation, which contributes to treatment resistance and a poorer clinical outcome.  Dabrafenib is given as a first-line targeted therapy for patients with progressive, recurrent, or metastatic PTC with a <em>BRAF</em>-mutant. Given the high glycolytic activity of PTC, hyperpolarized-MRI(HP-MRI) enables real-time, noninvasive quantification of pyruvate-to-lactate conversion (<em>k<sub>PL</sub></em>). Our study aims to develop a sensitive metabolic biomarker for assessing the therapeutic response to Dabrafenib in recurrent PTC, with the potential to improve early prediction of treatment outcomes.</p>\n\n<p><strong>Materials/Methods: </strong>TPC-1 (<em>BRAF </em>wild-type) and MDA-T-41 (<em>BRAF </em>Mutant) cell lines were authenticated by short tandem repeat profiling. Dabrafenib IC<sub>50</sub> were determined using MTT assays to assess drug sensitivity.  <em>k<sub>PL </sub></em>measurements were performed using HP-MRS on a 300-MHz NMR spectrometer. Basal and Dabrafenib-induced ATP alterations were measured using a Seahorse XF 96 ATP Rate Assay. Lactate levels were measured by Biochemical assays. Both cells were treated with 200uM Dabrafenib for 24 hours.</p>\n\n<p><strong>Results: </strong>The IC<sub>50</sub> confirmed that TPC-1 was Dabrafenib-resistant (IC<sub>50</sub> = 318.43± 65 nM) while MDA-T41 was Dabrafenib-sensitive (IC<sub>50</sub> = 5.657±1.67 nM). Baseline metabolic measurement using HP-MRS indicated that the resistant TPC-1 exhibited a higher <em>k<sub>PL </sub></em>(0.74s<sup>-1</sup>) compared to the sensitive MDA-T41 cells (0.301s<sup>-1</sup>), demonstrating a higher basal metabolic activity. This finding was supported by Seahorse analysis, which showed TPC-1 having a higher basal ATP production (31.6±1.8pmol/min) than MDA-T 41 (23.05±1.05pmol/min). Biochemical assays were consistent in showing TPC-1 having a significantly higher lactate production (p<0.05). Following Dabrafenib treatment, TPC-1 showed no significant metabolic change in <em>k<sub>PL </sub></em>or ATP production, consistent with their drug-resistant phenotype. In contrast, MDA-T41 cells demonstrated a significant metabolic response, including a significant reduction in <em>k<sub>PL</sub></em> to 0.18s<sup>-1</sup> (p<0.05), decreased ATP production (from 22.5 to 16.56 pmol/min) and a 28.9% reduction in lactate levels.</p>\n\n<p><strong>Conclusion:</strong> Real time metabolic imaging using HP-MRS effectively distinguishes Dabrafenib-responsive from resistant PTC based on changes in <em>k<sub>PL</sub></em>. Dabrafenib-sensitive cells demonstrated significant reduction in <em>k<sub>PL</sub></em>, ATP production, and lactate levels, whereas resistant cells maintained their metabolic signature under treatment. Combining HP-MRS, Seahorse XF 96 ATP Rate Assays, and biochemical lactate measurements provides a comprehensive metabolic assessment. These findings support<em> k<sub>PL</sub></em> as a promising noninvasive biomarker for predicting and monitoring therapeutic response to Dabrafenib in PTC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153720--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S389",
      "content_id": "153425",
      "abstract_number": "S389",
      "poster_number": "",
      "title": "PD-L1 targeted fluorescent imaging in oral cancer as a prediction tool for anti-PD1 neoadjuvant immunotherapy response",
      "summary": "PD-L1 binding by ATZ-IR800 is able to highlight lesions expressing PD-L1 and signal intensity increases with CPS score progression in a murine model of oral malignancy. Clinically, this tracer may offer a rapid alternative to traditional IHC-determined CPS score assessment, though further validation is needed to determine predictive value independent of dysplasia severity. This technology could improve the speed...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153425",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "M. Elyse Moore",
      "presenter": "M. Elyse Moore",
      "authors": "M. Elyse Moore ; Bhaskar Gurram, PhD; Stepan V Pulukchu, MD; Dieter Haemmerich, PhD; Evan Bagley, PhD; Angela J Yoon, DDS, MAMSc, MPH; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD",
      "normalized_authors": [
        "M. Elyse Moore",
        "Bhaskar Gurram",
        "Stepan V Pulukchu",
        "Dieter Haemmerich",
        "Evan Bagley",
        "Angela J Yoon, MAMSc",
        "Evan M Graboyes",
        "Jason G Newman",
        "Dauren Adilbay"
      ],
      "affiliations": [
        "Medical University of South Carolina"
      ],
      "normalized_institutions": [
        "Medical University of South Carolina"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 509,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "M. Elyse Moore ; Bhaskar Gurram, PhD; Stepan V Pulukchu, MD; Dieter Haemmerich, PhD; Evan Bagley, PhD; Angela J Yoon, DDS, MAMSc, MPH; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD",
        "Affiliations": "Medical University of South Carolina",
        "Background": "In addition to its use in the recurrent/metastatic setting, anti-PD1 neoadjuvant immunotherapy has now emerged as a new standard of care in the neoadjuvant and adjuvant setting for patients with locally advanced head and neck squamous cell carcinoma (SCC). The combined positive score (CPS) measures tumor and immune cell PD-L1 expression by immunohistochemistry (IHC), and a score greater than 1 is a key factor in therapeutic decision-making as demonstrated in KEYNOTE-048. Unfortunately, the wait for CPS determination can cause treatment delays. Predictive technology used at the point of care (POC) is needed to improve the speed of CPS or other response predictive determination and, therefore, improve treatment efficiency in patients with head and neck SCC. We present a method that leverages targeted fluorescent imaging of PD-L1 in the tumor and infiltrating cells to enable timely POC determination of PD-L1 expression.",
        "Methods": "We conjugated Atezolizumab (ATZ), a fully humanized monoclonal antibody directed against PD-L1 and IRDye800CW (IR800), a near-infrared fluorescent dye, using NHS conjugation (ATZ-IR800). Subsequently, conjugation success was confirmed using SDS-PAGE, IC50 values were obtained using flow cytometry, and cellular localization and specificity were confirmed using fluorescent microscopy in HSC-3 cells (PD-L1 36.4nTPM). Finally, in vivo performance of ATZ-IR800 in spontaneous oral malignancy was measured using a 4-nitroquinoline 1-oxide (4NQO) exposure model in C57BL/6 mice at 12, 18, and 22 weeks after 4NQO initiation. Treatment animals (Tx) received 0.124nM ATZ-IR800 and pretreatment animals (PT) received 0.45 µM ATZ followed by 0.124nM ATZ-IR800 suspended in vehicle (PBS). Median Fluorescence Intensity (MFI) of tumors was calculated based on images acquired by a preclinical imaging system (AMI HT, Spectral Instruments). Finally, CPS score was calculated using internal IHC of oral tumor samples and was subsequently compared with in vivo MFI.",
        "Results": "ATZ-RI800 conjugation success was confirmed using SDS-PAGE and binding efficiency and specificity were confirmed using flow cytometry in HSC-3 cells (Ab:Dye ratio 2.75, IC50 47.5nM). Furthermore, immunofluorescence in these cells confirmed localized signal and target specificity. Analysis of in vivo fluorescence after ATZ-IR800 administration revealed uptake localized to the region of the lesions 24-48 hours after dye administration both in vivo and ex vivo. A more intense signal was observed in weeks 18 and 22 as compared to week 12 (5.6e+06, 5.1e+06, and 2.6e+06 photons/second respectively). Finally, the calculated CPS score revealed 12.5%, 56%, and 100% of lesions assessed had CPS>1 at week 12, 18, and 22 respectively. This pattern mimics the increase in MFI seen across the time points.",
        "Conclusions": "PD-L1 binding by ATZ-IR800 is able to highlight lesions expressing PD-L1 and signal intensity increases with CPS score progression in a murine model of oral malignancy. Clinically, this tracer may offer a rapid alternative to traditional IHC-determined CPS score assessment, though further validation is needed to determine predictive value independent of dysplasia severity. This technology could improve the speed at which patients who meet criteria for anti-PD1 therapy are able to initiate treatment, thus potentially improving patient outcome.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>PD-L1 targeted fluorescent imaging in oral cancer as a prediction tool for anti-PD1 neoadjuvant immunotherapy response</span>. <u>M. Elyse Moore</u>; Bhaskar Gurram, PhD; Stepan V Pulukchu, MD; Dieter Haemmerich, PhD; Evan Bagley, PhD; Angela J Yoon, DDS, MAMSc, MPH; Evan M Graboyes, MD, MPH; Jason G Newman, MD; Dauren Adilbay, MD, PhD. Medical University of South Carolina<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>In addition to its use in the recurrent/metastatic setting, anti-PD1 neoadjuvant immunotherapy has now emerged as a new standard of care in the neoadjuvant and adjuvant setting for patients with locally advanced head and neck squamous cell carcinoma (SCC). The combined positive score (CPS) measures tumor and immune cell PD-L1 expression by immunohistochemistry (IHC), and a score greater than 1 is a key factor in therapeutic decision-making as demonstrated in KEYNOTE-048. Unfortunately, the wait for CPS determination can cause treatment delays. Predictive technology used at the point of care (POC) is needed to improve the speed of CPS or other response predictive determination and, therefore, improve treatment efficiency in patients with head and neck SCC. We present a method that leverages targeted fluorescent imaging of PD-L1 in the tumor and infiltrating cells to enable timely POC determination of PD-L1 expression. </p>\n\n<p><strong>Methods: </strong>We conjugated Atezolizumab (ATZ), a fully humanized monoclonal antibody directed against PD-L1 and IRDye800CW (IR800), a near-infrared fluorescent dye, using NHS conjugation (ATZ-IR800). Subsequently, conjugation success was confirmed using SDS-PAGE, IC50 values were obtained using flow cytometry, and cellular localization and specificity were confirmed using fluorescent microscopy in HSC-3 cells (PD-L1 36.4nTPM). Finally, in vivo performance of ATZ-IR800 in spontaneous oral malignancy was measured using a 4-nitroquinoline 1-oxide (4NQO) exposure model in C57BL/6 mice at 12, 18, and 22 weeks after 4NQO initiation. Treatment animals (Tx) received 0.124nM ATZ-IR800 and pretreatment animals (PT) received 0.45 µM ATZ followed by 0.124nM ATZ-IR800 suspended in vehicle (PBS). Median Fluorescence Intensity (MFI) of tumors was calculated based on images acquired by a preclinical imaging system (AMI HT, Spectral Instruments). Finally, CPS score was calculated using internal IHC of oral tumor samples and was subsequently compared with in vivo MFI. </p>\n\n<p><strong>Results: </strong>ATZ-RI800 conjugation success was confirmed using SDS-PAGE and binding efficiency and specificity were confirmed using flow cytometry in HSC-3 cells (Ab:Dye ratio 2.75, IC50 47.5nM). Furthermore, immunofluorescence in these cells confirmed localized signal and target specificity. Analysis of in vivo fluorescence after ATZ-IR800 administration revealed uptake localized to the region of the lesions 24-48 hours after dye administration both in vivo and ex vivo. A more intense signal was observed in weeks 18 and 22 as compared to week 12 (5.6e+06, 5.1e+06, and 2.6e+06 photons/second respectively). Finally, the calculated CPS score revealed 12.5%, 56%, and 100% of lesions assessed had CPS>1 at week 12, 18, and 22 respectively. This pattern mimics the increase in MFI seen across the time points.</p>\n\n<p><strong>Conclusions: </strong>PD-L1 binding by ATZ-IR800 is able to highlight lesions expressing PD-L1 and signal intensity increases with CPS score progression in a murine model of oral malignancy. Clinically, this tracer may offer a rapid alternative to traditional IHC-determined CPS score assessment, though further validation is needed to determine predictive value independent of dysplasia severity. This technology could improve the speed at which patients who meet criteria for anti-PD1 therapy are able to initiate treatment, thus potentially improving patient outcome.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153425--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S390",
      "content_id": "152662",
      "abstract_number": "S390",
      "poster_number": "",
      "title": "High-Resolution PET-CT Specimen Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Multi-Institutional Pilot Study",
      "summary": "High-resolution PET-CT shows promise as a reliable tool for intraoperative margin assessment in HNC. As recruitment for this study continues, statistical analysis will determine the diagnostic accuracy of high-resolution PET-CT and the scope of its use intraoperatively.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152662",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sara Friedman, BA",
      "presenter": "Sara Friedman, BA",
      "authors": "Sara Friedman, BA 1 ; Ashtyn McAdoo, BS 2 ; Kyrionna M Golliday, MS 2 ; Andreja Radevic, BS 2 ; Joaquin Austerlitz, BS 2 ; Bradley A Schiff, MD 3 ; Renee Moadel, MD 4 ; Stelby Augustine, RN 3 ; Michael Topf*, MD, MSCI 2 ; Vikas Mehta*, MD, MPH 3",
      "normalized_authors": [
        "Sara Friedman",
        "Ashtyn McAdoo",
        "Kyrionna M Golliday",
        "Andreja Radevic",
        "Joaquin Austerlitz",
        "Bradley A Schiff",
        "Renee Moadel",
        "Stelby Augustine",
        "Michael Topf*, MSCI",
        "Vikas Mehta*"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Vanderbilt University Medical Center, Nashville, TN, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Radiology and Nuclear Medicine – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Vanderbilt University Medical Center, Nashville, TN, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Radiology and Nuclear Medicine – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_04_36%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_04_36%E2%80%AFAM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152662"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_05_12%E2%80%AFAM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_05_12%E2%80%AFAM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152662"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 370,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Table 1",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sara Friedman, BA 1 ; Ashtyn McAdoo, BS 2 ; Kyrionna M Golliday, MS 2 ; Andreja Radevic, BS 2 ; Joaquin Austerlitz, BS 2 ; Bradley A Schiff, MD 3 ; Renee Moadel, MD 4 ; Stelby Augustine, RN 3 ; Michael Topf*, MD, MSCI 2 ; Vikas Mehta*, MD, MPH 3",
        "Affiliations": "1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Otorhinolaryngology – Head and Neck Surgery – Vanderbilt University Medical Center, Nashville, TN, USA; 3 Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA; 4 Department of Radiology and Nuclear Medicine – Montefiore Medical Center, Bronx, NY, USA",
        "Background": "Achieving negative surgical margins following resection is a critical prognostic factor in head and neck carcinoma (HNC). Positive margins increase the risk of local recurrence and often require reoperation, leading to higher healthcare costs, psychological stress, and greater morbidity. Frozen section analysis (FSA) is currently used for intraoperative margin assessment but has several limitations; it is time-consuming, labor-intensive, and requires an on-call pathologist. In addition, the complex anatomy of the head and neck makes precise, three-dimensional margin evaluation challenging.This study aims to assess the diagnostic accuracy of an FDA-approved, mobile, high-resolution, intraoperative PET-CT scanner for margin evaluation in HNC, comparing its performance to the gold standard of histopathological analysis, as well as FSA.",
        "Methods": "This ongoing observational multicenter study includes patients with HNC undergoing definitive surgical resection at two academic institutions. The total goal study accrual will be approximately 80 patients across both institutions. In each case, a dose of 18 F-FDG (1 MBq/kg) was administered intravenously, intraoperatively 30 minutes to 3 hours prior to resection. Excised specimens were imaged intraoperatively using high-resolution PET-CT. No surgical decisions were made based on PET-CT findings alone, and specimens were subsequently processed for FSA. PET-CT findings, including margin status and the distance of the closest margin to invasive tumor were compared with FSA and final histopathology.",
        "Results": "Eleven patients are included in this interim analysis (Table 1). In 9/11 cases (81.81%), margin status was concordant between high-resolution intraoperative PET-CT and final histopathology (Table 1). In two of those cases (22.22%), PET-CT and histopathology agreed on margin status, but differed in the closest margin location (Table 1). Among the 9 cases in which the closest margin to invasive tumor on final histopathology and intraoperative PET-CT were concordant, the intraoperative PET-CT predicted the final histopathology margin distance within 1 mm in 7 cases (78%).",
        "Conclusion": "High-resolution PET-CT shows promise as a reliable tool for intraoperative margin assessment in HNC. As recruitment for this study continues, statistical analysis will determine the diagnostic accuracy of high-resolution PET-CT and the scope of its use intraoperatively.",
        "Table 1": "Comparison of margin status and the distance of the closest margin to invasive tumor between frozen section analysis, final histopathology, and high-resolution intraoperative PET-CT.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>High-Resolution PET-CT Specimen Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Multi-Institutional Pilot Study</span>. <u>Sara Friedman, BA</u><sup>1</sup>; Ashtyn McAdoo, BS<sup>2</sup>; Kyrionna M Golliday, MS<sup>2</sup>; Andreja Radevic, BS<sup>2</sup>; Joaquin Austerlitz, BS<sup>2</sup>; Bradley A Schiff, MD<sup>3</sup>; Renee Moadel, MD<sup>4</sup>; Stelby Augustine, RN<sup>3</sup>; Michael Topf*, MD, MSCI<sup>2</sup>; Vikas Mehta*, MD, MPH<sup>3</sup>. <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>2</sup>Department of Otorhinolaryngology – Head and Neck Surgery – Vanderbilt University Medical Center, Nashville, TN, USA; <sup>3</sup>Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA; <sup>4</sup>Department of Radiology and Nuclear Medicine – Montefiore Medical Center, Bronx, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Achieving negative surgical margins following resection is a critical prognostic factor in head and neck carcinoma (HNC). Positive margins increase the risk of local recurrence and often require reoperation, leading to higher healthcare costs, psychological stress, and greater morbidity. Frozen section analysis (FSA) is currently used for intraoperative margin assessment but has several limitations; it is time-consuming, labor-intensive, and requires an on-call pathologist. In addition, the complex anatomy of the head and neck makes precise, three-dimensional margin evaluation challenging.This study aims to assess the diagnostic accuracy of an FDA-approved, mobile, high-resolution, intraoperative PET-CT scanner for margin evaluation in HNC, comparing its performance to the gold standard of histopathological analysis, as well as FSA.</p>\n\n<p><strong>Methods:</strong> This ongoing observational multicenter study includes patients with HNC undergoing definitive surgical resection at two academic institutions. The total goal study accrual will be approximately 80 patients across both institutions. In each case, a dose of <sup>18</sup>F-FDG (1 MBq/kg) was administered intravenously, intraoperatively 30 minutes to 3 hours prior to resection. Excised specimens were imaged intraoperatively using high-resolution PET-CT. No surgical decisions were made based on PET-CT findings alone, and specimens were subsequently processed for FSA. PET-CT findings, including margin status and the distance of the closest margin to invasive tumor were compared with FSA and final histopathology. </p>\n\n<p><strong>Results:</strong> Eleven patients are included in this interim analysis (Table 1). In 9/11 cases (81.81%), margin status was concordant between high-resolution intraoperative PET-CT and final histopathology (Table 1). In two of those cases (22.22%), PET-CT and histopathology agreed on margin status, but differed in the closest margin location (Table 1). Among the 9 cases in which the closest margin to invasive tumor on final histopathology and intraoperative PET-CT were concordant, the intraoperative PET-CT predicted the final histopathology margin distance within 1 mm in 7 cases (78%). </p>\n\n<p><strong>Conclusion:</strong> High-resolution PET-CT shows promise as a reliable tool for intraoperative margin assessment in HNC. As recruitment for this study continues, statistical analysis will determine the diagnostic accuracy of high-resolution PET-CT and the scope of its use intraoperatively.</p>\n\n<p><strong>Table 1:</strong> Comparison of margin status and the distance of the closest margin to invasive tumor between frozen section analysis, final histopathology, and high-resolution intraoperative PET-CT.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_04_36%E2%80%AFAM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152662/Screenshot%202025-12-05%20at%2010_05_12%E2%80%AFAM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152662--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S391",
      "content_id": "154702",
      "abstract_number": "S391",
      "poster_number": "",
      "title": "Assessing the Utility of a Novel Ex Vivo Lymph Node Scanner during Pathologic Processing of Neck Dissection Specimens",
      "summary": "A short infrared wave scanner may reduce the number of excess lymph node candidates.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154702",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joaquin Austerlitz",
      "presenter": "Joaquin Austerlitz",
      "authors": "Joaquin Austerlitz ; Andreja Radevic; Whitney Jin; Sindhura Sridhar; Mitra Mehrad, MD; Michael C Topf, MD, MSCI",
      "normalized_authors": [
        "Joaquin Austerlitz",
        "Andreja Radevic",
        "Whitney Jin",
        "Sindhura Sridhar",
        "Mitra Mehrad",
        "Michael C Topf, MSCI"
      ],
      "affiliations": [
        "Vanderbilt University"
      ],
      "normalized_institutions": [
        "Vanderbilt University"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joaquin Austerlitz ; Andreja Radevic; Whitney Jin; Sindhura Sridhar; Mitra Mehrad, MD; Michael C Topf, MD, MSCI",
        "Affiliations": "Vanderbilt University",
        "Background": "Lymph node yield in head and neck squamous cell carcinoma has shown associations with patient survival outcomes. During standard-of-care (SOC) processing, lymph node candidates are identified using visualization and palpation while lymph node yield is reported following final histologic assessment. This study seeks to evaluate the impact of a short infrared wave scanner on lymph node candidates and processing times versus standard of care nodal processing.",
        "Methods": "Patients undergoing SOC neck dissection were stratified by prior radiation history and randomized to receive SOC lymph node pathology processing or pathology processing with a novel lymph node scanner (LNS). The LNS utilizes short infrared light to differentiate lymph nodes from adipose tissue using water content. As lymph nodes are high in water content, they absorb more light thus they appear darker than surrounding adipose tissue. Lymph node processing times and lymph node candidate count of both LNS and SOC were recorded and assessed using the Mann-Whitney test.",
        "Results": "Fifty-two patients with squamous cell carcinoma of the head and neck undergoing neck dissection were enrolled at study completion (23 LNS, 29 SOC). Primary tumor sites include: oral cavity (24), larynx/hypopharynx (12), skin (8), oropharynx (6), and salivary (2). Pathologic nodal stage of the cohort was N0 (n = 24), N1(n = 8), N2a (n = 8), N2b (n = 4), N2c in (n = 3), and N3b (n = 4). Nine patients had a history of radiation therapy to the neck. Processing times were similar for LNS compared with the SOC (median 22.9 minutes [IQR, 15.9-35.0] vs 21.7 minutes [IQR, 11.9-42.0], p = 0.861). Median lymph node candidates identified per case were not significantly different between LNS and SOC (median 32.0 nodes [IQR, 26.0-43.0] vs 38.5 nodes [IQR, 28.5-47.0], p = 0.391). There was no significant difference between lymph node candidates identified on LNS alone and true lymph node yield (median 32 nodes [IQR, 26.0-43.0] vs 32 nodes [IQR, 23.0-41.4], p = 0.494). Lymph node candidates identified using SOC were higher than true lymph node yield on final pathology report though this failed to reach significance (median 38.5 nodes [IQR, 28.5-47.0] vs 32.0 nodes [IQR, 23.0-41.4], p = 0.066).",
        "Conclusions": "A short infrared wave scanner may reduce the number of excess lymph node candidates.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessing the Utility of a Novel Ex Vivo Lymph Node Scanner during Pathologic Processing of Neck Dissection Specimens</span>. <u>Joaquin Austerlitz</u>; Andreja Radevic; Whitney Jin; Sindhura Sridhar; Mitra Mehrad, MD; Michael C Topf, MD, MSCI. Vanderbilt University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Lymph node yield in head and neck squamous cell carcinoma has shown associations with patient survival outcomes. During standard-of-care (SOC) processing, lymph node candidates are identified using visualization and palpation while lymph node yield is reported following final histologic assessment. This study seeks to evaluate the impact of a short infrared wave scanner on lymph node candidates and processing times versus standard of care nodal processing.</p>\n\n<p><strong>Methods: </strong>Patients undergoing SOC neck dissection were stratified by prior radiation history and randomized to receive SOC lymph node pathology processing or pathology processing with a novel lymph node scanner (LNS). The LNS utilizes short infrared light to differentiate lymph nodes from adipose tissue using water content. As lymph nodes are high in water content, they absorb more light thus they appear darker than surrounding adipose tissue. Lymph node processing times and lymph node candidate count of both LNS and SOC were recorded and assessed using the Mann-Whitney test.</p>\n\n<p><strong>Results: </strong>Fifty-two patients with squamous cell carcinoma of the head and neck undergoing neck dissection were enrolled at study completion (23 LNS, 29 SOC). Primary tumor sites include: oral cavity (24), larynx/hypopharynx (12), skin (8), oropharynx (6), and salivary (2). Pathologic nodal stage of the cohort was N0 (n = 24), N1(n = 8), N2a (n = 8), N2b (n = 4), N2c in (n = 3), and N3b (n = 4). Nine patients had a history of radiation therapy to the neck. Processing times were similar for LNS compared with the SOC (median 22.9 minutes [IQR, 15.9-35.0] vs 21.7 minutes [IQR, 11.9-42.0], p = 0.861). Median lymph node candidates identified per case were not significantly different between LNS and SOC (median 32.0 nodes [IQR, 26.0-43.0] vs 38.5 nodes [IQR, 28.5-47.0], p = 0.391). There was no significant difference between lymph node candidates identified on LNS alone and true lymph node yield (median 32 nodes [IQR, 26.0-43.0] vs 32 nodes [IQR, 23.0-41.4], p = 0.494). Lymph node candidates identified using SOC were higher than true lymph node yield on final pathology report though this failed to reach significance (median 38.5 nodes [IQR, 28.5-47.0] vs 32.0 nodes [IQR, 23.0-41.4], p = 0.066).</p>\n\n<p><strong>Conclusions: </strong>A short infrared wave scanner may reduce the number of excess lymph node candidates.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154702--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S392",
      "content_id": "153861",
      "abstract_number": "S392",
      "poster_number": "",
      "title": "Spatial Analysis of Red-to-Green Autofluorescence using a Noninvasive Contact-Based Imaging Probe in Clinical Oral Cancer Samples",
      "summary": "Head and neck squamous cell carcinoma is projected to increase by 30% by 2030. Conventional oral examination with biopsy and histological grading remains the gold standard for diagnosis, but is often unable to identify early treatable high-risk or malignant lesions early.Autofluorescence of endogenous tissue fluorophores has shown promise for early detection of biochemical and tissue changes due to oral...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153861",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260145",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Victoria Teoh, BBA",
      "presenter": "Victoria Teoh, BBA",
      "authors": "Victoria Teoh, BBA 1 ; Paula Villarreal, BS 2 ; Daodang Wang, PhD 3 ; Lorelai Pop, BA 1 ; Viran Ranasinghe, MD 4 ; Sepehr Shabani, MD 4 ; Orly Coblens, MD 4 ; Suimin Qiu, MD 5 ; Rongguang Liang, PhD 3 ; Gracie Vargas, PhD 6",
      "normalized_authors": [
        "Victoria Teoh, BBA",
        "Paula Villarreal",
        "Daodang Wang",
        "Lorelai Pop",
        "Viran Ranasinghe",
        "Sepehr Shabani",
        "Orly Coblens",
        "Suimin Qiu",
        "Rongguang Liang",
        "Gracie Vargas"
      ],
      "affiliations": [
        "The University of Texas Medical Branch, John Sealy School of Medicine",
        "The University of Texas Medical Branch, Department of Institute for Translational Sciences",
        "The University of Arizona Wyant College of Optical Sciecnes",
        "The University of Texas Medical Branch, Department of Otolaryngology",
        "The University of Texas Medical Branch, Department of Pathology",
        "The University of Texas Medical Branch, Department of Neurobiology"
      ],
      "normalized_institutions": [
        "The University of Texas Medical Branch, John Sealy School of Medicine",
        "The University of Texas Medical Branch, Department of Institute for Translational Sciences",
        "The University of Arizona Wyant College of Optical Sciecnes",
        "The University of Texas Medical Branch, Department of Otolaryngology",
        "The University of Texas Medical Branch, Department of Pathology",
        "The University of Texas Medical Branch, Department of Neurobiology"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 429,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Victoria Teoh, BBA 1 ; Paula Villarreal, BS 2 ; Daodang Wang, PhD 3 ; Lorelai Pop, BA 1 ; Viran Ranasinghe, MD 4 ; Sepehr Shabani, MD 4 ; Orly Coblens, MD 4 ; Suimin Qiu, MD 5 ; Rongguang Liang, PhD 3 ; Gracie Vargas, PhD 6",
        "Affiliations": "1 The University of Texas Medical Branch, John Sealy School of Medicine; 2 The University of Texas Medical Branch, Department of Institute for Translational Sciences; 3 The University of Arizona Wyant College of Optical Sciecnes; 4 The University of Texas Medical Branch, Department of Otolaryngology; 5 The University of Texas Medical Branch, Department of Pathology; 6 The University of Texas Medical Branch, Department of Neurobiology",
        "Abstract": "Head and neck squamous cell carcinoma is projected to increase by 30% by 2030. Conventional oral examination with biopsy and histological grading remains the gold standard for diagnosis, but is often unable to identify early treatable high-risk or malignant lesions early.Autofluorescence of endogenous tissue fluorophores has shown promise for early detection of biochemical and tissue changes due to oral epithelial dysplasia and oral squamous cell carcinoma (OSCC). Commercial devices aimed at OSCC screening image loss of green autofluorescence with blue light excitation, attributed to changes in tissue structure and endogenous fluorophores, such as collagen and FAD. However, preclinical and clinical sample studies indicate red emission from blue light excitation may provide a promising second spectral window based on protoporphyrin accumulation, potentially indicating hypoxic regions of interest. Additionally, spatial heterogeneity may provide improved mapping to delineate neoplastic from non-neoplastic areas. Finally, there is an increased interest in compact imaging devices, including those in contact with the mucosal surface. In this study, we used a custom developed forward imaging probe, employing a 405nm excitation and an RGB CMOS microsensor (1.5mm 120° lens, Omnivision) for detection of red and green tissue autofluorescence. Forty-seven freshly resected oral cancer samples from eighteen patients were acquired and imaged using the imaging probe. Red and green channel intensities were acquired across a 1.10x1.10 cm field-of-view at sites grossly evaluated as tumor, non-tumor, or transition. Red/green (R/G) autofluorescence intensity ratios were calculated for whole tissues and compared with pixel-by-pixel (PBP) spatial analysis of the red and green intensity. Whereas R/G analysis yields a single averaged ratio per sample, PBP analysis generates a spatially resolved map that reveals heterogeneity in autofluorescence patterns. Comparisons with histopathology scoring of the tissue samples are in the process for quantitative associations. Normalized R/G ratios and PBP values increased from grossly non-tumor to tumor samples, indicating: 1) the microsensor is sensitive to detection of tissue autofluorescence, 2) averaged R/G ratios may be promising for broad delineation of tumor and non-tumor samples and 3) PBP analysis allows for the revealing of subtle spatial patterns within the tissue that might be lost in a more global quantification. This study demonstrates that CMOS microsensors have the sensitivity for detection of tissue autofluorescence and changes associated with neoplasia and are amenable to incorporation into a handheld contact-based probe for use in a clinical setting. The use of R/G and PBP analysis may also allow for spatial mapping, potentially revealing transitional areas that will help with biopsy guidance or margin analysis. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Spatial Analysis of Red-to-Green Autofluorescence using a Noninvasive Contact-Based Imaging Probe in Clinical Oral Cancer Samples</span>. <u>Victoria Teoh, BBA</u><sup>1</sup>; Paula Villarreal, BS<sup>2</sup>; Daodang Wang, PhD<sup>3</sup>; Lorelai Pop, BA<sup>1</sup>; Viran Ranasinghe, MD<sup>4</sup>; Sepehr Shabani, MD<sup>4</sup>; Orly Coblens, MD<sup>4</sup>; Suimin Qiu, MD<sup>5</sup>; Rongguang Liang, PhD<sup>3</sup>; Gracie Vargas, PhD<sup>6</sup>. <sup>1</sup>The University of Texas Medical Branch, John Sealy School of Medicine; <sup>2</sup>The University of Texas Medical Branch, Department of Institute for Translational Sciences; <sup>3</sup>The University of Arizona Wyant College of Optical Sciecnes; <sup>4</sup>The University of Texas Medical Branch, Department of Otolaryngology; <sup>5</sup>The University of Texas Medical Branch, Department of Pathology; <sup>6</sup>The University of Texas Medical Branch, Department of Neurobiology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma is projected to increase by 30% by 2030. Conventional oral examination with biopsy and histological grading remains the gold standard for diagnosis, but is often unable to identify early treatable high-risk or malignant lesions early.Autofluorescence of endogenous tissue fluorophores has shown promise for early detection of biochemical and tissue changes due to oral epithelial dysplasia and oral squamous cell carcinoma (OSCC). Commercial devices aimed at OSCC screening image loss of green autofluorescence with blue light excitation, attributed to changes in tissue structure and endogenous fluorophores, such as collagen and FAD. However, preclinical and clinical sample studies indicate red emission from blue light excitation may provide a promising second spectral window based on protoporphyrin accumulation, potentially indicating hypoxic regions of interest. Additionally, spatial heterogeneity may provide improved mapping to delineate neoplastic from non-neoplastic areas. Finally, there is an increased interest in compact imaging devices, including those in contact with the mucosal surface.</p>\n\n<p>In this study, we used a custom developed forward imaging probe, employing a 405nm excitation and an RGB CMOS microsensor (1.5mm 120° lens, Omnivision) for detection of red and green tissue autofluorescence. Forty-seven freshly resected oral cancer samples from eighteen patients were acquired and imaged using the imaging probe. Red and green channel intensities were acquired across a 1.10x1.10 cm field-of-view at sites grossly evaluated as tumor, non-tumor, or transition. Red/green (R/G) autofluorescence intensity ratios were calculated for whole tissues and compared with pixel-by-pixel (PBP) spatial analysis of the red and green intensity. Whereas R/G analysis yields a single averaged ratio per sample, PBP analysis generates a spatially resolved map that reveals heterogeneity in autofluorescence patterns. Comparisons with histopathology scoring of the tissue samples are in the process for quantitative associations.</p>\n\n<p>Normalized R/G ratios and PBP values increased from grossly non-tumor to tumor samples, indicating: 1) the microsensor is sensitive to detection of tissue autofluorescence, 2) averaged R/G ratios may be promising for broad delineation of tumor and non-tumor samples and 3) PBP analysis allows for the revealing of subtle spatial patterns within the tissue that might be lost in a more global quantification. This study demonstrates that CMOS microsensors have the sensitivity for detection of tissue autofluorescence and changes associated with neoplasia and are amenable to incorporation into a handheld contact-based probe for use in a clinical setting. The use of R/G and PBP analysis may also allow for spatial mapping, potentially revealing transitional areas that will help with biopsy guidance or margin analysis.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153861--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260145' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S393",
      "content_id": "153954",
      "abstract_number": "S393",
      "poster_number": "",
      "title": "Biomarkers for HPV+ OPSCC Recurrence and Survival: Early Results of U01 Funded Prospective Study",
      "summary": "We report on RNASeq tumor analyses and NavDx results on 76 patients with an average time since diagnosis (enrollment) of ## mos. The poor prognosis subtype comprised 38 patients (50%) and the good prognosis subtype 38 patients (50%) with mean pre-treatment NavDx(s) of 787.7 and 6760.1. At this interim analysis, recurrences were detected in 3 of 38 patients in the poor prognosis subtype and 1 of 38 patients in the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153954",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Travis Schrank, MD, PhD",
      "presenter": "Travis Schrank, MD, PhD",
      "authors": "Wendell G Yarbrough, MD 1 ; Travis Schrank, MD, PhD 1 ; Tan X 2 ; J Blumberg 1 ; T Hackman 1 ; C Lumley 1 ; M Patel 1 ; A Colaianni 1 ; R Ferris 1 ; K van Abel 3 ; D Ma 4 ; D Neskey 5 ; T Day 5 ; N Issaeva 1 . 1 Dept",
      "normalized_authors": [
        "Wendell G Yarbrough",
        "Travis Schrank",
        "Tan X",
        "J Blumberg",
        "T Hackman",
        "C Lumley",
        "M Patel",
        "A Colaianni",
        "R Ferris",
        "K van Abel",
        "D Ma",
        "D Neskey",
        "T Day",
        "N Issaeva . Dept"
      ],
      "affiliations": [
        "of Otolaryngology/Head and Neck Surgery, UNC School of Medicine",
        "Dept of Biostatistics, Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health",
        "Dept of Otolaryngology/Head and Neck Surgery, Mayo Clinic",
        "Dept of Radiation Oncology, Mayo Clinic",
        "Head and Neck Specialists, Sarah Cannon Cancer Network"
      ],
      "normalized_institutions": [
        "of Otolaryngology/Head and Neck Surgery, UNC School of Medicine",
        "Dept of Biostatistics, Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health",
        "Dept of Otolaryngology/Head and Neck Surgery, Mayo Clinic",
        "Dept of Radiation Oncology, Mayo Clinic",
        "Head and Neck Specialists, Sarah Cannon Cancer Network"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Wendell G Yarbrough, MD 1 ; Travis Schrank, MD, PhD 1 ; Tan X 2 ; J Blumberg 1 ; T Hackman 1 ; C Lumley 1 ; M Patel 1 ; A Colaianni 1 ; R Ferris 1 ; K van Abel 3 ; D Ma 4 ; D Neskey 5 ; T Day 5 ; N Issaeva 1 . 1 Dept",
        "Affiliations": "of Otolaryngology/Head and Neck Surgery, UNC School of Medicine; 2 Dept of Biostatistics, Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health; 3 Dept of Otolaryngology/Head and Neck Surgery, Mayo Clinic; 4 Dept of Radiation Oncology, Mayo Clinic; 5 Head and Neck Specialists, Sarah Cannon Cancer Network",
        "Introduction": "Reliable biomarkers to identify tumors with good survival and for early detection of recurrences may improve outcomes for HPV+ oropharyngeal SCC (OPSCC). Our group identified two subtypes of HPV+ HNSCC, one associated with new mechanism of HPV-driven carcinogenesis and good survival and the other subtype driven by canonical HPV-carcinogenesis and associated with poor outcome. Here, we present preliminary results from a U01-funded prospective study examining potential biomarkers: HPV subtype classification and circulating tumor HPV DNA (ctHPVDNA) by NavDx.",
        "Methods": "Prospectively enrolled multi-institutional biomarker study for HPV+ OPSCC with targeted enrollment of 220. Paraffin-embedded tumor was analyzed by RNASeq to identify subtypes and circulating tumor tissue modified viral (TTMV) DNA detected by NavDx (Naveris).",
        "Results": "We report on RNASeq tumor analyses and NavDx results on 76 patients with an average time since diagnosis (enrollment) of ## mos. The poor prognosis subtype comprised 38 patients (50%) and the good prognosis subtype 38 patients (50%) with mean pre-treatment NavDx(s) of 787.7 and 6760.1. At this interim analysis, recurrences were detected in 3 of 38 patients in the poor prognosis subtype and 1 of 38 patients in the good prognosis subtype. For ctHPVDNA, NavDx was not detected in pre-treatment samples for 8 of 76 patients (10.5%). Excluding these patients and those with missing data 17 of 56 patients (30.3%) had a post-treatment positive ctHPVDNA. Fifteen of these patients had a single positive ctHPVDNA and biopsy proven recurrence occurred in 1 of 15 (6.7%). Amongst patients with 2 or more positive post-treatment ctHPVDNA recurrences were found in 2 or 2 (100%). For patients with recurrence detected by ctHPVDNA, positive ctHPVDNA preceded clinical diagnosis by between 8 days and 9.0 months. One patient had recurrence with a negative ctHPVDNA pre-treatment and negative ctHPVDNA before recurrence was detected. For those with 1 positive ctHPVDNA, but with no recurrence to date, the median follow up time after the first positive ctHPVDNA is 23.7 mos.",
        "Discussion": "Here we present initial findings from a U01 prospective biomarker trial of HPV+ HNSCC. This study revealed promising early results for identification of patients with poor prognosis and for early detection of recurrences. Seventy-five percent of patients with recurrences as of 12/2025 were in the poor prognosis subtype, and two or more positive post-treatment ctHPVDNA detected all recurrences for patients who had positive pre-treatment ctHPVDNA. Ten percent of patients had indeterminate or non-detectable ctHPVDNA before treatment and one of these patients recurred. The two subtypes identified in this study have been shown to be associated with different mechanisms of HPV-driven carcinogenesis defined by different mutation and methylation patterns and HPV gene expression. Consistent with differences in HPV carcinogenesis, this study for the first time shows that subtypes of HPV+ OPSCC have differences in pre-treatment ctHPVDNA.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biomarkers for HPV+ OPSCC Recurrence and Survival: Early Results of U01 Funded Prospective Study</span>. Wendell G Yarbrough, MD<sup>1</sup>; <u>Travis Schrank, MD, PhD</u><sup>1</sup>; Tan X<sup>2</sup>; J Blumberg<sup>1</sup>; T Hackman<sup>1</sup>; C Lumley<sup>1</sup>; M Patel<sup>1</sup>; A Colaianni<sup>1</sup>; R Ferris<sup>1</sup>; K van Abel<sup>3</sup>; D Ma<sup>4</sup>; D Neskey<sup>5</sup>; T Day<sup>5</sup>; N Issaeva<sup>1</sup>. <sup>1</sup>Dept. of Otolaryngology/Head and Neck Surgery, UNC School of Medicine; <sup>2</sup>Dept of Biostatistics, Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health; <sup>3</sup>Dept of Otolaryngology/Head and Neck Surgery, Mayo Clinic; <sup>4</sup>Dept of Radiation Oncology, Mayo Clinic; <sup>5</sup>Head and Neck Specialists, Sarah Cannon Cancer Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Reliable biomarkers to identify tumors with good survival and for early detection of recurrences may improve outcomes for HPV+ oropharyngeal SCC (OPSCC). Our group identified two subtypes of HPV+ HNSCC, one associated with new mechanism of HPV-driven carcinogenesis and good survival and the other subtype driven by canonical HPV-carcinogenesis and associated with poor outcome. Here, we present preliminary results from a U01-funded prospective study examining potential biomarkers: HPV subtype classification and circulating tumor HPV DNA (ctHPVDNA) by NavDx.</p>\n\n<p><strong>Methods:</strong> Prospectively enrolled multi-institutional biomarker study for HPV+ OPSCC with targeted enrollment of 220. Paraffin-embedded tumor was analyzed by RNASeq to identify subtypes and circulating tumor tissue modified viral (TTMV) DNA detected by NavDx (Naveris).</p>\n\n<p><strong>Results:</strong> We report on RNASeq tumor analyses and NavDx results on 76 patients with an average time since diagnosis (enrollment)  of ## mos. The poor prognosis subtype comprised 38  patients (50%) and the good prognosis subtype 38 patients (50%) with mean pre-treatment NavDx(s) of 787.7 and 6760.1. At this interim analysis, recurrences were detected in 3 of 38 patients in the poor prognosis subtype and 1 of 38 patients in the good prognosis subtype. For ctHPVDNA, NavDx was not detected in pre-treatment samples for 8 of 76 patients (10.5%). Excluding these patients and those with missing data 17 of 56 patients (30.3%) had a post-treatment positive ctHPVDNA. Fifteen of these patients had a single positive ctHPVDNA and biopsy proven recurrence occurred in 1 of 15 (6.7%). Amongst patients with 2 or more positive post-treatment ctHPVDNA recurrences were found in 2 or 2 (100%). For patients with recurrence detected by ctHPVDNA, positive ctHPVDNA preceded clinical diagnosis by between 8 days and 9.0 months. One patient had recurrence with a negative ctHPVDNA pre-treatment and negative ctHPVDNA before recurrence was detected. For those with 1 positive ctHPVDNA, but with no recurrence to date, the median follow up time after the first positive ctHPVDNA is 23.7 mos.</p>\n\n<p><strong>Discussion: </strong>Here we present initial findings from a U01 prospective biomarker trial of HPV+ HNSCC. This study revealed promising early results for identification of patients with poor prognosis and for early detection of recurrences. Seventy-five percent of patients with recurrences as of 12/2025 were in the poor prognosis subtype, and two or more positive post-treatment ctHPVDNA detected all recurrences for patients who had positive pre-treatment ctHPVDNA.  Ten percent of patients had indeterminate or non-detectable ctHPVDNA before treatment and one of these patients recurred. The two subtypes identified in this study have been shown to be associated with different mechanisms of HPV-driven carcinogenesis defined by different mutation and methylation patterns and HPV gene expression. Consistent with differences in HPV carcinogenesis, this study for the first time shows that subtypes of HPV+ OPSCC have differences in pre-treatment ctHPVDNA.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153954--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S394",
      "content_id": "154055",
      "abstract_number": "S394",
      "poster_number": "",
      "title": "HPV Genome Sequencing from Plasma and Saliva Reveals Biofluid-Specific Cell-free DNA Fragmentation Signatures in Oropharyngeal Cancer",
      "summary": "Plasma and saliva both serve as biofluid sources for the identification of HPV-associated OPC. Confirming prior findings, HPV-seq revealed higher sensitivity for the detection of HPV DNA when compared to dPCR. Biofluid-specific differences in detection performance appear to reflect tumor proximity, patterns of viral co-infection, and distinct nuclease activities that shape cfDNA fragmentation. Together these...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154055",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Patricia J Brooks",
      "presenter": "Patricia J Brooks",
      "authors": "Patricia J Brooks ; Jinfeng Zou; Emma Collier; Lucas Penny; Katrina Rey-McIntyre; Zhen Zhao; Yangqiao Zheng; Jonathan Irish; Shao Hui Huang; Scott V Bratman",
      "normalized_authors": [
        "Patricia J Brooks",
        "Jinfeng Zou",
        "Emma Collier",
        "Lucas Penny",
        "Katrina Rey-McIntyre",
        "Zhen Zhao",
        "Yangqiao Zheng",
        "Jonathan Irish",
        "Shao Hui Huang",
        "Scott V Bratman"
      ],
      "affiliations": [
        "Princess Margaret Cancer Centre"
      ],
      "normalized_institutions": [
        "Princess Margaret Cancer Centre"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose/Objective(s)",
        "Materials/Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Patricia J Brooks ; Jinfeng Zou; Emma Collier; Lucas Penny; Katrina Rey-McIntyre; Zhen Zhao; Yangqiao Zheng; Jonathan Irish; Shao Hui Huang; Scott V Bratman",
        "Affiliations": "Princess Margaret Cancer Centre",
        "Purpose/Objective(s)": "Human papillomavirus (HPV) DNA has been shown to be detectable in both plasma and saliva from patients with oropharyngeal cancer (OPC). While polymerase chain reaction (PCR)-based techniques predominate, HPV genome sequencing (HPV-seq) enables more sensitive detection of HPV DNA in cell-free DNA (cfDNA). Beyond this improved sensitivity, the ability of HPV-seq to reveal other tumor-specific molecular features is poorly understood. Moreover, the performance of HPV-seq compared to digital PCR (dPCR) in salivary cfDNA analysis has not been described.",
        "Materials/Methods": "We recruited 40 patients with newly diagnosed, treatment-naïve p16-positive OPC (TNM 8th Ed. stage I-IV). Each patient had peripheral blood plasma and saliva collected prior to treatment. dPCR was performed using a validated multiplexed assay targeting high-risk HPVE6/E7. HPV-seq was performed using a validated hybrid capture panel targeting 38 HPV genomes, 14 of which are whole genome, and 15 recurrently mutated genes in OPC. HPV DNA levels within plasma and saliva were expressed as copies/10 ng cfDNA and log-transformed for statistical tests. Patient disease stage and subsite comparisons were evaluated in relation to HPV DNA copy numbers. HPV DNA subtype and integration profiles within plasma and saliva were assessed using SearcHPV. Fragment ends of cfDNA sequences were compared among conditions using principle component analysis.",
        "Results": "We performed dPCR and HPV-seq on pretreatment samples from 40 patients. Stage distribution was: I=21, II=8, III=9, IV=2. With dPCR, HPV was detected in 39/40 (97.5%) plasma samples with 4.04-8768 copies/10 ng cfDNA, and 35/40 (87.5%) saliva samples with 1.19-22527 copies/10 ng cfDNA. With HPV-seq, HPV was detected in 40/40 (100%) plasma samples with 0.309-13348 copies/10ng cfDNA, and 38 (95%) saliva samples with 0.0290-23324 copies/10ng DNA. Copies of hrHPV DNA were strongly correlated between dPCR and HPV-seq (R=0.9567, p=1.2x10-23). Plasma HPV DNA copy number was higher in patients with late stage (III-IV) compared with early stage (I-II) disease (p=0.0363). Paired plasma and saliva HPV DNA copy numbers were moderately correlated in patients with tonsillar tumors (R=0.482, p=0.043) but not base-of-tongue tumors (R=0.0775, p=0.725). The mean number of hrHPV strains in saliva cfDNA (2.35±1.33) was higher than that in plasma cfDNA (1.3±0.52), indicating that detectability of co-infection with HPV differed between the biofluids (p=2.412x10-5). Fragment end-motif profiling of human genome cfDNA from plasma and saliva revealed discernible differences in motif enrichment, indicating that different nucleases contribute to DNA fragmentation in each biofluid.",
        "Conclusion": "Plasma and saliva both serve as biofluid sources for the identification of HPV-associated OPC. Confirming prior findings, HPV-seq revealed higher sensitivity for the detection of HPV DNA when compared to dPCR. Biofluid-specific differences in detection performance appear to reflect tumor proximity, patterns of viral co-infection, and distinct nuclease activities that shape cfDNA fragmentation. Together these findings indicate that each biofluid provides complementary insights into HPV biology and tumor behaviour.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>HPV Genome Sequencing from Plasma and Saliva Reveals Biofluid-Specific Cell-free DNA Fragmentation Signatures in Oropharyngeal Cancer</span>. <u>Patricia J Brooks</u>; Jinfeng Zou; Emma Collier; Lucas Penny; Katrina Rey-McIntyre; Zhen Zhao; Yangqiao Zheng; Jonathan Irish; Shao Hui Huang; Scott V Bratman. Princess Margaret Cancer Centre<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose/Objective(s): </strong>Human papillomavirus (HPV) DNA has been shown to be detectable in both plasma and saliva from patients with oropharyngeal cancer (OPC). While polymerase chain reaction (PCR)-based techniques predominate, HPV genome sequencing (HPV-seq) enables more sensitive detection of HPV DNA in cell-free DNA (cfDNA). Beyond this improved sensitivity, the ability of HPV-seq to reveal other tumor-specific molecular features is poorly understood. Moreover, the performance of HPV-seq compared to digital PCR (dPCR) in salivary cfDNA analysis has not been described.</p>\n\n<p><strong>Materials/Methods: </strong>We recruited 40 patients with newly diagnosed, treatment-naïve p16-positive OPC (TNM 8th Ed. stage I-IV). Each patient had peripheral blood plasma and saliva collected prior to treatment. dPCR was performed using a validated multiplexed assay targeting high-risk HPVE6/E7. HPV-seq was performed using a validated hybrid capture panel targeting 38 HPV genomes, 14 of which are whole genome, and 15 recurrently mutated genes in OPC. HPV DNA levels within plasma and saliva were expressed as copies/10 ng cfDNA and log-transformed for statistical tests. Patient disease stage and subsite comparisons were evaluated in relation to HPV DNA copy numbers. HPV DNA subtype and integration profiles within plasma and saliva were assessed using SearcHPV. Fragment ends of cfDNA sequences were compared among conditions using principle component analysis.</p>\n\n<p><strong>Results:</strong> We performed dPCR and HPV-seq on pretreatment samples from 40 patients. Stage distribution was: I=21, II=8, III=9, IV=2. With dPCR, HPV was detected in 39/40 (97.5%) plasma samples with 4.04-8768 copies/10 ng cfDNA, and 35/40 (87.5%) saliva samples with 1.19-22527 copies/10 ng cfDNA. With HPV-seq, HPV was detected in 40/40 (100%) plasma samples with 0.309-13348 copies/10ng cfDNA, and 38 (95%) saliva samples with 0.0290-23324 copies/10ng DNA. Copies of hrHPV DNA were strongly correlated between dPCR and HPV-seq (R=0.9567, p=1.2x10-23). Plasma HPV DNA copy number was higher in patients with late stage (III-IV) compared with early stage (I-II) disease (p=0.0363). Paired plasma and saliva HPV DNA copy numbers were moderately correlated in patients with tonsillar tumors (R=0.482, p=0.043) but not base-of-tongue tumors (R=0.0775, p=0.725). The mean number of hrHPV strains in saliva cfDNA (2.35±1.33) was higher than that in plasma cfDNA (1.3±0.52), indicating that detectability of co-infection with HPV differed between the biofluids (p=2.412x10-5). Fragment end-motif profiling of human genome cfDNA from plasma and saliva revealed discernible differences in motif enrichment, indicating that different nucleases contribute to DNA fragmentation in each biofluid.</p>\n\n<p><strong>Conclusion: </strong>Plasma and saliva both serve as biofluid sources for the identification of HPV-associated OPC. Confirming prior findings, HPV-seq revealed higher sensitivity for the detection of HPV DNA when compared to dPCR. Biofluid-specific differences in detection performance appear to reflect tumor proximity, patterns of viral co-infection, and distinct nuclease activities that shape cfDNA fragmentation. Together these findings indicate that each biofluid provides complementary insights into HPV biology and tumor behaviour.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154055--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S395",
      "content_id": "152224",
      "abstract_number": "S395",
      "poster_number": "",
      "title": "Characterizing Specificity and Sensitivity of Oral HPV DNA Testing among HPV-Positive Oropharynx Cancer Patients and Controls: The SPOT-HPV Study",
      "summary": "Salivary HPV DNA is highly specific and moderately sensitive for HPV+OPC, detecting a low prevalence of bystander oral HPV infections among male controls. It yields only a minor increase in sensitivity over plasma testing alone. Salivary HPV DNA may be useful as a standalone or noninvasive screening test, but is unlikely to meaningfully augment the clinical diagnostic utility of the plasma TTMV-HPV test currently...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152224",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Julianna Miller, BS",
      "presenter": "Julianna Miller, BS",
      "authors": "Julianna Miller, BS 1 ; Bethany Sargent, MS 2 ; Glenn J Hanna, MD, MPH 3 ; Jonathan Schoenfeld, MD, MPhil, MPH 4 ; Eleni M Rettig, MD 4",
      "normalized_authors": [
        "Julianna Miller",
        "Bethany Sargent",
        "Glenn J Hanna",
        "Jonathan Schoenfeld, MPhil",
        "Eleni M Rettig"
      ],
      "affiliations": [
        "Nova Southeastern University College of Allopathic Medicine",
        "University of New England College of Osteopathic Medicine",
        "Dana-Farber Cancer Institute",
        "Brigham and Women's Hospital"
      ],
      "normalized_institutions": [
        "Nova Southeastern University College of Allopathic Medicine",
        "University of New England College of Osteopathic Medicine",
        "Dana-Farber Cancer Institute",
        "Brigham and Women's Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152224/figure%201%20.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152224/figure%201%20.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152224"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 546,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions",
        "Figure"
      ],
      "sections": {
        "Authors": "Julianna Miller, BS 1 ; Bethany Sargent, MS 2 ; Glenn J Hanna, MD, MPH 3 ; Jonathan Schoenfeld, MD, MPhil, MPH 4 ; Eleni M Rettig, MD 4",
        "Affiliations": "1 Nova Southeastern University College of Allopathic Medicine; 2 University of New England College of Osteopathic Medicine; 3 Dana-Farber Cancer Institute; 4 Brigham and Women's Hospital",
        "Background": "Minimally invasive biomarkers may facilitate earlier detection and prevent diagnostic delays for HPV-positive oropharynx cancer (HPV+OPC). Plasma tumor tissue modified viral (TTMV)-HPV DNA is detectable among ~90% of newly diagnosed HPV-positive OPC patients. Direct oropharynx sampling may improve upon the diagnostic sensitivity of plasma testing alone. However, salivary HPV DNA testing is subject to bystander oral HPV infections. Our objectives were to evaluate the specificity of a ddPCR-based salivary HPV DNA assay for detecting HPV+OPC among individuals without HPV+OPC (‘controls’), and the sensitivity compared with plasma testing among HPV+OPC patients (‘cases’).",
        "Methods": "This cross-sectional study prospectively enrolled non-metastatic (M0) HPV+OPC cases and adult male controls without HPV-associated malignancies at a tertiary academic center from 11/2022-2/2024. All subjects provided salivary rinse samples. Cases and controls with positive oral rinses also provided plasma samples. Saliva samples were tested for HPV DNA from HPV 16/18/31/33/35 using a ddPCR-based assay (NavRinz) and reported as positive/negative/indeterminate. Salivary HPV score and fragmentation patterns were also reported. Plasma was tested for TTMV-HPV DNA using a validated commercial ddPCR-based assay (NavDx®; Naveris TM ) and reported as positive/negative/indeterminate, with TTMV score. Controls with detectable salivary HPV DNA were informed of their result, and underwent plasma testing and clinical evaluation. Salivary HPV DNA detection performance metrics were reported, and compared with plasma TTMV-HPV DNA and clinicopathologic characteristics.",
        "Results": "Among 300 male controls, most (91%) were white and median age was 67 (IQR=61-73). 42% were former/current smokers, and 31% of survey respondents reported ≥10 lifetime oral sexual partners. Salivary HPV DNA was detected in 5 controls (3 HPV16, 1 HPV33, 1 HPV35), yielding 98.3% specificity (95% CI=96.2-99.5%); 7 controls were indeterminate. Plasma TTMV-HPV DNA was undetectable for all 5 saliva-positive controls, and head and neck examinations were normal.",
        "Abstract": "Among 59 cases, most were male (86%) and white (90%), with median age 64 (IQR=58-70). Salivary HPV DNA was detected in 79.7% of cases, and plasma TTMV-HPV DNA in 91.5%. Two cases, staged cT2N1 and cT1N1, had HPV detectable in saliva but not plasma. Combined saliva/plasma sensitivity was 94.8%, not significantly higher than plasma alone. Salivary HPV DNA detection was strongly associated with T stage, while plasma TTMV-HPV DNA detection was associated with N stage (Figure). Salivary HPV score increased with increasing TTMV-HPV DNA scores (β:0.53, 95%CI=[0.18, 0.89]). The mean percentages of HPV16 DNA fragment size detected in saliva were 29.4% small (SD=16.5), 26.6% intermediate (SD=11.2), and 43.9% large (SD=21.7). Smaller fragment size was associated with lower HPV score (β:-2.3, 95%CI=[-4.5, -0.17]). View in Agenda and Add to Schedule",
        "Conclusions": "Salivary HPV DNA is highly specific and moderately sensitive for HPV+OPC, detecting a low prevalence of bystander oral HPV infections among male controls. It yields only a minor increase in sensitivity over plasma testing alone. Salivary HPV DNA may be useful as a standalone or noninvasive screening test, but is unlikely to meaningfully augment the clinical diagnostic utility of the plasma TTMV-HPV test currently in use .",
        "Figure": "Heatplot of (A) salivary HPV DNA and (B) plasma TTMV-HPV DNA prevalence by N and T stage."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Characterizing Specificity and Sensitivity of Oral HPV DNA Testing among HPV-Positive Oropharynx Cancer Patients and Controls: The SPOT-HPV Study</span>. <u>Julianna Miller, BS</u><sup>1</sup>; Bethany Sargent, MS<sup>2</sup>; Glenn J Hanna, MD, MPH<sup>3</sup>; Jonathan Schoenfeld, MD, MPhil, MPH<sup>4</sup>; Eleni M Rettig, MD<sup>4</sup>. <sup>1</sup>Nova Southeastern University College of Allopathic Medicine; <sup>2</sup>University of New England College of Osteopathic Medicine; <sup>3</sup>Dana-Farber Cancer Institute; <sup>4</sup>Brigham and Women's Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Minimally invasive biomarkers may facilitate earlier detection and prevent diagnostic delays for HPV-positive oropharynx cancer (HPV+OPC). Plasma tumor tissue modified viral (TTMV)-HPV DNA is detectable among ~90% of newly diagnosed HPV-positive OPC patients. Direct oropharynx sampling may improve upon the diagnostic sensitivity of plasma testing alone. However, salivary HPV DNA testing is subject to bystander oral HPV infections. Our objectives were to evaluate the specificity of a ddPCR-based salivary HPV DNA assay for detecting HPV+OPC among individuals without HPV+OPC (‘controls’), and the sensitivity compared with plasma testing among HPV+OPC patients (‘cases’).</p>\n\n<p><strong>Methods: </strong>This cross-sectional study prospectively enrolled non-metastatic (M0) HPV+OPC cases and adult male controls without HPV-associated malignancies at a tertiary academic center from 11/2022-2/2024. All subjects provided salivary rinse samples. Cases and controls with positive oral rinses also provided plasma samples. Saliva samples were tested for HPV DNA from HPV 16/18/31/33/35 using a ddPCR-based assay (NavRinz) and reported as positive/negative/indeterminate. Salivary HPV score and fragmentation patterns were also reported. Plasma was tested for TTMV-HPV DNA using a validated commercial ddPCR-based assay (NavDx®; Naveris<sup>TM</sup>) and reported as positive/negative/indeterminate, with TTMV score. Controls with detectable salivary HPV DNA were informed of their result, and underwent plasma testing and clinical evaluation. Salivary HPV DNA detection performance metrics were reported, and compared with plasma TTMV-HPV DNA and clinicopathologic characteristics.</p>\n\n<p><strong>Results: </strong>Among 300 male controls, most (91%) were white and median age was 67 (IQR=61-73). 42% were former/current smokers, and 31% of survey respondents reported ≥10 lifetime oral sexual partners. Salivary HPV DNA was detected in 5 controls (3 HPV16, 1 HPV33, 1 HPV35), yielding 98.3% specificity (95% CI=96.2-99.5%); 7 controls were indeterminate. Plasma TTMV-HPV DNA was undetectable for all 5 saliva-positive controls, and head and neck examinations were normal.</p>\n\n<p>Among 59 cases, most were male (86%) and white (90%), with median age 64 (IQR=58-70). Salivary HPV DNA was detected in 79.7% of cases, and plasma TTMV-HPV DNA in 91.5%. Two cases, staged cT2N1 and cT1N1, had HPV detectable in saliva but not plasma. Combined saliva/plasma sensitivity was 94.8%, not significantly higher than plasma alone.</p>\n\n<p>Salivary HPV DNA detection was strongly associated with T stage, while plasma TTMV-HPV DNA detection was associated with N stage (Figure). Salivary HPV score increased with increasing TTMV-HPV DNA scores (β:0.53, 95%CI=[0.18, 0.89]).</p>\n\n<p>The mean percentages of HPV16 DNA fragment size detected in saliva were 29.4% small (SD=16.5), 26.6% intermediate (SD=11.2), and 43.9% large (SD=21.7). Smaller fragment size was associated with lower HPV score (β:-2.3, 95%CI=[-4.5, -0.17]).</p>\n\n<p><strong>Conclusions: </strong>Salivary HPV DNA is highly specific and moderately sensitive for HPV+OPC, detecting a low prevalence of bystander oral HPV infections among male controls. It yields only a minor increase in sensitivity over plasma testing alone. Salivary HPV DNA may be useful as a standalone or noninvasive screening test, but is unlikely to meaningfully augment the clinical diagnostic utility of the plasma TTMV-HPV test currently in use .</p>\n\n<p><strong>Figure: </strong>Heatplot of (A) salivary HPV DNA and (B) plasma TTMV-HPV DNA prevalence by N and T stage.</p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152224/figure%201%20.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152224--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S396",
      "content_id": "153396",
      "abstract_number": "S396",
      "poster_number": "",
      "title": "The Prognostic Significance of HPV Genotypes and their Impact on Tumor Microenvironment Profiling in Oropharyngeal Cancer?",
      "summary": "The incidence of HPV-associated oropharyngeal cancer (OPC) is steadily rising in recent years. Although patients with HPV-positive OPC generally have better outcomes than those with HPV-negative disease, locoregional recurrence and distant failure rates remain a problem. Information on the prognostic impact of different HPV genotypes and their influence on the tumor microenvironment (TME) remains limited and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153396",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karim Botros, MD",
      "presenter": "Karim Botros, MD",
      "authors": "Karim Botros, MD ; Orr Dimitstein, MD; Gabriel Berberi; Michael Hier, MD; Marco Mascarella, MD; Alex Mlynarek; Nader Sadeghi, MD; Christophe Goncalves; Sonia del Rincon; Sabrina Wurzba, DDS, PhD",
      "normalized_authors": [
        "Karim Botros",
        "Orr Dimitstein",
        "Gabriel Berberi",
        "Michael Hier",
        "Marco Mascarella",
        "Alex Mlynarek",
        "Nader Sadeghi",
        "Christophe Goncalves",
        "Sonia del Rincon",
        "Sabrina Wurzba"
      ],
      "affiliations": [
        "McGill University"
      ],
      "normalized_institutions": [
        "McGill University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 348,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Preliminary Results",
        "Expected Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Karim Botros, MD ; Orr Dimitstein, MD; Gabriel Berberi; Michael Hier, MD; Marco Mascarella, MD; Alex Mlynarek; Nader Sadeghi, MD; Christophe Goncalves; Sonia del Rincon; Sabrina Wurzba, DDS, PhD",
        "Affiliations": "McGill University",
        "Background": "The incidence of HPV-associated oropharyngeal cancer (OPC) is steadily rising in recent years. Although patients with HPV-positive OPC generally have better outcomes than those with HPV-negative disease, locoregional recurrence and distant failure rates remain a problem. Information on the prognostic impact of different HPV genotypes and their influence on the tumor microenvironment (TME) remains limited and controversial. This study aims to investigate the role of specific HPV genotypes on altering the TME and subsequently the survival outcomes in OPC patients.",
        "Methods": "We retrospectively analyzed patients with p16+ OPC treated at two cancer centers in Montreal from 2010 to 2025. Patients were included based on confirmed p16+ status and the availability of all pertinent pathological specimens. They were included irrespective of the treatment modality used. Serving as a control, a smaller cohort of p16– OPC patients was included. Additionally, a third cohort of patients with p16+ tumors outside the oropharynx was also identified to study the effect of HPV infection in non-oropharyngeal sites (eg. oral cavity, hypopharynx, nasopharynx, etc.). All pertinent tissue blocks were retrieved, including primary site and/or nodal biopsies as well as surgical resections. DNA was extracted for HPV genotyping. Tissue microarrays (TMAs) were constructed for TME imaging, focusing on key infiltrating immune cell populations.",
        "Preliminary Results": "Specimens from 266 p16+ OPC patients were collected, of which 79.6% were male. Mean age was 62.5 years. Genotyping of HPV was done in 120 cases to date, and the presence of multiple strains was 15%. Mean follow-up duration in these cases was 5.2 years. Treatment modalities included conventional chemoradiation, surgery and adjuvant radiation, and neoadjuvant chemotherapy followed by surgery and risk-adjusted adjuvant radiation. Patients with non-HPV16 subtypes demonstrated significantly worse overall survival (OS) and recurrence-free survival (RFS) than those with HPV16-associated tumors (p=0.005). Patients with multi-strain-associated tumors experienced intermediate survival (p=0.09).",
        "Expected Conclusion": "Non-HPV16 genotypes represent a negative prognostic factor in OPC. Routine p16 immunohistochemistry should be supplemented with commercially available HPV genotyping assays to guide treatment decisions, potentially enabling safer treatment de-escalation strategies for patients with favorable genotypes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Prognostic Significance of HPV Genotypes and their Impact on Tumor Microenvironment Profiling in Oropharyngeal Cancer?</span>. <u>Karim Botros, MD</u>; Orr Dimitstein, MD; Gabriel Berberi; Michael Hier, MD; Marco Mascarella, MD; Alex Mlynarek; Nader Sadeghi, MD; Christophe Goncalves; Sonia del Rincon; Sabrina Wurzba, DDS, PhD. McGill University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The incidence of HPV-associated oropharyngeal cancer (OPC) is steadily rising in recent years. Although patients with HPV-positive OPC generally have better outcomes than those with HPV-negative disease, locoregional recurrence and distant failure rates remain a problem. Information on the prognostic impact of different HPV genotypes and their influence on the tumor microenvironment (TME) remains limited and controversial. This study aims to investigate the role of specific HPV genotypes on altering the TME and subsequently the survival outcomes in OPC patients. </p>\n\n<p><strong>Methods:</strong> We retrospectively analyzed patients with p16+ OPC treated at two cancer centers in Montreal from 2010 to 2025. Patients were included based on confirmed p16+ status and the availability of all pertinent pathological specimens. They were included irrespective of the treatment modality used. Serving as a control, a smaller cohort of p16– OPC patients was included. Additionally, a third cohort of patients with p16+ tumors outside the oropharynx was also identified to study the effect of HPV infection in non-oropharyngeal sites (eg. oral cavity, hypopharynx, nasopharynx, etc.). All pertinent tissue blocks were retrieved, including primary site and/or nodal biopsies as well as surgical resections. DNA was extracted for HPV genotyping. Tissue microarrays (TMAs) were constructed for TME imaging, focusing on key infiltrating immune cell populations. </p>\n\n<p><strong>Preliminary Results:</strong> Specimens from 266 p16+ OPC patients were collected, of which 79.6% were male. Mean age was 62.5 years. Genotyping of HPV was done in 120 cases to date, and the presence of multiple strains was 15%. Mean follow-up duration in these cases was 5.2 years. Treatment modalities included conventional chemoradiation, surgery and adjuvant radiation, and neoadjuvant chemotherapy followed by surgery and risk-adjusted adjuvant radiation. Patients with non-HPV16 subtypes demonstrated significantly worse overall survival (OS) and recurrence-free survival (RFS) than those with HPV16-associated tumors (p=0.005). Patients with multi-strain-associated tumors experienced intermediate survival (p=0.09).</p>\n\n<p><strong>Expected Conclusion:</strong> Non-HPV16 genotypes represent a negative prognostic factor in OPC. Routine p16 immunohistochemistry should be supplemented with commercially available HPV genotyping assays to guide treatment decisions, potentially enabling safer treatment de-escalation strategies for patients with favorable genotypes. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153396--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S397",
      "content_id": "154442",
      "abstract_number": "S397",
      "poster_number": "",
      "title": "Molecular Characteristics of HPV-Positive and HPV-Negative Recurrent Oropharyngeal Squamous Cell Carcinoma: A Retrospective Cohort Analysis (2015–2023)",
      "summary": "Recurrent OPSCC demonstrates distinct genomic and temporal characteristics by HPV status. HPV-positive tumors more frequently recur early, whereas HPV-negative disease disproportionately contributes to very-late recurrence (≥5 years), suggesting differing biological mechanisms including potential immune escape or tumor dormancy. Observed trends in PI3K pathway signaling, chromatin remodeling mutations, and TP53...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154442",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eric Sokhn, BS",
      "presenter": "Eric Sokhn, BS",
      "authors": "Eric Sokhn, BS 1 ; Muhammad El Shatanofy, MD 2 ; Soumil Prasad, BS 1 ; Carlos L Nava, BS 1 ; Zoukaa Sargi, MD, MPH 2",
      "normalized_authors": [
        "Eric Sokhn",
        "Muhammad El Shatanofy",
        "Soumil Prasad",
        "Carlos L Nava",
        "Zoukaa Sargi"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine",
        "University of Miami Hospital"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine",
        "University of Miami Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Eric Sokhn, BS 1 ; Muhammad El Shatanofy, MD 2 ; Soumil Prasad, BS 1 ; Carlos L Nava, BS 1 ; Zoukaa Sargi, MD, MPH 2",
        "Affiliations": "1 University of Miami Miller School of Medicine; 2 University of Miami Hospital",
        "Background": "Although HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) demonstrates favorable treatment responsiveness, 13–25% of patients experience recurrence, most commonly within two years. The biological mechanisms underlying recurrence remain incompletely defined, particularly among HPV-positive patients who present with aggressive recurrence despite favorable initial prognosis. Genomic alterations implicated in OPSCC pathogenesis, including disruptions in PI3K signaling, chromatin remodeling, and cell cycle regulation, may contribute to recurrence biology. This study aimed to characterize molecular features of recurrent OPSCC and evaluate associations between HPV status, recurrence timing, and post-recurrence survival.",
        "Methods": "A retrospective cohort study was performed including 152 patients with recurrent OPSCC treated from 2015–2023. Clinical variables included HPV status, age at recurrence, primary site, recurrence timing (early: 6–24 months; late: 2–5 years; very late: ≥5 years), treatment modality, and survival outcomes. Next-generation sequencing (NGS) was available for a subset of tumors and included pathogenic mutations. Mutation pathways and clusters were assigned based on established biologic classifications annotated in COSMIC and TCGA-derived head and neck cancer frameworks. Descriptive statistics, chi-square comparisons, and pathway-level clustering analyses were performed. Cox proportional hazards modeling evaluated associations between molecular alterations and post-recurrence survival adjusting for HPV status.",
        "Results": "Among 152 recurrent cases, 63.8% were HPV-positive and 36.2% HPV-negative. Early recurrence was most common (61.2%), followed by late (25.7%) and very-late recurrence (13.2%). NGS data was available for 31 patients. Mutation profiling demonstrated recurrent pathway involvement in chromatin regulation (CREBBP, EP300, KMT2C), epigenetic remodeling (ARID1A), PI3K signaling (PIK3CA, PIK3CB, PTEN), cell-cycle regulation (CCND1), and head and neck cancer drivers (TP53, HRAS). HPV-positive tumors exhibited proportionally higher rates of PIK3CA, KMT2C, and EP300 alterations, consistent with viral-mediated epigenetic disruption, while TP53 mutations occurred predominantly in HPV-negative tumors, consistent with carcinogen-associated genomic instability. Pathway-level clustering revealed distinct molecular signatures between HPV-positive and HPV-negative recurrent disease, despite limited gene-level statistical significance related to low mutation frequency per locus.",
        "Abstract": "In Cox modeling, no mutation pathway reached statistical significance after adjusting for HPV status; however, directional trends were observed. TP53-associated DNA damage–repair alterations were associated with increased post-recurrence mortality (HR 2.67; 95% CI 0.68–10.41; p=0.16). The Receptor Tyrosine Kinase gene cluster demonstrated a similar trend (HR 2.71; p=0.18), whereas immune-escape pathway mutations trended toward improved survival (HR 0.24; p=0.24). HPV status was not independently associated with post-recurrence survival (HR 1.21; p=0.37). View in Agenda and Add to Schedule",
        "Conclusion": "Recurrent OPSCC demonstrates distinct genomic and temporal characteristics by HPV status. HPV-positive tumors more frequently recur early, whereas HPV-negative disease disproportionately contributes to very-late recurrence (≥5 years), suggesting differing biological mechanisms including potential immune escape or tumor dormancy. Observed trends in PI3K pathway signaling, chromatin remodeling mutations, and TP53 dysregulation highlight candidate pathways influencing recurrence phenotype and survival. These findings support incorporating molecular profiling into post-recurrence prognostics and underscore the need for extended long-term surveillance, particularly among HPV-negative patients. Larger molecularly annotated datasets are needed to validate pathway-level associations and evaluate therapeutic implications."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Molecular Characteristics of HPV-Positive and HPV-Negative Recurrent Oropharyngeal Squamous Cell Carcinoma: A Retrospective Cohort Analysis (2015–2023)</span>. <u>Eric Sokhn, BS</u><sup>1</sup>; Muhammad El Shatanofy, MD<sup>2</sup>; Soumil Prasad, BS<sup>1</sup>; Carlos L Nava, BS<sup>1</sup>; Zoukaa Sargi, MD, MPH<sup>2</sup>. <sup>1</sup>University of Miami Miller School of Medicine; <sup>2</sup>University of Miami Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Although HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) demonstrates favorable treatment responsiveness, 13–25% of patients experience recurrence, most commonly within two years. The biological mechanisms underlying recurrence remain incompletely defined, particularly among HPV-positive patients who present with aggressive recurrence despite favorable initial prognosis. Genomic alterations implicated in OPSCC pathogenesis, including disruptions in PI3K signaling, chromatin remodeling, and cell cycle regulation, may contribute to recurrence biology. This study aimed to characterize molecular features of recurrent OPSCC and evaluate associations between HPV status, recurrence timing, and post-recurrence survival.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed including 152 patients with recurrent OPSCC treated from 2015–2023. Clinical variables included HPV status, age at recurrence, primary site, recurrence timing (early: 6–24 months; late: 2–5 years; very late: ≥5 years), treatment modality, and survival outcomes. Next-generation sequencing (NGS) was available for a subset of tumors and included pathogenic mutations. Mutation pathways and clusters were assigned based on established biologic classifications annotated in COSMIC and TCGA-derived head and neck cancer frameworks. Descriptive statistics, chi-square comparisons, and pathway-level clustering analyses were performed. Cox proportional hazards modeling evaluated associations between molecular alterations and post-recurrence survival adjusting for HPV status.</p>\n\n<p><strong>Results: </strong>Among 152 recurrent cases, 63.8% were HPV-positive and 36.2% HPV-negative. Early recurrence was most common (61.2%), followed by late (25.7%) and very-late recurrence (13.2%). NGS data was available for 31 patients. Mutation profiling demonstrated recurrent pathway involvement in chromatin regulation (CREBBP, EP300, KMT2C), epigenetic remodeling (ARID1A), PI3K signaling (PIK3CA, PIK3CB, PTEN), cell-cycle regulation (CCND1), and head and neck cancer drivers (TP53, HRAS). HPV-positive tumors exhibited proportionally higher rates of PIK3CA, KMT2C, and EP300 alterations, consistent with viral-mediated epigenetic disruption, while TP53 mutations occurred predominantly in HPV-negative tumors, consistent with carcinogen-associated genomic instability. Pathway-level clustering revealed distinct molecular signatures between HPV-positive and HPV-negative recurrent disease, despite limited gene-level statistical significance related to low mutation frequency per locus.</p>\n\n<p>In Cox modeling, no mutation pathway reached statistical significance after adjusting for HPV status; however, directional trends were observed. TP53-associated DNA damage–repair alterations were associated with increased post-recurrence mortality (HR 2.67; 95% CI 0.68–10.41; p=0.16). The Receptor Tyrosine Kinase gene cluster demonstrated a similar trend (HR 2.71; p=0.18), whereas immune-escape pathway mutations trended toward improved survival (HR 0.24; p=0.24). HPV status was not independently associated with post-recurrence survival (HR 1.21; p=0.37).</p>\n\n<p><strong>Conclusion: </strong>Recurrent OPSCC demonstrates distinct genomic and temporal characteristics by HPV status. HPV-positive tumors more frequently recur early, whereas HPV-negative disease disproportionately contributes to very-late recurrence (≥5 years), suggesting differing biological mechanisms including potential immune escape or tumor dormancy. Observed trends in PI3K pathway signaling, chromatin remodeling mutations, and TP53 dysregulation highlight candidate pathways influencing recurrence phenotype and survival. These findings support incorporating molecular profiling into post-recurrence prognostics and underscore the need for extended long-term surveillance, particularly among HPV-negative patients. Larger molecularly annotated datasets are needed to validate pathway-level associations and evaluate therapeutic implications.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154442--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S398",
      "content_id": "153800",
      "abstract_number": "S398",
      "poster_number": "",
      "title": "Detection of circulating tumor HPV16-DNA in liquid biopsy using qPCR and ddPCR – Comparison of methods in patients with HPV-related oropharyngeal squamous cell carcinomas",
      "summary": "Across 489 longitudinal samples from 60 HPV16+ OPSCC patients, qPCR and ddPCR assays targeting HPV16-E6 were performed. HPV status was confirmed by p16-IHC, PCR for HPV16-E6/L1, and viral load analysis in tumor tissue. ddPCR showed higher sensitivity and specificity (>80%) and correlated strongly with qPCR results (p < 0.001). HPV16-E6 ctDNA levels were significantly associated with tumor stage and tumor volume...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153800",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jens P Klussmann",
      "presenter": "Jens P Klussmann",
      "authors": "Jens P Klussmann ; Oliver. Siefer, Msc; Zurwa M Uzun, Msc; Jannik Johannsen, MD; Dustin Firmenich; Julie George, PhD",
      "normalized_authors": [
        "Jens P Klussmann",
        "Oliver. Siefer",
        "Zurwa M Uzun",
        "Jannik Johannsen",
        "Dustin Firmenich",
        "Julie George"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 297,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Discussion"
      ],
      "sections": {
        "Authors": "Jens P Klussmann ; Oliver. Siefer, Msc; Zurwa M Uzun, Msc; Jannik Johannsen, MD; Dustin Firmenich; Julie George, PhD",
        "Affiliations": "Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne",
        "Introduction": "The incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is increasing in Western countries. Although HPV+ OPSCC generally shows a favorable prognosis, approximately 25% of patients develop local recurrences or distant metastases. This underscores the need for minimally invasive biomarkers that allow close monitoring of treatment response and early detection of disease progression.",
        "Methods": "Our biobank contains 1,822 plasma samples with circulating tumor DNA (ctDNA) from more than 300 OPSCC patients collected at diagnosis, during therapy, throughout follow-up, and at recurrence or metastatic progression. This project aims to establish HPV-specific ctDNA detection using qPCR and digital droplet PCR (ddPCR) and to compare their sensitivity and specificity for early diagnosis and longitudinal disease monitoring.",
        "Abstract": "The effects of blood storage time, plasma preparation protocols, and freeze–thaw cycles on ctDNA levels were also evaluated. An initial cohort included 60 HPV16+ OPSCC patients, 5 patients with OPSCC caused by other high-risk HPV types, 10 HPV-negative OPSCC patients, 25 patients with other tumor entities, and 32 healthy controls. View in Agenda and Add to Schedule",
        "Results": "Across 489 longitudinal samples from 60 HPV16+ OPSCC patients, qPCR and ddPCR assays targeting HPV16-E6 were performed. HPV status was confirmed by p16-IHC, PCR for HPV16-E6/L1, and viral load analysis in tumor tissue. ddPCR showed higher sensitivity and specificity (>80%) and correlated strongly with qPCR results (p < 0.001). HPV16-E6 ctDNA levels were significantly associated with tumor stage and tumor volume (p < 0.05). Importantly, viral load in the primary tumor significantly correlated with ctDNA copy number in plasma. In several patients, HPV16-E6 ctDNA was detectable months before clinically or radiologically confirmed recurrence.",
        "Discussion": "ddPCR-based quantification of HPV16-E6 ctDNA is a promising biomarker for monitoring treatment response and disease progression in HPV+ OPSCC. Prospective clinical studies are required to validate its utility for routine surveillance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Detection of circulating tumor HPV16-DNA in liquid biopsy using qPCR and ddPCR – Comparison of methods in patients with HPV-related oropharyngeal squamous cell carcinomas</span>. <u>Jens P Klussmann</u>; Oliver. Siefer, Msc; Zurwa M Uzun, Msc; Jannik Johannsen, MD; Dustin Firmenich; Julie George, PhD. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is increasing in Western countries. Although HPV+ OPSCC generally shows a favorable prognosis, approximately 25% of patients develop local recurrences or distant metastases. This underscores the need for minimally invasive biomarkers that allow close monitoring of treatment response and early detection of disease progression.</p>\n\n<p><strong>Methods: </strong>Our biobank contains 1,822 plasma samples with circulating tumor DNA (ctDNA) from more than 300 OPSCC patients collected at diagnosis, during therapy, throughout follow-up, and at recurrence or metastatic progression. This project aims to establish HPV-specific ctDNA detection using qPCR and digital droplet PCR (ddPCR) and to compare their sensitivity and specificity for early diagnosis and longitudinal disease monitoring.</p>\n\n<p>The effects of blood storage time, plasma preparation protocols, and freeze–thaw cycles on ctDNA levels were also evaluated. An initial cohort included 60 HPV16+ OPSCC patients, 5 patients with OPSCC caused by other high-risk HPV types, 10 HPV-negative OPSCC patients, 25 patients with other tumor entities, and 32 healthy controls.</p>\n\n<p><strong>Results: </strong>Across 489 longitudinal samples from 60 HPV16+ OPSCC patients, qPCR and ddPCR assays targeting HPV16-E6 were performed. HPV status was confirmed by p16-IHC, PCR for HPV16-E6/L1, and viral load analysis in tumor tissue. ddPCR showed higher sensitivity and specificity (>80%) and correlated strongly with qPCR results (p < 0.001). HPV16-E6 ctDNA levels were significantly associated with tumor stage and tumor volume (p < 0.05). Importantly, viral load in the primary tumor significantly correlated with ctDNA copy number in plasma. In several patients, HPV16-E6 ctDNA was detectable months before clinically or radiologically confirmed recurrence.</p>\n\n<p><strong>Discussion: </strong>ddPCR-based quantification of HPV16-E6 ctDNA is a promising biomarker for monitoring treatment response and disease progression in HPV+ OPSCC. Prospective clinical studies are required to validate its utility for routine surveillance.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153800--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S399",
      "content_id": "155518",
      "abstract_number": "S399",
      "poster_number": "",
      "title": "Rapid Clearance of Circulating Tumor DNA is Associated with Improved Survival in HPV Associated Oropharyngeal Squamous Cell Carcinoma",
      "summary": "In this large single-center cohort, rapid clearance of ctHPVDNA was independently associated with improved disease-free survival across treatment modalities. CtHPVDNA kinetics may represent an early, dynamic biomarker of treatment response that could identify patients with favorable disease suitable for treatment de-escalation, as well as those with delayed clearance who may benefit from treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155518",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jack Birkenbeuel",
      "presenter": "Jack Birkenbeuel",
      "authors": "Jack Birkenbeuel ; Amy Lin; Katherina Brown; Lauren Miller; Enver Ozer; Amit Agrawal; Kyle VanKoevering; Nolan Seim; Sujith Baliga; Emile Gogineni; Dukagjin Blakaj; Priyanka Bhateja; Marcelo Bonomi; Stephen Kang; James Rocco; Catherine Haring",
      "normalized_authors": [
        "Jack Birkenbeuel",
        "Amy Lin",
        "Katherina Brown",
        "Lauren Miller",
        "Enver Ozer",
        "Amit Agrawal",
        "Kyle VanKoevering",
        "Nolan Seim",
        "Sujith Baliga",
        "Emile Gogineni",
        "Dukagjin Blakaj",
        "Priyanka Bhateja",
        "Marcelo Bonomi",
        "Stephen Kang",
        "James Rocco",
        "Catherine Haring"
      ],
      "affiliations": [
        "The Ohio State University"
      ],
      "normalized_institutions": [
        "The Ohio State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 544,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jack Birkenbeuel ; Amy Lin; Katherina Brown; Lauren Miller; Enver Ozer; Amit Agrawal; Kyle VanKoevering; Nolan Seim; Sujith Baliga; Emile Gogineni; Dukagjin Blakaj; Priyanka Bhateja; Marcelo Bonomi; Stephen Kang; James Rocco; Catherine Haring",
        "Affiliations": "The Ohio State University",
        "Background": "Circulating tumor HPV DNA (ctHPVDNA) is increasingly used to assess tumor burden in HPV- associated oropharyngeal squamous cell carcinoma (OPSCC). Prior studies suggest that rapid ctHPVDNA clearance after surgery or chemoradiation (CRT) correlates with disease control; however, low event rates have limited evaluation of survival outcomes. Whether ctHPVDNA clearance kinetics predict oncologic outcomes and inform risk-adapted therapy remains unknown.",
        "Methods": "A single-center retrospective cohort study included patients with HPV associated OPSCC treated between July 2021 and September 2025. Eligible patients had HPV status confirmed by p16 staining and/or high- risk HPV in situ hybridization, pre-treatment ctHPVDNA measured by NavDx assay and underwent curative intent therapy with surgery +/- adjuvant therapy, CRT, or induction chemotherapy followed by CRT. Covariates included age, sex, race, TNM stage, tumor subsite, smoking and alcohol use, comorbidities, and ECOG performance status. Multivariable Cox Regression with backward selection identified factors associated with disease free survival (DFS) and overall survival (OS). Rapid clearance of ctHPVDNA evaluated in the subset with available serial ctHPVDNA testing. Rapid clearance was defined as undetectable ctHPVDNA counts within 10 days after surgery, within 4 weeks of CRT or after induction chemotherapy before CRT.",
        "Results": "A total of 674 patients were included (85.8% male), treated with surgery +/- adjuvant therapy (N=160), CRT (N=454), or induction chemotherapy followed by CRT (N=53). After a median follow-up of 18.5 months, 24-month DFS was 85% and OS was 90% with a recurrence rate of 12.3% (83/674).",
        "Abstract": "In patients with serial ctHPVDNA testing, rapid ctHPVDNA clearance was independently associated with improved DFS on multivariable analysis adjusting for treatment modality, baseline ctHPVDNA level and other covariates (HR 0.38, 95% CI 0.20-0.76, p=0.005). The recurrence rate was 8.3% (13/156) in patients with rapid clearance compared with 17.6% (39/222) in those with delayed clearance. Time to recurrence was also longer in patients with rapid clearance (14.0 ± 12.4 vs 9.3 ± 6.5 months, p=0.05). Rapid ctHPVDNA clearance varied by treatment modality, with patients treated with upfront surgery more likely to experience rapid clearance compared with CRT (66.7% vs 37.8%), but clearance was not associated with TNM stage. The association between rapid clearance and improved DFS remained significant in both surgical and non-surgical cohorts. On multivariable analysis, advanced TNM stage (HR 1.9, 95% CI 1.3–2.7, p=0.002) was associated with poorer DFS, while treatment with CRT compared with surgery (HR 0.27 (95% CI 0.12-0.61), p=0.002) was associated with improved DFS. Factors associated with poorer OS included advanced TNM stage (HR 1.7, 95% CI 1.2–2.3, p<0.001) and ECOG performance status (HR 3.1, 95% CI 2.2–4.4, p<0.001). CtHPVDNA kinetics were not associated with OS. View in Agenda and Add to Schedule",
        "Conclusions": "In this large single-center cohort, rapid clearance of ctHPVDNA was independently associated with improved disease-free survival across treatment modalities. CtHPVDNA kinetics may represent an early, dynamic biomarker of treatment response that could identify patients with favorable disease suitable for treatment de-escalation, as well as those with delayed clearance who may benefit from treatment intensification. These findings support the incorporation of ctHPVDNA dynamics into prospective risk-adapted clinical trials."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rapid Clearance of Circulating Tumor DNA is Associated with Improved Survival in HPV Associated Oropharyngeal Squamous Cell Carcinoma</span>. <u>Jack Birkenbeuel</u>; Amy Lin; Katherina Brown; Lauren Miller; Enver Ozer; Amit Agrawal; Kyle VanKoevering; Nolan Seim; Sujith Baliga; Emile Gogineni; Dukagjin Blakaj; Priyanka Bhateja; Marcelo Bonomi; Stephen Kang; James Rocco; Catherine Haring. The Ohio State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Circulating tumor HPV DNA (ctHPVDNA) is increasingly used to assess tumor burden in HPV- associated oropharyngeal squamous cell carcinoma (OPSCC). Prior studies suggest that rapid ctHPVDNA clearance after surgery or chemoradiation (CRT) correlates with disease control; however, low event rates have limited evaluation of survival outcomes. Whether ctHPVDNA clearance kinetics predict oncologic outcomes and inform risk-adapted therapy remains unknown.</p>\n\n<p><strong>Methods: </strong>A single-center retrospective cohort study included patients with HPV associated OPSCC treated between July 2021 and September 2025. Eligible patients had HPV status confirmed by p16 staining and/or high- risk HPV in situ hybridization, pre-treatment ctHPVDNA measured by NavDx assay and underwent curative intent therapy with surgery +/- adjuvant therapy, CRT, or induction chemotherapy followed by CRT. Covariates included age, sex, race, TNM stage, tumor subsite, smoking and alcohol use, comorbidities, and ECOG performance status. Multivariable Cox Regression with backward selection identified factors associated with disease free survival (DFS) and overall survival (OS). Rapid clearance of ctHPVDNA evaluated in the subset with available serial ctHPVDNA testing. Rapid clearance was defined as undetectable ctHPVDNA counts within 10 days after surgery, within 4 weeks of CRT or after induction chemotherapy before CRT.</p>\n\n<p><strong>Results: </strong>A total of 674 patients were included (85.8% male), treated with surgery +/- adjuvant therapy (N=160), CRT (N=454), or induction chemotherapy followed by CRT (N=53). After a median follow-up of 18.5 months, 24-month DFS was 85% and OS was 90% with a recurrence rate of 12.3% (83/674).</p>\n\n<p>In patients with serial ctHPVDNA testing, rapid ctHPVDNA clearance was independently associated with improved DFS on multivariable analysis adjusting for treatment modality, baseline ctHPVDNA level and other covariates (HR 0.38, 95% CI 0.20-0.76, p=0.005). The recurrence rate was 8.3% (13/156) in patients with rapid clearance compared with 17.6% (39/222) in those with delayed clearance. Time to recurrence was also longer in patients with rapid clearance (14.0 ± 12.4 vs 9.3 ± 6.5 months, p=0.05). Rapid ctHPVDNA clearance varied by treatment modality, with patients treated with upfront surgery more likely to experience rapid clearance compared with CRT (66.7% vs 37.8%), but clearance was not associated with TNM stage. The association between rapid clearance and improved DFS remained significant in both surgical and non-surgical cohorts.</p>\n\n<p>On multivariable analysis, advanced TNM stage (HR 1.9, 95% CI 1.3–2.7, p=0.002) was associated with poorer DFS, while treatment with CRT compared with surgery (HR 0.27 (95% CI 0.12-0.61), p=0.002) was associated with improved DFS. Factors associated with poorer OS included advanced TNM stage (HR 1.7, 95% CI 1.2–2.3, p<0.001) and ECOG performance status (HR 3.1, 95% CI 2.2–4.4, p<0.001). CtHPVDNA kinetics were not associated with OS.</p>\n\n<p><strong>Conclusions: </strong>In this large single-center cohort, rapid clearance of ctHPVDNA was independently associated with improved disease-free survival across treatment modalities. CtHPVDNA kinetics may represent an early, dynamic biomarker of treatment response that could identify patients with favorable disease suitable for treatment de-escalation, as well as those with delayed clearance who may benefit from treatment intensification. These findings support the incorporation of ctHPVDNA dynamics into prospective risk-adapted clinical trials.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155518--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S400",
      "content_id": "152354",
      "abstract_number": "S400",
      "poster_number": "",
      "title": "Loss of HPV 16 E7 expression, recurrence, and poor survival in oropharyngeal cancer: a preliminary primary vs recurrent tumor investigation",
      "summary": "All 14 patients were male, age 65±9 years, and average survival duration following recurrence was 1.7±1.3 years. All patients received initial treatment of CXRT. 4 patient received surgery as part of the initial treatment, with 3 occurring prior to CXRT. 64% were white, 36% were black, and 86% were non-Hispanic. A significant difference in survival was observed between patients with and without recurrence...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152354",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Janice J Chung, MD",
      "presenter": "Janice J Chung, MD",
      "authors": "Janice J Chung, MD 1 ; Saroj K Basak, PhD 2 ; Bhavani S Gowda 2 ; Manasvini Kala 2 ; Jin Zhong, MD, PhD 3 ; Eri S Srivatsan, PhD 4 ; Marilene B Wang, MD 5",
      "normalized_authors": [
        "Janice J Chung",
        "Saroj K Basak",
        "Bhavani S Gowda",
        "Manasvini Kala",
        "Jin Zhong",
        "Eri S Srivatsan",
        "Marilene B Wang"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA",
        "Department of Surgery, VAGLAHS, Los Angeles, CA",
        "Department of Pathology, VAGLAHS, Los Angeles, CA",
        "Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA",
        "Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA",
        "Department of Surgery, VAGLAHS, Los Angeles, CA",
        "Department of Pathology, VAGLAHS, Los Angeles, CA",
        "Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA",
        "Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Method",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Janice J Chung, MD 1 ; Saroj K Basak, PhD 2 ; Bhavani S Gowda 2 ; Manasvini Kala 2 ; Jin Zhong, MD, PhD 3 ; Eri S Srivatsan, PhD 4 ; Marilene B Wang, MD 5",
        "Affiliations": "1 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; 2 Department of Surgery, VAGLAHS, Los Angeles, CA; 3 Department of Pathology, VAGLAHS, Los Angeles, CA; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA; 4 Department of Surgery, VAGLAHS, Los Angeles, CA; Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; 5 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Surgery, VAGLAHS, Los Angeles, CA",
        "Background": "Recurrences in p16+ oropharyngeal cancer (OPC) have been associated with poorer survival. As such, prognostic evaluation of OPC recurrence has been of interest, particularly with regards to clinical and radiologic metrics. Our group previously demonstrated that tumor suppressor gigaxonin expression is associated with a decreased risk of aggressive tumor growth. In association with p16, gigaxonin ubiquitinates and thereby downregulates the pro-tumorigenic NFκB pathway.",
        "Objective": "We hypothesized that decreased gigaxonin expression and elevated NFκB levels would correlate with p16+ OPC recurrence, thereby providing an additional dimension to our ability to identify patients at elevated risk of recurrence.",
        "Method": "In this retrospective, single-institution study conducted at Veterans Affairs Greater Los Angeles Hospital System (VAGLAHS) Medical Center, tumor samples were obtained with Institutional Review Board approval. A database of 612 cancer patients treated at VAGLAHS between the years 2007 and 2024 were screened. 116 patients had OPC, 60 of which were p16+. 14 of the p16+ patients had a recurrence. Nine had FFPE specimen from both primary and recurrent tumors. HPV 16 E7, gigaxonin, NFκB, and a panel of head and neck cancer-associated biomarkers were analyzed in the primary and recurrent cancer samples.",
        "Results": "All 14 patients were male, age 65±9 years, and average survival duration following recurrence was 1.7±1.3 years. All patients received initial treatment of CXRT. 4 patient received surgery as part of the initial treatment, with 3 occurring prior to CXRT. 64% were white, 36% were black, and 86% were non-Hispanic. A significant difference in survival was observed between patients with and without recurrence (p=0.017). Loss of HPV 16 E7 expression was observed in 66.6% of patients with poorer survival following recurrence, defined as <3 years. There was no significant correlation between survival and age, nor between HPV 16 E7 and gigaxonin expression. There was no statistically significant difference in gigaxonin and NFκB expressions in primary and recurrent specimen (t-Test, p=0.426 and p=0.174, respectively). Notably, however, gigaxonin and NFκB expression levels demonstrated a statistically significant inverse correlation (R=0.894, R-square=0.800, p=0.016).",
        "Discussion": "Our results demonstrated an inverse relationship between gigaxonin and NFκB expression levels when compared across primary and recurrent specimens. The majority of primary tumors that resulted in recurrence and the recurrent tumors that resulted in poorer survival were found to have loss of HPV 16 E7 expression. While limited due to small sample size, there may be an inverse relationship between gigaxonin and HPV 16 E7 expression levels when compared across primary and recurrent specimens. While preliminary, to our knowledge, this study is the first to suggest a mechanistic role of HPV 16 E7 in the recurrence and poorer survival of patients with HPV positive oropharyngeal cancer. This highlights the potential value of HPV 16 E7 expression in the management of HPV positive oropharyngeal cancer. Future studies will benefit from greater sample size to determine the prognostic significance of the HPV 16 E7, p16, gigaxonin, and NFκB expression in OPC recurrence and subsequent survival.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Loss of HPV 16 E7 expression, recurrence, and poor survival in oropharyngeal cancer: a preliminary primary vs recurrent tumor investigation</span>. <u>Janice J Chung, MD</u><sup>1</sup>; Saroj K Basak, PhD<sup>2</sup>; Bhavani S Gowda<sup>2</sup>; Manasvini Kala<sup>2</sup>; Jin Zhong, MD, PhD<sup>3</sup>; Eri S Srivatsan, PhD<sup>4</sup>; Marilene B Wang, MD<sup>5</sup>. <sup>1</sup>Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; <sup>2</sup>Department of Surgery, VAGLAHS, Los Angeles, CA; <sup>3</sup>Department of Pathology, VAGLAHS, Los Angeles, CA; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA; <sup>4</sup>Department of Surgery, VAGLAHS, Los Angeles, CA; Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; <sup>5</sup>Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Surgery, VAGLAHS, Los Angeles, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Recurrences in p16+ oropharyngeal cancer (OPC) have been associated with poorer survival. As such, prognostic evaluation of OPC recurrence has been of interest, particularly with regards to clinical and radiologic metrics. Our group previously demonstrated that tumor suppressor gigaxonin expression is associated with a decreased risk of aggressive tumor growth. In association with p16, gigaxonin ubiquitinates and thereby downregulates the pro-tumorigenic NFκB pathway.</p>\n\n<p><strong>Objective: </strong>We hypothesized that decreased gigaxonin expression and elevated NFκB levels would correlate with p16+ OPC recurrence, thereby providing an additional dimension to our ability to identify patients at elevated risk of recurrence.</p>\n\n<p><strong>Method: </strong>In this retrospective, single-institution study conducted at Veterans Affairs Greater Los Angeles Hospital System (VAGLAHS) Medical Center, tumor samples were obtained with Institutional Review Board approval. A database of 612 cancer patients treated at VAGLAHS between the years 2007 and 2024 were screened. 116 patients had OPC, 60 of which were p16+. 14 of the p16+ patients had a recurrence. Nine had FFPE specimen from both primary and recurrent tumors. HPV 16 E7, gigaxonin, NFκB, and a panel of head and neck cancer-associated biomarkers were analyzed in the primary and recurrent cancer samples.</p>\n\n<p><strong>Results: </strong>All 14 patients were male, age 65±9 years, and average survival duration following recurrence was 1.7±1.3 years. All patients received initial treatment of CXRT. 4 patient received surgery as part of the initial treatment, with 3 occurring prior to CXRT. 64% were white, 36% were black, and 86% were non-Hispanic. A significant difference in survival was observed between patients with and without recurrence (p=0.017). Loss of HPV 16 E7 expression was observed in 66.6% of patients with poorer survival following recurrence, defined as <3 years. There was no significant correlation between survival and age, nor between HPV 16 E7 and gigaxonin expression. There was no statistically significant difference in gigaxonin and NFκB expressions in primary and recurrent specimen (t-Test, p=0.426 and p=0.174, respectively). Notably, however, gigaxonin and NFκB expression levels demonstrated a statistically significant inverse correlation (R=0.894, R-square=0.800, p=0.016).</p>\n\n<p><strong>Discussion: </strong>Our results demonstrated an inverse relationship between gigaxonin and NFκB expression levels when compared across primary and recurrent specimens. The majority of primary tumors that resulted in recurrence and the recurrent tumors that resulted in poorer survival were found to have loss of HPV 16 E7 expression. While limited due to small sample size, there may be an inverse relationship between gigaxonin and HPV 16 E7 expression levels when compared across primary and recurrent specimens. While preliminary, to our knowledge, this study is the first to suggest a mechanistic role of HPV 16 E7 in the recurrence and poorer survival of patients with HPV positive oropharyngeal cancer. This highlights the potential value of HPV 16 E7 expression in the management of HPV positive oropharyngeal cancer. Future studies will benefit from greater sample size to determine the prognostic significance of the HPV 16 E7, p16, gigaxonin, and NFκB expression in OPC recurrence and subsequent survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152354--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S401",
      "content_id": "153701",
      "abstract_number": "S401",
      "poster_number": "",
      "title": "Modeling the effective sensitivity of HPV-DeepSeek",
      "summary": "We developed an approach to measure ctHPVDNA assay sensitivity and applied this to an ultrasensitive HPV WGS liquid biopsy, HPV-DeepSeek finding an estimated LOD of 0.13 PPM in 38 test samples which is lower than existing liquid biopsy approaches at market. This superior performance is present in high HPV to human copy number cells and is highly dependent on this ratio.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153701",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dipon Das, PhD",
      "presenter": "Dipon Das, PhD",
      "authors": "Dipon Das, PhD 1 ; Samuli Eldfors, PhD 1 ; Qin Wang, PhD 1 ; Gjystina Lumaj, MS 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Lori J Wirth, MD 2 ; Jarrod W Stein 1 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen L Feng 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
      "normalized_authors": [
        "Dipon Das",
        "Samuli Eldfors",
        "Qin Wang",
        "Gjystina Lumaj",
        "Jonathan J Paly",
        "Ross D Merkin",
        "Lori J Wirth",
        "Jarrod W Stein",
        "Manisha J Patel",
        "Jong C Park",
        "Annie Chan",
        "Chirayu Patel",
        "Allen L Feng",
        "Daniel G Deschler",
        "Jeremy D Richmon",
        "Derrick T Lin",
        "William C Faquin",
        "Peter M Sadow",
        "Bayan A Alzumaili",
        "Thomas J Roberts",
        "Adam S Fisch",
        "Daniel L Faden"
      ],
      "affiliations": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "normalized_institutions": [
        "Massachusetts Eye & Ear",
        "Massachusetts General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "Table 1",
          "rows": [
            [
              "",
              "",
              "Detection threshold range (PPM)"
            ],
            [
              "Assay Name",
              "Developer",
              "Limit of Detection (LOD)"
            ],
            [
              "FoundationOne Liquid CDx",
              "Foundation Medicine",
              "4000"
            ],
            [
              "Signatera",
              "Natera",
              "100"
            ],
            [
              "Guardant Reveal",
              "Guardant Health",
              "50"
            ],
            [
              "RaDaR",
              "NeoGenomics",
              "10"
            ],
            [
              "NeXT Personal",
              "Personalis",
              "1.5"
            ],
            [
              "HPV-DeepSeek",
              "Faden Lab",
              "0.1"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 433,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Dipon Das, PhD 1 ; Samuli Eldfors, PhD 1 ; Qin Wang, PhD 1 ; Gjystina Lumaj, MS 1 ; Jonathan J Paly, DO 2 ; Ross D Merkin, MD 2 ; Lori J Wirth, MD 2 ; Jarrod W Stein 1 ; Manisha J Patel, MD 2 ; Jong C Park, MD 2 ; Annie Chan, MD 2 ; Chirayu Patel, MD 2 ; Allen L Feng 1 ; Daniel G Deschler, MD 1 ; Jeremy D Richmon, MD 1 ; Derrick T Lin, MD 1 ; William C Faquin, MD, PhD 2 ; Peter M Sadow, MD, PhD 2 ; Bayan A Alzumaili, MD 2 ; Thomas J Roberts, MD, MBA 2 ; Adam S Fisch, MD, PhD 2 ; Daniel L Faden, MD 1",
        "Affiliations": "1 Massachusetts Eye & Ear; 2 Massachusetts General Hospital",
        "Introduction": "We developed an ultrasensitive HPV whole-genome sequencing (WGS) liquid biopsy, HPV-DeepSeek, for improved detection of low-level circulating human papillomavirus DNA (ctHPVDNA). HPV-DeepSeek demonstrates superior sensitivity, specificity, and diagnostic accuracy compared to existing HPV liquid biopsy approaches. However, comparison to HPV-agnostic approaches, including both commonly utilized and emerging human tumor-informed liquid biopsies, is challenging due to the detection of different types of analytes (ctHPVDNA vs mutated ctDNA). Here, we develop an approach to quantify ctHPVDNA detection levels in parts per million (PPM), the unit commonly used for various liquid biopsies and compare HPV-DeepSeek sensitivity to commercially available tumor-informed liquid biopsy approaches.",
        "Methods": "To calculate the PPM for HPV-DeepSeek, we derived a tumor-adjusted metric to quantify ctHPVDNA in plasma relative to the HPV burden using paired plasma and tissue samples from 38 pre-treatment HPV+HNC patients. HPV genomes copy number in tumor cells varies from one to several thousand; therefore, similar ctHPVDNA counts in plasma can correspond to widely different tumor burdens. To address this, we calculated HPV copy number in tissue samples and used this value to normalize plasma HPV signal. This metric reports HPV parts per million in plasma after correcting tumor purity in the tissue biopsy, referred to as the tumor-adjusted HPV PPM: HPV: GAPDH depth ratio divided by HPV copies per tumor cell in the tissue, then multiplied by 10^6. To model assay performance at its detection threshold, we each sample was downsampled to the assay’s limit of detection, while keeping the plasma GAPDH depth, tumor fraction, and HPV copies per tumor cell unchanged. This approach normalizes tumor burden and estimates the expected PPM signal at the lowest detectable level. We compared HPV-DeepSeek's PPM metrics with those of existing published liquid biopsies.",
        "Results": "The calculated HPV to human genome ratio ranged from 0.0014 - 35.3672 with a median of 0.3252. HPV-DeepSeek had a PPM range of 54.5 to 3.1×10^8 PPM (median 7590 PPM) when tested on 38 pre-treatment plasma samples. In analytical downsampling, the estimated detection limit was 0.13 PPM (range 0.13–1.4×10 ^5 PPM; median 7.2 PPM). We then compared this metric among key commercially available liquid biopsies (Table 1).",
        "Conclusion": "We developed an approach to measure ctHPVDNA assay sensitivity and applied this to an ultrasensitive HPV WGS liquid biopsy, HPV-DeepSeek finding an estimated LOD of 0.13 PPM in 38 test samples which is lower than existing liquid biopsy approaches at market. This superior performance is present in high HPV to human copy number cells and is highly dependent on this ratio.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Modeling the effective sensitivity of HPV-DeepSeek</span>. <u>Dipon Das, PhD</u><sup>1</sup>; Samuli Eldfors, PhD<sup>1</sup>; Qin Wang, PhD<sup>1</sup>; Gjystina Lumaj, MS<sup>1</sup>; Jonathan J Paly, DO<sup>2</sup>; Ross D Merkin, MD<sup>2</sup>; Lori J Wirth, MD<sup>2</sup>; Jarrod W Stein<sup>1</sup>; Manisha J Patel, MD<sup>2</sup>; Jong C Park, MD<sup>2</sup>; Annie Chan, MD<sup>2</sup>; Chirayu Patel, MD<sup>2</sup>; Allen L Feng<sup>1</sup>; Daniel G Deschler, MD<sup>1</sup>; Jeremy D Richmon, MD<sup>1</sup>; Derrick T Lin, MD<sup>1</sup>; William C Faquin, MD, PhD<sup>2</sup>; Peter M Sadow, MD, PhD<sup>2</sup>; Bayan A Alzumaili, MD<sup>2</sup>; Thomas J Roberts, MD, MBA<sup>2</sup>; Adam S Fisch, MD, PhD<sup>2</sup>; Daniel L Faden, MD<sup>1</sup>. <sup>1</sup>Massachusetts Eye & Ear; <sup>2</sup>Massachusetts General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>We developed an ultrasensitive HPV whole-genome sequencing (WGS) liquid biopsy, HPV-DeepSeek, for improved detection of low-level circulating human papillomavirus DNA (ctHPVDNA). HPV-DeepSeek demonstrates superior sensitivity, specificity, and diagnostic accuracy compared to existing HPV liquid biopsy approaches. However, comparison to HPV-agnostic approaches, including both commonly utilized and emerging human tumor-informed liquid biopsies, is challenging due to the detection of different types of analytes (ctHPVDNA vs mutated ctDNA). Here, we develop an approach to quantify ctHPVDNA detection levels in parts per million (PPM), the unit commonly used for various liquid biopsies and compare HPV-DeepSeek sensitivity to commercially available tumor-informed liquid biopsy approaches.</p>\n\n<p><strong>Methods: </strong>To calculate the PPM for HPV-DeepSeek, we derived a tumor-adjusted metric to quantify ctHPVDNA in plasma relative to the HPV burden using paired plasma and tissue samples from 38 pre-treatment HPV+HNC patients. HPV genomes copy number in tumor cells varies from one to several thousand; therefore, similar ctHPVDNA counts in plasma can correspond to widely different tumor burdens. To address this, we calculated HPV copy number in tissue samples and used this value to normalize plasma HPV signal. This metric reports HPV parts per million in plasma after correcting tumor purity in the tissue biopsy, referred to as the tumor-adjusted HPV PPM: HPV: GAPDH depth ratio divided by HPV copies per tumor cell in the tissue, then multiplied by 10^6. To model assay performance at its detection threshold, we each sample was downsampled to the assay’s limit of detection, while keeping the plasma GAPDH depth, tumor fraction, and HPV copies per tumor cell unchanged. This approach normalizes tumor burden and estimates the expected PPM signal at the lowest detectable level. We compared HPV-DeepSeek's PPM metrics with those of existing published liquid biopsies.</p>\n\n<p><strong>Results: </strong>The calculated HPV to human genome ratio ranged from 0.0014 - 35.3672 with a median of 0.3252. HPV-DeepSeek had a PPM range of 54.5 to 3.1×10^8 PPM (median 7590 PPM) when tested on 38 pre-treatment plasma samples. In analytical downsampling, the estimated detection limit was 0.13 PPM (range 0.13–1.4×10 ^5 PPM; median 7.2 PPM). We then compared this metric among key commercially available liquid biopsies (Table 1).</p>\n\n<p><strong>Table 1. Comparison of key commercial liquid biopsies</strong></p>\n\n<table border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td> </td>\n\t\t\t<td> </td>\n\t\t\t<td><strong>Detection threshold range (PPM)</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Assay Name</strong></td>\n\t\t\t<td><strong>Developer</strong></td>\n\t\t\t<td><strong>Limit of Detection (LOD)</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>FoundationOne Liquid CDx</td>\n\t\t\t<td>Foundation Medicine</td>\n\t\t\t<td>4000</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Signatera</td>\n\t\t\t<td>Natera</td>\n\t\t\t<td>100</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Guardant Reveal</td>\n\t\t\t<td>Guardant Health</td>\n\t\t\t<td>50</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>RaDaR</td>\n\t\t\t<td>NeoGenomics</td>\n\t\t\t<td>10</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>NeXT Personal</td>\n\t\t\t<td>Personalis</td>\n\t\t\t<td>1.5</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>HPV-DeepSeek</td>\n\t\t\t<td>Faden Lab</td>\n\t\t\t<td>0.1</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Conclusion: </strong>We developed an approach to measure ctHPVDNA assay sensitivity and applied this to an ultrasensitive HPV WGS liquid biopsy, HPV-DeepSeek finding an estimated LOD of 0.13 PPM in 38 test samples which is lower than existing liquid biopsy approaches at market. This superior performance is present in high HPV to human copy number cells and is highly dependent on this ratio.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153701--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S402",
      "content_id": "146887",
      "abstract_number": "S402",
      "poster_number": "",
      "title": "Transoral Resection and Circulating Tumor DNA Monitoring in HPV-Related Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Transoral resection with ctDNA surveillance was feasible and correlated with disease burden. CtDNA clearance may serve as a biomarker for treatment response in HPV-related OPSCC. CtDNA markers as early as 2 weeks postoperatively can demonstrate ctDNA clearance, although it is unknown if this represents true disease clearance.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146887",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chase Hintelmann",
      "presenter": "Chase Hintelmann",
      "authors": "Chase Hintelmann 1 ; Audrey Abend, MD 2 ; Matin Imanguli, MD 3 ; Danielle Tang, BA 4 ; Nicole Casper, DPN 1 ; Lady Quintero Urego, MA 1 ; Nicole Caltabellotta 4 ; Dylan Roden, MD 5",
      "normalized_authors": [
        "Chase Hintelmann",
        "Audrey Abend",
        "Matin Imanguli",
        "Danielle Tang",
        "Nicole Casper, DPN",
        "Lady Quintero Urego, MA",
        "Nicole Caltabellotta",
        "Dylan Roden"
      ],
      "affiliations": [
        "Rutgers Robert Wood Johnson Medical School",
        "Duke University School of Medicine",
        "Hackensack Meridian Health",
        "Cancer Institute of New Jersey, Rutgers",
        "Rutgers New Jersey Medical School"
      ],
      "normalized_institutions": [
        "Rutgers Robert Wood Johnson Medical School",
        "Duke University School of Medicine",
        "Hackensack Meridian Health",
        "Cancer Institute of New Jersey, Rutgers",
        "Rutgers New Jersey Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chase Hintelmann 1 ; Audrey Abend, MD 2 ; Matin Imanguli, MD 3 ; Danielle Tang, BA 4 ; Nicole Casper, DPN 1 ; Lady Quintero Urego, MA 1 ; Nicole Caltabellotta 4 ; Dylan Roden, MD 5",
        "Affiliations": "1 Rutgers Robert Wood Johnson Medical School; 2 Duke University School of Medicine; 3 Hackensack Meridian Health; 4 Cancer Institute of New Jersey, Rutgers; 5 Rutgers New Jersey Medical School",
        "Background": "This study evaluated circulating tumor DNA (ctDNA) clearance kinetics in an upfront surgically treated patient population with HPV-related oropharyngeal squamous cell carcinoma (OPSCC).",
        "Methods": "Patients with OPSCC underwent transoral resection with selective neck dissection. Adjuvant therapy was administered per NCCN guidelines. ctDNA levels were measured preoperatively and postoperatively at weeks 2, 4, 10, 24, and 52.",
        "Results": "18 patients were enrolled in the study after presenting to the office with OPSCC. The mean age at surgery was 64.9 years (range: 51–78, SD: 7.5). Most had T1–T2 disease (T0: 1, T1:10, T2:6, T3:1) and N1 disease (N0:1, N1:15, N2:2), with no distant metastases (M0 in all cases). The overall stage was predominantly early (I:15, II: 3). The primary tumor site was most commonly the base of tongue (61.1%) followed by the tonsil (33.3%). Two patients had a primary tumor site of both the base of tongue and the tonsil. Tumor size varied (median: 17 mm, range: 9–44 mm). The largest lymph node (LN) measured 70 mm, with median largest LN size of 36 mm. Extracapsular nodal extension (ENE) was present in 5.6% of patients, and 27.8% had positive surgical margins. 2 patients had positive perineural invasion (11.1%) while 3 patients had lymphovascular space invasion (16.7%). 15 patients received radiation therapy (83.3%) and 9 underwent chemotherapy (50%). 3 patients (16.7%) required enteral feeding tubes postoperatively, while none required tracheostomy. At the 4-week time point, 1 patient rescinded their consent for inclusion in the study, therefore all ctDNA data reported is based on a sample size of 17. Baseline ctDNA was detectable in 12 patients (70.6%), 3 patients had no ctDNA detected at baseline (17.6%), 1 patient lacked a sample (5.8%), and 1 patient had an indeterminate test (5.8%). The median and mean level of ctDNA copies at baseline were 92 copies/mL and 5719.5 copies/mL, respectively (range: 0–81,991). All patients with positive baseline levels of ctDNA were noted to be HPV16+. Median ctDNA level for stage 1 tumors was 73 and for stage 2 was 40995.5. By 2 weeks postoperatively, 75% (9/12) of patients had ctDNA clearance. By week 10, 83.3% (10/12) had confirmed ctDNA clearance. 2 patients with a baseline ctDNA of 0 had a lack of samples, 1 following their baseline measurement and the other following their week 4 measurement. Only 1 patient could not clear their ctDNA load by 52 weeks post-surgery, and this patient was found to have recurrent cancer. The average patient length of follow-up was 27±8.4 months, with most patients continuing to follow-up to this day.",
        "Conclusion": "Transoral resection with ctDNA surveillance was feasible and correlated with disease burden. CtDNA clearance may serve as a biomarker for treatment response in HPV-related OPSCC. CtDNA markers as early as 2 weeks postoperatively can demonstrate ctDNA clearance, although it is unknown if this represents true disease clearance.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transoral Resection and Circulating Tumor DNA Monitoring in HPV-Related Oropharyngeal Squamous Cell Carcinoma</span>. <u>Chase Hintelmann</u><sup>1</sup>; Audrey Abend, MD<sup>2</sup>; Matin Imanguli, MD<sup>3</sup>; Danielle Tang, BA<sup>4</sup>; Nicole Casper, DPN<sup>1</sup>; Lady Quintero Urego, MA<sup>1</sup>; Nicole Caltabellotta<sup>4</sup>; Dylan Roden, MD<sup>5</sup>. <sup>1</sup>Rutgers Robert Wood Johnson Medical School; <sup>2</sup>Duke University School of Medicine; <sup>3</sup>Hackensack Meridian Health; <sup>4</sup>Cancer Institute of New Jersey, Rutgers; <sup>5</sup>Rutgers New Jersey Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>This study evaluated circulating tumor DNA (ctDNA) clearance kinetics in an upfront surgically treated patient population with HPV-related oropharyngeal squamous cell carcinoma (OPSCC). </p>\n\n<p><strong>Methods: </strong>Patients with OPSCC underwent transoral resection with selective neck dissection. Adjuvant therapy was administered per NCCN guidelines. ctDNA levels were measured preoperatively and postoperatively at weeks 2, 4, 10, 24, and 52. </p>\n\n<p><strong>Results: </strong>18 patients were enrolled in the study after presenting to the office with OPSCC. The mean age at surgery was 64.9 years (range: 51–78, SD: 7.5). Most had T1–T2 disease (T0: 1, T1:10, T2:6, T3:1) and N1 disease (N0:1, N1:15, N2:2), with no distant metastases (M0 in all cases). The overall stage was predominantly early (I:15, II: 3). The primary tumor site was most commonly the base of tongue (61.1%) followed by the tonsil (33.3%). Two patients had a primary tumor site of both the base of tongue and the tonsil. Tumor size varied (median: 17 mm, range: 9–44 mm). The largest lymph node (LN) measured 70 mm, with median largest LN size of 36 mm. Extracapsular nodal extension (ENE) was present in 5.6% of patients, and 27.8% had positive surgical margins. 2 patients had positive perineural invasion (11.1%) while 3 patients had lymphovascular space invasion (16.7%). 15 patients received radiation therapy (83.3%) and 9 underwent chemotherapy (50%). 3 patients (16.7%) required enteral feeding tubes postoperatively, while none required tracheostomy. At the 4-week time point, 1 patient rescinded their consent for inclusion in the study, therefore all ctDNA data reported is based on a sample size of 17. Baseline ctDNA was detectable in 12 patients (70.6%), 3 patients had no ctDNA detected at baseline (17.6%), 1 patient lacked a sample (5.8%), and 1 patient had an indeterminate test (5.8%). The median and mean level of ctDNA copies at baseline were 92 copies/mL and 5719.5 copies/mL, respectively (range: 0–81,991). All patients with positive baseline levels of ctDNA were noted to be HPV16+. Median ctDNA level for stage 1 tumors was 73 and for stage 2 was 40995.5. By 2 weeks postoperatively, 75% (9/12) of patients had ctDNA clearance. By week 10, 83.3% (10/12) had confirmed ctDNA clearance. 2 patients with a baseline ctDNA of 0 had a lack of samples, 1 following their baseline measurement and the other following their week 4 measurement. Only 1 patient could not clear their ctDNA load by 52 weeks post-surgery, and this patient was found to have recurrent cancer. The average patient length of follow-up was 27±8.4 months, with most patients continuing to follow-up to this day. </p>\n\n<p><strong>Conclusion: </strong>Transoral resection with ctDNA surveillance was feasible and correlated with disease burden. CtDNA clearance may serve as a biomarker for treatment response in HPV-related OPSCC. CtDNA markers as early as 2 weeks postoperatively can demonstrate ctDNA clearance, although it is unknown if this represents true disease clearance. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146887--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S403",
      "content_id": "154280",
      "abstract_number": "S403",
      "poster_number": "",
      "title": "QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Head and Neck tumors",
      "summary": "The QUILT-3.100 trial successfully enrolled participants to determine the MTD (5e11 VP/dose) for IBRX-042 in participants with HPV-associated solid tumors, including head and neck. The safety profile for this HPV-directed cancer vaccine was well tolerated with no DLTs and future clinical studies in combination with other immune-activating therapies are planned.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154280",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chaitali Nangia",
      "presenter": "Chaitali Nangia",
      "authors": "Sarina Piha-Paul, MD 1 ; Chaitali Nangia 2 ; Leylah Drusbosky, PhD 3 ; Elizabeth Gabitzsch 3 ; Lennie Sender, MD 3 ; Sandeep Reddy, MD 3 ; Patrick Soon-Shiong, MD 3",
      "normalized_authors": [
        "Sarina Piha-Paul",
        "Chaitali Nangia",
        "Leylah Drusbosky",
        "Elizabeth Gabitzsch",
        "Lennie Sender",
        "Sandeep Reddy",
        "Patrick Soon-Shiong"
      ],
      "affiliations": [
        "M.D. Anderson Cancer Center",
        "Chan Soon-Shiong Institute for Medicine",
        "ImmunityBio, Inc"
      ],
      "normalized_institutions": [
        "M.D. Anderson Cancer Center",
        "Chan Soon-Shiong Institute for Medicine",
        "ImmunityBio, Inc"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 443,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sarina Piha-Paul, MD 1 ; Chaitali Nangia 2 ; Leylah Drusbosky, PhD 3 ; Elizabeth Gabitzsch 3 ; Lennie Sender, MD 3 ; Sandeep Reddy, MD 3 ; Patrick Soon-Shiong, MD 3",
        "Affiliations": "1 M.D. Anderson Cancer Center; 2 Chan Soon-Shiong Institute for Medicine; 3 ImmunityBio, Inc",
        "Background": "Infection with human papilloma virus (HPV) confers a risk of subsequent malignancy. While prophylactic vaccines against HPV are available, there is a need for a therapeutic vaccine that effectively treats HPV-associated cancers. IBRX-042 is a recombinant non-replicating human adenovirus serotype 5 (hAd5) vector that has been modified by removal of early 1 (E1), E2b, and E3 gene regions and insertion of non-oncogenic HPV 16 early gene 6 (E6) and early gene 7 (E7). Importantly, the hAd5 recombinant vector replicates episomally and doesn’t insert its genome into the host cell, thereby ensuring that there is no gene integration and the virus maintains independent antigen production.",
        "Methods": "QUILT-3.100 (NCT05976828) is a phase 1, open-label study to evaluate the safety and maximum tolerated dose (MTD) of IBRX-042 in participants with HPV-associated solid tumors. Two dose levels were tested in this study: Cohort (C) 1 received 1e11 virus particles (VP)/dose (n=3); C2 received 5e11 VP/dose (n=7). Primary endpoint was MTD, secondary endpoints included safety, serum antibody titers, and peripheral blood T-cell responses. Key inclusion criteria included participants with histologically confirmed HPV- or p16-positive carcinoma who have received at least one standard of care therapy per NCCN guidelines. Administration of IBRX-042 was via subcutaneous injection in the arm at weeks 1, 4, and 7.",
        "Results": "The safety population enrolled 10 participants with HPV-positive solid tumors; nine participants had a head and neck tumor, including tongue, tonsils, and tonsils + lymph nodes. The median age was 65.5 years and 80% were male. Seventy percent of participants had baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0; 30% had ECOG of 1. All participants experienced at least one treatment-related adverse event (TRAE) which were limited to grade 1 or grade 2 events. TRAEs generally included administration site reactions (pain, erythema, swelling) and musculoskeletal disorders (myalgia). Serious adverse events (SAEs) were observed in 30% of participants: one participant in C1 experienced disease progression; two participants in C2 experienced overlapping SAEs including hemoptysis, pleural effusion, respiratory failure, atrial fibrillation, and/or hypertension. All SAEs were considered unrelated. No dose limiting toxicities (DLTs) were observed. MTD was determined to be 5e11 VP/dose. Five participants were contacted for survival status and 4/5 participants were alive at the time of this report. The expired patient was treated on C1.",
        "Conclusion": "The QUILT-3.100 trial successfully enrolled participants to determine the MTD (5e11 VP/dose) for IBRX-042 in participants with HPV-associated solid tumors, including head and neck. The safety profile for this HPV-directed cancer vaccine was well tolerated with no DLTs and future clinical studies in combination with other immune-activating therapies are planned.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Head and Neck tumors</span>. Sarina Piha-Paul, MD<sup>1</sup>; <u>Chaitali Nangia</u><sup>2</sup>; Leylah Drusbosky, PhD<sup>3</sup>; Elizabeth Gabitzsch<sup>3</sup>; Lennie Sender, MD<sup>3</sup>; Sandeep Reddy, MD<sup>3</sup>; Patrick Soon-Shiong, MD<sup>3</sup>. <sup>1</sup>M.D. Anderson Cancer Center; <sup>2</sup>Chan Soon-Shiong Institute for Medicine; <sup>3</sup>ImmunityBio, Inc.<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Infection with human papilloma virus (HPV) confers a risk of subsequent malignancy. While prophylactic vaccines against HPV are available, there is a need for a therapeutic vaccine that effectively treats HPV-associated cancers. IBRX-042 is a recombinant non-replicating human adenovirus serotype 5 (hAd5) vector that has been modified by removal of early 1 (E1), E2b, and E3 gene regions and insertion of non-oncogenic HPV 16 early gene 6 (E6) and early gene 7 (E7). Importantly, the hAd5 recombinant vector replicates episomally and doesn’t insert its genome into the host cell, thereby ensuring that there is no gene integration and the virus maintains independent antigen production.</p>\n\n<p><strong>Methods: </strong>QUILT-3.100 (NCT05976828) is a phase 1, open-label study to evaluate the safety and maximum tolerated dose (MTD) of IBRX-042 in participants with HPV-associated solid tumors. Two dose levels were tested in this study: Cohort (C) 1 received 1e11 virus particles (VP)/dose (n=3); C2 received 5e11 VP/dose (n=7). Primary endpoint was MTD, secondary endpoints included safety, serum antibody titers, and peripheral blood T-cell responses. Key inclusion criteria included participants with histologically confirmed HPV- or p16-positive carcinoma who have received at least one standard of care therapy per NCCN guidelines. Administration of IBRX-042 was via subcutaneous injection in the arm at weeks 1, 4, and 7.</p>\n\n<p><strong>Results: </strong>The safety population enrolled 10 participants with HPV-positive solid tumors; nine participants had a head and neck tumor, including tongue, tonsils, and tonsils + lymph nodes. The median age was 65.5 years and 80% were male. Seventy percent of participants had baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0; 30% had ECOG of 1. All participants experienced at least one treatment-related adverse event (TRAE) which were limited to grade 1 or grade 2 events. TRAEs generally included administration site reactions (pain, erythema, swelling) and musculoskeletal disorders (myalgia). Serious adverse events (SAEs) were observed in 30% of participants: one participant in C1 experienced disease progression; two participants in C2 experienced overlapping SAEs including hemoptysis, pleural effusion, respiratory failure, atrial fibrillation, and/or hypertension. All SAEs were considered unrelated. No dose limiting toxicities (DLTs) were observed. MTD was determined to be 5e11 VP/dose. Five participants were contacted for survival status and 4/5 participants were alive at the time of this report. The expired patient was treated on C1.</p>\n\n<p><strong>Conclusion:</strong> The QUILT-3.100 trial successfully enrolled participants to determine the MTD (5e11 VP/dose) for IBRX-042 in participants with HPV-associated solid tumors, including head and neck. The safety profile for this HPV-directed cancer vaccine was well tolerated with no DLTs and future clinical studies in combination with other immune-activating therapies are planned.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154280--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S404",
      "content_id": "155489",
      "abstract_number": "S404",
      "poster_number": "",
      "title": "Real-World Discordance Between ctHPVDNA Liquid Biopsy and HPV Status in HPV-Positive OPSCC: A Prospective Single-Institution",
      "summary": "Here we describe and analyze discordances between ctHPVDNA liquid biopsy and confirmatory HPV testing at baseline in HPV-positive OPSCC. Subtype coverage differences between platforms account for some discordance, however notably 4 patients with subtype 16, the primary target of the assay, remained NavDx-negative. Larger prospective studies are needed to characterize the clinical significance of baseline NavDx...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155489",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260146",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joanne Soo, MD",
      "presenter": "Joanne Soo, MD",
      "authors": "Hlu Vang, BS 1 ; Nikita Bedi, BS 1 ; Po Ling Chan, MD 1 ; Huiying Tsang, PA 2 ; Jake J Lee, MD 1 ; Michelle M Chen, MD, MHS, FACS 1 ; Andrey Finegeresh, MD, PhD 1 ; Joanne Soo, MD 1 ; F. Christopher Holsinger, MD, FACS 1",
      "normalized_authors": [
        "Hlu Vang",
        "Nikita Bedi",
        "Po Ling Chan",
        "Huiying Tsang, PA",
        "Jake J Lee",
        "Michelle M Chen, MHS",
        "Andrey Finegeresh",
        "Joanne Soo",
        "F. Christopher Holsinger"
      ],
      "affiliations": [
        "Stanford University School of Medicine",
        "Stanford Medicine"
      ],
      "normalized_institutions": [
        "Stanford University School of Medicine",
        "Stanford Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 362,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hlu Vang, BS 1 ; Nikita Bedi, BS 1 ; Po Ling Chan, MD 1 ; Huiying Tsang, PA 2 ; Jake J Lee, MD 1 ; Michelle M Chen, MD, MHS, FACS 1 ; Andrey Finegeresh, MD, PhD 1 ; Joanne Soo, MD 1 ; F. Christopher Holsinger, MD, FACS 1",
        "Affiliations": "1 Stanford University School of Medicine; 2 Stanford Medicine",
        "Background": "Circulating tumor DNA (ctDNA) has become a standard “liquid biopsy” tool for managing various cancers, offering utility in clinical management including early diagnosis, therapy monitoring, and survival prediction. Specifically, ctHPVDNA- DNA derived from tumor-integrated HPV- shows significant potential in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). NavDx, a ctHPVDNA liquid biopsy assay detecting HPV subtypes 16, 18, 31, 33, and 35, is increasingly used in the management of HPV-positive OPSCC. However, false-negative results at baseline present a clinical challenge. We investigated the rate of NavDx discordance in a prospectively enrolled OPSCC cohort and performed reflex molecular subtyping via NeoGenomics, a CLIA-certified laboratory, to characterize NavDx-negative cases.",
        "Methods": "Single-institution prospective review of patients with newly diagnosed p16+/HPV+ OPSCC enrolled July 2023 to February 2026. Baseline NavDx was collected for all patients. Patients with non-detectable results underwent reflex HPV subtyping via NeoGenomics (subtypes 16, 18, 31, 33, 45, 58, 6/11) on initial biopsy tissue.",
        "Results": "Of 73 enrolled patients, 11 (15.1%) had non-detectable baseline ctHPVDNA by NavDx despite confirmed HPV positivity by ISH and/or p16 by IHC. Reflex subtyping was performed in all 11 patients via NeoGenomics; 8 (72.7%) tested positive for high-risk HPV: subtype 16 in 50% (4/8), subtype 18 in 12.5% (1/8), subtype 33 in 12.5% (1/8), subtype 45 in 12.5% (1/8), and subtype 58 in 12.5% (1/8). Subtypes 45 and 58 fall outside NavDx's detection panel, accounting for 2 cases of discordance. Notably, 6 patients were negative on NavDx despite harboring subtypes within its detection range, including 4 patients with subtype 16. Three patients remained negative on NeoGenomics despite confirmed HPV positivity by ISH. Molecular and genomic differences across these patients with discordance reporting between traditional HPV testing, NavDx, and Neogenomics panel.",
        "Conclusion": "Here we describe and analyze discordances between ctHPVDNA liquid biopsy and confirmatory HPV testing at baseline in HPV-positive OPSCC. Subtype coverage differences between platforms account for some discordance, however notably 4 patients with subtype 16, the primary target of the assay, remained NavDx-negative. Larger prospective studies are needed to characterize the clinical significance of baseline NavDx negativity in confirmed HPV-positive disease.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-World Discordance Between ctHPVDNA Liquid Biopsy and HPV Status in HPV-Positive OPSCC: A Prospective Single-Institution</span>. Hlu Vang, BS<sup>1</sup>; Nikita Bedi, BS<sup>1</sup>; Po Ling Chan, MD<sup>1</sup>; Huiying Tsang, PA<sup>2</sup>; Jake J Lee, MD<sup>1</sup>; Michelle M Chen, MD, MHS, FACS<sup>1</sup>; Andrey Finegeresh, MD, PhD<sup>1</sup>; <u>Joanne Soo, MD</u><sup>1</sup>; F. Christopher Holsinger, MD, FACS<sup>1</sup>. <sup>1</sup>Stanford University School of Medicine; <sup>2</sup>Stanford Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Circulating tumor DNA (ctDNA) has become a standard “liquid biopsy” tool for managing various cancers, offering utility in clinical management including early diagnosis, therapy monitoring, and survival prediction. Specifically, ctHPVDNA- DNA derived from tumor-integrated HPV- shows significant potential in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). NavDx, a ctHPVDNA liquid biopsy assay detecting HPV subtypes 16, 18, 31, 33, and 35, is increasingly used in the management of HPV-positive OPSCC. However, false-negative results at baseline present a clinical challenge. We investigated the rate of NavDx discordance in a prospectively enrolled OPSCC cohort and performed reflex molecular subtyping via NeoGenomics, a CLIA-certified laboratory, to characterize NavDx-negative cases.</p>\n\n<p><strong>Methods: </strong>Single-institution prospective review of patients with newly diagnosed p16+/HPV+ OPSCC enrolled July 2023 to February 2026. Baseline NavDx was collected for all patients. Patients with non-detectable results underwent reflex HPV subtyping via NeoGenomics (subtypes 16, 18, 31, 33, 45, 58, 6/11) on initial biopsy tissue.</p>\n\n<p><strong>Results: </strong>Of 73 enrolled patients, 11 (15.1%) had non-detectable baseline ctHPVDNA by NavDx despite confirmed HPV positivity by ISH and/or p16 by IHC. Reflex subtyping was performed in all 11 patients via NeoGenomics; 8 (72.7%) tested positive for high-risk HPV: subtype 16 in 50% (4/8), subtype 18 in 12.5% (1/8), subtype 33 in 12.5% (1/8), subtype 45 in 12.5% (1/8), and subtype 58 in 12.5% (1/8). Subtypes 45 and 58 fall outside NavDx's detection panel, accounting for 2 cases of discordance. Notably, 6 patients were negative on NavDx despite harboring subtypes within its detection range, including 4 patients with subtype 16. Three patients remained negative on NeoGenomics despite confirmed HPV positivity by ISH.  Molecular and genomic differences across these patients with discordance reporting between traditional HPV testing, NavDx, and Neogenomics panel.</p>\n\n<p><strong>Conclusion: </strong>Here we describe and analyze discordances between ctHPVDNA liquid biopsy and confirmatory HPV testing at baseline in HPV-positive OPSCC. Subtype coverage differences between platforms account for some discordance, however notably 4 patients with subtype 16,  the primary target of the assay, remained NavDx-negative. Larger prospective studies are needed to characterize the clinical significance of baseline NavDx negativity in confirmed HPV-positive disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155489--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260146' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S405",
      "content_id": "153449",
      "abstract_number": "S405",
      "poster_number": "",
      "title": "Cellular Mechanisms of Pigmentation Alteration in Dermis Resected Free Flaps",
      "summary": "This study provides the first cellular evidence that melanocytes transplanted via STSG survive, proliferate, and repopulate a new anatomical niche to restore pigmentation harmony. These findings advance understanding of the mechanisms driving color restoration in facial reconstruction and establish a biologic framework for future work aimed at optimizing cutaneous color match outcomes and addressing aesthetic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153449",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nicole J Reynoso",
      "presenter": "Nicole J Reynoso",
      "authors": "Nicole J Reynoso ; Jeffrey P North, MD; Jamie D Chan; Neil N Patel, MD; Andrea M Park, MD; P",
      "normalized_authors": [
        "Nicole J Reynoso",
        "Jeffrey P North",
        "Jamie D Chan",
        "Neil N Patel",
        "Andrea M Park"
      ],
      "affiliations": [
        "Daniel Knott, MD. University of California, San Francisco"
      ],
      "normalized_institutions": [
        "Daniel Knott, MD. University of California, San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 303,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nicole J Reynoso ; Jeffrey P North, MD; Jamie D Chan; Neil N Patel, MD; Andrea M Park, MD; P",
        "Affiliations": "Daniel Knott, MD. University of California, San Francisco",
        "Background": "Achieving optimal facial skin color match is central to aesthetic and psychosocial success in facial cutaneous free tissue transfer. Epithelial preservation including dermis resection microvascular (EPIDERM) technique using split-thickness skin grafts (STSG) harvested from lightly pigmented donor sites have been found to darken in color and offer better color match when transferred to the face. This phenomenon has been objectively shown via colorimetric and photometric analysis. The cellular mechanisms underlying this pigmentary improvement have not been defined.",
        "Methods": "Adult patients undergoing head and neck oncologic reconstruction with the EPIDERM technique were prospectively enrolled (n=14). Three skin biopsies were collected per participant: (1) a 4-mm full thickness punch biopsy from the anterolateral thigh (ALT) donor site at the time of flap harvest, (2) a remnant of the STSG harvested from the ALT skin paddle, and (3) a 4-mm punch biopsy from the healed recipient STSG facial site obtained 1-3 months postoperatively. All specimens underwent immunohistochemical staining and confocal microscopy to quantify melanocyte density and melanin pigmentation by dermatopathologists.",
        "Results": "Specimens treated with the EPIDERM technique demonstrated a significant increase in melanocyte density (45.4 cells/mm vs. 31.5 cells/mm, mean difference 13.9, 95% CI 6.2–21.6, p = 0.004), upper epidermal (0.53 vs. 1.3), lower epidermal (1.8 vs. 2.1), and dermal (1 vs. 1.6) pigmentation indicating postoperative proliferation or migration of melanocytes within the reconstructed site.",
        "Conclusion": "This study provides the first cellular evidence that melanocytes transplanted via STSG survive, proliferate, and repopulate a new anatomical niche to restore pigmentation harmony. These findings advance understanding of the mechanisms driving color restoration in facial reconstruction and establish a biologic framework for future work aimed at optimizing cutaneous color match outcomes and addressing aesthetic preferences in head and neck cancer survivors.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cellular Mechanisms of Pigmentation Alteration in Dermis Resected Free Flaps</span>. <u>Nicole J Reynoso</u>; Jeffrey P North, MD; Jamie D Chan; Neil N Patel, MD; Andrea M Park, MD; P. Daniel Knott, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Achieving optimal facial skin color match is central to aesthetic and psychosocial success in facial cutaneous free tissue transfer. Epithelial preservation including dermis resection microvascular (EPIDERM) technique using split-thickness skin grafts (STSG) harvested from lightly pigmented donor sites have been found to darken in color and offer better color match when transferred to the face. This phenomenon has been objectively shown via colorimetric and photometric analysis. The cellular mechanisms underlying this pigmentary improvement have not been defined.</p>\n\n<p><strong>Methods: </strong>Adult patients undergoing head and neck oncologic reconstruction with the EPIDERM technique were prospectively enrolled (n=14). Three skin biopsies were collected per participant: (1) a 4-mm full thickness punch biopsy from the anterolateral thigh (ALT) donor site at the time of flap harvest, (2) a remnant of the STSG harvested from the ALT skin paddle, and (3) a 4-mm punch biopsy from the healed recipient STSG facial site obtained 1-3 months postoperatively. All specimens underwent immunohistochemical staining and confocal microscopy to quantify melanocyte density and melanin pigmentation by dermatopathologists.</p>\n\n<p><strong>Results: </strong>Specimens treated with the EPIDERM technique demonstrated a significant increase in melanocyte density (45.4 cells/mm vs. 31.5 cells/mm, mean difference 13.9, 95% CI 6.2–21.6, p = 0.004), upper epidermal (0.53 vs. 1.3), lower epidermal (1.8 vs. 2.1), and dermal (1 vs. 1.6) pigmentation indicating postoperative proliferation or migration of melanocytes within the reconstructed site.</p>\n\n<p><strong>Conclusion:</strong> This study provides the first cellular evidence that melanocytes transplanted via STSG survive, proliferate, and repopulate a new anatomical niche to restore pigmentation harmony. These findings advance understanding of the mechanisms driving color restoration in facial reconstruction and establish a biologic framework for future work aimed at optimizing cutaneous color match outcomes and addressing aesthetic preferences in head and neck cancer survivors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153449--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S406",
      "content_id": "153973",
      "abstract_number": "S406",
      "poster_number": "",
      "title": "Comparative Analysis of Surgical and Oncologic Outcomes in Head and Neck Cancer Patients Undergoing Free Flap Reconstruction: A Single-Community based Institution Review",
      "summary": "A community-based head and neck oncology and microvascular free flap program can achieve outcomes comparable to high -volume academic centers. Opportunities of improvement include reducing biopsy-to-surgery time adjuvant therapy intervals with multidisciplinary cooperation. With intentional program design, perioperative monitoring, and strategic operative planning, complex free flap reconstruction can be...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153973",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ashley C Mays, MD",
      "presenter": "Ashley C Mays, MD",
      "authors": "Erica Kropp, BS 1 ; Shea Fincher, BS 1 ; Said Turfe, BS 1 ; Brian Burkey, MD, MEd 2 ; Ashley C Mays, MD 2",
      "normalized_authors": [
        "Erica Kropp",
        "Shea Fincher",
        "Said Turfe",
        "Brian Burkey, MEd",
        "Ashley C Mays"
      ],
      "affiliations": [
        "Edward Via College of Osteopathic Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "normalized_institutions": [
        "Edward Via College of Osteopathic Medicine",
        "Cleveland Clinic Indian River Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 543,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Erica Kropp, BS 1 ; Shea Fincher, BS 1 ; Said Turfe, BS 1 ; Brian Burkey, MD, MEd 2 ; Ashley C Mays, MD 2",
        "Affiliations": "1 Edward Via College of Osteopathic Medicine; 2 Cleveland Clinic Indian River Hospital",
        "Introduction": "Advanced head and neck cancer ablative and microvascular free flap reconstruction cases are associated with significant peri operative demand and complex post operative care. Understanding institutional outcomes helps identify areas for improvement in multidisciplinary cancer care as surgical subspecialties expand into community hospital settings. This study evaluates outcomes of patients undergoing advanced head and neck oncology and free flap surgery in a community setting with limited classical support structure, highlighting factors contributing to success.",
        "Methods": "A retrospective chart review was conducted of all head and neck free flap reconstructions performed at our community hospital from 2022 to present. Data included demographics, tumor stage, flap type, comorbidity burden, intraoperative metrics, and postoperative outcomes. Time to treat variables were analyzed.",
        "Results": "101 head and neck free flap cases were included based on data availability. As markers of complexity, 65 cases (64%) were advanced stage T4/T3, 17 cases (19%) were early stage T2/T1, and 19 cases for non-cancer purpose such as osteoradionecrosis; 34% were performed for surgical salvage. Patients averaged 2.44 comorbidities. Free flap type included anterolateral thigh (48.1%), radial forearm (29.2%), ulnar forearm, fibula, latissimus, lateral arm and deep inferior epigastric. An analysis of oncologic outcomes revealed 19 patients (12%) developed some form of recurrence at last follow-up: 6 distantly, 13 locoregionally. Biopsy-to-surgery time (mean 69.48 ± 63.29 days) and adjuvant therapy interval (mean 52.37 ± 19.16 days) exceeded national targets of 4–6 weeks. However, time to adjuvant therapy did not differ significantly between patients receiving treatment within our system versus those managed externally (51.55 ± 20.7 vs. 52.66 ± 17.51 days, p = 0.43). The mean duration of tracheostomy dependence (13.2 ± 16.3 days) aligned with national standards; complexity increased tracheostomy duration. Discharge disposition analysis showed that age, tumor stage, and comorbidity burden were associated with more complex discharge pathways such as need for inpatient rehab placement.",
        "Abstract": "In our community free flap practice, there is 98% flap survival rate with 12 inpatient return to OR: 3 washouts/fistula repair all of which resolved, 7 for wound dehiscence/wound management revision (1 required new fibula flap after failure), 1 for hematoma, and 1 for anastomotic issue (vein). There were three 30-day perioperative deaths (fulminant DIC, sudden PE/MI, and an airway event at home), and six surgery-related 30-day readmissions. We theorize that several strategies have contributed to flap success and complication avoidance in this community free flap practice, including: extended ICU monitoring (mean 4.38 ± 2.60 days), longer inpatien admission length (mean 9.94 ± 5.33 days) compared to academic institutions (mean 7.9± 4.7 days), short ischemia time (65.40 ± 25.15 minutes), efficient operative duration (480.72 ± 136.68 minutes) less than the national average (534 minutes), and consistent selection of large-caliber arterial inflow with dual venous anastomoses when feasible. View in Agenda and Add to Schedule",
        "Conclusion": "A community-based head and neck oncology and microvascular free flap program can achieve outcomes comparable to high -volume academic centers. Opportunities of improvement include reducing biopsy-to-surgery time adjuvant therapy intervals with multidisciplinary cooperation. With intentional program design, perioperative monitoring, and strategic operative planning, complex free flap reconstruction can be performed safely and effectively in community settings supporting continued expansion of surgical care beyond academic environments"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Analysis of Surgical and Oncologic Outcomes in Head and Neck Cancer Patients Undergoing Free Flap Reconstruction: A Single-Community based Institution Review</span>. Erica Kropp, BS<sup>1</sup>; Shea Fincher, BS<sup>1</sup>; Said Turfe, BS<sup>1</sup>; Brian Burkey, MD, MEd<sup>2</sup>; <u>Ashley C Mays, MD</u><sup>2</sup>. <sup>1</sup>Edward Via College of Osteopathic Medicine; <sup>2</sup>Cleveland Clinic Indian River Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advanced head and neck cancer ablative and microvascular free flap reconstruction cases are associated with significant peri operative demand and complex post operative care. Understanding institutional outcomes helps identify areas for improvement in multidisciplinary cancer care as surgical subspecialties expand into community hospital settings. This study evaluates outcomes of patients undergoing advanced head and neck oncology and free flap surgery in a community setting with limited classical support structure, highlighting factors contributing to success.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted of all head and neck free flap reconstructions performed at our community hospital from 2022 to present. Data included demographics, tumor stage, flap type, comorbidity burden, intraoperative metrics, and postoperative outcomes. Time to treat variables were analyzed.</p>\n\n<p><strong>Results: </strong>101 head and neck free flap cases were included based on data availability. As markers of complexity, 65 cases (64%) were advanced stage T4/T3, 17 cases (19%) were early stage T2/T1, and 19 cases for non-cancer purpose such as osteoradionecrosis; 34% were performed for surgical salvage. Patients averaged 2.44 comorbidities. Free flap type included anterolateral thigh (48.1%), radial forearm (29.2%), ulnar forearm, fibula, latissimus, lateral arm and deep inferior epigastric. An analysis of oncologic outcomes revealed 19 patients (12%) developed some form of recurrence at last follow-up: 6 distantly, 13 locoregionally. Biopsy-to-surgery time (mean 69.48 ± 63.29 days) and adjuvant therapy interval (mean 52.37 ± 19.16 days) exceeded national targets of 4–6 weeks. However, time to adjuvant therapy did not differ significantly between patients receiving treatment within our system versus those managed externally (51.55 ± 20.7 vs. 52.66 ± 17.51 days, p = 0.43). The mean duration of tracheostomy dependence (13.2 ± 16.3 days) aligned with national standards; complexity increased tracheostomy duration. Discharge disposition analysis showed that age, tumor stage, and comorbidity burden were associated with more complex discharge pathways such as need for inpatient rehab placement.</p>\n\n<p>In our community free flap practice, there is 98% flap survival rate with 12 inpatient return to OR: 3 washouts/fistula repair all of which resolved, 7 for wound dehiscence/wound management revision (1 required new fibula flap after failure), 1 for hematoma, and 1 for anastomotic issue (vein). There were three 30-day perioperative deaths (fulminant DIC, sudden PE/MI, and an airway event at home), and six surgery-related 30-day readmissions. We theorize that several strategies have contributed to flap success and complication avoidance in this community free flap practice, including: extended ICU monitoring (mean 4.38 ± 2.60 days), longer inpatien admission length (mean 9.94 ± 5.33 days) compared to academic institutions (mean 7.9± 4.7 days), short ischemia time (65.40 ± 25.15 minutes), efficient operative duration (480.72 ± 136.68 minutes) less than the national average (534 minutes), and consistent selection of large-caliber arterial inflow with dual venous anastomoses when feasible. </p>\n\n<p><strong>Conclusion: </strong>A community-based head and neck oncology and microvascular free flap program can achieve outcomes comparable to high -volume academic centers. Opportunities of improvement include reducing biopsy-to-surgery time adjuvant therapy intervals with multidisciplinary cooperation. With intentional program design, perioperative monitoring, and strategic operative planning, complex free flap reconstruction can be performed safely and effectively in community settings supporting continued expansion of surgical care beyond academic environments</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153973--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S407",
      "content_id": "153804",
      "abstract_number": "S407",
      "poster_number": "",
      "title": "Neoglossus Morphology and Functional Outcomes in Total Glossectomy",
      "summary": "Longterm neoglossus morphology significantly influences functional outcomes, a convex mound (Grade 1/2) optimizes speech, whereas a flat mound (Grade 3) facilitates faster swallowing recovery. The FALT flap appears to offer better functional outcomes and mound stability compared to PMMC, supporting its preference in reconstruction. These findings highlight the importance of balancing reconstructive bulk for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153804",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karthik Rao, MCh",
      "presenter": "Karthik Rao, MCh",
      "authors": "Karthik Rao, MCh ; Radhika K, MCh; Teertha Shetty; Prajwal Dange, MCh; Sreeram MP",
      "normalized_authors": [
        "Karthik Rao, MCh",
        "Radhika K, MCh",
        "Teertha Shetty",
        "Prajwal Dange, MCh",
        "Sreeram MP"
      ],
      "affiliations": [
        "Sri Shankara Cancer Hospital and Research Center"
      ],
      "normalized_institutions": [
        "Sri Shankara Cancer Hospital and Research Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153804/Neoglossus%20grade(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153804/Neoglossus%20grade(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153804"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Karthik Rao, MCh ; Radhika K, MCh; Teertha Shetty; Prajwal Dange, MCh; Sreeram MP",
        "Affiliations": "Sri Shankara Cancer Hospital and Research Center",
        "Purpose": "This study analyzed functional outcomes specifically tracheostomy tube (TT) and nasogastric tube (NGT) decannulation times and speech intelligibility following total or neartotal glossectomy, correlating them with long term neoglossus morphology and the choice of reconstructive flap.",
        "Methods": "We conducted a retrospective analysis of 31 patients who underwent total or near total glossectomy with microvascular free flap reconstruction (23 ALT, 8 PMMC) between Jan 2024 and June 2025. The cohort had a mean age of 55.6 years (range: 35–78 years) with a male predominance (80.6%). Functional outcomes were assessed using TT decannulation time (days), NGT decannulation time (days), and the 7point Speech Intelligibility Rating (SIR) scale by Ali Yavar Jung National Institute of Speech and Hearing was used. The NMG is a fourpoint grading scale based on structures seen: Grade 1 is a convex dome (pharyngeal structures unseen); Grade 2 is a convex mound (upper faucial pillars seen); Grade 3 is flat (all structures seen except epiglottis); and Grade 4 is concave (all structures fully seen) was developed. Neoglossus morphology was serially evaluated using the NMG at 1, 3, and 6 months postoperatively, with the 6month grade used for final correlation. Statistical comparisons were performed using oneway ANOVA and independent samples t-tests.",
        "Results": "Neoglossus morphology demonstrated progressive flattening over time. Immediately postoperatively, all patients had favorable mound grades (Grade 1: 45.2%, Grade 2: 54.8%). By 3 months, 71.0% remained in Grade 2, while 29.0% had progressed to Grade 3. At 6 months, further flattening was observed: Grade 2 (48.4%), Grade 3 (29.0%), and Grade 4 (12.9%). A distinct tradeoff in functional recovery was observed based on the 6month NMG: Speech intelligibility correlated positively with mound convexity (ANOVA p = 0.068). Mean SIR scores were best in Grade 1 (2.00), followed by Grade 2 (2.71) and Grade 3 (3.00), and worst in Grade 4 (3.75). Decannulation times did not differ significantly across grades (TT p = 0.099, NGT p = 0.370). However, the fastest decannulation was observed in Grade 3 (mean TT: 31.44 days; NGT: 30.89 days), while Grade 4 had the slowest TT decannulation (46.25 days) and Grade 2 the slowest NGT decannulation (42.82 days).",
        "Abstract": "The FALT flap group demonstrated better outcomes compared to PMMC, including faster NGT decannulation (36.6 vs. 44.7 days), better mean SIR (2.78 vs. 3.25), and a higher proportion of favorable NMGs (Grade 1/2: 65.2% vs. 37.5%). The hyomental stitch did not significantly affect longterm NMG or decannulation times. View in Agenda and Add to Schedule",
        "Conclusion": "Longterm neoglossus morphology significantly influences functional outcomes, a convex mound (Grade 1/2) optimizes speech, whereas a flat mound (Grade 3) facilitates faster swallowing recovery. The FALT flap appears to offer better functional outcomes and mound stability compared to PMMC, supporting its preference in reconstruction. These findings highlight the importance of balancing reconstructive bulk for speech with contour for swallowing rehabilitation. Large scale multicenter study will validate the results."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoglossus Morphology and Functional Outcomes in Total Glossectomy</span>. <u>Karthik Rao, MCh</u>; Radhika K, MCh; Teertha Shetty; Prajwal Dange, MCh; Sreeram MP. Sri Shankara Cancer Hospital and Research Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>This study analyzed functional outcomes specifically tracheostomy tube (TT) and nasogastric tube (NGT) decannulation times and speech intelligibility following total or neartotal glossectomy, correlating them with long term neoglossus morphology and the choice of reconstructive flap.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective analysis of 31 patients who underwent total or near total glossectomy with microvascular free flap reconstruction (23 ALT, 8 PMMC) between Jan 2024 and June 2025. The cohort had a mean age of 55.6 years (range: 35–78 years) with a male predominance (80.6%). Functional outcomes were assessed using TT decannulation time (days), NGT decannulation time (days), and the 7point Speech Intelligibility Rating (SIR) scale by Ali Yavar Jung National Institute of Speech and Hearing was used. The NMG is a fourpoint grading scale based on structures seen: Grade 1 is a convex dome (pharyngeal structures unseen); Grade 2 is a convex mound (upper faucial pillars seen); Grade 3 is flat (all structures seen except epiglottis); and Grade 4 is concave (all structures fully seen) was developed. Neoglossus morphology was serially evaluated using the NMG at 1, 3, and 6 months postoperatively, with the 6month grade used for final correlation. Statistical comparisons were performed using oneway ANOVA and independent samples t-tests.</p>\n\n<p><strong>Results: </strong>Neoglossus morphology demonstrated progressive flattening over time. Immediately postoperatively, all patients had favorable mound grades (Grade 1: 45.2%, Grade 2: 54.8%). By 3 months, 71.0% remained in Grade 2, while 29.0% had progressed to Grade 3. At 6 months, further flattening was observed: Grade 2 (48.4%), Grade 3 (29.0%), and Grade 4 (12.9%). A distinct tradeoff in functional recovery was observed based on the 6month NMG: Speech intelligibility correlated positively with mound convexity (ANOVA p = 0.068). Mean SIR scores were best in Grade 1 (2.00), followed by Grade 2 (2.71) and Grade 3 (3.00), and worst in Grade 4 (3.75). Decannulation times did not differ significantly across grades (TT p = 0.099, NGT p = 0.370). However, the fastest decannulation was observed in Grade 3 (mean TT: 31.44 days; NGT: 30.89 days), while Grade 4 had the slowest TT decannulation (46.25 days) and Grade 2 the slowest NGT decannulation (42.82 days).</p>\n\n<p>The FALT flap group demonstrated better outcomes compared to PMMC, including faster NGT decannulation (36.6 vs. 44.7 days), better mean SIR (2.78 vs. 3.25), and a higher proportion of favorable NMGs (Grade 1/2: 65.2% vs. 37.5%). The hyomental stitch did not significantly affect longterm NMG or decannulation times.</p>\n\n<p><strong>Conclusion: </strong>Longterm neoglossus morphology significantly influences functional outcomes, a convex mound (Grade 1/2) optimizes speech, whereas a flat mound (Grade 3) facilitates faster swallowing recovery. The FALT flap appears to offer better functional outcomes and mound stability compared to PMMC, supporting its preference in reconstruction. These findings highlight the importance of balancing reconstructive bulk for speech with contour for swallowing rehabilitation. Large scale multicenter study will validate the results.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153804/Neoglossus%20grade(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153804--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S408",
      "content_id": "154008",
      "abstract_number": "S408",
      "poster_number": "",
      "title": "Cognitive Vulnerability and Surgical Morbidity: Dementia and Delirium in Free Flap Reconstruction",
      "summary": "Both postoperative delirium and preoperative dementia are strongly associated with advanced age, prolonged hospitalization, non-home discharge, and worse postoperative outcomes following free flap reconstruction. Recognizing these risk factors provides an opportunity to implement pre and post-operative strategies aimed at improving patient outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154008",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Claudia N Gutierrez, MD, MS",
      "presenter": "Claudia N Gutierrez, MD, MS",
      "authors": "Claudia N Gutierrez, MD, MS 1 ; Madeline Pyle, MD 1 ; Mark K Wax, MD 2 ; Joseph M Curry, MD 3 ; Carissa M Thomas, MD, PhD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 2 ; Jason Leibowitz, MD 1 ; Michael DiLeo, MD 6 ; Nicolaus D Knight, MS 4 ; Elise Krippaehne, BS 7 ; Javier K Nishikawa, BS 4 ; Yasaman Baghshomali, MSc, PhD 8 ; Madeline Otto, BS 2 ; Sruti Tekumalla, MD 3 ; Sumanth Chandrupatla, BS 4 ; Larissa Sweeny, MD 1",
      "normalized_authors": [
        "Claudia N Gutierrez",
        "Madeline Pyle",
        "Mark K Wax",
        "Joseph M Curry",
        "Carissa M Thomas",
        "Sallie Long",
        "Dev Amin",
        "Caroline Bonaventure",
        "Farshid Taghizadeh",
        "Jason Leibowitz",
        "Michael DiLeo",
        "Nicolaus D Knight",
        "Elise Krippaehne",
        "Javier K Nishikawa",
        "Yasaman Baghshomali",
        "Madeline Otto",
        "Sruti Tekumalla",
        "Sumanth Chandrupatla",
        "Larissa Sweeny"
      ],
      "affiliations": [
        "University of Miami",
        "Oregon Health and Science University",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Medical College of Georgia",
        "Louisiana State University Health Science Center",
        "Western University of Health Sciences",
        "University of Colorado"
      ],
      "normalized_institutions": [
        "University of Miami",
        "Oregon Health and Science University",
        "Thomas Jefferson University",
        "University of Alabama at Birmingham",
        "Medical College of Georgia",
        "Louisiana State University Health Science Center",
        "Western University of Health Sciences",
        "University of Colorado"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Method",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Claudia N Gutierrez, MD, MS 1 ; Madeline Pyle, MD 1 ; Mark K Wax, MD 2 ; Joseph M Curry, MD 3 ; Carissa M Thomas, MD, PhD 4 ; Sallie Long, MD 5 ; Dev Amin, MD 3 ; Caroline Bonaventure, MD 6 ; Farshid Taghizadeh, MD 2 ; Jason Leibowitz, MD 1 ; Michael DiLeo, MD 6 ; Nicolaus D Knight, MS 4 ; Elise Krippaehne, BS 7 ; Javier K Nishikawa, BS 4 ; Yasaman Baghshomali, MSc, PhD 8 ; Madeline Otto, BS 2 ; Sruti Tekumalla, MD 3 ; Sumanth Chandrupatla, BS 4 ; Larissa Sweeny, MD 1",
        "Affiliations": "1 University of Miami; 2 Oregon Health and Science University; 3 Thomas Jefferson University; 4 University of Alabama at Birmingham; 5 Medical College of Georgia; 6 Louisiana State University Health Science Center; 7 Western University of Health Sciences; 8 University of Colorado",
        "Objective": "Free tissue transfer is a highly reliable method for reconstructing complex head and neck defects. However, these patients often carry multiple risk factors for postoperative delirium, including prolonged operative times, malnutrition, and substance use disorders. Postoperative delirium—a cerebral disturbance marked by fluctuating levels of consciousness and disorganized thinking—is a well-recognized complication associated with increased morbidity, prolonged hospitalization, and poorer surgical outcomes. Understanding the role of preexisting cognitive impairment and comorbidities is essential to improving perioperative care.",
        "Method": "CPT codes were used to identify free flap reconstructions performed at four tertiary institutions from 2010 to 2024. Retrospective chart review captured demographics, surgical indication, T-stage, free flap type, total operative time, pre-operative dementia, post-operative delirium, medical comorbidities, and post-operative course.",
        "Results": "A total of 2,905 patients were identified, with a mean age of 63.4 years (median 64, range 18–96) and 71% male. The overall incidence of postoperative delirium was 5% rising to 8% among patients older than 75. Patients over 75 had significantly higher odds of delirium than younger patients (8% vs 5%; OR = 1.8, 95% CI 1.3–2.6). Preoperative dementia was present in 1.4% of the cohort and was more common in patients older than 75 (4% vs 1%; OR = 4.5, 95% CI 2.4–8.4).",
        "Abstract": "Delirium was associated with a history of stroke with residual deficit, pulmonary disease, active smoking, alcohol use/withdrawal, ICU escalation of care, and postoperative pulmonary or cardiac complications. Patients who developed delirium were older at the time of surgery (mean 66.3 vs 63.3 years; p = 0.004), had significantly worse preoperative performance status (mean ECOG difference 0.3; p = 0.0002), and were more likely to be functionally dependent, with delirium rates of 5% in functionally independent patients, 15% in partially dependent patients, and 19% in totally dependent patients (Pearson χ² = 40, p < 0.0001). Both postoperative delirium and preoperative dementia were associated with significantly prolonged hospitalization. Patients who developed delirium stayed an average of 6 days longer (15 vs 9.5 days; p < .0001) and patients with dementia remained hospitalized an additional 8 days (18 vs 10 days; p < .0001). Discharge disposition was also adversely affected: only 65% of patients with delirium and 63% of patients with dementia were discharged home, compared with approximately 86% of those without these conditions. Delirium was additionally associated with higher rates of flap compromise (13% vs 8%), flap failure (11% vs 5%), increased postoperative mortality (10.5% vs 5.8%; OR = 1.9, p = 0.02) and 30-day readmission (20.4% vs 14.2%; OR = 1.5, p = 0.03). In contrast, preoperative dementia was not associated with flap-related complications or 30-day readmission but was linked to increased ICU escalation, pulmonary complications, and higher 6-month mortality. View in Agenda and Add to Schedule",
        "Conclusion": "Both postoperative delirium and preoperative dementia are strongly associated with advanced age, prolonged hospitalization, non-home discharge, and worse postoperative outcomes following free flap reconstruction. Recognizing these risk factors provides an opportunity to implement pre and post-operative strategies aimed at improving patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cognitive Vulnerability and Surgical Morbidity: Dementia and Delirium in Free Flap Reconstruction</span>. <u>Claudia N Gutierrez, MD, MS</u><sup>1</sup>; Madeline Pyle, MD<sup>1</sup>; Mark K Wax, MD<sup>2</sup>; Joseph M Curry, MD<sup>3</sup>; Carissa M Thomas, MD, PhD<sup>4</sup>; Sallie Long, MD<sup>5</sup>; Dev Amin, MD<sup>3</sup>; Caroline Bonaventure, MD<sup>6</sup>; Farshid Taghizadeh, MD<sup>2</sup>; Jason Leibowitz, MD<sup>1</sup>; Michael DiLeo, MD<sup>6</sup>; Nicolaus D Knight, MS<sup>4</sup>; Elise Krippaehne, BS<sup>7</sup>; Javier K Nishikawa, BS<sup>4</sup>; Yasaman Baghshomali, MSc, PhD<sup>8</sup>; Madeline Otto, BS<sup>2</sup>; Sruti Tekumalla, MD<sup>3</sup>; Sumanth Chandrupatla, BS<sup>4</sup>; Larissa Sweeny, MD<sup>1</sup>. <sup>1</sup>University of Miami; <sup>2</sup>Oregon Health and Science University; <sup>3</sup>Thomas Jefferson University; <sup>4</sup>University of Alabama at Birmingham; <sup>5</sup>Medical College of Georgia; <sup>6</sup>Louisiana State University Health Science Center; <sup>7</sup>Western University of Health Sciences; <sup>8</sup>University of Colorado<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Free tissue transfer is a highly reliable method for reconstructing complex head and neck defects. However, these patients often carry multiple risk factors for postoperative delirium, including prolonged operative times, malnutrition, and substance use disorders. Postoperative delirium—a cerebral disturbance marked by fluctuating levels of consciousness and disorganized thinking—is a well-recognized complication associated with increased morbidity, prolonged hospitalization, and poorer surgical outcomes. Understanding the role of preexisting cognitive impairment and comorbidities is essential to improving perioperative care.</p>\n\n<p><strong>Method:</strong> CPT codes were used to identify free flap reconstructions performed at four tertiary institutions from 2010 to 2024. Retrospective chart review captured demographics, surgical indication, T-stage, free flap type, total operative time, pre-operative dementia, post-operative delirium, medical comorbidities, and post-operative course. </p>\n\n<p><strong>Results:</strong> A total of 2,905 patients were identified, with a mean age of 63.4 years (median 64, range 18–96) and 71% male. The overall incidence of postoperative delirium was 5% rising to 8% among patients older than 75. Patients over 75 had significantly higher odds of delirium than younger patients (8% vs 5%; OR = 1.8, 95% CI 1.3–2.6). Preoperative dementia was present in 1.4% of the cohort and was more common in patients older than 75 (4% vs 1%; OR = 4.5, 95% CI 2.4–8.4).</p>\n\n<p>Delirium was associated with a history of stroke with residual deficit, pulmonary disease, active smoking, alcohol use/withdrawal, ICU escalation of care, and postoperative pulmonary or cardiac complications. Patients who developed delirium were older at the time of surgery (mean 66.3 vs 63.3 years; p = 0.004), had significantly worse preoperative performance status (mean ECOG difference 0.3; p = 0.0002), and were more likely to be functionally dependent, with delirium rates of 5% in functionally independent patients, 15% in partially dependent patients, and 19% in totally dependent patients (Pearson χ² = 40, p < 0.0001).</p>\n\n<p>Both postoperative delirium and preoperative dementia were associated with significantly prolonged hospitalization. Patients who developed delirium stayed an average of 6 days longer (15 vs 9.5 days; p < .0001) and patients with dementia remained hospitalized an additional 8 days (18 vs 10 days; p < .0001). Discharge disposition was also adversely affected: only 65% of patients with delirium and 63% of patients with dementia were discharged home, compared with approximately 86% of those without these conditions. Delirium was additionally associated with higher rates of flap compromise (13% vs 8%),  flap failure (11% vs 5%), increased postoperative mortality (10.5% vs 5.8%; OR = 1.9, p = 0.02) and 30-day readmission (20.4% vs 14.2%; OR = 1.5, p = 0.03). In contrast, preoperative dementia was not associated with flap-related complications or 30-day readmission but was linked to increased ICU escalation, pulmonary complications, and higher 6-month mortality.</p>\n\n<p><strong>Conclusion: </strong>Both postoperative delirium and preoperative dementia are strongly associated with advanced age, prolonged hospitalization, non-home discharge, and worse postoperative outcomes following free flap reconstruction. Recognizing these risk factors provides an opportunity to implement pre and post-operative strategies aimed at improving patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154008--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S409",
      "content_id": "154247",
      "abstract_number": "S409",
      "poster_number": "",
      "title": "Comprehensive Nomogram to prevent Mandible Osteoradionecrosis in Patients Who Received Marginal Mandibulectomy and Free Flap Reconstruction for Oral Cavity Squamous Cell Carcinoma",
      "summary": "For patients with Remnant mandibular height < 50 % after marginal mandibulectomy, periosteal stripping status and total dose of RT can be used to construct a nomogram to predict ORN in planned marginal mandibulectomy and to recommend conversion to segmental mandibulectomy when the risk is beyond clinical threshold. Key words: Oral cancer, osteoradionecrosis, mandibulectomy, radiotherapy, nomogram.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154247",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dante De Paz, MD, MSc",
      "presenter": "Dante De Paz, MD, MSc",
      "authors": "Dante De Paz, MD, MSc ; Wei Fu Chan, MD, FACS",
      "normalized_authors": [
        "Dante De Paz",
        "Wei Fu Chan"
      ],
      "affiliations": [
        "Chang Gung Memorial Hospital"
      ],
      "normalized_institutions": [
        "Chang Gung Memorial Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 341,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Dante De Paz, MD, MSc ; Wei Fu Chan, MD, FACS",
        "Affiliations": "Chang Gung Memorial Hospital",
        "Objectives": "In this study we will study Oral Cavity Squamous Cell Carcinoma (OCSCC) patients that received marginal mandibulectomy and their different risk factors to develop mandible osteoradionecrosis (ORN). According to these results we will evaluate the benefit of deciding on intraoperative conversion from marginal into segmental mandibulectomy avoiding the late complications of radiotherapy and it consequences.",
        "Methods": "We reviewed restrospectively clinical data of 119 patients with OCSCC who underwent Marginal Mandibulectomy with free tissue transfer reconstruction that received different modalities of post operative RT, from December 2007 to March 2019. The association of ORN with different clinicopathological and surgical factors was evaluated, furthermore after Classification And Regression Tree (CART) and logistic regression analysis, we established a nomogram.",
        "Results": "The development of ORN was significantly associated with advanced stage of OCSCC (p<0.05), the resected bone/original bone ratio <50% (p<0.01), the resection of facial and inferior alveolar arteries or the preservation of only facial artery (p<0.01), periosteal stripping of the buccal side or lingual and buccal sides of the remnant mandible (p<0.01); Intensity Modulated RT-Conventional RT and total dose ≥ 6600 cGy (p<0.01and p<0.01, respectively). Multivariate analysis revealed that periosteal stripping of the buccal side or lingual and buccal sides of the remnant mandible and total dose of RT ≥ 6600 cGy were independent risk factors for postoperative ORN. In the next step, CART with univariate and multivariate logistic regression analysis to predict ORN were used. A nomogram consisting of total dose of RT and periosteal stripping for patients with remnant bone height ≤ 50 % after marginal mandibulectomy was established; the C-index of this nomogram was 0.855, with a mean absolute error = 0.028.",
        "Conclusions": "For patients with Remnant mandibular height < 50 % after marginal mandibulectomy, periosteal stripping status and total dose of RT can be used to construct a nomogram to predict ORN in planned marginal mandibulectomy and to recommend conversion to segmental mandibulectomy when the risk is beyond clinical threshold. Key words: Oral cancer, osteoradionecrosis, mandibulectomy, radiotherapy, nomogram.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comprehensive Nomogram to prevent Mandible Osteoradionecrosis in Patients Who Received Marginal Mandibulectomy and Free Flap Reconstruction for Oral Cavity Squamous Cell Carcinoma</span>. <u>Dante De Paz, MD, MSc</u>; Wei Fu Chan, MD, FACS. Chang Gung Memorial Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> In this study we will study Oral Cavity Squamous Cell Carcinoma (OCSCC) patients that received marginal mandibulectomy and their different risk factors to develop mandible osteoradionecrosis (ORN). According to these results we will evaluate the benefit of deciding on intraoperative conversion from marginal into segmental mandibulectomy avoiding the late complications of radiotherapy and it consequences.</p>\n\n<p><strong>Methods:</strong> We reviewed restrospectively clinical data of 119 patients with OCSCC who underwent Marginal Mandibulectomy with free tissue transfer reconstruction that received different modalities of post operative RT, from December 2007 to March 2019. The association of ORN with different clinicopathological and surgical factors was evaluated, furthermore after Classification And Regression Tree (CART) and logistic regression analysis, we established a nomogram.</p>\n\n<p><strong>Results:</strong> The development of ORN was significantly associated with advanced stage of OCSCC (p<0.05), the resected bone/original bone ratio <50% (p<0.01), the resection of facial and inferior alveolar arteries or the preservation of only facial artery (p<0.01), periosteal stripping of the buccal side or lingual and buccal sides of the remnant mandible (p<0.01); Intensity Modulated RT-Conventional RT and total dose ≥ 6600 cGy (p<0.01and p<0.01, respectively). Multivariate analysis revealed that periosteal stripping of the buccal side or lingual and buccal sides of the remnant mandible and total dose of RT ≥ 6600 cGy were independent risk factors for postoperative ORN. In the next step, CART with univariate and multivariate logistic regression analysis to predict ORN were used. A nomogram consisting of total dose of RT and periosteal stripping for patients with remnant bone height ≤ 50 % after marginal mandibulectomy was established; the C-index of this nomogram was 0.855, with a mean absolute error = 0.028.</p>\n\n<p><strong>Conclusions:</strong> For patients with Remnant mandibular height < 50 % after marginal mandibulectomy, periosteal stripping status and total dose of RT can be used to construct a nomogram to predict ORN in planned marginal mandibulectomy and to recommend conversion to segmental mandibulectomy when the risk is beyond clinical threshold. Key words: Oral cancer, osteoradionecrosis, mandibulectomy, radiotherapy, nomogram.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154247--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S410",
      "content_id": "154322",
      "abstract_number": "S410",
      "poster_number": "",
      "title": "Hemorrhagic Outcomes Following Transoral Robotic Surgery for OPSCC With and Without Free Flap Reconstruction: A Large Single-Institution Series",
      "summary": "A total of 1,076 patients underwent TORS woFFR, and 253 underwent TORS wFFR. Patients woFFR were significantly more likely to return to the OR for postoperative OPH than were patients wFFR (5.76% vs. 2.77%, p=0.04). Among patients who experienced OPH, patients wFFR experienced significantly lower EBL compared with patients woFFR (mean EBL 39.9 vs. 162.6 mL, p<0.001). Two patients woFFR died from postoperative OPH...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154322",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annie E Arrighi-Allisan, MD",
      "presenter": "Annie E Arrighi-Allisan, MD",
      "authors": "Annie E Arrighi-Allisan, MD ; Dante Merlino, MD, PhD; Ryan Carey, MD; Karthik Rajasekaran, MD; Ara A Chalian, MD; Robert M Brody, MD; Gregory S Weinstein, MD; Steven B Cannady, MD",
      "normalized_authors": [
        "Annie E Arrighi-Allisan",
        "Dante Merlino",
        "Ryan Carey",
        "Karthik Rajasekaran",
        "Ara A Chalian",
        "Robert M Brody",
        "Gregory S Weinstein",
        "Steven B Cannady"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 525,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion/Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Annie E Arrighi-Allisan, MD ; Dante Merlino, MD, PhD; Ryan Carey, MD; Karthik Rajasekaran, MD; Ara A Chalian, MD; Robert M Brody, MD; Gregory S Weinstein, MD; Steven B Cannady, MD",
        "Affiliations": "Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System",
        "Introduction": "Transoral robotic surgery (TORS) has become a cornerstone in the surgical management of oropharyngeal squamous cell carcinoma (OPSCC), offering excellent oncologic and functional outcomes with reduced morbidity. While TORS is traditionally performed without complex reconstruction, select patients with larger tumors, exposed great vessels, or prior radiation may require free flap reconstruction (FFR). The role of FFR in TORS remains debated, with concerns that reconstruction may dilute the minimally invasive advantages while introducing added operative risk. Despite low rates of oropharyngeal hemorrhage (OPH) in modern series (3-10%), OPH remains a feared and potentially catastrophic complication after TORS. This study examines the impact of FFR on postoperative hemorrhage patterns and perioperative outcomes following TORS for OPSCC.",
        "Methods": "All cases of TORS for OPSCC with and without free flap reconstruction (wFFR, woFFR) between 6/8/2018 and 10/22/2025 were included. Returns to the operating room (OR) for bleeding, perioperative estimated blood loss (EBL), hemorrhage location and source, airway interventions, and perioperative outcomes were reviewed. Group comparisons were performed using Chi-squared, Welch’s t-test, and Fisher exact tests.",
        "Results": "A total of 1,076 patients underwent TORS woFFR, and 253 underwent TORS wFFR. Patients woFFR were significantly more likely to return to the OR for postoperative OPH than were patients wFFR (5.76% vs. 2.77%, p=0.04). Among patients who experienced OPH, patients wFFR experienced significantly lower EBL compared with patients woFFR (mean EBL 39.9 vs. 162.6 mL, p<0.001). Two patients woFFR died from postoperative OPH (0.19%, 0% wFFR). Patients wFFR were less likely to require urgent tracheostomy/recannulation or prolonged intubation following hemorrhage (0.04% vs. 1.6%, p=0.22). Patients wFFR were more likely to return to the OR for neck hematoma compared to those who underwent neck dissection alone (4.35% vs. 0.84%, p<0.001). The flap pedicle was proven to be the causative vessel in 45.5% of hematoma cases. Overall flap compromise from postoperative bleeding occurred in 1.2%.",
        "Discussion/Conclusions": "In this large single-institution series, TORS wFFR was associated with significantly lower rates and severities of postoperative OPH. This finding is particularly compelling given that patients selected for reconstruction typically possess larger tumors and exposed vascular structures – anatomic features that would be expected to amplify hemorrhage risk and, in some cases, redirect patients towards definitive high-dose chemoradiation rather than surgery. Instead, free flap reconstruction appears to mitigate, rather than magnify, the risk of catastrophic oropharyngeal bleeding following TORS.",
        "Abstract": "While rates of neck hematoma were higher in patients wFFR, these rates parallel those reported in contemporary microvascular series, while our institution’s post-neck dissection hematoma rate woFFR remains markedly lower than published benchmarks. Flap compromise remained rare, and nearly half of hematomas originated from the flap pedicle, underscoring the critical role of meticulous microvascular technique and postoperative surveillance. Our findings demonstrate that TORS wFFR can be performed with lower OPH incidence and severity than TORS alone, without introducing prohibitive reconstructive risk. Rather than negating the advantages of minimally invasive surgery, selective reconstruction may expand the boundaries of surgical candidacy, offering high-risk patients a safe surgical alternative to nonsurgical management. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Hemorrhagic Outcomes Following Transoral Robotic Surgery for OPSCC With and Without Free Flap Reconstruction: A Large Single-Institution Series</span>. <u>Annie E Arrighi-Allisan, MD</u>; Dante Merlino, MD, PhD; Ryan Carey, MD; Karthik Rajasekaran, MD; Ara A Chalian, MD; Robert M Brody, MD; Gregory S Weinstein, MD; Steven B Cannady, MD. Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Transoral robotic surgery (TORS) has become a cornerstone in the surgical management of oropharyngeal squamous cell carcinoma (OPSCC), offering excellent oncologic and functional outcomes with reduced morbidity. While TORS is traditionally performed without complex reconstruction, select patients with larger tumors, exposed great vessels, or prior radiation may require free flap reconstruction (FFR). The role of FFR in TORS remains debated, with concerns that reconstruction may dilute the minimally invasive advantages while introducing added operative risk. Despite low rates of oropharyngeal hemorrhage (OPH) in modern series (3-10%), OPH remains a feared and potentially catastrophic complication after TORS. This study examines the impact of FFR on postoperative hemorrhage patterns and perioperative outcomes following TORS for OPSCC.</p>\n\n<p><strong>Methods</strong>: All cases of TORS for OPSCC with and without free flap reconstruction (wFFR, woFFR) between 6/8/2018 and 10/22/2025 were included. Returns to the operating room (OR) for bleeding, perioperative estimated blood loss (EBL), hemorrhage location and source, airway interventions, and perioperative outcomes were reviewed. Group comparisons were performed using Chi-squared, Welch’s t-test, and Fisher exact tests.</p>\n\n<p><strong>Results</strong>: A total of 1,076 patients underwent TORS woFFR, and 253 underwent TORS wFFR. Patients woFFR were significantly more likely to return to the OR for postoperative OPH than were patients wFFR (5.76% vs. 2.77%, p=0.04). Among patients who experienced OPH, patients wFFR experienced significantly lower EBL compared with patients woFFR (mean EBL 39.9 vs. 162.6 mL, p<0.001). Two patients woFFR died from postoperative OPH (0.19%, 0% wFFR). Patients wFFR were less likely to require urgent tracheostomy/recannulation or prolonged intubation following hemorrhage (0.04% vs. 1.6%, p=0.22). Patients wFFR were more likely to return to the OR for neck hematoma compared to those who underwent neck dissection alone (4.35% vs. 0.84%, p<0.001). The flap pedicle was proven to be the causative vessel in 45.5% of hematoma cases. Overall flap compromise from postoperative bleeding occurred in 1.2%.</p>\n\n<p><strong>Discussion/Conclusions</strong>: In this large single-institution series, TORS wFFR was associated with significantly lower rates and severities of postoperative OPH. This finding is particularly compelling given that patients selected for reconstruction typically possess larger tumors and exposed vascular structures – anatomic features that would be expected to amplify hemorrhage risk and, in some cases, redirect patients towards definitive high-dose chemoradiation rather than surgery. Instead, free flap reconstruction appears to mitigate, rather than magnify, the risk of catastrophic oropharyngeal bleeding following TORS.</p>\n\n<p>While rates of neck hematoma were higher in patients wFFR, these rates parallel those reported in contemporary microvascular series, while our institution’s post-neck dissection hematoma rate woFFR remains markedly lower than published benchmarks. Flap compromise remained rare, and nearly half of hematomas originated from the flap pedicle, underscoring the critical role of meticulous microvascular technique and postoperative surveillance.</p>\n\n<p>Our findings demonstrate that TORS wFFR can be performed with lower OPH incidence and severity than TORS alone, without introducing prohibitive reconstructive risk. Rather than negating the advantages of minimally invasive surgery, selective reconstruction may expand the boundaries of surgical candidacy, offering high-risk patients a safe surgical alternative to nonsurgical management.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154322--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S411",
      "content_id": "151733",
      "abstract_number": "S411",
      "poster_number": "",
      "title": "Head and Neck Free Flap Reconstruction Outcomes in GLP-1 Users",
      "summary": "Head and neck cancer patients with a history of GLP-1 agonist use are at increased risk of flap complications and delayed wound dehiscence after free flap reconstructive surgery, however, at lower risk of mortality in comparison to non-users of GLP-1 agonists. These results highlight the complex interplay between metabolic therapy and surgical outcomes and the need for further investigation into perioperative...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151733",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mona Wong, BS",
      "presenter": "Mona Wong, BS",
      "authors": "Mona Wong, BS 1 ; Ella P Jackert, BS 1 ; Niels Kokot, MD 2",
      "normalized_authors": [
        "Mona Wong",
        "Ella P Jackert",
        "Niels Kokot"
      ],
      "affiliations": [
        "Keck School of Medicine",
        "Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California"
      ],
      "normalized_institutions": [
        "Keck School of Medicine",
        "Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 306,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Goal",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mona Wong, BS 1 ; Ella P Jackert, BS 1 ; Niels Kokot, MD 2",
        "Affiliations": "1 Keck School of Medicine; 2 Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California",
        "Goal": "This study investigates the post-operative and functional outcomes of free flap reconstruction in head and neck cancer patients with a history of GLP-1 agonist use.",
        "Methods": "The TriNetX US Collaborative Network identified patients who underwent free flap reconstructive surgery for head and neck malignancies from 2005-2025. Patients were stratified by history of GLP-1 agonist use versus non-users. Cohorts were propensity score matched by demographics, nicotine, tobacco, and alcohol use, relevant comorbidities including indications for GLP-1 agonist use, and primary tumor site. Primary outcomes included flap complications, early flap revisions, and mortality; secondary outcomes encompassed surgical-site infection (SSI), wound dehiscence, tracheostomy dependence, gastrostomy dependence, and opioid use and were compared at three postoperative time points: 1 day-6 months, 1-6months, 6-12months.",
        "Results": "After matching, each cohort (GLP-1 agonist users and non-users) consisted of 482 patients. At 1 day to 6 months, flap complications were rare in both cohorts, but GLP-1 agonist users were at a statistically significantly increased risk compared to non-users (RR: 1.941, 95% CI: [1.096,3.437]). However, GLP-1 agonist users had lower mortality risk (RR: 0.578, 95% CI: [0.363,0.921]. At 1-6 months, GLP-1 agonist users were at a statistically significantly increased risk of wound dehiscence (RR: 1.895, 95% Cl: [1.103,3.256]). There was no significant difference in rates of flap revisions, SSI, tracheostomy dependence, gastrostomy dependence, and opioid use at any post-operative time point.",
        "Conclusion": "Head and neck cancer patients with a history of GLP-1 agonist use are at increased risk of flap complications and delayed wound dehiscence after free flap reconstructive surgery, however, at lower risk of mortality in comparison to non-users of GLP-1 agonists. These results highlight the complex interplay between metabolic therapy and surgical outcomes and the need for further investigation into perioperative management strategies for this patient population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Head and Neck Free Flap Reconstruction Outcomes in GLP-1 Users</span>. <u>Mona Wong, BS</u><sup>1</sup>; Ella P Jackert, BS<sup>1</sup>; Niels Kokot, MD<sup>2</sup>. <sup>1</sup>Keck School of Medicine; <sup>2</sup>Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Goal:</strong> This study investigates the post-operative and functional outcomes of free flap reconstruction in head and neck cancer patients with a history of GLP-1 agonist use.</p>\n\n<p><strong>Methods:</strong> The TriNetX US Collaborative Network identified patients who underwent free flap reconstructive surgery for head and neck malignancies from 2005-2025. Patients were stratified by history of GLP-1 agonist use versus non-users. Cohorts were propensity score matched by demographics, nicotine, tobacco, and alcohol use, relevant comorbidities including indications for GLP-1 agonist use, and primary tumor site. Primary outcomes included flap complications, early flap revisions, and mortality; secondary outcomes encompassed surgical-site infection (SSI), wound dehiscence, tracheostomy dependence, gastrostomy dependence, and opioid use and were compared at three postoperative time points: 1 day-6 months, 1-6months, 6-12months.</p>\n\n<p><strong>Results:</strong> After matching, each cohort (GLP-1 agonist users and non-users) consisted of 482 patients. At 1 day to 6 months, flap complications were rare in both cohorts, but GLP-1 agonist users were at a statistically significantly increased risk compared to non-users (RR: 1.941, 95% CI: [1.096,3.437]). However, GLP-1 agonist users had lower mortality risk (RR: 0.578, 95% CI: [0.363,0.921]. At 1-6 months, GLP-1 agonist users were at a statistically significantly increased risk of wound dehiscence (RR: 1.895, 95% Cl: [1.103,3.256]). There was no significant difference in rates of flap revisions, SSI, tracheostomy dependence, gastrostomy dependence, and opioid use at any post-operative time point.</p>\n\n<p><strong>Conclusion: </strong>Head and neck cancer patients with a history of GLP-1 agonist use are at increased risk of flap complications and delayed wound dehiscence after free flap reconstructive surgery, however, at lower risk of mortality in comparison to non-users of GLP-1 agonists. These results highlight the complex interplay between metabolic therapy and surgical outcomes and the need for further investigation into perioperative management strategies for this patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151733--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S412",
      "content_id": "146856",
      "abstract_number": "S412",
      "poster_number": "",
      "title": "Free Flap Reconstruction in Head and Neck Angiosarcoma: Insights from a 21-Year, Multi-Institutional Cohort",
      "summary": "Age at presentation (range: 21-88 years; SD 14 years) and initial tumor size (range: 1.2-14.5 cm; SD 3.6 cm) demonstrated substantial variability. Latissimus dorsi (46.0%) and anterolateral thigh (27.0%) were the most frequently employed reconstructive flaps, and the scalp represented the most common primary site (72.7%). Clear margins were obtained in 75.7% of cases. The superficial temporal and facial arteries...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146856",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Annie E Arrighi-Allisan, MD",
      "presenter": "Annie E Arrighi-Allisan, MD",
      "authors": "Annie E Arrighi-Allisan, MD 1 ; Matthew M Hanasono, MD 2 ; Mark Wax, MD 3 ; Andres Bur, MD 4 ; Naomi Wang, MD 4 ; Punam Thakkar, MD 5 ; Sandhya Ganesan, MS 5 ; Brett Miles, MD, DDS 6 ; Ryan Winters, MD 7 ; Yadranko Ducic, MD 8 ; Jolly S Grewal, MD 8 ; Steven B Cannady, MD 9",
      "normalized_authors": [
        "Annie E Arrighi-Allisan",
        "Matthew M Hanasono",
        "Mark Wax",
        "Andres Bur",
        "Naomi Wang",
        "Punam Thakkar",
        "Sandhya Ganesan",
        "Brett Miles",
        "Ryan Winters",
        "Yadranko Ducic",
        "Jolly S Grewal",
        "Steven B Cannady"
      ],
      "affiliations": [
        "University of Pennsylvania Health System",
        "Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center",
        "Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University",
        "Department of Otolaryngology – Head and Neck Surgery, University of Kansas Medical Center",
        "Department of Otolaryngology, George Washington University School of Medicine and Health Sciences",
        "Department of Otolaryngology, Head and Neck Surgery, Northwell Cancer Institute",
        "Department of Otolaryngology - Head & Neck Surgery, John Hunter Hospital, New Lambton Heights, Australia and Tulane University",
        "Department of Otolaryngology, Baylor Scott & White All Saints Medical Center",
        "Department of Otolaryngology - Head and Neck Surgery, University of Pennsylvania Health System"
      ],
      "normalized_institutions": [
        "University of Pennsylvania Health System",
        "Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center",
        "Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University",
        "Department of Otolaryngology – Head and Neck Surgery, University of Kansas Medical Center",
        "Department of Otolaryngology, George Washington University School of Medicine and Health Sciences",
        "Department of Otolaryngology, Head and Neck Surgery, Northwell Cancer Institute",
        "Department of Otolaryngology - Head & Neck Surgery, John Hunter Hospital, New Lambton Heights, Australia and Tulane University",
        "Department of Otolaryngology, Baylor Scott & White All Saints Medical Center",
        "Department of Otolaryngology - Head and Neck Surgery, University of Pennsylvania Health System"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 496,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction/Background",
        "Methods",
        "Results",
        "Conclusions/Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Annie E Arrighi-Allisan, MD 1 ; Matthew M Hanasono, MD 2 ; Mark Wax, MD 3 ; Andres Bur, MD 4 ; Naomi Wang, MD 4 ; Punam Thakkar, MD 5 ; Sandhya Ganesan, MS 5 ; Brett Miles, MD, DDS 6 ; Ryan Winters, MD 7 ; Yadranko Ducic, MD 8 ; Jolly S Grewal, MD 8 ; Steven B Cannady, MD 9",
        "Affiliations": "1 University of Pennsylvania Health System; 2 Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center; 3 Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University; 4 Department of Otolaryngology – Head and Neck Surgery, University of Kansas Medical Center; 5 Department of Otolaryngology, George Washington University School of Medicine and Health Sciences; 6 Department of Otolaryngology, Head and Neck Surgery, Northwell Cancer Institute; 7 Department of Otolaryngology - Head & Neck Surgery, John Hunter Hospital, New Lambton Heights, Australia and Tulane University; 8 Department of Otolaryngology, Baylor Scott & White All Saints Medical Center; 9 Department of Otolaryngology - Head and Neck Surgery, University of Pennsylvania Health System",
        "Introduction/Background": "Angiosarcomas of the head and neck are rare and aggressive vascular malignancies with high rates of local recurrence and distant metastasis. Surgical resection with adjuvant therapy remains the cornerstone of treatment, often necessitating complex reconstruction that provides durable protection for critical structures in the setting of high-dose postoperative radiation. Although free flaps provide reliable vascularized coverage, their role in the reconstruction of head and neck angiosarcomas (HNA) remains nuanced in the context of overall poor prognosis. This study evaluates the clinical and oncologic outcomes of patients undergoing free flap reconstruction following the resection of head and neck angiosarcomas.",
        "Methods": "A retrospective review was conducted across seven institutions over a 21-year time period (2005-2025); data of 37 patients who underwent free flap reconstruction after HNA resection were reviewed. Patient demographics, tumor and free flap characteristics, perioperative complications, and oncologic outcomes were analyzed. Prolonged length of stay was defined as greater than 7 days. Mean follow-up time was 9.4 years.",
        "Results": "Age at presentation (range: 21-88 years; SD 14 years) and initial tumor size (range: 1.2-14.5 cm; SD 3.6 cm) demonstrated substantial variability. Latissimus dorsi (46.0%) and anterolateral thigh (27.0%) were the most frequently employed reconstructive flaps, and the scalp represented the most common primary site (72.7%). Clear margins were obtained in 75.7% of cases. The superficial temporal and facial arteries (67.6% and 29.7%, respectively) and veins (64.9% and 18.9%, respectively) were the most common recipient vessels. Average length of stay was 7.3 days, with 29.7% receiving ICU care for an average of 4.55 days. Non-home discharge occurred in 21.6% of patients. Postoperative complications were observed in 43.2% of patients, including unexpected return to OR (13.5%) and 30-day ED visit (10.1%) and readmission (10.8%). Prolonged hospitalization was noted in 29.7%. One patient suffered total flap loss (2.7%). Recurrent disease developed in 51.4% of patients (35.1% within one year of free flap reconstruction), 68.4% of which occurred within the primary site and 57.9% of which developed metastatically. Mortality was significant: 13.5% died within 6 months of free flap reconstruction, and 21.6% within one year. At the time of analysis, 48.6% of patients had succumbed to their disease.",
        "Conclusions/Discussion": "This study represents the largest multi-institutional series to date examining clinical and oncologic outcomes of patients with HNAs reconstructed with free tissue transfer. Despite the aggressive nature of this disease and its propensity for early endothelial invasion, technical flap success was high and comparable to that of free flaps reconstructing other malignancies in this region. However, the oncologic outcomes observed, marked by frequent local recurrence, high rates of distant metastases, and substantial mortality, highlight the dismal prognosis of HNA rather than the limitations of reconstructive technique. These results support the continued use of free tissue transfer as a cornerstone of reconstruction following oncologic resection in this challenging disease.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Flap Reconstruction in Head and Neck Angiosarcoma: Insights from a 21-Year, Multi-Institutional Cohort</span>. <u>Annie E Arrighi-Allisan, MD</u><sup>1</sup>; Matthew M Hanasono, MD<sup>2</sup>; Mark Wax, MD<sup>3</sup>; Andres Bur, MD<sup>4</sup>; Naomi Wang, MD<sup>4</sup>; Punam Thakkar, MD<sup>5</sup>; Sandhya Ganesan, MS<sup>5</sup>; Brett Miles, MD, DDS<sup>6</sup>; Ryan Winters, MD<sup>7</sup>; Yadranko Ducic, MD<sup>8</sup>; Jolly S Grewal, MD<sup>8</sup>; Steven B Cannady, MD<sup>9</sup>. <sup>1</sup>University of Pennsylvania Health System; <sup>2</sup>Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center; <sup>3</sup>Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University; <sup>4</sup>Department of Otolaryngology – Head and Neck Surgery, University of Kansas Medical Center; <sup>5</sup>Department of Otolaryngology, George Washington University School of Medicine and Health Sciences; <sup>6</sup>Department of Otolaryngology, Head and Neck Surgery, Northwell Cancer Institute; <sup>7</sup>Department of Otolaryngology - Head & Neck Surgery, John Hunter Hospital, New Lambton Heights, Australia and Tulane University; <sup>8</sup>Department of Otolaryngology, Baylor Scott & White All Saints Medical Center; <sup>9</sup>Department of Otolaryngology - Head and Neck Surgery, University of Pennsylvania Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction/Background: </strong>Angiosarcomas of the head and neck are rare and aggressive vascular malignancies with high rates of local recurrence and distant metastasis. Surgical resection with adjuvant therapy remains the cornerstone of treatment, often necessitating complex reconstruction that provides durable protection for critical structures in the setting of high-dose postoperative radiation. Although free flaps provide reliable vascularized coverage, their role in the reconstruction of head and neck angiosarcomas (HNA) remains nuanced in the context of overall poor prognosis. This study evaluates the clinical and oncologic outcomes of patients undergoing free flap reconstruction following the resection of head and neck angiosarcomas.</p>\n\n<p><strong>Methods:</strong> A retrospective review was conducted across seven institutions over a 21-year time period (2005-2025); data of 37 patients who underwent free flap reconstruction after HNA resection were reviewed. Patient demographics, tumor and free flap characteristics, perioperative complications, and oncologic outcomes were analyzed. Prolonged length of stay was defined as greater than 7 days. Mean follow-up time was 9.4 years.</p>\n\n<p><strong>Results:</strong> Age at presentation (range: 21-88 years; SD 14 years) and initial tumor size (range: 1.2-14.5 cm; SD 3.6 cm) demonstrated substantial variability. Latissimus dorsi (46.0%) and anterolateral thigh (27.0%) were the most frequently employed reconstructive flaps, and the scalp represented the most common primary site (72.7%). Clear margins were obtained in 75.7% of cases. The superficial temporal and facial arteries (67.6% and 29.7%, respectively) and veins (64.9% and 18.9%, respectively) were the most common recipient vessels. Average length of stay was 7.3 days, with 29.7% receiving ICU care for an average of 4.55 days. Non-home discharge occurred in 21.6% of patients. Postoperative complications were observed in 43.2% of patients, including unexpected return to OR (13.5%) and 30-day ED visit (10.1%) and readmission (10.8%). Prolonged hospitalization was noted in 29.7%. One patient suffered total flap loss (2.7%). Recurrent disease developed in 51.4% of patients (35.1% within one year of free flap reconstruction), 68.4% of which occurred within the primary site and 57.9% of which developed metastatically. Mortality was significant: 13.5% died within 6 months of free flap reconstruction, and 21.6% within one year. At the time of analysis, 48.6% of patients had succumbed to their disease.</p>\n\n<p><strong>Conclusions/Discussion:</strong> This study represents the largest multi-institutional series to date examining clinical and oncologic outcomes of patients with HNAs reconstructed with free tissue transfer. Despite the aggressive nature of this disease and its propensity for early endothelial invasion, technical flap success was high and comparable to that of free flaps reconstructing other malignancies in this region. However, the oncologic outcomes observed, marked by frequent local recurrence, high rates of distant metastases, and substantial mortality, highlight the dismal prognosis of HNA rather than the limitations of reconstructive technique. These results support the continued use of free tissue transfer as a cornerstone of reconstruction following oncologic resection in this challenging disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146856--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S413",
      "content_id": "154170",
      "abstract_number": "S413",
      "poster_number": "",
      "title": "Preoperative Functional Status as the Dominant Predictor of Major Complications After Head and Neck Free-Flap Reconstruction",
      "summary": "Preoperative functional status, as measured by ECOG performance status, is the dominant independent predictor of major complications following head and neck free-flap reconstruction, outperforming traditional medical comorbidities. ECOG demonstrates a clear dose–response relationship with medical complications, flap-specific complications, return to the operating room, and mortality, independent of operative...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154170",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Pozin, MSE",
      "presenter": "Michael Pozin, MSE",
      "authors": "Michael Pozin, MSE ; Molly E Heft Neal, MD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; Chaz L Stucken, MD; Mark EP Prince, MD; Kelly M Malloy, MD, MBA; David Forner, MD, MSc; Pratyusha Yalamanchi, MD, MBA",
      "normalized_authors": [
        "Michael Pozin, MSE",
        "Molly E Heft Neal",
        "Marisa R Buchakjian",
        "Keith A Casper",
        "Chaz L Stucken",
        "Mark EP Prince",
        "Kelly M Malloy",
        "David Forner",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "Department of Otolaryngology, University of Michigan"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 527,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michael Pozin, MSE ; Molly E Heft Neal, MD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; Chaz L Stucken, MD; Mark EP Prince, MD; Kelly M Malloy, MD, MBA; David Forner, MD, MSc; Pratyusha Yalamanchi, MD, MBA",
        "Affiliations": "Department of Otolaryngology, University of Michigan",
        "Introduction": "Postoperative morbidity following head and neck free-flap reconstruction remains substantial despite advances in surgical technique and perioperative care. Postoperative morbidity following head and neck free-flap reconstruction remains substantial despite advances in surgical technique and perioperative care. Although commonly used risk stratification tools incorporate composite risk indices (e.g., ASA class, NSQIP predictors, and frailty measures), they may not fully capture global functional reserve. This study evaluates the relationship between preoperative Eastern Cooperative Oncology Group (ECOG) performance status and postoperative outcomes, with specific attention to medical versus flap-specific complications.This study evaluates the relationship between preoperative Eastern Cooperative Oncology Group (ECOG) performance status and postoperative outcomes, with specific attention to medical versus flap-specific complications.",
        "Methods": "A retrospective cohort study was performed of 945 patients undergoing head and neck free-flap reconstruction at a single institution. Preoperative variables included ECOG performance status, age, body mass index, renal disease, congestive heart failure, diabetes mellitus, and chronic obstructive pulmonary disease. The primary outcome was major complication, defined as Clavien–Dindo grade III–V, return to the operating room, or death. Secondary outcomes included flap-specific complications (flap loss, thrombosis, or return to the operating room for flap compromise), medical complications (including pneumonia, respiratory complications, and urinary tract infection), 30-day readmission, and mortality. Univariable and multivariable logistic regression were used to identify independent predictors of major complications. ECOG was modeled as an ordinal (0–4) variable to assess dose–response. Receiver operating characteristic (ROC) analysis assessed discriminative performance. Intraoperative time was analyzed to assess potential confounding by operative complexity.",
        "Results": "A total of 945 patients were included (mean age 63.4 ± 12.6 years). ECOG performance status was 0 in 45.8%, 1 in 45.9%, 2 in 7.2%, and ≥3 in only 1.1% of patients, reflecting expected preoperative surgical selection. Rates of major complications increased monotonically with worsening ECOG: 16.4% (ECOG 0), 21.4% (ECOG 1), 45.6% (ECOG 2), and 60.0% (ECOG ≥3) (p < 0.001). On univariable logistic regression, ECOG demonstrated a strong dose–response relationship with major complications (OR 1.84 per point, 95% CI 1.47–2.29, p < 0.001) and remained the only independent predictor on multivariable analysis (OR 1.85, 95% CI 1.47–2.33, p < 0.001). ECOG also independently predicted both flap-specific complications (OR 1.50, 95% CI 1.04–2.17, p = 0.029) and medical complications (OR 2.16, 95% CI 1.45–3.22, p < 0.001). Operative time did not differ by ECOG (p = 0.099). Discrimination for ECOG was modest but statistically significant (AUC 0.596, 95% CI 0.555–0.638).",
        "Conclusion": "Preoperative functional status, as measured by ECOG performance status, is the dominant independent predictor of major complications following head and neck free-flap reconstruction, outperforming traditional medical comorbidities. ECOG demonstrates a clear dose–response relationship with medical complications, flap-specific complications, return to the operating room, and mortality, independent of operative duration. These findings emphasize that global physiologic reserve rather than isolated comorbid diagnoses is the primary driver of reconstructive risk. Routine incorporation of formal functional status assessment may significantly improve preoperative counseling, surgical decision-making, and perioperative risk stratification.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Functional Status as the Dominant Predictor of Major Complications After Head and Neck Free-Flap Reconstruction</span>. <u>Michael Pozin, MSE</u>; Molly E Heft Neal, MD; Marisa R Buchakjian, MD, PhD; Keith A Casper, MD; Chaz L Stucken, MD; Mark EP Prince, MD; Kelly M Malloy, MD, MBA; David Forner, MD, MSc; Pratyusha Yalamanchi, MD, MBA. Department of Otolaryngology, University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Postoperative morbidity following head and neck free-flap reconstruction remains substantial despite advances in surgical technique and perioperative care. Postoperative morbidity following head and neck free-flap reconstruction remains substantial despite advances in surgical technique and perioperative care. Although commonly used risk stratification tools incorporate composite risk indices (e.g., ASA class, NSQIP predictors, and frailty measures), they may not fully capture global functional reserve. This study evaluates the relationship between preoperative Eastern Cooperative Oncology Group (ECOG) performance status and postoperative outcomes, with specific attention to medical versus flap-specific complications.This study evaluates the relationship between preoperative Eastern Cooperative Oncology Group (ECOG) performance status and postoperative outcomes, with specific attention to medical versus flap-specific complications.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was performed of 945 patients undergoing head and neck free-flap reconstruction at a single institution. Preoperative variables included ECOG performance status, age, body mass index, renal disease, congestive heart failure, diabetes mellitus, and chronic obstructive pulmonary disease. The primary outcome was major complication, defined as Clavien–Dindo grade III–V, return to the operating room, or death. Secondary outcomes included flap-specific complications (flap loss, thrombosis, or return to the operating room for flap compromise), medical complications (including pneumonia, respiratory complications, and urinary tract infection), 30-day readmission, and mortality. Univariable and multivariable logistic regression were used to identify independent predictors of major complications. ECOG was modeled as an ordinal (0–4) variable to assess dose–response. Receiver operating characteristic (ROC) analysis assessed discriminative performance. Intraoperative time was analyzed to assess potential confounding by operative complexity.</p>\n\n<p><strong>Results: </strong>A total of 945 patients were included (mean age 63.4 ± 12.6 years). ECOG performance status was 0 in 45.8%, 1 in 45.9%, 2 in 7.2%, and ≥3 in only 1.1% of patients, reflecting expected preoperative surgical selection. Rates of major complications increased monotonically with worsening ECOG: 16.4% (ECOG 0), 21.4% (ECOG 1), 45.6% (ECOG 2), and 60.0% (ECOG ≥3) (p < 0.001). On univariable logistic regression, ECOG demonstrated a strong dose–response relationship with major complications (OR 1.84 per point, 95% CI 1.47–2.29, p < 0.001) and remained the only independent predictor on multivariable analysis (OR 1.85, 95% CI 1.47–2.33, p < 0.001). ECOG also independently predicted both flap-specific complications (OR 1.50, 95% CI 1.04–2.17, p = 0.029) and medical complications (OR 2.16, 95% CI 1.45–3.22, p < 0.001). Operative time did not differ by ECOG (p = 0.099). Discrimination for ECOG was modest but statistically significant (AUC 0.596, 95% CI 0.555–0.638).</p>\n\n<p><strong>Conclusion: </strong>Preoperative functional status, as measured by ECOG performance status, is the dominant independent predictor of major complications following head and neck free-flap reconstruction, outperforming traditional medical comorbidities. ECOG demonstrates a clear dose–response relationship with medical complications, flap-specific complications, return to the operating room, and mortality, independent of operative duration. These findings emphasize that global physiologic reserve rather than isolated comorbid diagnoses is the primary driver of reconstructive risk. Routine incorporation of formal functional status assessment may significantly improve preoperative counseling, surgical decision-making, and perioperative risk stratification.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154170--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S414",
      "content_id": "154302",
      "abstract_number": "S414",
      "poster_number": "",
      "title": "Lower Lip Innervation: A Literature Review and Discussion of Implications for the Head and Neck Surgeon",
      "summary": "The cervical branch plays a clinically meaningful role in lower lip depression through its contribution to the DLI. Awareness of this innervation pathway is critical for head and neck surgeons aiming to minimize facial asymmetry. The dual innervation of the DLI by both the MMN and CB may explain the generally favorable recovery patterns seen post-injury, which can help inform patient counseling and management....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154302",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Syed Shahzeb Hasan, MD",
      "presenter": "Syed Shahzeb Hasan, MD",
      "authors": "Joy Chen, MD; Syed Shahzeb Hasan, MD ; Eric Genden, MD; Mingyang Gray, MD, MPH",
      "normalized_authors": [
        "Joy Chen",
        "Syed Shahzeb Hasan",
        "Eric Genden",
        "Mingyang Gray"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154302/screenshot%202025-12-05%20at%2011_17_42%E2%80%AFam.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154302/screenshot%202025-12-05%20at%2011_17_42%E2%80%AFam.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154302"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 421,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joy Chen, MD; Syed Shahzeb Hasan, MD ; Eric Genden, MD; Mingyang Gray, MD, MPH",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Background": "An asymmetric smile is a potentially devastating morbidity of head and neck surgery. Although preservation of the marginal mandibular nerve (MMN) is a well-established surgical priority, the contribution of the cervical branch (CB) to lower lip symmetry remained less understood. Recent in vitro and in vivo studies, however, suggest the CB may directly innervate the depressor labii inferioris (DLI). This challenges the traditional belief that the CB’s impact is mediated solely by the platysma. We present a review of the anatomical evidence regarding the cervical branch and its specific contribution to lower lip movement to provide surgical recommendations based on these findings.",
        "Methods": "A comprehensive literature search was conducted using the PubMed database in October 2025. Search terms include: (\"marginal mandibular nerve\" OR \"marginal mandibular branch\" OR \"cervical branch\") AND (\"facial nerve anatomy\" OR \"dual innervation\" OR \"lower lip palsy\" OR \"lower lip weakness\") AND (\"head and neck surgery\" OR \"neck dissection\" OR \"facial plastic surgery\" OR \"anatomic study\"). Following the primary database search, the reference lists of all included articles were hand-searched (backward citation searching) to identify additional studies that may not have been included by the initial search terms, but were deemed relevant based on the predefined inclusion criteria.",
        "Results": "Eight studies met inclusion criteria, encompassing both cadaveric dissections and intraoperative mapping analyses. Two were in vivo studies utilizing intraoperative nerve mapping. The first, involving 60 patients, demonstrated a unique lower lip innervation pattern with contribution from the CB, distinct from the MMN, via muscle activation following nerve branch stimulation. The second in vivo study, with 20 patients undergoing selective neurectomies, specifically showed that the DLI has dual innervation from both the MMN and CB. The remaining studies included one cadaveric study in identifying the location of the CB, one cadaveric study on communication between the transverse cutaneous nerve and the CB, one review on CB surgical anatomy for injury avoidance, and three papers focusing on MMN identification techniques.",
        "Conclusion": "The cervical branch plays a clinically meaningful role in lower lip depression through its contribution to the DLI. Awareness of this innervation pathway is critical for head and neck surgeons aiming to minimize facial asymmetry. The dual innervation of the DLI by both the MMN and CB may explain the generally favorable recovery patterns seen post-injury, which can help inform patient counseling and management. Future studies incorporating intraoperative nerve monitoring, objective facial analysis, and patient-reported outcomes are needed to further define the functional importance of the CB and to develop strategies for its preservation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lower Lip Innervation: A Literature Review and Discussion of Implications for the Head and Neck Surgeon</span>. Joy Chen, MD; <u>Syed Shahzeb Hasan, MD</u>; Eric Genden, MD; Mingyang Gray, MD, MPH. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>An asymmetric smile is a potentially devastating morbidity of head and neck surgery. Although preservation of the marginal mandibular nerve (MMN) is a well-established surgical priority, the contribution of the cervical branch (CB) to lower lip symmetry remained less understood. Recent in vitro and in vivo studies, however, suggest the CB may directly innervate the depressor labii inferioris (DLI). This challenges the traditional belief that the CB’s impact is mediated solely by the platysma. We present a review of the anatomical evidence regarding the cervical branch and its specific contribution to lower lip movement to provide surgical recommendations based on these findings.</p>\n\n<p><strong>Methods: </strong>A comprehensive literature search was conducted using the PubMed database in October 2025. Search terms include: (\"marginal mandibular nerve\" OR \"marginal mandibular branch\" OR \"cervical branch\") AND (\"facial nerve anatomy\" OR \"dual innervation\" OR \"lower lip palsy\" OR \"lower lip weakness\") AND (\"head and neck surgery\" OR \"neck dissection\" OR \"facial plastic surgery\" OR \"anatomic study\"). Following the primary database search, the reference lists of all included articles were hand-searched (backward citation searching) to identify additional studies that may not have been included by the initial search terms, but were deemed relevant based on the predefined inclusion criteria.</p>\n\n<p><strong>Results: </strong>Eight studies met inclusion criteria, encompassing both cadaveric dissections and intraoperative mapping analyses. Two were in vivo studies utilizing intraoperative nerve mapping. The first, involving 60 patients, demonstrated a unique lower lip innervation pattern with contribution from the CB, distinct from the MMN, via muscle activation following nerve branch stimulation. The second in vivo study, with 20 patients undergoing selective neurectomies, specifically showed that the DLI has dual innervation from both the MMN and CB. The remaining studies included one cadaveric study in identifying the location of the CB, one cadaveric study on communication between the transverse cutaneous nerve and the CB, one review on CB surgical anatomy for injury avoidance, and three papers focusing on MMN identification techniques.</p>\n\n<p><strong>Conclusion:</strong> The cervical branch plays a clinically meaningful role in lower lip depression through its contribution to the DLI. Awareness of this innervation pathway is critical for head and neck surgeons aiming to minimize facial asymmetry. The dual innervation of the DLI by both the MMN and CB may explain the generally favorable recovery patterns seen post-injury, which can help inform patient counseling and management. Future studies incorporating intraoperative nerve monitoring, objective facial analysis, and patient-reported outcomes are needed to further define the functional importance of the CB and to develop strategies for its preservation.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154302/screenshot%202025-12-05%20at%2011_17_42%E2%80%AFam.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154302--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S415",
      "content_id": "154306",
      "abstract_number": "S415",
      "poster_number": "",
      "title": "Longitudinal Analysis of Quality of Life Outcomes for Patients with Osteoradionecrosis of the Jaw",
      "summary": "The cohort consisted of 84 patients (70% male; mean age 70 years). Most had squamous cell carcinoma of the oral cavity (53%) or oropharynx (28%), with predominantly advanced primary tumors (77% T2–T4; 47% N2–N3). ORNJ developed after a mean of 6.4 years following radiotherapy (median 3.4 years). At ORNJ diagnosis, patients exhibited a substantial symptom burden, with the highest scores in dry mouth, social eating...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154306",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Benoît Trap, MD",
      "presenter": "Benoît Trap, MD",
      "authors": "Benoît Trap, MD 1 ; Robert Haddad, MD 2 ; Nathaniel S Treister, DMD 3 ; Rosh K Sethi, MD, MPH 4",
      "normalized_authors": [
        "Benoît Trap",
        "Robert Haddad",
        "Nathaniel S Treister",
        "Rosh K Sethi"
      ],
      "affiliations": [
        "Mass General Brigham",
        "Dana-Farber Cancer Institute",
        "Mass General Brigham Division of Oral Medicine and Dentistry",
        "Mass General Brigham Department of Otolaryngology-Head and Neck Surgery and Harvard Medical School"
      ],
      "normalized_institutions": [
        "Mass General Brigham",
        "Dana-Farber Cancer Institute",
        "Mass General Brigham Division of Oral Medicine and Dentistry",
        "Mass General Brigham Department of Otolaryngology-Head and Neck Surgery and Harvard Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154306/AbstractORNGraph.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154306/AbstractORNGraph.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154306"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting, and Participants",
        "Exposures",
        "Main Outcomes and Measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Benoît Trap, MD 1 ; Robert Haddad, MD 2 ; Nathaniel S Treister, DMD 3 ; Rosh K Sethi, MD, MPH 4",
        "Affiliations": "1 Mass General Brigham; 2 Dana-Farber Cancer Institute; 3 Mass General Brigham Division of Oral Medicine and Dentistry; 4 Mass General Brigham Department of Otolaryngology-Head and Neck Surgery and Harvard Medical School",
        "Importance": "Osteoradionecrosis of the jaw (ORNJ) is a serious late complication of radiotherapy for head and neck cancer and may contribute to worse physical, psychological and social well-being that compounds the burden of cancer survivorship. However, the long-term patient experience and the impact of different treatment approaches on quality of life remain poorly described.",
        "Objective": "To better understand the real-world impact of ORNJ in individuals over an extended follow-up period.",
        "Design, Setting, and Participants": "This patient-centered study included prospectively collected patient reported outcome measures (PROM) data from ORNJ patients treated at a tertiary care center between October 2021 and October 2025. Patients completed the EORTC QLQ-H&N43 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Head and Neck Cancer Module 43 items) questionnaire as part of routine follow-up. All consecutive questionnaire responses were retrospectively analyzed.",
        "Exposures": "Patients had previously received radiotherapy for head and neck cancer and subsequently developed ORNJ. Treatment pathways for ORNJ included observation, antibiotics, pentoxifylline/Vitamin E, hyperbaric oxygen therapy, bony sequestrectomy, and segmental resection with reconstruction, or a combination of these.",
        "Main Outcomes and Measures": "Longitudinal symptom scores derived from the QLQ-H&N43 domains, evaluated across repeated assessments in time.",
        "Results": "The cohort consisted of 84 patients (70% male; mean age 70 years). Most had squamous cell carcinoma of the oral cavity (53%) or oropharynx (28%), with predominantly advanced primary tumors (77% T2–T4; 47% N2–N3). ORNJ developed after a mean of 6.4 years following radiotherapy (median 3.4 years). At ORNJ diagnosis, patients exhibited a substantial symptom burden, with the highest scores in dry mouth, social eating difficulties, mouth-opening problems, and body-image concerns (range 50–65). Shoulder problems and fear of progression were comparatively mild (range 20–25). In follow-up analyses using standardized follow-up windows (0–6 months, 6–12 months, 12–24 months, 24–36 months, and ≥36 months) and continuous time mixed models demonstrated no significant time effects across all domains (e.g., speech: p = 0.114). Pre/post comparisons revealed no significant changes around diagnosis (e.g., swallowing p = 0.660). Differences between treatment pathways (conservative, adjunctive, surgical) were minimal and not statistically significant (e.g., treatment group main effect: p = 0.505; treatment × time interaction: p = 0.229). ORNJ stage was associated with overall symptom severity in a consistent pattern across time-window analyses, higher stages showing worse PROM scores.",
        "Conclusions and Relevance": "ORNJ is associated with substantial and enduring impairments in multiple quality-of-life domains. This longitudinal study provides valuable insight into which domains are most affected and suggests disease severity (ORNJ stage) as a primary determinant of symptom severity over time. These findings can be used by clinicians to better understand the challenges patients face in daily life, in counseling patients, and setting realistic expectations regarding the course of ORNJ-related dysfunction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Longitudinal Analysis of Quality of Life Outcomes for Patients with Osteoradionecrosis of the Jaw</span>. <u>Benoît Trap, MD</u><sup>1</sup>; Robert Haddad, MD<sup>2</sup>; Nathaniel S Treister, DMD<sup>3</sup>; Rosh K Sethi, MD, MPH<sup>4</sup>. <sup>1</sup>Mass General Brigham; <sup>2</sup>Dana-Farber Cancer Institute; <sup>3</sup>Mass General Brigham Division of Oral Medicine and Dentistry; <sup>4</sup>Mass General Brigham Department of Otolaryngology-Head and Neck Surgery and Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Osteoradionecrosis of the jaw (ORNJ) is a serious late complication of radiotherapy for head and neck cancer and may contribute to worse physical, psychological and social well-being that compounds the burden of cancer survivorship. However, the long-term patient experience and the impact of different treatment approaches on quality of life remain poorly described.</p>\n\n<p><strong>Objective:</strong> To better understand the real-world impact of ORNJ in individuals over an extended follow-up period.</p>\n\n<p><strong>Design, Setting, and Participants:</strong> This patient-centered study included prospectively collected patient reported outcome measures (PROM) data from ORNJ patients treated at a tertiary care center between October 2021 and October 2025. Patients completed the EORTC QLQ-H&N43 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Head and Neck Cancer Module 43 items) questionnaire as part of routine follow-up. All consecutive questionnaire responses were retrospectively analyzed.</p>\n\n<p><strong>Exposures:</strong> Patients had previously received radiotherapy for head and neck cancer and subsequently developed ORNJ. Treatment pathways for ORNJ included observation, antibiotics, pentoxifylline/Vitamin E, hyperbaric oxygen therapy, bony sequestrectomy, and segmental resection with reconstruction, or a combination of these.</p>\n\n<p><strong>Main Outcomes and Measures:</strong> Longitudinal symptom scores derived from the QLQ-H&N43 domains, evaluated across repeated assessments in time.</p>\n\n<p><strong>Results:</strong> The cohort consisted of 84 patients (70% male; mean age 70 years). Most had squamous cell carcinoma of the oral cavity (53%) or oropharynx (28%), with predominantly advanced primary tumors (77% T2–T4; 47% N2–N3). ORNJ developed after a mean of 6.4 years following radiotherapy (median 3.4 years). At ORNJ diagnosis, patients exhibited a substantial symptom burden, with the highest scores in dry mouth, social eating difficulties, mouth-opening problems, and body-image concerns (range 50–65). Shoulder problems and fear of progression were comparatively mild (range 20–25). In follow-up analyses using standardized follow-up windows (0–6 months, 6–12 months, 12–24 months, 24–36 months, and ≥36 months) and continuous time mixed models demonstrated no significant time effects across all domains (e.g., speech: p = 0.114). Pre/post comparisons revealed no significant changes around diagnosis (e.g., swallowing p = 0.660). Differences between treatment pathways (conservative, adjunctive, surgical) were minimal and not statistically significant (e.g., treatment group main effect: p = 0.505; treatment × time interaction: p = 0.229). ORNJ stage was associated with overall symptom severity in a consistent pattern across time-window analyses, higher stages showing worse PROM scores.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154306/AbstractORNGraph.jpg' /></p>\n\n<p><strong>Conclusions and Relevance:</strong> ORNJ is associated with substantial and enduring impairments in multiple quality-of-life domains. This longitudinal study provides valuable insight into which domains are most affected and suggests disease severity (ORNJ stage) as a primary determinant of symptom severity over time. These findings can be used by clinicians to better understand the challenges patients face in daily life, in counseling patients, and setting realistic expectations regarding the course of ORNJ-related dysfunction.</p>\n\n<p> </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154306--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S416",
      "content_id": "153404",
      "abstract_number": "S416",
      "poster_number": "",
      "title": "Triple Nerve Reanimation and Free Flap Reconstruction After Radical Parotidectomy: Early Evidence for Neuroprotective Benefit from a Vascularized Flap Environment",
      "summary": "Simultaneous triple facial reanimation with vascularized soft tissue coverage enhances facial symmetry and patient-reported psychosocial outcomes after radical parotidectomy with radiation therapy. Vascularized flaps may support nerve recovery by optimizing the local microenvironment, representing a feasible adjunct in complex head and neck reconstruction.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153404",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260147",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eun-Jae Chung",
      "presenter": "Eun-Jae Chung",
      "authors": "Joon Yong Park 1 ; Seo Young Kim 2 ; Eun-Jae Chung 2",
      "normalized_authors": [
        "Joon Yong Park",
        "Seo Young Kim",
        "Eun-Jae Chung"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea",
        "Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 237,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joon Yong Park 1 ; Seo Young Kim 2 ; Eun-Jae Chung 2",
        "Affiliations": "1 Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea; 2 Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
        "Background": "Radical parotidectomy often requires resection of the facial nerve, resulting in significant functional and psychosocial impairment. Triple facial nerve reanimation has shown promising outcomes, but the effect of combining this technique with vascularized soft tissue flap coverage-particularly in the setting of postoperative radiation therapy-remains unclear. This study evaluates the functional and aesthetic outcomes of simultaneous triple facial reanimation and vascularized free flap reconstruction in patients undergoing radical parotidectomy followed by radiation therapy.",
        "Methods": "Fourteen patients with parotid malignancy requiring facial nerve trunk sacrifice underwent radical parotidectomy, neck dissection, and triple nerve reanimation, combined with immediate radial forearm free flap (RFFF) reconstruction. Objective facial function was assessed using Emotrics+ software across five facial symmetry parameters immediately postoperatively and at one year. Surgeon-based grading systems were applied, and patient-reported outcomes were measured using the Facial Disability Index (FDI).",
        "Results": "All five Emotrics+ parameters-brow height, marginal reflex distance 1 (MDR-1), commissure height, commissure excursion, and upper lip slope-showed significant improvement at one year (p<0.05). FDI analysis demonstrated significant improvement in the Social/Well-being subscale and Total score (p<0.05), while the Physical Function subscale did not reach statistical significance.",
        "Conclusion": "Simultaneous triple facial reanimation with vascularized soft tissue coverage enhances facial symmetry and patient-reported psychosocial outcomes after radical parotidectomy with radiation therapy. Vascularized flaps may support nerve recovery by optimizing the local microenvironment, representing a feasible adjunct in complex head and neck reconstruction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Triple Nerve Reanimation and Free Flap Reconstruction After Radical Parotidectomy: Early Evidence for Neuroprotective Benefit from a Vascularized Flap Environment</span>. Joon Yong Park<sup>1</sup>; Seo Young Kim<sup>2</sup>; <u>Eun-Jae Chung</u><sup>2</sup>. <sup>1</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Republic of Korea; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Radical parotidectomy often requires resection of the facial nerve, resulting in significant functional and psychosocial impairment. Triple facial nerve reanimation has shown promising outcomes, but the effect of combining this technique with vascularized soft tissue flap coverage-particularly in the setting of postoperative radiation therapy-remains unclear. This study evaluates the functional and aesthetic outcomes of simultaneous triple facial reanimation and vascularized free flap reconstruction in patients undergoing radical parotidectomy followed by radiation therapy.</p>\n\n<p><strong>Methods: </strong>Fourteen patients with parotid malignancy requiring facial nerve trunk sacrifice underwent radical parotidectomy, neck dissection, and triple nerve reanimation, combined with immediate radial forearm free flap (RFFF) reconstruction. Objective facial function was assessed using Emotrics+ software across five facial symmetry parameters immediately postoperatively and at one year. Surgeon-based grading systems were applied, and patient-reported outcomes were measured using the Facial Disability Index (FDI).</p>\n\n<p><strong>Results: </strong>All five Emotrics+ parameters-brow height, marginal reflex distance 1 (MDR-1), commissure height, commissure excursion, and upper lip slope-showed significant improvement at one year (p<0.05). FDI analysis demonstrated significant improvement in the Social/Well-being subscale and Total score (p<0.05), while the Physical Function subscale did not reach statistical significance.</p>\n\n<p><strong>Conclusion: </strong>Simultaneous triple facial reanimation with vascularized soft tissue coverage enhances facial symmetry and patient-reported psychosocial outcomes after radical parotidectomy with radiation therapy. Vascularized flaps may support nerve recovery by optimizing the local microenvironment, representing a feasible adjunct in complex head and neck reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153404--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260147' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S417",
      "content_id": "154059",
      "abstract_number": "S417",
      "poster_number": "",
      "title": "High Morbidity and Poor Functional Outcomes after Functional Salvage Total Laryngectomy",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154059",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Georges E Daoud, MD",
      "presenter": "Georges E Daoud, MD",
      "authors": "Humzah Ali, BS 1 ; Celeste S Kim, MD 2 ; Georges E Daoud, MD 2 ; Andrew M Peterson, MD 3 ; Patrik Pipkorn, MD 3 ; Katherine W Chang, MD 2 ; Lauren Ottenstein, CCCSLP 2 ; Nicole C Schmitt, MD 2 ; Brian J Boyce, MD 2 ; Azeem S Kaka, MD 2 ; Harry M Baddour, MD 2 ; Jennifer H Gross, MD 2",
      "normalized_authors": [
        "Humzah Ali",
        "Celeste S Kim",
        "Georges E Daoud",
        "Andrew M Peterson",
        "Patrik Pipkorn",
        "Katherine W Chang",
        "Lauren Ottenstein, CCCSLP",
        "Nicole C Schmitt",
        "Brian J Boyce",
        "Azeem S Kaka",
        "Harry M Baddour",
        "Jennifer H Gross"
      ],
      "affiliations": [
        "Medical College of Georgia at Augusta University",
        "Winship Cancer Institute of Emory University, Department of Otolaryngology Head & Neck Surgery",
        "Washington University in St. Louis, Department of Otolaryngology Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "Medical College of Georgia at Augusta University",
        "Winship Cancer Institute of Emory University, Department of Otolaryngology Head & Neck Surgery",
        "Washington University in St. Louis, Department of Otolaryngology Head & Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 428,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSIONS",
        "Abstract"
      ],
      "sections": {
        "Authors": "Humzah Ali, BS 1 ; Celeste S Kim, MD 2 ; Georges E Daoud, MD 2 ; Andrew M Peterson, MD 3 ; Patrik Pipkorn, MD 3 ; Katherine W Chang, MD 2 ; Lauren Ottenstein, CCCSLP 2 ; Nicole C Schmitt, MD 2 ; Brian J Boyce, MD 2 ; Azeem S Kaka, MD 2 ; Harry M Baddour, MD 2 ; Jennifer H Gross, MD 2",
        "Affiliations": "1 Medical College of Georgia at Augusta University; 2 Winship Cancer Institute of Emory University, Department of Otolaryngology Head & Neck Surgery; 3 Washington University in St. Louis, Department of Otolaryngology Head & Neck Surgery",
        "BACKGROUND": "Salvage functional total laryngectomy (STL) is performed to improve aerodigestive dysfunction after radiation, but patients who undergo STL can experience disproportionately high post-operative morbidity related to surgical manipulation in a radiated tissue bed. Prior radiotherapy (RT) induces progressive, irreversible tissue toxicity that significantly compromises tissue integrity and wound healing, with a nonfunctional larynx (NFL) representing the most severe end of this spectrum. It is important to anticipate and appropriately counsel this patient population on the post-operative impaired healing process, potential for fistula formation, and serious risk of long-term enteral dependence. The aim of this study is to characterize post-operative outcomes and morbidity following STL for NFL.",
        "METHODS": "This retrospective study examined all patients who underwent STL for NFL from January 2009 to September 2023 at two high-volume tertiary care centers. Patients with a previous head and neck cancer requiring radiation therapy were included. Those with recurrent head and neck cancer were excluded. Data collection included demographics, clinicopathologic characteristics, post-operative complications, and long-term functional outcomes, including rates of post-operative pharyngocutaneous fistula (PCF), hypocalcemia, esophageal stricture (ES), gastrostomy tube (GT) dependence, tracheoesophageal puncture (TEP) placement, and electrolarynx (EL) usage. Descriptive statistical analyses were performed.",
        "RESULTS": "Forty-five patients met inclusion criteria. Mean age was 69.5 years (SD: 9.4 years), and most patients were Caucasian (71%) and male (82%). Prior to STL, 93% (42/45) of patients had either a tracheostomy or GT, and 62.2% (28/45) had both. Almost all patients (44/45) underwent regional or free flap reconstruction at the time of laryngectomy. Post-operatively, patients experienced substantial short- and long-term morbidity including hypocalcemia in 58% (26/45) and PCF in 56% (25/45). Among those who developed PCF, the majority (56%, 14/25) required secondary surgical repair. Functionally, 73% (33/45) were GT-dependent post-operatively, and 61% (20/33) remained dependent on enteral nutrition at 1 year post-operatively. Additionally, 33% (15/45) developed esophageal strictures requiring operative dilation. Most patients required EL for communication (53%, 24/45), and only 26.7% (12/45) of patients were able to utilize TEP.",
        "CONCLUSIONS": "STL for NFL was associated with profound post-operative morbidity, with most patients developing hypocalcemia, PCF requiring revision surgical repair, and/or long-term GT dependence. One third of patients developed esophageal strictures requiring repeated dilation. Our findings illustrate the severe and irreversible RT-induced tissue injury present in this patient population and highlight the risk of post-operative complications and further diminished quality of life. Though STL is an important treatment modality for NFL, it is essential to appropriately counsel patients pre-operatively in this high-risk population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>High Morbidity and Poor Functional Outcomes after Functional Salvage Total Laryngectomy</span>. Humzah Ali, BS<sup>1</sup>; Celeste S Kim, MD<sup>2</sup>; <u>Georges E Daoud, MD</u><sup>2</sup>; Andrew M Peterson, MD<sup>3</sup>; Patrik Pipkorn, MD<sup>3</sup>; Katherine W Chang, MD<sup>2</sup>; Lauren Ottenstein, CCCSLP<sup>2</sup>; Nicole C Schmitt, MD<sup>2</sup>; Brian J Boyce, MD<sup>2</sup>; Azeem S Kaka, MD<sup>2</sup>; Harry M Baddour, MD<sup>2</sup>; Jennifer H Gross, MD<sup>2</sup>. <sup>1</sup>Medical College of Georgia at Augusta University; <sup>2</sup>Winship Cancer Institute of Emory University, Department of Otolaryngology Head & Neck Surgery; <sup>3</sup>Washington University in St. Louis, Department of Otolaryngology Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Salvage functional total laryngectomy (STL) is performed to improve aerodigestive dysfunction after radiation, but patients who undergo STL can experience disproportionately high post-operative morbidity related to surgical manipulation in a radiated tissue bed. Prior radiotherapy (RT) induces progressive, irreversible tissue toxicity that significantly compromises tissue integrity and wound healing, with a nonfunctional larynx (NFL) representing the most severe end of this spectrum. It is important to anticipate and appropriately counsel this patient population on the post-operative impaired healing process, potential for fistula formation, and serious risk of long-term enteral dependence. The aim of this study is to characterize post-operative outcomes and morbidity following STL for NFL.</p>\n\n<p><strong>METHODS: </strong>This retrospective study examined all patients who underwent STL for NFL from January 2009 to September 2023 at two high-volume tertiary care centers. Patients with a previous head and neck cancer requiring radiation therapy were included. Those with recurrent head and neck cancer were excluded. Data collection included demographics, clinicopathologic characteristics, post-operative complications, and long-term functional outcomes, including rates of post-operative pharyngocutaneous fistula (PCF), hypocalcemia, esophageal stricture (ES), gastrostomy tube (GT) dependence, tracheoesophageal puncture (TEP) placement, and electrolarynx (EL) usage. Descriptive statistical analyses were performed.</p>\n\n<p><strong>RESULTS: </strong>Forty-five patients met inclusion criteria. Mean age was 69.5 years (SD: 9.4 years), and most patients were Caucasian (71%) and male (82%). Prior to STL, 93% (42/45) of patients had either a tracheostomy or GT, and 62.2% (28/45) had both. Almost all patients (44/45) underwent regional or free flap reconstruction at the time of laryngectomy. Post-operatively, patients experienced substantial short- and long-term morbidity including hypocalcemia in 58% (26/45) and PCF in 56% (25/45). Among those who developed PCF, the majority (56%, 14/25) required secondary surgical repair. Functionally, 73% (33/45) were GT-dependent post-operatively, and 61% (20/33) remained dependent on enteral nutrition at 1 year post-operatively. Additionally, 33% (15/45) developed esophageal strictures requiring operative dilation. Most patients required EL for communication (53%, 24/45), and only 26.7% (12/45) of patients were able to utilize TEP.</p>\n\n<p><strong>CONCLUSIONS: </strong>STL for NFL was associated with profound post-operative morbidity, with most patients developing hypocalcemia, PCF requiring revision surgical repair, and/or long-term GT dependence. One third of patients developed esophageal strictures requiring repeated dilation. Our findings illustrate the severe and irreversible RT-induced tissue injury present in this patient population and highlight the risk of post-operative complications and further diminished quality of life. Though STL is an important treatment modality for NFL, it is essential to appropriately counsel patients pre-operatively in this high-risk population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154059--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S418",
      "content_id": "154338",
      "abstract_number": "S418",
      "poster_number": "",
      "title": "A Novel Extratracheal Device for Spirometry in Laryngectomized Patients",
      "summary": "This newly developed extratracheal device demonstrates excellent reliability and effectiveness for comprehensive pulmonary function assessment in laryngectomized patients, successfully addressing the technical challenges that have historically limited spirometry in this population. The device offers a practical solution that combines secure tracheostoma fixation, reliable air seal maintenance, and patient comfort...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154338",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rogério Aparecido Dedivitis, PhD, MD",
      "presenter": "Rogério Aparecido Dedivitis, PhD, MD",
      "authors": "Carlos Eduardo M Nardi, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Daniel A Ribeiro, PhD 3 ; Luiz Paulo Kowalski, PhD, MD 4 ; Bruno P Duarte, Mr 5 ; Rogério Aparecido Dedivitis, PhD, MD 4",
      "normalized_authors": [
        "Carlos Eduardo M Nardi",
        "Mario Augusto F Castro",
        "Daniel A Ribeiro",
        "Luiz Paulo Kowalski",
        "Bruno P Duarte, Mr",
        "Rogério Aparecido Dedivitis"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, Hospital Ana Costa, Santos, Brazil",
        "Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil",
        "Department of Head and Neck Surgery, University of São Paulo School of Medicine, São Paulo, Brazil",
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, Hospital Ana Costa, Santos, Brazil",
        "Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil",
        "Department of Head and Neck Surgery, University of São Paulo School of Medicine, São Paulo, Brazil",
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 491,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Carlos Eduardo M Nardi, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Daniel A Ribeiro, PhD 3 ; Luiz Paulo Kowalski, PhD, MD 4 ; Bruno P Duarte, Mr 5 ; Rogério Aparecido Dedivitis, PhD, MD 4",
        "Affiliations": "1 Department of Head and Neck Surgery, Hospital Ana Costa, Santos, Brazil; 2 Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; 3 Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil; 4 Department of Head and Neck Surgery, University of São Paulo School of Medicine, São Paulo, Brazil; 5 School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "Background": "Laryngectomized patients undergo total surgical removal of the larynx, resulting in permanent anatomical alterations that fundamentally change their respiratory physiology. These patients breathe exclusively through a tracheostoma, eliminating the normal upper airway pathway. Accurate spirometric assessment in this population presents significant technical challenges due to these anatomical modifications, making standard spirometry techniques inadequate or impossible to perform. Current methods for pulmonary function testing in laryngectomized patients have substantial limitations, including frequent air leakage around connection sites, patient discomfort during testing procedures, and inconsistent seal quality that compromises measurement accuracy. These technical difficulties often result in unreliable data or prevent testing altogether, limiting clinicians' ability to monitor pulmonary health in this vulnerable population.",
        "Objectives": "This study aimed to develop and validate a simple, comfortable, and cost-effective extratracheal device specifically designed for accurate pulmonary function testing in laryngectomized patients, addressing the critical gap in postoperative respiratory surveillance.",
        "Methods": "We designed an innovative silicone-based extratracheal device featuring a central connector that enables direct coupling with standard spirometry equipment without requiring specialized adapters. The device incorporates a medical-grade adhesive layer specifically engineered for secure fixation around the tracheostoma, ensuring an airtight seal during forced expiratory maneuvers while maintaining patient comfort throughout the testing procedure. Ten consecutive laryngectomized patients with stable tracheostomas were prospectively enrolled to undergo comprehensive spirometry testing using this newly developed device. All patients were instructed according to standard spirometry protocols, performing maximal inspiration followed by forced expiration. Key pulmonary function parameters including Forced Vital Capacity, Forced Expiratory Volume in one second, and the FEV1/FVC ratio were systematically measured and recorded. These measurements were subsequently compared to age, height, and gender-adjusted predicted values to assess pulmonary function status. Device performance was independently evaluated by two experienced pulmonologists who assessed technical adequacy, ease of use, and reliability of generated spirometric data according to established quality criteria for pulmonary function testing.",
        "Results": "The extratracheal device successfully maintained an adequate air seal during spirometric testing in all 10 enrolled patients throughout the complete testing protocol, with no documented air leakage at any point during forced expiratory maneuvers. This consistent seal quality ensured the integrity and reliability of all measurements obtained. All recorded spirometric measurements met the technical quality standards required for clinical interpretation according to international guidelines for pulmonary function testing, including acceptable repeatability and proper expiratory effort. The pulmonologists who independently evaluated the device performance confirmed that all generated spirograms demonstrated adequate quality for formal pulmonary function reporting and clinical decision-making. Patients reported minimal discomfort during the testing procedure, and the device demonstrated consistent performance across different tracheostoma sizes and configurations, suggesting broad applicability in the laryngectomized population.",
        "Conclusion": "This newly developed extratracheal device demonstrates excellent reliability and effectiveness for comprehensive pulmonary function assessment in laryngectomized patients, successfully addressing the technical challenges that have historically limited spirometry in this population. The device offers a practical solution that combines secure tracheostoma fixation, reliable air seal maintenance, and patient comfort during testing procedures.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Novel Extratracheal Device for Spirometry in Laryngectomized Patients</span>. Carlos Eduardo M Nardi, MD<sup>1</sup>; Mario Augusto F Castro, PhD, MD<sup>2</sup>; Daniel A Ribeiro, PhD<sup>3</sup>; Luiz Paulo Kowalski, PhD, MD<sup>4</sup>; Bruno P Duarte, Mr<sup>5</sup>; <u>Rogério Aparecido Dedivitis, PhD, MD</u><sup>4</sup>. <sup>1</sup>Department of Head and Neck Surgery, Hospital Ana Costa, Santos, Brazil; <sup>2</sup>Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; <sup>3</sup>Department of Biosciences, Federal University of São Paulo – Campus Baixada Santista, Santos, Brazil; <sup>4</sup>Department of Head and Neck Surgery, University of São Paulo School of Medicine, São Paulo, Brazil; <sup>5</sup>School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Laryngectomized patients undergo total surgical removal of the larynx, resulting in permanent anatomical alterations that fundamentally change their respiratory physiology. These patients breathe exclusively through a tracheostoma, eliminating the normal upper airway pathway. Accurate spirometric assessment in this population presents significant technical challenges due to these anatomical modifications, making standard spirometry techniques inadequate or impossible to perform. Current methods for pulmonary function testing in laryngectomized patients have substantial limitations, including frequent air leakage around connection sites, patient discomfort during testing procedures, and inconsistent seal quality that compromises measurement accuracy. These technical difficulties often result in unreliable data or prevent testing altogether, limiting clinicians' ability to monitor pulmonary health in this vulnerable population. </p>\n\n<p><strong>Objectives:</strong> This study aimed to develop and validate a simple, comfortable, and cost-effective extratracheal device specifically designed for accurate pulmonary function testing in laryngectomized patients, addressing the critical gap in postoperative respiratory surveillance.</p>\n\n<p><strong>Methods: </strong>We designed an innovative silicone-based extratracheal device featuring a central connector that enables direct coupling with standard spirometry equipment without requiring specialized adapters. The device incorporates a medical-grade adhesive layer specifically engineered for secure fixation around the tracheostoma, ensuring an airtight seal during forced expiratory maneuvers while maintaining patient comfort throughout the testing procedure. Ten consecutive laryngectomized patients with stable tracheostomas were prospectively enrolled to undergo comprehensive spirometry testing using this newly developed device. All patients were instructed according to standard spirometry protocols, performing maximal inspiration followed by forced expiration. Key pulmonary function parameters including Forced Vital Capacity, Forced Expiratory Volume in one second, and the FEV1/FVC ratio were systematically measured and recorded. These measurements were subsequently compared to age, height, and gender-adjusted predicted values to assess pulmonary function status. Device performance was independently evaluated by two experienced pulmonologists who assessed technical adequacy, ease of use, and reliability of generated spirometric data according to established quality criteria for pulmonary function testing.</p>\n\n<p><strong>Results:</strong> The extratracheal device successfully maintained an adequate air seal during spirometric testing in all 10 enrolled patients throughout the complete testing protocol, with no documented air leakage at any point during forced expiratory maneuvers. This consistent seal quality ensured the integrity and reliability of all measurements obtained. All recorded spirometric measurements met the technical quality standards required for clinical interpretation according to international guidelines for pulmonary function testing, including acceptable repeatability and proper expiratory effort. The pulmonologists who independently evaluated the device performance confirmed that all generated spirograms demonstrated adequate quality for formal pulmonary function reporting and clinical decision-making. Patients reported minimal discomfort during the testing procedure, and the device demonstrated consistent performance across different tracheostoma sizes and configurations, suggesting broad applicability in the laryngectomized population.</p>\n\n<p><strong>Conclusion:</strong> This newly developed extratracheal device demonstrates excellent reliability and effectiveness for comprehensive pulmonary function assessment in laryngectomized patients, successfully addressing the technical challenges that have historically limited spirometry in this population. The device offers a practical solution that combines secure tracheostoma fixation, reliable air seal maintenance, and patient comfort during testing procedures.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154338--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S419",
      "content_id": "153678",
      "abstract_number": "S419",
      "poster_number": "",
      "title": "Primary Versus In-Office Secondary Tracheoesophageal Prosthesis Placement: A Retrospective Comparative Outcomes Study",
      "summary": "Both primary and in-office secondary TEP provide reliable post-laryngectomy voice restoration. Primary TEP offers the convenience of a single intraoperative procedure under general anesthesia, whereas in-office secondary TEP requires a separate procedure but is safe, well-tolerated, and highly effective, with a lower risk of early prosthesis dislodgement and pharyngocutaneous fistula. Procedure selection should...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153678",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Julia Meehan, BA",
      "presenter": "Julia Meehan, BA",
      "authors": "Abdullah A Adil, MD; Andrew D Prince, MD; Julia Meehan, BA ; Mohamad Almasri, MD; Teresa Lyden, CCC, SLP; Anna Blakely, CCC, SLP; Madison Ambrose, CCC, SLP; Keith A Casper, MD; Kelly M Malloy, MD; Chaz L Stucken, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; David W Forner, MD; Molly E Heft-Neal, MD; Mark E Prince, MD",
      "normalized_authors": [
        "Abdullah A Adil",
        "Andrew D Prince",
        "Julia Meehan",
        "Mohamad Almasri",
        "Teresa Lyden, CCC, SLP",
        "Anna Blakely, CCC, SLP",
        "Madison Ambrose, CCC, SLP",
        "Keith A Casper",
        "Kelly M Malloy",
        "Chaz L Stucken",
        "Marisa R Buchakjian",
        "Pratyusha Yalamanchi",
        "David W Forner",
        "Molly E Heft-Neal",
        "Mark E Prince"
      ],
      "affiliations": [
        "University of Michigan"
      ],
      "normalized_institutions": [
        "University of Michigan"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 328,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Abdullah A Adil, MD; Andrew D Prince, MD; Julia Meehan, BA ; Mohamad Almasri, MD; Teresa Lyden, CCC, SLP; Anna Blakely, CCC, SLP; Madison Ambrose, CCC, SLP; Keith A Casper, MD; Kelly M Malloy, MD; Chaz L Stucken, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; David W Forner, MD; Molly E Heft-Neal, MD; Mark E Prince, MD",
        "Affiliations": "University of Michigan",
        "Objective": "To compare procedural and functional outcomes of primary tracheoesophageal puncture (TEP) performed at the time of total laryngectomy with in-office secondary TEP for post-laryngectomy voice restoration.",
        "Methods": "Records of 486 laryngectomized patients undergoing primary TEP (n = 116) or in-office secondary TEP (n = 370) from 2000–2024 were reviewed. Primary TEP was performed intraoperatively under general anesthesia; secondary TEP was performed in the office using local anesthesia and transnasal esophagoscopy. Patient demographics, clinical characteristics, procedural complications, prosthesis outcomes, and voicing results were analyzed.",
        "Results": "Median (range) age was 63 (37 – 83) and 63 (19 – 94) years for the primary and secondary TEP group, respectively. There were 68 (58.6%) salvage laryngectomies in the primary TEP cohort and 236 (63.8%) in the secondary TEP cohort. Free flap reconstruction was performed in 24 patients (20.7%) in the primary TEP group and in 303 (81.9%) of the secondary TEP group. Procedural success was high in both groups (100% primary, 98.9% secondary). Early prosthesis dislodgement occurred more frequently after primary TEP (25% vs. 14.9%, p = 0.001), and pharyngocutaneous fistula was also more common (42.2% vs. 25.1%, p < 0.001). Leakage rates were similar (74.1% vs. 77.3%, p = 0.483). Successful voicing was achieved in 96.6% of primary and 93.2% of secondary TEP patients (p = 0.368), with median follow-up of 49.4 and 28 months, respectively. Long-term TEP use remained high (88.7% vs. 85.3%, p = 0.357). In-office secondary TEP was well-tolerated, with rare complications including transient syncope (0.3%) and pneumothorax (0.5%).",
        "Conclusion": "Both primary and in-office secondary TEP provide reliable post-laryngectomy voice restoration. Primary TEP offers the convenience of a single intraoperative procedure under general anesthesia, whereas in-office secondary TEP requires a separate procedure but is safe, well-tolerated, and highly effective, with a lower risk of early prosthesis dislodgement and pharyngocutaneous fistula. Procedure selection should consider patient-specific factors, wound-healing risk, and preference.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Primary Versus In-Office Secondary Tracheoesophageal Prosthesis Placement: A Retrospective Comparative Outcomes Study</span>. Abdullah A Adil, MD; Andrew D Prince, MD; <u>Julia Meehan, BA</u>; Mohamad Almasri, MD; Teresa Lyden, CCC, SLP; Anna Blakely, CCC, SLP; Madison Ambrose, CCC, SLP; Keith A Casper, MD; Kelly M Malloy, MD; Chaz L Stucken, MD; Marisa R Buchakjian, MD; Pratyusha Yalamanchi, MD; David W Forner, MD; Molly E Heft-Neal, MD; Mark E Prince, MD. University of Michigan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To compare procedural and functional outcomes of primary tracheoesophageal puncture (TEP) performed at the time of total laryngectomy with in-office secondary TEP for post-laryngectomy voice restoration.</p>\n\n<p><strong>Methods:</strong> Records of 486 laryngectomized patients undergoing primary TEP (n = 116) or in-office secondary TEP (n = 370) from 2000–2024 were reviewed. Primary TEP was performed intraoperatively under general anesthesia; secondary TEP was performed in the office using local anesthesia and transnasal esophagoscopy. Patient demographics, clinical characteristics, procedural complications, prosthesis outcomes, and voicing results were analyzed.</p>\n\n<p><strong>Results:</strong> Median (range) age was 63 (37 – 83) and 63 (19 – 94) years for the primary and secondary TEP group, respectively. There were 68 (58.6%) salvage laryngectomies in the primary TEP cohort and 236 (63.8%) in the secondary TEP cohort. Free flap reconstruction was performed in 24 patients (20.7%) in the primary TEP group and in 303 (81.9%) of the secondary TEP group. Procedural success was high in both groups (100% primary, 98.9% secondary). Early prosthesis dislodgement occurred more frequently after primary TEP (25% vs. 14.9%, p = 0.001), and pharyngocutaneous fistula was also more common (42.2% vs. 25.1%, p < 0.001). Leakage rates were similar (74.1% vs. 77.3%, p = 0.483). Successful voicing was achieved in 96.6% of primary and 93.2% of secondary TEP patients (p = 0.368), with median follow-up of 49.4 and 28 months, respectively. Long-term TEP use remained high (88.7% vs. 85.3%, p = 0.357). In-office secondary TEP was well-tolerated, with rare complications including transient syncope (0.3%) and pneumothorax (0.5%).</p>\n\n<p><strong>Conclusion: </strong>Both primary and in-office secondary TEP provide reliable post-laryngectomy voice restoration. Primary TEP offers the convenience of a single intraoperative procedure under general anesthesia, whereas in-office secondary TEP requires a separate procedure but is safe, well-tolerated, and highly effective, with a lower risk of early prosthesis dislodgement and pharyngocutaneous fistula. Procedure selection should consider patient-specific factors, wound-healing risk, and preference.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153678--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S420",
      "content_id": "153850",
      "abstract_number": "S420",
      "poster_number": "",
      "title": "Caregiver Quality of Life in HNC Survivorship and Dysphagia: A Scoping Review of Standardized Tools",
      "summary": "This is the first inventory of psychometrically tested QoL-related tools for HNC caregivers targeting dysphagia. These findings did not identify a comprehensive QoL dysphagia-related tool for caregivers of HNC survivors. Given the cumulative impact of HNC and dysphagia on the caregiver, this review highlights a critical gap of QoL-related tools with a HNC- and dysphagia-specific focus for caregivers.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153850",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ala Refai",
      "presenter": "Ala Refai",
      "authors": "Ala Refai 1 ; Aliaa Sabry 2 ; Margaret Fitch 1 ; Jill I Cameron 1 ; Andrew McPartlin 2 ; Rosemary Martino 1",
      "normalized_authors": [
        "Ala Refai",
        "Aliaa Sabry",
        "Margaret Fitch",
        "Jill I Cameron",
        "Andrew McPartlin",
        "Rosemary Martino"
      ],
      "affiliations": [
        "University of Toronto",
        "University Health Network"
      ],
      "normalized_institutions": [
        "University of Toronto",
        "University Health Network"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 513,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ala Refai 1 ; Aliaa Sabry 2 ; Margaret Fitch 1 ; Jill I Cameron 1 ; Andrew McPartlin 2 ; Rosemary Martino 1",
        "Affiliations": "1 University of Toronto; 2 University Health Network",
        "Purpose": "Patients with head and neck cancer (HNC) may experience dysphagia related to cancer and treatments. As dysphagia predicts poor quality of life (QoL) for patients, it may also negatively impact their caregivers. Early work suggests that caregivers of patients with HNC have poorer psychological well-being and higher levels of distress, even compared to HNC patients themselves. Assessing the QoL of caregivers is critical to address the negative consequences of caregiving such as risks of poor psychological health; and there is a crucial need to better understand for HNC caregivers the effects of high prevalence and severity of dysphagia in HNC patients However, there is no inventory of QoL-related measurements to inform the selection of tools that have undergone psychometric testing solely in HNC caregivers, which includes dysphagia-related questions. This scoping review had three aims: (1) identify QoL-related tools psychometrically tested in HNC caregivers, (2) outline which of the six QoL domains outlined by the World Health Organization are targeted in each tool (i.e., physical capacity, psychological, level of independence, social relationships, environment, and spirituality/religion/spiritual beliefs), and (3) identify if any of these caregiver-oriented tools included items related to dysphagia.",
        "Methods": "This scoping review adhered to the Joanna Briggs Institute guidelines. Seven databases were searched from inception to October 27th, 2025. Screening of abstracts and then full articles of accepted abstracts abided by apriori criteria, which includes psychometrically tested QoL tools used with unpaid caregivers of solid tumour cancer patients. Interrater reliability on a random selection of 20% of abstracts was excellent (ICC=0.9). Data extracted related to psychometric properties guided by COSMIN definitions.",
        "Results": "Databases generated 14,448 abstracts, and of the 2,433 accepted for full-text screening, 62 articles solely recruited caregivers of HNC patients. Within these articles, data were extracted for 84 tools that included measures of reliability and/or validity in the HNC caregiver sample. Of the 84 tools, 58 tools were retrieved, of which, only 19 were developed specifically for caregivers and only 13 specifically for use in oncology. Of the 58 tools, four targeted all six QoL domains (7%), 11 targeted five domains (19%), five targeted four domains (9%), six targeted three domains (10%), 17 targeted two domains (30%), and 15 targeted one domain (26%). Only four tools included dysphagia-related questions. Of these four, only one tool targeted all six QoL domains; however, not in reference to dysphagia, and the number of dysphagia questions was 1 out of 54 (2%). Of the remaining, two tools targeted 1/6 domains and had 2/12 (16.67%) and 4/12 (33.33%) dysphagia-related questions. The fourth tool measured mealtime distress using an adaptation of the NCCM Distress Thermometer and covered 3/6 domains.",
        "Conclusion": "This is the first inventory of psychometrically tested QoL-related tools for HNC caregivers targeting dysphagia. These findings did not identify a comprehensive QoL dysphagia-related tool for caregivers of HNC survivors. Given the cumulative impact of HNC and dysphagia on the caregiver, this review highlights a critical gap of QoL-related tools with a HNC- and dysphagia-specific focus for caregivers.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Caregiver Quality of Life in HNC Survivorship and Dysphagia: A Scoping Review of Standardized Tools</span>. <u>Ala Refai</u><sup>1</sup>; Aliaa Sabry<sup>2</sup>; Margaret Fitch<sup>1</sup>; Jill I Cameron<sup>1</sup>; Andrew McPartlin<sup>2</sup>; Rosemary Martino<sup>1</sup>. <sup>1</sup>University of Toronto; <sup>2</sup>University Health Network<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> Patients with head and neck cancer (HNC) may experience dysphagia related to cancer and treatments. As dysphagia predicts poor quality of life (QoL) for patients, it may also negatively impact their caregivers. Early work suggests that caregivers of patients with HNC have poorer psychological well-being and higher levels of distress, even compared to HNC patients themselves. Assessing the QoL of caregivers is critical to address the negative consequences of caregiving such as risks of poor psychological health; and there is a crucial need to better understand for HNC caregivers the effects of high prevalence and severity of dysphagia in HNC patients However, there is no inventory of QoL-related measurements to inform the selection of tools that have undergone psychometric testing solely in HNC caregivers, which includes dysphagia-related questions. This scoping review had three aims: (1) identify QoL-related tools psychometrically tested in HNC caregivers, (2) outline which of the six QoL domains outlined by the World Health Organization are targeted in each tool (i.e., physical capacity, psychological, level of independence, social relationships, environment, and spirituality/religion/spiritual beliefs), and (3) identify if any of these caregiver-oriented tools included items related to dysphagia.</p>\n\n<p><strong>Methods:</strong> This scoping review adhered to the Joanna Briggs Institute guidelines. Seven databases were searched from inception to October 27th, 2025. Screening of abstracts and then full articles of accepted abstracts abided by apriori criteria, which includes psychometrically tested QoL tools used with unpaid caregivers of solid tumour cancer patients. Interrater reliability on a random selection of 20% of abstracts was excellent (ICC=0.9). Data extracted related to psychometric properties guided by COSMIN definitions.</p>\n\n<p><strong>Results:</strong> Databases generated 14,448 abstracts, and of the 2,433 accepted for full-text screening, 62 articles solely recruited caregivers of HNC patients. Within these articles, data were extracted for 84 tools that included measures of reliability and/or validity in the HNC caregiver sample. Of the 84 tools, 58 tools were retrieved, of which, only 19 were developed specifically for caregivers and only 13 specifically for use in oncology. Of the 58 tools, four targeted all six QoL domains (7%), 11 targeted five domains (19%), five targeted four domains (9%), six targeted three domains (10%), 17 targeted two domains (30%), and 15 targeted one domain (26%). Only four tools included dysphagia-related questions. Of these four, only one tool targeted all six QoL domains; however, not in reference to dysphagia, and the number of dysphagia questions was 1 out of 54 (2%). Of the remaining, two tools targeted 1/6 domains and had 2/12 (16.67%) and 4/12 (33.33%) dysphagia-related questions. The fourth tool measured mealtime distress using an adaptation of the NCCM Distress Thermometer and covered 3/6 domains.</p>\n\n<p><strong>Conclusion:</strong> This is the first inventory of psychometrically tested QoL-related tools for HNC caregivers targeting dysphagia. These findings did not identify a comprehensive QoL dysphagia-related tool for caregivers of HNC survivors. Given the cumulative impact of HNC and dysphagia on the caregiver, this review highlights a critical gap of QoL-related tools with a HNC- and dysphagia-specific focus for caregivers. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153850--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S421",
      "content_id": "153782",
      "abstract_number": "S421",
      "poster_number": "",
      "title": "Living Beyond Treatment: Post-Radiotherapy Long-Term Toxicities and Impact on Quality of Life in Nasopharyngeal Carcinoma Survivors",
      "summary": "Among local NPC survivors post-RT, dysphagia and depressive symptoms are strongly associated with poorer QOL. These findings highlight the need for comprehensive, multidisciplinary survivorship care—including targeted dysphagia rehabilitation, proactive psychological support, and systematic screening for other chronic toxicities—to optimise long-term functional and QOL outcomes in NPC survivors.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153782",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Si Ying Julienne Keong, MD, MRCSGlasg",
      "presenter": "Si Ying Julienne Keong, MD, MRCSGlasg",
      "authors": "Si Ying Julienne Keong, MD, MRCSGlasg 1 ; Irene Eng Ai Teo, PhD Clinical Psychology 2 ; Kimberley Liqin Kiong, MBBS, MRCSEdin, MMEDORL, FAMSORL 1 ; Chwee Ming Lim, MBBS, MRCSEdin, MMedORL, FAMSORL 1 ; Isabelle Jia Hui Jang, MD, MRCSGlasg, MMedORL, FAMSORL 1",
      "normalized_authors": [
        "Si Ying Julienne Keong, MRCSGlasg",
        "Irene Eng Ai Teo, Clinical Psychology",
        "Kimberley Liqin Kiong, MBBS, MRCSEdin, MMEDORL, FAMSORL",
        "Chwee Ming Lim, MBBS, MRCSEdin, MMedORL, FAMSORL",
        "Isabelle Jia Hui Jang, MRCSGlasg, MMedORL, FAMSORL"
      ],
      "affiliations": [
        "Singapore General Hospital",
        "National Cancer Centre Singapore"
      ],
      "normalized_institutions": [
        "Singapore General Hospital",
        "National Cancer Centre Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 563,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Si Ying Julienne Keong, MD, MRCSGlasg 1 ; Irene Eng Ai Teo, PhD Clinical Psychology 2 ; Kimberley Liqin Kiong, MBBS, MRCSEdin, MMEDORL, FAMSORL 1 ; Chwee Ming Lim, MBBS, MRCSEdin, MMedORL, FAMSORL 1 ; Isabelle Jia Hui Jang, MD, MRCSGlasg, MMedORL, FAMSORL 1",
        "Affiliations": "1 Singapore General Hospital; 2 National Cancer Centre Singapore",
        "Introduction": "Advances in radiotherapy (RT) for nasopharyngeal carcinoma (NPC) have improved survival, shifting focus toward long-term toxicities that significantly impact quality of life (QOL). Reported prevalence and severity of these toxicities vary due to heterogeneity in assessment tools and patient characteristics. Understanding the long-term burden among NPC survivors is essential. This study aimed to evaluate the association between clinical characteristics, post-RT long-term toxicities, and patient-reported QOL.",
        "Methods": "A cross sectional survey was administered during routine follow up at a single tertiary centre in a NPC endemic region. Informed consent was obtained. QOL was measured using the Functional Assessment of Cancer Therapy–Nasopharyngeal (FACT-NP), and psychological symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS). Clinical data was retrospectively collected. Collected data included demographics, treatment details, long-term toxicities and the Adult Comorbidity Evaluation-27 (ACE-27) index. Univariable analyses examined associations between patient reported outcomes (PRO), clinical toxicities and total FACT-NP scores. Multivariable analyses was performed to identify significant associations with lower FACT-NP scores (i.e. poorer QOL).",
        "Results": "80 NPC survivors who had completed RT treatment were surveyed. The median time from treatment was 4.0 years (IQR: 2.8-8.0). The median age was 50.5 years (mean 52.3 years); 75% were male and 98.8% Chinese. Eastern Cooperative Oncology Group (ECOG) Performance Status 0–1 at diagnosis was recorded in 97.6% of patients. 57.5% had advanced stage III–IV disease. Treatment included RT alone (38.8%), concurrent chemoradiotherapy (31.3%), and induction chemotherapy followed by chemoradiotherapy (30.0%). 23 patients had a ≥10 pack-year smoking history. The mean total FACT score was 121.2. The proportion with HADS-anxiety>7 was 16.25% and HADS-depression>7 was 20.0%.",
        "Abstract": "On univariable analyses, the following long-term toxicities were significantly associated with lower FACT-NP scores: carotid blowout (p=0.001, beta -37.9, 95% CI [-67.0, -8.8]), recurrent epistaxis (p=0.004, beta -35.6, 95% CI [-59.3, -11.8]), otitis media with effusion/chronic suppurative otitis media (p=0.030, beta -14.2, 95% CI [-27.1, -1.4]), osteoradionecrosis (p=0.033, beta -19.0, 95% CI [-36.4, -1.6]), dysphagia (p<0.001, beta -22.8, 95% CI [-35.1, -10.5]), trismus (p=0.003, beta -36.3, 95% CI [-60.1, -12.6]), and dysphonia (p=0.028, beta -19.1, 95% CI [-36.0, -2.1]). The need for tracheostomy (p=0.031, beta -45.5, 95% CI [-86.5, -4.31]) and feeding tube (p=0.044, beta -25.2, 95% CI [-49.6, -0.75]) were also associated with lower FACT-NP scores. Age, sex, ECOG performance status, disease stage, treatment modality, and ACE-27 score were not significantly associated with QOL. Psychological measures were strongly associated with poorer QOL; HADS-depression score >7 (p < 0.001) and HADS-anxiety score >7 (p = 0.012) were both associated with lower FACT-NP scores. In multivariable analysis, dysphagia (p = 0.007) and HADS-depression >7 (p = 0.007) remained significantly associated with poorer FACT-NP scores after adjusting for relevant toxicities and clinical variables. View in Agenda and Add to Schedule",
        "Conclusion": "Among local NPC survivors post-RT, dysphagia and depressive symptoms are strongly associated with poorer QOL. These findings highlight the need for comprehensive, multidisciplinary survivorship care—including targeted dysphagia rehabilitation, proactive psychological support, and systematic screening for other chronic toxicities—to optimise long-term functional and QOL outcomes in NPC survivors."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Living Beyond Treatment: Post-Radiotherapy Long-Term Toxicities and Impact on Quality of Life in Nasopharyngeal Carcinoma Survivors</span>. <u>Si Ying Julienne Keong, MD, MRCSGlasg</u><sup>1</sup>; Irene Eng Ai Teo, PhD Clinical Psychology<sup>2</sup>; Kimberley Liqin Kiong, MBBS, MRCSEdin, MMEDORL, FAMSORL<sup>1</sup>; Chwee Ming Lim, MBBS, MRCSEdin, MMedORL, FAMSORL<sup>1</sup>; Isabelle Jia Hui Jang, MD, MRCSGlasg, MMedORL, FAMSORL<sup>1</sup>. <sup>1</sup>Singapore General Hospital; <sup>2</sup>National Cancer Centre Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Advances in radiotherapy (RT) for nasopharyngeal carcinoma (NPC) have improved survival, shifting focus toward long-term toxicities that significantly impact quality of life (QOL). Reported prevalence and severity of these toxicities vary due to heterogeneity in assessment tools and patient characteristics. Understanding the long-term burden among NPC survivors is essential. This study aimed to evaluate the association between clinical characteristics, post-RT long-term toxicities, and patient-reported QOL.</p>\n\n<p><strong>Methods: </strong>A cross sectional survey was administered during routine follow up at a single tertiary centre in a NPC endemic region. Informed consent was obtained. QOL was measured using the Functional Assessment of Cancer Therapy–Nasopharyngeal (FACT-NP), and psychological symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS). Clinical data was retrospectively collected. Collected data included demographics, treatment details, long-term toxicities and the Adult Comorbidity Evaluation-27 (ACE-27) index. Univariable analyses examined associations between patient reported outcomes (PRO), clinical toxicities and total FACT-NP scores. Multivariable analyses was performed to identify significant associations with lower FACT-NP scores (i.e. poorer QOL).</p>\n\n<p><strong>Results: </strong>80 NPC survivors who had completed RT treatment were surveyed. The median time from treatment was 4.0 years (IQR: 2.8-8.0). The median age was 50.5 years (mean 52.3 years); 75% were male and 98.8% Chinese. Eastern Cooperative Oncology Group (ECOG) Performance Status 0–1 at diagnosis was recorded in 97.6% of patients. 57.5% had advanced stage III–IV disease. Treatment included RT alone (38.8%), concurrent chemoradiotherapy (31.3%), and induction chemotherapy followed by chemoradiotherapy (30.0%). 23 patients had a ≥10 pack-year smoking history. The mean total FACT score was 121.2. The proportion with HADS-anxiety>7 was 16.25% and HADS-depression>7 was 20.0%.</p>\n\n<p>On univariable analyses, the following long-term toxicities were significantly associated with lower FACT-NP scores: carotid blowout (p=0.001, beta -37.9, 95% CI [-67.0, -8.8]), recurrent epistaxis (p=0.004, beta -35.6, 95% CI [-59.3, -11.8]), otitis media with effusion/chronic suppurative otitis media (p=0.030, beta -14.2, 95% CI [-27.1, -1.4]), osteoradionecrosis (p=0.033, beta -19.0, 95% CI [-36.4, -1.6]), dysphagia (p<0.001, beta -22.8, 95% CI [-35.1, -10.5]), trismus (p=0.003, beta -36.3, 95% CI [-60.1, -12.6]), and dysphonia (p=0.028, beta -19.1, 95% CI [-36.0, -2.1]). The need for tracheostomy (p=0.031, beta -45.5, 95% CI [-86.5, -4.31]) and feeding tube (p=0.044, beta -25.2, 95% CI [-49.6, -0.75]) were also associated with lower FACT-NP scores.</p>\n\n<p>Age, sex, ECOG performance status, disease stage, treatment modality, and ACE-27 score were not significantly associated with QOL. Psychological measures were strongly associated with poorer QOL; HADS-depression score >7 (p < 0.001) and HADS-anxiety score >7 (p = 0.012) were both associated with lower FACT-NP scores.</p>\n\n<p>In multivariable analysis, dysphagia (p = 0.007) and HADS-depression >7 (p = 0.007) remained significantly associated with poorer FACT-NP scores after adjusting for relevant toxicities and clinical variables.</p>\n\n<p><strong>Conclusion: </strong>Among local NPC survivors post-RT, dysphagia and depressive symptoms are strongly associated with poorer QOL. These findings highlight the need for comprehensive, multidisciplinary survivorship care—including targeted dysphagia rehabilitation, proactive psychological support, and systematic screening for other chronic toxicities—to optimise long-term functional and QOL outcomes in NPC survivors.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153782--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S422",
      "content_id": "153837",
      "abstract_number": "S422",
      "poster_number": "",
      "title": "Clinical and Molecular Signatures Associated with Pain and Smoking in Long-term Head and Neck Cancer Survivors",
      "summary": "Neck pain/tightness, and smoking are both prevalent among head and neck cancer (HNC) survivors, and evidence indicates that patients who continue smoking after diagnosis experience greater pain compared to nonsmokers or former smokers. Radiation-induced fibrosis (RIF), often accompanied by pain and functional limitations, is another common late effect that impacts quality of life. Although cigarette smoking is...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153837",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Monica A Wagner, PhD, RN",
      "presenter": "Monica A Wagner, PhD, RN",
      "authors": "Monica A Wagner, PhD, RN 1 ; Fredrick R Schumacher, PhD 1 ; Quintin Pan, PhD 1 ; Marci L Nilsen, PhD, RN 2",
      "normalized_authors": [
        "Monica A Wagner",
        "Fredrick R Schumacher",
        "Quintin Pan",
        "Marci L Nilsen"
      ],
      "affiliations": [
        "Case Western Reserve University",
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "Case Western Reserve University",
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Monica A Wagner, PhD, RN 1 ; Fredrick R Schumacher, PhD 1 ; Quintin Pan, PhD 1 ; Marci L Nilsen, PhD, RN 2",
        "Affiliations": "1 Case Western Reserve University; 2 University of Pittsburgh",
        "Abstract": "Neck pain/tightness, and smoking are both prevalent among head and neck cancer (HNC) survivors, and evidence indicates that patients who continue smoking after diagnosis experience greater pain compared to nonsmokers or former smokers. Radiation-induced fibrosis (RIF), often accompanied by pain and functional limitations, is another common late effect that impacts quality of life. Although cigarette smoking is known to influence systemic biology, its role in HNC survivors with RIF remains unclear. This study examined clinical characteristics and transcriptomic profiles associated with smoking status in HNC survivors (Hypopharynx=3, Larynx=10, Nasopharynx=1, Oropharynx=39) with mild (n=27) or moderate (n=26) RIF. Understanding these associations may inform targeted survivorship care strategies to improve symptom management, functional outcomes, and equity by addressing biologically driven disparities. Participants (n = 53) were categorized as never smokers (n=26) or ever smokers (n=27), including 20 former and 7 current smokers. This nonoperative cohort was assessed an average of 59.66±52.20 months post-treatment, highlighting long-term survivorship considerations. Whole blood sample underwent bulk RNA sequencing via the Illumina NovaSeq 6000 platform. Differential expression analysis was performed using DESeq2 to compare current smokers with former and never smokers. Genes were considered significant at an adjusted p-value < 0.10 to enhance sensitivity in this exploratory analysis. The cohort was predominantly male (79.2%) with a mean age of 67.32±9.08 years; oropharyngeal cancer was the most common diagnosis (73.6%). There were no significant differences in cancer site or stage between cohorts; however, HPV-positivity differed significantly by smoking status (p=0.034), with more smokers being HPV-negative. Current smokers reported higher average neck-specific pain scores compared to former smokers (3.14±2.61 vs 1.65±1.50; p=0.198), suggesting a trend towards increased pain sensitivity. Transcriptomic analysis revealed a notable molecular signature in current smokers (in overall sample and when limited to oropharynx patients), including upregulation of PTGES , a mediator of inflammatory pain, and FMN1 , involved in cytoskeletal remodeling. Overlapping differentially expressed genes between current vs. former smokers and current vs. never smokers included GPR15, LRRN3, ERFE, SEMA6B , and STXBP1 , genes linked to immune regulation, axonal guidance, and neurotransmitter release. Heatmap clustering demonstrated that current smokers cluster together, indicating a unique transcriptomic profile enriched for inflammatory and signaling pathways that may contribute to pain and fibrosis progression. Persistent smoking among HNC survivors with mild or moderate RIF was associated with molecular profiles and an emerging trend toward higher pain scores. Upregulation of PTGES suggests a biologic mechanism for pain amplification, consistent with the established relationship between smoking and increased pain severity in cancer populations. Overlapping differentially expressed genes highlight immune dysregulation and neural signaling as potential pathways linking smoking to pain. These findings underscore the importance of continued smoking cessation efforts and integrated symptom management strategies. Further research should examine smoking effects during treatment and replicate these findings in larger cohorts. Molecular profiling may help identify HNC survivors at risk for more severe pain and guide personalized interventions to improve outcomes and promote equity in survivorship care. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and Molecular Signatures Associated with Pain and Smoking in Long-term Head and Neck Cancer Survivors</span>. <u>Monica A Wagner, PhD, RN</u><sup>1</sup>; Fredrick R Schumacher, PhD<sup>1</sup>; Quintin Pan, PhD<sup>1</sup>; Marci L Nilsen, PhD, RN<sup>2</sup>. <sup>1</sup>Case Western Reserve University; <sup>2</sup>University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Neck pain/tightness, and smoking are both prevalent among head and neck cancer (HNC) survivors, and evidence indicates that patients who continue smoking after diagnosis experience greater pain compared to nonsmokers or former smokers. Radiation-induced fibrosis (RIF), often accompanied by pain and functional limitations, is another common late effect that impacts quality of life. Although cigarette smoking is known to influence systemic biology, its role in HNC survivors with RIF remains unclear. This study examined clinical characteristics and transcriptomic profiles associated with smoking status in HNC survivors (Hypopharynx=3, Larynx=10, Nasopharynx=1, Oropharynx=39) with mild (n=27) or moderate (n=26) RIF. Understanding these associations may inform targeted survivorship care strategies to improve symptom management, functional outcomes, and equity by addressing biologically driven disparities. Participants (n = 53) were categorized as never smokers (n=26) or ever smokers (n=27), including 20 former and 7 current smokers. This nonoperative cohort was assessed an average of 59.66±52.20 months post-treatment, highlighting long-term survivorship considerations. Whole blood sample underwent bulk RNA sequencing via the Illumina NovaSeq 6000 platform. Differential expression analysis was performed using DESeq2 to compare current smokers with former and never smokers. Genes were considered significant at an adjusted p-value < 0.10 to enhance sensitivity in this exploratory analysis. The cohort was predominantly male (79.2%) with a mean age of 67.32±9.08 years; oropharyngeal cancer was the most common diagnosis (73.6%). There were no significant differences in cancer site or stage between cohorts; however, HPV-positivity differed significantly by smoking status (p=0.034), with more smokers being HPV-negative. Current smokers reported higher average neck-specific pain scores compared to former smokers (3.14±2.61 vs 1.65±1.50; p=0.198), suggesting a trend towards increased pain sensitivity. Transcriptomic analysis revealed a notable molecular signature in current smokers (in overall sample and when limited to oropharynx patients), including upregulation of <em>PTGES</em>, a mediator of inflammatory pain, and <em>FMN1</em>, involved in cytoskeletal remodeling. Overlapping differentially expressed genes between current vs. former smokers and current vs. never smokers included <em>GPR15, LRRN3, ERFE, SEMA6B</em>, and <em>STXBP1</em>, genes linked to immune regulation, axonal guidance, and neurotransmitter release. Heatmap clustering demonstrated that current smokers cluster together, indicating a unique transcriptomic profile enriched for inflammatory and signaling pathways that may contribute to pain and fibrosis progression. Persistent smoking among HNC survivors with mild or moderate RIF was associated with molecular profiles and an emerging trend toward higher pain scores. Upregulation of <em>PTGES</em> suggests a biologic mechanism for pain amplification, consistent with the established relationship between smoking and increased pain severity in cancer populations. Overlapping differentially expressed genes highlight immune dysregulation and neural signaling as potential pathways linking smoking to pain. These findings underscore the importance of continued smoking cessation efforts and integrated symptom management strategies. Further research should examine smoking effects during treatment and replicate these findings in larger cohorts. Molecular profiling may help identify HNC survivors at risk for more severe pain and guide personalized interventions to improve outcomes and promote equity in survivorship care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153837--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S423",
      "content_id": "151936",
      "abstract_number": "S423",
      "poster_number": "",
      "title": "Patient-reported dysphagia and body weight loss in nasopharyngeal Carcinoma: prospective comparison of proton (IMPT) and photon (VMAT) radiotherapy",
      "summary": "IMPT provides superior dosimetric sparing of several swallowing-related structures and reduces the risk of clinically significant early weight loss; however, these advantages do not translate into measurable improvements in patient-reported swallowing-related QoL. The S-PCM dose is the most important determinant of acute and subacute swallowing outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151936",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fu-Min Fang, MD",
      "presenter": "Fu-Min Fang, MD",
      "authors": "Fu-Min Fang, MD",
      "normalized_authors": [
        "Fu-Min Fang"
      ],
      "affiliations": [
        "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung Taiwan"
      ],
      "normalized_institutions": [
        "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung Taiwan"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 337,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fu-Min Fang, MD",
        "Affiliations": "Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung Taiwan",
        "Background": "Intensity-modulated proton therapy (IMPT) may reduce radiation dose to swallowing-related organs-at-risk (OARs) compared with volumetric modulated arc therapy (VMAT), but its impact on patient-reported swallowing outcomes remains unclear in patients with nasopharyngeal carcinoma (NPC). This study compared OAR dosimetry, nutritional outcomes, and swallowing-related quality of life (QoL) between IMPT and VMAT for NPC patients.",
        "Methods": "A total of 104 NPC patients were analyzed, including 58 treated with IMPT and 46 with VMAT. Baseline characteristics were balanced between groups except for education level and smoking status, which were adjusted for in all multivariable models. Mean OAR doses, weight loss, tube feeding, and MD Anderson Dysphagia Inventory (MDADI) scores were compared across three timepoints: baseline (T1), end of radiotherapy (T2), and 1 year post-treatment (T3). Linear regression identified clinical and dosimetric predictors of MDADI Composite scores.",
        "Results": "IMPT significantly reduced mean doses to the oral cavity, middle pharyngeal constrictor (M-PCM), and inferior constrictor compared with VMAT (all P < .01), with similar sparing of parotid glands, submandibular glands, and the superior constrictor (S-PCM). Adjusted mean body weight loss differed modestly at T2 (5.5% VMAT vs 3.4% IMPT; P = .019), and IMPT independently reduced the likelihood of >10% weight loss at T2 (OR 0.10; 95% CI, 0.01–0.80; P = .031). Feeding-tube use was rare in both groups. Across all MDADI domains, no significant differences in swallowing-related QoL were observed between IMPT and VMAT after adjustment. QoL declined during treatment and recovered by one year, with no interaction by treatment modality. Baseline MDADI score was the strongest predictor of T2 and T3 outcomes. Higher S-PCM dose was consistently associated with worse Composite scores at T2 and T3, with additional short-term effects from M-PCM dose at T2.",
        "Conclusions": "IMPT provides superior dosimetric sparing of several swallowing-related structures and reduces the risk of clinically significant early weight loss; however, these advantages do not translate into measurable improvements in patient-reported swallowing-related QoL. The S-PCM dose is the most important determinant of acute and subacute swallowing outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient-reported dysphagia and body weight loss in nasopharyngeal Carcinoma: prospective comparison of proton (IMPT) and photon (VMAT) radiotherapy</span>. <u>Fu-Min Fang, MD</u>. Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung Taiwan<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Intensity-modulated proton therapy (IMPT) may reduce radiation dose to swallowing-related organs-at-risk (OARs) compared with volumetric modulated arc therapy (VMAT), but its impact on patient-reported swallowing outcomes remains unclear in patients with nasopharyngeal carcinoma (NPC). This study compared OAR dosimetry, nutritional outcomes, and swallowing-related quality of life (QoL) between IMPT and VMAT for NPC patients.</p>\n\n<p><strong>Methods: </strong>A total of 104 NPC patients were analyzed, including 58 treated with IMPT and 46 with VMAT. Baseline characteristics were balanced between groups except for education level and smoking status, which were adjusted for in all multivariable models. Mean OAR doses, weight loss, tube feeding, and MD Anderson Dysphagia Inventory (MDADI) scores were compared across three timepoints: baseline (T1), end of radiotherapy (T2), and 1 year post-treatment (T3). Linear regression identified clinical and dosimetric predictors of MDADI Composite scores.</p>\n\n<p><strong>Results: </strong>IMPT significantly reduced mean doses to the oral cavity, middle pharyngeal constrictor (M-PCM), and inferior constrictor compared with VMAT (all P < .01), with similar sparing of parotid glands, submandibular glands, and the superior constrictor (S-PCM). Adjusted mean body weight loss differed modestly at T2 (5.5% VMAT vs 3.4% IMPT; P = .019), and IMPT independently reduced the likelihood of >10% weight loss at T2 (OR 0.10; 95% CI, 0.01–0.80; P = .031). Feeding-tube use was rare in both groups. Across all MDADI domains, no significant differences in swallowing-related QoL were observed between IMPT and VMAT after adjustment. QoL declined during treatment and recovered by one year, with no interaction by treatment modality. Baseline MDADI score was the strongest predictor of T2 and T3 outcomes. Higher S-PCM dose was consistently associated with worse Composite scores at T2 and T3, with additional short-term effects from M-PCM dose at T2.</p>\n\n<p><strong>Conclusions: </strong>IMPT provides superior dosimetric sparing of several swallowing-related structures and reduces the risk of clinically significant early weight loss; however, these advantages do not translate into measurable improvements in patient-reported swallowing-related QoL. The S-PCM dose is the most important determinant of acute and subacute swallowing outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151936--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S424",
      "content_id": "154731",
      "abstract_number": "S424",
      "poster_number": "",
      "title": "Improving Nutritional Outcomes for Head and Neck Cancer Survivors Through Speech-Language Pathology in the Context of Neighborhood Deprivation",
      "summary": "Although neighborhood socioeconomic deprivation was significantly associated with poorer oral dietary status at the last SLP follow-up, ADI was not associated with weight loss, BMI decline, acute toxicities, or SLP adherence. The overall high rate of adherence to SLP appointments throughout all of the ADI quartiles suggests that consistent engagement in swallowing rehabilitation as part of the multidisciplinary...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154731",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amani Alvi, BA",
      "presenter": "Amani Alvi, BA",
      "authors": "Amani Alvi, BA 1 ; Joyce Jeong, BS 2 ; Aneek Mirza, BS 2 ; Joshua Teitcher, MS, CCCSLP 3 ; Ashley Heidtmann, MS, CCCSLP 3 ; Vanessa Stubbs, MD 1 ; Samer Al-Khudari, MD 1 ; Mihir K Bhayani, MD 1",
      "normalized_authors": [
        "Amani Alvi",
        "Joyce Jeong",
        "Aneek Mirza",
        "Joshua Teitcher, CCCSLP",
        "Ashley Heidtmann, CCCSLP",
        "Vanessa Stubbs",
        "Samer Al-Khudari",
        "Mihir K Bhayani"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612",
        "Rush Medical College, Rush University Medical Center, Chicago, IL 60612",
        "Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612",
        "Rush Medical College, Rush University Medical Center, Chicago, IL 60612",
        "Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 475,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amani Alvi, BA 1 ; Joyce Jeong, BS 2 ; Aneek Mirza, BS 2 ; Joshua Teitcher, MS, CCCSLP 3 ; Ashley Heidtmann, MS, CCCSLP 3 ; Vanessa Stubbs, MD 1 ; Samer Al-Khudari, MD 1 ; Mihir K Bhayani, MD 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612; 2 Rush Medical College, Rush University Medical Center, Chicago, IL 60612; 3 Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612",
        "Background": "Eating difficulties after treatment for head and neck cancer (HNC) are among the most common and debilitating survivorship challenges. After curative therapy, many patients experience lasting impairments in swallowing, taste, and eating, which can impact nutritional status, body weight, and quality of life. However, the influence of neighborhood-level socioeconomic disadvantage, measured by the area deprivation index (ADI), on nutritional recovery remains largely unexplored. Therefore, the aim of this study is to evaluate whether ADI is associated with nutritional recovery outcomes for patients who completed chemoradiation treatment for HNC.",
        "Methods": "We performed a retrospective cohort study of 596 patients treated with chemoradiation therapy for HNC from 2019 to 2024 at Rush University Medical Center. Patients with available ZIP code-linked ADI data were included. ADI was categorized into quartiles, with Q1 consisting of patients in the top 25th percentile, indicating the least deprived neighborhoods, and Q4 consisting of patients in the bottom 25th percentile, indicating the most deprived neighborhoods. Nutritional outcomes included changes in weight, body mass index, dietary status before and after treatment, adherence to speech-language pathology (SLP) appointments, and presence of treatment-related toxicities. Multivariable linear regression, Kruskal-Wallis H test, and ordinal logistic models evaluated associations between ADI and each outcome, adjusting for age, race, ethnicity, and gender.",
        "Results": "The preliminary data included a total of 142 patients (mean age 66.81 ± 11.54 years; 73.2% male; 74.5% White; mean ADI 45.65 ± 23.46). At the last SLP follow-up, patients in the most deprived neighborhood quartile (Q4) were significantly more likely to be on a limited (nutritional supplements, purees, etc.) or feeding tube diet than patients in the least deprived quartile (Q1) who were more likely to be on a normal or unrestricted diet (β=–1.26, OR=0.28, p=0.022). Interestingly, ADI quartile was not significantly associated with change in weight (χ²(3)=1.11, p=0.776), or BMI changes (χ²(3)=3.10, p=0.376) before and after HNC treatment. In adjusted linear regression models, ADI quartile remained unassociated with weight change or BMI change, although Q4 showed a nonsignificant trend toward greater declines. ADI was also not associated with SLP adherence (p=0.77), and 91.2% of patients had a high or moderate level of adherence (>50% attendance) to their SLP appointments.",
        "Conclusion": "Although neighborhood socioeconomic deprivation was significantly associated with poorer oral dietary status at the last SLP follow-up, ADI was not associated with weight loss, BMI decline, acute toxicities, or SLP adherence. The overall high rate of adherence to SLP appointments throughout all of the ADI quartiles suggests that consistent engagement in swallowing rehabilitation as part of the multidisciplinary treatment plan helps mitigate the downstream effects of socioeconomic deprivation on nutritional outcomes. Therefore, our study highlights the importance of coordinated incorporation of SLP care to support equitable nutritional recovery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Improving Nutritional Outcomes for Head and Neck Cancer Survivors Through Speech-Language Pathology in the Context of Neighborhood Deprivation</span>. <u>Amani Alvi, BA</u><sup>1</sup>; Joyce Jeong, BS<sup>2</sup>; Aneek Mirza, BS<sup>2</sup>; Joshua Teitcher, MS, CCCSLP<sup>3</sup>; Ashley Heidtmann, MS, CCCSLP<sup>3</sup>; Vanessa Stubbs, MD<sup>1</sup>; Samer Al-Khudari, MD<sup>1</sup>; Mihir K Bhayani, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, Rush University Medical Center, Chicago, IL 60612; <sup>2</sup>Rush Medical College, Rush University Medical Center, Chicago, IL 60612; <sup>3</sup>Department of Hematology/Oncology, Rush University Medical Center, Chicago, IL 60612<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Eating difficulties after treatment for head and neck cancer (HNC) are among the most common and debilitating survivorship challenges. After curative therapy, many patients experience lasting impairments in swallowing, taste, and eating, which can impact nutritional status, body weight, and quality of life. However, the influence of neighborhood-level socioeconomic disadvantage, measured by the area deprivation index (ADI), on nutritional recovery remains largely unexplored. Therefore, the aim of this study is to evaluate whether ADI is associated with nutritional recovery outcomes for patients who completed chemoradiation treatment for HNC.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study of 596 patients treated with chemoradiation therapy for HNC from 2019 to 2024 at Rush University Medical Center. Patients with available ZIP code-linked ADI data were included. ADI was categorized into quartiles, with Q1 consisting of patients in the top 25th percentile, indicating the least deprived neighborhoods, and Q4 consisting of patients in the bottom 25th percentile, indicating the most deprived neighborhoods. Nutritional outcomes included changes in weight, body mass index, dietary status before and after treatment, adherence to speech-language pathology (SLP) appointments, and presence of treatment-related toxicities. Multivariable linear regression, Kruskal-Wallis H test, and ordinal logistic models evaluated associations between ADI and each outcome, adjusting for age, race, ethnicity, and gender.</p>\n\n<p><strong>Results: </strong>The preliminary data included a total of 142 patients (mean age 66.81 ± 11.54 years; 73.2% male; 74.5% White; mean ADI 45.65 ± 23.46). At the last SLP follow-up, patients in the most deprived neighborhood quartile (Q4) were significantly more likely to be on a limited (nutritional supplements, purees, etc.) or feeding tube diet than patients in the least deprived quartile (Q1) who were more likely to be on a normal or unrestricted diet (β=–1.26, OR=0.28, p=0.022). Interestingly, ADI quartile was not significantly associated with change in weight (χ²(3)=1.11, p=0.776), or BMI changes (χ²(3)=3.10, p=0.376) before and after HNC treatment. In adjusted linear regression models, ADI quartile remained unassociated with weight change or BMI change, although Q4 showed a nonsignificant trend toward greater declines. ADI was also not associated with SLP adherence (p=0.77), and 91.2% of patients had a high or moderate level of adherence (>50% attendance) to their SLP appointments.</p>\n\n<p><strong>Conclusion: </strong>Although neighborhood socioeconomic deprivation was significantly associated with poorer oral dietary status at the last SLP follow-up, ADI was not associated with weight loss, BMI decline, acute toxicities, or SLP adherence. The overall high rate of adherence to SLP appointments throughout all of the ADI quartiles suggests that consistent engagement in swallowing rehabilitation as part of the multidisciplinary treatment plan helps mitigate the downstream effects of socioeconomic deprivation on nutritional outcomes. Therefore, our study highlights the importance of coordinated incorporation of SLP care to support equitable nutritional recovery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154731--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S425",
      "content_id": "154134",
      "abstract_number": "S425",
      "poster_number": "",
      "title": "Incidence and Survival of Secondary Primary Tongue Malignancies Following Radiation Treatment Among HPV+ Oropharyngeal Cancer Patients: A SEER Analysis",
      "summary": "HPV+OPC survivors treated with RT have a 10-year cumulative risk of 0.9% for developing SPMs of the tongue, approximately five times the risk observed in matched thyroid cancer survivors. SPMs of the tongue after RT are associated with markedly poorer survival than matched primary tongue cancer controls, though it is unclear whether this reflects differences in tumor biology or constraints in treatment options....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154134",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nina D Ham, BA",
      "presenter": "Nina D Ham, BA",
      "authors": "Nina D Ham, BA 1 ; Soroush Ershadifar, MD 2 ; Michael Li, MD 1 ; Marianne Abouyared, MD 1 ; Andrew C Birkeland, MD 1 ; Arnaud F Bewley, MD 1",
      "normalized_authors": [
        "Nina D Ham",
        "Soroush Ershadifar",
        "Michael Li",
        "Marianne Abouyared",
        "Andrew C Birkeland",
        "Arnaud F Bewley"
      ],
      "affiliations": [
        "Department of Otolaryngolgoy - Head and Neck Surgery, University of California – Davis, Sacramento, California, USA",
        "Department of Otolaryngology - Head and Neck Surgery, University of Kansas, Kansas City, Kansas, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngolgoy - Head and Neck Surgery, University of California – Davis, Sacramento, California, USA",
        "Department of Otolaryngology - Head and Neck Surgery, University of Kansas, Kansas City, Kansas, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Nina D Ham, BA 1 ; Soroush Ershadifar, MD 2 ; Michael Li, MD 1 ; Marianne Abouyared, MD 1 ; Andrew C Birkeland, MD 1 ; Arnaud F Bewley, MD 1",
        "Affiliations": "1 Department of Otolaryngolgoy - Head and Neck Surgery, University of California – Davis, Sacramento, California, USA; 2 Department of Otolaryngology - Head and Neck Surgery, University of Kansas, Kansas City, Kansas, USA",
        "Background": "Radiation induced malignancies are a late side effect of radiation therapy (RT) and can result in significant long-term morbidity. RT is a key component of standard treatment for many patients diagnosed with HPV+ oropharyngeal cancers (HPV+OPC). This study aimed to: (1) quantify the incidence of second primary malignancy (SPM) of the tongue among HPV+OPC survivors treated with RT and compare to the rate after other RT-treated head and neck cancers, and 2) determine whether these second primary tumors exhibit worse survival when compared to matched patients with primary tongue cancer.",
        "Methods": "The Surveillance, Epidemiology, and End Results (SEER) database (2010 to 2020) was queried for patients with a documented primary diagnosis of HPV+ OPC treated with RT. In addition, data for RT-treated primary cancers of the larynx and nasopharynx and RAI-treated cancers of the thyroid was queried for comparison. SPMs of the tongue arising after these index cancers were identified. Cumulative incidence for each index cancer was estimated using Fine-Gray competing-risks regression, with early death coded as the competing event. Ten-year cumulative incidences were calculated. Overall Survival (OS) for primary versus SPMs of the tongue was evaluated using a 3:1 matched cohort (matched by age, race, and diagnosis year) and compared using Kaplan-Meier survival curves, log-rank testing, and Cox proportional hazards models.",
        "Results": "A total of 75,849 patients were included in the incidence analysis: 6,924 HPV+ OPC, 10,243 larynx, 53,530 thyroid, and 5,152 nasopharynx patients. At 10 years, the cumulative incidence of SPMs of the tongue was 0.90% for HPV+OPC. In a Fine-Gray model adjusted for age, sex, and race and restricted to patients surviving => 36 months, thyroid cancer survivors had a significantly lower cumulative incidence (SHR = 0.20, 95% CI: 0.01–0.44, p = 0.001) of SPMs of the tongue when compared to HPV+OPC survivors. Patients with RT treated cancers of the larynx and nasopharynx had higher cumulative incidences of SPMs of the tongue (SHR = 4.66, 95% CI: 2.50–8.59, p < 0.001; SHR = 3.30, 95% CI: 1.67–6.76, p = 0.001).",
        "Abstract": "212 patients (n=53 SPMs, n=159 primary tumors) were included in the survival analysis. After adjusting for T-stage (T1/2 vs T3/4) and N-stage (N0 vs N1+) with a Cox proportional hazards model, patients with SPMs of the tongue after HPV+OPC treated with RT had significantly worse OS than matched primary tongue cancer controls (HR 4.48, 95% CI 2.68 – 7.49, p < 0.001). View in Agenda and Add to Schedule",
        "Conclusion": "HPV+OPC survivors treated with RT have a 10-year cumulative risk of 0.9% for developing SPMs of the tongue, approximately five times the risk observed in matched thyroid cancer survivors. SPMs of the tongue after RT are associated with markedly poorer survival than matched primary tongue cancer controls, though it is unclear whether this reflects differences in tumor biology or constraints in treatment options. As the number of HPV+OPC survivors rises dramatically, further research is needed to better understand this growing population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidence and Survival of Secondary Primary Tongue Malignancies Following Radiation Treatment Among HPV+ Oropharyngeal Cancer Patients: A SEER Analysis</span>. <u>Nina D Ham, BA</u><sup>1</sup>; Soroush Ershadifar, MD<sup>2</sup>; Michael Li, MD<sup>1</sup>; Marianne Abouyared, MD<sup>1</sup>; Andrew C Birkeland, MD<sup>1</sup>; Arnaud F Bewley, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngolgoy - Head and Neck Surgery, University of California – Davis, Sacramento, California, USA; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, University of Kansas, Kansas City, Kansas, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Radiation induced malignancies are a late side effect of radiation therapy (RT) and can result in significant long-term morbidity. RT is a key component of standard treatment for many patients diagnosed with HPV+ oropharyngeal cancers (HPV+OPC). This study aimed to: (1) quantify the incidence of second primary malignancy (SPM) of the tongue among HPV+OPC survivors treated with RT and compare to the rate after other RT-treated head and neck cancers, and 2) determine whether these second primary tumors exhibit worse survival when compared to matched patients with primary tongue cancer.</p>\n\n<p><strong>Methods: </strong>The Surveillance, Epidemiology, and End Results (SEER) database (2010 to 2020) was queried for patients with a documented primary diagnosis of HPV+ OPC treated with RT. In addition, data for RT-treated primary cancers of the larynx and nasopharynx and RAI-treated cancers of the thyroid was queried for comparison. SPMs of the tongue arising after these index cancers were identified. Cumulative incidence for each index cancer was estimated using Fine-Gray competing-risks regression, with early death coded as the competing event. Ten-year cumulative incidences were calculated. Overall Survival (OS) for primary versus SPMs of the tongue was evaluated using a 3:1 matched cohort (matched by age, race, and diagnosis year) and compared using Kaplan-Meier survival curves, log-rank testing, and Cox proportional hazards models.</p>\n\n<p><strong>Results: </strong>A total of 75,849 patients were included in the incidence analysis: 6,924 HPV+ OPC, 10,243 larynx, 53,530 thyroid, and 5,152 nasopharynx patients. At 10 years, the cumulative incidence of SPMs of the tongue was 0.90% for HPV+OPC. In a Fine-Gray model adjusted for age, sex, and race and restricted to patients surviving => 36 months, thyroid cancer survivors had a significantly lower cumulative incidence (SHR = 0.20, 95% CI: 0.01–0.44, p = 0.001) of SPMs of the tongue when compared to HPV+OPC survivors. Patients with RT treated cancers of the larynx and nasopharynx had higher cumulative incidences of SPMs of the tongue (SHR = 4.66, 95% CI: 2.50–8.59, p < 0.001; SHR = 3.30, 95% CI: 1.67–6.76, p = 0.001).</p>\n\n<p>212 patients (n=53 SPMs, n=159 primary tumors) were included in the survival analysis. After adjusting for T-stage (T1/2 vs T3/4) and N-stage (N0 vs N1+) with a Cox proportional hazards model, patients with SPMs of the tongue after HPV+OPC treated with RT had significantly worse OS than matched primary tongue cancer controls (HR 4.48, 95% CI 2.68 – 7.49, p < 0.001).</p>\n\n<p><strong>Conclusion:</strong> HPV+OPC survivors treated with RT have a 10-year cumulative risk of 0.9% for developing SPMs of the tongue, approximately five times the risk observed in matched thyroid cancer survivors. SPMs of the tongue after RT are associated with markedly poorer survival than matched primary tongue cancer controls, though it is unclear whether this reflects differences in tumor biology or constraints in treatment options. As the number of HPV+OPC survivors rises dramatically, further research is needed to better understand this growing population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154134--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S426",
      "content_id": "154293",
      "abstract_number": "S426",
      "poster_number": "",
      "title": "Disparities in Long-term Wellbeing of Head and Neck Cancer Survivors",
      "summary": "While health disparities in head and neck cancer (HNC) regarding survival, mortality, and quality of life are well-documented, the broader construct of “wellbeing”, which is defined as an optimal state of physical, psychological, social, and spiritual health remains understudied in this population. This study aimed to identify demographic, clinical, and lifestyle predictors of wellbeing in long-term HNC survivors...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154293",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdulghafoor Alani, BS",
      "presenter": "Abdulghafoor Alani, BS",
      "authors": "Abdulghafoor Alani, BS 1 ; Nishant Kumar, BS 1 ; Eric A Boakye, PhD 1 ; Kathryn Genoa-Obradovic, PhD, CCCSLP 2 ; Japnam Jassal, MD 1 ; Ranjani Balakrishnan 1 ; Samntha Tam, MD, MPH 1 ; Jeffrey Searl, PhD 2",
      "normalized_authors": [
        "Abdulghafoor Alani",
        "Nishant Kumar",
        "Eric A Boakye",
        "Kathryn Genoa-Obradovic, CCCSLP",
        "Japnam Jassal",
        "Ranjani Balakrishnan",
        "Samntha Tam",
        "Jeffrey Searl"
      ],
      "affiliations": [
        "Henry Ford Health",
        "Michigan State University"
      ],
      "normalized_institutions": [
        "Henry Ford Health",
        "Michigan State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 382,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Abdulghafoor Alani, BS 1 ; Nishant Kumar, BS 1 ; Eric A Boakye, PhD 1 ; Kathryn Genoa-Obradovic, PhD, CCCSLP 2 ; Japnam Jassal, MD 1 ; Ranjani Balakrishnan 1 ; Samntha Tam, MD, MPH 1 ; Jeffrey Searl, PhD 2",
        "Affiliations": "1 Henry Ford Health; 2 Michigan State University",
        "Abstract": "While health disparities in head and neck cancer (HNC) regarding survival, mortality, and quality of life are well-documented, the broader construct of “wellbeing”, which is defined as an optimal state of physical, psychological, social, and spiritual health remains understudied in this population. This study aimed to identify demographic, clinical, and lifestyle predictors of wellbeing in long-term HNC survivors using the standardized Five-Factor Wellness Inventory (FFWEL).This cross-sectional study recruited survivors (disease free at least three years following diagnosis) of oropharyngeal cancer from a tertiary academic medical center. Patients were recruited using paper and electronic mail, and through the telephone. Patients had the opportunity to complete the assessments electronically, through mail, or on the telephone. Outcomes assessed included the five domains of wellbeing on the FFWEL: Creative, Coping, Social, Essential, and Physical Self. Demographic, clinical, and lifestyle (e.g. substance abuse, education level, marital status) data were extracted from medical records. Statistical analysis utilized t-tests and one-way ANOVA to evaluate associations between patient characteristics and wellness scores.187 Patients were contacted, 72 of which completed the study. The average age was 60 years, and most participants were male (87.5%), White (79.2%) and married (77.8%). Approximately, 35% had college degree or higher, 40.3% had private insurance, 20.8% were current cigarette smokers, 38.9% presented at early stage (i.e., I and II) and 68.2% received systemic treatment. Lifestyle and treatment factors were significant predictors of wellbeing. Specifically, patients who were current smokers reported lower wellbeing compared to never-smokers in the Creative (p=0.0417), Coping (p=0.0139), Essential (p=0.0254), and Physical (p=0.0201) domains. Patients who received systemic therapy reported lower wellbeing across all five domains: Creative (133.4 vs. 200.9, p=0.0191), Coping (p=0.0062), Social (p=0.0166), Essential (p=0.0062), and Physical (p=0.0140). Finally, patients with late-stage disease reported a lower physical wellbeing (P=0.0409).In this pilot cohort of long-term HNC survivors of oropharyngeal cancer, wellbeing was heavily influenced by treatment factors (systemic therapy) and lifestyle factors (smoking status) rather than baseline sociodemographic variables. These findings suggest that survivorship interventions should consider smoking cessation and targeted support for patients undergoing systemic therapy to optimize long-term wellbeing. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Disparities in Long-term Wellbeing of Head and Neck Cancer Survivors</span>. <u>Abdulghafoor Alani, BS</u><sup>1</sup>; Nishant Kumar, BS<sup>1</sup>; Eric A Boakye, PhD<sup>1</sup>; Kathryn Genoa-Obradovic, PhD, CCCSLP<sup>2</sup>; Japnam Jassal, MD<sup>1</sup>; Ranjani Balakrishnan<sup>1</sup>; Samntha Tam, MD, MPH<sup>1</sup>; Jeffrey Searl, PhD<sup>2</sup>. <sup>1</sup>Henry Ford Health; <sup>2</sup>Michigan State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>While health disparities in head and neck cancer (HNC) regarding survival, mortality, and quality of life are well-documented, the broader construct of “wellbeing”, which is defined as an optimal state of physical, psychological, social, and spiritual health remains understudied in this population. This study aimed to identify demographic, clinical, and lifestyle predictors of wellbeing in long-term HNC survivors using the standardized Five-Factor Wellness Inventory (FFWEL).This cross-sectional study recruited survivors (disease free at least three years following diagnosis) of oropharyngeal cancer from a tertiary academic medical center. Patients were recruited using paper and electronic mail, and through the telephone. Patients had the opportunity to complete the assessments electronically, through mail, or on the telephone. Outcomes assessed included the five domains of wellbeing on the FFWEL: Creative, Coping, Social, Essential, and Physical Self. Demographic, clinical, and lifestyle (e.g. substance abuse, education level, marital status) data were extracted from medical records. Statistical analysis utilized t-tests and one-way ANOVA to evaluate associations between patient characteristics and wellness scores.187 Patients were contacted, 72 of which completed the study. The average age was 60 years, and most participants were male (87.5%), White (79.2%) and married (77.8%). Approximately, 35% had college degree or higher, 40.3% had private insurance, 20.8% were current cigarette smokers, 38.9% presented at early stage (i.e., I and II) and 68.2% received systemic treatment. Lifestyle and treatment factors were significant predictors of wellbeing. Specifically, patients who were current smokers reported lower wellbeing compared to never-smokers in the Creative (p=0.0417), Coping (p=0.0139), Essential (p=0.0254), and Physical (p=0.0201) domains. Patients who received systemic therapy reported lower wellbeing across all five domains: Creative (133.4 vs. 200.9, p=0.0191), Coping (p=0.0062), Social (p=0.0166), Essential (p=0.0062), and Physical (p=0.0140). Finally, patients with late-stage disease reported a lower physical wellbeing (P=0.0409).In this pilot cohort of long-term HNC survivors of oropharyngeal cancer, wellbeing was heavily influenced by treatment factors (systemic therapy) and lifestyle factors (smoking status) rather than baseline sociodemographic variables. These findings suggest that survivorship interventions should consider smoking cessation and targeted support for patients undergoing systemic therapy to optimize long-term wellbeing.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154293--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S427",
      "content_id": "155543",
      "abstract_number": "S427",
      "poster_number": "",
      "title": "A digital speech cloud-based platform for head and neck cancer",
      "summary": "Our digital platform provides a modern AI-powered scalable, automated toold for clinical and remote monitoring of oropharyngeal function in head and neck cancer patients. The platform supports data-driven rehabilitation planning and has the potential to enable earlier detection and rehabilitation in HNC patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155543",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Benjamin Sanchez",
      "presenter": "Benjamin Sanchez",
      "authors": "Lucas Takanori Sanchez Shiromizu 1 ; Jacob McCoy 1 ; Yelizaveta Semikina 1 ; Fernando Lopez 1 ; Danny Nguyen 1 ; Katherine Hutcheson 2 ; Benjamin Sanchez 1",
      "normalized_authors": [
        "Lucas Takanori Sanchez Shiromizu",
        "Jacob McCoy",
        "Yelizaveta Semikina",
        "Fernando Lopez",
        "Danny Nguyen",
        "Katherine Hutcheson",
        "Benjamin Sanchez"
      ],
      "affiliations": [
        "University of Illinois Chicago",
        "MD Anderson Cancer Center"
      ],
      "normalized_institutions": [
        "University of Illinois Chicago",
        "MD Anderson Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Lucas Takanori Sanchez Shiromizu 1 ; Jacob McCoy 1 ; Yelizaveta Semikina 1 ; Fernando Lopez 1 ; Danny Nguyen 1 ; Katherine Hutcheson 2 ; Benjamin Sanchez 1",
        "Affiliations": "1 University of Illinois Chicago; 2 MD Anderson Cancer Center",
        "Introduction": "Head and neck cancer and its treatment including surgery, radiation, and chemotherapy frequently result in progressive impairment of speech, voice, and swallowing. Longitudinal monitoring of bulbar function is essential for timely rehabilitation, yet clinical assessments remain subjective and resource intensive. We present a digital speech cloud-based and smartphone platform to enable continuous, quantitative, and objective speech monitoring both at the clinic and at-home in head and neck cancer patients.",
        "Methods": "The platform consists of two integrated components: a patient-facing mobile application and a physician-facing application, connected by a fully automated cloud backend processing pipeline. Patients download and install the smartphone application to complete standardized speech sessions. Each session consists of ten recordings: five read sentences targeting intelligibility and prosody, two sustained vowels (/a/ and /e/) targeting articulation and phonation, and three diadochokinesis (DDK) syllable repetitions (PA, TA, KA) targeting oropharyngeal motor agility. The physician application provides physicians with a structured interface to schedule recording sessions, review uploaded audio files, and access generated reports for each patient. The system supports longitudinal tracking across multiple sessions, enabling direct comparison of patient performance over time.",
        "Abstract": "Upon session completion, an automated processing pipeline is triggered. The pipeline downloads the ten audio files and performs acoustic feature extraction across five clinical domains: phonation (jitter, shimmer, amplitude perturbation quotient, degree of unvoiced frames), articulation (first and second formant frequencies for vowels /a/ and /e/, reflecting tongue height and frontness), prosody (fundamental frequency, speech rate, voiced rate, silence duration), motor speech via DDK (syllable rate, regularity, and pause rate), and intelligibility. Intelligibility is assessed using an automatic speech recognition system, computing word error rate and dynamic time warping similarity against a target transcription baseline. The pipeline generates a clinician-ready PDF report containing trend plots and bar charts comparing the current session against all prior sessions, with gender-specific normative reference speech feature ranges. We also have deployed a large language model that interprets the acoustic findings in the context of oropharyngeal physiology, linking feature values to probable clinical mechanisms such as tongue mobility restriction, laryngeal instability, or radiation fibrosis, and providing domain-specific rehabilitation strategy recommendations. All outputs are stored securely and made immediately accessible through the physician interface. View in Agenda and Add to Schedule",
        "Results": "We successfully deployed the smartphone patient application, physician interface, and cloud-based platform from audio recordings to physician report delivery in under 5 minutes. Feature extraction, report generation, and AI clinical report are performed without clinician involvement. Our system can easily be deployed and supports multi-language for broad use.",
        "Conclusions": "Our digital platform provides a modern AI-powered scalable, automated toold for clinical and remote monitoring of oropharyngeal function in head and neck cancer patients. The platform supports data-driven rehabilitation planning and has the potential to enable earlier detection and rehabilitation in HNC patients."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A digital speech cloud-based platform for head and neck cancer</span>. Lucas Takanori Sanchez Shiromizu<sup>1</sup>; Jacob McCoy<sup>1</sup>; Yelizaveta Semikina<sup>1</sup>; Fernando Lopez<sup>1</sup>; Danny Nguyen<sup>1</sup>; Katherine Hutcheson<sup>2</sup>; <u>Benjamin Sanchez</u><sup>1</sup>. <sup>1</sup>University of Illinois Chicago; <sup>2</sup>MD Anderson Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancer and its treatment including surgery, radiation, and chemotherapy frequently result in progressive impairment of speech, voice, and swallowing. Longitudinal monitoring of bulbar function is essential for timely rehabilitation, yet clinical assessments remain subjective and resource intensive. We present a digital speech cloud-based and smartphone platform to enable continuous, quantitative, and objective speech monitoring both at the clinic and at-home in head and neck cancer patients.</p>\n\n<p><strong>Methods: </strong>The platform consists of two integrated components: a patient-facing mobile application and a physician-facing application, connected by a fully automated cloud backend processing pipeline. Patients download and install the smartphone application to complete standardized speech sessions. Each session consists of ten recordings: five read sentences targeting intelligibility and prosody, two sustained vowels (/a/ and /e/) targeting articulation and phonation, and three diadochokinesis (DDK) syllable repetitions (PA, TA, KA) targeting oropharyngeal motor agility. The physician application provides physicians with a structured interface to schedule recording sessions, review uploaded audio files, and access generated reports for each patient. The system supports longitudinal tracking across multiple sessions, enabling direct comparison of patient performance over time.                                                  </p>\n\n<p>Upon session completion, an automated processing pipeline is triggered. The pipeline downloads the ten audio files and performs acoustic feature extraction across five clinical domains: phonation (jitter, shimmer, amplitude perturbation quotient, degree of unvoiced frames), articulation (first and second formant frequencies for vowels /a/ and /e/, reflecting tongue height and frontness), prosody (fundamental frequency, speech rate, voiced rate, silence duration), motor speech via DDK (syllable rate, regularity, and pause rate), and intelligibility. Intelligibility is assessed using an automatic speech recognition system, computing word error rate and dynamic time warping similarity against a target transcription baseline.</p>\n\n<p>The pipeline generates a clinician-ready PDF report containing trend plots and bar charts comparing the current session against all prior sessions, with gender-specific normative reference speech feature ranges. We also have deployed a large language model that interprets the acoustic findings in the context of oropharyngeal physiology, linking feature values to probable clinical mechanisms such as tongue mobility restriction, laryngeal instability, or radiation fibrosis, and providing domain-specific rehabilitation strategy recommendations. All outputs are stored securely and made immediately accessible through the physician interface.</p>\n\n<p><strong>Results: </strong>We successfully deployed the smartphone patient application, physician interface, and cloud-based platform from audio recordings to physician report delivery in under 5 minutes. Feature extraction, report generation, and AI clinical report are performed without clinician involvement. Our system can easily be deployed and supports multi-language for broad use.</p>\n\n<p><strong>Conclusions: </strong>Our digital platform provides a modern AI-powered scalable, automated toold for clinical and remote monitoring of oropharyngeal function in head and neck cancer patients. The platform supports data-driven rehabilitation planning and has the potential to enable earlier detection and rehabilitation in HNC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155543--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S428",
      "content_id": "155502",
      "abstract_number": "S428",
      "poster_number": "",
      "title": "Pre-treatment survivorship clinic attendance is associated with improved survival in head and neck cancer patients undergoing radiation therapy",
      "summary": "These data suggest that attending the HNC Survivorship Clinic prior to completing radiotherapy is independently associated with lower hazards of death and/or recurrence within 1 year of diagnosis. While further research is needed to determine the mechanisms by which pre-radiation therapy survivorship care improves survival and decreases risk of recurrence, health-seeking behavior may partially explain this...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155502",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260148",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maryanna S Owoc, MD, PhD",
      "presenter": "Maryanna S Owoc, MD, PhD",
      "authors": "Maryanna S Owoc, MD, PhD ; Katie M Carlson, MPH; Yvonne M Mowery, MD, PhD; Jonas T Johnson, MD; Angela L Mazul, PhD, MPH; Marci L Nilsen, PhD, RN, CHPN",
      "normalized_authors": [
        "Maryanna S Owoc",
        "Katie M Carlson",
        "Yvonne M Mowery",
        "Jonas T Johnson",
        "Angela L Mazul",
        "Marci L Nilsen, CHPN"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155502/SurvivalCurve.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155502/SurvivalCurve.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155502"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 480,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Maryanna S Owoc, MD, PhD ; Katie M Carlson, MPH; Yvonne M Mowery, MD, PhD; Jonas T Johnson, MD; Angela L Mazul, PhD, MPH; Marci L Nilsen, PhD, RN, CHPN",
        "Affiliations": "University of Pittsburgh Medical Center",
        "Introduction": "The importance of multidisciplinary survivorship care is becoming increasingly recognized, particularly for head and neck cancer (HNC) patients, who face high risks of recurrence and mortality. Since radiotherapy (RT) contributes significantly to treatment-related adverse effects, our institution’s multidisciplinary HNC Survivorship Clinic encourages patients to be evaluated prior to completing RT. While this effort has been successful in increasing Survivorship Clinic attendance among patients treated with radiotherapy, the impact on oncologic outcomes remains unknown. The present study aims to determine the association between early survivorship clinic attendance (prior to radiation therapy completion) with disease-free and recurrence-free survival.",
        "Methods": "Our analysis population consisted of 922 patients diagnosed with primary HNC between January 2018 and April 2024, treated with RT, and with no evidence of metastatic disease. Covariates were sex, age at diagnosis, tobacco history at diagnosis, alcohol history at diagnosis, race, cancer site, clinical T and N staging, definitive surgery, systemic therapy, and insurance status. The primary exposure variable was whether the patient attended the Survivorship Clinic prior to completing RT. The primary outcomes were recurrence-free survival (RFS) and disease-free survival (DFS). Analysis was performed using a Fine-Gray model for RFS within 1-year post-diagnosis and a Cox proportional hazards regression model for DFS within 1-year post-diagnosis.",
        "Results": "Among 922 patients, 336 (36.4%) attended the Survivorship Clinic before completing radiation, while 586 (63.6%) did not. Compared to patients who did not attend the Survivorship Clinic prior to RT completion, those who did had?a?significantly?lower incidence of recurrence within 1-year post-diagnosis, accounting for death as a competing risk (subdistribution hazard ratio (sHR): 0.63, 95% confidence interval [CI]: 0.43, 0.90). In adjusted analysis, patients who visited pre-RT completion had a significantly lower incidence of recurrence within 1-year post-diagnosis, accounting for death as a competing risk, than those who did not visit (sHR: 0.67, 95% CI: 0.46, 1.001). Additionally, we found that compared to those who did not visit pre-RT completion, those who did had significantly lower hazards of death?or?recurrence within 1-year post-diagnosis (HR: 0.52, 95% CI: 0.38, 0.72, Figure 1). Importantly, risk of death or recurrence remained significantly reduced after adjusting for covariates (HR: 0.59, 95% CI: 0.42, 0.82).",
        "Conclusions": "These data suggest that attending the HNC Survivorship Clinic prior to completing radiotherapy is independently associated with lower hazards of death and/or recurrence within 1 year of diagnosis. While further research is needed to determine the mechanisms by which pre-radiation therapy survivorship care improves survival and decreases risk of recurrence, health-seeking behavior may partially explain this association. Our findings suggest that early, proactive, multidisciplinary survivorship care can significantly improve clinical outcomes in HNC patients undergoing RT. Further research is needed to determine whether these benefits are observed among HNC patients undergoing other treatment modalities and over longer periods of follow up.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pre-treatment survivorship clinic attendance is associated with improved survival in head and neck cancer patients undergoing radiation therapy</span>. <u>Maryanna S Owoc, MD, PhD</u>; Katie M Carlson, MPH; Yvonne M Mowery, MD, PhD; Jonas T Johnson, MD; Angela L Mazul, PhD, MPH; Marci L Nilsen, PhD, RN, CHPN. University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/155502/SurvivalCurve.jpg' /></p>\n\n<p><strong>Introduction: </strong>The importance of multidisciplinary survivorship care is becoming increasingly recognized, particularly for head and neck cancer (HNC) patients, who face high risks of recurrence and mortality. Since radiotherapy (RT) contributes significantly to treatment-related adverse effects, our institution’s multidisciplinary HNC Survivorship Clinic encourages patients to be evaluated prior to completing RT. While this effort has been successful in increasing Survivorship Clinic attendance among patients treated with radiotherapy, the impact on oncologic outcomes remains unknown. The present study aims to determine the association between early survivorship clinic attendance (prior to radiation therapy completion) with disease-free and recurrence-free survival.</p>\n\n<p><strong>Methods: </strong>Our analysis population consisted of 922 patients diagnosed with primary HNC between January 2018 and April 2024, treated with RT, and with no evidence of metastatic disease. Covariates were sex, age at diagnosis, tobacco history at diagnosis, alcohol history at diagnosis, race, cancer site, clinical T and N staging, definitive surgery, systemic therapy, and insurance status. The primary exposure variable was whether the patient attended the Survivorship Clinic prior to completing RT. The primary outcomes were recurrence-free survival (RFS) and disease-free survival (DFS). Analysis was performed using a Fine-Gray model for RFS within 1-year post-diagnosis and a Cox proportional hazards regression model for DFS within 1-year post-diagnosis.</p>\n\n<p><strong>Results:</strong> Among 922 patients, 336 (36.4%) attended the Survivorship Clinic before completing radiation, while 586 (63.6%) did not. Compared to patients who did not attend the Survivorship Clinic prior to RT completion, those who did had?a?significantly?lower incidence of recurrence within 1-year post-diagnosis, accounting for death as a competing risk (subdistribution hazard ratio (sHR): 0.63, 95% confidence interval [CI]: 0.43, 0.90). In adjusted analysis, patients who visited pre-RT completion had a significantly lower incidence of recurrence within 1-year post-diagnosis, accounting for death as a competing risk, than those who did not visit (sHR: 0.67, 95% CI: 0.46, 1.001). Additionally, we found that compared to those who did not visit pre-RT completion, those who did had significantly lower hazards of death?or?recurrence within 1-year post-diagnosis (HR: 0.52, 95% CI: 0.38, 0.72, Figure 1). Importantly, risk of death or recurrence remained significantly reduced after adjusting for covariates (HR: 0.59, 95% CI: 0.42, 0.82).</p>\n\n<p><strong>Conclusions: </strong>These data suggest that attending the HNC Survivorship Clinic prior to completing radiotherapy is independently associated with lower hazards of death and/or recurrence within 1 year of diagnosis. While further research is needed to determine the mechanisms by which pre-radiation therapy survivorship care improves survival and decreases risk of recurrence, health-seeking behavior may partially explain this association. Our findings suggest that early, proactive, multidisciplinary survivorship care can significantly improve clinical outcomes in HNC patients undergoing RT. Further research is needed to determine whether these benefits are observed among HNC patients undergoing other treatment modalities and over longer periods of follow up.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155502--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260148' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S429",
      "content_id": "153258",
      "abstract_number": "S429",
      "poster_number": "",
      "title": "Accelerated biologic aging and early-onset and non-smoking oral cavity cancer risk",
      "summary": "In this large prospective cohort, accelerated biologic aging quantified by residual PhenoAge was independently associated with higher OCC risk in all-comers, never-smokers, and early-onset patients. Furthermore, by quantifying how accelerated biologic aging relates to OCC risk across the age spectrum, we highlight PhenoAge as a scalable risk-stratification tool which may help identify individuals for targeted OCC...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153258",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hosam H Alkhatib, MD",
      "presenter": "Hosam H Alkhatib, MD",
      "authors": "Hosam H Alkhatib, MD 1 ; Mateo Useche, MD, MPH 1 ; Kara L Cushing-Haugen, MS 2 ; Luis Cortina, MD 1 ; Rocco M Ferrandino, MD, MSc 1 ; Emily J Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren C Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 2 ; Brittany R Barber, MD, MSc 1",
      "normalized_authors": [
        "Hosam H Alkhatib",
        "Mateo Useche",
        "Kara L Cushing-Haugen",
        "Luis Cortina",
        "Rocco M Ferrandino",
        "Emily J Marchiano",
        "Zain H Rizvi",
        "Lauren C Shih",
        "Cristina P Rodriguez",
        "Neal D Futran",
        "Matthew O Old",
        "Holly R Harris, ScD",
        "Brittany R Barber"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA",
        "Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA",
        "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 522,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hosam H Alkhatib, MD 1 ; Mateo Useche, MD, MPH 1 ; Kara L Cushing-Haugen, MS 2 ; Luis Cortina, MD 1 ; Rocco M Ferrandino, MD, MSc 1 ; Emily J Marchiano, MD 1 ; Zain H Rizvi, MD 1 ; Lauren C Shih, MD 3 ; Cristina P Rodriguez, MD 3 ; Neal D Futran, MD, DMD 1 ; Matthew O Old, MD 1 ; Holly R Harris, ScD, MPH 2 ; Brittany R Barber, MD, MSc 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; 2 Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA; 3 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA",
        "Background": "Chronologic age is linked with oral cavity cancer (OCC), but biologic age varies among individuals of the same chronologic age. PhenoAge is a validated measure of biologic age derived from nine routine biomarkers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count) and has been associated with increased risk of early-onset colorectal and breast cancers. However, the association between accelerated aging (defined as biologic age exceeding chronologic age) and OCC risk remains unknown, particularly among never-smokers and early-onset patients.",
        "Objective": "To quantify the association between accelerated biologic aging (PhenoAge) and OCC incidence in all-comers, never-smokers, and early-onset patients.",
        "Methods": "This is a prospective cohort analysis of 395,397 UK Biobank participants without prior malignancy enrolled between 2006 and 2010 with cancer registry follow-up through January 2024. Baseline PhenoAge (biologic age) was calculated using the biomarkers listed above. Residual PhenoAge (accelerated aging) in years was derived by regressing PhenoAge on chronologic age; positive residuals denoted accelerated biologic age. We estimated absolute risk per 100,000 people and fit logistic regression models of OCC incidence by residual PhenoAge quartiles (quartiles estimating accelerated aging; Q1-Q4) and per-5-year increments, adjusting for pack-year smoking history and alcohol intake frequency. The first residual PhenoAge quartile (Q1), representing participants with the most decelerated biologic aging, served as the reference group. Subanalyses were performed for never-smokers and early-onset (age less than 50 years at diagnosis) participants.",
        "Results": "There were 172,178 participants with accelerated biologic age [mean residual PhenoAge: +4.7 (5.5) years] and 223,219 participants with decelerated or equal biologic age [mean residual PhenoAge: −3.7 (2.6) years]. PhenoAge (biologic age) correlated strongly with chronologic age (r = 0.82). During follow-up, 366 incident OCC cases were identified. Absolute risk of OCC during the study period rose across residual PhenoAge quartiles: 61.7, 74.9, 97.1, and 136.6 per 100,000 people in Q1-Q4, respectively. Adjusting for pack-year smoking history and alcohol intake frequency, higher residual PhenoAge quartiles also had significantly higher odds of OCC incidence compared to the first quartile: Q3 aOR 1.45 (95% CI 1.05–2.00) and Q4 aOR 1.90 (1.40–2.58); P -trend < 0.0001. Among early-onset cases, those in the highest quartile of accelerated aging had a four-fold increase in odds of OCC (Q4 aOR 4.09, 95% CI 1.55–10.85; P -trend = 0.0005). In never-smokers, each 5-year increase in PhenoAge was associated with a 14% increase in OCC odds (aOR 1.14, 95% CI 1.05–1.24).",
        "Conclusions": "In this large prospective cohort, accelerated biologic aging quantified by residual PhenoAge was independently associated with higher OCC risk in all-comers, never-smokers, and early-onset patients. Furthermore, by quantifying how accelerated biologic aging relates to OCC risk across the age spectrum, we highlight PhenoAge as a scalable risk-stratification tool which may help identify individuals for targeted OCC prevention and screening strategies. Ongoing and subsequent studies will involve biologic and behavioral mediators impacting accelerated aging in all-comer OCC and in specific subpopulations, including young and never-smoking men and women.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Accelerated biologic aging and early-onset and non-smoking oral cavity cancer risk</span>. <u>Hosam H Alkhatib, MD</u><sup>1</sup>; Mateo Useche, MD, MPH<sup>1</sup>; Kara L Cushing-Haugen, MS<sup>2</sup>; Luis Cortina, MD<sup>1</sup>; Rocco M Ferrandino, MD, MSc<sup>1</sup>; Emily J Marchiano, MD<sup>1</sup>; Zain H Rizvi, MD<sup>1</sup>; Lauren C Shih, MD<sup>3</sup>; Cristina P Rodriguez, MD<sup>3</sup>; Neal D Futran, MD, DMD<sup>1</sup>; Matthew O Old, MD<sup>1</sup>; Holly R Harris, ScD, MPH<sup>2</sup>; Brittany R Barber, MD, MSc<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA; <sup>2</sup>Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA; <sup>3</sup>Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>:  Chronologic age is linked with oral cavity cancer (OCC), but biologic age varies among individuals of the same chronologic age. PhenoAge is a validated measure of biologic age derived from nine routine biomarkers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count) and has been associated with increased risk of early-onset colorectal and breast cancers. However, the association between accelerated aging (defined as biologic age exceeding chronologic age) and OCC risk remains unknown, particularly among never-smokers and early-onset patients. </p>\n\n<p><strong>Objective</strong>: To quantify the association between accelerated biologic aging (PhenoAge) and OCC incidence in all-comers, never-smokers, and early-onset patients.</p>\n\n<p><strong>Methods</strong>: This is a prospective cohort analysis of 395,397 UK Biobank participants without prior malignancy enrolled between 2006 and 2010 with cancer registry follow-up through January 2024. Baseline PhenoAge (biologic age) was calculated using the biomarkers listed above. Residual PhenoAge (accelerated aging) in years was derived by regressing PhenoAge on chronologic age; positive residuals denoted accelerated biologic age. We estimated absolute risk per 100,000 people and fit logistic regression models of OCC incidence by residual PhenoAge quartiles (quartiles estimating accelerated aging; Q1-Q4) and per-5-year increments, adjusting for pack-year smoking history and alcohol intake frequency. The first residual PhenoAge quartile (Q1), representing participants with the most decelerated biologic aging, served as the reference group. Subanalyses were performed for never-smokers and early-onset (age less than 50 years at diagnosis) participants.</p>\n\n<p><strong>Results</strong>: There were 172,178 participants with accelerated biologic age [mean residual PhenoAge: +4.7 (5.5) years] and 223,219 participants with decelerated or equal biologic age [mean residual PhenoAge: −3.7 (2.6) years]. PhenoAge (biologic age) correlated strongly with chronologic age (r = 0.82). During follow-up, 366 incident OCC cases were identified. Absolute risk of OCC during the study period rose across residual PhenoAge quartiles: 61.7, 74.9, 97.1, and 136.6 per 100,000 people in Q1-Q4, respectively. Adjusting for pack-year smoking history and alcohol intake frequency, higher residual PhenoAge quartiles also had significantly higher odds of OCC incidence compared to the first quartile: Q3 aOR 1.45 (95% CI 1.05–2.00) and Q4 aOR 1.90 (1.40–2.58); <em>P</em>-trend < 0.0001. Among early-onset cases, those in the highest quartile of accelerated aging had a four-fold increase in odds of OCC (Q4 aOR 4.09, 95% CI 1.55–10.85; <em>P</em>-trend = 0.0005). In never-smokers, each 5-year increase in PhenoAge was associated with a 14% increase in OCC odds (aOR 1.14, 95% CI 1.05–1.24).  </p>\n\n<p><strong>Conclusions</strong>: In this large prospective cohort, accelerated biologic aging quantified by residual PhenoAge was independently associated with higher OCC risk in all-comers, never-smokers, and early-onset patients. Furthermore, by quantifying how accelerated biologic aging relates to OCC risk across the age spectrum, we highlight PhenoAge as a scalable risk-stratification tool which may help identify individuals for targeted OCC prevention and screening strategies. Ongoing and subsequent studies will involve biologic and behavioral mediators impacting accelerated aging in all-comer OCC and in specific subpopulations, including young and never-smoking men and women.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153258--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S430",
      "content_id": "153338",
      "abstract_number": "S430",
      "poster_number": "",
      "title": "Per- and polyfluoroalkyl substances (PFAS) concentrations in water are associated with increased incidence of breast, colon, and oral cavity/pharyngeal cancer at the county level and at the zip c",
      "summary": "We found a significant association between “forever chemicals” such asPFBS and incidence of oral cavity/pharyngeal cancer across the nation. Granular, institutional analysis of patients with oral cavity dysplasia that transformed into SCC found a non-significant association between living in the same zip code as a PFAS contamination site. Further research is needed to explore these relationships in larger...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153338",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Colleen G Hochfelder, MD, MS",
      "presenter": "Colleen G Hochfelder, MD, MS",
      "authors": "Colleen G Hochfelder, MD, MS 1 ; Michael Pozin, MSE 2 ; Abdullah Adil, MD 1 ; Pratyusha Yalamanchi, MD 1",
      "normalized_authors": [
        "Colleen G Hochfelder",
        "Michael Pozin, MSE",
        "Abdullah Adil",
        "Pratyusha Yalamanchi"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Michigan",
        "Carle-Illinois College of Medicine, University of Illinois"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, University of Michigan",
        "Carle-Illinois College of Medicine, University of Illinois"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154066/figure%201%20ahns(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154066/figure%201%20ahns(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153338"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 431,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Colleen G Hochfelder, MD, MS 1 ; Michael Pozin, MSE 2 ; Abdullah Adil, MD 1 ; Pratyusha Yalamanchi, MD 1",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, University of Michigan; 2 Carle-Illinois College of Medicine, University of Illinois",
        "Introduction": "Per- and polyfluoroalkyl substances (PFAS) and perfluorobutanesulfonic acid (PFBS) are ubiquitous synthetic chemicals in modern manufacturing proposed as a potential risk factor for malignancy.",
        "Methods": "Data was collected from the U.S. Environmental Protection Agency (EPA) Unregulated Contaminant Monitoring Rule Third (UCRM3) and Fifth (UCRM5) data releases. UCRM3 included levels of 6 different PFAS from 6000 public water systems (PWS) from 2013-2015. UCRM5 included 29 different PFAS from 6900 systems from 2023-2025. We collected county-level cancer incidences from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database (2017-2021). The CDC’s social vulnerability index (SVI) was used to adjust for average socioeconomic status at the county-level. For a more granular analysis, we then evaluated a retrospective cohort of patients at our institution from 2012 to 2025 with oral cavity dysplasia (N=670), which included a subset that transformed into squamous cell carcinoma (SCC, N=79). Zip codes with PFAS contamination sites were identified using the publicly available Michigan Department of Environment, Great Lakes, and Energy (EGLE) Maps and Database.",
        "Results": "We compared PFAS levels and cancer incidence from 6033 counties. There was an association between counties with PFBS over the MCL (10.0 ng/L) and increased oral cavity/pharyngeal cancer incidence (increase of 1.95 cases/100,000, p<0.04). Perfluorooctanoic acid (PFOA) levels over the maximum contaminant level set by the EPA (MCL; 4.0 ng/L) were associated with higher average incidence of breast cancer (increase of 2.9 cases/100,000, p=0.0001) and colon cancer (increase of 1.7 cases/100,000, p=0.0001). GIS spatial analysis demonstrated counties with higher PFAS levels had a incidence of malignancy (Figure 1). PFOS concentrations were significantly associated with higher SVI (coefficient 4.88, 95% CI 1.98 to 7.78, p<0.01). Among the institutional cohort of patients with oral cavity dysplasia in Michigan, there was a trend towards living in a zip code with a known PFAS contamination site and increased rates of transformation from dysplasia to SCC after adjusting for smoking incidence, though this association did not reach significance (OR 1.58, 95% CI: 0.96 to 2.60, p=0.07).",
        "Conclusions": "We found a significant association between “forever chemicals” such asPFBS and incidence of oral cavity/pharyngeal cancer across the nation. Granular, institutional analysis of patients with oral cavity dysplasia that transformed into SCC found a non-significant association between living in the same zip code as a PFAS contamination site. Further research is needed to explore these relationships in larger multi-institutional cohort analysis.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Per- and polyfluoroalkyl substances (PFAS) concentrations in water are associated with increased incidence of breast, colon, and oral cavity/pharyngeal cancer at the county level and at the zip code level for oral cavity cancer within Michigan.</span>. <u>Colleen G Hochfelder, MD, MS</u><sup>1</sup>; Michael Pozin, MSE<sup>2</sup>; Abdullah Adil, MD<sup>1</sup>; Pratyusha Yalamanchi, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, University of Michigan; <sup>2</sup>Carle-Illinois College of Medicine, University of Illinois<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Per- and polyfluoroalkyl substances (PFAS) and perfluorobutanesulfonic acid (PFBS) are ubiquitous synthetic chemicals in modern manufacturing proposed as a potential risk factor for malignancy. </p>\n\n<p><strong>Methods:</strong> Data was collected from the U.S. Environmental Protection Agency (EPA) Unregulated Contaminant Monitoring Rule Third (UCRM3) and Fifth (UCRM5) data releases. UCRM3 included levels of 6 different PFAS from 6000 public water systems (PWS) from 2013-2015. UCRM5 included 29 different PFAS from 6900 systems from 2023-2025. We collected county-level cancer incidences from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database (2017-2021). The CDC’s social vulnerability index (SVI) was used to adjust for average socioeconomic status at the county-level. For a more granular analysis, we then evaluated a retrospective cohort of patients at our institution from 2012 to 2025 with oral cavity dysplasia (N=670), which included a subset that transformed into squamous cell carcinoma (SCC, N=79). Zip codes with PFAS contamination sites were identified using the publicly available Michigan Department of Environment, Great Lakes, and Energy (EGLE) Maps and Database. </p>\n\n<p><strong>Results: </strong>We compared PFAS levels and cancer incidence from 6033 counties. There was an association between counties with PFBS over the MCL (10.0 ng/L) and increased oral cavity/pharyngeal cancer incidence (increase of 1.95 cases/100,000, p<0.04). Perfluorooctanoic acid (PFOA) levels over the maximum contaminant level set by the EPA (MCL; 4.0 ng/L) were associated with higher average incidence of breast cancer (increase of 2.9 cases/100,000, p=0.0001) and colon cancer (increase of 1.7 cases/100,000, p=0.0001). GIS spatial analysis demonstrated counties with higher PFAS levels had a incidence of malignancy (Figure 1). PFOS concentrations were significantly associated with higher SVI (coefficient 4.88, 95% CI 1.98 to 7.78, p<0.01). Among the institutional cohort of patients with oral cavity dysplasia in Michigan, there was a trend towards living in a zip code with a known PFAS contamination site and increased rates of transformation from dysplasia to SCC after adjusting for smoking incidence, though this association did not reach significance (OR 1.58, 95% CI: 0.96 to 2.60, p=0.07). </p>\n\n<p><strong>Conclusions:</strong> We found a significant association between “forever chemicals” such asPFBS and incidence of oral cavity/pharyngeal cancer across the nation. Granular, institutional analysis of patients with oral cavity dysplasia that transformed into SCC found a non-significant association between living in the same zip code as a PFAS contamination site. Further research is needed to explore these relationships in larger multi-institutional cohort analysis.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154066/figure%201%20ahns(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153338--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S431",
      "content_id": "154408",
      "abstract_number": "S431",
      "poster_number": "",
      "title": "Radon Exposure and Thyroid Cancer in Kentucky",
      "summary": "Our study found a statistically significant increase the incidence of thyroid cancer among adults residing in the geographic region with high radon exposure compared with the region with low exposure. Though these results support a potential link between radon exposure and thyroid cancer, our findings must be validated and further characterized with additional investigations.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154408",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Melina Windon, MD",
      "presenter": "Melina Windon, MD",
      "authors": "Kaitlin Sclater, MD; Melina Windon, MD ; Bin Huang, PhD; Ning Li; Todd Burus, MAS; Maisha Rahman",
      "normalized_authors": [
        "Kaitlin Sclater",
        "Melina Windon",
        "Bin Huang",
        "Ning Li",
        "Todd Burus, MAS",
        "Maisha Rahman"
      ],
      "affiliations": [
        "University of Kentucky"
      ],
      "normalized_institutions": [
        "University of Kentucky"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kaitlin Sclater, MD; Melina Windon, MD ; Bin Huang, PhD; Ning Li; Todd Burus, MAS; Maisha Rahman",
        "Affiliations": "University of Kentucky",
        "Objective": "Radon gas decays into radioactive particles which can then cause tissue and DNA damage, and the health effects of exposure are largely unknown. Though existing literature has established an associated increased risk lung cancer over time, whether there is an association between radon exposure and thyroid cancer is not yet established. The increasing incidence of thyroid cancer in the United States and worldwide without known etiology supports the examination of environmental exposures such as radon.",
        "Study Design": "Population-based geo-spatial epidemiological study utilizing the secondary radon and cancer incidence data at the census tract level.",
        "Methods": "Geospatial analysis was utilized comparing radon measurement by household data collected through the University of Kentucky Geological Survey with primary invasive thyroid cancer incidents from 2010 to 2022 utilizing the Kentucky Cancer Registry. A Kentucky Census tract map was developed with 1306 tracts. The estimates of radon measurement at census tract were quantified utilizing 3rd quartile (3Q). Hot spot analysis was then performed with Getis-Ord Gi with fixed distance bands in a 10 miles radius defining the nearest neighborhood census tracts. Negative Binomial models were used to estimate the correlations between cancer incidence and radon exposure while controlling other confounders. Sensitive analysis was performed using mean and median as the estimates of radon exposure, and a 25 miles radius for the hot spot analysis.",
        "Results": "8752 adults (age > 20) with thyroid cancer were identified for inclusion in analysis. 217499 households were accessed for radon exposure. Hot spot analysis of radon exposure by census tract with fixed distance band of 25 miles with 3Q radon estimates identified 477 tracts in the cold spot and 210 in the hot spot. In the negative binomial model controlling for urban/rural status and area deprivation index, the incidence rate ratio (IRR) of thyroid cancer was significant greater for the hot spot area (1.10, 95% CI 1.04-1.17, p=0.002) compared to the cold spot. Sensitivity analysis utilizing mean or median identified similarly significance findings using a fixed distance band of 25 miles.",
        "Conclusion": "Our study found a statistically significant increase the incidence of thyroid cancer among adults residing in the geographic region with high radon exposure compared with the region with low exposure. Though these results support a potential link between radon exposure and thyroid cancer, our findings must be validated and further characterized with additional investigations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Radon Exposure and Thyroid Cancer in Kentucky</span>. Kaitlin Sclater, MD; <u>Melina Windon, MD</u>; Bin Huang, PhD; Ning Li; Todd Burus, MAS; Maisha Rahman. University of Kentucky<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>Radon gas decays into radioactive particles which can then cause tissue and DNA damage, and the health effects of exposure are largely unknown. Though existing literature has established an associated increased risk lung cancer over time, whether there is an association between radon exposure and thyroid cancer is not yet established. The increasing incidence of thyroid cancer in the United States and worldwide without known etiology supports the examination of environmental exposures such as radon.</p>\n\n<p><strong>Study Design: </strong>Population-based geo-spatial epidemiological study utilizing the secondary radon and cancer incidence data at the census tract level.</p>\n\n<p><strong>Methods: </strong>Geospatial analysis was utilized comparing radon measurement by household data collected through the University of Kentucky Geological Survey with primary invasive thyroid cancer incidents from 2010 to 2022 utilizing the Kentucky Cancer Registry. A Kentucky Census tract map was developed with 1306 tracts. The estimates of radon measurement at census tract were quantified utilizing 3rd quartile (3Q). Hot spot analysis was then performed with Getis-Ord Gi with fixed distance bands in a 10 miles radius defining the nearest neighborhood census tracts. Negative Binomial models were used to estimate the correlations between cancer incidence and radon exposure while controlling other confounders. Sensitive analysis was performed using mean and median as the estimates of radon exposure, and a 25 miles radius for the hot spot analysis.</p>\n\n<p><strong>Results: </strong>8752 adults (age > 20) with thyroid cancer were identified for inclusion in analysis. 217499 households were accessed for radon exposure. Hot spot analysis of radon exposure by census tract with fixed distance band of 25 miles with 3Q radon estimates identified 477 tracts in the cold spot and 210 in the hot spot. In the negative binomial model controlling for urban/rural status and area deprivation index, the incidence rate ratio (IRR) of thyroid cancer was significant greater for the hot spot area (1.10, 95% CI 1.04-1.17, p=0.002) compared to the cold spot. Sensitivity analysis utilizing mean or median identified similarly significance findings using a fixed distance band of 25 miles.</p>\n\n<p><strong>Conclusion:</strong> Our study found a statistically significant increase the incidence of thyroid cancer among adults residing in the geographic region with high radon exposure compared with the region with low exposure. Though these results support a potential link between radon exposure and thyroid cancer, our findings must be validated and further characterized with additional investigations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154408--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S432",
      "content_id": "154397",
      "abstract_number": "S432",
      "poster_number": "",
      "title": "Global Association between Ambient Air Pollution and Head and Neck Cancer Incidence: An Ecological Study",
      "summary": "We observed significant positive associations between PM 2.5 exposure and laryngeal and lip and oral cavity cancer incidence. PM 2.5 levels at the 5-year lag period were most strongly associated and remained positively associated at the 10-year lag period. To better understand the relationships between ambient pollution exposure and the changing landscape of HNC epidemiology, further subgroup and sensitivity...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154397",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alicia B Yang",
      "presenter": "Alicia B Yang",
      "authors": "Alicia B Yang ; Ethan Gomez; Ryan Sicard; Seungjun Ahn, PhD; Scott A Roof, MD; Maaike van Gerwen, MD, PhD",
      "normalized_authors": [
        "Alicia B Yang",
        "Ethan Gomez",
        "Ryan Sicard",
        "Seungjun Ahn",
        "Scott A Roof",
        "Maaike van Gerwen"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 542,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alicia B Yang ; Ethan Gomez; Ryan Sicard; Seungjun Ahn, PhD; Scott A Roof, MD; Maaike van Gerwen, MD, PhD",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Introduction": "Environmental factors may account for global geographic variations in head and neck cancer (HNC). Studies have shown that PM 2.5 —fine particulate matter with a diameter of 2.5 micrometers or less—is associated with decreased oral health and increased rates of HNC. This study evaluated the association between PM 2.5 and HNC incidence globally.",
        "Methods": "An ecological study was conducted using Global Burden of Disease Study 2023 data of 203 countries and territories. Each country/territory was categorized into 21 regions grouped by geographic proximity and epidemiology. These regions were divided into four quartiles based on average PM 2.5 exposure level over a 5-year period. Using annual PM 2.5 levels, 5-year averages were calculated from 1990–2014 at 5-, 10-, 15-, 20-, and 25-year lag intervals from the 5-year cumulative age-standardized HNC incidence risk period from 2019-2023. Four HNC subsites were included: larynx, lip and oral cavity, nasopharynx, and other pharynx. Gamma generalized linear mixed models were used to estimate the associations between PM 2.5 exposure and site-specific cumulative incidence risk (CIR) at the five different lag periods for each subsite. Percent changes in incidence rates per 10 μg/m 3 increase in PM 2.5 were calculated from exponentiated coefficients, and 95% confidence intervals were obtained using 10,000 parametric bootstrap replications. Models were adjusted for population socioeconomic and lifestyle covariates (socio-demographic index (SDI) and smoking prevalence), as well as additional air pollution covariates (nitrogen dioxide (NO 2 ) and ozone (O 3 )). A random intercept for region quartiles was included to account for within-region correlation.",
        "Results": "From 2019-2023, the median CIRs (cases per 100,000) of larynx, lip and oral cavity, nasopharynx, and other pharynx cancers were 8.9 (range: 0.5–81), 14.7 (0.7–143), 3.5 (0.09–67.6), and 3.7 (0.08–45.8), respectively. From 1990-2014, global average PM 2.5 exposure levels were largely decreasing, although some countries in Asia and Africa showed a positive trend. In the unadjusted gamma mixed-effects model, a 10 μg/m 3 increase in 5-year lagged PM 2.5 was associated with an 11.9% (95% CI: 3.0%, 21.8%) higher incidence of laryngeal cancer. After adjusting for SDI and smoking, a 10 μg/m 3 increase in 5-year lagged PM 2.5 was associated with a 10.1% (95% CI: 2.0%, 18.8%) higher incidence of lip and oral cavity cancer in addition to a statistically significant increased incidence of laryngeal cancer. These associations held at the 10-year lag. Interestingly, at the 20- and 25-year lag period, increased PM 2.5 was associated with a decreased incidence of nasopharyngeal cancer (percent change: -7.8%; 95% CI: -14.8%, -0.5%) after adjusting for all covariates. There were no associations between PM 2.5 exposure and other pharynx cancers.",
        "Conclusions": "We observed significant positive associations between PM 2.5 exposure and laryngeal and lip and oral cavity cancer incidence. PM 2.5 levels at the 5-year lag period were most strongly associated and remained positively associated at the 10-year lag period. To better understand the relationships between ambient pollution exposure and the changing landscape of HNC epidemiology, further subgroup and sensitivity analyses will be conducted.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Global Association between Ambient Air Pollution and Head and Neck Cancer Incidence: An Ecological Study</span>. <u>Alicia B Yang</u>; Ethan Gomez; Ryan Sicard; Seungjun Ahn, PhD; Scott A Roof, MD; Maaike van Gerwen, MD, PhD. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Environmental factors may account for global geographic variations in head and neck cancer (HNC). Studies have shown that PM<sub>2.5</sub>—fine particulate matter with a diameter of 2.5 micrometers or less—is associated with decreased oral health and increased rates of HNC. This study evaluated the association between PM<sub>2.5</sub> and HNC incidence globally.</p>\n\n<p><strong>Methods</strong>: An ecological study was conducted using Global Burden of Disease Study 2023 data of 203 countries and territories. Each country/territory was categorized into 21 regions grouped by geographic proximity and epidemiology. These regions were divided into four quartiles based on average PM<sub>2.5</sub> exposure level over a 5-year period. Using annual PM<sub>2.5</sub> levels, 5-year averages were calculated from 1990–2014 at 5-, 10-, 15-, 20-, and 25-year lag intervals from the 5-year cumulative age-standardized HNC incidence risk period from 2019-2023. Four HNC subsites were included: larynx, lip and oral cavity, nasopharynx, and other pharynx. Gamma generalized linear mixed models were used to estimate the associations between PM<sub>2.5</sub> exposure and site-specific cumulative incidence risk (CIR) at the five different lag periods for each subsite. Percent changes in incidence rates per 10 μg/m<sup>3</sup> increase in PM<sub>2.5</sub> were calculated from exponentiated coefficients, and 95% confidence intervals were obtained using 10,000 parametric bootstrap replications. Models were adjusted for population socioeconomic and lifestyle covariates (socio-demographic index (SDI) and smoking prevalence), as well as additional air pollution covariates (nitrogen dioxide (NO<sub>2</sub>) and ozone (O<sub>3</sub>)). A random intercept for region quartiles was included to account for within-region correlation.</p>\n\n<p><strong>Results</strong>: From 2019-2023, the median CIRs (cases per 100,000) of larynx, lip and oral cavity, nasopharynx, and other pharynx cancers were 8.9 (range: 0.5–81), 14.7 (0.7–143), 3.5 (0.09–67.6), and 3.7 (0.08–45.8), respectively. From 1990-2014, global average PM<sub>2.5</sub> exposure levels were largely decreasing, although some countries in Asia and Africa showed a positive trend. In the unadjusted gamma mixed-effects model, a 10 μg/m<sup>3</sup> increase in 5-year lagged PM<sub>2.5</sub> was associated with an 11.9% (95% CI: 3.0%, 21.8%) higher incidence of laryngeal cancer. After adjusting for SDI and smoking, a 10 μg/m<sup>3</sup> increase in 5-year lagged PM<sub>2.5</sub> was associated with a 10.1% (95% CI: 2.0%, 18.8%) higher incidence of lip and oral cavity cancer in addition to a statistically significant increased incidence of laryngeal cancer. These associations held at the 10-year lag. Interestingly, at the 20- and 25-year lag period, increased PM<sub>2.5</sub> was associated with a decreased incidence of nasopharyngeal cancer (percent change: -7.8%; 95% CI: -14.8%, -0.5%) after adjusting for all covariates. There were no associations between PM<sub>2.5</sub> exposure and other pharynx cancers.</p>\n\n<p><strong>Conclusions</strong>: We observed significant positive associations between PM<sub>2.5</sub> exposure and laryngeal and lip and oral cavity cancer incidence. PM<sub>2.5</sub> levels at the 5-year lag period were most strongly associated and remained positively associated at the 10-year lag period. To better understand the relationships between ambient pollution exposure and the changing landscape of HNC epidemiology, further subgroup and sensitivity analyses will be conducted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154397--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S433",
      "content_id": "153753",
      "abstract_number": "S433",
      "poster_number": "",
      "title": "Opportunities for Human Papillomavirus Vaccination in the Otolaryngology Outpatient Setting",
      "summary": "Almost 70% of otolaryngology clinic patients remain unvaccinated for HPV, which represents a substantial opportunity for vaccination. This study demonstrates multiple group differences in vaccination rates, who may benefit from targeted messaging for future vaccine interventions, particularly older patients, males over the age of 11, and MENA patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153753",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdurrahman Abdurrob, MD, MS",
      "presenter": "Abdurrahman Abdurrob, MD, MS",
      "authors": "Abdurrahman Abdurrob, MD, MS 1 ; Eric Adjei, PhD 1 ; Kyle Leonard, MD 1 ; Sruthi Suprapaneni 2 ; Zoe Baxter 2 ; Steven Chang, MD 1 ; Kathleen Yaremchuk, MD 1 ; Samantha Tam, MD, MPH 1",
      "normalized_authors": [
        "Abdurrahman Abdurrob",
        "Eric Adjei",
        "Kyle Leonard",
        "Sruthi Suprapaneni",
        "Zoe Baxter",
        "Steven Chang",
        "Kathleen Yaremchuk",
        "Samantha Tam"
      ],
      "affiliations": [
        "Henry Ford Health",
        "Michigan State University School of Medicine"
      ],
      "normalized_institutions": [
        "Henry Ford Health",
        "Michigan State University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 519,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Abdurrahman Abdurrob, MD, MS 1 ; Eric Adjei, PhD 1 ; Kyle Leonard, MD 1 ; Sruthi Suprapaneni 2 ; Zoe Baxter 2 ; Steven Chang, MD 1 ; Kathleen Yaremchuk, MD 1 ; Samantha Tam, MD, MPH 1",
        "Affiliations": "1 Henry Ford Health; 2 Michigan State University School of Medicine",
        "Background": "More than 90% of the human papillomavirus (HPV) associated cancers could be prevented through vaccination. Approximately 46,000 cases of HPV-attributable cancer are diagnosed annually in the United States, with a majority of these being oropharyngeal squamous cell carcinoma (OPSCC). However, vaccination rates consistently fall below the Healthy People 2030 goal of 80%, with vaccines primarily administered in primary care settings. Patient-physician counseling is a barrier to this, but otolaryngologists are uniquely placed to bridge this gap given our role in the routine management of OPSCC. Specialty clinics that do not traditionally offer HPV vaccination present an opportunity to improve vaccine uptake. The objective of this study is to quantify vaccination opportunities among patients attending otolaryngology clinics.",
        "Methods": "This is a cross-sectional study of patients aged 9-45 years at a single tertiary academic institution who had an otolaryngology clinic visit between 2018 and 2025. Outcome variables were HPV vaccination initiation (receipt of at least one dose) and completion (receipt of ≥3 doses). Patient-level characteristics examined included age, gender, race, and marital status. Multivariable logistic regression models were used to estimate the association between patient characteristics and HPV vaccination initiation and completion. Regression analyses were conducted for overall sample and stratified by age 9-11 vs. 12-45 years.",
        "Results": "A total of 35,931 patients (mean age=29.5, 58.1% female) were included in this sample. HPV vaccination initiation was 30.6% and completion was 14.8%. Among those aged 9-11, vaccination initiation was 41.8% and completion was 15.9%. For all ages, younger and female patients had higher odds of initiating the vaccination (aOR=0.91, 95% CI: 0.91, 0.92 and aOR=0.54, 95% CI: 0.51, 0.57, respectively). Compared with White patients, Black, Asian, and Hispanic patients had higher odds of vaccination initiation (aOR=1.60, 95% CI: 1.50, 1.70; aOR 1.52, 95% CI 1.35, 1.71; aOR 1.20, 95% CI 1.05, 1.37, respectively), while Middle Eastern/North African (MENA) patients had lower odds of initiation (aOR=0.25, 95% CI 0.81, 1.71). Younger age (aOR=0.97, 95% CI 0.97, 0.97) and female patients (aOR=0.45, 95% CI 0.42, 0.48) had higher odds of completing the vaccine. Asian patients had higher odds of completing the vaccine series than White patients (aOR=1.33, 95% CI 1.16, 1.52), while MENA (aOR=0.28, 95% CI 0.85, 1.95) had lower odds of completing the vaccine than White patients. When stratified by age, among those between 9-11 years old, there was no statistically significant difference in vaccination initiation between male and female. However, among those aged 12-45, females (aOR=0.38; 95% CI: 0.10, 1.47) had higher odds of initiating the vaccination.",
        "Conclusion": "Almost 70% of otolaryngology clinic patients remain unvaccinated for HPV, which represents a substantial opportunity for vaccination. This study demonstrates multiple group differences in vaccination rates, who may benefit from targeted messaging for future vaccine interventions, particularly older patients, males over the age of 11, and MENA patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Opportunities for Human Papillomavirus Vaccination in the Otolaryngology Outpatient Setting</span>. <u>Abdurrahman Abdurrob, MD, MS</u><sup>1</sup>; Eric Adjei, PhD<sup>1</sup>; Kyle Leonard, MD<sup>1</sup>; Sruthi Suprapaneni<sup>2</sup>; Zoe Baxter<sup>2</sup>; Steven Chang, MD<sup>1</sup>; Kathleen Yaremchuk, MD<sup>1</sup>; Samantha Tam, MD, MPH<sup>1</sup>. <sup>1</sup>Henry Ford Health; <sup>2</sup>Michigan State University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> More than 90% of the human papillomavirus (HPV) associated cancers could be prevented through vaccination. Approximately 46,000 cases of HPV-attributable cancer are diagnosed annually in the United States, with a majority of these being oropharyngeal squamous cell carcinoma (OPSCC). However, vaccination rates consistently fall below the Healthy People 2030 goal of 80%, with vaccines primarily administered in primary care settings. Patient-physician counseling is a barrier to this, but otolaryngologists are uniquely placed to bridge this gap given our role in the routine management of OPSCC. Specialty clinics that do not traditionally offer HPV vaccination present an opportunity to improve vaccine uptake. The objective of this study is to quantify vaccination opportunities among patients attending otolaryngology clinics.</p>\n\n<p><strong>Methods:</strong> This is a cross-sectional study of patients aged 9-45 years at a single tertiary academic institution who had an otolaryngology clinic visit between 2018 and 2025. Outcome variables were HPV vaccination initiation (receipt of at least one dose) and completion (receipt of ≥3 doses). Patient-level characteristics examined included age, gender, race, and marital status. Multivariable logistic regression models were used to estimate the association between patient characteristics and HPV vaccination initiation and completion. Regression analyses were conducted for overall sample and stratified by age 9-11 vs. 12-45 years.</p>\n\n<p><strong>Results:</strong> A total of 35,931 patients (mean age=29.5, 58.1% female) were included in this sample. HPV vaccination initiation was 30.6% and completion was 14.8%. Among those aged 9-11, vaccination initiation was 41.8% and completion was 15.9%. For all ages, younger and female patients had higher odds of initiating the vaccination (aOR=0.91, 95% CI: 0.91, 0.92 and aOR=0.54, 95% CI: 0.51, 0.57, respectively). Compared with White patients, Black, Asian, and Hispanic patients had higher odds of vaccination initiation (aOR=1.60, 95% CI: 1.50, 1.70; aOR 1.52, 95% CI 1.35, 1.71; aOR 1.20, 95% CI 1.05, 1.37, respectively), while Middle Eastern/North African (MENA) patients had lower odds of initiation (aOR=0.25, 95% CI 0.81, 1.71). Younger age (aOR=0.97, 95% CI 0.97, 0.97) and female patients (aOR=0.45, 95% CI 0.42, 0.48) had higher odds of completing the vaccine. Asian patients had higher odds of completing the vaccine series than White patients (aOR=1.33, 95% CI 1.16, 1.52), while MENA (aOR=0.28, 95% CI 0.85, 1.95) had lower odds of completing the vaccine than White patients. When stratified by age, among those between 9-11 years old, there was no statistically significant difference in vaccination initiation between male and female. However, among those aged 12-45, females (aOR=0.38; 95% CI: 0.10, 1.47) had higher odds of initiating the vaccination.</p>\n\n<p><strong>Conclusion: </strong>Almost 70% of otolaryngology clinic patients remain unvaccinated for HPV, which represents a substantial opportunity for vaccination. This study demonstrates multiple group differences in vaccination rates, who may benefit from targeted messaging for future vaccine interventions, particularly older patients, males over the age of 11, and MENA patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153753--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S434",
      "content_id": "154629",
      "abstract_number": "S434",
      "poster_number": "",
      "title": "The Impact Of Post-Diagnosis Tobacco Cessation On Oral Cancer Outcomes",
      "summary": "Our data documents that there is greater risk of recurrence for patients who continue to smoke through treatment compared to those who quit after diagnosis. Thus, smoking cessation is essential to mitigate oral cancer recurrence. Counseling patients regarding cessation even at time of cancer diagnosis is vital in improving their life after cancer treatment and in lowering their chances of recurrence.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154629",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joanna George, BS",
      "presenter": "Joanna George, BS",
      "authors": "Joanna George, BS 1 ; Matthew Krutz, MD 2 ; Avery Richardson, BA 1 ; Pawan Acharya, PhD 3 ; Lurdes Queimado, MD, PhD 2",
      "normalized_authors": [
        "Joanna George",
        "Matthew Krutz",
        "Avery Richardson",
        "Pawan Acharya",
        "Lurdes Queimado"
      ],
      "affiliations": [
        "University of Oklahoma College Of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "General Surgery Department, University of Alabama at Birmingham"
      ],
      "normalized_institutions": [
        "University of Oklahoma College Of Medicine",
        "Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma",
        "General Surgery Department, University of Alabama at Birmingham"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 335,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joanna George, BS 1 ; Matthew Krutz, MD 2 ; Avery Richardson, BA 1 ; Pawan Acharya, PhD 3 ; Lurdes Queimado, MD, PhD 2",
        "Affiliations": "1 University of Oklahoma College Of Medicine; 2 Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma; 3 General Surgery Department, University of Alabama at Birmingham",
        "Background": "Oral cancer is the sixth most common cancer in the world and has a well-established link to tobacco use. While it is known that quitting tobacco use lowers the risk of oral cancer, little is understood regarding the impact of tobacco cessation at diagnosis and its impact on oral cancer recurrence. This study looks at the impact of quitting smoking after diagnosis on recurrence and overall survival after oral cancer diagnosis.",
        "Methods": "We performed a retrospective chart review and identified 119 patients newly diagnosed with oral cavity cancer between 2002 and 2023 who were current smokers and treated with intent to cure. Demographic and clinical data of these patients were retrospectively collected. Patients were further separated in two groups based on whether they quit smoking prior to treatment initiation (quitters) or not (active smokers) Recurrence-free survival and overall survival were calculated. Chi-square tests, logistic regression, Kaplan Meier curves and Cox-proportional hazards survival analyses were done to understand the impact of smoking on recurrence. Analyses were adjusted for sex, race, alcohol use, primary site, tumor stage, and treatment group.",
        "Results": "Our study population was 65% male and 86% white. Eighty-six percent had early-stage cancer, and 48% were alcohol users. Of the 119 patients who smoked at time of diagnosis, 52 (44%) quit smoking before initiating first-line therapy. There was no significant difference between sex, race, and stage between those who quit and those who did not. Quitters had only a 7% recurrence rate compared to active smokers at 27% (p=0.016). On multivariable analysis, the odds of recurrence were significantly lower among quitters than active smokers (p=0.003).",
        "Conclusions": "Our data documents that there is greater risk of recurrence for patients who continue to smoke through treatment compared to those who quit after diagnosis. Thus, smoking cessation is essential to mitigate oral cancer recurrence. Counseling patients regarding cessation even at time of cancer diagnosis is vital in improving their life after cancer treatment and in lowering their chances of recurrence.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Impact Of Post-Diagnosis Tobacco Cessation On Oral Cancer Outcomes</span>. <u>Joanna George, BS</u><sup>1</sup>; Matthew Krutz, MD<sup>2</sup>; Avery Richardson, BA<sup>1</sup>; Pawan Acharya, PhD<sup>3</sup>; Lurdes Queimado, MD, PhD<sup>2</sup>. <sup>1</sup>University of Oklahoma College Of Medicine; <sup>2</sup>Department of Otolaryngology – Head and Neck Surgery, University of Oklahoma; <sup>3</sup>General Surgery Department, University of Alabama at Birmingham<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral cancer is the sixth most common cancer in the world and has a well-established link to tobacco use. While it is known that quitting tobacco use lowers the risk of oral cancer, little is understood regarding the impact of tobacco cessation at diagnosis and its impact on oral cancer recurrence. This study looks at the impact of quitting smoking after diagnosis on recurrence and overall survival after oral cancer diagnosis.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective chart review and identified 119 patients newly diagnosed with oral cavity cancer between 2002 and 2023 who were current smokers and treated with intent to cure. Demographic and clinical data of these patients were retrospectively collected. Patients were further separated in two groups based on whether they quit smoking prior to treatment initiation (quitters) or not (active smokers) Recurrence-free survival and overall survival were calculated. Chi-square tests, logistic regression, Kaplan Meier curves and Cox-proportional hazards survival analyses were done to understand the impact of smoking on recurrence. Analyses were adjusted for sex, race, alcohol use, primary site, tumor stage, and treatment group.</p>\n\n<p><strong>Results: </strong>Our study population was 65% male and 86% white. Eighty-six percent had early-stage cancer, and 48% were alcohol users. Of the 119 patients who smoked at time of diagnosis, 52 (44%) quit smoking before initiating first-line therapy. There was no significant difference between sex, race, and stage between those who quit and those who did not.  Quitters had only a 7% recurrence rate compared to active smokers at 27% (p=0.016). On multivariable analysis, the odds of recurrence were significantly lower among quitters than active smokers (p=0.003).</p>\n\n<p><strong>Conclusions: </strong>Our data documents that there is greater risk of recurrence for patients who continue to smoke through treatment compared to those who quit after diagnosis. Thus, smoking cessation is essential to mitigate oral cancer recurrence. Counseling patients regarding cessation even at time of cancer diagnosis is vital in improving their life after cancer treatment and in lowering their chances of recurrence.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154629--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S435",
      "content_id": "154179",
      "abstract_number": "S435",
      "poster_number": "",
      "title": "AGE-DEPENDENT CLINICOPATHOLOGICAL FEATURES AND THE PARADOXICAL IMPACT OF TOBACCO AND ALCOHOL ABSTINENCE ON SURVIVAL IN YOUNG ADULTS WITH ORAL SQUAMOUS CELL CARCINOMA: A 35-YEAR INSTITUTIONAL EXPE",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154179",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Alvaro L Oliveira, MD; Hugo F Kohler, MD; Jose G Vartanian, MD, PhD ; Thiago B Oliveira, MD, PhD; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Alvaro L Oliveira",
        "Hugo F Kohler",
        "Jose G Vartanian",
        "Thiago B Oliveira",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "MATERIALS AND METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alvaro L Oliveira, MD; Hugo F Kohler, MD; Jose G Vartanian, MD, PhD ; Thiago B Oliveira, MD, PhD; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "BACKGROUND": "Oral cavity squamous cell carcinoma (OCSCC) in young adults remains a subject of ongoing controversy regarding clinical behavior, prognostic determinants, and treatment outcomes. While traditional risk factors such as tobacco and alcohol consumption are well-established in older populations, their prognostic significance in younger patients requires clarification. This study aimed to comprehensively compare clinicopathological characteristics and survival outcomes between younger and older OCSCC patients, with particular emphasis on evaluating the impact of carcinogen exposure in the young adult cohort.",
        "MATERIALS AND METHODS": "We conducted a retrospective cohort analysis of all OCSCC patients treated with curative intent at A.C. Camargo Cancer Center, Brazil, between June 1, 1985, and June 30, 2020. Patients were stratified by age at diagnosis: 45 years or younger versus older than 45 years. Comprehensive demographic, clinical, and pathological data were collected through standardized questionnaires. Statistical analyses included Student t-test for continuous variables (presented as mean ± standard deviation), chi-square test for categorical variables (presented as frequencies), Kaplan-Meier method for survival estimation, and Cox proportional hazards regression for multivariable analysis. Primary endpoints comprised disease-specific survival (DSS) and overall survival (OS).",
        "RESULTS": "The cohort included 1,917 patients: 285 young adults (14.8%) and 1,632 older patients (85.2%). Significant differences emerged between age groups regarding tobacco exposure (p<0.001), alcohol consumption (p<0.001), pathological nodal stage (p=0.001), clinical stage (p=0.014), extranodal extension (p<0.001), and histological grade (p=0.023). Conversely, pathological T stage, lymphovascular invasion, perineural infiltration, and adjuvant treatment distribution demonstrated no significant differences, although a trend toward increased chemoradiation utilization in younger patients approached statistical significance (p=0.090). The entire cohort achieved five-year DSS of 67.7% and OS of 56.8%. Log-rank analysis revealed no significant survival differences between age groups, with a trend favoring superior OS in younger patients (p=0.06). Multivariable Cox regression identified pathological T classification, pathological N classification, and adjuvant radiotherapy as independent predictors of DSS, while age at diagnosis lacked prognostic significance. Remarkably, subset analysis restricted to young adults revealed a counterintuitive finding: patients without tobacco and/or alcohol exposure experienced significantly worse prognosis compared to their exposed counterparts.",
        "CONCLUSION": "Young adults with OCSCC demonstrate equivalent long-term oncological outcomes compared to older patients despite exhibiting distinct clinicopathological profiles characterized by more advanced nodal disease and higher rates of extranodal extension. The absence of age as an independent prognostic factor in multivariable analysis challenges historical assumptions regarding the clinical behavior of OCSCC in younger populations. Most intriguingly, the paradoxical association between lack of carcinogen exposure and inferior survival in young adults suggests fundamental biological differences in tumor etiology and behavior. This finding implies that OCSCC arising in the absence of traditional risk factors may represent a distinct molecular subtype with potentially more aggressive characteristics, possibly driven by alternative carcinogenic mechanisms including human papillomavirus infection, hereditary predisposition, or spontaneous genetic alterations. These observations underscore the critical need for comprehensive molecular profiling of age-stratified OCSCC cohorts to identify actionable therapeutic targets.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AGE-DEPENDENT CLINICOPATHOLOGICAL FEATURES AND THE PARADOXICAL IMPACT OF TOBACCO AND ALCOHOL ABSTINENCE ON SURVIVAL IN YOUNG ADULTS WITH ORAL SQUAMOUS CELL CARCINOMA: A 35-YEAR INSTITUTIONAL EXPERIENCE</span>. Alvaro L Oliveira, MD; Hugo F Kohler, MD; <u>Jose G Vartanian, MD, PhD</u>; Thiago B Oliveira, MD, PhD; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>Oral cavity squamous cell carcinoma (OCSCC) in young adults remains a subject of ongoing controversy regarding clinical behavior, prognostic determinants, and treatment outcomes. While traditional risk factors such as tobacco and alcohol consumption are well-established in older populations, their prognostic significance in younger patients requires clarification. This study aimed to comprehensively compare clinicopathological characteristics and survival outcomes between younger and older OCSCC patients, with particular emphasis on evaluating the impact of carcinogen exposure in the young adult cohort.</p>\n\n<p><strong>MATERIALS AND METHODS: </strong>We conducted a retrospective cohort analysis of all OCSCC patients treated with curative intent at A.C. Camargo Cancer Center, Brazil, between June 1, 1985, and June 30, 2020. Patients were stratified by age at diagnosis: 45 years or younger versus older than 45 years. Comprehensive demographic, clinical, and pathological data were collected through standardized questionnaires. Statistical analyses included Student t-test for continuous variables (presented as mean ± standard deviation), chi-square test for categorical variables (presented as frequencies), Kaplan-Meier method for survival estimation, and Cox proportional hazards regression for multivariable analysis. Primary endpoints comprised disease-specific survival (DSS) and overall survival (OS).</p>\n\n<p><strong>RESULTS: </strong>The cohort included 1,917 patients: 285 young adults (14.8%) and 1,632 older patients (85.2%). Significant differences emerged between age groups regarding tobacco exposure (p<0.001), alcohol consumption (p<0.001), pathological nodal stage (p=0.001), clinical stage (p=0.014), extranodal extension (p<0.001), and histological grade (p=0.023). Conversely, pathological T stage, lymphovascular invasion, perineural infiltration, and adjuvant treatment distribution demonstrated no significant differences, although a trend toward increased chemoradiation utilization in younger patients approached statistical significance (p=0.090). The entire cohort achieved five-year DSS of 67.7% and OS of 56.8%. Log-rank analysis revealed no significant survival differences between age groups, with a trend favoring superior OS in younger patients (p=0.06). Multivariable Cox regression identified pathological T classification, pathological N classification, and adjuvant radiotherapy as independent predictors of DSS, while age at diagnosis lacked prognostic significance. Remarkably, subset analysis restricted to young adults revealed a counterintuitive finding: patients without tobacco and/or alcohol exposure experienced significantly worse prognosis compared to their exposed counterparts.</p>\n\n<p><strong>CONCLUSION: </strong>Young adults with OCSCC demonstrate equivalent long-term oncological outcomes compared to older patients despite exhibiting distinct clinicopathological profiles characterized by more advanced nodal disease and higher rates of extranodal extension. The absence of age as an independent prognostic factor in multivariable analysis challenges historical assumptions regarding the clinical behavior of OCSCC in younger populations. Most intriguingly, the paradoxical association between lack of carcinogen exposure and inferior survival in young adults suggests fundamental biological differences in tumor etiology and behavior. This finding implies that OCSCC arising in the absence of traditional risk factors may represent a distinct molecular subtype with potentially more aggressive characteristics, possibly driven by alternative carcinogenic mechanisms including human papillomavirus infection, hereditary predisposition, or spontaneous genetic alterations. These observations underscore the critical need for comprehensive molecular profiling of age-stratified OCSCC cohorts to identify actionable therapeutic targets.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154179--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S436",
      "content_id": "154209",
      "abstract_number": "S436",
      "poster_number": "",
      "title": "Risk of Head and Neck Cancer Associated with Exposure to Immunosuppressive Treatment for Autoimmune Diseases",
      "summary": "Exposure to systemic immunosuppressive therapy was associated with an increased risk of HNC, primarily among patients with rheumatoid arthritis and most evident after longer follow-up. Prospective and mechanistic studies are warranted to clarify causal pathways and to evaluate whether targeted HNC surveillance and risk disclosure should be considered for patients with autoimmune disease being considered for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154209",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Albert Li, BS",
      "presenter": "Albert Li, BS",
      "authors": "Albert Li, BS ; Oluwatobiloba Ayo-Ajibola, BS; Vimawala Swar, MD; Daniel I Kwon, MD",
      "normalized_authors": [
        "Albert Li",
        "Oluwatobiloba Ayo-Ajibola",
        "Vimawala Swar",
        "Daniel I Kwon"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 484,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Albert Li, BS ; Oluwatobiloba Ayo-Ajibola, BS; Vimawala Swar, MD; Daniel I Kwon, MD",
        "Affiliations": "Department of Otolaryngology-Head and Neck Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA",
        "Background": "Autoimmune diseases (ADs) are frequently managed with systemic immunosuppressive therapies (IST), yet the long-term oncologic implications in this setting remain poorly defined. Although prior studies suggest that ADs may confer an elevated risk of head and neck cancer (HNC), it is unclear whether this risk reflects the baseline pro-inflammatory state of disease or the effects of immunosuppression, particularly given that carcinogenesis has been linked to chronic inflammation as well as a breakdown in immune surveillance. This study aims to clarify this association using a propensity score matched cohort analysis of a large healthcare claims database.",
        "Methods": "This retrospective cohort study utilized de-identified electronic medical record data from the TriNetX US Collaborative Network, encompassing 68 healthcare organizations across the United States. Adults (≥18 years) with at least one diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus, and inflammatory bowel disease (Crohn’s and Ulcerative Colitis), and at least five outpatient encounters with the target code were included. Stratification was based on exposure to at least one IST after the initial AD diagnosis in the intervention group, or on no history of systemic IST in the unexposed cohort. Those with a history of HNC prior to diagnosis or IST use were excluded. Cohorts were matched using propensity scores based on demographics (age at the index event, sex, race/ethnicity), as well as nicotine, tobacco, cannabis, and alcohol use, along with HPV- and EBV-related diseases. The primary endpoint was incident specified HNC diagnosis (ICD C00-14, C30-32) within 5 years and 10 years, and lifetime after diagnosis, with risk ratios (RRs) calculated with 95% CIs. Further sub-analyses were conducted to examine each diagnosis (SLE, RA, IBD) within mutually exclusive cohorts.",
        "Results": "Prior to matching, 723,031 patients with autoimmune disease met the criteria, of which 299,675 had been exposed to immunosuppressive therapy. Among the aggregate autoimmune cohort (matched n=269,000), IST was associated with an increased risk of lifetime HNC (RR 1.112, 95% CI 1.011–1.229). Within disease-specific subgroups, only RA patients treated with IST showed an elevated lifetime HNC risk (RR 1.254, 1.109–1.418). Systemic lupus erythematosus, Crohn’s Disease, and Ulcerative Colitis showed no significant difference in lifetime HNC risk based on IST exposure. Under the 5-year time window, the overall cohort displayed a slightly increased risk of HNC (RR 1.210, 1.074–1.364). At 10 years, both the overall (RR 1.312, 1.188–1.450) and RA-specific cohort (RR 1.147, 1.008–1.305) displayed an increased risk of HNC.",
        "Conclusion": "Exposure to systemic immunosuppressive therapy was associated with an increased risk of HNC, primarily among patients with rheumatoid arthritis and most evident after longer follow-up. Prospective and mechanistic studies are warranted to clarify causal pathways and to evaluate whether targeted HNC surveillance and risk disclosure should be considered for patients with autoimmune disease being considered for immunosuppressive therapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Risk of Head and Neck Cancer Associated with Exposure to Immunosuppressive Treatment for Autoimmune Diseases</span>. <u>Albert Li, BS</u>; Oluwatobiloba Ayo-Ajibola, BS; Vimawala Swar, MD; Daniel I Kwon, MD. Department of Otolaryngology-Head and Neck Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Autoimmune diseases (ADs) are frequently managed with systemic immunosuppressive therapies (IST), yet the long-term oncologic implications in this setting remain poorly defined. Although prior studies suggest that ADs may confer an elevated risk of head and neck cancer (HNC), it is unclear whether this risk reflects the baseline pro-inflammatory state of disease or the effects of immunosuppression, particularly given that carcinogenesis has been linked to chronic inflammation as well as a breakdown in immune surveillance. This study aims to clarify this association using a propensity score matched cohort analysis of a large healthcare claims database.</p>\n\n<p><strong>Methods: </strong>This retrospective cohort study utilized de-identified electronic medical record data from the TriNetX US Collaborative Network, encompassing 68 healthcare organizations across the United States. Adults (≥18 years) with at least one diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus, and inflammatory bowel disease (Crohn’s and Ulcerative Colitis), and at least five outpatient encounters with the target code were included. Stratification was based on exposure to at least one IST after the initial AD diagnosis in the intervention group, or on no history of systemic IST in the unexposed cohort.  Those with a history of HNC prior to diagnosis or IST use were excluded. Cohorts were matched using propensity scores based on demographics (age at the index event, sex, race/ethnicity), as well as nicotine, tobacco, cannabis, and alcohol use, along with HPV- and EBV-related diseases. The primary endpoint was incident specified HNC diagnosis (ICD C00-14, C30-32) within 5 years and 10 years, and lifetime after diagnosis, with risk ratios (RRs) calculated with 95% CIs. Further sub-analyses were conducted to examine each diagnosis (SLE, RA, IBD) within mutually exclusive cohorts.</p>\n\n<p><strong>Results: </strong>Prior to matching, 723,031 patients with autoimmune disease met the criteria, of which 299,675 had been exposed to immunosuppressive therapy. Among the aggregate autoimmune cohort (matched n=269,000), IST was associated with an increased risk of lifetime HNC (RR 1.112, 95% CI 1.011–1.229). Within disease-specific subgroups, only RA patients treated with IST showed an elevated lifetime HNC risk (RR 1.254, 1.109–1.418). Systemic lupus erythematosus, Crohn’s Disease, and Ulcerative Colitis showed no significant difference in lifetime HNC risk based on IST exposure. Under the 5-year time window, the overall cohort displayed a slightly increased risk of HNC (RR 1.210, 1.074–1.364).  At 10 years, both the overall (RR 1.312, 1.188–1.450) and RA-specific cohort (RR 1.147, 1.008–1.305) displayed an increased risk of HNC.</p>\n\n<p><strong>Conclusion: </strong>Exposure to systemic immunosuppressive therapy was associated with an increased risk of HNC, primarily among patients with rheumatoid arthritis and most evident after longer follow-up. Prospective and mechanistic studies are warranted to clarify causal pathways and to evaluate whether targeted HNC surveillance and risk disclosure should be considered for patients with autoimmune disease being considered for immunosuppressive therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154209--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S437",
      "content_id": "154590",
      "abstract_number": "S437",
      "poster_number": "",
      "title": "Radiation Safety Assessment During Intraoperative PET/CT Imaging of Surgical Specimens in Head and Neck Surgery: A Feasibility Report",
      "summary": "Intraoperative low dose [18F]FDG PET/CT was safely integrated into HNSCC resections with limited surgical workflow or exceeding radiation safety thresholds. In comparison with the long-established standard sentinel node biopsy procedures in which pathologist hand exposure is approximately 18.62 mRem/hr with surgeon hand exposure of 34.25 mRem/hr, intraoperative [18F]FDG PET/CT specimen handling demonstrates a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154590",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kyrionna M Golliday, MS",
      "presenter": "Kyrionna M Golliday, MS",
      "authors": "Kyrionna M Golliday, MS ; Ashtyn G McAdoo, BS; Marcus Balanky, MPH, CHP, CIH, CLSO; Carleigh R Burns, BS; Nicole L Jones, MS, CCRP; Makenna L Brown, BA; Brandee T Brown, BS; Joseph Hoang, MD; Adam J Rosenberg; Eben L Rosenthal, MD; Michael C Topf, MD, MSCI",
      "normalized_authors": [
        "Kyrionna M Golliday",
        "Ashtyn G McAdoo",
        "Marcus Balanky, CHP, CIH, CLSO",
        "Carleigh R Burns",
        "Nicole L Jones, CCRP",
        "Makenna L Brown",
        "Brandee T Brown",
        "Joseph Hoang",
        "Adam J Rosenberg",
        "Eben L Rosenthal",
        "Michael C Topf, MSCI"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kyrionna M Golliday, MS ; Ashtyn G McAdoo, BS; Marcus Balanky, MPH, CHP, CIH, CLSO; Carleigh R Burns, BS; Nicole L Jones, MS, CCRP; Makenna L Brown, BA; Brandee T Brown, BS; Joseph Hoang, MD; Adam J Rosenberg; Eben L Rosenthal, MD; Michael C Topf, MD, MSCI",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "Intraoperative PET/CT imaging of surgical specimens is a new margin technology in head and neck squamous cell carcinoma (HNSCC) that requires intraoperative infusion of [18F]FDG. This creates unique regulatory challenges and safety concerns. Successful implementation of intraoperative PET/CT scanning requires formal approval by the Radiation Safety Committee and strict adherence to the As Low as Reasonably Achievable (ALARA) principles. At our institution, radiation safety training is required for all Clinical Research Coordinators and faculty listed as radiation workers, including an initial 1-hour classroom course and an annual 1-hour online refresher. The critical question for surgeons remains, what is the real risk to my team and the patient, as well as what are the regulatory requirements?",
        "Methods": "Patients received a low dose of [18F]FDG radiotracer (~10-20% of the standard PET dosage) 30-90 minutes prior to tumor resection. Upon tumor excision, standard of care (SOC) frozen section margins were obtained. Immediately after resection, margins were surveyed using a Ludlum 26-1 Geiger meter and/or a Ludlum 9DP ion chamber to confirm radiation activity levels measured £ 3x background. Thus, ensuring no contamination or exposure risk to personnel outside of the controlled area.",
        "Abstract": "We assessed regulatory requirements for transportation, designation of radiation areas, identification of essential personnel, arranged dosimeters for surgeons and specimen handlers, real-time electronic dose monitoring, radium shielding of foley catheter bags, intraoperative workflow, and post-operative OR and scrub-area contamination surveys to clear the OR for regular cleaning. All radioactive waste and tissue decayed overnight for 24 hours. Environmental radiation safety logs revealed no contamination of designated areas (hallway, scrub area, entrance floor, trash can(s), experimental floor, and OR table with surgical tools) below the background. All personnel contamination screenings were negative. There were no instances of specimens or waste that remained radioactive past the allotted 24-hour mark. View in Agenda and Add to Schedule",
        "Results": "First, we assessed the safe release of frozen section to pathology analysis. Background from these specimens ranged from 29-45 cpm with all frozen section margins demonstrating activity below 3x the background which is considered safe. Margin counts ranged from 16-17.1 mR/hr and 24-75 cpm depending on anatomical location and uptake time. Therefore, all tumor bed based margins were able to be sent to pathology per standard of care. Pathologist hand exposure to radiation in the use of [18F]FDG with a half-life of 110 minutes was found to be 0.298 mRem/hr.",
        "Conclusion": "Intraoperative low dose [18F]FDG PET/CT was safely integrated into HNSCC resections with limited surgical workflow or exceeding radiation safety thresholds. In comparison with the long-established standard sentinel node biopsy procedures in which pathologist hand exposure is approximately 18.62 mRem/hr with surgeon hand exposure of 34.25 mRem/hr, intraoperative [18F]FDG PET/CT specimen handling demonstrates a significantly lower exposure rate of 0.298 mRem/hr (62x lower than Tc-99m). These findings support the feasibility of intraoperative PET/CT for margin assessment in complex head and neck oncologic surgery and justify a broader adoption of this method as standard of care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Radiation Safety Assessment During Intraoperative PET/CT Imaging of Surgical Specimens in Head and Neck Surgery: A Feasibility Report</span>. <u>Kyrionna M Golliday, MS</u>; Ashtyn G McAdoo, BS; Marcus Balanky, MPH, CHP, CIH, CLSO; Carleigh R Burns, BS; Nicole L Jones, MS, CCRP; Makenna L Brown, BA; Brandee T Brown, BS; Joseph Hoang, MD; Adam J Rosenberg; Eben L Rosenthal, MD; Michael C Topf, MD, MSCI. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Intraoperative PET/CT imaging of surgical specimens is a new margin technology in head and neck squamous cell carcinoma (HNSCC) that requires intraoperative infusion of [18F]FDG. This creates unique regulatory challenges and safety concerns. Successful implementation of intraoperative PET/CT scanning requires formal approval by the Radiation Safety Committee and strict adherence to the As Low as Reasonably Achievable (ALARA) principles. At our institution, radiation safety training is required for all Clinical Research Coordinators and faculty listed as radiation workers, including an initial 1-hour classroom course and an annual 1-hour online refresher. The critical question for surgeons remains, what is the real risk to my team and the patient, as well as what are the regulatory requirements?</p>\n\n<p><strong>Methods: </strong>Patients received a low dose of [18F]FDG radiotracer (~10-20% of the standard PET dosage) 30-90 minutes prior to tumor resection. Upon tumor excision, standard of care (SOC) frozen section margins were obtained. Immediately after resection, margins were surveyed using a Ludlum 26-1 Geiger meter and/or a Ludlum 9DP ion chamber to confirm radiation activity levels measured £ 3x background. Thus, ensuring no contamination or exposure risk to personnel outside of the controlled area.</p>\n\n<p>We assessed regulatory requirements for transportation, designation of radiation areas, identification of essential personnel, arranged dosimeters for surgeons and specimen handlers, real-time electronic dose monitoring, radium shielding of foley catheter bags, intraoperative workflow, and post-operative OR and scrub-area contamination surveys to clear the OR for regular cleaning. All radioactive waste and tissue decayed overnight for 24 hours.</p>\n\n<p><strong>Results: </strong>First, we assessed the safe release of frozen section to pathology analysis. Background from these specimens ranged from 29-45 cpm with all frozen section margins demonstrating activity below 3x the background which is considered safe. Margin counts ranged from 16-17.1 mR/hr and 24-75 cpm depending on anatomical location and uptake time. Therefore, all tumor bed based margins were able to be sent to pathology per standard of care. Pathologist hand exposure to radiation in the use of [18F]FDG with a half-life of 110 minutes was found to be 0.298 mRem/hr.</p>\n\n<p>Environmental radiation safety logs revealed no contamination of designated areas (hallway, scrub area, entrance floor, trash can(s), experimental floor, and OR table with surgical tools) below the background. All personnel contamination screenings were negative. There were no instances of specimens or waste that remained radioactive past the allotted 24-hour mark.</p>\n\n<p><strong>Conclusion: </strong>Intraoperative low dose [18F]FDG PET/CT was safely integrated into HNSCC resections with limited surgical workflow or exceeding radiation safety thresholds. In comparison with the long-established standard sentinel node biopsy procedures in which pathologist hand exposure is approximately 18.62 mRem/hr with surgeon hand exposure of 34.25 mRem/hr, intraoperative [18F]FDG PET/CT specimen handling demonstrates a significantly lower exposure rate of 0.298 mRem/hr (62x lower than Tc-99m). These findings support the feasibility of intraoperative PET/CT for margin assessment in complex head and neck oncologic surgery and justify a broader adoption of this method as standard of care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154590--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S438",
      "content_id": "154088",
      "abstract_number": "S438",
      "poster_number": "",
      "title": "Smoking Cessation After Diagnosis: A Powerful Predictor of Therapy Response in Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Our data indicate that patients with newly diagnosed oropharyngeal squamous cell carcinoma are more likely to have a complete response to treatment if they quit smoking before treatment initiation than those who continue smoking through treatment. Although HPV is the predominant cause of modern oropharyngeal cancer, smoking cessation interventions are still an important adjunct in patients who are smokers and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154088",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Avery L Richardson, BA",
      "presenter": "Avery L Richardson, BA",
      "authors": "Avery L Richardson, BA 1 ; Matthew Krutz, MD 2 ; Pawan Acharya, PhD 3 ; Joanna George, BS 1 ; Lurdes Queimado, MD, PhD 2 ; Rachad Mhawej, MD 2",
      "normalized_authors": [
        "Avery L Richardson",
        "Matthew Krutz",
        "Pawan Acharya",
        "Joanna George",
        "Lurdes Queimado",
        "Rachad Mhawej"
      ],
      "affiliations": [
        "College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
        "Department of Otolaryngology-Head and Neck Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
        "Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA"
      ],
      "normalized_institutions": [
        "College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
        "Department of Otolaryngology-Head and Neck Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA",
        "Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 416,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Financial support",
        "Abstract"
      ],
      "sections": {
        "Authors": "Avery L Richardson, BA 1 ; Matthew Krutz, MD 2 ; Pawan Acharya, PhD 3 ; Joanna George, BS 1 ; Lurdes Queimado, MD, PhD 2 ; Rachad Mhawej, MD 2",
        "Affiliations": "1 College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2 Department of Otolaryngology-Head and Neck Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 3 Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA",
        "Background": "Although HPV has become the primary etiology of oropharyngeal cancer, smoking prevalence remains significant and current smokers have been shown to have a higher risk of developing oropharyngeal cancer compared to never smokers. Much of the current existing literature has focused on current smoking at diagnosis and the effect of continued smoking through treatment remains understudied. This study aims to investigate how tobacco cessation after cancer diagnosis affects treatment response in patients with newly diagnosed oropharyngeal cancer.",
        "Methods": "We performed a retrospective chart review including newly diagnosed oropharyngeal cancer patients treated at OU Health with curative intent from 2005 to 2025. We collected demographic and clinical information from electronic medical records. Patients who smoked at the time of diagnosis and had information on smoking status at the time of first-line therapy were included (n=143). Never-smokers, previous smokers, unknown primary, and incomplete records were excluded. Patients were further separated into groups based on whether they stopped smoking before treatment initiation (quitters) or not (active smokers). We assessed the association between patient demographics and treatment response using χ2 and logistic regression analysis. Multivariable analyses were adjusted for sex, race, age, alcohol use, primary site, tumor stage, and treatment group.",
        "Results": "Among our population, 86.7% were male, 90.2% were white and 92.3% were late stage. 7.7% of patients received definitive radiation and 90.2% received definitive chemoradiation. The average age at diagnosis was 58. 31.5% of patients quit before treatment initiation. There were no significant differences between smoking status groups based on age, sex, race, stage, or treatment received, however, there were significantly fewer people who used alcohol in the quitter group than the active smokers (p= 0.001). Patients who quit before treatment had a higher rate of complete response to first-line therapy (93.3%) versus those who continued smoking (69.4%; p= 0.002). Moreover, quitters had 6 times higher odds of achieving a complete response to first-line therapy than active smokers (odds ratio: 6.014 [1.670-21.654]; p= 0.0061).",
        "Conclusions": "Our data indicate that patients with newly diagnosed oropharyngeal squamous cell carcinoma are more likely to have a complete response to treatment if they quit smoking before treatment initiation than those who continue smoking through treatment. Although HPV is the predominant cause of modern oropharyngeal cancer, smoking cessation interventions are still an important adjunct in patients who are smokers and should be incorporated into their care.",
        "Financial support": "NIH/NCI (R01CA242168); TSET HPRC (R23-02); PHF CTGA.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Smoking Cessation After Diagnosis: A Powerful Predictor of Therapy Response in Oropharyngeal Squamous Cell Carcinoma</span>. <u>Avery L Richardson, BA</u><sup>1</sup>; Matthew Krutz, MD<sup>2</sup>; Pawan Acharya, PhD<sup>3</sup>; Joanna George, BS<sup>1</sup>; Lurdes Queimado, MD, PhD<sup>2</sup>; Rachad Mhawej, MD<sup>2</sup>. <sup>1</sup>College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; <sup>3</sup>Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Although HPV has become the primary etiology of oropharyngeal cancer, smoking prevalence remains significant and current smokers have been shown to have a higher risk of developing oropharyngeal cancer compared to never smokers. Much of the current existing literature has focused on current smoking at diagnosis and the effect of continued smoking through treatment remains understudied. This study aims to investigate how tobacco cessation after cancer diagnosis affects treatment response in patients with newly diagnosed oropharyngeal cancer.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective chart review including newly diagnosed oropharyngeal cancer patients treated at OU Health with curative intent from 2005 to 2025. We collected demographic and clinical information from electronic medical records. Patients who smoked at the time of diagnosis and had information on smoking status at the time of first-line therapy were included (n=143). Never-smokers, previous smokers, unknown primary, and incomplete records were excluded. Patients were further separated into groups based on whether they stopped smoking before treatment initiation (quitters) or not (active smokers). We assessed the association between patient demographics and treatment response using χ2 and logistic regression analysis. Multivariable analyses were adjusted for sex, race, age, alcohol use, primary site, tumor stage, and treatment group.</p>\n\n<p><strong>Results:</strong> Among our population, 86.7% were male, 90.2% were white and 92.3% were late stage. 7.7% of patients received definitive radiation and 90.2% received definitive chemoradiation. The average age at diagnosis was 58. 31.5% of patients quit before treatment initiation. There were no significant differences between smoking status groups based on age, sex, race, stage, or treatment received, however, there were significantly fewer people who used alcohol in the quitter group than the active smokers (p= 0.001). Patients who quit before treatment had a higher rate of complete response to first-line therapy (93.3%) versus those who continued smoking (69.4%; p= 0.002). Moreover, quitters had 6 times higher odds of achieving a complete response to first-line therapy than active smokers (odds ratio: 6.014 [1.670-21.654]; p= 0.0061). </p>\n\n<p><strong>Conclusions:</strong> Our data indicate that patients with newly diagnosed oropharyngeal squamous cell carcinoma are more likely to have a complete response to treatment if they quit smoking before treatment initiation than those who continue smoking through treatment. Although HPV is the predominant cause of modern oropharyngeal cancer, smoking cessation interventions are still an important adjunct in patients who are smokers and should be incorporated into their care.</p>\n\n<p><strong>Financial support:</strong> NIH/NCI (R01CA242168); TSET HPRC (R23-02); PHF CTGA.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154088--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S439",
      "content_id": "155565",
      "abstract_number": "S439",
      "poster_number": "",
      "title": "GLP-1 Receptor Agonist and Head and Neck Cancer Risk: A Large Propensity-Matched Cohort Study",
      "summary": "After matching, 158,969 pairs were created (mean age 53.0 years; 63.1% female; all SMD <0.1). GLP1-RA use was associated with significantly lower incident HNC compared to insulin (0.13% vs 0.22%; HR=0.55, 95% CI 0.46–0.65; p<0.001). Risk reductions were consistent across all subsites: nasopharyngeal/sinonasal (HR=0.37), laryngeal (HR=0.38), salivary gland (HR=0.43), oropharyngeal (HR=0.54), and oral cavity...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155565",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mishek Thapa, BS",
      "presenter": "Mishek Thapa, BS",
      "authors": "Mishek Thapa, BS 1 ; Nathan V Pham, BS 1 ; Albert Y Li, BA 2 ; Matthew E Lin, MD 3 ; Abdul Abdel-Raheem, MD 3 ; Carlos Castellanos, MD 3 ; Shady I Soliman, MD 3 ; Ian Kim, PhD 4 ; Dinesh Chhetri, MD 3 ; Peter S Han, MD 3 ; Joel A Sercarz, MD 3",
      "normalized_authors": [
        "Mishek Thapa",
        "Nathan V Pham",
        "Albert Y Li",
        "Matthew E Lin",
        "Abdul Abdel-Raheem",
        "Carlos Castellanos",
        "Shady I Soliman",
        "Ian Kim",
        "Dinesh Chhetri",
        "Peter S Han",
        "Joel A Sercarz"
      ],
      "affiliations": [
        "David Geffen School of Medicine, UCLA",
        "Keck School of Medicine, University of Southern California, Los Angeles, CA",
        "Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA",
        "Department of Disease Prevention, Stanford University, Palo Alto, CA"
      ],
      "normalized_institutions": [
        "David Geffen School of Medicine, UCLA",
        "Keck School of Medicine, University of Southern California, Los Angeles, CA",
        "Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA",
        "Department of Disease Prevention, Stanford University, Palo Alto, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155565/figure_panels_cumulative_incidence_matched.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155565/figure_panels_cumulative_incidence_matched.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155565"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Mishek Thapa, BS 1 ; Nathan V Pham, BS 1 ; Albert Y Li, BA 2 ; Matthew E Lin, MD 3 ; Abdul Abdel-Raheem, MD 3 ; Carlos Castellanos, MD 3 ; Shady I Soliman, MD 3 ; Ian Kim, PhD 4 ; Dinesh Chhetri, MD 3 ; Peter S Han, MD 3 ; Joel A Sercarz, MD 3",
        "Affiliations": "1 David Geffen School of Medicine, UCLA; 2 Keck School of Medicine, University of Southern California, Los Angeles, CA; 3 Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA; 4 Department of Disease Prevention, Stanford University, Palo Alto, CA",
        "Introduction": "Hyperinsulinemia and chronic inflammation are implicated in head and neck cancer (HNC) pathogenesis. GLP-1 receptor agonists (GLP1-RAs) reduce postprandial hyperinsulinemia, improve insulin sensitivity, mechanisms with plausible relevance to HNC development. With GLP1-RAs increasingly prescribed for diabetes and obesity management, and their use expanding rapidly in the general population, understanding their oncologic safety profile is essential.",
        "Methods": "We performed a propensity-matched cohort study examining incident HNC among GLP1-RA users versus insulin users in the United States using the TriNetX US Network. Adults with endocrine, nutritional, or metabolic disease initiating a GLP1-RA or insulin between January 1, 2005 and January 1, 2021, with no prior HNC history, were included. Propensity score matching balanced cohorts across demographics, BMI, HbA1c, oncologic risk factors (tobacco, alcohol, cannabis use), comorbidities, social determinants of health, and prior medications. Primary outcome was incident HNC. Secondary analyses compared GLP1-RAs to other antidiabetics and examined HNC subsites, cancer stage, duration of use, and extended follow-up at 7 and 9 years. Validation analyses used liver, thyroid, and breast cancers.",
        "Results": "After matching, 158,969 pairs were created (mean age 53.0 years; 63.1% female; all SMD <0.1). GLP1-RA use was associated with significantly lower incident HNC compared to insulin (0.13% vs 0.22%; HR=0.55, 95% CI 0.46–0.65; p<0.001). Risk reductions were consistent across all subsites: nasopharyngeal/sinonasal (HR=0.37), laryngeal (HR=0.38), salivary gland (HR=0.43), oropharyngeal (HR=0.54), and oral cavity (HR=0.56; all p<0.001).",
        "Abstract": "Increasing duration of GLP1-RAs was associated with decreasing incidence of HNC: <1.5 years (HR=1.03) and 1.5–3 years (HR=0.98) of use did not significantly alter risk, while 3–5 years (HR=0.73, 95% CI 0.46–0.98) and >5 years (HR=0.65, 95% CI 0.41–0.93) conferred significant risk reduction. Risk reduction persisted at 7 years (HR=0.55) and 9 years (HR=0.72). Stage-specific analyses showed reduced risk for stages 1–3 but not stage 4 or metastatic disease. Effects were consistent across sex, age, BMI, HbA1c, and comorbidity profile; attenuated but present among tobacco users (HR=0.66). Compared to metformin (HR=0.73), DPP4-inhibitors (HR=0.86), SGLT2-inhibitors (HR=0.84), and sulfonylureas (HR=0.83), GLP1-RAs remained associated with lower overall HNC risk. Validation analyses confirmed specificity: significant liver cancer reduction (HR=0.35) with no significant associations for thyroid (HR=0.89) or breast cancer (HR=0.96). View in Agenda and Add to Schedule",
        "Discussion": "GLP1-RA use is associated with reduced incident HNC risk across all major anatomic subsites, with a duration-dependent effect suggesting prolonged metabolic modulation is required for oncologic benefit. The duration-dependent pattern, with no association at shorter exposures and progressive risk reduction beyond three years, combined with specificity across validation cancers, supports biological plausibility. These findings contribute to the oncologic safety profile of GLP1-RAs and are consistent with mechanisms linking inflammatory mediators, insulin resistance, and metabolic dysfunction to HNC pathogenesis."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>GLP-1 Receptor Agonist and Head and Neck Cancer Risk: A Large Propensity-Matched Cohort Study</span>. <u>Mishek Thapa, BS</u><sup>1</sup>; Nathan V Pham, BS<sup>1</sup>; Albert Y Li, BA<sup>2</sup>; Matthew E Lin, MD<sup>3</sup>; Abdul Abdel-Raheem, MD<sup>3</sup>; Carlos Castellanos, MD<sup>3</sup>; Shady I Soliman, MD<sup>3</sup>; Ian Kim, PhD<sup>4</sup>; Dinesh Chhetri, MD<sup>3</sup>; Peter S Han, MD<sup>3</sup>; Joel A Sercarz, MD<sup>3</sup>. <sup>1</sup>David Geffen School of Medicine, UCLA; <sup>2</sup>Keck School of Medicine, University of Southern California, Los Angeles, CA; <sup>3</sup>Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA; <sup>4</sup>Department of Disease Prevention, Stanford University, Palo Alto, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Hyperinsulinemia and chronic inflammation are implicated in head and neck cancer (HNC) pathogenesis. GLP-1 receptor agonists (GLP1-RAs) reduce postprandial hyperinsulinemia, improve insulin sensitivity, mechanisms with plausible relevance to HNC development. With GLP1-RAs increasingly prescribed for diabetes and obesity management, and their use expanding rapidly in the general population, understanding their oncologic safety profile is essential.</p>\n\n<p><strong>Methods: </strong>We performed a propensity-matched cohort study examining incident HNC among GLP1-RA users versus insulin users in the United States using the TriNetX US Network. Adults with endocrine, nutritional, or metabolic disease initiating a GLP1-RA or insulin between January 1, 2005 and January 1, 2021, with no prior HNC history, were included. Propensity score matching balanced cohorts across demographics, BMI, HbA1c, oncologic risk factors (tobacco, alcohol, cannabis use), comorbidities, social determinants of health, and prior medications. Primary outcome was incident HNC. Secondary analyses compared GLP1-RAs to other antidiabetics and examined HNC subsites, cancer stage, duration of use, and extended follow-up at 7 and 9 years. Validation analyses used liver, thyroid, and breast cancers.</p>\n\n<p><strong>Results: </strong>After matching, 158,969 pairs were created (mean age 53.0 years; 63.1% female; all SMD <0.1). GLP1-RA use was associated with significantly lower incident HNC compared to insulin (0.13% vs 0.22%; HR=0.55, 95% CI 0.46–0.65; p<0.001). Risk reductions were consistent across all subsites: nasopharyngeal/sinonasal (HR=0.37), laryngeal (HR=0.38), salivary gland (HR=0.43), oropharyngeal (HR=0.54), and oral cavity (HR=0.56; all p<0.001).</p>\n\n<p>Increasing duration of GLP1-RAs was associated with decreasing incidence of HNC:  <1.5 years (HR=1.03) and 1.5–3 years (HR=0.98) of use did not significantly alter risk, while 3–5 years (HR=0.73, 95% CI 0.46–0.98) and >5 years (HR=0.65, 95% CI 0.41–0.93) conferred significant risk reduction. Risk reduction persisted at 7 years (HR=0.55) and 9 years (HR=0.72). Stage-specific analyses showed reduced risk for stages 1–3 but not stage 4 or metastatic disease. Effects were consistent across sex, age, BMI, HbA1c, and comorbidity profile; attenuated but present among tobacco users (HR=0.66). Compared to metformin (HR=0.73), DPP4-inhibitors (HR=0.86), SGLT2-inhibitors (HR=0.84), and sulfonylureas (HR=0.83), GLP1-RAs remained associated with lower overall HNC risk. Validation analyses confirmed specificity: significant liver cancer reduction (HR=0.35) with no significant associations for thyroid (HR=0.89) or breast cancer (HR=0.96).</p>\n\n<p><strong>Discussion: </strong>GLP1-RA use is associated with reduced incident HNC risk across all major anatomic subsites, with a duration-dependent effect suggesting prolonged metabolic modulation is required for oncologic benefit. The duration-dependent pattern, with no association at shorter exposures and progressive risk reduction beyond three years, combined with specificity across validation cancers, supports biological plausibility. These findings contribute to the oncologic safety profile of GLP1-RAs and are consistent with mechanisms linking inflammatory mediators, insulin resistance, and metabolic dysfunction to HNC pathogenesis.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155565/figure_panels_cumulative_incidence_matched.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155565--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S440",
      "content_id": "146749",
      "abstract_number": "S440",
      "poster_number": "",
      "title": "Beyond the Smoke: The Role of E-Cigarettes in Head and Neck Cancer Development",
      "summary": "Use of e-cigarettes was linked with an elevated incidence of most HNC subtypes, including oropharyngeal carcinoma (RR, 1.83; 95% CI, 1.34–2.52), hypopharyngeal carcinoma (RR, 3.80; 95% CI, 1.89–7.63), and laryngeal carcinoma (RR, 2.57; 95% CI, 1.81–3.65). No significant difference was found for salivary gland cancer (RR, 0.90; 95% CI, 0.58–1.41).",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146749",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260149",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sudhanvan Iyer",
      "presenter": "Sudhanvan Iyer",
      "authors": "Sudhanvan Iyer ; Robert E Africa, MD; Amber Dunmire, MD; Shahruhk R Ali, MD; Viran J Ranasinghe, MD",
      "normalized_authors": [
        "Sudhanvan Iyer",
        "Robert E Africa",
        "Amber Dunmire",
        "Shahruhk R Ali",
        "Viran J Ranasinghe"
      ],
      "affiliations": [
        "University of Texas Medical Branch at Galveston"
      ],
      "normalized_institutions": [
        "University of Texas Medical Branch at Galveston"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 450,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design, Setting, and Participants",
        "Exposure",
        "Main Outcomes and Measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sudhanvan Iyer ; Robert E Africa, MD; Amber Dunmire, MD; Shahruhk R Ali, MD; Viran J Ranasinghe, MD",
        "Affiliations": "University of Texas Medical Branch at Galveston",
        "Importance": "The long-term health effects of electronic cigarette (e-cigarette) exposure are not yet entirely known. Although combustible tobacco exposure is a well-established risk factor for head and neck cancer (HNC), the oncologic risk of exclusive non-tobacco nicotine exposure through vaping is less established. E-cigarette use has risen dramatically over the past decade, particularly among adolescents and young adults, many of whom have never smoked traditional tobacco products. Determining whether vaping confers an independent oncogenic risk is crucial for both clinical counseling and the development of effective public health interventions.",
        "Objective": "To determine the risk of exclusive e-cigarette exposure leading to subsequent head and neck cancer development in the absence of simultaneous use of tobacco. We also aimed to assess the differences in risk across distinct HNC subsites",
        "Design, Setting, and Participants": "Our retrospective cohort study used de-identified electronic health record information over 20 years between January 1, 2004, and January 1, 2024, in 102 healthcare systems in the TriNetX global research network. Patients were allocated either to a cohort of patients with sole e-cigarette exposure without tobacco exposure or to a control cohort with no nicotine or tobacco exposure. Propensity score matching was employed to balance demographic and clinical variables, including age, sex, race, and relevant comorbidities between cohorts. Follow up was extended up to 20 years to capture long-term outcomes.",
        "Exposure": "Diagnosis of vaping-associated disorder or unspecified nicotine dependence (ICD-10-CM U07.0 or F17.200) without history of tobacco use.",
        "Main Outcomes and Measures": "The main outcome was the incidence of head and neck cancer (HNC). Outcomes were further divided by the following subsites: oral cavity, oropharyngeal, nasopharyngeal, hypopharyngeal, laryngeal, and salivary gland cancers. Risk ratios (RRs) were calculated to quantify risk.",
        "Results": "Use of e-cigarettes was linked with an elevated incidence of most HNC subtypes, including oropharyngeal carcinoma (RR, 1.83; 95% CI, 1.34–2.52), hypopharyngeal carcinoma (RR, 3.80; 95% CI, 1.89–7.63), and laryngeal carcinoma (RR, 2.57; 95% CI, 1.81–3.65). No significant difference was found for salivary gland cancer (RR, 0.90; 95% CI, 0.58–1.41).",
        "Conclusions and Relevance": "In this matched cohort study, e-cigarette use was related to an increased risk of head and neck cancers of the pharynx and larynx. Our data, along with current literature, indicate that e-cigarettes might impart direct carcinogenic effects on epithelial surfaces of the upper aerodigestive tract. Our results also draw attention to the need for longitudinal surveillance of e-cigarette users, incorporation of vaping history into clinical risk assessment for HNC, and formulation of public health policies addressing the potential oncogenic risks of vaping. Clinicians and policymakers should recognize that the perception of e-cigarettes as a “safer alternative” to combustible tobacco may underestimate their true carcinogenic potential.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Beyond the Smoke: The Role of E-Cigarettes in Head and Neck Cancer Development</span>. <u>Sudhanvan Iyer</u>; Robert E Africa, MD; Amber Dunmire, MD; Shahruhk R Ali, MD; Viran J Ranasinghe, MD. University of Texas Medical Branch at Galveston<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance: </strong>The long-term health effects of electronic cigarette (e-cigarette) exposure are not yet entirely known. Although combustible tobacco exposure is a well-established risk factor for head and neck cancer (HNC), the oncologic risk of exclusive non-tobacco nicotine exposure through vaping is less established. E-cigarette use has risen dramatically over the past decade, particularly among adolescents and young adults, many of whom have never smoked traditional tobacco products. Determining whether vaping confers an independent oncogenic risk is crucial for both clinical counseling and the development of effective public health interventions.</p>\n\n<p><strong>Objective: </strong>To determine the risk of exclusive e-cigarette exposure leading to subsequent head and neck cancer development in the absence of simultaneous use of tobacco. We also aimed to assess the differences in risk across distinct HNC subsites</p>\n\n<p><strong>Design, Setting, and Participants: </strong>Our retrospective cohort study used de-identified electronic health record information over 20 years between January 1, 2004, and January 1, 2024, in 102 healthcare systems in the TriNetX global research network. Patients were allocated either to a cohort of patients with sole e-cigarette exposure without tobacco exposure or to a control cohort with no nicotine or tobacco exposure. Propensity score matching was employed to balance demographic and clinical variables, including age, sex, race, and relevant comorbidities between cohorts. Follow up was extended up to 20 years to capture long-term outcomes.</p>\n\n<p><strong>Exposure: </strong>Diagnosis of vaping-associated disorder or unspecified nicotine dependence (ICD-10-CM U07.0 or F17.200) without history of tobacco use.</p>\n\n<p><strong>Main Outcomes and Measures: </strong>The main outcome was the incidence of head and neck cancer (HNC). Outcomes were further divided by the following subsites: oral cavity, oropharyngeal, nasopharyngeal, hypopharyngeal, laryngeal, and salivary gland cancers. Risk ratios (RRs) were calculated to quantify risk.</p>\n\n<p><strong>Results: </strong>Use of e-cigarettes was linked with an elevated incidence of most HNC subtypes, including oropharyngeal carcinoma (RR, 1.83; 95% CI, 1.34–2.52), hypopharyngeal carcinoma (RR, 3.80; 95% CI, 1.89–7.63), and laryngeal carcinoma (RR, 2.57; 95% CI, 1.81–3.65). No significant difference was found for salivary gland cancer (RR, 0.90; 95% CI, 0.58–1.41).</p>\n\n<p><strong>Conclusions and Relevance: </strong>In this matched cohort study, e-cigarette use was related to an increased risk of head and neck cancers of the pharynx and larynx. Our data, along with current literature, indicate that e-cigarettes might impart direct carcinogenic effects on epithelial surfaces of the upper aerodigestive tract. Our results also draw attention to the need for longitudinal surveillance of e-cigarette users, incorporation of vaping history into clinical risk assessment for HNC, and formulation of public health policies addressing the potential oncogenic risks of vaping. Clinicians and policymakers should recognize that the perception of e-cigarettes as a “safer alternative” to combustible tobacco may underestimate their true carcinogenic potential. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146749--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260149' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S441",
      "content_id": "154754",
      "abstract_number": "S441",
      "poster_number": "",
      "title": "PROTON BEAM THERAPY VERSUS INTENSITY-MODULATED RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA: LONG-TERM OUTCOMES OF A COMPARATIVE ANALYSIS",
      "summary": "Tumor control and survival outcomes were comparable between patients treated with proton therapy and IMRT. However, a trend toward a higher incidence of temporal lobe enhancement on follow-up MRI was observed with proton therapy. These findings warrant validation in prospective randomized trials.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154754",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nima M Taghizadeh, MD",
      "presenter": "Nima M Taghizadeh, MD",
      "authors": "Nima M Taghizadeh, MD ; Elizabeth A Weyman, DNP; Saveli Goldberg, PhD; Annie W Chan, MD",
      "normalized_authors": [
        "Nima M Taghizadeh",
        "Elizabeth A Weyman, DNP",
        "Saveli Goldberg",
        "Annie W Chan"
      ],
      "affiliations": [
        "Massachusetts General Hospital, Harvard Medical School"
      ],
      "normalized_institutions": [
        "Massachusetts General Hospital, Harvard Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 440,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Material/Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nima M Taghizadeh, MD ; Elizabeth A Weyman, DNP; Saveli Goldberg, PhD; Annie W Chan, MD",
        "Affiliations": "Massachusetts General Hospital, Harvard Medical School",
        "Background": "Proton therapy offers a dosimetric advantage over intensity-modulated radiation therapy (IMRT) by significantly reducing low-to-moderate radiation doses to healthy tissues. Both modalities are standard for nasopharyngeal carcinoma (NPC), yet comparative data on long-term outcomes remain scarce. The purpose of this study was to directly compare the long-term tumor control and toxicity profiles between proton therapy and IMRT in patients with NPC.",
        "Material/Methods": "Between July 2003 and December 2024, a total of 118 consecutive patients with newly diagnosed, non-metastatic nasopharyngeal carcinoma received definitive radiotherapy (RT) +/- chemotherapy at our institution. The median age at diagnosis was 52 years. Sixty-four percent of patients were male. Eighty-six percent of patients were diagnosed at AJCC Stage III and IV. Radiation treatment modalities were IMRT only in 40% of patients, 44% mixed IMRT-proton therapy, and 16% proton therapy only. The median radiation dose for the gross target volume (GTV) was 70 Gy, while the clinical target volume (CTV) received a median dose of 60 Gy. The Kaplan-Meier product-limit method was used to estimate local control, nodal control, and survival probabilities. Treatment-related toxicities were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, with late radiation-attributed adverse events defined as those occurring between one to five years after treatment. The chi-square test was used to compare outcomes between different treatment groups.",
        "Results": "The median follow-up of the entire cohort was 77 months. The median follow-up was 60 months, 122 months, and 68 months for the IMRT, IMRT+proton, and proton groups, respectively. The 5-year local control rates were 90% (IMRT-only), 85% (IMRT+proton), and 89% (proton-only) (p = 0.96). The corresponding nodal control rates were 100%, 98%, and 90%, respectively (p = 0.06). The overall survival rates at 5 years were 90%, 82%, and 82% in IMRT-only, IMRT+proton, and proton-only groups, respectively (p=0.51). There was no statistical difference in the incidence of adverse late effects between the treatment groups. There was a trend of higher incidence of ≥ grade 2 temporal lobe toxicity (TLE), defined by new temporal lobe enhancement on MRI with or without symptoms, in patients treated with proton therapy than those treated with IMRT-only (p = 0.08). TLE occurred in 7 patients in the proton-only and IMRT+proton groups, and none of the IMRT-only patients. Notably, 5 of these 7 cases occurred in patients who had received the double-scattered proton technique.",
        "Conclusions": "Tumor control and survival outcomes were comparable between patients treated with proton therapy and IMRT. However, a trend toward a higher incidence of temporal lobe enhancement on follow-up MRI was observed with proton therapy. These findings warrant validation in prospective randomized trials.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>PROTON BEAM THERAPY VERSUS INTENSITY-MODULATED RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA: LONG-TERM OUTCOMES OF A COMPARATIVE ANALYSIS</span>. <u>Nima M Taghizadeh, MD</u>; Elizabeth A Weyman, DNP; Saveli Goldberg, PhD; Annie W Chan, MD. Massachusetts General Hospital, Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Proton therapy offers a dosimetric advantage over intensity-modulated radiation therapy (IMRT) by significantly reducing low-to-moderate radiation doses to healthy tissues. Both modalities are standard for nasopharyngeal carcinoma (NPC), yet comparative data on long-term outcomes remain scarce. The purpose of this study was to directly compare the long-term tumor control and toxicity profiles between proton therapy and IMRT in patients with NPC.</p>\n\n<p><strong>Material/Methods: </strong>Between July 2003 and December 2024, a total of 118 consecutive patients with newly diagnosed, non-metastatic nasopharyngeal carcinoma received definitive radiotherapy (RT) +/- chemotherapy at our institution. The median age at diagnosis was 52 years. Sixty-four percent of patients were male. Eighty-six percent of patients were diagnosed at AJCC Stage III and IV. Radiation treatment modalities were IMRT only in 40% of patients, 44% mixed IMRT-proton therapy, and 16% proton therapy only. The median radiation dose for the gross target volume (GTV) was 70 Gy, while the clinical target volume (CTV) received a median dose of 60 Gy. The Kaplan-Meier product-limit method was used to estimate local control, nodal control, and survival probabilities. Treatment-related toxicities were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, with late radiation-attributed adverse events defined as those occurring between one to five years after treatment.  The chi-square test was used to compare outcomes between different treatment groups.</p>\n\n<p><strong>Results: </strong>The median follow-up of the entire cohort was 77 months. The median follow-up was 60 months, 122 months, and 68 months for the IMRT, IMRT+proton, and proton groups, respectively.  The 5-year local control rates were 90% (IMRT-only), 85% (IMRT+proton), and 89% (proton-only) (p = 0.96). The corresponding nodal control rates were 100%, 98%, and 90%, respectively (p = 0.06).  The overall survival rates at 5 years were 90%, 82%, and 82% in IMRT-only, IMRT+proton, and proton-only groups, respectively (p=0.51). There was no statistical difference in the incidence of adverse late effects between the treatment groups. There was a trend of higher incidence of ≥ grade 2 temporal lobe toxicity (TLE), defined by new temporal lobe enhancement on MRI with or without symptoms, in patients treated with proton therapy than those treated with IMRT-only (p = 0.08). TLE occurred in 7 patients in the proton-only and IMRT+proton groups, and none of the IMRT-only patients. Notably, 5 of these 7 cases occurred in patients who had received the double-scattered proton technique.</p>\n\n<p><strong>Conclusions: </strong>Tumor control and survival outcomes were comparable between patients treated with proton therapy and IMRT. However, a trend toward a higher incidence of temporal lobe enhancement on follow-up MRI was observed with proton therapy. These findings warrant validation in prospective randomized trials.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154754--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S442",
      "content_id": "154493",
      "abstract_number": "S442",
      "poster_number": "",
      "title": "Surgical Salvage of Recurrent or Residual Nasopharyngeal Carcinoma: A Systematic Review Comparing Endoscopic and Open Nasopharyngectomy",
      "summary": "52 studies with a total of 3197 patients were included in the systematic review. All studies reported. For endoscopic nasopharyngectomy, our systematic review included 32 studies involving 1,914 patients. Seventeen studies reported 2-year OS rates ranging from 25% to 100% with an average of 76%. Thirteen studies reported 5-year OS rates ranging from 38.3% to 84.6% with an average of 60.5%. Eleven studies reported...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154493",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rizwan Aslam, DO",
      "presenter": "Rizwan Aslam, DO",
      "authors": "Soren McLeod, BS; Cameron Galic, MS; Hunter Leggett, BS; Gabriel Montclare, BS; Aundria Parkman, MLIS; Rizwan Aslam, DO",
      "normalized_authors": [
        "Soren McLeod",
        "Cameron Galic",
        "Hunter Leggett",
        "Gabriel Montclare",
        "Aundria Parkman, MLIS",
        "Rizwan Aslam"
      ],
      "affiliations": [
        "Tulane University School of Medicine"
      ],
      "normalized_institutions": [
        "Tulane University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Soren McLeod, BS; Cameron Galic, MS; Hunter Leggett, BS; Gabriel Montclare, BS; Aundria Parkman, MLIS; Rizwan Aslam, DO",
        "Affiliations": "Tulane University School of Medicine",
        "Background": "Nasopharyngeal carcinoma (NPC) is a head and neck cancer arising from the nasopharyngeal epithelium. The primary treatment for NPC is either radiation therapy alone or in combination with chemotherapy. Despite advances in chemoradiation therapy (CRT), as well as novel surgical techniques, many patients with primary NPC ultimately fail to remain disease free and develop residual or recurrent NPC. If this occurs, re-irradiation is less effective as the tumor can develop resistance to radiation. In the past two decades, salvage nasopharyngectomy has emerged as a viable treatment option for recurrent or residual NPC. The purpose of this systematic review is to assess the effectiveness and safety of endoscopic versus open nasopharyngectomy in the treatment of locally recurrent or residual nasopharyngeal carcinoma.",
        "Methods": "Following PRISMA guidelines, we conducted a comprehensive literature search across PubMed, Embase, and Cochrane. The search strategy combined terms for recurrent and residual nasopharyngeal carcinomas and salvage nasopharyngectomies, with no search restrictions. Inclusion criteria included histologically confirmed recurrent or residual NPC after treatment with radiation, chemotherapy or both. The primary objective was to report overall survival (OS) and disease-free survival (DFS) at yearly intervals. Secondary outcomes included local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), margin status, and complications. Screening and data extraction were performed through Covidence with dual verification, and the Cochrane risk of bias in non-randomized studies - of interventions (ROBINS-I) tool was used to assess bias.",
        "Results": "52 studies with a total of 3197 patients were included in the systematic review. All studies reported. For endoscopic nasopharyngectomy, our systematic review included 32 studies involving 1,914 patients. Seventeen studies reported 2-year OS rates ranging from 25% to 100% with an average of 76%. Thirteen studies reported 5-year OS rates ranging from 38.3% to 84.6% with an average of 60.5%. Eleven studies reported 2-year DFS rates ranging from 29.2% to 90% with an average of 64.9%. Seven studies reported 5-year DFS rates ranging from 25% to 69.1% with an average of 45.7%. For open nasopharyngectomy, our systematic review included 20 studies with 1,283 patients. Eight studies reported 2-year OS rates ranging from 51.3% to 90% with an average of 68.9%. Fifteen studies reported 5-year OS rates ranging from 42% to 72.7% with an average of 52.7%. Five studies reported 5-year DFS ranging from 42% to 56% with an average of 51%. Most complications in these procedures were minor, including but not limited to hearing loss, trismus, neck pain, and aural fullness. Major complications included osteonecrosis, osteomyelitis, and internal carotid injury. Both surgical interventions displayed decreasing OS and DFS rates with increasing stage of tumor.",
        "Discussion": "Nasopharyngectomy remains the mainstay of treatment for recurrent or residual NPC in recent years. Over the last two decades, endoscopic nasopharyngectomy has emerged as a viable alternative surgical treatment for rNPC, with OS and DFS comparable to those of traditional open nasopharyngectomy at multiple yearly intervals. Both endoscopic and open approaches are viable salvage options and provide favorable long-term outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Salvage of Recurrent or Residual Nasopharyngeal Carcinoma: A Systematic Review Comparing Endoscopic and Open Nasopharyngectomy</span>. Soren McLeod, BS; Cameron Galic, MS; Hunter Leggett, BS; Gabriel Montclare, BS; Aundria Parkman, MLIS; <u>Rizwan Aslam, DO</u>. Tulane University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a head and neck cancer arising from the nasopharyngeal epithelium. The primary treatment for NPC is either radiation therapy alone or in combination with chemotherapy. Despite advances in chemoradiation therapy (CRT), as well as novel surgical techniques, many patients with primary NPC ultimately fail to remain disease free and develop residual or recurrent NPC. If this occurs, re-irradiation is less effective as the tumor can develop resistance to radiation. In the past two decades, salvage nasopharyngectomy has emerged as a viable treatment option for recurrent or residual NPC. The purpose of this systematic review is to assess the effectiveness and safety of endoscopic versus open nasopharyngectomy in the treatment of locally recurrent or residual nasopharyngeal carcinoma. </p>\n\n<p><strong>Methods: </strong>Following PRISMA guidelines, we conducted a comprehensive literature search across PubMed, Embase, and Cochrane. The search strategy combined terms for recurrent and residual nasopharyngeal carcinomas and salvage nasopharyngectomies, with no search restrictions. Inclusion criteria included histologically confirmed recurrent or residual NPC after treatment with radiation, chemotherapy or both. The primary objective was to report overall survival (OS) and disease-free survival (DFS) at yearly intervals. Secondary outcomes included local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), margin status, and complications. Screening and data extraction were performed through Covidence with dual verification, and the Cochrane risk of bias in non-randomized studies - of interventions (ROBINS-I) tool was used to assess bias.</p>\n\n<p><strong>Results: </strong>52 studies with a total of 3197 patients were included in the systematic review. All studies reported. For endoscopic nasopharyngectomy, our systematic review included 32 studies involving 1,914 patients. Seventeen studies reported 2-year OS rates ranging from 25% to 100% with an average of 76%. Thirteen studies reported 5-year OS rates ranging from 38.3% to 84.6% with an average of 60.5%. Eleven studies reported 2-year DFS rates ranging from 29.2% to 90% with an average of 64.9%. Seven studies reported 5-year DFS rates ranging from 25% to 69.1% with an average of 45.7%. For open nasopharyngectomy, our systematic review included 20 studies with 1,283 patients. Eight studies reported 2-year OS rates ranging from 51.3% to 90% with an average of 68.9%. Fifteen studies reported 5-year OS rates ranging from 42% to 72.7% with an average of 52.7%. Five studies reported 5-year DFS ranging from 42% to 56% with an average of 51%. Most complications in these procedures were minor, including but not limited to hearing loss, trismus, neck pain, and aural fullness. Major complications included osteonecrosis, osteomyelitis, and internal carotid injury. Both surgical interventions displayed decreasing OS and DFS rates with increasing stage of tumor.</p>\n\n<p><strong>Discussion:</strong> Nasopharyngectomy remains the mainstay of treatment for recurrent or residual NPC in recent years. Over the last two decades, endoscopic nasopharyngectomy has emerged as a viable alternative surgical treatment for rNPC, with OS and DFS comparable to those of traditional open nasopharyngectomy at multiple yearly intervals. Both endoscopic and open approaches are viable salvage options and provide favorable long-term outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154493--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S443",
      "content_id": "153565",
      "abstract_number": "S443",
      "poster_number": "",
      "title": "Identifying Practice Gaps in the Evolving Management of Nasopharyngeal Carcinoma: Analysis of an Online Educational Survey",
      "summary": "This educational initiative revealed critical multidisciplinary practice gaps regarding optimal care pathways in NPC. While medical oncologists showed comparatively stronger baseline understanding, substantial opportunities remain to strengthen competencies among surgeons, pathologists, and especially NPs/PAs, ultimately reflecting the evolving complexity of NPC diagnosis and management. These findings underscore...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153565",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nimish Mehta, PhD, MBA, CHCP",
      "presenter": "Nimish Mehta, PhD, MBA, CHCP",
      "authors": "Michelle A Worst, PharmD, BCOP, MBA, CHCP 1 ; Nimish Mehta, PhD, MBA, CHCP 1 ; Nabil F Saba, MD, FACP 2",
      "normalized_authors": [
        "Michelle A Worst, PharmD, BCOP, CHCP",
        "Nimish Mehta, CHCP",
        "Nabil F Saba, FACP"
      ],
      "affiliations": [
        "Medscape, LLC",
        "Winship Cancer Institute of Emory University"
      ],
      "normalized_institutions": [
        "Medscape, LLC",
        "Winship Cancer Institute of Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [
        {
          "table_index": 1,
          "caption": "Remaining gaps by clinician type",
          "rows": [
            [
              "",
              "Clinician Remaining Gaps (N = 25 to 133)"
            ],
            [
              "Learning Theme",
              "Medical Oncologists",
              "Pathologists",
              "Surgeons",
              "NPs/PAs"
            ],
            [
              "Understanding of NPC diagnosis and staging",
              "29%",
              "46%",
              "47%",
              "54%"
            ],
            [
              "Awareness of NPC disease characteristics",
              "31%",
              "53%",
              "43%",
              "78%"
            ],
            [
              "Ability to mitigate treatment-related adverse events (AEs)",
              "58%",
              "64%",
              "66%",
              "70%"
            ],
            [
              "Recognizing optimal treatment approaches for NPC",
              "60%",
              "54%",
              "63%",
              "61%"
            ]
          ],
          "footer": ""
        }
      ],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 335,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions",
        "Acknowledgements"
      ],
      "sections": {
        "Authors": "Michelle A Worst, PharmD, BCOP, MBA, CHCP 1 ; Nimish Mehta, PhD, MBA, CHCP 1 ; Nabil F Saba, MD, FACP 2",
        "Affiliations": "1 Medscape, LLC; 2 Winship Cancer Institute of Emory University",
        "Background": "Nasopharyngeal carcinoma (NPC) in its advanced and metastatic stages has long been associated with limited therapeutic options and suboptimal long-term outcomes, underscoring the need for more effective strategies. Emerging evidence supporting the use of immune checkpoint inhibitors (ICIs) offers a promising avenue to address these gaps, yet integrating immunotherapy (IO) into an already complex treatment landscape presents challenges for many clinicians. This study aimed to assess the knowledge and skills of medical oncologists, pathologists, surgeons, nurse practitioners (NPs), and physician assistants (PAs) in the management of NPC, and to identify critical educational gaps.",
        "Methods": "An online, text-based continuing medical education (CME) survey instrument comprising 23 multiple-choice knowledge, practice-based, and confidence questions assessed participants’ understanding of dynamic clinical paradigms associated with NPC care. The activity launched March 2025, and data were collected through September 2025. Responses from medical oncologists, pathologists, surgeons, and NPs/PAs were analyzed and compared by grouping questions into clinical themes and calculating the percentage of correct responses in each area.",
        "Results": "Analysis of participant data revealed several notable trends, with meaningful variation across specialties. Medical oncologists consistently demonstrated fewer gaps than other clinician groups, while NPs/PAs showed the highest remaining needs across nearly all learning themes. The most persistent gaps were in recognizing optimal treatment approaches and ability to mitigate treatment-related adverse events.",
        "Abstract": "Clinician Remaining Gaps Awareness of NPC disease characteristics Ability to mitigate treatment-related adverse events (AEs) Recognizing optimal treatment approaches for NPC View in Agenda and Add to Schedule",
        "Conclusions": "This educational initiative revealed critical multidisciplinary practice gaps regarding optimal care pathways in NPC. While medical oncologists showed comparatively stronger baseline understanding, substantial opportunities remain to strengthen competencies among surgeons, pathologists, and especially NPs/PAs, ultimately reflecting the evolving complexity of NPC diagnosis and management. These findings underscore the urgent need for targeted, multidisciplinary education. Further studies are planned to evaluate the impact of ongoing medical education initiatives in addressing these multidisciplinary clinical practice gaps.",
        "Acknowledgements": "The CME activity described within this analysis was supported by an independent educational grant from Coherus Oncology."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Identifying Practice Gaps in the Evolving Management of Nasopharyngeal Carcinoma: Analysis of an Online Educational Survey</span>. Michelle A Worst, PharmD, BCOP, MBA, CHCP<sup>1</sup>; <u>Nimish Mehta, PhD, MBA, CHCP</u><sup>1</sup>; Nabil F Saba, MD, FACP<sup>2</sup>. <sup>1</sup>Medscape, LLC; <sup>2</sup>Winship Cancer Institute of Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Nasopharyngeal carcinoma (NPC) in its advanced and metastatic stages has long been associated with limited therapeutic options and suboptimal long-term outcomes, underscoring the need for more effective strategies. Emerging evidence supporting the use of immune checkpoint inhibitors (ICIs) offers a promising avenue to address these gaps, yet integrating immunotherapy (IO) into an already complex treatment landscape presents challenges for many clinicians. This study aimed to assess the knowledge and skills of medical oncologists, pathologists, surgeons, nurse practitioners (NPs), and physician assistants (PAs) in the management of NPC, and to identify critical educational gaps. </p>\n\n<p><strong>Methods</strong>: An online, text-based continuing medical education (CME) survey instrument comprising 23 multiple-choice knowledge, practice-based, and confidence questions assessed participants’ understanding of dynamic clinical paradigms associated with NPC care. The activity launched March 2025, and data were collected through September 2025. Responses from medical oncologists, pathologists, surgeons, and NPs/PAs were analyzed and compared by grouping questions into clinical themes and calculating the percentage of correct responses in each area.</p>\n\n<p><strong>Results</strong>: Analysis of participant data revealed several notable trends, with meaningful variation across specialties. Medical oncologists consistently demonstrated fewer gaps than other clinician groups, while NPs/PAs showed the highest remaining needs across nearly all learning themes. The most persistent gaps were in recognizing optimal treatment approaches and ability to mitigate treatment-related adverse events.</p>\n\n<table align='center' border='1' cellpadding='1' cellspacing='1' style='width:500px'>\n\t<caption>Remaining gaps by clinician type</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope='row'> </th>\n\t\t\t<th colspan='4' rowspan='1' scope='col'>\n\t\t\t<p>Clinician Remaining Gaps</p>\n\t\t\t(N = 25 to 133)</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<th scope='row'>Learning Theme</th>\n\t\t\t<td>Medical Oncologists</td>\n\t\t\t<td>Pathologists</td>\n\t\t\t<td>Surgeons</td>\n\t\t\t<td>NPs/PAs</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>Understanding of NPC diagnosis and staging </th>\n\t\t\t<td>29%</td>\n\t\t\t<td>46%</td>\n\t\t\t<td>47%</td>\n\t\t\t<td>54%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>\n\t\t\t<p>Awareness of NPC disease characteristics</p>\n\t\t\t</th>\n\t\t\t<td>31%</td>\n\t\t\t<td>53%</td>\n\t\t\t<td>43%</td>\n\t\t\t<td>78%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>\n\t\t\t<p>Ability to mitigate treatment-related adverse events (AEs)</p>\n\t\t\t</th>\n\t\t\t<td>58%</td>\n\t\t\t<td>64%</td>\n\t\t\t<td>66%</td>\n\t\t\t<td>70%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th scope='row'>\n\t\t\t<p>Recognizing optimal treatment approaches for NPC</p>\n\t\t\t</th>\n\t\t\t<td>60%</td>\n\t\t\t<td>54%</td>\n\t\t\t<td>63%</td>\n\t\t\t<td>61%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Conclusions</strong>: This educational initiative revealed critical multidisciplinary practice gaps regarding optimal care pathways in NPC. While medical oncologists showed comparatively stronger baseline understanding, substantial opportunities remain to strengthen competencies among surgeons, pathologists, and especially NPs/PAs, ultimately reflecting the evolving complexity of NPC diagnosis and management. These findings underscore the urgent need for targeted, multidisciplinary education. Further studies are planned to evaluate the impact of ongoing medical education initiatives in addressing these multidisciplinary clinical practice gaps.</p>\n\n<p><strong>Acknowledgements</strong>: The CME activity described within this analysis was supported by an independent educational grant from Coherus Oncology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153565--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S444",
      "content_id": "154054",
      "abstract_number": "S444",
      "poster_number": "",
      "title": "Gene expression differences between anatomically divergent nasopharyngeal cancer",
      "summary": "We observed that anatomically divergent NPC tumors harbour compartment-specific transcriptional programs: “up” tumors are characterized by ECM remodelling and EMT promoting local invasiveness, whereas “down” tumors display higher proliferation activity and immune cell infiltration. Collectively, these findings provide mechanistic insight into NPC progression patterns and therapeutic targeting strategies based on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154054",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Raymond K Tsang, MS, FRCSEd",
      "presenter": "Raymond K Tsang, MS, FRCSEd",
      "authors": "Yi Ren, PhD 1 ; Wei Keat Teo, PhD 1 ; Bingcheng Wu, MBBS 2 ; Chee Yit Lim, MBBS 3 ; Joe W Foley, PhD 1 ; Serene C Siow 1 ; Han Lee Goh 1 ; Kwok Seng Loh, MBBS 1 ; Joshua K Tay, MBBS, PhD 1 ; Raymond K Tsang, MS, FRCSEd 1",
      "normalized_authors": [
        "Yi Ren",
        "Wei Keat Teo",
        "Bingcheng Wu, MBBS",
        "Chee Yit Lim, MBBS",
        "Joe W Foley",
        "Serene C Siow",
        "Han Lee Goh",
        "Kwok Seng Loh, MBBS",
        "Joshua K Tay, MBBS",
        "Raymond K Tsang, FRCSEd"
      ],
      "affiliations": [
        "Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore",
        "Department of Pathology, National University Hospital, Singapore",
        "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore",
        "Department of Pathology, National University Hospital, Singapore",
        "Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154054/Screen%20Shot%202025-12-05%20at%2021_40_53.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154054/Screen%20Shot%202025-12-05%20at%2021_40_53.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154054"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Yi Ren, PhD 1 ; Wei Keat Teo, PhD 1 ; Bingcheng Wu, MBBS 2 ; Chee Yit Lim, MBBS 3 ; Joe W Foley, PhD 1 ; Serene C Siow 1 ; Han Lee Goh 1 ; Kwok Seng Loh, MBBS 1 ; Joshua K Tay, MBBS, PhD 1 ; Raymond K Tsang, MS, FRCSEd 1",
        "Affiliations": "1 Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore; 2 Department of Pathology, National University Hospital, Singapore; 3 Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore",
        "Background": "Nasopharyngeal cancer (NPC) exhibits heterogeneous anatomic patterns of progression, yet the molecular mechanisms underlying these differences remain poorly understood. Clinically, a subset of tumors extends toward the skull base with minimal nodal spread (“up” tumors, T3/T4 & N0/N1), whereas another subset shows limited local invasion but extensive lymph node involvement (“down” tumors, T1/T2 & N2/N3). These divergent patterns suggest distinct biological programs within the tumor epithelia (TUM) and the surrounding tumor microenvironment (TME). However, significant and heterogenous immune infiltration in NPC obscures compartment-level signals using conventional bulk RNA sequencing (RNAseq). To investigate the molecular basis of this anatomic divergence, we applied laser-capture microdissection (LCM) to isolate TUM and TME compartments from formalin-fixed paraffin-embedded (FFPE) NPC tissues, followed by transcriptomic profiling using a specialized RNAseq protocol optimized for low-input FFPE tissue. This study aims to define compartment-specific gene expression differences between “up” and “down” NPC tumors, providing insights into the biological pathways that contribute to distinct patterns of disease progression and potentially informing therapeutic strategies.",
        "Methods": "LCM was performed on 19 FFPE NPC biopsies (7 up and 12 down tumors) obtained from to isolate TUM and TME compartments based on H&E staining and pathologist annotation. RNAseq libraries were prepared from microdissected tissues, followed by differential expressing gene (DEG) analysis using edgeR. Gene set enrichment analysis (GSEA) was performed with fgsea using MSigDB pathway collections to identify enriched biological pathways.",
        "Results": "After quality control, 49 TUM and 41 TME libraries were analyzed. In TUM, 177 genes were significantly upregulated in “up” tumors (n=18), such as TGFB2, ASPN, SPARC, ITGA1, TIMP3, and COL15A1, suggesting strong extracellular matrix (ECM) remodelling and epithelial-mesenchymal transition (EMT) activity. In contrast, 359 genes were enriched in “down” tumors (n=31), including proliferation-associated genes PRC1, KIF14, CCNB1IP1, ATR and UBE2T, as well as immune-related genes CXCL10, IL15, GLNY, and IRF1. These data suggested that “up” tumors exhibit enhanced local invasiveness driven by ECM-EMT programs, whereas “down” tumors display elevated proliferative activity and stronger epithelial-immune crosstalk. Consistent with DEG findings, GSEA with Hallmark Pathways also revealed enrichment of EMT in “up” tumors, while E2F targes and G2M checkpoint signatures predominated in “down” tumors. In TME, although fewer DEGs were observed between “up” (n=16) and “down” (n=25) tumors, “down” TME showed strong enrichment of interferon response pathways, aligning with observations from TUM that enhanced epithelial-immune interactions characterize “down” tumors. Importantly, the enrichment of EMT processes in “up” tumors was validated in an independent NPC RNAseq cohort (1), comprising 42 TUM and 19 TME libraries.",
        "Conclusions": "We observed that anatomically divergent NPC tumors harbour compartment-specific transcriptional programs: “up” tumors are characterized by ECM remodelling and EMT promoting local invasiveness, whereas “down” tumors display higher proliferation activity and immune cell infiltration. Collectively, these findings provide mechanistic insight into NPC progression patterns and therapeutic targeting strategies based on tumor anatomic behaviour.",
        "Abstract": "1. Tay JK et al., The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-kappaB signaling. Sci Adv 8, eabh2445 (2022). View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Gene expression differences between anatomically divergent nasopharyngeal cancer</span>. Yi Ren, PhD<sup>1</sup>; Wei Keat Teo, PhD<sup>1</sup>; Bingcheng Wu, MBBS<sup>2</sup>; Chee Yit Lim, MBBS<sup>3</sup>; Joe W Foley, PhD<sup>1</sup>; Serene C Siow<sup>1</sup>; Han Lee Goh<sup>1</sup>; Kwok Seng Loh, MBBS<sup>1</sup>; Joshua K Tay, MBBS, PhD<sup>1</sup>; <u>Raymond K Tsang, MS, FRCSEd</u><sup>1</sup>. <sup>1</sup>Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore; <sup>2</sup>Department of Pathology, National University Hospital, Singapore; <sup>3</sup>Department of Otolaryngology - Head and Neck Surgery, National University Hospital, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/154054/Screen%20Shot%202025-12-05%20at%2021_40_53.jpg' /></p>\n\n<p><strong>Background: </strong>Nasopharyngeal cancer (NPC) exhibits heterogeneous anatomic patterns of progression, yet the molecular mechanisms underlying these differences remain poorly understood. Clinically, a subset of tumors extends toward the skull base with minimal nodal spread (“up” tumors, T3/T4 & N0/N1), whereas another subset shows limited local invasion but extensive lymph node involvement (“down” tumors, T1/T2 & N2/N3). These divergent patterns suggest distinct biological programs within the tumor epithelia (TUM) and the surrounding tumor microenvironment (TME). However, significant and heterogenous immune infiltration in NPC obscures compartment-level signals using conventional bulk RNA sequencing (RNAseq). To investigate the molecular basis of this anatomic divergence, we applied laser-capture microdissection (LCM) to isolate TUM and TME compartments from formalin-fixed paraffin-embedded (FFPE) NPC tissues, followed by transcriptomic profiling using a specialized RNAseq protocol optimized for low-input FFPE tissue. This study aims to define compartment-specific gene expression differences between “up” and “down” NPC tumors, providing insights into the biological pathways that contribute to distinct patterns of disease progression and potentially informing therapeutic strategies.</p>\n\n<p><strong>Methods: </strong>LCM was performed on 19 FFPE NPC biopsies (7 up and 12 down tumors) obtained from to isolate TUM and TME compartments based on H&E staining and pathologist annotation. RNAseq libraries were prepared from microdissected tissues, followed by differential expressing gene (DEG) analysis using edgeR. Gene set enrichment analysis (GSEA) was performed with fgsea using MSigDB pathway collections to identify enriched biological pathways.</p>\n\n<p><strong>Results: </strong>After quality control, 49 TUM and 41  TME libraries were analyzed. In TUM, 177 genes were significantly upregulated in “up” tumors (n=18), such as TGFB2, ASPN, SPARC, ITGA1, TIMP3, and COL15A1, suggesting  strong extracellular matrix (ECM) remodelling and epithelial-mesenchymal transition (EMT) activity. In contrast, 359 genes were enriched in “down” tumors (n=31), including proliferation-associated genes PRC1, KIF14, CCNB1IP1, ATR and UBE2T, as well as immune-related genes CXCL10, IL15, GLNY, and IRF1. These data suggested that “up” tumors exhibit enhanced local invasiveness driven by ECM-EMT programs, whereas “down” tumors display elevated proliferative activity and stronger epithelial-immune crosstalk. Consistent with DEG findings, GSEA with Hallmark Pathways also revealed enrichment of EMT in “up” tumors, while E2F targes and G2M checkpoint signatures predominated in “down” tumors. In TME, although fewer DEGs were observed between “up” (n=16) and “down” (n=25) tumors, “down” TME showed strong enrichment of interferon response pathways, aligning with observations from TUM that enhanced epithelial-immune interactions characterize “down” tumors. Importantly, the enrichment of EMT processes in “up” tumors was validated in an independent NPC RNAseq cohort (1), comprising 42 TUM and 19 TME libraries.</p>\n\n<p><strong>Conclusions: </strong>We observed that anatomically divergent NPC tumors harbour compartment-specific transcriptional programs: “up” tumors are characterized by ECM remodelling and EMT promoting local invasiveness, whereas “down” tumors display higher proliferation activity and immune cell infiltration. Collectively, these findings provide mechanistic insight into NPC progression patterns and therapeutic targeting strategies based on tumor anatomic behaviour.</p>\n\n<p>1. Tay JK et al., The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-kappaB signaling. Sci Adv 8, eabh2445 (2022).</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154054--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S445",
      "content_id": "151866",
      "abstract_number": "S445",
      "poster_number": "",
      "title": "Evaluating a nasopharyngeal Epstein Barr Virus swab (NP Screen) performance in early detection and surveillance of Nasopharyngeal Carcinoma: a pilot study",
      "summary": "In our cohort, NP screen shows a sensitivity of 73.7%, specificity of 50%, PPV of 82.4% and a NPV of 37.5%. No clinical complications were encountered during administration of NP screen. In our EBV positive NPC cohort, negative plasma and nasopharyngeal EBV DNA concordance at diagnosis was 14.3%, and positive concordance was highest 4-6 weeks post treatment at 85.7%, suggesting a role of NP-EBV in disease...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151866",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Pei Yuan Fong, MD",
      "presenter": "Pei Yuan Fong, MD",
      "authors": "Pei Yuan Fong, MD 1 ; Mark M Ong 1 ; Isabelle Jang 1 ; Jia Jia Wee 1 ; Corrina Z Tan 2 ; Chwee Ming Lim 1",
      "normalized_authors": [
        "Pei Yuan Fong",
        "Mark M Ong",
        "Isabelle Jang",
        "Jia Jia Wee",
        "Corrina Z Tan",
        "Chwee Ming Lim"
      ],
      "affiliations": [
        "Department of Otolaryngology- Head and Neck Surgery, Singapore General Hospital",
        "Clinical Translational Research, Singapore General Hospital"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology- Head and Neck Surgery, Singapore General Hospital",
        "Clinical Translational Research, Singapore General Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_09_06%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_09_06%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151866"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_08_35%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_08_35%E2%80%AFPM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151866"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 510,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods and Materials",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Pei Yuan Fong, MD 1 ; Mark M Ong 1 ; Isabelle Jang 1 ; Jia Jia Wee 1 ; Corrina Z Tan 2 ; Chwee Ming Lim 1",
        "Affiliations": "1 Department of Otolaryngology- Head and Neck Surgery, Singapore General Hospital; 2 Clinical Translational Research, Singapore General Hospital",
        "Introduction": "Epstein Barr Virus (EBV) infection is associated with the pathogenesis of nasopharyngeal carcinoma (NPC). Following definitive treatment with radiotherapy, plasma cell free EBV DNA detection is routinely performed, in addition to clinical examination plus nasal endoscopy, to detect possible cancer recurrence. Recently, nasopharyngeal EBV DNA (NP-EBV) detection can be reliably tested via nasopharyngeal swab. Therefore, we aim to evaluate the diagnostic performance of NP swab in detecting biopsy proven EBV-NPC, and to compare the concordance of plasma with NPC EBV detection.",
        "Methods and Materials": "NP Screen™ is a new NPC nasopharyngeal brush biopsy device that uses a quantitative polymerase chain reaction (Q-PCR) to detect EBV from DNA extracted from the epithelium of the nasopharynx. NP Screen was administered via transoral or transnasal routes for patients who underwent routine post nasal space biopsy for a nasopharyngeal mass (Figure 1A, 1B). Plasma EBV DNA testing was performed at point of diagnosis (t0), 4-6 weeks (t1) and 12 weeks post treatment (t2). In the control group (negative for NPC), NP-EBV DNA titres were compared against plasma EBV DNA levels. In the NPC group, NP Screen was administered at equivalent post-treatment time points for correlation. We measured diagnostic sensitivity and specificity of NP Screen, concordance between NP and plasma EBV DNA, and safety of NP screen during application.",
        "Results": "28 patients were recruited in this study, comprising 21 patients with newly diagnosed EBV positive NPC and 7 controls. The cohort comprised 67.9% males, and median age of 55.7 years. 32% received primary radiotherapy (RT), 32% received primary proton beam therapy (PBT), while the remaining 36% received concurrent chemoradiation treatment for NPC. No patient developed recurrent disease during this study.",
        "Abstract": "In diagnostic performance, NP screen demonstrated a sensitivity of 73.7% (48.8-90.9%), specificity of 50% (11.8-88.2%), positive predictive value (PPV) of 82.4% and a negative predictive value (NPV) of 37.5%. In the longitudinal NPC cohort, the concordance in NP-EBV DNA and plasma EBV titres was 52.9% at diagnosis (t0), 85.7% at t1 and 75% at t2. 100% of post-treatment NP-EBV titres were undetectable immediately post-treatment. There was no significant difference in concordance comparing pre-treatment (t0) against t1(p= 0.131), or t2 (p= 0.643), or comparing pre-treatment (t0) and post- treatment values (p=0.119) (Table 1). No patients developed procedural complications including severe pain or nasopharyngeal/oropharyngeal hemorrhage. On subgroup analysis, concordance in post-treatment NP-EBV DNA and plasma EBV titres were highest in NPC patients treated with primary chemoradiation (100%), followed by primary RT (83.3%) and primary proton beam therapy (75%), though small sample sizes precluded furtheranalysis. View in Agenda and Add to Schedule",
        "Conclusions": "In our cohort, NP screen shows a sensitivity of 73.7%, specificity of 50%, PPV of 82.4% and a NPV of 37.5%. No clinical complications were encountered during administration of NP screen. In our EBV positive NPC cohort, negative plasma and nasopharyngeal EBV DNA concordance at diagnosis was 14.3%, and positive concordance was highest 4-6 weeks post treatment at 85.7%, suggesting a role of NP-EBV in disease surveillance."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating a nasopharyngeal Epstein Barr Virus swab (NP Screen) performance in early detection and surveillance of Nasopharyngeal Carcinoma: a pilot study</span>. <u>Pei Yuan Fong, MD</u><sup>1</sup>; Mark M Ong<sup>1</sup>; Isabelle Jang<sup>1</sup>; Jia Jia Wee<sup>1</sup>; Corrina Z Tan<sup>2</sup>; Chwee Ming Lim<sup>1</sup>. <sup>1</sup>Department of Otolaryngology- Head and Neck Surgery, Singapore General Hospital; <sup>2</sup>Clinical Translational Research, Singapore General Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Epstein Barr Virus (EBV) infection is associated with the pathogenesis of nasopharyngeal carcinoma (NPC). Following definitive treatment with radiotherapy, plasma cell free EBV DNA detection is routinely performed, in addition to clinical examination plus nasal endoscopy, to detect possible cancer recurrence. Recently, nasopharyngeal EBV DNA (NP-EBV) detection can be reliably tested via nasopharyngeal swab. Therefore, we aim to evaluate the diagnostic performance of NP swab in detecting biopsy proven EBV-NPC, and to compare the concordance of plasma with NPC EBV detection.</p>\n\n<p><strong>Methods and Materials: </strong>NP Screen™ is a new NPC nasopharyngeal brush biopsy device that uses a quantitative polymerase chain reaction (Q-PCR) to detect EBV from DNA extracted from the epithelium of the nasopharynx. NP Screen was administered via transoral or transnasal routes for patients who underwent routine post nasal space biopsy for a nasopharyngeal mass (Figure 1A, 1B). Plasma EBV DNA testing was performed at point of diagnosis (t0), 4-6 weeks (t1) and 12 weeks post treatment (t2). In the control group (negative for NPC), NP-EBV DNA titres were compared against plasma EBV DNA levels. In the NPC group, NP Screen was administered at equivalent post-treatment time points for correlation. We measured diagnostic sensitivity and specificity of NP Screen, concordance between NP and plasma EBV DNA, and safety of NP screen during application.</p>\n\n<p><strong>Results: </strong>28 patients were recruited in this study, comprising 21 patients with newly diagnosed EBV positive NPC and 7 controls. The cohort comprised 67.9% males, and median age of 55.7 years. 32% received primary radiotherapy (RT), 32% received primary proton beam therapy (PBT), while the remaining 36% received concurrent chemoradiation treatment for NPC. No patient developed recurrent disease during this study.</p>\n\n<p>In diagnostic performance, NP screen demonstrated a sensitivity of 73.7% (48.8-90.9%), specificity of 50% (11.8-88.2%), positive predictive value (PPV) of 82.4% and a negative predictive value (NPV) of 37.5%. In the longitudinal NPC cohort, the concordance in NP-EBV DNA and plasma EBV titres was 52.9% at diagnosis (t0), 85.7% at t1 and 75% at t2. 100% of post-treatment NP-EBV titres were undetectable immediately post-treatment. There was no significant difference in concordance comparing pre-treatment (t0) against t1(p= 0.131), or t2 (p= 0.643), or comparing pre-treatment (t0) and post- treatment values (p=0.119) (Table 1). No patients developed procedural complications including severe pain or nasopharyngeal/oropharyngeal hemorrhage.</p>\n\n<p>On subgroup analysis, concordance in post-treatment NP-EBV DNA and plasma EBV titres were highest in NPC patients treated with primary chemoradiation (100%), followed by primary RT (83.3%) and primary proton beam therapy (75%), though small sample sizes precluded furtheranalysis. </p>\n\n<p><strong>Conclusions: </strong>In our cohort, NP screen shows a sensitivity of 73.7%, specificity of 50%, PPV of 82.4% and a NPV of 37.5%. No clinical complications were encountered during administration of NP screen. In our EBV positive NPC cohort, negative plasma and nasopharyngeal EBV DNA concordance at diagnosis was 14.3%, and positive concordance was highest 4-6 weeks post treatment at 85.7%, suggesting a role of NP-EBV in disease surveillance. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_09_06%E2%80%AFPM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151866/Screenshot%202025-12-04%20at%203_08_35%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151866--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S447",
      "content_id": "153617",
      "abstract_number": "S447",
      "poster_number": "",
      "title": "Impact of Metastasis Directed Therapy with Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma",
      "summary": "Multimodality treatment integrating LRRT and MDT was feasible and associated with encouraging survival outcomes in de novo mNPC. Subgroup analysis of oligometastatic patients did not show a clear difference between MDT and non-MDT, reflecting limited statistical power. These findings support the inclusion of MDT into treatment strategies for de novo mNPC, while underscoring the need for validation in larger...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153617",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anuj Kumar, MD",
      "presenter": "Anuj Kumar, MD",
      "authors": "Anuj Kumar, MD ; Sarbani Ghosh Laskar, MD; Rahat Malhotra, MD; Shwetabh Sinha, MD; Samarpita Mohanty, MD; Ashwini Budrukkar, MD; Monali Swain, MD; Amiya Agrawal, MD; Rishi Mittal, MD; Kumar Prabhash, DM; Vanita Noronha, DM; Nandini Menon, DM; Minit Shah, DM; Amit Joshi",
      "normalized_authors": [
        "Anuj Kumar",
        "Sarbani Ghosh Laskar",
        "Rahat Malhotra",
        "Shwetabh Sinha",
        "Samarpita Mohanty",
        "Ashwini Budrukkar",
        "Monali Swain",
        "Amiya Agrawal",
        "Rishi Mittal",
        "Kumar Prabhash, DM",
        "Vanita Noronha, DM",
        "Nandini Menon, DM",
        "Minit Shah, DM",
        "Amit Joshi"
      ],
      "affiliations": [
        "Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"
      ],
      "normalized_institutions": [
        "Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 322,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Anuj Kumar, MD ; Sarbani Ghosh Laskar, MD; Rahat Malhotra, MD; Shwetabh Sinha, MD; Samarpita Mohanty, MD; Ashwini Budrukkar, MD; Monali Swain, MD; Amiya Agrawal, MD; Rishi Mittal, MD; Kumar Prabhash, DM; Vanita Noronha, DM; Nandini Menon, DM; Minit Shah, DM; Amit Joshi",
        "Affiliations": "Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India",
        "Objectives": "De novo metastatic nasopharyngeal carcinoma (mNPC) has poor prognosis with systemic therapy alone. While locoregional radiotherapy (LRRT) improves survival, the role of metastasis-directed therapy (MDT) remains less defined.",
        "Methods": "We retrospectively reviewed 54 patients with de novo mNPC treated from 2013-2024 at a tertiary cancer centre. All received platinum-based induction chemotherapy (NACT) followed by definitive LRRT. Seventeen patients (31%) also underwent MDT to metastases (SBRT, IMRT, or radiofrequency ablation). Patients were categorised as oligometastatic (≤5 lesions; n=30) or polymetastatic (>5; n=24). In the oligometastatic subgroup, outcomes with MDT (n=15) versus no MDT (n=15) were compared. Survival outcomes were estimated by Kaplan-Meier method, and multivariable Cox regression was performed.",
        "Results": "At a median follow-up of 27 months, the estimated 2-year OS, RFS, and DRFS were 67.5%, 45.4%, and 52.7%, respectively. Oligometastatic disease was associated with superior 2-year RFS (59.2% vs 27.8%, p=0.007) and DRFS (69% vs 31.4%, p=0.004) compared with polymetastatic disease. In the overall cohort, MDT was associated with favourable OS, RFS, and DRFS. Within the oligometastatic subset (15 MDT vs 15 no MDT), outcomes appeared comparable, though interpretation is limited by sample size and event numbers. Patients achieving CR/PR after NACT had improved outcomes, whereas progression predicted poor survival. Maintenance capecitabine (44%) showed a trend towards OS benefit without RFS advantage. On multivariable analysis, MDT was independently associated with improved RFS (HR 0.27, p=0.047) and showed a trend towards improved OS (HR 0.25, p=0.072).",
        "Conclusion": "Multimodality treatment integrating LRRT and MDT was feasible and associated with encouraging survival outcomes in de novo mNPC. Subgroup analysis of oligometastatic patients did not show a clear difference between MDT and non-MDT, reflecting limited statistical power. These findings support the inclusion of MDT into treatment strategies for de novo mNPC, while underscoring the need for validation in larger prospective trials.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Metastasis Directed Therapy with Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma</span>. <u>Anuj Kumar, MD</u>; Sarbani Ghosh Laskar, MD; Rahat Malhotra, MD; Shwetabh Sinha, MD; Samarpita Mohanty, MD; Ashwini Budrukkar, MD; Monali Swain, MD; Amiya Agrawal, MD; Rishi Mittal, MD; Kumar Prabhash, DM; Vanita Noronha, DM; Nandini Menon, DM; Minit Shah, DM; Amit Joshi. Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives:</strong> De novo metastatic nasopharyngeal carcinoma (mNPC) has poor prognosis with systemic therapy alone. While locoregional radiotherapy (LRRT) improves survival, the role of metastasis-directed therapy (MDT) remains less defined.</p>\n\n<p><strong>Methods: </strong>We retrospectively reviewed 54 patients with de novo mNPC treated from 2013-2024 at a tertiary cancer centre. All received platinum-based induction chemotherapy (NACT) followed by definitive LRRT. Seventeen patients (31%) also underwent MDT to metastases (SBRT, IMRT, or radiofrequency ablation). Patients were categorised as oligometastatic (≤5 lesions; n=30) or polymetastatic (>5; n=24). In the oligometastatic subgroup, outcomes with MDT (n=15) versus no MDT (n=15) were compared. Survival outcomes were estimated by Kaplan-Meier method, and multivariable Cox regression was performed.</p>\n\n<p><strong>Results: </strong> At a median follow-up of 27 months, the estimated 2-year OS, RFS, and DRFS were 67.5%, 45.4%, and 52.7%, respectively. Oligometastatic disease was associated with superior 2-year RFS (59.2% vs 27.8%, p=0.007) and DRFS (69% vs 31.4%, p=0.004) compared with polymetastatic disease. In the overall cohort, MDT was associated with favourable OS, RFS, and DRFS. Within the oligometastatic subset (15 MDT vs 15 no MDT), outcomes appeared comparable, though interpretation is limited by sample size and event numbers. Patients achieving CR/PR after NACT had improved outcomes, whereas progression predicted poor survival. Maintenance capecitabine (44%) showed a trend towards OS benefit without RFS advantage. On multivariable analysis, MDT was independently associated with improved RFS (HR 0.27, p=0.047) and showed a trend towards improved OS (HR 0.25, p=0.072).</p>\n\n<p><strong>Conclusion: </strong>Multimodality treatment integrating LRRT and MDT was feasible and associated with encouraging survival outcomes in de novo mNPC. Subgroup analysis of oligometastatic patients did not show a clear difference between MDT and non-MDT, reflecting limited statistical power. These findings support the inclusion of MDT into treatment strategies for de novo mNPC, while underscoring the need for validation in larger prospective trials.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153617--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S449",
      "content_id": "154695",
      "abstract_number": "S449",
      "poster_number": "",
      "title": "Survival Outcomes in Patients with Extensive Perineural Invasion at the Skull Base After Surgery and Adjuvant Therapy",
      "summary": "Maximal safe resection combined with adjuvant therapy yields meaningful survival and acceptable morbidity for patients with perineural invasion, irrespective of age, comorbidity, or margin status. The absence of a measurable survival difference across margin groups indicates that margin negativity should not be considered an absolute prerequisite for surgical management in skull base–directed PNI. These findings...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154695",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Uralov, MD",
      "presenter": "Daniel Uralov, MD",
      "authors": "Daniel Uralov, MD 1 ; Sophia Linguiti, BA 1 ; Parvesh Kumar Jr., BA 1 ; Anika Walia, BA 1 ; Domenica Voli, BA 2 ; Alina Galaria, BA 2 ; Sarah Harrington, BA 1 ; Kelly Brigham, MD 1 ; D. Alexander Cronkite, MD 1 ; Adam Luginbuhl, MD 1",
      "normalized_authors": [
        "Daniel Uralov",
        "Sophia Linguiti",
        "Parvesh Kumar Jr",
        "Anika Walia",
        "Domenica Voli",
        "Alina Galaria",
        "Sarah Harrington",
        "Kelly Brigham",
        "D. Alexander Cronkite",
        "Adam Luginbuhl"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA",
        "Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Daniel Uralov, MD 1 ; Sophia Linguiti, BA 1 ; Parvesh Kumar Jr., BA 1 ; Anika Walia, BA 1 ; Domenica Voli, BA 2 ; Alina Galaria, BA 2 ; Sarah Harrington, BA 1 ; Kelly Brigham, MD 1 ; D. Alexander Cronkite, MD 1 ; Adam Luginbuhl, MD 1",
        "Affiliations": "1 Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 2 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA",
        "Introduction": "Perineural invasion (PNI) of major cranial nerve pathways is associated with aggressive tumor biology, high local recurrence rates, and poor survival. Achieving negative proximal nerve margins is often not feasible when there is PNI at the skull base as R0 resection attempts in this region may result in unnecessary morbidity. At our institution, management of skull base tumors with PNI emphasizes maximal safe surgical resection up to the limits of skull base/intracranial boundaries, accepting microscopic (R1) or even gross residual disease (R2), when necessary, followed by adjuvant radiotherapy with or without chemotherapy. This study evaluates the outcomes of this treatment approach and examines whether margin status impacts survival.",
        "Methods": "A retrospective analysis was performed on 54 patients with head and neck cancer and PNI involving the trigeminal (V2/V3), facial, or vidian nerves treated between 2010–2022. Demographic variables, Charlson Comorbidity Index (CCI), nerve involvement patterns, margin status, imaging findings, perioperative morbidity, and adjuvant treatment were collected. Overall survival (OS), disease-free survival (DFS), and local recurrence were assessed using Kaplan–Meier analysis with log-rank testing. Cox proportional hazards modeling evaluated predictors of survival.",
        "Results": "Mean age was 67.7 ± 14.8 years, 59.3% were male, and patients demonstrated high comorbidity burden (mean CCI 5.8 ± 2.9). Squamous cell carcinoma accounted for 55.6% of cases, followed by adenoid cystic carcinoma (16.7%). Most tumors originated from the parotid-region (25.9%) followed by the orbitomaxillary region (24.1%), and infratemporal and pterygopalatine fossae (14.8%). Multiple-nerve PNI occurred in 29.6% of patients. V3 (58.5%) and V2 (57.1%) were the most commonly involved nerves. R0 resection was achieved in 36.5% (19/52), while 63.5% (33/52) had R1 or R2 margins. Thirty-day morbidity was low, with postoperative infection in 16.7% (9/54), cerebrospinal fluid leak in 1.9% (1/53), and no perioperative mortality. The mean length of hospital stay was 6.9 ± 4.9 days. Adjuvant therapy was widely utilized, with 81.5% receiving radiation and 55.8% receiving chemotherapy. Mean OS was 3.60 ± 3.25 years, and mean DFS was 1.97 ± 2.16 years. There was no difference in OS between R0 and R1/R2 resections (median OS 2.73 vs 2.72 years; log-rank p = 1.00). DFS also did not differ across margin groups. Multiple-nerve involvement, older age, and high comorbidity burden did not preclude meaningful survival. Cox regression identified no independent predictors of OS.",
        "Conclusions": "Maximal safe resection combined with adjuvant therapy yields meaningful survival and acceptable morbidity for patients with perineural invasion, irrespective of age, comorbidity, or margin status. The absence of a measurable survival difference across margin groups indicates that margin negativity should not be considered an absolute prerequisite for surgical management in skull base–directed PNI. These findings support a treatment paradigm emphasizing maximal safe resection plus adjuvant therapy, rather than aggressive attempts to achieve negative margins or nonsurgical treatment alone. In the era of expanding neoadjuvant immunotherapy, this surgical paradigm will need to be re-examined in future cohorts to determine its evolving role.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Survival Outcomes in Patients with Extensive Perineural Invasion at the Skull Base After Surgery and Adjuvant Therapy</span>. <u>Daniel Uralov, MD</u><sup>1</sup>; Sophia Linguiti, BA<sup>1</sup>; Parvesh Kumar Jr., BA<sup>1</sup>; Anika Walia, BA<sup>1</sup>; Domenica Voli, BA<sup>2</sup>; Alina Galaria, BA<sup>2</sup>; Sarah Harrington, BA<sup>1</sup>; Kelly Brigham, MD<sup>1</sup>; D. Alexander Cronkite, MD<sup>1</sup>; Adam Luginbuhl, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; <sup>2</sup>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Perineural invasion (PNI) of major cranial nerve pathways is associated with aggressive tumor biology, high local recurrence rates, and poor survival. Achieving negative proximal nerve margins is often not feasible when there is PNI at the skull base as R0 resection attempts in this region may result in unnecessary morbidity. At our institution, management of skull base tumors with PNI emphasizes maximal safe surgical resection up to the limits of skull base/intracranial boundaries, accepting microscopic (R1) or even gross residual disease (R2), when necessary, followed by adjuvant radiotherapy with or without chemotherapy. This study evaluates the outcomes of this treatment approach and examines whether margin status impacts survival. </p>\n\n<p><strong>Methods: </strong>A retrospective analysis was performed on 54 patients with head and neck cancer and PNI involving the trigeminal (V2/V3), facial, or vidian nerves treated between 2010–2022. Demographic variables, Charlson Comorbidity Index (CCI), nerve involvement patterns, margin status, imaging findings, perioperative morbidity, and adjuvant treatment were collected. Overall survival (OS), disease-free survival (DFS), and local recurrence were assessed using Kaplan–Meier analysis with log-rank testing. Cox proportional hazards modeling evaluated predictors of survival. </p>\n\n<p><strong>Results: </strong>Mean age was 67.7 ± 14.8 years, 59.3% were male, and patients demonstrated high comorbidity burden (mean CCI 5.8 ± 2.9). Squamous cell carcinoma accounted for 55.6% of cases, followed by adenoid cystic carcinoma (16.7%). Most tumors originated from the parotid-region (25.9%) followed by the orbitomaxillary region (24.1%), and infratemporal and pterygopalatine fossae (14.8%). Multiple-nerve PNI occurred in 29.6% of patients. V3 (58.5%) and V2 (57.1%) were the most commonly involved nerves. R0 resection was achieved in 36.5% (19/52), while 63.5% (33/52) had R1 or R2 margins. Thirty-day morbidity was low, with postoperative infection in 16.7% (9/54), cerebrospinal fluid leak in 1.9% (1/53), and no perioperative mortality. The mean length of hospital stay was 6.9 ± 4.9 days. Adjuvant therapy was widely utilized, with 81.5% receiving radiation and 55.8% receiving chemotherapy. Mean OS was 3.60 ± 3.25 years, and mean DFS was 1.97 ± 2.16 years. There was no difference in OS between R0 and R1/R2 resections (median OS 2.73 vs 2.72 years; log-rank p = 1.00). DFS also did not differ across margin groups. Multiple-nerve involvement, older age, and high comorbidity burden did not preclude meaningful survival. Cox regression identified no independent predictors of OS. </p>\n\n<p><strong>Conclusions: </strong>Maximal safe resection combined with adjuvant therapy yields meaningful survival and acceptable morbidity for patients with perineural invasion, irrespective of age, comorbidity, or margin status. The absence of a measurable survival difference across margin groups indicates that margin negativity should not be considered an absolute prerequisite for surgical management in skull base–directed PNI. These findings support a treatment paradigm emphasizing maximal safe resection plus adjuvant therapy, rather than aggressive attempts to achieve negative margins or nonsurgical treatment alone. In the era of expanding neoadjuvant immunotherapy, this surgical paradigm will need to be re-examined in future cohorts to determine its evolving role. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154695--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S450",
      "content_id": "154494",
      "abstract_number": "S450",
      "poster_number": "",
      "title": "Oncologic Outcomes and Patterns of Failure in Clinically T3/T4 Sinonasal Malignancies: A Single-Institution Experience",
      "summary": "Eighty-five (84.2%) patients underwent definitive surgical resection. Of this cohort, 72 patients (84.5%) received additional therapies postoperatively, including adjuvant radiation (n=48) and chemoradiation (n=24). Pathologic analysis revealed positive margins in 40/67 (59.7%), perineural invasion in 21/50 (42.0%), lymphovascular invasion in 8/46 (17.4%), and skull base involvement in 64/82 (78.0%). Nine...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154494",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christopher Nielson",
      "presenter": "Christopher Nielson",
      "authors": "Christopher Nielson ; Jacob Beiriger; Ashlynn Gober; Richard Cannon; Marcus Monroe; Luke Buchmann; Sarah Drejet; Jason Hunt; Jeremiah Alt; Hilary McCrary; Ying Hitchcock",
      "normalized_authors": [
        "Christopher Nielson",
        "Jacob Beiriger",
        "Ashlynn Gober",
        "Richard Cannon",
        "Marcus Monroe",
        "Luke Buchmann",
        "Sarah Drejet",
        "Jason Hunt",
        "Jeremiah Alt",
        "Hilary McCrary",
        "Ying Hitchcock"
      ],
      "affiliations": [
        "University of Utah"
      ],
      "normalized_institutions": [
        "University of Utah"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 471,
      "section_labels": [
        "Authors",
        "Affiliations",
        "OBJECTIVE",
        "METHODS",
        "RESULTS",
        "Abstract",
        "CONCLUSIONS"
      ],
      "sections": {
        "Authors": "Christopher Nielson ; Jacob Beiriger; Ashlynn Gober; Richard Cannon; Marcus Monroe; Luke Buchmann; Sarah Drejet; Jason Hunt; Jeremiah Alt; Hilary McCrary; Ying Hitchcock",
        "Affiliations": "University of Utah",
        "OBJECTIVE": "Despite their high mortality, sinonasal malignancies remain under investigated. Data is specifically limited regarding improving outcomes in patients with locally advanced sinonasal cancers. Our study aims to evaluate treatment patterns, survival outcomes, and recurrence patterns in patients with locally advanced (clinical T3/T4) sinonasal malignancies.",
        "METHODS": "This is a retrospective analysis of consecutive patients with clinically T3/T4 sinonasal malignancies. Patient demographics were collected, and groups were stratified by histology, treatment modality, and pathologic features. Oncologic outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed using Chi-square and Fisher's exact tests.",
        "RESULTS": "101 patients were identified in the treatment period from 2010-2025, with a median age of 63 years (IQR 54-70; 66.3% male). Median follow-up was 47.2 months. Squamous cell carcinoma (SCC) was the predominant histologic subtype (40.6%), followed by olfactory neuroblastoma (ONB, 32.7%), sinonasal undifferentiated carcinoma (SNUC, 12.9%), and other histologies (13.9%). Known clinical T staging was T3 in 14 (13.9%) and T4 in 50 (49.5%), with 37 (36.6%) assumed T3/T4 by dataset design. Clinical nodal disease (cN+) was present in 12 patients (11.9%).",
        "Abstract": "Eighty-five (84.2%) patients underwent definitive surgical resection. Of this cohort, 72 patients (84.5%) received additional therapies postoperatively, including adjuvant radiation (n=48) and chemoradiation (n=24). Pathologic analysis revealed positive margins in 40/67 (59.7%), perineural invasion in 21/50 (42.0%), lymphovascular invasion in 8/46 (17.4%), and skull base involvement in 64/82 (78.0%). Nine patients were managed nonoperatively with definitive chemoradiation, and one patient received definitive radiation alone. The median radiation dose was 66 Gy and 95.2% received IMRT. At median follow-up of 47.2 months, overall survival was 61.3% (n=62). Surgery was associated with reduced mortality (35.3% vs 56.2%, p=0.161; OR 0.42, 95% CI 0.14-1.25). Survival varied significantly by histology: SCC 46.3%, ONB 84.8%, SNUC 69.2%, other 42.9%. Twenty-two patients (21.8%) experienced disease progression in this interval, which was predominated by distant metastasis (9.9%). PFS was highest in the SCC (82.9%) and ONB (81.8%) cohorts. Patients treated with definitive surgical resection with or without adjuvant radiation therapy had the highest survival rates and demonstrated the lowest risk of disease recurrence. View in Agenda and Add to Schedule",
        "CONCLUSIONS": "Our analysis revealed that a surgery-dominant, multimodal treatment approach for locally advanced sinonasal malignancies yielded favorable progression-free and overall survival outcomes. In our cohort, ONB demonstrated superior outcomes compared to SCC, and survival outcomes were comparable to those reported in historical series. Distant failure (9.9%) was the most predominant pattern of disease progression across histologic analysis. The magnitude of benefit from surgical resection was found to have an OR of 0.42 for mortality across all T3/T4 sinonasal malignancies."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Oncologic Outcomes and Patterns of Failure in Clinically T3/T4 Sinonasal Malignancies: A Single-Institution Experience</span>. <u>Christopher Nielson</u>; Jacob Beiriger; Ashlynn Gober; Richard Cannon; Marcus Monroe; Luke Buchmann; Sarah Drejet; Jason Hunt; Jeremiah Alt; Hilary McCrary; Ying Hitchcock. University of Utah<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>OBJECTIVE: </strong>Despite their high mortality, sinonasal malignancies remain under investigated. Data is specifically limited regarding improving outcomes in patients with locally advanced sinonasal cancers. Our study aims to evaluate treatment patterns, survival outcomes, and recurrence patterns in patients with locally advanced (clinical T3/T4) sinonasal malignancies.</p>\n\n<p><strong>METHODS:</strong> This is a retrospective analysis of consecutive patients with clinically T3/T4 sinonasal malignancies. Patient demographics were collected, and groups were stratified by histology, treatment modality, and pathologic features. Oncologic outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed using Chi-square and Fisher's exact tests.</p>\n\n<p><strong>RESULTS: </strong>101 patients were identified in the treatment period from 2010-2025, with a median age of 63 years (IQR 54-70; 66.3% male). Median follow-up was 47.2 months. Squamous cell carcinoma (SCC) was the predominant histologic subtype (40.6%), followed by olfactory neuroblastoma (ONB, 32.7%), sinonasal undifferentiated carcinoma (SNUC, 12.9%), and other histologies (13.9%). Known clinical T staging was T3 in 14 (13.9%) and T4 in 50 (49.5%), with 37 (36.6%) assumed T3/T4 by dataset design. Clinical nodal disease (cN+) was present in 12 patients (11.9%).</p>\n\n<p>Eighty-five (84.2%) patients underwent definitive surgical resection. Of this cohort, 72 patients (84.5%) received additional therapies postoperatively, including adjuvant radiation (n=48) and chemoradiation (n=24). Pathologic analysis revealed positive margins in 40/67 (59.7%), perineural invasion in 21/50 (42.0%), lymphovascular invasion in 8/46 (17.4%), and skull base involvement in 64/82 (78.0%). Nine patients were managed nonoperatively with definitive chemoradiation, and one patient received definitive radiation alone. The median radiation dose was 66 Gy and 95.2% received IMRT.</p>\n\n<p>At median follow-up of 47.2 months, overall survival was 61.3% (n=62). Surgery was associated with reduced mortality (35.3% vs 56.2%, p=0.161; OR 0.42, 95% CI 0.14-1.25). Survival varied significantly by histology: SCC 46.3%, ONB 84.8%, SNUC 69.2%, other 42.9%. Twenty-two patients (21.8%) experienced disease progression in this interval, which was predominated by distant metastasis (9.9%). PFS was highest in the SCC (82.9%) and ONB (81.8%) cohorts.  Patients treated with definitive surgical resection with or without adjuvant radiation therapy had the highest survival rates and demonstrated the lowest risk of disease recurrence.</p>\n\n<p><strong>CONCLUSIONS: </strong>Our analysis revealed that a surgery-dominant, multimodal treatment approach for locally advanced sinonasal malignancies yielded favorable progression-free and overall survival outcomes. In our cohort, ONB demonstrated superior outcomes compared to SCC, and survival outcomes were comparable to those reported in historical series. Distant failure (9.9%) was the most predominant pattern of disease progression across histologic analysis. The magnitude of benefit from surgical resection was found to have an OR of 0.42 for mortality across all T3/T4 sinonasal malignancies.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154494--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S451",
      "content_id": "155388",
      "abstract_number": "S451",
      "poster_number": "",
      "title": "Prognostic Determinants in Surgically Treated Sinonasal Squamous Cell Carcinoma involving the Skull Base: An International Multi-Institutional Collaborative Study",
      "summary": "Survival for sinonasal squamous cell carcinoma involving the skull base remains modest. Risk stratification tools derived from this large cohort support individualized treatment planning and future trial design.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155388",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shorook Naara, MD, PhD",
      "presenter": "Shorook Naara, MD, PhD",
      "authors": "Shorook Naara, MD, PhD 1 ; Ehab Hanna 1 ; Shirly Y Su 1 ; Shaan M Raza 1 ; Franco DeMonte 1 ; Helena Levyn 2 ; Cristina Valero 2 ; Dauren Adilbay 2 ; Alana Eagan 2 ; Marc Cohen 2 ; Snehal Patel 2 ; Ian Ganly 2 ; Prathamesh Pai 3 ; Paolo Castelnuovo 4 ; Fang Jugao 5 ; Cesare Piazza 6 ; Piero Nicolai 6 ; Ben Panizza 7 ; James Bowman 7 ; Catherine Barnett 7 ; Luiz P Kowalski 8 ; Ronaldo Toledo 8 ; Dan M Fliss 9 ; John DeAlmeida 10 ; Ian Witterick 10 ; Philippe Herman 11 ; Walter Fontanella 12 ; Gregorio S Aniceto 13 ; Sefik Hosal 14 ; Serdar Ozer 14 ; Subramania Iyer 15 ; Richard Harvey 16 ; C. Rene Leemans 17 ; Jan-Jaap Hendrickx 17 ; Marcelo Figari 18 ; Luis Boccalatte 18 ; Ken Ichi Nibu 19 ; Peter Clarke 20 ; Catherine Rennie 20 ; Zhu Yi Ming 21 ; Claudio Cernea 22 ; Sergio Goncalves 23 ; Rodney Schlosser 24 ; Fernando Diaz 25 ; Zoukaa Sargi 26 ; Shahzada Ahmed 27 ; Wojciech Golusinski 28 ; Se Heon Kim 29 ; Jatin P Shah 2",
      "normalized_authors": [
        "Shorook Naara",
        "Ehab Hanna",
        "Shirly Y Su",
        "Shaan M Raza",
        "Franco DeMonte",
        "Helena Levyn",
        "Cristina Valero",
        "Dauren Adilbay",
        "Alana Eagan",
        "Marc Cohen",
        "Snehal Patel",
        "Ian Ganly",
        "Prathamesh Pai",
        "Paolo Castelnuovo",
        "Fang Jugao",
        "Cesare Piazza",
        "Piero Nicolai",
        "Ben Panizza",
        "James Bowman",
        "Catherine Barnett",
        "Luiz P Kowalski",
        "Ronaldo Toledo",
        "Dan M Fliss",
        "John DeAlmeida",
        "Ian Witterick",
        "Philippe Herman",
        "Walter Fontanella",
        "Gregorio S Aniceto",
        "Sefik Hosal",
        "Serdar Ozer",
        "Subramania Iyer",
        "Richard Harvey",
        "C. Rene Leemans",
        "Jan-Jaap Hendrickx",
        "Marcelo Figari",
        "Luis Boccalatte",
        "Ken Ichi Nibu",
        "Peter Clarke",
        "Catherine Rennie",
        "Zhu Yi Ming",
        "Claudio Cernea",
        "Sergio Goncalves",
        "Rodney Schlosser",
        "Fernando Diaz",
        "Zoukaa Sargi",
        "Shahzada Ahmed",
        "Wojciech Golusinski",
        "Se Heon Kim",
        "Jatin P Shah"
      ],
      "affiliations": [
        "UT MD Anderson Cancer Center, Houston, Texas, USA",
        "Memorial Sloan Kettering Cancer Center, New York, New York, USA",
        "Tata Memorial Hospital, Mumbai, India",
        "University of Insubria, Varese, Italy",
        "Beijing Tongren Hospital, Beijing, China",
        "University of Brescia, Brescia, Italy",
        "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
        "Head and Neck Reference Center, AC Camargo, Brazil",
        "Tel-Aviv University, Tel Aviv, Israel",
        "University Health Network, Toronto, Ontario, Canada",
        "Hispital Lariboisiere APHP, Paris, France",
        "University of Milan, Milan, Italy",
        "12 de Octubre University Hospital, Madrid, Spain",
        "Atilim University, Medicana International Ankara, Ankara, Turkey",
        "Amrita Institute of Medical Sciences, Kochi, India",
        "Sydney Ear Nose Throat Clinic, Darlinghurst, NewSouth Wales, Australia",
        "Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands",
        "Hospital Italiano de Buenos Aires, Buenos Aires, Argentina",
        "Kobe University Graduate School of Medicine, Kobe, Japan",
        "Imperial College Health care NHS Trust, Charing Cross Hospital, London, UK",
        "Beijing Cancer Center, Beijing, China",
        "Hospital Israelita Albert Einstein, São Paulo, SP, Brazil",
        "ICESP, São Paulo, Brazil",
        "Medical University of South Carolina, Charleston, South Carolina, USA",
        "Instituto Nacional de Câncer, Rio de Janeiro, Brazil",
        "University of Miami, Florida, USA",
        "University of Birmingham, University Hospitals Birmingham, Birmingham, UK",
        "The Greater Poland Cancer Centre, Poznan, Poland",
        "Yonsei University Health System, Seoul, South Korea"
      ],
      "normalized_institutions": [
        "UT MD Anderson Cancer Center, Houston, Texas, USA",
        "Memorial Sloan Kettering Cancer Center, New York, New York, USA",
        "Tata Memorial Hospital, Mumbai, India",
        "University of Insubria, Varese, Italy",
        "Beijing Tongren Hospital, Beijing, China",
        "University of Brescia, Brescia, Italy",
        "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
        "Head and Neck Reference Center, AC Camargo, Brazil",
        "Tel-Aviv University, Tel Aviv, Israel",
        "University Health Network, Toronto, Ontario, Canada",
        "Hispital Lariboisiere APHP, Paris, France",
        "University of Milan, Milan, Italy",
        "12 de Octubre University Hospital, Madrid, Spain",
        "Atilim University, Medicana International Ankara, Ankara, Turkey",
        "Amrita Institute of Medical Sciences, Kochi, India",
        "Sydney Ear Nose Throat Clinic, Darlinghurst, NewSouth Wales, Australia",
        "Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands",
        "Hospital Italiano de Buenos Aires, Buenos Aires, Argentina",
        "Kobe University Graduate School of Medicine, Kobe, Japan",
        "Imperial College Health care NHS Trust, Charing Cross Hospital, London, UK",
        "Beijing Cancer Center, Beijing, China",
        "Hospital Israelita Albert Einstein, São Paulo, SP, Brazil",
        "ICESP, São Paulo, Brazil",
        "Medical University of South Carolina, Charleston, South Carolina, USA",
        "Instituto Nacional de Câncer, Rio de Janeiro, Brazil",
        "University of Miami, Florida, USA",
        "University of Birmingham, University Hospitals Birmingham, Birmingham, UK",
        "The Greater Poland Cancer Centre, Poznan, Poland",
        "Yonsei University Health System, Seoul, South Korea"
      ],
      "session_type": "Proffered Paper",
      "track": "Nasopharynx / Paranasal Sinus / Skull Base",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Nasopharynx / Paranasal Sinus / Skull Base"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 420,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Shorook Naara, MD, PhD 1 ; Ehab Hanna 1 ; Shirly Y Su 1 ; Shaan M Raza 1 ; Franco DeMonte 1 ; Helena Levyn 2 ; Cristina Valero 2 ; Dauren Adilbay 2 ; Alana Eagan 2 ; Marc Cohen 2 ; Snehal Patel 2 ; Ian Ganly 2 ; Prathamesh Pai 3 ; Paolo Castelnuovo 4 ; Fang Jugao 5 ; Cesare Piazza 6 ; Piero Nicolai 6 ; Ben Panizza 7 ; James Bowman 7 ; Catherine Barnett 7 ; Luiz P Kowalski 8 ; Ronaldo Toledo 8 ; Dan M Fliss 9 ; John DeAlmeida 10 ; Ian Witterick 10 ; Philippe Herman 11 ; Walter Fontanella 12 ; Gregorio S Aniceto 13 ; Sefik Hosal 14 ; Serdar Ozer 14 ; Subramania Iyer 15 ; Richard Harvey 16 ; C. Rene Leemans 17 ; Jan-Jaap Hendrickx 17 ; Marcelo Figari 18 ; Luis Boccalatte 18 ; Ken Ichi Nibu 19 ; Peter Clarke 20 ; Catherine Rennie 20 ; Zhu Yi Ming 21 ; Claudio Cernea 22 ; Sergio Goncalves 23 ; Rodney Schlosser 24 ; Fernando Diaz 25 ; Zoukaa Sargi 26 ; Shahzada Ahmed 27 ; Wojciech Golusinski 28 ; Se Heon Kim 29 ; Jatin P Shah 2",
        "Affiliations": "1 UT MD Anderson Cancer Center, Houston, Texas, USA; 2 Memorial Sloan Kettering Cancer Center, New York, New York, USA; 3 Tata Memorial Hospital, Mumbai, India; 4 University of Insubria, Varese, Italy; 5 Beijing Tongren Hospital, Beijing, China; 6 University of Brescia, Brescia, Italy; 7 Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; 8 Head and Neck Reference Center, AC Camargo, Brazil; 9 Tel-Aviv University, Tel Aviv, Israel; 10 University Health Network, Toronto, Ontario, Canada; 11 Hispital Lariboisiere APHP, Paris, France; 12 University of Milan, Milan, Italy; 13 12 de Octubre University Hospital, Madrid, Spain; 14 Atilim University, Medicana International Ankara, Ankara, Turkey; 15 Amrita Institute of Medical Sciences, Kochi, India; 16 Sydney Ear Nose Throat Clinic, Darlinghurst, NewSouth Wales, Australia; 17 Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands; 18 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 19 Kobe University Graduate School of Medicine, Kobe, Japan; 20 Imperial College Health care NHS Trust, Charing Cross Hospital, London, UK; 21 Beijing Cancer Center, Beijing, China; 22 Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; 23 ICESP, São Paulo, Brazil; 24 Medical University of South Carolina, Charleston, South Carolina, USA; 25 Instituto Nacional de Câncer, Rio de Janeiro, Brazil; 26 University of Miami, Florida, USA; 27 University of Birmingham, University Hospitals Birmingham, Birmingham, UK; 28 The Greater Poland Cancer Centre, Poznan, Poland; 29 Yonsei University Health System, Seoul, South Korea",
        "Introduction": "Sinonasal squamous cell carcinoma involving the skull base represents a rare and aggressive malignancy with persistently limited survival despite advances in surgery, reconstruction, radiotherapy, and systemic therapy. Contemporary, large-scale data remain limited. This study evaluates long-term outcomes and prognostic factors in a large, international, multi-institutional cohort of surgically treated patients.",
        "Methods": "A retrospective international collaborative study included patients with histologically confirmed sinonasal squamous cell carcinoma involving the skull base treated surgically between 1995 and 2015 at 28 institutions. Overall survival, disease-specific survival, recurrence-free survival, and local recurrence–free survival were estimated using Kaplan–Meier methods. Multivariable Cox regression identified independent prognostic factors. Nomograms were developed to estimate individualized survival probabilities and internally validated using bootstrap resampling.",
        "Results": "A total of 867 patients were included with a median age of 59 years (range, 12–97) and a median follow-up of 54 months. Most tumors were locally advanced, with 66.2% classified as pT4 and 7.8% presenting with regional nodal metastases. The most frequent primary sites were the maxillary sinus (35.8%), ethmoid sinus (20.9%), and nasal cavity (15.5%). Surgical approaches included open (70.7%), endoscopic (22.4%), and combined approaches (6.9%). Orbital involvement was present in 51.4% of patients and intracranial extension in 51.9%. Adjuvant radiotherapy was administered in 28.8% of patients, while 28.7% received multimodality chemoradiation.",
        "Abstract": "Five-year OS was 42.6%, DSS 52.7%, RFS 48.6%, and LRFS 61.1%. Survival differed significantly by tumor epicenter, with nasal cavity tumors demonstrating the most favorable outcomes. Negative surgical margins were achieved in 53.6% of cases and were strongly associated with improved survival across all endpoints (p<0.01). Orbital invasion, intracranial extension, and regional nodal metastases were associated with significantly worse survival outcomes. On multivariable analysis, younger age, negative nodal status, use of adjuvant radiotherapy, and negative surgical margins independently predicted improved OS and DSS. In contrast, maxillary sinus origin and intracranial invasion were independently associated with worse survival. Prognostic models derived from the multivariable Cox analysis demonstrated good discriminatory performance (C-index 0.698 for OS and 0.691 for DSS). Nomograms constructed from these models provided individualized predictions of 3-, 5-, and 8-year survival probabilities. Risk stratification using model-derived scores separated patients into low-, intermediate-, and high-risk groups with significantly distinct survival outcomes (log-rank p<0.001). View in Agenda and Add to Schedule",
        "Conclusions": "Survival for sinonasal squamous cell carcinoma involving the skull base remains modest. Risk stratification tools derived from this large cohort support individualized treatment planning and future trial design."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Determinants in Surgically Treated Sinonasal Squamous Cell Carcinoma involving the Skull Base: An International Multi-Institutional Collaborative Study</span>. <u>Shorook Naara, MD, PhD</u><sup>1</sup>; Ehab Hanna<sup>1</sup>; Shirly Y Su<sup>1</sup>; Shaan M Raza<sup>1</sup>; Franco DeMonte<sup>1</sup>; Helena Levyn<sup>2</sup>; Cristina Valero<sup>2</sup>; Dauren Adilbay<sup>2</sup>; Alana Eagan<sup>2</sup>; Marc Cohen<sup>2</sup>; Snehal Patel<sup>2</sup>; Ian Ganly<sup>2</sup>; Prathamesh Pai<sup>3</sup>; Paolo Castelnuovo<sup>4</sup>; Fang Jugao<sup>5</sup>; Cesare Piazza<sup>6</sup>; Piero Nicolai<sup>6</sup>; Ben Panizza<sup>7</sup>; James Bowman<sup>7</sup>; Catherine Barnett<sup>7</sup>; Luiz P Kowalski<sup>8</sup>; Ronaldo Toledo<sup>8</sup>; Dan M Fliss<sup>9</sup>; John DeAlmeida<sup>10</sup>; Ian Witterick<sup>10</sup>; Philippe Herman<sup>11</sup>; Walter Fontanella<sup>12</sup>; Gregorio S Aniceto<sup>13</sup>; Sefik Hosal<sup>14</sup>; Serdar Ozer<sup>14</sup>; Subramania Iyer<sup>15</sup>; Richard Harvey<sup>16</sup>; C. Rene Leemans<sup>17</sup>; Jan-Jaap Hendrickx<sup>17</sup>; Marcelo Figari<sup>18</sup>; Luis Boccalatte<sup>18</sup>; Ken Ichi Nibu<sup>19</sup>; Peter Clarke<sup>20</sup>; Catherine Rennie<sup>20</sup>; Zhu Yi Ming<sup>21</sup>; Claudio Cernea<sup>22</sup>; Sergio Goncalves<sup>23</sup>; Rodney Schlosser<sup>24</sup>; Fernando Diaz<sup>25</sup>; Zoukaa Sargi<sup>26</sup>; Shahzada Ahmed<sup>27</sup>; Wojciech Golusinski<sup>28</sup>; Se Heon Kim<sup>29</sup>; Jatin P Shah<sup>2</sup>. <sup>1</sup>UT MD Anderson Cancer Center, Houston, Texas, USA; <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, New York, USA; <sup>3</sup>Tata Memorial Hospital, Mumbai, India; <sup>4</sup>University of Insubria, Varese, Italy; <sup>5</sup>Beijing Tongren Hospital, Beijing, China; <sup>6</sup>University of Brescia, Brescia, Italy; <sup>7</sup>Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; <sup>8</sup>Head and Neck Reference Center, AC Camargo, Brazil; <sup>9</sup>Tel-Aviv University, Tel Aviv, Israel; <sup>10</sup>University Health Network, Toronto, Ontario, Canada; <sup>11</sup>Hispital Lariboisiere APHP, Paris, France; <sup>12</sup>University of Milan, Milan, Italy; <sup>13</sup>12 de Octubre University Hospital, Madrid, Spain; <sup>14</sup>Atilim University, Medicana International Ankara, Ankara, Turkey; <sup>15</sup>Amrita Institute of Medical Sciences, Kochi, India; <sup>16</sup>Sydney Ear Nose Throat Clinic, Darlinghurst, NewSouth Wales, Australia; <sup>17</sup>Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands; <sup>18</sup>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; <sup>19</sup>Kobe University Graduate School of Medicine, Kobe, Japan; <sup>20</sup>Imperial College Health care NHS Trust, Charing Cross Hospital, London, UK; <sup>21</sup>Beijing Cancer Center, Beijing, China; <sup>22</sup>Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; <sup>23</sup>ICESP, São Paulo, Brazil; <sup>24</sup>Medical University of South Carolina, Charleston, South Carolina, USA; <sup>25</sup>Instituto Nacional de Câncer, Rio de Janeiro, Brazil; <sup>26</sup>University of Miami, Florida, USA; <sup>27</sup>University of Birmingham, University Hospitals Birmingham, Birmingham, UK; <sup>28</sup>The Greater Poland Cancer Centre, Poznan, Poland; <sup>29</sup>Yonsei University Health System, Seoul, South Korea<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Sinonasal squamous cell carcinoma involving the skull base represents a rare and aggressive malignancy with persistently limited survival despite advances in surgery, reconstruction, radiotherapy, and systemic therapy. Contemporary, large-scale data remain limited. This study evaluates long-term outcomes and prognostic factors in a large, international, multi-institutional cohort of surgically treated patients.</p>\n\n<p><strong>Methods</strong>: A retrospective international collaborative study included patients with histologically confirmed sinonasal squamous cell carcinoma involving the skull base treated surgically between 1995 and 2015 at 28 institutions. Overall survival, disease-specific survival, recurrence-free survival, and local recurrence–free survival were estimated using Kaplan–Meier methods. Multivariable Cox regression identified independent prognostic factors. Nomograms were developed to estimate individualized survival probabilities and internally validated using bootstrap resampling.</p>\n\n<p><strong>Results</strong>: A total of 867 patients were included with a median age of 59 years (range, 12–97) and a median follow-up of 54 months. Most tumors were locally advanced, with 66.2% classified as pT4 and 7.8% presenting with regional nodal metastases. The most frequent primary sites were the maxillary sinus (35.8%), ethmoid sinus (20.9%), and nasal cavity (15.5%). Surgical approaches included open (70.7%), endoscopic (22.4%), and combined approaches (6.9%). Orbital involvement was present in 51.4% of patients and intracranial extension in 51.9%. Adjuvant radiotherapy was administered in 28.8% of patients, while 28.7% received multimodality chemoradiation.</p>\n\n<p>Five-year OS was 42.6%, DSS 52.7%, RFS 48.6%, and LRFS 61.1%. Survival differed significantly by tumor epicenter, with nasal cavity tumors demonstrating the most favorable outcomes. Negative surgical margins were achieved in 53.6% of cases and were strongly associated with improved survival across all endpoints (p<0.01). Orbital invasion, intracranial extension, and regional nodal metastases were associated with significantly worse survival outcomes. On multivariable analysis, younger age, negative nodal status, use of adjuvant radiotherapy, and negative surgical margins independently predicted improved OS and DSS. In contrast, maxillary sinus origin and intracranial invasion were independently associated with worse survival.</p>\n\n<p>Prognostic models derived from the multivariable Cox analysis demonstrated good discriminatory performance (C-index 0.698 for OS and 0.691 for DSS). Nomograms constructed from these models provided individualized predictions of 3-, 5-, and 8-year survival probabilities. Risk stratification using model-derived scores separated patients into low-, intermediate-, and high-risk groups with significantly distinct survival outcomes (log-rank p<0.001).</p>\n\n<p><strong>Conclusions</strong>: Survival for sinonasal squamous cell carcinoma involving the skull base remains modest. Risk stratification tools derived from this large cohort support individualized treatment planning and future trial design.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155388--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S452",
      "content_id": "154727",
      "abstract_number": "S452",
      "poster_number": "",
      "title": "Pediatric Head and Neck NUT Carcinoma: A Systematic Review and Individual Patient Data Analysis of Clinicopathologic Features, Treatment Strategies, and Survival Outcomes",
      "summary": "Pediatric head and neck NUT carcinoma demonstrates highly aggressive behavior with poor survival. Metastasis at presentation and treatment response—particularly PD—are the principal prognostic determinants, while the benefit of resection appears dependent on achieving a favorable biological response. These findings support early diagnosis, aggressive multimodality therapy, and incorporation of emerging targeted...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154727",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260150",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ebrahim Farashi, MD",
      "presenter": "Ebrahim Farashi, MD",
      "authors": "Ebrahim Farashi, MD 1 ; Maria Polania-Sandoval, MD 2 ; Gabriela Cendejas, MS 2 ; Kian Tartibi, MS 2 ; Joseph Lopez, MD 3",
      "normalized_authors": [
        "Ebrahim Farashi",
        "Maria Polania-Sandoval",
        "Gabriela Cendejas",
        "Kian Tartibi",
        "Joseph Lopez"
      ],
      "affiliations": [
        "Sinonasal and Skull Base Tumor Program, Division of Head and Neck Cancer, National Cancer Institute, National Institute of Health, Bethesda, MD, USA",
        "Adventhealth Orlando",
        "Department of Children’s Surgery, Division of Pediatric Head & Neck Surgery, AdventHealth for Children, Orlando, FL, USA"
      ],
      "normalized_institutions": [
        "Sinonasal and Skull Base Tumor Program, Division of Head and Neck Cancer, National Cancer Institute, National Institute of Health, Bethesda, MD, USA",
        "Adventhealth Orlando",
        "Department of Children’s Surgery, Division of Pediatric Head & Neck Surgery, AdventHealth for Children, Orlando, FL, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154727/Figure1_%20Multivariant%20Cox%20Regression.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154727/Figure1_%20Multivariant%20Cox%20Regression.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154727"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 527,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Ebrahim Farashi, MD 1 ; Maria Polania-Sandoval, MD 2 ; Gabriela Cendejas, MS 2 ; Kian Tartibi, MS 2 ; Joseph Lopez, MD 3",
        "Affiliations": "1 Sinonasal and Skull Base Tumor Program, Division of Head and Neck Cancer, National Cancer Institute, National Institute of Health, Bethesda, MD, USA; 2 Adventhealth Orlando; 3 Department of Children’s Surgery, Division of Pediatric Head & Neck Surgery, AdventHealth for Children, Orlando, FL, USA",
        "Background": "Pediatric head and neck NUT carcinoma is a very rare and aggressive epithelial malignancy driven by NUTM1 rearrangements. Limited, heterogeneous case-based reporting has constrained efforts to define its clinical spectrum and prognostic determinants. This study presents the first pooled individual–patient dataset focused exclusively on pediatric head and neck NUT carcinoma, enabling harmonized survival modeling using multivariable Cox and restricted mean survival time (RMST) approaches not previously reported.",
        "Methods": "Demographic, clinical, molecular, treatment, and outcome variables from published cases (age ≤21) were harmonized into a unified dataset. Tumor sites were consolidated into clinically relevant anatomic groups, and treatment modalities were categorized as surgery-based multimodality therapy, chemoradiotherapy (CRT)–based therapy, single-modality treatment, or no definitive therapy. Limited use of BET inhibitors and immunotherapy was documented but sample sizes were insufficient for analysis. Resection status was classified as R0 (complete), R1 (microscopically margin-positive), R2 (subtotal), or biopsy/no resection. Treatment response categories included Complete Response (CR), Partial Response (PR), and Progressive Disease (PD). Overall survival (OS) and event-free survival (EFS) were estimated via Kaplan–Meier analyses; predictors were evaluated using univariable and multivariable Cox models. RMST at 51 months quantified long-term survival differences.",
        "Results": "Forty-eight patients were included (median age 12.9 years; 52% male). Age distribution was skewed toward adolescents, with 50% in the permanent-dentition age group (>12 years). Sinonasal/orbital primaries comprised the largest subset (50%), followed by salivary gland (22.9%) and upper aerodigestive tract (18.8%) sites. Lymph-node involvement occurred in 43.7%, and distant metastasis at diagnosis in 37.5%. BRD4–NUTM1 fusion was the most common rearrangement (67.9%). Distant metastasis at diagnosis was strongly associated with inferior outcomes (EFS 2.5 vs 23.3 months, p=0.00021; OS 9.7 vs 30.2 months, p=0.005).",
        "Abstract": "Treatment response was the strongest discriminator of survival. Median OS was not reached for CR, whereas PD had a median OS of 10 months (log-rank p=2×10?5). RMST demonstrated marked long-term separation (CR 47.1 vs PD 14.6 months). Resection status influenced OS (global p=0.05), with R0 showing more favorable outcomes. In univariable Cox analyses, metastasis (HR 2.85, p=0.0069), biopsy/no resection vs R0 (HR 3.14, p=0.041), and PD vs CR (HR 18.30, p=0.004) were significant predictors of OS, whereas age (p=0.86) and treatment modality (p=0.55) were not. Multivariable models confirmed metastasis as an independent predictor of mortality, with HR 3.27 (95% CI 1.31–8.17; p=0.011). Incorporating treatment response showed PD to be the dominant determinant of mortality, with HR 24.68 (95% CI 2.99–203.91; p=0.003), while resection status lost statistical significance, suggesting mediation through biological responsiveness. No proportional hazards violations were detected. View in Agenda and Add to Schedule",
        "Conclusion": "Pediatric head and neck NUT carcinoma demonstrates highly aggressive behavior with poor survival. Metastasis at presentation and treatment response—particularly PD—are the principal prognostic determinants, while the benefit of resection appears dependent on achieving a favorable biological response. These findings support early diagnosis, aggressive multimodality therapy, and incorporation of emerging targeted or immune-based strategies in future management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pediatric Head and Neck NUT Carcinoma: A Systematic Review and Individual Patient Data Analysis of Clinicopathologic Features, Treatment Strategies, and Survival Outcomes</span>. <u>Ebrahim Farashi, MD</u><sup>1</sup>; Maria Polania-Sandoval, MD<sup>2</sup>; Gabriela Cendejas, MS<sup>2</sup>; Kian Tartibi, MS<sup>2</sup>; Joseph Lopez, MD<sup>3</sup>. <sup>1</sup>Sinonasal and Skull Base Tumor Program, Division of Head and Neck Cancer, National Cancer Institute, National Institute of Health, Bethesda, MD, USA; <sup>2</sup>Adventhealth Orlando; <sup>3</sup>Department of Children’s Surgery, Division of Pediatric Head & Neck Surgery, AdventHealth for Children, Orlando, FL, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Pediatric head and neck NUT carcinoma is a very rare and aggressive epithelial malignancy driven by NUTM1 rearrangements. Limited, heterogeneous case-based reporting has constrained efforts to define its clinical spectrum and prognostic determinants. This study presents the first pooled individual–patient dataset focused exclusively on pediatric head and neck NUT carcinoma, enabling harmonized survival modeling using multivariable Cox and restricted mean survival time (RMST) approaches not previously reported.</p>\n\n<p><strong>Methods: </strong>Demographic, clinical, molecular, treatment, and outcome variables from published cases (age ≤21) were harmonized into a unified dataset. Tumor sites were consolidated into clinically relevant anatomic groups, and treatment modalities were categorized as surgery-based multimodality therapy, chemoradiotherapy (CRT)–based therapy, single-modality treatment, or no definitive therapy. Limited use of BET inhibitors and immunotherapy was documented but sample sizes were insufficient for analysis. Resection status was classified as R0 (complete), R1 (microscopically margin-positive), R2 (subtotal), or biopsy/no resection. Treatment response categories included Complete Response (CR), Partial Response (PR), and Progressive Disease (PD). Overall survival (OS) and event-free survival (EFS) were estimated via Kaplan–Meier analyses; predictors were evaluated using univariable and multivariable Cox models. RMST at 51 months quantified long-term survival differences.</p>\n\n<p><strong>Results: </strong>Forty-eight patients were included (median age 12.9 years; 52% male). Age distribution was skewed toward adolescents, with 50% in the permanent-dentition age group (>12 years). Sinonasal/orbital primaries comprised the largest subset (50%), followed by salivary gland (22.9%) and upper aerodigestive tract (18.8%) sites. Lymph-node involvement occurred in 43.7%, and distant metastasis at diagnosis in 37.5%. BRD4–NUTM1 fusion was the most common rearrangement (67.9%). Distant metastasis at diagnosis was strongly associated with inferior outcomes (EFS 2.5 vs 23.3 months, p=0.00021; OS 9.7 vs 30.2 months, p=0.005).</p>\n\n<p>Treatment response was the strongest discriminator of survival. Median OS was not reached for CR, whereas PD had a median OS of 10 months (log-rank p=2×10?5). RMST demonstrated marked long-term separation (CR 47.1 vs PD 14.6 months). Resection status influenced OS (global p=0.05), with R0 showing more favorable outcomes.</p>\n\n<p>In univariable Cox analyses, metastasis (HR 2.85, p=0.0069), biopsy/no resection vs R0 (HR 3.14, p=0.041), and PD vs CR (HR 18.30, p=0.004) were significant predictors of OS, whereas age (p=0.86) and treatment modality (p=0.55) were not. Multivariable models confirmed metastasis as an independent predictor of mortality, with HR 3.27 (95% CI 1.31–8.17; p=0.011). Incorporating treatment response showed PD to be the dominant determinant of mortality, with HR 24.68 (95% CI 2.99–203.91; p=0.003), while resection status lost statistical significance, suggesting mediation through biological responsiveness. No proportional hazards violations were detected.</p>\n\n<p><strong>Conclusion: </strong>Pediatric head and neck NUT carcinoma demonstrates highly aggressive behavior with poor survival. Metastasis at presentation and treatment response—particularly PD—are the principal prognostic determinants, while the benefit of resection appears dependent on achieving a favorable biological response. These findings support early diagnosis, aggressive multimodality therapy, and incorporation of emerging targeted or immune-based strategies in future management.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154727/Figure1_%20Multivariant%20Cox%20Regression.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154727--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260150' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S453",
      "content_id": "153364",
      "abstract_number": "S453",
      "poster_number": "",
      "title": "Pre-operative lymphocyte-to-monocyte ratio predicts recurrence for head and neck melanoma",
      "summary": "A pre-operative LMR of >3 predicted improved 3-year RFS following WLE of head and neck melanoma. These data support the notion that pre-operative CBC-derived inflammatory markers have the potential to serve as cost-effective and accessible predictors of outcomes in head and neck melanoma.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153364",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Akshaya Raman, BA",
      "presenter": "Akshaya Raman, BA",
      "authors": "Akshaya Raman, BA 1 ; Micah K Harris, MD 2 ; Shivam D Patel, MD 2 ; Joshua D Smith, MD 2 ; Steven B Chinn, MD 2 ; Jessica Maxwell, MD 2 ; Kevin J Contrera, MD, MPH 2 ; Matthew E Spector, MD 2 ; Diwakar Davar, MD 2 ; Shaum S Sridharan, MD 2",
      "normalized_authors": [
        "Akshaya Raman",
        "Micah K Harris",
        "Shivam D Patel",
        "Joshua D Smith",
        "Steven B Chinn",
        "Jessica Maxwell",
        "Kevin J Contrera",
        "Matthew E Spector",
        "Diwakar Davar",
        "Shaum S Sridharan"
      ],
      "affiliations": [
        "University of Pittsburgh School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"
      ],
      "normalized_institutions": [
        "University of Pittsburgh School of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153364/RFS_LMR_melanoma(2).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153364/RFS_LMR_melanoma(2).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153364"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 512,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Akshaya Raman, BA 1 ; Micah K Harris, MD 2 ; Shivam D Patel, MD 2 ; Joshua D Smith, MD 2 ; Steven B Chinn, MD 2 ; Jessica Maxwell, MD 2 ; Kevin J Contrera, MD, MPH 2 ; Matthew E Spector, MD 2 ; Diwakar Davar, MD 2 ; Shaum S Sridharan, MD 2",
        "Affiliations": "1 University of Pittsburgh School of Medicine; 2 Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA",
        "Introduction": "Complete blood count (CBC)-derived inflammatory markers such as lymphocyte-to-monocyte ratio (LMR) have consistently been shown to prognosticate survival in head and neck cancer, potentially due to shifts in the tumor-specific innate and adaptive immune response being reflected systemically in peripheral blood. The relationship for such markers is particularly relevant in highly immunogenic cancers such as melanoma. Despite this, the role of perioperative CBC-derived inflammatory markers has not been investigated in head and neck melanoma.",
        "Methods": "A retrospective review of patients who underwent wide local excision (WLE) for head and neck melanoma from November 2012 to December 2024 was performed. Pre-operative CBCs were collected within 6 months of surgery. Exclusion criteria included perioperative steroid use or hematologic abnormalities. Data collected included age, race, smoking status at diagnosis, histopathology, adjuvant therapy, pre-operative CBC, T and N category, follow-up duration, recurrence-free survival (RFS), and overall survival (OS). LMR (lymphocytes/monocytes), neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and pan-immune-inflammation were calculated. Survival analysis was performed with Kaplan-Meier analysis with log-rank testing and Cox regression analyses. Receiver operating characteristic (ROC) curve analyses were performed to identify optimal thresholds.",
        "Results": "Sixty-nine patients were included (71% male, 98.6% Caucasian, 65 ±17 years old) who had pre-operative CBCs collected at a median of 15 days (IQR 17 days) prior to surgery. The mean follow-up was 1,719 days (SD 948; range 3,340 days). Of this cohort, 21 patients (30.4%) had a smoking history, 15 (21.7%) received adjuvant immunotherapy, and no patients received neoadjuvant immunotherapy. There were 17 T1 (24.6%), 21 T2 (30.4%), 21 T3 (30.4%), and 10 T4 (14.5%) tumors. Ulceration was present in 28 (40.6%), and 46 (68.7%) had a mitotic rate >1/mm². Overall, 3-year RFS and OS were 57.9% and 75.3%, respectively. The average LMR was higher in those who remained recurrence-free at 3-years (3.56 ±1.3 vs. 2.80 ±1.5, P=0.03), and in those who remained alive at 3-years (3.43±1.5 vs. 2.65±1.2, P=0.049). The remaining CBC-derived inflammatory markers did not differ with recurrence or survival (all P>0.05). On ROC analysis, the optimal threshold for LMR to predict 3-year RFS was 3 (AUC 0.73, sensitivity 0.63, specificity 0.85). Using this threshold, patients with LMR >3 demonstrated lower 3-year recurrence (27.8% vs 60.0% HR 0.34, 95% CI 0.15-0.76, log-rank P=0.009) on Kaplan-Meier analysis and remained independently associated with lower recurrence (HR 0.33, 95% CI 0.12–0.88, P=0.026) on multivariable Cox regression when controlling for age, gender, T category, adjuvant immunotherapy, and smoking. For 3-year OS, no significant difference was observed between LMR ≤3 and LMR >3 groups (P=0.21).",
        "Conclusion": "A pre-operative LMR of >3 predicted improved 3-year RFS following WLE of head and neck melanoma. These data support the notion that pre-operative CBC-derived inflammatory markers have the potential to serve as cost-effective and accessible predictors of outcomes in head and neck melanoma.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pre-operative lymphocyte-to-monocyte ratio predicts recurrence for head and neck melanoma</span>. <u>Akshaya Raman, BA</u><sup>1</sup>; Micah K Harris, MD<sup>2</sup>; Shivam D Patel, MD<sup>2</sup>; Joshua D Smith, MD<sup>2</sup>; Steven B Chinn, MD<sup>2</sup>; Jessica Maxwell, MD<sup>2</sup>; Kevin J Contrera, MD, MPH<sup>2</sup>; Matthew E Spector, MD<sup>2</sup>; Diwakar Davar, MD<sup>2</sup>; Shaum S Sridharan, MD<sup>2</sup>. <sup>1</sup>University of Pittsburgh School of Medicine; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Complete blood count (CBC)-derived inflammatory markers such as lymphocyte-to-monocyte ratio (LMR) have consistently been shown to prognosticate survival in head and neck cancer, potentially due to shifts in the tumor-specific innate and adaptive immune response being reflected systemically in peripheral blood.  The relationship for such markers is particularly relevant in highly immunogenic cancers such as melanoma. Despite this, the role of perioperative CBC-derived inflammatory markers has not been investigated in head and neck melanoma.</p>\n\n<p><strong>Methods</strong>: A retrospective review of patients who underwent wide local excision (WLE) for head and neck melanoma from November 2012 to December 2024 was performed. Pre-operative CBCs were collected within 6 months of surgery. Exclusion criteria included perioperative steroid use or hematologic abnormalities. Data collected included age, race, smoking status at diagnosis, histopathology, adjuvant therapy, pre-operative CBC, T and N category, follow-up duration, recurrence-free survival (RFS), and overall survival (OS). LMR (lymphocytes/monocytes), neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and pan-immune-inflammation were calculated. Survival analysis was performed with Kaplan-Meier analysis with log-rank testing and Cox regression analyses. Receiver operating characteristic (ROC) curve analyses were performed to identify optimal thresholds.</p>\n\n<p><strong>Results</strong>: Sixty-nine patients were included (71% male, 98.6% Caucasian, 65 ±17 years old) who had pre-operative CBCs collected at a median of 15 days (IQR 17 days) prior to surgery. The mean follow-up was 1,719 days (SD 948; range 3,340 days). Of this cohort, 21 patients (30.4%) had a smoking history, 15 (21.7%) received adjuvant immunotherapy, and no patients received neoadjuvant immunotherapy. There were 17 T1 (24.6%), 21 T2 (30.4%), 21 T3 (30.4%), and 10 T4 (14.5%) tumors. Ulceration was present in 28 (40.6%), and 46 (68.7%) had a mitotic rate >1/mm². Overall, 3-year RFS and OS were 57.9% and 75.3%, respectively. The average LMR was higher in those who remained recurrence-free at 3-years (3.56 ±1.3 vs. 2.80 ±1.5, P=0.03), and in those who remained alive at 3-years (3.43±1.5 vs. 2.65±1.2, P=0.049). The remaining CBC-derived inflammatory markers did not differ with recurrence or survival (all P>0.05). On ROC analysis, the optimal threshold for LMR to predict 3-year RFS was 3 (AUC 0.73, sensitivity 0.63, specificity 0.85). Using this threshold, patients with LMR >3 demonstrated lower 3-year recurrence (27.8% vs 60.0% HR 0.34, 95% CI 0.15-0.76, log-rank P=0.009) on Kaplan-Meier analysis and remained independently associated with lower recurrence (HR 0.33, 95% CI 0.12–0.88, P=0.026) on multivariable Cox regression when controlling for age, gender, T category, adjuvant immunotherapy, and smoking.  For 3-year OS, no significant difference was observed between LMR ≤3 and LMR >3 groups (P=0.21).</p>\n\n<p><strong>Conclusion</strong>: A pre-operative LMR of >3 predicted improved 3-year RFS following WLE of head and neck melanoma. These data support the notion that pre-operative CBC-derived inflammatory markers have the potential to serve as cost-effective and accessible predictors of outcomes in head and neck melanoma.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153364/RFS_LMR_melanoma(2).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153364--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S454",
      "content_id": "154594",
      "abstract_number": "S454",
      "poster_number": "",
      "title": "Variables Associated with Residual Disease in Head and Neck Cutaneous Melanoma",
      "summary": "Residual pigmentation persisting after biopsy, positive peripheral or deep margins on the initial biopsy, and mitotic activity were associated with the presence of RD in HNCM. Combining information from these 3 factors helps stratify patients into 3 distinct risk groups for residual disease. Identification of patients with a high likelihood of not having residual disease may be candidates for less aggressive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154594",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amna Ramadan",
      "presenter": "Amna Ramadan",
      "authors": "Amna Ramadan ; Salma Ramadan; Ankit Chhajed; Dorina Kallogjeri; Jason Rich",
      "normalized_authors": [
        "Amna Ramadan",
        "Salma Ramadan",
        "Ankit Chhajed",
        "Dorina Kallogjeri",
        "Jason Rich"
      ],
      "affiliations": [
        "Washington University"
      ],
      "normalized_institutions": [
        "Washington University"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 504,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amna Ramadan ; Salma Ramadan; Ankit Chhajed; Dorina Kallogjeri; Jason Rich",
        "Affiliations": "Washington University",
        "Background": "The potential for subclinical (non-visible) disease extending beyond the melanoma lesion, as well as the inability to assess margins intraoperatively, drives the recommendation of wide surgical margins around melanomas. Yet, this quandary often results in either excessive resection of normal tissue or positive surgical margins. In addition, reconstruction is frequently delayed until clear margins are confirmed, requiring patients to manage an open surgical wound and undergo a second surgical procedure. Identifying risk factors associated with residual disease in head and neck cutaneous melanoma or melanoma in situ (HNCM) following the initial biopsy is crucial for creating novel approaches for margin management and timing of reconstruction.",
        "Objective": "To describe the rate of residual disease (RD) and the extent of subclinical disease (non-visible) in resection specimens of HNCM, as well as identify patient and pathological variables associated with RD.",
        "Methods": "A retrospective cohort study at a single academic center of patients surgically treated for HNCM between 2017 and 2024 was performed. Demographics, physical exam findings, pathological features, and resection data were collected through chart review. Residual disease was defined as melanoma or melanoma in situ present in the oncologic resection. Logistic regression was conducted to explore the association of variables with residual disease. Odds ratios (OR) with 95% confidence intervals (CIs) were reported. Conjunctive consolidation was used to classify patients into risk categories based on important risk factors identified.",
        "Results": "Of the 288 eligible patients, 177 patients (61.5%) had RD in the oncologic resection specimen. Fourteen patients (4.9%) had positive margins on oncologic resection (13 with melanoma in situ and 1 with invasive melanoma at the margin). The average extent of subclinical disease was 6.45 mm. 66 (23%) patients had staged reconstruction. Factors associated with residual disease were residual pigmentation persisting after biopsy (OR 4.50; 95% CI 2.71-7.52), positive peripheral margins on the initial biopsy report (OR 5.60; 95% CI 2.55-12.27), positive deep margins on the initial biopsy report (OR 3.21; 95% CI 1.80-5.74), and mitotic rate ≥1 on biopsy report (OR 2.24; 95% CI 1.34-3.79). Conjunctive consolidation was used to stratify patients into 3 risk groups: Patients with residual pigmentation, peripheral margins, and deep margins had the highest rate of RD (84%). Among patients with any two of the factors in the pathology report (deep margins, residual pigmentation, peripheral margin) the RD rate was 62%, and among patients with at most one of the three factors the rate of RD was 33%. The risk stratification system had good discriminative power with c-index=0.74 (95% CI: 0.66 to 0.82)",
        "Conclusion": "Residual pigmentation persisting after biopsy, positive peripheral or deep margins on the initial biopsy, and mitotic activity were associated with the presence of RD in HNCM. Combining information from these 3 factors helps stratify patients into 3 distinct risk groups for residual disease. Identification of patients with a high likelihood of not having residual disease may be candidates for less aggressive margins and immediate reconstruction.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Variables Associated with Residual Disease in Head and Neck Cutaneous Melanoma</span>. <u>Amna Ramadan</u>; Salma Ramadan; Ankit Chhajed; Dorina Kallogjeri; Jason Rich. Washington University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The potential for subclinical (non-visible) disease extending beyond the melanoma lesion, as well as the inability to assess margins intraoperatively, drives the recommendation of wide surgical margins around melanomas. Yet, this quandary often results in either excessive resection of normal tissue or positive surgical margins. In addition, reconstruction is frequently delayed until clear margins are confirmed, requiring patients to manage an open surgical wound and undergo a second surgical procedure. Identifying risk factors associated with residual disease in head and neck cutaneous melanoma or melanoma in situ (HNCM) following the initial biopsy is crucial for creating novel approaches for margin management and timing of reconstruction.</p>\n\n<p><strong>Objective: </strong>To describe the rate of residual disease (RD) and the extent of subclinical disease (non-visible) in resection specimens of HNCM, as well as identify patient and pathological variables associated with RD.</p>\n\n<p><strong>Methods:</strong> A retrospective cohort study at a single academic center of patients surgically treated for HNCM between 2017 and 2024 was performed. Demographics, physical exam findings, pathological features, and resection data were collected through chart review. Residual disease was defined as melanoma or melanoma in situ present in the oncologic resection. Logistic regression was conducted to explore the association of variables with residual disease. Odds ratios (OR) with 95% confidence intervals (CIs) were reported. Conjunctive consolidation was used to classify patients into risk categories based on important risk factors identified.</p>\n\n<p><strong>Results: </strong>Of the 288 eligible patients, 177 patients (61.5%) had RD in the oncologic resection specimen. Fourteen patients (4.9%) had positive margins on oncologic resection (13 with melanoma in situ and 1 with invasive melanoma at the margin). The average extent of subclinical disease was 6.45 mm. 66 (23%) patients had staged reconstruction. Factors associated with residual disease were residual pigmentation persisting after biopsy (OR 4.50; 95% CI 2.71-7.52), positive peripheral margins on the initial biopsy report (OR 5.60; 95% CI 2.55-12.27), positive deep margins on the initial biopsy report (OR 3.21; 95% CI 1.80-5.74), and mitotic rate ≥1 on biopsy report (OR 2.24; 95% CI 1.34-3.79). Conjunctive consolidation was used to stratify patients into 3 risk groups: Patients with residual pigmentation, peripheral margins, and deep margins had the highest rate of RD (84%). Among patients with any two of the factors in the pathology report (deep margins, residual pigmentation, peripheral margin) the RD rate was 62%, and among patients with at most one of the three factors the rate of RD was 33%. The risk stratification system had good discriminative power with c-index=0.74 (95% CI: 0.66 to 0.82)</p>\n\n<p><strong>Conclusion: </strong>Residual pigmentation persisting after biopsy, positive peripheral or deep margins on the initial biopsy, and mitotic activity were associated with the presence of RD in HNCM. Combining information from these 3 factors helps stratify patients into 3 distinct risk groups for residual disease. Identification of patients with a high likelihood of not having residual disease may be candidates for less aggressive margins and immediate reconstruction.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154594--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S455",
      "content_id": "152049",
      "abstract_number": "S455",
      "poster_number": "",
      "title": "Imputed Immune Niche Scores are Associated with Pathologic Response to Immune Checkpoint Blockade in Cutaneous Squamous Cell Carcinoma",
      "summary": "Using deep learning to impute transcriptomic features from H&E images, we derived immune niche scores that demonstrated meaningful ability to distinguish responders from non-responders to ICB in cSCC. This approach shows promise as a scalable, tissue-efficient biomarker and merits evaluation in expanded cohorts and other malignancies. Further optimization of the analysis pipeline is underway to improve predictive...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152049",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Maxwell Y Lee",
      "presenter": "Maxwell Y Lee",
      "authors": "Maxwell Y Lee 1 ; Luis Martinez Ramirez 1 ; Mobeen Rahman 2 ; John B Sunwoo 1 ; Vasu Divi 1",
      "normalized_authors": [
        "Maxwell Y Lee",
        "Luis Martinez Ramirez",
        "Mobeen Rahman",
        "John B Sunwoo",
        "Vasu Divi"
      ],
      "affiliations": [
        "Stanford University School of Medicine, Department of Otolaryngology - Head and Neck Surgery",
        "Stanford University School of Medicine, Department of Pathology"
      ],
      "normalized_institutions": [
        "Stanford University School of Medicine, Department of Otolaryngology - Head and Neck Surgery",
        "Stanford University School of Medicine, Department of Pathology"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 519,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Maxwell Y Lee 1 ; Luis Martinez Ramirez 1 ; Mobeen Rahman 2 ; John B Sunwoo 1 ; Vasu Divi 1",
        "Affiliations": "1 Stanford University School of Medicine, Department of Otolaryngology - Head and Neck Surgery; 2 Stanford University School of Medicine, Department of Pathology",
        "Background": "Neoadjuvant immune checkpoint blockade (ICB) has shown robust activity in cutaneous squamous cell carcinoma (cSCC), however it is difficult to predict which patients will respond. The ability to predict response to neoadjuvant ICB is important to inform early and efficient pivot to other therapy modalities in non-responders. We previously performed single cell spatial transcriptomic profiling of tumors treated with ICB and uncovered six distinct immune niches that are associated with and predict pathological response to ICB with area under the curve (AUC) 0.782. Given single cell spatial transcriptomic profiling is resource-intensive and difficult to integrate into clinical workflows, we sought to investigate alternative methods to predict the presence of these niches. We hypothesized that application of a deep learning framework to impute immune niches would be able to accurately predict response to ICB in cSCC.",
        "Methods": "Tumor samples of cSCC were obtained from before, after one dose, and after three-four doses of neoadjuvant ICB from patients enrolled on two clinical trials of neoadjuvant ICB at a single tertiary care institution. Samples were stained with hematoxylin and eosin (H&E) and digitized. A published deep learning framework (DeepPT) was trained on 310 squamous cell carcinoma slides with matching RNAseq data from The Cancer Genome Atlas Project (TCGA) and then modified to predict the presence of immune niches and generate an immune niche score for each whole slide image. Results were validated against CosMx single cell spatial transcriptomic profiling of tissue microarrays (TMA) consisting of 1x1mm tissue cores obtained from the same tissues. Receiver operating characteristic analyses were applied to evaluate the ability of the immune niche score to predict pathological response. Response status was defined as responder (complete pathological response [CR] or major pathological response [mPR]) or non-responder (all other patients).",
        "Results": "A total of 57 whole slide images from 27 patients – 12 of whom experienced CR or mPR – were included in the study. When compared to CosMx spatial transcriptomic profiles, DeepPT was able to significantly predict a low antigen presentation myeloid niche (r=0.41, p=0.002) and showed moderate ability to predict a B/plasma cell enriched niche (r=0.23, p=0.085). When applied to 1x1mm tissue cores from the CosMx TMA, the DeepPT imputed immune niche score was able to predict responders with AUC of 0.691 (95% CI 0.546-0.836). When applied to whole slide images, the imputed immune niche score was able to predict responders with AUC of 0.668 (95% CI 0.508-0.829). At the optimal threshold, the imputed immune niche score achieves a sensitivity of 0.79, specificity of 0.57, positive predicted value of 0.54, and negative predictive value of 0.81 for response status when applied to whole slide images.",
        "Conclusions": "Using deep learning to impute transcriptomic features from H&E images, we derived immune niche scores that demonstrated meaningful ability to distinguish responders from non-responders to ICB in cSCC. This approach shows promise as a scalable, tissue-efficient biomarker and merits evaluation in expanded cohorts and other malignancies. Further optimization of the analysis pipeline is underway to improve predictive ability.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Imputed Immune Niche Scores are Associated with Pathologic Response to Immune Checkpoint Blockade in Cutaneous Squamous Cell Carcinoma</span>. <u>Maxwell Y Lee</u><sup>1</sup>; Luis Martinez Ramirez<sup>1</sup>; Mobeen Rahman<sup>2</sup>; John B Sunwoo<sup>1</sup>; Vasu Divi<sup>1</sup>. <sup>1</sup>Stanford University School of Medicine, Department of Otolaryngology - Head and Neck Surgery; <sup>2</sup>Stanford University School of Medicine, Department of Pathology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Neoadjuvant immune checkpoint blockade (ICB) has shown robust activity in cutaneous squamous cell carcinoma (cSCC), however it is difficult to predict which patients will respond. The ability to predict response to neoadjuvant ICB is important to inform early and efficient pivot to other therapy modalities in non-responders. We previously performed single cell spatial transcriptomic profiling of tumors treated with ICB and uncovered six distinct immune niches that are associated with and predict pathological response to ICB with area under the curve (AUC) 0.782. Given single cell spatial transcriptomic profiling is resource-intensive and difficult to integrate into clinical workflows, we sought to investigate alternative methods to predict the presence of these niches. We hypothesized that application of a deep learning framework to impute immune niches would be able to accurately predict response to ICB in cSCC.</p>\n\n<p><strong>Methods: </strong>Tumor samples of cSCC were obtained from before, after one dose, and after three-four doses of neoadjuvant ICB from patients enrolled on two clinical trials of neoadjuvant ICB at a single tertiary care institution. Samples were stained with hematoxylin and eosin (H&E) and digitized. A published deep learning framework (DeepPT) was trained on 310 squamous cell carcinoma slides with matching RNAseq data from The Cancer Genome Atlas Project (TCGA) and then modified to predict the presence of immune niches and generate an immune niche score for each whole slide image. Results were validated against CosMx single cell spatial transcriptomic profiling of tissue microarrays (TMA) consisting of 1x1mm tissue cores obtained from the same tissues. Receiver operating characteristic analyses were applied to evaluate the ability of the immune niche score to predict pathological response. Response status was defined as responder (complete pathological response [CR] or major pathological response [mPR]) or non-responder (all other patients).</p>\n\n<p><strong>Results: </strong>A total of 57 whole slide images from 27 patients – 12 of whom experienced CR or mPR – were included in the study. When compared to CosMx spatial transcriptomic profiles, DeepPT was able to significantly predict a low antigen presentation myeloid niche (r=0.41, p=0.002) and showed moderate ability to predict a B/plasma cell enriched niche (r=0.23, p=0.085). When applied to 1x1mm tissue cores from the CosMx TMA, the DeepPT imputed immune niche score was able to predict responders with AUC of 0.691 (95% CI 0.546-0.836). When applied to whole slide images, the imputed immune niche score was able to predict responders with AUC of 0.668 (95% CI 0.508-0.829). At the optimal threshold, the imputed immune niche score achieves a sensitivity of 0.79, specificity of 0.57, positive predicted value of 0.54, and negative predictive value of 0.81 for response status when applied to whole slide images.</p>\n\n<p><strong>Conclusions: </strong>Using deep learning to impute transcriptomic features from H&E images, we derived immune niche scores that demonstrated meaningful ability to distinguish responders from non-responders to ICB in cSCC. This approach shows promise as a scalable, tissue-efficient biomarker and merits evaluation in expanded cohorts and other malignancies. Further optimization of the analysis pipeline is underway to improve predictive ability.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152049--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S456",
      "content_id": "153223",
      "abstract_number": "S456",
      "poster_number": "",
      "title": "Facility-Level Differences in Sentinel Lymph Node Biopsy Utilization for Older Adults with Head and Neck Melanoma",
      "summary": "Facility type is a strong and independent predictor of SLNB utilization in older adults with H/N melanoma, with community hospitals demonstrating the greatest underuse relative to national guidelines. Although adjusted overall survival did not differ by facility type, omission of SLNB was associated with significantly worse survival, highlighting SLNB as a critical component of high-quality melanoma care. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153223",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alekhya Pidugu",
      "presenter": "Alekhya Pidugu",
      "authors": "Alekhya Pidugu 1 ; Isha Shah 1 ; Felipe Porto-Gutierrez, MD 2 ; Valentina Montanez-Azcarate, MD 2 ; Alexa Kacin, MD 2 ; Scharukh Jalisi, MD 2",
      "normalized_authors": [
        "Alekhya Pidugu",
        "Isha Shah",
        "Felipe Porto-Gutierrez",
        "Valentina Montanez-Azcarate",
        "Alexa Kacin",
        "Scharukh Jalisi"
      ],
      "affiliations": [
        "Tufts University School of Medicine",
        "Beth Israel Deaconess Medical Center - Harvard Medical School"
      ],
      "normalized_institutions": [
        "Tufts University School of Medicine",
        "Beth Israel Deaconess Medical Center - Harvard Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 371,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alekhya Pidugu 1 ; Isha Shah 1 ; Felipe Porto-Gutierrez, MD 2 ; Valentina Montanez-Azcarate, MD 2 ; Alexa Kacin, MD 2 ; Scharukh Jalisi, MD 2",
        "Affiliations": "1 Tufts University School of Medicine; 2 Beth Israel Deaconess Medical Center - Harvard Medical School",
        "Introduction": "Sentinel lymph node biopsy (SLNB) is a critical staging procedure in melanoma and is recommended for most intermediate-thickness head and neck (H/N) tumors. However, its use remains inconsistent, particularly among older adults and in anatomically complex H/N sites where surgical expertise and institutional resources vary. Underutilization in these settings may result in understaging, delayed adjuvant therapy, and worse oncologic care. This study evaluates facility-level differences in SLNB utilization for older adults with H/N melanoma and assesses the association between SLNB performance and overall survival.",
        "Methods": "Using the National Cancer Database, we identified patients aged ≥65 years with cutaneous H/N melanoma diagnosed between 2004–2019. Facility type was categorized as academic, integrated network, comprehensive community, or community hospital. Multivariable logistic regression assessed predictors of SLNB utilization, and Cox proportional hazards modeling evaluated overall survival after adjustment for demographics, tumor characteristics, and treatment variables.",
        "Results": "Among 7,679 eligible patients, SLNB utilization varied substantially by facility type. Community hospitals demonstrated the lowest rates of SLNB performance, with patients treated in these settings being significantly less likely to undergo SLNB compared to academic centers (OR = 0.65; p < 0.001). Comprehensive community facilities showed modestly lower odds of SLNB use compared to academic centers, while integrated network facilities demonstrated similar utilization patterns. SLNB performance was independently associated with improved overall survival (HR = 0.65; 95% CI 0.59–0.72; p < 0.001). In contrast, after adjustment for case mix and treatment variables, facility type itself was not independently associated with survival.",
        "Conclusion": "Facility type is a strong and independent predictor of SLNB utilization in older adults with H/N melanoma, with community hospitals demonstrating the greatest underuse relative to national guidelines. Although adjusted overall survival did not differ by facility type, omission of SLNB was associated with significantly worse survival, highlighting SLNB as a critical component of high-quality melanoma care. These findings emphasize a meaningful quality-of-care gap: while common or low-complexity melanoma cases may be managed effectively across settings, more complex H/N presentations in older adults appear vulnerable to under-staging in lower-resourced facilities. Targeted quality improvement and consistent SLNB implementation at community hospitals may reduce disparities and improve oncologic outcomes for this growing population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Facility-Level Differences in Sentinel Lymph Node Biopsy Utilization for Older Adults with Head and Neck Melanoma</span>. <u>Alekhya Pidugu</u><sup>1</sup>; Isha Shah<sup>1</sup>; Felipe Porto-Gutierrez, MD<sup>2</sup>; Valentina Montanez-Azcarate, MD<sup>2</sup>; Alexa Kacin, MD<sup>2</sup>; Scharukh Jalisi, MD<sup>2</sup>. <sup>1</sup>Tufts University School of Medicine; <sup>2</sup>Beth Israel Deaconess Medical Center - Harvard Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Sentinel lymph node biopsy (SLNB) is a critical staging procedure in melanoma and is recommended for most intermediate-thickness head and neck (H/N) tumors. However, its use remains inconsistent, particularly among older adults and in anatomically complex H/N sites where surgical expertise and institutional resources vary. Underutilization in these settings may result in understaging, delayed adjuvant therapy, and worse oncologic care. This study evaluates facility-level differences in SLNB utilization for older adults with H/N melanoma and assesses the association between SLNB performance and overall survival.</p>\n\n<p><strong>Methods: </strong>Using the National Cancer Database, we identified patients aged ≥65 years with cutaneous H/N melanoma diagnosed between 2004–2019. Facility type was categorized as academic, integrated network, comprehensive community, or community hospital. Multivariable logistic regression assessed predictors of SLNB utilization, and Cox proportional hazards modeling evaluated overall survival after adjustment for demographics, tumor characteristics, and treatment variables.</p>\n\n<p><strong>Results: </strong>Among 7,679 eligible patients, SLNB utilization varied substantially by facility type. Community hospitals demonstrated the lowest rates of SLNB performance, with patients treated in these settings being significantly less likely to undergo SLNB compared to academic centers (OR = 0.65; p < 0.001). Comprehensive community facilities showed modestly lower odds of SLNB use compared to academic centers, while integrated network facilities demonstrated similar utilization patterns. SLNB performance was independently associated with improved overall survival (HR = 0.65; 95% CI 0.59–0.72; p < 0.001). In contrast, after adjustment for case mix and treatment variables, facility type itself was not independently associated with survival.</p>\n\n<p><strong>Conclusion: </strong>Facility type is a strong and independent predictor of SLNB utilization in older adults with H/N melanoma, with community hospitals demonstrating the greatest underuse relative to national guidelines. Although adjusted overall survival did not differ by facility type, omission of SLNB was associated with significantly worse survival, highlighting SLNB as a critical component of high-quality melanoma care. These findings emphasize a meaningful quality-of-care gap: while common or low-complexity melanoma cases may be managed effectively across settings, more complex H/N presentations in older adults appear vulnerable to under-staging in lower-resourced facilities. Targeted quality improvement and consistent SLNB implementation at community hospitals may reduce disparities and improve oncologic outcomes for this growing population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153223--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S457",
      "content_id": "153413",
      "abstract_number": "S457",
      "poster_number": "",
      "title": "Blurred Lines: A Scoping Review of Surgical Margin Assessment and Response-Adapted Surgery After Neoadjuvant Immunotherapy in Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Car",
      "summary": "Current HNSCC and cSCC neoadjuvant immunotherapy studies show substantial variability and frequent under-reporting of how surgical margins and response adapted procedures are determined. Standardized, transparent methodology for operative planning in this setting is largely lacking.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153413",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fahad Hasnain, MD",
      "presenter": "Fahad Hasnain, MD",
      "authors": "Fahad Hasnain, MD ; Tyler Gathman, MD, MS; Akarsh Lal, BS; Nihal Punjabi, MD; John Cramer, MD",
      "normalized_authors": [
        "Fahad Hasnain",
        "Tyler Gathman",
        "Akarsh Lal",
        "Nihal Punjabi",
        "John Cramer"
      ],
      "affiliations": [
        "Wayne State University School of Medicine"
      ],
      "normalized_institutions": [
        "Wayne State University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 327,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Evidence Review",
        "Findings",
        "Conclusion",
        "Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fahad Hasnain, MD ; Tyler Gathman, MD, MS; Akarsh Lal, BS; Nihal Punjabi, MD; John Cramer, MD",
        "Affiliations": "Wayne State University School of Medicine",
        "Importance": "Neoadjuvant immunotherapy is an emerging component of curative treatment for resectable head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (cSCC). Tumor regression after neoadjuvant therapy blurs traditional anatomic landmarks, creating uncertainty in defining surgical margins and in determining when response-adapted (de-escalated) surgery is oncologically appropriate.",
        "Objective": "To map the existing literature on surgical margin assessment and the use of response-adapted surgery after neoadjuvant immunotherapy for resectable HNSCC and cSCC, and to characterize how these concepts are defined and reported.",
        "Evidence Review": "A comprehensive literature search was performed using EBSCO, Scopus, Web of Science, ClinicalTrials.gov, MEDLINE, Cochrane, and Embase. The search yielded 672 records. Studies were included if they reported patients with mucosal or cutaneous squamous cell carcinoma of the head and neck and were treated with neoadjuvant immunotherapy followed by surgical resection. Exclusion criteria were unavailable full text, unresectable or metastatic disease at the time of immunotherapy and salvage surgery.",
        "Findings": "Sixty-seven met inclusion criteria. Across these studies, there was marked heterogeneity in how surgical extent was determined after neoadjuvant immunotherapy. Most studies (n=42, 62.7%) did not specify criteria for defining surgical margins in the post-immunotherapy setting. Nearly half (n=31, 46.2%) did not state whether response-adpated surgery was permitted. Only 7 studies (10.4%) explicity incorporated post-neoadjuvant variables (e.g., clinical, radiologic or pathologic response) into surgical margin decision-making, and only 12 studies (17.9%) allowed any form of response-adapted surgery.",
        "Conclusion": "Current HNSCC and cSCC neoadjuvant immunotherapy studies show substantial variability and frequent under-reporting of how surgical margins and response adapted procedures are determined. Standardized, transparent methodology for operative planning in this setting is largely lacking.",
        "Relevance": "Future neoadjuvant immunotherapy studies in HNSCC and cSCC should prospectively define surgical margin protocols, clearly state whether and how reponse-adpated surgery is allowed, and report oncologic outcomes in relation to these decisions. Consistent reporting will be essential to understanding the safety and effectiveness of tailoring surgery to treatment response.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Blurred Lines: A Scoping Review of Surgical Margin Assessment and Response-Adapted Surgery After Neoadjuvant Immunotherapy in Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma</span>. <u>Fahad Hasnain, MD</u>; Tyler Gathman, MD, MS; Akarsh Lal, BS; Nihal Punjabi, MD; John Cramer, MD. Wayne State University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Neoadjuvant immunotherapy is an emerging component of curative treatment for resectable head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (cSCC). Tumor regression after neoadjuvant therapy blurs traditional anatomic landmarks, creating uncertainty in defining surgical margins and in determining when response-adapted (de-escalated) surgery is oncologically appropriate.</p>\n\n<p><strong>Objective:</strong> To map the existing literature on surgical margin assessment and the use of response-adapted surgery after neoadjuvant immunotherapy for resectable HNSCC and cSCC, and to characterize how these concepts are defined and reported.  </p>\n\n<p><strong>Evidence Review</strong>: A comprehensive literature search was performed using EBSCO, Scopus, Web of Science, ClinicalTrials.gov, MEDLINE, Cochrane, and Embase. The search yielded 672 records. Studies were included if they reported patients with mucosal or cutaneous squamous cell carcinoma of the head and neck and were treated with neoadjuvant immunotherapy followed by surgical resection. Exclusion criteria were unavailable full text, unresectable or metastatic disease at the time of immunotherapy and salvage surgery.</p>\n\n<p><strong>Findings:</strong> Sixty-seven met inclusion criteria. Across these studies, there was marked heterogeneity in how surgical extent was determined after neoadjuvant immunotherapy. Most studies (n=42, 62.7%) did not specify criteria for defining surgical margins in the post-immunotherapy setting. Nearly half (n=31, 46.2%) did not state whether response-adpated surgery was permitted. Only 7 studies (10.4%) explicity incorporated post-neoadjuvant variables (e.g., clinical, radiologic or pathologic response) into surgical margin decision-making, and only 12 studies (17.9%) allowed any form of response-adapted surgery.</p>\n\n<p><strong>Conclusion:</strong> Current HNSCC and cSCC neoadjuvant immunotherapy studies show substantial variability and frequent under-reporting of how surgical margins and response adapted procedures are determined. Standardized, transparent methodology for operative planning in this setting is largely lacking.</p>\n\n<p><strong>Relevance:</strong> Future neoadjuvant immunotherapy studies in HNSCC and cSCC should prospectively define surgical margin protocols, clearly state whether and how reponse-adpated surgery is allowed, and report oncologic outcomes in relation to these decisions. Consistent reporting will be essential to understanding the safety and effectiveness of tailoring surgery to treatment response.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153413--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S458",
      "content_id": "153933",
      "abstract_number": "S458",
      "poster_number": "",
      "title": "Outcomes in Transplant Patients with Cutaneous Squamous Cell Carcinoma",
      "summary": "In this study, we describe survival outcomes in one of the largest cohorts of head and neck cSCC in transplant patients, a poorly characterized patient population. Transplant patients with lower levels of immunosuppression – kidney and liver transplant patients – showed improved survival outcomes, suggesting a direct correlation between immunosuppression levels and disease course. However, reduction of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153933",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alice C Yu, MD",
      "presenter": "Alice C Yu, MD",
      "authors": "Alice C Yu, MD 1 ; Yasmine Ibrahim, BS 1 ; Maxwell Zywica, BS 1 ; Milan Carter, BS 1 ; Deborah Wong, MD, PhD 2 ; Wanxing Chai-Ho, MD 2 ; Maie A St",
      "normalized_authors": [
        "Alice C Yu",
        "Yasmine Ibrahim",
        "Maxwell Zywica",
        "Milan Carter",
        "Deborah Wong",
        "Wanxing Chai-Ho",
        "Maie A St"
      ],
      "affiliations": [
        "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery",
        "UCLA Department of Hematology Oncology",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery",
        "UCLA Department of Hematology Oncology",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alice C Yu, MD 1 ; Yasmine Ibrahim, BS 1 ; Maxwell Zywica, BS 1 ; Milan Carter, BS 1 ; Deborah Wong, MD, PhD 2 ; Wanxing Chai-Ho, MD 2 ; Maie A St",
        "Affiliations": "John, MD, PhD 3 . 1 UCLA Department of Head and Neck Surgery; 2 UCLA Department of Hematology Oncology; 3 Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery",
        "Introduction": "Immunosuppression of solid-organ transplant patients has long been associated with markedly increased risk of development of cutaneous squamous cell carcinomas (cSCC). Patients with cancers that are recurrent, deep, or aggressive are often evaluated by otolaryngologists. However, the outcomes of this specific patient population are poorly characterized in the literature. Additionally, while immunotherapies have increasingly been used to treat cSCCs in the general population, their application in the transplant population has been limited due to fear of inducing rejection. While preliminary studies have looked at the application of cemiplimab in kidney transplant patients, more studies are needed to investigate its safety in all transplant patients.",
        "Objectives": "To understand outcomes and risk-modifying clinical factors of transplant patients with head and neck cSCC.",
        "Methods": "Solid tumor transplant patients who underwent otolaryngologic evaluation at a single institution between October 2015 to October 2024 were evaluated. Exclusion criteria included less than 3 months of documented follow-up after an initial otolaryngology consult, diagnosis with a co-existing malignancy besides cSCC, or lack of cSCC in the head and neck region. Clinical and demographic information, including survival outcomes, disease course, treatment modality, and transplant medications and history were collected. Analysis was performed with a combination of descriptive statistics and Kaplan-Meier survival curves using IBM SPSS v30.",
        "Results": "A total of 101 patients were included. The mean age of the cohort was 64.5 ± 11.1 years; kidney transplant patients comprised 26.7% of the cohort, 10.9% had undergone liver transplantation, 14.9% had undergone heart transplantation, 36.6% had undergone lung transplants, and 10.9% had undergone two or more transplants. Five-year survival rates after initial diagnosis of cSCC were 61.1% overall, with 69.6% disease-specific survival. Disease-free and metastasis-free survival rates at 5 years were 50.9% and 72.7%, respectively. Most patients experienced multiple recurrences, with 50.5% of patients with more than 4 discrete episodes of cSCC in the head and neck region. Survival rates after surgery were 65.8% at 2 years and 33.6% at 5 years. Kidney and liver transplants were associated with significantly improved survival relative to heart, lung, or multiple transplants (p = 0.047). Reductions in immunosuppression within the first year of SCC diagnosis did not result in significant improvement in survival outcomes (p = 0.963). In our cohort, 12 patients underwent immunotherapy – 7 with kidney transplants, 2 with heart transplants, 1 with lung, and 2 with multiple. None experienced transplant rejection after treatment with immunotherapy.",
        "Conclusion": "In this study, we describe survival outcomes in one of the largest cohorts of head and neck cSCC in transplant patients, a poorly characterized patient population. Transplant patients with lower levels of immunosuppression – kidney and liver transplant patients – showed improved survival outcomes, suggesting a direct correlation between immunosuppression levels and disease course. However, reduction of immunosuppressive regimen did not result in improved survival outcomes. Interestingly, our cohort included 7 transplant patients who underwent immunotherapy with no episodes of transplant rejection. Additional work needs to be done to improve understanding of this unique patient population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes in Transplant Patients with Cutaneous Squamous Cell Carcinoma</span>. <u>Alice C Yu, MD</u><sup>1</sup>; Yasmine Ibrahim, BS<sup>1</sup>; Maxwell Zywica, BS<sup>1</sup>; Milan Carter, BS<sup>1</sup>; Deborah Wong, MD, PhD<sup>2</sup>; Wanxing Chai-Ho, MD<sup>2</sup>; Maie A St. John, MD, PhD<sup>3</sup>. <sup>1</sup>UCLA Department of Head and Neck Surgery; <sup>2</sup>UCLA Department of Hematology Oncology; <sup>3</sup>Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Immunosuppression of solid-organ transplant patients has long been associated with markedly increased risk of development of cutaneous squamous cell carcinomas (cSCC). Patients with cancers that are recurrent, deep, or aggressive are often evaluated by otolaryngologists. However, the outcomes of this specific patient population are poorly characterized in the literature. Additionally, while immunotherapies have increasingly been used to treat cSCCs in the general population, their application in the transplant population has been limited due to fear of inducing rejection. While preliminary studies have looked at the application of cemiplimab in kidney transplant patients, more studies are needed to investigate its safety in all transplant patients.</p>\n\n<p><strong>Objectives: </strong>To understand outcomes and risk-modifying clinical factors of transplant patients with head and neck cSCC.</p>\n\n<p><strong>Methods:</strong> Solid tumor transplant patients who underwent otolaryngologic evaluation at a single institution between October 2015 to October 2024 were evaluated. Exclusion criteria included less than 3 months of documented follow-up after an initial otolaryngology consult, diagnosis with a co-existing malignancy besides cSCC, or lack of cSCC in the head and neck region. Clinical and demographic information, including survival outcomes, disease course, treatment modality, and transplant medications and history were collected. Analysis was performed with a combination of descriptive statistics and Kaplan-Meier survival curves using IBM SPSS v30.</p>\n\n<p><strong>Results: </strong>A total of 101 patients were included. The mean age of the cohort was 64.5 ± 11.1 years; kidney transplant patients comprised 26.7% of the cohort, 10.9% had undergone liver transplantation, 14.9% had undergone heart transplantation, 36.6% had undergone lung transplants, and 10.9% had undergone two or more transplants. Five-year survival rates after initial diagnosis of cSCC were 61.1% overall, with 69.6% disease-specific survival. Disease-free and metastasis-free survival rates at 5 years were 50.9% and 72.7%, respectively. Most patients experienced multiple recurrences, with 50.5% of patients with more than 4 discrete episodes of cSCC in the head and neck region. Survival rates after surgery were 65.8% at 2 years and 33.6% at 5 years. Kidney and liver transplants were associated with significantly improved survival relative to heart, lung, or multiple transplants (p = 0.047). Reductions in immunosuppression within the first year of SCC diagnosis did not result in significant improvement in survival outcomes (p = 0.963). In our cohort, 12 patients underwent immunotherapy – 7 with kidney transplants, 2 with heart transplants, 1 with lung, and 2 with multiple. None experienced transplant rejection after treatment with immunotherapy.</p>\n\n<p><strong>Conclusion: </strong>In this study, we describe survival outcomes in one of the largest cohorts of head and neck cSCC in transplant patients, a poorly characterized patient population. Transplant patients with lower levels of immunosuppression – kidney and liver transplant patients – showed improved survival outcomes, suggesting a direct correlation between immunosuppression levels and disease course. However, reduction of immunosuppressive regimen did not result in improved survival outcomes. Interestingly, our cohort included 7 transplant patients who underwent immunotherapy with no episodes of transplant rejection. Additional work needs to be done to improve understanding of this unique patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153933--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S459",
      "content_id": "153643",
      "abstract_number": "S459",
      "poster_number": "",
      "title": "Immunotherapy uptake and surgical intensity after early PD-1 inhibitor initiation in advanced cutaneous head and neck squamous cell carcinoma: a national EHR cohort, 2018-2025",
      "summary": "Using a post-diagnosis landmark (12-month) design in a national EHR network, we show that a measurable subset of advanced cHNSCC patients undergo high-intensity reconstruction (free flap) after early PD-1 therapy, and that regional disease surgery (parotidectomy/neck dissection) remains common in both ICI and non-ICI pathways. Clinically, neoadjuvant PD-1 is often reserved for unresectable or very high-risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153643",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Allen Khudaverdyan, BA",
      "presenter": "Allen Khudaverdyan, BA",
      "authors": "Allen Khudaverdyan, BA 1 ; Christie Hung, BA 1 ; Lindsey Moses, MD 2 ; Umamaheswar Duvvuri, MD, PhD 2",
      "normalized_authors": [
        "Allen Khudaverdyan",
        "Christie Hung",
        "Lindsey Moses",
        "Umamaheswar Duvvuri"
      ],
      "affiliations": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "normalized_institutions": [
        "NYU Grossman School of Medicine",
        "NYU Langone Department of Otolaryngology"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Allen Khudaverdyan, BA 1 ; Christie Hung, BA 1 ; Lindsey Moses, MD 2 ; Umamaheswar Duvvuri, MD, PhD 2",
        "Affiliations": "1 NYU Grossman School of Medicine; 2 NYU Langone Department of Otolaryngology",
        "Background": "Cutaneous head & neck squamous cell carcinoma (cHNSCC) disproportionately affects older and medically complex patients. The introduction of PD-1 inhibitors (cemiplimab, pembrolizumab), first for unresectable/metastatic disease and now increasingly used peri-operatively, has shifted treatment paradigms. Yet, real-world data quantifying post-immunotherapy surgical intensity (e.g. need for microvascular free-flap reconstruction) are sparse. We sought to benchmark patterns of free flap and regional disease surgery after early PD-1 exposure in advanced cHNSCC.",
        "Methods": "Retrospective cohort (Epic Cosmos, 2018-2025). Adults (≥18 y) with AJCC stage III/IV cHNSCC were identified using ICD-10 subsites C44.02 (lip), C44.12x (eyelid/canthus), C44.22x (ear/EAC), C44.32x (face), and C44.42 (scalp/neck). ICI exposure was any pembrolizumab or cemiplimab within 12 months of first advanced cHNSCC diagnosis; non-ICI had no PD-1 in that window. ICI receipt was plotted by year from 2018-2025. To equalize opportunity for outcome ascertainment, we excluded patients with a free flap during the first 12 months in both cohorts (grace period). Primary outcome was microvascular free-flap reconstruction after the grace window; secondary outcomes were parotidectomy, neck dissection, and external-beam radiation. Aggregate counts were used to estimate risks (%) and crude risk ratios (RRs, 95% CIs).",
        "Results": "The share of stage III/IV cHNSCC patients receiving ICI increased from 6.4% (2018) to 22.3% (2025) (Figure 1), with early rapid diffusion that continued to rise in later years. We identified 2,061 early-ICI and 9,632 non-ICI patients with stage III/IV cHNSCC who were free-flap-naïve during the grace period. Age and sex distributions were similar (≥65 y 73.8% vs 76.0%; male 76.8% vs 78.6%), with frequent public insurance among ICI recipients (63.5%). The proportion undergoing free flap after the grace window was 11.35% in early-ICI vs 9.04% in non-ICI (RR 1.26, 95% CI 1.10-1.44). Parotidectomy occurred in 8.4% vs 7.23% (RR 1.16, 95% CI 0.99-1.37), and neck dissection in 20.4% vs 17.84% (RR 1.14, 95% CI 1.04-1.26) for early-ICI vs non-ICI, respectively.",
        "Conclusions": "Using a post-diagnosis landmark (12-month) design in a national EHR network, we show that a measurable subset of advanced cHNSCC patients undergo high-intensity reconstruction (free flap) after early PD-1 therapy, and that regional disease surgery (parotidectomy/neck dissection) remains common in both ICI and non-ICI pathways. Clinically, neoadjuvant PD-1 is often reserved for unresectable or very high-risk tumors, or cases in which upfront resection would cause unacceptable functional morbidity; thus, surgery after ICI in this cohort likely includes patients converted to resectability with acceptable morbidity following systemic therapy. These real-world benchmarks of post-ICI surgical workload can inform reconstructive capacity planning and multidisciplinary pathways, while patient-level studies are needed to clarify intent, timing, and selection factors that underlie surgical intensity after immunotherapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immunotherapy uptake and surgical intensity after early PD-1 inhibitor initiation in advanced cutaneous head and neck squamous cell carcinoma: a national EHR cohort, 2018-2025</span>. <u>Allen Khudaverdyan, BA</u><sup>1</sup>; Christie Hung, BA<sup>1</sup>; Lindsey Moses, MD<sup>2</sup>; Umamaheswar Duvvuri, MD, PhD<sup>2</sup>. <sup>1</sup>NYU Grossman School of Medicine; <sup>2</sup>NYU Langone Department of Otolaryngology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Cutaneous head & neck squamous cell carcinoma (cHNSCC) disproportionately affects older and medically complex patients. The introduction of PD-1 inhibitors (cemiplimab, pembrolizumab), first for unresectable/metastatic disease and now increasingly used peri-operatively, has shifted treatment paradigms. Yet, real-world data quantifying post-immunotherapy surgical intensity (e.g. need for microvascular free-flap reconstruction) are sparse. We sought to benchmark patterns of free flap and regional disease surgery after early PD-1 exposure in advanced cHNSCC.</p>\n\n<p><strong>Methods: </strong>Retrospective cohort (Epic Cosmos, 2018-2025). Adults (≥18 y) with AJCC stage III/IV cHNSCC were identified using ICD-10 subsites C44.02 (lip), C44.12x (eyelid/canthus), C44.22x (ear/EAC), C44.32x (face), and C44.42 (scalp/neck). ICI exposure was any pembrolizumab or cemiplimab within 12 months of first advanced cHNSCC diagnosis; non-ICI had no PD-1 in that window. ICI receipt was plotted by year from 2018-2025. To equalize opportunity for outcome ascertainment, we excluded patients with a free flap during the first 12 months in both cohorts (grace period). Primary outcome was microvascular free-flap reconstruction after the grace window; secondary outcomes were parotidectomy, neck dissection, and external-beam radiation. Aggregate counts were used to estimate risks (%) and crude risk ratios (RRs, 95% CIs).  </p>\n\n<p><strong>Results:</strong> The share of stage III/IV cHNSCC patients receiving ICI increased from 6.4% (2018) to 22.3% (2025) (Figure 1), with early rapid diffusion that continued to rise in later years. We identified 2,061 early-ICI and 9,632 non-ICI patients with stage III/IV cHNSCC who were free-flap-naïve during the grace period. Age and sex distributions were similar (≥65 y 73.8% vs 76.0%; male 76.8% vs 78.6%), with frequent public insurance among ICI recipients (63.5%). The proportion undergoing free flap after the grace window was 11.35% in early-ICI vs 9.04% in non-ICI (RR 1.26, 95% CI 1.10-1.44). Parotidectomy occurred in 8.4% vs 7.23% (RR 1.16, 95% CI 0.99-1.37), and neck dissection in 20.4% vs 17.84% (RR 1.14, 95% CI 1.04-1.26) for early-ICI vs non-ICI, respectively.</p>\n\n<p><strong>Conclusions:</strong> Using a post-diagnosis landmark (12-month) design in a national EHR network, we show that a measurable subset of advanced cHNSCC patients undergo high-intensity reconstruction (free flap) after early PD-1 therapy, and that regional disease surgery (parotidectomy/neck dissection) remains common in both ICI and non-ICI pathways. Clinically, neoadjuvant PD-1 is often reserved for unresectable or very high-risk tumors, or cases in which upfront resection would cause unacceptable functional morbidity; thus, surgery after ICI in this cohort likely includes patients converted to resectability with acceptable morbidity following systemic therapy. These real-world benchmarks of post-ICI surgical workload can inform reconstructive capacity planning and multidisciplinary pathways, while patient-level studies are needed to clarify intent, timing, and selection factors that underlie surgical intensity after immunotherapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153643--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S460",
      "content_id": "154543",
      "abstract_number": "S460",
      "poster_number": "",
      "title": "Abbreviated Length of Stay in Patients Receiving Free Tissue Transfer for Cutaneous Defects",
      "summary": "Patients undergoing free tissue transfer for cutaneous defects demonstrate excellent surgical outcomes, and an abbreviated postoperative stay of three days or less appears safe. Early discharge was not associated with higher rates of complications, readmission, or reoperation within our cohort, which supports the feasibility of a shorter hospital stay pathway.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154543",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dang-Khoa Nguyen, MD, MBA, MS",
      "presenter": "Dang-Khoa Nguyen, MD, MBA, MS",
      "authors": "Noah Bogart, BS; Andrew Griffin, BS; Kenny Nguyen, MD; James R Gardner, MD; Dang-Khoa Nguyen, MD, MBA, MS ; Emre Vural, MD; Jumin Sunde, MD; Mauricio A Moreno, MD",
      "normalized_authors": [
        "Noah Bogart",
        "Andrew Griffin",
        "Kenny Nguyen",
        "James R Gardner",
        "Dang-Khoa Nguyen",
        "Emre Vural",
        "Jumin Sunde",
        "Mauricio A Moreno"
      ],
      "affiliations": [
        "University of Arkansas for Medical Sciences"
      ],
      "normalized_institutions": [
        "University of Arkansas for Medical Sciences"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 458,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Noah Bogart, BS; Andrew Griffin, BS; Kenny Nguyen, MD; James R Gardner, MD; Dang-Khoa Nguyen, MD, MBA, MS ; Emre Vural, MD; Jumin Sunde, MD; Mauricio A Moreno, MD",
        "Affiliations": "University of Arkansas for Medical Sciences",
        "Background": "Microvascular free tissue transfer is increasingly commonplace in reconstructive surgery of head and neck defects. However, perioperative management remains highly variable across institutions and individual surgeons. Standard postoperative hospital stays often range from five to seven days for routine flap monitoring and recovery. This study evaluates whether an abbreviated postoperative hospital stay of three days or less is feasible and associated with acceptable surgical outcomes in patients undergoing flap reconstruction of primarily cutaneous defects.",
        "Methods": "This was a retrospective chart review of patients who underwent free flap reconstruction at an academic tertiary care facility between 2010 and 2025. Only patients who received free tissue transfer for cutaneous defects were included. Flaps performed for oral cavity, pharyngeal, skull base, orbital, or bony defects were excluded. Patients who required a tracheostomy at the time of surgery or postoperative admission to the ICU were also excluded. Data collected included demographics, social history, medical comorbidities and intraoperative metrics such as ASA physical risk assessment, duration of surgery, blood loss, and flap ischemia time. Subsequent outcomes evaluated included surgical complications, medical complications, readmissions, and ED visits. Continuous variables were analyzed with t-tests or ANOVA, and categorical variables with chi-square tests. A p-value less than 0.05 was considered statistically significant.",
        "Results": "Ninety six patients met inclusion criteria, of whom 39 were discharged in three days or less. The cohort was predominantly male (80.2%) and white (91.7%) with a mean age of 70.7 years. Anterolateral thigh flaps were most common, followed by latissimus dorsi flaps, with smaller numbers of radial forearm and other flap types. Most reconstructions were performed for cancer-related defects (83.3%), with remaining indications including osteoradionecrosis, trauma, and vascular malformations. Demographic factors, social history, and medical cormobdities did not differ significantly between the abbreviated stay group and the rest of the cohort. Surgical outcomes were favorable overall, with more than 80% of patients experiencing no complications. The abbreviated stay group had a significantly lower complication rate compared to patients who were hospitalized longer (p=0.02). Rates of reoperation, 30-day readmission, and 30-day ED utilization did not differ between groups (p=0.12, p=0.47, p=0.13, respectively). Of the seven reoperations, one was from the abbreviated stay group while the other six wre from the longer stay group. No patients died because of surgical complications, and only one complete flap loss occurred, in a patient within the abbreviated stay group.",
        "Conclusions": "Patients undergoing free tissue transfer for cutaneous defects demonstrate excellent surgical outcomes, and an abbreviated postoperative stay of three days or less appears safe. Early discharge was not associated with higher rates of complications, readmission, or reoperation within our cohort, which supports the feasibility of a shorter hospital stay pathway.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Abbreviated Length of Stay in Patients Receiving Free Tissue Transfer for Cutaneous Defects</span>. Noah Bogart, BS; Andrew Griffin, BS; Kenny Nguyen, MD; James R Gardner, MD; <u>Dang-Khoa Nguyen, MD, MBA, MS</u>; Emre Vural, MD; Jumin Sunde, MD; Mauricio A Moreno, MD. University of Arkansas for Medical Sciences<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Microvascular free tissue transfer is increasingly commonplace in reconstructive surgery of head and neck defects. However, perioperative management remains highly variable across institutions and individual surgeons. Standard postoperative hospital stays often range from five to seven days for routine flap monitoring and recovery. This study evaluates whether an abbreviated postoperative hospital stay of three days or less is feasible and associated with acceptable surgical outcomes in patients undergoing flap reconstruction of primarily cutaneous defects.</p>\n\n<p><strong>Methods:</strong> This was a retrospective chart review of patients who underwent free flap reconstruction at an academic tertiary care facility between 2010 and 2025. Only patients who received free tissue transfer for cutaneous defects were included. Flaps performed for oral cavity, pharyngeal, skull base, orbital, or bony defects were excluded. Patients who required a tracheostomy at the time of surgery or postoperative admission to the ICU were also excluded. Data collected included demographics, social history, medical comorbidities and intraoperative metrics such as ASA physical risk assessment, duration of surgery, blood loss, and flap ischemia time. Subsequent outcomes evaluated included surgical complications, medical complications, readmissions, and ED visits. Continuous variables were analyzed with t-tests or ANOVA, and categorical variables with chi-square tests. A p-value less than 0.05 was considered statistically significant. </p>\n\n<p><strong>Results: </strong>Ninety six patients met inclusion criteria, of whom 39 were discharged in three days or less. The cohort was predominantly male (80.2%) and white (91.7%) with a mean age of 70.7 years. Anterolateral thigh flaps were most common, followed by latissimus dorsi flaps, with smaller numbers of radial forearm and other flap types. Most reconstructions were performed for cancer-related defects (83.3%), with remaining indications including osteoradionecrosis, trauma, and vascular malformations. Demographic factors, social history, and medical cormobdities did not differ significantly between the abbreviated stay group and the rest of the cohort. Surgical outcomes were favorable overall, with more than 80% of patients experiencing no complications. The abbreviated stay group had a significantly lower complication rate compared to patients who were hospitalized longer (p=0.02). Rates of reoperation, 30-day readmission, and 30-day ED utilization did not differ between groups (p=0.12, p=0.47, p=0.13, respectively). Of the seven reoperations, one was from the abbreviated stay group while the other six wre from the longer stay group. No patients died because of surgical complications, and only one complete flap loss occurred, in a patient within the abbreviated stay group.</p>\n\n<p><strong>Conclusions: </strong>Patients undergoing free tissue transfer for cutaneous defects demonstrate excellent surgical outcomes, and an abbreviated postoperative stay of three days or less appears safe. Early discharge was not associated with higher rates of complications, readmission, or reoperation within our cohort, which supports the feasibility of a shorter hospital stay pathway.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154543--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S461",
      "content_id": "154226",
      "abstract_number": "S461",
      "poster_number": "",
      "title": "Negative Pathologic Resection After Definitive Surgical Resection of Cutaneous Head and Neck Melanoma",
      "summary": "The surprisingly high rate of negative resection reported herein, particularly in cases of early T stage, lesions located on the scalp/neck/ear, and excisional/shave biopsy methods, provide important information for providers to use in counseling patients with cutaneous head and neck melanoma prior to resection. To our knowledge, this is the first report of negative resection limited to the head and neck, a...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154226",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sarah Toti, MD",
      "presenter": "Sarah Toti, MD",
      "authors": "Sarah Toti, MD ; Nicholas Van Maele, MD; Rony Aouad; Melina Windon, MD; Gerek Meinhardt, BBA, MBA; Anthony Mangino, PhD; Kelsey Karnik, PhD",
      "normalized_authors": [
        "Sarah Toti",
        "Nicholas Van Maele",
        "Rony Aouad",
        "Melina Windon",
        "Gerek Meinhardt, BBA",
        "Anthony Mangino",
        "Kelsey Karnik"
      ],
      "affiliations": [
        "University of Kentucky"
      ],
      "normalized_institutions": [
        "University of Kentucky"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 336,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Educational Objective",
        "Abstract",
        "Study Design",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sarah Toti, MD ; Nicholas Van Maele, MD; Rony Aouad; Melina Windon, MD; Gerek Meinhardt, BBA, MBA; Anthony Mangino, PhD; Kelsey Karnik, PhD",
        "Affiliations": "University of Kentucky",
        "Educational Objective": "The purpose of this study is to evaluate the incidence of surgical pathology specimens with no residual melanoma from wide local excision procedures after initial biopsy demonstrating malignant melanoma. The high proportion of negative (no residual tumor) specimens from selective variables in the study's cohort may be used to guide both preoperative patient counseling and consideration of cosmetic and facial subunit preservation in oncologic guidelines.",
        "Abstract": "1. Determine the frequency of negative margins in head and neck cutaneous melanoma treated with wide local excision after biopsy. 2. To investigate the correlation between types of biopsy and tumor characteristics for negative surgical specimens. View in Agenda and Add to Schedule",
        "Study Design": "Retrospective cohort study",
        "Methods": "Consecutive patients who underwent definitive surgical resection for cutaneous head and neck melanoma at the author's cancer institution between 2006 and 2021 were included. Factors associated with negative biopsy were determined using univariable and multivariable logistic regression models.",
        "Results": "The overall proportion of negative resection was 44.2%. In univariable analysis, the initial biopsy stage but not lesion location or initial biopsy time correlated with statistically significant increase for the incidence of a negative resection after an initial positive biopsy. In the multivariable analysis, lesion location, initial stage, and biopsy type demonstrated significantly higher association with negative resection (p=0.041, 0.008, 0.027, respectively). Biopsy depth (mm), time to surgery, and gender did not reach the threshold for evidence of a statistically significant overall effect.",
        "Conclusion": "The surprisingly high rate of negative resection reported herein, particularly in cases of early T stage, lesions located on the scalp/neck/ear, and excisional/shave biopsy methods, provide important information for providers to use in counseling patients with cutaneous head and neck melanoma prior to resection. To our knowledge, this is the first report of negative resection limited to the head and neck, a cosmetically and functionally sensitive region with significant morbidity even with small excisions. Further studies evaluating the long-term association of negative resection with recurrence may inform planned margin and margin assessment in future oncologic guidelines."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Negative Pathologic Resection After Definitive Surgical Resection of Cutaneous Head and Neck Melanoma</span>. <u>Sarah Toti, MD</u>; Nicholas Van Maele, MD; Rony Aouad; Melina Windon, MD; Gerek Meinhardt, BBA, MBA; Anthony Mangino, PhD; Kelsey Karnik, PhD. University of Kentucky<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Educational Objective: </strong>The purpose of this study is to evaluate the incidence of surgical pathology specimens with no residual melanoma from wide local excision procedures after initial biopsy demonstrating malignant melanoma. The high proportion of negative (no residual tumor) specimens from selective variables in the study's cohort may be used to guide both preoperative patient counseling and consideration of cosmetic and facial subunit preservation in oncologic guidelines.</p>\n\n<p><strong>Objectives:</strong></p>\n\n<p>1. Determine the frequency of negative margins in head and neck cutaneous melanoma treated with wide local excision after biopsy.</p>\n\n<p>2. To investigate the correlation between types of biopsy and tumor characteristics for negative surgical specimens.</p>\n\n<p><strong>Study Design: </strong>Retrospective cohort study</p>\n\n<p><strong>Methods: </strong>Consecutive patients who underwent definitive surgical resection for cutaneous head and neck melanoma at the author's cancer institution between 2006 and 2021 were included. Factors associated with negative biopsy were determined using univariable and multivariable logistic regression models.</p>\n\n<p><strong>Results: </strong>The overall proportion of negative resection was 44.2%. In univariable analysis, the initial biopsy stage but not lesion location or initial biopsy time correlated with statistically significant increase for the incidence of a negative resection after an initial positive biopsy. In the multivariable analysis, lesion location, initial stage, and biopsy type demonstrated significantly higher association with negative resection (p=0.041, 0.008, 0.027, respectively). Biopsy depth (mm), time to surgery, and gender did not reach the threshold for evidence of a statistically significant overall effect.</p>\n\n<p><strong>Conclusion: </strong>The surprisingly high rate of negative resection reported herein, particularly in cases of early T stage, lesions located on the scalp/neck/ear, and excisional/shave biopsy methods, provide important information for providers to use in counseling patients with cutaneous head and neck melanoma prior to resection. To our knowledge, this is the first report of negative resection limited to the head and neck, a cosmetically and functionally sensitive region with significant morbidity even with small excisions. Further studies evaluating the long-term association of negative resection with recurrence may inform planned margin and margin assessment in future oncologic guidelines.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154226--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S462",
      "content_id": "154399",
      "abstract_number": "S462",
      "poster_number": "",
      "title": "Durability of ICI Therapy-Based Regimens in Cutaneous Squamous Cell Carcinoma",
      "summary": "Cutaneous squamous cell carcinoma (cSCC) is the second most common malignant neoplasm of the skin, frequently involving the head and neck region where anatomical constraints can limit surgical management. While surgical excision remains the mainstay of therapy, a subset of patients requires systemic treatment due to locally advanced or recurrent disease. Immune checkpoint inhibitors (ICIs) have demonstrated high...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154399",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Peter Vo 2 ; Bryan Trieu 1 ; Parag Sanghvi, MD 3 ; Soo Park, MD 4 ; Theresa Guo, MD 5",
      "normalized_authors": [
        "Vivian Vo",
        "Peter Vo",
        "Bryan Trieu",
        "Parag Sanghvi",
        "Soo Park",
        "Theresa Guo"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "California University of Science and Medicine",
        "Department of Radiation Oncology, University of California San Diego Health",
        "Division of Hematology and Oncology, Department of Medicine, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "California University of Science and Medicine",
        "Department of Radiation Oncology, University of California San Diego Health",
        "Division of Hematology and Oncology, Department of Medicine, University of California San Diego Health",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Skin Cancer",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Skin Cancer"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 500,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Peter Vo 2 ; Bryan Trieu 1 ; Parag Sanghvi, MD 3 ; Soo Park, MD 4 ; Theresa Guo, MD 5",
        "Affiliations": "1 UC San Diego School of Medicine; 2 California University of Science and Medicine; 3 Department of Radiation Oncology, University of California San Diego Health; 4 Division of Hematology and Oncology, Department of Medicine, University of California San Diego Health; 5 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "Cutaneous squamous cell carcinoma (cSCC) is the second most common malignant neoplasm of the skin, frequently involving the head and neck region where anatomical constraints can limit surgical management. While surgical excision remains the mainstay of therapy, a subset of patients requires systemic treatment due to locally advanced or recurrent disease. Immune checkpoint inhibitors (ICIs) have demonstrated high response rates, but the optimal sequence, duration, and combination with local therapies required to achieve durable disease control remain undefined. We conducted a retrospective cohort study of 84 cSCC patients treated with ICI-based regimens at our NCI-designated institution from 2019-2025. Patients were stratified into four treatment cohorts: ICI monotherapy, ICI with radiation therapy (IRT), ICI with surgery, and trimodality (ICI with surgery and RT). Clinical, radiologic, and pathologic response data were collected, along with treatment duration, number of cycles, adverse events, recurrence, and survival outcomes. Decision regarding surgery and radiation treatment was based on clinician discretion. Surgery was offered to patients with resectable disease who were medically suitable and amenable to surgical therapy. Radiation therapy was included based on tumor characteristics including large primary tumor, slower response to ICI, or poor pathologic features on surgical pathology. Our cohort consisted primarily of patients with locally advanced, recurrent disease (65%) of head and neck cSCC (89%), most of whom received cemiplimab-based therapy. In the ICI monotherapy group, 82% (40/49) achieved an overall clinical or radiographic response, and 85% (34/40) of responders maintained ongoing disease control. Median ICI treatment duration was 5 months (8 cycles). In the IRT cohort, 10 of 13 patients (77%) responded, and 80% of responders achieved durable benefit; median ICI treatment duration was 2 months (4.5 cycles). Patients treated with ICI plus surgery received a median of 2 neoadjuvant cycles with 89% (8/9) achieving a complete pathologic response and all responders remaining disease-free. The trimodality cohort, again with median 2 cycles of neoadjuvant therapy, had the lowest response rate, with 46% (6/13) of patients achieving any response and no complete pathologic response. Of the responders, 83% (5/6) maintained disease control. Among RT-containing regimens, the median delivered dose was 6000 cGy. Four recurrences occurred after ICI discontinuation, including two in patients with underlying hematologic malignancies. Overall, long-term control was preserved even after discontinuation of immunotherapy, suggesting that early, deep responses confer lasting antitumor immunity. Durability of response appeared to depend more on the depth of initial response than to cumulative treatment duration. Median ICI duration was shorter in combination therapy cohorts, likely response-driven discontinuation. In contemporary management, these patterns align with several practical treatment pathways: ICI monotherapy for patients suitable for definitive systemic therapy; IRT for bulky tumors, slower responders, or to rescue inadequate early response; ICI with surgery when resection and pathology guide adjuvant therapy; and trimodality treatment for the most aggressive or refractory disease. Our findings support this response-adapted paradigm, highlighting that strategic integration of local therapies around ICIs can optimize tumor clearance while maintaining durable control. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Durability of ICI Therapy-Based Regimens in Cutaneous Squamous Cell Carcinoma</span>. <u>Vivian Vo</u><sup>1</sup>; Peter Vo<sup>2</sup>; Bryan Trieu<sup>1</sup>; Parag Sanghvi, MD<sup>3</sup>; Soo Park, MD<sup>4</sup>; Theresa Guo, MD<sup>5</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>California University of Science and Medicine; <sup>3</sup>Department of Radiation Oncology, University of California San Diego Health; <sup>4</sup>Division of Hematology and Oncology, Department of Medicine, University of California San Diego Health; <sup>5</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Cutaneous squamous cell carcinoma (cSCC) is the second most common malignant neoplasm of the skin, frequently involving the head and neck region where anatomical constraints can limit surgical management. While surgical excision remains the mainstay of therapy, a subset of patients requires systemic treatment due to locally advanced or recurrent disease. Immune checkpoint inhibitors (ICIs) have demonstrated high response rates, but the optimal sequence, duration, and combination with local therapies required to achieve durable disease control remain undefined.</p>\n\n<p>We conducted a retrospective cohort study of 84 cSCC patients treated with ICI-based regimens at our NCI-designated institution from 2019-2025. Patients were stratified into four treatment cohorts: ICI monotherapy, ICI with radiation therapy (IRT), ICI with surgery, and trimodality (ICI with surgery and RT). Clinical, radiologic, and pathologic response data were collected, along with treatment duration, number of cycles, adverse events, recurrence, and survival outcomes. Decision regarding surgery and radiation treatment was based on clinician discretion. Surgery was offered to patients with resectable disease who were medically suitable and amenable to surgical therapy. Radiation therapy was included based on tumor characteristics including large primary tumor, slower response to ICI, or poor pathologic features on surgical pathology.</p>\n\n<p>Our cohort consisted primarily of patients with locally advanced, recurrent disease (65%) of head and neck cSCC (89%), most of whom received cemiplimab-based therapy. In the ICI monotherapy group, 82% (40/49) achieved an overall clinical or radiographic response, and 85% (34/40) of responders maintained ongoing disease control. Median ICI treatment duration was 5 months (8 cycles). In the IRT cohort, 10 of 13 patients (77%) responded, and 80% of responders achieved durable benefit; median ICI treatment duration was 2 months (4.5 cycles). Patients treated with ICI plus surgery received a median of 2 neoadjuvant cycles with 89% (8/9) achieving a complete pathologic response and all responders remaining disease-free. The trimodality cohort, again with median 2 cycles of neoadjuvant therapy, had the lowest response rate, with 46% (6/13) of patients achieving any response and no complete pathologic response. Of the responders, 83% (5/6) maintained disease control. Among RT-containing regimens, the median delivered dose was 6000 cGy. Four recurrences occurred after ICI discontinuation, including two in patients with underlying hematologic malignancies.</p>\n\n<p>Overall, long-term control was preserved even after discontinuation of immunotherapy, suggesting that early, deep responses confer lasting antitumor immunity. Durability of response appeared to depend more on the depth of initial response than to cumulative treatment duration. Median ICI duration was shorter in combination therapy cohorts, likely response-driven discontinuation. In contemporary management, these patterns align with several practical treatment pathways: ICI monotherapy for patients suitable for definitive systemic therapy; IRT for bulky tumors, slower responders, or to rescue inadequate early response; ICI with surgery when resection and pathology guide adjuvant therapy; and trimodality treatment for the most aggressive or refractory disease. Our findings support this response-adapted paradigm, highlighting that strategic integration of local therapies around ICIs can optimize tumor clearance while maintaining durable control.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154399--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S463",
      "content_id": "154287",
      "abstract_number": "S463",
      "poster_number": "",
      "title": "Eosinophil Count Dynamics and Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers in Cemiplimab-Treated Cutaneous Squamous Cell Carcinoma",
      "summary": "An early rise in eosinophil counts and baseline high NLR represent independent, readily obtainable prognostic biomarkers in cemiplimab-treated advanced cSCC. The treatment-induced eosinophil mobilization suggests an active immunologic mechanism underlying cemiplimab efficacy. Combined assessment of baseline NLR and serial eosinophil monitoring could enable risk-stratified management strategies, including...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154287",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ido Amir, MD",
      "presenter": "Ido Amir, MD",
      "authors": "Ido Amir, MD 1 ; Yuval Avidor, MD 1 ; Daniel Krutik 2 ; Nofar Edri, MD 1 ; Eyal Yosefof, MD 3 ; Ethan Soudry, MD 1",
      "normalized_authors": [
        "Ido Amir",
        "Yuval Avidor",
        "Daniel Krutik",
        "Nofar Edri",
        "Eyal Yosefof",
        "Ethan Soudry"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel",
        "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel",
        "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
        "Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 398,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ido Amir, MD 1 ; Yuval Avidor, MD 1 ; Daniel Krutik 2 ; Nofar Edri, MD 1 ; Eyal Yosefof, MD 3 ; Ethan Soudry, MD 1",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel; 2 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3 Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel",
        "Background": "Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy, with advanced disease presenting significant treatment challenges. Cemiplimab, an anti-PD-1 immune checkpoint inhibitor, has demonstrated efficacy in advanced cSCC; however, clinical response remains inconsistent, and robust prognostic biomarkers to predict treatment outcomes are needed. While peripheral blood biomarkers offer accessibility and cost-effectiveness, their utility in cemiplimab-treated cSCC remains unestablished. We hypothesized that dynamic eosinophil changes and baseline neutrophil-lymphocyte ratio (NLR) could serve as readily available prognostic indicators in real-world clinical practice.",
        "Methods": "A retrospective cohort study of patients with locally advanced or metastatic cSCC treated with cemiplimab at a single tertiary center between January 2019 and November 2023. Inclusion criteria required complete baseline and serial complete blood counts (CBC). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Multivariable Cox proportional hazards models were constructed, adjusting for established prognostic factors including Eastern Cooperative Oncology Group (ECOG) performance status, presence of distant metastases, histologic tumor grade, and prior treatment modality. Age was modeled using restricted natural cubic splines with three knots to account for potential non-linear effects. Eosinophil surge was prospectively defined as either baseline absolute eosinophil count >500 cells/µL or a ≥3-fold increase from baseline within the first 6 months of treatment. Baseline high NLR was defined as >3.",
        "Results": "Among 85 patients analysed, 28 (33%) demonstrated an eosinophil surge. The median age at cemiplimab initiation was 80.3. Eosinophil surge was independently associated with improved OS (HR=0.22, 95% CI 0.06–0.83, p=0.02), representing a 78% reduction in mortality risk. A consistent favorable trend was observed for PFS, though not reaching statistical significance in this cohort size. Paired analysis confirmed a statistically significant increase in mean eosinophil counts at 6 months compared to baseline (P<0.05), supporting treatment-induced eosinophil mobilization. Baseline high NLR was associated with worse OS (HR=3.93, 95% CI 1.15-13.4, p=0.03).",
        "Conclusions": "An early rise in eosinophil counts and baseline high NLR represent independent, readily obtainable prognostic biomarkers in cemiplimab-treated advanced cSCC. The treatment-induced eosinophil mobilization suggests an active immunologic mechanism underlying cemiplimab efficacy. Combined assessment of baseline NLR and serial eosinophil monitoring could enable risk-stratified management strategies, including treatment intensification or alternative approaches for high-risk patients. Prospective validation is warranted to establish standardized thresholds and assess whether biomarker-guided interventions improve outcomes in this population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Eosinophil Count Dynamics and Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers in Cemiplimab-Treated Cutaneous Squamous Cell Carcinoma</span>. <u>Ido Amir, MD</u><sup>1</sup>; Yuval Avidor, MD<sup>1</sup>; Daniel Krutik<sup>2</sup>; Nofar Edri, MD<sup>1</sup>; Eyal Yosefof, MD<sup>3</sup>; Ethan Soudry, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel; <sup>2</sup>Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; <sup>3</sup>Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy, with advanced disease presenting significant treatment challenges. Cemiplimab, an anti-PD-1 immune checkpoint inhibitor, has demonstrated efficacy in advanced cSCC; however, clinical response remains inconsistent, and robust prognostic biomarkers to predict treatment outcomes are needed. While peripheral blood biomarkers offer accessibility and cost-effectiveness, their utility in cemiplimab-treated cSCC remains unestablished. We hypothesized that dynamic eosinophil changes and baseline neutrophil-lymphocyte ratio (NLR) could serve as readily available prognostic indicators in real-world clinical practice.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study of patients with locally advanced or metastatic cSCC treated with cemiplimab at a single tertiary center between January 2019 and November 2023. Inclusion criteria required complete baseline and serial complete blood counts (CBC). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Multivariable Cox proportional hazards models were constructed, adjusting for established prognostic factors including Eastern Cooperative Oncology Group (ECOG) performance status, presence of distant metastases, histologic tumor grade, and prior treatment modality. Age was modeled using restricted natural cubic splines with three knots to account for potential non-linear effects. Eosinophil surge was prospectively defined as either baseline absolute eosinophil count >500 cells/µL or a ≥3-fold increase from baseline within the first 6 months of treatment. Baseline high NLR was defined as >3.</p>\n\n<p><strong>Results: </strong>Among 85 patients analysed, 28 (33%) demonstrated an eosinophil surge. The median age at cemiplimab initiation was 80.3. Eosinophil surge was independently associated with improved OS (HR=0.22, 95% CI 0.06–0.83, p=0.02), representing a 78% reduction in mortality risk. A consistent favorable trend was observed for PFS, though not reaching statistical significance in this cohort size. Paired analysis confirmed a statistically significant increase in mean eosinophil counts at 6 months compared to baseline (P<0.05), supporting treatment-induced eosinophil mobilization. Baseline high NLR was associated with worse OS (HR=3.93, 95% CI 1.15-13.4, p=0.03).</p>\n\n<p><strong>Conclusions: </strong>An early rise in eosinophil counts and baseline high NLR represent independent, readily obtainable prognostic biomarkers in cemiplimab-treated advanced cSCC. The treatment-induced eosinophil mobilization suggests an active immunologic mechanism underlying cemiplimab efficacy. Combined assessment of baseline NLR and serial eosinophil monitoring could enable risk-stratified management strategies, including treatment intensification or alternative approaches for high-risk patients. Prospective validation is warranted to establish standardized thresholds and assess whether biomarker-guided interventions improve outcomes in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154287--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S464",
      "content_id": "155401",
      "abstract_number": "S464",
      "poster_number": "",
      "title": "Clinical and Racial Correlates of Cemiplimab Response in Cutaneous Squamous Cell Carcinoma",
      "summary": "To our knowledge, this is the first study to demonstrate that response to cemiplimab in locally advanced cSCC varies significantly by race and tumor site. In addition, primary vs. recurrent disease presentation was strongly associated with treatment response. Excellent responders experienced significantly improved progression-free and overall survival, supporting response status as a marker of long-term treatment...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155401",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260151",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sara Friedman, BA",
      "presenter": "Sara Friedman, BA",
      "authors": "Sara Friedman, BA 1 ; Carolyn Rachofsky, BA 1 ; Lawrence Leung, PhD 2 ; Bijal Amin, MD 3 ; Keivan Shifteh, MD 4 ; Beth N McLellan, MD 5 ; Bradley Schiff, MD 6 ; Vikas Mehta, MD, MPH 6 ; Richard V Smith, MD 6 ; Yvonne M Saenger, MD 2 ; Helena Levyn, MD 6",
      "normalized_authors": [
        "Sara Friedman",
        "Carolyn Rachofsky",
        "Lawrence Leung",
        "Bijal Amin",
        "Keivan Shifteh",
        "Beth N McLellan",
        "Bradley Schiff",
        "Vikas Mehta",
        "Richard V Smith",
        "Yvonne M Saenger",
        "Helena Levyn"
      ],
      "affiliations": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Oncology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Pathology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Radiology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Dermatology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "normalized_institutions": [
        "Albert Einstein College of Medicine, Bronx, NY, USA",
        "Department of Oncology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Pathology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Radiology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Dermatology – Montefiore Medical Center, Bronx, NY, USA",
        "Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_18_03%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_18_03%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155401"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_33_33%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_33_33%E2%80%AFPM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155401"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_18_48%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_18_48%E2%80%AFPM.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155401"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_30_51%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_30_51%E2%80%AFPM.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155401"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 521,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sara Friedman, BA 1 ; Carolyn Rachofsky, BA 1 ; Lawrence Leung, PhD 2 ; Bijal Amin, MD 3 ; Keivan Shifteh, MD 4 ; Beth N McLellan, MD 5 ; Bradley Schiff, MD 6 ; Vikas Mehta, MD, MPH 6 ; Richard V Smith, MD 6 ; Yvonne M Saenger, MD 2 ; Helena Levyn, MD 6",
        "Affiliations": "1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Oncology – Montefiore Medical Center, Bronx, NY, USA; 3 Department of Pathology – Montefiore Medical Center, Bronx, NY, USA; 4 Department of Radiology – Montefiore Medical Center, Bronx, NY, USA; 5 Department of Dermatology – Montefiore Medical Center, Bronx, NY, USA; 6 Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA",
        "Introduction": "Management of locally advanced cutaneous squamous cell carcinoma (cSCC) is challenging due to surgical morbidity and variability of response to systemic therapies. Cemiplimab, a programmed cell death-1 receptor inhibitor, has demonstrated efficacy in advanced cSCC; however, predictors of response remain poorly defined, and data examining racial and ethnic differences are limited.",
        "Methods": "Patients treated with cemiplimab were classified as excellent/poor responders based on treating physician assessment and longitudinal radiologic and pathologic changes documented in the medical record. Patient and tumor characteristics were compared between response groups. Univariable and multivariable logistic regression analyses were performed. Kaplan–Meier curves were generated to evaluate survival outcomes.",
        "Results": "Out of 81 patients, 26 met response criteria (13 excellent and 13 poor responders). Cemiplimab response differed by race, with White patients demonstrating a higher proportion of excellent responses compared with Black and Hispanic patients (78.6%, 0%, and 28.6%, respectively; p = 0.006, Table 1). Response also varied by tumor site, with head and neck tumors demonstrating a higher proportion of excellent responses compared with extremity tumors (65% vs 0%; p = 0.015, Table 1). Recurrent tumors were associated with a higher proportion of excellent responses compared with primary tumors (76.9% vs 23.1%; p = 0.017, Table 1).",
        "Abstract": "Multivariable analysis including race, primary vs. recurrent disease, cancer site, and N stage was used to construct a nomogram predictive of response (Figure 1). On multivariable analysis, race (OR 0.09, 95% CI 0.001–0.95; p = 0.046) and tumor site (OR 0.014, 95% CI 0.000002–0.37; p = 0.006) remained significant independent predictors of response. AUC was 0.956 on receiver operating characteristic (ROC) analysis (Figure 2). Kaplan–Meier analysis demonstrated significantly improved progression-free survival (PFS) among excellent responders compared with poor responders (log-rank p = 0.001; HR 0.077, 95% CI 0.018–0.329). Median PFS was not reached in excellent responders versus 1.28 years in poor responders. Overall survival was also significantly improved among excellent responders (log-rank p = 0.015; HR 0.159, 95% CI 0.055–0.923), with median OS not reached compared with 1.38 years in poor responders (Figure 3).Progression-free survival also differed by race. White patients demonstrated significantly improved PFS compared with non-White patients (log-rank p = 0.004; HR 0.12, 95% CI 0.03–0.52), with median PFS not reached versus 1.28 years, respectively (Figure 3). View in Agenda and Add to Schedule",
        "Conclusions": "To our knowledge, this is the first study to demonstrate that response to cemiplimab in locally advanced cSCC varies significantly by race and tumor site. In addition, primary vs. recurrent disease presentation was strongly associated with treatment response. Excellent responders experienced significantly improved progression-free and overall survival, supporting response status as a marker of long-term treatment benefit. Survival analysis also revealed significant racial differences in progression-free survival, with non-White patients experiencing worse outcomes. Together, these findings suggest that clinical and demographic features may contribute to response stratification and highlight the need for further investigation into biologic determinants of immunotherapy response, including tissue-based biomarker analyses and tumor mutational burden, to improve patient selection in cSCC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical and Racial Correlates of Cemiplimab Response in Cutaneous Squamous Cell Carcinoma</span>. <u>Sara Friedman, BA</u><sup>1</sup>; Carolyn Rachofsky, BA<sup>1</sup>; Lawrence Leung, PhD<sup>2</sup>; Bijal Amin, MD<sup>3</sup>; Keivan Shifteh, MD<sup>4</sup>; Beth N McLellan, MD<sup>5</sup>; Bradley Schiff, MD<sup>6</sup>; Vikas Mehta, MD, MPH<sup>6</sup>; Richard V Smith, MD<sup>6</sup>; Yvonne M Saenger, MD<sup>2</sup>; Helena Levyn, MD<sup>6</sup>. <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA; <sup>2</sup>Department of Oncology – Montefiore Medical Center, Bronx, NY, USA; <sup>3</sup>Department of Pathology – Montefiore Medical Center, Bronx, NY, USA; <sup>4</sup>Department of Radiology – Montefiore Medical Center, Bronx, NY, USA; <sup>5</sup>Department of Dermatology – Montefiore Medical Center, Bronx, NY, USA; <sup>6</sup>Department of Otorhinolaryngology – Head and Neck Surgery – Montefiore Medical Center, Bronx, NY, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Management of locally advanced cutaneous squamous cell carcinoma (cSCC) is challenging due to surgical morbidity and variability of response to systemic therapies. Cemiplimab, a programmed cell death-1 receptor inhibitor, has demonstrated efficacy in advanced cSCC; however, predictors of response remain poorly defined, and data examining racial and ethnic differences are limited.</p>\n\n<p><strong>Methods:</strong> Patients treated with cemiplimab were classified as excellent/poor responders based on treating physician assessment and longitudinal radiologic and pathologic changes documented in the medical record. Patient and tumor characteristics were compared between response groups. Univariable and multivariable logistic regression analyses were performed. Kaplan–Meier curves were generated to evaluate survival outcomes. </p>\n\n<p><strong>Results: </strong>Out of 81 patients, 26 met response criteria (13 excellent and 13 poor responders). Cemiplimab response differed by race, with White patients demonstrating a higher proportion of excellent responses compared with Black and Hispanic patients (78.6%, 0%, and 28.6%, respectively; p = 0.006, Table 1). Response also varied by tumor site, with head and neck tumors demonstrating a higher proportion of excellent responses compared with extremity tumors (65% vs 0%; p = 0.015, Table 1). Recurrent tumors were associated with a higher proportion of excellent responses compared with primary tumors (76.9% vs 23.1%; p = 0.017, Table 1). </p>\n\n<p>Multivariable analysis including race, primary vs. recurrent disease, cancer site, and N stage was used to construct a nomogram predictive of response (Figure 1). On multivariable analysis, race (OR 0.09, 95% CI 0.001–0.95; p = 0.046) and tumor site (OR 0.014, 95% CI 0.000002–0.37; p = 0.006) remained significant independent predictors of response. AUC was 0.956 on receiver operating characteristic (ROC) analysis (Figure 2). </p>\n\n<p>Kaplan–Meier analysis demonstrated significantly improved progression-free survival (PFS) among excellent responders compared with poor responders (log-rank p = 0.001; HR 0.077, 95% CI 0.018–0.329). Median PFS was not reached in excellent responders versus 1.28 years in poor responders. Overall survival was also significantly improved among excellent responders (log-rank p = 0.015; HR 0.159, 95% CI 0.055–0.923), with median OS not reached compared with 1.38 years in poor responders (Figure 3).Progression-free survival also differed by race. White patients demonstrated significantly improved PFS compared with non-White patients (log-rank p = 0.004; HR 0.12, 95% CI 0.03–0.52), with median PFS not reached versus 1.28 years, respectively (Figure 3). </p>\n\n<p><strong>Conclusions:</strong> To our knowledge, this is the first study to demonstrate that response to cemiplimab in locally advanced cSCC varies significantly by race and tumor site. In addition, primary vs. recurrent disease presentation was strongly associated with treatment response. Excellent responders experienced significantly improved progression-free and overall survival, supporting response status as a marker of long-term treatment benefit. Survival analysis also revealed significant racial differences in progression-free survival, with non-White patients experiencing worse outcomes. Together, these findings suggest that clinical and demographic features may contribute to response stratification and highlight the need for further investigation into biologic determinants of immunotherapy response, including tissue-based biomarker analyses and tumor mutational burden, to improve patient selection in cSCC.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_18_03%E2%80%AFPM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-08%20at%2010_33_33%E2%80%AFPM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_18_48%E2%80%AFPM.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155401/Screenshot%202026-03-13%20at%202_30_51%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155401--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260151' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S465",
      "content_id": "154245",
      "abstract_number": "S465",
      "poster_number": "",
      "title": "Metastatic Anaplastic Thyroid Carcinoma Reveals Distinct Molecular Subgroups and Pathways by Hierarchical Clustering",
      "summary": "Metastatic ATC comprises six genomically distinct subtypes, each characterized by unique mutational signatures and biological pathways. The high frequency of BRAF mutations in the metastatic cohort reinforces its role as a principal oncogenic driver and a promising target for therapeutic intervention, necessitating early identification for targeted therapy. The identified molecular clusters encompass a range of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154245",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Laura M Dooley, MD",
      "presenter": "Laura M Dooley, MD",
      "authors": "Xiaoming Zhang, MD 1 ; Naiwei Chen, PhD 1 ; Dean C Pavlick 2 ; Matthew C Hiemenz, MD, MS 2 ; Laura M Dooley, MD 1 ; Richard D Hammer, MD 1",
      "normalized_authors": [
        "Xiaoming Zhang",
        "Naiwei Chen",
        "Dean C Pavlick",
        "Matthew C Hiemenz",
        "Laura M Dooley",
        "Richard D Hammer"
      ],
      "affiliations": [
        "University of Missouri",
        "Foundation Medicine"
      ],
      "normalized_institutions": [
        "University of Missouri",
        "Foundation Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154245/Met%20table.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154245/Met%20table.jpg",
          "alt": "Table 1: Molecular Clusters and Characteristic Mutations in 184 Cases of Metastatic Anaplastic Thyroid Carcinoma",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154245"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154245/Hierarchical%20clusters.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154245/Hierarchical%20clusters.jpg",
          "alt": "Figure 1. Heatmap of Somatic Mutation Profiles in Metastatic Anaplastic Thyroid Carcinoma Reveals Six Distinct Molecular Clusters",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154245"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154245/t-sne.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154245/t-sne.jpg",
          "alt": "t-sne",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154245"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Design",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Xiaoming Zhang, MD 1 ; Naiwei Chen, PhD 1 ; Dean C Pavlick 2 ; Matthew C Hiemenz, MD, MS 2 ; Laura M Dooley, MD 1 ; Richard D Hammer, MD 1",
        "Affiliations": "1 University of Missouri; 2 Foundation Medicine",
        "Introduction": "Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, therapeutic resistance, and poor prognosis. Its lethality is driven in part by a heterogeneous genomic landscape. Comprehensive molecular characterization, particularly of metastatic ATC, is essential for identifying biologically and clinically relevant subgroups that may inform prognosis and support development of targeted therapies.",
        "Design": "Next-generation sequencing (NGS) data was obtained from 680 ATC cases using FoundationOne® and FoundationOne®CDx platforms (≥294 genes), including 184 cases with confirmed distant metastases and 496 non-metastatic cases. To classify mutational patterns, hierarchical clustering was applied. The number of clusters was determined based on the average silhouette width to the overall clustering’s quality and clinical interpretability. Dimensionality reduction was performed through t-distributed stochastic neighbor embedding (t-SNE) algorithm to map the mutation-based clustering across the top 48 frequent characteristic alterations.",
        "Results": "BRAF alterations were present in 50.5% of metastatic ATC cases, a significantly elevated frequency compared to 31.3% observed in the non-metastatic cases (p<0.0001). This highlights BRAF as a major molecular driver of metastatic progression in ATC. Prior studies showed no difference in BRAF vs RAS in metastatic ATC risk but was evaluated on only 126 cases.",
        "Abstract": "Hierarchical clustering of metastatic cases identified six distinct molecular subgroups, each with a characteristic mutational profile. Cluster 2 (23.9% of cases), was defined by nearly universal BRAF alterations (97.7%) and frequent co-alteration of PIK3CA (47.7%), indicating strong MAPK and PI3K pathway co-activation. Cluster 3, the largest subgroup (38.6%), was enriched for BRAF alterations (64.8%) in combination with DNMT3A , suggesting epigenetic involvement in tumor progression. Cluster 1 (11.4%) exhibited high frequencies of CDKN2A / CDKN2B inactivation, indicating disruption of cell cycle checkpoints. Cluster 4 (5.4%) was defined by concurrent alterations in JAK2 , CD274 (PD-L1), and PDCD1LG2 (PD-L2), suggesting potential immune evasion mechanisms. Cluster 5 (9.2%) included alterations in PTEN , NF2 , and RB1 , reflecting multifaceted tumor suppressor loss. Cluster 6 (11.4%) was defined by NRAS mutations (90.5%) with co-occurring DNMT3A alterations, representing a RAS-driven MAPK activation pathway that is molecularly distinct from the BRAF -associated clusters, despite comparable mutation frequencies of NRAS and BRAF in metastatic ATCs. Combined TP53 and TERT alterations were common and most prevalent in cluster 3 while TERT alterations were absent in cluster 5. Dimensionality reduction with t-SNE showed well-separated cluster distributions, supporting the biological distinctiveness of the identified subgroups. View in Agenda and Add to Schedule",
        "Conclusion": "Metastatic ATC comprises six genomically distinct subtypes, each characterized by unique mutational signatures and biological pathways. The high frequency of BRAF mutations in the metastatic cohort reinforces its role as a principal oncogenic driver and a promising target for therapeutic intervention, necessitating early identification for targeted therapy. The identified molecular clusters encompass a range of oncogenic mechanisms, including MAPK pathway activation, tumor suppressor gene inactivation, immune modulation, and epigenetic dysregulation, highlighting the biological heterogeneity of ATC. Together, these findings provide a molecular framework for development of precision oncology approaches tailored to distinct genomic subtypes. Validation in independent cohorts and further functional characterization of these clusters are essential steps toward clinical application."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Metastatic Anaplastic Thyroid Carcinoma Reveals Distinct Molecular Subgroups and Pathways by Hierarchical Clustering</span>. Xiaoming Zhang, MD<sup>1</sup>; Naiwei Chen, PhD<sup>1</sup>; Dean C Pavlick<sup>2</sup>; Matthew C Hiemenz, MD, MS<sup>2</sup>; <u>Laura M Dooley, MD</u><sup>1</sup>; Richard D Hammer, MD<sup>1</sup>. <sup>1</sup>University of Missouri; <sup>2</sup>Foundation Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, therapeutic resistance, and poor prognosis. Its lethality is driven in part by a heterogeneous genomic landscape. Comprehensive molecular characterization, particularly of metastatic ATC, is essential for identifying biologically and clinically relevant subgroups that may inform prognosis and support development of targeted therapies.</p>\n\n<p><strong>Design: </strong>Next-generation sequencing (NGS) data was obtained from 680 ATC cases using FoundationOne® and FoundationOne®CDx platforms (≥294 genes), including 184 cases with confirmed distant metastases and 496 non-metastatic cases. To classify mutational patterns, hierarchical clustering was applied. The number of clusters was determined based on the average silhouette width to the overall clustering’s quality and clinical interpretability. Dimensionality reduction was performed through t-distributed stochastic neighbor embedding (t-SNE) algorithm to map the mutation-based clustering across the top 48 frequent characteristic alterations. </p>\n\n<p><strong>Results: </strong>BRAF alterations were present in 50.5% of metastatic ATC cases, a significantly elevated frequency compared to 31.3% observed in the non-metastatic cases (p<0.0001). This highlights <em>BRAF</em> as a major molecular driver of metastatic progression in ATC. Prior studies showed no difference in <em>BRAF</em> vs <em>RAS</em> in metastatic ATC risk but was evaluated on only 126 cases. </p>\n\n<p>Hierarchical clustering of metastatic cases identified six distinct molecular subgroups, each with a characteristic mutational profile. Cluster 2 (23.9% of cases), was defined by nearly universal <em>BRAF</em> alterations (97.7%) and frequent co-alteration of <em>PIK3CA</em> (47.7%), indicating strong MAPK and PI3K pathway co-activation. Cluster 3, the largest subgroup (38.6%), was enriched for <em>BRAF</em> alterations (64.8%) in combination with <em>DNMT3A</em>, suggesting epigenetic involvement in tumor progression. Cluster 1 (11.4%) exhibited high frequencies of <em>CDKN2A</em>/<em>CDKN2B</em> inactivation, indicating disruption of cell cycle checkpoints. Cluster 4 (5.4%) was defined by concurrent alterations in <em>JAK2</em>, <em>CD274</em> (PD-L1), and <em>PDCD1LG2</em> (PD-L2), suggesting potential immune evasion mechanisms. Cluster 5 (9.2%) included alterations in <em>PTEN</em>, <em>NF2</em>, and <em>RB1</em>, reflecting multifaceted tumor suppressor loss. Cluster 6 (11.4%) was defined by <em>NRAS</em> mutations (90.5%) with co-occurring <em>DNMT3A</em> alterations, representing a RAS-driven MAPK activation pathway that is molecularly distinct from the <em>BRAF</em>-associated clusters, despite comparable mutation frequencies of <em>NRAS</em> and <em>BRAF</em> in metastatic ATCs. Combined <em>TP53</em> and <em>TERT</em> alterations were common and most prevalent in cluster 3 while <em>TERT</em> alterations were absent in cluster 5. </p>\n\n<p>Dimensionality reduction with t-SNE showed well-separated cluster distributions, supporting the biological distinctiveness of the identified subgroups.</p>\n\n<p><strong>Conclusion: </strong>Metastatic ATC comprises six genomically distinct subtypes, each characterized by unique mutational signatures and biological pathways. The high frequency of <em>BRAF</em> mutations in the metastatic cohort reinforces its role as a principal oncogenic driver and a promising target for therapeutic intervention, necessitating early identification for targeted therapy. The identified molecular clusters encompass a range of oncogenic mechanisms, including MAPK pathway activation, tumor suppressor gene inactivation, immune modulation, and epigenetic dysregulation, highlighting the biological heterogeneity of ATC. Together, these findings provide a molecular framework for development of precision oncology approaches tailored to distinct genomic subtypes. Validation in independent cohorts and further functional characterization of these clusters are essential steps toward clinical application.</p>\n\n<p><img alt='Table 1: Molecular Clusters and Characteristic Mutations in 184 Cases of Metastatic Anaplastic Thyroid Carcinoma' src='https://www.submitmyabstract.com/abs/images/154245/Met%20table.jpg' /></p>\n\n<p><img alt='Figure 1. Heatmap of Somatic Mutation Profiles in Metastatic Anaplastic Thyroid Carcinoma Reveals Six Distinct Molecular Clusters' src='https://www.submitmyabstract.com/abs/images/154245/Hierarchical%20clusters.jpg' /></p>\n\n<p><img alt='t-sne' src='https://www.submitmyabstract.com/abs/images/154245/t-sne.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154245--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S466",
      "content_id": "153972",
      "abstract_number": "S466",
      "poster_number": "",
      "title": "Proteomic Analysis of a Cohort of Anaplastic Thyroid Cancer Patients",
      "summary": "ATC, compared to PTC, displays disruptions in various avenues of metabolic processes, as well as enrichment of pathways involved in cytoplasmic translation and immune response. Identification of these pathways isolates key dependencies from the progression of PTC to ATC that may be targeted with systemic therapies. Moreover, this work lends insight into the protein changes that underlie the aggressive nature of ATC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153972",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alice C Yu, MD",
      "presenter": "Alice C Yu, MD",
      "authors": "Alice C Yu, MD 1 ; Mao Tian, PhD 2 ; David A Cronkite, MD 3 ; Yazeed Alhiyari, PhD 1 ; Michael Woolman, BS 4 ; Anthony Nichols, MD, FRCSC, FACS 5 ; Thomas Kislinger, PhD 4 ; Paul Boutros, PhD 2 ; Maie A St",
      "normalized_authors": [
        "Alice C Yu",
        "Mao Tian",
        "David A Cronkite",
        "Yazeed Alhiyari",
        "Michael Woolman",
        "Anthony Nichols, FRCSC",
        "Thomas Kislinger",
        "Paul Boutros",
        "Maie A St"
      ],
      "affiliations": [
        "John, MD, PhD 6 . 1 UCLA Department of Head and Neck Surgery",
        "Jonsson Comprehensive Cancer Center",
        "Thomas Jefferson University Department of Otolaryngology - Head & Neck Surgery",
        "University of Toronto Department of Medical Biophysics",
        "University of Western Ontario Department of Otolaryngology – Head and Neck Surgery",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "normalized_institutions": [
        "John, MD, PhD 6 . 1 UCLA Department of Head and Neck Surgery",
        "Jonsson Comprehensive Cancer Center",
        "Thomas Jefferson University Department of Otolaryngology - Head & Neck Surgery",
        "University of Toronto Department of Medical Biophysics",
        "University of Western Ontario Department of Otolaryngology – Head and Neck Surgery",
        "Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 369,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objectives",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alice C Yu, MD 1 ; Mao Tian, PhD 2 ; David A Cronkite, MD 3 ; Yazeed Alhiyari, PhD 1 ; Michael Woolman, BS 4 ; Anthony Nichols, MD, FRCSC, FACS 5 ; Thomas Kislinger, PhD 4 ; Paul Boutros, PhD 2 ; Maie A St",
        "Affiliations": "John, MD, PhD 6 . 1 UCLA Department of Head and Neck Surgery; 2 Jonsson Comprehensive Cancer Center; 3 Thomas Jefferson University Department of Otolaryngology - Head & Neck Surgery; 4 University of Toronto Department of Medical Biophysics; 5 University of Western Ontario Department of Otolaryngology – Head and Neck Surgery; 6 Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery",
        "Introduction": "Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a 2-year survival rate of 42%. As patients often present with unresectable or metastatic disease, many patients must rely upon medical and surgical salvage therapies. ATC is thought to evolve from the accumulation of mutations in papillary thyroid cancer (PTC). There is histologic co-occurrence of PTC or poorly differentiated thyroid cancer (PDTC) in many ATCs, supporting this theory. However, due to the rare nature of the disease, limited work has been done investigating the proteomic changes between PTC, ATC, and normal thyroid tissue.",
        "Objectives": "To assess differential protein expression between ATC and co-occuring PTC in a cohort of 51 patients.",
        "Methods": "Only samples that contain more than 70% of the same tumor type were selected. These samples underwent protein extraction and digestion, then fractionation and analysis by LC-MS/MS. Peptide sequences were imputed against the UniProt database to determine original protein abundance, and differential protein abundance was calculated between ATC, PTC, and normal samples. The R package clusterProfiler was used for pathway enrichment analysis and DeMixT was used for deconvolution analysis to delineate tumor tissue from surrounding muscle and stromal tissue.",
        "Abstract": "Clinical information for anaplastic thyroid patients was collected, including stage at presentation, overall, disease-free, and metastasis-free survival time, pathologic details, clinical course, and any genetic and molecular testing. View in Agenda and Add to Schedule",
        "Results": "Gene Set Enrichment Analysis (GSEA) demonstrated enrichment of proteins involved in the immune response in ATC samples relative to normal samples. Gene ontology (GO) analysis revealed significant dysregulation in metabolism of small molecules, organic acids, cellular lipids in ATC samples compared to both normal samples; notably, these changes were not seen in PTC samples compared to normal samples. ATC samples also demonstrated significantly increased enrichment of proteins implicated in cytoplasmic and cytoskeleton organization as well as the immune response.",
        "Conclusion": "ATC, compared to PTC, displays disruptions in various avenues of metabolic processes, as well as enrichment of pathways involved in cytoplasmic translation and immune response. Identification of these pathways isolates key dependencies from the progression of PTC to ATC that may be targeted with systemic therapies. Moreover, this work lends insight into the protein changes that underlie the aggressive nature of ATC."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Proteomic Analysis of a Cohort of Anaplastic Thyroid Cancer Patients</span>. <u>Alice C Yu, MD</u><sup>1</sup>; Mao Tian, PhD<sup>2</sup>; David A Cronkite, MD<sup>3</sup>; Yazeed Alhiyari, PhD<sup>1</sup>; Michael Woolman, BS<sup>4</sup>; Anthony Nichols, MD, FRCSC, FACS<sup>5</sup>; Thomas Kislinger, PhD<sup>4</sup>; Paul Boutros, PhD<sup>2</sup>; Maie A St. John, MD, PhD<sup>6</sup>. <sup>1</sup>UCLA Department of Head and Neck Surgery; <sup>2</sup>Jonsson Comprehensive Cancer Center; <sup>3</sup>Thomas Jefferson University Department of Otolaryngology - Head & Neck Surgery; <sup>4</sup>University of Toronto Department of Medical Biophysics; <sup>5</sup>University of Western Ontario Department of Otolaryngology – Head and Neck Surgery; <sup>6</sup>Johns Hopkins University Department of Otolaryngology-Head and Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a 2-year survival rate of 42%. As patients often present with unresectable or metastatic disease, many patients must rely upon medical and surgical salvage therapies. ATC is thought to evolve from the accumulation of mutations in papillary thyroid cancer (PTC). There is histologic co-occurrence of PTC or poorly differentiated thyroid cancer (PDTC) in many ATCs, supporting this theory. However, due to the rare nature of the disease, limited work has been done investigating the proteomic changes between PTC, ATC, and normal thyroid tissue.</p>\n\n<p><strong>Objectives: </strong>To assess differential protein expression between ATC and co-occuring PTC in a cohort of 51 patients.</p>\n\n<p><strong>Methods:</strong> Only samples that contain more than 70% of the same tumor type were selected. These samples underwent protein extraction and digestion, then fractionation and analysis by LC-MS/MS. Peptide sequences were imputed against the UniProt database to determine original protein abundance, and differential protein abundance was calculated between ATC, PTC, and normal samples. The R package clusterProfiler was used for pathway enrichment analysis and DeMixT was used for deconvolution analysis to delineate tumor tissue from surrounding muscle and stromal tissue.</p>\n\n<p>Clinical information for anaplastic thyroid patients was collected, including stage at presentation, overall, disease-free, and metastasis-free survival time, pathologic details, clinical course, and any genetic and molecular testing.</p>\n\n<p><strong>Results: </strong>Gene Set Enrichment Analysis (GSEA) demonstrated enrichment of proteins involved in the immune response in ATC samples relative to normal samples. Gene ontology (GO) analysis revealed significant dysregulation in metabolism of small molecules, organic acids, cellular lipids in ATC samples compared to both normal samples; notably, these changes were not seen in PTC samples compared to normal samples. ATC samples also demonstrated significantly increased enrichment of proteins implicated in cytoplasmic and cytoskeleton organization as well as the immune response.</p>\n\n<p><strong>Conclusion: </strong>ATC, compared to PTC, displays disruptions in various avenues of metabolic processes, as well as enrichment of pathways involved in cytoplasmic translation and immune response. Identification of these pathways isolates key dependencies from the progression of PTC to ATC that may be targeted with systemic therapies. Moreover, this work lends insight into the protein changes that underlie the aggressive nature of ATC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153972--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S467",
      "content_id": "154155",
      "abstract_number": "S467",
      "poster_number": "",
      "title": "Prognostic Implications of Tumor Focality in Thyroid Carcinoma: A 5-Year Retrospective Cohort Study from a South Asian Tertiary Care Center",
      "summary": "In this tertiary-care cohort, multifocal thyroid carcinoma exhibited trends toward more aggressive histopathologic features but did not confer worse short-term survival compared to unifocal disease. These findings support individualized treatment planning while emphasizing the overall favorable prognosis of differentiated thyroid malignancies. Larger multicentric prospective studies incorporating molecular data...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154155",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fatima Syed Amanullah, Dr",
      "presenter": "Fatima Syed Amanullah, Dr",
      "authors": "Muhammad Shahzaib Arshad 1 ; Hamzah Jehanzeb 1 ; Ainul Akbar Mughal, Dr 1 ; Hussain Ali Lanewala, Dr 1 ; Hamdan Pasha, MD 1 ; Fatima Syed Amanullah, Dr 2",
      "normalized_authors": [
        "Muhammad Shahzaib Arshad",
        "Hamzah Jehanzeb",
        "Ainul Akbar Mughal, Dr",
        "Hussain Ali Lanewala, Dr",
        "Hamdan Pasha",
        "Fatima Syed Amanullah, Dr"
      ],
      "affiliations": [
        "Aga Khan University",
        "University of Massachusetts"
      ],
      "normalized_institutions": [
        "Aga Khan University",
        "University of Massachusetts"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 324,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Muhammad Shahzaib Arshad 1 ; Hamzah Jehanzeb 1 ; Ainul Akbar Mughal, Dr 1 ; Hussain Ali Lanewala, Dr 1 ; Hamdan Pasha, MD 1 ; Fatima Syed Amanullah, Dr 2",
        "Affiliations": "1 Aga Khan University; 2 University of Massachusetts",
        "Background": "The prognostic significance of tumor multifocality in thyroid carcinoma remains controversial. While age, tumor size, histologic subtype, and nodal status are well-established prognostic determinants, the independent impact of multifocal disease on outcomes is less clear. This study evaluates the clinicopathologic characteristics and survival outcomes associated with multifocal versus unifocal thyroid carcinoma in a South Asian tertiary care population.",
        "Methods": "A retrospective cohort study was conducted using data from the Aga Khan University cancer registry, including all patients undergoing thyroidectomy for thyroid malignancy between January 2017 and January 2022. Demographic variables, tumor focality, histologic subtype, capsular and vascular invasion, extrathyroidal extension, lymph node metastases, and survival outcomes were compared between multifocal and unifocal groups. Statistical analyses included chi-square tests, t-tests, Kaplan–Meier survival estimation, and log-rank testing, with significance defined at p<0.05.",
        "Results": "A total of 215 patients were included (multifocal n=77; unifocal n=138), with female predominance in both cohorts. Patients with multifocal disease were significantly younger than those with unifocal tumors (44.8 ± 12.5 vs. 48.5 ± 15.3 years; p=0.038). Papillary carcinoma was the predominant subtype across groups. Multifocal tumors showed higher frequencies of extrathyroidal extension (34.3% vs. 27.2%) and lymph node metastases (67.6% vs. 50.0%), although these differences did not reach statistical significance. Survival outcomes were excellent in both groups, with 3- and 5-year survival at 100% for multifocal disease and 96.0% for unifocal disease. No significant difference in restricted mean survival time was observed (92.87 vs. 92.67 months; p=0.140).",
        "Conclusion": "In this tertiary-care cohort, multifocal thyroid carcinoma exhibited trends toward more aggressive histopathologic features but did not confer worse short-term survival compared to unifocal disease. These findings support individualized treatment planning while emphasizing the overall favorable prognosis of differentiated thyroid malignancies. Larger multicentric prospective studies incorporating molecular data and recurrence endpoints are warranted to refine prognostic stratification in South Asian populations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Implications of Tumor Focality in Thyroid Carcinoma: A 5-Year Retrospective Cohort Study from a South Asian Tertiary Care Center</span>. Muhammad Shahzaib Arshad<sup>1</sup>; Hamzah Jehanzeb<sup>1</sup>; Ainul Akbar Mughal, Dr<sup>1</sup>; Hussain Ali Lanewala, Dr<sup>1</sup>; Hamdan Pasha, MD<sup>1</sup>; <u>Fatima Syed Amanullah, Dr</u><sup>2</sup>. <sup>1</sup>Aga Khan University; <sup>2</sup>University of Massachusetts<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The prognostic significance of tumor multifocality in thyroid carcinoma remains controversial. While age, tumor size, histologic subtype, and nodal status are well-established prognostic determinants, the independent impact of multifocal disease on outcomes is less clear. This study evaluates the clinicopathologic characteristics and survival outcomes associated with multifocal versus unifocal thyroid carcinoma in a South Asian tertiary care population.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using data from the Aga Khan University cancer registry, including all patients undergoing thyroidectomy for thyroid malignancy between January 2017 and January 2022. Demographic variables, tumor focality, histologic subtype, capsular and vascular invasion, extrathyroidal extension, lymph node metastases, and survival outcomes were compared between multifocal and unifocal groups. Statistical analyses included chi-square tests, t-tests, Kaplan–Meier survival estimation, and log-rank testing, with significance defined at p<0.05.</p>\n\n<p><strong>Results: </strong>A total of 215 patients were included (multifocal n=77; unifocal n=138), with female predominance in both cohorts. Patients with multifocal disease were significantly younger than those with unifocal tumors (44.8 ± 12.5 vs. 48.5 ± 15.3 years; p=0.038). Papillary carcinoma was the predominant subtype across groups. Multifocal tumors showed higher frequencies of extrathyroidal extension (34.3% vs. 27.2%) and lymph node metastases (67.6% vs. 50.0%), although these differences did not reach statistical significance. Survival outcomes were excellent in both groups, with 3- and 5-year survival at 100% for multifocal disease and 96.0% for unifocal disease. No significant difference in restricted mean survival time was observed (92.87 vs. 92.67 months; p=0.140).</p>\n\n<p><strong>Conclusion: </strong>In this tertiary-care cohort, multifocal thyroid carcinoma exhibited trends toward more aggressive histopathologic features but did not confer worse short-term survival compared to unifocal disease. These findings support individualized treatment planning while emphasizing the overall favorable prognosis of differentiated thyroid malignancies. Larger multicentric prospective studies incorporating molecular data and recurrence endpoints are warranted to refine prognostic stratification in South Asian populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154155--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S468",
      "content_id": "153869",
      "abstract_number": "S468",
      "poster_number": "",
      "title": "GLUT1 Inhibition and T2R Activation Synergistically Reduce Viability in Papillary Thyroid Carcinoma Cells",
      "summary": "Tumor cell proliferation is heavily driven by metabolic reprogramming that supports high energy and biosynthetic demands of growth through the Warburg Effect. Cancer cells preferentially use aerobic glycolysis, converting glucose to lactate despite sufficient oxygen. Upregulation of glucose transporter GLUT1 (SLC2A1) in many epithelial cancers provide a ubiquitous growth advantage through enhanced glucose uptake...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153869",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kim B Le, BS",
      "presenter": "Kim B Le, BS",
      "authors": "Kim B Le, BS ; Sarah Sywanycz, BS; Margaret A Heller, MD; Brianna L Buchler, PhD; Kyle Polen, BS; Robert J Lee, PhD; Ryan M Carey, MD",
      "normalized_authors": [
        "Kim B Le",
        "Sarah Sywanycz",
        "Margaret A Heller",
        "Brianna L Buchler",
        "Kyle Polen",
        "Robert J Lee",
        "Ryan M Carey"
      ],
      "affiliations": [
        "University of Pennsylvania"
      ],
      "normalized_institutions": [
        "University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_18_04%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_18_04%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153869"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_10%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_10%E2%80%AFPM.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153869"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153869/screenshot%202025-12-04%20at%201_19_26%E2%80%AFpm.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153869/screenshot%202025-12-04%20at%201_19_26%E2%80%AFpm.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153869"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_30%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_30%E2%80%AFPM.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153869"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 348,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kim B Le, BS ; Sarah Sywanycz, BS; Margaret A Heller, MD; Brianna L Buchler, PhD; Kyle Polen, BS; Robert J Lee, PhD; Ryan M Carey, MD",
        "Affiliations": "University of Pennsylvania",
        "Abstract": "Tumor cell proliferation is heavily driven by metabolic reprogramming that supports high energy and biosynthetic demands of growth through the Warburg Effect. Cancer cells preferentially use aerobic glycolysis, converting glucose to lactate despite sufficient oxygen. Upregulation of glucose transporter GLUT1 (SLC2A1) in many epithelial cancers provide a ubiquitous growth advantage through enhanced glucose uptake leading to elevated glycolytic activity. In head and neck squamous cell carcinoma (HNSCC), GLUT1 localizes both to the plasma membrane and to perinuclear compartments—likely the Golgi apparatus—and its inhibition with the small-molecule inhibitor BAY-876 reduces cell viability, an effect amplified by co-activation of bitter taste receptors (T2Rs). Because papillary thyroid carcinoma (PTC) shares features of metabolic dysregulation, we hypothesized that GLUT1 blockade, alone or in combination with T2R agonists, would similarly impair PTC cell viability. Three PTC cell lines (MDA-T32, MDA-T68, MDA-T85) were treated with GLUT1 inhibitor BAY-876, bitter agonist lidocaine, or both. Cell viability (crystal violet) and caspase-3/7 activation (CellEvent) were quantified following treatment. GLUT1 subcellular localization was assessed via immunofluorescence, and GLUT1 (SLC2A1) gene expression was measured via RT-qPCR. In MDA-T85 cells, treatments with either BAY-876 or lidocaine alone decreased cell viability by ~25% compared to control, whereas co-treatment produced a ~75% reduction (Figure 1). Co-treatment also induced significantly greater caspase-3/7 activation than untreated cells or single-agent treatments (Figure 2). Immunofluorescence revealed perinuclear localization of GLUT1 in all three PTC cell lines, suggestive of Golgi association (Figure 3). Basal GLUT1 expression ranged from 30-60% of housekeeping gene ubiquitin across cell lines (Figure 4). These data demonstrate that GLUT1 inhibition via BAY-876 has pro-apoptotic signaling in PTC, paralleling findings in HNSCC , and that T2R activation markedly enhances this effect. Perinuclear GLUT1 localization and moderate GLUT1 expression further support the relevance of GLUT1-dependent metabolic pathways in thyroid cancer biology. Together, these findings highlight GLUT1 blockade—especially in combination with T2R agonists—as a promising therapeutic strategy across epithelial malignancies. Future studies exploring synergistic bitter agonist and GLUT1-targeted therapies in other epithelial cancers and validation via in vivo models will help optimize translational potential. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>GLUT1 Inhibition and T2R Activation Synergistically Reduce Viability in Papillary Thyroid Carcinoma Cells</span>. <u>Kim B Le, BS</u>; Sarah Sywanycz, BS; Margaret A Heller, MD; Brianna L Buchler, PhD; Kyle Polen, BS; Robert J Lee, PhD; Ryan M Carey, MD. University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Tumor cell proliferation is heavily driven by metabolic reprogramming that supports high energy and biosynthetic demands of growth through the Warburg Effect. Cancer cells preferentially use aerobic glycolysis, converting glucose to lactate despite sufficient oxygen. Upregulation of glucose transporter GLUT1 (SLC2A1) in many epithelial cancers provide a ubiquitous growth advantage through enhanced glucose uptake leading to elevated glycolytic activity. In head and neck squamous cell carcinoma (HNSCC), GLUT1 localizes both to the plasma membrane and to perinuclear compartments—likely the Golgi apparatus—and its inhibition with the small-molecule inhibitor BAY-876 reduces cell viability, an effect amplified by co-activation of bitter taste receptors (T2Rs). Because papillary thyroid carcinoma (PTC) shares features of metabolic dysregulation, we hypothesized that GLUT1 blockade, alone or in combination with T2R agonists, would similarly impair PTC cell viability.</p>\n\n<p>Three PTC cell lines (MDA-T32, MDA-T68, MDA-T85) were treated with GLUT1 inhibitor BAY-876, bitter agonist lidocaine, or both. Cell viability (crystal violet) and caspase-3/7 activation (CellEvent) were quantified following treatment. GLUT1 subcellular localization was assessed via immunofluorescence, and GLUT1 (SLC2A1) gene expression was measured via RT-qPCR.</p>\n\n<p>In MDA-T85 cells, treatments with either BAY-876 or lidocaine alone decreased cell viability by ~25% compared to control, whereas co-treatment produced a ~75% reduction (Figure 1). Co-treatment also induced significantly greater caspase-3/7 activation than untreated cells or single-agent treatments (Figure 2). Immunofluorescence revealed perinuclear localization of GLUT1 in all three PTC cell lines, suggestive of Golgi association (Figure 3). Basal GLUT1 expression ranged from 30-60% of housekeeping gene ubiquitin across cell lines (Figure 4).</p>\n\n<p>These data demonstrate that GLUT1 inhibition via BAY-876 has pro-apoptotic signaling in PTC, paralleling findings in HNSCC , and that T2R activation markedly enhances this effect. Perinuclear GLUT1 localization and moderate GLUT1 expression further support the relevance of GLUT1-dependent metabolic pathways in thyroid cancer biology. Together, these findings highlight GLUT1 blockade—especially in combination with T2R agonists—as a promising therapeutic strategy across epithelial malignancies. Future studies exploring synergistic bitter agonist and GLUT1-targeted therapies in other epithelial cancers and validation via in vivo models will help optimize translational potential.</p>\n\n<p><strong>Figure 1.</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_18_04%E2%80%AFPM.png' /></p>\n\n<p><strong>Figure 2.</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_10%E2%80%AFPM.png' /></p>\n\n<p><strong>Figure 3.</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153869/screenshot%202025-12-04%20at%201_19_26%E2%80%AFpm.png' /></p>\n\n<p><strong>Figure 4.</strong></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153869/Screenshot%202025-12-04%20at%201_19_30%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153869--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S469",
      "content_id": "154777",
      "abstract_number": "S469",
      "poster_number": "",
      "title": "Impact of Serum and Tumor PD-L1 Expression on Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma",
      "summary": "These findings suggest that higher serum and tumor PD-L1 expression were associated with aggressive clinicopathologic features of PTC, supporting PD-L1 as a potential prognostic biomarker in this population.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154777",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Srivatsa Surya Vasudevan, MD, MS",
      "presenter": "Srivatsa Surya Vasudevan, MD, MS",
      "authors": "Srivatsa Surya Vasudevan, MD, MS 1 ; Janmaris Marin Fermin, MD 1 ; Lindsay Boven, MD 1 ; Abhijit Gundale, MD 2 ; Tara Moore-Medlin 1 ; Alok R Khandelwal, PhD 1 ; Cherie-Ann O Nathan, MD, FACS 1",
      "normalized_authors": [
        "Srivatsa Surya Vasudevan",
        "Janmaris Marin Fermin",
        "Lindsay Boven",
        "Abhijit Gundale",
        "Tara Moore-Medlin",
        "Alok R Khandelwal",
        "Cherie-Ann O Nathan"
      ],
      "affiliations": [
        "Louisiana State University Health Sciences Center",
        "University of Florida College of Medicine"
      ],
      "normalized_institutions": [
        "Louisiana State University Health Sciences Center",
        "University of Florida College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 280,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Srivatsa Surya Vasudevan, MD, MS 1 ; Janmaris Marin Fermin, MD 1 ; Lindsay Boven, MD 1 ; Abhijit Gundale, MD 2 ; Tara Moore-Medlin 1 ; Alok R Khandelwal, PhD 1 ; Cherie-Ann O Nathan, MD, FACS 1",
        "Affiliations": "1 Louisiana State University Health Sciences Center; 2 University of Florida College of Medicine",
        "Background": "Aggressive variant of papillary thyroid cancer (PTC) accounts for 5% of cases and occasionally becomes radioactive-iodine refractory, leaving limited treatment options. Although previous reports support the role of PD-L1 expression as a predictive biomarker in PTC tumor samples, there is a scarcity of studies evaluating PD-L1 in serum in aggressive PTC. We aimed to assess the prognostic value of PD-L1 levels in serum of patients with PTC and determine its association with clinicopathologic characteristics, including aggressiveness and lymph node metastasis.",
        "Methods": "A retrospective chart review was conducted to identify patients with PTC at our institution and the Veterans Affairs Medical Center. Enzyme-linked immunosorbent assay (ELISA) determined serum levels of PD-L1. Tumor was immunostained for PD-L1 (E1L3N). Logistic and linear regression analysis models were utilized to assess the impact of serum PD-L1 and tumor PD-L1 expression as prognostic markers in PTC.",
        "Results": "Among 156 subjects included in the analysis. Within the PTC subgroup, aggressive PTC was associated with significantly higher serum PD-L1 levels than non-aggressive PTC (β = 24.9, 95% CI 11.5–38.3; p = 0.0003). Extrathyroidal extension (β = 30.80; 95% CI 10.11-51.49; p = 0.004), advanced T4 stage (β = 29.17; 95% CI, 9.92-48.42; p = 0.003), and aggressive histology (β = 39.26; 95% CI, 5.98-72.54; p = 0.02) were associated with higher PD-L1 serum levels. PD-L1 expression in the tumor was associated with positive BRAFV600E mutation (OR: 5.06; 95% CI 1.03-30.7, p = 0.04).",
        "Conclusions": "These findings suggest that higher serum and tumor PD-L1 expression were associated with aggressive clinicopathologic features of PTC, supporting PD-L1 as a potential prognostic biomarker in this population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Serum and Tumor PD-L1 Expression on Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma</span>. <u>Srivatsa Surya Vasudevan, MD, MS</u><sup>1</sup>; Janmaris Marin Fermin, MD<sup>1</sup>; Lindsay Boven, MD<sup>1</sup>; Abhijit Gundale, MD<sup>2</sup>; Tara Moore-Medlin<sup>1</sup>; Alok R Khandelwal, PhD<sup>1</sup>; Cherie-Ann O Nathan, MD, FACS<sup>1</sup>. <sup>1</sup>Louisiana State University Health Sciences Center; <sup>2</sup>University of Florida College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Aggressive variant of papillary thyroid cancer (PTC) accounts for 5% of cases and occasionally becomes radioactive-iodine refractory, leaving limited treatment options. Although previous reports support the role of PD-L1 expression as a predictive biomarker in PTC tumor samples, there is a scarcity of studies evaluating PD-L1 in serum in aggressive PTC. We aimed to assess the prognostic value of PD-L1 levels in serum of patients with PTC and determine its association with clinicopathologic characteristics, including aggressiveness and lymph node metastasis.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted to identify patients with PTC at our institution and the Veterans Affairs Medical Center. Enzyme-linked immunosorbent assay (ELISA) determined serum levels of PD-L1. Tumor was immunostained for PD-L1 (E1L3N). Logistic and linear regression analysis models were utilized to assess the impact of serum PD-L1 and tumor PD-L1 expression as prognostic markers in PTC.</p>\n\n<p><strong>Results: </strong>Among 156 subjects included in the analysis. Within the PTC subgroup, aggressive PTC was associated with significantly higher serum PD-L1 levels than non-aggressive PTC (β = 24.9, 95% CI 11.5–38.3; p = 0.0003). Extrathyroidal extension (β = 30.80; 95% CI 10.11-51.49; p = 0.004), advanced T4 stage (β = 29.17; 95% CI, 9.92-48.42; p = 0.003), and aggressive histology (β = 39.26; 95% CI, 5.98-72.54; p = 0.02) were associated with higher PD-L1 serum levels. PD-L1 expression in the tumor was associated with positive BRAFV600E mutation (OR: 5.06; 95% CI 1.03-30.7, p = 0.04).</p>\n\n<p><strong>Conclusions:</strong> These findings suggest that higher serum and tumor PD-L1 expression were associated with aggressive clinicopathologic features of PTC, supporting PD-L1 as a potential prognostic biomarker in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154777--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S470",
      "content_id": "154659",
      "abstract_number": "S470",
      "poster_number": "",
      "title": "Targeting TGF-β Sensitivity in Cancer Associated Fibroblast-Directed Therapy in Head and Neck Cancer",
      "summary": "Patient-derived CAFs exhibit a dysregulated TGF-β–SMAD7 feedback loop that distinguishes them from matched NFs and confers heightened sensitivity to TGF-β pathway inhibitors. These findings identify a fibroblast-specific therapeutic window within the HNSCC microenvironment and support development of CAF-directed strategies using agents such as pirfenidone or ALK5 inhibitors. Ongoing studies will define downstream...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154659",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shu-Yun Cheng, MS",
      "presenter": "Shu-Yun Cheng, MS",
      "authors": "Shu-Yun Cheng, MS ; Ella P Jackert; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD",
      "normalized_authors": [
        "Shu-Yun Cheng",
        "Ella P Jackert",
        "Liyang Tang",
        "Daniel Kwon",
        "Niels Kokot",
        "Uttam Sinha",
        "Yang Chai",
        "Albert Y Han"
      ],
      "affiliations": [
        "University of Southern California"
      ],
      "normalized_institutions": [
        "University of Southern California"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 319,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shu-Yun Cheng, MS ; Ella P Jackert; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD",
        "Affiliations": "University of Southern California",
        "Background": "Fibroblasts within the tumor microenvironment strongly influence treatment failure in head and neck squamous cell carcinoma (HNSCC). Cancer-associated fibroblasts (CAFs) comprise heterogeneous subpopulations with distinct functional programs, yet the signaling pathways that maintain these phenotypes remain poorly defined. We sought to establish patient-derived CAF models and identify actionable signaling vulnerabilities that distinguish CAFs from their matched normal fibroblasts (NFs).",
        "Methods": "Fresh surgical tissue from a patient with tongue HNSCC was enzymatically dissociated to derive matched CAF and NF cultures. Fibroblast identity was confirmed morphologically and by α-smooth muscle actin (α-SMA) expression. TGF-β pathway activity was perturbed using TGF-β1 ligand (10 ng/mL), the ALK5 inhibitor SB431542 (10 µM), and pirfenidone (10 mg/mL). After 48 hours, RNA was harvested for RT-qPCR. RNA-sequencing was used to identify transcriptional features distinguishing CAFs and NFs.",
        "Results": "Matched CAF and NF cultures were successfully established. CAFs demonstrated α-SMA upregulation consistent with activated myofibroblast phenotype. RNA-sequencing revealed marked suppression of SMAD7, a negative regulator of canonical TGF-β signaling, in CAFs relative to NFs, implicating loss of TGF-β feedback control as a defining CAF feature. Exogenous TGF-β1 increased SMAD7 expression in CAFs (fold-change 1.45; p < 0.05) but not NFs, indicating heightened pathway responsiveness. Pharmacologic blockade of TGF-β signaling further amplified SMAD7 expression in CAFs, SB431542 (1.71-fold; p < 0.05) and pirfenidone (2.48-fold; p < 0.0001), with minimal or no induction in NFs. This selective response suggests CAF-restricted vulnerability to TGF-β pathway disruption.",
        "Conclusion": "Patient-derived CAFs exhibit a dysregulated TGF-β–SMAD7 feedback loop that distinguishes them from matched NFs and confers heightened sensitivity to TGF-β pathway inhibitors. These findings identify a fibroblast-specific therapeutic window within the HNSCC microenvironment and support development of CAF-directed strategies using agents such as pirfenidone or ALK5 inhibitors. Ongoing studies will define downstream transcriptional programs affected by SMAD7 restoration and evaluate whether pharmacologic modulation of CAF behavior enhances antitumor immune responses and therapeutic sensitivity.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Targeting TGF-β Sensitivity in Cancer Associated Fibroblast-Directed Therapy in Head and Neck Cancer</span>. <u>Shu-Yun Cheng, MS</u>; Ella P Jackert; Liyang Tang, MD; Daniel Kwon, MD; Niels Kokot, MD; Uttam Sinha, MD; Yang Chai, DDS, PhD; Albert Y Han, MD, PhD. University of Southern California<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Fibroblasts within the tumor microenvironment strongly influence treatment failure in head and neck squamous cell carcinoma (HNSCC). Cancer-associated fibroblasts (CAFs) comprise heterogeneous subpopulations with distinct functional programs, yet the signaling pathways that maintain these phenotypes remain poorly defined. We sought to establish patient-derived CAF models and identify actionable signaling vulnerabilities that distinguish CAFs from their matched normal fibroblasts (NFs).</p>\n\n<p><strong>Methods: </strong>Fresh surgical tissue from a patient with tongue HNSCC was enzymatically dissociated to derive matched CAF and NF cultures. Fibroblast identity was confirmed morphologically and by α-smooth muscle actin (α-SMA) expression. TGF-β pathway activity was perturbed using TGF-β1 ligand (10 ng/mL), the ALK5 inhibitor SB431542 (10 µM), and pirfenidone (10 mg/mL). After 48 hours, RNA was harvested for RT-qPCR. RNA-sequencing was used to identify transcriptional features distinguishing CAFs and NFs.</p>\n\n<p><strong>Results: </strong>Matched CAF and NF cultures were successfully established. CAFs demonstrated α-SMA upregulation consistent with activated myofibroblast phenotype. RNA-sequencing revealed marked suppression of SMAD7, a negative regulator of canonical TGF-β signaling, in CAFs relative to NFs, implicating loss of TGF-β feedback control as a defining CAF feature. Exogenous TGF-β1 increased SMAD7 expression in CAFs (fold-change 1.45; p < 0.05) but not NFs, indicating heightened pathway responsiveness. Pharmacologic blockade of TGF-β signaling further amplified SMAD7 expression in CAFs, SB431542 (1.71-fold; p < 0.05) and pirfenidone (2.48-fold; p < 0.0001), with minimal or no induction in NFs. This selective response suggests CAF-restricted vulnerability to TGF-β pathway disruption.</p>\n\n<p><strong>Conclusion: </strong>Patient-derived CAFs exhibit a dysregulated TGF-β–SMAD7 feedback loop that distinguishes them from matched NFs and confers heightened sensitivity to TGF-β pathway inhibitors. These findings identify a fibroblast-specific therapeutic window within the HNSCC microenvironment and support development of CAF-directed strategies using agents such as pirfenidone or ALK5 inhibitors. Ongoing studies will define downstream transcriptional programs affected by SMAD7 restoration and evaluate whether pharmacologic modulation of CAF behavior enhances antitumor immune responses and therapeutic sensitivity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154659--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S471",
      "content_id": "154268",
      "abstract_number": "S471",
      "poster_number": "",
      "title": "NDSI and RNR as Novel Prognostic Indices in Node-Positive Oral Cancer",
      "summary": "NDSI and RNR are simple, reproducible histopathological indices that enhance nodal assessment in OSCC by quantifying tumor occupation and residual lymphoid tissue. These metrics correlate meaningfully with advanced nodal stage, ENE, LVI, and immune contexture (low TILs), offering a novel prognostic layer beyond conventional nodal size. Further validation in prospective, multicenter studies is warranted to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154268",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Karthik Rao, MCh",
      "presenter": "Karthik Rao, MCh",
      "authors": "Karthik Rao, MCh ; Teertha Shetty; Shanthi Velusamy, MD; Prajwal Dange, MCh; Sreeram MP",
      "normalized_authors": [
        "Karthik Rao, MCh",
        "Teertha Shetty",
        "Shanthi Velusamy",
        "Prajwal Dange, MCh",
        "Sreeram MP"
      ],
      "affiliations": [
        "Sri Shankara Cancer Hospital and Research Center"
      ],
      "normalized_institutions": [
        "Sri Shankara Cancer Hospital and Research Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154268/NDSI.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154268/NDSI.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154268"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 409,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Materials and Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Karthik Rao, MCh ; Teertha Shetty; Shanthi Velusamy, MD; Prajwal Dange, MCh; Sreeram MP",
        "Affiliations": "Sri Shankara Cancer Hospital and Research Center",
        "Introduction": "Cervical lymph node status remains the most critical prognostic factor in oral squamous cell carcinoma (OSCC). Current staging systems primarily rely on the maximum dimension of the metastatic lymph node, often overlooking the actual tumor burden and the extent of nodal replacement by the deposit. This study introduces and evaluates two simple, quantifiable histopathological indices—the Nodal Deposit-to-Size Index (NDSI) and the Residual Nodal Ratio (RNR) to assess the degree of tumor infiltration within metastatic nodes and correlate these measures with established adverse pathological features.",
        "Materials and Methods": "This retrospective, single-center observational study was conducted at a tertiary cancer center from 2024 to 2025 and included 94 patients with node-positive (pN+) OSCC. For patients with multiple positive nodes, the largest metastatic node was selected for analysis. The NDSI was calculated as the maximum diameter of the metastatic deposit divided by the maximum nodal diameter, expressed as a percentage. The RNR was defined as the complementary percentage to NDSI, representing the residual lymphoid tissue volume, such that NDSI + RNR = 100%. Primary outcomes included correlations of NDSI and RNR with extranodal extension (ENE), N category (N1, N2, N3), lymphovascular invasion (LVI), and tumor-infiltrating lymphocytes (TILs). Statistical analyses included receiver operating characteristic (ROC) curves for predictive accuracy, Spearman correlation for associations, and logistic regression for composite outcome prediction.",
        "Results": "The mean NDSI was 57.3% ± 16.9, and the mean RNR was 42.7% ± 16.9, indicating that most involved nodes retain substantial residual lymphoid architecture. NDSI demonstrated strong predictive accuracy for ENE, with a cutoff of 77.5% yielding an area under the curve (AUC) of 0.760 (p < 0.001), 74% sensitivity, and 76% specificity. Higher NDSI was significantly correlated with advanced N category (N3 disease) and increased ipsilateral lymph node density. Conversely, higher RNR was associated with lower N category (N1 disease). Furthermore, high NDSI and low RNR were significantly linked to the presence of LVI and, notably, to lower TIL density. In multinomial logistic regression, NDSI trended toward association with adverse composite outcomes (p = 0.042).",
        "Conclusion": "NDSI and RNR are simple, reproducible histopathological indices that enhance nodal assessment in OSCC by quantifying tumor occupation and residual lymphoid tissue. These metrics correlate meaningfully with advanced nodal stage, ENE, LVI, and immune contexture (low TILs), offering a novel prognostic layer beyond conventional nodal size. Further validation in prospective, multicenter studies is warranted to standardize definitions and evaluate their impact on long term disease free and overall survival.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>NDSI and RNR as Novel Prognostic Indices in Node-Positive Oral Cancer</span>. <u>Karthik Rao, MCh</u>; Teertha Shetty; Shanthi Velusamy, MD; Prajwal Dange, MCh; Sreeram MP. Sri Shankara Cancer Hospital and Research Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Cervical lymph node status remains the most critical prognostic factor in oral squamous cell carcinoma (OSCC). Current staging systems primarily rely on the maximum dimension of the metastatic lymph node, often overlooking the actual tumor burden and the extent of nodal replacement by the deposit. This study introduces and evaluates two simple, quantifiable histopathological indices—the Nodal Deposit-to-Size Index (NDSI) and the Residual Nodal Ratio (RNR) to assess the degree of tumor infiltration within metastatic nodes and correlate these measures with established adverse pathological features. </p>\n\n<p><strong>Materials and Methods: </strong>This retrospective, single-center observational study was conducted at a tertiary cancer center from 2024 to 2025 and included 94 patients with node-positive (pN+) OSCC. For patients with multiple positive nodes, the largest metastatic node was selected for analysis. The NDSI was calculated as the maximum diameter of the metastatic deposit divided by the maximum nodal diameter, expressed as a percentage. The RNR was defined as the complementary percentage to NDSI, representing the residual lymphoid tissue volume, such that NDSI + RNR = 100%. Primary outcomes included correlations of NDSI and RNR with extranodal extension (ENE), N category (N1, N2, N3), lymphovascular invasion (LVI), and tumor-infiltrating lymphocytes (TILs). Statistical analyses included receiver operating characteristic (ROC) curves for predictive accuracy, Spearman correlation for associations, and logistic regression for composite outcome prediction.</p>\n\n<p><strong>Results: </strong>The mean NDSI was 57.3% ± 16.9, and the mean RNR was 42.7% ± 16.9, indicating that most involved nodes retain substantial residual lymphoid architecture. NDSI demonstrated strong predictive accuracy for ENE, with a cutoff of 77.5% yielding an area under the curve (AUC) of 0.760 (p < 0.001), 74% sensitivity, and 76% specificity. Higher NDSI was significantly correlated with advanced N category (N3 disease) and increased ipsilateral lymph node density. Conversely, higher RNR was associated with lower N category (N1 disease). Furthermore, high NDSI and low RNR were significantly linked to the presence of LVI and, notably, to lower TIL density. In multinomial logistic regression, NDSI trended toward association with adverse composite outcomes (p = 0.042).</p>\n\n<p><strong>Conclusion: </strong>NDSI and RNR are simple, reproducible histopathological indices that enhance nodal assessment in OSCC by quantifying tumor occupation and residual lymphoid tissue. These metrics correlate meaningfully with advanced nodal stage, ENE, LVI, and immune contexture (low TILs), offering a novel prognostic layer beyond conventional nodal size. Further validation in prospective, multicenter studies is warranted to standardize definitions and evaluate their impact on long term disease free and overall survival.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154268/NDSI.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154268--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S472",
      "content_id": "153698",
      "abstract_number": "S472",
      "poster_number": "",
      "title": "Clinicopathological significance of MYB-NFIB fusion and its breakpoint variants in head and neck Adenoid Cystic Carcinoma",
      "summary": "The TruSight RNA Fusion Panel demonstrates robust fusion and breakpoint detection. MYB-NFIB fusion-positive tumors predominantly arise in minor salivary glands, whereas fusion-negative tumors occur more frequently from major salivary glands. Although MYB breakpoint categorization did not demonstrate statistically significant differences in outcomes, numerical trends suggest that more proximal MYB truncations may...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153698",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sarah Honjo, MD",
      "presenter": "Sarah Honjo, MD",
      "authors": "Sarah Honjo, MD ; Anita Pothukuchi; Joseph O Humtsoe, PhD; Annemieke van Zante, MD, PhD; Patrick K Ha, MD",
      "normalized_authors": [
        "Sarah Honjo",
        "Anita Pothukuchi",
        "Joseph O Humtsoe",
        "Annemieke van Zante",
        "Patrick K Ha"
      ],
      "affiliations": [
        "University of California, San Francisco"
      ],
      "normalized_institutions": [
        "University of California, San Francisco"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sarah Honjo, MD ; Anita Pothukuchi; Joseph O Humtsoe, PhD; Annemieke van Zante, MD, PhD; Patrick K Ha, MD",
        "Affiliations": "University of California, San Francisco",
        "Background": "Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy, characterized by a high incidence of perineural invasion (PNI) and distant metastasis. Up to 60% of cases harbor MYB-NFIB fusions, which typically result from t(6;9) chromosomal translocation. This event leads to loss of the 3' end of MYB , including the negative regulatory domain and the 3’ untranslated region. These alterations are thought to contribute to increased MYB overexpression, promoting uncontrolled cellular proliferation and tumor progression. Although distinct breakpoint variants within MYB and NFIB may influence MYB expression, signalling pathways, and tumor aggressiveness, their clinical relevance remains unclear. Here, we report the incidence of MYB-NFIB fusion variants and examine their association with clinicopathological parameters in head and neck ACC.",
        "Methods": "Patients diagnosed with head and neck ACC between January 1999 and January 2024 were retrospectively reviewed (N=44). Formalin-fixed paraffin-embedded (FFPE) ACC specimens from those patients were collected. An expert pathologist confirmed the diagnosis, tissue morphology, and cellularity. MYB-NFIB fusion variants and MYB breakpoint locations were identified with TruSight RNA Fusion Panel (Illumina). In cases with multiple MYB-NFIB breakpoints, transcripts with the highest read counts were selected for analysis. Cases harboring any MYB-NFIB fusion were classified as MYB-NFIB fusion-positive. Associations between fusion status and clinicopathological parameters were analyzed using Fisher’s exact, Chi-square, and Mann-Whitney tests in Prism v10.6.1 (GraphPad), with p <0.05 considered statistically significant. Time to recurrence was defined as the interval from completion of primary treatment to the first recurrence.",
        "Results": "Among 44 patients, 21 harbored MYB-NFIB fusions, 9 had non- MYB-NFIB fusion types, and 14 had no fusion. Twelve patients had single fusion products, and eighteen patients had multiple fusion products. MYB-NFIB positive tumors arose significantly more from minor salivary glands (76.2%, p = 0.017) compared with fusion-negative tumors, which more frequently originated in major salivary glands. No statistically significant differences were detected between MYB-NFIB fusion-positive and fusion-negative tumors with respect to age, sex, T-stage, histologic patterns, PNI, local recurrence, distant metastasis, recurrence-free survival, or overall survival. Within MYB-NFIB fusion-positive tumors, MYB breakpoints were observed at exons 8 (n=4), exon 9 (n=4), exon 13 (n=2), and exon 15 (n=9). Two patients had MYB breakpoints at both exon 8 and 9. When categorized by breakpoint location, MYB exon 8-13 fusions (n=12) showed numerically higher rates of PNI (100% vs 57% for exon 15 fusions; p=0.063) and more frequent distant metastasis (4/12 vs 0/9; p=0.104), although neither association reached statistical significance.",
        "Conclusions": "The TruSight RNA Fusion Panel demonstrates robust fusion and breakpoint detection. MYB-NFIB fusion-positive tumors predominantly arise in minor salivary glands, whereas fusion-negative tumors occur more frequently from major salivary glands. Although MYB breakpoint categorization did not demonstrate statistically significant differences in outcomes, numerical trends suggest that more proximal MYB truncations may be associated with aggressive clinicopathological features. Expanding our cohort will help clarify the clinical significance of MYB-NFIB fusion variants and help advance more personalized, biology-guided care for ACC patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinicopathological significance of MYB-NFIB fusion and its breakpoint variants in head and neck Adenoid Cystic Carcinoma</span>. <u>Sarah Honjo, MD</u>; Anita Pothukuchi; Joseph O Humtsoe, PhD; Annemieke van Zante, MD, PhD; Patrick K Ha, MD. University of California, San Francisco<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy, characterized by a high incidence of perineural invasion (PNI) and distant metastasis. Up to 60% of cases harbor <em>MYB-NFIB</em> fusions, which typically result from t(6;9) chromosomal translocation. This event leads to loss of the 3' end of <em>MYB</em>, including the negative regulatory domain and the 3’ untranslated region. These alterations are thought to contribute to increased <em>MYB</em> overexpression, promoting uncontrolled cellular proliferation and tumor progression. Although distinct breakpoint variants within <em>MYB</em> and <em>NFIB </em>may influence <em>MYB</em> expression, signalling pathways, and tumor aggressiveness, their clinical relevance remains unclear. Here, we report the incidence of<em> MYB-NFIB</em> fusion variants and examine their association with clinicopathological parameters in head and neck ACC. </p>\n\n<p><strong>Methods: </strong>Patients diagnosed with head and neck ACC between January 1999 and January 2024 were retrospectively reviewed (N=44). Formalin-fixed paraffin-embedded (FFPE) ACC specimens from those patients were collected. An expert pathologist confirmed the diagnosis, tissue morphology, and cellularity. <em>MYB-NFIB</em> fusion variants and <em>MYB</em> breakpoint locations were identified with TruSight RNA Fusion Panel (Illumina). In cases with multiple <em>MYB-NFIB</em> breakpoints, transcripts with the highest read counts were selected for analysis. Cases harboring any <em>MYB-NFIB</em> fusion were classified as <em>MYB-NFIB</em> fusion-positive. Associations between fusion status and clinicopathological parameters were analyzed using Fisher’s exact, Chi-square, and Mann-Whitney tests in Prism v10.6.1 (GraphPad), with p <0.05 considered statistically significant. Time to recurrence was defined as the interval from completion of primary treatment to the first recurrence.</p>\n\n<p><strong>Results: </strong>Among 44 patients, 21 harbored <em>MYB-NFIB</em> fusions, 9 had non-<em>MYB-NFIB</em> fusion types, and 14 had no fusion. Twelve patients had single fusion products, and eighteen patients had multiple fusion products. <em>MYB-NFIB</em> positive tumors arose significantly more from minor salivary glands (76.2%, p = 0.017) compared with fusion-negative tumors, which more frequently originated in major salivary glands. No statistically significant differences were detected between <em>MYB-NFIB</em> fusion-positive and fusion-negative tumors with respect to age, sex, T-stage, histologic patterns, PNI, local recurrence, distant metastasis, recurrence-free survival, or overall survival. Within <em>MYB-NFIB</em> fusion-positive tumors, <em>MYB</em> breakpoints were observed at exons 8 (n=4), exon 9 (n=4), exon 13 (n=2), and exon 15 (n=9). Two patients had <em>MYB</em> breakpoints at both exon 8 and 9. When categorized by breakpoint location, <em>MYB</em> exon 8-13 fusions (n=12) showed numerically higher rates of PNI (100% vs 57% for exon 15 fusions; p=0.063) and more frequent distant metastasis (4/12 vs 0/9; p=0.104), although neither association reached statistical significance. </p>\n\n<p><strong>Conclusions: </strong>The TruSight RNA Fusion Panel demonstrates robust fusion and breakpoint detection. <em>MYB-NFIB</em> fusion-positive tumors predominantly arise in minor salivary glands, whereas fusion-negative tumors occur more frequently from major salivary glands. Although <em>MYB</em> breakpoint categorization did not demonstrate statistically significant differences in outcomes, numerical trends suggest that more proximal <em>MYB</em> truncations may be associated with aggressive clinicopathological features. Expanding our cohort will help clarify the clinical significance of <em>MYB-NFIB</em> fusion variants and help advance more personalized, biology-guided care for ACC patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153698--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S473",
      "content_id": "154105",
      "abstract_number": "S473",
      "poster_number": "",
      "title": "Enhancing anti-tumor immunity by targeting polyamines in the head and neck tumor microenvironment",
      "summary": "Immune checkpoint inhibition (ICI) has emerged as a well-tolerated treatment both in the recurrent/metastatic (R/M) setting and as neoadjuvant therapy for locoregionally advanced head and neck squamous cell carcinoma (HNSCC). While ICI delivers promising results, the tumor microenvironment (TME) diminishes ICI efficacy by recruiting tolerogenic cells, depleting nutrients, generating hypoxia, altering pH, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154105",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Richard A Harbison",
      "presenter": "Richard A Harbison",
      "authors": "Cody Huffman; Jing Wu; Kevin Cho; Leah Shriver; Ryan S Jackson; Jason Rich; Paul Zolkind; Patrik Pipkorn; Benjamin Wahle; Nikhil Rammohan; Anthony J Apicelli; Christine Auberle; Guangyong Peng; Gary Patti; Sidharth V Puram; Richard A Harbison",
      "normalized_authors": [
        "Cody Huffman",
        "Jing Wu",
        "Kevin Cho",
        "Leah Shriver",
        "Ryan S Jackson",
        "Jason Rich",
        "Paul Zolkind",
        "Patrik Pipkorn",
        "Benjamin Wahle",
        "Nikhil Rammohan",
        "Anthony J Apicelli",
        "Christine Auberle",
        "Guangyong Peng",
        "Gary Patti",
        "Sidharth V Puram",
        "Richard A Harbison"
      ],
      "affiliations": [
        "Washington University - St. Louis, MO"
      ],
      "normalized_institutions": [
        "Washington University - St. Louis, MO"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154105/Fold%20change%20Plasma%20vs%20TIF%20ORN%20PUT%2C%20SPD%2C%20SPM%20-%20Split.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154105/Fold%20change%20Plasma%20vs%20TIF%20ORN%20PUT%2C%20SPD%2C%20SPM%20-%20Split.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154105"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 437,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results and Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Cody Huffman; Jing Wu; Kevin Cho; Leah Shriver; Ryan S Jackson; Jason Rich; Paul Zolkind; Patrik Pipkorn; Benjamin Wahle; Nikhil Rammohan; Anthony J Apicelli; Christine Auberle; Guangyong Peng; Gary Patti; Sidharth V Puram; Richard A Harbison",
        "Affiliations": "Washington University - St. Louis, MO",
        "Background": "Immune checkpoint inhibition (ICI) has emerged as a well-tolerated treatment both in the recurrent/metastatic (R/M) setting and as neoadjuvant therapy for locoregionally advanced head and neck squamous cell carcinoma (HNSCC). While ICI delivers promising results, the tumor microenvironment (TME) diminishes ICI efficacy by recruiting tolerogenic cells, depleting nutrients, generating hypoxia, altering pH, and through prodigious production of polyamines (PAs). PAs are molecular chaperones that facilitate protein translation. However, malignant cells excrete these metabolites at high levels into the tumor interstitial fluid (TIF) which impairs the anti-tumor immune response. CD8 + T cell activation depends on tight regulation of intracellular polyamine levels. We report the first human HNSCC TIF data of polyamines and reveal detrimental effects of these molecules on cytotoxic immune responses.",
        "Methods": "Fresh human HNSCC specimens were taken from the operating room, washed, and centrifuged at 400g suspended on a 20 μM mesh to collect TIF. TIF was frozen at -80°C and subjected to UHPLC/MS to quantify polyamine levels. Human CD8 + T cells were isolated from healthy human donor peripheral blood mononuclear cells (PBMCs), activated, and exposed to TIF-equivalent (TIF-Eq) polyamines with or without a polyamine transporter inhibitor (AMXT 1501) to test the effect on cytokine responses. CRISPR ribonucleoprotein complexes with guide RNA specific to ATP13A3 (polyamine transporter) were used to generate knockouts in primary human CD8 + T cells. Co-cultures were performed to test the effect of polyamines on cytotoxic killing function using HLA-A*02-restricted, E7-specific, T cell receptor (TCR) T cells with HPV16 E7-expressing target cells.",
        "Results and Conclusions": "TIF polyamine levels were up to 500 times higher than that found in healthy human donor plasma ( Figure ). Median (interquartile ranges) for plasma vs TIF polyamines were as follows: ornithine 177 μM (101 μM, 349 μM) and 43 μM; putrescine 10 -5 μM (10 -5 μM, 1.13 uM) and 33 μM (15 μM, 79 μM); spermidine 5 μM (1 μM, 7 μM) and 36 μM (12 μM, 121 μM); spermine 0.8 μM (0.7 μM, 1.4 μM) and 30 μM (11 μM, 155 μM). CD8 + T cells rapidly acquire exogenous polyamines over the first 24 hours of activation, catabolize the excess, and excrete acetylated polyamines. TIF-Eq polyamines decrease CD8 + T cell proliferation, IFN?? production, and antigen-specific cytotoxic T cell function which is partially restored by AMXT 1501 or ATP13A3 (polyamine transporter) CRISPR knockout. Polyamine inhibition improves E7-specific CD8 + T cell cytotoxic killing function of E7-expressing targeted cells in a T cell-dependent manner. Ongoing studies aim to identify optimal strategies for depleting polyamines in the TME to provide preclinical evidence supporting translation to a human HNSCC clinical trial.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Enhancing anti-tumor immunity by targeting polyamines in the head and neck tumor microenvironment</span>. Cody Huffman; Jing Wu; Kevin Cho; Leah Shriver; Ryan S Jackson; Jason Rich; Paul Zolkind; Patrik Pipkorn; Benjamin Wahle; Nikhil Rammohan; Anthony J Apicelli; Christine Auberle; Guangyong Peng; Gary Patti; Sidharth V Puram; <u>Richard A Harbison</u>. Washington University - St. Louis, MO<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Immune checkpoint inhibition (ICI) has emerged as a well-tolerated treatment both in the recurrent/metastatic (R/M) setting and as neoadjuvant therapy for locoregionally advanced head and neck squamous cell carcinoma (HNSCC). While ICI delivers promising results, the tumor microenvironment (TME) diminishes ICI efficacy by recruiting tolerogenic cells, depleting nutrients, generating hypoxia, altering pH, and through prodigious production of polyamines (PAs). PAs are molecular chaperones that facilitate protein translation. However, malignant cells excrete these metabolites at high levels into the tumor interstitial fluid (TIF) which impairs the anti-tumor immune response. CD8<sup>+</sup> T cell activation depends on tight regulation of intracellular polyamine levels. We report the first human HNSCC TIF data of polyamines and reveal detrimental effects of these molecules on cytotoxic immune responses.</p>\n\n<p><strong>Methods: </strong>Fresh human HNSCC specimens were taken from the operating room, washed, and centrifuged at 400g suspended on a 20 μM mesh to collect TIF. TIF was frozen at -80°C and subjected to UHPLC/MS to quantify polyamine levels. Human CD8<sup>+</sup> T cells were isolated from healthy human donor peripheral blood mononuclear cells (PBMCs), activated, and exposed to TIF-equivalent (TIF-Eq) polyamines with or without a polyamine transporter inhibitor (AMXT 1501) to test the effect on cytokine responses. CRISPR ribonucleoprotein complexes with guide RNA specific to ATP13A3 (polyamine transporter) were used to generate knockouts in primary human CD8<sup>+</sup> T cells. Co-cultures were performed to test the effect of polyamines on cytotoxic killing function using HLA-A*02-restricted, E7-specific, T cell receptor (TCR) T cells with HPV16 E7-expressing target cells.</p>\n\n<p><strong>Results and Conclusions: </strong>TIF polyamine levels were up to 500 times higher than that found in healthy human donor plasma (<strong>Figure</strong>). Median (interquartile ranges) for plasma vs TIF polyamines were as follows: ornithine 177 μM (101 μM, 349 μM) and 43 μM; putrescine 10<sup>-5</sup> μM (10<sup>-5</sup> μM, 1.13 uM) and 33 μM (15 μM, 79 μM); spermidine 5 μM (1 μM, 7 μM) and 36 μM (12 μM, 121 μM); spermine 0.8 μM (0.7 μM, 1.4 μM) and 30 μM (11 μM, 155 μM). CD8<sup>+</sup> T cells rapidly acquire exogenous polyamines over the first 24 hours of activation, catabolize the excess, and excrete acetylated polyamines. TIF-Eq polyamines decrease CD8<sup>+</sup> T cell proliferation, IFN?? production, and antigen-specific cytotoxic T cell function which is partially restored by AMXT 1501 or ATP13A3 (polyamine transporter) CRISPR knockout. Polyamine inhibition improves E7-specific CD8<sup>+</sup> T cell cytotoxic killing function of E7-expressing targeted cells in a T cell-dependent manner. Ongoing studies aim to identify optimal strategies for depleting polyamines in the TME to provide preclinical evidence supporting translation to a human HNSCC clinical trial.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154105/Fold%20change%20Plasma%20vs%20TIF%20ORN%20PUT%2C%20SPD%2C%20SPM%20-%20Split.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154105--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S474",
      "content_id": "154402",
      "abstract_number": "S474",
      "poster_number": "",
      "title": "FOSL1–p63 Cooperativity Guards Cellular Plasticity at the Tumor Invasive Front in HNSCC",
      "summary": "Head and Neck Squamous Cell Carcinoma (HNSCC) exhibits profound intratumor heterogeneity with recalcitrant tumor responses to therapy, posing a major clinical challenge. HNSCC heterogeneity is driven by cancer stem cells (CSCs) that reside in a hybrid epithelial–mesenchymal transitory (EMT) state, enabling tumor cell survival and promoting invasion. The master epithelial regulator p63 is essential for restraining...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154402",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jennifer Sosa",
      "presenter": "Jennifer Sosa",
      "authors": "Jennifer Sosa ; Satrajit Sinha, PhD",
      "normalized_authors": [
        "Jennifer Sosa",
        "Satrajit Sinha"
      ],
      "affiliations": [
        "University at Buffalo"
      ],
      "normalized_institutions": [
        "University at Buffalo"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 309,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jennifer Sosa ; Satrajit Sinha, PhD",
        "Affiliations": "University at Buffalo",
        "Abstract": "Head and Neck Squamous Cell Carcinoma (HNSCC) exhibits profound intratumor heterogeneity with recalcitrant tumor responses to therapy, posing a major clinical challenge. HNSCC heterogeneity is driven by cancer stem cells (CSCs) that reside in a hybrid epithelial–mesenchymal transitory (EMT) state, enabling tumor cell survival and promoting invasion. The master epithelial regulator p63 is essential for restraining EMT while maintaining epithelial identity and plasticity in these CSCs; however, the factors that cooperate with p63 to preserve this hybrid state remain unknown. To define the transcriptional and epigenomic landscape of CSCs and map their spatial organization within patient tumors, we integrated single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and spatial transcriptomics datasets of HNSCC patients. Our analyses identified a 144-gene CSC signature that reliably marked the CSC populations across matched scRNA-seq and scATAC-seq patient datasets. Motif enrichment of CSC-accessible chromatin regions revealed several oncogenic drivers, such as AP-1 family of Transcription factors and p63, which showed preferential expression at the tumor leading edge – a site populated by tumor cells exhibiting partial EMT and exhibiting enhanced tumor-stromal interactions. In concordance with these findings, single-cell analysis of co-culture experiments further demonstrated that signaling emanating from cancer-associated fibroblasts (CAFs) likely maintains an enhanced EMT state and contributes to the expression of CSC-defining transcription factors, including p63, AP-1, and ETS1. Finally, we leverage ChIP-seq and RNA-seq datasets from HNSCC preclinical models to show that p63 and the AP-1 member directly target a subset of CSC-accessible regulatory regions such as those associated with EGFR, a known modulator of the quasi-mesenchymal CSC state. Collectively, our findings identify a FOSL1/p63 axis stemming from a spatially organized fibroblast–CSC niche in sustaining partial EMT programs in CSCs at the tumor invasive front and highlights transcriptional cooperation as a therapeutic opportunity aimed at disrupting malignant tumor–stroma interactions in HNSCC. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>FOSL1–p63 Cooperativity Guards Cellular Plasticity at the Tumor Invasive Front in HNSCC</span>. <u>Jennifer Sosa</u>; Satrajit Sinha, PhD. University at Buffalo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and Neck Squamous Cell Carcinoma (HNSCC) exhibits profound intratumor heterogeneity with recalcitrant tumor responses to therapy, posing a major clinical challenge. HNSCC heterogeneity is driven by cancer stem cells (CSCs) that reside in a hybrid epithelial–mesenchymal transitory (EMT) state, enabling tumor cell survival and promoting invasion. The master epithelial regulator p63 is essential for restraining EMT while maintaining epithelial identity and plasticity in these CSCs; however, the factors that cooperate with p63 to preserve this hybrid state remain unknown.</p>\n\n<p>To define the transcriptional and epigenomic landscape of CSCs and map their spatial organization within patient tumors, we integrated single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and spatial transcriptomics datasets of HNSCC patients. Our analyses identified a 144-gene CSC signature that reliably marked the CSC populations across matched scRNA-seq and scATAC-seq patient datasets. Motif enrichment of CSC-accessible chromatin regions revealed several oncogenic drivers, such as AP-1 family of Transcription factors and p63, which showed preferential expression at the tumor leading edge – a site populated by tumor cells exhibiting partial EMT and exhibiting enhanced tumor-stromal interactions. In concordance with these findings, single-cell analysis of co-culture experiments further demonstrated that signaling emanating from cancer-associated fibroblasts (CAFs) likely maintains an enhanced EMT state and contributes to the expression of CSC-defining transcription factors, including p63, AP-1, and ETS1. Finally, we leverage ChIP-seq and RNA-seq datasets from HNSCC preclinical models to show that p63 and the AP-1 member directly target a subset of CSC-accessible regulatory regions such as those associated with EGFR, a known modulator of the quasi-mesenchymal CSC state.</p>\n\n<p>Collectively, our findings identify a FOSL1/p63 axis stemming from a spatially organized fibroblast–CSC niche in sustaining partial EMT programs in CSCs at the tumor invasive front and highlights transcriptional cooperation as a therapeutic opportunity aimed at disrupting malignant tumor–stroma interactions in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154402--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S475",
      "content_id": "153836",
      "abstract_number": "S475",
      "poster_number": "",
      "title": "Tumor neutrophils mediate immunosuppression through the hypoxia-EGR1-PTGS2 signaling axis in advanced head and neck carcinomas unrelated to HPV",
      "summary": "Circulating neutrophils become immunosuppressive upon entry into the tumor microenvironment and are the most frequent leukocyte within the immune compartment of head and neck carcinomas unrelated to human papillomavirus. Induction of immunosuppressive function in tumor neutrophils is due at least to the function of EGR1, a zinc-finger developmental transcription factor, that is induced by hypoxia and the...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153836",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "C T Allen",
      "presenter": "C T Allen",
      "authors": "M S Dar; A Huynh; M Craveiro; Y Robbins; C T Allen",
      "normalized_authors": [
        "M S Dar",
        "A Huynh",
        "M Craveiro",
        "Y Robbins",
        "C T Allen"
      ],
      "affiliations": [
        "National Institutes of Health"
      ],
      "normalized_institutions": [
        "National Institutes of Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 410,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "M S Dar; A Huynh; M Craveiro; Y Robbins; C T Allen",
        "Affiliations": "National Institutes of Health",
        "Abstract": "Circulating neutrophils become immunosuppressive upon entry into the tumor microenvironment and are the most frequent leukocyte within the immune compartment of head and neck carcinomas unrelated to human papillomavirus. Induction of immunosuppressive function in tumor neutrophils is due at least to the function of EGR1, a zinc-finger developmental transcription factor, that is induced by hypoxia and the resulting endoplasmic reticulum (ER) stress. Hypoxia-induced alterations resulting in induction of EGR1 and downstream targets of EGR1 transcriptional regulation that mediate neutrophil immunosuppressive function remain poorly understood. Here, using DMSO-differentiated HL60 cells as a model for human neutrophils, we show that hypoxia-induced EGR1 expression is reduced in the presence of the IRE-1/ER stress inhibitor B-I09 or the MEK1/2 inhibitor trametinib but not reduced in the presence of the HIF1 inhibitor BAY87-2243 or the HIF2 inhibitor PT2399. These data infer that hypoxia-induced EGR1 occurs independently of the HIF oxygen sensing pathway in neutrophils. Using EGR1 cut and run of DMSO-differentiated HL60 cells, we map multiple transcriptional targets of EGR1 including OSM (encoding oncostatin M), PTSG2 (encoding COX2) and IL1B. Inhibitor-assisted functional ex vivo study of tumor neutrophils isolated from advanced stage oral carcinomas (n=8) consistently reveals prostaglandin E2 (PGE2), produced by tumor neutrophils downstream of COX2 function, to be the dominant mechanism of immunosuppression in stimulated T cell co-culture assays across many clinical carcinoma samples. Although also robustly produced by tumor neutrophils, oncostatin M and IL-1b do not directly mediate tumor neutrophil immunosuppression. Importantly, immunosuppressive function of human peripheral blood neutrophils exposed to hypoxia was abrogated in the presence of celecoxib (COX2 inhibitor) but not OSM or IL-1b neutralization, confirming the role of PGE2 in hypoxic neutrophil immunosuppression. MEK1/2 inhibition with trametinib but not HIF inhibition with BAY87-2243 or PT2399 reduced PGE2 production from and abrogated the immunosuppressive capacity of isolated tumor neutrophils or peripheral blood neutrophils exposed to hypoxia. Syngeneic murine studies in mice with selective neutrophil loss of Ptgs2 using a Cre/Flox system are ongoing to explore whether loss of neutrophil COX2 enhances response to immune checkpoint blockade immunotherapy. Together, these data indicate that tumor neutrophils immunosuppress T cell function through the function of COX2 and downstream production of PGE2 and that this pathway can be abrogated with MAPK-pathway inhibition, possibly resulting in enhanced response to immunotherapy. This data informs neoadjuvant combination immunotherapy studies in patients with advanced head and neck carcinomas that aim to maximize pathologic response to treatment. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Tumor neutrophils mediate immunosuppression through the hypoxia-EGR1-PTGS2 signaling axis in advanced head and neck carcinomas unrelated to HPV</span>. M S Dar; A Huynh; M Craveiro; Y Robbins; <u>C T Allen</u>. National Institutes of Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Circulating neutrophils become immunosuppressive upon entry into the tumor microenvironment and are the most frequent leukocyte within the immune compartment of head and neck carcinomas unrelated to human papillomavirus. Induction of immunosuppressive function in tumor neutrophils is due at least to the function of EGR1, a zinc-finger developmental transcription factor, that is induced by hypoxia and the resulting endoplasmic reticulum (ER) stress. Hypoxia-induced alterations resulting in induction of EGR1 and downstream targets of EGR1 transcriptional regulation that mediate neutrophil immunosuppressive function remain poorly understood. Here, using DMSO-differentiated HL60 cells as a model for human neutrophils, we show that hypoxia-induced EGR1 expression is reduced in the presence of the IRE-1/ER stress inhibitor B-I09 or the MEK1/2 inhibitor trametinib but not reduced in the presence of the HIF1 inhibitor BAY87-2243 or the HIF2 inhibitor PT2399. These data infer that hypoxia-induced EGR1 occurs independently of the HIF oxygen sensing pathway in neutrophils. Using EGR1 cut and run of DMSO-differentiated HL60 cells, we map multiple transcriptional targets of EGR1 including OSM (encoding oncostatin M), PTSG2 (encoding COX2) and IL1B. Inhibitor-assisted functional ex vivo study of tumor neutrophils isolated from advanced stage oral carcinomas (n=8) consistently reveals prostaglandin E2 (PGE2), produced by tumor neutrophils downstream of COX2 function, to be the dominant mechanism of immunosuppression in stimulated T cell co-culture assays across many clinical carcinoma samples. Although also robustly produced by tumor neutrophils, oncostatin M and IL-1b do not directly mediate tumor neutrophil immunosuppression. Importantly, immunosuppressive function of human peripheral blood neutrophils exposed to hypoxia was abrogated in the presence of celecoxib (COX2 inhibitor) but not OSM or IL-1b neutralization, confirming the role of PGE2 in hypoxic neutrophil immunosuppression. MEK1/2 inhibition with trametinib but not HIF inhibition with BAY87-2243 or PT2399 reduced PGE2 production from and abrogated the immunosuppressive capacity of isolated tumor neutrophils or peripheral blood neutrophils exposed to hypoxia. Syngeneic murine studies in mice with selective neutrophil loss of Ptgs2 using a Cre/Flox system are ongoing to explore whether loss of neutrophil COX2 enhances response to immune checkpoint blockade immunotherapy. Together, these data indicate that tumor neutrophils immunosuppress T cell function through the function of COX2 and downstream production of PGE2 and that this pathway can be abrogated with MAPK-pathway inhibition, possibly resulting in enhanced response to immunotherapy. This data informs neoadjuvant combination immunotherapy studies in patients with advanced head and neck carcinomas that aim to maximize pathologic response to treatment.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153836--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S476",
      "content_id": "155444",
      "abstract_number": "S476",
      "poster_number": "",
      "title": "Extracellular Vesicle Production and Surrogate Marker Expression in Mouse and Human Models of Oral Premalignancy and Malignancy",
      "summary": "Our findings indicated that exosome production is upregulated in oral malignancy compared to premalignant stages. We show that CD63 expression levels are distinct and stable in individual cell lines, providing validated PDX and cell line models with which to test our hypothesis. The successful suppression of exosome release through Rab27a knockdown and pharmacological inhibition in vitro provides a foundation for...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155444",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260152",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Subin Surendran, PhD",
      "presenter": "Subin Surendran, PhD",
      "authors": "Subin Surendran, PhD 1 ; Joshua Sorrentino, BS 2 ; Carl B Clay Jr, BS 3 ; William J Magner, PhD 1 ; Lixia Zhang, PhD 4 ; Lynn Sigurdson, PhD 1 ; Amritha Suresh, PhD 5 ; Sumsum Sunny, MDS, PhD 5 ; Jenny Romero, MD 1 ; Kimberly E Wooten, MD 1 ; Wesley L Hicks Jr, DDS, MD 1 ; Zhibin Cui, DDSPhD 4 ; Mihai Merzianu, MD 1 ; Keith L Kirkwood, DDS, PhD 4 ; Moni A Kuriakose, MD 6",
      "normalized_authors": [
        "Subin Surendran",
        "Joshua Sorrentino",
        "Carl B Clay Jr",
        "William J Magner",
        "Lixia Zhang",
        "Lynn Sigurdson",
        "Amritha Suresh",
        "Sumsum Sunny, MDS",
        "Jenny Romero",
        "Kimberly E Wooten",
        "Wesley L Hicks Jr",
        "Zhibin Cui, DDSPhD",
        "Mihai Merzianu",
        "Keith L Kirkwood",
        "Moni A Kuriakose"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Howard University",
        "University at Buffalo School of Dental Medicine, Buffalo, NY",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "Lakeshore Hospital, Kochi, India"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Howard University",
        "University at Buffalo School of Dental Medicine, Buffalo, NY",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "Lakeshore Hospital, Kochi, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 439,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Subin Surendran, PhD 1 ; Joshua Sorrentino, BS 2 ; Carl B Clay Jr, BS 3 ; William J Magner, PhD 1 ; Lixia Zhang, PhD 4 ; Lynn Sigurdson, PhD 1 ; Amritha Suresh, PhD 5 ; Sumsum Sunny, MDS, PhD 5 ; Jenny Romero, MD 1 ; Kimberly E Wooten, MD 1 ; Wesley L Hicks Jr, DDS, MD 1 ; Zhibin Cui, DDSPhD 4 ; Mihai Merzianu, MD 1 ; Keith L Kirkwood, DDS, PhD 4 ; Moni A Kuriakose, MD 6",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 University at Buffalo Jacobs School of Medicine and Biomedical Sciences; 3 Howard University; 4 University at Buffalo School of Dental Medicine, Buffalo, NY; 5 Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; 6 Lakeshore Hospital, Kochi, India",
        "Background": "Head and neck squamous cell carcinoma (HNSCC), especially human papillomavirus (HPV) negative oral squamous cell carcinoma (OSCC), remains a significant global health burden with suboptimal five-year survival rates despite advances in multi-modal therapy. While most OSCC cases evolve from oral potentially malignant disorders (OPMD) through a spectrum of progressive dysplasia, the mechanisms driving this transformation and the associated immunosuppressive tumor microenvironment (TME) remain understudied. Exosomes are 30–150?nm extracellular vesicles involved in cellular communication, are produced in substantially greater numbers by cancer cells than by healthy cells and contribute to the development of oral cancer. Tumor-derived exosomes carry immunosuppressive and immunostimulatory receptors and ligands that may serve as unintended targets for immunotherapy. We have shown that elevated expression of the exosomal marker CD63 is associated with pathological progression across human oral carcinogenesis cohorts and the 4-nitroquinoline-1-oxide (4NQO) mouse model. We hypothesized that progression from premalignant dysplasia to oral malignancy is accompanied by increased CD63-associated exosome production, driven in part by Rab27a-dependent secretory pathways. Targeting Rab27a-mediated exosome secretion may therefore represent a promising therapeutic strategy for OSCC.",
        "Methods": "We performed immunohistochemical (IHC) analysis to quantify CD63 in 4 patient-derived xenograft (PDX) models. To model our patient results, IHC data were extended to western blotting using MOC2 (mouse oral cancer), HSC2 (human OSCC), and DOK (human dysplastic) cell lines. Exosome yield and size distribution from each cell line were characterized using Nanoparticle Tracking Analysis (NTA). Exosome inhibition was achieved through treatment with GW4869, a neutral sphingomyelinase inhibitor, and shRNA-mediated knockdown of Rab27a. Western blot was used to evaluate the knockdown effect.",
        "Results": "IHC analysis revealed human PDX tumors grown in immunodeficient mice showed elevated but varying levels of CD63, mirroring the heterogeneity observed in human clinical samples. Consistently, the malignant HSC2 cell line produced a higher exosome yield compared to the premalignant dysplastic DOK line. The murine oral cancer cell line, MOC2, also expressed high levels of CD63, which correlated with its production of extracellular vesicles. Treatment with GW4869 significantly inhibited exosome production in both MOC2 and HSC2 cells. Furthermore, Rab27a knockdown in MOC2 cells significantly reduced Rab27a and CD63 protein expression, reflecting >90% decrease in exosome production (p < 0.0001).",
        "Conclusions": "Our findings indicated that exosome production is upregulated in oral malignancy compared to premalignant stages. We show that CD63 expression levels are distinct and stable in individual cell lines, providing validated PDX and cell line models with which to test our hypothesis. The successful suppression of exosome release through Rab27a knockdown and pharmacological inhibition in vitro provides a foundation for future therapeutic strategies aimed at disrupting exosome-mediated tumor progression and immunosuppression in the TME.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Extracellular Vesicle Production and Surrogate Marker Expression in Mouse and Human Models of Oral Premalignancy and Malignancy</span>. <u>Subin Surendran, PhD</u><sup>1</sup>; Joshua Sorrentino, BS<sup>2</sup>; Carl B Clay Jr, BS<sup>3</sup>; William J Magner, PhD<sup>1</sup>; Lixia Zhang, PhD<sup>4</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Amritha Suresh, PhD<sup>5</sup>; Sumsum Sunny, MDS, PhD<sup>5</sup>; Jenny Romero, MD<sup>1</sup>; Kimberly E Wooten, MD<sup>1</sup>; Wesley L Hicks Jr, DDS, MD<sup>1</sup>; Zhibin Cui, DDSPhD<sup>4</sup>; Mihai Merzianu, MD<sup>1</sup>; Keith L Kirkwood, DDS, PhD<sup>4</sup>; Moni A Kuriakose, MD<sup>6</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences; <sup>3</sup>Howard University; <sup>4</sup>University at Buffalo School of Dental Medicine, Buffalo, NY; <sup>5</sup>Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; <sup>6</sup>Lakeshore Hospital, Kochi, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC), especially human papillomavirus (HPV) negative oral squamous cell carcinoma (OSCC), remains a significant global health burden with suboptimal five-year survival rates despite advances in multi-modal therapy. While most OSCC cases evolve from oral potentially malignant disorders (OPMD) through a spectrum of progressive dysplasia, the mechanisms driving this transformation and the associated immunosuppressive tumor microenvironment (TME) remain understudied. Exosomes are 30–150?nm extracellular vesicles involved in cellular communication, are produced in substantially greater numbers by cancer cells than by healthy cells and contribute to the development of oral cancer. Tumor-derived exosomes carry immunosuppressive and immunostimulatory receptors and ligands that may serve as unintended targets for immunotherapy. We have shown that elevated expression of the exosomal marker CD63 is associated with pathological progression across human oral carcinogenesis cohorts and the 4-nitroquinoline-1-oxide (4NQO) mouse model. We hypothesized that progression from premalignant dysplasia to oral malignancy is accompanied by increased CD63-associated exosome production, driven in part by Rab27a-dependent secretory pathways. Targeting Rab27a-mediated exosome secretion may therefore represent a promising therapeutic strategy for OSCC.</p>\n\n<p><strong>Methods: </strong>We performed immunohistochemical (IHC) analysis to quantify CD63 in 4 patient-derived xenograft (PDX) models. To model our patient results, IHC data were extended to western blotting using MOC2 (mouse oral cancer), HSC2 (human OSCC), and DOK (human dysplastic) cell lines. Exosome yield and size distribution from each cell line were characterized using Nanoparticle Tracking Analysis (NTA). Exosome inhibition was achieved through treatment with GW4869, a neutral sphingomyelinase inhibitor, and shRNA-mediated knockdown of Rab27a. Western blot was used to evaluate the knockdown effect.</p>\n\n<p><strong>Results: </strong>IHC analysis revealed human PDX tumors grown in immunodeficient mice showed elevated but varying levels of CD63, mirroring the heterogeneity observed in human clinical samples. Consistently, the malignant HSC2 cell line produced a higher exosome yield compared to the premalignant dysplastic DOK line. The murine oral cancer cell line, MOC2, also expressed high levels of CD63, which correlated with its production of extracellular vesicles. Treatment with GW4869 significantly inhibited exosome production in both MOC2 and HSC2 cells. Furthermore, Rab27a knockdown in MOC2 cells significantly reduced Rab27a and CD63 protein expression, reflecting >90% decrease in exosome production (p < 0.0001).</p>\n\n<p><strong>Conclusions: </strong>Our findings indicated that exosome production is upregulated in oral malignancy compared to premalignant stages. We show that CD63 expression levels are distinct and stable in individual cell lines, providing validated PDX and cell line models with which to test our hypothesis. The successful suppression of exosome release through Rab27a knockdown and pharmacological inhibition in vitro provides a foundation for future therapeutic strategies aimed at disrupting exosome-mediated tumor progression and immunosuppression in the TME.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155444--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260152' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S477",
      "content_id": "154459",
      "abstract_number": "S477",
      "poster_number": "",
      "title": "Scapular Tip Osseous Free Flap in (Sub-)Total Nasal Reconstruction Using Virtual Surgical Planning: Clinical, Functional and Cephalometric Outcomes",
      "summary": "This is the largest case series involving the scapular free flap for complex nasal reconstruction, and the first to utilize VSP for the preplanning of each reconstruction. This technology aided the surgeons in accurately recreating the pre-operative nasal structure and following the reconstructive plan. The scapular free flap can be used in the reconstruction of complex nasal defects with low morbidity and good...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154459",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rohan Birk, BASc",
      "presenter": "Rohan Birk, BASc",
      "authors": "Rohan Birk, BASc 1 ; Alex Chen, BASc 2 ; Cornelius Kürten, MD 2 ; Khanh Linh Tran, BSc 2 ; Amelie Marshall 1 ; Amanda Ding 2 ; Antony Hodgson, PhD 3 ; Sidney Fels, PhD 4 ; J Scott Durham, MD 2 ; Eitan Prisman, MD 2",
      "normalized_authors": [
        "Rohan Birk, BASc",
        "Alex Chen, BASc",
        "Cornelius Kürten",
        "Khanh Linh Tran",
        "Amelie Marshall",
        "Amanda Ding",
        "Antony Hodgson",
        "Sidney Fels",
        "J Scott Durham",
        "Eitan Prisman"
      ],
      "affiliations": [
        "School of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
        "Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada",
        "Department of Mechanical Engineering, Faculty of Applied Science, University of British Columbia",
        "Department of Electrical and Computer Engineering, Faculty of Applied Science, University of British Columbia"
      ],
      "normalized_institutions": [
        "School of Biomedical Engineering, Faculty of Applied Science, University of British Columbia",
        "Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada",
        "Department of Mechanical Engineering, Faculty of Applied Science, University of British Columbia",
        "Department of Electrical and Computer Engineering, Faculty of Applied Science, University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154459/VSP%20Workflow.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154459/VSP%20Workflow.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154459"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154459/Graphs.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154459/Graphs.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154459"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 523,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Figure 1.",
        "Figure 2.",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rohan Birk, BASc 1 ; Alex Chen, BASc 2 ; Cornelius Kürten, MD 2 ; Khanh Linh Tran, BSc 2 ; Amelie Marshall 1 ; Amanda Ding 2 ; Antony Hodgson, PhD 3 ; Sidney Fels, PhD 4 ; J Scott Durham, MD 2 ; Eitan Prisman, MD 2",
        "Affiliations": "1 School of Biomedical Engineering, Faculty of Applied Science, University of British Columbia; 2 Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada; 3 Department of Mechanical Engineering, Faculty of Applied Science, University of British Columbia; 4 Department of Electrical and Computer Engineering, Faculty of Applied Science, University of British Columbia",
        "Background": "Rehabilitation or reconstruction of the nose after ablative surgery poses multifaceted challenges to the treatment team due to both the functional and aesthetic role of the nose. The scapular free flap, with its unique geometry, abundance of vascularity and soft tissue options, has recently been applied for complex nasal reconstructions. However, there is very limited description regarding this surgical experience, patient outcomes or how virtual surgical planning (VSP) can guide this reconstruction.",
        "Objective": "The objective of this study is to assess the utility of VSP-guided nasal reconstructions with the tip of the scapular free flap. We evaluate clinical and pathological results, bioinformatical image-analysis (cephalometric measurements) and patient-reported outcomes.",
        "Methods": "Eight consecutive (sub-)total nasal reconstructions were planned with an in-house VSP and intraoperatively guided using 3D-printed models and cutting guides. Intraoperative variables were collected. Patient-reported outcomes (SCHNOS, NAFEQ, DASH) were administered. Cephalometric measurements (nasal bridge length, nasal tip projection, nasal height, alar base width, nasofrontal angle, nasal tip angle, and nasolabial angle) on the pre-operative CT, VSP, and post-operative CT scans were collected. Two one-sided tests for equivalence with predefined tolerance ranges of ±4mm and ±10° were employed to test for statistical significance in deviation.",
        "Results": "From 01/2023 to 08/2024, VSP was successfully applied to simultaneous nasal resection and tip of scapular harvest and reconstruction in eight cases, with an average operative time of 258±122.1 minutes. 4 patients received reconstruction with a “tip-up” scapular tip orientation, and 4 patients with a “tip-down” orientation. Post-operative nasal stenosis was recorded in three patients, with one unilateral stenosis and two bilateral stenosis, and there was one class II Clavien-Dindo complication recorded for infectious complication, which was managed conservatively. There were no flap compromises, and recurrence was noted in one case. Patients reported adequate functional and aesthetic outcomes (SCHNOS cosmesis sub-scale: 34±39.4/100, NAFEQ function sub-scale: 22.4±4/35) as well as low donor site morbidity (21.5±15.2/100). The mean signed difference between the pre-operative and post-operative soft-tissue CT for the nasal bridge length, nasofrontal angle, and nasal tip angle was 0.45 ± 3.9 mm, 7.2 ± 11.8°, and 8.7 ± 14.8°, respectively, indicating that the VSP-guided reconstructions can accurately recreate the pre-operative nasal aesthetics. The mean signed difference between the VSP model, and the post-operative bony CT for the nasal bridge, nasal height, nasal projection, and nasofrontal angle, was 0.98 ± 3.7 mm, 0.43 ± 5.4 mm, -1.9 ± 3.63 mm, and -7.0 ± 12.2°, respectively, indicating that the VSP plan was accurately followed intraoperatively.",
        "Conclusions": "This is the largest case series involving the scapular free flap for complex nasal reconstruction, and the first to utilize VSP for the preplanning of each reconstruction. This technology aided the surgeons in accurately recreating the pre-operative nasal structure and following the reconstructive plan. The scapular free flap can be used in the reconstruction of complex nasal defects with low morbidity and good patient-reported outcomes.",
        "Figure 1.": "Representative workflow of VSP pipeline, with virtual resection (A), alignment of scapula (B), models to 3D-print (C), and post-operative outcome (D).",
        "Figure 2.": "Box-plots of post-operative deviations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Scapular Tip Osseous Free Flap in (Sub-)Total Nasal Reconstruction Using Virtual Surgical Planning: Clinical, Functional and Cephalometric Outcomes</span>. <u>Rohan Birk, BASc</u><sup>1</sup>; Alex Chen, BASc<sup>2</sup>; Cornelius Kürten, MD<sup>2</sup>; Khanh Linh Tran, BSc<sup>2</sup>; Amelie Marshall<sup>1</sup>; Amanda Ding<sup>2</sup>; Antony Hodgson, PhD<sup>3</sup>; Sidney Fels, PhD<sup>4</sup>; J Scott Durham, MD<sup>2</sup>; Eitan Prisman, MD<sup>2</sup>. <sup>1</sup>School of Biomedical Engineering, Faculty of Applied Science, University of British Columbia; <sup>2</sup>Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada; <sup>3</sup>Department of Mechanical Engineering, Faculty of Applied Science, University of British Columbia; <sup>4</sup>Department of Electrical and Computer Engineering, Faculty of Applied Science, University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Rehabilitation or reconstruction of the nose after ablative surgery poses multifaceted challenges to the treatment team due to both the functional and aesthetic role of the nose. The scapular free flap, with its unique geometry, abundance of vascularity and soft tissue options, has recently been applied for complex nasal reconstructions. However, there is very limited description regarding this surgical experience, patient outcomes or how virtual surgical planning (VSP) can guide this reconstruction. </p>\n\n<p><strong>Objective</strong>: The objective of this study is to assess the utility of VSP-guided nasal reconstructions with the tip of the scapular free flap. We evaluate clinical and pathological results, bioinformatical image-analysis (cephalometric measurements) and patient-reported outcomes. </p>\n\n<p><strong>Methods</strong>: Eight consecutive (sub-)total nasal reconstructions were planned with an in-house VSP and intraoperatively guided using 3D-printed models and cutting guides. Intraoperative variables were collected. Patient-reported outcomes (SCHNOS, NAFEQ, DASH) were administered. Cephalometric measurements (nasal bridge length, nasal tip projection, nasal height, alar base width, nasofrontal angle, nasal tip angle, and nasolabial angle) on the pre-operative CT, VSP, and post-operative CT scans were collected. Two one-sided tests for equivalence with predefined tolerance ranges of ±4mm and ±10° were employed to test for statistical significance in deviation. </p>\n\n<p><strong>Results</strong>: From 01/2023 to 08/2024, VSP was successfully applied to simultaneous nasal resection and tip of scapular harvest and reconstruction in eight cases, with an average operative time of 258±122.1 minutes. 4 patients received reconstruction with a “tip-up” scapular tip orientation, and 4 patients with a “tip-down” orientation. Post-operative nasal stenosis was recorded in three patients, with one unilateral stenosis and two bilateral stenosis, and there was one class II Clavien-Dindo complication recorded for infectious complication, which was managed conservatively. There were no flap compromises, and recurrence was noted in one case. Patients reported adequate functional and aesthetic outcomes (SCHNOS cosmesis sub-scale: 34±39.4/100, NAFEQ function sub-scale: 22.4±4/35) as well as low donor site morbidity (21.5±15.2/100). The mean signed difference between the pre-operative and post-operative soft-tissue CT for the nasal bridge length, nasofrontal angle, and nasal tip angle was 0.45 ± 3.9 mm, 7.2 ± 11.8°, and 8.7 ± 14.8°, respectively, indicating that the VSP-guided reconstructions can accurately recreate the pre-operative nasal aesthetics. The mean signed difference between the VSP model, and the post-operative bony CT for the nasal bridge, nasal height, nasal projection, and nasofrontal angle, was 0.98 ± 3.7 mm, 0.43 ± 5.4 mm, -1.9 ± 3.63 mm, and -7.0 ± 12.2°, respectively, indicating that the VSP plan was accurately followed intraoperatively. </p>\n\n<p><strong>Conclusions</strong>: This is the largest case series involving the scapular free flap for complex nasal reconstruction, and the first to utilize VSP for the preplanning of each reconstruction. This technology aided the surgeons in accurately recreating the pre-operative nasal structure and following the reconstructive plan. The scapular free flap can be used in the reconstruction of complex nasal defects with low morbidity and good patient-reported outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154459/VSP%20Workflow.png' /></p>\n\n<p><strong>Figure 1. </strong>Representative workflow of VSP pipeline, with virtual resection (A), alignment of scapula (B), models to 3D-print (C), and post-operative outcome (D).</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154459/Graphs.png' /></p>\n\n<p><strong>Figure 2. </strong>Box-plots of post-operative deviations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154459--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S478",
      "content_id": "154580",
      "abstract_number": "S478",
      "poster_number": "",
      "title": "Update on a Phase II Randomized Controlled Clinical Trial comparing Virtual Surgical planning and Free Hand Surgery for mandibular reconstruction",
      "summary": "This interim report comparing VSP to FHS for mandibular reconstruction demonstrates feasibility in recruitment and the ability to plan, print, and support reconstruction at the primary centre and satellite sites. Further recruitment and time are required to determine the primary outcome of union rates at one year.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154580",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jovan Cheema",
      "presenter": "Jovan Cheema",
      "authors": "Jovan Cheema ; Tayo Steininger; Eitan Prisman, MD, FRCSC",
      "normalized_authors": [
        "Jovan Cheema",
        "Tayo Steininger",
        "Eitan Prisman, FRCSC"
      ],
      "affiliations": [
        "Division of Otolaryngology, Department of Surgery, Faculty of Medicine, University of British Columbia"
      ],
      "normalized_institutions": [
        "Division of Otolaryngology, Department of Surgery, Faculty of Medicine, University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154580/picture1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154580/picture1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154580"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Jovan Cheema ; Tayo Steininger; Eitan Prisman, MD, FRCSC",
        "Affiliations": "Division of Otolaryngology, Department of Surgery, Faculty of Medicine, University of British Columbia",
        "Background": "Advanced oral cavity cancer with mandibular invasion requires vascularized osseous free tissue reconstruction. Traditionally, this was performed in free hand fashion (FHS), relying on surgeon proficiency and intraoperative judgement in recreating the curved contour of the mandible. Alternatively, Virtual surgical planning (VSP) has emerged as a method where the reconstruction is preoperatively planned and optimized in a virtual space and subsequent patient-specific 3D printed surgical cutting guides and models are printed and brought to the OR to guide the ablation and reconstruction. While retrospective reports highlight decreased operating time and improved reconstruction accuracy, there remains debate as to the cost benefit, and long-term outcomes such as bony union rates are lacking. This review aims to reaffirm the trial’s viability and contrast early in-house VSP implementation to FHS.",
        "Objective": "This phase II trial is meant to assess feasibility of patient recruitment and retention as well as intervention fidelity and supporting satellite centres. Meanwhile, Phase III is powered to assess bony union rate of segment appositions at 12 months for each site, with secondary objectives including functional, aesthetic, and patient-reported outcomes, complication rates, and reconstruction accuracy.",
        "Methods": "Patients undergoing mandibular reconstruction with osseous free flap were consented and randomized into one of two treatment arms (1:1): either the current standard of care using FHS, or VSP. If randomized to VSP, Trial research engineers virtually pre-planned the reconstruction through medical scans and provided corresponding 3D reconstruction models and cutting guides. Patients were subject to follow-up for 12 months post-operatively. Union assessments were conducted by our site radiologist.",
        "Results": "To date, 77 of the 80 patients offered the study at the primary site were enrolled (~2 patients per month), including 39 and 38 VSP and FHS patients and 37 and 40 fibular and scapular reconstructions. 4 of 39 VSP surgeries did not employ cutting guides, demonstrating a crossover rate of 10.3%. Moreover, for the 47 patients with at least 1 year follow-up, survival rates do not differ for VSP and FHS (86.2% and 88.9%). Additionally, 36 patients were enrolled at a satellite site, and 3 further sites are being onboarded or beginning data collection.",
        "Abstract": "VSP vs. FHS mean Ischemia times are not different (88.0 vs. 87.5 minutes, p = .482) nor are overall operative times (316.3 vs. 303.5 minutes, p = .339) across both sites. Primary site VSP vs. FHS nonunion rates for malignant cases, per bony interface, are equal (11.5%) and similar for complete (81.5% vs. 76.9%) and partial (7.4% vs. 11.5%) union. Primary site VSP vs. FHS rates for plate exposure (3.8% vs. 2.1%) and flap failure (3.8% vs. 4.2%) are also similar. Moreover, bony and soft tissue margin statuses were not significantly different between treatments at the primary site. View in Agenda and Add to Schedule",
        "Conclusions": "This interim report comparing VSP to FHS for mandibular reconstruction demonstrates feasibility in recruitment and the ability to plan, print, and support reconstruction at the primary centre and satellite sites. Further recruitment and time are required to determine the primary outcome of union rates at one year."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Update on a Phase II Randomized Controlled Clinical Trial comparing Virtual Surgical planning and Free Hand Surgery for mandibular reconstruction</span>. <u>Jovan Cheema</u>; Tayo Steininger; Eitan Prisman, MD, FRCSC. Division of Otolaryngology, Department of Surgery, Faculty of Medicine, University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Advanced oral cavity cancer with mandibular invasion requires vascularized osseous free tissue reconstruction. Traditionally, this was performed in free hand fashion (FHS), relying on surgeon proficiency and intraoperative judgement in recreating the curved contour of the mandible. Alternatively, Virtual surgical planning (VSP) has emerged as a method where the reconstruction is preoperatively planned and optimized in a virtual space and subsequent patient-specific 3D printed surgical cutting guides and models are printed and brought to the OR to guide the ablation and reconstruction. While retrospective reports highlight decreased operating time and improved reconstruction accuracy, there remains debate as to the cost benefit, and long-term outcomes such as bony union rates are lacking. This review aims to reaffirm the trial’s viability and contrast early in-house VSP implementation to FHS. </p>\n\n<p><strong>Objective:</strong> This phase II trial is meant to assess feasibility of patient recruitment and retention as well as intervention fidelity and supporting satellite centres. Meanwhile, Phase III is powered to assess bony union rate of segment appositions at 12 months for each site, with secondary objectives including functional, aesthetic, and patient-reported outcomes, complication rates, and reconstruction accuracy. </p>\n\n<p><strong>Methods:</strong> Patients undergoing mandibular reconstruction with osseous free flap were consented and randomized into one of two treatment arms (1:1): either the current standard of care using FHS, or VSP. If randomized to VSP, Trial research engineers virtually pre-planned the reconstruction through medical scans and provided corresponding 3D reconstruction models and cutting guides. Patients were subject to follow-up for 12 months post-operatively. Union assessments were conducted by our site radiologist. </p>\n\n<p><strong>Results: </strong>To date, 77 of the 80 patients offered the study at the primary site were enrolled (~2 patients per month), including 39 and 38 VSP and FHS patients and 37 and 40 fibular and scapular reconstructions. 4 of 39 VSP surgeries did not employ cutting guides, demonstrating a crossover rate of 10.3%. Moreover, for the 47 patients with at least 1 year follow-up, survival rates do not differ for VSP and FHS (86.2% and 88.9%). Additionally, 36 patients were enrolled at a satellite site, and 3 further sites are being onboarded or beginning data collection.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154580/picture1.png' /></p>\n\n<p>VSP vs. FHS mean Ischemia times are not different (88.0 vs. 87.5 minutes, p = .482) nor are overall operative times (316.3 vs. 303.5 minutes, p = .339) across both sites. Primary site VSP vs. FHS nonunion rates for malignant cases, per bony interface, are equal (11.5%) and similar for complete (81.5% vs. 76.9%) and partial (7.4% vs. 11.5%) union. Primary site VSP vs. FHS rates for plate exposure (3.8% vs. 2.1%) and flap failure (3.8% vs. 4.2%) are also similar. Moreover, bony and soft tissue margin statuses were not significantly different between treatments at the primary site. </p>\n\n<p><strong>Conclusions:</strong> This interim report comparing VSP to FHS for mandibular reconstruction demonstrates feasibility in recruitment and the ability to plan, print, and support reconstruction at the primary centre and satellite sites. Further recruitment and time are required to determine the primary outcome of union rates at one year. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154580--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S479",
      "content_id": "154630",
      "abstract_number": "S479",
      "poster_number": "",
      "title": "Custom Anatomic Reconstruction for Head and Neck Bony Reconstruction",
      "summary": "The Custom Anatomic Reconstruction approach was associated with reduced early readmission rates without delaying adjuvant therapy, increasing surgical complication rates, or prolonging post-operative length of stay. CAR serves as a cost-efficient, patient-specific alternative to IPS for head and neck mandibular reconstruction without sacrificing the quality of patient care.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154630",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kelly L Staricha, MD",
      "presenter": "Kelly L Staricha, MD",
      "authors": "Kelly L Staricha, MD ; Allison Rollins, MD; Joshua D Smith, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin J Contrera, MD; Steven B Chinn, MD; Jose P Zevallos, MD, MPH; Anish Ghodadra, MD; Matthew E Spector, MD; Shaum Sridharan, MD",
      "normalized_authors": [
        "Kelly L Staricha",
        "Allison Rollins",
        "Joshua D Smith",
        "Jessica Maxwell",
        "Seungwon Kim",
        "Kevin J Contrera",
        "Steven B Chinn",
        "Jose P Zevallos",
        "Anish Ghodadra",
        "Matthew E Spector",
        "Shaum Sridharan"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_16%E2%80%AFPM.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_16%E2%80%AFPM.jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154630"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_23%E2%80%AFPM.jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_23%E2%80%AFPM.jpeg",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154630"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 431,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kelly L Staricha, MD ; Allison Rollins, MD; Joshua D Smith, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin J Contrera, MD; Steven B Chinn, MD; Jose P Zevallos, MD, MPH; Anish Ghodadra, MD; Matthew E Spector, MD; Shaum Sridharan, MD",
        "Affiliations": "University of Pittsburgh Medical Center",
        "Introduction": "Surgical planning has become increasingly utilized in head and neck bony reconstruction to enhance accuracy and streamline intraoperative workflow. Despite high cost, its overall benefit and effect on perioperative efficiency and oncologic timelines remains unclear. Working with our institutional 3-D printing lab, we have established a workflow for in-house fabricated patient-specific models used for real-time surgical planning, templating and plate bending as an alternative to outsourced industry models, cutting guides and custom plates. This study describes our methodology and compares operative and postoperative outcomes between this Custom Anatomic Reconstruction (CAR) vs. traditional industry Individualized Patient Solutions (IPS) for bony reconstruction.",
        "Methods": "A retrospective review was performed on patients undergoing osseous reconstruction for head and neck defects between 2018-2025 at a tertiary academic center. Patients were categorized into CAR and IPS groups. Primary outcomes included post-operative length of stay (LOS), flap failure rate, and 30-day readmission. Secondary outcomes were overall surgical complication rate, time to adjuvant radiation therapy (RT) initiation, proportion of patients starting RT within 6 weeks postoperatively, and cost. Statistical comparisons were performed using appropriate univariate and multivariate analyses.",
        "Results": "A total of 175 patients met inclusion criteria (61 CAR, 114 IPS). The CAR group utilized in-house fabricated patient-specific 3-D models of the ablative site and donor site, with optional use of cutting guides based on surgeon preference, and intraoperative hand-bent plates (Figure 1). The IPS group utilized traditional virtual surgical planning with custom industry models, cutting guides, and custom plates. The CAR group demonstrated significantly lower 30-day readmission rates (7% CAR vs 25% IPS, p=0.001). There was no significant difference in post-operative length of stay (8 days CAR vs 10 days IPS, p=0.126). There was an overall 1.71% total free flap failure rate, with no significant difference between groups nor an association with a greater number of bony segments. There was no difference in surgical complication rate between groups (11% for both). Median days to radiation amongst the CAR and IPS groups were not significantly different (60 vs 59.5 days, p=0.604), nor were there differences in the ability to initiate RT within 6 weeks between groups (Figure 2). Within our institution, we report a cost saving of $10,000 per case by using CAR as compared to IPS.",
        "Conclusions": "The Custom Anatomic Reconstruction approach was associated with reduced early readmission rates without delaying adjuvant therapy, increasing surgical complication rates, or prolonging post-operative length of stay. CAR serves as a cost-efficient, patient-specific alternative to IPS for head and neck mandibular reconstruction without sacrificing the quality of patient care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Custom Anatomic Reconstruction for Head and Neck Bony Reconstruction</span>. <u>Kelly L Staricha, MD</u>; Allison Rollins, MD; Joshua D Smith, MD; Jessica Maxwell, MD, MPH; Seungwon Kim, MD; Kevin J Contrera, MD; Steven B Chinn, MD; Jose P Zevallos, MD, MPH; Anish Ghodadra, MD; Matthew E Spector, MD; Shaum Sridharan, MD. University of Pittsburgh Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Surgical planning has become increasingly utilized in head and neck bony reconstruction to enhance accuracy and streamline intraoperative workflow. Despite high cost, its overall benefit and effect on perioperative efficiency and oncologic timelines remains unclear. Working with our institutional 3-D printing lab, we have established a workflow for in-house fabricated patient-specific models used for real-time surgical planning, templating and plate bending as an alternative to outsourced industry models, cutting guides and custom plates. This study describes our methodology and compares operative and postoperative outcomes between this Custom Anatomic Reconstruction (CAR) vs. traditional industry Individualized Patient Solutions (IPS) for bony reconstruction.</p>\n\n<p><strong>Methods: </strong>A retrospective review was performed on patients undergoing osseous reconstruction for head and neck defects between 2018-2025 at a tertiary academic center. Patients were categorized into CAR and IPS groups. Primary outcomes included post-operative length of stay (LOS), flap failure rate, and 30-day readmission. Secondary outcomes were overall surgical complication rate, time to adjuvant radiation therapy (RT) initiation, proportion of patients starting RT within 6 weeks postoperatively, and cost. Statistical comparisons were performed using appropriate univariate and multivariate analyses.</p>\n\n<p><strong>Results: </strong>A total of 175 patients met inclusion criteria (61 CAR, 114 IPS). The CAR group utilized in-house fabricated patient-specific 3-D models of the ablative site and donor site, with optional use of cutting guides based on surgeon preference, and intraoperative hand-bent plates (Figure 1). The IPS group utilized traditional virtual surgical planning with custom industry models, cutting guides, and custom plates. The CAR group demonstrated significantly lower 30-day readmission rates (7% CAR vs 25% IPS, p=0.001). There was no significant difference in post-operative length of stay (8 days CAR vs 10 days IPS, p=0.126). There was an overall 1.71% total free flap failure rate, with no significant difference between groups nor an association with a greater number of bony segments. There was no difference in surgical complication rate between groups (11% for both). Median days to radiation amongst the CAR and IPS groups were not significantly different (60 vs 59.5 days, p=0.604), nor were there differences in the ability to initiate RT within 6 weeks between groups (Figure 2). Within our institution, we report a cost saving of $10,000 per case by using CAR as compared to IPS.</p>\n\n<p><strong>Conclusions: </strong>The Custom Anatomic Reconstruction approach was associated with reduced early readmission rates without delaying adjuvant therapy, increasing surgical complication rates, or prolonging post-operative length of stay. CAR serves as a cost-efficient, patient-specific alternative to IPS for head and neck mandibular reconstruction without sacrificing the quality of patient care.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_16%E2%80%AFPM.jpeg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154630/Image%2012-5-25%20at%204_23%E2%80%AFPM.jpeg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154630--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S480",
      "content_id": "153300",
      "abstract_number": "S480",
      "poster_number": "",
      "title": "Utilization of a Novel Microsurgical Robotic Device for Head & Neck Microvascular Free Flap Surgery - A Single-Institution Experience",
      "summary": "This represents the first U.S. single-institution case series evaluating Symani-assisted microsurgery for head and neck free flap reconstruction. Robotic microanastomosis was feasible, safe, and reproducible, achieving 100% flap survival with no anastomotic revisions or major complications. Efficiency improved significantly over the first 22 cases, even with early trainee participation, and vessel diameter did...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153300",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Richard Wu, MD, MPH",
      "presenter": "Richard Wu, MD, MPH",
      "authors": "Richard Wu, MD, MPH ; Alexander Jones, MD; Philip Brauer, MD; Conrad Blunck, MD; Danielle Bottalico, MD; Jamie A Ku, MD",
      "normalized_authors": [
        "Richard Wu",
        "Alexander Jones",
        "Philip Brauer",
        "Conrad Blunck",
        "Danielle Bottalico",
        "Jamie A Ku"
      ],
      "affiliations": [
        "Cleveland Clinic Foundation"
      ],
      "normalized_institutions": [
        "Cleveland Clinic Foundation"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153300/Symani%20Table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153300/Symani%20Table%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153300"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153300/Symani%20Figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153300/Symani%20Figure%201.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153300"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 488,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Richard Wu, MD, MPH ; Alexander Jones, MD; Philip Brauer, MD; Conrad Blunck, MD; Danielle Bottalico, MD; Jamie A Ku, MD",
        "Affiliations": "Cleveland Clinic Foundation",
        "Background": "Microvascular free flap reconstruction remains the cornerstone of addressing complex defects in head and neck oncologic surgery, yet it demands extreme technical precision and is vulnerable to physiological tremor, operator fatigue, and challenging anatomy. Robotic microsurgical platforms such as the Symani Surgical System offer motion scaling, tremor filtration, and improved access to constrained operative fields, with early data suggesting outcomes comparable or superior to manual microsurgery. Despite growing adoption in other surgical specialties, robotic-assisted microsurgery remains understudied in head and neck reconstruction. This study presents a single tertiary-care institution’s first consecutive 22 cases of robotic-assisted microvascular free tissue transfer using the Symani system, describing performance metrics, learning-curve indicators, and perioperative outcomes.",
        "Methods": "A retrospective review was performed for all patients undergoing Symani-assisted arterial microanastomosis between January and July 2025. Demographics, comorbidities, tumor characteristics, operative details, and postoperative outcomes were abstracted from the electronic medical record. Intraoperative metrics—including total operative time, TeleOp time (total time the surgeon was actively engaged with the robot), number of knots, rescue stitches, and anastomotic revisions—were obtained from real-time observations, representative logs, and video analysis. Seven cases with complete recordings allowed analysis of knot-throwing time, total anastomosis time, and frequency of meaningful assistant interventions. Vessel diameter was correlated with operative metrics using Spearman’s rank coefficients. Linear regression assessed changes in TeleOp time across successive cases as a measure of learning curve.",
        "Results": "The cohort was predominantly male (77.3%) with mean age 63.5 years. Oral cavity was the most common subsite (45.5%), and squamous cell carcinoma represented 77.3% of cases. The anterolateral thigh was the most common donor site (50%). Recipient artery diameter ranged widely from 0.6-2.5mm. Mean operative time was 504.5 minutes and mean TeleOp time 30.2 minutes, which significantly decreased across successive cases (slope –1.18 min/case, p = 0.002). Using 7 intra-operative recordings, the mean number of knots was 7.6, with a median time per knot being 3.35 minutes. Median arterial anastomosis time was 26 minutes. Rescue stitches were required in 59.1% of cases. There was no incidence of intraoperative takedown and revision of an arterial anastomosis. There was no flap compromise or OR takebacks, and all flaps survived with no perioperative complications. Vessel diameter was not significantly correlated with number of knots, operative time, arterial anastomosis time, or need for rescue stitch.",
        "Conclusions": "This represents the first U.S. single-institution case series evaluating Symani-assisted microsurgery for head and neck free flap reconstruction. Robotic microanastomosis was feasible, safe, and reproducible, achieving 100% flap survival with no anastomotic revisions or major complications. Efficiency improved significantly over the first 22 cases, even with early trainee participation, and vessel diameter did not adversely affect operative performance. These findings support robotic-assisted microsurgery as a promising adjunct in complex reconstruction, meriting further study to define indications, cost-effectiveness, impact on training, and future applications such as lymphatic surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Utilization of a Novel Microsurgical Robotic Device for Head & Neck Microvascular Free Flap Surgery - A Single-Institution Experience</span>. <u>Richard Wu, MD, MPH</u>; Alexander Jones, MD; Philip Brauer, MD; Conrad Blunck, MD; Danielle Bottalico, MD; Jamie A Ku, MD. Cleveland Clinic Foundation<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Microvascular free flap reconstruction remains the cornerstone of addressing complex defects in head and neck oncologic surgery, yet it demands extreme technical precision and is vulnerable to physiological tremor, operator fatigue, and challenging anatomy. Robotic microsurgical platforms such as the Symani Surgical System offer motion scaling, tremor filtration, and improved access to constrained operative fields, with early data suggesting outcomes comparable or superior to manual microsurgery. Despite growing adoption in other surgical specialties, robotic-assisted microsurgery remains understudied in head and neck reconstruction. This study presents a single tertiary-care institution’s first consecutive 22 cases of robotic-assisted microvascular free tissue transfer using the Symani system, describing performance metrics, learning-curve indicators, and perioperative outcomes.</p>\n\n<p><strong>Methods: </strong>A retrospective review was performed for all patients undergoing Symani-assisted arterial microanastomosis between January and July 2025. Demographics, comorbidities, tumor characteristics, operative details, and postoperative outcomes were abstracted from the electronic medical record. Intraoperative metrics—including total operative time, TeleOp time (total time the surgeon was actively engaged with the robot), number of knots, rescue stitches, and anastomotic revisions—were obtained from real-time observations, representative logs, and video analysis. Seven cases with complete recordings allowed analysis of knot-throwing time, total anastomosis time, and frequency of meaningful assistant interventions. Vessel diameter was correlated with operative metrics using Spearman’s rank coefficients. Linear regression assessed changes in TeleOp time across successive cases as a measure of learning curve.</p>\n\n<p><strong>Results: </strong>The cohort was predominantly male (77.3%) with mean age 63.5 years. Oral cavity was the most common subsite (45.5%), and squamous cell carcinoma represented 77.3% of cases. The anterolateral thigh was the most common donor site (50%). Recipient artery diameter ranged widely from 0.6-2.5mm. Mean operative time was 504.5 minutes and mean TeleOp time 30.2 minutes, which significantly decreased across successive cases (slope –1.18 min/case, p = 0.002). Using 7 intra-operative recordings, the mean number of knots was 7.6, with a median time per knot being 3.35 minutes. Median arterial anastomosis time was 26 minutes. Rescue stitches were required in 59.1% of cases. There was no incidence of intraoperative takedown and revision of an arterial anastomosis. There was no flap compromise or OR takebacks, and all flaps survived with no perioperative complications. Vessel diameter was not significantly correlated with number of knots, operative time, arterial anastomosis time, or need for rescue stitch.</p>\n\n<p><strong>Conclusions: </strong>This represents the first U.S. single-institution case series evaluating Symani-assisted microsurgery for head and neck free flap reconstruction. Robotic microanastomosis was feasible, safe, and reproducible, achieving 100% flap survival with no anastomotic revisions or major complications. Efficiency improved significantly over the first 22 cases, even with early trainee participation, and vessel diameter did not adversely affect operative performance. These findings support robotic-assisted microsurgery as a promising adjunct in complex reconstruction, meriting further study to define indications, cost-effectiveness, impact on training, and future applications such as lymphatic surgery.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153300/Symani%20Table%201.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153300/Symani%20Figure%201.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153300--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S481",
      "content_id": "154048",
      "abstract_number": "S481",
      "poster_number": "",
      "title": "Robotic-Assisted Microsurgery in Head and Neck Reconstruction: Outcomes From 37 Consecutive Cases Using the Symani System",
      "summary": "Our experience suggests that robotic microsurgery with the Symani system is feasible, safe, and ergonomically advantageous in head and neck reconstruction. As technology evolves, we anticipate continued improvements in speed, precision, and reliability, representing the early stages of a broader robotic shift in microsurgical practice.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154048",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chareeni Kurukulasuriya, MD",
      "presenter": "Chareeni Kurukulasuriya, MD",
      "authors": "Andrew C Prince, MD; Chareeni Kurukulasuriya, MD ; David L Tran, MD; Nicholas Elmer, MD; Thomas Sorenson, MD; Alexis Gursky, BS; Hailey Wyatt, MD; Jamie P Lavine, MD; Adam S Jacobson, MD",
      "normalized_authors": [
        "Andrew C Prince",
        "Chareeni Kurukulasuriya",
        "David L Tran",
        "Nicholas Elmer",
        "Thomas Sorenson",
        "Alexis Gursky",
        "Hailey Wyatt",
        "Jamie P Lavine",
        "Adam S Jacobson"
      ],
      "affiliations": [
        "NYU-Langone Health"
      ],
      "normalized_institutions": [
        "NYU-Langone Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 486,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Andrew C Prince, MD; Chareeni Kurukulasuriya, MD ; David L Tran, MD; Nicholas Elmer, MD; Thomas Sorenson, MD; Alexis Gursky, BS; Hailey Wyatt, MD; Jamie P Lavine, MD; Adam S Jacobson, MD",
        "Affiliations": "NYU-Langone Health",
        "Introduction": "Robot-assisted microsurgery has emerged as a promising adjunct in microvascular reconstruction, offering tremor filtration, enhanced dexterity, and improved surgeon ergonomics. In October 2024, our institution adopted the Symani surgical robot for microvascular free-flap reconstruction in the head and neck. We report our early high-volume experience, focusing on feasibility, efficiency, vascular outcomes, and technical considerations during the learning curve.",
        "Methods": "Starting January 2025 till the present, the Symani robot was used in 37 free flap reconstructions, with 35 successful deployments. Two robotic attempts were aborted intraoperatively due to technical problems: failure of instruments to engage the system and an internal error that disabled right-arm function. Across the cohort, the robot assisted in 12 arterial and 23 venous end-to-end anastomoses. Flap types included 20 radial forearm, 7 anterolateral thigh, 7 fibular, and 1 latissimus dorsi flaps. Deployment was rapid, requiring <5 minutes in all cases, with the robot positioned ipsilateral to the anastomosis while an assistant operated contralaterally. Mean ischemia time was 30.8 minutes (95% CI 25.3-36.3).",
        "Abstract": "As part of our stepwise integration strategy, surgeons typically performed the back wall of the anastomosis manually before transitioning to the robot for the front wall. Arterial anastomoses required an average of 9 stitches (95% CI 8.23–9.77), of which ~70% (mean 6.33; 95% CI 4.80–7.87) were placed robotically. Venous anastomoses required 10 stitcheson average (95% CI 9.21–10.79), with ~51% (mean 5.12; 95% CI 4.33–5.91) placed robotically. Rescue stitches were necessary in 5 arterial anastomoses (42%) and 2 venous anastomoses (9%), all performed manually. The system’s ergonomic advantages were clear: operating from a seated position with arm support and tremor filtration substantially reduced physical and mental fatigue. However, several limitations were noted, including a significant capital cost and currently available instruments that inconsistently grasp vessel adventitia, necessitating active manual assistant participation. Newly released instrument designs—expected to be implemented in December 2025—may mitigate this limitation. View in Agenda and Add to Schedule",
        "Results": "Three patients (8%) required postoperative take-back for perfusion issues. Two presented with arterial thrombosis—one involving an artery partially sewn robotically—and one developed venous thrombosis in a partially robotically sewn vein. All takebacks were successfully salvaged, and all flaps survived to fill their reconstructive defects appropriately. No flap failures occurred.",
        "Discussion": "In our early institutional experience, Symani-assisted vascular anastomoses demonstrated outcomes not inferior to classical manual microsurgical techniques. Based on surgeon performance and fluidity, we estimate a learning curve of approximately 10 anastomoses, after which robotic movements become increasingly efficient. Given the multi-surgeon academic environment, we also developed a synthetic anastomosis model to accelerate pre-clinical skill acquisition.",
        "Conclusion": "Our experience suggests that robotic microsurgery with the Symani system is feasible, safe, and ergonomically advantageous in head and neck reconstruction. As technology evolves, we anticipate continued improvements in speed, precision, and reliability, representing the early stages of a broader robotic shift in microsurgical practice."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Robotic-Assisted Microsurgery in Head and Neck Reconstruction: Outcomes From 37 Consecutive Cases Using the Symani System</span>. Andrew C Prince, MD; <u>Chareeni Kurukulasuriya, MD</u>; David L Tran, MD; Nicholas Elmer, MD; Thomas Sorenson, MD; Alexis Gursky, BS; Hailey Wyatt, MD; Jamie P Lavine, MD; Adam S Jacobson, MD. NYU-Langone Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Robot-assisted microsurgery has emerged as a promising adjunct in microvascular reconstruction, offering tremor filtration, enhanced dexterity, and improved surgeon ergonomics. In October 2024, our institution adopted the Symani surgical robot for microvascular free-flap reconstruction in the head and neck. We report our early high-volume experience, focusing on feasibility, efficiency, vascular outcomes, and technical considerations during the learning curve.</p>\n\n<p><strong>Methods: </strong>Starting January 2025 till the present, the Symani robot was used in 37 free flap reconstructions, with 35 successful deployments. Two robotic attempts were aborted intraoperatively due to technical problems: failure of instruments to engage the system and an internal error that disabled right-arm function. Across the cohort, the robot assisted in 12 arterial and 23 venous end-to-end anastomoses. Flap types included 20 radial forearm, 7 anterolateral thigh, 7 fibular, and 1 latissimus dorsi flaps. Deployment was rapid, requiring <5 minutes in all cases, with the robot positioned ipsilateral to the anastomosis while an assistant operated contralaterally. Mean ischemia time was 30.8 minutes (95% CI 25.3-36.3).</p>\n\n<p>As part of our stepwise integration strategy, surgeons typically performed the back wall of the anastomosis manually before transitioning to the robot for the front wall. Arterial anastomoses required an average of 9 stitches (95% CI 8.23–9.77), of which ~70% (mean 6.33; 95% CI 4.80–7.87) were placed robotically. Venous anastomoses required 10 stitcheson average (95% CI 9.21–10.79), with ~51% (mean 5.12; 95% CI 4.33–5.91) placed robotically. Rescue stitches were necessary in 5 arterial anastomoses (42%) and 2 venous anastomoses (9%), all performed manually.</p>\n\n<p><strong>Results: </strong>Three patients (8%) required postoperative take-back for perfusion issues. Two presented with arterial thrombosis—one involving an artery partially sewn robotically—and one developed venous thrombosis in a partially robotically sewn vein. All takebacks were successfully salvaged, and all flaps survived to fill their reconstructive defects appropriately. No flap failures occurred.</p>\n\n<p><strong>Discussion: </strong>In our early institutional experience, Symani-assisted vascular anastomoses demonstrated outcomes not inferior to classical manual microsurgical techniques. Based on surgeon performance and fluidity, we estimate a learning curve of approximately 10 anastomoses, after which robotic movements become increasingly efficient. Given the multi-surgeon academic environment, we also developed a synthetic anastomosis model to accelerate pre-clinical skill acquisition.</p>\n\n<p>The system’s ergonomic advantages were clear: operating from a seated position with arm support and tremor filtration substantially reduced physical and mental fatigue. However, several limitations were noted, including a significant capital cost and currently available instruments that inconsistently grasp vessel adventitia, necessitating active manual assistant participation. Newly released instrument designs—expected to be implemented in December 2025—may mitigate this limitation.</p>\n\n<p><strong>Conclusion: </strong>Our experience suggests that robotic microsurgery with the Symani system is feasible, safe, and ergonomically advantageous in head and neck reconstruction. As technology evolves, we anticipate continued improvements in speed, precision, and reliability, representing the early stages of a broader robotic shift in microsurgical practice.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154048--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S482",
      "content_id": "153709",
      "abstract_number": "S482",
      "poster_number": "",
      "title": "In-house virtual surgical planning for head and neck reconstruction: a 10-year institutional experience",
      "summary": "The in-house VSP workflow presents a beneficial tool for head and neck reconstructions with osseous free flaps, particularly for reducing operative time and improving efficiency. Furthermore, the in-house workflow was successfully sustained in clinical practice over the last 10 years and shows great potential to improve disease outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153709",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Diane Pan, BSc",
      "presenter": "Diane Pan, BSc",
      "authors": "Diane Pan, BSc ; Linh Tran, BSc; Nadia Hua, MD; Eitan Prisman, MD",
      "normalized_authors": [
        "Diane Pan",
        "Linh Tran",
        "Nadia Hua",
        "Eitan Prisman"
      ],
      "affiliations": [
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153709/gam%20for%20operative%20time.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153709/gam%20for%20operative%20time.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153709"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 528,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Diane Pan, BSc ; Linh Tran, BSc; Nadia Hua, MD; Eitan Prisman, MD",
        "Affiliations": "University of British Columbia",
        "Background": "Head and neck reconstruction using osseous free flaps remains a technically challenging procedure, where conventionally, the donor bone is harvested and shaped in a free hand fashion (FHS) to reconstitute the premorbid anatomical structures. This process may be time-consuming and iterative, largely relying on the surgeon’s own expertise and judgement. Virtual surgical planning (VSP) with 3D-printed cutting guides may improve reconstructive accuracy, patient outcomes, and operative efficiency. However, this technology is largely available through commercial services, which can be expensive and time consuming with added delays. In-house VSP workflows are a potential solution to minimize costs and planning lead times, while facilitating greater clinical collaboration. This study reviews an in-house VSP workflow within a high-volume tertiary care center by comparing operative time and postoperative outcomes between VSP and FHS for mandibular and maxillary reconstruction.",
        "Methods": "A retrospective analysis of all maxilla and mandible reconstructions with osseous free flaps from February 2015 to May 2025 was performed. Demographic, clinical, and postoperative parameters were collected and compared between patients who received VSP and FHS. Case volume and operative times were compared across the total study period. A subgroup of patients with malignant disease was extracted and further compared for tumor pathology and disease outcomes.",
        "Results": "A total of 377 reconstructions of the mandible (76%) and maxilla (24%) were performed on 358 patients, with 19 patients undergoing re-operations. The median numbers of cases performed per year were 14 and 19 for FHS and VSP respectively (range, 15-50). There was a significant reduction in mean operative time (249 vs. 339 min, p<0.001), tracheostomy rate (27% vs. 56%, p<0.001), and increase utilization of a two-team surgical approach (79% vs. 67%, p=0.01) for the VSP cohort. Associations between operative time and VSP were evaluated using a generalized additive model with a non-linear term for surgical date and covariates for VSP and surgical team approach (1-team vs. 2-team). VSP remained a significant factor in reducing operative time (p=0.014). The model explained 49.5% of the variability in operative time (R²=0.495). Among postoperative outcomes, VSP patients trended toward lower rates of surgical site infection (p=0.054), with no other differences in surgical complications. The FHS group showed a higher percentage of patients with a length of hospital stay greater than 10 days (63% vs. 47%, p=0.002). Of the entire cohort, 273 (72%) cases were for malignant disease, where tumor (T) staging did not differ between VSP and FHS groups (p=0.28). The VSP group demonstrated a significant reduction in positive soft tissue margins (12% vs. 22%, p=0.034) and no difference in bony margins (14% vs. 11%, p=0.48). In addition, VSP patients showed lower rates of recurrence within 2 years post-operation (26% vs. 53%, p<0.001) and improved disease-free survival overall (p<0.001).",
        "Conclusions": "The in-house VSP workflow presents a beneficial tool for head and neck reconstructions with osseous free flaps, particularly for reducing operative time and improving efficiency. Furthermore, the in-house workflow was successfully sustained in clinical practice over the last 10 years and shows great potential to improve disease outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>In-house virtual surgical planning for head and neck reconstruction: a 10-year institutional experience</span>. <u>Diane Pan, BSc</u>; Linh Tran, BSc; Nadia Hua, MD; Eitan Prisman, MD. University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Head and neck reconstruction using osseous free flaps remains a technically challenging procedure, where conventionally, the donor bone is harvested and shaped in a free hand fashion (FHS) to reconstitute the premorbid anatomical structures. This process may be time-consuming and iterative, largely relying on the surgeon’s own expertise and judgement. Virtual surgical planning (VSP) with 3D-printed cutting guides may improve reconstructive accuracy, patient outcomes, and operative efficiency. However, this technology is largely available through commercial services, which can be expensive and time consuming with added delays. In-house VSP workflows are a potential solution to minimize costs and planning lead times, while facilitating greater clinical collaboration. This study reviews an in-house VSP workflow within a high-volume tertiary care center by comparing operative time and postoperative outcomes between VSP and FHS for mandibular and maxillary reconstruction. </p>\n\n<p><strong>Methods: </strong>A retrospective analysis of all maxilla and mandible reconstructions with osseous free flaps from February 2015 to May 2025 was performed. Demographic, clinical, and postoperative parameters were collected and compared between patients who received VSP and FHS. Case volume and operative times were compared across the total study period. A subgroup of patients with malignant disease was extracted and further compared for tumor pathology and disease outcomes. </p>\n\n<p><strong>Results:</strong> A total of 377 reconstructions of the mandible (76%) and maxilla (24%) were performed on 358 patients, with 19 patients undergoing re-operations. The median numbers of cases performed per year were 14 and 19 for FHS and VSP respectively (range, 15-50). There was a significant reduction in mean operative time (249 vs. 339 min, p<0.001), tracheostomy rate (27% vs. 56%, p<0.001), and increase utilization of a two-team surgical approach (79% vs. 67%, p=0.01) for the VSP cohort. Associations between operative time and VSP were evaluated using a generalized additive model with a non-linear term for surgical date and covariates for VSP and surgical team approach (1-team vs. 2-team). VSP remained a significant factor in reducing operative time (p=0.014). The model explained 49.5% of the variability in operative time (R²=0.495). Among postoperative outcomes, VSP patients trended toward lower rates of surgical site infection (p=0.054), with no other differences in surgical complications. The FHS group showed a higher percentage of patients with a length of hospital stay greater than 10 days (63% vs. 47%, p=0.002). Of the entire cohort, 273 (72%) cases were for malignant disease, where tumor (T) staging did not differ between VSP and FHS groups (p=0.28). The VSP group demonstrated a significant reduction in positive soft tissue margins (12% vs. 22%, p=0.034) and no difference in bony margins (14% vs. 11%, p=0.48). In addition, VSP patients showed lower rates of recurrence within 2 years post-operation (26% vs. 53%, p<0.001) and improved disease-free survival overall (p<0.001).  </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153709/gam%20for%20operative%20time.png' /></p>\n\n<p><strong>Conclusions: </strong>The in-house VSP workflow presents a beneficial tool for head and neck reconstructions with osseous free flaps, particularly for reducing operative time and improving efficiency. Furthermore, the in-house workflow was successfully sustained in clinical practice over the last 10 years and shows great potential to improve disease outcomes. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153709--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S483",
      "content_id": "154469",
      "abstract_number": "S483",
      "poster_number": "",
      "title": "Virtual Surgical Planning to Reconstruct Total Maxillectomy Defects Including the Orbital Floor with a Two-Segment Scapular Free Flap",
      "summary": "Quantitative metrics demonstrate the ability of VSP to guide complex midface reconstruction with high accuracy. The VSP-guided reconstruction can leverage the natural curvature of the lateral border of the SFF to reconstruct the maxillary alveolus, zygomaticomaxillary buttress, and a greenstick fracture of the medial border of the SFF can effectively restore the orbital floor geometry.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154469",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amelie Marshall, BASc",
      "presenter": "Amelie Marshall, BASc",
      "authors": "Amelie Marshall, BASc ; Cornelius Kurten, MD; Rohan Birk, BASc; Jamie Kwon, BSc, MSc; Eitan Prisman, MD",
      "normalized_authors": [
        "Amelie Marshall, BASc",
        "Cornelius Kurten",
        "Rohan Birk, BASc",
        "Jamie Kwon",
        "Eitan Prisman"
      ],
      "affiliations": [
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154469/Screenshot%202025-12-05%20144800.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154469/Screenshot%202025-12-05%20144800.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154469"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 381,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Amelie Marshall, BASc ; Cornelius Kurten, MD; Rohan Birk, BASc; Jamie Kwon, BSc, MSc; Eitan Prisman, MD",
        "Affiliations": "University of British Columbia",
        "Introduction": "Total maxillectomy defects involving the orbital floor are challenging to reconstruct. These reconstructions must recreate the maxillary volume while maintaining the orbital height and providing sufficient vascularized tissue to withstand adjuvant chemoradiation. The scapular free flap (SFF), with its lateral border positioned to reconstruct the maxillary alveolus and zygomaticomaxillary buttress along with a \"greenstick” folding technique to reconstruct the orbital floor, offers unique versatility and geometric advantages. This study evaluates the accuracy of virtual surgical planning (VSP)-guided total maxillectomy defects including the orbital floor.",
        "Methods": "Ten consecutive total maxillectomy reconstructions (8 male, 2 female) with the SFF, with an in-house VSP, were retrospective reviewed (Sep 2022 - Oct 2024). Postoperative CT scans on days 5-10 were segmented to compare orbital floor height between the reconstructed orbit to the contralateral orbit. To assess reconstruction accuracy the volumetric overlap between the reconstructed maxilla, based on the postoperative CT scan, was compared the VSP. The cephalometric Dice score, and Hausdorff-95 (HD95) distance metrics were calculated, and represent the volume overlap and outer contour respectively, between the panned VSP and executed reconstruction.",
        "Results": "Ten total maxillectomy defects involving the orbital floor for oncological resections were reconstructed with an in-house VSP-guided SFF. A chimeric pedicle flap with soft tissue including the serratus muscle was used in 4 patients, and the latissimus dorsi muscle was used in 3 patients. Two patients required orbital exenteration. The mean operative time was 5.5 hours, and the mean length of stay was 15 days, with only one patient requiring a tracheostomy. Based on the segmented postoperative CT, there was on average a 5.3 mm difference between the reconstructed and contralateral orbital height. In addition, comparing the planned virtual surgical plan and the executed reconstruction, demonstrated a Dice coefficient of 0.62 and HD95 of 7.4mm.",
        "Abstract": "Figure 1. The VSP reconstruction model of the maxilla and orbital floor (left) and the reconstruction segmented from a post-operative CT scan (right). View in Agenda and Add to Schedule",
        "Conclusion": "Quantitative metrics demonstrate the ability of VSP to guide complex midface reconstruction with high accuracy. The VSP-guided reconstruction can leverage the natural curvature of the lateral border of the SFF to reconstruct the maxillary alveolus, zygomaticomaxillary buttress, and a greenstick fracture of the medial border of the SFF can effectively restore the orbital floor geometry."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Virtual Surgical Planning to Reconstruct Total Maxillectomy Defects Including the Orbital Floor with a Two-Segment Scapular Free Flap</span>. <u>Amelie Marshall, BASc</u>; Cornelius Kurten, MD; Rohan Birk, BASc; Jamie Kwon, BSc, MSc; Eitan Prisman, MD. University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Total maxillectomy defects involving the orbital floor are challenging to reconstruct. These reconstructions must recreate the maxillary volume while maintaining the orbital height and providing sufficient vascularized tissue to withstand adjuvant chemoradiation. The scapular free flap (SFF), with its lateral border positioned to reconstruct the maxillary alveolus and zygomaticomaxillary buttress along with a \"greenstick” folding technique to reconstruct the orbital floor, offers unique versatility and geometric advantages. This study evaluates the accuracy of virtual surgical planning (VSP)-guided total maxillectomy defects including the orbital floor.</p>\n\n<p><strong>Methods: </strong>Ten consecutive total maxillectomy reconstructions (8 male, 2 female) with the SFF, with an in-house VSP, were retrospective reviewed (Sep 2022 - Oct 2024). Postoperative CT scans on days 5-10 were segmented to compare orbital floor height between the reconstructed orbit to the contralateral orbit. To assess reconstruction accuracy the volumetric overlap between the reconstructed maxilla, based on the postoperative CT scan, was compared the VSP. The cephalometric Dice score, and Hausdorff-95 (HD95) distance metrics were calculated, and represent the volume overlap and outer contour respectively, between the panned VSP and executed reconstruction.</p>\n\n<p><strong>Results: </strong>Ten total maxillectomy defects involving the orbital floor for oncological resections were reconstructed with an in-house VSP-guided SFF. A chimeric pedicle flap with soft tissue including the serratus muscle was used in 4 patients, and the latissimus dorsi muscle was used in 3 patients. Two patients required orbital exenteration. The mean operative time was 5.5 hours, and the mean length of stay was 15 days, with only one patient requiring a tracheostomy. Based on the segmented postoperative CT, there was on average a 5.3 mm difference between the reconstructed and contralateral orbital height. In addition, comparing the planned virtual surgical plan and the executed reconstruction, demonstrated a Dice coefficient of 0.62 and HD95 of 7.4mm.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154469/Screenshot%202025-12-05%20144800.png' /></p>\n\n<p>Figure 1. The VSP reconstruction model of the maxilla and orbital floor (left) and the reconstruction segmented from a post-operative CT scan (right).</p>\n\n<p><strong>Conclusion: </strong>Quantitative metrics demonstrate the ability of VSP to guide complex midface reconstruction with high accuracy. The VSP-guided reconstruction can leverage the natural curvature of the lateral border of the SFF to reconstruct the maxillary alveolus, zygomaticomaxillary buttress, and a greenstick fracture of the medial border of the SFF can effectively restore the orbital floor geometry.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154469--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S484",
      "content_id": "154738",
      "abstract_number": "S484",
      "poster_number": "",
      "title": "Combined Maxillary and Nasal Reconstruction Using a Virtual Surgical Plan-Guided “Tip-on-top” Orthogonal Scapular Free-Flap: A Case Series",
      "summary": "The “tip-on-top” surgical technique, guided by a VSP utilizing a two-piece, orthogonal scapular free flap, is effective in recreating the premaxilla and nasal native anatomy in patients requiring resection of the nasal bone and palate. This choice of flap shows promise as an option in these complex cases. Joint palatal-nasal reconstructions can be supported using VSP, with cases showing high reconstruction accuracy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154738",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amelie Marshall, BASc",
      "presenter": "Amelie Marshall, BASc",
      "authors": "Amelie Marshall, BASc ; Connor Holmes; Eitan Prisman",
      "normalized_authors": [
        "Amelie Marshall, BASc",
        "Connor Holmes",
        "Eitan Prisman"
      ],
      "affiliations": [
        "University of British Columbia"
      ],
      "normalized_institutions": [
        "University of British Columbia"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154738/Screenshot%202025-12-05%20151220.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154738/Screenshot%202025-12-05%20151220.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154738"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 466,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Figure 1.",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amelie Marshall, BASc ; Connor Holmes; Eitan Prisman",
        "Affiliations": "University of British Columbia",
        "Background": "Advanced malignancies that involve both the premaxilla and the nose, whose resection involve both a partial maxillectomy and rhinectomy, pose a significant reconstructive challenge. The scapular free flap is a versatile reconstructive option that can be leveraged to reconstruct both the nasal bone and premaxilla by positioning at least a 2-piece scapula in orthogonal planes. While such reconstructions are challenging, virtual surgical planning (VSP) can optimize and guide the parts of the scapula to be harvested and their position in the craniofacial skeleton to best reconstruct the planned resection. This study presents a VSP case series of reconstructions using the novel “tip-on-top” (TOT) scapular free flap in joint rhinectomy-maxillectomies.",
        "Methods": "This retrospective study included five patients who underwent palatal-nasal resections, reconstructed with TOT scapular free flaps. These reconstructions were guided through VSP using an in-house software (Artisynth), generating cutting guides and reconstruction models. Patient pre-operative and post-operative CT scans were segmented in 3D Slicer to assess facial aesthetics following the reconstruction surgery. Volumetric measurements, including Hausdorff-95 (HD95) distance and volume overlap, were collected between the reconstruction model and post-operative CT segmentation to evaluate reconstruction accuracy.",
        "Figure 1.": "Reconstruction model (left), post-operative CT segmentation (middle), and registration of both models (right) for one case.",
        "Results": "From January 2023 to August 2025, five patients with maxillary-nasal defects received a joint partial maxillectomy and rhinectomy that had a VSP guided two-segment, TOT scapular free flap. For each, the distal part of the scapular tip was used to reconstruct the nasal septum, while a second, more proximal segment, of the lateral border of the scapula was harvested to repair the pre-maxilla. The mean volume overlap and HD95, a measure of the ability to reconstruct the outer contour, between the reconstruction model and the post-operative segmentation were 0.27 and 9.88mm, respectively. Mean operative time was 324 minutes (range 229–553), with the longest case prolonged by neurosurgical resection of intracranial extension. Flap survival occurred in four of five patients; one had early flap failure requiring contralateral scapular reconstruction. One patient developed a late oro-nasal fistula after radiation, and another developed a small fistula during the initial hospitalization. Two patients required revision rhinoplasty for contour refinement and nasal stenosis at approximately one year. Two patients underwent concomitant tracheostomy; one was decannulated before discharge and one remained trach-dependent. At discharge, four patients tolerated an oral diet without gastrostomy tube support, while one remained gastrostomy tube dependent.",
        "Conclusion": "The “tip-on-top” surgical technique, guided by a VSP utilizing a two-piece, orthogonal scapular free flap, is effective in recreating the premaxilla and nasal native anatomy in patients requiring resection of the nasal bone and palate. This choice of flap shows promise as an option in these complex cases. Joint palatal-nasal reconstructions can be supported using VSP, with cases showing high reconstruction accuracy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Combined Maxillary and Nasal Reconstruction Using a Virtual Surgical Plan-Guided “Tip-on-top” Orthogonal Scapular Free-Flap: A Case Series</span>. <u>Amelie Marshall, BASc</u>; Connor Holmes; Eitan Prisman. University of British Columbia<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Advanced malignancies that involve both the premaxilla and the nose, whose resection involve both a partial maxillectomy and rhinectomy, pose a significant reconstructive challenge. The scapular free flap is a versatile reconstructive option that can be leveraged to reconstruct both the nasal bone and premaxilla by positioning at least a 2-piece scapula in orthogonal planes. While such reconstructions are challenging, virtual surgical planning (VSP) can optimize and guide the parts of the scapula to be harvested and their position in the craniofacial skeleton to best reconstruct the planned resection. This study presents a VSP case series of reconstructions using the novel “tip-on-top” (TOT) scapular free flap in joint rhinectomy-maxillectomies.</p>\n\n<p><strong>Methods: </strong>This retrospective study included five patients who underwent palatal-nasal resections, reconstructed with TOT scapular free flaps. These reconstructions were guided through VSP using an in-house software (Artisynth), generating cutting guides and reconstruction models. Patient pre-operative and post-operative CT scans were segmented in 3D Slicer to assess facial aesthetics following the reconstruction surgery. Volumetric measurements, including Hausdorff-95 (HD95) distance and volume overlap, were collected between the reconstruction model and post-operative CT segmentation to evaluate reconstruction accuracy.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154738/Screenshot%202025-12-05%20151220.png' /></p>\n\n<p><strong>Figure 1.</strong> Reconstruction model (left), post-operative CT segmentation (middle), and registration of both models (right) for one case.</p>\n\n<p><strong>Results: </strong>From January 2023 to August 2025, five patients with maxillary-nasal defects received a joint partial maxillectomy and rhinectomy that had a VSP guided two-segment, TOT scapular free flap. For each, the distal part of the scapular tip was used to reconstruct the nasal septum, while a second, more proximal segment, of the lateral border of the scapula was harvested to repair the pre-maxilla. The mean volume overlap and HD95, a measure of the ability to reconstruct the outer contour, between the reconstruction model and the post-operative segmentation were 0.27 and 9.88mm, respectively. Mean operative time was 324 minutes (range 229–553), with the longest case prolonged by neurosurgical resection of intracranial extension. Flap survival occurred in four of five patients; one had early flap failure requiring contralateral scapular reconstruction. One patient developed a late oro-nasal fistula after radiation, and another developed a small fistula during the initial hospitalization. Two patients required revision rhinoplasty for contour refinement and nasal stenosis at approximately one year. Two patients underwent concomitant tracheostomy; one was decannulated before discharge and one remained trach-dependent. At discharge, four patients tolerated an oral diet without gastrostomy tube support, while one remained gastrostomy tube dependent.</p>\n\n<p><strong>Conclusion: </strong>The “tip-on-top” surgical technique, guided by a VSP utilizing a two-piece, orthogonal scapular free flap, is effective in recreating the premaxilla and nasal native anatomy in patients requiring resection of the nasal bone and palate. This choice of flap shows promise as an option in these complex cases. Joint palatal-nasal reconstructions can be supported using VSP, with cases showing high reconstruction accuracy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154738--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S485",
      "content_id": "155342",
      "abstract_number": "S485",
      "poster_number": "",
      "title": "Rate and Predictors of Virtual Surgical Planning Abandonment During Osseous Free Flap Reconstruction for Head and Neck Neoplasms",
      "summary": "Of 186 patients, 155 met inclusion criteria; 18 were excluded for not using VSP and 13 for non-neoplastic indications. The cohort was 66% male (n=103) with a mean age of 61.6 ± 14.5 years. Most cases were malignant (94%), with squamous cell carcinoma (SCC) comprising 78%. Reconstruction utilized fibula flaps in 73% of cases and scapula flaps in 27%. Most defects involved the mandible (73%). VSP was abandoned in 7...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155342",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lauren Gabra, MD",
      "presenter": "Lauren Gabra, MD",
      "authors": "Lauren Gabra, MD ; Zoe Zhang, BS; Natalia Swiatowiec, MD, FACS; Thomas Houser, MD; Ariel Frost, MD, FACS; Eli Gordin, MD, FACS",
      "normalized_authors": [
        "Lauren Gabra",
        "Zoe Zhang",
        "Natalia Swiatowiec",
        "Thomas Houser",
        "Ariel Frost",
        "Eli Gordin"
      ],
      "affiliations": [
        "University of Texas at Southwestern"
      ],
      "normalized_institutions": [
        "University of Texas at Southwestern"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 337,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance",
        "Objective",
        "Design",
        "Setting",
        "Participants",
        "Exposure",
        "Main Outcomes and Measures",
        "Results",
        "Conclusions and Relevance",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lauren Gabra, MD ; Zoe Zhang, BS; Natalia Swiatowiec, MD, FACS; Thomas Houser, MD; Ariel Frost, MD, FACS; Eli Gordin, MD, FACS",
        "Affiliations": "University of Texas at Southwestern",
        "Importance": "Virtual surgical planning (VSP) is increasingly used for osseous free flap reconstruction for head and neck neoplasms, but its intraoperative abandonment rate and associated predictors are not well characterized.",
        "Objective": "To quantify the rate of VSP abandonment during osseous free flap reconstruction for head and neck neoplasms and identify factors associated with abandonment.",
        "Design": "Retrospective cohort study of patients undergoing osseous free flap reconstruction using VSP from September 2017 to June 2024.",
        "Setting": "Tertiary academic medical center.",
        "Participants": "Patients who underwent resection of mandibular or midface neoplasms necessitating fibula or scapula free flap reconstruction. Patients were excluded if VSP was not used or if reconstruction was performed for non-neoplastic indications.",
        "Exposure": "Preoperative VSP with patient-specific cutting guides and custom reconstruction plates.",
        "Main Outcomes and Measures": "Primary outcome was intraoperative abandonment of VSP, defined as deviation from the preoperatively planned osteotomy placement. Demographic, oncologic, and treatment factors were evaluated as potential predictors of abandonment.",
        "Results": "Of 186 patients, 155 met inclusion criteria; 18 were excluded for not using VSP and 13 for non-neoplastic indications. The cohort was 66% male (n=103) with a mean age of 61.6 ± 14.5 years. Most cases were malignant (94%), with squamous cell carcinoma (SCC) comprising 78%. Reconstruction utilized fibula flaps in 73% of cases and scapula flaps in 27%. Most defects involved the mandible (73%). VSP was abandoned in 7 cases (4.5%). All abandonment cases were SCC; one had a positive bony margin. All were abandoned due to unanticipated intraoperative need for margin expansion. Positive margin rates were low overall and did not differ significantly between abandonment and non-abandonment groups (14% vs 3%, p=0.246). No other significant differences were observed between groups with respect to age, sex, pathology, tumor size, prior treatment, tumor site, flap type, or ischemia time.",
        "Conclusions and Relevance": "VSP abandonment is rare and substantially lower than previously reported rates. It occurred primarily in the setting of aggressive tumors or salvage surgery. These findings support the safety and utility of VSP in head and neck resections and osseous reconstruction for neoplasms.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Rate and Predictors of Virtual Surgical Planning Abandonment During Osseous Free Flap Reconstruction for Head and Neck Neoplasms</span>. <u>Lauren Gabra, MD</u>; Zoe Zhang, BS; Natalia Swiatowiec, MD, FACS; Thomas Houser, MD; Ariel Frost, MD, FACS; Eli Gordin, MD, FACS. University of Texas at Southwestern<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance:</strong> Virtual surgical planning (VSP) is increasingly used for osseous free flap reconstruction for head and neck neoplasms, but its intraoperative abandonment rate and associated predictors are not well characterized. </p>\n\n<p><strong>Objective:</strong> To quantify the rate of VSP abandonment during osseous free flap reconstruction for head and neck neoplasms and identify factors associated with abandonment.</p>\n\n<p><strong>Design:</strong> Retrospective cohort study of patients undergoing osseous free flap reconstruction using VSP from September 2017 to June 2024.</p>\n\n<p><strong>Setting: </strong>Tertiary academic medical center.</p>\n\n<p><strong>Participants: </strong>Patients who underwent resection of mandibular or midface neoplasms necessitating fibula or scapula free flap reconstruction. Patients were excluded if VSP was not used or if reconstruction was performed for non-neoplastic indications.</p>\n\n<p><strong>Exposure: </strong>Preoperative VSP with patient-specific cutting guides and custom reconstruction plates. </p>\n\n<p><strong>Main Outcomes and Measures:</strong> Primary outcome was intraoperative abandonment of VSP, defined as deviation from the preoperatively planned osteotomy placement. Demographic, oncologic, and treatment factors were evaluated as potential predictors of abandonment.</p>\n\n<p><strong>Results: </strong>Of 186 patients, 155 met inclusion criteria; 18 were excluded for not using VSP and 13 for non-neoplastic indications. The cohort was 66% male (n=103) with a mean age of 61.6 ± 14.5 years. Most cases were malignant (94%), with squamous cell carcinoma (SCC) comprising 78%. Reconstruction utilized fibula flaps in 73% of cases and scapula flaps in 27%. Most defects involved the mandible (73%). VSP was abandoned in 7 cases (4.5%). All abandonment cases were SCC; one had a positive bony margin. All were abandoned due to unanticipated intraoperative need for margin expansion. Positive margin rates were low overall and did not differ significantly between abandonment and non-abandonment groups (14% vs 3%, p=0.246). No other significant differences were observed between groups with respect to age, sex, pathology, tumor size, prior treatment, tumor site, flap type, or ischemia time.</p>\n\n<p><strong>Conclusions and Relevance: </strong>VSP abandonment is rare and substantially lower than previously reported rates. It occurred primarily in the setting of aggressive tumors or salvage surgery. These findings support the safety and utility of VSP in head and neck resections and osseous reconstruction for neoplasms.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155342--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S486",
      "content_id": "154332",
      "abstract_number": "S486",
      "poster_number": "",
      "title": "BIOENGINEERED HYBRID CAD/CAM SCAFFOLD FOR BONE REGENERATION: DEVELOPMENT OF AN ANIMAL MODEL OF SEGMENTAL MANDIBULECTOMY",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154332",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Giulio Badin, MD",
      "presenter": "Giulio Badin, MD",
      "authors": "Giulio Badin, MD 1 ; Harley Chan, PhD 2 ; Antonino Cassarà, MD 3 ; Alessandra Ruaro, MD 3 ; Stefano Taboni, MD, PhD 3 ; Chiara Pasini, PhD 4 ; Micheal Daly, PhD 2 ; Jason Townson, PhD 2 ; Domenico Russo, MD 4 ; Luciana Sartore, PhD 4 ; Marco Ferrari, MD, PhD 3 ; Piero Nicolai, MD 3 ; Ralph W Gilbert, MD, FRCSC, BSc 5 ; Jonathan C Irish, MD, MSc, FRCSC, FACS, FCAHS 1",
      "normalized_authors": [
        "Giulio Badin",
        "Harley Chan",
        "Antonino Cassarà",
        "Alessandra Ruaro",
        "Stefano Taboni",
        "Chiara Pasini",
        "Micheal Daly",
        "Jason Townson",
        "Domenico Russo",
        "Luciana Sartore",
        "Marco Ferrari",
        "Piero Nicolai",
        "Ralph W Gilbert, FRCSC",
        "Jonathan C Irish, FRCSC, FCAHS"
      ],
      "affiliations": [
        "Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada",
        "Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada",
        "Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy",
        "University of Brescia, italy",
        "Department of Otolaryngology-Head & Neck Surgery, UHN, Toronto, ON, Canada"
      ],
      "normalized_institutions": [
        "Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada",
        "Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada",
        "Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy",
        "University of Brescia, italy",
        "Department of Otolaryngology-Head & Neck Surgery, UHN, Toronto, ON, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154332/Segmental%20mandibulectomy(1).jpeg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154332/Segmental%20mandibulectomy(1).jpeg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154332"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 404,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Giulio Badin, MD 1 ; Harley Chan, PhD 2 ; Antonino Cassarà, MD 3 ; Alessandra Ruaro, MD 3 ; Stefano Taboni, MD, PhD 3 ; Chiara Pasini, PhD 4 ; Micheal Daly, PhD 2 ; Jason Townson, PhD 2 ; Domenico Russo, MD 4 ; Luciana Sartore, PhD 4 ; Marco Ferrari, MD, PhD 3 ; Piero Nicolai, MD 3 ; Ralph W Gilbert, MD, FRCSC, BSc 5 ; Jonathan C Irish, MD, MSc, FRCSC, FACS, FCAHS 1",
        "Affiliations": "1 Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada; 2 Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, ON, Canada; 3 Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy; 4 University of Brescia, italy; 5 Department of Otolaryngology-Head & Neck Surgery, UHN, Toronto, ON, Canada",
        "BACKGROUND": "The standard of care for the reconstruction of segmental mandibular defects involves the use of autologous microvascular bone flaps, a technique that requires specifically trained personnel, extends operative time, and may increase patient morbidity. To overcome these limitations, research has focused on developing novel materials capable of providing mechanical support, ensuring biocompatibility, and promoting bone regeneration. The present study aims to develop an in vivo animal model of segmental mandibulectomy and to evaluate the mechanical, osteoinductive, and osteoconductive properties of a resorbable hybrid Polylactic Acid–Hydrogel (PLA-Hy) CAD/CAM scaffold seeded with human mesenchymal stromal cells (hMSCs).",
        "METHODS": "This proof-of-principle study was conducted in accordance with protocol AUP #6010.13, approved by our institution Animal Care Committee. The animal model was performed on adult New Zealand rabbits (Oryctolagus cuniculus, weight ~3.5kg). A unilateral 7.5 mm segmental mandibulectomy was conducted at the diastema, followed by reconstruction with a PLA-Hy hybrid CAD/CAM bioengineered scaffold colonized with hMSCs. The animals will undergo clinical, biochemical, and radiological monitoring. After reaching the primary endpoint (3 months), tissue samples will be analyzed by microCT and histology to assess osteoinduction, osteoconductivity, and bone integration. Results will be compared with the contralateral hemimandible and with data from previous studies.",
        "RESULTS": "The mandibular defect was successfully created using a patient-specific 3D cutting guide. The defect volume matched the exact dimensions of the scaffold designed for reconstruction. Prior to reconstruction, the scaffold was seeded with hMSCs for 24 hours under sterile conditions. During the procedure (Fig. 1), a 4-cm cervicotomic incision was made along the inferior border of the left mandible. After subperiosteal dissection, the diastema was exposed. This approach substantially reduces morbidity in the animal model, avoids oral mucosa incision, does not require extraction of the rabbit’s cheek teeth, does not place facial nerve branches at risk, and preserves the masseter and digastric muscles. Subsequently, the cutting guide was installed for bone resection. The mandible was reconstructed with the novel scaffold. The results of the procedure performed under survival-surgery conditions will be presented at the 12th International AHNS Conference, along with clinical, biochemical, radiological, and histopathological data after reaching the endpoint.",
        "CONCLUSION": "The proof-of-principle study represents the application of knowledge on bioengineered hybrid scaffolds, aiming to evaluate their osteoinductive, osteoconductive, and mechanical properties in a replicable in vivo model of segmental mandibulectomy. The results provide a framework for future translational progress in mandibular bone regeneration.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>BIOENGINEERED HYBRID CAD/CAM SCAFFOLD FOR BONE REGENERATION: DEVELOPMENT OF AN ANIMAL MODEL OF SEGMENTAL MANDIBULECTOMY</span>. <u>Giulio Badin, MD</u><sup>1</sup>; Harley Chan, PhD<sup>2</sup>; Antonino Cassarà, MD<sup>3</sup>; Alessandra Ruaro, MD<sup>3</sup>; Stefano Taboni, MD, PhD<sup>3</sup>; Chiara Pasini, PhD<sup>4</sup>; Micheal Daly, PhD<sup>2</sup>; Jason Townson, PhD<sup>2</sup>; Domenico Russo, MD<sup>4</sup>; Luciana Sartore, PhD<sup>4</sup>; Marco Ferrari, MD, PhD<sup>3</sup>; Piero Nicolai, MD<sup>3</sup>; Ralph W Gilbert, MD, FRCSC, BSc<sup>5</sup>; Jonathan C Irish, MD, MSc, FRCSC, FACS, FCAHS<sup>1</sup>. <sup>1</sup>Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada; <sup>2</sup>Guided Therapeutics (GTx) Program, Techna Institute,  University Health Network, Toronto, ON, Canada; <sup>3</sup>Section of Otorhinolaryngology-Head and Neck Surgery, Department of  Neurosciences, University of Padua, Padua, Italy; <sup>4</sup>University of Brescia, italy; <sup>5</sup>Department of Otolaryngology-Head & Neck Surgery, UHN, Toronto, ON, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND: </strong>The standard of care for the reconstruction of segmental mandibular defects involves the use of autologous microvascular bone flaps, a technique that requires specifically trained personnel, extends operative time, and may increase patient morbidity. To overcome these limitations, research has focused on developing novel materials capable of providing mechanical support, ensuring biocompatibility, and promoting bone regeneration. The present study aims to develop an in vivo animal model of segmental mandibulectomy and to evaluate the mechanical, osteoinductive, and osteoconductive properties of a resorbable hybrid Polylactic Acid–Hydrogel (PLA-Hy) CAD/CAM scaffold seeded with human mesenchymal stromal cells (hMSCs).</p>\n\n<p><strong>METHODS: </strong>This proof-of-principle study was conducted in accordance with protocol AUP #6010.13, approved by our institution Animal Care Committee. The animal model was performed on adult New Zealand rabbits (Oryctolagus cuniculus, weight ~3.5kg). A unilateral 7.5 mm segmental mandibulectomy was conducted at the diastema, followed by reconstruction with a PLA-Hy hybrid CAD/CAM bioengineered scaffold colonized with hMSCs. The animals will undergo clinical, biochemical, and radiological monitoring. After reaching the primary endpoint (3 months), tissue samples will be analyzed by microCT and histology to assess osteoinduction, osteoconductivity, and bone integration. Results will be compared with the contralateral hemimandible and with data from previous studies.</p>\n\n<p><strong>RESULTS: </strong>The mandibular defect was successfully created using a patient-specific 3D cutting guide. The defect volume matched the exact dimensions of the scaffold designed for reconstruction. Prior to reconstruction, the scaffold was seeded with hMSCs for 24 hours under sterile conditions. During the procedure (Fig. 1), a 4-cm cervicotomic incision was made along the inferior border of the left mandible. After subperiosteal dissection, the diastema was exposed. This approach substantially reduces morbidity in the animal model, avoids oral mucosa incision, does not require extraction of the rabbit’s cheek teeth, does not place facial nerve branches at risk, and preserves the masseter and digastric muscles. Subsequently, the cutting guide was installed for bone resection. The mandible was reconstructed with the novel scaffold. The results of the procedure performed under survival-surgery conditions will be presented at the 12th International AHNS Conference, along with clinical, biochemical, radiological, and histopathological data after reaching the endpoint.</p>\n\n<p><strong>CONCLUSION: </strong>The proof-of-principle study represents the application of knowledge on bioengineered hybrid scaffolds, aiming to evaluate their osteoinductive, osteoconductive, and mechanical properties in a replicable in vivo model of segmental mandibulectomy. The results provide a framework for future translational progress in mandibular bone regeneration.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154332/Segmental%20mandibulectomy(1).jpeg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154332--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S487",
      "content_id": "154075",
      "abstract_number": "S487",
      "poster_number": "",
      "title": "An Institutional Experience With IPS Implants®: Clinical Outcomes and Early Lessons Learned",
      "summary": "In total 6 patients underwent IPS; in our cohort 50% of patients underwent IPS at time of their cancer resection and reconstruction. In total 50% of patients had a radial forearm free flap at time of surgery. 100% of the implants inserted at the time of surgery were successful including those placed into a maxillary defect. One patient had his prosthesis removed at 203 days due to granulation tissue. The median...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154075",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Amanda J Bastien",
      "presenter": "Amanda J Bastien",
      "authors": "Amanda J Bastien 1 ; Julian Wilson 2 ; Andrew Larson 2 ; Alice Lin 2",
      "normalized_authors": [
        "Amanda J Bastien",
        "Julian Wilson",
        "Andrew Larson",
        "Alice Lin"
      ],
      "affiliations": [
        "Cedars Sinai, Kaiser Permanente",
        "Kaiser Permanente"
      ],
      "normalized_institutions": [
        "Cedars Sinai, Kaiser Permanente",
        "Kaiser Permanente"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154075/ips.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154075/ips.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154075"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 248,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion/Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Amanda J Bastien 1 ; Julian Wilson 2 ; Andrew Larson 2 ; Alice Lin 2",
        "Affiliations": "1 Cedars Sinai, Kaiser Permanente; 2 Kaiser Permanente",
        "Introduction": "An IPS (IPS Implants® Preprosthetic) prosthesis is a custom-fabricated implant system designed for dental rehabilitation (DR) in patients for whom conventional endosseous implants may not be feasible, such as those with extensive maxillofacial resections or patients with insufficient bone volume. This technique offers immediate DR, which increases access to DR and may lead to faster improvements in patients’ quality of life.",
        "Methods": "This ongoing case series includes patients treated at a single institution who underwent IPS performed by one surgical team.",
        "Results": "In total 6 patients underwent IPS; in our cohort 50% of patients underwent IPS at time of their cancer resection and reconstruction. In total 50% of patients had a radial forearm free flap at time of surgery. 100% of the implants inserted at the time of surgery were successful including those placed into a maxillary defect. One patient had his prosthesis removed at 203 days due to granulation tissue. The median follow-up time was 240 days (SD=61, range 261- 426 days).",
        "Discussion/Conclusion": "This ongoing case series represents one of the largest cohorts to date reporting outcomes and complications associated with the IPS Implants® preprosthetic implant system, complementing the previously published series by Gillrich et al. The technique offers the potential for immediate dental rehabilitation and is an option for more difficult reconstructive locations including the midface. Although long-term clinical data remain limited due to this system’s recent introduction, the findings from this ongoing series demonstrate promising surgical and prosthetic outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>An Institutional Experience With IPS Implants®: Clinical Outcomes and Early Lessons Learned</span>. <u>Amanda J Bastien</u><sup>1</sup>; Julian Wilson<sup>2</sup>; Andrew Larson<sup>2</sup>; Alice Lin<sup>2</sup>. <sup>1</sup>Cedars Sinai, Kaiser Permanente; <sup>2</sup>Kaiser Permanente<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>An IPS (IPS Implants® Preprosthetic) prosthesis is a custom-fabricated implant system designed for dental rehabilitation (DR) in patients for whom conventional endosseous implants may not be feasible, such as those with extensive maxillofacial resections or patients with insufficient bone volume. This technique offers immediate DR, which increases access to DR and may lead to faster improvements in patients’ quality of life.</p>\n\n<p><strong>Methods: </strong>This ongoing case series includes patients treated at a single institution who underwent IPS performed by one surgical team.</p>\n\n<p><strong>Results: </strong>In total 6 patients underwent IPS; in our cohort 50% of patients underwent IPS at time of their cancer resection and reconstruction. In total 50% of patients had a radial forearm free flap at time of surgery. 100% of the implants inserted at the time of surgery were successful including those placed into a maxillary defect. One patient had his prosthesis removed at 203 days due to granulation tissue. The median follow-up time was 240 days (SD=61, range 261- 426 days).</p>\n\n<p><strong>Discussion/Conclusion: </strong>This ongoing case series represents one of the largest cohorts to date reporting outcomes and complications associated with the IPS Implants® preprosthetic implant system, complementing the previously published series by Gillrich et al. The technique offers the potential for immediate dental rehabilitation and is an option for more difficult reconstructive locations including the midface. Although long-term clinical data remain limited due to this system’s recent introduction, the findings from this ongoing series demonstrate promising surgical and prosthetic outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154075/ips.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154075--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S488",
      "content_id": "154562",
      "abstract_number": "S488",
      "poster_number": "",
      "title": "Model-Based Evaluation of an Augmented Reality Cutting Guide for Fibula Osteotomies in Complex Mandibular Reconstruction",
      "summary": "Preliminary analysis of the first six participants shows comparable accuracy between CG and AR workflows. Median segment-length error was 1.57 mm (CG) vs 3.1 mm (AR), and angular error was 4.19° (CG) vs 5.68° (AR). No significant improvement was observed between AR1 and AR2, indicating minimal learning curve. Cutting time favored CG (134 ± 73 s) over AR (276 ± 109 s).",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154562",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260153",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Li, MD",
      "presenter": "Michael Li, MD",
      "authors": "Michael Li, MD 1 ; Brandon Strong, MS 1 ; Nicole Farber, MD 1 ; Sukhkaran Aulakh, MD 1 ; Peter Lancione, MD 1 ; Andrew Birkeland, MD, PhD 1 ; Marianne Abouyared, MD 1 ; Marc Fischer, BS 1 ; Andrew Hernandez, PhD 1 ; Alexander P Marston, MD 1 ; Pim Schreuder, MD 2 ; Jean-Pierre Ho, MD 2 ; Ruud Schreurs, PhD 2 ; Arnaud Bewley, MD 1 ; Brad Strong, MD 1",
      "normalized_authors": [
        "Michael Li",
        "Brandon Strong",
        "Nicole Farber",
        "Sukhkaran Aulakh",
        "Peter Lancione",
        "Andrew Birkeland",
        "Marianne Abouyared",
        "Marc Fischer",
        "Andrew Hernandez",
        "Alexander P Marston",
        "Pim Schreuder",
        "Jean-Pierre Ho",
        "Ruud Schreurs",
        "Arnaud Bewley",
        "Brad Strong"
      ],
      "affiliations": [
        "University of California, Davis",
        "University of Amsterdam"
      ],
      "normalized_institutions": [
        "University of California, Davis",
        "University of Amsterdam"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Engineering / Technology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Engineering / Technology"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154562/AHNS%20abstract_image%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154562/AHNS%20abstract_image%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154562"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 473,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Abstract",
        "Results",
        "Discussion & Conclusions"
      ],
      "sections": {
        "Authors": "Michael Li, MD 1 ; Brandon Strong, MS 1 ; Nicole Farber, MD 1 ; Sukhkaran Aulakh, MD 1 ; Peter Lancione, MD 1 ; Andrew Birkeland, MD, PhD 1 ; Marianne Abouyared, MD 1 ; Marc Fischer, BS 1 ; Andrew Hernandez, PhD 1 ; Alexander P Marston, MD 1 ; Pim Schreuder, MD 2 ; Jean-Pierre Ho, MD 2 ; Ruud Schreurs, PhD 2 ; Arnaud Bewley, MD 1 ; Brad Strong, MD 1",
        "Affiliations": "1 University of California, Davis; 2 University of Amsterdam",
        "Background": "Virtual surgical planning (VSP) with patient-specific implants (PSIs) improves precision in segmental mandibulectomy reconstruction but increases cost, delays surgery, and limits intraoperative flexibility. Augmented reality (AR)–based navigation offers a potential middle ground, enabling real-time guidance without the need for physical guides. Our preliminary clinical applications of AR for plate bending, fibular osteotomies, and bone tracking have demonstrated feasibility and surgical utility. Building on our prior work developing AR surgical navigation tools with real-time, infrared (IR) instrument tracking — we designed a controlled study to evaluate the accuracy of AR-guided fibula cutting.",
        "Methods": "A patient who previously underwent complex three-segment mandibular reconstruction (planned with KLS Martin) was selected as the template case. Fibulas and the corresponding PSI cutting guide were 3D printed. Fifteen users participated (5 head & neck faculty, 3 craniofacial faculty, 2 H&N fellows, 5 otolaryngology residents). Each user performed three trials: one osteotomy with the physical cutting guide (CG) and two using our AR-guided system (to see if improvement was observed over time: AR1 and AR2).",
        "Abstract": "The AR workflow used a custom fibula-mounted tracking array and a tracked oscillating saw integrated into our AR navigation platform. Surgeons received continuous, heads-up visualization of saw angulation and position relative to the planned osteotomy planes. Objective metrics included segment-length deviation, angular error, and cutting time. All harvested fibula segments underwent post-procedure CT imaging to establish ground-truth spatial accuracy. Segment endpoints and osteotomy planes were segmented from the CT, registered back to the preoperative plan, and analyzed for angular deviation and linear error . A post-task survey assessed surgeon confidence, perceived accuracy, and likelihood of clinical adoption. CT-based assessments confirmed that AR-guided osteotomies consistently matched planned cut geometry. When segments were transferred to a mandibulectomy reconstruction model, all 15 users reported satisfaction with the AR-generated segments, and all 5 head & neck faculty rated the AR cuts as clinically acceptable. AR cutting guides offer unique advantages: reduced waste, lower cost, rapid turnaround, and intraoperative adaptability. Clinical trials are planned for early 2026. AR-based workflows should be viewed not as replacements for PSI planning, but as a flexible, lower-cost alternative to freehand reconstruction with precision approaching PSI standards. View in Agenda and Add to Schedule",
        "Results": "Preliminary analysis of the first six participants shows comparable accuracy between CG and AR workflows. Median segment-length error was 1.57 mm (CG) vs 3.1 mm (AR), and angular error was 4.19° (CG) vs 5.68° (AR). No significant improvement was observed between AR1 and AR2, indicating minimal learning curve. Cutting time favored CG (134 ± 73 s) over AR (276 ± 109 s).",
        "Discussion & Conclusions": "While physical guides remain faster, their perceived accuracy advantage may be overstated. AR-guided osteotomies demonstrated comparable precision to CGs, with user surveys supporting clinical feasibility. The primary source of AR error — saw chatter without a physical edge to steady the blade — is being addressed through development of an “anchored-saw” mechanism."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Model-Based Evaluation of an Augmented Reality Cutting Guide for Fibula Osteotomies in Complex Mandibular Reconstruction</span>. <u>Michael Li, MD</u><sup>1</sup>; Brandon Strong, MS<sup>1</sup>; Nicole Farber, MD<sup>1</sup>; Sukhkaran Aulakh, MD<sup>1</sup>; Peter Lancione, MD<sup>1</sup>; Andrew Birkeland, MD, PhD<sup>1</sup>; Marianne Abouyared, MD<sup>1</sup>; Marc Fischer, BS<sup>1</sup>; Andrew Hernandez, PhD<sup>1</sup>; Alexander P Marston, MD<sup>1</sup>; Pim Schreuder, MD<sup>2</sup>; Jean-Pierre Ho, MD<sup>2</sup>; Ruud Schreurs, PhD<sup>2</sup>; Arnaud Bewley, MD<sup>1</sup>; Brad Strong, MD<sup>1</sup>. <sup>1</sup>University of California, Davis; <sup>2</sup>University of Amsterdam<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><img alt='' src='https://www.submitmyabstract.com/abs/images/154562/AHNS%20abstract_image%201.png' /></p>\n\n<p><strong>Background: </strong>Virtual surgical planning (VSP) with patient-specific implants (PSIs) improves precision in segmental mandibulectomy reconstruction but increases cost, delays surgery, and limits intraoperative flexibility. Augmented reality (AR)–based navigation offers a potential middle ground, enabling real-time guidance without the need for physical guides. Our preliminary clinical applications of AR for plate bending, fibular osteotomies, and bone tracking have demonstrated feasibility and surgical utility. Building on our prior work developing AR surgical navigation tools with real-time, infrared (IR) instrument tracking — we designed a controlled study to evaluate the accuracy of AR-guided fibula cutting.</p>\n\n<p><strong>Methods: </strong>A patient who previously underwent complex three-segment mandibular reconstruction (planned with KLS Martin) was selected as the template case. Fibulas and the corresponding PSI cutting guide were 3D printed. Fifteen users participated (5 head & neck faculty, 3 craniofacial faculty, 2 H&N fellows, 5 otolaryngology residents). Each user performed three trials: one osteotomy with the physical cutting guide (CG) and two using our AR-guided system (to see if improvement was observed over time: AR1 and AR2).</p>\n\n<p>The AR workflow used a custom fibula-mounted tracking array and a tracked oscillating saw integrated into our AR navigation platform. Surgeons received continuous, heads-up visualization of saw angulation and position relative to the planned osteotomy planes. Objective metrics included segment-length deviation, angular error, and cutting time.</p>\n\n<p>All harvested fibula segments underwent post-procedure CT imaging to establish ground-truth spatial accuracy. Segment endpoints and osteotomy planes were segmented from the CT, registered back to the preoperative plan, and analyzed for angular deviation and linear error .</p>\n\n<p>A post-task survey assessed surgeon confidence, perceived accuracy, and likelihood of clinical adoption.</p>\n\n<p><strong>Results: </strong>Preliminary analysis of the first six participants shows comparable accuracy between CG and AR workflows. Median segment-length error was 1.57 mm (CG) vs 3.1 mm (AR), and angular error was 4.19° (CG) vs 5.68° (AR). No significant improvement was observed between AR1 and AR2, indicating minimal learning curve. Cutting time favored CG (134 ± 73 s) over AR (276 ± 109 s).</p>\n\n<p>CT-based assessments confirmed that AR-guided osteotomies consistently matched planned cut geometry. When segments were transferred to a mandibulectomy reconstruction model, all 15 users reported satisfaction with the AR-generated segments, and all 5 head & neck faculty rated the AR cuts as clinically acceptable.</p>\n\n<p><strong>Discussion & Conclusions: </strong>While physical guides remain faster, their perceived accuracy advantage may be overstated. AR-guided osteotomies demonstrated comparable precision to CGs, with user surveys supporting clinical feasibility. The primary source of AR error — saw chatter without a physical edge to steady the blade — is being addressed through development of an “anchored-saw” mechanism.</p>\n\n<p>AR cutting guides offer unique advantages: reduced waste, lower cost, rapid turnaround, and intraoperative adaptability. Clinical trials are planned for early 2026. AR-based workflows should be viewed not as replacements for PSI planning, but as a flexible, lower-cost alternative to freehand reconstruction with precision approaching PSI standards.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154562--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260153' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S489",
      "content_id": "154353",
      "abstract_number": "S489",
      "poster_number": "",
      "title": "Population screening for early diagnosis of nasopharyngeal cancer in Singapore: Interim update from an ongoing community screening program",
      "summary": "Our interim analysis suggests that EBV based community screening has the potential to identify asymptomatic individuals and inform sustainable, cost-effective screening strategies for use in endemic populations.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154353",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yiu Tsun Kwan, MBBS",
      "presenter": "Yiu Tsun Kwan, MBBS",
      "authors": "Yiu Tsun Kwan, MBBS 1 ; Ren Yi 2 ; Wei Keat Teo 2 ; Chee Yit Lim, MBBS 1 ; Li Ann Loh, MBBS 1 ; Chor Hiang Siow 2 ; Han Lee Goh 1 ; Zhi Kang Chin 1 ; Ying Yu Tan 1 ; Javier Cher An Chee 2 ; Rachel Jia Xuan Ng 2 ; Adena Li Tyin Peh 2 ; Yee Yan Sia 3 ; Fei Yao 3 ; Ching-Yuan Wang 3 ; Laura Teo 2 ; Sheng Liang 4 ; Wee Hian Tan 5 ; Hui Nan Yeo 5 ; Sing Cheer Kwek 5 ; Ying Xian Chua 5 ; Zhi Peng Zhang 5 ; Franco Wong 5 ; Anandan Gerard Thiagarajah 5 ; Abiramy D/O Anathan 5 ; Ming Hann Cheah 5 ; Jiawei Chen 5 ; Minsheng Hou 5 ; Lawrence Lam 5 ; Haresh S/O Singaraju 5 ; Dhanam Raghupathy 6 ; Constance Li 6 ; Elaine Lee 6 ; Christina Yip 6 ; Wei Sian Lim, MBBS 1 ; Charmaine Tan, MBBS 1 ; Donovan Eu, MBBS 1 ; Raymond KY Tsang, MBChB 1 ; Eric A Finkelstein 7 ; Junxing Chay 7 ; Ian Cheong 8 ; Melvin Chua 9 ; Jianjun Liu 3 ; Joshua K Tay, MBBS, PhD 1 ; Kwok Seng Loh, MBBS 1",
      "normalized_authors": [
        "Yiu Tsun Kwan, MBBS",
        "Ren Yi",
        "Wei Keat Teo",
        "Chee Yit Lim, MBBS",
        "Li Ann Loh, MBBS",
        "Chor Hiang Siow",
        "Han Lee Goh",
        "Zhi Kang Chin",
        "Ying Yu Tan",
        "Javier Cher An Chee",
        "Rachel Jia Xuan Ng",
        "Adena Li Tyin Peh",
        "Yee Yan Sia",
        "Fei Yao",
        "Ching-Yuan Wang",
        "Laura Teo",
        "Sheng Liang",
        "Wee Hian Tan",
        "Hui Nan Yeo",
        "Sing Cheer Kwek",
        "Ying Xian Chua",
        "Zhi Peng Zhang",
        "Franco Wong",
        "Anandan Gerard Thiagarajah",
        "Abiramy D/O Anathan",
        "Ming Hann Cheah",
        "Jiawei Chen",
        "Minsheng Hou",
        "Lawrence Lam",
        "Haresh S/O Singaraju",
        "Dhanam Raghupathy",
        "Constance Li",
        "Elaine Lee",
        "Christina Yip",
        "Wei Sian Lim, MBBS",
        "Charmaine Tan, MBBS",
        "Donovan Eu, MBBS",
        "Raymond KY Tsang, MBChB",
        "Eric A Finkelstein",
        "Junxing Chay",
        "Ian Cheong",
        "Melvin Chua",
        "Jianjun Liu",
        "Joshua K Tay, MBBS",
        "Kwok Seng Loh, MBBS"
      ],
      "affiliations": [
        "Department of Otolaryngology – Head & Neck Surgery, National University Hospital, Singapore",
        "Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Human Genomics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore",
        "Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
        "National University Polyclinics, Singapore",
        "National University Health System Diagnostics, Singapore",
        "Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore",
        "Pathnova Laboratories, Singapore",
        "Department of Head and Neck and Thoracic Oncology, Division of Radiation Oncology, National Cancer Center, Singapore"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology – Head & Neck Surgery, National University Hospital, Singapore",
        "Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore",
        "Human Genomics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore",
        "Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore",
        "National University Polyclinics, Singapore",
        "National University Health System Diagnostics, Singapore",
        "Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore",
        "Pathnova Laboratories, Singapore",
        "Department of Head and Neck and Thoracic Oncology, Division of Radiation Oncology, National Cancer Center, Singapore"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Discussion",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Yiu Tsun Kwan, MBBS 1 ; Ren Yi 2 ; Wei Keat Teo 2 ; Chee Yit Lim, MBBS 1 ; Li Ann Loh, MBBS 1 ; Chor Hiang Siow 2 ; Han Lee Goh 1 ; Zhi Kang Chin 1 ; Ying Yu Tan 1 ; Javier Cher An Chee 2 ; Rachel Jia Xuan Ng 2 ; Adena Li Tyin Peh 2 ; Yee Yan Sia 3 ; Fei Yao 3 ; Ching-Yuan Wang 3 ; Laura Teo 2 ; Sheng Liang 4 ; Wee Hian Tan 5 ; Hui Nan Yeo 5 ; Sing Cheer Kwek 5 ; Ying Xian Chua 5 ; Zhi Peng Zhang 5 ; Franco Wong 5 ; Anandan Gerard Thiagarajah 5 ; Abiramy D/O Anathan 5 ; Ming Hann Cheah 5 ; Jiawei Chen 5 ; Minsheng Hou 5 ; Lawrence Lam 5 ; Haresh S/O Singaraju 5 ; Dhanam Raghupathy 6 ; Constance Li 6 ; Elaine Lee 6 ; Christina Yip 6 ; Wei Sian Lim, MBBS 1 ; Charmaine Tan, MBBS 1 ; Donovan Eu, MBBS 1 ; Raymond KY Tsang, MBChB 1 ; Eric A Finkelstein 7 ; Junxing Chay 7 ; Ian Cheong 8 ; Melvin Chua 9 ; Jianjun Liu 3 ; Joshua K Tay, MBBS, PhD 1 ; Kwok Seng Loh, MBBS 1",
        "Affiliations": "1 Department of Otolaryngology – Head & Neck Surgery, National University Hospital, Singapore; 2 Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; 3 Human Genomics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore; 4 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 5 National University Polyclinics, Singapore; 6 National University Health System Diagnostics, Singapore; 7 Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore; 8 Pathnova Laboratories, Singapore; 9 Department of Head and Neck and Thoracic Oncology, Division of Radiation Oncology, National Cancer Center, Singapore",
        "Background": "Nasopharyngeal carcinoma (NPC) is characterized by a unique epidemiological distribution in Southeast Asia and is closely linked to Epstein-Barr virus (EBV) infection. Early studies have demonstrated that serum IgA antibodies against EBV antigens and plasma cell-free EBV DNA are useful biomarkers for the early detection of NPC. We aim to evaluate the effectiveness of a community screening programme for early detection of NPC and the performance of EBV biomarkers in the Singapore population. This abstract presents our interim findings from the first 9369 participants recruited to date.",
        "Methods": "Our study aims to recruit 20,000 participants aged between 35 and 60 years, of Chinese, Malay, or mixed ethnicity. Participants undergo EBV-EA IgA serology and plasma EBV DNA testing, along with saliva collected for EBV strain-typing. High-risk individuals (defined by EBV-EA IgA and/or EBV DNA positivity) will receive a comprehensive head and neck examination including nasoendoscopy, nasopharyngeal biopsy and annual follow-up. Low-risk participants will be followed up with annual phone calls. The disease status of participants will also be verified through the National Registry of Disease Office. The stage distribution of NPC cases detected through screening will be compared with NPC patients routinely diagnosed in the outpatient clinic. Statistical analysis will evaluate sensitivity, specificity, PPV and NPV of EBV biomarkers.",
        "Results": "A total of 9369 participants have been enrolled to date. The mean age was 50.69 ± 6.62 years, and the cohort consisted of 57.1% male participants. Ethnic distribution comprised 90.34% Chinese, 8.62% Malay, and 1.04% other ethnicities. Symptoms associated with NPC were reported, including tinnitus (15.19%), blocked nose (9.63%), blocked ear (2.54%), neck masses (1.00%), epistaxis (0.76%), and blood-stained sputum (0.34%). Individuals with positive EBV-EA IgA was 1.83% (n=171), while first-round EBV DNA positivity was 1.30% (n=122), and repeat EBV DNA positivity was 9.84% amongst those with an initial positive result (n=12). The overlap between EBV-EA IgA and EBV DNA biomarkers was minimal, with only 8 individuals positive on both tests.",
        "Abstract": "Within the high-risk group, five cases of NPC have been identified to date. EBV-EA IgA was positive in four of the five cases (titre range 1:10–1:40) and negative in one. Plasma EBV DNA was detectable in two cases and undetectable in the remaining three. None of the low-risk participants were diagnosed with NPC on follow-up. Our current findings indicate that EBV-EA IgA demonstrated high sensitivity in identifying individuals with NPC in the community. View in Agenda and Add to Schedule",
        "Discussion": "Our study demonstrates the feasibility of NPC screening using EBV biomarkers in endemic regions such as Southeast Asia. Further cost-effectiveness analysis is required to optimise strategies for risk stratification. We will complete our recruitment towards the planned cohort of 20,000 participants, further enabling a more robust evaluation of EBV biomarkers to guide the development of future screening guidelines.",
        "Conclusion": "Our interim analysis suggests that EBV based community screening has the potential to identify asymptomatic individuals and inform sustainable, cost-effective screening strategies for use in endemic populations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Population screening for early diagnosis of nasopharyngeal cancer in Singapore: Interim update from an ongoing community screening program</span>. <u>Yiu Tsun Kwan, MBBS</u><sup>1</sup>; Ren Yi<sup>2</sup>; Wei Keat Teo<sup>2</sup>; Chee Yit Lim, MBBS<sup>1</sup>; Li Ann Loh, MBBS<sup>1</sup>; Chor Hiang Siow<sup>2</sup>; Han Lee Goh<sup>1</sup>; Zhi Kang Chin<sup>1</sup>; Ying Yu Tan<sup>1</sup>; Javier Cher An Chee<sup>2</sup>; Rachel Jia Xuan Ng<sup>2</sup>; Adena Li Tyin Peh<sup>2</sup>; Yee Yan Sia<sup>3</sup>; Fei Yao<sup>3</sup>; Ching-Yuan Wang<sup>3</sup>; Laura Teo<sup>2</sup>; Sheng Liang<sup>4</sup>; Wee Hian Tan<sup>5</sup>; Hui Nan Yeo<sup>5</sup>; Sing Cheer Kwek<sup>5</sup>; Ying Xian Chua<sup>5</sup>; Zhi Peng Zhang<sup>5</sup>; Franco Wong<sup>5</sup>; Anandan Gerard Thiagarajah<sup>5</sup>; Abiramy D/O Anathan<sup>5</sup>; Ming Hann Cheah<sup>5</sup>; Jiawei Chen<sup>5</sup>; Minsheng Hou<sup>5</sup>; Lawrence Lam<sup>5</sup>; Haresh S/O Singaraju<sup>5</sup>; Dhanam Raghupathy<sup>6</sup>; Constance Li<sup>6</sup>; Elaine Lee<sup>6</sup>; Christina Yip<sup>6</sup>; Wei Sian Lim, MBBS<sup>1</sup>; Charmaine Tan, MBBS<sup>1</sup>; Donovan Eu, MBBS<sup>1</sup>; Raymond KY Tsang, MBChB<sup>1</sup>; Eric A Finkelstein<sup>7</sup>; Junxing Chay<sup>7</sup>; Ian Cheong<sup>8</sup>; Melvin Chua<sup>9</sup>; Jianjun Liu<sup>3</sup>; Joshua K Tay, MBBS, PhD<sup>1</sup>; Kwok Seng Loh, MBBS<sup>1</sup>. <sup>1</sup>Department of Otolaryngology – Head & Neck Surgery, National University Hospital, Singapore; <sup>2</sup>Department of Otolaryngology – Head & Neck Surgery, National University of Singapore, Singapore; <sup>3</sup>Human Genomics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore; <sup>4</sup>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; <sup>5</sup>National University Polyclinics, Singapore; <sup>6</sup>National University Health System Diagnostics, Singapore; <sup>7</sup>Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore; <sup>8</sup>Pathnova Laboratories, Singapore; <sup>9</sup>Department of Head and Neck and Thoracic Oncology, Division of Radiation Oncology, National Cancer Center, Singapore<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is characterized by a unique epidemiological distribution in Southeast Asia and is closely linked to Epstein-Barr virus (EBV) infection. Early studies have demonstrated that serum IgA antibodies against EBV antigens and plasma cell-free EBV DNA are useful biomarkers for the early detection of NPC. We aim to evaluate the effectiveness of a community screening programme for early detection of NPC and the performance of EBV biomarkers in the Singapore population. This abstract presents our interim findings from the first 9369 participants recruited to date.</p>\n\n<p><strong>Methods: </strong>Our study aims to recruit 20,000 participants aged between 35 and 60 years, of Chinese, Malay, or mixed ethnicity. Participants undergo EBV-EA IgA serology and plasma EBV DNA testing, along with saliva collected for EBV strain-typing. High-risk individuals (defined by EBV-EA IgA and/or EBV DNA positivity) will receive a comprehensive head and neck examination including nasoendoscopy, nasopharyngeal biopsy and annual follow-up. Low-risk participants will be followed up with annual phone calls. The disease status of participants will also be verified through the National Registry of Disease Office. The stage distribution of NPC cases detected through screening will be compared with NPC patients routinely diagnosed in the outpatient clinic. Statistical analysis will evaluate sensitivity, specificity, PPV and NPV of EBV biomarkers.</p>\n\n<p><strong>Results: </strong>A total of 9369 participants have been enrolled to date. The mean age was 50.69 ± 6.62 years, and the cohort consisted of 57.1% male participants. Ethnic distribution comprised 90.34% Chinese, 8.62% Malay, and 1.04% other ethnicities. Symptoms associated with NPC were reported, including tinnitus (15.19%), blocked nose (9.63%), blocked ear (2.54%), neck masses (1.00%), epistaxis (0.76%), and blood-stained sputum (0.34%). Individuals with positive EBV-EA IgA was 1.83% (n=171), while first-round EBV DNA positivity was 1.30% (n=122), and repeat EBV DNA positivity was 9.84% amongst those with an initial positive result (n=12). The overlap between EBV-EA IgA and EBV DNA biomarkers was minimal, with only 8 individuals positive on both tests.</p>\n\n<p>Within the high-risk group, five cases of NPC have been identified to date. EBV-EA IgA was positive in four of the five cases (titre range 1:10–1:40) and negative in one. Plasma EBV DNA was detectable in two cases and undetectable in the remaining three. None of the low-risk participants were diagnosed with NPC on follow-up. Our current findings indicate that EBV-EA IgA demonstrated high sensitivity in identifying individuals with NPC in the community.</p>\n\n<p><strong>Discussion: </strong>Our study demonstrates the feasibility of NPC screening using EBV biomarkers in endemic regions such as Southeast Asia. Further cost-effectiveness analysis is required to optimise strategies for risk stratification. We will complete our recruitment towards the planned cohort of 20,000 participants, further enabling a more robust evaluation of EBV biomarkers to guide the development of future screening guidelines.</p>\n\n<p><strong>Conclusion: </strong>Our interim analysis suggests that EBV based community screening has the potential to identify asymptomatic individuals and inform sustainable, cost-effective screening strategies for use in endemic populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154353--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S490",
      "content_id": "154343",
      "abstract_number": "S490",
      "poster_number": "",
      "title": "Diagnostic Accuracy of a Bespoke Circulating Tumor DNA Assay in HPV Negative Head and Neck Squamous Cell Carcinoma",
      "summary": "This bespoke ctDNA assay offers excellent sensitivity and specificity in both the initial diagnostic and surveillance setting. Reasons for a failure rate of 12% in the initial diagnostic remain unclear. However, the tissue-informed test accuracy supports this as a promising ctDNA approach for disease monitoring in all head and neck cancers.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154343",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Sicard",
      "presenter": "Ryan Sicard",
      "authors": "Ryan Sicard 1 ; Alyssa Steinbaum 1 ; Diana Shaari 1 ; Alicia Yang 1 ; Ethan Gomez 1 ; Daniel Kraft 2 ; Peter Cooke 2 ; Michael Berger 2 ; Marita Teng 2 ; Mohammed Khan 2 ; Eric Genden 2 ; Raymond Chai 2 ; Krzysztof Misiukiewicz 3 ; Elisabet Pujadas 4 ; Richard Bakst 3 ; Kunal Sindhu 3 ; Scott Roof 2",
      "normalized_authors": [
        "Ryan Sicard",
        "Alyssa Steinbaum",
        "Diana Shaari",
        "Alicia Yang",
        "Ethan Gomez",
        "Daniel Kraft",
        "Peter Cooke",
        "Michael Berger",
        "Marita Teng",
        "Mohammed Khan",
        "Eric Genden",
        "Raymond Chai",
        "Krzysztof Misiukiewicz",
        "Elisabet Pujadas",
        "Richard Bakst",
        "Kunal Sindhu",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology at Mount Sinai",
        "Department of Hematology and Oncology at Mount Sinai",
        "Department of Pathology at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology at Mount Sinai",
        "Department of Hematology and Oncology at Mount Sinai",
        "Department of Pathology at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ryan Sicard 1 ; Alyssa Steinbaum 1 ; Diana Shaari 1 ; Alicia Yang 1 ; Ethan Gomez 1 ; Daniel Kraft 2 ; Peter Cooke 2 ; Michael Berger 2 ; Marita Teng 2 ; Mohammed Khan 2 ; Eric Genden 2 ; Raymond Chai 2 ; Krzysztof Misiukiewicz 3 ; Elisabet Pujadas 4 ; Richard Bakst 3 ; Kunal Sindhu 3 ; Scott Roof 2",
        "Affiliations": "1 Icahn School of Medicine at Mount Sinai; 2 Department of Otolaryngology at Mount Sinai; 3 Department of Hematology and Oncology at Mount Sinai; 4 Department of Pathology at Mount Sinai",
        "Introduction": "Circulating tumor DNA(ctDNA) is an emerging biomarker in head and neck cancer, with the most robust data in HPV-associated oropharyngeal carcinoma(HPV-OPSCCa). HPV-OPSCCa is an ideal disease for a tissue-agnostic ctDNA assay, given the unique and highly conserved E6 and E7 oncogenes, which can be readily identified on predefined panels. However, a lack of common mutations in HPV-negative head and neck cancer (HNSCC), limits the utility of a tissue-agnostic ctDNA approach. More recently, tissue-informed assays, which are developed using individualized mutational profiles for each unique patient’s tumor have been developed. This study aims to measure the diagnostic characteristics of one of these commercially-available tissue-informed assays compared to gold standard tissue biopsies for initial diagnosis and detection of recurrence of HNSCC.",
        "Methods": "This is a retrospective cohort study of adults who received a tissue-informed circulating tumor DNA(ctDNA) assay as part of their oncologic treatment at a single large urban tertiary care center from December 2024 to December 2025. A tumor tissue sample(e.g. core needle, surgical specimen) was used to create an individualized ctDNA assay for subsequent blood samples. The cohort was evaluated at time of diagnosis as well as during surveillance. For diagnosis, the sensitivity and miss rate were evaluated. As all patients were known to have cancer, true positives and false negatives had positive and negative blood tests, respectively. In the surveillance setting, sensitivity, specificity, negative predictive value(NPV), and positive predicted value(PPV) were calculated on a per test basis. Standard-of-care tissue biopsy was used to classify true positives and negatives. False positives were defined as positive tests that then remained negative thereafter or didn’t have pathological recurrence detection within 12 months. False negatives were defined as negative tests with pathological evidence of recurrence within 3 months.",
        "Results": "134 adults were included with median age of 66.6(IQR:56.3-75.4) and a 69% male predominance. The initial diagnostic cohort and surveillance cohort contained 60 and 87 patients, respectively. CtDNA was detected in 53/60 patients in the initial diagnosis setting(sensitivity:88.3%; 95% CI:77.4-95.2%). In the surveillance setting, the assay demonstrated a sensitivity of 100%(14/14) (95% CI:76.8-100%), specificity of 95.2-100%* (139/146) (95% CI:90.4-98.1%), PPV of 66.7%-100%*(14-21/21) (95% CI: 49.3-80.5%), and a NPV of 100%(139/139) (95% CI:97.4-100%). Three patients, responsible for 7 positive tests, have had sequentially positive tests but no pathological confirmation of recurrence currently. Thus, they are to be properly classified under the current criteria, so specificity and PPV have been reunableported as a range.",
        "Abstract": "*Unclear if 7 positive tests are false positive or true positive with lead-time. Definitive characterization will be finalized by May 2026. View in Agenda and Add to Schedule",
        "Conclusions": "This bespoke ctDNA assay offers excellent sensitivity and specificity in both the initial diagnostic and surveillance setting. Reasons for a failure rate of 12% in the initial diagnostic remain unclear. However, the tissue-informed test accuracy supports this as a promising ctDNA approach for disease monitoring in all head and neck cancers."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic Accuracy of a Bespoke Circulating Tumor DNA Assay in HPV Negative Head and Neck Squamous Cell Carcinoma</span>. <u>Ryan Sicard</u><sup>1</sup>; Alyssa Steinbaum<sup>1</sup>; Diana Shaari<sup>1</sup>; Alicia Yang<sup>1</sup>; Ethan Gomez<sup>1</sup>; Daniel Kraft<sup>2</sup>; Peter Cooke<sup>2</sup>; Michael Berger<sup>2</sup>; Marita Teng<sup>2</sup>; Mohammed Khan<sup>2</sup>; Eric Genden<sup>2</sup>; Raymond Chai<sup>2</sup>; Krzysztof Misiukiewicz<sup>3</sup>; Elisabet Pujadas<sup>4</sup>; Richard Bakst<sup>3</sup>; Kunal Sindhu<sup>3</sup>; Scott Roof<sup>2</sup>. <sup>1</sup>Icahn School of Medicine at Mount Sinai; <sup>2</sup>Department of Otolaryngology at Mount Sinai; <sup>3</sup>Department of Hematology and Oncology at Mount Sinai; <sup>4</sup>Department of Pathology at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Circulating tumor DNA(ctDNA) is an emerging biomarker in head and neck cancer, with the most robust data in HPV-associated oropharyngeal carcinoma(HPV-OPSCCa). HPV-OPSCCa is an ideal disease for a tissue-agnostic ctDNA assay, given the unique and highly conserved E6 and E7 oncogenes, which can be readily identified on predefined panels. However, a lack of common mutations in HPV-negative head and neck cancer (HNSCC), limits the utility of a tissue-agnostic ctDNA approach.  More recently, tissue-informed assays, which are developed using individualized mutational profiles for each unique patient’s tumor have been developed. This study aims to measure the diagnostic characteristics of one of these commercially-available tissue-informed assays compared to gold standard tissue biopsies for initial diagnosis and detection of recurrence of HNSCC.</p>\n\n<p><strong>Methods: </strong>This is a retrospective cohort study of adults who received a tissue-informed circulating tumor DNA(ctDNA) assay as part of their oncologic treatment at a single large urban tertiary care center from December 2024 to December 2025. A tumor tissue sample(e.g. core needle, surgical specimen) was used to create an individualized ctDNA assay for subsequent blood samples. The cohort was evaluated at time of diagnosis as well as during surveillance. For diagnosis, the sensitivity and miss rate were evaluated. As all patients were known to have cancer, true positives and false negatives had positive and negative blood tests, respectively. In the surveillance setting, sensitivity, specificity, negative predictive value(NPV), and positive predicted value(PPV) were calculated on a per test basis. Standard-of-care tissue biopsy was used to classify true positives and negatives. False positives were defined as positive tests that then remained negative thereafter or didn’t have pathological recurrence detection within 12 months. False negatives were defined as negative tests with pathological evidence of recurrence within 3 months.</p>\n\n<p><strong>Results: </strong>134 adults were included with median age of 66.6(IQR:56.3-75.4) and a 69% male predominance. The initial diagnostic cohort and surveillance cohort contained 60 and 87 patients, respectively. CtDNA was detected in 53/60 patients in the initial diagnosis setting(sensitivity:88.3%; 95% CI:77.4-95.2%). In the surveillance setting, the assay demonstrated a sensitivity of 100%(14/14) (95% CI:76.8-100%), specificity of 95.2-100%* (139/146) (95% CI:90.4-98.1%), PPV of 66.7%-100%*(14-21/21) (95% CI: 49.3-80.5%), and a NPV of 100%(139/139) (95% CI:97.4-100%). Three patients, responsible for 7 positive tests, have had sequentially positive tests but no pathological confirmation of recurrence currently. Thus, they are  to be properly classified under the current criteria, so specificity and PPV have been reunableported as a range.</p>\n\n<p>*Unclear if 7 positive tests are false positive or true positive with lead-time. Definitive characterization will be finalized by May 2026.</p>\n\n<p><strong>Conclusions:</strong> This bespoke ctDNA assay offers excellent sensitivity and specificity in both the initial diagnostic and surveillance setting. Reasons for a failure rate of 12% in the initial diagnostic remain unclear. However, the tissue-informed test accuracy supports this as a promising ctDNA approach for disease monitoring in all head and neck cancers.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154343--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S491",
      "content_id": "154740",
      "abstract_number": "S491",
      "poster_number": "",
      "title": "Analyzing Performance of Circulating Tumor DNA Assay in Head and Neck Cancer Surveillance",
      "summary": "Baseline ctDNA demonstrated excellent sensitivity and PPV for detecting active disease in this predominantly HPV-negative HNC cohort. Post-CRT ctDNA was strongly prognostic of overall survival, identifying patients at substantially higher risk of death, whereas 1-month postoperative ctDNA negativity was associated with a trend toward better survival, although this did not reach statistical significance. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154740",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "R Powszok, MD, MS",
      "presenter": "R Powszok, MD, MS",
      "authors": "S Kim, MD; R Powszok, MD, MS ; A Markopoulos, MD; A McIntosh, BS; M Meyer, BA; A Tate, BS; S Alkhudari, MD; V Stubbs; K Stenson, MD; N Joshi, MD; D Golden, MD, MHPE; K Paydary, MD; M Jelinek, MD; M Bhayani, MD",
      "normalized_authors": [
        "S Kim",
        "R Powszok",
        "A Markopoulos",
        "A McIntosh",
        "M Meyer",
        "A Tate",
        "S Alkhudari",
        "V Stubbs",
        "K Stenson",
        "N Joshi",
        "D Golden, MHPE",
        "K Paydary",
        "M Jelinek",
        "M Bhayani"
      ],
      "affiliations": [
        "Rush University Medical Center"
      ],
      "normalized_institutions": [
        "Rush University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 505,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "S Kim, MD; R Powszok, MD, MS ; A Markopoulos, MD; A McIntosh, BS; M Meyer, BA; A Tate, BS; S Alkhudari, MD; V Stubbs; K Stenson, MD; N Joshi, MD; D Golden, MD, MHPE; K Paydary, MD; M Jelinek, MD; M Bhayani, MD",
        "Affiliations": "Rush University Medical Center",
        "Background": "Post-treatment surveillance in head and neck cancer (HNC) relies on clinical exams and imaging, which may miss early recurrence, be confounded by therapy-related anatomical changes, and generate added costs and radiation exposure. Circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection and treatment response monitoring across solid tumors. While ctDNA is well studied in HPV-positive HNC, its role in HPV-negative disease remains understudied. This study evaluates a personalized tumor-informed ctDNA assay (Signatera) for disease detection at baseline and its prognostic value following treatment for patients with predominantly HPV-negative HNCs.",
        "Methods": "A retrospective chart review was conducted on patients with HNC who underwent ctDNA testing between June 2022 and October 2025. Diagnostic performance was assessed across all patients with baseline samples, using clinical examination and contemporaneous imaging as the reference standard to calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). To evaluate the prognostic significance of post-treatment ctDNA, survival analyses were performed in two defined cohorts: patients treated with primary surgery followed by adjuvant therapy who had ctDNA collected one month postoperatively and patients treated with definitive chemoradiation (CRT) who had ctDNA collected within three months post-treatment. Overall survival (OS) was defined as the interval between biopsy date and death or last known clinical follow-up, with patients alive at last follow-up censored. Kaplan-Meier curves stratified by ctDNA positivity were compared using the log-rank test, and hazard ratios (HRs) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression.",
        "Results": "Oral primaries accounted for approximately one-third of the cohort, while non-oral head and neck cancers comprised the rest. A total of 866 ctDNA tests were available. Across all baseline ctDNA samples (n=91), sensitivity was 81.1%, PPV 100%, and NPV 0%; specificity was not measurable due to the scarcity of disease-negative cases. In the surgery cohort of 35 patients, ctDNA negativity at one month post-operatively trended toward improved overall survival but was not significant (log-rank p=0.41). Cox modeling showed a similar non-significant pattern (HR 2.7; 95% CI 0.24–29.35), consistent with the low number of events (three deaths). In the CRT cohort, 30 patients had evaluable ctDNA at approximately three months post-treatment. ctDNA positivity at this timepoint was associated with significantly worse OS (log-rank p-value 0.04), with ctDNA-negative patients demonstrating approximately 94% survival and ctDNA-positive patients approximately 56% survival at three years. Cox regression reflected a strong but imprecise effect of ctDNA status on OS due to limited events (HR 6.8; 95% CI 0.80-58.55).",
        "Conclusion": "Baseline ctDNA demonstrated excellent sensitivity and PPV for detecting active disease in this predominantly HPV-negative HNC cohort. Post-CRT ctDNA was strongly prognostic of overall survival, identifying patients at substantially higher risk of death, whereas 1-month postoperative ctDNA negativity was associated with a trend toward better survival, although this did not reach statistical significance. These findings support the integration of ctDNA into surveillance strategies and highlight the need for prospective validation with standardized sampling methods and longer follow-up.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Analyzing Performance of Circulating Tumor DNA Assay in Head and Neck Cancer Surveillance</span>. S Kim, MD; <u>R Powszok, MD, MS</u>; A Markopoulos, MD; A McIntosh, BS; M Meyer, BA; A Tate, BS; S Alkhudari, MD; V Stubbs; K Stenson, MD; N Joshi, MD; D Golden, MD, MHPE; K Paydary, MD; M Jelinek, MD; M Bhayani, MD. Rush University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Post-treatment surveillance in head and neck cancer (HNC) relies on clinical exams and imaging, which may miss early recurrence, be confounded by therapy-related anatomical changes, and generate added costs and radiation exposure. Circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection and treatment response monitoring across solid tumors. While ctDNA is well studied in HPV-positive HNC, its role in HPV-negative disease remains understudied. This study evaluates a personalized tumor-informed ctDNA assay (Signatera) for disease detection at baseline and its prognostic value following treatment for patients with predominantly HPV-negative HNCs.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted on patients with HNC who underwent ctDNA testing between June 2022 and October 2025. Diagnostic performance was assessed across all patients with baseline samples, using clinical examination and contemporaneous imaging as the reference standard to calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). To evaluate the prognostic significance of post-treatment ctDNA, survival analyses were performed in two defined cohorts: patients treated with primary surgery followed by adjuvant therapy who had ctDNA collected one month postoperatively and patients treated with definitive chemoradiation (CRT) who had ctDNA collected within three months post-treatment. Overall survival (OS) was defined as the interval between biopsy date and death or last known clinical follow-up, with patients alive at last follow-up censored. Kaplan-Meier curves stratified by ctDNA positivity were compared using the log-rank test, and hazard ratios (HRs) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression.</p>\n\n<p><strong>Results: </strong>Oral primaries accounted for approximately one-third of the cohort, while non-oral head and neck cancers comprised the rest. A total of 866 ctDNA tests were available. Across all baseline ctDNA samples (n=91), sensitivity was 81.1%, PPV 100%, and NPV 0%; specificity was not measurable due to the scarcity of disease-negative cases. In the surgery cohort of 35 patients, ctDNA negativity at one month post-operatively trended toward improved overall survival but was not significant (log-rank p=0.41). Cox modeling showed a similar non-significant pattern (HR 2.7; 95% CI 0.24–29.35), consistent with the low number of events (three deaths). In the CRT cohort, 30 patients had evaluable ctDNA at approximately three months post-treatment. ctDNA positivity at this timepoint was associated with significantly worse OS (log-rank p-value 0.04), with ctDNA-negative patients demonstrating approximately 94% survival and ctDNA-positive patients approximately 56% survival at three years. Cox regression reflected a strong but imprecise effect of ctDNA status on OS due to limited events (HR 6.8; 95% CI 0.80-58.55).</p>\n\n<p><strong>Conclusion: </strong>Baseline ctDNA demonstrated excellent sensitivity and PPV for detecting active disease in this predominantly HPV-negative HNC cohort. Post-CRT ctDNA was strongly prognostic of overall survival, identifying patients at substantially higher risk of death, whereas 1-month postoperative ctDNA negativity was associated with a trend toward better survival, although this did not reach statistical significance. These findings support the integration of ctDNA into surveillance strategies and highlight the need for prospective validation with standardized sampling methods and longer follow-up.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154740--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S492",
      "content_id": "153077",
      "abstract_number": "S492",
      "poster_number": "",
      "title": "Bespoke ctDNA assessment for non-virally mediated head and neck squamous cell carcinoma: A real-world analysis",
      "summary": "Among patients with nonmetastatic non-virally associated HNSCC, higher baseline pre-treatment Signatera ctDNA values trend toward inferior overall but not recurrence free survival, despite no observed differences in ctDNA levels by clinical T or N stage. These results suggest that Signatera ctDNA should be evaluated in a larger cohort of HPV-negative HNSCC as shedding rate may be an important prognostic tool....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153077",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Grayson Buning, BS",
      "presenter": "Grayson Buning, BS",
      "authors": "Grayson Buning, BS ; Luke Higgins, MD; Nathan Hemenway, MSc; Menggang Yu, PhD; David Booth, BS; Mandy Losiewicz, BS, MBA; Anish Palli, MSc; Jordan Currie, MSc; Jennifer Shah, MD; Keith Casper, MD; David WA Forner, MD, MSc; Marisa R Buchakjian, MD, PhD; Molly E Heft Neal, MD; Francis Worden, MD; Michelle Mierzwa, MD; Chad Brenner, PhD, MSE",
      "normalized_authors": [
        "Grayson Buning",
        "Luke Higgins",
        "Nathan Hemenway",
        "Menggang Yu",
        "David Booth",
        "Mandy Losiewicz",
        "Anish Palli",
        "Jordan Currie",
        "Jennifer Shah",
        "Keith Casper",
        "David WA Forner",
        "Marisa R Buchakjian",
        "Molly E Heft Neal",
        "Francis Worden",
        "Michelle Mierzwa",
        "Chad Brenner, MSE"
      ],
      "affiliations": [
        "University of Michigan Medical School"
      ],
      "normalized_institutions": [
        "University of Michigan Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 522,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Grayson Buning, BS ; Luke Higgins, MD; Nathan Hemenway, MSc; Menggang Yu, PhD; David Booth, BS; Mandy Losiewicz, BS, MBA; Anish Palli, MSc; Jordan Currie, MSc; Jennifer Shah, MD; Keith Casper, MD; David WA Forner, MD, MSc; Marisa R Buchakjian, MD, PhD; Molly E Heft Neal, MD; Francis Worden, MD; Michelle Mierzwa, MD; Chad Brenner, PhD, MSE",
        "Affiliations": "University of Michigan Medical School",
        "Background": "The use of ctDNA biomarkers in HPV-negative head and neck squamous cell carcinoma (HNSCC) is nascent and further characterizations in real-world and trial populations are necessary to guide clinical utilization.",
        "Methods": "We retrospectively evaluated a bespoke, tumor-informed, commercial ctDNA assay (Signatera, Natera) in patients with non-virally mediated HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx who underwent Signatera testing at a major US tertiary academic center between 2023 and 2025. Chart review was performed for all patients to collect demographics, treatment characteristics, and oncologic outcomes. Primary objectives included correlation of ctDNA levels and kinetics with de novo clinical staging, disease recurrence, and mortality.",
        "Results": "Forty-eight patients met our inclusion criteria (median age: 64 years, 71% male, 81% smokers). 6/48 (13%) of patients failed Signatera testing due to insufficient tissue and were excluded from subsequent analyses. Most patients (30/42, 71%) had clinical stage IV disease at diagnosis; 5/42 patients (12%) had distant metastases at diagnosis. Oral cavity was the most common disease site (20/42, 48%). A minority of patients (8/42, 19%) had previously undergone definitive treatment at time of index Signatera testing. Earlier distinct primary cancers of the head and neck were recorded in 10/42 patients (24%). Pretreatment ctDNA levels were obtained for 31/42 patients (74%); levels were detectable for all but 1 of these patients (97%). Unpaired t-tests showed significantly higher baseline pretreatment log-transformed ctDNA values amongst patients with metastatic versus non-metastatic disease at diagnosis (Effect size: 2.267, 95% CI: [0.622, 3.913], t = 4.24, p=0.021) but no differences based on clinical nodal staging (cN+ vs cN0: Effect size: 0.422, 95% CI: [-0.214, 1.059], t = 1.369, p = 0.184) or clinical tumor staging (cT< 4 vs cT4: Effect size: -0.29, 95% CI: [-0.881, 0.303], t = -1.000, p = 0.326). When stratified by baseline Signatera (low values were those <1.5 MTM/mL), nonmetastatic patients with low values trended towards improved overall survival (log-rank p = 0.084) but not recurrence-free survival (log-rank p = 0.77). All recurrences were among patients with baseline Signatera values >1 MTM/mL. Among 2 patients with de novo metastatic disease and markedly elevated baseline values (>3000 MTM/mL), average survival was 79 days (range 12-146). Excluding baseline values, three patients with Signatera values >100 MTM/mL in surveillance had an average survival of 147 days (range 79 – 254) after first measurement >100 MTM/mL. Due to institutional practice patterns, we were unable to generate biochemical lead times or negative and positive predictive values, as many surveillance studies were ordered after clinical evidence of recurrence.",
        "Conclusion": "Among patients with nonmetastatic non-virally associated HNSCC, higher baseline pre-treatment Signatera ctDNA values trend toward inferior overall but not recurrence free survival, despite no observed differences in ctDNA levels by clinical T or N stage. These results suggest that Signatera ctDNA should be evaluated in a larger cohort of HPV-negative HNSCC as shedding rate may be an important prognostic tool. Further research is warranted to clarify the utility of ctDNA assays for guiding treatment decision-making in this setting.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Bespoke ctDNA assessment for non-virally mediated head and neck squamous cell carcinoma: A real-world analysis</span>. <u>Grayson Buning, BS</u>; Luke Higgins, MD; Nathan Hemenway, MSc; Menggang Yu, PhD; David Booth, BS; Mandy Losiewicz, BS, MBA; Anish Palli, MSc; Jordan Currie, MSc; Jennifer Shah, MD; Keith Casper, MD; David WA Forner, MD, MSc; Marisa R Buchakjian, MD, PhD; Molly E Heft Neal, MD; Francis Worden, MD; Michelle Mierzwa, MD; Chad Brenner, PhD, MSE. University of Michigan Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The use of ctDNA biomarkers in HPV-negative head and neck squamous cell carcinoma (HNSCC) is nascent and further characterizations in real-world and trial populations are necessary to guide clinical utilization. </p>\n\n<p><strong>Methods: </strong>We retrospectively evaluated a bespoke, tumor-informed, commercial ctDNA assay (Signatera, Natera) in patients with non-virally mediated HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx who underwent Signatera testing at a major US tertiary academic center between 2023 and 2025. Chart review was performed for all patients to collect demographics, treatment characteristics, and oncologic outcomes. Primary objectives included correlation of ctDNA levels and kinetics with de novo clinical staging, disease recurrence, and mortality.</p>\n\n<p><strong>Results: </strong>Forty-eight patients met our inclusion criteria (median age: 64 years, 71% male, 81% smokers). 6/48 (13%) of patients failed Signatera testing due to insufficient tissue and were excluded from subsequent analyses. Most patients (30/42, 71%) had clinical stage IV disease at diagnosis; 5/42 patients (12%) had distant metastases at diagnosis. Oral cavity was the most common disease site (20/42, 48%). A minority of patients (8/42, 19%) had previously undergone definitive treatment at time of index Signatera testing. Earlier distinct primary cancers of the head and neck were recorded in 10/42 patients (24%). Pretreatment ctDNA levels were obtained for 31/42 patients (74%); levels were detectable for all but 1 of these patients (97%). Unpaired t-tests showed significantly higher baseline pretreatment log-transformed ctDNA values amongst patients with metastatic versus non-metastatic disease at diagnosis (Effect size: 2.267, 95% CI: [0.622, 3.913], t = 4.24, p=0.021) but no differences based on clinical nodal staging (cN+ vs cN0: Effect size: 0.422, 95% CI: [-0.214, 1.059], t = 1.369, p = 0.184) or clinical tumor staging (cT< 4 vs cT4: Effect size: -0.29, 95% CI: [-0.881, 0.303], t = -1.000, p = 0.326). When stratified by baseline Signatera (low values were those <1.5 MTM/mL), nonmetastatic patients with low values trended towards improved overall survival (log-rank p = 0.084) but not recurrence-free survival (log-rank p = 0.77). All recurrences were among patients with baseline Signatera values >1 MTM/mL. Among 2 patients with de novo metastatic disease and markedly elevated baseline values (>3000 MTM/mL), average survival was 79 days (range 12-146). Excluding baseline values, three patients with Signatera values >100 MTM/mL in surveillance had an average survival of 147 days (range 79 – 254) after first measurement >100 MTM/mL. Due to institutional practice patterns, we were unable to generate biochemical lead times or negative and positive predictive values, as many surveillance studies were ordered after clinical evidence of recurrence.</p>\n\n<p><strong>Conclusion: </strong>Among patients with nonmetastatic non-virally associated HNSCC, higher baseline pre-treatment Signatera ctDNA values trend toward inferior overall but not recurrence free survival, despite no observed differences in ctDNA levels by clinical T or N stage. These results suggest that Signatera ctDNA should be evaluated in a larger cohort of HPV-negative HNSCC as shedding rate may be an important prognostic tool. Further research is warranted to clarify the utility of ctDNA assays for guiding treatment decision-making in this setting.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153077--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S493",
      "content_id": "154070",
      "abstract_number": "S493",
      "poster_number": "",
      "title": "Early Detection of Head and Neck Squamous Cell Carcinoma Using RNA Aptamers Targeting Tumor Specific Myeloid Derived Suppressor Cells in Saliva",
      "summary": "Despite advanced surgery and therapeutic strategies, the overall survival of head and neck squamous cell carcinoma (HNSCC) patients has largely remained unchanged. This is due in part to the lack of early disease detection. Detection of particular tumor biomarkers in the saliva or in the oral rinse can potentially increase early diagnosis and detect asymptomatic malignant lesions because they contain proteins,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154070",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daria Ivanova, MD",
      "presenter": "Daria Ivanova, MD",
      "authors": "Emeil Stewart, MS; Daria Ivanova, MD ; Marlene Redlich, BS; Victoria Kuznetsova, BS; Elizabeth Franzmann; Donald T Weed, MD; Paolo Serafini, PhD",
      "normalized_authors": [
        "Emeil Stewart",
        "Daria Ivanova",
        "Marlene Redlich",
        "Victoria Kuznetsova",
        "Elizabeth Franzmann",
        "Donald T Weed",
        "Paolo Serafini"
      ],
      "affiliations": [
        "University of Miami Miller School of Medicine"
      ],
      "normalized_institutions": [
        "University of Miami Miller School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emeil Stewart, MS; Daria Ivanova, MD ; Marlene Redlich, BS; Victoria Kuznetsova, BS; Elizabeth Franzmann; Donald T Weed, MD; Paolo Serafini, PhD",
        "Affiliations": "University of Miami Miller School of Medicine",
        "Abstract": "Despite advanced surgery and therapeutic strategies, the overall survival of head and neck squamous cell carcinoma (HNSCC) patients has largely remained unchanged. This is due in part to the lack of early disease detection. Detection of particular tumor biomarkers in the saliva or in the oral rinse can potentially increase early diagnosis and detect asymptomatic malignant lesions because they contain proteins, peptides, lipids, and nucleic acids that are continuously shed by the tumor and premalignant lesions. However, most diagnostic assays rely on a particular biomarker often present in only a subset of tumors or in few neoplastic cells, potentially reducing the sensitivity of these assays. Myeloid Derived Suppressor Cells (MDSCs) are a suppressive immune cell population that participates in tumor initiation and promotes tumor growth and escape from immune surveillance. MDSCs can represent up to 50% of the tumor mass even at the earliest state of tumorigenesis, and are continually renewed, releasing their proteomic signature in the tumor microenvironment and nearby fluids. At the tumor site, MDSCs acquire a unique suppressive function and phenotype that differentiate them from their myeloid counterpart in circulation and in healthy tissues. This study tests the hypothesis that the proteomic signature of tumor associated MDSCs can be detected in saliva as a reliable screening tool for detection of HNSCC. We identified 4 RNA aptamers that specifically recognize MDSC in human HNSCC but not myeloid cells in the blood or in healthy tissue of the same patient. RNA aptamers, or synthetic antibodies, are small oligonucleotides that recognize their target with high specificity because of their tridimensional structure. Their fluorinated backbone makes them RNAse resistant, not immunogenic, and stable. To test the hypothesis that MDSC signature in the oral rinse is predictive of HNSCC, we utilized an unblinded retrospective training set and a blinded prospective experimental set. Both data sets consist of healthy controls and pathologically proven HNSCC (stage I- IV) according to the AJCC 8th edition. Oral rinses are assayed against MDSC specific aptamers in linear surface plasmon resonance (LSPR) experiments. This label free, real-time technique allows the accurate evaluation of interaction between ligands (aptamers) and analytes (aptamer’s targets) at low cost and with high resolution. Our training set (n=76) is composed of 31 cancers and 45 controls. Aptamer testing discriminated tumors from healthy tissue in this cohort with an Area Under Curve (AUC) of 0.717. Performance varied by sex. Females displayed an AUC of 0.847 and males had an AUC of 0.579. Our experimental set has a current enrollment of n=212 (104 cancer/108 control). Our prospective cohort is balanced for race and ethnicity (p>0.9). Cancer patients had a significant higher mean age (65.6 vs 58.7 years; p<0.001) and smoking pack years (15.5 vs 6.6; p<0.001) compared to controls. Accrual goal for the experimental set is 250, and once reached we will test the sensitivity and specificity of the MDSC-aptamer assay in saliva as a screening tool for HNSCC detection. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Early Detection of Head and Neck Squamous Cell Carcinoma Using RNA Aptamers Targeting Tumor Specific Myeloid Derived Suppressor Cells in Saliva</span>. Emeil Stewart, MS; <u>Daria Ivanova, MD</u>; Marlene Redlich, BS; Victoria Kuznetsova, BS; Elizabeth Franzmann; Donald T Weed, MD; Paolo Serafini, PhD. University of Miami Miller School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Despite advanced surgery and therapeutic strategies, the overall survival of head and neck squamous cell carcinoma (HNSCC) patients has largely remained unchanged. This is due in part to the lack of early disease detection. Detection of particular tumor biomarkers in the saliva or in the oral rinse can potentially increase early diagnosis and detect asymptomatic malignant lesions because they contain proteins, peptides, lipids, and nucleic acids that are continuously shed by the tumor and premalignant lesions. However, most diagnostic assays rely on a particular biomarker often present in only a subset of tumors or in few neoplastic cells, potentially reducing the sensitivity of these assays. Myeloid Derived Suppressor Cells (MDSCs) are a suppressive immune cell population that participates in tumor initiation and promotes tumor growth and escape from immune surveillance. MDSCs can represent up to 50% of the tumor mass even at the earliest state of tumorigenesis, and are continually renewed, releasing their proteomic signature in the tumor microenvironment and nearby fluids. At the tumor site, MDSCs acquire a unique suppressive function and phenotype that differentiate them from their myeloid counterpart in circulation and in healthy tissues. This study tests the hypothesis that the proteomic signature of tumor associated MDSCs can be detected in saliva as a reliable screening tool for detection of HNSCC.</p>\n\n<p>We identified 4 RNA aptamers that specifically recognize MDSC in human HNSCC but not myeloid cells in the blood or in healthy tissue of the same patient. RNA aptamers, or synthetic antibodies, are small oligonucleotides that recognize their target with high specificity because of their tridimensional structure. Their fluorinated backbone makes them RNAse resistant, not immunogenic, and stable.</p>\n\n<p>To test the hypothesis that MDSC signature in the oral rinse is predictive of HNSCC, we utilized an unblinded retrospective training set and a blinded prospective experimental set. Both data sets consist of healthy controls and pathologically proven HNSCC (stage I- IV) according to the AJCC 8th edition. Oral rinses are assayed against MDSC specific aptamers in linear surface plasmon resonance (LSPR) experiments. This label free, real-time technique allows the accurate evaluation of interaction between ligands (aptamers) and analytes (aptamer’s targets) at low cost and with high resolution. Our training set (n=76) is composed of 31 cancers and 45 controls. Aptamer testing discriminated tumors from healthy tissue in this cohort with an Area Under Curve (AUC) of 0.717. Performance varied by sex. Females displayed an AUC of 0.847 and males had an AUC of 0.579. Our experimental set has a current enrollment of n=212 (104 cancer/108 control). Our prospective cohort is balanced for race and ethnicity (p>0.9). Cancer patients had a significant higher mean age (65.6 vs 58.7 years; p<0.001) and smoking pack years (15.5 vs 6.6; p<0.001) compared to controls.  Accrual goal for the experimental set is 250, and once reached we will test the sensitivity and specificity of the MDSC-aptamer assay in saliva as a screening tool for HNSCC detection.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154070--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S494",
      "content_id": "153298",
      "abstract_number": "S494",
      "poster_number": "",
      "title": "Thematic Analysis of Patient Experiences with ctHPV DNA-guided Surveillance After Treatment for HPV-positive Oropharyngeal Cancer",
      "summary": "Patient perceptions of ctHPVDNA testing were favorable, even amongst those for whom it was inaccurate. Patients relied upon their physicians to guide implementation and interpretation of the test, placing the onus on providers caring for this population to understand its strengths and limitations prior to routine clinical use.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153298",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Grace E Fleming",
      "presenter": "Grace E Fleming",
      "authors": "Grace E Fleming ; Hannah Roth; Glenn J Hanna, MD; Jonathan D Schoenfeld, MD, MPhil, MPH; Jacqueline Minken; Dev Mukundan; Melina J Windon, MD; Eleni M Rettig, MD",
      "normalized_authors": [
        "Grace E Fleming",
        "Hannah Roth",
        "Glenn J Hanna",
        "Jonathan D Schoenfeld, MPhil",
        "Jacqueline Minken",
        "Dev Mukundan",
        "Melina J Windon",
        "Eleni M Rettig"
      ],
      "affiliations": [
        "Dana Farber Cancer Institute"
      ],
      "normalized_institutions": [
        "Dana Farber Cancer Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153298/WTP_Figure1.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153298/WTP_Figure1.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153298"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 508,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Grace E Fleming ; Hannah Roth; Glenn J Hanna, MD; Jonathan D Schoenfeld, MD, MPhil, MPH; Jacqueline Minken; Dev Mukundan; Melina J Windon, MD; Eleni M Rettig, MD",
        "Affiliations": "Dana Farber Cancer Institute",
        "Introduction": "Circulating tumor HPV DNA (ctHPVDNA) has emerged as a promising biomarker for disease surveillance after treatment for HPV-positive oropharyngeal cancer (HPV+OPC). We recently reported that prospective ctHPVDNA-guided surveillance yielded 75% sensitivity for recurrence overall, with higher sensitivity (90%) among patients with detectable ctHPV16DNA pre-treatment, and yielded unexpected false positive results. Despite growing clinical use, patient perspectives regarding its perceived role, emotional impact, and monetary value are not well understood. This study represents an in-depth characterization of patient experiences in order to guide practice and future research.",
        "Methods": "We conducted a mixed-methods cross-sectional interview study of adults treated for HPV+OPC who underwent ≥1 post-treatment commercial ctHPVDNA test (TTMV-HPV DNA assay, NavDx, Naveris) >3 months before enrollment. Purposive sampling was employed to ensure representation of diverse patient experiences with regard to test performance. Subjects completed semi-structured interviews regarding their ctHPVDNA testing experience, understanding of results and care. Willingness to pay (WTP) for the test out-of-pocket was assessed using iterative bidding.",
        "Abstract": "Interviews were audio-recorded and transcribed. A codebook was developed during transcript review and shared. Researchers met throughout to review and resolve coding disagreements. Themes were identified and organized using a categorical inductive approach, then summarized and reported. Thematic analysis revealed four major themes. First, participants expressed general enthusiasm and support for ctHPVDNA testing in general, including participants with inaccurate results, citing such advantages as the ease and minimal risk of blood testing and a universal perceived benefit to early detection of disease. Second, we encountered an overarching confidence in the healthcare team that surpassed trust in the test itself, with most participants reporting a heavy reliance on their providers to interpret and act upon ctHPVDNA results to their benefit. Third, there was a perception of ctHPVDNA testing as a useful ‘add-on’ to standard care, rather than a replacement for any component of standard care, that should be made available to cancer patients despite its limitations. Fourth, participants reported a wide range of emotional experiences, such as anxiety, reassurance, hope, excitement, disappointment, confusion, depression, determination, and indifference. These emotions were discussed in the context of ctHPVDNA testing, but were typically attributed to the cancer journey overall rather than to the blood test itself. The median willingness to pay (WTP) was $325 per ctHPVDNA test, with a wide range of $0-$9000. WTP was higher among those with higher household income (Figure). The median ‘reasonable’ price was $225 (range=$0-$2500). View in Agenda and Add to Schedule",
        "Results": "Twenty participants completed interviews (median duration 23:59 minutes, range 6:31-44:04 minutes). Median age was 63 years (IQR=55-70); most were male (16/20, 80%) and all were white. Purposive sampling yielded 8 participants with true negative test results (40%), 6 true positives (30%), 4 false negatives (20%), and 2 false positives (10%).",
        "Conclusions": "Patient perceptions of ctHPVDNA testing were favorable, even amongst those for whom it was inaccurate. Patients relied upon their physicians to guide implementation and interpretation of the test, placing the onus on providers caring for this population to understand its strengths and limitations prior to routine clinical use."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Thematic Analysis of Patient Experiences with ctHPV DNA-guided Surveillance After Treatment for HPV-positive Oropharyngeal Cancer</span>. <u>Grace E Fleming</u>; Hannah Roth; Glenn J Hanna, MD; Jonathan D Schoenfeld, MD, MPhil, MPH; Jacqueline Minken; Dev Mukundan; Melina J Windon, MD; Eleni M Rettig, MD. Dana Farber Cancer Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction</strong>: Circulating tumor HPV DNA (ctHPVDNA) has emerged as a promising biomarker for disease surveillance after treatment for HPV-positive oropharyngeal cancer (HPV+OPC). We recently reported that prospective ctHPVDNA-guided surveillance yielded 75% sensitivity for recurrence overall, with higher sensitivity (90%) among patients with detectable ctHPV16DNA pre-treatment, and yielded unexpected false positive results. Despite growing clinical use, patient perspectives regarding its perceived role, emotional impact, and monetary value are not well understood. This study represents an in-depth characterization of patient experiences in order to guide practice and future research.</p>\n\n<p><strong>Methods</strong>: We conducted a mixed-methods cross-sectional interview study of adults treated for HPV+OPC who underwent ≥1 post-treatment commercial ctHPVDNA test (TTMV-HPV DNA assay, NavDx, Naveris) >3 months before enrollment. Purposive sampling was employed to ensure representation of diverse patient experiences with regard to test performance. Subjects completed semi-structured interviews regarding their ctHPVDNA testing experience, understanding of results and care. Willingness to pay (WTP) for the test out-of-pocket was assessed using iterative bidding.</p>\n\n<p>Interviews were audio-recorded and transcribed. A codebook was developed during transcript review and shared. Researchers met throughout to review and resolve coding disagreements. Themes were identified and organized using a categorical inductive approach, then summarized and reported.</p>\n\n<p><strong>Results</strong>: Twenty participants completed interviews (median duration 23:59 minutes, range 6:31-44:04 minutes). Median age was 63 years (IQR=55-70); most were male (16/20, 80%) and all were white. Purposive sampling yielded 8 participants with true negative test results (40%), 6 true positives (30%), 4 false negatives (20%), and 2 false positives (10%).</p>\n\n<p>Thematic analysis revealed four major themes. First, participants expressed general enthusiasm and support for ctHPVDNA testing in general, including participants with inaccurate results, citing such advantages as the ease and minimal risk of blood testing and a universal perceived benefit to early detection of disease. Second, we encountered an overarching confidence in the healthcare team that surpassed trust in the test itself, with most participants reporting a heavy reliance on their providers to interpret and act upon ctHPVDNA results to their benefit. Third, there was a perception of ctHPVDNA testing as a useful ‘add-on’ to standard care, rather than a replacement for any component of standard care, that should be made available to cancer patients despite its limitations. Fourth, participants reported a wide range of emotional experiences, such as anxiety, reassurance, hope, excitement, disappointment, confusion, depression, determination, and indifference. These emotions were discussed in the context of ctHPVDNA testing, but were typically attributed to the cancer journey overall rather than to the blood test itself.</p>\n\n<p>The median willingness to pay (WTP) was $325 per ctHPVDNA test, with a wide range of $0-$9000. WTP was higher among those with higher household income (Figure). The median ‘reasonable’ price was $225 (range=$0-$2500).</p>\n\n<p><strong>Conclusions</strong>: Patient perceptions of ctHPVDNA testing were favorable, even amongst those for whom it was inaccurate. Patients relied upon their physicians to guide implementation and interpretation of the test, placing the onus on providers caring for this population to understand its strengths and limitations prior to routine clinical use.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153298/WTP_Figure1.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153298--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S495",
      "content_id": "154274",
      "abstract_number": "S495",
      "poster_number": "",
      "title": "Lead Time Detection of Recurrent HPV Associated Oropharyngeal Squamous Cell Carcinoma Utilizing Circulating Tumor HPV DNA Testing",
      "summary": "Of applicable patients with TTMV-HPV DNA assays in the 3 months before recurrence detection, almost 43% of patients were first identified by routine ctDNA testing. This shows the potential benefit and utility of incorporating this assay into clinical practice. Fortunately, almost 80% were subsequently detected on imaging. However, it is important to recognize that 20% remained without clinical evidence of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154274",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Sicard",
      "presenter": "Ryan Sicard",
      "authors": "Ryan Sicard 1 ; Alicia Yang 1 ; Ethan Gomez 1 ; Daniel Kraft 2 ; Peter Cooke 2 ; Michael Berger 2 ; Marita Teng 2 ; Mohammed Khan 2 ; Eric Genden 2 ; Raymond Chai 2 ; Krzysztof Misiukiewicz 3 ; Richard Bakst 3 ; Kunal Sindhu 3 ; Scott Roof 2",
      "normalized_authors": [
        "Ryan Sicard",
        "Alicia Yang",
        "Ethan Gomez",
        "Daniel Kraft",
        "Peter Cooke",
        "Michael Berger",
        "Marita Teng",
        "Mohammed Khan",
        "Eric Genden",
        "Raymond Chai",
        "Krzysztof Misiukiewicz",
        "Richard Bakst",
        "Kunal Sindhu",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology at Mount Sinai",
        "Department of Hematology and Oncology at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai",
        "Department of Otolaryngology at Mount Sinai",
        "Department of Hematology and Oncology at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 484,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Intro",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryan Sicard 1 ; Alicia Yang 1 ; Ethan Gomez 1 ; Daniel Kraft 2 ; Peter Cooke 2 ; Michael Berger 2 ; Marita Teng 2 ; Mohammed Khan 2 ; Eric Genden 2 ; Raymond Chai 2 ; Krzysztof Misiukiewicz 3 ; Richard Bakst 3 ; Kunal Sindhu 3 ; Scott Roof 2",
        "Affiliations": "1 Icahn School of Medicine at Mount Sinai; 2 Department of Otolaryngology at Mount Sinai; 3 Department of Hematology and Oncology at Mount Sinai",
        "Intro": "Circulating tumor DNA (ctDNA) is an increasingly utilized biomarker in the setting of surveillance of HPV-associated head and neck squamous cell carcinoma (HNSCC). Assays identifying tumor tissue-modified viral (TTMV) HPV DNA have been shown to be highly sensitive at detecting recurrences with potential lead time detection compared to conventional surveillance modalities. However, as some TTMV-HPV DNA tests are ordered due to clinical suspicion of recurrence while others are ordered routinely as part of a patient’s surveillance plan, the potential benefit of lead time detection of TTMV-HPV DNA assays in otherwise asymptomatic patients is unknown at this point.",
        "Methods": "This is a retrospective cohort study of adults with HPV-associated HNSCC who received a TTMV-HPV DNA assay as part of their oncologic care at a single large urban tertiary care center from December 2021 to June 2025 and who subsequently developed disease recurrence. Patients who received a TTMV-HPV DNA test within 3 months of pathological confirmation of disease recurrence were identified and separated into two groups. The first group had their test drawn due to clinical symptoms or imaging findings while the second group had their test drawn as part of routine surveillance. The second group was then sub-divided into patients whose positive test resulted in clinical findings or imaging demonstrative of recurrent disease and patients who did not show any signs of disease at the time of their initial positive test. The median and interquartile range of the time from initial positive test to pathological confirmation of recurrence was recorded for this last group as well as their most recent TTMV-HPV DNA test score at time of confirmation compared to their first positive score.",
        "Results": "Of the 123 patients with recurrences contained in the institutional database, 63 (51.2%) patients had a TTMV-HPV DNA test within 3 months of confirmation of recurrence. Of those, 36 (57.1%) were drawn due to clinical symptoms or imaging findings while 27 (42.9%) were part of routine surveillance testing in asymptomatic patients. Twenty-one (21/27) of the positive TTMV-HPV DNA tests resulted in clinical examination or imaging that showed evidence of recurrence while the remaining 6 were clinically and radiologically undetectable after initial positive test. Of the asymptomatic, TTMV-HPV DNA positive cohort, the median time to pathological detection was 177 days (IQR:96-219). The median ratio of TTMV-HPV DNA score at time of diagnosis to initial positive score was 14.8 (IQR:2.0-30.3).",
        "Conclusion": "Of applicable patients with TTMV-HPV DNA assays in the 3 months before recurrence detection, almost 43% of patients were first identified by routine ctDNA testing. This shows the potential benefit and utility of incorporating this assay into clinical practice. Fortunately, almost 80% were subsequently detected on imaging. However, it is important to recognize that 20% remained without clinical evidence of disease, with a median lead time of 6 months, which could contribute to uncertainty and patient anxiety.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lead Time Detection of Recurrent HPV Associated Oropharyngeal Squamous Cell Carcinoma Utilizing Circulating Tumor HPV DNA Testing</span>. <u>Ryan Sicard</u><sup>1</sup>; Alicia Yang<sup>1</sup>; Ethan Gomez<sup>1</sup>; Daniel Kraft<sup>2</sup>; Peter Cooke<sup>2</sup>; Michael Berger<sup>2</sup>; Marita Teng<sup>2</sup>; Mohammed Khan<sup>2</sup>; Eric Genden<sup>2</sup>; Raymond Chai<sup>2</sup>; Krzysztof Misiukiewicz<sup>3</sup>; Richard Bakst<sup>3</sup>; Kunal Sindhu<sup>3</sup>; Scott Roof<sup>2</sup>. <sup>1</sup>Icahn School of Medicine at Mount Sinai; <sup>2</sup>Department of Otolaryngology at Mount Sinai; <sup>3</sup>Department of Hematology and Oncology at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Intro: </strong>Circulating tumor DNA (ctDNA) is an increasingly utilized biomarker in the setting of surveillance of HPV-associated head and neck squamous cell carcinoma (HNSCC). Assays identifying tumor tissue-modified viral (TTMV) HPV DNA have been shown to be highly sensitive at detecting recurrences with potential lead time detection compared to conventional surveillance modalities. However, as some TTMV-HPV DNA tests are ordered due to clinical suspicion of recurrence while others are ordered routinely as part of a patient’s surveillance plan, the potential benefit of lead time detection of TTMV-HPV DNA assays in otherwise asymptomatic patients is unknown at this point.</p>\n\n<p><strong>Methods: </strong>This is a retrospective cohort study of adults with HPV-associated HNSCC who received a TTMV-HPV DNA assay as part of their oncologic care at a single large urban tertiary care center from December 2021 to June 2025 and who subsequently developed disease recurrence. Patients who received a TTMV-HPV DNA test within 3 months of pathological confirmation of disease recurrence were identified and separated into two groups. The first group had their test drawn due to clinical symptoms or imaging findings while the second group had their test drawn as part of routine surveillance. The second group was then sub-divided into patients whose positive test resulted in clinical findings or imaging demonstrative of recurrent disease and patients who did not show any signs of disease at the time of their initial positive test. The median and interquartile range of the time from initial positive test to pathological confirmation of recurrence was recorded for this last group as well as their most recent TTMV-HPV DNA test score at time of confirmation compared to their first positive score.</p>\n\n<p><strong>Results: </strong>Of the 123 patients with recurrences contained in the institutional database, 63 (51.2%) patients had a TTMV-HPV DNA test within 3 months of confirmation of recurrence. Of those, 36 (57.1%) were drawn due to clinical symptoms or imaging findings while 27 (42.9%) were part of routine surveillance testing in asymptomatic patients. Twenty-one (21/27) of the positive TTMV-HPV DNA tests resulted in clinical examination or imaging that showed evidence of recurrence while the remaining 6 were clinically and radiologically undetectable after initial positive test. Of the asymptomatic, TTMV-HPV DNA positive cohort, the median time to pathological detection was 177 days (IQR:96-219). The median ratio of TTMV-HPV DNA score at time of diagnosis to initial positive score was 14.8 (IQR:2.0-30.3).</p>\n\n<p><strong>Conclusion: </strong>Of applicable patients with TTMV-HPV DNA assays in the 3 months before recurrence detection, almost 43% of patients were first identified by routine ctDNA testing. This shows the potential benefit and utility of incorporating this assay into clinical practice. Fortunately, almost 80% were subsequently detected on imaging. However, it is important to recognize that 20% remained without clinical evidence of disease, with a median lead time of 6 months, which could contribute to uncertainty and patient anxiety.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154274--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S496",
      "content_id": "154115",
      "abstract_number": "S496",
      "poster_number": "",
      "title": "Biomarker based detection of oral tumor precursors",
      "summary": "Head and Neck Squamous Cell Carcinoma is known to cause local recurrences in up to 50% of patients with advanced disease. It has been hypothesized that a Tumor Precursor Field (TPF), that surrounds the tumor can be one of the major causes of this recurrence. A TPF has already incurred the first mutations and cellular dysregulations that are required for tumorigenesis, but still largely behaves like normal...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154115",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Wisse E Haakma",
      "presenter": "Wisse E Haakma",
      "authors": "Wisse E Haakma 1 ; Laura J Tafe 2 ; Kimberley S Samkoe 1",
      "normalized_authors": [
        "Wisse E Haakma",
        "Laura J Tafe",
        "Kimberley S Samkoe"
      ],
      "affiliations": [
        "Dartmouth College",
        "Dartmouth Health"
      ],
      "normalized_institutions": [
        "Dartmouth College",
        "Dartmouth Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 279,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Wisse E Haakma 1 ; Laura J Tafe 2 ; Kimberley S Samkoe 1",
        "Affiliations": "1 Dartmouth College; 2 Dartmouth Health",
        "Abstract": "Head and Neck Squamous Cell Carcinoma is known to cause local recurrences in up to 50% of patients with advanced disease. It has been hypothesized that a Tumor Precursor Field (TPF), that surrounds the tumor can be one of the major causes of this recurrence. A TPF has already incurred the first mutations and cellular dysregulations that are required for tumorigenesis, but still largely behaves like normal epithelia, making their identification difficult. In this study, we perform immunofluorescence stains to examine biomarkers such as P53, Ki-67 and differentiation markers for abnormal patterns of expression in the tumor-adjacent epithelia of Formalin-Fixed Paraffin Embedded patient tissue. Based on these staining results, the epithelia will be divided into areas of potential TPF and areas of potential healthy tissue. DNA from both these areas are isolated and investigated for shared somatic mutations with the primary tumor to conclude if the area indicated by the biomarker status corresponds with an actual TPF. Simultaneously, we are developing a TPF mouse model by using long-term exposure to the carcinogenic agent 4-Nitroquinoline 1-oxide (4-NQO) to induce tumor and TPF development in the oral mucosa of mice. These studies will identify and validate novel in-vivo biomarkers for TPF detection and improve our understanding of TPF formation and its tumor-generating properties. In the future, we aim to expand our method of in-vivo TPF detection to apply it in a Fluorescence Guided Surgery setting. Our overarching goal is to develop tools that allow for the visualization of the TPF, which then enable surgeons to remove the tumor precursor cells and will lead to a reduced rate of recurrence in Head and Neck Cancer. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Biomarker based detection of oral tumor precursors</span>. <u>Wisse E Haakma</u><sup>1</sup>; Laura J Tafe<sup>2</sup>; Kimberley S Samkoe<sup>1</sup>. <sup>1</sup>Dartmouth College; <sup>2</sup>Dartmouth Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and Neck Squamous Cell Carcinoma is known to cause local recurrences in up to 50% of patients with advanced disease. It has been hypothesized that a Tumor Precursor Field (TPF), that surrounds the tumor can be one of the major causes of this recurrence. A TPF has already incurred the first mutations and cellular dysregulations that are required for tumorigenesis, but still largely behaves like normal epithelia, making their identification difficult. In this study, we perform immunofluorescence stains to examine biomarkers such as P53, Ki-67 and differentiation markers for abnormal patterns of expression in the tumor-adjacent epithelia of Formalin-Fixed Paraffin Embedded patient tissue. Based on these staining results, the epithelia will be divided into areas of potential TPF and areas of potential healthy tissue. DNA from both these areas are isolated and investigated for shared somatic mutations with the primary tumor to conclude if the area indicated by the biomarker status corresponds with an actual TPF. Simultaneously, we are developing a TPF mouse model by using long-term exposure to the carcinogenic agent 4-Nitroquinoline 1-oxide (4-NQO) to induce tumor and TPF development in the oral mucosa of mice. These studies will identify and validate novel in-vivo biomarkers for TPF detection and improve our understanding of TPF formation and its tumor-generating properties. In the future, we aim to expand our method of in-vivo TPF detection to apply it in a Fluorescence Guided Surgery setting. Our overarching goal is to develop tools that allow for the visualization of the TPF, which then enable surgeons to remove the tumor precursor cells and will lead to a reduced rate of recurrence in Head and Neck Cancer.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154115--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S497",
      "content_id": "154355",
      "abstract_number": "S497",
      "poster_number": "",
      "title": "Risk of Developing Thyroid Malignancy in Females with Breast Cancer",
      "summary": "Our study found a clearly elevated risk of developing thyroid malignancy in females with breast cancer compared to those without the diagnosis. Patients are at highest risk of thyroid cancer development 6-12 months following breast cancer diagnosis. These findings highlight the need for greater monitoring of patients with breast cancer for future development of thyroid cancer, through thyroid ultrasound or...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154355",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Veenadhari Kollipara, BA",
      "presenter": "Veenadhari Kollipara, BA",
      "authors": "Kunal A Koka, BS; Veenadhari Kollipara, BA ; Jeffrey F Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS",
      "normalized_authors": [
        "Kunal A Koka",
        "Veenadhari Kollipara",
        "Jeffrey F Lorenz",
        "Neerav Goyal",
        "David Goldenberg"
      ],
      "affiliations": [
        "Penn State College of Medicine"
      ],
      "normalized_institutions": [
        "Penn State College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 456,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kunal A Koka, BS; Veenadhari Kollipara, BA ; Jeffrey F Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS",
        "Affiliations": "Penn State College of Medicine",
        "Background": "Breast and thyroid cancers are two malignancies with the highest incidence in women. These cancers often occur in a metachronous manner. Women with thyroid cancer are at increased risk for subsequent breast cancer and vice versa. Proposed mechanisms behind this association include shared hormonal pathways, genetic susceptibilities, treatment-related effects, and detection bias. Current literature suggests that breast cancer patients have approximately 1.5-1.6 times greater risk of developing thyroid cancer. However, the time interval after breast cancer diagnosis when patients are at the highest risk of developing thyroid cancer is unclear. The aim of this study is to quantify the risk of developing thyroid cancer at various time periods following breast cancer in females using a large retrospective cohort.",
        "Methods": "The TriNetX Research Database was queried for adult females diagnosed with breast cancer between 2009-2018 with at least 5 years of follow up as well as a control cohort propensity score matched for age, race, and ethnicity. Patients with potentially confounding factors, such as hereditary cancer syndromes, radiation therapy, and estrogen-altering medications were excluded. The primary outcome was the rate of thyroid gland malignancy diagnosis. The secondary outcome was the time interval after breast cancer diagnosis where patients are at highest risk of developing thyroid cancer (0-6 months, 6 months - 1 year, 1-3 years, 3-5 years, and 5+ years). Statistical analyses were conducted within TriNetX.",
        "Results": "We identified 272,238 females diagnosed with breast cancer and 14,705,785 females in the control cohort. The average age of patients was 58.8 for the breast cancer cohort and 43.3 for the control cohort before propensity score matching (PSM). After PSM for demographic factors, the breast cancer cohort had a 0.22% risk of developing thyroid malignancy within 5 years of the breast cancer diagnosis, compared to a 0.06% risk amongst females without breast cancer (Risk Ratio (RR): 3.68, 95% confidence interval (CI): 3.08-4.39, p < 0.0001). Patients were at the highest risk of developing thyroid cancer in the 6 months - 1 year following breast cancer diagnosis (RR: 6.00, 95% CI: 3.17-11.37, p < 0.0001) with diminishing risk afterwards.",
        "Conclusions": "Our study found a clearly elevated risk of developing thyroid malignancy in females with breast cancer compared to those without the diagnosis. Patients are at highest risk of thyroid cancer development 6-12 months following breast cancer diagnosis. These findings highlight the need for greater monitoring of patients with breast cancer for future development of thyroid cancer, through thyroid ultrasound or palpation, especially within the 6 months – 1 year window. Further study is needed to disentangle the contributions of shared risk factors (e.g. hormonal, genetic, environmental, and lifestyle) from treatment-related effects and surveillance bias.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Risk of Developing Thyroid Malignancy in Females with Breast Cancer</span>. Kunal A Koka, BS; <u>Veenadhari Kollipara, BA</u>; Jeffrey F Lorenz, MD; Neerav Goyal, MD, MPH, FACS; David Goldenberg, MD, FACS. Penn State College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Breast and thyroid cancers are two malignancies with the highest incidence in women. These cancers often occur in a metachronous manner. Women with thyroid cancer are at increased risk for subsequent breast cancer and vice versa. Proposed mechanisms behind this association include shared hormonal pathways, genetic susceptibilities, treatment-related effects, and detection bias. Current literature suggests that breast cancer patients have approximately 1.5-1.6 times greater risk of developing thyroid cancer. However, the time interval after breast cancer diagnosis when patients are at the highest risk of developing thyroid cancer is unclear. The aim of this study is to quantify the risk of developing thyroid cancer at various time periods following breast cancer in females using a large retrospective cohort.</p>\n\n<p><strong>Methods:</strong> The TriNetX Research Database was queried for adult females diagnosed with breast cancer between 2009-2018 with at least 5 years of follow up as well as a control cohort propensity score matched for age, race, and ethnicity. Patients with potentially confounding factors, such as hereditary cancer syndromes, radiation therapy, and estrogen-altering medications were excluded. The primary outcome was the rate of thyroid gland malignancy diagnosis. The secondary outcome was the time interval after breast cancer diagnosis where patients are at highest risk of developing thyroid cancer (0-6 months, 6 months - 1 year, 1-3 years, 3-5 years, and 5+ years). Statistical analyses were conducted within TriNetX.</p>\n\n<p><strong>Results: </strong>We identified 272,238 females diagnosed with breast cancer and 14,705,785 females in the control cohort. The average age of patients was 58.8 for the breast cancer cohort and 43.3 for the control cohort before propensity score matching (PSM). After PSM for demographic factors, the breast cancer cohort had a 0.22% risk of developing thyroid malignancy within 5 years of the breast cancer diagnosis, compared to a 0.06% risk amongst females without breast cancer (Risk Ratio (RR): 3.68, 95% confidence interval (CI): 3.08-4.39, p < 0.0001). Patients were at the highest risk of developing thyroid cancer in the 6 months - 1 year following breast cancer diagnosis (RR: 6.00, 95% CI: 3.17-11.37, p < 0.0001) with diminishing risk afterwards.</p>\n\n<p><strong>Conclusions: </strong>Our study found a clearly elevated risk of developing thyroid malignancy in females with breast cancer compared to those without the diagnosis. Patients are at highest risk of thyroid cancer development 6-12 months following breast cancer diagnosis. These findings highlight the need for greater monitoring of patients with breast cancer for future development of thyroid cancer, through thyroid ultrasound or palpation, especially within the 6 months – 1 year window. Further study is needed to disentangle the contributions of shared risk factors (e.g. hormonal, genetic, environmental, and lifestyle) from treatment-related effects and surveillance bias.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154355--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S498",
      "content_id": "153275",
      "abstract_number": "S498",
      "poster_number": "",
      "title": "Cost Effective Analysis of Pleomorphic Adenoma Surveillance: A Markov Model",
      "summary": "Limited follow-up represents the most cost-effective strategy for PMA surveillance, as recurrence rates are very low and routine annual monitoring provides minimal additional benefit. A targeted approach with three well-timed visits over seven years appears sufficient for safe, cost-effective long-term surveillance.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153275",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shireen Gohari, MBBS",
      "presenter": "Shireen Gohari, MBBS",
      "authors": "Geethanjeli Mahendran, MD, MPH 1 ; Emilie de Groot 2 ; Shireen Gohari, MBBS 1 ; Nathan Huey 3 ; Derrick Lin, MD 1 ; Mark Varvares, MD 1 ; Daniel Deschler, MD 1 ; Allen Feng 1 ; Daniel Faden, MD 1 ; Jeremy Richmon, MD 1",
      "normalized_authors": [
        "Geethanjeli Mahendran",
        "Emilie de Groot",
        "Shireen Gohari, MBBS",
        "Nathan Huey",
        "Derrick Lin",
        "Mark Varvares",
        "Daniel Deschler",
        "Allen Feng",
        "Daniel Faden",
        "Jeremy Richmon"
      ],
      "affiliations": [
        "Department of Otolaryngology Head and Neck Surgery Massachusetts Eye and Ear/Harvard Medical School",
        "Department of Otolaryngology-Head and Neck surgery Amsterdam",
        "Mass Eye and Ear"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology Head and Neck Surgery Massachusetts Eye and Ear/Harvard Medical School",
        "Department of Otolaryngology-Head and Neck surgery Amsterdam",
        "Mass Eye and Ear"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Geethanjeli Mahendran, MD, MPH 1 ; Emilie de Groot 2 ; Shireen Gohari, MBBS 1 ; Nathan Huey 3 ; Derrick Lin, MD 1 ; Mark Varvares, MD 1 ; Daniel Deschler, MD 1 ; Allen Feng 1 ; Daniel Faden, MD 1 ; Jeremy Richmon, MD 1",
        "Affiliations": "1 Department of Otolaryngology Head and Neck Surgery Massachusetts Eye and Ear/Harvard Medical School; 2 Department of Otolaryngology-Head and Neck surgery Amsterdam; 3 Mass Eye and Ear",
        "Introduction": "Pleomorphic adenoma (PA) is the most common benign salivary gland tumor, accounting for approximately two-thirds of all salivary gland neoplasms. While surgery generally achieves excellent outcomes with low recurrence rates, there is a lack of consensus on post-treatment surveillance. This study aims to identify cost-effective surveillance strategies through development of a Markov Model.",
        "Methods": "This retrospective cohort study included patients surgically treated for PA between 2014 and 2018 with a minimum five-year follow-up. All follow-up visits, imaging studies, and recurrence events were collected. A seven-year Markov model was developed to evaluate the cost-effectiveness of alternative long-term surveillance strategies. Model inputs included recurrence rates, surveillance frequency, screening and treatment costs, and state utilities for the different arms. The three arms tested were 1) Annual imaging visits 2) No imaging visits 3) Biennial imaging visits (3 total). Recurrence rates were derived from cohort data and costs were obtained from the CMS database. Model uncertainty was assessed using Monte Carlo simulation and one-way sensitivity analyses to evaluate the influence of recurrence rates, utilities, and screening frequency on the incremental cost-effectiveness ratio (ICER). Scenario analysis determined the maximum number of screening visits remaining below a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY).",
        "Results": "Ninety-seven patients (58.8% female, median age 54 years) underwent surgical treatment for PA with minimum of five-year follow-up. Five patients (5.2%) developed recurrence. Recurrence rates declined from 1.14% in year one to 0.25% in year seven. Sensitivity analyses demonstrated model stability by perturbing initial model parameters. When comparing surveillance strategies, annual imaging was more expensive and provided only marginal additional health benefits. The annual surveillance strategy had an ICER of $117,543 per QALY gained (compared to no surveillance), while the biennial strategy had an ICER of $89,975 per QALY, staying below the commonly used $100,000/QALY threshold. In practical terms, in our model, a schedule of just three follow-up visits, at years 2, 4, and 6, still remained cost-effective while lowering total costs by an average of $1,126 per patient over seven years compared to annual imaging.",
        "Conclusion": "Limited follow-up represents the most cost-effective strategy for PMA surveillance, as recurrence rates are very low and routine annual monitoring provides minimal additional benefit. A targeted approach with three well-timed visits over seven years appears sufficient for safe, cost-effective long-term surveillance.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Cost Effective Analysis of Pleomorphic Adenoma Surveillance: A Markov Model</span>. Geethanjeli Mahendran, MD, MPH<sup>1</sup>; Emilie de Groot<sup>2</sup>; <u>Shireen Gohari, MBBS</u><sup>1</sup>; Nathan Huey<sup>3</sup>; Derrick Lin, MD<sup>1</sup>; Mark Varvares, MD<sup>1</sup>; Daniel Deschler, MD<sup>1</sup>; Allen Feng<sup>1</sup>; Daniel Faden, MD<sup>1</sup>; Jeremy Richmon, MD<sup>1</sup>. <sup>1</sup>Department of Otolaryngology Head and Neck Surgery Massachusetts Eye and Ear/Harvard Medical School; <sup>2</sup>Department of Otolaryngology-Head and Neck surgery Amsterdam; <sup>3</sup>Mass Eye and Ear<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Pleomorphic adenoma (PA) is the most common benign salivary gland tumor, accounting for approximately two-thirds of all salivary gland neoplasms. While surgery generally achieves excellent outcomes with low recurrence rates, there is a lack of consensus on post-treatment surveillance. This study aims to identify cost-effective surveillance strategies through development of a Markov Model. </p>\n\n<p><strong>Methods: </strong>This retrospective cohort study included patients surgically treated for PA between 2014 and 2018 with a minimum five-year follow-up. All follow-up visits, imaging studies, and recurrence events were collected. A seven-year Markov model was developed to evaluate the cost-effectiveness of alternative long-term surveillance strategies. Model inputs included recurrence rates, surveillance frequency, screening and treatment costs, and state utilities for the different arms. The three arms tested were 1) Annual imaging visits 2) No imaging visits 3) Biennial imaging visits (3 total). Recurrence rates were derived from cohort data and costs were obtained from the CMS database. Model uncertainty was assessed using Monte Carlo simulation and one-way sensitivity analyses to evaluate the influence of recurrence rates, utilities, and screening frequency on the incremental cost-effectiveness ratio (ICER). Scenario analysis determined the maximum number of screening visits remaining below a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY). </p>\n\n<p><strong>Results: </strong>Ninety-seven patients (58.8% female, median age 54 years) underwent surgical treatment for PA with minimum of five-year follow-up. Five patients (5.2%) developed recurrence. Recurrence rates declined from 1.14% in year one to 0.25% in year seven. Sensitivity analyses demonstrated model stability by perturbing initial model parameters. When comparing surveillance strategies, annual imaging was more expensive and provided only marginal additional health benefits. The annual surveillance strategy had an ICER of $117,543 per QALY gained (compared to no surveillance), while the biennial strategy had an ICER of $89,975 per QALY, staying below the commonly used $100,000/QALY threshold. In practical terms, in our model, a schedule of just three follow-up visits, at years 2, 4, and 6, still remained cost-effective while lowering total costs by an average of $1,126 per patient over seven years compared to annual imaging. </p>\n\n<p><strong>Conclusion: </strong>Limited follow-up represents the most cost-effective strategy for PMA surveillance, as recurrence rates are very low and routine annual monitoring provides minimal additional benefit. A targeted approach with three well-timed visits over seven years appears sufficient for safe, cost-effective long-term surveillance. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153275--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S499",
      "content_id": "154700",
      "abstract_number": "S499",
      "poster_number": "",
      "title": "Closing the Gap: Houston Methodist Hospital’s First Annual Oral, Head and Neck Cancer Screening and Awareness Campaign for Houston's Underrepresented Communities",
      "summary": "A multi-faceted, targeted OHNC screening and awareness campaign is effective in reaching and engaging diverse, underrepresented communities, as demonstrated by the high participation and screening rates. The identification of a highly suspicious malignancy underscores the clinical utility of such programs. The significant gap in HPV vaccination rates and persistent misunderstanding of key risk factors highlights...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154700",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sebastian Guadarrama-Sistos-Vazquez",
      "presenter": "Sebastian Guadarrama-Sistos-Vazquez",
      "authors": "Sebastian Guadarrama-Sistos-Vazquez 1 ; Justina R Varghese 1 ; Akshay Prabhakar 1 ; Alexa De la Fuente Hagopian 2 ; Faizaan Khan 1 ; Anjali Keshavamurthy 1 ; Cynthia Ogoro 1 ; Alan Shattuck 1 ; Omar G Ahmed 1 ; Masayoshi Takashima 1 ; Laura M Kim 1 ; Nadia G Mohyuddin 1",
      "normalized_authors": [
        "Sebastian Guadarrama-Sistos-Vazquez",
        "Justina R Varghese",
        "Akshay Prabhakar",
        "Alexa De la Fuente Hagopian",
        "Faizaan Khan",
        "Anjali Keshavamurthy",
        "Cynthia Ogoro",
        "Alan Shattuck",
        "Omar G Ahmed",
        "Masayoshi Takashima",
        "Laura M Kim",
        "Nadia G Mohyuddin"
      ],
      "affiliations": [
        "Houston Methodist Hospital",
        "SUNY Downstate"
      ],
      "normalized_institutions": [
        "Houston Methodist Hospital",
        "SUNY Downstate"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 331,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sebastian Guadarrama-Sistos-Vazquez 1 ; Justina R Varghese 1 ; Akshay Prabhakar 1 ; Alexa De la Fuente Hagopian 2 ; Faizaan Khan 1 ; Anjali Keshavamurthy 1 ; Cynthia Ogoro 1 ; Alan Shattuck 1 ; Omar G Ahmed 1 ; Masayoshi Takashima 1 ; Laura M Kim 1 ; Nadia G Mohyuddin 1",
        "Affiliations": "1 Houston Methodist Hospital; 2 SUNY Downstate",
        "Introduction": "Racial and socioeconomic disparities contribute to delayed diagnosis and poorer outcomes in Oral, Head, and Neck Cancer (OHNC). To address these healthcare gaps, a pilot comprehensive awareness and screening campaign was initiated by Houston Methodist Hospital (HMH) targeting underrepresented communities in Houston, Texas. The primary objective was to improve OHNC awareness, screening rates, and patient navigation to follow-up care.",
        "Methods": "The \"Closing the Gap\" campaign was executed over two days in April 2025 and utilized culturally and linguistically sensitive outreach, leveraging HMH internal resources, community partners, and social media influencers. The campaign offered free OHNC screenings by physician providers. Participants completed pre- and post-screening surveys assessing demographics, socioeconomic factors, OHNC risk factor knowledge (including smoking, alcohol, and HPV), and symptom awareness. Data collected included registration rates, screening completion, survey responses, and clinical follow-up recommendations.",
        "Results": "A total of 104 individuals registered for the campaign, exceeding the initial goal of 80 participants. Of these, 77 individuals were successfully screened. Demographically, the cohort (n=62 completed surveys) was diverse, with Hispanic attendees exhibiting a considerably lower average age (39.4 years) compared to White attendees (64.3 years). Key knowledge deficits were identified: only 21% of participants reported having completed the HPV vaccination regimen, despite 70% being aware of the vaccine. Furthermore, while 60% correctly identified tobacco as a risk factor, only 50% identified alcohol, and knowledge of HPV transmission routes was uncertain for 25% of respondents. Clinically, one participant was referred for definitive follow-up due to a finding highly suggestive of oropharyngeal cancer.",
        "Conclusion": "A multi-faceted, targeted OHNC screening and awareness campaign is effective in reaching and engaging diverse, underrepresented communities, as demonstrated by the high participation and screening rates. The identification of a highly suspicious malignancy underscores the clinical utility of such programs. The significant gap in HPV vaccination rates and persistent misunderstanding of key risk factors highlights critical areas for targeted public health messaging and education in future iterations to improve early detection and prevention efforts.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Closing the Gap: Houston Methodist Hospital’s First Annual  Oral, Head and Neck Cancer Screening and Awareness Campaign for Houston's Underrepresented Communities</span>. <u>Sebastian Guadarrama-Sistos-Vazquez</u><sup>1</sup>; Justina R Varghese<sup>1</sup>; Akshay Prabhakar<sup>1</sup>; Alexa De la Fuente Hagopian<sup>2</sup>; Faizaan Khan<sup>1</sup>; Anjali Keshavamurthy<sup>1</sup>; Cynthia Ogoro<sup>1</sup>; Alan Shattuck<sup>1</sup>; Omar G Ahmed<sup>1</sup>; Masayoshi Takashima<sup>1</sup>; Laura M Kim<sup>1</sup>; Nadia G Mohyuddin<sup>1</sup>. <sup>1</sup>Houston Methodist Hospital; <sup>2</sup>SUNY Downstate<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Racial and socioeconomic disparities contribute to delayed diagnosis and poorer outcomes in Oral, Head, and Neck Cancer (OHNC). To address these healthcare gaps, a pilot comprehensive awareness and screening campaign was initiated by Houston Methodist Hospital (HMH) targeting underrepresented communities in Houston, Texas. The primary objective was to improve OHNC awareness, screening rates, and patient navigation to follow-up care.</p>\n\n<p><strong>Methods: </strong>The \"Closing the Gap\" campaign was executed over two days in April 2025 and utilized culturally and linguistically sensitive outreach, leveraging HMH internal resources, community partners, and social media influencers. The campaign offered free OHNC screenings by physician providers. Participants completed pre- and post-screening surveys assessing demographics, socioeconomic factors, OHNC risk factor knowledge (including smoking, alcohol, and HPV), and symptom awareness. Data collected included registration rates, screening completion, survey responses, and clinical follow-up recommendations.</p>\n\n<p><strong>Results:</strong> A total of 104 individuals registered for the campaign, exceeding the initial goal of 80 participants. Of these, 77 individuals were successfully screened. Demographically, the cohort (n=62 completed surveys) was diverse, with Hispanic attendees exhibiting a considerably lower average age (39.4 years) compared to White attendees (64.3 years). Key knowledge deficits were identified: only 21% of participants reported having completed the HPV vaccination regimen, despite 70% being aware of the vaccine. Furthermore, while 60% correctly identified tobacco as a risk factor, only 50% identified alcohol, and knowledge of HPV transmission routes was uncertain for 25% of respondents. Clinically, one participant was referred for definitive follow-up due to a finding highly suggestive of oropharyngeal cancer.</p>\n\n<p><strong>Conclusion:</strong> A multi-faceted, targeted OHNC screening and awareness campaign is effective in reaching and engaging diverse, underrepresented communities, as demonstrated by the high participation and screening rates. The identification of a highly suspicious malignancy underscores the clinical utility of such programs. The significant gap in HPV vaccination rates and persistent misunderstanding of key risk factors highlights critical areas for targeted public health messaging and education in future iterations to improve early detection and prevention efforts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154700--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S500",
      "content_id": "155447",
      "abstract_number": "S500",
      "poster_number": "",
      "title": "A promising Exhaled Breath Analysis approach for the Detection of Head and Neck Malignancies",
      "summary": "Standardized breath analysis combining Mistral technology with TD-GC/MS represents a promising non-invasive strategy for HNSCC detection. While the model demonstrated acceptable discriminatory performance, further refinements — including larger sample sizes and improved balancing of tumor stages — will be required to enhance sensitivity and support clinical applicability in a point-of-care setting.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155447",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260154",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Giulia Di Vincenzo",
      "presenter": "Giulia Di Vincenzo",
      "authors": "Francesco Mazzola, ENT Specialist; Antonello Vidiri, Radiology Specialist, Chief of the ra; Federica Rossi, ENT Specialist; Milena Fior, ENT Specialist; Raul Pellini, ENT Specialist, Chief of ENT Department; Giulia Di Vincenzo",
      "normalized_authors": [
        "Francesco Mazzola, ENT Specialist",
        "Antonello Vidiri, Radiology Specialist, Chief of the ra",
        "Federica Rossi, ENT Specialist",
        "Milena Fior, ENT Specialist",
        "Giulia Di Vincenzo"
      ],
      "affiliations": [
        "Istituto Fitoterapici Ospedalieri"
      ],
      "normalized_institutions": [
        "Istituto Fitoterapici Ospedalieri"
      ],
      "session_type": "Proffered Paper",
      "track": "Imaging and Screening",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Imaging and Screening"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 261,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Francesco Mazzola, ENT Specialist; Antonello Vidiri, Radiology Specialist, Chief of the ra; Federica Rossi, ENT Specialist; Milena Fior, ENT Specialist; Raul Pellini, ENT Specialist, Chief of ENT Department; Giulia Di Vincenzo",
        "Affiliations": "Istituto Fitoterapici Ospedalieri",
        "Background": "Head and neck squamous cell carcinomas (HNSCC) are frequently diagnosed at advanced stages, owing to the absence of effective non-invasive screening tools, which contributes to poor long-term survival outcomes. This study evaluates the diagnostic performance of a standardized breath analysis workflow for HNSCC detection through the identification of exhaled volatile organic compounds (VOCs).",
        "Methods": "Exhaled breath samples were collected from 103 eligible subjects — 60 patients with confirmed \"full-blown\" HNSCC and 43 healthy controls — using the Mistral device, a patented automated system that ensures standardized sampling through multi-material sorbent tubes (Tenax/Carboxen). The two groups were well matched for sex, age, and tobacco use. Samples were analyzed by thermal desorption gas chromatography–mass spectrometry (TD-GC/MS). Statistical feature selection based on ANOVA F-scores was applied to identify the 70 most discriminative VOCs. A classification model was then constructed using Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) with Leave-One-Out Cross-Validation (LOOCV).",
        "Results": "The multivariate model successfully discriminated cancer patients from healthy controls, achieving an overall accuracy of 70%, a specificity of 71%, and a sensitivity of 70%. Although partial overlap was observed in the multidimensional space, the OPLS-DA score plot revealed distinct clustering of the two populations.",
        "Conclusion": "Standardized breath analysis combining Mistral technology with TD-GC/MS represents a promising non-invasive strategy for HNSCC detection. While the model demonstrated acceptable discriminatory performance, further refinements — including larger sample sizes and improved balancing of tumor stages — will be required to enhance sensitivity and support clinical applicability in a point-of-care setting.",
        "Keywords": "Head and neck cancer, volatile organic compounds, Mistral device, breathomics.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A promising Exhaled Breath Analysis approach for the Detection of Head and Neck Malignancies</span>. Francesco Mazzola, ENT Specialist; Antonello Vidiri, Radiology Specialist, Chief of the ra; Federica Rossi, ENT Specialist; Milena Fior, ENT Specialist; Raul Pellini, ENT Specialist, Chief of ENT Department; <u>Giulia Di Vincenzo</u>. Istituto Fitoterapici Ospedalieri<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinomas (HNSCC) are frequently diagnosed at advanced stages, owing to the absence of effective non-invasive screening tools, which contributes to poor long-term survival outcomes. This study evaluates the diagnostic performance of a standardized breath analysis workflow for HNSCC detection through the identification of exhaled volatile organic compounds (VOCs).</p>\n\n<p><strong>Methods:</strong> Exhaled breath samples were collected from 103 eligible subjects — 60 patients with confirmed \"full-blown\" HNSCC and 43 healthy controls — using the Mistral device, a patented automated system that ensures standardized sampling through multi-material sorbent tubes (Tenax/Carboxen). The two groups were well matched for sex, age, and tobacco use. Samples were analyzed by thermal desorption gas chromatography–mass spectrometry (TD-GC/MS). Statistical feature selection based on ANOVA F-scores was applied to identify the 70 most discriminative VOCs. A classification model was then constructed using Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) with Leave-One-Out Cross-Validation (LOOCV).</p>\n\n<p><strong>Results:</strong> The multivariate model successfully discriminated cancer patients from healthy controls, achieving an overall accuracy of 70%, a specificity of 71%, and a sensitivity of 70%. Although partial overlap was observed in the multidimensional space, the OPLS-DA score plot revealed distinct clustering of the two populations.</p>\n\n<p><strong>Conclusion:</strong> Standardized breath analysis combining Mistral technology with TD-GC/MS represents a promising non-invasive strategy for HNSCC detection. While the model demonstrated acceptable discriminatory performance, further refinements — including larger sample sizes and improved balancing of tumor stages — will be required to enhance sensitivity and support clinical applicability in a point-of-care setting.</p>\n\n<p><strong>Keywords:</strong> Head and neck cancer, volatile organic compounds, Mistral device, breathomics.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155447--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260154' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S501",
      "content_id": "153802",
      "abstract_number": "S501",
      "poster_number": "",
      "title": "Global Disparities in Affordability of Targeted and Immunotherapy Agents for Head and Neck Cancers",
      "summary": "Despite wide pricing variation, modern immunotherapies remain economically unattainable in most global settings. TKIs such as gefitinib and erlotinib, though less efficacious, offer substantially broader budgetary reach and approach affordability thresholds in parts of South Asia. The findings underscore that innovation in oncology has outpaced affordability and that current pricing structures threaten equity and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153802",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Arjun G Singh",
      "presenter": "Arjun G Singh",
      "authors": "Arjun G Singh 1 ; Labani Kole 1 ; Richard Sullivan 2 ; Shwetabh Sinha 1 ; Rathan Shetty 1 ; Poonam Joshi 1 ; Sudhir Nair 1 ; Sarbani Ghosh Laskar 1 ; Kumar Prabhash 1 ; Pankaj Chaturvedi 1",
      "normalized_authors": [
        "Arjun G Singh",
        "Labani Kole",
        "Richard Sullivan",
        "Shwetabh Sinha",
        "Rathan Shetty",
        "Poonam Joshi",
        "Sudhir Nair",
        "Sarbani Ghosh Laskar",
        "Kumar Prabhash",
        "Pankaj Chaturvedi"
      ],
      "affiliations": [
        "Tata Memorial Centre",
        "Kings Institute of Cancer Policy"
      ],
      "normalized_institutions": [
        "Tata Memorial Centre",
        "Kings Institute of Cancer Policy"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153802/Figure%201a%20new.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153802/Figure%201a%20new.png",
          "alt": "Figure 1a",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153802"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153802/Figure%201b%20new(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153802/Figure%201b%20new(1).png",
          "alt": "Figure 1b",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153802"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153802/Figure%202.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153802/Figure%202.png",
          "alt": "Figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153802"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153802/Figure%203.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153802/Figure%203.png",
          "alt": "Figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153802"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 515,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Arjun G Singh 1 ; Labani Kole 1 ; Richard Sullivan 2 ; Shwetabh Sinha 1 ; Rathan Shetty 1 ; Poonam Joshi 1 ; Sudhir Nair 1 ; Sarbani Ghosh Laskar 1 ; Kumar Prabhash 1 ; Pankaj Chaturvedi 1",
        "Affiliations": "1 Tata Memorial Centre; 2 Kings Institute of Cancer Policy",
        "Introduction": "The introduction of immune checkpoint inhibitors has transformed the treatment of recurrent and metastatic head-and-neck squamous cell carcinoma (HNSCC), yet affordability remains a major barrier. Although newer agents offer modest survival benefits, their costs may exceed annual household incomes in low- and middle-income countries (LMICs). Even in high-income countries (HICs), drug expenditures are among the fastest-growing components of healthcare spending. This study assessed global disparities in the pricing and affordability of immunotherapy and targeted agents used in HNSCC and evaluated their economic feasibility across seven representative health-system contexts.",
        "Methods": "We conducted a cross-sectional, comparative pricing analysis of five drugs commonly used in HNSCC: pembrolizumab, nivolumab, gefitinib, erlotinib, and cetuximab. Seven countries were selected to represent different income levels—United States, United Kingdom, and Australia (HICs); South Africa (upper-middle income); and India, Pakistan, and Bangladesh (LMICs). Prices were extracted from national formularies and public procurement databases and converted into U.S. dollars using nominal exchange rates and purchasing power parity (PPP) adjustments. Affordability was estimated relative to monthly household income and GDP per capita. Treatments were considered catastrophically unaffordable if six-month costs exceeded 240% of monthly income (WHO–World Bank definition). Dosing schedules were standardized. We calculated affordability ratios (% of monthly income), PPP-adjusted values, and a budget-reach multiplier, representing the number of patients who could receive six months of tyrosine kinase inhibitor (TKI) therapy for the cost of one patient on immunotherapy. Analyses were stratified by income group.",
        "Results": "Nominal six-month prices varied widely: pembrolizumab ranged from USD 7,676 (Bangladesh) to USD 38,254 (Australia); nivolumab from USD 3,666 (Bangladesh) to USD 12,708 (United States); gefitinib from USD 420 (Bangladesh) to USD 1,030 (India); erlotinib from USD 1,237 (Pakistan) to USD 16,452 (United States); and cetuximab from USD 1,025 (Pakistan) to USD 7,374 (India). PPP adjustment narrowed cross-country gaps but did not change affordability rankings.",
        "Abstract": "Affordability analysis showed that immunotherapy remained catastrophically unaffordable across all settings. In India, six months of pembrolizumab required 7,994% of monthly income, nivolumab 2,197%, gefitinib 412%, erlotinib 3,772%, and cetuximab 2,950 %. Only gefitinib in Pakistan (192%) and Bangladesh (171%), erlotinib in the UK (120%), and cetuximab in Australia (22%) fell below catastrophic thresholds. The budget-reach analysis demonstrated profound opportunity costs. In South Asia, one pembrolizumab course could fund 18–22 gefitinib treatments or 2–10 erlotinib courses; nivolumab, though cheaper, could fund 5–9 gefitinib patients per treated case. In contrast, in HICs, parity was approached: one pembrolizumab course equated to ~9 gefitinib courses in Australia, 1.3 in the UK, and 0.7 in the USA. Across all regions, immunotherapy costs exceeded those of TKIs and cetuximab byseveral-fold, confirming their economic inaccessibility (Figures 1–3). View in Agenda and Add to Schedule",
        "Conclusions": "Despite wide pricing variation, modern immunotherapies remain economically unattainable in most global settings. TKIs such as gefitinib and erlotinib, though less efficacious, offer substantially broader budgetary reach and approach affordability thresholds in parts of South Asia. The findings underscore that innovation in oncology has outpaced affordability and that current pricing structures threaten equity and sustainability in cancer care."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Global Disparities in Affordability of Targeted and Immunotherapy Agents for Head and Neck Cancers</span>. <u>Arjun G Singh</u><sup>1</sup>; Labani Kole<sup>1</sup>; Richard Sullivan<sup>2</sup>; Shwetabh Sinha<sup>1</sup>; Rathan Shetty<sup>1</sup>; Poonam Joshi<sup>1</sup>; Sudhir Nair<sup>1</sup>; Sarbani Ghosh Laskar<sup>1</sup>; Kumar Prabhash<sup>1</sup>; Pankaj Chaturvedi<sup>1</sup>. <sup>1</sup>Tata Memorial Centre; <sup>2</sup>Kings Institute of Cancer Policy<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The introduction of immune checkpoint inhibitors has transformed the treatment of recurrent and metastatic head-and-neck squamous cell carcinoma (HNSCC), yet affordability remains a major barrier. Although newer agents offer modest survival benefits, their costs may exceed annual household incomes in low- and middle-income countries (LMICs). Even in high-income countries (HICs), drug expenditures are among the fastest-growing components of healthcare spending. This study assessed global disparities in the pricing and affordability of immunotherapy and targeted agents used in HNSCC and evaluated their economic feasibility across seven representative health-system contexts.</p>\n\n<p><strong>Methods: </strong>We conducted a cross-sectional, comparative pricing analysis of five drugs commonly used in HNSCC: pembrolizumab, nivolumab, gefitinib, erlotinib, and cetuximab. Seven countries were selected to represent different income levels—United States, United Kingdom, and Australia (HICs); South Africa (upper-middle income); and India, Pakistan, and Bangladesh (LMICs). Prices were extracted from national formularies and public procurement databases and converted into U.S. dollars using nominal exchange rates and purchasing power parity (PPP) adjustments. Affordability was estimated relative to monthly household income and GDP per capita. Treatments were considered catastrophically unaffordable if six-month costs exceeded 240% of monthly income (WHO–World Bank definition). Dosing schedules were standardized. We calculated affordability ratios (% of monthly income), PPP-adjusted values, and a budget-reach multiplier, representing the number of patients who could receive six months of tyrosine kinase inhibitor (TKI) therapy for the cost of one patient on immunotherapy. Analyses were stratified by income group.</p>\n\n<p><strong>Results: </strong>Nominal six-month prices varied widely: pembrolizumab ranged from USD 7,676 (Bangladesh) to USD 38,254 (Australia); nivolumab from USD 3,666 (Bangladesh) to USD 12,708 (United States); gefitinib from USD 420 (Bangladesh) to USD 1,030 (India); erlotinib from USD 1,237 (Pakistan) to USD 16,452 (United States); and cetuximab from USD 1,025 (Pakistan) to USD 7,374 (India). PPP adjustment narrowed cross-country gaps but did not change affordability rankings.</p>\n\n<p><img alt='Figure 1a' src='https://www.submitmyabstract.com/abs/images/153802/Figure%201a%20new.png' /></p>\n\n<p><img alt='Figure 1b' src='https://www.submitmyabstract.com/abs/images/153802/Figure%201b%20new(1).png' /></p>\n\n<p>Affordability analysis showed that immunotherapy remained catastrophically unaffordable across all settings. In India, six months of pembrolizumab required 7,994% of monthly income, nivolumab 2,197%, gefitinib 412%, erlotinib 3,772%, and cetuximab 2,950 %. Only gefitinib in Pakistan (192%) and Bangladesh (171%), erlotinib in the UK (120%), and cetuximab in Australia (22%) fell below catastrophic thresholds.</p>\n\n<p><img alt='Figure 2' src='https://www.submitmyabstract.com/abs/images/153802/Figure%202.png' /></p>\n\n<p>The budget-reach analysis demonstrated profound opportunity costs. In South Asia, one pembrolizumab course could fund 18–22 gefitinib treatments or 2–10 erlotinib courses; nivolumab, though cheaper, could fund 5–9 gefitinib patients per treated case. In contrast, in HICs, parity was approached: one pembrolizumab course equated to ~9 gefitinib courses in Australia, 1.3 in the UK, and 0.7 in the USA. Across all regions, immunotherapy costs exceeded those of TKIs and cetuximab byseveral-fold, confirming their economic inaccessibility (Figures 1–3).</p>\n\n<p><img alt='Figure 3' src='https://www.submitmyabstract.com/abs/images/153802/Figure%203.png' /></p>\n\n<p><strong>Conclusions: </strong>Despite wide pricing variation, modern immunotherapies remain economically unattainable in most global settings. TKIs such as gefitinib and erlotinib, though less efficacious, offer substantially broader budgetary reach and approach affordability thresholds in parts of South Asia. The findings underscore that innovation in oncology has outpaced affordability and that current pricing structures threaten equity and sustainability in cancer care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153802--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S502",
      "content_id": "154432",
      "abstract_number": "S502",
      "poster_number": "",
      "title": "A 2025 Assessment of HPV Vaccination Perceptions Among Hispanic and Underserved Communities",
      "summary": "HPV vaccine awareness and uptake remain limited among minority and underserved populations, but participants with some familiarity recognized the importance of vaccinating all sexes for cancer prevention. Traditionally cited barriers, such as language discordance, difficulty completing multivalent series, and the misconception that only girls should be vaccinated, did not emerge as leading obstacles in this...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154432",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gabriel Carrillo, BS",
      "presenter": "Gabriel Carrillo, BS",
      "authors": "Gabriel Carrillo, BS 1 ; Libby Ward Schafer, MD 2 ; Kassidy Collins, BS 3 ; Adriana Vélez-Avilés, BS 4 ; Brinda Emu, MD 5 ; Avanti Verma, MD 2",
      "normalized_authors": [
        "Gabriel Carrillo",
        "Libby Ward Schafer",
        "Kassidy Collins",
        "Adriana Vélez-Avilés",
        "Brinda Emu",
        "Avanti Verma"
      ],
      "affiliations": [
        "Yale School of Medicine",
        "Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery",
        "Yale School of Public Health",
        "Yale Graduate School of Arts and Sciences",
        "Yale Department of Internal Medicine, Division of Infectious Diseases"
      ],
      "normalized_institutions": [
        "Yale School of Medicine",
        "Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery",
        "Yale School of Public Health",
        "Yale Graduate School of Arts and Sciences",
        "Yale Department of Internal Medicine, Division of Infectious Diseases"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 517,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gabriel Carrillo, BS 1 ; Libby Ward Schafer, MD 2 ; Kassidy Collins, BS 3 ; Adriana Vélez-Avilés, BS 4 ; Brinda Emu, MD 5 ; Avanti Verma, MD 2",
        "Affiliations": "1 Yale School of Medicine; 2 Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery; 3 Yale School of Public Health; 4 Yale Graduate School of Arts and Sciences; 5 Yale Department of Internal Medicine, Division of Infectious Diseases",
        "Background": "Human papillomavirus (HPV)-related cancers are a growing public health concern, with HPV-mediated head and neck squamous cell carcinoma (HNSCC) now surpassing cervical cancer in incidence among U.S. adults. Misconceptions that HPV only causes cervical cancer persist, and vaccination rates are three times higher in females than males. Uptake is also historically lower in minority and underserved communities. Hispanics aged 27 to 45 are 27% less likely to vaccinate than non-Hispanic Whites, with some Hispanic parents concerned about the vaccine promoting sexual activity. Other traditionally cited barriers include language discordance, transportation, mistrust of medical professionals, and limited culturally relevant information. This study reassessed present-day barriers in a predominantly Hispanic, underserved community to ensure culturally appropriate educational materials reflect current challenges.",
        "Methods": "This cross-sectional study surveyed adults aged 18 years or older at a free, student-run clinic serving a predominantly Hispanic and underserved population. Questions included multiple-choice, Likert-scale, and free-response items assessing HPV knowledge, vaccination status, perceived barriers, and attitudes toward vaccinating eligible children. Surveys were administered in English or Spanish, and participants were confidentially walked through each question to ensure comprehension. Responses were anonymized, and participants received a $10 gift card as remuneration.",
        "Results": "Among 50 participants, the median age was 44 years (range 24–75), 56% were female, 64% Hispanic, 50% preferred Spanish, and 36% lacked insurance. HPV awareness was 76%, vaccine awareness 60%, and 76% were unvaccinated or unsure. Sex, ethnicity, and language preference were not significantly associated with vaccination status (p = 0.186, 1.0, 0.33). Of 44 participants with children, 36% did not know if their children were eligible for vaccination. Most agreed the vaccine is effective and supported vaccination for all eligible children. Key barriers to child vaccination included limited knowledge of eligible ages (48%) and locations offering vaccination (42%). Language barriers (20%) and transportation for follow-up doses (24%) were noted but less prominent. Only 10% believed vaccination should be limited to girls. Among 28 participants aware that HPV can cause cancer, 86% recognized its link to cervical cancer, but only 61% identified its association with HNSCC. Spanish-speaking and Hispanic participants were significantly more likely to recognize HPV’s link to HNSCC (Fisher’s exact test, two-sided p = 0.0023; OR 8.91; 95% CI 2.10–37.78) and cervical cancer (Fisher’s exact test, two-sided p = 0.0465; OR 3.56; 95% CI 1.09–11.55).",
        "Conclusions": "HPV vaccine awareness and uptake remain limited among minority and underserved populations, but participants with some familiarity recognized the importance of vaccinating all sexes for cancer prevention. Traditionally cited barriers, such as language discordance, difficulty completing multivalent series, and the misconception that only girls should be vaccinated, did not emerge as leading obstacles in this study. This may reflect increased dissemination of knowledge in participants’ country of origin or larger shifts in perception within these communities locally. Hispanic and Spanish-speaking participants were more likely to recognize HPV’s association with cervical cancer and HNSCC, but HNSCC awareness remains low overall. Outreach efforts should prioritize clarifying age eligibility for children and advertising accessible locations for HPV vaccination.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A 2025 Assessment of HPV Vaccination Perceptions Among Hispanic and Underserved Communities</span>. <u>Gabriel Carrillo, BS</u><sup>1</sup>; Libby Ward Schafer, MD<sup>2</sup>; Kassidy Collins, BS<sup>3</sup>; Adriana Vélez-Avilés, BS<sup>4</sup>; Brinda Emu, MD<sup>5</sup>; Avanti Verma, MD<sup>2</sup>. <sup>1</sup>Yale School of Medicine; <sup>2</sup>Yale Department of Surgery, Division of Otolaryngology-Head and Neck Surgery; <sup>3</sup>Yale School of Public Health; <sup>4</sup>Yale Graduate School of Arts and Sciences; <sup>5</sup>Yale Department of Internal Medicine, Division of Infectious Diseases<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Human papillomavirus (HPV)-related cancers are a growing public health concern, with HPV-mediated head and neck squamous cell carcinoma (HNSCC) now surpassing cervical cancer in incidence among U.S. adults. Misconceptions that HPV only causes cervical cancer persist, and vaccination rates are three times higher in females than males. Uptake is also historically lower in minority and underserved communities. Hispanics aged 27 to 45 are 27% less likely to vaccinate than non-Hispanic Whites, with some Hispanic parents concerned about the vaccine promoting sexual activity. Other traditionally cited barriers include language discordance, transportation, mistrust of medical professionals, and limited culturally relevant information. This study reassessed present-day barriers in a predominantly Hispanic, underserved community to ensure culturally appropriate educational materials reflect current challenges. </p>\n\n<p><strong>Methods:</strong> This cross-sectional study surveyed adults aged 18 years or older at a free, student-run clinic serving a predominantly Hispanic and underserved population. Questions included multiple-choice, Likert-scale, and free-response items assessing HPV knowledge, vaccination status, perceived barriers, and attitudes toward vaccinating eligible children. Surveys were administered in English or Spanish, and participants were confidentially walked through each question to ensure comprehension. Responses were anonymized, and participants received a $10 gift card as remuneration. </p>\n\n<p><strong>Results:</strong> Among 50 participants, the median age was 44 years (range 24–75), 56% were female, 64% Hispanic, 50% preferred Spanish, and 36% lacked insurance. HPV awareness was 76%, vaccine awareness 60%, and 76% were unvaccinated or unsure. Sex, ethnicity, and language preference were not significantly associated with vaccination status (p = 0.186, 1.0, 0.33). Of 44 participants with children, 36% did not know if their children were eligible for vaccination. Most agreed the vaccine is effective and supported vaccination for all eligible children. Key barriers to child vaccination included limited knowledge of eligible ages (48%) and locations offering vaccination (42%). Language barriers (20%) and transportation for follow-up doses (24%) were noted but less prominent. Only 10% believed vaccination should be limited to girls. Among 28 participants aware that HPV can cause cancer, 86% recognized its link to cervical cancer, but only 61% identified its association with HNSCC. Spanish-speaking and Hispanic participants were significantly more likely to recognize HPV’s link to HNSCC (Fisher’s exact test, two-sided p = 0.0023; OR 8.91; 95% CI 2.10–37.78) and cervical cancer (Fisher’s exact test, two-sided p = 0.0465; OR 3.56; 95% CI 1.09–11.55). </p>\n\n<p><strong>Conclusions:</strong> HPV vaccine awareness and uptake remain limited among minority and underserved populations, but participants with some familiarity recognized the importance of vaccinating all sexes for cancer prevention. Traditionally cited barriers, such as language discordance, difficulty completing multivalent series, and the misconception that only girls should be vaccinated, did not emerge as leading obstacles in this study. This may reflect increased dissemination of knowledge in participants’ country of origin or larger shifts in perception within these communities locally. Hispanic and Spanish-speaking participants were more likely to recognize HPV’s association with cervical cancer and HNSCC, but HNSCC awareness remains low overall. Outreach efforts should prioritize clarifying age eligibility for children and advertising accessible locations for HPV vaccination.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154432--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S504",
      "content_id": "153631",
      "abstract_number": "S504",
      "poster_number": "",
      "title": "Survival in Tonsil Squamous Cell Carcinoma: Key Socioeconomic and Clinical Predictors",
      "summary": "In this large, population-based study of squamous cell carcinoma of the tonsil, nearly half of the patients presented with advanced disease, and socioeconomic disadvantage was strongly associated with poorer survival. Machine learning analysis identified metastasis, disease stage, nodal involvement, and social factors as key predictors, suggesting that integrating clinical and social context into prognostic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153631",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shama Karanth, PhD, MDS",
      "presenter": "Shama Karanth, PhD, MDS",
      "authors": "Shama Karanth, PhD, MDS 1 ; Pamela Sandow, DMD 1 ; Mihika Shinde, MPH, BDS 1 ; Nimish Valvi, DrPH, MPH, MBBS 2 ; Kathryn Hitchcock, MD, PhD 1 ; Dejana Braithwaite, PhD 1 ; Cesar Migliorati, DDS, MS, PhD 1",
      "normalized_authors": [
        "Shama Karanth, MDS",
        "Pamela Sandow",
        "Mihika Shinde, BDS",
        "Nimish Valvi, DrPH, MBBS",
        "Kathryn Hitchcock",
        "Dejana Braithwaite",
        "Cesar Migliorati"
      ],
      "affiliations": [
        "University of Florida",
        "Ball State University"
      ],
      "normalized_institutions": [
        "University of Florida",
        "Ball State University"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 501,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shama Karanth, PhD, MDS 1 ; Pamela Sandow, DMD 1 ; Mihika Shinde, MPH, BDS 1 ; Nimish Valvi, DrPH, MPH, MBBS 2 ; Kathryn Hitchcock, MD, PhD 1 ; Dejana Braithwaite, PhD 1 ; Cesar Migliorati, DDS, MS, PhD 1",
        "Affiliations": "1 University of Florida; 2 Ball State University",
        "Background": "Tonsillar cancer represents a distinct and understudied subset of head and neck malignancies with rising incidence, largely driven by human papillomavirus (HPV)–associated oropharyngeal cancers. Understanding the roles of clinical characteristics and socioeconomic factors is critical for optimizing early detection and improving outcomes in this population. This study aimed to identify key demographic, clinical, and socioeconomic predictors of treatment delay and overall survival (OS) among patients with tonsillar cancer.",
        "Methods": "We conducted a population-based retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, including individuals aged 20–85+ years diagnosed with primary tonsil cancer between 2010 and 2021. Incidence and mortality rates were estimated for this period, stratified by median household income and rurality. Individual-level data were extracted using SEER*Stat version 9.0.41.4. The primary endpoint was overall survival (OS). Multivariable Cox proportional hazards regression and machine learning models enhanced with Shapley additive explanations (SHAP) were used to evaluate prognostic factors and improve model interpretability. Model performance was compared with random survival forest (RSF) analyses.",
        "Results": "From 2010 to 2021, incidence and mortality rates showed a steady upward trend, with higher rates among individuals with annual incomes ≤$74,999 and those residing in rural areas. Among 6,148 patients with Stage I–IV squamous cell carcinoma of the tonsil, 1,457 (23.7%) deaths occurred during follow-up (median overall survival [OS], 46 months; interquartile range [IQR], 18–85). Nearly half (47.5%) presented with stage IV disease, and most patients were male (84.3%). Regarding treatment, 2,574 (42%) received chemoradiation alone, while 1,381 (22.5%) underwent combined chemoradiation and surgery. The cohort was predominantly non-Hispanic (NH) White (81%), followed by Hispanic (7.1%), NH Black (6.6%), and Other/Unknown (5.3%). In adjusted Cox proportional hazards analyses, poorer survival was independently associated with stage IV disease (HR, 2.21; 95% CI, 1.72–2.47), tumor size >40 mm (HR, 2.09 95% CI, 1.73–2.54), older age (HR, 2.71; 95% CI, 2.22–3.31), distant metastases (HR, 3.47; 95% CI, 2.78–4.32), rural residence (HR, 1.28; 95% CI, 1.10–1.50), and low household income (HR, 1.17; 95% CI, 1.04–1.33), and NH Black race (HR, 1.57; 95% CI, 1.33–1.88). The random survival forest (RSF) model demonstrated good discrimination (C-index, 0.715), comparable to the Cox model (C-index, 0.759). SHAP feature importance analysis identified overall stage, metastasis, nodal involvement, household income, rurality, and race/ethnicity as the most influential predictors of survival.",
        "Conclusions": "In this large, population-based study of squamous cell carcinoma of the tonsil, nearly half of the patients presented with advanced disease, and socioeconomic disadvantage was strongly associated with poorer survival. Machine learning analysis identified metastasis, disease stage, nodal involvement, and social factors as key predictors, suggesting that integrating clinical and social context into prognostic models may guide targeted early detection and precision survivorship strategies to reduce disparities.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Survival in Tonsil Squamous Cell Carcinoma: Key Socioeconomic and Clinical Predictors</span>. <u>Shama Karanth, PhD, MDS</u><sup>1</sup>; Pamela Sandow, DMD<sup>1</sup>; Mihika Shinde, MPH, BDS<sup>1</sup>; Nimish Valvi, DrPH, MPH, MBBS<sup>2</sup>; Kathryn Hitchcock, MD, PhD<sup>1</sup>; Dejana Braithwaite, PhD<sup>1</sup>; Cesar Migliorati, DDS, MS, PhD<sup>1</sup>. <sup>1</sup>University of Florida; <sup>2</sup>Ball State University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Tonsillar cancer represents a distinct and understudied subset of head and neck malignancies with rising incidence, largely driven by human papillomavirus (HPV)–associated oropharyngeal cancers. Understanding the roles of clinical characteristics and socioeconomic factors is critical for optimizing early detection and improving outcomes in this population. This study aimed to identify key demographic, clinical, and socioeconomic predictors of treatment delay and overall survival (OS) among patients with tonsillar cancer.</p>\n\n<p><strong>Methods: </strong>We conducted a population-based retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, including individuals aged 20–85+ years diagnosed with primary tonsil cancer between 2010 and 2021. Incidence and mortality rates were estimated for this period, stratified by median household income and rurality. Individual-level data were extracted using SEER*Stat version 9.0.41.4. The primary endpoint was overall survival (OS). Multivariable Cox proportional hazards regression and machine learning models enhanced with Shapley additive explanations (SHAP) were used to evaluate prognostic factors and improve model interpretability. Model performance was compared with random survival forest (RSF) analyses.</p>\n\n<p><strong>Results: </strong>From 2010 to 2021, incidence and mortality rates showed a steady upward trend, with higher rates among individuals with annual incomes ≤$74,999 and those residing in rural areas. Among 6,148 patients with Stage I–IV squamous cell carcinoma of the tonsil, 1,457 (23.7%) deaths occurred during follow-up (median overall survival [OS], 46 months; interquartile range [IQR], 18–85). Nearly half (47.5%) presented with stage IV disease, and most patients were male (84.3%). Regarding treatment, 2,574 (42%) received chemoradiation alone, while 1,381 (22.5%) underwent combined chemoradiation and surgery. The cohort was predominantly non-Hispanic (NH) White (81%), followed by Hispanic (7.1%), NH Black (6.6%), and Other/Unknown (5.3%). In adjusted Cox proportional hazards analyses, poorer survival was independently associated with stage IV disease (HR, 2.21; 95% CI, 1.72–2.47), tumor size >40 mm (HR, 2.09 95% CI, 1.73–2.54), older age (HR, 2.71; 95% CI, 2.22–3.31),  distant metastases (HR, 3.47; 95% CI, 2.78–4.32), rural residence (HR, 1.28; 95% CI, 1.10–1.50), and low household income (HR, 1.17; 95% CI, 1.04–1.33), and NH Black race (HR, 1.57; 95% CI, 1.33–1.88). The random survival forest (RSF) model demonstrated good discrimination (C-index, 0.715), comparable to the Cox model (C-index, 0.759). SHAP feature importance analysis identified overall stage, metastasis, nodal involvement, household income, rurality, and race/ethnicity as the most influential predictors of survival.</p>\n\n<p><strong>Conclusions:</strong> In this large, population-based study of squamous cell carcinoma of the tonsil, nearly half of the patients presented with advanced disease, and socioeconomic disadvantage was strongly associated with poorer survival. Machine learning analysis identified metastasis, disease stage, nodal involvement, and social factors as key predictors, suggesting that integrating clinical and social context into prognostic models may guide targeted early detection and precision survivorship strategies to reduce disparities.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153631--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S505",
      "content_id": "153746",
      "abstract_number": "S505",
      "poster_number": "",
      "title": "Impact of relationship status on stage of presentation in oropharyngeal cancer: An analysis of over 5,000 patients in South Carolina",
      "summary": "Relationship status had a significant impact on stage of cancer presentation and this notion although highlighted in previous cancer literature has yet to be examined in OPSCC. In this large statewide cohort over the past two decades in patients presenting with OPSCC, partnered patients were significantly more likely to present with early stage disease and less likely to present with distant metastases compared...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153746",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Thomas Hendriks, MBBS, MPhil, FRACS",
      "presenter": "Thomas Hendriks, MBBS, MPhil, FRACS",
      "authors": "Thomas Hendriks, MBBS, MPhil, FRACS ; Brian Reisenberg; Usman Khan; Terry Day; David Neskey; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich; Shimrit Sharav",
      "normalized_authors": [
        "Thomas Hendriks, MBBS, MPhil, FRACS",
        "Brian Reisenberg",
        "Usman Khan",
        "Terry Day",
        "David Neskey",
        "Eric Lentsch",
        "Jeffrey Houlton",
        "Joshua Hornig",
        "Peter Horwich",
        "Shimrit Sharav"
      ],
      "affiliations": [
        "Sarah Cannon Cancer Institute, Charleston, SC, United States"
      ],
      "normalized_institutions": [
        "Sarah Cannon Cancer Institute, Charleston, SC, United States"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Thomas Hendriks, MBBS, MPhil, FRACS ; Brian Reisenberg; Usman Khan; Terry Day; David Neskey; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich; Shimrit Sharav",
        "Affiliations": "Sarah Cannon Cancer Institute, Charleston, SC, United States",
        "Introduction": "The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen significantly over the past few decades, with early detection significantly impacting treatment morbidity and overall survival. Social determinants of health such as relationship status are associated with access to health care, cancer screening and survival in several malignancies, however, the impact on stage at presentation in OPSCC remains poorly defined.",
        "Methods": "We sought to describe the impact of relationship status on the stage of presentation in patients diagnosed with OPSCC between 1996 and 2023. A retrospective analysis of over 5,000 patients utilising a statewide cancer registry in South Carolina was conducted. Relationship status was defined as partnered (married, or unmarried but in a stable relationship) or non-partnered (single, divorced, widowed, or separated). Stage at presentation was categorized into local disease, regional disease, and distant metastatic disease as per the surveillance, epidemiology, and end results (SEER) summary stage categorization. Comparative analyses assessed differences in stage of presentation distributions and baseline demographic data between these two groups.",
        "Results": "5480 patients were identified as being diagnosed with OPSCC during the study period, with 746 having unknown relationship status, leaving 4734 patients for inclusion and analysis. There was a male predominance (82%) and the median age at diagnosis overall was 60.7 years. Just over half (n=2822, 59.6%) the patients were partnered and 1912 (40.4%) patients non-partnered. Statistical significance was seen in partnered patients vs. non-partnered patients with regards to race (predominately white population), geographic location (urban regions as opposed to rural regions) and insurance status (private insurance). Partnered individuals presented significantly more often with early (local) disease compared with non-partnered individuals (31.3% vs. 26.8%, p<0.001). Conversely, partnered patients were substantially less likely to present with distant metastases (10.8% vs. 15.5%, p<0.001). On further binary logistic regression model analyses, non-partnered status (OR=1.84, p<0.001) was an independent predictor of presenting with distant metastases after adjusting for all other factors.",
        "Conclusions": "Relationship status had a significant impact on stage of cancer presentation and this notion although highlighted in previous cancer literature has yet to be examined in OPSCC. In this large statewide cohort over the past two decades in patients presenting with OPSCC, partnered patients were significantly more likely to present with early stage disease and less likely to present with distant metastases compared with non-partnered patients. Possible explanations for this may relate to higher socioeconomic status and include heightened social support, close symptom monitoring, psychosocial factors and improved access to healthcare (relating to both insurance and financial situation), all of which influence cancer detection. Cancer diagnosis at an earlier stage has significant impacts regarding treatment options, morbidity and ultimately overall survival therefore targeted interventions for at-risk populations such as non-partnered individuals may improve outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of relationship status on stage of presentation in oropharyngeal cancer: An analysis of over 5,000 patients in South Carolina</span>. <u>Thomas Hendriks, MBBS, MPhil, FRACS</u>; Brian Reisenberg; Usman Khan; Terry Day; David Neskey; Eric Lentsch; Jeffrey Houlton; Joshua Hornig; Peter Horwich; Shimrit Sharav. Sarah Cannon Cancer Institute, Charleston, SC, United States<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen significantly over the past few decades, with early detection significantly impacting treatment morbidity and overall survival. Social determinants of health such as relationship status are associated with access to health care, cancer screening and survival in several malignancies, however, the impact on stage at presentation in OPSCC remains poorly defined. </p>\n\n<p><strong>Methods: </strong>We sought to describe the impact of relationship status on the stage of presentation in patients diagnosed with OPSCC between 1996 and 2023. A retrospective analysis of over 5,000 patients utilising a statewide cancer registry in South Carolina was conducted. Relationship status was defined as partnered (married, or unmarried but in a stable relationship) or non-partnered (single, divorced, widowed, or separated). Stage at presentation was categorized into local disease, regional disease, and distant metastatic disease as per the surveillance, epidemiology, and end results (SEER) summary stage categorization. Comparative analyses assessed differences in stage of presentation distributions and baseline demographic data between these two groups.</p>\n\n<p><strong>Results: </strong>5480 patients were identified as being diagnosed with OPSCC during the study period, with 746 having unknown relationship status, leaving 4734 patients for inclusion and analysis. There was a male predominance (82%) and the median age at diagnosis overall was 60.7 years. Just over half (n=2822, 59.6%) the patients were partnered and 1912 (40.4%) patients non-partnered. Statistical significance was seen in partnered patients vs. non-partnered patients with regards to race (predominately white population), geographic location (urban regions as opposed to rural regions) and insurance status (private insurance). Partnered individuals presented significantly more often with early (local) disease compared with non-partnered individuals (31.3% vs. 26.8%, p<0.001). Conversely, partnered patients were substantially less likely to present with distant metastases (10.8% vs. 15.5%, p<0.001). On further binary logistic regression model analyses, non-partnered status (OR=1.84, p<0.001) was an independent predictor of presenting with distant metastases after adjusting for all other factors.</p>\n\n<p><strong>Conclusions: </strong>Relationship status had a significant impact on stage of cancer presentation and this notion although highlighted in previous cancer literature has yet to be examined in OPSCC. In this large statewide cohort over the past two decades in patients presenting with OPSCC, partnered patients were significantly more likely to present with early stage disease and less likely to present with distant metastases compared with non-partnered patients. Possible explanations for this may relate to higher socioeconomic status and include heightened social support, close symptom monitoring, psychosocial factors and improved access to healthcare (relating to both insurance and financial situation), all of which influence cancer detection. Cancer diagnosis at an earlier stage has significant impacts regarding treatment options, morbidity and ultimately overall survival therefore targeted interventions for at-risk populations such as non-partnered individuals may improve outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153746--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S506",
      "content_id": "152637",
      "abstract_number": "S506",
      "poster_number": "",
      "title": "Geographic and Socioeconomic Disparities in Access to Thyroid Cancer Clinical Trials Across the United States",
      "summary": "Access to thyroid cancer clinical trials in the US is strongly influenced by socioeconomic deprivation. Communities in the most-disadvantaged areas must travel nearly twice as fa r to reach a trial site and are two-thirds less likely to live within 60 miles of one. These findings demonstrate structural inequities in the national trial landscape and highlight the need for approaches to improve trial accessibility...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152637",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jacob W Rosenthal, BA",
      "presenter": "Jacob W Rosenthal, BA",
      "authors": "David Z Allen, MD; Jacob W Rosenthal, BA ; Meredith Lilly, MD; Merry Sebelik, MD, FACS, MAMSE",
      "normalized_authors": [
        "David Z Allen",
        "Jacob W Rosenthal",
        "Meredith Lilly",
        "Merry Sebelik, MAMSE"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152637/ahnsfig.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152637/ahnsfig.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152637"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 526,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD; Jacob W Rosenthal, BA ; Meredith Lilly, MD; Merry Sebelik, MD, FACS, MAMSE",
        "Affiliations": "Emory University",
        "Background": "Widespread access to cancer clinical trials is of paramount importance to not only improve oncologic outcomes but also for dissemination of treatment. However, the geographic distribution of thyroid cancer trials in the United States has never been studied. Because socioeconomic deprivation may influence the proximity of trial sites, understanding how the Area Deprivation Index (ADI) and other community factors are associated with thyroid cancer trial access is important for identifying barriers to trial participation.",
        "Methods": "All U.S.-based trials containing the term “thyroid cancer” on ClinicalTrials.gov through 2023 were extracted, yielding 390 unique domestic recruitment sites after geocoding by ZIP code. These locations were linked to 2023 U.S. Census Block Group–level ADI and 2019–2023 American Community Survey indicators, including median household income, racial and ethnic composition, and educational attainment. For approximately 237,000 continental U.S. block groups, distance to the nearest trial site was computed in miles. Accessibility was defined as residing within 60 miles of a study site. Multivariable linear regression models estimated associations between community characteristics and distance to the nearest site, while logistic regression assessed factors associated with accessibility. Model performance was evaluated using receiver-operating-characteristic (ROC) curves.",
        "Results": "Significant geographic disparities in thyroid cancer clinical trial availability were observed. The median distance to the nearest trial site was 189 miles (IQR: 90 - 330 miles) and only 17% of all block groups located within 60 miles of a site. Socioeconomic deprivation demonstrated a strong relationship with geographic access. Communities in the least-deprived ADI quintile had a mean distance of 126 miles compared with 203 miles in the most-deprived quintile ( p < 0.05). The share of communities within 60 miles of a trial site decreased from 40.6% in the least-deprived areas to just 8.2% in the most-deprived ( p < 0.05). In adjusted models, each one-standard-deviation increase in ADI corresponded to a 24.5-mile increase in distance to the nearest site (95% CI 23.4–25.7; p < 0.001) and a 67% reduction in the odds of residing within 60 miles (OR 0.33; 95% CI 0.32–0.33; p < 0.001). Higher median household income modestly improved access (OR 0.78; p < 0.001), whereas locations with larger proportions of Black residents exhibited significantly lower access (OR 0.90; p < 0.001), independent of deprivation. In contrast, higher proportions of Hispanic residents were associated with increased access (OR 1.31; p < 0.001), likely reflecting grouping of trial sites in Florida, Texas, and the Southwest. In an adjusted multivariate model including ADI, income, race/ethnicity, and education, all these factors collectively demonstrated good predictive accuracy for trial access within 60 miles, with an AUC of 0.738 (95% CI 0.735–0.741).",
        "Conclusions": "Access to thyroid cancer clinical trials in the US is strongly influenced by socioeconomic deprivation. Communities in the most-disadvantaged areas must travel nearly twice as fa r to reach a trial site and are two-thirds less likely to live within 60 miles of one. These findings demonstrate structural inequities in the national trial landscape and highlight the need for approaches to improve trial accessibility for marginalized populations.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Geographic and Socioeconomic Disparities in Access to Thyroid Cancer Clinical Trials Across the United States</span>. David Z Allen, MD; <u>Jacob W Rosenthal, BA</u>; Meredith Lilly, MD; Merry Sebelik, MD, FACS, MAMSE. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Widespread access to cancer clinical trials is of paramount importance to not only improve oncologic outcomes but also for dissemination of treatment. However, the geographic distribution of thyroid cancer trials in the United States has never been studied. Because socioeconomic deprivation may influence the proximity of trial sites, understanding how the Area Deprivation Index (ADI) and other community factors are associated with thyroid cancer trial access is important for identifying barriers to trial participation.</p>\n\n<p><strong>Methods: </strong>All U.S.-based trials containing the term “thyroid cancer” on ClinicalTrials.gov through 2023 were extracted, yielding 390 unique domestic recruitment sites after geocoding by ZIP code. These locations were linked to 2023 U.S. Census Block Group–level ADI and 2019–2023 American Community Survey indicators, including median household income, racial and ethnic composition, and educational attainment. For approximately 237,000 continental U.S. block groups, distance to the nearest trial site was computed in miles. Accessibility was defined as residing within 60 miles of a study site. Multivariable linear regression models estimated associations between community characteristics and distance to the nearest site, while logistic regression assessed factors associated with accessibility. Model performance was evaluated using receiver-operating-characteristic (ROC) curves.</p>\n\n<p><strong>Results: </strong>Significant geographic disparities in thyroid cancer clinical trial availability were observed. The median distance to the nearest trial site was 189 miles (IQR: 90 - 330 miles) and only 17% of all block groups located within 60 miles of a site. Socioeconomic deprivation demonstrated a strong relationship with geographic access. Communities in the least-deprived ADI quintile had a mean distance of 126 miles compared with 203 miles in the most-deprived quintile (<em>p</em> < 0.05). The share of communities within 60 miles of a trial site decreased from 40.6% in the least-deprived areas to just 8.2% in the most-deprived (<em>p</em> < 0.05). In adjusted models, each one-standard-deviation increase in ADI corresponded to a 24.5-mile increase in distance to the nearest site (95% CI 23.4–25.7; <em>p</em> < 0.001) and a 67% reduction in the odds of residing within 60 miles (OR 0.33; 95% CI 0.32–0.33; <em>p</em> < 0.001). Higher median household income modestly improved access (OR 0.78; <em>p</em> < 0.001), whereas locations with larger proportions of Black residents exhibited significantly lower access (OR 0.90; <em>p</em> < 0.001), independent of deprivation. In contrast, higher proportions of Hispanic residents were associated with increased access (OR 1.31; <em>p</em> < 0.001), likely reflecting grouping of trial sites in Florida, Texas, and the Southwest. In an adjusted multivariate model including ADI, income, race/ethnicity, and education, all these factors collectively demonstrated good predictive accuracy for trial access within 60 miles, with an AUC of 0.738 (95% CI 0.735–0.741).</p>\n\n<p><strong>Conclusions: </strong>Access to thyroid cancer clinical trials in the US is strongly influenced by socioeconomic deprivation. Communities in the most-disadvantaged areas must travel nearly twice as fa r to reach a trial site and are two-thirds less likely to live within 60 miles of one. These findings demonstrate structural inequities in the national trial landscape and highlight the need for approaches to improve trial accessibility for marginalized populations.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152637/ahnsfig.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152637--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S507",
      "content_id": "153168",
      "abstract_number": "S507",
      "poster_number": "",
      "title": "Quantifying the impact of neighborhood socioeconomic status on disparities in thyroid cancer survival",
      "summary": "When nSES-related disparities in DTC features at presentation are alleviated, 10-year all-cause and thyroid cancer-specific mortality risks are significantly reduced for those in the lowest nSES. These findings illuminate the impact of neighborhood-level social determinants of health on survival among patients with DTC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153168",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nazineen Kandahari, MD, MS",
      "presenter": "Nazineen Kandahari, MD, MS",
      "authors": "Nazineen Kandahari, MD, MS 1 ; Mindy C DeRouen, PhD, MPH 2 ; Serge Atherwood, PhD 3 ; Stephen Li, MPH 3 ; Trevor G Hackman, MD, FACS 1 ; Catherine A Colaianni, MD, MPhil 1 ; Gregory W Randolph, FACS, FACE 4 ; Marika D Russell, MD, FACS 4",
      "normalized_authors": [
        "Nazineen Kandahari",
        "Mindy C DeRouen",
        "Serge Atherwood",
        "Stephen Li",
        "Trevor G Hackman",
        "Catherine A Colaianni, MPhil",
        "Gregory W Randolph, FACE",
        "Marika D Russell"
      ],
      "affiliations": [
        "Department of Otolaryngology, University of North Carolina-Chapel Hill",
        "Department of Public Health Sciences, New Mexico State University",
        "Department of Epidemiology and Biostatistics, University of California, San Francisco",
        "Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology, University of North Carolina-Chapel Hill",
        "Department of Public Health Sciences, New Mexico State University",
        "Department of Epidemiology and Biostatistics, University of California, San Francisco",
        "Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153168/abstract%20table%20-%20final.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153168/abstract%20table%20-%20final.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153168"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 482,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nazineen Kandahari, MD, MS 1 ; Mindy C DeRouen, PhD, MPH 2 ; Serge Atherwood, PhD 3 ; Stephen Li, MPH 3 ; Trevor G Hackman, MD, FACS 1 ; Catherine A Colaianni, MD, MPhil 1 ; Gregory W Randolph, FACS, FACE 4 ; Marika D Russell, MD, FACS 4",
        "Affiliations": "1 Department of Otolaryngology, University of North Carolina-Chapel Hill; 2 Department of Public Health Sciences, New Mexico State University; 3 Department of Epidemiology and Biostatistics, University of California, San Francisco; 4 Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary",
        "Background": "Significant socioeconomic disparities have been demonstrated in the presentation, treatment, and survival of differentiated thyroid cancer (DTC). Neighborhood socioeconomic status (nSES) is a less explored but increasingly recognized contributor to these disparities, with recent studies showing that neighborhood disadvantage is an independent predictor of advanced tumor stage, presence of an aggressive histopathologic variant, and worse cancer-related survival.",
        "Objective": "To explore how nSES-related disparities in DTC survival would be affected by alleviating nSES-related disparities in DTC features at presentation.",
        "Methods": "We conducted a population-based study of adults diagnosed with DTC from 1988 to 2012 with data from the California Cancer Registry. Neighborhood SES is an established index that incorporates U.S. Census and American Community Survey data on education, occupation, employment, household income, poverty, rent, and house values. Each patient’s census tract was assigned to a nSES quintile based on the statewide distribution of index values, with the first quintile (Q1) corresponding to the lowest nSES and the highest quintile (Q5) to the highest nSES. We used multivariable logistic regression to examine the odds of late-stage disease at presentation according to nSES, with Q5 as the referent. In addition, we estimated the 10-year predicted probability of death per nSES quintile for death due to any cause and for thyroid cancer-specific death. Finally, we estimated changes to the 10-year predicted probability of death under the counterfactual scenario where each quintile’s distribution of DTC stage is the same as observed among the highest SES neighborhoods.",
        "Results": "Of 51,367 individuals diagnosed with DTC, 78% were female, 90% had papillary histology, and 65% were diagnosed with localized stage disease. More thyroid cancers were diagnosed among residents of higher SES neighborhoods (26% Q5 vs. 13% Q1). In multivariable models, the odds of presenting with distant metastases increased with decreasing nSES (OR Q1 vs. Q5=1.33; 95% CI=1.17, 1.50). The observed 10-year all-cause mortality risk was 10.4% in Q1, 9.53% in Q2, 9.40% in Q3, 8.95% in Q4, and 8.85% in Q5 (reference). Under the counterfactual scenario whereby Q1 had the same distribution of disease presentation as Q5, the 10-year overall mortality risk for Q1 was 8.81% (95% CI=8.44, 9.26), a reduction in 10-year mortality risk of 15.3%. Observed 10-year thyroid-cancer specific mortality risk was 3.07% (95% CI=2.82, 3.37) for Q1 and 2.00% (95% CI=1.92, 4.22) for Q5; under the counterfactual scenario whereby Q1 had the same distribution of disease presentation as Q5, the risk fell by one-third to 2.05% (95% CI=1.86, 2.25).",
        "Conclusion": "When nSES-related disparities in DTC features at presentation are alleviated, 10-year all-cause and thyroid cancer-specific mortality risks are significantly reduced for those in the lowest nSES. These findings illuminate the impact of neighborhood-level social determinants of health on survival among patients with DTC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Quantifying the impact of neighborhood socioeconomic status on disparities in thyroid cancer survival</span>. <u>Nazineen Kandahari, MD, MS</u><sup>1</sup>; Mindy C DeRouen, PhD, MPH<sup>2</sup>; Serge Atherwood, PhD<sup>3</sup>; Stephen Li, MPH<sup>3</sup>; Trevor G Hackman, MD, FACS<sup>1</sup>; Catherine A Colaianni, MD, MPhil<sup>1</sup>; Gregory W Randolph, FACS, FACE<sup>4</sup>; Marika D Russell, MD, FACS<sup>4</sup>. <sup>1</sup>Department of Otolaryngology, University of North Carolina-Chapel Hill; <sup>2</sup>Department of Public Health Sciences, New Mexico State University; <sup>3</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco; <sup>4</sup>Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Significant socioeconomic disparities have been demonstrated in the presentation, treatment, and survival of differentiated thyroid cancer (DTC). Neighborhood socioeconomic status (nSES) is a less explored but increasingly recognized contributor to these disparities, with recent studies showing that neighborhood disadvantage is an independent predictor of advanced tumor stage, presence of an aggressive histopathologic variant, and worse cancer-related survival.</p>\n\n<p><strong>Objective</strong>: To explore how nSES-related disparities in DTC survival would be affected by alleviating nSES-related disparities in DTC features at presentation.  </p>\n\n<p><strong>Methods</strong>: We conducted a population-based study of adults diagnosed with DTC from 1988 to 2012 with data from the California Cancer Registry. Neighborhood SES is an established index that incorporates U.S. Census and American Community Survey data on education, occupation, employment, household income, poverty, rent, and house values. Each patient’s census tract was assigned to a nSES quintile based on the statewide distribution of index values, with the first quintile (Q1) corresponding to the lowest nSES and the highest quintile (Q5) to the highest nSES. We used multivariable logistic regression to examine the odds of late-stage disease at presentation according to nSES, with Q5 as the referent. In addition, we estimated the 10-year predicted probability of death per nSES quintile for death due to any cause and for thyroid cancer-specific death. Finally, we estimated changes to the 10-year predicted probability of death under the counterfactual scenario where each quintile’s distribution of DTC stage is the same as observed among the highest SES neighborhoods. </p>\n\n<p><strong>Results</strong>: Of 51,367 individuals diagnosed with DTC, 78% were female, 90% had papillary histology, and 65% were diagnosed with localized stage disease. More thyroid cancers were diagnosed among residents of higher SES neighborhoods (26% Q5 vs. 13% Q1). In multivariable models, the odds of presenting with distant metastases increased with decreasing nSES (OR Q1 vs. Q5=1.33; 95% CI=1.17, 1.50). The observed 10-year all-cause mortality risk was 10.4% in Q1, 9.53% in Q2, 9.40% in Q3, 8.95% in Q4, and 8.85% in Q5 (reference). Under the counterfactual scenario whereby Q1 had the same distribution of disease presentation as Q5, the 10-year overall mortality risk for Q1 was 8.81% (95% CI=8.44, 9.26), a reduction in 10-year mortality risk of 15.3%. Observed 10-year thyroid-cancer specific mortality risk was 3.07% (95% CI=2.82, 3.37) for Q1 and 2.00% (95% CI=1.92, 4.22) for Q5; under the counterfactual scenario whereby Q1 had the same distribution of disease presentation as Q5, the risk fell by one-third to 2.05% (95% CI=1.86, 2.25). </p>\n\n<p><strong>Conclusion</strong>: When nSES-related disparities in DTC features at presentation are alleviated, 10-year all-cause and thyroid cancer-specific mortality risks are significantly reduced for those in the lowest nSES. These findings illuminate the impact of neighborhood-level social determinants of health on survival among patients with DTC. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153168/abstract%20table%20-%20final.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153168--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S508",
      "content_id": "153971",
      "abstract_number": "S508",
      "poster_number": "",
      "title": "Geographic Disparities in Head and Neck Cancer Clinical Trial Availability in the United States",
      "summary": "Significantly more trial sites exist in higher-SVI areas compared to lower-SVI areas. This reflects a greater presence of medical centers in urban areas which generally still have substantially underserved populations. However, despite proximity of clinical trial centers, additional social and structural barriers such as lack of insurance may hinder entry into these healthcare systems. The clinical trial sites...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153971",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sana Khan",
      "presenter": "Sana Khan",
      "authors": "Sana Khan 1 ; Muhammad Khan 2 ; Ebrahim Chaudhry 3 ; Andrew Day 1 ; Zainab Farzal, Dr 1",
      "normalized_authors": [
        "Sana Khan",
        "Muhammad Khan",
        "Ebrahim Chaudhry",
        "Andrew Day",
        "Zainab Farzal, Dr"
      ],
      "affiliations": [
        "University of Texas Southwestern Medical Center",
        "UT Heath San Antonio",
        "Southern Methodist University"
      ],
      "normalized_institutions": [
        "University of Texas Southwestern Medical Center",
        "UT Heath San Antonio",
        "Southern Methodist University"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sana Khan 1 ; Muhammad Khan 2 ; Ebrahim Chaudhry 3 ; Andrew Day 1 ; Zainab Farzal, Dr 1",
        "Affiliations": "1 University of Texas Southwestern Medical Center; 2 UT Heath San Antonio; 3 Southern Methodist University",
        "Introduction": "To achieve equitable access to cancer clinical trials, patients must overcome structural barriers to trial enrollment, including greater geographical distance to clinic site and mobility limitations. Socially vulnerable groups have lower participation in cancer clinical trials due to structural and social barriers, but little is known specifically about head and neck cancer (HNC) trial availability. Identifying communities deprived of HNC trial access is critical for guiding the equitable expansion of trial centers and developing targeted interventions to reduce these barriers. This study aims to determine whether significant differences exist in the availability of HNC clinical trials across areas with varying levels of social vulnerability, as measured by the Centers for Disease Control and Prevention (CDC) Social Vulnerability Index (SVI).",
        "Methods": "We conducted a retrospective analysis of HNC clinical trials registered on ClinicalTrials.gov between 1995 and 2025. The initial dataset included global trials, with site locations reported as site name, city, state, and ZIP code. For multi-site trials, site-specific data in the United States were analyzed. SVI scores and their subthemes were obtained from the CDC at the ZIP Code Tabulation Area (ZCTA) level for 2022, the most recent year with available data. ZIP codes from each trial site were matched to their corresponding ZCTAs using a crosswalk provided by the U.S. Department of Housing and Urban Development. These ZCTAs were then used to assign SVI values ranging from 0.0 (least vulnerable) to 1.0 (most vulnerable) and categorized into CDC-recommended quartiles: low (0.0–0.2500), low-medium (0.2501–0.5000), medium-high (0.5001–0.7500), and high (0.7501–1.0). Sites were designated as non-urban or urban per the 2020 census provided by the U.S. Census Bureau designation.",
        "Results": "A total of 267 HNC clinical trials met inclusion criteria, comprising 5,051 trial sites across the United States. Of these, 2003 sites (39.7%) were located in high social vulnerability areas, 1,806 (35.8%) in medium-high vulnerability areas, 1,139 (22.5%) in low-medium vulnerability areas, and 103 (2.0%) in low vulnerability areas(p<0.001). Clinical trial sites had a greater distribution in higher-SVI (SVI: 0.5-1.0) compared to lower-SVI (SVI <0.5) areas (p < 0.0001). Trial sites in urban areas (3484, 69.0%) catered to significantly more vulnerable populations compared to those in non-urban areas (1568, 31.0%, p< 0.001). The highest observed SVI was 0.9999 (0.02% trials), found in San Antonio, Texas. The lowest observed SVI was 0.0032 (0.04% trials), found in Danville, Pennsylvania.",
        "Conclusion": "Significantly more trial sites exist in higher-SVI areas compared to lower-SVI areas. This reflects a greater presence of medical centers in urban areas which generally still have substantially underserved populations. However, despite proximity of clinical trial centers, additional social and structural barriers such as lack of insurance may hinder entry into these healthcare systems. The clinical trial sites were disproportionately concentrated in urban areas which reinforces the disparity in the lack of availability of clinical sites in suburban and rural areas. Further analysis is needed based on SVI subthemes and neighborhood level data.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Geographic Disparities in Head and Neck Cancer Clinical Trial Availability in the United States</span>. <u>Sana Khan</u><sup>1</sup>; Muhammad Khan<sup>2</sup>; Ebrahim Chaudhry<sup>3</sup>; Andrew Day<sup>1</sup>; Zainab Farzal, Dr<sup>1</sup>. <sup>1</sup>University of Texas Southwestern Medical Center; <sup>2</sup>UT Heath San Antonio; <sup>3</sup>Southern Methodist University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>To achieve equitable access to cancer clinical trials, patients must overcome structural barriers to trial enrollment, including greater geographical distance to clinic site and mobility limitations. Socially vulnerable groups have lower participation in cancer clinical trials due to structural and social barriers, but little is known specifically about head and neck cancer (HNC) trial availability. Identifying communities deprived of HNC trial access is critical for guiding the equitable expansion of trial centers and developing targeted interventions to reduce these barriers. This study aims to determine whether significant differences exist in the availability of HNC clinical trials across areas with varying levels of social vulnerability, as measured by the Centers for Disease Control and Prevention (CDC) Social Vulnerability Index (SVI). </p>\n\n<p><strong>Methods:</strong> We conducted a retrospective analysis of HNC clinical trials registered on ClinicalTrials.gov between 1995 and 2025. The initial dataset included global trials, with site locations reported as site name, city, state, and ZIP code. For multi-site trials, site-specific data in the United States were analyzed. SVI scores and their subthemes were obtained from the CDC at the ZIP Code Tabulation Area (ZCTA) level for 2022, the most recent year with available data. ZIP codes from each trial site were matched to their corresponding ZCTAs using a crosswalk provided by the U.S. Department of Housing and Urban Development. These ZCTAs were then used to assign SVI values ranging from 0.0 (least vulnerable) to 1.0 (most vulnerable) and categorized into CDC-recommended quartiles: low (0.0–0.2500), low-medium (0.2501–0.5000), medium-high (0.5001–0.7500), and high (0.7501–1.0). Sites were designated as non-urban or urban per the 2020 census provided by the U.S. Census Bureau designation.</p>\n\n<p><strong>Results: </strong>A total of 267 HNC clinical trials met inclusion criteria, comprising 5,051 trial sites across the United States. Of these, 2003 sites (39.7%) were located in high social vulnerability areas, 1,806 (35.8%) in medium-high vulnerability areas, 1,139 (22.5%) in low-medium vulnerability areas, and 103 (2.0%) in low vulnerability areas(p<0.001). Clinical trial sites had a greater distribution in higher-SVI (SVI: 0.5-1.0) compared to lower-SVI (SVI <0.5) areas (p < 0.0001). Trial sites in urban areas (3484, 69.0%) catered to significantly more vulnerable populations compared to those in non-urban areas (1568, 31.0%, p< 0.001). The highest observed SVI was 0.9999 (0.02% trials), found in San Antonio, Texas. The lowest observed SVI was 0.0032 (0.04% trials), found in Danville, Pennsylvania.</p>\n\n<p><strong>Conclusion: </strong>Significantly more trial sites exist in higher-SVI areas compared to lower-SVI areas. This reflects a greater presence of medical centers in urban areas which generally still have substantially underserved populations. However, despite proximity of clinical trial centers, additional social and structural barriers such as lack of insurance may hinder entry into these healthcare systems. The clinical trial sites were disproportionately concentrated in urban areas which reinforces the disparity in the lack of availability of clinical sites in suburban and rural areas. Further analysis is needed based on SVI subthemes and neighborhood level data.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153971--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S509",
      "content_id": "154529",
      "abstract_number": "S509",
      "poster_number": "",
      "title": "Diagnostic and Treatment Delays in Head and Neck Cancer Care Pathways, and Barriers to Healthcare access, in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis",
      "summary": "This review is the first to generate pooled estimates of patient, professional, diagnostic, and treatment delays in HNC within LMICs. Patients in these settings experience substantial delays across the care pathway, largely driven by socioeconomic barriers and health-system limitations. Targeted investments in early detection, streamlined referral pathways, and expanded diagnostic and treatment capacity are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154529",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Syeda Maria Ahmad Zaidi, MD",
      "presenter": "Syeda Maria Ahmad Zaidi, MD",
      "authors": "Hania Fatima 1 ; Syeda Maria Ahmad Zaidi, MD 2 ; Taha Shaikh 1 ; Umaymah Uzair 1 ; Manaal Tariq 1 ; Muhammad Ahmed 3 ; Hamna Bilal 1 ; Hamdan Ahmed Pasha, MD 4 ; Ryan H",
      "normalized_authors": [
        "Hania Fatima",
        "Syeda Maria Ahmad Zaidi",
        "Taha Shaikh",
        "Umaymah Uzair",
        "Manaal Tariq",
        "Muhammad Ahmed",
        "Hamna Bilal",
        "Hamdan Ahmed Pasha",
        "Ryan H"
      ],
      "affiliations": [
        "Belcher, MD, MPH 2 . 1 Aga Khan University",
        "Vanderbilt University Medical Center",
        "Dow Medical College",
        "Aga Khan University Hospital"
      ],
      "normalized_institutions": [
        "Belcher, MD, MPH 2 . 1 Aga Khan University",
        "Vanderbilt University Medical Center",
        "Dow Medical College",
        "Aga Khan University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Survivorship",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Survivorship"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154529/Layout%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/154529/Layout%201.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154529"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 504,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hania Fatima 1 ; Syeda Maria Ahmad Zaidi, MD 2 ; Taha Shaikh 1 ; Umaymah Uzair 1 ; Manaal Tariq 1 ; Muhammad Ahmed 3 ; Hamna Bilal 1 ; Hamdan Ahmed Pasha, MD 4 ; Ryan H",
        "Affiliations": "Belcher, MD, MPH 2 . 1 Aga Khan University; 2 Vanderbilt University Medical Center; 3 Dow Medical College; 4 Aga Khan University Hospital",
        "Introduction": "Head and neck cancers cancer (HNC) is the 7 th most common solid malignancy worldwide, with a disproportionately high burden in low- and lower-middle-income countries (LMICs), due to late-stage presentation of diease. Delays across the care pathway, including patient, professional, diagnostic, and treatment intervals contribute substantially to disease dissemenation and poorer prognosis.",
        "Objective": "To pool delay intervals in HNC and to synthesize associated key patient and system level barriers.",
        "Methods": "A systematic review was conducted according to PRISMA 2020 guidelines. Searches were performed across PubMed/MEDLINE, Scopus, Embase (Ovid), CINAHL, Web of Science and Cochrane Library for studies up till October 2025. Two independent reviewers screened 429 records. Data analysis and descriptive statistics were conducted using R version 4.2.2. Risk of bias was assessed using Newcastle-Ottawa Scale (NOS).",
        "Results": "30 studies comprising over 14,862 patients met the inclusion criteria. Reported mean ages ranged from 44 to 62 years, with majority in the 4 th and 6 th decades of life. There was a consistent male predominance (79.9%) across cohorts. The highest proportion of studies originated from India (43.3%), followed by Pakistan (16.7%), Indonesia (13.3%), Nigeria (10%) and Iran (6.7%). Addiotnally, single studies from the Philippines, Tanzania, Uganda, and Senegal (Dakar), each accounted for 3.3% of the total. The vast majority reported biopsy-confirmed diagnoses (92-100%). Notably, oral cavity neoplasms accounted for 45–70% of cases across studies, with buccal mucosa and tongue/floor of mouth as predominant subsites. Oropharyngeal tumors were reported in ~10–30% of cases, laryngeal and hypopharyngeal cancers in 15–35%, while nasopharyngeal, thyroid, salivary gland, and sinonasal tumors were less frequent (<10% each). Overall, 73% (range 60–85%) of cases were stage III–IV. Across studies, substantial heterogeneity was observed across all delay intervals. The pooled mean patient delay was 211.9 days (95% CI: 54.4–369.4; I² = 98.2%; p < 0.0001), the pooled professional delay was 85.7 days (95% CI: 23.3–148.2; I² = 98.8%; p < 0.0001), the pooled diagnostic delay was 152.4 days (95% CI: 30.6–274.3; I² = 98.5%; p < 0.0001), and the pooled treatment delay was 171.6 days (95% CI: –78.2–421.3; I² = 98.3%; p < 0.0001). Total delay showed the greatest variability, with reported medians ranging from 36 to 360 days and ranges spanning 23 to 940 days. Prolonged delays were linked to socioeconomic barriers (low education, rural residence, financial and insurance constraints), limited symptom awareness, and misdiagnosis in primary care. System-level factors, particularly long clinic waiting times (15-52%) and poor geographic accessibility, also contributed considerably.",
        "Conclusion": "This review is the first to generate pooled estimates of patient, professional, diagnostic, and treatment delays in HNC within LMICs. Patients in these settings experience substantial delays across the care pathway, largely driven by socioeconomic barriers and health-system limitations. Targeted investments in early detection, streamlined referral pathways, and expanded diagnostic and treatment capacity are essential to reduce late-stage presentation and improve outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Diagnostic and Treatment Delays in Head and Neck Cancer Care Pathways, and Barriers to Healthcare access, in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis</span>. Hania Fatima<sup>1</sup>; <u>Syeda Maria Ahmad Zaidi, MD</u><sup>2</sup>; Taha Shaikh<sup>1</sup>; Umaymah Uzair<sup>1</sup>; Manaal Tariq<sup>1</sup>; Muhammad Ahmed<sup>3</sup>; Hamna Bilal<sup>1</sup>; Hamdan Ahmed Pasha, MD<sup>4</sup>; Ryan H. Belcher, MD, MPH<sup>2</sup>. <sup>1</sup>Aga Khan University; <sup>2</sup>Vanderbilt University Medical Center; <sup>3</sup>Dow Medical College; <sup>4</sup>Aga Khan University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Head and neck cancers cancer (HNC) is the 7<sup>th</sup> most common solid malignancy worldwide, with a disproportionately high burden in low- and lower-middle-income countries (LMICs), due to late-stage presentation of diease. Delays across the care pathway, including patient, professional, diagnostic, and treatment intervals contribute substantially to disease dissemenation and poorer prognosis. </p>\n\n<p><strong>Objective:</strong> To pool delay intervals in HNC and to synthesize associated key patient and system level barriers.</p>\n\n<p><strong>Methods:</strong> A systematic review was conducted according to PRISMA 2020 guidelines. Searches were performed across PubMed/MEDLINE, Scopus, Embase (Ovid), CINAHL, Web of Science and Cochrane Library for studies up till October 2025. Two independent reviewers screened 429 records. Data analysis and descriptive statistics were conducted using R version 4.2.2. Risk of bias was assessed using Newcastle-Ottawa Scale (NOS). </p>\n\n<p><strong>Results:</strong> 30 studies comprising over 14,862 patients met the inclusion criteria. Reported mean ages ranged from 44 to 62 years, with majority in the 4<sup>th</sup> and 6<sup>th</sup> decades of life. There was a consistent male predominance (79.9%) across cohorts. The highest proportion of studies originated from India (43.3%), followed by Pakistan (16.7%), Indonesia (13.3%), Nigeria (10%) and Iran (6.7%). Addiotnally, single studies from the Philippines, Tanzania, Uganda, and Senegal (Dakar), each accounted for 3.3% of the total. The vast majority reported biopsy-confirmed diagnoses (92-100%). Notably, oral cavity neoplasms accounted for 45–70% of cases across studies, with buccal mucosa and tongue/floor of mouth as predominant subsites. Oropharyngeal tumors were reported in ~10–30% of cases, laryngeal and hypopharyngeal cancers in 15–35%, while nasopharyngeal, thyroid, salivary gland, and sinonasal tumors were less frequent (<10% each). Overall, 73% (range 60–85%) of cases were stage III–IV. Across studies, substantial heterogeneity was observed across all delay intervals. The pooled mean patient delay was 211.9 days (95% CI: 54.4–369.4; I² = 98.2%; p < 0.0001), the pooled professional delay was 85.7 days (95% CI: 23.3–148.2; I² = 98.8%; p < 0.0001), the pooled diagnostic delay was 152.4 days (95% CI: 30.6–274.3; I² = 98.5%; p < 0.0001), and the pooled treatment delay was 171.6 days (95% CI: –78.2–421.3; I² = 98.3%; p < 0.0001). Total delay showed the greatest variability, with reported medians ranging from 36 to 360 days and ranges spanning 23 to 940 days. Prolonged delays were linked to socioeconomic barriers (low education, rural residence, financial and insurance constraints), limited symptom awareness, and misdiagnosis in primary care. System-level factors, particularly long clinic waiting times (15-52%) and poor geographic accessibility, also contributed considerably.</p>\n\n<p><strong>Conclusion:</strong> This review is the first to generate pooled estimates of patient, professional, diagnostic, and treatment delays in HNC within LMICs. Patients in these settings experience substantial delays across the care pathway, largely driven by socioeconomic barriers and health-system limitations. Targeted investments in early detection, streamlined referral pathways, and expanded diagnostic and treatment capacity are essential to reduce late-stage presentation and improve outcomes. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154529/Layout%201.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154529--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S510",
      "content_id": "153574",
      "abstract_number": "S510",
      "poster_number": "",
      "title": "Neighborhood Deprivation Impacts Oncologic Outcomes Among Patients Undergoing Free Flap Reconstructions",
      "summary": "Social disadvantage was significantly associated with increased cancer stage and delays to starting adjuvant therapy but did not impact the likelihood of receiving adjuvant therapy or alter overall survival. These findings highlight the persistent upstream inequities that impact when patients seek care for head and neck cancer. The absence of a difference in adjuvant treatment completion or overall survival...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153574",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Atif M Islam, BS",
      "presenter": "Atif M Islam, BS",
      "authors": "Atif M Islam, BS 1 ; Alec E Dallas, BS 1 ; Robert B Baldwin, BA 1 ; Brandon J Dyer, BS 1 ; Emma Dunn, BS 1 ; Alisa Vidwans, ScM 1 ; Samer T Elsamna, MD 2 ; Tara Mokhtari, MD 2 ; Christopher J Nickel, MD 2 ; Matthew Mifsud, MD 2",
      "normalized_authors": [
        "Atif M Islam",
        "Alec E Dallas",
        "Robert B Baldwin",
        "Brandon J Dyer",
        "Emma Dunn",
        "Alisa Vidwans, ScM",
        "Samer T Elsamna",
        "Tara Mokhtari",
        "Christopher J Nickel",
        "Matthew Mifsud"
      ],
      "affiliations": [
        "USF Health Morsani College of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine"
      ],
      "normalized_institutions": [
        "USF Health Morsani College of Medicine",
        "Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 385,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Atif M Islam, BS 1 ; Alec E Dallas, BS 1 ; Robert B Baldwin, BA 1 ; Brandon J Dyer, BS 1 ; Emma Dunn, BS 1 ; Alisa Vidwans, ScM 1 ; Samer T Elsamna, MD 2 ; Tara Mokhtari, MD 2 ; Christopher J Nickel, MD 2 ; Matthew Mifsud, MD 2",
        "Affiliations": "1 USF Health Morsani College of Medicine; 2 Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine",
        "Introduction": "Social determinants of health are known to be significant factors affecting cancer occurrence, severity, and outcomes. The Area Deprivation Index (ADI) is a validated tool that combines a vast array of social determinants into a single measure of “neighborhood disadvantage”. The connection between this ADI and head and neck cancer outcomes among those undergoing free flap reconstruction has not been well defined. Therefore, we aimed to evaluate whether higher social deprivation, as measured by the ADI, is associated with cancer stage severity, treatment delays, and overall survival.",
        "Methods": "538 patients who underwent a free flap reconstruction from August 2017 through September 2025 were retrospectively reviewed. Primary outcomes included cancer stage severity, overall survival, and days from initial surgical consultation to surgery as well as surgery to the start of adjuvant therapy. Neighborhood socioeconomic disadvantage was evaluated using national percentile and state decile ADI. Spearman correlations, Kruskal-Wallis, Mann-Whitney, and Kaplan-Meier log-rank analyses were performed.",
        "Results": "State ADI demonstrated a significant correlation with stage severity (ρ=0.105, p=0.0428), while national ADI showed a similar but non-significant trend (p=0.0695). ADI was not found to correlate with time from consultation to surgery. However, higher ADI was associated with an increased delay between surgery and the initiation of chemotherapy (National ADI ρ=0.265, p=0.0377; State ADI ρ=0.259, p=0.0422) and radiotherapy (National ADI: ρ=0.200, p=0.0180; State ADI ρ=0.195, p=0.0206). Notably, neighborhood deprivation was not associated with receipt of postoperative adjuvant therapy as rates were comparable across ADI strata. Global Kaplan-Meier log-rank testing demonstrated no significant difference in survival across ADI quartiles (National ADI: p=0.121; State ADI: p=0.278).",
        "Conclusions": "Social disadvantage was significantly associated with increased cancer stage and delays to starting adjuvant therapy but did not impact the likelihood of receiving adjuvant therapy or alter overall survival. These findings highlight the persistent upstream inequities that impact when patients seek care for head and neck cancer. The absence of a difference in adjuvant treatment completion or overall survival suggests robust multidisciplinary care may neutralize these effects and enable equitable oncologic outcomes. These results further underscore the need for proactive interventions that reduce structural barriers in order to promote equal access to high-quality cancer care.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neighborhood Deprivation Impacts Oncologic Outcomes Among Patients Undergoing Free Flap Reconstructions</span>. <u>Atif M Islam, BS</u><sup>1</sup>; Alec E Dallas, BS<sup>1</sup>; Robert B Baldwin, BA<sup>1</sup>; Brandon J Dyer, BS<sup>1</sup>; Emma Dunn, BS<sup>1</sup>; Alisa Vidwans, ScM<sup>1</sup>; Samer T Elsamna, MD<sup>2</sup>; Tara Mokhtari, MD<sup>2</sup>; Christopher J Nickel, MD<sup>2</sup>; Matthew Mifsud, MD<sup>2</sup>. <sup>1</sup>USF Health Morsani College of Medicine; <sup>2</sup>Department of Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Social determinants of health are known to be significant factors affecting cancer occurrence, severity, and outcomes. The Area Deprivation Index (ADI) is a validated tool that combines a vast array of social determinants into a single measure of “neighborhood disadvantage”. The connection between this ADI and head and neck cancer outcomes among those undergoing free flap reconstruction has not been well defined. Therefore, we aimed to evaluate whether higher social deprivation, as measured by the ADI, is associated with cancer stage severity, treatment delays, and overall survival.</p>\n\n<p><strong>Methods:</strong> 538 patients who underwent a free flap reconstruction from August 2017 through September 2025 were retrospectively reviewed. Primary outcomes included cancer stage severity, overall survival, and days from initial surgical consultation to surgery as well as surgery to the start of adjuvant therapy. Neighborhood socioeconomic disadvantage was evaluated using national percentile and state decile ADI. Spearman correlations, Kruskal-Wallis, Mann-Whitney, and Kaplan-Meier log-rank analyses were performed.</p>\n\n<p><strong>Results:</strong> State ADI demonstrated a significant correlation with stage severity (ρ=0.105, p=0.0428), while national ADI showed a similar but non-significant trend (p=0.0695). ADI was not found to correlate with time from consultation to surgery. However, higher ADI was associated with an increased delay between surgery and the initiation of chemotherapy (National ADI ρ=0.265, p=0.0377; State ADI ρ=0.259, p=0.0422) and radiotherapy (National ADI: ρ=0.200, p=0.0180; State ADI ρ=0.195, p=0.0206). Notably, neighborhood deprivation was not associated with receipt of postoperative adjuvant therapy as rates were comparable across ADI strata. Global Kaplan-Meier log-rank testing demonstrated no significant difference in survival across ADI quartiles (National ADI: p=0.121; State ADI: p=0.278).</p>\n\n<p><strong>Conclusions:</strong> Social disadvantage was significantly associated with increased cancer stage and delays to starting adjuvant therapy but did not impact the likelihood of receiving adjuvant therapy or alter overall survival. These findings highlight the persistent upstream inequities that impact when patients seek care for head and neck cancer. The absence of a difference in adjuvant treatment completion or overall survival suggests robust multidisciplinary care may neutralize these effects and enable equitable oncologic outcomes. These results further underscore the need for proactive interventions that reduce structural barriers in order to promote equal access to high-quality cancer care.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153574--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S511",
      "content_id": "153287",
      "abstract_number": "S511",
      "poster_number": "",
      "title": "The Silent Epicenter: Unequal Burden of Head & Neck Cancer Across SAARC Nations",
      "summary": "SAARC nations carry a substantial and unevenly distributed burden of head and neck cancers. Bangladesh showed the highest incidence and mortality rates, whereas Nepal and the Maldives exhibited the lowest mortality rates, and Afghanistan and Nepal the lowest incidence rates. MIR patterns revealed marked survival disparities, with Afghanistan having the highest (0.67) and Sri Lanka, the lowest (0.36). Oral cavity...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153287",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Taral K Jella, BA",
      "presenter": "Taral K Jella, BA",
      "authors": "Taral K Jella, BA 1 ; Jazlyn Selvasingh, BA 1 ; Tara P Menon, BS 1 ; Justin R Shinn, MD 2 ; William P Magdycz, MD 2",
      "normalized_authors": [
        "Taral K Jella",
        "Jazlyn Selvasingh",
        "Tara P Menon",
        "Justin R Shinn",
        "William P Magdycz"
      ],
      "affiliations": [
        "Virginia Tech Carilion School of Medicine",
        "Carilion Clinic Otolaryngology and Audiology"
      ],
      "normalized_institutions": [
        "Virginia Tech Carilion School of Medicine",
        "Carilion Clinic Otolaryngology and Audiology"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Taral K Jella, BA 1 ; Jazlyn Selvasingh, BA 1 ; Tara P Menon, BS 1 ; Justin R Shinn, MD 2 ; William P Magdycz, MD 2",
        "Affiliations": "1 Virginia Tech Carilion School of Medicine; 2 Carilion Clinic Otolaryngology and Audiology",
        "Introduction": "Head and neck cancers (HNC) constitute a disproportionate share of the cancer burden in South Asia. The members of the South Asian Association for Regional Cooperation (SAARC)—Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka—represent nearly one-fourth of the world’s population yet experience some of the world’s highest HNC incidence and mortality. Despite this burden, contemporary region-wide epidemiologic comparisons remain limited. This study provides the first unified GLOBOCAN-based assessment of incidence, mortality, and mortality-to-incidence ratio (MIR) patterns across all eight SAARC nations.",
        "Methods": "GLOBOCAN 2022 (IARC) was used to extract age-standardized incidence rates (ASIR) and mortality rates (ASMR) for the seven major HNC subsites. Cutaneous malignancies were excluded, as GLOBOCAN does not differentiate skin cancers arising in the head and neck region from those originating at other anatomic sites. Countries analyzed were Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri Lanka. Country-level MIRs, a validated metric, were calculated (MIR = ASMR ÷ ASIR). HNC burden and MIRs were compared across countries and subsites, emphasizing cross-country variation and relative contributions to regional burden.",
        "Results": "Across SAARC countries in 2022, HNC accounted for 346,915 new cases (18.8% of incident cancers) and 185,759 deaths (15.4% of cancer deaths). ASIRs (per 100,000) demonstrated wide regional variation, ranging from 8.8 (Afghanistan) to 24.6 (Bangladesh). ASMRs (per 100,000) showed a similarly stratified gradient, ranging from 4.3 (Nepal) to 13.8 (Bangladesh). MIRs highlighted marked survival disparities: Afghanistan demonstrated the poorest outcomes (MIR 0.67), followed by Bhutan (0.62), Pakistan (0.60), Bangladesh (0.56), and India (0.53); Nepal (0.47) and the Maldives (0.42) showed intermediate survival, while Sri Lanka had the most favorable MIR (0.36).",
        "Abstract": "Subsite-specific analyses confirmed oral cavity cancers as the dominant contributor to regional HNC burden (ASIR 9.7, ASMR 5.5, MIR 0.57). Laryngeal cancer (ASIR 2.6, ASMR 1.7, MIR 0.65), thyroid cancer (1.5, 0.38, 0.25), hypopharyngeal (2.3, 0.89, 0.39), oropharyngeal (1.6, 0.99, 0.62), nasopharyngeal (0.45, 0.34, 0.76), and salivary gland cancers (0.55, 0.34, 0.62) also contributed in varying degrees. View in Agenda and Add to Schedule",
        "Conclusions": "SAARC nations carry a substantial and unevenly distributed burden of head and neck cancers. Bangladesh showed the highest incidence and mortality rates, whereas Nepal and the Maldives exhibited the lowest mortality rates, and Afghanistan and Nepal the lowest incidence rates. MIR patterns revealed marked survival disparities, with Afghanistan having the highest (0.67) and Sri Lanka, the lowest (0.36). Oral cavity cancer is the leading contributor to regional HNC burden, consistent with widespread exposure to smoked and smokeless tobacco, areca-nut/betel quid use, and limited early-detection infrastructure. These findings underscore the urgent need for region-specific cancer control strategies—including tobacco and betel quid reduction, earlier oral lesion detection, and expansion of diagnostic and treatment capacity. Strengthening SAARC-wide cancer registries is critical for guiding targeted prevention, resource allocation, and intervention efforts."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Silent Epicenter: Unequal Burden of Head & Neck Cancer Across SAARC Nations</span>. <u>Taral K Jella, BA</u><sup>1</sup>; Jazlyn Selvasingh, BA<sup>1</sup>; Tara P Menon, BS<sup>1</sup>; Justin R Shinn, MD<sup>2</sup>; William P Magdycz, MD<sup>2</sup>. <sup>1</sup>Virginia Tech Carilion School of Medicine; <sup>2</sup>Carilion Clinic Otolaryngology and Audiology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Head and neck cancers (HNC) constitute a disproportionate share of the cancer burden in South Asia. The members of the South Asian Association for Regional Cooperation (SAARC)—Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka—represent nearly one-fourth of the world’s population yet experience some of the world’s highest HNC incidence and mortality. Despite this burden, contemporary region-wide epidemiologic comparisons remain limited. This study provides the first unified GLOBOCAN-based assessment of incidence, mortality, and mortality-to-incidence ratio (MIR) patterns across all eight SAARC nations.</p>\n\n<p><strong>Methods: </strong>GLOBOCAN 2022 (IARC) was used to extract age-standardized incidence rates (ASIR) and mortality rates (ASMR) for the seven major HNC subsites. Cutaneous malignancies were excluded, as GLOBOCAN does not differentiate skin cancers arising in the head and neck region from those originating at other anatomic sites. Countries analyzed were Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri Lanka. Country-level MIRs, a validated metric, were calculated (MIR = ASMR ÷ ASIR). HNC burden and MIRs were compared across countries and subsites, emphasizing cross-country variation and relative contributions to regional burden.</p>\n\n<p><strong>Results: </strong>Across SAARC countries in 2022, HNC accounted for 346,915 new cases (18.8% of incident cancers) and 185,759 deaths (15.4% of cancer deaths). ASIRs (per 100,000) demonstrated wide regional variation, ranging from 8.8 (Afghanistan) to 24.6 (Bangladesh). ASMRs (per 100,000) showed a similarly stratified gradient, ranging from 4.3 (Nepal) to 13.8 (Bangladesh). MIRs highlighted marked survival disparities: Afghanistan demonstrated the poorest outcomes (MIR 0.67), followed by Bhutan (0.62), Pakistan (0.60), Bangladesh (0.56), and India (0.53); Nepal (0.47) and the Maldives (0.42) showed intermediate survival, while Sri Lanka had the most favorable MIR (0.36).</p>\n\n<p>Subsite-specific analyses confirmed oral cavity cancers as the dominant contributor to regional HNC burden (ASIR 9.7, ASMR 5.5, MIR 0.57). Laryngeal cancer (ASIR 2.6, ASMR 1.7, MIR 0.65), thyroid cancer (1.5, 0.38, 0.25), hypopharyngeal (2.3, 0.89, 0.39), oropharyngeal (1.6, 0.99, 0.62), nasopharyngeal (0.45, 0.34, 0.76), and salivary gland cancers (0.55, 0.34, 0.62) also contributed in varying degrees.</p>\n\n<p><strong>Conclusions: </strong>SAARC nations carry a substantial and unevenly distributed burden of head and neck cancers. Bangladesh showed the highest incidence and mortality rates, whereas Nepal and the Maldives exhibited the lowest mortality rates, and Afghanistan and Nepal the lowest incidence rates. MIR patterns revealed marked survival disparities, with Afghanistan having the highest (0.67) and Sri Lanka, the lowest (0.36). Oral cavity cancer is the leading contributor to regional HNC burden, consistent with widespread exposure to smoked and smokeless tobacco, areca-nut/betel quid use, and limited early-detection infrastructure. These findings underscore the urgent need for region-specific cancer control strategies—including tobacco and betel quid reduction, earlier oral lesion detection, and expansion of diagnostic and treatment capacity. Strengthening SAARC-wide cancer registries is critical for guiding targeted prevention, resource allocation, and intervention efforts.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153287--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S512",
      "content_id": "153411",
      "abstract_number": "S512",
      "poster_number": "",
      "title": "Emergency Department Visits Prior to Head and Neck Cancer Diagnoses: National Trends in Diagnosis and Outcomes",
      "summary": "Among 33,675 patients with HNC, 1,691 (5.0%) had an ED visit within 90 days prior to diagnosis (EDV), while 31,984 did not (nEDV). Compared with nEDV patients, the EDV group included a higher proportion of Black (+12.0% absolute difference), Hispanic (+4.7%), and Asian (+1.5%) patients, as well as a greater rate of unhoused individuals (+1.5%). The EDV group demonstrated more advanced disease at presentation,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153411",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260155",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mishek Thapa, BS",
      "presenter": "Mishek Thapa, BS",
      "authors": "Mishek Thapa, BS 1 ; Nathan Vu Pham, BS 1 ; Albert Y Li, BS 2 ; Erik Vanstrum, MD 3 ; Shady I Soliman, MD 3 ; Joel A Sercarz, MD 3 ; Peter S Han, MD 3",
      "normalized_authors": [
        "Mishek Thapa",
        "Nathan Vu Pham",
        "Albert Y Li",
        "Erik Vanstrum",
        "Shady I Soliman",
        "Joel A Sercarz",
        "Peter S Han"
      ],
      "affiliations": [
        "David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA",
        "Keck School of Medicine, University of Southern California, Los Angeles, CA",
        "Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA"
      ],
      "normalized_institutions": [
        "David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA",
        "Keck School of Medicine, University of Southern California, Los Angeles, CA",
        "Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153411/km_edvisit.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153411/km_edvisit.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153411"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 495,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Discussion"
      ],
      "sections": {
        "Authors": "Mishek Thapa, BS 1 ; Nathan Vu Pham, BS 1 ; Albert Y Li, BS 2 ; Erik Vanstrum, MD 3 ; Shady I Soliman, MD 3 ; Joel A Sercarz, MD 3 ; Peter S Han, MD 3",
        "Affiliations": "1 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; 2 Keck School of Medicine, University of Southern California, Los Angeles, CA; 3 Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA",
        "Introduction": "Diagnosis of cancer following presentation to the emergency department (ED) represents a high-risk pathway associated with advanced stage at presentation and worse overall survival. We examined mortality patterns amongst head and neck cancer (HNC) patients with and without a preceding ED visit.",
        "Methods": "A retrospective cohort study was conducted using TriNetX Global Network. We included adults with a primary cancer at one of 6 major HNC subsites (oral cavity, oropharynx, laryngeal, nasopharyngeal, hypopharyngeal, and salivary gland), and restricted subgroup analysis to high-volume sites to ensure adequate sampling. Patients with and without ED visits were identified. Mortality was assessed using a multivariable Cox proportional hazards model with an index at diagnosis. A second analysis was performed in which those with an ED visit were propensity score-matched 1:1 with those without ED visits on demographics, substance use, chronic medical comorbidities, cancer stage at diagnosis, and variables impacting healthcare utilization (homelessness, employment, education). Mortality was compared using hazard ratios (HRs) with 95% confidence intervals (CI).",
        "Results": "Among 33,675 patients with HNC, 1,691 (5.0%) had an ED visit within 90 days prior to diagnosis (EDV), while 31,984 did not (nEDV). Compared with nEDV patients, the EDV group included a higher proportion of Black (+12.0% absolute difference), Hispanic (+4.7%), and Asian (+1.5%) patients, as well as a greater rate of unhoused individuals (+1.5%). The EDV group demonstrated more advanced disease at presentation, with higher rates of stage IV (+16.0%) and stage 3 (+4.5%) tumors, and fewer stage I malignancies (+4.2%), and greater comorbidity burden (+28.1% nicotine dependence, +28.7% hypertension, +10.5% diabetes, and +4.9% strokes) (all p<0.001).",
        "Abstract": "On multivariable analysis, higher 5-year mortality was associated with male sex (HR[95%CI]=1.053[1.001–1.107]), greater age (1.031[1.028–1.033]), stage 4 disease (1.573[1.496–1.654]), prior stroke (1.308 [1.141–1.499]), homelessness (1.646[1.172–2.312]), nicotine dependence (1.487[1.394–1.586]), Hispanic race (1.135[1.021–1.26]), and Black race (1.137[1.026–1.259]). An emergency department visit before diagnosis was independently associated with higher mortality (1.712[1.569–1.868]). Subgroup analyses confirmed this association across laryngeal (1.729[1.438–2.078]), oral (1.649[1.42–1.916]), and oropharyngeal cancers (1.701[1.378–2.098]). Sensitivity analysis with propensity-matched cohorts yielded similar results, re-demonstrating greater mortality amongst the EDV cohort (1.64[1.45–1.85]; Figure 1A), with the greatest absolute risk difference observed in oral cavity cancer (Figure 1C). View in Agenda and Add to Schedule",
        "Discussion": "An ED visit before HNC diagnoses was independently associated with substantially worse survival and disproportionately affected racial minorities, unhoused patients, and those with advanced disease. These findings highlight an urgent need for earlier detection, expedited diagnostic pathways for suspected HNC in the ED, and system-level reforms to improve screening and treatment."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Emergency Department Visits Prior to Head and Neck Cancer Diagnoses: National Trends in Diagnosis and Outcomes</span>. <u>Mishek Thapa, BS</u><sup>1</sup>; Nathan Vu Pham, BS<sup>1</sup>; Albert Y Li, BS<sup>2</sup>; Erik Vanstrum, MD<sup>3</sup>; Shady I Soliman, MD<sup>3</sup>; Joel A Sercarz, MD<sup>3</sup>; Peter S Han, MD<sup>3</sup>. <sup>1</sup>David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>Keck School of Medicine, University of Southern California, Los Angeles, CA; <sup>3</sup>Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Diagnosis of cancer following presentation to the emergency department (ED) represents a high-risk pathway associated with advanced stage at presentation and worse overall survival. We examined mortality patterns amongst head and neck cancer (HNC) patients with and without a preceding ED visit.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using TriNetX Global Network. We included adults with a primary cancer at one of 6 major HNC subsites (oral cavity, oropharynx, laryngeal, nasopharyngeal, hypopharyngeal, and salivary gland), and restricted subgroup analysis to high-volume sites to ensure adequate sampling. Patients with and without ED visits were identified. Mortality was assessed using a multivariable Cox proportional hazards model with an index at diagnosis. A second analysis was performed in which those with an ED visit were propensity score-matched 1:1 with those without ED visits on demographics, substance use, chronic medical comorbidities, cancer stage at diagnosis, and variables impacting healthcare utilization (homelessness, employment, education). Mortality was compared using hazard ratios (HRs) with 95% confidence intervals (CI).</p>\n\n<p><strong>Results: </strong>Among 33,675 patients with HNC, 1,691 (5.0%) had an ED visit within 90 days prior to diagnosis (EDV), while 31,984 did not (nEDV). Compared with nEDV patients, the EDV group included a higher proportion of Black (+12.0% absolute difference), Hispanic (+4.7%), and Asian (+1.5%) patients, as well as a greater rate of unhoused individuals (+1.5%). The EDV group demonstrated more advanced disease at presentation, with higher rates of stage IV (+16.0%) and stage 3 (+4.5%) tumors, and fewer stage I malignancies (+4.2%), and greater comorbidity burden (+28.1% nicotine dependence, +28.7% hypertension, +10.5% diabetes, and +4.9% strokes) (all p<0.001). </p>\n\n<p>On multivariable analysis, higher 5-year mortality was associated with male sex (HR[95%CI]=1.053[1.001–1.107]), greater age (1.031[1.028–1.033]), stage 4 disease (1.573[1.496–1.654]), prior stroke (1.308 [1.141–1.499]), homelessness (1.646[1.172–2.312]), nicotine dependence (1.487[1.394–1.586]), Hispanic race (1.135[1.021–1.26]), and Black race (1.137[1.026–1.259]). An emergency department visit before diagnosis was independently associated with higher mortality (1.712[1.569–1.868]). Subgroup analyses confirmed this association across laryngeal (1.729[1.438–2.078]), oral (1.649[1.42–1.916]), and oropharyngeal cancers (1.701[1.378–2.098]). Sensitivity analysis with propensity-matched cohorts yielded similar results, re-demonstrating greater mortality amongst the EDV cohort (1.64[1.45–1.85]; Figure 1A), with the greatest absolute risk difference observed in oral cavity cancer (Figure 1C).</p>\n\n<p><strong>Discussion: </strong>An ED visit before HNC diagnoses was independently associated with substantially worse survival and disproportionately affected racial minorities, unhoused patients, and those with advanced disease. These findings highlight an urgent need for earlier detection, expedited diagnostic pathways for suspected HNC in the ED, and system-level reforms to improve screening and treatment. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153411/km_edvisit.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153411--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260155' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S514",
      "content_id": "151679",
      "abstract_number": "S514",
      "poster_number": "",
      "title": "Immune Cell Signatures in Surgical Drain Fluid May Associate with Postoperative Wound Complications in Head and Neck Squamous Cell Carcinoma",
      "summary": "This study provides proof of concept that immune profiling of SDF can identify early immunologic signatures associated with postoperative wound complications following head and neck cancer resection. These findings support the potential of immune-based monitoring to guide postoperative management and inform targeted interventions to optimize wound healing in high-risk patients. Further prospective studies in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151679",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vanessa Helou, MD",
      "presenter": "Vanessa Helou, MD",
      "authors": "Vanessa Helou, MD 1 ; Joshua D Smith, MD 1 ; Micah Harris, MD 1 ; Zhongping Xu, PhD 1 ; Lazar Vujanovic, PhD 1 ; Matthew E Spector, MD 1 ; Steven B Chinn, MD 1 ; Jessica H Maxwell, MD, MPH, FACS 1 ; Shaum Sridharan, MD 1 ; Seungwon W Kim, MD 1 ; Kevin J Contrera, MD, MPH 1 ; Aadel A Chaudhuri, MD, PhD 2 ; Jose P Zevallos 1",
      "normalized_authors": [
        "Vanessa Helou",
        "Joshua D Smith",
        "Micah Harris",
        "Zhongping Xu",
        "Lazar Vujanovic",
        "Matthew E Spector",
        "Steven B Chinn",
        "Jessica H Maxwell",
        "Shaum Sridharan",
        "Seungwon W Kim",
        "Kevin J Contrera",
        "Aadel A Chaudhuri",
        "Jose P Zevallos"
      ],
      "affiliations": [
        "University of Pittsburgh",
        "Mayo Clinic Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "University of Pittsburgh",
        "Mayo Clinic Comprehensive Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Discussion",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vanessa Helou, MD 1 ; Joshua D Smith, MD 1 ; Micah Harris, MD 1 ; Zhongping Xu, PhD 1 ; Lazar Vujanovic, PhD 1 ; Matthew E Spector, MD 1 ; Steven B Chinn, MD 1 ; Jessica H Maxwell, MD, MPH, FACS 1 ; Shaum Sridharan, MD 1 ; Seungwon W Kim, MD 1 ; Kevin J Contrera, MD, MPH 1 ; Aadel A Chaudhuri, MD, PhD 2 ; Jose P Zevallos 1",
        "Affiliations": "1 University of Pittsburgh; 2 Mayo Clinic Comprehensive Cancer Center",
        "Background": "Over 20% of patients develop wound complications following surgical resection of head and neck squamous cell carcinoma (HNSCC). These complications prolong hospitalization, delay adjuvant therapy, and worsen oncologic outcomes. While preoperative risk factors for impaired wound healing are known, no postoperative biomarker exists. Emerging evidence suggests the local immune microenvironment plays a critical role in wound repair and infection control. Surgical drains, routinely placed to remove fluid from the wound bed, represent a novel bioresource for sampling the local postoperative wound environment.",
        "Objective": "To determine whether immune cell profiles in surgical drain fluid (SDF) differ between patients with uneventful recovery and those who develop postoperative wound complications following head and neck cancer resection.",
        "Methods": "We conducted a prospective cohort study of 63 patients with HNSCC undergoing surgical resection with free flap reconstruction. Postoperative wound complications were defined as wound dehiscence or necrosis, neck cellulitis, neck infection, and/or salivary leak within 10 days after surgery. SDF was collected within 24 hours postoperatively, and flow cytometry was performed to characterize immune cell profiles.",
        "Results": "Among 63 patients, 44 (69.8%) were male and all were Caucasian. Most presented with oral cavity SCC (n = 37, 58.7%), followed by laryngeal SCC (n = 15, 23.8%) and oropharyngeal SCC (n = 11, 17.5%). The majority had late-stage (T3-4 or N2-3) disease (n = 42, 66.6%). Twelve patients (20%) developed wound complications at a median of 7 days (range, 3–10). Complications included salivary leak (n = 7, 58.3%), neck cellulitis (n = 6, 50.0%), neck infection (n = 6, 50.0%), and flap dehiscence or necrosis (n = 5, 41.7%). Immune profiling of SDF revealed that patients with wound complications had reduced frequencies of CD3+ (P = .004) and CD8+ (P = .018) T cells, as well as decreased total (P = .030) and plasmacytoid (P=.030) dendritic cell subsets. Conversely, these patients demonstrated increased levels of nonclassical monocytes (P=.020) and CD56^dim natural killer cells (P = .026).",
        "Discussion": "SDF is an ideal resource to sample the surgical wound healing environment as it is immediately proximal to the wound. Here, we demonstrate that immune cell compositions in SDF may be associated with postoperative wound healing complications. Specifically, the observed depletion of T cells and dendritic cells, coupled with enrichment of nonclassical monocytes and CD56^dim NK cells, may indicate a shift from tissue repair toward infection-driven immunity in patients who develop postoperative wound complications. These findings support immune cell compositions in SDF as a potential biomarker for early postoperative risk stratification. Notably, this represents one of the earliest postoperative timepoints to predict wound complications.",
        "Conclusions": "This study provides proof of concept that immune profiling of SDF can identify early immunologic signatures associated with postoperative wound complications following head and neck cancer resection. These findings support the potential of immune-based monitoring to guide postoperative management and inform targeted interventions to optimize wound healing in high-risk patients. Further prospective studies in larger cohorts are needed to validate these findings and establish their clinical utility.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Immune Cell Signatures in Surgical Drain Fluid May Associate with Postoperative Wound Complications in Head and Neck Squamous Cell Carcinoma</span>. <u>Vanessa Helou, MD</u><sup>1</sup>; Joshua D Smith, MD<sup>1</sup>; Micah Harris, MD<sup>1</sup>; Zhongping Xu, PhD<sup>1</sup>; Lazar Vujanovic, PhD<sup>1</sup>; Matthew E Spector, MD<sup>1</sup>; Steven B Chinn, MD<sup>1</sup>; Jessica H Maxwell, MD, MPH, FACS<sup>1</sup>; Shaum Sridharan, MD<sup>1</sup>; Seungwon W Kim, MD<sup>1</sup>; Kevin J Contrera, MD, MPH<sup>1</sup>; Aadel A Chaudhuri, MD, PhD<sup>2</sup>; Jose P Zevallos<sup>1</sup>. <sup>1</sup>University of Pittsburgh; <sup>2</sup>Mayo Clinic Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Over 20% of patients develop wound complications following surgical resection of head and neck squamous cell carcinoma (HNSCC). These complications prolong hospitalization, delay adjuvant therapy, and worsen oncologic outcomes. While preoperative risk factors for impaired wound healing are known, no postoperative biomarker exists. Emerging evidence suggests the local immune microenvironment plays a critical role in wound repair and infection control. Surgical drains, routinely placed to remove fluid from the wound bed, represent a novel bioresource for sampling the local postoperative wound environment.     </p>\n\n<p><strong>Objective</strong>: To determine whether immune cell profiles in surgical drain fluid (SDF) differ between patients with uneventful recovery and those who develop postoperative wound complications following head and neck cancer resection.</p>\n\n<p><strong>Methods</strong>: We conducted a prospective cohort study of 63 patients with HNSCC undergoing surgical resection with free flap reconstruction. Postoperative wound complications were defined as wound dehiscence or necrosis, neck cellulitis, neck infection, and/or salivary leak within 10 days after surgery. SDF was collected within 24 hours postoperatively, and flow cytometry was performed to characterize immune cell profiles.</p>\n\n<p><strong>Results</strong>: Among 63 patients, 44 (69.8%) were male and all were Caucasian. Most presented with oral cavity SCC (n = 37, 58.7%), followed by laryngeal SCC (n = 15, 23.8%) and oropharyngeal SCC (n = 11, 17.5%). The majority had late-stage (T3-4 or N2-3) disease (n = 42, 66.6%). Twelve patients (20%) developed wound complications at a median of 7 days (range, 3–10). Complications included salivary leak (n = 7, 58.3%), neck cellulitis (n = 6, 50.0%), neck infection (n = 6, 50.0%), and flap dehiscence or necrosis (n = 5, 41.7%). Immune profiling of SDF revealed that patients with wound complications had reduced frequencies of CD3+ (P = .004) and CD8+ (P = .018) T cells, as well as decreased total (P = .030) and plasmacytoid (P=.030) dendritic cell subsets. Conversely, these patients demonstrated increased levels of nonclassical monocytes (P=.020) and CD56^dim natural killer cells (P = .026).</p>\n\n<p><strong>Discussion: </strong>SDF is an ideal resource to sample the surgical wound healing environment as it is immediately proximal to the wound. Here, we demonstrate that immune cell compositions in SDF may be associated with postoperative wound healing complications. Specifically, the observed depletion of T cells and dendritic cells, coupled with enrichment of nonclassical monocytes and CD56^dim NK cells, may indicate a shift from tissue repair toward infection-driven immunity in patients who develop postoperative wound complications. These findings support immune cell compositions in SDF as a potential biomarker for early postoperative risk stratification. Notably, this represents one of the earliest postoperative timepoints to predict wound complications.</p>\n\n<p><strong>Conclusions</strong>: This study provides proof of concept that immune profiling of SDF can identify early immunologic signatures associated with postoperative wound complications following head and neck cancer resection. These findings support the potential of immune-based monitoring to guide postoperative management and inform targeted interventions to optimize wound healing in high-risk patients. Further prospective studies in larger cohorts are needed to validate these findings and establish their clinical utility.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151679--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S515",
      "content_id": "153892",
      "abstract_number": "S515",
      "poster_number": "",
      "title": "TTMV Score at Molecular Recurrence Predicts Response to Salvage Therapy in HPV-driven Cancers",
      "summary": "When molecular recurrence is detected, patients with lower positive TTMV scores demonstrate higher rates of return to negative testing, as well as faster kinetics of molecular clearance, consistent with undetectable disease status. These findings suggest that TTMV-HPV DNA testing provides clinically significant information on patient prognosis and therapeutic response, enabling early intervention when the TTMV...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153892",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jamie Jabalee, PhD",
      "presenter": "Jamie Jabalee, PhD",
      "authors": "Jamie Jabalee, PhD 1 ; Charlotte Kuperwasser, PhD 2 ; Stephen P Naber, MD 1 ; Barry M Berger, MD 1 ; Piyush B Gupta, PhD 1",
      "normalized_authors": [
        "Jamie Jabalee",
        "Charlotte Kuperwasser",
        "Stephen P Naber",
        "Barry M Berger",
        "Piyush B Gupta"
      ],
      "affiliations": [
        "Naveris, Inc",
        "Tufts University School of Medicine"
      ],
      "normalized_institutions": [
        "Naveris, Inc",
        "Tufts University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 355,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jamie Jabalee, PhD 1 ; Charlotte Kuperwasser, PhD 2 ; Stephen P Naber, MD 1 ; Barry M Berger, MD 1 ; Piyush B Gupta, PhD 1",
        "Affiliations": "1 Naveris, Inc.; 2 Tufts University School of Medicine",
        "Purpose": "TTMV-HPV DNA testing is established for post-treatment surveillance of patients with HPV-driven cancer. Whether lower TTMV-HPV DNA scores at recurrence are associated with improved response to salvage therapy remains underdefined. We analyzed negative-to-positive surveillance test conversions to determine whether positive TTMV levels (molecular recurrence) correlate with successful treatment indicated by a return to undetectable disease (molecular clearance).",
        "Methods": "Within a nationwide cohort of 39,619 patients with HPV-associated cancers (primarily oropharyngeal [91.8%], anal [3.3%], and cervical [0.7%] squamous cell carcinomas), 1,097 patients converted from a negative to positive TTMV score during post-treatment surveillance. Of these, 799 (72.8%) had subsequent testing (median 295 days, IQR: 150-587 days; median 3 tests per patient). Patients were stratified by TTMV score at first positive detection into quartiles (Q1 ≤7.1; Q2: 7.1-17; Q3: 17-72; Q4: >72 TTMV score). The primary endpoint was molecular clearance (reversion from a positive to a negative TTMV score) analyzed using Kaplan-Meier methods.",
        "Results": "Overall, 367 of 1,097 patients (33.4%) achieved molecular clearance. Patients with the lowest positive TTMV scores at recurrence (Q1) demonstrated significantly higher molecular clearance rates compared to those with the highest scores (Q4): 36.7% (95% CI: 31.0-42.8%) versus 24.5% (95% CI: 19.6-29.9%), representing a 12.2 percentage point absolute difference (p<0.001). Median time to clearance differed significantly: Q1 patients cleared in 119 days (IQR: 64-230) compared to 186 days (IQR: 124-281) for Q4 patients, a 67-day difference (p=0.007). A relationship between increasing TTMV scores and decreasing clearance rate was observed across all quartiles, with clearance rates of 36.7%, 39.4%, 33.2%, and 24.5% for Q1 through Q4, respectively.",
        "Conclusion": "When molecular recurrence is detected, patients with lower positive TTMV scores demonstrate higher rates of return to negative testing, as well as faster kinetics of molecular clearance, consistent with undetectable disease status. These findings suggest that TTMV-HPV DNA testing provides clinically significant information on patient prognosis and therapeutic response, enabling early intervention when the TTMV score is low and when disease is more responsive to salvage therapy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>TTMV Score at Molecular Recurrence Predicts Response to Salvage Therapy in HPV-driven Cancers</span>. <u>Jamie Jabalee, PhD</u><sup>1</sup>; Charlotte Kuperwasser, PhD<sup>2</sup>; Stephen P Naber, MD<sup>1</sup>; Barry M Berger, MD<sup>1</sup>; Piyush B Gupta, PhD<sup>1</sup>. <sup>1</sup>Naveris, Inc.; <sup>2</sup>Tufts University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>TTMV-HPV DNA testing is established for post-treatment surveillance of patients with HPV-driven cancer. Whether lower TTMV-HPV DNA scores at recurrence are associated with improved response to salvage therapy remains underdefined. We analyzed negative-to-positive surveillance test conversions to determine whether positive TTMV levels (molecular recurrence) correlate with successful treatment indicated by a return to undetectable disease (molecular clearance).</p>\n\n<p><strong>Methods: </strong>Within a nationwide cohort of 39,619 patients with HPV-associated cancers (primarily oropharyngeal [91.8%], anal [3.3%], and cervical [0.7%] squamous cell carcinomas), 1,097 patients converted from a negative to positive TTMV score during post-treatment surveillance. Of these, 799 (72.8%) had subsequent testing (median 295 days, IQR: 150-587 days; median 3 tests per patient). Patients were stratified by TTMV score at first positive detection into quartiles (Q1 ≤7.1; Q2: 7.1-17; Q3: 17-72; Q4: >72 TTMV score). The primary endpoint was molecular clearance (reversion from a positive to a negative TTMV score) analyzed using Kaplan-Meier methods.</p>\n\n<p><strong>Results: </strong>Overall, 367 of 1,097 patients (33.4%) achieved molecular clearance. Patients with the lowest positive TTMV scores at recurrence (Q1) demonstrated significantly higher molecular clearance rates compared to those with the highest scores (Q4): 36.7% (95% CI: 31.0-42.8%) versus 24.5% (95% CI: 19.6-29.9%), representing a 12.2 percentage point absolute difference (p<0.001). Median time to clearance differed significantly: Q1 patients cleared in 119 days (IQR: 64-230) compared to 186 days (IQR: 124-281) for Q4 patients, a 67-day difference (p=0.007). A relationship between increasing TTMV scores and decreasing clearance rate was observed across all quartiles, with clearance rates of 36.7%, 39.4%, 33.2%, and 24.5% for Q1 through Q4, respectively.</p>\n\n<p><strong>Conclusion: </strong>When molecular recurrence is detected, patients with lower positive TTMV scores demonstrate higher rates of return to negative testing, as well as faster kinetics of molecular clearance, consistent with undetectable disease status. These findings suggest that TTMV-HPV DNA testing provides clinically significant information on patient prognosis and therapeutic response, enabling early intervention when the TTMV score is low and when disease is more responsive to salvage therapy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153892--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S516",
      "content_id": "153572",
      "abstract_number": "S516",
      "poster_number": "",
      "title": "A Multicenter Study of Implementation of Tissue-free Molecular Residual Disease (MRD) Testing for Patients With Head and Neck Cancer Treated With Curative Intent",
      "summary": "An estimated 20% to 35% of patients with head and neck squamous cell carcinoma (HNSCC) treated with curative intent will develop recurrence, typically within the first 2 years. Recurrent/metastatic disease is associated with poor survival; early detection of recurrence may facilitate opportunity for salvage treatment approaches. Although molecular residual disease (MRD) testing has emerged as a strategy for early...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153572",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ari J Rosenberg, MD",
      "presenter": "Ari J Rosenberg, MD",
      "authors": "Ari J Rosenberg, MD 1 ; R Bryan Bell, MD, DDS 2 ; Ashish A Patel, MD, DDS 2 ; Jonathan D Schoenfeld, MD, MPhil, MPH 3 ; Michael J Dennis, MD 4 ; Andrew M Harding 5 ; Varsha C Yarra, BDS, MPH 5 ; Maya C Downs 5 ; Owen Hall, MS 6 ; Yarong Wang, MA 6 ; Melanie L Styers, PhD 6 ; Elizabeth Lightbody, PhD 6 ; Brian Allen, MSc 6 ; Jing Zhang, PhD 6 ; Anne-Renee Hartman, MD 6",
      "normalized_authors": [
        "Ari J Rosenberg",
        "R Bryan Bell",
        "Ashish A Patel",
        "Jonathan D Schoenfeld, MPhil",
        "Michael J Dennis",
        "Andrew M Harding",
        "Varsha C Yarra, BDS",
        "Maya C Downs",
        "Owen Hall",
        "Yarong Wang, MA",
        "Melanie L Styers",
        "Elizabeth Lightbody",
        "Brian Allen",
        "Jing Zhang",
        "Anne-Renee Hartman"
      ],
      "affiliations": [
        "Section of Hematology and Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
        "Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA",
        "University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
        "Adela, Inc., Foster City, CA"
      ],
      "normalized_institutions": [
        "Section of Hematology and Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
        "Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA",
        "Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA",
        "University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL",
        "Adela, Inc., Foster City, CA"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153572/Table%201(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153572/Table%201(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153572"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 370,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ari J Rosenberg, MD 1 ; R Bryan Bell, MD, DDS 2 ; Ashish A Patel, MD, DDS 2 ; Jonathan D Schoenfeld, MD, MPhil, MPH 3 ; Michael J Dennis, MD 4 ; Andrew M Harding 5 ; Varsha C Yarra, BDS, MPH 5 ; Maya C Downs 5 ; Owen Hall, MS 6 ; Yarong Wang, MA 6 ; Melanie L Styers, PhD 6 ; Elizabeth Lightbody, PhD 6 ; Brian Allen, MSc 6 ; Jing Zhang, PhD 6 ; Anne-Renee Hartman, MD 6",
        "Affiliations": "1 Section of Hematology and Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL; 2 Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR; 3 Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA; 4 Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 5 University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL; 6 Adela, Inc., Foster City, CA",
        "Abstract": "An estimated 20% to 35% of patients with head and neck squamous cell carcinoma (HNSCC) treated with curative intent will develop recurrence, typically within the first 2 years. Recurrent/metastatic disease is associated with poor survival; early detection of recurrence may facilitate opportunity for salvage treatment approaches. Although molecular residual disease (MRD) testing has emerged as a strategy for early detection of recurrence in some tumor types, limited data are available to understand the real-world use of MRD testing in HNSCC, particularly in patients with human papillomavirus (HPV)-negative disease and using tissue-free approaches. This multicenter, observational, retrospective study reports outcomes with implementation of a newly available technology for clinical MRD testing among adult patients with non-metastatic HNSCC treated with curative intent. As of the cutoff date of November 14, 2025, 53 patients had completed treatment between September 22, 2022 and August 22, 2025 and received MRD testing with a genome-wide methylation enrichment assay based on cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMeDIP-seq). A majority of patients received radiation therapy (33/53; 62%) and/or chemotherapy (30/53; 57%); blood samples were collected for MRD testing at least 30 days after completing surgery and/or radiation therapy. Patients were predominately male (37/53, 70%) and had a median age of 66 (range, 29-89). The most common tumor locations included oropharynx (24/53, 45%) and lip/oral cavity (19/53, 36%). Nineteen of 53 patients (36%) had confirmed HPV-negative disease. Of the 49 samples with results available, 5 (10%) were positive for MRD. Evaluation of recurrence is ongoing in patients with MRD-positive results, with a recurrence suspected in 1 patient and a confirmed secondary cancer in another at the time of data cutoff. Average turnaround time for receipt of test results was 6.3 business days. Updated results of a larger tested population and descriptive summaries of representative cases will be presented at the time of the meeting to demonstrate real-world application of MRD test results for clinical decision-making. Results of this study provide insight into the feasibility and potential clinical utility of tissue-free, blood-based MRD testing for patients with head and neck cancer treated with curative intent, regardless of HPV status. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Multicenter Study of Implementation of Tissue-free Molecular Residual Disease (MRD) Testing for Patients With Head and Neck Cancer Treated With Curative Intent</span>. <u>Ari J Rosenberg, MD</u><sup>1</sup>; R Bryan Bell, MD, DDS<sup>2</sup>; Ashish A Patel, MD, DDS<sup>2</sup>; Jonathan D Schoenfeld, MD, MPhil, MPH<sup>3</sup>; Michael J Dennis, MD<sup>4</sup>; Andrew M Harding<sup>5</sup>; Varsha C Yarra, BDS, MPH<sup>5</sup>; Maya C Downs<sup>5</sup>; Owen Hall, MS<sup>6</sup>; Yarong Wang, MA<sup>6</sup>; Melanie L Styers, PhD<sup>6</sup>; Elizabeth Lightbody, PhD<sup>6</sup>; Brian Allen, MSc<sup>6</sup>; Jing Zhang, PhD<sup>6</sup>; Anne-Renee Hartman, MD<sup>6</sup>. <sup>1</sup>Section of Hematology and Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL; <sup>2</sup>Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR; <sup>3</sup>Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA; <sup>4</sup>Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; <sup>5</sup>University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL; <sup>6</sup>Adela, Inc., Foster City, CA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>An estimated 20% to 35% of patients with head and neck squamous cell carcinoma (HNSCC) treated with curative intent will develop recurrence, typically within the first 2 years. Recurrent/metastatic disease is associated with poor survival; early detection of recurrence may facilitate opportunity for salvage treatment approaches. Although molecular residual disease (MRD) testing has emerged as a strategy for early detection of recurrence in some tumor types, limited data are available to understand the real-world use of MRD testing in HNSCC, particularly in patients with human papillomavirus (HPV)-negative disease and using tissue-free approaches. This multicenter, observational, retrospective study reports outcomes with implementation of a newly available technology for clinical MRD testing among adult patients with non-metastatic HNSCC treated with curative intent. As of the cutoff date of November 14, 2025, 53 patients had completed treatment between September 22, 2022 and August 22, 2025 and received MRD testing with a genome-wide methylation enrichment assay based on cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMeDIP-seq). A majority of patients received radiation therapy (33/53; 62%) and/or chemotherapy (30/53; 57%); blood samples were collected for MRD testing at least 30 days after completing surgery and/or radiation therapy. Patients were predominately male (37/53, 70%) and had a median age of 66 (range, 29-89). The most common tumor locations included oropharynx (24/53, 45%) and lip/oral cavity (19/53, 36%). Nineteen of 53 patients (36%) had confirmed HPV-negative disease. Of the 49 samples with results available, 5 (10%) were positive for MRD. Evaluation of recurrence is ongoing in patients with MRD-positive results, with a recurrence suspected in 1 patient and a confirmed secondary cancer in another at the time of data cutoff. Average turnaround time for receipt of test results was 6.3 business days. Updated results of a larger tested population and descriptive summaries of representative cases will be presented at the time of the meeting to demonstrate real-world application of MRD test results for clinical decision-making. Results of this study provide insight into the feasibility and potential clinical utility of tissue-free, blood-based MRD testing for patients with head and neck cancer treated with curative intent, regardless of HPV status.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153572/Table%201(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153572--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S517",
      "content_id": "153806",
      "abstract_number": "S517",
      "poster_number": "",
      "title": "Clinical Utility of ctDNA in Post-Surgical Lymphatic Drain Fluid (SDF) for Recurrence Risk Stratification in Stage III – IVA/B HPV-Independent Head and Neck Squamous Cell Carcinoma (HPV[-] HNSCC)",
      "summary": "Patients with locally advanced HPV[-] HNSCC who undergo curative-intent surgery remain at high risk for recurrence. To mitigate this risk, patients are treated with adjuvant radiation (RT), concurrent cisplatin and RT (CRT), and, more recently, neoadjuvant immunotherapy; however, RT/CRT is associated with significant acute and late toxicities that impair quality of life and may increase non-cancer mortality....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153806",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kevin J Contrera, Assistant Professor",
      "presenter": "Kevin J Contrera, Assistant Professor",
      "authors": "Joshua D Smith, MD 1 ; Zhuosheng Gu 2 ; Seka Lazare 2 ; Noah Earland 3 ; Michael A Harmon 2 ; Megan Long 2 ; Ashley Tellis 2 ; Adam Benson 2 ; Marra Francis 2 ; Wendy Winckler 2 ; Haluk Tezcan 2 ; Aadel Chaudhuri 4 ; Jose Zevallos 1 ; Kevin J Contrera, Assistant Professor 1",
      "normalized_authors": [
        "Joshua D Smith",
        "Zhuosheng Gu",
        "Seka Lazare",
        "Noah Earland",
        "Michael A Harmon",
        "Megan Long",
        "Ashley Tellis",
        "Adam Benson",
        "Marra Francis",
        "Wendy Winckler",
        "Haluk Tezcan",
        "Aadel Chaudhuri",
        "Jose Zevallos",
        "Kevin J Contrera, Assistant"
      ],
      "affiliations": [
        "University of Pittsburgh Medical Center",
        "Droplet Biosciences",
        "Washington University School of Medicine",
        "Mayo Clinic"
      ],
      "normalized_institutions": [
        "University of Pittsburgh Medical Center",
        "Droplet Biosciences",
        "Washington University School of Medicine",
        "Mayo Clinic"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 483,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joshua D Smith, MD 1 ; Zhuosheng Gu 2 ; Seka Lazare 2 ; Noah Earland 3 ; Michael A Harmon 2 ; Megan Long 2 ; Ashley Tellis 2 ; Adam Benson 2 ; Marra Francis 2 ; Wendy Winckler 2 ; Haluk Tezcan 2 ; Aadel Chaudhuri 4 ; Jose Zevallos 1 ; Kevin J Contrera, Assistant Professor 1",
        "Affiliations": "1 University of Pittsburgh Medical Center; 2 Droplet Biosciences; 3 Washington University School of Medicine; 4 Mayo Clinic",
        "Abstract": "Patients with locally advanced HPV[-] HNSCC who undergo curative-intent surgery remain at high risk for recurrence. To mitigate this risk, patients are treated with adjuvant radiation (RT), concurrent cisplatin and RT (CRT), and, more recently, neoadjuvant immunotherapy; however, RT/CRT is associated with significant acute and late toxicities that impair quality of life and may increase non-cancer mortality. While surgical pathology stratifies general recurrence risk, biomarkers that define individual recurrence risk are needed to guide adjuvant treatment decisions. ctDNA in surgical drain fluid (SDF), here “lymMRD”, collected 18-30 hours after surgery, has 71% sensitivity for predicting recurrence. We present a post hoc analysis of our proof-of-concept study to explore the clinical utility of this assay in stage III-IVA/B disease. Of 76 enrolled patients, 3 failed sample QC, leaving 73 evaluable patients. Twenty did not receive adjuvant RT or CRT. In this surgery-only cohort with ≥2 years of follow-up, lymMRD positivity had a PPV of 80% for recurrence. lymMRD[+] surgery-only patients had a median RFS of 6 months and a 3-year RFS of 33%. Among stage III–IVA patients (n=31), lymMRD[-] patients (n=17) showed excellent 3-year RFS of 92.9% with adjuvant RT alone (one pT3N0 margin-negative laryngeal SCC received CRT). One lymMRD[-] patient – a pT2N1 oral cavity SCC without LVI, PNI, or positive margins – had a locoregional recurrence at 16 months. In contrast, lymMRD[+] stage III–IVA patients had substantially worse outcomes despite 4 receiving CRT, with a 3-year RFS of 47% and a median RFS of 13.4 months. Stage IVB patients who received RT (n=4) or CRT (n=14) had an overall median RFS of 11.3 months. lymMRD[+] stage IVB patients had a median RFS of 6.4 months, with 5 of 6 recurring, whereas lymMRD[-] patients had a median RFS of 12 months, with 6 of 12 recurring. All RT-only stage IVB patients recurred. Among CRT-treated stage IVB patients, the median RFS was 11.3 months; 3-year RFS was 60% for lymMRD[-] and 25% for lymMRD[+] patients (overall 49%). Nineteen stage III–IV patients had evaluable plasma ctDNA time-matched to SDF samples. Plasma MRD missed 7 of 10 recurrences, yielding 30% sensitivity. In conclusion, SDF lymMRD status robustly stratifies recurrence risk in stage III–IVA HPV[-] HNSCC. lymMRD[-] patients experience excellent outcomes with adjuvant RT alone, supporting investigation of RT de-escalation strategies to reduce long-term toxicity. lymMRD[+] stage III–IVA patients have a high risk of recurrence despite standard adjuvant therapy and may be excellent candidates for treatment escalation and enrollment on trials of novel agents. In stage IVB disease, lymMRD[-] patients derive meaningful—but incomplete—benefit from CRT, whereas lymMRD[+] patients remain at very high risk and require innovative therapeutic approaches. An ongoing larger clinical validation study will expand this dataset and is expected to further substantiate the clinical utility of ctDNA analysis from this unique biofluid. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Clinical Utility of ctDNA in Post-Surgical Lymphatic Drain Fluid (SDF) for Recurrence Risk Stratification in Stage III – IVA/B HPV-Independent Head and Neck Squamous Cell Carcinoma (HPV[-] HNSCC)</span>. Joshua D Smith, MD<sup>1</sup>; Zhuosheng Gu<sup>2</sup>; Seka Lazare<sup>2</sup>; Noah Earland<sup>3</sup>; Michael A Harmon<sup>2</sup>; Megan Long<sup>2</sup>; Ashley Tellis<sup>2</sup>; Adam Benson<sup>2</sup>; Marra Francis<sup>2</sup>; Wendy Winckler<sup>2</sup>; Haluk Tezcan<sup>2</sup>; Aadel Chaudhuri<sup>4</sup>; Jose Zevallos<sup>1</sup>; <u>Kevin J Contrera, Assistant Professor</u><sup>1</sup>. <sup>1</sup>University of Pittsburgh Medical Center; <sup>2</sup>Droplet Biosciences; <sup>3</sup>Washington University School of Medicine; <sup>4</sup>Mayo Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Patients with locally advanced HPV[-] HNSCC who undergo curative-intent surgery remain at high risk for recurrence. To mitigate this risk, patients are treated with adjuvant radiation (RT), concurrent cisplatin and RT (CRT), and, more recently, neoadjuvant immunotherapy; however, RT/CRT is associated with significant acute and late toxicities that impair quality of life and may increase non-cancer mortality. While surgical pathology stratifies general recurrence risk, biomarkers that define individual recurrence risk are needed to guide adjuvant treatment decisions. ctDNA in surgical drain fluid (SDF), here “lymMRD”, collected 18-30 hours after surgery, has 71% sensitivity for predicting recurrence. We present a post hoc analysis of our proof-of-concept study to explore the clinical utility of this assay in stage III-IVA/B disease.</p>\n\n<p>Of 76 enrolled patients, 3 failed sample QC, leaving 73 evaluable patients. Twenty did not receive adjuvant RT or CRT. In this surgery-only cohort with ≥2 years of follow-up, lymMRD positivity had a PPV of 80% for recurrence. lymMRD[+] surgery-only patients had a median RFS of 6 months and a 3-year RFS of 33%. </p>\n\n<p>Among stage III–IVA patients (n=31), lymMRD[-] patients (n=17) showed excellent 3-year RFS of 92.9% with adjuvant RT alone (one pT3N0 margin-negative laryngeal SCC received CRT). One lymMRD[-] patient – a pT2N1 oral cavity SCC without LVI, PNI, or positive margins – had a locoregional recurrence at 16 months. In contrast, lymMRD[+] stage III–IVA patients had substantially worse outcomes despite 4 receiving CRT, with a 3-year RFS of 47% and a median RFS of 13.4 months.</p>\n\n<p>Stage IVB patients who received RT (n=4) or CRT (n=14) had an overall median RFS of 11.3 months. lymMRD[+] stage IVB patients had a median RFS of 6.4 months, with 5 of 6 recurring, whereas lymMRD[-] patients had a median RFS of 12 months, with 6 of 12 recurring. All RT-only stage IVB patients recurred. Among CRT-treated stage IVB patients, the median RFS was 11.3 months; 3-year RFS was 60% for lymMRD[-] and 25% for lymMRD[+] patients (overall 49%).</p>\n\n<p>Nineteen stage III–IV patients had evaluable plasma ctDNA time-matched to SDF samples. Plasma MRD missed 7 of 10 recurrences, yielding 30% sensitivity.</p>\n\n<p>In conclusion, SDF lymMRD status robustly stratifies recurrence risk in stage III–IVA HPV[-] HNSCC. lymMRD[-] patients experience excellent outcomes with adjuvant RT alone, supporting investigation of RT de-escalation strategies to reduce long-term toxicity. lymMRD[+] stage III–IVA patients have a high risk of recurrence despite standard adjuvant therapy and may be excellent candidates for treatment escalation and enrollment on trials of novel agents. In stage IVB disease, lymMRD[-] patients derive meaningful—but incomplete—benefit from CRT, whereas lymMRD[+] patients remain at very high risk and require innovative therapeutic approaches. An ongoing larger clinical validation study will expand this dataset and is expected to further substantiate the clinical utility of ctDNA analysis from this unique biofluid.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153806--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S518",
      "content_id": "153323",
      "abstract_number": "S518",
      "poster_number": "",
      "title": "Excitation-Light Blocking Filter for Photoimmunotherapy Tailored to the ORBEYE 4K 3D Exoscope",
      "summary": "Photoimmunotherapy is a treatment method that utilizes an antibody-drug conjugate (ADC) activated by light. Specifically, an antibody-photoabsorber conjugate (APC), composed of a monoclonal antibody that targets cell surface antigens and IR700, which is excited by 690 nm light, is used. The drug is administered intravenously, and on the following day, laser light is applied to the tumor. When the APC-bound cells...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153323",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryuhei Okada",
      "presenter": "Ryuhei Okada",
      "authors": "Ryuhei Okada 1 ; Hideki Kanebako 2 ; Ryosuke Takahashi 1 ; Taisei Nagahisa 1 ; Shigeru Kondo 1 ; Takaaki Sato 1 ; Tomoaki Asamori 1 ; Kazuchika Ohno 1 ; Michiko Machida 2 ; Takahiro Asakage 1",
      "normalized_authors": [
        "Ryuhei Okada",
        "Hideki Kanebako",
        "Ryosuke Takahashi",
        "Taisei Nagahisa",
        "Shigeru Kondo",
        "Takaaki Sato",
        "Tomoaki Asamori",
        "Kazuchika Ohno",
        "Michiko Machida",
        "Takahiro Asakage"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, Institute of Science Tokyo",
        "Rakuten Medical K.K"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, Institute of Science Tokyo",
        "Rakuten Medical K.K"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 372,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ryuhei Okada 1 ; Hideki Kanebako 2 ; Ryosuke Takahashi 1 ; Taisei Nagahisa 1 ; Shigeru Kondo 1 ; Takaaki Sato 1 ; Tomoaki Asamori 1 ; Kazuchika Ohno 1 ; Michiko Machida 2 ; Takahiro Asakage 1",
        "Affiliations": "1 Department of Head and Neck Surgery, Institute of Science Tokyo; 2 Rakuten Medical K.K",
        "Abstract": "Photoimmunotherapy is a treatment method that utilizes an antibody-drug conjugate (ADC) activated by light. Specifically, an antibody-photoabsorber conjugate (APC), composed of a monoclonal antibody that targets cell surface antigens and IR700, which is excited by 690 nm light, is used. The drug is administered intravenously, and on the following day, laser light is applied to the tumor. When the APC-bound cells are illuminated, the excitation of the APC has been observed in pre-clinical studies to result in damage to the cell membrane, leading to swelling and rupture of the targeted cells. In Japan, since 2021, photoimmunotherapy using cetuximab has been employed for patients with unresectable locally advanced or locally recurrent head and neck cancers. Known adverse events of this therapy include local edema and tumor hemorrhage. Since laryngeal edema can be a fatal complication, prophylactic tracheostomy is sometimes performed when there is a risk of its occurrence. Additionally, when tumor bleeding is anticipated, vascular ligation may be performed concurrently with excitation laser light illumination of photoimmunotherapy. However, strong light sources such as surgical shadowless lamps cannot be used during treatment, as they may inadvertently excite the APC and cause adverse effects like dermatitis. Currently, a headlight is used for procedures, but it may not always provide adequately bright surgical field. In this study, we report the development of a filter for the 4K 3D exoscope (ORBEYE) that blocks excitation light. After attaching the filter, the color tone shifts to a bluish-white hue; however, by recalibrating the white balance, natural color tones were successfully restored, as confirmed using human skin and a color checker. We also evaluated cytotoxicity in vitro using the human oral cancer cell line HSC-3. Cell death was observed when the cells were exposed to cetuximab-IR700 and illuminated with ORBEYE light, but cell death was inhibited when the filter was applied. Furthermore, we evaluated the safety of using this filter in six patients during minor procedures (e.g., tracheostomy and vascular ligation) performed in conjunction with laser light illumination. While not a controlled study, we did not observe adverse skin reactions or other complications in these 6 patients. This filter may allow for safer intraoperative procedures during photoimmunotherapy when brighter light is required. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Excitation-Light Blocking Filter for Photoimmunotherapy Tailored to the ORBEYE 4K 3D Exoscope</span>. <u>Ryuhei Okada</u><sup>1</sup>; Hideki Kanebako<sup>2</sup>; Ryosuke Takahashi<sup>1</sup>; Taisei Nagahisa<sup>1</sup>; Shigeru Kondo<sup>1</sup>; Takaaki Sato<sup>1</sup>; Tomoaki Asamori<sup>1</sup>; Kazuchika Ohno<sup>1</sup>; Michiko Machida<sup>2</sup>; Takahiro Asakage<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, Institute of Science Tokyo; <sup>2</sup>Rakuten Medical K.K<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Photoimmunotherapy is a treatment method that utilizes an antibody-drug conjugate (ADC) activated by light. Specifically, an antibody-photoabsorber conjugate (APC), composed of a monoclonal antibody that targets cell surface antigens and IR700, which is excited by 690 nm light, is used. The drug is administered intravenously, and on the following day, laser light is applied to the tumor. When the APC-bound cells are illuminated, the excitation of the APC has been observed in pre-clinical studies to result in damage to the cell membrane, leading to swelling and rupture of the targeted cells. In Japan, since 2021, photoimmunotherapy using cetuximab has been employed for patients with unresectable locally advanced or locally recurrent head and neck cancers. Known adverse events of this therapy include local edema and tumor hemorrhage. Since laryngeal edema can be a fatal complication, prophylactic tracheostomy is sometimes performed when there is a risk of its occurrence. Additionally, when tumor bleeding is anticipated, vascular ligation may be performed concurrently with excitation laser light illumination of photoimmunotherapy. However, strong light sources such as surgical shadowless lamps cannot be used during treatment, as they may inadvertently excite the APC and cause adverse effects like dermatitis. Currently, a headlight is used for procedures, but it may not always provide adequately bright surgical field. In this study, we report the development of a filter for the 4K 3D exoscope (ORBEYE) that blocks excitation light. After attaching the filter, the color tone shifts to a bluish-white hue; however, by recalibrating the white balance, natural color tones were successfully restored, as confirmed using human skin and a color checker. We also evaluated cytotoxicity in vitro using the human oral cancer cell line HSC-3. Cell death was observed when the cells were exposed to cetuximab-IR700 and illuminated with ORBEYE light, but cell death was inhibited when the filter was applied. Furthermore, we evaluated the safety of using this filter in six patients during minor procedures (e.g., tracheostomy and vascular ligation) performed in conjunction with laser light illumination. While not a controlled study, we did not observe adverse skin reactions or other complications in these 6 patients. This filter may allow for safer intraoperative procedures during photoimmunotherapy when brighter light is required.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153323--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S519",
      "content_id": "153859",
      "abstract_number": "S519",
      "poster_number": "",
      "title": "APR1051, a Next-Generation WEE1 Inhibitor, Overcomes Cisplatin Resistance and Suppresses Tumor Progression in KEAP1/NRF2 Hyperactivated Head and Neck Squamous Cell Carcinoma",
      "summary": "APR-1051 effectively overcomes cisplatin resistance in HNSCC. Our findings suggest that combining APR-1051 with cisplatin may offer a promising therapeutic strategy for patients with head and neck tumors exhibiting dysregulation of the KEAP1/NRF2 pathway.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153859",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tsung-You Tsai, MD",
      "presenter": "Tsung-You Tsai, MD",
      "authors": "Tsung-You Tsai, MD 1 ; Mutsuki Kawabe, DDS, PhD 1 ; Arisa Nishikawa Kaga, DDS, PhD 1 ; Kento Okamoto, DDS, PhD 1 ; Mitchell J Frederick, PhD 2 ; Vlad C Sandulache, MD, PhD 2 ; Abdullah A Osman, PhD 1 ; Jeffrey N Myers 1",
      "normalized_authors": [
        "Tsung-You Tsai",
        "Mutsuki Kawabe",
        "Arisa Nishikawa Kaga",
        "Kento Okamoto",
        "Mitchell J Frederick",
        "Vlad C Sandulache",
        "Abdullah A Osman",
        "Jeffrey N Myers"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center",
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center",
        "Baylor College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 499,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tsung-You Tsai, MD 1 ; Mutsuki Kawabe, DDS, PhD 1 ; Arisa Nishikawa Kaga, DDS, PhD 1 ; Kento Okamoto, DDS, PhD 1 ; Mitchell J Frederick, PhD 2 ; Vlad C Sandulache, MD, PhD 2 ; Abdullah A Osman, PhD 1 ; Jeffrey N Myers 1",
        "Affiliations": "1 The University of Texas MD Anderson Cancer Center; 2 Baylor College of Medicine",
        "Background": "Head and neck squamous cell carcinoma (HNSCC) affects more than 500,000 people worldwide each year, and roughly half of those diagnosed will die from the disease. Multimodal chemotherapy, most commonly cisplatin administered in the neoadjuvant setting or concurrently with radiation, has become the standard of care for patients with locally advanced HNSCC. However, despite therapeutic advances, the development of acquired cisplatin resistance remains a major barrier, ultimately limiting treatment efficacy and contributing to therapeutic failure in most patients. Alterations in the KEAP1/NFE2L2 (NRF2)/CUL3 pathway are present in roughly 20% of head and neck squamous cell carcinomas (HNSCC). Using patient-level datasets and preclinical HNSCC models, we have demonstrated that hyperactivation of NRF2 signaling is tightly associated with acquired cisplatin resistance and enhanced tumor metastasis. This phenotype appears to arise primarily from metabolic adaptation to elevated oxidative stress, inactivating mutations in KEAP1, and epigenetic reprogramming of NFE2L2 (NRF2). WEE1 tyrosine kinase is a critical regulator of the G1-S and G2-M checkpoints and a central mediator of cellular responses to DNA damage. We and others have shown that WEE1 inhibition increases CDK1 and CDK2 activity and re-sensitizes cisplatin-resistant HNSCC cells by impairing their ability to repair cisplatin-induced DNA damage, ultimately triggering mitotic catastrophe and cell death. APR-1051 is an orally bioavailable, highly potent, and selective small-molecule WEE1 inhibitor that exhibits robust anti-proliferative activity in multiple in vivo cancer models. Its improved selectivity compared with other WEE1 inhibitors may help mitigate myelosuppressive toxicity. This study investigates whether adding APR-1051 can overcome cisplatin resistance in NRF2-hyperactivated preclinical HNSCC models.",
        "Methods": "HNSCC cells with intrinsic or acquired cisplatin resistance were used for in vitro studies. An orthotopic mouse model of oral cancer was employed to assess in vivo therapeutic efficacy. Clonogenic survival, western blot, cell-invasion, cell-cycle, and Annexin V assays were used to assess drug specificity and underlying mechanisms. Immunofluorescence of phospho-γH2AX evaluated DNA damage response, while H&E staining visualized primary tumors and spontaneous metastases.",
        "Results": "NRF2-hyperactivated, cisplatin-resistant HNSCC cell lines (HN30-R8, HN31), cisplatin-sensitive HN30-P, and HN30-P-KEAP1-KO cells exhibited sensitivity to APR-1051, with half-maximal inhibitory concentrations (IC50) ranging from 50 to 150 nmol/L. Combination index (CI) analysis using the Talalay-Chou method revealed strong synergy between APR-1051 and cisplatin in cisplatin-resistant HN30-R8 and HN31 cells (CI = 0.33).In vivo, APR-1051 significantly enhanced cisplatin sensitivity and suppressed tumor growth in HN30-R8 oral xenografts (P < 0.0001). The combination therapy also reduced cervical lymph node and lung metastases and improved animal survival (P = 0.03) compared with controls or either agent alone, without causing weight loss, indicating good tolerability. Combination treatment induced G2/M arrest, increased apoptosis, and triggered DNA damage and replication stress, associated with cGAS/STING activation and STAT3 pathway inhibition, providing a mechanistic basis for its synergistic anti-tumor effect.",
        "Conclusions": "APR-1051 effectively overcomes cisplatin resistance in HNSCC. Our findings suggest that combining APR-1051 with cisplatin may offer a promising therapeutic strategy for patients with head and neck tumors exhibiting dysregulation of the KEAP1/NRF2 pathway.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>APR1051, a Next-Generation WEE1 Inhibitor, Overcomes Cisplatin Resistance and Suppresses Tumor Progression in KEAP1/NRF2 Hyperactivated Head and Neck Squamous Cell Carcinoma</span>. <u>Tsung-You Tsai, MD</u><sup>1</sup>; Mutsuki Kawabe, DDS, PhD<sup>1</sup>; Arisa Nishikawa Kaga, DDS, PhD<sup>1</sup>; Kento Okamoto, DDS, PhD<sup>1</sup>; Mitchell J Frederick, PhD<sup>2</sup>; Vlad C Sandulache, MD, PhD<sup>2</sup>; Abdullah A Osman, PhD<sup>1</sup>; Jeffrey N Myers<sup>1</sup>. <sup>1</sup>The University of Texas MD Anderson Cancer Center; <sup>2</sup>Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) affects more than 500,000 people worldwide each year, and roughly half of those diagnosed will die from the disease. Multimodal chemotherapy, most commonly cisplatin administered in the neoadjuvant setting or concurrently with radiation, has become the standard of care for patients with locally advanced HNSCC. However, despite therapeutic advances, the development of acquired cisplatin resistance remains a major barrier, ultimately limiting treatment efficacy and contributing to therapeutic failure in most patients. Alterations in the KEAP1/NFE2L2 (NRF2)/CUL3 pathway are present in roughly 20% of head and neck squamous cell carcinomas (HNSCC). Using patient-level datasets and preclinical HNSCC models, we have demonstrated that hyperactivation of NRF2 signaling is tightly associated with acquired cisplatin resistance and enhanced tumor metastasis. This phenotype appears to arise primarily from metabolic adaptation to elevated oxidative stress, inactivating mutations in KEAP1, and epigenetic reprogramming of NFE2L2 (NRF2). WEE1 tyrosine kinase is a critical regulator of the G1-S and G2-M checkpoints and a central mediator of cellular responses to DNA damage. We and others have shown that WEE1 inhibition increases CDK1 and CDK2 activity and re-sensitizes cisplatin-resistant HNSCC cells by impairing their ability to repair cisplatin-induced DNA damage, ultimately triggering mitotic catastrophe and cell death. APR-1051 is an orally bioavailable, highly potent, and selective small-molecule WEE1 inhibitor that exhibits robust anti-proliferative activity in multiple in vivo cancer models. Its improved selectivity compared with other WEE1 inhibitors may help mitigate myelosuppressive toxicity. This study investigates whether adding APR-1051 can overcome cisplatin resistance in NRF2-hyperactivated preclinical HNSCC models.</p>\n\n<p><strong>Methods:</strong> HNSCC cells with intrinsic or acquired cisplatin resistance were used for in vitro studies. An orthotopic mouse model of oral cancer was employed to assess in vivo therapeutic efficacy. Clonogenic survival, western blot, cell-invasion, cell-cycle, and Annexin V assays were used to assess drug specificity and underlying mechanisms. Immunofluorescence of phospho-γH2AX evaluated DNA damage response, while H&E staining visualized primary tumors and spontaneous metastases.</p>\n\n<p><strong>Results:</strong> NRF2-hyperactivated, cisplatin-resistant HNSCC cell lines (HN30-R8, HN31), cisplatin-sensitive HN30-P, and HN30-P-KEAP1-KO cells exhibited sensitivity to APR-1051, with half-maximal inhibitory concentrations (IC50) ranging from 50 to 150 nmol/L. Combination index (CI) analysis using the Talalay-Chou method revealed strong synergy between APR-1051 and cisplatin in cisplatin-resistant HN30-R8 and HN31 cells (CI = 0.33).In vivo, APR-1051 significantly enhanced cisplatin sensitivity and suppressed tumor growth in HN30-R8 oral xenografts (P < 0.0001). The combination therapy also reduced cervical lymph node and lung metastases and improved animal survival (P = 0.03) compared with controls or either agent alone, without causing weight loss, indicating good tolerability. Combination treatment induced G2/M arrest, increased apoptosis, and triggered DNA damage and replication stress, associated with cGAS/STING activation and STAT3 pathway inhibition, providing a mechanistic basis for its synergistic anti-tumor effect.</p>\n\n<p><strong>Conclusions:</strong> APR-1051 effectively overcomes cisplatin resistance in HNSCC. Our findings suggest that combining APR-1051 with cisplatin may offer a promising therapeutic strategy for patients with head and neck tumors exhibiting dysregulation of the KEAP1/NRF2 pathway.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153859--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S520",
      "content_id": "154095",
      "abstract_number": "S520",
      "poster_number": "",
      "title": "H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in surgically resectable, HPV negative oral cavity squamous cell carcinoma (OCSCC): a phase 2 study",
      "summary": "Peri-operative pembrolizumab significantly improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC) in KEYNOTE-689, establishing a new standard of care (SOC). However, major pathological response (MPR) was achieved in only ~10% of participants, highlighting an opportunity to enhance neoadjuvant efficacy. Multikinase inhibitors (MKIs) have demonstrated clinical activity...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154095",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Yashvi Vardhan",
      "presenter": "Yashvi Vardhan",
      "authors": "Yashvi Vardhan 1 ; Sumita Trivedi, MD 2 ; Jeffrey M Blumberg, MD, FACS 3 ; Catherine J Lumley, MD 3 ; Travis Schrank, MD, PhD 3 ; Catherine Colaianni, MD, MPhil 3 ; Jared Weiss, MD 2 ; Trevor Hackman, MD, FACS 3 ; Wendell Yarbrough, MD, MMHC, FACS 3 ; Robert Ferris, MD, PhD 4 ; Mihir Patel, MD 3 ; Siddharth Sheth 2",
      "normalized_authors": [
        "Yashvi Vardhan",
        "Sumita Trivedi",
        "Jeffrey M Blumberg",
        "Catherine J Lumley",
        "Travis Schrank",
        "Catherine Colaianni, MPhil",
        "Jared Weiss",
        "Trevor Hackman",
        "Wendell Yarbrough, MMHC",
        "Robert Ferris",
        "Mihir Patel",
        "Siddharth Sheth"
      ],
      "affiliations": [
        "UNC Chapel Hill School of Medicine",
        "Division of Oncology, University of North Carolina at Chapel Hill",
        "Department of Otolaryngology – Head & Neck Surgery, UNC Chapel Hill",
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "UNC Chapel Hill School of Medicine",
        "Division of Oncology, University of North Carolina at Chapel Hill",
        "Department of Otolaryngology – Head & Neck Surgery, UNC Chapel Hill",
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 293,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract"
      ],
      "sections": {
        "Authors": "Yashvi Vardhan 1 ; Sumita Trivedi, MD 2 ; Jeffrey M Blumberg, MD, FACS 3 ; Catherine J Lumley, MD 3 ; Travis Schrank, MD, PhD 3 ; Catherine Colaianni, MD, MPhil 3 ; Jared Weiss, MD 2 ; Trevor Hackman, MD, FACS 3 ; Wendell Yarbrough, MD, MMHC, FACS 3 ; Robert Ferris, MD, PhD 4 ; Mihir Patel, MD 3 ; Siddharth Sheth 2",
        "Affiliations": "1 UNC Chapel Hill School of Medicine; 2 Division of Oncology, University of North Carolina at Chapel Hill; 3 Department of Otolaryngology – Head & Neck Surgery, UNC Chapel Hill; 4 UNC Lineberger Comprehensive Cancer Center",
        "Introduction": "Peri-operative pembrolizumab significantly improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC) in KEYNOTE-689, establishing a new standard of care (SOC). However, major pathological response (MPR) was achieved in only ~10% of participants, highlighting an opportunity to enhance neoadjuvant efficacy. Multikinase inhibitors (MKIs) have demonstrated clinical activity in HNSCC. In LEAP-010, the combination of lenvatinib and pembrolizumab improved objective response rate (ORR) and progression-free survival (PFS), although this did not translate into overall survival (OS) benefit. HPV-unrelated HNSCC commonly exhibits EGFR and MET overexpression, supporting strategies that simultaneously target angiogenesis, growth-factor signaling, and immune modulation. Zanzalintinib (XL092), a next-generation MKI with a shorter half-life and improved tolerability profile, may potentiate and accelerate anti-tumor responses when combined with pembrolizumab. We hypothesize that this regimen will increase MPR rates and improve long-term outcomes in resectable, HPV-negative disease.",
        "Methods": "LCCC 2517 is a multicenter, investigator-initiated, phase 2 trial evaluating neoadjuvant zanzalintinib plus pembrolizumab in patients with human papilloma virus negative, resectable Stage III–IVa HNSCC of the oral cavity. Key inclusion criteria include negative p16 status (if known), PD-L1 CPS ≥1 by local testing, and no prior therapy in the locally advanced setting. Participants receive zanzalintinib 60 mg orally once daily for 6 weeks, plus pembrolizumab 200 mg every 3 weeks for 2 cycles, followed by definitive surgery. Patients who proceed to resection will receive adjuvant radiation plus pembrolizumab (± cisplatin) for 3 cycles per SOC, then 12 cycles of maintenance pembrolizumab.",
        "Abstract": "The primary endpoint is MPR, defined as <10% viable tumor following surgery. A Simon’s two-stage design is used: Stage 1 enrolls 11 patients, and if ≥2 achieve MPR, the study expands to 26 total patients. Key secondary endpoints include EFS, OS, and safety. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in surgically resectable, HPV negative oral cavity squamous cell carcinoma (OCSCC): a phase 2 study</span>. <u>Yashvi Vardhan</u><sup>1</sup>; Sumita Trivedi, MD<sup>2</sup>; Jeffrey M Blumberg, MD, FACS<sup>3</sup>; Catherine J Lumley, MD<sup>3</sup>; Travis Schrank, MD, PhD<sup>3</sup>; Catherine Colaianni, MD, MPhil<sup>3</sup>; Jared Weiss, MD<sup>2</sup>; Trevor Hackman, MD, FACS<sup>3</sup>; Wendell Yarbrough, MD, MMHC, FACS<sup>3</sup>; Robert Ferris, MD, PhD<sup>4</sup>; Mihir Patel, MD<sup>3</sup>; Siddharth Sheth<sup>2</sup>. <sup>1</sup>UNC Chapel Hill School of Medicine; <sup>2</sup>Division of Oncology, University of North Carolina at Chapel Hill; <sup>3</sup>Department of Otolaryngology – Head & Neck Surgery, UNC Chapel Hill; <sup>4</sup>UNC Lineberger Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Peri-operative pembrolizumab significantly improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC) in KEYNOTE-689, establishing a new standard of care (SOC). However, major pathological response (MPR) was achieved in only ~10% of participants, highlighting an opportunity to enhance neoadjuvant efficacy. Multikinase inhibitors (MKIs) have demonstrated clinical activity in HNSCC. In LEAP-010, the combination of lenvatinib and pembrolizumab improved objective response rate (ORR) and progression-free survival (PFS), although this did not translate into overall survival (OS) benefit. HPV-unrelated HNSCC commonly exhibits EGFR and MET overexpression, supporting strategies that simultaneously target angiogenesis, growth-factor signaling, and immune modulation. Zanzalintinib (XL092), a next-generation MKI with a shorter half-life and improved tolerability profile, may potentiate and accelerate anti-tumor responses when combined with pembrolizumab. We hypothesize that this regimen will increase MPR rates and improve long-term outcomes in resectable, HPV-negative disease.</p>\n\n<p><strong>Methods: </strong>LCCC 2517 is a multicenter, investigator-initiated, phase 2 trial evaluating neoadjuvant zanzalintinib plus pembrolizumab in patients with human papilloma virus negative, resectable Stage III–IVa HNSCC of the oral cavity. Key inclusion criteria include negative p16 status (if known), PD-L1 CPS ≥1 by local testing, and no prior therapy in the locally advanced setting. Participants receive zanzalintinib 60 mg orally once daily for 6 weeks, plus pembrolizumab 200 mg every 3 weeks for 2 cycles, followed by definitive surgery. Patients who proceed to resection will receive adjuvant radiation plus pembrolizumab (± cisplatin) for 3 cycles per SOC, then 12 cycles of maintenance pembrolizumab.</p>\n\n<p>The primary endpoint is MPR, defined as <10% viable tumor following surgery. A Simon’s two-stage design is used: Stage 1 enrolls 11 patients, and if ≥2 achieve MPR, the study expands to 26 total patients. Key secondary endpoints include EFS, OS, and safety.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154095--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S521",
      "content_id": "153612",
      "abstract_number": "S521",
      "poster_number": "",
      "title": "Neoadjuvant Pembrolizumab/Cetuximab for the Treatment of Betel Nut Associated Oral Cavity Cancer: A Case Series",
      "summary": "Pembrolizumab/Cetuximab is a promising option for the neoadjuvant treatment of advanced BNA OCSCC, particularly in resource limited settings with challenging referral patterns. Our findings are topical given recent investigations into the application of immunotherapy in the curative treatment of advanced head and neck cancer. Prospective investigation of this novel treatment paradigm is being pursued.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153612",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Stephanie Wong, MD",
      "presenter": "Stephanie Wong, MD",
      "authors": "Jonathan D West, MD 1 ; Stephanie Wong, MD 1 ; William Moss, MD 2 ; Peter Brett, MD 3 ; Daniel I Kwon, MD 1",
      "normalized_authors": [
        "Jonathan D West",
        "Stephanie Wong",
        "William Moss",
        "Peter Brett",
        "Daniel I Kwon"
      ],
      "affiliations": [
        "Caruso Department of Otolaryngology - Head and Neck Surgery, Keck SOM of USC",
        "Division of Otolaryngology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands",
        "Division of Medical Oncology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands"
      ],
      "normalized_institutions": [
        "Caruso Department of Otolaryngology - Head and Neck Surgery, Keck SOM of USC",
        "Division of Otolaryngology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands",
        "Division of Medical Oncology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 371,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Intro",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jonathan D West, MD 1 ; Stephanie Wong, MD 1 ; William Moss, MD 2 ; Peter Brett, MD 3 ; Daniel I Kwon, MD 1",
        "Affiliations": "1 Caruso Department of Otolaryngology - Head and Neck Surgery, Keck SOM of USC; 2 Division of Otolaryngology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands; 3 Division of Medical Oncology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands",
        "Intro": "The Northern Mariana Islands (NMI) is a remote, resource-limited US territory in the western Pacific Ocean with high rates of betel nut use, a well-known carcinogen causing oral cavity squamous cell carcinoma (OCSCC). Patients in this region often present with advanced stage or unresectable disease that requires referral to the mainland US for treatment. Prior studies have demonstrated the efficacy of Pembrolizumab/Cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. We present a case series documenting the application of this treatment to the neoadjuvant setting for advanced betel nut-associated (BNA) OCSCC in a remote population.",
        "Methods": "Retrospective case series from September 2023 to December 2025. All patients were residents of the NMI who were diagnosed with advanced BNA OCSCC and underwent at least 1 cycle of neoadjuvant immunotherapy. The treatment regimen was Pembrolizumab 400mg IV on day 1 and Cetuximab 500 mg/sq m IV on days 1, 15, 29. This cycle was repeated every 42 days until surgery. Indications for neoadjuvant therapy included advanced T stage (T4a/b), involvement of the pterygopalatine/infratemporal fossa, cutaneous or oral commissure involvement, or anticipated progression to unresectable disease during referral process. Treatment response was evaluated by RECIST criteria when possible. Overall and disease-free survival were determined.",
        "Results": "Eight patients were treated with a median treatment duration of 3.2 months, median time to treatment response determination of 3.3 months, and median time to surgery of 5.3 months. Two patients (25%) had partial response, two (25%) had complete response with one demonstrating no malignancy on surgical pathology and three (38%) had stable disease. One patient (12.5%) had partial response based on clinical evaluation alone. The majority of patients are alive (75%) and disease free (75%), with a median overall survival of 12.1 months and median disease-free survival of 11.8 months. Median follow up was 12.3 months.",
        "Conclusion": "Pembrolizumab/Cetuximab is a promising option for the neoadjuvant treatment of advanced BNA OCSCC, particularly in resource limited settings with challenging referral patterns. Our findings are topical given recent investigations into the application of immunotherapy in the curative treatment of advanced head and neck cancer. Prospective investigation of this novel treatment paradigm is being pursued.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Neoadjuvant Pembrolizumab/Cetuximab for the Treatment of Betel Nut Associated Oral Cavity Cancer: A Case Series</span>. Jonathan D West, MD<sup>1</sup>; <u>Stephanie Wong, MD</u><sup>1</sup>; William Moss, MD<sup>2</sup>; Peter Brett, MD<sup>3</sup>; Daniel I Kwon, MD<sup>1</sup>. <sup>1</sup>Caruso Department of Otolaryngology - Head and Neck Surgery, Keck SOM of USC; <sup>2</sup>Division of Otolaryngology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands; <sup>3</sup>Division of Medical Oncology, Commonwealth Healthcare Corportation, Saipan, Northern Mariana Islands<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Intro: </strong>The Northern Mariana Islands (NMI) is a remote, resource-limited US territory in the western Pacific Ocean with high rates of betel nut use, a well-known carcinogen causing oral cavity squamous cell carcinoma (OCSCC). Patients in this region often present with advanced stage or unresectable disease that requires referral to the mainland US for treatment. Prior studies have demonstrated the efficacy of Pembrolizumab/Cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. We present a case series documenting the application of this treatment to the neoadjuvant setting for advanced betel nut-associated (BNA) OCSCC in a remote population.</p>\n\n<p><strong>Methods: </strong>Retrospective case series from September 2023 to December 2025. All patients were residents of the NMI who were diagnosed with advanced BNA OCSCC and underwent at least 1 cycle of neoadjuvant immunotherapy. The treatment regimen was Pembrolizumab 400mg IV on day 1 and Cetuximab 500 mg/sq m IV on days 1, 15, 29. This cycle was repeated every 42 days until surgery. Indications for neoadjuvant therapy included advanced T stage (T4a/b), involvement of the pterygopalatine/infratemporal fossa, cutaneous or oral commissure involvement, or anticipated progression to unresectable disease during referral process. Treatment response was evaluated by RECIST criteria when possible. Overall and disease-free survival were determined.</p>\n\n<p><strong>Results: </strong>Eight patients were treated with a median treatment duration of 3.2 months, median time to treatment response determination of 3.3 months, and median time to surgery of 5.3 months. Two patients (25%) had partial response, two (25%) had complete response with one demonstrating no malignancy on surgical pathology and three (38%) had stable disease. One patient (12.5%) had partial response based on clinical evaluation alone. The majority of patients are alive (75%) and disease free (75%), with a median overall survival of 12.1 months and median disease-free survival of 11.8 months. Median follow up was 12.3 months.</p>\n\n<p><strong>Conclusion: </strong>Pembrolizumab/Cetuximab is a promising option for the neoadjuvant treatment of advanced BNA OCSCC, particularly in resource limited settings with challenging referral patterns. Our findings are topical given recent investigations into the application of immunotherapy in the curative treatment of advanced head and neck cancer. Prospective investigation of this novel treatment paradigm is being pursued.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153612--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S522",
      "content_id": "154228",
      "abstract_number": "S522",
      "poster_number": "",
      "title": "High pathologic response with neoadjuvant chemo-immunotherapy (NACI) in oral, oropharyngeal, and other head neck squamous cell carcinomas (HNSCC)",
      "summary": "Here we present data on two different neoadjuvant immunotherapy regimens. The results provide further insight into the pathologic effects of immunotherapy in an off-trial setting. Although this study cannot establish a direct comparison, the outcomes suggest that chemotherapy augments the efficacy of immunotherapy in achieving pCR or MPR. Emerging studies have demonstrated that pathologic response to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154228",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ethan Gomez",
      "presenter": "Ethan Gomez",
      "authors": "Ethan Gomez ; Yehia Elkersh; Daniel Kraft; Peter Cooke; Ryan Sicard; Alicia Yang; Mudassir Mumtaz; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof",
      "normalized_authors": [
        "Ethan Gomez",
        "Yehia Elkersh",
        "Daniel Kraft",
        "Peter Cooke",
        "Ryan Sicard",
        "Alicia Yang",
        "Mudassir Mumtaz",
        "Thomas Barrett",
        "Michael Berger",
        "Marita Teng",
        "Diana Kirke",
        "Mark Urken",
        "Mohemmed Khan",
        "Raymond Chai",
        "Nasrin Ghesani",
        "Azita Khorsandi",
        "Richard Bakst",
        "Krzysztof Misiukiewicz",
        "Kunal Sindhu",
        "Jerry Liu",
        "Margaret Brandwein",
        "Elisabet Pujadas",
        "Eric Genden",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 474,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ethan Gomez ; Yehia Elkersh; Daniel Kraft; Peter Cooke; Ryan Sicard; Alicia Yang; Mudassir Mumtaz; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Background": "Patient outcomes for resectable head and neck squamous cell carcinomas (HNSCC) have remained unchanged until the recent introduction of immune checkpoint inhibitors. The paradigm-changing KEYNOTE-689 phase 3 trial showed that neoadjuvant and adjuvant pembrolizumab, in addition to standard therapy, significantly improved major pathologic response (MPR) rates and event-free survival (EFS). Still, a substantial portion of patients exhibit inadequate response. Ongoing studies are therefore investigating combination neoadjuvant immunotherapy (NAI) regimens. Early investigations of neoadjuvant chemo-immunotherapy (NACI) have reported superior rates of MPR and complete pathologic response (pCR) compared with NAI alone. This study describes the pathologic responses to NAI and NACI in patients undergoing definitive treatment.",
        "Methods": "This is a retrospective review of HNSCC patients at a large, urban, academic hospital. All patients received neoadjuvant pembrolizumab, either alone (NAI), or with additional docetaxel and cisplatin chemotherapy (NACI). Histopathologic evidence of treatment effect was the primary aim of this study. Pathologic treatment response was categorized as: complete response (pCR), (no viable tumor); major pathologic response (MPR), (1-10% viable tumor) and partial pathologic response (PR), (11-90% viable tumor).",
        "Results": "Fifty patients received NAI or NACI plus surgery (mean age 62, 72% male). Twenty-eight (56%) patients had oropharyngeal cancer (OPX; 22/28 HPV+), 15 (30%) had oral cancer, 6 (12%) had nasal cavity cancer, and 1 (2%) patient had laryngeal cancer. The median number of days from treatment initiation to surgery was 51 (SD=18). None of the patients delayed surgery due to treatment-related complications or toxicity. NACI was administered to 31 (62%) patients and 19 (38%) received NAI alone. On pathologic review of entire surgical specimens, all 50 patients revealed some treatment effect. Forty-nine (98%) specimens had evidence of treatment effect at the primary tumor; the remaining specimen showed treatment effect only in the lymph nodes. Features of treatment response included dense acute inflammation, necrosis, dense fibrosis, keratin granulomas, among others. Fifteen (30%) patients demonstrated pCR, 7 (14%) MPR, and 28 (56%) PR. In those who received NACI, 21/31 (68%) patients demonstrated pCR or MPR. In those who received NAI alone, 1/19 (5%) patients demonstrated pCR or MPR. When stratifying NACI recipients by HPV status, pCR or MPR was achieved in 7/22 (32%) HPV+ OPX and 1/6 (17%) in HPV- OPX cases.",
        "Conclusion": "Here we present data on two different neoadjuvant immunotherapy regimens. The results provide further insight into the pathologic effects of immunotherapy in an off-trial setting. Although this study cannot establish a direct comparison, the outcomes suggest that chemotherapy augments the efficacy of immunotherapy in achieving pCR or MPR. Emerging studies have demonstrated that pathologic response to immunotherapy is an independent predictor of EFS and overall survival across several cancer types. This relationship has not yet been established in HNSCC. Further research into the hypothesized association between pathologic response and long-term clinical outcomes in HNSCC is warranted.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>High pathologic response with neoadjuvant chemo-immunotherapy (NACI) in oral, oropharyngeal, and other head neck squamous cell carcinomas (HNSCC)</span>. <u>Ethan Gomez</u>; Yehia Elkersh; Daniel Kraft; Peter Cooke; Ryan Sicard; Alicia Yang; Mudassir Mumtaz; Thomas Barrett; Michael Berger; Marita Teng; Diana Kirke; Mark Urken; Mohemmed Khan; Raymond Chai; Nasrin Ghesani; Azita Khorsandi; Richard Bakst; Krzysztof Misiukiewicz; Kunal Sindhu; Jerry Liu; Margaret Brandwein; Elisabet Pujadas; Eric Genden; Scott Roof. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Patient outcomes for resectable head and neck squamous cell carcinomas (HNSCC) have remained unchanged until the recent introduction of immune checkpoint inhibitors. The paradigm-changing KEYNOTE-689 phase 3 trial showed that neoadjuvant and adjuvant pembrolizumab, in addition to standard therapy, significantly improved major pathologic response (MPR) rates and event-free survival (EFS). Still, a substantial portion of patients exhibit inadequate response. Ongoing studies are therefore investigating combination neoadjuvant immunotherapy (NAI) regimens. Early investigations of neoadjuvant chemo-immunotherapy (NACI) have reported superior rates of MPR and complete pathologic response (pCR) compared with NAI alone. This study describes the pathologic responses to NAI and NACI in patients undergoing definitive treatment.</p>\n\n<p><strong>Methods: </strong>This is a retrospective review of HNSCC patients at a large, urban, academic hospital.  All patients received neoadjuvant pembrolizumab, either alone (NAI), or with additional docetaxel and cisplatin chemotherapy (NACI).  Histopathologic evidence of treatment effect was the primary aim of this study. Pathologic treatment response was categorized as: complete response (pCR), (no viable tumor); major pathologic response (MPR), (1-10% viable tumor) and partial pathologic response (PR), (11-90% viable tumor).</p>\n\n<p><strong>Results: </strong>Fifty patients received NAI or NACI plus surgery (mean age 62, 72% male). Twenty-eight (56%) patients had oropharyngeal cancer (OPX; 22/28 HPV+), 15 (30%) had oral cancer, 6 (12%) had nasal cavity cancer, and 1 (2%) patient had laryngeal cancer. The median number of days from treatment initiation to surgery was 51 (SD=18). None of the patients delayed surgery due to treatment-related complications or toxicity. NACI was administered to 31 (62%) patients and 19 (38%) received NAI alone. On pathologic review of entire surgical specimens, all 50 patients revealed some treatment effect. Forty-nine (98%) specimens had evidence of treatment effect at the primary tumor; the remaining specimen showed treatment effect only in the lymph nodes. Features of treatment response included dense acute inflammation, necrosis, dense fibrosis, keratin granulomas, among others.  Fifteen (30%) patients demonstrated pCR, 7 (14%) MPR, and 28 (56%) PR. In those who received NACI, 21/31 (68%) patients demonstrated pCR or MPR. In those who received NAI alone, 1/19 (5%) patients demonstrated pCR or MPR. When stratifying NACI recipients by HPV status, pCR or MPR was achieved in 7/22 (32%) HPV+ OPX and 1/6 (17%) in HPV- OPX cases.</p>\n\n<p><strong>Conclusion: </strong>Here we present data on two different neoadjuvant immunotherapy regimens.  The results provide further insight into the pathologic effects of immunotherapy in an off-trial setting. Although this study cannot establish a direct comparison, the outcomes suggest that chemotherapy augments the efficacy of immunotherapy in achieving pCR or MPR. Emerging studies have demonstrated that pathologic response to immunotherapy is an independent predictor of EFS and overall survival across several cancer types.  This relationship has not yet been established in HNSCC. Further research into the hypothesized association between pathologic response and long-term clinical outcomes in HNSCC is warranted.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154228--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S523",
      "content_id": "154746",
      "abstract_number": "S523",
      "poster_number": "",
      "title": "Real-World Adoption of Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Patterns, Disparities, and Survival Outcomes Using NCDB Data",
      "summary": "In this national cohort, immunotherapy was associated with a threefold improvement in median OS and enhanced long-term survival. Despite comparable disease stage, treatment patterns differed substantially. Subsite preferences and sociodemographic trends reveal evolving standards and highlight persistent disparities. These findings support the survival benefit of immunotherapy in R/M HNSCC and emphasize the need...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154746",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alex Vaicius",
      "presenter": "Alex Vaicius",
      "authors": "Alex Vaicius ; Vishal Gupta",
      "normalized_authors": [
        "Alex Vaicius",
        "Vishal Gupta"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 389,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Alex Vaicius ; Vishal Gupta",
        "Affiliations": "Roswell Park Comprehensive Cancer Center",
        "Abstract": "Real-World Survival Impact of Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Insights from 3,473 Patients in the NCDB (2013–2020) Although both groups had similar overall disease extent, a larger share of immunotherapy patients had Stage IV disease (92.5% vs 89.0%, p < .001). Immunotherapy recipients were less likely to receive chemotherapy (28.4% vs 71.6%) and more likely to undergo radiation (39.0% vs 27.0%, both p < .001), signaling a shift toward multimodal regimens. Subsite trends revealed increased immunotherapy use in tongue (29.7%) and tonsil (22.6%) cancers compared to non-immunotherapy patients (24.9% and 13.0%, respectively; p < .001), reflecting practice patterns favoring immunotherapy in oropharyngeal disease, despite missing HPV data. Patients treated with immunotherapy were younger (mean 64.1 vs 67.5 years, p < .001), predominantly male (83.1% vs 74.2%, p < .001), and more likely to be privately insured or from higher-income areas (p < .001), suggesting access disparities. Treatment initiation was delayed compared to cytotoxic therapy, aligning with real-world sequencing practices. View in Agenda and Add to Schedule",
        "Introduction": "Immunotherapy has reshaped the management of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), though real-world survival data and adoption trends remain underexplored. This study assesses survival outcomes and clinical characteristics linked to immunotherapy in a large national cohort.",
        "Methods": "A retrospective analysis was conducted using the National Cancer Database (NCDB) from 2013–2020, including patients with R/M HNSCC treated with either immunotherapy or other systemic therapies. Demographic, clinical, and treatment data were compared using Pearson’s χ² and Wilcoxon rank-sum tests. Kaplan–Meier analysis was used to assess overall survival (OS).",
        "Results": "Among 3,473 patients, 1,741 (50.1%) received immunotherapy. Median OS was significantly longer for the immunotherapy group (13.9 vs 3.9 months, p < .001), with higher 3-year (25% vs 14%) and 5-year (16% vs 10%) survival rates.",
        "Conclusion": "In this national cohort, immunotherapy was associated with a threefold improvement in median OS and enhanced long-term survival. Despite comparable disease stage, treatment patterns differed substantially. Subsite preferences and sociodemographic trends reveal evolving standards and highlight persistent disparities. These findings support the survival benefit of immunotherapy in R/M HNSCC and emphasize the need for: 1. Biomarker-driven patient selection. 2. Optimized integration with radiation and systemic therapy. 3. Equitable treatment access across populations."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Real-World Adoption of Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Patterns, Disparities, and Survival Outcomes Using NCDB Data</span>. <u>Alex Vaicius</u>; Vishal Gupta. Roswell Park Comprehensive Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Real-World Survival Impact of Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Insights from 3,473 Patients in the NCDB (2013–2020)</p>\n\n<p><strong>Introduction: </strong>Immunotherapy has reshaped the management of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), though real-world survival data and adoption trends remain underexplored. This study assesses survival outcomes and clinical characteristics linked to immunotherapy in a large national cohort.</p>\n\n<p><strong>Methods: </strong>A retrospective analysis was conducted using the National Cancer Database (NCDB) from 2013–2020, including patients with R/M HNSCC treated with either immunotherapy or other systemic therapies. Demographic, clinical, and treatment data were compared using Pearson’s χ² and Wilcoxon rank-sum tests. Kaplan–Meier analysis was used to assess overall survival (OS).</p>\n\n<p><strong>Results: </strong>Among 3,473 patients, 1,741 (50.1%) received immunotherapy. Median OS was significantly longer for the immunotherapy group (13.9 vs 3.9 months, p < .001), with higher 3-year (25% vs 14%) and 5-year (16% vs 10%) survival rates.</p>\n\n<p>Although both groups had similar overall disease extent, a larger share of immunotherapy patients had Stage IV disease (92.5% vs 89.0%, p < .001). Immunotherapy recipients were less likely to receive chemotherapy (28.4% vs 71.6%) and more likely to undergo radiation (39.0% vs 27.0%, both p < .001), signaling a shift toward multimodal regimens.</p>\n\n<p>Subsite trends revealed increased immunotherapy use in tongue (29.7%) and tonsil (22.6%) cancers compared to non-immunotherapy patients (24.9% and 13.0%, respectively; p < .001), reflecting practice patterns favoring immunotherapy in oropharyngeal disease, despite missing HPV data.</p>\n\n<p>Patients treated with immunotherapy were younger (mean 64.1 vs 67.5 years, p < .001), predominantly male (83.1% vs 74.2%, p < .001), and more likely to be privately insured or from higher-income areas (p < .001), suggesting access disparities. Treatment initiation was delayed compared to cytotoxic therapy, aligning with real-world sequencing practices.</p>\n\n<p><strong>Conclusion: </strong>In this national cohort, immunotherapy was associated with a threefold improvement in median OS and enhanced long-term survival. Despite comparable disease stage, treatment patterns differed substantially. Subsite preferences and sociodemographic trends reveal evolving standards and highlight persistent disparities. These findings support the survival benefit of immunotherapy in R/M HNSCC and emphasize the need for: 1. Biomarker-driven patient selection. 2. Optimized integration with radiation and systemic therapy. 3. Equitable treatment access across populations.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154746--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S524",
      "content_id": "154033",
      "abstract_number": "S524",
      "poster_number": "",
      "title": "A Multicenter Phase III Study Assessing Neoadjuvant APG-157 in Resectable HNSCC and Induction plus Maintenance APG-157 in Unresectable HNSCC",
      "summary": "APG-157 is an oral NF-κB-modulating immunotherapy that reshapes TME by increasing immune-cell infiltration, supporting cytotoxic memory niches, and shifting M2 to M1 macrophages. In a Phase 2A (n=24) in oral cavity and oropharyngeal cancers, neoadjuvant or induction APG-157 caused no delay to definitive surgery and/or (chemo)radiotherapy. The regimen achieved 91% two-year EFS (median not reached), a 16.7% ORR,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154033",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260156",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jonathan D Schoenfeld",
      "presenter": "Jonathan D Schoenfeld",
      "authors": "Jonathan D Schoenfeld 1 ; Sid Puram 2 ; John B A Hanen 3 ; Makoto Tahara 4 ; Marilene B Wang 5 ; Elizabeth J Franzmann 6 ; Maie A St John 7 ; Deborah J Wong 8 ; Trisha Wise-Draper 9 ; Aditya Shreenivas 10 ; Sagus Sampath 11 ; Krupal Patel 12 ; Jessica R Bauman 13 ; Anshu Giri 13 ; Francis Worden 14 ; Michelle Mierzwa 15 ; Kedar S Kirtane 16 ; David M Neskey 17 ; Winston Wong 18 ; Haythem Ali 19 ; Susanne Flach 20 ; Vanessa Chin 21 ; Jia Liu 22 ; Daniel Brungs 23 ; Udit Nindra 23 ; Daniel S Shin 24 ; Apar Kishor Ganti 25 ; Lisa Licitra 26 ; Sandra LIop Serna 27 ; Zara V Sepulveda 27 ; Doru M Paul 28 ; Vlad C Sandulache 29 ; David J Hernandez 29 ; Ray Y Wang 29 ; José López L López 30 ; Sahin Laçin 31 ; Fatih Selcukbiricik 31 ; Osman Kostek 32 ; Uttam K Sinha 33 ; Paolo Bossi 34 ; Carlo Resteghini 34 ; Mansoor Saleh 35 ; Tjoson Tjoa 36 ; Yarah Haidar 36 ; Luis Avila 37 ; Murat Budak 37 ; Anjali Desai 37 ; Selda Samakoglu 37 ; Kevin Harrington 38",
      "normalized_authors": [
        "Jonathan D Schoenfeld",
        "Sid Puram",
        "John B A Hanen",
        "Makoto Tahara",
        "Marilene B Wang",
        "Elizabeth J Franzmann",
        "Maie A St John",
        "Deborah J Wong",
        "Trisha Wise-Draper",
        "Aditya Shreenivas",
        "Sagus Sampath",
        "Krupal Patel",
        "Jessica R Bauman",
        "Anshu Giri",
        "Francis Worden",
        "Michelle Mierzwa",
        "Kedar S Kirtane",
        "David M Neskey",
        "Winston Wong",
        "Haythem Ali",
        "Susanne Flach",
        "Vanessa Chin",
        "Jia Liu",
        "Daniel Brungs",
        "Udit Nindra",
        "Daniel S Shin",
        "Apar Kishor Ganti",
        "Lisa Licitra",
        "Sandra LIop Serna",
        "Zara V Sepulveda",
        "Doru M Paul",
        "Vlad C Sandulache",
        "David J Hernandez",
        "Ray Y Wang",
        "José López L López",
        "Sahin Laçin",
        "Fatih Selcukbiricik",
        "Osman Kostek",
        "Uttam K Sinha",
        "Paolo Bossi",
        "Carlo Resteghini",
        "Mansoor Saleh",
        "Tjoson Tjoa",
        "Yarah Haidar",
        "Luis Avila",
        "Murat Budak",
        "Anjali Desai",
        "Selda Samakoglu",
        "Kevin Harrington"
      ],
      "affiliations": [
        "Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA",
        "Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",
        "Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan",
        "Department of Otolaryngology - Head and Neck Surgery, University of California, Los Angeles, CA, USA",
        "Department of Otolaryngology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System, Baltimore, USA",
        "Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA",
        "Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA",
        "Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA",
        "Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA",
        "Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA",
        "Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA",
        "Head and Neck Specialists, Sarah Cannon Canner Network, Charleston, SC, USA",
        "Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA",
        "Department of Internal Medicine-Medical Oncology, Henry Ford Health System, Detroit, MI, USA",
        "Department of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany",
        "Department of Otolaryngology, Head and Neck Surgery, St. Vincent's Hospital, Darlinghurst, NSW, Australia. Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia",
        "The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Sydney, NSW, Australia. School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, NSW, Australia. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia",
        "Illawarra Cancer Centre, Wollongong Hospital, NSW, Australia. Graduate School of Medicine, University of Wollongong, NSW, Australia",
        "Section of Hematology-Oncology, Baylor College of Medicine, Staff Physician at Michael E DeBakey VA Medical Center, Houston, TX, USA",
        "Division of Hematology & Oncology, Department of Medicine, University of Nebraska Medical Center",
        "VA Nebraska-Western Iowa Health Center, Omaha, NE, USA",
        "Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy",
        "Department of Medical Oncology, Catalan, Institute of oncology (ICO, L’Hospitalet), Barcelona, Spain",
        "Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA",
        "Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
        "Department of Dentistry, University of Barcelona. Member of the oral health research group at DIBELL. Medical Director of the University of Barcelona Dental Hospital (HOUB), Spain",
        "Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey",
        "Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey",
        "Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA",
        "Department of Biomedical Sciences, Humanitas University, Milan, Italy, IRCCS Humanitas Research Hospital, Milan, Italy",
        "Humanitas Cancer Center",
        "Department of Hematology-Oncology, Aga Khan University, 3rd Parklands Avenue, Nairobi, Kenya",
        "Department of Otolaryngology, Head and Neck Surgical Oncology and Microvascular Reconstruction, University of California Irvine, CA, USA",
        "Aveta Biomics",
        "The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom"
      ],
      "normalized_institutions": [
        "Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA",
        "Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",
        "Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan",
        "Department of Otolaryngology - Head and Neck Surgery, University of California, Los Angeles, CA, USA",
        "Department of Otolaryngology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA",
        "Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System, Baltimore, USA",
        "Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA",
        "Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA",
        "Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA",
        "Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA",
        "Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA",
        "Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA",
        "Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA",
        "Head and Neck Specialists, Sarah Cannon Canner Network, Charleston, SC, USA",
        "Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA",
        "Department of Internal Medicine-Medical Oncology, Henry Ford Health System, Detroit, MI, USA",
        "Department of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany",
        "Department of Otolaryngology, Head and Neck Surgery, St. Vincent's Hospital, Darlinghurst, NSW, Australia. Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia",
        "The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Sydney, NSW, Australia. School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, NSW, Australia. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia",
        "Illawarra Cancer Centre, Wollongong Hospital, NSW, Australia. Graduate School of Medicine, University of Wollongong, NSW, Australia",
        "Section of Hematology-Oncology, Baylor College of Medicine, Staff Physician at Michael E DeBakey VA Medical Center, Houston, TX, USA",
        "Division of Hematology & Oncology, Department of Medicine, University of Nebraska Medical Center",
        "VA Nebraska-Western Iowa Health Center, Omaha, NE, USA",
        "Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy",
        "Department of Medical Oncology, Catalan, Institute of oncology (ICO, L’Hospitalet), Barcelona, Spain",
        "Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA",
        "Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
        "Department of Dentistry, University of Barcelona. Member of the oral health research group at DIBELL. Medical Director of the University of Barcelona Dental Hospital (HOUB), Spain",
        "Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey",
        "Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey",
        "Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA",
        "Department of Biomedical Sciences, Humanitas University, Milan, Italy, IRCCS Humanitas Research Hospital, Milan, Italy",
        "Humanitas Cancer Center",
        "Department of Hematology-Oncology, Aga Khan University, 3rd Parklands Avenue, Nairobi, Kenya",
        "Department of Otolaryngology, Head and Neck Surgical Oncology and Microvascular Reconstruction, University of California Irvine, CA, USA",
        "Aveta Biomics",
        "The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 522,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jonathan D Schoenfeld 1 ; Sid Puram 2 ; John B A Hanen 3 ; Makoto Tahara 4 ; Marilene B Wang 5 ; Elizabeth J Franzmann 6 ; Maie A St John 7 ; Deborah J Wong 8 ; Trisha Wise-Draper 9 ; Aditya Shreenivas 10 ; Sagus Sampath 11 ; Krupal Patel 12 ; Jessica R Bauman 13 ; Anshu Giri 13 ; Francis Worden 14 ; Michelle Mierzwa 15 ; Kedar S Kirtane 16 ; David M Neskey 17 ; Winston Wong 18 ; Haythem Ali 19 ; Susanne Flach 20 ; Vanessa Chin 21 ; Jia Liu 22 ; Daniel Brungs 23 ; Udit Nindra 23 ; Daniel S Shin 24 ; Apar Kishor Ganti 25 ; Lisa Licitra 26 ; Sandra LIop Serna 27 ; Zara V Sepulveda 27 ; Doru M Paul 28 ; Vlad C Sandulache 29 ; David J Hernandez 29 ; Ray Y Wang 29 ; José López L López 30 ; Sahin Laçin 31 ; Fatih Selcukbiricik 31 ; Osman Kostek 32 ; Uttam K Sinha 33 ; Paolo Bossi 34 ; Carlo Resteghini 34 ; Mansoor Saleh 35 ; Tjoson Tjoa 36 ; Yarah Haidar 36 ; Luis Avila 37 ; Murat Budak 37 ; Anjali Desai 37 ; Selda Samakoglu 37 ; Kevin Harrington 38",
        "Affiliations": "1 Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2 Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA; 3 Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 4 Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan; 5 Department of Otolaryngology - Head and Neck Surgery, University of California, Los Angeles, CA, USA; 6 Department of Otolaryngology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA; 7 Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System, Baltimore, USA; 8 Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA; 9 Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 10 Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA; 11 Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA; 12 Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA; 13 Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 14 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; 15 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; 16 Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA; 17 Head and Neck Specialists, Sarah Cannon Canner Network, Charleston, SC, USA; 18 Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA; 19 Department of Internal Medicine-Medical Oncology, Henry Ford Health System, Detroit, MI, USA; 20 Department of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany; 21 Department of Otolaryngology, Head and Neck Surgery, St. Vincent's Hospital, Darlinghurst, NSW, Australia. Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; 22 The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Sydney, NSW, Australia. School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, NSW, Australia. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; 23 Illawarra Cancer Centre, Wollongong Hospital, NSW, Australia. Graduate School of Medicine, University of Wollongong, NSW, Australia; 24 Section of Hematology-Oncology, Baylor College of Medicine, Staff Physician at Michael E DeBakey VA Medical Center, Houston, TX, USA; 25 Division of Hematology & Oncology, Department of Medicine, University of Nebraska Medical Center; VA Nebraska-Western Iowa Health Center, Omaha, NE, USA; 26 Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; 27 Department of Medical Oncology, Catalan, Institute of oncology (ICO, L’Hospitalet), Barcelona, Spain; 28 Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; 29 Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA; 30 Department of Dentistry, University of Barcelona. Member of the oral health research group at DIBELL. Medical Director of the University of Barcelona Dental Hospital (HOUB), Spain; 31 Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey; 32 Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; 33 Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 34 Department of Biomedical Sciences, Humanitas University, Milan, Italy, IRCCS Humanitas Research Hospital, Milan, Italy; Humanitas Cancer Center; 35 Department of Hematology-Oncology, Aga Khan University, 3rd Parklands Avenue, Nairobi, Kenya; 36 Department of Otolaryngology, Head and Neck Surgical Oncology and Microvascular Reconstruction, University of California Irvine, CA, USA; 37 Aveta Biomics; 38 The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom",
        "Abstract": "APG-157 is an oral NF-κB-modulating immunotherapy that reshapes TME by increasing immune-cell infiltration, supporting cytotoxic memory niches, and shifting M2 to M1 macrophages. In a Phase 2A (n=24) in oral cavity and oropharyngeal cancers, neoadjuvant or induction APG-157 caused no delay to definitive surgery and/or (chemo)radiotherapy. The regimen achieved 91% two-year EFS (median not reached), a 16.7% ORR, 45% primary-tumor reduction, no ENT, 46.2% clinical-to-pathological downstaging, 90% ctDNA clearance in 80% of patients, and 100% primary-lesion disease control, no Grade ≥3 AEs AVTA-30-01 is a pivotal, randomized, multicenter Phase 3 trial (N~718) comprising two independently powered cohorts. Cohort A (n~ 336) will enroll patients with oral cavity or oropharyngeal cancer eligible for curative-intent surgical resection, as confirmed by multidisciplinary review, and for whom PD-1 inhibitors are not indicated, including: (1) patients with locally recurrent disease after definitive surgery and/or (chemo)radiotherapy who are candidates for salvage surgery, including individuals previously treated with perioperative immunotherapy; (2) patients with locally advanced (Stage III/IVA) disease and PD-L1 CPS 0; (3) those with Stage III/IVA disease with unavailable or indeterminate PD-L1 CPS; and (4) Stage III/IVA patients medically ineligible for PD-1 inhibitors due to anticipated immune-related toxicity or other contraindications, irrespective of PD-L1 CPS status. Patients will be randomized 1:1 to receive (a) neoadjuvant APG-157 (900 mg orally daily for 6 weeks) followed by definitive surgery and subsequent (chemo)radiotherapy or salvage surgery followed by SOC adjuvant therapy or (b) definitive or salvage surgery followed by SOC adjuvant therapy alone. Adjuvant therapy will follow contemporary guidelines and may be individualized based on prior treatment and postoperative clinical eligibility. Cohort B (n~382) will enroll previously untreated oropharyngeal cancer patients who are non-surgical candidates or have unresectable disease, for whom definitive chemoradiotherapy is SOC. Eligible disease groups include HPV-negative Stage III–IVA (T3–T4, N0–N2b, M0) and high-risk HPV-positive Stage III (T3–T4, N0–N3, M0 with ≥10 pack-year smoking history). Participants will be randomized 1:1 to receive either (a) induction APG-157 (900 mg orally daily for 6 weeks) followed by definitive chemoradiotherapy and up to one year of maintenance APG-157, or (b) chemoradiotherapy alone. The primary endpoint is EFS per RECIST v1.1, with progression confirmed pathologically and evaluated by blinded independent central review. Key secondary endpoints include ctDNA clearance, radiologic and pathologic response, overall survival, safety, and patient-reported outcomes. Exploratory endpoints include TME profiling by spatial biology, PBMC immunophenotyping, metabolic imaging biomarkers, and additional translational analyses. Safety oversight includes early Data Monitoring Committee review, predefined rules for treatment modification, and rapid initiation of SOC therapy if Week 4 CT/MRI shows progression. This pivotal Phase 3 trial investigates whether APG-157 can augment curative-intent treatment in both surgical candidates and patients requiring non-surgical management for locally advanced or locally recurrent HNSCC. By integrating ctDNA monitoring and evaluating improvements in EFS, the study aims to determine whether APG-157 can improve long-term disease control. If successful, this trial could establish APG-157 as the first orally administered immunomodulatory agent with the potential to shift the treatment paradigm in HNSCC. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Multicenter Phase III Study Assessing Neoadjuvant APG-157 in Resectable HNSCC and Induction plus Maintenance APG-157 in Unresectable HNSCC</span>. <u>Jonathan D Schoenfeld</u><sup>1</sup>; Sid Puram<sup>2</sup>; John B A Hanen<sup>3</sup>; Makoto Tahara<sup>4</sup>; Marilene B Wang<sup>5</sup>; Elizabeth J Franzmann<sup>6</sup>; Maie A St John<sup>7</sup>; Deborah J Wong<sup>8</sup>; Trisha Wise-Draper<sup>9</sup>; Aditya Shreenivas<sup>10</sup>; Sagus Sampath<sup>11</sup>; Krupal Patel<sup>12</sup>; Jessica R Bauman<sup>13</sup>; Anshu Giri<sup>13</sup>; Francis Worden<sup>14</sup>; Michelle Mierzwa<sup>15</sup>; Kedar S Kirtane<sup>16</sup>; David M Neskey<sup>17</sup>; Winston Wong<sup>18</sup>; Haythem Ali<sup>19</sup>; Susanne Flach<sup>20</sup>; Vanessa Chin<sup>21</sup>; Jia Liu<sup>22</sup>; Daniel Brungs<sup>23</sup>; Udit Nindra<sup>23</sup>; Daniel S Shin<sup>24</sup>; Apar Kishor Ganti<sup>25</sup>; Lisa Licitra<sup>26</sup>; Sandra LIop Serna<sup>27</sup>; Zara V Sepulveda<sup>27</sup>; Doru M Paul<sup>28</sup>; Vlad C Sandulache<sup>29</sup>; David J Hernandez<sup>29</sup>; Ray Y Wang<sup>29</sup>; José López L López<sup>30</sup>; Sahin Laçin<sup>31</sup>; Fatih Selcukbiricik<sup>31</sup>; Osman Kostek<sup>32</sup>; Uttam K Sinha<sup>33</sup>; Paolo Bossi<sup>34</sup>; Carlo Resteghini<sup>34</sup>; Mansoor Saleh<sup>35</sup>; Tjoson Tjoa<sup>36</sup>; Yarah Haidar<sup>36</sup>; Luis Avila<sup>37</sup>; Murat Budak<sup>37</sup>; Anjali Desai<sup>37</sup>; Selda Samakoglu<sup>37</sup>; Kevin Harrington<sup>38</sup>. <sup>1</sup>Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA; <sup>3</sup>Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; <sup>4</sup>Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan; <sup>5</sup>Department of Otolaryngology - Head and Neck Surgery, University of California, Los Angeles, CA, USA; <sup>6</sup>Department of Otolaryngology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA; <sup>7</sup>Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System, Baltimore, USA; <sup>8</sup>Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA, USA; <sup>9</sup>Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA; <sup>10</sup>Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA; <sup>11</sup>Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA; <sup>12</sup>Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA; <sup>13</sup>Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; <sup>14</sup>Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; <sup>15</sup>Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; <sup>16</sup>Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA; <sup>17</sup>Head and Neck Specialists, Sarah Cannon Canner Network, Charleston, SC, USA; <sup>18</sup>Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA; <sup>19</sup>Department of Internal Medicine-Medical Oncology, Henry Ford Health System, Detroit, MI, USA; <sup>20</sup>Department of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany; <sup>21</sup>Department of Otolaryngology, Head and Neck Surgery, St. Vincent's Hospital, Darlinghurst, NSW, Australia. Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; <sup>22</sup>The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Sydney, NSW, Australia. School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, NSW, Australia. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; <sup>23</sup>Illawarra Cancer Centre, Wollongong Hospital, NSW, Australia. Graduate School of Medicine, University of Wollongong, NSW, Australia; <sup>24</sup>Section of Hematology-Oncology, Baylor College of Medicine, Staff Physician at Michael E DeBakey VA Medical Center, Houston, TX, USA; <sup>25</sup>Division of Hematology & Oncology, Department of Medicine, University of Nebraska Medical Center; VA Nebraska-Western Iowa Health Center, Omaha, NE, USA; <sup>26</sup>Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; <sup>27</sup>Department of Medical Oncology, Catalan, Institute of oncology (ICO, L’Hospitalet), Barcelona, Spain; <sup>28</sup>Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; <sup>29</sup>Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA; <sup>30</sup>Department of Dentistry, University of Barcelona. Member of the oral health research group at DIBELL. Medical Director of the University of Barcelona Dental Hospital (HOUB), Spain; <sup>31</sup>Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey; <sup>32</sup>Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey; <sup>33</sup>Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; <sup>34</sup>Department of Biomedical Sciences, Humanitas University, Milan, Italy, IRCCS Humanitas Research Hospital, Milan, Italy; Humanitas Cancer Center; <sup>35</sup>Department of Hematology-Oncology, Aga Khan University, 3rd Parklands Avenue, Nairobi, Kenya; <sup>36</sup>Department of Otolaryngology, Head and Neck Surgical Oncology and Microvascular Reconstruction, University of California Irvine, CA, USA; <sup>37</sup>Aveta Biomics; <sup>38</sup>The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>APG-157 is an oral NF-κB-modulating immunotherapy that reshapes TME by increasing immune-cell infiltration, supporting cytotoxic memory niches, and shifting M2 to M1 macrophages. In a Phase 2A (n=24) in oral cavity and oropharyngeal cancers, neoadjuvant or induction APG-157 caused no delay to definitive surgery and/or (chemo)radiotherapy. The regimen achieved 91% two-year EFS (median not reached), a 16.7% ORR, 45% primary-tumor reduction, no ENT, 46.2% clinical-to-pathological downstaging, 90% ctDNA clearance in 80% of patients, and 100% primary-lesion disease control, no Grade ≥3 AEs</p>\n\n<p>AVTA-30-01 is a pivotal, randomized, multicenter Phase 3 trial (N~718) comprising two independently powered cohorts.</p>\n\n<p>Cohort A (n~ 336) will enroll patients with oral cavity or oropharyngeal cancer eligible for curative-intent surgical resection, as confirmed by multidisciplinary review, and for whom PD-1 inhibitors are not indicated, including: (1) patients with locally recurrent disease after definitive surgery and/or (chemo)radiotherapy who are candidates for salvage surgery, including individuals previously treated with perioperative immunotherapy; (2) patients with locally advanced (Stage III/IVA) disease and PD-L1 CPS 0; (3) those with Stage III/IVA disease with unavailable or indeterminate PD-L1 CPS; and (4) Stage III/IVA patients medically ineligible for PD-1 inhibitors due to anticipated immune-related toxicity or other contraindications, irrespective of PD-L1 CPS status.</p>\n\n<p>Patients will be randomized 1:1 to receive (a) neoadjuvant APG-157 (900 mg orally daily for 6 weeks) followed by definitive surgery and subsequent (chemo)radiotherapy or salvage surgery followed by SOC adjuvant therapy or (b) definitive or salvage surgery followed by SOC adjuvant therapy alone. Adjuvant therapy will follow contemporary guidelines and may be individualized based on prior treatment and postoperative clinical eligibility.</p>\n\n<p>Cohort B (n~382) will enroll previously untreated oropharyngeal cancer patients who are non-surgical candidates or have unresectable disease, for whom definitive chemoradiotherapy is SOC. Eligible disease groups include HPV-negative Stage III–IVA (T3–T4, N0–N2b, M0) and high-risk HPV-positive Stage III (T3–T4, N0–N3, M0 with ≥10 pack-year smoking history). Participants will be randomized 1:1 to receive either (a) induction APG-157 (900 mg orally daily for 6 weeks) followed by definitive chemoradiotherapy and up to one year of maintenance APG-157, or (b) chemoradiotherapy alone.</p>\n\n<p>The primary endpoint is EFS per RECIST v1.1, with progression confirmed pathologically and evaluated by blinded independent central review. Key secondary endpoints include ctDNA clearance, radiologic and pathologic response, overall survival, safety, and patient-reported outcomes. Exploratory endpoints include TME profiling by spatial biology, PBMC immunophenotyping, metabolic imaging biomarkers, and additional translational analyses. Safety oversight includes early Data Monitoring Committee review, predefined rules for treatment modification, and rapid initiation of SOC therapy if Week 4 CT/MRI shows progression.</p>\n\n<p>This pivotal Phase 3 trial investigates whether APG-157 can augment curative-intent treatment in both surgical candidates and patients requiring non-surgical management for locally advanced or locally recurrent HNSCC. By integrating ctDNA monitoring and evaluating improvements in EFS, the study aims to determine whether APG-157 can improve long-term disease control. If successful, this trial could establish APG-157 as the first orally administered immunomodulatory agent with the potential to shift the treatment paradigm in HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154033--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260156' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S525",
      "content_id": "154648",
      "abstract_number": "S525",
      "poster_number": "",
      "title": "De-escalated chemoradiation is non-inferior after primary surgery and retropharyngeal node excision in HPV-positive OPSCC with retropharyngeal metastasis",
      "summary": "Retropharyngeal nodal metastasis in HPV-positive OPSCC should not be considered a contraindication to treatment de-escalation when retropharyngeal node excision is incorporated into the primary surgical procedure.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154648",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Zachary M Huttinger, MD, PhD",
      "presenter": "Zachary M Huttinger, MD, PhD",
      "authors": "Zachary M Huttinger, MD, PhD ; Ruth N Agwaze, BS; Aaron W Bogan, MA; Kendall K Tasche, MD; Daniel L Price, MD; Eric J Moore, MD; Linda X Yin, MD; David M Routman, MD; Kathryn M Van Abel, MD",
      "normalized_authors": [
        "Zachary M Huttinger",
        "Ruth N Agwaze",
        "Aaron W Bogan, MA",
        "Kendall K Tasche",
        "Daniel L Price",
        "Eric J Moore",
        "Linda X Yin",
        "David M Routman",
        "Kathryn M Van Abel"
      ],
      "affiliations": [
        "Mayo Clinic"
      ],
      "normalized_institutions": [
        "Mayo Clinic"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 372,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Zachary M Huttinger, MD, PhD ; Ruth N Agwaze, BS; Aaron W Bogan, MA; Kendall K Tasche, MD; Daniel L Price, MD; Eric J Moore, MD; Linda X Yin, MD; David M Routman, MD; Kathryn M Van Abel, MD",
        "Affiliations": "Mayo Clinic",
        "Background": "Presence of retropharyngeal (RP) nodal metastatic disease in HPV-associated oropharyngeal squamous cell carcinoma (HPV-positive OPSCC) is relatively rare with prevalence reported at less than 15%, however, it is classically thought of as a negative prognostic factor. Patients with RP nodal metastasis had been demonstrated to have higher rates of locoregional recurrence and distant metastasis when treated with primary chemoradiation therapy (CRT). We aim to examine if the same negative prognostic implications of RP nodal disease remains true in patients treated with primary surgery and RP nodal excision followed by adjuvant CRT.",
        "Methods": "A retrospective study was conducted in patients who underwent surgical resection for HPV-positive OPSCC involving the base of tongue, tonsil, or unknown primary, and concurrent surgical resection of retropharyngeal lymph node(s) at a tertiary care academic hospital system. Data was extracted from the departmental Oropharynx RedCAP Registry. Forty patients were identified as undergoing surgical resection and retropharyngeal lymph node excision. Patients who had evidence of RP metastatic disease were grouped based by treatment strategy (standard of care vs de-escalation). Demographic data including age, gender, and TNM staging was collected. Overall and disease-free survival at 2 years following completion of treatment was assessed. Statistical analysis (Chi-squared, Student's t test) was performed using SPSS.",
        "Results": "Of the 40 patients who underwent oropharyngectomy and concurrent retropharyngeal nodal excision, 26 (65%) had evidence of RP metastatic disease, and 25 received post operative CRT, while one patient refused adjuvant therapy. All but two patients were male and the average age of patients was 61.1 years. There were no significant differences between the two groups with respect to age, gender, and TNM staging. Seventeen patients (68.0%) were treated with standard of care CRT (60 Gy with weekly cisplatin) and eight patients (32.0%) were treated with de-escalation therapy (30 Gy with docetaxel for 2 weeks). There was no significant difference in 2-year overall survival (100% vs 87.5%, p = 0.3200) nor 2-year disease-free survival (82.4% vs 62.5%, p = 0.3442) between the standard of care and de-escalation groups, respectively.",
        "Conclusions": "Retropharyngeal nodal metastasis in HPV-positive OPSCC should not be considered a contraindication to treatment de-escalation when retropharyngeal node excision is incorporated into the primary surgical procedure.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>De-escalated chemoradiation is non-inferior after primary surgery and retropharyngeal node excision in HPV-positive OPSCC with retropharyngeal metastasis</span>. <u>Zachary M Huttinger, MD, PhD</u>; Ruth N Agwaze, BS; Aaron W Bogan, MA; Kendall K Tasche, MD; Daniel L Price, MD; Eric J Moore, MD; Linda X Yin, MD; David M Routman, MD; Kathryn M Van Abel, MD. Mayo Clinic<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Presence of retropharyngeal (RP) nodal metastatic disease in HPV-associated oropharyngeal squamous cell carcinoma (HPV-positive OPSCC) is relatively rare with prevalence reported at less than 15%, however, it is classically thought of as a negative prognostic factor. Patients with RP nodal metastasis had been demonstrated to have higher rates of locoregional recurrence and distant metastasis when treated with primary chemoradiation therapy (CRT). We aim to examine if the same negative prognostic implications of RP nodal disease remains true in patients treated with primary surgery and RP nodal excision followed by adjuvant CRT.   </p>\n\n<p><strong>Methods: </strong>A retrospective study was conducted in patients who underwent surgical resection for HPV-positive OPSCC involving the base of tongue, tonsil, or unknown primary, and concurrent surgical resection of retropharyngeal lymph node(s) at a tertiary care academic hospital system. Data was extracted from the departmental Oropharynx RedCAP Registry. Forty patients were identified as undergoing surgical resection and retropharyngeal lymph node excision. Patients who had evidence of RP metastatic disease were grouped based by treatment strategy (standard of care vs de-escalation). Demographic data including age, gender, and TNM staging was collected. Overall and disease-free survival at 2 years following completion of treatment was assessed. Statistical analysis (Chi-squared, Student's t test) was performed using SPSS. </p>\n\n<p><strong>Results: </strong>Of the 40 patients who underwent oropharyngectomy and concurrent retropharyngeal nodal excision, 26 (65%) had evidence of RP metastatic disease, and 25 received post operative CRT, while one patient refused adjuvant therapy. All but two patients were male and the average age of patients was 61.1 years. There were no significant differences between the two groups with respect to age, gender, and TNM staging. Seventeen patients (68.0%) were treated with standard of care CRT (60 Gy with weekly cisplatin) and eight patients (32.0%) were treated with de-escalation therapy (30 Gy with docetaxel for 2 weeks). There was no significant difference in 2-year overall survival (100% vs 87.5%, p = 0.3200) nor 2-year disease-free survival (82.4% vs 62.5%, p = 0.3442) between the standard of care and de-escalation groups, respectively. </p>\n\n<p><strong>Conclusions: </strong>Retropharyngeal nodal metastasis in HPV-positive OPSCC should not be considered a contraindication to treatment de-escalation when retropharyngeal node excision is incorporated into the primary surgical procedure.  </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154648--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S526",
      "content_id": "153033",
      "abstract_number": "S526",
      "poster_number": "",
      "title": "Robotic versus Non-robotic Transoral Surgery for T1-T2 Oropharyngeal Cancer: A National Propensity-Matched Comparison of Peri-operative Quality, Adjuvant Therapy, and Early Safety",
      "summary": "In a national propensity-matched cohort of early OPSCC patients, robotic TOS reduced margin positivity while maintaining similar LOS, readmission, and early mortality compared with non-robotic TOS. The adjuvant radiation use and timing were equivalent, suggesting that the margin advantage was not driven by differential RT delivery. Lower chemotherapy utilization after robotic TOS may reflect the selection...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153033",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nir Tsur, MD",
      "presenter": "Nir Tsur, MD",
      "authors": "Nir Tsur, MD ; Andrea Costantino, MD; Scott Magnuson, MD",
      "normalized_authors": [
        "Nir Tsur",
        "Andrea Costantino",
        "Scott Magnuson"
      ],
      "affiliations": [
        "Adventhealth Orlando"
      ],
      "normalized_institutions": [
        "Adventhealth Orlando"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 417,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nir Tsur, MD ; Andrea Costantino, MD; Scott Magnuson, MD",
        "Affiliations": "Adventhealth Orlando",
        "Background": "Transoral surgery (TOS) is widely used for early oropharyngeal squamous cell carcinoma (OPSCC); however, comparative data for robotic vs. non-robotic approaches remain limited. We compared perioperative quality and early safety and examined downstream adjuvant therapy.",
        "Methods": "Using the 2022 National Cancer Database, we presumptively identified HPV-related OPSCC of the tonsil/base of the tongue (cT1–2, cN0–2, M0) treated surgically. Exposure was surgical approach (robotic vs non-robotic TOS). A propensity score (age, sex, race, insurance, facility type/region, site, cT, cN, and distance) was used for 1:2 nearest-neighbor matching (caliper 0.2 SD of the logit; no replacement). The primary endpoints were positive margins and length of stay (LOS). Secondary endpoints were unplanned 30-day readmission, 30-/90-day mortality, and adjuvant therapy (radiation and chemotherapy) use and timing. Cluster-robust models produced odds ratios (ORs) for binary outcomes and mean differences (Δ) for LOS, and quantile regression was used to assess median/upper-tail LOS.",
        "Results": "Of the 5,831 surgically treated cases (85.2% robotic), matching yielded 781 sets (one non-robotic matched to up to two robotic cases). Robotic TOS had lower odds of positive margins (OR, 0.748; 95% CI, 0.611–0.914; P=.0046). The LOS was similar (Δ −0.071 days; 95% CI −0.698 to 0.555; P=.823) with no differences at the median or upper tail. Thirty-day readmission did not differ (OR 1.271; 95% CI 0.864–1.871; P=.217). Early mortality was rare with no significant 30- or 90-day differences (30-day OR 2.031; 95% CI 0.569–7.249; P=.275; 90-day OR 1.625; 95% CI 0.582–4.541; P=.354). Adjuvant radiation use and time to initiation were comparable (median 44 days; IQR 38–54). Chemotherapy use was lower after robotic TOS (25.1% vs. 32.7%; absolute difference −7.6%, 95% CI −11.5 to −3.7; P=.0001); the three-category distribution (administered/recommended-not-administered/not recommended) also differed (χ² P=.0001).",
        "Conclusions": "In a national propensity-matched cohort of early OPSCC patients, robotic TOS reduced margin positivity while maintaining similar LOS, readmission, and early mortality compared with non-robotic TOS. The adjuvant radiation use and timing were equivalent, suggesting that the margin advantage was not driven by differential RT delivery. Lower chemotherapy utilization after robotic TOS may reflect the selection patterns and/or opportunities for de-escalation in appropriately selected patients. Future studies should incorporate detailed pathologic risk features and radiation dose/fractionation to clarify the decision pathways and long-term outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Robotic versus Non-robotic Transoral Surgery for T1-T2 Oropharyngeal Cancer: A National Propensity-Matched Comparison of Peri-operative Quality, Adjuvant Therapy, and Early Safety</span>. <u>Nir Tsur, MD</u>; Andrea Costantino, MD; Scott Magnuson, MD. Adventhealth Orlando<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral surgery (TOS) is widely used for early oropharyngeal squamous cell carcinoma (OPSCC); however, comparative data for robotic vs. non-robotic approaches remain limited. We compared perioperative quality and early safety and examined downstream adjuvant therapy.</p>\n\n<p><strong>Methods: </strong>Using the 2022 National Cancer Database, we presumptively identified HPV-related OPSCC of the tonsil/base of the tongue (cT1–2, cN0–2, M0) treated surgically. Exposure was surgical approach (robotic vs non-robotic TOS). A propensity score (age, sex, race, insurance, facility type/region, site, cT, cN, and distance) was used for 1:2 nearest-neighbor matching (caliper 0.2 SD of the logit; no replacement). The primary endpoints were positive margins and length of stay (LOS). Secondary endpoints were unplanned 30-day readmission, 30-/90-day mortality, and adjuvant therapy (radiation and chemotherapy) use and timing. Cluster-robust models produced odds ratios (ORs) for binary outcomes and mean differences (Δ) for LOS, and quantile regression was used to assess median/upper-tail LOS.</p>\n\n<p><strong>Results: </strong>Of the 5,831 surgically treated cases (85.2% robotic), matching yielded 781 sets (one non-robotic matched to up to two robotic cases). Robotic TOS had lower odds of positive margins (OR, 0.748; 95% CI, 0.611–0.914; P=.0046). The LOS was similar (Δ −0.071 days; 95% CI −0.698 to 0.555; P=.823) with no differences at the median or upper tail. Thirty-day readmission did not differ (OR 1.271; 95% CI 0.864–1.871; P=.217). Early mortality was rare with no significant 30- or 90-day differences (30-day OR 2.031; 95% CI 0.569–7.249; P=.275; 90-day OR 1.625; 95% CI 0.582–4.541; P=.354). Adjuvant radiation use and time to initiation were comparable (median 44 days; IQR 38–54). Chemotherapy use was lower after robotic TOS (25.1% vs. 32.7%; absolute difference −7.6%, 95% CI −11.5 to −3.7; P=.0001); the three-category distribution (administered/recommended-not-administered/not recommended) also differed (χ² P=.0001).</p>\n\n<p><strong>Conclusions: </strong>In a national propensity-matched cohort of early OPSCC patients, robotic TOS reduced margin positivity while maintaining similar LOS, readmission, and early mortality compared with non-robotic TOS. The adjuvant radiation use and timing were equivalent, suggesting that the margin advantage was not driven by differential RT delivery. Lower chemotherapy utilization after robotic TOS may reflect the selection patterns and/or opportunities for de-escalation in appropriately selected patients. Future studies should incorporate detailed pathologic risk features and radiation dose/fractionation to clarify the decision pathways and long-term outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153033--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S527",
      "content_id": "153738",
      "abstract_number": "S527",
      "poster_number": "",
      "title": "Technical Feasibility and Initial User Perspectives on Use of a Virtual Reality Headset during Transoral Robotic Surgery",
      "summary": "This novel work describes the technical feasibility of using a VR headset for improved visualization of the operative field during TORS. The setup provides the bedside assistant a larger, high-resolution, zero-latency view while preserving environmental awareness through passthrough. User perspectives reflected moderate perceived usefulness and safety. Future work will objectively assess ergonomic impact with and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153738",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Daniel Bu, MD, MPP, MBA",
      "presenter": "Daniel Bu, MD, MPP, MBA",
      "authors": "Obinna Nwosu, MD; Justine Philteos, MD; Daniel Bu, MD, MPP, MBA ; Allen Feng, MD; Jeremy Richmon, MD",
      "normalized_authors": [
        "Obinna Nwosu",
        "Justine Philteos",
        "Daniel Bu, MPP",
        "Allen Feng",
        "Jeremy Richmon"
      ],
      "affiliations": [
        "Mass Eye and Ear"
      ],
      "normalized_institutions": [
        "Mass Eye and Ear"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153738/VRTORS(2).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153738/VRTORS(2).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153738"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 489,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Obinna Nwosu, MD; Justine Philteos, MD; Daniel Bu, MD, MPP, MBA ; Allen Feng, MD; Jeremy Richmon, MD",
        "Affiliations": "Mass Eye and Ear",
        "Introduction": "In transoral robotic surgery (TORS), the bedside assist’s (BA) view of the surgical monitor is often obscured by the robotic console which is suspended over the patient. Projection of the robot’s live video display to a virtual reality (VR) headset could afford the BA an environment-agnostic view of the surgical field, unhindered by surrounding equipment, and consequently improve ergonomics. This study describes the technical feasibility and the initial subjective user perspectives of casting the live operative video feed of the da Vinci Single Port robot (Intuitive, Inc) to the display of a Meta Quest 3 (Meta, Inc) headset worn by the BA during TORS.",
        "Methods": "The study protocol was approved by the Mass General Brigham IRB. The headset was worn by the BA in all eligible TORS cases of the upper aerodigestive tract (Figure 1A).",
        "Abstract": "The Quest 3 weighs 1.13 pounds and has passthrough capability which enables the user to simultaneously visualize VR content and interact with their real environment. Consequently, BAs can view the patient, their hands, instruments, and the surrounding operating room while visualizing the operative video feed. The robot’s video feed is routed from the da Vinci tower through a DVI-HDMI cable connected to a USB capture card plugged into the headset and finally displayed on the headset using HDMI Link, a native streaming application available on the headset. Frame-by-frame event synchronization, with an external stopwatch, was utilized to assess the latency between the robot and headset video streams. The technology acceptance model (TAM) instrument, a validated questionnaire used to assess opinions toward novel technologies in healthcare, was utilized to ass?ess the BA’s subjective experience after each case. The questionnaire is comprised of 20 Likert-style questions (5-point scale) with higher scores indicating more positive perspectives. The instrument is divided into the following categories: perceived usefulness (PU), perceived ease of use (PEOU), intent to use (ITU), perceived safety of technology (PS), and overall attitudes toward the technology (ATT). The mean question score for each category is reported. View in Agenda and Add to Schedule",
        "Results": "The operative feed was displayed on the headset at 60 frames per second with an image resolution of 1920x1080 (Figure 1B). Frame-by-frame event synchronization showed corresponding stopwatch timestamps appeared simultaneously in the robot feed and the headset display, indicating zero (or unmeasurable) latency in the described wired setup. The headset was used and a questionnaire response recorded for a total of 12 cases. Mean TAM scores (out of 5) were highest for PU (3.7) followed by PS (3.6), ATT (3.6), ITU (3.6), and PEOU (3.5).",
        "Conclusion": "This novel work describes the technical feasibility of using a VR headset for improved visualization of the operative field during TORS. The setup provides the bedside assistant a larger, high-resolution, zero-latency view while preserving environmental awareness through passthrough. User perspectives reflected moderate perceived usefulness and safety. Future work will objectively assess ergonomic impact with and without headset use."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Technical Feasibility and Initial User Perspectives on Use of a Virtual Reality Headset during Transoral Robotic Surgery</span>. Obinna Nwosu, MD; Justine Philteos, MD; <u>Daniel Bu, MD, MPP, MBA</u>; Allen Feng, MD; Jeremy Richmon, MD. Mass Eye and Ear<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>In transoral robotic surgery (TORS), the bedside assist’s (BA) view of the surgical monitor is often obscured by the robotic console which is suspended over the patient. Projection of the robot’s live video display to a virtual reality (VR) headset could afford the BA an environment-agnostic view of the surgical field, unhindered by surrounding equipment, and consequently improve ergonomics. This study describes the technical feasibility and the initial subjective user perspectives of casting the live operative video feed of the da Vinci Single Port robot (Intuitive, Inc) to the display of a Meta Quest 3 (Meta, Inc) headset worn by the BA during TORS.</p>\n\n<p><strong>Methods: </strong>The study protocol was approved by the Mass General Brigham IRB. The headset was worn by the BA in all eligible TORS cases of the upper aerodigestive tract (Figure 1A).</p>\n\n<p>The Quest 3 weighs 1.13 pounds and has passthrough capability which enables the user to simultaneously visualize VR content and interact with their real environment. Consequently, BAs can view the patient, their hands, instruments, and the surrounding operating room while visualizing the operative video feed.</p>\n\n<p>The robot’s video feed is routed from the da Vinci tower through a DVI-HDMI cable connected to a USB capture card plugged into the headset and finally displayed on the headset using HDMI Link, a native streaming application available on the headset. Frame-by-frame event synchronization, with an external stopwatch, was utilized to assess the latency between the robot and headset video streams.</p>\n\n<p>The technology acceptance model (TAM) instrument, a validated questionnaire used to assess opinions toward novel technologies in healthcare, was utilized to ass?ess the BA’s subjective experience after each case. The questionnaire is comprised of 20 Likert-style questions (5-point scale) with higher scores indicating more positive perspectives. The instrument is divided into the following categories: perceived usefulness (PU), perceived ease of use (PEOU), intent to use (ITU), perceived safety of technology (PS), and overall attitudes toward the technology (ATT). The mean question score for each category is reported.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153738/VRTORS(2).png' /></p>\n\n<p><strong>Results: </strong>The operative feed was displayed on the headset at 60 frames per second with an image resolution of 1920x1080 (Figure 1B). Frame-by-frame event synchronization showed corresponding stopwatch timestamps appeared simultaneously in the robot feed and the headset display, indicating zero (or unmeasurable) latency in the described wired setup.  The headset was used and a questionnaire response recorded for a total of 12 cases. Mean TAM scores (out of 5) were highest for PU (3.7) followed by PS (3.6), ATT (3.6), ITU (3.6), and PEOU (3.5).</p>\n\n<p><strong>Conclusion: </strong>This novel work describes the technical feasibility of using a VR headset for improved visualization of the operative field during TORS. The setup provides the bedside assistant a larger, high-resolution, zero-latency view while preserving environmental awareness through passthrough. User perspectives reflected moderate perceived usefulness and safety. Future work will objectively assess ergonomic impact with and without headset use.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153738--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S528",
      "content_id": "154396",
      "abstract_number": "S528",
      "poster_number": "",
      "title": "Steroid-refractory epiglottitis following nivolumab in a patient with oropharyngeal cancer and subsequent resolution with initiation of infliximab",
      "summary": "With the success of KEYNOTE 689 and impending widespread implementation of adjuvant and neoadjuvant immunotherapy for treatment of head and neck cancers, clinicians should be aware of epiglottitis as an uncommon but potentially life-threatening immune-related adverse event.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154396",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Brandon L Prendes, MD",
      "presenter": "Brandon L Prendes, MD",
      "authors": "Kayla E Baker, MD 1 ; Tamara A Sussman, MD 2 ; Michelle York, CCCSLP 1 ; Shauna R Campbell, DO 3 ; Joanna W Bodmann, CNP 2 ; Rhiannon Sutch, BSN, RN 2 ; Bridgett Harr, CNP 3 ; Carol Rouphael, MD 4 ; Regina Kahnert, CNP 1 ; Brandon L Prendes, MD 1",
      "normalized_authors": [
        "Kayla E Baker",
        "Tamara A Sussman",
        "Michelle York, CCCSLP",
        "Shauna R Campbell",
        "Joanna W Bodmann, CNP",
        "Rhiannon Sutch, BSN",
        "Bridgett Harr, CNP",
        "Carol Rouphael",
        "Regina Kahnert, CNP",
        "Brandon L Prendes"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH",
        "Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
        "Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
        "Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland OH"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH",
        "Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
        "Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH",
        "Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland OH"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154396/epiglottitis%20labeled.JPG",
          "source_url": "https://www.submitmyabstract.com/abs/images/154396/epiglottitis%20labeled.JPG",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154396"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 422,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Case presentation",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kayla E Baker, MD 1 ; Tamara A Sussman, MD 2 ; Michelle York, CCCSLP 1 ; Shauna R Campbell, DO 3 ; Joanna W Bodmann, CNP 2 ; Rhiannon Sutch, BSN, RN 2 ; Bridgett Harr, CNP 3 ; Carol Rouphael, MD 4 ; Regina Kahnert, CNP 1 ; Brandon L Prendes, MD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland OH; 2 Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH; 3 Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland OH; 4 Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland OH",
        "Introduction": "With the success of KEYNOTE 689 and impending widespread implementation of adjuvant and neoadjuvant immunotherapy for treatment of head and neck cancers, clinicians should be aware of epiglottitis as an uncommon but potentially life-threatening immune-related adverse event.",
        "Case presentation": "We describe a case of an elderly male patient with locally advanced p16/HPV+ oropharyngeal SCC who experienced epiglottitis following definitive chemoradiation and 12 cycles of adjuvant nivolumab as part of an ongoing clinical trial. Three months after completion of immunotherapy, he was admitted with concern for tumor recurrence due to recent onset of severe odynophagia and resulting weight loss that had not improved with antibiotic and antifungal agents. Histologic analysis of buccal and vallecula biopsies revealed inflamed mucosa with reactive changes, ruling out infectious and oncologic etiologies. High dose systemic corticosteroids and tube feeds were initiated with resulting stabilization, but he had persistent epiglottic edema and fluctuating degrees of odynophagia. He was re-admitted multiple times with worsened symptoms when steroid tapers were attempted. His clinical course was complicated by spontaneous bowel perforation, which required resection with colostomy. He was considered refractory to steroid treatment due to persistent epiglottitis and continuing inflammation throughout his aerodigestive tract. He was initiated on infliximab due to known success in treating immune checkpoint inhibitor-induced colitis and underwent a rapid steroid taper once started on infliximab. After three doses of infliximab over six weeks, he experienced complete resolution of epiglottitis and significant improvement of odynophagia, leading to resumed oral intake after 10 months of tube feed dependence as well as consideration of colostomy reversal. At the time of this abstract submission, the patient has no evidence of disease from an oncologic standpoint.",
        "Discussion": "To our knowledge, this is the first report of epiglottitis following immune checkpoint inhibitor (ICI) treatment in a patient with oropharyngeal SCC. This is a rare but serious adverse event of ICI use that clinicians should be aware of. To date, ICI-related epiglottitis that adequately resolved with steroid treatment has been reported in four patients with melanoma, bladder, laryngeal, and recurrent hypopharyngeal cancers, respectively. Another case of ICI-related epiglottitis has been reported in a patient with melanoma who achieved resolution with infliximab in addition to continued steroid use; this established infliximab as a potential add-on treatment. Our case is the first report of ICI-related epiglottitis resolution using infliximab with rapid steroid taper, which supports the use of infliximab in steroid-refractory patients and potential reduction in extended steroid tapers.",
        "Abstract": "Figure 1. (A) Epiglottis at initial admission; (B) following two cycles of infliximab. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Steroid-refractory epiglottitis following nivolumab in a patient with oropharyngeal cancer and subsequent resolution with initiation of infliximab</span>. Kayla E Baker, MD<sup>1</sup>; Tamara A Sussman, MD<sup>2</sup>; Michelle York, CCCSLP<sup>1</sup>; Shauna R Campbell, DO<sup>3</sup>; Joanna W Bodmann, CNP<sup>2</sup>; Rhiannon Sutch, BSN, RN<sup>2</sup>; Bridgett Harr, CNP<sup>3</sup>; Carol Rouphael, MD<sup>4</sup>; Regina Kahnert, CNP<sup>1</sup>; <u>Brandon L Prendes, MD</u><sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, Integrated Surgical Institute, Cleveland \tClinic, Cleveland OH; <sup>2</sup>Department of Hematology and Medical Oncology, Taussig Cancer Institute, \tCleveland Clinic, Cleveland OH; <sup>3</sup>Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, \tCleveland OH; <sup>4</sup>Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease \tInstitute, Cleveland Clinic, Cleveland OH<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>With the success of KEYNOTE 689 and impending widespread implementation of adjuvant and neoadjuvant immunotherapy for treatment of head and neck cancers, clinicians should be aware of epiglottitis as an uncommon but potentially life-threatening immune-related adverse event. </p>\n\n<p><strong>Case presentation: </strong>We describe a case of an elderly male patient with locally advanced p16/HPV+ oropharyngeal SCC who experienced epiglottitis following definitive chemoradiation and 12 cycles of adjuvant nivolumab as part of an ongoing clinical trial. Three months after completion of immunotherapy, he was admitted with concern for tumor recurrence due to recent onset of severe odynophagia and resulting weight loss that had not improved with antibiotic and antifungal agents. Histologic analysis of buccal and vallecula biopsies revealed inflamed mucosa with reactive changes, ruling out infectious and oncologic etiologies. High dose systemic corticosteroids and tube feeds were initiated with resulting stabilization, but he had persistent epiglottic edema and fluctuating degrees of odynophagia. He was re-admitted multiple times with worsened symptoms when steroid tapers were attempted. His clinical course was complicated by spontaneous bowel perforation, which required resection with colostomy. He was considered refractory to steroid treatment due to persistent epiglottitis and continuing inflammation throughout his aerodigestive tract. He was initiated on infliximab due to known success in treating immune checkpoint inhibitor-induced colitis and underwent a rapid steroid taper once started on infliximab. After three doses of infliximab over six weeks, he experienced complete resolution of epiglottitis and significant improvement of odynophagia, leading to resumed oral intake after 10 months of tube feed dependence as well as consideration of colostomy reversal. At the time of this abstract submission, the patient has no evidence of disease from an oncologic standpoint. </p>\n\n<p><strong>Discussion: </strong>To our knowledge, this is the first report of epiglottitis following immune checkpoint inhibitor (ICI) treatment in a patient with oropharyngeal SCC. This is a rare but serious adverse event of ICI use that clinicians should be aware of. To date, ICI-related epiglottitis that adequately resolved with steroid treatment has been reported in four patients with melanoma, bladder, laryngeal, and recurrent hypopharyngeal cancers, respectively. Another case of ICI-related epiglottitis has been reported in a patient with melanoma who achieved resolution with infliximab in addition to continued steroid use; this established infliximab as a potential add-on treatment. Our case is the first report of ICI-related epiglottitis resolution using infliximab with rapid steroid taper, which supports the use of infliximab in steroid-refractory patients and potential reduction in extended steroid tapers. </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154396/epiglottitis%20labeled.JPG' /></p>\n\n<p>Figure 1. (A) Epiglottis at initial admission; (B) following two cycles of infliximab.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154396--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S529",
      "content_id": "153969",
      "abstract_number": "S529",
      "poster_number": "",
      "title": "Presurgical Chemotherapy for Locoregionally Advanced HPV- Oral Cavity and Oropharyngeal Cancers",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153969",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "John T Loree, MD",
      "presenter": "John T Loree, MD",
      "authors": "John T Loree, MD 1 ; Saurin R Popat, MD 2 ; Mark S Burke, MD 2 ; Naheed Alam 3 ; Anne Grandmaison, MD 3 ; Michael Y Nagai, MD, DDS 2 ; Thom R Loree, MD 2",
      "normalized_authors": [
        "John T Loree",
        "Saurin R Popat",
        "Mark S Burke",
        "Naheed Alam",
        "Anne Grandmaison",
        "Michael Y Nagai",
        "Thom R Loree"
      ],
      "affiliations": [
        "Corewell East Department of Plastic Surgery",
        "Erie County Medical Center Department of Head and Neck and Plastic Surgery",
        "Erie County Medical Center Department of Medical Oncology"
      ],
      "normalized_institutions": [
        "Corewell East Department of Plastic Surgery",
        "Erie County Medical Center Department of Head and Neck and Plastic Surgery",
        "Erie County Medical Center Department of Medical Oncology"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 498,
      "section_labels": [
        "Authors",
        "Affiliations",
        "BACKGROUND",
        "METHODS",
        "RESULTS",
        "DISCUSSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "John T Loree, MD 1 ; Saurin R Popat, MD 2 ; Mark S Burke, MD 2 ; Naheed Alam 3 ; Anne Grandmaison, MD 3 ; Michael Y Nagai, MD, DDS 2 ; Thom R Loree, MD 2",
        "Affiliations": "1 Corewell East Department of Plastic Surgery; 2 Erie County Medical Center Department of Head and Neck and Plastic Surgery; 3 Erie County Medical Center Department of Medical Oncology",
        "BACKGROUND": "Despite the improving prognosis of oropharyngeal squamous cell carcinomas (OPSCC), the prognosis of oral cavity squamous cancers (OCSCC) and HPV negative OPSCC remains poor. This trend likely is the result of the rise in prevalence of HPV related OPSCC. There is still significant treatment morbidity and poor overall survival of locoregionally advanced HPV negative oral squamous cancers (OSCC) of approximately 25-50%. Induction chemotherapy is a possible means to improve survival in the setting of OSCC and avoid the additional morbidity of (chemo)radiotherapy in select patients. Most studies on this topic have discussed induction regimens with primary treatment using (chemo)radiotherapy, which have shown mixed results. We present a large series of HPV negative OSCCs treated with a regimen of presurgical induction chemotherapy and surgery, with or without adjuvant (chemo)radiotherapy.",
        "METHODS": "A retrospective review of all treatment naïve patients with advanced OSCC treated between 2005 and 3/2021 was conducted. Patients were excluded if they had distant metastasis at presentation. All patients received a regimen of presurgical chemotherapy inclusive of cisplatin and docetaxel (TP) of 1-5 cycles followed by surgery with or without adjuvant (chemo)radiation. Adjuvant chemoradiotherapy was deferred if patients had complete response (pCR) to induction chemotherapy at the primary and neck; pCR in the neck and partial response (pPR) at the primary with negative surgical margins or had N1 disease in pre- and perioperatively without adverse features. There were 110 total patients. Mean age was 59 years with 81 active smokers (mean 42 PY), and 27 non/former smokers. 13 patients had stage three disease and 97 were stage four. The most common site was the oral tongue. Mean follow-up time for surviving patients was 6.9 years.",
        "RESULTS": "76% (84/110) of patients had either significant (>50% tumor necrosis) partial or complete response to induction chemotherapy in both their primary and neck. There were no deaths during induction chemotherapy.19/81 (23%) patients receiving TP only required reduced doses of induction chemotherapy. 59% (65/110) patients received adjuvant, postoperative radiotherapy following surgery for residual disease. 41% (45/110) of patients deferred adjuvant (chemo)radiotherapy due to refusal, prior radiotherapy, death prior to initiation of adjuvant therapy, or other constraints. 31% (34/110) patients suffered recurrence, of which 8 (24%) had distant metastasis. 4 with local recurrence were salvaged (4/36,12%). Disease-specific survival in this cohort was 67% (74/110), while disease free survival was 64% (70/110). (Chemo)radiotherapy, complete vs. partial response to chemotherapy, gender, age and treatment de-escalation were not predictive of overall survival. Smoking, oropharynx site, stage IV and N+ stage showed a trend toward poorer survival. No response to induction was significantly associated with poorer prognosis (p<.05).",
        "DISCUSSION": "This is a large, retrospective series of patients with advanced disease. Using historical controls as present in the literature, induction chemotherapy followed by surgery improves survival in HPV- OSCC. In select patients, presurgical chemotherapy may reduce the utilization of adjuvant (chemo)radiotherapy without sacrificing survival.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Presurgical Chemotherapy for Locoregionally Advanced HPV- Oral Cavity and Oropharyngeal Cancers</span>. <u>John T Loree, MD</u><sup>1</sup>; Saurin R Popat, MD<sup>2</sup>; Mark S Burke, MD<sup>2</sup>; Naheed Alam<sup>3</sup>; Anne Grandmaison, MD<sup>3</sup>; Michael Y Nagai, MD, DDS<sup>2</sup>; Thom R Loree, MD<sup>2</sup>. <sup>1</sup>Corewell East Department of Plastic Surgery; <sup>2</sup>Erie County Medical Center Department of Head and Neck and Plastic Surgery; <sup>3</sup>Erie County Medical Center Department of Medical Oncology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>BACKGROUND:</strong> Despite the improving prognosis of oropharyngeal squamous cell carcinomas (OPSCC), the prognosis of oral cavity squamous cancers (OCSCC) and HPV negative OPSCC remains poor. This trend likely is the result of the rise in prevalence of HPV related OPSCC. There is still significant treatment morbidity and poor overall survival of locoregionally advanced HPV negative oral squamous cancers (OSCC) of approximately 25-50%. Induction chemotherapy is a possible means to improve survival in the setting of OSCC and avoid the additional morbidity of (chemo)radiotherapy in select patients. Most studies on this topic have discussed induction regimens with primary treatment using (chemo)radiotherapy, which have shown mixed results. We present a large series of HPV negative OSCCs treated with a regimen of presurgical induction chemotherapy and surgery, with or without adjuvant (chemo)radiotherapy.</p>\n\n<p><strong>METHODS:</strong> A retrospective review of all treatment naïve patients with advanced OSCC treated between 2005 and 3/2021 was conducted. Patients were excluded if they had distant metastasis at presentation. All patients received a regimen of presurgical chemotherapy inclusive of cisplatin and docetaxel (TP) of 1-5 cycles followed by surgery with or without adjuvant (chemo)radiation. Adjuvant chemoradiotherapy was deferred if patients had complete response (pCR) to induction chemotherapy at the primary and neck; pCR in the neck and partial response (pPR) at the primary with negative surgical margins or had N1 disease in pre- and perioperatively without adverse features. There were 110 total patients. Mean age was 59 years with 81 active smokers (mean 42 PY), and 27 non/former smokers. 13 patients had stage three disease and 97 were stage four. The most common site was the oral tongue. Mean follow-up time for surviving patients was 6.9 years.</p>\n\n<p><strong>RESULTS:</strong> 76% (84/110) of patients had either significant (>50% tumor necrosis) partial or complete response to induction chemotherapy in both their primary and neck. There were no deaths during induction chemotherapy.19/81 (23%) patients receiving TP only required reduced doses of induction chemotherapy. 59% (65/110) patients received adjuvant, postoperative radiotherapy following surgery for residual disease. 41% (45/110) of patients deferred adjuvant (chemo)radiotherapy due to refusal, prior radiotherapy, death prior to initiation of adjuvant therapy, or other constraints. 31% (34/110) patients suffered recurrence, of which 8 (24%) had distant metastasis. 4 with local recurrence were salvaged (4/36,12%). Disease-specific survival in this cohort was 67% (74/110), while disease free survival was 64% (70/110). (Chemo)radiotherapy, complete vs. partial response to chemotherapy, gender, age and treatment de-escalation were not predictive of overall survival. Smoking, oropharynx site, stage IV and N+ stage showed a trend toward poorer survival. No response to induction was significantly associated with poorer prognosis (p<.05).</p>\n\n<p><strong>DISCUSSION: </strong>This is a large, retrospective series of patients with advanced disease. Using historical controls as present in the literature, induction chemotherapy followed by surgery improves survival in HPV- OSCC. In select patients, presurgical chemotherapy may reduce the utilization of adjuvant (chemo)radiotherapy without sacrificing survival.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153969--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S530",
      "content_id": "154657",
      "abstract_number": "S530",
      "poster_number": "",
      "title": "Characterizing False-Negative Results in Diagnostic Liquid Biopsy for HPV-Associated Head and Neck Squamous Cell Carcinoma",
      "summary": "249 patients with oropharyngeal cancer received pre-treatment HPV DNA liquid biopsy testing from May 21, 2020 to September 12, 2024. Twenty one patients (8.4%) had false-negative liquid biopsy results and 228 (91.6%) had true-positive results. Demographic factors including age, sex, BMI, smoking history, and comorbidities (diabetes and immunocompromised status) did not differ significantly between groups....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154657",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Peter Cooke",
      "presenter": "Peter Cooke",
      "authors": "Ethan Gomez; Peter Cooke ; Ryan Sicard; Daniel Kraft; Alicia Yang; Michael Berger; Marita Teng; Raymond Chai; Eric Genden; Scott Roof",
      "normalized_authors": [
        "Ethan Gomez",
        "Peter Cooke",
        "Ryan Sicard",
        "Daniel Kraft",
        "Alicia Yang",
        "Michael Berger",
        "Marita Teng",
        "Raymond Chai",
        "Eric Genden",
        "Scott Roof"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 387,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ethan Gomez; Peter Cooke ; Ryan Sicard; Daniel Kraft; Alicia Yang; Michael Berger; Marita Teng; Raymond Chai; Eric Genden; Scott Roof",
        "Affiliations": "Icahn School of Medicine at Mount Sinai",
        "Background": "While the national incidence of human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) continues to rise, circulating tumor tissue–modified viral (cTTMV) HPV DNA has shown promise as a biomarker for diagnosis and surveillance. Although prior studies demonstrate high diagnostic sensitivity for TTMV HPV DNA testing, the non-detectable results prior to treatment in a subgroup of patients remain poorly understood. In this study, we investigate patients who tested negative in the pre-treatment phase despite having pathologically confirmed HPV+ tumors. Our goal is to identify clinical or disease-related factors that may predispose liquid biopsy testing to a pre-treatment false-negative result.",
        "Methods": "This is a retrospective cohort study of patients with HPV+ OPSCC who underwent cTTMV HPV DNA testing prior to treatment initiation. All patients had biopsy-confirmed, HPV-positive tumors. HPV status was determined via polymerase chain reaction or in situ-hybridization testing. Demographic and clinical variables were abstracted from the electronic medical record and comparisons were made between patients with false-negative and those with true-positive pre-treatment liquid biopsy results.",
        "Results": "249 patients with oropharyngeal cancer received pre-treatment HPV DNA liquid biopsy testing from May 21, 2020 to September 12, 2024. Twenty one patients (8.4%) had false-negative liquid biopsy results and 228 (91.6%) had true-positive results. Demographic factors including age, sex, BMI, smoking history, and comorbidities (diabetes and immunocompromised status) did not differ significantly between groups. Clinical T-stage was also similar across cohorts. Although clinical N-stage distributions did not reach statistical significance, cN0 stage were more common in false-negative patients compared with true-positive patients (33.3% vs 12.9%). Other disease characteristics such as M-stage and tumor p16 status were similar between the two cohorts.",
        "Discussion": "In this study, we explore the differences in patient characteristics for those who have false-negative diagnostic liquid biopsy results in HPV+ OPSCC. Our findings suggest lower nodal burden may be associated with false-negative diagnostic liquid biopsy results. As many patients are currently in surveillance, it is important to know the status of their pre-treatment liquid biopsy to understand the utility of a negative result in surveillance. Without a baseline positive value, it is hard to know whether a negative surveillance cTTMV HPV DNA result is a true-negative or a false-negative, a predicament for H&N oncologists that will occur in approximately one in every ten cases of HPV+OPSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Characterizing False-Negative Results in Diagnostic Liquid Biopsy for HPV-Associated Head and Neck Squamous Cell Carcinoma</span>. Ethan Gomez; <u>Peter Cooke</u>; Ryan Sicard; Daniel Kraft; Alicia Yang; Michael Berger; Marita Teng; Raymond Chai; Eric Genden; Scott Roof. Icahn School of Medicine at Mount Sinai<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>While the national incidence of human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) continues to rise, circulating tumor tissue–modified viral (cTTMV) HPV DNA has shown promise as a biomarker for diagnosis and surveillance. Although prior studies demonstrate high diagnostic sensitivity for TTMV HPV DNA testing, the non-detectable results prior to treatment in a subgroup of patients remain poorly understood. In this study, we investigate patients who tested negative in the pre-treatment phase despite having pathologically confirmed HPV+ tumors. Our goal is to identify clinical or disease-related factors that may predispose liquid biopsy testing to a pre-treatment false-negative result.</p>\n\n<p><strong>Methods: </strong>This is a retrospective cohort study of patients with HPV+ OPSCC who underwent cTTMV HPV DNA testing prior to treatment initiation. All patients had biopsy-confirmed, HPV-positive tumors. HPV status was determined via polymerase chain reaction or in situ-hybridization testing. Demographic and clinical variables were abstracted from the electronic medical record and comparisons were made between patients with false-negative and those with true-positive pre-treatment liquid biopsy results.</p>\n\n<p><strong>Results: </strong>249 patients with oropharyngeal cancer received pre-treatment HPV DNA liquid biopsy testing from May 21, 2020 to September 12, 2024. Twenty one patients (8.4%) had false-negative liquid biopsy results and 228 (91.6%) had true-positive results. Demographic factors including age, sex, BMI, smoking history, and comorbidities (diabetes and immunocompromised status) did not differ significantly between groups. Clinical T-stage was also similar across cohorts. Although clinical N-stage distributions did not reach statistical significance, cN0 stage were more common in false-negative patients compared with true-positive patients (33.3% vs 12.9%). Other disease characteristics such as M-stage and tumor p16 status were similar between the two cohorts.</p>\n\n<p><strong>Discussion: </strong>In this study, we explore the differences in patient characteristics for those who have false-negative diagnostic liquid biopsy results in HPV+ OPSCC. Our findings suggest lower nodal burden may be associated with false-negative diagnostic liquid biopsy results. As many patients are currently in surveillance, it is important to know the status of their pre-treatment liquid biopsy to understand the utility of a negative result in surveillance. Without a baseline positive value, it is hard to know whether a negative surveillance cTTMV HPV DNA result is a true-negative or a false-negative, a predicament for H&N oncologists that will occur in approximately one in every ten cases of HPV+OPSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154657--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S531",
      "content_id": "146665",
      "abstract_number": "S531",
      "poster_number": "",
      "title": "Provider Satisfaction with P16+ Oropharyngeal Cancer Guidelines; An International Survey Study",
      "summary": "The findings highlight considerable dissatisfaction and ethical concerns among providers regarding the current p16+ OPC guidelines. A significant proportion of respondents support treatment de-escalation, reflecting the need for guideline updates that address emerging evidence and provider perspectives to enhance treatment satisfaction and patient outcomes.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=146665",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Neil Gildener-Leapman",
      "presenter": "Neil Gildener-Leapman",
      "authors": "Barak Spector 1 ; Matthew Holdaway 2 ; Madhavi Kambam 3 ; Neil Gildener-Leapman 4",
      "normalized_authors": [
        "Barak Spector",
        "Matthew Holdaway",
        "Madhavi Kambam",
        "Neil Gildener-Leapman"
      ],
      "affiliations": [
        "Tel Aviv University, Sackler School of Medicine",
        "Beth Israel Deaconess Medical Center, Department of Otolayrngology-Head & Neck Surgery",
        "New York Oncology Hematology",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center"
      ],
      "normalized_institutions": [
        "Tel Aviv University, Sackler School of Medicine",
        "Beth Israel Deaconess Medical Center, Department of Otolayrngology-Head & Neck Surgery",
        "New York Oncology Hematology",
        "Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 234,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Barak Spector 1 ; Matthew Holdaway 2 ; Madhavi Kambam 3 ; Neil Gildener-Leapman 4",
        "Affiliations": "1 Tel Aviv University, Sackler School of Medicine; 2 Beth Israel Deaconess Medical Center, Department of Otolayrngology-Head & Neck Surgery; 3 New York Oncology Hematology; 4 Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center",
        "Objectives": "To evaluate healthcare provider satisfaction, adherence, and perceptions regarding current clinical guidelines for the treatment of p16-positive oropharyngeal cancer (OPC), specifically focusing on their perceived adaptability, personal treatment preferences, and associated moral burdens.",
        "Methods": "An international online survey was administered to attending otolaryngologists, medical oncologists, and radiation oncologists. Participants provided information about their specialty, the guidelines they follow, opinions on guideline adaptability, frequency of deviation from guidelines, preferred treatment if personally diagnosed with T1N1 p16+ OPC, and perceived moral burden related to guideline-based treatments. Responses were collected and analyzed using descriptive statistics.",
        "Results": "A total of 133 providers completed the survey. The majority of respondents utilized NCCN guidelines (94%). Regarding guideline adaptability, 53.4% of providers felt guidelines were not adapting quickly enough. Most providers occasionally (81.9%) or regularly (6.9%) deviated from guidelines. When presented with a hypothetical personal diagnosis of T1N1 p16+ OPC, only 37.3% preferred guideline-based care, while others indicated preferences for various treatment de-escalation strategies, including transoral robotic surgery and reduced radiation dosages. Additionally, 62.9% of respondents reported feeling a significant moral burden associated with current guideline-based treatments.",
        "Conclusions": "The findings highlight considerable dissatisfaction and ethical concerns among providers regarding the current p16+ OPC guidelines. A significant proportion of respondents support treatment de-escalation, reflecting the need for guideline updates that address emerging evidence and provider perspectives to enhance treatment satisfaction and patient outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Provider Satisfaction with P16+ Oropharyngeal Cancer Guidelines; An International Survey Study</span>. Barak Spector<sup>1</sup>; Matthew Holdaway<sup>2</sup>; Madhavi Kambam<sup>3</sup>; <u>Neil Gildener-Leapman</u><sup>4</sup>. <sup>1</sup>Tel Aviv University, Sackler School of Medicine; <sup>2</sup>Beth Israel Deaconess Medical Center, Department of Otolayrngology-Head & Neck Surgery; <sup>3</sup>New York Oncology Hematology; <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, Albany Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>To evaluate healthcare provider satisfaction, adherence, and perceptions regarding current clinical guidelines for the treatment of p16-positive oropharyngeal cancer (OPC), specifically focusing on their perceived adaptability, personal treatment preferences, and associated moral burdens.</p>\n\n<p><strong>Methods: </strong>An international online survey was administered to attending otolaryngologists, medical oncologists, and radiation oncologists. Participants provided information about their specialty, the guidelines they follow, opinions on guideline adaptability, frequency of deviation from guidelines, preferred treatment if personally diagnosed with T1N1 p16+ OPC, and perceived moral burden related to guideline-based treatments. Responses were collected and analyzed using descriptive statistics.</p>\n\n<p><strong>Results: </strong>A total of 133 providers completed the survey. The majority of respondents utilized NCCN guidelines (94%). Regarding guideline adaptability, 53.4% of providers felt guidelines were not adapting quickly enough. Most providers occasionally (81.9%) or regularly (6.9%) deviated from guidelines. When presented with a hypothetical personal diagnosis of T1N1 p16+ OPC, only 37.3% preferred guideline-based care, while others indicated preferences for various treatment de-escalation strategies, including transoral robotic surgery and reduced radiation dosages. Additionally, 62.9% of respondents reported feeling a significant moral burden associated with current guideline-based treatments.</p>\n\n<p><strong>Conclusions: </strong>The findings highlight considerable dissatisfaction and ethical concerns among providers regarding the current p16+ OPC guidelines. A significant proportion of respondents support treatment de-escalation, reflecting the need for guideline updates that address emerging evidence and provider perspectives to enhance treatment satisfaction and patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 146665--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S532",
      "content_id": "154253",
      "abstract_number": "S532",
      "poster_number": "",
      "title": "Patient-Level Predictors of Disease-Specific Survival in HPV-Related Oropharyngeal Squamous Cell Carcinoma.",
      "summary": "In patients with HPV-OPSCC, appointment non-adherence independently predicts decreased disease-specific survival. These results emphasize the link between continuity of care, patient behaviors, and clinical factors with oncologic outcomes. The use of adherence metrics in care delivery, targeted navigation assistance, simplified recurrence monitoring, and accessible survivorship programs may identify at-risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154253",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "John Vieth, BS",
      "presenter": "John Vieth, BS",
      "authors": "John Vieth, BS 1 ; Anthony Mangino, PhD 2 ; Melina Windon, MD 3 ; Joseph Valentino, MD 3",
      "normalized_authors": [
        "John Vieth",
        "Anthony Mangino",
        "Melina Windon",
        "Joseph Valentino"
      ],
      "affiliations": [
        "College of Medicine, University of Kentucky",
        "Department of Biostatistics, University of Kentucky",
        "Department of Otolaryngology, University of Kentucky"
      ],
      "normalized_institutions": [
        "College of Medicine, University of Kentucky",
        "Department of Biostatistics, University of Kentucky",
        "Department of Otolaryngology, University of Kentucky"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 345,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "John Vieth, BS 1 ; Anthony Mangino, PhD 2 ; Melina Windon, MD 3 ; Joseph Valentino, MD 3",
        "Affiliations": "1 College of Medicine, University of Kentucky; 2 Department of Biostatistics, University of Kentucky; 3 Department of Otolaryngology, University of Kentucky",
        "Background": "HPV-related oropharyngeal squamous cell carcinoma (HPV-OPSCC) carries an excellent prognosis, although disparities in access and adherence to care knowingly contribute to variable outcomes. Previous work demonstrated high appointment non-adherence rates among HPV-OPSCC patients at our institution, with no-show rates of 4.6% and cancellation rates of 31.0%. This study evaluates whether appointment non-adherence is associated with disease-specific survival (DSS) when controlling for demographic and clinical covariates.",
        "Methods": "A retrospective cohort of patients ≥18 years of age with p16-positive HPV-OPSCC between January 1, 2013, and April 1, 2023, was analyzed. Demographic (age, race, insurance), clinical (tumor site, tumor stage, tobacco use), and behavioral (appointment adherence) variables were extracted from institutional registries. No-show profile was defined as missing one or more head and neck surgical oncology appointment without prior cancellation. DSS was assessed via Kaplan–Meier analysis and multivariable Cox proportional hazards modeling, adjusting for age, sex, stage, smoking, and insurance type.",
        "Results": "Among 334 p16-positive HPV-OPSCC patients with median follow up time of 38.7 months, 5-year overall survival was 63.0% and DSS was 83.7% Unadjusted analyses identified age at diagnosis, insurance type, ever smoker, tumor status post treatment, and no-show profile as associated with decreased DSS (all p < 0.05). Patients with ≥1 no-show and ≥ 2 no-shows had 5-year DSS of 89.2% and 78.0%, respectively (p = 0.05), compared to 92% with fully adherent patients. In multivariable analysis, total no-shows (HR 1.05, 95% CI 1.00–1.11), cigarette pack years (HR 1.03, 95% CI 1.01–1.04), and age at diagnosis (HR 1.06, 95% CI 1.01–1.12) were associated with worse DSS (all p < 0.05).",
        "Conclusions": "In patients with HPV-OPSCC, appointment non-adherence independently predicts decreased disease-specific survival. These results emphasize the link between continuity of care, patient behaviors, and clinical factors with oncologic outcomes. The use of adherence metrics in care delivery, targeted navigation assistance, simplified recurrence monitoring, and accessible survivorship programs may identify at-risk patients and guide implementations to improve access to head and neck cancer survivorship.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patient-Level Predictors of Disease-Specific Survival in HPV-Related Oropharyngeal Squamous Cell Carcinoma.</span>. <u>John Vieth, BS</u><sup>1</sup>; Anthony Mangino, PhD<sup>2</sup>; Melina Windon, MD<sup>3</sup>; Joseph Valentino, MD<sup>3</sup>. <sup>1</sup>College of Medicine, University of Kentucky; <sup>2</sup>Department of Biostatistics, University of Kentucky; <sup>3</sup>Department of Otolaryngology, University of Kentucky<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>HPV-related oropharyngeal squamous cell carcinoma (HPV-OPSCC) carries an excellent prognosis, although disparities in access and adherence to care knowingly contribute to variable outcomes. Previous work demonstrated high appointment non-adherence rates among HPV-OPSCC patients at our institution, with no-show rates of 4.6% and cancellation rates of 31.0%. This study evaluates whether appointment non-adherence is associated with disease-specific survival (DSS) when controlling for demographic and clinical covariates.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of patients ≥18 years of age with p16-positive HPV-OPSCC between January 1, 2013, and April 1, 2023, was analyzed. Demographic (age, race, insurance), clinical (tumor site, tumor stage, tobacco use), and behavioral (appointment adherence) variables were extracted from institutional registries. No-show profile was defined as missing one or more head and neck surgical oncology appointment without prior cancellation. DSS was assessed via Kaplan–Meier analysis and multivariable Cox proportional hazards modeling, adjusting for age, sex, stage, smoking, and insurance type.</p>\n\n<p><strong>Results: </strong>Among 334 p16-positive HPV-OPSCC patients with median follow up time of 38.7 months, 5-year overall survival was 63.0% and DSS was 83.7% Unadjusted analyses identified age at diagnosis, insurance type, ever smoker, tumor status post treatment, and no-show profile as associated with decreased DSS (all p < 0.05). Patients with ≥1 no-show and ≥ 2 no-shows had 5-year DSS of 89.2% and 78.0%, respectively (p = 0.05), compared to 92% with fully adherent patients. In multivariable analysis, total no-shows (HR 1.05, 95% CI 1.00–1.11), cigarette pack years (HR 1.03, 95% CI 1.01–1.04), and age at diagnosis (HR 1.06, 95% CI 1.01–1.12) were associated with worse DSS (all p < 0.05).</p>\n\n<p><strong>Conclusions: </strong>In patients with HPV-OPSCC, appointment non-adherence independently predicts decreased disease-specific survival. These results emphasize the link between continuity of care, patient behaviors, and clinical factors with oncologic outcomes. The use of adherence metrics in care delivery, targeted navigation assistance, simplified recurrence monitoring, and accessible survivorship programs may identify at-risk patients and guide implementations to improve access to head and neck cancer survivorship. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154253--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S534",
      "content_id": "154017",
      "abstract_number": "S534",
      "poster_number": "",
      "title": "Nutritional Outcomes Associated with Definitive Chemoradiation in Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Lower BMI and reduced functional oral intake prior to treatment were associated with increased mortality and local recurrence in patients receiving definitive CRT for OPSCC. Advanced clinical T stage and treatment with IMRT were associated with worse functional oral intake during CRT. These findings demonstrate the importance of early nutritional evaluation and optimization to identify patients at increased risk...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154017",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jane Y Tong, MD",
      "presenter": "Jane Y Tong, MD",
      "authors": "Jane Y Tong, MD ; Vera Bzhilyanskaya, BS; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD",
      "normalized_authors": [
        "Jane Y Tong",
        "Vera Bzhilyanskaya",
        "Kelly Moyer",
        "Jeffrey Wolf",
        "Rodney Taylor",
        "Ranee Mehra",
        "Kyle M Hatten"
      ],
      "affiliations": [
        "University of Maryland School of Medicine"
      ],
      "normalized_institutions": [
        "University of Maryland School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 485,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Study Design",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jane Y Tong, MD ; Vera Bzhilyanskaya, BS; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD",
        "Affiliations": "University of Maryland School of Medicine",
        "Objectives": "Nutritional compromise is a well-recognized toxicity of definitive chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC), yet the patient and oncologic characteristics that predispose individuals to worse nutritional outcomes are not fully understood. This study evaluates factors associated with weight loss, functional oral intake, and feeding tube dependence in patients treated with CRT for OPSCC.",
        "Study Design": "Retrospective review of patients treated with definitive CRT for OPSCC from January 2016 to December 2024 at a tertiary academic medical center.",
        "Methods": "Patient demographics, oncologic characteristics, and nutritional variables were extracted from electronic medical records.",
        "Results": "117 patients were included. Most were male (86.3%) with HPV-associated OPSCC (88.0%). Median age was 64 years. The majority had a clinical T stage of cT2 (42.7%) or cT3 (23.1%). Proton beam therapy (PBT) was used in 61.5% of patients. At treatment initiation, 23.1% had a BMI under 25. Enteral feeding was required in 34.2% of patients at some point during their disease course. Median follow-up was 2.26 years. Local recurrence occurred in 7.7% and 19.7% died by last follow-up.",
        "Abstract": "HPV-negative OPSCC was associated with a pre-treatment BMI less than 25 ( p = 0.005). While clinical T stage was not associated with BMI or weight loss, it was associated with lower functional oral intake scale (FOIS) scores at the start ( p = 0.049) and end of CRT ( p < 0.001). Baseline BMI above 25 was associated with a greater percent total weight loss at three months ( p = 0.003), six months ( p = 0.03), and nine months ( p = 0.03). Markers of nutritional status were also associated with oncologic outcomes. Lower pre-treatment FOIS score and any feeding tube requirement were associated with death at last follow-up ( p < 0.001). A BMI less than 25 during the first month of treatment, including at treatment initiation ( p = 0.008), week one ( p = 0.005), week three ( p = 0.002), and week four ( p = 0.04), was associated with increased mortality. Local recurrence was associated with pre-treatment BMI less than 25 ( p = 0.007) and feeding tube requirement ( p < 0.001). Although radiation modality was not associated with BMI or weight loss, patients treated with IMRT had lower FOIS scores at CRT treatment start ( p = 0.03) and end ( p = 0.001) compared to those treated with PBT. FOIS scores were similar between radiation modalities at last follow-up ( p = 0.24). Patients treated with IMRT were more likely to require enteral feeding during treatment ( p = 0.02). View in Agenda and Add to Schedule",
        "Conclusion": "Lower BMI and reduced functional oral intake prior to treatment were associated with increased mortality and local recurrence in patients receiving definitive CRT for OPSCC. Advanced clinical T stage and treatment with IMRT were associated with worse functional oral intake during CRT. These findings demonstrate the importance of early nutritional evaluation and optimization to identify patients at increased risk for nutritional decline during CRT."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Nutritional Outcomes Associated with Definitive Chemoradiation in Oropharyngeal Squamous Cell Carcinoma</span>. <u>Jane Y Tong, MD</u>; Vera Bzhilyanskaya, BS; Kelly Moyer, MD; Jeffrey Wolf, MD; Rodney Taylor, MD; Ranee Mehra, MD; Kyle M Hatten, MD. University of Maryland School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>Nutritional compromise is a well-recognized toxicity of definitive chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC), yet the patient and oncologic characteristics that predispose individuals to worse nutritional outcomes are not fully understood. This study evaluates factors associated with weight loss, functional oral intake, and feeding tube dependence in patients treated with CRT for OPSCC.</p>\n\n<p><strong>Study Design: </strong>Retrospective review of patients treated with definitive CRT for OPSCC from January 2016 to December 2024 at a tertiary academic medical center.</p>\n\n<p><strong>Methods:</strong> Patient demographics, oncologic characteristics, and nutritional variables were extracted from electronic medical records.</p>\n\n<p><strong>Results: </strong>117 patients were included. Most were male (86.3%) with HPV-associated OPSCC (88.0%). Median age was 64 years. The majority had a clinical T stage of cT2 (42.7%) or cT3 (23.1%). Proton beam therapy (PBT) was used in 61.5% of patients. At treatment initiation, 23.1% had a BMI under 25. Enteral feeding was required in 34.2% of patients at some point during their disease course. Median follow-up was 2.26 years. Local recurrence occurred in 7.7% and 19.7% died by last follow-up.</p>\n\n<p>HPV-negative OPSCC was associated with a pre-treatment BMI less than 25 (<em>p</em> = 0.005). While clinical T stage was not associated with BMI or weight loss, it was associated with lower functional oral intake scale (FOIS) scores at the start (<em>p</em> = 0.049) and end of CRT (<em>p </em>< 0.001). Baseline BMI above 25 was associated with a greater percent total weight loss at three months (<em>p</em> = 0.003), six months (<em>p </em>= 0.03), and nine months (<em>p</em> = 0.03).</p>\n\n<p>Markers of nutritional status were also associated with oncologic outcomes. Lower pre-treatment FOIS score and any feeding tube requirement were associated with death at last follow-up (<em>p </em>< 0.001). A BMI less than 25 during the first month of treatment, including at treatment initiation (<em>p </em>= 0.008), week one (<em>p</em> = 0.005), week three (<em>p </em>= 0.002), and week four (<em>p</em> = 0.04), was associated with increased mortality. Local recurrence was associated with pre-treatment BMI less than 25 (<em>p</em> = 0.007) and feeding tube requirement (<em>p</em> < 0.001).</p>\n\n<p>Although radiation modality was not associated with BMI or weight loss, patients treated with IMRT had lower FOIS scores at CRT treatment start (<em>p</em> = 0.03) and end (<em>p </em>= 0.001) compared to those treated with PBT. FOIS scores were similar between radiation modalities at last follow-up (<em>p </em>= 0.24). Patients treated with IMRT were more likely to require enteral feeding during treatment (<em>p</em> = 0.02).</p>\n\n<p><strong>Conclusion:</strong> Lower BMI and reduced functional oral intake prior to treatment were associated with increased mortality and local recurrence in patients receiving definitive CRT for OPSCC. Advanced clinical T stage and treatment with IMRT were associated with worse functional oral intake during CRT. These findings demonstrate the importance of early nutritional evaluation and optimization to identify patients at increased risk for nutritional decline during CRT.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154017--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S535",
      "content_id": "154445",
      "abstract_number": "S535",
      "poster_number": "",
      "title": "Association of HIV Status with Clinical Outcomes in HPV-Positive Oropharyngeal Squamous Cell Carcinoma",
      "summary": "Among people with HIV (PWH), HIV-related immunosuppression impairs HPV clearance, leading to higher rates of persistent HPV infection and an increased incidence of HPV-positive oropharyngeal squamous cell carcinomas (OPSCC). However, the impact of HIV status on survival following HPV-positive OPSCC remains poorly defined. This study evaluated differences in survival outcomes, time to treatment initiation, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154445",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivian Vo",
      "presenter": "Vivian Vo",
      "authors": "Vivian Vo 1 ; Amelia Nichols, MPH, CPH 2 ; Jessica Islam, PhD, MPH 3 ; Brittney Dickey, PhD 2 ; Jesse Qualliotine, MD 4",
      "normalized_authors": [
        "Vivian Vo",
        "Amelia Nichols, CPH",
        "Jessica Islam",
        "Brittney Dickey",
        "Jesse Qualliotine"
      ],
      "affiliations": [
        "UC San Diego School of Medicine",
        "Department of Epidemiology, University of Nebraska Medical Cente",
        "Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "normalized_institutions": [
        "UC San Diego School of Medicine",
        "Department of Epidemiology, University of Nebraska Medical Cente",
        "Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute",
        "Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health"
      ],
      "session_type": "Proffered Paper",
      "track": "Oropharynx / HPV Related Disease",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oropharynx / HPV Related Disease"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 407,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Vivian Vo 1 ; Amelia Nichols, MPH, CPH 2 ; Jessica Islam, PhD, MPH 3 ; Brittney Dickey, PhD 2 ; Jesse Qualliotine, MD 4",
        "Affiliations": "1 UC San Diego School of Medicine; 2 Department of Epidemiology, University of Nebraska Medical Cente; 3 Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute; 4 Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health",
        "Abstract": "Among people with HIV (PWH), HIV-related immunosuppression impairs HPV clearance, leading to higher rates of persistent HPV infection and an increased incidence of HPV-positive oropharyngeal squamous cell carcinomas (OPSCC). However, the impact of HIV status on survival following HPV-positive OPSCC remains poorly defined. This study evaluated differences in survival outcomes, time to treatment initiation, and treatment modalities between PWH and people without HIV (PWoH) using the National Cancer Database (NCDB). Patients diagnosed with HPV-positive OPSCC between 2004 and 2019 were identified in the NCDB. Only patients with a documented HIV status were included and stratified as PWH or PWoH. Demographic (sex, age, race), clinical (stage, primary site), and treatment characteristics were descriptively compared between groups. Kaplan Meier survival analysis and Cox proportional hazards models were used to assess overall survival by HIV status and to evaluate whether delays in treatment initiation or receipt of adjuvant radiation therapy (among surgical patients) were associated with survival. Of 146,539 patients identified with HPV-positive OPSCC, 24,474 had a known HIV status(161 were PWH and 24,313 were PWoH). The median age at diagnosis for PWH was 56 years, with most aged 50-59 (p < 0.0001). PWH were more likely to receive treatment at academic or research centers, which was associated with greater travel distances compared with other facility types (p < 0.0001). Clinically, PWH presented with higher T stage and more frequent tonsillar primary sites (p < 0.0001), but lower nodal involvement (p = 0.048). Radiation therapy, with or without systemic therapy, was the most common treatment among PWH (63.8% vs 60.3% in PWoH; p < 0.001), and overall treatment distributions differed significantly by HIV status (p < 0.001). Compared with PWoH, PWH had significantly worse survival (p < 0.0001), a finding that persisted after stratification by treatment type and by early versus late stage. PWH also experienced a longer median time to treatment initiation (32 vs 26 days). Time-to-first treatment analyses using Kaplan-Meier curves demonstrated that PWH had significantly longer time to first treatment compared with PWoH ( p = 0.0012), and this difference remained significant when restricted to patients initiating treatment within 90 days (p = 0.007). Overall, PWH with HPV-positive OPSCC demonstrated distinct clinical and treatment characteristics compared with PWoH, including higher T stage, more frequent tonsillar primaries, and longer time to treatment initiation. PWH experienced poorer survival, even after adjustment for treatment modality and cancer staging. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of HIV Status with Clinical Outcomes in HPV-Positive Oropharyngeal Squamous Cell Carcinoma</span>. <u>Vivian Vo</u><sup>1</sup>; Amelia Nichols, MPH, CPH<sup>2</sup>; Jessica Islam, PhD, MPH<sup>3</sup>; Brittney Dickey, PhD<sup>2</sup>; Jesse Qualliotine, MD<sup>4</sup>. <sup>1</sup>UC San Diego School of Medicine; <sup>2</sup>Department of Epidemiology, University of Nebraska Medical Cente; <sup>3</sup>Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute; <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Among people with HIV (PWH), HIV-related immunosuppression impairs HPV clearance, leading to higher rates of persistent HPV infection and an increased incidence of HPV-positive oropharyngeal squamous cell carcinomas (OPSCC). However, the impact of HIV status on survival following HPV-positive OPSCC remains poorly defined. This study evaluated differences in survival outcomes, time to treatment initiation, and treatment modalities between PWH and people without HIV (PWoH) using the National Cancer Database (NCDB).</p>\n\n<p>Patients diagnosed with HPV-positive OPSCC between 2004 and 2019 were identified in the NCDB. Only patients with a documented HIV status were included and stratified as PWH or PWoH. Demographic (sex, age, race), clinical (stage, primary site), and treatment characteristics were descriptively compared between groups. Kaplan Meier survival analysis and Cox proportional hazards models were used to assess overall survival by HIV status and to evaluate whether delays in treatment initiation or receipt of adjuvant radiation therapy (among surgical patients) were associated with survival.</p>\n\n<p>Of 146,539 patients identified with HPV-positive OPSCC, 24,474 had a known HIV status(161 were PWH and 24,313 were PWoH). The median age at diagnosis for PWH was 56 years, with most aged 50-59 (p < 0.0001). PWH were more likely to receive treatment at academic or research centers, which was associated with greater travel distances compared with other facility types (p < 0.0001). Clinically, PWH presented with higher T stage and more frequent tonsillar primary sites (p < 0.0001), but lower nodal involvement (p = 0.048). Radiation therapy, with or without systemic therapy, was the most common treatment among PWH (63.8% vs 60.3% in PWoH; p < 0.001), and overall treatment distributions differed significantly by HIV status (p < 0.001). Compared with PWoH, PWH had significantly worse survival (p < 0.0001), a finding that persisted after stratification by treatment type and by early versus late stage.  PWH also experienced a longer median time to treatment initiation (32 vs 26 days). Time-to-first treatment analyses using Kaplan-Meier curves demonstrated that PWH had significantly longer time to first treatment compared with PWoH ( p = 0.0012), and this difference remained significant when restricted to patients initiating treatment within 90 days (p = 0.007).</p>\n\n<p>Overall, PWH with HPV-positive OPSCC demonstrated distinct clinical and treatment characteristics compared with PWoH, including higher T stage, more frequent tonsillar primaries, and longer time to treatment initiation. PWH experienced poorer survival, even after adjustment for treatment modality and cancer staging. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154445--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S536",
      "content_id": "153328",
      "abstract_number": "S536",
      "poster_number": "",
      "title": "Improving Timeliness Between Surgery and the Initiation of Post-Operative Radiotherapy (PORT) for Patients with Head and Neck Cancer: An Improvement Project in a Canadian Cancer Centre",
      "summary": "Implementation of a standardized early-identification and referral process increased PORT timeliness from 43% to 46%. However, the target of 70% compliance was not achieved due to the high proportion of unavoidable delays. Future efforts will focus on dedicated patient navigation, automated follow-up scheduling, and improved visualization of the care pathway to further reduce preventable delays.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153328",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260157",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Madette Galapin, MRTT, MScHQ",
      "presenter": "Madette Galapin, MRTT, MScHQ",
      "authors": "Antoine Eskander, MD, ScM, FRCSC 1 ; Kimya Manouchehri, MD 1 ; Kara Jonas 2 ; Danny Enepekides, MD, MPH, FRCSC 1 ; Kevin Higgins, MD, FRCSC 1 ; Irene Karam, MD, FRCPC 3 ; Ian Poon, MD, FRCPC 3 ; Andrew Bayley, MD, FRCPC 3 ; Amir H Safavi, MD, MSc, FRCPC 3 ; Michael Tjong, MD, FRCPC 3 ; Madette Galapin, MRTT, MScHQ 4",
      "normalized_authors": [
        "Antoine Eskander, ScM, FRCSC",
        "Kimya Manouchehri",
        "Kara Jonas",
        "Danny Enepekides, FRCSC",
        "Kevin Higgins, FRCSC",
        "Irene Karam, FRCPC",
        "Ian Poon, FRCPC",
        "Andrew Bayley, FRCPC",
        "Amir H Safavi, FRCPC",
        "Michael Tjong, FRCPC",
        "Madette Galapin, MRTT, MScHQ"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, ON, Canada",
        "Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada",
        "Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada",
        "Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, ON, Canada",
        "Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada",
        "Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada",
        "Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 440,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Antoine Eskander, MD, ScM, FRCSC 1 ; Kimya Manouchehri, MD 1 ; Kara Jonas 2 ; Danny Enepekides, MD, MPH, FRCSC 1 ; Kevin Higgins, MD, FRCSC 1 ; Irene Karam, MD, FRCPC 3 ; Ian Poon, MD, FRCPC 3 ; Andrew Bayley, MD, FRCPC 3 ; Amir H Safavi, MD, MSc, FRCPC 3 ; Michael Tjong, MD, FRCPC 3 ; Madette Galapin, MRTT, MScHQ 4",
        "Affiliations": "1 Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, ON, Canada; 2 Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 3 Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; 4 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada",
        "Background": "The American College of Surgeons Commission on Cancer (ACS/CoC) quality metric for head and neck (HN) cancer recommends post-operative radiotherapy (PORT) begin within 42 days of surgery. A 2021-2022 quality improvement (QI) audit at our centre demonstrated that only 43% of eligible patients met this benchmark. Root cause analysis identified that radiation oncologist (RO) consultation within 21 days post-operatively was strongly associated with timely PORT. This QI initiative aimed to increase compliance with the ACS/CoC PORT timeliness metric from 43% to 70% by the end of 2024.",
        "Methods": "This multidisciplinary QI project introduced a standardized process for earlier identification and triage of patients requiring PORT. Patients with mucosal and cutaneous squamous cell carcinoma (SCC), melanoma, salivary gland malignancies, and other high-risk skin carcinomas who underwent surgery followed by PORT between January and December 2024 were included. Patients with prior HN radiotherapy were excluded. The intervention involved: (1) creation of a process to identify relevant patients and communicate PORT goal dates to RO; and (2) standardized booking of a 3-week post-operative follow-up with RO through a computerized order system. Measures included: (1) the percentage of patients initiating PORT ≤42 days after surgery (primary outcome); (2) RO consultation ≤21 days post-operatively (process measure); and (3) PORT initiated ≤42 days requiring a rushed planning interval <14 days from simulation to treatment (balancing measure). Quarterly reports, team feedback sessions, and iterative adjustments supported implementation and sustainability.",
        "Results": "A total of 135 patients met inclusion criteria, of whom 62 (46%) initiated PORT within 42 days. Among those with mucosal SCC, 36/65 (55%) achieved timely PORT, compared with 26/70 (37%) of patients with non-mucosal SCC or other histology. Quarterly performance fluctuated, with timely PORT achieved in 46% in Q1, 39% in Q2, 43% in Q3, and 54% in Q4. RO consultation ≤21 days occurred in 40% of patients, ranging from 38% in Q1 to 44% in Q4. When timely RO consultation occurred, 70% of patients went on to receive PORT within 42 days. Rushed planning increased from 33% in Q1 to 63% in Q3, then decreased to 38% in Q4. Among the 73 patients with delayed PORT, the primary causes were care coordination issues (56%), post-operative complications (32%), and patient- or system-related factors (12%). Notably, 70% of all delays were deemed unavoidable.",
        "Conclusions": "Implementation of a standardized early-identification and referral process increased PORT timeliness from 43% to 46%. However, the target of 70% compliance was not achieved due to the high proportion of unavoidable delays. Future efforts will focus on dedicated patient navigation, automated follow-up scheduling, and improved visualization of the care pathway to further reduce preventable delays.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Improving Timeliness Between Surgery and the Initiation of Post-Operative Radiotherapy (PORT) for Patients with Head and Neck Cancer: An Improvement Project in a Canadian Cancer Centre</span>. Antoine Eskander, MD, ScM, FRCSC<sup>1</sup>; Kimya Manouchehri, MD<sup>1</sup>; Kara Jonas<sup>2</sup>; Danny Enepekides, MD, MPH, FRCSC<sup>1</sup>; Kevin Higgins, MD, FRCSC<sup>1</sup>; Irene Karam, MD, FRCPC<sup>3</sup>; Ian Poon, MD, FRCPC<sup>3</sup>; Andrew Bayley, MD, FRCPC<sup>3</sup>; Amir H Safavi, MD, MSc, FRCPC<sup>3</sup>; Michael Tjong, MD, FRCPC<sup>3</sup>; <u>Madette Galapin, MRTT, MScHQ</u><sup>4</sup>. <sup>1</sup>Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; <sup>3</sup>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; <sup>4</sup>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> The American College of Surgeons Commission on Cancer (ACS/CoC) quality metric for head and neck (HN) cancer recommends post-operative radiotherapy (PORT) begin within 42 days of surgery. A 2021-2022 quality improvement (QI) audit at our centre demonstrated that only 43% of eligible patients met this benchmark. Root cause analysis identified that radiation oncologist (RO) consultation within 21 days post-operatively was strongly associated with timely PORT. This QI initiative aimed to increase compliance with the ACS/CoC PORT timeliness metric from 43% to 70% by the end of 2024.</p>\n\n<p><strong>Methods: </strong>This multidisciplinary QI project introduced a standardized process for earlier identification and triage of patients requiring PORT. Patients with mucosal and cutaneous squamous cell carcinoma (SCC), melanoma, salivary gland malignancies, and other high-risk skin carcinomas who underwent surgery followed by PORT between January and December 2024 were included. Patients with prior HN radiotherapy were excluded. The intervention involved: (1) creation of a process to identify relevant patients and communicate PORT goal dates to RO; and (2) standardized booking of a 3-week post-operative follow-up with RO through a computerized order system. Measures included: (1) the percentage of patients initiating PORT ≤42 days after surgery (primary outcome); (2) RO consultation ≤21 days post-operatively (process measure); and (3) PORT initiated ≤42 days requiring a rushed planning interval <14 days from simulation to treatment (balancing measure). Quarterly reports, team feedback sessions, and iterative adjustments supported implementation and sustainability.</p>\n\n<p><strong>Results: </strong>A total of 135 patients met inclusion criteria, of whom 62 (46%) initiated PORT within 42 days. Among those with mucosal SCC, 36/65 (55%) achieved timely PORT, compared with 26/70 (37%) of patients with non-mucosal SCC or other histology. Quarterly performance fluctuated, with timely PORT achieved in 46% in Q1, 39% in Q2, 43% in Q3, and 54% in Q4. RO consultation ≤21 days occurred in 40% of patients, ranging from 38% in Q1 to 44% in Q4. When timely RO consultation occurred, 70% of patients went on to receive PORT within 42 days. Rushed planning increased from 33% in Q1 to 63% in Q3, then decreased to 38% in Q4. Among the 73 patients with delayed PORT, the primary causes were care coordination issues (56%), post-operative complications (32%), and patient- or system-related factors (12%). Notably, 70% of all delays were deemed unavoidable.</p>\n\n<p><strong>Conclusions:</strong> Implementation of a standardized early-identification and referral process increased PORT timeliness from 43% to 46%. However, the target of 70% compliance was not achieved due to the high proportion of unavoidable delays. Future efforts will focus on dedicated patient navigation, automated follow-up scheduling, and improved visualization of the care pathway to further reduce preventable delays.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153328--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260157' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S538",
      "content_id": "153543",
      "abstract_number": "S538",
      "poster_number": "",
      "title": "Intraosseous Mucoepidermoid Carcinoma: Systematic Review of Treatment Outcomes and Prognostic Factors with Staging Considerations",
      "summary": "This review is the largest of IMEC cases to date and illuminates that reported treatment algorithms and respective outcomes are heterogeneous. We highlight how traditional salivary gland staging does not correlate with the presentation, treatment and natural history of IMEC. Further analysis could help establish more relevant staging and facilitate clinical decision making.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153543",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jordan Hanson, BS",
      "presenter": "Jordan Hanson, BS",
      "authors": "Jordan Hanson, BS 1 ; Trenton House, BS 1 ; Deborah Xie, MD 2 ; Ameya Jategaonkar, MD 2",
      "normalized_authors": [
        "Jordan Hanson",
        "Trenton House",
        "Deborah Xie",
        "Ameya Jategaonkar"
      ],
      "affiliations": [
        "University of Arizona College of Medicine - Phoenix",
        "Barrow Neurologic Institute"
      ],
      "normalized_institutions": [
        "University of Arizona College of Medicine - Phoenix",
        "Barrow Neurologic Institute"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 493,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jordan Hanson, BS 1 ; Trenton House, BS 1 ; Deborah Xie, MD 2 ; Ameya Jategaonkar, MD 2",
        "Affiliations": "1 University of Arizona College of Medicine - Phoenix; 2 Barrow Neurologic Institute",
        "Background": "Mucoepidermoid carcinoma comprises 5-10% of salivary gland neoplasms, and 2-3% of these tumors are of intraosseous origin. Fewer than 250 cases of intraosseous (or central) mucoepidermoid carcinoma (IMEC) have been reported in the literature since 1975. The pathogenesis of IMEC remains poorly understood, and the paucity of reported cases complicates the drawing of conclusions regarding epidemiology and outcomes of varying treatment modalities. The mainstay of treatment is surgical resection, with adjuvant radiation or systemic therapies advocated for heterogeneously across the literature. Staging systems have been proposed; however, these have not been shown to associate with outcome. Some authors have staged IMEC lesions according to traditional TMN staging of salivary gland cancers.",
        "Abstract": "The TMN staging of salivary gland cancers denotes bony involvement as a stage T4a regardless of other tumor characteristics. National Comprehensive Cancer Network (NCCN) guidelines for the treatment of T4a salivary gland tumors advocate complete resection with neck dissection and adjuvant radiotherapy (RT), which guides treatment decisions. There is no analogous staging tool specifically for IMEC proposed to guide treatment modalities, and thus extent of resection and employment of adjuvant therapies is heterogeneous across the literature. We aim to provide an updated review of the prognostic factors and treatment outcomes of IMEC and highlight how the traditional T staging model for salivary gland cancers may not fully reflect the nature of IMEC. All cases were treated surgically, 147 underwent radical resection, 65 with neck dissection. 59 (25.5%) of patients received adjuvant RT, and 6 (2.6%) adjuvant chemotherapy. Radiated patients’ tumors were larger than non-radiated (average greatest diameter 4.0 versus 3.3cm) though this was not statistically significant. A greater proportion of radiated tumors were of higher pathologic grade (64.6% vs. 24.4% G2 or 3). Those treated with adjuvant RT developed recurrent or progressive disease in 18.5% of cases, compared to 15% of those treated with surgery alone. There was no significant difference in follow-up duration or patient age between groups. View in Agenda and Add to Schedule",
        "Methods": "We conducted a PRISMA-based systematic review of PubMed, Cochrane and Embase databases for case reports and series reporting treatment outcomes of histologically-confirmed IMEC published in the last 50 years.",
        "Results": "Of 667 articles retrieved, 82 articles were included for a total of 231 patients. In agreement with prior reports, there was a female predilection with male to female ratio of 1:1.2. Mean (SD) age at presentation was 46.7 (17.4) years. 69.2% of IMEC involved the mandible. 64.6% of tumors were histologically low-grade, 21.5% intermediate-grade, and 13.8% high-grade (G1, 2, or 3) per Armed Forces Institute of Pathology (AFIP) definitions.",
        "Conclusion": "This review is the largest of IMEC cases to date and illuminates that reported treatment algorithms and respective outcomes are heterogeneous. We highlight how traditional salivary gland staging does not correlate with the presentation, treatment and natural history of IMEC. Further analysis could help establish more relevant staging and facilitate clinical decision making."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraosseous Mucoepidermoid Carcinoma: Systematic Review of Treatment Outcomes and Prognostic Factors with Staging Considerations</span>. <u>Jordan Hanson, BS</u><sup>1</sup>; Trenton House, BS<sup>1</sup>; Deborah Xie, MD<sup>2</sup>; Ameya Jategaonkar, MD<sup>2</sup>. <sup>1</sup>University of Arizona College of Medicine - Phoenix; <sup>2</sup>Barrow Neurologic Institute<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Mucoepidermoid carcinoma comprises 5-10% of salivary gland neoplasms, and 2-3% of these tumors are of intraosseous origin. Fewer than 250 cases of intraosseous (or central) mucoepidermoid carcinoma (IMEC) have been reported in the literature since 1975. The pathogenesis of IMEC remains poorly understood, and the paucity of reported cases complicates the drawing of conclusions regarding epidemiology and outcomes of varying treatment modalities. The mainstay of treatment is surgical resection, with adjuvant radiation or systemic therapies advocated for heterogeneously across the literature. Staging systems have been proposed; however, these have not been shown to associate with outcome. Some authors have staged IMEC lesions according to traditional TMN staging of salivary gland cancers.</p>\n\n<p>The TMN staging of salivary gland cancers denotes bony involvement as a stage T4a regardless of other tumor characteristics. National Comprehensive Cancer Network (NCCN) guidelines for the treatment of T4a salivary gland tumors advocate complete resection with neck dissection and adjuvant radiotherapy (RT), which guides treatment decisions. There is no analogous staging tool specifically for IMEC proposed to guide treatment modalities, and thus extent of resection and employment of adjuvant therapies is heterogeneous across the literature.</p>\n\n<p>We aim to provide an updated review of the prognostic factors and treatment outcomes of IMEC and highlight how the traditional T staging model for salivary gland cancers may not fully reflect the nature of IMEC.</p>\n\n<p><strong>Methods: </strong>We conducted a PRISMA-based systematic review of PubMed, Cochrane and Embase databases for case reports and series reporting treatment outcomes of histologically-confirmed IMEC published in the last 50 years.</p>\n\n<p><strong>Results: </strong>Of 667 articles retrieved, 82 articles were included for a total of 231 patients. In agreement with prior reports, there was a female predilection with male to female ratio of 1:1.2. Mean (SD) age at presentation was 46.7 (17.4) years. 69.2% of IMEC involved the mandible. 64.6% of tumors were histologically low-grade, 21.5% intermediate-grade, and 13.8% high-grade (G1, 2, or 3) per Armed Forces Institute of Pathology (AFIP) definitions.</p>\n\n<p>All cases were treated surgically, 147 underwent radical resection, 65 with neck dissection. 59 (25.5%) of patients received adjuvant RT, and 6 (2.6%) adjuvant chemotherapy. Radiated patients’ tumors were larger than non-radiated (average greatest diameter 4.0 versus 3.3cm) though this was not statistically significant. A greater proportion of radiated tumors were of higher pathologic grade (64.6% vs. 24.4% G2 or 3). Those treated with adjuvant RT developed recurrent or progressive disease in 18.5% of cases, compared to 15% of those treated with surgery alone. There was no significant difference in follow-up duration or patient age between groups.</p>\n\n<p><strong>Conclusion: </strong>This review is the largest of IMEC cases to date and illuminates that reported treatment algorithms and respective outcomes are heterogeneous. We highlight how traditional salivary gland staging does not correlate with the presentation, treatment and natural history of IMEC. Further analysis could help establish more relevant staging and facilitate clinical decision making.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153543--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S539",
      "content_id": "154531",
      "abstract_number": "S539",
      "poster_number": "",
      "title": "Prognostic Value of Lymph Node Ratio and Nodal Distribution Compared With TNM Staging in Oral Squamous Cell Carcinoma.",
      "summary": "In OSCC, LNR and the absolute number of positive nodes strongly outperform TNM N-stage for predicting both survival and recurrence, with substantially higher hazard estimates than those seen for nodal stage. Involvement of lower cervical levels (IV–V) independently signals aggressive disease biology. Incorporating LNR and nodal level into routine postoperative assessment may significantly enhance prognostic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154531",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Stergios Doumas",
      "presenter": "Stergios Doumas",
      "authors": "Niall Kent, BSc (Hons), MBChB, BDS, PhD, MRCS 1 ; Clare Schilling 2 ; Karl Payne 2 ; Michael Ho 3 ; Evan Graboyes 4 ; Jonathan M Hughes, BS 4 ; Peter Steele 5 ; Parth Tagdiwala 2 ; Michael C. Topf 6 ; Eiling Wu 5 ; Joseph Smith 7 ; James Barraclough 3 ; Josh Twigg 3 ; Whitney Jin 6 ; Stergios Doumas 7 ; Sindhura Sridhar 6",
      "normalized_authors": [
        "Niall Kent, , MBChB, BDS, MRCS",
        "Clare Schilling",
        "Karl Payne",
        "Michael Ho",
        "Evan Graboyes",
        "Jonathan M Hughes",
        "Peter Steele",
        "Parth Tagdiwala",
        "Michael C. Topf",
        "Eiling Wu",
        "Joseph Smith",
        "James Barraclough",
        "Josh Twigg",
        "Whitney Jin",
        "Stergios Doumas",
        "Sindhura Sridhar"
      ],
      "affiliations": [
        "Royal Free Foundation Trust",
        "University College Hospital",
        "Leeds Teaching Hospital",
        "Medical University of South Carolina",
        "Queen Elizabeth University Hospital Glasgow",
        "Vanderbilt University Medical Centre",
        "Queen Victoria Hospital"
      ],
      "normalized_institutions": [
        "Royal Free Foundation Trust",
        "University College Hospital",
        "Leeds Teaching Hospital",
        "Medical University of South Carolina",
        "Queen Elizabeth University Hospital Glasgow",
        "Vanderbilt University Medical Centre",
        "Queen Victoria Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Niall Kent, BSc (Hons), MBChB, BDS, PhD, MRCS 1 ; Clare Schilling 2 ; Karl Payne 2 ; Michael Ho 3 ; Evan Graboyes 4 ; Jonathan M Hughes, BS 4 ; Peter Steele 5 ; Parth Tagdiwala 2 ; Michael C. Topf 6 ; Eiling Wu 5 ; Joseph Smith 7 ; James Barraclough 3 ; Josh Twigg 3 ; Whitney Jin 6 ; Stergios Doumas 7 ; Sindhura Sridhar 6",
        "Affiliations": "1 Royal Free Foundation Trust; 2 University College Hospital; 3 Leeds Teaching Hospital; 4 Medical University of South Carolina; 5 Queen Elizabeth University Hospital Glasgow; 6 Vanderbilt University Medical Centre; 7 Queen Victoria Hospital",
        "Background": "Lymph node metastasis is one of the strongest prognostic factors in oral squamous cell carcinoma (OSCC). Although the AJCC 8th edition tumour–node–metastasis (TNM) system classifies nodal disease by number, size, and laterality, alternative nodal metrics, including lymph node ratio (LNR; ratio of positive to total nodes), absolute number of positive nodes, and lowest cervical level involved may offer improved prognostic precision. This multicentre retrospective study compared the prognostic value of these nodal parameters with TNM N-stage for overall survival (OS) and recurrence-free survival (RFS).",
        "Methods": "A retrospective cohort of 781 surgically treated OSCC patients across six centres was identified. After excluding patients with <24 months of follow-up without recurrence or death, 730 patients were eligible for OS and RFS analysis. Data analysed included number of positive nodes, total nodes, LNR, lowest level of nodal involvement, adjuvant therapy, survival status, and recurrence outcomes. Survival was assessed using Kaplan–Meier estimates and Cox proportional hazards modelling. LNR was analysed both continuously (log10-scale) and categorically; optimal thresholds were explored using time-dependent ROC methods.",
        "Results": "Greater nodal burden was strongly associated with poorer outcomes. Patients with five or more positive nodes had a median OS of 1.2 years, compared with 7.9 years for node-negative patients, corresponding to the risk of death increasing by a factor of 4.28 (95% CI 3.12–5.87). For recurrence, patients with ≥5 positive nodes experienced the risk of recurrence increasing by a factor of 3.86 (95% CI 2.64–5.66) compared with node-negative patients.",
        "Abstract": "LNR demonstrated strong and consistent prognostic significance. A 10-fold increase in LNR (one-unit increase on the log10 scale) was associated with the risk of death increasing by a factor of 3.37 (95% CI 2.55–4.46) and the risk of recurrence increasing by a factor of 3.41 (95% CI 2.42–4.81). Categorically, patients with LNR ≥10% had substantially poorer outcomes; for OS, the hazard of death increased by a factor of 4.59 (95% CI 2.95–7.12), and for recurrence, by a factor of 3.08 (95% CI 2.15–4.41), compared with LNR 0%. Nodal level further refined prognosis. Metastasis to levels IV–V was associated with significantly earlier recurrence than levels I–III, corresponding to hazard ratios of 1.67 (95% CI 1.07–2.61) and 1.82 (95% CI 1.18–2.82) in multivariable models. Total nodes harvested did not show a consistent or clinically meaningful association with either OS or RFS. View in Agenda and Add to Schedule",
        "Conclusions": "In OSCC, LNR and the absolute number of positive nodes strongly outperform TNM N-stage for predicting both survival and recurrence, with substantially higher hazard estimates than those seen for nodal stage. Involvement of lower cervical levels (IV–V) independently signals aggressive disease biology. Incorporating LNR and nodal level into routine postoperative assessment may significantly enhance prognostic accuracy beyond current TNM classification and supports consideration of refined nodal-based risk stratification and intensified follow-up or treatment for patients with heavy nodal burden."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prognostic Value of Lymph Node Ratio and Nodal Distribution Compared With TNM Staging in Oral Squamous Cell Carcinoma.</span>. Niall Kent, BSc (Hons), MBChB, BDS, PhD, MRCS<sup>1</sup>; Clare Schilling<sup>2</sup>; Karl Payne<sup>2</sup>; Michael Ho<sup>3</sup>; Evan Graboyes<sup>4</sup>; Jonathan M Hughes, BS<sup>4</sup>; Peter Steele<sup>5</sup>; Parth Tagdiwala<sup>2</sup>; Michael C. Topf<sup>6</sup>; Eiling Wu<sup>5</sup>; Joseph Smith<sup>7</sup>; James Barraclough<sup>3</sup>; Josh Twigg<sup>3</sup>; Whitney Jin<sup>6</sup>; <u>Stergios Doumas</u><sup>7</sup>; Sindhura Sridhar<sup>6</sup>. <sup>1</sup>Royal Free Foundation Trust; <sup>2</sup>University College Hospital; <sup>3</sup>Leeds Teaching Hospital; <sup>4</sup>Medical University of South Carolina; <sup>5</sup>Queen Elizabeth University Hospital Glasgow; <sup>6</sup>Vanderbilt University Medical Centre; <sup>7</sup>Queen Victoria Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Lymph node metastasis is one of the strongest prognostic factors in oral squamous cell carcinoma (OSCC). Although the AJCC 8th edition tumour–node–metastasis (TNM) system classifies nodal disease by number, size, and laterality, alternative nodal metrics, including lymph node ratio (LNR; ratio of positive to total nodes), absolute number of positive nodes, and lowest cervical level involved may offer improved prognostic precision. This multicentre retrospective study compared the prognostic value of these nodal parameters with TNM N-stage for overall survival (OS) and recurrence-free survival (RFS).</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of 781 surgically treated OSCC patients across six centres was identified. After excluding patients with <24 months of follow-up without recurrence or death, 730 patients were eligible for OS and RFS analysis. Data analysed included number of positive nodes, total nodes, LNR, lowest level of nodal involvement, adjuvant therapy, survival status, and recurrence outcomes. Survival was assessed using Kaplan–Meier estimates and Cox proportional hazards modelling. LNR was analysed both continuously (log10-scale) and categorically; optimal thresholds were explored using time-dependent ROC methods.</p>\n\n<p><strong>Results: </strong>Greater nodal burden was strongly associated with poorer outcomes. Patients with five or more positive nodes had a median OS of 1.2 years, compared with 7.9 years for node-negative patients, corresponding to the risk of death increasing by a factor of 4.28 (95% CI 3.12–5.87). For recurrence, patients with ≥5 positive nodes experienced the risk of recurrence increasing by a factor of 3.86 (95% CI 2.64–5.66) compared with node-negative patients.</p>\n\n<p>LNR demonstrated strong and consistent prognostic significance. A 10-fold increase in LNR (one-unit increase on the log10 scale) was associated with the risk of death increasing by a factor of 3.37 (95% CI 2.55–4.46) and the risk of recurrence increasing by a factor of 3.41 (95% CI 2.42–4.81). Categorically, patients with LNR ≥10% had substantially poorer outcomes; for OS, the hazard of death increased by a factor of 4.59 (95% CI 2.95–7.12), and for recurrence, by a factor of 3.08 (95% CI 2.15–4.41), compared with LNR 0%.</p>\n\n<p>Nodal level further refined prognosis. Metastasis to levels IV–V was associated with significantly earlier recurrence than levels I–III, corresponding to hazard ratios of 1.67 (95% CI 1.07–2.61) and 1.82 (95% CI 1.18–2.82) in multivariable models. Total nodes harvested did not show a consistent or clinically meaningful association with either OS or RFS.</p>\n\n<p><strong>Conclusions: </strong>In OSCC, LNR and the absolute number of positive nodes strongly outperform TNM N-stage for predicting both survival and recurrence, with substantially higher hazard estimates than those seen for nodal stage. Involvement of lower cervical levels (IV–V) independently signals aggressive disease biology. Incorporating LNR and nodal level into routine postoperative assessment may significantly enhance prognostic accuracy beyond current TNM classification and supports consideration of refined nodal-based risk stratification and intensified follow-up or treatment for patients with heavy nodal burden.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154531--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S540",
      "content_id": "154652",
      "abstract_number": "S540",
      "poster_number": "",
      "title": "Sentinel Lymph Node Biopsy vs Elective Neck Dissection in Oral Cavity SCC: Upstaging and Oncologic Outcomes",
      "summary": "Although END yielded more pathologic upstaging, this did not improve recurrence or DFS outcomes. SLNB achieved equivalent oncologic performance while avoiding the morbidity of a full neck dissection, supporting its use in suitable early-stage patients.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154652",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vivienne Au, MD",
      "presenter": "Vivienne Au, MD",
      "authors": "Udeerna Tippabhatla, Bs 1 ; Jin Hua Li, Bs 1 ; Rachel Harter, Bs 1 ; Vivienne Au, MD 2 ; Aviram Mizrachi, MD 2",
      "normalized_authors": [
        "Udeerna Tippabhatla",
        "Jin Hua Li",
        "Rachel Harter",
        "Vivienne Au",
        "Aviram Mizrachi"
      ],
      "affiliations": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA",
        "Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 313,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Udeerna Tippabhatla, Bs 1 ; Jin Hua Li, Bs 1 ; Rachel Harter, Bs 1 ; Vivienne Au, MD 2 ; Aviram Mizrachi, MD 2",
        "Affiliations": "1 Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; 2 Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA",
        "Background": "Sentinel lymph node biopsy (SLNB) is increasingly used as an alternative to elective neck dissection (END) for staging the clinically node-negative (cN0) neck in oral cavity squamous cell carcinoma (OCSCC). Whether differences in pathologic upstaging between SLNB and END translate into meaningful oncologic differences remains uncertain.",
        "Methods": "A retrospective cohort of patients with OCSCC undergoing primary surgery with either SLNB or END was analyzed. Clinical and pathologic TNM staging were recorded, and upstaging was defined as advancement from clinical to higher pathologic stage, including cN0 to pN+ transitions. Multivariable Firth logistic regression was used to identify predictors of upstaging. Oncologic outcomes included any recurrence, early recurrence (<12 months), and disease-free survival (DFS). Group comparisons used Fisher’s exact test and Kaplan–Meier analysis with log-rank testing.",
        "Results": "SLNB and END cohorts included 37 and 53 patients, respectively. Upstaging rates differed significantly between approaches (SLNB 88% [30/34] vs END 100% [52/52]; p=0.0218), with SLNB preserving a small concordant subgroup (n=4) while all END patients were upstaged. On multivariable Firth logistic regression, only higher clinical N stage independently predicted upstaging (OR≈0.10; p=0.0088), whereas surgical approach (SLNB vs END), depth of invasion, age, and smoking status were not significant predictors. Overall recurrence rates were not significantly different between SLNB and END (16% [6/37] vs 28% [15/53]; p=0.213). Early recurrence within 12 months was likewise similar (SLNB 5% [2/37] vs END 11% [6/53]; p=0.4629). Kaplan–Meier analysis demonstrated no significant difference in DFS between groups (p=0.78), with nearly overlapping survival curves and comparable numbers at risk over time.",
        "Conclusions": "Although END yielded more pathologic upstaging, this did not improve recurrence or DFS outcomes. SLNB achieved equivalent oncologic performance while avoiding the morbidity of a full neck dissection, supporting its use in suitable early-stage patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Sentinel Lymph Node Biopsy vs Elective Neck Dissection in Oral Cavity SCC: Upstaging and Oncologic Outcomes</span>. Udeerna Tippabhatla, Bs<sup>1</sup>; Jin Hua Li, Bs<sup>1</sup>; Rachel Harter, Bs<sup>1</sup>; <u>Vivienne Au, MD</u><sup>2</sup>; Aviram Mizrachi, MD<sup>2</sup>. <sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, USA; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Sentinel lymph node biopsy (SLNB) is increasingly used as an alternative to elective neck dissection (END) for staging the clinically node-negative (cN0) neck in oral cavity squamous cell carcinoma (OCSCC). Whether differences in pathologic upstaging between SLNB and END translate into meaningful oncologic differences remains uncertain.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort of patients with OCSCC undergoing primary surgery with either SLNB or END was analyzed. Clinical and pathologic TNM staging were recorded, and upstaging was defined as advancement from clinical to higher pathologic stage, including cN0 to pN+ transitions. Multivariable Firth logistic regression was used to identify predictors of upstaging. Oncologic outcomes included any recurrence, early recurrence (<12 months), and disease-free survival (DFS). Group comparisons used Fisher’s exact test and Kaplan–Meier analysis with log-rank testing.</p>\n\n<p><strong>Results: </strong>SLNB and END cohorts included 37 and 53 patients, respectively. Upstaging rates differed significantly between approaches (SLNB 88% [30/34] vs END 100% [52/52]; p=0.0218), with SLNB preserving a small concordant subgroup (n=4) while all END patients were upstaged. On multivariable Firth logistic regression, only higher clinical N stage independently predicted upstaging (OR≈0.10; p=0.0088), whereas surgical approach (SLNB vs END), depth of invasion, age, and smoking status were not significant predictors. Overall recurrence rates were not significantly different between SLNB and END (16% [6/37] vs 28% [15/53]; p=0.213). Early recurrence within 12 months was likewise similar (SLNB 5% [2/37] vs END 11% [6/53]; p=0.4629). Kaplan–Meier analysis demonstrated no significant difference in DFS between groups (p=0.78), with nearly overlapping survival curves and comparable numbers at risk over time.</p>\n\n<p><strong>Conclusions: </strong>Although END yielded more pathologic upstaging, this did not improve recurrence or DFS outcomes. SLNB achieved equivalent oncologic performance while avoiding the morbidity of a full neck dissection, supporting its use in suitable early-stage patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154652--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S541",
      "content_id": "154611",
      "abstract_number": "S541",
      "poster_number": "",
      "title": "Prediction model of death for patients with HPV unrelated head and neck squamous cell carcinoma using logistic regression and machine learning techniques – Can we do better than TNM?",
      "summary": "View in Agenda and Add to Schedule",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154611",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Leonardo F Rios, PhD",
      "presenter": "Leonardo F Rios, PhD",
      "authors": "Leonardo F Rios, PhD ; Pamela O Soares, PhD; Leandro L Matos, PhD; Luiz P Kowalski, PhD; Raquel A Moyses, PhD",
      "normalized_authors": [
        "Leonardo F Rios",
        "Pamela O Soares",
        "Leandro L Matos",
        "Luiz P Kowalski",
        "Raquel A Moyses"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, University of Sao Paulo Medical School"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, University of Sao Paulo Medical School"
      ],
      "session_type": "Proffered Paper",
      "track": "Precision Medicine",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Precision Medicine"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 355,
      "section_labels": [
        "Authors",
        "Affiliations",
        "INTRODUCTION",
        "OBJECTIVES",
        "METHODS",
        "RESULTS",
        "CONCLUSION",
        "Abstract"
      ],
      "sections": {
        "Authors": "Leonardo F Rios, PhD ; Pamela O Soares, PhD; Leandro L Matos, PhD; Luiz P Kowalski, PhD; Raquel A Moyses, PhD",
        "Affiliations": "Department of Head and Neck Surgery, University of Sao Paulo Medical School",
        "INTRODUCTION": "Head and neck squamous cell carcinoma (HNSCC) is among the most prevalent neoplasms worldwide. Although HPV related HNSCC is increasing, HPV negative tumors are still a majority in low- and middle-income countries. Likewise in other malignancies, the TNM System is the main tool for the prediction of 5-year overall survival and is based on anatomical, histological, and clinical information. However, the efficacy of this system is criticized by joining heterogeneous patients into equal categories, as well as for not being able to predict individualized probabilities of death.",
        "OBJECTIVES": "To create a 5-year mortality prediction model to be easily applied at the first clinical presentation, that is simpler and superior to TNM in terms of prediction and discrimination, and that could also predict individualized prognosis.",
        "METHODS": "a retrospective study of prospectively collected data from HNSCC patients between July 2000 and August 2011 by the GENCAPO study group. Data were mined using Classification and Regression Trees, Random Forests, and Boosted and Regression Trees, for optimization of variables use. An all-sites Logistic Regression (LR) was created. Methods of internal validation, discrimination – by the area under the ROC curve (AUC) – and calibration – Goodness of Fit test – were performed. Kaplan Meier survival curves were used to visually compare the models to TNM.",
        "RESULTS": "1797 patients were analyzed. After data mining the predictive variables, 28 were pre-selected. The stepwise selection in the LR model for all sites selected tumor volume, sex, age, weight loss, degree of tumor differentiation and lymph node enlargement as predictive variables. Our population was divided into three sets (training, validation and testing) and the final model had an AUC of 0.76 (independent testing set). We also created survival curves for the new predictive model and compared them with the survival curves of the TNM system, with the former appearing graphically more distinct than the latter.",
        "CONCLUSION": "Thanks to machine learning techniques associated to logistic regression, it was possible to develop a multivariate logistic model with good discrimination and calibration to predict 5-year survival, with easy to retrieve information, which were superior to the TNM System and able to predict individualized risk of death.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Prediction model of death for patients with HPV unrelated head and neck squamous cell carcinoma using logistic regression and machine learning techniques – Can we do better than TNM?</span>. <u>Leonardo F Rios, PhD</u>; Pamela O Soares, PhD; Leandro L Matos, PhD; Luiz P Kowalski, PhD; Raquel A Moyses, PhD. Department of Head and Neck Surgery, University of Sao Paulo Medical School<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>INTRODUCTION:</strong> Head and neck squamous cell carcinoma (HNSCC) is among the most prevalent neoplasms worldwide. Although HPV related HNSCC is increasing, HPV negative tumors are still a majority in low- and middle-income countries. Likewise in other malignancies, the TNM System is the main tool for the prediction of 5-year overall survival and is based on anatomical, histological, and clinical information. However, the efficacy of this system is criticized by joining heterogeneous patients into equal categories, as well as for not being able to predict individualized probabilities of death.</p>\n\n<p><strong>OBJECTIVES: </strong>To create a 5-year mortality prediction model to be easily applied at the first clinical presentation, that is simpler and superior to TNM in terms of prediction and discrimination, and that could also predict individualized prognosis.</p>\n\n<p><strong>METHODS: </strong>a retrospective study of prospectively collected data from HNSCC patients between July 2000 and August 2011 by the GENCAPO study group. Data were mined using Classification and Regression Trees, Random Forests, and Boosted and Regression Trees, for optimization of variables use. An all-sites Logistic Regression (LR) was created. Methods of internal validation, discrimination – by the area under the ROC curve (AUC) – and calibration – Goodness of Fit test – were performed. Kaplan Meier survival curves were used to visually compare the models to TNM.</p>\n\n<p><strong>RESULTS: </strong>1797 patients were analyzed. After data mining the predictive variables, 28 were pre-selected. The stepwise selection in the LR model for all sites selected tumor volume, sex, age, weight loss, degree of tumor differentiation and lymph node enlargement as predictive variables. Our population was divided into three sets (training, validation and testing) and the final model had an AUC of 0.76 (independent testing set). We also created survival curves for the new predictive model and compared them with the survival curves of the TNM system, with the former appearing graphically more distinct than the latter.</p>\n\n<p><strong>CONCLUSION: </strong>Thanks to machine learning techniques associated to logistic regression, it was possible to develop a multivariate logistic model with good discrimination and calibration to predict 5-year survival, with easy to retrieve information, which were superior to the TNM System and able to predict individualized risk of death.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154611--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S542",
      "content_id": "154477",
      "abstract_number": "S542",
      "poster_number": "",
      "title": "Does TNM Staging Predict Survival in Hürthle Cell Carcinoma as Effectively as in Other Differentiated Thyroid Cancers?",
      "summary": "TNM staging demonstrates significantly diminished predictive accuracy for Hürthle cell carcinoma compared to other differentiated thyroid cancers, with limited discriminatory capability for survival stratification. Despite comparable survival outcomes to papillary carcinoma, current staging fails to adequately risk-stratify HCC patients, potentially compromising treatment individualization. These findings support...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154477",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jose G Vartanian, MD, PhD",
      "presenter": "Jose G Vartanian, MD, PhD",
      "authors": "Hugo F Kohler, MD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
      "normalized_authors": [
        "Hugo F Kohler",
        "Jose G Vartanian",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "A C Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "A C Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 332,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Hugo F Kohler, MD; Jose G Vartanian, MD, PhD ; Luiz P Kowalski, MD, PhD",
        "Affiliations": "A C Camargo Cancer Center",
        "Background": "Hürthle cell carcinoma (HCC) represents approximately 3% of thyroid malignancies and exhibits distinct biological behavior compared to papillary and follicular variants. Despite classification within differentiated thyroid cancers, HCC demonstrates reduced iodine avidity and conflicting evidence regarding radioactive iodine efficacy. The current TNM staging system, designed primarily from papillary and follicular thyroid carcinoma data, may inadequately capture prognostic nuances in HCC given its unique molecular profile and clinical characteristics.",
        "Objective": "To compare the predictive performance of TNM staging between Hürthle cell carcinoma and other differentiated thyroid cancers using population-based data and concordance index analysis.",
        "Methods": "We analyzed a comprehensive São Paulo State, Brazil, population database including treatment-naive patients with differentiated thyroid cancer. Baseline characteristics were compared between HCC and other histological subtypes. Survival outcomes were evaluated using Kaplan-Meier methods and Cox regression. TNM staging predictive performance was assessed using Harrell's concordance index (C-index).",
        "Results": "Among 17,066 patients, 231 cases (1.35%) represented HCC. HCC patients were significantly younger (45.3 versus 50.1 years, p<0.001) with higher cervical lymph node metastasis rates at diagnosis (p<0.001). Disease-specific and overall survival for HCC were comparable to papillary thyroid carcinoma (PTC) and superior to follicular cell carcinoma (FCC), with overlapping 95% confidence intervals between HCC and PTC.",
        "Abstract": "Radioactive iodine utilization showed no difference across histological subtypes (p=0.875). Among HCC patients staged as pT2-4NxMx or pT1N1Mx, radioiodine conferred no survival benefit (p=0.277). Critical differences emerged in staging performance: Harrell's C-index was 0.72 for PTC but only 0.59 for HCC, indicating poor discriminatory capability approaching random prediction. View in Agenda and Add to Schedule",
        "Conclusion": "TNM staging demonstrates significantly diminished predictive accuracy for Hürthle cell carcinoma compared to other differentiated thyroid cancers, with limited discriminatory capability for survival stratification. Despite comparable survival outcomes to papillary carcinoma, current staging fails to adequately risk-stratify HCC patients, potentially compromising treatment individualization. These findings support development of HCC-specific prognostic models incorporating molecular markers and emphasize the need to reconsider radioiodine therapy indications in advanced-stage disease."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Does TNM Staging Predict Survival in Hürthle Cell Carcinoma as Effectively as in Other Differentiated Thyroid Cancers?</span>. Hugo F Kohler, MD; <u>Jose G Vartanian, MD, PhD</u>; Luiz P Kowalski, MD, PhD. A C Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Hürthle cell carcinoma (HCC) represents approximately 3% of thyroid malignancies and exhibits distinct biological behavior compared to papillary and follicular variants. Despite classification within differentiated thyroid cancers, HCC demonstrates reduced iodine avidity and conflicting evidence regarding radioactive iodine efficacy. The current TNM staging system, designed primarily from papillary and follicular thyroid carcinoma data, may inadequately capture prognostic nuances in HCC given its unique molecular profile and clinical characteristics.</p>\n\n<p><strong>Objective: </strong>To compare the predictive performance of TNM staging between Hürthle cell carcinoma and other differentiated thyroid cancers using population-based data and concordance index analysis.</p>\n\n<p><strong>Methods:</strong> We analyzed a comprehensive São Paulo State, Brazil,  population database including treatment-naive patients with differentiated thyroid cancer. Baseline characteristics were compared between HCC and other histological subtypes. Survival outcomes were evaluated using Kaplan-Meier methods and Cox regression. TNM staging predictive performance was assessed using Harrell's concordance index (C-index).</p>\n\n<p><strong>Results: </strong>Among 17,066 patients, 231 cases (1.35%) represented HCC. HCC patients were significantly younger (45.3 versus 50.1 years, p<0.001) with higher cervical lymph node metastasis rates at diagnosis (p<0.001). Disease-specific and overall survival for HCC were comparable to papillary thyroid carcinoma (PTC) and superior to follicular cell carcinoma (FCC), with overlapping 95% confidence intervals between HCC and PTC.</p>\n\n<p>Radioactive iodine utilization showed no difference across histological subtypes (p=0.875). Among HCC patients staged as pT2-4NxMx or pT1N1Mx, radioiodine conferred no survival benefit (p=0.277). Critical differences emerged in staging performance: Harrell's C-index was 0.72 for PTC but only 0.59 for HCC, indicating poor discriminatory capability approaching random prediction.</p>\n\n<p><strong>Conclusion:</strong> TNM staging demonstrates significantly diminished predictive accuracy for Hürthle cell carcinoma compared to other differentiated thyroid cancers, with limited discriminatory capability for survival stratification. Despite comparable survival outcomes to papillary carcinoma, current staging fails to adequately risk-stratify HCC patients, potentially compromising treatment individualization. These findings support development of HCC-specific prognostic models incorporating molecular markers and emphasize the need to reconsider radioiodine therapy indications in advanced-stage disease.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154477--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S543",
      "content_id": "151803",
      "abstract_number": "S543",
      "poster_number": "",
      "title": "A National Database Assessment of Changes to Thyroid Cancer Staging and Treatment Patterns in Response to American Thyroid Association Recommendations from 2010-2024",
      "summary": "Compared to pre-2018, rates of T3 thyroid cancer diagnoses and total thyroidectomies have shown a remarkable decline suggesting providers are incorporating ATA and AJCC recommendations into their treatment decisions. However, the greater number of white T1/T2 patients still receiving total thyroidectomies suggests there is an opportunity for critical examination of practice patterns to ensure white patients are...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151803",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gillian Michaelson",
      "presenter": "Gillian Michaelson",
      "authors": "Gillian Michaelson ; Akina Tamaki, MD; Jobran Mansour, MD",
      "normalized_authors": [
        "Gillian Michaelson",
        "Akina Tamaki",
        "Jobran Mansour"
      ],
      "affiliations": [
        "Lewis Katz School of Medicine at Temple University"
      ],
      "normalized_institutions": [
        "Lewis Katz School of Medicine at Temple University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/151803/Abstract%20Table%201.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/151803/Abstract%20Table%201.jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151803"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 452,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Gillian Michaelson ; Akina Tamaki, MD; Jobran Mansour, MD",
        "Affiliations": "Lewis Katz School of Medicine at Temple University",
        "Introduction": "In June 2025 the American Thyroid Association (ATA) published the first thyroid cancer management update in 10 years, which solidifies prior ATA guidance recommending against T3 disease classification and routine total thyroidectomies for patients with minimal extra thyroidal extension or microscopic metastatic disease (per the 2018 revised American Joint Committee on Cancer (AJCC) staging guidelines). Preliminary follow-up studies found that post-2018, physicians appeared to adhere to this guidance with fewer advanced TNM stage patient diagnoses and total thyroidectomies. This study aims to build on that research by assessing national-level data across recent years and examining longitudinal results to articulate provider adherence to the updated guidelines and their impact on patient survival.",
        "Methods": "A retrospective cohort study was conducted using de-identified data from the TriNetX global network. Thyroid cancer patients were identified using International Code of Disease 10 (ICD-10) codes for thyroid malignancy (C73.*). TNM staging was based on TriNetX medical record abstraction of AJCC TNM status. Total, partial, and completion thyroidectomies and radioactive iodine ablation were determined based on Current Procedural Terminology (CPT) codes. Patients were divided into the 2010-2017 group vs the 2018-2024 group based on date of surgical intervention. Chi-square and Kaplan-Meier analyses were used to compare intergroup demographics and 7-year survival.",
        "Results": "Overall, 61,806 thyroid cancer patients received a surgical intervention from 2010-2024. Compared with 2018-2024 patients, those treated in 2010-2017 were more likely to receive a T3 diagnosis (p<0.0001), a total thyroidectomy (p<0.0001), and radioactive iodine ablation (p<0.0001); and they were less likely to receive a partial thyroidectomy (p<0.0001) (Table 1). There was no significant difference in completion thyroidectomies between the 2010-2017 and 2018-2024 groups.",
        "Abstract": "Additionally, there was no difference in overall 7-year survival of T1/T2 patients between the 2010-2017 group and the 2018-2024 group (hazard ratio (HR): 1.099; 95% CI: 0.855-1.411). Finally, in an analysis of treatment for T1/T2 patients from 2010-2024 based on demographics, white patients were more likely to receive a total thyroidectomy than non-white patients (p=0.013). This significance persisted among T1/T2 patients from 2018-2024 (p=0.025). View in Agenda and Add to Schedule",
        "Conclusion": "Compared to pre-2018, rates of T3 thyroid cancer diagnoses and total thyroidectomies have shown a remarkable decline suggesting providers are incorporating ATA and AJCC recommendations into their treatment decisions. However, the greater number of white T1/T2 patients still receiving total thyroidectomies suggests there is an opportunity for critical examination of practice patterns to ensure white patients are not being overtreated and non-white patients are not being undertreated. Finally, the lack of survival difference among lower stage cancer patients suggests that this de-escalation of care has been clinically appropriate and led to effective disease management."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A National Database Assessment of Changes to Thyroid Cancer Staging and Treatment Patterns in Response to American Thyroid Association Recommendations from 2010-2024</span>. <u>Gillian Michaelson</u>; Akina Tamaki, MD; Jobran Mansour, MD. Lewis Katz School of Medicine at Temple University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>In June 2025 the American Thyroid Association (ATA) published the first thyroid cancer management update in 10 years, which solidifies prior ATA guidance recommending against T3 disease classification and routine total thyroidectomies for patients with minimal extra thyroidal extension or microscopic metastatic disease (per the 2018 revised American Joint Committee on Cancer (AJCC) staging guidelines). Preliminary follow-up studies found that post-2018, physicians appeared to adhere to this guidance with fewer advanced TNM stage patient diagnoses and total thyroidectomies. This study aims to build on that research by assessing national-level data across recent years and examining longitudinal results to articulate provider adherence to the updated guidelines and their impact on patient survival.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using de-identified data from the TriNetX global network. Thyroid cancer patients were identified using International Code of Disease 10 (ICD-10) codes for thyroid malignancy (C73.*). TNM staging was based on TriNetX medical record abstraction of AJCC TNM status. Total, partial, and completion thyroidectomies and radioactive iodine ablation were determined based on Current Procedural Terminology (CPT) codes. Patients were divided into the 2010-2017 group vs the 2018-2024 group based on date of surgical intervention. Chi-square and Kaplan-Meier analyses were used to compare intergroup demographics and 7-year survival.</p>\n\n<p><strong>Results: </strong>Overall, 61,806 thyroid cancer patients received a surgical intervention from 2010-2024. Compared with 2018-2024 patients, those treated in 2010-2017 were more likely to receive a T3 diagnosis (p<0.0001), a total thyroidectomy (p<0.0001), and radioactive iodine ablation (p<0.0001); and they were less likely to receive a partial thyroidectomy (p<0.0001) (Table 1). There was no significant difference in completion thyroidectomies between the 2010-2017 and 2018-2024 groups.</p>\n\n<p>Additionally, there was no difference in overall 7-year survival of T1/T2 patients between the 2010-2017 group and the 2018-2024 group (hazard ratio (HR): 1.099; 95% CI: 0.855-1.411). Finally, in an analysis of treatment for T1/T2 patients from 2010-2024 based on demographics, white patients were more likely to receive a total thyroidectomy than non-white patients (p=0.013). This significance persisted among T1/T2 patients from 2018-2024 (p=0.025).</p>\n\n<p><strong>Conclusion: </strong>Compared to pre-2018, rates of T3 thyroid cancer diagnoses and total thyroidectomies have shown a remarkable decline suggesting providers are incorporating ATA and AJCC recommendations into their treatment decisions. However, the greater number of white T1/T2 patients still receiving total thyroidectomies suggests there is an opportunity for critical examination of practice patterns to ensure white patients are not being overtreated and non-white patients are not being undertreated. Finally, the lack of survival difference among lower stage cancer patients suggests that this de-escalation of care has been clinically appropriate and led to effective disease management.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/151803/Abstract%20Table%201.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151803--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S544",
      "content_id": "153520",
      "abstract_number": "S544",
      "poster_number": "",
      "title": "Assessing GenAI Performance in Head and Neck Multidisciplinary Tumor Boards",
      "summary": "Interim findings from this blinded evaluation suggest that, in its current form, RAG contributes less to decision quality than the choice of underlying model. The present retrieval configuration did not enhance performance and modestly diminished GPT-5 accuracy, underscoring the need to refine retrieval scope, indexing strategies, and prompt orchestration. Final analyses incorporating the full dataset,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153520",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Eric Remer",
      "presenter": "Eric Remer",
      "authors": "Sholem Hack, MBBS 1 ; Alex Dobriyan, DMD 2 ; Eran E Alon, MD 3 ; Naseem Saleh, MD 3 ; Naomi Rabinovics 3 ; Eric Remer 3",
      "normalized_authors": [
        "Sholem Hack, MBBS",
        "Alex Dobriyan",
        "Eran E Alon",
        "Naseem Saleh",
        "Naomi Rabinovics",
        "Eric Remer"
      ],
      "affiliations": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otolaryngology-Head and Neck Surgery, Sheba Medical Center"
      ],
      "normalized_institutions": [
        "City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel",
        "Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Ramat Gan, Israel",
        "Department of Otolaryngology-Head and Neck Surgery, Sheba Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 457,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Sholem Hack, MBBS 1 ; Alex Dobriyan, DMD 2 ; Eran E Alon, MD 3 ; Naseem Saleh, MD 3 ; Naomi Rabinovics 3 ; Eric Remer 3",
        "Affiliations": "1 City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; 2 Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Ramat Gan, Israel; 3 Department of Otolaryngology-Head and Neck Surgery, Sheba Medical Center",
        "Introduction": "Large-language-model (LLM) decision support is emerging in multidisciplinary tumor boards, yet the contribution of guideline-linked retrieval-augmented generation (RAG) remains unclear. This blinded study compared GPT-4 and GPT-5, each with and without RAG to NCCN content, using authentic head and neck cancer cases from routine practice. The objective was to determine whether RAG enhances staging, treatment, prognostic accuracy, or guideline adherence in real-world clinical scenarios.",
        "Methods": "Seventy-three consecutive tumor board cases were compiled. For each case, four model outputs (GPT-4, GPT-4 with RAG, GPT-5, GPT-5 with RAG) were independently evaluated by experts on five domains—staging accuracy, treatment accuracy, prognosis accuracy, adherence to NCCN recommendations, and overall usefulness—each rated on a 1 to 5 scale. This abstract reflects an interim, partial dataset. Preliminary analyses included mean scores with 95 percent confidence intervals and Welch contrasts; mixed-effects modeling and inter-rater reliability will be applied once full accrual is complete.",
        "Results": "GPT-5 without RAG achieved the highest overall performance, with treatment accuracy averaging 4.84 (95 percent confidence interval 4.73 to 4.94) and NCCN adherence 4.89 (4.81 to 4.97). GPT-4 without RAG scored 4.55 (4.38 to 4.71) for treatment and 4.64 (4.50 to 4.78) for adherence. The addition of RAG did not improve results: GPT-5 with RAG averaged 4.45 (4.28 to 4.61) for treatment and 4.53 (4.34 to 4.71) for adherence, while GPT-4 with RAG averaged 4.55 (4.38 to 4.72) and 4.53 (4.35 to 4.71), respectively.",
        "Abstract": "Across the pooled sample, RAG configurations demonstrated small but statistically significant reductions in performance compared with non-RAG outputs. The mean reduction in treatment accuracy was 0.19 (p = 0.013), and the mean reduction in NCCN adherence was 0.23 (p = 0.003). These effects were driven predominantly by GPT-5, in which treatment accuracy decreased by 0.39 (p < 0.001) and adherence by 0.36 (p = 0.001) with RAG. In direct comparison, GPT-5 outperformed GPT-4 in the non-RAG condition for both treatment accuracy (mean difference 0.29, p = 0.003) and adherence (mean difference 0.25, p = 0.003). Absolute performance across all arms remained high, with most scores at or above 4. View in Agenda and Add to Schedule",
        "Conclusion": "Interim findings from this blinded evaluation suggest that, in its current form, RAG contributes less to decision quality than the choice of underlying model. The present retrieval configuration did not enhance performance and modestly diminished GPT-5 accuracy, underscoring the need to refine retrieval scope, indexing strategies, and prompt orchestration. Final analyses incorporating the full dataset, mixed-effects modeling, inter-rater reliability, and an error taxonomy will support the development of rigorous guardrails for guideline-concordant GenAI decision support in head and neck oncology."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Assessing GenAI Performance in Head and Neck Multidisciplinary Tumor Boards</span>. Sholem Hack, MBBS<sup>1</sup>; Alex Dobriyan, DMD<sup>2</sup>; Eran E Alon, MD<sup>3</sup>; Naseem Saleh, MD<sup>3</sup>; Naomi Rabinovics<sup>3</sup>; <u>Eric Remer</u><sup>3</sup>. <sup>1</sup>City St. George's University London School of Medicine, Program Delivered by University of Nicosia at the Chaim Sheba Medical Center, Ramat Gan, Israel; <sup>2</sup>Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Ramat Gan, Israel; <sup>3</sup>Department of Otolaryngology-Head and Neck Surgery, Sheba Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong><strong>Introduction:</strong></strong> Large-language-model (LLM) decision support is emerging in multidisciplinary tumor boards, yet the contribution of guideline-linked retrieval-augmented generation (RAG) remains unclear. This blinded study compared GPT-4 and GPT-5, each with and without RAG to NCCN content, using authentic head and neck cancer cases from routine practice. The objective was to determine whether RAG enhances staging, treatment, prognostic accuracy, or guideline adherence in real-world clinical scenarios.</p>\n\n<p><strong><strong>Methods:</strong></strong> Seventy-three consecutive tumor board cases were compiled. For each case, four model outputs (GPT-4, GPT-4 with RAG, GPT-5, GPT-5 with RAG) were independently evaluated by experts on five domains—staging accuracy, treatment accuracy, prognosis accuracy, adherence to NCCN recommendations, and overall usefulness—each rated on a 1 to 5 scale. This abstract reflects an interim, partial dataset. Preliminary analyses included mean scores with 95 percent confidence intervals and Welch contrasts; mixed-effects modeling and inter-rater reliability will be applied once full accrual is complete.</p>\n\n<p><strong><strong>Results</strong></strong>: GPT-5 without RAG achieved the highest overall performance, with treatment accuracy averaging 4.84 (95 percent confidence interval 4.73 to 4.94) and NCCN adherence 4.89 (4.81 to 4.97). GPT-4 without RAG scored 4.55 (4.38 to 4.71) for treatment and 4.64 (4.50 to 4.78) for adherence. The addition of RAG did not improve results: GPT-5 with RAG averaged 4.45 (4.28 to 4.61) for treatment and 4.53 (4.34 to 4.71) for adherence, while GPT-4 with RAG averaged 4.55 (4.38 to 4.72) and 4.53 (4.35 to 4.71), respectively.</p>\n\n<p>Across the pooled sample, RAG configurations demonstrated small but statistically significant reductions in performance compared with non-RAG outputs. The mean reduction in treatment accuracy was 0.19 (p = 0.013), and the mean reduction in NCCN adherence was 0.23 (p = 0.003). These effects were driven predominantly by GPT-5, in which treatment accuracy decreased by 0.39 (p < 0.001) and adherence by 0.36 (p = 0.001) with RAG. In direct comparison, GPT-5 outperformed GPT-4 in the non-RAG condition for both treatment accuracy (mean difference 0.29, p = 0.003) and adherence (mean difference 0.25, p = 0.003). Absolute performance across all arms remained high, with most scores at or above 4.</p>\n\n<p><strong><strong>Conclusion</strong></strong>: Interim findings from this blinded evaluation suggest that, in its current form, RAG contributes less to decision quality than the choice of underlying model. The present retrieval configuration did not enhance performance and modestly diminished GPT-5 accuracy, underscoring the need to refine retrieval scope, indexing strategies, and prompt orchestration. Final analyses incorporating the full dataset, mixed-effects modeling, inter-rater reliability, and an error taxonomy will support the development of rigorous guardrails for guideline-concordant GenAI decision support in head and neck oncology.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153520--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S545",
      "content_id": "154325",
      "abstract_number": "S545",
      "poster_number": "",
      "title": "Outcomes in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Analysis of Salvage Therapies",
      "summary": "Within this large cohort of patients treated with modern surgery and radiotherapy techniques, we observed a median survival of approximately 3 years for patients with locoregionally confined recurrent mucosal HNSCC. We did not, however, observe any significant differences when stratified by specific treatment modality. The quality of treatment remains an important consideration with treatment package time delays,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154325",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sobia F Khaja, MD",
      "presenter": "Sobia F Khaja, MD",
      "authors": "Sobia F Khaja, MD 1 ; Christopher T Wilke, MD, PhD 2",
      "normalized_authors": [
        "Sobia F Khaja",
        "Christopher T Wilke"
      ],
      "affiliations": [
        "University of Minnesota",
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Minnesota",
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Abstract",
        "Methods",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Sobia F Khaja, MD 1 ; Christopher T Wilke, MD, PhD 2",
        "Affiliations": "1 University of Minnesota; 2 University of Pittsburgh",
        "Background": "The recent decades have witnessed several significant advances in the management of patients with head and neck cancer. Despite this progress, a number of patients will develop recurrent disease which portends significant morbidity and mortality. Management of these patients is difficult and frequently requires multimodality therapy with surgery, radiation and chemo/immunotherapy. These modalities are not without drawbacks, though, as the toxicities associated with salvage therapies far outstrip those commonly observed in the de-novo disease setting while the efficacy of salvage therapies similarly lags their upfront counterparts.",
        "Abstract": "Due to the inherent difficulty in conducting randomized trials in this patient population, high quality data to guide treatment decisions is limited. Prior studies, though, have suggested a potential survival benefit when surgical intervention is incorporated into the management scheme. We sought to explore this hypothesis and add to the growing body of literature by conducting a single institutional retrospective review of patients receiving treatment for recurrent/metastatic mucosal head and neck squamous cell carcinomas (HNSCC). View in Agenda and Add to Schedule",
        "Methods": "A retrospective chart review was conducted of patients receiving salvage treatment (curative or palliative) of their first mucosal recurrence of HNSCC at a single institution from 2011 to 2025. Patients who received salvage therapies outside of the institution or had an initial diagnosis prior to 2011 were excluded. Patient demographics, disease characteristics and treatment details were collected for initial and salvage treatment along with patient outcomes. Data was analyzed using JMP version 19 (JMP Statistical Discovery LLC, Cary, NC).",
        "Results": "Records from a total of 302 patients that met inclusion criteria were identified. Of these, 213 had locoregionally confined recurrent disease while 89 presented with the addition of at least 1 or more distant metastatic sites. The majority of patients with locoregional disease received salvage surgery (n=166), while 26 received chemotherapy +/- immunotherapy, 8 received radiotherapy alone and 13 received salvage chemoradiotherapy. Within the surgery cohort, adjuvant radiotherapy and chemoradiotherapy were administered in 18 and 33 patients, respectively. The median overall survival for the entire cohort was 24.9 months. Expectedly, the median survival was dramatically better in patients with locoregional versus metastatic disease (36.3 vs 13.5 mo, p<0.01). While the subgroups were small, we did not observe a significant difference in median survival for patients with locoregionally recurrent disease when stratified by treatment modality. We did, however, observe a strong correlation with treatment package time and survival for patients receiving adjuvant radiotherapy +/- chemotherapy following salvage surgery. Notably, no patient with a treatment package time exceeding 100 days was alive at the time of last follow-up in our study.",
        "Conclusions": "Within this large cohort of patients treated with modern surgery and radiotherapy techniques, we observed a median survival of approximately 3 years for patients with locoregionally confined recurrent mucosal HNSCC. We did not, however, observe any significant differences when stratified by specific treatment modality. The quality of treatment remains an important consideration with treatment package time delays, similar to the de-novo disease setting, adversely affecting survival in this patient population."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Outcomes in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Analysis of Salvage Therapies</span>. <u>Sobia F Khaja, MD</u><sup>1</sup>; Christopher T Wilke, MD, PhD<sup>2</sup>. <sup>1</sup>University of Minnesota; <sup>2</sup>University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The recent decades have witnessed several significant advances in the management of patients with head and neck cancer. Despite this progress, a number of patients will develop recurrent disease which portends significant morbidity and mortality. Management of these patients is difficult and frequently requires multimodality therapy with surgery, radiation and chemo/immunotherapy. These modalities are not without drawbacks, though, as the toxicities associated with salvage therapies far outstrip those commonly observed in the de-novo disease setting while the efficacy of salvage therapies similarly lags their upfront counterparts.</p>\n\n<p>Due to the inherent difficulty in conducting randomized trials in this patient population, high quality data to guide treatment decisions is limited. Prior studies, though, have suggested a potential survival benefit when surgical intervention is incorporated into the management scheme. We sought to explore this hypothesis and add to the growing body of literature by conducting a single institutional retrospective review of patients receiving treatment for recurrent/metastatic mucosal head and neck squamous cell carcinomas (HNSCC).</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted of patients receiving salvage treatment (curative or palliative) of their first mucosal recurrence of HNSCC at a single institution from 2011 to 2025. Patients who received salvage therapies outside of the institution or had an initial diagnosis prior to 2011 were excluded. Patient demographics, disease characteristics and treatment details were collected for initial and salvage treatment along with patient outcomes. Data was analyzed using JMP version 19 (JMP Statistical Discovery LLC, Cary, NC).</p>\n\n<p><strong>Results: </strong>Records from a total of 302 patients that met inclusion criteria were identified. Of these, 213 had locoregionally confined recurrent disease while 89 presented with the addition of at least 1 or more distant metastatic sites. The majority of patients with locoregional disease received salvage surgery (n=166), while 26 received chemotherapy +/- immunotherapy, 8 received radiotherapy alone and 13 received salvage chemoradiotherapy. Within the surgery cohort, adjuvant radiotherapy and chemoradiotherapy were administered in 18 and 33 patients, respectively. The median overall survival for the entire cohort was 24.9 months. Expectedly, the median survival was dramatically better in patients with locoregional versus metastatic disease (36.3 vs 13.5 mo, p<0.01). While the subgroups were small, we did not observe a significant difference in median survival for patients with locoregionally recurrent disease when stratified by treatment modality. We did, however, observe a strong correlation with treatment package time and survival for patients receiving adjuvant radiotherapy +/- chemotherapy following salvage surgery. Notably, no patient with a treatment package time exceeding 100 days was alive at the time of last follow-up in our study.</p>\n\n<p><strong>Conclusions: </strong>Within this large cohort of patients treated with modern surgery and radiotherapy techniques, we observed a median survival of approximately 3 years for patients with locoregionally confined recurrent mucosal HNSCC. We did not, however, observe any significant differences when stratified by specific treatment modality. The quality of treatment remains an important consideration with treatment package time delays, similar to the de-novo disease setting, adversely affecting survival in this patient population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154325--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S546",
      "content_id": "154627",
      "abstract_number": "S546",
      "poster_number": "",
      "title": "The Oncologic Outcomes of Buccal Squamous Cell Carcinoma: A Multi-institutional Study",
      "summary": "SCC originating in the buccal mucosa tend to exhibit aggressive pathologic features, such as occult nodal metastasis, ENE and positive resection margins. We demonstrate that ENE and positive margins are powerful predictors of recurrence, resulting in a greater than three-fold hazard of death or recurrence.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154627",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Vishal Gupta",
      "presenter": "Vishal Gupta",
      "authors": "Usman Khan 1 ; Jae Gardella 2 ; Grayson Buning 3 ; David Forner 3 ; Colin Mackay 1 ; Vishal Gupta 4 ; Matthew Rigby 1 ; Wesley Hicks Jr 4 ; William Magner 4 ; Ayham Al Afif 1",
      "normalized_authors": [
        "Usman Khan",
        "Jae Gardella",
        "Grayson Buning",
        "David Forner",
        "Colin Mackay",
        "Vishal Gupta",
        "Matthew Rigby",
        "Wesley Hicks Jr",
        "William Magner",
        "Ayham Al Afif"
      ],
      "affiliations": [
        "Dalhousie University",
        "Weill Cornell Medicine",
        "University of Michigan",
        "Roswell Park Cancer Center"
      ],
      "normalized_institutions": [
        "Dalhousie University",
        "Weill Cornell Medicine",
        "University of Michigan",
        "Roswell Park Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 278,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Usman Khan 1 ; Jae Gardella 2 ; Grayson Buning 3 ; David Forner 3 ; Colin Mackay 1 ; Vishal Gupta 4 ; Matthew Rigby 1 ; Wesley Hicks Jr 4 ; William Magner 4 ; Ayham Al Afif 1",
        "Affiliations": "1 Dalhousie University; 2 Weill Cornell Medicine; 3 University of Michigan; 4 Roswell Park Cancer Center",
        "Objectives": "Contemporary data remain scarce regarding the prognosticators of primary buccal squamous cell carcinoma. The aim of our study is to determine the oncologic outcomes and recurrence prognosticators for patients with primary SCC of the buccal mucosa",
        "Methods": "A multi-institutional, retrospective review was performed for buccal SCC patients undergoing treatment at three tertiary care cancer centers in the USA and Canada between the years 2009 and 2022. Survival analysis was performed using the Kaplan-Meier method. Multivariable models, including cox-proportional hazards method, were constructed and tested for best fit using Akaike’s Information Criterion (AIC) values.",
        "Results": "A total of 115 patients met our inclusion criteria, with 105 patients undergoing primary surgical resection and 10 undergoing primary chemoradiation treatment. The mean age of patients was 67 (SD 12.5) with a gender ratio of 56.5% male to 43.5% female. Occult nodal metastasis was observed in 25% of patients, whereas positive margins, perineural invasion, and extra-nodal extension were present in 10%, 21% and 20% respectively. The 5-year overall survival (OS) and disease specific survival (DSS) were 57.2% (SE 10, 95% CI 47-69.6) and 64.8% (SE 9.3, 95% CI 54.1-77.7) respectively. The presence of ENE (HR 3.08, CI 1.47-6.45) and positive margins (HR 3.39, CI 1.37-8.38) resulted in a significant hazard of death or recurrence (p<0.05).",
        "Conclusion": "SCC originating in the buccal mucosa tend to exhibit aggressive pathologic features, such as occult nodal metastasis, ENE and positive resection margins. We demonstrate that ENE and positive margins are powerful predictors of recurrence, resulting in a greater than three-fold hazard of death or recurrence.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Oncologic Outcomes of Buccal Squamous Cell Carcinoma: A Multi-institutional Study</span>. Usman Khan<sup>1</sup>; Jae Gardella<sup>2</sup>; Grayson Buning<sup>3</sup>; David Forner<sup>3</sup>; Colin Mackay<sup>1</sup>; <u>Vishal Gupta</u><sup>4</sup>; Matthew Rigby<sup>1</sup>; Wesley Hicks Jr<sup>4</sup>; William Magner<sup>4</sup>; Ayham Al Afif<sup>1</sup>. <sup>1</sup>Dalhousie University; <sup>2</sup>Weill Cornell Medicine; <sup>3</sup>University of Michigan; <sup>4</sup>Roswell Park Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objectives: </strong>Contemporary data remain scarce regarding the prognosticators of primary buccal squamous cell carcinoma. The aim of our study is to determine the oncologic outcomes and recurrence prognosticators for patients with primary SCC of the buccal mucosa</p>\n\n<p><strong>Methods: </strong>A multi-institutional, retrospective review was performed for buccal SCC patients undergoing treatment at three tertiary care cancer centers in the USA and Canada between the years 2009 and 2022. Survival analysis was performed using the Kaplan-Meier method. Multivariable models, including cox-proportional hazards method, were constructed and tested for best fit using Akaike’s Information Criterion (AIC) values.</p>\n\n<p><strong>Results: </strong>A total of 115 patients met our inclusion criteria, with 105 patients undergoing primary surgical resection and 10 undergoing primary chemoradiation treatment. The mean age of patients was 67 (SD 12.5) with a gender ratio of 56.5% male to 43.5% female. Occult nodal metastasis was observed in 25% of patients, whereas positive margins, perineural invasion, and extra-nodal extension were present in 10%, 21% and 20% respectively. The 5-year overall survival (OS) and disease specific survival (DSS) were 57.2% (SE 10, 95% CI 47-69.6) and 64.8% (SE 9.3, 95% CI 54.1-77.7) respectively. The presence of ENE (HR 3.08, CI 1.47-6.45) and positive margins (HR 3.39, CI 1.37-8.38) resulted in a significant hazard of death or recurrence (p<0.05).</p>\n\n<p><strong>Conclusion: </strong>SCC originating in the buccal mucosa tend to exhibit aggressive pathologic features, such as occult nodal metastasis, ENE and positive resection margins. We demonstrate that ENE and positive margins are powerful predictors of recurrence, resulting in a greater than three-fold hazard of death or recurrence. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154627--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S547",
      "content_id": "153350",
      "abstract_number": "S547",
      "poster_number": "",
      "title": "Impact of Referral Patterns and Geographic Distance on Delays in Head and Neck Cancer Care",
      "summary": "Geographic distance significantly impacts access to ENT specialty care for head and neck cancer patients requiring complex reconstruction. As Community ENT/General ENT represents the largest referral source, this distance-related delay affects nearly half of all patients in this population. Patients living farther from tertiary care centers experience systematically longer wait times for specialist evaluation,...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153350",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sofia Beseth, MA",
      "presenter": "Sofia Beseth, MA",
      "authors": "Claudia I Cabrera, MD, MS; Sofia Beseth, MA ; Rod Rezaee, MD",
      "normalized_authors": [
        "Claudia I Cabrera",
        "Sofia Beseth, MA",
        "Rod Rezaee"
      ],
      "affiliations": [
        "University Hospitals Cleveland"
      ],
      "normalized_institutions": [
        "University Hospitals Cleveland"
      ],
      "session_type": "Proffered Paper",
      "track": "Care Delivery Innovation",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Care Delivery Innovation"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153350/Distance%20vs%20Time%20of%20referral%20by%20specialty.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153350/Distance%20vs%20Time%20of%20referral%20by%20specialty.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153350"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153350/time%20from%20referral%20to%20first%20visit.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153350/time%20from%20referral%20to%20first%20visit.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153350"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 400,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Study Design & Methodology",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Claudia I Cabrera, MD, MS; Sofia Beseth, MA ; Rod Rezaee, MD",
        "Affiliations": "University Hospitals Cleveland",
        "Background": "Head and neck cancer patients face significant delays in diagnostic evaluation, cancer diagnosis, and treatment initiation that can adversely impact clinical outcomes and survival. A prior institutional study of head and neck cancer patients from 2018-2020 identified a concerning median total delay of 71 days from initial presentation to treatment, comprising 23 days from presentation to diagnostic evaluation, 9.5 days for cancer diagnosis, and 38.5 days to treatment initiation. Understanding referral patterns and sources of delay is critical for improving timely access to specialized care. This study aimed to evaluate sources of referral in the head and neck free flap reconstruction population and to identify factors contributing to delays in care, with particular emphasis on the relationship between geographic distance and time to specialist evaluation.",
        "Study Design & Methodology": "A retrospective chart review was conducted of patients who underwent head and neck free flap reconstruction between 2010-2023. Demographic information and temporal data including referral source, referral type, and time from referral to first visit were collected. Descriptive statistics summarized patient characteristics and referral patterns. Correlation analyses examined relationships between travel distance, referral specialty, referral type, and time to first visit.",
        "Results": "Among 257 patients (64.3% male, median age 64.9 years, 88.0% White), 17 different referring specialties were identified, with 257 total referrals analyzed. Community ENT/General ENT was the predominant referral source, accounting for 44.7% of all head and neck free flap cases. The majority of referrals across specialties were outpatient-to-outpatient transfers. Emergency room and oncology referrals demonstrated the shortest median time to first visit at 1.0 and 7.0 days, respectively. Overall, travel distance showed minimal correlation with time to first visit across most specialties. However, Community ENT/General ENT referrals demonstrated a statistically significant positive correlation between patient travel distance and time to first ENT visit (R=0.41, p<0.001).",
        "Conclusion": "Geographic distance significantly impacts access to ENT specialty care for head and neck cancer patients requiring complex reconstruction. As Community ENT/General ENT represents the largest referral source, this distance-related delay affects nearly half of all patients in this population. Patients living farther from tertiary care centers experience systematically longer wait times for specialist evaluation, potentially contributing to disease progression and worse outcomes. Addressing access disparities through telemedicine consultations, regional outreach clinics, or streamlined referral pathways may reduce treatment delays and improve outcomes for geographically disadvantaged patients",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Referral Patterns and Geographic Distance on Delays in Head and Neck Cancer Care</span>. Claudia I Cabrera, MD, MS; <u>Sofia Beseth, MA</u>; Rod Rezaee, MD. University Hospitals Cleveland<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer patients face significant delays in diagnostic evaluation, cancer diagnosis, and treatment initiation that can adversely impact clinical outcomes and survival. A prior institutional study of head and neck cancer patients from 2018-2020 identified a concerning median total delay of 71 days from initial presentation to treatment, comprising 23 days from presentation to diagnostic evaluation, 9.5 days for cancer diagnosis, and 38.5 days to treatment initiation. Understanding referral patterns and sources of delay is critical for improving timely access to specialized care. This study aimed to evaluate sources of referral in the head and neck free flap reconstruction population and to identify factors contributing to delays in care, with particular emphasis on the relationship between geographic distance and time to specialist evaluation.</p>\n\n<p><strong>Study Design & Methodology: </strong>A retrospective chart review was conducted of patients who underwent head and neck free flap reconstruction between 2010-2023. Demographic information and temporal data including referral source, referral type, and time from referral to first visit were collected. Descriptive statistics summarized patient characteristics and referral patterns. Correlation analyses examined relationships between travel distance, referral specialty, referral type, and time to first visit.</p>\n\n<p><strong>Results: </strong>Among 257 patients (64.3% male, median age 64.9 years, 88.0% White), 17 different referring specialties were identified, with 257 total referrals analyzed. Community ENT/General ENT was the predominant referral source, accounting for 44.7% of all head and neck free flap cases. The majority of referrals across specialties were outpatient-to-outpatient transfers. Emergency room and oncology referrals demonstrated the shortest median time to first visit at 1.0 and 7.0 days, respectively. Overall, travel distance showed minimal correlation with time to first visit across most specialties. However, Community ENT/General ENT referrals demonstrated a statistically significant positive correlation between patient travel distance and time to first ENT visit (R=0.41, p<0.001).</p>\n\n<p><strong>Conclusion: </strong>Geographic distance significantly impacts access to ENT specialty care for head and neck cancer patients requiring complex reconstruction. As Community ENT/General ENT represents the largest referral source, this distance-related delay affects nearly half of all patients in this population. Patients living farther from tertiary care centers experience systematically longer wait times for specialist evaluation, potentially contributing to disease progression and worse outcomes. Addressing access disparities through telemedicine consultations, regional outreach clinics, or streamlined referral pathways may reduce treatment delays and improve outcomes for geographically disadvantaged patients</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153350/Distance%20vs%20Time%20of%20referral%20by%20specialty.png' /></p>\n\n<p> </p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153350/time%20from%20referral%20to%20first%20visit.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153350--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S548",
      "content_id": "153567",
      "abstract_number": "S548",
      "poster_number": "",
      "title": "The Effects of Malpractice Litigation on Otolaryngologist Well-Being",
      "summary": "Malpractice litigation is common among otolaryngologists, is strongly associated with years in practice, and varies across subspecialties. Recent lawsuits carry greater adverse effects on burnout, emotional well-being, and professional priorities than distant lawsuits. Notably, institutional support during a lawsuit improves long term outcomes in workplace burnout, stress, exhaustion, fulfillment, and perceived...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153567",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260158",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Richard Hausman, BS",
      "presenter": "Richard Hausman, BS",
      "authors": "Richard Hausman, BS 1 ; Shiven Sharma, JD 1 ; Tanner Frahm, BS 1 ; Shaun Edalati, MD 2 ; Eric Gong, BA 1 ; Mohemmed N Khan, MD 1 ; Alfred M Iloreta, MD 1 ; Satish Govindaraj, MD 1",
      "normalized_authors": [
        "Richard Hausman",
        "Shiven Sharma, JD",
        "Tanner Frahm",
        "Shaun Edalati",
        "Eric Gong",
        "Mohemmed N Khan",
        "Alfred M Iloreta",
        "Satish Govindaraj"
      ],
      "affiliations": [
        "Icahn School of Medicine at Mount Sinai",
        "Thomas Jefferson University Hospital"
      ],
      "normalized_institutions": [
        "Icahn School of Medicine at Mount Sinai",
        "Thomas Jefferson University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153567/figure%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153567/figure%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153567"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153567/figure%202.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153567/figure%202.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153567"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153567/Table%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153567/Table%201.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153567"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 504,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Richard Hausman, BS 1 ; Shiven Sharma, JD 1 ; Tanner Frahm, BS 1 ; Shaun Edalati, MD 2 ; Eric Gong, BA 1 ; Mohemmed N Khan, MD 1 ; Alfred M Iloreta, MD 1 ; Satish Govindaraj, MD 1",
        "Affiliations": "1 Icahn School of Medicine at Mount Sinai; 2 Thomas Jefferson University Hospital",
        "Introduction": "Malpractice litigation is a common and stressful experience for physicians, yet its impact on the wellness of otolaryngologists remains poorly characterized. Prior work in other specialties demonstrates persistent emotional and professional effects of lawsuits, but no otolaryngology-specific analysis exists. We characterised the prevalence of lawsuits and their effect on well-being, burnout, and sleep among practicing otolaryngologists in several subspecialties.",
        "Methods": "One hundred and twenty otolaryngologists from American Head and Neck Society and American Rhinologic Society completed a survey on malpractice litigation history, practice history, and well-being. Responses included Facial Plastics (3), Head and Neck (39), Rhinology (49), Skull Base (2), Sleep (4), and General (23). Logistic regression modeled the risk of experiencing at least one lawsuit, while multivariable negative binomial regression modeled the number of lawsuits. One-way ANOVA tests and t-tests were used to detect well-being impacts of subspecialty, institutional support, and the recency of the respondent’s last lawsuit, with “recent” meaning within the last two years. Linear regression modeled the impact of institutional litigation support on wellness outcomes, controlling for recency.",
        "Results": "Fifty-one respondents (42.5%) had been involved in at least one lawsuit, with Rhinology having the lowest average (0.8). The likelihood of having at least one lawsuit increased 17% per year in practice (OR: 1.17, 95% CI: 1.11-1.25, p < 0.001). Subspecialty was not predictive of having experienced a lawsuit. However, in multivariable analysis adjusting for weekly hours, call, and practice setting, subspecialty was associated with different numbers of lawsuits. Facial Plastics (IRR 2.79, p=0.015) and Sleep (IRR 2.77, p=0.011) reported higher lawsuit counts compared to General, whereas Rhinology reported fewer (IRR 0.48, p=0.020). Weekly work hours were independently associated with lawsuit count (IRR 1.02 / hour, p=0.006). While Facial Plastics and Sleep reported many lawsuits, they had small sample sizes.",
        "Abstract": "Those who had experienced a recent lawsuit (n=15) reported a higher burnout impact (p=0.012), long-term emotional impact (p=0.021), and reconsideration of professional priorities (p=0.035) from their lawsuits than the “distant” group (n=53). Across subspecialties wellness outcomes generally did not differ. However, Head and Neck surgeons reported significantly less reconsideration of their professional priorities following a lawsuit compared to General otolaryngologists and Rhinologists (p=0.029). Otolaryngologists who reported receiving more institutional support during litigation also reported higher perceived fairness (β = +0.29, p = 0.003) and fulfillment, and reduced workplace burnout impact (β = –0.26, p = 0.023), stress, and emotional exhaustion. View in Agenda and Add to Schedule",
        "Conclusion": "Malpractice litigation is common among otolaryngologists, is strongly associated with years in practice, and varies across subspecialties. Recent lawsuits carry greater adverse effects on burnout, emotional well-being, and professional priorities than distant lawsuits. Notably, institutional support during a lawsuit improves long term outcomes in workplace burnout, stress, exhaustion, fulfillment, and perceived fairness of the outcome. Therefore, these findings support the need for intentional institutional support for surgeons navigating active litigation, as burnout has implications for physician and patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The Effects of Malpractice Litigation on Otolaryngologist Well-Being</span>. <u>Richard Hausman, BS</u><sup>1</sup>; Shiven Sharma, JD<sup>1</sup>; Tanner Frahm, BS<sup>1</sup>; Shaun Edalati, MD<sup>2</sup>; Eric Gong, BA<sup>1</sup>; Mohemmed N Khan, MD<sup>1</sup>; Alfred M Iloreta, MD<sup>1</sup>; Satish Govindaraj, MD<sup>1</sup>. <sup>1</sup>Icahn School of Medicine at Mount Sinai; <sup>2</sup>Thomas Jefferson University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Malpractice litigation is a common and stressful experience for physicians, yet its impact on the wellness of otolaryngologists remains poorly characterized. Prior work in other specialties demonstrates persistent emotional and professional effects of lawsuits, but no otolaryngology-specific analysis exists. We characterised the prevalence of lawsuits and their effect on well-being, burnout, and sleep among practicing otolaryngologists in several subspecialties.</p>\n\n<p><strong>Methods:</strong> One hundred and twenty otolaryngologists from American Head and Neck Society and American Rhinologic Society completed a survey on malpractice litigation history, practice history, and well-being. Responses included Facial Plastics (3), Head and Neck (39), Rhinology (49), Skull Base (2), Sleep (4), and General (23). Logistic regression modeled the risk of experiencing at least one lawsuit, while multivariable negative binomial regression modeled the number of lawsuits. One-way ANOVA tests and t-tests were used to detect well-being impacts of subspecialty, institutional support, and the recency of the respondent’s last lawsuit, with “recent” meaning within the last two years. Linear regression modeled the impact of institutional litigation support on wellness outcomes, controlling for recency.</p>\n\n<p><strong>Results:</strong> Fifty-one respondents (42.5%) had been involved in at least one lawsuit, with Rhinology having the lowest average (0.8). The likelihood of having at least one lawsuit increased 17% per year in practice (OR: 1.17, 95% CI: 1.11-1.25, p < 0.001). Subspecialty was not predictive of having experienced a lawsuit. However, in multivariable analysis adjusting for weekly hours, call, and practice setting, subspecialty was associated with different numbers of lawsuits. Facial Plastics (IRR 2.79, p=0.015) and Sleep (IRR 2.77, p=0.011) reported higher lawsuit counts compared to General, whereas Rhinology reported fewer (IRR 0.48, p=0.020). Weekly work hours were independently associated with lawsuit count (IRR 1.02 / hour, p=0.006). While Facial Plastics and Sleep reported many lawsuits, they had small sample sizes.</p>\n\n<p>Those who had experienced a recent lawsuit (n=15) reported a higher burnout impact (p=0.012), long-term emotional impact (p=0.021), and reconsideration of professional priorities (p=0.035) from their lawsuits than the “distant” group (n=53). Across subspecialties wellness outcomes generally did not differ. However, Head and Neck surgeons reported significantly less reconsideration of their professional priorities following a lawsuit compared to General otolaryngologists and Rhinologists (p=0.029). Otolaryngologists who reported receiving more institutional support during litigation also reported higher perceived fairness (β = +0.29, p = 0.003) and fulfillment, and reduced workplace burnout impact (β = –0.26, p = 0.023), stress, and emotional exhaustion.</p>\n\n<p><strong>Conclusion:</strong> Malpractice litigation is common among otolaryngologists, is strongly associated with years in practice, and varies across subspecialties. Recent lawsuits carry greater adverse effects on burnout, emotional well-being, and professional priorities than distant lawsuits. Notably, institutional support during a lawsuit improves long term outcomes in workplace burnout, stress, exhaustion, fulfillment, and perceived fairness of the outcome. Therefore, these findings support the need for intentional institutional support for surgeons navigating active litigation, as burnout has implications for physician and patient outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153567/figure%201.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153567/figure%202.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153567/Table%201.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153567--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260158' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S549",
      "content_id": "153065",
      "abstract_number": "S549",
      "poster_number": "",
      "title": "Free Flap Education in Head and Neck Cancer Patients: A Local Quality Improvement Endeavor",
      "summary": "Early findings show that a standardized digital education pathway is feasible, well-received, and associated with improved patient engagement, including shorter length of stay among patients who reviewed materials preoperatively. Differences in perceived educational needs and strong interest in supplemental video-based resources highlight opportunities to refine and expand patient-facing content. Ongoing data...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153065",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Hallie Samuel, BS",
      "presenter": "Hallie Samuel, BS",
      "authors": "Courtney Hunter, MD 1 ; J. Quinn Odom, BS 2 ; Kenny Nguyen, MD, MEd 1 ; Grace Bryant, BS 2 ; Hallie Samuel, BS 2 ; Neoni Yustana, PAC 1 ; J. Reed Gardner, MD 1 ; Emre Vural, MD 1 ; Mauricio Moreno, MD 1 ; Jumin Sunde, MD 1",
      "normalized_authors": [
        "Courtney Hunter",
        "J. Quinn Odom",
        "Kenny Nguyen, MEd",
        "Grace Bryant",
        "Hallie Samuel",
        "Neoni Yustana, PAC",
        "J. Reed Gardner",
        "Emre Vural",
        "Mauricio Moreno",
        "Jumin Sunde"
      ],
      "affiliations": [
        "University of Arkansas for Medical Sciences",
        "University of Arkansas for Medical Sciences College of Medicine"
      ],
      "normalized_institutions": [
        "University of Arkansas for Medical Sciences",
        "University of Arkansas for Medical Sciences College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 492,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Courtney Hunter, MD 1 ; J. Quinn Odom, BS 2 ; Kenny Nguyen, MD, MEd 1 ; Grace Bryant, BS 2 ; Hallie Samuel, BS 2 ; Neoni Yustana, PAC 1 ; J. Reed Gardner, MD 1 ; Emre Vural, MD 1 ; Mauricio Moreno, MD 1 ; Jumin Sunde, MD 1",
        "Affiliations": "1 University of Arkansas for Medical Sciences; 2 University of Arkansas for Medical Sciences College of Medicine",
        "Introduction": "Postoperative recovery after head and neck free flap reconstruction is complex and often requires patients and caregivers to manage tracheostomies, feeding tubes, wound care, and multiple follow-up appointments. Inadequate or inconsistent education can contribute to confusion, unplanned encounters, and disruptions in postoperative care. Digital platforms such as MyChart allow for distribution of standardized education materials and provide objective measures of engagement. This quality improvement initiative evaluates whether a structured digital education pathway improves patient understanding and is associated with improved postoperative recovery.",
        "Methods": "This prospective quality improvement study began in January 2025 with the implementation of a standardized MyChart-delivered education program for all eligible adult free flap reconstruction patients treated at our academic tertiary medical center. Adult patients undergoing aerodigestive soft tissue or bony free tissue transfer for malignancy or chronic wounds were included. Materials were sent with read-receipt functionality, followed by an automated REDCap survey after the first postoperative visit. Patients receiving total laryngectomy were excluded, as they receive separate counseling pathways. Survey domains assessed perceived usefulness, preparedness, comprehension of postoperative goals, readability, and multimedia preferences. Additional data included demographics, surgical characteristics, complications, readmissions, and adjuvant therapy timelines. Associations between engagement and postoperative understanding, complications, and treatment delays were evaluated using standard quality-improvement methods.",
        "Results": "Seventy-six patients met inclusion criteria, of whom 50 received the pamphlet (26 read before surgery and 24 did not), and 26 did not receive it. Baseline age and flap type were similar between groups. Among those that received the pamphlets preoperatively, 84% used it two or more times and 72% reported that it helped them prepare for surgery. These patients also had a shorter hospital stay compared to those that did not review the pamphlet (5.9 + 2.3 versus 7.0 + 2.8 days; p=0.045). Responses regarding material readability were mixed, with comparable proportions reporting that the pamphlet was easy to understand or had confusing elements. Requests for additional education before surgery varied by topic, most notably with nursing care/hospital experience selected by 19% of pamphlet users compared to 4% of non-users, and wound appearance selected by 20% compared to 26%. Most patients reported regular internet access (91%), and interest in supplemental video-based education was greater among non-pamphlet users compared to pamphlet users (75% v. 48%). Educational backgrounds varied, with 40% having a high school education or less and 14% holding advanced degrees. Postoperative complication and readmission rates were low, and other clinical measures including tumor characteristics, adjuvant therapy referrals, and time to treatment initiation were similar between groups.",
        "Conclusion": "Early findings show that a standardized digital education pathway is feasible, well-received, and associated with improved patient engagement, including shorter length of stay among patients who reviewed materials preoperatively. Differences in perceived educational needs and strong interest in supplemental video-based resources highlight opportunities to refine and expand patient-facing content. Ongoing data collection will strengthen analytic power and guide refinement of a comprehensive education pathway for free flap patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Free Flap Education in Head and Neck Cancer Patients: A Local Quality Improvement Endeavor</span>. Courtney Hunter, MD<sup>1</sup>; J. Quinn Odom, BS<sup>2</sup>; Kenny Nguyen, MD, MEd<sup>1</sup>; Grace Bryant, BS<sup>2</sup>; <u>Hallie Samuel, BS</u><sup>2</sup>; Neoni Yustana, PAC<sup>1</sup>; J. Reed Gardner, MD<sup>1</sup>; Emre Vural, MD<sup>1</sup>; Mauricio Moreno, MD<sup>1</sup>; Jumin Sunde, MD<sup>1</sup>. <sup>1</sup>University of Arkansas for Medical Sciences; <sup>2</sup>University of Arkansas for Medical Sciences College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Postoperative recovery after head and neck free flap reconstruction is complex and often requires patients and caregivers to manage tracheostomies, feeding tubes, wound care, and multiple follow-up appointments. Inadequate or inconsistent education can contribute to confusion, unplanned encounters, and disruptions in postoperative care. Digital platforms such as MyChart allow for distribution of standardized education materials and provide objective measures of engagement. This quality improvement initiative evaluates whether a structured digital education pathway improves patient understanding and is associated with improved postoperative recovery.</p>\n\n<p><strong>Methods: </strong>This prospective quality improvement study began in January 2025 with the implementation of a standardized MyChart-delivered education program for all eligible adult free flap reconstruction patients treated at our academic tertiary medical center. Adult patients undergoing aerodigestive soft tissue or bony free tissue transfer for malignancy or chronic wounds were included. Materials were sent with read-receipt functionality, followed by an automated REDCap survey after the first postoperative visit. Patients receiving total laryngectomy were excluded, as they receive separate counseling pathways. Survey domains assessed perceived usefulness, preparedness, comprehension of postoperative goals, readability, and multimedia preferences. Additional data included demographics, surgical characteristics, complications, readmissions, and adjuvant therapy timelines. Associations between engagement and postoperative understanding, complications, and treatment delays were evaluated using standard quality-improvement methods.</p>\n\n<p><strong>Results: </strong>Seventy-six patients met inclusion criteria, of whom 50 received the pamphlet (26 read before surgery and 24 did not), and 26 did not receive it. Baseline age and flap type were similar between groups. Among those that received the pamphlets preoperatively, 84% used it two or more times and 72% reported that it helped them prepare for surgery. These patients also had a shorter hospital stay compared to those that did not review the pamphlet (5.9 + 2.3 versus 7.0 + 2.8 days; p=0.045). Responses regarding material readability were mixed, with comparable proportions reporting that the pamphlet was easy to understand or had confusing elements. Requests for additional education before surgery varied by topic, most notably with nursing care/hospital experience selected by 19% of pamphlet users compared to 4% of non-users, and wound appearance selected by 20% compared to 26%. Most patients reported regular internet access (91%), and interest in supplemental video-based education was greater among non-pamphlet users compared to pamphlet users (75% v. 48%). Educational backgrounds varied, with 40% having a high school education or less and 14% holding advanced degrees. Postoperative complication and readmission rates were low, and other clinical measures including tumor characteristics, adjuvant therapy referrals, and time to treatment initiation were similar between groups.</p>\n\n<p><strong>Conclusion: </strong>Early findings show that a standardized digital education pathway is feasible, well-received, and associated with improved patient engagement, including shorter length of stay among patients who reviewed materials preoperatively. Differences in perceived educational needs and strong interest in supplemental video-based resources highlight opportunities to refine and expand patient-facing content. Ongoing data collection will strengthen analytic power and guide refinement of a comprehensive education pathway for free flap patients.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153065--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S550",
      "content_id": "154234",
      "abstract_number": "S550",
      "poster_number": "",
      "title": "Use of the ZIP Flap for Oncologic Maxillary Defect Reconstruction: A South American cancer center Experience",
      "summary": "The ZIP-flap technique is a safe approach that enables a higher proportion of patients to achieve definitive dental rehabilitation compared to other reconstructive strategies previously used in our institution.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154234",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Carolina Contador, MD",
      "presenter": "Carolina Contador, MD",
      "authors": "Carolina Contador, MD ; Matías Lavín, MD; Yerko Leighton, DDS; David Cohn, MD; Daniel Ledezma, MD; Gustavo Vial, MD; Ximena Mimica, MD; Felipe Contreras, MD; Luis Marín, MD",
      "normalized_authors": [
        "Carolina Contador",
        "Matías Lavín",
        "Yerko Leighton",
        "David Cohn",
        "Daniel Ledezma",
        "Gustavo Vial",
        "Ximena Mimica",
        "Felipe Contreras",
        "Luis Marín"
      ],
      "affiliations": [
        "Instituto Oncológico Fundación Arturo López Pérez"
      ],
      "normalized_institutions": [
        "Instituto Oncológico Fundación Arturo López Pérez"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 358,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Carolina Contador, MD ; Matías Lavín, MD; Yerko Leighton, DDS; David Cohn, MD; Daniel Ledezma, MD; Gustavo Vial, MD; Ximena Mimica, MD; Felipe Contreras, MD; Luis Marín, MD",
        "Affiliations": "Instituto Oncológico Fundación Arturo López Pérez",
        "Background": "Maxillary defects resulting from extensive oncologic resections significantly impair patients’ quality of life. Dental rehabilitation is essential for restoring part of the function and facial aesthetics; however, it is not always feasible. The development of the ZIP-flap technique has facilitated reconstructive strategies, enabling higher rates of dental rehabilitation.",
        "Methods": "This retrospective study from a South American cancer institution describes a case series of patients who underwent maxillectomy for cancer and reconstruction using the ZIP-flap technique since its implementation in 2009. Data were obtained from electronic patient records.",
        "Results": "From 2009 to the present, 17 patients underwent maxillectomy and reconstruction using the ZIP flap technique, with either bilateral or unilateral zygomatic implants combined with conventional implants in the remaining bone. 14 of them for cancer and 3 patients for benign tumors afectting de maxilla. The median age was 47 years, and 64% were male (11). Twelve patients (70%) underwent Class II maxillectomy, one patient underwent Class III maxillectomy, and four patients required Class IV maxillectomy. Ten of the 17 patients received an anterolateral thigh (ALT) flap, while seven received a radial forearm flap. The mean operative time was 10.7 hours, and the average hospital stay was 14 days. Twelve patients received radiotherapy as part of their treatment. Complications were infrequent and included two cases of oronasal fistula, one nasocutaneous fistula, and two cases of flap dehiscence at the naso-orbital region. No implant losses in this serie. There were no free flap failures with one flap being salvaged in few hours and only one patient experienced partial loss of the skin paddle. Two patients died due to progression of their oncologic disease. Seven patients (41%) achieved dental rehabilitation within one year, all of them with low level maxillectomies, while four additional patients are currently undergoing rehabilitation. Dental rehabilitation has not been achieved in any of the patients with larger defects involving the orbit, due to greater challenges related to midfacial support and soft-tissue flap anchorage",
        "Conclusion": "The ZIP-flap technique is a safe approach that enables a higher proportion of patients to achieve definitive dental rehabilitation compared to other reconstructive strategies previously used in our institution.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Use of the ZIP Flap for Oncologic Maxillary Defect Reconstruction: A South American cancer center Experience</span>. <u>Carolina Contador, MD</u>; Matías Lavín, MD; Yerko Leighton, DDS; David Cohn, MD; Daniel Ledezma, MD; Gustavo Vial, MD; Ximena Mimica, MD; Felipe Contreras, MD; Luis Marín, MD. Instituto Oncológico Fundación Arturo López Pérez<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Maxillary defects resulting from extensive oncologic resections significantly impair patients’ quality of life. Dental rehabilitation is essential for restoring part of the function and facial aesthetics; however, it is not always feasible. The development of the ZIP-flap technique has facilitated reconstructive strategies, enabling higher rates of dental rehabilitation.</p>\n\n<p><strong>Methods: </strong>This retrospective study from a South American cancer institution describes a case series of patients who underwent maxillectomy for cancer and reconstruction using the ZIP-flap technique since its implementation in 2009. Data were obtained from electronic patient records.</p>\n\n<p><strong>Results: </strong>From 2009 to the present, 17 patients underwent maxillectomy and reconstruction using the ZIP flap technique, with either bilateral or unilateral zygomatic implants combined with conventional implants in the remaining bone. 14 of them for cancer and 3 patients for benign tumors afectting de maxilla. The median age was 47 years, and 64% were male (11). Twelve patients (70%) underwent Class II maxillectomy, one patient underwent Class III maxillectomy, and four patients required Class IV maxillectomy. Ten of the 17 patients received an anterolateral thigh (ALT) flap, while seven received a radial forearm flap. The mean operative time was 10.7 hours, and the average hospital stay was 14 days. Twelve patients received radiotherapy as part of their treatment. Complications were infrequent and included two cases of oronasal fistula, one nasocutaneous fistula, and two cases of flap dehiscence at the naso-orbital region. No implant losses in this serie. There were no free flap failures with one flap being salvaged in few hours and only one patient experienced partial loss of the skin paddle. Two patients died due to progression of their oncologic disease. Seven patients (41%) achieved dental rehabilitation within one year, all of them with low level maxillectomies, while four additional patients are currently undergoing rehabilitation. Dental rehabilitation has not been achieved in any of the patients with larger defects involving the orbit, due to greater challenges related to midfacial support and soft-tissue flap anchorage</p>\n\n<p><strong>Conclusion:</strong> The ZIP-flap technique is a safe approach that enables a higher proportion of patients to achieve definitive dental rehabilitation compared to other reconstructive strategies previously used in our institution.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154234--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S551",
      "content_id": "153398",
      "abstract_number": "S551",
      "poster_number": "",
      "title": "Large skull base defect reconstruction with free flaps",
      "summary": "Based on the data from our case series, free flap reconstruction yields highly favorable and reliable therapeutic outcomes in patients requiring large anterior skull base defect restoration following extensive tumor resection. The versatility of utilizing muscle, fascia, skin and subcutaneous tissue from various body locations eliminates the concerns relating to tissue availability. With high success rate and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153398",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Michael Chang, BS Biology",
      "presenter": "Michael Chang, BS Biology",
      "authors": "Michael Chang, BS Biology 1 ; Changxing Liu, MD 2",
      "normalized_authors": [
        "Michael Chang, Biology",
        "Changxing Liu"
      ],
      "affiliations": [
        "University of Pennsylvania",
        "Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center"
      ],
      "normalized_institutions": [
        "University of Pennsylvania",
        "Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 393,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Michael Chang, BS Biology 1 ; Changxing Liu, MD 2",
        "Affiliations": "1 University of Pennsylvania ; 2 Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center",
        "Background": "Reconstruction for extensive anterior and lateral skull base defects after tumor resection is still very challenging today. Traditional ways of reconstruction with grafts are associated with notable risks, such as persistent or delayed cerebrospinal fluid leakage, volume impact to the brain tissue, delayed would healing and infection, especially when patient underwent adjuvant therapies. In contrast, free flap reconstruction serves as a safe approach to mitigate these risks, while enhancing tolerance of postoperative radiation therapy.",
        "Methods": "We reviewed the clinical data from a tertiary care medical center (level I trauma center) for the patients who underwent surgical resection of large skull base tumors with subsequent free flap reconstruction during the past 5 years, and analyzed their recovery process. The clinic information collected included patient selection criteria, type of free flaps, free flap viability, early postoperative complications, occurrences of cerebrospinal fluid leaks, incidence of infection, hematoma, and stroke, during both the postoperative recovery and post adjuvant therapy periods. Additionally, we examined the charts of patients for demographic information, other operative specifics, perioperative events, and radiographic, pathological, and adjuvant therapy data.",
        "Results": "35 cases, between 2021 and 2025, were selected for this case series study. They all underwent extensive resection, including dura resection with extensive bony skull base resection. The free flaps used for large skull base defect mainly included anterolateral thigh free flaps, rectus abdominis free flap, greater omentum free flap and latissimus dorsi free flaps. The average age of the patients was 63 years, ranging from 41 to 78. Approximately 57% of the patients were male. Notably, the flap survival rate was 100%, with no observed cases of partial or complete free flap failure, early or delayed cerebrospinal fluid leakage or infections, or hematoma. All free flaps survived adjuvant chemoradiation therapies. However, there was an 17% incidence of stroke, and all of them were ischemic.",
        "Conclusion": "Based on the data from our case series, free flap reconstruction yields highly favorable and reliable therapeutic outcomes in patients requiring large anterior skull base defect restoration following extensive tumor resection. The versatility of utilizing muscle, fascia, skin and subcutaneous tissue from various body locations eliminates the concerns relating to tissue availability. With high success rate and minimal complications, free flap reconstruction is optimal for reconstruction of large skull base defects, with direct brain exposure. Stroke after surgery still needs close observation and prevention.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Large skull base defect reconstruction with free flaps</span>. <u>Michael Chang, BS Biology</u><sup>1</sup>; Changxing Liu, MD<sup>2</sup>. <sup>1</sup>University of Pennsylvania ; <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, Ascension St John Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Reconstruction for extensive anterior and lateral skull base defects after tumor resection is still very challenging today.  Traditional ways of reconstruction with grafts are associated with notable risks, such as persistent or delayed cerebrospinal fluid leakage, volume impact to the brain tissue, delayed would healing and infection, especially when patient underwent adjuvant therapies. In contrast, free flap reconstruction serves as a safe approach to mitigate these risks, while enhancing tolerance of postoperative radiation therapy.</p>\n\n<p><strong>Methods: </strong>We reviewed the clinical data from a tertiary care medical center (level I trauma center) for the patients who underwent surgical resection of large skull base tumors with subsequent free flap reconstruction during the past 5 years, and analyzed their recovery process. The clinic information collected included patient selection criteria, type of free flaps, free flap viability, early postoperative complications, occurrences of cerebrospinal fluid leaks, incidence of infection, hematoma, and stroke, during both the postoperative recovery and post adjuvant therapy periods. Additionally, we examined the charts of patients for demographic information, other operative specifics, perioperative events, and radiographic, pathological, and adjuvant therapy data.</p>\n\n<p><strong>Results: </strong>35 cases, between 2021 and 2025, were selected for this case series study. They all underwent extensive resection, including dura resection with extensive bony skull base resection. The free flaps used for large skull base defect mainly included anterolateral thigh free flaps, rectus abdominis free flap, greater omentum free flap and latissimus dorsi free flaps. The average age of the patients was 63 years, ranging from 41 to 78. Approximately 57% of the patients were male. Notably, the flap survival rate was 100%, with no observed cases of partial or complete free flap failure, early or delayed cerebrospinal fluid leakage or infections, or hematoma. All free flaps survived adjuvant chemoradiation therapies. However, there was an 17% incidence of stroke, and all of them were ischemic.</p>\n\n<p><strong>Conclusion: </strong>Based on the data from our case series, free flap reconstruction yields highly favorable and reliable therapeutic outcomes in patients requiring large anterior skull base defect restoration following extensive tumor resection. The versatility of utilizing muscle, fascia, skin and subcutaneous tissue from various body locations eliminates the concerns relating to tissue availability. With high success rate and minimal complications, free flap reconstruction is optimal for reconstruction of large skull base defects, with direct brain exposure. Stroke after surgery still needs close observation and prevention.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153398--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S552",
      "content_id": "153750",
      "abstract_number": "S552",
      "poster_number": "",
      "title": "Impact of Anesthetic Modality on Outcomes and Hospital Course Following Head and Neck Free Flap Reconstruction",
      "summary": "Among patients undergoing head and neck free flap reconstruction, anesthetic modality was significantly associated with differences in ICU admission rates and ICU length of stay, with volatile-only anesthesia linked to higher ICU utilization and longer ICU stays. Although overall hospital length of stay and 30-day mortality did not differ significantly between groups, a trend toward prolonged hospitalization was...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153750",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Alisa Vidwans, ScM",
      "presenter": "Alisa Vidwans, ScM",
      "authors": "Alisa Vidwans, ScM 1 ; Emma Dunn, BS 1 ; Jacob Parker, BS 1 ; Atif Islam, BS 1 ; William N Doyle, MD 2 ; Mayte Diaz, DNP, CRNA 1 ; Veena Jajoo, MPH 1 ; Rahul Mhaskar, MPH, PhD 1 ; Christopher Nickel, MD 1 ; Tara Mokhrari, MD 1 ; Matthew Mifsud, MD 1",
      "normalized_authors": [
        "Alisa Vidwans, ScM",
        "Emma Dunn",
        "Jacob Parker",
        "Atif Islam",
        "William N Doyle",
        "Mayte Diaz, DNP, CRNA",
        "Veena Jajoo",
        "Rahul Mhaskar",
        "Christopher Nickel",
        "Tara Mokhrari",
        "Matthew Mifsud"
      ],
      "affiliations": [
        "USF Health Morsani College of Medicine",
        "Rush University"
      ],
      "normalized_institutions": [
        "USF Health Morsani College of Medicine",
        "Rush University"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 534,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alisa Vidwans, ScM 1 ; Emma Dunn, BS 1 ; Jacob Parker, BS 1 ; Atif Islam, BS 1 ; William N Doyle, MD 2 ; Mayte Diaz, DNP, CRNA 1 ; Veena Jajoo, MPH 1 ; Rahul Mhaskar, MPH, PhD 1 ; Christopher Nickel, MD 1 ; Tara Mokhrari, MD 1 ; Matthew Mifsud, MD 1",
        "Affiliations": "1 USF Health Morsani College of Medicine; 2 Rush University",
        "Background": "Head and neck free flap surgery is common in oncologic and reconstructive settings, however, the influence of perioperative anesthetic factors influencing flap outcomes and hospital course remains incompletely characterized. The type of anesthesia administered and how it is maintained during the procedure can have effects on microvascular perfusion, flap viability, and hospital resource utilization. Existing studies primarily compare total intravenous anesthesia (TIVA) and volatile techniques, while multimodal anesthesia is increasingly used but underreported in the literature. This study examines the association between anesthetic modality and post-surgical outcomes in patients undergoing free flap head and neck surgery.",
        "Methods": "A retrospective review of all patients undergoing head and neck free flap reconstruction at a single academic hospital (August 2017–November 2023) identified 301 patients. Patients were stratified based on whether they received volatile anesthesia (n=28), total intravenous anesthesia (TIVA) (n=69), or multimodal anesthesia (n=204). Outcomes of interest included initial postoperative disposition to the ICU or medical-surgical floor, hospital length of stay (LOS), and 30-day mortality. Statistical analyses included chi-square, ANOVA, Fisher’s exact tests, and Welch’s t-tests.",
        "Results": "Baseline demographics, including age, BMI, ASA class, and Charlson Comorbidity Index, were similar between groups, except for sex distribution, with a higher proportion of females in the volatile-only group (67.9%) compared with TIVA (42.0%) or multimodal (28.9%, p<0.001). Patients in each group received either a radial forearm, fibula, scapula, chimeric scapula and latissimus, anterolateral thigh, gracilis, or a latissimus dorsi flap. Flap types were comparable overall (p=0.103), though chimeric scapula/latissimus flaps were more frequent with TIVA (17.4%) than volatile-only (14.3%) or multimodal (6.4%, p=0.01). Patients who received volatile-only anesthesia were more likely to be admitted to the ICU (80.8% ICU vs 19.2% floor) compared with those receiving TIVA (50.0% ICU vs 50.0% floor) or multimodal anesthesia (52.9% ICU vs 47.1% floor, p=0.018). A statistically significant difference in the distribution of ICU LOS was also observed. Patients who received volatile-only anesthesia were found to have longer ICU LOS (3.35 ± 2.60), compared to those receiving TIVA (2.82 ± 4.14) or multimodal anesthesia (2.36 ± 1.70, p=0.037). No significant differences were noted in the hospital LOS (p=0.072). While overall hospital LOS did not differ significantly between groups (p=0.072), patients who received volatile-only anesthesia had a longer average hospital stay (10.30 ± 5.76) compared with TIVA (9.83 ± 7.58) and multimodal anesthesia (8.48 ± 5.83). No significant differences were observed in discharge disposition or 30-day mortality.",
        "Conclusion": "Among patients undergoing head and neck free flap reconstruction, anesthetic modality was significantly associated with differences in ICU admission rates and ICU length of stay, with volatile-only anesthesia linked to higher ICU utilization and longer ICU stays. Although overall hospital length of stay and 30-day mortality did not differ significantly between groups, a trend toward prolonged hospitalization was observed in the volatile-only cohort. These findings suggest that anesthetic approach may influence postoperative resource utilization and highlight the need for prospective studies to inform anesthetic protocols to improve microsurgical outcomes and reduce ICU burden.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Impact of Anesthetic Modality on Outcomes and Hospital Course Following Head and Neck Free Flap Reconstruction</span>. <u>Alisa Vidwans, ScM</u><sup>1</sup>; Emma Dunn, BS<sup>1</sup>; Jacob Parker, BS<sup>1</sup>; Atif Islam, BS<sup>1</sup>; William N Doyle, MD<sup>2</sup>; Mayte Diaz, DNP, CRNA<sup>1</sup>; Veena Jajoo, MPH<sup>1</sup>; Rahul Mhaskar, MPH, PhD<sup>1</sup>; Christopher Nickel, MD<sup>1</sup>; Tara Mokhrari, MD<sup>1</sup>; Matthew Mifsud, MD<sup>1</sup>. <sup>1</sup>USF Health Morsani College of Medicine; <sup>2</sup>Rush University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Head and neck free flap surgery is common in oncologic and reconstructive settings, however, the influence of perioperative anesthetic factors influencing flap outcomes and hospital course remains incompletely characterized. The type of anesthesia administered and how it is maintained during the procedure can have effects on microvascular perfusion, flap viability, and hospital resource utilization. Existing studies primarily compare total intravenous anesthesia (TIVA) and volatile techniques, while multimodal anesthesia is increasingly used but underreported in the literature. This study examines the association between anesthetic modality and post-surgical outcomes in patients undergoing free flap head and neck surgery.</p>\n\n<p><strong>Methods</strong>: A retrospective review of all patients undergoing head and neck free flap reconstruction at a single academic hospital (August 2017–November 2023) identified 301 patients. Patients were stratified based on whether they received volatile anesthesia (n=28), total intravenous anesthesia (TIVA) (n=69), or multimodal anesthesia (n=204). Outcomes of interest included initial postoperative disposition to the ICU or medical-surgical floor, hospital length of stay (LOS), and 30-day mortality. Statistical analyses included chi-square, ANOVA, Fisher’s exact tests, and Welch’s t-tests.</p>\n\n<p><strong>Results</strong>: Baseline demographics, including age, BMI, ASA class, and Charlson Comorbidity Index, were similar between groups, except for sex distribution, with a higher proportion of females in the volatile-only group (67.9%) compared with TIVA (42.0%) or multimodal (28.9%, p<0.001). Patients in each group received either a radial forearm, fibula, scapula, chimeric scapula and latissimus, anterolateral thigh, gracilis, or a latissimus dorsi flap. Flap types were comparable overall (p=0.103), though chimeric scapula/latissimus flaps were more frequent with TIVA (17.4%) than volatile-only (14.3%) or multimodal (6.4%, p=0.01). Patients who received volatile-only anesthesia were more likely to be admitted to the ICU (80.8% ICU vs 19.2% floor) compared with those receiving TIVA (50.0% ICU vs 50.0% floor) or multimodal anesthesia (52.9% ICU vs 47.1% floor, p=0.018). A statistically significant difference in the distribution of ICU LOS was also observed. Patients who received volatile-only anesthesia were found to have longer ICU LOS (3.35 ± 2.60), compared to those receiving TIVA (2.82 ± 4.14) or multimodal anesthesia (2.36 ± 1.70, p=0.037). No significant differences were noted in the hospital LOS (p=0.072). While overall hospital LOS did not differ significantly between groups (p=0.072), patients who received volatile-only anesthesia had a longer average hospital stay (10.30 ± 5.76) compared with TIVA (9.83 ± 7.58) and multimodal anesthesia (8.48 ± 5.83). No significant differences were observed in discharge disposition or 30-day mortality.</p>\n\n<p><strong>Conclusion</strong>: Among patients undergoing head and neck free flap reconstruction, anesthetic modality was significantly associated with differences in ICU admission rates and ICU length of stay, with volatile-only anesthesia linked to higher ICU utilization and longer ICU stays. Although overall hospital length of stay and 30-day mortality did not differ significantly between groups, a trend toward prolonged hospitalization was observed in the volatile-only cohort. These findings suggest that anesthetic approach may influence postoperative resource utilization and highlight the need for prospective studies to inform anesthetic protocols to improve microsurgical outcomes and reduce ICU burden.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153750--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S553",
      "content_id": "154185",
      "abstract_number": "S553",
      "poster_number": "",
      "title": "Patterns and techniques for detecting free flap compromise",
      "summary": "In this early dataset, free flap compromise was most often detected clinically rather than through doppler signal change, and recognition most frequently occurred outside designated monitoring intervals. Residents were the primary detectors of compromise, although the majority of events (61%) were identified by non-resident personnel. Ongoing data accrual will enable more robust characterization of detection...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154185",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Caroline Rozzo, BS",
      "presenter": "Caroline Rozzo, BS",
      "authors": "Amrita Bonthu, MS 1 ; Caroline Rozzo, BS 1 ; Claire M Gleadhill, MD 2 ; Rod P Rezaee, MD 2 ; Madelyn N Stevens, MD 2",
      "normalized_authors": [
        "Amrita Bonthu",
        "Caroline Rozzo",
        "Claire M Gleadhill",
        "Rod P Rezaee",
        "Madelyn N Stevens"
      ],
      "affiliations": [
        "Case Western Reserve School of Medicine",
        "University Hospitals Cleveland Medical Center"
      ],
      "normalized_institutions": [
        "Case Western Reserve School of Medicine",
        "University Hospitals Cleveland Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 436,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Amrita Bonthu, MS 1 ; Caroline Rozzo, BS 1 ; Claire M Gleadhill, MD 2 ; Rod P Rezaee, MD 2 ; Madelyn N Stevens, MD 2",
        "Affiliations": "1 Case Western Reserve School of Medicine; 2 University Hospitals Cleveland Medical Center",
        "Background": "Free tissue transfer remains the cornerstone of complex head and neck reconstruction. Although flap failure is uncommon, its consequences can include increased morbidity, prolonged hospitalization, and costly interventions. Continuous postoperative monitoring aims to detect early compromise and maximize salvage rates; however, current surveillance practices are highly variable, often subjective, and dependent on provider experience. Despite the clinical importance of early recognition, there is limited literature detailing who detects compromise, when it is recognized, and which features most frequently prompt intervention. This study seeks to clarify patterns of free flap compromise detection and the circumstances and techniques surrounding initial recognition.",
        "Methods": "An institutional review board–approved retrospective review was conducted using billing records to identify all patients undergoing free flap reconstruction at a single institution between October 2023 and November 2025. Operative reports and clinical documentation were examined to determine episodes of flap compromise and to extract demographic, surgical, and detection-related data.",
        "Results": "Preliminary analysis identified 286 patients undergoing free flap reconstruction, of which 14 patients had 19 compromise events, with 2 excluded due to incomplete documentation. All patients received an implantable arterial Doppler and standard postoperative monitoring (q4–6 hour resident flap checks, q1–2 hour nursing assessments). The cohort was 35.7% male and 64.3% female, with a mean age of 64.1 ± 10.4 years. Flap types included latissimus dorsi (35.3%), radial forearm (23.5%), scapula (11.8%), anterolateral thigh (11.8%), and gracilis (5.9%); most had an externalized skin paddle.",
        "Abstract": "Detection of compromise was most commonly made by residents (38.9%), followed by attendings (27.8%), the head and neck fellow (22.2%), nurses (5.6%), or family members (5.6%). Events were more frequently identified outside scheduled flap assessments. Clinical exam findings predominated as triggers for intervention, including skin paddle color change (88.2%), swelling (35.3%), abnormal pinprick bleeding (35.3%), and loss of implantable Doppler signal (23.5%). Most compromised flaps underwent operative exploration (88.9%) with high salvage rates; partial failures comprised 94.4% of cases. Median time to identification of flap compromise was 15.4 hours postoperatively (IQR 2.2–101.5 hours), and median time from detection to initiating intervention was 133 minutes (IQR 100–149 minutes). View in Agenda and Add to Schedule",
        "Conclusion": "In this early dataset, free flap compromise was most often detected clinically rather than through doppler signal change, and recognition most frequently occurred outside designated monitoring intervals. Residents were the primary detectors of compromise, although the majority of events (61%) were identified by non-resident personnel. Ongoing data accrual will enable more robust characterization of detection patterns and further development of monitoring protocols."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Patterns and techniques for detecting free flap compromise</span>. Amrita Bonthu, MS<sup>1</sup>; <u>Caroline Rozzo, BS</u><sup>1</sup>; Claire M Gleadhill, MD<sup>2</sup>; Rod P Rezaee, MD<sup>2</sup>; Madelyn N Stevens, MD<sup>2</sup>. <sup>1</sup>Case Western Reserve School of Medicine; <sup>2</sup>University Hospitals Cleveland Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Free tissue transfer remains the cornerstone of complex head and neck reconstruction. Although flap failure is uncommon, its consequences can include increased morbidity, prolonged hospitalization, and costly interventions. Continuous postoperative monitoring aims to detect early compromise and maximize salvage rates; however, current surveillance practices are highly variable, often subjective, and dependent on provider experience. Despite the clinical importance of early recognition, there is limited literature detailing who detects compromise, when it is recognized, and which features most frequently prompt intervention. This study seeks to clarify patterns of free flap compromise detection and the circumstances and techniques surrounding initial recognition.</p>\n\n<p><strong>Methods: </strong>An institutional review board–approved retrospective review was conducted using billing records to identify all patients undergoing free flap reconstruction at a single institution between October 2023 and November 2025. Operative reports and clinical documentation were examined to determine episodes of flap compromise and to extract demographic, surgical, and detection-related data.</p>\n\n<p><strong>Results: </strong>Preliminary analysis identified 286 patients undergoing free flap reconstruction, of which 14 patients had 19 compromise events, with 2 excluded due to incomplete documentation. All patients received an implantable arterial Doppler and standard postoperative monitoring (q4–6 hour resident flap checks, q1–2 hour nursing assessments). The cohort was 35.7% male and 64.3% female, with a mean age of 64.1 ± 10.4 years. Flap types included latissimus dorsi (35.3%), radial forearm (23.5%), scapula (11.8%), anterolateral thigh (11.8%), and gracilis (5.9%); most had an externalized skin paddle.</p>\n\n<p>Detection of compromise was most commonly made by residents (38.9%), followed by attendings (27.8%), the head and neck fellow (22.2%), nurses (5.6%), or family members (5.6%). Events were more frequently identified outside scheduled flap assessments. Clinical exam findings predominated as triggers for intervention, including skin paddle color change (88.2%), swelling (35.3%), abnormal pinprick bleeding (35.3%), and loss of implantable Doppler signal (23.5%). Most compromised flaps underwent operative exploration (88.9%) with high salvage rates; partial failures comprised 94.4% of cases. Median time to identification of flap compromise was 15.4 hours postoperatively (IQR 2.2–101.5 hours), and median time from detection to initiating intervention was 133 minutes (IQR 100–149 minutes).</p>\n\n<p><strong>Conclusion: </strong>In this early dataset, free flap compromise was most often detected clinically rather than through doppler signal change, and recognition most frequently occurred outside designated monitoring intervals. Residents were the primary detectors of compromise, although the majority of events (61%) were identified by non-resident personnel. Ongoing data accrual will enable more robust characterization of detection patterns and further development of monitoring protocols.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154185--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S554",
      "content_id": "154759",
      "abstract_number": "S554",
      "poster_number": "",
      "title": "Late Surgical Revisions After Head and Neck Free-Flap Reconstruction: Clinical Predictors and Implications for Long-Term Surveillance",
      "summary": "While most reconstructive studies emphasize early flap outcomes, this analysis provides critical insight into the underrecognized problem of late surgical revision. Nearly one in five patients required delayed reoperation, most commonly for bulky or infected flaps. Prolonged hospitalization emerged as a predictor of late revision, potentially serving as a surrogate for early postoperative complexity. These...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154759",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jobran Mansour",
      "presenter": "Jobran Mansour",
      "authors": "Hen Chaushu 1 ; Roee Domany 2 ; Nidal Muhanna 1 ; Jobran Mansour 3",
      "normalized_authors": [
        "Hen Chaushu",
        "Roee Domany",
        "Nidal Muhanna",
        "Jobran Mansour"
      ],
      "affiliations": [
        "Tel Aviv Sourasky Medical Center",
        "Te Aviv University",
        "Fox Chase Cancer Cente, Temple Health, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "Tel Aviv Sourasky Medical Center",
        "Te Aviv University",
        "Fox Chase Cancer Cente, Temple Health, Philadelphia, PA"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 398,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Hen Chaushu 1 ; Roee Domany 2 ; Nidal Muhanna 1 ; Jobran Mansour 3",
        "Affiliations": "1 Tel Aviv Sourasky Medical Center; 2 Te Aviv University; 3 Fox Chase Cancer Cente, Temple Health, Philadelphia, PA",
        "Introduction": "Free-flap reconstruction is a cornerstone of head and neck oncologic surgery, offering reliable restoration of form and function. While flap survival rates are high, a notable subset of patients experience late complications that necessitate revision surgery more than 30 days postoperatively. These delayed revisions may result from functional issues, infections, or aesthetic concerns, yet their predictors remain poorly defined. Understanding which patients are at highest risk may guide surgical planning, optimize follow-up strategies, and improve long-term outcomes. This study aimed to identify clinical and perioperative predictors of late revision following head and neck free-flap reconstruction.",
        "Methods": "We retrospectively analyzed 196 consecutive patients who underwent free-flap reconstruction for head and neck malignancies between 2003-2023 at a tertiary academic cancer center. Late revision was defined as any return to the operating room for flap-related intervention occurring more than 30 days after the index surgery. Demographic, oncologic, and perioperative variables were collected. Kaplan–Meier survival analysis with log-rank testing was performed to assess univariate associations, and variables with p < 0.1 were entered into a multivariable Cox proportional hazards regression model to identify independent predictors of late revision.",
        "Results": "Late revision occurred in 36 patients (18.4%). The most common indications were bulky flap causing functional impairment (n=13), infection (n=8), fistula (n=5), dental rehabilitation (n=4), aesthetic contouring (n=4), and oncologic recurrence (n=2). Univariate analysis identified prior chemotherapy (p=0.024) and preoperative anticoagulation (p=0.017) as significantly associated with increased revision risk. In multivariable analysis, prolonged hospitalization, measured as days to discharge following the index surgery, was the only independent predictor (hazard ratio [HR] 1.045 per day; 95% confidence interval [CI] 1.017–1.075; p=0.002). Other factors, including age, sex, body mass index (BMI), ASA class, smoking status, tumor site, previous radiotherapy, and medical comorbidities, were not statistically significant.",
        "Conclusion": "While most reconstructive studies emphasize early flap outcomes, this analysis provides critical insight into the underrecognized problem of late surgical revision. Nearly one in five patients required delayed reoperation, most commonly for bulky or infected flaps. Prolonged hospitalization emerged as a predictor of late revision, potentially serving as a surrogate for early postoperative complexity. These findings highlight the need for long-term surveillance, proactive patient counseling, and optimization of perioperative care to reduce delayed morbidity. Late revision must be acknowledged as a meaningful endpoint in reconstructive success.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Late Surgical Revisions After Head and Neck Free-Flap Reconstruction: Clinical Predictors and Implications for Long-Term Surveillance</span>. Hen Chaushu<sup>1</sup>; Roee Domany<sup>2</sup>; Nidal Muhanna<sup>1</sup>; <u>Jobran Mansour</u><sup>3</sup>. <sup>1</sup>Tel Aviv Sourasky Medical Center; <sup>2</sup>Te Aviv University; <sup>3</sup>Fox Chase Cancer Cente, Temple Health, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Free-flap reconstruction is a cornerstone of head and neck oncologic surgery, offering reliable restoration of form and function. While flap survival rates are high, a notable subset of patients experience late complications that necessitate revision surgery more than 30 days postoperatively. These delayed revisions may result from functional issues, infections, or aesthetic concerns, yet their predictors remain poorly defined. Understanding which patients are at highest risk may guide surgical planning, optimize follow-up strategies, and improve long-term outcomes. This study aimed to identify clinical and perioperative predictors of late revision following head and neck free-flap reconstruction.</p>\n\n<p><strong>Methods: </strong>We retrospectively analyzed 196 consecutive patients who underwent free-flap reconstruction for head and neck malignancies between 2003-2023 at a tertiary academic cancer center. Late revision was defined as any return to the operating room for flap-related intervention occurring more than 30 days after the index surgery. Demographic, oncologic, and perioperative variables were collected. Kaplan–Meier survival analysis with log-rank testing was performed to assess univariate associations, and variables with p < 0.1 were entered into a multivariable Cox proportional hazards regression model to identify independent predictors of late revision.</p>\n\n<p><strong>Results: </strong>Late revision occurred in 36 patients (18.4%). The most common indications were bulky flap causing functional impairment (n=13), infection (n=8), fistula (n=5), dental rehabilitation (n=4), aesthetic contouring (n=4), and oncologic recurrence (n=2). Univariate analysis identified prior chemotherapy (p=0.024) and preoperative anticoagulation (p=0.017) as significantly associated with increased revision risk. In multivariable analysis, prolonged hospitalization, measured as days to discharge following the index surgery, was the only independent predictor (hazard ratio [HR] 1.045 per day; 95% confidence interval [CI] 1.017–1.075; p=0.002). Other factors, including age, sex, body mass index (BMI), ASA class, smoking status, tumor site, previous radiotherapy, and medical comorbidities, were not statistically significant.</p>\n\n<p><strong>Conclusion: </strong>While most reconstructive studies emphasize early flap outcomes, this analysis provides critical insight into the underrecognized problem of late surgical revision. Nearly one in five patients required delayed reoperation, most commonly for bulky or infected flaps. Prolonged hospitalization emerged as a predictor of late revision, potentially serving as a surrogate for early postoperative complexity. These findings highlight the need for long-term surveillance, proactive patient counseling, and optimization of perioperative care to reduce delayed morbidity. Late revision must be acknowledged as a meaningful endpoint in reconstructive success.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154759--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S555",
      "content_id": "154420",
      "abstract_number": "S555",
      "poster_number": "",
      "title": "A collaborative hybrid team-based approach to head and neck oncologic and reconstructive surgery improves operative efficiency and reduces postoperative complications in patients undergoing free",
      "summary": "The findings suggest that hybrid reconstructive teams for complex head and neck microvascular reconstruction may decrease complication rates including overall complications and rates of return to the OR with subsequent decreased length of hospital stay and improvement in the rates of timely radiation therapy. Hybrid reconstructive model likely increases operative efficiency and optimizes intraoperative decision...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154420",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chelsea Gelboin Burkhart, MD",
      "presenter": "Chelsea Gelboin Burkhart, MD",
      "authors": "Chelsea Gelboin Burkhart, MD ; Anthony DiPalma, BS; Amaan Rahman, BS; Anthony DiPalma, BS; Joshua E Smith, MD; Steven Chinn, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Matthew E Spector, MD",
      "normalized_authors": [
        "Chelsea Gelboin Burkhart",
        "Anthony DiPalma",
        "Amaan Rahman",
        "Joshua E Smith",
        "Steven Chinn",
        "Kevin Contrera",
        "Shaum Sridharan",
        "Matthew E Spector"
      ],
      "affiliations": [
        "University of Pittsburgh"
      ],
      "normalized_institutions": [
        "University of Pittsburgh"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 476,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Chelsea Gelboin Burkhart, MD ; Anthony DiPalma, BS; Amaan Rahman, BS; Anthony DiPalma, BS; Joshua E Smith, MD; Steven Chinn, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Matthew E Spector, MD",
        "Affiliations": "University of Pittsburgh",
        "Introduction": "Collaborative hybrid team-based approaches to head and neck reconstructive surgery have previously been shown to reduce operative time with differing effects on postoperative complications. While many groups use an “ablative surgeon” and “reconstructive surgeon” model, an important distinction is made in the new era of head and neck surgical training in which both surgeons have ablative and reconstructive training, allowing for the creation of a collaborative hybrid reconstructive team with a greater overlap of surgical care between surgeons. The objective of this study was to compare perioperative patient outcomes and complications, between patients who underwent hybrid versus standard two-team reconstructive surgical delivery models.",
        "Methods": "Retrospective data was collected on patients undergoing head and neck reconstructive surgery in an academic tertiary medical center. A total of 818 patients were included from November 2017 until May 2025.",
        "Abstract": "Patient data collected included age, sex, Charleston comorbidity index (CCI), tumor stage, history of chemotherapy or radiation. Outcomes measures included intraoperative time, length of stay and length of ICU stay, intraoperative fluid usage, postoperative complication rates and time to radiation therapy. Complications recorded included partial or total flap failure, dehiscence, wound infection, fistula and hematoma or seroma. Outcomes were compared between the collaborative two-surgeon surgery groups versus a single reconstructive surgeon. View in Agenda and Add to Schedule",
        "Results": "Among a total of 815 patients, the standard two-team model with a single reconstructive surgeon group comprised 480 patients and hybrid 2 reconstructive surgeon group, 335 patients. Median age was 64 (range 16-91) and 69% were male. Median CCI was 2, with high CCI (>3) in 49% of patients. Patients had prior radiation or chemotherapy in 17% of single-surgeon cases versus 25% in two-surgeon cases. Osseous flaps comprised 19% of the single-surgeon cohort and 14% of the two-surgeon cohort (p=0.3); soft tissue flap selection differed slightly between groups primarily due to a larger number of parascapular flaps in the two-surgeon group. Between the single-surgeon vs two-surgeon cohorts, there were significant decreases in rates of postoperative complications (25% vs 10%, p<0.0001) and return trips to the operative room (21% vs 11%, p=0.0001). Both OR time and intraoperative fluid usage were reduced in the hybrid cohort (402 min vs 618 min, p<0.0001; 3.2 L vs 5.9 L, p<0.0001). Patients in the hybrid surgery group were almost 2 times more likely to receive radiation within 6 weeks than in one-surgeon group. (p<0.01). There was no difference in 30-day readmission rates between cohorts.",
        "Conclusions": "The findings suggest that hybrid reconstructive teams for complex head and neck microvascular reconstruction may decrease complication rates including overall complications and rates of return to the OR with subsequent decreased length of hospital stay and improvement in the rates of timely radiation therapy. Hybrid reconstructive model likely increases operative efficiency and optimizes intraoperative decision making, contributing to improved patient outcomes."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A collaborative hybrid team-based approach to head and neck oncologic and reconstructive surgery improves operative efficiency and reduces postoperative complications in patients undergoing free flap reconstruction</span>. <u>Chelsea Gelboin Burkhart, MD</u>; Anthony DiPalma, BS; Amaan Rahman, BS; Anthony DiPalma, BS; Joshua E Smith, MD; Steven Chinn, MD; Kevin Contrera, MD; Shaum Sridharan, MD; Matthew E Spector, MD. University of Pittsburgh<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Collaborative hybrid team-based approaches to head and neck reconstructive surgery have previously been shown to reduce operative time with differing effects on postoperative complications. While many groups use an “ablative surgeon” and “reconstructive surgeon” model, an important distinction is made in the new era of head and neck surgical training in which both surgeons have ablative and reconstructive training, allowing for the creation of a collaborative hybrid reconstructive team with a greater overlap of surgical care between surgeons. The objective of this study was to compare perioperative patient outcomes and complications, between patients who underwent hybrid versus standard two-team reconstructive surgical delivery models.</p>\n\n<p><strong>Methods: </strong>Retrospective data was collected on patients undergoing head and neck reconstructive surgery in an academic tertiary medical center. A total of 818 patients were included from November 2017 until May 2025.</p>\n\n<p>Patient data collected included age, sex, Charleston comorbidity index (CCI), tumor stage, history of chemotherapy or radiation. Outcomes measures included intraoperative time, length of stay and length of ICU stay, intraoperative fluid usage, postoperative complication rates and time to radiation therapy. Complications recorded included partial or total flap failure, dehiscence, wound infection, fistula and hematoma or seroma. Outcomes were compared between the collaborative two-surgeon surgery groups versus a single reconstructive surgeon.</p>\n\n<p><strong>Results: </strong>Among a total of 815 patients, the standard two-team model with a single reconstructive surgeon group comprised 480 patients and hybrid 2 reconstructive surgeon group, 335 patients. Median age was 64 (range 16-91) and 69% were male. Median CCI was 2, with high CCI (>3) in 49% of patients. Patients had prior radiation or chemotherapy in 17% of single-surgeon cases versus 25% in two-surgeon cases. Osseous flaps comprised 19% of the single-surgeon cohort and 14% of the two-surgeon cohort (p=0.3); soft tissue flap selection differed slightly between groups primarily due to a larger number of parascapular flaps in the two-surgeon group. Between the single-surgeon vs two-surgeon cohorts, there were significant decreases in rates of postoperative complications (25% vs 10%, p<0.0001) and return trips to the operative room (21% vs 11%, p=0.0001). Both OR time and intraoperative fluid usage were reduced in the hybrid cohort (402 min vs 618 min, p<0.0001; 3.2 L vs 5.9 L, p<0.0001). Patients in the hybrid surgery group were almost 2 times more likely to receive radiation within 6 weeks than in one-surgeon group. (p<0.01). There was no difference in 30-day readmission rates between cohorts.</p>\n\n<p><strong>Conclusions: </strong>The findings suggest that hybrid reconstructive teams for complex head and neck microvascular reconstruction may decrease complication rates including overall complications and rates of return to the OR with subsequent decreased length of hospital stay and improvement in the rates of timely radiation therapy. Hybrid reconstructive model likely increases operative efficiency and optimizes intraoperative decision making, contributing to improved patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154420--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S556",
      "content_id": "153570",
      "abstract_number": "S556",
      "poster_number": "",
      "title": "Site-Specific Associations of Nicotine Dependence and Postoperative Outcomes in Head and Neck Free Flap Reconstruction",
      "summary": "Among patients undergoing reconstructive surgery for oral cavity cancers, nicotine dependence was significantly associated with increased rates of chronic pain (25.97% vs 21.89%, p=0.0040), opioid use (3.25% vs 1.91%, p=0.0022), and respiratory complications (20.79% vs 16.52%, p=0.0007). No significant differences were observed for salivary gland, oropharyngeal, hypopharyngeal, or nasopharyngeal cancers. Among...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153570",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shivani L Lotlikar, BA, BS",
      "presenter": "Shivani L Lotlikar, BA, BS",
      "authors": "Shivani L Lotlikar, BA, BS ; Sudhanvan Iyer, BS; Orly Coblens, MD",
      "normalized_authors": [
        "Shivani L Lotlikar",
        "Sudhanvan Iyer",
        "Orly Coblens"
      ],
      "affiliations": [
        "The University of Texas Medical Branch"
      ],
      "normalized_institutions": [
        "The University of Texas Medical Branch"
      ],
      "session_type": "Proffered Paper",
      "track": "Functional Outcomes / Quality",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Functional Outcomes / Quality"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shivani L Lotlikar, BA, BS ; Sudhanvan Iyer, BS; Orly Coblens, MD",
        "Affiliations": "The University of Texas Medical Branch",
        "Background": "Head and neck cancer patients often have a high prevalence of nicotine dependence at the time of diagnosis. Many of them undergo major head and neck surgeries that include free flap reconstructive procedures. Nicotine dependence is linked to heightened postoperative pain, increased opioid requirements, and greater respiratory complications, but it is unclear whether these effects vary by cancer site or whether flap selection modifies postoperative risk. Therefore, this subset of head and neck cancer patients is an important population to evaluate as it pertains to postoperative risk. Additionally, osteocutaneous (OCF), myocutaneous (MCF), and fascial (FF) flaps differ in bone vs. soft-tissue composition, which may influence healing, pain, and airway stability. This study examined (1) whether nicotine dependence affects postoperative outcomes across cancer subsites requiring flap reconstruction, and (2) whether flap type (OF vs MF vs FF) influences these outcomes in nicotine-dependent patients.",
        "Methods": "A retrospective cohort study was conducted using the TriNetX Research Network. Adult patients undergoing reconstruction for oral cavity, salivary gland, pharyngeal, and laryngeal cancers were divided into those with nicotine dependence (ICD-10 F17) and those without. Outcomes included: new chronic pain (G89), opioid use disorder (F11.2/F11.9), postoperative respiratory complications (J98), outpatient follow-up (G0463), and opioid poisoning (T40.2). Propensity score matching (1:1) was performed on demographics and comorbidities including COPD, diabetes, depression, anxiety, alcohol/substance use, chronic pain, and opioid-related disorders. Within each nicotine subgroup, an additional matched comparison evaluated OCF vs MCF vs FF flaps, excluding patients who received multiple flap types. Risk differences, risk ratios, and 95% confidence intervals were calculated.",
        "Results": "Among patients undergoing reconstructive surgery for oral cavity cancers, nicotine dependence was significantly associated with increased rates of chronic pain (25.97% vs 21.89%, p=0.0040), opioid use (3.25% vs 1.91%, p=0.0022), and respiratory complications (20.79% vs 16.52%, p=0.0007). No significant differences were observed for salivary gland, oropharyngeal, hypopharyngeal, or nasopharyngeal cancers. Among nicotine-dependent patients, flap type was not associated with differences in postoperative outcomes. Between OCF, MCF, and FF, there were no significant differences in chronic pain, opioid use, respiratory complications, and outpatient follow-up. Similarly, among patients without nicotine dependence, OCF vs MCF vs FF reconstruction showed no significant differences in chronic pain, opioid use, respiratory complications, outpatient follow-up, or opioid poisoning in a 20-year follow-up period.",
        "Discussion": "Nicotine dependence significantly increased postoperative pain, opioid use, and respiratory complications among oral cavity cancer patients undergoing free flap reconstruction. However, across both nicotine-dependent and non-dependent groups, flap type (OCF vs MCF vs FF) did not influence postoperative outcomes These findings suggest that the impact of nicotine dependence on postoperative outcomes may vary by cancer site, likely reflecting differences in procedure-related factors and airway vulnerability rather than reconstructive technique or flap-specific healing demands. Additionally, due to the absence of a significant difference in post-operative outcomes among flap types, surgeons do not need to prioritize flap type when considering reconstructive options for oncologic procedures. Targeted perioperative strategies, including smoking cessation and enhanced pain and respiratory management, may improve outcomes for nicotine-dependent oral cancer patients undergoing reconstructive surgery.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Site-Specific Associations of Nicotine Dependence and Postoperative Outcomes in Head and Neck Free Flap Reconstruction</span>. <u>Shivani L Lotlikar, BA, BS</u>; Sudhanvan Iyer, BS; Orly Coblens, MD. The University of Texas Medical Branch<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck cancer patients often have a high prevalence of nicotine dependence at the time of diagnosis. Many of them undergo major head and neck surgeries that include free flap reconstructive procedures. Nicotine dependence is linked to heightened postoperative pain, increased opioid requirements, and greater respiratory complications, but it is unclear whether these effects vary by cancer site or whether flap selection modifies postoperative risk. Therefore, this subset of head and neck cancer patients is an important population to evaluate as it pertains to postoperative risk. Additionally, osteocutaneous (OCF), myocutaneous (MCF), and fascial (FF) flaps differ in bone vs. soft-tissue composition, which may influence healing, pain, and airway stability. This study examined (1) whether nicotine dependence affects postoperative outcomes across cancer subsites requiring flap reconstruction, and (2) whether flap type (OF vs MF vs FF) influences these outcomes in nicotine-dependent patients. </p>\n\n<p><strong>Methods: </strong>A retrospective cohort study was conducted using the TriNetX Research Network. Adult patients undergoing reconstruction for oral cavity, salivary gland, pharyngeal, and laryngeal cancers were divided into those with nicotine dependence (ICD-10 F17) and those without. Outcomes included: new chronic pain (G89), opioid use disorder (F11.2/F11.9), postoperative respiratory complications (J98), outpatient follow-up (G0463), and opioid poisoning (T40.2). Propensity score matching (1:1) was performed on demographics and comorbidities including COPD, diabetes, depression, anxiety, alcohol/substance use, chronic pain, and opioid-related disorders. Within each nicotine subgroup, an additional matched comparison evaluated OCF vs MCF vs FF flaps, excluding patients who received multiple flap types. Risk differences, risk ratios, and 95% confidence intervals were calculated.</p>\n\n<p><strong>Results: </strong>Among patients undergoing reconstructive surgery for oral cavity cancers, nicotine dependence was significantly associated with increased rates of chronic pain (25.97% vs 21.89%, p=0.0040), opioid use (3.25% vs 1.91%, p=0.0022), and respiratory complications (20.79% vs 16.52%, p=0.0007). No significant differences were observed for salivary gland, oropharyngeal, hypopharyngeal, or nasopharyngeal cancers. Among nicotine-dependent patients, flap type was not associated with differences in postoperative outcomes. Between OCF, MCF, and FF, there were no significant differences in chronic pain, opioid use, respiratory complications, and outpatient follow-up. Similarly, among patients without nicotine dependence, OCF vs MCF vs FF reconstruction showed no significant differences in chronic pain, opioid use, respiratory complications, outpatient follow-up, or opioid poisoning in a 20-year follow-up period.</p>\n\n<p><strong>Discussion: </strong>Nicotine dependence significantly increased postoperative pain, opioid use, and respiratory complications among oral cavity cancer patients undergoing free flap reconstruction. However, across both nicotine-dependent and non-dependent groups, flap type (OCF vs MCF vs FF) did not influence postoperative outcomes These findings suggest that the impact of nicotine dependence on postoperative outcomes may vary by cancer site, likely reflecting differences in procedure-related factors and airway vulnerability rather than reconstructive technique or flap-specific healing demands. Additionally, due to the absence of a significant difference in post-operative outcomes among flap types, surgeons do not need to prioritize flap type when considering reconstructive options for oncologic procedures. Targeted perioperative strategies, including smoking cessation and enhanced pain and respiratory management, may improve outcomes for nicotine-dependent oral cancer patients undergoing reconstructive surgery. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153570--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S557",
      "content_id": "154147",
      "abstract_number": "S557",
      "poster_number": "",
      "title": "A Novel Skin Graft Technique to Minimize Donor Site Morbidity for Latissimus Free Flap Reconstruction of the Head and Neck",
      "summary": "Harvesting STSGs from redundant back skin after latissimus free flap reconstruction provides adequate tissue coverage with low rates of seroma and wound dehiscence. Future work will compare this approach with a historical cohort of patients who underwent traditional thigh STSG harvest to determine whether this technique reduces donor-site morbidity.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154147",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Shradha Sreeprakash, BS",
      "presenter": "Shradha Sreeprakash, BS",
      "authors": "Shradha Sreeprakash, BS ; Sida Chen, MD; Zain Rizvi, MD; Brittany Barber, MD, MS; Emily Marchiano, MD; Neal Futran, MD, DMD; Rocco Ferrandino, MD, MSCR",
      "normalized_authors": [
        "Shradha Sreeprakash",
        "Sida Chen",
        "Zain Rizvi",
        "Brittany Barber",
        "Emily Marchiano",
        "Neal Futran",
        "Rocco Ferrandino, MSCR"
      ],
      "affiliations": [
        "University of Washington School of Medicine"
      ],
      "normalized_institutions": [
        "University of Washington School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 318,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Shradha Sreeprakash, BS ; Sida Chen, MD; Zain Rizvi, MD; Brittany Barber, MD, MS; Emily Marchiano, MD; Neal Futran, MD, DMD; Rocco Ferrandino, MD, MSCR",
        "Affiliations": "University of Washington School of Medicine",
        "Background": "The latissimus free flap remains a workhorse reconstructive technique for large cutaneous scalp defects. Split-thickness skin grafts (STSGs), typically harvested from the thigh, are frequently applied to the muscle to facilitate epithelialization. However, thigh graft harvest is associated with donor-site morbidity including pain, scarring, infection, and delayed re-epithelialization. We present a series of patients in whom STSGs were harvested from redundant back skin, providing adequate coverage while minimizing donor-site morbidity.",
        "Objective": "To evaluate donor-site morbidity associated with STSGs harvested from redundant back skin during latissimus free flap reconstruction.",
        "Methods": "We conducted a retrospective case series of 15 patients who underwent latissimus free flap reconstruction of the scalp followed by STSG harvested from redundant back skin. Flaps were harvested in either the supine or lateral decubitus position. After flap harvest, redundant skin was excised from the donor site to permit primary closure. On a side table, a Padgett dermatome was used to obtain an STSG from the excised skin. Donor sites were closed primarily, and skin grafts were meshed and inset over the muscle flap. Charts were reviewed for graft size, seroma or hematoma formation, donor-site complications, narcotic consumption, and other clinical outcomes. Results are reported descriptively using non-parametric testing for continuous variables and proportions for categorical variables.",
        "Results": "Fifteen patients underwent latissimus free flap reconstruction of the head and neck. Median graft size was 132 cm² (range 40–200 cm²). Postoperative seromas requiring drainage occurred in 13% of patients. One patient experienced wound dehiscence requiring local wound care. Pain was well tolerated, with a median opioid consumption of 11.1 morphine milligram equivalents per day.",
        "Conclusions": "Harvesting STSGs from redundant back skin after latissimus free flap reconstruction provides adequate tissue coverage with low rates of seroma and wound dehiscence. Future work will compare this approach with a historical cohort of patients who underwent traditional thigh STSG harvest to determine whether this technique reduces donor-site morbidity.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Novel Skin Graft Technique to Minimize Donor Site Morbidity for Latissimus Free Flap Reconstruction of the Head and Neck</span>. <u>Shradha Sreeprakash, BS</u>; Sida Chen, MD; Zain Rizvi, MD; Brittany Barber, MD, MS; Emily Marchiano, MD; Neal Futran, MD, DMD; Rocco Ferrandino, MD, MSCR. University of Washington School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The latissimus free flap remains a workhorse reconstructive technique for large cutaneous scalp defects. Split-thickness skin grafts (STSGs), typically harvested from the thigh, are frequently applied to the muscle to facilitate epithelialization. However, thigh graft harvest is associated with donor-site morbidity including pain, scarring, infection, and delayed re-epithelialization. We present a series of patients in whom STSGs were harvested from redundant back skin, providing adequate coverage while minimizing donor-site morbidity.</p>\n\n<p><strong>Objective: </strong>To evaluate donor-site morbidity associated with STSGs harvested from redundant back skin during latissimus free flap reconstruction.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective case series of 15 patients who underwent latissimus free flap reconstruction of the scalp followed by STSG harvested from redundant back skin. Flaps were harvested in either the supine or lateral decubitus position. After flap harvest, redundant skin was excised from the donor site to permit primary closure. On a side table, a Padgett dermatome was used to obtain an STSG from the excised skin. Donor sites were closed primarily, and skin grafts were meshed and inset over the muscle flap. Charts were reviewed for graft size, seroma or hematoma formation, donor-site complications, narcotic consumption, and other clinical outcomes. Results are reported descriptively using non-parametric testing for continuous variables and proportions for categorical variables.</p>\n\n<p><strong>Results:</strong> Fifteen patients underwent latissimus free flap reconstruction of the head and neck. Median graft size was 132 cm² (range 40–200 cm²). Postoperative seromas requiring drainage occurred in 13% of patients. One patient experienced wound dehiscence requiring local wound care. Pain was well tolerated, with a median opioid consumption of 11.1 morphine milligram equivalents per day.</p>\n\n<p><strong>Conclusions:</strong> Harvesting STSGs from redundant back skin after latissimus free flap reconstruction provides adequate tissue coverage with low rates of seroma and wound dehiscence. Future work will compare this approach with a historical cohort of patients who underwent traditional thigh STSG harvest to determine whether this technique reduces donor-site morbidity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154147--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S558",
      "content_id": "152239",
      "abstract_number": "S558",
      "poster_number": "",
      "title": "Comparison of Patient Outcomes between a Combined Transoral–Submandibular Approach and the Traditional Transcervical Approach in Free Flap Reconstruction for Mandibular Osteoradionecrosis",
      "summary": "The modified transoral-submandibular FFF approach is a reliable option for reconstruction of segmental mandibular defects due to ORN and has lower rates of both overall and late complications when compared with the traditional transcervical approach.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152239",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jennifer S Lin, BS",
      "presenter": "Jennifer S Lin, BS",
      "authors": "Jennifer S Lin, BS 1 ; Gabrielle L Wolter, MD 2 ; Ray Y Wang, MD 2 ; N. Eddie Liou, MD 2 ; Andrew T Huang, MD 2",
      "normalized_authors": [
        "Jennifer S Lin",
        "Gabrielle L Wolter",
        "Ray Y Wang",
        "N. Eddie Liou",
        "Andrew T Huang"
      ],
      "affiliations": [
        "Baylor College of Medicine, Houston, TX, USA",
        "Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine, Houston, TX, USA",
        "Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 511,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Importance and Objective",
        "Design, Setting, and Participants",
        "Main Outcomes",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Jennifer S Lin, BS 1 ; Gabrielle L Wolter, MD 2 ; Ray Y Wang, MD 2 ; N. Eddie Liou, MD 2 ; Andrew T Huang, MD 2",
        "Affiliations": "1 Baylor College of Medicine, Houston, TX, USA; 2 Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA",
        "Importance and Objective": "Jaw osteoradionecrosis (ORN) is a potential complication of head and neck radiation therapy that can severely impair speech, mastication, and swallowing. Following failure of nonsurgical management and surgical debridement, free fibula flap (FFF)reconstruction remains the gold standard treatment for segmental mandibular defects. However, the traditional transcervical approach has been associated with wound healing complications, with reported incidences ranging from 8% to 43%. Our team previously described a modified contralateral transoral–submandibular approach designed to reduce these complications by avoiding dissection through irradiated fields. This study represents the first outcomes comparison between the modified transoral–submandibular and traditional transcervical FFF reconstruction techniques.",
        "Design, Setting, and Participants": "A retrospective cohort study was conducted at tertiary care hospitals affiliated with multiple academic institutions between January 2015 and December 2024. Patients with mandibular ORN who underwent FFF reconstruction using either the modified or traditional approach were included.",
        "Main Outcomes": "The primary outcomes were postoperative complication rates and frequency of required revision surgery or hardware removal.",
        "Results": "16 patients were included, with 6 undergoing the traditional approach and 10 undergoing the modified approach. The two groups were comparable in age, sex, comorbidities, tobacco and alcohol history, cancer histology, T stage, and subsite. Surgery with adjuvant radiation was more common as the primary treatment in the traditional than modified group (66.7% vs 10.0%; 95% CI, -85.5% to –6.2%), while the distribution of other treatment modalities did not differ significantly. H-class mandibular defects were more frequent in the modified group (70% vs 0%; 95% CI, 19.0% to 89.3%), but the groups were otherwise similar across remaining HCL classifications. Other preoperative characteristics, including primary radiotherapy site, re-irradiation rates, time from radiotherapy completion to ORN diagnosis, and presence of ORN-related fistulas or pathologic fractures, were comparable between groups.",
        "Abstract": "The median rate of revision surgery or hardware removal was significantly lower in the modified group (20%) compared with the traditional group (83.3%) (95% CI, -88.7% to –11.3%). Median follow-up duration was also shorter in the modified group (7 [IQR, 5 to 11] months vs 29 [IQR, 16 to 40] months; p = 0.006). Number of osteotomies, operative time, and estimated blood loss did not significantly differ between groups. Median post-operative length of hospital stay was 9 days (IQR, 7 to 10) in the traditional group and 6 days (IQR, 5 to 7) in the modified group (p = 0.10). Early postoperative complications (<30 days) occurred in 8 instances in the traditional group and 6 in the modified group (p = 0.14). Late complications (≥30 days) were significantly fewer in the modified group (0.4 vs 2.67 complications/patient; p = 0.0007). Overall, total complication events were significantly reduced in the modified group (1 vs 4 complications/patient; p = 0.0002), with lower rates of seroma, infection, external incisional dehiscence, and bone and/or hardware exposure. View in Agenda and Add to Schedule",
        "Conclusion": "The modified transoral-submandibular FFF approach is a reliable option for reconstruction of segmental mandibular defects due to ORN and has lower rates of both overall and late complications when compared with the traditional transcervical approach."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparison of Patient Outcomes between a Combined Transoral–Submandibular Approach and the Traditional Transcervical Approach in Free Flap Reconstruction for Mandibular Osteoradionecrosis</span>. <u>Jennifer S Lin, BS</u><sup>1</sup>; Gabrielle L Wolter, MD<sup>2</sup>; Ray Y Wang, MD<sup>2</sup>; N. Eddie Liou, MD<sup>2</sup>; Andrew T Huang, MD<sup>2</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, USA; <sup>2</sup>Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Importance and Objective:</strong> Jaw osteoradionecrosis (ORN) is a potential complication of head and neck radiation therapy that can severely impair speech, mastication, and swallowing. Following failure of nonsurgical management and surgical debridement, free fibula flap (FFF)reconstruction remains the gold standard treatment for segmental mandibular defects. However, the traditional transcervical approach has been associated with wound healing complications, with reported incidences ranging from 8% to 43%. Our team previously described a modified contralateral transoral–submandibular approach designed to reduce these complications by avoiding dissection through irradiated fields. This study represents the first outcomes comparison between the modified transoral–submandibular and traditional transcervical FFF reconstruction techniques.</p>\n\n<p><strong>Design, Setting, and Participants:</strong> A retrospective cohort study was conducted at tertiary care hospitals affiliated with multiple academic institutions between January 2015 and December 2024. Patients with mandibular ORN who underwent FFF reconstruction using either the modified or traditional approach were included.</p>\n\n<p><strong>Main Outcomes:</strong> The primary outcomes were postoperative complication rates and frequency of required revision surgery or hardware removal.</p>\n\n<p><strong>Results: </strong>16 patients were included, with 6 undergoing the traditional approach and 10 undergoing the modified approach. The two groups were comparable in age, sex, comorbidities, tobacco and alcohol history, cancer histology, T stage, and subsite. Surgery with adjuvant radiation was more common as the primary treatment in the traditional than modified group (66.7% vs 10.0%; 95% CI, -85.5% to –6.2%), while the distribution of other treatment modalities did not differ significantly. H-class mandibular defects were more frequent in the modified group (70% vs 0%; 95% CI, 19.0% to 89.3%), but the groups were otherwise similar across remaining HCL classifications. Other preoperative characteristics, including primary radiotherapy site, re-irradiation rates, time from radiotherapy completion to ORN diagnosis, and presence of ORN-related fistulas or pathologic fractures, were comparable between groups. </p>\n\n<p>The median rate of revision surgery or hardware removal was significantly lower in the modified group (20%) compared with the traditional group (83.3%) (95% CI, -88.7% to –11.3%). Median follow-up duration was also shorter in the modified group (7 [IQR, 5 to 11] months vs 29 [IQR, 16 to 40] months; p = 0.006). Number of osteotomies, operative time, and estimated blood loss did not significantly differ between groups. Median post-operative length of hospital stay was 9 days (IQR, 7 to 10) in the traditional group and 6 days (IQR, 5 to 7) in the modified group (p = 0.10). </p>\n\n<p>Early postoperative complications (<30 days) occurred in 8 instances in the traditional group and 6 in the modified group (p = 0.14). Late complications (≥30 days) were significantly fewer in the modified group (0.4 vs 2.67 complications/patient; p = 0.0007). Overall, total complication events were significantly reduced in the modified group (1 vs 4 complications/patient; p = 0.0002), with lower rates of seroma, infection, external incisional dehiscence, and bone and/or hardware exposure.</p>\n\n<p><strong>Conclusion: </strong>The modified transoral-submandibular FFF approach is a reliable option for reconstruction of segmental mandibular defects due to ORN and has lower rates of both overall and late complications when compared with the traditional transcervical approach. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152239--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S559",
      "content_id": "155500",
      "abstract_number": "S559",
      "poster_number": "",
      "title": "Accuracy of margin determination in Osteoradionecrosis with various imaging techniques, with specificity and sensitivity",
      "summary": "SPECT/CT appears to be the most promising modality for preoperative margin determination given its demonstrated correlation with pathological findings and high sensitivity/specificity. The combination of CT with functional imaging (SPECT or DCE-MRI) may be the best approach for virtual surgical planning. The literature reveals a critical gap in validated imaging criteria for preoperative margin determination in...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155500",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Srinivasa R Chandra, MD, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon",
      "presenter": "Srinivasa R Chandra, MD, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon",
      "authors": "Philopateer Hanein 1 ; Katie Humphrey 1 ; Srinivasa R Chandra, MD, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon 2",
      "normalized_authors": [
        "Philopateer Hanein",
        "Katie Humphrey",
        "Srinivasa R Chandra, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon"
      ],
      "affiliations": [
        "University of Toronto, Faculty of Dentistry",
        "Section Chief, OMS VA Portland, OR Consultant Surgeon, Swedish Providence Hospitals, Seattle"
      ],
      "normalized_institutions": [
        "University of Toronto, Faculty of Dentistry",
        "Section Chief, OMS VA Portland, OR Consultant Surgeon, Swedish Providence Hospitals, Seattle"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 434,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Philopateer Hanein 1 ; Katie Humphrey 1 ; Srinivasa R Chandra, MD, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon 2",
        "Affiliations": "1 University of Toronto, Faculty of Dentistry; 2 Section Chief, OMS VA Portland, OR Consultant Surgeon, Swedish Providence Hospitals, Seattle",
        "Introduction": "Osteoradionecrosis (ORN) of the craniomaxillofacial skeleton is a severe complication of head and neck radiation therapy that patients are at a lifelong risk for. Surgical resection is often required for advanced disease. Accurate preoperative determination of disease margins is critical for surgical planning, particularly when virtual surgical planning (VSP) is employed for microvascular reconstruction as VSP cannot compensate for the lack of accuracy of surgical margins. However, no validated imaging-based criteria exist for defining adequate bony resection margins.",
        "Methods": "A systematic literature search was conducted in MEDLINE. Studies evaluating computed tomography (CT), magnetic resonance imaging (MRI), cone-beam computed tomography (CBCT), panoramic radiography, bone scintigraphy, single photon emission computed tomography (SPECT/CT), and photon emission computed tomography (PET/CT) for ORN margin determination were included. Sensitivity, specificity, and diagnostic accuracy were extracted where available.",
        "Results": "The literature search yielded 150 studies to conduct a systematic review. 17 studies met the inclusion criteria for systematic review. SPECT/CT demonstrated the highest reported sensitivity (95-100%) and specificity (91%) for determining ORN extent and margins. MRI demonstrated high sensitivity for detecting bone marrow changes that may precede CT-visible destruction, though limited specificity. While panoramic radiography was effective for initial screening, its two-dimensional nature underestimated osseous changes compared to CT. However, paired CT and panoramic imaging significantly improved diagnostic performance (p<0.001). While PET/CT remains limited in distinguishing ORN from tumor recurrence due to overlapping standard uptake values, CT-based radiomics models have achieved 88% accuracy in differentiating ORN from healthy tissue. CBCT detected more lesions than SPECT/CT (100% vs 92%) though its role in margin determination requires further validation. Furthermore, the analysis revealed a lack of correlation between histologic margin status and disease progression. To date, no imaging modality has been validated to predict bone viability or clinical outcomes, highlighting a significant void in current diagnostic criteria and the urgent need for validated, functional imaging protocols to guide surgical resection.",
        "Conclusion": "SPECT/CT appears to be the most promising modality for preoperative margin determination given its demonstrated correlation with pathological findings and high sensitivity/specificity. The combination of CT with functional imaging (SPECT or DCE-MRI) may be the best approach for virtual surgical planning. The literature reveals a critical gap in validated imaging criteria for preoperative margin determination in ORN. While multiple modalities can detect and characterize ORN, the correlation between radiologic findings and histologic margins remains poorly established.These findings highlight the need for further clinical investigation of the role of multimodal imaging in the surgical treatment of ORN to resolve the lack of consensus and optimize surgical outcomes for patients.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Accuracy of margin determination in Osteoradionecrosis with various imaging techniques, with specificity and sensitivity</span>. Philopateer Hanein<sup>1</sup>; Katie Humphrey<sup>1</sup>; <u>Srinivasa R Chandra, MD, BDS, FDSRCS, Eng, FIBCSOMS, OncRecon</u><sup>2</sup>. <sup>1</sup>University of Toronto, Faculty of Dentistry; <sup>2</sup>Section Chief, OMS VA Portland, OR Consultant Surgeon, Swedish Providence Hospitals, Seattle<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Osteoradionecrosis (ORN) of the craniomaxillofacial skeleton is a severe complication of head and neck radiation therapy that patients are at a lifelong risk for. Surgical resection is often required for advanced disease. Accurate preoperative determination of disease margins is critical for surgical planning, particularly when virtual surgical planning (VSP) is employed for microvascular reconstruction as VSP cannot compensate for the lack of accuracy of surgical margins. However, no validated imaging-based criteria exist for defining adequate bony resection margins.</p>\n\n<p><strong>Methods:</strong> A systematic literature search was conducted in MEDLINE. Studies evaluating computed tomography (CT), magnetic resonance imaging (MRI), cone-beam computed tomography (CBCT), panoramic radiography, bone scintigraphy, single photon emission computed tomography (SPECT/CT), and photon emission computed tomography (PET/CT) for ORN margin determination were included. Sensitivity, specificity, and diagnostic accuracy were extracted where available.</p>\n\n<p><strong>Results: </strong>The literature search yielded 150 studies to conduct a systematic review. 17 studies met the inclusion criteria for systematic review. SPECT/CT demonstrated the highest reported sensitivity (95-100%) and specificity (91%) for determining ORN extent and margins. MRI demonstrated high sensitivity for detecting bone marrow changes that may precede CT-visible destruction, though limited specificity. While panoramic radiography was effective for initial screening, its two-dimensional nature underestimated osseous changes compared to CT.  However, paired CT and panoramic imaging significantly improved diagnostic performance (p<0.001). While PET/CT remains limited in distinguishing ORN from tumor recurrence due to overlapping standard uptake values, CT-based radiomics models have achieved 88% accuracy in differentiating ORN from healthy tissue. CBCT detected more lesions than SPECT/CT (100% vs 92%) though its role in margin determination requires further validation. Furthermore, the analysis revealed a lack of correlation between histologic margin status and disease progression. To date, no imaging modality has been validated to predict bone viability or clinical outcomes, highlighting a significant void in current diagnostic criteria and the urgent need for validated, functional imaging protocols to guide surgical resection.</p>\n\n<p><strong>Conclusion: </strong>SPECT/CT appears to be the most promising modality for preoperative margin determination given its demonstrated correlation with pathological findings and high sensitivity/specificity. The combination of CT with functional imaging (SPECT or DCE-MRI) may be the best approach for virtual surgical planning. The literature reveals a critical gap in validated imaging criteria for preoperative margin determination in ORN. While multiple modalities can detect and characterize ORN, the correlation between radiologic findings and histologic margins remains poorly established.These findings highlight the need for further clinical investigation of the role of multimodal imaging in the surgical treatment of ORN to resolve the lack of consensus and optimize surgical outcomes for patients. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155500--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S560",
      "content_id": "155593",
      "abstract_number": "S560",
      "poster_number": "",
      "title": "Recent Preoperative Radiation Therapy and Early Postoperative Complications in Head and Neck Free-Flap Reconstruction",
      "summary": "In this large multi-institutional cohort, radiation therapy within 90 days before head and neck free-flap reconstruction was associated with significantly worse early postoperative outcomes, including higher rates of SSI, wound dehiscence, return to OR, and flap complications at 30 days. These findings are consistent with recent literature suggesting that preoperative radiation adversely affects flap...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155593",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260159",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Sergio A Segrera, MS",
      "presenter": "Sergio A Segrera, MS",
      "authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis K Gursky, BS 1 ; Hailey P Wyatt 1 ; Adam S Jacobson, MD 2 ; Jamie P Levine 1",
      "normalized_authors": [
        "Sergio A Segrera",
        "Anandhini Narayanan",
        "Alexis K Gursky",
        "Hailey P Wyatt",
        "Adam S Jacobson",
        "Jamie P Levine"
      ],
      "affiliations": [
        "NYU Langone - Hansjörg Wyss Department of Plastic Surgery",
        "NYU Langone - Department of Otolaryngology—Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "NYU Langone - Hansjörg Wyss Department of Plastic Surgery",
        "NYU Langone - Department of Otolaryngology—Head & Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 474,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Sergio A Segrera, MS 1 ; Anandhini Narayanan, MD 1 ; Alexis K Gursky, BS 1 ; Hailey P Wyatt 1 ; Adam S Jacobson, MD 2 ; Jamie P Levine 1",
        "Affiliations": "1 NYU Langone - Hansjörg Wyss Department of Plastic Surgery; 2 NYU Langone - Department of Otolaryngology—Head & Neck Surgery",
        "Purpose": "Head and neck free-flap reconstruction remains the standard approach for restoration of complex oncologic defects, but postoperative wound and flap-related complications continue to impose substantial morbidity. Prior studies evaluating the effect of preoperative radiation on reconstructive outcomes have reported mixed findings, with recent studies linking preoperative radiation to higher rates of complications and flap failure. Proposed mechanisms include radiation-related endothelial injury, fibrosis, impaired tissue perfusion, and deterioration of the recipient wound bed. We therefore evaluated whether radiation therapy within 90 days before surgery is associated with worse early postoperative outcomes after head and neck free-flap reconstruction.",
        "Methods": "We performed a retrospective cohort study within the TriNetX Research Network including adult patients who underwent head and neck free-flap reconstruction paired with same-day ablative surgery and linked to head and neck malignancy diagnoses. Preoperative radiation exposure was defined as any documented radiation therapy to the head and neck region within 90 days before surgery. Patients without radiation therapy 90 days before surgery served as the comparator group. Cohorts were matched 1:1 using nearest-neighbor propensity-score matching based on logistic regression, with a prespecified balance target of standardized mean difference <0.1. Covariates included demographics, procedure type, cancer site and treatment history, obesity, diabetes, hypertension, tobacco use, alcohol use, chronic kidney disease, liver disease, malnutrition, and other clinically relevant comorbidities. Outcomes were assessed at 30 days after surgery and included surgical-site infection (SSI), wound dehiscence, return to the operating room (OR), and flap complications. Associations were reported as risk ratios (RRs) with 95% confidence intervals, with significance defined as p<0.05.",
        "Results": "Across 56 health systems, 30,239 patients met inclusion criteria; 5,186 had radiation therapy within 90 days before surgery and 25,053 served as comparators. After matching, 1,622 exposed and 1,622 unexposed patients achieved covariate balance across all prespecified variables. At 30 days, patients with recent preoperative radiation had a significantly higher risk of wound dehiscence (10.3% vs 7.52%; RR 1.37; p<0.005), SSI (16.28% vs 12.27%; RR 1.33; p<0.001), return to OR (7.71% vs 5.86%; RR 1.32; p<0.03), and flap complications (4.07% vs 2.84%; RR 1.43; p<0.001).",
        "Conclusions": "In this large multi-institutional cohort, radiation therapy within 90 days before head and neck free-flap reconstruction was associated with significantly worse early postoperative outcomes, including higher rates of SSI, wound dehiscence, return to OR, and flap complications at 30 days. These findings are consistent with recent literature suggesting that preoperative radiation adversely affects flap reconstruction through impaired vascularity and wound-bed quality. Recent preoperative radiation may therefore represent an important risk marker for perioperative counseling, surgical planning, and postoperative surveillance. Future studies should evaluate radiation dose, field, and timing to better define whether specific preoperative windows confer heightened reconstructive risk.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Recent Preoperative Radiation Therapy and Early Postoperative Complications in Head and Neck Free-Flap Reconstruction</span>. <u>Sergio A Segrera, MS</u><sup>1</sup>; Anandhini Narayanan, MD<sup>1</sup>; Alexis K Gursky, BS<sup>1</sup>; Hailey P Wyatt<sup>1</sup>; Adam S Jacobson, MD<sup>2</sup>; Jamie P Levine<sup>1</sup>. <sup>1</sup>NYU Langone - Hansjörg Wyss Department of Plastic Surgery; <sup>2</sup>NYU Langone - Department of Otolaryngology—Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose: </strong>Head and neck free-flap reconstruction remains the standard approach for restoration of complex oncologic defects, but postoperative wound and flap-related complications continue to impose substantial morbidity. Prior studies evaluating the effect of preoperative radiation on reconstructive outcomes have reported mixed findings, with recent studies linking preoperative radiation to higher rates of complications and flap failure. Proposed mechanisms include radiation-related endothelial injury, fibrosis, impaired tissue perfusion, and deterioration of the recipient wound bed. We therefore evaluated whether radiation therapy within 90 days before surgery is associated with worse early postoperative outcomes after head and neck free-flap reconstruction. </p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study within the TriNetX Research Network including adult patients who underwent head and neck free-flap reconstruction paired with same-day ablative surgery and linked to head and neck malignancy diagnoses. Preoperative radiation exposure was defined as any documented radiation therapy to the head and neck region within 90 days before surgery. Patients without radiation therapy 90 days before surgery served as the comparator group. Cohorts were matched 1:1 using nearest-neighbor propensity-score matching based on logistic regression, with a prespecified balance target of standardized mean difference <0.1. Covariates included demographics, procedure type, cancer site and treatment history, obesity, diabetes, hypertension, tobacco use, alcohol use, chronic kidney disease, liver disease, malnutrition, and other clinically relevant comorbidities. Outcomes were assessed at 30 days after surgery and included surgical-site infection (SSI), wound dehiscence, return to the operating room (OR), and flap complications. Associations were reported as risk ratios (RRs) with 95% confidence intervals, with significance defined as p<0.05. </p>\n\n<p><strong>Results:</strong> Across 56 health systems, 30,239 patients met inclusion criteria; 5,186 had radiation therapy within 90 days before surgery and 25,053 served as comparators. After matching, 1,622 exposed and 1,622 unexposed patients achieved covariate balance across all prespecified variables. At 30 days, patients with recent preoperative radiation had a significantly higher risk of wound dehiscence (10.3% vs 7.52%; RR 1.37; p<0.005), SSI (16.28% vs 12.27%; RR 1.33; p<0.001), return to OR (7.71% vs 5.86%; RR 1.32; p<0.03), and flap complications (4.07% vs 2.84%; RR 1.43; p<0.001).  </p>\n\n<p><strong>Conclusions: </strong>In this large multi-institutional cohort, radiation therapy within 90 days before head and neck free-flap reconstruction was associated with significantly worse early postoperative outcomes, including higher rates of SSI, wound dehiscence, return to OR, and flap complications at 30 days. These findings are consistent with recent literature suggesting that preoperative radiation adversely affects flap reconstruction through impaired vascularity and wound-bed quality. Recent preoperative radiation may therefore represent an important risk marker for perioperative counseling, surgical planning, and postoperative surveillance. Future studies should evaluate radiation dose, field, and timing to better define whether specific preoperative windows confer heightened reconstructive risk. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155593--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260159' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S561",
      "content_id": "154144",
      "abstract_number": "S561",
      "poster_number": "",
      "title": "Construct Validation of a Synthetic Tissue-Based Simulator for Transoral Robotic Surgical Training",
      "summary": "A total of 20 participants (5 medical students, 11 residents, and 4 faculty) performed a tongue base resection on the PVA models in a real operating room using training instruments installed in a clinical da Vinci Sp system. Compared to medical students and residents, faculty completed the procedure with shorter completion times (p<0.01), higher GEARS scores (p<0.001), and lower perceived TLX workload scores...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154144",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Lauren E Schlegel, MD",
      "presenter": "Lauren E Schlegel, MD",
      "authors": "Lauren E Schlegel, MD 1 ; Brett A Campbell, MD 1 ; Dervishan Sezer, PhD 2 ; Liam P O'Brien, BSc 1 ; Scharukh M Jalisi, MD, MS, MBA, FACS 1 ; Suvranu De, PhD 3 ; Doga Demirel, PhD 2 ; Ernest D Gomez, MD, MTR, FACS 1",
      "normalized_authors": [
        "Lauren E Schlegel",
        "Brett A Campbell",
        "Dervishan Sezer",
        "Liam P O'Brien",
        "Scharukh M Jalisi",
        "Suvranu De",
        "Doga Demirel",
        "Ernest D Gomez, MTR"
      ],
      "affiliations": [
        "Beth Israel Deaconess Medical Center",
        "University of Oklahoma",
        "FAMU-FSU College of Engineering"
      ],
      "normalized_institutions": [
        "Beth Israel Deaconess Medical Center",
        "University of Oklahoma",
        "FAMU-FSU College of Engineering"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154144/PTORS%20abstract(1).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154144/PTORS%20abstract(1).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154144"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 512,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Discussion and Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Lauren E Schlegel, MD 1 ; Brett A Campbell, MD 1 ; Dervishan Sezer, PhD 2 ; Liam P O'Brien, BSc 1 ; Scharukh M Jalisi, MD, MS, MBA, FACS 1 ; Suvranu De, PhD 3 ; Doga Demirel, PhD 2 ; Ernest D Gomez, MD, MTR, FACS 1",
        "Affiliations": "1 Beth Israel Deaconess Medical Center; 2 University of Oklahoma; 3 FAMU-FSU College of Engineering",
        "Background": "Transoral Robotic Surgery (TORS) training outside of the operating room has historically consisted of online modules, low-fidelity task trainers, and virtual reality-based modules that are not specific to TORS. Live animal and human cadaver labs are realistic but are resource intensive and low frequency. TORS has a significant learning curve for operative technique, so efforts to provide high quality training are of value to the field of head and neck surgery.",
        "Objective": "To determine whether a low-cost, high-fidelity physical TORS simulator (PTORS) for tongue base resection training can effectively differentiate between levels of surgical experience (novice, intermediate, expert).",
        "Methods": "A Three-Dimensional (3D) model of a tongue base with an ulcerative mass was developed in Blender and 3D printed using a rigid polylactic acid (PLA) printer. The PLA model was used to create a silicone mold, which was used to cast synthetic tongue base cancer models using a soft, electroconductive polyvinyl alcohol (PVA) polymer. A PVA model of the soft palate and pharynx was also developed. The soft tissue models were placed into a skull encasement which was connected to the electrosurgical unit of a da Vinci Sp surgical robot in a hospital operating room. The robot was docked and the tongue base was exposed using a tonsillectomy gag. Medical students, otolaryngology residents, and otolaryngology faculty were recruited to perform a tongue base hemiglossectomy on the PVA model using the da Vinci Sp robot using real electrocautery. Performance metrics including task completion time, surgical margins, and blinded observer-based Global Evaluative Assessment of Robotic Skill (GEARS) ratings were recorded for each trial. Participants were asked to complete a Task Load Index (TLX) survey after each trial. Groups were compared using a Kruskal-Wallis test with a significance level of 0.05.",
        "Results": "A total of 20 participants (5 medical students, 11 residents, and 4 faculty) performed a tongue base resection on the PVA models in a real operating room using training instruments installed in a clinical da Vinci Sp system. Compared to medical students and residents, faculty completed the procedure with shorter completion times (p<0.01), higher GEARS scores (p<0.001), and lower perceived TLX workload scores (p<0.001). Faculty participants achieved negative deep margins in 100% (4/4) of their trials compared to 25% of medical students and residents (4/16). Appropriate mucosal margins (anterior, posterior, medial, and lateral) were achieved by 75% (2/4) of faculty and 43.8% (7/16) medical students and residents. Recursive partitioning analysis was used to determine what post-graduate year (PGY) thresholds would most appropriately categorize participants by a composite quality of surgical performance on the simulator, with the terminal nodes determined to be medical student to PGY-2 as the first group, PGY-3 to PGY-5 as the second, and faculty as the third.",
        "Discussion and Conclusions": "This study demonstrates that PTORS is the first procedure-specific simulator for TORS that demonstrates construct validity, i.e. the ability to differentiate between clinically relevant skill levels. The simulator was successfully implemented in a real operating room outside of active clinical use without need to move the robot.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Construct Validation of a Synthetic Tissue-Based Simulator for Transoral Robotic Surgical Training</span>. <u>Lauren E Schlegel, MD</u><sup>1</sup>; Brett A Campbell, MD<sup>1</sup>; Dervishan Sezer, PhD<sup>2</sup>; Liam P O'Brien, BSc<sup>1</sup>; Scharukh M Jalisi, MD, MS, MBA, FACS<sup>1</sup>; Suvranu De, PhD<sup>3</sup>; Doga Demirel, PhD<sup>2</sup>; Ernest D Gomez, MD, MTR, FACS<sup>1</sup>. <sup>1</sup>Beth Israel Deaconess Medical Center; <sup>2</sup>University of Oklahoma; <sup>3</sup>FAMU-FSU College of Engineering<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Transoral Robotic Surgery (TORS) training outside of the operating room has historically consisted of online modules, low-fidelity task trainers, and virtual reality-based modules that are not specific to TORS. Live animal and human cadaver labs are realistic but are resource intensive and low frequency. TORS has a significant learning curve for operative technique, so efforts to provide high quality training are of value to the field of head and neck surgery.</p>\n\n<p><strong>Objective: </strong>To determine whether a low-cost, high-fidelity physical TORS simulator (PTORS) for tongue base resection training can effectively differentiate between levels of surgical experience (novice, intermediate, expert).</p>\n\n<p><strong>Methods: </strong>A Three-Dimensional (3D) model of a tongue base with an ulcerative mass was developed in Blender and 3D printed using a rigid polylactic acid (PLA) printer. The PLA model was used to create a silicone mold, which was used to cast synthetic tongue base cancer models using a soft, electroconductive polyvinyl alcohol (PVA) polymer. A PVA model of the soft palate and pharynx was also developed. The soft tissue models were placed into a skull encasement which was connected to the electrosurgical unit of a da Vinci Sp surgical robot in a hospital operating room. The robot was docked and the tongue base was exposed using a tonsillectomy gag. Medical students, otolaryngology residents, and otolaryngology faculty were recruited to perform a tongue base hemiglossectomy on the PVA model using the da Vinci Sp robot using real electrocautery. Performance metrics including task completion time, surgical margins, and blinded observer-based Global Evaluative Assessment of Robotic Skill (GEARS) ratings were recorded for each trial. Participants were asked to complete a Task Load Index (TLX) survey after each trial. Groups were compared using a Kruskal-Wallis test with a significance level of 0.05.</p>\n\n<p><strong>Results: </strong>A total of 20 participants (5 medical students, 11 residents, and 4 faculty) performed a tongue base resection on the PVA models in a real operating room using training instruments installed in a clinical da Vinci Sp system. Compared to medical students and residents, faculty completed the procedure with shorter completion times (p<0.01), higher GEARS scores (p<0.001), and lower perceived TLX workload scores (p<0.001). Faculty participants achieved negative deep margins in 100% (4/4) of their trials compared to 25% of medical students and residents (4/16). Appropriate mucosal margins (anterior, posterior, medial, and lateral) were achieved by 75% (2/4) of faculty and 43.8% (7/16) medical students and residents. Recursive partitioning analysis was used to determine what post-graduate year (PGY) thresholds would most appropriately categorize participants by a composite quality of surgical performance on the simulator, with the terminal nodes determined to be medical student to PGY-2 as the first group, PGY-3 to PGY-5 as the second, and faculty as the third.</p>\n\n<p><strong>Discussion and Conclusions: </strong>This study demonstrates that PTORS is the first procedure-specific simulator for TORS that demonstrates construct validity, i.e. the ability to differentiate between clinically relevant skill levels. The simulator was successfully implemented in a real operating room outside of active clinical use without need to move the robot.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154144/PTORS%20abstract(1).png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154144--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S562",
      "content_id": "153227",
      "abstract_number": "S562",
      "poster_number": "",
      "title": "How Surgeons Teach Surgeons – Creating a Codebook for Open Surgery",
      "summary": "This study highlights a new coding schema for attending behaviors in open surgery in the context of surgical education. This study serves as a step towards the creation of a validated framework for analyzing competency in surgical video of open procedures.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153227",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Joaquin Austerlitz",
      "presenter": "Joaquin Austerlitz",
      "authors": "Joaquin Austerlitz ; Andreja Radevic; Sarah L Rohde, MD, MMHC; Kyle Mannion, MD; Michael C Topf, MD, MSCI; Robert J Sinard, MD; Eben L Rosenthal, MD; Alexander J Langerman, MD, SM",
      "normalized_authors": [
        "Joaquin Austerlitz",
        "Andreja Radevic",
        "Sarah L Rohde, MMHC",
        "Kyle Mannion",
        "Michael C Topf, MSCI",
        "Robert J Sinard",
        "Eben L Rosenthal",
        "Alexander J Langerman, SM"
      ],
      "affiliations": [
        "Vanderbilt University"
      ],
      "normalized_institutions": [
        "Vanderbilt University"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Joaquin Austerlitz ; Andreja Radevic; Sarah L Rohde, MD, MMHC; Kyle Mannion, MD; Michael C Topf, MD, MSCI; Robert J Sinard, MD; Eben L Rosenthal, MD; Alexander J Langerman, MD, SM",
        "Affiliations": "Vanderbilt University",
        "Introduction": "Surgical trainees must graduate residency with the skill and confidence to operate independently. This requires trainees taking on greater levels of autonomy as they advance through residency. However, ensuring autonomy while preserving adequate oversight remains a challenge to educators. Using video recordings of neck dissections, we examined attending actions while teaching to investigate how these actions might promote or impede autonomy.",
        "Methods": "This study was approved by the Vanderbilt University Medical Center Institutional Review Board (IRB# 232054). Patients undergoing standard-of-care unilateral level IIA/B neck dissections were filmed by otolaryngology residents wearing a head-mounted camera. Videos were blinded and reviewed for quality and a preliminary codebook was developed by 3 researchers (A.R, J.A, A.L.) using a grounded theory approach. Five videos were then cross-coded by A.R and J.A. to assess consistency and further refine the codebook, with A.L. adjudicating disagreements. Actions and behaviors performed by the attending surgeon were coded in the context of resident teaching – i.e., how much these actions represented attending control versus resident autonomy in the progress of the case.",
        "Results": "Nineteen surgical videos were coded during this study, thematic saturation was reached after 9 videos. In these 19 videos, we identified 1644 instances of attending surgeon actions; these were classified into sixteen distinct actions that we then grouped into four overarching categories. Categories, ordered by increasing level of resident autonomy, were as follows: “intervening” (216 instances, 13.1%) reflected maximal attending control (e.g., dissecting key structures); “guiding” (958, 58.3%) involved active support (e.g., pre-treating tissue to indicate where to cut); “presenting” (270, 16.4%) entailed indirect leading through manipulation of exposure; and “assisting” (200, 12.2%) represented minimal control (e.g., counter-traction or cutting tissue prepared by the resident). Residents were PGY-3 (n=2 videos), PGY-4 (n=15), and PGY-5 (n=2). Stratified by training level, intervening decreased (20.8%, 11.8%, 9.3%) and assisting increased (0.07%, 13.9%, 18.6%) from PGY-3 to PGY-5.",
        "Discussion": "We present the first study coding attending behaviors in open surgery and their implications for trainee learning and independence. While the impetus behind these behaviors is multifactorial, this study may elucidate patterns in behavior attendings perform unknowingly. Providing video examples of these patterns may then prompt self-reflection by attending surgeons regarding actions that may detract from competency development by being “too helpful”. Level of training showed trends in increasing autonomy however, more videos are needed to further investigate possible associations. Video examples of the actions described in this manuscript will be presented.",
        "Conclusion": "This study highlights a new coding schema for attending behaviors in open surgery in the context of surgical education. This study serves as a step towards the creation of a validated framework for analyzing competency in surgical video of open procedures.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>How Surgeons Teach Surgeons – Creating a Codebook for Open Surgery</span>. <u>Joaquin Austerlitz</u>; Andreja Radevic; Sarah L Rohde, MD, MMHC; Kyle Mannion, MD; Michael C Topf, MD, MSCI; Robert J Sinard, MD; Eben L Rosenthal, MD; Alexander J Langerman, MD, SM. Vanderbilt University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Surgical trainees must graduate residency with the skill and confidence to operate independently. This requires trainees taking on greater levels of autonomy as they advance through residency. However, ensuring autonomy while preserving adequate oversight remains a challenge to educators. Using video recordings of neck dissections, we examined attending actions while teaching to investigate how these actions might promote or impede autonomy.</p>\n\n<p><strong>Methods: </strong>This study was approved by the Vanderbilt University Medical Center Institutional Review Board (IRB# 232054). Patients undergoing standard-of-care unilateral level IIA/B neck dissections were filmed by otolaryngology residents wearing a head-mounted camera. Videos were blinded and reviewed for quality and a preliminary codebook was developed by 3 researchers (A.R, J.A, A.L.) using a grounded theory approach. Five videos were then cross-coded by A.R and J.A. to assess consistency and further refine the codebook, with A.L. adjudicating disagreements. Actions and behaviors performed by the attending surgeon were coded in the context of resident teaching – i.e., how much these actions represented attending control versus resident autonomy in the progress of the case.   </p>\n\n<p><strong>Results: </strong>Nineteen surgical videos were coded during this study, thematic saturation was reached after 9 videos. In these 19 videos, we identified 1644 instances of attending surgeon actions; these were classified into sixteen distinct actions that we then grouped into four overarching categories. Categories, ordered by increasing level of resident autonomy, were as follows: “intervening” (216 instances, 13.1%) reflected maximal attending control (e.g., dissecting key structures); “guiding” (958, 58.3%) involved active support (e.g., pre-treating tissue to indicate where to cut); “presenting” (270, 16.4%) entailed indirect leading through manipulation of exposure; and “assisting” (200, 12.2%) represented minimal control (e.g., counter-traction or cutting tissue prepared by the resident). Residents were PGY-3 (n=2 videos), PGY-4 (n=15), and PGY-5 (n=2). Stratified by training level, intervening decreased (20.8%, 11.8%, 9.3%) and assisting increased (0.07%, 13.9%, 18.6%) from PGY-3 to PGY-5.  </p>\n\n<p><strong>Discussion: </strong>We present the first study coding attending behaviors in open surgery and their implications for trainee learning and independence. While the impetus behind these behaviors is multifactorial, this study may elucidate patterns in behavior attendings perform unknowingly. Providing video examples of these patterns may then prompt self-reflection by attending surgeons regarding actions that may detract from competency development by being “too helpful”. Level of training showed trends in increasing autonomy however, more videos are needed to further investigate possible associations. Video examples of the actions described in this manuscript will be presented.</p>\n\n<p><strong>Conclusion: </strong>This study highlights a new coding schema for attending behaviors in open surgery in the context of surgical education. This study serves as a step towards the creation of a validated framework for analyzing competency in surgical video of open procedures.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153227--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S563",
      "content_id": "154354",
      "abstract_number": "S563",
      "poster_number": "",
      "title": "Defining Core Competencies in Head and Neck Surgery Education: A Consensus Framework",
      "summary": "This consensus-derived competency framework provides comprehensive and structured educational objectives for head and neck surgery training across three progressive levels, addressing a critical need for standardization in surgical education. Implementation of these competencies in training programs should ensure that residents at each level develop appropriate and measurable skills for both routine clinical...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154354",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rogério Aparecido Dedivitis, PhD, MD",
      "presenter": "Rogério Aparecido Dedivitis, PhD, MD",
      "authors": "Rogério Aparecido Dedivitis, PhD, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Fátima Cristina M De Matos, PhD, MD 3 ; Marianne Y Nakai, MD 4 ; Leandro L de Matos, PhD, MD 5 ; Marco Aurélio V Kulcsar, PhD, MD 1 ; Carlos T Chone, PhD, MD 6 ; Luiz Paulo Kowalski, PhD, MD 1 ; Fernando Luiz Dias, MD 7 ; André C Martins, MD 2 ; Bruna C Silva, MD 2 ; Bruno P Duarte, Mr 2",
      "normalized_authors": [
        "Rogério Aparecido Dedivitis",
        "Mario Augusto F Castro",
        "Fátima Cristina M De Matos",
        "Marianne Y Nakai",
        "Leandro L de Matos",
        "Marco Aurélio V Kulcsar",
        "Carlos T Chone",
        "Luiz Paulo Kowalski",
        "Fernando Luiz Dias",
        "André C Martins",
        "Bruna C Silva",
        "Bruno P Duarte, Mr"
      ],
      "affiliations": [
        "University of São Paulo School of Medicine, São Paulo, Brazil",
        "Universidade Metropolitana de Santos, Santos, Brazil",
        "Universidade Estadual de Pernambuco, Recife, Brazil",
        "Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil",
        "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
        "Universidade Estadual de Campinas, Campinas, Brazil",
        "Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil"
      ],
      "normalized_institutions": [
        "University of São Paulo School of Medicine, São Paulo, Brazil",
        "Universidade Metropolitana de Santos, Santos, Brazil",
        "Universidade Estadual de Pernambuco, Recife, Brazil",
        "Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil",
        "Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil",
        "Universidade Estadual de Campinas, Campinas, Brazil",
        "Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Rogério Aparecido Dedivitis, PhD, MD 1 ; Mario Augusto F Castro, PhD, MD 2 ; Fátima Cristina M De Matos, PhD, MD 3 ; Marianne Y Nakai, MD 4 ; Leandro L de Matos, PhD, MD 5 ; Marco Aurélio V Kulcsar, PhD, MD 1 ; Carlos T Chone, PhD, MD 6 ; Luiz Paulo Kowalski, PhD, MD 1 ; Fernando Luiz Dias, MD 7 ; André C Martins, MD 2 ; Bruna C Silva, MD 2 ; Bruno P Duarte, Mr 2",
        "Affiliations": "1 University of São Paulo School of Medicine, São Paulo, Brazil; 2 Universidade Metropolitana de Santos, Santos, Brazil; 3 Universidade Estadual de Pernambuco, Recife, Brazil; 4 Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil; 5 Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil; 6 Universidade Estadual de Campinas, Campinas, Brazil; 7 Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil",
        "Background": "Head and neck surgery encompasses a broad spectrum of anatomical regions, pathological conditions, and technical skills that require structured and progressive educational approaches. The complexity of this surgical subspecialty demands clear definition of learning objectives appropriate to each training level. Currently, there is significant variability in educational expectations and competency requirements across different institutions and training programs, potentially resulting in inconsistent preparation of surgeons entering the field.",
        "Objectives": "This study aimed to establish standardized, evidence-based competency frameworks for head and neck surgery education across three distinct and progressive training levels: medical students during clinical clerkship rotations, general surgery residents who receive exposure to head and neck conditions, and head and neck surgery specialty residents pursuing advanced subspecialty training.",
        "Methods": "A rigorous modified Delphi consensus process was conducted with an expert panel comprising nationally recognized head and neck surgeons, surgical educators, and program directors with extensive experience in resident training and curriculum development. The systematic process comprised multiple sequential phases. First, expert panel members were selected. Second, a comprehensive structured questionnaire was developed based on literature review, existing curricula, and expert input, organized by training level and clinical domain. Third, this questionnaire was electronically distributed to all panel members, who were asked to independently review each proposed competency and indicate whether it should be maintained, removed, or modified. Fourth, responses from the first round were systematically analyzed, and a refined questionnaire was prepared incorporating modifications and new suggestions. A second round was conducted requiring panel members to indicate agreement or disagreement with each reformulated or newly proposed competency. Finally, consensus thresholds were applied to determine which competencies achieved sufficient agreement for inclusion in the final framework.",
        "Results": "The comprehensive consensus process successfully established a hierarchical competency framework appropriate to each training level. For medical students during clinical clerkship, 12 core competencies were defined. These foundational competencies prepare students for subsequent training while providing essential knowledge for general medical practice. For general surgery residents, 22 competencies were established, encompassing more advanced diagnostic skills, initial management of common head and neck conditions, basic surgical techniques including tracheostomy and neck exploration, and understanding of oncologic principles relevant to head and neck malignancies. For head and neck surgery specialty residents, 46 detailed competencies were defined, representing comprehensive training requirements for independent subspecialty practice. This extensive framework encompasses progressive complexity across all domains, including advanced surgical techniques for complex oncologic and reconstructive procedures, multidisciplinary management of head and neck cancer, mastery of endoscopic and microsurgical approaches, and sophisticated clinical decision-making skills required for complex cases.",
        "Conclusion": "This consensus-derived competency framework provides comprehensive and structured educational objectives for head and neck surgery training across three progressive levels, addressing a critical need for standardization in surgical education. Implementation of these competencies in training programs should ensure that residents at each level develop appropriate and measurable skills for both routine clinical scenarios and complex surgical procedures. The framework supports systematic educational program development, facilitates objective assessment of trainee progress, and promotes consistency in surgical training quality across institutions.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Defining Core Competencies in Head and Neck Surgery Education: A Consensus Framework</span>. <u>Rogério Aparecido Dedivitis, PhD, MD</u><sup>1</sup>; Mario Augusto F Castro, PhD, MD<sup>2</sup>; Fátima Cristina M De Matos, PhD, MD<sup>3</sup>; Marianne Y Nakai, MD<sup>4</sup>; Leandro L de Matos, PhD, MD<sup>5</sup>; Marco Aurélio V Kulcsar, PhD, MD<sup>1</sup>; Carlos T Chone, PhD, MD<sup>6</sup>; Luiz Paulo Kowalski, PhD, MD<sup>1</sup>; Fernando Luiz Dias, MD<sup>7</sup>; André C Martins, MD<sup>2</sup>; Bruna C Silva, MD<sup>2</sup>; Bruno P Duarte, Mr<sup>2</sup>. <sup>1</sup>University of São Paulo School of Medicine, São Paulo, Brazil; <sup>2</sup>Universidade Metropolitana de Santos, Santos, Brazil; <sup>3</sup>Universidade Estadual de Pernambuco, Recife, Brazil; <sup>4</sup>Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil; <sup>5</sup>Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil; <sup>6</sup>Universidade Estadual de Campinas, Campinas, Brazil; <sup>7</sup>Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Head and neck surgery encompasses a broad spectrum of anatomical regions, pathological conditions, and technical skills that require structured and progressive educational approaches. The complexity of this surgical subspecialty demands clear definition of learning objectives appropriate to each training level. Currently, there is significant variability in educational expectations and competency requirements across different institutions and training programs, potentially resulting in inconsistent preparation of surgeons entering the field. </p>\n\n<p><strong>Objectives: </strong>This study aimed to establish standardized, evidence-based competency frameworks for head and neck surgery education across three distinct and progressive training levels: medical students during clinical clerkship rotations, general surgery residents who receive exposure to head and neck conditions, and head and neck surgery specialty residents pursuing advanced subspecialty training. </p>\n\n<p><strong>Methods: </strong>A rigorous modified Delphi consensus process was conducted with an expert panel comprising nationally recognized head and neck surgeons, surgical educators, and program directors with extensive experience in resident training and curriculum development. The systematic process comprised multiple sequential phases. First, expert panel members were selected. Second, a comprehensive structured questionnaire was developed based on literature review, existing curricula, and expert input, organized by training level and clinical domain. Third, this questionnaire was electronically distributed to all panel members, who were asked to independently review each proposed competency and indicate whether it should be maintained, removed, or modified. Fourth, responses from the first round were systematically analyzed, and a refined questionnaire was prepared incorporating modifications and new suggestions. A second round was conducted requiring panel members to indicate agreement or disagreement with each reformulated or newly proposed competency. Finally, consensus thresholds were applied to determine which competencies achieved sufficient agreement for inclusion in the final framework.</p>\n\n<p><strong>Results: </strong>The comprehensive consensus process successfully established a hierarchical competency framework appropriate to each training level. For medical students during clinical clerkship, 12 core competencies were defined. These foundational competencies prepare students for subsequent training while providing essential knowledge for general medical practice. For general surgery residents, 22 competencies were established, encompassing more advanced diagnostic skills, initial management of common head and neck conditions, basic surgical techniques including tracheostomy and neck exploration, and understanding of oncologic principles relevant to head and neck malignancies. For head and neck surgery specialty residents, 46 detailed competencies were defined, representing comprehensive training requirements for independent subspecialty practice. This extensive framework encompasses progressive complexity across all domains, including advanced surgical techniques for complex oncologic and reconstructive procedures, multidisciplinary management of head and neck cancer, mastery of endoscopic and microsurgical approaches, and sophisticated clinical decision-making skills required for complex cases.</p>\n\n<p><strong>Conclusion: </strong>This consensus-derived competency framework provides comprehensive and structured educational objectives for head and neck surgery training across three progressive levels, addressing a critical need for standardization in surgical education. Implementation of these competencies in training programs should ensure that residents at each level develop appropriate and measurable skills for both routine clinical scenarios and complex surgical procedures. The framework supports systematic educational program development, facilitates objective assessment of trainee progress, and promotes consistency in surgical training quality across institutions.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154354--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S564",
      "content_id": "154649",
      "abstract_number": "S564",
      "poster_number": "",
      "title": "ENHANCING AIRWAY SAFETY FOR SURGICAL AIRWAY PATIENTS: ASSESSING EMERGENCY MEDICINE PROVIDER KNOWLEDGE GAPS TO GUIDE AN AIRWAY BANNER WITHIN THE ELECTRONIC HEALTH RECORD",
      "summary": "Baseline data revealed substantial gaps in emergency provider comfort, recognition, and management of tracheostomy and laryngectomy airways, as well as difficulty identifying airway status within the EHR. Survey participants will subsequently complete a structured educational program guided by this data, followed by a post-intervention survey identical to the baseline instrument. Comparative analysis of pre- and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154649",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Danae Alexandrou, MD",
      "presenter": "Danae Alexandrou, MD",
      "authors": "Danae Alexandrou, MD 1 ; Hayley Mann, MD 1 ; Michael Lasarev, MS 2 ; Tiffany Glazer, MD 1",
      "normalized_authors": [
        "Danae Alexandrou",
        "Hayley Mann",
        "Michael Lasarev",
        "Tiffany Glazer"
      ],
      "affiliations": [
        "University of Wisconsin - Department of Head & Neck Surgery",
        "University of Wisconsin - Biostatistics and Medical Informatics"
      ],
      "normalized_institutions": [
        "University of Wisconsin - Department of Head & Neck Surgery",
        "University of Wisconsin - Biostatistics and Medical Informatics"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Danae Alexandrou, MD 1 ; Hayley Mann, MD 1 ; Michael Lasarev, MS 2 ; Tiffany Glazer, MD 1",
        "Affiliations": "1 University of Wisconsin - Department of Head & Neck Surgery; 2 University of Wisconsin - Biostatistics and Medical Informatics",
        "Introduction": "Patients with complex surgical airways, such as tracheostomies or laryngectomies, are particularly vulnerable in emergent settings within the emergency department or inpatient wards. Many healthcare professionals may have limited experience or comfort in managing these airways, which can lead to delays in care, inappropriate interventions, or patient harm. These vulnerabilities often arise not from negligence, but from a lack of easily accessible information, unfamiliarity with surgical airway anatomy, and misunderstanding of critical management principles. Clear, accessible documentation of a patient's surgical airway status–including device types, intubation recommendations, surgical history, and special equipment needs–within the electronic health record (EHR) may mitigate these challenges and provide safer and more efficient care in this population.",
        "Objective": "To evaluate emergency medicine providers’ understanding of complex surgical airways which will be used to guide development of: (1) an educational intervention and (2) a comprehensive EHR airway banner that streamlines appropriate recognition and management of surgical airways in emergent settings.",
        "Methods": "This study was IRB exempt (2023-1128). A REDCap survey link was sent to emergency department multidisciplinary staff at a single academic institution in November, 2024. Surveys assessed baseline comfort, anatomic knowledge, device recognition, and management practices of tracheostomy and laryngectomy patients.",
        "Results": "Forty individuals completed the survey: 25 attendings (62%), eight residents (20%), six physician assistants (15%), and one other provider (2%). Thirteen out of forty respondents (32%) agreed or strongly agreed that they felt comfortable providing acute care to both laryngectomy and tracheostomy patients. Sixteen out of forty respondents (43%) disagreed or strongly disagreed that they could confidently differentiate between these two airway types, and 17/40 (42%) believed that the two surgical airway stoma sites were located at different positions within the airway.",
        "Abstract": "Most participants—31/40 (78%)—disagreed or strongly disagreed that they could quickly determine a patient’s surgical airway status in the EHR during an emergency. Although 33/40 (82%) correctly identified that laryngectomy patients cannot be orally intubated, only 2/40 (5%) correctly identified appropriate laryngectomy stoma tubing. Sixteen out of forty respondents (40%) believed laryngectomy patients can achieve voice, but only one respondent correctly identified the devices that facilitate speech. Regarding tracheostomy care, 14/40 (35%) correctly identified the recommended frequency for changing tracheostomy tubing. Twenty-one out of forty respondents (52%) correctly identified the appropriate steps for replacing a dislodged or false-passaged tracheostomy tube, and 12/40 (30%) correctly recognized a tracheostomy tube obturator. At survey conclusion, 38/40 (98%) expressed desire for additional education on surgical and emergent airway management. View in Agenda and Add to Schedule",
        "Conclusion": "Baseline data revealed substantial gaps in emergency provider comfort, recognition, and management of tracheostomy and laryngectomy airways, as well as difficulty identifying airway status within the EHR. Survey participants will subsequently complete a structured educational program guided by this data, followed by a post-intervention survey identical to the baseline instrument. Comparative analysis of pre- and post-intervention survey data can demonstrate gaps in knowledge and identify key elements for the development of an EHR surgical airway banner aimed at improving emergency identification, standardizing communication, and enhancing patient safety."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>ENHANCING AIRWAY SAFETY FOR SURGICAL AIRWAY PATIENTS: ASSESSING EMERGENCY MEDICINE PROVIDER KNOWLEDGE GAPS TO GUIDE AN AIRWAY BANNER WITHIN THE ELECTRONIC HEALTH RECORD</span>. <u>Danae Alexandrou, MD</u><sup>1</sup>; Hayley Mann, MD<sup>1</sup>; Michael Lasarev, MS<sup>2</sup>; Tiffany Glazer, MD<sup>1</sup>. <sup>1</sup>University of Wisconsin - Department of Head & Neck Surgery; <sup>2</sup>University of Wisconsin - Biostatistics and Medical Informatics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Patients with complex surgical airways, such as tracheostomies or laryngectomies, are particularly vulnerable in emergent settings within the emergency department or inpatient wards. Many healthcare professionals may have limited experience or comfort in managing these airways, which can lead to delays in care, inappropriate interventions, or patient harm. These vulnerabilities often arise not from negligence, but from a lack of easily accessible information, unfamiliarity with surgical airway anatomy, and misunderstanding of critical management principles. Clear, accessible documentation of a patient's surgical airway status–including device types, intubation recommendations, surgical history, and special equipment needs–within the electronic health record (EHR) may mitigate these challenges and provide safer and more efficient care in this population.  </p>\n\n<p><strong>Objective: </strong>To evaluate emergency medicine providers’ understanding of complex surgical airways which will be used to guide development of: (1) an educational intervention and (2) a comprehensive EHR airway banner that streamlines appropriate recognition and management of surgical airways in emergent settings.</p>\n\n<p><strong>Methods: </strong>This study was IRB exempt (2023-1128). A REDCap survey link was sent to emergency department multidisciplinary staff at a single academic institution in November, 2024. Surveys assessed baseline comfort, anatomic knowledge, device recognition, and management practices of tracheostomy and laryngectomy patients.</p>\n\n<p><strong>Results: </strong>Forty individuals completed the survey: 25 attendings (62%), eight residents (20%), six physician assistants (15%), and one other provider (2%). Thirteen out of forty respondents (32%) agreed or strongly agreed that they felt comfortable providing acute care to both laryngectomy and tracheostomy patients. Sixteen out of forty respondents (43%) disagreed or strongly disagreed that they could confidently differentiate between these two airway types, and 17/40 (42%) believed that the two surgical airway stoma sites were located at different positions within the airway.</p>\n\n<p>Most participants—31/40 (78%)—disagreed or strongly disagreed that they could quickly determine a patient’s surgical airway status in the EHR during an emergency. Although 33/40 (82%) correctly identified that laryngectomy patients cannot be orally intubated, only 2/40 (5%) correctly identified appropriate laryngectomy stoma tubing. Sixteen out of forty respondents (40%) believed laryngectomy patients can achieve voice, but only one respondent correctly identified the devices that facilitate speech.</p>\n\n<p>Regarding tracheostomy care, 14/40 (35%) correctly identified the recommended frequency for changing tracheostomy tubing. Twenty-one out of forty respondents (52%) correctly identified the appropriate steps for replacing a dislodged or false-passaged tracheostomy tube, and 12/40 (30%) correctly recognized a tracheostomy tube obturator. At survey conclusion, 38/40 (98%) expressed desire for additional education on surgical and emergent airway management.</p>\n\n<p><strong>Conclusion: </strong>Baseline data revealed substantial gaps in emergency provider comfort, recognition, and management of tracheostomy and laryngectomy airways, as well as difficulty identifying airway status within the EHR. Survey participants will subsequently complete a structured educational program guided by this data, followed by a post-intervention survey identical to the baseline instrument. Comparative analysis of pre- and post-intervention survey data can demonstrate gaps in knowledge and identify key elements for the development of an EHR surgical airway banner aimed at improving emergency identification, standardizing communication, and enhancing patient safety.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154649--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S565",
      "content_id": "154394",
      "abstract_number": "S565",
      "poster_number": "",
      "title": "Entrustable Professional Activities Framework for Head and Neck Surgery Residency Training",
      "summary": "This Delphi-based consensus process produced a comprehensive and clinically relevant Entrustable Professional Activities framework specifically designed for head and neck surgery residency training. This framework provides clear milestones and assessment criteria for progressive competence development throughout residency, enabling objective evaluation of trainee readiness for independent practice. Implementation...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154394",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Rogério Aparecido Dedivitis, PhD, MD",
      "presenter": "Rogério Aparecido Dedivitis, PhD, MD",
      "authors": "Mario Augusto F Castro, PhD, MD 1 ; Rogério Aparecido Dedivitis, PhD, MD 2 ; Fátima Cristina M de Matos, PhD, MD 3 ; Marco Aurélio V Kulcsar, PhD, MD 2 ; Luiz Paulo Kowalski, PhD, MD 2 ; José Guilherme Vartanian, PhD, MD 4 ; Ricardo R Gama, PhD, MD 5 ; Flávio C Hojaij, PhD, MD 2 ; Bruno P Duarte, Mr 1 ; Pedro Cesar M Silveira, Mr 1",
      "normalized_authors": [
        "Mario Augusto F Castro",
        "Rogério Aparecido Dedivitis",
        "Fátima Cristina M de Matos",
        "Marco Aurélio V Kulcsar",
        "Luiz Paulo Kowalski",
        "José Guilherme Vartanian",
        "Ricardo R Gama",
        "Flávio C Hojaij",
        "Bruno P Duarte, Mr",
        "Pedro Cesar M Silveira, Mr"
      ],
      "affiliations": [
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "University of São Paulo School of Medicine, São Paulo, Brazil",
        "Universidade Estadual de Pernambuco, Recife, Brazil",
        "Sociedade Brasileira de Cirurgia de Cabeça e Pescoço, São Paulo, Brazil. A.C.Camargo Cancer Center, Sao Paulo, Brazil",
        "Barretos Cancer Hospital, São Paulo, Brazil"
      ],
      "normalized_institutions": [
        "School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil",
        "University of São Paulo School of Medicine, São Paulo, Brazil",
        "Universidade Estadual de Pernambuco, Recife, Brazil",
        "Sociedade Brasileira de Cirurgia de Cabeça e Pescoço, São Paulo, Brazil. A.C.Camargo Cancer Center, Sao Paulo, Brazil",
        "Barretos Cancer Hospital, São Paulo, Brazil"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mario Augusto F Castro, PhD, MD 1 ; Rogério Aparecido Dedivitis, PhD, MD 2 ; Fátima Cristina M de Matos, PhD, MD 3 ; Marco Aurélio V Kulcsar, PhD, MD 2 ; Luiz Paulo Kowalski, PhD, MD 2 ; José Guilherme Vartanian, PhD, MD 4 ; Ricardo R Gama, PhD, MD 5 ; Flávio C Hojaij, PhD, MD 2 ; Bruno P Duarte, Mr 1 ; Pedro Cesar M Silveira, Mr 1",
        "Affiliations": "1 School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; 2 University of São Paulo School of Medicine, São Paulo, Brazil; 3 Universidade Estadual de Pernambuco, Recife, Brazil; 4 Sociedade Brasileira de Cirurgia de Cabeça e Pescoço, São Paulo, Brazil. A.C.Camargo Cancer Center, Sao Paulo, Brazil; 5 Barretos Cancer Hospital, São Paulo, Brazil",
        "Background": "The transition from supervised training to independent professional practice represents a critical juncture in surgical education that requires careful assessment and validation of clinical competence. Entrustable Professional Activities represent an innovative educational framework that provides a practical and structured approach to assess clinical readiness and competence among surgical residents. This framework shifts focus from abstract competency domains to concrete professional activities that practitioners must perform independently in clinical practice. By defining specific clinical tasks that trainees can be progressively entrusted to perform with decreasing supervision, Entrustable Professional Activities bridge the gap between competency assessment and real-world clinical practice requirements. This approach enables educators to make informed decisions about the level of supervision appropriate for each trainee in specific clinical scenarios, ultimately enhancing patient safety while promoting trainee autonomy as competence develops.",
        "Objective": "To develop a comprehensive and standardized set of Entrustable Professional Activities specifically tailored to head and neck surgery residency training, providing clear assessment criteria and progressive entrustment levels that guide resident development from novice to independent practitioner capable of supervising others.",
        "Methods": "An expert panel of experienced head and neck surgeons and surgical educators was assembled. The panel utilized a modified Delphi consensus methodology to achieve agreement among experts through iterative rounds of structured feedback. The process began with identification and initial mapping of core competencies required for safe and effective head and neck surgery specialty practice, derived from analysis of existing competency frameworks, clinical practice requirements, and educational standards. A preliminary Entrustable Professional Activities framework was subsequently developed, defining specific clinical activities that encompass these core competencies. This draft framework was distributed electronically to all panel members for independently evaluate each proposed activity for clarity, clinical relevance, appropriateness for the specialty, and feasibility of assessment. Two sequential rounds of review were conducted, an 85% agreement threshold was established for definitive consensus and the associated entrustment levels. Activities not achieving consensus underwent revision based on panel feedback and were reconsidered in subsequent rounds.",
        "Results": "The consensus process successfully established 18 distinct Entrustable Professional Activities that comprehensively represent the scope of head and neck surgery practice. Each activity was systematically mapped to multiple core surgical competencies, ensuring comprehensive coverage of the knowledge, skills, and professional behaviors required for specialty practice. The activities span the full range of clinical practice including diagnostic evaluation, surgical procedures of varying complexity, perioperative management, multidisciplinary collaboration, and patient counseling. Each Entrustable Professional Activity was further stratified into five progressive entrustment levels that define the trajectory of resident development, ranging from direct supervision (Level 1) to independent practice (Level 5).",
        "Conclusion": "This Delphi-based consensus process produced a comprehensive and clinically relevant Entrustable Professional Activities framework specifically designed for head and neck surgery residency training. This framework provides clear milestones and assessment criteria for progressive competence development throughout residency, enabling objective evaluation of trainee readiness for independent practice. Implementation of this framework can guide both resident assessment practices and curriculum design, ensuring that training experiences align with the activities residents will perform in independent practice.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Entrustable Professional Activities Framework for Head and Neck Surgery Residency Training</span>. Mario Augusto F Castro, PhD, MD<sup>1</sup>; <u>Rogério Aparecido Dedivitis, PhD, MD</u><sup>2</sup>; Fátima Cristina M de Matos, PhD, MD<sup>3</sup>; Marco Aurélio V Kulcsar, PhD, MD<sup>2</sup>; Luiz Paulo Kowalski, PhD, MD<sup>2</sup>; José Guilherme Vartanian, PhD, MD<sup>4</sup>; Ricardo R Gama, PhD, MD<sup>5</sup>; Flávio C Hojaij, PhD, MD<sup>2</sup>; Bruno P Duarte, Mr<sup>1</sup>; Pedro Cesar M Silveira, Mr<sup>1</sup>. <sup>1</sup>School of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; <sup>2</sup>University of São Paulo School of Medicine, São Paulo, Brazil; <sup>3</sup>Universidade Estadual de Pernambuco, Recife, Brazil; <sup>4</sup>Sociedade Brasileira de Cirurgia de Cabeça e Pescoço, São Paulo, Brazil. A.C.Camargo Cancer Center, Sao Paulo, Brazil; <sup>5</sup>Barretos Cancer Hospital, São Paulo, Brazil<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>The transition from supervised training to independent professional practice represents a critical juncture in surgical education that requires careful assessment and validation of clinical competence. Entrustable Professional Activities represent an innovative educational framework that provides a practical and structured approach to assess clinical readiness and competence among surgical residents. This framework shifts focus from abstract competency domains to concrete professional activities that practitioners must perform independently in clinical practice. By defining specific clinical tasks that trainees can be progressively entrusted to perform with decreasing supervision, Entrustable Professional Activities bridge the gap between competency assessment and real-world clinical practice requirements. This approach enables educators to make informed decisions about the level of supervision appropriate for each trainee in specific clinical scenarios, ultimately enhancing patient safety while promoting trainee autonomy as competence develops.</p>\n\n<p><strong>Objective:</strong> To develop a comprehensive and standardized set of Entrustable Professional Activities specifically tailored to head and neck surgery residency training, providing clear assessment criteria and progressive entrustment levels that guide resident development from novice to independent practitioner capable of supervising others.</p>\n\n<p><strong>Methods:</strong> An expert panel of experienced head and neck surgeons and surgical educators was assembled. The panel utilized a modified Delphi consensus methodology to achieve agreement among experts through iterative rounds of structured feedback. The process began with identification and initial mapping of core competencies required for safe and effective head and neck surgery specialty practice, derived from analysis of existing competency frameworks, clinical practice requirements, and educational standards. A preliminary Entrustable Professional Activities framework was subsequently developed, defining specific clinical activities that encompass these core competencies. This draft framework was distributed electronically to all panel members for independently evaluate each proposed activity for clarity, clinical relevance, appropriateness for the specialty, and feasibility of assessment. Two sequential rounds of review were conducted, an 85% agreement threshold was established for definitive consensus and the associated entrustment levels. Activities not achieving consensus underwent revision based on panel feedback and were reconsidered in subsequent rounds.</p>\n\n<p><strong>Results:</strong> The consensus process successfully established 18 distinct Entrustable Professional Activities that comprehensively represent the scope of head and neck surgery practice. Each activity was systematically mapped to multiple core surgical competencies, ensuring comprehensive coverage of the knowledge, skills, and professional behaviors required for specialty practice. The activities span the full range of clinical practice including diagnostic evaluation, surgical procedures of varying complexity, perioperative management, multidisciplinary collaboration, and patient counseling. Each Entrustable Professional Activity was further stratified into five progressive entrustment levels that define the trajectory of resident development, ranging from direct supervision (Level 1) to independent practice (Level 5).</p>\n\n<p><strong>Conclusion:</strong> This Delphi-based consensus process produced a comprehensive and clinically relevant Entrustable Professional Activities framework specifically designed for head and neck surgery residency training. This framework provides clear milestones and assessment criteria for progressive competence development throughout residency, enabling objective evaluation of trainee readiness for independent practice. Implementation of this framework can guide both resident assessment practices and curriculum design, ensuring that training experiences align with the activities residents will perform in independent practice. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154394--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S566",
      "content_id": "154351",
      "abstract_number": "S566",
      "poster_number": "",
      "title": "Ergonomic Assessment of Otolaryngologists During Major Reconstructive Surgery",
      "summary": "Major ablative and reconstructive surgeries take an ergonomic toll on the surgeon. Our findings using objective RULA scoring show that the ergonomic burden was significantly higher during the reconstructive portions of the case, and higher with more use of assistive devices. The use of surgical assistive devices can contribute negatively to ergonomic burden as a case continues. Surgeons consistently reported...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154351",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kayla Jackson",
      "presenter": "Kayla Jackson",
      "authors": "Kayla Jackson ; James O'Brien; Rusha Patel, MD; Michael Machiorlatti, PhD",
      "normalized_authors": [
        "Kayla Jackson",
        "James O'Brien",
        "Rusha Patel",
        "Michael Machiorlatti"
      ],
      "affiliations": [
        "University of Oklahoma College of Medicine"
      ],
      "normalized_institutions": [
        "University of Oklahoma College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Reconstruction / Microvascular Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Reconstruction / Microvascular Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 507,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Kayla Jackson ; James O'Brien; Rusha Patel, MD; Michael Machiorlatti, PhD",
        "Affiliations": "University of Oklahoma College of Medicine",
        "Background": "Ergonomic burden is a known part of complex head and neck reconstruction cases. There is limited data comparing objective ergonomic metrics between these two phases of a single operation. Understanding ergonomic differences between dissection and reconstruction may help identify modifiable risk factors and guide ergonomic interventions.",
        "Objective": "This study aims to evaluate ergonomic burden during the dissection and reconstruction phases of major head and neck surgeries using Rapid Upper Limb Assessment (RULA) scores collected at 30-minute intervals, as well as surgeon surveys on perceived ergonomic burden.",
        "Methods": "Otolaryngology faculty and residents at the University of Oklahoma Health Campus who met eligibility criteria were observed during major ablative and reconstructive head and neck cancer surgeries. Pre-study biometrics were collected. Intraoperative surgeon positioning was assessed by independent observers using the RULA tool at 30-minute intervals, with each score categorized by operative phase (dissection vs reconstruction). The use of surgical assistive devices, including headlamps, loupes, stools, and microscopes, were also recorded. A postoperative survey assessed perceived case difficulty and intraoperative discomfort or pain. A mixed model analysis was used to explore the association between covariates and RULA scores. R v4.3.2 and R Studio (2023.12.1+402) were used for all analysis.",
        "Results": "7 otolaryngologists, 4 male and 3 female were observed over 21 cases. The mean age was 34.43 years, average height was 166.57 cm, average weight was 158.71 lbs., and mean glove size was 6.71. Perceived case difficulty was mostly rated as ‘average’ (46.7%), followed by ‘more difficult than average’ (40%); the minority (13.3%) of cases were rated ‘easier than average’. The average operating time was 6.86 hours.",
        "Abstract": "The mean RULA score was 4.26 for all surgeries, with a mean of 4.24 (range: 3-7) during dissection and 4.30 (range: 1-6.5) during reconstruction. Surgeons had a significantly higher RULA during the reconstruction with an average increase score of 0.62 (95% CI 0.32-0.92, p = 0.043). The use of 3 or more surgical assistive devices was significantly associated with differences in RULA score by length of the case (p =.0153) showing differential trends throughout the length of the case. Post-survey data showed a mean maximum discomfort score was 2.67/10, with pain or discomfort requiring positional adjustment in 40% of cases. In 13.3% of cases, surgeons reported being distracted by their discomfort and felt the need to take a break due to strain. No surgeons indicated that discomfort interfered with their ability to operate. View in Agenda and Add to Schedule",
        "Conclusion": "Major ablative and reconstructive surgeries take an ergonomic toll on the surgeon. Our findings using objective RULA scoring show that the ergonomic burden was significantly higher during the reconstructive portions of the case, and higher with more use of assistive devices. The use of surgical assistive devices can contribute negatively to ergonomic burden as a case continues. Surgeons consistently reported self-adjustment for discomfort and several cited ergonomic strain as distracting. These results provide an opportunity for continued education and intervention to preserve surgical longevity."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ergonomic Assessment of Otolaryngologists During Major Reconstructive Surgery</span>. <u>Kayla Jackson</u>; James O'Brien; Rusha Patel, MD; Michael Machiorlatti, PhD. University of Oklahoma College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Ergonomic burden is a known part of complex head and neck reconstruction cases. There is limited data comparing objective ergonomic metrics between these two phases of a single operation. Understanding ergonomic differences between dissection and reconstruction may help identify modifiable risk factors and guide ergonomic interventions. </p>\n\n<p><strong>Objective</strong>: This study aims to evaluate ergonomic burden during the dissection and reconstruction phases of major head and neck surgeries using Rapid Upper Limb Assessment (RULA) scores collected at 30-minute intervals, as well as surgeon surveys on perceived ergonomic burden. </p>\n\n<p><strong>Methods</strong>: Otolaryngology faculty and residents at the University of Oklahoma Health Campus who met eligibility criteria were observed during major ablative and reconstructive head and neck cancer surgeries. Pre-study biometrics were collected. Intraoperative surgeon positioning was assessed by independent observers using the RULA tool at 30-minute intervals, with each score categorized by operative phase (dissection vs reconstruction). The use of surgical assistive devices, including headlamps, loupes, stools, and microscopes, were also recorded. A postoperative survey assessed perceived case difficulty and intraoperative discomfort or pain. A mixed model analysis was used to explore the association between covariates and RULA scores. R v4.3.2 and R Studio (2023.12.1+402) were used for all analysis. </p>\n\n<p><strong>Results</strong>: 7 otolaryngologists, 4 male and 3 female were observed over 21 cases. The mean age was 34.43 years, average height was 166.57 cm, average weight was 158.71 lbs., and mean glove size was 6.71. Perceived case difficulty was mostly rated as ‘average’ (46.7%), followed by ‘more difficult than average’ (40%); the minority (13.3%) of cases were rated ‘easier than average’. The average operating time was 6.86 hours. </p>\n\n<p>The mean RULA score was 4.26 for all surgeries, with a mean of 4.24 (range: 3-7) during dissection and 4.30 (range: 1-6.5) during reconstruction. Surgeons had a significantly higher RULA during the reconstruction with an average increase score of 0.62 (95% CI 0.32-0.92, p = 0.043). The use of 3 or more surgical assistive devices was significantly associated with differences in RULA score by length of the case (p =.0153) showing differential trends throughout the length of the case. Post-survey data showed a mean maximum discomfort score was 2.67/10, with pain or discomfort requiring positional adjustment in 40% of cases. In 13.3% of cases, surgeons reported being distracted by their discomfort and felt the need to take a break due to strain. No surgeons indicated that discomfort interfered with their ability to operate. </p>\n\n<p><strong>Conclusion</strong>: Major ablative and reconstructive surgeries take an ergonomic toll on the surgeon. Our findings using objective RULA scoring show that the ergonomic burden was significantly higher during the reconstructive portions of the case, and higher with more use of assistive devices. The use of surgical assistive devices can contribute negatively to ergonomic burden as a case continues. Surgeons consistently reported self-adjustment for discomfort and several cited ergonomic strain as distracting. These results provide an opportunity for continued education and intervention to preserve surgical longevity. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154351--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S567",
      "content_id": "153133",
      "abstract_number": "S567",
      "poster_number": "",
      "title": "Development of a stereoscopic solution for recording and reviewing microsurgical operations in training centers",
      "summary": "The binocular microscope used in Otolaryngologic surgeries is a unique piece of optical equipment. Through a single objective lens, the prism splits the light into two channels, projecting two similar yet distinct images into the surgeon's eyes. Compared to monocular optic systems, these stereoscopic images can provide operators with a sense of depth perception. A commercial solution that could record these...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Worabun Romtrairut",
      "presenter": "Worabun Romtrairut",
      "authors": "Worabun Romtrairut ; Phitthawat Yingsukamol; Piamkhun Siritantikorn; Doungporn Rodpitaks, RN; Sivaporn Kiatthanabumrung, MD; Pawin Numthavaj, Asst Prof, PhD, MD",
      "normalized_authors": [
        "Worabun Romtrairut",
        "Phitthawat Yingsukamol",
        "Piamkhun Siritantikorn",
        "Doungporn Rodpitaks",
        "Sivaporn Kiatthanabumrung",
        "Pawin Numthavaj, Asst Prof"
      ],
      "affiliations": [
        "Faculty of Medicine Ramathibodi Hospital, Mahidol University"
      ],
      "normalized_institutions": [
        "Faculty of Medicine Ramathibodi Hospital, Mahidol University"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%201.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%201.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%202.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%202.png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%203.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%203.png",
          "alt": "Source figure 3",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%204.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%204.png",
          "alt": "Source figure 4",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%205.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%205.png",
          "alt": "Source figure 5",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%206.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%206.jpg",
          "alt": "Source figure 6",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153133/Image%207.jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/153133/Image%207.jpg",
          "alt": "Source figure 7",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153133"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 470,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Worabun Romtrairut ; Phitthawat Yingsukamol; Piamkhun Siritantikorn; Doungporn Rodpitaks, RN; Sivaporn Kiatthanabumrung, MD; Pawin Numthavaj, Asst Prof, PhD, MD",
        "Affiliations": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
        "Abstract": "The binocular microscope used in Otolaryngologic surgeries is a unique piece of optical equipment. Through a single objective lens, the prism splits the light into two channels, projecting two similar yet distinct images into the surgeon's eyes. Compared to monocular optic systems, these stereoscopic images can provide operators with a sense of depth perception. A commercial solution that could record these stereoscopic operations through specialized equipment exists, but might not be available at all Otolaryngology training centers. We developed a recording solution that connects two commercially available cameras to an optical side viewing module in an attempt to record stereoscopic video. We took measurements of the eyepieces of the microscope model (Carl Zeiss OPMI Sensera) and modelled in Fusion 360 software version 2604.1.48. A fixture system was then designed to hold the camera on the microscope's eyepiece. We selected Sony RX0MKII for their high-resolution (4K, 30 frames per second) recording capability through the HDMI output. To determine the optimal camera placement, a flying-gantry style attachment was designed and integrated into the fixture system, allowing the camera to be positioned in all 3 dimensions. We also later used this device to determine the optimal location for the observer side tube. After determining the optimal camera position relative to each eyepiece, a compact fixture was designed and tested. Footage for each eye was then recorded in each camera’s memory. The early prototypes experienced overheating issues, which were subsequently rectified, allowing the cameras to record continuous 4K-resolution videos for 2 hours. The recorded footage from both cameras was then combined into a single 7680 by 2160 video resolution in OBS Studio software 32.0.2, and converted to an SBS file using FFMpeg 8.0.0. The footage was then displayed and evaluated on Apple Vision Pro virtual reality goggles (Version 1, Apple Inc.). In the testing stage, we prospectively recorded footage of an in vivo myringotomy procedure performed by a skilled Otolaryngology surgeon after obtaining permission from the ethics committee and informed consent from the patient. (COA. NO. MURA2025/282) The resulting stereoscopic video proved that our recording system is capable of capturing 4K stereoscopic footage from a Zeiss microscope system through the observer tubes, while keeping the total cost of all equipment under $3,500. A significant portion of the equipment cost was attributed to the two cameras and a custom-built recording computer, which needs sufficient computing power to process the recorded videos from two PCIe capture cards. The remaining components are manufactured via 3D printing, resulting in lower hardware production costs. To the best of our understanding, our solution is the first to provide a simple upgrade solution for microscopes in small training centers, enabling stereoscopic recording capabilities making the experience of reviewing microsurgical operations more realistic for young trainees. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development of a stereoscopic solution for recording and reviewing microsurgical operations in training centers</span>. <u>Worabun Romtrairut</u>; Phitthawat Yingsukamol; Piamkhun Siritantikorn; Doungporn Rodpitaks, RN; Sivaporn Kiatthanabumrung, MD; Pawin Numthavaj, Asst Prof, PhD, MD. Faculty of Medicine Ramathibodi Hospital, Mahidol University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The binocular microscope used in Otolaryngologic surgeries is a unique piece of optical equipment. Through a single objective lens, the prism splits the light into two channels, projecting two similar yet distinct images into the surgeon's eyes. Compared to monocular optic systems, these stereoscopic images can provide operators with a sense of depth perception. A commercial solution  that could record these stereoscopic operations  through specialized equipment exists, but might not be available at all Otolaryngology training centers. We developed a recording solution that connects two commercially available cameras to an optical side viewing module in an attempt to record stereoscopic video.</p>\n\n<p>We took measurements of the eyepieces of the microscope model (Carl Zeiss OPMI Sensera) and modelled in Fusion 360 software version 2604.1.48. A fixture system was then designed to hold the camera on the microscope's eyepiece. We selected Sony RX0MKII for their high-resolution (4K, 30 frames per second) recording capability through the HDMI output. To determine the optimal camera placement, a flying-gantry style attachment was designed and integrated into the fixture system, allowing the camera to be positioned in all 3 dimensions. We also later used this device to determine the optimal location for the observer side tube. After determining the optimal camera position relative to each eyepiece, a compact fixture was designed and tested. Footage for each eye was then recorded in each camera’s memory. The early prototypes experienced overheating issues, which were subsequently rectified, allowing the cameras to record continuous 4K-resolution videos for 2 hours. The recorded footage from both cameras was then combined into a single 7680 by 2160 video resolution in OBS Studio software 32.0.2, and converted to an SBS file using FFMpeg 8.0.0. The footage was then displayed and evaluated on Apple Vision Pro virtual reality goggles (Version 1, Apple Inc.). In the testing stage, we prospectively recorded footage of an in vivo myringotomy procedure performed by a skilled Otolaryngology surgeon after obtaining permission from the ethics committee and informed consent from the patient. (COA. NO. MURA2025/282)</p>\n\n<p>The resulting stereoscopic video proved that our recording system is capable of capturing 4K stereoscopic footage from a Zeiss microscope system through the observer tubes, while keeping the total cost of all equipment under $3,500. A significant portion of the equipment cost was attributed to the two cameras and a custom-built recording computer, which needs sufficient computing power to process the recorded videos from two PCIe capture cards. The remaining components are manufactured via 3D printing, resulting in lower hardware production costs.</p>\n\n<p>To the best of our understanding, our solution is the first to provide a simple upgrade solution for microscopes in small training centers, enabling stereoscopic recording capabilities making the experience of reviewing microsurgical operations more realistic for young trainees.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%201.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%202.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%203.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%204.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%205.png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%206.jpg' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153133/Image%207.jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153133--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S568",
      "content_id": "153285",
      "abstract_number": "S568",
      "poster_number": "",
      "title": "Current State of Human Papillomavirus-Related Oropharyngeal Cancer Content in United States Medical Education",
      "summary": "While popular third-party medical education resources adequately cover fundamental knowledge about HPV, its vaccine, and HNC, gaps persist in HPV+ OPSCC-specific content. HPV+ OPSCC must be increasingly emphasized in U.S. medical education so future physicians can better identify, counsel, and refer patients at risk for, or with suspected, malignancy.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153285",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Matthew E Lin, MD",
      "presenter": "Matthew E Lin, MD",
      "authors": "Matthew E Lin, MD 1 ; Diego E Razura, MD 2 ; Keer Zhang, BS 3 ; Carine Tamanian, BS 4 ; Jun Yun, BS 3 ; Gabriella Cote 5 ; Abdul-Rahman K Abdul-Reheem, MD 1 ; Lauran K Evans, MD, MPH 1 ; Eden R Brauer, PhD 6 ; Maie St",
      "normalized_authors": [
        "Matthew E Lin",
        "Diego E Razura",
        "Keer Zhang",
        "Carine Tamanian",
        "Jun Yun",
        "Gabriella Cote",
        "Abdul-Rahman K Abdul-Reheem",
        "Lauran K Evans",
        "Eden R Brauer",
        "Maie St"
      ],
      "affiliations": [
        "John, MD, PhD 7 . 1 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles",
        "Department of Otolaryngology–Head & Neck Surgery, Mayo Clinic Arizona",
        "David Geffen School of Medicine at UCLA",
        "University of California San Diego School of Medicine",
        "East Tennessee State University Quillen College of Medicine",
        "School of Nursing, David Geffen School of Medicine at UCLA",
        "Department of Otolaryngology–Head & Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System"
      ],
      "normalized_institutions": [
        "John, MD, PhD 7 . 1 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles",
        "Department of Otolaryngology–Head & Neck Surgery, Mayo Clinic Arizona",
        "David Geffen School of Medicine at UCLA",
        "University of California San Diego School of Medicine",
        "East Tennessee State University Quillen College of Medicine",
        "School of Nursing, David Geffen School of Medicine at UCLA",
        "Department of Otolaryngology–Head & Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153285/Screenshot%202025-12-04%20at%209_13_12%E2%80%AFPM.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153285/Screenshot%202025-12-04%20at%209_13_12%E2%80%AFPM.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153285"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 550,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Matthew E Lin, MD 1 ; Diego E Razura, MD 2 ; Keer Zhang, BS 3 ; Carine Tamanian, BS 4 ; Jun Yun, BS 3 ; Gabriella Cote 5 ; Abdul-Rahman K Abdul-Reheem, MD 1 ; Lauran K Evans, MD, MPH 1 ; Eden R Brauer, PhD 6 ; Maie St",
        "Affiliations": "John, MD, PhD 7 . 1 Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles; 2 Department of Otolaryngology–Head & Neck Surgery, Mayo Clinic Arizona; 3 David Geffen School of Medicine at UCLA; 4 University of California San Diego School of Medicine; 5 East Tennessee State University Quillen College of Medicine; 6 School of Nursing, David Geffen School of Medicine at UCLA; 7 Department of Otolaryngology–Head & Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System",
        "Introduction": "Despite the rising epidemic of human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), practicing physicians possess variable knowledge about this disease. Standardizing medical education may better prepare future physicians to manage HPV+ OPSCC. Because third-party resources designed for medical board examination are nearly ubiquitously used among medical students, we evaluated commonly used resources to characterize the state of HPV+ OPSCC-related medical education.",
        "Methods": "We conducted a cross-sectional analysis of 13 third-party medical education resources classified by exam (USMLE STEP 1, STEP 2) and resource type (question bank, textbook, video bank, notecard deck, educational platform). Resources were queried for a list of 34 topics spanning 9 categories (HPV-related cancers, HPV warts, HPV+ OPSCC, head and neck cancer (HNC) risk factors/symptoms, virology/microbiology, epidemiology, HPV vaccine, prevention strategies, counseling) assembled and reviewed by four head and neck surgery residents, one HNC researcher, and one HNC surgeon. Nine of the 34 topics were designated by the research team as “HPV+ OPSCC Essentials.”",
        "Abstract": "Each resource was assessed by two independent reviewers; disagreements between reviewers were resolved by a third reviewer. Topic inclusion was marked as yes/no; topic mentions were manually transcribed into a separate document. Descriptive statistics were used to characterize the cohort and topic prevalence. Chi-square and Fisher’s exact tests were used to assess differences in topic inclusion within individual themes and across resources. Multivariable logistic regression was used to assess resource-specific factors associated with mentioning HPV+ OPSCC Essentials. Inductive thematic analysis of transcribed materials is ongoing. Mention of topics within the HNC risk factor (p=0.006) and vaccine indication (p<0.001) themes varied. OPSCC preventative measures were less frequently mentioned than those for cervical cancer (30.8% vs 100.0%, p<0.001). Mentions of HNC symptoms (p=0.012) and HPV+ OPSCC’s favorable prognosis (p=0.006) varied across resource types. Through multivariable logistic regression, textbook, video, and notecard-based resources were less likely than question-based resources to include key HPV+ OPSCC topics (all p<0.05). View in Agenda and Add to Schedule",
        "Results": "Resources reviewed were most commonly video databases (n=4, 30.8%) or textbooks (n=3, 23.1%), evenly distributed between STEP 1 (n=7, 53.8%) and STEP 2 (n=6, 46.2%). Across all resources, cervical cancer (n=13, 100.0%) was more frequently mentioned than OPSCC (n=11, 84.62%) in relation to HPV. While tobacco (n=11, 84.6%) and alcohol (n=10, 76.9%) were commonly listed as HNC risk factors, HPV p16 (n=4, 30.8%) was included less frequently. HNC symptoms (n=8, 61.5%) and the HPV vaccine’s protection against oncogenic subtypes (n=12, 92.3%), age eligibility (n=8, 61.5%), and indication for both sexes (both n=9, 69.2%) were frequently reported. However, HPV+ OPSCC’s favorable prognosis (n=4, 30.8%) and the vaccine’s indication for OPSCC (n=2, 15.4%) were less mentioned; HPV+ OPSCC exceeding HPV+ cervical cancer in annual incidence was altogether absent (n=0, 0.0%).",
        "Conclusion": "While popular third-party medical education resources adequately cover fundamental knowledge about HPV, its vaccine, and HNC, gaps persist in HPV+ OPSCC-specific content. HPV+ OPSCC must be increasingly emphasized in U.S. medical education so future physicians can better identify, counsel, and refer patients at risk for, or with suspected, malignancy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Current State of Human Papillomavirus-Related Oropharyngeal Cancer Content in United States Medical Education</span>. <u>Matthew E Lin, MD</u><sup>1</sup>; Diego E Razura, MD<sup>2</sup>; Keer Zhang, BS<sup>3</sup>; Carine Tamanian, BS<sup>4</sup>; Jun Yun, BS<sup>3</sup>; Gabriella Cote<sup>5</sup>; Abdul-Rahman K Abdul-Reheem, MD<sup>1</sup>; Lauran K Evans, MD, MPH<sup>1</sup>; Eden R Brauer, PhD<sup>6</sup>; Maie St. John, MD, PhD<sup>7</sup>. <sup>1</sup>Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles; <sup>2</sup>Department of Otolaryngology–Head & Neck Surgery, Mayo Clinic Arizona; <sup>3</sup>David Geffen School of Medicine at UCLA; <sup>4</sup>University of California San Diego School of Medicine; <sup>5</sup>East Tennessee State University Quillen College of Medicine; <sup>6</sup>School of Nursing, David Geffen School of Medicine at UCLA; <sup>7</sup>Department of Otolaryngology–Head & Neck Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Health System<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Despite the rising epidemic of human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), practicing physicians possess variable knowledge about this disease. Standardizing medical education may better prepare future physicians to manage HPV+ OPSCC. Because third-party resources designed for medical board examination are nearly ubiquitously used among medical students, we evaluated commonly used resources to characterize the state of HPV+ OPSCC-related medical education.</p>\n\n<p><strong>Methods: </strong>We conducted a cross-sectional analysis of 13 third-party medical education resources classified by exam (USMLE STEP 1, STEP 2) and resource type (question bank, textbook, video bank, notecard deck, educational platform). Resources were queried for a list of 34 topics spanning 9 categories (HPV-related cancers, HPV warts, HPV+ OPSCC, head and neck cancer (HNC) risk factors/symptoms, virology/microbiology, epidemiology, HPV vaccine, prevention strategies, counseling) assembled and reviewed by four head and neck surgery residents, one HNC researcher, and one HNC surgeon. Nine of the 34 topics were designated by the research team as “HPV+ OPSCC Essentials.”</p>\n\n<p>Each resource was assessed by two independent reviewers; disagreements between reviewers were resolved by a third reviewer. Topic inclusion was marked as yes/no; topic mentions were manually transcribed into a separate document.</p>\n\n<p>Descriptive statistics were used to characterize the cohort and topic prevalence. Chi-square and Fisher’s exact tests were used to assess differences in topic inclusion within individual themes and across resources. Multivariable logistic regression was used to assess resource-specific factors associated with mentioning HPV+ OPSCC Essentials. Inductive thematic analysis of transcribed materials is ongoing.</p>\n\n<p><strong>Results: </strong>Resources reviewed were most commonly video databases (n=4, 30.8%) or textbooks (n=3, 23.1%), evenly distributed between STEP 1 (n=7, 53.8%) and STEP 2 (n=6, 46.2%). Across all resources, cervical cancer (n=13, 100.0%) was more frequently mentioned than OPSCC (n=11, 84.62%) in relation to HPV. While tobacco (n=11, 84.6%) and alcohol (n=10, 76.9%) were commonly listed as HNC risk factors, HPV p16 (n=4, 30.8%) was included less frequently. HNC symptoms (n=8, 61.5%) and the HPV vaccine’s protection against oncogenic subtypes (n=12, 92.3%), age eligibility (n=8, 61.5%), and indication for both sexes (both n=9, 69.2%) were frequently reported. However, HPV+ OPSCC’s favorable prognosis (n=4, 30.8%) and the vaccine’s indication for OPSCC (n=2, 15.4%) were less mentioned; HPV+ OPSCC exceeding HPV+ cervical cancer in annual incidence was altogether absent (n=0, 0.0%).</p>\n\n<p>Mention of topics within the HNC risk factor (p=0.006) and vaccine indication (p<0.001) themes varied. OPSCC preventative measures were less frequently mentioned than those for cervical cancer (30.8% vs 100.0%, p<0.001). Mentions of HNC symptoms (p=0.012) and HPV+ OPSCC’s favorable prognosis (p=0.006) varied across resource types. Through multivariable logistic regression, textbook, video, and notecard-based resources were less likely than question-based resources to include key HPV+ OPSCC topics (all p<0.05).</p>\n\n<p><strong>Conclusion: </strong>While popular third-party medical education resources adequately cover fundamental knowledge about HPV, its vaccine, and HNC, gaps persist in HPV+ OPSCC-specific content. HPV+ OPSCC must be increasingly emphasized in U.S. medical education so future physicians can better identify, counsel, and refer patients at risk for, or with suspected, malignancy.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/153285/Screenshot%202025-12-04%20at%209_13_12%E2%80%AFPM.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153285--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S569",
      "content_id": "154489",
      "abstract_number": "S569",
      "poster_number": "",
      "title": "Insights in Teaching Point-of-Care Ultrasound in South Africa",
      "summary": "There were 22 complete responses and 1 partial response for the pre-course survey. The majority of respondents had never received ultrasound education (63.6%), and none reported using ultrasound regularly. In addition, access to ultrasound was quite limited as only 9% of participants reported consistent access to a machine. The most commonly reported barriers to POCUS were lack of support from ultrasound mentors...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154489",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Celeste Kim, MD",
      "presenter": "Celeste Kim, MD",
      "authors": "Alexander Abodllahzadeh 1 ; Matthew White, MD 2 ; Celeste Kim, MD 1 ; Merry Sebelik, MD 1 ; Maxwell Kligerman, MD, MPH 1",
      "normalized_authors": [
        "Alexander Abodllahzadeh",
        "Matthew White",
        "Celeste Kim",
        "Merry Sebelik",
        "Maxwell Kligerman"
      ],
      "affiliations": [
        "Emory University School of Medicine",
        "University of Cape Town"
      ],
      "normalized_institutions": [
        "Emory University School of Medicine",
        "University of Cape Town"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 433,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Alexander Abodllahzadeh 1 ; Matthew White, MD 2 ; Celeste Kim, MD 1 ; Merry Sebelik, MD 1 ; Maxwell Kligerman, MD, MPH 1",
        "Affiliations": "1 Emory University School of Medicine; 2 University of Cape Town",
        "Objective": "To quantify baseline understanding and availability of point-of-care ultrasonography (POCUS) among otolaryngology providers in sub-Saharan Africa and evaluate early impact of a head and neck POCUS training course.",
        "Introduction": "Portable point-of-care ultrasonography (POCUS) is an accessible diagnostic modality valuable for evaluating head and neck (H&N) pathology including thyroid disease and H&N malignancy. POCUS has been associated with reduced delays in diagnosis, cost-effective imaging, and improved clinical outcomes. However, implementation in low-resource settings is challenged by limited equipment availability and insufficient formal ultrasound training. Despite reports of successful POCUS training initiatives in sub-Saharan Africa, the longitudinal educational impact of these programs remains poorly characterized. We developed and implemented a H&N POCUS training course for otolaryngologists in South Africa with the goal of establishing baseline knowledge, perceived barriers, and access to ultrasound prior to the course, while tracking short-term post-course changes in confidence and skill perception.",
        "Methods": "A H&N ultrasonography training course was held at the University of Cape Town. Participants included otolaryngologists and trainees representing multiple sub-Saharan African countries. Pre-course and post-course surveys were distributed electronically using REDCap to assess ultrasound experience, access, perceived barriers, and confidence with image acquisition and interpretation. Pre-course surveys were collected immediately prior to the training, while post-course surveys were emailed after 6 months. Responses were anonymous.",
        "Results": "There were 22 complete responses and 1 partial response for the pre-course survey. The majority of respondents had never received ultrasound education (63.6%), and none reported using ultrasound regularly. In addition, access to ultrasound was quite limited as only 9% of participants reported consistent access to a machine. The most commonly reported barriers to POCUS were lack of support from ultrasound mentors (66.7%), insufficient access to training (61.9%), and limited access to machines (61.9%). The vast majority of respondents (81.8%) overall felt that with training and access, POCUS would be a benefit to patients. The six month post-course survey received only five complete responses, limiting the interpretability of this data.",
        "Discussion": "Analysis of the collected data reveals that barriers are primarily centered around education, skill development, and long-term mentorship in the use of POCUS. While few participants reported frequent ultrasound use, most indicated they could access a machine if needed, though confidence remained low at baseline. Despite this, 82.2% expressed optimism regarding the benefit of POCUS with appropriate training. These findings underscore the need for ongoing mentorship and structured training pathways in POCUS education. Overall, this work offers valuable insight that supports future development of programs aimed at improving diagnostic capacity for H&N pathology in low-resource settings.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Insights in Teaching Point-of-Care Ultrasound in South Africa</span>. Alexander Abodllahzadeh<sup>1</sup>; Matthew White, MD<sup>2</sup>; <u>Celeste Kim, MD</u><sup>1</sup>; Merry Sebelik, MD<sup>1</sup>; Maxwell Kligerman, MD, MPH<sup>1</sup>. <sup>1</sup>Emory University School of Medicine; <sup>2</sup>University of Cape Town<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>To quantify baseline understanding and availability of point-of-care ultrasonography (POCUS) among otolaryngology providers in sub-Saharan Africa and evaluate early impact of a head and neck POCUS training course.</p>\n\n<p><strong>Introduction: </strong>Portable point-of-care ultrasonography (POCUS) is an accessible diagnostic modality valuable for evaluating head and neck (H&N) pathology including thyroid disease and H&N malignancy. POCUS has been associated with reduced delays in diagnosis, cost-effective imaging, and improved clinical outcomes. However, implementation in low-resource settings is challenged by limited equipment availability and insufficient formal ultrasound training. Despite reports of successful POCUS training initiatives in sub-Saharan Africa, the longitudinal educational impact of these programs remains poorly characterized. We developed and implemented a H&N POCUS training course for otolaryngologists in South Africa with the goal of establishing baseline knowledge, perceived barriers, and access to ultrasound prior to the course, while tracking short-term post-course changes in confidence and skill perception.</p>\n\n<p><strong>Methods: </strong>A H&N ultrasonography training course was held at the University of Cape Town. Participants included otolaryngologists and trainees representing multiple sub-Saharan African countries. Pre-course and post-course surveys were distributed electronically using REDCap to assess ultrasound experience, access, perceived barriers, and confidence with image acquisition and interpretation. Pre-course surveys were collected immediately prior to the training, while post-course surveys were emailed after 6 months. Responses were anonymous.</p>\n\n<p><strong>Results: </strong>There were 22 complete responses and 1 partial response for the pre-course survey. The majority of respondents had never received ultrasound education (63.6%), and none reported using ultrasound regularly. In addition, access to ultrasound was quite limited as only 9% of participants reported consistent access to a machine. The most commonly reported barriers to POCUS were lack of support from ultrasound mentors (66.7%), insufficient access to training (61.9%), and limited access to machines (61.9%). The vast majority of respondents (81.8%) overall felt that with training and access, POCUS would be a benefit to patients. The six month post-course survey received only five complete responses, limiting the interpretability of this data.</p>\n\n<p><strong>Discussion: </strong>Analysis of the collected data reveals that barriers are primarily centered around education, skill development, and long-term mentorship in the use of POCUS. While few participants reported frequent ultrasound use, most indicated they could access a machine if needed, though confidence remained low at baseline. Despite this, 82.2% expressed optimism regarding the benefit of POCUS with appropriate training. These findings underscore the need for ongoing mentorship and structured training pathways in POCUS education. Overall, this work offers valuable insight that supports future development of programs aimed at improving diagnostic capacity for H&N pathology in low-resource settings.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154489--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S570",
      "content_id": "154265",
      "abstract_number": "S570",
      "poster_number": "",
      "title": "Lessons from Global Thyroid Surgery: A Comparison of Environmental Impact and Surgical Outcomes",
      "summary": "Climate change has been identified as one of the leading threats to human health by the World Health Organization. Surgery, which is particularly resource intensive, represents a substantial contributor to greenhouse gas emissions through single-use materials, energy consumption, and anesthetic gases. Efforts to improve sustainability are frequently met with concerns about infection control and the risk of...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154265",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Emerson Bouldin, MD",
      "presenter": "Emerson Bouldin, MD",
      "authors": "Emerson Bouldin, MD ; David Z Allen, MD; Merry Sebelik, MD",
      "normalized_authors": [
        "Emerson Bouldin",
        "David Z Allen",
        "Merry Sebelik"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 481,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Emerson Bouldin, MD ; David Z Allen, MD; Merry Sebelik, MD",
        "Affiliations": "Emory University",
        "Abstract": "Climate change has been identified as one of the leading threats to human health by the World Health Organization. Surgery, which is particularly resource intensive, represents a substantial contributor to greenhouse gas emissions through single-use materials, energy consumption, and anesthetic gases. Efforts to improve sustainability are frequently met with concerns about infection control and the risk of compromising outcomes. Global surgery, however, offers a natural experiment to investigate this question as surgeons are often required to operate with only essential instruments and minimal disposable equipment while still maintaining rigorous standards of safety. Our institution has participated in an annual thyroid surgery initiative in Kigali, Rwanda, where recurrent laryngeal nerve outcomes and clinical outcome data have been systematically collected since 2017. This setting provides a rare opportunity to evaluate whether streamlined, resource-limited surgical practice can preserve high-quality outcomes while reducing environmental impact. We hypothesize that surgical outcomes in Rwanda are comparable to those achieved in a high-resource environment in Atlanta, Georgia, and that the environmental footprint of the Rwanda cases is substantially lower. For this study, we collected pre- and postoperative voice assessments, clinical outcomes, and detailed surgical equipment lists from hemithyroidectomy cases performed in 2023. Although longitudinal data does exist from earlier Rwanda trips, we restricted the comparison to 2023 because a transition to a new electronic medical record system in Atlanta in late 2022 limits access to prior U.S. cases. Travel to Rwanda did not occur in 2024 due to political unrest. Hemithyroidectomy for presumed benign disease represents the dominant case type performed by our team in Rwanda, driven by the need to ensure safe postoperative recovery in a low-resource setting. We identified 21 eligible patients operated on by our team in Kigali in 2023. At our tertiary U.S. center, a retrospective review of all 2023 thyroid surgeries performed by two fellowship-trained head and neck endocrine surgeons yielded 41 hemithyroidectomy cases for benign disease. Only one of these surgeons participates in the Rwanda initiative, but both share similar training, operative technique, and case mix, supporting their inclusion in the comparison cohort. Data extraction is ongoing, including confirmation of final pathology for the Rwanda cohort. Once cohorts are finalized, we will evaluate differences in postoperative voice and clinical outcomes using comparative analysis. Environmental impact will be quantified using life-cycle assessment of all equipment and consumables used per case. Itemized equipment data are available through the EMR for Atlanta cases and through detailed packing lists maintained during the Rwanda 2023 mission. This project utilizes a unique global surgery model to interrogate whether high-quality thyroid surgery truly requires the environmental cost borne by high-resource systems, or whether streamlined, essential-only surgical practice can maintain equivalent outcomes with markedly reduced environmental impact. If outcomes prove equivalent while environmental burden is substantially lower, this work could inform sustainability reforms in high-resource operating rooms without compromising patient safety. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Lessons from Global Thyroid Surgery: A Comparison of Environmental Impact and Surgical Outcomes</span>. <u>Emerson Bouldin, MD</u>; David Z Allen, MD; Merry Sebelik, MD. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Climate change has been identified as one of the leading threats to human health by the World Health Organization. Surgery, which is particularly resource intensive, represents a substantial contributor to greenhouse gas emissions through single-use materials, energy consumption, and anesthetic gases. Efforts to improve sustainability are frequently met with concerns about infection control and the risk of compromising outcomes. Global surgery, however, offers a natural experiment to investigate this question as surgeons are often required to operate with only essential instruments and minimal disposable equipment while still maintaining rigorous standards of safety.</p>\n\n<p>Our institution has participated in an annual thyroid surgery initiative in Kigali, Rwanda, where recurrent laryngeal nerve outcomes and clinical outcome data have been systematically collected since 2017. This setting provides a rare opportunity to evaluate whether streamlined, resource-limited surgical practice can preserve high-quality outcomes while reducing environmental impact. We hypothesize that surgical outcomes in Rwanda are comparable to those achieved in a high-resource environment in Atlanta, Georgia, and that the environmental footprint of the Rwanda cases is substantially lower.</p>\n\n<p>For this study, we collected pre- and postoperative voice assessments, clinical outcomes, and detailed surgical equipment lists from hemithyroidectomy cases performed in 2023. Although longitudinal data does exist from earlier Rwanda trips, we restricted the comparison to 2023 because a transition to a new electronic medical record system in Atlanta in late 2022 limits access to prior U.S. cases. Travel to Rwanda did not occur in 2024 due to political unrest.</p>\n\n<p>Hemithyroidectomy for presumed benign disease represents the dominant case type performed by our team in Rwanda, driven by the need to ensure safe postoperative recovery in a low-resource setting. We identified 21 eligible patients operated on by our team in Kigali in 2023. At our tertiary U.S. center, a retrospective review of all 2023 thyroid surgeries performed by two fellowship-trained head and neck endocrine surgeons yielded 41 hemithyroidectomy cases for benign disease. Only one of these surgeons participates in the Rwanda initiative, but both share similar training, operative technique, and case mix, supporting their inclusion in the comparison cohort.</p>\n\n<p>Data extraction is ongoing, including confirmation of final pathology for the Rwanda cohort. Once cohorts are finalized, we will evaluate differences in postoperative voice and clinical outcomes using comparative analysis. Environmental impact will be quantified using life-cycle assessment of all equipment and consumables used per case. Itemized equipment data are available through the EMR for Atlanta cases and through detailed packing lists maintained during the Rwanda 2023 mission.</p>\n\n<p>This project utilizes a unique global surgery model to interrogate whether high-quality thyroid surgery truly requires the environmental cost borne by high-resource systems, or whether streamlined, essential-only surgical practice can maintain equivalent outcomes with markedly reduced environmental impact. If outcomes prove equivalent while environmental burden is substantially lower, this work could inform sustainability reforms in high-resource operating rooms without compromising patient safety.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154265--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S571",
      "content_id": "154614",
      "abstract_number": "S571",
      "poster_number": "",
      "title": "Implementing a Sustainable Framework for Global Head and Neck Reconstruction: A Bidirectional Exchange Experience",
      "summary": "This bidirectional, continuity-focused model provides a practical framework for ethically grounded global reconstructive collaboration. By prioritizing local leadership, shared learning, and sustained engagement, the partnership demonstrated meaningful and durable capability building. As international microsurgical exchanges expand, long-term, collaborative models may offer a more impactful alternative to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154614",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chareeni Kurukulasuriya, MD",
      "presenter": "Chareeni Kurukulasuriya, MD",
      "authors": "Andrew Prince, MD 1 ; Chareeni Kurukulasuriya, MD 1 ; Thomas J Sorenson, MD 1 ; Narin Ratanaprasert, MD 2 ; Joseph Connors, MD 1 ; Michael Chow, MD 3 ; Jamie P Levine, MD 1 ; Adam S Jacobson, MD 1",
      "normalized_authors": [
        "Andrew Prince",
        "Chareeni Kurukulasuriya",
        "Thomas J Sorenson",
        "Narin Ratanaprasert",
        "Joseph Connors",
        "Michael Chow",
        "Jamie P Levine",
        "Adam S Jacobson"
      ],
      "affiliations": [
        "NYU-Langone",
        "Siriraj Hospital",
        "UCSF"
      ],
      "normalized_institutions": [
        "NYU-Langone",
        "Siriraj Hospital",
        "UCSF"
      ],
      "session_type": "Proffered Paper",
      "track": "Education / Care Delivery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Education / Care Delivery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 344,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Andrew Prince, MD 1 ; Chareeni Kurukulasuriya, MD 1 ; Thomas J Sorenson, MD 1 ; Narin Ratanaprasert, MD 2 ; Joseph Connors, MD 1 ; Michael Chow, MD 3 ; Jamie P Levine, MD 1 ; Adam S Jacobson, MD 1",
        "Affiliations": "1 NYU-Langone; 2 Siriraj Hospital; 3 UCSF",
        "Background": "International surgical outreach is frequently modeled as short-term, unidirectional expertise transfer from high-resource centers to lower-resource settings. Although well-intentioned, these missions often involve externally selected cases, limited continuity, and minimal investment in local capability. To address these limitations, we participated in a bidirectional international exchange in head and neck reconstruction designed to prioritize local leadership, skill development, and ongoing collaboration.",
        "Methods": "As part of a longitudinal partnership, our team traveled to Siriraj Hospital in Bangkok, Thailand, following a prior observership during which Thai residents trained at our home institution. The visit began with a full day of jointly delivered didactic and laboratory instruction on reconstructive techniques, including introduction of the Global Excellence in Microsurgery (GEM) venous coupler—previously unused in Thailand. Thai attending surgeons identified three complex reconstructive cases for collaborative management. Over the next three operative days, resident teams worked side-by-side performing flap harvests, microvascular anastomoses, and a flap takeback, while incorporating the GEM coupler into live venous anastomoses. We continue the bidirectional collaboration through continued through digital communication platforms to support follow-up and ongoing capability building. In 2026, several additional resident surgeons and attending surgeons are planning to visit our institution again to participate in further training.",
        "Results": "All three collaboratively selected cases were successfully completed with joint operative participation. The GEM coupler was adopted intraoperatively for the first time at Siriraj Hospital, providing a standardized technique suitable across varying levels of microsurgical experience. Continued communication enabled remote postoperative discussion and mentorship, culminating in the Thai team completing their first independently performed anterolateral thigh free flap. Throughout the exchange, clinical decision-making remained under local surgeon leadership, ensuring contextual appropriateness and patient-centered care. Post-exchange we have electronically provided our thoughts on approach and surgical management on 10 cases to-date.",
        "Conclusion": "This bidirectional, continuity-focused model provides a practical framework for ethically grounded global reconstructive collaboration. By prioritizing local leadership, shared learning, and sustained engagement, the partnership demonstrated meaningful and durable capability building. As international microsurgical exchanges expand, long-term, collaborative models may offer a more impactful alternative to traditional short-term outreach.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Implementing a Sustainable Framework for Global Head and Neck Reconstruction: A Bidirectional Exchange Experience</span>. Andrew Prince, MD<sup>1</sup>; <u>Chareeni Kurukulasuriya, MD</u><sup>1</sup>; Thomas J Sorenson, MD<sup>1</sup>; Narin Ratanaprasert, MD<sup>2</sup>; Joseph Connors, MD<sup>1</sup>; Michael Chow, MD<sup>3</sup>; Jamie P Levine, MD<sup>1</sup>; Adam S Jacobson, MD<sup>1</sup>. <sup>1</sup>NYU-Langone; <sup>2</sup>Siriraj Hospital; <sup>3</sup>UCSF<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>International surgical outreach is frequently modeled as short-term, unidirectional expertise transfer from high-resource centers to lower-resource settings. Although well-intentioned, these missions often involve externally selected cases, limited continuity, and minimal investment in local capability. To address these limitations, we participated in a bidirectional international exchange in head and neck reconstruction designed to prioritize local leadership, skill development, and ongoing collaboration.</p>\n\n<p><strong>Methods: </strong>As part of a longitudinal partnership, our team traveled to Siriraj Hospital in Bangkok, Thailand, following a prior observership during which Thai residents trained at our home institution. The visit began with a full day of jointly delivered didactic and laboratory instruction on reconstructive techniques, including introduction of the Global Excellence in Microsurgery (GEM) venous coupler—previously unused in Thailand. Thai attending surgeons identified three complex reconstructive cases for collaborative management. Over the next three operative days, resident teams worked side-by-side performing flap harvests, microvascular anastomoses, and a flap takeback, while incorporating the GEM coupler into live venous anastomoses. We continue the bidirectional collaboration through continued through digital communication platforms to support follow-up and ongoing capability building. In 2026, several additional resident surgeons and attending surgeons are planning to visit our institution again to participate in further training.  </p>\n\n<p><strong>Results: </strong>All three collaboratively selected cases were successfully completed with joint operative participation. The GEM coupler was adopted intraoperatively for the first time at Siriraj Hospital, providing a standardized technique suitable across varying levels of microsurgical experience. Continued communication enabled remote postoperative discussion and mentorship, culminating in the Thai team completing their first independently performed anterolateral thigh free flap. Throughout the exchange, clinical decision-making remained under local surgeon leadership, ensuring contextual appropriateness and patient-centered care. Post-exchange we have electronically provided our thoughts on approach and surgical management on 10 cases to-date.  </p>\n\n<p><strong>Conclusion: </strong>This bidirectional, continuity-focused model provides a practical framework for ethically grounded global reconstructive collaboration. By prioritizing local leadership, shared learning, and sustained engagement, the partnership demonstrated meaningful and durable capability building. As international microsurgical exchanges expand, long-term, collaborative models may offer a more impactful alternative to traditional short-term outreach.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154614--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S572",
      "content_id": "155552",
      "abstract_number": "S572",
      "poster_number": "",
      "title": "Automated Multi-Model AI Consensus System for Surgical Laterality Verification in Otolaryngology",
      "summary": "A two-model LLM consensus system for preoperative laterality verification is feasible in real-world otolaryngology practice and provides an independent safety layer upstream of the surgical timeout. Early deployment across a multi-hospital academic health system demonstrated high specificity and practical clinical integration. This approach represents a scalable strategy to strengthen wrong-site surgery...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155552",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260160",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Dante J Merlino, MD, PhD",
      "presenter": "Dante J Merlino, MD, PhD",
      "authors": "Dante J Merlino, MD, PhD ; Jillian Blackwell, BSN, RN, CORLN; D. Greg Farwell, MD; Steven Cannady, MD",
      "normalized_authors": [
        "Dante J Merlino",
        "Jillian Blackwell, BSN, CORLN",
        "D. Greg Farwell",
        "Steven Cannady"
      ],
      "affiliations": [
        "Department of Otorhinolaryngology –Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"
      ],
      "normalized_institutions": [
        "Department of Otorhinolaryngology –Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 344,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Dante J Merlino, MD, PhD ; Jillian Blackwell, BSN, RN, CORLN; D. Greg Farwell, MD; Steven Cannady, MD",
        "Affiliations": "Department of Otorhinolaryngology –Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA",
        "Background": "Wrong-site surgery is a preventable “Never Event” and remains a major patient safety concern. Laterality discrepancies may arise between the scheduled procedure, surgeon-authored preoperative documentation, and signed consent forms because of transcription errors, scheduling changes, or ambiguous documentation. These inconsistencies are often not identified until the day of surgery, and routine manual chart review is labor-intensive. We developed a daily automated large language model (LLM)-based surveillance system to identify potential laterality discrepancies before operative intervention.",
        "Methods": "Upcoming otolaryngology cases scheduled within 14 days were identified from the Epic Clarity/Caboodle data warehouse. Surgeon-authored preoperative clinic notes written up to 30 days before the scheduled surgical date, and signed consent forms were retrieved and submitted for LLM analysis. Using a protected, HIPAA-compliant Microsoft Azure Databricks environment, Anthropic Claude Sonnet 4.5 and Meta Llama 3.3-70B LLMs independently reviewed each case using a structured output framework to determine documented procedure laterality and extract supporting text. Cases were flagged when both models identified a clear conflict between the scheduled laterality and the clinical documentation. The automated pipeline ran daily and sent an email to the departmental safety officer indicating either an all-clear result or flagged cases for review. The safety officer then discussed flagged cases with the performing surgeon and adjudicated each as a true positive or false positive. False-positive feedback was incorporated into subsequent runs, and only new or changed cases were reprocessed.",
        "Results": "From February 5 to March 6, 2026, 727 cases were examined, and 18 cases (2.5%) were flagged for potential laterality discrepancy. 11 mismatches were ultimately confirmed; no unflagged cases were identified as a literality mismatch, resulting in a 99.0% specificity and 100% sensitivity.",
        "Conclusions": "A two-model LLM consensus system for preoperative laterality verification is feasible in real-world otolaryngology practice and provides an independent safety layer upstream of the surgical timeout. Early deployment across a multi-hospital academic health system demonstrated high specificity and practical clinical integration. This approach represents a scalable strategy to strengthen wrong-site surgery prevention and warrants broader validation across additional surgical specialties.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Automated Multi-Model AI Consensus System for Surgical Laterality Verification in Otolaryngology</span>. <u>Dante J Merlino, MD, PhD</u>; Jillian Blackwell, BSN, RN, CORLN; D. Greg Farwell, MD; Steven Cannady, MD. Department of Otorhinolaryngology –Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Wrong-site surgery is a preventable “Never Event” and remains a major patient safety concern. Laterality discrepancies may arise between the scheduled procedure, surgeon-authored preoperative documentation, and signed consent forms because of transcription errors, scheduling changes, or ambiguous documentation. These inconsistencies are often not identified until the day of surgery, and routine manual chart review is labor-intensive. We developed a daily automated large language model (LLM)-based surveillance system to identify potential laterality discrepancies before operative intervention.</p>\n\n<p><strong>Methods</strong>: Upcoming otolaryngology cases scheduled within 14 days were identified from the Epic Clarity/Caboodle data warehouse. Surgeon-authored preoperative clinic notes written up to 30 days before the scheduled surgical date, and signed consent forms were retrieved and submitted for LLM analysis. Using a protected, HIPAA-compliant Microsoft Azure Databricks environment, Anthropic Claude Sonnet 4.5 and Meta Llama 3.3-70B LLMs independently reviewed each case using a structured output framework to determine documented procedure laterality and extract supporting text. Cases were flagged when both models identified a clear conflict between the scheduled laterality and the clinical documentation. The automated pipeline ran daily and sent an email to the departmental safety officer indicating either an all-clear result or flagged cases for review. The safety officer then discussed flagged cases with the performing surgeon and adjudicated each as a true positive or false positive. False-positive feedback was incorporated into subsequent runs, and only new or changed cases were reprocessed.</p>\n\n<p><strong>Results</strong>: From February 5 to March 6, 2026, 727 cases were examined, and 18 cases (2.5%) were flagged for potential laterality discrepancy. 11 mismatches were ultimately confirmed; no unflagged cases were identified as a literality mismatch, resulting in a 99.0% specificity and 100% sensitivity.</p>\n\n<p><strong>Conclusions</strong>: A two-model LLM consensus system for preoperative laterality verification is feasible in real-world otolaryngology practice and provides an independent safety layer upstream of the surgical timeout. Early deployment across a multi-hospital academic health system demonstrated high specificity and practical clinical integration. This approach represents a scalable strategy to strengthen wrong-site surgery prevention and warrants broader validation across additional surgical specialties.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155552--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260160' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S573",
      "content_id": "153453",
      "abstract_number": "S573",
      "poster_number": "",
      "title": "Extracellular matrix proteins inhibit delivery of anti-EGFR antibody therapy in head and neck cancer",
      "summary": "These preliminary findings demonstrate how ECM composition and fiber architecture may appear to influence Pan800 distribution at lower doses, contributing to the heterogeneous distribution demonstrated in these tumors. However, co-administration of an unlabeled loading dose mitigates these effects, resulting in uniform drug penetration despite variations in the ECM. Hence, this data supports the use of loading...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153453",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mabrooka Kazi, MBBS",
      "presenter": "Mabrooka Kazi, MBBS",
      "authors": "Mabrooka Kazi, MBBS ; Hidenori Tanaka, MD, PhD; Georgii Vasuikov, MD, PhD; Eben Rosenthal, MD",
      "normalized_authors": [
        "Mabrooka Kazi, MBBS",
        "Hidenori Tanaka",
        "Georgii Vasuikov",
        "Eben Rosenthal"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 450,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mabrooka Kazi, MBBS ; Hidenori Tanaka, MD, PhD; Georgii Vasuikov, MD, PhD; Eben Rosenthal, MD",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "Despite EGFR-targeted therapies showing promise in head and neck squamous cell carcinoma (HNSCC), heterogeneous tumor penetration limits both therapeutic efficacy and intraoperative imaging applications. While the 'binding site barrier' is known to restrict antibody penetration, the contribution of tumor microenvironment (TME) architecture—particularly extracellular matrix (ECM) composition and collagen fiber organization—remains poorly characterized. Understanding these barriers is critical for optimizing fluorescence-guided surgery and antibody-drug conjugate delivery.",
        "Objective": "The aim of this study is to identify TME features which exert an influence on Pan800 distribution in HNSCC with a focus on ECM composition and architecture. It also aims to assess whether the effect of these TME resistance barriers can be modulated by co-administration of a loading dose.",
        "Methods": "FFPE tumor sections were analyzed from four patients: two receiving a flat dose of Pan800 (50mg) and two receiving the same 50mg labeled dose along with a weight-based loading dose of unlabeled panitumumab. Fluorescent multiplex immunostaining was performed in the sections for EGFR, collagen I, and periostin. Slide scanning was performed with Olympus VS200 system and stained sections were registered with corresponding drug sections using Fiji. Qupath and CT-Fire were used for image analysis. Tumor regions were segmented into periphery (15 μm) and adjacent stroma (100 μm), and mean fluorescence intensities (MFI) for Pan800 and ECM markers were measured respectively. Correlation analyses were conducted for ECM markers and Pan800 uptake. Fiber analysis with mean fiber number, length, width, straightness, and angular orientation were quantified for high and low drug regions within samples using CT-Fire.",
        "Results": "In patients who received a low dose of the tracer (n=2), Pan800 uptake was heterogeneous distribution revealing weak negative correlations with collagen I (r = –0.27 and –0.17) and periostin (r = –0.29 and –0.22), though none were statistically significant. CT-FIRE analysis of collagen I fibers revealed noteworthy differences in structure, with one patient showing significant changes in fiber number and mean angle (p < 0.05), suggesting ECM organization may influence drug penetration at lower doses. However, Pan800 distribution was saturated and uniform across the tumor in patients receiving high doses (n=2), despite significant collagen fiber metric differences (e.g. number of fibers, p = 0.003). This indicates that at higher saturating doses ECM organization may not substantially affect drug distribution.",
        "Conclusion": "These preliminary findings demonstrate how ECM composition and fiber architecture may appear to influence Pan800 distribution at lower doses, contributing to the heterogeneous distribution demonstrated in these tumors. However, co-administration of an unlabeled loading dose mitigates these effects, resulting in uniform drug penetration despite variations in the ECM. Hence, this data supports the use of loading doses to overcome microenvironmental barriers and increase intratumoral delivery of EGFR-targeted agents.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Extracellular matrix proteins inhibit delivery of anti-EGFR antibody therapy in head and neck cancer</span>. <u>Mabrooka Kazi, MBBS</u>; Hidenori Tanaka, MD, PhD; Georgii Vasuikov, MD, PhD; Eben Rosenthal, MD. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Despite EGFR-targeted therapies showing promise in head and neck squamous cell carcinoma (HNSCC), heterogeneous tumor penetration limits both therapeutic efficacy and intraoperative imaging applications. While the 'binding site barrier' is known to restrict antibody penetration, the contribution of tumor microenvironment (TME) architecture—particularly extracellular matrix (ECM) composition and collagen fiber organization—remains poorly characterized. Understanding these barriers is critical for optimizing fluorescence-guided surgery and antibody-drug conjugate delivery. </p>\n\n<p><strong>Objective: </strong>The aim of this study is to identify TME features which exert an influence on Pan800 distribution in HNSCC with a focus on ECM composition and architecture. It also aims to assess whether the effect of these TME resistance barriers can be modulated by co-administration of a loading dose. </p>\n\n<p><strong>Methods: </strong>FFPE tumor sections were analyzed from four patients: two receiving a flat dose of Pan800 (50mg) and two receiving the same 50mg labeled dose along with a weight-based loading dose of unlabeled panitumumab. Fluorescent multiplex immunostaining was performed in the sections for EGFR, collagen I, and periostin. Slide scanning was performed with Olympus VS200 system and stained sections were registered with corresponding drug sections using Fiji. Qupath and CT-Fire were used for image analysis. Tumor regions were segmented into periphery (15 μm) and adjacent stroma (100 μm), and mean fluorescence intensities (MFI) for Pan800 and ECM markers were measured respectively. Correlation analyses were conducted for ECM markers and Pan800 uptake. Fiber analysis with mean fiber number, length, width, straightness, and angular orientation were quantified for high and low drug regions within samples using CT-Fire. </p>\n\n<p><strong>Results: </strong>In patients who received a low dose of the tracer (n=2), Pan800 uptake was heterogeneous distribution revealing weak negative correlations with collagen I (r = –0.27 and –0.17) and periostin (r = –0.29 and –0.22), though none were statistically significant. CT-FIRE analysis of collagen I fibers revealed noteworthy differences in structure, with one patient showing significant changes in fiber number and mean angle (p < 0.05), suggesting ECM organization may influence drug penetration at lower doses. However, Pan800 distribution was saturated and uniform across the tumor in patients receiving high doses (n=2), despite significant collagen fiber metric differences (e.g. number of fibers, p = 0.003). This indicates that at higher saturating doses ECM organization may not substantially affect drug distribution. </p>\n\n<p><strong>Conclusion:</strong> These preliminary findings demonstrate how ECM composition and fiber architecture may appear to influence Pan800 distribution at lower doses, contributing to the heterogeneous distribution demonstrated in these tumors. However, co-administration of an unlabeled loading dose mitigates these effects, resulting in uniform drug penetration despite variations in the ECM. Hence, this data supports the use of loading doses to overcome microenvironmental barriers and increase intratumoral delivery of EGFR-targeted agents. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153453--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S574",
      "content_id": "154231",
      "abstract_number": "S574",
      "poster_number": "",
      "title": "Comparative Metabolomics in Epithelial-Mesenchymal Transition Populations in Oral Cavity Squamous Cell Carcinoma",
      "summary": "EMT is a critical program in cancer invasion, and the interplay between EMT and tumor invasion with cancer metabolism is unknown. In this study we utilize a powerful in vitro EMT tool to compare metabolomics between distinct OSCC EMT subpopulations. We demonstrate an emphasis on fatty acid synthesis in the SCC-9 M invasive cells and a pattern of glycolysis and pentose phosphate pathway dominance in SCC-9 E cells....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154231",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Chelsey A Witsberger, MD, MSc",
      "presenter": "Chelsey A Witsberger, MD, MSc",
      "authors": "Chelsey A Witsberger, MD, MSc 1 ; Guillermo Flores, MD, PhD 2 ; Andrea Stoddard, BA 1 ; Michael D Henry, PhD 3 ; Chad Brenner, PhD 1 ; Molly E Heft Neal, MD 1 ; Marisa Buchakjian, MD, PhD 1",
      "normalized_authors": [
        "Chelsey A Witsberger",
        "Guillermo Flores",
        "Andrea Stoddard",
        "Michael D Henry",
        "Chad Brenner",
        "Molly E Heft Neal",
        "Marisa Buchakjian"
      ],
      "affiliations": [
        "University of Michigan",
        "University of Iowa Hospital and Clinics",
        "Eastern Virginia Medical College"
      ],
      "normalized_institutions": [
        "University of Michigan",
        "University of Iowa Hospital and Clinics",
        "Eastern Virginia Medical College"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 502,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Chelsey A Witsberger, MD, MSc 1 ; Guillermo Flores, MD, PhD 2 ; Andrea Stoddard, BA 1 ; Michael D Henry, PhD 3 ; Chad Brenner, PhD 1 ; Molly E Heft Neal, MD 1 ; Marisa Buchakjian, MD, PhD 1",
        "Affiliations": "1 University of Michigan; 2 University of Iowa Hospital and Clinics; 3 Eastern Virginia Medical College",
        "Background": "Oral cavity squamous cell carcinoma (OSCC) is a carcinogen-derived cancer which is characterized by tumoral heterogeneity and aggressive behavior. Several molecular processes have the ability to support aggressive tumor growth and invasion, including the epithelial-mesenchymal transition (EMT) program as well as pro-oncogenic alterations in metabolism. We used a novel EMT in vitro tool created in our lab with genetically and phenotypically distinct “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) cell subpopulations in order to compare metabolomics and expression of metabolic enzymes in distinct EMT states. We have expanded this work to an exciting technology, spatial metabolomics, to examine dynamic metabolic differences in primary OSCC samples at the tumor-normal interface.",
        "Objective": "The goal of this research is to better understand how alterations in metabolism correlate with EMT and invasion in OSCC, with the long-term objective of identifying modifiers of metabolic flux and cellular growth.",
        "Methods": "Our lab has previously isolated and characterized “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) EMT OSCC subpopulations with distinct epigenetic and RNA expression profiles as well as unique phenotypic characteristics consistent with epithelial (cell-cell contact) and mesenchymal (invasive) behavior. Using this powerful in vitro model we performed metabolomics analysis (GC-MS, LC-MS) to compare metabolite profiles between EMT subpopulations. To supplement the metabolomic findings we also performed in vitro assays measuring citric acid cycle and fatty acid synthase flux as well as immunoblot analysis of metabolic enzyme expression. Additional experiments utilize high-throughput drug delivery techniques to measure EMT SCC-9 cell viability in the presence of metabolic inhibitors such as 6-AN (pentose phosphate pathway) and Orlistat (fatty acid synthesis). We have also probed a primary OSCC sample for spatial metabolomics, with emphasis on comparing metabolites at the tumor-invasive front.",
        "Results": "Comparative metabolomics between OSCC epithelial and mesenchymal SCC-9 cells highlights significant alterations in several core metabolic pathways. SCC-9 epithelial cells demonstrate increased levels of glycolytic and pentose phosphate pathway metabolites, whereas SCC-9 mesenchymal cells display increased fatty acid and citric acid cycle intermediates. Interestingly, SCC-9 mesenchymal cells demonstrate elevated expression of the fatty acid synthase enzyme as well as increased flux through the fatty acid synthase pathway on colorimetric in vitro analysis. Metabolic set enrichment analysis on the OSCC spatial metabolomics sample highlights a greater intensity of metabolites involved in glycolysis, the pentose phosphate pathway, and pyruvate metabolism in OSCC tumor tissue compared to adjacent normal tissue. Normal tissue displayed a greater intensity of citric acid cycle metabolites as well as increased glucose-6-phosphate.",
        "Conclusions": "EMT is a critical program in cancer invasion, and the interplay between EMT and tumor invasion with cancer metabolism is unknown. In this study we utilize a powerful in vitro EMT tool to compare metabolomics between distinct OSCC EMT subpopulations. We demonstrate an emphasis on fatty acid synthesis in the SCC-9 M invasive cells and a pattern of glycolysis and pentose phosphate pathway dominance in SCC-9 E cells. We extend this work to demonstrate feasibility of an exciting new platform, spatial metabolomics, in studying metabolic differences at the tumor invasive front in OSCC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Comparative Metabolomics in Epithelial-Mesenchymal Transition Populations in Oral Cavity Squamous Cell Carcinoma</span>. <u>Chelsey A Witsberger, MD, MSc</u><sup>1</sup>; Guillermo Flores, MD, PhD<sup>2</sup>; Andrea Stoddard, BA<sup>1</sup>; Michael D Henry, PhD<sup>3</sup>; Chad Brenner, PhD<sup>1</sup>; Molly E Heft Neal, MD<sup>1</sup>; Marisa Buchakjian, MD, PhD<sup>1</sup>. <sup>1</sup>University of Michigan; <sup>2</sup>University of Iowa Hospital and Clinics; <sup>3</sup>Eastern Virginia Medical College<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral cavity squamous cell carcinoma (OSCC) is a carcinogen-derived cancer which is characterized by tumoral heterogeneity and aggressive behavior. Several molecular processes have the ability to support aggressive tumor growth and invasion, including the epithelial-mesenchymal transition (EMT) program as well as pro-oncogenic alterations in metabolism. We used a novel EMT in vitro tool created in our lab with genetically and phenotypically distinct “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) cell subpopulations in order to compare metabolomics and expression of metabolic enzymes in distinct EMT states. We have expanded this work to an exciting technology, spatial metabolomics, to examine dynamic metabolic differences in primary OSCC samples at the tumor-normal interface.</p>\n\n<p><strong>Objective: </strong>The goal of this research is to better understand how alterations in metabolism correlate with EMT and invasion in OSCC, with the long-term objective of identifying modifiers of metabolic flux and cellular growth.</p>\n\n<p><strong>Methods: </strong>Our lab has previously isolated and characterized “epithelial” (SCC-9 E) and “mesenchymal” (SCC-9 M) EMT OSCC subpopulations with distinct epigenetic and RNA expression profiles as well as unique phenotypic characteristics consistent with epithelial (cell-cell contact) and mesenchymal (invasive) behavior. Using this powerful in vitro model we performed metabolomics analysis (GC-MS, LC-MS) to compare metabolite profiles between EMT subpopulations. To supplement the metabolomic findings we also performed in vitro assays measuring citric acid cycle and fatty acid synthase flux as well as immunoblot analysis of metabolic enzyme expression. Additional experiments utilize high-throughput drug delivery techniques to measure EMT SCC-9 cell viability in the presence of metabolic inhibitors such as 6-AN (pentose phosphate pathway) and Orlistat (fatty acid synthesis). We have also probed a primary OSCC sample for spatial metabolomics, with emphasis on comparing metabolites at the tumor-invasive front.</p>\n\n<p><strong>Results: </strong>Comparative metabolomics between OSCC epithelial and mesenchymal SCC-9 cells highlights significant alterations in several core metabolic pathways. SCC-9 epithelial cells demonstrate increased levels of glycolytic and pentose phosphate pathway metabolites, whereas SCC-9 mesenchymal cells display increased fatty acid and citric acid cycle intermediates. Interestingly, SCC-9 mesenchymal cells demonstrate elevated expression of the fatty acid synthase enzyme as well as increased flux through the fatty acid synthase pathway on colorimetric in vitro analysis. Metabolic set enrichment analysis on the OSCC spatial metabolomics sample highlights a greater intensity of metabolites involved in glycolysis, the pentose phosphate pathway, and pyruvate metabolism in OSCC tumor tissue compared to adjacent normal tissue. Normal tissue displayed a greater intensity of citric acid cycle metabolites as well as increased glucose-6-phosphate. </p>\n\n<p><strong>Conclusions:</strong> EMT is a critical program in cancer invasion, and the interplay between EMT and tumor invasion with cancer metabolism is unknown. In this study we utilize a powerful in vitro EMT tool to compare metabolomics between distinct OSCC EMT subpopulations. We demonstrate an emphasis on fatty acid synthesis in the SCC-9 M invasive cells and a pattern of glycolysis and pentose phosphate pathway dominance in SCC-9 E cells. We extend this work to demonstrate feasibility of an exciting new platform, spatial metabolomics, in studying metabolic differences at the tumor invasive front in OSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154231--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S575",
      "content_id": "153846",
      "abstract_number": "S575",
      "poster_number": "",
      "title": "Nanoparticle-mediated Photo-Chemical Immune Stimulation in neoadjuvant treatment of pre-clinical oral cavity cancer models",
      "summary": "Our preliminary results in preclinical OCSCC models shows evidence of tumor volume re-growth control after PS-PDT treatment, suggesting the existence of photo-chemically induced immune system activation. Further experiments are currently ongoing to quantify and optimize the PCIS effect on tumor progression. Effective development of PDT mediated PCIS would be beneficial in patient populations at risk of local...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153846",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "A Ruaro, MD",
      "presenter": "A Ruaro, MD",
      "authors": "A Ruaro, MD ; J Townson, PhD; Christopher Kopp, MD; JC Irish, MD, MSc, FRCSC, FACS, FCAHS",
      "normalized_authors": [
        "A Ruaro",
        "J Townson",
        "Christopher Kopp",
        "JC Irish, FRCSC, FCAHS"
      ],
      "affiliations": [
        "University of Toronto"
      ],
      "normalized_institutions": [
        "University of Toronto"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 446,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods and materials",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "A Ruaro, MD ; J Townson, PhD; Christopher Kopp, MD; JC Irish, MD, MSc, FRCSC, FACS, FCAHS",
        "Affiliations": "University of Toronto",
        "Introduction": "Photodynamic therapy (PDT) is a nonsurgical and tissue sparing ablation technique, able to selectively target tumour cells by activating a photosensitizer with light to produce well localized cytotoxicity. We previously reported development of porphysome (PS), porphyrin-lipid nanoparticles capable of potent PDT in multiple tumor models. As well as destroying the targeted tumor tissue, recent evidence suggest that PS-based PDT can stimulate a systemic anti-tumor immune response. Oral cavity squamous cell carcinoma (OCSCC) represents the most prevalent form of head and neck cancer, with a risk of local or local-regional recurrence following surgical treatment that increases with stage of disease, ranging from 15 to 60%. The present study is intended to explore Photo-Chemical Immune Stimulation (PCIS) in preclinical OCSCC models when treated with PS-based PDT in the neoadjuvant setting.",
        "Methods and materials": "A group of 30 mice was employed. Mouse oral squamous cell carcinoma (MOC2) cells were injected subcutaneously in the right flank in immune competent 8–10 weeks old female C57BL/6J mice. After 7 days, PS nanoparticles were intravenously administered to MOC2 bearing mice at a dose of 10 mg/kg and mice were then randomized in 2 groups: (1) the control group, where mice (nr 15) had surgery only (day 10 after tumour injection); (2) the treatment group, where mice (nr 15) underwent PDT (35J) twenty-four hours post-PS injection, followed by surgery after 48 hours (day 10 after tumour injection). Surgery was standardized for each animal, performing a tumor gross resection with intentional microscopic residual disease, proven by histological analysis. Time to tumour recurrence and volume growth rate were determined over a 2 month time follow-up. Also, a luminol assay was performed after PDT treatment in 2 different timepoints, 1hr and 24hrs after PDT.",
        "Results": "Time to recurrence was delayed in the PDT treatment group, with only 30% of cases presenting tumor recurrence. In the control group, all animals presented obvious disease within 12 days after surgery. In the control group, the tumor volume regrowth was significantly higher in comparison to the treatment group; in such cases, the tumor volume, when recurrence occurred, showed an overall stablity over time.",
        "Abstract": "A luminol assay was performed in both groups, 1 hr and 24 hrs after PDT, showing an increased neutrophilic activity in the PDT treatment group when compared to the control group. View in Agenda and Add to Schedule",
        "Conclusions": "Our preliminary results in preclinical OCSCC models shows evidence of tumor volume re-growth control after PS-PDT treatment, suggesting the existence of photo-chemically induced immune system activation. Further experiments are currently ongoing to quantify and optimize the PCIS effect on tumor progression. Effective development of PDT mediated PCIS would be beneficial in patient populations at risk of local recurrence and regional progression."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Nanoparticle-mediated Photo-Chemical Immune Stimulation in neoadjuvant treatment of pre-clinical oral cavity cancer models</span>. <u>A Ruaro, MD</u>; J Townson, PhD; Christopher Kopp, MD; JC Irish, MD, MSc, FRCSC, FACS, FCAHS. University of Toronto<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Photodynamic therapy (PDT) is a nonsurgical and tissue sparing ablation technique, able to selectively target tumour cells by activating a photosensitizer with light to produce well localized cytotoxicity. We previously reported development of porphysome (PS), porphyrin-lipid nanoparticles capable of potent PDT in multiple tumor models.  As well as destroying the targeted tumor tissue, recent evidence suggest that PS-based PDT can stimulate a systemic anti-tumor immune response. Oral cavity squamous cell carcinoma (OCSCC) represents the most prevalent form of head and neck cancer, with a risk of local or local-regional recurrence following surgical treatment that increases with stage of disease, ranging from 15 to 60%. The present study is intended to explore Photo-Chemical Immune Stimulation (PCIS) in preclinical OCSCC models when treated with PS-based PDT in the neoadjuvant setting.</p>\n\n<p><strong>Methods and materials: </strong>A group of 30 mice was employed. Mouse oral squamous cell carcinoma (MOC2) cells were injected subcutaneously in the right flank in immune competent 8–10 weeks old female C57BL/6J mice. After 7 days, PS nanoparticles were intravenously administered to MOC2 bearing mice at a dose of 10 mg/kg and mice were then randomized in 2 groups: (1) the control group, where mice (nr 15) had surgery only (day 10 after tumour injection); (2) the treatment group, where mice (nr 15) underwent PDT (35J) twenty-four hours post-PS injection, followed by surgery after 48 hours (day 10 after tumour injection). Surgery was standardized for each animal, performing a tumor gross resection with intentional microscopic residual disease, proven by histological analysis. Time to tumour recurrence and volume growth rate were determined over a 2 month time follow-up. Also, a luminol assay was performed after PDT treatment in 2 different timepoints, 1hr and 24hrs after PDT.  </p>\n\n<p><strong>Results:</strong> Time to recurrence was delayed in the PDT treatment group, with only 30% of cases presenting tumor recurrence. In the control group, all animals presented obvious disease within 12 days after surgery. In the control group, the tumor volume regrowth was significantly higher in comparison to the treatment group; in such cases, the tumor volume, when recurrence occurred, showed an overall stablity over time.</p>\n\n<p>A luminol assay was performed in both groups, 1 hr and 24 hrs after PDT, showing an increased neutrophilic activity in the PDT treatment group when compared to the control group.</p>\n\n<p><strong>Conclusions:</strong> Our preliminary results in preclinical OCSCC models shows evidence of tumor volume re-growth control after PS-PDT treatment, suggesting the existence of photo-chemically induced immune system activation. Further experiments are currently ongoing to quantify and optimize the PCIS effect on tumor progression. Effective development of PDT mediated PCIS would be beneficial in patient populations at risk of local recurrence and regional progression.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153846--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S576",
      "content_id": "154551",
      "abstract_number": "S576",
      "poster_number": "",
      "title": "Uncovering the Genomic Landscape of HNSCC in Never-Smokers, Never-Drinkers Patients Through Whole-Genome Sequencing",
      "summary": "Head and neck squamous cell carcinoma (HNSCC) in never-smoker, never-drinker (NSND) HPV-negative patients represents a distinct clinical entity with unclear etiology and poorly characterized mutational features. This study aims to evaluate the mutation profile of this understudied subgroup to support the identification of alternative mechanisms of tumorigenesis. Patients with histologically confirmed HNSCC and no...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154551",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Beatriz F. de Souza, MSc",
      "presenter": "Beatriz F. de Souza, MSc",
      "authors": "Beatriz F",
      "normalized_authors": [
        "Beatriz F"
      ],
      "affiliations": [
        "de Souza, MSc 1",
        "Simone Maistro, PhD 2",
        "Maria Lucia Hirata Katayama, PhD 1",
        "Vinícius Marques Rocha, MSc 1",
        "Laerte Luchini Jr. 2",
        "Brenda Iwakura Alves 2",
        "Ingrid Kathleen Nakamuta, MSc 1",
        "Alexandre Bezerra dos Santos, PhD 1",
        "Fabio Albuquerque Marchi, PhD 2",
        "Fátima Solange Pasini, PhD 1",
        "Luiz Paulo Kowalski, PhD 1",
        "Maria Aparecida Azevedo Koike Folgueira, PhD 1 . 1 Faculdade de Medicina da USP",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "normalized_institutions": [
        "de Souza, MSc 1",
        "Simone Maistro, PhD 2",
        "Maria Lucia Hirata Katayama, PhD 1",
        "Vinícius Marques Rocha, MSc 1",
        "Laerte Luchini Jr. 2",
        "Brenda Iwakura Alves 2",
        "Ingrid Kathleen Nakamuta, MSc 1",
        "Alexandre Bezerra dos Santos, PhD 1",
        "Fabio Albuquerque Marchi, PhD 2",
        "Fátima Solange Pasini, PhD 1",
        "Luiz Paulo Kowalski, PhD 1",
        "Maria Aparecida Azevedo Koike Folgueira, PhD 1 . 1 Faculdade de Medicina da USP",
        "Instituto do Câncer do Estado de São Paulo"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Beatriz F",
        "Affiliations": "de Souza, MSc 1 ; Simone Maistro, PhD 2 ; Maria Lucia Hirata Katayama, PhD 1 ; Vinícius Marques Rocha, MSc 1 ; Laerte Luchini Jr. 2 ; Brenda Iwakura Alves 2 ; Ingrid Kathleen Nakamuta, MSc 1 ; Alexandre Bezerra dos Santos, PhD 1 ; Fabio Albuquerque Marchi, PhD 2 ; Fátima Solange Pasini, PhD 1 ; Luiz Paulo Kowalski, PhD 1 ; Maria Aparecida Azevedo Koike Folgueira, PhD 1 . 1 Faculdade de Medicina da USP; 2 Instituto do Câncer do Estado de São Paulo",
        "Abstract": "Head and neck squamous cell carcinoma (HNSCC) in never-smoker, never-drinker (NSND) HPV-negative patients represents a distinct clinical entity with unclear etiology and poorly characterized mutational features. This study aims to evaluate the mutation profile of this understudied subgroup to support the identification of alternative mechanisms of tumorigenesis. Patients with histologically confirmed HNSCC and no history of tobacco or alcohol use were prospectively enrolled. NSND status was defined as fewer than 100 cigarettes and fewer than 12 alcoholic drinks over a lifetime. HPV status was assessed using the InnoLiPA assay. DNA was extracted from fresh- frozen tumor samples using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Whole- genome sequencing was performed with the Illumina DNA PCR-Free Prep and sequenced on the NovaSeq6000 platform. Sequencing data were analyzed using DRAGEN Somatic (Illumina) and the Illumina Connected Insights (ICI) platform. Selection of variants followed the criteria of: VAF ≥0.01 and ≤0.35 and included only genes listed in the Cancer Gene Census. Variants classified as benign or likely benign were excluded. Pathogenic and likely pathogenic variants were classified using the databases AlphaMissense and OncoKB. We also evaluated genes present in a panel of 523 genes (TruSight Oncology 500, Illumina), retaining variants annotated oncogenic or likely oncogenic using ICI oncogenicity predictor, without applying any VAF-based filtering. Ten patients NSND (7 females and 3 males) were included between July 2023 and March 2025. The median age of patients was 56.2 years; tongue was the primary tumor site in 80% of cases and 60% of patients presented with clinical stage IVa. All patients tested negative for HPV. The mean deep WGS coverage was 86.9x (69 - 111x), with >97.36% mapped bases. All samples met the quality thresholds required for subsequent analyses of somatic variants and mutational signatures. Considering both coding and non-coding regions, the number of all small variants varied from 20,920 to 74,411. TP53 was affected in 90% of the samples. Besides that, at least one other tumor suppressor gene was affected in all tumor samples. Affected TSG included: NF2, CASP8, FAT1, TP63, ERCC4, CUX1, SMARCB1, TGFBR2, NOTCH1, NOTCH2 and CDKN2A; and affected oncogenes: DDX5, SF3B1, PIK3CA and ERBB3. These genes are involved in cancer-related pathways, such as PI3K/AKT signaling (PIK3CA and ERBB3); Notch signaling (NOTCH1 and NOTCH2); TGF-β pathway represented (TGFBR2); apoptosis regulation (CASP8); RNA splicing (SF3B1) and chromatin remodeling (SMARCB1, DDX5) that influence transcriptional control; cell-cycle regulation (CDKN2A); DNA repair (ERCC4 and CUX1); adhesion and Wnt/Hippo signaling (FAT1 and NF2). Other affected genes are involved in cancer-related pathways, such as PI3K/AKT signaling involves PIK3CA and ERBB3; Notch signaling, mediated by NOTCH1 and NOTCH2; TGF-β pathway represented by TGFBR2, apoptosis regulation by CASP8; RNA splicing (SF3B1) and chromatin remodeling (SMARCB1, DDX5) that influence transcriptional control; cell- cycle regulation by CDKN2A, DNA repair by ERCC4 and CUX1; adhesion and Wnt/Hippo signaling involving FAT1 and NF2; epithelial identity, regulated by TP63. In this group of never-smoker, never-drinker, HPV negative tumor samples, TP53 mutation was highly frequently affected. Other affected genes are involved in many cancer related pathways. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Uncovering the Genomic Landscape of HNSCC in Never-Smokers, Never-Drinkers Patients Through Whole-Genome Sequencing</span>. <u>Beatriz F. de Souza, MSc</u><sup>1</sup>; Simone Maistro, PhD<sup>2</sup>; Maria Lucia Hirata Katayama, PhD<sup>1</sup>; Vinícius Marques Rocha, MSc<sup>1</sup>; Laerte Luchini Jr.<sup>2</sup>; Brenda Iwakura Alves<sup>2</sup>; Ingrid Kathleen Nakamuta, MSc<sup>1</sup>; Alexandre Bezerra dos Santos, PhD<sup>1</sup>; Fabio Albuquerque Marchi, PhD<sup>2</sup>; Fátima Solange Pasini, PhD<sup>1</sup>; Luiz Paulo Kowalski, PhD<sup>1</sup>; Maria Aparecida Azevedo Koike Folgueira, PhD<sup>1</sup>. <sup>1</sup>Faculdade de Medicina da USP; <sup>2</sup>Instituto do Câncer do Estado de São Paulo<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Head and neck squamous cell carcinoma (HNSCC) in never-smoker, never-drinker (NSND) HPV-negative patients represents a distinct clinical entity with unclear etiology and poorly characterized mutational features. This study aims to evaluate the mutation profile of this understudied subgroup to support the identification of alternative mechanisms of tumorigenesis. Patients with histologically confirmed HNSCC and no history of tobacco or alcohol use were prospectively enrolled. NSND status was defined as fewer than 100 cigarettes and fewer than 12 alcoholic drinks over a lifetime. HPV status was assessed using the InnoLiPA assay. DNA was extracted from fresh- frozen tumor samples using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Whole- genome sequencing was performed with the Illumina DNA PCR-Free Prep and sequenced on the NovaSeq6000 platform. Sequencing data were analyzed using DRAGEN Somatic (Illumina) and the Illumina Connected Insights (ICI) platform. Selection of variants followed the criteria of: VAF ≥0.01 and ≤0.35 and included only genes listed in the Cancer Gene Census. Variants classified as benign or likely benign were excluded. Pathogenic and likely pathogenic variants were classified using the databases AlphaMissense and OncoKB. We also evaluated genes present in a panel of 523 genes (TruSight Oncology 500, Illumina), retaining variants annotated oncogenic or likely oncogenic using ICI oncogenicity predictor, without applying any VAF-based filtering. Ten patients NSND (7 females and 3 males) were included between July 2023 and March 2025. The median age of patients was 56.2 years; tongue was the primary tumor site in 80% of cases and 60% of patients presented with clinical stage IVa. All patients tested negative for HPV. The mean deep WGS coverage was 86.9x (69 - 111x), with >97.36% mapped bases. All samples met the quality thresholds required for subsequent analyses of somatic variants and mutational signatures. Considering both coding and non-coding regions, the number of all small variants varied from 20,920 to 74,411. TP53 was affected in 90% of the samples. Besides that, at least one other tumor suppressor gene was affected in all tumor samples. Affected TSG included: NF2, CASP8, FAT1, TP63, ERCC4, CUX1, SMARCB1, TGFBR2, NOTCH1, NOTCH2 and CDKN2A; and affected oncogenes: DDX5, SF3B1, PIK3CA and ERBB3. These genes are involved in cancer-related pathways, such as PI3K/AKT signaling (PIK3CA and ERBB3); Notch signaling (NOTCH1 and NOTCH2); TGF-β pathway represented (TGFBR2); apoptosis regulation (CASP8); RNA splicing (SF3B1) and chromatin remodeling (SMARCB1, DDX5) that influence transcriptional control; cell-cycle regulation (CDKN2A); DNA repair (ERCC4 and CUX1); adhesion and Wnt/Hippo signaling (FAT1 and NF2). Other affected genes are involved in cancer-related pathways, such as PI3K/AKT signaling involves PIK3CA and ERBB3; Notch signaling, mediated by NOTCH1 and NOTCH2; TGF-β pathway represented by TGFBR2, apoptosis regulation by CASP8; RNA splicing (SF3B1) and chromatin remodeling (SMARCB1, DDX5) that influence transcriptional control; cell- cycle regulation by CDKN2A, DNA repair by ERCC4 and CUX1; adhesion and Wnt/Hippo signaling involving FAT1 and NF2; epithelial identity, regulated by TP63. In this group of never-smoker, never-drinker, HPV negative tumor samples, TP53 mutation was highly frequently affected. Other affected genes are involved in many cancer related pathways.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154551--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S577",
      "content_id": "153235",
      "abstract_number": "S577",
      "poster_number": "",
      "title": "cGAS-STING Activation Upregulates T2R14 Gene Expression in Head and Neck Squamous Cell Carcinoma",
      "summary": "The cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS–STING) pathway is a central innate immune sensor that detects cytosolic double-stranded DNA and triggers interferon and inflammatory cytokine production. Activation of cGAS by cytosolic DNA generates cGAMP, which binds STING and initiates TBK1–IRF3 and NF-κB signaling, ultimately driving REL-dependent transcription of interferon-stimulated and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153235",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Kyle Polen, BS",
      "presenter": "Kyle Polen, BS",
      "authors": "Kyle Polen, BS 1 ; Sarah Sywanycz, BS 2 ; Brianna L Buchler, PhD 2 ; Kim B Le, BS 1 ; Robert J Lee, PhD 3 ; Ryan M Carey, MD 2",
      "normalized_authors": [
        "Kyle Polen",
        "Sarah Sywanycz",
        "Brianna L Buchler",
        "Kim B Le",
        "Robert J Lee",
        "Ryan M Carey"
      ],
      "affiliations": [
        "Perelman School of Medicine, University of Pennsylvania",
        "Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System",
        "Department of Physiology, University of Pennsylvania"
      ],
      "normalized_institutions": [
        "Perelman School of Medicine, University of Pennsylvania",
        "Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System",
        "Department of Physiology, University of Pennsylvania"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20(3).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20(3).png",
          "alt": "Figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153235"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20IL6.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20IL6.png",
          "alt": "Figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153235"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 392,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Kyle Polen, BS 1 ; Sarah Sywanycz, BS 2 ; Brianna L Buchler, PhD 2 ; Kim B Le, BS 1 ; Robert J Lee, PhD 3 ; Ryan M Carey, MD 2",
        "Affiliations": "1 Perelman School of Medicine, University of Pennsylvania; 2 Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System; 3 Department of Physiology, University of Pennsylvania",
        "Abstract": "The cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS–STING) pathway is a central innate immune sensor that detects cytosolic double-stranded DNA and triggers interferon and inflammatory cytokine production. Activation of cGAS by cytosolic DNA generates cGAMP, which binds STING and initiates TBK1–IRF3 and NF-κB signaling, ultimately driving REL-dependent transcription of interferon-stimulated and inflammatory genes. The cGAS–STING pathway is suppressed by high-risk HPV in head and neck squamous cell carcinoma (HNSCC), facilitating viral persistence and tumorigenesis. In HPV-positive HNSCC, bitter taste receptor T2R14 is increasingly being recognized for its functional importance in solid tumors, showing enriched expression and mediating pro-apoptotic signaling in response to bitter agonists such as lidocaine. Because activation of the cGAS–STING pathway induces NF-κB signaling and thereby engages REL-family transcription factors, we hypothesized that the T2R14-encoding gene ( TAS2R14 ) may contain NF-κB/REL regulatory motifs and therefore cGAS–STING activation would upregulate TAS2R14 expression in HPV-positive HNSCC. Transcription factor binding sites within the TAS2R14 promoter were queried using the JASPAR Transcription Factor Binding Site Database. HPV-positive UM-SCC-47 cells were cultured with or without 2′3′-cGAMP, a potent endogenous activator of STING signaling. Because interleukin-6 is a well-established downstream output of canonical STING signaling, IL6 gene expression was used as a positive control to confirm pathway activation in response to 2’3’-cGAMP. After 24 hours, mRNA was extracted and RT-qPCR was performed to quantify IL6 and TAS2R14 expression. JASPAR analysis revealed nine predicted REL protein binding sites within the TAS2R14 promoter region. In UM-SCC-47 cells, 2′3′-cGAMP induced more than a 3-fold increase in TAS2R14 expression ( p < 0.01) relative to untreated controls (Figure 1). IL6 expression also increased significantly in the presence of 2′3′-cGAMP ( p < 0.05) (Figure 2). Preliminary results with HPV-negative cell lines (FaDu, RPMI-2650) showed no significant changes in TAS2R14 expression. These findings demonstrate that cGAS–STING activation upregulates TAS2R14 expression in HPV-positive HNSCC cells, supported by predicted REL-family transcriptional binding sites within its promoter. Given that the T2R14 agonist lidocaine is currently being evaluated as a neoadjuvant therapeutic in a Phase I clinical trial for HNSCC, these data suggest that enhancing cGAS–STING signaling may potentiate T2R-mediated antitumor responses in HPV-positive HNSCC. Ongoing studies using calcium imaging, viability assays, and apoptosis profiling will define the functional consequences of STING-driven T2R14 induction. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>cGAS-STING Activation Upregulates T2R14 Gene Expression in Head and Neck Squamous Cell Carcinoma</span>. <u>Kyle Polen, BS</u><sup>1</sup>; Sarah Sywanycz, BS<sup>2</sup>; Brianna L Buchler, PhD<sup>2</sup>; Kim B Le, BS<sup>1</sup>; Robert J Lee, PhD<sup>3</sup>; Ryan M Carey, MD<sup>2</sup>. <sup>1</sup>Perelman School of Medicine, University of Pennsylvania; <sup>2</sup>Department of Otorhinolaryngology-Head & Neck Surgery, University of Pennsylvania Health System; <sup>3</sup>Department of Physiology, University of Pennsylvania<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>The cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS–STING) pathway is a central innate immune sensor that detects cytosolic double-stranded DNA and triggers interferon and inflammatory cytokine production. Activation of cGAS by cytosolic DNA generates cGAMP, which binds STING and initiates TBK1–IRF3 and NF-κB signaling, ultimately driving REL-dependent transcription of interferon-stimulated and inflammatory genes. The cGAS–STING pathway is suppressed by high-risk HPV in head and neck squamous cell carcinoma (HNSCC), facilitating viral persistence and tumorigenesis. In HPV-positive HNSCC, bitter taste receptor T2R14 is increasingly being recognized for its functional importance in solid tumors, showing enriched expression and mediating pro-apoptotic signaling in response to bitter agonists such as lidocaine. Because activation of the cGAS–STING pathway induces NF-κB signaling and thereby engages REL-family transcription factors, we hypothesized that the T2R14-encoding gene (<em>TAS2R14</em>) may contain NF-κB/REL regulatory motifs and therefore cGAS–STING activation would upregulate <em>TAS2R14 </em>expression in HPV-positive HNSCC.</p>\n\n<p>Transcription factor binding sites within the <em>TAS2R14 </em>promoter were queried using the JASPAR Transcription Factor Binding Site Database. HPV-positive UM-SCC-47 cells were cultured with or without 2′3′-cGAMP, a potent endogenous activator of STING signaling. Because interleukin-6 is a well-established downstream output of canonical STING signaling, <em>IL6 </em>gene expression was used as a positive control to confirm pathway activation in response to 2’3’-cGAMP. After 24 hours, mRNA was extracted and RT-qPCR was performed to quantify <em>IL6 </em>and <em>TAS2R14 </em>expression.</p>\n\n<p>JASPAR analysis revealed nine predicted REL protein binding sites within the <em>TAS2R14 </em>promoter region. In UM-SCC-47 cells, 2′3′-cGAMP induced more than a 3-fold increase in <em>TAS2R14 </em>expression (<em>p </em>< 0.01) relative to untreated controls (Figure 1). <em>IL6 </em>expression also increased significantly in the presence of 2′3′-cGAMP (<em>p</em> < 0.05) (Figure 2). Preliminary results with HPV-negative cell lines (FaDu, RPMI-2650) showed no significant changes in <em>TAS2R14 </em>expression. </p>\n\n<p>These findings demonstrate that cGAS–STING activation upregulates <em>TAS2R14 </em>expression in HPV-positive HNSCC cells, supported by predicted REL-family transcriptional binding sites within its promoter. Given that the T2R14 agonist lidocaine is currently being evaluated as a neoadjuvant therapeutic in a Phase I clinical trial for HNSCC, these data suggest that enhancing cGAS–STING signaling may potentiate T2R-mediated antitumor responses in HPV-positive HNSCC. Ongoing studies using calcium imaging, viability assays, and apoptosis profiling will define the functional consequences of STING-driven T2R14 induction.</p>\n\n<p><img alt='Figure 1' src='https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20(3).png' /></p>\n\n<p><img alt='Figure 2' src='https://www.submitmyabstract.com/abs/images/153235/Abstract%20qpcr%20figure%20IL6.png' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153235--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S578",
      "content_id": "154536",
      "abstract_number": "S578",
      "poster_number": "",
      "title": "An integrative, parallel in vitro and in vivo CRISPR/Cas9 kinome screen identifies PNKP as a targetable fitness kinase in HPV- HNSCC",
      "summary": "HPV-negative head and neck squamous cell carcinoma (HNSCC), primarily driven by tobacco and alcohol use, remains recalcitrant disease with poor clinical outcomes. Despite advances in multidisciplinary management, the 5-year overall survival rate for this patient population has remain stagnant over the past several decades. While extensive research has elucidated the genetic alterations and dysregulated pathways...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154536",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Gurleen K Tung, PhD",
      "presenter": "Gurleen K Tung, PhD",
      "authors": "Gurleen K Tung, PhD 1 ; Kate Chatfield-Reed, PhD 2 ; Heping Yu 1 ; Masaru Miyagi, PhD 3 ; Wendi Quinn O'Neill, DDS 1 ; Quintin Pan, PhD 1",
      "normalized_authors": [
        "Gurleen K Tung",
        "Kate Chatfield-Reed",
        "Heping Yu",
        "Masaru Miyagi",
        "Wendi Quinn O'Neill",
        "Quintin Pan"
      ],
      "affiliations": [
        "University Hospitals Seidman Cancer Center",
        "Yukon University",
        "Case Western Reserve University School of Medicine"
      ],
      "normalized_institutions": [
        "University Hospitals Seidman Cancer Center",
        "Yukon University",
        "Case Western Reserve University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 357,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Gurleen K Tung, PhD 1 ; Kate Chatfield-Reed, PhD 2 ; Heping Yu 1 ; Masaru Miyagi, PhD 3 ; Wendi Quinn O'Neill, DDS 1 ; Quintin Pan, PhD 1",
        "Affiliations": "1 University Hospitals Seidman Cancer Center; 2 Yukon University; 3 Case Western Reserve University School of Medicine",
        "Abstract": "HPV-negative head and neck squamous cell carcinoma (HNSCC), primarily driven by tobacco and alcohol use, remains recalcitrant disease with poor clinical outcomes. Despite advances in multidisciplinary management, the 5-year overall survival rate for this patient population has remain stagnant over the past several decades. While extensive research has elucidated the genetic alterations and dysregulated pathways in HPV- HNSCC, the identification of novel, actionable therapeutic targets remains elusive. To address this critical knowledge gap, we performed integrative, parallel in vitro and in vivo CRISPR/Cas9 kinome screening strategy using HPV- HNSCC model systems. Our screen identified twenty-four candidate kinases essential for tumor cell fitness across both cell-based and xenograft mouse models. Among these candidates, polynucleotide kinase 3’-phosphatase (PNKP) emerged as a leading and highly promising therapeutic target. PNKP depletion with shRNA significantly reduced the proliferation of HPV- HNSCC CAL27 and FaDu cells by 81% (p<0.01) and 65% (p<0.01), respectively. PNKP knockdown significantly decreased clonogenic survival by 83% (p<0.05) in CAL27 and 62.5% (p<0.05) in FaDu. Similarly, a pharmacologic inhibitor which targets the phosphatase activity of PNKP significantly reduced the proliferation of CAL27 and FaDu cells. PNKP knockdown in CAL27 and FaDu markedly suppressed in vivo tumor growth in athymic nude mice; 93% inhibition (n=8, p<0.05) in CAL27 (31.4 mm3 for the PNKP knockdown group vs. 484.3 mm3 for the control group) and 87% inhibition (n=8, p<0.05) in FaDu (109.4 mm3 for the PNKP knockdown group vs.823 mm3 for the control group). Using Seahorse extracellular flux analysis, PNKP inhibition in these HPV- HNSCC cells attenuated oxidative phosphorylation and glycolytic reserve, indicative of dampened metabolic plasticity in PNKP depleted tumor cells. Immunoprecipitation-proteomics analysis demonstrated that PNKP directly binds to several non-canonical proteins intimately involved in cellular metabolism, including surfeit locus protein 4 (SURF4), transmembrane protein 33 (TMEM33), ribosomal protein L19 (RPL19), and 7-dehydrocholesterol reductase (DHCR7). In summary, our study identified and validated PNKP as an essential kinase for the maintenance of HPV- HNSCC cells, and revealed a novel metabolic interactome modulated by PNKP. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>An integrative, parallel in vitro and in vivo CRISPR/Cas9 kinome screen identifies PNKP as a targetable fitness kinase in HPV- HNSCC</span>. <u>Gurleen K Tung, PhD</u><sup>1</sup>; Kate Chatfield-Reed, PhD<sup>2</sup>; Heping Yu<sup>1</sup>; Masaru Miyagi, PhD<sup>3</sup>; Wendi Quinn O'Neill, DDS<sup>1</sup>; Quintin Pan, PhD<sup>1</sup>. <sup>1</sup>University Hospitals Seidman Cancer Center; <sup>2</sup>Yukon University; <sup>3</sup>Case Western Reserve University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>HPV-negative head and neck squamous cell carcinoma (HNSCC), primarily driven by tobacco and alcohol use, remains recalcitrant disease with poor clinical outcomes. Despite advances in multidisciplinary management, the 5-year overall survival rate for this patient population has remain stagnant over the past several decades. While extensive research has elucidated the genetic alterations and dysregulated pathways in HPV- HNSCC, the identification of novel, actionable therapeutic targets remains elusive. To address this critical knowledge gap, we performed integrative, parallel in vitro and in vivo CRISPR/Cas9 kinome screening strategy using HPV- HNSCC model systems. Our screen identified twenty-four candidate kinases essential for tumor cell fitness across both cell-based and xenograft mouse models. Among these candidates, polynucleotide kinase 3’-phosphatase (PNKP) emerged as a leading and highly promising therapeutic target. PNKP depletion with shRNA significantly reduced the proliferation of HPV- HNSCC CAL27 and FaDu cells by 81% (p<0.01) and 65% (p<0.01), respectively. PNKP knockdown significantly decreased clonogenic survival by 83% (p<0.05) in CAL27 and 62.5% (p<0.05) in FaDu. Similarly, a pharmacologic inhibitor which targets the phosphatase activity of PNKP significantly reduced the proliferation of CAL27 and FaDu cells. PNKP knockdown in CAL27 and FaDu markedly suppressed in vivo tumor growth in athymic nude mice; 93% inhibition (n=8, p<0.05) in CAL27 (31.4 mm3 for the PNKP knockdown group vs. 484.3 mm3 for the control group) and 87% inhibition (n=8, p<0.05) in FaDu (109.4 mm3 for the PNKP knockdown group vs.823 mm3 for the control group). Using Seahorse extracellular flux analysis, PNKP inhibition in these HPV- HNSCC cells attenuated oxidative phosphorylation and glycolytic reserve, indicative of dampened metabolic plasticity in PNKP depleted tumor cells. Immunoprecipitation-proteomics analysis demonstrated that PNKP directly binds to several non-canonical proteins intimately involved in cellular metabolism, including surfeit locus protein 4 (SURF4), transmembrane protein 33 (TMEM33), ribosomal protein L19 (RPL19), and 7-dehydrocholesterol reductase (DHCR7). In summary, our study identified and validated PNKP as an essential kinase for the maintenance of HPV- HNSCC cells, and revealed a novel metabolic interactome modulated by PNKP.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154536--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S579",
      "content_id": "148365",
      "abstract_number": "S579",
      "poster_number": "",
      "title": "CUDC-101 Synergizes with miR-27a* to Restrict Head and Neck Squamous Cell Carcinoma Growth",
      "summary": "Combinatorial treatment with CUDC-101 and miR-27a* restricts HNSCC cell growth and also induces apoptosis in HNSCC cells, but the individual treatments do not. This apoptosis is associated with decreased P21 protein expression. Further studies with the miR-27a*-CUDC-101 combination using in vivo models are needed.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=148365",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tajinder Kainth, MS",
      "presenter": "Tajinder Kainth, MS",
      "authors": "Nikhil S Chari, PhD 1 ; Tajinder Kainth, MS 1 ; Reid T Powell, PhD 2 ; Ahmad Abubaker, MD 1 ; Nghi Nguyen 2 ; M Sobieski 2 ; Clifford C Stephen, PhD 2 ; Stephen Y Lai, MD, PhD, FACS 3",
      "normalized_authors": [
        "Nikhil S Chari",
        "Tajinder Kainth",
        "Reid T Powell",
        "Ahmad Abubaker",
        "Nghi Nguyen",
        "M Sobieski",
        "Clifford C Stephen",
        "Stephen Y Lai"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Center for Translational Cancer Research, Texas A&M Health Science Center Institute of Biosciences & Technology",
        "Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Center for Translational Cancer Research, Texas A&M Health Science Center Institute of Biosciences & Technology",
        "Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 437,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nikhil S Chari, PhD 1 ; Tajinder Kainth, MS 1 ; Reid T Powell, PhD 2 ; Ahmad Abubaker, MD 1 ; Nghi Nguyen 2 ; M Sobieski 2 ; Clifford C Stephen, PhD 2 ; Stephen Y Lai, MD, PhD, FACS 3",
        "Affiliations": "1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Center for Translational Cancer Research, Texas A&M Health Science Center Institute of Biosciences & Technology; 3 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Introduction": "The current 5-year overall survival rate for advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. With almost 300,000 annual deaths worldwide, improvement of treatment options for patients with HNSCC is a clear need. Epidermal growth factor receptor (EGFR) overexpression occurs in more than half of HNSCCs and is associated with decreased survival. Current efforts targeting EGFR have resulted in marginal clinical benefits, indicating the need to target additional oncogenic pathways simultaneously. MicroRNAs are small noncoding RNAs that have evolved to simultaneously target multiple proteins. Our prior findings demonstrated that the microRNA miR-27a* (miR-27a-5p) targets multiple components of the EGFR/AKT1/mammalian target of rapamycin pathway, the most frequently altered mitogenic pathway in HNSCC cases. Expression of miR-27a* is repressed in HNSCCs and this repression correlates with survival in patient populations. Ectopic expression of miR-27a* in both in vivo and in vitro models inhibits tumor growth. Using a combinatorial assay, we previously identified that CUDC-101, a dual histone deacetylase (HDAC)/EGFR inhibitor, synergizes with miR-27a* to restrict HNSCC cell growth. Using real-time live-cell imaging, we validated the combined effect of miR-27a* and CUDC-101 in inhibiting tumor cell growth. The objectives of this study were to validate the identified synergism of miR-27a* and CUDC-101 in restricting HNSCC cell growth and characterize pathways and processes affected by the combinatorial treatment.",
        "Methods": "UM-SCC-22A cells engineered to conditionally express miR-27a* were treated with miR-27a* and CUDC-101 individually and in combination. Effects of the treatments on cell survival and proliferation were analyzed using MTT and clonogenic assays. Changes in apoptosis were analyzed using immunoblots. Effects on pathways and molecules, including EGFR and HDAC, following CUDC-101 treatment and induction of miR-27a* expression were examined using immunoblotting for proteins and quantitative polymerase chain reaction for transcripts.",
        "Results": "We observed that the combined treatment with miR-27a* and CUDC-101 inhibited cell growth, proliferation, and survival to a far greater extent than did either treatment alone. Furthermore, we found that simultaneous treatment with miR-27a* and CUDC-101 induced apoptosis, which we did not see with the individual treatments at similar concentrations. We observed a sharp drop in the expression of P21 protein in cells treated simultaneously with miR-27a* and CUDC-101 but not in the other treatment groups. CUDC-101 and miR-27a* affected EGFR protein differently: CUDC-101 altered EGFR protein phosphorylation, whereas miR-27a* targeted EGFR protein expression.",
        "Conclusion": "Combinatorial treatment with CUDC-101 and miR-27a* restricts HNSCC cell growth and also induces apoptosis in HNSCC cells, but the individual treatments do not. This apoptosis is associated with decreased P21 protein expression. Further studies with the miR-27a*-CUDC-101 combination using in vivo models are needed.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>CUDC-101 Synergizes with miR-27a* to Restrict Head and Neck Squamous Cell Carcinoma Growth</span>. Nikhil S Chari, PhD<sup>1</sup>; <u>Tajinder Kainth, MS</u><sup>1</sup>; Reid T Powell, PhD<sup>2</sup>; Ahmad Abubaker, MD<sup>1</sup>; Nghi Nguyen<sup>2</sup>; M Sobieski<sup>2</sup>; Clifford C Stephen, PhD<sup>2</sup>; Stephen Y Lai, MD, PhD, FACS<sup>3</sup>. <sup>1</sup>\tDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>\tCenter for Translational Cancer Research, Texas A&M Health Science Center Institute of Biosciences & Technology; <sup>3</sup>\tDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>The current 5-year overall survival rate for advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. With almost 300,000 annual deaths worldwide, improvement of treatment options for patients with HNSCC is a clear need. Epidermal growth factor receptor (EGFR) overexpression occurs in more than half of HNSCCs and is associated with decreased survival. Current efforts targeting EGFR have resulted in marginal clinical benefits, indicating the need to target additional oncogenic pathways simultaneously. MicroRNAs are small noncoding RNAs that have evolved to simultaneously target multiple proteins. Our prior findings demonstrated that the microRNA miR-27a* (miR-27a-5p) targets multiple components of the EGFR/AKT1/mammalian target of rapamycin pathway, the most frequently altered mitogenic pathway in HNSCC cases. Expression of miR-27a* is repressed in HNSCCs and this repression correlates with survival in patient populations. Ectopic expression of miR-27a* in both in vivo and in vitro models inhibits tumor growth. Using a combinatorial assay, we previously identified that CUDC-101, a dual histone deacetylase (HDAC)/EGFR inhibitor, synergizes with miR-27a* to restrict HNSCC cell growth. Using real-time live-cell imaging, we validated the combined effect of miR-27a* and CUDC-101 in inhibiting tumor cell growth. The objectives of this study were to validate the identified synergism of miR-27a* and CUDC-101 in restricting HNSCC cell growth and characterize pathways and processes affected by the combinatorial treatment.</p>\n\n<p><strong>Methods: </strong>UM-SCC-22A cells engineered to conditionally express miR-27a* were treated with miR-27a* and CUDC-101 individually and in combination. Effects of the treatments on cell survival and proliferation were analyzed using MTT and clonogenic assays. Changes in apoptosis were analyzed using immunoblots. Effects on pathways and molecules, including EGFR and HDAC, following CUDC-101 treatment and induction of miR-27a* expression were examined using immunoblotting for proteins and quantitative polymerase chain reaction for transcripts.</p>\n\n<p><strong>Results: </strong>We observed that the combined treatment with miR-27a* and CUDC-101 inhibited cell growth, proliferation, and survival to a far greater extent than did either treatment alone. Furthermore, we found that simultaneous treatment with miR-27a* and CUDC-101 induced apoptosis, which we did not see with the individual treatments at similar concentrations. We observed a sharp drop in the expression of P21 protein in cells treated simultaneously with miR-27a* and CUDC-101 but not in the other treatment groups. CUDC-101 and miR-27a* affected EGFR protein differently: CUDC-101 altered EGFR protein phosphorylation, whereas miR-27a* targeted EGFR protein expression.</p>\n\n<p><strong>Conclusion: </strong>Combinatorial treatment with CUDC-101 and miR-27a* restricts HNSCC cell growth and also induces apoptosis in HNSCC cells, but the individual treatments do not. This apoptosis is associated with decreased P21 protein expression. Further studies with the miR-27a*-CUDC-101 combination using in vivo models are needed.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 148365--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S580",
      "content_id": "154644",
      "abstract_number": "S580",
      "poster_number": "",
      "title": "Therapeutic potential of p300 bromodomain inhibition as a senescence-inducing strategy for HPV-associated oropharyngeal squamous cell carcinoma",
      "summary": "High-risk human papillomavirus (HPV) is the primary cause of oropharynx squamous cell carcinoma (OPSCC). While current standard of care, multimodal therapies are effective for HPV-associated OPSCC, they often cause significant toxicity and long-term morbidity. Consequently, there is a critical need for alternative treatment strategies with improved toxicity profiles to manage these HPV-associated OPSCC patients....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154644",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "John Teknos",
      "presenter": "John Teknos",
      "authors": "Jessica Catarine Frutuoso do Nascimento, PhD; John Teknos ; Wendi O'Neill, DDS, MS, MA; Quintin Pan, PhD",
      "normalized_authors": [
        "Jessica Catarine Frutuoso Nascimento",
        "John Teknos",
        "Wendi O'Neill, MA",
        "Quintin Pan"
      ],
      "affiliations": [
        "University Hospitals Seidman Cancer Center"
      ],
      "normalized_institutions": [
        "University Hospitals Seidman Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 337,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jessica Catarine Frutuoso do Nascimento, PhD; John Teknos ; Wendi O'Neill, DDS, MS, MA; Quintin Pan, PhD",
        "Affiliations": "University Hospitals Seidman Cancer Center",
        "Abstract": "High-risk human papillomavirus (HPV) is the primary cause of oropharynx squamous cell carcinoma (OPSCC). While current standard of care, multimodal therapies are effective for HPV-associated OPSCC, they often cause significant toxicity and long-term morbidity. Consequently, there is a critical need for alternative treatment strategies with improved toxicity profiles to manage these HPV-associated OPSCC patients. The pathogenesis of HPV-associated OPSCC presents a unique opportunity for targeted therapeutic intervention since these cancers are addicted to the HPV oncoproteins E6 and E7. HPVE6 and HPVE7 co-opt the transcriptional coactivator p300 to facilitate the inactivation of two key tumor suppressor pathways, p53 and pRb. We hypothesized that a p300 bromodomain inhibitor (BDI) would disrupt the protein-protein interactions between p300 and the HPV oncoproteins E6 and E7, thereby restoring p53 and pRb tumor suppressor function. Two p300 BDIs, CCS1477 and GNE-781, demonstrated potent anti-proliferative activity in the HPV16+ UMSCC47 cell line. Proliferation was inhibited in a dose-dependent manner, with IC50 values of 23 nM for CCS1477 and 9 nM for GNE-781. Both inhibitors suppressed colony formation by 94% (p<0.001) and 98% (p<0.001), respectively. Treatment with these p300 BDIs induced G1 cell cycle arrest, reflected by a 15% (p<0.01) increase in G1 phase cells and a 30% reduction (p<0.01) in S phase cells. Importantly, both inhibitors resulted in an >8-fold increase (p<0.001) in cellular senescence as measured by b-galactosidase staining. Immunoblot analyses supported this finding, showing increased total and acetylated (K382Ac) p53 and p21 but no change in apoptotic markers, confirming that senescence is the predominant mechanism responsible for the anti-proliferative effects of these p300 BDIs. In an HPV16+ HNSCC xenograft model, CCS-1477 was active and significantly retarded tumor growth by 45% (p=0.014, n=6). In summary, CCS1477 and GNE-781 show robust anti-tumor activity in HPV16+ UMSCC47 cells, primarily through induction of cellular senescence. Our findings strongly support further evaluation of p300 BDIs as single-agent and in combination with senolytics in HPV+ model systems. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Therapeutic potential of p300 bromodomain inhibition as a senescence-inducing strategy for HPV-associated oropharyngeal squamous cell carcinoma</span>. Jessica Catarine Frutuoso do Nascimento, PhD; <u>John Teknos</u>; Wendi O'Neill, DDS, MS, MA; Quintin Pan, PhD. University Hospitals Seidman Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>High-risk human papillomavirus (HPV) is the primary cause of oropharynx squamous cell carcinoma (OPSCC). While current standard of care, multimodal therapies are effective for HPV-associated OPSCC, they often cause significant toxicity and long-term morbidity. Consequently, there is a critical need for alternative treatment strategies with improved toxicity profiles to manage these HPV-associated OPSCC patients. The pathogenesis of HPV-associated OPSCC presents a unique opportunity for targeted therapeutic intervention since these cancers are addicted to the HPV oncoproteins E6 and E7. HPVE6 and HPVE7 co-opt the transcriptional coactivator p300 to facilitate the inactivation of two key tumor suppressor pathways, p53 and pRb. We hypothesized that a p300 bromodomain inhibitor (BDI) would disrupt the protein-protein interactions between p300 and the HPV oncoproteins E6 and E7, thereby restoring p53 and pRb tumor suppressor function. Two p300 BDIs, CCS1477 and GNE-781, demonstrated potent anti-proliferative activity in the HPV16+ UMSCC47 cell line. Proliferation was inhibited in a dose-dependent manner, with IC50 values of 23 nM for CCS1477 and 9 nM for GNE-781. Both inhibitors suppressed colony formation by 94% (p<0.001) and 98% (p<0.001), respectively. Treatment with these p300 BDIs induced G1 cell cycle arrest, reflected by a 15% (p<0.01) increase in G1 phase cells and a 30% reduction (p<0.01) in S phase cells. Importantly, both inhibitors resulted in an >8-fold increase (p<0.001) in cellular senescence as measured by b-galactosidase staining. Immunoblot analyses supported this finding, showing increased total and acetylated (K382Ac) p53 and p21 but no change in apoptotic markers, confirming that senescence is the predominant mechanism responsible for the anti-proliferative effects of these p300 BDIs. In an HPV16+ HNSCC xenograft model, CCS-1477 was active and significantly retarded tumor growth by 45% (p=0.014, n=6). In summary, CCS1477 and GNE-781 show robust anti-tumor activity in HPV16+ UMSCC47 cells, primarily through induction of cellular senescence. Our findings strongly support further evaluation of p300 BDIs as single-agent and in combination with senolytics in HPV+ model systems.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154644--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S581",
      "content_id": "154664",
      "abstract_number": "S581",
      "poster_number": "",
      "title": "Detection of EGFR positive cells in Cervical Lymph Nodes and Perinodal Adipose Tissue",
      "summary": "The presence of fluorescently labeled panitumumab (pan800) within macrophages and EGFR positive tissue suggests that systemically administered antibodies are being absorbed non-specifically by macrophages, but also by EGFR expressing cells which is suggestive of in transit metastasis with the adipose tissue.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154664",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Makenna L Brown, CRC",
      "presenter": "Makenna L Brown, CRC",
      "authors": "Makenna L Brown, CRC ; Syeda Maria Ahmad Zaidi, Research Fellow; Brandee Brown, Research Manager; Adam Rosenburg, Research Assoc Professor; Micheal Topf, Assoc Professor; Eben Rosenthal, Dept Chairperson, Professor",
      "normalized_authors": [
        "Makenna L Brown, CRC",
        "Syeda Maria Ahmad Zaidi, Research Fellow",
        "Brandee Brown, Research Manager",
        "Adam Rosenburg, Research Assoc",
        "Micheal Topf, Assoc",
        "Eben Rosenthal, Dept Chairperson"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/154664/H%26E%20(1A).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154664/H%26E%20(1A).png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154664"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154664/IHC%20(1B).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154664/IHC%20(1B).png",
          "alt": "Source figure 2",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154664"
        },
        {
          "url": "https://www.submitmyabstract.com/abs/images/154664/Pan800%20(1C).png",
          "source_url": "https://www.submitmyabstract.com/abs/images/154664/Pan800%20(1C).png",
          "alt": "Figure 1: Representative images of perinodal adipose tissue and proposed mechanisms of tracer retention. (A) Hematoxylin and eosin (H&E) staining shows adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel (left), providing structural context for tracer distribution. (B) Immunofluorescence panel illustrating EGFR (blue) and CD68 (red) within adipose tissue. Regions containing EGFR-positive cells and CD68+ macrophages (arrow, left and right), indicating biologically active zones where tracer uptake may occur. Additionally, high pan800 uptake within the vessel with low macrophage and EGFR signaling indication potential free-dye accumulation (arrow labeled ‘Free-Dye’). (C) Pan800 fluorescence (green) overlaid with nuclear staining (blue) demonstrates tracer localization within the same perinodal adipose region. Pan800 signal is concentrated near the vessel and within vacuole clusters (arrow, left and right), supporting uptake by both EGFR-expressing cells and macrophages.",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154664"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 462,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Makenna L Brown, CRC ; Syeda Maria Ahmad Zaidi, Research Fellow; Brandee Brown, Research Manager; Adam Rosenburg, Research Assoc Professor; Micheal Topf, Assoc Professor; Eben Rosenthal, Dept Chairperson, Professor",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "Near-infrared (NIR) tracers such as panitumumab-IRDye800 (pan800) are tumor specific probes that enable intraoperative visualization of tumor margins. While strong fluorescence in metastatic lymph nodes is expected, low-level signal in perinodal adipose tissue raises questions about tracer specificity and the presence of residual cancer in the fibroadipose tissues of the neck. Understanding these patterns is critical for accurate interpretation during head and neck cancer surgery.",
        "Objective": "To characterize pan800 distribution in lymph nodes and surrounding adipose tissue, and to identify potential sources of signal including macrophage uptake, free-dye accumulation and EGFR-positive cells.",
        "Methods": "We imaged cervical lymph nodes and perinodal adipose tissue and correlated with FFPE sections that underwent hematoxylin and eosin staining and immunofluorescence for EGFR (tumor marker) and CD68 (macrophage marker). Fluorescence intensity from pan800 was quantified and correlated with histopathology controlling for autofluorescence.",
        "Results": "[A close-up of a microscope AI-generated content may be incorrect.] Histologic evaluation (Figure 1A) confirmed adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel, providing structural context for tracer distribution. Immunofluorescence (Figure 1B) revealed biologically active regions adjacent to the vessel, containing EGFR-positive cells (blue) and CD68+ macrophages (red), suggesting potential mechanisms for tracer retention. Pan800 fluorescence (Figure 1C) localized to these same regions, with signal concentrated near the vessel and within the adipose vacuoles.",
        "Abstract": "Quantitative analysis demonstrated that pan800 uptake was not random: 55% of CD68+ macrophages and 51% of EGFR-expressing cells exhibited pan800 positivity. These findings support dual mechanisms of tracer retention—nonspecific incorporation by macrophages and uptake by EGFR-positive cells, which may represent in-transit tumor cells within adipose tissue. Adipose tissue without pan800 tracer served as control tissue and exhibited minimal autofluorescence, confirming that observed signal was tracer derived. Figure 1 A-C: Representative images of perinodal adipose tissue and proposed mechanisms of tracer retention. (A) Hematoxylin and eosin (H&E) staining shows adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel (left), providing structural context for tracer distribution. (B) Immunofluorescence panel illustrating EGFR (blue) and CD68 (red) within adipose tissue. Regions containing EGFR-positive cells and CD68+ macrophages (arrow, left and right), indicating biologically active zones where tracer uptake may occur. Additionally, high pan800 uptake within the vessel with low macrophage and EGFR signaling indication potential free-dye accumulation (arrow labeled ‘Free-Dye’). (C) Pan800 fluorescence (green) overlaid with nuclear staining (blue) demonstrates tracer localization within the same perinodal adipose region. Pan800 signal is concentrated near the vessel and within vacuole clusters (arrow, left and right), supporting uptake by both EGFR-expressing cells and macrophages. View in Agenda and Add to Schedule",
        "Conclusion": "The presence of fluorescently labeled panitumumab (pan800) within macrophages and EGFR positive tissue suggests that systemically administered antibodies are being absorbed non-specifically by macrophages, but also by EGFR expressing cells which is suggestive of in transit metastasis with the adipose tissue."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Detection of EGFR positive cells in Cervical Lymph Nodes and Perinodal Adipose Tissue</span>. <u>Makenna L Brown, CRC</u>; Syeda Maria Ahmad Zaidi, Research Fellow; Brandee Brown, Research Manager; Adam Rosenburg, Research Assoc Professor; Micheal Topf, Assoc Professor; Eben Rosenthal, Dept Chairperson, Professor. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Near-infrared (NIR) tracers such as panitumumab-IRDye800 (pan800) are tumor specific probes that enable intraoperative visualization of tumor margins. While strong fluorescence in metastatic lymph nodes is expected, low-level signal in perinodal adipose tissue raises questions about tracer specificity and the presence of residual cancer in the fibroadipose tissues of the neck. Understanding these patterns is critical for accurate interpretation during head and neck cancer surgery.</p>\n\n<p><strong>Objective: </strong>To characterize pan800 distribution in lymph nodes and surrounding adipose tissue, and to identify potential sources of signal including macrophage uptake, free-dye accumulation and EGFR-positive cells.</p>\n\n<p><strong>Methods: </strong>We imaged cervical lymph nodes and perinodal adipose tissue and correlated with FFPE sections that underwent hematoxylin and eosin staining and immunofluorescence for EGFR (tumor marker) and CD68 (macrophage marker). Fluorescence intensity from pan800 was quantified and correlated with histopathology controlling for autofluorescence.  </p>\n\n<p><strong>Results: </strong>[A close-up of a microscope AI-generated content may be incorrect.] Histologic evaluation (Figure 1A) confirmed adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel, providing structural context for tracer distribution. Immunofluorescence (Figure 1B) revealed biologically active regions adjacent to the vessel, containing EGFR-positive cells (blue) and CD68+ macrophages (red), suggesting potential mechanisms for tracer retention. Pan800 fluorescence (Figure 1C) localized to these same regions, with signal concentrated near the vessel and within the adipose vacuoles.</p>\n\n<p>Quantitative analysis demonstrated that pan800 uptake was not random: 55% of CD68+ macrophages and 51% of EGFR-expressing cells exhibited pan800 positivity. These findings support dual mechanisms of tracer retention—nonspecific incorporation by macrophages and uptake by EGFR-positive cells, which may represent in-transit tumor cells within adipose tissue. Adipose tissue without pan800 tracer served as control tissue and exhibited minimal autofluorescence, confirming that observed signal was tracer derived.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154664/H%26E%20(1A).png' /></p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/154664/IHC%20(1B).png' /></p>\n\n<p><img alt='Figure 1: Representative images of perinodal adipose tissue and proposed mechanisms of tracer retention.  (A) Hematoxylin and eosin (H&E) staining shows adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel (left), providing structural context for tracer distribution. (B) Immunofluorescence panel illustrating EGFR (blue) and CD68 (red) within adipose tissue. Regions containing EGFR-positive cells and CD68+ macrophages (arrow, left and right), indicating biologically active zones where tracer uptake may occur. Additionally, high pan800 uptake within the vessel with low macrophage and EGFR signaling indication potential free-dye accumulation (arrow labeled ‘Free-Dye’). (C) Pan800 fluorescence (green) overlaid with nuclear staining (blue) demonstrates tracer localization within the same perinodal adipose region. Pan800 signal is concentrated near the vessel and within vacuole clusters (arrow, left and right), supporting uptake by both EGFR-expressing cells and macrophages.' src='https://www.submitmyabstract.com/abs/images/154664/Pan800%20(1C).png' /></p>\n\n<p>Figure 1 A-C: Representative images of perinodal adipose tissue and proposed mechanisms of tracer retention.</p>\n\n<p>(A) Hematoxylin and eosin (H&E) staining shows adipose tissue architecture with large vacuolated adipocytes and a prominent blood vessel (left), providing structural context for tracer distribution. (B) Immunofluorescence panel illustrating EGFR (blue) and CD68 (red) within adipose tissue. Regions containing EGFR-positive cells and CD68+ macrophages (arrow, left and right), indicating biologically active zones where tracer uptake may occur. Additionally, high pan800 uptake within the vessel with low macrophage and EGFR signaling indication potential free-dye accumulation (arrow labeled ‘Free-Dye’). (C) Pan800 fluorescence (green) overlaid with nuclear staining (blue) demonstrates tracer localization within the same perinodal adipose region. Pan800 signal is concentrated near the vessel and within vacuole clusters (arrow, left and right), supporting uptake by both EGFR-expressing cells and macrophages.</p>\n\n<p><strong>Conclusion: </strong>The presence of fluorescently labeled panitumumab (pan800) within macrophages and EGFR positive tissue suggests that systemically administered antibodies are being absorbed non-specifically by macrophages, but also by EGFR expressing cells which is suggestive of in transit metastasis with the adipose tissue.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154664--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S582",
      "content_id": "152892",
      "abstract_number": "S582",
      "poster_number": "",
      "title": "Nanoparticle Photosenzitizer Accumulation in Radiated Oropharyngeal Tumors: Potential Options for Salvage Photodynamic Therapy",
      "summary": "In this HPV-positive PDX flank model, preliminary data suggest that prior sub-therapeutic radiation does not impair porphysome uptake in recurrent tumors relative to non-irradiated controls and adjacent tongue. These results indicate porphysome-based PDT as a biologically plausible local salvage approach after radiation failure. Ongoing experiments will increase the number of animals, add histopathology, and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152892",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christopher Kopp, MD",
      "presenter": "Christopher Kopp, MD",
      "authors": "Christopher Kopp, MD 1 ; Esmat Najjar, MD 2 ; Jason Townson, PhD 1 ; Alessandra Ruaro, MD 3 ; Gang Zhang, Prof, PhD 1 ; Michael Valic, PhD 1 ; Jonathan Irish, MD, MSc, FRCSC, FACS 1",
      "normalized_authors": [
        "Christopher Kopp",
        "Esmat Najjar",
        "Jason Townson",
        "Alessandra Ruaro",
        "Gang Zhang, Prof",
        "Michael Valic",
        "Jonathan Irish, FRCSC"
      ],
      "affiliations": [
        "University of Toronto",
        "Rabin Medical Center, Petah Tikva",
        "Azienda Ospedaliera Università di Padova"
      ],
      "normalized_institutions": [
        "University of Toronto",
        "Rabin Medical Center, Petah Tikva",
        "Azienda Ospedaliera Università di Padova"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/152892/image.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/152892/image.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152892"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 394,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Christopher Kopp, MD 1 ; Esmat Najjar, MD 2 ; Jason Townson, PhD 1 ; Alessandra Ruaro, MD 3 ; Gang Zhang, Prof, PhD 1 ; Michael Valic, PhD 1 ; Jonathan Irish, MD, MSc, FRCSC, FACS 1",
        "Affiliations": "1 University of Toronto; 2 Rabin Medical Center, Petah Tikva; 3 Azienda Ospedaliera Università di Padova",
        "Background": "Local and regional recurrences after radiation for HPV-positive oropharyngeal cancer are difficult to manage. Salvage surgery can control disease but often at high functional cost. Photodynamic therapy (PDT) with porphysomes, fully organic porphyrin-lipid nanoparticles, is a repeatable, tissue-sparing local treatment. This potentially makes it a candidate for salvage treatment. Copper-64-labeled porphysomes enable quantitative in vivo and ex vivo measurements without altering nanoparticle behavior, allowing precise quantification of uptake. Whether radiation impairs or enhances porphysome delivery to recurrent tumors is unknown.",
        "Methods": "We used an HPV-positive patient-derived xenograft (PDX-64482) that had recurred after clinical radiation and is propagated as a subcutaneous flank tumor. Tumors injected either underwent radiation (n = 11) or were assisgned as a non-radiated control (n = 9). Radiated tumors received a sub-therapeutic, four-fraction external beam scheme (4x 5 Gy per day; total 20 Gy) chosen to induce regression followed by regrowth. Tumor regrowth occurred at a median of 12 days after radiation, which defined the “recurrent” time point. The control tumors were matched to have equivalent tumor volume of about 3-6mm. All animals then received intravenous 64Cu-porphysomes. Autoradiography and ex vivo fluorscent/DAPI scanning were performed 24 h post-injection. A PET-CT was perfomed on 13 tumors in vivo (7 radiated tumors, 6 controls). The primary endpoint was % injected dose per gram (%ID/g) and the tumor-to-tongue ratio, using the uninvolved tongue as internal reference tissue in each mouse. Fluorescence imaging was used qualitatively to confirm nanoparticle localization. This data represents the first experimental cohort of an ongoing multi-stage study.",
        "Results": "Recurrent radiated tumors showed overall comparable porphysome accumulation than non-radiated tumors. Mean tumor-to-tongue ratios (%ID/g) in the radiation group (n = 11) were 7.4 ± 3.6 versus 6.2 ± 2.8 in non-radiated controls (n = 9). Both PET-CT and autoradiography confirmed similar signal intensity within both tumors, with low uptake in the uninvolved tongue. We did not observe off-target accumulation or acute toxicity during the imaging period.",
        "Conclusions": "In this HPV-positive PDX flank model, preliminary data suggest that prior sub-therapeutic radiation does not impair porphysome uptake in recurrent tumors relative to non-irradiated controls and adjacent tongue. These results indicate porphysome-based PDT as a biologically plausible local salvage approach after radiation failure. Ongoing experiments will increase the number of animals, add histopathology, and incorporate PDT treatment with tumor-control readouts to test whether radiation-enhanced uptake translates into measurable pre-clinical outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Nanoparticle Photosenzitizer Accumulation in Radiated Oropharyngeal Tumors: Potential Options for Salvage Photodynamic Therapy</span>. <u>Christopher Kopp, MD</u><sup>1</sup>; Esmat Najjar, MD<sup>2</sup>; Jason Townson, PhD<sup>1</sup>; Alessandra Ruaro, MD<sup>3</sup>; Gang Zhang, Prof, PhD<sup>1</sup>; Michael Valic, PhD<sup>1</sup>; Jonathan Irish, MD, MSc, FRCSC, FACS<sup>1</sup>. <sup>1</sup>University of Toronto; <sup>2</sup>Rabin Medical Center, Petah Tikva; <sup>3</sup>Azienda Ospedaliera Università di Padova<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Local and regional recurrences after radiation for HPV-positive oropharyngeal cancer are difficult to manage. Salvage surgery can control disease but often at high functional cost. Photodynamic therapy (PDT) with porphysomes, fully organic porphyrin-lipid nanoparticles, is a repeatable, tissue-sparing local treatment. This potentially makes it a candidate for salvage treatment. Copper-64-labeled porphysomes enable quantitative in vivo and ex vivo measurements without altering nanoparticle behavior, allowing precise quantification of uptake. Whether radiation impairs or enhances porphysome delivery to recurrent tumors is unknown.</p>\n\n<p><strong>Methods: </strong>We used an HPV-positive patient-derived xenograft (PDX-64482) that had recurred after clinical radiation and is propagated as a subcutaneous flank tumor. Tumors injected either underwent radiation (n = 11) or were assisgned as a non-radiated control (n = 9). Radiated tumors received a sub-therapeutic, four-fraction external beam scheme (4x 5 Gy per day; total 20 Gy) chosen to induce regression followed by regrowth. Tumor regrowth occurred at a median of 12 days after radiation, which defined the “recurrent” time point. The control tumors were matched to have equivalent tumor volume of about 3-6mm. All animals then received intravenous 64Cu-porphysomes. Autoradiography and ex vivo fluorscent/DAPI scanning were performed 24 h post-injection. A PET-CT was perfomed on 13 tumors in vivo (7 radiated tumors, 6 controls). The primary endpoint was % injected dose per gram (%ID/g) and the tumor-to-tongue ratio, using the uninvolved tongue as internal reference tissue in each mouse. Fluorescence imaging was used qualitatively to confirm nanoparticle localization. This data represents the first experimental cohort of an ongoing multi-stage study.</p>\n\n<p><strong>Results: </strong>Recurrent radiated tumors showed overall comparable porphysome accumulation than non-radiated tumors. Mean tumor-to-tongue ratios (%ID/g) in the radiation group (n = 11) were 7.4 ± 3.6 versus 6.2 ± 2.8 in non-radiated controls (n = 9). Both PET-CT and autoradiography confirmed similar signal intensity within both tumors, with low uptake in the uninvolved tongue. We did not observe off-target accumulation or acute toxicity during the imaging period.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/152892/image.png' /></p>\n\n<p> </p>\n\n<p><strong>Conclusions: </strong>In this HPV-positive PDX flank model, preliminary data suggest that prior sub-therapeutic radiation does not impair porphysome uptake in recurrent tumors relative to non-irradiated controls and adjacent tongue. These results indicate porphysome-based PDT as a biologically plausible local salvage approach after radiation failure. Ongoing experiments will increase the number of animals, add histopathology, and incorporate PDT treatment with tumor-control readouts to test whether radiation-enhanced uptake translates into measurable pre-clinical outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152892--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S583",
      "content_id": "153894",
      "abstract_number": "S583",
      "poster_number": "",
      "title": "Identifying Pevonedistat-Based Combinatorial Treatments that Inhibit the Growth of Head and Neck Squamous Cell Carcinoma",
      "summary": "Our unbiased screens identified a number of compounds that demonstrated additive/synergistic effects with pevonedistat in inhibiting HNSCC growth. We validated a number of compounds, including afatinib, that enhanced the ability of pevonedistat to inhibit tumor cell growth. Treatment with pevonedistat sensitized an EGFR-insensitive HNSCC cell line to treatment with the EGFR inhibitor afatinib. Studies designed to...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153894",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Nikhil S Chari, PhD",
      "presenter": "Nikhil S Chari, PhD",
      "authors": "Nikhil S Chari, PhD 1 ; Reid T Powell, PhD 2 ; Tajinder S Kainth, MS 1 ; Nghi Nguyen, BS 2 ; Mary Sobieski 2 ; Clifford Stephan, PhD 2 ; Stephen Y Lai, MD, PhD, FACS 1",
      "normalized_authors": [
        "Nikhil S Chari",
        "Reid T Powell",
        "Tajinder S Kainth",
        "Nghi Nguyen",
        "Mary Sobieski",
        "Clifford Stephan",
        "Stephen Y Lai"
      ],
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center",
        "Texas A&M Health Science Center Institute of Biosciences & Technology"
      ],
      "normalized_institutions": [
        "The University of Texas MD Anderson Cancer Center",
        "Texas A&M Health Science Center Institute of Biosciences & Technology"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 469,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Nikhil S Chari, PhD 1 ; Reid T Powell, PhD 2 ; Tajinder S Kainth, MS 1 ; Nghi Nguyen, BS 2 ; Mary Sobieski 2 ; Clifford Stephan, PhD 2 ; Stephen Y Lai, MD, PhD, FACS 1",
        "Affiliations": "1 The University of Texas MD Anderson Cancer Center; 2 Texas A&M Health Science Center Institute of Biosciences & Technology",
        "Introduction": "Elevated expression of epidermal growth factor receptor (EGFR) occurs in 40-70% of head and neck squamous cell carcinomas (HNSCCs) and is associated with decreased patient survival. Multiple small molecule inhibitors and antibodies targeting EGFR have been generated and have produced promising results in preclinical models of HNSCC but have resulted in only minimal improvements in overall survival of patients with advanced HNSCC. Acquired resistance to EGFR-targeting therapies due to either further mutations of EGFR that allow cells to evade therapeutic inhibition or alterations in other pathways that confer resistance may promote tumor survival. Pevonedistat (MLN4924) is a NEDD8-activating enzyme inhibitor that blocks neddylation. Neddylation is a posttranscriptional modification in which NEDD8, a ubiquitin-like protein, attaches to other proteins, affecting their function. Alterations in neddylation pathways have been indicated in multiple tumor types. Pevonedistat has been shown to induce cell death and suppress tumor growth in preclinical models. The objective of this study was to identify tyrosine kinase inhibitors that, in combination with pevonedistat, restrict the growth of HNSCC cells that are otherwise resistant to EGFR inhibition.",
        "Methods": "A high-throughput screen (HTS) with a well-annotated library of receptor tyrosine kinase inhibitors was performed using the HNSCC cell lines UM-SCC-22A and HN31. UM-SCC-22A is sensitive to EGFR inhibitors, whereas HN31 is insensitive to EGFR inhibitors. Following the unbiased HTS studies, the BLISS synergy model was used to identify compounds that exhibited synergistic/additive effects in combination with pevonedistat in restricting the proliferation of HN31 cells compared with UM-SCC-22A cells. Real-time live-cell imaging was used to validate and visualize the effects of the combinatorial therapies on the kinetics of cell growth. Secondary phenotypic screens including MTT and clonogenic assays were performed to further validate the results of the HTS. Immunoblotting was used to examine the effects of combinatorial treatment on cell death and inhibition of the respective pathways by the molecular therapeutic combinations.",
        "Results": "Our unbiased HTS identified several compounds that demonstrated additive and synergistic effects in restricting HNSCC proliferation. Live-cell imaging and additional phenotypic assays validated the synergistic/additive pevonedistat-based combinations. One of the compounds that exhibited synergism with pevonedistat was afatinib, an EGFR inhibitor. Combined treatment of cells with pevonedistat and afatinib inhibited cell growth when administered at lower concentrations than those of either drug administered alone. We observed apoptosis in cells treated with the afatinib-pevonedistat combination.",
        "Conclusion": "Our unbiased screens identified a number of compounds that demonstrated additive/synergistic effects with pevonedistat in inhibiting HNSCC growth. We validated a number of compounds, including afatinib, that enhanced the ability of pevonedistat to inhibit tumor cell growth. Treatment with pevonedistat sensitized an EGFR-insensitive HNSCC cell line to treatment with the EGFR inhibitor afatinib. Studies designed to understand the mechanism underlying this synergism are ongoing. Further validation of these in vitro findings in orthotopic HNSCC models is needed.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Identifying Pevonedistat-Based Combinatorial Treatments that Inhibit the Growth of Head and Neck Squamous Cell Carcinoma</span>. <u>Nikhil S Chari, PhD</u><sup>1</sup>; Reid T Powell, PhD<sup>2</sup>; Tajinder S Kainth, MS<sup>1</sup>; Nghi Nguyen, BS<sup>2</sup>; Mary Sobieski<sup>2</sup>; Clifford Stephan, PhD<sup>2</sup>; Stephen Y Lai, MD, PhD, FACS<sup>1</sup>. <sup>1</sup>The University of Texas MD Anderson Cancer Center; <sup>2</sup>Texas A&M Health Science Center Institute of Biosciences & Technology<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Elevated expression of epidermal growth factor receptor (EGFR) occurs in 40-70% of head and neck squamous cell carcinomas (HNSCCs) and is associated with decreased patient survival. Multiple small molecule inhibitors and antibodies targeting EGFR have been generated and have produced promising results in preclinical models of HNSCC but have resulted in only minimal improvements in overall survival of patients with advanced HNSCC. Acquired resistance to EGFR-targeting therapies due to either further mutations of EGFR that allow cells to evade therapeutic inhibition or alterations in other pathways that confer resistance may promote tumor survival. Pevonedistat (MLN4924) is a NEDD8-activating enzyme inhibitor that blocks neddylation. Neddylation is a posttranscriptional modification in which NEDD8, a ubiquitin-like protein, attaches to other proteins, affecting their function. Alterations in neddylation pathways have been indicated in multiple tumor types. Pevonedistat has been shown to induce cell death and suppress tumor growth in preclinical models. The objective of this study was to identify tyrosine kinase inhibitors that, in combination with pevonedistat, restrict the growth of HNSCC cells that are otherwise resistant to EGFR inhibition.</p>\n\n<p><strong>Methods:</strong> A high-throughput screen (HTS) with a well-annotated library of receptor tyrosine kinase inhibitors was performed using the HNSCC cell lines UM-SCC-22A and HN31. UM-SCC-22A is sensitive to EGFR inhibitors, whereas HN31 is insensitive to EGFR inhibitors. Following the unbiased HTS studies, the BLISS synergy model was used to identify compounds that exhibited synergistic/additive effects in combination with pevonedistat in restricting the proliferation of HN31 cells compared with UM-SCC-22A cells. Real-time live-cell imaging was used to validate and visualize the effects of the combinatorial therapies on the kinetics of cell growth. Secondary phenotypic screens including MTT and clonogenic assays were performed to further validate the results of the HTS. Immunoblotting was used to examine the effects of combinatorial treatment on cell death and inhibition of the respective pathways by the molecular therapeutic combinations.</p>\n\n<p><strong>Results:</strong> Our unbiased HTS identified several compounds that demonstrated additive and synergistic effects in restricting HNSCC proliferation. Live-cell imaging and additional phenotypic assays validated the synergistic/additive pevonedistat-based combinations. One of the compounds that exhibited synergism with pevonedistat was afatinib, an EGFR inhibitor. Combined treatment of cells with pevonedistat and afatinib inhibited cell growth when administered at lower concentrations than those of either drug administered alone. We observed apoptosis in cells treated with the afatinib-pevonedistat combination.</p>\n\n<p><strong>Conclusion:</strong> Our unbiased screens identified a number of compounds that demonstrated additive/synergistic effects with pevonedistat in inhibiting HNSCC growth. We validated a number of compounds, including afatinib, that enhanced the ability of pevonedistat to inhibit tumor cell growth. Treatment with pevonedistat sensitized an EGFR-insensitive HNSCC cell line to treatment with the EGFR inhibitor afatinib. Studies designed to understand the mechanism underlying this synergism are ongoing. Further validation of these in vitro findings in orthotopic HNSCC models is needed.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153894--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S584",
      "content_id": "153317",
      "abstract_number": "S584",
      "poster_number": "",
      "title": "The pre-treatment presence of tumor antigen–reactive T cells as a surrogate marker of PD-1 blockade efficacy in HNSCC",
      "summary": "Immunotherapy has emerged as a distinct therapeutic modality complementing surgery, radiotherapy, and chemotherapy. The introduction of immune checkpoint inhibitors (ICIs) has particularly transformed the management of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Because effective antitumor immunity relies on the presence of tumor antigen–reactive T cells, identifying these cells...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153317",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260161",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Takahiro Inoue",
      "presenter": "Takahiro Inoue",
      "authors": "Takahiro Inoue ; Hisataka Ominato; Ryosuke Sato; Risa Wakisaka; Hiroki Komatsuda; Michihisa Kono; Hidekiyo Yamaki; Kenzo Ohara; Takumi Kumai; Kan Kishibe; Miki Takahara",
      "normalized_authors": [
        "Takahiro Inoue",
        "Hisataka Ominato",
        "Ryosuke Sato",
        "Risa Wakisaka",
        "Hiroki Komatsuda",
        "Michihisa Kono",
        "Hidekiyo Yamaki",
        "Kenzo Ohara",
        "Takumi Kumai",
        "Kan Kishibe",
        "Miki Takahara"
      ],
      "affiliations": [
        "Department of Otolaryngology - Head & Neck Surgery"
      ],
      "normalized_institutions": [
        "Department of Otolaryngology - Head & Neck Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 369,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Abstract"
      ],
      "sections": {
        "Authors": "Takahiro Inoue ; Hisataka Ominato; Ryosuke Sato; Risa Wakisaka; Hiroki Komatsuda; Michihisa Kono; Hidekiyo Yamaki; Kenzo Ohara; Takumi Kumai; Kan Kishibe; Miki Takahara",
        "Affiliations": "Department of Otolaryngology - Head & Neck Surgery",
        "Abstract": "Immunotherapy has emerged as a distinct therapeutic modality complementing surgery, radiotherapy, and chemotherapy. The introduction of immune checkpoint inhibitors (ICIs) has particularly transformed the management of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Because effective antitumor immunity relies on the presence of tumor antigen–reactive T cells, identifying these cells prior to therapy may offer a valuable surrogate marker for predicting ICI efficacy. To detect tumor-reactive T cells, we focused on tumor-associated antigens c-Met, a receptor tyrosine kinase whose interaction with its ligand HGF promotes cell growth, invasion, and survival across numerous malignancies. We first confirmed robust c-Met expression in HNSCC cell lines and clinical tumor specimens. As an immunological target, we identified three novel c-Met–derived helper T lymphocyte (HTL) epitopes restricted by several common HLA-DR alleles. HTL lines specific for these epitopes directly recognized and killed c-Met–expressing HNSCC cells, and also recognized dendritic cells pulsed with lysates from c-Met–positive tumors. Notably, pharmacologic inhibition of c-Met enhanced HTL recognition by suppressing tumor-derived TGF-β production, suggesting that c-Met signaling contributes to immune evasion. To explore surrogate markers for PD-1 blockade, we next evaluated clinical and immunological variables in responders (CR/PR) versus non-responders (SD/PD) treated with PD-1 antibody monotherapy. The two groups showed no significant differences in tumor-infiltrating T cells, PD-L1 expression—including combined positive score—or in the expression of negative immune checkpoints on peripheral CD4? or CD8? T cells, except for lymphocyte counts. Strikingly, only responders mounted detectable T-cell responses against c-Met epitopes in short-term peptide stimulation assays, indicating the presence of pre-existing tumor-reactive T cells in the peripheral circulation. Collectively, these findings support c-Met as a relevant immunologic target in HNSCC and demonstrate that peptide-specific T-cell reactivity can be detected before initiating PD-1 blockade. The ability of responders—but not non-responders—to elicit c-Met–reactive T-cell responses suggests that the pre-treatment presence of tumor antigen–reactive T cells may serve as a potent surrogate marker for predicting clinical benefit from ICI therapy. This concept highlights the importance of functional immune monitoring in guiding immunotherapy and provides a rationale for integrating tumor antigen–specific T-cell assays into future biomarker development for HNSCC. View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>The pre-treatment presence of tumor antigen–reactive T cells as a surrogate marker of PD-1 blockade efficacy in HNSCC</span>. <u>Takahiro Inoue</u>; Hisataka Ominato; Ryosuke Sato; Risa Wakisaka; Hiroki Komatsuda; Michihisa Kono; Hidekiyo Yamaki; Kenzo Ohara; Takumi Kumai; Kan Kishibe; Miki Takahara. Department of Otolaryngology - Head & Neck Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p>Immunotherapy has emerged as a distinct therapeutic modality complementing surgery, radiotherapy, and chemotherapy. The introduction of immune checkpoint inhibitors (ICIs) has particularly transformed the management of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Because effective antitumor immunity relies on the presence of tumor antigen–reactive T cells, identifying these cells prior to therapy may offer a valuable surrogate marker for predicting ICI efficacy.</p>\n\n<p>To detect tumor-reactive T cells, we focused on tumor-associated antigens c-Met, a receptor tyrosine kinase whose interaction with its ligand HGF promotes cell growth, invasion, and survival across numerous malignancies. We first confirmed robust c-Met expression in HNSCC cell lines and clinical tumor specimens. As an immunological target, we identified three novel c-Met–derived helper T lymphocyte (HTL) epitopes restricted by several common HLA-DR alleles. HTL lines specific for these epitopes directly recognized and killed c-Met–expressing HNSCC cells, and also recognized dendritic cells pulsed with lysates from c-Met–positive tumors. Notably, pharmacologic inhibition of c-Met enhanced HTL recognition by suppressing tumor-derived TGF-β production, suggesting that c-Met signaling contributes to immune evasion.</p>\n\n<p>To explore surrogate markers for PD-1 blockade, we next evaluated clinical and immunological variables in responders (CR/PR) versus non-responders (SD/PD) treated with PD-1 antibody monotherapy. The two groups showed no significant differences in tumor-infiltrating T cells, PD-L1 expression—including combined positive score—or in the expression of negative immune checkpoints on peripheral CD4? or CD8? T cells, except for lymphocyte counts. Strikingly, only responders mounted detectable T-cell responses against c-Met epitopes in short-term peptide stimulation assays, indicating the presence of pre-existing tumor-reactive T cells in the peripheral circulation.</p>\n\n<p>Collectively, these findings support c-Met as a relevant immunologic target in HNSCC and demonstrate that peptide-specific T-cell reactivity can be detected before initiating PD-1 blockade. The ability of responders—but not non-responders—to elicit c-Met–reactive T-cell responses suggests that the pre-treatment presence of tumor antigen–reactive T cells may serve as a potent surrogate marker for predicting clinical benefit from ICI therapy. This concept highlights the importance of functional immune monitoring in guiding immunotherapy and provides a rationale for integrating tumor antigen–specific T-cell assays into future biomarker development for HNSCC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153317--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260161' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S585",
      "content_id": "155467",
      "abstract_number": "S585",
      "poster_number": "",
      "title": "Integrative multi-omics analysis to decipher the molecular landscape of oral potentially malignant disorders",
      "summary": "Integrated transcriptomic and genomic analyses with positional mapping revealed progressive molecular alterations from benign to dysplastic/cancer states. The epithelium at the stromal interface and TME emerged as key contributors to these changes. These results lay the framework for understanding molecular landscape of OPMDs, paving way for future research/development of prognostic methods and therapeutic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155467",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "William Magner, PhD",
      "presenter": "William Magner, PhD",
      "authors": "Neerada Meenakshi Warrier, PhD 1 ; Gangotri Siddappa, PhD 1 ; Anela Thomas, MDS 2 ; Vaishnav Vasudevan 1 ; Reba Elsa Sam 1 ; Uma Mohan, MDS 2 ; Lekshmi Pradeep, MDS 2 ; Sumsum P Sunny, PhD 2 ; Manjunath Prasad 3 ; Shashikala Balanna 3 ; Coral Karunakaran 3 ; Manju Moorthy 4 ; William Magner, PhD 5 ; Vijayalakshmi Bhat 4 ; Litika Vermani, PhD 6 ; Ritesh Tapkire, MS, Mch 6 ; Monoj K Deka, MD 6 ; Vivek Shetty, MS, MCh 7 ; Vidyabhushan R, MS 7 ; Yogesh Dokhe, MS, MCh 7 ; Naveen BS, MDS 7 ; Praveen Birur, MDS, PhD 8 ; Gopalakrishna Ramaswamy, PhD 4 ; Ravi Kannan, MS, MCh 6 ; Vijay Pillai, MD 7 ; Moni A Kuriakose, MD, FRCS 9 ; Rajeev Kumar, PhD 6 ; Sujan K Dhar, PhD 10 ; Amritha Suresh, PhD 11 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; 2 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 3 MedGenome Labs, Bangalore, India, 560099; 4 TheraCUES Innovations Pvt",
      "normalized_authors": [
        "Neerada Meenakshi Warrier",
        "Gangotri Siddappa",
        "Anela Thomas, MDS",
        "Vaishnav Vasudevan",
        "Reba Elsa Sam",
        "Uma Mohan, MDS",
        "Lekshmi Pradeep, MDS",
        "Sumsum P Sunny",
        "Manjunath Prasad",
        "Shashikala Balanna",
        "Coral Karunakaran",
        "Manju Moorthy",
        "William Magner",
        "Vijayalakshmi Bhat",
        "Litika Vermani",
        "Ritesh Tapkire, Mch",
        "Monoj K Deka",
        "Vivek Shetty, MCh",
        "Vidyabhushan R",
        "Yogesh Dokhe, MCh",
        "Naveen MDS",
        "Praveen Birur, MDS",
        "Gopalakrishna Ramaswamy",
        "Ravi Kannan, MCh",
        "Vijay Pillai",
        "Moni A Kuriakose",
        "Rajeev Kumar",
        "Sujan K Dhar",
        "MedGenome Labs, Bangalore, India",
        "TheraCUES Innovations Pvt"
      ],
      "affiliations": [
        "Ltd., Bangalore, India, 560092",
        "Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
        "Cachar Cancer Hospital and Research Centre, Silchar, Assam, India, 788015",
        "Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Bangalore, India, 560022",
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099",
        "Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
        "Computational Biology, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099"
      ],
      "normalized_institutions": [
        "Ltd., Bangalore, India, 560092",
        "Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
        "Cachar Cancer Hospital and Research Centre, Silchar, Assam, India, 788015",
        "Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099",
        "Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Bangalore, India, 560022",
        "Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099",
        "Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
        "Computational Biology, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 561,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Objectives",
        "Methodology",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Neerada Meenakshi Warrier, PhD 1 ; Gangotri Siddappa, PhD 1 ; Anela Thomas, MDS 2 ; Vaishnav Vasudevan 1 ; Reba Elsa Sam 1 ; Uma Mohan, MDS 2 ; Lekshmi Pradeep, MDS 2 ; Sumsum P Sunny, PhD 2 ; Manjunath Prasad 3 ; Shashikala Balanna 3 ; Coral Karunakaran 3 ; Manju Moorthy 4 ; William Magner, PhD 5 ; Vijayalakshmi Bhat 4 ; Litika Vermani, PhD 6 ; Ritesh Tapkire, MS, Mch 6 ; Monoj K Deka, MD 6 ; Vivek Shetty, MS, MCh 7 ; Vidyabhushan R, MS 7 ; Yogesh Dokhe, MS, MCh 7 ; Naveen BS, MDS 7 ; Praveen Birur, MDS, PhD 8 ; Gopalakrishna Ramaswamy, PhD 4 ; Ravi Kannan, MS, MCh 6 ; Vijay Pillai, MD 7 ; Moni A Kuriakose, MD, FRCS 9 ; Rajeev Kumar, PhD 6 ; Sujan K Dhar, PhD 10 ; Amritha Suresh, PhD 11 . 1 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; 2 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 3 MedGenome Labs, Bangalore, India, 560099; 4 TheraCUES Innovations Pvt",
        "Affiliations": "Ltd., Bangalore, India, 560092; 5 Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, Buffalo, New York; 6 Cachar Cancer Hospital and Research Centre, Silchar, Assam, India, 788015; 7 Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; 8 Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Bangalore, India, 560022; 9 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; Roswell Park Comprehensive Cancer Centre, Buffalo, New York; 10 Computational Biology, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; 11 Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Roswell Park Comprehensive Cancer Centre, Buffalo, New York",
        "Background": "Understanding the genomic and transcriptomic landscape regulating carcinogenic processes is a prerequisite for uncovering novel insights into oral potentially malignant disorders(OPMDs) and malignant signatures, enabling efficient strategies for early detection/prevention.",
        "Objectives": "i) Understanding the genomics and transcriptomic landscape of oral potentially malignant lesions and early-stage oral cancer; ii) Identifying molecular differences between epithelium and stroma for positional mapping of transcriptional activity; iii) Integrative analysis of multi-omics profiling data and validation to identify the significant differentials associated with malignant transformation datasets",
        "Methodology": "Tissue samples were collected from patients diagnosed with histologically confirmed OPMLs/Stage I–II cancers and previously untreated (chemotherapy/radiotherapy) after ethical approval. Transcriptomic profiling(n=87) was performed using Illumina HiSeq 4000 (Medgenome Labs). Differentially expressed genes (DEGs; p-adj ≤0.05, log2FC ≥ ±1) that specify the shift from benign(n=20) to dysplasia(n=67), or between grades of dysplasia [high-grade dysplasia (HGD, n=43) vs low-grade dysplasia (LGD, n=44)] were identified and functionally annotated using clusterprofiler/MSigDB(hallmarks). Whole Exome Sequencing (WES-UTR) was performed(n=72) and sample-wise variant calling files (VCF) containing merged variants from haplotype caller and genotype caller were generated; those common were selected, normalized, and used to calculate Ti/Tv ratio. These VCF files were analyzed using VariMAT annotation pipeline and VEP(Variant Effect Predictor) tool to identify mutations and DNA variations. Spatial transcriptomics profiling of an independent cohort of patients(benign(n=6), hyperplasia(n=4), and severe dysplasia(n=6)) was performed using Nanostring’s GeoMx DSP(TheraCues Pvt. Ltd). DEGs and pathways/processes in the epithelium(panCK+) and tumor microenvironment(TME; panCK-/CD45+) were assessed in severe dysplasia compared to hyperplasia/benign. Integrative Analysis combining transcriptomics (FC≥±1.5, p<0.05 (bulk/spatial) with WES is currently being performed. In each cohort(benign, dysplasia, cancer, and epithelium/stroma), genes altered at the exome level and at the transcriptomic level will be identified and types of mutations will be assessed in association with their regulatory trends in expression. Additionally, functionally relevant candidate molecules will be validated in external datasets with malignant transformation information(N=3 public datasets) for identifying candidates involved in cancer progression.",
        "Results": "Transcriptomic data analysis identified processes and DEGs (FC≥±1.5; p<0.05) that specified the shift from benign to dysplasia and LGD to HGD. Pathway analysis revealed the involvement of DNA repair/G2M checkpoint pathways in dysplasia, MYC-MTORC1 signaling in HGD, and KRAS/IL2-STAT5 signaling in LGD. Genomic profiling indicated overall alterations in benign(n=17237), dysplasia(n=21565), and cancer(n=12306) cohorts. Analysis indicated a high frequency of intronic, 3’UTR, missense, silent, 5’UTR, and exonic-nc alterations with missense mutations being the highest contributor in coding areas. Alteration burden was higher in dysplastic samples as compared to cancers. Spatial transcriptomics demonstrated higher DEG burden in the TME and during the shift from benign to hyperplasia; severe dysplasia showed processes/pathways involved in chemokine signaling/immune exhaustion, whereas hyperplasia showed increased mitochondrial metabolic activity. The integrated analysis is currently ongoing.",
        "Conclusion": "Integrated transcriptomic and genomic analyses with positional mapping revealed progressive molecular alterations from benign to dysplastic/cancer states. The epithelium at the stromal interface and TME emerged as key contributors to these changes. These results lay the framework for understanding molecular landscape of OPMDs, paving way for future research/development of prognostic methods and therapeutic candidates.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Integrative multi-omics analysis to decipher the molecular landscape of oral potentially malignant disorders</span>. Neerada Meenakshi Warrier, PhD<sup>1</sup>; Gangotri Siddappa, PhD<sup>1</sup>; Anela Thomas, MDS<sup>2</sup>; Vaishnav Vasudevan<sup>1</sup>; Reba Elsa Sam<sup>1</sup>; Uma Mohan, MDS<sup>2</sup>; Lekshmi Pradeep, MDS<sup>2</sup>; Sumsum P Sunny, PhD<sup>2</sup>; Manjunath Prasad<sup>3</sup>; Shashikala Balanna<sup>3</sup>; Coral Karunakaran<sup>3</sup>; Manju Moorthy<sup>4</sup>; <u>William Magner, PhD</u><sup>5</sup>; Vijayalakshmi Bhat<sup>4</sup>; Litika Vermani, PhD<sup>6</sup>; Ritesh Tapkire, MS, Mch<sup>6</sup>; Monoj K Deka, MD<sup>6</sup>; Vivek Shetty, MS, MCh<sup>7</sup>; Vidyabhushan R, MS<sup>7</sup>; Yogesh Dokhe, MS, MCh<sup>7</sup>; Naveen BS, MDS<sup>7</sup>; Praveen Birur, MDS, PhD<sup>8</sup>; Gopalakrishna Ramaswamy, PhD<sup>4</sup>; Ravi Kannan, MS, MCh<sup>6</sup>; Vijay Pillai, MD<sup>7</sup>; Moni A Kuriakose, MD, FRCS<sup>9</sup>; Rajeev Kumar, PhD<sup>6</sup>; Sujan K Dhar, PhD<sup>10</sup>; Amritha Suresh, PhD<sup>11</sup>. <sup>1</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; <sup>2</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; <sup>3</sup>MedGenome Labs, Bangalore, India, 560099; <sup>4</sup>TheraCUES Innovations Pvt. Ltd., Bangalore, India, 560092; <sup>5</sup>Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, Buffalo, New York; <sup>6</sup>Cachar Cancer Hospital and Research Centre, Silchar, Assam, India, 788015; <sup>7</sup>Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; <sup>8</sup>Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences, Bangalore, India, 560022; <sup>9</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Head and Neck Oncology Department, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, India, 560099; Roswell Park Comprehensive Cancer Centre, Buffalo, New York; <sup>10</sup>Computational Biology, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; <sup>11</sup>Integrated Head and Neck Oncology Research Program, Mazumdar Shaw Medical Foundation, Bangalore, India, 560099; Roswell Park Comprehensive Cancer Centre, Buffalo, New York<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Understanding the genomic and transcriptomic landscape regulating carcinogenic processes is a prerequisite for uncovering novel insights into oral potentially malignant disorders(OPMDs) and malignant signatures, enabling efficient strategies for early detection/prevention.</p>\n\n<p><strong>Objectives:</strong> i) Understanding the genomics and transcriptomic landscape of oral potentially malignant lesions and early-stage oral cancer; ii) Identifying molecular differences between epithelium and stroma for positional mapping of transcriptional activity; iii) Integrative analysis of multi-omics profiling data and validation to identify the significant differentials associated with malignant transformation datasets</p>\n\n<p><strong>Methodology: </strong>Tissue samples were collected from patients diagnosed with histologically confirmed OPMLs/Stage I–II cancers and previously untreated (chemotherapy/radiotherapy) after ethical approval. Transcriptomic profiling(n=87) was performed using Illumina HiSeq 4000 (Medgenome Labs). Differentially expressed genes (DEGs; p-adj ≤0.05, log2FC ≥ ±1) that specify the shift from benign(n=20) to dysplasia(n=67), or between grades of dysplasia [high-grade dysplasia (HGD, n=43) vs low-grade dysplasia (LGD, n=44)] were identified and functionally annotated using clusterprofiler/MSigDB(hallmarks). Whole Exome Sequencing (WES-UTR) was performed(n=72) and sample-wise variant calling files (VCF) containing merged variants from haplotype caller and genotype caller were generated; those common were selected, normalized, and used to calculate Ti/Tv ratio. These VCF files were analyzed using VariMAT annotation pipeline and VEP(Variant Effect Predictor) tool to identify mutations and DNA variations. Spatial transcriptomics profiling of an independent cohort of patients(benign(n=6), hyperplasia(n=4), and severe dysplasia(n=6)) was performed using Nanostring’s GeoMx DSP(TheraCues Pvt. Ltd). DEGs and pathways/processes in the epithelium(panCK+) and tumor microenvironment(TME; panCK-/CD45+) were assessed in severe dysplasia compared to hyperplasia/benign. Integrative Analysis combining transcriptomics (FC≥±1.5, p<0.05 (bulk/spatial) with WES is currently being performed. In each cohort(benign, dysplasia, cancer, and epithelium/stroma), genes altered at the exome level and at the transcriptomic level will be identified and types of mutations will be assessed in association with their regulatory trends in expression. Additionally, functionally relevant candidate molecules will be validated in external datasets with malignant transformation information(N=3 public datasets) for identifying candidates involved in cancer progression.</p>\n\n<p><strong>Results: </strong>Transcriptomic data analysis identified processes and DEGs (FC≥±1.5; p<0.05) that specified the shift from benign to dysplasia and LGD to HGD. Pathway analysis revealed the involvement of DNA repair/G2M checkpoint pathways in dysplasia, MYC-MTORC1 signaling in HGD, and KRAS/IL2-STAT5 signaling in LGD. Genomic profiling indicated overall alterations in benign(n=17237), dysplasia(n=21565), and cancer(n=12306) cohorts. Analysis indicated a high frequency of intronic, 3’UTR, missense, silent, 5’UTR, and exonic-nc alterations with missense mutations being the highest contributor in coding areas. Alteration burden was higher in dysplastic samples as compared to cancers. Spatial transcriptomics demonstrated higher DEG burden in the TME and during the shift from benign to hyperplasia; severe dysplasia showed processes/pathways involved in chemokine signaling/immune exhaustion, whereas hyperplasia showed increased mitochondrial metabolic activity. The integrated analysis is currently ongoing.</p>\n\n<p><strong>Conclusion:</strong> Integrated transcriptomic and genomic analyses with positional mapping revealed progressive molecular alterations from benign to dysplastic/cancer states. The epithelium at the stromal interface and TME emerged as key contributors to these changes. These results lay the framework for understanding molecular landscape of OPMDs, paving way for future research/development of prognostic methods and therapeutic candidates.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155467--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S586",
      "content_id": "155441",
      "abstract_number": "S586",
      "poster_number": "",
      "title": "A Novel Artificial Intelligence/Machine Learning Enhanced Fourier Transform Infrared Microscopy Platform for Risk Identification of Oral Potentially Malignant Disorders",
      "summary": "The integration of multi-modality imaging and AI interpretation provides a robust, objective framework for oral dysplasia risk identification. By correlating biochemical spectral features with molecular expression and clinical outcomes, these models provide actionable risk scores. This approach simplifies the characterization of oral lesions and enhances the prediction of malignant potential without requiring...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155441",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Subin Surendran, PhD",
      "presenter": "Subin Surendran, PhD",
      "authors": "Subin Surendran, PhD 1 ; Keerthivani Balraj, PhD 2 ; Mehrdad Pournaderi, BS 3 ; Christine R Burton, MD 1 ; William J Magner, PhD 1 ; Ashok Z Samuel, PhD 2 ; Lynn Sigurdson, PhD 1 ; Christian Gluck, MD, PhD 4 ; Amritha Suresh, PhD 5 ; Sumsum Sunny, MDS, PhD 5 ; Yjun Sun, PhD 3 ; Rohit Bhargava, PhD 2 ; Moni A Kuriakose, MD 6",
      "normalized_authors": [
        "Subin Surendran",
        "Keerthivani Balraj",
        "Mehrdad Pournaderi",
        "Christine R Burton",
        "William J Magner",
        "Ashok Z Samuel",
        "Lynn Sigurdson",
        "Christian Gluck",
        "Amritha Suresh",
        "Sumsum Sunny, MDS",
        "Yjun Sun",
        "Rohit Bhargava",
        "Moni A Kuriakose"
      ],
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center",
        "Beckman Institute for Advanced Science and Technology, University of Illinois Urbana- Champaign",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Penn State Health",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "Lakeshore Hospital, Kochi, India"
      ],
      "normalized_institutions": [
        "Roswell Park Comprehensive Cancer Center",
        "Beckman Institute for Advanced Science and Technology, University of Illinois Urbana- Champaign",
        "University at Buffalo Jacobs School of Medicine and Biomedical Sciences",
        "Penn State Health",
        "Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India",
        "Lakeshore Hospital, Kochi, India"
      ],
      "session_type": "Proffered Paper",
      "track": "Artificial Intelligence",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Artificial Intelligence"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 482,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Subin Surendran, PhD 1 ; Keerthivani Balraj, PhD 2 ; Mehrdad Pournaderi, BS 3 ; Christine R Burton, MD 1 ; William J Magner, PhD 1 ; Ashok Z Samuel, PhD 2 ; Lynn Sigurdson, PhD 1 ; Christian Gluck, MD, PhD 4 ; Amritha Suresh, PhD 5 ; Sumsum Sunny, MDS, PhD 5 ; Yjun Sun, PhD 3 ; Rohit Bhargava, PhD 2 ; Moni A Kuriakose, MD 6",
        "Affiliations": "1 Roswell Park Comprehensive Cancer Center; 2 Beckman Institute for Advanced Science and Technology, University of Illinois Urbana- Champaign; 3 University at Buffalo Jacobs School of Medicine and Biomedical Sciences; 4 Penn State Health; 5 Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; 6 Lakeshore Hospital, Kochi, India",
        "Background": "Oral Potentially Malignant Disorders (OPMD) are the precursors of over 80% of oral cancers. For every oral cancer patient, however, there are 30 OPMD patients; this huge population must be diagnosed and treated effectively to reduce oral cancer burden. Although histological examination by hematoxylin and eosin (H&E) stained slides is the diagnostic gold standard in OPMD, it fails to reliably predict malignant transformation, which varies in the literature from 0.13% to 40.8%. Despite many adjuncts to identifying OPMDs early, none offer reliable diagnoses in a primary or community healthcare setting that are comparable to the diagnostic gold standard. This highlights a need for reliable biomarkers able to assess malignant transformation potential. Fourier Transform Infrared (FTIR) imaging offers a label-free, chemically specific method to quantify the molecular composition of tissue, providing a digital fingerprint that can be decoded by advanced artificial intelligence (AI)/machine learning(ML) algorithms. We hypothesize that FTIR microscopy and AI/ML workflows can provide a more accurate and reproducible assessment of OPMD than current histological standards. Specifically, by mapping the unique IR spectral signatures of high-value diagnostic and prognostic biomarkers such as CD44, SNA1, Podoplanin, and S100A7 directly from unstained tissue, this platform will enhance OPMD diagnosis and prognosis.",
        "Methods": "This study used patient samples representing non-dysplastic, OPMD, and oral cancer lesions to develop an objective, AI-driven diagnostic framework. Serial 5 µm sections were prepared for gold-standard pathological review and label-free FTIR microscopy. Adjacent sections underwent immunohistochemical (IHC) profiling for diagnostic (CD44, SNA1) and prognostic (S100A7, Podoplanin) biomarkers to establish a spatially resolved \"ground truth\" through side-by-side alignment with darkfield images in Matlab. To decode the IR spectral fingerprints, a deep learning approach was implemented for these four biomarkers. Feature selection was optimized through a signal-to-noise ratio (SNR) screening process and refined using Squeeze-and-Excitation (SE) modules with the knockoff procedure to ensure statistically rigorous channel selection and minimize false discoveries.",
        "Results": "The integrated FTIR and AI/ML-based approach successfully identified specific, objective spectral features for each of the four biomarkers, establishing a direct link between biochemical fingerprints and OPMD malignant potential. By utilizing IHC staining for CD44, SNA1, S100A7, and Podoplanin, this study created a verified map of biomarker localization and intensity. These IR signatures were proven to be independent predictors of progression, enabling the AI workflow to achieve significant diagnostic accuracy. Ultimately, this framework provides a reproducible molecular contrast that categorizes lesions into high-risk or low-risk cohorts based on their biochemical profiles, offering a clinically actionable tool to predict malignant transformation kinetics.",
        "Conclusions": "The integration of multi-modality imaging and AI interpretation provides a robust, objective framework for oral dysplasia risk identification. By correlating biochemical spectral features with molecular expression and clinical outcomes, these models provide actionable risk scores. This approach simplifies the characterization of oral lesions and enhances the prediction of malignant potential without requiring additional reagents or specialized human operators.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>A Novel Artificial Intelligence/Machine Learning Enhanced Fourier Transform Infrared Microscopy Platform for Risk Identification of Oral Potentially Malignant Disorders</span>. <u>Subin Surendran, PhD</u><sup>1</sup>; Keerthivani Balraj, PhD<sup>2</sup>; Mehrdad Pournaderi, BS<sup>3</sup>; Christine R Burton, MD<sup>1</sup>; William J Magner, PhD<sup>1</sup>; Ashok Z Samuel, PhD<sup>2</sup>; Lynn Sigurdson, PhD<sup>1</sup>; Christian Gluck, MD, PhD<sup>4</sup>; Amritha Suresh, PhD<sup>5</sup>; Sumsum Sunny, MDS, PhD<sup>5</sup>; Yjun Sun, PhD<sup>3</sup>; Rohit Bhargava, PhD<sup>2</sup>; Moni A Kuriakose, MD<sup>6</sup>. <sup>1</sup>Roswell Park Comprehensive Cancer Center; <sup>2</sup>Beckman Institute for Advanced Science and Technology, University of Illinois Urbana- Champaign; <sup>3</sup>University at Buffalo Jacobs School of Medicine and Biomedical Sciences; <sup>4</sup>Penn State Health; <sup>5</sup>Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India; <sup>6</sup>Lakeshore Hospital, Kochi, India<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Oral Potentially Malignant Disorders (OPMD) are the precursors of over 80% of oral cancers. For every oral cancer patient, however, there are 30 OPMD patients; this huge population must be diagnosed and treated effectively to reduce oral cancer burden. Although histological examination by hematoxylin and eosin (H&E) stained slides is the diagnostic gold standard in OPMD, it fails to reliably predict malignant transformation, which varies in the literature from 0.13% to 40.8%. Despite many adjuncts to identifying OPMDs early, none offer reliable diagnoses in a primary or community healthcare setting that are comparable to the diagnostic gold standard. This highlights a need for reliable biomarkers able to assess malignant transformation potential. Fourier Transform Infrared (FTIR) imaging offers a label-free, chemically specific method to quantify the molecular composition of tissue, providing a digital fingerprint that can be decoded by advanced artificial intelligence (AI)/machine learning(ML) algorithms. We hypothesize that FTIR microscopy and AI/ML workflows can provide a more accurate and reproducible assessment of OPMD than current histological standards. Specifically, by mapping the unique IR spectral signatures of high-value diagnostic and prognostic biomarkers such as CD44, SNA1, Podoplanin, and S100A7 directly from unstained tissue, this platform will enhance OPMD diagnosis and prognosis.</p>\n\n<p><strong>Methods: </strong>This study used patient samples representing non-dysplastic, OPMD, and oral cancer lesions to develop an objective, AI-driven diagnostic framework. Serial 5 µm sections were prepared for gold-standard pathological review and label-free FTIR microscopy. Adjacent sections underwent immunohistochemical (IHC) profiling for diagnostic (CD44, SNA1) and prognostic (S100A7, Podoplanin) biomarkers to establish a spatially resolved \"ground truth\" through side-by-side alignment with darkfield images in Matlab. To decode the IR spectral fingerprints, a deep learning approach was implemented for these four biomarkers. Feature selection was optimized through a signal-to-noise ratio (SNR) screening process and refined using Squeeze-and-Excitation (SE) modules with the knockoff procedure to ensure statistically rigorous channel selection and minimize false discoveries.</p>\n\n<p><strong>Results: </strong>The integrated FTIR and AI/ML-based approach successfully identified specific, objective spectral features for each of the four biomarkers, establishing a direct link between biochemical fingerprints and OPMD malignant potential. By utilizing IHC staining for CD44, SNA1, S100A7, and Podoplanin, this study created a verified map of biomarker localization and intensity. These IR signatures were proven to be independent predictors of progression, enabling the AI workflow to achieve significant diagnostic accuracy. Ultimately, this framework provides a reproducible molecular contrast that categorizes lesions into high-risk or low-risk cohorts based on their biochemical profiles, offering a clinically actionable tool to predict malignant transformation kinetics.</p>\n\n<p><strong>Conclusions: </strong>The integration of multi-modality imaging and AI interpretation provides a robust, objective framework for oral dysplasia risk identification. By correlating biochemical spectral features with molecular expression and clinical outcomes, these models provide actionable risk scores. This approach simplifies the characterization of oral lesions and enhances the prediction of malignant potential without requiring additional reagents or specialized human operators.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155441--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S587",
      "content_id": "155482",
      "abstract_number": "S587",
      "poster_number": "",
      "title": "Using Depth of Invasion to Create a Predictive Model for Contralateral Nodal Disease in Lateralized Oral Tongue Squamous Cell Carcinoma",
      "summary": "This study has successfully created and validated a model to predict contralateral neck disease in lateralized oral tongue squamous cell carcinoma based on depth of invasion with key modifiers being recurrence and margin status of the patient.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155482",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Abdurrahman Abdurrob, MD, MS",
      "presenter": "Abdurrahman Abdurrob, MD, MS",
      "authors": "Abdurrahman Abdurrob, MD, MS 1 ; Jake Sims, DO 1 ; Jun Jin, PhD 1 ; Steven Chang, MD 1 ; Samantha Tam, MD, MPH 1 ; Rushil Dang, BDS, DMD 2",
      "normalized_authors": [
        "Abdurrahman Abdurrob",
        "Jake Sims",
        "Jun Jin",
        "Steven Chang",
        "Samantha Tam",
        "Rushil Dang, BDS"
      ],
      "affiliations": [
        "Henry Ford Hospital - Department of Otolaryngology",
        "Henry Ford Hospital - Department of Oral and Maxillofacial Surgery"
      ],
      "normalized_institutions": [
        "Henry Ford Hospital - Department of Otolaryngology",
        "Henry Ford Hospital - Department of Oral and Maxillofacial Surgery"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 406,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Abdurrahman Abdurrob, MD, MS 1 ; Jake Sims, DO 1 ; Jun Jin, PhD 1 ; Steven Chang, MD 1 ; Samantha Tam, MD, MPH 1 ; Rushil Dang, BDS, DMD 2",
        "Affiliations": "1 Henry Ford Hospital - Department of Otolaryngology; 2 Henry Ford Hospital - Department of Oral and Maxillofacial Surgery",
        "Background": "Standard of care management of the neck for oral cavity squamous cell carcinoma (SCC) has been an elective neck dissection For T1-T4, N0. Depth of invasion (DOI) has been shown to be a predictor for nodal disease and the American Joint Commission on Cancer (AJCC) classification criteria incorporated DOI into the latest staging for oral cavity SCC in 2017. While depth of invasion can guide the decision for ipsilateral neck management, there is very limited guidance on management of the contralateral neck for lateralized oral tongue SCC. Our institution recently found DOI ≥10mm is associated with a significantly increased risk of contralateral nodal disease (CND). The objective of this study is to create a predictive model for the risk of CND for lateralized oral tongue SCC using DOI.",
        "Methods": "Patients were reviewed from a single tertiary care institutional database from 1998 to 2021. All patients with lateralized oral tongue SCC who underwent surgical resection were included and evaluated for CND in both primary and recurrent settings. We conducted a retrospective analysis to model the probability of contralateral spread using depth of invasion (mm) and clinical/pathologic covariates.",
        "Results": "A total of 103 patients underwent a total of 104 surgeries in this analysis. Most patients were female (60.2%), with a mean age of 59.9 years. The most common T-stage was T2 (39.4%) followed by T1 (32.7%). The predictive model demonstrated stable discrimination (AUC = 0.830; 95% CI, 0.601–0.982). Recurrence and positive margin status were associated with higher odds of CND (OR 7.88; 95% CI, 2.13–29.15, OR 6.10; 95% CI, 0.64–58.59, respectively). The model-predicted risk as a function of DOI and this was stratified across four groups defined by these two significant variables: in the non-recurrence/negative-margin stratum, the predicted risk remained low even at higher DOI values. Whereas in recurrence strata, predicted risk was elevated even at lower DOI levels. For example, a DOI of 10mm (at least T3 by the latest AJCC guidelines), is associated with a 75.89% risk in recurrence/positive-margin, 36.60% in recurrence/negative-margin, 28.81% in negative-recurrence/positive-margin, and 6.91% in negative-recurrence/negative-margin.",
        "Conclusion": "This study has successfully created and validated a model to predict contralateral neck disease in lateralized oral tongue squamous cell carcinoma based on depth of invasion with key modifiers being recurrence and margin status of the patient.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Using Depth of Invasion to Create a Predictive Model for Contralateral Nodal Disease in Lateralized Oral Tongue Squamous Cell Carcinoma</span>. <u>Abdurrahman Abdurrob, MD, MS</u><sup>1</sup>; Jake Sims, DO<sup>1</sup>; Jun Jin, PhD<sup>1</sup>; Steven Chang, MD<sup>1</sup>; Samantha Tam, MD, MPH<sup>1</sup>; Rushil Dang, BDS, DMD<sup>2</sup>. <sup>1</sup>Henry Ford Hospital - Department of Otolaryngology; <sup>2</sup>Henry Ford Hospital - Department of Oral and Maxillofacial Surgery<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Standard of care management of the neck for oral cavity squamous cell carcinoma (SCC) has been an elective neck dissection For T1-T4, N0. Depth of invasion (DOI) has been shown to be a predictor for nodal disease and the American Joint Commission on Cancer (AJCC) classification criteria incorporated DOI into the latest staging for oral cavity SCC in 2017. While depth of invasion can guide the decision for ipsilateral neck management, there is very limited guidance on management of the contralateral neck for lateralized oral tongue SCC. Our institution recently found DOI ≥10mm is associated with a significantly increased risk of contralateral nodal disease (CND). The objective of this study is to create a predictive model for the risk of CND for lateralized oral tongue SCC using DOI.</p>\n\n<p><strong>Methods</strong>: Patients were reviewed from a single tertiary care institutional database from 1998 to 2021. All patients with lateralized oral tongue SCC who underwent surgical resection were included and evaluated for CND in both primary and recurrent settings. We conducted a retrospective analysis to model the probability of contralateral spread using depth of invasion (mm) and clinical/pathologic covariates.</p>\n\n<p><strong>Results</strong>: A total of 103 patients underwent a total of 104 surgeries in this analysis. Most patients were female (60.2%), with a mean age of 59.9 years. The most common T-stage was T2 (39.4%) followed by T1 (32.7%). The predictive model demonstrated stable discrimination (AUC = 0.830; 95% CI, 0.601–0.982). Recurrence and positive margin status were associated with higher odds of CND (OR 7.88; 95% CI, 2.13–29.15, OR 6.10; 95% CI, 0.64–58.59, respectively). The model-predicted risk as a function of DOI and this was stratified across four groups defined by these two significant variables: in the non-recurrence/negative-margin stratum, the predicted risk remained low even at higher DOI values. Whereas in recurrence strata, predicted risk was elevated even at lower DOI levels. For example, a DOI of 10mm (at least T3 by the latest AJCC guidelines), is associated with a 75.89% risk in recurrence/positive-margin, 36.60% in recurrence/negative-margin, 28.81% in negative-recurrence/positive-margin, and 6.91% in negative-recurrence/negative-margin.</p>\n\n<p><strong>Conclusion</strong>: This study has successfully created and validated a model to predict contralateral neck disease in lateralized oral tongue squamous cell carcinoma based on depth of invasion with key modifiers being recurrence and margin status of the patient.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155482--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S588",
      "content_id": "155531",
      "abstract_number": "S588",
      "poster_number": "",
      "title": "Surgical margin-associated histopathological features in oral cancer as determinants of malignant transformation",
      "summary": "Loss of epithelial cohesion, extending into the middle and upper epithelial thirds, represents a reproducible histological marker of malignant potential in OSCC-associated surgical margins. Spatial assessment of dysplastic alterations offers a more objective and reliable approach to risk stratification than conventional grading systems.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155531",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "William Magner, PhD",
      "presenter": "William Magner, PhD",
      "authors": "Anela Thomas, BDS, MDS 1 ; Sumsum P Sunny, MDS, PhD 1 ; Laksmi Pradeep, BDS, MDS 1 ; Shivani M, MSc 2 ; Pavithra Chandrashekhar, MDS 3 ; Keerthy G, MDS 4 ; Shubha Gurudath, MDS 4 ; Vijay Pillai, MDS 1 ; Praveen Birur, BDS, MDS, PhD 4 ; William Magner, PhD 5 ; Moni A Kuriakose, MDS 5 ; Amritha Suresh, PhD 1",
      "normalized_authors": [
        "Anela Thomas, BDS, MDS",
        "Sumsum P Sunny, MDS",
        "Laksmi Pradeep, BDS, MDS",
        "Shivani M",
        "Pavithra Chandrashekhar, MDS",
        "Keerthy G, MDS",
        "Shubha Gurudath, MDS",
        "Vijay Pillai, MDS",
        "Praveen Birur, BDS, MDS",
        "William Magner",
        "Moni A Kuriakose, MDS",
        "Amritha Suresh"
      ],
      "affiliations": [
        "Department of Head and Neck Oncology, Mazumdar Shaw Cancer Centre, Narayana Health City, Bangaluru, Karnataka 560099",
        "Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Bangaluru, Karnataka 560099",
        "Department of Pathology, KLE Institute of Dental Sciences, Yeswanthpur, Bengaluru, Karnataka 560022",
        "Department of Oral Medicine and Radiology, KLE Institute of Dental Sciences, Bangaluru, 560022",
        "Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, New York, 14263"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Oncology, Mazumdar Shaw Cancer Centre, Narayana Health City, Bangaluru, Karnataka 560099",
        "Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Bangaluru, Karnataka 560099",
        "Department of Pathology, KLE Institute of Dental Sciences, Yeswanthpur, Bengaluru, Karnataka 560022",
        "Department of Oral Medicine and Radiology, KLE Institute of Dental Sciences, Bangaluru, 560022",
        "Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, New York, 14263"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155531/oed2(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155531/oed2(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155531"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 284,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methodology",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Anela Thomas, BDS, MDS 1 ; Sumsum P Sunny, MDS, PhD 1 ; Laksmi Pradeep, BDS, MDS 1 ; Shivani M, MSc 2 ; Pavithra Chandrashekhar, MDS 3 ; Keerthy G, MDS 4 ; Shubha Gurudath, MDS 4 ; Vijay Pillai, MDS 1 ; Praveen Birur, BDS, MDS, PhD 4 ; William Magner, PhD 5 ; Moni A Kuriakose, MDS 5 ; Amritha Suresh, PhD 1",
        "Affiliations": "1 Department of Head and Neck Oncology, Mazumdar Shaw Cancer Centre, Narayana Health City, Bangaluru, Karnataka 560099; 2 Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Bangaluru, Karnataka 560099; 3 Department of Pathology, KLE Institute of Dental Sciences, Yeswanthpur, Bengaluru, Karnataka 560022; 4 Department of Oral Medicine and Radiology, KLE Institute of Dental Sciences, Bangaluru, 560022; 5 Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, New York, 14263",
        "Background": "Eighty per cent of oral squamous cell carcinomas (OSCCs) arise from oral potentially malignant disorders (OPMDs), with epithelial dysplasia serving as the key histopathological indicator of malignant transformation. However, its predictive reliability is limited by biological heterogeneity and substantial inter-observer variability. This study evaluated the spatial distribution of architectural and cytological features in OSCC-associated surgical margins and OPMDs to identify histological correlates of malignant potential and evaluate diagnostic consistency among observers.",
        "Methodology": "Formalin-fixed, paraffin-embedded tissues comprising OPMDs and OSCC surgical margins were analysed. Haematoxylin and eosin–stained whole-slide images were independently reviewed by two blinded oral pathologists. Seventeen WHO 2017–based histopathological features (nine architectural, eight cytological) were scored for vertical epithelial distribution (0 = absent; 1 = lower third; 2 = middle third; 3 = full thickness). Inter-observer agreement for individual features, spatial distribution, and WHO grading was assessed using Cohen’s κ. Logistic regression identified features significantly associated with surgical margins, with OPMDs as baseline.",
        "Results": "Independent of 278 whole slide images (191 patients; 155 OPMDs, 123 surgical margins) revealed that most lesions exhibited low-grade dysplasia (>60%). In OPMDs, dysplastic changes were mainly confined to the lower epithelial thirds, whereas surgical margins showed extended alterations, including loss of cohesion, loss of polarity, keratin pearls, and drop-shaped rete ridges. Inter-observer agreement was poor for WHO grading (κ = 0.19) but slightly higher with binary categorization (κ = 0.22). Loss of epithelial cohesion was the most reproducible and margin-associated feature.",
        "Conclusion": "Loss of epithelial cohesion, extending into the middle and upper epithelial thirds, represents a reproducible histological marker of malignant potential in OSCC-associated surgical margins. Spatial assessment of dysplastic alterations offers a more objective and reliable approach to risk stratification than conventional grading systems.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical margin-associated histopathological features in oral cancer as determinants of malignant transformation</span>. Anela Thomas, BDS, MDS<sup>1</sup>; Sumsum P Sunny, MDS, PhD<sup>1</sup>; Laksmi Pradeep, BDS, MDS<sup>1</sup>; Shivani M, MSc<sup>2</sup>; Pavithra Chandrashekhar, MDS<sup>3</sup>; Keerthy G, MDS<sup>4</sup>; Shubha Gurudath, MDS<sup>4</sup>; Vijay Pillai, MDS<sup>1</sup>; Praveen Birur, BDS, MDS, PhD<sup>4</sup>; <u>William Magner, PhD</u><sup>5</sup>; Moni A Kuriakose, MDS<sup>5</sup>; Amritha Suresh, PhD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Oncology, Mazumdar Shaw Cancer Centre, Narayana Health City, Bangaluru, Karnataka 560099; <sup>2</sup>Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Bangaluru, Karnataka 560099; <sup>3</sup>Department of Pathology, KLE Institute of Dental Sciences, Yeswanthpur, Bengaluru, Karnataka 560022; <sup>4</sup>Department of Oral Medicine and Radiology, KLE Institute of Dental Sciences, Bangaluru, 560022; <sup>5</sup>Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Comprehensive Cancer Centre, New York, 14263<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background:</strong> Eighty per cent of oral squamous cell carcinomas (OSCCs) arise from oral potentially malignant disorders (OPMDs), with epithelial dysplasia serving as the key histopathological indicator of malignant transformation. However, its predictive reliability is limited by biological heterogeneity and substantial inter-observer variability. This study evaluated the spatial distribution of architectural and cytological features in OSCC-associated surgical margins and OPMDs to identify histological correlates of malignant potential and evaluate diagnostic consistency among observers.</p>\n\n<p><strong>Methodology: </strong>Formalin-fixed, paraffin-embedded tissues comprising OPMDs and OSCC surgical margins were analysed. Haematoxylin and eosin–stained whole-slide images were independently reviewed by two blinded oral pathologists. Seventeen WHO 2017–based histopathological features (nine architectural, eight cytological) were scored for vertical epithelial distribution (0 = absent; 1 = lower third; 2 = middle third; 3 = full thickness). Inter-observer agreement for individual features, spatial distribution, and WHO grading was assessed using Cohen’s κ. Logistic regression identified features significantly associated with surgical margins, with OPMDs as baseline.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155531/oed2(1).jpg' /></p>\n\n<p><strong>Results:</strong> Independent of 278 whole slide images (191 patients; 155 OPMDs, 123 surgical margins) revealed that most lesions exhibited low-grade dysplasia (>60%). In OPMDs, dysplastic changes were mainly confined to the lower epithelial thirds, whereas surgical margins showed extended alterations, including loss of cohesion, loss of polarity, keratin pearls, and drop-shaped rete ridges. Inter-observer agreement was poor for WHO grading (κ = 0.19) but slightly higher with binary categorization (κ = 0.22). Loss of epithelial cohesion was the most reproducible and margin-associated feature.</p>\n\n<p><strong>Conclusion:</strong> Loss of epithelial cohesion, extending into the middle and upper epithelial thirds, represents a reproducible histological marker of malignant potential in OSCC-associated surgical margins. Spatial assessment of dysplastic alterations offers a more objective and reliable approach to risk stratification than conventional grading systems.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155531--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S589",
      "content_id": "155407",
      "abstract_number": "S589",
      "poster_number": "",
      "title": "Development and internal validation of a Multivariable Predictive Model for Occult Nodal Metastasis in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma",
      "summary": "In this large national cohort of cN0 OCSCC, tumor grade, lymphovascular invasion, clinical T classification, and anatomic subsite were independently associated with occult nodal metastasis. The internally validated model provides a quantitative framework for individualized risk estimation and may support clinical decision-making regarding elective neck dissection and sentinel lymph node biopsy in this population.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155407",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Felipe Porto-Gutierrez, MD",
      "presenter": "Felipe Porto-Gutierrez, MD",
      "authors": "Felipe Porto-Gutierrez, MD ; Fatima Amanullah, MD; Brett Campbell, MD; Alexa Kacin, MD; Scharukh Jalisi, MD, MBA",
      "normalized_authors": [
        "Felipe Porto-Gutierrez",
        "Fatima Amanullah",
        "Brett Campbell",
        "Alexa Kacin",
        "Scharukh Jalisi"
      ],
      "affiliations": [
        "BIDMC"
      ],
      "normalized_institutions": [
        "BIDMC"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 435,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Felipe Porto-Gutierrez, MD ; Fatima Amanullah, MD; Brett Campbell, MD; Alexa Kacin, MD; Scharukh Jalisi, MD, MBA",
        "Affiliations": "BIDMC",
        "Background": "Management of the clinically node-negative (cN0) neck in oral cavity squamous cell carcinoma (OCSCC) remains controversial. Occult nodal metastasis occurs in approximately 15–30% of cN0 OCSCC patients, depending on subsite and tumor characteristics, yet reliable preoperative risk stratification tools remain lacking. Current staging parameters provide an incomplete, individualized risk estimate. Accurate probability estimation may support individualized decision-making regarding elective neck dissection (END) and emerging nodal staging strategies such as sentinel lymph node biopsy (SLNB). We aimed to develop and internally validate a national multivariable model to estimate the probability of occult nodal metastasis in cN0 OCSCC.",
        "Methods": "We conducted a retrospective cohort study using the National Cancer Database (NCDB) to identify patients with clinically node-negative OCSCC who underwent primary surgical resection with pathologic nodal evaluation between 2004 and 2021. Patients with clinical distant metastasis, neoadjuvant therapy, or missing nodal pathology data were excluded. Occult nodal metastasis was defined as pathologic nodal positivity in patients staged clinically N0. Multivariable logistic regression identified independent predictors of nodal positivity. Covariates included age, insurance status, facility type, Charlson-Deyo comorbidity index, anatomic subsite, clinical T classification, tumor grade, and lymphovascular invasion. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), with internal validation performed via bootstrap resampling.",
        "Results": "A total of 14,441 patients met the inclusion criteria, of whom 2,127 (14.7%) had occult nodal metastasis. Lymphovascular invasion was the strongest independent predictor (OR 4.2), followed by poorly differentiated (OR 2.8) and moderately differentiated tumors (OR 2.0). Clinical T2 classification was independently associated with increased risk (OR 1.7). High comorbidity burden (Charlson-Deyo ≥3) was also independently associated with nodal positivity (OR 1.5). Significant subsite heterogeneity was observed, with oral tongue (OR 1.4) and retromolar trigone (OR 1.3) associated with higher odds of nodal positivity, whereas lip tumors were protective (OR 0.6). Demographic and facility-level variables were not independently predictive after adjustment. The model demonstrated moderate discrimination (AUC 0.68; 95% CI 0.67–0.69), with an optimism-corrected AUC of 0.664 on bootstrap internal validation, confirming acceptable model stability. Based on these findings, a nomogram and a web-based risk calculator were developed to enable individualized probability estimation of occult nodal metastasis in clinical practice.",
        "Conclusion": "In this large national cohort of cN0 OCSCC, tumor grade, lymphovascular invasion, clinical T classification, and anatomic subsite were independently associated with occult nodal metastasis. The internally validated model provides a quantitative framework for individualized risk estimation and may support clinical decision-making regarding elective neck dissection and sentinel lymph node biopsy in this population.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Development and internal validation of a Multivariable Predictive Model for Occult Nodal Metastasis in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma</span>. <u>Felipe Porto-Gutierrez, MD</u>; Fatima Amanullah, MD; Brett Campbell, MD; Alexa Kacin, MD; Scharukh Jalisi, MD, MBA. BIDMC<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Management of the clinically node-negative (cN0) neck in oral cavity squamous cell carcinoma (OCSCC) remains controversial. Occult nodal metastasis occurs in approximately 15–30% of cN0 OCSCC patients, depending on subsite and tumor characteristics, yet reliable preoperative risk stratification tools remain lacking. Current staging parameters provide an incomplete, individualized risk estimate. Accurate probability estimation may support individualized decision-making regarding elective neck dissection (END) and emerging nodal staging strategies such as sentinel lymph node biopsy (SLNB). We aimed to develop and internally validate a national multivariable model to estimate the probability of occult nodal metastasis in cN0 OCSCC.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study using the National Cancer Database (NCDB) to identify patients with clinically node-negative OCSCC who underwent primary surgical resection with pathologic nodal evaluation between 2004 and 2021. Patients with clinical distant metastasis, neoadjuvant therapy, or missing nodal pathology data were excluded. Occult nodal metastasis was defined as pathologic nodal positivity in patients staged clinically N0. Multivariable logistic regression identified independent predictors of nodal positivity. Covariates included age, insurance status, facility type, Charlson-Deyo comorbidity index, anatomic subsite, clinical T classification, tumor grade, and lymphovascular invasion. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), with internal validation performed via bootstrap resampling.</p>\n\n<p><strong>Results:</strong> A total of 14,441 patients met the inclusion criteria, of whom 2,127 (14.7%) had occult nodal metastasis. Lymphovascular invasion was the strongest independent predictor (OR 4.2), followed by poorly differentiated (OR 2.8) and moderately differentiated tumors (OR 2.0). Clinical T2 classification was independently associated with increased risk (OR 1.7). High comorbidity burden (Charlson-Deyo ≥3) was also independently associated with nodal positivity (OR 1.5). Significant subsite heterogeneity was observed, with oral tongue (OR 1.4) and retromolar trigone (OR 1.3) associated with higher odds of nodal positivity, whereas lip tumors were protective (OR 0.6). Demographic and facility-level variables were not independently predictive after adjustment. The model demonstrated moderate discrimination (AUC 0.68; 95% CI 0.67–0.69), with an optimism-corrected AUC of 0.664 on bootstrap internal validation, confirming acceptable model stability. Based on these findings, a nomogram and a web-based risk calculator were developed to enable individualized probability estimation of occult nodal metastasis in clinical practice.</p>\n\n<p><strong>Conclusion: </strong>In this large national cohort of cN0 OCSCC, tumor grade, lymphovascular invasion, clinical T classification, and anatomic subsite were independently associated with occult nodal metastasis. The internally validated model provides a quantitative framework for individualized risk estimation and may support clinical decision-making regarding elective neck dissection and sentinel lymph node biopsy in this population.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155407--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S590",
      "content_id": "155476",
      "abstract_number": "S590",
      "poster_number": "",
      "title": "Preoperative Cardiometabolic Vulnerability Predicts Systemic Complications After Oral Cavity Free Flap Reconstruction: A 2016–2023 NSQIP Analysis",
      "summary": "In contemporary national data, systemic morbidity following oral cavity free flap reconstruction reflects baseline cardiometabolic reserve rather than chronologic age, sex, or body habitus. These findings identify a discrete physiologically vulnerable cohort, including patients with insulin-dependent diabetes, congestive heart failure, COPD, and elevated ASA classification, who may benefit from focused...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155476",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Fatima S Amanullah, MBBS",
      "presenter": "Fatima S Amanullah, MBBS",
      "authors": "Fatima S Amanullah, MBBS 1 ; Hamdan A Pasha, FCPS, MD, FRCSInt 2 ; Felipe Porto, MD 1 ; Muhammad S Arshad, MBBS 2 ; Scharukh Jalisi, MD, MBA, FACS 1",
      "normalized_authors": [
        "Fatima S Amanullah, MBBS",
        "Hamdan A Pasha, FCPS, FRCSInt",
        "Felipe Porto",
        "Muhammad S Arshad, MBBS",
        "Scharukh Jalisi"
      ],
      "affiliations": [
        "Beth Israel Deaconess Medical Center",
        "Aga Khan University Hospital"
      ],
      "normalized_institutions": [
        "Beth Israel Deaconess Medical Center",
        "Aga Khan University Hospital"
      ],
      "session_type": "Proffered Paper",
      "track": "Oral Cavity",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Oral Cavity"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 304,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Fatima S Amanullah, MBBS 1 ; Hamdan A Pasha, FCPS, MD, FRCSInt 2 ; Felipe Porto, MD 1 ; Muhammad S Arshad, MBBS 2 ; Scharukh Jalisi, MD, MBA, FACS 1",
        "Affiliations": "1 Beth Israel Deaconess Medical Center; 2 Aga Khan University Hospital",
        "Background": "Although comorbidities are broadly recognized to increase postoperative risk, not all comorbid conditions reflect equivalent physiologic vulnerability. Systemic medical complications, including myocardial infarction, pneumonia, prolonged ventilator dependence, and sepsis, represent substantial morbidity following oral cavity free flap reconstruction, yet they are less frequently examined than surgical site outcomes. We sought to identify which patients undergoing oral cavity cancer reconstruction are at highest risk for systemic postoperative complications.",
        "Methods": "We performed a retrospective cohort study using the ACS NSQIP Participant Use Files (2016–2023). Adults undergoing microvascular free flap reconstruction for oral cavity malignancy were identified using CPT–ICD-10 alignment. The primary outcome was a composite 30-day systemic medical complication (pulmonary, cardiac, thromboembolic, renal, and septic events). Multivariable logistic regression evaluated independent associations between demographic, anthropometric, and cardiometabolic variables and systemic complications. Model discrimination was assessed using area under the receiver operating characteristic curve (AUC).",
        "Results": "Among 3,090 patients, 396 (12.8%) developed a systemic medical complication. On multivariable analysis, insulin-dependent diabetes (OR 2.18), congestive heart failure (OR 2.42), ASA class III–V (OR 1.66), and chronic obstructive pulmonary disease (OR 1.53) were independently associated with systemic morbidity (all p < 0.05). These conditions shifted complication risk from a baseline of 12.8% toward approximately 20–26% in affected patients. Chronologic age, sex, and BMI were not independently predictive after adjustment. Model discrimination was modest (AUC 0.62; 95% CI 0.593–0.651).",
        "Conclusion": "In contemporary national data, systemic morbidity following oral cavity free flap reconstruction reflects baseline cardiometabolic reserve rather than chronologic age, sex, or body habitus. These findings identify a discrete physiologically vulnerable cohort, including patients with insulin-dependent diabetes, congestive heart failure, COPD, and elevated ASA classification, who may benefit from focused preoperative optimization and proactive postoperative planning, including early ICU resource anticipation.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Preoperative Cardiometabolic Vulnerability Predicts Systemic Complications After Oral Cavity Free Flap Reconstruction: A 2016–2023 NSQIP Analysis</span>. <u>Fatima S Amanullah, MBBS</u><sup>1</sup>; Hamdan A Pasha, FCPS, MD, FRCSInt<sup>2</sup>; Felipe Porto, MD<sup>1</sup>; Muhammad S Arshad, MBBS<sup>2</sup>; Scharukh Jalisi, MD, MBA, FACS<sup>1</sup>. <sup>1</sup>Beth Israel Deaconess Medical Center; <sup>2</sup>Aga Khan University Hospital<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Although comorbidities are broadly recognized to increase postoperative risk, not all comorbid conditions reflect equivalent physiologic vulnerability. Systemic medical complications, including myocardial infarction, pneumonia, prolonged ventilator dependence, and sepsis, represent substantial morbidity following oral cavity free flap reconstruction, yet they are less frequently examined than surgical site outcomes. We sought to identify which patients undergoing oral cavity cancer reconstruction are at highest risk for systemic postoperative complications.</p>\n\n<p><strong>Methods: </strong>We performed a retrospective cohort study using the ACS NSQIP Participant Use Files (2016–2023). Adults undergoing microvascular free flap reconstruction for oral cavity malignancy were identified using CPT–ICD-10 alignment. The primary outcome was a composite 30-day systemic medical complication (pulmonary, cardiac, thromboembolic, renal, and septic events). Multivariable logistic regression evaluated independent associations between demographic, anthropometric, and cardiometabolic variables and systemic complications. Model discrimination was assessed using area under the receiver operating characteristic curve (AUC).</p>\n\n<p><strong>Results: </strong>Among 3,090 patients, 396 (12.8%) developed a systemic medical complication. On multivariable analysis, insulin-dependent diabetes (OR 2.18), congestive heart failure (OR 2.42), ASA class III–V (OR 1.66), and chronic obstructive pulmonary disease (OR 1.53) were independently associated with systemic morbidity (all p < 0.05). These conditions shifted complication risk from a baseline of 12.8% toward approximately 20–26% in affected patients. Chronologic age, sex, and BMI were not independently predictive after adjustment. Model discrimination was modest (AUC 0.62; 95% CI 0.593–0.651).</p>\n\n<p><strong>Conclusion:</strong> In contemporary national data, systemic morbidity following oral cavity free flap reconstruction reflects baseline cardiometabolic reserve rather than chronologic age, sex, or body habitus. These findings identify a discrete physiologically vulnerable cohort, including patients with insulin-dependent diabetes, congestive heart failure, COPD, and elevated ASA classification, who may benefit from focused preoperative optimization and proactive postoperative planning, including early ICU resource anticipation.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155476--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S591",
      "content_id": "155480",
      "abstract_number": "S591",
      "poster_number": "",
      "title": "AAV-CRISPR-mediated mutagenic-screen reveals malignant transformation of tissue-resident stem cells in a novel immunocompetent aging mouse model of head and neck cancer",
      "summary": "These data, for the first time, directly implicate the role of epithelial stem and progenitor cells as oncogenic reservoirs for HNC, reveal novel driver mutations of HNC, and recapitulate variant emergence patterns observed in human HNCs. These findings strongly suggest that mutated epithelial stem and progenitor cells may be the cells-of-origin for HNCs of epithelial origin, answering a long-standing and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155480",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Heidi Kletzien",
      "presenter": "Heidi Kletzien",
      "authors": "Heidi Kletzien 1 ; Nguyen-Anh Nguyen 2 ; David J Anderson 2 ; Amy J Wagers 3",
      "normalized_authors": [
        "Heidi Kletzien",
        "Nguyen-Anh Nguyen",
        "David J Anderson",
        "Amy J Wagers"
      ],
      "affiliations": [
        "University of Minnesota",
        "Harvard University",
        "Harvard Stem Cell Institute",
        "Harvard Medical School",
        "Joslin Diabetes Center"
      ],
      "normalized_institutions": [
        "University of Minnesota",
        "Harvard University",
        "Harvard Stem Cell Institute",
        "Harvard Medical School",
        "Joslin Diabetes Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Cancer Biology",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Cancer Biology"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 464,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Purpose",
        "Methods/Results",
        "Conclusions",
        "Abstract"
      ],
      "sections": {
        "Authors": "Heidi Kletzien 1 ; Nguyen-Anh Nguyen 2 ; David J Anderson 2 ; Amy J Wagers 3",
        "Affiliations": "1 University of Minnesota; Harvard University; Harvard Stem Cell Institute; Harvard Medical School; 2 Harvard University; Harvard Stem Cell Institute; Harvard Medical School; 3 Harvard University; Harvard Stem Cell Institute; Harvard Medical School; Joslin Diabetes Center",
        "Purpose": "Head and neck cancers (HNC) are heterogeneous tumors of the upper aerodigestive tract, often treated with multimodal approaches that remain largely ineffective and severely impact speech, swallowing, and quality of life. While their clinical impact is significant, the mechanisms underlying HNC initiation are poorly understood, hindering the development of targeted interventions. Using a novel immunocompetent preclinical model developed in our lab that involves the in vivo introduction of human-relevant HNC mutations by CRISPR-mediated gene editing, our research tests the highly intriguing, but as yet unproven, hypothesis that HNC initiation can be driven by the acquisition and accumulation of mutations in head and neck somatic tissue stem and progenitor cells, a process of mutagenesis that may be influenced by sex and accelerated following tobacco carcinogen exposure.",
        "Methods/Results": "Our data shows effective AAV transduction and targeted mutagenesis of multiple stem cell lineages (epithelial stem and progenitor cells, mesenchymal stromal stem cells, and muscle stem cells) by numerous AAV serotypes after local AAV injection into the tongue, oral epithelium, pharynx/esophagus, and neck. Delivery of a custom AAV-CRISPR-library (10 sgRNAs/gene + 10 non-targeting control sgRNAs), targeting the 20 most frequently mutated genes in human HNCs (multiple HNC subtypes included in this broad screen), into young and aged male and female mice (n=309) conditionally expressing Cas9 in a lineage-selective manner, exposed to either the tobacco mimetic 4NQO or water, produced morphologically and anatomically distinct tumors that recapitulate the genetic heterogeneity and age- and sex-variant emergence patterns of human HNCs (p< 0.001). Tumorigeneis was accelerated in AAV and 4NQO treated compared to 4NQO only treated mice (p< 0.001). In AAV only treated mice, tongue tumors only developed in those animals that had gene editing cargo restricted to epithelial stem and progenitor cells, and within that group tongue lesion and tumor development was accelerated in aged AAV only treated animals compared to young AAV only treated mice (p< 0.001), no vehicle injected mice developed lesions or tumors. Molecular sequencing analysis (whole exome sequencing) from AAV-CRISPR-HNC tumors (n=97) reveal striking genetic diversity across treatment conditions and ages, and high mutational burden that is reminiscent of human HNCs (Cosine Similarity=0.6-09.2), and suggests that mutations in NOTCH1, FAT1, and TRP53 may be early HNC drivers.",
        "Conclusions": "These data, for the first time, directly implicate the role of epithelial stem and progenitor cells as oncogenic reservoirs for HNC, reveal novel driver mutations of HNC, and recapitulate variant emergence patterns observed in human HNCs. These findings strongly suggest that mutated epithelial stem and progenitor cells may be the cells-of-origin for HNCs of epithelial origin, answering a long-standing and unresolved question in the field, and also nominate novel therapeutic targets and pathways that could transform how HNCs are treated in premalignancy and malignancy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>AAV-CRISPR-mediated mutagenic-screen reveals malignant transformation of tissue-resident stem cells in a novel immunocompetent aging mouse model of head and neck cancer</span>. <u>Heidi Kletzien</u><sup>1</sup>; Nguyen-Anh Nguyen<sup>2</sup>; David J Anderson<sup>2</sup>; Amy J Wagers<sup>3</sup>. <sup>1</sup>University of Minnesota; Harvard University; Harvard Stem Cell Institute; Harvard Medical School; <sup>2</sup>Harvard University; Harvard Stem Cell Institute; Harvard Medical School; <sup>3</sup>Harvard University; Harvard Stem Cell Institute; Harvard Medical School; Joslin Diabetes Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Purpose:</strong> Head and neck cancers (HNC) are heterogeneous tumors of the upper aerodigestive tract, often treated with multimodal approaches that remain largely ineffective and severely impact speech, swallowing, and quality of life. While their clinical impact is significant, the mechanisms underlying HNC initiation are poorly understood, hindering the development of targeted interventions. Using a novel immunocompetent preclinical model developed in our lab that involves the in vivo introduction of human-relevant HNC mutations by CRISPR-mediated gene editing, our research tests the highly intriguing, but as yet unproven, hypothesis that HNC initiation can be driven by the acquisition and accumulation of mutations in head and neck somatic tissue stem and progenitor cells, a process of mutagenesis that may be influenced by sex and accelerated following tobacco carcinogen exposure.</p>\n\n<p><strong>Methods/Results:</strong> Our data shows effective AAV transduction and targeted mutagenesis of multiple stem cell lineages (epithelial stem and progenitor cells, mesenchymal stromal stem cells, and muscle stem cells) by numerous AAV serotypes after local AAV injection into the tongue, oral epithelium, pharynx/esophagus, and neck. Delivery of a custom AAV-CRISPR-library (10 sgRNAs/gene + 10 non-targeting control sgRNAs), targeting the 20 most frequently mutated genes in human HNCs (multiple HNC subtypes included in this broad screen), into young and aged male and female mice (n=309) conditionally expressing Cas9 in a lineage-selective manner, exposed to either the tobacco mimetic 4NQO or water, produced morphologically and anatomically distinct tumors that recapitulate the genetic heterogeneity and age- and sex-variant emergence patterns of human HNCs (p< 0.001). Tumorigeneis was accelerated in AAV and 4NQO treated compared to 4NQO only treated mice (p< 0.001). In AAV only treated mice, tongue tumors only developed in those animals that had gene editing cargo restricted to epithelial stem and progenitor cells, and within that group tongue lesion and tumor development was accelerated in aged AAV only treated animals compared to young AAV only treated mice (p< 0.001), no vehicle injected mice developed lesions or tumors. Molecular sequencing analysis (whole exome sequencing) from AAV-CRISPR-HNC tumors (n=97) reveal striking genetic diversity across treatment conditions and ages, and high mutational burden that is reminiscent of human HNCs (Cosine Similarity=0.6-09.2), and suggests that mutations in NOTCH1, FAT1, and TRP53 may be early HNC drivers.</p>\n\n<p><strong>Conclusions:</strong> These data, for the first time, directly implicate the role of epithelial stem and progenitor cells as oncogenic reservoirs for HNC, reveal novel driver mutations of HNC, and recapitulate variant emergence patterns observed in human HNCs. These findings strongly suggest that mutated epithelial stem and progenitor cells may be the cells-of-origin for HNCs of epithelial origin, answering a long-standing and unresolved question in the field, and also nominate novel therapeutic targets and pathways that could transform how HNCs are treated in premalignancy and malignancy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155480--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S592",
      "content_id": "155493",
      "abstract_number": "S592",
      "poster_number": "",
      "title": "Androgen Deprivation Therapy for Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis",
      "summary": "This meta-analysis represents a comprehensive evaluation of AR-targeted therapy for SDC to date. Our findings support that this approach provides clinically meaningful responses in a substantial portion of patients. The data strongly support the superior efficacy of combined androgen blockade over monotherapy, suggesting it as the preferred AR-targeted treatment strategy for patients with advanced, recurrent, or...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155493",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Jacob W Rosenthal, BS",
      "presenter": "Jacob W Rosenthal, BS",
      "authors": "Jacob W Rosenthal, BS ; David Z Allen, MD; Jordan Sternthal, BS; Isabella Romeo, MPH; Gurel Ari; Erin E Reardon, MFA; Jose A Monteiro de Oliveira Novaes, MD; Nabil Saba, MD; Jennifer Gross, MD; Nicole C Schmitt, MD",
      "normalized_authors": [
        "Jacob W Rosenthal",
        "David Z Allen",
        "Jordan Sternthal",
        "Isabella Romeo",
        "Gurel Ari",
        "Erin E Reardon, MFA",
        "Jose A Monteiro de Oliveira Novaes",
        "Nabil Saba",
        "Jennifer Gross",
        "Nicole C Schmitt"
      ],
      "affiliations": [
        "Emory University School of Medicine"
      ],
      "normalized_institutions": [
        "Emory University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Salivary Gland",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Salivary Gland"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 442,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Jacob W Rosenthal, BS ; David Z Allen, MD; Jordan Sternthal, BS; Isabella Romeo, MPH; Gurel Ari; Erin E Reardon, MFA; Jose A Monteiro de Oliveira Novaes, MD; Nabil Saba, MD; Jennifer Gross, MD; Nicole C Schmitt, MD",
        "Affiliations": "Emory University School of Medicine",
        "Background": "Salivary duct carcinoma (SDC) is a rare and aggressive malignancy characterized by high rates of androgen receptor (AR) expression, providing a strong biological rationale for AR-targeted therapy. However, the supporting clinical evidence is limited to single-arm trials and retrospective studies, with sparse randomized controlled trial data available to guide treatment decisions. To better define the role of this therapeutic strategy, we conducted a systematic review and the first meta-analysis to synthesize the published outcomes of AR-targeted therapy in patients with AR-positive SDC.",
        "Methods": "A health sciences librarian developed a comprehensive search strategy that was deployed across six databases (Ovid MEDLINE, Embase.com, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov) from their inception to January 7, 2026. We included studies evaluating AR-targeted therapy in patients with histologically confirmed, AR-positive SDC in the recurrent and metastatic setting. The primary outcome was overall response rate (ORR). Secondary outcomes included clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS). Pooled proportions and their 95% confidence intervals (CI) were calculated using a random-effects model. Pre-specified subgroup analyses were performed to compare outcomes based on the type of AR therapy and the line of treatment.",
        "Results": "Eleven studies, including four prospective phase II trials and seven retrospective analyses, met the inclusion criteria, comprising a total of 532 patients. The methodological quality of the included studies was generally moderate to high. The pooled ORR for all patients receiving AR-targeted therapy was 26.3% (95% CI: 17.8%–37.1%), with moderate heterogeneity observed among studies (I²=65.3%). The pooled CBR was 50.6% (95% CI: 43.0%–58.1%). The weighted median PFS was 6.1 months, and the weighted median OS was 27.6 months. Subgroup analysis revealed that combined androgen blockade, utilized in six studies (n=409), resulted in a significantly higher pooled ORR of 36.6% (95% CI: 25.5%–48.9%) compared to just 7.7% (95% CI: 3.1%–18.0%) with AR antagonist monotherapy (p<0.001). Furthermore, the efficacy was greatest when used as a first-line treatment, which achieved a pooled ORR of 30.4% (n=221), compared to 21.0% in the second-line or later setting (n=58). Treatment was generally well-tolerated, with most adverse events being mild and related to androgen suppression.",
        "Conclusion": "This meta-analysis represents a comprehensive evaluation of AR-targeted therapy for SDC to date. Our findings support that this approach provides clinically meaningful responses in a substantial portion of patients. The data strongly support the superior efficacy of combined androgen blockade over monotherapy, suggesting it as the preferred AR-targeted treatment strategy for patients with advanced, recurrent, or metastatic AR-positive SDC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Androgen Deprivation Therapy for Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis</span>. <u>Jacob W Rosenthal, BS</u>; David Z Allen, MD; Jordan Sternthal, BS; Isabella Romeo, MPH; Gurel Ari; Erin E Reardon, MFA; Jose A Monteiro de Oliveira Novaes, MD; Nabil Saba, MD; Jennifer Gross, MD; Nicole C Schmitt, MD. Emory University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Salivary duct carcinoma (SDC) is a rare and aggressive malignancy characterized by high rates of androgen receptor (AR) expression, providing a strong biological rationale for AR-targeted therapy. However, the supporting clinical evidence is limited to single-arm trials and retrospective studies, with sparse randomized controlled trial data available to guide treatment decisions. To better define the role of this therapeutic strategy, we conducted a systematic review and the first meta-analysis to synthesize the published outcomes of AR-targeted therapy in patients with AR-positive SDC.</p>\n\n<p><strong>Methods: </strong>A health sciences librarian developed a comprehensive search strategy that was deployed across six databases (Ovid MEDLINE, Embase.com, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov) from their inception to January 7, 2026. We included studies evaluating AR-targeted therapy in patients with histologically confirmed, AR-positive SDC in the recurrent and metastatic setting. The primary outcome was overall response rate (ORR). Secondary outcomes included clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS). Pooled proportions and their 95% confidence intervals (CI) were calculated using a random-effects model. Pre-specified subgroup analyses were performed to compare outcomes based on the type of AR therapy and the line of treatment.</p>\n\n<p><strong>Results: </strong>Eleven studies, including four prospective phase II trials and seven retrospective analyses, met the inclusion criteria, comprising a total of 532 patients. The methodological quality of the included studies was generally moderate to high. The pooled ORR for all patients receiving AR-targeted therapy was 26.3% (95% CI: 17.8%–37.1%), with moderate heterogeneity observed among studies (I²=65.3%). The pooled CBR was 50.6% (95% CI: 43.0%–58.1%). The weighted median PFS was 6.1 months, and the weighted median OS was 27.6 months. Subgroup analysis revealed that combined androgen blockade, utilized in six studies (n=409), resulted in a significantly higher pooled ORR of 36.6% (95% CI: 25.5%–48.9%) compared to just 7.7% (95% CI: 3.1%–18.0%) with AR antagonist monotherapy (p<0.001). Furthermore, the efficacy was greatest when used as a first-line treatment, which achieved a pooled ORR of 30.4% (n=221), compared to 21.0% in the second-line or later setting (n=58). Treatment was generally well-tolerated, with most adverse events being mild and related to androgen suppression.</p>\n\n<p><strong>Conclusion: </strong>This meta-analysis represents a comprehensive evaluation of AR-targeted therapy for SDC to date. Our findings support that this approach provides clinically meaningful responses in a substantial portion of patients. The data strongly support the superior efficacy of combined androgen blockade over monotherapy, suggesting it as the preferred AR-targeted treatment strategy for patients with advanced, recurrent, or metastatic AR-positive SDC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155493--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S593",
      "content_id": "155604",
      "abstract_number": "S593",
      "poster_number": "",
      "title": "Intraoperative Doxycycline Use for Chyle Leak Management Following Neck Dissection",
      "summary": "Intraoperative thoracic duct ligation with doxycycline sclerosis may represent a safe and effective strategy for preventing postoperative chyle leak following neck dissection. Early results demonstrate absence of postoperative chyle leak in patients treated with the protocol and suggest a potential reduction in prolonged hospital stays compared with patients who developed leaks managed with standard approaches....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155604",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ryan Bowman, MD",
      "presenter": "Ryan Bowman, MD",
      "authors": "Ryan Bowman, MD ; Brette Harding, MD",
      "normalized_authors": [
        "Ryan Bowman",
        "Brette Harding"
      ],
      "affiliations": [
        "Southern Illinois University School of Medicine"
      ],
      "normalized_institutions": [
        "Southern Illinois University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Hypopharynx / Larynx",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Hypopharynx / Larynx"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 353,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Abstract",
        "Results",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Ryan Bowman, MD ; Brette Harding, MD",
        "Affiliations": "Southern Illinois University School of Medicine",
        "Introduction": "Chyle leaks are rare but serious complications of neck dissection in head and neck surgery that increase morbidity, length of stay, and healthcare costs. Existing management strategies can be prolonged and ineffective, particularly for high-output leaks, prompting interest in preventive intraoperative approaches.",
        "Methods": "A retrospective case series and preliminary comparative review was conducted at a single tertiary academic medical center by the SIU Head and Neck Surgery Division between 8/1/2023 and 1/31/2026 to evaluate prevention of postoperative chyle leak following neck dissection.",
        "Abstract": "A novel intraoperative protocol was implemented consisting of thoracic duct ligation followed by doxycycline sclerosis, with doxycycline (500 mg diluted in 50 mL normal saline) instilled via the surgical drain and maintained in situ for one hour at the conclusion of surgery. Four patients underwent the protocol and were compared with patients managed with standard care. The primary outcome was development of a postoperative chyle leak. The independent variable was use of the combined thoracic duct ligation and doxycycline sclerosis protocol. This represents a preliminary analysis of an ongoing retrospective study evaluating feasibility, safety, and early outcomes. In comparison, nine patients who developed postoperative chyle leaks and were managed with conventional treatment strategies experienced prolonged hospital stays. These findings suggest a potential association between the preventive protocol and reduced postoperative morbidity, particularly with respect to avoidance of chyle leak and shorter hospitalization. View in Agenda and Add to Schedule",
        "Results": "All four patients treated with the combined thoracic duct ligation and doxycycline sclerosis protocol had no evidence of postoperative chyle leak. No complications attributable to doxycycline instillation were observed. Three of the four patients treated with the protocol did not experience prolonged hospital stays.",
        "Conclusions": "Intraoperative thoracic duct ligation with doxycycline sclerosis may represent a safe and effective strategy for preventing postoperative chyle leak following neck dissection. Early results demonstrate absence of postoperative chyle leak in patients treated with the protocol and suggest a potential reduction in prolonged hospital stays compared with patients who developed leaks managed with standard approaches. While these preliminary findings are encouraging, larger retrospective and prospective studies are needed to further evaluate efficacy, safety, and generalizability."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Intraoperative Doxycycline Use for Chyle Leak Management Following Neck Dissection</span>. <u>Ryan Bowman, MD</u>; Brette Harding, MD. Southern Illinois University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Chyle leaks are rare but serious complications of neck dissection in head and neck surgery that increase morbidity, length of stay, and healthcare costs. Existing management strategies can be prolonged and ineffective, particularly for high-output leaks, prompting interest in preventive intraoperative approaches.</p>\n\n<p><strong>Methods: </strong>A retrospective case series and preliminary comparative review was conducted at a single tertiary academic medical center by the SIU Head and Neck Surgery Division between 8/1/2023 and 1/31/2026 to evaluate prevention of postoperative chyle leak following neck dissection. </p>\n\n<p>A novel intraoperative protocol was implemented consisting of thoracic duct ligation followed by doxycycline sclerosis, with doxycycline (500 mg diluted in 50 mL normal saline) instilled via the surgical drain and maintained in situ for one hour at the conclusion of surgery. Four patients underwent the protocol and were compared with patients managed with standard care. The primary outcome was development of a postoperative chyle leak. The independent variable was use of the combined thoracic duct ligation and doxycycline sclerosis protocol. This represents a preliminary analysis of an ongoing retrospective study evaluating feasibility, safety, and early outcomes.</p>\n\n<p><strong>Results: </strong>All four patients treated with the combined thoracic duct ligation and doxycycline sclerosis protocol had no evidence of postoperative chyle leak. No complications attributable to doxycycline instillation were observed. Three of the four patients treated with the protocol did not experience prolonged hospital stays.</p>\n\n<p>In comparison, nine patients who developed postoperative chyle leaks and were managed with conventional treatment strategies experienced prolonged hospital stays. These findings suggest a potential association between the preventive protocol and reduced postoperative morbidity, particularly with respect to avoidance of chyle leak and shorter hospitalization.</p>\n\n<p><strong>Conclusions: </strong>Intraoperative thoracic duct ligation with doxycycline sclerosis may represent a safe and effective strategy for preventing postoperative chyle leak following neck dissection. Early results demonstrate absence of postoperative chyle leak in patients treated with the protocol and suggest a potential reduction in prolonged hospital stays compared with patients who developed leaks managed with standard approaches. While these preliminary findings are encouraging, larger retrospective and prospective studies are needed to further evaluate efficacy, safety, and generalizability.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155604--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S595",
      "content_id": "155403",
      "abstract_number": "S595",
      "poster_number": "",
      "title": "Underutilization of Radioactive Iodine in Resectable Metastatic Thyroid Cancer",
      "summary": "RAI therapy is independently associated with improved survival in WDTC, with greatest relative benefit in advanced disease. However, more than half of metastatic patients did not receive RAI, and many underwent total thyroidectomy without subsequent RAI or alternative systemic therapy. These findings suggest potential undertreatment of metastatic WDTC and a disconnect between evolving treatment patterns and...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155403",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Anna Christina Clements, MD",
      "presenter": "Anna Christina Clements, MD",
      "authors": "Anna Christina Clements, MD 1 ; Mateo Useche, MD, MPH 1 ; Matthew Old, MD 1 ; Neal Futran, MD, DMD 1 ; Brittany Barber, MD, MSc 1 ; Rocco Ferrandino, MD, MSCR 1 ; Mara Roth, MD 2 ; Emily Marchiano, MD 1",
      "normalized_authors": [
        "Anna Christina Clements",
        "Mateo Useche",
        "Matthew Old",
        "Neal Futran",
        "Brittany Barber",
        "Rocco Ferrandino, MSCR",
        "Mara Roth",
        "Emily Marchiano"
      ],
      "affiliations": [
        "University of Washington, Department of Otolaryngology - Head and Neck Surgery",
        "University of Washington, Division of Metabolism, Endocrinology, and Nutrition"
      ],
      "normalized_institutions": [
        "University of Washington, Department of Otolaryngology - Head and Neck Surgery",
        "University of Washington, Division of Metabolism, Endocrinology, and Nutrition"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155403/AHNS_RAI%20use%20in%20M1%20WDTC_figure%201(1).jpg",
          "source_url": "https://www.submitmyabstract.com/abs/images/155403/AHNS_RAI%20use%20in%20M1%20WDTC_figure%201(1).jpg",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155403"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 503,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Anna Christina Clements, MD 1 ; Mateo Useche, MD, MPH 1 ; Matthew Old, MD 1 ; Neal Futran, MD, DMD 1 ; Brittany Barber, MD, MSc 1 ; Rocco Ferrandino, MD, MSCR 1 ; Mara Roth, MD 2 ; Emily Marchiano, MD 1",
        "Affiliations": "1 University of Washington, Department of Otolaryngology - Head and Neck Surgery; 2 University of Washington, Division of Metabolism, Endocrinology, and Nutrition",
        "Introduction": "Radioactive iodine (RAI) therapy remains a key component in treatment of well-differentiated thyroid carcinoma (WDTC). However, evolving risk stratification frameworks and increasing recognition of RAI-refractory disease have led to more selective use. National trends in RAI utilization and survival implications of withholding RAI in metastatic WDTC remain incompletely characterized. This study evaluated treatment patterns and survival outcomes associated with RAI use in a national WDTC cohort.",
        "Methods": "Patients with papillary and follicular thyroid carcinoma diagnosed between 2004-2022 were identified from the National Cancer Database. Patients were analyzed according to treatment modalities, including total thyroidectomy, RAI therapy, systemic therapy, and combinations thereof. Overall survival (OS) was estimated using Kaplan-Meier analyses and compared using log-rank testing. Multivariable Cox proportional hazards models were used to evaluate factors associated with survival after adjusting for demographic, socioeconomic, tumor, and treatment variables. Interaction terms evaluated effect modification by stage. A metastatic (M1) subgroup analysis was performed, and temporal trends in RAI utilization were evaluated using annual proportions with LOESS regression.",
        "Results": "A total of 415,353 patients with WDTC were identified, including 106,869 who received RAI and 308,484 who did not. On multivariable analysis, RAI was independently associated with improved OS. In stage-adjusted models, RAI was associated with a 26% reduction in mortality (HR 0.74, 95% CI 0.73-0.76). This remained significant after adjustment for tumor burden (HR 0.78, 95% CI 0.76-0.80) and in fully adjusted models incorporating demographic and socioeconomic variables (HR 0.80, 95% CI 0.78-0.82). Interaction analysis demonstrated effect modification by stage (p<0.01), with progressively greater benefit in advanced disease (Stage I HR 0.85; Stage II HR 0.75; Stage III HR 0.78; Stage IV HR 0.61).",
        "Abstract": "Among metastatic patients (M1), 4,211 met inclusion criteria. In this cohort, 1,902 (45.2%) received RAI while 2,309 (54.8%) did not. Among patients undergoing total thyroidectomy, systemic therapy use was low in both groups (5.9% with RAI vs 8.4% without RAI), indicating that omission of RAI was generally not offset by alternative systemic treatment. Within the M1 cohort, patients receiving total thyroidectomy and RAI demonstrated the best survival. After adjustment, patients undergoing total thyroidectomy without RAI (HR 1.44), RAI without total thyroidectomy (HR 2.23), or neither therapy (HR 3.26) had significantly worse OS compared to patients receiving both treatments. Kaplan-Meier analysis confirmed significant survival differences by treatment strategy (p<0.0001) (Figure 1). Despite these findings, RAI utilization in metastatic patients declined substantially during the study period, from 60-65% in the mid-2000s to 25-30% by 2020-2022. View in Agenda and Add to Schedule",
        "Conclusion": "RAI therapy is independently associated with improved survival in WDTC, with greatest relative benefit in advanced disease. However, more than half of metastatic patients did not receive RAI, and many underwent total thyroidectomy without subsequent RAI or alternative systemic therapy. These findings suggest potential undertreatment of metastatic WDTC and a disconnect between evolving treatment patterns and population-level survival outcomes in patients with potentially resectable disease."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Underutilization of Radioactive Iodine in Resectable Metastatic Thyroid Cancer</span>. <u>Anna Christina Clements, MD</u><sup>1</sup>; Mateo Useche, MD, MPH<sup>1</sup>; Matthew Old, MD<sup>1</sup>; Neal Futran, MD, DMD<sup>1</sup>; Brittany Barber, MD, MSc<sup>1</sup>; Rocco Ferrandino, MD, MSCR<sup>1</sup>; Mara Roth, MD<sup>2</sup>; Emily Marchiano, MD<sup>1</sup>. <sup>1</sup>University of Washington, Department of Otolaryngology - Head and Neck Surgery; <sup>2</sup>University of Washington, Division of Metabolism, Endocrinology, and Nutrition<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Radioactive iodine (RAI) therapy remains a key component in treatment of well-differentiated thyroid carcinoma (WDTC). However, evolving risk stratification frameworks and increasing recognition of RAI-refractory disease have led to more selective use. National trends in RAI utilization and survival implications of withholding RAI in metastatic WDTC remain incompletely characterized. This study evaluated treatment patterns and survival outcomes associated with RAI use in a national WDTC cohort.</p>\n\n<p><strong>Methods: </strong>Patients with papillary and follicular thyroid carcinoma diagnosed between 2004-2022 were identified from the National Cancer Database. Patients were analyzed according to treatment modalities, including total thyroidectomy, RAI therapy, systemic therapy, and combinations thereof. Overall survival (OS) was estimated using Kaplan-Meier analyses and compared using log-rank testing. Multivariable Cox proportional hazards models were used to evaluate factors associated with survival after adjusting for demographic, socioeconomic, tumor, and treatment variables. Interaction terms evaluated effect modification by stage. A metastatic (M1) subgroup analysis was performed, and temporal trends in RAI utilization were evaluated using annual proportions with LOESS regression.</p>\n\n<p><strong>Results: </strong>A total of 415,353 patients with WDTC were identified, including 106,869 who received RAI and 308,484 who did not. On multivariable analysis, RAI was independently associated with improved OS. In stage-adjusted models, RAI was associated with a 26% reduction in mortality (HR 0.74, 95% CI 0.73-0.76). This remained significant after adjustment for tumor burden (HR 0.78, 95% CI 0.76-0.80) and in fully adjusted models incorporating demographic and socioeconomic variables (HR 0.80, 95% CI 0.78-0.82). Interaction analysis demonstrated effect modification by stage (p<0.01), with progressively greater benefit in advanced disease (Stage I HR 0.85; Stage II HR 0.75; Stage III HR 0.78; Stage IV HR 0.61).</p>\n\n<p>Among metastatic patients (M1), 4,211 met inclusion criteria. In this cohort, 1,902 (45.2%) received RAI while 2,309 (54.8%) did not. Among patients undergoing total thyroidectomy, systemic therapy use was low in both groups (5.9% with RAI vs 8.4% without RAI), indicating that omission of RAI was generally not offset by alternative systemic treatment.</p>\n\n<p>Within the M1 cohort, patients receiving total thyroidectomy and RAI demonstrated the best survival. After adjustment, patients undergoing total thyroidectomy without RAI (HR 1.44), RAI without total thyroidectomy (HR 2.23), or neither therapy (HR 3.26) had significantly worse OS compared to patients receiving both treatments. Kaplan-Meier analysis confirmed significant survival differences by treatment strategy (p<0.0001) (Figure 1). Despite these findings, RAI utilization in metastatic patients declined substantially during the study period, from 60-65% in the mid-2000s to 25-30% by 2020-2022.</p>\n\n<p><strong>Conclusion: </strong>RAI therapy is independently associated with improved survival in WDTC, with greatest relative benefit in advanced disease. However, more than half of metastatic patients did not receive RAI, and many underwent total thyroidectomy without subsequent RAI or alternative systemic therapy. These findings suggest potential undertreatment of metastatic WDTC and a disconnect between evolving treatment patterns and population-level survival outcomes in patients with potentially resectable disease.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155403/AHNS_RAI%20use%20in%20M1%20WDTC_figure%201(1).jpg' /></p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155403--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S596",
      "content_id": "155381",
      "abstract_number": "S596",
      "poster_number": "",
      "title": "GLP-1 Receptor Agonists Show No Head and Neck Cancer Signal in FDA Adverse Event Data, Despite Persistent Thyroid Disproportionality",
      "summary": "Using an active-comparator FAERS framework, we found no signal suggesting increased HNC reporting with GLP-1 RAs, despite persistent thyroid-neoplasm disproportionality across eras. The positive-control pancreatitis finding supports assay sensitivity. While FAERS cannot establish causality or incidence, these data are reassuring for HNC and do not support altering current oncologic management based solely on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155381",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260162",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "David Z Allen, MD",
      "presenter": "David Z Allen, MD",
      "authors": "David Z Allen, MD ; J. Walker Rosenthal, BS; Merry Sebelik, MD, FACS, MAMSE",
      "normalized_authors": [
        "David Z Allen",
        "J. Walker Rosenthal",
        "Merry Sebelik, MAMSE"
      ],
      "affiliations": [
        "Emory University"
      ],
      "normalized_institutions": [
        "Emory University"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [
        {
          "url": "https://www.submitmyabstract.com/abs/images/155381/AHNS_LBA_One_Good_Figure_Clean_2026-03-07.png",
          "source_url": "https://www.submitmyabstract.com/abs/images/155381/AHNS_LBA_One_Good_Figure_Clean_2026-03-07.png",
          "alt": "Source figure 1",
          "record_url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=155381"
        }
      ],
      "has_images": true,
      "is_structured": true,
      "word_count": 520,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusion",
        "Figure 1.",
        "Abstract"
      ],
      "sections": {
        "Authors": "David Z Allen, MD ; J. Walker Rosenthal, BS; Merry Sebelik, MD, FACS, MAMSE",
        "Affiliations": "Emory University",
        "Background": "Use of glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss is expanding rapidly, yet head and neck cancer (HNC)-specific oncologic safety data remain limited. With substantial report accrual in 2022-2026, we performed an active-comparator pharmacovigilance analysis to test for increased HNC reporting and characterize concurrent thyroid-neoplasm reporting.",
        "Methods": "We queried openFDA FAERS on 2026-03-07 and compared GLP-1 class reports with non-GLP1 diabetes comparator reports. Comparator reports were restricted to reports containing non-GLP1 diabetes medications using a drug-based FAERS comparator approach intended to reduce indication-field misclassification. Primary outcomes were broad and strict HNC MedDRA Preferred Term sets while thyroid neoplasm was a key secondary outcome. Broad HNC included head and neck cancer, head and neck squamous cell carcinoma, oral cavity/oral squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal, and nasopharyngeal cancer terms while strict HNC included only head and neck cancer and head and neck squamous cell carcinoma. Pancreatitis was prespecified as an internal positive control. Odds ratios and Wald confidence intervals were computed from 2x2 tables using a Haldane-Anscombe continuity correction (+0.5 cells). Prespecified robustness analyses included era stratification (2004-2017, 2018-2021, 2022-2026) and single-agent sensitivity.",
        "Results": "Among 383,637 GLP-1 reports and 1,057,522 active-comparator reports, there was no increased HNC reporting signal with GLP-1 RAs. Broad HNC events were 28 versus 177 and showed an inverse disproportionality signal (OR 0.443, 95% CI 0.298-0.657, p =0.00005), while strict HNC events were 12 versus 36 and were null (OR 0.944, 95% CI 0.497-1.795, p =0.86). In contrast, thyroid-neoplasm reporting was enriched (1291 vs 1025; OR 3.480, 95% CI 3.206-3.778, p <0.001), and the prespecified pancreatitis positive control was also enriched (OR 2.309, 95% CI 2.251-2.368, p <0.001). Broad-HNC ORs remained below 1 across eras (2004-2017, 0.376, p =0.026; 2018-2021, 0.541, p =0.140; 2022-2026, 0.460, p =0.0059), whereas thyroid-neoplasm ORs remained consistently elevated (4.940, 5.241, and 3.640, respectively; all p <0.001). Single-agent analyses were directionally concordant for HNC, with the lowest broad-HNC OR observed for tirzepatide (OR 0.320, 95% CI 0.146-0.700), while thyroid-neoplasm signals varied across agents (tirzepatide OR 1.369; liraglutide OR 7.898).",
        "Conclusion": "Using an active-comparator FAERS framework, we found no signal suggesting increased HNC reporting with GLP-1 RAs, despite persistent thyroid-neoplasm disproportionality across eras. The positive-control pancreatitis finding supports assay sensitivity. While FAERS cannot establish causality or incidence, these data are reassuring for HNC and do not support altering current oncologic management based solely on class-level GLP-1 RA safety concerns. Definitive evaluation now requires patient-level pharmacoepidemiologic studies with explicit comparators and thyroid subtype-specific outcomes.",
        "Figure 1.": "Active-comparator FAERS safety signals for GLP-1 receptor agonists.",
        "Abstract": "Forest plots show odds ratios (ORs, 95% CIs) for GLP-1 reports versus non-GLP1 diabetes comparator reports across primary endpoints and era-stratified analyses (2004–2017, 2018–2021, 2022–2026). HNC broad/strict endpoints show no increased reporting signal, while thyroid neoplasm and pancreatitis (positive control) are enriched; directional patterns are stable across eras. ORs were computed using Haldane-Anscombe continuity correction (+0.5). View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>GLP-1 Receptor Agonists Show No Head and Neck Cancer Signal in FDA Adverse Event Data, Despite Persistent Thyroid Disproportionality</span>. <u>David Z Allen, MD</u>; J. Walker Rosenthal, BS; Merry Sebelik, MD, FACS, MAMSE. Emory University<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>Use of glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss is expanding rapidly, yet head and neck cancer (HNC)-specific oncologic safety data remain limited. With substantial report accrual in 2022-2026, we performed an active-comparator pharmacovigilance analysis to test for increased HNC reporting and characterize concurrent thyroid-neoplasm reporting.</p>\n\n<p><strong>Methods: </strong>We queried openFDA FAERS on 2026-03-07 and compared GLP-1 class reports with non-GLP1 diabetes comparator reports. Comparator reports were restricted to reports containing non-GLP1 diabetes medications using a drug-based FAERS comparator approach intended to reduce indication-field misclassification. Primary outcomes were broad and strict HNC MedDRA Preferred Term sets while thyroid neoplasm was a key secondary outcome. Broad HNC included head and neck cancer, head and neck squamous cell carcinoma, oral cavity/oral squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal, and nasopharyngeal cancer terms while strict HNC included only head and neck cancer and head and neck squamous cell carcinoma. Pancreatitis was prespecified as an internal positive control. Odds ratios and Wald confidence intervals were computed from 2x2 tables using a Haldane-Anscombe continuity correction (+0.5 cells). Prespecified robustness analyses included era stratification (2004-2017, 2018-2021, 2022-2026) and single-agent sensitivity. </p>\n\n<p><strong>Results: </strong>Among 383,637 GLP-1 reports and 1,057,522 active-comparator reports, there was no increased HNC reporting signal with GLP-1 RAs. Broad HNC events were 28 versus 177 and showed an inverse disproportionality signal (OR 0.443, 95% CI 0.298-0.657, <em>p</em>=0.00005), while strict HNC events were 12 versus 36 and were null (OR 0.944, 95% CI 0.497-1.795, <em>p</em>=0.86). In contrast, thyroid-neoplasm reporting was enriched (1291 vs 1025; OR 3.480, 95% CI 3.206-3.778,<em> p</em><0.001), and the prespecified pancreatitis positive control was also enriched (OR 2.309, 95% CI 2.251-2.368, <em>p</em><0.001). Broad-HNC ORs remained below 1 across eras (2004-2017, 0.376, <em>p</em>=0.026; 2018-2021, 0.541, <em>p</em>=0.140; 2022-2026, 0.460, <em>p</em>=0.0059), whereas thyroid-neoplasm ORs remained consistently elevated (4.940, 5.241, and 3.640, respectively; all <em>p</em><0.001). Single-agent analyses were directionally concordant for HNC, with the lowest broad-HNC OR observed for tirzepatide (OR 0.320, 95% CI 0.146-0.700), while thyroid-neoplasm signals varied across agents (tirzepatide OR 1.369; liraglutide OR 7.898).</p>\n\n<p><strong>Conclusion: </strong>Using an active-comparator FAERS framework, we found no signal suggesting increased HNC reporting with GLP-1 RAs, despite persistent thyroid-neoplasm disproportionality across eras. The positive-control pancreatitis finding supports assay sensitivity. While FAERS cannot establish causality or incidence, these data are reassuring for HNC and do not support altering current oncologic management based solely on class-level GLP-1 RA safety concerns. Definitive evaluation now requires patient-level pharmacoepidemiologic studies with explicit comparators and thyroid subtype-specific outcomes.</p>\n\n<p><img alt='' src='https://www.submitmyabstract.com/abs/images/155381/AHNS_LBA_One_Good_Figure_Clean_2026-03-07.png' /></p>\n\n<p><strong>Figure 1. </strong>Active-comparator FAERS safety signals for GLP-1 receptor agonists.</p>\n\n<p>Forest plots show odds ratios (ORs, 95% CIs) for GLP-1 reports versus non-GLP1 diabetes comparator reports across primary endpoints and era-stratified analyses (2004–2017, 2018–2021, 2022–2026). HNC broad/strict endpoints show no increased reporting signal, while thyroid neoplasm and pancreatitis (positive control) are enriched; directional patterns are stable across eras. ORs were computed using Haldane-Anscombe continuity correction (+0.5).</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 155381--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260162' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S597",
      "content_id": "153975",
      "abstract_number": "S597",
      "poster_number": "",
      "title": "Evaluating a novel pan-RAF inhibitor in RAS mutant and BRAF/MEK inhibitor-resistant anaplastic thyroid carcinoma",
      "summary": "This is one of the first reported studies to evaluate and compare a novel pan-RAF inhibitor JZP815 to SoC therapy for ATC in a pre-clinical setting. We demonstrated strong therapeutic potential in both NRAS_Q61K mutant and BRAFm ATC tumors that have acquired resistance to BRAF/MEK inhibitors. This work warrants further investigation and remains promising for translation to early-phase clinical trials in ATC.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153975",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ahmad Abubaker, MD",
      "presenter": "Ahmad Abubaker, MD",
      "authors": "Ahmad Abubaker, MD 1 ; Ying Henderson, MD, PhD 1 ; Jieru Meng, PhD 1 ; Maria E Cabanillas, MD 2 ; Mark Zafereo, MD 1 ; Stephen Y Lai, MD, PhD 3 ; Robin Humphryes, PhD 4 ; Anastasios Maniakas, MD, PhD 1",
      "normalized_authors": [
        "Ahmad Abubaker",
        "Ying Henderson",
        "Jieru Meng",
        "Maria E Cabanillas",
        "Mark Zafereo",
        "Stephen Y Lai",
        "Robin Humphryes",
        "Anastasios Maniakas"
      ],
      "affiliations": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Oncology Research, Jazz Pharmaceuticals Palo Alto, CA, USA"
      ],
      "normalized_institutions": [
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
        "Oncology Research, Jazz Pharmaceuticals Palo Alto, CA, USA"
      ],
      "session_type": "Proffered Paper",
      "track": "Translational Research/Science",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Translational Research/Science"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 518,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Aim",
        "MDA-ATC8",
        "MDA-ATC1-R",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ahmad Abubaker, MD 1 ; Ying Henderson, MD, PhD 1 ; Jieru Meng, PhD 1 ; Maria E Cabanillas, MD 2 ; Mark Zafereo, MD 1 ; Stephen Y Lai, MD, PhD 3 ; Robin Humphryes, PhD 4 ; Anastasios Maniakas, MD, PhD 1",
        "Affiliations": "1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; 4 Oncology Research, Jazz Pharmaceuticals Palo Alto, CA, USA",
        "Introduction": "Anaplastic Thyroid Carcinoma (ATC) is the most aggressive subtype of thyroid cancer, causing half of thyroid cancer related deaths(1). Although the introduction of BRAF/MEK inhibitors (BRAF/MEKi) for BRAFV600E-mutant (BRAFm) ATC drastically improved overall survival(2), this population only represents 40% of ATC patients. Moreover, patients usually progress on this combination due to acquired resistance, with no effective salvage options. Pan-RAF inhibitors represent a novel class of therapies that inhibit all three RAF kinase isoforms, offering a potential therapy for both BRAF and RAS-mutated tumors, as well as BRAFm disease resistant to standard of care (SoC) therapy.",
        "Aim": "Evaluate the efficacy of a next generation pan-RAF inhibitor (JZP815), as a single agent and in combination with other drugs, on our established and characterized(3,4) BRAF/MEK inhibitor-resistant patient-derived xenograft (PDX) model and a BRAF wild-type/RAS mutant PDX.",
        "MDA-ATC8": "(BRAF WT, NRAS_Q61K) and MDA-ATC1-R (BRAF/MEKi resistant; BRAFm and PI3K_E545K) models were expanded into athymic nude mice. Once tumors reached an average volume of 150mm3, mice were randomized into four groups. Mice with MDA-ATC8 were treated with vehicle control (V), 0.25 mg/kg QD trametinib (T), 30 mg/kg BID JZP815 (J), or combination of T and J (TJ). Mice with MDA-ATC1-R, were treated with V, 30 mg/kg QD dabrafenib + 0.5 mg/kg QD trametinib (DT), DT QD + J BID (DTJ), or DT alone QD followed by introduction of J BID as salvage (s) therapy once tumors reached 500mm3 (DTJs). All treatments followed a 5 days on/2 days off dosing schedule. Tumors were measured 3 times a week. Drug toxicity was evaluated by daily observation and regular body weight measurement. At trial completion, tumors were measured, harvested, and preserved for future analyses. significant tumor growth inhibition was seen when comparing V and TJ (p=0.03), with tumors in the TJ cohort showing regression relative to their baseline volume. Mild toxicity occurred during the first week of treatment, with one mouse requiring euthanasia. Overall, weight improved over the course of the trial.",
        "MDA-ATC1-R": "significant tumor growth inhibition was seen when comparing V and DTJ (p=0.002) and V vs DTJs (p=0.02). Notably, mice that initially received DT alone exhibited exponential tumor growth, but following the addition of J at day 16, tumor growth was arrested, and partial regression was observed compared to mice remaining on DT alone. Toxicity was observed in all groups receiving J, particularly during the first week, with one mouse requiring euthanasia. Overall, most mice exhibited gradual weight recovery by the end of the trial. In both experiments, mice who received J in combination with standard of care showed sustained therapeutic response during the weekly two-day drug holiday.",
        "Conclusion": "This is one of the first reported studies to evaluate and compare a novel pan-RAF inhibitor JZP815 to SoC therapy for ATC in a pre-clinical setting. We demonstrated strong therapeutic potential in both NRAS_Q61K mutant and BRAFm ATC tumors that have acquired resistance to BRAF/MEK inhibitors. This work warrants further investigation and remains promising for translation to early-phase clinical trials in ATC.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Evaluating a novel pan-RAF inhibitor in RAS mutant and BRAF/MEK inhibitor-resistant anaplastic thyroid carcinoma</span>. <u>Ahmad Abubaker, MD</u><sup>1</sup>; Ying Henderson, MD, PhD<sup>1</sup>; Jieru Meng, PhD<sup>1</sup>; Maria E Cabanillas, MD<sup>2</sup>; Mark Zafereo, MD<sup>1</sup>; Stephen Y Lai, MD, PhD<sup>3</sup>; Robin Humphryes, PhD<sup>4</sup>; Anastasios Maniakas, MD, PhD<sup>1</sup>. <sup>1</sup>Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Department of Endocrine Neoplasia and Hormonal Disorders,  The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>3</sup>Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4.\tDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; <sup>4</sup>Oncology Research, Jazz Pharmaceuticals Palo Alto, CA, USA<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Anaplastic Thyroid Carcinoma (ATC) is the most aggressive subtype of thyroid cancer, causing half of thyroid cancer related deaths(1). Although the introduction of BRAF/MEK inhibitors (BRAF/MEKi) for BRAFV600E-mutant (BRAFm) ATC drastically improved overall survival(2), this population only represents 40% of ATC patients. Moreover, patients usually progress on this combination due to acquired resistance, with no effective salvage options. Pan-RAF inhibitors represent a novel class of therapies that inhibit all three RAF kinase isoforms, offering a potential therapy for both BRAF and RAS-mutated tumors, as well as BRAFm disease resistant to standard of care (SoC) therapy.</p>\n\n<p><strong>Aim: </strong>Evaluate the efficacy of a next generation pan-RAF inhibitor (JZP815), as a single agent and in combination with other drugs, on our established and characterized(3,4) BRAF/MEK inhibitor-resistant patient-derived xenograft (PDX) model and a BRAF wild-type/RAS mutant PDX.</p>\n\n<p><strong>Methods:</strong></p>\n\n<p><strong>MDA-ATC8</strong> <u>(BRAF WT, NRAS_Q61K)</u> and <strong>MDA-ATC1-R</strong> <u>(BRAF/MEKi resistant; BRAFm and PI3K_E545K)</u> models were expanded into athymic nude mice. Once tumors reached an average volume of 150mm3, mice were randomized into four groups. Mice with MDA-ATC8 were treated with vehicle control (V), 0.25 mg/kg QD trametinib (T), 30 mg/kg BID JZP815 (J), or combination of T and J (TJ). Mice with MDA-ATC1-R, were treated with V, 30 mg/kg QD dabrafenib + 0.5 mg/kg QD trametinib (DT), DT QD + J BID (DTJ), or DT alone QD followed by introduction of J BID as salvage (s) therapy once tumors reached 500mm3 (DTJs). All treatments followed a 5 days on/2 days off dosing schedule. Tumors were measured 3 times a week. Drug toxicity was evaluated by daily observation and regular body weight measurement. At trial completion, tumors were measured, harvested, and preserved for future analyses.</p>\n\n<p><strong>Results:</strong></p>\n\n<p><strong>MDA-ATC8:</strong> significant tumor growth inhibition was seen when comparing V and TJ (p=0.03), with tumors in the TJ cohort showing regression relative to their baseline volume. Mild toxicity occurred during the first week of treatment, with one mouse requiring euthanasia. Overall, weight improved over the course of the trial.</p>\n\n<p><strong>MDA-ATC1-R:</strong> significant tumor growth inhibition was seen when comparing V and DTJ (p=0.002) and V vs DTJs (p=0.02). Notably, mice that initially received DT alone exhibited exponential tumor growth, but following the addition of J at day 16, tumor growth was arrested, and partial regression was observed compared to mice remaining on DT alone. Toxicity was observed in all groups receiving J, particularly during the first week, with one mouse requiring euthanasia. Overall, most mice exhibited gradual weight recovery by the end of the trial. In both experiments, mice who received J in combination with standard of care showed sustained therapeutic response during the weekly two-day drug holiday.</p>\n\n<p><strong>Conclusion: </strong>This is one of the first reported studies to evaluate and compare a novel pan-RAF inhibitor JZP815 to SoC therapy for ATC in a pre-clinical setting. <u>We demonstrated strong therapeutic potential in both NRAS_Q61K mutant and BRAFm ATC tumors that have acquired resistance to BRAF/MEK inhibitors.</u> This work warrants further investigation and remains promising for translation to early-phase clinical trials in ATC.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153975--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S598",
      "content_id": "153130",
      "abstract_number": "S598",
      "poster_number": "",
      "title": "Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta Analysis with Reconstructed Survival and Time to Event Data",
      "summary": "Pembrolizumab shows meaningful clinical activity in ATC, achieving durable survival and substantial disease control with a manageable safety profile. These findings support its therapeutic role in patients with Anaplastic thyroid cancer/advanced thyroid carcinoma , and highlight the need for prospective trials to optimize its use.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153130",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Mohamad Mahameed, Dr",
      "presenter": "Mohamad Mahameed, Dr",
      "authors": "Mohamad Mahameed, Dr ; Areeb Iraqi",
      "normalized_authors": [
        "Mohamad Mahameed, Dr",
        "Areeb Iraqi"
      ],
      "affiliations": [
        "Ziv Medical Center, Safad Israel"
      ],
      "normalized_institutions": [
        "Ziv Medical Center, Safad Israel"
      ],
      "session_type": "Proffered Paper",
      "track": "Immunotherapy / Systemic Therapy",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Immunotherapy / Systemic Therapy"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 307,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Conclusions",
        "Keywords",
        "Abstract"
      ],
      "sections": {
        "Authors": "Mohamad Mahameed, Dr ; Areeb Iraqi",
        "Affiliations": "Ziv Medical Center, Safad Israel",
        "Background": "Anaplastic thyroid carcinoma (ATC) is an aggressive poorly differentiated thyroid malignancy with limited treatment options and poor outcomes. Pembrolizumab, a PD 1 inhibitor, has shown promise; however, the evidence remains scattered.",
        "Methods": "A systematic review and meta analysis, conducted in accordance with the PRISMA guidelines, was performed to evaluate the efficacy and safety of pembrolizumab in ATC. PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus were searched through August 2025. Studies reporting outcomes in adults with ATC treated with pembrolizumab were included. Time to event outcomes were reconstructed from published Kaplan Meier curves. Pooled estimates were calculated using generalized linear mixed models (GLMM), with Freeman Tukey and arcsine transformations for sensitivity analyses.",
        "Results": "Eight studies with 231 patients with ATC were included in this study. The pooled median overall survival was 15.6 months (95% CI: 10.3 26.9 months), and the median progression free survival was 10.1 months (95% CI: 5.8 26.9 months). Survival rates were 72.2% at 6 months and 54.9% at 12 months. Pembrolizumab achieved a pooled objective response rate of 43.75%, a partial response rate of 35.66%, a stable disease rate of 27.66%, and a disease control rate of 71.58%, while progressive disease occurred in 26.47% of patients. Severe (grade ≥3) adverse events were observed in 23.7% of cases. Sensitivity analyses confirmed robust and consistent results across models, with low heterogeneity (I² = 0 18.5%).",
        "Conclusions": "Pembrolizumab shows meaningful clinical activity in ATC, achieving durable survival and substantial disease control with a manageable safety profile. These findings support its therapeutic role in patients with Anaplastic thyroid cancer/advanced thyroid carcinoma , and highlight the need for prospective trials to optimize its use.",
        "Keywords": "anaplastic thyroid carcinoma, pembrolizumab, PD 1 inhibitors, immune checkpoint blockade, meta analysis, survival, disease control",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta Analysis with Reconstructed Survival and Time to Event Data</span>. <u>Mohamad Mahameed, Dr</u>; Areeb Iraqi. Ziv Medical Center, Safad Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background</strong>: Anaplastic thyroid carcinoma (ATC) is an aggressive poorly differentiated thyroid malignancy with limited treatment options and poor outcomes. Pembrolizumab, a PD 1 inhibitor, has shown promise; however, the evidence remains scattered.</p>\n\n<p><strong>Methods:</strong> A systematic review and meta analysis, conducted in accordance with the PRISMA guidelines, was performed to evaluate the efficacy and safety of pembrolizumab in ATC. PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus were searched through August 2025. Studies reporting outcomes in adults with ATC treated with pembrolizumab were included. Time to event outcomes were reconstructed from published Kaplan Meier curves. Pooled estimates were calculated using generalized linear mixed models (GLMM), with Freeman Tukey and arcsine transformations for sensitivity analyses.</p>\n\n<p><strong>Results:</strong> Eight studies with 231 patients with ATC were included in this study. The pooled median overall survival was 15.6 months (95% CI: 10.3 26.9 months), and the median progression free survival was 10.1 months (95% CI: 5.8 26.9 months). Survival rates were 72.2% at 6 months and 54.9% at 12 months. Pembrolizumab achieved a pooled objective response rate of 43.75%, a partial response rate of 35.66%, a stable disease rate of 27.66%, and a disease control rate of 71.58%, while progressive disease occurred in 26.47% of patients. Severe (grade ≥3) adverse events were observed in 23.7% of cases. Sensitivity analyses confirmed robust and consistent results across models, with low heterogeneity (I² = 0 18.5%).</p>\n\n<p><strong>Conclusions</strong>: Pembrolizumab shows meaningful clinical activity in ATC, achieving durable survival and substantial disease control with a manageable safety profile. These findings support its therapeutic role in patients with Anaplastic thyroid cancer/advanced thyroid carcinoma , and highlight the need for prospective trials to optimize its use.</p>\n\n<p><strong>Keywords</strong>: anaplastic thyroid carcinoma, pembrolizumab, PD 1 inhibitors, immune checkpoint blockade, meta analysis, survival, disease control</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153130--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S599",
      "content_id": "154567",
      "abstract_number": "S599",
      "poster_number": "",
      "title": "Incidental Parathyroidectomy During Thyroidectomy: Novel Insights into the Paradoxical Relationship with Thyroid Gland Dimensions",
      "summary": "This investigation reveals a previously unrecognized paradox in thyroid surgery: smaller thyroid glands confer a higher risk of incidental parathyroidectomy. This finding challenges conventional surgical wisdom and has significant implications for preoperative risk stratification and intraoperative decision-making. Surgeons should exercise heightened vigilance when operating on patients with smaller thyroid...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154567",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Haia Darawshe, MD",
      "presenter": "Haia Darawshe, MD",
      "authors": "Haia Darawshe, MD",
      "normalized_authors": [
        "Haia Darawshe"
      ],
      "affiliations": [
        "Ziv medical center- Israel"
      ],
      "normalized_institutions": [
        "Ziv medical center- Israel"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 292,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Haia Darawshe, MD",
        "Affiliations": "Ziv medical center- Israel",
        "Introduction": "Incidental parathyroidectomy represents a persistent challenge in thyroid surgery, with reported rates ranging from 3-30%. While previous studies have explored various risk factors, the relationship between thyroid gland dimensions and parathyroid preservation remains incompletely characterized. This investigation addresses this critical knowledge gap by examining the association between thyroid gland metrics and inadvertent parathyroidectomy.",
        "Methods": "We conducted a comprehensive retrospective analysis of 173 consecutive thyroidectomy cases at a single tertiary referral center (2018-2023). Primary outcome was incidental parathyroidectomy, confirmed by histopathological examination. We meticulously documented thyroid gland volume and weight, parathyroid gland identification in surgical specimens, demographic variables, surgical approach, and final pathology. Statistical methodology included correlation analysis and multivariate regression with appropriate controls for confounding variables.",
        "Results": "The cohort comprised 126 patients (73%) with benign pathology and 47 (27%) with papillary thyroid carcinoma. Notably, we observed a paradoxical relationship between gland size and parathyroid preservation: smaller thyroid glands were associated with higher rates of incidental parathyroidectomy. This inverse correlation was statistically significant for both gland volume (r=-0.214, p<0.05) and weight (r=-0.321, p<0.001). This unexpected finding persisted after controlling for extent of surgery and underlying pathology, suggesting a fundamental biomechanical or anatomical basis for this relationship.",
        "Conclusion": "This investigation reveals a previously unrecognized paradox in thyroid surgery: smaller thyroid glands confer a higher risk of incidental parathyroidectomy. This finding challenges conventional surgical wisdom and has significant implications for preoperative risk stratification and intraoperative decision-making. Surgeons should exercise heightened vigilance when operating on patients with smaller thyroid glands, potentially employing advanced parathyroid identification techniques in these high-risk cases. These insights contribute to our evolving understanding of thyroid surgical anatomy and may lead to refined approaches for parathyroid preservation and improved patient outcomes.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Incidental Parathyroidectomy During Thyroidectomy: Novel Insights into the Paradoxical Relationship with Thyroid Gland Dimensions</span>. <u>Haia Darawshe, MD</u>. Ziv medical center- Israel<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Incidental parathyroidectomy represents a persistent challenge in thyroid surgery, with reported rates ranging from 3-30%. While previous studies have explored various risk factors, the relationship between thyroid gland dimensions and parathyroid preservation remains incompletely characterized. This investigation addresses this critical knowledge gap by examining the association between thyroid gland metrics and inadvertent parathyroidectomy.</p>\n\n<p><strong>Methods:</strong> We conducted a comprehensive retrospective analysis of 173 consecutive thyroidectomy cases at a single tertiary referral center (2018-2023). Primary outcome was incidental parathyroidectomy, confirmed by histopathological examination. We meticulously documented thyroid gland volume and weight, parathyroid gland identification in surgical specimens, demographic variables, surgical approach, and final pathology. Statistical methodology included correlation analysis and multivariate regression with appropriate controls for confounding variables.</p>\n\n<p><strong>Results: </strong>The cohort comprised 126 patients (73%) with benign pathology and 47 (27%) with papillary thyroid carcinoma. Notably, we observed a paradoxical relationship between gland size and parathyroid preservation: smaller thyroid glands were associated with higher rates of incidental parathyroidectomy. This inverse correlation was statistically significant for both gland volume (r=-0.214, p<0.05) and weight (r=-0.321, p<0.001). This unexpected finding persisted after controlling for extent of surgery and underlying pathology, suggesting a fundamental biomechanical or anatomical basis for this relationship.</p>\n\n<p><strong>Conclusion:</strong> This investigation reveals a previously unrecognized paradox in thyroid surgery: smaller thyroid glands confer a higher risk of incidental parathyroidectomy. This finding challenges conventional surgical wisdom and has significant implications for preoperative risk stratification and intraoperative decision-making. Surgeons should exercise heightened vigilance when operating on patients with smaller thyroid glands, potentially employing advanced parathyroid identification techniques in these high-risk cases. These insights contribute to our evolving understanding of thyroid surgical anatomy and may lead to refined approaches for parathyroid preservation and improved patient outcomes.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154567--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S600",
      "content_id": "154507",
      "abstract_number": "S600",
      "poster_number": "",
      "title": "Concurrent Parathyroidectomy During Thyroidectomy in ESRD Patients: Risks, Benefits, and Long-Term Endocrine Outcomes in a Nationwide Cohort",
      "summary": "Although concurrent parathyroidectomy decreases long-term cinacalcet use in ESRD patients undergoing thyroidectomy, it significantly increases the risk of acute and chronic PTH suppression, hypercalcemia episodes, and ongoing calcium and calcitriol supplementation. These findings support selective, indication-driven parathyroid resection during thyroidectomy and highlight the importance of counseling patients on...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154507",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christian J Leonardo",
      "presenter": "Christian J Leonardo",
      "authors": "Christian J Leonardo ; Patricia Cerri-Droz; Lukasz Czerwonka, MD",
      "normalized_authors": [
        "Christian J Leonardo",
        "Patricia Cerri-Droz",
        "Lukasz Czerwonka"
      ],
      "affiliations": [
        "SUNY - University at Stony Brook (SSO)"
      ],
      "normalized_institutions": [
        "SUNY - University at Stony Brook (SSO)"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 447,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Christian J Leonardo ; Patricia Cerri-Droz; Lukasz Czerwonka, MD",
        "Affiliations": "SUNY - University at Stony Brook (SSO)",
        "Introduction": "Patients with end-stage renal disease (ESRD) commonly develop thyroid nodules and are frequently treated with medications for secondary hyperparathyroidism. When they require thyroidectomy for treatment of their thyroid nodules, the risk vs benefit profile of adding concurrent parathyroidectomy for definitive management of their secondary hyperparathyroidism is poorly understood. This study evaluates long-term parathyroid function, calcium supplementation, and medication dependence in ESRD patients undergoing thyroidectomy with versus without concurrent parathyroidectomy.",
        "Methods": "A retrospective cohort analysis was conducted using the TriNetX database, a global collaborative network with data from over 128 million patients. Concurrent parathyroidectomy was defined as parathyroidectomy performed within one day of thyroidectomy. Cohorts were compared on demographics, preoperative laboratory values (one year pre-index), pre- and post-operative medication use, and rates of persistent hyperparathyroidism and hypoparathyroidism. Endocrine outcomes were assessed in the early post-operative period (1–90 days) and long-term follow-up (≥90 days post-operation).",
        "Results": "A total of 613 ESRD patients underwent thyroidectomy; 454 (74.1%) underwent thyroidectomy alone, and 159 (25.9%) had concurrent parathyroidectomy. There were no significant between-group differences in age, sex, or preoperative calcium levels. Mean preoperative PTH levels were also comparable (203 vs 168 pg/mL, P=0.2316), although the concurrent parathyroidectomy cohort had more patients with very high PTH levels (>600 pg/mL; 18.7 vs 6.4%). Pre-operative creatinine levels were modestly higher in the concurrent parathyroidectomy group (P=0.003). Cinacalcet use was significantly more common pre-operatively among patients undergoing concurrent parathyroidectomy (57% vs 27%, P<0.0001).",
        "Abstract": "Within 90 days post-operation, concurrent parathyroidectomy was associated with markedly higher rates of severe PTH suppression (PTH <15 pg/mL: 36.5% vs 21.1%, P<0.0001), hypercalcemia >10 mg/dL (36.5% vs 21.2%, P=0.0001), and greater dependency on calcium carbonate (76.7% vs 55.1%, P<0.0001) and calcitriol (74.8% vs 34.6%, P<0.0001). At long-term follow-up (≥90 days), patients who underwent concurrent parathyroidectomy continued to demonstrate higher rates of severe hypoparathyroidism (17.9% vs 9.1%, P=0.0008) and increased calcitriol dependence (42.8% vs 31.1%, P=0.0073). There was no significant difference between the groups in long-term rates of hyperparathyroidism or cinacalcet use; however, cinacalcet use decreased markedly from preoperative levels in the concurrent parathyroidectomy group (12.6% vs 57%). View in Agenda and Add to Schedule",
        "Conclusion": "Although concurrent parathyroidectomy decreases long-term cinacalcet use in ESRD patients undergoing thyroidectomy, it significantly increases the risk of acute and chronic PTH suppression, hypercalcemia episodes, and ongoing calcium and calcitriol supplementation. These findings support selective, indication-driven parathyroid resection during thyroidectomy and highlight the importance of counseling patients on the potential for long-term medication dependence and parathyroid insufficiency following concurrent surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Concurrent Parathyroidectomy During Thyroidectomy in ESRD Patients: Risks, Benefits, and Long-Term Endocrine Outcomes in a Nationwide Cohort</span>. <u>Christian J Leonardo</u>; Patricia Cerri-Droz; Lukasz Czerwonka, MD. SUNY - University at Stony Brook (SSO)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Patients with end-stage renal disease (ESRD) commonly develop thyroid nodules and are frequently treated with medications for secondary hyperparathyroidism. When they require thyroidectomy for treatment of their thyroid nodules, the risk vs benefit profile of adding concurrent parathyroidectomy for definitive management of their secondary hyperparathyroidism is poorly understood. This study evaluates long-term parathyroid function, calcium supplementation, and medication dependence in ESRD patients undergoing thyroidectomy with versus without concurrent parathyroidectomy.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort analysis was conducted using the TriNetX database, a global collaborative network with data from over 128 million patients. Concurrent parathyroidectomy was defined as parathyroidectomy performed within one day of thyroidectomy. Cohorts were compared on demographics, preoperative laboratory values (one year pre-index), pre- and post-operative medication use, and rates of persistent hyperparathyroidism and hypoparathyroidism. Endocrine outcomes were assessed in the early post-operative period (1–90 days) and long-term follow-up (≥90 days post-operation).</p>\n\n<p><strong>Results: </strong>A total of 613 ESRD patients underwent thyroidectomy; 454 (74.1%) underwent thyroidectomy alone, and 159 (25.9%) had concurrent parathyroidectomy. There were no significant between-group differences in age, sex, or preoperative calcium levels. Mean preoperative PTH levels were also comparable (203 vs 168 pg/mL, P=0.2316), although the concurrent parathyroidectomy cohort had more patients with very high PTH levels (>600 pg/mL; 18.7 vs 6.4%). Pre-operative creatinine levels were modestly higher in the concurrent parathyroidectomy group (P=0.003). Cinacalcet use was significantly more common pre-operatively among patients undergoing concurrent parathyroidectomy (57% vs 27%, P<0.0001).</p>\n\n<p>Within 90 days post-operation, concurrent parathyroidectomy was associated with markedly higher rates of severe PTH suppression (PTH <15 pg/mL: 36.5% vs 21.1%, P<0.0001), hypercalcemia >10 mg/dL (36.5% vs 21.2%, P=0.0001), and greater dependency on calcium carbonate (76.7% vs 55.1%, P<0.0001) and calcitriol (74.8% vs 34.6%, P<0.0001).</p>\n\n<p>At long-term follow-up (≥90 days), patients who underwent concurrent parathyroidectomy continued to demonstrate higher rates of severe hypoparathyroidism (17.9% vs 9.1%, P=0.0008) and increased calcitriol dependence (42.8% vs 31.1%, P=0.0073). There was no significant difference between the groups in long-term rates of hyperparathyroidism or cinacalcet use; however, cinacalcet use decreased markedly from preoperative levels in the concurrent parathyroidectomy group (12.6% vs 57%).</p>\n\n<p><strong>Conclusion: </strong>Although concurrent parathyroidectomy decreases long-term cinacalcet use in ESRD patients undergoing thyroidectomy, it significantly increases the risk of acute and chronic PTH suppression, hypercalcemia episodes, and ongoing calcium and calcitriol supplementation. These findings support selective, indication-driven parathyroid resection during thyroidectomy and highlight the importance of counseling patients on the potential for long-term medication dependence and parathyroid insufficiency following concurrent surgery.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154507--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S601",
      "content_id": "154616",
      "abstract_number": "S601",
      "poster_number": "",
      "title": "Surgical Success in Image Concordant Focused Parathyroidectomy",
      "summary": "Our data suggests that at high volume endocrine centers, preoperative concordant imaging of a parathyroid adenoma is sufficient to normalize calcium levels and reduce symptoms in patients with primary hyperparathyroidism. This can help to reduce time spent in the OR and possibly reduce healthcare resource use. Future directions can include a larger cohort, and investigation comparing adverse outcomes between...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154616",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Ethan Meiburg",
      "presenter": "Ethan Meiburg",
      "authors": "Ethan Meiburg ; Nitin Pagedar",
      "normalized_authors": [
        "Ethan Meiburg",
        "Nitin Pagedar"
      ],
      "affiliations": [
        "University of Iowa"
      ],
      "normalized_institutions": [
        "University of Iowa"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 411,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Ethan Meiburg ; Nitin Pagedar",
        "Affiliations": "University of Iowa",
        "Introduction": "Primary hyperparathyroidism is defined as inappropriate secretion of PTH and is usually a result of a single parathyroid adenoma. Surgery remains the first line treatment for parathyroid adenoma. Many surgeons utilize preoperative imaging to Identify abnormal parathyroids, with imaging which may include neck ultrasounds, CT scans, or nuclear scans. Intraoperative PTH (ioPTH) testing is also available as an means of confirming the removal of dysfunctional parathyroid tissue. There is controversy about the optimal utilization of preoperative and intraoperative studies. We sought to characterize the surgical success of focused parathyroidectomy without the use of ioPTH.",
        "Methods": "We identified a retrospective cohort of patients treated with parathyroidectomy for primary hyperparathyroidism by the senior author from January 2020 – April 2025. Patients had two preoperative imaging studies. Patients with concordant imaging studies were offered single gland surgery without ioPTH. We collected data including lab studies at one month and six months postop. This data was then collected into REDCap database for analysis. Surgical success was defined as normalization of the patient’s calcium levels at 6 month follow up.",
        "Results": "We identified 160 patients who had parathyroidectomy during this time period, 37 of whom met study inclusion criteria. Of the 37 patients who had focused parathyroidectomy, 35 (94.6%) had normalization of their calcium levels 6 months post operatively. The two patients whose calcium levels did not normalize had resolution of their symptoms. 36 (97.3%) of patients had a preoperative ultrasound localization. 21 (56.8%) had CT scan imaging localization. 21 (56.8%) had nuclear medicine localization scans preoperatively. Furthermore, 20 (54.1%) had ultrasound and CT scan concordant imaging localization. 21 (56.8%) had ultrasound and nuclear medicine scan concordant imaging localization. 1 (2.7%) had nuclear medicine and CT scan concordant imaging localization. 6 (16.2%) patients had all three imaging modalities with concordant localization. Of the two patients whose 6 month post operative PTH did not normalize, 1 (50%) had all three imaging modalities, and 1(50%) had ultrasound and CT scan concordant imaging localization.",
        "Conclusion": "Our data suggests that at high volume endocrine centers, preoperative concordant imaging of a parathyroid adenoma is sufficient to normalize calcium levels and reduce symptoms in patients with primary hyperparathyroidism. This can help to reduce time spent in the OR and possibly reduce healthcare resource use. Future directions can include a larger cohort, and investigation comparing adverse outcomes between ioPTH and focused parathyroidectomies to determine safety profile of the focused parathyroidectomy.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Surgical Success in Image Concordant Focused Parathyroidectomy</span>. <u>Ethan Meiburg</u>; Nitin Pagedar. University of Iowa<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Primary hyperparathyroidism is defined as inappropriate secretion of PTH and is usually a result of a single parathyroid adenoma. Surgery remains the first line treatment for parathyroid adenoma. Many surgeons utilize preoperative imaging to Identify abnormal parathyroids, with imaging which may include neck ultrasounds, CT scans, or nuclear scans. Intraoperative PTH (ioPTH) testing is also available as an means of confirming the removal of dysfunctional parathyroid tissue. There is controversy about the optimal utilization of preoperative and intraoperative studies. We sought to characterize the surgical success of focused parathyroidectomy without the use of ioPTH.</p>\n\n<p><strong>Methods: </strong>We identified a retrospective cohort of patients treated with parathyroidectomy for primary hyperparathyroidism by the senior author from January 2020 – April 2025. Patients had two preoperative imaging studies. Patients with concordant imaging studies were offered single gland surgery without ioPTH. We collected data including lab studies at one month and six months postop. This data was then collected into REDCap database for analysis. Surgical success was defined as normalization of the patient’s calcium levels at 6 month follow up.</p>\n\n<p><strong>Results: </strong>We identified 160 patients who had parathyroidectomy during this time period, 37 of whom met study inclusion criteria. Of the 37 patients who had focused parathyroidectomy, 35 (94.6%) had normalization of their calcium levels 6 months post operatively. The two patients whose calcium levels did not normalize had resolution of their symptoms. 36 (97.3%) of patients had a preoperative ultrasound localization. 21 (56.8%) had CT scan imaging localization. 21 (56.8%) had nuclear medicine localization scans preoperatively. Furthermore, 20 (54.1%) had ultrasound and CT scan concordant imaging localization. 21 (56.8%) had ultrasound and nuclear medicine scan concordant imaging localization. 1 (2.7%) had nuclear medicine and CT scan concordant imaging localization. 6 (16.2%) patients had all three imaging modalities with concordant localization. Of the two patients whose 6 month post operative PTH did not normalize, 1 (50%) had all three imaging modalities, and 1(50%) had ultrasound and CT scan concordant imaging localization.</p>\n\n<p><strong>Conclusion: </strong>Our data suggests that at high volume endocrine centers, preoperative concordant imaging of a parathyroid adenoma is sufficient to normalize calcium levels and reduce symptoms in patients with primary hyperparathyroidism. This can help to reduce time spent in the OR and possibly reduce healthcare resource use. Future directions can include a larger cohort, and investigation comparing adverse outcomes between ioPTH and focused parathyroidectomies to determine safety profile of the focused parathyroidectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154616--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S602",
      "content_id": "152181",
      "abstract_number": "S602",
      "poster_number": "",
      "title": "Association of Parathyroidectomy with Incident Diabetes in Patients with Primary Hyperparathyroidism: A U.S. Multi-Institutional Cohort Study",
      "summary": "Our findings suggest that parathyroidectomy is associated with lower odds of incident diabetes in patients with primary hyperparathyroidism. This association was consistent across all subgroups, including in adults over age 65. While more studies are needed, our findings suggest an additional benefit to consider in the definitive treatment of primary hyperparathyroidism.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=152181",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Albert Li, BA",
      "presenter": "Albert Li, BA",
      "authors": "Zachary E Thompson, BS; Oluwatobiloba Ayo-Ajibola, BS; Albert Li, BA ; Chinazo Onyema, BA; Daniel I Kwon, MD",
      "normalized_authors": [
        "Zachary E Thompson",
        "Oluwatobiloba Ayo-Ajibola",
        "Albert Li",
        "Chinazo Onyema",
        "Daniel I Kwon"
      ],
      "affiliations": [
        "University of Southern California Keck School of Medicine"
      ],
      "normalized_institutions": [
        "University of Southern California Keck School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 516,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Zachary E Thompson, BS; Oluwatobiloba Ayo-Ajibola, BS; Albert Li, BA ; Chinazo Onyema, BA; Daniel I Kwon, MD",
        "Affiliations": "University of Southern California Keck School of Medicine",
        "Introduction": "Primary hyperparathyroidism is a common endocrine condition that often presents with mild or asymptomatic disease. Although surgical treatment is definitive, observation is frequently chosen, given the indolent course of the disease. Hyperparathyroidism, however, is associated with hypercalcemia and its many systemic manifestations. While hyperparathyroidism has a known association with insulin resistance, no prior study has evaluated the association between parathyroidectomy and incident diabetes within the diverse U.S. population. Understanding the potential implications of long-term hyperparathyroidism in this population is important, particularly in cases where the risks and benefits of treatment are equivocal. This retrospective propensity score-matched study evaluated whether parathyroidectomy is associated with reduced diabetes incidence among U.S. adults with primary hyperparathyroidism.",
        "Methods": "The TriNetX multi-institutional U.S. Collaborative Network research database was queried for U.S. adults ≥18 years with hyperparathyroidism as defined by ICD-10 code (E21.0). Exclusion criteria included a history of MEN-1, MEN-2, secondary, tertiary, or other hyperparathyroidism (E21.1, E21.2, E21.3, E21.4, E21.5, N25.81, N25.89), thyroid or parathyroid neoplasms, dialysis, nephrectomy, or use of bisphosphonates, cinacalcet, thiazides, or lithium. The exposure cohort included patients who underwent parathyroidectomy within five years of hyperparathyroidism diagnosis. The control cohort included patients with no history of parathyroidectomy. Propensity score matching based on demographics and comorbidities was conducted, and a standardized mean difference <0.1 was considered acceptable. The primary outcome was the odds of incident diabetes defined by ICD-10 codes (E08, E11) within five years of the index event. The index event was the date of surgery for the exposure cohort and the date of diagnosis for the control cohort. Individuals with the outcome of interest prior to the index event were excluded. Subanalyses, including by age and sex, were performed. Additional analyses comparing time to surgery were also performed. Odds ratios were assessed using z-scores with p-values ≤0.05 considered to be significant.",
        "Results": "After matching, 6,035 patients were included in each cohort. Parathyroidectomy was associated with 43% lower odds of diabetes compared with no surgery (OR, 0.67; 95% CI: 0.54 – 0.82). When diabetes was defined as A1C ≥6.5%, results were similar, with 37% lower odds (OR, 0.63; 95% CI: 0.50 – 0.79). Subanalyses including patients ≤65 (OR, 0.49; 95% CI: 0.34 – 0.70), patients >65 (OR, 0.67; 95% CI: 0.48 – 0.93), female patients (OR, 0.73; 95% CI: 0.59 – 0.90), and male patients (OR, 0.49; 95% CI: 0.33 – 0.73) also showed significant differences between cohorts. In a separate analysis, patients who had surgery within 1 year of hyperparathyroidism diagnosis also had lower odds of diabetes compared with those who did not have surgery (OR, 0.59; 95% CI: 0.46 – 0.75).",
        "Conclusion": "Our findings suggest that parathyroidectomy is associated with lower odds of incident diabetes in patients with primary hyperparathyroidism. This association was consistent across all subgroups, including in adults over age 65. While more studies are needed, our findings suggest an additional benefit to consider in the definitive treatment of primary hyperparathyroidism.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association of Parathyroidectomy with Incident Diabetes in Patients with Primary Hyperparathyroidism: A U.S. Multi-Institutional Cohort Study</span>. Zachary E Thompson, BS; Oluwatobiloba Ayo-Ajibola, BS; <u>Albert Li, BA</u>; Chinazo Onyema, BA; Daniel I Kwon, MD. University of Southern California Keck School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Primary hyperparathyroidism is a common endocrine condition that often presents with mild or asymptomatic disease. Although surgical treatment is definitive, observation is frequently chosen, given the indolent course of the disease. Hyperparathyroidism, however, is associated with hypercalcemia and its many systemic manifestations. While hyperparathyroidism has a known association with insulin resistance, no prior study has evaluated the association between parathyroidectomy and incident diabetes within the diverse U.S. population. Understanding the potential implications of long-term hyperparathyroidism in this population is important, particularly in cases where the risks and benefits of treatment are equivocal. This retrospective propensity score-matched study evaluated whether parathyroidectomy is associated with reduced diabetes incidence among U.S. adults with primary hyperparathyroidism.</p>\n\n<p><strong>Methods: </strong>The TriNetX multi-institutional U.S. Collaborative Network research database was queried for U.S. adults ≥18 years with hyperparathyroidism as defined by ICD-10 code (E21.0). Exclusion criteria included a history of MEN-1, MEN-2, secondary, tertiary, or other hyperparathyroidism (E21.1, E21.2, E21.3, E21.4, E21.5, N25.81, N25.89), thyroid or parathyroid neoplasms, dialysis, nephrectomy, or use of bisphosphonates, cinacalcet, thiazides, or lithium. The exposure cohort included patients who underwent parathyroidectomy within five years of hyperparathyroidism diagnosis. The control cohort included patients with no history of parathyroidectomy. Propensity score matching based on demographics and comorbidities was conducted, and a standardized mean difference <0.1 was considered acceptable. The primary outcome was the odds of incident diabetes defined by ICD-10 codes (E08, E11) within five years of the index event. The index event was the date of surgery for the exposure cohort and the date of diagnosis for the control cohort. Individuals with the outcome of interest prior to the index event were excluded. Subanalyses, including by age and sex, were performed. Additional analyses comparing time to surgery were also performed. Odds ratios were assessed using z-scores with p-values ≤0.05 considered to be significant.</p>\n\n<p><strong>Results: </strong>After matching, 6,035 patients were included in each cohort. Parathyroidectomy was associated with 43% lower odds of diabetes compared with no surgery (OR, 0.67; 95% CI: 0.54 – 0.82). When diabetes was defined as A1C ≥6.5%, results were similar, with 37% lower odds (OR, 0.63; 95% CI: 0.50 – 0.79). Subanalyses including patients ≤65 (OR, 0.49; 95% CI: 0.34 – 0.70), patients >65 (OR, 0.67; 95% CI: 0.48 – 0.93), female patients (OR, 0.73; 95% CI: 0.59 – 0.90), and male patients (OR, 0.49; 95% CI: 0.33 – 0.73) also showed significant differences between cohorts. In a separate analysis, patients who had surgery within 1 year of hyperparathyroidism diagnosis also had lower odds of diabetes compared with those who did not have surgery (OR, 0.59; 95% CI: 0.46 – 0.75).</p>\n\n<p><strong>Conclusion: </strong>Our findings suggest that parathyroidectomy is associated with lower odds of incident diabetes in patients with primary hyperparathyroidism. This association was consistent across all subgroups, including in adults over age 65. While more studies are needed, our findings suggest an additional benefit to consider in the definitive treatment of primary hyperparathyroidism.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 152181--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S603",
      "content_id": "153147",
      "abstract_number": "S603",
      "poster_number": "",
      "title": "Pre-Operative Risk Factors Associated with Hypocalcemia Following Surgical Intervention for Primary Hyperparathyroidism",
      "summary": "Postoperative hypocalcemia occurred in nearly one-third of patients following parathyroidectomy for primary hyperparathyroidism. Osteoporosis, elevated preoperative PTH, ipsilateral thyroid nodules, and challenging gland localizations were significant predictors of this complication. These findings highlight the importance of preoperative bone health optimization, careful surgical planning in anatomically complex...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153147",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Christian J Leonardo",
      "presenter": "Christian J Leonardo",
      "authors": "Christian J Leonardo ; Radhika Patel; Haeun Jung; David Shimunov, MD; Christopher Vanison, MD",
      "normalized_authors": [
        "Christian J Leonardo",
        "Radhika Patel",
        "Haeun Jung",
        "David Shimunov",
        "Christopher Vanison"
      ],
      "affiliations": [
        "SUNY - University at Stony Brook (SSO)"
      ],
      "normalized_institutions": [
        "SUNY - University at Stony Brook (SSO)"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 408,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Christian J Leonardo ; Radhika Patel; Haeun Jung; David Shimunov, MD; Christopher Vanison, MD",
        "Affiliations": "SUNY - University at Stony Brook (SSO)",
        "Introduction": "Parathyroidectomy is the definitive treatment for primary hyperparathyroidism; however, postoperative hypocalcemia remains a common and sometimes clinically significant complication. This condition, characterized by perioral numbness, paresthesias, or muscle cramping, can prolong hospitalization and impair quality of life. Despite the high surgical volume of parathyroidectomies performed annually, the population most at risk of postoperative hypocalcemia remains poorly defined. To our knowledge, this is the largest study to date to examine preoperative risk factors associated with the development of clinically significant hypocalcemia following parathyroidectomy for primary hyperparathyroidism.",
        "Methods": "A retrospective chart review was conducted of adult patients who underwent parathyroidectomy for primary hyperparathyroidism at Stony Brook University Hospital (Long Island, New York) between 2013 and 2023. After applying inclusion and exclusion criteria, 384 patients were analyzed. Data were extracted from Cerner electronic medical records, entered into a RedCap database, and analyzed using SPSS. Clinically significant postoperative hypocalcemia was defined as serum calcium ≤8.5 mg/dL requiring calcium supplementation. Univariate analyses were performed, followed by multivariate logistic regression including variables with p ≤ 0.25 to identify independent predictors of hypocalcemia.",
        "Results": "The cohort’s mean age was 60.7 ± 13.6 years; 75.5% were female, and 85.7% identified as White. The incidence of postoperative hypocalcemia was 30.05%. Patients who developed hypocalcemia had significantly higher mean preoperative PTH levels (144.9 ± 175.4 pg/mL vs. 118.0 ± 72.4 pg/mL; p = 0.036) and lower 24-hour urine calcium levels (276.7 ± 165.0 mg/day vs. 337.3 ± 185.1; p = 0.044). On multivariate analysis, independent predictors of postoperative hypocalcemia included osteoporosis (OR 2.43; 95% CI 1.35-4.40; p = 0.003), elevated preoperative PTH (OR 1.00; 95% CI 1.00-1.01; p = 0.007), ipsilateral thyroid nodules (OR 2.04; 95% CI 1.15-3.59; p = 0.014), right upper gland localization (OR 2.82; 95% CI 1.07-7.38; p = 0.035), and other complex gland localizations (OR 2.58; 95% CI 1.14-5.85; p = 0.023).",
        "Conclusion": "Postoperative hypocalcemia occurred in nearly one-third of patients following parathyroidectomy for primary hyperparathyroidism. Osteoporosis, elevated preoperative PTH, ipsilateral thyroid nodules, and challenging gland localizations were significant predictors of this complication. These findings highlight the importance of preoperative bone health optimization, careful surgical planning in anatomically complex cases, and individualized postoperative calcium management. Incorporating these variables into preoperative risk assessment models may improve perioperative care and reduce hypocalcemia-related morbidity.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Pre-Operative Risk Factors Associated with Hypocalcemia Following Surgical Intervention for Primary Hyperparathyroidism</span>. <u>Christian J Leonardo</u>; Radhika Patel; Haeun Jung; David Shimunov, MD; Christopher Vanison, MD. SUNY - University at Stony Brook (SSO)<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Parathyroidectomy is the definitive treatment for primary hyperparathyroidism; however, postoperative hypocalcemia remains a common and sometimes clinically significant complication. This condition, characterized by perioral numbness, paresthesias, or muscle cramping, can prolong hospitalization and impair quality of life. Despite the high surgical volume of parathyroidectomies performed annually, the population most at risk of postoperative hypocalcemia remains poorly defined. To our knowledge, this is the largest study to date to examine preoperative risk factors associated with the development of clinically significant hypocalcemia following parathyroidectomy for primary hyperparathyroidism.</p>\n\n<p><strong>Methods: </strong>A retrospective chart review was conducted of adult patients who underwent parathyroidectomy for primary hyperparathyroidism at Stony Brook University Hospital (Long Island, New York) between 2013 and 2023. After applying inclusion and exclusion criteria, 384 patients were analyzed. Data were extracted from Cerner electronic medical records, entered into a RedCap database, and analyzed using SPSS. Clinically significant postoperative hypocalcemia was defined as serum calcium ≤8.5 mg/dL requiring calcium supplementation. Univariate analyses were performed, followed by multivariate logistic regression including variables with p ≤ 0.25 to identify independent predictors of hypocalcemia.</p>\n\n<p><strong>Results: </strong>The cohort’s mean age was 60.7 ± 13.6 years; 75.5% were female, and 85.7% identified as White. The incidence of postoperative hypocalcemia was 30.05%. Patients who developed hypocalcemia had significantly higher mean preoperative PTH levels (144.9 ± 175.4 pg/mL vs. 118.0 ± 72.4 pg/mL; p = 0.036) and lower 24-hour urine calcium levels (276.7 ± 165.0 mg/day vs. 337.3 ± 185.1; p = 0.044). On multivariate analysis, independent predictors of postoperative hypocalcemia included osteoporosis (OR 2.43; 95% CI 1.35-4.40; p = 0.003), elevated preoperative PTH (OR 1.00; 95% CI 1.00-1.01; p = 0.007), ipsilateral thyroid nodules (OR 2.04; 95% CI 1.15-3.59; p = 0.014), right upper gland localization (OR 2.82; 95% CI 1.07-7.38; p = 0.035), and other complex gland localizations (OR 2.58; 95% CI 1.14-5.85; p = 0.023).</p>\n\n<p><strong>Conclusion: </strong>Postoperative hypocalcemia occurred in nearly one-third of patients following parathyroidectomy for primary hyperparathyroidism. Osteoporosis, elevated preoperative PTH, ipsilateral thyroid nodules, and challenging gland localizations were significant predictors of this complication. These findings highlight the importance of preoperative bone health optimization, careful surgical planning in anatomically complex cases, and individualized postoperative calcium management. Incorporating these variables into preoperative risk assessment models may improve perioperative care and reduce hypocalcemia-related morbidity.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153147--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S604",
      "content_id": "154706",
      "abstract_number": "S604",
      "poster_number": "",
      "title": "Ethnicity as a Critical Predictor of Increased Risk after Thyroid Surgery Not Adequately Predicted by a Standard Frailty Scoring System",
      "summary": "These results indicate that while Hispanic patients are in general considered to be less frail according to mFI-5 scores, they are at higher risk for poorer outcomes when specifically considering hypocalcemia with prolonged length of stay following total thyroidectomy surgery. This disconnect suggests that frailty, as currently measured, may not fully capture the post-surgical risks faced by certain ethnic...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154706",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aruni Areti, BA",
      "presenter": "Aruni Areti, BA",
      "authors": "Aruni Areti, BA ; Angela D Haskins, MD",
      "normalized_authors": [
        "Aruni Areti",
        "Angela D Haskins"
      ],
      "affiliations": [
        "Baylor College of Medicine"
      ],
      "normalized_institutions": [
        "Baylor College of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 392,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Conclusion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Aruni Areti, BA ; Angela D Haskins, MD",
        "Affiliations": "Baylor College of Medicine",
        "Introduction": "Hispanic patients have been shown to experience worse outcomes after thyroid surgery compared to White patients. Higher 5-item Modified Frailty Index (mFI-5) scores have been consistently linked to increased postoperative risk after thyroidectomy; however, no studies to date have examined whether frailty burden differs by ethnicity, nor whether the predictive strength of frailty for adverse outcomes is equivalent across ethnic groups. In this study, we sought to determine whether Hispanic patients are at risk for worse outcomes after thyroid surgery, specifically investigating risk of hypocalcemia with extended length of hospital stay, and whether mFI-5 scores correlate directly with this disparity. Understanding whether mFI-5 performs differently by ethnicity is critical, as frailty indices are increasingly used to guide surgical decision-making, risk counseling, and postoperative monitoring in thyroid surgery.",
        "Methods": "We conducted a retrospective cohort study of all patients undergoing thyroid surgery from 2022 to 2024 at a large safety-net county hospital. The primary outcome investigated was postoperative hypocalcemia with prolonged hospital stay following surgery, as defined by hospitalization greater than 23 hours. Demographic and clinical data were abstracted from the electronic health record required to calculate mFI-5 scores. Patients were grouped as Hispanic and non-Hispanic, and outcomes were compared between these groups using univariate and multivariable logistic analyses.",
        "Results": "A total of 215 patients underwent thyroidectomy, of whom 150 (69.8%) were Hispanic. Among patients undergoing total thyroidectomy (n = 142), Hispanic ethnicity was associated with higher odds of hospitalization with prolonged length of stay (OR 2.91, 95% CI 1.29–6.54, p = 0.010). Mean mFI-5 scores were significantly lower among Hispanic patients compared to non-Hispanic patients undergoing thyroid surgery (1.10 ± 0.95 vs. 1.49 ± 1.05, p = 0.011).",
        "Conclusion": "These results indicate that while Hispanic patients are in general considered to be less frail according to mFI-5 scores, they are at higher risk for poorer outcomes when specifically considering hypocalcemia with prolonged length of stay following total thyroidectomy surgery. This disconnect suggests that frailty, as currently measured, may not fully capture the post-surgical risks faced by certain ethnic groups. Our findings highlight that ethnicity itself remains an independent and clinically relevant predictor of risk—even when frailty scores do not differ. We suggest further development of updated risk models which incorporate additional relevant social determinants of health when caring for different ethnic groups.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Ethnicity as a Critical Predictor of Increased Risk after Thyroid Surgery Not Adequately Predicted by a Standard Frailty Scoring System</span>. <u>Aruni Areti, BA</u>; Angela D Haskins, MD. Baylor College of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction: </strong>Hispanic patients have been shown to experience worse outcomes after thyroid surgery compared to White patients. Higher 5-item Modified Frailty Index (mFI-5) scores have been consistently linked to increased postoperative risk after thyroidectomy; however, no studies to date have examined whether frailty burden differs by ethnicity, nor whether the predictive strength of frailty for adverse outcomes is equivalent across ethnic groups. In this study, we sought to determine whether Hispanic patients are at risk for worse outcomes after thyroid surgery, specifically investigating risk of hypocalcemia with extended length of hospital stay, and whether mFI-5 scores correlate directly with this disparity. Understanding whether mFI-5 performs differently by ethnicity is critical, as frailty indices are increasingly used to guide surgical decision-making, risk counseling, and postoperative monitoring in thyroid surgery.</p>\n\n<p><strong>Methods: </strong>We conducted a retrospective cohort study of all patients undergoing thyroid surgery from 2022 to 2024 at a large safety-net county hospital. The primary outcome investigated was postoperative hypocalcemia with prolonged hospital stay following surgery, as defined by hospitalization greater than 23 hours. Demographic and clinical data were abstracted from the electronic health record required to calculate mFI-5 scores. Patients were grouped as Hispanic and non-Hispanic, and outcomes were compared between these groups using univariate and multivariable logistic analyses.</p>\n\n<p><strong>Results: </strong>A total of 215 patients underwent thyroidectomy, of whom 150 (69.8%) were Hispanic. Among patients undergoing total thyroidectomy (n = 142), Hispanic ethnicity was associated with higher odds of hospitalization with prolonged length of stay (OR 2.91, 95% CI 1.29–6.54, p = 0.010). Mean mFI-5 scores were significantly lower among Hispanic patients compared to non-Hispanic patients undergoing thyroid surgery (1.10 ± 0.95 vs. 1.49 ± 1.05, p = 0.011).</p>\n\n<p><strong>Conclusion: </strong>These results indicate that while Hispanic patients are in general considered to be less frail according to mFI-5 scores, they are at higher risk for poorer outcomes when specifically considering hypocalcemia with prolonged length of stay following total thyroidectomy surgery. This disconnect suggests that frailty, as currently measured, may not fully capture the post-surgical risks faced by certain ethnic groups. Our findings highlight that ethnicity itself remains an independent and clinically relevant predictor of risk—even when frailty scores do not differ. We suggest further development of updated risk models which incorporate additional relevant social determinants of health when caring for different ethnic groups.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154706--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S605",
      "content_id": "151959",
      "abstract_number": "S605",
      "poster_number": "",
      "title": "Association Between the Modified Frailty Index and Short-Term Complications Following Total Thyroidectomy: A National Database Study",
      "summary": "Higher mFI-5 scores were independently associated with increased odds of multiple postoperative complications following total thyroidectomy, including hypocalcemia, vocal cord paralysis, hematoma, surgical-site infection, and emergency department admission. These findings highlight the importance of frailty as a clinically meaningful predictor of surgical risk beyond chronological age or isolated comorbidities....",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151959",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tyler Jung",
      "presenter": "Tyler Jung",
      "authors": "Tyler Jung 1 ; Eman Ahmad, BS 1 ; Oluwatobiloba Ayo-Ajibola 1 ; Matthew E Lin, MD 2 ; Lauran K Evans, MD, MPH 2 ; Carlos X Castellanos 2 ; Josef Madrigal, MD 2 ; Ian Kim, PhD 3 ; Dinesh K Chhetri, MD 2 ; Peter S Han, MD 2",
      "normalized_authors": [
        "Tyler Jung",
        "Eman Ahmad",
        "Oluwatobiloba Ayo-Ajibola",
        "Matthew E Lin",
        "Lauran K Evans",
        "Carlos X Castellanos",
        "Josef Madrigal",
        "Ian Kim",
        "Dinesh K Chhetri",
        "Peter S Han"
      ],
      "affiliations": [
        "Keck School of Medicine of USC",
        "UCLA Department of Head and Neck Surgery",
        "Stanford Department of Pediatrics"
      ],
      "normalized_institutions": [
        "Keck School of Medicine of USC",
        "UCLA Department of Head and Neck Surgery",
        "Stanford Department of Pediatrics"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 563,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Methods",
        "Results",
        "Abstract",
        "Conclusion"
      ],
      "sections": {
        "Authors": "Tyler Jung 1 ; Eman Ahmad, BS 1 ; Oluwatobiloba Ayo-Ajibola 1 ; Matthew E Lin, MD 2 ; Lauran K Evans, MD, MPH 2 ; Carlos X Castellanos 2 ; Josef Madrigal, MD 2 ; Ian Kim, PhD 3 ; Dinesh K Chhetri, MD 2 ; Peter S Han, MD 2",
        "Affiliations": "1 Keck School of Medicine of USC; 2 UCLA Department of Head and Neck Surgery; 3 Stanford Department of Pediatrics",
        "Objective": "The Modified Frailty Index-5 (mFI-5) is a validated measure of physiological vulnerability increasingly used for surgical risk assessment. This study evaluated the predictive value of the mFI-5 for short-term postoperative complications following total thyroidectomy.",
        "Methods": "A retrospective cohort analysis was performed using the TriNetX U.S. Collaborative Network, which aggregates de-identified electronic health records from 67 healthcare organizations across the United States. Adult patients who underwent total thyroidectomy (CPT 60240) between 2006 and 2025 were identified. Frailty was assessed using the mFI-5, assigning one point each for the presence of hypertension, diabetes mellitus, chronic obstructive pulmonary disease, heart failure, or dependency status, resulting in frailty strata of 0, 1, 2, or ≥3. Propensity score matching (1:1) was employed to balance demographic and clinical variables between frail and non-frail cohorts. Postoperative outcomes within 30 days included hypocalcemia, vocal cord paralysis, surgical-site infection, hematoma, tracheostomy, emergency department (ED) admission, and mortality. Odds ratios (OR) with 95% confidence intervals (CI) were estimated using Poisson regression, comparing each frailty category (≥1) to the non-frail reference group (mFI-5=0).",
        "Results": "A total of 65,866 patients met inclusion criteria, with 44.6% (n=29,391) demonstrating an mFI-5 score of at least one. Increasing frailty was significantly associated with a greater likelihood of postoperative complications. The odds of hypocalcemia rose progressively with frailty, from mFI-5=1 (OR=1.22, 95% CI 1.14–1.32) and mFI-5=2 (OR=1.27, 95% CI 1.14–1.41) to mFI-5≥3 (OR=1.59, 95% CI 1.29–1.95). Vocal cord paralysis and postoperative neck hematoma were significantly elevated at mFI-5≥3 (OR=2.27, 95% CI 1.49–3.46; OR=2.60, 95% CI 1.45–4.64, respectively). Surgical-site infection (OR=1.93, 95% CI 1.20–3.10) and tracheostomy (OR=2.00, 95% CI 1.08–3.73) risks were highest in the mFI-5=2 group. ED admissions demonstrated a stepwise relationship with frailty, increasing from mFI-5=1 (OR=1.36, 95% CI 1.23–1.51) to mFI-5≥3 (OR=2.28, 95% CI 1.72–3.03).",
        "Abstract": "When examined individually, COPD, heart failure, and dependency were each associated with higher odds of hypocalcemia (OR=1.44, 95% CI 1.09–1.90; OR=1.61, 95% CI 1.14–2.26; and OR=1.96, 95% CI 1.05–3.66, respectively). COPD was also linked to increased vocal cord paralysis (OR=1.96, 95% CI 1.07–3.61), while hypertension and diabetes were associated with postoperative infection (OR=1.48, 95% CI 1.05–2.10 and OR=2.19, 95% CI 1.07–4.47). All four–hypertension, diabetes, COPD, and heart failure–were linked to greater risk of ED admission. Due to extensive matching across mFI-5 variables, sample sizes were limited for some outcomes, particularly tracheostomy and smaller comorbidity groups. Mortality remained infrequent across all cohorts. View in Agenda and Add to Schedule",
        "Conclusion": "Higher mFI-5 scores were independently associated with increased odds of multiple postoperative complications following total thyroidectomy, including hypocalcemia, vocal cord paralysis, hematoma, surgical-site infection, and emergency department admission. These findings highlight the importance of frailty as a clinically meaningful predictor of surgical risk beyond chronological age or isolated comorbidities. Incorporating mFI-5–based frailty screening into standard preoperative workflows may enable more precise perioperative planning, tailored postoperative monitoring, and improved shared decision-making for patients undergoing thyroidectomy."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Association Between the Modified Frailty Index and Short-Term Complications Following Total Thyroidectomy: A National Database Study</span>. <u>Tyler Jung</u><sup>1</sup>; Eman Ahmad, BS<sup>1</sup>; Oluwatobiloba Ayo-Ajibola<sup>1</sup>; Matthew E Lin, MD<sup>2</sup>; Lauran K Evans, MD, MPH<sup>2</sup>; Carlos X Castellanos<sup>2</sup>; Josef Madrigal, MD<sup>2</sup>; Ian Kim, PhD<sup>3</sup>; Dinesh K Chhetri, MD<sup>2</sup>; Peter S Han, MD<sup>2</sup>. <sup>1</sup>Keck School of Medicine of USC; <sup>2</sup>UCLA Department of Head and Neck Surgery; <sup>3</sup>Stanford Department of Pediatrics<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective: </strong>The Modified Frailty Index-5 (mFI-5) is a validated measure of physiological vulnerability increasingly used for surgical risk assessment. This study evaluated the predictive value of the mFI-5 for short-term postoperative complications following total thyroidectomy.</p>\n\n<p><strong>Methods: </strong>A retrospective cohort analysis was performed using the TriNetX U.S. Collaborative Network, which aggregates de-identified electronic health records from 67 healthcare organizations across the United States. Adult patients who underwent total thyroidectomy (CPT 60240) between 2006 and 2025 were identified. Frailty was assessed using the mFI-5, assigning one point each for the presence of hypertension, diabetes mellitus, chronic obstructive pulmonary disease, heart failure, or dependency status, resulting in frailty strata of 0, 1, 2, or ≥3. Propensity score matching (1:1) was employed to balance demographic and clinical variables between frail and non-frail cohorts. Postoperative outcomes within 30 days included hypocalcemia, vocal cord paralysis, surgical-site infection, hematoma, tracheostomy, emergency department (ED) admission, and mortality. Odds ratios (OR) with 95% confidence intervals (CI) were estimated using Poisson regression, comparing each frailty category (≥1) to the non-frail reference group (mFI-5=0).</p>\n\n<p><strong>Results: </strong>A total of 65,866 patients met inclusion criteria, with 44.6% (n=29,391) demonstrating an mFI-5 score of at least one. Increasing frailty was significantly associated with a greater likelihood of postoperative complications. The odds of hypocalcemia rose progressively with frailty, from mFI-5=1 (OR=1.22, 95% CI 1.14–1.32) and mFI-5=2 (OR=1.27, 95% CI 1.14–1.41) to mFI-5≥3 (OR=1.59, 95% CI 1.29–1.95). Vocal cord paralysis and postoperative neck hematoma were significantly elevated at mFI-5≥3 (OR=2.27, 95% CI 1.49–3.46; OR=2.60, 95% CI 1.45–4.64, respectively). Surgical-site infection (OR=1.93, 95% CI 1.20–3.10) and tracheostomy (OR=2.00, 95% CI 1.08–3.73) risks were highest in the mFI-5=2 group. ED admissions demonstrated a stepwise relationship with frailty, increasing from mFI-5=1 (OR=1.36, 95% CI 1.23–1.51) to mFI-5≥3 (OR=2.28, 95% CI 1.72–3.03).</p>\n\n<p>When examined individually, COPD, heart failure, and dependency were each associated with higher odds of hypocalcemia (OR=1.44, 95% CI 1.09–1.90; OR=1.61, 95% CI 1.14–2.26; and OR=1.96, 95% CI 1.05–3.66, respectively). COPD was also linked to increased vocal cord paralysis (OR=1.96, 95% CI 1.07–3.61), while hypertension and diabetes were associated with postoperative infection (OR=1.48, 95% CI 1.05–2.10 and OR=2.19, 95% CI 1.07–4.47). All four–hypertension, diabetes, COPD, and heart failure–were linked to greater risk of ED admission. Due to extensive matching across mFI-5 variables, sample sizes were limited for some outcomes, particularly tracheostomy and smaller comorbidity groups. Mortality remained infrequent across all cohorts.</p>\n\n<p><strong>Conclusion: </strong>Higher mFI-5 scores were independently associated with increased odds of multiple postoperative complications following total thyroidectomy, including hypocalcemia, vocal cord paralysis, hematoma, surgical-site infection, and emergency department admission. These findings highlight the importance of frailty as a clinically meaningful predictor of surgical risk beyond chronological age or isolated comorbidities. Incorporating mFI-5–based frailty screening into standard preoperative workflows may enable more precise perioperative planning, tailored postoperative monitoring, and improved shared decision-making for patients undergoing thyroidectomy.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151959--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S606",
      "content_id": "151883",
      "abstract_number": "S606",
      "poster_number": "",
      "title": "Completion Thyroidectomy vs. Observation Following Lobectomy for Patients with Thyroid Cancer > 4cm on Final Pathology",
      "summary": "This study, which includes a majority of cases that are not PTC (65% of cases are oncocytic or follicular carcinoma), provides a nuanced view of observation as an alternative to completion thyroidectomy for select cases of tumors >4cm. There were no cases of recurrence among those managed with observation following thyroid lobectomy, indicating that this may be sufficient treatment in certain subgroups while...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=151883",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Aviva Mattingly",
      "presenter": "Aviva Mattingly",
      "authors": "Aviva Mattingly ; Whitney Jin; Andreja Radevic; Joaquin Austerlitz; Andrea Lopez; Vivian Weiss; Matthew Gonzalez; Lindsay Bischoff; Sarah Rohde",
      "normalized_authors": [
        "Aviva Mattingly",
        "Whitney Jin",
        "Andreja Radevic",
        "Joaquin Austerlitz",
        "Andrea Lopez",
        "Vivian Weiss",
        "Matthew Gonzalez",
        "Lindsay Bischoff",
        "Sarah Rohde"
      ],
      "affiliations": [
        "Vanderbilt University Medical Center"
      ],
      "normalized_institutions": [
        "Vanderbilt University Medical Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 506,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Background",
        "Methods",
        "Results",
        "Abstract",
        "Conclusions"
      ],
      "sections": {
        "Authors": "Aviva Mattingly ; Whitney Jin; Andreja Radevic; Joaquin Austerlitz; Andrea Lopez; Vivian Weiss; Matthew Gonzalez; Lindsay Bischoff; Sarah Rohde",
        "Affiliations": "Vanderbilt University Medical Center",
        "Background": "According to the 2025 American Thyroid Association guidelines, initial management for patients with thyroid cancer >4 cm is total thyroidectomy. However, for nodules that are indeterminate on imaging or preoperative fine needle aspiration (FNA), management may include diagnostic thyroid lobectomy. We investigated management decisions for patients who initially underwent lobectomy for any thyroid nodule but were found to have a thyroid malignancy >4cm and compared outcomes for those receiving immediate completion total thyroidectomy vs observation.",
        "Methods": "Patients were retrospectively identified through surgical pathology reports 2017-2025 at a single institution. Patients undergoing thyroid lobectomy found to have >4cm thyroid cancer on final pathology were included. Anyone with a planned total thyroidectomy that was staged due to intraoperative factors was excluded. There was no exclusion criteria based on histology or other pathology factors.",
        "Results": "A total of 36 cases met study criteria of which 50% underwent immediate completion thyroidectomy and 50% underwent observation, with a mean follow up of 29 months across the cohort. Preoperatively, median nodule size was 4.8 cm, and on FNA, only one nodule was malignant (Bethesda VI), while all other nodules were Bethesda II-IV. On final surgical pathology, 36% of cases were follicular thyroid carcinoma (FTC), 28% were oncocytic thyroid carcinoma (OTC), 28% papillary thyroid carcinoma (PTC: 22% follicular variant, 3% classical, 3% high grade), and 8% poorly differentiated carcinoma.",
        "Abstract": "No patients had gross extrathyroidal extension (ETE); all patients with microscopic ETE underwent completion. All patients with extensive vascular invasion (>4 vessels) were recommended completion, however 2 deferred due to comorbidities and patient preference. Among those who had a completion thyroidectomy, 50% received radioactive iodine therapy (RAI). Among those undergoing observation, 50% ultimately required thyroid hormone supplementation in the follow up period. In the FTC group, 9/13 cases were observed without completion surgery and there were no recurrences among any patients over a 2 year follow up period. In the OTC group, 4/10 cases were observed while 6/10 underwent completion. There were 2 cases of OTC that were found to have either recurrence or metastatic disease on follow up after completion and RAI. There were no other cases of recurrence or residual disease in the cohort. No cases of FTC received RAI and 50% of OTC cases received RAI. View in Agenda and Add to Schedule",
        "Conclusions": "This study, which includes a majority of cases that are not PTC (65% of cases are oncocytic or follicular carcinoma), provides a nuanced view of observation as an alternative to completion thyroidectomy for select cases of tumors >4cm. There were no cases of recurrence among those managed with observation following thyroid lobectomy, indicating that this may be sufficient treatment in certain subgroups while minimizing need for hormone replacement and surgical complications. A major indication for completion total thyroidectomy is to facilitate RAI, however OTC are rarely iodine-avid; therefore, the benefit of RAI treatment in this subgroup is uncertain. Interestingly, more cases of OTC received RAI than FTC, representing an area for improvement based on current RAI evidence. Size criteria alone (>4cm) may not require completion surgery."
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Completion Thyroidectomy vs. Observation Following Lobectomy for Patients with Thyroid Cancer > 4cm on Final Pathology</span>. <u>Aviva Mattingly</u>; Whitney Jin; Andreja Radevic; Joaquin Austerlitz; Andrea Lopez; Vivian Weiss; Matthew Gonzalez; Lindsay Bischoff; Sarah Rohde. Vanderbilt University Medical Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Background: </strong>According to the 2025 American Thyroid Association guidelines, initial management for patients with thyroid cancer >4 cm is total thyroidectomy. However, for nodules that are indeterminate on imaging or preoperative fine needle aspiration (FNA), management may include diagnostic thyroid lobectomy. We investigated management decisions for patients who initially underwent lobectomy for any thyroid nodule but were found to have a thyroid malignancy >4cm and compared outcomes for those receiving immediate completion total thyroidectomy vs observation. </p>\n\n<p><strong>Methods:</strong> Patients were retrospectively identified through surgical pathology reports 2017-2025 at a single institution. Patients undergoing thyroid lobectomy found to have >4cm thyroid cancer on final pathology were included. Anyone with a planned total thyroidectomy that was staged due to intraoperative factors was excluded. There was no exclusion criteria based on histology or other pathology factors.</p>\n\n<p><strong>Results:</strong> A total of 36 cases met study criteria of which 50% underwent immediate completion thyroidectomy and 50% underwent observation, with a mean follow up of 29 months across the cohort. Preoperatively, median nodule size was 4.8 cm, and on FNA, only one nodule was malignant (Bethesda VI), while all other nodules were Bethesda II-IV. On final surgical pathology, 36% of cases were follicular thyroid carcinoma (FTC), 28% were oncocytic thyroid carcinoma (OTC), 28% papillary thyroid carcinoma (PTC: 22% follicular variant, 3% classical, 3% high grade), and 8% poorly differentiated carcinoma. </p>\n\n<p>No patients had gross extrathyroidal extension (ETE); all patients with microscopic ETE underwent completion. All patients with extensive vascular invasion (>4 vessels) were recommended completion, however 2 deferred due to comorbidities and patient preference. Among those who had a completion thyroidectomy, 50% received radioactive iodine therapy (RAI). Among those undergoing observation, 50% ultimately required thyroid hormone supplementation in the follow up period. </p>\n\n<p>In the FTC group, 9/13 cases were observed without completion surgery and there were no recurrences among any patients over a 2 year follow up period. In the OTC group, 4/10 cases were observed while 6/10 underwent completion. There were 2 cases of OTC that were found to have either recurrence or metastatic disease on follow up after completion and RAI. There were no other cases of recurrence or residual disease in the cohort. No cases of FTC received RAI and 50% of OTC cases received RAI. </p>\n\n<p><strong>Conclusions: </strong>This study, which includes a majority of cases that are not PTC (65% of cases are oncocytic or follicular carcinoma), provides a nuanced view of observation as an alternative to completion thyroidectomy for select cases of tumors >4cm. There were no cases of recurrence among those managed with observation following thyroid lobectomy, indicating that this may be sufficient treatment in certain subgroups while minimizing need for hormone replacement and surgical complications. A major indication for completion total thyroidectomy is to facilitate RAI, however OTC are rarely iodine-avid; therefore, the benefit of RAI treatment in this subgroup is uncertain. Interestingly, more cases of OTC received RAI than FTC, representing an area for improvement based on current RAI evidence. Size criteria alone (>4cm) may not require completion surgery. </p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 151883--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S607",
      "content_id": "154427",
      "abstract_number": "S607",
      "poster_number": "",
      "title": "Transoral Robotic Thyroidectomy (TORT): Surgical Outcomes in a Latin American Reference Center",
      "summary": "The study included 49 (71%) females and 20 (29%) males, with a mean age of 40 years. There were 35 (50.7%) total thyroidectomies, 27 (39.1%) lobectomies and 7 (10%) thyroidectomies combined with neck dissection. All cases were performed by a single surgeon (RBL), who accumulates an experience of more than 350 transoral thyroid surgeries. We didn’t have any conversions, reoperations, infections, hematomas, skin...",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=154427",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Renan B Lira, MD, PhD",
      "presenter": "Renan B Lira, MD, PhD",
      "authors": "Renan B Lira, MD, PhD 1 ; Andressa T Ramos, MD 1 ; Luiz P Kowalski, MD, pHD 2",
      "normalized_authors": [
        "Renan B Lira",
        "Andressa T Ramos",
        "Luiz P Kowalski"
      ],
      "affiliations": [
        "Einstein Hospital Israelita",
        "AC Camargo Cancer Center"
      ],
      "normalized_institutions": [
        "Einstein Hospital Israelita",
        "AC Camargo Cancer Center"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 262,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Introduction",
        "Methods",
        "Results",
        "Discussion",
        "Abstract"
      ],
      "sections": {
        "Authors": "Renan B Lira, MD, PhD 1 ; Andressa T Ramos, MD 1 ; Luiz P Kowalski, MD, pHD 2",
        "Affiliations": "1 Einstein Hospital Israelita; 2 AC Camargo Cancer Center",
        "Introduction": "Conventional thyroidectomy via Kocher’s incision has been the standard technique for more than a century now. In the last decades, remote approaches to the thyroid avoiding the visible and variable neck scar associated with conventional thyroidectomy were described. In this scenario, transoral endoscopic thyroidectomy vestibular approach (TOETVA) is the most recently and widely adopted technique. This approach can also be performed combined with robotic instrumentation – transoral robotic thyroidectomy (TORT). In this paper, we evaluate the feasibility and surgical outcomes of TORT in a robotic surgery reference center in Latin America.",
        "Methods": "This was a retrospective review of 69 patients who underwent TORT in a single center.",
        "Results": "The study included 49 (71%) females and 20 (29%) males, with a mean age of 40 years. There were 35 (50.7%) total thyroidectomies, 27 (39.1%) lobectomies and 7 (10%) thyroidectomies combined with neck dissection. All cases were performed by a single surgeon (RBL), who accumulates an experience of more than 350 transoral thyroid surgeries. We didn’t have any conversions, reoperations, infections, hematomas, skin lesion or mental nerve definitive paresthesia. The transient vocal cord palsy rate was 1.4% (1 patient). Temporary hypocalcemia was observed in five patients. Mean hospital stay was 1.2 day and no readmission was registered.",
        "Discussion": "This is a study with the largest cohort of TORT patients treated in Latin America published to date that, despite its retrospective nature and selection bias, reached outcomes comparable to previously reported series, reinforcing safeness and feasibility for this technique when performed by high volume trained surgeons.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Transoral Robotic Thyroidectomy (TORT): Surgical Outcomes in a Latin American Reference Center</span>. <u>Renan B Lira, MD, PhD</u><sup>1</sup>; Andressa T Ramos, MD<sup>1</sup>; Luiz P Kowalski, MD, pHD<sup>2</sup>. <sup>1</sup>Einstein Hospital Israelita; <sup>2</sup>AC Camargo Cancer Center<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Introduction:</strong> Conventional thyroidectomy via Kocher’s incision has been the standard technique for more than a century now. In the last decades, remote approaches to the thyroid avoiding the visible and variable neck scar associated with conventional thyroidectomy were described. In this scenario, transoral endoscopic thyroidectomy vestibular approach (TOETVA) is the most recently and widely adopted technique. This approach can also be performed combined with robotic instrumentation – transoral robotic thyroidectomy (TORT). In this paper, we evaluate the feasibility and surgical outcomes of TORT in a robotic surgery reference center in Latin America.</p>\n\n<p><strong>Methods: </strong>This was a retrospective review of 69 patients who underwent TORT in a single center.</p>\n\n<p><strong>Results: </strong>The study included 49 (71%) females and 20 (29%) males, with a mean age of 40 years. There were 35 (50.7%) total thyroidectomies, 27 (39.1%) lobectomies and 7 (10%) thyroidectomies combined with neck dissection. All cases were performed by a single surgeon (RBL), who accumulates an experience of more than 350 transoral thyroid surgeries. We didn’t have any conversions, reoperations, infections, hematomas, skin lesion or mental nerve definitive paresthesia. The transient vocal cord palsy rate was 1.4% (1 patient). Temporary hypocalcemia was observed in five patients. Mean hospital stay was 1.2 day and no readmission was registered.</p>\n\n<p><strong>Discussion:</strong> This is a study with the largest cohort of TORT patients treated in Latin America published to date that, despite its retrospective nature and selection bias, reached outcomes comparable to previously reported series, reinforcing safeness and feasibility for this technique when performed by high volume trained surgeons.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 154427--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    },
    {
      "uid": "S608",
      "content_id": "153264",
      "abstract_number": "S608",
      "poster_number": "",
      "title": "Retrospective Analysis of Targeted Therapy for Anaplastic Thyroid Cancer in a Predominantly Underserved Patient Population at an NCI-Designated Cancer Center",
      "summary": "In this predominantly underserved cohort, targeted therapy for BRAF-V600E-mutated ATC was associated with a high rate of radiologic disease control and prolonged survival in most treated patients, supporting the feasibility and clinical value of incorporating targeted agents into management at safety-net cancer centers.",
      "meeting": "AHNS 12th International Conference on Head and Neck Cancer",
      "meeting_short": "AHNS 2026",
      "meeting_dates": "July 18-22, 2026",
      "location": "Menino Convention and Exhibition Center, Boston, Massachusetts",
      "url": "https://eppro02.ativ.me/web/page.php?page=IntHtml&project=AHNS26&id=153264",
      "agenda_url": "https://eppro02.ativ.me/web/page.php?page=urn&project=AHNS26&urn=urn:eventpilot:all:agenda:id:20260163",
      "source_pdf_url": "",
      "source_pdf_page": null,
      "primary_person": "Tyler J Gathman, MD, MSE",
      "presenter": "Tyler J Gathman, MD, MSE",
      "authors": "Tyler J Gathman, MD, MSE 1 ; Alexandra E Turfe, BS 2 ; Jacob B Nielsen, BS 2 ; Nihal Punjabi, MD 1 ; John Cramer, MD 1 ; Ho-Sheng Lin, MD 1",
      "normalized_authors": [
        "Tyler J Gathman, MSE",
        "Alexandra E Turfe",
        "Jacob B Nielsen",
        "Nihal Punjabi",
        "John Cramer",
        "Ho-Sheng Lin"
      ],
      "affiliations": [
        "Wayne State University, Department of Otolaryngology Head & Neck Surgery",
        "Wayne State University School of Medicine"
      ],
      "normalized_institutions": [
        "Wayne State University, Department of Otolaryngology Head & Neck Surgery",
        "Wayne State University School of Medicine"
      ],
      "session_type": "Proffered Paper",
      "track": "Endocrine Surgery",
      "display_date": "",
      "start_time": "",
      "end_time": "",
      "location_detail": "",
      "topics": [
        "Endocrine Surgery"
      ],
      "keywords": [],
      "tables": [],
      "images": [],
      "has_images": false,
      "is_structured": true,
      "word_count": 341,
      "section_labels": [
        "Authors",
        "Affiliations",
        "Objective",
        "Study Design",
        "Setting",
        "Patients",
        "Interventions",
        "Main Outcome Measures",
        "Results",
        "Conclusions",
        "Learning Objective",
        "Level of Evidence -",
        "Indicate IRB or IACUC",
        "Abstract"
      ],
      "sections": {
        "Authors": "Tyler J Gathman, MD, MSE 1 ; Alexandra E Turfe, BS 2 ; Jacob B Nielsen, BS 2 ; Nihal Punjabi, MD 1 ; John Cramer, MD 1 ; Ho-Sheng Lin, MD 1",
        "Affiliations": "1 Wayne State University, Department of Otolaryngology Head & Neck Surgery; 2 Wayne State University School of Medicine",
        "Objective": "Anaplastic thyroid cancer (ATC) is a rare, highly aggressive malignancy accounting for approximately 2% of thyroid cancers. Targeted therapies, including dabrafenib and trametinib for BRAF V600E-mutated ATC, have emerged as important options alongside surgery and chemoradiation. This study describes treatment patterns and outcomes for patients with ATC treated at an NCI-designated cancer center serving a predominantly underserved population.",
        "Study Design": "Retrospective cohort study.",
        "Setting": "Tertiary, NCI-designated academic cancer center.",
        "Patients": "We identified 22 patients with biopsy-proven ATC treated with surgery, chemoradiation, and/or targeted therapy between 2015 and 2025. The mean age at diagnosis was 69.9 years (range 46 – 89), and 54.5% (n = 12) were male. Five patients received targeted therapy; three had AJCC stage IVc disease, and two had stage IVb disease.",
        "Interventions": "BRAF V600E-directed targeted systemic therapy (dabrafenib plus trametinib or similar regimens).",
        "Main Outcome Measures": "Radiologic tumor control, defined as the absence of progression or recurrence, was evaluated by serial computed tomography. Overall survival following the initial therapy was also assessed.",
        "Results": "Among the five patients who received targeted therapy, four (80%) had durable radiologic disease control without progression at last follow-up, and one (20%) had an initial partial response that progressed on subsequent imaging and clinical examination. Of patients who did not experience disease-related death, the mean follow-up duration was 3.83 years (range 1.50–4.58). In the patient with progression, the time to progression was 9 months after initiation of targeted therapy, and disease-related death occurred 3.80 years after ATC diagnosis. Targeted therapy was generally well tolerated with no treatment-limiting toxicities documented.",
        "Conclusions": "In this predominantly underserved cohort, targeted therapy for BRAF-V600E-mutated ATC was associated with a high rate of radiologic disease control and prolonged survival in most treated patients, supporting the feasibility and clinical value of incorporating targeted agents into management at safety-net cancer centers.",
        "Learning Objective": "To recognize the early efficacy and tolerability of targeted therapies, such as dabrafenib and trametinib, for ATC within predominantly underserved populations.",
        "Level of Evidence -": "Level III, Retrospective Cohort Study",
        "Indicate IRB or IACUC": "The study was reviewed and approved by Wayne State University's IRB committee.",
        "Abstract": "View in Agenda and Add to Schedule"
      },
      "raw_source_html": "<head><meta http-equiv='Content-Type' content='text/html';  name='HandheldFriendly' content='TRUE' /><meta name = 'viewport' content = 'width = device-width' /><style>.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px; } .abstract { overflow-x:scroll; } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px; } .abstract td,th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; }</style></head><body><div class='abstract'><span style='font:small-caps bold 18px Georgia, serif'>Retrospective Analysis of Targeted Therapy for Anaplastic Thyroid Cancer in a Predominantly Underserved Patient Population at an NCI-Designated Cancer Center</span>. <u>Tyler J Gathman, MD, MSE</u><sup>1</sup>; Alexandra E Turfe, BS<sup>2</sup>; Jacob B Nielsen, BS<sup>2</sup>; Nihal Punjabi, MD<sup>1</sup>; John Cramer, MD<sup>1</sup>; Ho-Sheng Lin, MD<sup>1</sup>. <sup>1</sup>Wayne State University, Department of Otolaryngology Head & Neck Surgery; <sup>2</sup>Wayne State University School of Medicine<hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><p><strong>Objective:</strong> Anaplastic thyroid cancer (ATC) is a rare, highly aggressive malignancy accounting for approximately 2% of thyroid cancers. Targeted therapies, including dabrafenib and trametinib for BRAF V600E-mutated ATC, have emerged as important options alongside surgery and chemoradiation. This study describes treatment patterns and outcomes for patients with ATC treated at an NCI-designated cancer center serving a predominantly underserved population.</p>\n\n<p><strong>Study Design:</strong> Retrospective cohort study.</p>\n\n<p><strong>Setting: </strong>Tertiary, NCI-designated academic cancer center.</p>\n\n<p><strong>Patients:</strong> We identified 22 patients with biopsy-proven ATC treated with surgery, chemoradiation, and/or targeted therapy between 2015 and 2025. The mean age at diagnosis was 69.9 years (range 46 – 89), and 54.5% (n = 12) were male. Five patients received targeted therapy; three had AJCC stage IVc disease, and two had stage IVb disease.</p>\n\n<p><strong>Interventions:</strong> BRAF V600E-directed targeted systemic therapy (dabrafenib plus trametinib or similar regimens).</p>\n\n<p><strong>Main Outcome Measures:</strong> Radiologic tumor control, defined as the absence of progression or recurrence, was evaluated by serial computed tomography. Overall survival following the initial therapy was also assessed.           </p>\n\n<p><strong>Results: </strong>Among the five patients who received targeted therapy, four (80%) had durable radiologic disease control without progression at last follow-up, and one (20%) had an initial partial response that progressed on subsequent imaging and clinical examination. Of patients who did not experience disease-related death, the mean follow-up duration was 3.83 years (range 1.50–4.58). In the patient with progression, the time to progression was 9 months after initiation of targeted therapy, and disease-related death occurred 3.80 years after ATC diagnosis. Targeted therapy was generally well tolerated with no treatment-limiting toxicities documented.</p>\n\n<p><strong>Conclusions:</strong> In this predominantly underserved cohort, targeted therapy for BRAF-V600E-mutated ATC was associated with a high rate of radiologic disease control and prolonged survival in most treated patients, supporting the feasibility and clinical value of incorporating targeted agents into management at safety-net cancer centers.</p>\n\n<p><strong>Learning Objective:</strong> To recognize the early efficacy and tolerability of targeted therapies, such as dabrafenib and trametinib, for ATC within predominantly underserved populations.</p>\n\n<p><strong>Level of Evidence -</strong> Level III, Retrospective Cohort Study</p>\n\n<p><strong>Indicate IRB or IACUC: </strong>The study was reviewed and approved by Wayne State University's IRB committee.</p><hr style='margin:25px 0; height:1px; border:0; background:black; background:-webkit-gradient(linear,0 0,100% 0,from(white),to(white),color-stop(50%,black)); '/><!-- 153264--><p><button type='button' align='center' data-role='none'><a style='text-decoration:none' href='urn:eventpilot:all:agenda:id:20260163' rel='external'>View in Agenda and Add to Schedule</a></button></p></body></html>"
    }
  ]
}